From bd9244206d2b2e1a0ab0173d3c2d4d5c53e75641 Mon Sep 17 00:00:00 2001 From: Matthijs Berends Date: Thu, 13 Aug 2026 11:12:12 +0200 Subject: [PATCH] (v3.0.1.9086) new eucast update flow --- DESCRIPTION | 4 +- NEWS.md | 2 +- R/sysdata.rda | Bin 119244 -> 119244 bytes R/tidymodels.R | 30 +- ...roduction_of_clinical_breakpoints_eucast.R | 725 + data-raw/breakpoints_eucast_raw.csv | 15011 ++++++++++++++++ data-raw/breakpoints_eucast_raw.rds | Bin 0 -> 176078 bytes data-raw/v_09.0_Breakpoint_Tables.xlsx | Bin 0 -> 2775130 bytes data-raw/v_16.1_Breakpoint_Tables.xlsx | Bin 0 -> 2679948 bytes data/antibiotics.rda | Bin 45376 -> 45256 bytes data/antimicrobials.rda | Bin 45392 -> 45392 bytes man/AMR.Rd | 2 +- man/g.test.Rd | 2 +- man/ggplot_pca.Rd | 5 +- 14 files changed, 15757 insertions(+), 24 deletions(-) create mode 100644 data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R create mode 100644 data-raw/breakpoints_eucast_raw.csv create mode 100644 data-raw/breakpoints_eucast_raw.rds create mode 100644 data-raw/v_09.0_Breakpoint_Tables.xlsx create mode 100644 data-raw/v_16.1_Breakpoint_Tables.xlsx diff --git a/DESCRIPTION b/DESCRIPTION index 89ce806b8..b8365893a 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,6 +1,6 @@ Package: AMR -Version: 3.0.1.9085 -Date: 2026-07-09 +Version: 3.0.1.9086 +Date: 2026-08-13 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) data analysis and to work with microbial and antimicrobial properties by diff --git a/NEWS.md b/NEWS.md index 927ea33a1..10796428b 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,4 +1,4 @@ -# AMR 3.0.1.9085 +# AMR 3.0.1.9086 Planned as v3.1.0, end of June 2026. diff --git a/R/sysdata.rda b/R/sysdata.rda index 21d77208cf921f0b34dc99fa001bf6a4bea23d53..2ea67d6a9404aa4db774e14e5ed9d683eee289bc 100755 GIT binary patch literal 119244 zcmV(lK=i-;H+ooF0004LBHlIv03iV!0000G&sfaq;(+h|T>vQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6Wr)f^1_CEM0+Xj~AoW)he{Dt~YT!x@bizKMl`_Kw%$AR~7HT%OGMlvD71%Si<&2*;W-YWiv2JMY6=fRzhrfFjzr!UuVT z!C8|(uij8|pC@e3jg6`;!dW#jkO#@_9*U$5IGnSB&7e}S!-nlJs;g#P%&TQ9yDY$~ z&Ab#%umHHryeS`1dJ4YeC1CWHv(BY{I_qr#=x8otxm`6FZ6q3^0rXm_*sijEp}E+X zq%2B)(xRtO)X=;8n?9Y}>bCnP)Ev{i)_<1Q%Vzt|E?Olz3#C1^5Fy4`V8o6cVwvvEyYc7(m z8m;{9_cZOB6uyWxv+@Qczr_9Yp6cF)HK14NhPKTY3Z`Y0b7#N7ILB7vQkSMmOLePo zbAWqkbJT5BEi`4K*gFBuoT;BT4tejox=?Hw%$=xaf^&iSD*;Ks5`0FesBt4S-pmCe zGC=_#fCo5BW=T8<9?=cBu!v>i{}9caTDo+vSR%E}^06=>+4g}zRK z2cYzDK71tq^E~7Y)t+RVG2fWC>pvWxyZHk9#Fb841SK6Hw=8DWnN}PLV+XU@i=M{9 zRcEk{#3}CZYYQ}1J7cxL-?Yn=BX@Wdmo*10dX-bwKWs{54C;}0Fn?KPs}KfSnaQiS zy#vpcaH71zwxM-IYCa@D?im=U_uYr+!BU$wMvH7Vsc0ZZMU{7*q|0c<>YO1Nk`7~- zeyhobt9i{ONEoBbYr`O{BY2?TLz9%zDa*Dz%t^vi9dETJr18?c>iF+l6fqG5ZvvsF z#k2WoDEH3+@SPB8b9l>~+<$-PLFyD=vQ|drgQTt*p&NDDeyONMi(oQDE+31Id9MKX)gHux0e-wNDM7aIcbi zYI3CQIc6`)6ETsGKzb9}$ktAok5=aDBT&J8BjPSB#O3!hrmf&{yV6)X8F>h z($@L8J2&rA$H@}lna2VT1qzEtnS`~87a?@x0e^998(14=oECq?VsVxhs!H&z47y1- z(ZzdyIOiAZo@DySA*%=0#c9I%SCnV%5H1cNCap^POv1?5$?-a1K0_%@>@Z=V=>aqJ4cGx+K@p$JBxLS&PE>N z=9OqQ7(=bGktW|127uq8W0Gac1eX^@B14l~*fB1pNNT*CT_NCSl)7bAn&fz68StOu z&}7RMtWfqD1?fW`yD`M*IUTEB$+n}aTL6+y81bYFX(TpOdF`l^j=f@wGP`oS_qdjW z_QoyPeb+#L&vL9W?R{J-Lhata_~8>CGl)!BF9ou4Q}IadOCH`_(Q+>huxNW$bh(n+ zK`uF$xZfGBG8*XfV>-qrf_jG}8J``C28b%*vc)ei6yb~~STsK_@#;p+I#Ku7HTf;Q zs^Tm+$+i_16Lw&_+$r||vzZz6bkr|^lAbSP62?W%LYO`G({wG?;wU5PJY_dE%aTcG z(3bHG^#N-ox#dcE$eIVkhhBLR#u2Qk%Edv(-?Bg8(W9p;@89(wRWnBdC^*UeFPZ6mpphW53pC$*R9|5 zEA^uMgYRzG1g2?4CD>bQ50F=Q|t3kBlGIZ?kJSh zTwmc9=zqkmnwlX0y9l0t*HZZfsM`nSWS&k3nIA88Y?jz#ot62Dna5h*7g$-ruj!i?k<(ZZq!UkyVHbJ{T-7h_yhif6j#tq2l9axuzN2MpKXW*R-1QP7^ zpaCT$`^?`4T*6#9&X)zYEPW35xpC=O^C^oAI(lDVJOT8@v)ZS@9*&GHm?_Tfh>BT` zGdz~p$^Z+6&3o17)E$~I9~jIyTU`Un*`AYv%1_z=igK%C4lCwt^m(q~9`UN%(u1P${%08s$G^DuTavOFUx?7mSYKw~J8dcZfdGLS z>zGb{SdkDo+-V+J`^{fus85(YrlrNKpiM;%JOr*1v9bBy>`~>g$OE6CzW+Qdp{q{1 z5{=K2g_e!e>WK0Y+RCxJ+m-|YT`Z-7B90GzQ@daO zmh-+48*q!{bVMeLcEPV-19wwe(>&kY?E`T*S6N&>g{Ib=Al=95Im)Q|5M}QOk}j7r zKo&rzRf>$+l{XI~!}+a1TTr;-s>*tSZt%t{71=7iDAC|un`5xQi5hh`OXMX!pn&h!eILtnrl?ZVEu&bs;yW2H>U&|D+b zySV7gg?_>v*v6jGB#B5kJL?giRGHJPc*?hEr_!Eg z$~kNPojs$xnKGszU0(x|9cd$JD-Uu;(KwB3x|g$yJQae0TlN$|;52cttZVk`k0hiNa0P9y9HyBt=!L-oLCvTH6mDGBc3}!RdWZO8P@+EuAzk0hYvuzh^5cfR>zq)q5+4AJG zC)H+igHdFcXt7Fqt`XaooM_~vGhkhYhdS}Zmt|Cj*!;nK zjdtc^J0IKpBh%`)ZA@@9ky_1>!#UlfV8(3xdV?f>Tc5Vl0MES4CcUHSWEiz|eE9bc zo_C~QtDHV#iLCS#o8f5GU(`v%k#U>Fo+s%SZ)4^@#83KU)E_(5EovTl zu8c0WLfXT?qqGGE>5xE)MO7r5vZh3eLml?+%ozDJr1K6RrEUAx7jjEhzd#&;rVz(K z@G5^mrVvM_G-DS%Ny6}%cUaZ+9t34(g8vveG9A7c!R<`|a@_@x1jLds(*f6Hs7Y?J zm{zQA_qqdt4Z#b?01x&gBb;?(9mJ&Nd&{}>o2`H1sf!mI7a&o^5sKW_>y^Y;8=0f; zsba+8fib_e2-Td+D<|y~If|wdnTc&5i4h@?JcY=G0A(TiCjh@cshdVG(2f~f#y?(=+fS1OzL`{u>qT;>RYpiZx#!Ba} zgx70btjFopGn&?s#auMQpVK?hBtt*!w^-|irtV_DlZ37YG;T^J*WiiVEodmM4wbum zH|YrP5{l{>CVzq@+?2NOqsrIO+!2#q{g}R_Th3#Kk#Tn-$M1xN9VmLmd@e?Pjhodp zAmnN4?k5^YzacnYmd&r=u0R?nmGq3Z1WTv+bOMF&PoLKj@@duG_;@aV!|XWemlp-teX(CB5CiQS>M3L|YZTj2_$=Ec~Gpz{qE zB@Mor^iVPYlqO68IzN}5py0sQWR!PoLDshcsyeB{-8 zvWb;%7c98pPcdvEi!)iviQpF4IZ}f)wi-yv08=_^GaWf%e81}~O#NI&uzVVJ6NFk| zDo7iQ0SKqXhkM3xByt=vz&M5?X@X}-q4K=*Im*Y!Jmz7o3n;uOt+%GQi_&h_oNHVb zRdd91eVMF{#-&^Qvd{ET?;=C6^Zm%ZqNF>~Q5O3U&G5UQazfg&^{yt^vDfy3*3V&3 z>F_%HI&0ScO)}9z0|5Q#xlk&9Wk_=U^AH*T%qMnqMVT$3AR#iXg7Lm9r}}0BhQ?_h z(Km(fHphfWmX`B+m~*!fJ*gHu+GX=GD$X&F$tU!r!8^+9dtjK`w?9hZ~|u4&qf)SDmp+os#WJWCyOE~dCp+OrUT zJ0pM`vwMIkYIN9j@vpn*+{y$_3qVh{? zekwg@QY9QQhe)VZ?tA;Y-Iku?oY*^T2KpLI004sJMM(KgUk64#j+Y?VWG~;{d9cu6 zfOuPt=WyV;7rX}Jd=A|!(6k829n-1(V%L0b@#amfj&B|6c-31BV$_DLGHi?ve7|b= zIPq|(sftO`n5o0t<8@wuX8eOHTi{;#iO&}nTTfwIk6Ss7~m z6`5ne`Si1Lr2lag`o0Kt{0LQDrE~3z{NKJ+pHm+K53E_FnPW8CMtCxAqa1+{V*ciy zGvAEErDRVp@h6&>4K@--u;HMn%HK&Se2l_^$C~vw!rn|=i7(rB8ZU)f#EOf77#%Zv7FzsbQ zD;$3{yc?Qc@;&`r_?ljeAv&mkRV&p`F%{C8gznVz?b1H+`6U27`~U1h@qa6*XM&%j z8r~hHpG_Tw4~E+Yo^XfJkVdBbv}L!VbmI!z(m#@5kNSA02f|F{V>B?vS$%@j9RosR ziva;AuF9BfNSbVuISL4jvWu(b&swCBVC*2kqJnB;ex|glmV!TP73$HW&96rU*hwS) zDGrk`M%+e$yj=9tOBs_2B~nqH)dZ;B1{agt?&t5#fM=zv{t>ZT(9&Init@f;@-&0< zA^Rv|_MI3IrA4;Up_@_`XexWZ`DMZIk!k(V2AU8tzTU!GFD&ke;RWYVq6`_15$2P z&fXzRd8U%Ert}*$XxeibqNLbLz0%HZ941xA?syU-oAVMItM+e|s)ZS!46cVr-fCR- zJLx?B7@ia?=Umg!V@2VH#)%{bDjEOnZxp2(3~=#@6n%}1Sa6TWb_d86m&c;+-cWFP zQp1Iu!x#`EOM4$=1SleBQV>pEiJxDbiz_2tecIoBaU^JHW^ZvX!|$r4}}UiI=);eY1A< zhjWku24v@>p-`>MI^z}Hd=zzzWlzLKk@r`CcboPSAT{CqAev)#YsZRH*_4*|=ZxZm zjM#4bm9ge%>T(OUjq;S++Z&C?Tns@MyS~{0xNO6Rj`|6T?u=HNs4L#ic-(J7y@}!N zyHWSWN=Ey zIn+sCdJ!v^^lJ24e=c3#=ReiNSpmQzyhrl#UP5aq`hfo_EyI3)C3{cdg5Ngt+XF-> zc8IZe&l&2O5#d}oIR zGD1E##B?;4S0XvKJp9tGoxgN-s~`wl9g&H;DW&DiT{S#S1Hs=8WL^s964TA)lFcI~ z;fO5IJhJ)4)z14QBbDQ8LD&axS@iTGcKvv)jx3Q8bAsw?il_~<(ps5K7|MrsF+H_? z9Kx}^n+$x=Ziib#E(DY332HaW$4L!_jnnC*>ls2DlYB4{N>yj6{oM4xl1^dJ4NKx=HKm0fU-+aB!vCAvNjHKN(=s|w3naNWhlKtkXlxNbPXsalABDHnW-Ueo!3mVrZZOm?V9u^qHPPzIz&?5IN1H|%NfD_cjhUu)% zH8j97WwgOKqHA#sy!SC1#X-}yEL2bkwKaB*Aej&ILyA528Zp}?fahUx8jTRq_}dt` zNhdsGP(qNrW>UR9TAVz3w7^RWqXW{byNYnbX4^G+YW947@*0l)A`G8@-r>=Iq~;?B zy<=ZH{Q}@Lq-qRO4qUoGQb|l>Wd^!;$IG9Z@{N1oIda3n;{Jl$_&Y~qS)Bl%tR6Sv zWMqF;Sv6s75rg|^Gif@419B^0;G$^r$F(ON5Q+yI`BiDpFwR-+d6pYFKvJQPAiNQi zT^aQOkBdb%^_%D$K91V@oMwI507vrdHA1iRCOTLd(1uR_I>PiG8Beo zdEv3l8?M>IBq!sBxh}0>@If~l+mN^nN7xC|H^yYGliYb?(qkC4?mHbT}_cD$pYxmtCaqco3d8yyU6L(Y@$rFTB5k#KgA;m>~e#20lq4T8}f zBh@5h+5mVyW1=FM=@lG?dYa3OPKpX8`HoA({n=j)-V-t%C7ya~iA0yENgtbm=n(-B zR3KFN$EQthG5KHakQ}`-b^V@ToeXorc#{&6;e$-mCOb2XnhJV;qS(RWfp%t|x-^(w z8iC_pLm#uTw*pA+wg!*!TcB|z(4K6dy$OT=go(ZwlkbOabnedCLx;etq_z4Qqx#BL z=cqnQ&3@ROnPIv@6ouFY*j1Clt*^64!p(G}Lukz|b5qGH<5Xx^yCqw0RHQFqW}4`+ zsfv_%>@7G*mrbOrNI55gyCl5|yj(WVOv*jrxL-Q&hwLcRuXQEzr((h=itJMq+$0mn zlJs$g7$fhY7GG9x#bqT8#38-BtpVGwi+IlwdiwWBq5H#$g@`@p!qtE2C%O}bh*aAS za(UbHfkBl)h^j(0SZ)m{9n}Pg6l~vQ?mvAH9a`F&KOQ@!JtN)R4M|Ea{S{@j((UO_ z=amE0^z$b>UbXb=pN^^J5Xz>3hlcK$TMIrKhs6S^6{tXcKrvBej)#Z? zxd|`!gMllK%q+D2^%V@XK1*T>3J=-U{PC2p&m7y8ixQ{YH*khwUgDO#Ztn2=Y+^EEN zUsh4;Wu5~ewd3EER19L>1FEp$15a{G=_r6`_Hpg1jwAZbZbe5oFL&zGh?dP8>g!ca z0(8Hcu=GH_|Nm6?8yx&UXU-p-Y>)P3#u%)dL+NgmhdSY*rEVVCR^Y>m$`Ff`aiX5P zK-?NviannaY83LKs|}mT?Ef{56Yn6_`Ovl6?upk`$93LA8DV6>K_@_GmM zndBjS``67k3W^bBQ7nnC@h3M>R;a)HnFH*mJ8Wu}sv)R1rm1TU5P=BjX-JE!b-u{_ zGGH2ex47pY?mpVPpg zJf>ZOJ!k!l%K;U8SQE6zLh1eOVRbLMtw6pt-NPAZ-{1BRrhV5%Vrd)J`*>&e%$O&t zYRHbK!lo-+kUFFi1_=t}I{#x@3Kx9pB$JxOnfWdZMU}6!8TUSpm`P8eg_*jt8F#d+ zAf*k&UCJ|l?0grtj3?)=q!_R_lyrcg6Z`y~Qgcz_i9QzLJjm#!#9nJ|IN%KOmLSj~ zy+7T-5;LS*2=6QL4h2@ym;JGvJc?-BG{&7xh4J~Ki;jc-aA~<|gDc|@mFxoQU=bW> zr^DO}7~4kmovyoeBIuoV(V1ERQk;Qdl=hi=?ZU(WTMA#`!h2&zPJnu4AlzyXgohEM z1U|cSZUhUKE@xefUjdNrUgzRK}h5_^$Jn4cFf52E_c=_~M^lcSv?1im&yjUz;&-g5daeSj><_*XNPv0h- z*4E86HcZ}>yWa3wu8g-UrtEidy`{4-EH_JOQ~Nm+htfB^flGqUFX1XmMqXPs^2>#yY{#pw|NP3j)U2N|6#%F~qr(ygovef&fUhfXCWRfb>$)*$!vE^&%R(Xh6 zfN3!ZZW0yl8920*nJ*^^SpO_)P1la5Kl5 zic&5nHR+k1mz2n>^RS}Ed^GAyF2T7;HV5efp^Hb!7_5}~frO24ud5;J`4rJG&T0Z$ z#?6B*QmDGRUcEcfXwc}R?&Q}P`ej2t{u|awkD3>JF?~%&h6}B)J+ib8UN%$V*`5KD zbgZZwWZ(HHw9F4P($MwwL#-v7b%M^S?1;sw6Y8368G^~yMjC=BoW@u17d0+v6v3)_ zrTH5W7SZxe`wK3?*K=piE?Y)GSi)n!U>tQ)H_Xh=g%`wfOFmb~-b^0C05FE}k-e!n zn@68z^_p~?IC$O_&PzSTREfL)OssB;`d)hc-!5t+VmktG`51}nQF3Q8WWP5n{C^{S z4kD}q!Jho1^4f-%NF+o#Q;nbgMWIe|Fm&uSt9Bm+P^icSx=a$dR`PDps5%k^A4&_T ztC1@neoEYOqJNiUX?GUD(xCbE%1o-;jPjhBgg}D%MA4pd{Ux!qCmPVZI zC`f&(&7>4jAUP-oTucD)D5rZJMbU}&nC*NNN>KxNR&D`U48xF>(NCM%TE9ElGvPA2 z-Bttt!KI-kyyR>IsPzz_D-)j|yR}L$`$Wd9X~0tZKMX|Le6Y1zmj2Na8g@+xvhQ## zd_mt;_nPug-Q$X)D>Bp1U;PdnCy3dX(i9-$4Hbfppe)#j!^J-J-q!+H%-`?kz63vy z)tcbNZ_@$^ISLsYtkPB@+}_SzT>I>ZPO(%15@9+vRrhf}M;F+4*x`oBoqy*LZhvoY zzTgE>y_gH>dREO1wY)pGhk*~SZSFk@QOMXwe0oww|NBMWvV1g(8miU+1pyaIc?sw|3Z89K61JDt(sN)O65LEuRD0c$8ZXM z^V`^*Na-NM?3Vr!l&*(PiZ7%6>|~#r*7x*Y zc#VFoWCx$K{#HtLB5^|t{|pHmY1DrWy%g+l)U9}1SgmC}Ck_#VkU%+D+Q^B(6T~W2 z0-?mMv=z^J2AxKH{T%v3yV#~zw8T{}c@;-7Hd4b=SCqQUK3Uw64h*Zf;R7*Pki(L-cj84s( zd7TRM8@~YG{LErhq2a77zsI|%hjOJ03O{ysT5kH56k#Iw_GZY4dEU!C@5llH zEgG$@ZGwhGbZ-lmGZ~kMEkw8CAth*6uh651Y|XaUNq?v6+mX^{ujpfR)`AUzUZR__sjpAehZYHo$W|;zga!8P z84`5`mgoP;li2lk@nTSUJi^C>*F;QWW=@Toc?k?CcBrl$mCf6@tC0U?G;Ve#VS@jK zqmEiVvlGrbn@=bEAiMbX713J8M_9m!Oop`*Uje~!JuV|sNN6mb2mh0#{kiwsuV6|d zzJ_4VS2egCMCmE|Su1sH+jc$Vs;c5* zS?U&tBKy`8s-yI))^;#d!4{B|8|Ht;Rv>GO7yahnaTSe{eQb)HsGEwfx+)EuzO2~g z89Dc$rwWU^3vX8Z#Vf-H*wsna<%5p-+ES83mo?IvkS=Wtf!TT4>i#VLJ zLsreZHA&zmRkLC*)H#cniRpDq>TkS;X_FajE~uvWfV)`n==dt6G~2l?hc}x0r){## zhE%_Ynx^UvxV}05EP9dd8t%kM?wgo_<(*i;7$)Uk!EoI)UfATRI?4QnW%T9eLL8!} zTa{+KHDXIa_P&~Hrrwd^qV)T1ELP-V45wwN1tGbOTD{#N14XiBC6|HKTwtKI#1zL! zxe?4M(xJc(<^J~CVFh%ZYxuEL-g6%@{*{~3-JXMS6Uc%cj13mZ?YYTZ4yzL2EP@+~ zbK1V)`ZMmMQDNia%4+{Q(}F74Yoq9YS$EHf}~#v@9tVLDiG_Ecsg$6q5wx#jj^WN!(#%a1gM`qrBG8K1Y5S4n^aXQvE72y0-j>4}yr>rCI+JcmP zTDx(nsXouwrI-!tb&f)gHX}ac8R)0b`aQ2h!Zmg8(kb0HU&CVNzPiM=pVstI)fkq< zW**%jQ?S(LUMCHNl<3gKHecDbnb}4$hAsc)?u@>qH+ptfCK{j{woNq1b5GTTN~wyS z!cbt)5rxe{T$aIa75r9$w{;qM-9>!J(LY2W-PC5;d5HfzB!mq%Z*g(EGQa#B07^RF zA)QZ5((hO_u=4{q8t!KnK_4}i)v;nw0vAPOBO)($ap7bL{E~|x7;4L6`SKaP8km`` z11k|s2jWP5IrBBl8_0b zAn<{jvuS119}%8^&=>!~T)qLaz9Hk?RZh=nr3N=Un3N#s)px--Tmu*KCu!Y37-l(` zWP=!@6(5cw^6?YnA~u1dNlB`2vJ1fqF+;!{%;sq}+4Nq8f4aK^h+3j~SB5&nf#1?z z4TLo>Y2WxP2-u`EQiji;VkrP*&#UC&FI|*ji}`5i`trOQmz0u+W0s*3QT)&q1FH`9 zCc7!SrTOAyE_r%+jdZ(BmXRign*SWRF#AgmkC>zI;vPoKw&AN_zW439*J*@Zk~NTs z`u`7Jmxx1DzH-+n$rHrvQP9h~f@A$$xHNQKWD}51hYJ+OA8WA&_ldfNN&OS7T}&F_ zcAu3E%zC8~HK27$kI#`9#Z^57NI8e%PhX#VD6NQ!b?^=b6!*K+E)W-#i|6K0?WuKjGd+Esjelg}P<# z*0}%O@bxm)%q)-N?7cc-@0K~`%nV_sRYzsB;iVFl=AeLZKSjR8_0t$*nry0_=sp^* z+e481OcDh}0!IR4QZo3ra}UV9zrCD7Sy15h7ATZ15RJ~>J;D#&APPBb&J30KO>kSz$T+px2sP|39r1_KRdx_GMH+NnC4$I`dS6SxVu^EwFjNP zEQZkfqSa5Ll+?F1zNk}LOaB^DmfK7+lw#+6dQD{^c~w?o7wP~vil#^P7s3L!l52iwCMf9zR`fSO05N1y?f??aOIS|gmKL|( zG74m7RoO>+frBsr`w0Ia7sI#vr z4LQjJc`Wz5I*&WbhU&-$|3nu>RU?3=>4-nY&aZME?4;p8QB8l*cyk!F_Cq6harhDA=p{{s)4dT&@} z=um>zq=T*I0ycY~+z8fJ zkV5@o`KrZR4(RqYSGZ5@m}s=Pzu$;vqRka#d=$0v=dYZ&n;wRg2l3CB@y_4I2$eH# z|LC~+&Yr92-fgK6Ja56v;uHmU5#SXQ<6kqt$iA-YXMC`$r9~B=6qGbNY&r-5XomDB zlyNHO;dAi_>I17h7;#OyiL}i`26Fp2 zbJ0)tG0L}s-$GT9pX)rrPXZ2&Nd3|4w1N=g8h5z0yqasF5Wdo{5;xcVdN>*pwa5P6 zz9`sIE2yPGHV{oEVx(4BO~+>!IYv=ruO?m3!KPeVOCoh*q>Rg9dG>#zhp51je=Fz9 z2EBv+#MG;ji!9`XY$p3Df);kmtvSdw`TO6Xyx((P57yAk){Zz}!COmZax^3lD)WV6 zji3^u)LMnj)B6tFGo+Uv-2o5%5icWv+KSiCBI}AgohOFhQJ(J# zE0(Uo-t@DMBB8cfoOLd?)-k-Oaiaf)N5rEr8fkS8n}hi9a3D%7Mg7Q>rH5x_BJL}f zx|^Km3g3nKx@yILYyvACwbb06z=oB1P_T3fM0&NY<&muoVk-6d$7$QE8E*lK5#)|IV?^k2x0+jl;R*4nWE24=_jJ=df#v#`4Qp%C{cc_Gi-!vy zvQR=6_H8fMwx~oziZH12Y~3GyLkEj7e^uL_1nvB{{u<|LMrdc7@8@(S&*5S9902}$ z*&{=W%-%<|tPg(^+ooU*zl$#X$q7E!Io$t`^!|SU*ee_R9v0#0iIT-Qc4O9YtPv`t z=H;v<$=VO_?>+AnJFmu1_n=0?036&Riy zcn@H+yZy&55LCW$5Ag5~qWwKbmgo;VfT!J$T&zGD+|HL*CB^O>y6Blh7g0PW7d5oA z$$~6duZYg7+JZgTZ0!QdLi4s>hqpM6o&=1@2?$o%;G6{g@$;C=Hc(Liot~^}UPqhM zys2lAw@9(=|HN`kE|!buxnFUHZOjOCI22Z0OdGND-B>(_p&$<8$=6 z0(h6hdz$>1vtxvE&wO2aM6tkk7jOMNb~dnxdz44~nBUJ=4$i5{1f0 zFc2r$h7*C$OF`IE6SPeK0;Cs+jyFCzLJW8JnT82YIB&|xS;)lHG9On1i9T2x|DrOv zn>om2o$3G%@W>-0u*Y|AJhGGL(NJ1ren2I*-qZ)PSaV$AI4dle0w+_9{ zyuE+h2FIl}--Qr8mI&`EZapQ9!UEFMWBnH6A@CWqAvi<*9Q!%37r`WQK`g6wUis;} z^4*({I(eKxdLAV&L#lsmfRY~e&MfUi+rQ(n`?h7h9ed{VOU|srcggO5Ldhe9le+d6 zXTxS{+|M*d&JqqbnXL+aDfxr`lL}#zcj2@z#HT&vAyRERcKD|a^T0%N8Mh(u1}uce z|3^h&{SNPAP5Wl9r-dYk$OqG=+1?dS0q7Hj94es{;8i1+lpR)KUyQ~5##K@N5vIkF zePo;{uMF@hXS!Fp4mDT|+$0c~aTr+XhQ}oF`i(3()PFJcQF*QJ=y+o#pE|yQS7i7p zhgFAY-f8$eN)mY~y5<>R1f6*PbfYg=0t@bOzm)PLy?dhL^;*%$77eUea`( z+$;^O#lYCO6I;>VwqsD?)k|D^%syZba~d19Mam{F9Y$BBSR%-qnv#R+_O^5NVPQza z6etHd5LC#(@}}HheS)_}H0*-pSsl3?ViiB)%z<@2xzMZpOg{ z%x{BysePi;g$(rHoTpm}*BHGCUrPl`egKYx!Lu$Q<8oYP$MKRcCya=_Az5Ac6hL3h zu@ioODGopr`1C>6=bNB6YYk5Z=w?N39deLu&rVQBf3EXFb3iB`;^S z7=b+`CW<)K3%O`EQgu`V%AF%&@JTW1`q@HodA8yQ+^PN-3-GSC;?kUscEKn!c%z~W z^V4j4Pwp~HmHT1zqk!bDR~N~xS`(;+-Zhqv1_+>-bU5d*gO@5m2TSPx3R8Iv8(vd2 zRY`wiFdwRp83H4YiCC~u31I zasyq~sm8J)r1B|Cz3*>ejnWDdBpHRC0uc$qNqO&~d)AjyEBlOTS3LL*ZJui~iksUM zF?FCj&Es-={4>PrSW6l%&0}_!J38=9k17aUmWEJf(6J#yj#R7M0-z6nh!ePqxZ}J) z3j3XSJz+Tq*8j;p3>CdCrXw4&s`>WTjH{O?JNs<)lesOh{-re&K&L?nn4M%jpq1iz zHEqvn35JRF7?qNg9|YuJS?!-8m%F`Sct2L#e9?SLCtO2vf*74n4Ib2Oh3wY+cK!8& zx}naF#PRpVRc)WTpx(c7NF5f9?%GDzmw+^R-HLI^y(hl4;4jqDmv`U@Q?8~9Jsy`S zM14~K!VXX_xblUl^2yPX%fJmqN_(r(>yDKUwm}8uK|`-Vq6u}}NOGL~n=t+30{{-# zYtuFQ0xYbZ5k+iW2>WNE#8>hUG9JomF}hDp<>CX?7hCM>)9PSpyylH<9kpDI{5K^k zblZBd1HKTc>6R%p)!dsD^>u9S7H~!L3s#%CkUh(#ZR)!~0@cF8%V3P@uOiWzErDgg zu!5mytTT#DemYZac#7#awM3am@dunOHt|(X#b$e4(X%+Brrn~iEgaP0iAoU?><2#$ zTV{#5c@mmx`TcE7CdONzG*JNzz;Q_eZJ#zR+{SgRA6~ zI`wNea!uBz%?~22@*2ZV)FZX7j%Z6uP{bEj%KR{`(XL7J?jGJ}oiPZPc-5+M)-GAv zZ>+-<1+;^kZ(}4?S*&_9;L}=H)_7T$ED~HAYGgk)JH)Fi?5u~BhF5D4B}tpSzlP4* zHN|EhUQ4ocm}!XU+kpHqenxpna zCjT$psV>ATJ$F4NaueS@^q$~t|A&bD4rY>C5F;o~*^ZNC(P!sFN*e1{$2W7F-W3=fWnT6g2^4g=G3P1e!A)h zqH^oLqDT;X~qL%rnRiwC<% zt%e$0O@x1RgPXM?q4ZvJid&j*>4WssxKi08+fRz!BMogKSN^)T(I>968g#oWqLqx8 zL`zdK@)y!ns1$?@b`z#&8dd5R4O~*7?!2*OD%^i#RoB=k+V;P@ZY-9P-imYVOKvMk zG4HI|4xFr*-twxx#0+*K?>)&IG#AeNQ=G-mmaJivf@$*;E>rU$Q#XoU13ucwgbJ#Q zJesX7q2$pEcA*_uBMVIuX=V^ql`zMr#3pv8rca!o5$v2)S^hKDo4(4RpSi?FEu0#e zAzkb016r-C?tns7F}m>^C@L69)CqO$v4$v2tAugPQAQZyO11Z!DD3yY`R}r_C8qb& ze_!klxo4YVQ}&MO6pZB%utO``v=uiV&8Y`uD&V*Fwf2&7x{2BF_GSmjaPn>nqPqcx+YU0iPM~#D`)a{skJw&| zg;=f=Vvz={2k}SuHx^alXTli4z%a5Xx<&>y5O(@p9m5l8d(0hUYTSiYhS9*5E9qz{ z`0mBXqCH|3P|Sj(TOmz6Up;{kioNzvh(g&k$t0-L68|tnkAro#oep zrwlyn3pcXk7l#STey=T=7hV9=!<7I8k;N4uDa`)#UKzWbGl96x zz;--l%0Wk?trKbZye`-GEZzxS&tVEe*@p*o5O$2F3h8G3;DzFK#Euej{AgiON61Dr zS*EvCGS!_il&*>$bj(O}Ywaypsqd!nzXekJH(h0i9g{R=O0BXzFBCb#PJ$2&*A&+0 zMalzwj?7QH732ZYu2Xi|V@I_0n{<6`L{@3)wE2+i13%$_=%sma`@KBmPdBu))6OYwf=H^Xdcb+a*10jKXrX{eGt` z31UU#_sWZmR%A!CN(k+fQ?w$ec!;^E9(+GFByV0i9HS!TjR6v>O|hxZD*1H3#FTQL z^)@Bsf<;iF!L@t}RO5jYEp3O!7}kB)`x2v7w)9x8T)e_}`FXz8=oFM_Oe1!<}ES z$^;!TGz606yyig-*3E^tHnXeRrYB%yTcZqpbZ^W3kJ)@Rujq#A6 zw!cl7M4G>A{2x|~0w;APy)?sol+gQrHOD8YC_?xP$VlQ;3u!5@6DP`KR`6tqFao$5 zqw6rD(1H;#=--JMYA5GCnwKVLxDwc{7L0F9Ae-tV|A7y%=}x}SX!PkX^8l);c4hbI zTe5DTQA$>c>W-&&TvUl6o$FM4-j>=b)qTRBtj7`BaG3t4Bou>vWk^XvOl(YoaYlj8rE!86I<;mzUGVonq5UF z?VwIwCZ$LGkk8<(ILZ41%v@VQ1l^zIay!>J5iu~*_-D@ysOrg!Pxg*ol%1Ag`;SK0 zAHOE{M9vBrP-l72o?e+Z{Cdb7i{&=OQxc!U4Pg=5Az@bx8uxkqt5d-s>oCj_+O0O9 z*8XDx(w%!~TRv~u8BIm$h|DSLszDnMy&}7V01R*Z47Y0`>DI2`5=0i5xMWsZTo4|u z-wD|-Yxd>cHLVeL1}<2<^Uza3E|7e15u3lAe${}=Gy^UR97z$E`xHU}CS-Ove)Vn4 zocWUMFxj;vC6p!^F9=_*MO$tT4})!DIFK&o(g1{kr4QRmm_utF#R^uVERc|^Qx}zp zc||I+6+pBl{D!`rIkArRGAJg@XwP-vP+4{a89J&pXTep|&j@BD&oq7SjCNDYG~Mh0 zB4J$;K%;@@!zX`4EiLd+i=1F76&DDl)w8wz-&R#9&@W|T`44L^BorkMoALul#>zIZ zEkaGlUrupF0e8g8kJ<)Vq%(bOHJs6*8n3J4kN(K+n9?614@+OUZ+7EJ%}woYejW*4 z$4fZQXJ;-<1{lq|Sb~O^VHL+4Kzu83_gaxrgEDz(iu~Sdf~a8yD^sF&p0UlYcdgZJ zup5ou9x`5BbXQyZX#C6)7pdVdvI(dI>wrGorqspK`%6V2v7HwQXyAgLI>}%3OG;s| zZ-`eNsplN@k!8F5GC!%utH&PFuUm?qT?aH3g5vvgORGSQS!G$3P~N9TFw#8r+$rMm zsimRLBt<0IEf8Q&h3Vx9mbtEK6YQtT;Ahb1PeW3%7lYf`gV53V=xt2cdsy9T2jA+K zx34u(2RS4_FX+$-=ky5d_tA%lxfri?hEm(mK(4i(z-fV9{#2y5ZhG zl6G=J$(<9^_g@l4zxih4=jx#Sx#DSyCp=m@^0yo?bM5m~>h+`(ZH)b+IsblJockLf zg9bJu=T!iFyB0%tS4NTnxtR$NxvAOt)1|<85~MN~T+ZsYnyq&m^ckZ7 zB}oInhg;bTu3&6PNeEI#Q-Hq%xZHIFW08&iiO5?hxaHgNxfQ1CZ)(9nQxBQ|2jR`t zNaR5il}w%#KzBPQ?QBmZ4TVP;2p_s@EFm!TLsfFyM#wK_qM?(%lpd+R3f9~Z5e&&t zj>Q@Wc%pM~iXcWaFFPNJ$P)psd|r-iqt87@ukL(?1W-bl3hlAJ@^JHf|`YU zsO@aTJ)W7?5Xz`l+}k|4-k>>CIU2sEVSeI&l!o5Sqh#fVQix5+w^VbRhR6V4?p&%l zz$3=nD5*)db923g36+(IRFE)EEt*RH-7;#2yuVOqMCRR)u4f@$(7>QFj228>HZXJG z9S|rw0qB4+|2=WnR>363$z8Nt_wkD*KW4X?cZqoM?omqK^WAIh7NjV$tzR&)Dq3%5 ziCgT{;JNH`Bbz8em2JMLwl)O%C{uTZmeaT+aAzlIO3Y1~;8;-uT^ktEd>p}`VYbQL zm9Ryxh zu*|>*l-eYy$;|!HA}@#=`xmIqcZha+!Kb_|VXcr;qq-Wp2cD(z z^h=H^+a4B%^d?#sj49d@l-f1Mbi)L4ZqzRHWtw^OMM2PFc6RZCBLi|*A&*-sUK|z7 z0jZkv_=aI_&MVPD5oGCz?|h?`41O{Hy|$O|wXAJ?V_J1l@SKv!m$HWPF>3tF`P01R zn~Q`4yVd4j1}8~k>n18|5^gsC5AbnDbr&EoD~Tuk{s%_7p6>ytQB3fi=g?+q*_xf|4tneF|E4Y$SQYgF_bzt z@2uC2%Hb(F@Php|c_y+HA8S{y+GmmQ-wQlp8WOv|o;q~S%`j%2zw{EXxGMR0S!v^>)CB9 zagnM%4&T2yx~l__^m!ntNM~+H{n$#e#(EF_(kM$~56SWjxAi>F$-O;t;F=J0JBzeL zB={?Cz6hdz+J zyzm%&Xu+`^s>hJCG9!+|iU1h<{)H|Bx2^3^qm+GKI?s1qpAoW_c-W3)DKd#IjLI&X zn&H}0gIsk5|2n1P*pxisM{L2ZRY_$Nl1l%<3>Cp^!cq>RWESiOFpWG=^4Lq78f*oa zmx9eo$h>M=CQ5!?T;LE~uD0hry$Sy5`;Vr3wl?36i|Cc!2z z0onZ6X%!4^4P?Q675Zs@xN{3%gdz~nl=g0;LfSNHQp>BDNF9k=f{}(jBqAuSLa_QV zDcTQ1r0}kfPag?}@U!sg@?ECs*F4=w6-b8|-?LetwUVQd@y zzu_EQ!d`^YxT)1^lic~Vm&+$VhK?PF-SLA-i+h3!xH;Q|q|g6i4eECj;yeW%qkwV$c&n&@DzPI^a&!`q$xvOvB&Dfvu(bYrPRJ`qnP6 zK$JG{)Ttt|3H7Y$j}HYLUIkb|mHQ|a0>G#jt8BN5)MJeR#+&v@e)+xwh>q!~eLJGj zyF5S*&cB_BayQBH3u*S3ki6+mROe}~DHaVqhI#^)$=5{6Jo@G&G*XT#)&f^H-T%Z_ z(PVwDmhNSSyShC^#y0x3DLKbk zpX1v_A4qD)zP>fb+42@ahfs1MdO3vzf&1{N8Gl(wEaKZDd~pGL_u|0;NF zZ{I<%+ZUwAmX3<6Y;slvY)!sAX;*}%aDz(9CZ$Uq9T#yC*|f-SINr&B#T);n4j6j* zc2x?I{Y_F`(2qxx8~J@{_99*gd_p%?vnflu3g*B(CZi(QF`iFM!41)~iFMfKh&ZUAOSv!{nLxvX9J zPKH}|hbo42VDy>LoeIE~e-O#=_5zu{04<32CIA^>dz(obCJ6UvF|caUK_hp-srArV zKk6m~xLIUBa#A>;`J?tE5OidKx8t zK72*PvaKdI) zc<)$^2iH(Ezw6$ro`I%tuC;+$ud7o~I4Sj__^c&x7Bh6Tb78#<{g}!j5c?{|u|%&2 zR8ejHOHZ%pdBY zc%m|E4p)7M@t9hV8QsY^?;Zl{;B4ih=TT;g;itmdFN57M9X`QfDEwm6}kme4LG|pyCNpnxP)Gc1Vi@9uuTj^hJ{m zhb_G0jd${z{Qf(&+z#R#9pU;Xg*ScDTr|UPJdnb06)bf*J!MiI3{)p22*3GD+qav> z!Yp3po}YIiIO}8N(eg{(I8x z%v<)*b(6!--gaDDa0I%v9+D3)pBVdECJJ4e;W?Kr4$?WVTuo4A@C496oXag#&rt!x zo)tOK`6-o?R=GMWhou%>mDt`>Y9zBI9tER$W=|sR<~UZS*FF0iyIu`PZ_mS8sXI0e zQGB-cG?e4W6IBbofT_ihIo(Um7A-Pd2_M{Zj`yTL4U&kR&jwfOzrChBpv(x#t%Sjp z*d{CvV`}%=krHJ&mA}bAp%5K?Q@>evV_D{X2@R`k!3c;8QVBa%>>?yTr>6dl{I|~1`B!HufT6N@qe$rkj1s&Q zqMHoGM(Q71Ry3bLw#K?mJyn@rdjlen6c(1p(hGxYm*K3!Wyk#70kv*T^> z2v4r{RE{`}U0RSA0f#pVQfjHT7_36jS71-4twJzE_HAr6Xzxw|oAVpXH3RXEZc6y zy@*xt*Bp5e(#y;izX7U0C>GPT_dF%V?abck4G7$ZRB1pz)8jYp7O`t&7szz{!FAl_ zrmgNFk}wDO{S8p92dIt7vpA1gP<$5EhGOw=so5CzXTdfT4;0HOHkVkz%-!rxYbF2m zUrQQP@GJPjPhba(RMSSB)-ESfh=a`gc0(T=X_Q*mj_&k~`7U)!EG9*xbS7tmIf=n{ z!&0wwp&P?3^MaycW<0#yfui<8v4t7Dy1Qe`D)^Nn>gn({$Wk?c5e%Vg#EpfQVdQGf zwLLoO2Cm>b0{J1^w-uzU*;Oe3WZt4_^Y(*xNVCw-SD~Njo;n#~#_#X{XeYf7OIgEf zFTV(xV1BeS5D5T=)2Tx+IYB2ncE_Gyz#4Ay2gpfhotj(7&W>XR^~uYbBj>oEdR#{% z^kt#h1a_i~_v2s;9aOW55^wybU$*1=_KU*8y_J1HA?QHs{dEMt!Vg7vouR>;e@SC+ z(RgRZ=sPW-4_k!8PL7NuTS-~iWR|xXr-Htuw42D;OAGBZ>-P}ugS7b_Bpy=nX7hf( z3%=zj{m$NeZWP;+^RvLU)J?<;!rccO;cCtZC_u~+pETU77bk`p?fu}L z^$c&3^UlAjYuh`ffM*y+3}QebO&%irorS2%k2vv!e$6kS`BbQhHeHM0i-J@mVlqP8 zv0JMm;y~GJ!-Lqx$@y&~1>ato6;=IZC!9c0%uPC(xT0hZ1U37-mWpOw6qU|XwObjU z8SLg%JhuO)zn5ZS5kV!tA3)PiEE}|AMK=C;Zx*Aa@fE}wZn|FLQI5+;4WKpw_VmW6 zP~QFKW;FZO*bK9hHhoK*^>SY%qRGM&-2d1KUi43AY4TqRGgh zD{2NPXi;mBR(hYF(*&NC%HdPlepA8wUoB>Bc07r1)vZ~;4Xx~-w5u&eLkJQ4JQEh? zWu%cOuKHx#d-a4pA?C-(c{+JPk`2qR*#C-utqWztwT@@YI}wC_5;B=*2zHu+Q7|7b z6JT*VN}ZpCGnJU~-Srd==#HmQG3GbwWbF=1@fF;H7+A%qd0HFyE8kts{s#;6fkjWY zh@C5OG9XjvRp1rtAV!0OVYAwV<;_zd={RDts+zFse(>&=8s-dJyiidu*i6=X&hj(g zAnMygiUJP`agl!U%MJs^{5&x#C|g<8EZs80HnfNRi*wWyHsKjC)Cq3PvzA4m7z+dU zy4?MHEqTu}*Oz*9HjT%s{&X(}ODvdvJ)2nU2Q}>ois06YGib`bt~}MNu6wD8`9iaw z=L5{HW&HV>Q^W{?zGr-rFvvVA?ywrQpig?-rgroT;*A2{+bkkif?we*1lR$6>ji&V zWQ{|OR)L5Go~#6AZ}NotO>%_z%PLVCwW~)iBkuiH=@Hv)*Hd`4c^sa=P2RcbnoO^f zvhvV)B+Jk= z04-q8{)z%2GtL794}Q30dRgL;o}<4?CFNkZoRqxcjy2yuR2&AE|*TTL52v~mPZ(Poo#8lXAkGNV8KC_BM zUU&Hv_W`%gmn#Qnl8O-mT%-#5Y4Re^Zcx643(FW(Snu{6TW?my;2wJ*M#TwM>ll@h zh&~!+-#(cOj3lOO)lFG=8%C$?1_@Be9A0LinCO`DhH5V(L?07aSs}b)_SOTd*y$Y- z1Ah@I^9ih24|6gX89%O~HSd+FQl?JgRLzw=9)|0b>LJ86i_TKdqpY-Lw|?ei?}m>8 z)NS%+GG8s{XuBr^e7WQ}XdA`MN}EF^%zPVWm7#CSaL*pZ)kcV(qGtGulU|pr`B^mh za!k{BY~>Z}nc8eUAw4q~krwl#&^&-vg6v{pc3J4Tk>$0w6NSDNA}zDtb0bkWG!d>> zZ8_e?l7A$#E2CHIgvT2ME`y}wXR!n#! z`;7hmGgc$FsVi)<)7X@_>A{f2#?`(0bRfJl$0-n0c=jVKhJv;ASap8C+;9z_$HSBQ zf>xIx(!yx|*U5u^Va@+P^z<~#R+LMa1TWdwXKysQ-Nu*&dNU3!HjdwX5ofia03_T+ zh{=DI67h9n-*+g=>09xE&ok!c8X5QTB#+dMz}r|LdNP)9R!u550ZmynyLnfeYYP~r6tGxK_}!T z6TMY@ONKBdJj8I=&Tr( z8iE-RhUd$s#E>PIH7T#u!<5P&%-i=b~BmcVih z$2p%v>%pGiG+}GY*n-yOkDS?v{#J&>4W=kFy8i$GbO#$hm-)jQB$tEb) zKi`U-o4^YDaXv-WgWaY7<#PHoeM=a+03@G0fvZM8n4`tP6Tr@F1`QqIEt#%kl`WiX zB;nM&My&hBvr_Zp zm7Vn4A+wp)AVpP+hJPD*HRDkj)ftFsd|!Id8|?sIQiC9``+NtLx2>uRNp~o6PIsxm zuz8&n`p@^NV*3EFUNMG&|Exqzw|=PI{kGhdC2kAa*uzU$gF;Vg%TE2XuI)~=ffvyu zFI&2im8k#`FEhQr|Lp>!ZWg_u>T2*NO24D4qiZJ)HR4zlf@wF&fW);pmUnaihs!EZ zw`g0!I=1`dz!vYCsB*|g51k{_1e;^cx;C>?S4`h+bBtP{IRD4@c(_&+B_C~$e-G^Pjr;5#FbF0zgMoLICNQ;C9{A>U{bCF z@Uqa6a5u}rVTzp2nIl4`MD?8JhLwBLLc!K5CMGM=m=N>F*3nb;gkD6UHZ3M$LwTkE zZ@Kr+EY?ftHZoq?)fy3R)K@yyqH&2ff|F_yP8H_*`X_dr$$F zD%jZCE-eTy6CGfxruhr6Hzt7~zO`{O=!XL7UvL8~HvmRq$gCvlH<s!B8-~s3zMyOF*{L*oFu)-`2gP2 zQhqx>)%(`cyzB<+uf0KN8Ls0?Nufgsuk*aUO1=~sB0SJ**bA8i?KCF3HS1xp*0=Gn zvHvtyl(NZ$-ZPGnK`RAS396%evUkUb!-cmhN)w3D?Syx7mR(2g;yT2j{{v2|%jKIf zf8jL;qQ{93G+2ug5J>&oR=lXwhJQSi)|1H%@5J;p?Z5YD$0Q5ISq}$`oLX@8*{jn+ z-KQiF1J!GEGvj}Ea6i~xrv|e*cL_ofb8{5A5`pu>(RigMa7Ay0fQL=SV7}YhyaQD- z1<2X{%-vLkF03oVMi+ALS?!?ZL6{1?I`|1Vg^M z(otq}>;Sx#QC)`3ZuX~0_}gPZh^dz>y0>`2eyZ=RdLb1s`(h7J;vt5@T-?u2lIx^SLdqyFsGi9#&&mQ84EnxQNwU`u%>~KLYEi z8HKgI4QB!c`1+H>bAQ3N&~KDdc7%SH(WHPJpGo~T2AhBMT&Hz6qKhDZIp2%U1DjqsD{$6C;-u0F6i@)k;KTx}>syRe zkUcofgtDT_X7bMzlIZLAyYxh!E6c~kP+sbWiNi^T_!1%JlNrBP>&15q8GR zz(QU;=vSwc+=A*=i_@I}cdR-sY#EuVJZoctfqo+a{S@PPzDlJhNPn^KwRT|Qmoi5< zMb!3jSY5DQU~GNqXbVE3wi4pS`4ZH-sb211FDQ2Fq5|hDqb7*P9 zhl`c2L3f?c83Z_VT5(i{9iD?=a{{2<%P@L*@%mTk;3LPHM5SwkTq=*Y7p9@5Bu@Dnm<+GSK(A#;QY%H!Ch5-92B?CS zgl7J9=2W3VsIhk&hj;g~?dwIa3_zD0gtN#_$j=vu;P`T~%MqF_-K@1TOJZ{CL7O?H z0FF!0zaR6qjiu)O@mbB)Yeri!F9PWJRik?75`YY=O9b#Ow6m(_+tt-!G z)GLUWc7_Of$@ZjL&TakylAFG$a_h=lB>MEQKh!lBfuHYqJb_{3=cHl$^}Gp4bOBl8 zLurCih}Yaoy1~`#!9NxL)`DjR?68U3q4ehS7n5G-0OJ>0iXjG=OVp!Qq4YPuEapn) zsLF7FLVuW-?K)^1VqYf!SCSzg0fSeG=j!;sJ^RUKE}3JQ;f#h4M?ZYMh=a$5A8-Mw zqGfk@+I*P7tgXCl=0W>tI6alQ~k@ZuoO3@L#|NWLNvHW02?rQd6!B|)sK?L~0jt;WkADnAZ-{N9lIPCjmB?pF>`MG=HZnBVnM>m9fw9;e(|t;U z>y5bc{D>T92Siz9n{aPy>Q2+q*P=YggDYfu>b*5FJP#7=E2=N;f7Lxb&)P5y8*Muy z({;3{XRMd6xZkWky)QxZ54G0N$d?^79rcieQ49uup>o3Ei<7ckLpG1iWHQQdOVpke zmLi~!to{)q@#HJJU9QGDuauwmAr2beV`acV*oM-8uG0CJT7)e}woqx3&?K%~d7);7 z$Nu7qrg?473in!+BnD(f4hun_-1U6OlQWw&?K>DJfiPl;KKIUC#gl0*@hHH(#R8aC? zBQ6A9qa5{|qbve%-4d4`K}k_qme2Gj`%Te+Ov^Kk+~r5mwjfX zBN>4mn+tosB=|8R4FQESoj;8wX0edps31AZ-em$+m>_CqP0W|th zGTqD17@O3Lbq>epw22I5!ckN9lHga{lI+TbuEWQie`&ViQs>6)1@i9+L(0&TM_`*M z3=_7ldI9wX_b~7>rEXu~(fOavu_gYTSdVjGiX{^Z1XK>?HGo)^Or3ck&cJ?w|Fk;Q zn*2y&f5b?umW!-+N@R%497%)ZXH%cXW0$!JkDYT^WNq8qD4g^;5ZVTD#j+P zPOTXhzz>a?rYT#%o!iY)yEl$;(^)D2=t}0G~)R9e9G|+PoAZs=nuR%tEK(zn- zM)QLb__G!pe=hm-xDhvhIu%0e)H%P8V1aBg!c$4GQ{lIO^D#o`R)bOixc2pwepcV)xpM$p*Zl5bdSmj5 zKC`<%jZ}v4gvw3ZCS_J$AchU$O%QvU{Z{R(XkOv9~!=idl%^8|!J93mE3_mce^fJ!Qj{e!^b`#)v~=0Y^f9*yCM;Hx=+| zwTy@MX#}Sf2RsNwI`Z7(!VM8uzBo;sq)6xaOz$2wO5hUj7$?Bv-$8$TYGP^I1}LbA z;w$oh*#j(g@+U)uz*-JXLo~yInaR+fl)|#MyYbrtBo8dXz|+verksTK+KA8D4h^_wVgyB~9lSV;_*^&-X4mSkWuCX$2$07+ykPK#3G%;CdOS}) zK6}=EtwgXysY=(()a6E7$YC;%sz$Zw@9nnLzwN>LJ7O>wWo=@b4dPZT@&)T`p-U!?WtixQeaj= zXomp5ckHm*Oq2A-Hhpt>$`B`U?ly)ecZ^t7N=aKpVxJPAXptiuAo>^FA5VUws44zQ z>c?1{TQEj0EVdANSjBTP60g{jbCR>drv2ZuM0R8J9;bGXAdG0%bD!8>3^zI`l?U}` zEpVzvw)irl%VX&nyDlBG)($qg_GwF{G{#+aef_kV8OaXiHV&LlGWRYbJ`JUbf#8x` zKi)E3*rHV4J^_c-T8~*VFm^r4HbOHb{uhupX!{Br9RlMIi|k#^h{{W|YjwP&9%o{htZ1Rmt&}v?;ie*XzUUIt zmbMohTFPL<@!qFU=_foHZxDq1;iTLECsg-`-yHdi_8ut(wm zWc>i%41~;S>ACo0r2WbB4)!lB{<||{2tD89YMrEp3Gv$CCROTDg)`*NWQ>+u{j&pv z`-l6g^O`BN!CWvQ7Oj90vMzP*z^p|eJu{*SO?GG+8o`Kwxs-nPx~DGn(f*?l7IGme zW^${nS0CH`C_RUWUh!#8@X%hHR2fq$S#Nzx$0czM%|5I1G9sIy_2$9Ng3ceyDd3mOcuRo# zMh=6KRoefS_E-&hp2S>HSKu#}0xe-1c^Y33uFqT)LG(nAv<>Z8Nwq@OG`%5_6{U4p z-p0`cqeWd}q40Sd0CQ^%6nzZZ3X`Br!xx0*nj+o(^kp#IeGy!=JwWf82*{4KX|TV7 zw$+mSu^-?lc*9ZtaXxg0`LRYgUW?O@9;Cl-SkLUuPE8X%%ip0V^b}qck>WP z_U)pN<@T7J-DxYYX1qeJS}d|bda@i1)BWH-4&-Qrg7Hxv`K|Ge<-k??S}&R|xcPil z;l{b`us4E{Z{?Yu_u451Jq0K5I8K{N0HF*-`q>Y$6dn3DA*Emh2i3%J7H;+yGD`It zC8RFAdPb35p#(|fisU#t0SME~Up6Xw+@=?E4F26=O`gZoLsjE;Nia6Hq*xkhu%=bJsINoE_9*Eb5}yagz4-Yxuhb&qY=`rrdf^-%t{yeZ!MV8w0{?WP8l~gBcZlx@A181G42; zQkiEU7Oy+gSH_4O9uy*r3)S8IOBB9Q?kZC@Znja4q3?cVlIT?b7l4I|$l02M?_9Gg z9qNU>0V(GpNKx=v=8=Xz<)@aO8mU{}US(Ewv;F9)OgpKlP!cGZv*<^W!=0Zh&`3b% zgSp(|nr8;Tie6JgwX;>^R)?G-YEUT1zE&N9xAOeNM+mWIN}Jsue2G*kOI?E2iVb(j zg28@W{`(n6)&wF)^!i0TB3QlHnG+PeX8M7BRh_tP?^<##^nWUQqlQMlfDLkRaUxH$ zC<4p!P{I);i$X190&i}`iCymjgdznz zl`Fyj+~ZZsyYB(AZEgiz3Zh|n5jBr!;S#bLIjfeMQSFz+PW5tbB1}Ax35T4te$-Ur z7s4*waEuL78JV1Dn%i%ln2(gz4%vLo3aRUrz_Cd839EZZUvJ;Z5{{dSsMXa5oH9Gq zzA>oFT%kLHhqNzucJyf%Lyyk&CR|9|U&?`Tap1X7hQgZ+0q3xC;fb~ekwNArVga1M zjYqDsIiT?JO=)wm?sB2p zk7(vUOuFZl`L`RK!7o(B%!)p$j`%}cfR?8$*nV#-$(Z>TjdYCwcIye|*2Yb>vn-a* zNi7As9T$2${{m>UQKu{jc084)$Wyb)w_$T)ArIbAJ2F0Nf14oS>Pbz;te~U5kB}0u zXM-%&% zZfTvn0E}h)>?@8n2!!b>w9B5YzhcgT1~|C6$xW+(th*!<^pd7EvoQnc!SFff6ib&< zz5+h%IO1zIz61+x|&taZ!Ls-x3%oi*C6_fPFKT1u?3QB0CatLZ5CSv;T2;2E!p_fNm*Ikpe zVDo>bPsCZDk{BRMy>w9%oXJO@UGCVsu#{Me7hmRa`mk;gRBo2#X{qc;B?Fo z?5?j-ng8QOu_0oo#tjmxN#9y`Y(-xia-OC%Yf8qZB+0MCnfa{8Z`P0^(MDHpV=S26 zo9Cqa3}ZH6ivR`>n8k_Tlo(y{xqzKA;8s7B+bo+wgCLt(0ymWiFFWv5w09<7e+h3a zvWy8GPBF_jd#%9nVPK0C+fgQIC?0+Xv@46VTh^FvKRkwugQefhGt>^jvzd5J?IgbL z2x4kh3}6^oS!ItE+G(4{hamgQ*QZHI2!3uW)duJgT1VL1!iQ8TZ3TOAI7Qc6_+pL7 zVX+9l64B;y%qyB}qWGQ1W=J{JVScGJ1Q0AGopg^1`@R8WcVG@2pYVgX%2C354E+Yo zm#+^*hk6s;PV+3f$KK55Mpp33A+~&x1Jy@l=(kqGI{L$bW5TGhM9L|xf5_G!jrGE3 zn|K<3o86`+0kx;{Y^`%jQc=*e3#yf#yYe68C^aAKUgw~)uF4K%E*|h8{y~T`o$*R7 za8Qws7SmBt?Q$)HMZ>r+QmX6-xjFtc60{R||6@=r493VXX8Zb=tsD8dKSq-}2$Y#Q zBqFf7+eYDiQallz<-m@Mgn*9`^SE$(_u68}@k?O)8K1SY!N%wYJak%{0X!5U*D?ov z#MJXXTy)7?g-I8wG$V8-OjuB<+?VCLuTIRCyQ&MoVpH<+4b^z&_405ZxPqeVXJr>3 zfAou-FzgCO4qWMcUevOMM<-n1b<)}%+uNNs)q!4^_35iH=^n|23E-XDUD+=wb_1N9`Bg7EV)bgdQ;nlMDK^e_61?Da5?h)HCPSGiXqk(T?H!0b$3S z-<(N)Dbz>0w8Ob1b9Oj=v$ME*cGsZ+37S9gh+{!~M5XByqr!h$AJHx}jWReHZdHt#K%}EvHGc5BPR|oNbu=wxGvON{ULH{>NbZes zUMK+?eK?B^d(I<*_?bv2%-HDd4Gx2x{pCY`=K-O)7B4Nsl7pdY;U-Oqzq=)zKX11& zPmdU1ToBe_xW~7?T<*XuACUA^VaWFNJN|5WhmNh4VH9o2nb}z$=2CsaP@*ToL6*S- z2r5@@5g!gZh%CFv1Voy0H&p3C2&Bi{yt|eQ{w?cy^#`8T{wz$t4S%0|F3J)A&yO!ltW>@sq>rpgy$r*HM)%wvp5M{ z2}ptVot`y7N*>^8T}rvLfthuA(Qu02@r7U2oNE4{oulr75<0;yIPn&bRjJT42Q#oK z5Ps$x{TL}vc@9$E1KsLNnzcD~T3jBbZI_60WsqV0?MdkaGa|hCO#s-KnBiV;eh4^x zs0Kj-dMb$yR205;1Y&n$7YwHIK|A@2_oSz9=$)WNLk8;GB)V6ja!qZ}?i5iAC(+GLcU#BYqmtzB$60!UpRn>Pl1vYTGR7Lgv*V5Mo(2ZU#jxa*Ni8 z&XyWNpM*6)Xi#%fG-_P$050-=m=%Aw9?i-R2N;BH_}28ttbZh5Fyi(a9^GL~Yg^lbA2LcCNS6y!R18hrM;`Hy$iPZSbYmfb5_W7VY2Z(eCKjKwPx z_q{jDuu4=Qts7pywX&sB=0-vwkJxrUkBT%eK8ab?c-2@*4I2?8VrW#fzS{Xj{_6s= zVg7?Fq8D0sOq@jf34ZM98%x}T{$zZ+yxtnMaxwFe#|1(W$ zQkO-XYG;J5bc0mJYB@UhY3rJEdu~*}+_Y%apD;UCAX2fN)AF_rdK#RFq|+upXs0Dc zkzM$H@j|{QL{;E)96pY7m^7)1SZcgsy)$~>7KDm9LRL08b)gnT6#mSC$?^TV;}l*i z4wZCQjVL8P|HUnf4Zs!59ysrwtQJif6?zp^UzR=G(6B?77%Z##$8*Uiy99 zGP@8s=k{{#8JMfXsc+2R;VbxIi8VfW0K8K4A+LXudVN3_j1t7Nf@Bdf6$jUNxS&$q zpAR&Vi-xO<2owz<{Yi>io#ivJ0ULgA4m{o|(H)L$(IG)10NOA*H=9nfnx8wW8bmkY zy(XFpE&WKG-jks%#Nh$jpUv3FUqq?gj}z93;lF9;b@GTQ({ zA5+2ZZGn^ib;=Et82Ea%voV;>ASp+EDFY`BHS;?uYbYRPkjX#T{o$f@2Ky^p;~djE zDs}CzEU(gA+l@0ZfbBe^YiqU4G)+ww$H|$hO}t1S9+8&G-{L<)?;Wq0zNV5;IzuI= zIiY@+0*+!drlHqkMnTLAqJ#^dX`5*satCurFwu<1U0CkLGr{WN6#zuMxW~nMW^0L$m@c}xDWk@2Y;6n0hskHxtd3RvNbf7yrP4;7A>?Pw_HR(DUK@CkumM-J%reIj#ZM8E zxt%7%>aKU3!QdloFaw_v3*xdPYP{f81bqYN!yzhHWKQd4r&osoz`I&q#_r9_hWud- zI!r}?z~TJr1_w-l=D7i0ZKo$;07F2$zd@R6;=W8nU-tQcw6evCxqQ zIRpx+j7cJ>OP+INzG@Gd3PXu(?Mq1^(w2ad^D;V04@YTWIVhGR#c}6BwxJf>Y4n8B zS2u~3=Qg#krq`19Y`R7rSXH}Vz@^Gai%QACJ2W0kzO|V5e_|P^+`q--5uSNFj@wE| z$i?WqJYleC{E!?VbCkow*rdAV@W z&T2WnahYciEVM4(X*e_+ehAAsrc~*#W>r##tqfy2ml^k`{hihR+?$`d3}A0kIyEPB z1lHwY!sPh|h$2t67!oqO8RfII*nsmNV)n$?qS~%@3%Jf0&hM2!Oi?FRlS$#Pk9bqi zyvGUwZtK!tL8hzlTyjQuimmEdnB`%JmU8dsHkL4@@}b!jk;gp6?ip3?w#~&Lxbmgk zTbw}r{BDE`a}-b|oLcag)34OEr;py zlN2LVwS4FO*v!F41#J#vg=R2GCVsbwkhhSg1%0Yu1#Z=%c;4DQ?p&jE6JrKIMk$0Y zoXTuFrLB<`q`s%G5gU0`C{7qzQd;-(k*&N5iO+jz&b+30LeS>4?qJy+q4`A87*yBoz}+3!M_CT)2vbUvz?`(4_^{?vNXt1(&s6vXCK z4&O3NtjTJ^sci4|eHyp<#s46NDvAbz_~H-{YSYaf7!gxnJFR%++k0c6{fLeMMyKQ` zF*VZ_Mjj7Fn2xG}kwD(;zqVE&R=1M(E0N%=MB$y3uPn|&2aa_VVf43ptr4`dZ1ru| zZ=Qlyo>>|D(sg5)eM(OPYWqmSm#zVwPSV!LH z9&5p}H!6n5zEmB904ru0cJFjuc&mqWqvw}M)4NgSa8G9D2y_F$h`R}wg%jy=0JnBR zr$3>!pVJoQ#IGI)SZ#2ir2M0LM5MF!C|Y>h$4P2?Qjo@rQr)G=LCB7vJj)tO|-- z=9MFb*ItXeqB-HeRp3qHz_fi495`utaJE9=?-KkGa?_n-JFR=m+R31C#g!}PBD4e^ zWgxx<&dx9TMfzYqO4TC2D*jTU2}x89_lx>yAK9HSgPkz~0xM1oW{f8;N$6zc-}Bb$ z5!GKKp$-_XmWbBQX?j#zGplFjsocHNhIzH4%i@}I`f2L3QV7^n%B5kvujVwhz4ssJ z>JPLvS+O43Cw-Q5;g$8W;SH+T=&-i@Y~36`D4G+CjEEAcJ=$?F)7U4S-sW{cm{_#_ zN{8zrb5LawNq|w0JE!o3V%F*W|?rel9_2g0El@EEp zBMNn@bS>ZT=aj0tPlcES)?81dKVLv9pV;OCE@9LK(Od|c+(N(SPL$p|vxv7ZO$Jj< zQ6*`W98jW-zL=Zn@TjBlsQ~#KgiWcz&=ig3`hu@!`1JWY#fhUGoEhs#MQt^QzrQ;6 zJ4vdROlB}oXl&ULWdTKpp1!{1q#~*<*&8@2AQief56wa&V$W)=-=y=OW$|!gYVxYC zr&s^^!wE@eBg+DCG7W{N*r?rV?}N{|_qXMQ6|}c`*7psR01MMZ`T{0*t!!LAtCDYF z$8RXeuYdHA39iK>-*7_*H%ZL<6)8Y4(Xa6H!UMYR3r&||ESPh#Mb-;g#-MZrd$K_s zn703wqGv&v$y;E;OFwR_-X%(J5WTh!&}@Vy#%egtCk^uzu01)Q-FMarocZBNgKv53 zflnIzvEZ?O3?F{0Uh%S9OzsY6{Lq%3YO88jI**trB>C&4TXR~Xxtj#b!(8BmamssT z>P)_FsakUc1keZhD_g{^=e(1!0-~hXYB#|H0Y86JjfEryB}(I>FopjI95oGz94Aq&1Z#~EDPX7l_loJp+D z=K_eAWx!#Ypcy)E#xDn&{j@`kw6Z;bXZ{=>lL5S`6kW;!M97#akqCX3y5@4MtTti# zU}aXBa*R`F6HR}iP%{^B%}wV9uR=$5j_EE!lLYPI{9U0WWcM-CjIZ4`>98U# zWWZ2LhW>N9G%6Pn30AL38OI-EIDqH6IpSOP5h;HJIEB=MCInOP8F|rawSOK9PI8Jc zp)Sx%V0^!F$`LqD_)cZQe5?516T+^G>TuXQCtnj?%JW)pG3vE|#HudTB`n`&(TS|i zYUdJQ$~Rsgud~BF7KJs`y;wMv2{?kcTD5x>if0f{sfRXmUxZl1ylb-IyL1-}g17+q zQX8>Wc)w%_0B9RlfdAIgkY%qjxndd6wilrUoA2olE*4yUtPr7!93U!n`h`EsH1W|v zDWgaz1}Vt5b5zvY1sJgWXTA?t4o@yR z>}xbS69HJ4tC<3F1|_8lFH&`OFbg5w-q z|MmYu?4JeGt9KHRImIm<1-IeM%SQ1qQz)ol`(Ts{?E2xlIdTv|4LWE)P};-ZaQzV^ zC<7@=;1Qwo>eU3c@Ddp;-&N(Op-RkIU^5lKhcT?Bq!t7Uv=%xVL)cp{>@V~*sI?bb z3q%n`sHl8_@x3Qejt*0wT&UOIb`e?6$nE#M>+#{uj(aS5Bb5m1xZWx)9cN z>ftf!zFADDlAV>yuKASI9w?r;LV&hZvlR4zy&a=VTdCmj&KSA(HvnE*ocZo%VYNLd5FOu2 zeN=XGLY-M{NZuCbIn+1+zV~T<7+oT24Zy`8(A!n!rQLgR@H7Dn@!R4VoFMR|y z*EM^DAgL$sKrhd~F@B(-zMDk8M`M&gaEFo0qDIhEOoS5QK#!UhKon;qn;P&KABM_3 zU0#|sPD||_bK8(7C{JWWg~yg$lrHh9G{^F^Gc6&ZbCOCYB6cWv`W@fU7Uo1IM8v9l z*-We(`oU@C9V;$JvEiggCqs)oT$THU=Md2@ipE(?rn<+=!G2AQ84d^C&1Twn&P2}h zl!(&PV}7AqB?>VB5_B+T3v>3DX@MxMq>Yu>%~6DNN7IP{2s>DqW|SexKEfG(0LW)V zJZL{PF{T68fPAe+K>R;IUV)jqD7(+gk0#|hqP#)9&`H@mGhhxBP zM$DYbVlRDAdAQ{=9}Y(Z*k0k39ar*c-Ej?5|8CaIQQ)tRaYORr>$U)rLbbjV28h2k zj-X2%URlFW^;&^C*$quM6JvVq^1w}eOtO!&5Lyaotf4A-Op(*s8OXWEHqFpp#uki@ zM|m5py+g8z&CEj$jhC*gx=L6lNO(f%XK}Ji4jp5-%Ck;q(#$Y%EMF_QGwA=FMgBRE z03lc#7OUn~9TrN7INI%&mdftBqFR8TguWnD_{fAMUxz6}-xq)noLoRp_SyRe<5E>% z7Qw$c&`0Jl76LeGV7c8QFn^!74Bef=ZT454`{8FI>u!+Z=3}XQtU`<)p$fAvI`&C8&btjDO&`7Z=7u0|O)x7M}ASNt|?YXl2jVeQ^ za?n<^rlA+#?C+pM>uWEDui9f6+&(;;L7J5kfvr0o!98Im_dB@@1}wQ8B|a<8aSN?P7u8I7Es*)bg6wjP=0t_`2nA~z=}_w=Gfy-Rf(u!m#ZQaH=7iYx z6Rx)0_&d`g%?xF!uyJy=;Eo*xu1N4NJ_{~Vy!j-Mwwz@e+CC#gG=C7E0Yd}eYV`4q zk8N^09C;}({Zh#TeWo0iJeYy>(p^NA(|wBmU*E?YY|?Na}VSt71b=kC72 z|A<-319cgD5=RK*6IzYVMO#&vy>Fww+y`t&C0$MmhJE6t?fO4>ECqbWl{7Vn8?gHnBW*;=?D5bld$ z13ly1KZU*HO9+)tQQ=s;E3o73h)P70ewg`D?$?~zSqAjr@KWktvg zTTWg6iX&f?Jd;D}NV!WWkuZ;YdOU5veA_=|Ch*6x7x;mNQIt#<66rB7T*pC=of{3oRT%|1gPgkn1 z$lchLjPqZ;+lqI>^F?&-?@=RaKgC-uItm@PHF;=gZo zDgN-WLGitTPYLa;U@1FVziwMDN?{G#`IzeVZ%UURlW!#Up`s@J4$(edY5}4>!s|#B zn0OL?uj!E6?^$y>SFbc$#4iSX29rDT6SK>$tM9GRO<2vMUOk>y7QhT9@v;bm(~`3q zV>x(M6A+TH%F~`DB~V1_^+tSzgcRkiT?_jgF&aYUi<;zOg*P|{`3Xh(_Q~;{90GX) zBtNxOgl(Vmr@UzRE|h1Z>q-*nO@9y7+1X(H9%xOBb$gsFwTK7PO3^}d+9~CjEa>Qe zh9xi|h#j_OxW+*AXy3#YNlZn&Pnfy=Fp=Ahif;P)*}r5+lG%PJ@{1%+3;pC2=Df<| z;eE@IkTp}ra2GcZnxHoocW7R*^n*mAAy<^b^VVKMsws#UndU4cq+!v^q7Pp6@~Gqn z&5JDCiJ9|XrLYXX8M(GT*Er+ebHdsTA#-M1K;)|8W(e)nA>o|y#b`y5YjSdcd~~RV z;3iePUL&wX-`?b=C=mGjARx+iVs`YN=12nwR2Wn*ZVVfp0C9r+4C@HAQ;=MSE-At; zg2+MNhVv*3@Cwd39pB3#&}go!yxCD103n6E2w}5YU@~pm1Bu=IexD97i80&5sP4BP-jV*BSwiyOBSi!hN=&tx$j*k@Q zYDeZsCuFF3r?7iJoQMsi3X-O}{FLwCeXUnogrs{*j_!{vfhq#ul*ffTnMig7ZAA=iz5s6aP@Dv9= zZ%R=9oL$M;+iU4luQ&q%gim@OJ2W&EoSxzuu9>#5exUX(OBGoD6Y&x}+|GzhA-Ew$vK%dz?HQz5kU@oV z0cTEH(LLCV$qiqro>`F*Rp~2j$60LJ%iU(e(BLJXG zDdrktYO*T~=RR1bmg!_JTnC6SOv~e-W^MwYxuC&8{e4c4*8tlu(6T_a;DiS)lW6Q{ z*-8VY1|H!&P0eTROka8}8oqW~APh2IC9sz$3`Q)uB-(6sEB52J5PZiErfP$jf(Ux* z<(i{0T&e&DuOL;L&aX2eOYe$fp-HQ$1o-#kp)Dyc zG2M6}VlCp;BQLV*AhjWoCVzrmG*vDRN^3xeGjU)GaUR4Za`cm|5M#EGP?vcY9xP5E zHh>faIq7&z znZAUEK$T-CQ0Y4=($?UB{4P1;PAKTMo^nzvq%Iu=o<;qj@uvg!L!V9|u}hlH!0ly5Iwtr1wvqFjirk%jSeY6b6idz;bV(bUa`7HXkS<>A_G2TKq@8yLWaqtMY zqeomVu~rL**$uujO`~J!G0rU&wX5Y#6DEdXn+>duoqb9ZKqCtM)!YY41!$28su;C` zo?$f%MuO&Zd!ColTTR(7*_Y8mL$*4iZXa-TyZB*}Z&e}u-2!|ry6kcO;smXoIr}I9 z&W(z7{&$Flh}6WEHc(V|J0e#X4Wt2-M~RwTYpj#-K#a8WgilHJIup zJ7J~+{jzLb-4>~)T12pTb8QgrR)t1OERwOqv&&2mUQNF8d_K7KCRp?Q2I8bz=hZe5 zH9cR#YU&m=Ok?1C%IW=9oQD(i9Bp0+l%7kBTG$DP;dg~QCl(6G0DeFd< zrbCNnV6gK-BzwIEc694aK6|N)%G~{Fa;N&sRX+GH*DqWenE=jTM_Pi1wRf%toxva7OV8}3=#+#-$JL{YP!iV0L?^C-c;$~X;9Pm_1 z2a-1?l}Fr+J%|fJU{WL@QdBYm%C&^{W$A4>Ue#~V>TJI64=YykzzEm;5xp_P!G18^ zYmVp5QX0T@ZECndNm~#MFsUA%R zbWQE_tY5RzfW5Lj`Ze26ZK6@HDW22Fv<-vR1;BIXKNWmg1^}?<($4pcfqoH>2UVDt zK9K61I}y(uo;gYIyRR%zMz;R#y9tuAFFXTX$(#<)fjeGk(bs0G5eQW97<5D^)Y zSuF%eILl@i{u>M1OZ|yFl?%&;)U#7;rDh}|; za@zo7BignXoq-G;Jj?a4#y4Cbde#AcHY3<3%LzA4gb>W5Y0nNra!A{DRvZ^gBAzE< zuT!dI zW%x}n+TDZ5W|^2Q8o7{f`q9obml{%#hdVExN~NIX*Ma)MGgr^iWkw~Yn#M$HH1bP{ z-o(n$+QxZD8%^w0J(Ik?aUuAcdA@Q`AnY?g<1*zq&9T4J{kiD7~+hHvEIxD*d-2Y~dE(|TuD-{B{$71SnE76-w4;2KpK z63owe`YhdSj^Mcfu)iasQ(_ExqZ_v?V(D^K@xrehdR_z{&~f(SU!2>(R0zh0-E(#{mz^1Rb*UZLq&FLP5;N*6 z!%PRD(=zlgoSi@FvLptL5rg}@LleMHO~kkckXu0jjxn0Vp}g-A7ccJ%Q#iYM(Iyt` zdk6Ysv?}FCIgiV2(J2{!H+9WtO0_I|5uBh&w;wu5LS-5PNf7>PN@7VA;#-A>PpwEO|_Fqj7AJ2-(caCPQoz}K9|!=KJ0t|#(rl!T!rP^~($yY$7zt&ok&eAjBO2FpR(@Q%QEg~Lq$j)yMSs&M5aH_N0#licmI`?kipC$aTW+>cx;c5Isq-{RH-AEKZe=?-svHNx5#O4pocIMsjKCo`lL4O)m-}$@@s`k4jTpnGn`RRXquj#M zbWeLaVy#_{Uyy7L2tt zZbDEsSowhyO}DBNEo1ZWNYH)K9=<>&qPWRm3gL4 zNb&&fpp3~%Il`C)Oh8x+W&5IQ^hRS%r_h;oXxA9ASgLs!WkTThs7FK?3h7$r!w;vc zQRw3by=wThn#om_g*Zv`-v7V;CHFxej&$jlvHAmLxVLEqh8 zkKSmo{0)EP9_eUdL(8Djxwyhq2K}!9VHTS5U(|ck0+^CVbT%q)n=G3fq71Mh$Ir2t zM|y$boljCrOX8nn7lzR7o81{*1sU-8CPviEOAis49=tT5*vr}LHBNE0!x%oiE<^cXZOwy_-yk%4aOiBVE=zvcN{i;D& z_(ZzPEPMyA<&#JW)M>Fvok{Zr&1R934!xtCkiC=?Q6|8{Vm;`i1mk=)L7H}J(IgVJ z{|3D3&zzGfSM^6=oRL3kQ|Y z+W0fWkS#Ezk=0uC{SNrC1+0x`KobJ0~U_UY;=|A}4 z2pdi8rhJ|^xRR19f5iDqSnD37XddGvikvqrwe|%>6W<_OAjrb;FS7+fvi?a9p>Ccm zbE{)ct4emKfzSC@nNf_MTx!vhVyCzwiv+-q5sf>IUx&?39Zb;s=qARPhL8%_S}9(e z+O%|4C2O?q0*Bh4$q~C*yy12#C)CWF+;LD14ZBq%8jMZPAVJIe_|z*eyXLhi3`q=y z36^3m6-0>SA77f(5Xgy`La8;Gj=rXK3(Fh~&rLU0CPP>^pK6P=7M5jr=cBG{leL$b zr`=HdAoMyDd|SjR@A4AD=(ZV~+s!v!Di!hY(LMHPT&ahVe|T#0YV=<0)kz?4?yOOV zz;M8mO+xFsi}ar5^0wtCbUSq(YScJjC8txO-}p{>N{_wVj2l}n5VrV&Rn%XbSqJi| zA25qNnudHnZ_O;i=<`zr8%0V#t%NG$?UO^^3AxWuuj=SGSytDF0#+>bLBEotj-Fk9 z#}xJ)pgP*J7+L_FVj39?S&~~WSiq`tn2v%Bv-6f`{>m@>{+Cu<$Wuu_t!mML8yHUc zEu>527_5X|MI>-m28JC3dv3v)!bL(~-mS*^ox7537RL+0#PrrcZ}wMr_T=P=#V#ZV z@oJlUp3SD#1F`HN-hO)$OQAD`IRIhdVN$D*8U07>(^(9**a*-;YhSfX1l6$jSyUJj z;P}d=Xv>dVFJUv%dFKJJ0-&UCpatG)m?q|$3@-ktVTTNlXj-W_u6F#U*|26KxKvp9W)npel4;x5@LFbX8SLZe$1Bt-Oi#YI4F^Ief}oMpGHPVYtL zAY2^%AY#;6EK7Z#;L*{BT_ijm_x;E*5;h1q@sRhMT_3!yT2~|ysDVMwpCE{$!{gZz z2_Oq!42UXm5OZ#L!W2b@F?Ur3&N}Ra#-|tG0i}7+OiMY@;U+iaNDxR;U|iBw0KDDL zN5qm`IdYy-L#MJJ*sm#<_=~$_=HklepAx+qBTtO(yhZtETj7L9)>6USd-o>xX)}Kg z9q{dt1Kwj;Er01PoYb;VX0=!EM>wn!(#_1+W$#S(N~99Ds6hO!1Wk`_MdYOC(ht#E zCkOE0sBO1;xsM{pqLmO8aB5|)o}9B4KMT~hr8i+7A=+m&P^yn|JeFM-IERfo<14{h zJOkF8=WR9EHcbHYV35{i%LyL#|Ki4sMZ-LKT zIt->}Qk=vv&Kfd4PK`+|Nf`@UekhWAr}8ds>lc7J6z*~@Ge+nP1r`-3dWjn1bkI9m z9ya`dHqDuF&%p>M4#4-7ly?oAu+pWQMIgr1>CpLDFDk+_Kdes<>V!NR0uAATF)NGy z>PLMsSCl3$4=uh06=d~PjDrC`D|qXvZ^O3HTnd}8aw-l%RASxNP+f09ofIBSC8YiI z#j{?JO6?CD0B(uJpP6K$d6cR>F=C<3dCwa;=U_4=zKIm)E|~fP z4misw*y!*^8#bANg_Eh)+$)t#w|W80N+o4v1RdtP+sfQ3NQZV~QEnOBy{_U+jF2EM zqRYm?G2`(%hwj~tb?dF1=ZOJ8WNzFm1Zgr=ays2q&mHEgC*9NBR2Ep>+AH}ES)&9i zR5B#4_*8&TQS9?+lHRmTW}%?<4R_MFZOY;HeX*}Rda?RSr0;g1gXDh(%^x5oK*)gQs(A?fNU(h4GkDIDk*QQhhKigAhlBKKm7;Y+8D5GJ(na$WZVV(+re@Axcz%cp?TN_Gt z^bi|o+ga33a+`wU51GLw=y?=9yO8;9!gX{SCc_5Bz<_A^099i2)~vDTB&NXi7}M%Z zxM0C!)PxiLO-R5m25B(^i{Ju?B_qPLW;4{URtaM0jh=9V&EnD*f@Pw2sPMj0b7UbB z4!>YXOVkiB;Hj=W&gYBm6?*>ho4NY9jdtq%fJRFk#b3ur=YB!!=NxrCl=blfxE%8LGCU^A{eNP~oz z=RyM8vqReNOSEK+b)yYIk=NlgURb941FHjw2g4HOaWDZ#>h9g6CYTX=onq#cAuxg{ z;o`-~LgR&3t|xEs!H#Jof@yMY*f4zIWfVQp4qsfe7Kaf6YXQ}fgdXb68h`FW1sUx4 zk~E_XE=IQfZzfcZ&oB@zhpZ0zh}E0i-Vi++!3}?J;Mk_k?`Dzv!7CC_k6xiHOm@de zE#NIK57bO1>Dy!9v+Hv3fq2d{O(sMKt=VP|_L`@8WAatnCfSOwVeqRZ<+i(#O)kHz zMbja6oX+JR%mn_t(Feyxl?%FiC1toF81{kj$pnbofO=f}K{ChWJRr%sSv9p~v7<+< zTYz~lYKh5EWX?Q?KKex2zfh&+iL$A)X#X72Y}>XX9t_n}?SPPs|6`xGHXM#T2J_d$ z_L5#Y{g4Sg@`W|)5z}Z8aSq)kLdL@ju&y_EcoaXXnv6h#Epye;aE582LP1YPYq^d` zjeLDInwdqKeNwYH<`-}&43KdFo}$o(XU{_4kyh(^>{Djjp#^whK%_y#C`K1Z;Xmap zk)FKhe+u|`T@&!?Q@$9x1^21*DE0H7S}2Rc*e2V!Ek?X%C6LH@Bo^)CEylu5g>Kn7 zCiM3epQ2@}7Y!RuL;PF)ZWvp1StL}RkRN}m>tOK?NBwRh9=DM`fts^Ea(Jag*9E>=5+Yaf$SkTLo7ZaU`j@Vs_I<*Z?-Hg!8hqdcpvMfPQi%hyc@hIyKv> zvM_4oGrPgD(AH_3aGUknuxLiyOcZNu26FF2W`jC`USUFx4;fiyyM6<62mMX(<)H4z z_C)l|_@y{fFQ{+!qz&=gMT^~uH8IQW6{EE66rb4GWtvJ?w770~V1h3}Yxm6c8QszS_5T_ad=(#Mv zY}|;tcL*hlyo`2mE_KdaP^=HmK*<-)=!v}`g_RYkX~2pEtM-+)5gjCgj8B7NVvTu& z1>uTGSy(^Ru>Futm+p)LLkvr7F+(0HfU{k`N&MCSHMRG*&;cd0$8b)M)B`b~TUy5| z!~=&Jw+pq0%tL5K5Y}K$nVYBl0MYctIlL#+Poqu;Z}-d(${R_`UiN4TZoKVSfQ>7p z(c|H3jw0nre?py8I*$pLON*1S+Te{sVIF0Vioz*R%=mW{NW(-ErjR|)GS6cVLLy9W%x4eTM%7>rsB4~hz5+Fe z@GK(Dao2mSL5=_~4cT=TT-pT+@k#3spt)8Rpk0(jn7$8Wb}6Lzz#bO=RKjOK`JK<# zqiN_w7cjFQ$WGxSD`m#PePtwXpk@CGfdOombALG6F(;ZmtuFVho#@!Gkf&oSu=SY> zWDOk}Lh^_HSbrRg*V+k=hIjz-6{``jZ8bTR3$6C2W!BtJo31`5hZ340YQE<29~8x^ z;!%;_9bT1Hr3TNCHgEP66JCmiH-9_N@blxq0U(YZfPI+Dpvz=LX1QA0_iR91p&Lyu zNY9f&kM%x8L#iq5{Hd+=)VmVM%xjFADQ*rFCd=}r?w%qTw2M_w?M-P^H*sPm8ZJ4@ zI|zX@dg3QCN8CwJg7!e7>(|91@sVg~I#b(!zi<}Cvlj;ncfN{Lm0#EdBS(B+$8%Al zk$(NHFr4Jm6t$k@6~wc~q4ni+mBZlp>n?D=P{P31);93ZQ#~um~aN=uSy6#_mwhxPxz4RCE}>St8r`WPyL*vdr~XHR0NSapba5`Pa7 zB3{TaikVTO){Jx6WasW>W0I~+nwf;Qw8tScd>4O^M)a&f`Y4xx%nNq&!@Hwi)32yA z36M8dR)!E8oRgmp(ckIC57WI$v@hXo&gX-<0u?v#EHG=q- z3!3%C7~}xf;z!yL_`uBO(8&yCnKUs(n_RJL-b^1NbR_R?7<`*!r~%W=N$?>4mr@xR z-1~YTUWirkfa-a+)gt!HE8i9?^A0{oS)? zPkcLJs+embFjsf{4BlXYLzL}OMhra3t>aEKpf2SYV;XH(+P z;x0e!xNJ_=uOBjs=1?u)@yt)4o5(Yq8iW$S@W8FeEj>#?)P#9Gi(VokNvS%$(aLgO>B_zA zi0EKrzyI5xQSwH9G{KWBkH0oJn=;_Xz z{6n)^a!x4Z03+@>yCoM+>m#%>EC>R1h5pmr~|@UsWD!s3=P_jpqwn zT;ON2!I5dTh_p4g-gVwQ$z;!Xo-mgk@3oCV^5t6aHT0eHV+cq&zB<2aa=rTct~$4| z+XVoPT%BgduYzZe0Qtc#n32VctEa?y4tb<*{!8(?$v*9xng{d*T~La;9g>-efk=Q} z`<>FH`Tij;rrOj#SNVqFFCp@coFF`X!9xSoOTco1J|7ObfY0w~pxhx&=<`68q3F&n z)U>H}-){}oP!=90gO2W|h`W4j#bJDpj=6lXE%qyc$wsIG9x@$8JsW?oIrIX&V6Rt~ z(3~TVdC0o_zQ=B#=3Ctf;iptrXA{zB$!j&hupd)fw=tB#?Awd1!sfL3Jgkj8A2vnU zo25b7)ZGBaNzkpd^r(kMF$-x(cD{zg|OKjhVFs&Da|apI7JQ<`I6~ z7(%N!;c`sYvFcv%=K}AY?XRDWx#7sJ3XuL|$T4)_dsjnm4vH`^)r45fBSwx)d1~g#bo{9?b+~Nyy3SYetO#kCZ2Vr&!`K!|D~+ zV#&;H5^4Fd9)?HqV{-`uQV**BNPL`xPvo}}UsrqVo@JcY0RHFP3OdDWTgg9SHu?SW6eRL1e@K*XzV213z# zjK9=L;(D58C)|xO7zG!uVsG`on`AnzuKV(b(~=vfvp?8ijOU*d&lMDNEpKQ*TV8yf z3zuE*SCbL1{@Tg)D{X;=^B)bOScH_9^SqLrqV3=<1TL7#`(z9e4+EqD+w`FR00B6fEH>`6h<)3u!=yVk8+oMqPb27wTv+C}fmkDrG4rM&JkeTe6?Sdd~=lHHBc zw%(HMNSPk>XX%`8(;jfdxj~lk(RYo&tC`j_j_hkf{O84L!&$_v1>e6=_koVe>Q^1< zq5VixKH;m^8I#)uwAdhx_A1$it6}XawUkXU1JLN}ZyjMXdCKl__yl3*v%{4#^`#QW zAt!XNQwZfr7yt|_Ov+U79_tE*@xGCG9}x{bb0bAVxS?2j6AiV7X1Gg7+gz-6G^sLH(}U(XJSRWT~-a##~fWQBJ6J)xJLX9AP;D`XYb;L zF30FVx~rg!MMFFqL5grxFb)Qq#RiT1r3ZzG(mrSq?~&zBMvYf_IKK3_(FYF`pJ50f z{pQ!Q#|L`pAmRze{&4TzU*`yyauc#YM+Nq1xvrM2zLgos$268>N2)O zJiPKgLBd3-6-0}^-!bmNZSqm2^TbCF8`rUc54!`2lD&)_B*FQvO3YEwl>fftM-^jB zz+Zi|Qkf)aW2@Hg-aJHvZ_8-5>FO~m*~^uCkKN00gK@{fRjSBy??%i*vh{`cVINRE z_Xc@jqzLRqU&%C&$$wugLLm3RUH~OKxNIa0P1%FHS!3=MNX-wXg-r5f!GA0Z6M*7; zV&;04W|R`D;&ncfgZ@E0E0&~?Te!~6e3uiDFAQdp#~cj)^3^`R9udJ6{NkSJ<@@c! znB8wk(WLSFCVqj4YKE}i1+&YUv54s5LI?CX{+YN01w>n}LgBzAIvZd1L|r9z6CPqE z(3+jaU&qej?gU>}uq<}V6CGHp$5u~Y1WBKl5BG5_UrcFhRpmHkfv}lk!4a7U@^l*b zoaO>kBdNe!V^=7|W@k|i$*4j*8U%-g!d8cPZY*HeHBBWym{G8-MKcBx+o<`fKL`k4 z?Be7IW^M9lQ0Zery0ivEe2X3$k%s11m-1aRlinzrwaAFdWD#&nK0n7Ka;D&t$$%-! zUf7Oh&E(|n(n9^oWwVkJzP&s&w+g8g4uP75)!)5KZ!Id0T5~}CM)%CNKSZk99dK?U ztzib=j{TS*&?ql!P8`aI9GEdPj%3hBz9_*IZcLvjT+vK0#AXbyS$M{3C(?rBh>LyS z`p>f@M)s|U7)-j+3xOsFj-q-{CMC2krXZRvyK8?xXgNM5XoZi{rG2x87~WCdGX_lm zFD$A6=j$_sUurw?yVc8n>DSBkL(FThp1eNNT~Wt&59NRURmMqk_twRxF^LVi27e(e z;2_(1*(t&O0P0WJ{W()%A^{*#8!s}j9<3+jP}I8h&~u8HsbeG|JrJ1=|3g(EsTCu@HF7}&boWnLbw`eWHjsUqPsJ%4 zP;0-+CgK}+fkPHt^jL4CRImU9T!9`~!y?9a)W<^oIKth<%X zF;yps4`MzFpD3n*XL`?Tw3x^NU^yj~zD`2Cs#wMZCG(z)TO|}B23OD&GDObRv=%PW z!10s!ZT)dBCVEzT*~@lY<4w3_m2D zkyCaQ5!&1Ic3HfO|cHN=dyI0oTd%Gjt|c{4scSQo|BF z2qYKfoa6$~W`7|kJ9#_L2#$)7dB&+5D%t}Sd#u5>FJg^)teHTPC&2d)#F|AI-?q~Y z9!0>aUimT$ca2)f5g9XlG4_1JXy0NDgZyVuHBR1KM2iP^t*qF52Y4nL`lP2zHOQW= zOHcd}G3x}d?$#qWI`V#kKjt%_X5r3l1JR@%~hwbSwU z!aEF~Fa;MqKx$oHx{g`=yY#?Af6BPyV>}KZd?pU0&c9c13gFfNT>8G`Qm zO~8$l_O|gI&E4M1;t#|q?u_2|cPbULge<;299*8b|I9j)tbBu{X1(NY*9x+r4RqVx z6*>(DVTw-w>OF?G`;bCJk<2X2i88?Wv)tDc?09BB< zmSmCet~#fx>UW1MAX&*3?^v|y*q$jHSq;H<02Q zyG{qGs*StE0?+sb;;g~eIkHorhqaair!hmpez26(B2{;3MkFW6cCDTr*jnso5)uRk0a=$l6PQZJA8S(o1e|gfPFw9uGXtRcd(?YX zaMs|1LUB7x>P|xgFtw}5+VWK{02D$nJ^fh)RdB=F8upna-;nEGjcFfi|cD-95 zfpb1aKuj@OF?4&pV;w)q4QJ$#+56wD6t}iey1zLZF$FCL_%&Iu3C`=U5+pgEVn^b+ z4iyhFGhtL8DIfC3!#L~V03lOd6w!O$5!a0wi@U+z+!l_($W?czH0S=>%;z~7EmOipE z&B~kywnZkI+Ewb_IvG^YnT@=_$m-iNk7OB|Ae^9D6D>A5(Wx6 z8E~&JI^rPHZq*DCk6ZH49G|@1;J57N$eW}~R$@ ze6*031jv}vCM1ID%VUDhIoL-#xB8-J$%<2DyNUVQf^Ye2Oy+GUb-syHj~9V7^v_=(c;y0sy!g0C|N*ze247I2N9f-`}s>8?X!1dITVQfJ8c zq^_9!luG4_$>uK1lb$_<1dCU#Hk2zlA_|RlfwV&qH`~+iwxo~F^d`Z*^8eayt8hcE z#y(~pYbzzxX-em@C9r9&uP$UOsu~kHRmtd4Y|+|ew|vClc(fiejz%#tbamev*}k$n zP-(EzkVJ=c4uv}5WRpF0OFID=iBpA4pid(t60)2JpS_gW)TQpOQ}5%tX(x_@x>+^& zpl$F-TQ6QiRK7s9m-q*%KX_gqF`L#i@;ZhK+=n(bJO!%$kL=!Ql}XfModFg5oLDEj z%+U#((6aB>0|N&53T|=S(=w0dP{Zrz287+BS_wVxLWgtWXEAZ@`SPpaS+(bfv>|&)ooU zgOY_JfnxAOH_q@J76_6Kj=KA_kMsY=$Wp%CPO{pKf^7vco~ysM?*r^HE1_#|M}1!|TWk5hF^D z6n2hpD>xC~9aDnk5q0^{jXv1O9n(m!PQ)=p_eFVQuo=e=j8IUWSU$O?KBn7$p7M{b zYiR4p%$^gIna2}DE4zY@u(R6ND&gAkiDyvCh$y} zrw4i~)=MXS1N**UGrVXYtT<=+Mt@71A)7sJE9qOj;W#X`gaS*#{8M*HBv(6u@}nU< zX>-sOF(qCC1~8NOlaz+EQ(oAHqwrFxd#8F)2kX@3fsXxL2uY=4 zOPQGf!`OgFun?RTegMs8$G&s079#Gd(Q!jzzz6!x=Xr3v8akk)Kkao2kMQ&qp!&Or z^*L5&uqfv6yi3;AC|NSNFA=OLv`AwmneO@jx{+KBXJH%%zHFj8aR-&qhefT#mC<5m zmsXfw%)3OcsUc4(23+gdP7o6pSb6F}!RcJj3N!0&7bWT!x`6eB@xgd2tJ}1g{Mmvr z)-1~kdh7m%RK|gmDWY-=h^J{s%<$18CNtUP-^ljh@RNU_9C{CByb4AB7>Al}DdEn3 z9xFA3Ob_Wv-~Lqkq!vzwjHXLql9c!TNuG3U0%YiiH_K~=WK<3UhlOdv3pg=m?p zA&byh-EC`wzR=%jF{JyLSLj!eIYryaj>JQWtw=}FS}U(-!%0;{2sw~W{6EU{iX?3B zlYl{tH+!6 zN2o1~+FTHd$^gZ%XXmt^Ei{Z?LNF(ut7P5LW(fRf)S?}r|K%M$Ul_w-v*+^BouiG@J+`df{+xS_d=vWmhP#I#DpmtrGnp{`_dsS z)x5hKwc`ZpVTLz7iU?%72a-Hwg1T>40L^eyiW2e!A5-C3!3kSm^_6A*)<|4`Co+iv zfGtG1*y`|@jMX80UaJ7i5>tw4NevfRY2(p-!Y<_f3Y!GDo%)?i6SRGEhKewcDUqf|Z*%Cx#7@&_z%zrr_*ZOW)1T#0S{vAO^kKaXjI9L7&1)|d@WQQ(?*a|zUC3g4o}1)zP@+d16xRSfg>|tjL&;{oqQH=#5sBz zU{U!zjvs^eGe`hw=UwG_`x2e)+Mj64;FcCEjL`K6EO~0=i{_!ui_>YFL@SK#$AhDA zET5#-fyR6InpP*)Q|E5=|NUtFWO1=yA!oZ-&Fkg!d7GsadzT@mZP6If6p%>WFb>bj zM#4XTzcd;+n}L6`FZ*{urFA5FF|)@GUXlf{0ab{qTpjbXqFWgXPB1N1_pK$d5PQOGoY z-FSp1na8*p8RlzFIrw=dgCg58aa4b%R|`!>ZbWl#xA{7HE)?Qna3hBtQ> zPYDOMjarK&jFw5ZZRx>NDFu72%H7AzdtS{st8z}z|H63z%C~MAPm_kZ8k9AN#=|v@ zX<@Jb;N&3=DP7m&(9MQkGQQgE_8RcFUIo33_@NHt>qTTHHIlei-T(fX$ac=NCOqaI zVb~|;c(7mEAY!{b=YyA4XRPS5BtvtRsLkVU9bSLXa~Vw*$#&eW$jcLAv5<87nhnH+ zkuA9GRz6dyjxP#62df%m=J0-CAOjml9d(FlFQgd)94bb5izW&!Me005wdDdr_9+xr@gm|y zDN7^$cKdrDVut2?ffCsugLrIaF8S_`);lPm;^|G}Mk?#@Uas{U>S4$A>NO`?uaHm3 zlUB|w^`y>sy0Rp~(X{Ar9J~kW3WD1`%g@Wy`z$;{#;0o8IT?Naa@b`a*Gc%){~L1j zc}(E9?`2MgtFXUV;xa8=@M(U1qm1G;q|E9E?YcQp&{lPz<>EE@vgHeq|3+iHmd0jq z5>U>Ab(%C&bMx688NY43Y1}>ZfXsNCv9#R4*^J6ElqFkCKMTWiETe&=_`RllKq<5f z(Wz9|_tuZDM(3-0{=dSAGdi2>#BkB_GY(SBPWG3Y65$->vKQ%?-g+;v}o^?R!EnUZQ)HjNOO66`Zp! z#XlTXri!&~9$UKZchot}{w&M=UJk|YPU*+AqvuSpWs6&Gh7x+=1jmI&IMly%9%le{ zGm{pDEtmykLB>j8?Wfohy>m?bu4~*Ok1taa`bK_U_jn z{JlNM&AZAIp<$*lv?<@6c@}?va3rp5i|=ohr<-o$4R*>GD5gvKEKAlMDU!f3HN+co zV7BaX4J<-tu}Eej%;Hb_KWH00X2@(!4zWxQ6?!sYJOso#sh)q8?=|~fu5!J;;yUPr zE`)K5hUoH}K;8pC*pUoq0NJr&1|Krnoet@>6nT(hyM65;F#q|og;#_~%7xkPm(9YE zncV@bA{^l13kP2ferwmW6LGzZEon}pff+=|N5%LQJ(Ym+3sYlww>2o1pG2lMYwSp^ zh|5oMc}Bm<52@C@Of|2#Mz&FRr}GrN_cBVXj@T}?XMAt-1&XPpDJ0|V(gpfyML+I5 zSEcf9-CnZOylY&Qo|vW{4EnTtpF#6nT}PTlS;Mba;PUYE(r>u*JZ8ZAH-EQlE`|8}VAeNFYA z@FGJ;QXnI|2dS+M1@1v_x^RP2vUOqOMvUJH66=UwAuB#Z!6`ud;1B<|;xWxe5+p=D z;BQK6FtJMnM5K3W)Yl8*Zb#Dl>9TNxf0~@?G?;~|=(%>c09DI{#3_ahG!D#5|2#&`%c)O}BJ4N7?jwryvQD!}>nI9R^Kpot~;1yzp+fwckFq9LG`@XwF zPYjql9ol2aqr|ujwq``e^xW8=ak8?bck!bm^iY;_T5kO-U|k47(?XZ;hGS;XUd7y2 zIv9j`<}mlLiqqOf?5OHcP{6aFY7qoWi=C5r~ZC8CK*TdgsY^NxKxX`1(9unBe$Wx`vZbK&LBos3*-Avu+O^8bn6PYuM&%TIxx2VPo=L(RUM{XY@T5(1X9NY!IZzyw z1v6&QU=5}}+0hmAs2JE0@^I77;0}2*mPy27`}FCQEGzSh zg-oC0hd-{a>heJ4`|2GzW1*4|wdxQEbXky+z!6eeIG(zZ$%^X^%>&u5D8jQ6uS70B z1G)kr-!iyre4TQrmv5r4v-F(+kMIv(6a9}!$$Ai0Qj!B~5OtE)89htylT3PO`P z_o}LLN5TS2C0Y@njlKqXcQPBEU@+UvF2)!7Ubs<`02~*bkldFnQ zbxXV@RH`(D|C#R_ zuQIN`8+%plzA(f5cdJYFXg=rOm`%(=OdJ7MM-J^RMzlzOaj(2ar9-zF&pOHOcq8a~ zxhEMZmcz?&V#C$B4U1|=jyH$lMS#^1&PxDa4fLiqrgR*_+0L+-28x;jQCG2D;fAd| zVxeNt{-aKE99jhHwDV}y@;o_^`BE4V0>ySSNYCB`$666Y18e{-@L?7b_JCoue|!oB zu}~PKFV*p*!?BA(+=GS#B`sp;!(^>ekkUpUz@*n96Spv56Ifzna2rzgZyO(vW=Pby zfe+?=st53kp{KdZoG?VD1lV}0YPfbw_sdzmM8X7EvFWN+g_fwv3-*vFetz4mD@wbM z96SBD6*Gimi$pg8ykX%loW?qVIenV*f8*I@2^*-%^&}GrCbEXYarz(o-BG>5#M;+F zKp~h5bKr zmG48LT=ssz=WLK29@12^#i9wta$k=V;>J`O9T*|-d(^x(Xb@Dxn$aV@qcp+$=ZD5OlP~@Hw?hZt>RI(Cd#sW_ki0|+&mc1LwlCcX+B9{19tg7y`qJALs$l?i9QDm#!Pf6mK5+fO?>D%x{G}iAkw9Jc4o?1hj~OK z7YOG3BiZ~as692$e#Jm8@;`CWSbV{Ns(g+klN%yJK0L@)OJhu99ms-&?eI?I<>;B} zTuWN7lRk}2NyzyYx_C(fGDlJFLKs)0>9Pf^3dQuDtFk3>{lUSCPys_TmeE$hqv>Pa zQG!b!4+|gT-dY?v&lG`PE!GX4JYI#myHL&Lj60uX@D32d%QiP@-=Fa0^$FSg(wFrw zrebGnEalaDq1@~)CPot1$UqhU$MDRhN;T35vCfg5k81VPq}iprZ6T5t_nC^BCeHcI3H@l8f>jWjp~viA=C(*;uMO7c5rg8lMvSSLtb+_LIC5#9 z%1?t|*;X^DCH(`Td2XbOAKQRI4H`IbGqSduVYlH1IT%|$<_V|HUhA;QK^OB>2~T52 z>NTnoi1JUjJy(L@ScB-l0VhI^o1@Q0-uyEu1*)%Rc&(W%ic5hCGZS9s&?RjUH4m|q zE(b&xNB=E_#>Rq64bx6gC}LZi`asLG1Kp2)r#kpem)mjveW%oTbYi64X1*G?+>2Tc#w6P@kd^erx z=CJuFjm}Wx&Ac%ndAgUYArf9_bLAnC6I(blRQpma1Uv?MCse`BRx{V?DT=L13bm8Y z@&J-^Kl;IMZ$_-&P~wD%UXdIh)eJ*S3-7kAv)g?^ZV^}F3D_`ag%|NOJL(&CKgz0* zeRCY~_H{n2qJR%Y88p#6g%dx=bRFS>^iCHsLU@!&(Z9_()&cCXub8Q;p^2WeZ?BV0 zz;jaPCmBH{r4Otcl`DDJ8f%Y1kc~cg#9^GOhTA1C$mp7*l1^&iI7H*u=FRo8HqkQY zJYmlDqs4N*7^-LRr->QbFUT6}2GfodJLQbCOFB%{?lAj3)ZlvTB-7 zfK`R4#)_Q)=Zq-&(|W^Pe(@q(YJd{F#j33iDrCa5zmLep7Ijx++L1-T3w!Te;CAR1 znGE*lSmnD4rb+p^Xc6*Orc&?emB@FIT-iZ#NKZlTmi=Ia{Zu}WXQT`~8f>?g}T43=iL7cU|VMWM2}G(*+;+?O>k&Cj+&r|Jn*TGw2-NOw1J^{4~VI zBgmifz&V!M1;2jgn)AgwX05Gy`;qljcR&Y456CmZsdRD7I_90=I`O=z!VTLmmGdT{k;GF3m#{O_9o3L>Zjj;_+cTgHGc48=r>w| zVG=yID?PqRX#@FIbpt#r>XrU{%V<=8@ zP)+6vq|F0ae-jmLj-kf6MDUISTvP>K*B{i-Y4-`Kr^h~zoX*X7 zwMH6Y$@hpN@NMPb0x9tnlH%GhxW5gl4K~(yE;GCo#mf{AG1iiMvr(O^X^VAq;UFRy z$Aybu4t()?cGLIUS{U0r%{eR~PJ~*;u4Rtt3`JaGzK4*yeX(7R zjKbvyi$WF^T2?{lK35Ng#S@5b(#k1sX26{PB_kYM&Ap(B^KGcWMM5ZBA{CwZN^0?= z_z9MT*2>*%@0gG!&o>;e$7&l=2>-snl}YnhL5UBJv$?V4$V8SS$fnRzx&LkBh*Ylj zdZ(A$M~r7HjCr_`;XVgT-F<`J$%KzF_{koZ?{_w2oxtXI&!r3mV#$lS?ME|`7J+L} z;!;23@xo#@?ICC;u0I83x`B1qQnq6E&w2(%yuNovCC!1R*=>uA3eLo+Yj{fn_aO@h zB|8fdAet%TYz226ie$N=UGEh|U!B9~z8X1#ouj#8`Mk541o{A5T6~J707d2{?i?zi z3&b01B}@=HGdGQX=>D%sC}KKM#U6WK$jKCr6~58W41zD|mLcRhRSrS=c}Kl1-zf zZ5epA5xxVCbi}oI+0S{~vb6a+*i5(QjIo@1u~!$HF-kvzyR}(~H$RuUesc+b=Bj&q zpt0JcLUoIN0oHXygm;}+If7{!KJHAS`MU58pYi&H6>)mfsq!I+mqfINQ5?;d}MfPo2_&{J$S~@#iJ8LRn~^9G)vUP7ZI% zy@gRCqUBnp&i~b6>L@yN=)5SiK}Xh0XE_%(4C2|Q!OK&J<9@uyLpwX%kB%L0Cc=m$uNBE=hs$Nt}(Z&c54u*~4skS&s;_Dc} zRHtm*4ZoxNI6H;6O1{5TwfTsNFFc-g=)-k%YKViTyI|L}Fpr|#Hu$N3Dw=6>`;gL$ z>(Vry9LiXgq*gk>sOB(T{fkp-DA=A`>9V@DFg==%zMzD9sKAiF3-f4MQdo|1gitOP zqeuU}*i2A6MPtI64P621LO?;L@Er}p|8?VlyOdMTCI5D(xk$l-Wb-fn^b=j=z{wv< zV4l63DFN?MPF=Jmx{4|C()`G!@(2W8`HZn6U1ey)H zs*v6y6It$ljuj`*#bei-o)D8r_V0!5;H@T!5d3{T%aP1KG~aoNv=Xb!aV&JJIC)TN zoY9ZK+L=zx0J>xc5q!Q4p9UbZBtyzj>`}{(6{J-byVD(~Lf4F) z`?&cx!Clo%qjdTw;xO;Tn&^u=Aj?3(DC68{UA@21y#wzbA8OPlue0X)?$m!8sA=>~ z=u>vv&Ll6ZdLeumO_7tG!#>G(y>t;>=v?NVDCfKPx-jBu1FL=h$5rGF-fqiSr9Hvb zIrUX-l2pN(SkGR%Z^F2UGyeT7&gF_pKL69B0##~OLR2q3%8(B2BHtE>y|ry1O~cwpd-GyEIpRgddLeT1bK@?cLf z?U%{@X!LyaX$1OLkTuTFdF_hBk#^dXkrf1-px)h05Id@2-P45uzW>DDL`fJ_sRO6! zCp#5+{5~4fl_#9=_Cc=;(=1eyCb8;lpuhR-GZRiiK@+wgsaP@uMN|4}x^oGbp-FPQ zxTc`hA@)~;90f2WMIU2xV?@-msH|%&7k@Sg_c{w_W8AL z#5+#?@|Vas{{QRO%0YxIB+d0(Iz)UsCn>;NX$(@!7j6`|zUl%pyRd7oU?1(~JZvaW zr08!d!HrIl{#d^W;{8{}dQyPnoYLx;w39=LYq#B?CK^n`RajQ~&#G!0K6dMcP&QL6 zTlEmY4-4!D2_!{#>G_U;U@qdvi&j3-13Aon#BDn20q~}*S%aDlss?tTdtr!a)jUIJ z)|i7w0XAE$$*R|1K#EEg)=$F|lFv1^`2zCoLfpej0XG}KC^fhz9?gWPiL2ceZ}i-0 z9_RyRb%v&_JXSo3m&u-Q20E5Vqv>K-yxA|!aMF12wyI~q^thN#VGn)q(qyz!Y^hM54&+~H7 zG`~5n)iUN&){JW=_~*6J6F>kRNec)}-9rK01{em>m?LJ85q8}noW4hNV0!Ha{bw`! zi`?tL8AjK+fxJ2WraUjQ3y;?BX_Ys&E(rm+ohtpUE&Ge6FmsDV zv2e`rcyb#tg`|IxUMWXs2YsAA4@94Sfdb$n271;hCx0WYH+qrDUl-fnz!^~oGcW_d zG=>*L>x@G^`rm>05IH~C9(x8>AY~s=jM6!k&WX+9*z9pdv~*DGpgfgQbvxwc0?6-l|_aTu6wwuePmjWI{RO z&6Khm{P}ZgfX3DonD^4nw9Ks^q+RwuqIc$2La(uNx0MJe$q88FP9$M%K~%t*z4 zE1`3pw{*Yc(Kbt-Vjwco0|=cvFBicR8+uX|sh)RWUoZgOGw+V}>AW92x?1{8%AwN^ z=DqwNCk5&$n_zG*@DUVfU&B-R=EOCrJP>-+GWpu7zifGQ5E9{GdQSdj9xd$t(Uvsx z^*GXbHv-YTYzsc(`lvgLUnVcC2fd&$B<6h4S-rDqtyeL-$a3I~wtC`#J!IEYRVK08?zRJmn<~HdI_Yb6?0@Yz+3> zp7z+0pL@4y~x27mND5`bWL%I6yk2d(I0ZT?9ApvxxK_wqWYrHzJ=I%@y(Rl zKi|hbw+4mu)(DabNiGox(!TExjX4M6jk&ug!r;%pCEmG|Atn|BA0!#%m7=#!9cy}a z46&x1F1_3u4$VnGTV?1XOlEc+1Pa|`^bs!jbfhA+r1mrh{B0GJ*tkQLq!0uD<3Ees z1)+3$<6W;aa0@zkLmoA=ahKxWhJ{}h(;Vw|PA174IHVuS#7q%~0F#`o(=0QTmyTfp zScidv?BGff7U9Bqc&CofL+Pc9SAD5cVn%>MFAAx5Lm%01#FpLP*-ByHnPbsg4ya$= zGjhXQH)+5b|5*W2C{kEGp;1KL53QuS-TX!9R2}bD-c(6 z$b8>Zbs8&gli}CQBDKM%{@wR~JG=Ha6ozw`LzTb%E{_@h61tuL@ zb&bEOy(3-x$mj$GV7op4Aw?G3+waS;zgcb)V&p}av0LT2hz~Yz+PmrGw{B- zFaQqQu3P63v-|BwXyqD-plgeGmOO@RgPKsh_9e8R!JBQAppP!-$DUB%uGXYbmNRcu zeOCy>?F!SuTEv)j_ ztO5^3esN8K#;ZFVu#tL$&8p}rtDllm3*pWPGn6B+Pf5R-eW?;wd6cz7Jfqj5Wam~P zr1ww|rmaVd7FXVj#LOxZ#ck)c1AlZFSyK4%tT1u0Qbc{uYReGBIxh=DceVbZs2lxs z8i=~fjGY`G`U}7lq$m);)Lk@*5_U1;(l4{VAeB#@7e2~J45{*?iq_v&AUiltB6?c_O6XB$y{33Ugt8TZ?QA!CotN_JUlIY$VWERt8 z+G}fKi<;(n_rwsoXao&;12?F&wl<$c{$2Cal$TC^^f5>9cXdLP3CKAVf!UFpEtblR zLOx0c8Hms~vcxau#|si0I5QM9G_7j5$z9bs`ae59eGySLV}ic-SM^1b9$6#^r5TeS|Ap*sM6OhC4QgIylH-h? zPn(``D?rM7))xQYI47gXy69FX6%jA#XA8Bg4}3O_4;G1o%s7WOTEddx(g>3nbG}C^ z#0gCmO2!jG|3TFL#*#{&w1nsw4wU63*zE&5bNdx)!7!R?8^q1;8TCIqOkd`bV* zgl7S0ibKZYvxEr-|N|J&aP; z(9cN&rs^y|{idj+xBHFqdf5(wfM71+4n=Z3)GL%F!)z^G`f?L^2EAh9JDx;H#_)p| zV(VuwM;gJjT(vmu_~Am=dK3XrFJ4UB8e2(A>UBkvBQ_&MeY2s~0rh{@X{a9C$}B0r zgCq5H`B{0kqDKuFW7A&ILu(R7^R(ZWwS{)L6ps2aaMCRTGhGXSPKKg*sR`c(AN81K zG}Ap(Vj%`sq4$r-)P_6CHAj=8_)+lWWux{_N6{LN;-KPOA-uS7 zr3`T;GX{c7Pe>fK7yGbB3EO`Mif$q0E1@yY1yHtosn@COfkB!~0K$knED(`5wvM&1 zzfJ$Om7M$ZP1JkyupcI;wCQ(JTp-3VddB%1Cq5ZdD@G_d0Sn1%vHwje0hC+>8nMdC zfZcrs)vX8}04hzD2ClpKumz`mgrKZn2D3 zu&R}XIkVLjff4k&dm7^M!-N3&zpH_TX8yt|El0n{bVXm)hG_UuWmF*l#bo_aAPM={ z35)>apigM?AGmkq*-aLgJF+Jw7|`i_MZ=Jqbx9W&Ioh1r+w&gRy_mfTRt zy-WQP7Fz&b0i7Av!j;m^0cLji2fB5O+F1ZX7PmoS7=rm#22&SPkf5jLOkGFZ&{$!G z5b_k`5sjHfJweRU!i9Qy)#e_kDW8}7V3@%?FS~q%#WE6|#Ey`oVanP{7U;vR;l4|K zUp$MpvfFW;PTy!rZdQ@Mk44-jNpu+;gI{%UF@m1&>S+aBx-)alL65}ZTI5on}y zhYaz6})qR6+*`YU&Oi}RiJYF7G@M#JP1;Y;9G)6pU&?f5IhG9p0aeLJp5eiun{HAe^ID0M=Nut1kh(~(v|d6(6dbT_ zEhv$_t;8j>H0xnTDzUlRbeA?P(n{SH+DQ;&e8NLnKb3hwT{^ zTG{DavKE<@jL?c}S*~GTd7_$NNRZP<+rd$R_}Ax>%TM<9)ECgw!;OXPv=Kt2L<>~h1I zgB_bsZ0BJ{;ECc>D-)aZGICUI`_u+6fWnMcH#tjQW}O(V4%_7gAbHbE%Ed(}rNM$|(eC%#*XIvK93wiku7JEZJm>3mncb&uiT|=S zSMIF1MI0bwG^{`Nn#%N+Ia@zHUa|P24Jp}f_S|Y{d~TPDGz2VQ(!UR^nRnw~iv%49 z{KaXr#NjhenX_f`O&cb8fRYaTfU|U134V(SV?CB!si8cou_-P7k&NKhx5_w(<3+D< zik`*$3(+hmI3A;1k*WA0BrW}mSSUN%vQlY+dMT&#__w;Pu9CKEil;|R>;*fOXQKE+ zxVs`|Dsr?Bdzp=syT6XbD#Q%-O1#61j7uV_|CmW7O&Og= zYlj7jei*z3+rHT{H93*^+aD2d2Nn!r2kN)*2ekfD$DzbITu*^c2%r6A{(ep>wULdi zF%_YZlwpQ zb+76`QgZ_AO|~{VfnQ%mTm&6%q4Y*0zyA@*(YMd`(deqrt^~ylI(ait%B< z7LRZ18>Yh2I7(2Ps)=~Nq>#M1w_jJR9J(xAq}m+rk`wIfU3fuC8EsYD%vZxyLqcGL z)iS%fHn`ay111k`_zrLTGg*$N+~f+#ktoOwhlEwOo26kJLKe-b$mGfbOHykAJeazi zAhvyF$Sb@&D|D>zUgo)q&Lb#CwSBA$?tT%8;dre6G%)@n3L)Ex8$TMpAvk31 zj!DIui0`M?!RirEH+VFx5n%pFDy7An5=SBwE}vzD$J4@Yx7Z!%0GO16ewI``-*8D+ zS!8P`)yRCs?Ik?&Puc_Y{W|--Mrlj!$?$Yzg~h9!LVJ^Gy-rb}))8lVgeaSwx7xUJ zxp;N_0&Mk0PtC3c07XE$zr|@-S@%t$;rm0moywjM1KQL7m=26@q%YZKuomUR35)Dp zheUlSnt@wk|4w9(r|X+B1UJX6n}JYhTu}dHg=?Pygz9)pq(P>>Tf`e#bCh8>FV+iY zfLv?3f0C{TcPS}3&ow4@cui~8`FF_BvM4URIz#K7RCbii1QYK%GDjnF%*Td*XsO@dxJ;Ogk0EV4M*LMWF)IytEoo1YOCjQecHm@4<5clWT{mI{gCD&~;t* ze0a%!E(O@A710$jY*NgaxBohUM$r`!6Rw~01zm;f%jBx1@VP{C=kuu-4sGvd{8JYMg)PW5&#`grQ6x+`EE|i0A4|57X4Ses)4dT9+jX6 zbu_*?-CMuwVikb5gJb0jMewJC!cf;QLr0t=pvf@JK|$w5To#Y#>7rna^S{vjsLFH$ z{?ZuLYY66dcM1Jw1Z=L37#x8pflNfIeqi?eAP`Bdq=a*+0Xz}~b*TDnLEfRfR>F9fa_8V%Q;#n;fDC2;|Cn7iJi_EHeKW^l47JLUGWdAT3La#Ti zj=fNQ2emTS{rQGV1cUwM;*T5&p%iE~0Z^6P0>}19q=y6as z#?)q!~_lI9dGyHG|)I{YEn=8DZ+wOOCt+KMSW zPCpOa^gw17>oQxQ991c~gb8Bg!sf3=AQB!3YQJ5yDPgR*2A65v*Ryc@kQo{1pb_8f zcK+s5lO;<@!@O}!KKX?hDq+)Sk#D>th?`iBgfCXiDb+O!uHihSBg&&9<~rpiGA=Z;2u706}5#uXxz zDt555P53OV3S;Do9O8$IGr^gQI+-WCFDx}N?-pb*Gh{Jq|Cb{c=6cu;KJ$spIK0ZH zBxQJXn~`b2#~zHAU_ni$7c|q+MUrBxb`DX65yIB{uCB6SEvTbTIfI{>$EA#uRl#@1 zCE#2Qxf`jo;Z2}f9oiF`R}~R4pO+cqcJy9>7#&9yowFjFK&$6^V7ea<&1~6K--}-% zcYIo`2wmh?ygsS>+GnT8G4^x_uze-S!(M2#@SS5}J0zQFfo1AQr)a2_%4A2L^fB}Y zmGI@t_wUVfIL*`nsl(z-9t|UsV;%I~*Pzi30N)|Vs)hrFsyPp`rDz9}-|=6xO*?h! zm9#7Lb5T?L{)X>gng}n0NZt4V_t$zW5ocV_#*ZUY!TTf?n_F1&A z>92Fud^429zL_&aE7fE1VrQClTXY&931LctoB4>)taB^NI znOOJ6CXTtdE7j;qj^%3OeZ$ewnT+Y1X#}ckTCI19)Z6KfJnZy(&AXo8&#aioLqUga z!4R&tHjv6>V7alE)KlPISELZFhlrnX$qrq3ssLh+ ztOxiT7M#0j+VYu>#i5+W-N(0)@>7)Q5yYn}IH+7pNpU&p%b+{5FP{SDs$7SG$WSct zs6KZv@1?irSsPSz=VZz>c^xG4cIJxZ5UZNnN$|In51gl8ZG0)2Xei~~xdCOu!mizL zENt6Z(s2y|m2yW{p%C%m`02F>3bM#X?k+UsE_`7Mf2vF{$w)7!HWMn7kns2)HXXl- zAKj4iU7x=fRNs8t7YGgFUX_P%L-W6jqC)4(}1V^v+j)wCUkb)5(RFfY=)h z%I-~B51<%S$(Kksq$5HI(U}X$t1C4X%*w#Wvozt;Tqn9O38tM;RK%k%oUTB?ntz4A zUsdF77Tr>xB3h*`sY6P=;FdprH>3z~cG{uvT=ZN)H`6*~^F?-a!r`CZZTc5(QTd*J z`m&+w>N)SIl9{yTJ=sKTgPu7k%8<@EM_kaUJwnHG3mt5 zTSHcL(i!wD`WzH;C~cxuyCvCD7b|DtWJl1YVEE9_UjHP9_l#*L!j%Va92*wz+DZ)f<9PL%HAcrr+`DJ+`tUG>PuM+{9C8I6fLqGzhie*R zUYb7IuN6#k`5a|j_tnBAW0e7u_aKLRxH#Xlnovl;5zlq?-m$2SS|eFaV>nfBNZ24Q z4Ah8=E7~5YX3nUQ=;okf=--_i;CaP~D{vOzTK~T)niy2l`FO?iN#)mKQmr}8`_7ViG1P8F0fJ> znfc}c&OYN`)oI%o zegYvxAoASh^(Vh@`c6m0$aEz&xti*Zbt97DN6n?;p*9^1p-blD>QDl zIG81@{klj5`7>3^K+z~ia7bVfLaO_IC@)=#P z6jb$hpeIkP111bYqU1EPPQ@o&(tKcv6=RZ%a92WGT?JJf{v-0Tv3Sri2bGfH_6Pib^v z6zz#?Wkg(x?O-al?N?hW6BJ*SjY~JV7TCR$<+G{hDvrBMGTt<*bZ8RA+`x`&JtkXJ zqwwwfHXV8;VnBFtl9{dorO)?V%u?V14<7S2c9#sJy2|*j7qAQxu-uR0JZP#|ns2WF zUeY--2OSQ{GF47He?y(?YzaF~by~ZxA<=GgMscjbO)z_a7G$7}8Xlyi^GmP#9h@z} zC5teyE64B6QBBbTI==?>caj35R6fM%2yhr3T9l6fE8%N~1*_$0Q+!Ik2LF86W(}y( zA+IbVS{D{*FKk#9h9Rf#B&IvxYTV~a)+QJ&?S%XAMPw9Pdp+aPD$^sZ?KTI8-s(tVUk216z zkk*({)Sv>bA@advq8ejLb4?7njx#iWfB_I9AmoSc;~gNXgv5QT!}E_UZv7@~s-bJ- zwnG=kTfBkhSbTpeFhPx-eR-Ng?5&aJj&4jHff49T)TbrwxqdDq*ZcTewLSOl!H#nM z7@$t8cX>CGH(Far-H@&vQS_&jIK$*ZF>}H2_VaKuWiNrvsy;&-`MJLoajbb9#qX#n z__dR*{Y=Re45hvi<}sgFj>YKzcz4&fX1==9OVYUD==h%)(d`hL{+K@}5C*tRz+#UD zaB43xtK_iuqJFHvzgc5kVyFF9BB^NocCSNm9X|FVBuJUUrPw4yW9{m&SMtzlkqpJD zu>GfrP>>9~Nv>cyEPH}sRKeCv0i17}#)NO|kap*&%Cs>`qie}*h~_g0h?y;+7g$n% z$EjMQxF{r<_ZA0-J;r|h`OC$jgWO&=-gIX@QFg6Z*Y6(K(O5{HYIfydBxdk43YPI* z50o|CBW%#z2MHW$(qss^2F+&KE&Z?=e2xB=Icpnl4|J$~DlvLtx1NbZ0 z5l(F-%139}pNGpjGB|sdl%XNv?^TdX`0Uw;r!(huM;T5j5EMkBj5BHFSsohdtlNq; zrxBTjgU8Tt77GH(9mO(@umz-0RV_+6XMv;L8^0$T71ScC5A9ze%#$(IOr>LY$YftNGKW-ZrDD~M~n<~4`8%%#fd)&RrV+VD?!?&v`V${6w)L%)HGkg zZ(D0QZGeh`qm%mEbvFo}bA04J>S`h1bBY~R=f+wbL9F&aeJGl2My-ku#LkElpMIM@XT|FsT@sfx5nF9R-Dw2+v1k%qWXQU`i`*@HD~7GwJU^}$O*bE2F(f>S^zDkfd)v#=YDFNH=3CMO5F;m0|y4b ztByp3%;PH7+!?j`!Z>v5SazGCL{DN6h+giu6CPvU#2P3b$Xj3ny_)y~9(|i^GE9mZf?IgZY!hku?u_ zRP08nsz4pA#Z7Iwcm}}D?Bo#Rn5*4`cU@>CV*WzXfCa3(_;v&*7R=47|2H?vNh*sT z!Xgt&`Db+%gR#aiE_ZBcs02*uA<<3>3#(jWEHOG^`wwKh&1>Gk4oc=&?w>5eo7n;O z&NI9tV4>McTk}$;Es!)+Nm4ik$jkcwx7hGLO}zOFEvI&Z zo!rhSDaqD@#OQ0`4)*#}xvYE^o}Abjo6OUDnt!nbV=O1ZYh*@?+X2_T<#45}1`f5W zR)S|iNEjNK<|8w~LwQ-?O}DDJ7n*z%OTo)lD?pkA!U4w-GWp5DMIPw*V~!o^Jg3JG8mXI~ic>uxf>CbIbI zfRC3(ot{~jhuZp<7?2OGdLfO_;CWOcUX@t&63d7YwBvkwnh)2ZSLy%t4AhyD(>pe( znDa67xLU|`yK4;1f74O6zu}GZbm224u~(HYg??W#FPld@yhU8|-j`p^*lR{Nf=@>{ z469xf$M{fK9i=Oo+e2-6#D99$qRizYjm4RjXf$FT)f>kM^?t|ydqa@k#kgM{55W1@ z%a5&)>}Xn0Ylg4(OJ#vZ&4^3A-^M?3!{# zd2as|uMFfO60qO1YFeVt_!KfXQ0YF+vo~T~$&;8A&2I%_*=9!Y*$YDWxw`y}Dc0lN z=F2e>gA8t|)3oOBZe>3xMNnQ&1Rj&tAnT zn+VVi3h!iRSgkYC!^9%HU&x+FIUqo}n!n3INw&_){6#NHi}s;E7d6@wxoTD%hro6G zOK#4X>-O-HRbyd#7TA&fwiG|zIPQ$o6o6ot_BwM5zt}~xmhGN{=vtar+wX>v4;F5N ztGpQtw^5`VWfOnzGv4L=GKx(`HaNsAbe<|EaMyo0O7eg;z?Xm?GL^*1`p+!=t;y-J zql5(l^huowI0>HEdz{krtPl)mDL$_QRt0f>1B@3U-Xqx#Z8!JLJfbMvAZp;v_-@4e z<;(z<*)!H8758KO8Xd!cOa$#2Ejs*A^^AI}(gj^sJXqbSwa>mgX@4*pFIA@(oi+kP zIQ8c5@BwN<&pdLWq*YfgK5=S^XGe`Tm*u;&E zU*-Qa3apZ|>%3ok|_cEHcy&v>rC+X|_Ue%{Gt=UP8y+?DN!(66W3Ij2zvjPPXfrv{pH8 z`Rjw()g{IMoKSJfR_x4Xb)akE4rbZF+(tuKySdfj*1OA(C*t9dUm!NxjU4kPxNCxVlA13wvF?Mes)Ii{F+~mQ zTSuPSXij8Y1m_!E+bP>zJFU@4iCwu<>8at?;2gc+NAh>ded|LfWVLk6crl2 z1LGP2e~c695G<@|z(i{}KcEHv9C2^aYtrI+V24#uq*QM4ScQ6>GpC)ok*LBaA(xX^nbNHi6T zS;{JIPbA=wB&R2l3f;Lw~i{5-=P?y6 zILpR3T>A5dilsT;4Bpp*>oE%4i)Ir8l73e5iT={MK278uQ0j^xNAp&x4>m5mnw*aL z{{b;du;&?uhe0X_kbtg&KajiV6wk%1J^T`^fRrFM?@wZ)Z+J3_yEa6A^WU-cqqM)O zeTq;DK$Cfr?h~domS{*=49AB7(qD;)IHMS1Kh0!0-IJuG zo)h5r`le%)hCl+rC0)p*h1#YiwCco!kMqea;H1!(D(ekg-Cs@r8cvQX=|b;diay6! zNMA{i_1^!PU%=TWP5c%vM|=Cjp7{hP= zeSsHm4#aSK&5lfQoh^TVm3=s;NVby;s^FG>e1w&TaFhivC8!7oICS$(B>cCV((Gz;N)}J&4oRYGKubaM$iGll^Dg3CQ%Rd6i|4k~b`0rZe(JQGUto;q~AYkB(E_cM2U{0sl}zS~#FlVB04h{JVh- ziBk2N!x{cCE_!O-p@Y#6_m# zjeC030s%wlnXYeOx zU?m1(&X^;}_|_ss?m=1VElNSbIumu^q3p)s;l~K-Z3aP+^0NA;^Qqyv z#g2y;Gud0U-}`gkoeyWSP>48c!UL)()+%|f z^9JN2CY^oLZYQN`_WR|Kv^(F<=NF>e#pLJRDf9Z&ttIXs$%CnAi=GvkDpoJYrQc?^ zdaU{Zvr1j-P{IK$o;kU5K_D@2mH`a1xl;xs8PS$tsvan~46s-s*RjrjXtXpTU(}|g zUrZI`e2>XFB?A$fq@Bu*hQ?1GhevFAQsazjCOkl>6lvSTwO@@2CIHe4qk`i5p)1{8 zyg{(Lt^z}`b!`8kvr=<(OXm1zbPbju3J&jXNjRgmY_$>vGg(?weo>NyM2;;`HGo)Q z_MybkGQeGg6C*+wfJQYV%pZ=#nG=-xJDu8q0&$o)3LIjE;{{Tp@YnAjbgIw|-l64L zh0Yb-Gf)3Z#WLLX+HD4=e-LKAcF~Yt9`G{!Z~KaOiSuyZMm*D)zTi!kIcd^tO{0t` z8SpbXVig&P1Ru3^QSN%&Mv_39IDniW;=#Lgm#2(VcHL)OTM2&IUvDHix1~&M5!YQqa!Z_(XxGRzrn=a5?y~aS_?I_tD{+bnSj5E-!53%p< zl5*VZrXPy}Etp5f+QLUms0k#cY{F4B-jOvc^GJ6&#)Z=HPbSZB(;UD?{qm*?wfY=V zB~0aHRq1>YXWCl&<@co)Mo5Xg6Lhf8+dk6QKjyvo1@ZTb*JNN4!fQ4N`bz$Q)>NM| z3rTI$v?tNB{ytrxN!kyqD;isOWeftHN!PKx|Cqk-B>C%!DXmuBne<=Kj*KokiW{_} zKvv(79nOsh%hSIt4_8BUXuKY<*e)&;3+ovITHIS!G4^E$-=&EPOe^Kb@Fa=g)__|t z4CI#&EN5fHMrUG-GWZAz+mda?Bb)E+0$#OCgK&c({^E24+hcC2rj$_SUJvwtf`P4!aAF&or z`cHH(uUNDmN*WJXOT#C(nqkRi&Y?iW#3BO3nUEO;V{lf%c#{`e@mZ)<=(i|*OS2ix zps4&3It-W+m#K6gA)Hzj>+O;zBCx46s}+dmw!*gp0Bkf+@?ZeoHz4H4U^*Y#_8iHT!#uLLM#vsT&zW0uyjsfQ^*n27z@s;>LhS{~i%l0}$9k{` zX(E|sv1Y&x$%9ZvgENiDkgVr2kU2rkEHpj`6~F}umN*9i_1pyy?nr9U}6GoD6-&sL3jg={1gfq>tA!&oMtFj9@YF`j^H`dPbZb zM2e+oNG`#E4_nSWG^bweOe56E(QR~bv}G#%7&9vAYfFyEME&e4UH_LV*7=LUF<<&vEE=Q-_#phOc>7X(c2wdR`L>3UvM~F6k z!^O@jPh;p}QQ$=_zwBG{&P}`P1hXf-UemQo(em)GuQif{vY>j2_pjo`(EuzbX8C>0 z&2?I>scDcR$e>gJ*5%q*>0qx_p!!npEoqe*WbnUsU*zlAky{ibN+baa9%3t5dEnlJUOv;sk&zazfbwUX({@O`40&XGY z*YlphaLaZ^dPJ&E&$#n!q3q|58C6nD&L4SBY2<~U&mlmM4 zskK4%4LL1)QgN7t6w$C%M)Y`kV>(E6)|jS+K=BrE6(S8 zMJ!fRR+E0Z7;s)CvH74n+4^PDZD5_xToYIZch^*zNbdJ?f(2GmZix6J`h-QRZ61tl zktYmh(4v>KV&J75G;S7`4rHrjVVimrgF3%xKY&4PYYr` zO&ZSDl4Z)??!Ig{jp)xNnZ%LvVzn!GhAcRHay&XCh$CLCWji%|zsE!zuCUEV$G{`& z1p$zAlyO27rpbcH66ZE~)9Q~dZf+?bSJmj#))|@m!>UT#W+r|DKu;%M)ZzRr7!|FL zLAR{w7p)Vq1PS|{%#=hEoWId`dUVCTnH$R@Dl0ZOL~kUgDbh{0t9H8+Wxm_1*%BES zo*ZZ-KG=f8#hIwNJ*1`&NOIxwO!pX0-a5tPKIszShBN+B&)H}M@Ou&tJ6$lg&{#}u ziAXzS4X_Y}f`z$2vM!`YkL1WEmYdRP&opQO%=Ak!JV9fg2q@r?o~wgY1xU~d=z<2Y7(>~vPEewg$q;5+ zd$whzqW9G+CG}ol%1s%lh;yvS?+FP|N7pKRGQ$5=b@9$g=#ivm!^UOh0kDRK4%K1g z1+P^KvS_7nh~K8vh}@2FTOTKUC~5kYif>+^njt(BU>AEQ4u?n!i~WG5Xhk_@Cs6Z= zzUG^45{iKNkMf@9&spQLH&ImJXia6d-IiHOZ%Rl{YQtJ3nWN=pIEUt&QRX=9jZThY ziR>-F2%*9KMPm*kE+0SFb^Fa?NvPA3WWP&o>53zvQtG_u#52e?M0$j3vbSvH^!`Jm zc(pJ%-a;kV0~W8R&PIMs3|Y)On2PX>7N{R19C$;$5{%WyhaQ)CyR>kSxBtog+P@Wu zD+hW&eqf9spLTG7L}(Z{hUGxM;uG(&ehT5k-=z>nXQ5}(Zh#y|d-R;m-=X$}f-fE# zH3F1C@w6aqFCzzphip?H&hxZkBI?D{;EnBf9zm{kIr|LtUf#5TqvAcZZGnN zaRV{0l7(MEq}qaCse8ZcDj%sBhPMu{O%i*0B5GM48FLCMiiL8hjE= zDw>;2o#)wI12};FgwOHA-T>LVPhLm+P>JpV?l#*UY^1tlnSy%=nH=)EK_-50_d zHy2bm)#tO7^(H_29h30l27>*|pE+=2)VY@7TuMsEgNo=|Qyi!ZVTw{tRlm*czHeXA zy1WCVS1=B~SlF*Xu7DHIk%#8AQBH643%?y@sWxTmVM85oHl^a0QLR=Bz@dNG%_W2% z5h@zE72(|obJMN~q3>%)m*qX{)f=*QEqCG~(s2Z!UI(famarnNai@odWvS~CC|4&& zjos&JIQV1OiT2l4+UQ>(G6ffpr(#o$+v8p;!O{_B*$ia{<93=8ODGs*55$`&lMGP9 z@!jJ!5VR-8lKa^L=->5d9j<(+#Z(M*E@-ySG6VgXNItN}F2yGTD+T(2W16#2BYlegPLC%?)u^usFasA z*O^DJRo1KS#L=%TV@2qOMzM*}bAUk0h}}z*>lT1S5&DRjaL3;Ct@R4Xfb&pUq!NA%} z&Vm$Xk#ng&rDQv<85V)-&?RQI8mPsUogR8|5(H<&rz4!NWTNBq&>krzb)Ss1dds=T ztKf)TNJ(C4mE2p~OC^RwBDvqf@eO~lsr34Bf@3Tz)!5ZJzEOxg_99&Ju`~>x=Yy~a zSS>MzINS%Yp*~|ZA-+>k!!b4!q>FTBI7xldCO_|947R$yX*aonV)$}GFNIwRq_~#A zl*xQwpj6&(g+zN{HBVwc*?PHXGHPdS21N@cJLx*rlxh+WA}j@_<;eLod#nuRTD*m7 zwW?0U>D|p$t)badUDaWA>NHT2TH{0H+sa zEVz)jtBAxiKu{Ut2Js8buJc5;^&VB(`> zTF6y|raVo99`2{MKm_dDYNHuLE<}bD5Bk3f{(K4{&fK}qO;Ol*uF(G@67qUD(%XJi-})?( zbp3fY*S#RR`>Yy7iKD6Gg|aVY=;SMoJ6l?f`5n$K7bff-V{APz(NgxHE2v%{SL#wEZ2l`fyx2xwtrD6YU^B& zk4*Zva5V@}pULAlju6rbb4J$CA5cVCwD@6fIl2Q7$|(-++LrcaZ_qETz2h{;Qvsj0 zz2(DLK=59358&3rX+HYJ=yVp8M5EUvhGj)Q3q42QaJVfgb+-s4Gg1|i5AnzEe%u~Edh{=fYt$#H9(21(|D$c9U zk_}Wua_%7f3r8LqNMPx%r?3$Jy!a?&2MxR5>T|rWRFxeO#mw_7q7@}qlC-f=!pBx! zw*2L6eWO6avjq-`)5WeFv~VEAzac$utS9oZWy}5$nRLzy%UuT4oI|Yk73s**^xHeW zY(DYOq_sIt5dYEpOV|RT#pW8^%#2==jt%sBf%o|XuW8XYosZ<5LUpZ1N6#I4{>EXP;-MR%_Agsb zW#%^b3hBp=$g`>Q;Dkq>K~u_M$R!VpBHx2JO>6;q0q9hqz2)a#if78|(<}4-XnV55 zCYS`q!oXT&3>a#x~*d=Ud_3$v&eiB_TIug^74=`yX5K9;3 z?)RBUj{tJU_1ao~>TL});lk2OqNTfBZvn_{zzlWFvZSo^u z{S>D~KH-sCP3qST%p>Ei3El* zf#G-M(^#q%g9D3F2ZRv#OZCT??N~RBUPY0r z*UkdLKf@0(G!jtC-2j7Lv^Jph+LkrxjRMBSOD#66Lna^Aq-`o@LJikG5JY~aldW&4!$Phq<^HXAjujBMnFvTlEL-jsqF*ltK$rC7af8;?gAnneD7f%OUlF& z3H?F9U}WMN2T@9=0>4hh7k4vz6fuLXse~0b8@MSX1}|~4x4Vj&%-a!5TP= z(|itsv|VA&tz`rlJPk408CMNY`Y)}!{S4Du!qa|Qu()$IrR6x23}92?Qoxd$;{Y!| zv082_-@R?3u;_a0&eq^*B!(JW4LOVU1x|cXC$@{$(r>i}c=IUo9@~$XGvn9BNYWWbU%ezD3-Y^Z18!{TtC)!oMAB9!7ucdsBZLJ%X_D7h%Sn;rc>)_mUMpG>a zvUx~IZBpk;Lp3d>xH8iRJp1|J3>$1S1DscX+wja#&Zq}Rs}w;oi-^VX5p&s&9%mvU z`bIt(0fT@2shI41EP&OCO%s_yqTiasS}bs3%duS3f6^ckX2=t>R17IYL*~0SpB0?| zT+t5QGaNeCsuIm3*BBY5GO9myWaV)asJ(-j|2E3sw}&O}I#L!w#1}pGHFGj1!->-g z_D(Ly3jrp_G@7t8e*JjujVg0qw4jsWCH({aYAi%FVu7^SL#s(Xp($m1EHAzrcFPF< zre?&FTww!c;UVzVSKCz>k@L=?tX1`jb!Lld6eSLw?Jr3nm}eJT`^{&|UMF2&L2z(T zb~~qS6(y|6(4!LjjPRoicOHtso=SUX)`b5$s<>tY6(G8=&)xO&I9{e+KZTZ+g?hym ztv$5@)O(Q*ZY~2e@LZ}H2!sXMzrn#R@{jzCA+v384jPCTGE_D-YVXr|_?7dKSr~{< zG$Tbxl9KPWdRIN^Bb@zeE5gSqpbJl@qqTQ0M}HFJzlj&YP1!mw71tS26f0>&6ZLmAj}~K(dqEhm7OJ za^wemrNjfbBv~`s>QsUqP&_iGD|)STMX(=?{)yYZf+!Vd^%F>*i>Q6(iOy!Vo`m9FLwYuLkm@tP%s^g+OgeU4N0!)6z@eyXTs=a zt{R$V>>&TEROqFu4sS#V?Ec^;5P~E2xA_BcMR#+nxxn!m+Wz2B2zA3QdadbDkn?lQ z@Wn#6QBdM?e+p@8x#{M}+x_gxkm;t$WZXr_H6xKR(KSU`BywOy~+yR3Mm^09cJLWtfy=gTXM)S2X7t`d%Xbx}}(c!u4HVt!`@wV+2 z9VNlC=?iLcHi;%I@egm14GGr<>oYzp)fL)4U_2@2^PTvxt@~|zWzpQlCtL<%+RVDz zoO^wQBnNgrz|GEO_=Za|@?%H^mSC%Y;nz^ct?Ee^JK=UubT(&-TM3o+;EJf1KOaY>*=%|`PR7wlXzip=+won(6);zmJ}3Oc{)6@-5R`yi~RIxM{_%$#=TSOpkd=aMa`ftKGqg9 zDAs=sUy@kai=#U=-N7Wd!3~4tt^>Li)|?;h)@`^b&13+ob1u@X7qXy5EkdWhI_d>+ zFAkps+EPqW8X*YY9u?HO8(_m?<~i)^Wi`iS8uI zPzU`y69Uk~*7yV2Pu*>&gU2gU-R_FIVX8X<_J+*JHH!b~-hUy9gqi>KmG!CHVit{B ziY>d+-DQ@;b`LSuE!h|~{S)Qx-_XgokD=cR?+%3B%4 zW#$iHoKIao-@VHy{r*Hsn`1TvAy)vzm6d2#f`~P6Lmd)2#+CKe)riSzjd@7U@|?h3 zBb#fUS`kNQ|EEJ*h)k}cBE@8TRHm<=W$N?&3PHz7H2a<;)X(3A- z(-)o$4L@;(>MK&4dediXONNmzAiNZBF*|QxQZPLXOZcz-xp68wi;^v5F8N|Lo2(&8 z#i#f3!58HCe8J+0%u#u#~0R-EtOEP1-y*Qj+jt0#3RYF<(`8(4vRe&a`5iv@`E!p8>)c9|&)Sc@ z5ArEP*=Ib=raTjV+8X-O3Awer029qc^&P&o8-BMZM{nJ}@7pU&(8eMFzJ%EGH-uf7 zy2v-Driar%y-c{pH6}~z--{;W#UlAAiEB_O%eqm3Mo!JMnERd3=LfWoUASzL{I25Rcld}pa+-DdxIpVcUWaZ~eRVy(XdJThBqAs$NknqD9 z7EkDeY9vb?E@1h}STZTW_|w4rm$$TF&Qk(dg43?X9IcT@MQ(){h($y)#_h~T^`nxS26%PK*hhkh1xyXH(rX< zbD@=APuYl95z}-rnVvuy?mSZHM5i&ubd!Xj(ns8>oS^W8kREME#eA=WL|~$#q=@fA z1O=oPB}^tKsDUC6_P$>a)J8&^<7rvh!U>YIFvY>=zt+3PgV-da^Uc=}FS|&K?Il&v8bs){6V_sA}}gl~7d3uA2L`LFZA`UYj4s_wGiB3Non%8zgIEr=B9elzFOzR;5U5$i0=HVt2j z^|~oY^Q#VxU^!!r?>sU=_`Gq5qY`hXGo@hIk=o#8vq5L`@2B;D1cbLo~Qj^bVe3H zkrbhH)l3s5C!uJaMdJGn@fD}_wD*7HYUy*vm1m#^=+}q1Bnn>CYx~}Q5}1A9GuDxq zK^b{2sX{X5yJR(UFLff_`r|NEvF#BvtWaqy{)2df@1kPbzKkop-Kl$D>r)kU4K)%4 zWBZ-GT4sa?2fLLiB62f!Tws3pw`aDoY zjc(9E=TQ_6O@oN3!t0GxWZerT*591m0Dtr8g6<$F9-1z{R|YThzq8N{XMKO-O)%jw zmDAwBdCyPa_F4qV&V-l-2MLhj5raO#ny1qqJDwl_M+KKzO29&+2mk5CgbLZ5d^Ci1^vfv7JyJ* zGy}dUK-#KgF%2j^B3YQ;=9I`aG-y8qiRAa$buKtp#e?UsLek{RHVKV%^P9P{>EuCO(6ib!7?%8u$zEV!1qf2u~=7;a2%C{nPk*w zQD3)z5NXR3wyt5u=I^YT>LTel^WQy=>A>*Sw?!Hoo@XvRGZnw+4%^OqA*4-4imuo) z=6amuv9te>E}2cKV)?Xe1sJ0v7izXz>vSv%%ykxIhALs^)9HKTn7)Vc%fZdS{7NOf z=j}mHI!`Y>gVZE%<2^mwsh4A5=MZ%+$ft#beLwVRdub#=Mfdsq{YLQG>g;a8aK z&Xx4s>FMNIEF$hEuw_kXlIyZlKI?IRsI$zqwbc7j6yXSPBVvqk6qA4%Yh|Z^RQ}V# z)#zj^p&yF6`5c^5LV(b-?gjBbpr=U!N0&koADJpk#EAi;y6;y@)=zXTiA7Xt3ikH# z7aaIj`F`2JSon2NnHZ53I z1*V{G!FA4vfPd-fID8n4hS5U-yRwAhuT~RSi@3XF27J2TjszWy5^?G*>D?FRbo!qs zV}l<$PP3K!i9S}wYz|(d#=t8S!7k zSt16mnx_&HfqLh^bOa4B!4MjwjzT`d%jFBixEH~)?Hi++?{RF(mKN8~-37C2@yfyB zcHa-ktO7sUx5ucEwT!avZpc-&kS>Tx68}=UQH!kVQ5sua%W=i|{mU-%C;$jAgQ#dA zHm+GnLEuo4BW$`hoZe{#4v85nXT znwszy&;JnCUTYHv{oQV3A<_M&3iR)VjhmDQrPFkJ4G`7AIe~+Bh|yKc3MnjkQ8ND% z+rk;c{n~27NJ;yUeT{Ud#-(Q3tfq_b<@0b{Un1g>4-{*GJ9rHsC!jb7F|~pa6a@vz z;cEn}SUv{gPqDL+ zGy&qJEMB9WL1*QY2fh-}NT;)Kg8p1CjAO~M(0Drk*7^RF2KxH_eMX@+PnARF{}_n? zJ~x+AtD4qD3xpv_Bxp)g=P?D8xT-rBM2sN3rBOBI|Ak1DWL>gyt(45u(tWHic{$h& z={lH5PSk@-j_j8}x;Vp^DVnQtmB?t0Z(pNQxm+1#BZG^ibny=b>;NqWF6Z|3OqSHe z|LD>zDAylY#P5_A>XMJ4y}p3CgJ3?-Og>(lQ#!gKLa)?!ck)m&Qf6VDL%4l%xj?1I zEejx(dz7tJ{YkQ+za)b(ZL=k^F@cc-Glr>KiPIS$CcS^a(n;;S7X|0eNUneMvuJA~ zf6tURB~+7@smCyMr9K;MR?-drt{})-P}ma9UCiLwKx6ERm{NQmw?do#%<^B60Q!WC z5i)b;&amqmON*&hBX0Kg1&@}Bq4gI}PSMy#8WzI>Y<48^HEVXmq_(Aj?ubjmSI|J* zw%OXiz6_T6l9%m#!9uDiFK-^El@G9ivgZ=w4Im`F!iVy%_gm|z{X9rkQ-=2xH%4uN zZ~xS(`A@B&B0i8%2oyz~Mfo06-nRlRo#fgk0cA@Fgw#x_^!8>aQeaw@`<XBcZdQJx;Usf#FEp$UJ*+dihTxn)Gv8&>bg zWu?lgToG?i<9!}D&AxB$<4*a_&TVAlW&nvV!UR!kFJ-|?hgRKRhG6Bklf=ZAS96LD zZr8s%ErcgHa!d3SyJ*@_H#4T$*%Q@>O&^s^A>hgK|MB~=k5G?bbvMJqY`$zxXR5nf z?X(X}MeGU+;Mt)K$wk=We>_=~N-_5jrwDiu%Xhg0Cm}8r=2o(3iNP=R@BeXBkEp!S z(354G3xa5AF1t4j`3nV@f;be)y}_#EMAOG|%7wv}j=BOrGSrA%gffSMrn%G-f|%Yz zm6Y`|Fs^TKNJV{$O4pO-Xv6SuUfNfV2X&S8<^g!{#mF`dE}ixS<&&`y+N&!Jv1@Hb zh#8jYM6u4LowhYZ2NK?t!612EKorn)e$dFxZ*X zvI&NctI9PSs>*sN5^`XcJbH0#F(`2~&LMIywAjl1O)mM<0H0>-R3%O}K6FA|BF>uS zSF*m7cE8JGfG3lT;tBjXIhs8ST03NiOnel!m0*uw&HhML?Jgx#vkkWZn(1zlB38`P z&dZg24yzmZ5i)`^qc{PIt_XdE%en@@$;lS3i0<`O>n~J-Y3f$@?mr!b#Fd1uWs@!Z@k8VV~s!^u!}e5e&_5TzhWRJfQYP*!3C4fgE}HV8 zVyo}hk2Q<7)|RU%h@4KBV4qNI2oq4EFL9Or<|U5B)Id;mY9#Vr3&*apK-f6jRX0z_ z*%xc)xWQc;(-yx>s{#4RC@S^(XXCY7nTL$o?{|=MKw(`;Zc{t@n z-}?E*iht7>HZs9SJC{RDCBVE6^2uH`orFa0WjN}6wVB0EfzNIxvH;fP*Vv=81Fn)f z1WJcb{0SUN=zKx?#TwxqYUGOAVI?MZ6COV=jXlLljGTBbzJJ zm#SpFStRD*&fo^icQ-xd18&r~%Fod+O@m9O*)-_O-K;!9a?Vj|sTX)c9((GZfafee z3G{?wi)o^Jo=kuO+|4&8Pk^E7QTqUdsYHR7viGp%lC}N@Mv=okezV2vL=_F#$KG^m zZj91T+bQR6w_|?49?Y(-2*V$0;Yol?mhvRA@!3{|#l{nWzdJS2MzgM0#+(qF!BCA* zy?in|OaaHT`0kNw*pHTooKE_(SOmHbZwkG8NQ2@Fr^2+)6Qj8DU8+$jJZVy$L!zN{ z$i;Gq0zD5kyRQfck{l@2d&(mWi@0VW2KsbhV>f8Qzf7H(Qvf}IN~GEK(68PB?8XAx zjUmeBiU&NwCDN4P>)DieVH9#NM{=Lw)2JBVg_Lue?gYu%NB-p-J{1lHO(}yikh>op z90COa-N-9Y9ZUV`&b+=mfmsGuk~ofGn=K~#1U-Tu(WKc&=}MdhI_gz{>jb$AQuc#rsQnk3=a%AvwL zI85uOh=&e-(@5pVJW@=zix3<&bTp~AraHx|{mam>RQ2TBKc6oS+t8JU_Wo4@&h*0^{)O{Q+Xy7;VTg+9|Tp-Y_;z_b!$+B}Oy6oB5QJA5O$*NYd=m zLmPzNj`<`M5L5glAt9W?@d$Q6s!#9p(bDpzrUZ!OX@1+?;pN1T%Rgrrf3$`0g(&i5 zT^Y?Q>rKpu6m2wXS*Ry1m0NQ}YX%WpIEQm3bTzq=KAp3klsY*aE8b9cpQ=z?Ms<^=(5~&w6w#Cv z&Q8?DFS@1n#FD^l1+9~7@bqKgg0x%Yavdx;dqb?`m8s>Z{9geKFc9!STNsUibu+&$ zC!m^ZowOPity&JK#ae9OdmfwWwhjNbM`zmPOSr7zSzA#lO_8Q&sbNre)etpUG+5sy z^|HLMTqiSQ9}E#qR=$%xCiVf^F3*QWUwz1JGxt;kChb%DMSZSV>eZbCAWvL@BJOGt zL}LNyML2Q{)?C-|D2iET(MeYrij!u6pbPVpk`#{r6j!r8QWhQ4X}>}Op+4}8h2a*O z3bT5;+cq1}e)e`_nVpx4Dn&nMN~8I@x8MRx?b=Qu5=5meNQX91A~a4ZTiv>0_e@WBT&ZrJ+DQ+O<$R1!TckdWPZR-eEPV^zl#&3KALGKJ9Es2;teps@79nURI ziV2?kNp$zxv!E(qfbaTqn~q4|49B;uf%%T_8UOL-+F9A-vL&ymOGJw9NzGw`wNj1l z2oSBY`Q_snFaUsSV{-MeC~wj!vHi!ccyd(!Y;%_Z6Fe!dk_IZ2uLA>}9oQ%Ry4yaE z)~Eive}kc1nX(5`smcBqVMA89glq772ZCUcPG*c~dUpn$xbWNvkg22jJnp6&4PyG_r-3zsMZ_7d~RuVc8G@VNB&<~*D*{0>r-C|5V{Ez zTm(nD?NEAwhF-xKpye=oJyR=hVd5|>+I?qO5Z;$a&^P&&Q zJM3~gs%&?4pXt}?hRb5KvF0!{TN)bUo^G;Ue#Tom*%qk=^*J1o-MgG{jKPpm?F7}^ z?TUi^VAF75S9@h`WT{4)Etkc6pH8(ia&<#-Dert4)Be;G|MSps{tB}X+!<*PbE;OXqqEmQwtX#4b!0W=R46r5i zJaSe#Uo&hU9#@(!8Uzn8uanBy{1=9cpn0JCJ-xaEW{Td;ywx|$bim4BJa&R@8@z z!iGsTdF}=EBkpqE1LyKa9caWz4AN`tV^vg|io-)Ih8LUIg8$%d5Yn{-3R3(=W;4hZ zo%W!sCM$7xBwR}k2`t7Lnhu8l18*3mxQMCCT$rba{F^HwVuDNAV&eVB8~(ZxDaE7* zy0sC^Rs^7z`tfh;wm}{hBdKu`A;KcJi>#NMZzX5s>b-F#3lX!10IYo*29|KK0zEo09FtWA}>Rpg^``3!s~%}Op{y>q#?2{+RHX8*oF_iWF5^5ycW~rHq5-QZr-Ld)jN|ijpTCVyTezV(U$* z8d+l6Y8FAf(7haQ?}np3JF2Tm;0?(DBs#QGZ-<8>JJ}7*5^#~K6apr&e57G-jC*PX zB?DvLlOQ{ZJT0MdP8Z9=`l-zIs@-fOjOT$=4r)^|j2gBCZz4?_QU1BQWCC2!qViw~ zBk&T?x`C|6uaJc1Et4yd6?D5#MsyNM=1*ODSmEm}aCrni6q}++hS2D3N-1gGwEiB0 z$ahU~K~lL@8}^kNMNBNsUFX9tWu9gz#hQ`FubW99AvnjO__GtZ7m^v0UyVt2HW^o0^rVoDCm~x^82N;QIKdgUBBUn|u&x+p_Gmf$ zD|cUnsTgTYyX{|f%Y5za;Pmzx#9wnln_u^{bHz0G^r9*|o6;kh1Pk$UGT%c600l&9 z-JTb&3KO0Gs)LTC4N1AW1%%<(alDMg&r{a!mW|$71?bzt@my=g3K?S|#i8n&zWM!1 zhY(H!g<$zGl#@6ml#G(!iqUL!=y@>BH@@)jbry%|N%i`LE&@Ith?xY;U3KbPJN8ZN zvv#hK`DMZPtI%H!T2uwHrnZM=h`mg}L+^4PKwj=!9|}GZ%>3j25Scwv1{aEg7L0Jo z1j=_h*#3bF-heKSx5(Jc%}2|m67GD5VRS<^`e@xik_6isu{iGe<<-X^rQk@W6A!+q z3PB>mh+mK=7RAOVWPHT&t`lL%d@Kw>ois7&yT`L=j}VIM2996C-{N-sh#FLrvr=Jb5_&?9`b6L&EJVMQ#V2 zLp+IUg`!!*t7EM@t+z8d3;ci-sZ}@?6X(W8Lpb@n|6vhrYGGvr-?QE*=(s%}^HLYw zpfr%iR_0U|;-IY@!jBJ(GnzYc!5D1KlNq`fF}s{S`hzn$7N5mi^zng@O)h!anO~<+ zH%w#21$|ZPAc`XLuWZmryqOzuX|LVX!3y$w#)03T@eH1HJb%#L zxQx5U1m-WwEU9@{$tSQOG9Yp$E8R1GZ^~tc`6<1nC z;MR-2x08C(+qG8RhO(zL5~bs=QENOiPLO4$2kMxyco+B1hnIR`y>Zz!(Qf;djXX5( zkWNq0z{VjpO{mvFY>!dj2?0u{#5s`2-}|8It!e3S>G0zSV$6OtKJ+1sk@e$n;0i?E z&ai(1l|fQMK>XtsoybEPPu&zSclt-;$D=!KRbNYVi>mY7y93)(^9T>cB1BlZ!a7CQ z)cK*Fho)%2bZ`k$`m0~Q9*Uldf9OTNw4MAo5(#dcALz#qgKPG92s z&gZ`zN07`sTdAv)3|b#EN{imXrAC<3Ygwbvt8pb)ixCMG>7$C9M z{zGxVZ7xB77TlO^Wy7#$D0*c29e$ zdHje;Ahgj2$>8yd#pO7BFggeOCo`e$|5pVvQf$aY9C7JzzF~?t3o08+JLlaxg0np% z9{Ek%gd6knVHYHEO!zQm7dzKBbh_pUVkW_+l;4stpdGTR)cPNIEg2@R$s{=PO-!f{9Y zn5?m41i{T9i>1XBrjnrRe}m9aEH$kV1Wl6h;cPmhh3Cq8CLH30btHOUuCxog*Im{G zc=YQQ4GTcs>!CMwLi^PTN))bfe-eTd%OmD@m+ZkIk34p#WCd7Z9ta%2>*bB*`Ctkv zsK=9BX{*G4hFs|S^^ZwKkbm~ckOX8B5`V!-!{w~3b;?71&JT;QLL`GyBirk?V=6DK z%ayAld$ml)&Z9BE8lL>V-tO%NU5v|=nO{4}X@Kj{cEJ8*YVsiNsl_;6>zL;6TK*F# zcf-GL^*+`^uqbTzeaK?DIAbBOko^f0{zqPMdm5`aciFf?MO;k?MFA-_zVvTrzvj!( zYvnj4fSLJ3W_uAV&U*36`%AfYJfAMGa_&aA`N)q)y(rwTH7JtaT}hQ1fL~KqpHn?~-2i{bW#7_WrW?daDJ7#b)0>DlbJvs;UXmt4f#d=d$;P&uZp^ z*42_af*11=qx%$nlpU@LC`&1O# zy=V1IYEy3{*I>!=2Z)d|7E2XjEo2_(eJ%SOj(l>?_Zn>9`VPhlc4N57FXPlUJ@np* zk*c&r{(a30IG1+i9oO2;%#EhqwuXua5K4Zip$1JQf0u+H6)V@Rs^&=6N9T%G0sNmd zqk-WWrHlR-i)$?#t{X8tO9qjUTW%Q4w>mYU?Bg)5S8=y9bw*&wCm>b&O)3M8%(i0B zsV}(t6#H@51p=8{r$5u{yXW)c7wBktiX+$rYmtk^XABvYXO;G}U_iYWv({b4EhF~dV8 zfIp5?Eb63((dO4^7WPIXAeEp~Lkmy|S{K*a>;`|osN}UEt3M&PJ!suS%-8cUC*LwP z27uXJAVMQipQqn4h3EMI9*|`VFx>r^6(rwKcTW@oTi))JyG{qxx9rXde=)oFYrXNU ztM5s^Yh7YFO{55JTVXhbKZ?!ZZ}aOCC2w#^JQ zI4Rx23=1mOqiJcopj@_A{Vb!k(x@5N7TMaO~v>7#R(* z=xv|BgGOy>3V;#=J<~EvJsDT9N zFZiAle;~@qRO8d z-J52^j0L)NvFE*Ix{_@7L>|pQMORj|!@8r>Hb%)g8^^`bQ*^T(U1L^En7DWt$>ATR z2lE(;{-w(!I+90d^Pb%OL~g;8%N+S`>*FdFOpE!CpcJQF?<#8O;(m8I6iV;Hxo6$m zl5Whkca>cEYDTez1tCZv5SG%$(%3ZSE2j4C;F_HRwbG<9mXmQQ=4TR{!LXOnINWEy zTc&8HD&kpbL!MGU4)}T%Hd5UNSS&ObWmn=7dWhs~ypF$3hc1p?ICYky8kDa}AlN1G zhLWl?D(4t9JD=FI7-b2gk>1O}6f+WajUq1Nxn+JjOQyU%R@<+u?pkY!51|!?vNEzS zb4HJ=CBlcgvNX0`#AT1jvTf#S;+WkJYJnD`ifO;7vR?Mho1Pc`JU&aiIn{tkFes8+ zMaoo2Ae3=CC}pHO((fdxC@59ai|NJjVQ z&t2qzShn}58Hj6DzkLi_I}vIA9i0BbP=k@U<<2-ktO{XZuh|Kz-IQ_RrJ>oSO*D;>lU{9BI+qH(&xq9N~MHdqooc#pL zq#9iP+2PYjOasV}K~F6z=;T~`cf3Qyq$nE+ZLDOV7%PO^qESS$d?`Q0YV~!1(7L>A z!x=MH#x=T$ac0dS6>b!)zXR1-p~O-oa+Q$=2t8>1iM{z$K>Q?eLO+m0P=$t|BX46; zq`@l!myz+8l9X)SX!?+%6n6VSn#E_?SP)Tz1!oOF%7`ZPJyOVn|Cmf!h2&A5ZTbqq z1Ea`F7j&<&X8qZ_l?c~utlcpG-a16sManBfREOistUW0EXVijPM6K>ei%^ zO3*?L#SlyX-vL9TDJW<6Alymk**~^;S9oNWz4_8mw|0uuxAeJMs(Rwd3mJzfJYp1C zR|E=cE(j~E&9<&4-3gJ(-ue^ZUF~RZTJYvzJcV6GiG2okx!I{(MOMlO`G#}sM^(;! zbq3OiBY#4ZbKm!d?5*H6u+b1s! zcZA+J51N3as%ROCas@@}G%bRq3qZ7CQIk56>RQQ+ZCT|k@-6F>daY-zdbub>QKF*I zN2F?~Pe_>9v^je~!&&1dTsy}+t3Xcp>$BKWzhG&!l=0Cm6(CNr@_Dl25X+7FAf9QZxe9XNaGxC)XOTd4`(7u}qi@W+3@9 z2_54Ma!(i^`I8v0j_!Hkd#>@6s^R%1pTw2oyBp)UaDw`ZJ24+d+aZ0=Q{S3 z@W^uR<@~xDO75OSqKxp)%U_btJ^BVM9_}DjJ*woWNs=OxVuK3XO!aFB5@H(Y5>|@H z$o47m=?1oyRNc?qJNocW`-46)OYtSHlWT(<6SLBs1q4ct;n^)1XY^BNBdv*Am)?F=&Ldy}jEC1Gk8j$5TO=`EllTmo<#t>^x9Q z1G_Wm;O%ZE1dj6Z4>RhTjQC025+6f$N~SHhex=SVt5&>-pS^5E?E7qyfE7HTjFUdA zlELdIZrqWX0#BFMiT>RVkCFy~7sQ}sTW~Hq)HpNV+XmiuwBmK|&K;!2)`8KKF24)g zK#;mARj!=WVaxjx<)PSHW|1D;v%9~DJJGsw!eCpOzzA%t1Rrzhq^QHCkpmuIf5xG* zfDF|8xHn<40apq+Bf8shU-o*?{u`gaeI~Z!=D3M=H}$$h-S3>%E`7@G5)dBg;WG$F zk27xf`+;kuC0bCttyjB^wBLC}ReHZr7pCLt@pc-gZ-yi{gtmIpD-#J;C<<(1Yc32CzmA0FB^ZxVd^Y|q&iYS&&3elz|kSRBQv}zNx%N*cu6ce2Nu9I@!XFu z?_u<;02=N3R`I8~B~4rOrvPB?5SFQUPuPC!j_9Kz$KXtHs(bTxCVwLV4UwZq7hIFB z6imN+LdS)Zmq-sf2h#UT0|ElCwfb*H|DQY9(x%f&U+ z@T}61-2x+dS(7T8r17SyZ!M1{_J&1G1GRxD~O#{CfNiodl! zn1!<~Vo=R}QQ(&u3)}wIB9TBlbbMoeg!dRL%!ktlQfl z{Sz_^OO6mo09bBio2S+U`b>0pX+?hO7)$@)hK6=;_xbYu_`hrkdWGdeQsqo!rKBmL z-falY-I1!M)1lmH2WeG7d~lNCf+MyuXXgtAU}Rx_zn^^v#5_D%?MgJ^3yq|qL!DFn zlWYk|T2=fo8dR>l9R%tJStH+dfYdZ?xMN*bXPLy|q=Dkph`>t>?sdBAY(JUdb+l*n zzU!4OWnT3+_a&{bEOk*D1NfEu&k?G*jY84U>&{NdHm8p`wiuqcdr%W>%2VL>e~I~U zFn~GP4D7g!NyH8z1?U7XQdw_XKX?->yS4n-AoRqBpvDkqil5`cUTPc()TEvuJIJzS z%rV?=6TC&LV?;XHOEbhg1e&|=ufQ3+AQMKEwa;4XES$d7)tty}po%j;%(n!*Bqi#D z_{{v@6Onmjl&9G6KeTfd;;h96AEZD4WG%9TAv?9O(ezckOpSr58rMOJ@;L*=dVv}dsp5`q(YAMu z=$($Y3`u={H+guuYM7GMJ!J`y7BGaFh<>Rn#~}qzkaO$aY~Ss$Y=}J)j*fXq3f%qwMwAcXkFcaHY-i{_%7J`?0S!>%akQVH7!BEUtsQU1^5QC@D`X);g=k1m ze8H64`^@!qH>>}7HrrYhdq zZC3~mQ;}wGh8!j+y9d$WYcnNvTLXLA#7$b3%{;Lm9Wj<3v@Io^=tmcgDX80vwGBq) zO$X;~bM)&v5B%G+pcHw!HEcw8vtvTjzdxMsyLc@l@X~`1BDR{0Rr<^@u=KQ9+nbGkIYu{1LH$+=<NnxTLpmhK$2t)75^?(Lao zBdzT4Lu)_wk?YIp2k#q&O#loW7BmkqON!mbk9cB>kd2{-%+hN>!RTDg(IxBycf_-& ze{YIBy5?J2Zo!y4@VIS3L0-Jb4}<3wHtS}ZxesLbd3n)_{P6hC_ z5Tm}2E@|1$fFCCcmX|aLN|n@k|6whaK)wyh$|kI`!tfhVxJvkfJ+Ss!#(|zN$1k_Qure|~*%dEyr@6M(dz&S#F$RhWkHD$~|7 zdZ$E#aS#Ua4D8h&fhA$@2x+fOjUhQrMG)?{g@6dNRMgE!F!y-9cz{0$PM!{?(Z?vEWLiF-@eAJxzL;ry}s zb2BTfnm>wLlEl^tB0!}X=_)d~P1i0rP@7Gk`$jc*7_lcz=?!of(1nWfiDF?Q6FlsR z3q^5Ec4hv@^$$r_a#g<=?z@|>1Cjx{U<=ms7kj1f%C?3T2DT~<8;4E?|CAhtBn^vB ztFLO4sE902D2Alg6R=Vbwfg-f<+;i}7iO)jG$3Rj7w+N~up_T-aoBOy6}3swL{V*& zENRM?w<_?;a4US~pW>dcDuXY0sl?dP&a^>M&Fw7rbc@*}@Ck4OnGGdygn1>X|IbmA z@&AX03p)@Bp@*?>&BZ|Zl#=_V*rsVasw;S3-Or%qzKul~MWQiG(e(0pFHVRz_P|^o zT9Fqn^$R^3cttu$-qdb{Uf2^s05qUF%&eFs0Q6{m6QxsBX3|jF@)GV(Uwt?7yFuJs zEy@ew>fnmm?jA%h02f;SAE73L%*n9wd)*|*?ArEMb=s_7y+ z8FXr#E+ah=0*plgk7*0%@r8+Exe~qvo>BR{!n*q;t3cU9_E%>Wx zkp~j*K+|fcvWE`8!GD`T_KLdD`-JdHi((%=(p>%`~3!$tJTh`z=>AkbBwyFN5tQYjS(}d+t zjCLq)&Pkc5UDK7WN|*3P1);L7W)Zf(pe!}F1vI>0EHZ&bcT!f{N&^{6VZv;im&$|4 zJF^c4%)PP}vViiN8d1tn$}7id4zQCBwe)Z(F6BWtI*20v&Rac^^PuiZZ&?E=CW|wQ zj!=mk$?NQH#ZI(BSEuLmSfp^w6X<(7F8>dH*I)thY>(vUQHR{VzwQGT*{ z+;u~Da=pM^;I$q;w*_*Oo2ws2W}^CU&Mf}yXO=Gw9%(s}a9)!=(Sr~rEn&~pb1t+8 zam=X802=ik#t>0DdFxJmRgH78fend?^5d-D

(0z?pjgqDogMHLJ@V#TBQ7CKm1BGCe@%P37drzi0Xqh(gIVhLo`$(g0%Vw ztH`^YA^m2VS6%Tmb#2Z=SWtTX=eZs43vJAz`&WYP?0#;!m-aL2?{I8u0QWl##c;8KPL!ftVpj}xrY>1OA7DH1xTv;8&_N+V5Zt|wUg#Bi+!4x zQ>a^of3wTTFzfHgT{L1OBlTOXV5nEIB#(pszPjx)hWJBVB+Wi%`$1 zYP~k5d)R4O52LqsryiH;iE-smP}1tLzirRjbNq-E0L%@fylR}6a@zEh@nN#wKh~46 z`fRT2QpWEK@XMpDB?q%=(jfs^KWN1gVg3%?v6i0dw$H$38^-KaOR)L4WTMzp69J8Q zcT5IBY%R0^FM#F8I4&lm6%~9~Q66#@A?AgFlmB$(WfsPRlBo)n`qD=}lgdp@1%9M>mF1Ry2=$*RC`_i*OdVNAef4+S z#(J&XF}7MU@h4(kv`j&a3IYiaNt~vwWy7PQORCOh?23g+#1&%7<5*2q*tgFDc~JGb zR=roovmFf^>e~y89OL0dc)h`^^LkQMqx|k3E;nM@*rXYPN3;tqFzsbD-+f) z#-^G*EX+(AHe!l6axA8(>Qi2V!U5T!^v!%3>*}O!IovrpVrcCMj#I0i_DkL*{iOJ= z)_@4NiEe(%+iD40+eS=O8c9bd&Jxp%DWCOPT;Bn_o(f8iqF|>?L+-sc*Wp+kPJ08L zIt9G&zjLcAXmzqMtmP8k)tx{&k)VCD%hV(c2dXFRNBad#Ws0Ymm4ILbeRybu*jZoX z+HXNZC(CR;jt~CDQ@qu(#T$kqHKqYa2#woY4_xvl4mbXZ72d5-O~glwv{oHD7Qi;W zkb8uOxXxxLAT}X>kG04;_n^cl^?CFslDYVUY|7(zMYhT_P!+G|qXJ87r5r8UhP^^5 z8WJwD`Dv$ySGyWxeHRtq?QG@lsZtU@O;wmrs(9SxPdPps^dpDNS5d)fIMOZVn2cw6J1w{h75nq%eVOCBqUC;bRg~3!mdU$lj?-3?7{h99 z>x8 zUZ;>~v*~c~0|=EMh3}oO#~J2uCr-@uSV#xR?j<72XYGWU`7CyD*#@y_%T z1A|Mc{v!!qwaS?im;Y+MC=00#7Pz-8DZ< zd=D#Lr?W|j?;3wZKNn$tJj~KWz4Xc~oz0#j4AS05^tP8K+QOo`g`Q=X-6RTtu50H6 zzB{X8>G@v;wIe#@sT!}n?gJ4zM!R)km)iSU0#{=Fp)Pd=O~RiBbj)#qkcjk4KZ{YO zartIos_GJv+o+9j#Q*zgx4)I?1=WCd>VuBg)77me_*xSJx1&f#9p@_gsDf5sI%Csx zs*EX@=)?4iD{5UT%fB6Ob%(xdv~Ue|Tp##(1aeSfx>e|`4I1Jc1BhkIUCDW*eSg~$ zR{{c#_&{va8mGL+Wi9S2&9RD!B|NWpU>NZ83~nEe^@q@S*K_N6JRY`Udo zqbAKD15jq?F>nhWMGe@2i&jP3dil9Ep*}*urkPd|xB~CycPyK3E21x=uy#Z&{+L(T(7G=4s91v$fFunj5S=;IN5JsgG{H7&ClN9SkVeZ zw4q^;Q9=wI)zN3b3f;KOScfN)nk$Y*DKR6GiL;SL){5X?Xz9TE7`MT!Mb8umi^Jc! z2~*9TdDuV}rAaD8S^R zC8%@VTRN|matW~sf~&Z^Uf`X<_gWAdv5(L(lfjGv7F~bEu6A!RZ4{g`auYs=x(Fym zlHD*4O7kabe%yMADR{`P=Kb1ul7@RZMI`2xu#jqGBX+Rs^W<=kO23u_l0Ps7B?``I z#u>fU;D=&#IYzSDm&v#I>9!qNwA1dE*~jn+l-AkJ;@Ss6yYDviS3IU@>o~K!!qW~`|jrx~o zJkI|?@ql(Idu;@OF(LY%Y(JpC!~5x-1cXKQ+nTs|l>swD?XE2uh#?f&F$S#keuw}Q z;DwbVjd&j(9zDV?)tY-NlN$J7@$SNl$w>p%Fe=9ZyJinR*#bRTf2Q6k_Q$kgSvA zJrFfa&I!ZhHvyAfuCV#;DMel*D-(3a4+sKgI4<|CZvV`ZFY`5WF1tu1k)U&?lzuTs z3;-%X)xT)BTaY8k7tc_PGr+ukaA+xhUkGZswAySK2lJpr8#s~cHat-7y%Nw~`IWZH z+s@CTn-5M#Jhiz_Jpu^}$ztYg*l*e`Ezkk+?JTCXaen!u{2k z*-gfN_HIz<9Z^f?igMYhB*ayOXU+}145A|}QDdGao*^MfXX1Jh<_*#s$z>^d(V*ur z7ey+5!o$ny0?h9thxPQ-83Oy`g&xdFp4M-*Wk)>%iO z6q;({9xB|2%Jk4qgzolY9kPFOz*kPL$d(9^%e?@kS0t(2vpO!CH1Cgn06Ap1)2hMb z(hXZpjo8#>AP#@bUn<7tq&!wZ=7=OVTXx;NPkghqLYB&^!{mcB+l5br^d-5$uq`v~7W!|O9YWb#IdZ)|! z3Xrr7cJjFkkaJy#}{Mpl3~Yl(Cc;&djRGf|!zW$2}@6bTp7- zL%q`r@E*EtGrG0r!Mw1G9NNv8bp6cws3LeEZbJ&9gK*NBV)@jLsBIl8Th;4v{!eUP z%LxH&Zz3L0d$(jh8jni>phr&+EGWBWdG%8a8Die&$M0IZcP6y9E1tB)O)&iA;5ngz%W8}Fr}Ufvl@y_kKr-JmEn8P$7Y(AN z?*2VWF&2A>2UjM~q}b{cvVddHz0!qA&#ozD*6tb+_JUri!I;`{;xDD{9RkTq6qM zDws+;qnKXb;xk^eQObp@_#CCOZtUf_lZuX#(dsSG?hrO^B)~WsP?p3EiHvD7Ha`A2 zG7`50x_WdwV&|#CkE098NFrDjRc{+zUR%}gB*qoyTV~yyFOeyn0~j9lIgTRut!6C`Bxcx z&n%6%UorOei(*!|_pI7IM^;dT??z6JdF2YEa3xPl;T%k<;*%iLLyyGe=tq%w;J?8D z?HW|`JlH2${=4r}LEBEb|NjORJTTLAb^8E*dhGo|nqD;vR)}I|yR4{%Gc++U4S*?A zWn3~WP%7D(u$IQAY<~gEiQ}#_=1S((Sio6^QG5P!vb8tAw&t6NkBt54WO3=jr1&B? z*)%YgtLpCgK-^Io#b-=Gjnp{>!?0qcJ&L=9eaW@-6oj3~Ya@l_#Y{L#*w*P0YmC@? zC4>Cnu8tjA>~(d*$#GoHM{Vkjo51+b7zd^GM>JUW6fpYSa(`8HO9_cEGUx#rH3bR< z9WW?g0gS}a9{V9u4P;aT%=%ybDsn@9tN{0JrkLrOnbI@Wy#^s9CeAeye~@nAHgJ}O z@MF>+@f8R8YWRq_=URzMQZ^J;@g!SoZG&tiepd9d2^Xy+-S7u|0ckz zqte*VcHrYQA64QhC$Fx5uL;aG0DThnoPOw+0ZQbQal9$*%t;bFJS(w-=tdQ%JIn8% z@Li3;veNw%2w@Fsy_W&{Nr-R#3X3^nE#zrW3Jt)HJ`Pl*gp9(B-%}1?tj|zX&VII+ z`67*}Z|s-xn60(~>3x3h%R1Apd5>#fX&~m76C9G3vn9c+MuW1KJL+`4dCG82`Ex+b z2rp*~-0TB%3oh4hmkJ>%&G&x_l4sHNpTlccmcZp^PXh=<;+2IV=(YbA@kt)Ffs0N> zP9Vm07xk|`jdKmmP9aWFEDcseTzYHaDpnvM&}9`+1PxjX);nr;OeWYyjh^+CCX4Cu zs%RsjLTo|HHQDG{nMC7cG|g{z!X(g~#LdF|oV3||<}tOeq@&-DkyJX8)lj8)kST7S zw(PVS%M_f-rj!5ME8?sn@8f1h?E+SP_AdVG=ae?XZ@+7#ZL{vox+<54ULJ+0>qC{d z<#->JCNc=lAnM<{Y-F)B0y< zvr)*oMXtW=@zDL={_f zOT({nUYCtXF=FK71uA{c?ne%)a$K;xk#jyS<@@s$+Hjn^4uFQgGs*`A-P-phS6nz{ z<#CRJhUYhkE{3^=E^WQJ1B)TDZl)x1T za)5~}lfRWoV`#^~qYab1LF*;VW$)oibr5~7pW9wBZ6&KDgs1iEfHZ8C!5~Z5l~Odm zR?lvy(Fj79_Kq1pXm)&&qP0GmIS4Yr=kp`!>d!G!KVgW_-i2jA=Bcr(!^cz2(!}2> zs&Yeg?j(XVWu_>;7Xv|7j)!rY6;`!qkJbogKCQOMb~kfQz-j8g10zC#=7p+l*&h)` zbhsz@0Dp*L8muHD!EmJ0GZ(t0hz`hM*F#5*{~T9V4pSFq!(zEP%0xFXn7s0n&k!G_ z74?!Cu#l}hyi$_h^u=d37(elVheE<=YLAT}^}@qcTZdcEU?Yu+iJiM0)dY+Ek#Zer z9miyl9i=B16O>EMdMR&?cvIt|u@Q-J!qO!3Er{5a_`BShK@W4~N@!h({sFtNqln4D2Zk7x;4iDVr#=XY6lpP6{rIEzPwehq@x8mV2 zDnBB+Q{cX4m!s6nSkR_Bp$MmKsUBq(<@ozOgotUwHu+~&Bb1Y9ScHYbt6vkWRh*+3 zt;YM!ej}A?2Hv<%MrDFcw+s60h&j1dPTS=whhbi$0;o#7++c7mE*C#;uA@dB-K=nS z7Ox%|<5Pd0FduBs-BDH{nmx`g``mlD5{b=nQYr!>32Cy=HHIFGTFR0YneKI3YZA&kuoir`vK3 zAe~n_$nCp%*CR=xzSFt~jf#x-zBr0i{0H|z2wYfs5WT=QrkLH zb4GTAc}!ULfj6#KtfR@N+ay`Tv&r$7r0I-B5vgeK93&dJycM{A$J|OM4B|m4hr?CQ z#W5g6J>?SU)ci2(RwmN?1%N(bJ@3B=jxqiqtDUdBVvULpXNk+WCwwLENURs^+*>>o zTe`I2$Y+2tiqCqcWs}vg!6DH4(Em82YRGkG$5NRDjPf{g!}c7(#HN)S4lD;R{PS#& zuUnw3XtTOVN_WndRc5%2%0Cfx$=}3r?6NpSl7PPH<=MDY?t%NB6(!GRbj6(?LrdxW z)F({Q86QT{dvr?%krl=-R|9Ih35uhyx`5PL3a7$vkHvw3-+lmcr994#22Vz1Rl1lZ z-V!iL_n*@uOz)`kn5`?21^$Sl$h3HulYKsK6n8l^>dyzI9y=(eQmg?XKmU)Xl1nis zufe|70l8zMzn6eE*9EO+RPa4>Uk+XU-O-zhILj|#3|FL@n20z#-204un9N+0H<<8{ zx90yw(UIXAFhEv3@kE3{QTPu4PpZ?2zQYsVsM;SV{>zzS=(L)7ahl|wyxU7Timf3Q z!Qj~|UXiX==j9s$bDC&d0uvN~T+u`whG-;(3P$*tnV`{YxRY)Sgnt*&Oc8&%A)3!p ztT&N>rdSJ@Gv{l;e5QwkPoklWYunT#gf1qMyUSViR~M$Rp`)@!<36m$1YT&wowJ^x z8@&2SW1Q8{dk6LOMT`eC+iSVO0Baz7b~B(+O1iFcbkLz{!37l%-(Tn1U!bqk*Pon6 za1A26o$y_GK7M0S%sgqsrz$ac2le;6{$Q+#WVMZ3W8?k`>8-7tP+DkWh3-5cO`5Hu zbl@`~J0s@urD^x_?hv`aC(*;cU;6c`7mP$;pvV1D2rudAbxnU_d-A63#2u-&3VYw{oZSEA+TGImL2wf=J zmu9}}`Hs^>`rTqmeb6V$T?-~%oWD`kiDR(Fjpf>)hYIAO7&ju?M*E@xE463`@{UigzB+melwYU*|NaCh_EoG!<4?B z;uB;B%@|;G=%p+I5ju{5Jgo(k1inh^eXMavZmPdlpge(3=_` zO<%E;Zw-BG9?SX&Xe*=pWUx|K96+t#76@MvfB*ARs5gZSM@cZPD+YMSt8(C=K>kpZ zepn^ z)p*~h*oX3qt(M>dN3Dtk71E6b0SiD>2P2E{?Eby~xqxHMgie(rM3@WSclUi0RbU{E zowKAN$zJ*ACb->QJE^~p3AF9CqeXc(;$@jW zF!Zr`?YY4J@0us`^07}zhbEf1H+-*w`w@r3f|A#M(xkH(>;zk>XOioe-npypsRU z^hp0ed%yKqiIYLFQeSXs5i$U3S$vZcS*~tJ2b3*lBOTZBWo`R?MK;e|DIC&fDbpoDE@ES>fb8=9@vpXCI8Bn9%bljDwOK7@DzWxbPzikNJSqqkxwN}GnQ$ZrrRMfLp$S`{BOR4d^rKPsN zo^>Dj3-cK4(}hg2Xsoc3O@$AW-P5JU<$2G(NA{-DM|`KYW9x}%&kaHQcXzpXZat?p zF`P%e&~GgtE9}X}m}Wl9P<*$N)4E5qFq~{p{QV7!cH577j|Rz+B>io7{WDYizBpROa*U=Wps$2>7w>2}|`y0+7A0!|X;4mRWeput^)b2ccG*$`6805u(xPNS*%_kP~1=55703~EBpod#8k}j zt%)X~)MRmsBcO0~_%7+$A?uyG8sTXT2?{x=!l0sM-Ron@czfNJXV9NxFD;36^eV!2 z63X;!WJa^-H6Yj=hIzVkG<5>HleYFGob3fNKdUvbwCp5^-8ObG0HI;I2{7j+S?T(3 z?8wmRAg$L3(=_O!ud73%0wa378{DG&-f&;ebKm&*r(eiG2E~H?FOnwXM$#tk8`$>z)9Hl%^=RkGRWQ z9Ow6;uiRN|!t=M|S0zT6-VM~!xeith-+QbeB9b<9(IM}6;IhW$b(u|N_V1m8N;eWR z6?_&Y2h{;8D^HUy4Bwq0#w`Vt1T^cUL3)&@qY{Bt@b(&C3`bX<8uNVPB6%@IUe{eU z=L$kG(%UK^FRYCj&(wldOw8|#iL-M}zRceO820eLW?Xp=#kpj0!ctgXYT-n;x)&iU z!ElB6?0|jlzU&+c;ub9Se%cA#BGbIggFPtJXop=z!#)yuSs4L?`i0s*c;gN(7 zYC&p8{)YD^hAkXyR#;m+GN7_Is2S`A#5j_L7gJ@A5G5Z@N=LysHcR}VVH!12pP|Am zIfr4ORP^Uv!DwA?EG{rwZzpp<8x3+yhuFfHkNN6eIVTXzfY4)JzWlb>1;j1yt}{n1 z2s1MWx36T4?XxJUj|l6pmI6B8JNA7tVPKFps111NAyG?R);k9d8;d zW~~1qUfw%A~;n;<7O`Rq#Zmm_0qr0RLN!vwP1N4C_$EC}A;uYY?^2apONrJg5SD;)LlPx1_SE$ok%obXrVp1#gsO%NAc5nK|W znBo0$qD=W&C?M7Rhn(%^HXqm6K|$jx@_~|o#HP?@V%js69gn;qH}^g!jhQY zpgH5tQWoV4U)KoLxWhX!6=xK`x8hzK+n*{l#vNDiaN|9+7qh^VtX4UNie|<=AynG*k=UcTTVr?A7--7A*-4=? zNSqkJ_QpT9!(P2(hf4E-uX^D!8|+?5E?hs|Jt?_Cg1wxnvRRYX>*A@99>!)va@zdS zSWe{$;SisxR(u3}yUU{EPd_hZUg!HN=n;i}iAnVEqZi$EmJLL4L9;}*-GQU(CbneK zQ#(3mdVcgE_%Ka`BdJzX>*00VDIt!a8>I=9snzRM*Ze9Y(s}=>bBSF1H>Lqp2tVc> z?3Jqe$URIzt?T9KqNIsmHQ+%sOkm&SOZ;}8U_TIAmNseH`{H(uX^9eEcWLmkL&#dC zFVI5LCvw_JoRWG`3@9m0PP$AZm9uxMkL=@eC?dV^AoD;8RK(KP4wG86Zz6vA3j?F7 zWUMW(Zzc5`C)rcyiqcNPZs~4H<^OceFDa_sPh^&eC_5wE7DD7T8X~w;Qf?tvKxWo9 zuy*|Jb5g##99js8;cTuCIG&Ag-wQA13URD<=b^^$zH<^dO&dOTy$TKZtKx~b4j<+<@<)EQ0umWcYfiLNa#}R zLyN~^P_y)$M^}6R(-NEt`*ycMosNlAQFIu$=PK&j`fLk}a!Gvq($6rz$b(NEEselE z;;*{aQbkP%#}6FkM5e@CC2jfx15!R+w2Eh5BjMYvzb<1@{f$zz!E zZhY@1Y=uhT)59{DiyGD5mJ#rCoI_d0IbqEKXf|#9)?jmX^y`4|B}eh+q!=cLad8}D zR>fW`BffZ;8Ggei9dK6$t<%4DM@A_JVOB8OC+raa+3>3EsPmte=fg5w2a!T`NdDc* zGU%5tSMj-3*DJ>Jm(IT3*?8L41cbs<2YmHA@V)pp??MNYi2XEC{#N!Z1;2I3#9?nm zq4eEY=8q^pdVD2mKO!N927 zYThqXp(BKSq7?fse^-=iSc->rb04f>C$P#>>wKQ_v35*3lJ}%3)(nB<`W&fbxUsZG znOcz)ChtV&^}*(T7IaY`< zJ)0j#D%}1@h#aIbdI^6ht*e^zIfA~Su=G~|hpJHmnYpMGP;1=;3}i~S*@AD$WJa*4 zdGcg}I-T;J4-`-p{#XOU^t;qgbnT>bbUt-ZeH}m#M>!kkb!TJzvNMAs$IKZybo03{ zj2Wq29Vl$Z+fFmkkVo|L`lj0%Nh01{c^=Dv2?dJ-7!littn49w*3?iGO$1K8aWI+nRKoPsF@Dp{ad-TcopD}Mz6ug%#?2CCs$w3xbM?wm zoCN&}?ycX7QPtv|E*-J_7#83}0 zPfSdMyPLT_)h&*J*Z%YTHXX9jU@EAse+CIxZTnK>nCTKj8X4A*Pbg|~nK?u%xgA}Raihg)Yk80mtkbj!%-n`U8 zz!eQuF_Al@xLK43m7VdHl(4)CFSkPTL|3QUuFbmSSs{lgFJE;3!MT~?@6Ci>$cE^< zBWa$h4e9V0MP_rtd@Lduf-Scp7z(Cb1_-Kb%L*;+v7~LF=2C~XK;}N$dciOhB8x^=@hQ83#Elbf+cZHuW*CRek++nl2PCk@-x!n`^8f50D^03p4@umo4p#oWWII2bKV^is3P^OgNp*o_I}Zp?8AV_+>M{wLPl zuC|lvmo`zc-chIR6CO5kGV$Uf^y{86nR${TXW;|O;I>G)mpw-ZV-hy|`xr}f_eR_8 zrXDJl%z3`%0`8K*s(tt(2s&!DNm}@;q9bySa%C5vtyOpe^dRj6RFMZ0x4#`Wqxm+( z1|GNmx-y&F<7(hrR?P%(jLvjB0BpwhgkEEBDNNv_cT=$y$Lw=`6CyWB8I zxN?mW3{a+IH30X`-yTguwuztl27MTdga48{YCw!}`RFA!b$TxM!`3G8E$g^DC5S!` z==U8#p{_uojiA~n)${tvsF66k-`mhH1NU%I0eAf5A$g;XX8ONhe>>w*U???iq}gl^ z2_%&y~u1iPd)Ggj@Tg4_lu9Rph()jZ4`X-_sml z!fjO-0kt6s6Psn$uo-QDa$#Qx4e+jXur+?(L`fqa-C3Yuv!iZ;{OLXjW?b>co=>Y2 za8<2Kh0!uGpKJ+Y{=&*CF~v456dt$Gg7vmzqwfi4g74g}=g-SOy6D5dg&i>}N1T<6 zX^nSPyXQ;G@K{Z)>YL5T7tbcosx6w{OgMm#9KKh+&5Dvo7Q2iYg)6^KAY_gGe4JJz8Oq7HURiYJ~u+ly|tq!6>DbdYrvgJ&!A7`1x5tfvG1n(ASaF z60?yG450$MXa57g=B<7-Pq+_%r$JMnN9T3RFE!ownW6VDJ4`5;=q|~P+F@t8AkjLI$eq4HLNmgh8&_<^UY+3|f#CF~s7WTgG z2x(_oo8T(J^BesXb3IYMnV8fFC0W3B*cg9SAS!6xE`QYfG=0MQBHSeCr~Wp(CrNpZ z03Yb918ZTiQ9DgZjmm0~f;Q*@KIj4?-$`X4d%`^S7K?@EH15<4!&IMA(-cYz%Pa`K zc0OcGuLZDez9axb;V2hjeT^7|^rQ#CUo0^g^OMi%M>Rml;fyWGt-Gr%gvVjm6Q)CA zUC!tMFvv=9r#14Zjq^f;zjkwDu??L81t{XCh(^b3#UI&LH;ieu@I!8xmj3tjIrbAQ z{$zLB5b=7qb7%j?_|DLHk=M3S7-y%=Z*md_;Ug!ZJXs5Mo z7`IP9y^Z~7uz*9SdR_nkagf<{gc@vVU%GroLgx-|A(b65yy8{eZlY`~)eI#!*mz2W zwAWdBa6p6UckIa;GR)8Q6iF3uQ89$v@z0*-5XZ(UAAEo=K`?rPPobLgodGPWu8b|Gs+HqIV}&^Th0?FBh-U7wR4o_Yx#PS$2-XlyUgm{hC790)P1Lwg!PPBeq~ZWn9HocFu>uo zb!av8w5SGhUmm6&&VZJj_uj^iJTFlI8FEJfW3)JQ}$eQ(MGl&LB*-^b3_5Q-tikE^wo z1G$HB2X5``Bq%aH@eW@N25ET|Pk*A#1fIeEsS z(D82xXWqOJre<)4WX0{zONjJohuM49!GYyNlrih2Dlh=9cQ?{cfj-KmojxUmDr5G8 z;haPOV8<)KK#N|XFv__e#ir}YeD~pmFFe1Ql#w&mL&A7R>$8Djp(QvZg(nDM1l$2J zJj|{w!n~BbpE@swIun6>f%)r76fX06q-UUk6&z|S;-Na+PvRp0l3yH7_ZZBogQw}6 z)z7Y0AGyU#;+dZK#9-d+Y=v6cdoWFPNhWo|3ieBJU5&br6YT)#%9XU#pfbSA!ODsU5vBriJNR6^sJ&3uNU zbOeWxiXu2Z_Q1LL{N^MfuDg1qctHxxBLVUU2d~fUBST=|vYheY>R#{~gsfB5G;hv_ zlur4=W{ps@arTv^kUmcdTq2Dq*&`Jr(3lojtVq9Pu!_?yDy!LxObIUuAd5 z9}&cyl(z$MmF%bE?O)B$Dz$(BH5*b}!jUWnQy7UT*zn}BFT$2PnmuCeGsFh+)JAVT z@ui-$Qjyu)^{qv-FBuH8|A)zhU64{(%i$P*a}P(k8%uSV5;cSS?ge@(I=PnzeD~pB zu>5oTDM2JZm8}y9Gyc}GfN~Uq?f(g2p4JJGh1`%gcJsbfsXT$R&&XSU)QkFu-MlFI`d zh@7+I{6*EI%1?-&AHKlq6n`zbPTDjt;OX5uxNUF?RJHgM@wjk5sRAS5pn$}+1~OQk z4nrTU(wm(*V3?qxoYGVOSo1XY-ALhXYZ6<1V88-dcosijNdW~udjswGNF{gMR)H;431kL6=w1@|=(wl8vl}zXHS$eBLEF8}{ijCv%SQIH_M4or2fGO)7>ljE5Vs^AkqaXMMa( z{bE7ac$yV>u2k6+$IFufm70;=t-wL^!*}Biz|V9}rFr6sp}bA~pd=?GHN5g=7UMAv zfRN|Y;+hgB&Wh=QPR|XU7(0t&i-*JJ%to>m%g4U@e&MLAl+;Ny#EmP`nWR7-$hjLXe+I7l=PeS> zHl7fDcQ6k!3l+J~+s2y-XVJ_PaDOR*9zv0Wo8Vo8n>2^%1oKT<2*f7e@|R%+g*i?5 z2t02J>xGvt^`py=Ppt?>a7qX7T47h~m6LEkWx~A)E-SpS?xWa%RLhLzwMbN)oJpy; z4HMgYX8w5e4F)1b_W*iytPL>Hl_>XJZMx+DG?e;b0IlW^T<9-_4!eq=^|asbI`TAx4i_nA0qD|MY(@C;;ygFZhNkS>93L8NjgpJ( zIJo^_68PYF=?8UlkD|O?9#UX3>M`yj&9(73WwL-)xvtm3u&TWbl|Hk@=Te^irxLMo zave=?#T@PgEYa`L_x*30eqwN5dlezL12=1n`p>8LkDH3>M}X#I#**|*R~_dN_uUhg zg6L`X-nFiHM}Bdp;U~2w6NbQ1{x!`6MD;TniQw_cQx<=xhSsMccO5wydkY&}Ad!l2 zEm>4V*D?;Kn8%SEYcJDaIPT&ijOby)1dt0wNxrJVfYR+T*$zxt1Lr$PP^qmLv9_qK zPx#hRVU&^AO`zERZAnr)x%qBOlGOSu0?G**ML0&|$(QkApg(G>xDbHv)0kEkuqHgf zxtg~ISlWE?NDC6VrQb6zn90GmXqkrgcYxLQ%U&zS!9GN zlB2`eOmq{)_r`R68`iO`!11QO6|_$k=~%EGh9GX*xse#2lD6nn`aY?lVZPY z%Hvl2_QX0HouvztCa3a*z!(DjRK4C%pa~AcJz*UxAEHs@*_4;(cnP(tl#VPIA8kFs zQ-3Y$66o`41L6x#fAT;w!jhHrR`rI7!w^{GMXlU6T?a$!KWK1Z>^#bn8F$TQrmV#> zqH=pPIi?g>>6yj-qml5PxHI8RVOFy`O0=O9RA&D7%HUeU{Y0C34YU2O$lcn}+-(zd zP&}}Y6NrUS^JZ5VrI(|_Z|>#O0l{QjANZimp_igLx2E^7M(;1T(vsqJCCQ8pN*Jp* z7#*tBF&)-qm9Xs|{%1#u&PcvZdGuWoc%F6CR?eg3Sq|?kgLktJhYecLSZMsm$JC*< zFGG({+>|oS`zF~C%+3xRB&Kb7=pNwERsI%Y-mTvE9fh2kX);=9ZpK(6$*hD5URL0! z4JN@7G@<11@A05_WjV~}pGIX(sRLnZQM&UegLwaWGgnGEl$=&ihYg+~>oq-*mEu?Y0vh$GFC&5x&w@|TmLi{?D z*&HzJV>b|hVymg1ASD~q(;r(+Ip9cBTHdXS{c1r41Y#ip32mJ<2TwjJCzL6zd zdPvR`d2kx0I8jom411++_iwlroEYt{QYP^9&a2?1Q@7#e1P4(m?Zw&bu!r zFL+NW0;k4sXV?podlIfY&}~1l5Pa6e2+W= zN^(S`{TJxOjsp9RpDK#j%2e9#CB@u|$+Y5%D+}g)Etpe&j4w?&kLA+k@p>qHcH@n) zCKnCnu`w=mC#(}gXa!Kl|LY6D{DV62{xG1yVG`o#`Ou_)Md(A`kkCBQmMT7&rE+46 zPJAY%%*@60%cW?kPr`gFkUL&J|Ix}xQ{7J&4ok6j>WtN5L!J8IcX`s=Sxiyq9g`L5 zCWo&IqwlIkZX%5HLj9cmH};cixMlybn_emg-2i0UITlF0q47%9UKxhXz^9_S7c32z zEjxRc%8FY)Z=FiVb=6N`@GyT~9m!BfMFhpJmqn(?_f8U>)HwmEum#U6rlo)9Ys4WV zOq-4Hr#CRW#!}IYSS=k>#80(jHu(Il_rG2RqfX1oADL&suGr|PLe9v+a;%$NyQh@w zYVC<%STWjpOe%cidKGml+<@20_Q<5r9kc)PZ-T9~Z7y*JZlHHy zc-goCz>-Ocf^hLS1{1K{vwNaYsgr)`E-pPYp{Qh)2q7r2#d2Q-q0XoB0C)3ouzN4H zs%{}kkW546q2RyGOWNHu59m$2Xr#A`CNO$YcqPyO1acm_Yh9*k9)>{Vb8Sg3Wjmc< zApHbFiR!N|mk5*kyJdhCof`w@$QPDhz$I>@?HHG(pgPy3yY{ux=Cxkr@Erjj5lrCO zWVdUM={Kj1>s4yO1@ik%uYDA~MT5W`!i9kd03@fDH7_yB-we18J9s5_;gF~sy+p#u|ZjMMdbU%GY}HE_J-K({B=OT37|W>*w^!w1-#yNWX~ zkE4liFDvTv!N5C)9uhw-k&t}m*t{Re+kG5rU+v-lJ~J{E=DQ8$+^V`W%fbySlpiP~ zywN2jI!Q-!jyDy7IKxtAg9J7UdF~Udek6OROMSm^80U4!KDB)76yurf zqE~R-cBt#O5&PM<y z0;F;VvC*cp59ql$&89-g4PRn(Mk1p2o{1`mDAsj%f!(IkUuJz5+(UQ*0ORQrok!lQ zfe@CYPDC6)E%x#aWf~bH7E~l5fQfsT;LQ^2gbxo65(njAbQv!R;ruD-^Em$70eUQ# zF$+p;x4OF38UG;_zSnAJ&S5sHXlQLBF%ZDJwgh*E1!w@d^^#E zRmhM4hX0{chmPFvNOW{1-V?cOw-2=g6VPF}1}7s~Yp4Lx(?9#ee-&Au(vs8rtqLRE zenamkv)p|ta*Nc+5@XLX{2|=>*zqWZ`i&YgyIs1uXTr?_&_BflFq@AMu{?gWVi!WKwD@t*cCyTp>)@QF zvuq1y|430(;pUXxpz@>P-%n+jY*XpTE5n7VGOLQ?*GT1;KAdjLu9L3vngeFn6PC1&v*9f^W*b4V|1N zI~*1V_hdw!H2c32m&iq9iL+dMLCCBtcqOSW{qbs$i`K+zT5CQ&pQpyGzI;^PQ%QY@ zo&H!RKLUL%qIX#huTk>auob=$oFEOfG^zZR6v=J*z&#sgd?e)wRmgU*7N#DD;Ngegj%(2@e4M5RLL#982RvMm2* zw0N55$F13rOF3j(jk9T%Zn&I^yG}0BrbQMkv&&R>PVH#F1M$Qh%$8#ZZ%1($*uPHs3p6uDgefKME2-#?EYb-j`^XX=-CN9rIKUW}zDw2($E#S;o6>6$*4d~|&CRzOEN;wy z=lUC1F}lUHe>_W~Py~j}GqMP2XJ$Al^(|B6td%u&PAf zIg11l%C6JQb5-||jkMt|Q1fr{fkX_*TfpIPq2+7@01+-SEc@p5Ik9bZDuS)RXW86j zuf2_+BlY;Gqn(rzWh#wa%RZY0Eikmn6j-rw^J5;K@RD-DB_#b9|5YCXG_3*Fi}bd{ zS8cE*t&+Ce&3uW+xE(^6pLah{hsC%eTFq{JRIj2XWqW{3zG3Oo+>RDvV*CecaOQ`4 z%&V^(omm$96x9~Ud_fUn1p%AgiAg$nir8Duj~|X#H0$D@ogC1xB7RK0REZ!x`Ct@H zhJCs&=p=&XQtjwSfMqZ+)KGfP|HP-s|Bf@0(DkLhNBIx}=f=K(OWsp8m}W4&W1C`F zvvO;({~xMYx5Ac4*YgLHfexYGf9o9-nJ-CH`F3`UJ+qM$_@UhYTLLc$msP?)HSG)b zy}TNb-zeOn4AlrN4sr5nm-t}pVoWBbcs%=FYY7C)Kfl(N=wzYn?TgAaQ+p7=ia{za zewpAKxuZZ@vBHs?4zH91JbcP`u2JfiO8kZ z0c{YH@7Z2@8b^c@Uw*)*6@SrA&4&TyZ5Tyn$iOWHXbEkYK&8IG&bGi6zcXq7rMg-j zBVy*O-tJGD{7m=F_ZuG;--PUfzKU~>ubKm{f__-T#IuZh*qHnX`odFU z1&AXL%+JyaaS^;_KBd*vji0>{<2#q`i2K38yh2q25i9=ZLU%O$T1w?K30qDBON&zz zaSgouirpz|Oe!ti>^ar;OT&#~=TNe_E?lW#rtop0xUsBr`AF|YB#_Bu=^ps#1~7DG zh`JtRZam3_zW2>x9&~t1&*@L$(jK_&$ok#hyLxonR+~0Bklvl&`#Le7T6gy~FE$>8 zV+_5fGA=SAnKN7G-=eqwQ7(%wSnu+ifSw)V#02l)Pj#aZb{;+cXn!T3N&LyKuOH6k-;aAqY>; zT5ZN8O}Z+q@dbN?VzN-PH4aMul6$A^g;aQz=UqH`uZkQO&scUooF;3lDQbh(A|JUn ze0B9@n}C;sIqXXMLjCIFPg^h&*IDeAgsJ?kn=171d->A)?M$N~!;U=qqlGIsw<(YU zFc#W)8a`tGK|>G`z|N^ikwz8@k8!6Rym2*sGz}VRMSQ7WuZ8IXWO^yu=2e` zPsC^(V{puVOZYVYqm)s6($(RW2^U)UZe)SJyBnQenVe(hCMT)KP~$U?R146d-!w-> zyVw5ilthd=^$X6>@v@7B!H=m%0PS8o=OxwS!>WtVV#exVr1c&uTHKnEIP0pnG?eFI zI;U}NmR0RV0@ClGH|i0MFeAD5HM)ju4hs^LlMS4P*hp8BX|VpArn>1;V741smUKXO z;%D6Al4>jhu^-m#Q^=E&M(D6a^7#|TA?99lt`i8So~$N03sU`JA(IVyxrijkR9&R0 z3B{*L<-Z1_R9d&$o1nfqf%>Sw@ejx4_AO&jD=-rTZ3Zl6_Zg_d9~kru+_2#_cB}W~ zo`y%TsMM;{&A#}PRZ1)5DdCH_X&J2qYQgo=K(TiXBAir7#?l9CX@p(kd(QD38LFZFUJF)tq zKXb1X5HA(9`*R2@_tYIK*1&cmzJwA3ygdT+l&2-5M(y|bzE~yV-|6z(eGlnp^&oAM z)pUH|_Zd9UUd8fSy(7>iTUw}NN6LEU%R`SUi=42phbc2TRl}s{43k8j{Ejlg{jYm} zRq{ab>J_Vn@8<{adLOz4Wy+gNC5+@Yyh;2{BHGumg1~3J?&}z5@|$sF^(>fS6Gtdz+C82uBVmg^={1n>oL*d(>DH5S4CrRIpb)e@$V;xm+>A{_N3SwFL*p&j_Q z{tw~Njo_`o9`T3d6n$wg!#&4x51YRasE`T#vPjj+=?1s2;N~RTfw}f(EzKeT+v!yg z$k6o_t$4{H-q3JqN@)Edw+=mro>eDCcmiN({)m*tH8MuSN5pf}BQK8Z z+x#^M8_F5Lw;3)$h|RM|S9tbZP+DQS49MC$`uWgE2^I1V{PO9KoUuOm*#t8p=$|*0 zZwQWU+Y5xl4ics(KJlePd<&!-0gYL4W0vuNj~IU@8UfWeour3rFBk1caIpC0?bt^x z>RO}bzS)PmQ!(q7!(1?zukqepE}zL?N&}EqxhvP$kQ+yl!SOtY4 zxu3akPykqHExrVLEww~3r#5{ZQ>aW4GjAmF-TFc0!X+VM8k7kSn)0pUD&C}vLoalz z@pJBZci4A7%XgJMLiFOZNde&1ic=_rUb%+{_UkmZsR)`q$y0e?+xktvU-DaTrtFi} zuYE$A5w?C;lOjm$eL|dTb+bHGs4|#<(+H3KOD|Av&$K<-?2Wy%{}Npw7tje=>Vi4o zID@qAk;tUOV^9B3>FDogSn;swA#fcGCn~hSSNCdN3o3mFDSK9E<_;e~zh}7W4Ys`3 zQy`ct60&B98+!CML=B`jg$%glKgsGd>O?RY1q#Hk5bT5rpXbooXQE0$p&Dtuj za^6aDd12PPQ@&(6z%g7Du* z_OoZAY$UnzR3j=U^e>bB`W+sfH^Vy@7zcP*R~xBH&mmnZqq|*Q+_SQ{Jy-;2$@?{8 z{1QpM%5Wtctt>y{WYxnHU8_#yY((M#3`2EWG|h5E%80E6XjhN>kJ4umYQ8D4w2M7L z$aIh&M&JGPcw(Jh5}360^M@6keJq+xJ>sdiCLo;&fK5n%Cy@O$F@o;g=Xa11%|TNAnPy2=h!HM^OcF`JFC7uEih>AyR=pV>t{YV5 zrBAUM%D~*j7l#;AnGHP?V(Uv(l`U;Ufct`Xpo^}hBg^P9#z%NIFXSjby?$JvTdPlf zMZ52M+dCM^j$P^ae5iwcL~xV(mm8V(sik+sDK4?_viQ%ml&iVMx|a}P58xYow^NQ7 zoin2=hXDTD!$mk^#K8JSh4RpoVcGK^EF1o>RnEA-v1*TGFR`7R&Ij#x%6 znlZ=Cp|!kvIht8qV`Vvl!to5>b+${}ml0hkp$^{&ly+6je7@QBlqke-OZ8u|0$in} zU=zw1Q?bY}U~_cp|Jw{#BryK|wN0qH1vcJ?yr~4=xe4d{!_dZj>>;J0FCS_UHKeo8 z+_T%fab8K@>T5N@FjR$z@a7v-;0Fed($95VdM5?hHv$m;=~kcnsA$QzvivBoU3p;UNopp!2LvCA#?#QrdCez6vQUwuIEXj%{!9LwoJB8 zv~QCG)H#_0bnI*QjxzdYqX3jdM(ggc8B0JBp9gTsb01_%r))}h=(q(YWV$7L#ijf}GZ)kWC#@1tPl!6KZ6+;__ zehuI*lm9qKkXMCP` zN@z$r#|0ef(u!W!fzZ-JS%rh7TcNB28!1Emx4Y)mnp>H%=#8`uVgs$9`--YE!=cBm zTpsAZiJXWzB$xF5H0&PaJSJwll3TV8_M%Lw%soybTOhj+TRVXxeb_V-M|37-w(pqT zPLL7`M^%dX1TIDFNfoRa$IC!|k{Vmpa>A@)soO4!ebm(rL2#?K%5DbS4wmrv%w4U`F=)VB=#-e8@k!UlT?R&v;iqdLn289%0^{Z zftO)+Tdqn($B0jmWkhMy_7Kp;fNW%rh zaqloRMG8gx->N8Iu5@rZ?9N4wH`(@mPDpl`2gBw)u-$~TbQtC(Q^2ev<&pPZ84q=( z9o6=fYCDzDpE^j$u^_Xrfd3beMit{AJB;$=+TC-N06`9wI&MQ9lR1$-vgbp9RT^Ic zzma3|F3`5F*31TXGJ+%m0udpllcyr79nCUi>aD83tvWWubTdqDHm9tko_hMN-L(g; zrg3^NXU-7BDfM_qSXmBA;U!ISSCdt1cA}d#1)1^Fs+pamgef0QI&mr5^>xaBP>$

al->O0!BK^ybx_SwFls ztDI0kx3ncqVb8j_y8uFMO^5q!16zz-`S^>~L572K6A4AvPpLzWr)8F*hYkJdpQ9fF z>_NY?F%cS;4jpr}db+H6Yb}bv^!>L}Xu+x|;@-EAslB6*vr)$fFs2xLCY7~PaD?*I-^b03Ym#2gdZg-=EC_iy+ z$^v`XJNG)A;BWFCOnFooxOV`S#5UyahMw`_4A{I3Gf8-Joo8y}O_3PPw|9*Bpy18J zLcDbaBXggq_g)B+(7lIN#O2CQaQ^Ov&zV(?E?DQB;5Z?3-y`mKz7RWW$1&%zFe0 z`66<_c?vQ&2UJ%gRpOV=n z2LrlYLx69K3#_U(S_h9Pe4dp>ERsYGi%~$w)Fl>#_sZ;@^L;2lmC$*zX z!Dq4M5x!zjyu>1<0ZD26<=L^C>w85}ey=%?w7p>J>=gZf%xjA5;?tqSE|704qj zdVtFwVo9YHCa`+{a(yDx7%P*?ULpWx{M-Bx?k!YB`#mH&%ig-iKKgzt(QAi|Xkp-6 z6Or4g%KtW^uMU@6_yI}v2kXJ|Iu5>-M*1bC-ghU;-6_OX6HHR6(y;wJuQw?K+V%ff1S=f5|xQg?+&DdkS^w$QmNe-+8!IAjI-{%HK?! zgk|Ps4Xk(lYhm9fP$8z}Vu9EYb^k#ue635LjLRibBa`}N!^nFgr2bmaL}VzdSaG2# zsP*!SA0CqnBdsa@l-qaH;|-fF7IS}hu==NRAa7VzqcJB(f;V>8b1Lr-h-iPq0}PIf zDA%O(U!KL$8>fID>{|9szRpgWw-igyPI&mj33Q=ctKDV8Q+L=!O_(y8U3k~v%^pnJ zC{Z4v1%LL+{a`;(=v~Vn`mTFRp?Er$u1SJy0qlj^Mi7D-<3pdGrE+g44GCVBO60R8 zt>sww$TB@1E?hQ!hL1%rG{Bcf)N%Weu~D!=oB|C~aAVE)b4!@s6;Gjd-5GWlP=j|Ef;u!+d^Px zeSCYKt*>9#64$mtWJUVl_<}xFV#xv9$y% z=v54;U?p(U;-KR1n}V= zd9tp@D>mbFE$%h9y$CXVrgY@9y|@DN9_exFOJW;0C&ZI}Ga%G}Q@d8Iyu6w32N--gDP;z_K?Ps;rWU_tyaCmgN>!7v!wG>95Kvi4ce^vgyUe~-YT(=_3h0;54TZE2 z`wPQ~ZPwz%JrWF^!<8L1T*p~l38!M50FwvuSPip(5qRqcvA7cWux-~g6>)rJxS^g_ zik@RXc>vP4NS-rlkzkrr~lG`|L9D6?;n&Ms}@k>2@JslAE5R%pF-CAH^O|rg^oHSGd~iHTvW>oBKZ_bA)6uwM96LLJ-c0e z4aCB=3r;h#6zVSMq?B+XN1O_`=hjc})r?t~bW)75LR;~U9H>H4o>xAvEnRm5XNBoU zS@tgrPl14W?Df^>FE4s)Gc5-JL*`#ir(4Y(g0jn4-T!k;Ay@&5BXrdSkUb=#jn;l< zba$cVlK7|*)C$Um_T&t(E;p5@dLA<}niR}PJmO4?8aGE$$>z!k^4W9fylxOVu% zO$()hT5=%nvb9{zPDz^?D}?c#o2ePjM@W;`_oRB^iL&#^^d2e_Wr&b@4Ygs^5N)FY z9RW+^N3krFxklSKe3F>%_Cn!eiUIPA)t(pPY-==cQ7Q5BF_x9XzK0$BJFGT*x!96> zfYCU_eP51JCUdY@pDN$`^Da8R_l{S#Rq!h3$SWu{jCB|j?I-$Vadb>f?YFKN?2^D4EX4PN%DUWvD!Uzu{FZP&5uxB}YBG=ARvF7_AaOB}Q4eh9YSK zJ9wBPClrH7HLs*j-;Oxesl>0=8>T60{UYQQITEy@mn1IMHd0#4M%H!+sHQDz*|UE2 z^l_~Y!!)gm@9Ab%(YKu#ELpAZ+`beGpZBzJTEb*)2WSsO+#Iq;d+>-Fz5qeoatw>} z1DrV=cUZ3VG*VF*q3$#tM{xZi>s|cBY{!e&J`EQ0mg_1ay(I9M=C~@dtANJ-1Q>!s zpzggt%ST^!eGIyEj)3IiXs6vcFzciaOzOR1Nu@dxg};yQd!WgbDFg$fC* zbl2>W;}k~VBPVgS>O3WU0t%}bV8-5UE(KE>m_FKw$r=3T9{L8~0o-x}CEi3J#CB}) zJz1MNRXK}%Yns_p^%N*f83RnJ)A8y|@>v)cu zNMwrsumJLV1p==Geo#X623L<%vF_6^%6PZLFXD3Bpucq%{S9>re2vaYcLf-$^MvcvZmgu;#wnEfGqwfg#BVT814wbGX=lL=gws?SU{cf6S zsl1lOT}kM*0w$_2aBUFa2o8Ko_rLQK3wcfTykySbE>=V3<#^xEa=dt%uun=T6uJb7 zXE}7FH2KH$%RnG^TeKH%;lTI?)Oc6@%i)j)2^jJ^x8=R_#NQP0c?*ORx{Z5K?K zS~TmDeRwI1v~d5peeG&^DV_6)gr! zW*K4stG(G*e{JvU&9|yB$tIo zHv)5t8p{$ui_}p2-_J=t3S|^!8a?&Ntq25fOLRGSonNNDHsyIG=h6O+-=3zucNC>e z1MLZ?R9ph>zr>-X_#VE^ie&{1f)X$jf+uFod^_2Je~K|W<*Nd`W zZUhupGsD$ph#~DTxH8fMXXU?dv=`}7)eMGR>Tx8{O?BpCs=86{YSQ{RRcBqT(Q_?O z1F3yQ=ff@5bz_1APAvZPAZigI`Xaogb|Ye9e0)iyPYN1 zIW*G9X#QGBR=W|*&^`U?9I}CwIrF#YQRY*baWINGB&LHQ7#;7Vz&EiW-YsyzYdl== zHa?PWLGr>7FSsnBuy^dI^arYAlHlK{{B$Trlw_#j0*{Aixj(GFGQ!gX}@oM7w3Ttdwc!+CL8)UQoWdQ(4b z>u%7KXgBWQMZGl~7ek;Q|HEXy&p6-4$>UyBcmuWw1j@T!8W)Y7oUap=ojV?v+@ex9 zum4%zsr**|VE;jjQ2o}M{(ulu%)}iHJEKS0urP$ccwdG6dcUsW?K`})K_q?GdPq~d zkc+=czH4k1=O2b-O_d@>$1ix`R*Tw|q8^o;2iflZ;%IC&h&MW^Wavv*I-eOUSQEZ; z`gP|R7)RS-mwFWr;_Io-6ecFD1*wFY2#k-Btk4mT3uEfA^f6);MwB8QH3wJgw7OQS z_2QazQ0hKdW^{i9xAi1p!3hUt8c2fnkDNBS3PMMxD!;=;1WbZx~ zT%GsfBo;@yCKB?nAuIf_5&xOn{gmwxI6Ue0s_$n4o*BHYiVQ6KfJTS39#)pLVx9u{ z@`8AMcz>kwzgQx|z0RnBa^WULQ(l)nO22eC(ab*|$##jH#O(o`F^fL$0ZD^+%)cVztcR3OzEtvlrYl`ad)hGG%)kp9wWf z{m7$B1Se~V@Yrp;gElB^bW2d7N0{#i7dyhu>CFk^J0)}KiPNXixh*NYL}mX}&un>6 z+dlLi&HPA^bLll}l6oum=u!U}^J;mWxY6|FaHQ~yGb61iqucCndR4j#(nb(MQqA?H zZ_GpPFG-m&wS167ZIQ>92wgi+=w)6r9=e(b$Y3o6 zesHT(i)<37SM{o?yb^E+vivBzGE+730#Q|G4VO(*0t{>lm1bf@wtAc6d_=gUp?jiF(*5}}b?50V`D#RUv0 zpyhm6gUx(n3Q7eS6#t-Cu7+O2-*QID3lv$c{SJsWG-KHt<>0YRU~5K-^544EHZdx$ ztt2$9y+PZ2G9)}oj?t}B5O@d(v>-V06vLTLuW2+c+N_gK2T@G=TW^v(c`OBX?Ni<1 zWwYrwbBJp-S_e91s+wD^hj&N- zJN4-+`Ajrq&9H;Gx?DrEy~Ig^>lCnsEF{N+o11|j$@TY49o)({Ebfc+W)volc;+U9$ioL+&Jz z<|n7=&ZExq2&bL%|70u@;J4a%Wzb-`rYYD1HGTS5tl_B*yUYA2*KADO-68L}z+{Y~ zN42ffcw4M>!h=-R4Bq^uIfMFd7IIep#WZT9;ht;d!WX%6&O13huMOPpNS%9EoW2q_ z5dn?o$)iQotwTii+p|XDr74s~ujL^{(OWFTqGJ%l-T$VQc1B1`!Qa3kfv+ukc#R8J z1J{@a?E&LmUjc0lB6d%4Iw(r1ZQeoB(as+}RDRVrCrzwS5(2IY&#h5J^D(dHQtRrL zAPZzE)98zw;BxnxeoqGLXxr?>f6bd~9okAY>>VU=D+?s<3<}E6g}j_RwE7o(iLb4Q ziAY4DQIG*eG7%G@zOT}W&y>XGnfdu{KhqKo!BC`{|No<&n0;E?1}%TP6TjYr+X{&Ex z1F|6%xQxvJByBts)=trVJ(s0kok+fQ&Fx(ndzO-$&TSet_~rbYk%=ph?!$MfX^rA_Vwb2FB;nn%kQ{txdWFX7Hf*@hN*-QY}Gfi6HG_U@;2>F zLDbPjn6i3vuJRyH>yc6-G275f#+TiH+!Fuh-@*OMAOdPCr}hTE*02!sutIjh8UenXi`im!1i- zl`>pkSi5p@2)%~*i^mzUk(CqLNgBcZK9`s|Fq~JKDj%IQwArR0bh8x3Nw!j6=2sR_ zvh-Zk^&^4WL%JmiX7s}nSsa9<0rqJKZcX$4AhcX)1r1sPC#ePEkp6UU-unPuxNT$fN^yP=Ua7&opfO zP*=6~uguk9D2Gzebi5A)eTwXQRNefg9Ej^P{NE~Muz|(tjh5_WvAFpZxm!QSXi8i; zegILXBhQyi?XIIP_k>ruLg;qdOeJod0P{abj@q9AQ z0{3SAzBwlhVn#CxU|;ut?f|>D`iQA;72DLiUD!Y*;R8nYViT(nh$k+lG+|R(4{JZ% zFrtbX(Xnp9RKbYB@!Y#>#tF2bFu0dIa7|m=cGTDlQsk@Fm= zt=`UVLo!sa!$|~EF%^#pN@_CYBJ$8dy&IaG3M`?e^w~Q*Pei@-iz79|^7E@NQ@Wbc zGpE`03;;G<>)Ah1-S&pvRVh{X^ znHLffSi(!HG3^wE+rTf`pRmtrtG-cm2mDvQIf#PySFwl_12cM3Ro*Ml)3v;#H3nCC z`&sEUm5+klnp*CcH23)+ic$SI?pkzb)Be0uE~Q6Z7ezg>ZKgE$--89PK$1)tM0vBb zX0RFv-5W@7xm9L`D6f@nA-WiZ@xkrf;qRhw^=DSPJXLH{6MdMO}!&ECRzZ_sI zePr5}_01Di*mkE81ljCB>Nn@LyFB}4cVy59vyf9*P|}%00`2(Amh>4(TkM`Gc#2{wU0<{9KIT#GWcRni#eG(9y^gKltMweUC5rEPR_E@ z@LRCuy9g9La7W(BF|+53ug}TlSGIwT{8HOFKobaYqplyH$(FxM$$@d-eqnZPDGreC zfTgouWDOLi>cjhsSg7+@|Cm?NICN3f24^bD+|omCmq#>rW##~~Un5#5Vmv2*rKvO#R&o{N3;z6UMldrvn-1!_tu3JPh7g zygR=pHC!tsJ618Pht(laT|uhs*qy7j&DzZb#Q()@E#;I#)hE9c33eja7Rv1_8F|y} zAd{eK|vvAzvR8!)2tr2-u|$PMIfh z8-1tOm9UTVh@U2L+D0CjLZv?(zQY51u2p#Y24h*=%)3Jba>BSS?DDHKWqR!Rms8}O zC|Fc;1}-Ud$JXvDNST!OV|HssuDH`|jaTM%_>A$-)wZ$ui88)PMd4Mjo-M>k2 z#kIQrq#B<;EJlFQAq6Um{xiG5?sD0}dR>;{xeHlt)CeEy7c;zX-52jfGzBcqhqxBM zsPs$G@KmM|zvC*H4;8A5&p0shJKT2lBKr`{Ly^!psw&V>s0#Z}>X91;m4q7um-Lip zlqT0bm9{6=V~+Fnwon=osSoHaYP|MY^!15#yVGLt%Un;GDf>&B?JPpp)`oE_WfR>4 z*>KUf4>~}#Sui{(2A&iUiZ4O?+U@bff>Al@^u^lBrjhkR!SayZtn%C;*m_B;TL`JmFY5|dOgrBOq^z=NXYs!Tnzc%tEyAP3 z+GZN<%^t74tdJ{;aN+d9dKZ+fwZw_DLMFK~*e7|_qeVG6^#k^RV7#RX)w2SAaJUgr zIGPRH#M!|YR-|^@{_Ynj1CCce6!5h8KkylJ5#_SC2J0EZ$ph23Qp>rd&AB>y-JW{M zly!*AR4eAhg<=;sY;mzH!8h2)+UKz>{J=+Xh^OTQW25uXk0j153?Owyv zrn^&WveT92iUF^{MF0fM8DzV=g4J=GV`-?Y6K6@1>cKGP8u=p|;(`(FDrf(i%(V3C zJ4PT?00{F~;Y%v)7_!AG|KmgY@TCNf!&xBcoN#_A9}~>6@l-iV4{8{>ecgB5 zbkL5G=o2Hw%Z}5c$Z#;KTyr)FWUzgCzZ4DpEv**@+S;vF!CR@sAf+UXm;Y015ovNo zun)L4E36ZU>QfKpR!px7jy!H2N>*V2WBhPyNEFzXdV*WFrf%?xsz7;fh-*=JUl*Zy z&t3Hj)>a;)n8ims$;iLRmPXog`5ydsp!;Br>!VTKOHl=RIs0^13H4}dMVyd&i7u0_ zOVj-6Nr(EJ8+Rp8Z+CQZ)bDr;(n3$mxXCNC={kLLbT3HV7 zR-liYKSvKb_7R#w@A35?q3Z)#J!nS>Y#JQ@+Z>Jn%8yvVLuvZvi9n2)G7*qN75{l_I$J_PRwooX7zC=gIjOJy)_ zs={fLZ>kzB`&l|D)E0Opu}Iq`=cdzx7y6nQY$vAF@fnDkMC^AL6yn&fBfLTC%~5On zaUJgeFcjh&V`t@YWn$Y-+7?=L?Duko>{*KAV|(7|fjm5daUBDK@0aea__!CGUQL@9 zRr`Foa1Z9^u_2Pdr#b)e(Z_0rX;c5sEkjG{%Z8sC&!}RAi_m-NWz=NMIc1H~rZNvU zNE8LSxqCJ_xxbe^JWCN3m#2I6{#*n_=Q701{zz^im4l~6HJg1?JD)Emiy+r~?wA`5 z?5voeK?i9Q5ghU0+oR(Y<2Kgn>K8g_uPOCO;*>oD_?y|Dk>pZ4+yT~U4me7pF0G>S zA53SL#?J6B`Uz*PWu6l<-D1I=+sG=Ib2gerVd3!IXH=8WJ-$2Zbm2=MUkKHMP|ZWM z?F>*03T6ObZhQR9t+Fax4T9Gr2JL%%vTB&JP&*ZEiafQMWP`CbDbyW}0fTbGDgJY8 z7_mCpG2`Hzel3+Xt2pQzD97CN=-HMRF%#tuN!DYEq2K3` zrURlQ)&g%&j5AgRXdxOdP+0>_^~x(q*YLm-dr=L#g$uL&tUL*q_!XGDfGu9lkJA_> zMMVLE#}*2S@B*h(x$`JkFi-hYO4#fkNeIwp(hzuXwmXa)Tob_43W8b>V_^h5fN0ZkSC{~CS`m%mGXQ%Qnmo8( z{A%Gh09p!j%^p+hDEoy>$ei9Pj?*%5l~Y&H1hBBT;Ms*WZ(8i@>RK=Lk*Dul)Yi*5 zz)x)x0cp#-Phdtxrvay{G#uYwsL)POz7e)rdmvFQ00E-m6A}gAwRJ328;KL0(yt|& zj!rMc;5?wZ3>3?{zR}dX^E#iz7v1A_N!KyM!tAu8jGrGTn3R+{kDuQE&I2HcDq2dKS1lk*B)@q4?kiy>Z7d`kL zyDJA^`&eTz*JO6YPAXT8=eGJVO_9fiadD|_B8AC3aXIUp$AQSE??|@HjQy>7(cJ`s zXvOfTwD*fBjQW(ZHxJk0qU`67#I2Y7uo_*a$j7YooC=hJ60W0juoXa#ft*hET`*%h zr}20Wb+p*`tY;z6mt?Bx|f`-n=e!2M?H zfrA&d!iEaXyy=p+Dg`+nfGcIgN8r&-)IP8-Zql>G5q6Y6P_FH+J^sz}WloQXe z=I=~hmVPMm5!;)0uuML%5(jSP8x@R3_aI3bJIK#RU_xs+5 zw0z^tjE`c^Gi7@RzBRWp3N#+{T!^G)kU|?r`JZMP_N!fQ-y}|cZs(=G^XcS}YGZBg zK*51x`&%ny=X-^j+SFI_K#)E$-~1^(lwRksl0Vfg!A3vXjA5`(-ba+`p#M`ht1 zHdcsIh9&I(qjZ0|9f|OG0h;;`8k-$4OWIL{pR_<68=GNIn|Whq<(v zQIUX2f;g5i0bhed0u3vFpE4dsglcElfLBI8|Lr;bpy|ET2r?Slhn!Kd7Z{ z_#`YhRz+H$dga~Af2+Tm)eFHDIcFcj2%XjHddi(Xo=<5>#nKYLAKM>*nHelPSogV+E_`&t_}&(3|%r->F86mT&Md8RNPf%a-bz)T_nR=b~kqC~!C5$yis&-dwPH?ekz9j=W=6 z7n5*oEW#xt$%p<7i!5L^<72ja$YJYrxNpMs4XK{pI6O%9_&o65>$GFKXe*ak$WBvD&`&-*J*b3^vLAj|7WjF4P@5a7lSCMhWH#7i4S*0q-Oi14a~SEb(x) zI;jF#{w^*T(ze4PK$exWrffDMQ;pI&e-3GkZYQ^G>aaH=Cc}hD$8oav%{HA#& zgz}iMR*Lz@k=C~;t#~F2RL7;>Sp7=uSI#f0cG`IgW?{@WBH3r)f-N_Mz7}iu52v>i z?;z|c+>D60p{DQ8jyS=rwV5bzyjwcjuhx&I1a&ylv;?3eqrxpmA?FP+tUb=4%zPQf zC#r$fz94*YQntct*#yc^1O<0h%yS7*SA==|52OmEe2L^~4=4NJ0O0}qUH^%Ein{-A z>K!V@I@KonWH`C$MdtO>qQ*3JuZ4S;J|3@I7@OGT?Kfi}tMS3o&bdU0pA-JrSm};czWHt=$ud( zSJg|>Tf~r%5kIAdwjqBxm~z^}xK*;~l5mzOx@Fh=Md4j}WPHJ5$rGAY;2hO%NKw<$ z)JS_Yjjgmpzy%nca znt4=PC@Iy$giZR)uYA;%aq248lW9ue^ISDZARiba4|On)VBjn7vwwwaqsL{2$yzZA zpI}o9pasx-!xWC715)A#7auw=SYar8@i-xBW|d!9zc&dV;z-5RMVCC?05$O{zt`5pC|$4(O+TujI_3|SIXl8V3F zH+kj^3r}rKBWUTPsDXelW;XJu+KF4`kmk&tor+`cxiDFS-i)FK+@CZDV0Yx4 zfVoG|g6nOP>1S2f%iqkN-VLyn8FVfnv?BCz;l!I1ZRj!h;*vCN6QF#t@cAF)u-(L4 z$c={+^h$fGFx1#qE(lag3jK5|iV0e1pAvPFN+d87DA3yb5{%|q(gajUzcVE-35%u8 z-$~_p1*Sc@{hO-f(YpDM%dZ9}zK0a=NJJL;@Rw?YLd3WwH@@Gxy|+?qk)@+d5zP#> zWZaFlX;%kA2e~bwcfnOklJ}PXxe}NgunYMnw>0a(>Mr`Qq~`7P6%X5pOsBo0mYOW_ zJ^FF6`CJgSriM+sjFl*@XggXIajxbRlX$N1;Dz~9s5(-r>FjlvO~D$S0K@6>2Beb1 znnMkJc(9Yb%4Z|LM%YvW7Ix zA!Wk$Hkp;*;Sh^9WaV@M25+N<9V8imBG);3jR&wK2j(LGA$zHA-kdkf{BF?<)bW{M zGkpB($X+n&?XutnEU%!-Qv061iMTQ(7j)I?o?6FpAAGOc4`!LoZ>-C zC&@?X+ylo5t7c%74Rd0k0#kqHlnn}QA$KM4?15NAmbW$Or`=o-_m^ib%W0}Xz|%HK zX)s`Kho`bAt-J>Y`wRk zc0xRGRtDPj-=-KXxB>%2qM!ZsXO`BAg#d2nv;ieK|7qFGFKbg@+w?y`=!-#~{;T%) zmm58;yg4$ga`)MB3LrA;zc9-(HC**LY-p&Bn@y1KH9N{!bxP4nVxtQVY;I7O&7@2U zK9JSaVPKCj9JWPGf}*7K?;0p|sA~}0MR0fvJ?wE-gSGo;EjVcaxGvTr5#~`i>8Sq99 z7DdV)PuF;tme5`_6ON?Q6?_?;{#a<^cPD%kI6K=%S>8yh(0?ps5BF%CM- z1pL^_n++fEC@RtH5hqV>SLcLSS~z@SeE@Jek8vC9osPKZOEJo7P7!Cqrh7-IY6ui` zBTuigxthH6hBf4RsS&vzB9~iWZez8`4Xon&xj7sYxtf}Ty-mw-fkWE&YaILm!HkSw zl!`Lem=(7N^k4h9|2{~j)e!=jQ@F^P&nft1WNUDVl=f5os#rLPT5GRzu>KO$kc3tE zu|;CZJ<<4Myy{JX#9OxZtu!rlXI1+aE)-=rv4rDeR*!a6D)KN-%7>UMUcxY^TzA^x zJC1ZRPX=Qq7ucTGahZl_ucz9V6*P1VnzrgHs^WFZxDI}|qfXGC_7r+g( zJYh=Zv5oTnIMid3uce{nXWciETbiHASM3;v#hs)PKRWH=?Jve|MOf5ZwLzE|O!*{4 zs>{{>N#n5TjLF`^wryo+h_eer(gQtdD;Hj4)j(SJp?5EXD_*=&OkG@B8rP;9=5`_h zM@UOt^HISE;r5sSF-v4nL^xR8pG5X9{Kr3vZmy}3&M6}z8AfFGs$4)8QPO=xJrvh8 z0l97nCE1_wNE!M?dD2@_eAwz=yo-LoSRnRryyc2o$~RP%rJ7GjG~zAg+_0MateBrh zwr9`RfFz7N0hZ?q-ASYtb~j*jb(YJNw0(mv7fL;xd;{3_gu?-Otl>i*o2}4kqsP<3)3y)b?%mavbHY{_Zhs{p_ zU`ju6nq%2Z1-9RsTj&W;k&^on@zf`UGhZvd^B@mnzr! zRV^VX>d+pMo-QhSO*54#ias|j_w@Q@OD0`m4B~@M9&WZCAKhB+t(w}wtTa%0r}|4r zI+IC=6|P5vL8suxL%GB_X25AKW^p~R*MM(wOn)wVGA)J1Ys&E6ne`6M+Lqn zB7H(D$R!KC896JK$GL1x!s{|m_(gD%KRztc(KMs3*aI2^9hvnOlz0k>u6Q)+eORin z#Jzv=P`IOx-}1(YB5O*_b`;p@nd@I(jBrH~`YypblOPth^~e6)gMdK6}(w z&-&5ZFXdh!sqD-uPrSYtY)H{M+y z^FWicY0#(}+mSS-@dT+*3YV(S$?S}>{?LD%LFU6CYGiT!w_0**(`f0)CIx`e-q977 zqN_lWtrcm5e>|i4IXkD{aRpFCHRAd&b&?dSEM@zcbm^)01<|-GISMMUVkt@$2u(vm zRIE202qXwtFcDz#0M8wR(mCw&A{bYQKTKO?iAmPQ^cJTaRPj=OieJ#qvjp1@*N0^s zQ{*epQ-u3@5dTGOc{CZ39<4j^spA?RR+d27TY*4=V)`M(05UU50rNg85Xcp2#ChV; z0TVq^V>Z@BH|@6*@l+n(Z*sH2ZQ5jWr=?)$sMBAmVVgMbAOXfvBN2ixVFcFr-Pcq{ z5!LTrP#&sG>Pu?q2GpFcum+4bBzu%9s*EE}OB7$i4b~X?OS;CU=I$lZu?UE?!w65vmOA4LXF z&%xE^@=+uimM^@P6doit~A)2kig= zK#U>i=Tph_qiLT#$b0Q`cMJfXPXqjPzr91^j8x?bcij7@u}@X|xffn@)CNE26yr@thFIOWU6R6kTd5Xks7oMeK#( z>ys&d>Zf8#Cq-rK)_|B1^;oHX1-xx(nb7HnUQjeQI^)`zh_j1O?sqJE>pM{3PSqcY%h#X*a9sn%P) zGXFcnTS&WKGi?4(lR;_!7<)BY7M3b)=x782QQwIZul7TO#`$BR(bEfY-H_4JmL1w5 zD!mLKAFzEXD}ZaksX=e{mfb_ejLM%UPO6kyVYI&B^tPt zChpVl{ty3-JI{=Yk;z7OE8^-i4~CmL`MkF1z166W%2lh+Cv%lq9nwjvqgzZ^XW#?8 zMIbQb;qgGK1vMRav>V3G|JPwbgAJ_x6gXnyqfPLZQ@;%4o@+dP$vp=q>ea8pozvvm zU)bNBMk@m=3s=}bWd>ENEN8Uox+1PAFNw&RYA`j>7+Ij*hIUbw9MP-s*d~}&HX~Y%Rti>~-9>C6$h2e_A?l)lpYHy0K6QIUi@LWjimQ@G2cu|s^cVsb9+lHb#tlIsJF@|(E$)R8^ zBmKUuvb$IHZ6ZAE5eV||g|8vRR3LZj&eg8_8DlLC)JN~B648juJ#AU64!m#V8F*^n ztU4a9A0g9OUG__;>u7>f6CY=piwzfy)+Br8fd?BB$on9Akd}DEg?P_|2&bmkfefD2 zg6fh?z{agZ4nNpzz;td6I=r4{r<*t-5Jr)6d55>t3@bq26(vr`P)9Ck)Px!mw?R=E zS^qyTW87x#>i4&`8z!zmq+0{Bo3m{NPFUr&O{rsAe>`UI+!9^?l!^0@w1?OGl0k_p zCU3K}^vI547c-X)dBQye_~OY@JYKK$NI!kLo#{q{#UtXtw_TZrM3%QHm3a~es8(L0 zI{fw1%+0d1e0DADVFQ<*NDrJ{ZI545bbEVo7}Rg&@=4ydH|m&?;=ZVHgc7@{4wyy4 zq`+#3;l^Q9&!-wQNH|BZ%CjVbdUq|cSW?<-K77kDJf$to%)YB1L0O`D-Ijwixi$sB zjV|3Gt>{^V^jW0!+-z}LcNxNr4mN09)IkcgJ}EBba@9@eF5WPMth9bXCYHLMHj)4b z8&Rno@KwLpZd(J+8p;JShsgA)rqijJH8PS3k+a3=Vkzh5X?2j_eD2m;VzN2`Q3-cH z)|^=}$qw!?9$-xxXW^u)7@N8oBa%AsyxdSdn{u$v2$8qb86!J`W&L1s3BJJk^8y@{ z4~THAY+B&cHC`QxB6#_Xd4PdQ17K&AT8C5?6e9tu)MDlY_#HG*s=TJD;qbg<7roiE z-|#tmk7&p~D_EvIJ!qaP9uQH-8RrB+#oH|td?>S0Hbbl&yr>e!%)|HXd%_RXg~Jr( z40|C2`K~fk0K{qMUrkk*k;XAbZwqP2*)V91`l(esnGk6_v}|{+_f678IWi?$v*!dW zA70Bd%A+@7hkXbj$~WtC1`Mdzy{f(;oT;n~olGk^pH693E!?J*M5;biC^ozw9lf!I zhU4s3mk)!ru*w=zk?vz;JccZzpZ9bFO(1sko@&wpFpA$zay(pYK-lWBsie_-vY3&!36EKq=7b~x+ zF;lxnD^%TWiSct=grfUQmv~;WWK-rbis6+szR0Wp_QAGA;q#*ML6`;4@o{WoHbr<< zdX_(mrc04Gca?DHDnJBO3=vpKbiB}j5YM}8c-KoH<*mL<8>+JgFzq_zHbP-9=mv&s z5U}seFX8PMkVT&BG3h6Kfj^TEJ=MT_=r@&=Wks174;1sMsgK_Da8RRgCd>Mub5H1( zADpot9s(PV8{;9EvXPB0J8ZZ|u4(q5P*0BXB`Z_zUZCZLT)#Ixf#Ylk^&rZgunmMl z5=fNjHIpZf0`o?T-g>^ueomS~n&}oly%XjhSx*%p2*NkCsxFi0o?9`6K?cKV+$33l zt&S=!#I^~gbst_^noL6feNjUHfM_}Z_K zKvZwb&DXLE%#BTfx0WFmB_GlgI(EEyG7udR>h}OjKXKr|g(wI4f&lQD^g-4>t?msB zMm@Jk`!T1Bi6;DMuGL0KY%d{wIN}dr&4DGOHHyOoy8CGXn|%XMCIq)$9gA+U24Nh# zXHETxm>5gQS{b!q$81f}Axv&FQy5+bnRLg}GY(~0kH-g1ZFc*2^lzut%HLljiTQgg zB28%TSa+8l0KS+D{0c{yw!!urLc7cOiM(4txJrPiGb!AO{q&No$Q(}_X}%{Z%*ua_ zKs>9pldrZgjNF}0qRv|kc1RMkdnJl}NcdW??>%6r7C20oX4ziP>z7F~UMRgvyP1ng zD+C&3pY+`*_Ks!*AAZrrMg?6Ax@>_d4ms9~*dQs|ZiQOoQm#@CB6WLDnSysD>^|Xt zs4|j*w7KL@G;&i8bsbmGAkVvdL}piO&GliAyTAvev>>7BtG)t3%&QNizUkZ7mB|ED zTB_;`g_W^Iucr3(n77v&vPQc_QC%i&@!}=R)qwoDIQ23;An_n$dl#vj9KYAx`rtG0 zQ5@kU8!EKx5si;f}yG_rMubQe{+Q<5G$dK%Mo8e);ofBdKu2 zN3}4xEtvc0+Top~{Z!VCMnZH)3M~_&sQw4~q=DK16WmNiC7u91K*GOd#na*5ozOPt zfJ$#S8x5jzLk%LLK^A5@nbSanIG!h!S_30u7e};lFg1b92zZ99)fodbyROQUe<5iGHl zVC)dfD{Q93bGZqM1;`u3TcMT?=TtwP$i?5Q5&KH)-~nNvq`8L;Dat&AwGcV2oJ33^oX3|GaxjDfk9P=Ota-AWX)EIZ z1KBb?+at^85mBuOabkR1KU)7K7+{k7&|iKVh1K!1JySV?D`!5!(#BrFCEr#)z+LVHa^Gn^usd-T!dG(Ix7m>5cQBeP&>6&Rdr?n1>yIbQhBT}UP@~h z1NtosKBu9s1lPKZ!YP=N`_RD(kz3{7Y@0e}n(B8f%N6Pxyzj>M%kgDkgi`%_l0vR% z8NoJ^S)1<;N{y7zRq7t>-X*U*Cle;WHkr-?<7Sxu*Xwyf9I0tLmUWVZzu(%46gpF2o__iV+nBR_qx@^mes^@T)24g@MB+Ka)iugmk7d$C7Ta5qFl(wA zkbd&0dN4CufNskaIfYO5VKzqa9*|J9^MS)3p%hbem6_6MPo&@-Ty zsz|ZIlr(aLg-l|I3PnoNd;%_-wq}O(M!WFT+Pn^fUfr`Do50lKLXr9QWea3Zzzz+p z`KBr~j9}`scYnI^>-SxHjX{H(G#kOBk=k;lR>RY(-{f%1w_1>~>kzW#O z*IAvZS^9VL%`zw4cSO%?Kcta=ei;n4)eJ!=)Ie{at)OVsP2xkjT`!^&T`Qb}$rTbb z`nyn~Nj|lER%iH(d554$^p>~C9yW93T_js89xewv#NIiJu=>}^LhHSaB&e=r^m84xZs7E! zRE!!Egc-9q=-oz_808W>;^{4PQTY4e%*|>r`Qyc|FsHT=)2GUB#-cYrpSPT`bZu#h z%%PPc0$B-B#J`N%*2~PVa8Ukm8;B-fn;a#2{6{YSGqktjPT^+9BLBWQ%1F8V2i%E> zNn2+I<^xXJE*@uXqxB?BR{g_@nT>(3MS|##AkR30Ny5;O_D10GUp*YA`iAPMX24s_ zZUfRW;TSf&sYpK$e;G&CrX?;bQb@j`NFbBVXjonSU765MF4F49W{4WmvSXC5M#c;p zx;7Ba$8N!f+Wx$cQ#?$1p;i_-$QsTT1f%$;`%K8}IZlYL>A#BaGaHdLxS@wvQ@hEVU{(Cfi4T}|PFz+H?N=AA2->QHAnElJ-Ayb8tW zpS@H=b`=mgo1j#0$#r9Z_vo6F^IyYLU@gX(PIU=U0;>)-DdQDS6Au9Ym!H6rcl%6y z&-TxL%|aU7$%i*ab7Pps7-0fT`}}nQp*GDC05)gWehVx+*Rd9MG^6wCI4GH58Grl) z(wTG9(WcE$O#u>?$-sjMJB+Q)e3^am(LoU&J8#qk)%~8RF8As|+Q!=EzU;4f(piDm z`%N&^mDGyhPrR#N*;sv85x%L>GI^4FV~fu9TMPOlr)dp-Z0r<-;yu<&@LUV++8$Df zy{dO{6d)xlRhr#TP#ySv*ygIio>{cKc8DWW_7Ui`Y-6o?2|#x#JxmbIu=CUC)=a3 z;N0T>?68;t#ek2l`&7CYF`P$8t7YZEY(8Xq(MG3wiKx|3KnxdDz6_IL@E; zTJ&FMSf_0)hgC2vfGE@!N8QOsmZ!@_K!x29Q*C0nDBeN4xt|auW~aQevDvI3PXT2t zK+6#lw$#z+35C93l!S|m0h46E=)Z*xsS!sIi|Y&*u|s$Z!s-@BEU9jrs&9A{vKShK zD;t@6o6nNYpZO2rz*v$ItrK4zRHXcUl5_OF+}_@~@!~a-KDT*khQSX)ITlf0*5~6s z|M5_ySznhz$7h z@%Rle!V(*b^oICE;Uw*>yJ*4eyeA>m2*dPRaMH)1wOiSW348 z2dZjn4>|nK91wfd9HCCD7*gc(zo&Hf&k^zIo2%a;O%H%@g9(Q-dRoEE9Ql7FUb2ks z4z>*yw@y0_JH%eOVI2|6w^Qviyyusaxf@&}6DN zwR5*HF%ju4az{XL{}seke33Vpoq4o6&T904w*bg_0~6u*6@=cg`w8?-eqzCDjteGO zJ}U{sN7nms$LN=(o7pV|#!|Yl-U>PU9Y|JO!U+!tT|3F6USK@dwN!HNhK&X9J+DZ_ z4gGa2KI`-va93s@jZ(2VdJEixB)a(Bw^mVcpAgjn2fKKxlmm~U$frlLcGZhLAj;a> zeTFlEk+w|dq9kT!XC`m_x^`HNXQHKO}btQO9u9Jp_mB080FX~^X za=MJ}Z#|vuVM>EO<>))S9S9ym*z-rp@0&~yo4=DwLdYYF`M$#sjNd~}DcYJG?dqlT zb0~LKh@2xwhdg}Eshy!VK$63)*(R<~w2y3C7P=QvAWOijc_o{xL&4mwm_}LR(;SBw zbG9rS+k{hszsUsjZecZ&)zP#@E-Ib=(Zx*2QtlBuaDklwXpCeP= zx5gBCQ8r)5Nl&@Sf|pOMl@El2fXR>SF#?~mY=zjHR9_}9$?e__DNkP4WK}p(>ZX7d zmia~Vd#{-I=2&=YPK~#uv|Ew~$&yMRq)+a%ldxAw9|#pN z6#6v+v%$V<9!*I`lZ!nUZkR4=$yP(y`58ul{6uEFO<#~y-~?pJiCF-LMl;%mP3TV;FA<4S4JXpNd&`t&0xD2fCAm*IyOPeX~GG8)^VYj*B zerp3<-5@h!QQW=o&M2dAFKJIE*ZNv4?^r-NhnpVNi~@PUf0wCFq8u`1SioXHtKqGy z*?X7?@i98&;U&bBVWT6SVnMlP`{muwx|u_X<68Bavf*csQJp_*5S3BjIEHr|;P5~0 zIl_75CEyycI4ULAp5ZyVWm(xGcGJXRE9U+&5L8RjxNTpA_tB<^U+_ifmbnpzkYWqY zQ=n9VGsAQfn!sg z{u6rZ@V>;h^LrR}BePvC_$dhS;DRb^KZb(*E%u?~p0LJDJ(}4J#Bh8Q3fYfKMWA?1 zZJ&r|vX)h7iFQvv4RY`q$wZ>O$BSpHSGmS2Igg>(Oq}!RG|e3M=VjsO{?Fshb+>k| z@eN~rJNjx769LT^D%cmeurzZ74wn$O57Ac@@}z2`bOOQyB98mn*~>FKi#rSsq>H_R z%~XX*wWRf8tj_Tj$`#vg$Xplkrwt)?=j05Qvc`rcScnwreGfRuGbwPGebp?TJLvN* zR5zZ++GkGKZ)8o^P0~*g@{>R^dgnF-QDdE_Xh3x<=@VB;BAt9zJ3E7e)@R18(LUTX zb5_^5*;tlx5p_=YZDLk_*D)}3x>&c%sf7Rt;!ARn;BVNenI*+iT$aZ`q$xxBN=XfR z3}Iz}lS%hbTVucmA>`tf|7(`@U;r+8+8vAzsZV81RS0rjsLLY!B5am{0x=Yfk7Bt` z@asK{#(a^^;U0RCcbkW&KF9ip-hz4RwBNGHO$#P_C#ed@c65fd95bWwt7Q=V3WrS$ z;eAxB_Rg>#`8CM3uo~oj;U8Ds*z6Nq2<_rH;z|57dlGu+$fa$73C72b?<4gtNi)>w z#ejq!1Pgyc;%Vdg{Zje5kyXQG=Pesp@%H@e)4P0ie%<3g$WO;g;$P4{4=|2qUf92{ zAv5XoP7H(-xAz%w0^od?_y|it5x4MNE(KdUV&2S_L8NX|w$&*^ecwG+vzX;b|M0QS zZ;QAMkiDE!<=BP~gk?CsoaOy~H!*S!jhQcqvIuxv;qtA3=jC;k8%Qg875II~4-Wd{ zrajE+w`_A0d+4lQMx!K(sLZ|H4X(+LpGAM55XoWL9j{%*4Dkg?|ZhPlVi7b^+JdI!CxKxq#^)bqVTn2xD4t!lQKORvw@w-jF^0+vnA_k~9+s(DAb}u`92FoL z>x2(oSp_{PeYX^7@dy8J?_Ax6cR}`)d+FFZid%5@LxlI6%q(8p0w~a&oT-XHpIk1h zg#k^+n5AAKl|PCD|EshLuX3O3-2`s?6MYHI%s-elGEtdV<5>C!-`rvV}o1O2VX`Xzu9T9 zA9`Fl5b{SxEV*MwvXO*aA*$Zb{@&+KquTVo$mCxq`pNjCj$-v#7VgIt9DZ)O21p-a zyu@1hHIq;=oS5rWy=lFayC|M;F%~^8FyAS9d4JG=2(uH{1S3Iw9v<2 zVjG=Nw0?sGGjk)FLJb{tp3}5vv~|bALUAYstCgwE8y3EJaDeGYQG-fJiQOWeUr0Q} zuePrrUzTmL9bxEbX}%IiZ_N;Kjt}K1wv7gQcFmI*bYN6c$E*Ji*J2!q##0(}$H648Xn{(sPm!N9 z$$)(+%$JdG+7tL}4oa?jUk}M@X!djY`r7aX^%zz2uugz1j-Xz70ZM1g$()A~PfdUd zKri0Z@U1Jj!$ZXk%y7lwDwvGS%lC<^BA-mrj`nruWV9YZJ-`*J6C`cqw@;Mf_vz&< zTM3oJvBN_>V#{<0B+GM3*jz^%Lx!-_-b5mtBB;eVoGSL3Mg*f_{+DYy;%b7J_S)IP za@9k%N~ZMiThg(G!hzh$V<7#ap$>?)xRej6{`>^z2t+pUW)^vfdcKAC^ii9bw)dKo zf(^z?-c1irGTTk{Yi+H#CSc&gP*Ri*$QvmT{5pDPP23IK*Mn{29-g^Oe3Ic3U@FHG zlW!3PK(U%Fv8MA!1F$8;0I;~=d#6swP+D%m8zKqLhj)ftNH>4I)NUXy2X!vh-gw|F zoqTSqS5@VmQc4IyZEP|Zkne+zla#Q|slp4V4ShmxEA`o0Z+*7j6?tS-7QDpP% zXOQRbbYT<1!`3`P$v&5hxC%%GC^CVCqYi~;hFJo8#)(B1haA29Qqcn-O9qtN|F)xX ze)b6u5^K)l`QoqtJ_R{z?RU;@0P;n$=%~-Q5fNCJW+#%(b0$%~m6Q$?Rd_zp;(C8K zUxMalpWvrwTLU2jxO&jVpr$P;n~Ic5u%D+WJEGBSBqRaC&Y0)`hs>=u{XnndSQVnZ zdcG|^&RMiO_+94aRtHcbmx2s$X_?hqDUYAt&|g8%>4DO**@EO2C`TWw%np;9jYkh> z&7UlG93)f6}irmSX7vejbh!CyF1lpMLK09?PUFK*7tz6K`Z9gM$i#6suI z#PJ_vKvJVrGr_$I1AG-f-b0YUF$-@f0);^lF;cWpXu?R$?Hy@1n7M9>Y*&d^Ljhis zcrOn_C~b3>d~Er~ZwXXmriW2Mh8|AO^w;C3I|rzz7A^bRYONDYtNqy|S^3~M!qrQX zBM@e;Ta;7f8Sl#f4aEJ31-J>=qQ@3Xc{M%yERl4$9D$*|rV>z|5&+QAi`mqkLe0p{ zoNwd-;;ZMzg=~|KF_(Htc8{rp3i7n6!zMt!5ZI!ty)#hx==P617c+e8a^6*3z;33I z(?+tEQ3U2ZYV$wAlsa;(LK!pgRKEx8j?OGnL(vgfbLG13h^`n)s(Bz}?69Mn@&uc{ z`n}6>Y2(r=9FKFxZOO9A(RQW+ydFMp*%>R~sc`fT12CdxQj>mCWX{Zg?$+`F?^{j3 z3?vj=OiO35@I?8_Y5rJ9O5&RCQms=L0AJk3_xuQU@SF1dk^fwZ-&q&X#*&dQ$$ilv z6^C4B%H=};$Oztbi~BY)c6tlq$YeUY&~MB%JvWGEUmVZo2j;Q5jyf{s0PcLh^^LvX zW7~cH{Q-VkL1Tw?Jg|oH0l0P{ZJ%s|AdSYH^24CBbWML-2s;Y39Z23O!I5%39uBb; z3QYOy!+Gp&thM|>sQu{pp*gs@IRPd9XjG5Y3|!x|hkKM4^q++AGw0&|4Xo(<4Q(rf z1~Itf{B`ZUFhlzx%OC80Ma0^N*HM(td}sxki~WLyoVyl`nIx_fKN^!x@tXi8x1L=c zZG?0>G%ppMr9VCSR&kBd!=*64eoBcliq6t6T?bwWw-kP3nG(34xD#e9PaG$uHY^!1uiTuF57)&(B4CI^4t^Z<9j&9CIGDuEF(7o(@O_Fuc_?3j92t?5oN9sC<>x4)qbzdD~l{4 z%FO{byX55AU~c7aX&~uONm@9A+uQk|2_R1z`MV2H*UXB}sndq6E=>1~^E-i0Id1Nk ztz=vuUxjK;R#PsJ!_c!5%Q~VB`A0Ala>Ym<>3}y}5lqRR!00it6+R4VY0@BhU?tSr zkbmjpH+611Pi=gp22z5grd9TeBH_ktRmd$H6dd>C{LLGhnj@S%Qglvnrz%j*??Ouv zHCfm4l+RO<*%7));6eQQp;GZ9R@{(Se{HOCU>GubmW=>$)5g)+mBipE751golmuEc ze*XobB(u#%vFPV11CW+XMX4{{x8nq>m|WH9NnhLxT4aD_51iu=EEX}i9Xy+ph_=HC zC%C579$r)5pIG;Q4DB;a1=#F=D#L|$Z6mxJM!am|BxOwO8qbY|p)^fwFL#DzS(tQj z9nyUNifJ&toCY!FX<5w|=cAf-1FRJw004@`Fo!t%e2y6?rr>Y@!iY~@LCa@8*gj{< z205Zho+c5nqEka`gtC$fSK5F(Gc7$&0vPHXzq@4P+2|7@*Fay)&wl^(CWy@^yWnn|m|x&g&9Xyu-4u zexy_;nq)_pHU8-gg;?Kt*esL^@D035lZ)8Bbj$KKdS-L6-l`M`<2oFT09|-(adtl@Q!I;_b zBEt7Yn#os>`foXOUx`n9@L$`Ak_f-2Xdsyh3?1U75h&E%^K}h-s+qH z8&N_p+P}uR^A-?N(d0}ns*4K`lupg&tPlYB1b28z?9YsWkpCm{p%G6{|HJ<-P;n@}wf%YjzM?{nu=Gllp`$9GW!JR8V z5Q6mc(Iwuu0kKB>X4U#JVfo#-eW3~_wZvdHh>?&Yf*E2{7K29rPY8DY>+T6@avl(3$Lt)&Okvrli zkLWKVGKt{m$o#Ig(-1L|P3|bhF`PR-vCHb$cuH_bX%EWsL@;)FIJs>4@DL|urst*2 zL9ZUsg&(pNL%ERY@EgSy?p@PWzBRhKACMFFNj1{7qBheS4>htDacrbqKJuc!z0m=?jjgVQK2i4}e67F`jQ>*&c54}Qs z^MK8dh9&}$ks|UG`rpQh^(qqdARSLpGYoUfo2F8pl<4LA_MzGXR9-G!)U@0-!dijf zvK0u}B6HG!)``N&-sVWQSdD?rn87`Qo!zQUt@fnTQ{)v1SYM|ByqKVM`7ne6%3!vI z@!dk{ESU4VFx$w5beOx3vus0a#&FoS5ZCT4ek6UFru&nH=%Tgtr6Nmep;;)$ut_gy zfklmDk$#m}cI7%tmIj=+m}T1pt25r+NvEG26hxU8+^-T!mK^&%0wdNUsF!;%b8c$4 zy8_%yA!ZWGA0*`_j>DV-OR;_OAOWd_+1gtTbv=$%8qQFfPb$`ehnWLLl#EM8L7c018F@d3B=MYAZ_AypDiw2-s4INp>ckT+6ZDT;=%R%W9J=AN}r_Xn3dg@uH+<*0Km1F+ z@>sz5IEDnGQbZ|wG`nLJ0&oeNsov?QmeFBf<+P)*msY z^IwH#H^MR)-9!(RQ(;2^T8pogV84d-WbD9DStrw13`2@zfL?k^#w2x%Zsun?;wd%h zalhp;eA%;7qOGg(ZN?bB*B{H7Q9yx;L;OmJcM|5Xt+^tTe(Q_QytTpvC3CG@dV@~9 zXn3H|X=cLLPG-}`IVFTJ&%M2?aD<%=-f^JKEY0IcB)lp>XfMtzBPQDj`%rM0_yrRw zRKQxk?65ye6^75{L0nL)NrLM8?E1s?X%&>AuCkHbKyTp|U|YUf7Hs{Sb#J<b~m1;F(!-D*aQ{yTbPokLW(aU+#a>BVTj9bMg>PtDslRjaY>lhTh4gWosb zPU9BW8gDPrt>I-C9gQ$b+G=6@wRvAe+|6V4!IMd#s$I((v}6_-R!#_d7jap3mn?4n$MkKkshBx zGN&Z3{GO&1@T52vf}!Ix8tCTWa|~A9SZUGCeb#ty!Ww6Gk%l7?qWP7dO2IZg8wc3) zma1`09gx-CB*Xm-KDkfQCvehK0XQO+6%054MnXhVlJ9@-gwO@&6#-SDpj`OqOBe|= zV@g7V^aW$54@rxgo4wlloK!!zlKAkfI;JB+{#T@;G30`E{)pzb#Qm-v3P!!uOREof zrg&X?CUG37=Z%o3^^$u^Ss~!~$%q7qf!ol=H1$peOXzh!dn+iHy396YbAnw{$}^Y4 zA~TC0_glvKMSXawWF8ha^F<;g`|0Xv;KFrxP_6KIV4@y2q7g`LZT&0Gy_$T-Ui<}# z3AeQ7r*unRQ3|C)Zv93`Dv>hYG3^WBv;EjM{oDe%F`OZXhmFX=Jae5PgHNF?5LFvZ zut`NZGI@oxw#}reYHj0zm2$Y)KrL_~!OZ=yG!uT_ok!02f3+rD0ZABo8wv*0K7>U?0{y_@YxMyQT`z0xW;Hs^WY;*Cx}=;_{yN8~1X3rNkxNIy)7gD=dGqMxCvYyPy8oT-(W|wu zoYPomq&&Yr$8c3mhIg2TKwhoW6*;CLXAcFOpVPa-U0k~0RRlU`>FdpY`!G_`{t(bn@{C~c< zLiI)o-peK;uyHWEk#*^qN>*{Av1t1G?BJimF7Vb@ zbmBof3i?Qv%O{O*AgP5S6byR*th(jq>XP*F470~mI#8BIHYy0hy>9OS2liQ6ZL>0cm-56#fo=yr1lVFVD_g$q;YnHUW!f60U)6|g$mbeCWAa#{rs_olAA)&t z7MHtgeuIexd*)6ZqaeiMfApFLneltbVm# z+`sbrW)Jb5DXb!>R(!wjpgBsd&t%^v8tL zOk5m-KpdBEm!;e_)N@%UIcsXpU5t~i!cNa}Cd%vs@WdUi$dmhtdU>F!>t8 zWuIb}#V4aA?=h!=w~Ggy)?aQ-T^)|d&NK-XnX2psVM*ZiJWF3x_o|p7$|t=(9c7+b z8gXsh3FL_}MyLQ5AL082#1Pa@NxAjf4OG#-?G#MSuyt!IVVE*Zeji|ohC58q;i^WG z6W^f+AHPXts`29k9h9woeKE`l^I9d!dE53M5jRgjU*fQKggI&wW8RrShIO>YQSznH z;x_>P@X3@YHnZoz=c#%dV3GvRw)1$*rL|96p32yYJ7>{wcH5hylmdU?c#{rS>2^$J_&H&pLzp`*)F z@ax#imm*I}-e7t%GH+m8%^2HE0kvXnl95w(nu&R!y7v#3L@Z?gGN@rhiiXSo+d^Z$ z2yQXBS8bD!G8!hgmf!n(VpCDF;N|EXqhm;ZAKW^u7&-8&7y!N&Zw2Qf_Sx@I^&RBN_l49bGUF^e=l#Ymh7~u|HpmDU!b0@qQhj)3bjICg%M7Mr z;?5=JB8}9+2;tXc-CYnZyJBMy;+$$3E<)d2mh_kKIF>V|t!K)pEeqv>1CX|-S0#3d zm6iqBy(C4RmCV2ikG%?HR?B{e7N(xAyf@~HIm30_`@T0VZeVo3c~Vh}!MT6uo_i|a zAlpRr2k)%tco*NmtWg3`<5=`#-Z1!7Org~XX>>7@dIvS4z0aB7IE08zvG?xP2l5Tv z=hG1~Z?VJ;(U0t#=?OUc$P_lw|I*Iok^o-Vuv6YU_(@m|`vxqY$#7$nDZR*8>GkW- z7h`z;80wTHg|b#k2V@|HB!wWzvH|55gNNBqK-Cv92A8=G2@T{{{$PAegPQ8ST8E;t z)jL!_<3q+v!G?LtyfBQ4@bc*Aig|;Wr#s;>HA#62G*JFjFpfDaTZ3-2MQLKD+5ZuqQ169s)6E1_zL0{BHo8@S7le#-RzU{YM8f#)nShq%TY@?w;BAo0#w&nWyvozuV09$wco(R z22~&)!7|>t%DxdQ`$r-DFQ$Q}<8Zmro9`C%q(ud;gvoy@f*hrdc=H87wA==`c8wAT z<}-aet}XI9{#|#lFwi*6w0-*H`aoWJkI#?pVz|G$50yVzAA%5gEn##Ez16tqlvViITD)jk*co zJuPOGQF%%qwnavZaBxG+h`bh<=)6`q@alx|G7B{GuW8JCQ>%h7Q8O>C7N+q}8%H|f zhb$&9p9@-~jjc0}g`V=n{wySI=M!^t*e>z=XPZw4B991SaB1tWCQOSAshHLv? znC^mRK#{2rrklAxYq16?%MQFu-P%RI`c)g>phpd`)(UtR8pnB6>k&i zXR*RdUm*e_ML2KP85Qi%MzPZAS(FgMo=>I^d`%IebRno206QGy>=H(gs&XNR2*|8B zDw@a!E&@+UpAev+bV&aDe=$HRfADzDBNJ+*k3hTz2A2~T3_Z6vc$dMX>FjdqPLea1 z!yl?#32Czj=!EDq6@7=!>oNAUvTgde*Qn?f776!irQ=f=RQkG-U@)6rG%68O5Xv!% zJzvf(s$`RT*Q1cd?YcC0ObGCD?s$V{mSa0HRpx9ix4toKfId0Mi{+yE33U)zK;Z!_ zj>xd9JsSP}6WgLj+<{dY67KL`26_6>FE;K8lrhMm+$i}I)USOilFgN}Z07sn=_@b8 zGIx(tXO`(I3W|GYelUdS29?cS$SYG7Fy5tad20~K<#0JX(p>>fvao1~KIldaaP6(FLogO|s9&L=tX z$kRBZ!Qq5I6OXRD#Uer3JP8-JP<+CH%De0@qjbw~_M#^pWl$jC3_eB$vNajw=+@x{ zaGWIDXQTbqe)c?8Wgz0FVcm>2&CK-{STPQP4}=FiXI#fW!kg1Mv1QAuB)Nhn+bmP_ zckmMmA8{hQH0tz1!vyaG1NkT&x9=yHsb>=m8+K8W%2=AQ{Kw64Tp%Iq?g3q|hzqgw zg;%mdaah69i0-P{Ny^yCacSehr1D*9{&RPe>O7QZuvdzy3q+njno`8?O()Z4Tkp!Z z)X%=`65hbbV|ni2^*gjJ8`uoKR}{+#ZRUU(-dOv63&LuKTFo$14_%f*!M^k=s_^Js zfr6ND7elbfWt*)5v%jqs5!mRV6lNj_N7Pwnp?RH_J*PrWEd^lwqmXFZ({?f1*}QoU zFjnEf6)JSCo28xzYn10jFm*v`h~nW=sT>)3Zw2bWBq?n}-F7uoHc&8Xurfj1Oh~~E zjpKw5j=U_)eiTc^{~^!iFfTvV$YClknR>7vMU|WJ;=^c9;U;P8I`~(1H_CPxo!V@^ z|6MsSTda_uYo!nwkjM@Y%W@& zk?m=fcX1TX&I<}Qevw(mKID5mtO3!h4ly819(rdD&a4!SXcm6jv2OJO*4ur*(j2A&oeu&hhael0SjzZzHkH*7$A_ zUv>U9e+)j@ zAU4^vyMnLT{5C$hz#q`!%YUmN%yQK$BJbxp$}m2d;+PDn=<1cUQN-l5)DW5>u@xNn zPQ-^4&Z^ zakm?a=XRO1bfk}Wyg=cf$$007x!YS`zKxd7>3NP@s1UmZ0E)?IGxnkeNj_=ot;Cho zVB`GlJt_uzw_k0NOfRe-q8g{hvLf|puJ~KsQBruEEZG}h`%FbK;Q2}w*Ky>RjAWBz zbil5=zKngvM!(Z#qVE-$$SqYv7>6*#GWHXTmV0BUw@vG~D$)w2wH15dmUQDhHi2V0 z2@*Hkh>o!_IG_R})f$&kkb~E>O@Ya?{$+qC(Ql5v^Y$62r<1vGCWJyN1%|9N4|5no z9&F1Vw1$n*!4^mH~SbhN`aR)({-(+<;mtY~K$JF<|IR zb8?d#3QoF@$Aa|IOezv*{sP9Dt;&_bRRB%phc731e**`597XIUX*OF^ws?@u0{+RM zeu2Rt;oUhUL7#XeR+Vh5(t;wKpp|#B*1W>1R+Dg#XOV&8fEDG)zqgY$aEY{^Zd~@v zUYKJ-fzgizhG;(-3Qo{Od-FIS$HD!2TwYntvcg}0#HcpcKIakcl$cmMpZi}i*dNz% zkZ28FMpbkKYh~4VlOos1JK|b#)!J?-@|2DAhFY_L70D0I8EZM}QMz*Co%#ld zdCPONuu0qjGIRL=hK<;RZGV+%T_Ake(fx)G)~Io=7P0Dt*K-xYy#z(+jQI=Ql?Rh; z%rSF~4~bR(h(W!0oU0B$0AV}(*_FpIEV6Y*>5@EMOD~&VTXlpIwZBossE|k}yAKgY zc{hDnJ=~#_RhW&f#7jx4STFCXz*SClmX(^n(R9VgokCs`ele{U3maaTxNs3y*iPxC zoEC9ZY#h#^w4$sci~jA|2;zvcvI7{>#0Cgk{G{FSG=zC2V4B>E zL(P&NmXZ_|32YuGycmJ2bUoFUrD0s(Mf*;X0rIYiamXMqeuO&$dj&s4*Xm?ZV)W#R ziHbaPV-9#rx_EK6BH~1Nap_4=$H7-jgA5VON9|fbquMAhQ^HzRRrH=V+$>re8&<(j zDt$|HChcgvGFJ{0)xL$hp)D2}lS_!KtzWsVztQpH+6O8Db{SrUV|JvySIWbQW7P)x zTSR4#*#>c<&|cVJkbBz2h2I-!r{6+p*c@r_lchRNuQR%;)&>AxyIt7HyDsneES&62bCn^{k>Xp(Kf|pNGaEn7kPjLVadAj+@#<*~0}X+f>ADy+X01OGunT zCTMYpJl0T@FM#1=%%T|$km*HvYr|IlZN1i7011g4rT_d)Chwy-kNxj;TF;*}L9u@z zeZ3WqJf<($^&*2z3#)+DNrh1Q+m|Ru&+Hr!B_tEHbPS6*mTHxYkHszE9T8yuARr5# zD2&|DVSCswyT#%BAi$7N^CFSDtYc~i+x$S-%lvE~*vbGpyn`+(lilbZ6sTSW>n!EX z$k#S$nKS&P5g&kH`OHrA=w)GKdk-V>4&KFiA+vjVdrC6$8J_vlGjwm|?CpP!!F$Td z+vzPp`CBX3S>Hg!_kC?dMe~jY7{Po|dH&OUQu_a~eih?K{i#HQMtCM=ef^PTrbxjq^R7K@Rp1J#%GmC zBPs&Ti2INLUSJcBlzw)Axvvh~KGOh>s@cN6+2+dtoSY`r(DIl}alclhZ@@-p@6Y8A zns8;BgqBmLCU42*Tfb<#EW?%y{Oc-G6tUbMZebdz(`MB186Lb-`o#7$&}I2AtRf@g z(5)W;3TA88T9>^4_wL4xAM&cfM4gn{E+XALRfZ_&&M)$QiH8x#IH2q*_tc5;eJeVy z%w#s!)9RQs;6^(51ZPYG+ceqdzq%?43gSdM2?IFVUsUFSFuAvE$xqsOe=;&Zy+2#L z{p5O(UJWsQvz+{MMIpdHavDJomX6{Wgv_aIP>@l0waF_vRyv>^c1Nk0^P*79TbJ=jNS}a7mcLPT?yn!SEn29_g{_QMn<)%3 zTcqwc1q!~JSK-1_C*?oxajYKHvd3*I(3C2eDA-7ohT*-^_3P^mVVy!7cnh$APvv z%yLmL0{`61jhJAfK}A0}ZE}dDc{GUp(}NZ+LDv9~0WT&IYei;IX%={;`sO)ysj-5! z`hSaR0p`T#hxsh{b3@9eo+{V}fP9t2Rye7zy7l;5k{z~88jB4Cd)YdETj5*X>4(Pb z$rK9dV`CHUl6_5*n8YA=046$m`)nGWn#gDuVqDAXJAfp3hu1Lhcpz7)LbX^VNS=kJ zU`kr87@EVo!Y zp2&9sV_PRA^gc!V$y7vgO|mTw+;-cWwKZX+iL5;_<{hC6A>7+qHot^mL7?_2ql~o< zI=^gjEDpP!+(P~;SxAjjO!46H2L9JYkkx})R2FTzVkQjOuSiqxbMsh+R!O-FV2r>r zIRdp_x7ED9a~%JhN4VWcVdyL$gL2{&5&N0{&3str;1(B=Ih;smvGMRHD956QE0CJP z;(4+wcs2-Q6LlW)V0{O3=-%5ZCpPNS_c>?+#vIzw4u*? zM|H8eXtu0w`IRH<2u2nA7h6E0;aWFavXO{0v?I6vpXX>DZM@I8R->#XJ%u^B`k26b zmfcfNo0m$h_{s$7J?3KIi=y zKpUplVdlbta9)$l!F8~HPuI%(N?;qLRgYAo`QV5;=llOhyvq>l6|B*I?=*DZj2HPi z0_^l*=f&g9Yn3y;@`z`3648vgZA>5A10ZyL>#s?r-1E>*;Z^ljK7B2d>b?nV#nV#4 zAkxNSW(Nb|;Lf0oqRxiiS#Bg(wo_o#Q_2V$Z`b{VjGExn2xyL3E$-q$ErQ10ge=wV zLxJB!nk(Wt2XK=`G>_>^$JSDMbw(DmQbGwRj^)W)tAs=zJ2Bj}u2{M2r5O|NVox#> zNdb@!MD_&!kybLs4O||}=Wl_wP78afFL7&i%-9u;%-nohBMxP?*1fFrVPFnE-5@UC z`Sf$Oegp$|`p#?K^C`258W}V9{&|!Z&NS!@>P3x4$>e!W@^TcLxN|;TJbt?Z;rO1~ zQLUiD06Rd$zl)*1kj*QrcXn5kU3d~HB)Z?n??d;ZwV~la$O|`EMHL9++Vc5kLv!Z$ z!d;y&$5ZbSsLC=}|CjX}tKBT`BEs}sY8nC zMEeKca4oN`ek$C^mh}GNJ+k*SYSR^0!q{z|v#R`ECz?MUXj*BJB!H2bNmZ0B?l7}7 z(Y<2cg9%zv^jut%$@m+8e_(|}I#bL_&}_zU2qCMu4DAz6fpn)A7Zi;F4FEQ|)!A_7 zy+j=cC$~axz?t+V=vgh(8kS+W?B#$N;`1cy%l*ETkpg+?tE)OJP`4z%&+5Oe-1X~X z$vD^B|LKO5XIROCC-x^_YwGTUPEH8QdE4~XEY;x~v=yM(#h~%dMx~F}+25@_CbN}L z?^@)C#s|)JvI(bzE9Miak_pUi)NmYxLQw_0Fhodx`uH^|$i@Te56&LmjIyX*En04C zE1$eCa-Ml7Q0VV^d^*mrzu&S53RveEP~t$1%|Xq%rA2+QtiJxfkSZ&^3Px%} zkCl}#fiox3fT;pLjlq#$e!K`+OrcD_n4B^~O@ua9<$>H9-*4ZrT2*`V#8-ZVoY*~aK^D7^)H24*Jw~-(DjgF-{ zJVka2O9s?(&){)2;5FXmE@K{o0I%#DT?osN%R63fW+vDC!F7!aXmM;epA@I_U|RiQ zS=3SY8X~9(aXHmt)S30NDDXG!?mqb&Xl_>MmyROcPZkf0NeP#PzT&>JXwV0OS!8+W zEr@RBG>5T@LQ55pi(@jXHyan!@W$V*ej`Y^@GcKYHB@e*hq?Gu6qE(y|F-th2DTry z@Sbkgy&h0)`RBBn;>jyuh;pqMw)W}05Y9^>D9eGew<{FY+eJn|X#U@MXNK@0<^YCG zK@tJmzG3R(E!-+V)YH2;w-Yk%ao3em1_j*vF5De}D8o=DmcF)gvwHsmfMU_(rPA2tLwU^bpS>VW6jM^`4u0zvdg6X1 zfrm^lmsQHen0Bo>+pl6%;w_BoUZ~u?q;3`qo_ifFrYDxas|FpV5)%vDat2G=9C265 zXu%A*my?Jl!$~%Vh4MfZn7pn6OUh8No4qxXGk_&F9$PfqLZ&H4-Y98m4;>NJ0H+W` z{?pFoW%F4R^gkN0oq-(LD41H)R^Q_!E(#UHVn{Q+Pt6rkpFWtRj5ezxMS8F37V5t? zk;{X7G)cQ5j~yxDmiwrRh$PQ~C;A}e8stM|I7HeDJp2PQVN~z!CW)>B_*xf!N$1ch z+PNqA;%E)~%0sHfDb}MBR_n0K6aERN$uAXfXl4awf1P%IA%I+WzyhV)J-@b?NP|_T zydKj0VqTdV=DCWyo1X!m+M7jdBh?IbCPxfD{4`T(q0SsrbFI}Tn6a4#9>={D~6!IQ+_L8^SZMPx-vk605|?A>GBm3uj3f${8@2L zdHIOd8qqmvhB!#LAmuwI(rlR$L`6Nw=ps;X`}u3mkl|m5J<&y-x$afu(`^^G0$V0r z8Wm@wIY6 z%Y>QjKE%N$s$~|s!{qWHE#;Qc@QY9)xn`n5ZsyuHG2yAlO9vY!zE-+9ckS{jgn`n=P3&g(v6Lwy)Z$^Aw`{+|Q(3F$C{X3ZaM$$D}65E_pL*j?EfhZvl%)}jqr@MO30`MT+xfxwU>&=M|xK~eqk3tKn zGBeiRphGPXm(>44B3ps^QHfAoU9Mgg( z&j{(`spUeuHyz&unv$40II@0Q&(pPY>eC#8j?%k+?N!Xj_24^03PQsa^wk=FQA~0) zw*AjPuZcdFclKVMS9wJ&R#70C7yCJgh#O)!@oj^b0EVyGF6)n2yzZWd0I|$wy?p~f zVgz;R_Lpn>a|vHA>uln`_b(1Pv`v^Ib836%J`7|SYb0$qtMQ{n^6#;&vf61n%T(54 zx!@kMI`rN-NTZAUw<9ean(DOe10WP02lfqWAqh3&L+H{t?5ki398$6z$H}$^Imtuo zs1%`Ds!O(*UB74G2#4w5M8X$*S@6o`{ih6Jl_XT@HvONrn@2A<7#S zha(I6N#i7NfIBneL?@t%ryPO=?_esMrsQR`wQUTscw)r$+i|kJR2+JA`yW_Yf_7O#u2`PyiEtvf6J`7oA$lUYx@AkR`QRDpY2$ zjQgT?&qj4cH+>2b-UUDp2dQil=Q_D|Wc+*F4G|amI~x#rDnS+Nxdtmg$pd>tb;E6_ z>j3UN3sE!OqDTJ^2Vzxfg=VXvgb*38oa$LUGb2NKFcm4$^sSQUz%ok$Ur<=O8!sup zp>M2|v6Ae&ZLfagA;#1|%s&Dx1NYY%3Zzxcde?ZQAou92{cffK7%RyuXoxR8yny+& z?_kb7FHM_3csaqSC!OYrS}{W9MYnur>RmKtV`C z&ir>BZD=hCtopSKFBM`t_~p$e>gVAW zI7Uxx5Z=V)U4M6wFbIl~xHL;tOLbdpdiYGye68yc?@MHpy@K6<0zB{seR#xMDCPOR zmOBj?D*5Z$6obkJ1dMh`Tl%LFp1|onyx_~l5n=dH2%y5DVV(}{p5uf!tJhR?jGODY z2-V+FsWrf)b4ycP*TPss{Jk53nq63C<-Z(+q)3GIYZc!A~3v zqrWUErc||*CR85yDm)$GqHF*A?&Xsc@$mt!^98x8c8{h{EpNWfX;Dw1c)B^f=qsI) z|L)|Z5pl!}YudeyXRnYEMLc(3xjQ%)?6kT{#-o4bA|#_ojMZ;%hQpOr<*5k$&7Vvr zap*)hI!NiX-bBA42_Cj1Pi8)Ig8X?PG?U7*qC8dp(5#brCW?CBNzIWK`J#@>i>jX62gwQCze{cx|+x zgK76eb){Mub9>YUB10Q*TDW|^$6yrRN%pq>DNzv~Q--d{)@*9^Y=4 za^lwX(Vw(Gxw+siT&e&O=B14tZ1-~zSVh4~KUzy8lyH5@jXXTdky3jNa6M^}(5uO^ zj~C!+e)CqPw3hCA7yhM;+93^#!_&q5UQuoR2Frfnc4TGp+RRxq6zeu-FMiGPmwnYy zcKr0ful5)SB(Jh)h@>@Ldc0w6I8J!|e2TtENa-nxi&g2{N6Z~v8Wmu4X}izpjot{n zYEdx;8zn|;1fHvLEk^m}0=%t>Df?UZ%yPWKH>THKmZ0Sd{ROQo0ynxqX9Fi!d9Di} zeMra1oj-ld0&?B1vcKMD7M)-&8w+}BreiR%2}q=hjk8X0F4@%M1Ztc%tQVv`J{-K` z8qD-soKuUQU8swVBBdOLGyN$=hxv<1rhZQX8vUkq@_MO0=of~hf{1s98v>wh8~T${ zGcJ15GQ%g)OrW^ufvu8c)0ceG#S~$HXNQ!nhl69ol%!QN;oPqXoCyLTGcI6azBtCG zDMBqz37bBZ!2aBnP0!PCq4Sv} zGK6~|SeslU6k~4D0an~PXC-BbUF&Zp$10AA?UMA>t~l^Xan~ZB9m6@KihFqLioz2Q zP6uU0!Ev<+!$yvdrLk@O%Yr5EuA=OR!q)t>>Sexf`}}7QHLQWErFg zOu*{!s+Do=i5oR^fkI3kF9&EdYuc96GnqEAu?Mg(1Q6CEq8fzuX%eezb!!RY(oKR1 zj#Rx>LJf=?I9P_qi-iO6uU9@$VX?RHtBwh?RKwY7^ET}}cpo!fLUwbcfv+*m;$Pj- zY(yBy@@Pns)zl|JQp1p1jD0K=eilI9CjSXY7znL>vDKMA0F(K2Gh*3RMkBm#bqArJf540JCKv|FEpU?>7u4>rv<@k&w3Ae?iv1|HGfxQy8-LvY-3( z(VY1%N5F<;YnHc(xz&l}mexm&*5@)nQA(tiHmDG^|0*-zw;Qoy>MasKSc0t#wnvYr zP0y#{vyYTqcRHzJwen;X=qdd5yB^tousR1Oo-aq6G}ePvkZVv`rwliI0hz;=hqt#L z4A-mPKS)PIpcUobZd?1AS!anEXh;c?r9s$fXr_4!>1hwz&FiWim=AUZ%}(MUHKnDn z-}75RTFjaDDnk`)xvQ$nebniH<&*582pjE{Ht|f+`1`oY!=8>cHv&w5WX-NOd{)HK zQ$VzoS>la!c^WYLTH9GCa7eS<8BK!h=g1@AJXoy{#NI)818LUkuru4*G0HMx1bYdo z=NDFbKw=t3m}VrT{1SXi~#+^5jW$iwL$rlKxKLC4In#W~I6zHqCSngfgO zGARm4oL1(I{U5U{VRkK&q5$tp(^=$9KV6%bf_OC{*29fMV}9S?>Fg3{-1Na*mA{#H zmWWXxSrD%;Lbegta^cc0-r2uPcy1hIcD|y}WbrrX_*_=i*@Xom0P*o4dEC?75O_HB z$dWiO#};(Mlpn&CuSOO#doQRp*`1_Rn5*}1eW|r%f*;H($r=O4E5;ohtdzW1q+fGg zhyU+8X9AQWzI*+BC!p$IQ5*jdNd!H8V)32(JFU^$B|13O!KCIfORfO#{EX9wRaS8H z9J>S=VmApbl_j@3X%+VPG+I{*M;zOvZ8NX~v%El98{`}7i``F234~G**nzXG=(E;4XaB;R%9YzNa3qTN#)_zQ zM^QDLU4r2%Qq^g4AdfAI6^mJ;*pjdlGs5l4L3+H0JQssZt5ZMugug^U`!`eMXYa^i;}N|q45FUxAYJ7jrDmngV3fW?xT0*3W~A~Pjm=UtY@nwQfh&L$#x#$* zFhEvCPaay=4Hy-KBQSPKc&4JZMwka9ZQTC~d}RZT>&Q=InRPCQ6QiEz!6ANK-&>_i z#S~(zlJ6!IP%49{=)t;-m%sd?050#I*|=ASdwR-KQ9b<}Z#OfoL%ab%g3~;h86@FI zA$dM5{?=zAaq`3-ApARg>PDiz%Q)b|pLD*b!-eZLFWtwPmTPuEPh>f#k2-I*5+U|_Q z9&9Kka?IVT&BBNZ0h2q1>CYWBI)p}UQgU(Q&54IhCNi}m%e636IK=3$4(15#p?I=$ z%M}5#igvh8P|0O7CF6Dqds^=#;vH39KOFwf!EIwKq}3glPwAy(swr-(FJv}9y*Djk ztR;gr<%}KOaY&8ZL2$6CV@+^0qaAywrbkG+5sJ&GR7*j)G|b&{6<@qHl2TC2|JYs@ zzc^3gv@(TofUDD)E;6v%EzBdp2%{l|-XIMdmS;@0*biXBJMJ%(hU>iE%09|p?ogr( z%V3=MtC+54c63>8+@0G^Jk>)JF5SjVBENwtM68IrjG!icRs;Oz;vEMAkjRM zk5WM2SNZaE2=Vo{Wg~&fUwO>qda2c=cz_W5wSX)R#&4D{LWg1oTVD!)1Y>)MO5N(@ zaK#JtUozvCZuDQwiEYXCr$RXm%ccR*QXtimC);yG`x7xM!gIrPaKxay?@r^R3ze>X z%ffEPAD(wK^_5YlOKIc1C#xga)$9H>*5QeRSD%UW$)}AXTHNkdYGQzGH^2$SFB$CF z1pIFCJ3==LZIOw9*yQ>nbZfFsNbSxn{xs=APr@*c&q>!HGFPbMGU_mkTp-t`J=EFJvC zR+d2GA?>MYlmCicWSLMcO&}5UW%*$u900ZxVgKyuqY97d_m%iYZ;<-A(V9`Zp{a{d z+{JGMaE<(&uySUb1#%HQAMDz@MVWIJ??(J|lb;D5g^qsSy1PB~usg0uuc~6o(nfak z7E^J1vDXjDu~o`9F}zdM9G~bHDt)Gz5I5UjR7sjEOq8+Q*K3uRo4tnTGEa=y3CI%Q zTSOGg`#Z@`d5>Y-NK=g{CrLSYPA&OQ;o;44BZdgyZk;WW0a1R$pc4DC=NzO;1$9|D zX!R6usInNPr@=+aLH#Py^Jyf*;7rF1jS9%FD%^?)#u|PEE}X%CNRH*1otsDFRp*~8 zB+!V7#Ap!yWl%d2=tvw&X<#gdSud!e36v}f!MX5*mZ9py3SyRXAw2Y(dn@A0ItRoC zeJb>VFAKDGT$E4oK}Y2CpQh{7`1p0vW&xEU^2~@1Qx+99>|jk*(LreZ;H#>+wT^CQ@$0(T|(u z8vE%)XP?u@Qla&tyb%aRO2$AxSlsnv3~Xf)*oTngS5QH01G-{bz}V`&VQC}p7+3LH zujo6owl0jf zEU|B(h}(q7V~kAtsB8@(UXzL~C|g|*GAep=U27LMugk7#cck+9D?$8;V5E|`c_Po< z$km*+HKipNHjfo_v0kYlPav!Gj2mg;Axf_=C&vw*cN?F!Kv_-Pw4et<$o6Pn@Oi~U zV|8s#1|=nQ^S$DEk@oguXvr@stlfH7p%8R{WaG8l@P$;e-r_xia@jyuB%iW*q8*z~ zU-4A;8f{3f()G(R8;j(dNvTOVdLUaGl9)p(guYfN4*6JH4%I5n=IHlkUjVANwdVl{ zRSmhl*58_w|7Nx2dkRDHts+Z?p`7i+BQ9mUI?-_q`ZyO%+c~S6xuRp&<$`*v^*2JA zJpOHam=k^lm@pokNLzC`+EP`%&uNV%z)ZDZ`xr@XMoOs3N09jlR2Q86vZ$|~J_;RE zb7I0DKAjvNXR&%|bhK-f?uP11)$phSr!aleCdziomfo+2e$c+uF$eiDzJeknJ zYBmv{A{`zVHj>`Rl{7~kYJU8+g?St3%q6t6z7)S}GUsUo=UXaf0=4ac>JNhb$tluK zc&5p%H(nyNE5C+AV(70D>BQpE;Uab*egC1V(595XO|A?0kF!zELS@@vpNu7!>bPPS z^WZu+MgC}nkvRZR9^SDG+pm(H^6XQklznE7@aY{%&Hebn%xiuW4DnL1%jEqeBR;a# zn|7b`Kx~1>T<|m{?vgKs6YHs^q99mULVPOkbZu3@i;H*;#*%&yGA;%-xI{u2!i%a9 z2E!7-wsiLV2<8l$rTR@+!-H^*WU}nGL%J#|rQMI};`$k0XoT?5U5DMdR$E*JRxrFS z|Hfi+slqK;NLiNVA@)*>>c}-ipt`R+GUB8c3r%%nZx3#Oe&*$6dm{Q*RapZ9PUcnj zDrHm*MHeI1)m9*{Z-qFN@E-Zlu$4{IOw8YSHaMWp9=Ao8H7AGeJ&ccyWZsTs4-^Bu z0aaM^M3Xbq(~FPV!NWhWc!^okMj9Id2RbBi>qi|@OpFWH_39yxHXGa|5|Z;k{MiJ% zat2Xy8rxx{0bH%QuK^FPePCT?_?BX}ow}|pl!ge`e-IA-0?vxgAwf{;ofCAY`{|nm z3GOZ3RQPNcq*?G7Jeendsdy!yu;H03WdTsH(Z|>vM;0<++0-lW_bL-tfUV&jg%&$6 zW|zlQh$jsL>^F!2q3XZ2zHF;acr}L!8fCjh4d%2NcE$iH*I?oP45QMMxf2_&l+T*F z#X-rc!*C@^-LljATWRWy>#OzVvljhH-)=|{Q-p~+ez*OD%#1(*i))N$`hmbnVR3RH zef^LTuO0D+&7;hfXYh0}TWi|8MLeX7k}V4mR(6GTl^*REFgv$5ZRp-^+d)G~zvV8a zxxE^|o#%NcGFT=(F&@FRcdoF{UiM6l8LEa{0gB^`%XKh>T~BDJhCp39w-)otl&NW< zjTNsSBE2Hf4ZI5r9^wE>S`!{gNi6#r+=xVLUfi3zU~}5#y)UD+ih|k6fdyN%+qm;!Q`oL21^o zrjLa>;1*|&e3fSeS*j0an9|={!?2?9P5L-G%hT;cdBSIIP6eg^bSE0(%2So> z2cBG}-ZJw{Wz6;U7)vDiVNd^0KV-T)xpzEP@Z4B04!X^|%D|rWYB1Wm58m={tA`oz z>5ZBINCD5hMGQYMVp<(^&dBkHXVr@9b#cJc5mMwSUN~7?D?to|HRBcC;T7W*Eeu!o zADZ}tLvFVwWxZSVUAxoaCnUz&Xf#u9>Y) z+gq<<-xTvi_A#+K9VNW6a3Zj$etxC89`FWm;9OdlHW44dl$7DbB>m}LQlQxweEJLx z5#hHdK?d#M2a70LY=gtoXzsSgLOX69OPvqByey7}@5rNfqAN>zV_|*`e$F#YW;jy-AYe)BcnY)zx4(H-byAy#|R^gm~s}&(k0N%QNKctcHd4^S%oO z4dVYz+(5XGr~+5hm%B;yDD1v`nnl5vl|Kn;$5nwNve<)A)^+2!-P6g!>|^fuBJ^4u zEqj~KJlpyZ_V3c6o z52Yoq{!wt~F^A(fwXGP%&UG=<0ES0|c`$#}Zm_p152$D7uy$xV*}gGQmcy8e_<~0S zapC-2h2j18ul=V{ZLl7Non;t?s@y(gTyVTE_zw>Z>3>`;n_{7y6#?oW7p3utt(5Ea z_#OB8h!58_C@_lnu{G%0Ff4S_dMH!v<<9aV)k6JR)@>$wmt{2k#g~#|)F&l5K_Gm{ z>|m!0|2@&F)q%DreK2;0L0}9zPJyBmAVn<8Z!Y0ztRbmL6@9&pZ=o!W{=LSGeNYvE zcVwI;Lao{Er$s%UU=;;kcmJUwg$_;U@~vxHN|UL0*H9|Fl&m{}poiS?q@Lq8sn6ji zKliyl79ZzC5>53<7SVJojj&Pka6*r%*dX-qD6UZ%N)`~20qYTD$cwpmiLJPh$KlDOI{{1g^v7=9z$D z^g!T_#~r2CkrdGGAHGY`U{i=D2$$AvB*g_0_e0Bn=D+vqUG)F2DM`m=O?H#Og2Xl$ z;){}MQM;I?rrZ%_f?S&9mP698A(qxLItE+e*G7Kv&f^I2y=d{2-oZ*A{nx@ESC)tQ zavXM>N&S=ixK09S+Zwv+cp<@$hua*FmazL)j0$=N>qXh%UH$6b%+HLF58^1hBl)T3-ok z<~6?4OwQRh)|RS;gsz~^Q`*AcfD?Pzbpg}*D%(jzOv006jI8AnogS^Gs;?>^+N8(} zw;G`2oppa5lNVvA@6E$`zQc&ew&{nR&#K64L2`|Zgk@A*0u*$EM&PNmq^#UAc!7nV%Ry!v zN81TPB9%mAtOFn#b$GD{SBOD=1)j&TXl%^my#}{$u08Vlg@wGrtvwFo%e=P~xJy)2%{ZnkQ3kHYrMk(V*r=IcR+esbiyA71*xSRWjGptGYHeV9pgsa*5D|dq#A<-VA zNeDP92bgP$Hgnrn!aaNMsn6`@SxXqq(;Kv|0DC!7>`|@T5KbZZB7kMg#8dtijg%Dd&1`2WU*bbd=oK!VnU-{GS{E{lpBfo8Srp`~L z!Lo=p!c^vg3jcT?!Q7{snv6~IU#h~*gC^s6MOY(g`f-IG9IF1Z$g2^~^G_jKhp(jt zk`rhKgCl>saurtYn-~#^pM=!1ebHZm1ASG`gAKSst*Jqn`Q(P%vN6g+QC<-Ar*7hH zcm2-I`*fvD)8tS=TAz8(uQZf7+WD8zSR&daImz*y8=60x7 ze{}qAW4y5-&tY`Qpe3}Sk}KhYu^deL4UeX6)~t@UOt}Q#wtu&%Q|xk_GS7~!pC+&w z8b*koR`z*6UEFRxp$!(ar}Hf^Y9U)HZ_j+b5_lbG!EjESZF(FtX|}h|+NGZ-2LOeQ zIZ1EsXIoZHaB_GFpPYJ>Y;VXPVrH%m366(hF^d%igft(ne+OYBCg#gB{waQ7Kp*+* zHt0VLl;YUx>uJ=ndy68Eo;sr*g?}b(v;*!S&s#YS*2;zi=l9p~&j+JivaVW=V9Ep| znONY4caD&&lncFB9DG&D+V{n3q%GJf7Q2WOzgqi#74nIh>|{-Vi7swpgj{KkS%1(_ zzk)m;1N7$~-Dbt+d$<~+%L0#pneJ;N_@JJ+l3GfXa@^NFQ2gz)g8lHTqB$8k*72%~ zAltlZUTl~C0D}c<>eX?%tS#SsQN~HpP&D@?Z(+&9Q3qH9A@y>yJ#DqSp zhW{DTC!qY**y)xDb1e9BZ+pG-s!w|v1z+BD5c;2HJsI#K4Qw@~U3Q&aO>m4agS8uJ z65vaI``qs>WcmA)7Om&L6}~?~rhK|c<^*1;tw~u#Cg6N{)WHFQ&vh3FjVIJUp0?Vd zP{`NK)L6Zjut*ptp0%7VOza^zWbjG8)%=lXQz9yG8M#?NIg(|{BQsA02MiB>OQoHA z>-=J4NfRCJz`Sr0aG`W`K@m*C8?!F1ICGUv=wbFkgk}W%4|w0%#>05vvHd^sKOn{M z-1ek}$6sLHBpi%*^Zimz#vM^`n!7Ks3`E4z$4)V4)pZfWy5}qm2hs+69fhCN=Rxv7 z60retLUiBP*vKvy)Iq$_PAQI)16!U?GJ6L%Q5^)h&u}#v&f(P+$`L~&0T1$V@AgqA z$C_SGl%r~PfUdJj6_nsCP78cjWyw@SUddFa$7FE1*??Y0M*(5kaL{8VK5Q{GXN>7sQXcN5-BpI zgU*Hou52GyPI+_j97ir<9TFW+jQt6~UV4ZjYt`JYD_6Clc%qX5SYje8S-j5jXPN29 z9Y>3h_|FN!o*26zQbFnQY8r*1p($c4tG7wtwOqQy2yn4xDM9V6;L^SeA7qCm8g_i> z^U>Kzs~XX$k)$cO_n$<$6&OXtWlYguy$liCIaO0{oA&|?KB`o_bB*(EWWTa@5j$W>w`rImD}=EY^31jgi_~kX zpTEN;sBGL3?lR0;Gv;8tQ7`G=4{2GY>S`Qqx=jg=#`cwA><>vNO%x4=FA|b^3@+TS zRR#cv9aloKvEVb)5>lFsZ;ylJGPU~e*mJS{EdNjUiZYm9bl^uUP!>6#+k{16Qz zqpK?1w|KgUZrY?=6o6Pva9Ix{k#%cY%!R``P^=g-IqUGdeR>O zFC!d7qxt_#+3=)|Y!4o<9V&l%{+ZF+< zI&S1BL0OTpEy#CT->K{!iHe~eVmi~OgUsBDJ!zO~IaGn4>C6_m&hAvWl2(Qh@Gy~r ziZZI90kl{PrS9{w%9XX9Ve5sF6)PLJT`D`Q`Xheb=5m;l_Y0j$*MbUVuDWs#=`N%IGNe zka|-Sk}2L>Lc+3J-%MtO_m};Egp)zd%GS%i`vN^*XWPOBg*+@K`XjctWcfDCw#hHe$Ex-lN2 z%mEN_)&r?OJqx97xJ3~l0An;G(}kq-aiWv_LNaxX1OUzgtGDO_dYJit%2|u-dZDpk z8{*JQrpIc%^f!{)wG*Wb))stj($Y%&m@|5NBuPUJkFS;*`2=RTwI$i931JULcpm}O zRaUeEar)$)o_`E(X1UW@MVm-6$m}yi$#d#6=z*myelGCj7SD-la?G=FQ$y^s!lndU zYs%uucS!_=30h>6p~9e}WTFBEMW+hCk9F{%C&N0Otg+2VsB@Rck^hWFsy*D`@u?n? z*R1cVl=^odp#W4LAbd7f^?KkzdvEV#_-*P5X|sw@r1bNb_&_Q5kzm$7ynSS9BT$K&+E zMgXQ0GA+#}A0WVYafIeB6E*YLak#RIkukB7j{xxZ;f4Hm01 zG_rflF2q)f@Y+cwW>)#Q$hQNDysDXDoG$?@P_68e$U>qH%W-VPX$k# zl!%Ws(Y_>Zo|{!NHiCSLuQpjXLK~MII^p5p6WdR$Cf|y|AgP2EyJZvKNi#=0&WWJc z(b}vxS=dXQ^u>VSczx1OEE7Ql0bHL_bQHT~OmRi@K+0RK)b0}lqMI2sA$Qs2>2&jL z5I-*M?5aS1e$S}^c#|I< zI$)6vS`_cl0~?wyeX`c9)=W$N-l|dIR^1-`ddeN~{MpMXhV-gEfd3xK9Sacyz;&Wz zL&7Ucn@a>8of4IcTc_7h&hM70p1ES{GMv7QozBpY>9?90t6YuKLWjP`r0CyKHX<-8 zJ*<5CFZ=BoE+KdfStch19MhV#8hal^Ns~6eqKw118P`DRa*zRQ6}JRZ5)hhDgQx%D zz>Pdl(b9>>h&3&^nFE!su++h}N&_kxE~8-v_UVGRnkjjob=p<2l%S#hp5(%Bb5*$Q zP#Zh9r-YaT@FsAGgSar+95N&7yr_SU(iu!!K*r2RCn)jBH524%mW#r`&2)RkJ2g~4 z-Hq_K&13)~1e>j$T&6MHZ3WslT&4AGsp0Kuc!AgNnN606f6YG1Rxd5XU-zP&Ezz!S zq1M^A2yb5C`t2DnMezS4aE-!Ujg6KMtGGdl4>PNQ^+IeaLjhf=Piq7%Z$UvkXR(~g zE(-n4YV-erFh*U2TZjd_(!&t%0AKCb>)y%!npaMZVV8NRdev0pgfFJQ!+ab6-}k!M z20!7XAR6`r7N288tdu#cG#PBn_<~M zi*-ezKQ)S-wSm{*-Oq_JW0b$n_zi%6gJg#M2Jy7JZU@_zbS4Qj%RjdRuRMI~oH^9Z zs{Ncar7frgeEK_V@`code{A_&G<}`Fi2cD&x%}m=Par25lkaUVSvUXgQ%x!|9|N%Y zuY~gF#ph66UDWA)_g5YMy@PznQR&u6#%Oh0deS6%{->=qS$i7O<(Eu$R{MdxB8FEb z#iI1@`ON!|MvXc)7EE8e{Gsvx2%VKFN9dxcjEPGjVv;O);+zgRWy+K49}RddLQmjJ z0AgN9skBz#p4#K*ZD=UsRsM<%o}M;EIAE@s1_CBc{ZvHqUb^mbra&VkoA85RalxYB zO+LCW%=P|9aWB&LPpTqY!b;j9(h5Lc0AOKMg!3KqfA|?%}n&)zONAd=%Mo z2tXJT(ck1bV-Z_ed8xzCrAGwsvaMlB&wFq!FDB|!U~2L-zM3nji8yk93v3D=DUS7~ z{B)FO1#`UEOy&}K8h5D_gLfFQV0+`k5s>JJ=yaO@qCQsf+8HY|bVmt1ejO98 z;v2zLj8p(7tRPT9DC{84bhgU21i}GAcOX8f@K(Nu`oW$}L}PJXINeXsoYPd5Z~0pP z6d1#B@t$-C9uN0+?aHi-P2?N^#08o4oA4cH(rc3;Y7lokFD(XVCPOPNv zY*9Ez)%MNeSF;;}v*OQ;SVQOBgjJ)$53*Zm6THJKa~T|tNGdN#P69ohFg7V_OKq;A-7k(=IIZ2zr1(p?B2)Oj5 zd0j;iCI>XPXe~Bv#`6p9ZCKqp+ONHBnmpN(zonxqZxe1x{NvdJnh`5(!k>wXT%L4s zz%0sYNtK_y79yidK?pcWX9V(N=KMz$vA)Z5ux`bkv3Zhx%TLl>1^UD;CLCdFM7#DB z+GH8^fn%krt=vP&N25B^2jTiEeq|Eu?kynxbO zVZBGug>m`ob`Up=Bc%k?jJcxWHB(_o;@y262o7_yuNOQx**A1xT|rYQD+&Ul0@uCQ zPQ+6-(JH&?g=O`0`-Ds_^5r0a13Wg7%F3j*QLMT&p%$$4ehtM!b1I@|rUwNeblo1S zG9#mQOg|MdRSqbeb;ZdvC#H6%E4Bc^U-CeowexfMr>!?t+RQi==P1pKPFT5z* zwH4uCa&HTrYB2ETTNp0u>h=Sb`gb?ijpw2>>AkMQWgR!$SNpR3hUx` zQ+WNSIMN&6_}?^`RAkkrwtTw4tW+}D?`tq3T^ zXO?yqBnUHvq7I}7&aAvS9xO8YEV{0f;^VF_)kCkBqgC~&ImQW&x}*( z!IE)GlHR!TXU&IZUzD;z!>&8xiyj`A28OnJnru);!_$vMJe6$VFA_=Rv^5kF3v1}Q z5;kLZ?3NI$&SE>`6Z;PnHv!c$az%b~0R?%{eGi`P+^6|b=9|>`*h!Qy~kOVL%B^u2@mm4{6IghBCc$c{AD0Fjl zr1?v-2uI8a^%r}YX0ez89#I*^gVna>er`grmynaBSXD}9A;$FoEySV7M3E6;9ew&hGPye*4Lp9c> z-Ky&)zEX^BbW%E?K3@ereauVgOwD1bc2K>uXWt_ka+Zt3$8#0{4izhNiKI-7KL`b6 z=`(CdL+ulQ7~hKc(3G5<>Tgmvwxhd0H)&7&{?Y=i>Q?|trBl2AvfFDMr>b2cY}66@ z4fP|39|BBjv%K+~@Xmo9dSjsT6!qOk_mkfe-PeJX%6hPWl)wVGEpRFr$5hF2b63|TjyMgJ*zk5?R;a2b# zGP37+2R$xHj=#^qTAm)tF84w%i1|erMqxBbk|{Xd3uKr{vERM&OWWlr2Ue8@OUFv9 zCSU0F#F}9H7%CPI1+!9}`lpbbk>w0P0!aRNHdQS&BoBYxEmHt)EWlrQsZ|$ag-D~# z(0tUsbf*Gr!7DtW`(x=Pc7{;=3M_ZgfUQ#XgGKAcVLG1jl?_0_MF&{gkX$Dql`MHG zDj7WzrCIOt0!U(!PMRxDymkz_^}!M&n$QOGfP7muJZJK3gLf<$Qau6_{NMv5YM{v& zbgi9eENB!~CW_r!-S>NQ)SSxN_eZ{z2-K z<BGw>0`8mVkOOn-5WtW{-|U9u+7WqA3Vs(){BM!*-7?EU9tfZ(Gk7A3CmikL$N+x> zb8A|w%4=mmiMYw%wAC!!M|o&9phQx=JWSn$UshO=9sUhr9f(tbbJ#ll0h?c-;6#2) zBcwElA~*xn{AbVE9waP{ym`wV0}#V5#x~*QvqMA907F2$zwz|Fxl&8u&U%T;K%6)mZXEz&i!D>&IuA^7kd=E1`<>-%SO^691&IJK>{Gm_GvU`dg0gfjQ7Mj@bKt`r;avbZ{=e196Wg^L1MEn4+=fmjtA;vkY z-cl!>d6D`h(pQkFGv@H?C}0kIKnxu0?H|y35z#H^u}PLpt0%$WmNY!~8?rR6( zQfl5x)8`2w5}b8~yz}?R50|i15b&)k6knA7DwT9*`O||)U%LHPFrLjnhnl61j@i3} z`W!cSnlPD6;4eeFRtmJ{z`dACDoN4{6b-TuP`Q+1v;OU}Erc)P+hy3N#4E9r+ErJc z{zp@{{Iq2yR6jj^(Whf0QE;>1kY!7k4`p1;P} z0jzpST4J0n9pl!l#3*$dn#HMqdSldIolGOK3204Y|A65Rg!igpGKVyywm5ssA{*}` z$%!vHqsH_04D#+xMNSAS5a&?EaloW6d-Xle0v&g!&8n+C&wo817eOC{ z1fm(5L|+19)c0ktY&~!t<~FP_g?>qk^=Ov@p9uIVXN;3RSOTzK{*(WPHPnTQUA%E8 zsvwE8Qcx2D)r8vg54a=H0OXiw5+xxI%LSTZ917vZ9H)#D*5^pO@8TMlr%$3MH&v_F zf7uK+h$ef=paqmIhi?h4%w(Jx+iV!EH<~{ka|B0~>KUMklo&^zZF*uDRW3YwH%3%2 zKRLRC|G4CoVeWmbU%Ca(zFsM%#5yLUJ|p!Xbb0H-^11YY06`_=VOY*?Xzv%M8({At z>nEQ`FP$LJeD_x-47zi+g5u&od4KkJT>!DcIXb46W*jqzzPPpLu|R86-f=TR7ib}L zOV^Jjr@GNgNW>P1b2A9B<|VeTSY&c)in>nt^LN#dPYd+ABR$=>_6huFvtU6T4)iK7 zTd%HYf6;90-5R;?ByV~xuq&WhdO5a8bkdRHk9e+DD~RVOjzUf*i3N&HgeP`-CfrH@ zsSqnos+x!Q(G9FpCgH(_wM>Ke{LS8z6raA8Fl;AkhkED#?MmVxRA3ijG{4;GHzL=L zPL`pef($MO;jC&c4k#(EN}dyG0L)!qPJA?dx?G8&+#b%unEu=jk&MYKL~#~4q3EC> zL|g(xkdw#GAv_F1L}~Kx(O8_*bmQfGv4hakevHLB9#_rbcW(D2YpTt@J34m_5yid0 zE!K7^Ix;?yS8QG5^dY%n4e0Z%6qzEU^?ktYp;L^O$j0P7iI#!&fdTJIx2-`}*$~gt zh`i`T&u8hiE82>!ep?5BT-yWp`z@ki1mCUj$b^J9jADegJ)ct7am7&3;~80XJ-%Q^ z8)4qsTP>eCmQN7CZ(P;}W8VUQi zYM`vPa3{nqKppWaN>CR z#spG#;d#c8_HA4-Y&G5hj#TZZ2qxm*zp2cH%oa-Uj1Wi4o_tP$pN4Q961ul#L$5-Wd_=0 z=Zh^C&RF6F$dX?}+S2Aco{1DLq4CdKspiAeXTeW2h4<(c) z^&=;8+%yx)4AeE=71|Gvzw~szk^|P@{XfeKjb0t_=bf4Cnu`8NAJ(XNADrTwmx{B^ z*xzq~susCcyJ$4R5^!H&`>$gt_v}=2)KO%;?Sl2$FP_9)i zdyRP^)DOtMv%^7p`ieMKWx_nI>VK^+QN*w`C#fU;A%yh(=?zC*)Jc@<3&p`riXb*Ah~lT8Sc;3(9~!qp-@(0lY?*8Gk?b^ zVKTVRx|N&@`1U&b>UIN7)r9nUgGmEML1*OG^BmJAo7kL#5P@RS=Qr`KSgTbi8v&oV zV)T(pA3}i!Y-o3rEfLhm8t2qeobzZJ1SCQo3wDicsMB=kFPJZ&MmaXniyK>kq%@?W z%wlR@j$r%}HTL*jG&N<7-=`a*z~UXQ`eW%(o@7hN80N!Q=|q5M@MsdMLzlL{0i$1x zh$Rs1qqx`<^dPYPCk}pC?8=vec||q1>9@k?Gb*QR$Y)r*PK|w`hC7LwgR=A|KHxaW z-pQU$whh?Y1lc)ybaf{VMU0{fv3_Eq)-$ft|v%M3?aHLv4Vei9;6@guj_&Jn)0GSXs|bJ`(wwq*ZbRZ~6kX}iYK_6)UJBi_laD4Z}Z9{d}Wpp2M9;XogG_j2UhKolk_ zOf5`u9;&~D57dLT)=3rMZ`GstV!huAKau)UD5Q4mDW~tH&jPqtN+xVy^hRgqe6@lN zDBA4Sza%nPBK7TnJvzZXb?TqjPm@^gAO>8`IYPowZc2E;N$I3jq1hytjV#epny81pMnz?)fBI0S9 zNSUMJxbIeI5yRP%{romonYsaEkJ-)tH|ZPO<#!s}F^WnAS4SEkspw2{VyG7jQUhac ziu$dKF%XMGY1}n)=mA4i+5c^Bo>3FL4T_AcmZyr8F@ox8p1P8C&~Qu6;>3Z_vnLcFN>8Ee)xFTkw`)W4s978800Ioa{{GGHr#E>DBS9gg+}&1o5YoxwgE z^*wjh*mi=CG7ld7WDLIl%(2&*-9Q?tx{zF*^(ex29-O7;Z;l_-&&spXefYl7LEIit zSzzAMYF`W%C!TgwFdGST_@HCjfNHc##Nb2`VY|Yr+riCU6+!4ntj3o_{3)>Wq<&uOV6XwaGrF(@l%*$Dmr*cKZ_Lq2`qhQeq_IP(Q-U2BqA(Bj*?EmQX&e4!pA4#}D_nRT|I}I;Cl`&3wDTVy$c9b-`XaX#(TMN2 z(cZ{$8>uf#0jFd1RORl;Gsx1ZFS+vF5!ucCLp8`-k&Rt&tZP$(+R z@GVGGP`qVDQ}JUuz1AYduWiE5PLEWg-p)^b*$Nr42u)x#rd1-RZpwpKjRag`l@<>U zFVvG;!G(u^B568zI+fwV)vzZysa z{~jznh(m+UADFgBpCjYA7qbGd1Kk|uoO`S6UTFX!04N^I^obGyo``DR@62)I>M^ma zeROs92kF@KF0pH&dh$=<%%2P!XGq~Xdm!s+csW}SF^BK~F~ecOJb?v~2(ygC;Ey)n zRoEQ|Q@T21S&5@T1M=)-u2JMYM0?9?NZ3_;gZ;*^71| zped`7U}BBluPzl(zinkcHGc2J7~b_YH0MC4sHi7^tB`&obD-o{9lL+%goee^jAd|6 z;8P|bfjdv}Bu~T6Wx_aXz=PWzAV9BGtu(#GLqItPCwzrmE-q(X`Mp*dV?2>t>FWpy z6qlhX2?Ma-Sssbjb zAR;{0;yfy=tH`#?fNWE0WltqL7#1@dGIb#G?XO&AT>{3d0wgx5pA`F}rQN_Z3U9JkEmjvfHKcEndMjXMt>+J}5%Tovr$u;k*M* zgvBw)rG$e8i-GXmF9P9N{`<{{OYw3KMh9sCVgJjL$x8Bd!`AZnkUHS=Gd@pE)XUQVjO*8@`HYPX3PHI%4*W17M7 z-l)5>`9y0HwB_)G75Kb5%Cr;zwPvwAIC98&c)B&eB<$FTqz&J#sH*r7X#vM;$I`F? z+&2WJ35p~@jyczGDI9)2-U8S8?6A&Lg$zmbNaU|onUU@SeCvjhU-Jg|y3m?N=vFk7 z?u)JevZDeC-#8393-gYU`)oMB zI%kfJNXoPetTVxRjyW|Fx+m9ySLNQ^sT|)&n;oa0S+bC5-0P$H_W~usea&*eY6h4> zhw~H~J1AJ>K0IKyS%dp3H`-KKCC*k5&_L7vXa`VK&=1~ug6Nib>UvCjjK8sY9XGj6 zf(-x)ZGn}PBrb5I4i!3!kz9q!<|yas?~TyF7$IPeDo3pe_w)K%Dpt~SJi`4!j@>=Y zumQfAnDo4*s0KlbE?&n7l)b4?pL)Gsw28)~g4xEiuff0wm4Mo7JOIpf4Cn#ArDwBj zUmvZiBit_gAhgv&iuBf7Kh2-e6*u<)?jjpMM<3jbjr5iV!mEz|cNbm~Ac^6%Am zc)y158IZ6X}Q9{;RaE0Nd*R zTy-KLgm&aXU-G#r<%Q1lE5K>Z9*$Lp;me0;NZQ36@|ZLkXrfiv);xAPr>ky^HXt1G zK>ge|^tRxKohIzkqU@(s2#5`{U45~{g*I4oY5GR^hxnX_pH0pcI%gh)#9-3`m08}s zQ+#bSq2$Ez4>!__VjTRnU4n~Rak%Ll?%y;e!0dA;=x-yr$7cLUW&{H=G|n2V9~Q{l ztVZ(M)>Z354-Foq^!5Wo4F#i?e1gQ-NC~J%B)omC6uFB_&QyzWfmrX-%gav?DFjXfQIv~S%d9bNT9FT^REHQ-PM zpqzOHYZF1Qsj~jacw>;j;{^l%!MnKv^YhEBx>b9p1fX<)99jY91XU98a{jX1&A~c( zMHui?RsS(Dp4OKNcKuan2%;26n;SD?I{Ghr(F$i_@5Oqckhh=aoIK+heH_b3mYPX^ z^Pl-#WB=C=?~mcbKdS`KIy@@o=KhCB6-JShBwxAaB*G)g!g}z^fmu{PSV;+D{M`Lh z<+Eg4M&rw-U{7J?WU8tQ{>5sAh)}nfJ%pb~VLotAJ@^xOD153SnDKwcusmQ}Noa~Y z&rZ<-$u7jA-Jlz13JgASYSNA1PX*EEt2(h+pqZuA`*ey4GHy2+-P#M;v@EM2 z{fF_z0h8YdrtZ*J^FSnl)E5;i@zQJ}46*K#(12D9RP|nDOP^~GHkLUub7+I)JMgqSP9@Wm~`r=jO@G#D>d z%tX|FfBW0pS1$6Y#+C_!^lb*dyUaZg?8g-1SS6wIz1PH0{GWB z#_>al6oH3h)?Qi2cl|qT?>_%O!b$GnyHWB`?tyT3aeax^FX6vQQE-`ulXm!<5;@C4 zG1X*c?xgG@r+L=uMBVG{4=k2p@Er?`;?!1BHP3*it`zNy)ldHet(Al&K2Fa5y1>to zRzEEh&F^aZ(?q8`F)F=`?m1%;J|Ykm$MUAh_{5w|)8w!2NU1cP;iKOdFP&raA6hx$ zQ;&gUU#-H20ed0OWKp9j7VUIGXDeRuFqK6=cWjuvZLF2{o~>nru9ZUugJ|?X6k;v; z{V9;1g9@+6kbdmh8VHK$4oUt&%dG*bB^XopB~k@)#ZRu%Y$)zrOuJ1a?p6j zLDf{=1{)QO(egj>qQH7^zmmgIkR7l-Uae!wI=poOzcq_B`4ykyHW6zt@%S<=tMp$6 zXII1L6(dcK5}T@DPGo;EFhXbu-I;tc7MYnpDbruBqM@;wgMcF9>DVJhogu*JZR_~BnH0_5r#fGiPJ29IGO-D+%`Xo zP@I^A#bpP>9kXDQ%e_3C4gSgbw}>@ z_O%}bP=WHrN&Y@j+UMFoaq?1I4u~YhW`5gg$&;za$NTCul$#6@2}sCDl8~o!HHvtN z7>GO!-SbLsP_0O&a}t2=3CNPEWO*~rrPcq}?GXqjYEm3FMUXB0*(9ypQp)EsqlKGw8SVH!DFs92!#L{rTtf#R;9+OwO4qot!&%o2E;hZv0J655ujkG(7zd_|w^ z)Fv5SM#k!mY1IO(^KHJSu@Y4=ts4!kQk-!beX7!y+#$Ef8_%Kpi6iAy!=sRo>H;x8l$s5-=$DXrjM~bldoGiwc zE?FQrh(NIj`d1|`SHrUwLoci!E9;$kdF>>Iu$}K*PIB_Pv{1^d^^=$CW@4sm8f~Bf zw7v?Y^qjzNR*d9Q%By_p@587#jv!qo<}t=j`&^faARr2$I@(hil8rW+1r4+&&`;N0 zD#jt&k+{;bKW&K`#**z;rn|Q=f}~=8`=Es?1LOM{7)afIzP06`l{_NsH}$2~Qms`d zlrDoYvcyzKv%M!XRtDzJnsj{#JwD_o{3Pui1~m^Lg)N07Fc#=6Td^}P`49XGzIoRv zr)FA|GKHs-s;;6-dZ3VW;lxezlh7nH|T|B6|C5rjiU%2teTgn zx6Jv@M1VM?(g6(dY=C9L!XY3!PJ*0*s9f&6d$6>+fn zwt(+nrn4y4W*nMuYyGqZvhBqmq$JQ>i?HJ9R%O@QYMM-?Dd@GmJI}FKyt`P3r45kD z{w%iL46|AL1{>iGap(Kc1=p?qSb}Zrj5cKbpU~e-wCShY->0V^nuQ`?2r;NplDJE^ z^{#nz>|gbSDYJLx-JUdx3pZv7Mc|1CFSd_@jR_Z~fddzuR{_jh`g%!heulUfg=p9ux6XOk$Fqt{hpN z{%lb#Fu%NAS1Qv!D~F;_?d<_OaWXBwXBmY?>aL*ad+>KF$od4ce!g&l~(e zy)b}j>A z^d~v1UFZk@O%Ol!u!68}6>6!&onDo`n4)}I1e!cqr8X6jwkkEHI&7ecpy*yx2jeJh zYAm)v5lQu~Ga4u~OC7CkZ~OLzfbicfWr7v|4PRk#`D^*)<-hIjzUzgsLJH&kZDuLh z^I^#j$^!Eu+W#t=NlPJHKz!+3buBJ4wsXiSY2R!+i`{ls6By(Hy-R5g_QE-c1*KIn z28oQp>=a;h&N~BS0fy!VI>!$9EukRKJy|@UqAp_?f4~>nW2o%W^->~sW^4o4QW|Jb_dXPSmQA&EYo#PDeC>N=+<>cp-l%Bb3uH15a2nXpNGNETW~{j748! zqvs6?z|!fh8hd~{--{^F=zT>$8iu}J(5zBwSDf9~T8jLsep_W;N27MRTE|>`ioOvE z-}D0}Y*=@32d$>$xsb749Wd6lyorfR2Fy3mHGv*arg<#2_bR-y%K-KdFD41m8B7+h zV9zVF+=#@+mTYyO6+wF*3gVv`LQSpL5N0!7MMOU@PCJv4zihBH0*mDQs0Zr-ChJI2 zg9Pv;C5G#OUc&(>4OyQdX31P^s0TV1f1|TK(h~B{di~3hK61MA!P<}Z9wLP*4;gS$ z#de7(9s1`^%t)XJ*drDDak%xxBJ6jw&b%mnc5&O9u=b%^i zv+>*7CchE{-RZ}24lYqwUlsmq90u{voVMfecLkHEHqN6h#xkxm5(`~`7{7G?^huR= zaOxjq;TgVXr!~Y{`3$i^nS5ZJuHzO5#aq>mbWk{jnMgMOlSj^ArR!P#5p{+C*C7to zq5OU$EdpbXi(&qy1wS;7VA|)w@ZwgU4j5H$!b_PlOh*crOVd>y+}8S)!UR2dO_Zby zz)?`Tn@K)Fl=mS)sPC#W-3)BzwJVfG$Kkzm7zlS7Xk^ks%btl6n|#Rw|I2s#3=h9F zebGbv@4JlErpZZ7tp=;;Q(}P)pH$s}QMzh2_fIrb@%EMZ#vj6Ate;@{%mx7RjQND$YHK>1C@s>A)Y=*Wmb}uqu0VmBncI^NWGrfkg40YYcLI z334FDkrf!Oh;}lU$@gK#R~yowH(hvCi6(+~WjE6AibTMDP>LtarALnyMJ%)6^z6-+VE? z*qUP%1r%5ByQZ`0QA%&pH%e8BN|q}BntYf`5zGX6*HQ#k*0A2-%9k(3#lEXhipGho zzuZBnm_~oQ1valJW)V9$Ydyb_0ap!zEdSvMSw+Cqq|(k}~bAh2A{6Vn&oF zQBv})AE=y#?W!ADj~7XzZjqPsRmm?sXqm-By<1A(OEB($ zosZeHZc*%l%l{W~yh~L@<9XY6-R_F#HEwSHZ7+MQBeS9HE-?p>ue9?qz^OzwuuyZc zN8qXMB9kcqKgAG1j&|G?_pwD7BxQ7wK^)f&V^_L(Q_-G3U~sA6P8LAiYW1(88(|;g z=WYQpg7og}2UqH>hGKQQ)@4k8FQE|z6h1rIru7$ue~p#KLBY8)war zd%p3RYqa3Ee2SR@v&}65B7FdQ-uF9xRHx-9gHfd>^P^N3024do zLLaI!jv>;M5cVy_8=?%}f7sCk=Tuh#6WCmdPYH@&W~lz*TBUnd{*20Ij@Kp@ir z=7dM`?SHomX-ogQ)y+@j{co$6ZvrDkfw6WDI_?g?-_3$SH|M6&&d8H{$#1<4>Ht<` zs(V1gFW{%&R*-ZsauIx`{2%oo*E@y!BN}_on*%5n2077S9jo2%yx8tQ8G3!g5<(Bq zN&Hs508Dp2Zk(CcjdC`~ewlnBSO?@jM7-ZlF&ft;Ku=VQ-6KHGsWA@Ky;H9O8-;pZ zZd_}R*s>1SA@aR%EuwXq&wHC_+>QQPd4L1$ZY?+@MdisU=2Y7!LuP&e)(vrD!UVGD zy*?TfcK%>h5KK!er8wqpWW32iet2vN)_p#Q$X5!>Qmb2r-Yf+*yjYUhif-!D5E6`E z(_4SGLsZ!nb;We=nmCOaSY)}tWw^&tA71q>2B>5oqB_D!jv?yo(WGF`7j|xz%W(~^ zD117Q9;)Knk)V#|4*bQ7LWlFn8z>}g`G&F#OEWHoGsh&S{A)FUS2I(twMQHeDv7SN zug;F;F;GwrII$q7JXr?k-1I16hU2;+_1blL&f6rJT;fo&f0;$R&AqhoVt z%~yga0dni4pB}RH!rCV(Gg3{e?c}|c9>#v>j53S4y7wEjD+GEZ+(F|h~x*dgN(G9yDg^c)tbK#HFd}RVUStXh=RGa=M-)P_BVVgrC z?BS8rPOBObYm5i6-LP&GXybi}lb+I!zI)>yhL{eTW<>EbP08E6!}dEbRtSl{(tt)- zHQ$iCr%RQ-sbR8K+CAJ)OKkU{!G=3RY2g$Jmcjjc`$r-*Cn3L9vuUhX4rHBr)74f( z?2wyUpoCw;J1oSxiGxDJ2(F|mpw;Z6QjR=j=ys@aU!vE?%G5gYT0Q3PX2;a1LHujN z)6<+eQ~BAo7VnevcX20yS}p}A0+UB=2O^yBDLBhe5>hvWOLIVlXf&EP3DfcLvfF7_ zd?aWzdF=X~4<+vDT`I=ojK3k|KPe0PQ`> z1g${@P!6nbQS5p!@Y;^n0>gmw|3kevC|g2DCP40(uf?QJA-!wh3sbutENX}5Y>ku_k zAAoWd0tJ{0v26Z5F@Qmm2@Rd;BqhvR7g2f5=n$ z8`IEH%P_iKFOMA-p59q6yakZ?ylqVrRu)8y@pAxw)sP{}ZSQD!klA7#j=*J}+0_k9 zP5TDVbo^|U-m(?!I8iM-ULDpQ|M3G1g;Lkl}U|J(I#HneoVMTix|TL zd92P2N!qg3Pr^89#&bA{j;GZwS*x|-=kE$L;f}dn&ol!7&?}c*-|xtH!eVSm7IleY z1C+f?>h>-eg^!NZsvnv8V@)JH{GQ&i@u4e%i{>_km_LwuH`B+ab?9^TR z>*mnaEwf+6g*5T*!3*|IYI|LNO|r7rGiaxogzCSM3p9{%Q~tp@5JNQWvavQd6WEa| zILDPVfS%#cpyv>+sp-iZS($9*v`b#re#xcb*YojJ7Abv6D3;gNxv7hpHMM@J_S!+`;;}>!|}rX4cLoiElMGXieCf{@u!CsSig%VS6eCil)Ks zJM#^R&d_iXQN&^N`W}P0=4_j?&vK99=fuG z#JptE{!iOS7G5%>(I5$p=s+C$<3=tyfk!YwsNFMEnLPv#i6ZEXXd{)OL8ew3#B}5n z@7vGDvLiKQv#LyagQ)>ZFbn7@7=bXx=hVHO4mhmGXE=s!@pM2jZC&zLKzZEQaGKF_ zP-aVKm@}R8>K@#PjHnwy#^@<6# zthV`VUQLl@-(zg|A0u6;4hfj_%7U}pTXL`C64N3-+Ux}A(EUAUbMMy<4u%F$nJ%T$ zXLHNXc$6Ul3)f(i8pRTZR?6UPb3V!-elHKqM5j?5VsUG zaN7MKF1TO$bI1?$q(832nxn#vX6Vfc)|xJ;58&}b>I3&TN~SPZqJ~G2jVl}uiMnzi z$xTGczvCv6v2?*Emgp2XHGsu385MoHutq%`&!jYDW3^5^D0rQl>m}=J=Pr67b07Nn zqG2t~#b6V~q>MW!2?XV8`#8qL{KF9EmMVj;)&u6rGt1bbFxM|8m`I zp7z+0pL@401YuAn6+Dk|X+cbYTcnTHq!0+vXxF@3Lep)I2-4S`N2R zmObPK6MH8dp2_;GiPjlP7rA*}k98RJCy8dJxwEAr-9Uqwr)<*6g5lOC43B2%%%(M{ z2w;&c;fd>Nfi?HJSsszs3{v5p*!}}LJUDGe+8A*IYg79x{eeZd*S3;Y_%!1Ps##2J z0LvN9Cme0%O-j0u{neX**1fPyKcynwy%dnlV0Mfv|F%qK&O#%I z=bH?v7&5MMeNB)l<=@^avY}7&j9J6~ogA^o56DboYD0ZOi6w#s+-)>;j{B){!fSwPHks1nF-~WJwY#M4$Kq7^IkBBjliP1`3|9A zxoFu}ttDKYH~6uJ5gzPtiJd zc3o(C3}~8&EEE5-YIS2q(9;hNq5kb8*iWf127=N$Qf)|KB}e{#O#QMV0MnV-4PW~{ zsIFfPUC#OF?H!mNVZ?RoFJ67>sU;R^?2wvw?Wbfg-KMeOyiRAp)HL3K21^uo!4q6o zQk5n+nOA5$|n}rFPj8f1l0%$L0L|u?Ug#8Uki959H^G&G0F4qhIEkqevbM51afY zm6AVx%uAXY`UhqB-> zSI$=+!N?L;LHO-)M-Cyqq|j_|JLAXr)x9QxiaY;}B@}OaZMGq@XA2Tgt7P}Azid>8 zs(mi7)1MWd1VDGYW&rgXjfgTHZ-Jah-F#2+rmk&i`f)^ETPaz0%7XnGE*g0B?>#U$ z$Zy*uf*0}emTrI$P~4&|lZ$F986>ROyh5u0Gt3~exIU!pabD6#wFf-5{Y||#`-!zuqawO=`5-2y z-ZHTJ?Gv+T*=OCzOSZs|Yu^^Obj59bLRf+`C#ivHR!9VKvt1R8cK!%IKTP6aDi&0q zBz16en~3XroN8oL2N6kkLUvj?jLniBPHh&HmBSk>j7ZC9&HO8?&D?3J&Ei!% zCbchWt@EjM8N@Y@cC{97CECk53fB}}6;G&sZ70;T|Kc*SVmndykcv~K!mm5y@Qe$t zL|#^KnG-O|BJH@!@sJ69){%j1Q9T}8TGt%>B>tQ=rR;* z=U1TgVtT%rb9ri9A5M(!ap87PYBO3pZiYCJ-={X*spn2J2J!6v=XN6zBs_|oUG+)8 zI_TM5fr=>|lNN~hiu6psXl~bayjVo;jQ@A2q{A2MjMY-JiLc2AJA^}PO%8#bzB=XMlK(yAzUp~Z+@mQE zJ{bN|CsCfgqOz4-Y5}!=UFIe#K;?csA%!WT4sS-BE8m!7sQY1E-iWlz9cqRDh9Eu% zEM!0@keiO(kBj0ZW};^#TK)y)ChJO!Hc}Hqg8E7-Zw0toc?4c41aN3Gs_%60kp> zJ0!g(*I|aZqpl+Y^13U}_zxBmfx-6OPTe6pu^CE*(3het{MN1?%j)HpE1VJi2;3Q5 zB$n%-d5mWc*Ud7tJh;iN_kdBLYM*7PIymNf#QgfyPJ*vc0p3UAa zw+sNN5X`?+y_lZ=t7|;Bnvyw=h22GiFz?4$V2E^UK*ML1s1fwsa~A`LV}jfY7jh6r zc$xPOOBGyMrM|moY~(v;`gjjM{m{J-zQhl$XzNpCP4yqKhv$7%J_3lwOQBh-$IC9u z_XZ*0JOw_A!!Y!4!53~nZJ)iv82G`NXK1H@Es_V^F@^1?qu2Q`K9uE#ITzEYEEPC^d z`G&QDh_x!jP;~k;f4)mG$!NIh)if2BW&OU4UQJjbBc~r8avI>N1fv95?iLCjq3{;Y z)HoyHI&fC|g9B6sU?mBOeoQ~Ld?YRJ7M)Pk$?L{18kSr5wvf#FCM^FYafFlqf}&RX z$?&jvi7_I2@a!mdH~PiWB?ew*h(t`5W!P$MIELw#T>wtV;L`3Y?19Ko%qa+(S@~j? z21!YPKd6>&nXK}X6cM0V%G=5!CRQ#CK$r*{^I~YDNlUF|niw4|%6C^|Df3xIc~`@6 zPu>5~yj(#V#SYJ+>0!v;L^eDZhaRhv)SsKO%p7B}u_dTzm6j%`tl6)Gu|aR2js7y| zLQPA6eExvmWEnZ|&O;Njd^yI?&7hOdpZn!tB+Va-^RFbUI%wNc+wyBaRON@b}6LfKv%&@-?K3A({5|fIzrueMd5GvN_D_INu1)t z@FYD9W4|=pF5*8$66s&Gc1^t?*hQGMhpQPzv6{f(SiMRQ0D)Np)aXv&U|r*^yTS%} zM*%wxzHn1+K2RxlLA5u+I9W_n_SJcInyz6N@gMiX2EuLX-I7rGeKhg`cPU#GM7sCh ziAKMG->{_P$C(T(Lnq<3-%}PxkdB{#+_910utkc}XvUs7zbAEgt>)4aNE2tdux&KSDrF#Obrv%IO&iak`6JhI_0$v@ zWC?Iem85WOU<^hSs*a6jYj7L)7hxUKIa}Joad25g4gOH@*~{)T1x^-7Q>jzSCFR*8 z35etA4fl_ZA^2`+P|@c1Yy*2>9`^1a zc@;LWPP0U7%a6NC_D5U+%RAFKmf^QLl)hd4Gq@)OphZGwQqj~<8%ex|s_LSo;!uFV zNv~~?i5*%Ag?Wfx4SoY0W00Jui`8#9W@Xvl#-|O#5BSLHt1F6bUTo;dzn9uQ*+J)O z90M{JUWTYzeUg|lJSKm67L)td1*=@+^@I7CAuNfk9$J)JDtXYxoo9BvAGjS5Icgs$>eQHh@xGaNWr9er^ROfc6pGJUD zl&e6}v1tm2H`6I9S(4P!P$qzU#<$`%GuIDXo@L3Deb2uo9&#W-E8Ou4PifbZL6hFY zZ4=afGVXT%vK)!_!ty?w_GcHk_=6u&VdYPujPIUvk1hh^LaK{rvH}-!&47GeC3#1f z2o41t*g)T8Yq{3k7KgfmNK^caF*JRVsjC2y3Xcdr$WuBf!G^bxg0|c6=eRwP;hmed z`*rtvXtuP)?P7pO?ZrI%T0FPH6`fPgWFfQev1Z<#VeAvEfdQA%K!EP&nd5!kMm^RB z)S~n$i9PZrzbkysvO08cvzn_AxxI|T+Pb{el>P2Nd z9N5YFY+;~@()^s971h^!6Um`o;ZK;<3A@r-VQ8EeW{`m|^Xq1GUSXC{mCDf<7&@gT zqIl=uynm(SCF7=WFj0KXtgZ+n8Ex_^)brZD_5}8 zbZtEjQ+uY@(^KW<{Kou4Ba#cHizRw~Bh9SNV#U>TqvjD6@!@y5o~$e`3Ll3XZQCLD-2xqyhGy9TQyw08v1$zYlM@ zu+bYZ{mpHE?@wuxTh}s;%_JzfV)93)g9LUrZSDf4PMe8h_!wUW;e>2gUp@v_I5?B~ z?y-DxVG@4lPOZ)&5fw-(Dd5@tv&zC-9S_o2KY&@eOGE%1^ zNe#nVQ-3OyOC?i|jPaR(+pzxl`jf+&tEGG_UHilGZ|Wyj=jEtD(Zf$fy^)uqfQgHz z@uO_&MP7?fd9zYl0| z?7o_`SwyKOOki(nQk?qy_nVp>hq*IIxhB1uqvauHmeQlL+cz9h)%7nAA^5KtduhYF zJ;i*_z=Zer)}P2sMq!GKiTvOakZLX`-%td_#F-Qm__Ppo8BU9dUnZr``apUy8Z5E! z7$9Q~*_!Xtd}i3&P2E=q1p#?uHFv*?fa1B2ThL7hOidD(epB7)Uw*-d(qPKn4q7B; z+#DMqVmqQknI;dRwhjev*!v8Z9o+GDvpRPf32lY0w&w5rrqykbtO|BS;f>u2VYsH0 zwlGOpezH09x7~(y5v{G2V;<%%depC(3I5vuYl|zz(cXl;y9)#XaBwCA=B6S4;0!sd zq9*|zj#RVr1(r$o(!nV9uFU22=Ur+I*;TB>kVcwGcu$}~w+1O~xt{f#A6FER?v=Sc zpy9aLCIOxk9;p3t{M2GVtPL}>G$(*{^?8uSHVAh}t$c!o3$o^%`_fYM3Cd}$oArBQ2sV-; zLsU_x8kEqMEIH;p)5cWXl^vtOSpFtFVxD*+0xkYQ6aZo{5m zPxXk-bBdBmwxdIhXU=#jbK0;lzR%5Ti{_c_a5$Rjr4lZa%WIK5CwY|xrNp~Sz@NoK z=fXL#hG)}w=4G|&L|nS-!V2Yd8FCf5ucob0OxlyN;)b+YE#w7O>$I$LH*q=06y%_1 zuODcP(P06>jJp>>t>78vF;Qu#9=JH_Z}VL!<_v^#B51g*Gp^A}N-aF4!e9qy?OhYD zl+dq!^g|VMzaN@Ey9iyABrxt7NuDyn9!btugIvzex&YcxTx@ErI!jaYd5tmFJD=Mo z#eS~p?_$b}`J}vL87>*GZGzeu?Jp32RnB17s1kC5K=+9cHNsP7d;|9)N6%y?sU=t$ zjZlIx->`oW%fJjwtW-{8pi@_38?TqYfEI1?5SoM$SWqWtqc%?HK&yq8LN(h98GW!R*C8x$S<_~S`NY_owS=WvGpK2Qu6?Ji_d$MB!tTc}A z!}3&WOZ90u&wy!0s;$U7^Q7@o{*Eq0Bir@@6zZPol#R9Llrp`oAfiy(H?hG+F-v^I zhxH`k1MSmxIILM-Lkh{;&?t#SAkM6pnLkB<7E}s=2(k6s0_ri$4|>E&$P3)T!{mtB zP;i0tUS6=Mm77$`4r4-CvLbUwm4!of+`~nW?2C9Kpr-RppoUwkISXv)=>{O%(hcIr zPTNG=@@;>*y9E*PWb%9>VhB3>)Dz4fuWxuN35iw`D*+=IntHOqZBxEh6$Y_%i=x1$ z8j)uGw5c zzi3*@K9NCz-CTG$@b5oIoLy`2a(@dfSfpbtUE1#D^x*Y^$5?SvE-rj%mB>L3nzYIg zLweeoVecCDfh{S&)xpE@sZvS&t}TrDPdfiFl+@03k%4wFLVaEmV=z8!>6vmN%#WyS zZeBlzd4l%wSplMM^r&~sIOHdlZN#8v$)0;^bFFu*jJg=-K%c!RcY01v#M^Fqof23s{f5$@uz<(A|a{{NyPZh z2Vx4J_NF}0(vOA9O@|J>wO~lo>&|X90&3!}^Z%2Z!c3V$C5dlHMP2t_W(b^XCtMGe zNN|JmFzI2Y_gwAo#D)(O--UCONF#j-2ZFL(W@emu)qrt1S-M5eOxHfsXbLH0>?puHzwdZld{8+Hw2Z;me+ z!SEr=#5*4#MdPBBGs1O<%*3)DMGhOB*K;W_pNfNQ#G9z>8J-AGp1mtSAb%G87|eu- zq(eTzOP?)pK|P$qcH?UVC;e&Me)}&-qkvb-;~TOL$Vsr~X*8*rka8t7`DhpN%#sua z z=6%4rf4GiAAlf}QvSTMv$&WlE^kq_KOyVW-#JFS}&0JXbfhR=+kOp%eiBo%nm_SKr z`CF~;_&BxA2=YFF)1dgGdIJpK3bf!}Kj!FJTj<&M9bj)U@{fRK(eab(Y+{A}!%V7PNB%cqvy#|1w2Z#OLH5zRM8zHX^)f_@K|(HF8L_jm61Q~23hS3 zyii}@8AnbngMHSY!MhMlW7s&c31haO%=XYd+?hKrVSNp?OGtX8gKey*_y>}Uo2+19 ztfXMlHZFhk%8r3~EJbCp_bBP%OEQp3C&*!gPx=cGC%A{K5z4)3Gaxp{!Qfcksi+(k*15>HwjKh&_tCm0p+_H?SRDCt9P4vm(*k`Ca95$6tHb zzdC;5R^>Wl7=3_0CDfV0qW}&E^FHnybi2NfGO0q*YjZnPcacaV!UXa-3M=DNCn#Lz z7-fE;0ExIpx(;c@aK%v{JKM8PG(2 zBZHr&kGRT%MV|6omQd}z2Ad6rbN6!C)Y^}n$`d{sB5$}V?1gcV-aneJGJGZdf=8K3 zC0iYEg>o2%ct>8JHacGCt&7k)jQ-o59Ox_OH^!{8R3|*)2Xc$572^hac4NGCgZ7+r zB`SvgXAm@SV-qmQo39Tp>M40CSGiI-{YHj$-z5x_)-*n`a`dA&U}S$X&buPHIt$<1 z2k(l;^^?REKk+~A?!gQEHt3KeG%5p0oE8;PgwOs>*uwDsM)#Rzm}#PCJ#FeN2eLYE zQ8HaH58v>Gko;I_di+TxCR@L1wm+Ph ze=s%E2}Yjs#g6me1v&A?i0)T+Q2KVau@T;EWEO5+Kh*h4avbguQ^tbbM z75S-`4b5o;w36$2=|w6->CGQC4mj=MJKFn)8Zxtq{}20+is)m18wKEN8!`a05a5!# z7ujgNg+{|oNrKV+HyT(CzpUr-)!Bc2EaiQcLmE2-GcmGeV^?)teW)}%B#Cao`~;== z32Pjz6e2pQ@}%n#rsXPH@jxs^1ETP0_e@36vSrYd{jHg(D3r`oneSba`BbV&F31TJ zMUi>uhV|tNaHsz>9;;8a`6@CImg05Kx|Idz^?`ut zs+zSgVPB}ct~rr_s;g8GLytndIlC{g0R0QLy8LudIbA@dxSFYZZv>ACkoVy67njDP z)}#AbBfy>L24}X{>A|flrrxbW9W;OLj_fpF+RL!%h2N%#+YBa^I(&g09e27abd3qh z2AA<@9?Y-Ie&ZZa|-@<7i9kVoGby=Ls{U_E3OO0Ed?2vop@dQhc@wXLX~kw z)wBLivAa43RcP<_gdgWM%|9?K#<|%{O8o>{AgGqW4XOL{S*y$=qT+J_UjvVJrMt@J zc(ch;DijnOzpzXv$`#kS({IJ?Rhy36nc>|B;L(x#qQixMR3cP3|Huoc>OmIGcAZ{0z>R(5-uu06}9B3UpT-ZU5J# zQ;qP`Sne}$oAte+D*_SGQ2`Ttp50>wK-f=kUOV2aD)&t~d1a!vj9`5BLvO>~M0%LO zGKrqC?jee%Lm0m^MlZaj*^d%RbPXeahu{ha8f%*VUeWsd;;_ZLXVkOKo1) zH-W7MyUO>}333KOgOH78N^K`5%xedZ2yF!WE;Siu=W&>1qi%aTnmT78OT}2i<~^_6 zG%Jr0X;!Mr835tiy#i^~)Af0_OY%Z#ng1GE|N0SY`y%7x6?C(_FK{1qu+LyBSDIVzr1e^eovF6=(B&yPQ#iF~w(;V`U)}?qbQ6dY|UBAnM4`+^L zz1^M5QmRE~*ScX0(rF&-Xz&)#sO81!v^&D@cmN6#ekY}R+n>XdA{Q_0=#ymV@69S$ z2Xb|y?QB~DJZwPd_iV=>Ttx-FnXWn^rF+^JwMPWJ9$0TG+kw)hbjtkSrLQxRIP46< z0b`8Qx@GoWJT6G!?HojZ}r_2`{ z>PX2%M>gK&+J<2w%&vl^p~5XeN*MLLt2C&m13?<0a8$9IP1yF2m5pg~V8*E&Cu`N+ zh4vPNZ=9ZbHOp!?*dFYkisOp~U_c)!g6xkk6^?QBMgzZRz+PUcqf2SaXk)>*inuwI zxo@!{W1r@zx3lsPxFQK&-A*4q0s+Egk&hh8^Xt<{fdkNU2A+ zIZWefZgy)1Em}_89Ar6@qG7|VxTQ(of96PrujGtGYvJPq!*%_3$`lW#hraupb;q+d zD%rg&9R~wb?Ko&R;FuFcqsmx;a}+=Y+b{;i0l-%Uu!97n=SZlD!jtdk(I|R~O_|h8 zfM!R%!#WQyXF*XX zJ8xC3KvDWg6MQ9RIc;+Ubn2cXU;&!{Kv*cx5`5tf9XRQgQC;J$dR9=Ry65+|ech?S zmkP3?G>xQ^U3T?%N3EpIbP-lY^j~m9U|_c#9nxIdI#ybHqYrr0r;3_n^EKH_(fm{r zP-0mkE1I8>Ci{P-lJ~-_nLa|ITrt={7?^;~Pw=DE3mexL7G*bYzq~RGNQkI7v$4kA z?}Q`0;f1c=Lc-;3hWjaM+}H9|{hLv}_kfg#Zaw%;jt_AHIN>&G!p9q|oh>@mj81f#=er*0U>UNP6?keXpQ4#s?b@>(2cq zKYnRkut$s|nsmLOT)AfYx}kl^yx{9x>iZoTl+X=clJRo5p#pR|BvPch~7ZOpp`s z&N_Oo?Yn)F*p9v>Df5-HJ#mWHDu3$BJ(;Zd2>@;_FG--=8xjU;lNKyUa-c2OPVtH5 z4Z6^(5T?c{unuFm^^!{E+qGf@haDO4mN{T>|5k^hKxght?p=t~R>-qP1dR<|xEG=$ zPgZ|A)Hv(6vu7cd2K@IX2N&)6Kz$F4n7%Y2m}gH@#>*TUPQ@sf{V~haW;XlP&2UF* z1BxOmKYqiRUBy>JIv`cWD1(niSugttKjrMYhJh<^pUEVM5CfHpEuN&O~Rb zeT|nUHu#X2^Gj7p?3r6Leaq;3(*0f6=FCZMY_V7wv#F3m6pXo#sGXSs(5^JXcFgU2 zE^TVDo3WR~>5mh=JZ3`ixdI%c!lY{aq$i$c4b-GuJJ`!EstEp; z<8-Ur;1o);XZW}lm78eIGj32L?t*iZiAcdF9y%!bJGx(KWc|lKIabe=u@a#_5a+$#a$B|JrX#%bxeHu0`39mfBnzTN)mxvM z{sa!kMrxg!h(;KKEh4{h;$=D{fNEMqy+Z4P1PY4yVolD_HYJ?2n*_**WQjqZgyc(C zyz~TLg$Pnth)^aARf>j;XDMiE7E&Q4Fa!QsAYpCQ{~JFcI9nUFVUr8 z!X;F=I{zla^w!OplV@a2mzj$S)-Te-Sgr?|1o^mchzMmDl2u_T_Cl@XB50a*t505I zo@okfHKt2n!W6j0!jbjcm?t0+10>GHF;w#}h*5ki7=tRwj`p&n2e2_*@Z#*UaL0*D ze{5R_sm9)FAkT(da$xLEa6uW4WMV$^v3$(7VH&?WN>4GUAj_Mm`TBC10kFPcX?-^{ zS|G>D4Z08oE-ZUh+vIT<>5@IQhT|&qI)Fm^5dvZ5ykzCDFjS>qufI*%5O9X?$DLwf zg}=8Ivwjpp@Go?0gs~5%V``VpsE5UeS!nkJUS>J#PFd-EjmQKLx2_)5DsgFODdiVL z&+z%e^?`sB5oCbHJV)`oXVAXaK@UW5+B2E+d@iycIA#V8{RUDYF@sfL@-M2CO?}v^ z)-qy5yUmPjkIDn_r-MIQ<$E4b5jSDl#B3CWx$xkzZ#>%u{y?JLetLYHLITCH*q7wt zDSAb*zBOn(zj_Gp5{1GH;q)&ELkoH&sLu)XN;+J;7;!PDvz2>zTt%t zk1N)gF;(Jw&aXxj2yVqCoX;|fg4Ad=dfG8x>5Q?zgGatNZAK0kQHCeOolAww3`eF9 zj*8OZHO9*LGM4eSy!dNeuRGhY_(;2CL!ljE@es72+B5D1AD#y~ZQ&;4rmevalzd*F z8k{aKm44%+36?+Y$N@wohgdO(>*>Q?X?|Qo>AZKaXDNhzVXsD`caSgo@s7}GHJtWN zelfEG!2O^s1!Jiz1t(19^?$)mZwud~up?dho4qO>0R(}Q$UgDD0;B_u2`5hg#X#d*-N2Dki85kXiA2MNDRb%a$ePDQt-Trz9-LLSEYGC$$Yo*LOBlHXvY3#V-NAnOCZ)VzI=luMw>p?3je) z7g+Ln)p$1!5x*HkA8u| zpFRgv%;YSEOq^wQnP7&_RJ9Z+I0uqa6Sk|KhYu&8B_|@5Z=;W%ZD|+4@(e@0!y`xsVkWsQv(y$9HfP#Y z9ujdGWEo)N(Z!f`pyA0R;4$UH!YDEJ0zK2LEhtFC(f0GGbTXESoGbz^8x5cDq*duZ zcJ}=PU%+GNLzdJF%t2wauqK;H^Fv4>`VHab^7%fh`Iu-UNjO;yE$A{xsEW!58}Mw6I!@DQkBm-xa~F#+wX z6_JyaXYWwkyO3Z5L6uqWaW2v`cxdPNs`v0%>nd_o(XC}WP9uJuY3LZ5G76+pOaf-l zwgjE);`0zHsEh=b&g7)@fn79=oqX)Z*JfNiA5U`wge2q~Xlv(zDfI0tda<~icw$@C zY`+w_E9uu0a1b5YWM>+u@4t-sKyYduRq3?I2aBqr?-+Zfz$^BEg6VlG#*Pv}&4taS za~m#vZx>9QYNH%;aw2GE+`&(52yQD22z%OITdnq*nA9IOF-klSo|xH@Zed-S57B?T zh$6NLoZ)FKz|JeiSNiMeS*J3Rqj%DsgSjqyIDYlp8Sqo=1;@=^;)U!ve&dj$SUc~r zg1pRkcN}V;YWQN2kDk( zv%bUBx5kPir>ImHb)~wILI|7rcm+3XLrj|ajp4@`#uayZ|HBYp4l?ff&Sa#AWDMc1 zVtCQr85ggVAa5NSQHK*s59e%lt=9dJ-(teYGYS{^#D<8ih1edsb5a$Pt!c>~Ib*K% z`_-*&hR^7NfA|UXxVtV$&so?FEu5z|EP7JPb3mNs}l(MQ!r)dr{hRwg)AtQNR{a}6q>>q3-odQwS zubQoxom~0IeuGUVAf3F3qn;>3N1k*pg(3?;yGqN_E+eP`<GQI*F*|0zoJCFb?#%9EKiwzsM@EH&ufqH*K@Q}7m>#KIACEa3Ot1M~B|i>i z=qNy5bs3QeJc6gr#?m4TMNns|-+7g|&K!H37Ms%A@AEqOsckj+2Ni<|39fm7@0L5~_Dhz)?^rdWxAJcv!JU zuu;s$6Td%y&@Zn)KzL5Y%7LT|1=7G|vEn2xTuA~?6B^syvG-AWac7KcOfWxM0B=@L zbI2z*M5;XZ90}A=OSn74*1V1$fwxg5#^c`;yqT_DOOe!Wf*12OMVTbyi)dLrKx)CO zclkslzQz-|XLx{T%$uPe{zxenQ&B1qf}__j0R8%>TfIZX_P!0}EUcacsyWd{JvRVI z+K9aD&c9=6Q^%f(nNwrq$|XS58q>I)a7pWip0&u}o(+JzX5TeiJ@C9%7ybba!l|4h z;^0NRl&is8{+zXAI+0GqlYipo4?QvVm^`N zgW(3$`8MA(=8CMW)D1S7jhV-AtM~#k zg)e)>7+e&>-?xC_=+t4CE2-4QI6mcEH`T>~HG9QjADm+ZRE*G)QzVaC1ud~`?UzKkEUak3EtnRlhWL*vHI^Te9)tjrpp@|wxj zSV@)fY@p^5w~=kO*E`3qk0JIbcZYG@qn$3}rNgYd$ArGVz{j`X_c)>8MUV0V+zr%1 z> z{qs8;_vx*syl$?IzQhkjo9JmCWt|KREym2BgJhF3%M7TiD~-sx@xw__QG1jJUWZ`0rh`}-a4Jis1nIdHvFUo0WU$tGcx06#HHf+Z3 z+;zub4uEq1=C2GPsBzmPAu$FwXK-054dx?B1nO}NMuS-0zImpD0D zEjAo2&&C<$hE0cvSQ4S>b*cj(%hBGRsFo1$)sZ{&gSK0%I(LEc)|C_@O-A( z)&e|y-b6712fL;yNF6h)80?QHYebVfBh{$wV<2MJq(REWGe_e??W{~@L7E6dpPH^+ z{=rcU(*)hp&pVTVIn)MRup@{SzZ;J;WR@GF#mQJ6(~&&6|q%V^;32W=6X*# z2#nl0z))(|jf&yt2l0=lx}rm?VMaK~;~Q5y?9)V#r5YgiG0Om4PfQL7A9mr9LV=6X z0jiy6!sue5El9XU@W4lXt1nar+2(NA1UzfHS|!-m5O5i%EVOLMpQ4mpsnteM-c&Lw zUm>fIhX5}`X=$vAo)b7^_GcF*6|^EuTdRO03(7@J9I;5_ZpTn5;@I=wm=o8*7FkI@ zUg;uSQ|Ekv4n_VV0Ag6#I2_$cPZ|)DkD0fNHJq>yDg~9o@x^((sg`Q28o%&xhG#1O z6ssOJR=Qdl>_8VWNT+I4PW}&%C`}1sDO$EG1mk_Fv#0bdXUa+!_dZ@>Z|U#G@Guup$*6-3Uq%RZ^v@qdxg ziv(osktz>)%;|owhfaPwIVjXG>wuK12SGTwA=@%7#9bY}$Q!+r4GR-|6R+D%a#)JP z+XHZ)Mqfi^1O3#d*sm8CL+qfrqDL|TckhqXu}Ql7Y);0#)Nyteixvwn^>2=a5_7#+ zD!PnFCKjEL!F@)1-iStQAKtZ}z|NLX4<2e$>Q``mp`{JYlY*U8gA3ryIqOLI26Nn^9DoNCBF!vWRvm19>_Pc) zZpGG+N6E|dTGBRT*`qeFyOT~5H3&J;)t3YhmdXT$YzG$id7PAqg3LZ zgVn~{i2Ut#Z*_6E-@7beE)smo zHn71nP&42xD|%cc6##Nsr-HcdpU#R^y;nN?4S`eKgwo1T`zxS!eFd=e=qO8m9Hw`4 zeJ<3qZG$qQ7)sDkx6b9|*3C)|6E^fDtWhH7NsebqVZZ36`k^}VnkAEyqzVW{s6|~R ziezFs@}$15HHu|`{($!^#xK&c`lEzf9M5K%-uCm0yud!(U?)h?8zw!_qRM)5^_4_s zu-9J2Zqda)AZdY8eapQhgbjxLB94nsz^g}8K1B?n03!r04qlHCDMpPW);PXE9+R+yTmS*gctHVBBO5pSu$OG>mN0-B!fftRbmxyF=R(bF(+AZ#bKBYa&569*3ZDpv4T zk~$cE5Q%tb>HlLnsbnC6dpzNNvZD7^x;k7PXMMD055g7M8)m2|u)D>v*}$^bk(B2T zjcYp_VV|>ArliwvYdw&G<)nJlb!n@9phpUfb_}Pu<9 zC5etfI;@7?Y1KUB1vnpBwEt@vc~Nb()*7AYf8sR2E5fP*_go3MtkU2+d(xS+P7i1L zm-QHTOYl02R0Sp>d8rD`)W79Or*xg zml{C%1W}x%xJ+=e+Ag9vM#(BNnGJvsgj}uwMc`ero>0!djt)r^eM#%v-Qs$jXKV|{$njXiG)?&SW0Le@3#{M|Ni!C8i_7i3N>qjF-tCa>`e}@ zSXB?&l)XBIY8Rs&5_s0}Ta+fP7xHD!dJBGwXnVdn-b35Fls%;l;sT##_XN#d?(3Fb z{)nuXwITe`{d(DQ2^eDMoXM*;*@H#fx@$8WTJ3q-vt9MQN{u2keo1S{vRP0bpq~#d zogy>{kYoi6pN#`NKcmFz17bVMlc-$bGrjsi0pxxFkV}WVwtrW@xKz285tdfBqQEh? zcU7DB{U&@a1)KsbUpin=GL&Gdsx`&8_>9&9E!ZH9wpIkQphjN7j0FTPU^NE4Hs-rq z7iDvVg2P)Q0fr@9AM31407fw4ISB$I)b4KLuo#o_4e+K9TQ-zUg>c5W%|~*b(wCmnGIysLC8j1d~@j(>OL>>2fL8!t(>sYFU}VT_g0{4G*X1 z#SC2l(cff8>3|(PI(}&<(2o?Q#+8Ib2QH3Lq}%}v2F*(@x!OqRxYn_hzQ%zfhKO2) zw|_#AP4>fthn%kLI3Kaxij_{I4E&(H;X9HMl;~GnQTsiqKMi-YP!T+(p#~2dKWiM6 zz#6u(hxsJKAaOoU90p+GLKot9saP@|8_0fp4#<#Mrb1mw_xIt_uC#^o`RQ*>8y37%q=@aP00TmBU^tyw zzuj*dzH)Zv_Q%1fUZ`h6*=o-P60+&dbUtbuM*?`GJ3WhWwFF4D97bY>bqSvpdy>j4 zy3zrr`A26Cp&s)D)KiS+xz+ByE}jgnA^90idy&>{ zzmqTsq4TjEnF`Hv=sZRoPPk*1fpw5HS!)ZLI z#l5?qwm?pX!Hs5SQpr4H-5X1vC!|t>*lGv`EK-Ka>2(E>j{=u)PNlzhH0*JVtn;H1 z>gS$ccdABriOvi1tm3oQYy4A?wg&Gnt~$mxlgiV4_M;bkmq4Vs6Pn6T%&c%mHU7)g z+yfy80RjJA@@qH`O?!I98~uyOo-!(yj*(kwB`n-s{`dWxra%#-2;z zC|y4i#O&L6Dzf=Srwd%U*;3FlYbxSy(<>E4gfrRNMDdJzEY|{JS!Gq7R9I^Dzmwzgh6|%yx^a2jm2Kz!wxv}S`Ged?f+5MlAym&gIHUdRw1lWF zArpKnK+n#r>tHL23v^yAIO~#^-vnweYv;#wy>`TFB?Q`%ncJ^r5!&@3x#ParSwUgy zH@Oaf3UQQ`xmsAlT@yBzf*-;`HAP3;a^e2Av%_&3Q}Xk>*QSo%pSe?>(+`j808FG4 zC-cv&(i|Rmd1=Ap%#~`1WP53LJ!;G%rov|Oh^u3DnUaXZC@DZUMdVQUCokj3`QH*j z7J(Qrt%V?$0fjL_LyKuL;kApscP^nCHSGgLe1BD&4Ns21i;Q`l`Cdn zj&+$wqZ3Pr?b@m#tF-l_r__)(XFohDUoHX=6s}Jj;9O*6vm4vVPXh66Nij>&SW;B_ z<({f8EeFaImOJcJ>_C3RLmKt!nCxCTWj{eE z{ul2Us7(ua*wY+Tin!4H@f_DW1AUU@5fO3P473Ga6MW0tDVy+&Z^G3&5<-5WmkVoMzcv6;Uw}uBu(VCG^wx z^Lg^(gy$V7CXTRy0~POcq((S}0B+)>(Rxx&&a!Q0NXg|?lA5G#SGO3aX5I25#5M)? zmG0UV2=R4-Mg-0zZR!A7IdjNz2=cDRUCfN#HM7QR0?FzRe3bqIC-y}3A7({z3%#*v z28j(+7!;Ym5owto5bH@=x%Qu#?hdTII6kXx_&p4`%X9CXXZ$Aag>L=719b-+=TtX2 z`MVgbrltrM-eVMAPbJOH?IP+}rH+pl`PG<+KzNF&vowwLExaP!$ECr%U>LnB1ifnn?jJA% z1-OXrwYb+3Baqxxw8urKW)BOr z`S?t)`eO#(XGz=8irQamg`wjRN7Gizw55R8b4ujpP+z(fbBVZ;s9G57;eh9?=sz8x z!^71;$hW7_P-;U;}2s)kn5w}qb9{7?f&~eN4k;_#3_~6UOJ6%dR zGT#iyKg*1g_2OPrcD3Q-tqP%w3VY;$4jk7tbce@AfxT1FntVZH`~gy7b}~~LbB*6G z*7@yLgPnyK5Sn1>p^oL9Zm10CWRD&OXu$7op?ap*^TluSC@aEWs=_5FrtyAD%FMf0 z*#&bmM))w>><0OirG+KOvHWd-Z_^@0!-(USa8w?DS;EO98&=qwRcX(cJMD23h}zFN z+u3JEKXw$3OiyP=^|p3zMs5W^AzNg^v>SMlXd~USQ{+Zw>JHX$YILe*j#l+Y)jxJ55%9}Q{xXY z#FloW`kZcjbw{rT1kmArHrM7rRf_)zib;RN~t$G zFhAdePl^^W&;lbZ`q&o6+7=Xx9+-#jE6j{n(!Wj@|6EvF$?GZ4;sFRjy$R5SR(!vI zS9VL02U6Aq4{r*BUv`P^NsTFu-Z-(G8zGWF^(9B_sta5@R);=hCg!hIg}sV`hzfq= zH%;uLX`9M=cuR^G@DjLh?249qIrB-yB!bOW;!<(|(6pcC*) z_~35XVW9*pX3*?2ULqTRw26k~A{?eDTalS=mEHuzI&)kE1;C-h_e;MK?$N3;{K9}2 zS2Apr9*1nA{YQucRPj$PM$nlrr*G;77II9V~;q7mf;FF>k2_P zoHj?aLZDpV&Up|acPGpwpYnM~_~-pj(cc?AfM!uAxM9DHe{FguuA{6?0b3ZiLs-jJg%V$HIqArDv&$GfiQaaWrKcAo z7`{)OLuj9flE#R(i8IK#B;4rE2cDCN`m?1qYhh$J*leLlCKmDFu0U{LX$k>yUwJ`M za_@T#&QA*Rb&`GxH#!1A+fkJthOxwpEtJ{Ef87Fc?=!m^&;ip`6EoDLoSzsXjO+2b z9FV5W!xx*Fsd-OS1T4l+OTOKVlOl)q(*c0=_niLdAvf^*JOJ3zb^uy{7j4K;uJu>a7TAzwn))P@m~RdHHhC1H&gpYgS}5$#01 z-*swo-yTP`r?{Tzd50s=@Ah0nmb3D`_KdMbkE$XM|V z8x%D&>C0VvB^ebwnYU^-#M1vkpg0tx-;#cO1*IYT&n(%Cqu321Il{hCg`HiBy-r7S zlifEDyqkh5_vs{r=3Q9+^Z!mWUB{s9t_?H`jFrm1Ql#;;*<(R5fzt5;^1mw9>gOw; z6iKtnKM_%$`|Bm^|W+v|8a$lpFWAfB9~n#a(;73T|3 z4eB5k&w)!(xd4)r&lP7g;pM!3gO=4T(O8k2R{LYyXp6g0n{KNs3bwEcgyHdI`4C(+ z83R(_P>uj2%&w%Wf12_lCpo`No3s&y$$(mNM%D9l0OvNEpDABEa)Y;|`(A;KZYg1u zHHR!BWN@N_#5A?a3G71wu*-UHNo3>h(N{>i$FRmuW~}g5CK7#t#F6mJ`B9kMoNH)^ zsg8!9G;iyo=rVn99gWTV0@&6zAD=oR3qj;7 zH@2WKfLED3^mq$62~B$Z%%&~@xxg?f z_~s3d4h+H%!=5vhZR7lAmjnCMboHOuC%}TmuNzX zE~&lm$=h{SBlOuijl$}WhTEX`+vKg}QwvA61`sduiD#T(gvsPCP|S;fjj;LTWy*Pc zm7M|A!TzzsIkicSc-XriPg%irMC%0K*nVQTDbPJG&E0C%6pdRk-kF;p2)Uoy+T83* zeGUlp&$TR@pULv6HT%9T?uNC?O=COcK@8%OaVQbEj3&ynmx>aL;h46z3r{CO7m3ke z%_^^drq5>OkhHWT)#i?G6I+!cBM%<$=MkUkxYg!b>63b5=#vi;-t4FGW4e3@Hm{+5 zdBPPU6$9Q<4>G&G6|ZXDt>PbNVZ1J<05TXGuM5S*pGnN-x4^j}V~YZ6vX?}_?|8_= zq(bEN zw!?jyD}x0Ykk7u{wZ9Acu;ELYjfhI?-JGHFNy5v@Vu2Q+v2gXHq}u3WVX!<;A2*o| zGNniVu-5#E2Mi^&Xv@iqQ@YX9&^cTb?hWQrsf>(R^k+nReH9^g?6|~kt!7>f?v z3M@)1^+3CoqAqO*4HU19XNo=xe&@8TeCyg)EN`0epX8dTyS49&QFqoIVmoyWc@vS_ zkr$r!?{SQbzWN%Q$y5M%auY6#k*?N&dp(xf`7sfR4&-vW#V@WHks;5d?};Z_@4_A^ zVH)D$+x^nD_%KkCnX-%`aH#5*L%%hp8rK_B!pr9J{lJ;|Gk}XAy)$6&=x0rL z2|@E@s&!p##n1@3YbUaxZxuJLl!c@EeX2m(X4qZe{u40&2fb^u04S5^-}c512b(nm zF6X5or|0Ez*o1CXUSu5n1(4c3%$u-#-;W?QL&lfK{&)Fh_%~Ffw7n6c>0h6GZdxcv zE0P`SG%fHOiqON%PhbBR>Io-+@OV_(G0j7(V3K+pTQjM99{{Zvs_8M{+$_v^3vX3| ztm)G{@j)Ofbh-0QJ8Z6Sc31$nKHo!Uh|# zf9W_2modHqZz$CQfm>|vaI#ge7RvE*y)x;wtjDXMFS;@oJT3H{TZ71r?63ZFT8h3G zBHb(;QFn9&Kibpq{J6a}O@yE09a?>(k6IF?O4{Y_X~gbGkF*&<=wv#7Lvi{!SD@6;92{E|Fpc~P&;tnpgsetL84TpRwB@QbO&N1>|*$wC*kRRhh z^f(Xr!h6ovgY<7qrIv7*CIyvOPUln^0d9q-qlcDgW(ewg1kmO#e>uy=Eo*F zhFcZ1{&;kWtW+sS{|T>loI?|*i9tcvy8Hsel%{FsugHJepqdY#CVb?FI&e#`!YBTB(Mnmy* ztvnt}2EyCMyInp^AzgUcK$YLpfMLHPS+=*KeTcq7&Cd~J;+9527MLP%8EgtkXlfor zN7J{iCI{?NT+_{iJBOfo@F+mg^779+IjV9aU7GW^0+ulw+3=1b)l5f5EdM%B+5Yoy z&r|>^f@Wer4wa3cyT7Vkn0?I_-xE~h{@QH3A?vCf;FvMKrlz;ZOBKQFLcNu__+H^Kin@8=NV*X#GZ;UGK08g(*_AFk`iO~vm3lx0}K)o@A1~Vlw(aD9i49IKbuZ9iv z2X)aXm_!2JW!;nnTZAx<&avg`1>cBo-h{ zXA!>uKS{|rUwl7UwpvJua{D^4{9lAqVsb}O=H+i?$rN>H_i^!3^WSN86%WJqc+&~i z$_-H?eMUs%gC?>Bn~oN^<<~Bg0Ua?2VKdeuZ+2FH-D)kz7YjOoE|T{HUYrK_GFWw{ zn6(LO$ADE_5ti)gC;U3Szo#C^el2V0>Lz{4agli=X2M%DS&Ajb4H?adEpfKT|FqyzUz7{ z`Y?Vit$^5ZXpvI2a-AEd3emo0f_Oa#RGCg<*M|Y;Wc|*E@=t%%F6`j?YK8fNM0%vB z6>8K;=1BBzGwjgfpp;x1O$C`Y;`sHR>asb*iPBT%(Ef_)+wNPvZH9B$h)tXX%;qx{ zv9`SZy~U#TQi9Fd_itudw{~eE8xqQ$fM~o0b3c>Y8+LGGJ){#yev%uM zHzrZo2hS(pb|6CT7GJpP6=}CVfdYfHVQJsCI%9$p2dY0be~bpC7|_aFZ9+LB(Eiaa zBpZ7Kf5bPtbr}1*s$FE&46pR0v_44fbiHlRA6k%pyVk8DVqJ;Tqrkt2p+?s=n#P*z zr>}t7$GMOsed3voZ^~uV?cOsn>TY@Ka^kK5?>L&g~HZ+ zH2!A^pUFZqyhJ5_N8#TQ&Kuxy1F>+Cb}$Su7Ky@t8Co2W1EncoE)XIt!Ec$MOJI`Z z$gsr$CrCb|$6d)iQ8)J>r67W6$*7Pylkqb_UVy5IcxSTPJUDh;7DMw(Hv*c_+o){B zZF~}OdWU16r#t}p6y$Va+k`^db*?)$OB9kDsImMbvn#|2S7zz&(zIod@w4ImegcYY zEFGxxh2-ibEh?=$9D}2;&O#X#EgK{t?8khnbvr0+Kbi`A@R`#=i;ycz$^@sBiM|LE zq)a7|J-b}Waki0*kRd>~_Q02|t*y;=dToq<4%l_&j=uvZn%uFC;Gq0`Qrabkxid*$P$q z>0@KAXn^0oDhHg+hLP_@ZiD5-Akce~sZzXM7v$iMqh9Ru)+KiX02QATgr?FK4{2C? zkl8hh6D081dkJ|YC@Qe2mXR&ilf7@oG6YNs>>;k(Fq$!i#xdLo zMd_fv@2G5w#ZBSK!1a`ylE}Zm?SrNd{Ct{7hc6zcQo_P0Da>Wiw~9UsBDGy?K@+6K z59KW~>Lt^6@ihq9{?Qo{@8<=uf%4ch&#Ct8AeD1nnXS=edLrB%+%>E&oVtd29ea~v zpo)^fm~%k$){SLY|A~fsC@ckWBBiYg7_{0Vhwz1t7;ev(?h@IV*Tz`q2C>WOu=3lc z62-OI=3QG-Pw1n=)2yYcQSEVRz|MBlussW`E{hu|c-m!+C0pd8ece5lEA?l46>uN>4j8mSr&*tasoLoMTb&Bteup%bbZw(o#V>(^aTN^XSx@0I zV!18uZvh}I7!CGhI7i2-<{ z5%n6mp5^!SkXT6eLz6Kgy*S>sG@kflI*|Wm-)=eZc?uT>e+qABNA4~VeEB8ZCe?i$ zd0^B2{PTWl*ourBjv-QA?#1|G|Fwf?lUulkhH-$lz~<}q)JHFVdunYUhH*NNQlrn( z64ujV@b_l5t7BY&pd{ci;7L&7=Rv|i#O7UMGu{ruITjY*8HrnHL^2RaDeNWqa*JG` zB+Mb3heyp;$pE&JoZ>Qpc3zAWTJCn5sQ(U#JFYAz?*DD1pP zgrym=oE}zql&~rKlQcO@Tn|c)ijIZdC^A_ic&CplHg$;6u!Oh$2LV2(I0i%@VDF@9 zEF#mZCO6#aW2e0Wnz&t4WU)*3~s*xUSX@R1VPRv+UCJ*|Mr^muCD^i&i{$>du4H z-sukH4tgE{D+yDu4ERd9;qxio2{?Hk;Z}+YFcdTpo2)F*+8rZ9oBb3QeA!Q|JW?$S zY``3SJ45@zni(zLyGV3%Yz~2~njKh~oEJ54#v0#W=)fgt(JXkT2@jFft9V9V_9}K8 zi(hr%`J?AHB^ZnWFm*b#Y;sEs#SLViFyz4$-xo^6o%YVA%d;&3+XokN`BTwR4_Z$>KK7jgyv3)zu#6zW3QzvH+-uDO z6NG1T%=^G~2MFsjAo^)oTEsNZiYtT}OLp)|;-sfwR~mB*CuF9zoW1FJhYH8MYm!*e z7J(XVgD9GzKC7D4(O>vRfapNA8?w1so&2xUpU*txRyud&!HSW;6;{844WnFZ(M?I z&F_KpE``|EIf_)5w5eZ*D?B;I{9^A&s6b{rl2>* z9X~%NKz$T`rmYJt<%OH4tYpS;WN3f1ToGecg|gp#rv7urU9_Hvll-B?)GEM0iFEfI zT0}}CJTCa>WQ;wMB2IskaWdPYq^`MA7^Qk@{Obf#5ZEsT~<{m^m0jCqY&xKstRhI7ujOv z5Y+7Btw8i0dn3qbh#U6==#st~Hb8LJy8NYLw8MqBtmj9aY{)+mby$P!#uP-O+_w*4 zt>}lOGciUO)#+dqrqcrLzVzn2zf#G*25`5T)w*FK0O_1VyYds)Kxd9CQiSSNjv-21 zipuZ2QcN!W5>7MNT)xKNz1phdzV_s#ApWpoipCSbZ*0X^OD2lOr|-2sdn}8}$TBdm zLD@oYXXPA|X1nO^G%5J3Wa$(qG=q}~xH(6+0#Rnp>@2;cD)Ft4ioN&GA4()7S^%Hq zT{-quk%>y2_2XBJNdxKw5L3nhBkkpFX;w=6yp^Y5M`dpsj4Z;c1pc_tw^DMD7tMkJ)f`C;iV=;d|AR)%NOqz>_?nvHqV20$ z<;{9MjsJ;HYT*&g(@9ayS!&$6OUS{nLv@Fqdv=KZREK+X7$&to|D;0(NyIT4ja#1F z5#FC6AkHGmQWI{qLXhK0c6FT!OIG;7u-ig^OqNv#*%j>E-aA645ItY+im<=A9+$W| zPWaQ#yoDEWq;CvSq#n_I&OVApH`k{D9)Sf7gj)PWAV&R1BIzFY+s%0jZLX{SJr{!- zN59iDt_H1ly8nTu0-9YY!g*<`8LTrMVeWho^aymbJnuTl>hizEi{IDJ1K<4$(ouTx za~y}EXw$@HK~CvW^yQ}EcqJcfzmjg=b$%=3)g3ztvFPr-b(kvM>|)&AZF zf%&I^z`&>o-;y z;ps0oqx`cy^wV~W2(B7Q1NI7b(*6LF;E8XsPoi6Kr!Wg`GCx0Fe0IIT_jbKaqO$`p zjHFnU-Wpe%r+>~~tH+83=3*#r^*B^T`YhmM5t_52;Q-ptAFO)ZPM@_U$$K&W*ybf@ z+o_cRydE4c!zu~svBKK!%0)%#&kI#p9E`8yJMpT}IwSy9wcNGk-I1p%x(%NSDs3UZ zY@0Rk33X3e<7o46b<`woRK7?%s375NBjiUe$`~*1rCD3&TEEjG#nwAR7C{8RQMM(} z=1IUl@uu94+*KX-aCa^2$>d&vCN8eCTwu~V+xKNv5>}A6D#~c{)xRDWTvAtc2S-3N zDThT`d+75=`4pH!F2J<JIn-@^lfvN2L-Rr;?I*Ee-L;&BswcoaV>SxK_1<%0 z1cyX&?l==#!11;2KzgXv4QvQ#rMliVW&`L;>O8?h>_*MCiSbE@`}br!WHD+GxG1Cs z7@W){gy47zs(!x^KSr2jD@GJin*t5}hkJ4QriH=PvLcESPd`bRF;?L+Mvz1g6AE9LNmA|S@>r&347s-$emhpr&RBu+5#e@gX*?9<+%Q3Ovb zw0uk9^O%zq7)b*PnhhT)7CuQ?>Dmen_Jg?C z4OcDew~@^hRA$jFq1&0nv0j8N1E0>0HwwdAEH7wu;XU8de?0d69jIiF1DC;siDS{3 zx|fq(d=_o&HI>v@?d%AS6c_kOmyd=$eCeydh2)xfu3)IhUc*_d!XG_@){-VT;=kU7 zioE?$_c%mK*U6L~gD)EA>#CbhFn8*U#8v6Nys8=L5R0TBDE;Yl$K_{z1DZ7f2VdP2 z0Ux`GP(%s^nQC-nO(ubczl4*QbCrP=Rj_s~*8UG~(+DS=oOUJ7kF(_0@udaIEb+}Z z=vgINh24VqkZip?qmwfX+^8H0x;m|ofkakCY`xdjX6tUPw%qzZ04a9>XKQ%x`d|*I z;0pve*GYlLw9TH3fgh5%ai1`n!ZYLTH}pyC7tfvkwB)awEQac;UvSKTJ$P{%W50pe)94&zSd?UNncs}oxOCYsxUM+9 z1=T?&>tgUNx&}%9CfU@lJ2Y5P$WEVi*Lbgt2=r3>-r$Jozj*gs&~sWH+yR%u{g@0A z*)kN_U8-@`aj^iW#^s7nDJ9C42#>1F;}Y_Zx+#6q;j%sf*M=@9<@uZSYpjrm?Du=K zOm6SR1!rrotG>FO0F?MAAia;RP|f&ruyro*P<59Qn}A1o^w9efbDrZp>fL;3?UE9v z2D{O74{wvVD3YKjT7gTjB_Gcu*fG!Z`i>dyJ_aN_>F!&%3SL9xn#LAZxou!VQV(-2QR%S5x zQ1}l*4cAPuFO-txqrhzv##-I)bu&}g-U$MoIobe|wO0$-=q&PbE|QR`lR+h%|5U7J zM+=N@b7v)9<-1>q;Rn z2+gFrtv0I(81G^K^BlG7nDpQ?}UF1K37y z?JFl#(HU{_AQiC2n_)MZv0BG9NJQzeeaz=my$syG@s?YE=Izf)Xf1rJ^h?QS@6F7| z&kvXapEMEO5XuGfeC?-J$!$;Iguu+xk$@Cgjflfw;A!c;4v3N2dBESh-+*No8lDWV zpWZQ+IZD%fgmkVDR;A2)*vQ^)AGSnv8i2V3g&LGYQ{$T@b*w*K$-+N4i?SCsfG*Q@ z&7?o?g056w>_oA?&IX9;ge_sWi^_^>pqvTxi-*R8@+1kO%^4u&1n3SAa%0O2DXp<* zp2>_Cmd(Qik2|L`?2YRkg5tK~Ll%WXyDkfkct!siuBmz}m%4tMRCbJl2giQCVW(%4 zOMI&pm*cXL@g`2d}>5ielu$YrU{f}i`YDX?&X8U{#hMkzu zw&tm(VH2byfsBE>#Ox?Jg$s4OLA1rMg!sK%K|aWoea}k^x|y zsS8FjP|HFskO{g!(HDpf!h(i)pcM84ER|{ z%H=hW(?{o7{C`j?t~wOy>;1xw<% zD^84yruCujBzri;XAGy9^2zA z)Y=ZL-pRWOEw?iJ;rXTC=^Q5fDcmhPLksyn`9kzN&S*lGtSV+&F_i=pHe_`J*u`X=DZl(uH(2W`bg}0OC8_?!>yi%+a zWiDYJKhK+s!Vly)gWid<1_W0JdTB40E(>91kin`d%MBO_|C0Juh*6pqh zqd4P22;Y<%@r|gyx9C`Y;%0>Pb>B}K{7ObLFYxoASDfN3iM>bH1-#ro8LK~JifeN* zrJ>`!%+T7-d?4zr)z>OBMJ>h+KmETI)c`dTLUX+<)tCYlzf28FQV&B;Py+Hd>pJWu z&mH(@xJ^5FeG!7a3>->%T_!FK;2BxV)B(4CFpZn7(^P)h*lwDzm&>yr-{u4&lx;lq z27$STpxv^b0vkpiEhb$7%3an;=<#kVKA1mh-qE`T^su=cd*qdSJcTS=o@kNN7X>a~ zw4q5oi179XE@h`l+5rPV+i?Y#$)t7!L-Ws?@kyAX5gTH8$x(sN-v%cb+ty@fLBOI= z<#atE(`(H0HgK^eXH`@MA-IV4ve4PMku@3Q@Jr{s>;)d<&E8u@K|HV)!jnBu zmy_?s9N=Zwzn&PZIKB8Py9^}cdBV$!B)6$MMGO=vQjxs`L{vHdMs6;VU$#M(NV+4e z1MbyE$s2+e!Dhc51~pdJQcw!SZA$bxqkDseHk*ZjZ`^?_OhNk?zR|;HtsLbCKi!Z* zA<2~k;}9c`J{i5Vh{tfyw-d&Med6HG{LUE!)H+@Tyw2u=`jf(f??T|i040rUf`n8_ zFrfz(z14HJ2U!yQ2cxX$%)rw&C_fx#OjxSE?VC)5WmS`Au+S*Fjg7HZl@vGTZK4-f z1UC7E51DvIJM6GsaG^tweqM_^P%_%H8tw}74I()1|J1I7tHw9qOMfT2;j5A3VCNO^olK+0vZBC zCy7q;S_p7$)`G>!zA}yH>(J)g^d^c+alwLsbT8jnyY(iN=1M;S)m@a(w-dLs>+3TU z9O~z>VN@RNr-{w>0dR|=QWtM`{=Z!vdiynrW1hOrUrqZNVS()aJ`vh9E{hTC!d)8; zzBR17hQhl%)6*I2cpi-^uK-0FgItTZY}6?32#+%_HPL}d z03;@wKp#I4!PmRh!D?y148?O?Ck?qZI(;X~kE2%02xG9iH3<&6rj7HhOXIF*;vS(p z>Tb9O`HF0LHr&o|ZElkO$7RH@Yzmxu*V<1zNiQ`{X>iwqSH-gtgg2z&?3`Ft)HMJRvWn4o!Lz`T)>VK=I`BaSEfy6^945z(3hJJ8 z0(8;b8<-~Bn!5I8#^wb+FO&oV2*$Sao9=l_ZVrCYB+ewJ=@b-*K`zeM!`qImDzM5p zVfloO1*WTQ_{FIg6uXUez6rI4Qv>bD+Ki(3Ny_o?xW$sc7lEuP85!>-C&j{lZl`jHtH#(7oDv|R}P~iqt zcb^HS*XC{!WsM1)v~|79mhg8`qUk9>(g(MswW2vWslzPDP{2zK)j|y10)SKLVuGF0 zf9T)DFOqWO?Ys0%<1{4NSq}1HxjYR>jYx!zNV5i{Q{ zg=2KgOZJCsbRKz7Eed|*&v+3V)~y?BbM*qR2|;)op&h1E5M|2u_hZf z_nl?9UaS$5+ZTDe*SVS08{xXy21b5>M^$ZB`po~VrV~oM_$Z@l?c5ndo_n_SJ$x41UUb!9*EpBT9S=72WZghLiLvR`mLRMo zVJpiCoYm^YiPGTY^@TexjVxB_lxfn9Dl)_O@CRC-{;YrkK6m1yfK^a-zFs}X3*Z7T zX|*GJ*?JI_um_a*Z{9om65(P5U#%W1z~StQ!(X@%HrbkTwr1d~RUx13@%YDPeS`~> zj_svfuwg5cwQ0@p5~b-*_fAW_`q7Ed5iIABKK|hPjq3x<=fVavDMMIg%2J(P$@EEY zU8j4}rRAZjRXY}-Anb0Vww7!d<$*l=e$p!8@aL(FUyIyD zhtinY`lu3!s)ts?3&v}L8;|8PD{|*b(X=1X6>P0Ulsw$EY*$Qfxd*HkD)j8 z9vdhx{5k!J%X`1s82#!U_;@YX#*?W{8SnEo*py))h z=MX-*$D9!=hA2o}(dxvC^ZqpxAuQg~LbhY@=^BBr3kR|i!*oA+~IWnI5e2o4WLy96sl1PIrda~Av~a# z!^u&4{MApP4dqEE{JYv9`fA@@plA(|W=CVw)~{q_f*l_JjrTRRYwM>=34r!&7WOId zIR-S$xs{%H*nXlLg3<(p16l<4tBOd2OmGQ%9sG|vt!(DGdf)&fbEAK0ya-5$ z&kdb{BJ5FPFh*Rj)9i&yVwuoB7>GRrP;Yn50xxR;(u{ExiRiTm7=On0J@NR`(q}4o zC6-=Vi|j|pE`irRVYjdyJI8Ta^Ja^jJ2}=8ku-WkNf{$DY|6yZYaQu#&LzPuAB|Em z6%9grDpFwBLY5f%qmC)!DY^O00%=bQmCQ26fTN!7HG7IqUavDa!g-g6iYbTLski-< zHr+uoX1+8x4a`cp5e=!KD>==+UWHSYJN4cQyWyvO{}2j=bf#!|cadTYG`@Tt<7y@( z!L?TQkqXOeMy4(Mf#IoI3=a9TZbYF9i5b>HIr|q1EJ_edg1c1qM0yhp9u6oJ z)+X-eI-$^zGrF3UbDH-5r$UnkKS{B^jgHxUE5al67zLYo z#mcH}SW&Q~5o8WZq@nsc?1>xf3AF!y+1iksdb|_WYnKJFbIM12q*P@Gx5CAcSX5~Y z!F>aI3{1G`^LKUw0EWrCQyS*M+F+s96(I~LUl&=c#rXp?>cf?Jlek%RS-f}Lh|#N* zmej>bfl`K7%@~ep!k2m&Zqkn5_9>U@;?{SXtLJ4@+Uu_e6`KenPcWTO^ApyciMTy! zceFOPX3@*9yGe#ME8d^AF2&MCRdEOj>yS6YA?=zGU{mR^!c3FMlc%Ie{Y38SBj^ z4Walb{ZV10TSP7D&(A5H*aWmEpx$6c!(RQO@+X1Jo)sDFo!g^@YGQN#BCA! zNRZP`u>ssP*)_Jw*z5G8i;$iYJP2gHGkLsW^yNk#a%Nuzp1c+^=*TNSr7*;sTm?TT z9%{-$<)NsL0aCu&|5|LWo>|xTXy-juXT@DYG6>Xfq7kFmde;_ylyeCv;5L={zN$v> z&0CMVNuG5JUqq^drzA8BeI3itRGBGXSX}C?LqC;|M zf_u3&{#z|2Bl|Xuj)>e+%0=FWO*GsUaQ&mrmbaXqZepSy=zR1-_-k3#>b%Ihg>oeS;N!dFa2p#n7QOph-9%CRp~5)K8Bm6 zRQCTP8*RbFE^fFot@uOt`fCymbr`ar1m4Ar%J?~OS6|VD#+I-)Q3d3ze$YE0v1e(= z(^4W(oZNV;T-xEs=1_)dQ|Rp+$O5-k zdbQ1lb$w}OIP{6aWs=tfxP$KUuycdDWUWC3H=}`N3Hk`T23Ga94-THuV6Q-iS>qO8 zuQ%x1SOq$D=kJNI6>C)hF6OV-MZQsLlZtD#x{sAQthq(N5d>*B(eY!v9BFzCX!4dA|q=w%8~k(7pi3x%Zr_w)+Tb znY8+Ynv*uPxAF)!d~td>=RtAR$?-Pv?1jfOTjs9O=e1fmx!MAprR^jkRI^At#Tr{P zI$AW-T68AB77Tz*5pt%`;&W`KVo;OE{*Xw@l$-J}$0Zh&qURG`cxJEV-?u_$$*hyk z-{qPF=Dp|z$XPA1Y>WWD0QdGZjVQNs3MkVE-^wrGmF8~yK$lF}MtIZZ1_WhIwp-rO*>zpN+|5K+=L(hWC4{r8wy|_er z7rbEcfup6auOyy z&GF{Qz)SHjc*y!nC_%QH3DmB)G*s8zLLuQ$;VJQc?A zT~7-ZB1=j%?FZe$lz&kxi0pCdYG7W&bm9_H(-H%zr90pXvKaXrSqGVEcP*KnuXXF` zm9RT6%{hqTvf;VKgw_3(Y?*2KpxO-Oj=` zAYJIO`Om7Pp~kiiGu#p*l*C!4`Vz&fT(#uuWuJ|ix#`Z$J#3+8JT-rQ2$p+vTK(i2 z>Qf9B*=^AGmkL=0b=J0HtDXNThfNyELCDxB*F6NL{EKsichn1MxNlx?=<19Ze_jTh zMZU(!OC#u{iB#eKuZKGAQPt1sSB*84j8G&7Qf|z|yYzKzHqi3AM>nt08T%lv9z<~{s^tZ(iR-K2Go7yXn;#CaSt-(xPTUqn6=}^ zfQ;dO$$>q|iC>Gx#Q-N)!SkU##C-qAELWDLOFiqn8g$5LGXE#X!^2!3psV9aE9$&l z#Fi-_4g`=^Qt!u!jj5vT_>M375g}yzFU3`w&93~6Tuc_syz*5y{_(d;TFi&4v28%) zGAdk`{(jR_b8Y~lh6>>gBDsAA<8D2~R9d&0g%~{GlC+HW?$09?Xex;k}-6!=1r zVPJJ_%f(a5t|nKNq9gKiT2<)(ZWA;hX9qi`u8lejf!`lnaW`EPiTHa7?|~$cI14$= zrSK`-%xiHBGwPftPRt!(TsI4ebi`q`9R_d0%~>oT6TN7LiyAMuj98k$cf^i65C|td z8w~8tZ>PV08plQjL|_x{)!hYpz{h5XBA-ifol6pMY0;WGxshmJspD)Os@i(iO~?k! z8(<2>Z(vswD&5Q!O(uy<7R)yB2h_HmLN@Hk75NKFUYO}HbT z?C7%#9|aRAj`6#f9iOMBV}O`qAvxZyR+p^Q+2PuVa4T~UFo{D4MPWR{o}48MGWZ=O z74Q2xtxC-VHv=Uuxos}8{Z7nWDlxqj7~mLJIl&Hp5HlF&=R<8yHIglKNHc;%UJRf@ z8aRH3m{&bvTB@zi7X=}}VxmLtNIxY*&6fFJ99^S zhI8LUE9FN1pcEw*Xx}+yihm7Oe2t(;wnd^8@XB~wUhWpY4yLa_z$Ui$D z0M%@dC0t&19^TAf>iz=+pWII64$hrPAG`+3+3o_;By^)vqd$}mqnycb=ZTKWAF7RMv>Q}AhS-sO8rrmFU(1U z@nr0h;L((4@zBs9-8zhIcT=8}r_|!IBl|F)x?w}lID2HYAsBmqzwf-Ezow$Agb2iB z6}l7GC(-HJ6Uk=zLWmQRZ;E}5u0c1a6O2+O!gsh%4f89yKF01j-*&)wq5blreQf=k zY8SWxlIsI27um2X1pOvyl;HjI%*6PIoxn(WUxmk=Hcp&?q=hjo}JJ?s$xYq>b)1?MA+(p%}OO`qwT?c=+iS-oqNE2IdL-E>g1DR#WU`$Q#wwjy6|? zB4g*~-fn}A%GW+njQjGdk(IUJk*amLJDtRs9QB})+nTQ*FZ-#t;qDO zePC*~Hvp6z?1~J^WDRM3RJ3=GVSXX;7kNk7F=4H8j&VRvcby*6#6)jxOH3C_yxxtF zvjF@E#ypN#CNh1`(9n7us?3vDeHpjx@F_N~Nh8)p@!{WKrXqh_)JMLimS=GjRixv&mWRYdi({rhHY$mr9)3hFK;+go-871%Ee3?22SEFJ~XsV2K0Ciw(^8}_4?^%0|w zRp$Jvz!V9=iM)i&E9i(vLe$`xo^WAmyylO)A~K3VkKF=F+A9;JbDIX1Au}unFGzU2 zM+8fl0NJP5H=rh?P=v}@_ip~YJI)^q<=|LYjW4=p2t>;qb3J*P zbQ%jbcvn+;f4)mu2>U*sMny}*wl+jca{12}Z$C05Talg^Q?Z~McpM~tbBm&VkoLZ* zN{W7AHFZ`?;|p@qoV^WoR(eUb3hyu5M-a-VJf+T3_!d${aR(NmV}syZ+G776KwG>ik7$64&KpDkoGZV);fx%#o-!rTko$V#?@*vYA|Bs&aWI|%t ztL3)OiF~ejWc$mlRzUiXnOy(~KJ1XsAnmaQB~3Q^SU{4IQv=*N!TTR2WdO z+Jnj$3PLlcm;KENOH+4aBXtKH!kQ*I3Md`6)FTUC!Z;PfoTYIC_m%Y3L2UM=9QBG& zw!~X2=W6LuY;N;@+Lma>d>$OfKGS=Ic#0_l3wuR5+f8!&Y?n@Z%?v;9n-hITbq55MWa5CqZ z^$dn4WK8p&t%!o_97QhGU<$orLzoXBR-1V0SvHwTVIqc7aLT5XE((mwa1o4D_WkIXXEJE@h{G6Qct)6Q_;&TijkCkEQ-`A1DDHJ2K0Ved9_K8rv7mY_$Ctu7zHJ@wK2R*TY3xkS4q$LgV<|IOjnY7BFa34w0d?k3YrBA6K(#)`z)D4Asv*1` z#QOC^vG~ku4Ybm;mAn{?sD$v9?%-TLwc&ow7NwZt(CO6zpmES~Fq_}#C%5*R>W&NT zagy>q*!m{}?4WKy;yln?yD3O1!|++HJoN4Q(}>jMC z=Aon1R7NoI-VD8*@rn#Gogg4wP#olf)-ku!m1>~*Zz0=N?X}A%%-cG3%XAdA-KkOR z2+mn7k=tz5ic(KnUsunxwDSw!VobcAV0TNj`;zlz1&8%()J!bZ1kxZoO{sPUy%iP+ z3zPInx_(VL2;q?0tq$Uz`LKdsOhV{klI+D^VIQU1NuKxL3Yvl^iV}77_g{suG?8)$ z8ie`|IA=w00d_j$S&03KlPix_I(|(TdUDKM*Q^ki1}cwO^(6|ay=8BIK;sBA|MB)G6}P+rS1@juUEHnnGi%=V zdK$@aG7c7iu9INHGOJO-1Bp!>P~cXXh};fAj}!yMMQNX~@5Zk5(B#|_5M4o#uYTQi zano;!uLgyA?9Ggm5{P>ue_hGt!Hl~flT0GRzUSnK?jVyInC6Sp+vmIZxOXHSW${ms zggTf!aS0RMKqxR{CL1O{__3P>hHizxDlcT9b0Yz|2&O3{7i?}^`0m+I2dL3lLzT^_t|BC?M zR>aX&5~WGNba;LdAa>k$kP`)E zyE3MA9AArr_YH!}U`n%X4VI=JuKfbH)kL;w)jCfn$H%-@Zwb`9s;(@rth}cj;cA7v zk&_C;7zBhn5q6ZB^)dd}^Vj>)0Em&V_92s7nqT-NT3^nN)q#V<@w?@%%N6|g@=Fln zF)g!yuG7Eu)0N#W3VDYQAp^_gQz#BsyCn{uT20&>W_}Q!#3BI}}PsNS!pdiVT?YOH!FF zj3ti!kra6%u_w^D#H3pRiO1cC>e>G1=rE;XQl(jr*we*xz!_zxpScygDSA*u7h+s~AA0Mjg7F{+j< zrKOuK97G29x`TR9Pqj|Vk*_q(&aw4{hB60Q7zbHpkf%X?Xw_5<8y(^0pmeJox023- zx%Dx;{Je8Bc7}=k7aL{*l*E~8{musTOpDw})y zB&1Z;Vs8MK2T&0WkcI<%He!=>du{;KCSU}`?ark*0`5~~Kz%f|7NICA`H;rTNA53m z0=`OvxVr^W^lSguzF*wWaMSy#_@*CZQcS>Ra-Uo!xB3fQ#+hTL#GhSHhBtsn76iX= zk3!ch9+|AoV6KU(!(D!M;wekO64yo!uLYJZl+yasKCC9k*E*FIdz>kT5f}N6_G1V}fC={hadm2! zV6)i`Umf|ux%ct4MCEyI(l`r3E_cJtCvMKsPe_~CQ5wuyRtf5b)!)-wV8g)7;}^4X z{_y%5)xDiNrzB4&vDhlpB51AP{=X%7`jQHyvbq+jKLEDwK4YPwQ*>bweALD~vgOT1mhxCvI@P)Ve4e#D{#Lo!T?k%u=(~CJ<&|9;gkEq)ys$~q z(OT6U$}=Zp^W7p+OiaI+DUW&bx&jqID>w%Hs8^#D_Bopyt!nb9!M97Jqqd=fb1&iZ z^by7AHdFt%QY&~cO`aun~-=lNmBNtYyfa&m_z!QqC3ali}n zp|(P&8JmPG8$g`S31rq4BLqUIp+A_&FQp%D6DN-nj2ddwX~e zzk{e+?{F+uJYhrMV|5uLJY9#GyR91SXa3o+ZoL%{yLiBd+O-@6CZW*Hkd5;*Es|kH z-yB>A?2lgP3S&ixnFcKjU${FyqqjSU#@dY>7i6AE2eiub<67@KrR@r#KjT1+z6&+2 zONL|POSsyj)cXVxF|*>cNTZm#Q|q>wJ8*CcN*OS;t}a3j{iy7u;vmp6}sM`wog5yyT~#wtJqp4g_Vd!#&h>r%VCveQVL zO;+=z%pp->W|D4Vxua>Cg5t;@RRKP&v^$c zuCMm+1gI=Q!20~_?jShrKa8`=Q4rAIU&TtZIbYHKth=iScD<2=+GF`p3bCkpc32z8 z0zrdhG!F<5j+Ex9S4-bqJtT@H7oFTArZp9U@=+TS4FXelx8|F(0>-?Td0R} zo~wcL&0>BPGoD`=e*_-m>c|)>`p@k(qVPW=!9nYz?EEJz*I$hzU1EG1RZ7U z4_0{)1rmPNx?P0Yt?Xmp3f~FPas%er)FAyVW~rn{Yl)W-$*Q`jtz0_|>e>F0pi$xn zbnD=^MHIvY+KFfMb~{*#BO8`nhNSC#0nshJLvkYPCfDcYY>fhE65QRkCO;Bp7QKL( zZ!2~a-R+!gz8tIAvZmJMREtGM|Ef%{Mu2(3f7ze}b$Bw+q8&YDvInM*kMviBSfE#N z@aiJBkq(l@uda&RkFAU<4;|0K-1d>-^8+w61uM9)my1;`^2bcoY3IS0KiA^a<0LD- z#mz^Sy%RFRTts}Z2Ge&xsnRUy4u{7=1;4^UpWFoM75B*>PWvK3m?a*bNeM&Yidei+ zxh(B&kQ6{{Gr*-3 zDxu4CH!(Tqk$X}{!i=#H2+sGDguesy$7?gUN-((h2$8?U&_b!L{a56XA^oFKLAO@% zomD%L$>3~Ek~pZBfzR5TLeUbjp~qBOO`w(A#54$i>yFzgzbJ*p<%LTrQiGaK>*FuQ z#{|jxpsW~U5oyuPe>DbC2@QC)u{y#FWZU8V*k>c6e=6Ks?2PIBq#yJbfEkT z_-86!7m($542XI4Rz*5Z4dJ#hL;?^@5uEAEoh(M`-|iU1@ZKu4TX)VrrqrYNJCRkP zm=gWCgD_Gt57=IT3Nh!QO+1Du>vg>E_H~XAUlBo1)+Gal)8Ze!EPqPO%uH7kP7^82 zFm&snQ|hvv>L2rA0Xs3Y_v#PhO@1U>1A81%E*0QmM}P(CXKl^y%Qx}VZtg{@pCPuX zdvS3ijz-zdg^q-81bbK+tvKX*u;7Ic!brrzG`BWVD65Ze>UL(^=TGgW<(ICvK z$whWh|DAgF)N5W=WXK{haxIE}C9IIwR9bkifwxjJ8eKL)FpuSe;RsPlulQ!KVhf5<0jk zA7ae=ZW>;KR`|FUAoeYuc;}#TLq+N`GzL=6G%v^~#q@P;s4xKI`KxJSJ_a(WzkM-Fgr0u=2${bmQaTvH+}+8&K(C!-m6U~tw{ zq-dx_&$utZuCl>3TIH;`s>B$tZ7E2{`0iGU=URup*TGhB%{wo%Yp5le>h7v4NdVD3 zJ8W5u1s}4yQ%r1T`9GTAn1id($KC8rhFAbFaHwliv>sJz(Cn)EAP;izcyq}FAqI8K zUhgwv!ZI6&rdj>5v1@L5Gb1~Qf4}%w&U0CRK6D0rm;+K=PQTyxXLL@(`eEXtz(cU1 zX!uK=<}jbW3ZpMi}?dLpwBo_bVBw=+>jOEUi7K4 zCqP3vHh-SFU-~zGGzLtUZp6dI0UT0o;C3)O!grHi^UXHpOL_vfNzzdR3?hR%dJKid z>kXXv{tlUv?NfNL>brTle(K@S z^h?MN%Fa75{*mwCc1@-?XDA6;7k7|uL;{ZMVxQxdTiX~fGUqb8_F5RWgvnc8BEsdx z8GCu0_B--wz|iOU6Su~oa4!aqz<&NDR1@IR|Dh2U-YqmMZj*b1mcW<$YwTCSb(5_M0W8Ec`qIw!IvVa&L1?lge$ z_bov!KAo**t-sE;#T}Yd>A-gUrAKLmTOmz!4-ia4hP_dYf49I21y)Xidh$YzE8{8JuXFcme3OFg{EpBnL|_al?W`)V z*6)()ZNGiluibmK2^i&HfGLHdjIFwz-POqkE|@}WyCCW7gyy5SVeQDwEF!Abtcop? zt~qHKVz9usfH+HH*k~t*vZSW0IS4X+DD1T&J?yXF)90xL&=aRht1HLcF4s)f=wZ#W z$_S1u|F(p9%`Rm%Xup6_Q!_z!!>9)rEmE1tM|Lss+uVNFcJO56KBfX#zxI_)dCgB_RtYNZZ!GSMl+Y3nb>>Se;|!@)c_Y?(aDPshl)`hy;lKkzV+DHOsw{`WJ&WPg4t{A zjHmCmxrH{&rJz}h_HH-)!gq33@ z^i;SU*=Qx*DaB)KeV|)5VzIJXE>q2RB%RSc2Q9zoj2%Bdg8;=%8(9ku}G< zY!zuAFmnw^6N{ifvz@y9M8_+#I}{HwgBj=4V(r zrccDnetoFq_-dPUiRKESOq$7XZx~DX;Wruc#o5jt^i|xbbL(|Zlt+Jy~n5i9X zJVEXJztKZP7B#@}@G}sMfpEfv;W@1zinPDdYF)lPtKVScZFBEPU{%YOtKb2eXNzU; zD=)QDVifF;beNFppPPzm#|U-Jkw%B1z#JUOQb8uA`SWVYXaP@6M#ptjjZrn#=P=h}M#88L_#b3F*6IxVyZ5UXLJV z#cfd}Y|$jm6zeG#pKx@7h+CQSq_L3iNrHN~$QcZBS(5g)C%?8s!8fQ2?~vT;4^ctp z;CE4-bfL5*3w%6$R=*&d=%0r-^WPI*h&N38do$P7qW=`pYs7)BibZj_Mq=k{QSr)2 zUaA`a1C(;ioziy6$r0syXj*PAF)@w*CTco`9W_wz1R~G5%U03iE`D~xP2OAA;w<0y#yju|*d2)++5l_P*M7UOv)EgjTMtSYZo zWBXxN;AaPG&i;CS6z8K4{?u)j7(-e|j+)`gQ!4ROF;O+jy_1wLytJJwV4KujPhxmw zQVGzweHa4A6?BX07pQSFQ<0Se+mSCUvKHW#)JX9iFj7A9fI|ksW!tv^mVHB|gBluR zolb5V%6y0VrDX~-gGf9X9t)tJ)XACNnI}D|KLg|mxZbE zSY51~*W=*!7vspUbbv%{0E;3is@aH%)9MsL--R#FT37B|B(<>*Atk(b0WM2$p$v1^ zR&Vy|7T{iCy(m+)9NIWbFQjkA!@HP!wHE~tZN>LH(@#&sjZA|>&Et#_GhzwnH{HFu z%RvWF1}yt`j(QlpOG1n$_cXRBit1<((EW%vykAJF$91_*p#tZJ!M}QYXqVjE$}^)p zxK*zB^pb6;1R-h^3QkC>Y0n_s5b{lubnTZqm|QK^q@KhmaDY433VZ06{&*z_l^McO zYjk|s5);yMZxSaO9K@**E~nvEP|xsLjS_Jl>Nz~gTZcB(GhT{{9F*K>P+QT*4VMhG zkniB-&T;$P4M0-2jBamD*}I)^nH$a5=Avw%X20^}Y%nk8!`|XX^MKOLf2g}|jdTnk zGT5+l7^xycZlLOxPU4AZ4zNv3VfhG=Q#XB4je2@GfRC#UeZcztDKSOt-yy_@~u>wUsZ*S1djbe_Mv6r;%DBOMjZ=7P_iga&#G8 z-spQ2e`gboAN!(QXR$O@D|3nY*ZTG6L;@s=8K}tL7!BlLxQF$SF=qgw&P-!jF`bQ$ z2HO4hZsWxD*t{UCe#+j!$mdb`r~I3g+U6c2e}AGmaWZQcbmZT0pQZ|e8md&ew_JRQ zIi2sAfw^`PbKUqSAePe9MT-8|OF6V)!P=k5pgE`lV)MiWX2jGXWuy?>K>JeRwd0 zTPAM{6#`6tvn%YYn%wx`b^g7Z=&jYp9;(IOng9%Ccnk@^!#-!<*J0eWTT8OTosMaL zQblorm&vXJ8Ab(cf@ni!Cn7>xcwd@TAQK{2iYJ{MP(uLpDx%~8x44n4O_uU!r&6h| zr3*@LgzA@3dcYZl__n5>gK$FNzvL1;uql|Vy6|JlJs4yK_;O}VcN@#>TO`Uj1m-0E zJ*iAZB-{CfmnB*ZrnT;^xi+a4zPjom4wl_tdsnE&IByo_{0xyh0~)~ram_VXSUoK# zo_2h1!chD_t+Fko;IS>t$%O@RmRuCfVyfZDN)YUADQX(nNB{pYWppwYR|{24(I{$P z)X}>Tdeep`RQAlK-?9RTRk~jV5DNmU;1k?owk9Q*kzU@-=Ww^Q-@}ss8H5f3Rxh?C*(Qa)KiVF!Ygg~9C z^*4e+3_MQ`9r&VX3IQ!BLhl}y-QNVj2purm<|;KigYot-16ENix5Z|4BLInku>;WU zC)UqZ94ZCh^VtigwOGmxMgSzUyO(bP1tG)HlC37aNI_)p&pZ3u9REXmU8358>uF~b zm)tKHYg_FnEK=lIJj!;ymcqZWGM!eMMk2M%LcWOAc+x*PlR-w8gOfKxcHYx#F%VPd zyN#HO*hsSe%pM-IuUUS*yXd1|w@XdO0khRqy{xvf!ce4l75zQw@yl_-ntQE|~2&>`r zHEolIblSFd0TSsQ(C4WuyQU1nI_>PJoT7k$Wz5%y9Xrx1n)|KjC1jkgmkghIrUeL> z!p;ay@eRYGld)2z-!6!u8I(f|>U!$yA*=q}oYp|#RlwESOSSxI27k3By(7j&x)>3}n>5JSw{hRXm z12f}B_qZ{hr|#U)zGOAPg7)780~W|(MJ|f~{{Kr;XN*P=P#+%aIK$!j3&6ceB>>~Q zr0G&gr?TaO=q|qW4vXiOXkvNc5Y&FABnvF{PAXLH?E6c5cu;?aPBlV9#*ru<)I8-9 z4eyr9aQ~C#W5A=)wNms{4olhVAE``Ytgo&}1|BajLOsp!@9R%6&If-J1sTz2c|jrh z?l~a{&$D{PtYy{8wmgoy|CY!kaS2o<k6qT-KcsghI85urEZ^w(Gep&RIZDq%q6~ zm6tBp+-ouvf#sUCZ}zbQKV&udYD77kZAbKfDMSM^9t$FlF=@lLNCL@nmL(UK;KRx} z6UJ4nvSumkadY#9Bu+0rIRd5W1R*TDE>%^SFkwOtF{T@9Zv8PVlcGW+^J_$w^Z6~n z9Tf!L$p*3RSHyV5xfe*^Fj;k2wzXH?ZbLH>c4G68n11r|%@7qg{WjlSm)z}dGB=7L($v@`D z_(#K}pJa95b}&7B3g!Q!s3e#;)aA}Tr$ucVm3F*+gb8C4M#kE#5i(3}z=R2d2Q$c> zh|ciG^)du*Y5^*7^cmFm6U^SRRJ>`?Z4%@dHNH8TM<`VKPI$x&-s<$XavIc~AGcjN zd^VsHFFK0W*0>Jo>h15&vbINQ^m;ak4?`JTqc57dH zX9w(N`ll1^>$F8)_l%6+s}YaJ4@yx|CFZ6wGhK@Aoyz>C(kP2^wPoRod`2nqlI$PT zi=a`Lt!fodDw5VxbQWAgsq-VGy`>k}(lS~4`Au*<3pbd9p5(62RjFJK*BnWmj2~kH zs0hNPCR|=7YDYb!w(w%L{*khNAYcUPc3Ij3!8lDz3^(cMlE>MRw|xjPMzM@tnV$>> zPlJ^GwT)^n2JwZ(oHfm!+``aVxz-uwhjgxADDTD@OKFU2ACURg^EJUd}|ZTyM)d^hhre< z_oejqtnh&Bn@1adlj-TNk9D_$0=jz}Yp<<=|FtX=2>oonm(LIOUe9k_^(}IXha#<* ziZMegcn2KhmE$f==mmiJMY5E!R7{h12oj_vNG_To*H-l~TzTQKiReRy5Nb#<_a24w zcBddLnxk2x+}LNJJhdW;csvL8Vnpe+7UHk6>JLcSrOG&C*^Wb(_RSrU_GoJV;yx+)!U|pgm2R(aPP0DSN zhjroQf(Y6RZo*Xircp)wAj!hZ&hz4&f*jCHWlUQK4WyQNKjw8FaxBCjB|p`+E|=`+ZEWwAwzE*{!aAZxLz&ruuLiP9kSqe8X52Ap6pgYuU??2dW+$i673|Dv{ zLL6CoAAovY{V%yMvO&xoQL4Q=>4t= z2>I+zAjg)ot;DkxA9q~x{zas1A?-?v{hbA6jv@J#a@_gzsTlKLce-rMN+h?P6$7(j z#bmMJtyZawlBhDL9p34#JhHPF^YA(G534m8MO=TScgwbd!VgOj2oAnv8{HUVtEJ!y z#$sE_ctUl!aqDqEr&1W_HjCh?*Ii7)A@jwvLF^#GqrRJ8A>kD<3NP|UglYVXb&td+_aapFjCn7IyPwtpGqJzSI zf+WBNP4bllSa~XNjd-OFWUFUmjh+`iTqK>CDwa*h_Ijk)UW-@0YTc4S^Lae?@<|c% zl%~jwmw%u#z0Ban9eByA1NRutc%vQiML*e)Y)(?75hdMH;LYfCq9ps-nN4LfPoN`! znfA6!eEL{`8scncl?LU{UtG0LfO;GAGgxI!kOow#P1b+R54XmW8XdQWYvSxwc>|Q; zD4%J4zI$sjFi3dW8nW~(l0a;IcP6&bygOSd0qiadxsV7OC ztY1?rxFIN`;&X?}x?kBI;?krG$X3->4jy8`F=VP{)> z>dL%&I=YA-3`*8OE|0nh{2&N9X&2QH&2s1(&mvW&uB7r1Q`;WX0-WQslX4!qaV?4W zV%XXUGlI~cRZxQa0|$WL=)6@-SRM{dRm7FNEbN`9NPYC)yIeyAJ^TMQ=@Rhy*^ipu z6v9VC-bFty9JL^PMBrrwLYk9SX90$U3qZ%E^f!vtGZV|NE?MG)nF;O*TqMbhF#p1& zQW&8K@CY-ZZB$e8S5iW*NUmn(xfSRLrf5M0TI37-u||+Mk&D0Axu8~f9{x^d2~Ys{ zuJqCBX)y;w8_7vMtn}3KetH<==P;G*)-{3z+<%R86j1?5nFRfZc{L#m0sk(?xp~WX-hUAx%bF+gqAJMM?t1#fg=Ec zhr0-QJE*mrpU+r<|I&--1bLvjuwKetS__M^IAyxRwGb@Dp(H2&7wN-G?cC(K|AXlQ z1cqwS6hqt4E4V%I55ErBe9t{f2cif#SO z$F`8xf?pcC+F$f}qd;eC=O@Z8SBq=Xsnv{-=d#pA3BOq_5cAc=mtM};ANZ2(Zl_RC zBxRH|Ibb(BWK!777ZSK(Yf!n>GMjqa=egc$p#@Aje}JR#;A-m&iPo+2A={&PGN)C+ z7*PjD9K=`ICeZu-ADNa%8pl95rR@%%kw+rw_6t55?AKlo zqkwgi@yiFejyMyYz?jhj2xrHPUar=H(C*3C?o5yTm5YGJW#v`(ZIC3CW9;dpyj5NM~WaPimi22ySC_konPi z7TNjo_GmI|?^itviTp|sgJ6xtzj@Yc&>~iq#Rna?p$))1TQ9Y^Qy`(gepoBrZp^w_ zB~--_$0usY$xvrBJ_hN)IA@#8{1FC7Wp+(YR4FGvI<%h1OkB)^(^JJo87)~Q6~{XC9kB+Ww926Y=z%O-`71{3LIqmfdX>vrwdmC76jsrJp`?*l*; z#LB`mObj@9bI0&%8&e-$eTx2*e<5jQ+* zF}!OFGAxO`3L|kHs>N)TOoY82iM1m4ap)PF^cbYJXIV1&|8UFNn>jvu8Q(JkYO7VY z_SUQlosfPl!xAn?TfQnNnZr63c^;^roN!NUU^r~!Mh1m1Gv)fO^dGSKO%Pe~ZNM}_ zx7(6y;<#n(2eCFd&Oj9Ah5%y&f3WuT4{Y?RA!)b9(y_$uXcM5?@araSl^X^xkq@1K zRH8Jw2+68&9TuKDLc3-sSC{V8R-Zh<^hQ6Lk5Kp*6CK>d{$MV6S_}R0FsqNS;HK>S zfxaMc`&ojN(Ddjg@O?KQz!-*rk1M#cbe+Ghbmc<^r%UV$_@m35v)=dX-3%|cw}qB* znwhPyljK)kYt`b`ng1s+Ph0ktlcx-1)VS;1`-mO?>v+R9daHt{&l?Ovfefad9iZsS z$!Dr0mur>X;fh|$pAiJIW^ACf1Q*Ft>tKFVenxMe!fX~r6dEEFeI1Ute}O`tS)e-`64@!IeP7B75s+&;GFrYDNgYkF|)y6%|0$1FmK9e z;25xN&&5*M|J(!j9V-OilZsrSky=^U;{zqE#2ZM784hwq3CKC4! z3q~;L;}q&HEvvd=Quo0h1r3++y;Tp_Qw8ymcqE(|4?L0U`AyeY0YEU~569-}@Rg)Q zuUWP&|46fDpd&39{f7N!~56BUTMs?RxWa{MCi+eT5H*VLpe-4 z;>2&+b(Ge1gf`heA#??VOYaC5G1@SD4e=Ql?uFv5e2 z%2Ps~xD!q@n|AUCQ+Nu(YuEjao!(qm2mzbx`KQ);oFewbA2&drF-;L^YRwaXWP5)Xo!o2G@ygo_ z4s#d1P%B1}1i7iK8-FMAZm+r7ne6{qigH;FTYrS8Q&y>>q>46j;?WXwg&@k%i#@tK zl3$~Kj`c zeDvh-D9#sWG?n2SV19Z=@R?CYNH2~hymR|^9&hjEF#hB|*sgF|@g%$fKAo?}891h| zqcI*Bb-2Fq5^)^J(>56(ObiS^8Bw);dKT2W85wYN0`7vXla$e0q=6=f-}KhG5K2fv zKojp`1-64y%d6!oebs6Y8x-Lbx9&41n=+XY2ZyJx&H~jveAN43?PoaFi)Z|6S!HrQ z4uUqE_l!31St_smz?#g39R?a}RCS!Q=o;m85KGQm@{+R2n3>ceW5Dc+I*lXUE&Zpk zMu6hPQ;gbw`6ZQNNT6`P0@F7IcraRzpK~vnA@sN+ie$qP4_tNzmOJBLN0Yz;w58ky za)Xk7z4tjx1pr*&oU*W!Q?a1Z5GwjG-X` zfxje-6QD1zH(Eko;hw67@~u+cM2h4EYHW4K2HXVyb55-lo zu<0ZQsFa26s>@An%#)4jSAD2gdGUT!=ZG16V-3K&_wmt~OTaD`TvNiP{<{j~_{X(S z8VluQpg~@%gXQnOf}5oMD`*wWCv<-TouSfkz%JcjEuzOj1YjmsnruPn6U-7}c1sE* zXRXhoBjYtd{AsWGP!wJKBV zIlqtb=hwIyqJeucAjBkxhURT??E6S64nW*JRq4)57wemby)7HFIQz6mV6~wnz)mSP z-?wr$em+6mO-|lz4;aiI-dOYt(hIRJ08FaSj_{_hlk8z> z%z;&#VFQBX&=72mcz+5? z#(pho@A6>1Wk07IV?bg6q0{VN)1;+)ZWR3H=5DSM4R3f;ly{R?eud+L`R?16HiwtL zxw3YhF#O2;3WV*1==)-VDB`5-l=vP)W)Z06?vEp(IH4H6_cRv$t`f8Bg_A`@@~$DF zGf9vh;d)PYf*oBeIB$G*i#+G&MZ1#r1XQ}cnI%^wX%fckhRNPBYf4_a1rW&#`@Sal z%chZpBcN2bF~340oG)(o$np#wr#@l5OKUjAS9d08H?@N6k0}$RF6IH+tYPSu$h@hB zWsGgd>;^RWurtMa%+)WHncaBhdX?TY0~dB)g4#v&Hbk_3w$D%fRq?{xL6DO%Q0y;}(tz*Hj$BiCxoev=8$B?_ z`Pl4&|Qsgk%g^l zCx;Z;)nuN{S9!#|>_?tTK*Q13^?FvHNsIPTeR^M!Qooi&M{;UyjZCH5Ipp@?mh4m- zNRi=w0w0}azLUODGV>de^r%Oj4>%% z`3Bedj6t2y3Jt2Y-4Y+D)cfW0A4#G5rx_f7B|7clBRxJhLVc$wp{4Dm%($Ro#V5OVFS5K%8W>X&qeR)y|(v^ z@e+o;1I<&{fU2K!VrNo5>Dh8+T4hzcC7i!qO|Cl@?I}ut)nx#*p2gKeoJCLG3&QtB z%!ktXV(K5e`WF)IUR1P6ZPnd<(knxPhU(;~9N~ZV!I~HZ%RLeJIF`@UBPYCF4SJUT zH)}Fr7<-|*GPr&dblj}iUtU!mGj&hb6UFtI?8flt!r|Ql{+0>wlo-aI<+EeHHzw)K z%8;@cq}gtxj-xs7jOIxN9NcoNss`FSLt7AlC`eKWd!elQe^2zZl>yMLtd-4WvPj0% zu0PsE;e!A7%NgG)aGs+7=Wsmh1eawc6hx2{RqeKuuP(ySAEb)B0v;~nq0kZw6`!E5 z0!aDO{oTfpDsdJ7T)K`-vEE|=S)rKDP*xq50Hpai8SKYJR<`SI4bwXAL^v}0yxo1u zHT2oO=`8_TEQaC@0NTh}upXSd=P3L=3}gCTUul5%wK@uHr4*L=uvrJ@P_Rp&q0=2D z0>nkCw*ueT`{kfB6KsHBHLC~Py+2#q0$#%Rv0AT>VU7`T3|DCPUtvUt5gUr*pykB% z+#^ZZTB@m;oOd1rR!87qNu3FeQN{byF0iK>{DFQ(>CC(+_=tAy%TCG6@ks<*nn*8$ z<#m4Q(7duqM9cCM2yd)ZnsF3NIR*t|YYL~{=HtI(l^wf4;pTHXsp_}i+K9!L`bx3E zI-AaZN|>dhkSgYSZ*riocfzugml~QxqhM7^sDM5p@F9&Yjf91sfjYS;C$}K9#UH0F zizh}Zs(KZrFS9?+`y-sLeQRUao>`jeV0(Bv~{5 zA-o74O1E+DesoG$^a2h+y)bVvZG=UW4=6_aNyp@yE< zb77KR!5KTKx<$r<%SR6Bb0DNfk~2h=8$y*(J^}Zq=#8Tdh8Moug-9T8>5cs+S~ZcW zgi%DRM4XV){?1vyMX-VgjH+=?t}V+{-6PeFAj-`%K4U;rM2kuCE_E4I2L&qYszr7O z7jNTXZ6Cq$12?U{9yIwL1@&ZCPJ`5k%{{?#Yg7Sgr?m^EIKyFvZ+@U|QL0BhxE+4e z>sjvyaz8Qm^x3zeMLD*ZK_F9*uZ*T&c{=+in7Ckk|0nkLCq%Lm*!a4A<4} z`mFb_l;JbSP0jNG(8U2Ba+FB76B;^sQn;ANh4ziR1PBt*a z5}qTasLavqx0x%_tkPOd7qs6gc>%ZGy66+0tp+=UH$_sXP1JkuuxjYGCA0I(3_gdY z2n0@&V51=#(;#l`LejLnef1Qk?x1jqW@`WWftXGK5;TpTH&{@){Mas^BR92}+Mv?a zcz-$Az+r7=7}ZZu$PTP*pbZ12S@(GIhAJ8mAw8T=@!i;2;>f6XTV(|%qZHE586Nes zQBBt-^+wi|@=>qN-5L_%7p#X=cqHZZWIBp2ecOZHQ9YX1?w2pvmooLYmI9FRSYE`8 z);@u&gf|ZT_J_8SLQCU_mmf$J%Nte4pN7lw>mcuf|5*5Q%WVTvOg$Y;k~tBNnuF2? zqiBXL2T=2aCjR9*C5Hu_gDpd3FNf<4wStHR*4`tP&kjh8Oiqa9OPVM_2X#sGJJ{{}`Qs}a1n#k^fr$bGKenZ%CE zYhE|ipJCbWnMwQtT});l2wKo5cnS!P4qGXy(ODN!%M)3vV*nVoRH{BK#u7d*c1JrJ z`@u2JzQ%=D{dHiLJi}{ssD_<3L84%rUTxWWD)f<1YUwd1$1_~%uGE?fuH*+SPu6^L z^b)|K92^YkGF^$qhdZ{b;xFu8kMtLHSKPB+QJ$mty771S3Di?ldcER;HdV?fg1mMr zWn!~ypl&Jpd|34C!6il6$@Nl(gopT1gQSXnFMsVaE02h=S5N&GbT%T6JmL!yw~@kZ zIzB_nDQX7$Cp+ZoS0rZFq98BiAuAv-nC}W;R&Q6k1FOptJvCx~5E`3P4FdCU`b|rf z|6M6TUHx4|f68TuRnk;(F>uFas3+)JtvSf&(v#mlQsCYb#twN%3i@R^$Pr+lrNQS6 z%%K$FjbCaA!BmUVZ1xQn89hA#a3bV2SqCT=C_KM0Q-;~Qx0G1LRP0T0`*&Pax7etV z{jW`CQ%r6zzMMhhriHIJ&8j>^p$46gHFemM33r_lF$6n_w z-sLR|nZ+Jq@}(7hW_6GOsmxT+RTp^-ZHdO@tx#YaiX7u6Jfk=;IB!3J`Dk^$g#XX^ zZKp-m`d^ri0=u@rUfDhS-%2$Z# zn`CIH%s<-El&Njnmp8isQj{Id>)YFD?}{l1NQUmwy%1Gt*fvjxQbH8=>I{M5Fz)9R z@is#j52c%qEx60x?u0xy?H!=nCO@H+pzaMp_ zBl+6HxKnc%dnCkU=_)iRNsbQ4VRd{0x#4+6;1sr^T~1-VDs-0>)BC|RmpsP${)f>d zKNXXa?si!6-e4+zqanPjRU&oTGmuB+4&%_H8UsdIZ{0$uiqi{ji;}tIQ?My3#m%_Q zj*0Vs{0Yf#@W}2Fb6ozOP1U3rm?1H)E^hx5!S`V}4O14tl&$+juuQZXjL|klq_yh6 zI#1C)pvQ%cK;B6`N4+|E+)){cskToWujILho3Df4Zo3zgNwj@9=m-=<<@@7{f`yng5+9%s6;rf8w} zqZe_~Y(4>NelNYOlxOr&ZlIvUpBYD>a2Kx^LT2p zA-f5Cu5UY2gUb5{K@x6)FTNSxZhERVjboWx)C{6JTe*9T{;c)yDtg+U;S4r6ZvK$B zhy~y(c(j_qAm49Ku%E_D=Au)q}4R`vfZpErrhhL;Q2o&7{wd732ZLchq&QNiR-CyqM&uuC$HK zq-@ zY48p!rau=6_he%|Hh<$ty^JK(E|kIr_(Y#D4kT?x7%X!`Ywls!sg&%0`~zX(h0C`C z%wIx9#+*x`Ts@IFx@w=%C_8lQ0gV3=%Ala%m!x7HQ#xZpMk9lY*kG*JPWxAkCsoGGO{aFbwp@+U&qAYi#n5OF}7o zTX$gNC>n8k0z9s(Una@#$OG2_-@LH`kJ$c9V4ugqYLjMO$)kn~Z}tQRM*^J)YzMSCE;2MrlwFDqXX>HB+AoUSQ~anXpGzYA3skC1j8y+!ak zj|u~2LCUseUBtvk(RI{1=^5v_`>%Y?nR@j)l96@s2mPBIKxFfwlWu(Tf3O8UxrrWq6(wV zQ9S~dbkIhe8pO%S@~-vqlaO5;YQv5A$TyOPh8&i=?n>o z|J&9Ty|35b`OD%eOwcRO$00F{V;%+$GiX7X8Z011TS7DG+s)VA%!^&)pGpB1WY+1( zPa1g;L@%Zn9%}sLH*uw8@q*yX&TxSfYd8Tohdvx4M-w1g!L!9tFZKRc%2p$bI<&arqNi*95}-U8SL{=)i diff --git a/R/tidymodels.R b/R/tidymodels.R index b2513e0aa..f357b815f 100755 --- a/R/tidymodels.R +++ b/R/tidymodels.R @@ -120,14 +120,13 @@ all_disk_predictors <- function() { #' @rdname amr-tidymodels #' @export step_mic_log2 <- function( - recipe, - ..., - role = NA, - trained = FALSE, - columns = NULL, - skip = FALSE, - id = recipes::rand_id("mic_log2") -) { + recipe, + ..., + role = NA, + trained = FALSE, + columns = NULL, + skip = FALSE, + id = recipes::rand_id("mic_log2")) { recipes::add_step( recipe, step_mic_log2_new( @@ -196,14 +195,13 @@ tidy.step_mic_log2 <- function(x, ...) { #' @rdname amr-tidymodels #' @export step_sir_numeric <- function( - recipe, - ..., - role = NA, - trained = FALSE, - columns = NULL, - skip = FALSE, - id = recipes::rand_id("sir_numeric") -) { + recipe, + ..., + role = NA, + trained = FALSE, + columns = NULL, + skip = FALSE, + id = recipes::rand_id("sir_numeric")) { recipes::add_step( recipe, step_sir_numeric_new( diff --git a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R new file mode 100644 index 000000000..f347e6c3f --- /dev/null +++ b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R @@ -0,0 +1,725 @@ +# ==================================================================== # +# TITLE: # +# AMR: An R Package for Working with Antimicrobial Resistance Data # +# # +# SOURCE CODE: # +# https://github.com/msberends/AMR # +# # +# PLEASE CITE THIS SOFTWARE AS: # +# Berends MS, Luz CF, Friedrich AW, et al. (2022). # +# AMR: An R Package for Working with Antimicrobial Resistance Data. # +# Journal of Statistical Software, 104(3), 1-31. # +# https://doi.org/10.18637/jss.v104.i03 # +# # +# Developed at the University of Groningen and the University Medical # +# Center Groningen in The Netherlands, in collaboration with many # +# colleagues from around the world, see our website. # +# # +# This R package is free software; you can freely use and distribute # +# it for both personal and commercial purposes under the terms of the # +# GNU General Public License version 2.0 (GNU GPL-2), as published by # +# the Free Software Foundation. # +# We created this package for both routine data analysis and academic # +# research and it was publicly released in the hope that it will be # +# useful, but it comes WITHOUT ANY WARRANTY OR LIABILITY. # +# # +# Visit our website for the full manual and a complete tutorial about # +# how to conduct AMR data analysis: https://amr-for-r.org # +# ==================================================================== # + +# Generic parser for EUCAST Clinical Breakpoint Table xlsx files. +# Works for any organism sheet by auto-detecting: +# - Header rows (via "MIC breakpoint" in col 2) +# - Sub-header rows (via "S " pattern in col 2, one row below header) +# - Organism names (row 1 for single-organism sheets, or discovered above +# each header row for multi-organism sheets like Anaerobic bacteria) +# - Data rows (between sub-header and next header/end) +# - Notes (col 9, resolved per-row via superscript references) +# +# Uses tidyxl to parse rich text cells, separating base values from +# superscript footnote references that EUCAST uses for notes. +# +# Output mimics the AMR::clinical_breakpoints structure with added columns: +# version, is_screening, note + + +library(tidyxl) +library(dplyr, warn.conflicts = FALSE) +library(purrr) +devtools::load_all() + +# ============================================================================== +# 1. Rich text parser +# ============================================================================== +split_rich_text <- function(fmt_list) { + map_dfr(fmt_list, function(fmt) { + if (is.null(fmt) || nrow(fmt) == 0) + return(tibble(base_text = NA_character_, note_super = NA_character_)) + is_super <- !is.na(fmt$vertAlign) & fmt$vertAlign == "superscript" + tibble( + base_text = paste0(fmt$character[!is_super], collapse = ""), + note_super = paste0(fmt$character[is_super], collapse = "") + ) + }) +} + +# ============================================================================== +# 2. Notes block parser +# ============================================================================== +parse_notes_block <- function(txt) { + if (is.na(txt) || txt == "") return(list()) + + txt <- gsub("\r\n", "\n", txt) + txt <- gsub("\r", "\n", txt) + txt <- gsub("\u00A0", " ", txt) + + find_keys <- function(pattern, txt) { + m <- gregexpr(pattern, txt, perl = TRUE)[[1]] + if (m[1] == -1) + return(data.frame(pos = integer(0), key = character(0), + mlen = integer(0), stringsAsFactors = FALSE)) + lens <- attr(m, "match.length") + keys <- gsub("[.\\s]+$", "", trimws(substring(txt, m, m + lens - 1))) + data.frame(pos = as.integer(m), key = keys, mlen = as.integer(lens), + stringsAsFactors = FALSE) + } + + # Combined key: 1/A. or 5/A. + r1 <- find_keys("(?:^|(?<=\\n)|(?<=\\.))\\s*\\d+/[A-Z]\\.\\s*", txt) + # Numbered with dot: "1." "2." + r2 <- find_keys("(?:^|(?<=\\n)|(?<=\\.))\\s*\\d+\\.\\s+", txt) + # Lettered: "A." followed by uppercase (not species names like "C. difficile") + r3 <- find_keys("(?:^|(?<=\\n)|(?<=\\.)|(?<=\\s))\\s*[A-Z]\\.\\s+(?=[A-Z])", txt) + # Numbered without dot (e.g. C. difficile style): digit space uppercase + r4 <- find_keys("(?:^|(?<=\\n))\\d+\\s+(?=[A-Z])", txt) + + all_keys <- rbind(r1, r2, r3, r4) + if (nrow(all_keys) == 0) return(list()) + all_keys <- all_keys[order(all_keys$pos), ] + + # Remove overlapping matches (keep longer/more specific) + keep <- rep(TRUE, nrow(all_keys)) + for (i in seq_len(nrow(all_keys))) { + if (!keep[i]) next + for (j in seq_len(nrow(all_keys))) { + if (i == j || !keep[j]) next + if (all_keys$pos[j] >= all_keys$pos[i] && + all_keys$pos[j] < all_keys$pos[i] + all_keys$mlen[i]) { + if (nchar(all_keys$key[i]) >= nchar(all_keys$key[j])) { + keep[j] <- FALSE + } else { + keep[i] <- FALSE + } + } + } + } + all_keys <- all_keys[keep, ] + + # Build note lookup, allowing multiple bodies per key + notes <- list() + add_note <- function(key, body) { + if (is.null(notes[[key]])) { + notes[[key]] <<- body + } else if (!body %in% notes[[key]]) { + notes[[key]] <<- c(notes[[key]], body) + } + } + + for (i in seq_len(nrow(all_keys))) { + body_start <- all_keys$pos[i] + all_keys$mlen[i] + body_end <- if (i < nrow(all_keys)) all_keys$pos[i + 1] - 1 else nchar(txt) + body <- trimws(substr(txt, body_start, body_end)) + key <- all_keys$key[i] + + if (grepl("/", key)) { + subkeys <- unlist(strsplit(key, "/")) + for (sk in subkeys) add_note(sk, body) + add_note(key, body) + } else { + add_note(key, body) + } + } + notes +} + +# ============================================================================== +# 3. Note resolver +# ============================================================================== +resolve_notes <- function(notes_list, mic_super, disk_super) { + nl <- notes_list + if (is.null(nl) || length(nl) == 0) return(NA_character_) + + mic_refs <- character(0) + disk_refs <- character(0) + if (!is.na(mic_super) && mic_super != "") + mic_refs <- trimws(unlist(strsplit(mic_super, ","))) + if (!is.na(disk_super) && disk_super != "") + disk_refs <- trimws(unlist(strsplit(disk_super, ","))) + all_refs <- unique(c(mic_refs, disk_refs)) + if (length(all_refs) == 0) return(NA_character_) + + # Detect combined keys (e.g. "1/A") + combined_keys <- grep("/", names(nl), value = TRUE) + used_combined <- character(0) + consumed_refs <- character(0) + + for (ck in combined_keys) { + parts <- unlist(strsplit(ck, "/")) + if (all(parts %in% all_refs)) { + used_combined <- c(used_combined, ck) + consumed_refs <- c(consumed_refs, parts) + } + } + + remaining_refs <- setdiff(all_refs, consumed_refs) + + parts_out <- character(0) + bodies_seen <- character(0) + + # Combined notes + for (ck in used_combined) { + bodies <- nl[[ck]] + if (!is.null(bodies)) { + for (body in bodies) { + if (!body %in% bodies_seen) { + parts_out <- c(parts_out, paste0("[", ck, "] ", body)) + bodies_seen <- c(bodies_seen, body) + } + } + } + } + + # Remaining individual notes: prefer duplicated over missing + for (ref in remaining_refs) { + if (!is.null(nl[[ref]])) { + for (body in nl[[ref]]) { + # Include all notes, even if body was already seen under a combined key + entry <- paste0("[", ref, "] ", body) + if (!entry %in% parts_out) { + parts_out <- c(parts_out, entry) + } + } + } + } + + if (length(parts_out) == 0) return(NA_character_) + paste(parts_out, collapse = " | ") +} + +# ============================================================================== +# 4. Cell helpers +# ============================================================================== +get_cell <- function(df, r, c) { + hit <- df[df$row == r & df$col == c, ] + if (nrow(hit) == 0) return(list(base = NA_character_, super = NA_character_)) + list(base = hit$base_text[1], super = hit$note_super[1]) +} + +parse_bp <- function(txt) { + if (is.na(txt) || txt == "") return(NA_real_) + t <- trimws(txt) + # if (toupper(t) %in% c("NOTE", "IE", "IP", "NA", "-")) return(NA_real_) + if (toupper(t) %in% c("NA", "-")) return(NA_real_) + t <- gsub("^\\((.+)\\)$", "\\1", t) + # suppressWarnings(as.numeric(t)) + t +} + +is_screening_fn <- function(txt) { + if (is.na(txt)) return(FALSE) + grepl("^\\(.+\\)$", trimws(txt)) +} + +format_disk_dose <- function(dose) { + if (is.na(dose) || dose == "") return(NA_character_) + d <- trimws(dose) + if (grepl("mcg|unit", d, ignore.case = TRUE)) return(d) + d <- gsub("-", "/", d) + paste0(d, " mcg") +} + +# ============================================================================== +# 5. Detect version and guideline from workbook +# ============================================================================== +detect_version <- function(cells) { + # Version string is typically in col 5+ of row 1 (or sometimes col 9) + # e.g. "EUCAST Clinical Breakpoint Tables v. 13.1, valid from 2023-06-29" + version_cells <- cells |> + filter(row == 1, !is_blank, col >= 5) |> + mutate(text = coalesce(character, "")) + version_text <- paste(version_cells$text, collapse = " ") + + version <- regmatches(version_text, + regexpr("v\\.?\\s*[\\d.]+", version_text, perl = TRUE)) + version <- gsub("v\\.?\\s*", "", version) + if (length(version) == 0) version <- NA_character_ + + major <- suppressWarnings(as.integer(sub("\\..*", "", version))) + guideline <- if (!is.na(major)) paste0("EUCAST ", major + 2010) else NA_character_ + + list(version = version, guideline = guideline) +} + +# ============================================================================== +# 6. Main parser: parse a single sheet +# ============================================================================== +parse_sheet <- function(xlsx_path, sheet_name) { + cells <- xlsx_cells(xlsx_path, sheets = sheet_name) + + # --- Detect version --- + ver <- detect_version(cells) + + # --- Parse rich text for cols A:I --- + target <- cells |> filter(col >= 1, col <= 9, !is_blank) + rich <- split_rich_text(target$character_formatted) + + parsed <- target |> + bind_cols(rich) |> + mutate( + base_text = case_when( + !is.na(base_text) & base_text != "" ~ trimws(base_text), + !is.na(character) ~ trimws(character), + !is.na(numeric) ~ as.character(numeric), + TRUE ~ NA_character_ + ), + note_super = if_else(is.na(note_super) | note_super == "", + NA_character_, note_super) + ) |> + select(row, col, base_text, note_super) + + # --- Detect header rows (col 2 contains "MIC breakpoint") --- + header_rows <- parsed |> + filter(col == 2, grepl("MIC breakpoint", base_text, fixed = TRUE)) |> + pull(row) |> + sort() + + if (length(header_rows) == 0) { + message(" No MIC breakpoint headers found in sheet '", sheet_name, "', skipping") + return(NULL) + } + + # Sub-header rows: one row below each header (contains "S " pattern) + sub_header_rows <- header_rows + 1 + + # --- Detect sheet type: single-organism vs multi-organism --- + # Multi-organism: col A at header rows contains "Antimicrobial agent" + header_col_a <- parsed |> + filter(row %in% header_rows, col == 1) |> + pull(base_text) + + is_multi_organism <- all(grepl("Antimicrobial agent", header_col_a, fixed = TRUE)) + + # --- Detect organisms and their table ranges --- + max_data_row <- max(parsed$row) + + if (is_multi_organism) { + # Multi-organism: discover organism names above each header row. + # Organism name is a standalone row (col A only, no data in B:H) + # found between the previous table's end and this header row. + rows_with_b <- parsed |> filter(col == 2) |> pull(row) + + tables <- list() + for (i in seq_along(header_rows)) { + hr <- header_rows[i] + shr <- sub_header_rows[i] + + # Search backwards from the header row for the organism name + search_from <- if (i == 1) 1 else sub_header_rows[i - 1] + 1 + candidates <- parsed |> + filter(col == 1, row >= search_from, row < hr, + !row %in% rows_with_b) |> + # Exclude known non-organism text patterns + filter(!grepl("Antimicrobial|MIC determination|Disk diffusion|Breakpoints for|Expert Rules|For abbreviations|For species|Examples of|haze|Isolated|Ignore haemolysis|Numbered|Lettered|Medium:|Inoculum:|Incubation:|Reading:|Quality control:|See disk", + base_text)) + + # Take the last candidate (closest to the header) + if (nrow(candidates) > 0) { + org_row <- candidates |> slice_max(row, n = 1) + organism <- org_row$base_text + } else { + # Fallback: use sheet name + organism <- sheet_name + } + + # Data range: from sub_header + 1 to the row before the next organism + # or end of data + first_data <- shr + 1 + if (i < length(header_rows)) { + # End before the next organism name (or header) + last_data <- header_rows[i + 1] - 1 + # Walk back to find actual last data row + while (last_data >= first_data) { + has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + if (has_data) break + last_data <- last_data - 1 + } + } else { + last_data <- max_data_row + while (last_data >= first_data) { + has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + if (has_data) break + last_data <- last_data - 1 + } + } + + # Notes cell: col 9, in the data range (usually at first_data, merged) + note_cell <- parsed |> filter(col == 9, row >= first_data, row <= last_data) |> + slice_min(row, n = 1) + note_text <- if (nrow(note_cell) > 0) note_cell$base_text[1] else NA_character_ + notes_parsed <- parse_notes_block(note_text) + + tables[[i]] <- list(organism = organism, first_data = first_data, + last_data = last_data, notes = notes_parsed) + } + } else { + # Single-organism: organism name from row 1, col A + org_cell <- parsed |> filter(row == 1, col == 1) + organism <- if (nrow(org_cell) > 0) org_cell$base_text[1] else sheet_name + # Clean: remove trailing * or whitespace + organism <- gsub("[*]+$", "", trimws(organism)) + + # Notes: col 9, within each class section + # For single-organism sheets, there is one notes block per class. + # Notes cell is at the header row or first data row of each class. + tables <- list() + for (i in seq_along(header_rows)) { + hr <- header_rows[i] + shr <- sub_header_rows[i] + first_data <- shr + 1 + + if (i < length(header_rows)) { + last_data <- header_rows[i + 1] - 1 + while (last_data >= first_data) { + has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + if (has_data) break + last_data <- last_data - 1 + } + } else { + last_data <- max_data_row + while (last_data >= first_data) { + has_data <- nrow(parsed |> filter(row == last_data, col %in% 2:8)) > 0 + if (has_data) break + last_data <- last_data - 1 + } + } + + # Notes: look in col 9 from header row through end of section + note_cells <- parsed |> + filter(col == 9, row >= hr, row <= last_data, + !grepl("^Notes", base_text)) + note_text <- if (nrow(note_cells) > 0) { + paste(note_cells$base_text, collapse = "\n") + } else { + NA_character_ + } + notes_parsed <- parse_notes_block(note_text) + + tables[[i]] <- list(organism = organism, first_data = first_data, + last_data = last_data, notes = notes_parsed) + } + } + + # --- Extract breakpoint rows --- + results <- vector("list", 500) + idx <- 0L + + for (tbl in tables) { + org <- tbl$organism + nl <- tbl$notes + + for (r in tbl$first_data:tbl$last_data) { + agent <- get_cell(parsed, r, 1) + if (is.na(agent$base)) next + # Skip category headers (rows that have col A text but no data in B:H) + has_any_data <- any(!is.na(c( + get_cell(parsed, r, 2)$base, + get_cell(parsed, r, 3)$base, + get_cell(parsed, r, 5)$base, + get_cell(parsed, r, 6)$base, + get_cell(parsed, r, 7)$base + ))) + if (!has_any_data) next + + mic_s <- get_cell(parsed, r, 2) + mic_r <- get_cell(parsed, r, 3) + mic_atu <- get_cell(parsed, r, 4) + disk_dose_cell <- get_cell(parsed, r, 5) + disk_s <- get_cell(parsed, r, 6) + disk_r <- get_cell(parsed, r, 7) + disk_atu <- get_cell(parsed, r, 8) + + note_text <- resolve_notes(nl, mic_s$super, disk_s$super) + + # MIC row + s_val <- parse_bp(mic_s$base) + r_val <- parse_bp(mic_r$base) + if (!is.na(s_val) || !is.na(r_val)) { + idx <- idx + 1L + results[[idx]] <- tibble( + guideline = ver$guideline, + version = ver$version, + type = "human", + host = "human", + method = "MIC", + site = NA_character_, + mo = org, + rank_index = NA_integer_, + ab = agent$base, + ref_tbl = org, + disk_dose = NA_character_, + breakpoint_S = s_val, + breakpoint_R = r_val, + uti = FALSE, + is_SDD = FALSE, + is_screening = is_screening_fn(mic_s$base), + note = note_text + ) + } + + # DISK row + s_val <- parse_bp(disk_s$base) + r_val <- parse_bp(disk_r$base) + if (!is.na(s_val) || !is.na(r_val)) { + idx <- idx + 1L + results[[idx]] <- tibble( + guideline = ver$guideline, + version = ver$version, + type = "human", + host = "human", + method = "DISK", + site = NA_character_, + mo = org, + rank_index = NA_integer_, + ab = agent$base, + ref_tbl = org, + disk_dose = format_disk_dose(disk_dose_cell$base), + breakpoint_S = s_val, + breakpoint_R = r_val, + uti = FALSE, + is_SDD = FALSE, + is_screening = is_screening_fn(disk_s$base), + note = note_text + ) + } + } + } + + if (idx == 0) return(NULL) + bind_rows(results[seq_len(idx)]) +} + +# ============================================================================== +# 7. Parse "Topical agents" sheet (transposed layout) +# ============================================================================== +parse_topical_sheet <- function(xlsx_path) { + cells <- xlsx_cells(xlsx_path, sheets = "Topical agents") + + ver <- detect_version(cells) + + target <- cells |> filter(!is_blank) + rich <- split_rich_text(target$character_formatted) + parsed <- target |> + bind_cols(rich) |> + mutate( + base_text = case_when( + !is.na(base_text) & base_text != "" ~ trimws(base_text), + !is.na(character) ~ trimws(character), + !is.na(numeric) ~ as.character(numeric), + TRUE ~ NA_character_ + ), + note_super = if_else(is.na(note_super) | note_super == "", + NA_character_, note_super) + ) |> + select(row, col, base_text, note_super) + + # Antimicrobial names from row 6, cols 4:18 + ab_cols <- 4:18 + ab_info <- list() + for (col_idx in ab_cols) { + name_cell <- get_cell(parsed, 6, col_idx) + dose_cell <- get_cell(parsed, 10, col_idx) + if (is.na(name_cell$base)) next + ab_info[[as.character(col_idx)]] <- list( + name = gsub("\r\n", " ", name_cell$base), + name_super = name_cell$super, + dose = if (!is.na(dose_cell$base) && !dose_cell$base %in% c("-", "ND")) + paste0(dose_cell$base, " mcg") else NA_character_ + ) + } + + # Organism rows: col 1 from row 11 onwards, excluding "Notes" + org_cells <- parsed |> + filter(col == 1, row >= 11, !grepl("^Notes", base_text)) + + organism_pairs <- list() + for (i in seq_len(nrow(org_cells))) { + mic_row <- org_cells$row[i] + disk_row <- mic_row + 1 + mic_check <- get_cell(parsed, mic_row, 2) + disk_check <- get_cell(parsed, disk_row, 2) + if (is.na(mic_check$base) || !grepl("MIC", mic_check$base)) next + if (is.na(disk_check$base) || !grepl("Zone", disk_check$base)) next + organism_pairs[[length(organism_pairs) + 1]] <- list( + organism = gsub("\r\n", " ", org_cells$base_text[i]), + mic_row = mic_row, disk_row = disk_row + ) + } + + # Notes: find in col 1, rows after the last organism data row + last_data_row <- if (length(organism_pairs) > 0) + max(vapply(organism_pairs, function(x) x$disk_row, numeric(1))) else 0L + notes_cells <- parsed |> + filter(col == 1, row > last_data_row, !grepl("^Notes$", base_text)) + notes_text <- if (nrow(notes_cells) > 0) + paste(notes_cells$base_text, collapse = "\n") else "" + if (is.na(notes_text)) notes_text <- "" + notes_lookup <- parse_notes_block(notes_text) + + results <- vector("list", 200) + idx <- 0L + + for (od in organism_pairs) { + for (col_idx in ab_cols) { + cc <- as.character(col_idx) + if (is.null(ab_info[[cc]])) next + ab_entry <- ab_info[[cc]] + ab_name <- ab_entry$name + ab_super <- ab_entry$name_super + ab_dose <- ab_entry$dose + + # MIC + mic_cell <- get_cell(parsed, od$mic_row, col_idx) + mic_val <- parse_bp(mic_cell$base) + # Combine superscripts from the cell and the agent name + all_supers <- c(mic_cell$super, ab_super) + all_supers <- all_supers[!is.na(all_supers) & all_supers != ""] + mic_note <- resolve_notes(notes_lookup, paste(all_supers, collapse = ","), NA) + + if (!is.na(mic_val)) { + idx <- idx + 1L + results[[idx]] <- tibble( + guideline = ver$guideline, version = ver$version, + type = "human", host = "human", method = "MIC", + site = "Topical", mo = od$organism, rank_index = NA_integer_, + ab = ab_name, ref_tbl = "Topical agents", + disk_dose = NA_character_, + breakpoint_S = mic_val, breakpoint_R = mic_val, + uti = FALSE, is_SDD = FALSE, is_screening = TRUE, + note = mic_note + ) + } + + # DISK + disk_cell <- get_cell(parsed, od$disk_row, col_idx) + disk_val <- parse_bp(disk_cell$base) + all_supers_d <- c(disk_cell$super, ab_super) + all_supers_d <- all_supers_d[!is.na(all_supers_d) & all_supers_d != ""] + disk_note <- resolve_notes(notes_lookup, NA, paste(all_supers_d, collapse = ",")) + + if (!is.na(disk_val)) { + idx <- idx + 1L + results[[idx]] <- tibble( + guideline = ver$guideline, version = ver$version, + type = "human", host = "human", method = "DISK", + site = "Topical", mo = od$organism, rank_index = NA_integer_, + ab = ab_name, ref_tbl = "Topical agents", + disk_dose = ab_dose, + breakpoint_S = disk_val, breakpoint_R = disk_val, + uti = FALSE, is_SDD = FALSE, is_screening = TRUE, + note = disk_note + ) + } + } + } + + if (idx == 0) return(NULL) + bind_rows(results[seq_len(idx)]) +} + +# ============================================================================== +# 8. Parse all data sheets +# ============================================================================== +parse_workbook <- function(xlsx_path, + skip_sheets = c("Content", "Changes", "Notes", + "Guidance", "Dosages", + "Technical uncertainty", + "Non-species related breakpoints", + "PKPD breakpoints", + "PK PD breakpoints")) { + all_sheets <- xlsx_sheet_names(xlsx_path) + data_sheets <- setdiff(all_sheets, skip_sheets) + + results <- list() + for (s in data_sheets) { + message("Parsing ", basename(xlsx_path), ": ", s) + res <- tryCatch({ + if (s == "Topical agents") { + parse_topical_sheet(xlsx_path) + } else { + parse_sheet(xlsx_path, s) + } + }, + error = function(e) { + message(" ERROR: ", conditionMessage(e)) + NULL + }) + if (!is.null(res) && nrow(res) > 0) { + res$sheet <- s + results[[s]] <- res + message(" -> ", nrow(res), " rows") + } + } + + bind_rows(results) +} + +# ============================================================================== +# 8. Run +# ============================================================================== + +breakpoint_files <- list.files(path = "data-raw", + pattern = "breakpoint_table.*xlsx", + full.names = TRUE, + recursive = FALSE, + ignore.case = TRUE) +breakpoint_files <- breakpoint_files[breakpoint_files %unlike% "dosages"] + +breakpoints_eucast <- tibble() + +for (xlsx_path in breakpoint_files) { + + message("Parsing ", basename(xlsx_path)) + result <- suppressMessages(parse_workbook(xlsx_path)) + + # cat("\n============================\n") + cat("Total rows:", nrow(result), "\n\n") + # glimpse(result) + + # cat("\n--- Rows per sheet ---\n") + # result |> count(sheet) |> print(n = 40) + + # cat("\n--- Rows per organism (top 20) ---\n") + # result |> count(mo) |> arrange(desc(n)) |> head(20) |> print() + + breakpoints_eucast <- breakpoints_eucast |> + bind_rows(result) + + # saveRDS(result, "/home/claude/eucast_all_breakpoints.rds") + # write.csv(result, "/home/claude/eucast_all_breakpoints.csv", row.names = FALSE) + # cat("\nSaved.\n") +} + +breakpoints_eucast_raw <- breakpoints_eucast + +saveRDS(breakpoints_eucast_raw, "data-raw/breakpoints_eucast_raw.rds") +write.csv(breakpoints_eucast_raw, "data-raw/breakpoints_eucast_raw.csv", row.names = FALSE) + +breakpoints_eucast <- breakpoints_eucast_raw |> + filter(!breakpoint_S %in% c("NOTE", "IE", "IP", "NA", "-"), + !breakpoint_R %in% c("NOTE", "IE", "IP", "NA", "-")) |> + mutate(breakpoint_S = as.numeric(breakpoint_S), + breakpoint_R = as.numeric(breakpoint_R), + uti = uti | ab %like_case% "UTI") |> + filter(!(is.na(breakpoint_S) & is.na(breakpoint_R))) + +breakpoints_eucast %>% count(guideline, version) diff --git a/data-raw/breakpoints_eucast_raw.csv b/data-raw/breakpoints_eucast_raw.csv new file mode 100644 index 000000000..c898b142a --- /dev/null +++ b/data-raw/breakpoints_eucast_raw.csv @@ -0,0 +1,15011 @@ +"guideline","version","type","host","method","site","mo","rank_index","ab","ref_tbl","disk_dose","breakpoint_S","breakpoint_R","uti","is_SDD","is_screening","note","sheet" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only) +E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only) +E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen),Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales","10 mcg","15","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","18","18",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","18","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.","10 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.","10 mcg","12","12",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"4","4",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia" +"EUCAST 2019","9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.","30 mcg","19","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages. +2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages. +2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. pseudintermedius","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","21","18",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","4",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. For oxacillin non-susceptible isolates, always determine the MIC of benzylpenicillin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.03","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","4",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","16","16",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2020","10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test. +C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test. +C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C] ","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","25","25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","30","30",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), +S. pseudintermedius and S. schleiferi","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefiderocol","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doripenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes +except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes +except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Lefamulin","Gram-positive anaerobes +except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes +except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes +except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile" +"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem","Gram-negative anaerobes",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp.,  +Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp.,  +Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudinter-medius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and +P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), +S. pseudintermedius, S. schleiferi and +S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, +B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available.","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), +E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), +E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim +(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Susceptibility can be inferred from the nalidixic acid screening test. | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available.","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime +(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral +(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), +E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, +Enterobacterales except Serratia spp.","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, +Enterobacterales except Serratia spp.","Enterobacterales","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, +Serratia spp.","Enterobacterales",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, +Serratia spp.","Enterobacterales","1.25/23.75 mcg","50","15",FALSE,FALSE,FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than +P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than +P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, +P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except +S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except +S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, +Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, +Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, +Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, +Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), +S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. +Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), +E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), +E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin +Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), +S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci","1 unit","12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. +Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis" +NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","30/6 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum","5 mcg","30","30",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum","10/10 mcg","28","28",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum","2 mcg","17","17",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum","10/10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum","10 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum",NA,"4","4",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum","2/1 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum","30/6 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum","2 mcg","24","24",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium","2 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium","10/10 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium","5 mcg","13","13",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium","5 mcg","20","20",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33A","33",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum","1 unit","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum","10/10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum","5 mcg","24","24",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum","2 mcg","33","33",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.","30/6 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.","2 mcg","23","23",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra","1 unit","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra","2 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra","10/10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra","2/1 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra","30/6 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra","10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra","10 mcg","40","40",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra",NA,"1","1",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra","2 mcg","18","18",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra",NA,"1","1",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra","5 mcg","28","28",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius","10/10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius","10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius","10 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius","2 mcg","17","17",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius","5 mcg","22","22",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.","30/6 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.","10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.","10 mcg","37","37",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.","2 mcg","15","15",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori" +NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas" +"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Imipenem","Bacillus spp. +except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Meropenem","Bacillus spp. +except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Ciprofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Levofloxacin","Bacillus spp. +except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp. +except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Vancomycin","Bacillus spp. +except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Erythromycin","Bacillus spp. +except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Clindamycin","Bacillus spp. +except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp. +except B. anthracis",NA,"Linezolid","Bacillus spp. +except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis " +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei" +"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents" +"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents" diff --git a/data-raw/breakpoints_eucast_raw.rds b/data-raw/breakpoints_eucast_raw.rds new file mode 100644 index 0000000000000000000000000000000000000000..fcad05d9c604e63344c2b6a5b0e90c985d344f3b GIT binary patch literal 176078 zcmeFZby!tf*FLNuT_Vz@QVJ4Ew@OKONF&|dB`qx=Et_uGNNqZ#yL;1Jo9_HJcs$4B zInVn(bzQ$dzW3f`>?yo+-D>ZE zhDqYRr{Q<}`C#q|f4X?)*-?FUO@rmn4+y>99;Q(QUaZhuFAd+E6(bKja<3OoMs;8U7(4Ti0cep`vuPt{rPbzkI2ScwA@BN1;5$}tnDY(=)^c(*=9uSIB zvecJj{Vk_k!R6kg-;lK4*DC4p;lF_ijQq3NW>ZF$-F}Y`PZ8UaUi}piPac^6CX^9N z*3TIja9!%&iVoo4zfbXyoe1%7U=WcM`rqm0kC9TolYb_G-vu|*KNxNUfA3z2+5L2k z`+tkRfh5Tv#r`|z38efpy_a2ZQ#&K!2XO!6!~eEL|G~|^qgT1Le&`YB7eBgU#44eJ zY4F3Kemy6F_!436{x?y2NBM9nItHbZuY_U^<+sVs(km{;_JIE%Y)hH)0O8lh{m0*v zf;|*mHyD@0&4{v^Nma8S3BI=zn<2U?E9heCx;L z{Bn--h~d2Rj|RyI*Ji0Bm`0Ju`7r#f*L~7C0Gmc3PpR;I^Z$OauA=Cgv!4-XdIAFL zs~sw8l#ctFf4D7goqxTQnmJae-5Ns7X}9^$UQAn^=diY!#6#-|N#J^|-28LtqmoOq zf4ZhW6+{CSI9+orzwd!H5It*8>-4^f#3V(S>p|*z4CB{E%EkAeTd*`Q&Unc zLJ}da-v8c=+>}z$*Ep@&;dH4~nn{$pqQe--@S2>d@70jB4w6;=x!k-h3Q_pbNn zcu7^2uREi!T`q`s-p|?jBFE6fp`xOSIdj{y+pX+noxfpf?>mjJa zcF+U1Mf^<(hg}P7W9K(D-z+%!;84Ys5#Zq|ug#f*Zsd^hdsE48<5wM^gu4i4jFUZ5 zcg@MgFlSiG6Ov(;VPRmQFvo-5-Zg5%U?9DZhgW`iTMM)Wv52VEz?&~!(J++Vcjys- z(7Li%@yztIK6ogieQy!O3ye=a`v&huxv_#L0DGWITN_ST^hxBKC%~)QrU2D;^FaMG zJ@iH0TBf}lC5)-2!dVUr-R=mQnzKjWpuJ$Yg$0ck0cL%@&fS~ajo)wYjNJ5+VF#z- zrn5A&(9YuF;jy797J{gT>YHy{TJ7__!PROvXH|rjTlHvK1j=+Xpb{g4i}9spV0fol zQ822`!oLcQYCs3<`O<#ULuuJFpSu z(a3`XcQR~|Q71(l$V7JR1WldQ^Zf<8j0p817i?gnk)vt}&i%f%iEeUDhfOsHYwFXYN7` zA?76}^aw@y5`#Fp<}7tZ8aLGF;NjIT7ogqu@OYNs;h}Q(@0w-DMFK6Khk}YaNpjOd zI`6{wYDJ~o{-n^UrG>J}$dnp#RNYBgpQfm(iR_>`3;ISV?OMuc8#nAOzuyv2YC3YXhz_0lQs|uLlx7cu_vzyAM5se+ zob~V+y*K?)IX^)fr8?h&jD)4%PUAIK-Vx1n-bWh;rX$E^;_L5B=gn4H@BT0@=oxBZ z4`YsS7%X68Gry17t=U1X&jz}BjNXNfaDukUL-EefR6`XbfrE!P!?-aq+yp~Kdl1s#eAtq&gHPc;*X!eIQ;dN4BUycU+}F?Lg~u_ zUjFPz8eo`mtC@GDBa%=N=yH_vQscaC9RusX18d{%IehW!!wSw%QHEqsZUKxfU(dKl z`A=fms4MEZz5xF%@~D87&piD9SyYG>Q*=6De#eG?u9=AD`+piEtSUv%@xPZX1pF&a zzUi4>;duDc%E#|GY?5cCV0iJbU?Yb1T~z4z;!2XLwz4q);)KYKnzY-Y-i{h5U+bUl z_0PWunlfnz@!eF>R0J9Sp1Bk~X;GAT#C6y%50pSN`o?o=#YPCYDLe>bcG`}LC zqt~*WsI+=mOx9Z?)QA?DPk4l<(RL$qm~$1Uk$HB)JUP7wT>xzL%t#QHlkBysqKw}q zW5E3a`B#@tY@xULq(Zl*#)Wz;FU=+!ZdRg`mSQz+_fa+mu}p0jFUmNB6#u^*&fl)=*ewmgKm+m3zxF^gObnu1fPtf`~`RrrYKuDLGl_pxfMsHot#~+Y1GJ zs8f{%o)P86vxAYl?yE$c1X{Gr`H2^mg@`r#s&ferVL<9jby~f>hp1+F7|x~PtGfc} zn*#g7c6TwOj72|#_}02%N2@HFq=bAg7hi)cECweV_5B$`#WM*-goamg9Q+65SB3St zG6E^%z!|4!_5*7zr4UiwyYSO`Cr+Qu^~^p`a~wn-1CG5d9bT*-2{Ieq2O#z$n~p}; z8igDpfY?~mw8!TRK8iXtAbqB92uJo8iDQ(tMM!w%NUY4w$31UB4+)hSV|+e{`TCK4 z@i=*S>U)5bjAIH6J~xx>QWJN?6`*h%X@99cQaZ+IIhH}SwU$A`+X8hCVcDPd60nMw z2~;G(o6oUQRjYVW?eQK@HiMgl_|6XtMVLXpF;RVxB0M@e`ZUW${=zFZv)Kx-X^L@H z$fM~Yn%}LnpI>7h=|&W7beAj|***O;vd}WzxW8C>-R9bqunXzz3sV1TeNc;BJ~R5= z0z*QtKKT6v(mf2fD8Ob+k1kc`4%PaDKTHsM)h}0Zng8r;clT}1IBkL~=ffWQ1wGd1 ze_+$8unb+Tmn(EzrKqd^pc-H(O8VdjWI``qzn#GaFa-lQ$^&eg)AEs!D&!X-NaMI6 zHkB_wC0Oct_;hRYUbirwOTq&S`WUrhLhz?#C@vCm=O-U{)w6w7@uQMN^`tah8KUMLIS=`6)!#FV#bI4v9+2UrwM0_V6j_*b5s5n}(H*}pN_>Vs31W4O1we0vNYVpS&IlM)1VL#~!6S>=fQZ-=d ziuD!dq=iv5Cy$jt>g`YvL#MVnr$Qp-0sks&-u*G@`mR$wFePRF&Z*I4EOkNh!ft~yKvBa7B|K@<3 z>BySTZv7dD>rc3dr1{n%CCj@Z?sv~3j0IKfd{Re{R)0~x;F-l`0a&To!<$P$34I{IH;YiViuZLZ8X z=v}whA7VREq7J@D1*`egS<8P>d4C@d0knYtu$t=#*$EEe;{KDtw_XNJ&ZsfCQ=uo4 zRqAoL^!4?1_p#PtgGvN(=g{d)Mk638X72Qtnqxjz#G^kJUDJRXTODeagZZ#wHv$Lii8L6VZiswycZ#3JS-<o6Ll9lC-?Y2l z;ggf1$9BL8omyuSb18MsV88PW3Wx!|%Yo-Yf9oZ;JRUr^WEiv_^tc}c*?rnsf8(^{ zLA2z^@tHdvxxLN}Y}I(dDuPpSkGL=a*f}pH&T=Fte;Riqk_x zJ$aZ>>>9dy2hR_-0mHJPtM^R^Ru7N?X4D0mTobXjBIo ziV7dRpkNLBg&7D*BDc&K`Gpw>_kJP9!-qpgSsECbp^tA<87#3%(P*N7r$%n?ZKU5) zV;1jE%;37XxKSjyGh)n}X@pn&YAK$`)LBWtAM*S0JxEB4g(|A^AjFm{MS<%`_i`2&m z*&f|w6oV^L`yu!J>Fi9aPZln#&Hbzx4X-440u0&T2WD3-v=QLw5j#3j(;5ac&zZZ? zm>34rr4y-+0ja+kjT^^oYd5MDJcxgxTKV zhY57t)@SnP*`Kn4-EMsgMFG^eWVn|{9|`Un>WsF@y^!QKjFn)@ zPjc!0vr9SX`yX8j>XX!`FM*SI)Bfy1$b%%3SRd#SX4qw(y>ie}O8h9=@e>%{(m4GIVD?@H>vxj9L=>md4kF==`QOv11vX#+G#k;iJi&&GgI zgW_C0jDY+rjNU-?JsQgGc5z{QQ>97un}6U``c=OyPn9fpJ=Wj(GZcYbC-0ngv2_|H zKy#8q6h9Lu$+IIx{<~K}O zp)~i7yf;yVIMndldf2=g8q6@9wRvkpIwFa~ICL##cSl3HESKRem#QmvY6|$S_flTq zAE5~;?Fxjbj|nBmH6*}-4`C&j@B}ct?box3$caduEDyT97(PXWzE=(zd%wQLR^;pR zP6z-H5uJE1eiA=}tfHK1jDdg)+Gw|vE~|@nW5|0XuhL(Ms2Yjax{Fb@wHbV)tytAW zJ7;nH20PJRIvq%8wzmkp!j12B?ND>yF5zN+mtMBI5Ne9<_2c%u?hu1@g5}(;h zaxAP7eU=t{Cv*yBnB_>;@rBI04<2RswIsR;wHqtnws5{!` z)8Gs?=Iz9itZW~JHR3$5m?=pkHpTX@|4ng@&B#V7_3b}gOZ8tSFqj5o)I@WSZZ%m; z!)kaFmzht1K0P%7G|&|AY$Gk~G>GIqLTbR8dzYLOlV+}D=B^oN&BqZ%9J1WvL-plV zI=Pmx4}bRoqwMMSJ!(fEgU8%ltb8#f73h3_uP1=_G+#Z znZNZ;>z3pM`G56JkH>GklYr*$-ie*~hj-$8`WNr?tqh%)Kq5dk32koMVu5=xHbME+z1Q)H{sTX|BH9J z6>jP-aN}PiOi!?E{r}{gl8Ou>!836wq@<0RPR|*SKh-z<43J-q?W)sq#aC0t1sS2Y zKhPHZ#Qpxju@9Aa>IMh!iP{T8e7-kt=wf~fm3xxDeuetBvCx84D_x;9iFfzRsjkk# zsCp(JnW^3}$8y=;=&P&dlJIqH#8hx$&%`~Fex;>`y+t$zBz4FUlsS0ikO|01_FmxQ zGk@T^{|I%FoGd1aEGcOuv655bxDjOZ3)55_e`eZdT}6no+C3n(V#`lVo0>(KL7ilS z2GG8>UEuEl^lMWDXJ2Rl!+r3;>Dp%22{$B0u1s3l$_rqHbs$DHu+{dO9wzOXAc;4K zg3Eexx(SQx8y1&gBo(QcvnSS<*?UyR%ZvTRP2DybgJ|igXInYLq}jZ(>rma7izX$A zuS>i%S{LZsl{&rud$?_T2Gq_NaW^4#x{e(VobA+#*oWo-ruI)_K9>%b9~E=$rp3E( zLtnVYl)bzv;|QI;1Tv@Ub(vW1|r?kZY~eWIpUP0Buxf?&aO7 z-R%kwK@{W;;ZMcZbL=v1T_5xYAi93QhT%kxsc6)S|7Kf}`9Pd0klDU=DxO;q`Rlu# zN~0IO0L43%N+qWGmKHx@$9Fe%&Kq)IMRjv?M{l<*1a_|cwaZ1{r_Fe~`!mvyy0KUD z+$J7CleT*2G4ZV)?5k>H3kkwfzam~3>dx4|yR*AtIjy2%Yl?VBlEFV8YL z{EQRvS<;K=H7CkNT2$kI6C?Fgm(?)~@bWy7JXF%#qV(|j8KzNxP_0Pt2h-lR;ryDE zGKV@kT(N1uC)c^RnKZED`1(>xV-PL#%~o87iXt)@eH2f61oz7}EPb>4tT-RakZO-@ zS2fh#DI06&5NT?|2T;zRCVd6|rUm62pE^CNmX#c4YuHUrX7#Uiybo^`jw#lODJ8Wb zIYpd#uBB2+CMlUtVOmIe@jYc#Q}lDn>Znz<6`C(ljHFpO@l&%uY6;68>x(zr@%oEX zLoEK6oSOOkKX7Vp%ztre!>~_NgNj1-Hf99)mZi5((~IuFnlrj^cW}6lzL4GE1!2@& zcdZNTEPZW1^?{siIlA0wpD*%u zl8Q5pzS<8ir0im0WIe9w3s50))#`l3#xt}m{d*|Zwg2~OvXjQ{9?V!H` z$}J+<+vH^lY*RobQ^f7|f~f18}UNf%eJbypd7$1Whu{eoK(QV-2N^7^Z!gnB;{ z!1sVGbXV?jG1j@_&jFeKxQZW8AAka8VWcC3rXzkJsGZdNz;#Y|aJ4cd_pPGX#L%Zt zpK{5~CEIE((gq_vHiN9`pFht-zfqN?JvXZI=pi&Wv>^mwv-T>-hN%|+t}A=qe%F=U zwNPDo*T+`A-1;VMoJ}Cu4?CCOl+%J4f`L{e{9RfGX)1?&@Kkn(ipwbsaL%uB*#gPW zaT)J22hbL?JVzD3m3OnUnDr)iJZcVKTP`@dJfA-S6?mqn+p%$vgB%AoqwDCco z=<4O5$A%i)dzmRg!*(>M4)H$5gtt{>2sMbGGVmPlPeko>Svq4$?%b2yNs|Y-FhFj! zCDxa`*a)HC2a3FL60Dy?)~j+A+|#bavYiL;3%Fk4>wdQVtZ_|8@G{h?_xJqX$XZoM ztnziC>*}Sx0=*}_pLh?w$*6tr0+uvL=C}CmWx((88zJ4#@tXkN@9~>?5VIC2wxVL& zM`6-v4MhbWx@@t8R+f=E(K`dD{PhbEY7sfjW=c#SOOJ8+D5|?oW3|lrL@E{Gds8(O zzZpi2tktTx^q}oQTT`-QQx+%Vn!A@XeLw1<+hpN)Pe>i{w_#n${M*yGY^!;IuzT;= zvG=LfY{zOc_r4e&P+J3!>J6Lk4(xtYl$)eYknCvZ5vBhoCO*HQw2o@UZe;5G>`Q7f z=b~@~muEjE3$3y0Spn|`Fu!Gi6Ia>IF!m=317iBHk}>)oeog%l8)!WOry3m?)Ni6- zy#lTow{B;_s0L0D79$Af5l(Sh6CMu0e*K^o)5Zv z^V%iYm#KeTDPg!b@FuP^A^knB^Sb|QSch!HJXGMLaI-}nHZLScSKkQDv z4eY)-{W-4N*~wkLrC~?s+#|pLk%k!L@=zKQHvK~y0xkbd8oKx1(C`WNFEk{*$&7&M zb#F5xtPh+!ND|gxH2X%;c0Jl$z-wh|c@a|9yZb%fE1iDGev>Luw*KxO-57;MTP^b~ zz97s_^iGLc0mkiJpJoNwECjxOM9Wq_Vv(JeJE7&_J;6_nx|o)1svNSDoWv6AWF5c} zk-+bdh)||BxuGE{WTRF^Hkf)?U!NTdz2J<1dMVdbdfMK52n8SNTpyZlOK$FAxHj5| z%~epnJdl2alrHeJ29t(;&q`Y^h2PJ^5KzHMVunYzxAuLbDG$m0CYQfqb=Hsf)0$xM zIDVsiL}1pgIn5oVYAes^^)nV|+DydbSKsU~)%Xpd1x?dn)Ob(x65nJsDHm9Omcdy8 zY=6k$>XCRj+^fn^7E>I-;+xT zAMsc3{P{w`=r`{yi21`i_YaNt$XlBEzt-H`&JJK$bqqM@=eI^rYoXVp|ejVLsQguIB7-ugZ{ z_|&eAR_CxPUkC>ZH!Vuy1aH)F&Ex0KF3PptZ&N+;lz*2cO|Wnfd6m)O?@W2gtv!Ra z-04A+>UY$|s8t@~s`UkN4zB^D3rppUyZ?oR8a+6kyhuprKE6Phr zuIvPZeSXRwCC;3x^Yz2$q3^L|JE zhH!csUR6hV+kniPjt?Z{NmNm$03XoW+fD}B@qWeAl2^?Ryf!!5EnOErMf)Oj<=O-~ zzq{pk%iQhB5gHg}%|H803BQ+w*~ewYmZvxPuVFCDuDA^CuXlmF5o^A7 z4AP7VA%)h52ED7Iyqyej(SIXj zoUXGrNGD3*JmLNLYJ#H8`nZYl99N(%zkqAMtAs8uO9WqEfp~9frHDpwk^-A*+lzZ4 zeFLSSXnq5MTLqi)^0j0ZCBPWBv5rIP>f{?aPUd1lf!g&@@Qi$9i@@wQmZoYz}h{t*H7X?mMXV+f~FE$X?Vm- zl>les2d?BWGnfe&JTp~a$;|tfH_GKgUkq1HSjrr)?m6rT0U$FuIfZi#O9XcIbY z%~5oDd?|E_IPufIJ*&P;*SQNTEsPXFr7yL1q4NGXPC3S@`MdGY(Kt8l-UzYP=4BnN z1;tV8VW<}8KB%Dwu%#Ho?}_2nu45lTci60GjfdVlGPLi9t<+|RC&?hEF{9`Cc5t9F znX4lm?Yup_H@P49G&qCz+Qw;c^rBT&9729L5xTO5mv9$IjEYk5-e5)4aLr@14#cO% zWP}%od}Otl8{sjdx>&l)X7+d|(0Bz_7fm5ycg#J3I8@xFzuep~(uJ`R&8dOW6R^fl zCy&U{u#qd6U)QA1)#cd26<62UPjvER^DULsL<(8!+LiMAw;ZHr+V3aX@lm!#GqG$Z z(l$=o%ZS;YY*vLZk+Lp*YvjUM?yHX2^zXt!q9~c}+m|pBD@Sy3HF{f$2XNo94ue!z z4SKoDS}L}cbh794v7&Fs^iFWOj-J zymH=ey|BQslyu9({G=RW7UJ}<*yCvuN$9igRyjKhL!AD=LrDvnw(6GZ@#b^j?*@ALv*hb^DfiyV9jC zp{L;3>mD^e%)OLhPN=z39ZMZ$yI4DU_rhgEpOHYT=d@N}Q9XRjxrKL=L-I%@HAniIvfw zz=l$K`Bqb-G##AE2tZd{He;Y+&5QUtXF3>jr+ZIf2MNKB5NF-cGl>M%*$SghT$thI zA)uQfy5|t<7lDJ7;j68UK1J?`0|S2eBOwSo@QYSV1^0=V`GoOfV8Io+WVb_BTe|>B zI%StgMkn<%R#u+!XDE!(jOq#_oad%FWU@!txrV$VM;rw5bVh5@!9(sZ3^fS05gIU{ zik#7@2<-emkWq^;z*MII^3NrB6(3n3x)1APdrWKc)b=E{k1aF9h0 z#H+`|Titk9IfYy44h4bXY2UE$0u5`11VCD8Vei5sH*d}4}H{OMY^=PGSm9mhMY#K01L!wb6} zNv4{p@~o+NS_u4Q*3^4>=3#)Aow$mwsbP+uzN$R_dFr$* z7wF8PaC$vx+9h+?n>d8sh{x`(I?JdX;9YbiXZMUEHS`6i0r$xd;4=NG5jkZY<142W zOrC7D;(kJ5Ch4l>x$TFhs3hk(nYs@RDFE5IWnTcz310vnB$q7?%_Ci_^1{YtrukA+ zILnn~4-$jo9kG!EltU=dI)Y&MBGM8>I3w+hs=(Q2`|%v6b;H4Lr{hgm(-^tlUekpGgO z1ZJw*_sU);i1ZWGXUU-PJ>+;}urR@H%==ZwREpodeqpK|noV>Ya>N7bf#hFrXG&@e z$*W%8CG8G+4GqFP;lJ6jAdW2Edy}IL{VY&)(aI5qX0bLTs$D)*q{2@(GSpJce?CZ) zV1tqn3qwZ3XOv;oy%-mUZXbfsfc$x5Q5N@Tt+ZD8vR0#UCbj=#PrU1wSYlP(+T0h^ z3I)*>S2%n`2{zf4c-PvBdcu+^a|Ewx^z1-j-l z^-Sr2$pN*EGh*IN3qtfpnm7;fcdXHIW16;@Z~ z?v`4lXFJ|qD5N2ZGXc>lZ4J!m(K#wLBf3~y?o34Im`^FP>wh)`LIOihqopY8I(+jC zmd)Chy6n_XLlIA}Dd_ZvYC1O`-szk0GHs?V1{ z&N)4Sm!Z{_-%A^Qx$Ajs5IkVWv`S1by{DttZ15-nXqjV#K(>lRcJOdf4Nn@AlsuI& z04|?qL*cZ~ZaUg=Me_`Gj~)0;wN;d{F6KFJRvaF|elj--Nx56Z25a%6om$;#W*Dm^ zS8~d_mAOojlU!t|xoV5@yfE5%Azh$FTs8cGeeviA^g(mbS$-Bh!>;xEK*tj+YdTC< z{gS4)0%Ja;A8Uiu=vGKYq3DjL`0V3@s~{5hr>5MJ!5^wT9!1qh-?b%Gn;X_SRRg4O?E{x+rXaC>v?Fp zV6RFKd0mXFK}Et;cIHkalUS?5>6V;TUF-zFHzcV>=S^k2w zysm2ca_U%b1VcjYom!3stE|?Zw+v6k5ku$ogDVLf-rZX7Wzp#A2B)~>Czh0ED0l2aSb*2k-4G(|#dRB? z#LBu29kYrFu3@cc)0UVMO>C+kMgBUd)UIsl>cA<#zq^(_=!gNLHPJ|GhGE`;4cT6t zx*yMD8R#(`wUsgpIBI6{WU>6z9ix`;1wXpdX%eT`ba!Ls%{=Jjs00pAZTzzxl41+J z)!v?#-T6~<>n~B1jc?;wgNBx^BWzTB%ynnX<#zK#fURnpoW_vWnDTr8c)cPY;3K!e z+rk$t3H{Vn64X_kooclhh^;!BjiP#M*~!avlZF{yQ7&w96qKWPKJ5?{9iwj6EA^DB z`Hn`%S#5&3e{I%LH`_#d}yN0d8hY!)(HV)d&Ev_{Jx z>3aB;V8@2HjjJf^eu-)|2 zszgi?g9q<(O!Tt2wwZ>jb6LWtR88t|f;$f7p?mIT8a7>Z-Y;VjY?hUnmL<2KOHFr> z_i}{p={?!fk9EA20}EDeGo|!rxcvfq=c)GPmtN&x#HFZr&r#BWtt{C6O=P=c84lHn zCayrko>6WNE#S$tB8dQYGdZ39r&07qkAq2=*$K%f3C4ot%XOtYfA}-G<6PV?F ztGSs+Ky!&%Xw59rK++|`qSB+mlzci0ShoH0sp@>jYo2#TvWLixyTNN!E%qR`-Sn@f zgF6V&NW=9u^WlQ4QLt$zFFE8+l*r*wqJNOC4`^$DoJE7y5PAL4bLW~kK2XBFAQ7%Gk>}Xm1#2H)GqXZ<51Kq`|1NlUAnOq)V+TkgGu0k_cfisySo#bma+e4X^ ziy`B@E~sFXpx1ucBY!a+=cGY?xL$KS$uk*OVL}?xz9a1L*u*vb&VnGn8<{)DgJp}ek`4-HwDNPQZJerv++enIwe^o11M0E@ zhsz2tOs03V#%CKYo8C5<4FMH{rx|#7I)+C2Hfn35$N9RC3Il*H zj6-Xx9zUnm(+=CHof2Uvudz>R&0HEWl<3aI+M0<+L5WJYZA=J_*V+u$GwC^A9xTj# zd#d)1TcvHV{r((S+uhDj+&9n9@R^$EBzrstByB5@7N#I`+liK+btS_O+P5tR5tpi=XA+Yz>9A2&%>h? zt7iJn`_99XLH6%^TAVSDg&>j7*!cvlop)lV-$(kCkFakqg^e_C+kTEGM40-F=HH1A zRuQ8z3KQ~K>rtTHdRy2+mrBPu?|y|sj%x+Cgu2&kIqNT72)HET%?`utsc`KZAE~L0 zcIWLdEpF;0mlW4(|EeK$I^9Ju{*jdm%qN1qrAI9Wkm{fs9o0M4XqaiAr<#uL6K4vr ziDNGaCM0pJ&y>e$k!b$LWi~Tt$THNY=GW5D#iZ?{OT1rxX*FW{#&Gl_I74kvAu@+a zUaWOAh2T8(4a3$FZ38`lq&$IS;)>YwEmdwn6J%9JWyS$yOw_cGH^a1e<<*|I2$Qf$ znSqVFrbo|ATcM;VIk+D;VJSU2RoNA@PCGsrtC&zhrU^g$hD~ocE=FEunAtpis_GD8 zX0p<@dp3hS+JmV+WeMJ+8wj14`r?4;Z5u`OwyOL}!Ri{>&))eSt0pi-U6QdT?2!G?xWe_x)K!mD!s}93*UTkTxp;0D*aspX6`rKTW zVsuv$<_Y7CuM#R%w4+iR8xTwF+(&B$&zJ{gl*P_{cg0&+S@m74V`)2cBUFT}!dOap z$Q1XuAc4px(gKrcQl5Y)|)me-TR zU!rjI@vKyy%T@eh6djJAJ|p%zN?yufnWfw0Gy4{IqzN=;>mRR_pvH65?m)pmrWGk7 zrS#*VdCn=y9=}vdX^5Nf3fH32;gGB$Uc5h;a=0v`V>1tTB$4u+p!7TKS5@jlIXbg! z8%`dh64Of7k7v{Aqci4iwXad>-lOI;?i#|}sG~Kc>Q9TaQ7x+9dyO=O zzOo)=wEnz6b@`=mLh?7{#usso&p8^YoQO}(+w&sUB&}yE-*7$GWLUC$NxTi+{k?tn zNqIAV&}6=$?TLi-eF5vSR3r85`!jKkcFM3u94IqPo%l6yx|O?%wSC5zfdz3ig&m#S z0wi^1<=TfL_KU0J*)xV_OF(GA=UrHxlecR-mo8j++F>0@cG#_e*f}Mi$~da*R%Vu3 ztQe%6d{NvdpX)womYEHQto-a~V?HGu6YFtrw*E*$VEZ?ZwOCkW$zF z7uOFubc$&SqPKDpi52C90Em+hQwHgVW14F0$y?SK8I|LDv6hM_hk2SW`?~b-44tKDkD3X1Jrr3vgkXCT%Oe!gK!O9AkZKSOqDdrzeYF}67PaTAIYeF9k-fV7b~3hClqdI^ zdBUHaYpt5S`|8`O$pQO->O&OeHM2+zQ$72xs#LfdUCiA4avlWMY5W5C4in|ieRbj{ z+b^JMO`=u4e*{bg{ohx9s5N?#8?`nnJ!~@-gV8y*Qlc)Td!=HOlmClEV{ylxv1GDG zv;%^eP{lXxoH^p8-YPv z2j5I{wxYCMS90mSEvBJkKH)lwPqihYTqi2ll4dk&a;UP#H&iP^+eA$sKRtP(ZWLF% zsm|;=wWsB0FG%=E-dpX&V>Op#CQZUsRd{3HUm@SfQTvo)5^OLLsCZAyB}>a=<4Jo%F$Mn4a;HYz(U z$DF7tu?LS$(;73cqg5ANwH0<7m#sEmTriu1L%UVGrLdUcpdSIFy_|m7k^}S>>fD65 zTze8Rb5}x=U{a?i2Z!=OV%R^D_&LW03g$`*XCC+om+aLrr6GG>!fFIl`SbCOgZ!|D z;?rfSy2Mdhrs|!uT0Iqyir1uXg_=E(q+CzYrvX=zs9#>7Ikrtq#*Y^epNcKhF8t|4 z%PVXDS!#P8m1}=kGHGh0t65DbDP-&{k^D9_3!i&@6Haby9}?)KL=yZ`IAP4GjhDl8GsueOtuaj18@;8Q-igg+`J zRqPDwdDNIM9L=-99dMKJC(dvJ9&BaRa$B!yy{vBD%x^-9tBP#Hh)BDl8MZk(TU6?u zYD^4C#BMC3Y!%k2w!(yN8ywb|(JJP0B`>=@=zN~t!8~$mCR_u{w3RmcyjzZ^*`_#i zE}C>%8dykt{CQ)m*u~nVXKS;JW}atMjVY3GXEew;SY8grs=%6LICY31uSk0_=P4_z zNzF57-Dt+QRWVy@PeNY~C8(-ShWS;Bwu@Gw=_<~4xu+k$p@U0&UCV~f^@4h=IB|iB z`DFt;G{;4SzRFx(ERi=(R9SoI-r%lEVe@H}_EvQ7~jQ&F+;=1eqED-~32soB- zFjXmsTT^FttSnnRa{0R}EHiPHkcFno)VigqJkruC zkzJ{5vrfkwS=a%Uh4vHq0~ks-ve3|YYofsExPWePWQ3j0mUf;;Vj6|2m)g6mwi98H z&NzE<${^aWPS%EQsr+%~A9;2&i}v&&U7H?)HGYirtd$|LP(4@lQm8SCl=VValzap2NFGJ9nd#iZUF(+2hnntqhIMh*Nl6IcM#7XkvFSr zJFGXd+?y(xYfh{HFfKzRG;*)uHZ#K}C#Fr;n-B>!oMVvaU|U-bil8etb+ol&m!uo; zJ?LV?{>EHf?UR!EisLvX zR{jPNGmFQnN&Q&)v_POx;Gq-2u%KZ)k%z1OfM0pF8pm|FK`!!$+DM9m-If7s< z(A9937;{cX5Or!bd4ZIaB8|&ofGkAjW$Hovv$i5+nReLtv!wKNyWMu3*Lqd)>DLL^% zal^)pgHyTQvUNDt&BxAU%d+e_Np~;D1#Rv~JmFkKNF9;MD9fM@>4H0J-_n^LT-or1 zEcNwIhhEmKa-G(HrY@|^fm^8PQ3ZCy7dpu%ar#l$stMVJ+p171+2)wnmM>niTwdBl zQQSwUv`ktW9HnM~?hIT%gUz`g&n{d0Zdg!)l{%IC^J&(2B*I1=;U=s9kv!8VK(@*_ z$FKy8Ne+pv6{3EhQ$zG<`sUz|~#Gp?bJ26;K!upVTmfTuM;#6EzJIY1ck)O?b8 zl(*nM1_~Z&WkMImpEnK4xyn8c65$RIwP(jEQa6@MV}2~c3Y>KNUl zeebGfO`+hppc|ISO}F*1bs%4bLwMajuIg$dyNpxoc>%St%bL4kxLNI<>e3=#F?NGh znZ%kHY4i-^^s4ulWn6PQbeySk6VbP}9iCNKI-@6!y=O#6BNKqC1J_0F{Nb@s*{C{j(;5tc?GR##38vQ1(Yk68~0~=7me0?vf04jpJ8!74yy-jt}LDBg((LR_8=T z7_dh9V9e`ZPm~s=rSl4WAZ{}sd7>o7VVr~N=xoH`-pDIW7+{*B%GqHrW1S!{dyd2q z=R`*+o1c@Ybiwj&ip9|d>C%!ie}D3ft|0T+3^&Cc0H_GfFcB*2qJCwUt_|NGS1voO z5j^q;KRNT!cEd-JvfY7^j0;Du4awb31-qT;Jg>PXn-(TZ>?z8!GSWy>l>+>#z`f(p zr7Ilw&(K}hl1Z;gdgvzR5)n~fmtMYm;&ZfuvxEg>uN3^{|K+U}OPAy3en5XT!0`!{ zSHX|8r2CD=T^O)=)O)7AX?dkJy0AjZAK}oCAY=Fh`PEB)_jBW*3rGQPteFAA!mFHF zPLb<@aVcY3FSd(M+aVHjw4E^%0q*V$wcBa0hga)8=dho38%`jkipm>h&ao+%hVLRL zj(4?m+Y331+sFh&&7Tn=S?N~?QWj@xyt!s6+#edNP_E2N2>?ywDAX8!P(fPtccdHy zlLxlZQxd*625~JPYvHR{jBYS|b{D0M%~IapB9I*xQO7R2d5b06wY^!9tcTb$A(s}7 z4~wucF@*ADKpalq^sGg92VJcockcsoD23RI%&ICZ`_hyDkF~c9i*o(KzKyLY2&hPd zs3=HFH>i{}(v3*Bbc3LjlrZE_(%sE4pdiiA0}=z$3`2MG-UI4(*Z+Cm_js@I*xN6D zyYKrt*SXHMeoQPCua=cDzZ?m?>FMIl{*tRT{jKbT^ZZe%&1+&wVTYspgi2_+G@;u`k&&Dk&}ph*Bp|7?DH}=B8MryE)9kU}WIY2+_U9ND#LBDXw1k!%Ug4%m|FB`j z3c-dnt{~$_ECgN!M$t12b5!V?m1AsQ-B1Pywr4L+dRgKAci9=&vu(MjqfFm7gcA{4>*9E^kw3H*aHx)oxlXH^` zFE(KIkfIyb>ykI~Rrsjr*+5`KufB?oo&G}0C#!Aq`?5ZqWGQ?hSIeiwxKm$2`FCtN z1tU#qw0Mb>Kec^j!&-KuVc=go7;?x8j6(2w*q2mMq?X{fhk!W&cXx|s}`;|HK9xu1X9__E`72xu!Y;P#%aVAs~ z%;b-M+4Yp7ztwIrFI#X4%uqbH^If<7ogv%m!xmY(ezL;)qv`EcnL_-S11f_fF@;(O zd$rL?qc+Rb^}5-e!(_^Lfz%n>(Q+;+3NefGw#S)eW~b=~6!;p&O}Mo^m=P`|RwYD& zD-R)G&+W}QR1E~ANgj4<*eT@tz= zf|--S8K?Rn`F#H|>F}ETcO;f~)0M>{6K<=ER99OYC%oe%w%0Pxv&}UOapwtyycooT9Ez2W>QMs79x=sx$+gYYL{+(?#>H-UF z74>LEoTFUwry|C9x4>Rm_=sfSid;%U9IjSEna<{|;Aw1%*^1aHczI?F3ORVuA{Fl)F1NKaQbPQIsz+rh|sR7CFnQT^hPeh$wNz_34gsY&ctj72R`t* zH14E5lg6~?(zxwR8WaAI#`Klr;o^)J=Wnm=bjlYjPOY3v;|kjum*dra%lT`iD^=Fc zgh;VvOBue_oY6(CkCi-xRX_&iH@nnyg`myF(UoaNbd8(w1{0u*DRkBE*KTVG#5kx) zK3er2;HzzG6b>$#W}sVS$i#A`&cwx#1`q*U4dR zsdtJt1TU$V1#FqMoU)Gc&=`HMKC@ODCcw$UdFG1FvDIfi))VjPl#c^kQHgU`v>EM+ zzD5;cYC;kQMQA z!PxB8Tr;{3biCD@&=RW4MawJv<_8zd_wOg6oXJ1uT#W)s3(vA~f%OvDef7$8Q}gkj zVXk6p_n2}DngWjY(V1&25Kvka?vsM#4$#kUi1+u2hAiAH#AnZxt z`%zYj(Ybe>CMrDzpR{^4>AveWzcBvQPk!B%l$y_l%IT$z$@gTZRS3>uNo{}3)JAt_ z0FJ2xol=BEbUr>d#4O44e$HBHVwl?L{61SBV$0_r^4eDZOX~}-3=1PI^SX~=+bP0F zx;9U$8?s)u57Q@wWlTtfT%4;tq0au2LG#FN#`v~>LV^H`NQIArt(ZFGe;wOPukoDmLz<(C;GSJgk5RDaor}D zjB`xbsMr)&9+~atJ&mRvJMk#{n$B~`Hmp~$CcRj5SX87JO)Acwpv2&2H@LxQD_zj_ z&D3X|9%fCOuucuV^>HJ^z&7;;)R&c@ecfHaWkN3z8F)PrZ-_TELSPL}l><+U zDs4*m>VI=N$|NM{nT!1gg$vs{hra8S!L@L95I1Sc{%tx*1dH(4EoNoOM&2P80S)qBK z-dDLk#6(ddZqInsltKv*#U<&KxqEkm*>08v8s}@jaLz4@l~7{>b)NQuCH&!o)NIk_ zg+J0gyg0pVS~?;NRbI9;0iUJs^YE(#+q3N6z9MQ^#+C#K>)T3bVNHmuQ*g!pr?9>p zF6iG8F7=;2?$Pvr`?wvhEdOY`Ta^B6yOYoIW^->pSUdiMh{5{txv*B`R%7S>i?Hs# z^H}(l5BmHeIGzIWAn(F(WC*b^)*V?TPj+>b;rm4IS}aOhM6+Z@+{XNRo?sJ`#_$){ zQXF5&n=Ax>DE3-xeDg^ynZ9G%ypnQstXEy%L}6fwE5NXOZ?^+B?T~;|wzu0B^)6?E zyY3#Xx@3`=n^7R14(2Eaw&#;?tmA}dGl-6^zBGK5bYzo)Awy3nmWkbwvD7v!do_Lc zH1|UvUpt+byK(smqx5;Ff1V;(z~kf@TL7W^y-2E*3lD_=*SNWL;^g2gMvjw)S(m!S zgl_e-_&4J2uPk)Vl>}wy@9knt$61gl28WCiY5VraXShG95y*5P2}xC=BQ9Kvg_&RT za4ho^r%pGfDd_g%aBPN@vcw%c+Oopq1qUbOrgzZh7^5tL2ji|*MZQgpF=BxpSNI>j zF6pf??9lU|h$=33g@$bGR}O>+10wkLSZQ8e>DjKKJeO*gmSnx|yZ~u_g!UMe7UcV%DQDoWRW>t2H5_x4G#s$wv z^-`@D9PS^#x@K?V7;v5}qM||t>sWcrpEvcOvsjB&GPIjNvRJ0Lov85_chfX)%4k6c zzI1Mnys$m|WLxCNOuWMAVI>V^3U}EaceSLjgpIvS?2HqcfwZBTK;%U~gWs>qnGbY= z=ZbChk12Ts#NS$@9@SehlV7*xa#x?7+qgRBo@M*axoi@0%cx!w(WEk>mYX#`wvk~^ zf}khOuSy~Ue+wpQ%ONLkp0|q|A#pjL++~5(4htyv!k4oJ+E)S%UDd^_YbjnI{tkg3O%gIv zUvWu=p)ZJ~9kxZpd_8U)D0dTVC^|LXZ=W`nqw|Ph#T*>f6Lj2E$d2kOf2Vr|EG1Ri z(-qykX4 zRbf%8Kxh2P>@!xdWB7Dtq)CCf>PaNFW9AU1)X(mJP2TcaseWaz(}d08aZlKnCcORw z$;bS?G*a7})h7xg<)`w;p&##OTCZ84 zqv9yPiVR4fEp0pDt1+_RYn^q{7t48*%PwoQ!1BdcJveUq%z*yLKCV&^v1`V)ly*T8 zuf7ysc_hC41a523V7>1kVCOm~zpU>RIIIz1R_;g_MnNThtdfIV+HQl5L;M8E1?haP zq`N%YoMs=`Fo`dEBGd~wRxA@9A$SWMRHdCqStUX~{*fMhyZ^F}^64ji;GSnT}|-GCI0|7<`7! z87iNf+Aeb~KV@u;tE?+IE~tjFLZPNr!PMRei_j6Azw%(Uuj~1+$lL7fil=*Cx5y&~ zK!|ZXjri-Ma`Dp+%UB&sK1EOXCUadB*_DLn^tBi$>_|p+$S@L#l<0=L*Fhx2lkq@v zN9frWcy#DC_Tr_-yrJ_RkjgK5(a0|24{BLQu!)jdETx}w))DvLfWm! z%X=4goN<4bLdr0ba6zAw8Nc=gr)zfhOj8Xo0uVSD5?He`Xb`1g)%K9E!?xJX)sRNT zp4iP~*U}wAI?8PWJ#lQQw0*DUI962~xRvU_NqtuzZn4eSs*%v4QP;n?yQFN=$n?2m zd-V;wqk;+aaEj2T^&AuoHsuNQeB?4#TEQQ){I|zSr?0vo*EH z?po=WDH*J0G7g#=Q>O z$85H7h8*qjVlfgG=#=JT4r=_MpgYDR4uk1)Sj1}Qt}=)&h$Q`|t4#Fj%vCo3;VKU= zQ9*Fft}?|#Uu7F_^_Zi2FiB9%h92iSEvPEc@tR?+T50t|%KduKi<9OGfc(8215W9bwzl6=c{q_9bjiCqg?ULT67 zc`+(g@yo=*hcnxlTQDcm3Lv;xe$6(N*%_rGch)-Sv+NBsX*;hOhisvOzN3QgM>}@K zk;>+y&FJp>f11%mK!TmDWr)nV@Z5~<3>%D>(ZjE`tTkr)gP=%8y)dE|3}v)nQ`!p$ zmn!4l?uD9VDUOD{(^h17p|Ft47FQRyACfz|J*0_HOngA#%(5{h!^eoA%~xR?G`U9L-OPYv=04D6#)oeo&LF+iXZ{0F~v99I`0Q+t~t zP~1p5^1hX<^r-nBwW(0CbcC7MzKp31^qQOCMNvtz_GZQ0Me3+@U<-xRU7hEi@!}{x zpy7o=DyU)h3d$DV44|49+byCy_pNWQp83`&l3%`c2Iz0T_3igTS1u~q#qm|mWi34g zgNq@LJx^6vtk%V1N8ibI@V6e@Y*uMyQhJ@Zmzd-(I))T}3mm+?L^3fv^)l-(Jc ze_F&ljmVG1KE8cW8Gv^`2vFF8XoXGAkj#1g&3TaaV9)!(Mqt}BeD+cD&BLOgROUg{ z<1)awj>%F-0mgNtg!UD*am`|{{bK!5LmaU;6^@uQ4|qh9^R}W7k~G?j*A7}BaZ1Y; zMa0yei#m_Y1_oL5LL#3(smCQN-jy-^X8L2463_fm{x)Ahp}90*RbN~LtZH+@@S0T5 zQ`Txbb!tKqU~W^1+is@X>)Nq6(uST-Rzz#Dk^bo7YWkpV1Y)+JP(y(6plgBX{`T@& zkk-$ouhZ#AS|h5xb|rY`*8Y{r0k|Z2wNBwS2hb`O;~)mH=_3gUpS_(!nh8UUEAx))+U-p%Jzwm?)P;6I?=8nL zVXKrf7$!iFqkQ#~MKi*$7-H*KC6o8PVN^8!n9-iv!Xy)t;$j;(FlZ7~V?KcNcdB1bf#qHAil5NuW(&21O9tcS0KxaB7{tcN*_j@ho_Mlme8#lSh+-GG>F60N-( z!F)@7&~eZD6ne3?5(1w!y+kpT!eDpRMqUDccEZr%G$s6v$1(?nwge=}!IO0K*dX8N zI8}1n&`R0Uf1jsZ3vG6fL}Lk-yfDQAet`pHhN)sUDDrZICN^9XvH8k{`e+T@2yBcf zEPSn>^D}>|1QjcFX_SZKb}p=`DjBFo<)t3Il22O65j&h);~IIY4%%fK2ea+h zp3HMVha)ly_d~0}yejA+&gbWm-Ki-leX1zWV?d`fv`Ti#HUT<4L5?{1@y?k}m+AN! z=WyHOBB2bVSPt^u-`OLE>}M-WB1gUyElN`rsQos)xuudCY0kX?Z_6n|&u%^_eSS|H z8Ho{r9fmYdp_s|zmv~sbr>FiXz?iK%Q#1QsmanCb17r7vZu%|d?J=egiI9gBC*`ev zzBVH)iOG(xy%cz;Hk(5nkOrkuM@2QiQ_RLEVi<3m*GM~?<3p42_TKO0;*Obw(Z7`X z>wL6QR~h)WHP^lzQRY*z3P3bv^0!p(a47v;0M=xA}khi{mXm1`fKQ zUn_==WRy25cEih=q~RC&SQErQvwj*CbYZD_Z`i2OIqq^ct9e&xOao5+%m40H`r^2M z`=@db!EFCcxerdW@Io6wE60+L6W)ApntmzEli|Lojah@~(t?i=XZj4z#`%C$()_66 zkvCx0twfl7Gphn;=}gR1B(T3*2*qDqdEsg6);nxoOK6>hDiCWYmNaXIHeX7=QeDr^ zJ;9usNBh7LlxCTr(+Eo)n93>9dz}kpKyaWmyI%B01NO{XFp;}TdAx;HRg}T@p)yR% zmm(0EhZEr-n=@aW!ECHaG3Z>$ixfHaIr467JpdPdFl0WMvQDjAU`s!BBXfGK2<=?Y z10vYm45Ed)?hL(ljBjr+#HdSP^z|fgL-=;YDl9K6bnk0yNjjz@D?XL%<5^Jddg&3<;eNxtbdn5ZB7_IcB^U+HGvl={DR);`)uFULfzPyrlmhW32W_<3L z_rB6sjA;?+dT^BTMJ4^qu5*`u#bTt?lyc;$bo!+{11aZell!H z80cYCp_UXjx?L8tqk6K^us@Q8Vjnm@tZfWQ8Lz>kU||LGp}lm{OpQ@H^_f>CVFI7o z&b{<;dP6mZX79AvCjNSHws1^sRba65_=wN6tWmkLK@$=@D3=R(>6AJ5o}m-Qm(-;o zKI<=D+gfvgLxwB8#V)z8;8@?XH|9+r311+iFUIJLK*fUBihNex2w zWgm?uOh2>h0fR6_MKRedcu~HGK0)4ukEU=zm+SFGo#eX=_k-Aum2GMn=eGsLv2RGz z&_E2tj7%Ls3X~F6?^sBMGoJ@Hd^wz%FB|T`6&)Ot4yCHfYp2Fp$|B9AS z`bY@bR*LB}@N=E?;Vnd`qb4GxdTude<4$p_LLi|di8XRgH=$wL5j@{Dpr9lCvN$9- zs<{%vuGWfVv?g+6GG?;gO=(exRur!LwjSiQc0rSkssIY3uZC=s!L6Jmi0P z>iaDl;L~$YeZkk4IF|#XAhYr_ehN&?+V;4VqvB+K0^aZBX0{c3%IF**e6gY{_=6$1 zz(q;?az7Xwe+WKE#X&eav?J1TB>5ObOs}5O57Y%+vSNvHNV^F5auMn_1>_$vGacg_`v9M`qR^ZMDRfb=jgIc`R$|^GJKe-rG_A#-kFo-c2Aa zWX!WN?#Th$L(v{Q(FKvpQ(%-A$uZ6dj}QzsI;Qa$ZpRsqvwxzQ1u8br_+SZYp(Kwa zcU5F{Ae>#L=s0FLc?|e?Ce;|#I+k}UQFdzs^|BSD%Ew*nK7qX-;{H#8mRe8bkKHRE znh!ri+k$?tiQZb9@O(5nX5QgCl@DLv#7)UwS-70dcI(PL;*=k=%1Kh3W$&!-DXmSL zDf@N#s+$pio%D0t{k~E0{+IVYh4$W?NVFM;;^#WniJ|5FZ^-f$+PGNp3s=GnO8Xr} zH}EF6n#==~0q_*=#)|Q3sSItuyk?RRY9+|g-pBz@Vqt=+ixVB~{a*9Rct(o!&BUf#Ld$b#ddRycid!chJ=+cW_R4BCl1!@Ge&yN&@QXA_~k zmEkoo*Wx_V`1KRSS2=k8U(NV6V3oy>d`rmXZ)Xwi??kO}dap9pm_Ch*V@EENv}7P0 z6RcSZ)5;SuUPk3t)IfIvDiRv!6hF_Sz^pv}cd@=SSSo zp1pZ2Gw}h_@1DKgkny-gA}y;z%^e`(-4!$}y`zr16BJ#*RNMXmKF1Es-W_&_)ypJk zD?=#jZcaF4y2X(f1+8EtPQYAgI3YsR{Y_Tb2-({;*1VkcggnQKfUBS5UTMR6wyg!y zXm5Unked^okby)=LblNf8R1G9y@fz>d`J?}rO{v>y_|Z2X2-f1z}cT>Ts6SS*FRJh zQE?QWdASoKcDADBFxQ|%nZj@z!IG3-xSuIOUfQ(3&ZH-3SIe~lY;;v>X_d;Rhff2M zn(p`rd6E6fSVVsoS%Qx1OXw(^{E1Zkdk=Ba!$$`B4#)5Ox98Fb60O)bQ^#-hxQOu< zo@~6gH@&==4%#2RuSpRhB7YhE%MhI-fwDa-V*&jnVy|Y{ai<1u9ur`UMBAPNrunrRl2SfDX@s?y{lh{l06(&KYvTH2g?vhnH8jY(D*rgR69$#lc(u zcO0Dg=Fd2|tK?Z69Hjkc9306m$@*Iy+(lS%Um_zemH7jDF3^EG!r>LFs+yhHDh6Bl z{{F*frh)}glnJ+jH9+g{f_5LHH@-N;ES_(C2{p<95q(bdu{>R9`+ggYZN==0s{RwlnUt)r53^hA8IUS8U$P*CN{#H=LQ&tX9}`sv8CO){tUX4UE-I%m#gBpVrok{pLM30VXqxeyNNf1`(I9>?)j`dubY=F&s9k z6hT^B_v~;ca9<`P%SPhsl&pbMj&0xbvccVfJIYg?qctmFzI@&7Op2rGuIpEci~Ax3 zcf&6)uRr*fgSk3;1KyqMN>`kkM^fFId%?~qhtSdB?F#&1I-;Q@Zt_&a2FwZUMHQZ3 z3iczvGhL;1*kGenPM^4i2;qbJXFN@HF0OML%VOd|=)tgD2^wj9An}zHTb@;xM{JRv#U6GWy_L;1kBg!8n72MmlxeK+UEyJ)7Hn6|ctRhLqDXNdI%M1EWyPlu zyufAU&RW>$8Dmexxd+L}&oMB`F%C{3Iqcv?(??aEqNUr_pm{SNpZcp6(Azt(O#hJ%( zn)<|k@F$MYqiR$}G&koUzPS;nFv>Iz8{FMf+nLtO{&n=p>L=bfxp9Vrmk={NTqvsI zJ>g7#mp#XX$+o>iZW)U3yMb*&USS!NJ)ulXxl|$EvQNOMN~wk($+o%GV5v{_!D@i` z2X61NkDL@z2(5Y|YI{gH2GTjoS-b36p+hEA{bL+ye<{Z!Cr~N7=rEa>2z1tNV0Ff> zj2#)@bec+HA~k=}LOXQA_wFRX2D_)6xnR~Dw+kAlf9hH7u7U7CCE3gH!JQz0AsD}5 zbPK1VkOGQ~i$iwwM`tokOtHV8h3?O4?;doS%Q8^zE}FP2=S~j?p(gI^a?#}+E9O<0 zJr<67j@@T{IxGr?jGvJqr8QXN=zPzlHKCY zTVSKmcFrHQ6^)gFE;*4AgC-v;W3`qyw*^NLU&b=TTPEho(}{xPc-C(@q>6tZVFV}s zVQ%H9AJ*?8dT?)N?AsvRtfr$V#wUSTlEo;B^MtB*{jrm-R(Y(J!Dd!(r5d6x*MOFb&~ zfe2>#J1u>vyOXo?+FnDK3Hfd8w93Jztf>c& znc#GHM&OuJv?944FSFJD=!(!(d-Tpwbf8l=R_IuP#%12=W&+P*ns-O zt)$_cYRJW9eOdNZBx)#$lQ8c8-6cI`11_W9eW0FRWy{Ge3}lI36m!#wm5?-YQ;HDtf9@26 zF=iepx(YR#V>#ZfwCb+O&)$m5j+Et2xF^jXyb|Ht4%JV3MAws!S=mBU3S^47U#L#T z4cPDMPG+fCK7`v<_+Rpfy;9!wP;rxx26dwvg^e5S7(>cOr73uq;K>C~-dG9;K+&Ly z5ib~aU?zj|)k^RB$x?>M6o2$Q6hj9eO8wdMxTA*dd8Ga5dGt&DN6!Nmsgj!;*RJsO zL8ybySlDv9>yABU=!D7L+sd-;w?vwFIMhidZVl<*&xCmE`fTpO2!cBp_S%&_v7-f! z&zc_lA7bXtnjRC^g2pi`H~4y^c6(`w1nL{<$1i_91hHgg^|l63?L z75idGXGIWY8P-oK%C~B%`TpQLj*BK=w-(*UbGAuH_FAKzvxCF_apQjf-Oku@LEAHIU zPEm&iMa`9}?eol-CQY4q(K@FbA4QL<{2C?weggDJ>Qw&hkx2TtZ1{gSVEK617S#!! zyNFPjoo~C2o*~VykqNj}LUX?MBl}Tt+|BB^HJn(L8^&&e3G~}L15)3>qP@Pgz9%A| zSE-*SpkC)Lc02a2{j7TWCJr~Z9)OHJPTAB?DP&h&OGqi^7VLr*;IZu9iBF!(J{$MB zRW973ArIa#T90O^&$KnM!A4Nw+Hup?f2dMkVr-v)>s&fEN$7|peFKpZn>{+zmsEkT zlIhTsFo=C)uPbc|VDhnu^A#joB3=!&mAr9j8p7YGm@rbXIB*a;4I}^A014{+j|RvP z3f%yKT^9YX1_*^tC9fUFfO^M09Kjg~M)a;+gn^VrQ@tS3M9jBOrgryw*20_S*mOc< zU*sqFP8%mkG{>3Q{MhGRBfE4WB0#jZ7y!rTkkf&t+ zw=8v|RT2dydF}1evyKR(_<9rStRtcebVP8)IhhshQGe-(6k_K6>WH|*e{@8?s;tJu zIm$PxLYj+BcD0P+JLyc^*~&*=@=BQT)(XxRg@_J600Gmg{q+(IY)lXB#V(&3*)&zk zjI$pUE9LZ|T5T`iIsmaCRh<$))C~Bk?Oh(1WVk^?{4(d0hJXyvAE|oqqd!9J(Z}Wd zqd&3(L-$9D_t5?vB18-t_W8X(^32g>B!4E1lr>%Q*1qM`(_n;t;r5>c ztzDBUscj=<`>28IFUxrWaNqK-LLCf8wQF?>8WD&{euqq{^j)F8j;IQbo4A~S(?=%b zSbys>=f{Kwc~?gdPT6v+2Ub7(CBj+XM>c_eNj;boM0n%5!LDr7%qcbagqjq4llQph zjkpq72R8#auR@}xGAje>EVkE2m##9>tZkx}Bz>Bt10`Xl!PJ^CR!ekvip0G7fXpHiU-2a?cpD}*U` zksk~vjmq(OB}y%rOWRnYj~*pBusa_m5XU$hC1~d%)2)`tf9J>TDBhL9<_`1hgpXCb zd!vBTKE2)*G%?~VFSej>w6_L{F= zUQ4f&*^#l)ozBXZ?r$*Ja&?Iz9A70X7HimZUY+(~)Dr8LrMT77USQZKcdk{1+Dz6K zh(bw;jEV?OU^Buwh%Qpi%99Wk@<djo_0FK}eFn#y+ig=P1p@oJ;RBxO;4W>?0?fLO=pPF)&1}?_o9PJAYgA5AgEr+< zgj%KvtPZO>&ynvhGu`cV>0@42*p=^5>fwbUWn7qNr0nIS3a7xZ4c2~b*MgdBK2OWp zV=L>}#EilX(oP<1aEh~d<~>u8_7qmwy%{HHod2kkxFW7&J#Lzm!bmUQ|4`FW|4CQp=c z_$&tq6S}68KrMA$=Y1NKTp^t^L$4bB+uQC{=st~ARNxWEu(iZYp_3d+K1#Pf zYG+h@S@+hXDfZ*+YIgE;v1<2d#BhtU{GhgfQCUGVTzpi3u-EFFARKYTs^v3e$7#!a zcw;SghalN$v@7Ctv)V&8lUYm1ksMq^VL*RE6y@1_m3XFaE5ZTK9j}PK1j#1mQsKq$#vbSN@}R+CHnDyo1har-ifH3I9I2b|N>E z7Jl%ear>I{+i}xN(A4Y#861yxktpjjyv?JIq^|lyW&>aaBpX=eY@f`thtM%TRxoh>9=O+M+v+7 zO-1!DDW{0?kH&4A>lW-}GA0&MEY7(dylT&E;>sRX;(O7J=-f=fb}8pwhI@~V#Ux&* z{Sp^{k)?f3nigo*Pa^2%_Ry^VS`t_cys_yC0C5>v+2Lb4IdKeU7=HcS({0uP4ccfdXH31yQovxwFS& zQ=C_&!&pvA&&T_MNBsRDOS*<$VTTYh4*1yy}Ss<=T7V ztV;r_wcWCKh#^{Ll_7-26~rtpkNsf}#Us~1rAykQlcOT;2nh)k+x4+dlS`Z1uSO9f zTK4nBu_kRm@dWgg^LW;i-=+n6DUDe2sZo>yP&}od z7f<{yK=EXzhG48PU|Il*r`gBo;)w?uYItymGeaZeQI&SmE7?^0SY}+M4)}5Qpdop1 zO@41Ed#0{olIq0lJCo>g#h73<>A=0knM=c(`gO{-q$|*%M4Ik?-H$#DaA|e<-6s&A zcs}dQ5-Q2%3R`2(O_|q2%d)lG@3Kk6a|WvD*H8)H%t65ayhYmG}(b6L3-75SB}4i!{GS*q+gu%N}%TE#*+V--68 z+&lRPBI$;=xD;#*B5#0+U$Xic;55pnFQ8jVbvfu((iG52vZwD#H-tW$=M`6hH-iKR z)cikM)3}^XXpBurF!sQlk7ea^#WEuz5GARpWstU$wrP=>cNhWdp!iQ5QLJ@fo!5tqEC53yJHvl-o68(SDK04Y}iq#KjbtE?D1A1i(bJqMBB28}iuH zp^^#j0T#ojx_1+^iR#hBpFS*xV!|`M<;7zaWt<1cq6gLN2kcD0qr$O<7I+!%6K-G+ zos!Cj51!Uo>nhTSpk!Kg6){`FE)V$gdHC~HXg^gvVE;(+0z2)h zypSHhM1qk={#ZPutx1en&gV`{DK(85nB53lzInuZX((>^-fs5JMf_6R%*`ry*Fg(u zU`vpNXGg5|kYayK){tCvbUb$Vc?&DB0;u1rkMbHgvr#LJ4cm&1I#4@f?A%0 z3d}$uc0%_>`ndrOC)K(;sb4x4wx)G2O7dD!Z#J#~yWi2E%qaf*`d&W#D|mU0nN`x_iiB|z7pl++zTRb zZ#JJgiBcpacJ-U4b9qfoHlGOn#-%S!S~pZ(uBOUNuJghgr%~BVDOsv5qLS0|_s~tO zm0-0=oG`<{=2-$agF{TexJ8eb3_TCB+zOR8&lmRyi&(AdJ0}`<94f>_OS{8v8w#DuiKXx^K zNdX4Ofzj+EyP4~eb>aS9k3TkFU2zRCWoHF80U6Hnj^(<4IK;@A36Qa_lIlae-a!tQoUoW@lVyHR?0b2P}@xCa-D+$0g zmY8~t5zBuD@71eUgR#}lWHG(YE(Npd$_qlz{&w&I5MWp88NfM@VtvhK8uqAvd+g13 z(r$;~W3B0Xb)NI2|ITPJe~M<6efKX~3%qD$N5hiVBWn_@!~GD3JDXN~rKkGe4>0-he33D|{FDt7KOlE! zq|NF#24Z`n0OU{9@dDNvz`TWj#k!v5ZxHh>|GNGBqIC9}TBA3*kVJDr`$JbGMx)Hz zMGAF7uTlIiuA?IHok28{EU?A@Aep=>YANR9$Ag(sU^!>|+i2%?AE#S9ECK=z0By6+ z;W5-1jQ}KCY%NOSYbE$Wshul6qtqT~;xoOh!32ONEp`BSWRy+kRE7spRpFjZ|M~Oi z4V};pSZ8pbhF{&r_!)ms6fvG9ihahqTt4Viffb*8CYblNqvs{Vw!SXQ<+UM#1~H4< z8s@Bg!h2jOlxvhFM)ns{IY*qZjbf*QEUm2Ky;MKLocJoEz6sVHe%(5wq^^|`BAVI8_H_uM)gTdJq`+tA_ zG z=4mmV17O$PCC{EfRtqG6q5N?c!vwD(4;w%kz4qiPVFfW|?Dy|ie)yeGNncdt{CBdr zM$Y@clf`@C<$d85pMi%j)D`_4nxRfsy!Uyn_sDwL`zPP|`VOX@W0Eb2Nqr1chl+nU&~`hAit`r#11jDf?>nlwGFkeSdHRelxoDsyC5)up zN@KlCB#H;K=yyBjMcPfPZ~o%lapsV|&ah1TCa^W`u>f7FcA#E~#{LWb=IHqR;Y`JU zd71VMfK!2z)G1H-1;Al@LjypuXnU_o(mu>l?UI_U2f)X7)cJ+dvj7sSpoDIBk(AgU zUSqI_pjOKY*UbS?J1&0nLToH8^-Ap4Zjifd3=>8{koN#<_xnkn9Utol@Aa+;K9My? z?h3bX*+b2(!dvgYRASC4(DYov8JMIGU!TL*&oC(SV1>QSdOw%5?^uM1adRJ7>cBifGXohaA7t)!( zKT6;?K6v=wAji_!{{lH~z!~nYU++8td7B(sQuf zpP$*#L;UJ`$g2|>G669=nBCr|E8I))7_0$8|%_ijWRX=1j4nuWR0B+ z-Z|d8APip(>&hm_oR7Ay#~}FqRPZn53k|V$qg`x+s~Pj#QW^&Ugz@JQ-@v%yW_=g!6cXs=5eeu&w#Q`;vdwZJeL^tlW6?yCjY-m-*qMyTe^%A}3&lf>f6afBv zQ+sau9RDpv(NX?LVl;Vc?wro3OEpsW=1u=tqftNyp;RWRgjo3%#r50ixpL(KEtFya z3)2D&z}4*QQ$}`vy9y3pXEbA1{y?Ap`Ht*VIFJl^L{TT&feJAO92O?)OvHKBV@bSt zRnF!jit95?i$2ZM^oilY*n4V!vK9TBul_4rF-8^h-+11>oqzJYE&eyp+vLiu+5Z=g z+JUX(r@L09hAPlcxPMX%M~GaebN8+u=(aSLUHJt_1pcxY4lok`nA+MPJ!2%g>}j-k zy&1bV-o^XyFoXQ75xK;l7YOFP^9zKCd~VMA6^;wxj*}VIoxh)f_rL{0Lh#!Kl8bEY zKrQ~dKp=JhmlsI!-|mke7sz^~Mx#u{zq~FfN|v5xA3WS{BrO)dm>Bjaij;V&ogEv2}+nrs-M+Cn( zroYI+ngjn%4yJqIeMSzZr9zTMjZ%D@8v7Vx;Fnr$J$ap4jz%0^Ij|mgDxUCqNofBo zoY46A?FPHT>{ou!Nn-Kp_08GOk-b8$bFoh}Tk4+3ynl0J5@Rla;W%-DD6=4XS^D-c zC5wMhN^6zPaW$`8XeD-Ou67T`pPJv|26R0V&%%w^;jj15yLU{)0PX&s3{(9@v`+hz zcF%iGyI<1iuEhHZ>}LE0?7sWsB8o>}M85&MDQV7u-E#l;!0!Co zzW}=@{%?WZpDOR>2 zDYo5{TCR<*%*7W;v62pb=|(cl&Y}cVe=EsdjQ^t~FM*0ba2389_VNy~ zN`asw#^QQ~t^*wF;J1P#I2n!X4xKKU)*ZR@(@aAD->q>CxVC1uHtznFa6i^{Mz~LE zWBQ*;Z}saxUa%3V#i7PFwQFa`|KY#BU836ck~ZF7$oeCToToamrpl_tBqmJhr#O^HNs-#ad5lZbH%ux(NGa^f~Tm0|HV;l6}v zdYlcJwi7hZb(leBm!&ZbzOO&`o>Uxu_nuB-&X~J7HU?y;MX0WEE*5-Jmws%IHQ49i z%cT?s3mvt`Xup@3LKj%br&_?!E5ww%D~nO!IO#8LPn!OSbAg8QS-0JTWneJj!Bg<- znP@s|D)EVF#?~E8<4A zE*E~?U#)!qxWA5Dc9M6K)S%bu$T+y`i?k;ALvin^@dld-cHqg@v<+Q0<=uKSQIEmjO&;O-wzwk&D9aATL-2xnG;`Y@f+b={Pos3 z-~IQuuG--Itz%U@@SWYksNmvE(;J>NeiXF!9xuy9NL7CC|KaYf0^$g^b>SpP5&}Vj zy9EdigKKby;O;QETksGx!6CT24mP+32tK$Du7kS;|0mgJpS|}z=iz_2Pq!XwYO1Td zs#bN^s`XX(x15UZ|Ejf8`Ty0t8n>qSzr9#wkh)pQ=rT>+(7JcyI z;Y5G_H&olMufg4Ch_IS8!$a8rnbXEcFfe?G&<1eG3!8@0XEeWs>?R0upxf zNIwd-n~o9?Oh~NlNj>52z^Sj5Omaepdm4>D%(eGtc`%wIb0L{+ex;{g5wSt$z62$b zDl`#uXzoOBCunpsy2?ZKO=&RvesE?YzHu-2HjUOw3kdpI5tyEVxCp zlcJcv1ZM(3lva%pcx5N|8P?eL?a$ir^8~$;Q1TVx-^XtTGLUESt&Hq{_`B95&Hksq zYqS)pw(X?B7pSenCzo{l7y5njpeHyw_XsG%>rCpV*~Y8iZ`nTmMyFfibZFtZF2hYA z@zE}n^e8Q{HV-Wcv(ZI8UDpHy9}Z(s{(&)kImY!6hPiuFSr;ISi`SwI_H`G*ObBbg zKcz`6Eugn03Cw6!tvs!cQ@+oz8n4r6euu?@ zcb5;Zqxr>HrY8;RY&A>7I|^d4-vOQ`avijMy(RnR-tppBVW^aObnO3z^x<9n6X~&dc;X3J;eUs* z#laH)_UOs+{hyDX=I~#5V=J~>Le$dE5*y@J70W;__tRt8}t|V4dtX<_2Dk>^Dck> zEJ=YU_~U(N*?jX@m_`v_R(|R5#kMmghT!wt#ulz6GpAa24h=l^3aXt2%w=Ue~^jq)00NkGE? zoVK>FJVP*2MuQyxPY83XYTzdL@b<{l=f}NNqmR`6}QYymDVD{nxJ(-V00sBnPFj?~RT_`={yujSpS0s4P{ z|E;&Jv=QBJ7^;bc|3d$z1oZ#D`mIfs{M_|gt&M{5!+oQvKal<@ix5)S_+wcth{ZRy7d?Gvc3QvVc*V6DG5WU4IWtK?ly=I_12$msNXzH z(<%wyGs@kOJ;rR^2;UpepId=REr`~5*}I%4}2M=}YLr(vy?%VSLahoikVUzwwue)x*+N49F^ z)2XQNd||4(bzdQtx#Cj&qGl%eEeKVk!mDg^dyC67QALrlbPAMs#Xf{9SXrw1%`;26 z2(2io(v3={Y=Fa|oxTDAR}cPic$7l#qj{^J3RdOi_Y)LDTH0WBt6WXU{drNbHQFo4 zC0E*D5*m4jujTt7q&NA9Ovv9@#b()lbw>g!?>-=LwNJ{(f<-uepc&R_yw7X0v` zE|;lZ3HXZ{X2Z9^Rx+j5xmioNE?X%~+sZvMbS>(-oJNFJ*Ulf^++WBZ6FgmRpo6VL z2zVAQ4=~Q*j13RGp)}$7(<8s9!bh7oq}&EG>(kKGK40>8G&9K#>&=ZU*7dX0l={>? z-dJWPn(LlT)zA#Hvay}Zy*zZcGFWT*Ei%&uvlH9;?1Wj!c|0Z_TA(tJspt{$P4;Iv`wDQsP(ZGg7gd84YUJjX1;eJE#TCCsMaV3x0S{~Ldk6+ z@jiK(Tf`AEl>|qhO@(hYy&Q+pLFVnbJ_XiLdRpaJ+q5sV`fw?!)-!oV;S41wA96D^ zeAR}w;xMFXckAs$aY72L8fC5ZCpjTW8!wuMz7x$QX+H3CSFd^naj95a7A(R{qE@G0 zFJmF_`{OwQ1&>g2^%xc^gve7dHK|G<+J#)1YFr#UHqF-sC9+=1J6Ii8FxymZ$D?$G z-(>qzB>WDwd4&NQ2>cF&EZDkLWJS|ARn_Gx)9JJ}=67|aou>u<_k}|f?g_!eK2bCt z2nrI$M0oqH^9KTZaW(RRZ@$jBmwkGewc?>vF)FZaQ|{^e8plTzRBI~RQa4bM!zX)g zc4*7wjydhQv~@^7VY6gpLNi=Q_!A@(1N3(R%VSWq@bRVT2iX-TO9YZCh6M* za7i}pkBIlm9uF@Dqv%0N8i`clO15tZzT34loe89$7t?U5PMzbW<-F%q$ls9d|n}sv>MLFQMxekT;?!RA^b$eR(5U@!^N{dawyFpsW@aAS| z7@7QGXf^`6COyFF{`HFya0x^D-b)FstB1DCI8S_iR3m7aD{Yf$V}vl*-?B8#>DxAi z>jJt}G$gsscdgC1AIkNe(!|TI&(vS552qGM3fVIwzb5s*)wse1y$J*UnwF+7Tc+>H zY^Qg_`jcA+oz&!C8-;(eZBk>Qo7Em|yKmE~w|HRZ`v#I7xs_826YykSV7a9Vnxxrr1{0b8n=5 zx?xpRGn;D7s*(K~O$_ibP!;VvGN8pCQ^#V!5XA0hx34oySyFcZnH;; z#?g$uPOUM^q_gaREC|7!lqEYTa;}JTgbrw}Yl4=QmyRo9Z^DH=AHM#` zNKc@GN5emy5gl&j!0|344VL;JIjAZmRkSaWo0y;j+D`r!b&**vU#G7lnZ1g3)4gT4 zD}$k?sr#oo!&M39?OTUz!;0|-ywlgpHfzo)DXIau-5~f2Z0!>;_N~^N@`pRw%L(I2 z*o3OsB$8zd%1@wBU+)oZ8!Fav61%EkZ%Mc7rnw zd@jd#g?525!<95_5A`JMhdr@%`HRTf_COgf9=Om!Z2}M;N$O2D)NS=}fvrA0w?@U( z$nM&ME8_+)zH0l%@1Mn;mEluhLA z7ZOnF@K=h#s2Sd$pau5%vsEUxDz}<$HGN3bOvpck?=Ik8t3f$8uERfDm6t#Qn)Hky z0ohdL>|>cr*??+dNkBNl+QB}(Q8R_k-26I3zxywR9(Pg>EcN}eq2qkB`;0s$Dyv=1 zgdi3n+#eUv@ls5wc?Eg+ML*DSco`m8PRrf%Y3DBQ*W}^+hg{vP|5L7WJr*p4W6iy`pMIzdPXj1njLV-fX54}O!%x461vv`b5CK{S4{+S#smu$~#4r3bp*o*AAR^HCZ%Jpt9j->1gZMcEE zD<5uKnJddqo9De9=HI=PSkoT6okSs0N)m9(dLXH(o3kF)*gwP2R6Mn4LV4N9U~d+k}kD>VV+Y8q7Y8{oB=3IuUcNx)v853IfcZQi6&}2KV zG;07y@{L>g6rs99+oy(nuW3dj`l%RG< zE*XzO_-$(q+y{$=<7RxaK7$HV{)*Vr3l&Uin!(h$1o1gVpy<Da$o(pS>Fp(uDz;OEDqCMnEP(sV8Z86pH`oq^TUq&L++rMzLmgd3bd>(Qq*jM zLWsoEzOoThgM2D&f{Tub&70^017#3ImGdH9qbj?zv-Ooj#ZX6oFalcnT6v-R@wwdu z%}x)tTY?TTksozu4d9%zW7TVGd3XrqRrf@BZrf(zWY+1Pnxudn#lGt1xzuZ@>FuEF zy`D`cKy3agyGI!r{zJMx_#rb7bue>S85zyYUXf$WYXB$1@)Jc+y30@AmzN?VykiP7 z=`O6Jc($D)FT$BNVA0nz8GNkPYG%hET{Fuhe2UZ?V61Lz(n;8DRuAON<0JK}%F$W3le&mPSg7-uhnl@b8 z?!!*2b%CZ>gH8qz?Mi@O=h2!2ewSdlmfVCRAGfg7!GA%yq{?84Pafs6&!+kCp)d zxZ_#qH~V^gsJQM%)BKgH3d(X&h?*pC zpW$fNFc83a`Rln;l_h{b3S7q%6}AyJD5lqhyvdVWW8p%qjF6JH5msvuw-E+^1DbG4 z+DWw7FpJ|3MFB6S#~5BnmdvTM0J#ryno*qRTQSEVkw5V6Ed~AC9p_vTK=c$dsCL;& zq}{N|d1EkP)Syk=@aBHvEKBHC4dIqWxG^Ak`fj8DYM{^b08CI9on)3Px=fGh`|jEF4rvcb|@Lm&SbUZI^d}&T6h@6 z!JWf5z2MfV&{}fv$p!9Q{7JoSL6v?L1kr2r;WKbWZrs7JXt571mG9fncWu>CXKT~qwiW?uB zyky(r16yfKnT*_Vn5!;&E5etk5x#Ch0J#+1uc7oz@V>zVG=(9a|LVr=fZojf0RO@9R%DRz@6< z^4v}gDa6-PI~UD(nm*%u%Tv7GrLq-gru=W-Xu3g**LCH}m>IMM46|{2j3Bsay=5`4 zZ~h^toaT|5;q5!$zG#c=v*yo0x=M~FAhypg{Z(Gdi5Y5;!uR@gib??iZ?!U$=Ha{I z;bKi@oZekpuU#iyAbWrEr5(pa!Q0FY15*+IZdK8&3=BbuyA}X!($=SIRtF`FJCjbZ@`XJ9wqk-O}C9{wNdM38( zQ8s5yz8RsYU`TTT2a=ik9+|~vg;$ezCU+&_(0MICiuZf3;rK#3D5xB@C;jmgbX9cM zVsIzWmjj^miA5V*34qh%+$?TuV%d8CA&*kR!SSAq{Xtp{PYDe4;e4}tcKjqGIeJ6J z&M60ErjdA<^eI;PO3!d4?5Pu`*yGZR>QxBto$M{;Gik>0IZbv^-jnrN9jzmc(O($3 zu&H@>+xSUWye@@JJrzpXuX7(mCmN12+4ME(G!hv4-0f`Nc9s?4HourRTe;BerR9D0 zK`yhysi^XVb?I2eGS;Z2UJ}FXK)io)FbZH{lL|M%GDYmV$woo;4LJQr49nE5o>F+6 zxxGt;sJExQ|CN>GkImLEFruO&9oLmoR;O0>1>IDRthf>$V}J9)`~E73{Q0m>t*IMv zuIBgVFZ0Jj`!cY6*}B{7gp{?X@@+E-yE6#@u9-P#Dp?=1_P4aYG;u-Pb-tw>O?`^F z0)Z8`X`La=QU+F7K_Rjj0XDQK|m56QJ|9|LvyT9qf#f?N?X?l z%8A%Afd-Nj>;tggoB{1rjYkyAv@1byH%$P)xcI%k@l+_X0upNrchYQ%B8Rs1TN4Ye z3l}#4KeKk*{5R`0>%H;{4fk^%m!C|g0bOK(To!d)hr2!Zgs+)G8MVoh@B0Z^yhgRG zgmhO64e!vwSvezJ*Yacln(M?iT%iUG-DS#~(tQ}`b~K6}u-5_fA5|mYEaBPul!J;dlP_<+!x$M_L$5-< zlzJmx#5t-bCFB7tL_W|Z8v?>I;l>x+!Gy%%vA{Eqetsyw}l z9CT2^y@d7(oM7zkU<;J5dB1>86J?P`!Zh#qDMuo{?xl!oBnaik@#>kA`ze1*)73^U zOQMyjA;ML`b{SWY8?*OF7btx_UJxtKvDPM995zS5Po1h+sTUQYs$_s?OjIwu31zU$ zC{|Ik!8WulE7r5Fv)7eS6#L2; zx4W(00P(oa5D8JiO*1_6l-AxFFH{mCHiIOs7Mynx$lX*))pDs#k+X+KXVW-KMYXnL zuV4wSK(F_gmoU#;5T1L&v@K$bF)r9k!}S%EC?*GZp@xVpBWdhIp8 z_XijHk{Lbqj21wFW5S(<_VY3>>tz0l*nSOwlA_ua!6(T%Ky-5I^blQ@-|w2ATp#k@ z4CHRLOkWpahZfVVdfBwgS+BL89zmwG+%+C-3-5|qW&5mCw&s3G47^}`F!v&uj8duh9Xcl{HWYcjb>7cB!1hB_1lbjUjRgayHe1juj+<1PW=rT$p|WsslYvoXUs@6mNIL{I|zdu zd>P^DA)3cbSz=q-^Nnk|X}B^NxJQ2OO}9`J%FZ2<*xbNw@luV5e$}pCQNN>@8FKG{j)YLfOdC!AGsGjcqSlzs%ZmN=n$ITDa3{vyCRD~}tb`U0QV!c|;hStX4 z)Mc(y#Xsi23-f|4=df-hJJ_(yJH9jnqPzLBxjp`B-$c&mYPY%5*c@LgphE*g&(qp6 zc&Mtpyp6WYPH|iNc)Dk~j=1c324_t+oMeU~hWkA^t$OO-HW_}FS%`H*P6?Owtp8wP zfm;8e$f*89G?rMeXl;ZE*bLM4j3Vp)33_*jFB8Woj8V1+U2_VJJEDH^0_hcxCPLW& zHh@aFw6p=bU`xKAXJPHp+)`f_3NTT0GTybvT+<~z5_*hHQRWK(Q?hw59R`fOzMY$_ zAdi`(4nlCna6(ulqjn<168QcCZ~b-5uW0_~NEp~|7>K9jhbXj;mzgR4EuKMAKyje> z<|wNm4(6^s+3~|N*aCPg2tcni@npivG2*EgWdGWYAONPe#RSpk!lCuAzh`bzOP;B)RxWVe{nv z#6*gsI|;5kig2Vs3|Xm>ZRthkdeNVnOP;zEv~s)(|gqT?s;}b@rlV;~IR_CDD zN*Vm7PR!3y<+TF$sM{?h*Mo!!W#iD_0jI82sL_l>rKqJfTQ=5@BA4Uri6^nu?^QJ; zg-Hpd=GO{lW&lz&h4_M(5T{=-)v336{vo=uQW$RDeLnTy)Y^W$s$Nwnr@$qyUIo04 z(mFxb#(cB<+e*;1bG!HLu+C4&X--<+3Lo*JY>xeC_E!FaTaBd<+|R|k*kikOeI^)k z>@mqG#aY`7Fw2w?KBza#(8apjFa6iSLUyj3ck8F8OQBAHyxrk!{#3AhGKr_dt8coj z`2GR?-WzOmxu*)b;gA-10GwyG7(@+-C_4%W$!qW12(cxBPq_bI}om;BJ= z?E4!jd~VY0l{_cJ4a4o>VB_gEiD0AqsAa01M+0@GS$~PKhd3ds9a52N@MgZ)XPv%s z;Jcp(Jzz}k;?dO7S(eOYpNn9+yI#|!Qj;95Aa!}yaNXUo8pEB3k6w*}!#@@?644F^teve&OEszN_w5`K7m_1nT8M{hPp z3yAF-YE$AwAm9+_t&qEe$>xBCEeYh9O#g7L8;q{pz+xj6g9 z+W8xw<<*lL^`OCPq4Aw98?L^nMehq5RMpOx`cQ&|Xux7nMW#|Yc!KnRuYPZcmy zt$tQT9Fx&wEb0VOZArtT>vNKpS!w*S+n}K5E?nZVtl8iuo6F~~5pe(H05T=Jz7T-$ zZN6B(nu=fpKi-~_!=Zb zj?}0-JAzoqi)DMex0TZPRr#aR_+Nsa|6@R2j{O;sDR?b~?_N@)T9yPdzmE!f&Z)rV zeSoZ;_RbN01b$9oR^`67*W`NhTMpd;3u@HlyDFy>c)gS~Sjgp)>XgRMu#m}(e|GWV z{%Jw>=n(waV+6c2ms^YO@Qfknk6mAaIf?$3k`;otPV_;f>lrmFJR3I<-VNEsKYjeI zl@|2;PYCV5Adk^I{Zr+c0gQyz z+XljgySKA@ikX-BRa!gmRJ0(U3E|~yO{&l=?4l@xd+Oj>J18nzBtliDoo2FWBZV@^#J00t1@%*B`kJV604(6)bg?m!eJ0_h@4*_47a#M8kV&CA7G zjrHgY6=!da5EUn~iYX*6{_UC-iLFPa3Tk*W((=f+MguEWuVOsvF0D^nt`pebSgpNm zuIA7txM*YS1>YIFs=R&8esa^CImOM?yZ;fK;3N4JwYyt7__UZhjRL3FXXEt^Yeji% z3_8LMYds4YGP@x@-h>Cud5>PjhzUiFarp$z(yA?fzfS-J&yH6T_GZHiA%$g6Y$XbU z*Y8;U$v+~~)xz=%HfugEqf9STiFxy8*|Zos4G6Mf1hcQ)-#Uz!n>X0LFXh< zw0}W)Y8>LG(W2Xi9X22f2*RojJV|1YCZzONkPBh9^5>!Av#+jI>!+Kz^Dx8S?K(mO zVrvWZ=7b0L)7JbFBG2j<&5BXl)KN10P}ILTcBL@NFtHo}XPS^iMM&GGsYZe)UcT)Y zs);zD(qDMfFFPUrTgC5a&4WW}te#JIK(DC1}weGOiza()^IA*&_tzd~Q&OM2A<(;wlWAXfZTwRrE1Sr=g{#`xUHDjK^*m z#YaxGz(-Q#IX6?+KSojq7e10hXO=WjSelXakh6JY?a8mj>q*K?Q235qzW=V8jj#0g z3zj$cQ5P)S$&WqvWt}eL_&u!=n`}1esz7KKOmbI$;Gj`uzh8gyF=CN3ye@E&Qy+PR z-es22l9VxK66i-}PvJSt1uWT}|K>MF_^>EwV^*9}L=}@$h&Q!8Xtls44og*Zb1Hyv zo^$flK*`e-$c|R@xYD9tm-}npMLWu!&%34+_q(}lJ1@B+Hc~+qX7^AA>|+j)2kg}r zq}^3X2;-K>p=fbS7jo{CR{rGE3LE2>GHw75Z`2QtdwCyG(&tB|1MHC;7x!XPkxI0I=k@^!&s4x1#o(Psjh63cMQ4p|4)uxkE2=DUdUl;b7tGSf z6G~>W%Ugq4xVEIb`V|kbuHQ$2iK)#Q;G9rI7Mt-jx4Q^LmWI6X*wun>9l;jf)SpYn zkC~}I@8-BgFbtXuy9DkU&A)VmZIDt2rQqF02eD4a+KGzdciW56cE(U4XC+aXb2D}B ze+-2`l|uO4-Tg1m;bYl6X118CB`cXcB3tq0nm6*Q1i0YbrDyZb26OUVlPRCN5!o4q z2joQul?MdJr4OR~*iYiJkcB%)5-7k{#<3Gi3#@j>jr?FJO>D6hwVSRInFbF3`Igr# zMvUfe*YT}FtQgQ3Qt=r9k=G1&58b(+JQUTrKlxewtcw`08Q+WgSdqfxSFs{M<6??H zh@^Q8+uc(+O@O>_6$wpaN;A#nG{choov}-Eil>upZ$pCs6vFsKAy$|er4H(RU;LY6 z5`&9(D)sQq`D3otsacf%F)+&M*eS7zowj%iqsD-fKtYC<4}XEgc9Aw9P~;6!k}XNu z^-Gcrz!xi;I5f57-Ia-`uw-xodmkxa(~9-8v7qI3p6T;NVT#FFQURWn&|jp0kO2xX zm2h|Kfjpm)#x=OBYb_8 z9qA=@uoEk?4MF^3b@O>DcT(Vb?P{d(!>_jbB`fxl2yJCluLi?Gtc}8_MN=VDA+WuD z+T>b_Dpsn1%(ADEqK#Q?!a^DOB+j*+U4XcoeuPAB^X(Y$ed#`#L4>#)jRA!+3Dz{{ zhe&ZZIXSi2ke67~DH)l2{PKZ;2_D_4kXegjleqFCF>CbDQfI zSG01Qy{{h=yswwx?QqtThSAoB-a{vMlM3I{untq1Zmya0s-|D$zkzYYq@lMt0It;)`rZZN{fFrfQpF(W6GE6HH<_q3&=g3w>a*+5==?Q zWN_Ik!ZpMw7jZA-eWU?oOtm)cY#ipF8+F2Huzy&llAnxa59(;dSI{wDB8x1Wp6HvqiBy^*;&J9-S+9Q zz=Dw7)s+Os;?vF>s}8!JpcLc>6n? z+s+{qO}P`jUp?Plde!%TO);y;u>s1i>y0j7VHrKwH$9o-&AbE(2M)N-PsKk6*I90r z4`ZaWdygdZhc3Z_gt@<-1g}ZCK-7;D#vrZ?vxz%4NEXb}TWE@L6W#$URD>5jjB(7_ zMv>qz6!rVoKaG?>3~t=bE6dQ9Wa6jcufkLd{V%j7aLH>r zy`6L9DfEFGFc^xqWk@Qh5;t=W%^n}X^m3B<(D=OQtwc?^ErrX-fzDEj=g@5A<`e6Q z#mr+SRK`d$7hOy=n!!5GQ$+2&?Uw_!LfCcx0>}ypmqhgBq3Ll6ZP< z4&rzD#re)@>c=^!!n=2`QHij7jcB@C05#@QBQm98+GS<+04!x&=ookjO zMeSeB9Pf0$kJ#+*^kiEv_R;h62R2W4)(LdUE7mv2k0)UC6JKc_Ziy=Uw^7}5@i{x# zmz{UG;itmHsf?5;p64b)2R?dT_LI?GDr4 z)^WVbD&n30m0>Cj;rN1qZ4`Gk0#O7mSub;@j%zvCpkX5Z_StZ*d+Xaav&~FKFHXt$ z0V}6cbB?nTPm;O|g|vNSy9Mvtn9P|3B{r^df0$k)aP#X;xt%dyUrIEEyK$%SC{+*e z7c)LE%=6byjf94II0eMG!VAFS2gCHA@l*3h9F8?cYC>CG{o(!{!5 z&Or$a*%96z=7qL2mwd4d8;%S~UfQXlq=pH9Fa9R6RVQe%>^JpGPlyEo%r(W`5iGja zBqw?&Wo+qwPDwwXX(gweZ5J#|Hkxt19}=R$D6R8Li@Y~?=B&9#i#+?qbDUSjT8!CU zn*|(0Yu+=LR6yHA{#PM|^NQ&in4|!~z7-ocph6`9TTS^xx(J)^t!r;lTnyl;aVlH} zc44W}cgL$Un&QyH1&VyPF5uuQ<_eLI!;L1u(YWcQujEUSd9o(cS@0j)?+*0)&4E=^ zkz--pWZP7JC&{d_E4SXBrQxkSwDxsL+jmM2i5;2fwCd95ctw7kIT|%OrArDJ+=5@Y zdiB<_1B0)71gQVsPBJLNIJ(5JR%+pM241MeD{QtYF4J!U=O2P#Oncj`efHXZmImIM z-hou-K+3DVPA~8;4~=^RrMq@P%*E-L_Ne&dh1VDRI}mwP{20q*7+QF==UdlT*ayfx z&Im~R$lYAcg`=Zkj(9>WR6b+n_(xiFYcJ?+>_kzwGZV>+t6ESHaZ>kmwLcm673_Ne zrW_yh!b6DMM<2>AbdNa2nCu-Ltnf`}gY7v4s;QDKNnrCW_ns6#84-wQv1i?~p>X?c zuljtT<=v&_ZLL9UjK0X1H+}}2jIKvmR?{_5Vf&hEWcj||c#d28l5<;>dRo2U@VTH@ z;|FEZn7PoVGft9E`c(EVBk4`}KOE*9Q-=nme982tKrQ}S+jR*tPh@y?-5OTmlzT1} zz3B^zD<8)sK3mT@q&G3~;<-MIS^)9w_lflQvii_%eoyWD8f5*Rf=1eZf>^HvT!1TQ`Rd)G7>>#vXK%i*2guNlY!G!BY`^Zc z3vM&eyiFuSUw9rIWi(gN)9((EX^Z^v*v&36l$dqfJA75{AgOk!cLdSubY-Hc7owaU zTk(s{pG}+BATG2ib~}9Go+N*)5Vn+&=ZHDFK>DE3cRn(M8g`nIXNa+}u(zlmd1^Py zwKCf~b%by}7m*8~A|BXG@iY4sL_rVsoi}=AtCgh%Jh$bL%d#_3JBL_eh;z>RiK>AI zsHN0g5MsitM?9-`TLr8m4|6)s7j$`MiiwtQR19Lwe6k19c+#!xSBPx z!2_GRX&<*A@4mcp+G~$soWj-(vGzH$?*l6zC48X@yoC3J4`jlStTr#vXV1)RyjnL@<>#oJ;XjgHPhU+E^rRpBjunc>#L)q%d5R8h{ z36V`#xqJ-X$bKtv#nECr-q^_m8pv%!kz5m-AFy6y-%$wg3x(k8VDkvVa3~jzBBdg+ z)B5bUcibn>oYt?stjvCWYq%Yozc(--!=P;+D~gPI*CEMq!|9(+Aj-urv~&XF6rHgM zDN4K2$EaDx(g-RaMb$o5QIc#ZJ_7Zs_tXfdPiH8En;RZzIZnQq$87bZ{W`my#ky!o z?j0&){srOd4BlrKV{*4=&qVe~+N2!46cqP6D0zHkvM|#Po^~sci$;Y=Y)!ib2GV?~ zBk+^8Hz;FwdhChufq_PV}pbCb_Z%ODV9r&&KI? zILdtKi?MBH@yhvcibw9x+!(0FDvK1i8`*|E5cCDKdj-(Jev<=`;V=91Zy4a-PCTuL z17SMinN)*|)D&Ut9m{Yzv2%kCj-4ZT*9VS23*3mJU^>A7&v-TQ$VXbYku4Oyp!VYB z4k`?;D@r98I%sp!o|}YPY~Ubv2(D1o`xr}Ba@4odM;E@Fg%eY>PgQC=JSYPeneNWBO>Gc zP!!eUxx$v(VrEbcXKT6xP#!3FzYnW21P1voDDBc?Ub&DUVwiN~W86iRJQukFDZQ%6 z0%v_AzZ-#7Ous~gvRu3txzfDF6uD9eB2)~(G+Vh*^)3k__eO+X&v}-_VvAg%+5cFT zi1C$j3nv?(>~9~LzM@1Cx$^xo_52wk)Z>CwjC%nx!VJ`gO1*80FdD(g8VK8J+1s5B9!V+>B1Fw z6Vj+&)i{*#B0|aP{n_ursQTMI7~nbnk}(f@61)v0h|q>?Xh_1u%n1sEGyMY*X`; zl+={1^eKnU)hwTUHWe9*SiTJ4nNWPQ2RG%R%EH&QuCome(;DnoAOX>HXVLa zq!PT?4#$KL;~5paEav=7FFfM`K15UAY9U!bZ8hn;81*J!D>B@{}Q6M+o zS(-jzboNrS-HOfNFTfrr%Rwr68z%K0in>eXRn9}o>2FQ>mX~@@Ui9rZKSBgvYG9Mq z)xl3$7in_cpi_wR9asWlzRkEy5%`PVZUk+FJir#SANOzMWJ$d;0}TJD5r*V7>9CEZ zO)>v?cb@Q~Ml`v%BcdFm|LMy;IuqZhS(m6<`e>F=*mCkcdjDniytkPpdJ}2PevY*R z#jM!7{X(PZi5J#o$z90hR(E(yqZClFEV9^xoNiQ*!3XwpCY|xfCHw9J|TxBaxJr zud+CY#q^yY#;T%MDBg#hY-o?i9V+lsFIm<{e|PU7XZKU+hTIIXc*I$WF&z$l4U?5% zJ=1*u;${#vPT#kv{wD=4{^PFgeZHBM+E2>`WC?d^JtA!c=KPCWqu{a=P9X%xOcE*!qk^L-#_9qI^kqLkkmi zS@+qTXHER0{ZMu#7IF(Y^z6}uPn*uWC3F=(hRoZSCH?R=JyN=VrwtuXu;J;yMt-o9 zp9~~Q+%3pcF!Q&nx_xWrzxxV7>NcrD9ebjK{Nc?+M{#}ZV*zn8#q#rA!` zw@GkD%mG8f=n9#$BqUejxGs*C(0o>D6o8a$3^ou~c~;;9#5a&xANW1#&W;!))rA}A zQ>z~BnX)u*m*UU7!c8(5nXglVTG-xf^O9*rI_^iBjP+Nu_n@qp@_Y$yY6h#;?`H3% zHQ38Sh~za?9@R+wu7?dx=JIyM;s}nZpfcmsaT%`MHn*<_6mdzrY?CRW13J|FB_$)g zo(eHXW=vjS`>fcbO_(dsM21>R%ZX2vE3N*)^1LgpAR{8xRQTl}8jTdMee8hG$kz)x zJ9%9@%yY;l7ds#nmmD2nR;ew0&en(G_r#8 zuyYjFEa;|aB24zj;xG_?)B2W3#8EP0nFY$zYi2B?_R_JJTwrH0_2;uM(4wWN&8$s| zrl`emnkOLh*Az0&jN~HsimqFR8KxXlkMpMuiq7}{?8s!4kW5%Ur)4j#4U34N*VHQ> z)?;6BmP~-QAfM0l&m!VDmri~Al1|T*VKhN7H1oQ@B+j&k(>G;*e+9+4l)MNYLB?t8 z+UDv8N+zf-T&zB*?*$&RHVjXJBHXJH84p8;Uu(g7f(cfZ&n_6it$wggQSNjALDv^x znkr3$CRo9E#KcI4F(t6ICB@X0S7$D~Ei2GP$~xq2uRFf3;3P4AZI#ovnQ9gPv2k96 zWFVzyJyCRk#)Bx`Ht}ylRsq1%NB*Ev2EE&Q73`Fv*yh5t_=@5gZg4Uam9Fy2`TlpI zqX8GO{4`J35HZ~I7m)OfjeyQy$xf}ya6It|0JsZry5x88I!gZ*`MrjU`x_?0Ich}x z-DT@iis5jRe?(!8v3Du?K)I2wnf<;ABYT7TOD+Z% z-6u-}GyAgo2#8%TldWknE_(x5mxWrzZe3s>tCE9re$v+X!-)NEASzA z(Y-r_=eZv*a~~~vAMam(`hPOmSNLo!w_UgUEo6NB*Eh-k@1&Ykw}`Hf+O97bju8I` z>%kye(jC-ae`Wij-LBx6$03b$b-_L1&gF66>py5k&0B_AFDV~eyq|Iw4XnE6otK?mp1XJ@#PO)x@l>G$Yx7>ZRfZ+eM7CHiC*ds&R!a1) zHJQ$r+w9@=Z*uXy`W(kY z;VoU25RdiMyJSNH|S4)Qt(=slw*wJp*9cg5F1> zKh5buf#LjNH~Rt9o_R!q*ECq4C~^H^dv`i*rlr9b`Rh}K0jw>&=@uq8OM2A0eLEGd zk|=R$e|blfXue^sx?5FYuFbckrm49!WP8qxGll}Ej@t4KC`U z<)+%4%-n5$f9f2}wRm=J8<$qEZGX3j`Lxt>UAfqDy*zuobT>XaIr}udJKj0Ku5 ztu?^$V+J4`tL#W)dn@&syB=2pt@=}cusb%=TJgsz|Y&Zn-Wh*_IrM& zHpcR}2y(;RSA4a(S}mH|Nn|?ps!eHjQQ&o4U6Ao|g}&>!;~4p{>J zCK=jg!7AqbHTQJm) zehV5fGkUO@+1=2bIgcg7Xp>ZSjEyK^j@5d{Rws@xi+PHH=mAHP@6?h?c~3yeC2llW z-sM&&GW3EX+gpn|nV^6CZ-kadaX-ufh zV&0m>xwa5jOof%CCAtx%8vTu#X7Mz~d*Fv+d1$HW7lc(uBFDz8bkgUja?iWtHD`wS zF!ZuQNR-h-m02nHf(gETywfdu;D3@R?krG#>U5jRKKyn*^-f$|ZmvRAHKdPQfcpjZ zGo+8tKRv^K)?7`MnZ%9`XnYqVT>x;gjKnE(F8 zIK#fvb7idQAhQWs-_Y!jm%YrspDqm^BH_o{G-qC~1qXG>sgnV;RaKZv&T$6@dC1ce zLIh%Um@q7~Ziy2qRq&f-LoOy?Or(%HY9SyBF+{!56iH$5cwmcF;4EStcC#2X$?%>L zU$%QF`{3#&NdDc$qk_D$_M2bcqL8l}VCS=&;7mq1n4BGT?}2blW3m7LBknC=;|jKP zU2|fN?bwdlF~`izcFfGo%*@Qp%*@Qp%*@QpjJK0>=FWLDXY}5au5?wB|6Q%_-do~}(kUH&SUY)4HfOJ0+%TR-H$?XDNRDxDg+AxiCjDNDnH z)cj>c5xz-?1<_ySlD_;FhgtM$9}JAnw4;U947^504xtodDw<~7s)jYyp)$tG(!JJ! zz4QiN^EAzzE3HI@mv24Cpo}ZZK_EGLbF?e?GgJ66bFg?O1vw}_UWb(%RI;RtnX|Cyi`Eiw z+7^HKm>4n0;E8?C;gG0#PXCAN>o#)`p9-I-=^^tf#8AfK+p_+OGd;!0re7u;B#$vc z?o%rHH{rOIwNWKWzivG|{GK4g{#oYeSmw=zO9KpwHRBJ$Y$Mw;QLWXt)&U#+Kz%a1 z`79kgtZ?KtAf_%@D_#7i>XiB`$tSVa7OH{QEkl#mr3Cn3Oz0vdz$?unvdwZjI4ry=ac5c&0gcWlv*{rg=juOZ=9V`Y%ot4v%Y~YWf)O zQ+M+&RYjW{n*nwY4i1`@Hs$$DFrVO^PwZT7;e*}aNRm&oWDbHMGUI4T@a&NrwM0lB ztoN7=nnvsB{OtaUk^auZY3WiENmHXDYWi?d_E+FkF8MfystD(-bD?fq&XhUE2gtw4 zj`zTk)` z@_k^cC0I87G&Xz}Zxw552%@dzKlhTpq%_s{T@|XODxp+`D=y~GbxX0_MD3Zc_dKwHVFzpBXYc)joHT_6vp(tEEc@{ zUj!mxkyTR2BlmbXYhtvjhQ>2zPAoD8hP#oSuZoWx3|us}bne-x=7!7II*g6eFUK)s zUn^Hs%+8BuVb`5kOWmy3MihTv{Vb;%&2)Gq*MuSS%&5Z7%Lw-uES>PE{PsA`m;S$mI>@!y1(%@W|=cINNn*OMc0DsAL;KJa9z z0xPbj-!RSC{?<76VeL@YuY(JdT4jP5Y{t>5heNvTq>8l@y}UDs#I&8rK^ui=O01WotSf9QfKFRK zcPTf1o826UgMF))543AoBNx;9%8+s}7aHK*%q|^5k|s}#LxqlQG7))E^}S-^BqPi? z09s%yixvH`{$8mY>XuSEFiS#rk_CK4Y=%dGZC&)T9psCKcN5Kd| z5aU!0~`y?YH)En-Hg1%9VH4NybHM@9roPE>1Uja(wd|wqzG%&dHPD~A>;RO zlRvt%;GG~QnS7m4ocaVqgbeoMXC%Do?w(a#5C)z=-#1dmf;Nfj8Z?_nmdtaP2|<4> zLv}ajZ*i%Ec)-$_h3FH}`Hg}zrPP94wu0rhyPc)BKTAx7#Zo*;EK^<5Jg+FPJB+Du zlL<{lc;jZ5_FM7BNC@kj0$QFkm*@zK@lPaqc#`vNy-X!mz0=^|b8(=jbSgYI8K4NR zCKgE;a)u+A{!#D&ok6uZHYHY>r?Q-KBM8M|8d8H+G^dS09RB6ixNvFKW1!{g94>d) zhMAr0)eaLrL($Q^63dY`O222@mao={iK#lX=4tFDD$h~ zGvuU~9UO0rL5rR@*LCMLD`@8>bh92G;n3OI;C=h#V#U;hGm?7vzuQua&!PumN3ch* z(cu2xVh94z7~o+qJ#JduKX?2e-6n?NC#JuBfm__2r-Yj#&vTHQug-q#jQiKh4xhH? zXM=X%bw|(G$-?wcnm9LkiLeqcDR)o1IAIZuIkr~|F?xNUc;0Y58Yw)K3jZ7|b^n)h z{7ZNDfN=NlB3f_lvpOLxk!4(MQv7=$MiVqThoL~rhm-&UkMR$1B!-|E1nYKQ4%Yf^ zfyt)C3;sxa1WUETXMN4IR>P9o7sEs)%J-OW8dm~OHksJ)H-mL~tlm&nQ#2US-vQBG ze)Y-M6zeFLh!-|t9(3DA=i5qJF&}z(;dBcGQw<0t<#o6+sn#%Z8XybC+Z)*4B^ReF zx%c;W-^gxQE6{%o5C2^*XqoQdEk-t=Oz>Q}5dm=SwoSpENPj zOq>-I%#Q0>nA6qx>9J^}?9sq_R03YY{ zhg8+gT|`V>B9z5up;GuL!hQy83!(|w!VBZCn2|DFEWbDZ%%MXN(Ud^Z15e?Vb*w1< zdD-hhb1>d+R0QhpHk)AH!6|c+-BHePH-ii1k<`L@jH9^#2d-&A8@@1wuEJ-EvAS}3 z%_HogA#;I7Xu~g{X$GTS{$RRsfw;>3-0SL=Ci6Vd-TeEv849u|hMhw{{K=|Xa=4(n zR?HrXhPy|$M^ndcMyrI#g9ZhGZK-l=dO08q0>se!3m@~j@8a0zz4=1^s)ioFmsz== z+Fo!;uNX~E26Q9fI<~Ggn!r}|&=nj^ zA0fT?ab`>Ym35g+BA38jWqR=eY3gJJv%R&gZMn;7zecE4hZ3hUO>tP1&%uhKQGc&2!vE=PJ>@n8NmhOa%Pf+*N@D ze}Y(qMDa{EThviI$YAyJk@?$8@z>Zfzk^B8vt zW)%DSSLR8R#Psx9dun%#(}sl82J@_+B8yC_fCDCbKMl){Buvz8bmx@_0%>LV#^pL# zbD?&$8{*XbWbmo#eU&ac8*w6hnK5fqmba~{QI4s%_FZ_HrbAOdl zhx6izV~3-E>vu~Dy>aWaJ~74-G#H&~-}Alfn;HJj3L@r=(U)aQ3=WefT#F??yFX586V+dk-@FV$Uh~Co6 z*s2+poo~a_)(PDq@UrME$QvHd^RH=myw&)sy(*-k3Lc2#>!owWkp`4C6D{=mQNP7v z`K!<7N43+hvN=&0=B3u#mgD=oii!jCVv`u}_32YiXyhulwhqVy*M7fMwZY_%pV~Mk zX>LV3b~MZ2C|WujD+t}W@vNVUPDUC?-}2#8kd2j_!_gP5@YIl-1uJ0HC?Oas&gz|J zj7`%Yz*3mZq$)U`mtjRbTtCOGeEAaTD1V6OKqQ6gJB4F3KNEWc#OMX91-kU#WF2E^ zQnI)}5tddSLK#gFydAm15h0Itz?r&o8Xxo}H+NT=o6Ch6=eXX)RqOphiw&cm;>L|W zlo=;Qcs5cJkn-0Xc=gPM7CVv^Y5-w$Z7^zSE=r0J3VgD;VLumsomn<2Ig3eqViyG^ zq?$*lL5}?WU7_7EStUZ^ErCn-wwb`tY*KBsX4jB&We@ess1?Y8+l`u|wExYF&}Lim zMf`bW&KB={nms?qSRO%!n6F%OT_M4^G@jZy={aggiNhBBx)ELsE-99v9F->fbK2?D zL^bmFUk3pdHi@CZnFPtLC_l$1^K&93PpBZ<`Ukr5Vsw84|B4mL{X9?3`w%{T%4Q%M zSvgL=QAP90TpgIy_z36mu$~haBv`YmCA)@e_beU<$-oEOJctqu;IFt*fj!p5^4ECQ z=8|a7meQo^Pvy>kq?8_nn?EB~MQ-4b4;;-Vgo4!mHu&t8q)w2%!>BIdjg|*FTrr2V zSWBGg{zk*4V4zXrH>gMfsslbaxG3&VcQ9D%&G0>@Wa2`5xP$KbI1!)0^Fp7JpMVg- z8W+Ybus;{hY8?%4@)|*~(gu`*7mJJfz4&(x@Dcor??={W`Sd1x>IV`Q{4k&8Ahdx3 zS1i4JgAn?_!f?jD)1*rd`ey>3QNIxrktkp(_|#%WWl#o{nFORlM5)m5F=FNZcTEXr znEFIyLtT!t6P%qBB9;2lg^HsmvTT0piZJMxgW_*7((IhK;GrYV}Gs=h`lxZKHP zGW5Zj-1Wg@8tyn`;l@bJSibWMQ=9&giXRx#pe9T~W3zh!Lj4s6#J4N!+;FP>@)qXR zc-*+{ilTF?NvI;(Wyj^@V<@!RWLM3FXJ}$utT6yVYO=huf{daEa z>Jeh)D7%ZLZ^dX^{=|+8y&7@gDa~Sx2VhJAcPU3}zZknuGGIHyxen-!u{2Hd?kJse zdWZhi=oDm7@$u2JIn?Cmo~O+8ePjKa>RpF7KI_<1B}1x&569leNiV-6_2@kLY)-`Z z$cfy}q)N?lRCHAoi_@2!(y1i>A?`ux>LqaCo@3)vJ4X-M<|dF`aa{u6AIXrCl}JL| zh$kPN+;s6!AjE}rRyq3D4tdOu{g0+MLx$IVRY}*h!Jw96$8;Yhlf&mmt`~Do1J~Ew z&E#Jb&sYk*^diiVstKjT%vscuD2wP*fiBFhD8$z2w46b-(mAut#nVk`xV~E{b2o;E_S0$t7ZG)VgMw^IWH?p)d0=tJFZ2y1jA^Fox1s~ z*nLp1e+#HAhQ4@|xSQKb4>B7L^pXUMJbo5f6D~!n%FuGwr9A7v zWaL9BeD2D6nZWXZA9%57!6kwI{}(ebTMyJRWxfNwN9t+}6ok~;uM&BZ=Q8QymZiaA zAok{{uj<~Vsw48c5fkPe5rA*Z>P_jw%lh#v2a)r+N@D)TNlnd3qba@PAtC~OhyYWg zw3@dsnbpD*6xbBB;ug@KkjMV;sQ&I0FTrNL58k=^uE|-~z2VD3d(h?5ZI0sP`jEXJ zj%qH65FeR@(Q`VOgVw6WV@k_N3rp!k>3N`Yg-Xih*fPv&d%S+9$os7y*ss-F8#cdU zG?JD@Gb(&_j*_-#l)(7J=!06yzU0*m3`c>g!^Z+36(%SOZb&H=qBsfeCk!ID{WD!M zKU8jzs02s?F^g}oOTu1=SzsiXZGi|H)`Hf?>Mjn_Fg3W)XgLI##FS>)>WMfza4Qh|SfL3s0M zO)bzJZ9D=dyP+fl7Fr?4r#H60PgRsyrOVhq6LIUGT8=6T7e79mXTBbs+d5f1x|W#N zy4W12tm%v$Y-?yBUHmEccJwsB+y7{Rr=S*TxP1qsg_s0JMBy!b$Kbd_f>n|ysH zVAa=lu;sBEFuSJnx@5&TbvZJ}OeiXDo#mo@(tA@Qrv<45l5hc)aPf)LoyTB+2t7U9 z5wmf13~t)3QiW0mZo24Kf4RoxZii)Cs@*vsR-yYtJrxKC2$&n_8xR;kjDWkH#BM&> z+%H+Xg!)o}T;hCgdEv5$l z#}oa8lX4lOjJ0M0s3BkFO~(n&G(cdN+QHDNM=eNW?M9;EB{PjWh45Gol~TSXz9GnC zDpGPCNQmiu{|3F!uTRK=szI74E7&>r%L0xlla8r5u{qHJKQ_Wg+EJw|I}t+qs(0=l zl&WYg%xIMM5eJ>$SJCY117}y6Iu+)1Z@wS^T|G6HV9cSH1oyh*`^kcJiV4{!vn0=l zc;UCv&U?x1ai)Y4JDv4h1^Gr9^U&xmJ7bZF-$Ly$_=zbqQ1(_|zE!39WqD>4{fy^X0)Smsq&)#nSIY_ecN_GN%}-WUOW> zTA~5eWu!iSwKbMhDSUl;DWtcnkY^Y--%uuH8xH~|T&gyOm^dStf(NOToGJ(TqwY)y z9AZuekjIa^pXdvDW;XG6N24dF6TNm@{ZM6_%y4_S9=xvDE?6bUQB31kE6q^!FTX4= zxAs;pE0y+(@iDOQXU{0%s_MgN6vHn_e|TixA})D*+hTrgPp}P>4V|upx(&V~o$Snf z{_xB`>Oldvr_sM?TC2cElpY2d9DuQZ7_;4_DSVJgmv;{rG6_}r;sp%&r~pCyPeP3Y z!G;c@o+v{QL!u-3Y$VD=(Z+1FE{LEe5o%cUinIt{1K3hoSws((XkWo-rXE7*@8rHl<+&kHYkyYSbDFpCQJxTjm>p~XJ6@-hoMyg=t zyjt^Z?Cck@Pkp^aE)8XeXV|k+X7{F@@16k5YH&3BBgRya*gdb&a;^^Z7V3F@dGa|wvW>6t z!G6fGTreQ>T3epA{KDs3Uj91`dwmZ3a|DCdcB8c#7U%RD$h@L$e6usTTu$Fs-cfc@ zfAG$C_90pJy{g#2OCIlIF*m^D zl78Z@5+B#;jFJVjoh_cuXd=RpW`kDVQBu}!9FZROq71VPm?Bz~pFboGue&EF#w)(j6R2W?93VrI~ev3P0Q z@mLU}b;J8H7A_V@peSRip(^a`J4OsFMzAJ?g-tUE2w9K9;#z%GjcXY^;*0Jot#CRN zm2xMUr3+flRRwxtSyvCw)YZEKm-6Gk!IxRK>3v(_8IdKKN0`YQ80PR55l2z&dbNj6 zin=x9zI3iYe+l(wu*UDM3Ta+<)J%XaZOf(Su}R$1|ItT3=NMX-T>-TqPmFrkm%(aq zU>SC5qf)P-0?1;6?U|kAf@S3ku@D4-zI2S3l#rY>>GZInjyHDJU}LGo3TKlEa!PKX z1;(Lufe`mdg#-oSlK0auJ{D8T(_M=NpCt>ORTp#<7vHg?oqMLLWOG69c(4PtGDfLi zy1Dyn^DN{3{XQ?@QXe&YPFC43z{rd?ic~&CK&<1ixL57?dT?9nW_=L?Li7T|1qMhc zPfwHKjqfQT6kz<&vRLq)Z_vh0RARZaY{_n)75pN30$6X_=TN!$^4pK1gQa}<`c>(Q zn~6^QmkqL0KWe_Ldztx3F_gIPBJS4VD@uF#;lXn{WOw-_&9*|$l{2#-3(0A$@{J%WOG?i=c(fj)zc>BB@7ABRGI!129&@2%`lAELRhD>61Yn zww;PT#({Nv%f_1xC7_@`b@W>AUEUPkoTle{v9T$;u|21g0aLRbe>?QDEGf9szUMQ~ z-kS4GSl#+S96&Z`SXEzEbBWA5r);?YYJ)6hnnY5-3;;b1P1zK0PfxZ?IFKQM->qOh;9`!{{X_fqG?(Du(Mn6q2vFArVNZWm$ zp&=gLR*cn0N_RmJ9_vFER;Fc>fX1V;M!y{I8wTP;z{@*zYlf!R8l5gd-&tou25gsA z+a!~37+s|~N?_3p)hfbLkamABMuZAeyOvFq=&+;d;h*)h(fmAuAKUKOG_hUJjj?k! zYW996h&U~Vk?zp0Y~+hu=eDq~LYo3?0HnQ)^Y$2CVvB+GWK6}&2ya|~T4e-%u@gq| zWxc}_5VQ7X7B}-VZ1B%(DiPvkXmIE-Ovbq+I+jyE2Psga{d4c?b>k*ck5)1&%b)g7FHafjANj=n%gwvC%Yalk{wRgz=F0;?cys7^V!KNum{N< zriqRal^SwJN7VA)xQrnX@D>Qe|K2P#b>q~}wQgO2J{!bwLY$jpBa(Y7TkOG!rc~*x zBv7$2g(NTd46M}5QAUr0jCrkb>zFF3%2r@)BkG^|DX-b~sY_(~$v3L~4ZfBgY)yit z5LxPcdR?Wxf_+cZl`$6Il~?7|q}I^_jI3G)y2cQ*%xrhgXN2UKiz z~Z1?O0sY$?$Xmbqs*ny;yvxB6o2(SKC9Ru#+}}lv!$~OK7t=du;IM ziR)^jm@lmBWpxN?L%NA3rVhnkzqPE@tG>2Fky}D1c>nD*VY{w8emE!Ov6IFijEfu5 zNo@@AKQr%2JwSANQs%JNlPn)~%o*E!cbt@4__;ARoWW#~tTbsnek@65>_{7&6&O5X zK~Z8c;1SjmPCmIW8@k#$ir-nh6=$wW+zZt+R?9#KU-gx|0vaWo*n8Z*pXeVQZB3BU zR3CXQ1SK_8a!P%!T_VT*u$1@HjD!M7kQ^Lu5=_bVE;zGQc_k7gi{K=VI)F8<|NYeT zjyd}~SD*PIli+ujt}hF8;b9;#cT5w+d1?Jb_hb9x&?FCKR^;znHY4(jpHf5}Yo!`- z+yI-LhWRu=q-K8wZ^TAVh02s~_L0#_&jWu{>68e@{x%U)hD|uxD*F_VZ`)ac;EqT?@a;*4g9;E39 zQccXp8+mD+qx|?xhk4769|!yf-7_vfWpQ};36gDg0)>!4^zDPB-9vaV=oe_mE ziR)D`KqXfa6ecE~b)wpS_-V|Q%T_!TqO{gkvPACecOlLd15EA%+blGm;|TJ`ucye` zR}P9B0j!O`8>p6kinzW-zdymYmXy%^N@9<&zd4@0fou;x1+TtirYoDtxC?WBd|b|# zLam$5J@;7-H+Dks!glhG{;I;Yb^7!Q& zs(F5j<$vS`tIF|{ODh|tbtUN*l<@g09=-svqW-fz7T8}bb^xbC1KQ}B4?i~^E&@dG z($Jejy#oV0bv@dNc28^kU;>Oz0S3lent*0ko&{Sed>!HTud~Y7hkumEJQ6 zj}d;kF+?h+1OsqO$1j^s%p{7}cf+EB5+}8?r6>~$n)lu^-QpTE0JA&a|4wjueAt9O z4??K(2jPm1jC-&Nz7IQ^DXCTG@g_0KPj0xfNhALuSEw)`+upUUq=e0~ijeLrRBHt} z3FHe~cTxy-a2rL7BtyxKqz9cSpOEoSx1)=V{;w$5`=P`DcPG zWjV$hVow*bv5A^fCyE2hFN&E*EX&tFtd}Ql=xTjQEq#jw=pPP`*Upl}&Wr!)bEB-V z9;rIRC%2XM4FD&!bkUn?J45nKfV-JQkV=Rg5x8jk;OOrW>&B zFZinL-;OJk2=>1;57l_~hTyEd?7eDnzyJEGnvYoMhQhz^@bEp3{a@M}5vj8tq;E`M zOy{~eo)8`ZLQIoDOpsa);MU~?o{dC(6#^pwK?Dx=`ulkZ74E}vf&AOCSOte3WMpnw zZqQBL?3(i_2A37(tY;s!kg6Q6hTLixvy=TXI%n=3wn;qM$v&yL zkiS-jdt?sziq=b#R74YZK6nqcPv|MDYIGOodMvSr?J3fSv1shEjCy#Hyi@(LOc*u< zk}kXjZs|w$czliPdFG>MW5(jm`eWA6{I4Uf|3L!0zz^6PUVApFb$rz|UK^@XkJoJ% z#)DICPZSKP@Q2x6$Y@t08W)|g*%|+Z;_tixCPGLzC}n!3x$6hP&i5KO^GFv%r2ZuG z=N}s%M~-Fbhpk{73-0p|Fo&^3((>ftAd&D)&SK$X3f;<{xn0jja4>_q~ znjU_J(RpTzx0DY{W-%5o`DdUaE94=BJtOtKpzEinc)WqOB3+B<imglO`9$iVyx_|6yd^H290G4JWa z^Z5?Ixe5pC$D?Uq*L^K7`$|rq5w@#l<}8NBT+*B-hfPdaFITC6RUZvsb~!LpQb@@9 z*CJ1_iq|ulNP?eFf;S!uF}Q^Yawj(mwVy-rBGhV*sCsL51snb2l?PpBzU1jfSztQ( zXr?21DxC9Vq+2BktmF}3Oxz0^S;td!a1s^(Ojk@6(|Lk8lDH#uQt5y9KOUtB$k%vV zeb@f=Pvg9g0AQROnUJNR-#ovg>T*Jd2e5`GTC$!@K0?JmRN}nAw$lgs;1pCy&W2Kz ze(_uw6_d@b-*0gEoV;Rr46gQ2+;pXj58l6`arkzF`OGUY*XL&dy$_MI#?*1Gch$BA zEwLALhIA1hlzJ;|FJ|iy&hn{oO+G1px$uyoYP;XcE=x*&dzaAJJScd@Q=YMdA^wEb z{@^-j-BNENFw71^?O$#vbGK42j?V{Sa%ZRB1V-t{~9I- zv2~`xm*H}QZ=j6?xfD|VG=z-iTf6SR1HRQYfY9zV|l4Qlz{OO|e?uB|w z46AbO!v5o?BY2}NiHDLQ@?2S_kio#B;OAm#id5eix#NBN0^DZ35LMc5Z>ziuBv%|F zY1Uy45+$v@s_cQZVP)bVA46F>-A#G^G_dFu)t{liVZ|@W!~O;HRE+}XYh%T|U=dr_ zv<2Y>fq&HkA_qjkcz}@S---nu%H{hTj?}MDa7I9E)cq$m`rl794gP)3avv#))24%3 zgs2a9h?w1BTt*mPM)=3w!DYq&IPdf{I>&^AgOBw5=_#YnpIk&|lLH&QV%;u>kl|hm zO8h~H*BYe4W$Nj0-Xw9yj*4xcWK=ckb=|hbyGZ$FC)6i|kLDhmPNIv~L{#k1Y8c1g zK-Ly^QY}J%dnMl=*xIGhD|woBgd|qL!QO(ooet^2?${TyM(~<(sO+NhNQ8?f_Aca7 zu|*n}+H~by1z7aRiX*1gSPAm;fGJ3<8ty{DLVa#ym{T^jSnt<&|24tFgD@a$-@z>! zCm3u?sL0EAA^=)JA#M0}e!hqnY2*dKzLb4hgz_2}R)E*mh%72{JGe6$nFLAv5lC>y*WPj;Oj;R^e8XH|3o^_@V{wS#tla2AT zA(t6iwccvzA279tQH;G7VCSWgwOBB7s?pVoUv`Y>NN}roKQYi(pPRKbxYe<5pzh$L zvJ5}msL&%6)14DjC#2E@zI;#0Yac0KV>+HvKBSo*j&d=d>Qxxfyh;>Nij7%Tp>zAy z*4D;5yn?uA#hG8=;Ao4Dsk0T?v-a@j)+*I<_Hc?1u3sE*F=LpXt(v`OjQQ!E=L_w++PZ ziFoQ#O|9m&inkO{O1Hii!P`+0xk#(W5vpJ>kWX|8e`I>{E}?BO`_2AGz?`PSH7$+xRp2> zm9^AIMZVUS&a67Z%pv-jGNqVASmpW=gjXG=2@%*+Ey!A?-zL&Asku z@oz_)QbK4=xAZ*RyIlv&)sVbp+ej9|i4znNIS|lyZF77B%%{M_>a2V$US=rTzPoxD zt=u>qT|;K8k>yFaoT-dyRVJw;vY6`$^ba^iAZPFxp>jp;zS5j(`Fuz@YJz z#5Obzk;eRF)QEmww`hcmNz;0X{JT%vo|N=P`6T7|FSbo~n%(xdoB;!W{z=ri_Kv$Z zBNPTM`k9)ZwUiSRsd`_%Wq%=S#Niz=QB9q=Of@~@BVEp`Jfe2vd%4AxZ7&79#yV_F z_6_;;&?Sb1y92b(?vPg*>@J8ZU^4&}@n6Li^!54I{9Or8!3ZwdZplF{Y4gVKsFNRu z-E9JqFh`LQ5r)9;N84_BizVmY_p83=W^)Zgx6|Z1Zbn4nT%3TZ7IP`UP_k478|7&( zfHSzRdbzI;eL)F(^$eWE|CCEcC>){03l6Kn7~0QgWog{04&oIzj_6qYC78yoP2xFl zU@M%6e`aSTK&5j@3_u!K6!=;LT}=NQ@`)N4yeSw$7ST3|L+^97^tH zu-zoXObBV5q0Gy{xLu{0=XY?_l7lk*6Kx{GYd!Ql(mfhN;|Rp<6DiitAd3mO+uw-% z`L%H;`=P{{wpgq}zDckRr z6tzZu%%kO#a-9tpGkrff&38g_Y8H%3V1fI(&)iv3vMg)gL|O|r%JZYo+5&cJ2n&%q z-nYNr-w@oGH%0WsSk(}vaBxKRn5?*>!~vn&$5wqFHlOZ5aGodhRoc2WM>8VszA6!1 zD=H!=2vmEEth2bq>2%_ob3`OF5-igc-rP0lY^DkUhSx_H7l6swM1LP|=;fL=Mt3?o zH$z`e2^3Bt6(xt&J=L3ZX*1-I4)-iQZa*1-*zBe|?o4)xN7l+EG-t9=p{}1B$@wM+ zS2_ACGW(%s$E+++{+&;4owv+k*@eAJi$)0s#kc=|6o==(Ook{`xIb#2_BVC=wj)>< z-;FG$|B!JL*V#!^b9I+cz=NwZsa%bI8*$0KQ}N~(BcE4yNuZFL6PEP0u<*HE!sg3E zm4)jCe!ET2oIXcmU4jh4=TW~W6XBHRv{~$8>o1qkX)MEAY8uW|RwFp}ox+iHA-cvi ztx1tax4rUl<0iUXrrn!2X;0A)P{B8(6!_~J;ubDGw`Yl2cXwk&)SQkxPpUReezvYa zHmp>#pjuhq%&YVWm7K4i&{asbqpU@=!T2(V@3k&W*xFy4Ff{IE)mokjsFqi?JyV31 z$-a)2f3L2%Y&xunjqy5uD{PLuwzMu9aM*PG%z8Db|4>|K>tP$cXjue~icZzryj4v` zcZ^^CCm+JM5^h{NMYD^@^{;eDE%=o&1!vw@{N^nnD}90t=tZQpc>o>4r)-S*rN_>6 z3Hsg?NKvuVxzWOQF!wa`2z<8or2iInw=@dZxBTZuQ@^XL8;`)=0##MykO-;AfAEva zmu~$o+u#)S_7#ZA=P-&rre=aimt{aYr$1lTVZCvf$9s5QWLBS^eVO`nqFl# zapo73XE}Rt;Dc<0!_(uvVOzZN#isIe_PQ^GIADzsrEija6{vK+{0f4?CH5I>LK7ab|qyB8?j z#-P)2YuJGz@|>_BC_k0Q^PdG4H1;Prb;QW+%?4I+-WfA5+ux@z$K>Fi!vV9UM3^1* z6Lu#ZQ2FVFwxmqU(a82K^T~qwG1W1TyeihSDBjBaVbyQ7l?q-|HtB zD_!4qDQ;JRSXA#qwgOiJR{W=cFM2{XfmDzMoW?4S3vqF>8niLC{|s@Ogz|_KrDgU6aVqycHNi~{@tsYnG~tbB*sf@-SxQE_P; zxN0CI>)>gWBrpf;o?Np>CSblJ3_xIT{~|C}I;wsk6KSRZ1P0qd=a_A4aZJlwh$jzM zMhTQVk5M$Q3IgaqFR;sA*~%Z3cngY4yUT1=y8zz}kck#=xZwJXkc0(&d2Zm9@znsg zOYdSBXzO4F4+GvsHWl@P!37-xqWwQ4Ws2Xs0SPKMxDw&qDM1zJszkB6W zH`IyxTtPv|)Gq-V==|OAvWxI-SvKL#;_IHmmv-LN5xl$!;(v3t7DW&D9!l?i~Hn;7N^8`{}y1ij4#ivz7rkK z-kqA|RdX_8_!20Hb+dQia}|H-@2-Uurw`bf6t+#>3pbH)jixyF@pnp?~L1DDq zn^q80{v(S2{2e-V>yI6Wrsb%+CoE0h7Fjy5^81*8!fl9%c#Irc!LMb}1GN-n#b@XQ z{0yC7QGL}QQ>S|44+CMmD95UJFGh~hfE;>&ep`2QbLgStHYxp;yP~FFu+}xP0l>H^ zh(-tO(uN2SAL34IIWN*O}_S>k7sH5Zv*?44{yLgikfFK&CT4s1lF zX#rH<5Cs;t49R@K6kId8-&T$^v~Z;!f|=!0ydG8mGvt?Gxxo-gNFJyQg$PwHfv-mw z27tLU$8A3-f3SGd+(2mm%3g^Rkf>TLu3K zH9^0Xnj5?P18SOF`vWztq^{a78;lF&0%#O*R8ZDHi*3k7CNp z*vP?jAr@W2$Ol}W8h`@emMD-!h;iRwkvLb;Hqp1iqk!`CK_Fu>_(2{1E7b%>Vh$8n z;j9<^n!iD?YjgSgv=7Ry)QlQCi!F5yOAB(H$8jqC{%8VTBC^6Z)0Ke3xxiJvedIm6 zW8@uTRf(>qLfmnzc3k#iBbcVHXC9bZHhB;3cm_?0N{{~?-?kEl1B1N2B40`G5nzlz zAuFQ);h~I*X7U%cNohNH@yhf{5bJunQU`eK1RM@NUIP~o^Zd$Lm|RdwGll=8GdOF$3bNPBytu*Z+0~->i$hhj{=uO%aKA~) zrk+k8)M1Gc(blNbs_yT$nU#q2^z18gsC%<9!b3$mDvuSWZS~Iy)uJ+p zQJhC}06mV4(B0s7&I*{xA^cq-frn?-LBIh_h9y&U`zW+mR^}CIlU>sWoW>N5h(0{| zm+kgInEJ0A1zH%Daw4B+fk{M5Fhw5GI%pl=toW46?@%I-M0WFbKUC}W7`REJpz=V9 zxleAQUKS;Bu-V=9+s~};*nA(JefCaP6Rl6|FEtFv5Wao~8%gSi!-WW9!tUDyX7z%r z9lt88v@jLW1d{EVtD(8q1TXL^o=}E40%B#IzOLu8dpTl#u(w^4Cwu*&!1%36+LbB_ zLI^Yucm~MWi=G=D7d8qamOjZ%p~KC&Z5pmLER%j%oKv zZWp+xiR=Z5ppCZ^|+^pMg3I?2*nE=Fn<>y zzdL`Zbb(QOKLC-tys*4Ocj-`QUCRZ!K5p|)i&;yHIlA_r3zd|*xx&v{;N@~hBa#3? zeTQ;cf8RYIxqj{;d!&UoV^a56av$BD67?l{(mr|d9&9gL^OIHEce;h$Xh+zLhPeEs z$*`$SZk)WooRi8mwY^ZOU8jZ;N~1c~_ME)gbKb`|^d0IvPF=dOe7AJT3@Yx3FL#|Q zIavt5(&>ZX&B@d7n;WIJDgNb-@U{hqtHttI^3i=f4Q&4`%sDz_yC{tcW5boyV8fip zwIs{fP1F+sf}XgC@mXdG&wN>v7{iNN5}Az=Ob}E+ie>A7hAWP)HwMc=JLTkIBLiMq z&4#XOJ*1F9F?dibV#qK)~H& zu;_Qp;^<}L8XTBF`b2iuo8>{ALBPJ9AEb*Z{la-=k_?ehsXw}#^GnsVP)<$0XXj-l ztNe^CJb)*^9-y$)olQ1=VD40wdw%Y=esDcMVeH5b_mEGL%u{s!cqi{3M_mbuU_P}^ zqjglXSVRaeQY#o#fc^)sr8-?wTTq`Ss_fB4n ziW>))n_~&3HRC0%6{j_|FWttkXC)p+@^o{gzd#oL1Kw)=18?pAcX&(XI%2_zq4mbK z3=#luZT09st^?q$`z!F)vOn;aRQuK*!C!bwRelEmZ;{`F@T*I<5rWIqis8430zr)uT+6i+{R`fNyZ&>E29i zx5yl=>booQO_y*QT5;CEq_R$o-qqp42Bt^^y7*@NW+g+cQYeCdPf7PWpx!luE5Vmm zJ$^;TN!x?SWZYhB&uAu-&a4Zk9L*fzUF~uR_QNB&<6f;eJ=`p1nSEPPD7#$e{XV*1XmA~iXf z_cXcKT{ct1Lh3kT>Fsj80zKWFjNZ=*@%5W86xf+)cMqH|dT8cPH<$|=!7S5@&zR~6 z!j1IFav_tIwS~l_94_G~qymc#r{Q@>@a;K#nAZ2@uQTFbGG0|w?i?*uRNoIwXE;Kc zS!e2JMk7p5X-dGjOEBCHyO=oLP2Po1XK_c>WzXi|x!X(;0K10@_#v#Xh*i1c4+c@^ z+{ZJO#WmnS|CoM>{CeZ$=oF4n{uzW4+o&mf0a=fPxbNKig$@tq8BU5Py=E>u`1F-_ zh8W*XV4!f%5U+Z$juS8iJVs| z*^%;5r(=T6^Y*SgL~_V7Oz#I&Kuu0|lKm%qMdB(gf~8M$FstHffU}y;K6&eL0Kx0I zVq;&i$7HR{=1&r-_Ucn1^-Emao5`s-b4s?mZ^`5pVTR8}YXZ8ig^_SBOpf`EF6m2a zueF7PwQpa|S-!&^PTt(i;lG6vQ;iBW;_W@GkF=gZ8J!Tfz7LCn@S$J#PcBT{uD7i) zd8bS)ZjqeaivQhxp~8M;mxYYMW%dB5lYN8zKW$O~^2dpDK}Ir)Br#e=+x# zL2-5Kx;BL1fdma6+}+(ZxVyVsaEIXT4#C~s-Q9z`TX2W3A$iw&*V=2Jz3Z#<=zO6E&pH1w5UyY(%dE7Xc)@n+DL(yKyYogMvx2cBGh&*H);?Ch@Rw1f4q+Dz>+VVe-^WiL4|+L*;(V{O zqyE#H^NtQa$GlHiky+L%v!?pk4%cTx9=*M80Qy&2AL*{Jxhk7BKCR=PCx<6|BfYNI z2{kMmS-`KOnBp|`C_|bwdcy%LS#m-&*+k{bgu^#~@qYivO3O_ex~rs)?qY-^mL;q} zYCfCXMPcN=xyGlFs|26UV?L@rhZClpnc0 zs4ioK8&)1O)l0$%JjIF9Q~V2?X6Q+H!*{v0*Oz6PbjJ5?jB9pjO??%~8C0?dp2^4J zZTJ^idt!uTl9K7Il@cKxI~K*%^sypXc_Y`y(B^y>1cqitin?rZvU4(OPb+s9tU%(% znZ_x?D!6hd1B+EZl_^kOw?Jn=T^ex8>O1?P2o3Mfc>D?iA7Wu_WE{gEZSio1=O*9n@suSk=`J3j-9`J`+{~8lZU2kTQNN zhE%BO^3YOL+rdwc-3a`fbrVClOGo$lu(-VE5+9pYl3Xz=J=BJeI=vFbp0x9Ef{%?Wv3^mKd zD41&Y4@JfSX;wGOs`HeY1sttgod;*HY`OBU+|;^2Yf7_ z;gme)wBHyCCKlF1GgPHWCzdKW4h!s!FY*+SOubkSI*v>Js#f&%tD;$%p5o%iINqee znWCABlq;5|>8%9eJ_2II-Gui_88=P%fzm(VHX#Hk;j7u**3(M~Me_-kSq&8hw-J9V z;a;Uhw)XN~T@184V|LTpT=}Kt?~I^‹!y^!vJJ7w^wyQ{9zMI)+{%U)|Z2)^+c z*5g18>?eIb=}ol38Wc8BFD2d7hV^kw$idmMA7m*JZamx?Ox@(3IZRpU78T(b{A)W) z!n)P=QCKM7V9XTknD*>eO!I~C@f)$6b2Ra@!7?cKG5Ccm{Co3*hnregzbf$>PUH_$Ls&I(yVZ|19%;o`tyxtsn zX&L{;!C_1EqpJ@Jde80N=M0h4PtfIgDyX|$(+w0#vQf*F*BtUVeIC0Li-X-;urb%J z1|QhGpbnEhx%=P4*&Ccif5m1=Zf7lLD*(+>l+*qMQ?2u*vR96=EGr{kb>=E8_EZ`? zJB&PwX)wQ;&ctyK+1hxKo%hH_OTVFlO!PNN$Se6S`7lWQ_k+&X_XT2S6q zXj)?;{llE^8)LXS>owO~J@&?h+M+!SoGN&d>dQuf^pL~So8 zZ?%WEXV=H@Re(zgl#(kt zr10IIbEu@!oj_OnUfG!v|9Ua2)8h0mDS1wmgp={FBAP;hR!;zbPX1O7p24Se0t{$e za*oaW2SZX1TU`()>A?HSu?Rmu9!JG>d%w*i}I_2q_=;fZDbLeEi(Js;>3u3SrcU;aHa87mw?^Aq3N1 z@&I8(ImYBlyzTm++WGHyZ(w0e8cF0do1aAOlb~5`mD&7JcXw~R34d~yZDe8HdJMsw zV6=g%Z}dV~=~UP=jcwkKcQ|WVT|99$z>N@ZWyJ9*2h6%G5-9;T&uzByQTKH}0oS34v zFYTK@txX2{YiZ+hf4~OwMbXNG*0IX#0b)}}H^l$jVM+e$VWrg2`>+5#l>+1X5+Kgd#N?ExkV^P9ScNHShV&B97Ah z2Nn@t_^C>iFV2@$N3riOx&wC(Dw_#Ch7vVhcK0>l+lWgQ7hpR=!5_lGDUPvg`4CGrtZYAsGl zj#3!Aq*76}F_oN$TklrlTK9yBC=es}fBN7ZVfg%+Hj|K$9-Nd5b6c~@yRkNL#|WmR zMA`IamBa0PP^S&wK7vHD2%aSq32}~mBezHGcrL}3LZVHXeQ5Tgsb;Doj^TxJ@!Uj1 z2ZY_jHvB2oTZN;ij>oX<=|{y5aU38X#8qED9k)P#&SA-RPQ*AhXHLGsz}dxlcsDT} z=_#LbrM@&ib|7{Z%^C%^QXcDqAS!w-g=EVhzQ0%Ypr^ZrY>4Ifcq$1TLMG(rX2zHpNzw0A)EyGk(1z|3~xUA{64>EroB4_iOa8}0l*d7 zjKl=`p+;;Y*E1S+&30`%wC~c^24}{^BU@(I;JyAte|WgBc(smd>4v{T_QFWMVv6MM z>sFQc#>q0gXmym>0SXe~Ao6p&T_${K` z#-?~UN**R7KIFRF*O~6Tqjbe828h_z!nZ8Y6nLBNU~pxNLF!@`A!{5e$EFQPm7xT1 zZYByEHavf$jXr(JotrLgfdFfi=rpQ_%Y$7n9@^S2m1NuxO8EVf8haq7y1?Yae5&z0 zn3E~~Qvm9kJHT8xBwUdkT?Eai=KX4tI##YF$~9G=CaB&6|FL|2gR06&<<0E5h#F7 z%F{va_by~u&KI#gE)S+J=_9H|5++3jRSRmW17^a8p)sv(S@TcLUA4k`@Q^MhhjK6} zt)0O>vq`jX`;fa%=uB_R&w)s`X#uoM{8cM~2?uT~&KRo7uM5!KZwt`hu#0NjNh1wd zzREXi)RwzzNswUqLfxllrbpN^6tFrwPtBUt1wI5E`CWl`Kz z%7!vuMb%F#ztVe#aARZ2Djma2%h;cQA>RSu4DnYu!$C?;sq9ri<$R;Nu^=sVWM{Q% zGeyOwRdSTLwMeCnKaelIFNRNX;(e5hlF=xH*HB|H61P(}DhPdZ@amCzEJ5l6XrvSr zE1cf9IXH_QTEGz|4m7kI{CpKe;qra^_A51c6*#zU-UU2lum7`sK%wggYFDghE?pYd z0=t1wI#mMz4aoNRrI{9tZ?(vQjwun{d`*YM<&r#|{h{{8 z^4ciu-SY(-yaHVFebc zIgod$-wy{V;?uQ=QxAK8zm$dxHFdLpD5ECW7}i-zjqxJvkn~!7-UZ?4_AfH(T{P~} zwP;^}g5xrWC6j?qu)q#MW=qt39V^mhiakCNySLdx-i0G8v}e1}O=79a(cSLPdw7Xh zJ5#FpJaF`G18NMN1v~u=sj=omgo$lq)Gygni8&e1Fo9yGoS-6@+s1cf5_Y)#9F+k_==2s5WZO>SG*RyDuQFLy%sgzI-4IzV>U@R>?Hv zMVcVplI_KXqNLRRB;R0`VboW|=Q5Q2mvX%-5+cSyT;F^6mGkz&wzAzT%ZV`ni0SG? zT8#1rVs1C11}frAkJh!>p5L9c-}mO-VIG9|d>pieWdIHzyhecm%o+wJ&K{gEV%${F z;!WG0&WmpDaLs+|Q`#)ltRc2eo;Y0%-(AxXk|BfAxKG%q${-P5p|VoR@c-ppW?+`MexVqR#E8AAMLLbOb6ejVj;8 zZU1h9+{E1|Ti>^#Mt2BIo=rGzc@iNSmjqVja)kBH-Z^fSWk;6zRe%+aR)XnA6sfB6 z5fPC-&&@^LR}%wm=PF zzv`JU7R6I^$5miQmd+;`(cWZL^g|&2us!zEb#&k6XMC7azpL2oWt=94(io+0&}Nxj z7Ff#fds4*90O`OQ1k&D60ugSs0|>(VRN)&nypnw0hOr#W6|tMaYawZ?43kmTOe_N# zc*$Iz!mu9Ms2yUs(y-I>z`gs%RH%L0v7$Mc4qun76ENqB*vhK!<2>RY{( zHxl#4_+LoOncO!L)29kRV$y}Zl9(w83>>nsz97GB7jK<%sFOT5CoS-b;Q=7#Cu1)1 zM}6~4S0UIQ{43gU%p|eN^@trL`+4FhGJy2rM@6A+RxRdNaKUA}V{N`CfW=hXm~K)| z@xy0(s&)3S$7Z5FFo)(;3#)C@qPE)}$|G8s4Wz@A*&cRD1%n?StPfy(@103j-fNsV z7hWmT90Z}Q0$|PqH2ql`fMcs6M%xiSAx`zW!VPYxT}o;gZuH9wx1?96Q&IhDdh=pM5NZy`py=$& z=4Vzv<37^RR~m<#KoD=@QgixoVVjR{S8I+7)iWp;Jdne=p;;$B|HgQ{kgy-gj(Sg13IZ&gR z{cTpGn-`!rO3<%m8o*?6wt}_Fh7`MsM2K4%6{I;%43L9CGn&k@X;x@B@`#$Js*5PF zb;bTdTLiRgka@o9F}a+>@x%p)GrJe03#9V79#1Xeevvqq7+|dv=^*|(#+ikkdzNz< z{xhLT{q+^EW+q0)ytEQ`@fE8|bQ^Oz=5>~U#sf5Ih?m8(9XC{^9Fshhp6Ub^cwEs- z*Eq8{%qE(ZFb}=5R5fKXuY2eQ!)=X_w1EKaiKXO>^J`;<4Jk<;cbUMxe%Kt?lP43v zK(Zj^ybOJwTxH2BI}5{PTHEC=zZ-YJ`#Q(q9(r+tws~_^{+?uvsS-*GC=K8*Ioxao zmfK@t9$YFGEz&A?ra{7;H&ql{N_{waye&)Jt&+qVcW^IZhm{A%I;cPY4Tc)xvMq{K zE`AnxFr(uN-;9Z3O*bx`*vdK12`f%x8*TQC6iKM*%ky;dUQVsl4gC<4;&_(8%s#)_ zit2Lx+5i9xyE;VaH;qZ|k|n8yX!(s*aZ^0e1Z#lF`ucV&z%S><(p%|(*zZkmwz%Pf zZ5Zh4u6#xv`c3$|gs`$+f;@5LcO0sK>q<_NlG4Kkx@A5R9gCL9!L)U&V7A%|*E!*R zYRQ(Ssq9mK+x!P<5mh&$tq1|HpJ)}?cyL$%jRl*z;o?aj2rjq?*L!=LtW`KHkeIk90%oo_9{pq9wlT4)DO;#}q@b*m^Kc5!L07p6r zs(27CLr(6vao$sS6MVI9;=Ij@(E zQU(wzHyGfF|8Zd61nNKOw4j!Pk+UQz)cyoCQ_c$fKZB@@=z6RlI}GyxGXv8E$Uf@} zjQ5#?Fb9^SS|($V_}bXQw|7vg*;M`(m6awq@Sh;})IH5qxv#?kZ*7+I3?gYU?!hf> zg`4H65rv?IfwJlzVwv!?6repj^1&AJ$|nF~`1?iZ-2mOz_IbQ@0txM(B?k93nov<1 z3?-^S%MkVI+9d$~u6+$Vl+vBHyH@uH8?`AK^g=7VHjTr|5F+ZxQDrA{m0xU{FTBe|MfRzi!(RFD=c>a-G0@)eR(Fm-1sK{s53b*?&;AjD@ z9)8WzmUBW3o^^NRZngn$Nr--QEP}|wENXG%{V`f-se2}Z8RzR24vKIJ3fne=*v|4V zbaal9f7=0cHeg)!(OYnW7)`xgx@z_=h$#89p0iP~@arY6d}JNsDHVy^3={M8OC*ax zuT{UnVi=$$&3*l^mb6BV+dvdhvr1JqwFg-;{1*6sT;o1OESL=DGb$#MFqK!`IMBNU z4^+}%61^ILw^_3_XdM4309N+q1qgtvMvc@z$-V^DMk}-+(C9NWP4?v2GW0z_*-m8gKi4AOZ$vr#k4EEsd;a3~}G|?MvAD@fCJsgFkkJ&uT7H}+O zvZN+TMxN?4-R&+p%X0FQHuAS_r7Kc3PrnMz++*^T%sMU0FQL;X%y)TzTIP5xpKS{_ zxEu{-v!p@;YHL45Ub|Uk19hHz-|}|BSb;n0v{1sk?6d%K_tISZd<*(-L*2(V=rmK) zyhe`)`TArulM-?x_vnQwRpkyJ$R0r#mBv2xgv)2Xr%@@8qVzGAChuszhJf3Cx^62#@zb|? zoNiMpKJ@XfF^OkTEu{C)v6s}I>I=BeH0_%QcA8<_w{@g*~n@}Z2P-?>p zuR@x^(TFx~W)koT&o+8{QP6Tim^UxB;Zsv%fvS9&S zQ-ZiAPhwikbHMvhaJ!v&rSS9iPFW+HAvlHh>v?=Kg@BL|%kx^43bvXCEEr+7Hx+Y8 zCds-{)G@KW|5gfu*P(U2x=YdTj<@-`xYTFM(m9;hDeaq~(-udt1F) zN~`H?OUbWt2W~bJsxu^Vl;?w0Enr7lOo=8Co7E^&*nUF#j>Mk#xh*2>76|c|Q>aL@ z0f1XnCdD`l*(v*LyD9)~n~xUwp5Bq+OJu(_D2*zJm=PMC>`rH>Q&^;4Ibfp)B&j&T z@{;^a&oAzahoS?8R}PUc=Hkowhx zW#WHhaD}^YckMNsJnmQQvH_U_?=WPzsTozM0R--Qh)(#&h8c_f^ku|sgtCHlY(k)7 zoS)_*9t1{`_*$+=imdIQsMV;5cv05G5c3~^sp9sGIp4klr2M{4-VE%d8e;k;A{a(&{+okvoy&H*$4n29= z-<1QA13~|ND20G_o0;cgcC-3L4la1rX@aJY$Xq}%lPXqNHz8ax7gd@Wfso%6Oz5=< zdxd~=)g?)aQO#`19iuMDgz=S)q=<~N8*9&{AYkskvF3nbL8M4?+vSOJa%BUUw;bo^ z_>E@|uEyibyK*IHCH9$tuzRZvqulznnx>Ww1>G6>R?J9arby`@!jOP8sSxiHrqEh< z&mGmcWwlbbR+XieVFYW2QfCGDWjCRNe}cdDg-a}EE%?M$5X-JU4weA0v*W=dBs6#(bfjTs#a?7d1XvTw&bWeT4B%??P=6L*bxH?V`LBCFK0cYC z1ERNjH`GQ^Y6=_K5%dqN)$thj;Y-kX5A;zQTo=nxB1=)1fZvmE+uuES{5Y+1k17&z zI$@0p9DUMS7+jBd){;~{miUedN>8anX8pJb(u&t7Y7B+^$^t{mw9DGrg^e__?ii;H zpJoUVGN>X-6lyU5!hy(O=P7UWBPQweELGt^`~>rrQ;9FqAn^NlCh%qS5dJQ1L{J}$ zc;>VY^u}YLWfQ;lS&uOAusgPER_%}*^*MTX#~e8A%%jZNNhtV>gIk`GI@pdONJ=Kc zJSU>>VgWqPaWn2_t^~N>PCXC$ISYml*WWVBrtIav%aB> z;TSs;)iGUMq96;C>2u69;<9dVRD8PUS}R@S})}5xX?qq-OjAk{B=9S?yUZh zTgaK`eB*9&?|FAtxiWXu9ywAJKoNyAvQcG$BOAupH`ky_DbaFLw9WVj5Y}t?2OwOS zqqq1xl3E+~QKELr*z^z_BFthD=rnC^c^Ul-)A*CS-!Ho6Tyxq9vTnnfkwE}4y!wzk z0U(C?RaG+p#BeSCzYxRvJ(MW+S4{qY9MK6GX$j+#qd)jX6PTN$T+`2{Ec3u6Zr)Lk?3t}OE zJdbOcn!@D?G1(C|ocj%@+*p`Z4LP%OCzDxT+*lf*E6*p-q;A>GQ#`L#y9sJ=VU(e! z$Li4@O7n5KJsHN;`Q{j@ulAt*K&q~kFL|uA*bXlINiqJ_?#V^SR4pv^j$<|?ee%22 zx(!MPeN0c%3-8Y8d*7@_(7YO(t%ggZ$PyWYft{rS2OO}X(r5eP^N*DrnG$3QVx9BX zhju2^H~VaU4I_I#JK)mVoX{E$-TuK!G~3mgJ#uIB$dyYJ)Er$VpJ zweFHM{f^3dtZMmY*1*g1X|UZ{+!OhON8v0MLbZU51I)M0B`!&}`~6q(qtE2}*hiB@ zYUK?>X2M;5^oHHZ)zXTkkeXlUZbXqPQk$9BDOa?tm93aGIy=vE@h(tKp|X7p%u%2; z7WhGh>5Q^2dHO-;RkrcE6Y{*;u>~n}_j=9(Hu$)GXu(Xy%NN6&7#Jt_@`{(Z=w}ja zkas6*$cv91SB%dHXM_pp$~6m&!;cTU^D7Q=TCS9--}YMZjHBktM^@Hu#sp%@lnTK4 zWd+mhD(2)?}l#GrhSxm_Kr$Ue3$G0#4&_<$38N)n`8592q)9sT8(C1J*EQ_ z%ZV!y3wal(NQstluE5A#84gObiT68ij^>DMjziH{EtRTUe3?qisF$pHZR$+qf{(3A zQx-b>qASo!_`9*sY{RBft5&S_qewcGeQNF;O;3g<1x3_7Izl7`{?R7>zr$jSsU-yte-33ziDk!@jU`c~k6_rok5b*k^Cq z77p~j%eXb)w6Dmh;l?wD6;05Is;><4^(kyg=sy_bmt+8gJhI3^cExd1Q@wY(QeE3U z@>$;n+4@_yX-+)m+^nwL9j!dmtxS!j>;3e7banBN3=ERlh?Yycq%V&Jb>lqGMdb*FB3ZF*QSHPrS>wJ82ophg5NU`;lAKPi(;nL zw^HG`@pc;O9}T|+IYx8+8-a|3N??(n*w)(FJ>1ZT12$p!$;EFi*g$26{pSwr>Ep;0 zI2k8N8%>lpG0I?&pU&(PSG~r;P1;HvfKeS1H=KFpk5_hoRer#pcdy{PibUENbc}oG ziCTF%+s^{TDQXYcs8Pv#zw5fQ_@Vi2&A-1!8d&u^A0jI_EX=+$=GKOVhQ<#){{dsTRe>bkxV@jmp) zRf(R(K`_R^p>3PtBM87Vm`yicFh)y4*f8U?u-Pe_uk17G!zd9&{rp!Bp=$Sl=g~dL zlXXlZEEQ5py97}R=CKwKyqfil&5H|rQMn=Ndho?i<6Vn2+x>Zix@j??n44SrIp-9Q z4aRqPu;L0jlYB><`_Xtv!biT0R7t}1Xg4`miJg%(DRr%C+OIl)fwxHl#rK+8_@k4MR_M)L0@p{ zf`KNzT$BBlLD^fp3pqIt$e_$bMwWd|pL8J=C~m|MLUUGV+0ixythu(S2Ev$_>A|5T zEt~Yrqh$R+FF^-EmaB&DBbTF%taeuOJ4(j=5oGFXaAcDV(e0)nYl{~SUtuUHUQLK@ zh`y3yBcNV2O$#j7_%6vi9mbJk=fs-UXFQ(7u6@M5Lo*6e<{M%3d|sZUv6ImUAloa3 zuYmSNYhJVc*6~^TRnB2T2Zkg)7CQ=|ikI@?K{1F7L0X1Q)y*~Ufl;NB9eu0$$IsWM ziE5T!HqbCW@7lX#iEUmy@~Hf_!V+hK(h7@=W#K1roY;Rh1UN1V8LuqVY)`*@u8xZ{ zP9bTPoK8%Y;Y4tA-6f6Xm)tMfUzQoME#U=sG-w&L@SGbu3S4j@9dKlLCx1dv61G=7 zHtJ0{$j@rQO5%WuJMek=j2(ZI=0ZV04oZN2!!k|xP*RaE*F=nK*GH@-BNtYn1}iV9 zxd7`n+UqK5IIn*Op(LNs0mU<8u~(`J_CfScXTuLs#D3*`+2ExZ6G7j}Ou#*8WdGpl z%f(>M3*jAgfWLB_lttdsCvqDd)&^Vlho+)AmXs+`^NpL|NtInRhS)1C?%5n?Rl5uj z4yf48b@?8EP)9`46uO``<<%g$StIJi{{9_^aYr;F8~EK^b0$Us6lYR-L-aWHpsY}7 zi|zf`Q4j+HMqsAdAoN*A8<1~}psXb((3Wgd*nx*mj1)H1ZRdWCVRYdqC(2mD<4&Ho z6wKFb?aJB+4n1y01Pk@MUW25I^$X;e2hI@(F71_*g5?*DCjK9!icJ+a9r?KOKP_iINRO;qw=KP_Bg(|j2?y((_(P_OppT={^0ls)_zz0s8aP{1 zbpR-C)R)R@Iii*@upcUGb*u`lLYNT?LjEhnPsyYC>lvz!w`La*74|;qaE~DthTvO7 zbLw)dYhdjLmor99?oTh-z~>^|f*`kKtc~2VZqwRcjK0+N9nmR9 zpfR4t<^F)up3|KFw1$#THogtHgU$A&5;;u~M?sBIsg}vM``#p7fn9r+S+?PW%99J>O7h( zO<%O0`!w35xG%>9kh%;;qhWCtHp7pQ43%;U zd$Y9$nP&&`B!`GDGk@Y`&1??CHh<7&PEwo#Y;HCN)jih+Az_ov{Wrv|v$Vz0x_{s4 zL=vyp&=`JJAyA{nCIy!J1T}T5mL+-S_`(@T;h+dK?hegUhi^d2Am&$>xIswLVut~H zblBD9)EP|1i^_W!1&wKULdcepg(BL4&NbMQnCfpa5Ob$TeF#Vwj5<=E1iLD*4JPSI z+dOi4J<;P#GB?<0=^9X5c;x-Ev5ip;t7cUA7JwEo|CAeBO%sj%<|+#Zr(=|{%RkB7 zf@)Lw#zh85*RNl3LLE;7h?Q21VoQRQx|sG&(HgJEFJl4HAUHX}anw%ek@D9p7 zR!X^Gu!;h0zu24aOLu!d?_OYm#*NYsr`wOmBQV~>VAHSv^H!HG|5#>#_zYI@g14V)W1}IR&zQ~^rf1mxU z)c8$x_%KxvR1k{JLX|`LOnLrP34!J7m-$+Z!A#>Szbm;1-H76?N=7zd-cH9Xqj3p< z#+_B6vTb;!acj}#g(3Pnp>^QZ1)I^yj3yEwC#9*Swa6BO4v_{$pL4?$_EB#pQ~Nod zV*;2;ryeV*MwjUbLI5$De&o>dQSbkmlSvtX0mwI=zANRV{Vi#Mj`EHc(0`u?{F?muANq3_#s&tU#K9!qPIbfXSl%*QQY?DG9o945XzpQK}P zI)2v7FY|*6p@(0~SE+?=_Ll9x_;tmARK)iAoi}@8@Py3@grS6oYm(?(p1sqtZ-kXz z!EBtiGog2IKl?ulLHqjtTOsJm%kCvy(+w9Bk#Nbj(8%{%;qZk|AOtp)H-urf+S`%T z;IYD_AMJa)G468GtKkbKw6xrq;zHR~g=WXxStnu0>TX%Gxa6|9y7wyN!F}uf-c||c z;Nn;}Z_CnK`|57oCu#a|OEyy+`%ONclR5btXO|ez%Bp*OM^>EQIGnoq$f@y`oLMMB zEKNMYAeZ?czgX1|qAj;|4_z|+hPW}UDdYhn^uD>{h)F7oxqe5EXFUlYE3z^qVs?{V z>CZ8x81l{_>l)id#NqjNQ|$aJrj5hX&dn(kLh-XPqM ze}`~iFt;6S{SOul$bT?Y*BX>8d)xq|sliYAKLhjF1w^+36ztWi0xpuE#|l~e%~HNp z?=dHzpU#FIsE7tTIB91PifF)0uUu|9opotxya4u}T-=eMF>+;FYl|c&r&A8uP8trg zt0#vP>@SsQ@@ex-dgJTz`dmlvl_xq5GNV)-l@l+GVG#Y-f7nRs;uCeSAPkL^PR-Vl zH`?nb7PLg5^@8B=*p-!|tJw!Y(SFGTE2@e$f&WffrZt}tIvnZk=bRC1g{%A&E)8I;eH6!qPn`l7_zszcniW@ds+2LgcA>MVCMi*(-l`1k||2YZQ`^Ux`O z3WdGwlRjW2w|mWCx3~d<$UAxKMG&U*QO9tq18i5%0-ZMwyOO9AM+1oCdt*Z}dTGwpbs^LQ|g z-7KV#Q9ucJM5JtJTAWVFu9aNYAyo~(N6JHy9nNKe0T9+wrZ3R2S@bwa`UmCeGQj3_;9^H~nO^p&R@r1x5IC)HS(ESY6tZo-1LJ7PPFh( zS=ELY2i^LxrR;l|o%#y$M^=DAAwLO%_SK-^zNqstisC4FyE5PxT=jw{&1zSvLarSb zYbtfPi71Cj#!(XHEnmE?(ti90i$VZ?$_>oY=z9e!3^84z;R5c;_#=g7Idb?R|K^H_ z61Ap>l9R0G@h5i!>an~e$hnVigbF-syku)jdl!Z=t6nVk9H8D=|s<-P#ysZ5H1mr#fH4@Nn`-n?R{D8m<+Q{K{sb!%7v%NFAp{9(o< z81|kCgfqDBIV=ESHFPlQPs}=)>FK@hW+Ae4Fb@_yo&LUCpBu_OD<5$M3q|Y~f@8TD zF>;tTR$0Oq=3|e+qzId7ixGz)oT}xMrU-6J+I#l~p)Q)fLa0@^32zW;w#Us2PRC}2 z302fQ0}E0b6Yfj;**0ZOy+=*F+Q4mjo|fhiFb#6WN(?FdvGqCo-yqcWJ&E3&%hYyc zIFQ(ztQj^#S-v4RV#K{BU6bW?m@q?0&WBrF(>DBpiJ9ruXuu7q&TV zkuLpb7`cn@Df#YH*1_EdjUqJnX<#x%ad`TW96N!T|aSW6E7n%>*sSaQl^ z)Nl40NEd1e!-Oq_A5?4ab(k654pG+oEo$b3*@NHz z*wL}M%#({A*k-mkCx{3Few0WH2|`6Xy0JfuANO&d7g! z;YbO;RH@-8cXugI4P8KX;!F}q`8blj-$w)l<*7o)t$oll-4rWJ1;~B1L@zHp3@wug zeSvksc`TqcRE|}zWG=Kb-WoLT4(h{&V#r|`RU`7Xxg>DCqhtKy(nvcBfxwN~DVYE0GG0l_WOUBrX8=ObG8l;quAR{VGJh zP%8SxikP|$UkI)mxE6>^sfO%$?wN4E`Fov~Z`&+TlUFG85Xq7jImOh|jdR}8fvIYf1t(GE-as0Z)aB=POrN?bcLvUEcK$O?sl~p6 zzdi?+>!#x`CvDsKPuS7S8!xg)a}L2fJGQm?4iEt+)aafjNhVgY!1lTCRu_3xlw|Y^C+@L|YWGNlAd%t&#anq-lT*JCv=EQ$YX!5A$|AM=f78 z)2l8gl^l7*x>`tW|76dem{<DZBtb=lD=Tb<@Z!r+{pCvJZPc~Bfnh}Qn| zpLz~V7tuxerjGZwf~W1grlQ8j&tFQGVC1&2NOcb}?Ruo1(z2Shbrmvuk@%f2SZY^F zI5+R*GS&vS0dZW$_^UPcX{YB+Ge!Pj7p#aoB&&l>ah3EYCXy``1DHz91s(v5OC)x! z+1xr2pm!&UUe(XOqZpm7YEM0S3&M?&!M*u=D^cS1iL?lWTyHw=e0Zw_$1{OM%%>Xn zTENz|LEsOg;oVMKOp}iN*14x-(kJmUm*p>V2`g(GPKnTFux-DkY-3)Z8$_--+Ss3s zFivyk0psATH3+GW_%^ zZ15Bc0d8KR=dWfUhQrh{C938h@^uo56t6x)$A;s7LS-#|1x@^K+-!q>0f3t=b?$@q zo-^6WVDLc!b!97h3zpa5Mz|ka9qBV9YJL_rXULIDE+QXg1VCjkjkWm!ew67|D8g|FtOzpNu04|44Y zlhQZOe6j8s6V)i*;(wJn%8Czm1FQSI8_zL zgZ&;fXu~QD-Un3}baO)Ky`!bE{jy!gLx_#QM2JvSG4G|VSv;Jz^PZkoGD_AAmOcfbljopD??_0DfdbKZNK9wqb&9aCw>7 zpHdvzIy+kJfU0irQOG_mBc9epU`5)iHWa?oi?yUe#p(lWf_}lONDi3Xl%zXFMZjAej5IqjeiWw((T%1Xr5gf45OCV2oZsaEFD@2+=Nnf%)$ zMc}2eE1x1D``_zjMg+oCEux?8H706PPPl)9Lr5TPr76$=8&%_{`$T>8 z4+$%Ku0BZt$RWX5+>O7uX&S)Mb3W3&eKt2!3hWxb#$#kmRE&ugM@8EK^N@+y0;w zVX%N?oEHv*={&DCk9C>N0s5F6`-sSC+!#}HnVe}|p|ofPsG5T~@lpwV5(qd(b*4M}g+(y|kLpwt}C>pK8O zsRPD;KM>c7)qLgQBzyJz!drD|ZJT9A)C8B&>ba2GaT4|<^KV#ef9z{q^vNW)Rn3$1 zn0(4gViilHOEB@fct$VL-fzim(4{4GbB-Xg=C&SYtRzO0`9GZ&XfSp$TE-3;3Uis8 zS={APsHfQyCK~@g*4{EGu5I1d$04}8ySrO(_uvF~clY4Ig9LYXYX~0P-Q6L$yWLLK z+UM+b_ql(mx-~uwM$4p|DtgWy@AE!CKQ)bVSG^Ss_d$5GyBcCecchOMx99md?as#K z$EdZSzj1GdviCC@=Jxp%sJuW6;wJ?%+~k2}W87qD;GN)eLLC1w=_Ad-Wu05!_W(Iq zchKvfpphn1|L+`Zr8>c<|KeZ^LjUGqpE&-FgU$SR4tDj&F0&z!gLPc^Hx3rH^KT9| zclj?4woL7B4i-&;EbgF2(@xjy<7KC}S0Y08j7-U*&h!R7z~7Hz(R+edHo@!R zUb9z>66|X?f(EwOtW3tB!^Q_j3#nN>RubKA{J0LZMN*^W3&K#Z0~=mEiP1jo1pb$Q zeTQ?1W0-gj;cU1HWN&0_I2&<;mWyBp1}rs2UYL!$3j)eFO9J)0Y;u^4{RyhH*b+wcyN1M=qVfo=l569 zqMd&W)~+1QC&oz_zML+Is*Cj>LM1~1_)#)v98da&gadQ6H6mO?JOE`N@ND)>tzD>0Smz&_=C6(l3_6{>GM;^%Gn-nawlACWBF6apz1P$a89 zG}96TIQ)RqoX5f$#x5|UzE?jPH!D_>6I#m+@>?bg1HbGAwe~E?lx{_%OM6(G95-Y7 zyRoOV$((=Tl}pjxv5w`Ck+ZO#3+=GFLl-2^yq9d`NA+O#HqJX^`) zRumxpVmo!Utc-LkZ{1RnQDjSnD!#I$f$Ps0l5a(hI=MNwD|R)2(QAXtoNGBMmkP(V z|3UKG?Xt}yuKD4tc8nUP(txIra1p079%3HoRDgvLJ25UYLO7HdcpflLVXXS~ zyTV3mObPk6e1J2a)X<&OhXODa(9#qx_s@MKZTag6fc+24OAF64xF{onUu$vNp~xsg{^cRR-4Tr4d{%5juIXY>1m zfd+uAx`O^h1cxwchXezLqc5N*+y@M`MoVvkaR0=I#ILx-hXjU;TL(*5a0O1e4p9He z8vjZDXTl4Y#{UJHU>zi#VIc}a48lbZQX@kQVoe6}_XGY+cI1@r$LSH$D48FQ$}=j! zi33p#Ah1Ct0{(4kW{CQQ*Ye&4B-hM&WMCVoVPhq5AQh}+U6X2#Y}r*#00rgLyAVgi zYtlk6(~7~fNFPfbCbvJ^D7%F{IZ&S#R50QxA|u?m4)63LFt8o~p45Of>>Rza zGJ;|-WS~uo(%m2+&Pj^L49viU2m6ui=irm!Zc)q_#wk#Fj!pymK`0M0qLQl^NY#!l z;t3dVVL9o0RPE^P)5PP|Rg&}e_%lx6jAB#&YhxaoaHkCYIPmsc&M2wNe|dE~d-gw> ziDNX?Ed9mSnxPzUU|sjqpUM-|>Y_TRG=HCU_W#?ki#X9)YO~$90d>91)ZpORG3=6K z9vT{T1v*s!TX{ZgIU@P3n8vHZH)wSe@#3k)v!6r#ZS&?=K+6lcM)1LUHS6l|YesFm7SFtkCsV`KxAob~THDVX$qMiYZnlPez|CWe&_TA}o5$;GdbRnh zR<;y)^TfNiA1v1opbP_*kWqsnNS=R!;w2N^>51d3lwdu3dN9=Tw-T{0)Hy4PdVqw-q3t!*DGy4*^hg$p3ML$DoA zejU=!XabYZDvkGgy@}n>6OZRNLn{oS_T2L?hSm3x)m*66TX{_FK7fJ7xkuOa zJ|A-I+02z7gU9TmNdFDZFEz`Yr~1TvK54`F2p5pE+7=p*J+-(PbouCIptGt;9V>dexdr)WcJo7Xt^leuepH>ja8wq<*SCqqU1gQ!LQi-SyvDA--Vrd8|WkCs}BtOj3L@phw!xQE_tQNaG7sPCbEWfEVcqub#E2D2 zXqNWl)hV*Nh#IAhGqY?K{H!HbEBuhms>s~fIubfnJG=Tp>|;cm(~sC)DKRY-2EBdn zv;}k4=FLpVI(lQ@$rMV?rL0R`oQ=-XjQzphR(Q&)O1Yk4?n6j|SZ2(F<>>7w>qrX! z8c3bwVbi>DGbP`MrHhPkeX6$1$iX=QN5JD*+#yl3c_||AP%9Qy=}whraU;Qp6~2y@ z_48j`IzGKE&pgjkoKy^ZOiRNJ8vYhF06_S${9fe4YE>Hv+d(^?^Ci$eFu6ax;?qjY zMN_y?mZj2kion5d>+Q{@AR9HlK`#UVk58rf+|&y2tMAFy%1RFxQC|CG5}-agtPZ#u zxkgGd2dKnfwQBD;RV<&^V!pCp+%tVvz+gr&^(-TEUU)GoEONuf_hf7*9%Xn5eaaX# z!AA#`q$_`On+GAXcynDDH9{S4Os@VE)U4QPmIBR3CHOHM*4Xr}ZQ;hbBiHQh-e&jS zvdGSZLn^7c`~LK-qNRe~7dliG=UdM~rZ6#oz^ zzsIjQoS&YLuMGG$9qenlT3Zwiut_-u;V3^@asm`T>jk?3&B~2@dzU3=qC1&TtUWhd z2^^UAvmSNNV|6_@GMb)_^-~JZW%X-a42{i|dQI>AD+k4%iLWA_Mj4V+nfR0O>|4hX zg5E(JAF-4>^oj_PAsWv{Ifz|YVWG$sh3Q9KNGu-M(K?u&9M|QXC1GOX1(H4 zGX!4xHVF0Fsm0YbG3ybl)A#1!HuiIMERiZjMLK^jPw8vkC604#z6tm5hY?dYotPB7 z#qoSCrtM>l2Cvi?ooXwrbP_+*`|I67Fh%OOf^osMvI7k$qLXfJ)wBFR+45phrgUfq z9yk!dXO#AxeOOyArRRQVHy4Bk&n`_d*s9H|Tt*QEyoy^Nf}K2CM!G%PJ$PL0Y*elJ zb|Lw)8hk)iW-lt_J`cIehN(H6mFA31t_lJwg-)Z$$;>|iNL2Skco_0uz zYP%`n#$K|8_{v(M+bmjLn5}K!mM}tlApwMI(#A1g0l&hC6XWZq+YhT;lPSH`kG#*U zEe}hU(h9Qx?dB-5k}c|9OOCbz60S_iM^H=lL4Q-!QR8_Sk+)YMy{(v+%yZ55LDuEiIW<5i)@KIi_%s3Y;OVW5H8 z5{m`GFCRo5?5;(|NNc_FvgeIlR7jhBz8&i7Uw&=n+5ng z?_n`)ETRYI8UUGYUA*B}{Wc5?gsU~ztJHfnKZmDZP)4j88=;y!k#;S)_lh4GLE;~c zxGQ}wD6tMG+TV9(?)9{&f(b@|ahb&%F>HJ>HUdM>5xjC@r!VpajgR57wBqi`jS2{# zyS(|loGCiXfmpZx#4I4Z0f=?`T$T^$6hY7Wzx5@2ukz0fA=kK~yx>N()NL`G6@Gs_ z1b3@|T}0XdrZ8?gM7qwCNAp;>VGM`6cB(Gx+Y6 zYDEpyi%y^(!>sch>-l;81?~|3rq44~H36Tm%8&Ve+{yKtG==L=oEf1 zQwLkBu(rH|{b^hE&0!UXI@-Y^L3F8q2k)>!^w`KWvw?h;vbgD(VQY78%q3FDykKgu z;+?3Gtkrc&`T!+ATf%U7JsQs2W?vvhXq$Xqy);UbMSS`gMz?H17AiZ#9E9FFFgCf@ z-N%D8Mh(|D+hata#s$fwVD0RyL8m~>FXP903vmKP3w2BWv2UZfW1t*jx22sihkYe_ zx%$z>_yMC_qWk5UVVQapMW_d7pA)PK$gpFpz z5{R#Sw56b7;R+Gpd(vnV3CXNMe;+7{awJFlzl_NP~?HLhoVL)RyR|B7y_kZ!*?>fTg3A{>LvN648sY>n2IS)^%3hR*g~Z{K1)scPT1)__3y z(y76d*W%}Qbaz7@Pa*z+A3&l!DdGEa0pH!m3eteEoST~nGM`^T{yCf^o4N%oi%);< zUqpG*Cv^XMKl1K15;R{@vh@0oeKXwg37S*ehx7s(pNm)29d$pc=xpp&xkhGx8keC# zw5!12s<7RK`sD)WqCGd&RYYYw@#r+^V>N1T0xN6lM z4@s|BigeQ>x8=Pld%RFlnn)6>Yd%jvjr77g<(G?b5=yJ#!IbDXK%Bii(X%syQ*ypU@ZY0J-p4^Q)B z^I6s)!r6w6gno46G0{^R)F2fo4g(W(GBF(g9ElgnGx8zGm8SX*=ry&7U--%x8UY4Q zJ=8o~4y{i)gl!?Y-()m_ruj(EcoCBtTRei zA9l{)=4?3WKF%EghGUe>)_*uU41xZdb2GM<3}LmvUDn%++)?kKwSsSNxS9c~e_T># zQl_f8GAe+XAFlIs_ALXSnkl~txb5*E6*^Fi_3SQHYzt140ugq%cwL5x#KJrQk8?(| z$mO5YPe}zFS98~$9L(w*6jme&xfA_JE zv|%r_qDol&ccz`oE}Ej20wJ~N$i3Z&3-Lg7jwD3v<3xb^6sB%92ASojz&G4jadd4y zKOr?9OW{j?dpQRZQYuFMrTSR{rf#qA@a>s)+^d+f70`u z)!cBO{zlm)1&kn2a{e1-pO#}ET^553Hsy3>Ta7G(mrkEfn=nIbf*JuW0+WMGfn~-p zp#7<8fQb2=ok>W`S1vId;k;?9-$8lt$Sn&rSu5@w1w`DOPe0b1>F^q{gM zJ>Rsid|!1muMCIW7ry%_75|?GUKm-)r~eo;w_PZ+H2*OUpEhBR(Enq&_&Pwi!u}av z;72zHZwLSSZPq0Uxp_H%#=M@m?w9n+!1b2*j7n6tkbz^>YWew(fv<-p>`DyTybvB?(~bt8B-pOw@zm!e=T!Uyw|g zOpoubq)hsR9c4v0g|UCM+V-EmIuDiFM<1=M!NRIlSv*Q@bmkQX6?|=oRFs_gFG zo8)~rOm}W$m6YZCvIMkvR%F%_lWN^@b676LJAD>k$>_dmRaDUPQ(iwqk#@Z#vW}zK zc#=d0;AtyxaV0Pq}gI9SV@=sL$2+%N76v~_t?j1pllq@ z<;dlzz0sQ}>aUI$DT z7`LogU<=L(maWQtcf-1+M?P_m=$Ec7JwR==$$x31p)>ynZS*((zqHZoQvcLOJNn6% z3;vA$lO`$~{Usrk_cy41C11Uoe#9K2@m0d-+K5YaR~7=T7~5v|t853N2CxZ(46h^j zSq%dSs!uEae*@JK+vUqt|A6W&e}n469W0MC0k@<1LB&VsogNn~|G$jUKwN!~)$q|d zmWTOi2g*N9xd~28{+wg86wKjJnGXI-cp3bM{;IJK3R=~rf6AiqF)LTu64N1fVVoKm zoq9cdUSv>=^{Dxp22WfF^4j=ZN{?qP&R(`r%-aOa8g4^B{QB`FREYEwWdF!-XU&Vn z#M6stjJi2~>FR8U>s6n7s_nqQ^8nHz67VV~pw;VZc%0Vg3aQ*MX&r?Zudb{To1i{Q{?n@=*H- zdBo0VV`iRaCK;xZI4G!nd4f6B8}Ge@}Fbcrw{wQ^=c-}(l_P*vBr zP<&40)0Tnhyj!7`pp>VSXI&x&d_F4BtntsO2|L;A(*8cIFnnB$+LuQQIpMc+nuZ# zrIlC4=%I)%R-2+8WA;m<_Wyh05X96kA%FbBsveaC2shp>H>62sT!|i8n}_xG?00b5 zzE1a8F!zS7=l6%3E;_{7@JeZ1D$nr;i|r@&`yagMWEG#s34Z%~EO4?1U++AjgzK13@%=&aG++s3%*gL@runpX-#;0k)`c-IBzNY5BV+b9S&WmKzwe! zm?2^KI=CFMZC}Uajas-QSJF83Xm&d2X8C10!SvbgdRnr~&@L0r^UKg|mOoMmSsPnd ztob~KmJ*P*LQ?Y7Zep_}Rd}U8_HR6;^C6^P%0IDAYPn3&mSgld!Kykqp_-}L9`Cb9 zPBl8M5I4EHFKthF-G;r6=K=)9J^z{=RlUIGhl=eozVP_u;d9P4MRj8t!MkH`-#P9f z2LAH0H-tJXPTCHbN8H@!baW=Tg?wsg_HB9Z_}{_z@V~+L5WZMA+HTJC{eCXHDUuFQ zWgx1+@hcqZ^;*9ro!+-X-H8+QDbO#6=oj=~QH8U*PU{aY1g2O0u$OnC28~_$XwVHjYE(`3e>&R~vm~X;W@Y{6~k&Ig_ z3rGBN+HlhTGSqFT%e>U#^E*QHD$^f#Gu{20-R}HlnyUUVK3#I4_U|OwIaC(PDk31c zpx7&1lI5qu7zs`UT|O3f^>%BuF-Kc_Hq-c>?`xTjz9~@sLDZ5FS0;tqKlG@o(yn8L ztQ0UBphP^&i*}^<^Z9gGc$#3S&E2coXZzcu)=5;o(@4{H(($;SYnZ@B1yU(RF1Vfv zzu7rq(zIfU1y0^eC5Lq*k-u6`0kL0@@oG7jP2j{vxch&hVBW<8)fL60a;&0Gf%yqk z-OHY0`+L7O`K*2QL|k?gW0oMwb?^-y_+R|{&mgD(jLnW_)$pbTp=BGBZ*RiU?CKH4^ouLCAenUzw)2mKkr0Cg}lh?yqQhVY& z2|(JY?{e#F+1j|AjM=!&p(fAN#jAhz=H)}utu)8XjArjsik#Z%5qzsEOLpE#ac+{B z3VB9%U?90KRgHM>;C8;_?eNm9SO52kxoOy`IMUQLVa-4_itJvT4|z4EE6UmEPX1)qq>~I`QO48~B zd3lqcsHrVlDwbQPv3}-?%EHq6$8s%cG1ee&w%qRx4exz2^NrstQ@z{>0X{dU_(jg8 z1Le%^nmbEX%Pg5g;+a9HLNK2_Wv)7_$0Gk2oX77X3IF(;l@g1jNmF5QBk}yE`8M9h zhYotrfXsYx{tlt9(lQ7vZhoDB#L#a@(B-8=@W8ZqxnDm1cb~Se>+3HpjP;hcvhou3)ZEjcMT`2Myyi#gcR zQtM}1!RR_Fs~d7R_uw-BM&`9V{zm5cef5yM{MaMYh;S{n4DH5<{{rTRA5#*Qw$Sos zdJm}HQ?FG=5k>z3=2>Ux_}~>un;Ho5`PawhP%ppBqpQn1>JNi2f^Y&^_WzjN>*s^ z*eI5p%KrKQAq1*q4Mi>2p5oQybOc!gdSVNH=Sl`XmwK^bi1g*7+CFt zW*<#p>Q8PF`$6TDG%gicKZ~aV-+;6{VB|L~KQZx}mS5%iPg*{J_b*yr$t63S@X{BvSvE%M zONonwTD#BX?lmiH=NHnx)k!tbe4i49Z_U=y9j=R&H-Mj1x8EVwjf@Rc9L-dOhRLU~ zCH*K%{ik{TETSXo+`Ni>452p<8ZWPDQ9ACy5OX`D;gK!wpssaqdb;)JB_`Z=mE=^I zobPgn3fhh{>`(a3-%(gl@i+8tO)Ge~Xu0Ih=IW`keP3Aaj~(K~C%NEDt-F+h0RWdqpf3D)8bXbFv!!Ly#7vmVXxe`p(4KR==NZWNAP2* zf^-tP$~)d=h`*Z$cq!qxxtkhb)DUT^r(bEM(9$ppI3w6i7i~)hl|D(Id+RtdSgEA&vr{&ekvi$m!Ug~$(tXocS&j7$)XDi#2{ z_#@-$hcyBV04rZ4f(cCrQ4i68f(R_RDsj?ai zn4-{wbB}~E_Wa?Q-YRJ}8<~bIRDwnRAS1)(grCcLgS%rb zvN((v^@nnAEI29Tn(s*HKLrj_-oqqKRL#UpUNS(7>PfrTP8NBx3HaQAQ%y6}Y=eS! z_HL1PAbCv%!dsXUIv*L%fx5>L-bIeqocyB@SpX*bk|V+JDVrbDRP7@fftMeIBFJfK zED77u*WhoBaw0T7nnmA5GDt__nRu5c*9-bU3ju!-T3p8c<(zIMe%8vq5#$;c#1Kq0a2>Xv=B)w-AGT3HSQTW^vpF5STnO4WR3 zt>AFFxzwfP`5}kvcJv_P-K12|CRyyjoq1vfT5%$8RXB^nnT$zLJ`Q=E)Sf$w*}@;) zQc1g(-@{|~gb)xDqtFpAkZR_ef5VYT$Eb)V`DonsYbC{KAj!Rd^e%`X7GLrZZRz}^TBVriU#b$fi81>{E(98235nAFWX@w(m;Bcr(#Tzm ztGnP0ln0Mwfw>aySGml9Y0u9g)o_YZ`C_&9u%ZvVcI!>Wg9QVe`Ob%fCl7pTs5kn*M?{#0nqaWO3*DnEn(hXn6n7nY0o%mW8pN#S7*#q988|b>k zr=lI-<9;-dC$`erR?WvPW>yzx;o{)MQ`BeC&zCXpT*BK>Sq zaD;*DtPz3Pp>ktj?TEk?yQw%8f2kQ48$o+T z@CEOCS6ZRmyv`ah*FYK?&1K%>X+liz5kx35GU!z~LuaI8W;?#zX(_SD6O2{2P1f1ZkOz@pIezXazG@_Ow< zDjxUoQKzb%k&kLWGKAyWOIn0sME$vIU7tNI2DxCP^IX_RYEOiT_N#q%#IMH_9kub< zr8<7%v2@0+a(fk{&9`%t9+|RmrVj^{l!IG;bAv$wFF$&!-@>?oWf|L+OB8R#F-maW zHL9^vc!dZPr74Q5e`Wh3bUfu5`{||P$fXj>B2qYogHLoE3W_BtMR=6h44Ew)rx$*k zCosj`0N!x@oNbvC+1B3w_c0mFJ+rR2GdLp*75moU6G8YjpxF=(+OzY8cOB{3J%~G9 z)$ndOiAOu^mjoi2J!3BMcX%2TdHV6>vrLaWr%Zr{ULfeTe|JBHcIzvVoY6_L>t6>bG^!N2c0 zdhKy~z=D?q41`)Q`F&jAOE&uZ9dyuyKLZz+sK#E{_EAlHn`4w$51ykv@_r#8%LoWk z#MdKz81Sf1^oI6s(5xmC1UsJi6A2IeT=K&|j8_?O+$-L(!^#6h`w4bp90!0mv7BMM z+nlo?a^ZzV@%`i0|4YkCLsk*lWe&>A%}$Uut`|yN+z(=U}zxfEaU2M zLso9lY;O)CU>joT8O=mTJfWgQksa-?Pi+s(S@M0-G~XHnWm5T6$4MF>|@VgU{D!(MUmVOaA zw5|sH+UK%n$Lu%fT-s~K>GREpCJSEQePltdn(DY3W&@wx;*SJHsC5GzQ|3H_r^37B z1ZRBdMXjh#!Q4(7wp@m>RAHjdN|%~6Dq}`b?^Ld} zWJBQ}@>~#WxL{*#Im8+nZ?nqi-R&n4#Nia9h!|t|{?S1!T<1;q@HQO$U!QifBAt1~ zQ-?bzM#r(4$R`E@zd!Eyx<&NtqKu_JkL;Bt7eyA3$wNW+s}rT2qx5(pyKlC9v7P;sElZT80l6Q%GG7stbzrn#w;L zprWAMV=$8@R)IZjWq)9v?gbkwxvr1R;*U702m=r)YNKM@61Yqds6gNWf1TC{^8MdP_cnu4GlpYx{%QD5C_~ z2HuI4{`e-K95G~G(n>rHlY$RO;rWz$T_n|t$@<=5`j-EcitPxdm`Z!L+D>z1(EWj? zfkRcolQcXdYfAc;SYM2|uBQj{v1R}5xR|dvui^by@Tqnk{v89F%AiDCG|>TifLbyx zVexeCb3##00B>wvpK<59@o<~fX;QPPKqVdTZ>m44&Z~X5Xzw5Q{VGRB=WL1-M|d;JBMipovW`Qg?uS?j8bSn6#7uxU zAsG{t^vmL;EJel=*&P(0)TWFyY1086LqEaDE&Kj%MS!S9%p+^>Z|zLj4$j3dP`$Z}~gIC+h|^QF=eqYgK>;_JOU@YSQJ8GBRBc5nKu@<7**jGJ6`f z*fC|(RHZL43SpRV;gG#xMxeHB0cSo$O~OgLs)cmA&QgAWA9v}m2G7GBpFrm zq`|HvZahse{wrBB{&_8TvknNAFA1rmKA)l-0ww%PzaKB&_Z>4NPn3-mU+!<7n+}N& zj91 z&UBE~1PfwGLUb#;;had&Z;L;j#K$3xe3sc6>GOLqhs+BdlBQ?frAfNpd=ThZz&f>% z|1h&*%4b89jES;~qb6bO&+t{^0p(NkFYfT1P%9V)-mH%SwIGYw$7kab<+g>x0QGg< z_-kh`bHIVs7|T4)@k+>T)4S7imwcnNu}<~0*n~D6KCO8&7=JFpkKqF6Cr# zFR*#5Nf&emUc@+^_Jrz#9wz)%FoatAtb!Ui*-?`HWIOSfzi(tE#EJcT`J>8X_my+U zIq7of_oHzM-QU=D9KA0Gu?^raT6(cH+g&4o&-skOf7S8rvU&L7AJ6{Z4)%|wqxHpu z#sW%gw+n<4Ep$1EL_hRS&}G+yfe*7FHc=GPpJlCw&m!!=dztU~1;3~iqsrny7k2a= zs)h=NX5RdbR6~qvFOlM>!Y zk?w2NtVf%us%-&ckdlHTfoce(Uq8yX8L){b9J03Bz?cQ?+}Mt}u!+ipkdlXBhfQ`6 zBBF^5UhP5%YKG0Uh<)}-N9Z%HZJnkPWk^!wOVB@sUsq*YJNQ5R9B#et8vvj;KKqOs(N26 zbG=bD*gS07Fg2{fhTij zMr10fr&b14UOzC2Z^XEwrV#YdWYgk|Rrn}X&j!@)zRZ5gw;mt5N~^tmsbHtRAQmWW z;?zVD1PKMAXjAu^go6h`YM~w3VHADv%?St+z)el> zg>G4i&RF~F+<7OHGGekBD7^gz5(}^HWC$IV5vDtFGDJlPWyLI9StX!WJfK(YPFJ$+ z3zslbtb@d&*yXckKyPA4hx<1_rm>QTy9a`&eb2;aJqfm~KA- zl*sN1vU;@e(+Aq49mJ4u3T>8UVtYUzvjH|UJT??OcqnL3fZ@;oTz*Cf`UDqrfGTko za{(cx;Ao#bE{O3YBFm&ze1_iSILAQ1<-$D_a(XzTypB*~o&%QYm$j;Yrc8KjOM+-^ zwmXKibaG(U&nl7{KPqLmOV8`P?ti-V3wRN!q*UL_Bv*PbtL#I?Me_@v;%(P!+*+#K zVxv(*;{FGj(xIG^fz>n%e^=Z0SEzEg{MWoYZr464rd1w<<^o%82u%YdA`3Fc!gDzEdgdae{A|Y{56FvQ z#&wnrMx)9j^Gw6oA1PxT*YS^oKCAqK9UEqhtXLXBk^IG}vE^Nof_%FPX>(@eWQi!l zQ6>_sWcDR&=lr!%eLJI?VY?jAq0>C38_;+b$agH4VRyDhUsJZXC-JfcGp?M+E7$ID z2;bYs>SrdF2e^0)V*BWPO&fk1JzEei5Me^wfLk^QV3wN&(y-2QV-4TeYibYM&Zre5 zjw1QsWDP9o^6HkCwMh!$-Utcz>ymkWF3OIa1Zoy^%T`aGeR$B!RUyk-)Bds>r3naACU4z7B}If4nV>xQ;Lv_$^kfuA!i zOp~q;2j!FOtE-LND=SBdzG*k@>iQ+BUrtnrxrli=S$VujUT@W=Xrf2~b5;6!&@bu5 zZbWRB)!XE-&V@_4h2A##&P;aY?qOgMm%hEH}03(`x z*Q!Z07?C@KZHtILq!nqz#B89JY&Vv~mnw#d*jWDm!YxZ>Bbd*_vcv&)O>y<^EwT+JwT7cprR=S&R5Q=YTif>`SZ$KsH;-`42{ zZr9yT?3x7puu9!RSy>A0_fkx(Ft5hWY#ZmczMrO!atkEAz=p?a)60-W@A1PioCSJo zwi0H^9c>*wYNe&G%r5&>%%10}zbHXNW5J@$M2To+Y!99oX?C!Y#eSg*n_e(9n_8IN z66*KO)VJ5wymoF{t8MAe^tU%nVCr@^r!$F~#;f(PEe3;W~^tnS(LdshcHqWxVYfna}N?^|k#J`v~B2Wmd&i zAN{(9j)~R|Z-lIH&$L<)VwUDtXn4TfTo=LlcxU&dkn0!gD82T=<`OwNE$>>cZLH=s z=c?{h4A?6;eDIJeB=IcdrI{#ha`DxdTwb^zh+;RdlGxl{?#zmLM2)30L%CKXluw-C z|C}c`xr}lXYm2_%Je+`nhat8b5j7WA2OVKO~S&z4PEw8H$?tDelkM{J|u_*Bcenr**Q} ze)Cz>uXPqjZd*Pak4GWjQ4$W%V0yf9pw8$A$4Vd*A!cxmDji0~f5;YV4TZof7{1yfQqK z3A^m0T{Ue>2M89e1(IW~>KKG2fGM3!QSt4kB*N7A63Z@fx!H6S*Y>@TU0c;(=9EsHHN8AE7IsQA@Qm+H&|>3)e6@+zAaBBM=J{ zkp*d&>j(lBeFnn2gc0vfEQZ#x%XC414s`0!tcD@^PSPI0u3BHlc}O+!k-v?!goX8r zYSXO+v9$6bF~c4xGl-BOqv+ixF($VWl>D@d&El!gnKxVH=3nR{K6IK3dmAD=@VlJnvz$olA`F%mo17K+D{m0eINB=r&2^O~#Jy z3};SYSOcQyHczws^gc;tPu#lA_|)2PaS|GOOZ69ME>ieHW{*Znd|p*$Vd7{3o~{}u zIomaq+Lf?Z+KYoAv8N7p=#9S5k)RIBDg0D;?#|J6Zw`TKzv_?i`C$lqc@ee`aP3Gn zc6MZ%7TxENtHllW``dZg4c3y1J+8UkiDOK!EqvUqHhVCn3C`4KJYa~l$DQT7vC1UZ zm5~hy2~)5ih679xU~JCM3QiE~QFS~m5qFu%4*CXHve6m?{pWxu8IQw4yz%Ou1K87}5QXBo9ibSw8lsnM32Z=(eR zW9($b?T+JFP0;$IW;f()-#rN?W1gw|P0cGgv>0yWR&)}YC9GrC%yZ|u-$95o?4l$8 z9#x~4XyUS?!LjrW)v`6|?jxR*^>tukNjG>Xo%tm*#Q9jxzP6)=`&)A58J8v6;c(SO zjbL*upq`E3WHgHsIXQAgQ0*XAd`1)a3_Et#o{!{*TBcPTCTXV((l8!<_efIK)frpglVYKdCu>1dmICynQhjyS!M zWF2{Pj!|R9CFuHJFJ5p9I-gS@7x+;YA2C#WJ<`FQ0eWDj!T`aq_0MrPhgmblA@#uP z#~h}deE8YL9}EZ_R#%C1iKH;6ut+dHOiq=)yf71pBFM7a+bPEbls{O5hQp`Pa9+ZQ zEG1p0W_t34=Q= zSo%_MTt1N-R>AFjdh{5?Z?lRS){nRGQ-y-}jk+8iA@V6OcA>-iaWU(IKS+P&Io#xw z;mG5nHl`M+1^z;Z@%;*#)6v{jm8MbuQJKxC5H7`ycj7Ea_4rPH&6D`y7iH2W-dWVk z)I$m;-H(?AP3KYuh{!mMDwxNTS32*{fH1}6HzR>XyPB5SQOQzmIUZ`FKv;I-D9`u6INunU zXkUy(?ek4_?x%zbt%||LEHYP*-4kJ5sLcMd4H->zgKs|p-8TW^3Dd6G<7}IPTJ^n4 zSF=me(_-lREE%W}#o8e}*Qim};B=sQRJtd$hjE&1>9l%yvA6yWR(tq+q^rtak?OhceL-iNL?14?dco>_ zFs7yf+d}{!GtGG1EE&~Vs@Mr(j>u$4(X3CA^om#&xSzfzcRyGa+`Srm@7%AO)KP9yqk}m&D57v+&&3&*ClYB+5Xnp;!)(!ieNgyZ}AM~ zkhj2+l#u-+hYxX`2j-aHJ!VP1Pb8n}4TfBjR_xYtJOlUOiSU4xf1n zdiqDoE6wk{9XiB7 ziu(i5*{rS(PE}Mo-6M1dsE|JSXO>3`ERus49kufb3LogAstv;h^M)$NP%aCY zW;2JPAqwB6&}Q;`YQ^+?sT@SWR->x_^~=09TQL%LyA&`c3G-zbmBlP(N`J*jhb0pd zBld$Xf#>U<29+d6XZZ=OBChUrb8>L(47ygb*H=p}nQFfmIB24ejAME>*{H^t&)Ar~ zRxn21*N67!gZ3ws+e3V&SMv(hnvr%v#2&Kx|BJPI4v(x`^Tr?B9ox2zj&0jX$96h4 zJM7rDJ9g5sjgD>mt?uVJGv~~lxqg`UzwBLAJE>i{cI~z9@8@3F2iZ%bW+h}i%;=E( zY+)(%bu^z$Y>9zIwQ5t@snaR|xSN@Pc=@94is z!#rKm0{s+V5!1NBMx zanGq0i?;XRW;#LsDT4-HD=rY)%YMCSSf-F+J;GR%Cw>FhNF;(@-+B>okHLy$CtEac z{B?vbaQsd?cw47X&eeqfumb-M3tcvY?NNPmVn}Fw)!wCJI|>3cG{8 z^n1YhIw+|5dTqD5#r`Xl>vt9FFIB|?H*YBQd3k+#U8N*NtGPRiQ?nECqm2X~0~f{R znpf4wt!md$h5OMFw`6*P3=cS5ZO%zO*Hd@W1iY%x5^IOgl1JqotPhqPJ4|_-+!+~J z*iz|tBLrtVO19s3?~`!16|NO#PSbePR3%8PiA|eK4wmQZWHg;uL4DkiwdUZ7E0akp zYpT;eD(UHPW`aS7ue$WRmVnR+gY%1;EvCkhWZPg^YiT?zC}i?{UMV2@*-xcPS*YSz zvYei`cDA8cz-BAAq%^k5%YMe{CAdv(gt`iv#NRRr;ht+EwT)|^-AGrg5?kpio*1A& zP74k^)>V7HEiJ>>Iu$br(MpE#7G9jibU1KcAPWWc6OQ_+&7ddfjfyi*fIqSw!+zp! z^A9O%Cp~aa<`C0|+7TU~c|n+WN1o7Sylq`?^O_wNN@ukBIyiW&3UMh7M`YwGaFnpS5&3{5I`T{j>N z%mChwda2a?`-kzA0pB(sNB3lU_`QdDGde_qfK~~()*L@w(aJ|>r{LDEiLs*GRpl$c zIcd-Qa7Rb=$B>B5a57upF+;E67;ot>aHKROizP8*c3!pKYFhkud}dD-Mc(#5i*?e9 zMSJ(_LLhhuQ3TO%;Yei14Gr#(gb2MKvY- zvlk_oLdE_}bB!^n+nOw^qEBC22e{*1w%Jca);ia|D$23IeB35vrGRP3QjM6&&9i+e zZ`;GAPO|XWT+pwr2Q@>pNEwvec83N;J5|>rUlxvzr=r{@aetLra}oTg>aGARt+F3e z+t+z~ryLwNVPYagVTX&&+kIbRMxa_tg9<%=9wy~-AMwqN{uXAE|M@V%ym-P^94B>@ zzlfX;ifS?@FBbJ1SOC)g4dP0>1gLG}46x@vJt z{h`c7HES}-mG26Bc(0bpaueW!-7n&m4ZB2EvI}VyY?@Ye3+*8bChA$j4bj?&R-fgX2qUzC-=`C1G~}-{T#=`y!T#6dMre(_b%uXEzEW1w>^oXkV!lkO z&>11Vllg5)x>4!K8_B_>Cc}2|5SXa^kfw~ClHuwTo^vnDu@d|)|2qwOb)x!*Jz+?h zFw3NGrNJ=sB2Ml79S!m@sJo7NtS%7Gvu2W-m!H+2ihg~_FO%GuF3?Dnira{}#89eN zqc0+(*{-@q`m}LePX^H_DH;fia*ZnD3r5h0Bh(ed95eDj)p>pG(Tn=8zcjB__!SO7 zhT`a!F#&ZNVe^M0y-|-4mfAJ_zFfBiYO;9jvz>4c`t}%*3gb`>rYGTO&;6b)=Pp2` z!2u7B3@o9vmaVxr$gdl*WJT!per;U`s}@yuhX~fZAh0Cnh9?J!d7@(7MbM02Kg7h4d3HgblRP4o zBCvN22$d*BExDm=Z(0x=v=zz%X@#UlLe1Yhev(^$*vOk#a>*Unbpz6j$ye$ zV#1;_h_%d%(KN#B>6Kj2jOX6F1B2 z?YdE?rN`Dd1~{`-#I!bIkNP%Ufx$2Qsf@$k>z&)&*53mvu=P2Z7F;2XHNpAL9pd>q ztp#|!nX~a(b}Lj;DnvBHt8!3G|Lx~83LjFq{@PaGr<584Wl9KX7bbZg(Y9UHQl4~H z7P&<*`Qn~v+sZC)G=)m_%|p;qw$I6xx<)ioWKq6hI-7#pPn0FD&`Ejfxb%H*V}EVc z2`+)t##&zoD)>H(4b+iT(3mI{x4||b-V~xY37TB%mg&rlG646}+P(W~dKB4tw3l}6 zhUIfGUUF@gm9Z;BvUnm>E3u&{my1*yss_1U<5ZDqr1WqP-FMe3G69$ zI$dm5D$!aBbBs0O8z(}(8zLeDJ-rsQgD7fq!x7%f*L#$`t%{q5bhw&L;qz3U{g{KL zt4yA+N0VD$pEl2Sx|3boZ>m=x^nQs(4`Y!kX6!|AfTDG;*c}nyN0`m9>Z3FVX?I-WuQE3c(o&1K zj-x(&Z(IgJF@I4^${pm;8y!_QxEfg6eq&Wv)Mu1Ek)E9pJ`v&M$ZxSLb1K+!Hzw49 z6DeyD@!dc6*$N*5FZ}7Mx;Lm!O#wwi2&3#>B!t6zJJ|^cULYGc#??db6Wqi;4ZRw_ zGkv6f9qVG-*1vgLSI0EGuVv6lzY1#)=EIyMd!oEdh6*-RnPMK*-dH{VOQX-I5+QR9QR_!^KwmAfP%7)qO-cBsiIcAS8 zLAmWJxqq1Ks$F5H=u3gp?E7oU>&IN1`D1~i9p2uY$vT+LML8(J6ocYJCa@HgbmEfyY_oU;9JvGZS5n!TE6TC-)ICme39tvng03R-j%@5W0~i5Ac>y=nBPch z$l1S(_v;S7g;LtlK|8ukGq^a9v=&i1v7?(O28UZ7cg~se02C!(|ccA$-Yg4 z_bye_?jqM}r*xnV7-u4c?#27VZX+A{8hX{eeBug1wY9eXvmA!l_9$ zN~@tsHFRj{(J>+;2he1r5}zsgkOtPMvWn{l6l8XP>{uG0W?6RMpwfzXC~`B$=_U~n z(3dQaj}^?(euu}SA;;c$>H^}$@37~mH1|A?9L7&joE%HrK8MBnww zWc2Q&X7B!b2@z_9h@_&S0ZfBDE$S1dI1rHFnqvjXzWC%OkL1)^r#B zB&NE%e2yeI|Ab+2ADt=4kH6xi2Uk|98sQBX&mxw-9^QPjRu$n`$89|d z*-ct$AZo>+ss%D0%R|7KB!&y+H2IXGI`nx}-NK7dO!M7wWuo^B%okTwiCLUwrl4+n zD{6%b`6n1%JxUsm43%aO88!$KZrDlf3J$2(S5E0{4p4#3?7{H|Y!6Ko+X2Ed2N#gh znZz4p%3NOZ{-W?nx%b&$rBI+DInrN)XqlMjY1*LV4Vsa9Fp&(am5ViVuGINvpj??T>q!fU+ZyQ~}>CB$3=a72opo+pRnktyKF9PmpV z9as|Py&rB-gpW9)F*9{7CcahW2D_-&TOvM&pGPgnw2c!4J)11-?xP}yvZTb8_eNNC zz~oV{29lk8!!wfh%q+TVk%d?lm>j1dg$5>UB?3;QQ-R&FE6*OhRID&oC(?6PKgw8hd+yfc zI8vasj@Wsd$1*3AVaG7UtQLSn1^20xTj1sJ=cj^`lBA8CYAmI_wH~rQ@O)WDA^R&;^!ZsWmM`XQ zmR~KK_fe(3$47%7Mdd{S5xq7(B}nVziiB^X-CilR&vZ6mr78O)$F>#>K9s_XHr^-< z1#w3(OT#Mc`Cn7_Ry(8gl@V4-ns5ag3VVd4DH$EqjYC^k)&-z^AzT>sua*$+@hKPz zu{bMcs?7Nso$FbHPrXrgJT~C$81-~j6UZc%xn}ij8D&bhFL0CnH2K=a_CDFb-+tFc z_4&*yg}wxd?~GwKOsmE-fzeU!AyfQi0t@*D&&b}=Ye^%slO#}`q^n`I>aHPjc|gaI zWn~G^ZVe+9655!bY1oaSap$NGqT`Dl*i>-zC~{2O3~(+{T?OR_Qj%`#p5a#9B}H4f z7>Y>hxo;tH1ncsOVshKK9uTy>fGwqgru!c`kdd%J@#9QS5L(76@Pi0*U_xT>2UZq0 zB(H_Ki?Y}hQVzIih)(FYmneN1XKN72&@6(UPlDe2Cc_o2#Q6o42?`Me$w!q)#S%`t zkumHIT$W6qF^Qs(#Gpumkb9vFgBbt!o5MClyA#!$xI~vq`j6ZJTY4Cz03Fab$H=xS zC3}OnrJ8HoSYoKh#3nQDcz`*{1yBW=5Nuz)5ays}k*DHu8L4DO7UHiJUq~mb7#E+t zU@cvPF`GXZRHVRV8|yXC4zBoae=gz7Vn+;xE9`>{qDe?yalIo%?XkeJ zaa)Z|)Qva+ zr7LfEQs2%3i_I0!2`81><8iXdC7|r$IdEe!8w4U)DJwPbd3haOW3|M^DK>|*WSn{w zm2gG~Qz&BdE130eZDiVw2RmJ#jVNdP0~q&nFOwko+*K0M%Q;pSMB|*n3mI8AMNFZ& z*&WWfpj{;!U!tT#K}igd)%d}3H))_d$OjDLwXb13y#D0oMoYh_WcU`z2_ErQ^)3ce z6e#Agvm>G!#%1vr3^>qzk^&KHsQ(QI2+^nZVGk!BrZFFDn1leZ_U)Teyfc}$L{_BT}k?tcR1McRYFG#Wn?{xUENCJbYf9iJ~}FT zSV>17-AXmp;fbuRFs;s#hOShduKC$9kpnhx=o;?m;O7|z^g2d8o{5<5&ys!A<$vUA zd!t(O9kShVz{!)>Z0cR^q?<_l3VfKA?qH&Sl#9UXQ+d`jwuAuI87Mv+cBk!C0`AoG z!8Y$*_OUl97ptfv0eyU=f=Ei~fT*+~c#n=W9#`T$skG(c8!ZTg=C^}XKFTUR%5 zq2fZh^n<9pyHb`S&GwCX?p**KRjF-ve(O)z`_x}2hcD60Fm(wT;*E%hF+8r~W32an z>TcGY<5+RN1}))P6Pw63bN4(-fY%taLB!hK88}R1A&F+`@RG~f&#Kf8*VvnVb^Q6< zaCxW?A2ZRV>QG`O9R(2d1kMubc;60HHs|LrPgpu4AKbXB*~_?owg$t1Hn?tFmbc7f zwr;9?n=y)SMvR2M)jKxr+Tw+QUiE2R96orRvusuiJ%`!o)VD{6N|-s?jsl9u&S1E_ zK>sH=5Y?2P8-2zpMsUI{wz`mWh8P*9J&3bo7Wj=3lIwXVJsjlH`)i7~Z6Tz9vdRO$humyTP7_{p zq65~6*laC>_ryUm+iX6~5>4eDatGi6?GfCaX!6OryG;vbK*0Y5VY~UG?H;tvXfFSV zPCAp3iIEX&dCEy0^jE-A80}5;Nu=R6=(7%FO|WKTW>u?*>)-@5Jay#Go@MWB5M5dD znU*{L4FC_c-`}K0OJ$i_*{S?K?tj1mGo($_ejk7$a1UqV`z<9LFU>xAyz=gEk#~It zItzgyjeFYLhJk?gNv`2&1I4O4h`Hj8Igs?uN+&l3D1qcCo`tVbeX89={}j!S;%R!o z3{8*zS5EMM2@Wuwt3kQ38~2Exd8M9!$5Zgin=ZqMXi^Juz~xkPQ-{3s(g8zr4<1Nw z$NQg_xf_mO({5?@u6+Lw))3V;-n*Wrncvtp(v;pFV3GqLh4dY5&KyoQ2o+?RRYEhm z_v|^G{rN@&d_^1`qds?!7j%#)tfl$szUihuRgqto_JdU#>Z13n*GkE-TyDdj&Vfw& zfZ(v8ep!Y+vce~~(a9+Jo;FV4D_wmAmwVe2>VWH?nq%H3aJ+#sB`I-J2>Zvl)C|C^ z#VhdmqvG*QrNGMp@(6|_p=v@Sttvvf zw~dQh&Nu07*swb+>8ICgQQMu;g=n;`xO|#=^Ou3( zR`@I@WCXpSE(3cdwbyWFT#5o1!CD#_Z0v5zoHGv{tr<@KGaUG)`D4Dqy6Ib2ug}a- zja5@)gUR;+33l5QK0|^09&D~53do_F4+2i&e!7pUThD&re_ZXpTWe&o!}rsTJ4 zV!i^g&mA4Crmv5coQ&(5;gUpQ4Mb@vis|k-S<4`|-l!`nSFftlGlqwSy})21OQ{3D zT~2~wS{nJA%{?uP%V&wWEcC6!QqYA*JR`IoAWZS8Cqfpci8mVMo*#rW7Xtg0xE?j^ z5aGFad!5GZVphUP<4F`fqgbp@L`pBGs~Zt{@S zInQV)uZov9^^SGN(>$+}IJ3rU!2fWAF3X`NaY0BbIy~1nd4*aUK34f?>P=EvK`>K% zdAnBsg2_~`@&1>FQw!SU335}B>-ShUqm&v#Ick?BBY+36#qvT;8yMEs-Th5-e*!CMr96` zAyRHp0F=v`Vk?m~n#pWh!6;+V<;v%Kc}y9pcv_Y z(9M8}>ZM^&yjaW|tT-u8WCEt7yAy;fc}<3QWk?I*!~x$hTm10f?9u1>xJ|XRX-n_o z=V-llGdC@>+XX{J01*yGG8A20R!}qzqHWC2gkr>Gg61V}iUqQegU*+i!^?bM@bEId zNxU2h`I0pDU7{e=yhh}=iS;FJZNzVbuwJmcSsElIpoE0CK;itvQ5|A|>VD6X1++>= z0q%dA(SMN;of&6F<>*1ow7@7JN9SoEoML-bCu$WB))FzccnZ61yP*A zjg7eL%*WI75=Eml)_Uaph;L5(KD1v_CqpR&RxBL(2M*NwvFi!Cb;hpdNI90xBvo;d zc4_InjQbvpV@=9_n1v(BEs`Vmwj#AUw=?2~m6hDPz`2CDtNH(ls~g za{97;hdydPzc=gdboo%Xn`eCRG$e;o@)$un1UqWPo80#J2-ad(kCL)xd?PE~E-+8{ zos6Ki8_y1()t?F1!U0tuzoiqCoWG_UTqG}QD_1iCW0JU3AXA9vHWGbqdL2Jt{H1V z8JfXp+5B`Gcu0!B#isua2e9g31FZ9NFXdMr5COT1tZ^iMPFa*MsXrjAzV>31y(d9d z@GiU8$ugYu_?ZdXq2>sfrZUP@F)~k>tGeH<62j3#EE0FmTUfpGK;Q(P!PM}5_wLpJ zvW{|bGtZxIQrgp^xu_a`;_9ehacbPhJc+tH>wRAR`s3{v`D#IJrMhLkb8k9Xmi)=V zmmPo=_%C>XsrY83xog4qfP9t|y_z-q=Ox^76jm=w000k!Sy~O!_8i!~WwHfvLSePe zBTM*#E1pX|qA~KtMQw5*()>>OtAoW>FkoeuN6G&?H~=sK>b%#!>HjbR>hQ5VAK$N9 zI^0d*7$Mwsjo>OaTKj*S0vLP`{hyCIrr!U=4*o?7{CAYV=KflK5+-iQ4MLd|s0u{# z-{C;dqXsX(b@0ybK$m+K5h(`M>5f5^m{&MWDGaTml_#l|IQ4dHap~=mAgJf*C!#6j zezGU7RN2u2wvsm8qd`%pBliZ$(cypsn z&YW}7UJn?P0HDk6aH3-8dmu+mz)kC}Liz_0YkZq~5j0HeX^}dw=S-6)8rgqXNEITD zk*h>d^?UqXS(xI_D@#?UJHYw{t>~?d_s&btUXL0QITT)YoVWm@wWd~T?G4C*Hv%dL z7AF}=Bj!IYH?!Dbw9yq896MWNl&=ND$_1hQZ9Bn60)2*3`erD`#xs2KtjC}1D$AcI z7lXE=K0Wy{+72&P0`FyEQ#155O!0-6WAU=$*ZJD86-In`G^=pJqBvghcU5@ zAG52(vpwk7oO(y+r(g>qNF|C(IE}#=p`30gI#eU(et#hlg)f>S)}MMx2*DKm*xlje zh2<3~b(8iSQixvp6}o%yqsL^oLD$d3CeHu*?(`xXGiAQ)CUocth=kX?H-Ul105g<2 z{7jV-X2a4?N!7hXEVxbmQbnTIlb#bQ&PigO_vk|_Xe6b-$s^g7Vy5El^@`vlJxiJF zd-N1)+4*$f8fc`jCk`zoZrGI-CTh44zYN{)>Wy~i5c;_vr4rL7u6f1i{{ap#!c~Rz zlm_=WL6f+NyMvGxw{S?CXT$j97N%4vyG5+F94E)%aA)lH-rw#~UO+6dDEP|>$e%Mj zP{!UhA%(KBT<=F&-#f7wW90(i04a+jdM4LJ*S-BM;3kr?L~|RXXzrzuvNIta)j0;` zt0Uh5TY+lB#b!aIC*Pi{j#&5X}%9eq6x(dpDDPyKA~E^So23_Ri#pVT;m%2)dk8<10G9>60sF=s=k zCtHNtLEKF-E>i6oic|ql~(XKzLTDm()k$7j`C583%{MXn6v; zC$579+ZVXlkB#l+qlphs{~i!aN)T=b$QcVSR@L!-C6jOm`os(KtBOSZqH;OBZpu!$ z$sIVFOncS&36dOO&m6(cDr7!UoG^1wpf0nK?!m!c+npmUC12}4HAth~+g#1erNgcE zMRXPma)@>0Gq2GIa7`ug>~-2hz(wvh37IwWEZ^hpsr`*mn@I(TW{uE>-v0R+WRXKh zV8kOGh!anP^tU94ln{vNJ6!MU1FTb>ETe-wKxg9_dY|1P;t|Fn-}Vz|F}ZKy%!OBb zceqQF+wjP6`>7B!XUmYKyQd*(z5hYHNe~oYwbc1Db@~fD`HAMe%TEnt2Bv9Mzbu5s zd1z|ru>f!|W6#Qk2G=B-aOMiMqd6texJ0w>Zf()ac6gS2hAxkM3t;^LBei8(h3~9lkiH@>ypWL_0e?vsHZS-?%nfyBXHZa!cLZdi z0*%#-8jbEki)E5tfXxaCx=sI8C-uy^ny$I&erhcOr5TYArkw|4l>Qay^oovV${im@ z0QfzB5AJjx(64~H!?9gAhsIHEYercZ>zDDAII@ZOmDgPjMmkH=GV7^&z+C~|tcXK! zn3#J+7#XFkwV%oOq4}*H-!qFFWxjyuN7R#GBv*G-1_OyEK|TM5p3fNIVU}mCw^a-?sa)|gH{d|~>gTXXuff!|b*lgzi7KIyojb!i(3 z_&f{&uSFmKwvX#^3ccy5@#jF_PU?a#Xm2w2&N}LUzZE-%=O>H6$uPCZ_=;Ff0=sH{ zvwwbjlZTu5w-?T!=RcK?IS~Y;i6Q#8_C(FBMj) zn>b^3{QFx841ja-=U<|-q+m!oR!U1RcHH=V=f0K>T?ZXI?w2!|8fPe*R>(*KC^+AJ z$zbyzqc!fz(sp1@z~_N-HXR}nlq=7>2$2;9pef~U+vi&qq9^<#6Dv^kXS*}&h%V4= z1Z&QZ1~_m%Ux1L6L$kub;qobDU`Rv??V8DedSENC5m(E@D1mr;#1!}4syKYSyChR) z5+TVkPyJLC@F>~^cX@o65*utz4Xon(zqWu_HOy4mQYOkbu7xK40 zi7XRO7U>Coh)LmZI8?_1!1+1U{4;8`JgwoiiTr%OVQDd2 z&LxnIgXLxfpgK)}DMr3*@=snWsB*X=wR@xuvbG zveiwkQdg+f)t_OwhTOIyrD_w1u7q*3)xbm)FI*Nbpy$YUQGMl5P^^bP!*BqL=@NAO z@ENysZEoab`S;%gD~_!8suo$jY#K++e8 z&VCrZ1ji#EN2*XdYJ=mR{OIGVf+1cx-8t%zak+A3an!X=Yd|1IQtQ`)HWZ9HK zpfWZZmuH`|JN+*ZgMZ$S3Ibmyw#42rA0gRZ9m_s@leA?P>&9)Ckd8aQ_w@C2=6eFu zKdFzRFc~n1O>tzQ)Bwj7HQteI^3v+dyXmrKpUDYWXSX*Z?nSk^p8KA(eN^tB(?I68 zE%^-ClM;yUVWFw66MDJ6s8CeTjO?zm$t>W+-=(V$g&?V-&CWiTO2v*z%rzLGkROkS zwQe|0j|UE;Z>d(cIsRz&xVtBq63A{ns>X>`=Qp?JG;2@CW1gTnCz=y~8g8RofK?s4X=jc{jIqhsCGj7wa>fe1cqVaFu|;(KTexvqp@&Eo+4 zQC{4O4j%>a$ThV8tLDQc0NGd-dNG>09RQ1M@s^2NfD!kWccL_jGm*2`tmd0foG^TK zZolx}ZvT4y3lHb9HWJVk_5!NQ=i)J!1ycdkq6qGr0#@{n02j9-V9FW)jPgOs%>K(M z@A&B!vMw*WBA6XCt2foO$Q&dM=DnR6keNDW0IG#RYr06PNsm7RD|x1H=W{+^aYFx# z9LnQyp|dqgNJL@QeaD5LgjbWQ`?7KsUOrK893UK{rT=nSd$VYOld0!A`7lanwh^5= zR1S<79_n0P-UES<`P&H{aSgQ<*$9FnTH=NDJ2|Eoj0w_cO zieO3^URuj?I+x@H2x5CV1{msl`f<%0H8W5ZzCniH`dA`#M*hG6{gub)A;*5ckG=j% zWQy2+Pvsq-*G1IH+BVS>_)Dl_me99qi~PEv&U&H>d%F>8Y^{YO6r!T-8r2S8egvO) zYrWJTQJvJKMO$`<$XkXiV=pa;K_#|5pRk*kmyzi*3HT>A($dDd;N`INf9;jjkhCp5(++#$)dJV4@TxuWuqBNLe%ebHaUmPbors!XH zUl!&bE3%AFUz{ai4tU#QG$@cQSH(HJ(=^eRvvs9G4IYVIUJwfi0}-7kz_yzJ>ygZL zcKr(LDx^c^Ma73fG+hm;yQ$PxoF416G1srx->bh5B-0Vp^(HXdBGz&hM_iS66fCI4 z+|cldFG4!t>i9T0bJOE2_QM-e_BAT!5GlojY|0Y(n%6=8IjhURft^4ioSN65#StA* z_;Lg8OBI@%%Yj{^e9`>1gQ>bZgsUchs|=#Q@9SVn$`@X?Z5(UT+IaQW#LVmapB8gM zUl%$<{Z+AdE^8?*=(m`rxdKUh^GM_<;g5YKOQRB}d;BSc^@&Z{&K7fBr$6BZ14Yow zv^Vr3v||sDOLEj{j_RJhJcE>bZ<9`%{ZBw=a`sDbilC-KW$gATKdDda!L8-iX}KQ3 zA?zU~C>y)2v~YA9?;cDc)aSNd(B8{P9jk1F-ughK{%1)oFNWQf7*lncfvL0r#;tI@471t|{6W++8D#2tx%f#R@g@V{Pt||KW ztIet={!mMb;-DI;U*vaW2DRs~xdZMG7x~*Q%HSdPaDwQ}ZXB1qJ8o+3$E~TERMgW{ zV9$)26nz)o7f>o@Mel2|-5B`$_V%8QS!YsM04q!TjImE(aIj2-=H<(RA|uj(>e^F` zqwjVVw8cybYt<>vRb>eb_YEoHkl~Td`(>cu0f{*Y@NI;mX9JuL z;$tV!I9^jmY-I;O6$i!z^?|uJ zZ9b+EYBcZTbnjARtcsepzNi_NE{Lk)7p=Oa*L0*;3>3FOm~F zBg7_|G9Z#w7dfVkQGufjGuV4+Q}6^JIk}Ik^K*=UNX{me>)#{?Dd0EBi5!q0R#)}O zE5WKPYa;zjO0M9~`kUmSd6;E&FioC<+_!x%HVKDZV)Wpz+}Qw-oLWxvze!H>*eONO zZ;}I(+!W+d6v=F3il}D60{WZe=qCb5j`-gsr~EIHqyBnh!LDKpAUP7Xe@M;--x%Y~%y?fT46ew3q zI52X*V70w>YBf8v5O{-I;zEgpa&|Ck{r3+I>?wQ8RIoU15f~zJwV7=epGitD&Ys0ov6;ajf)MZ|ArVR?kEMerFgf zx=U8`xhYAVK`V~#oo7NxN3a_!Rnw8X7pPY%_@{ghTd<+!JP!1w0n$q6{J<-$#u)&X zi@48ZN;8W0(XpHNaA1)b$JVW#l6&N}o}T_bR%?dvY722n);c3seR8Lbqx8|8+}TlB zc^e(~Be_7k`lH&WRx%}^u@1S=N*zF3k9SKPGYH#80_n`pD1jwd*qsAoxZ+HYfT3)# zkLF{)ZvEOBDwGU4Q&w6wYU>HmfETj1ql-Ahdy4Mh;`Jz&*;vV?wVJj;>X&H?`*728 z!A(0I*1&yinC^?@U1q~=1rO3iFFl?SRFhYhxBx0xZHzS-mPAUi1vAts&jI>Q%soV4 znwD$9^Y%GCS=C#2juQ2GN0TVN+%Rew&?7{w2o065+W8$^#939Z%t2dhw9b6Fp2L49 zo(tdO2mcQ?$D0b|Qmdl{P2(Ay2eq$THat`UQwAym0IuU27T)2DXLML3i-7X;TKD2K zgp)sLX5!n@-ZGN*#1CDA8yc}o?O$7?mv=d7?8s^@fGo?Q^=40wq7PSZQMmvr^v&g_ zN1dpnu^ng)0=b1 zv*RCEs3evL!+R^SAKMSguz8Q_^U0L{mN2R$9Snxi6Ws$ce32U9-gmIoU6~%QF-2N^t@4qU_NtyGpXLr!meFCh2ie%Pt&Pe zKx@RuK^6f;+ZhF@31f4P{)x;^uv${0>%`7x{KCPlc5yIdlt9`xQ%P+ZPdb91oEX0r zOBiGhPa&|=uD@mMXv#7A5Jh32RiE;xbV+l%^|YM3UYyI4K%QMTykX%?YF|kBd3M}g zgAIPqZxzk?5aFJn6cdB*Ecttow7ml5IiR9P?5Srr}h>W-Rwu<5D2N~ zGa-}yC#|zq_pe%q_h+#v^ZUQmI)qCAty3HMU$jmW%aNZ!Y;C_r8bPwf=)>&h79D}z zQYrkq_*bgU6jRm!C#*xC#69u-qB21ijS!a zHFfPvRFn>Vv>Apc5K>ihY_KW9cgXrvThwa!&$THkgt5E%oczk`_PlpnLF#je)zf(f z5njp`<6nT3I-76oR3K>8(45mj2I|6-v5-^BWi_IbRFdaYS$m+s_{`5AKv3=o#6{6i+`~lH2v{P z&i{*SNBJ+d)Be9HHVCW0Ju7b3)%*pt}uE zK7Dq%QhGQ=T)#M_)ITVuN(-?Ku`#ucTXtVoKH;AeH#c&`8KBE}MER!vF@mkg|B5MU%3uUh>-x)kWL z-wlDv*9_4?F56>=UW%-oI3Q%FX}&KeEhzH76zAzTFuJ^n;JkU{foPO~YI2tcCy~xS z@qWhNT8X;!csUJrT3PA@+^wHUTP^Id;9$e{1d;MUMVb8yr}-pPab%n}uK@Ohd(bqr zdQPv}x`y-6G~aRd>icp93zY-!g$J|Ih^h_@+Ncw?cC6rc z4?%J??eT|;)ZVt?u;_Jc&4^lvgXCs2>q$lx~qgI2;9BoC;T!oQaF9^-?c#C z!c(eA{dAjpD@dHFqQ*FAY{NEnCDjtqxV(v&{JsOjU6IleLK4-S4R%Zre4)R4 zkCYZI6tPhtqT$Hz%>JLF4c|T=LpHR!z|nFVygork_b=#&b;3)BG8*fzx=i9bcdu}u z@=w9u_u-;BIc^}kLpjKX_pvQTrT*a$R6LMs;P6a9k5-HR$3=9%2S7*aIU#|(;?n*n`lk0K zh%2~XAHV}3g=ho0k^PN2bS@mWg4NKq(Zzi{`pptP^u{D>@zUyMSg2mZ(c2X?)W*Ke2sgQrd4axaVFe@Au?W|l|?-!jdU-SxTtb3Rl9Xw|= zGmp_vcZQ#3q)a@d@t9HFCm8cn70bs;c(C72P*KY~ne!)}2O(j`#@9Z@jL3an>Hd92k!XQn3jhaKf+4cUY>6|qRf_Izx+##Db7mL(+7bbz=hV{rM>d6EPrJ* zXH><}|AOE7JhTA91T`B4^>S&qR9DOu;&2D83Y8(zwInO6!O&Gb6JN`DN#zk7X0LfF z+*Zr(MG3dksTWd{9aNgMZXKVv8(=$W;@o4hQcYWh?5~r;2QdJm4)8)ua=*P0uuk1? zFT_agP}4w`Dx$J;Pq+>xvj$PqvLLBr_r@A&Mb{r}W&A}%PJ_L-KZyIAW+5EB3`}>! zRl4Xxw$RSbChXF=Hc*tUlMc&@udj!EY!ZV*+vyPQwRz zIlr8C5!LKlNXXUc@n2$ShX@Kp5+chrSjc3{fvsZ(i|atcwD#KuREUX*R%AU`xsqNa zf{e%($Z`>Dt*+)z0YKmqvg=$;+IoA<^CMNJuVX=VOd4yxzpvrV@jw*4D*2{^fB()l zhw(r|%z*7i-HG1{Aci!W-No1x^$O1c#g;xFBV^g}TH#$sgnD#Xw}fD;yMBT0jO3O@ zZk*8zSUZ*LspVf&N>!~jR9hjUiU?UIk;aI0wK4Y6)eqjX)J2fJ12c_QD_G;-r>R9;gh#U#8F3>|D zgeuhILM*)gc0>k1QAL$Wx;}p#(Za=zr>j6Wu&!laeB#QQD&183Q!7le5Um2WdXx=A zruq~%c@6>i%&l1RFC;L-XvBy^D*dQY>9M_{)Z>L4q=g-+xFe6qJBZ2x8<-!|KO6i* z_aTfDRjG5}`IbJ>9as^VFN2x?dVHCEe8YEKy_(AMX0dO`sNb#;7^%jWGsTxnTA@^| z@nsjJfoPvPJU4eCCRRxEmmoy5pu_}3jN(U}Z(E@yk8+nx&N7NfAta~={Y?bT`2l;k-$gTxF+_QesU z*OW*e)Z*XB2s>2R@2$}X9R_gA+rLfJK@L&Onk@t1QL$#BW?7<#)r|@F_R!$Rd&6{B zO3a%lP!&iWR!0=O*y_ymU=z?Ph&61@*%;st8Eropm9?Ax#zt!6KDS9(cdQ0Fn`XQM z)o?(Us7LBEKj3FNitt!R5vSWr8pxV&2{S4=JvFa%k<03ygvG$V+M7!@Gop~_0T)6I zSJlaw3l2seT!-q>G~x}wN{UbbtVH*~dJc>D_!m|p24E$q;J>gEb1x(x3Qrr+czh?= zF_WXn>cv9|CvQ_GhY-=)&vJE*X#SHf^IP!743y7^B!hy7B$*0~k|0WqoF7!X#KWlx z0}J6A=>f4KdjRc?N<}XP>=l%yFzw?d(p=4OkE;+Q#J*EL3v~!SzLx{dMkz{$qNFUu z23TlaLo)ksrZnaJg=q=XS{iKCjI+b^a-LcEQS$fQw1qc1TTPyb@DaQCr@*{MC zQ0v3jJ! zZ$@9J46KsS61$<;WS*3Szwj5ViF;ZHo%wp|19#iN%?m!*7pY)W=*UnEwXEiJSY#?v zJf!(z8*4@a)ROr-%ZFX`2TLWQ-J4ycl?t0N$ZW7iwwNao$UU|sCRg#xM83~KRM-;& zQ_HT@&toTbqYIwHh%4!dLM{2W)bVLqJl2IF)CchW%)T9*_WatE^DGMj$?BC=y@r%_ z+^rTGJS1%5(THnA#iz@BURqofyxF)NayC!vVkKnJG*?c=WSUvMbJ!^klf%yN%iRO$ zoT5GNvw}OxPE+a{Fdl4xUBdlsm!8fk?ub37YL1ICYUE1FEBJ=YPF)V4ka>aU%=tUV zQt6c*i+GN`<~ z-Q9viaCZyt1Shz=JHa)$ySux)yJi+7`TFbL-T&-8v*%#WQaRvSk*lg!)%(16`+Mzg zGy-V&{|ko|vhV9I4w(JH8z)hlL$zvW1R-9dC5fRQvJ2RVFc_7w*B}{0y3(?F57jIs|}h-q~DdigerRuS!WS4qC$htHMCk?3bU{- z5GrH+TjbYPC00x`Sm>l|kXTs2f~&sG^H znZA>P^XnG}YWi-;B{f7MZU>+O*jv04Zn+$tQMO>uDVA{V&WydHFLwOq zaRo7=6)E6wa9A6Ji?gz#EcK*vo$g4cVDv8r5btD4(5dg4ayMvoHDBf?j3b57E~Ib! zy>U3m_(KVu%n$HI>b=HA6L*v1^(dJFOyR`J#0%<7)Y!1lfP>1CDZ!sKSO>l;0KAit zoj=|QnMJtVe~Om2M*mZ^WC@6tK&SpSTIyK(muSg7G40_c0r;+y*9HrC>S5HP!U0S? z@W(q@N^$eOxYeB%T);r9SR~#5w8#Zm|KAOP`8vaYqQxf+4~fX$5WRzK)ZXH98CrTJ zu9{EwO;G9`83xO%c7pS&oj|n-j)qvZ0JM|0FWO1&Z|wvfpq=EPrcrbkoUQ}36DUUg zC`A>%QWcHg+6gHCt9BB(M{V%X^QxT$RQ!{6(tOGk=mOAAw$*2;=OEFduDbx?IKy%Y z0;OxtZrk)ah6PSrTIR-jIk@;0h2fQUGKAqxTSPH-d4DL>>P8-#pvE;q)epB@X39N- zIlurI4MfV4q*%^MJjqXGsGkA;E@Gd}e{4$Jjm8zv&Ch3NFrY3U{Fp%0V}s2^T-Mzo z=02X{WDs=HVMFQQoVcB%@%r`>HQfwAW&UcKY!=S@SpXc$>NS+s9j7hohujH4q`4UE zz#|m-(5V^@&pW1B;eL!g=a*}~itx#MdaWDbP2{TV0cESbY!)`A-%V4y$nng44*?UP zX)@j;DV})*B+jdSD+ko>EDAr@EAjO5lF(ebx~KX259r6UV`y^R%&+AV^P#iMOKhMz4{{S=p`ni*pei_X&r~|XU^EfMSM|tW>9VQ6Xo5s}MPYwNVP0))i zV)KUfq!q2bamBF89Dn|~^yN})9lO&-F$}E*cB%prUn2s&R=t8x`zKQZ2q#SOO*kQz z%KJV6o}PWZekBbUK&YKUdI{EQn$U>2qdROKloB0Bwo`-^^uurXCs?#ni8v&uC)L(O z+oODlA(Hr^*J3GG7++VC<)5Uvew zhWYG+Xj6O6I08m&Cb9v^(Nd&U&wZFxEhLNHD{AtmLb}G;_)=-rTl))M`18B}JBLe< zYr_T0^U%Al z!&H@Q*vj%2{)TA<07;?Hx8?<`rU}iXjxtnX4Wu%WRmhQ;v(B(i7|_0_8;v6)R(m_y z3Gk#g!@uxH`)CZ=!TBFe8qJxa!A?{zHS9#a5`2)_WL*MNI>7k6Cgo%eE z{bq~5*Zu3tV74&f40-e>)Nv7ZU%Dl5NGOu)&G)&kM#$Mk;>bv1nl8nH%q_}U2gz7^~&hRrS79 z{?h{2G%#(KVImROw&e5BCY4R{F!uGUY7+Sm%EwM}){C?4?lh z{9P!mycSB&fI^8u=TD)upNR*MD zF>>Ndq10WMKK@ssH2P8~4GrcqFPGA9plJ`17)+AU?~~!`>WYn~v_vM_FO^t(iV6rU zDz$!-u7}+9|4P&nv3FtnhFYBv90~=smN&Wi-Vnr@ zqtnvpTLF01&O*c)h{)_nc3awQMR}+*>>yXjdp=9#usk;wXA<5yRj{%q5^u39Cl!@V z99_ly52X^lfc821QNo^_!$>a*s=;~^JBl4OzLqgo54biWHu!*A$r^W{0PGTnf!Qo+ z3ZdnF{IJ*l?o6eDvv*;(I`$u`$={Ka?cgS64%I48^B3cU_SHBE&hmWse>6_A$}CiW z8z*CN|%)J_wbjNoZu|JgRO zmbJGQ!#~*|$%#gM)QV8J#~XjOcC%Xq5y{C|Bbn%p^|IcG3U)%|RCM^x6)N}XrZhQR z9V4rxDCyG};Hpt8g@yNC$nHkU36BzG11#W-vc>JZ{SNk<0QBS~d69@Y_>$Nm;uZSx z(e53Al5l_2I}n&aT_01{f=6H)=NiE3JrG>P;7J@RnUDe(Exi+7fsbKV@DpTsB8UUSP{#23rtn>fyL(CaBKPv{WVJ}^p`sq#E9x- zdd}T^k3%XSQ&-;OUgNBsMgACjQ3S4Xj9INazZ*`qZYtl`}XTI<4D zB(Wd|l66XAnV+Ms-)m_ObHF?wMLD`{URhjz!dbBo9Iy z@QD-+qfh-4VrjmFSgVOan9t>c(90-EB`ARECMJpZf9a^6YKK=;d zeiX1Xcb&zkHtdgdIoRk?p|JP3d0qC9_F-aDjA3?c6- zco*n9m4{X+X65>3vF3`XpM4PB%ifThp`3dPC?RLurxh{4)i89dzG`i#T$;~SUmzDlp-(yEkpBsCSSf2Wl2+5n>u--t3^`_0#eEzcMafd0olF z=2Ul zdFb3%IEunw1QvLXie^365<0HG?3R~^sssY(XA8h`*&thmH+JG^${+shn`B#chj$T8 zHHo~;s1!f_W-YL03H>7YjE0mc!w=om}uCGUd!p9NcLh#cp0SQ}P^r@cF4!A{+e z?KC5RU2X1!G$Vk|@mJerW&Yn}Ujiro4f~>?@i+E`bpD^%mxcsUQ;)x~FIS+Vs+vuw z95IHOm|2C6aNs~>-;GDe+d$Zk3ml=qdg+r5SxSL|!;+S09>M_aR(p^2r)Fiq+uxfI z=5K(Y=Bk0pzLhMg&+{}UkE)WPtr|jNg2~s3$ym;8O>O_LE?W)RrUuYu53Wnp6~lhT zK^;{HsMiA3{flrdIJA!`Loie)MC7vtR7_}E zYd`h3ZfSJjfwph95kcg_K0iRw9@TM!9pyPS_`d8HYODnCEke9~?YD0K^jq`NK>tj? z+#t|$z;Fs?*eWRE^7x%T@BqJaVW49UfU~Uu{LTKY-{R5j1SO|ss^b4(BVLOKF2{!| z1}tcn^g&1z7z`U2L21qb`wVjVEhk4ix;E7NLtSl5x%>NN(fcNbto4Nrhh5b~q4G=d z5pIbCG>#ffN^df5F=;l)hbsXJ$cYFERlFY?h52FZl=!hmUHJixQz-wQdwIcNCbYho zXrHRJ_b$QTyKW)*3+)LAX53_5M%ryiSRpB3%UJRIMEM z%a>8sGj)WPlOu*wDGewHqS5;RUdnJL{m#=2j{hUz)*6&?AYd!HzZ}W%i*?j^tIWDo z33Q`hRp9kglC4bXpz87NrahZ89q#c+UA5pyq}|UX-;!jkR11UM{%*K%!g^zn#pc@7 zBh0f{+u941?uMMP9jv~p?-i+1A15?xlG-mSY;5VYefewaIUjj2tw`N8)8l<<-O!$b zF+0gUl<#u1`O%!>e%)*x*)<$~qm0{TXv_dQ zC!{@_dFS-JH@8>0^C`_h8`WE`^5R&e+tylhn9Z{i?ldXKq7_W6XPwm!loe^~OXDiZ zyX`4VL7zpE-Aze+zSzkz!y^~wJ(8DjOHEY>H?8Kx@W2leh|~M>>SYC?+SV6jQUYk{ zNzWX>XbnL_^yLOi@G>VyV{NTbUnjE6;&`ru(a$;YXg~x0^0t?JaE;QQL$&c&vjq=m zw$df&nRH{I$TE{|(+L5Ku5hGDjjw_#>I$@uQ}s3DBv8%}qPE}eu6$8X@o=;8M7Q(M zl9-y9kCb65wdB?<&R+ajG#8<3>{VioC-Wm0pHa>PY@9QQ?!+FGo^Wk%eR-2Zgf#-0 z-;N_{j4@>DU$d?8vh|5sbTN8s5=7NGtbkD*(!=qmK$$=xlb2{q+$85(v?k80Ukz|~ z(#lkw23EkzkBqsh`o7T9I^>un`yHjpM|!{`GR2X2WBIB^(;>Eo$H^k@kB9DOHrl)6 z=06te=lL(l#1^?ONlv@fC>l;d%6e*wTC1%1*N9txdZK-Bu_GqpZ^qI`-3?5ZtG(3n ze*fBRsR+xsTxp>uZB)!59V+o%W>b>$kNNzYW-ISkv*q+N@PFQH)oTCyW-AD0Qs0j{ zVa+waCoik8OJpdxh~`|#YK#6|AN_)*{}FY<5%P}}6470W8It&|0Yg?xO2?Y6*Z3-) z@bJ!Hgn0z|r3{NvZV&x@?P|%?F{eF{dNQT+u|aF@qKVVYkol$NO519zUS0b2F9PsT z5($S`&u0;vx5~6$3$Ph|h!y2+_JIW#!-O$Fm8EfcF$R_fUySmfyR?h&5j$HXmhcRTOs9I#lHH%15FOwQDOGM{?5Bmk7!$`GyXT9~KCR|)$#b#(@8UhkM6NnaPue$bgHv5Q;(K$40m5QEF!!pS&K7*DPy`vZrX_9Jn{F!P z%W7zDep^s%v;1rM=@O6@vYm}O6!xVHuWBBnRN!`4c!K(PvofRR_|` zLr1gPS)sCg1D!o~T7@;}QsmUZF=<-j`IX@bC{O26llF2PgUk3dX4?SEagHIr-gDtw z21O6|jYWS!z;h9PriB;r0TCs`#3eb5%Va>(I8V}I1dW?i;sZnM!VowAyG4p6`4oIc z#ilk;jPngiV<_Mr{sNf3j@v8-=)Jqk*pd?k@rV28S^L(61AASoBTcCu*8r=A%5QgM zE3Ey7IKvJ^Mn~ZHJx4D7VTY6Qyk_$6BSsp&b>gt+gC}bmu~Gw%@+o@f!LQ6;u8w`H zh|l32pvfF2;he~?nNCFG3!!hWx?;mK^y zAF1p$X|eixWSoQq6_|Tdm$;_-3ajYu?9rpHg!G=ar({F~6uK^}+zZAD=n)tx%>n|P z=`%}e)NC)lbO|~t9FzdwS!gspy}KOAv$#JHa*vhzj0yYsWV>h81`?w9Mw7LmAv3D@ zV#MZgL=nb;NdKu$|J^Z@v!S-KIO%78 zq_HJ0yKA9%F78e9m_>8Zg(Dt0^Ls9)E!~MEZ2D(-LA0$N9wZk&sH9(Q*x{(Hy?CDZ z?XnY){McDOL%Xn`>UGvS;tH+KmvC=RsNzZ}$)gHRuID8bsvCEFZ>4tYb#IhmJZ%Zw z)X-}cj*mFwN3a1uD~{JboP|$|-HgI4jhv#iXQ}u&;{iYwv(tvFu{fbBfZ|fv51#}xI=i%<|hEmK+Z*9jWxef;qq})1D^J7f~#W!61{^z#k0cr+S@| z73}K!@Z+d=C-1jTYZB};Pi{ZF7y3Bfa^3IW^4nb+_Mgw-FzhPV336(L#<`ep2XISE z`|}l^{5ya@jH2`K8IBp|XzNQ6c9y(IWPA}mtu127v_m2{G|}$_z4Y9piwEx~i`H)$S_QSw)%F*M80+u&FVob1O0)G4?tK2ieKxqE1DPL=e`&UMJe~>m8pV;B(WL^Gh5~rXv@k zYniKnyO;S~iUghTQ>Y0H9PesBh{AqjnDJm%e6;IFPDpD0rw*(mAhQYy-%LBZ`Xg-s zu#;?C{zpXE?8~+Z`U;LAyy|xl%SpUL)tT$ZkHy!0RjS@4hma#4@W)xa?%q^@K zCgTV+`HjC&R;rT!mYaI_5}8h<8)_|s_<)>Hkwl$G;50%2<87g#MO!7;Zf+kqG1KE< zkim9HAGGXIvzOaLEFLWwp-Sv@sxHWD#nzWT6am{nM1xM%*9?~k&ZSNe^LsF@!Y|QR zDCe`+{+t0n0kBQss7D`P*(Q>I%EB;IFw);-U3S9$ToW#nI?2QwA}RnghRGHo4nNg3 z-U-+uME_VqgUu@_#Y3y*X{{*$uP_6{^Fzc_m$Y?N{-8rd?%;6aN@0@t6Zi?VR!k9R zNFszytnn`Rd=?;v%=`{`J#}$a6+bkfeQ`A`zEIn&smUCaQ9mxAW`tT9a$b4eLHKzA zfYC5o+`HOW#w?0x4!8CQUehkHXfB#n(jsA-moO-yEcRvJxo7cD%xyosX($7`YRP_R z8%XQXCK_OKB(|a_7_hK_fog9`9T=TkjEH z0oiLOT zy1d|!o!JrnCBjQZwSUFglK(?&&Z-)DLUf>U3{EkZKq^p$oOqqs5$nbwUD-~M?llc^ zAF#`1qwg?Ubr_*-JAiJYj`7>!1aaYrQ!m*4O*h#T0A6eZskDP(ZU+Ok^Oa@xoxxxG zqJt~7KTqb6oBXDmaLJ955CUl5p&=?+`?RM$e<$3mN`}I&ImaFhh!Uih-Z#S|>i$t= z0~Z}`oq{iKglpe!f*0)N>ld3l-hSqabgiI{E2@;USFDw_JR@4Fc~~vu*(qd)(BP6M zKvV11vI`}>C`hJ#_zsDUVPcGb56kdIl{{f7Ogu=3&`Er=(ZQ8ZN!?2GxG-)!FZzoc zu(?8_(d6J<=2esIdD*_{)bcgy#b&a$+c9!sDn^={>^9C6Mzrgcu#ixFgq$?4bf`BUk35^m zwP=B)V8&8*a!)=Clp|_a+T;l20+m~A0jCfmC!X9J4(*jxbF>aqq}mQ-d0xuXku>fL z`L+9D_UE6>&QkOscJjxwqw~4f1$zgk;;a`#L~JEVNYWei;?8-dRVT-lg)nKAWCTi4 zj*H#fzGiGDyKaRUBQiAY*o@0lyv$;67HP_*c?)eR^Vi+O_VwRO54Fn$1Qwlh<`b>d z#OE8SuC>E7*J%MIi~U9XdlYT$ zCab6U2UM66sQRlEw8OQ*(44U^@a_YkoHtifyvs@nX3=|q%A?**V~M5J^oP9n7XER~ z4*yY|*Xh0F<_Q~pfTp%Kcl za~A(3b3mcGBVe_|{fu#n`Qle+Cj8*gufTYK5y${u{QfbYIjAa$pbIArW7d~R!CGG! z1;eH(Ao9=3)EEgudA(-9fmD>gd?w|+{m zF5Nqi+0ye~nh^aUywU;fjjs|I2Rzh)%fS_mo>;CwHswx(76xq29QAS`*5MX=Xp!&Y zPY-yn4V*?P-*$#rU+zn#6t2HSZDAlO~e^t$=lAfnRdat#YmrzGE3D|;lSOcT-ktR@PM5OaaA#di1LCDpQ5^DnjCZpz(_RcV9k6_FQm;8 zE>cR-wH5tSf&tMDd5qoi!`O&8sB)YbZM-k;0*wdwihM01rWe(x%*?bf8V5Q1L!CT| zDaQ!~-+1*ggHMamhz`#Os#~4*(v2aEXf+O-%-1Lp#t$|#H0Dy;6GR)6D1ejJg2gC~ zWh$?@wyDxd2pSJ``oS9`qSC{(!8?KJgo_BXRE72Vo$@3OzSy(vuy85W+fPI*eaR0A zgj?jdxK^n5o{+Zoz(g&>{)UvIKJ4O+HhvIcZ&cx{kUps}Rs}w|DY`X2ufLNTp?y-b zCk;0%{Zc=G*L1??4zlJ+>J#@sQFC4e;^=Sw{@(F>W}koA82^Ti0+-U#q|Fo&%oXbL zkAe%35PuEjIX$`$e2uMoQ9(i#$*PnCy+RAv;r6i;&9j&+JJVWyH{^fSf=IX$nZIhm z?dujS?TIPez{k7W6OK6U#*DIbYegcUn+Pp)^oP2ts|=2g=<&?h_f?-js%833L>wbokk^egM2uZG)V;} z_aOuxEkB_YPZPdu(th2Ai51$fS6AkMC_?eGn!aW=IKR5eH5WQ;x;#^3>^o2*+NB^# z`twy;qQp!|+SnG^3-k7m?U?tr^fhhFA}OMt$!EzEaJZ;a;pCBYG>S|Y)j^lLVUF)k zC^F@`XCgj6;OZ*FHw?j!T!`~pM3^W|vK3{#Y;2{G1%Nk zGmtu~n+zrTa>hAzQrXCcKEIXpOP2%;7cBZKYR#?Zc*MQYfOI5X1^mKmyOFVFiHns( zJkIa@!K5b#W+q{d!Pe!D0q-huOR@bv4!Joa(^4lO372UBho_d| zM(i)r>teX37t?cit(1To@;Cds@jG|&ufhdZz!eNRmwMkR- zJ^;}RihWPO`2XLH;6Qf6e{BTG@1V2uXjJiCm49N@xoH-ZFa*|uuGFerB4}>1o#&|* z5hx2=REBmQ4L+f6Rb`z@aql^adN3Ymnr+Lg=P(pP!7|F*WzK1f%QAjK=n+46R{!8i zZUxZWh5x&OppCTXw_4eaKu8{eie6I{d2`zgCCBSA;WQ3*JA3x|R<&zd1!GhsXAO+S!YQA5a{9?4efjGP{1}bV#X#7P2Y=|0i;fTb zke#ebRoYrp0lit~Hc6R<)cd7*=@s{>Twtg~sqefTpDVgD)~x^0y1K~ruk~MWv|m&j z1?C^~owo~cE9cqX^kx)O({WN`pOVE^4x;2B zDJ%u0Q(e&JFUOM_%BNqL<^Wy zg%NMpow7leg<|V~Zox6`Cs<;0<*s}^K85(7VP5|te_7AH*j`8PjE@URSs|D4dOF=< zQlm?NaP0VsVHnWg1jhtLI7ZKA(7q3>?=s*(Zu0qQ+WuADYoI%d10im4ZnUi z2Bp)j5Wrm~jFfloaZym{VY|x!g?!0N_sj)3@8k=88SU|*HJTJ;WA1>uh0Uq##Pu9! z`L%BtR$F);NJgFqL;&sv#W#;Pku;507DB@$S$ZoFIluuh z$zda0qJlfAII=3Jw_2dGfm?e29`=GTjg%b!$o{qb33l1XWj^`wVaWRH%r?;;urEbm zri3@1O9az6qU{H0PiJ3Q&(b1;LU6#)F@~}`(hN#iO4?(sAv@8w`iDpYgg$ud)VZ-% zSo`COc@5I)q2Ib!Q;4SdSEzwZcN*>RyLxv)Yfm~*<>Cnoog#C%?kY&<#SMHH*Ez6^ z;k+JbR`MxAav8-;@_d1R53X5zYa28FJU%Q#$|c}K?`^}>iF~2G$d66*8}6g7A?yWr zR)BGIptiWj&4+E!INzL}uCHejA}R@3i6<>*JQ-5U z;H0KI&r5>U_G24-00IDEjh6LH6Xv5xO_5IO#@JnzU&$gwpyYl(;r8%l3(u)k`7A1% zGD5HkUor%qRs&esnHO>t1eGz`TxFonRhd!#UP7e8yVVFRwU(}pp_7X!2UakA#LB{@ z@#t7KXQ0W-Qgvxz_~ZrYmHytIme=*&1fYaX^!!r7Ks2m&1Mg-5N|>objkPWNkEzBW zOi9CfFyI@b!R-M9e)g=FlbISglKBm!=cc@}wt$2rpF93V|s;L!>1^kj|q zU4Mpx!Uf&~&lbb4_0A317sD1g16-V2&=68g?gYzL8Ha9L;BFOBl~&GnR7T1`x?GY#tL7BU3Bg{z_st7uH}aPqGTn+@ z#A6aGFI@eRWTtQ6O}pyjnBq18U|eeNPG;VXON1DK|sw{5j&`TOjR z=!Yv1l_fSX6fBzOM;{@b!YP3jza0Mf^3tPvLpV0ABTPu#UC;+@xH#e!VHB;GiRv;@ z5ZxYumCgnv0D&D79%_84&gE6l_Ow+jpFhtI;D2?{?<<@wAG9@Kqfbd_md^cE z_^pdJPDjNj3|EF3tJoyke#_p+9d7NK~xnNBG{6t|;*)7J8SoC(Aj_(@2a68(&#`=l6Rv zf^L9BZxVxUC!B?u%r_}7WiY9Xdd=fmm%v^mQ>Tw(4VgMi&E8Cp>kQ5b;gTaLtAHhUjgWl<>rrCIh;%hU>nIc!yGftWhE2R~Sj{~YEM z!>~`~1JK~W@)~u?JuMiKxdiIx1>GS3u#TVJ*G>F1CZD`Nk5%oB4lt%@A*y7Q;y_~p zR;^rm&6ouG@{vuvpDGEhCzYD|!nb=7f?qKmd3leecC9(UR+{2hk@6bzwNjGJRdz*s zvfuH>>x-CInah#eXO1-vHsg4VyE52E&`pI;4MYkmJ)U1_EZ<=ftVKv;2$=iL`l?E)?AOW4QDd_5Kn7$_aS5Oc0v0w@soV&)&V$^ z!Q(mliW#L_tP-#>6IDkikgA^I5guhds*I4%#ni%m*;I())iIT+^#OHqTGG z?Gz+o1py((4?`HGTdt*H0WBCLg9)+lpPMiilTZ6!7NXBHeL_P{0pFl;WI5A!uAqTD zKp+{qe#dkzseZ@O&1JAXZ*r`=W+~=Fe5Pqcmq@~MnJeD<!`2|kLXSjyxUulEHb;5#z+7V3H-!c0UJHj7Bp!yEI}gDwNJ_qf|EZGycwNf<6j- z1VZalOVyhpSfUzQxtXB|@TmRz|Jc(30y|80&E@_1@a*+oDu=2qQOpC5>_Su}Nn|9% zQ5fBbIJYSoD`dGX8N74((2wFg82hZ(W*P-w?*Cmos&X$)YfF=xrq z09_pqg>Y9M_J(1jV5F)hfC3AGZLBd*yD(F(KSW36M~Dut2qGa%KRK(y)ih(>i6hZe zw(!G4e_b&{py?`2R$hrY?z1P31}zk6^zekE5Y_SHf{0|A!s!ZfU`GGxCb&60R*r91 z`z;opRyJZFg(wdRSPXEN=3DgAic@!ZQ@OI3{KwnFsC5(-(!}s|B(i!0Z)pG>0ARpM zQUMIu2x&U%WW4wFWI9rcNSWl;v}0I-F6dY5l|9`I&uo61!meK3%_Wrc61x-O4gH#h z+QPa`i_)GH?lP1GXLS-)m+_w&S2~ZGhk?B7c^M&E*+^GX<@*!wh4Gx^fj6| zPU%d+?C+m+cs}28xuCFN=$B^=^YFiGb`J0(R8LO%QvHE&YshZ`qoL@tDpudELp80u z>tN8X82^$ZH>=P=%C-H~@(O$1%;f^h2a1m<2v7mORg`>*#zW2rUt@?2_QK5l^R=k% zK8}mSlo5!u_p&ZI;2g0V3Jf`jKoTm6=prw{*2_Ld+T>49P;HA?$-N7@g73lu3kSn# zS!E1rvJK-;;&z_Wn9PJ(-2(4X-}AsjR91}s`mNs|^~D0C+ARSyhdW~F7u@jgCkTTl z^y^(EI&)YHRUs~xIxm)pkU*cOy~T9|jbM+oY9<$bavwD)s^6O}Uf3l|q91bI8oeNJ zY(Lu3s2j|tmetn3fxi$(r)y#WAM%Jd5^3Hw;&-V=@%G|vOV^U7Awffeh6Drse|`8F zgXH+}eux*C`pUPI0PWb$stv$?y(Du>lP_glL$OE*VDz!r^^M%OZy;&?Pyr+@YjCEL zsf(bg)W}f3K^j1&p+Tup0?9Z?{$hh2V{NeZ0DjCs`nKhWCk9}>K3gORk+0|+o9uMg zwkB(L@q5w(!j7Hz$m6PVjDp(tWB^|Hooh^Gn?Y(BD}&Y^U{_uL$J`(4udC{W7M8BF zaumY>V($3D@JMWd>9(k%+N~wrA)J}AUcy8Q-axD>wRp-%!x?_+bPNtFK�I!a$mJ zRHS_^y_Nv`x95% z8eOAJh-`KY`);!1a%?CJQ(*wRBmS!jR(bhBpQ%PObvmq~(Q&MXRxkwpVSc-+T=c#6 zApaUUob%~54I|8SW%Y}S0V!5vlxevhA!>#&gR?m*3ZY2ONQJE*>>>CW9L2}o(i-?m zI|Ak64+@6N+)D}=!)9f|Ra!e}M;s@S!AyD=NFy>L<|FA~lpu{jlbP~QW7yrT{vpZ~ zDNr1^#4gq((bVCSL0ng~(ao^mJ?u26CEqP9tuI*GUlgA>nmvpkn+^l&l_WBIj6)il zxRC2Y{dZp~I2v?7I#a9+7nbIfSi%4zSXD93hk=yLz#=MKW7#BIbxCMKvE{!2R-SqU8584&q_bQf@;sa1;=a6B`X7!jSH@*Zi7j9!QUytbJ z<=WeU#3snI2=tEpRE0MEiJ>V3qV{N)7!bL_4TYm&}7Q6JO$ z9y?9!^20|OH7|Mr^^)Z=X`@;>nSjde19ELAylvN^)4%GdW`)o+Uy5JCs4}0 zNGac#?~^)Kjj+~^=qA408_4O4H^O{gyvj9cq2nf_c%mHGf>x5MS*ObJ;GdXjuM?w- zablFde(WORJ-VAe%wv#=5MG#e?4kPV+yWK9G{wIeGv!BnApG{5T?# z8d1nhu(D4#|Jv{^7-STe`!HsOjrG)rj{OKQdO!tC8^4HTYmQmrEEE@aMb195O&TA- zw5JcVlWFKqtH`03UCRV%#YJ_{rh-j`7_$;(hVl*M=?g630AE{mB`QZeUVl*DYs)u% zKv+B-Y$SAP@FCGbA$V_SL4mdaeG1cmzee@w;o4g0$v$AK9FYi2h>XAmxns(s6^{vj z;BgahBXA2OJOf;&J@1lNNEOjyg|a(1=E-5nG}ykT+)?Rg2%{<;yf@Xwa02yDpTm-- z-~sTlt`J66(Jg~(wpNF7A8zlibq~x3s8@DUt7^S?`O*l@wpHz!pTz0$&C*qSr`S^p z?W31Z^vhoAUNTs-7%Cc@SJz*VWKLrAWTN5IQ}HG`o-$bO$Z6vL*`KKuo=!%fboId%WnDT z?n@c1Tihj_kvgIh<24@)WDGBx1J2M~tU(E3!JdZU5LXDO^KJ4u{9A+`+wu)UeR{nz4-P_ORIOc znN1l`x(xyU&30G+AHiaz$p1I6SYJ`&1@dtam!EpYM@;!xsiEWdW`(nQzrDo zlP3Y+;`)hLsW3tJ?;<%9_8y)y1bkb(NCXdUEsq z*CJUpoGY#z{un$hMvh0t*Fep^FVKoA{}Nz=SfZFJwt}%exw=#)pkH-A*!^L}^o7(5 zwR(m%MI{?7lR}_lQ*JG#g8*yIJ(WZb1L&Jc+$Uxnz`BZ>9$3N9v4XNmPrdtQCLIqjZ|mxlMfQHU z$!it)4>`|oXH)UP7Tz2M$nKH2cp*fENjvan!_%;u(AwnE8N%o2+CMkzUuWGXpoU;c zMUWlOH<3Iwra+&=o46?!-cKVBB>z%;6@;rgaktGSZ~V(V<0J z>>X{uW_-Umjar_Qo!-L>PII^9=f8yIlWC%Wi;#FE1AoH5Rfd0re?u@1UlXiq=4)Lz6v-OlMRs@N-$qlo zCgL=@s7#_L@f+5t3A>(9b$Dshf})rulycB8P16|yoHI0+;J+7wfWszMUCZTiEcz7g zpGymNHF`>l*zs15*J`8htEc_ie@Z<#hSrq9FLSINt#Nzs^Pre2Paa+ZeOY1G0cw0xO442+_@^W{;(!*>2cJaNq!J*~x5ES_l`VZyRKV zfTy=zR!&iLhb;#7#hqK-z9U{#5vd%BNXrWeNbmHO-i@>RUizqoU5mVrhc7JkUwXm2 z<=(FgTte5b(w`8fP~o9b-+nqL_J?GcoN6wmhUKa1@4w-l_f<_0FUNDq+qMh z!&Rf?JY!^`n*kThhfd%(+VT$YvG2xpXf49gR?c4@#Q-*^y9uRgVqzblJdhf#@o_{0F2y%$2Ekkj=R zmEPo|z$X{F7AX>H{=G~rg&KTgMk3U8v#ta+i?XZgF#5PNXlQ3{-LQ>5ptu%hc;x}s z3GYzI-ebPnZq&_+R3?@F6D8xgk86m9o-nbNj(OwyuaRId>uWQ}Y&obbJaB@y?J?Vn z{t=$j$2b9+L5K33ZJh5Y4BwoMX4l(ac=%Z6V0U*Db1n*G?|Y|8J9d^QLF#!_ZErJ% z+X6hNc6T$FsRM}|nRYn;nztm}d8R8^EoRxv?P+^A9qqWliVs)Ytd!aS?jZtGB#5yZ zD3Loupbl%JF0*kt#1 z8xFRUctr(ExdchVCCi5Li(C61%IE^rcIRRDv?TkUif}N2pX{uwdId|njCG?<<8np` zJcdz}ypF0zhuOKz0!foLf}cAjH}w+=&C7QhpheBSbW z#Ymylcs}-{;Ure;%{A`FOnotDWzTq{jFEjFfP_>14%)+^_x&439dY=?lwJcg+Vd?w zL8C}ImvN~JnHlv6!rGD&nxuTCk?}og&%!5Ys>q8dm zzAJ((O`Y&)>snQLTZ>^n^tDGzw@e-Q2XPc!JCsLA`SGz?)x2VXn(5XOa?ICU2St~X zX)N88@@DnVUmvJza2NHG7=B!lna6%|tn9oneo`~%pmbC@ty=v%^R{iPad$m4f3m2T z*ts6FO^=@XA&HjXQRp;y6`j_6DE@oZ;fgZq9O4cc;=4gli`hnSe=sCsWetTrxjIjY5$`Dj5wwfn)8E&9H@8PG>3OfgG%Lqo;l2}tQW-%+u@^0dBH%yQr z{fNQz^-By$cl#>_)J^g;mB2DyaO!ZflU?9n{-QCNO444C0}17l)mvskHsGeZ)tq54 z>IZvJkgRJzOP192s}!`gtnL$+WAb%m(w0+OA@C=mlW%sv8C$|4@SvUVNfD9*Nc z2Og3>iISK@B+cvd z*(F32g+Ut0kPwgy%z{uRrhUuP0V?dvO>!IRmj+M+hy4M9c~RiI?%Pkpo5 z9QMzKs$ZWeCazuzL5{xt9|OMvLHoZ4g1mdgWgJkMwDLk8xj68O>S|x`8Gu^JPVTjg z2^gCG^4&^aeYg0vKYd`u{lEBbU|;|EZiIR<|LnVY#e8{vBqdXK?Mehvg{DTcrNh4f zUJ>8}#)?TRjRl(O&l$Yoo}Wvc^!`gn}Fn!C|aY!B7!tDu0WUAV)siVV(-hk z1x&3G9#FO?j=C1Hj0rJID62af0?XlE11Wg=SonTG6i7#4IF@knY#N5@KH2Q=mAK_& zB(_J+hRIeZYF6>d?t~dF2se*@IG5)3e6I zs8os1Yk{Q}Gu)#>YGNy>BnH~h@s1|lFb~MBpA?!G+bu z?X7!KU9XxN4AptE0apnE?wyA}dL3Et=I$FI54s~T$~)U5elcI;aHtz7-buc?*Fnm?vp8>_)_1ltb#FR0Wr0i0_DvT;{acc6W}|3w zZzS9Op#d;yxnoZ0<~-f~EkIwJ&>#acXBW|gOKxuFQ4gvwN`?hRiGw9MjH3%J;yd_v z_k)#jByckyU-Y%B#g~w8A^3q=oS1^Mm#qaU+O~_x(%LuT#a?3yW5bCeG1k3}kz9C7 zehB{%PKk zfU@%!RQ7zt%gt^ur!@3Cxf{^#OVKn>qhwXoPT;g&1o~CqSy9LgM&7&IWwhlDp6b&l z!(H9l+E$}|Pl!MkT2>Vc=cs(LpM8#;)6jkhv5*#_qBev8 z2?Pl45Zv7z5+u00ySsY`?!n#NoeA#lu7msF8vIU@SI)WToV)J&zWZnPbgvnx?&|JU zQ?;M{tXVVt5x1EP<*HAolSK1vY9hk_v7$L>C!S{*x7W3{xh8@=axW($0)*D**i&GU z+YJ+F`($q5A8xsS9^#7sONLEajjrCSmDS_h=;m5nTrzrRdAOS9G-4V5b3^+Qm|A)n zQj%?#EN6r(PyhR|0bZ}meuVjZ$zJ`K9mCTUj^Gr(7zRIYxQZp zu+1y~Zxw8Mi2qT+=I+JIPe2%L`?B3~@^E@pg7nINZ)Z26qRVCe$lkuELSSKSMYClh za{%S(yVuO$4a5@EP`5XEM?DO>IoEHotFj)373pnGzAf})vFvsEAf(AJh1bd?k<$^E6dJ2gchxR@yeYFib60h&9DtIB zd$p4FFBQLX5E1FoXeoZrG-&$Kld9j=kOY0ce}l<*>FMS`>5XrK;Vq4iXtcVZV>vZ8 z0d#qNGxU7Nrn&~4K59dnuBK?oBw^4el8Ny8M@G?t!xg&e^_9y=Li8&I?cECJYDNY$ z;vK>=HR8$MSm?C=l9K8Y9w8s^tcuv_NMG)~o7=w)!Ah z9It{VY*-z3ghHDQb_2?hi;1?hT8mtPvXJ7mjiF|7_%YUJi5>#ytwPpGa#vER^|(F$ z$X%DKiAhKfNe<sFJ1>4%e7R(Np+xxN!QWN@@|>G)Zx?99x7%w5 zs%bqg%rFV8^P4Y%*x)=w&+b(ke_lZrmU#MXckWP44QgT;jY?(EC?**;JS~^Q%PkGf z*S|=yX%)7O29(niDPEEA*)qQ1s$3Y%iT24cUDPG-h6XDY;P*DTU^d)_jrFJBiI2t_ zp8`x~tek2e!DDJFWgs?nhA>*<{?{ssLnlbq76giaVtLS%`>Y{V`4jR&Ghj8^VoNnr zI4Tx%HM~k@+dSRv{nA)BipkKI<_-SAoa_0LhRaeI;UObCV^#NQGu7=S7FtlXE2p!( zv;0c-8ogM1)OEq7@JD^IN`ipykWp1XNz1XfIZKHE7Xm>VbHnZ=_6W+tIRXt-p8$+V z93#K4oJDauNOz1VJt=yKfb_E?`0Cd&p9=!k47qw#7i9$F?nBZX7C373zUV-2h18!$ ztnpIm3%V}{#W$Tek}Ux!vZ0XdumaxBmr*QO$MTGGf?`Zq_|*(kdSAK*C67!$0r?}S zaD>4H5ymfsEFy3EJ~qL6GAX8l5@0&%74*__cA+~ce58`z2)((M;Aj6uH!DQ?uOw=R z&xYUIlFz`7uxl}uXJx*)52P^Dk$$s3bDxS>Ror$?=zOp4q ztR1opq*Y!LzGqf+xM>=v{UaxRs$~#p>wVWTx9Ux%WQN&NWo0~ssrj2sbUn$`Rs!uP zYovI=Ck}a#)cRZm8#TVwx4CRQJbq`%BYr~mw8hdak(;*)8$3Gm=T z$tU`_V?$8MQZ#wv@tW}CI}P_zv!ig7;%e#Ucz(G6;J6e2UHQl557QMQ8`n3`w{N)% z986&FUG$dRs0B=5e6kc5I=?t;v}?LU#coAOL?x`ZgL!ZGaPCyUumz^~Y+S#ly|_Y& z^n;ncipI+9w3jUX%@DByX}VjCkatkX1wgO%+7?W1941lmFT13f4S0}+U*8yd1|bIz zJdRV0KMt6C={yG^^j{$SHr9RM{A;YsAz+_VB&67sveq+aE?Q0f}kA20m*WuL~A;Qp02UsL-FyPer@*3x3dIBnz& z*vJ>Uz>N>3wEX!ew~rv!kSxo=DwQ^A z#o;kPSrAs-_XOG7y~%GkaG3^rqxnB;-k+_JrW^q++?vj71l3f^pxfp6s4w8(j545- z!L&1fQolYu0cM~ju+!8eB<%?zvN-5Ov_5m`*PT9TfccH>g5ZseiMNDO$v+at;2)VM zFDQFkq2mQ1$2gh~XVM`c5lUdV%uCyX$vCw%wLH&kcIPp97ggJQ5I=JhQd-z6lD|ie zva))YKni(#GWM-9^qYZDdEzI%5j)?miy%o&2X{)am~OZc!FXR2P#e$q*qGrx=2JSc zjFkA}#q`2EBrx1;37^kOUCUdj8V4fjl;~HZ`<=Y{61Rsw%f3*6{pP3Vr+hO zV9b1MujIoH6?9z2~Va>|j~hN;d!G~&%P(i2@;jcqK`*>L6g2dqtgoSk4n0iW%W z5t#5_W5a!&vt8l$G+#vX5FZ#At8QszUY+1g$ zfi`(J5M%l!u*-dzKN;v;46w_?t&5|N$)x?pSg7HpzRpsW`D@ST}e;W*;yD_b`Y*izRi$}{xaQinHOuB z#z49}h>+8OqMCkB`lPn(Zs0Bs6G|f`CU-$J`f>e_qb`1t`LCl6!k?!Ci9{N|&X#2o z3Yn;t<(qQtEvp5&gee@pkmt1}p$_XDc*dMR6{F6b%c@;ROBQ$G4g@m!ZK(_Sho#Qv z=UYq981M4_vE&Jx##r3L5$s<-2l-8K_ruey*@JTP#uE01zw@N9uG>19aj$sk>S4}j zza%-mqAyD-vV?1JH^TNMKn?drs82#*NjN{R^ARQK(M!itMf zv+Vsm6mx~0)nn96q*QUR{D_=|I9}OM+h&jDYQZx<8FcTg<1fncJNahe_AV^uG#30e zz}Z)kV5&`G=!VAlj+?ch&$NiPw?UnH|AX}yD6G!;(O$igGk z*G=}bBRiJWZr)=1r>gFIBb7Xc<2NR7VL8gD!z_)@G9yjx_B88V=?v=EZwi873=FJB zxbFntQ!P+^4!qT;D2M4TF3;39-*n@Ldn~Pt&M%w3madjR1LZF;+%6Xj8su?@0^1aG zQCHh_uc0YViIr`1WZy;{V50$0l2MT<ea<>43Im(rZD$QpUAn7t+P# zB43jLA^*2OPniSk&s&uf^&aRq;mZ6(K(3}WNW7Co1068z;SmBL7EY99VjIgQ@->3> znRn3XW?%l+6hzJ6@RjDUOT8VJMz<_Spb_VRm+o}V4HFhf2^Q$-^)0I$F3a{k6L2-K zz80HomI#Ze+!H9pjc7_KfwK-TDzry;1%rF%N_EUb@|+vDf3C@*Ujxcgk!Q~Vf(SF6 zgPOB<4aiU*07_~mCps}&#L{H)zPV~?O3tz&jI~6mf~iF$Q*p>w&hlOj{YPge?Z91f z_UC$j-*jMMO0=V`?ekY)4r9rZA!{@Dkp@k^F_u@eEul zbCwD1(}VeA*QR@-E=rjaIZU!YI!@p=RKGQ^vId>}GBlqwCbmJcgks8|8CB%#)h$o3 ztYCk_huQ1B8EGP+a#Zg~y^zeb0KY(1n&!1{(!G z@K->ZjKhoJqh|1W4ZM#t4XSKaY?>wIwbu@t%T$~#YQS81$J36HN6xbPSj(XMI>Fr* zwy+f%5o8A4IOzZkmd_p4+461FV`>Z%NT-qwKCgXh^C_*@lA$%vMEu#Z#q|p%+=M8O zf*NEe69z0l(^ugpm#%V5jY1KGHU;d1s1HV}eRNjE4;Jx#7RY!d>4KRP#C#OjtZbYR z;cb?LLbi}HpWZLe!Qz)803S$R4cx=-^CD_<@6%`JF(NM}tQv<;J{TKgNJZ#2%R4Pv zT}Z+o8z|aB(HWy>F!|Vl-F*`tZuWJ3cJprCfiAVlA=4H79H##U7{@Yo7Q$Qq4KT6* ze*=u%CmriAmbVrgj61j@dldpvOK5FcpZ@W{9F>QX#0&wM1#HgCjB5#rGGJb zefNWNC^7h%hOBVQLM+*qfoH1_SB8HsV|LD& zL$a(Z{U;U0>C*yWIP@gj4HwjHb2hk-a({mNxUk5Z(cBrw2|VG%kNF_{jcJWBlXP_t zIKy<7sp51ed@&yGD0EJ{rQTb208?jHSXU*G;8W@zUWn`XKrjcsjJDJyo}V0QH3QGa=L()__x>Uqx`nz4N!;(gyX_alp|w zxE79^N7RsE9nG_mbI?qN*rByDIGq@YR;V@Awkd%Ep&R$We{uj6CB2p(Nq{3(Wp_PX zC|bp8UfglssGLD)#;a$`^`=nBATA-u&3dsACfbOL#UfEQ!Nv2_Njb5!yk9>T07kMM z@NNAKl5S8H>>M3*vT&8C&(uFa}inZ^0o1jA>#u-dWK5@sZ=5#S}SXVuviO( zb}U$FYvG8*t4E){HMQckZ6kp^x|ttA#WIaL!U&}#pSBmpF7OP=K7!8hM@0Wve8Oia zfsk^FeAOFm-Y#Uu{MNcu`(%s1{>=ym19U6exk9HTCd>f6 zkJ@5ad3MEB4ZO8%g5G!aZ69*NKg3a~;=#i@PGjK2G41hVdy=5SWZqkURPJxG*`wWG z$uqlgM4=9;MibxZ&I^dytS6PyL=xL{aa3Zo^L^I@x@m~ zgl~l0?^2l;=PbTgr!+%i-#>)Jf7iK16zQG1h^~Btkb7v>K{jfpJh&L#-GwfAIi&R= z7>Y>=Kh^!#68cLb_4Gr=jl$)yQnHGfYgZg__&s59&-wA(;A=SqA z(H&47D6~-F`3VEGPX?L7BU%31c=*)l#<27~5t7^((2o%)NosrxmuyTpz7DgD8L1^Q z6@A16@ya?P9qjDSE#ORL^! zD~!^{e1@m~^_Xn@$_CF`MT8EM)pK=HD_RcI~id6_gDjrqJ7)xtV^ z=p%W!0~2>@>GSJS=GX2D8iR=`6@tDSlm^)`eP zatFHRh#HI0DHS^O@soouA@WY^XD&C1&X0NqiO6@ye?}UMuKeyub=*XPC54h3>HM!~ z7j_N~b`FF-)s!QsLQ{&J0lm@ol_G+WLa=Kd93-ak^0j9H)8Eoz$H7{i{5P($NK`qP zUeyM)A{TY-2Ht%SVK?X?nt9doDmC4jf9)u%?LTH^RFYf)~G9U0BCLYU+JVJ&5e zezTUMPVP9So#>_T?X?ee#L0C&|gKfnTG(l8Ozwn}|X2EH+Gp z_h8T?f=~GC?f3QhrH8p&KsDY2EUH@E3Z*J3ILv8*%5|k{8p>n;W4FDEeqZNKUR~;9kP-`E{^8Fd%ZPYbcZ>YJ2DFaL@X1JScrzrjbWcB(G(NiZ_WMs z)v&2Mq({{M!BaxOfBI3d2+mHV{qLlU2&$G0dw-;h>|{Leq#S=s7isM`4ZGq#j+S5m z_-g(Ko^r^W)^m9y6H^kHPq%+jr;2xMSdo=(x4I0h2!M^SmOGoiMbo+7l`~~nu4oH? z>^m-N6-Gk|RZ+%Z6(kGUk`H+xWq=n}_Ls;>aCasFSx~Yd4T7I%9d;k|m@0DF(OoQs zIUQW;w9BB%)^tGBK0=1W{kZ!pF7cXsv&A?uj9%z&7R9Y^;|-3c2e&;oGZc)f`i4Na zZ9P|*<6>N8BOuz_^Kzs3ZUR2I9+e{(p`!@A10pzCBG*Yod`N4k-NYvv_R{))GnE^q zGs$ycrV>;7KQom#DYgICOy$DeU#608^8bpdRF#AIkM2d4&k_H2FJ@-{AKi=5f8C2P zhg}dze0qMh;l}Ym5-%+_VSQt%@AaSZMnBLT<9|^3upy;13oEe&PrCQ{ehqTbyZ}p{ z`gL(3CK3X=+223soeYxQudj_WS7McjQ*xKoF0^2va$L%^kRkri)yLo5Ak__}>W0*$ z@aotwbw0f?BiKdL)kf5Q{h;d|@LL@I2Gpj(fqVhk<&(1QtgO>U;?tZeXGZ75@5DWO_K)mA59S!?{BVC;$jV~T-&AJD zz2UbC3$7&4hi6)Yphx}3k{CbZgTejv{^GACanEdI=2(APO2XxTwwFP7?u4KonkSBW#|(}Cgy z2`Q>q4prN7HJthwbkBA(CRXk!=YGBI z$tIN=&9nnsGUI#S)b%P}KFngYE##xF6o!1$%j44No~#qwh^yz{-^&;J3x6t-Yz z|BGK9e*J@As=Ut|{1|9r{!jdJ;XmM)AlJY6<<7`o{89y6GtC7mYfM)P7Y1P)@#TNO zFCE5f6r@~sSvi3EYRT%O8yg23kv8s$`}(l6ax-f#n9uI?eceJJvz88DDF|TM4sqTX z)A3T}hVF0~IlBq&v1sIiLpv;WZA@pnIX3bf{LqViE-s!rK_nSI}W)9wduQR*xdr!H)ASVyzrLx>NU{Uc0ejr z6II#EO~`K$UQ{USYYj_w?NGYmeyIeT@^|uZyd>FJYP3);jFW;B@63O6l}$ld1^mG; z@zno~UrztUFL%%m(DR8PbipXZc3kj0Q&~kGF@scs^ zxi`-s^8>_Pc#z#+one)65qf=438a`GYg-H%=UX8)!w?ycVWI9O1Q-)cEPKw0mYWaA z&V)S7e6}@fdSyH1<*`yO(5xIE^JuxqmavJxC$-<&gU=^SREI$1`WX?RiyUE6*bDWy z(Xe|p;*#;WWVEM50hbJJegejw^@J8Zm=!?+?D-9Km=iR?z>Qw$qY4}*0w?$nz zoF}+bf+wE%jkVL|c&YW>;Wd|vJ6VP?Qj~1rSnc+ss%)J^of6*e{N9jLZ*=7Avw5B` z1ODR;gch_BiwCxKL}Ni-q%~wC^dg4dN(xx5nB+c@l-A#<7~k8`o1FIQ>uHKfA|6Y4 zouci@=gBhT$PKEe$oMf$qkbCW;n41~FaSIhc0M~EujO&@xUoyR6=_5{iMY|2kLx4gYS!80+0Gg8SU0VOpx%^jp|nt*Rk9Sy9^f%jQ) z->5qyXzjK>7}o7*qLN^vz%&yKft+d79I*MCGI;P=S-BY-rYWpI! z4LUKe>g*}pTY;`NAzOwM`BZhZcV!;cJmGF$tYtNH14?7({WeptQyaVMG7^hxp(mF_ z&1F!dLr$8h&-mOXKx%|=_mwPqSzFqdTNy`h!yAKl>9@=G)AKT9cwTD{JZb0UOQ2;Q zb`*Y5^!<8bSwfK~NKCsO-FH1Gp7V%VuH!9I-73QlH9qE}?v8(P8Cy31c|xy> zUsaQ>Zu{MQqY39B8gX&?Vac_~Uc$c06MvOuu+m;BGvjkNJ$q7Ut`w|E>70ojUX~f{ zI#$cGr)d*^O>9m4ZjNTf*a6l)da+)YeAjB}0tvqd_ff6c#yUF=toO1kw5fY>16+4` zuP`|0C0;E0{@U0iUD^zg`-+AVC`?o#L6mWtcC)`L!hp}UwrP*(1~h9~t*{k+=gx71 zgS)mD1lU!$s-X!S{^Xmhx~9z|{!yinuit>Wp9NnX@p5EapCFcOEYs1i!M7`ssSolE%VO9tEy& zEfe`t5Q0AKIwiQ97amJ$MXg#5h~tl5rqWIXo~3*gGG$DeJ?lU^8#^Kd*C8PLv8&E; zg`)^VFPpPC7mAyFAJ0i96RNoN|1&t#T+sMFK9Sk@%p&K=NV^o#Ie|TtUlB^wPiCLo z_Wk&lOchB|rRQF+-+Qus`-#d8AR@+3cV%Bs?J7VZ_v(ZF7GW%D%;IC+=A@c5E5)y` zku)2Fqfqy&gbTRz(43z*`y+iZxDYI2B?u)^2jVKU>IhhJ<8T9L7}YR11- zbq42>59Z{K;S&l@$=~?HSWu2HVRFDE%Zj0d3ht$Nx@PB9hIn4Nxmub!R%U(*J^5_V z@-TwV;O>^csps)6_Y>tL)1srQ#eb%){qyVL{vt`Yp z)jpi(!^f97!`h{e(Mk`0Bh}zGr8H5RIM;U93C)iE^_II0)kmTco?)xuu(UClq|_!J zy3|9Y<3PM2BCXX8c`ZoO%T|idbF56PwkzSB<+{ULC&c5L-P-I)`5h(;Uu#K`!pf+D z(;+w9$!~2Ab4`_u@VQez`?}SW?6hqbe4~hWRSan9hG7U_iC0wNZ}}>fcePo34?`Xx z6^}KdIl~%Y-^5NFHnIjsrUbXB!2>M}DKCgNd5JlhuwI+tSA=?Ye06*B{U=EF^gTMa z>GdN%=0N5L=LN3ZlfjG1FUY{-bpiKOTl*`;R$YwkR55V|5NTc`OAet)^GGP7SQQc= z!T2!%@?#A0l7-kUi)M6IioBCOd~3O=#fl7%mrdB#lFH(2%j?GYGtzONeJ)MxsHQ7G zFpYJo0|2!BT%n6zsj($h-_Z7ULK9&7TD@3>mhx)A0aruV^{H+Bjn}t(C*X$ee z+oP&@78Yhn;n&jLym0&a^V*~6Frrx||N3Ey>->o_{sROZOJ>`uQHHE&pV#x!lcf)@ za&1eE-88x09(>`(hBpdh1Q{_sRyLsM4q>PX;aSL4d?3+@{ zJasdh<~y<6xvzj$XFRNvY=aUft@G$y$IgxDIbIm#$bah=rYYl)bL#2)3-$z@5Tke& zjC6`F5GPkLx>wDvwfMI3W4Y#nM`#f7|Z@s9tD(UOiO+%9zz~7=YtM_PplNej|ktw$EdeYb-XdZ!cUu|rBsCq*;UWo1<2E!-C2pr5w!2$s~}7lu(i z8B5N1OgH+**sP{mJ#%E(hgrEyt@~Qose!3okJ8Ru4fxWtS9*L--cOCs+s==9IVRDJ ztQMqfu{i1-IQOFPmOabW?B&)?<<`?~5TKq1Gf;J7L4D(Ewc{)OZBX0T>e^}|Cur8r z)9JnOwOe3F^YcRGNRwMP{^IyUNs(dw+<*W;n!ZfL!o@@f9H{?ZzYa-6b%gm&IC z6SQDy7SnGHba@TWn&k+VX%lxIGP;(uIN>_<;U-Ff(hTdxaNy4;jhC)pyROk7nnq;N zQ#l-cl$VnzCux>Z!*h(- z(sNqPb8Ito95u!1q6W*;`+M^rd;edA7MvyR*W}ZlrSzA!jRghCVzT=2MSPcFpuQ_O z0JK~HdTmoRb;Ba86+RWA&IS%<3Fy%aSgObps0XV43UiHin);Qf&&HJo_!{U)mi}kf zxP9s*#Es#RCr1pLwul9a!LkbYa90*rds2he>c$yQ(md!YT`}$HZE$Q%yN7F|jFcvI0s~3(-GF zr0Q+ONxyJd3-QfeWOy4BPk3mTJRAa(LTO9oI;>d{622SVs>68`<9Uc@4 zfEE~3ZQxkemYaMRgwH7tjWdMB_$)od7NWnt4MkM0(_o2kc3VlQ36g^4e&;ZAJHQ<6 zR35|)!Zj*-1#{PW-pgHQl=Xd!Kf$)y&_DT+hP>uTnVL6YI(9!;e_JL z;fdp)2PxQOk_)g2$_dLx%bWI!XcLY8sUCNPt4+53k1-U@E+HNCY1T=Gk9Uoa(#1D4 zN!+N>W|lld+Z8JS-vejq4pp(ej>X8JROUD#lbLkbKoy!PWf*7pv9VnChcz+lC)b? zB%wvc>5K{WourKC&Lnz(@~~H+oy|%oVJXF z`&xnsru)YzQSaJEl@*4*QI+0Qy8pPTh^5%-GD;5=gQXquR z)by*f<8r(q#DuQpYIkY0akNp*6D{<%C7g-CtBJK(YbZjQL$g0>K+SM%bKG{X6DiEK~>(JwO3)QD6_4E z@q$-`?ohcEI=A|~bcgTV>B~zy!$t~a4V}&$ZEOU>gW?-Ou}QKqcuc!|D3v~ z5@faDqW{1Ls=Uk-U!m!Do_*c1i5O6$ww)c?%~@CykMi4=d|jl3z2{?=NFX>=oEf;S zZj)@}0}LUIlvVBixusn7U0mT?$^bxbw?VRd;V-qQ_+r=+zPOF>zibQ-dbCd5LCU_n zfb~9F#&E;Y@0so=2!`gKdy52(!6*8j|2be~m6!`YmcY!+B)^ZJ1 zU*Laq6Jn;NFudeernKHR&6yf*K`R*OQt}|7{`?68e<-S{jbCJAP_%+9PWmRr^c3h9 z)l7Ukb_bwX9H$>a@fNHdK?y2In|bDZ#fW!-lZt(@@ibqgwDu2WvaU!<)nPeXeZ zWP7d_K~*2ekZz_q16BD{QQg&BXc*&r`>XAmbXRpe90nYO&X4NQ>Mm^b7?oaBOggE?JWyiW&G-sdhk%PcGO8Yy z{EU5AdEv;sEz+{Kyn5a|u1@2$L5fq+adLm{x*Lvuxe9wxIzp%Id&f`fi8t|F+SGJL$?k&L-tON??+KK9U_*Q)d85c1Zt0akn?IddjM z=2pgKL-VLBqJ^?TOzYXJ=K2%pm-oWV6W1HqO;OT3SsKgf(RqHRo_T?a~2&x!5Im z;exzR$5K9ungSjdZ?Sqm^HN?L=CSq+ekJ!~=6kA7GGV6PQy@^Ot)-d-*f@iRORM8PzfYiVtGGb>_-AxH zqARHCGa};}t@Tl->GS>@`cGNFM~X8Bwah0ezyip0UI}A|d00gJ*olMoWKpDkLdw|7 zy2@R<`fwh$z%!MkNV+Hu8v*tx*+j#J|La0ws{aJwaR@t{wqpy9TPt(-Rt~4;n zD7j0Kjzvl}IYF(EYHV}DJFIB0kL4n>+;`qp!pThF!J8pknSCt@%Q1?b<;*nLD-+03 zp|0e{QZ^o&zD3!62u!xdTM6ZlBxKQ7or9^9y#4S!tsc9RM~L$FaxH+GYSK$GZmeH9zkd#$iS&n)?G_mLnp?5lcP32V&R(xsinBV*ly#yk>{>GdhS zlm0&SaoA8}L=|uNxa?Ou~ZTpLzGz|$5{hVWd6TTtRjnp`_Kok@b21nM>zS#!7W;)v@Mg zHpy|^*T7P-Ii8#&Z>Q^^P<>~f{AO3#r1>qnJdLtd0~RM*XD=(m&HlCE8pC56lVjVp z<@*iZp8hXiriM2zApOOtXANX}73hjFl;BID=e}DAHDqhZ(T%Iokz0FuUg7d|_+(nd zhAyPCQCkc;%zm_Z%k~||ewAZei9Y!C^iAqdDkIbi8R?;g$zdq-{Qg3c(C19=8LHb5 zzWE-4@VaE*+N(|*raBCFCd_usM(yW{DV5wbce(U^`+J#Xu!5*WtA@S7Q{SFQ%${>~ zhjLt$ZbGM>=t0a{vtr97<}%WMht9VBSNl}vY!hD>L5`%~9`9+1M$9rDL(Gt9D@Uz>(&U_B0v3#5G^8v` zSw?%OpT&2*_VOPY6B1%9*x^%0T>||vkV_L4mlkp#=-#obxN9fSNw@0iOSaVB6r=BPPwDPa&*wCh=(pXp zSsPY0CXNbp&y8G!3A^1Oth}dw{0yawGLPV?Nip2M*+>gUXbU2L+O`*N9Sq?{mCH}QuAg-Y(mNmRdG4N?`S=Tx!td#4Z?~jD>fM$M%AnMR(yMiV7=F40{Z4gAnDeu^7toc~+U34UXX2K}Oy$_vBCqe&f|@~L?A zNi%73ju3r@ctEN(Lgv^Am6+E8rMLvi!{02zgBTrjd4KRr)GIEkmpzV(5Y633L?)B! zbB!8hm~af`C9CzG$SYkUrjPG_4qfrdlv84A9k8YMHbkS));=9T4Ip^g;5{9j=H*?+ zU3ycfeB8=m2*|vOI>-y3dV%h+<}Q1Ut98d&@v815&`V^~t+Rm!-2x~Fd^@hP$9Fk_ zQCVaoXk>um6oaDqqg^)4%kRbsTWcpx%thYxi86flS8*eS2Dd$48Wt zk`rdTk_qr6uyNJU1wh9a9<;pFBmk1ea}4>MZc8()ej7SUm7A4r`$d9W2ZY+d9?jXl z>fW*LQLp#>Z4$*4JPSQLGqJFI1_M1lI32PUmesWu*vv zT64^)g*my0^tnmMp>fx2GE)Gdg-^^J-sm$4$jnnMh1iS@rHgPsJYo*qb6SWcJ?W4O z^U74R7O@kzS_FD=PwPV@h^rhn^v@j>lQ9Cv}!ULrcG*=(wQ&G9v&Ys5>*BTy9(sAwjy-ly@@$Q8 zNFDM)p1))Ys9HLT-zH?o9x7kb#QI!`~01zuG1cbA|j zFG zaJe$Pxw2_eB}poqHmK6GIs86NBSuynpnNBy^;UGVyqRIofGNyq&O0W_SDvTrluZu& zGE#6E>S+Ff4a++RMahAvsQ37IZ`kd-cEzf}X*~qEF^owqA&TLY=}oJB>EDH8+$1yR z@`*9EH~l`Am1Ze3(Tz$y!4;?b5g8i)?TyVR+W_3Zc6Fc<1IF7XL%Iyl%Z$!dU*j1rx00V`SJEhV z(J6O1UU&*xISWSjLBtQ1$-LyzLxz|C2qOlUsy?+>lbH`dej{W*E8|cUSnkBQ0qE0b z@{tryxfr~O0J<5j{)>JFd1uU`BLl?b9^Ns(n@$lX*nc+VPm8Kjk{0AC#QD=7#bfXL z2FF6vn?92j8@W(#ekZr-)vyV4j6vlvn3Igrs*85@pOfdoe6lN=o-TVDmJQ=+GHvA+ zxZQ8~uGx^i?-zDflFDxn*D$BIsi(81ST!U_y7!J;K&VmV3Q*H;E zsy3W>zuD{i8iOj>woz@<@I-BD*X0KP_X?!9r1wJi^7E=jSz`j9ZzX#TK5)O#e{6&?JK!JV%) zj&qT9+G;8by)q_8&3+a(9IbrpJj$`qO2u(lWipZ|m!FPLM#5_LuB#blHVm4%Y%GXerht);gXbXOhNjJ{VD6`}V{`V84%v@P& zmeDov_wz%DEZumAmc$gBYs5|1=5=QLId?$2K_QOMc7e3qoKD?Enl*-beuf=6Q0LEZ zWbTZmN?`fnLX5Bg5Wd&~oNPelW+Gy_8XjG)7~4oZRLt7JWvz_7$Zx`(OOyc)c;2mB)=U8Z3v4=Ue z6N^-lX$6HAF2^<}^on3u_hWo-WYf$>lUxyX=2MOHIwHQtKPDJ?)UYZtS4`>+22$4w zWz$)ruPj@N`LSBk$fdzEi^rNG%f6OYI9H<$7XuRvZ%fk-REm+LO2b{4;ys}@vd|)# z)OK@IT%tO?`h(1IrM_G{F4ryt`L7cT`46D^9&cjfTu~R{;!`GK4}x)MqKI!!6-^ad zR%MptG--4Q45lyT7Mon$i3orV^Yt! z#Qh~Uz(5r3^ddXxv5V`Yv?r$HIvkk?p5@tKph4LKJPJaf!J% z>I#~50;;80hxvng19Rm%H!I#bz0*&omOI&n{-?PNSk!(GRQQMZx_z4a{xaF)XRH17 za4o47Ok79AiPNg(exrDg9El9ss$JX6TPURrqqOU1uEuSL)oAgr-l)t|CJ&lMS+WOD zvcJMqIna9Zw4Yv~XDeYme-yxCprNC~)6ORu?&C zHY3z!S~V7EYBSP#)>!s~LKf%+PK3|W`kPjDG|eZhp-y~SZ2-5a_G*b~w7AYG3=`I` zDBDj%_l;!fdoN?y1DoXWYfnN`Be*AmO3feqtV#-{oU%`r>+Z|bYQB(EODA~(%-0Y- za%67&fT|hGA#d=VMTj39(QjwC=b`Nztj`<8>`ed!O-Z407%c_NcMYnyLL$!SjwCf%Ut44SiTbP+JL$+LWSD=7)lYS`Q=+0C6sSOK zjQev~rOl>^;cW2D!<2t$;8hPSlGYSw1720kkTEm2COhrh(vQj^)K25ntTmVy9mCK1 z^C)3VyP>+49E+?ls71zXRKEJY9Tc%IT9x;RsS!>5-^$=yz`t~|wSuyKP2KUEr+D2^ zdxzCxn!Opo&9oSBiSTrY?mi+vbX5{nIPs$c^CgMAI9^zSzT6b`}u6I<;bP!EB zQ00H{W#oE@Inf8PKg1lubG-7Sh!*52UIW7U``j)?*O>KVz8gu$m3R1FBC02q#=QSw zfKY(46CcWLBS{y^t(jZ+s8tW6d1zX*#nC?c)d~}R<+a*!U>D`Gz6hnX#h2Xb#oe`9 z1oSOwu7ta_EiCK`({IDynSc*vh}pHc5$*lhgye|bfe}ca z`Ku8ol=Lup^3XbqHl|=?Y`XSUyPKFq(x_z3Ieqiyl4=!Oczv(<<(9v z%3xzoDjqMTP!?&uj#@|)o7QT*f{=8_(K^va2xPdsiOedkeSFPrEkm(JKi^p6J41TS z)~5Aa(tSPN8;o|w^tf7fz10%A=_nn=^T((63j7^8zLlavz=F}P>b z?w7&^XhI={!#Up&@=e8u=B5)d;!!6+-ey7a0wYHV#yLyt|!u5obFa5ZrWNrXc_5`7MMhfEB9qdykN z(fDlhzZ$#pcqsEfUaoQECQ6v4HVrkFLdcafIWmrsJNIJHPeg-8P0m~;G`TtqAz2y9 zeI+?N961_>T!YAwYxq4gn5Erz_rGUe^UU*lJ)igaeV%zekHnmI!#QpKeGE6MZFO5J zR?+8}E2F2>N3EcOi<~^FjA|Sq95=yqzc8vY8WF*=LaViI;E<(|9W!GxNgd_{_Wl8SKrOd zsn@HCXd<0viwsC+PAVcPfMQWXoSrGB=II=Rb3%kim1!p$kQLoYp6`U%gj0k2P1#bTYk!iyIz{Y=1W z21#s}8MY{aR)a=&w(JFO(hE4lH06A>jU5N0v6~M=7haADM1wkYCMF;3;LPTw5&JCd?Zj)rn!*1JqpvNv^aM zqLf)Kee@*41+u<8Z`(uHD){Wog6M&ql02!7L-K())Uc0-*xr`Pn=~vzwW9ccBd8$* zn>?Qa_Z1~T5Lk|X} zX2G@V!rCM%7PB|b)qAA+r!KAe*3O@O6k(46n8LbICfEh4CenksF+MDc}S)L=dMZ6@v zt>FdW*Fzx?t8t9d{Zmbo~;cT~k46?w9I-Wc^EM)$as+%fo zH0&Z@7{}l^`pUP%>=aP;F(@=o3=3m6rMnFZqiQCL(b1T>O$ypRAOF;HGzcsecUX{< zt?cd|3O<&uKgZ`I86W)bbv4%Pc{KSYY~EfZ2-jilSg^TI<8C-!L8x$O{|g*AQGYsX z%QgL41C72`lic%6k$kMm2F8l~Mu2bwHigUBxFy^ZF2>&b3af1M28ELlh^Op*6;-+! zo`D&@+)w=PuZ;I(G8*%3 zZn`B}E%8og3#}|w8lm|IE7yVdKx9jlhX4+sGd6+~4wwAUAI%KvO=)8hKt(v3;$VO& zT$KUj+PuRU(5W$>#eV%}2h7$tJlA*n{@+OEo)A?JDGyw@cT2{+9DL>So^ALrsr^U- zNQ7JGJ?CK6J0^-zR2{i#K*B{Ap)Rsrqfr^?8|;B8#}`EOLSQW!*fV1D>MMCKQnql?mgTm+HS)aK5^*zAG*KX(a;_5GYjbH4*+??1qarxKR zs0xzNEpu7&e@Lh{X1P>{<+EA+82p4F)23*E3@Wu_aKBLhvW@0O(XC)x26VQPSE(%& zU9o`f(Yrh1I)Qb=h#1<*mAH9#q;<)V5Q8DQH#3ae$H%#qoBSNPhBJHE_>Q!ywGAu@ zZD$-h72Vn5DF0tT3#D!S0W=W)A3&@53uvD1tNrkixM<)J`#hAC1PpH^SO3Hi)1RUu zyL_&7tUyd4Z*h&~>-xa>me(e92e!toO--s{ruzPX6^&Ger9~Q3;uM^xYt|n;f?$CI}7mauIEm$ z(X+$IGhpEB&!knN{3p|0H{nt@WQKj;w9_+d}Z?XS~KVhzyRoXTZGCi=LKljuc zt+d$r1(brU_p$jr=tsoElLjzlt6m-yb8YohSAa~j$AK{V1$RZvht;k(!3?E{%IT1uMFYtw#_t2wM(vP*bcqnt(WtIx^vbBmn z;FF=@ZOV0jbzKGQW$NXjz}>G8l@P3>9uz?OA~(>7K7|57)lKu<)015=>PvQ4cXwZR z&k{d1&o(y{3uj*A@V6a>#^J0a;hL?Qlj(#fsU4Y?I+vd^Rz`eMTahFJl%bvA$C`s) z&UTx5i#I#21<3hs=0C%Yj$1nv{B=vgXwYsadub^>AO0aQ^GqU6?Ep%Z?#*Da%u&NGi@BO z(h2h#^J67fK$QUqwLb?kfS(I_O=Sx=!s|T}vPatOAv^&Y^A@+^-4;D21H9i6Y}3mc zTYf+`hDL(UvonjO<%UOp*K8|RniG{qvIZn0n&6oOp9sV@_4|#Aadu)Va~j3CwZw0Z zLOFaELFs4dl@vO4p!XaFfYvNO_|<(`uVczVaFrCBIs8pBHarYA{KiaWotny+Bi1L^ z6fex$8VLb+i6Zj@Cn}A+G0v$+l`8usX>nPE;LE7$i?zyRuUx@MIZ-}9WW%sI0yxEQp*H4pAiybfHD!xQ+BcJ@eU0Vh z=xGjxQi_#;FQr&n_O_}Qe_+vtVs>VM8fad#V3CI0pSt77tgu1;lof3ff3l+M(H1Kt zyXgzR24!&h`R8@%`+Qz_ZzpWRxjW>^3#mVlstCnJlRjo()hiU8L~ab^S|IH#o3?~{ zqaN?0E;nC8Pi6(!D`5~;nP=~jey>)EmIKaSviLE^A(w!AYy7`4Wp3tj!GM)Q?)c`PH^*{OyJ;mz{O?gC zW40@5(zyO5YN9i!Wepi~O(E(|-b~mt1OPp*`Bz~{_Y&0G@#jZRFk}+_N z)%Me{R8B4sIy}esA^Ps8q=?V@^A&ir4|KQ|^5$5XyND+`+d++5X}_C|mzp6r8PeUPWYI$L z$Ij1ugXCeD!qSS^u$-&@s7bVehNy zE3rm&Q-ojre@Gw{L!7Z7I3PFa`-i4_*N8nh5d7Tb^HI*CFnU>QQRP8fU9CbT!!K3R zeG#{`Y*B@hR^#Vl^|+{oAo~u5n#J3qC?VkmLpB`gBN}h}*{b{^uCbJL106TUUGbgy zBxXU3auIh!VN`4K&8tzLTEB(7oZf}kk=%jVQ7E(3Gd6!?5^_oQGp71BCFDr6{Z5Rd zaoJsODc0o@#%%Tc@=Z*uNH4J&O;$+h73<^1RH^HmrwRG>d*?93cV`MgHVVOA^80(R z$as1RK|$cXOYHC%HHF|hVKf?pxP^AYWCKg8Ng&;js74r6H6nr*9(Ds8gZZ)c_+(>3 zsu>ymn5br4XbmBP4i9#d>;GhM4vDTJBIvL)n9qFT=!o%OKy3CX8l^DJWCr7scyj(l z0QqcE3zX}_!8|Yxiw!>Wo%-J25|brM2TX2qdS8j(hJQ@=G^@7jD#lmb(rl?~B}|0-E7#IQ7L`d8>xE>z3XAQOV}Yu8=7(bXQ z!8iWbrZx@*CvWDH@22UBF~WHmd{dssVwMP%b6XWzqEj-#SdTeNXcPZ{W)OK)oBB#m zpjK`dpj_m<^!_9NUX+{g~6G@{j`s^S>qoBPi-d|647AbM&2C00RJG zF#!O404$idJ@fyqC|*vkcBW2FcK`9w|5Itez8v+J?El%&tv&U%Xi&S!?@IiOSh&zTd(r{e)fNDwQIsT729d)D4I~W zsAKGGa{Sie>)XxOrK%Ir%IL7v!ldPgv+U~P%hu-=8+%@^yz+fqHHGV_Dyp$>ffqA% zYlG$7cdabdu40 zIr2E$a-YulWOv$D=*m=9uc!X*mZZ&vyhuBD- zOP@hUW#b6z>Ly5)lQFqd8jw%vfqOB86Vy(KF{C`U#~oHVx7aHlgNjg07Uo482u_hKF3S^I6j-%adrS=iBA zeTXoJmS|MyrqDlbHa5|d9%4s!lc<0vfdfCtS$ne@*Duw5uD`*Gr8r8lqQ>i3?5XlQ z(q4-PN9<%&$xKv%PGYkT8V5Z&;{>#9Q!`LZByAQ`9#ck5EP)`6i$2V9WU&@&XmwKB zE-o<3OwwZx^^bxtE1@F~$!})3RjK%hXs`dRLgY@Jdze8302xF80LqudmqPq^RjAR~ za?O@T{k~WA0W)1S$;^drJdxfcP5VH}L~W>Xr9f<8#*st?9Tr5E_NxWd3)7H7tZd&r z6>X95=C1T7^CmBE$!m&*rT38niw!@kb%h;?_|=uJ=ym@6^2QW2&Y?O|M2lcP9Dc&C zG~=~<+m|aiada;-DFp#g;pM=Q9iiTFykPboSCt#(ANbP)nlcyKQG5W?-V6{zeMx3?UY^wbpEcxHzz?|3_+X`9 zZy<0ULkH#lIR~Ui3HZ;Z3vk50dDhj+En_K$Z5}Q~z@x-il4>2irdVqp z$Q7@V%p^eAK*ZCcVO?2KDKml4^d_^zBN;Z>!?!ngLV6 zHUiVfnh6Vdgk;q6Kp}7Q)*WkDdi}-D?afZFPj2-{Dr{3V@8QQ=TiCh{B9Vwn!;P)d zs%)Hj=Nm|j`aPb^JV-v$TKM#Qgh*C*{2JC+Fw-GLoJHG5iBu`IwG?*fdwYG}N zRJ|*_xuc4-|0t)~JfBx9$p~)JMKEoTsomYACTfEs@`)=6Kgm^;>yOL(z9o9yqdTp;7{qQ`Yn}wZmX`LrTS1S62x0Dz z9xQE~>GMlHWwzUyt9A3zdA_?YD-J>Bs(Fh!Qyhno9*Z$AW4qVyUZ)8|L`lOWSspE0 zhi@l%S+mZ%5Tp9w{l^qV0?>92esaAd{3W}&Eg?OH9u9CDB1!Yq(4pyjH&J^`%v_Vv zT()+xm|TbDO20RQp|&&q=AQvOrPWt{&grJgH*Cx)ng+_T#~%KhC<#_ z5+Z3fXXTQ9UYjrC8PIQ=Y`%qI^rVSw^B|PkKzEI*D67Dc`8? zlW)`SUbd4ZfIyw(WnEKHQ(&l8Tx%wMj?iijNu|Vrvf0=S| zt^2DIab76K(e8S)V$J_wx$%aUrfLM&(K+?$h?=bH+qY5f@T-ltB_5rHdh@YwNT!sQ zkkJ{=K2VLCX6e*9{pJ8*8hh$~{nloUo!WVx<s&vWDutm0@VN_L6?g5z9iYKYW5@?L=rUK;mt!giME+i>_>pQIP#}!CPyhk(nIle)NnUx!7N(j z8fAf6@5vW(PRO(1Xt6}moZcvITxB#Pk*Z4JUw<^X=egF#t+Pcpb33oQN&LKQrd zP@v=<^)`{XcQ3b4$RMoTr7M@Xnhn3XoFTRE+U=qExUX&12@0U*7!Lh_tz7A9z8vFk z3MU-H?rs*&W$lISJSw6^7YVn?_27Pp!yo7<`~D2u@_`^w)`*yzu-kuaBd9Mb<+@2F zn8r>l&CO*_(B>xI)BvrwW#gx(h1+!xXx!aCjqroBBY4+75VmOdoy#X*yinRS(K&Mk z^7$LZMUSVC-fPEk2-FIB1xO3Q%}y*_%sI?~87Q71nUAf^1=?wEx&dqpt6l$I5m-}c z2@%XLoORe3o%1SOAue;2hN+zch10!6ENt+;Hc>2H#UAwv>4GhPFE(j)4Ap3z~%ji=w z>f(>n!>zw9QJzw*8AA2H7K<05|F-Fe|Dyi`WB?fnV}wi*Fu;Eb_E*o>rr*KB+{T32 z+T7XN$=!+d8fq! zP&dN=kWUZ|{%>^u|B#9Ldgj3Ypi#c&^Bgd~SThP?+Ob|>YfegQEhu;6gT zgLv=wS0&OwN?^);I{sEMR!uezE_0yoI6nr%BtbC|ahhp$puGA5=ZcqR!DiD|jGimd z=+k)1+&yT;eJ%Fj4fKNk7vdiP4D1s0h0(9S5N694BK-HCHjTg+qQm(@Yy%(wq-el@ zO$IDpG{PSr5(y3&-rA%jA)5_?1Ahmqaq4ZX&+IVmCRVtI(-45!Ee(vpmKY0yD7 zSwdDELp-@`jHY!kv7mjQ~+#} znm8%nlCpUt>^Uor4NH#sm6V5oE$`2IMgAf#rVdx1T*OVbOM5988(?pxNLg^|f%W)m~ zPP|7z7mSOrcKn2e^3oE`%@=_K2)h@)l9P(r#R@{H*-pB>!&VzZ$;5O{fBCi!P7~-6jhlsbdaHX_4 z97!5*YCd4*Lr6N+yS=aE|eW z=>~!kjuT}S(p*(YT83i@eaQL=a>Sr_QNm%rNlEt2Rwar;IbPFJgn#$8j^gMtWC(YS zh%hG!K*{N^^#%qGK^g$biU|$=|BcH~U;WxIu-R)E$Y>%M*mPPSBjU@V)$DxbV4?rLmw)yRaUEF)|ReEG>Syp zN($N{6s7;Z3cZ{f3(=;X?ls{5nPiSl|L3gZflw?X%!ZHsfS^o;3oHC?x>)kW*}~#Q za)UugMJOu*Ch#$Glj{f1p0Zhw<(RtM^lA8{gU+d5xr-oMOgXtFgoLmAdJXKvYj3UK zVn$07+kk{@x+}l?>nMZ4v%!|qR8ho$MNrL{)x1wNVN(_JHwM)=!KYy`AaDC}oenlh zJHtB|*yhK3J8T$@+xW*@wKze~@8Cx(RKq&IG^T}Dx_Xzl$rs>CjPBz1fy?FUL2R-y z$sX$Wed(2?+`a`59h0ET53cua z&=;hdZm~Ub=O7fH0t!Emd$!bT*nM0e<$AgiS1C-6c~kYUr?zpWMnkr=*43u1+wVbE zzJD}^igrYtdwtFIHd?xuX5(ifi5%LMz>hIut@&wK{^m`>B?_9AH*xVq()`Z-y$Wpc zbUSuW=RN+xs$E-%ImO89znVMd$y?TdpoRII7sr2p3NB15zQA!Bzl+$(nDkc5!;7QK z75teT14a$u+9h{Vs=r6um1hh2eyn2rg3@`9=+Jy$O!uOXJwfZjrMP<`FNz%EZ;Ekd znSs=Z@)P{XXP^Iop7h5p#M`94dDirrVvg-dcuu*F;QK?<{pRpDr0WiJLro->nA9st zMKT?lKKIl3U{{MA6UIem5UC<&Z(Hk`yEGz>uL!v-8?Vnj#=ND*w$2oARE(Y0oP%~W z#3-g-O5<{dePCC)jnPxbvUf03+}$AQ1HF#o&UIMd8h+Aq`I<|=hrj|h@;%F$?As{w z4`}z*l~G0XrtnHtwd9eF2mWoDIjt1oZFRceP+-Fr$B_)-#W)lXse68*x&7W~L?u=& zutzhm){XjHesFUp>udvQ_bhmeYD^n1zvm)%p2nends^chaQZ|IJ668ha7ObMmH*^u zC33D`ReX%P7RlgJ__5+v6Oe`zHD&>yk#mUp@a|!Fxu`k8vmzf-BwjglgrO64^V<$P zp6=Q`QmzljSF90%jOWok!Fq=9BcL0!^U%N78 zCPPddPqf&N+?;9n8CikKN0Vq-6l{THIQjDjd9IAbG5$gf{bVb_F>hca=31Z=Aw1ob zy3Ws#J`(V@qF~oQ8R&BC=?;*Hx>6vIDmKK%=;{Gb=^NVGhhW3X>64Rv}y7$Z0+ zd4VyDGK%>{!acC0BMgeV0Yr)p#N~(I&9F&??@VNP?_n>QvxImJ6|jF0oRZXN(K-Iq zd=+(*#qA)u=tWdC{su*3HtK3I2PJ?W|0f4|h@)};aKUb)Yd}!s$9|Gd4t<6GDIlD- zPgecCeye=9jLMHXVluCuWEm_$!HYEtA?8MzX|dS+9b81*!d7O(vwfatU*Nj7pAbS! z<(NwIh1C^x8`6&kfvlfbb3YI#GN&awA8|x1J%Le-vM7EppC`LM%Eoq*82j8iJ!BW` zZC+%meI^|UnEJ55yyr~We!f%2Ljp1FpE1)4 z?}baSSNfN+s(!DGq@Cj7U;{6W%KRyFn(OU1e2QZYT@bS$s(jczk4Abubul@dL$%QoYR+ zI}fxfc<_>HZ!9(zysa4Rv?=v}ycq<>8JMl@tbC&!4=K8iskUhfO=%iMO-N3nI&8%- zEQ@<0LnJUkRlFuioCXp-8dmx`imnk6GYKt11~zFJ9lJq-A%LRNoD3BVfEgk~L53DU zhAv$dim3^n0A!P45Rq0MhSx4(!!xA-6iP5QcZk%GnZlCN(@>}a6B3#dZ3b(m)?eAm z9U1hc^5r7ts4X@BklOb3T8JXfPO^EcNHJ3yo$WN=r)6et5~%Y?WTIIzJBMyNT1$WkX`v@&>*_K z^JE{qag1I|$kYPApVXggwlAl-Z8V<8qADOYHsgL35Wi)!L{?pEx%kgU8(686LI(2{@*h%^91RpuO$1sEQZ)T+yufu`8;{dPD@)XBl(PZd%v!8G_UuGc&xt1 zRYs}I%$kuBL&JFq#OdkV)87esMsGI6F_5oJQ6-tLcr-eTkJ#Sjot2uFj)TMI z=7ANx+T%+Gm`!#dP%;^e4tDwHFlxwW-c4ra@0weig4p(-AQZ{*sI>G1ef^ z1GP^k9Q24vP!^$7nYg(gtDU}XOiUwZrPt40To3oFA`tVBV4iWN z!F*TW+x$xZ?wG!{`R>eorMb+%VnVDS$)fN^lFq=!&(D7wFlAaZ{&JrK6K_Vbg5ep# zVge5jTrnYdBn2d11plegO)v@xECXw^=HQ+=y zBg0cHyV4{FJG*5D^JhRGGlkD|OpGq}!>kE8J6E$Q^8;lad}YMvYGLJ>gnVI)p`iVA z$TMi>0AuMvKB7J5!@N;`O6%x@ypNoL^wX7ud+PZKo&Ra!VI_^u1+RbcCGaed1c*YV z&zyM4JpU&NCV$FnP6HZu4Fn0hYa@Kx_1-~ap+=t9{IkUQr*wDtvzWHTd4nXL9Nybl znbSjhV;Miwv9p^hZX%L4k#|zZX@mZYODTvnx`z(#P{S!X4MgyE6`K8(B{Y) zyO3=Ai4VV@E-CqsM06RBU?wj)U)>fq$n(kJ{1~Nts>FzhKHo9TgU81yPAV0{(xVRx zCjV~GcOSPImW5s$A<+4F>@DO6g|E4@${aGMG8EO=hYpBLSi!((%Ga>n`N=Ljx5C zMsu4dfp}_hPCHhe$mxW=vyI>wXVRz%z<1N5k;PtUYH6i5^N<%pw7M?+%`Dbps4W(;PAiNZ$&rr6h^QT) zmMTfg9^GUroDfUy0?)L%A%jS19#w?oy&$@P9#Ch*^%e2h5rgIo^|$00?n0!a`k3}{ z1k$)zn+zNo#fm%gevmC*)P!{?*zd`V3Hi7MX@<)5CfE_uj}(h0pads_0-dy3nIrcx z3Pv%6B#VT9ZSJIxY@aZoN1Ioi1S66AGT2l+4%Ev?1m6&@f< zYO@t!U4QiTSK%RW7gfN70RU6fuN1nk8UXQi>l^S@i^m`i0uW>RzevD;F#u#$1v>hu zu#f-%;#a&9^@R&gB)&8N3;=e{BCtrf-%wBEc?6739Z8Rk-_}WQ!?3VRTe#|V{6HW> z&%OX8#3K(&M@pB<{7Mu`wS{C>UD+?=2K#OYIY6m_8%rf$D(PbdTXi846wmM8a z{z!#}#lF4@gN(t|Q+c3NyBat6y}!RsDrT6aGxmLqYwC7@COckD3jOo}^bXIum75-c1V;NwNa)Gc#@BEV&Z|kX3J>Q|eTHhhv6W|8bhXHM$Ys zcYdR;KTTX@(lPldP)EMWDtB}(YJ){#7S9=(?#U`k-Y{GFomlUx#%~H zY!5wQr?CFla>OU=-_}G|-XWj(&+)K?FbAre!X3te5S@BPC_8vA)6QmmyeDDIUZb|Z zwjPwgiDf<|*A)>XS47ar+M+FIzjo3pR08$JP4IN5)kFnHzudsRquJ z9M|7<{~!15+GC=RE5C5d`bKhVY|#jlT8d=AE-L9y_Pk^9u}rAp-0Y$W@-s!G6;ciSW-ZEu0aS9ii#D+Gr~Vi%MldWr2^G) zg*bY_8#%gAoNZOwT$Ham7aViLh>?>IjB4aUv+ZSyLhq`Z3aHZctMZ%^e3VyEC{Ck zhGyw-T4T-kF_N;wN%e9sjpQGWtZDd5K|JP%6>IyuqnHChr}4MX17v(W$JxID{dfC% zh=WE+_{mj}7w)QoD0}YG18eL)iORnv0vWf9k4=o=+nH!yP>!KEQ{wdE-e?^bY##f^ znXJqDjt4WRbOq%J!OZu{62Jfa*P2=eV*P!ITRx2j( zc7+DA;T%b*lc+mjhX>7|!x(?aMQD|xC!vqNnx6f}`W@=&vwza!v;U5q5K=D_~u$3qa0B&Od}4^yI=5fKTWQ&S$8knmne~FX%77c|fE!Mp61yPh>rOYmc~<=6JeIH!bFz2NKB0Qtj&wZMg~iS|I&6< zWHF!8mK>p`Im=WVuq~P;rNXF3e<0m}H%TXL(db78z-H=wgcP(3yH_@Qw|IwP4qK}R z8vl)W_y#RPi`w)nitTTLf=!I;D=x&ySaz$(%RdyKzXIElmiBKaMAi1k5bbUVm z#&amU85o1Ti|{zrCB=3p?cl^O=V%>h3pLU^KXBB_;zUx$OJ zt5v4CIv_R9R4syOD4B+cA&(hFxNWB*{F9W7O~#h=Ss1&l1MECbf%i zA<1fYD{7sR@fFs|^j`y2XWN7Fn&Y(Rn^<=ZI5lq*RKi6M{8u;O|Dq^xjDyEa_H!xw zJfYcN5$u0CW-tWE2hyO0gytw2D^%^MNDA^YWS;(*d{@=)ci?cPm<}39ajR<2 z03A-SCH0Nw8CDISSpwqo9334m7c~UIdVj95-Ty%yxuoY{*`&t zan3zgLR3ukTCBEPbg&Dpb`7%w1y*5G6u!9%$WY=gvga1Lr9xNM`yo62~Rbt-XW+)8vK;2SH z6t_OLSNl^!AXbL489sZda@Za^Bs08M)akdvqyDZB=5yB8N6qyksyEgaUfnnG^!mi4Q{>>RSH55e*>$bsD3P z-AM)}#ht#tH)os^`Th_$%~JBwq9Sb;1p;?WOFVp-63N6RQ{rKx{uI~cC%Cwpo2OLB zOGQr)PMquD;dZwrj4)iJjxn+UMOmq0Bigi=PTV-I8m6ee^9}l8PKcZ9M_ZTv*XFS^5xcI)n zKP)0sI_i6J2f3wkG`a#x(6wyU_0!?J=8p`@uA|haeqn>#9OhE7j5ejG)vN8NNk2$5 zp_@n9b4j6u_RPGcX}(C zV`-YvTuSOUx~8f@xJ|z+()q5HQ7YosRivaQRcoROk<`9$?mr+DAlPJK#l)ORGif#ozU(}#BN*7P$ zArk987d0VDdh#?C_5uV`-a$EP%29M}LF94cn2KT=mcnKDLu#A`!QRiJbv4hu?`Y|U{BAcwWZg=IY>Pm!a{)rk_Z;vV`t;DIpL zNfAMm0UQk(XWO#pW3==g>WEl#D-91(8hQGP%u~ARuF|d6#kFqGdq01PswbBua+f?5 zaJ7gYS%R}ahzSPG=Fxnrbr^T|Sygc4&8*5cBb;})Ve zESQb&4+J5i9-t~GToA@wa7KMgx=3P8--?GKYqBtnY<%-kA{w{L<-zT^{7^^iJ>`a$ zJB&z9a)K#|EhLBKAzE!8np1=N{4FS(h zHb^{EZ91$MIiFJ`YifZO58m!PEP8Hy@`Td{9MRy zeg`${QvSE!nW9>SsuC-nT8OWTlBmJmm$3tBX{Blf93nTA^47 z;?UfMfzXS=_xPT%ADN%7$*Y|NJUZl-{fLnDx1KCsGaXx-WBn||)PO|cL|B~w)2p+y zVVXBTck}!w!sp>vgg(kqr+m27i)M^28K0_8VM1f5xJ{ijqkEHL^R3e(a9m zY*drrE*v6!g2CK*y=M+h(@~^wAhPiT&Kiwu7Rv{+iLblUh{)M6NYHfI zJ$H0%9sO@;19AbIb}m6Qjdt5fA^sAViDS@1yZDaA5%>sj5bb;gCk)HEe^Ey{$7Pt; zVZOUsJ(Tz`YQ$Jrnawp>SGX53$&#B@y9wQODOj9>@&~3@p?OP+>JnMie5*x$_)iL%yW5bu;!!og35JTE6~6V1UB9cvGS9oF<`Ff_ zpQQ^+kc+fHy@mhlFQUWXA{MYl0L;MxzV1K%8-PKP0-!A||632_8P&jln*Rx1!#-$! zCCwoM5KukW2d`eIm#YsZC^IDRKO~>hgCyw}<%F(ln!aNISXGTV4r`Xi+X7J?_@YNk zWV1!kRkY?Pf}796I=l1i8R<|9Gdvd!Uxul-KI9_HJ@~0)_~BHWeR^NXpbK})J}27P zEP{I#sj2Y9T*azk(CVl^{S86 z@A#!ohte0~J@?S`#{ds}I7%Ef!*zwjIX&e%Cf4tKR)YQ4WGde!3{iZ$dAo6icy4;D z&ryZp>9gNMT#QRj=s3jNGol>Yrs%S)>bdIz8SwP1iwJnm`Ct07@wR*DCTp`)51P&i zQXPKc_J_b9iqcNDk@a*rL?q~{PZuTATSulgHOjdyqm0FOznDt~`~=<5YKm=ki_?@F zvB05YPFJ44L>C_d1rh}WkIm;kuUSp;28Dc)bgz|;-Nn$)c~jNUn9P zmq2@q^~4*)uO{*{EpC6+6m-mOfQ_X(-`MFb7@(tB=>-q9yELRaQna5lD&@e+TJ(Yj zB<|gQq~3X~?P5Hi{sOl~2^-BaP!1U9561~kE2PkH9Etehs(NW)m8T!nD3?s1==msz zuAS&~3*Q98I8wS-?jX?PV`b2!1cg>2nsqY5Sy5644RLs-yc_$GO!kuZP686UiU&3=2xZqF8kZC=By~|jXO&k~oFzIY?qf*i@sRN7x2*0c^n2n?Zu8{(T4Cv;=b{Yh zg_;<_e0bp@N{xDrow7UT+*jUw!K25dpOF`J*5nCAkK+IbYY`oukfRtBT0m!(-FhAl zTo}k8)q$N^|KAuEG|H*15!x84tpe`p!JPz5+ z=S_UUdLuho4VwEt*V+nyNgSn?B@Y{mSS{psI942_ddRbT5 zmm0HkO_UZQkH*d$l!rc8Qy3F(Ph}uN!6O+oY0gfbCmJEUjuNiSo)Z#X8w9Q&xaRQS zK?-Q_Zxod37uJEGa3Kwk_7odrw6nLdbt7l=dbR|F*9H1k{ui z?Kk<3BDLSpWI1;?qR@-aRrI+ISlL{x&KtPC?4A=#gfI|Z>#j!Lgy26&~UgZC7GIsZZH z6Tj74Ll@IM$9fca^~aKr&Hlw)r~sBw^!k=SBW}1}V+MYl<`|3SM@%4=@~f*augs=4 zK(vgAbq!>MTn~|{ByY7C5s&&IQfMM^wmxEau3!NNoc|v5N2giT5F-kWaAa)I!1Pzu zBSbT;b<8J?Kr1)CS|NRg(}(#xF5Ki-c1+baM>f@1P6kOeM?05vqI;7 zAiN-}^UgnAPI6~sDvmN7?`vW+H39$H!fuYwTWQ!6zBzV8r1z8ZTAY%*{Xqx2;0 z3>(#Kk!XsK~ zU=im=9PH=x@>;=Xhl~h`5XsCDH&wFQr`+%)V&uIpgm(QQ2YGtwysaiE8RFg5zof&Di+U!U7Y|KLf|?T$x=Mh6k^&Z) zmynn+S1ZuyzARlF=Zf|V{qxsTeICcM4;#?9M`PHvE_t{bO0CI@NO$aMOHO;XGCrF0 z`mT&#rC0ChxWe$K$8?trxImh`o^AVMj!IwuJMzEELeF2E-*r}Fw-p@b-{tQ15pD2w z|KjC1?2t5kz(q=uFE;S)5N^C;Hd7%N&FgmUZ2pZx%6>=b`VsgdK^dQ(^u)e*_T{@V z(B?x5bzoJ~lBO6ZF(U)gXo@170kR{QRRzkZ39=FrsVtO9kyx4$sMuhXX*7+rrhq01 z2~25h?SMjwG%|_^SlwgOR63fJ(2^z@2C0+v>BFPxNTy5>K546z|3avAa50b_HmEN* zvniAKE0^ej39TF?&*KA%7?k&67kWVS@CM4&t&JzHWR%L`xHre9Ss~{>3PDp^Rz#49 zf1DOaggjD6otUM`u`k_suq&81q@}a*v>};ap?TbkL{KWImxUupOO0y!lU90< z4*9V}DY)2#ahcX2F1yw{78Df!cPIn;^F9_%JW_Xb)*=or6qTocT!**HrGDaI*_0Dl{$-4 z+PfG2e89Hxu_tB+TLyrte|>-ilBB?;%aH_ zpq%l&&_#Qo_Ejy#%d7ZS=!}tQbAiNVQ(014rm{ro^lw5nEv{O+%-E+1w%2+=Of_|& zu{*WNXCGo+JwUn!dL}BINjzqGuDQWFWFLCXQJZ^6REAX~%(&eOC3JA81XGXY8v-6% zG$f5V670bKowT#EG>w9eaat{e&^Ioba(rz$B7(O3W?L@Z@g|=pvJTY6@sk;fKrQBs z*Fak{hGX^3#X|E=J*!LwH8*`s1?-^jT&BbFo69up1Mlmp``x{ljW&uuIr<7*7HaKe zOyR&FO^jgj!06>*?9icrMEL}XSP}6wcou;Bm_u-uJ8?WQAU8#B7i48WB1KSA84r*a zGB}Yu(E<&#b@>c`S_Bipv32oIAE|$M>@!S!R_304SS-=eDfq&rqD7ezeR>!bKG!_Y zt&}cXPSXp^SiN8UJR-La7!7Am?fl5kT?AHyIg941kd4(+g071#jt+DaTrY~6K8RKp zV&T-YCdadtR+z{gE$e@}jLkUK$FtPF?xrx9R-${gHONEQLtWs1`vV549yFy(FDh!= zomOux9QraWJ1X3qVA!n842s)mtEI`Qy^|8!d&kM|iR4X7n-hS8!{*0=m0?dpqIzH^ z>Zm*GAEcf1GfUE$Ty2{zhBDTd_GvBxV`^!&Z$-q#bC@!03AJnw#O{2_a$s`9bu&{A9Hyx#1Mzo^*8s?Qbe#sGLJ*kgQs1sk5(xL!H@lOI_lEO2(Zz zb4fez3DJDv@+q_`wNDq6*CNk;rpBh`!x?j-uKMDpq>LSOiriVSocv=!1U;Ii`IHYF z&*KH5#7AulV|fH{-^Qts79Ft^f=Qb#fh`6P45}Nf|0t~c-~rY771nP!8l~!IkqS5_ z`!a%$IZHU2eL|$1&YOk>l}`7|uFg62fE8<^Hq0)>A6gv@oB;pCvw+uq-!+Uxk_N63 zGTsA*UIvPG8PX9TWfn{W11!uomc5URo$eNPWvvc^o?V*jn<1YVF=pE|(uu(;*gIH! zByAkvUm)dOhn(yxOer@p$|XlZT@w#%aq~~NZ9}4{`-oO*?&P56W|pSq=EI{>r;G5z zXyLdkJQuf2ktv;wbqsK~hAUz3yycFAo#WO&SxF&Y4Oi9W>qGR^;>+8A>B&opo)}@# zoMc-nR8mq()obqzfBjzou0T=06%$K5raav*I5}!v9c*S~c%wiUC4qtLc{wv!9+kBe zSe>=7HHyQqJg3+dU>B`}aP6(NwuL&RC2N-3YXATN8Ib~~%qRpO6b=Mf!@?0Zi0O&B zgb0#BdkK_R>G%_2RW@#+NL{)x5RE};)rb~CPHC-A%21*KX78vPCV97%YEH}*o57bN z=7`=N(s2uft5CLpflHJSl?d*7y^)1z(*&8?)L5XF)rmUhn!|Yv9zMyUy8UUBdRX!= zZWbvb*O+(v+mMR}(EgLTA#y2{a30quwgQuS=pwIx%NP>@15 z0L6fW6eh=&FhE=J@H!;#w9YaM_51>abciuMOHqKL;@skbU&M2uB5FDrv^_-X5KYTL zg$z(h>lulFuC9!wvuZkALR9V_N~&(=%zFBy#E6+YlsqW%D7Q9*SjsmDSgmr7CWzIn zn?~s~g_aLRtTLCkU84~?NCFt*nr#4!*000000e}bq000004rT&_FbohN3;+NC06-7`0006A zwAvFu&@cc10RjL30#8Zxq|#_$0-OMRgWIENA{4di4gX6#_XYL=BcLc&uhPgpBpaI) zts+TrfCBD@l@4UpLD>#BFauqr`$%h)l#9SGHMtUbp}Rav5Vq zNKZ!OD+|f-_m`vut8^VpW~Lsp$vsAVwkHK_l$%ihtl3C4rm|6ZKuEOgb6^g&qyNC| zj+&O~=+j(Ic1?c^^xcNbs^GFlv25Sxma40x@~H@`$M|1OC;>g^fgk`eJe?knIQGNc zN4zYTm@JuwE2Tf0FX+zJBW8%s-GV6({{1RZkY;_K}yj2e4vZZ;Lkx=bs5~Vx@(O=c0hbys zPUA}A7+n-dk>*;}=HR&>LW1#SwVRv~j_v}zp6}D{G9PX5$$h=T3uY)AgwE&?4_iLr*UKw_qzQb$v#W514@SPOIz74>BWPAPVcxzsBn&5eB7 zJ5WjR;JP!J&%SiZIQMNRtLU*6T6Wg>9t+obM6m+PF+zV>E>Iq6)EiI$59l+K8v_HM zOBT`iexfL)j&`)s2+K-H;@>{=(FZTTo4{RS|4K&xP-3hy2gXowB)L$mk1p6x zw7*sz%ACLCl2WL0eC4;E;xZ;(sO<;XbwX0NJ7uWSuo0fK)jGo103z{sGd4kB>mEAG zo5f?-Iy5Paua&PHKee|Y0N$QI@jIAd9cfMPbSYO9toKd5Cf=4QEY7()V@BBuH7gT1 z#w2BAmeq&>Bw(xVeJyl2t=F%C1b(`lB4tWi+6u6Gq`LPWV;G`H0BqcoR`yQQp{U7s5{G0ZaiF@>~$_I5z0+VguA`Ba|<#2#_JU02~DZsDP*AMiP2WduoGep5g*d?!?`>`PpFnI)_ z;OStijtWuL{@E;6;g{KsVNF}ne0hmEqhCYS<#?C=5QB6)sGWB0003S zM<7B%#T2qimT@EsD20L)1PVza2v}g29Dr?+6hTo4QAmVk&5#0=0tg{M1q6~^})exO0ceBvvYrUmUnd;>KnOu2c2d zWyq~%Zz<21BE<8b^0n?V`=|E(Iu5yWA4MFbeCwKawW=2sr{^j+;aXmmau%}&5f?c& z2$DLK`I~Bj^sQ#J=nHx|3T;T`ym#TKbx4uX0Vkze-0^(zL#`ln2^N zL@o)^x4D`LYu8%_LHFN$x-Cl-Mb|J_4DPff%SpzrN(Wi5UX;nHXP{(Ov#Pmk%Vd@H ztN&h>M|N?hn_kOB{Ew(bqxNH@tuK1kv1F`y7pOxWa`m3HEoU7{b)#8n3f8DGr98(~ z(%)aHMWp7>1I#Fns5wWYQR(WIpNeUPwkO8;bXZ>F07ic8~KN`*k$R~fO`pQaE9ytH0wTn(#TLk+$h?V|w z^3s13eyjAfwlL)u`qrVBt!wqILZ_)M_h=%2{IrWCgDG zAkk|$Y_-mHl$7YWT3S)nKSxr>yK7=B_a{na%j6_`G}2-;ScS1T*QtZI+FI6>tt;c% zRIP4Ny7a%6RjqtMHLWGGQl0F2*CfF@sS?())is#9F)P>Wf7slj)|QwAjJ7%il3&-_ z(z>_bt07dKFKd5Vp|4#G(wEMPl&4}EDpM@)H4lZ7m8JBpZ?5;-*(F`K+kafvDuI%g zmW2Bf7h2YqmGrO-mc1z2^3=U$PWQ^qayh487%1snnty$QAd8>*@zOd{xoKI=>Pt#= zpVdg!Yh%u}t!qqhi%U0I8r_`TUzyJUNA*BMy{0IgO5e5W^2dE&T8`-gGnkYOo z)T_v4TO~{3XWqq$86zbu!w_7XM72UsBUbZ3r7-f+h=lLKT{#om>PV8Vi_Hk3jSvLJ zwX9(@sl;Xn(6|_*LbXC7h?k7)QmI`rE4RQTLEbGQ;)N4bsR}c}=1E4?LQ#u9L#nbL zyqxD`BBXOjB-3#ol=e7Oikw4U8c@?JR-cmuXnsPxt4{@q z*iY(MZ^(-UT6nQ$LrXQ#g(89|*f@}u4s&`nC`gk+GE3ZdtW`{jHoqw3bc$htJQ$GV zQIJj%TN@!0xGzple3J?^v88CCseXh6>NH&5hVf&P8pTx3`Ti)&Vi$_YV;k8iB9#d0 z4yhrk*5I{zY5TC@>#&Fd3ttpBuA`-2+Z4gnd0yC(=1=M_~X2~IU zmY5Q?(1Trup_obgiCEA$LfbM$qBv5jJX2z9oFH=JAOdMlf!Ub`(JUA?ZxyK+YchQ6 zY|3^^z)@%kUYi%jia9}eA;Utqa7v)9J=5wwb+j5hd`60eyu*famDhEixN{OIEt>H; zfC&#OzoLmrB&i}jfzXL9A!wM9_A}oUdkr!z2p!T5cW{L|bCneNUi+d`g)$O8p{odqk0DW z@_lHPv^I$wMQ^v-n^lAyHb^&Ra4_I4@UckQ)Urqvj6|WCBgR2t5X%t-4-XCHu>uE- zvabxf!9Jq;2rDW9VT{MoG-}~V1vm(%WM&8uPp!tl2__(@I0>*wAgqnB)DlRh?&Et) ztlFljxvCfQ04a&w(22%ZugU_$!Qhf5B&@qOB8thmW^ZWKJ$0jc_zddNDz=#Bn~{hI zlrw2G-ib*QBA-X1Zvqc%MO?{RMuc^KGkar35;9Y$q=5x|Yv^n7%7q49h}MM47JlQY zZfZ#>RL&Ujln7D_w$liN*qucg?MRSFIR-8r- z%fOt6cIdJX!B@OKgWk+Wf(oTH=lM(#zo`T^8jC0)ltv@8WHuGthHOZY^915%k`NUP zv8h>kVHPm6)v$pnHLv} zALR74;z@~wnQkvObVjl46POz?4r{aJy-;rFUdp7jrh5)wGf+i2YKB| zZw{3tn8btVrLmz7F8In8e$?$k%%$LOS{q;3>+F#Q1eI2(s7;;oj0g-weVP`vnguL5 zO_VVfVa75k=*aXf={V&YT`%(GDi*{;k3LqhrQA;4t0CgcVwa1*Ql6C9+1Fn9nbedv z1%mbIBEiK+)u=ogH>Eph5(SFy21v3v;JRMIC&5>Xdb`RZ9Wm;GB|1KCV4zw4q>d(u zgH}bw#~}32b+J}kQeX;wqW4c|(ZnCKFRW%yEvQ=-+NJIeowMrA3{O4}`cUfXG2 zBtvEE&S__bo46D%8X?4D5{#)eMU&93==Z`G zRFee8IG;UgMNVzXM%BP4VI2s!-Qq>Skdj^T1lK8fk%%3LUskrT7! zwAD#R7YY`8M=wu!SYvc}6cAe9R%nD+o*Vg~UCca%3nrH^%A;KfS~=0-tQT~UE-hqX zc(RSQxB}y3vC;+&@`=)@AQz6Na4uxIQI#y3%{Hl({WdL^nB7>}4+*=odFz8nK!Zqo zsQ6~A06rEQM%NgHHMl(yj0*U5j}X{27x=!u^dhf5g0hWE02tpJ~gDH$nWZ?|ZV)>XyzFAfm0^x9rkRx2} z+#rJS6mg^k`F;d^A7;X-DSWuHgoFF@faM2RzZEZ99$}zGpx4_bQs9l%RHe>rT~cR- ze4q}2V5MovPn0w8;#jp(D2?!tXd6kOfM5XR&@R|SfC5CdiG*r^2p9!?I^2hZv^gpU z5p#flaa-r_3fS~*v{(Vk36XOqy7e`0-q}xY&;n$v@PTgLBlr!25rYAcgy?(dI+7)b z1D89Eee_R$tR?s%Rlui$WDQ*vxkS<7Z|JSp&6NE4PN$-yw<0;+V2}xmH3CGW@LW9v zQ49nE>1pQ!nXAEc^t)z6?W3ZU?G37z;a0bj;{EP@XfzL~1AP;dR2mPSrK6(TZZrs3 z*fbsuM2QKh69-4?I;Dn#CPlS3SRM;uZ`XrekS;2K9LWWfL&-t_ugEJ$tL#EB#iN3U zhkI4vWdi~{9rqHV?^d|mkN<)qs6^WoU}?xJ7Qi2Npm-J#W>ao0;U;wZhiM+Vqd8+) zMR9-XB6`dJ*Xg$*5e5D-*l#dKX@iE~&78X)1VtL3oW|#^O3!;(D z(I&r#sD~v2DK687;Jj8)Z3%OxVD@3^wJJ4Tz>rHuNI`yw$I}s2(R3LTb^v@tTBY_x;2nTi`yK`I`9G&kmH}Wq)n0ovA)|xr_JXw??6!HF|1+xo;o z5s`U%G7m`AGs4m$M2L$nHgLAxEb2x9vIlFT)dB#^Ebbr_5alumxGs%zfNHm9=czIv z50){1a})4?QfEtV{&yB2`8bX4RxQ&!9FNhEMW3w#3PwkA4{5S3PWhki|FtS!T(pkH zjJ^J@W@JR@KcgjHMS`8z)*_-Z-2l;$1_9_c>k~`;pvkl9$mm$SxeigX zhjCkCM+K8QFh7&#o%^|0xdW3iif)(hrUDO^=;@L=#@$Ed*wqnpk^N`qY33UB5+qpy zsw@YP7jgwu%}kB^bds&xL9=%kff6Ln1VT%EM!{YLY7NrhD?@59*zFMmJj&4fV3HYO zOGS)d$xNc2pP`hQc3Q zOBrZ504_bEM`%MBz@Gos!Us*ihp#mU3Md8;;sWg?rBtdqNcd5~D1P<7I? z_1q}~wHynp29{F=0kUW-ngful;>QNFMHoIuYA z!^=`JZ!GhKp~jXiQzdB8BcrR3r_I8@RMW>y$h7~ha1;MH8mUt;K}VK*9!3O#M-HQn zfJhg0DhB!s#NrX$g%p_gRaZr;tE^3wo{w)1V=+8T_u|*!4--R@C@iAPQi2CRV3^1L zXSK;1*M>N`oc|yXQ&sg{?|3IRr#7NBq9*fMohOBSEiX^V0}mre6u)W*%6`kbB!1GD zGOdk{k|Xmi3!2BtBzS=T<;UiEOBsEG$W=yKdTN~9Oz9$3AE>CMS_ao44m8afOvK78 zD55b4D2hqa80j#nQS*yT8+cV>ET&Bl^bL&#y>6>0KTRrhAJ^)O2Q* z*+^}bMTIRZ$Ci|+LON?>|4UMZw7Gwg0O|NcR0EQNdLsbzd+0HN(m&&%6tZMLxX#3Wlj`iBNS}~UbOu;CI~S`Am+{tMIMdia&i$2;E_X#99nG=h~yNd zF3^%I3&NKOu%)a~ypLX8EUMEmIyO=1w8{_v|Mx0fhF%dp-$Wxt9q7#5!kHfF#nJ_i z3Oncq1dE$nRb-8+poOTSBQrD$hQ~aQQFBM={G*M!7dEtDf6M(SK)~O60Q^3nR39K- zeqi_nCZJwefc8>oTw|`dTPb$Dx%EyPAC_mktTKJr*y~m@#p*N z8Z3+N>N%NeIo~rtfZrl7Qq@mU`4TcVqKn*+`npC|_QwiXaMB7w&q?VeIgCXiz2wbR zI&z{~Bxp(R6$M2NmN<=Zmf}*ohY^g$83?BT?RV@%NR=W=mPe@d;Rjjy`RTlB;2ATJ zk;{{Z92-9u0VB$^N9fWD(f+FX1`YlWNTa8XKjTsBGAiXgrKgk=l?(neR-`Yn}N=YF^P;KI}po zS{Q^aqH{DBkvkTh8A%pZnf(fhDg)kF@0b720RB+~0dHV&%h7K#$wi+Jw}DFpU91PU zJK$S&MI27?lcr&|KiqiqOU3)NRW~ifSzLPax^!L9{`s>V@h{RhD!L-{dR38^pVi+) z&|Or7NRluOpio569R@y85=^j9t*cp*GgzL#lMqu*3)TGwQj+@z`e1xn-{Z$WUJ9fT9nZw2#j_o6HG>I5`3cMDRpWO zE20dB8}qJ4p0g8~=1Wc$XHxP&npoT~?8zj-ThIlOboLOgK$fg3pagEzdq}+0!>kW) z_mUV;r9p>LiOIvSAIU)_9E8=`@>Up_RTCycrY1(nTt7*fq)bfZ^790S}JsgCy9cg>Q>p4S-@HRy? zWM=xblFwj_L&V4s1r8!8ON1J(y(K>+{=0AK(B01yDc0000*8bV;&0AK(B00001 zJ*3Sksn8Ap0005w(LS1UM8 z)!|oeTpUWM09aN8ZP#q(N}}{mYo>wuOAsaQBzX6^YRDzUXqryIC@{z?9OB36ckj+%xyasCLt=r33}eDvy90aSv_GoskU7D zzD#g{EZ<2-%`VwIUa!N@DV?@fM zPnLwMA^DOq+!n~@WcbI~wUJac!3@f@8OEy>aa2a=kQ%2fV)q_FxOKwW7=4%CWS*a4 z*F^6tWjKBbCN}7}vl&Vy!o*jVsi`I)c|oEgumLEn8sSo!nxlw2h}vO5F}{Lwp@x1a%bep(KPZ}2HYwn`6wNE}xl@6Y z?EHhjwvK$&6cMeFZk|v4HLPp@7Tz{4T%C`1cg@=SUYGtC`-fC$c9qT6$)z!*#@t?` z5)8ghNU@lP9Ai@{YH1je1-m($hPvixsMM9_;zXH->H=8qZ{UgnJN)Em^?U#=gDoO3 znyq*fyjWl{hwv-D`=ufGW>w7x*M8*q2a%U$;?6cbf}i^DBOcLI=)j`nHYt@BK5<32 zcr;BS!%u1dXR0cSBv^Y4M;d(P&UTxpVn9)4ix%M&TB6Qo&~6)(2;*5HV@;&868NzY zn466kjE8T<{&_wv!?p$kb>0A)D^0Yy2Ya31dz#f#2oOlc%Db#ZaFtX!PqVPQMa|BB zTOrNQ>1=$md4FflP7V=Of`NCQtnj_%+}c8n$A`;h*=$ipxfv9+Xurzbe6^GZxI4ki zz=XufKHAVnKaCXq&Z!uSuEG62Oo8S-p31`)`*a*!@I*^GCYVzp!$ZO+%#ym&6+agP;U+1a*=>jDFTLDmQy2Zzq%D)gnz z9jD{!%77CD$@e$qp)m^S@(r0t`ktnjH<*T6B3(Y2((811Rvz+-IQ~=kb-1HPzI?PR z$<8Mt$`c^Gw_BPDF^W*5x47DWx<2%K(E2p&o3C{L;-$t%tKKlM-)ikI^`>$6iZErLqH9O&aCC>&8Ekko5oN#Ch=-k3)gZjr|tt47VdnF zh?lAiGLG9?ND~2`H;oHfArYT>)TBSpsDc|T*O60u?75%rJgL!Ux zg28|aAw&`mDV4XU8o6{a&Yc<34bBWMTtT&=r+^JDl&7bnh`IidzewJR zTuCu?__#?`jhD;Kqp0==z$*z%37T<44cgW$;BuB<@%^Yldh!w($?Wy>=H=lpr=ZbO zLApAu#cM&xFJb#>JpoBU>aP%3@W6M&nRpw6gzWa7U~7eeoBC^X+5LZMw>kC{f!tG< ztt#^&C5_%d89&CTZmAs<=0;bp=%{qWId5)x1@SIWHpIfmD{aM(&z*mLMZTBM6euiO ziPADE9iZ41RiMWlJ4kyID)H99Rv;}IzhN0 ziDhh+6crok^m`_ADGS}m5pwR!)Gk^+9orwAfxyN$BI*YgmFl{#L2??-2tw4iskAEv zm&8DpSW03KWX`U=7EJ+~YGG5W)GFK7gnE(dyU7PU2_l?|Naag+{4K!oEo?Ci2oqsV z^$x*zj3c#T-681U19onKRti^3C!m?ojL5lQP&lydLpIXl1aghkLvw;97e%sDe1~O- z0?~oyfCV~7O{E@FK@4o~W?v34N+lAop}2SOg}N!~P6fgngq!>j*dWkA2u%bMZiz(V zl{%Fmv%@%9%+?VH;tK`H4`{rpayC)C5KPbC7*AvoC1{oP3fTA(0LG4{h=>piOAl_K z@qBX7nOsT(AOh>80R$P*357_!V#jk%2yi1RbJyc9n2Ns|-gEM?V<#ACEQg^|K&OW# z*=Z)kri&_ajS-yvP{5j9trY4C6OOsZkbE-bi4~NBCUan5fkQwrSpSa~G&ldqM-(U2 z!bl5*GYEqSCSTs$bm6DBtPobBh>CIt#>}V`+|t%< z=!+x0yF2}nJl-bscu0yRF+GovoGG4L_ZM-vJ&~Vm z(c#{DEPHpdElCwrnj+%3Ib;)PZweMBVANZst1LHbQ6btD7D;BIrh$k^Xk;WDNC?Cc zP;rRE0UWI)#1fI2062yv9>xi zYhZniZ*d8Nmq=1MeMuOY>tO|kMvx`%;9^2=$O8tUsGfaSc3%UvtPPJ@dUlCE-ET~r zjWq&b+BOBk2WxKhiba+~bd#?$V0=(dh3T^f(WWUt{$L`M3IYI2lba5uU;qFCD;@<3 zf*1xNs6v{d0}xaSDPl@UBtpt!mH+^SB)6%X5QHG4zSRi}ECS_aA`q(4gcSvrSsQ6l z*x`s-QAz4;TC1$8K~_!MoRkH^%Lb66R!y3u^h)m4ZD;>k3qZE2Nli^XWGCwx`qo=C z?ZfU>%rw~81VIi83tHypx=Kpdc{i#xy-0#3MToW~lA;pV6;JC4@{3$(qyS}Nm4$3PCvLYKz~VR90P=&&`TQ4tjo^jF2_>zN&fsy*LIF0O*%?K@Sfz z&}s`Dv=T7bUX7mVcTqb5&M#Nh$Chvgv1_(2wL@|V&g7k$sT{eMpQ1qQ$dEORHm=^n zyd@?1*(!Kfad27hou3Ce=#ZdL4pfQ;Jl?Q%T|@)B|cO|i85lHXqB#>Pab5IlmNwSQSbUck+Evy)L)u2EhnJa568!?0m}#c@NNF2 zr!kF0LTUPyGTg}FkV%W!Fv1LmW+axg*ijDzEuF);yaDPo zO>|Xcy9?#EH_ttDG8h+@QvRS(je&)cf)v*~jdPs^i1&q@t07Ko?n@P&{{I@P{6&j? zxKgeB8_TLBf5_Kw&gD>9`(3q2zbuB}Q+ymG`Gr5sCy8W4Tt-Q<0<3qUY^nx?vIp8l#Jrvv+wLe)>Y8|5IN9p`2GXZrlLtp6?O4j28N@V8ooqIs-X zJ;5U)!D&b(fPLOvpMt|b__g9J?f2Oy9;!0){YU?oGZ;JJ>9P)xJ))qY$QV;4JQO6u zFyRs4fuTb}AjxE|Jn^u6w@DYH-2O5ySNA{6^wo!_%9saTh0E1^|B|F+S!6(psTXs< z9;=(=t{lGg5&o}@LjB1fSCn)f&Mc-Ws)9a}K4gsllSq|Dyy7A{4t~ih8y4g~5`E(( zP5X6&l&rkfN2~L3cyjex{L8!_4br7;CpY&y{Ucbh9%@8|c&~T67FQtIt>v?@0l$0~fr7yR$}k^WeP2{HW5T0Ox%WN9zt7R>eko84x*zo(3m z5h?-C!fj77G6R>R|5OkelpmthLJnk#!y?JPh)4Lp?4Uj~#@0B)Tka!20-h(S8Y^pm z)9tu@3P8qP#mL^ae=pw{nte~W{A*<(V9NQqe`1$4i@eFtcwHZn@` zRz#?kh3-c#Qd$1rMW0lyk1)T#F8@fBQttknu?Xa8%h;A^-Cv~e#=Sk|`D5|VofdgA zM8{G^R(zLoBV&v*(PzoI)E`JG+u?5y=^8a%3po!KRdhd{RvR%&q_=$ah@HIrK6rxO z%*!9{?eAuz|E2nW=(4p6A|+JDM;=I-i|Rcivhmq}L|y`o0;4=2k9^S;mF{s8MoNjn zk}_KK)Aphwjy=p?o-$Z+gy3?oqe4n+N zW-RD^Vbzdr~F1nPKZ%ju1c?wBvg?r zE&UI5^l6JxB-*y=e(OSh;5B{Dstd;f-4zMX#@~=zW^$9qC64e@KKGH~1&ER)TF2Do zWQz9pI?Bd8CD4}S4L3hr%zzGOSb9eK9?^KnGtR$L^-}h zUQVu{iDNz5=@_=;E&Mdcpn2}(+=7g_eGAY2qkVRyaw6RMFYRKZ9{FPBr4Q5(DM(xp zyz`{IHdu>EE#E&q1PCEQ7{VZs<{BFSO<64l?oBtI7=a`*goifHhB!nK1V$aq3&Vv7h%|bEaRUMo z!a@)z=r;}+Ac3LGD6p-;M2wAwp~Q0zyP-mvILdR15T+Vr?q|Fp#_l?Mp^#{4hddF5 zd@4BdAW+ba5bmQE6(B)Ihgxy_4nde=kXD?5p%6wvq0>18MiH2p`QfHAhLF5OF zFp#F;#Bt201Oy<#!W4*y&L~iqa^6WjrpOBn5P=z(a#Gj;gCXR5m{7<}C^rZZhJ;=Z z3Kj^|+OJH}7Ou)fUSvf+dW;Un8WC?QV=Mj>b9hAluK14J3U!aH5eLPlWLDJs@1$^f zX@4W`U%K}k+d53lVZ6C#@li7_$1#2pGWv7^99M2P20G6sB^iyyPz(kqCFwrpK9^#CLqs!)6(fi=IAY%jwVvQRqFwnoPw*CaDW}gyVPQ|QvATi(n z=5CB44|ewV5ig6&vr14NHbIYCk0|v4q(}PD4Bznt6@fINfkIRv5<}(`?acuuuH>YJ zl&w>46o)0G%6VRf;LF0@N#G!LLP|)LR4t!;c9f#2^)P;cqdO$^;KE#4;c%3?b>JtEvUj z>|zU0>On{;2wR0AE0X%K%!*=e4UIwt30gxb3l0M1fNAehw5uNdaznyhR~6J)*U=}M zW6Z~XxI^Yqgm%#8IVGtvwDl!l7c9uz+)aq?f$=OQiH4aHW?F>mJ{2uBQvg(AiX1T8A9aukbkam4F3|sO3IUIHJTvUSuC6j7pxFRDJ=|^6&TB6VdU? z50O&-DJA~OU8v0`wLHz2=}ncx^U5>RlY5^mE=gaa2pWjthu zTdoj8IB_%9OIjhW&7W zVDY=lbn^}yS3G~nq-5j%IFKvzm#Rk6p$-_t5*&=uv2cUi%afEE;zk@H1f{7B4G!Yw z9|P;Y_co7%ga`X*l59DTI4~G_)M8vZg^Pl*YGK?dG>D3jHAIuxAXp1i)p=t`iP-Tx z`5q_(A{toEWHs57$00yqf)D`>kYXrF3@yCO$WyTQjF99KlTK)w=40~nMkHAf|JIru zY*|7UMi7CaL{X&}VhG%2Y~Zo7K1kYrZc@XC9%OZhkg?=u6v*c(9N7g5X2%1I4^agk z8e|z_$H3ynLa6oIfgsVSVj8UIjJF=fBq9nC2i!=pH?&l9Gc!~Q*47mWU_8mCBOHkX zWr|E07ytkPEEoU)03ZMW01{9y`v3-jps)Y{0000000RIAgy1nCKF5Fn00A+9VB;K0 z7z-o}4j7VX88bXKp@c^f!Kuv4kDCXs?-ufH3ra;N^oN=u8A%e16_<9 zM@?vnzKs*Mm#vwA2R)BK#VVV=&>vM^IO11vf05LKJ{6LcNApo(H~OoxDo!(37!_=?E~)C*1u<{VhFTLMk| zK}n)E|5;bT3rM!EdAY0^ju4UqGMkeLPrMF=a?&+ZTC?O#z>*lcfQW`yI!?~B#3Ed3 zVoy>W@53@R7dA*({;6b9?Q4KFsBhiWgvduOpdlcW^Ii=2ES!r)rL%b+(4fY(1qJhN zlzmW6zzD7ExsQP|$QGmuHIQC7I3fbvF(DT9bx<@$2{)iYNc+qR=spplN@UXULUlu< zIrwN*0W=b3AP5k~%Ai2#DHx4{7Bp4>Q9_%*hHq5DQ{t5jJcR8|Ho9jRBT>eXAd`vj z--b>Th%y;y&cr!BM(rL`>s0^%0WvW2XghKfIn-dE1^~bS00000000000000023Z9l z26KV{22%k+0{{R4kRU*S009dxRtX7A00T$>00A%n00YKKJXcph8bW*k1poo*4)r@p z{Kh26#k)4XLD1AtC5j2I%~xs-gX1qX1#X0x2a`U&%GoDx6l(|wN$RR`Tp_Vo3KN3DX1^VFVaJhsKK!3LhpkdZhSS2OcArDQHq+@;xZK zd^l*xCW+;%Foh&4t0$7%Kq?N3^%@iy_#-}k&jXJ#Cd#Ikbv@w#v5n5AuToFr)u)!$ zqGB6-O%ilzCdM%*rGs0xjZ{dPPhfLY#cT~hYMzP~AR42vJ5p4)HubAn?x=^5M(d!o zY%n+g3+T4`rkofY?pX3F1NN3W(OQeDo_0J^MOC@$Vo)qRJSow{<*nVa_3^aYf>oLp zcv4Sit~sgkb@iVg-oXsDP?h*1jAuM$bbFacM)=PO=lXpN&-DcCIQV-lRV;)ceY%NY4}!FJU= zZz5(G9W78o4qyAyg+qrtqT4|q$%=~v>&*00d&cmHPuEK({gFo&zM6ZW zo}(@Frko-O+a-|cV|a{nJnnY&fU zHg5>~mNi;r`FBQao^>MrOLQo4x9D!iXc0jcD8VUX?5j$m4Ki7dr?XwLRa%ti-u=u`G4o|w+ZfQL+(X!&T9TXX?3+xU$5s73G<9h1~CHW3h4Nv z65W=3QOA>)#3{jgJ9A{zd>^CPx=&$M36P4Urbn5Ssd|*L?EZ5r7K@YWWXB!uoy#qn z9Zavnx=P)+uyaYh+K4qXGEJUD$Y}R9TFR~7QzD9=4zTM(JFiBtIrnsLKS+d67Ry~k zD9!ZKJp~u24TC`U?E(QL0OXE1REW?y3Zst|7_tDisqVQ; z==iNW0xm&l`)}T)ODkiw`@STrYSu&xL{v`F0u?Bn*nywMr~lEmbb%Y(NuQ{gCk%46wL;m@Ok5+4C2QP>u_fu?Ek=h(d_y zqM>`l48~UUmMF3G9fPbLbCJdrLD+%$gTVRQ+2=^)%iC^&FihA|zCE@Cj-ld7M+Sl8 z^2jzH_@g@|6LMVxhv5@ZLA|Mo8~1S^%o=b9lCU@{bpYORN_@Sei2NqsVpi zG?!De+kA0n_Fy#o0e%-YuanrX?ysW9Zu|QFhW$+#-Tf zQwXV;9CVMA6O9Wk*w-kCI^bnY@jYf3SHt-`JCJ^J^k@oB$-1%Q=3|zAybtG>YDML# zoS{zpsSl(7vZ4l&&BBt!O@4k7m18zFMVqE0M3l2p9g1G{ry+}$U63>I1BFGlA;`)v z#p!kTJWLQ11citYp@I$}#*mQ^!cPhWOp->(*eQYpL6`%rb=U%61Mu>T2Lw3%LAf8 zE{eae$6KhUW$Ko5c6Hg$4Pi#z1xu-Q@w%2%yyT14w%n#B>DFWsMn8yl*g&Iu2(rBs z2u)WEgqVYWdRi7RYybcdN>Q%4aE)X8Cf_gSxkkCOw?WtNrY;TiNNnShs6y2SQ9eztPZMJbyCsXVKW|aZ7OU1O%a)Ac-Vor7-`tiwp>l4fB*miGYg9@%Yvn&Y?1JQ z3lEAiOY=hLc<7o^umKca43KzenPOV4CbiS5m55j<6i5pMkZ;TdyZq z0!1o-6QCqQ5QR`h5>qUsSq-aXo6Rnv3K+74EK-nyf`f)2NUtR(;b;fZsX`$LKw(ct zp=1a`q~4`A&u9=V3qhz6OAty|xFV%N213Cgkpz7xL42K$-AZ+VWuVa{f>0~$u_1Xu z1p-hgz*S(S1J zl&>pNHENGShn`|xn3X7G1z#yoa+wt^tRLm#C@ABa?AGgGn+CUpjS^Q4Oa)~+Fc5H& zQ_P(N1CVKkK_SD73$iq9xiSXOkub6rL}r|{Bwpxes=)q{DCFsR56#NDYRo6CG_Y$b`oVA9zMdW4WUlau}+OMx5Jc-{ZqYsJGO$11h_s*b;NqGAd+ zKR-V!>!xWwKj-MmRBmpgBTti;7|mii|2oIRZeJXett*2{7fHzGanLiO_$VS?^F?R| zSStB@asCUQL=+|VC61LNKNqzX85MR89Q1KHQKDLe_3ewTL6o!kQ^lIZtV@yR^jJ6% zI6q-v)pb!Y@)9>x3RVslA*QzX-r z%=@rzB<;(Hy0=VWMA%vTs#YAyIu4A#8Tn`STUp@CRhWYay~EnlRtsL;lR3#`TyMD+ z>7^bgAUKpAgr0mjdY0bDRhp^VHdb)(4|x%_iD(3A)yFhmYS{2HvS1~Gl<4>6B}oxx zSm*^G3yJ6u5i!bmd3DH;x5h+A0EAD1Vsi9mSu08p%4UnA%8Eqz=@-r)fOOd_jB=N= zgrsPhpN0R40Yb|gEJPt>!BF2LmptiLIZTyYtcPpJrz+7yTNU0Z>zn@Xm8<6{jSOlf zO+1C?7kp+})5~|tqnH1dqbPD(;lflk74c^y*&;f$(=(b*GbKDl8JCRYkaV`^IU?`Q z)JYV({DtM5=DY9z6Oa2EFO&IA!gG)DmphvoNnT6k5zXHe?Uc$hpBs;JnE>ZE5&J{F z(j~{afdk-KEnis`pn$yRo8`5h_>QAe@X8pw+1YG)WYibslj$2rCbL5VWX0#=3~WMN8Z zc3Tobv4j{RFrF!~<1d`$GAYs`50s@6`Z9#-&Rne28tK(eH0l^sY({n{y!RVDM~+>Z zl|Pm;DXPU!hEJRn)P3I1g4Y{_o4fzPW#)dxByz|U3)82;btkfpR_8c(hVjsObIoH| zFYR#M|1DB;t~5B7y`HcCU(1S>q#m-AY^2kf0$&#*$dzZGJh)pOHx!MBfIe3QGsHv`_*8rTKe!AryyrR2 z)d$$~%PdofLL!apBFt$PE)$D~zhn3hIZVGQXy`dhyW*@9;-3$cM%7lFuktOq&Qm5b zxY3A*oz7QEa`|JY4Ls#$A{3>abMu*z5YNxaWzJO&N31^urY@g}Gf-eTmtAvDB6NSp z@m!UCNaBF&9dWnIdWz>M8eJX%(>kIxJ%kJm!yu64BbF+o$zY{A5k|yjSwB=88Ji^4 zt?A!nKUtjlQ~$1+u|ZJh|KI(-)*&GLzY_c$_%>xF`ITpAc z+PFhhk6aMBHi$RLPWFo7gtq+wGyV1fi8DUW1i zA%ifX$SD(^u@ip&@<~%MlegE&`+%BpgMR})XVkyiFz}De;7XsD_39~}$NzOn5N{6_ zC&3by^Y$m)|H*h`KQbi>w61+EP{J3b)Y5zrM6L65l33R^ViJ=`*FU#kOK*(N-VS_- zCNpsZg$RtuKBOFogX}P3hM006f(Z&@!jz~ya|pr^IB5;sA}0h8A;U3dB9L;NK!h2a zGsr2JR_+J@LBz~8LW2rvlXD3Sf4531W z4>SXR{;3C0u6M8?1{^trVa`_~IGK`6=(Ah@%juozop&ts$y3t^ogmXvM?ybOyb_rn zT^?JWdXRg}nokR)dRVy!wEZG2c77=6_KJM!c6JZVZM9`I7y zKyqlS&J;m~lt_}tnJkRPh^}V?7$5>M1foWYHsx`|IE1k9X5mH{#xNw3A!U{H~F zVV@(~d0#r_M!}r^KTrGo^``1kY^X|!>fBB8KX73a`}O?)r%^v9)!Mf@rBGjL5%#}q>s6%cgzPSu(`Z9jGkNIzlhU)uFBnz0YKn&w#N4z zkdWpQ8Wo|zlr)Tku-Kc?vYmGCrpVP4 z>RzCQaHM;Q050RuAz7E~0ZP9%Z>=B*FjwT|g0=K9r`J7YG7* zoqzjfjd~%KXpI+y{tdUpjl|pi@wu{nWK@ZBUpw;iFDMsH&O=jEIyc?gw-v zfL6mFOdhsCnuhp3-~a#tIjDmud^`Xq5)fQK!cb}Uk|~VztFucuQyWVAG-KHG!U!|y zz8^GSfl>t}HjpG~g|L|hiRcqxL53;>!;kbeDwiD5Q4=9+P^?;IuKjrS)`=>5(Lj?g zgeZx;_K8ABm}p`&m9YaFQ##Hl+ukf3I8YLkKY|KTh9X{xeOWAtF*IR6MXGCfuE-#7 z0h5+f2ARlO3+iE#jCCnA#|fE|H1m(^L_`X~rcA*#5^VCbA3WwJMU9e2TZY`*j5Vvt zMS;!Gi|Nx7q(IX|5+)IT6~P3Mf>Bt4n>pd6in#KiCUbHnx7#)nx%Oz-6mJ}^^f7B1 z$|GEHQ66NsgIUOEdT^qIv@0@kAtPhe-~&jBAOx~CBL%`1Y~&~`F}EZMU)7)?1Wzvj zy^}(<axlq- zSf&CHf16=!`C&!16&C8Tco!;N#a=f)Y%4`l{cFSvsJd$96;o5eJhwKxpGg{*Ifps8<- zo*NuvA5FbR6il?sRJ56h?Dl@31=s*ZTWkTwGNqX_RxeB0vX3a0X!x+73%F_cRLuCw zTq|=FNSc+aTb>wfeC<}uvf5fCx=7ZcCd&r8A}J*C+%(!P2Ck0-^w?vS=0I49xod@|D zds>IX=P7V6k(LTXBSoYd+q=2<2|a_~FW}9PieQ3a0mX|678ZSBHD8cytg)neJf8Wj z2+%98!s2}zLZx+h$Z^4K%Rn465pQ`Fmj!W=>1Up;T` zZc^l}*UH`IFBRTc%0E3O&uSlLT_y(Iu{t=>_#iu})yX09s8kJJ)&KzitOgz|5MFuW zW@md}4@%r18}l+0T2w^CIk7@j*nS-TCaPwc8XJ;`U4(_l*f-Pb{2qGiE!-=0k`bkR zH6HX$xH&SKTYw5hEQq7c-UdCT6Gq-*SQ8GnAZY{02 zeodAthQ2>7M8u6+vY80=td|ArtTu1^JHt-YeyN~HW{Jo9@2C1VOWBh^(7#x->%_7X zyuKT`x;}j5rmAGtdK(K6w5HSPMWNX2S@N{_nO$v&J$Xe~<;YO^1sRO#O4x(Ka8X2y z1no;y2#^DC+`LlJ<%cU)&-_IX%h3OMwTdV@*Fw{tAbvbg5Ed>FXc+{=gX;)j31!53RK;Q4f4MU?Dor$%uXvv^tC zi%Dy$zyWRm2%zGFsE`~E!tQ9!zD~`QFp>F*9KvTJ{6y_lDC}gsCL=L11GL+q{H*L1RQrC5*hjK{Uu0CS6?WEpHex=t1ubeGF5v;mOrCX3cTzVPB= zLZ3$xT#tZnD|J>7Qs~C{L;PWwr)EJDpUI6P8KVWJci-Yybix$(|ykAy-Q14#@9e z2Ohzq=DFzd$gp}TBHhtW1d^K3`B*yK^h9CjiQHb`OGJ?siYWHj zbR2{bx7SC$}D;($y1Ecl)5)Xv@=)I@>`b zXc_)0yG^hVSF6Prdc*eP6*EmV)k%Ux-4d*86S)%dQ``lBb)L$pQXk;(3x_Oj+a3jU z2LpBh9?yw`+JHyii4uKvYszO$_WW^d86PFZgUPLUM%5&NB1tDVAM|X>&gyGO3vbvH zILKyMV{lHH7=2ZRk{keEg7{%rNrCT}v7;#k zr*I9oFkl#FCBU2QKGAnBWK_tmV@%8h0003y6UY#fL=Zs)Eg522VM*uxN90I@Bq&1e zcgli1^23s|6@&o4Gc6KO6&t#KVjzhm|Me0fN`sV0krqq*%rOFwGw4WCGAj<0Y59bJ zW@qJ64FVEU3JDS<3XK{zheuS8{DTNdpE;|X)WH}}zGh}oubCTM>pdg_IEDVXpG(V0 z5{XIINhGhU(5&)Yi4@4py>DI;d5e0-k#k4l5ov>SHOh=-0cabb)gUiF@T_Set58*) zR;M~zfT%1k89)->u;rUR}A1G)+dTn%&|)$|uJ>=ZvKc|b4?N^}oZ6LRnS zkQD#Ua-@-8Ay!n1k!KQh%c0sO1p98GGLO!9=wF-yE)fo2dW1?z+w*1oSm&W-Lff41 z19_W~OvgC=AbY#TLtwM0mJU%+@nO#czvf%@VNHJBn+e@qkcDCxDV5d^j4*q1!0t@S}#WFf0*rlil7%Rn?vwS4-TF;tH`Vc+c z^A>kAB`B?MMfSzL0`;U6xNShHDF|pcjGX2;6Eonr63zpx6&xSAg9YLUh3J=&1H*Xx z@BUC`eydaNqQtFZ+1+bZjWDZQO(tnji<3X5_7rv1qlh;8*0q$U)*?-=Q&wLXqnYr`jOM89iZXb{A7>}jxIR=~`J!c~8OHsvx zct15IrN8V!!ISG+$plONYnQE%>WN$H1>jCDyFeu$1R}MT8y!W0S>+(mrmvK6kl~?` zC>2Y=7xSJEDDHj_IRXiJuy6Kq4^6fUn|lMvg0==L11B~oZI2a-0r`WJw+7(Ug!#AD z2Z8BiH4$q@TyEW9h0$jsrE{Z1S=n(S*2mU7{(1qujx0*oGzr=)L}p^`Zho*}_^{JGZVIqG-H(EK2;wUe@D`{AQQc|4nfK7@bRX^{J zXG@}ADH}jO@|7VYrD~<7qqYfw?z%Q;?EVY60EWc^I-u3g8KM;ZEM7ZOU8zFWwXJI! zEoocB$hEAh9ZQBjwv#=bpMQNIout#!q|#|R*n@&iEqdBZM?k4q9t$Zc7L^6)Nm^%; z2dxQ>)HUc_(t$-<(vW{eVyDZ~gL<@PY1^Ick_j<953az$cn!E7UQ{&C1HkhA{UQ&v zC;wmROQ55^q_r&-ES9yWXyXW#uh{CDZ_Op8$~sodp)|SmrD{xO@2^OtyL~PcQskux z{bPgrK$W`$@;4_^Nw_DPc&Ka}nm{dUN`@V3try=~@-)SR%aoz;*UR(1l_!84TF+y4 zDh7{y#8}Av{Mpiql_pXI$xXVg6U$y$Ygu&89&e^}FP;d=J1zFtOMP=5<=W8Yi>GC+ zdcnCUWQ*Wje6#e66qKMJ@NZIh3-oSSXk!B{9~UIdB z&dVn`YeL0&`5^pN;nbcYfT;lwpVq+&8HPcK?-CIi36X%25laT8 z%`Eh0e2{Mg`vZbph7GA8nQxCQ#e}gPsM&1u2b>k~J!^R}8|!{m^J)KXu_98ziQh~a z8uSRUy3t1w_3O%-yPjhLOtvThSIZ4dc6hhSgqVEz{D=}~;(>nx*b7q0L#3d11WcJL z*U~8vw3#hpl2X1iEa_U#Dv4mc8|}1#xTjy*eM0#~PNE zsdKM%5hk_xA{YNfl7IjJ0YSDyNlY9F2>=`{V4=zwj3Wq6?I03b3hG%&ilmV$B(>oX zK(Qfo3@o%E1#Ww*9z`%hgpZ(TT$!#vbVhXq(x5{)m&vw!Y}w%cRt>ru(enXbs`pqd}C}sJ^8y^rCHKChHfIfDkam zO+IYTEe*)Gj;A^=gb124RaNaxS!RlAqW`EVU!fO|H}|$}j>~j%eDB@j`SunwO$Q8MVv-2G@#8#2^=W zKo|!b`@eH9r0003(0uYig5QZ^;0002M0000006+r(000001F3>AWC4Nz0000005Avu z0000m3-8U#8u$8RgwkrYDp8|R z0~g?8A)r|`woMS7bly{^ZW0IPXTBZ2Z-yi7YBuHC&PvpuY#PW^z)L+miHu=F=2(Oq z#gf~JJrW6rxLcZtv$Jy;(K!J2=eK#B<~cEsd~H#M6$7!?7zVaWQ`@r{knur7HDjJ1d~@em3K zJ>ZZbECDM`cYz4l@mo4gAJ7kXa4I}KY3%?5_e_bF%Uv#KUh#{~k=B?tZ(qSlp8uej zb_Gh@t5~SiRIxslJYaeV3#37{lwxp8J06R8SX4-Zx}lU(jtJm3Hf9t80DL*l)kSj9 zUx4vbJR&eGS6d{Qyo$@9xiKKyl-4K_*#MK2*W|*GE1AXktCU9f3MeM2ynbB+N7EdY z`3QYLaT1Z?9u(?@N+kn{mg$HGqP`G;L-l}>)#(FU73AoY_8Q1W@P;Fv^^)OG;@PASiw#7Kd-=H4ns#Q)^@Mvn%+ST@C z(Z8n7m4b)o2vrh@DM3n&AY*L=DrHp4D9s^_fkYVjtwLsaiq zQRS0 zks=M;DnF!q1^cuy<&>0s_b*7+wnow@Q00d#Ry0N;9$DL2wG=7j9IpUQx5kU>kR`5} zjeDSk;{PqNE}mj#PFDh%rgCI-98}Gfg+WD8Xm&C~1)X@iWMOHhENVA;;#+qY0y_h| zEs<$o?%pa^l`LuIEf!Cq{bJD^Xn@;d1UYDS3@pWI65!{{)k&fxPAfj&$0OGod0&U= z%eHX~b!3*bSb_GFDxz`u#k_KUJ5f7CAks>zplVU68Xhd{xWv9ZcbH8YS|99A*l3OtO(K3&r4#xH8z9<2Nh*~=$|WVi^cJudu(aJ5a+qXEbK&c+9>yAa@468#hv#J$^riTSaPTa ze3Z0{1ZFHn5sl;FVIhv!odJOWROK5hjWWSHG|Z2vTp}(W&=D?WEOV`$8J5b!k>qli z95e#f%|Pq8#=pwTxGg8?HJs|w{(D`QVh!cmm8%op46*j%mMj4f$K0*dnpM~*S~qCC zkXhUFC(;yo_F)haFXAcUoTjb`MY&S>TNC51VX#9fm^ET{Z1Wa0FI(9-xR7H~B$opm zHbh}MmSF;Vd#E1}t4a-w={@Rcg`kIplsvHFoC!I&T0pBiP z5k!b;XIjK|TVr8xfZZN{up4%lRpWG6ZH}cMIRiOMhYJn}r#+f{J68a}3&DOOKKd;} zrfDq%gai6CzM7GEO2hoYOW7M`2>b8=@lw-lMS_yL_@dvPs`FOT5Rj>LJ*_c5z%fK+ zrZ3FmwIxG}YO?e6sThta@9%0yTaKxMAvAL{xOwl9w;u+fYpEA#Xoe4%)I+TGQZHoA ziTQ1@=0Lc5UCvlj+Z2RJ&)`P3<`!Ejk6qC@k2`~ku$?S%aLiQosPSbzhSck~vPM}9s0003)M7u>?wlK?EvT zhpLi59!9ZIXg?!(mh)a2Md^9dP$%~iVGXw&D8d3ZjDy0Uk!U*6cNDn5LaaGNq9qY1 zrojOq7ED>G|4{o31(sPc{ac#2114zpDFlM{fo_zv$^_0*IxU;==CFVFzKmBtUf*5e@>Ooc9y6d%g^oz3!ic1g0Km1+d=7$)wTLvq zlqHAnqQsAUkVAhgQ#5`N2m(dcm|vd64w#R%*swy~J6UdVltvRRSPVh&keGW;5o|Eg zjAO!w8xhGfHz(Z`D1?Oy0-Dl9l2?t*TQQ|hv25-mucy;hwpugkk_748ny$K5c_%)> zdOudaF%ow_Q2f0grD}>Ccv)vIQq@~-fk35~RTZeLungn+8xS|xfc5e{(tQGbBLDQL zWSKJYBP!P^83aP9ej2UPkh`RdKs8&TbKauht_upI-MU(g#L-&Zc*+tSrL1JjIc#y3 z3WUXYshtsE@!=4zBawte8Y&D{vZ5nAWezq=LTDdxnHeI!!CL7a`i5<4+&lrRRA1-& zMFl<8B|1ug8R-R#%?L~iU#av<&|=I!$kRMM__nfxJ*U`uS$t&j-Tz49T}S?_BHGRZ#9o*=o!$QgE)#LNb5w_#TiCo#+>F62kFxel(2%r!l0R*P@U9I z9=k*I*L;^lydnkJ#3e<0_;UT--<)bP$|%=W|Fch7s?rOdW@oB~k76Zwi_!TOToFn{ zjJ&_ruqs55nbm;iROqjLVN4gGevX)#TNYxi2+x1GzkP}Nd70N>j3|b9qs+|w&lvz! z8oa=0G1BUt0)>bQrEIURg|s`_K44ss4!w|d%=Ge`3KMN+ELP)9*aBjuVoxx9fxKo#o7Q3$ ze@8s0dS@9KyP(CORAq|WNX?8yk}Oz=y@-=m>FE;eR;yGQ*h;D+DZz}SG%^T;#KRz_ zxr8xn!$F{i5#WeN3T{|p`7@MAdgzMx|NScvnQOU) z_x8(qXxE7KiZa#Z=13t4AEWv2MwJbh`2S0=4y+2Q@}YO3VA<{FjZvSg@>CIfmF0?N zK!x>G<1#ZNwD-*vh>`gcG@xvYOI0FJdZB`(;7~M+*#ZSl&ZAPhTtW-d zw0cO$13*!kGz@2@|Nd%;6QBOG%RU|7N2<+<&$9f}x-00wv|m3G$r&>A17;#W488MI zUcEF33HcTxFQ!2RGB3Ld$dF}5$4$zW05?;jR;$w%*bUN%>yrwx#2O+&BTkS~KaMz# zF`*PGg$f)b`W)ARH9et#8ZF_-)q1f+5E?TZ3_%ovglQJnGG;D`lL1;OUiksOfd~@a z1oU66C_ws)|ETwUnGmYT)$2+GoYDD{SIPfBK+Ml3kHi|x-};eb#;G5o#H=6g$~L3_ zAkz61p?)w+^k4N>>ntrjxnOeDT5zQ49IbW@y!hciJ{*kWwINDlzt)s&@^Zi zgw=W${zPdNUvVnwvDG<|n>k1G1M0HMqv*HV=SKd>wD}1e-6{{G@*^^NvZU2&rCYn| zTw2ENipZUa%UYvH8!~xCNLds3F3rO4h`Pqt)m0ty*0Nu>`MHs>Z}zpRXwjo&GesBr z=~E$+dS-w6BxqJ;i{BX;jaqK*3avbPda63nC>>B$Xh#3lYOJNr)!AppuTruLIlda7 z6(mW7Lh|m@ws3>ok6%(quWQD4=%q873&*C;d=|+$9 z&@ZfEM#rW|)Mg2hk&_#hGdfIMW@dTgGZH*Y_3KsJ#Xy;!T$D3+UkeutK@o1RN!e7lvQ~b;x8ic%!@nS7$!pJD1e?# z1B|6xyQ)kS+8S(vvkSKoghIok55NPvh5msPou4glZU&p8Tz9%9Its|q7lP{ZY!`ha zcuO#?n#ajJb)J`r8WD(;lTjndEl~H)o6Z`U|AGZ(q?s9+;De@mfjZ30rlUSd*c07U zRa8M_*-_bgW@bE*@k!=KhK)A53ziZ_S}?0UHCQ@j$N&HVNrXXS3>pdoE(}EQ2%1Xh zsl{v;#y@w$5e_hcqQTKAvfaf~KbftPlA368JYYyF9<1)HCXiBcwqoZTPE^^Z5P*l6 zK`uVRHq9M{1SDvWH$rbF0hCtRvlZZNA|A*Wf8TNIdb z@D6ikTpN1r5JZm)NTRP}TqJ=Mh%}37Rn=uC!j{T#L`!5afd38r=^9v(#Fayk02ggh z0>H6BL>G`5UJ9pJa$Qww2PuS9Bm@q|S1I%)rAZG>ENCIZn-;n86EYsbqAgRVQtHq-x-UKsEDL-hq!EA?fLr7(t0Foy$bZM^)2Bkzwn(&np3jS8=82gHo?(83G~E3hW?>^-u|-^H3aF4%BHaJYHQWWA56$6Rd@i zrCIX@eLSdn{Q zca2#|D@kzFZ_y&cX{`t+I>4h$)@yz+ltaS82uO@fM->eJ`*hGV*O7^!BB&HV01N>I zETV18pPpjP5kb*IMGc@<5NN><2!tej-5$QX!6^beV|{W7r=XM(RAvxCMTQ7aj#NaZ zo5+VVn$El+kwn{wB8nfP!o!YE?0=IRFbFeq>!QPMAk7XEU&+zvr?kTT z;b4G501yacDFhFr6NU_d0{{_#NEbSALk=)Ni`M(lo!oOZ(AY4t6TCP|bQBdqLJgN- zn#H-wG0u%mWissCN=<;2%MY5}VsLn}|HY}bl2T3pz(61%oT|V85n=D45kk{n1#ks2 zi_G)THAh2nI4Ud%k^~-!OF|={==32JS`fG|7H4+MRJG1aTLe0mk{y|JkcyD4kmf8J zP!)?)Oe=tv&rJzBQNA>4Pa+tEl6ib+<->p+1Oowp005xapqR+a83O_>SS3s#AYc`z ztk$Z~RK1LJ9*2HrkS_HW5W>ALC157Z#^nVH><%IO*3|A}AaU;R3y| zifxmM_ZEJ)WZXeO0AN#g)WiTaZ&TQlk{=Q_?n=J&I3aso6Ycg9{t!GNI6>fmz&7!& zbpXAOruig49z02b;4)&t0W(P5as8wiEuhk^uZa`1o~J(>qBEUHQ9O7U$WtwDzDu86 zP!Pf)m}MX!CcrWP$O9t+@QP6+05+IX$+@7sNW`*LjpJbGI~yQ>n_JXa)S7GTmw_<7 zj;t6FR!MS~CYlqv1q6Ki2$E}55G2j1*>-})Hawid5d;bcoaRi6zI5C*em-X8EpSoi zxexRJ0000B4ZRHkm`Fe=hafIMP^J+EmX$fnT!6C@FVUW6Yi5e0R00@4sLF$5n6fh@ z?zn8gLl-gG=%1@iF|E5kqkOf&b8~;?bV`KwQV^g3Q2-186#@WY!I^-jLQ1GdVAEm{ zR1Bb?dE62f9+!n}8hDhhk;x{plC5Gd2n2{k_c7DX-4sF^976N81hV`t;tnQK7Fq~A z5F8=UL}VrcqFkeNzfC|LrnMd#rLa&yAb-tS36paBX@Qqk;K{%6k#%_i9(q{{M8E(5 z00JqI0R|)iAPWFc0G6P>00007fB+WFqk7eaLLWpw6PC3z2*Uns7!Jp{+#AAT0fJ@M zYG`--arFC1 zN3+YUETS%<{iF<5!anf?L?Hv-SSVBldGu);{ShF@@%?{p%5C_Xi85`>`Q;OssMV8cVbf)wNOGg~-e&OeCTbHEB6+^Khhnax%D^b6RzhC(NUDxS2oJKPbrfFon%8o7Yqm)6>axpK6}ZDN743^Py-r9qDvzutL9 zEJZZ`iJs3NsXhP`ev*0W_fIT-NvuGflQZgswl3SL`ln6r*Jfx{f$to=Qg4ov#1tW6 zpN`6=FoDE`DntGZng^fpzMP6KQ>u?PO@LDJ}e zyg2cOzOjQ#ks%me)|iR33}D;zhzD(U5p~Je8PK}K#Uxp>f6wIy+KE%(+_rv$vC~_| z2cp;E20VKVvs_lLLLvF)5m$Ku5OeFOry#=&V*sgsRNbAfZ3(&&klRE0q13z=Dy5lGqk4XWt^ z+a_z@*V%4>nmpZ7M?g(Qi~tPf0SI8&R;tAlkfZa%9w5CZTh;5jn;L_=&ouagj*EFf zGvjbHCwL$;5Qr~~T=WIVKQIPvl8w~V`U@x%J^w^DVkNRGy3Bl?8?MLja^y&YOInf_ zsfIhfN|PC(+{_xWN^pUlI&(wxoH)POV``Eetb-5mf4nnIAew}!i~IQbSB`d>OZ{bO z;tI7$$g>;WdzOk&M6kL#0{xF*EcL2hk*SOFY%x~^6|QtZs9c3+%6wxZ^))wHeiWR; zi;a_gx%666BK5A0CPk9e>x9RV6G2> zk%#;O_fskp9fit#0003?4E_j$B#|Vt%0(g~2_&onB+KTH&1$ReLIp(~5;SRj`2}GD zpx-+_uDq+rz8ayaynYqrYAaq5(q=_)1 zF_Jt^qRA|s_?L!ZkU};H6%;NwY2!?cd84hGl8H4=jvMmW1&SjKhUVrlLA2)1z^nvA z2&M4ctxRp&Oi!od6hztGK&QgR%X5fP;oc|pIK$=Rq^ui8opXa2Kn!`jiW9J5MktIp zeBFg2eUQb<1~IZT41!?jHcFfr$UIYvDWgdO5J3bKlGVvGV1bOHAh(U>VKO02gb)#D`{%-whISfZ*3psNF_5%ObTeKF%KnHejRehT7Crg)WsilY?*f$)Bd=$b0U zK<9JFnB~WnWjc)!8=}+~f76CXs6WE3K>qT@8#pSSo=h$(uU{t!B{huWvZdFOwIJ^P z0&-6}H+5i{=K*Vioq$-KF*LAdB`kJzaV_C#Dy}VVm8v|ZQ9h>hAW^!s>DR|dWg9!= z*1#YNb2#4=Qrh2olud%+11m;`kh3Kyis1$~AmFeFdPLdzOe%_$l#80MuxZGoS+O{l zgmAOe*!dg{0|c0cXwk>Ga#B*-)v?4rjnuWRPqwF0ZLTEH3C)yFiLgN(&aD@yDPkg6 z*dRn$BwG-koT|++u(T8<$|QL$x4CFQYG)E%nZ1C(fKtK`npAV>6#$%!>%(GNZKw znI$7`A~MSzGk^K4*NgsjY9?7{`6BbBQ6i{)&#^**LvH`LL2nS)_hoL2GuFTbK3|oL z=0PZh=2?-DB;YKzO{hS98QTv{bvBp;+VIf#9 zNtj+U>ee4;B6NCUHNuPN$+h$fbTAFPRbr7e|M5t))T(fWV|SG3fjHUn^o~qjPE6)= zG;qvHbqJGG(?_#1V+j>o5+nidfzS?VM2E=TT_Q3wBGZV}u?~$oIt^m1)Ca{<<9-!H znHpj?>V`e06$gHihaAs$CcPFHUliLL({aVGif43Q#%FiLcEXecSD2aNKeU6fu!N-N zz+kblGfkOewjUZl9h6$-G{(fph)AN0hrTg$#NRnU&a@e)B&c3VE#w8&jRV`z;+I-y zPWEYz+#t}Aw6R2iecN$iw)!QyP4qX9E~YUF7L1Bl#S{m)O&|7qyE-#m1G z>;BGO6`zuq5vG$73JGqP^CX&7Wy_KS>r9903F13KQpZo~0%eCwb+A1_a0C`H3xke$ z_;N&d9+V^@Peuhar?cr-xxj(o_A5t39Omu7BT`pL+x#eq({OF*h( zbtx34kOT4~U=^PA>zhDf4oGiZBs*~+fKMt%wTg_jDowNp0B(o1>wgg!i`XC>Xp46H zc7a3zN>jij0Hcx!9Q#Riy`GMOg93V(3!M>fSU)P(K9@?cLfI=R%6JD72nZg4mxAMG z$k^Pbk|8z*Q@|)d-_Tp=K~gjqWdJ2QO|hdGk+gh?PYyOqI4@N9A^yAo%s?~0%wdyk z%G+9w&;3B=_@V-!awP})Tg;;tlQBgg?|k=J7sh}U(emE2$s+&NVD&=?Iqv!cpK0p< zv!nA^Fn!*CrX5~11o3*HC2REr*n`u8uhZcDU!}`-*tr=Iy0Mf*Mjj(D?KJ|SmLOfx zCdAPNTji9QlPMq?Yyl+DScNsc)5`gJ0alus*UcM17g`2dVx$1Se9PVztN%=oRaTAL zv;+M~Ueoq0Ab%Gw4i4p#;`VC%v2gPq?v@~zrfk#-$fCSfvryOg2hVjt_mhM&Gw-}Y zUR7p#WD@uswLoN6IA4)^`1t=c6+uUSNR()s`u(F8Nk9(Xlo0Prro_1zy(O@BbpYm| zCJr}^Z&#qJO9-_YnXD02lQTy|HxdEBu@-%CkB z)5Qw+ITRyb8|nj#6X=Q~I#DeNyU!>JC$(2(XQby^yyJfwPKeV=x(Jj5eX>oHa}pHP zOHer)fR*!oGG&dm)rD7HS6P`SffaRXD&Cqo&*7jvTs)L!tWAY8@@t)Z9K5<1mP^Z5 z0ea4TK1Xt$s1-*IxBXCJx(@gE!51RBj1BWYU?^0e6QHOF90Sz@L%LV30@||l2F|Px zELB=+NTsFw|ELM50Nsa68DwUFzXgSYdSrh=7}ig&qIP7cJl|RuKg$=V<(Vvai?8zp z_^}Il_7Ryl3I|YB21k6jEoi{s0$O00GSMJ()dB|tg{c7(Mu-7a9;RtNps1|3{Y6Rw zv%pd?y&qWS`0awGCQ(f7}pa=g$EAM@mK@@JHP>BH&*NWV|(^Fq*q^G+FN z%V9bxXw)B`p+D_o0NTYHY7P(N2lTZ^WIonpW?%Xow_f2+K$Nww8Pm z3*Z0CHlSgI-1Xv?V3GDg=HJr)N8NDBD@wScMi)0fn0#{F&3{w}Om z#p}*`ED5p2FAZL${l=-tD0LgP2SFv{DH7=Q=otC+jDcDmjLX2|Tk*O(WkH7n?=Z5k z%2Ui9FidxfaxZ0Q_tGLiK9(@cVu*wC#mey-V1TRCT4sUAh4)| z!2oaw6Lrc4B)CI%67DV|i>bVc2u!UoRp9|JLaw!bN*_OQJxqoPhC;$8}wJ z1U3mLhr*=cu@jn3QpqLkucL&sfWjsw1F(ULEGz}5N0%m4t6`? z)DI|(>LMy;(gBT)--Z}01rQ7+aVlU=#HOuOgOIfzGHO!a*vius<8^GBqaa<0a7bQ z+j{A9Cw(ax*D*){000aC000V5DL@7Q000IROMn0X000000000003rYY0000000000 z0000000000000}|0X9bIN}#iIp;x0Zh(W0&gaB|+GoT2F5g-cHXoL)601!bS@Ni|j zj7uqKpSPl+|;#{8DDq&T|T8ePSw z-#`S|v_-UN>PcH!_)wTwAk>FIU;qehR2TpxUtkkPl6jR8JGaj$PECk`sw}f@?Gr29 z4IRO`+41m1Up{OG5uFQqP$7=>6vOS@+crQ&KuVsQ<*wA#VUZ)AJr<5P;Y*K`vZ3bx z%K3HjzC2W^eEwhOso+#?Sbzrm4**k8bXYVb7HVos=Ii?;#|?rZp(bIVMARWLA&Lnp z-~_#4Bnsf8MGV|Q%iuXIWDXh_^k<{~RJRSY+HlzCs~~+XqD9xsxD90dpFR%zcTrFM zl&c&<^MCmt74{X3ShrPBRfD{D*mqk)!5~0kp<@J|5^01eTI4VT_Z=s!5&{Wz>>$`c zaEw+CBn}8fEcU>IO|x-U3O^Zw%SZfYS~uwiyD(yliD;SbvTA+LigvO7Q2S7K?!7vE z(f1bV%+d2xx`fa9)Q8EICEhjBWw~7$FR%qZx=~(i*9-q4S z{$|C1y3kyol#dku9lsSAug}U*IL8m8X%9Dj5E5dE0;Tzdf+Qn}7~+q7XES5IY;!=vt!gPO`3Eg^gS)!M-k>jYzT5g@ z#4YYo@@&snI=6bUr?&^*-pZCQQ!~`rD?0fI1j)Z;!q2X=`FTBP{Oc}SC6Nd8zkZ~f z>h(y-$1g&N7gko;Q`Lkp;`puyBOCrI(;6D0;==h+6lAa-@Sian{xi~{t4@~L%Zc-i zeU;GiXQ0!ayoW1XVEyjsxv)LrXQ}huLcYwlr`e|~WLG3iBkp-;vITvqQjf<=3A~4~ z#pU3djWjQ_TTcLr;`Py^hr;*%3=S^-w4XntTj0TNn1Ct-2++GVY#knkB2Ui=o31B z$rd;2NkiShzZDJ*81Wp@hQRoKpT)>~P2yjwr%s4^vXd+PRL**4*iSEZ!W-P;v@qmc z$(R}O)2JqIerR7c*jf&qth>#NcPqTPRjoh0$Z|U?a@38aWyo(-pCPVx2%m(JC_l<7 zHj-f2DX#7h4|(L0X{6I)q5kzG66R^2xJWWO9`_vy!Mz;&9QjSO6p^i~KIBbbw9&}G zgM%H5nF(O+H>5=bYy5oCXMH&(k16O0J@RE0D*o*Qf!5~2~d z+AfuE{Ff#XH8~cl&|oyc0~n$FVt>2W2Q6Y28GlaSB*VMYSQy8-8fB-x7sk6K^}d>W zvOgUmM16C4B{1+<2ck^nJy81pu@a*<42&$;lMZ#$R&nc{Ci zN-lXfu$$YctzNYBaPy+RK#)#?!q46wKBY@VU=Ij7Ub1A1ZFEzMk>Qm6454SKY&O}z zud`HJKh7RCe`@V&ynl4=T9Uq8|C`VZWo~7WRzy`XL=xMP$ zg;VRrqUg8ie6?X9FIbh7RgU=^diPn7yWw3sF4l`=B5n<{P0MCVK$ZMqB`q64GVXAA zjc#ncX8aZDGwwhhd72bBZ>m@JzI~R52YQ0Zz5%eOF$C{I2P#nM#gKhq2WfPr7f!t_ z_z33ai~|_55dtF!yEz?Abpt&rKP|48)%5MXc^%zOWs4`vdhz~vhs3Em^?^$3k>PXj zH2BIch#>$h!Ym~9lkBciA)gff;pgYF=M8?BSkM=VGV%<*9Gg&Q$AA(q?@5GqNGi(3q8pFAzN=(gRdCfD;-WSlC2jm zT?BWBHmMQX-_WiR(emFdCpcNq@EMkb&*~I^0@Hj+}3?TWSf=7Ra$h`4vQ9-rU3vpo*<4-*%DtE!FX*!41 zLs4oZ8qO|qSzY=Ent+T1I~@|n+ba%AE-8Qj00C1Ehy#QeVjB`HEIc( z09zO!B}A32lTj_jyM2{}_dG9+Um7aqw^az8~ zI#Kl~%NgoLqVxa9RlE1_lRfp2DEZ!>nY2Xpe;P7q$P--_tI|zf`=IQ))}<@W(Yai{ zHYZo8LC079BUKO}TLjw}JMOc4K4#2Vg2nug7I|Xix^&AKB{UuW`L%MS zWPmd~qYpARn3Zlq=ac_8R)lZ=`H2KRb%X!8MNClleM4*x(DJaMDgWp;;GLiym#Scc#C}kBaxdvC!6Emk>cE4 zJY6u3*tCn>h6x`mMu9STrXv4%T0hsx`>Y;DNr#AoIAt;~Ab$@BY}qZ#7n~^_&v#DK zT^4ttZ_URp(vkbX{5s1-{#d<3chHVI@=*CRvFJo{uz|=u+US9br7I330);?Zo4r`A zHOVR195u!)*Z{$HG$pAOc3^_N*s$@1l)S*OKw)JyeI2qyf}k2a5jJE1QzAgtoj)>B?xPJn zjcc6H1c?hwxBNcH71B^}Gu-Iu8zqB?>zae7i;xoYKrtvfM2HE>W#EO=P(1-rU>+V| zYJx@YA|N_|pt^;<)C&9^*?ero1fl)@Ig}FK4Fyzt8UO>Vcj$0{5@r|Moyc&?${s0m#6h zPM`!#C71ADX}nCJ8UP1LNRSNx1#~I|FCNx4nOy2~1g^sK+uAq=!x+qT#rN;lK4kYv8S_w3S8JhJvyfC- z$u-zJ5#3jO5!#>|>QGvWxcj#wR? zrML)-#+4Rzpv|2PA#ba^3Q+8ibR;xb6bQjOHf)}4tc2T(>qMz@D3{~g7>2f^cz*1; zHTA6*nXZ|UInaXzW99V%K;KVDiIz1Pu4$387A5tFWM5P1gTx=xx?l||Pe_Y1Cp}rf zr86QU>w$imv7ARmxk5-R9AQKJDU1llRt@gvkHh}0dI z7tlFTOY<43=q_oBKwmmWg#(7ll(z0;^V@R!o;sbd+RDlnHt#=3bSL~8~G0gO3T3a?i|5z zDUFCC$K;E`<)*5f^!&8>l&k{+vp4f46TM*iDrPnuZkHere=TDfm+k#VN+rTnXbP-m z;-Pf3^;*^`(RiTbX|WNSGLU$TJgDfu)$gQcBtlqFXgzPrDpW>k%fzV2JZ8|7 zUQhR@>rm{+7bMoiODeWOwY&As1lDT6j0Gbiyy^d{>J3XHHAvBEwD>(Xs@l6{984v_ zpmhve*TN{_p=k7E#T>4y(gLE^fA2Z4yb2b;;NfPBWkn-IU;O=B5}ZCq)kFnGKtJS2 zNb9za^j#p^nt1BAI%x-Tjj(zo?B0~-e?*NR7bBdfg?Ma7HWa4fM9T08nGzI!@8n1t zUfpCCVrxD0$c#y5W@OGo0-W6$kp=04p2S`iK}N_v%VJBPB$~RfUMz8a8jqtpg>np(UN9dVMc*F7wi+ zRqb2DKR^CfS%;4L_E5r_FD0@kkFPp>qgegp^=)F3kC%^DTad;wnF`Gj9!KheZjb4g z{yTR^kVx$~YOqc?iVYbjO+}OuvF;&~a_Jwz!X^dLd>N+1X2yy?-81t~-fWC+y?Dr< z;d>cOIm+JGygW^Mhwk%(l6qBIEcb7FFYIWZ+nNRjZtf*LyMG|uE{pG{Aaj-t5an{M zSoeK4P6nbYYLk|dX+~y7MNsFyTk!+7a`d9yVTlA%&pKjej8Tx$o+8lM$k?>>v9=@w ziOfS$qPdjP9ugD}+j3~D`4OQ@zMvd8OU|^4@T*9*?6%dWlK|1$U^`a4P6zFe_fh2{Fkpgv#)c|HL zNUq^b={7NE9-jjk@*t#%FOqL0n3)mmw=A_?P|<2x?d2{gh7pa*>gA+plFJ)qGpF8u z*A;+@a*qp0CZdKTwoT+jcBDb&{+o3LtUxwQAVI2H42#LhQl_J4q68M3ffC#ZWP(^I zr05=nS*nlh4q)D<+KrJ~WCwYv@g%D3A8^=*4qLII%F4QywbE8J zQ=>wn2cd99kRkd;3YjBUp+ce&qNFCe46mY22PajZ7h{YOMkHk_b4(JTjB#E?AB2U} z6U1W>V&XVMEQX;G8&d__7?m#i6SE7_F495@n?|ZPM9o_qg$Ax6a@pb4IO;KtC4!Wl zk-Cx1{xaJKvW#l0<5f!#C#BSjNk~yW+;GuIfdd#-3Xs2{MsH?M3@;ErnN2|I%n%D~ z2T%jkSa}C_06KDOO&vR=kRGt*fCv^zM1V>WE0002M1^@s60S0s!RwfJp00amC00|MJti-FqhCl*X z0sa{TK^6`kzeKC|g?osUXkX~~(YJD!e7q<#tHP!=`Zx`ksapor8@1FfxHwvn15^{$ z& zAX%;RNkpf$sEY?wvc9%)xBwmfcS=6d=WIN}h!~iFN+4KqqJko9%RpRgQvi%Oh7h7L zMA7&*C~9@ZH!(IH>SA=Oq-<3Hi6o&s7{?SGKnd~Jl@a>FC91@L6n<5 zWshV}V@%jNlMWKmG5 zYT<$?B&NcPb`#J*a7^I9g2akIgtTNdeh@cHKDqFL5#bzh{B%0^n+yK`i|#FKXpIxR zdFVFY+=072MpxT4PcdSs6tyHC0h`)f#@_(Y;p+RlqdK%u8tO}nT;~i`d$=*)PIQ?I z=c(s31slLw8pza05IE57ixCLN6iDX|a_HNi%wqAD>EcH_ZxR69nuiocDVD%3mJ%Bm zCu*5Jd-VDW$bgnL88jRQ7^^_BDCSbqY7iH}D>K~P-|WfibOlTDaxWR3&Vtng%KMy0mh9S)KwbXAb29iP(st~I`T|g`$SOl+{a~4woqUl zU`=6uB`ORUk)y>Kx3?e{WVS}TV>d_JCbL?PmnQ6K5?xI5V{i4}1^geAn>-J{$%@ia zA}ITh1|kxub-g&Ui5EY#cJ+2P5ZG8viCHxmsTs`{a{-&&c+rsOQi@O}VhhDzHRSk? z!I34+Jm$q}iZTWBazS8fh)K0Uv#Hd;i-B82(~|u}>8;OISYjrj%6QDmNi#2Ty&hmY zy;aA#NGLa_-sR09#gTFhzCE8J zP%fc>CI=x{gqzK^5mHtjV`6|G_!%Q}4dowB*T?xKgZ`raSdgWMoH)F`*LhiIO^Y&v zVCM=6GB7g)3fY6N8AQ>>U)*Em)+nWJK{F7mE`fE3*M!SpNc3HT*0(yH(hQoykkyrs1=zP}(r}OQ2QLxF z%BYjGRk7C)BnMz~b?i>ye2fM+tpv{_g5BFNf!_bT+wchp(*BZya_qskD~dHrTk!+rSmtJ;_7Wh^|RRyU>;K z8b1#lQ*U4+!gR70G8|j`cbU#y?@KhOVnjM7KtZ}NF7tXlzKDLL-JH%b6yhh1_O{qI z2XRQ?$Qi$Q0h}UWGza6bz9dWGXYm2o%P&^!BX8S)BBv;tE$w%Lj6udIh`HXND8~k- z5d*p`5IDx87-9}FNBZf|k1=xh9T^YQ9JGRPHyQ?r3?vg;XU!VJU|=4#4{H=gQ9Dr| zAkP$HJHLuwlE=iBcc9jxPrsHPX}P*BXqECTugX-h=$KQ-=DoZG&Ic9&A>Jk;nD21Hp7qT(~H)QYE3WR{*v_B3^qF=Ev?-^76hR6>WEF0hfP#{BWI$<<0mBC~ zA|e$D2|ueQQDs`S^zc<`7zKh-2K5Y~OR(LZFUv(mkh0w(l0~S1A#7-gOBgAR<4mr26|@*U@vtG zGSWndx7=PqkujnP6=J-s)tP}NgG7SIXl|)2%nhz7)=66mHOZUY=0rq7G1W2+BL0+Y ziN*5EoFZe7XTv96#X^yu<_Lrz4Jkv6r5WS41c9DBg3ZDh1-P>}Es(IQWs=f>(?D#4 z$7J*l0;zyXgpj8>`OnVA5o=w3bDtyo*Lbk2^vu&7$3F?SUEykRNni8xtYgdn^A!g% z|Dbvb72UrsKPz2E*vP#C56)QK-af^yNdKL7Ty+gu(A_~-I);=+pqrt&*Xv4Y&bsPx z*E!C?L>T8j&zCK}>8xqC$B?+||IYadI_K(IgvaV#pXdb4KzJ-%(^lz|JeWM!rP4%O zYVSVUtM?$-0Acn9U1g)R~imdS-=t9q6~!dxm-4=9)7Ajt0wI?3sC z9J>SAOV-_c@4mc!eDcw7Z{WPDN>?9A_!%o?m`O_a!5H0W-sG=JT4F}}MomF2kIluH zw00?iP+n}4a9n;1;^EgoxM&2hCy`+1F_03F(u#*YIvHm6SZE#IDIQY>Rp$)OE4VVj zp&-gQE9IX4`qro-En*GVscDC*JbhC!)g)54z?@&cgp)}Ecs%2LMS{ll# zmB~KK20QL+6(5cZ#+0MIDI8HjxHXn}dGiB&w$H6=&JeI(y?(W=RxpHxt@VisS2a>7 z(V`;RnHF!yuOV?EV%u2fQ?8UE&%ME5@)8%R0$@fNNC+MSEaE|fOGv0lWZ<$X_75$= zUqW%M_uqYOt!YSuqf5y-Qc7J04BF+(r}SQuh_#4U<%_KBGUkP*yjNPX()bpLwb9x4 z*H7d`C(l1GQ=p}Ta2`d9=Y?@V*dC^psetxf1KBC)LgTU(n+|^O1M@zl{;^E2(p?LdOzms+hwO(hrlT1tOw&^zD$`dc9+ti&O(U&xQod<%HN)5*+lMJ`JC+LjG;rU>}?sygTBs2*j(-uE*%0j_@{`$#6Xxs1W zTJ@sQA6x5GkWD2j*Ie&l3C<)XK7^62Yg6cQT)F+ym=Wx}fe0ARh2D58?DI(^cwJ3Bev>sN=g!OP5^1NhrciuX}an|pJ? zQ7p znc+$dvUF8L_QnwAv39tM?66~1n~7+ai5#K{cEzZ~zQGX#0_=711|m<0cM1Jg21Ud< z{861f zp~H{Z@h0x^urQ{59ZuFXXt1(O&Wt(ICPGD$7s?AnLiAA*E)tG=Nwz%vxN#W#AVmBb zD8MgD)HYg%w$69-%6wsMWQjUPB6h1h6ZljVG+rk#&MMhn6hRW&93X)W8zaTgL@AC^ zAdsD+N4SKIMdu+%0~UTWk0004E1{ltAhy*YJhyVZp z06+i$000000ssI20~;7MHUB587LQdn)2$9#q(3iC(Z-w}u zATHVrSt-76ZDvv%s*qTpaG{pQ5f5o-{GxUQAl6!(+NoRVFi614}B^_ofk zRO8!*nLk~-*H;mD*gT;B^91{Xr&dbu1zk@Bu6}qB-4gp%M$4u3Z<=dhFu*G&k@nG1 z)9)glmD5&LWb8=Mxu$rQFyNmju{01G!qH~EO=iBHGEnJX5k=@+-xNnooSF~+ylC?y zqDET-;b_rB%Fi&~$iRJHfvUf0rcs<436|VJwyVtunA0HXBF6Zc0F*#BiCn}4Q1v9i z4e#8^2hKTz6?CwE!Kg`a&Xr;j6s z#LHm1MHvbrUOad9SP(|&qW}&27E>%;%fNUF6y2-%7$r~_P1pq#ewX>KOP6Ge6E(dTFRRveh@S`| zm*uW@z^u+PO8uiLD&%r>Lj>l{yOzocnE1We_BhOUBS%NpRhmz3=0I~rF(O7(%YuQ1 zmbHUY2yPH8nVXN5e|#XK8#Q_Y&;0jNX^P63z=MnOYB$;RgK4-`g*q3!uJCm9>6zZC zPQ{X;8W*;3RvAzrFf#msIpYZ^Fd|A=!r?d>P-w*YVPQsPcJKJ(7?#+OU1Q!38tG7O?lAg9=I-ILC|k# zOSG((Oz9UH8X96Mdi37~>Q;v+915CRk=xR=>uN>li)l*iiP3(P>l{-5x!gV30sXnp zDMz_wSPh*@z4CTa&l2zvKGu|G4Q)vxIHp@vx;sL;C`YzcT%=zQM`sBWQB=wlRIv>t z;*?{DFaQf#%><|XZ=2pF(V4NhKzr2!43!Oj>&bSC$&WGcbRMhiX!~s$&YiX?68;rZ2xbltz!EtWWHMwg?Jp~_D;EeA=NcDGrsZ-K zPckhet(*L+?~g@T{Q9cpQd!O+ikVjS8=M+OYR+^sDqYM#NQc;iUE2;M!nmk3CPkexC!HIugt2xG@MmE+lZ$!L8W^7SPR;vn)YiX$q|0B0nPH5PFS>V1>-#Y<|rk zK}=AS^P}N~%4y<*a-DB+0Y@{j2S&|WDALb?u!ZdqA~9Xb^vBE9{8_d+UuIB7VB#tK z!>JT~B2rKsgbJt;`9u&3g0aIbu7%5s!&!Yg*u?@^26VTz-y(vg)QeMM2Lam1Qh6Wt zUt$vD>n?_Z5k$lYAcPRGgD2Az=1TsJhl51I0~an`O_+-e-;0tYJ^x)=-CeEs%*mX{ zeU(IR{W|cvxcqjCdgid=#w6QpLq$j2Or) zG&VdCqXWSJjTk|*#49nVy*Q=VgG4y^llQC9AC(sS7u_6UfE8$PvEUHCe>V^kZOOPu zU>=9z`_u6d=jbortC5CCgTL+XR>=&FCPj2H^$0l%&N)LMB8HFg>@k8eMbSOM7(b@2pxJ}*Tfx=wn$sub3wrPP_^AEIcz zXSL9QG)kf*dW(&TIfWU+%*zH2%3>BHf%ad*`aU*zf(~q7T1G-WR>77pczj4=f@zx= zJ&h_HaA431jF1)Ovo|2uo3oH-Tp4|~1K(nj{S1k>s}kuM7RbIRVJ3x*W~Y#AFSlL< zBAOpT!G&v>P0%sCxH#N#ti1tbvaud_mP`n;pA;jUAZw((u@0O^RtX*p^}-nw=ILVX zX5i!V!rNoh`w>hTm@cW+Eso^mmc3xl&yYp+P?%>~SsX8Edk8EL{2;JGVqpVN_?f$m zNAq0e;g}IMBj2S~T(%kL?jga%S zG7cA_f{mB0N5vt`phGyUGklzd6X;Bk-+v(jKtF_GqO=79iT_>q3Uopzl2g!_HI>RT ziw-h|fq$;w**GM2U5tEVjgNS{LQTMl?=^Ri7zo1<0aO(jGe8W3fDFWi3Wtd`%Ynq| zz-hEq>091uC=YkSEl>Djf+JKP2Z?k-6v0w0tGzQig?<_VAAhQZ?IHQ_(NVG>RHUed z6P3`dmY)xG+`&^qCKN=L)PJMe3|?C1&_^nnqbot;pvK&3f{z|;yK1(d$#k8{;Icsg z#!%UaZL@AzblX*soUBSbt5zlWcfDg3LhmQA5#TJFSt%{XPB?` z*WHkBWO~6arb5M|3Rj8?pN|gZAQOk4VBla5d^&^x5VcBD8-fx51powq0Du6s5sV`M z0YDG{00Ig=L^J_F0sx=^1U2Lk5D*Y92tzzVfB*mh4+oi*2mk>Ez>&V;3L*phCnD1OP~a7D^-3kp*Q4qzEa1AVCEn3K1D+h6J=?2qP^SQlUiwU@TIR zB7(FekwpYLP^eNx6cPX^k|K&Kp)5!YCxD1aDvM!t14ZgJm(U`JiFK+FL778+QXa@{ zOUMGPI%Y&g&pjNAvh?Lo<>Ed_>1W7^`G&Jz`S>d6sTYSlBChc7oaWKbIoCe%_X zCPGxq)QtI{tqv6X6w4c^h%7@wPfes$`I{SGD>nqP^9PGh(Z*yeEVzAIyX_#g;cb3GmdE-Gb8#8@~WVq?@j!=&A)uTCC`IfPd$x;tcMEb|s8*0Zj3nJ+A z-05~WmUql-Y4N*bseWv8sx1WN8Wqg>V+Z0NIT-dpOxIo?|4757d*Q5ALTqvT;nEK( zS`&s`)loplaJ?cjEtN`=(TS>4A&ZtYaV)1AACEI=v!}45*`Fu7DTE&pY>!IGXt|hU zBCtKbZ}8*XD`Fd!$KPQj{e&Azl&OqpBG-j>FIX;O8FDFy9%-DGrZJ~gApbY=)P$lCG**%`~z7K7u@qbX1#H^*rmAf!bs9^nKi(qY2BF;_M->w`ftQS{aG z&)S3#tj_sU{E0hxqe1)Sh=`Z!Q-?1a0bL-e!g}b7=eGnc!{;n>>6$+kf&C46;_7Ei zLg=POR&3Uo<_J3wNd+gpD@Ur)hx1{K;^vJLTPAZUgdeXOrW99HuKfu!A8tP6zIAMsMl(Q<{9s0z%fp z-UY&*8zWR}P}Dw6eI%`kuEZxJ0l*e9l@d~ zik|oM2Md4Xi-Up+aas1=qr#-T3=9Cj$9dy$*k9z8C2Lwo{z|B%iT|S&gP9S`QNw4P zCU6w)$}F9|gd47N@s=`ZdWoMrRC#TWAf9h<%w?6xO36Lb$Q%#e|MTV zBUj1R&7`F$pfeBI%R4SfkHBOeIzDO?f zUP|)|Ne_K)jF?@-<)}MW)vfC_bGc@i(%p+(J9|_PcuPg2Zc@g(H>_(P-1EW8TO32$kCz{a|zW)kGnK_OoO zKO#@K2EI4&qrx+3L_aRnG_5 z9P%M1^37A-E4pMtC|7-wI7m}-n;~dh8jM;?=2vJ_4Qjy!qcUL;q)~M@?2T&avQ;H} zSPe7~&Sn;Mc`(f@+I8r2Avu+8v4M>kCQ>fJ% zqa!xg_KBo9tSDw4=t^f;h?40x;tZLiys+d`1PX~sC!uAl^uXNa2o*HuBq@Jwt??fw^zAQZ%0NAYfwz9*s5gTIkQ_ zLso>i)KzCw1K}$WpYs&f1W;FZ4jd$ac+jGcGmDH8KP}m5V{jV{2s; z;!i7&-GsF4_|al5g->AQK5uH2w5qZ}8z=5yE(TMKoU_&x*bxl|-sN2eMzzNE9#`N% zRM&kftb>pTxJYF0IP;bqh>^n7n(kOjh@$YOL@)GsJ+}ojtOyTO7D9+1xmkLv2k;Ih zW1`6dY7%P%Z~sT&{|o5D{XcC2OTKX)(O>;W}Fz}2dA`TTofUuXAMofcK43I{MyC+96FUK}$cBRQt9%9v@D0bo=D)vM$164EeS~Lkhstym<=t&M=(Mtk-5xt_2hxPur~FPsVm6Wy08DD zw2)Z#S{J!I{IKsa8mJse;Y^v;TvK+yHLa@fB{Pg{vEP`pgPyC)VPjMlD^GEc3NkIa zZ#6rKJf*?CGln!1?LCOCAc9@Ll1-6VrbG#>U-XuU9qKd?rBf>j0+AAb z9KW+F|LKZA;3u{Q5<#hgTegL_hPDSn2~^NY7R)5HE5Mo~;YdD9c0gOqS%kgek%d{1 z<7VpkSuqqDlnVNaG#vK@`AW&jb`spS_KkZJXIUMk(XyEB!bT{r!&PARMNfTgwcAE; zKH(7*hfb*Mw@INvi+!53!m!nUskxOHtnscmg-o!H2#BCfv$aIaXTz@eu=_~?5Mk(2 zxGtC?C{n}6Nzq|KrIznW9t)XbZd#hW2|7Jc3|9hYBJEjFVMFM*r**c#v8&!C3n$l2 zdYf>fmvE$1y(-6e^Ep<&Ex%q*)B*ZTEy*itEyRGSCnARmPXj+-+|VErc8zv&PDLJ7NRLX_u-90S5JBE)DEOO=>9r> zBikC+V&bqhb=E*hNvO>INs_$mf9VS9cjrdQ0JE7ios# z#;4<-qKP$iZJ@X~T^TbnsS$0PKn@f%S?oGBBOkM&l9;aNj7*Dj!p$ps)~YP}dbgQi z@5HAAHD+y84=T${7)sNXQvPTXUw9Y-Mzr%p8qx4S<6lvPQysyA$V8?|s@;i!YEnul z8+=sV#50CsQo=RdhfJ6&aY~2Xcd;JbG2VAcAO{|++)Wc*nOVB#_^9y>F!L$$pQL3X z->8-;bb4*U9P6tJRR*UHUQ#SB-!{-FM8WqhEZ5`Y6sTFphc|p;#!ds+k`8wH3!^*s zqUh#fd*3oeTjH-S)sp>wvagfy^Y%)u_BGEUzmgtj5ZgGiqKa$0bhrQH$(Jfy)@&M7 z#3cDr%Xo|2<+Ux+DH9CIml8QMhtD;X>nHUin?`0KPy$ zzYp6Sp|D}n!PuKCmN86s1tc}v-UVP+`K-A;FC>{*LKb@0vGy)Jo0cb} zyH#)3@+KGJsC2C2*S1FsM72*Go>#JpO$$CNY}@?J2c2))l}wLI99`z9pFwk8Xslb|9g_g*z2JB5i#&}+o!ory)J)sW=gVU75{a5V;N@A1e|O5n zYn3Qn>cP34{sfd!0{Ji=j);mJ-y42h|Mlvdu?W(lNypq90)P2tq!>fExG?x5l&;p~|3 zp%INcFU*HOmYm8Wqr%M{LD6nrB`Fkxn!WK-Gj+!aFo;Za9}>|btN%)*ME3MY8$9|f zIhj12U%IhV*IrgwYi^-CHfHzgCZ%&IuF?s3Ju5?Ljh%%~k-d zWjt4B2N@&B(^xeEvdb$q!x0PKMu?HBDAnqVn8Cd&RKoM@o!J#!pvOBH8HHBVO>}$}5apCyi$Sg43#FV$FlCg? zicEzDnFfDSkcu476e%t^@;z^HU`eZEPLT~M10*zu>0}PkusZWhbeU+vM2PX<+U6jl zWf@PJ*R7vKnqF|k!6rmY^y%99K|||cAf!N)fUO`9QZ^AmsPRZSgE9#!{s?|uijYf%Ufy`f?n%9-3igTM+W#R2v|1lp*0$SP)|S1owS35%ov;1`7sTxJgmIE*10^%Iin)M}rf`X! zmTT1LDEC9LEV^CvmM;m{)G(+MnCuUt)Oe#64?;4 zCinwkS{(0Cg2L8QHcB7Fps%gG%vs8t>Eu^K3}#hQv`@kTXM9PIRYr=lcRT{sJzFiV z&Yk%{nQzpv=DCz|yOC`rDUy`Ioic}UC9J;L?28J>6quOV4LQzEk4We_F{U$Ftwu?d z9ZhEy-6kyps!HVZ+AH zlXdfe^K!(<>H-+3^9l~Op_5lFR4L&I&=d=I@r67_KsF>H2Z+c9pYkG-MU`bTCxr%D z2%rD}0co27BMc@0A`A>1NDA8wwqVLKwi=2XmN#hj=1GgWdwxxeD4X`$9fTkTVo4f8 z*B?>s6j7sUAq|w(QG{=>fIy-qcW_&iL6Sc^p!=Cb2s9fcNvzDP1VB|5mZe<+*qB~Z3WICRYFKpVgQw(<(iy| z+Odh6wG@Ia#k$0hvTGKYNh2VNkW08Kbe7>K1@%>$W=tbNFw!=G!nMwF4eJ3DX*G5@ zEM7FO4MOQv4||6AlEG`59-A%*-V^amB8nsg$qadYyj;ehqh)DM2Q%f~ZiAf>E0>emej76YNgvF*I7n+CVlwqA|Y=vP6bi^gx;L=mlwh*o`1l=_f5lR+_ zlAO3;U1f^4=>Wuy0cyc>Jv~t{7gSO~0f<0l<=xcqnZ{#Wgaf<#XzlDH)01yFZk!W4 z`Uq0T2?=RKWDumqC>O&>l#0o(U1mi2h8ED;DbQ3-si`r6rYd5cEjLA|Y$BAwwh)7n z6D71EqRRcYKn@`g;!4}1fh`FJA}X+le&8thbK1-R00C+RFpN@xiU0rrFaZnz00000 zKm`y0000026;Q|%pauZ|KmY&$0sw#j000M203aAJ0RRC&0RRCP7hD8{fB}#I-YEHb zmLiLl8aUGvf+VgGwd0Y9Za)!{`it1zdY-R_--BVVGb9vD68!W<5^mXg*g!okmH25D z>sFv=k$|G&lQ$L;ghZPJ9y%KuY@8*~tzF}bu{RUjzDnHJ7;+TIXq}gEo~#^5;)sdnNAWQ}xr9-ad}bdI z;^QcYC`1{&u!#=;mt$f!9i}3U>HTeY8ZGD_8d%B=y{ayZ&@NJTf4((o2F6ENe{+9X z5bZ!z3c|2(_q9s<3JpXP7)l0pM2?JS5b9_}J|!_MB!lKG+)3Do5CS%`jx#O{St(^~ zPVs;y&PphHg2@XqN=z|4x~~Q2yfcaL@%8amm^Ma9Dt%Qi4u|N>Nr|&Qa%0J33m;g< zm`|HPfTL}Orlso<(6vj69(oa5HJ)^>NoipTxpx{8o)3M{(6qPK9$m3c_;f3 zURXou1V!^ki*7h^6e15eLT*YRgB(dSD9i3zAavhhPcsdecbI}knnI2XzZ2$vvnFRS z_@iB$&nqfIi;XuWSrhLW9s?%;fq*~|AQKImb?qbzWC0&c7g@UN9ASttd$T8}?L3bQ z_9b3DX))-dZs*151b_e_Ffmp~88f7e?MYR`Wx%s$x@FMcU-><&a*FVz27vyXF-{qY z8R?lDk)(u%;(lI&3+|9u=ak}ijOb*DBniJ93!nKg0DECTTcb*P(crK-tPhMvkd1X-taQvVGZW0ElbtbuWq(D?Y6PggBWJVHQF zL`D{R8N}p2DscG>km00)S!_azG_t6&M%4ef3JCPW^nxImy5awAJ%UbE5>gq6*E zWCqnUh*B^mW+YLVs2;SP!_v60lMV&;O(sN&Wjqdp#uK2=XpU&Wmvm7@gCZ{4@qBb)_6?LU4x2##C+n_^#E{_zTF-@c?L!h001Kd2caHMR2rEBdGDD z9oL&cPCSClOXLDHZRBP|m$>n+MhG^mL(+h30PL`8DzJ`Z0T}^l<#^1Hfq=!WM7PQR z;>Ll2czLUU0j5*-%bM7sz}2rDWKrm5h((}QHxB9^XV+(eXn@Kfu+5UoR_RK;dn_U> zPVYddmmUp+fAP>byhDmKL^NB#m5GOqOGS$fl)`9)BZ@Y&YfQ%a)Lt=UAq-p!`*uQi zJ@<5ai`k{o9=X&7^Gia7T^297Na2EXW>F`7W%V9R*2pNxLJm1ekjzHQ--J$WnHLl~ zZpdar$*&H6$L&?FOF9>1jDzH55wKM7Tp$<}WF962OmS2(k9Yfg#VWzm$wY;G zEV>Eki7gpGL=&-yTJa8Rc0d(C7C<#aoEakITJ)$`1{@;ImU<|}V{-1+G{gYSt(#d} zmQ#6VNfBDaIw+X8JGDttgiLALhr?u+^u=eRDp+j6DcOo=(YCqr(GVq=@aE4zA);i- zq{SJP0A5GgW4!VhN z5%~+4(bvq9?i=$O&q2Bh<6?CFyNn6E%wz%EdBZ4VXrafAG_tL0Y=y)-S7#oBMGf6^ z43Q8Zos6r{Gs)coQE3iQgp1(JHRvNF-&IPVq_7_(>XA%QlmlM5s5I{mG+Aa9qu!?R zoLB?~n@ZY@q!};=H+F0Rps%Sjk(HViu&}vg?%;CL{8&vw)pLWN2mi-;L0H>D;ZFL?f^x6 zhKW@k7LuVfQ&J2BBl@6uNKhHTPyr4k8^+h*0oo&qBAyf)V1gR6W_6>w4)@bp`VQE* zLQv@_H;yC?vt8p-To;{*&;$k;1ki1f01G)F*+z3yCM2Pk_!7QMEaY3@RCmFac?Edg zNa)KTBoIRMKREb>az5r+MB@mcq=TYsr%mFnCdQ*=2k-&V0|W-u0{8{KW2qMK0enKm zFlZuZAdo;aVqpM^vGGW1*3ZsJ!Mr5#NDBxy4-#YLaJcVp#Dp#gM@@=TVH`;JbZ<*i zWsEA+G-ui{$?a)zJnZpnxM}(fkUBe!1PF8`+tW`779@~q7{Fi@vzEpVO<)@n0t)UD z2D%6l6s1ahAxy*XbrvMls_2hR zlnlVs3e>0f&;`=dLaUPdrGPu2LL@t)s|Iz6p*odm;UADR@WS0y%{qYH-6d&Qtw}(t z^hg)XwQ8%~)Jj@#R_NhUcvNmUk)uTk)X4boswFU@g@%o-OLdbbB6wAc2Kl;xGb!Z2pkSTaN3Yu1;89mH5e$$fpgqvb>kv(U zNXe|l;89qQxz&o0OFaFpLR~M%t!WhZ$do-IsXX^^IEUU=8i&iv!<0?1o$hGaL!`UP zM$jl0fHsg^DhDG83_*!WkVs4!;t13bu;C%h!jN+yV1mdvMl}i!&8z`RqeY%ZfzRu~ zj+tJ@XP{LIn!rCG0=2HXROtH1!*$}_f@@}Kk+-A zLSgo3%2cR`)+Iq;I2_X4ZKSCdu5bnz&w?_2#}Y4x zofK%YG-F{ww^k<@LfdL_Y%dT&1Q0<4d0{}yYh_xocC`i=lM-9yk#C3~jBGIr&+j99 zqLE&6CXg>HbTBugneHtSNH+Y^g@RnUez-vhF$CT2pwXKWAh8jdVtmWTp6MBKdoPN_ zbLIc+%u+^(fTTu=YVa1b7>J1&$tNd=NR0IywQSNWD{9 zv`_VtL}W+%`Ngbmp^=#q>`641kq~mRyxH#w7Fth;Co>{r1*zHOV3?(X;m;x>ZAOwX zoy8PLQfqL+E}C~SXq>(%o_ABoh=_=rRkSTa=oHdz>18;g6jN^9%0fHdVqn-wSXnFg zmBvt~c@dG3?MC2#Aals%&tzf7jD;q%e`HN=DQB$o_6@`XNVy+|L-<9{HzX#6lrQqk~zyK{qtJ0Z-K`LYItyre=OxshJ2x-t@@d;-tu) zjM9bA-83DNKP!|k)*y>6?Pk7Yj46A|K}VTM`SCw?aM081{At9){c}fZvpx+PTwz^h z1xeKUd^7%x&5q=o1!7CD8&}-8BtIU`f>tkC+g0^(Bdmt@qfx|?%7n7ijugXt77--! zoyVe6jwq3oqPoI^V;olTHaj>{*g>@+VM3X$cv0n36gJyt*R%~rpmDqhbV{AxG<9bm zxeXshdlno_KFHlUjA-_DbVm%b(PiBPLm@C!gPA6N+ikXBR=^%>TO7&kY4oSW-f<|1 zn)XqPE{ZlgSwcd$VFW@GncM7l389}(j!`|FD#$43D#isUS>uXHVojF9 zh^W)SzKDU_Aq@>j&y}v3OXN9DIO8fO&SLQGDe#o~C~2(3A|_$`I8j>#?A8VOKVj`+ zrc+9T5v_#7WBkD|Q;Q!J(O~Odi(GreIQxE4lGc>5zc~y}@!oBZ9HQqarTosR37LE5I>b*+k0i5yP!rEkF(Br% z3s{~6bmJ-vVAyIU!qW0JVgH)fh33pNB22a(mZzBHa=uzyiyTxuejl*4n}4vg2&I@m zF|o1YQv+cmOO)$U6}GmuE!vd0VI);#f1bp9VoBCkqhpFk3TE>)bw`{*Fw>KqqOYf6 zoI=(UD5i0#xLG8+gmIK*3Kn5$-CvnLq|zsbN~-@$S^>t#6;nH~t@n38Y-KZ) zICEJn=Mu9QJ$tBDU139XqH;yIl{j3e*g0?E}g-Yga=S>ln~pX z5??BZZ{C#%K2Y=t!t?>ijarUwfM`H4nQZXOpz4NOW1KIq3${R=;}s|zU64536$0Rd z4?yjGJY1>Ay}%#4*5 zjo}L%_H4X^HUbY#hsbw%iElIFz=VYb6=HUj@n^(y-^q;Evnhdh9>9jo z6K@1;*CJE_aPeEP1`|7`)MS7X;K~?1l@mH)^>l}tV?ic7corUKTUX#NPEgh&Pc4!G zBUukJK#+nWJG|QVy|J}|0_HgiW(Xbn9A8w)7RJ*vZovb!RF_|3Ug0{gQNo2%m>?HT zNa{M(Bq%J8K#jwfnumq;k%Ry7H>R;+YUmRL7|IZY6jZ{HHWHMIGlZEKa>^c#MZCt{NzuAAc`ILYL}p)+S!G&@~^?7(Xu zd53bCvrEZlOj@5pOfdqYAZTWVh(ilbiylR>%+rs*N63K63m|0xld&qnN5h7*W-Xwg z`H}1DcveGX@|;Am2|#(zSp@NJ+XdO6lxvMH=|-xW5>6I$;HE*4yjf8!E59BIYvcw% zMgi1#bO{Jdp~wne9d?g=yW#=}Nb6$w(UpXFeH-nZs?QbNLQ!okyrpOETXW1=2GMsS znK>!#N~c#F1I&vu8e5V?-xiLr*Li_qJ(SA?NVYSL$IU~@ZidLDCG0H5yNFFp8OP^3 zsVOW3S8kIxTtHh&EM3-Ga`I|ULc@1GuCp(BtXp1-C)Om7nL=6SPE^Xx5g0O!Z`hS@ zOJYf-5Hvfr(=wviT6F@(FS?|d8^s)_yo<A1fni9Weu!fQRWsep zVi2)j#*B#D0h}ogcs76bS^V8+nw47>`&s0J@ljpb)x$=~Gu3uF4)ZzO)4>PGb@56B z0fS`nC9b)cS&XCQwZXpUSQ?4~Q`V=#Wz5SKwSE4DJ+-9$f_K!4Z9Dav$C`DEb3OyK zLPM6xl|{i&dXyyc2*lTvjRrWQ9eMFmn=HKVDf>TV0+}-Do)lS8!>-B_k5HbkLZvNy ztHsZ&T$M5URHSjha33c4$Z4$UdN9?tFTOIY2%mW;lXR)5)E{odHkg7$k>!K?RY9!u z_1y$9&53>00&hZfnQlZJSv^b}5#}_JFPk-vSZUjz0cY(`e9#!ys8&(jSr%*U+f@XS z-VT6Ij+s0Uh9cf*BWB%jHbAMJuT_vrm69uZq!cXlD;UM+o}V5Mxmx0-$AaKKqv%&WgwXq-sA!0A!~y!4%Mt$awnUA^JhtT3n@FgyEPu3 zK~x%~fSMfPU6oW811BIT?ny>1h6wS34r=CuftW5G2euMvmogDTz5&_9^_)rLP;zsL z?nNR4F49}ATh9d6YpU|Dqm>>V9J<{VS>S4{jFRhL#hQE5LFnJ-7JBYBMaffqu``8B zWDA&f6W2;-VM;PhGu1FbW<`RKJwQ-j*8fP*>(ZI8S^U9q$ z1Wf{(hP?M2 zpp)@+iw5VS_)Yam1A3LgxR6Il`4+=MrEgzx;fS0ndoY(DfpBeubZJQfB+633t|^7c zgr=rpCos2if~6_fy3c4DTv$$ebCHh<6o|)nEgLCa)r1e9Y#=!k1hq4!$#ihkJP9?D zDU6c*+cOkIu#^xJ!xSiU8c^VXkwj6KaI;8-Phq|K!y#d5lPai|Sd$Jks3~JHzRZ${ zhznn~aFEMVImAUh*A|LIbx`Q_f$6#;EL)nuQkf|tY7t1^aW3b(0o3v%=sYqb2WESL zi7=5hXAyJ_XjF)-;CzF(0;IS;9p8%15;o)xEjpP@3mT;zI8`~vvGp8|EIO46#-JVn z_zR+afi@F`AY+~plg>_~h*C?|Q3{QbpF+%(vCBIP zN%|=hcby`iX_r=Jq2}o+V01L0>UP^eNFs8ca7C#i(yFCY^tP8iC0jUGE-u0~Dbu6` z3k@C|^k@wtlgVr-yc@D+l6U$Bl{pa}2f$o6K_?UyJY=LKwB%V5h3{s+kWx(ty8kZF z4lWLxjagz8Jy|;?gihT_@U-*@)`=890XFq1#7zTy--4jJr)4YlbD;BhqF!h`dF^0m zWzP(NAm-n{C|MX9f~gN)U68sbyb@Xl3&C1)lNL7{1bovFu>4V+iG+;@6QzTbH{xx| zX=o$lj?3}^LZLt*^5+tIF;O6~j1Xflbnf|r3jzWA8W#cT=(K0;vlVl4^wYTaO53k_ z1sOjZw4e<UdHPm?LH+J*LlZMb;hVI zv4zPU>=b1mppsy0QijUrG^LFuYaC)Cp*-mX+>OX7ewcshleRbb+g-f!+E9@&S1fjX#J6(!ml5n85=gHEon1X&t z#km^T5p^U7Y1d}l%UX`{x#|Wv4YJPXiJ;u*3Ncq<62wRN$P37iJARDQSN|}pCK!-Q zq!AA)oS_C?8AVqW&j^Ee7$#7IR=JB4#I+9 zlR)RLRjVw(1Z#mXAdZPR(phFm;)#LjYmNkF$Kg2RK?S29B(!bSRIn8aQ=DfOnn^lW z_Z?$9TSMo1N~49E-B}jY(C_5Ug8@CDMwbWs)oHX^*4N+EgqYC`BtsrChm+SXRAyY1 z$%CNk4QD>t#0#T60GhO_D$*Kl;}n(AXe2>{9>YC96P#PAcXz}%kZ`4HCD^~cupB^tMtiDE1klCac!qZ{U6zV9m%h8*G-kXQ_h5=pwA&{c@Mn=1fd*eq=e zr$?Z)IEvV#TF48-VJ2s8+}DJ~%NF^w;juP8c7l(ZpkkHb0M6_@KZoSeamft`?AskVDSVf(8f;3<2YKqYF6gY-qy5YCg>i}n4QrZTapB*Eb*LN*2@wJL3DII>kM;1x@A5@ zSPL`U8-vKHhV=F1s|@W5y+O z{8~3ha!cDn!Ct#{5$O21jvXg6`#Y-&NQY$m~C{+N$ik{NZsE}t}jTun1KBG>=2={AG>_wUtNyS^8>|oAu z14P9H0!>>prvRd$J4TT23H-@#`bx+$S_CYm(ZR#U(yV4rg*Y>4yPZS{=Xm&X*^wes z&LQ`*trwg$Kw=@ZWhJ#OskN<*=*2@wuqtg20>NB_42uf~+qEjJAb+`FUGq31hiw03 zV)nFB3m%!dBzp)3`04uidykV4xf7OxpfVxor?-47x-}hSPRi2+3L+SSM2#F#n4dm6 zWOGLiQsb7*a9yAt3*pXLMJJn!W!T4FtW6RlW!kV z9KI|+!(dCy9CjDuvcY`C&B6vib3w0#BAIeuahUK-+QYK3F-OO4 zY^twL-2ym1P*FJ@G6?0Bqh|=|-<-Ycc_Qz6UFw!@_qPuv+l}}5M~as_#9k~pzleHP zn--67UWoF*6&4cQf7$#YZOAuAJte(@lHu%;q>XKfmUSU!MT%KkSyN3*#KVbGj<#s- zi)ay|ld`Rwh%)7@Zl7{ECB?^{Bopjk6e5^?s>ndt|T!jFRN>vNvbpFdUNg7y;C# zT9U}JXxiCCB7fstiXk~_$}4#TYzzd7_#R1HEf%xnp=IqT`#nj%5-$4?Vs_Pg7-JiF zEY_UO4ZcNqEbP%Vw|5WXEi{5Ky9X_FqE3vtRc4%@2ak)9%_@|x0_$Q_=<~5i6dPe+a-oAnAr98s}bW{NdN!Tjus{)}ik5>}- zrri=y(Hw`d9T5n;x3y)KVa2F{=F(_Fz0<92*Q3EY&MYFI=(KXycX=Pcfar7qu667q z2>EUj9yQ(GVug||;nS4VEL3JhisA%9@L2s2PJ2~SWo zJd@}2X|l^OVE-6t*G--sO{f&$8IwiaO+Fe&lR@%Sl`=iPf=&q?_~i?E>Jgo4K>A{+ z7rciFh@lG{-?s>!eTFJh`JVBh24>Zh6>8J2WOH2=%K0eA))tfLW!aZSqh!ldcdX%3 zPRciybPfB1ic6h$_KT}UMu}+tNdz(kc*BBnh~E9=wF~8+5Wb4}kZr~8zqcPjRy=7b z#+riY+?imO_kjkV(xlv!NH)8kA;lI3M+GQ6FU_TfS@L7g7I4g8yREA<(yOjRx=uz2 zBM}sB8_`Rj{|E$Vo*!oAWUG;5N}As$bO;;_9}#G|=%aMEkVVrD>60&;I063|IY8X= zFV4_xv!PP1Ft^U1v`=A@+7Vm0DzA=^P6~V4LhiEH>7p5S?dJ;urOaqQEU+pK3R8K` zG8S>LRR94OMKozUvetS82&uGTWGT~EK7^)84xexB}h1h;X-^i{?dS4Qzl); z5ec+aF1?`|xQxz=Fs`C2$~9CaB>|6cOjN;zlS>S;$L7jU-SD$O-Nv zg%)rG3kL?w$3SQmgfjTsEiuzH8uf%PAKl%jY(P)|00DCm@Q|Qp)c`^RdXb7Otx2;` zqEKnHNqY(wp3;quHz-L}uA|#YgH;j{Xj&6QmMEeI>#eq0p+|KJdY3kO@ULnaMBT*5 zXeNyx2qznMaSNoAHzEVW97EdOPStPsg8u~n8^7p!z`LhaL9 z%w9%O!M7n!EKkvf(lkfVD=3a=krKvk;~zeMPDX0cRx+Twe~u&RsxoFW2@#UD zV0O6gw?@>Iax71%4raf#kkLoBrP=>^J-WtH$LP@-G;B<<$7g>Zjc0}GuqzhgCt|Jb zpd9?qQHwZNBtS&TN`6v%Yx?z>s<>su;F9bblCtMT7nw6Yt(%RA9PJxW+;_Y3oHZC~e(>S;PYb}bU$}gsoZ;Tlt454LQ|jK) zzu@Wl#Ol!>{oPQp?OFNGgDxF^RIOURu%Oz8P{T1rqGxi15TcC7xQir03v!d(aY&&} zS1LS(gD7e}98^;rb7nxuLW^^d$l);zaYG1jWGZ{kfpCHdAc}2nHx4btFJloyQx8)J zf|G-=kkT>=7hQaJwZ={WBuL*P;u;Z)eS|jJjW@-FhHR!R zwN4TeP28ZcQSWbvm|P8dL~%-UovkEJhVboR=9*=Qh>5Ioq3`$G{kj6LQhcZWdG0n=LX6h7m*oa@y^9a^L@I9?4JhbF2;S#k?K$OPvVrjXJ-5E=~bY5 z19GfTQNGgM0#dQMQ?@5HbV8s@w(oI@wWZPMtFxB1rDF^Y@~E&z9dhArb zZ0MF{$ymb?vb@XjSu(3y&S^N}lydq)_He{X!gwZ9oE9;WC24kUZYwoOOe$uj__DWFDBYPHh5l6Qnhl{w`@nqW@x zh_%_AkfhuZh?XCrJ?fI!R!AO_E0Np_5K><@2|Ps#7)`0xThtixQkfDZFAW z$OMxObAcSp(%i6BvAJ|3Ov)k=5s~B(Ma42s3uyr&6glpz0?lx8c67w<1pt=@q+-9x zT1xng!AJF-)ug7I4)RN-kDh3no$9V9N3?bvs_E^gq8;)IalbCZRLrd_Dkm#9VMP}( zlf|}S2d7UetF0VQV%{DwUqM;rg;E2Yk+qwF$s3Ix)Q& zm=2xLF|8BRu!R?n0hHKe-mbq1g=r~ks&ScoqB$8xx;!IxmvS@m^= zlRmPtAb&J>CMa%4nEHM%&!(ACwV4WE1X6&dFeHz9W4=&Tb zptrBIe#6m5+XtUCxK7@}6wJO!6fZ<#pDIESu_Cbv4|x(>S>a%~G#iQ}R(YqNVW;@D zh*NHBnpq?R^f_)!xa5g?rLLub&67!Vkrc}+jms2S3HVYG*hRN6g#`GegO&p-*R9K) zUby6uD@5M?Ci!nER-b@y!i}EyLbjT3vvDM9rzN>jLch1dc$e{CiBVd(Vli2BH0FZs(J#arSQa^g2~T5Y zV1tMWdtF5k#bQrpLpIEHQQkxp$!feqHzowuR-^F9kJd+K#H^R(G4T*&qRXg*8KMJ& zZbL962R$K}6#c1q?u$ifliJl@L)kY6RA~cOb23Im3g_f9AW#y|KckktZ{`M8z-4&M z%m4rZdA0&(Tqp()3;=8(#>i_bL7@#bO={wjuF~O2EVZQQ$%^V{B;5ei@le65lX^;B zk)=sQ!3wDWMMNTDMlZnkT~>$K4AKLl5>e)cB(_QNDl$mdDQ3d0uCqN8qo#0JG{HfsP#b|T`JRY z`?SQjW1W*Wj(;N)qU_}wnSHD!_Q-35RTFLCS{gGV?`> zT8GBMHf1h-%B&P~$5|^&DrS6M)oVCvMJjQL)o7g(n-G@qFpYepJ6E-6(>&&Mbi(%3 zyV=Ra=#9voiV{k)MvT^&j3O64i#Vm$&`IW6%F(lkhJn2PxfC{%@{bncMi2|Zg!(x` zs3@}|u+nQoUd{H3;I<+|*n*?2ddi;6+?jVuL>j}{y1rXQ+DCnfoJA|Ml5+MAck;E}ux-bHjNLko7!!$`(K=b)wrW7xy$~F>_Z89PX*FUGlx?Mx$CwMwrq#AyJ!+tO6!P`$143^90N?QWqwWL`%BUB0M5X zmdFk<8uh>c00DXhDAG{?z(6nn7=Qp^00000F#rI-00000#1z4jk%KTs0e}Di07LS06CSNunHQA35lcz!ICQ9uBu&yQ1oGTgcNq$+WW%;)}~|%r->`f1Gj8| zSpr$GUh4_bC@v84!}d$p9&%nQe5KD(!N|3I9(S6a%5Cn^jrEJCUAf#=|K!u*d_$d(tB!jEnoFGG+8Y~dM1rSS0 zQEP$AlXv~P&>=V`S12AUz(&{jcj9B`Z6=sxm8g`~fyfSHerkx1Q`_H3THVa|Y+z72 z3l=fR1llb5J(;m&Z5!W^X0h{n5lB4ujB?ne_7zdUZc!l8-A3GaCV{p}N84&viK6Vz z)*TcTmW=PadSW#!0IvsMhv@brb69uXn>3_owq=9jA`|FN3IAdtY?J;gD_WaNJGisS za3DJpS@4m2)R) z617m{+A7&y)Rj`ju_E?Y@hy7RlQSVRR6>D~4=gXAC5OKzf^(yPN3Z4eP27$-tG4Z} z=^7s0=2cN0B%sF8yI{OYy+glwolJ9?X!Yv*qp1Cv}asZ{;8aOz}q18;-j2M@jgSeQH2JS*JkH`7&D@vBjAN$jaOFstocO2q* zQFgLBTx11KA7arZ1rc~ZGM*U#10WiJTgQmM$&H8)vRksYfCf)~*2uS{sJlB9Bdz8G zu88ssO6v`_BUy+fHecs8JVaCuLQsL~_mqK3rV=k-&!{-Skfgk_?1JHnq zF(HpuyPlHDxsbA(Q59ArDW6hu{_BWy6>(Sp5KlY!W@Vk#U@z$sM46GtB|Fo)EH4&u zX2?lMc^A+9+hWF_D6+UlqO_srFGQ9~XFM880!Gykrs9UwPQY`KL@mg!z@DaL5=llD zC-3s!c~IEUU>fZ7iiUGpD!l2Au30hygq*n$^Fj7-SoJQ3XeZfDQNk#-It>H@@n!kR zlcGY}aQ~BatyA0}BR!BsjObMoKtvD#fB*v8Ff=4%A3%hoV#rmP3UjPes1}ffsz97F zIiC-wG!*up1DmAzH8@Z`Uk#V9NXjx5x@v?|bxl0OO~9}$x* zNlQRDsX>zyn4*Nr8Y3go_uQ3(Urv}ZlP>iNKxhuo+^`)O3S~$%2LTf@iDBThDyoVr zL2gAq7ow=(%moo>$b0^+0;r=FJL51;?l7>*SWeGVQ(`{#!D7Dvi*BV4-s24ves-}*OP_I&$J_=MH7CT+bE zw_?B~Y6n!XvCc!SYI05VgscfAiI0OvE?e*1H};5EpFi>^zaUrer+Pnj<+I+REpZfZ|;*i;ync(EIZ3Fvj%eKDq*s1(N6$NLP9x$ zT>S&ESM*3;EQYqS-szQxFD4L$z>`WOMk+gzA;eEu(ur`1$tQ%xy!V#g!%5>ySr4w zn0PF0lzCTpKG7Un^Zodwn|8M8%ifzzLc|~ULOq!tcC_5~gfB}!tOsw$*(|QQl->u; z4_SIW@XC+yp6oL_elDH2p4=ImS&Db63J$+POjWx0gDKSCV$z|c%dam;qMSn>Kx03D z5A+>gQT&5#lN3IWcb>Cm@w|D2A$DBNpEFIHe~U_tax=NSBQmZe)?gBTp?WEyHu7EQP2JyKg)+W3C}`xl^vDOS2qx$Q(cO z4$n2#)@v?V(<7BE3)b?ar&|-zCZE5nXGD<89&N#9h0w>+&DQqay+e) zAW>RK7bnh7x4Nkg-4D^e+*u+XU1nnZ(>3bm3J0sLoD&y|@~$~k<#sv-WmMba+_!q3 zxTE-%Gx3&VQ2tD2{?awz)eXlg2f1|ce06X$G55i*+{TANQ{Jwf-Yl`n#ER{2FwYz( z>wnY5+;*vVt-gy&neVly46MH;dAUHLdC0D})IFb!{{3rsPyhBm(iZ(0F#iEYM{y_G zj7y$)|8($A3r`N^(a|g#)hf2$@m6rl+o$ylTfE?_uyaO5667|$3M;z*=1z1=YiS5& z&#FxFC7UqonyXLe<7+2-20(S~8oQQfDH~RV<&Ey$o@|-ma_afY+>y0OZeA{DYq)93 ztPPVN%VOL&FTN0X@#(heU!yDELN@&c51qgT_~Vrc?$^%Q`n|O2^GJGrY~zFTtiAUh zSY&`{@gFn(Jf)FYuZguOW`1z?yKGmqt3TPOV^i70)X(MNPZ<0qt2#nK>D!Kio+W8& z=hmz!7Hs+axNQdx&niYU%gc_4+~!@?5~KgZi`S+KHk7!OoI!WA@^_Ug+B}LznPw>O zxh7VRG8}DZes|0`TxS2$Rmiwo+ab8&|IfO^9MK;4q$>N3#?l7a<;gAvC-pqcUL?V76crr@L6{C_3|@o`Fq9BU3c6_`MMcA+w+cft@dvyqI4nQ zdQx^&BeDMUa9%dWHRQpfb#aR(*S{c6`u^sy^69SCkKA{4)Hc~*?tGbTH#z!X-VuZy4NVYI`S6ObcFo3h3*;VmKcsjIHN4%HeZbOC2Px6Qq%6ugX|{l#Y6b&#t3I&Qi1XZk!DRGzYR ztH-4aXWY{6K;MdhEYDq%gk%C4UuF4=zZeZ2WD`(7Ei7-OFOQQ@aW;*|2WLElV!4*oNGeKK2{6a25Jz zd~W7f94h#Cc&ANy-71GjgWkgAO{B`pbrHp2X=-B=_BeIfj-Efarvy)3G}<`qoOrtm zKlL`=|tTz^9^#%kG=)OZY=Zj--*I2PcCR}H>Kv*Zvf)Re|We~)itF%h3HD6g;PshD2yEB z>T>R~zTb90v|~g}%C1%Wk8~!Z7jFEe|DU6Q?wPN;_dzzaUAMlMEJCd{FI}_h(QEhR zK_A4X!@YBa!Z@Jz_w#ogw*Gk;Pn5fTso!960NNret3M&@v~@M!e*BMD9^2lDP%*Zj zEjRg5R*-Idts&mPen?Lb!HjJvdf0aR3EgXm0HNa65sq>k-!ZkYBd_!l5OQV;`Mqi6v_lx!rEt zw;%a*rrqQ6=p*^VTh}d3o+bSHR%?h(&TVf$9VxoJ9X=AcPmkXAW>62`Qc-mOoM?Ax8R&2r zXz$o*yu|jG-;)#i)WMoE4szLQ`L}ZycmBvIui*1`6-*)`;x|>yQO5l+tFG%$jO=`b zNgGYS{ot*hX+!-Oa;dJPlpMJG&9YoLiHZuzS537iKQ4Mu_TcXmxjmP2s6u8#wbo_R z(Mxxjb3SFJ3UfAft7n>RvH5k66{jsN+_qzv_vy>iS(v46OfI2T&~8mk@4{sw0pAp zt|G4$q>ltCW+E5A_2{p;b^49g$BRDisnP8(7Z%7be82TH{jiO%GDomg53kVw;;*In zON?`KcUv4=Yzm#KH+v9$IPKdflLfxhElKCK%a1Q!V#wHMSn~7CXxklC<1p&s&ZiEa zuC5;DUV_(bN=YoRczLu2X=A&5>OtqClhg50yH57RErO_F1VvWVR#H~P;@Z4_kLeBK z9qICwKtW2R{QOosqlhPoJPS)C%Bx4o^8_nh^MrQCt(*Ke8_KS73dh1tjrne%@3tcc ziuY98*e}A474cG)xBmV2-v|?nQ@^^dId@II_r~NA$`Q%YLX~n6aqWVK1yT3tcNHnY zZUyzlkIgT0kJmIf7KY~&N8Aq|#cl{cPFrVocBOK|fzE4>R&|-qk&8c@eNX;;S{k+R z*~aNh`K|f4!ZS9XnQwb!cT(v$cBMrNyjcAohqb$);j2%6UGiqlr?gk0_n9YFKT(I0 z4oEMP>)%D)^N;UxC@PrqXs628_&A~KP#4ePT71y;s@c0nybp1$j15jpKZZPf?k{yP zkuIN(mS1|{wq)dE$WmQ-$WE59vaNSE+bpB#tQSUG7I8Us$hU^vwze3UrdcYFXFN3*GU#@ptO%!h4Xx7F2EVroY%~>LQQd!Q) zXDaKzhd5$EpZjajmx+Ds2+t>M)8z01>=ueuhNH@OIqlBAkRTTDv3d)opKisH1)nZj zyvlEWKIK>O=KkJ$%Vp&oO$dWZAM?^~WL|R}?QCJow405gc9E|*rk608Sf*f(vLaAu zQ&`>pcQ^rmuBtnDauxvod)mUUWbRzPYg;mJ>vG<%tts2Q{5(?Awx#_0&fDS)^f1d%X0b>jXi!n0BVzDMB#-?VVx!IgKW_C7nEkOtSg^mvPcs#+?!=2!~ z)CG?x`aw%Qy+|a|LU&3a*_-O&L-PLbOAsa|CT4TYaOUPXZzsHy_y6bPUkzYwj2eO; z2xkCkjX+r={=E+@gaxP(e766c@c%v#NEF%#gEclWodbX1h82KBpioFO%E$-}JLHH% z@cRJT+Q`PqD+n_;W-Hd24|?Ymoi}y~zS?5T?wNA+Nlec*F`YLbXJ^02&7BA>Ci$-L zBUAiWuL%haqlYs%v1`|@->@+*DS6xW6fQ3{WADEG2Qss=^YROh96feiSX?4GeWtXm zTv}PBR8^~MYA;;7-f-jQt;VL`@3r37wzYS3KF}L_|LS}Ee?<{!e88kGQPixR7Wx3XT0QE(G!b{6tx!jhwvTMN(t1TlsUH zy>pDg;G*+aTTEPh*i*KN={=_NTuHAMP5&3#|BUSaU0}KYzaslTf&JgO`T;W(0={`D zYhV>{wd9n_?zs-l7Kbh=?B!L<%W84#1Qwdym0E6zH$x})yh~ty{2r4KTfBaXrXa^Ni*4iC?j+SnxixN zBp%Um7#9wGtZo%x*ubZmT9DP^RO@qbrw?%v?T>A(TWZsI6|WHjdw=`Gt2`QxigR<2 zhT0SFqvNgn1So@)7jNhoCRGp-C-vnol$5U2Q2Z=-AJtbOq(SNQ(Hvn|_8y9w69p{u zy54Q5ad8&7fU^_QU<@x4Zwi!%I01O}Cl!9LVs%z~^YS=jyYcWMx=|Z5#NACYtuK)R zk!&C;fIQek18~}a8zfE*A~Zv~<(>cv=mvN+je>J^g4WhOz`6P&mxw6)sBBlQ6j?L~ zf^-4kzyWQ5TaLL)zwkganv>vHhfWd3vuDIc1iKvRfmaM{c62s|FxYKG#En*nN8uRt za!I3|sy~2(^pCd(P_=3{!V}Agw`f%2^}~9Bsn=vg*eja(L>m;QFU;-^QUH!wYJ?Wx zmxKUrz-UP`Mm!6=>y;%@lwGN-XBDVFcvupU!PLwu0L!>E@CBdwD1e2;BO=@0g*fff ziKZEM_L6`pPk*+p8YP!Bhs;MPEE!w2Mi_2^=NQ0&pgw7aG&r3fF5^o96NMfzU?`P0 z+#3?C7!?O_erFqv7PebHD0QrqW)4Z_3IPjXkQ1a^GBPX$O#v)nv~WxnkVCiNA~Xs7 zXmrwxGXGIo<`|go+eFs+sj(#yIWl`=bT|4!=6KMm)2>N&o#(IX1qg9vZu%jJMjp!b zOXxv$)1O)<$168u=XcP+U z!}DovGZA7R>2~H@&a^mOVf3A=)Peb|H$I`B+{w_ugKNz~JMoUE=N)>JxN7lH{H%f& z?ZBl4b;WJ&trWOUN+UTr!*y7BHVZ{jnP)x5rP9*UfHIn?#A)Q#SLYe4lv&%U_|e@ zu2gzpw*)cIGux2kknx2h{A_Edp&lk__InfU6bl(~m{oPCD{;HX*+Yc|oCrAud;vXm zlvrrY$$~7MAL(6mD$Tc<=s;E{1=e~A0p>tACIoLd;+YY-n$`tcPcU&R{60kzFsn{N zR-9r)CTGyhN%@?5pCJ4+9V39U*~4Ixn*f0LVxNc{p>aFI%G|}BlwhAm9y%+;A#kMa zq7;?m6D2}ZRiYz;Ll|#Jpz%)6jxnf~>vO}0P5?&=MY6Fe^+%l64+N5gJnA%acYqI!%%b5@B3W`bHk zpjGF;>hDNOhn9XZkJf3tQqs@g$->r7&)p5$}v(#W;gxFoqh%Sjf~JF99xuLO;=_o?M_NnTEW>4gtm zL={=_?Wg1p`+y=Lnv_4nwvRu^aylv{?%ZAikGb}YP)I4$&&Z<);H;KFO_XE7djSSC zC`oE2TlllgPUbv|e4V^IPwZBE6i_K@y~7V*|$@-hrp1S0tKWWKemU z;d`5ne0E0x3!19XJsQ$<Ky6&>dHgSWq1SjQ1SrgU+W0gTO4N-Ie^qem;k|Pt zKpEC|!E)PW*uF9=F%;x3o*j+jDzFxLeWlcla2Y$-Sc`&hCyez3&}LiF23g(Dc=vgolaKsg{v3NY zOLR^sy};SA;oShcpi^xGZonMk)|!4IJ-;)>MKm*sz1UfBk<0tu#`(YR`KLW+tG=oX}9sc>2XDBC+8t{E-; zY6$PtdfMxxdzid0qh(JY1+W3Pg1>8TI483auW0B|K{!P*t3v6^0GwS_6S<0-!=$3% z%r_$B5=w%SWTwD-Iu_Ng&zo`V-LHULNWio(s%eBDq<|x|j9cBt%bZoUaS>pOL+z_5 z=cz1p37pWBziK$0Lxq3^U2QFI(Cqel#C51Op=dy}yh%E?aD~C2^ZRtv;amZlomC4= zMumK?jdlnD!cLvFbs{@JRST{&SM~xGJg-nXshNwQwP*7tn1N80I*6vNESD0I<#v>+ z8ns0zvCg`vi+Lk3!In3Ik8WFQFM{ zr$Z)_(QVoKg)Aa+#bzJjw#cxBk1DIZ(#(m~hMb`s(OR{V{-%0P+=LDIhY2CEaMW0T6gAbIVp+CMwra1J@$W8 z_J{I4yAG$t%W2#;q{O(h4ry)^9MW^}eA5xrdi7zL(ob1%-yjjXz)bK3FwVq^;Tg5Ep<0yif%{1*z&1m6TCgJXyuc!A zIeB=xYPUZtJDp2g`0KfhaQ-o!dM+Ttc^!&$cQA zDLK(GS{MabUOIpZbI9L(ah+qf?m=|S&CK&OJGUcP(u@0SM8rWus85u$WEf82jT2GS z8JbGr;f7UF!cLjeA2zLpRW;&H$ph|yPscs&sU z>zs@D`YL>{U@+Mf2;CzUXPd6hi=H!1YfJtX!%m2y3FqkZLTObKwELfRPT$9021QjP zx0g4L%CZe<<^b+}xL$(f1rOy|pmG?937T64ynbzTZ51`~l)mJJ0I=XGE$+$5fjmps zzsy9l@awr`<;q1R#mOsPJOR z5C*yi*fcB+O!i$*mg!Mo>F zeBIF*p`I2H&}}?&?w*X;PP$++PBT6PMW3&#l zz;w94pL5M$8abo&v@&Ew4}Pq!F=|qxGL_G|e4#C=o&iEYWWi@XNr&EGBRNw5;jFVe2E zB@i&Oz}LVxeR`Cq{ie|>3Plx&F(N~_mTy8U(+ghAQ3*oKv)oKt5&IiRfH+%jUtxoof^*q z4qfmY>8&sd6LS$4?ij8liT5B<%9hqqq<1{QOf*(BR7iNQ!wuzi z=-jfZox+ggZK0t|o@HF=Yp5Wcq~WS9o3#OZ$jULYQnNW4?DmQt5B2HKF*br`RV`i4 z;tDR}&ZyMFoN8E`RoRk2)x(q@IK=yc>!|jonjP#B9!5-t-vW(!C~#n!>EbTt?LXN7 z^vHVujBzxl=d)>Mw`)wX0Ot#MFOVk~5SOcgZ1%3sA$jHqpN=VtB77u$m(M1-s66fR zp0JBU0?_*uGkt~moT3tDI}DNX(}Y0(9{%xLFG}&8qjB*p^udGO9I9cuo#7Rt+3t_h zk=n=EvsC?{mPJ^cjzZk!jHV0}2nH5RKP2_Am*LDCYU`^(O>LqL`?q^jYP| zv|iwNkUd$AdgO1o-mY>I`m-G+4SEZ%)x)0NL?zS?=0vAjwG{*gunW4#T1t@GXbgPk z>`569#rpbqVBOBYImB%=0%FVF>m^C&t5G!7cjzG7p5`=8zi&2lWOphxS&xXOCYBqd z2YzK+Wr%w<%!VXzP{|RNM4}xa|NZJD5gSIa9(k|gpdt6OB1a4XiIPHMC$bRc!QPf6 zQ-8J`!v#iwbU|Rm_QgYv;j(F zp1c8gD@!~bMm4ObOhmut0r(WK3|D=oQ?0=10Mq92x|Uj#c4TEz3C*O~pL1lx7}(Oq zIPJezfgbNK)c+CUTuYS#*%lO)YCLi&7xB>KJ#8=}DwwZZ1?T#U@@woCBh5Km|55kG3lsnoKf z@tC3#+Oe+9&}x2%Iw6IunnN@D#>wgY#`c`8t|bUD3|^SN083F(-tvGlSeZ!+Gx`dz zsMv{f@fkXj$n>y*9zi6fDhn=hjsTMiC-297`Z zr~)-x<7cE>ZI^TCp$A!L7k5#tFp&2JJens2HcR$VlvVCG2o7={4b*t^zQA-}+-vkn zrCyk%1zh-aifW|<2my$AeuNxS4y%@f`Cg@@v&OZVN*yAdAUMPe=Cq$zTS(q{2bO_n z5B931UNqrDlbuN_Q{`W|&HP9QzHqgRadg~@*b0bWBn3{czd@~|F3*n7pjj8VTp^W> zs@k#*j2xQzH#U2y6a*xVS^}9gqZe4$heBoTq@N8|fC6J7i-DbpS;eW;1Uw?j9a90b z<6#moH|DBCZF`Y0a(iK$SxQm#Gsb+mX0~4+@R!Wx;WuNAayhs zP~-Pj!{?FmtG>p)j%+4k&BwElg0 zzXXAKqq2(whP4@eDvsD3HFsK(&JD~|jrZr65~)4Uq`Q6eu=sy@Kx%}=jnfcgs?co1 z^&BB@RA7ruJskx0;{L<(xs;W?jk5}NH)>N(AKZuvDNV5q08C(o1@baM#0vpJqeMyh zUSGVt6$)7DjV`9R?qV}%H%b*2XZ+w{b`u!&%NR%F`J4aU`ekY zOM$JMzgEi}B_GtJB)O62f>Uw+tTAb7iJS{OD+w1s!+~7#1P$rPm;Q#89&KjanHC0v z362ocD=aAdMOmw8-?x}sk3pq{PlR|DvEUyL;9kPM%Y^b1bIiK}q0lHNwZ}nwAkziU zE;>DQwqs0)y{hiU6y?zV{zIa6-K!A&RseWF#_9wPJ&=o#RF>j!ut1k0-h@)rNwQvA zilX+hUf{Bo;U&!4!eD;U60AIU1uJ)_vKnr4X<@>Bo>z2z5=TBP$bl4LFeVGH7xPAv z*+{SUzFeP2Jbs=IH6EflCR-RcC+SASb$5NqpLRMk{+nq`U*TK^9}1P_i4;jKc>ZSH$f;=3 zQBoD^Mag$~-X$JMUCr61RquI^@`xcypEw$sc9%X1;%h(wKIuaZE>d?0sB;q zl>(HwA-_cDFi!87pqUX$qGJKrvZL-D6b}Kkz4*uma{*7D|B~j%iT37j5&X zG(*ls%t7f8KOm+3uRC7k6kAA=NU=h1A1MG@5fizUD4wT%P_3|G4orPw+$ z-W2V(d!aOwf~&H#)A_mOlq8nmXM%5r@}6|K2^PR`m`RNheO4-w)-!DD_t6?fQsV_{ zOTtXV0Ou@4N1A(^tVHLE5+&(ak}|s+^&7)KovUfboP)y~C$NqvrYNw(qy*0Dj864OlJRb$&ZB=%HV|L(OvtiS5k^?;cn;u#XZgn_ z&&UjU7DED5%m;G@ohsbzL%ZMEPI_yIS|L~{^*d;ogHO4!W)nUpVcC*T>Up?{wJ7`5 z9@#xx=N(}0nPg=(frEpmGC~ApD?=#E#Z8CP%qbg6`c9agrLy1E+}f`iAR<{oN~-i! z8aSxYBL=7SA}M!g_a=Q|fo{P`PbsC^t978Ko8{jPyRDdav-;kH9LvrA-CiwU2V+&4 zI&aUw#SFBkNREM!gEP@o4l@cMJCdu%r0HS`=`9Pj;UUw)-G-U zDi*Iu(m}4>bNd8V$b0hnm{i}EP)Ag7i*t1$lh-@SWr z2r`~kY}MeDftfHwy213#OEakVh-R?!4Vr!;5VJak0$P}RP!vWn5n*vV@GQiOGtxj_ zHVa@9CnDk1@yIfm_PC5{!0AXDUuI~5JuvbzItIEZ;#{Lo&=EhpQ++xon6AU%`EUhV z^SSceO`!+Ir`nui(vFe8T)~e-VL{C~;Pa?72)xL2E;GaXk?#CgNFrN{>;YZ}sm#|2 z6$k~e(5{JRWeM4_qVu)4;W3g74xMZS%O;~2?(Ig!TBQcb>_sWmUg6<5<#!E$c0#)Upx!!98l6P5pnT&zR*`-k zFx>l(NZw)R`m@=SU5o?=o^o!VC?l882E6iUR+D3-q~@r4YpoHCXd*}GO{#Mv)$o|o zo(hyU`<{^nhWHC`i1CQLZcbzMPY@Vj!BvhYDi>jbr}coLz-KoUdeEM>vM`4c7zG0P z89K1(bM+6RRRvV1(Jis^7jE4u+gpt~Xvl9Q&sN*`#H@rzXrt>o2kx-%>Vwdr;ePv< z+9z`kUX8ixt_oe$sfBh^)LT)0bskejK564o`!ypm35zUOhv&Rsd#k9U`u+3Xo`j{? zPMy)0w$wj9U_yvHg-g-*NBB`)B+W<~vFi%SNJ|-)CUj++jEZC*m0nK>F^#9{794^3 zfatFc>yhoG_nro?mn3%mJNh-*NN*0Dy}o@^q4W9#O)KBZqZZVsdh#PgGySIpMGIuT z&8fdnW%?3!W=Pi|6FezZSK_!^McYrd?gOYO`3-_LwMG)WxxM)=pZlX zqXIxMD~k&;J`qBnkN|-FlT-nv!{gYJv0B8^<;2*8>>_>p6zzqgbY1z#p2R%{m~ zU14MmCQF%I1Y%a@C@E96V6T9{+YC*$6|EM+B?_!##SOmxFn$HTMhU&%Gbgo#xdO<~ zlED#%!0z^aH}4E4ZahN7;UY3eaXqe}e3dxH5` z)iU?M5T_BCknI}-zw_xvWHuszZDkHsmferHXz&X(g54qs!ah$gn=j|x69NGSjh%8% zcdsC^5X;!%Sf={UQzUl-7-m#tGXy3H@!w zTW?L47QosKojrB7jvn@FY-URv7a5O)y!uaPfw#jI@c-)zN2Eoi$TA{MAHagR)o!G7 zQi-1m!tYhathV;>hLqOKEvW|_#?3?-(I_x!Pcu0~Uv|X0i&Rx2Q~m9qtrA-(YMStDt~oP$R)qL#PYuH8nE8NTZeT`0D8vEk(pW`w>K33pfv_gi&m z>7ZYGHx3oby}9)^bEQcZi@p3&z1vSKagS2aih*qA>5rj)+%$d@OzErUhOmh{(q;`aY&&bIH`B+E4(m8K;4Jf4V<93UY+*CK{$ zTGQ}@=kC>EaD)2#xmWt+jSks=ZTs!)W%G#90~3sv^j)o_rZMs94NbMyjiaZJY>el$ z-=MkTElxY%1uvl+604Srd23`bTTivu+0N~3cQ~kD@{b;w3JLE^_Yq9v`Te38npXLq z`Fdr;^CpsDb8n++kUdvNLPawehb^E6jk%r91#i|3dkPJ=Gj(urJWs#_3{l`uwGe1g zptZ|D3BcJz8LG(Zlfm*Qv1DcMj>{qE&TI7PhQrNP0 zxnX96*UOFEGOLOqB;dnfVqg|QO6TGl8n)-ay#Jd)IKzNwFf$KB<_^RZ>2m|k0Y3_9 z3IbDZ1mK4Rcz=#-8d-6ZY-{~@(|JKZ^rccjgw&Rd6poI{?<;FNt;FLET}&g=sW?Dl zCJb&K2S3$%Nq4RWM$h$^2))xFK=hyc+3veMJ88F=(@FR5JIR%Bh$IttZ`%jswj7z&rXpInk=ygsgr`YKB_Xq_*HzOtEs` za~)~9oq|TOQ;4L@*(o0_uy|JesoG4qKMTfLtPo3j6HJ5)0&-sOAtJ3UFFe;gK*%Io zHG$2k)PGnDZg{%lV_uwX+^6(FRHIzYWxZ~ZDQ?vVhD+9NamemTXuRF|K9Xuk=Q9=v zl?D9r$xu38x}yUebH32If+hGX+~it!*R-sxn;T%Quncx>V2Ej#M3 z+^TuYvwvN5@-L}Q?i1c5nM!R6Z=#AHepMDv-bA+rrY;-1oUOOnkXVsB2#YzBfb05_ zlx!S+(0(auy2Gt7ufK?y=_U(H`^|JIdRuySQABYF(T<{+8aN!g0rPoWTDY%c=aQ z0vBI#m+sHh&O^3#Y!Cd+^vu(H;a!;8CAeoK(c3NiGvPs>k(oMo)4Ls68*w5BbzPFg zEZp_o#JRXV(v8{rJ!A!XY!&0cqC?R6Ygww7kA=W)oTEwY@agVa*K?_Yl^OJH6nHM_ z7B#Zd5w-af6T;4!GzfjoCXHJk|70e|4xDp3M%L%?dEtGojaLg=x^B+dEj#1ILAq#s zJANI4oo#;`-Oi1dL*$b_9G#nB%-7U&Yta`&OG`~sh-f4Q_UXRGntlP_`$$(Wt;!IV zQvb3Vm|j;T?v9F}g)^VE@hWA};1TeT-j{8Xlp6$;Sdu78?m5RuAW!E+wvgVAN?^pa zyD9e)TKIFK9Rdui=dWx?@M9pyN}`{MLy&eNGfoucn<4ZN7eUtI)H{b^E5kSwEbn4i zk{WRew6nCTkoP=_ygVDALHvkQsqyR^ER){{qT`$%dwf?(Wx z(ID8|P*$Z1r~?R&l13FSFeJcE0hrnE597dYm>&Z}AV|~fs4!#{(cDQU0yc5HvlgB^ zaqAY7rYQS%G2Upd)4}q zJ*jBoco2TCsy&+p=Y|WZtk4YB=US_w9AT@zFd^}r@R#xt7NYM=3HUY%wy@~2jyw%} z7Bm)#Gf9F(SrC?lm=LbE=uNs20CKDn&y*;X?;`=B4}(U^N9YSpdPj?XkGUq=qJhtS`#JRnNCt#ST|Ax?hPqekw4tW|3sk+Wa{8n?5mDhc1R?is+A4*}FEf z)biYmlJ)NHZng1${{3OWImWT)l$sMqDDJ{P*qiLeiYXMOc?qi{cFKPtgZ6B_oqC7q z$XkH3HvK@7Zvx$PW}G$bj{BaPI~?Y~b^Y{FZ50ZDpk{)GvGC@-JQ|nau3GNe?et?N zT>P`4+`&Y}5dtv+uOM8N3q=7_rLqeKS{F&}-i%sM&&63!&<8A_=R8lilWW1v)R5hO z858^%X(WWx?%sqXDS{K40ly(*vwsk&Y+y2!Qgy>E^U;4rD-jzOperjY&M`1RV%|W^ z3n7hEgA()3^S-on)j@bY;w*+2n^YG7^yHG?K!SmUDIzc?j34}51+!3E01hjcEG^g+ zSc`S(E7_ght+{18lq1fpjry>ca_K`=y&CO~wY6B}wj;zNEn9eQKQmQiUNC3;MIF?| zIBV1y(*)~kSJN5`gY@(^Q}5I`dk^Sqw*HJpw|*w{MML-B7j}Ag@T1Mg*MbgD-7dB3 z3p@btE?y!p< zMd60ZOd@w0reI%HNb{j43QV-bNNJe|5wm7K=8Qx>1UEP!VU>&!;&QYkqz$C}q;s*R zQ%J@!kEJm=F9eyR(zI+-j9G?u;a>I>w%JY3172h>TO7v!Nh7x30GxB9F)AQO=Ug+V z7<#Hv9Kw{0M+QRC%S47;#ETC zgpsQB0`p3tCs&=Y*w5u#Z037*VYn`|72oaoN#($+EF~*~z28;u>`#pxlkQl^0Ak&7 zzRPjrYx4?2Q}6wKRR=h&@&%QqEckQDpVUb%QW{0ol?YF=AP3^J2)LhyYj0HyHIbC; z$svI~)LKW-;0-swvF-_8M4?5bnr-l8Wl<&4{sPP!*1q|$^b1on}cZ3Ltn@W zktuD3&_6~F4WL|_-48dkme6*J53-ztg1+ffn*Guyr02~G_tngq>{6`^^WDspyj>!G z`SUNYCdV6_*FW(Ieh%{k7{%VDd1qbvr#4gbzOSxx`QK|*O=5ES{v)nQ<8iKT4_u2n z$O=Zb4+mw@tIxZfdMT>&o7gh$WP2bFW#uK8?D~1wo8w-uhntiuoG4@vrS%hJFkPhy z4tG!EKmFGVCFYr}mP^u^S#bZ}1hc~hPTL22#9X|5w)u+^IjNaoVDa`$NlJg2xr>bb zNlV18>@920jzqb#i`t@=5!?e;*#{fB$`^05`@Yydy|}6lw8aycZNGMBp+~G9Os~;kJubsDSdil~DfMUC1@!x|% z)L5Z5TdKIe+a0T7UZP{ppD#rVrkRd^p_32PN`yrNl59g`%`MI~cqXhY6z#1}{$`j7 z5v*lXNbmB%=e;SUoj}%S#oj6b$@)k<%}20+*KErwJ^7 zcD@GoRvcaf?qHI02|+)Lt40Oqh20>h`F~WpkbqX1K8H!zHB<(7F&;FuBc<4Ei}0aB z3l!BLP?#-qdzV>_EcS|Wr^d+i1y0wcG}s1(NnzS((H}8Vv`4T=DyV2D`J7R*xVVo) zrGZyzj&QNqXmFnr<({T`LxJm;p7TlU82b7pDO3(apNoy#+|cH;EA&s{>BegBVhje|!`yEj4g>q6k5!NgGz)HW zfHm0!#{xE{@!co@tbo2$=fI|`u>(JX*$%?Rn!Hbd}MR_ULqUXlk8LZnL|L9&M^gUHScYD4bVw1-=`rLN;wL!kOymRMh(Yfrg zW?o{*rZeqvJFae(?gmCh^4_;gPEux7BO*Arxl4nY7^2mSOl`Qs^@rgx{ZhpE#HMvi z7M{Vt?KSteZA(;BFoj<4mR!1Xmi~+RkmuY?rtNh1zd%8{sFB>YSpq2KO16XMAC_ej zGtk={AdtuGst6)OI(=Li;<_*u?XIJpodrxPbAAFz;HpnY(11ejrH=#s{Bl){+4%cyaFU#aL#; zU#|QjItqkI)A!^Ndmaw92|dYR^K__Bc#&)_4Qn^6GH)o+Iy5Rl!T#?uJtqq*J#bi} zi6841q4b3*&C6ZRE0KnD=*gH{3EcRW$4>zH>ng9G;oJyw?>k>`v)=r3)XvpuE>Rt= zr{aRWcQ5Pjk6!lkGd~LO{>Hhy&2PTh!}Rcp$nh^MFMquL9ay$Z>voR_cx2>6F1VH6 zZtHxxPiGdkyWx`e$1BVx9oGq1hv!@i+`Q?Ai>S9DKpJpwCOGmEU;04$_c_y5{?~UN zt)=$uGWXedD1(h!Tckm`DPOX^S!o&3k5a9Iz`u2<#_ueq(Q?-qk?8NXR7uDF@jWcUXlcB05g4wm^a5PvCzx_ z;AMv6pOmP6NiG-B)Wt{(>MIIMHFg~>Jc{aK>~j_^Bg;5QzeimBEL^y|psoeYK*w2S zjG-uKyo4T%^hZS%UDqhAr9h`5d37BXiDgJUC>llge0wA8mF&pR>g4Qh0&YC`WUGo~ zCd=a>GzxS-Q9UFCy2v`1BRafpsb)18n2MZn+9g_8Dxh5jyF{=@j=c=og@1=M`&A$U z!20^{t>WT^F|_ufv)zUQ2(Bs2M8KtUdlsMO^aSn@gMzBAkbnXEU8_Vt!Cjzn$OMzr z)1oD!fY>F9Na@`sk2#h^*!87nOS2p zkPba-`TKgzd{oibwMwUl0li^_8KyU$Z7mP+4kIqeQnjl*b1C2}nsIDi7peTm;>dR} z^}0vyP#6J-;?$6G$#=CdKczWvKg_@Odt@aZqSSOa@WM7rltVdYDA`b9-WS6M-ijG5 z;Pa(+z}g`7v@e|QsCF9i5{(rFt?L52>0>jsd6x$eIu!2GgTuQ|FK!GBLEJ);Yr+Xd z^yG&@WVJC$l&1?0pH+uITQ+m8bmBUJzdip2me70AZK3O0!St=oKWgk~;RE8+i2(&J zM*P*4a|?;{-n80joy=3%nYi=(H;^Ohe^7MpflTlJAOCD)L#~8Bngou73$QfzQ6bH|MrKr&*%Mq zzn+ihBp2eQO3ZGJqO9qqZ{{Sr*kvF{R&VEhe7l*MHXL`Hq@ z-g{9##58!%c5i#{YV03hP)mCrP@2-zOn!36Ey$rzJx><55Kjzq_=P!3Sr9oRonvPV6CnFyN(jXn_b|jsmG>ZI_373!5x(ET;`JA5$MqEp!N{**4E+OQy3_Yh9Mp?2MiCGfbRg`cfSDI5W*Ah6$cMTkXQ1%78nNR zsjY;)(gV`o){ZooQaD#-{daz|Owibju-SN<6ELrb*?^RVIt!d!Zjr`sk*=%a!Jab- zQBh||(P6(|q>>d7m(fW|>K72^p+I>F>0`oO;OF7SGe?whh%!^O&n_hU`^1~SPPX+`l-A~or3%sKk4+D&oqvevJp-v}#LG5FcP zv!&l?lfup`J7SLQ43S@RvMUKX?wOG!+jEAMGh4NQ+;;KW71W}L;K*$Z6tYkdX%lE| zS68nkl{Jl(`n`j_a48P$0RRcBpc!synWt=Hb2})01ou;5ZFIn56+}NGG6bbog+p32 z^sK{gB5oxLMfz2Fa)P!k$FOufr8;1j%%pX{GN>prv{G#>Drqss8f-0t+n+ z7?V|g){&|mMe*lK?46(yQFtMxDr1>8uDds=1H*Km=QgLl^jXW^*fQ`rN}x;;*lp=O zG_O@^f3Uc#hDyJ9HFCZ|FzNCE`n={kHhUaeCgD(izGqx0dzA(urJsm(Y7%rXMHZkQE|l~L z!avi!qt_nCOfcevIyYR<8dAN-@?l&8D;Qw^x2(z;+G%32wfVc!cDsixse!0{JWRu+6##wh)?pB@fXKSdmVc# zj@54m^W{u2rLF2td!`{xn>a%HxBXBD%&*!i&fmf}vDUF*P>~zZMmnm5^QhXtcPC9V z>#WbWOUmDG8aR2CU*tk*YKEegx4)p&oX%mn(NI?`*w>eUO@*-+N@}t#ptb5CBgHOQ zgSwIq{0r;Q&D8! zF5?yg>aFVcfjXmj&bpLB3w}JLNSvLf``7g|g9#8>w~A3#bxjK|M1XH=SUT10rk6Al zpqCQ9{tZ{o3$57qv{=l7VY9rWOYK?76~w$BiG>#Z7U}Tr@PiW0p|jUX8fghGQ5AxD z2)i?QDdAjgxYg}(lKW|kQi*%ShKLtyOWc<%+I)NjkE(Uwf+Cff^JbDwnaRbEJIuj& z&r}r5)1`$}JMq`O_`Yt{&o~gx4ID@${&_nih-M?s!xJxF_U=NM9CReDHXe!=dD_Wi zj-jwCboR@xPiWEdijr+z7JRY9jX-r<3Ah_B%Ssr5x-(8ad@hdZJ&wNIH&&Fz5r^YG zhq#CibTY~(-ULeIdbru;NctH|;`hG+UmeNb;r3ESrQba0f6MiC0=GGJ{9G*=ZqC`1 zc717gY3HY2Rgn*JWHYx~tCKWbdYpCCy~5Sjb*!MUveuuNYZJA7GukTJo`UP~D9Utm zN|7_XV_YdV6r1IV=5-0t*R|+_)-3oO&LlIgtC6A}!F5|20^-l_-HK+?DL&K9S(@Ah zKmi&RZA5j~t#GE2S_)I)0-HV*Z(`VTu7r_@Sr4?+JL3 zL3D5kyD+inxhR3)U-z+6b~Hw`k7@5%LHMBuO-zz$RKP^A897C;=#CgPMPsCTA~e{8 z2$K-qLB})5Q$-`A&xTHfW2y&|dkT8b&nsXNKcra>Q*`)x)rB%6i&}3PRe_MDQK`*t zv+AO$s5|g-fhfAdwfH*aQda&(QT5|#9n0w|ahKdKT{hq`&a=InwSI?gdwaWP_!e#B z{EZ&|A9~iqnkFM&7c{9ye4lMP<<}g^EAf`Ab`+wK z_o?;iwe7yo#{Nk?$(a--y1t^>O`JiZafugDE@+Qrz&pgxLLP!#(vfMHES{{2HO*5X zz~t^tKDWPk2ds0+!DSUZ8N_>JvE=M&@obF;vHd`t+gC*pZ|0kNC>lR9QTR z<|P#ZWZPuKGy{;)(AoX`sC=R(zYaHt)-0^b)ve_su>YSRC(KaibplqkMupl*K zk(FgWRikPevgP|5k<|-Wc_bNZy&%C(x;joAZQjLC5xN$9(PLfwJY~g@X|d?)z0)1; z^mTWlXeiHozZ1b77s>zi{10*{;|6MArbGQ-u&N zTZJr^Xa9d`fb}FjD6-h;*#XYb%`0Fk_W0|m)bpboE|A~n4qx9TWZY6)UqSA0W^bP> z%&C!%T~go=Z9)_=TWFw{$|U2W!vtJfawE|*!qkEum!k+Y=XYyVErvLl400Dm>&xQ! z-FvO6CW99$5iX=pW~&e)q$inz{xB|!xR)qSNFqU%C>h7#3o!`)&Jv;mn$DLcERyA- zO{sPD!>6T8hk6wjCyL|I@+JUKB#tft9X-O5SbDFeBQV6U&?h^{=$Oq66&& zxSG!jTDsKZ;7eK57rl5~6x@*p2lpQ#YS&wMIqze_pUOek)!b9GdmRmx1fU?+6?c6p z3Jt?5)g@#3_v-|^$cTvkfMznzE&|f-Y8@*JMXE5QUT8)lePqv-1d(w)A)?qMSsJQn z@I>DTnkV5%+`$p@jd1e+nb*75b-~G*!dPpEz2pzf9H?xn|IDrDzT$cC)o-35YoY&;))Ai-U=PPxeCX0Sn++)mbvq_ zd#$ha?7Vz#75{Ya2x^D<+7g6A+8|(QPyF0a{GCCeeAPvr8u&FjE`yHV72`}`16dl@ zYW`|Y<34aogdbo+Rn{-{R>>FMGK9Y3qpf(it=UoRFd{m+4WIsCNkLnU zCuS&7ux#XQoAM=q#m0G=9>hulACxrR)|NYa_C$Bks{WHfyZKb4r!3pqgOK1H>>hx^ zs$nvghdb32(MXe^(i7gp)FDrV+$M$bLqtJEqw6dH>Q67*Lm*Fdi;D6eL6^^jo*vF{ zk4849ULG=yt(JR>bR}7RnL%r?6lFkjI2a|JMO$47PESCw(?IR2mJkp2wWm<*6K8$L z&XkWAM8?i37g!QO6+;LJV>yp{$d6q0ZLBm0MGxo6yH*o5I99geX@`4&!*da{K~2C< z^bHG-`au_@CUH!d$kAZrdbtOog?OM&kcR8tG%Sx)twBF($tHc;&oM$5)WV%E zh;4~|+imG3hxf%K3xW}7<3*B5Z#uD6BRJN$%)se*5i`qG)6`08IqA6M zqQ?HuTB2j``9Es|T_%e~m*zA2W-mUW?M^TAf5U7ilf6QXj=jZu%43ODfJ9u))CcBA zPqJ4Sv}diLYEo5uqPDy|Y?u4pN7UT-<-}+Oed?%noppcB{22S1$!281^G3p`1O!2f zD4{5BJLn&B!vnfigm36Bk3Q#$U<)=B997}x>L1Xmo^EQYF-Q_&T>F2_^Ta;pd^d%u`7L=ed6KdDdNX`} zP;Tp({ElfQK7GTInC9T#_UorNQf3v&XGcoBO`jzStaWZT5&8-ML2B-e<+rG&I?*jr z;&B<0w3zKZnlnWwPto|Zpecks?{l(Oa-^1&`4GHmKggMs_r$yj&|e!9Soewce$wkf zzGpb6mXNDpuT|tx**eo?Frw$3tHu0$HzkAo>ufE0^WF6Vgx0<*IImJo+A{)h+HVuV zxkEF-Ayt0ww2t@*fqYJdCvvF}pyTFSAjP-6qa-~CNKmR@S{qVQ*9bW8PCm-H^fh{) z9#X?2qa&t7NG>3hA61N#Qe|lqx)tuQ&e~P+5litz=&fDPLF<0$e4p-{Md3;Ao$Nxv zrMapF*m2p`7enG7F@2cxHivn1jO);E8@oujw4hkD0ruZvPkP6PJim*}Wx0+uV$C*9)^M0M1gS-4q4IFBi zj&yMm|JS|95tJmhoop#?3~ljF?#?OhOow3j3CxT}y$cvJObK(KoW1SE--QVYW76x6 z=qHxJ1Z>8#2L-3N5vM-2XChIx0dH^GxyBrIE#&LdR)%Jra&Pn9(D=7iegsn#8x9lw zT@3fEPq~>^_gEuvXDJ1yww)dy;}?BVdbne7G3c~2p3NjvSuHH7=h;)C&fb!M5@mi< zx{wZ#1Srx^Zp3h@Z?*z~^<~)+0~}?rfjl(SWn2Sk6sCLBO!z*1K@et%z;v(5$)dg3 zNkV{R5b!V@h9-2l-!Wi^Y&tqWeKog>)u3}DbVNXhu+t1*b7@)SErfNgFLXg>gb#Aq zDcfuLKk%`rs3@wb0n1}1RF+AxS!$-K#Hi;(&B39lTKGazStr`A?hPQ3G?Ow3s9w1_=Nha9^n1knqG<3!y(r$>ifT%d&w=V51zvU#)nD`y|IW|5$27Cg zi@N+oed5jW;8*qLhH*|QvOd3by@OOg^Z3otAIywrey5a~IYR zbk`SWYN~gQxziPUyy7}&-|N+nV%qB-?L0hCpR{R>RY{2?*ZB^R1K}rDM$~O!Eo+%q zB-l?>xS>c2ZXpr;kz@+^X`DCWG*HxYRU?2v|K9dsb1Dw(AGvFo$;$zP*F*u-TX}OkQRopkv>oQi5CJx zoi8K=kSFNI3S$W_di4+s(d@Gq4RwT0gw3fCa>P0UfKMP^$l`L+$uitIm5-eiw1c8^ zW>^){BQLR4%ghc?(FH(n^5YlB!fqC_7J0AaSiG8GjAIm->V5j2qym;C!Wqufi@Ewz zM^Xd&umb{HDUKQxc#nTlK!EoO;rnER+OBaMdm&c&O{IM-OTe*&0EasHK-ku%Fhn6x zwf4BDTD~_II37kT(wb4Vpf_>LexaNNvWGm43gl6m#q=myIG6ENv2Gu0^cy%tJk_}$ z5A7NghIM%JXo0gNa9RT$o+?-~_Nz*xRJv3BCU_#)5c8g08Z77ZI9Xwi0gE#Dt0Y9D ztWWL|pts3Dk-G8>fJdMrztH+{;@yCeF6Im*H1^|1&tI4kmZ(}#-lr!Vtl6gJ?>_Z# zI#zt~=OubQ2TG)VOoLw+6M$j_5Y^JFWiRvMhEgtMhH59M#`5kE{6*@)gyE9HUqgSH zP+i$!ghjCBT4ChA;5%oNADVifq~G1K=h~sahU0_NRl277`aHS#y3Sv)roZUi+p0Xp zXVHni;@`P7urXH98eMU%8)7m#1b{-z%sl2Q;!How?n9kyohWj-fHt{t{?-9;42iwH zwKM&i(pJ4_Ms$5KTUcxd>VdG92%p`j^QVli&6y6;rlisELn11RVvj#hAf5rbhvtYR%4 zI_cX5o~FId`JQcxmG&&YET_wmg4`El%udUQo@CM7S=l0^}Lx=W(1Lzc%G!!5-7UO3H#HH$&(udmjRo1VyxLaKIU00 zwsuL_vVm~p@l!q<{w&}nABesC6*Kx)LcUxxyeTz%!$4)#j`c@f0cITRSllmv;X-=S zeQn`L4|^#BJ9eSIVGW|cX1ta#8nw+Ft7>(`DDCPi(a`-dxx3spEpw4UbO&mQ04Y|q zQgp6{%X*k)Np)k&)#ncfkshrNrr;;s)K{@y2X?J#zqaL^-{!KDuOt_49&H*IAstr^ z22>q(;teX_6UFzKaPCPyibutNrta6m1q($SmKm`#eN84*1%}1!_(No~1 zxu<+$Ut%GUNzE#uY;`7}vhEEPfFsuL3$lHt(GcDvh$N3Gzqoo*9Bqlvvg7oo{7g=t z28~pBo=Y#z=M>}+e@#GTV^W?*iOU8W9{Vo07Ep-i$<~QSqXp1t7o0nA0Bz~h75OGO zQU$kl%UfH5_jxK}BVACnD=-GLKb~so2KJL-gAxmj>YDM$*AZX#Uvfr(BjT2;sMAG@K=uGc#=LMogD$sndb@L%khTbdIEjxM*z87AaC3&_< zE|UUh@7+%|+bw2jU(c&|HKwmx@v5Pw7g~stLC04{BChgd21D`b*>PM}{-v%&frBMf zPtq&w8eO|!O+JF=n4(Xf)4f8YSLEUIt2&6AzgG#z*0d7Eh%U9x+zvvUAJGjCVbNdyjd%4;EucR{NPg8otB2R6)~3A-y@m8!Mmn8Q zfU(JG@f@sL7u2(Si=*rxD+g+IB9wD!o~ZSywS&{18u#!&0$ApCWhStxu#;?xZiT%$ z=LYOx-Rgy-=1pEU-?47c?7Q*HoW5My_)B_yQM=jDV7(1#p3-NuFb-hf?#9c zr=2Q~0^hL;N>!2wW)C)1Gp%EVpBV~MJ=`-GJe_Hd$TA2Qy@?lz%O-)m2WDhoXGk}0 zF~cY)s7K7}5)0QR5;bCAr?Mt1JMutFDkkqk`YFp{@?`9&jl-X~n4JNW8xC$L+`tQa z`;TKIr``ta^8H)t4nMjPx|?ghu)cXa?L(-u@>N4#_1XSgPABErs+R*%AVCs>oHb%` zuH>+?RT~HTEueFHabL{w=72~R6?CxOD(#3>9w*+{y(>#j6+~=x$Qgn3cv0(T39U(e zv(Q8OVhO13EXffUZX|!5pdLHe_uuQ<_3w*mkk4NxcdOl(qp@q zx~+b$u(F(=$iS4LbXmRsYSPNNU z=a$ws^1TZ-CGu<`uC+z6*I6hkUGxPqu(9>8S2a5at@3Xq3idJGL)akQvpa(>C*Y!{ zsV2rPX^ve_L+`kdAO-95cfHtjvA&?7g9xR9rqlon^5X=9M6iMr`Kp;TG*dv|ms16F zBym6Mfy5<1%@hCVg034S?Ai|fUV0lv!o})R{p(C<{ zod9F7Uas|>RfiJ(Ou7}&iggra8vYGX%H*Uji4XJ16SrWhVx@PtP}8bNJ`n17#kIMf zwq>kI7raGWED{SIs{QL=IUnC{g_FQvMf_WnmRb!44GF6 z7Uj1{P|=aog_%S(h$v4F9q>wj^}=XO5g35jwdLsc?>5U*PBfS{_@xizc6zaFhP*b# zH~#+!N|2fBWuJb?Xiihf_aNVk8!eO#Z2$Xd_-xDw&3Cp4C@`mAqhDS({ zXL1*kvZOQ(ojoix#C@w&feAg5NYSn0=a_sVUFv2oX8HGQ zYwal)1Czt&&SeFxn1~*rh-YGw6CYk#w#l*;XGq4o`t=zkR%IOVGDpRov=SLwyx<@$Cb=&|HL0WH&tv=dM zL#HG2>5ZGXtlF*(-_g4qQC_8ExWtMZ35jLa5m3upY}*9$Qlb0L_u1w2#0##Nw;ZAE zhzrTnZWi!JPm7<|Iv}={V#aT+kpRfnNb3x~$bCJzl%|R3#eW9{YbrPb^MVRb`lE3X z(|9=F2rUR`GY}OfQL4;=lSmWS zCcqcpx#A9dSc8Qp-!iaT64cwI;DrhM1@12=s3^WqR99A73z#`c%8A4fMjZ(Fy|Y1} z-k{N8$7|uH;$f+T2%7??$8#NJ=2Pd=11XciJbiHv7>ELn12I^boEhO`H``?_;80!u zp%Wisl^RB41ggsuOQ!LSaUtHyOuM zV_avao7Xs*u*j;d^=%}W9V4%8w#IUAk|;22u{2xR*OVE_UWeOi-1L)p`9<6cOzcpR z?9ZeEA=S!eC*LG(LOZzuQ{JcZOasetYCwgQ*Ecs;v%upcd>Li1G`HyHj84tlYb_vswvgoKAKi85D}4PA~fr z)f&ho6FbWE&;OM+LQ(qet(sE=78f&OF+cP$QS3Ce`Q(`WBK`FUNN1ZZA6&Y?U@YI zgLW!{fi7!C)Iz?J(P;WN^c&qu0^DD^S1lka6A!}Vc0pdHj!Q&qZPQK%2UDEScMRUz z_I>zbdxJqrt&zcFIU<5r(y_z!OK5GMrMbnQndx5lQ!rlO)Oj=K?#+V!8=K2kV`4$| z1DczP9mP(umjp}l96wdg=1n2!^a5iiHSwGa=M`0zyrw9E5;f@Yf&6Uo)BKXL1Ro$}`D z5ypt6SZ)#sevbc`&su%g~FGwp$%UIUzU^IBYLquX2?QeeX$At||m`#&14Ezpo)#^8Bcdk67J zAp{a3!H+Ho06ru6M2lK%C$g~lgV`E!_dlvNl7dM}@WS~kjSD}3a}U#@X`mGSj+>NN@_{Qv8i+dEuW68Sh$Lb%)h>ZYU! z6kJ~4>Q@6LOX}VLfdCow0rcmna5w%_phYR4$a0^iQBk;TWlO{=a2yTxq-x+6q`MLn zR`oLCT`tM!FZ@N29ckGa?sJN5;!lJQhDCY~^*u*9nhKzXEQ|1`75}PDD;nQv9|OAY zpA&?k5npD24prs47pCp9XpvZ;J}a^BB38u{#o@as@KS8kM`D0R74>|ua2`EJ6l5St zk2dZD;pR0*pgyYkzEsfc3ct9ZDt1^{=;WBQrTC>6CGb*(R$t7q(1jbVCE#qM*o9l3?q&e@~ZK_Y$911DDjn1Dfrf4xv})>NpRm0Y4{~J(;JY>^9n& zJghojxoguLQm(Hkp%1>@4w>9uwt8!uwO@L>=qkqHqQ+U7EX^jFpJ_%5;-X%P0wx$> zPmGHQ$eBsKBZ#cTyIh%r^EX~*!)%awB?0+6i+3Z=<7iJ2jq{BY>7}3 zkW7GYt_mU#m&>0DMd8B&JS_+suU$!0G+^V0ixp!ku(_6~Ye`{_PDzxDSNvQzw)&-e z7Q`%R{Mo&=31?0{VNOLfZW{<0ZM##ubKrKfQ_kfEs4zcot~PPqGGmi3#K-mrEZ94b z*U7srp#iS!Mi|Vd6ji&v-R4FRdG*3tFUCkQNVGC&6!hITb?8fkD0Sx^1&k|?Zhf4D zKK@|bw_9s(0_7e|D(JmbxNfHR^5G_^TPdat@g}J@Imw?x+cSeA-eR;*_BVSTgLOvf z%Z|2nlAiqRgID!YeR)x%5+iUNb9Bx}5@OrPBrDKXw%sW14(2xdj@w{Jf?RtpV@lqQ z@{0tnMMDx40<28$qxxhgI(2|~lk=nR&Q^cnb*p^$s4}h9BvV^+P!UE$ZcQUsYZv8? z74!>or$euyx&5b37k=Rg&e3=L`Y5e$YE}LfO>M@s7%o2Kl}nm=UO+VpIUoh=p>wgp zegfoz=P^q)Kf2GjLgBg|xoo57zW1C6ahh!g_@W)hG-#6UFBRBHhiD`XWm&hH9?tEaWK6cC zX&W8PO#IR)Xk}vYG}u#h|&YDU6IbckEMuP0(vR0OqilDf#Y8+b zw4M>k4t6S{jt+^!p-~ADZY9c%v*T>lCeYA=n@NX&7KQzOhi%)J?~alOx1QZ(wy%HO zt41xkR5PLqKXdu93s@5B9_eWQ(!&HSNSCOf^I=3JW^!9A{d)`_6n+i^n`UvB!M0F8 z*C@>d1MeQ;%Y=hTlqOr5f~o#o5rL>r<*F^%;R$+>m#@2Fh^y#1+JJQ~F9gky3_|68 zG%V_HkiCvZ6d#nYFoZHV|LUkwU>V=c?G-pRHzy}UpOZ53>W zse-dclWGCota|y8cr?wwDnDRYmSyIU=z6df?7Cw6Ea%0Z_A;h`!LayJ&7$+DiZeE} zQHiQTEz|wW5NiJUxNYO2n2eUv zj9@-1A=>iitRe~JWP7rZ7a5Ey_}-1Nj0_MV+**Po=!%b>>A7*AD7s}(&Gm+1)nZlP ziY+;zKyj8=wPx8*63qFvo4mr%YEx+D+a-o&JRu!R&kPFNy?5!&??sl2Fl`Exl~)&e zTzg1tLfr~{;b@cb$Kdspw#2N++Kn$I#HuCp{S#nnkf5wBjiy<+43?Q7T|NAFf2tw3 zn0aQ#_duDz#6@-?b$|Pt%fS0|8631ztK2`I=Y(;JDKg?dq~IU@4Dy=NWF$Nv?t6 zf5e36RZ@lpPN|p?(TTJ8cO$)(Nq}}W7-@97K9tOoClyBkNup8aXphLl{YQ@<1@-B? z)59!|khmzakuayFhZ=W`3`ARf0XAi)=~KityuqT^iEry?)ms!Ln~&!VMOzkJW#@o; zao)rPBdYlMOclxX7w2){l`Xa8WE_sQZQIL8dVB#1zNKHB&kcm}I*5I~wrRSxPQq}Y z#ydL|rj6&s^c)RbloO&tP&z@h*A*qKuwW-y59sG6f;|Wtc%f0KuP9ERya(ObLVz$j zdpw`@g-jC2N6^qPaEK?poKv+BG_L^K4R|_W$mGCh+LR8#T)MYyI9G;pM4RT&Cc^S5 zOU|4^LhAh-k0bDgvC=$Xee;nOr;h-EF)st7KDeS+`A6xkl`*`@2^#X~UJF&^0vk8f z2=fdoA-C$dJXL>O=$Sos#;FX0fA4a3?-L8V60A=r&K4@Vzb(oxS8cO1p*u5#4y7P- zDasapOnw0X{Zf3o7NL-(_dSIH2><(a2XVIyEbEj*39Ma-_kh;#Au(h`zCqV8l-ii` za(zR`GPZ%n##G5TUfjGn$ZLL*Dts|qQAda1!0xW$>3l8NrxAyZRS-hwl0i@`C;Cgv zR0tV=RFtDsATqu_jut35D0;PCwQ2-SIJ=O)iEs8#=GDvMiI3Q%X zttwwT=>haX3WLk2TIHx(d!HzFZ^n>V;v$)WhR@=LH9HKK9j-_xu0a&&Rjt*1sUqc) z1sSd$A?Zch^h4KN3oQqVZ`@o8jX&?L?OZ(~jFHcrWcT}6wjavO^PBM4Wa+vwV(=L@ z&d#U%x;^DRKbkLFSll^8Yzp;DFEktal{U(w^M~c$Sp?XHa9r_*^F@*CV(}KAMC;pe zzoqb1XFU4QE!4ba%u1oFeC|@l_jgpKVW4R$*@@MnkpyiX$uKvg#z6b4VUibqnSebu z9@op-wddMPB7H%4Is2Y?o*Fk&(Q~D-N!d1g(Xt!7_O%on;&iw@0szWK&X1KCYn^3j zE)q~)3~yLVk8W+Na`4GA4841Ox?iwll0kLyh8=_53> ze?MVhIqBNVX5W_s2RugcO*GzBvwqfChEEs8J z18%i6Ez@w0JcR#h%l?{=e+ukF0&seL0~34lr#~XNg)Y@w4@f#pEX(tKt*C) zR0WTgeD<1qfMdqKZk~*TQ5u~63?%I-AIw6UFr*<68k(L01}+ME4#x}d%_MFzYM&j! z)Fk%btKg`@>>}8*e)KKLrtQner-{HDd)nZWtEb?FZdI@BNdS1wbsQlp2T;Az;(_cc zdG?ax1fVE2up@5li^`8g3!o--*1w3xm2SjI*bbD?sameA>=>-ozVuBMm2U^>>1W8PLZQ-LCyql5+ICr z-;Jh%Oo5(CM&$yCK&IQVsey2bjDJai@qmvd9(zo`DdFZL_ZH;P{j2J4{XX zJ51=@t!%eVu&gA{te-hp`FlS9RQ2>$k(H)#CAw z-n!4&lQwY^H_Q6hi=|PgLegJYw%ZG%ZgZPmo-CqZ)SougxLX|>Um`9U6`hGKn?g)P z=Hg>+>$%S*Qq4upf(|aVBiENz!7y}{XM!6eMv56}&q^~%4<7oOfMQKE9IB^i8PeCD z)y@?RvTi+d{{A#7B_%P_jP|0MTTy@>O+*fimBn#=qc>;q^}uW*0Cn@j*QUak^P;Uf z!+UnBeVMCCR?m^LhYjdqqo14xAlk+vt{kXKn8g$O@H$cw1z#hWO*EqiLtaJ(h3QFP zq64+~a>0MvxM*JmzuRpeQ?mj5BT6$-tFoU}x~rd~4~`1ykz_z)K)4Y!?i`((=@vwo z^?PR!OjWjhOy9`##`Po*jTNmk^5Y=ERDM1x?&-Hup=jkYD_Q_~w%Qo7mYr##=s0Ny z7Bzgf8IriM93HpzS$tL&CxpCt1)uz*G3FR1P`$zd2YY>v{T09X;a9e=U7Y*MFa9Yl z^Y)$N-&9TH^he0HY_X4J!nC}N5ovXvS@iYjtWAU5WwlM=xK6r z2s8FD7~*n6skjYy-xzGF*yZmiPfg(!{I+STi(FI~lW%V1c>ZeEmA|%pYQA5&$d^#` zgb|ih>t2<2V2yd*hlH3rIj@r&PY{T@*Y(w}ccAQ-u=ry<)bf3KC3_QY~RMVzux*w6I^fdtnO;$k#2w@Gdj#w3##T)>a zvHrhR`5!t3)SFF^2vVZ>_a0o2m}%~<*C&bfK+j1%kRko~trC$zs~S!9T7thj){G*z zaOx=|b1Lk6jyUVSIgRu+rNuktY#~49>Y_KBz9|hbiFxO*S%mip8C+Vh859W9t!#QN zD{6Wf{+_c5fgm?K4>hi}4e5M^lvzrQf2JiEo@Ba$(E+$)>&Mf7a7nfHcw3=81#GBV zq2DECN1r_OTgEc@9vnhHhCZHVJbZb{P-10xlBhJ(rfB`8=Czs48)iJXviJyxQ*~uS zOyhJa@L&l5niItsXgu6!k8+P=L!KY7)Vnc))E4zM%PB zi6LpUOCiezLgk#Nkr$4O+v8msjT1^!$Bj zeFYfBl7>kk1J8L<<{QnGL4|hi0h19^y=VUcxCrjA^1u;PLF97c2_4G{A^Bb{KLNC) zNY}e!QJtm+|KQ`p-{?DQI&M$lvTQcK5lqL9GjXH5*ezFlY@b=Swi+aumn7=@BA+YB z)w#OJ9hnXWu%2f|H@Z{}%7(^2ZkBaP_&p0Z?$aVDzg&+vjdme4oy!LED>1&d>yrRE zR4KO(M}{my)c2fl-P2;`n{>;)%QIOxJEt(}T%pmC#;?_wV6?~!<7B5U`!-)t@tg$} zbulwW_`K2Gti_zu0JiPJ_vVzYo*D&Y-BTP^kuTsjvB|)EdT34;%vVW08D8bv6M_ZN;J#=M`P*m_D^hnvKi;jrckO;}eCXGUOVc0EAKdcbty58y zpwq=>c@~NplW#O6nh85PXBJOcX&*%hFA3}$*f(7H>G_G3BfUxbD=YFZ-PSa`wfNqt zTDU^HuIFYa>F|1#p~nAAC1tE(?ZRV2Uq0??3-}p%u01~{qvLKS!gqf<`QwrjQROA8 z=O|UCZRv5dJBOJx%qw#LUH*Tv?oVsaa8okqH!8nm@nt09gZA;Hh{1mb(T@-1tx(cB z@KV8!j_lLVNoV8A@ZEWK34Z&D)|i3WlkUcv?9SeEMSaf;Io?;U?z^}=)bxrbtCGB! zJ%?YBaY%Od`mxBUslaCjCC7VMQB=v=W`DcQ7B6>oV>`=GGgq89nMT|?3~rCscoaUg zm&`TgRx&IHN=+8{Zl|j2yD9Vi2-B>jv1Ui}bUId}0MkW~QHC}{E(ZwyJq2VPv6BtO z74@(((_BCS1g00D#nJn^uMcz?&Hg_D&Kp`qBN7>b`FA;8>Zz40P6N$wift3 zOijY|GyTFN_=%7>y=7RmU`)Bv!6{n>-5AUF1j;_etU>~ey)feM*FGgyb~87X49kAS&e1kPk@4;(KxAu3KWIDHBO^~GQETB4FhNMf4HBi$`q@ z5kB>*X}!QL4fC-v2;JRGwj)5QiO@l*EP-Gj%`I+T=@~XCNM4TVagq-`8%R+Uxn&Wo zpdYN=<3)6hD9KyJvK$*tIiHAPUtRjX2Go@O2d?m+DV>9I_J%fZ@Lg$CGw_j8U4~#^ z*o-uupn*#CK$4Iqu;l%CHs8~wc4ZbZaxuGc`)+hi=_FM=Y!Tlx>uY{%Z&dyuJRi;o z(Vb&g84X!HVv>9l>|E0xoc?~%2IJd(tQp~a200*%#Z$gt?BS(C`p38KG7T+N5m-zI zrKa!Cdog4~hIjYUqYGVJRL*c9DrXfJ^p;sIt|g7ic#=%w!;iCLhv5lHDzC=$@E^hm zd)qXl!@RJ9?_X6N#-#hBzrjsq>hz+_prDHM*u|^BY+=ZB98-NV-ZccPnXO71ENq4> zJ-nF#h?loq()~_A4%K};))ctQ=0RcW_pg3rZ2ASP;Yz#6I ziQLc$(G5Cu?3sCk4buxZ#iiQ@NCxhI;@$e|=*D%r?K?JlvbTJH>ijlpCh=g*8sEQP z$KUHhy;yI5-ZIlSOp|&@l)oX3eUSV&E=iCU{LkmxK>qOQi{SRWDnYC&A_w|N- zVGC{@4yTP2dKV2=clgK+T%Ysv*DXI=gjq6D-?{tq)uirSZ*EV(QR{L+~VWSIg>vrsQ+R3XM@ro1A)&676{#DA#ZhD9lf4j`+(^+J7 z>B&ljukBt;8>x2`EYzR1>ES|sK9>q&HzZ9lPMTJcKKBbuKjl`U8^%OXAT&W8E*%u_ z1u)sQUmQ1%7KMuzjKBqpesp;CPtJ6q|dscEjzU6Oc_> zs@S%D-TKFZ^w{Q&%&^#laVP2dMb3WJFBo>SZ>SJtP8dOdtV=92W@v!KQp%-m8$2bM z1tvV|k`pZz=z>5l1H8P|DQD?0MbZ&E(-1L92cy~DXjWdn2NMlD6HAR<&@f zNMeC3oWCQ$ocz(%v#2B3kErdJan2hT^1DaQR3_EURoS$*DoicL!vk-6x~Gg5(=P#> z05&YI^c96CN&jONQSHqSOYMlzWbU66u^tP#Es^OJpB?YiyJ_8|uu~78>n~o(VnoIh z!SC-5I|*83Fm}P@vY#u7>dHB(en+&pfVToh#!`YbIDZ!(|8U zQ;VXkbm5?ZZOQxX4ZE%cA&fetgx8cnh9z7=4(xO zPzXJ6V2_Qx`~7qD470TZ-83|Wn34Q^ekFHxSN}VA&m@nZ0|!b*(_`lAUMj9~K284= zEdTsJ$hX-FecOvjOuK0BN_n&8DBI<~%Wmm(0^(%jC+TCCABd~cJlF9;&Yo39$CsV1 zZ|whQ&Rmr=xive4OUn6Fr^mU9i^H#^%;H~8#Esp2vuW=5YyZu!0x+5newXCW?%PKi z&McKLt^A<;Fn zw~Ct!V%IJa=KJ635{-IwT1V{g(e4sB`ko%&`!6eTV``#z?AG8WuSG7mi$s^^melJO zKjN!?D@935R>C0Mf$Tv^emEB+& zuS(pR|DKLxu0)Fe+j!yM+eR|o_U+%b*v|Bs3Fw1Q*W)c#*9@Y$%`~7w%<$k+O|_&W zcG3|V5FK%wQ3ay-5cK{a$YD|(C1R#cwxOX+VrWw(X!P)?8YThLwxpl}Xqi#B32py> zhs6(lk~uNN&&AxvYYrvukd}4 zo299p^vtZ2?9$Xv|ov%m!A6I7|&h-Ar|Iao|?qzDz$X#qI$IWE!Y6vsTY^bD; z5S!DDwQ@7n*-WaPB|@~8hHY+2r6^A6P>pn&n@vtdju0(LiaMve@9%wnzyE%JbpATm z)w!;-&*$@gzh2Mh<1s1zg?t3RM@N7V(??%sco}`qcy$@N<+c8ly{b7`;3Yjdph*dd z>$DDNB;CgfRb^xWx*=pU?~F^5M{Wc9)f6aYDxKV^C?Sc6YN3N_S*R!V`F~O`{QUu| zAUzy%fDX$`Via;n=sJiA!ON0NnEs3iwongvo=l=qFGkg8;XI4osQm;wyvUv6`4{0o z4G}-quJ#IxHL z%`mTBeMn0~^RfEi;Bq^@t)Mu=m^-~UDkYcvIM@JMnx(sUHfqdPYPT#;a63Ub_aeSd zv~RSoY0K__yx{^-f2;TNvJ`(|kf*v~Igx1HkVAM38fV2JZmapHxrdW3?dy3Nd0I~f z;1-oDHV;HEe;`c`#>|8x)lGTEr4!k#Vwk7FSG6JQn)?*5-a(Hx~D(QFNv+R#&`H; z*G(coj>ziQz^F<8w2FGA-E7s}A?Vbcy5_k{yf(@~UFZRXE`iu|ODA2|aiV?kLrgCA z(Cp4<)yH?E(tBpF%AEPh_6I4>s>6IB<*NG5)dwHfi64*X zS(=V6DY*^f+`nx09bDUVsAk3gAg$fCY?Eb6J`JhL@;mMmvaE>h^^+$nUv3bkYb;+N zN_Mg*_WC~3Bot0#Ht%7VpKhG!fOiM3FLU+$i1YuBUtG2VjAS*5l< zGkmPADmow>bxPCbbm|H;KE6nlz4nnIwwB8ric&mEjK5GU;oNHjz$DwM|~#b;x7WfGO)^E5bjh*wJQ4zDURAju|V2vlK#O-oA)#DvWP z)97bK5xz5t4!g~v8tD4nN&sc5K%%r*cXM9^O{ZYG825&Cy8}ONF{Flx0E+O$_9lO4 zAHok^+f~iXy3|3E=q+}ELY$3^pFw@O4W$VlP6PP^FMx?YekBU0!qUf=WGi+1IMK5j zIe~t<$*rwcEy}80kZVqC6UGHX88? z92Ebna|Ty&qI(F##EAkso=81eg%2tkI_R_d)JCayl|sfSYI)4*nP9yEu+~Dvt(4(P z0ABHDkX3dir|G!Pxd>ql=s%bR$~*g_R^{b`^t}q&O!8lSuM~r62xw?~vrMY51#4My z{P`BJe8V{=cdY94KDAzSQyFT%XJ&S1mQ*D9D}1~o?CtOO?u|PBf%lnzUY3n)eggso zG4ZMYcbIuK57vI;tQot5Ep8407@huOhlAITG;VLKX@=c;e`L1d{oP~rtm`Z99Dsh9 zJ$tc(RkHFDe~ECPZNi?en~A)e)+5?-G3V+%Z^iU4bL-E^&RviF)wDsCed-Y0=uSQK zCcMV)c5ZIb!GJb-4lGCdBUlJ=<|Rg68(@acbXnaea7C!yE~_>9o&WPly&46yW&o8E%E%fY1 z@kn_lWp#Y8suIQ&6=+}poG{tp3K8YNcc%~fWQ(Yj=32=#ztA+n*DArZgPcfhkwO5u za!8(OJ%Xxyi_?Y?rMlnh=fi-ySY32yQK4xrIw#$I`~3ZY-#4RhJIfho{lFNFI2RoY zGP=EXPkjaA-z+oV_BhMqlRemUoz&E?V8RQ2qLbfPyovi#)V*+d4@wtR*%N5^=%1ZW zQlCaPw;VfgX-IQ<4f${5Em!9|Z@Af^Hy&>yW3KhK-bgTii1`I)18bPGzVo8)-O#nr zvr!Rd^HH($^q&%8v_IDYbUwu_x%RZeWlvSP0}9NPTWv9Qd?Av(q1ZE`3sYyqI@hJL zGZbbn5>%r!6DImYjskS^)Wrbu0X0P#Y-?)>Vv7&(YIwRN-A#ZLX`uzON1hQVNg@ck z0jw7dP*P0Pv@pvM+Nct=3bH|0VJG!{;tv=Z4YWm5sX zIK`f45m4`_POd<8Citq;DhLC{^@$v1v`8qrf`i{MacKc9uq(e8J=s>cy{eoX5_a>< zl(9fEapQ%RH|~E>4%U2!PNYLpUUp+bM~iz|6(%^h;N4DH-f&5_-MOfImw>ha*37?y zMQb;c`<{Mhtt#(hg#{TCs@x-kfyaCNJ!twqLD(?ShcC0jBI*Ag%@-d4FL*s?xzCRL z_bgFxW|UVR3}H_Mte!XF2b43N|D(UuB;>bCrv z>7U_6U|U=q=2VJhoKQLwtM#dQbPg4DfyFC(g$3=5my}NIC;4;FvxJVeOhk*$2X=^Pt6Hk7J+fRXZb4WRtUFC&=mdwJ-;ouNpD@&qCxS+>j!^x|jo!RE;xNmU(!v_-cd1?h^Xl!xq z$RkXVH-g_kx$~qjlCkz&Rpt-O0xT@>#xJ7P7yaYh$2*RC77%S}eje^%pkkz)8>*?n zJK-$-WAyM$V##W+fq&BejBouPbo!MYsoM~qd*!@10ru!+2#WsSMg>}XdZ9{wtf*^M z{ohWeQ^p6midviVshakgn$wJ(I}Z81Nc2~`r*X~z#eGSlh!Y-G|DD$2?=q@GiQK5-2VhLsf{#JsW04g8~qV`H_4FK)&TdAU94navKAYz zM|m}CNoIr8T|f!dN$1Q7srN+F`M4yV@wC!)VTAMHa)kAp1oV`LTf3p#$2az2fyO*ELyfasS8Yl5!T|{B$T4!yRYVhJV=Ly@K=LYQv0ixF zV0buLx8@i4^T&FZ>FQW9n0*FKdl&n27r~*wk zBV6TfGRjm;2zPP(o2>CK{?GGYN+i~y{ot{#HA1zP+yA;-SD8wr%FHq6LnmCl!)SGx*&uNA9=Pk4`cx94Cyn}v$f_2LlKzZ5PCw=Jv}N@=fGqvR=-{`8#e$-Ch0fM@ ztlr{hDnFmvy++IEA^kt!E3e3$Y_HGH_sEEJlNx%CJX0#x8nyQBYxg&$^v8@{_I$OW zb!$t$_euVnFq@%7157_RC?hP=TAJyy!P+wtN>}HDeyM2EKPKN41zGg5Lv!WQ0k~jeu)Utt$=m0o;%8DabmO?U4f8_4LzEB#$x zUJCa&Cz4kS}JT@u}NUeo$@QAFb=348<1{u5UmcRot0R z92)!dw$u*i`_nFxde!CG`-bB0lK^Raz6aqYZNcIw-)d@tANN4I{-i3WD7FsN`#RR zHVJai+$_9NqDsdr$Qv6$!mA)90~ah^pn5ykxpe%ZSU_ewsjGe zwhllO8N2&Bv5siD+JV3`rM4WBqvyj#nRwoBU2k&c;f8Vfj7pIz5M|h-?mWhmkQ6uWIuMe zO8EZ$&F|NCDaq}9#t|5g4;?HYRe-}%1Keb>(93K*bqMGuE*`_opcO`0nI1UQ-iLKY zbi-xB7=8#wvC2>!#FBjsJyLHbQ>PO~KPrKHK?b+@$ff|&bu}vlay3Sc4o0qv@d3Us zLXvqz(Z7w*EICvc(AHy0$$AHHP$_k7sS<~R4%X#Ib6KEWZE^t5-w=X&0%Vyw>A-ko zm5_}D&1NO!e%#AYz|degB;iOy!I|7|E}@BDp|MMiB=>$yqxxmH{w3r2SjCZ3O4jmi z30v=pMMb``MPG|p=akIw6#*=Cii91lXvQerjT}Frbzf;YKviAD`x1Y*w5eY~{P0ZpIryPhsh|jd z|Eii7uqtXHPOgou_)NF)S!x<8cl=t^wCFW?`*_Tk_yXV7$L289qrQCM0~@@ia@=!9gG$U1KY~g8Qd5)pTSo|6 zTz(LEuJO-$7gfQ|zsbd8fkqLlCJX&1P9Y!lHBP@XB;NV+WW3js*YWzCE5m;D;l0z8 zoNo8i+=+dye&>6=quq}_A^WAypb|5j%BQb#4$nHx6k6 z9e+J#{rdm}Xo8VuVI4o&7azf`4g_kBB4!uz8-UV?bx>s;ucg5ds5qXO6MAs?AqXQn ztVHST$T$Z4^-_bK?qT42%Jq!s$sqXvaD*PYR}Q{CGtVpj0I6DJ-E72s_;WyxUuA+U zVmc!P)R+<#fk%`kHxTRiZOZ}LTX(IyEsTtWhb`5L7-jn-Z93|=j#R5`Eo|4LJ_)8K z8x(uib}10smQ67>lxmh5{3gx=5!hB8!`Y}>wro9UFWgBN(>qO!-P=E-24~4g3zdWW zI7nRQ`yiXJuzn}Sr1f;xrDbM0pRE+sFv|na$F{_r2~uO${0`5m@4eK#t$p9|FmM`iq7*OWA6I zZ?|T`{+$rBYXpsKuLv9^Aq3?>2CVv@UB0)z>u7U)ed1*Q!R07pIg4-_5Y5A2Np zgAAe{@iH@b?EVbcQf+1r#kY#7^V1$+l1XWG1^sJ7;jY=}ez}w8DY$xA*Uv|&Fe=FP zB~?#qJ6&Z$lrHoADBOh_=Y+VMZAv(?bZK3Cj~BwOm!N;uc6OU4bmV%N<)t2Wf+T$YO%q9c=7k+|0NwT08|DBMSCQw%@H;0Pmdlku$8>lNrY>S_6#hUiVT=VW&l^}RnYhT?BHUlf7wfq$RJkxk zso(xS(KtFIH^}_gYm51sdwl%bdsXG;iw*K(a_CC*#CZ@nHvOZ6nBt?{G;aiQ%A`+H z9b1c%NC%`irmL6WK0iw;0I1m?EpORmfRHtPp~8W@+kTyoRBhzuT9k?Gi`o@HRYD@r z_dEeM{zr=d3`0z*csDk6b}np&l(^rKo~81;$&^A?)Ve0z#@YpNr58d`9jvfc-{KVT zSq$R>g0hX5?EvZ{CB=#_@r}_^EW6<fwW{X;6U;;qhzsan)O$TzfZS9*8YKAb0k)<*cOc>e;u zq=ckvjgw1*(otaS=%@aY%s<=`p$9%Xm-@g+=`7xLVlcgoOj z7Zai`uXN~eL+)9QKliYYD70Of$+jYH4+BdQ(6q4l!Jo z1k7v%M)-W_8=Xxc;^%9?+Vh^(VTv+hykq&rj8&kmaS+0q#SV?a5THLOxS1>91vFsi zPDQ}~qcORm+N9i=xk#PPnu@)st)csmGWGbS&nx8ag`N-Ppxo~XgbF!QBs*+C!!BBs z0_smDAtoGv9@?ghg$dai&

Qm=Z!5K%mR#$&Ou9niBw(=^@Qh*hh_PsHRPB?9fR` zS^*+4yS_4s!`J|Lk-Si2nowMLK6n3~iZdZMU%W@`!_15{rTG?OkYcT?YufGW+rxi$ zQy7T22d{7^JW-;%<<~t^u|>XW0B+jP>7gVQe8XX|X&0h4mUZL)3#z-gb~FU~%#ltu z^W3B3C#sDfs>tY6gJ7qJ&qN0@HWcWN=4m>S)pf;`@d5i<#Q?~(NkKwdpCe4UVv6b% z5CibkXrQxoK=pBy(5fv>uFt_ws;K2bXc$4l`0_DoPF-m{=~LT*lLIe<|YaQC1MD2=x{Q|KP1%fEVRMq zMY(doCp$Dx(%<+l>ZkqMKp@@Kg&?qhT+pgZ{U^mg-{Zl$q)W9OC@8C@XfaO+AtPf# z)IMl&;Fn~=RoF^5?=fuABnPL9PKHQ}Gv>cU)=vd>5>jBn2z|=7sB=P8< zWI*t-Ku$6NLukY>&*UGO9Owffql2}!R(|RuEU2YL^0~GI@D2f<#+8h^@Y-=hlTj5}`$>DN%JqWx)D#e>qMRcc1-p1p)%}z#Hbn zGWYRGLIEK7L81>t*@*CHpf&66V&{g*R=|!IZ>VbF1+l!b*>W%t40O1Hhy6;;Tsghe zw7hfiGI`q#Wd>;(Eh-ql!XffW87x#c=(wH&DH`6B+G&tkFZhgl-=iT2*QmVCi&=y+ zX#5$PU{p%h^+yaB>*3~Au18oPWy&5BdvNI@E@%PZV7YIYpvY+ABimWlnWcwQ;2-9b8TQ9B2q7(b-%P%daw)Cc;_QIrE^!l zF?qLLW|&uEGZqnXN0L_jr#S@-+pfHMFj1|qKO5DBbZCV)dps~WLv^Q>cQphrcb|)T zXkTeemoEQPeCkG(-;k(XO9q%&^N)+5e4u%nEh8lAC4K6~vogstY0zm(CYBKw-Q>py zZE9ZwH&Y4@hWkSQj`vZ(KlS<2(~HXLz{wfhKTH$!{SGiEHM5l5sdUi2rnr+m$1eOW zhJvfwv}Df#%_)!r5G~2SfF73wMq2iF2bk{yl@}MHfE@s{$KOh4L&YD%Wst8h@}ow$ z2O0#P0XJV7f-R856h{$fY=*5_rwru zntzrkN3_=+2l2?mcXJ6#B8K5iG0wvJX}8N(i-x#&YeOvxCa#nI?df1%N|A$S;zmhH zbWjGWcQ!tSZbF`@F7vm68p8YyA`#K3{PC5;6+kLHRAxlON!epU2%5gYGq$ZW0tIR8 zB!8>|%Zcbuh@9rF6p;0FakVHTXofJ3L(3e~o7`3s2`lQKeKpv{A)Pe3cq;U5LZvC8 zT^c9|K{2kGfmcp*Eq34tbCpR;t&r&)!0P-WhC)%5gfGFQPT&XIxTyA-4Y4x?SYwa~Ae+1fLxB?9G`en18mn~p*_l_r%JY{Qvi>bs=Nb-jIv zK8gZA;9(05#j1Y$V!TzE-DulBDFHU2PnMxba&xhr_p!@|$_#tc_fl>wfQK>3sPf3pqQ4533y^`pb^ zegnSh89vGId8ue|TIl`}L_pL+cR_>(*o=O-;+b!l4r9eg`=Uw}x^^})*+xSD5SEx1 zqiI4x7ygw)CLK&*%$C9a79)rGVq`1aC@D3j=-*o8u!sh%;ptVl9u)WoT1w}LH-g>m z0PJ}waV|n2c8g|^;XINLs+#o>xnNRev}~TD-_4x#r%Mhh?Vbh&Fk|{rudk(IzTwro zSL*<5myTmnRm;LYWd!a~k>dOx!V*Upk)IVJrn%Qze07--EKxjw;9LY5)uxnR-8G@Cl%B&@)jb-_(B}msvesQ4*|#lXWLlnGOb$i8OSej@CL|W-;;ol$TuND zIbN(YgXMW?gQfN#jAJl;zetb9UNRcq{TRKcel|f7j9;1-X9TZ;SQ3GXRyZv&K@u)} zV0PyMN_2^>cA~mzXnv&r!d%4P_M&8- zO98S}ocUSt5!~wmH1HeKK{73P$DBkN=`sCdif}$s2u}43SN_!D97EQbkZ@xphfo&* zmI|CwpZWCR96I#)r@rBkK;RcBq~Ty4EOrm7%}255PlJ39;JF4d8p1ghget7ihLe!g zvO`3SiN@CW;3IA$BK_4RTup(}aN6kj>%+e6-vZ%m&@X`ttwI zagdWcz^zoV0C*EXNU2Q37;lxP74!)S=CGP?SL->^wmS=ysId zEZ{p=mBmysK?_VG(Xg1X=wTt{zeGXOQVnk<{Ji=?6ak`RHMi41lKF9Z)8^Lzb-l6d z?MRni6k5(%54@4dCSX;MCv5Pts=Xu(ndWtstP>cf4m1^mTQl3|#21D6EOx@UAh2TR$8@a#3&`35D9HyxROXi+)!cqQ3W&)AHbag z^Lv#y;dqmi`&8A?aYuT(e+>Bdb$jR{dgW*mXheq)rVgPBb@Fp$lL4$Z=MvR2-Rt2p zyW1zQ^cBvf@ed+isZjulW#;trDA9X?m27}JQThi#6q?fjC*3WS9Sc92VVP14 zHLcou664V1r1Ma)zm;4!Jt46WF(!XAo~1p)N|&4zo1MxXtTU2aLJ8~r4SZv6150=| zC40}%_WE8K;#nt_arl0u?Uw;v2*0KQlGnahz$iqS)F9d9JFW}7&C3d%x%j-n$iT1! zcW_g)eht=WxLQIX&uB0r#7{r(AWBt-`thvRKe>?hh`Km|$3xi@qO_vLJ2Zs8tZq^W z3Vr&zz+J}#DIoAuM+^(WTWK}~USa(j<{lpXN!F=!Lx+U2hvfk-_9o0AG|9fkL3~k1 zc;X7I(Hw(BTkd@6?c~x=`2`9|3{MOH&DqkNZsNY>0_6;w2EW~ISz}hU`MkH~+;eft z?j1^fWVP}a2Ro5jsCz`?SPy%zk$FfaBK#S*X^?$ZXl5ProgZD-KX%sdgb{_R&Q+ufBlYxqiHJ>%s- zj~|r@*w%m;s!QItgvqQ0KB@~qKgBa%Ydw1Ukr?JL_=o1^_-QWey&B68FBPTnjU8w7 z%8~{SY!}BR9+K+x<;bRN@H5aP%4KTmQ?+QHIt*3g@x-<#a;Wzh03UAOe)QMwmQoR$ z7W$`1$Sy8gT4x9tLRo(eW`vD zd$57Z=0_$Ak7jrw8|nZ67it;fs4s@V&EQ8Gm@)-~&l~WK5knMwj!Xrux7LCY9gM~D zBy&ixPvGlJ2i^@Bo`qjFM>15QE_%yR(EIPrRIF$yXD*^mphT<|8Z3}kSFyfXL21w3 zL4>D(4r?P6fJQpay|UI?y9g|YwZyuTs1Z^@4bK=WBRnimx|IZ}h`i03t3))_AYX%8zKsrQ(I-dyU#p&K?lgU2OC91mg_ zQpe`W?Y*Acsn?|#Ygpr!o17OdpM`f2?R_M8OXQjS8@kUGm5D{mWIuOH+^awy)WkFV zmj5UDf4+$*{a^4P00~xGo>lml-kGKZm|4IAb>pI?%Se=+R+!|3s;ZPfcVij5Tm$p$ z^IL5$fIaVwW1Qq2mO+8L3w1WH0w7`d0oDYZic;t90boJB@r!aiLhjlFcEM3ZXOt1L zy$&%#xUSzxlSnv`;9vxI{JY9@CiE@X-B2R28h9|zhppgCAG5d^62D(XT#Rx}94Qvs}8 zfZg8MGHyyqB7m%CTMw76KTi&{ZqQY}!A%$A8NksT*!ACGz0S?$j|7_Zv&`y9 z4y-NN?;!X$_FNM2TjS=K`{q;^Uodjxe;_$Bww;7xXB3_>l1x0zT;;q+b8>3%zDNDn z$CHTvSo?8kfxJDS z-pVl@l~2`Ix^p?t%MeQP{X9fh?ct^mKVtvU1VmF>t*-pIfOj*DI|MC{9=_6O5gEf* zCWLfeemYR19FuoyDVKT@Xl`tBaR9ya6(1doU0|!AX5|=YM>N6SXhE5_{pEZA7Ir6uz)bUdjiZacIvvz z42OBELqcYLYC?4$LWuF;@4{;CFNBl9m3(=+Fe|K~{y6G(J?^L}g_6k*|4RZ+Zv$aX z2z$Qn8a%2DqMJv6$Mk{HTOKY9!ok4*QO${oQk1^C${Y2LDP8ByCr1%QB6SMrJMXF= zsnQ2l2Jxu{VKSOsg+GHaGB)G9x)rxnXXU#PTX{L{w;;d@;g>bs|I~CCM(c$RSG9(p z89aCEE>Wi3nwL$Aem_L)NvJlG>l6jb2v#X8&tw}c1Dn)~r%?Jq9?WI4VNPWq+>G7K z;I)wEmf4-bA;2`QVwyESgsJ@2j5K+IhE-8}AD-`^XDC{TH1JKnQ0NbqpLo&tBY2nv zi9A|!?$tGnUfn3UbK=~YRVbJ~(no2xX@l{$UALMx)7%#oI)}~4ImCv;&HN&lK)Blu z>C_>aE?el9XSJ=IPPcfcPU1gQz)IDnC29!_vCcibn+Z8i@W>#zk}cJBZd1Hd`tk5> z^Cb7qPg0xA5L-aeea$pW1@jn7geyl~`x*~(;DMrgk!P2bqZS{zP4gu662~ugm+(N* zVU$aYg2*X-9;^-%JfdVQ9}Hph)b*22`8n8upRMt{w}{X|2`9?2gt9sSV4(j&Yw08C z*yi%=)FcC5vjavO-gcFelt7L=@!0n#uaz<4JBD=X0#T$q!TSr5|=>+b}TnDe8 z*`vz{TE~7vHE+$@KBhHyXw{43JIm%qfikezGT;sAseNN}=R*Z@&rCJ}R_joIx@yV% zU|g>k?crOuTqU$Jsit^kioXFUa=XUVcP-IRNjw2tX@PHx59Hzok6Q!=dmnyUS3@|C7_Jj){7Xx;TO3Z(GF`UA(M<-T()bl_rWwVi z6k35~=qBNKch!W#K-bIca|6_XZW+fz|6$5_Bx7PG4pplKxqC)~Y=MFY!!0d2TwYTE zKfoQ-2onduwh(0Kqt-*VJ_OkW*mV%4h`THn0J?xnKPU;fEkZkdf@7#aft_X#h5 z8scslJ=FvsoF)qbM;I-T^x;;SG58x>c$^55X|LR7s4EoY{!CaV%s%j6<3y~*$nA>( zk^d$h|Kg*N=E34U!hbzt>FixecD% zi1m*o$qL7mCeN$fWOVHiK*s+M$^hpu_{ML8N-@pf9xwu748%}pQv(Ayn4)EV)aXYnEG6p68rw38W`1DS2cJ4QcUA|0iH@PPrdDqxYukQ#G#s<(i4&_l8VJ`?Y zL)Hy`A0t{dIs&o>)9iSaZe)p{fTyPy<>lZwC5n|}j?T_Fl#m`G6SBhgu?{P`9G7Op zUs-@^nho?iPyOiHF&KC775lG}m^s_2l7ARMmgunCfd3s=b}%tbLh7E-;Y`l1_45edC?sMUoqWBX-kyCwyZ-o?PZA%TJ(RtXBnG1(~-R2rHgkd`Jcv2 zePg5rsgMb&&!$e)&$@1~n46pyrg75*SqR_5Gug53#u7p`# z4OA;8brRQ;rKLc!bfl36O)FkGy3=OF=VDXj2;qUDQC$R9JyD#`rSn2{q2oqhz)b)V zifpnI!j|OPP-Y+N5F}SQF?$tmpX<`qV$h7y_XC*Ff^hnLyVy1gJc17sS2?74`|9AWAPb z{3O#kHzC{?2nM0^!LUg=iU-~kwn4(+VSWV3xF5X9(Wqpeb=#7YL|^G~mVYK|qLfHz z1Y0keXaI5Cf4Znefazu(sfT)+ys?_o)wN?{SRGnn4iF_J1N6NPa`-jX9fpChQp6z3 zlbQ`pT>RtmTQPx8HRj7O{*0)o8$uSF$*6I>JK4O-Q(7zO9VoX?^qjcgr6$@JG_$CQEe1H=cP~QtU z6)EDto`fuL_nP3Dbku9RF0B|bJbdrU4#S_XyVRWe9xgSywybtPQROF{5a;Zn!9{gJ ztj^NDC_)tu)03bR`P*7agEsPG_$GI4&~4q$0G2o04Vtbr-F~Ld1@|!`{Ptf>A-DG7 zAKqD-B^$bYJEX8PcpyA^-2^5#c-n`9hrvdisz2~D*gD298bse{I>Vo4*N?LO_Qn&P zpI^w$IQ!X&`11kS@THR(|I@d-P{W5D zO(_uXgD)p?K7O?hLZX2Hg-s{tp`tj?;8sCge}cg7JX)$ld#ZO~h%taD(Ndmb4M>}} zwe@NT=oUp!QvTe6z|slm#A%+bQSg*eN=Lx7>(^%|kDjah7lCnpuRw$NrvAtF>#Wx> zTa(4RJGbx!l#bX)8cdE^B|DQ+=pOzc}y|#fs956)3Aqm z;54N;?HB@dbf;z2ooN!tS{H$?btV{0^19^KKrjHBou8yBCntr0VMkey+{rqSKrO)$ zWxWm19B`}iz%2)}*odaj2sdbM4%pQa-Yt_8Mu8UyCG^k@{lJfDxx*$c_XN-Fsmwfs zP_hV1rYu4e$`1z7T@2D52n#u0XG7X}ixi zb_ebo>nZY9z-#PL!a&YM1zUl*@frXbc5L>I<+I)9X9UOlxg+21G#$c$&TB~ne zA7tx*8he6YluCgY_cbP`o??_FyxBP;JO+lxqXus!?6@iZ`Evg!YMBX3mLjL8-f#-Z z`CX(zyyC{!y4=!wq&UlLvL99ZT?M;uFuT zeKgNAbO(%l-i14h^%r$c)y~q3j+Rvea<$S7a(5^iDh#&nsk}(ZGc6UUf(2y5tc}}u zULrnfp0X0o!8*#Ep!MCp$u)63hhy&}b$%S|4AgkKliL^ z8H)VF87^~JThtO}=<98p%nP(#=48pA6k{y6>h781#GE)m+}QHHEhBjKnYt!-Su$J9 zIef1YWsnTRV>#62f^K{q?f2tEdhW*j%Wnp^$>02Dy5y(FUHZm??bwa(1UthJHzPKc zMs_hxAO)a{V2X(HOb-**ozwTu{U!MrUB7%KqG)l@7Ii<=!!x93S9cKi=)o6n0myQk z4uyl-dvjl4?NL_b?p%er3Pd3$ia&4%|E?;-f{g)S?8}xWD*m8=bsrqOcE960P0BJi zwm_ZBE*YlvokQA`FY^n{SX@ai`8H%!80GtB%+9gIO|+Oy^n!x8R_eP?WbG&I(jI3J zEkl5X@d^x^OSHdguZu=l8nG8tTjAB$P>?U*e|fD7}L?lsnli#`B~6ZP;d6Y)0+TJqQYKD5KwA4^Xn1Can3ZL`?H zrMYti6n(`8uG*x71^bDTkmOT0BMx3s)I#%Rn6=5k#Tq6=f?O*N!MA34@4O>n)Nj=@(#pA-a2kNrh)wA{_^;9|WnFYYn> zp~A9P8jrhPQsv?rKAW&kfE51r2$A3NZY^r7D8(y2kau+F-6vP>Atk+8E$l zRleJEca@xpbLmXit4$OpV?9g>7owmq13CT!aBRBVZnmo~lL=WtJ`PQ;c{B)Qg+%5g z(=C2vMMYAM%tz_#_;Iz)0BqWVvP!IJ8MOMx=Vbonlyy;Qz6B*^zb;ck_@i9f_3?3y zuULPcw0vIY3=8<*#K-T3c-I4gW?!g>vHdkH_sQYO4(yDNbXg@RA{xhh$R)fkk?l#B zLzL>Qsj3UQMsJ>4R;O3@=VH%XZosm?PiOS*FMrC#9$^7sgAqVD{sc;5GCs8RlKDbQ>9fQUBs^QEk;O?%22Igy{eHVbAMj&B=oEy+A0W)HTu z<qR%ku5VkaHbfLN&08B+ZD>AbcY4pGjak%T8}1_x0pI z!C+_fz*Fyl;z^QdBnOP52nP%Njt@_n2d$$DaBVQ|l^QXcK_W5wXbUvT9SC#~p8pek zlu`A247Q-Jjil~Aop2jV0c*;q6*pb>E!m>c6A}okhN3As@k+asbM)#-)RW)Z8_ad1 z3W@2h>v1%Eo*K==E;htbeH0Ctx_PuVoOjy~L|@hCry(DL#-qs=q9v@yN- zfK3!vkA5+d8%)&34O$;Zd~DD$9vx(#@&G{d>XRE=J+@1yKEBP^33VbqRP(pRozyZM zF;hc=E38hjO(!9!_I<+^gN+G+!veByZ$N`-Kt0mBzMq>7O$a@Ez&uJIyN9y(Nq#~X|F44~ypL$P zOOEr1_{ohYmX>i{$giEldSqbQCgn6TnR887UtZALnsy~M#U*TG`90;@ZjJ?Tan?VS zwz~j>P_b{d1L7|)|7=5v+vSn%4`+^Zd}lf$dqje+cQ|vIJ~&%H3H8~5-08w#clJzD z$G1VB8eq_nJLQTG;Zr~Z%r&gZ$>(8xAxC_4J|heE%yx)>J2sCmO(7IgjMsY-r+Ik; zI_EI81dS-I%mxPwm#*froOmI&jYJ z&{1G#fejUaB&$pcUF1d$nc;C}Zv|o8H0Ed?J&D-lorW`}KAb0Y?q+rJzMhyF7V86| z56mS}UPCW>B~E>)T=C%Q|Dc^Md*3N#mxuyEkG+O$%4Yz+C0L;P%0 zP6=Y>|9Ja%V#~YE=1KlQmSy;H|F}PzS42Guv)oZ$Hpyyo4Yqgj1)w^@H|)4Ds1Ar( zcRAaO1Cf?)}HV}Ak1%ysoo*bvu=!Z?Q;RRGbnLK=;l);+bXh= z$fo!)Q>T(G9S*hxXg>o0r36ZtUvmC&a7%_EtL2DWmMiqAoa00hM~Q&y0$5+8 zn>>y12=iHTuy87!VDt&x2+uGbi(nI#hG6{t_+#j@8Gjns=EC_Z|D@Q%{P27#4o=^K zQMr|92vysGS?}y*D}+xnMIi*GL4cvQsrTO-;^1b?uJAjz42-v#UqXo z<{dD##8wFP0#$Zr!I&xs8qVoROkIff{&Rp!(;fJ8=we1@rta<|@)4>0<8H5Y#?b^D z50?#XBzDQR8P$^0`6)k6U*1p|(@>5rTz%oE=Z2=T;qA)RZ85ZWHZ6>6 z{cedK(`7&TSQ`f!lTE3hjqolhXHrXV>P$u$4ejD-14%s>DZ%S|{FINpZOR+cFHx%L zjItkb{d%|qrY{*ioBr(Q#v|Hq-pPNdH;nn*aBpfsuz1DEPhjDzD7WpZDoCq5mviu8ov2)uzOLxFj`(_o%a-Z!0i7u! ztZSn3O4CCx+ZX^a=byC3hb~iyQUp=GHJuR>EX_FdYN;@Xz{_Ixb1A`U{%NGWM87-3 zykzV`DH-{WAgyW{q%8aID(xfh_EoQ6Z%uOZ1FX>&;EbALzzR#{8%6YMMl~015t0r{ z^@< zWEJRe=@6l_?EsY%6X8Tv3-*7kSKS|QPW(1eptB}r25R`C(Y?GbFntrH{W_kyrQ@e( z4i0uFlnGf*-Fu&ugc&aPG&pooh zJz(RA_2wpxkIn7{k^e!qYG_B?w%=Wy@Xp1XVR&Uv3#D89-a zfTM=?oyLlWu7eHS!h~P=!_BW;(uO@3hc&Y@U?|R;6)0fzT{&g#QJ-wtr!z6(* zd&ZD8cBtpOu;{rIq!dyfh10_MMV42(piZb18KsH7a zh$_$Aw|J_!HbZl5m8jLo2jsqT$f)jil;B*T7MZ)cGKKETL<$P-X2#Id2pp)V6w(CR zHPzdANe=J`5Jv@MAeBQEx72nP?jX5B^sm?EB*C*7tK``)CVHI?n9uWRFUJObC1ejm zrPw$;1fDxiwaf-BrayC1Vc+={#8773l-UE!%kAlV=`7@0-ugXatfMRt-l7Y13!>NN z!8o$MuIY6mzWFj{6uBIVDUkg(Cfzz`tp=Fo*VezN1TPOE07iP{FzGaduPupR+-kn6 zn9!ICGaX1R>zc`@%rUl}A~GpLR^@gsI;@B)hCJs51?N;JksQbg<3&1Bbr+HC8Vvf% z?Hl0FFlC>*WGC*YhIE7+{sGba?;`)EyWfxxO8LkKodD1{^$L|z*#M=Ikd5Bc4jZ-Jk5?SqH=E!%M08tX@6D`^+C101XkKT zVF-GB4Nnq&s3BxVUM5P%mlQG6P%nQQwH$n+ZUxOS;R&nf z4hfGJ6j+an^{s6w2p>xh0?9_Z@r!%9uEQ8UF{8}5LX+G60d6rmzA`^&?C5Cpruw4S zS7p^=tKY`5z1dCMsG>1Rbm&NJ3Q7N}YogGJXpog~HKO&ZKG3Rv>KYMasV;S|!jZ7i zXZs!kjaSv&k-t%1-msMA^Vcl`=kasEM#rAVQL^8|#$RDlz^OFAa{#i_CG_?wS+z_% z$H&*0=@*g7j(6lR!>YQdr)LRQ*n5VdZd}3z_kt>huyLO{%2P@BxINO21yYOSB7;T( ze`y|&(NsED`wMd37qkeGomJy`#q?$FUV-(Y_fGCHG;} zs71Lx;;;PeC^-{}RqF~LPOu4xJ~s93>}+nWt&_d=?`pI8=bP?nal~ijO0)evFlaCt zPHVXXRuN9KYa6_;37kkDSjDcm`=BQjE%tyKI04ho+1KdcKM*{#RImvOUaDh=K=-U? zcPEaR%hD-|ut=&_!gdW0D1SFZOo!`-vM7*AYLtaQbfTLNI|TT%xX(L~#T(b50MiW) z+EbqP!p9lA?X*C%ys+0fr-&M8q&)w1m8sPszk^LI6;4gz^vFXTs6a?myXttlUa}$xL^iHkBO173 zHFq)?q49tiP_E^rzoJT2mmBaUpX*K3UF@|iHVCo9ziN~QlMw~C_x2qM9#lK8yroAL zj0ubB!@hswXIsji=lpxf?p}n1fI$GtkI716NZ+yKn#2bUMgD?@s(p=AgiBwXsTavB z(mJ+5{xZT&FvzFjdbkRaTw|Tc$uyrfd|up*a^gZ;$BId86AI63Wdml5tbN1!Mg1O> zUKji-sxlMmfzc<)rKX3k%{px7tD?b@KIIoB52UYieI18)c3K{lUS}mnOmBuD*j@O> z6-y7N^O4Zpb3nzx)PDmC=3YYIzEFTSgSl5OOL@<$=-~=Lpy%YYw>+=83Ag<|in3>n zbT%HeYqA(YbaR&@nunK)#~EJlk|qgWB{aL?IWZ`R+Ux`9P698ILI*NK9aG}FR*`hvM75E6c1+GAQ2Z8;I#N*N&f~&5dy^b&O{j;cpFO%#8YX) zc8y8PNQs(&ScdFy9%qWiX!H^^i*Sa_pfN5zw4BK&fbk$4X?g$Hpb%dAYq}wEJ2N`M zN^=7G>=LL>6VW>@Y?tLZheQcT=TsUwLxk7C{c<2ur(0bBQM=;8?xn#df6d?wqx;w> ze|iT$OQN}y?@{4OU>HNRk7>LIGC^%znL8t_-HBHDmO#x6v<8Qx%ZV^<3h2xcypF$U zlu;~uyoyxcC-Vjn`0|?a2L8+phyvev*D|ZHW$C0cr(9>czLx$b{y@%H-vkp$)=El{ zji8;^U447S4~gF`ym)*tNS6D&syqPpi2$6YG{JX9Wv*6;G2?n>B3xpO+O1}=DgzB` z!tB9y{!hBx=m|skB3%!Lb9C#I4vagIORQi%juYEen*V^>ckn|Tv#9t!>P6a7^2Bsw zhqtPH^JJ?a9&a5*G5>l(0lDD$;UPCwwVfloAK(H?ua3Q_F_D3B{rC;1FlHJvK*;v+ zIY6s^T039MKRGle8#F~nf?v&50TZ@js1QP=$94@66+W&r(K*t!?ZZQfX$+=N%h$hC;D{Sr6n@>=Gck z!{jx76lrMb2zD3$rTw7NN{_2X$3%OFZ4LZ2iZnCFO(Pdf{>)T^Qm`)eczPWP;=K06 z@zK)^g#{X}(f4a5Z97h^5eMl^Z#=FIPdJhc8uz4muqTalUsR9P4D9}DwM6X}X3cio zZc39|O-m(h2V;mtWY&eead*9J>Oz_DM*+3=Qu6Yn^AciF0DX^{Q4wG)ejlSBAO<^P z>3~(;jO$jhaN(ql@c!WcwtK8vLfHYL3% z4*=FQ*9f!Sw`K#z5crF7JOrnq{u$A{0&u1P@0`W~G(#C*^z5gV?HKx=F(FYAXva{$ zG)Ei`9=1!Qd{M;sU_H)2lWjYO3g8vZ7XYHiwMm4q^3)SwrNU;wwGbOYt<`)ag9_U> z*730PuaeOP>4A%0A}eMRp9C z%s$FJWOLIp9##fvM6?T}0qbkP+DVyIfG!&XYizNa^$lJ$DFYbLDFQQOPxewtaG-9-_jD;x!n`U)=nX&D;@ry65}bb*wSr6OFrz~$>b zkLBt_B7#lm$t3qc+C<}xI=JGo@it&H-|jG0L=#_50H zi#lb=yT+?>aTZqv)o>&Ct>Qk3D=dBUz4Pj-&Mp+a594>Y2%;e`p>MqxUd=M-PP`Kl?|o}Ic>YD_8+*|3A0L{WvttuU3dceJAn@fdclL9&=JC&+ zB0vVXm)wiUq3j_ktm<9aV+WlpH^E=?G~?5)+ivK0kyStE?Coy6EkP7z1isBS!??E> z${7!Fg7c^HgY-ljoU^1MA@F(>+Y5_=kb3&?QqF)+v)ozl^>b7s0KaWK(~oJ^gRoK= z1}wF6Lm<;W(LI=&W(1;!evUsd3S^LvOywex;6#>yFAy;{k z`^)-Yx!I2pp6%NV^8T`O_@27q*-H)^FtN_ljol1r4NUzrGhHRadC11)J2#iw|B`_t z5R;}@UF2RT%`Hui$^Tx;d(qQR{X^Z5E%`5yB|47&2=FkEzV}ox7@LEr4)^uKcTv%o zu(F*(G-yka$1tM7-F)pa1#-AdRR&0q{UOu@NGW+Y9~5!AfB{w890;;MTp{>e+Nv8c z3k)BFn~x6qk_GjS5mK+L-}z=gi#u?UntUb{7j#aVOOvjr zwK6zb2FX}t5+%e5beWk;&pU;S$5enNs8C=g8^BgN2$;O>C>BYm<4>+EJ_{2&1`Xx* zHR!wd_23;>fugHGAYCYQ#VfTB0)6pH_pt~d)22snGQ;Ts(H6OA1CwhE;O&Z8AX>h$f(8$l zxe~@BE%GrqkgDh)TbTXqj3I<;kWg2`YT1tmkxIi)i53QL~852doOC*#w za+*1kI@AoEkMQjspXC~+{~?mXZh<5U$&KYPIU5r`T7 zUO5^G{IqA9_5@1pYXpQ>rg%(WBZkmqp6qJ^`Z`P(ylK7qPN~guXzE6_G^Q#Hrw-_=^;hS zL<#c!TY{c#OoNUiU9;&EBb({F4$NkP@4}zV*Bk++SEOhX0o4I=mXwtRhssY0i4A;)C>4ehSy`B zz$gl5m077}eoPu>kwt}%3C|C?8fyu_wpOXS4=n@eB-a36*%vDcn?I*xp_}wRBvyEj zzcw_#Q#xWczo7?}v(ltL(TOwLp|>=LN+FyHyo5hdRTi4C34uB?@WYTnN3V4b$cu8) zJhM6$Zl_rb4em!$H?TqQVqWt=RbP`L7s!v^ZjrI#v-?swNL(d7r{qvVxptrY+@}6i6Nuz`C``eZ!f+WguHm&qk+3JpM z{-Lf_y-(0e9j+N2Y!oy5#>B<?jINel#|F-!Gy9Me7 zStf!CTiPCc*%jb8TrsR@U`a;Y3)s3viR>AwUeSod^x~&aIf!m==ezgKKIvl3P1UlV z?FG+gaVsJ|XK|ykU#8Q5MJD{ODS(wq&t2HU-#(%Ey)q~W9y~58`1~y#=8Y8-a_{7- z+B#W{dGRGEyu7fzC@<}5Hm`r&eDOt6V=bv(!AbfjMpXy^nRc4)F7eYxTng-Ng=& z7scHntBxM$h(6c^%LtwAT9Ezb?6LLs!Tl%# zgP|q3h%$?vQeFyzp9$O5NFdRLk14Kak^*#8D5Ujy+k9F@9SG3^+8~m|EXBTU?l$kM zLUhKQSB@0U0?Z&;jYu37bdnxp;)&ch?Cs#~7Y<)1l2bqdnGdr$<-RdnKUV`9^bMG~ zk?G@7<&8_o@>ukfOw(R&jzaiHzzzWrTYfL@Rz?DYY8CdB7Zov?F}m1D zX$Z1B0T@e#07>xn9_5;Ztm(CL=*)SM2eky`wn+)BJW)6ce^Dd_Oz~3yGD6k?6Dqv8 z2lM8<$f`kRKJPOwgsbmu#H6X7D6qP@Nnal0jCSUno<<}gSKtYr5Z+0C&9q=W@*rRN z=a}_pg1^_ODS|Lh9BD+4ZB9)fsuLR;!ztjQ$`2)q)u*5OIQ%4UMtGHE?6H{i111%e zZ9Cq0Ym?xXj`b#wxedD|2E+08cNu6D=^;R{;gTxkyw+J}7iCDPb|OF4b=aFv(fi9< zN^VHDPsIvS`qVaN-7lo}qdcm2i}87|gFC19NqMZAZwN_vfJa`AaFJzq{+S7_=0+E) zuYD5`ZHRP0I~TlPROWuc?kp8rK`4$xitNbU^ji@0;E8Bm5yACX*)D*X67%Z=_XT3e zJzE1w`k?X-C+%7c?q=&)=?g4kxL709r%;g{ML#(wmD$w4iHVo}9c_TXR4}^i)Pw2ao_f}J?v7H99Gf8yeNDrW zWeYRSUCp&MaA9mN!&%%dxtPiOl~`W6^v^g*l!GKz>8KBXTM%!m%>8L}3 zQwIuCcLcvtXuy^DHb5uFJ`zVFZCNIy`1;gBB|C?Tu+?q8zr;d6zrcu{f1o+%S_^Cs z#NQI>ZYf5}BfWO6)*{K3_#xs!VOzy&c%&zj+&4&mbW80wSu7@f|F*=3{sDVHHh&Mj zDm8~_{wP@JA$T5*s$FrE{CfT{EexTgww;44*qj=Grjml&=j zd44#hcYKPr$mpMGU;P3RZLUq%r>k|atUogoWqRL$q+<4F0kK=u;~~Oxz21$ropszt ziv^9%DSIXIQz`=03iF3J)OLGJhw|WjO3XmUNH`fvkrx*d^x1LW`4-RXnM76c}C$3vytiLUE6G+ME>d(4k$<1x(skWPm`*2Rn-8q%j?UQTWF{9|f^uvSFa;`aKr!%&8G#qwmD&g*`gfEC|JyDPq`l*08cbDuxEl(833*I8zX zCvOzgp(4MiY1q%1J|c5ah1mFz%~GhHuWf!ak>yD8@Ds!tTvnx!1j!7Rv4XBO+$x1w zOehVaWdi6|;mg7MnX9iZ?*9WN-;a5fCTCEDob6i)*eNuqaWp!d+Ynn6Tnn}qU?cS) z$l2bHy<@GR(Y;-!OTQB#S*ACVA4R7fRW+VtiOhZq;oTvY*8{;(Wp!hzDpDbeKWz|# z10R2sU$Et_G%PQkIkDTNE`PY!+Trty5n0bGe3KKy* z{T7BMKo$;p8&>h@M>%D8>a(Wskw-ucz(P25LXXG#;LJPa7 zp4pegHKEoTzgo|r7<9a-^Ii?8`YP5_xo94bh5rM6zZkOi&QD6-A?_gxY*)h?^GSk< zAxzWB-;gY%ZNO?5>XnW);~!s}RIX53_obNB*p2NTd6!#90K;U7g(kaPkFE6AyHq~e z%Yp%PN^o49@$%A(bOQlEiguYFmp}7nP9@I43z>Xg2A&Nv^`T*Rd!XV?q-|HRy&wL0 zwPICs=yxR(#$IMuQ&H77Z)9|&FiK3SdB~KbMOunLr^qd?ax0s=xhBMZEgFG+OSMZh ztE$!u6~P4=f4oXn2K#1V7FbN3VoMN>W8bp2Fp%z3V zX8vj5K(NE}yY2(Ny6q!7>haQ&N0t~OaMO42n~~$*Xgn_}J&-nlKK6NLHEU%uLSO#s zO^$lMA-{6RHdeBBKmQyWRWCDcVh2yh&-x`5W#~ie$&&A3*Q_7;KMZWKhb+WqIFcg0uAiA|;>FsBPI%5S!8G1V|=PEpw=*99zrcc9nh#L1tD|@Ry&|_?P z9POg>G%jj^lu?D1lZzKg0=%)l8Eh?T^{0{oZZa!27BwrPVqL$8W3v8i6yHkeQ4=qB zb+Or{8G6Ifkwlhf;gV*vvqIm~i+fp~*<}D>rB`9lNo-*RwE{j(6qHuj zQN#*5Louk}f@7M=)Gaiq@}(z`&?E5nv!1oWtj6Edj8V!nR!*KqUQi|J*X(zdPM4IcRmb#h0`4G0Qtz$L8hWilF<*(Uw~w}#+DJ29URFoK+A<| zlOzE`$)&@fe5-+#qu>3~g)sU*UtyD>wD_6!L7)=+W;@^1>iKvYoe05KlTXod#hNsu zh5~L)*J^sp_kOW{qUF=ha_MsNc|P6rvYRw>(e^#N znCPd#wT*o0*5ajwKh6f7v((y+ndAk*ftnDvN8vRlh`ccD8C3}P`DI6jsVp?ovNS%) zA_MJ=W_{}6&cthRXo33pYYZR3-pJM56sQNTF>r;M<>g$wXu<>GXiYwK_g)R|iB`2g zp=Cy14XvGMNiz)XJz@{}!r9GjS1;<;G=3_|OCQ_9m&~Ugsp4HG;K!K2*`YG6?6HC5 z&PptgQf7A%tMTW=6rx$QJ8n#3o*0IUfOcYxzvPJk`rH^k!QXHE2e-7jwKmu2#nj&f zPx%hnjGx2;>MIh_wCh`q1a!u`{33T4;`Ao7CXL1O&ioT1Ic>Y5E^zcOa@wLQ6n%iA zL?5xTmXvr2OryoJSL4&3Ks>*CxCCdZKRjx)| z)^i~KrfkHE<bJUoOya1@6CI6NV*E?!#HPru8F$&tX+8ysj5~QP&&Veq)~Ly}$EfHrWaPK%ztKeArDpy&K)VSkP^<;H6G* zrL@TQdWyZlN|}6LgAQ`ACB#w2WBLWMN4|e3m|w3n_!c35?7L{3_ZF<5itbeimtNQc z8Wgi{rCl?|`HW$(!goNnf%8FmBImXF6!7HRHU$2KJ>DjMp+P$OjumeE{bO2Opa5FX zs{p(E)Oj_KlOcl0r6K-%nta0aZZ6GdJ_BFlu+V@|O080MQ1n5PrO85_AefrDEV* zvS%lWd{ieNu>JQ^t@(iB_93N7|7)ufA{)6)LX>#=&8K966Q_hZs;(^ck{!#+vxiLFg zArc+_bDC*pWp7Fw?~=J|W0nMleS8wp@>;e{vYQ2=7H$ng;(EKL{_jO2V{=5 zB%RpySM%Zuf$1LKqm)cT^OLyQV2fimwinOo2DeZlf;|vI)>JmKeBd7l&XcP50X1ME zErh17f^_M@V(@@{>OEgdXTWviv7!t$ipyv9$Id%VQ<`5*8WTkoWi9W23rd*Pi^AsI zuBQ(lqo(OPDIOV4CZf{Pyj%c}(({n-w(eWtv+X(pe<`MeV+ZtQ0Y*jxf0|7DhH>HjiU>jvNWY!)GWjF8R z!;04o#0&8&KdE(WF{ijYA`~KLHD)S|dN-S1UKDv4_&Bt&BF}3uNoz>;XSGJhOv~M= z4RS1;hlkDwg#yIwF9c5QwxgXc>a_^kpP$Nd`IaTRY$ENDRX=!?V~5oJta#FX>)mqXnb6gJ3Gdfj7oDU%$j7(Y~G|T?0w!2&QQYn#${-*sqTWgl+qVgb0;r# zoOGksGJmV?77GVn=j8TTtd-SAmS26ST~r+E=XJ+Na=L8NpHHW>DOc6-xzPtNmH8>f z+pGnd$S`>vQpn39Pa9UV8J_kG2E3j9eKQ9I#o8{pTgr_oy1Uap_=;{k{V0Bl3;D4S zOLeDQ;5e^mphSz)R@^@*sH4~-d8MHDV;Rr}7kSiS+d%>3D$UABCEKI)39 zs!h1uTU)aqnGvl&CNS|s8D)SUE*Q- z?>$aOPjR`~kwZTwKzX~}-laU4C~$akk7w0lV(S*mI~*bF%u#@4v(9QR$ia zO`gM1Ey$V&V`6|C+PW|i@>`dasA*IDt-Aj-hvV*!pK(n0T26gM{~$XC%iQ@o|NBd6 znKwbvy9E7+*5Sq~g**&fFH0a2rh3;(k6?cT_HOml@OO+CCs9G4tKIsBjR}feA4PxBfg`%?A&aCX9|4JfY|cdfoi^Gjr+5 z@h#cmHi1byzG&m8kB{~urug`p)Q6BeZ^dh8u8+*Tu$sj$ubU+!^Z657RJEP@(s_^9LJ_tYlN)=F94JQte)6x3a`rYIr zGnq4Gn6Az+)0~{G4icrw@ZRFd78Kt$Y0SfE?Syhw^V*~AA8=o228HzIm`8A0k~qbN zRZgAdUsRL?6iKQ)eB=GCsKfuwdS(~}-4Cmqp%_Wz z{VEU#2(qne!b(FpGjMhj3E29r_39SPEX(W^vetzv7H(Uw6 z0EjcDk&_Sux8IpKXI9vRm4=A=NEQhSN|~A#XZgEm4X`J>qRUWx5d-MKVY#D$N>goZ zb!sZmpoq%#Txl~zEx%6E;R*wE^$F2J@)}#Y_k03rfs;T-*(${-p?R#w4zyF46(1*w z+O&jSM0JqPXahk9UdMUDPmgIQAxWQyRQ~u_no+dK2bBy8zz|xGGonTyo};7EeIUqe-#9!7 z#YHB=tN;Q0GPU{w7*_kW1jT|Emay-SCahM|uJI0!iMI>7PrujE=&( z&Gxz;Z1*Xk6KM;F)Dig4#%R7l&fNsxhT;DAM?$WmcW_3u|qht^UpkxoKU<7|mG6vUy9 z6AyxnPYjr6a6VOI?_-^Rk5qHa;{2`oHh=cEr_It|#Zz9--Md$!ybM!`ue>R(E0xwA zdTax|!PFJLo)@1QTTI0O;p*BKUHN3@<@s!w_nX0bHOi>qaQLDWw}qFYuu&y*#O;aj z(n%ES!+O3Xwt$j6ZmWI!EvhHexA%TyPs}Bek3d6KjmpEbndM74(iVEe$^u32Z0`?u zuVJYaNoVbBQ)!p&e|PT)bjc8YNrdmsTEF!fw9+M!?pcQUuVexz=EA4UePfH$-;3+d z=V+J!2P&u$OkcU6(~HP7f{2MW#}I8a+_;~O`*?GZ1d#)7-dc>Z!UGf`^bz+fuIj{_ zGbF#@>MO?=E&A;&84Guiv;kQiafpK=&zldgEX0AvMRMf3P)XJO0YLWM7_Y$ z$Qdv!zFj6^hyv&Lf^7jpP0lc%uBYavbiQ5?Tj9zhQ$&718AOK+GxlZ!REZS4lN7lh z-NF!{AIs=ya>^Y zaD{eFGLlYWS@R%*Y7d*qEQa@d^^oyag6=O7{BtywJEl}klaGvKD!n7fd}5R z6ed4mLgGyw?QWJm6LJ;gK+x3z5g+h<&&O}q&ub~%m!i8Pzi#*q`sA404O!pnbT=0o zkRnjQ5~`cAaKNNb*Q?Nz&=*>ltAVytcAB-m>C!T8!}*BOvr28UN8u{wsfsxGmhO3o z<-=4)T5>=D!@$6{9MsxBfzfhFeT5pvM!sTt=1-Jv74lWs;DEu_68eL@VtJ(5v8Jzz!+dUAMrlfcNnc)bk5lJP~1RQudpVH zla?E`&%PvkZFiez(|Je5!v>M?(MyV*ZwClodzBAD^U3zU{k(n^^;Ig(Kpu=C=#ymm z3(%tOSQt}{x`K|-^NVUSO?l3nV-i;Q?zZF%L?-G&gfP?X6kxon>X1dVce@Xf0oTp$8vciKY z%?EaL4qtm>csH;kt@a|oxQQAPg zNOs!2rVSRGP4C={2%?~SyA0=LIq4x>glFV&7QaHc$b5}J>rwP>h5NfQUSSC~#eMT5 zApS(?7GMF5>w>Ang@^s&;bTN!RNIv0(H zBM$2yCDPckLKb+z`{vHKot$1Cds(zqs#d*VuCA9Jl;^XtxTM&yzZRA-&pXC#D$aWR z{^?U5K~p9Z5vG-c?ZA`_t;)^0@CThn^0b4Gxb#&PIOX9Eje%P|$A#IB>kcfZFqm9g zd&Q7=f$Bnv5&U#v1h%2FxuB}h@<_Qj{KN8uDd01$hZ0C@=w@S~bs0ohp7#tyRd3?OmJs$HZ>EkYXDhA>I^W~y)73z*rVv2nqbKrX*p0y!4-71F< zsYB7reQTthgt>eX0F7tVk;$^@f8?M_&FD@_Q2eK=?6fYU}1PaF2dI zQf9!urv>}7HI9Cj&LdjHoIh(=W_X6bEGG%~c*MdY{QfUsUW^BX04mS-N`6l1YICsv z1DzbHH8XVnu+Rk=d0!S5{rv;AB5{6LcV4;t$0>>oYTivWd-MEghQS7SfiNigQ2IW? zLW9|$S6CH2_~!xCiiz`i_}dl<^+(@|aVXD6U(}C*B(_AL0}8r-r%W#&wRn!OKv6Kf zo;_ZNT9_3vYhF%F&Ux+rn9`LNiYqg?`PoslRFN|_ydN^@mi@D{D8M;B0%en_ZgyFqj9GtfJk2_ui`n5PFg->Wf~yMIqcK{C`M(7@mgm=f4Z1p>bTgBXEU1n?wzLka@M zX8-db{r}q7|7#nNfx1nY9^+>3uhb6h(>zX^_(Y?}IK7)C+O<<3*wR$aFRSdn0fg zjoCl`7lP_Hg0u{^Np(t1oxBpg6@4y(Ht=-#Jwiy%=YMr9^#!fM|K0|@>*^=``=Bz0 zow@yQ$$fcZef8h|%3JyuR?iU7u?JP&)A6_NxDy)s_If1pfn(YGME9@PX%&Jm^S@T%~y#MZd{Z?mnuSL$Z(YZWjYLs@%oNVZ*U2hRzw#@M0|0 z60LKpF2fDs?@Qih(6rNoM;2xT|wL9&e9f#7>6WmCTZiQhtO z$`d2_A0h2bOXwHo?Z)($82I-Q(tZOcO%i1lqY?i5)3(X!xj5NozJn;RI9u;b^0kEZyZ8u->lzqXG+fVV+DD z?#YM#Z%LsUu?Q+pvDu7FHyU@6pA&rS&cen};k=>u>q<(Ks9wB;>@HjKxZD?=ZF7aR zJ>yoHYg=@A29a?Ja*`P#@a>W;9|gDS#L6g!buxj!v@%- zg1{uCn$EJ6E|y6Z|6M|~z>^fD@jn+WX3lJ}&UWR^@A*<=VQBebG5i4!uR*6pS4omWl5jjeqzEN?PP5*)VQ_Y zv_z9KQp@SQUT zUhc#})AL?(>+@LJ_-oaUWVN(ISx2gv9eL`|=AKp}vtrD46sMuLi))Z%lES~u1H&_=*lV+A_`4$Fk@5w-NpnJ%pYAC%@ z#3R`2qOX&Y2W-U;F^ua{T@*Nt_Upad7Sx^!2CSvS#{DjfalNzm%_w2Lw20eOZ1A7_ z(@={kAB1+YGOR$OH2r`rqO>s4m+wtGGgG{LZskoYi|uz=h0=^cJpuP?;U>Ed-(Cm` zvO)Ac?i04^5{_TG!yMgj7<8BZ_RNBm2HR$7h1X}U1{->Yy9GOe4u#HQohy7aoCO8S zFyiL)5y&KALI7!h5+7&fkm`~dA}CLURuZ!{{AqDO#!E#l;sapgG<#mjG627%>2|6wMBQk z{y<5jWwm5!h}A<4S6f11-vxQDjIO|6WmclSz{cMn5OT}DVu=xkAMU1N=okkiMo8XJ zOuvR&u?zP&^I7Y|e8MK&c}|U!)xzlWX9bT0TJL`yokXsbR9bv6Rl+$KrLoGRe(x(K z|1bpe(q180e*1MlIWx~mN;ae&;=dr-4=0~~GXgiC7kTVDYz(Tr6!L-_lUpa|KSs6i zGpD}^>LJ18r@&)|vd~9Aq}Q#qtOX-d0%=EvXmaGPK_5$b?e|G%u#v_32P@G&3Vv{6 z&UjN>>&v=u(s=vyHSol)A=9&tvt{e&6cmPmNvgd;1yr;NMb5kq{I{w!OUm~NGcNV4 z1=tDO?AXtXfAz|M&&4B}na?}FSr{bQtHY7DIJ^>l^m)bQ7Ry!C*erqwT{)8B>W5oaE35EFCsSxE|6&Ku9+U9no~nA_Uo zU-#IUk^}NzF&;@B`l?h~l9BzI$4`^&z$sN4Z4*2uE%@1nXlO{uIfPaIwuRlFKEFGi zM#FmbueB>^mX6+-^5f>C`-1l3B>d-|hBY3C_8Z+Mw_i@&cYEJa=TmK6 z+wfDEmMoZU%7B(VwZQMkP6FOz#0d0U^o)Te3C>5-n8ifKNEgap!l|a%>j{VT$RVAU zdVK#vNh%FmTj2Mlte}r#w@A8v&Jij}4VZg#l@^B`~CKiA4Yv%p7VN_+E33r$cgeX3+X#ig>} z6>FI)_tE`0c=2g(Dw(b|$v4vNTv_-vGZU5acT5MLACsn8U$4F)sybLXuydDCj5);qKLB|^hQIjdtHBN6+?LFvro*V#LVH=$<^^Hr1T$5Xxhd7Bi!@BP zX)HB!$>k?uRSJuyatP2VXTX$~DyquVl5D=O_&j54z#k9~W2kHRX^-oy{0(W?Bi zjI>z?r$Z-Zu^N~WIu69d^d}A z@&PPLEQ3uwQw|;+y@MZA0%wj6V3^J2xH5UbHI^GJ+}bZ`!)TClg5d(hA+RBq%?N)s z_m+h|iW)(oXBSOTI9^laLz#k>-ed=9%P`>Bo-wpTKVk`y%J^GE6F{}{7J33_2rKw< z3(`w=UYd}xr(nFMe5~E?@jRh)TB4-EtAGlaXOxKwR%-bK^-sV^6erFB-xCnB%;h*I z2%slS?6#siMrml+xD|M)E1k6uoU=F1j`FZ(L`)oviBsV9s!3RdP*=OymnVHeetV2O z5VH23)eD;lESC?KS6;(NtrsK{zn(EKZG+!?%GF=BRS>=*?N+HYkSL0&Mr*gt@vdNR z>3AM~xX_7Erd?q`)L2Yz9!m5~W~3xRflE=!vjFG{QVmj_2XK|tCKVAk(BbaTD3DTr zC@97ZY-5(0PFf)*C$L1r1iW*WG^%aGfX%>`+BPL&hl#P8&eY|NX9Je(iA{#v;0W&( zrVJwYocYJ2%P*j*R}w&ZE>^{ako}3LLR`{39l%0(Tk}MuTKC8Sq{n1|zyrR{%7`OO zyV?dM3IL*UoMDMvU27_SbucT@cF>YgpcWzk5Cp9tYnJ8qkD*S>5?KvxoVpo55vk1#E%bq2dq<;_1e%I{WWaFZaV#L(=ax+f%1O8mzI-VgF%b}H zRXw1?ZWss|dB=lw-HM0?#hWO_meFfYe~J2}1c2!RA>qIsN^KrPkPXF`cElojc5S7v zhJx|}_c*?aP2dc)NdY9*C;$Kf15Q4Tt>ni_k?Gm6?$J=9- zgz8n{WUY0^R&8O`_?X(z-Sx1Ym8y@Z*oSwTctcOjXi6$h{W%l(g%u-f5&l=6d zmrzXGO(@wD*0cRqAgflsYU(!X3r&vkDdqdH2o*uFRY)U_5;e5u}6|k%U zp;SvgB#Lf!V^s-M=i)=X#;)B~Zzs?!u`c_xojaFKNfJ!5T&%?XW>>Z}wtM*BGL})= zUDrCySDMp3Epaj~q(vj>`f^<40i(m|Hf*J2V`!t3$rMQ6YFe7DB{uPv>1p3`dfy_b zy5&1HU9B^1C7t47&WRMN0aVI%Q4_+Puy>j%1+P58_$Ak#dpy&tj8P4<$a|#{qofrJ zJkJi^RECHg2NUA9&Jlc|-1=e{;$$}|)_W4(;&c=44M(t6r6>thoSV#v7YQQICS7tx z5aLHIjFZ+`dnJ{Sk`0lq3UqGM|`3uh`tp&lo#H5`|0L9JlTihZPL~$6G~p|&zml>pPtG} zP4cO6caJ(q&S_{n5vgNgL9O{mr{7CHv*bPEkox{Oqld_U22~Fop2wZYbM?+5E69Pa zk?(sZeo$@)qxlkSVvA04LgkJd=F*&2NU{-sxmk%i`IGB)K1Z;#)V!|gMkz}kddrFl z!>)Lx$4eh2G3(!pPp^$5Z`o_KlWA1`HcWM6+`Rbv zwdVCpQRmNAb&b@gR=G-$UA$VAZoFt1vejs(z4kz1Wpl7^WFGRjuho+y^CeWIbJfU@ zp__ZLV6IDDJw|l0S#W*H>h_hnj~uovmtmWIF8i=pW!7^M#wJ$DQ%g1Gl^{0f zK`efELlXU6?ko38LH0RhA_jW4i>7EOLx&=yfaLOD@FQMblIS)4173$dKSM*IN}%nz zCgn640y#sLXmoJQUZv@AXUgY_i9Gq^);S!c=hynLIc?gwLfI@21bH&NLy~rB=8;oH z@)|5#Jp7FOd{t&*>5nV9A9&w;7`yK~;*SB7S}}@w$LlA=S4gUr3&*a9nYKuNz8pE7 z(#1X61RqvGI=OPZFT>6`6`<8e#me#MoltyX#TH~8WbI$^vbX@uNQ9z}Ih}3Z-xp492BDVZiUEw*=`_xKqazvcUUl^2#RHN}1BjtkVvmx34QpsM@F&w@m@<`NbEfq`1KdDnNqPXM7k%tB`U0fd)it;9qf8$J43c`4R znruj|(qH^m`$Ox;@@Oyh;tC+4H5)e%Zm6eoyQa_KWx*G$>75#3Rr}2s+z!?<%a`q2 z47!9wLM=Zb%P3U=_n!y&8gNR%d9s{{_)*nS9{Z;4(!a2YR?rb{Hoi%j=Y=;1u3!6q z8^vSD$fSIs+i3+f=-LDG+nSc<#_Qf;%%}u4*LG`-hfJX~jl2hmddPP)AD<#Gm{TSU z^A5`!){$YuttyoXoZMPZVz18S>lw9Us8)Og(b)7RBM|6GFG`s{Z6$5;)bmoav5+e_ zkzwhS-bJ|fQ5dr1mTrRRi35@*e=5Q&1|}4XcC_^eDUYP22B)6%P#sbXqok*&qBHcx zgi38&Y0|ivNP|cWNL7@SnKBL=aV6XE;CUA2MQ(=Iv@Jw>AKOvs{@G=W#hCMzb7{Dm zMu`(lNJy~Z$cav72n-}_B*K_=IMs&=X*)~FN*LKHxs%SF(pqAGwAqxJL_~4SEHVuU zh&5c_G?lNbzcv+Tu72+Bks8(Kkf*9cVue^VyH9RBD0NbfpN2d}mC9tvAac{}=!(_et|^!;RQzhp zp-l&chf0ZRXApQaDUKjKXvNH+&}1ZZHB#{{K*>%MXCdi*4g}?jz0+4fnb*SiOg#IP z+V7pYy;^7yUA9s`Ow*aCT`=Kntug#flo#1pkzCSpkE&m>zVF3fL*N!x9u-J< zj6y=1pJS#of2~`#n0S{&tt!{2$(6B7Eu?_8&^+%-=6A@p+1JC;xtzbr*8ho`2GVUM zinvy-1MP3q$ctBDfL#B!eOW+Jr!0REq$muz(|x4(zR`2Act);{D@6q+#?8e9u|eHw zLEx|iOCFm6%PgB=p;o!D3_8}6nLwk2LZr7zg%u{>|Nk58vcuCaDb;KwBThJiH==H$ zg@&4R+^f~|7{R90wf+E%De$)zXEV=TB0q@Hu#(z~k+C z!JqV;>?SDYw~pubD||{lKcXMtjrS0m}q~KW}(8H)X9_`eKsIB zKOR&sJA|S`XPJTRVp+2I=29Z~)LXM=V0gxJFs7f4RnuRKc6;2CynllCEi0|<+^h9f zM5C#|Dndd?IAllgKq&M}M9eryN<68vq#P-k_W~!lN>r)eK=MzVHgJRQ8e+F2+g%OM zD(-2UatNx9AwBH*>Jk#jG!Xg%GVlVS9`?!G%Oz5W^bX_>!u$bgLMu@r+D$1;fD%rf4XT0t#Ll8duW!#ZQ=90s#&b zC&(WSF>6)}U9kC*+|oUJxsdT8(b&8fLosFt0K==FsH761XoXb+fdGXGH~u)xESA!4 zQ8IytXt&~$oT5z^e}@HmTVPccBE5}x^UZbSrnsmE>6W`k zK9@9Gd8VBGTFkat&euKiAUN;Vg5Pai>QFrClvS$toYiPyWS+}mNiJ=?9J+LXBH2-W zz2^~$r_eI;hb!m2ec9y+;mlZRgo%YW2hM7AE1USQ+P)~|hCyqU03SRFcy_Ey1g4FU zX(&8Zwvbmm1Io_!2r8%rE+>!#s|L+&?Ltg7vf!7QuZt@J0R*R0kW#RCBou@*2lyA$ zU?S4#@h#w4LxzNGgGe=O0R*Kf#>K;v9T(uxKbT^KLEJQ66$pr=6ne&?WeW}wJw*zl z=kb61ItvwwEZGq0ct};ET*R|41%kqb(c1EIY1jo8LByYhhYC|up~h8Fvu~~CSO^73 z0xowqYZSlmg%yU#k3!cFU13HPkVMJ3bC+t7RhADN#iS~7Ai})U5eJqjBiPc*G_!K* zfjorVxE!s~;>~iEJkKJC0+4?jQjaIw(L$&vD)QjBWj0j00W&C}T)(4XkVt_aJg9&% z4T=vsbNr>7pi>nmvfg^81!pNIUM%=-Z;H2LtSLrO6wJWpfGAYR>O;U*fX|aJ2BzwGaMqDHk>+&{jznGw zs`g<@(qE5Ck>(O$aFb@jo75H@D6>Yw#kG=Jj-(s5rQ$M0!{jWjEWkv=gply-;P6<* zQr70FY)kP8AfX^uz{M>umW(D;sFaK^N@+&YUh4gG{RdM4>Qv4Tz%}lu7niNJ2tH=> zDe?<411j2jb1Gb7?VDnhTi4H;#)?o4^uuupTM=^U!7D*-79J_g#adW91K!d{h=EJY zxQ~^y=PqYFX;C#S&3^^MSIFseX(=z3fbL!px!QEN^*&~OQUk38lB;*|1#Hu}ISL_F z;!`tRZ~7*!8ZP@R4vC+xuC3--*sMsa!snl`*Lq}67ZX`pOajk|vWJLiH>bv3a)@}m zvq*Yklw7H&^b-Rm7aj_h9!EeqmgPMUOfyA+&YXL_eKO)ch0a&9l=VCHu#pwX&3MJ! zh^a`6j}8NTr6BHr8#9GAj%=VMKtpPOV)VD2yM43-{1n)+5GB8qfm2wK>`!b{(*lVbrP<9|{uZ<5zm#5@)8QmSQgzeYZ;yRub@}4CE{A9h9o$ zx6nwc8Tq9aZ(Kz!7P}M;K!D{wd~R71x0JRCf|SdTDrHO>{K}ahoKhwVfJ>z+3opuv zp`k$59O}?JW?@qP@^1pYmg~>0QNeIzBNDU9l%>7Td_f-FU#4=~fMjlQz=J)d9iZgX z#6tMh_i^5#A#1rKzpUi65%YYeSbjjg)c6lGiFBc-E7#BmEd8xHJ_D9XCz(V9Q@Tw~ zbB~HrPlx8yB3r5obdF148#j;&&=y+&3R*|YyTeCWy~}BJ21@Bd1!UgpJrF8-(cwPj zBS8{3rN1Mub3B&i;c1v#!)2P*?KNHJ&q8GiuQz3Hc`29H%U;>5|9K<+%TH%}k;(fh zQ_wz9rST7XiCqd(waf34$>FWRol4?zr5&qDpXZACe%_hYm3CN)U}8!f|7<;JFa4$u zb30V|m^qN3+v`h*%{9DRks99j_SS zR`*M97g-r@M`oF4xfI1C@3W9*k?Ir8f7OaeELmt1;ZBr1re02JVATRkDl4upoTroq z2FpBnp*cRS1n3d=S|$Yc*Oq>EK#^K#6>Jy1yTW)avbPs{X_3`Qe}5o62v>SWzC7U* zd6c_aOD=QGW6CRRg)fb0rJmM1#1;371;Qx2#0pZE-#S+r*!6`g=@q$Jv=1A%+o%TS zBDIirmf4cj&Ou4=`FD|4avR6ZZW!3;8i)Jm#V=u%XEHp0G``mQe^ur;+hn!m)9gtc zwX?{-tG|0&U8u?4Y*gd>DGpjil%W(5l78ClH05oE)IJYqPsH$cYW(l9-EB(`5vQM> z*lk30|HZE%h~CgdA!h6}AUkAF+N20FEZ&*$+L%jbi(^O%9uKVo$`{Gu{qcH( z7$pNwtMXe+^RWEbdKCbG&dGskmLX+{%*IyIPb#ne4@4|~*vWE*EDiomfswnbh z?Ue2F@fgmvOKgIf6lp&H>*?YofbNJY5VOigOzBMZ09rzoNpVFN^FJsGhzfZgpu-dv z%%K!7&{P*NAnRSZ*Gjm4Tptt7zY_81H?jYjV9M`5ud@Te-A_*WFGXtK1sHCaEA%Ijv|6ttEcQWGoV z@TG!Joo}_|*imgqE?x`Fg*VPFB?6lefSA_6R~Ok}5i_Q6bMZuPANuho97qJ^ASwZC zz0VY}MDV444y-DGAfk#N6l?OtEKx-)l#)-hjw$kid@?lN)u4P5X=`PLNw6p;iv>=1 zRK5AZI-osWFV;Lcz`r^#;$Dhc-@VSHgXc+UU8Uy#HWd$A+m-2b8+$<1 zR<^Yye-zTVmfqxsovz9UCR{8~oM{@M@T{6O+y=4*AZ&mmP%Ei&;hgT!#$M6v37 zC_K4r+Xx~Mg!#**3MJpqk=RPCf}a{#rEY-rn=4ZU21LWDV(g`!o@0uNQY`{Pj(|QA zcYqH8AtDW5L7=6DQ=Q>Zv`C;!cqRVADP^cd@$b|ks6=?Q3L#+N<%memW0nu$P>QTF z$K@f$2#N&=z8O6LILvWW1d1sl2udVS))ei8X7Ap)eS}PJ;z_00$%LP02W%ac{$b=d zr$3N>r}RdFr<5-VYWzycFv!P+1Hj_+S&&k=YCRHSO51`3MY&T8O5y3&Ucbt^-_Iil z$%BY_g(=j%DQ-@lQGGcTRZ-sd&YAqpiz}^~Sw(Vhx7!IS^8=_#_&@Z(sRfUAIyUgn3UOF?srJBHrdC<(C82^mErafI5?u7u^XpO=zKmANh&IYQNkpy z>-eImMHENl3@LEph$P_|C@^#KOF$M9;t3>hkz|Nji=vS%G?|JiGSb3|p%lnMh(eit z2!awJNI^gV009Zs$V?jn-~d2z0HBdZf&fVymo~Q0%ci=W3DvC{Z1As)*Zv<%q%syT z{RsR)u4-r_5fP<^P0Z3Q6BCkeN{W^_jRh`|5RAEsT6vb;ikTH6O&eJXwGEhCEMyh^ z@6r(-lpqk8qc<#3WrN~``wva`306!bteB&wu_`ET^s311s^GCl5=S(}$b5u=NQCXX z;!Ye?0Dyv__J}iLO_k;cIs{cfje=O%foT_(45J2h6;JvhE!E18%Y0wV<+I<1*EN^b zg+-07LU0N3yqE;yzxrehN}45H6985rxl@(;XDdDf?`yJ)Pn!q%YeKq{1vykd6- z8yF4hv?DeW>QQJSc+@C#t7RWBgDuX>dTRBHIZly`~)PJ zdg4V7Xq6(}jk*JEQd6ESbBAnS!h#VU;3BI=Ud(@gSau0I$vOt|RH3_LlZ5AS-8>rxH zj;FHS761SN3I-X$f)PptILJT%0)T)306+i$0ssI2004yUF?d!YHEB`+$N&H!0f1xy zfCvE-&4HZ4??{2L0003n0008z-{T-mx^S!&00CeD#Ij((NX-<5dy%&G$tlewf(n^L z(K|ELa4MYzh?xRwmOJJ=P-<>$CmoKskj6xdrm~64ku6(P2}^vpE2f0vW5UebTgf&Aw<3s$mOIDm5m#_%res>v$y?mMOX<9PGob*?kmj zhHR;SIEEHR>J<(2g2G1)JXfHXRJ{vwnHvm{Tma!D6)|d9uth6sik`M0q1QosmLc*{ zTnZjl$rd3xcuA`UL1AcYAuK8$m}(gAQ}SXH=q`H?#0NH#9n%QV*}c{$XH$4Mf58J~ zWWf3XLh_B#vo$DhpQ4Z6yeanJHi?Zz*68?=*7zpCz8ejToILi(tF5rzHv1tp4_7#5 zbuhBVGRP&AXrV-2VJt?xiO&WU(9=fN9b&m42`PvVhB&{gj<7 zivY_!Hrt|@q*w(!Ww#jW&Cz9ighGoO8*y#0Akp~6qe@Cru!Gqg z{-|U)WFZ7G3}gVc*q2SzI>R-h;|vVRRv&6QVvT%*6@q3zuj}PYt%|Jq)Kb#2 z)iA8xjsk93mB_ul4Lq+vENc=0%~+=zwB1Q=vKXG~&}qK@bVSn-La4q?C{kn3TScNJ zD-Sq_J@E(7M$@Wf%`^Gbb4cVY>*Yl(WEzW1;M-5R2tw4d424qP9jGW+Z8v=@=|(Xl z8V({D`z?GuB^H3g?$%DsD%cPJ0N{SU0RB)^EQ$(xYe6xB%AyS@kT`p$7ggn0JgpRS zkc2@D*JHx{AKa6iXF14H1R;om_Utj4n2Ma$*24ICA;?8KAQJk|wSw71|CFh0`l5!j7X_nVbS-699%@jdJ}L;l+m2wRO3*^^u>+nM17-nb(~zEoMz{tR^XdKKWoycfJqMdI&yMt3M5FU zEIuE5&)3{WUv{v1A%vB1L2-3X#Wi=5BNiEor7<|EKPPEknlK3`9MT1fmUIrG8 zrGLUH40N?L*yO*s_wowPx6M%?mIx@cVsu|m(;`pR?G-b_9UB=$_(m>4qzM~dn?YVf zOmz{|^w*sMQqJR4K@F1v#Laux(bViUXGae+d#>n^U{ag6h#^Q24cAPNF%Q^8R2M@K zIZ{5^L00=^{IX}-7YhWi6yuoA1Oq^;fe-a%^s9GdR_^o{_^MnCt#Q{Tc$t)*3ABKy zI$THz_K-)zu^Xs`SELf*S!{iXDp)17J`O?B|5sUW6M z*wIG(%!&~WY!ahr&{P1#003sZe~Q<13`qts?I8g#u;8EHB}geTp}w@3US%MXQMIZ` z2qw9$(=EBNKy?{5ED$LP{+28GusDCX_{B+D0)a9K8Xa2bQLPn#NC8EjrC^%;AiMVf zswo#F!H?|jBE6_8tXHpg7thJlmW@MiJc@f&5m-Q&cjd3N1;5d+-~-Q;!=w>d+L$gye{19n zi@1yCNwH#;dzG0m)G`)>RVE>2_}S{_+PEt*5z)4J`7SZX=ut=OMc9~%vymo6kugUt;7&1ck`xlY}F)ZP5vXxU5X>ec!yN% z;8>&%55nXILe?x4+2*+_R*LEU%j`gl39QOE-;GH@sgeVeLMJ~15-0wXJHVoc-GBIj zFfsESv&j@9#9ux+98;G#$t>oMKH-LCE1gc=6UygB#w;CaWO=WzS_IIbNJXAbO{ zpF`-uXz@)Rphxf`T*>@B6%@S=^P z_u@c5q)~f)#)*+nPdhpyT2~0}y)aRj=l^2;Y@teP7J2%!lAP&A28E})x;|1Q(E4qe zBT1BBI}yK6o#(AiEQODW^%PRdHdymyHzB@h9QKK(bm?anHjqPX){!B=iTQ}-F(e+i zuEnXu&p0md^1Rcqz}Ut_Dsi)HQy{2o^*E~;&{{4iF2R_Pp3R(>6p4_FNaDkmhAkys ztvfwKiTPi})=)*DOb`#Obd+EO--`CncTp`+O}zPsO!+t}Fsm90#*~L~*#j12Kl_DN zfVhD0jD>aQz3ra)WiZS$I=_LqR7hMPV@8S{OgxLjG6so+6lkKbw?aYDD2WoVgAEXq z+==OdVIFw!L9GDp?R}Qh(9=*L0003C9w>nS4V8FETDB@=>Itqs<-VPx8U&F7wH=fb zV}owu%&L;9X8KI~l@JLlH(V08DivIbLcd(`GLqv{>}B@2{A*&hi6&HN*93{v&1Pg@ z4JRt4t=Ts$PSLic6RWB9G##`gnbzCVb)~w4e58n^QngE|4K|72sfmgijnmzJ(JgKK zO26#@pRPSi+Yl9v%eQI?ud~`4f>6)U?UHrJ`9H&`(XbA6HU6=mS*Um6Ui)9Jl3}WX zeRJBQ`qWM2<+~PS#Enuj)^5b|0}Db;EbC^yy89=sjU}S8F`Tb9BbqsBI}iumWiZ}r zZtHK|R0$!9BE~BzbtJ^ssM}VlHx#~2%j+&sD7)c6G;OJDRCS%!o9x8xCL8)9pHh{! zq&0{qP-;0#AXGsU;O|H#$nIvuN<>i!c};ZiA0?BMx-^znP`4V6D_GRszN>wej7pnF z%%k^QlXQ?*wJ6wEFT}|WUZQBC^6Il7WxG}hetBW1naT!zZc z_1yln>QZ8V%~~Czb^0?RQ*xZY84m@!jgdTdARk#v%tUrCG5OCt@C^solc8`}jm0n= z673_+Mb_WT2_K*sJ&%r$h*kSwqz2^ z5ca*Vl1y(iO_?Tjs4Vl^R7*8M&7Ii=mcB5UBwJcylIaJ2z@{M(rgs1t*kp%<5J3-X z+Z~x&IqMJyDk9D9CNQ}Brb4pvN2a?wf&ekB8YHFF3`0j$>e6S?CT3vtas9A_h|N{( znVl)8O&(5V?z|fKN>AdBCfzTX^w}BpjYE-kA{hs8dU&NI6qk7!!U)ZeC>9BS*NqB9 z=Gx@u&vjj&k<(L6!wDZ>;tS;r+HJIjBv%k(h^C*%8acH)7{?s(n(A+B2bWoO5&GndbalW_zMuWxE4oHE%o>jJ3< zGk)=uStc~xnz+(yHWCtMOL+cdVxHThqUiJydOHcHWVNxu$KQ~c4;Vx#SV2S(TjH1I z&fx|2`03TWc`;*TWFJAc*&2>aye5q+#Cl&bM=sqq`b7wXnS&f@o1M{+nMFwl@bb6v z)h@##!-Z|a4HU{R;*K&JDbBD71eyiG02UCD<_p*Vic_72qgDzr38~2R zPrQR7mB?5x!V#@*;m4vq4i~m69LH`$MxAA19N=HDXC;^XG2xk`s|i%S*Rgh!bWbS}51Qd;pmKGEwgPFhCWYF)Sdy1bA^}@F|XY$#ML8D9m^`*TDkOg@+0m zN9ZG^^F`c?M(I*g2wP4?y;~v-JS|KKZm~~AZ@C_sFl%UuKlChgzA55M;@4i_fYYK; z8DUfc!D_FdrjZy>DzD6P=%FS@Vq#+mL`t+xXE^yim=A&jP8^Yb`lc~VibWgcp1CDA zTDAqJGjyi<96N>uM^oqo!@niAdB(8rUU>*znI_^qNU(_G(o zeXBs5t5Hv_pnGBHM1VT+B@MR7eM0%L%}pQa7-ChFM<&8)O+w{Zu51uZE3nOSR4e=| zm7`07h~st~7Ytc?A2z=^cx79^xo7zN*j`JzsS#47Ts_wbMxL^(D`kC9$co3cRZ3C} zMq(1!%$n{e=~gYafrCsn(PUH-A`uBC zlU)>J3|b@E}Zzee2>EY&#z}7i+BRmJrZ+7)**QLW+ zvRW;xZMyM7<^yR?;!Jjxj|Ka4eg_Q{c&09v$12RR+B-+RjZ3W z15*BM`C`-}v+*)pOi7VbV~f)pE5LGJO9soyO25UbqN?67a6ofp)y*kF&h$|Ci?Y>0 zV;~N}(qa>{FDu z)2mCZK{OPVW#skOA9-&Rxu>X@3sHHiIW5U{vvPyu$sc30_4%#6u6N|u-}$cLQ@ZIV zUe%+)gpN9l-*&B%cM`c3QnC`J2k$l31&V!$#mTW7UZiW%CWAXN(Nz6>Q(ZnYIILYI zKd3G@o3OD)v`5TKc!qH#o@cU`+@aUJdo`?3y>|9KC|bm*eb&$mmQ*6=usRY=03z&a z!ISq`-JagBCBC~R*1IW6g2^p+EBdvS-E+4^NGxUf!LF3!O8!Mjw12TQ3Ow8WL1pg5 zwEd__-lgq|jpQm$&3Vyh*L8(h#^$o4cG(xMsXG!l>P24GmSDsrn4C)vk$m5#gVm~v zCR+Y=2gBLqkBu>{)c#o+*xGIDTz831{do%&RI3y%LL3PTssyDfEJ&CE&85c5)h)CP z0WY(*G8m-4S_J$^`RH40w^LSR6PK+&S^SX{Ex;KfAd(RmlZg72UV=r5MN|=KiMEt0 zWa^e97P3dIZ)9O93UAPkS0v7)2(q&&wAGbB}U{lZP&MDf?43#I3xnNg{RO z8ng1U?MQf+r1kgzub0e+$m!7Wq?l;(29|@gMQk=(1jzd{m-OAPOr z$}d^=Cu|`2_Y=hf;&nxMN@%#8oVUl2y3odn_LpmN!+Y&1&2hdJEU4HHV6kB~OYhAU)Z@(9;;=ey43if=d|o(ssXJ%n;Jg_02Jwdf~*Jng_g*N zu6oz4UZrEsIl)n(ni`}4lC7pyZzcLZB?CZKnx9k>H`^%uxD6)pn}Bl4J&g$QE zSw-YqTz2(H5JF+BmzHbN(L6^L32RXCRZ&geR}(6Jwd{LK+Cs7R+6%K%*=%+?DTAlT z{q>W%XmugYMGvilR>80{9OWt>r&>XUQW7V6s8;P2rK0;%Q41F>D2Sb4FH%gZRJPrY%LLh96vWGw+C}}Zw$OaV&yVCNy&0{f_Jf&i zGz5~PzaemyVO5{&YOSUP)kPd#h+%rWvl{Xw(^^+wG)h%5fvqXKT@HArlFV%&;WVv^ z@o$!oldWa?K8f32%$-~YoKuiuR%(##9n0A99G}A0V#)#No34^nyQ>|zNibJB*BiuU z`bDpWJbPCio>FS{&o7^^sZmS+f&PxxpfI~7*l~fZ`nm;+r){t^^7Hdi)$guui9&rj?eK>jr zQXKK#3j9$G?5qp1D*XjO)^0gGsILcyT+D;K_?a2PH#SqSdj-xDM?Os=<QVdu!=tvkq3-)gt?MGo)P2TNSambB#w&siKZX(#T{_e@|@` zTG0xHPP%@Wkn&nOp7+&;Su>?QKEqj(WDHxx(~U!>v13S^BE4*vldmM*>6EumK+uyj zKT1T~r4^6SV};?Q?iyzGusu` z@B7rLoP86@U!}PvYKCHd&l`{M% zo`GKI`BJIzH;70AneyBbm(&1xmF*x3N{&C22Fh6%dMLa_d4+2pLGLQFr9*g2mQZ~` zc}uQ=8;4d3QZI->A;!eCrhZ67G%Ia|c5*8XZsZ(jB$jEoWI{yK;P9;2@T9g9V-$hF zD;ZM3z}Zo5bGFT7qAm>=EH;Bqre0-coqSjvENbuMm9PE7FX5_qs6IWh?4c8`cu&Qx zG=;IF7{Scgj4GHgLz4JQasm_2rqKMZ+9E1PH_?ca6z)2vtpABhwd*+TL{G%MQu$q8 zmgVPaF8aepnb=4ow8a=T%yg%l*ho=?kSY_nl5Ep((3ue<=~7tj!2&u&j^KdJB>XrR zF8h%cOw`k3r)H7WUvJxHC0^NQDQ(Yz%@nZVB&Q`MX4L)xNX{H1FyxT*;6_lz2$UiY zLO2u1DIeTS>lQP#JUKboC#8&)C(5^mOEZH1~{Kw}l zAA$KegNsU$v41yR9^S`=A~N~4({Ge{J4NLOPVi?OGEOKMFRR!y&;+Un4od%~M&gE2NeYZDrI0uCtzbRUB9_#n7-4wJo z$}%t4*O1@ubU?C~Sp67Fxp4C2J6dX5&zmf2DQeC5j~Y*U9Uk-FUg!Ei*1o*!IT4?o z4{P&3nsN_3Rv*HsFbm|_)BQgEEtEpG%Le-gykD00D%d+EZ?JahbQ`1(r>Crh)|H9v?<$f({+s%z|f6w&AtXUj4+2sg}U^W%E4KGXKZTWG?4i>Ekg&9^x zPoO#2d4x`NYd3EfQlt3hU!5cqDf^G}s(&Mv41v92_9&6A3gF1Yzv7t!UvJ4L*>^NP zMNoR|xmY{(Spp2bSW7(__`Yl$R)O_Pb$933k87Yv=t@Ou@oSa&O2uZs(`XfF9>OFO z%K6iXAdzb;Ota}jn(rS*!oe0zCn!OkL$c=6MNhDE11xc|HML^D+NTP_zysN`u2}J$@k~5@JO2@Nonbkp*5JpbH*_I!MRW+G9im8{miLV}(&3sC3;L zbahUnwOCa!gSqe#-ygcz1w}{GA~G?Y z_CQ17<6HVhS-UR%V5qK)=o9`4s(eYLo@$@};wDWrzF6uN`Zxs;OkQ2*2Ek{CXjfr4 zdF%r7^6mHKBj=WvmnqMRh$C_6SPr32+unMBD& zVI&acCOuq>t3Y)XJXn5?Zd2Y$m~Ty%B;FmQ3ZIrIq6cy9XGh4k9eEC1M2X$%*6P0wjWb`CHf69|gDkB&%{s2xUeAEmiYXQOGmZg#WYB1(Dj&^<_Tg=w=5@BHnas@hBB+bK5lcUX zf1Kc~DNbf+d1|2-+XaesrKNpRHzpu;PrRrsL_rG00RgvT+h4g{t>KgU-CGE5vTZD;&~fvuIhJO_s`dC+SATt{J|`h1-%V&JnxjJbN!J3 z0003Dxyyjd;AQd#3&5KM6`**`pkgo?wE`|C5ugb90uqc=qen*|3J`#LuuUKhps_Cl z5HW_x0YC=840ix5P!nf>K>-ZFQo#rY01QJ?N+cT+hB7HK3_Qb-z@tV5kO83~Dc}qQ zFaRP@5`YU}24Dgh0$>5Kz;Hk(j|OF-ZE!gWMu7kf0e}E707g{;ke~^?5HEsO00aPI z0ATSn8KB@5Rwrug&Dyqz`~SC0V{z`b;{UUbM#ydOm_tBeT8=u zGX#dpRAdI;gv1Dl<`iE8;#9+_=u&rJk%)6$gSd8uk|B(QQxDowu8YqCWdoCFLtsj9 zE&?MU^~HBhE()lLMaoG%V8#-W8e**z$c_?zK>$1lSelj%B{YIvhcA#o;}u4uWqQP~ zDN>wuX(Z}+les2Ea5$QJUswp7AZ$Qo*un!yc-HOt*tTHFeWjzakYVYpmD(be4=%*w z8fU|7yOZ3hC5l194;9FLz zi0y!zu1rCVHC;H(n4nSO~@iO5ajs^6$%dCw7!(@&VHaCXx5^gCj~*hH2Hnv z7)?wNQGgMIFpM-}j|&eE2tis;YHh@5us0-WPZ1cUPk=YAa7mxJF9pC;(?Zf#9(yq~ z$jPzJ-fv+dMwMpCSrK8Y7!w*5O;e|}lk^y-X`09-RWgG!sp{Tes7bEQ07gL!jAa}b zip~cb$yl)~l++y$l`)iDiHDtJK)oA^;&^R?gIHLG6qx9nXqBZlfOjaUzB(jld??uy zrz>RBoR@v*aP$)(YCf5$&=qmds1B+&f3Cs5?a3MIWK(uiK`vp8Ej5Wog5D-l@wY1S zd5nQ7Eb8}`paIp4?Sn~`Qqe%ii5n1vj0O+czAnR#JN%b-&uyl{(HFTM;-phdV2Nu% z*a?J<84Or7@?h{~pk&wF4)g28Hj_*@wDWUftu5GVkq*PPXA?uHTc*O$J!UZw!V5H5 z3w~yjh+3e(yD;W3+qW`|6N;EW`r*iPu%FO=(>o$k|MJdMruJ@VD(~$k_gNPA~ho=D!SNc zp>g!(C^mHKOWH5ZOPcK+QDL)kkIldvflj$-FX7_JoI)EEVp^hdIa*e&0k(8QqJN%* zyThkh(OS$~Qj4Csz@uVPMtimR*dQiR5R799zx+Ig5Vl{JXFjGj=@O=w+!0%XBrE)o z>`v2D5QSgaNItluhdGHUF*$ATPODCb1w3M=!l5o=iPIfqjqVO7)>E)^u&Vw;P>E?bC+ z6HV@)wHVCTk9j2b9!yP;RC_BtY)R<1-9+_ju__8L&M)po_^F19@tqSZ-cZ|hAU7kT z2^#`7$6wtyA<7SBaV+4jh4-M#CD_)KbpSKgBYSkRqlJAVK+FjMn?Pj0MasJh9x=rb zux3P>)>}0CMIw8K)737}k1UD$`y!q^K<%D5WALd0I94ePh^?Ij3_%klfW^(DlB9+T zvnO6DZ%2OW0J+0fv0}+5H4akr4=EE+L1gG7TZd)&!-+!(%0LiHvXcxX&&Gp?o@s>w z@U+NFQx+CW(iL#`&wZ8n&GeWl7^_t|$}sH(gVsq$g>Xwer@X3Ss+nnWn_w6t3>lyA0@sFZn-|3(oW^j7 zkSf5Q23iAh1Y~6HQ#vID4d$(O9FLL+Z9%I8K3Tb*6+ehrA6%!(^mQE&bu$hKoZ4Oh zDNWJo=7fvh54Q&s5@@|NUdNDmO_rEdlhs8f2tsVGn@ z5QIAxejtRm+!-kJ_=P==u!ChG_YQq0Y)4374a{YMejnP*%6UB zVZ3L92?JPGlWJsSDh)zx|0NF(gdH%V;$CKVYZQk#@@u5QXo&`(STfkM_GBzyLYz=q zg%acm;F=h-bWKuw07Qr>eVyDM%Iw^>mB}_KPUyAQ=4M1N8BPE&$pYdL6F5T4LOy_) z+crr{nREOU7zcy@Lbhkh{WK){y#gy26C-q-a>PBVfphid}!qXB4L_>p7 zdFQ+`OZ+N;s?p2R@pS$dF2&E`VI&4?;Q=nQ{A^JSyR#KYuMPkbl<%uKnVA;x>Fuw*!Er*jU5{X<< z{b7nafq+y}Oo$vP{CPJVfwBw)PyiT!q5$ylkN^M*V2s5h9efxAc4zFi7PEcG9|4Yo zII^uB;t#OCi7$(#cmY{#S<0Kr464kRmMv*sAmYZ8=bWz=py&*9SEjErE-Le3@k1hn z9qHNM=#x~04W~WcTH0i#g{F=ugpNIfjfowZ$gB(um$aFE6)>!|IOomO>u*c03p*XW z2%unQK|v4%P2i)f7$LK_QUW88;!(i^;2{PO2xdqQ{5yFD0h!AQ#g@(6D#d!&x|cdG z(6tR%4;jIOtT6%fZ77N4Sw_9KyBOtihc6a{MTcK_V2WO|O*8uXSu{VUo`q2iQqXtw zhD_YB*;xW!#}YvrNGG*P=ky|GfSruL#A*W>U=EA{RqTB-*)23WuQbqUN=q0 z!7D-p5}BRwYiVI#ay=D>IS4GVGoZ!HGJ!w!mJP**NMk07z2$M6|hkl>_Qg1!%<@RETvHVxwGmA zXBvd(fgLw{tS^8gm)6in2~6j)etDJ&n1qh$vI0w%VwfnC+YcL+x;NN{*|Jc7sq|if z($6tj7cv@HPYI@!3R0FH!V-&`DPR#FASFEt7kD6}6(CDAr{J*S^-Kiz{YWK|*b-n0 z!KV!%n4?5(rX8mMynuo>5FCTR`hSioMT8_#4`6Z%Ae8=itRNm11qsM{#9;-IV1~&6 zA7gxj+0?GW6$~v;!#~P%yI~ziVF`i((qiii#*}xkCgbXgqOc z!2V=HaeovPXLo#p+#^0AJw&8LM0r^e)xZD%0TWIV@>!mZMvkN0lNESQQjHVUP=s#Y zwC4t(l^a6zXxNmVB{RA=VoBd;DObu8x|>A2NHz_+%@gL5Q8bm2Sn?#SucM8|vnrhe zhOegN@S(Ez&1C@YG>x^=TN(j-s5a$mCfdQ<6z4>^=Y6xBnpq0dY-Vph>T458pwKT> zC&?~xCE-E-?xwcZZN&HKD~#J34mKwf(NlhnvXg1E1-bAP21rR~!z063+_j9p{8HpZ&#i1^@ z5NO64`ATv>z||Pg=%RqlIYnM7^05c3r05~Z9PlK1AeBXviU-sciiSI;7+HRE=ArZ0|3KCo6FYSTgVbL%V%`m~o; zaWMrED%g018Yq#F;!pKz3#;Q zLffinK?_th(P+D;zd63r{w@MES)&^QiX%S3?Sb^Axm(?6{c4KKAJdf_QmjTQ8QRU> z1dy3x2$Xku2QhWa6(OM~Nm&I>(oF`DjbhnEK$8>OlVd3+R2SdzZEsaw@#ezQo+UAN`_s#vxw zKg~l{QV?#w%LB`L*DUyKQ1gyQa5_yZ|4ftMC1NbT{UhyzaZ;}D!}(l_Z=fv^M;_R< z%_QlitU*L9`r5@Rwd3}ss+*F}b8`KQ)pl}H`APNjj>VN8+PsyLNrofY+WX{EwQi2( zYB6c`e;Ui9@~lnm^dN$Zov^iBLv~a?rqzJ!H*4jIEP71tyB=hUAM?sF_#G5+aVCH3 z`K2XY95hn7Rz3=>Ud3`*>q2v`0*=P@pTA==EcM5fEpZ27qC+Z-J(*p##!sw?SR955 z+A%l1Ps{}ya>L_~s4dQ1I@A4R`<6GV5z!XQLEOci#QBJ6tQNs_n5Op6*A|%6Nj-a7 z$++qqqVya@MHWj|om-aK5bIsYnhYw5)rh6kR=KnmA&7M>Qw`#vvZ{ok z2ukrILlCK$HP+DteXq2Lze5ckL!D?~1XBmri)c2LtxpyE-YWmZ@#)=CT9ax&XRHmo zCWAnM#`vlhZP@or%)w0!ih*V1%{e62Y1qvLNjHKAT1@8Y&y9*F#*Bv)NWA5z5tRuX zU$#}~#<6YwuBz=5W!GX#SexU)#THg(Mfy#0T$9xO7B7gK)T9$f%t~BC@?&&go9hU! zJ08UL^<;uGeNgcWv`X4CN$CXxp~?}N!ll=gLN?0MyEzd3agt<|vLL_4{BV?)mC1X$4W3P!D zM{Hd3za!MRDcs6UNy*VE0&W5}{!;wpmSX2o5fLoAgbEU{v8;)XG8<*o(v;58aXjI_ zo#jZcwijVknOl;=D1~&mDzPI<`p$i4%dBi$7GlHdys6@OsoIvs*vO4iN%9GvNKph7 zr0^(lA`qk^tfz(TDxd7xzWoTFCA_N>&`y%F*AaTf&CWqp>~VGGmEv$oa-CeC7r)o) zH5T06LLsu*mUVq|sHy(^*d z8*|(rS!FkTlyyFuY@~I@&rFu$PS%JwDy2=-Nm2H-NExnN*t5)iPpv@8LiV+&TFT(- zZHnn60PcK61C=hcHxyGGA0+Vn>$t|d_{WwQ|%9R6&LIMvm@$L z6ql~K>RxE{$QqP^?ALM*-!_;F(5`iJ+B#ZPY+G%H(EP%oe%WgQx=kDEdApQQqt|;l zl->aBEHXTmv*G z)@^!y)yrv*9oeFHs}j|WM(vzxq`{|I)c;dW8k9eY#JB3h+9#6+UkX1*)ZMlyU zg#9N&k_iAn4W23e&sfJrzEz!&rY0oRGz)6MfJ%Pkbb4QEL8nyT3?RSSDzUG zh4l?wdesG35EBwivKoLJ7FCs}C3}N+qzHy2vZV)F0Z|JZd5cMe#}RP2Eqwvtt0SWf zn}Tc_N2vLEAw)eN$*MqrK2|1m6*Vs6L;&BoBdzA**SeGjQh=!#vevC2l+&q5N7Srg zc80wkHSEOIEvr*`&1!1aErBMDPD?38M^@XuxkUoxFFM!r?HzkpPG}7oiP+*ki>)=k ztF7Z#pUL~=cZ&9P9Tu{oBsB>Q6YEFGNku-RE-$J&=ZjH9&f`S$ue0c`S|3TtLFBAl zP*#xh`Lwc#p_TP3@j4l*K>lCx?COFOPp`$Pmo`uu)FK-vw{>G&{yj&1OnDIJE~6?` zzK*KmiWEh8Mw~*9^Fzy;SNPDRA}Rxyq#T7B`klr(SmwtbSo=9Zxg}Dnh$@Q=iC0QX zM*>*wecMo0)+et=#mbhYg&& zeIbZi(UET@vL`25j=XD4b4(=+t(!IS%d&>G zshet-VpjfYDsCplh}m6y5fuQ13MpMzY-z%zrH>M`q%JbEDl2rJ_Jk{5JE@sOvX;Wy zCarI?wmzltJe6nK&Z-cjrXvQ1YF@0Z*O|ke4Eda`Tlu)~rE4i63-y?qNx5U}SH_Apkh9^dUYAc@*#jYB z%%oO78~Lw^<9|U2Ml0T|<>?QyWuiHCqK#N93epbsjZk?Na)xDzuUEMx?#1=f6l79( zzi~Vzt1@1!e<>BQN79p`-brRGc|B@7jngYSyslk%B!cAdRcu5c_t`?-4@P}w$s$u7 zKQF8hNPnq9wd_{?!Y{D&|4CMDAqyW{@gWG4L6#^j|0P|J9mq+(OB>`$LZq4;=cJlX zR%&@S!dDaybCT&kyu|{>lVyDD^17s$R{O}m!5%UL61$shsPG?N|!jloCJH3Q%{J4b9(NOQMNt z9KI;EZ5kH(o|8H z;^p=V=5=ffO%vzUnr{~0N3R=-T})RK^>2+wYN0b<)1?@LrEOiLsuf#7Jul2od<>vb z7qEt>SI-5)-b^y%cCt$>0*Q+iwEDC7k)PQ2z1OJ%52m7m?xYt-M~OY=v0mn8`>m8~yn5HF@@_>`+?kJ8wpA ziLew3Z_#g2^?`2GRFmd~#5pjA`|4tUsXDB7MI`rM%{eKSQs2;(jZi%w7PSSOuhbN=*3xC;*EsH3 zOw>uY^(`yh3jHM(R-~moS<~tqO(Kh}7gciGwalS>Nhy6c^b3~t4Dou@A-S?3o?WpFEVxz!{{yic#vid-^)6<=L2DLY>incG zHO7UU=}n&3weiTQOwTO;t5zZnoaZBnlPN3>liCQ{! za4|+?b!bedH`t!(WaPWVK60i~o0#X?wPRxcDbO-f?n6lgnrqTA?h zTd^-S{nblgYg-hWR`xr;5|rLcL*>f)nn5i~%B}RWuH_?`yq{vz*6Frgb4NoITmV^X z{wX)mYd5)Cq>WxD$tuO59&*iSdy2h^H8v~aK@(#s18GM0t6R5?{FZ86YS;-X&0aQ0 zJ4^X>|0LtSmU~qWQ`)U%C2=Xq4eC%Uh!x{vhWi@FlIqsAXa$?8JFQZ6K`MT(W@+#) zmLyn}7XFM_efpJFF<=>-nXn#E;R=TdGObs%D zYV6vRUE_iQWDYapg{uVWKCe;({ZSRb60c&CWs!()>_lqCY#xNBwNXJruXrC=X1%;TBaW9 zb$U--7W?~Pvn7@ik^=H*+LeNBw`B)d057Hm_PF1)2H!rjaXBYcGpLB39^lYq$fAll ze4J=a#cgZ3DHX44W#asB6)IGlsQWJ>_1W|JS(VW2xY}>K`JpJZG-w_bKx@f^nuMC9lF0Kfb6eVr&^z@TN9c?px|MJ|}aZ*TOLZrt>PHk?}lLqG?yhRz>Z65Gc`_r8U=vxLQo;D*kJpEKiLFnr@`A;3Wj7xRBiw zMA83O4KzqyzSX-O|62OuT;kWnxUO#eqxUY$Jt<|L@tD1qYuXi(oC?7Oj6=rEt|63U zJ*RzhMw{bGQ)oRW>}uc}n_AT1V?7+0igF>hj5}^k!;Au$!A$Pm_ z^?;F997|1o^{!VUll3ohzi<+OQqP(ywhYmSk!4c)Rmp2X5kMd~fHsRcCQ^Jz_Sb*D zqnqK#EI|g2Hk0yy1OdTn+dF&lQdqs&#r)#Ph)mm!M^$=t;ahJ(3tRiGJU>Tbx6LzZ zTJV&;AQ3E4GZe%?2q2;eG-1gCTlosXK!!*jM1k_j5R7JIL_|bFVx-9cnvf_0A`#0g z$c(9c@f8s111N zDN%s~DjGfni+`WVJSK@kxJe@2%hSQDjtK%GB%OmN6JB_($N(J1A|*vpV;n3vxM~Dd z6md!B;)sI~CdGy1g-=G35vFa8H0wui3IQDiM&VbY%^0s;>}ZL6b(;CX-Z}wD1%TZK5^A`;fpxOOrI8ET3ZfOQo!VHdZ}_1NdZlfLM9!Z%h~df z3$MXye4rlA6=!8`!?RhmyvnwopxrEj_LWNtpg~9nS^;85q63WyFtT@IJ6fEsMGF3N z%F368;GrY6r62|F>AhBQ4V>(jN2p^gP#3k}P%#~lDhbLJ3T}(%4-%Z?71_;M&L)_7 zKuAWsA;Y_YV6PQG-%OrTq!xgbj`Rfpe%|NN&i=t^a~en}PF8&V&t=iVnWEV^j@VGF_W8`$XF1`q7lY41M;~TX zjB4|bM2a~7yj=qXxb)-~TQH+xF|GLSdc#4Bjy`ARI2x+F}8)K(qQr#Jur0Tcib-~fk00gwlV05X7PFg}0+d4ZWg z4-f;Q0|o&e0Pz3;5D6Fs2Z6i*M?(de zuzDB>1^@^KKmg~E-~bB(1MmQhVt5!$6vPk!A^^}p2tZ{40T=;d0~vsT0EA!$fB*nH zSRiz4UEs$Y0L%aY0Nv&XfB*mh000030000W0000000000000000000000000009}; zSS%+1U;sccp&+n<0sxC7pQspoq|m?BnSgbU}RDWt zx?o0%L-7%W z6R7$+8mh6bqUE|iD(fnGa}+&}I&o(R3R-e#=Jw|=EO4b_+$10sghrt6YicHu6_x6o z1baEFZPP)86DbIT)ScxFM`+1!)W?p&XsmFD>!HyQ#@aSeka>}nz6?oXloB#y2u41Q zwCHT{ie*lEA11aCASf+>rX6Bi4XhsE0003R0w9tzfkp)xkRTWc00000002NB00000 z0697tswn_L%zyv@000qy00000kpC1@Lr=5mK)?V1V1NJsl5A0hL#@Oh05AdOya0u; zB8n%4Vq}x>Vi3X??ee$qLLgL{kV8h%*J(5cY7iSz6$u48?ue#LG6M$LQ>;lnq(%`a zQg{PFBANI%GGO{hf~m4zah18FB(I1+@r*E>QOIj zv)Gehy5udrg#z-!vqX&&G)UMaXwsjM*dc|mW{oj)gPRb9h(|nS&({U5-v@ci_Rku1 z9tW^~a$!rwbhFsm{j()d(yp(crunUUF@39G(L6?^-F^>8@$(QKjNp)J8G%M55-7$L z%X&*Ko*>9j^RTM}*@>7$)sLB(hrp*gGJz%PV8HDU@;@tm}IC4{P3~a?djG0u^$gHZcXCbeq8k z2#?tQVNj3|NC+hn(6H%IE=;~ww_uKdmL?R^qe4hUxrovqYfHkJ%u70rZp}J@#qeGd zO0Nvwuji%6E6`h`G9Y2F(!jaVvRw=7ot8bstV@1t!G=5--H48mVow?Km_a$&AFxtm zDjG7Rdf1Bigy&Ob3|Mwjk6%FG!xGZVEFdY(SfmjiDWRZ-Mz3FE$GHsL6*Oy6pmlp3za0f8-O zdNDO?cZ-sn2cBvSV|beIkuWg*;tWCSrof7Y83X|*G%YJ$TF{$*M(T*2DgloeaBmcz zLWM@la2&w$LY$bUQ)n@yPatwl9cFAc%N#}o$go^FJfeqdxV^G9iJ(%2$JSItbU~cw zK|w_jXv78(8heIwH3Ws+goJmSXJzPhgAG<7aAGgGVCH(9^OvG8Xrw4eRvC%-ULFP)aeCwkZn%EoozAq1ph0`^r=q1dBfs zCaTZ!RGTe>YNpNY8<~P(LrpZjlFcMQd@sv1Kn4Mp8FM)hS>d*NC2g-gb ziH$FZ`OjgD46+RZLgM2JT2-OYNT7AJv}aHXowOU^U&})w)2Nq(kZ`bIQs-ih6HzAT zJb?eG?LrQqFd{>R-5Nezp<}&K-=^I+0S-Y4hM8_4;X>8TEk{pwyMq5iE}#X-GJ%~4P^coHV>pIj0AH8spawE@kPOR< z0N9=DEmF|oD0UPTV|^H~ut0yQ-$Zn z40TB*#$+OQKEdHsVN>8@XPZGPAW^|kHQ@Sv9<%eaDp6=40U`(spD}9b+J~i{4w4=^ zkfsPWWm6)-2~Ggku&rQDPMAt42D+Pij#fzOlG|x@L134xr@XgEP#?e72JfvPPQJMu1RwdD4 zDHV{L=x+;|kaC7WualtPJ#CI12h`hEs;ZR=CI&R@lV^ZSZNe_Pz+UOymPKm(CNbFn z?3o}`h*mZ6L9}T!M|FUUQa&U{P+irWhR6fxiviep&yG-!!bFe5*%IoB3(3>not8Xo z0R)93FL`MRJPA+!KwnLwaO_YJ@*pH*DcEEsP((`3XUE%WTTu`yXLNxBt4V4A5GJKT zp_3k5x(p!cSJOGdDuz*Vy_x-Jnn|AMJt){$2u1JcAaPCo5_70%V2U&;k$Bazy@AF> zYKzd&xf3N3lsLFSRxFA`Y}ATyr25RUHZE0%6#2Ao4P`?WEQ}g9pxNK}T%!;T#3ukY zrF13UI*xMB$*c1z{v1ToRH&wtMVh*Ta>I zRFE8odPm+`W$sJ2fD5j{LJ=FGQjl^q`z?Z`Ap(|(wUHbu*x|->eCl{5^4WO_w6(7O z3@srEF_VlaPRb&3uC$PoDHm#iTa7tu76;SP#R#U?v;iGZ92{yfv~DKj!D5>a&u+~1xRRcrvr zOlPq*LtkLFMnxz9(4vb#0fTtMx>eG}ok}@5pRtVf2u;tJ8K|l#-M|4Dv?7=j)D=ox zPNav|&3jKmAt9-3m7}?U@UOjjLF?3|{E|Ri0&aQ>ez|n3HIb2{`RHBqVYJ3HCIck3 z&A2W=SMtl(v7Vr!qABE`k3z$zW@kZ$!63KBf;MN0yO`ow235W_5Y6gSj zJ4ALh3KbOF3~jVTsgQP8l>9nJN|>`|a8X6fQh<}`z#GDlR8!42Y}VqiMuGt$qu;OO zg@LC^f~8vi@gETg3|~SHDMY3I5P;1>pnk}vR}QOOX2XO~ayjDKo`q)83FoAhNV!Wv zuoG1|0Pf7l000C)6Dkuz7z`c6tS*mmoe~KR%x5G$$Kx)ypWT%8k&gp5CKL|yIMvzx%W)Th$NFgvleVzx=6VK|Br@U={eUzuZpWkkN^Mx0UJZ4KB6S8_R~h(xuaas`t2o3ZO$yqV|LwbQBoNg zg>8Uj%Mm4p@h#mzm5r499n`lHhpYl?6p|@Y(`^|^DnC=JQN34j5CNhDws0MwtND?Y5!Z6wz_TO`(0#p$|jq9Z-k7ASxmniE`@ zlX{s_Q8QP40#+vDNXvTVZ&Jyq+_2i)Rh**<{{^KJg+brc-X?_Iu%o+)9dM^j9^vd$ zOiV_$Ldg+T*qWqjgM6%_E833iXSK^YBKGo>3UX?Q0wn{s-dxi4#>Hq7?pg_myv^hu zc7yiX$7e1n?FX9*D6kp%dK{A;gWyJ)l=Ct#N@j6D+vDp_$g+OY?IP2~Wsgo!*>_)> zWvoglD}43kw({z9#gTQMo=_AvsgfMJb$MfKsa|qqwXMvY=_TEH##alsT`p~hz=bS#FCX9qhCiA z%4bL@kG7C!k140lh_dE#UK$c2PbzchpNOzCGw;yn0NUoSezqkg!C3K8xwwU#bvUxq z&{WYAq2hZJC>g9qQ_|hY1gWp2$!22%nv{{JC{mFLbEKcFthAZVls<9NlBHkkL3QeX zRWuYAK2AP@J@asp7Ya;qR9hThc~Zw<5?K;H+zozQ9zFMpa#f^;*!l3 z?Wdo1RBRtNk9UHh+Io9s99<5NQqs?Ilt2i&+>IM|WrcyJ{|+J)XwK8Z{T%TNAwTrm z_G!$lmPT)K6CpDXH7pu~SHAda)Xh#v(y;{)R%&SS3mwxg{B=SE}SuqOYD|L(rKSaU*(E z@{>0AnezfHPY=B8weKaxG$$`kU)#mDf@k~WQ<*{85o6|Jo}-Fo7WrD!3YkUGDSXMU zqTGDRvb&BLNti?$`f`lLr~l{S+T&(JocCGMUq&dJIap$uzRh>Ru1b;opt8=9YYCliVnT_JeAHA~eK8>+ zz>abwIZcwSz#~eVpCD?uCd8n5%v;hklF`=O;2>0>^)iIL#2`T8IfO)U5>vW%0SXz3 z=$6_>dTJSCi6&nt5F|U?pbMzG5sX$d9W%BPJdBV!#WOOo;|xTa zP*nn>!IlK1dDu#HwQt}AB#}RkaT+XkvLYm@OG!f^oH-qal(h=LMvri*BRI_1>5CP6 z43<%o4iwjF0uSS2-_YPlQzN>YAB0yUTK2Tiz4OR<#LIHSX`p+n_u=rWKO+YOszx+0ehfFLAv z58|AlZa}>vo)IkF(}2@u5F`K{1?nC_nUp}h45y1Ffxt-fS*4y)=AEPj)ZG=%LEom; z&=%QgfPOn>yt(MM|7lQ2o^crD4&>M&XCQgbDe{Q(D0UQ)Z*^cGGk%(!bj!(6{PQ=7 zT!g&!k}s$MKC~=8WEA&W@UBZIXbl^vD1dj1TI9`orEl}9|G~}Q0?DPXMVyT-{s^*A zMY&5zh{?LrI_%u7I`VjSZ0>bROAn)O9p{@XJxa*fmg4>xONX{o2ZIexh(&uSl#7ra zx|wqoCuN}Gmth|X3fJ~i$7^w6HPjN)u|guF*N_&ID-}AW{vMyXZ-rRdTKkGa)Cv&M z{;s~hit3)vU-4jw^it6gGH=QcN+poIU#CfR3vCXGedHMnjv96U>M&03V4wUsHL zA4*pUxGdcBjUzU}u*Q*{(r)xuDWwjJ3Ar8|d8^r_X?nka45DF3JN`^Q)Vvg_6+WK_X#S$=Lf$)PK^JbIW6$W5{P9Y|OHk z1O^0}tGJa@fkA5*Tb{U?)Uytz*$`p-5UL4DO8bfQi{uu(Z<+k>4FX5@0Lp&>M)Xy1WX+hY2*N*XE(p;2ERMTV)Ss z6<%%w4^mnnp^;V{OKxe*TIWQLPFD*GT-yaKCc(IKQ=P}-Y0o8ni-L7T$8tBRXw4Uga_+75)<9^l9>xC1b^Dpk3?b2?fn@7rumx ztyJUm(k>OxDYMniyvL@QcbiU4Zf;4h)E&uUV4pp+(8`D2!4q*f%f19OxcB&D#Rxk#utw z9qs4$WHPLkrKQ-H6ttf$R|Q&EG*gh-1#fW|oQ_F$C=X6qN)v&9r7kRh*rDq-cE`OO z%$s8-M_+S{flZ=|PDr4&oUaCXBC$HleZ7Mn=u$3*H|061*o})Rrz={Z9#KD~Vxdnm zBQI!5aO}!ts_o5N?}Af?XAG2BD$2|sSc<(^hdhYcAEpa)U|uYII%S#GpMb6$qM|*? z7=|`dOF4PKf^e4nYN-Nlj0L^F9lqJDW>_tH@NT%jpn2`dXX{^KX(M(TiE#?;jFv9xJcYoo?iokySmBG_|o_EI8!5)uz&rfkF+@=c)bWsdtTebg)aJc zB4NX_KF%^R_Z|skp~rh+NOar6Xcqv4M-CYfY6pgcK}<+S6lE}G$>k`%A8e{GjSUnu z14aTOB0a5Z6B<2yoSC^Ch{rH;Bzaj>mrG2(08()O!QpsvAS{2BveX?1nAoM^QIyEj z@Q_MyMww&}ixMdgM-ds%me!ODRF6FrBBT`b>5@&p$t^e(4FonEA`J>ZwIdNjkaOZl zotr8?cIb8AA7qYk zB`O!-wq9iJ9kc@z*21-M*s$rykCyg_?>W86w2bOd`chg|Fr+N+r(9QZ zWVT31Q8I?eDCKz&EKTidFIEJm-REk`NWV0zW~-xIqeqROdVA!{Pts>no*woKFk>+6u~>Fr`Fm?Pt*XtzD+@pxyM z5`LtygN&8}FPxOJSKbg+NieCYQ6~49Sff^7Sp}eu+erl?wDH($l>HD&OQ%gd%U5V0 z-jm{!cTX(yd!&)JNjxhkX6~C}x|?XYl=o)eOjM2N zBPF>^+3mQH?L_4#RkvcErsQUYDDb8~zoU(&o@)y`PD|rT_k0ev-p?i0!{y@(B(_LZ z(goH@3Jjxqt0k*C<05b7W_sH__bS9nrkD~a0thi<(34;3c7A%=VL_y%7{wx0wA7O! z33iko8`!*vqG$GuSzS)S#f2fUE>uaB*mEMDkT^2v$bsgRw!WgKMI*43MtD*`lw|TT zT_aTK7Zvu^j%!L%5*#>rR#v6L zZ!6tUNJy3AvriLvl2c=%SwXCPq60ETGEP*_iJU@A;Nl=oS@Cn!1VukAyOPC)x#UW@ zZAXG<0igAR6nG>3yGa@Sh(}hZ^N}2mu-Q1`4 zD{{0{%fJ+BaIzFT=4_5A81PBVx~O)=yE0b4B^9zeAV%bK#F+F22__m z#E}kN%y;>lZ(BJ>-})_9s3Vk|o2cpG`0sdr^ctSpL6V1G^;c&vKXT&qe9Yd+fNnD& zrTl7?LT8VTxm_cX8{>^J$mBMr1q|fZ(yz}_9z)K( zu@pg<5!^nq4g-!76v%(s?0Feog_m2!m@^cbZd7EMpsKU^9=0@eirTSAC|VO+qPwW) zyR*7cWt6c>yKOFAi!hO6@Z7_T#yC-^H8BW!`xxXw{pqwRJ+u3FCGm@%Z2W2qG8z``qP{#r>a%YkIX zj#&K?O4LxM70P~v{GL)9xebrI-V2;0%+Kh3GV=VMXjktgml@$M^3j0#bG}-9o#D_0 zDJ-QvDpc?$Bjs68Q2@(ik58HBasf~gfT=u!%Zn^4%1IH`uFhPkaXt$Xt~EP>)d2#4 zFT2Jpv0u5OCYTnAt$_^E(zacSjGfyK(VJ_&rn*U}NreqlC6vn#&+p^28C~uc2@ao; zlq`Wt1-YVbSe-YL8@HLTq()$QLY1ebEfJ)6Z3?P?2N1!y%Zd0N5OekzYC9 zS-hcAzr#%j2}(AkC_+pRTZjk4nW9)D%i&`RlWCx=%iEL{bC!~Lv4n*%q_)u-ln!mk zN#b1E1QekymzC~)4U^7A<_v%{6zAo(eMY`FiN}kbax>PrtVA?3B6o&3aOzDug_uSv zZ>`?^g{q{zf7X~VvU{^+#p_3FvQxqtLy(f|48@1}%Fy~HTy>NqC2!vPUw3mL`J0+_UA0XuxQ*H8CJ2tC-3c38i`|BC#C+ma15oyq8~dF^QtOv8~C$rZrK^lMhmWLxd8DVio)T~l9E z)xCC;y<=4L%I^J0B`$acrfiC$hG7s^Mf{>{jc#oW%s6ujQSEz5B;K^|LPou3wv=V8 z?cUdgJNPP$j)i-W#gM3W28fY&^y%q^T7d(YjuemoV3j~prF-KI(rwB#% zOA>`HoQh&NXk;S4nmMqDB*(ABt*m%x=i>NgLBm4TRKOC+>Kmuu3K3TYya+D(}3zM7grOi z#f!uX^)2ika<(xNUQ$ft!Ro>&d2iLa&fA!>AiZ_TU>v2r8!l|37+L17YvQxotoB#u zOOY0Fzdd=2-ui^#+lS1Es8%Io@QM>`w> zw6)XWPSePicOq(a$(`H8IVlHB#E{Ao5_8&kIRYSDRft?O|7=WH@6Q{fR)L$%g(80$ zMzsM8DSjY`D5W$Af+ktR7AS?FR~9H+)c~Tu6&1XMSpqLlP8=AB2QDbTN#-enYaEF_ zjjbFpW*m2=R`7eQog|%fB6dwZsuRu`0 z2|Z&Oj}-mk1&6e5QZkC4(}B+U#yVTg(r^-Nex{NL8?Y=U1mCArgy061tT|g4@yRb4&vV_Cm&KO#f1?= zg(DjxOkc8I2OW^EqtEKW?y!Fu-T$`?@-iM_|H~KpR*pPhM4-YIWKVWoiH=V)|B)2+ z0R!?wgNQQ0MHGPt29SzCqAmG%KoUYEQWBK)hycP?UO^wc^K5`umQ+bOaY9Wo7M^zi zV_Q!wp-_@r&k+GQL9lJs5)!r*0c8dCHnI@}J4vxgB$CBYst!Yx0SJ)Kh*hT{AZGro zvfEju`bj_KQBoCklp-Z16RK*TQZ@%A5JicC!N;xbnutQmz!XiqEUef{kra}mk_`JK z66z3AOB7KF2>QJ-LaYub(O|x~w^_0IYg-@)C`lG8>kyL3iVS1M=Uvz3Bdhqlvd_bD zX4@;~na8ec=%cB3ZpG~Wt}N+Bs;nGE%rc})U1A^G{@L;NFB|3mmGjEGw(4?HmDR~O z{n2&)mnX|M{c^q`JN5A>5?eT9c9oJAJFlt)uG!@<_af7sR-mv2PwU;~6--OFhx+AHbb+>wx=@6N z5>uHnkTG6rVY3vsqDpiQVt;uu?`uGvx-QIt&mcJ@hhzdPXG_!!V5~|hR7RzOWQes| z(#RB&Cj+9)a+%2!RWCZ+7MU2X*HO)x=(guQ zmoh?%uL}u|u@3cn#dck}g*5Aq1_EYhcmxA)k(mjo&}EY&BL_v9u*74*zouFltvIrL zk5MXl-^r8kZ09uUtPe#;LA;zmF{4lMYufYAi*7MyTZ%$LkA@Ny8;v{gtf$dOnQs(~ z!MWw66e*TKckv6B5$96spa1{?9NRDpAOWxf@Bj<|9^@{}0p=mtb`I76x;77k0_adR zpaFpf4cdhfnWd-0O%kS z01@K?2LRRpP7Dn}gCoGZ-GY*S1495%0bPg-@B{b&#w-Se1;7G+Kp6ld7#14x*RmbZ zU?G`hWHNvl02p2XFaQhyumD@YU;x8#7)%2pfM^Xp1SP>gI~nc(4cGu=;0zD}00D>r z009gDzy?47Fav-AfB}dAH~?Lg2Vnr+fExe6%LvolkD!T;aAw$d^)mScSOiR-ZRV39ajmOXk?rmeAN|3d!}r#O(L#o3cse9;ZlYUo8$9NI6`yQ5Jg*7RY} zfjxp~j1i{bgDen5f$}4yASj0EOnN*+V2Kk?Q=5UZ1Vn&_SXdAU0>mCfh>ppTkvu`j zICkP^@iV!Uyh^cA0!sW4iGl`<8)2mabSuE0W!o(&9~ZnDL%=ve6o^K_;*DDgh!nvV zoEsoP4ctKpuAwGXD25yR06bA!D#NxrAO#{M#fJ$rZ4rNJT|@<-q6t_cMk6wt%-Y6a zl28ead&WqQ<23{TKp7T0Vk2C3#C#`YkH^XkDez+y zQSxcmxFduUK!F?@K|>B9Xbz)T1XWbAO;uw%6M%5aaSDmah-sW+LXF~Riq{JuM!yS~ zAUg&z;5CNH09*h70U`qu3V;|0<^l{r0000m0000G0002M0002XXrzXqib#L}00000 zU;qFB00ba7RG8!+00000000094vCy?M55&`QzFo4k+i0>H-LJ{CojeCP3iT0tnzr+Q0bdq@SPa*?y+y0X5@kM47TB0=4lS+y(QHrG?ADX2t5gRMDUgs9R6?yQ4F&cHq+0pt*>EIp;b!GE4tjwPgju~uG`iwzLfPE4B79~Uh?e{9myaAyz}u)NNt zPt~T`+A>}+dI5{YX{vbW?p1-{hC=bQOB76KF(|1nGMf~SS4l5SV%4b-rVh-|DQ&$l zI$HgO4g%d^L5vbEoG4JJA-z5s&PfO0+(7_Q79cDV0t-XI_KM*78Fyl49I6Y5F+@WV z&_G#*L~X<&3;-Nn;vB8$8yUd!02nvc_y$~r**(v=BH5C16NB5`qm#nG7`7 zP$dwekNb-XTdk-~Ax&1V#dFMIqK79MdQvJ%q^4)L&eR0CLgg03ADrf;2yd%^Y}@5V zGNTr?B%Pig8A*^e2{i%Q6v*5y@?!@&x?cvl&6Hm zOv)#$F^dSp5IGCJw&hVo0qpC{s>te1CbfGN#dYH+ATZLgp-l!Fn7QI(&Zd!{0Th7uY<6o4@d1R$N%4<#UG0TGxZ zAc7TE76M#GbjIKW2f7B3CQx1EgW^RR{DtIgfQ$AD1Pb1H6uyf&Xj$|SgxHeS)NRp~ zI2`10#jUEi3l*iWtX|9z+zdWFi>=Y1rtj9K&OE6i-1FTY%swU#2p8##1g#>v8mWyc z&vU{`?#@a>07LP`9hIgebv#>SjVZzb8zuO4F{B28GBlt>U>d;b?YKWDvOqTAqNHmY^QsO0-2hfd2#2T0qJ`hlE7)0e%8f zW}Hhe##5w!mo(~FOUx1r2y8wO9f58pTv&I%c5x!Yyy8OCy}nEY5Dmn!ILkxTf~{&K z`#UJoM7_vFQvHjTiedd;q9yTAEvp+k#8(DG6&(=~mS|`k%n>z~xKQdIV1eGRnlH=? z1QOHgm#HvNCqDP$``KK#0Z)82S``qu(1Rj|AQ40{)fD40kT_HcNf`tK0T4obTQnt@dS=u*nsTg@ z47vyq?G%I{Bv1rP35y>E7Z(1He6!z?#;TrYB-J8?2Eh)&{8$BBF(^VsMya}6r1v2l zgNA`GWQ*C0hgk;R&<1ihpTa7{4lE`}uEzQZTo<6H8?%-rEG0B<66L%D)yb{02MdF0 zZrTv}f&)b{VVFqS&ypDj)Hpj14JyWvBBx?j(d?xNj=oJihd_i;nn=2lBnlx=!HO~* z0AnbMEtKS{jYqRHbOdMs22;>Qt-u;WbEPPvEMR4!vM*g%uIn1RpaFs=%eOM*G35+& zg0x1_5er3=P=J<{fe`s9KtmhAa00AQ*{6fmtQB3rkmphaa(`i*X z5Rg_m+TV!LGhHRiGLuk=8hba>w)|imqnU{a6Xleq&r+ErA==-l+mv7;K8a0PQC_Ve zZ7NYLsD;~8@Tux#nwO9e?WrmxsI5~d>os_G>QO^_Sb^8SzaAv))n$> zfeLa+XNkJFD5HAFcH$kQ5?NwVJl|}ZlWkC$vE4;1|65I^Z!|@0tFp30oeH1z9+>Tv za5EcQZ=-=PG;UZltaYo+8(E2%pLL*_C3DzLj-pd7t3WBqrLhF=K&_`(jN3V;OB;07EdSyFRl*O)YrG4u|8+)vq@njUd98{%GtxirPqYMa+8JuwqvCQ>O3Vw&GzM+rWB(Cy&ED^(Pdt5dK%N>! zPD}|!8#}v4q)5(t{xp zPvRe$kx@;3Q$2hYE|!Xsr{HiL5@*>*b5<%%;{CNIPEr|EzRJuDT@erce{nCm{ zn2S@>zp88Of!gEcrDP-WznJ7%ii71ka=o0U!KB=qsgmpGDCxY`A4N%PmhlT!YQR3r#=pHvATDnwiRFtFN}TM_)6ks!G)Z76)!Aty>%ZA^J5 z)yl74rO7IMTG-}srb_$PRankMs`Amq^O5OI$d?mkcFW}rWXqJ<@h2_i_rvJaXgT=P zetA3|NUrE~eoJ77;GE>YZj}-;2Oy)3R~tDZQp3G2wLP}-)?&k1T>_A@OoHc&$qG^i z7Hz=V*O(qgrzK>u?mru`WZQp$PLqEtpu9QcMLqV9Tr`W>e?648wW$-VS`}DCfa^rF z_q$|Di`;tJ*SlvNqCZ)upt4n5no@?*5lM-nY2R&LLi9>BDdL?dC+&Y8JMyjK-BMgK<+ojPvxieujGWrx+w%;JL5$ah<`vSXEv zJot8{!<3$!jeYnoCBL63Naf~Rn>4deL-@6i%kfEP<{|j{f&Y;yOKN8%QWA)~_NH6N zqrji|r^^e7Phx=caXm(Y=Qdqvp$cU(n1UXyjdsa>Gc_ndC!Hxrl$(u*IwVQ+1s?r2?@mEt^OP4( z>2h;3%tf-{OxktK{-dQ8#TID`$V<6Q__-_EJ@||-nw&yH@n|b4q)U^N%Y)U;YDc59 zEs7bEcr&7+!MemTWT)F6oxRHtjF{=RO5E{8G95Fr9&Di|%aY1ZX=4@EC?m*jYB`!Dd9T82?1HFU z2h&Uno>SJ)kCs6(H15a@Pm`C{8dRX<8%r}JtugD!q-Um7p8VJIeD}_Kwb1=>N$Zk* zRP;NL%GHHAYcouJHpyqymn04=dCGlpDnR7DHlCX;zod~aWJav0>*ApMT_}=#S=@mx z%#^w3L)9)z`l4EPdh%|U;+QR^PHAa<=sYvShdbv&=y?+4RzyZQYqBzGDd0^4l2lS& zy}c)SXYdBZHT5g`NU5hPe#<5hs#(2n9!m|G@9X@r6G5o4Nn}cAXo_+1idf1*6%pqq zUy?cHohhKLzWnbhK2WI{Kaag^`{rn0pHX*&g6FAGJMHq2Tv|bYSbFJB?L*C%eNcPO znf|_Y9R0nLG#8hmVyfjDrv;H|XPrFX<}CJ7Rz%xMzL;&6h<;ldURa4Yg3V=}JxAAu z*>8wR=Zh`+IWBT)`IPfID3*E0Wejf{U22zGb+UVXlvnZ#*sMDdd(T@wyY8aqKqhc9 zmJ5Qn%4~s(Zvd8yHXBnu;vyJLEemPxh{GEsnfPpN^ZM6i~EXA&^zNHHo?P4I!zzUFaA_6 zXR&SRNhLzd5HHVV-W-f5`q_KW3k|K8S}jV`_s}T41ssv)OzWq;=}h@5FBzog&3VWQ zTH^T=OOH9$I~x$^BYu{w>G3IZ%*giWzCJEV`}C8^i1I-CKL2TbbAwbO<}I$1=#fuK zL42{dEjFr|2bL#{?|`1~CB;6`+sC(4cbKggB6y~EY{A_)ha8Qmad2#0E@1TQ#>#$F ztw=T@c{Ag*jt_@A4=2PnScbT>r1D=lgg_el)hDVw@$v$=kKK~Ey3Urpc~IV-SWQ`( z>vmXyKH$1)r1f>Q^bor5^a$(4N znFHX2kg((#kct#|fBsRTL1P+Kg)jf$p+90XU_f!;w4u^|6%eDG0whF4L_l_lp-)r{ z_9iqa+Ouos&eG4NxD+_nvZ-}*!ogzU7?8*{(L|SrO0$g)v8QdQofaz6Je7quEm>oN z4Gu8t(G<-7a2QZ}#oZ}S{t*!)CT^1EVcs7pCl?v3%=Vz+9@E-K>z@ifG{d}%5RyA@ z>AEZ}|=ak;_EgAuu5NCcvF-h71 z_i^{D6r}`FV6VL(zi6FeEZ1(V_*B5owkiURTRQa9l~#aBt)|+Uy#NH18vhSr5wND~ z@ZWXh0*6h;mp~SOq|==&^WP7v2sol>R1QwMS(B}iX{Kk*XR8Lzgydd)l$f}bBK-t< zqyt=!TLYivWsuYv4m4}~`F63AyaEUlQK=b`)KHYgCj2!iGKNGHSm}WSp`Fr#H#N>& z={m5ZZcG&`3a?5#2%u2^_)P;s(O@c6Xe06pA4g@GDcEaANUR7Y3nnBaJD47)h|Inw zBd`q#SRr9ZIRfLYIA+ZtQ(s5?nSnITZE>@z6x6_UHPPb9hiMI13bs8H%D?~r!E|c2 zauX6gRfCk5pfn32qHGutI#e`GLNWuuDM2CJ*|hJN)fX@g8Wkguaqe-H6G%AQLERLr zF^dR-A*2*|dw2!W%1TX_@A9_9viWYg;6ekGJBI3I3OUK?*$RG90Ih}lBl-&KZe@O! z9>FwCJAwvHNNiYA3UELmk);TfG=fMPJi8}xA<~L|9D=yBZ1Ni*gtq-M0AL<3TEut7Q)a8VW@)g&?7j zaELXz8S*rF9s)J-8yVwv48s=b$qL&7vLP}2_JST8Sxh08SOGL=p zb_rU+bb^Md@Go$J|MS{f9whhXgE!Y+=~Up$mIuh0_z)^8gyxo*>4R1#F$9^1A`Y3j zce7f?>UoBTDDb1k$dh()HKgDwJsy-}SV{E3=+I**@QqqJb-MjxrULp7fYJ^ev_VYV z=ZL#LPT5>f4p%9jvb;}T{6dwg8%$?$hJ=?-bsdN{s7s|*!4$O~85mQ`RuKh;6j-9v+ULLN0YC`^f=Cl0x-MLoCBbl7_DWA8 ziUDPXcb7bpE6R{S>Vnuq<8m`YaZIqTqp;=t!G|58yV1q+aKqY|M_t zq^xAyN9Ih!sTJahut6x6c9qd(YJ%-XS;p9o>`eS>;ub@;({_7x7d24&wgb zz+F%DS`W!)g`j9#TAU!TX-YK2kp~WZM5{xPa~u-5(@jYj$r^9GD*ch--r!*NO6b(` zzk*W6MVn#(PZd4#D)CbI3Ff{riS&3>&TgA-s9U2;LO$h9Xo-QBH5R<$mk1;n)HqUb zqMzrwB*&pEG*^b1l9hNsVWn%Xji!uKtJVnQcODj&2%!pG_*9jie2Rq}8|N8W9GE z4iN|9DLx+jXgjm4q?iU_BcRYT)4HdoOiwHWNJ?UeI+H?KBnfL@vqSARchh+jYt`2J zE1hL3|IzR9b_GR+v9fDKtZMC(Nvl|x@UP%TG)*QHc|BO#|JV=V>B&V*ISUs|!1fn;i%D? zXI_QVDn{>dAtsZpU!>s$gQ%)P$jCW~jT4ZS-}&k0Q!Af|qv>;eJg+tSwt!y<3>q4d z%^Jxs-v~4<5*pH)DJZ)4-8T{z5b&?mEJvu10^HKv*N0g6d#7a_l#j0eO-)iqI4mv@ zhzeKQq)?ER)@#W_BOzh)NaBjA7#OFUY>wM*2!gg$aYd`u;#%UKQ*p}Bp1FvSlnKg* zBvM-Mb^}(;!)L)FPIEmn{G!>6}Ay*2zY=`&--OV&H8E>cFgH%+Xy2XQjg8c5pH@i3;Ff`oCVQ8L6B zVFqbai@lwrNu%<({2n`l7jA_da zFp$nptjUEit8B>OOej@vTndRf;Y=woHJ383?Y686>?(ZrmX+5hHDz%%tYIjw7PHAF z+u7mOiB%G$o#`=tB>XKT){RorAM*qXo+pGup~Acv0MfXOjLeg@)|%CdZABi^Bq4{U zgr%)&Ow^n`JA^WXK}SrV|MfFym)+HE0iZX;R}NorG4SCKalw2@s`h>C`ylo~zyJUN zDW$-sTm%RY1O^H?Fl>PEjwQfV+G(#4%{rse2%Kq9i}Da6O_jsi(#P^;DP$ z8(R$dqw1o{Sd~aS;wXyU`6GCeXjlxr(A6r4VE=rmA1AstGvJ7-EGGb30W}DrXizpzOvO+TXAt5KBBvjmk2T%tS(-Ao&Vd z$m`))vD{)$EQXsx`t3 zDnuFjhj*<5=mT9r2s%Y8Qxey^XxN2FJOBUzDkA1V`H;#&qyVKD0002M000311Q-B{ z0001T{&`!JMo2Y60000001N;CAOHXv&D92EO+l#u8Y2b(1z>>yz$e~LL`{>{nYtUy8niX7K4Wl@i!*1f34Ya_rQj< zwGA0RN|eww{H7&J6Z3`Zn5GMN(41O;yfyre~cWkr%tn?5BPqv^)J z6uu6EMvqvkMz%a}5Gy@C+l{!}IC5i$QPqsc2731w5;d%7%c4plFi8GaDg0TIMy(t> z6IpBy17g`S{4`LUwls^O#E8f$leYT58hSNS#u&B}_SGOI9Ug^qH{wa+*QT40t#eXh zVvsx!j37%Q7i>x*p(!QUlS}#~dg-T)EnK?P1KicP+|z5(!o5WwFTRy@9e3RL-13vI z%@~sftZ2$s#Gdme<9Z3YUR3g!3GaSUUtKR^qi)=TX*slKD4DRr%8tWs!*?|t73W?M zVJaES8@kzs;XqcQ!O%sSLb$goI5wM}bZw2L$8CBLj5dv=K{2)k zwdnPsn`P9fzCACU^lMZWSp{uNq}Wg_;v{(Yp>Uc{G{sdhVM-Cpf~mm_ihh2xiL@yf zCYfA-*;^A~^WHycUxO7o&R=mu-?-ZhTQOe&+KWkd!ipPcl;E;taXVFt5d&2g5Lig2 z#T@1qOR}|q*FQMnBzc6ew($ai=A@{0>TW$ejO7p3*RGxv5Zo-Qafjz{&ef zcySJI^REDc3DPSHbgf{J1SAh{Gt~%b@-Q4ks62$>cU{i-!2XB~UsbQ{AUM#mJhH9r zl}M4N!^zzDe{nX>@>Dk4ZCyY%5)lJJWLx*iu_uigP&f&p3y`+hzrne%w z_&Mt@c8#_#z0===BY1Z^j4}Z^1!($?VGDswUd?W`yQB#}w`M7cf6X`|K}3T8RdVJ6 zR&-*ogoLq+4pRY?avup->&b@9$+j$JobYH0$&*J5G=-i>c5iTk-w6toK#w<;Bq8w* zkYe@z0>)THC6GioO9Y8@-{q~U80gyo7=Ze4`*EHym<9#7F@hlV11O25hU3a)c;w^r zy3;gTJpH`ntW{N|8r>An+g@=YIG(!l)zNG&_!5@6P<+C6VI)+#92u6g;xQ2wsX!AM zOcgmGfn?{pBp_%kRp9b-mKuZ}c&LGEL?)7cz~RYd6d=xfsOEDTh@i!&{Y#o4Bp?hG z^cJLg7yu{;K)?^8h$1iq2@QfUb>S86iAF42@As-Ef{n1FU)f}f=`h1LBRej7QUNex zARrj+Sy=(9&0n34LGOjwXvVV5M4qbsmeP1@vEcC%JR23&8UwO&bVavShOD3L{y66$67N?Muu_7ukw z<&0zk5TpbQ@Qey5!gw-8A7i8~xJdv9Ahuo07Ns)9ixXY+)B1q{pY0s1o|rZgu+gPz z*g!#=qy`iS2D0{kQuYMCYb8dWjRh7TH@f8L^HLJkLG4m|U3uv7ySoa%3ntoSuaQgO|X<0~lw|_&i7!4DbLi2C**r=@7nJomeTw=wd z-}YH5_i)|4gy`vu?r8{ZI3d#AWWu62;~}tr1QdlyeS6i?Dk*3L7=&AXVSpxqFc^jE zUw>jmN(@Ghc1a?(rzfP09>Q?h*-k=k{3k_5%LZ1HK(Bc+#qs8)K)iNgBIjlZ+6u4M z{!h9@&-w*3!kkFRO*RS(sKc%uY#d06NL9t%AiIuN`s?iu0J6b|kdq_%D`yP^H3ETd zM2?2q(h3WU!KRD0D&W$u7%=>|yahB|k!s({6!t?x{O~$)Jc-Em$tx2Z5UYAb zGuKh!^4E!o2h62RW|$-aK72VPksw*SQW9WkTRxoM?*K_yCh}}t>zJOsH`4r%fl?@M z8T?4IQuWRj%%afZ(fMUKnOHLZiQ$|->R_S+FCeCt@RN2)XR`|-Suy4f;W5TT+4ivI zRFP_tG;RfhLswVM4pI}kfH6(_2K)~b&f#`@{h~7wP2zyG#~BYw1il=%MW3rymOJiT zY-N}!;Qun@#BrNGjpXaPmH-}TMgX&{BLo(i(>MSC0V^xuEME5qf4ZhzAZj} z4E&a%vlfwo$L`pMy)U+Q6P(q7`)oI@t!pA`0)bau40-h6Q))@IvD-bXF^yb?f~wem zdb%O|$tmA{kD_Bw`34f(STByXMg`^h9$Ix!APR zwpDT@*MYL;Q1gKkm?n6SF~M^&7qGH0qy_aq;4;24&YYwAL@W#KKx^)%xDlMiz`n`v z4dLPvo}-3-Qk2!cNS!}znfZzPUm3YK{$Z2*KDUQH94Vy>7}%$u24c@dfgYSt_vxXxNx zTJqQUKBX;FIQw4Jg-q$aSVlOq=6Uiqg(vwtqKAh+Qsic+L|ui$@Y1jo<(k^RW-`eo zVNqn;t3UEuaKwy8C-r}wyiKq*>RYIR~Bt}HplIcw-dG4MDB;K+- zh>d`63Ooy7>+_?<*5chB)i-_9VDiL7L{D+Rs0V1N$nCA~wUJIu%$VTN*%s*d{Mm>B z7OpE}X=k!avQMR%DNOQ^6008)(y*xPH6%nJ~_>=b8B19GF*27rNcrL5<^*63GjHaX$giS_JoD!eFKi~r+$BG%n~ge~?m;WHkAY>|Ke z?)C+xq(Ra)5iyC0u{2&)5(cQP%4NI%_7*Kc1!9Vsg*eHA%1rh+DO<1SC;!Rd6)696 z;GY>7gD3Ty9~Mc@i?K>Y4$)g6oJ#m&$ZrDP1*D=g{z{zePGh+&rc(l=z_s8K0eeic z(Nl#MUxwKY}Pg{@*@1;|*Q zyGg(Ov;Y{w=!kYQdl0wYWSABc6YPSL0<7}yzFzzL>p;Y+;gY|f@|G$NL{dfOA_{XX zTU<(iZtS5rN<@kvxJ=a;i7H>!s6qv*GRnE<%&!i7ff7UgJI_b|T!df$?cI(zDwutX zVxQ6+r6|&XHl*2@J}IJowoRB70MzM+WSgAFvk;caa%>|sSr7Nww0^!L^^MJnRaED;AHFDYCl&R+nX8DoBKd*$;u$4x>qCQw(% zrg49r`W9m8$5;P<{OvqceqM;3l%0|8GarbU$vyhBoRkgHRYgS5TA0(0QiW(OS+TSh z#7{`#>^uMdMZzU51ap-tQhLgWrNu;W61;Y`9{sHzvN(4)*I-Y1g!0=&Ok+PT3Te`C6n06uI=8 zi;u+SM6p%JBIP0=7fv*vo$-Xn|Egk&FedJ4QL1~`A`LOo|MM9=LH{bMme5g%NOVYo zi;LAbxMgZ;6IUx&)~;855xz1L(asKBjmn2<(J`gR=*tlp1-VcXpC|=yi2~ebs)vkO?b|llsK}t#9 z=C5f@b_{S)|NTo8|JlwjKufa3MMj{z^(`yqD1qqHfg6AF2S|oU_WfC_8f=RqA}?00 zSIL=67?FSYcY=%-Yg%h*{aaIfudP5FY^VW%oUuG zq9xJE5(!f}Fby13?CKIiu)%R;NQXiqO)8~g#5z<91d;+-IJLnhfS5pKbOK%0$<3rG zL?9(V#7Q2I>H5OKND2reE=dFrxk^d^MYyviH0Yrd5}U8WtRXfbA_qEXi(5sSs7au- zM%ySID6FbQw-w(iil8YP5Lsb`KYU1L`LZDU%wOHoKIVn3?G_fBTSDN}A;J3X^+Fmh zn+18cSWINQ)+b${HTUgJMMZnIM^i^jZn{wH%~`wh@s=Cb38s;BY%@W5DSD0so_oPt z*u}mf5wu(y2za14PLW!?sooWp-xRxoaRQ<%#4_E{51;9qz$`>c&;S4dGBmCUeDB}` zA;usW000000000KKym;K0000939Pcxv6&<^7@zA*IF@P% zgdhL_ATR&`Ey^U&tj-x4`f7_;q?@-A=lZ@_oB2kO zIX^a@v1P826#ka3Oo*=`Lqv}4c5-IIu+&rYTM+CNHnmXGkDeA^>4F7BvbfUMw!)|e zYOmi26cSEAVi1uu>&&tTfkcZ=q2#1hQ3C`X6((r~BV-|+TjS_n5To&=^a}(I4;Ysw z1pn|Hn?(bJ7MisS0)uFXfQU%whKU1#rmas~>yi#Ch9V4kt%;Jiy4;y3P{3UE9ldX4 zACN9PDAP3O9_S0%AKtT%pLEpYWxfee1Q~$MxqQ<|%>@l8le*0v8e#~5u#uxb zXz>yWE8-ZEiM+mJev>kVTE~`1V==F;t!fsXe6|S*vB^Biv1m(0{l#Zo7#M^WlzW`X zQnhuu$D1(|gjq;2r-q%dg+itbnPbZo(gx6WP%Uf zVVaykdrk7RkooKtrWNwd?sw57@{GT}=*B-Uilz39j^ln|JIq;GBA~N!kce1JQ}C2f zpT8`bu@q1~4>m$?p86gI*O>faA|WJSl9$tAa6%9y1p#FqOKq1_KtBvq(xf;-Azty3 z4d{K__o9G}h`7R2W{vL#D7b^qv;B*N{$p^QlsU`hr6Q1wnche9afuht7t3D4V&bqk zXi8xK_N^DjU%)RRw}C!EqI!H_jJSYY6z93V(Z$5>;)tVfZLtTsAC@#mApdURcSOP< zp+f&guPh(aTMF}PzEbum<^BeUDg*Xj4T`kFtuTszjWQYPT24h5IEgGlLxv!f1RTE~ zny2Zxb-5M`n^o?)h%#Vg%*&O6gm8Frw`wGD6aml2jNhBE8!C%Ki>W-d(gHsGDJ5U4 zY$pzOq1i#%L;m)q0 zC!*0#;dQRAIg#nf4^=B>HMi}-D(k@DnKCUXY$Bq%6l>M$Skg$ zq{|{hcRTJe%S2JmA1+-^IWpW{oKA-sQcf&VU>$i z)9vBm{gW3DQTk8j1jZHmJ9_erCbJgC1Auuu%VeyJpXbVVOz10Z`5iSfOER_Yow<+S zXHv(LCHlubl4LTY4J#*kHB5$occojFgRDb|9oJbKsQGb4&lf`l(m^`CjoljEdaA4%^rj_3yA;CoY*$q3yVVPrT$^B! z5C}OZBed1%8Pzc}Uuf5%v?#BzNT3_|ax9e(QBs5z)^DK&R&8CqLJ_8{)~j%n7#Hph$q# zsTY8b*;12eKmfU=ixdy(c4SHl0cBM%~>*K1tGIfo)Y-rSyYbm1?K|} z0@@oARmxFo;*F!cVvqgphoZLPk8`%≦Rc_}N(&Syql&fnOr~$O##lhht4wi$3wZ zxK1OH?}K|m)I3r-0nD1Xt4dzRys&aGIgMG^-Y=tkKcZ;y)S+ogxmZD>)tep|SPzO^ zPejHS@~jY)E#q`O zzGBX;d&PcO7wlJmmM}Sx(b^mwIg$rvhx6Pmq6KnCzOXo=5@uuw+K37aol^W*mo-XU z?owe6HrasNWj zMYZG{t%(^bgp6PRqQwQHht^e4M;ck(zL_8LfT&t+c9*sS-E-K)Q40e3 z676U07N`UN_3!Q=tXAMuN2rk#pDkkjT90ZuzTzc{m80KZ5jD@$wFCJgSksa6Le@pu zw&^M?UPM@$IOB36EJk(}86eOp5>0Ucu#zyv-LNosTjL9uQ2Fy>1^e(%&{e zw98T_A4^R?ug^`Cg1tr8)}&P`JWGIRCM1#hQ;;7#`S~zZBnxS7@>CM^J<^Fi7D&12 z^#`b3zGRHrX#e}BMuA1>ru+FlYU>cVc^ktk=@5TfwFjS>v1A0#NSTl#5%C%Q#rW9E zs`4Y@p8igbEi%Qw=EdqC;(X5C#pN+9@7R`4j+vA0s93z2-F@~;L6tcYGHNua=G%%m z;Rn=u@QW_)s{JNVb&=x5$*gTOywQ=1hGxN&`Qm0eRDb2@i!rHiM0~MwNSl^T(xY#d zk+eaTPoM6?i>{CNd_Cc5{3BVxw@ClfjTp5TpT#U%O>hwp)qgCs3bms$^Y<}CW%mAs zDF-QJWT?RpUo9{6UWV@Jx$Qsn7oFZrX_Nn|i!UxOcN3#T=cS9t-UpAo`=&^Z6sc!& z6ZNA>_?YuAx<+{4e)GrC`=l2=+?cwnK9uNZ`+s16%a<+Iv?3f!^`Z!6q@|!z$D&!9 zk^l7dQUj5TpBzYt)#+3J&@ia}{`snPxk@;!0sW%@;^x;0~+{=+N!>F;N=@5}HPYaY@T10`jKh|G>eD`HcKkke)pMA-VaGL<89Y9f8WC~5*E3wTjWXCVL< zip2!5-Nl>`tH&D!YvaEU3?n1Of;s;7C_%ptBC`$G4Q4&f4{C)%Z@ zg%Vk3p?c;GL~XrmJ9dWKr?dqRVVER!QRjxg-HCY=-Q(laLvLNlvG%d{{UDE>g{r`l zoUd$*Ha9Nvi58PA^o7tRS;p<=xK?jlu1=Wdxp)Wbk9Tl}!Dv-a*LLiM&l6(&lZ64l z*!z0{F5NLxs^GbQCxnIO^|(Eh3KUoB1Lyc&Jy>MdzyJUNIycq5U>Jl^2txsZ#2^p= z00007j*^G~00000AP7;606;MefS||#0001BjKEL;013ztVg?KbKmY&%AOHXXtV9-r zO)#`Wpa4M_7!OS-j#ka%0HF_s=$oK^sFQT!UNrq?f{cn{H=r`qVTBh~BjnY%8a*a2K{m+x+-Ep6%f;p7mW`hM$;aj6p1sBuRe7A=2Qbt6XoWS&D= zw8Um#jHjd!n5GgjMWaO8%4%`0#)!ofbrMJ#1b`H-0$BLNol)YlVn%o3h%6znxu8Z8 zd>G;oLl~O4ma!x)M9gkfdUWE*3d=;t8A4Z)8J@6(xJDURPhji{G>8OgiT|@uv@YZ{ z1z(#?uPTEWPG{vB(KU(Kq|%hRDzVsIzsU?3rjx)#6hXw@EUn#0ZRSbPu;CxDI6!bc zuqarZSd3z24>>3 z0fT4&3P$i?4k@b$uVnAy{M?nPjJm`TW;g#DiX~CrU)Ye=8A}H2LJB|0bf_i22eWPj zM@wZsT`i^nqBg+>YqH7Y$C9nZqS-MSSGLKrCcx(?(eWbbOLMP5wmF2;AETv9h(zX% zyJ|#$y=_zJTF^C<2BWuRQrTO}v?4PBKn6hh%)o675CBO+CWf)ImX66YU>LK-9|`fK zmV4(sbfx5YIP>kq5QoGG20)_h4kIdKE1o~h8)**F3tZT8fe7z#$BUyWS14(>OJ7Bv0f8VfuQ?vQf49Z=Cmr@JplP#_QGx1K8v zU|COdFUABDzt@PPYN=>fd0|mC)T~0;%_Ir)!nKCpu@H#&{0D-_2FmN){(CtVl zjQlTV6;}Gj0NMWRh%F=q!o))J@S;RX6}+|R|0a05^rFJVP1uX=_-BSJ&?;S_w(}bHD^? zGN2+Z=ayTYl4Z8oX)1}9Sd`Mr4FMmgclrH8jiCRfEnA%dl4URF7iHBjX3|*z54@Rr z?}wV_2UAV;HS4R-SxXoZw7s{+j!>>=)(_C%mh|S6c;MY8n$v(e;F*vbNUg+^>~KK+ z7*J7>dc?9QWYZ^J>OtLSGRj~^xsmRm0d2ql00BE5Dm7gBz)}}#sozT!F~Y2Hf$#Oe z5mb}wBbYVC3Lv5aMGV%+u#|7KOj`Q5DKZ5;?9Z`hcDq29YCgn77+|s~D#~zPi{tkJ zc5LSM8?&2Kp;}GrL|{pYtAbbo45tK&d={+#C$Xf~b5^2KZA?n)A`^CRn!x2TAlha* zP`nT!nh;P+q=?86O&0XmO7tgKf{DczuCJtmM#ZDPm*igfh>TRGiqc|=k)f#FWDutP zAZM=S$!p{uW+j@FE9oGbf@&f*yA(I3#|lZc+|;tg1oM{ABJ5lzzUfC2X>lZa+o`G` z3n5Z!(|hGAVp>}&Lsp!Xw3yPNQJRI^wX1(qaHU=Pg)R%Fdh)nLj1s3Lv;RHA0IN-FQBWy-_$3Apl{Iw=3{HCyqxPbsb29wi#Pr*yKEN-q+4eG&X$BfjOZZFu6s zPTBCi5Pw@1dsd^%mH9QOddExb`=feXOpiss4$GUb(mI#$=~s@~wGr$q_*7IZ$n~dI z+e?X=e(#-rRkr+S@4D88Pe+3cGYW39>nZI=Q1;hHZHA4K;=Md8I}lBkr81BEAbvF~ zd+(21@3+M@HH0NEA52n7`ZbI5C_hm!uy{&rMZbTMMRXMd_43r3`v4xb0I*q77#d#~ zTYO3;j!$mcV$gZ9TUD&#B&BRLpAhC2K~We2N(hw{MIlHntwf+wnx%v-MUo+?EJgx@ z5LzSg5f;D*Py~`wJ|tM4BFaJuiDIm?R+5UK#S~4Aij|Y0u=BBLO2p*$IO6A*Su({} z|NEr5jd;&nlJwS)5$*>ocFkDN~jGwE|EZh|Ghh|4ZL1aTyrzisGK56=Sp0 z98T2iPLAb_Nb)fAL*uSyIK0IA!M&5xQgYFRhU#5;L2FS9z-rz22lq?V3}+s+5hLrQ ztf*K8i;=D^1u~6`Mo?-pcu2B5piChVc_>7sUoA39@`x^6gD=m0h&t2X{XD+ZV45Y? zHFnd^p0oVxhc6(k7;XuHK|wl-ZRj_Rwl+Krku*n5zR0j#$qLv6R6sV|n#$O!TkJyR z7IKzVP-gp5!GKx+T5Rl7OlUT_`P(WxO;=XjS{MBL6)Rru`&|E)>nM+<&(W9qqe^$& zdTQ0S&sutVjsF6RSD8F=m~qbzM>*bmiPY>7uu<#sBnX8##9-D-or4NEr(R@DEtKVA zL(XJoY@+=m_8HY-GcwYQ(9R8$q+OqI3iCDw+ltF|R=<6<*B}|}ZbC7~I3**83eMdS zkdkZ^q9v_DB!AK^)q)K2<&rjPTJdt;WPUzmWiUv{$gyXl~;Evzjfp$YNPMF(?2KN zd1oq2kr~lM5r~~xtnm?kP7wipFi)JQOr!rXXfsq1W!0L9m2Q>?vp_1_MQ*B<9s$XqieOk~ggUZ~cAcv$c>l>{@FWou5GZZa)D$snmdW<|fJj;WNyX4ch-!gi{=DFpkE`OU^_$T;?i!MZh9@J+N%`>qG@#>;F z&2eZnddx)$ixH4-TKo8HS^X!p*uwhOuCm;d)M2LDtM_S=k(VF3Nd-G5M8}9hc@iM- zx_SH~5v42q@^7w#==lYjMTNS0dZAQ^Z&5$bPn7a5YK_ig?{k1mwBO-D;{P8e#9QVkdF~!CB_OYBH{_`F3e-4fQqBGLJE!H6dqdrEC zccX1J<69mkO5gfg|lV<n7&~30+3QozeP5_k z+Swzb5zclxAblM+5(&XP@$GCN8|G^D!l=q$asfJx`If9nTPAJN%FSO6Ak2z0R_sT@ zJx!R21m7;Wn3P`DQgzZTqF>1v7syiRSD`}Cuab%s)R60};>M7_vf6A%HWHoh;M0NtJ3Ug*i_TEV%n8U2Q-gH|7|xu`-CGnKXFu z1n99z=GALaGsiYpd+CS?+@@xxRB_6*p^SX$QoP<no9$RAJmBW-%(7R3z5 z9d)WmWL{g^A$VQsqjT}T-gUA=2IILekj+SXKuplgAt-Duc{@Ry2kitB#c$oj-nH43 zI@ulW3WcS3DISJM$2j8X7p+w%N4{x$ZC^Qv4Zm1vmm4+`YHn znFqyq0003(BqhnyleGgNfS@se0KfnM000Is5P$#x000eet|Z@O2YGM^fB*mh000!g z0000tVUkQaSRq1G#{kRWRppWxW-7KMwAPj5XG6i)|=Mk5W5cK3oBaM2b)3F6p0@iu(M%f7;jox zt2U!biusG#F42{OK0V%3&?Q=h%8f_j1Kuh&;{#0cs?gU{@j*rh-`gBN9cReOl>*NK zwA~ER7={H(t)c}71Tn&)_xy-Jx;vbayxL4jf=<#<6HqV{xbcvpV^z!G#EGJUxI?H! zE)O&{YVbqTVDmp1MWe>EgcfxPIg06{=mo=dEk6uwZhry?6Df#bDpRWs2T?Mg>@r#; za$tZ>8cEDjbY6~&ycS(eo2*C%0z`sa=53(Al=a6Z&*uU6hr_5un>eatH{}5L^4a>*amVbbZ}3E zb7K&%eosGoxEOslNC{m zQQ-uqI4q+5)+HI2IfK`8jIrRQiY;3J(fy4P^b*g`8&Z#EVNxxi$1qmmjP#x z9IF~~BNu~#Nx2^vDI8)7BOGx?U1YDLD)=-Dp??w+-tnGjx=D^3oQh(~D|NqBD|9HZ zCagR+5Q`fWdJPXDS<_HK5I%O0v4NS8Kx7ESwNnS9K!FHg+(2+h;Pua31y%w<1TMDF z$SM^8zs{#;67m6sYoCA|2S)a}djO>pSD=@M!izMwQ{q*`H>;c%6eGy^~LB z)HO5`$z>%L;x~M&{XZ$BfYQ3P1)fK|u@z3xz3KAgAVXO=y1d zq4hfYlM~?-pQ2wbWnPwiL|%=A5^jY?*Uk^S!a4(czrbio6G;s5<{3d3u0k)Bh&xOD zE@(f%hsr4iO~JWAa)Y?BM}6K-L}*3r>vFBb2M8Vu<9ptRLM6mjB%S!blGejibKXk& zCIQ6BPsQeoWI%#q4EeO4qj>=i4NQ5BsQ1d5gC*St*`}`IaDsaU|igT{HmWv(o z`|E1aq18q%>G?iX!|x5${1CZ%!LThz{Iuw7@|a0MAnorOubVA2C~6IR4h6mwKBao_ z0hS_ae#5)SK3l{pt(La$3E6Y93A%bOi~0mNR9pAYy29tSV(m`8Qz(=G00Bc0@kF8x z>d-s-+|oh`_J!ukJrEX6U+O$d-_9(%$w5?yDDgk~?g6Cik)o*FN}n~czoTpRut=f_ z;|ii|61JR;RwX8v$93;1r0LR7wn(B&1O7u$q6$(WYK@OZ$xx`~Hk_9*uejf!wZE5} zm2Klerr0YGZ^0-z#>S{8%V4nFYm!;~o`%bf=HM=eeOHoomrqnRARP|+ya$|G_}ond zmu_psv++B8_PvCSuWD_4CX?4?-Sij%5DDve80~Z8TM34ek0zh-Z>Xsfw@q0yBT~#l zLda67<4Ajuw#MWZAn=~oy~GB|8=CxA?j>I?R%O9L5I_YgNn(nW6fvx_Ni6aUBvY1= zN&s@jiXjGC6j@*;X)PHDHNYr3@dUmV0t?3`rzE6rMgqGO38U8v`LeU`uML3XWd)a;@s1~1736+f>g z|EZwjGk5Mug<}w=X(KN8f%Rk#LV+z91TMH7WfP zMwwelQu?pp@hyw6Y)OmE`#xar4g}>N zv=$vIO4U$U`q<@kY}kClpL=2>GBOYwG3!w(4(LD&-m`Mp&5=LQKvH z&LblPM9RL%)S_cs}Q7$D5&!pB4=R87$~I)0w|=a z6^t^FSt5!_Xy-RRWj*_PH*Frn6`WeesRMY}LV zFd0r`jU{>WJIiGag+;qFZ-TakTT|@$k=vrIN`Ut6l(dLT?0Q;@C>?#3M-t<&sPw78 z9=Zy9d`0Y2B`6^74W-5hw@HgsD|(^<4WAl*Ue=t4cf|PpS^lD)`gI7YyQ@>>PL#U! z-BacVa-nJ&g5{E=N`U8BlohHCmjF?#h!m4eb zu~J_wIpbHDFv^!Fhjoh)|LSX78(2}s#4%(N*`L^ki+jEnQkG|elr+M_%#Y1JB~7EC zR$4Oq>ZO%FHTm^B!8-~^F&+iBrbms4=W+!u&nbv0)_~xfFOp;RQ^Y9u;aLj;rS?0;_Ek06};9hrh#@43r9Wtvf`<1!iX<2SN> zC>Bp_4Dc_vHg-T=pD_&_SEzY}L`q;-B@%m?W+-;$ZE9%3tSh6ZILp4ej|qWO&Xo1o_ZqjZcg&LeBKKS0w6w z?-ZNjs+n!A%3a?JZOLQay-TBL{D^>@Y52V2;hxDXWM#&hUrKjb%7x{W`L7WlY;%w2 zgr8z2Fj*qg{Ed@2kPy3<*3f}_;@V#68v6<{sO6Tziah%6o+moAp2RYiCXY+b$j%44 z{VJee@KsEQ6SF^p?^#!4EL_B9kQYRck90_=TYnM+@v#|Hv;5R#X;3RCe2vgRDbcX!$Hs|{Q-m%4%`+?guzwFOe;mluB`r(X z=Zu4+&TwnSMANv^j@mSI!%Y?3wta1-$3_P7n_9#7tSe%$gJ`o`vmoDwiRzc0G`&4$ zN3yjQjbxD?j0-@WB10r5mRxpcbMLHWE)@LoQpTa)LBX*Xg+B!FxYLm2lslG)KF2BE;)##@TtYl^mWXtC`A)}9 zQV*RIBfm6zN_ooe%FSzSS)-**8FptDig5!}TC&HB*`a05NjtH|Ufks=@w=yLbF0G0 z?SI3xFo^I|NZesIhT9P$Mjy%z*lQ^l4M6MT{@8CYJ#|Kv9T*OLjRLCy@(0Q;#ZZG{ zm@zF&S~;fnA_g;@i=6u-80SAS$Mj;cKEEBLh2~>_A*a{v8Chl`^*G6>7yf-4|Vl8MS%#(sCYQG))6hJKL5e(wuTLogSdbq>S}>d_|KxEn=C=%`6nB%v6x(N5@8f_IlC!dKZsQ z9~YWO8}8%sbV^1O#p+vv`>xnS%! z`ZRx})&KwjNvVLQjM@N4or`Iup=?O!Ne6+V06AhZG`SPJ>bYSNMJMPhw9@#{?N7Tq zSmW?+E=eSxP+_VNjsTdG2@9i~B#|1}LE>8oTHvY(6ho9Yc|!WHqjhGC0l0j zyBs0tDMTl5$8lX}4$6snXsNN}Jc&x$3auhj8Wqts9*TuV+(^@?hy;^b&k2wQR*Jz@ zWDE&FA?}SM+FOZ~1R;$F=tfyLwBgji(Memwy>taOa~_eeRtY3mv84M;MU0L-r6Dm$ z$ifIyEC|;i@1C!N5eUkb%*pH|r?LeJ#3l1un*Kj2VU{dFCM%E%=jvjDf zY{EgeU|1xH;bqGakXz${BxtLgq@Ej` zWc`MX69&xofn35<-N6tHQJg~$NPaY5{o8?IE!={j(r$*(puz?LfJOvXU>!g}03s>H zT*Tj;q`P#tfLi|^5)zizs^}aO2?huOc{UQKdj}BW@MIPeCpS~C*F0V5NJvSLO@Psu zbr+*TvF#|udhC-NXh$OHLtO8m)9Fg@qv|W0gAPUn;t3oATNqP81YuASK8nFGV0t)~ z@`M6(i}p0Imc)%FH1aFbp*O8SiY*up%@Yz%=yqVBXt6vfR25}f&gcQdwnH_8<@oif~b{d+brLaI_ zXCbgkT|H2A{pS$SLyZW=A!;ih!X zsIqCU0O|q2nq83BP2hvPnIkpzG$1yZki%mKzV9E)uNP-|c_eS&KoGzYc|@g<4(7MW zOn*yb&Cg9s4&e%c5$U?PbfHF(zKVw3wXG7fivcw-l2hpgX__lKIUL3@Q5Fc1jWijS2@!&7(qMTe!g>^01Qi7BJ#?X|F!ESpx+V}dTbwIa9_#f0JQTFf z5dt8TsQZMt7?|a;;>0l}oyz@`U{-5USVWNUL9w-%TY(ayTzY`pG&8AlK`K?3VZJ4_WkQ)h&i*BVfy$d3g+aN5YQ6lW!NE-V6F26ror zd6@tomMAzG01J)Wh>RE|wZ-p(En7MjVoB6jEH0`!lY($`0&TCb8xTciT5SSPuuvdK zcrVA>M~o<>wUad1Tz6DiCq@D%2sD7b2ErLSUbVneq`ZJ&{SWO)yEKrH3?dA8XpomM zxRWWcqF4<4OtqOxs6IRAsgOmrO5{B)F;I0^dYB*pW@)8tc`}J$;~Q{cY$1wQND8(< z5cmL;g&W)u0X^qoYaYXN5vppcEh?}s21rQ!TEZpha9GS&M^GUp2w3;IXp=w_(i6a_ z@-~kP>zP z7|F1435Kwp2A-m6_BYCai-MvO0E!7ezbuvhLxOMvPF;}BSVM4t!{G*tfrf%2#K*pP zy<`s}0vv|SgnWYtOgCMM=KULlr7?I;hn=lHW$m!Ll?D6ql4v-R&S~`sgM^qiEHSd} zxQ-Ft0%tL(6t5K%78?_P!m?JluhJfN7SkenyTphJ;FR7i73Nfr+D4bu8WY}$B-gcG zDd^rnTKMlui|a5%N?l;Pph2J-q{pqi7lRT&C>4~xspvo`b+T?Z3y`s(Q^7)qgu>S? zB7w#lxnWU624$`&jWp284E;I?1%CM^)jKo0K)H26wh&6!Xdhy57cHAc!F+%=;T-Th zpQ2Zk+LpQ=M8&?mk|FK*$sc8=_%mQ75SA zcF1yo&XLzuBrJ<8;?cbcRRM3wU15X__dRCg`9L*_g6x2`*iY?n2;L9fxsN&TrKUyEpeZOoe@Y498#{?6!uKjMJ}?^SC`s<3#N zJli4SJ3l8bWgZTTx^h9bP^mUbpejJxqWvo)7o~TR_&`sB&)}-h+4vZ$hyVrxi6Rh@ z?$!i7;DBN_r+EYW@S5R&5*ZAF+Ff1(8BGY!mRz->{qo1xMy{r(T&C#QNH^ifP)D(I zykShdi{73-a*XBECD7aqwFv`lRUHPMS_X_Yt~?4LY)$Anm%uR3r00Bz}gp>G) zUUV-4MwO_w6TbMPsIupu8i)Zt~BQ8{!k2d0gVg<*quD{=Q*1D(Kx;6Zl?OroR>v`Gpnlt|*}* zv~LCU8=LJ)ZLJw-(TI&0f&#XtjbwB9%+z9u1f+=d&M0u1ZEK=*(tk_BxkN!fVAU*Y zZE}@Xxnc+)f(VVvJ-pYkrNqx!KvYO7gi=(ssVgEWOF}XlwPFEosZjt#>qc0qN>j@*HpEmw2t$%Y0YG}g6xEhUtBEmL z7D>g(6dEat5RlLYNUNVp%X*-bkZLN7m@ZY~4jvYU<1-ZhX0j3>RIHIC(JZF|7{i4R zL)%1&1+eh2(_%^WY&3TN#ek0u6eQCcr8JbLlAwXAf(ESfZnYGPsl=*rAw?8XMHGWW zB@m86Rc`uAbq9dnS<1BMK2K1(7XVXC=OU6`1l`*Wt932#HCPB*7UrW-%`HknjG?Jz zIIyLei=5MXO>omqk%g0zlsq(ujrG*;MISqhdr5aBS>{`mhB;)?++sqH0*x9nMnp%n zw1vUEq@6^(>;K)e5fKpy;uO_~ z0~}cz4fkC@9k5vt2VgKN3xA&Tr1e3v!*G-E3Lx{@#iYLSCc%g=jX+v7dZ~6#9sXK) zg+R!7=((3U6u$)VzMT5;BZUi@L&(gew0?P!+@xU)6PDqz5NR$KDUoDGYwKD0n+D0X zpIH}~F-40n<^IL+aGhcfKp7q9KzW^>`Vk%mfx8eon_szPyrDV_Qy}4q=a=H3+^pp}%Y4T46^T2EH6tq4_TJ9@)J9(Fc>B#itUn>OC zFy&v6UYeTQSmUe{Gd4nB-)FdnXVXvxvxyrQnUX1)2h8ogG;v7#7O&Gzi2q6j6I~TR zs4t|o_d=lk4|rQHT7}|E8=j4m1AvA^!$_b#(H5X}2F~cpOS>{YH_>99O)YzC>ES6O zHB6}{6pA?j1tZ;x}?@j_^8fsFolN>PE*m1lv_w4&RFM4hB*+u^wi{tD)U}Y$KJB* zi4(So+`}%Ici_OLUQ~U#Bg`LC%n~{{i5`4fhbz4z<-4GC6RsXp;kvkLbU>*b_xjP~ z{*Yv;HW;P*pcU^$02ACDFdNdb6Daz^wv_MGokS6E|57tAb9#j|9 z0B|{CPN#m-mpXvYN@QjzWR9p^toY6oQP>Vy-CG7u8E%2xUn9@C2~3NBD8G~oF7EkH z$l+&G<%b?D@R@aYfciV?npzf#&PlJ{BfD3?&O5!n9a*L@IzWM7j>2D@3U5%{l<*K!~(B0#2Y(b$QW z4>oJ{aruSNC=~-GBPcgo4NfmWfmkRNc(HO8IpeWj#qDCvpmheGOq2=*0~4uVssK6p zs2X}>Mo?r;=5cI(6E;HBd4I2*GV>&o%|$gA)K%P{~~MZB_x~U|mirpDAv3 z#5SQDV6xa38Sk(<1k=sAXmnvl27~Qst*)26T>2pKO8uI5I1c-YhiWW-k@+?ALH?dOFk7a1d#hmR!9lHH+8j>a}X{q%=C z9N9FWB>r#2K()F6KGgKDCs12jDC_eZ50>0o{ zAiC>KgRc=t^Jn&s#EpTGtg!xP|<%KLNA>e5(46s-5VVmGnXUjV@um;TJS8P za?3#B+2zFIq1I6F#|n)G$4*WU-g|rfI13ABmg-Lc-6pz$Vm9A1YG-v4nG7%f%*jyO zG#ljUaTBtlzXoNWOe!&Q2Pe8qr^W-GuF=`lSVrn)lE~Ie$*S5LDtl#*D3ttJf05@_ zR4-=6Df-kP6~+==`|=OH_?J4+c_ zKV-9%#$P8zph)4CNSuK(nWqY=23l3l5yQ#vD;m z=8pC|ZU=#EX2wXfnmtd6wlrlsYh*N!)V!BTb(!4+OKPXAO&zj2b0yYP?3E>IS~O$& zHiw-9Gmej$bD)Jfm%t&3+Sa6D@`ME)8q|K@*&cqaqp&?XR4~L`r70G99xADCX)#R^ zc<=f}|5{cuQJjIc<9=XQtNo$ohMzJXRD2gCvpz=XF_tIh&k~&#vua`=G;&=ND`YGd z=+yD{c&|KE=(S5r00001QNBY6tPTbR4*)cXW>*n4<_O{n^zJn`)Pex^2#O{k6p*T< z_;gLT2a^`-weXsy?8_=E>P?7%vNYTh;yX-RTMy1BG%pon=4XZ{xzKkJn+2M;t~kyM z0r1hfuZtTEV??4m5GxFw$H;dZVbQq_zMh<5Z?^=-Pn32bV>YaYXgH#7nQ9X%KGwC;MSDvJ1wEIg zVk>2@_>9Pbbd9QOzi7mKA7WQ7j+HP(W)K^QAq>adWaNfe6m}>ri#Ff$G+0=qYU3ii zOcE<Ibkh*Ta+pxSdm#YLbnR!V#}ajh7N(i4a*`^biq zqPVeGyxo7!grq%1iQ^U7^O35qg4%}gA%RCvSrk(m@hPA{ja>25rL6pABC&hPx@mcy zwv99aMVn+ZrU|M500B}HD2h=40ERFSgfIXA00000FaQ7m000045uvl0fB~2aK!5-M z015$s0000a&?usfKo9@`000000gP$T7y$qPTLuG+@KQ(xZJk_zi<1E}Xj24N-|QIBC<(rub4%skv`a=qmL?XEic2gO63VXz zp(Hfz>%08`q6!HjfL&0sA22l~wK;!AP^^8omj`d1#Pd+JbRlagK4+4nE zp)K@>*3WH>-UphO%hpnce$Q(4osTAqCtyYj`7FCFsu>Tep2wX;ZHJCt2HnVR9bwuqTe5t=9*+xD^; zT&gIb*de3aoccsYW+`2iY(ayRH!@gb~05~2?Nn;c1bWL zgoOY|G{#0ljDb(3-J$7KLeV0Ctt9b9V5(hR?HYLy#4GWH&JYL)8TZK2A+eAL;L#~^ zT4a+!Zf4rS&~Ytk6IxAz6v`e&s~`UY#t}^IZputL1~_IG4Ti+Z+QmMV>_!+!gcD4? z>7W_bROQTE5-y4lJ12cd&?7Se#hzsqaJ3KRo(@0`!FM;5#cC_N=V&ZCx-oB3u~Ifn zKgJLf84?owlko!?pNrRqJA^2^DdXbpL1)CvO^=&7NmiUay$Hp4n0PM~X_8fg6p5Ms z9}X-;ED?#qatfk4PRBW0?>_+R*p`7vIS0=k3#pcH3xzm@u7@1wGu#nk+)mp0xpGNH zPC>Al*S$gU;N6JPL0Cp29ne(`o>^}cv)T9j8!A!;6%AQq5~dPt1io83Qk6w1t=gIE z_p0DeXt8l%yNQ%?<3aOM22o~KpiU=XSwfRyh_oPeo3|Q};N)x#_oZ*4xJ4Ibv*q&9 zl&ywo=5T<`;Tvv19@1R7yH@&NNUE8?04bFQpv5nMK|EG_dI7d7b7B{hq?%4!qExk; zAi8%{Oo>jqFbfdqp0bN1?#GZ;rQ>|!%xFL~9d}{`T%ZwG$8jb7a?#HiOXVwYMzTFy zeL%u8EW6wcoIxjC|=ij6j0?9fz=W>p_thqNVzAv#Bh-5yuoXBGdJj_(ghnICoFFsk!>>AA_G-KHaBG` zB3oMHg04m*4?2T`-#HoVd*NKpKpGc5@dPQbL>zf7qucI*x;p~UjKb7p49B5URuknA zlL3IhB8Exu;4D)hB@wn1YLC~-4@G`SlDl)>lJ^(3bMTY3q2Yg~+?4`EtWd0E>TdDe zcqezO7B-cpytD=8mFlP^B7m3-ISZ|qx*CIgO``lpWWP_Mp)5zOfI~wPFbXQ85j@~8 z$rq~xMX(QEy?kX{5MY_$iVj#FA=C(xk{6*3!f}6{ct}p{6B-gZwz5jf#LI*R7V0!A z<;d^onYU*!_W&jAj@&>1oa!de^-%2B2>h947vu}(1CcGmR@wyG(vUzPf@8U>qv2<= z*|chH;=&$In)c2M%8+%Sg8Gh$LJrmB9V-JIVz@jWNzJYlp9gjfx_&uK6kV547+tE# zn@H;RgXlMhN)W7(=nn_S9Q-hN`+1F!4a-_jhfzqjMYhdaDVEfCVTr@ctaU=a1q@K+ zOHG%!Wdlf|&2!ggZf>Mf-BGiJ6P1gW6eT;z=fiF(8Oc z07C(Ly_^650aFb61`JtZueedjNQi`zfB=USNHjLG7_g#%fkhRmA;nZmpaKO9NTP}? zSe8nQ6j2C30vrKFETmAND-=_b7!oLiBnX795Kf6CmZ*eIQY1u@Y7M6?r4)%}mQ*N& zXhOwS8sV1sA6+xl36}EY4_Y@&55Dh=$`ApTES0jeF`%xV0qzF@!70!D1P(nh8B^D! z1Xi9}v4THKStp`Rgi*O42atp6&-ajPkh_3GN#?o2mzJWKhEeGgL5dE?ADNJ3nV67o zWJ27Yjmr`0F4MMMCc@jcpqbBx%z6>+fHVm>8)P}9MIxey4hJ@9L1~3`{`XcO%KT^K zWP%!m+m-6)FP4y5tp``Wzy6jWmzOtGYEJL+Kq*%;GuLj_CnUDqF)>>Pi#GwSI=`?j(>yEBn4> z>Dq==BlEmq}x=VVsaM9r?zZKX}bIOQLz?|k$m4tOZGL+*yE}hmCcAg%&YXLWT$i5y(Y{mw zI5b6ZqW`yZR!j|w#dy#hoja8)>q28lM2V#=id-;xhd_m}+}o8INU7rn1%Vnzx}1jG z8XcTO=bOam4wx^3X)+fZZEqJIYiR*7Ym7r}<-?z3O|Qsl!YRpo#Lpgi`d-1rmf>Fa z%NN=-&~)tdPi;`*A*vyJ>+Zv97UT`Npt9_AR5?cdgh->~%{={U9VbIodnXLdDKGz# zZ7xx{Lw!7!E_z7?wNu7(j(=Mi8&vbE5A5~Ur6OeOIe+-& zdwqNb+KnweXOVTZIA;M9{utR(3xDHDP?T8i)QlL7Z24XFiDkfl#N7~;+MQvJIrCCqeD-~CS%aQU&lKYASEe(OcrgR z)`_Sa-<6;*2Ujhj34b?y&&Q`>>4Qb)Me2I4k6bqz@RLG(w1~{;KeP_%Rb3J zJ#M$sC;enFY_3 z?Mv4)XKwHYDRl4Sc)SWf??zgF0~2-nCfkf8Pp9RxR`9Xt`;p)2Ve+pMCcZQyQC1CH z5SZ;Z$2I&y>}00Iq-J$0Atz`Kr5ji?POBjqO}9+7YEhR^7ORMP*4IHof|+lZuPr>) zV(V$gEF2rFeti@ZWZdwvg_dE8xu=X!cu+>9vM4-h+B62z8&I?8?s@ueKYg*>e(xIn zcfx%%0OMZquPr=kqRCGsPpTm^2q?x|m+(<9ZNBAeRVk9*8o z-wkr5&Q|0L*V8)Bpw(OY1rl6KEp`1|-#iQP-l%guOiXptVu%jd-L~!dbw-vME-aGAojD z#ZJg8PucJRhY5)S;X7OGZrKDTcv9%E-r7}EjGx)8`^EZ|tO6_Fg92$SOgzJ{gG4RzR}w~r#OpN4QF`)Ud5Jn zc*HtdvYUGmvXvkGX$l zRFML3itR;RfzBT^1QoJO6AI_6O%(%QQHi-n6rdz}l)&J+BM7XdaeLq4y0-c3GG6p! z#rMR>c^J}o!l+RHi1&s_?_vteVW1#QnLxd5aPvm$BwMh3C_kXw)U9S?N-v>;9jaCg zdp|uPUaPdyF>wbknQpvkHp=f|N^9scxSBt+M^@v`HDl1eI-Gu3@Jo6{uhK=d*3#S6 z!!xnq_)|OW@?@-Zh7aDw0j^*xI@n!|Coea9IlOh&0x}9>!wFGCp(5*>Qkj_3_*WH$B%jVWOjBAO;M6K!d?3;Fa(EKLyz;Z6z;US-Jo!VE|&X8&AeCjF{zSt#QvI~ni!?D&_kU6E}Je{nOBZv1eLzJnZV?ie{H*W;gx zZmR6t$3nvoAmiHDtg^8^nS0-9+0OHDha~^R?oJdUzi?DE)$bXGEjdjT?nCp(yA$8E zRpRI^s*sLdlMC2+Z~=cz$m4;5X=yY);~DQXCW&`;?;Z!n0C|L%st`+WOfIYd--H1R zS*lu{k`hMM2Z@VN|BYA4oRJgK!Ya<7#<%Ilz?r9^N-0Y zo0`Sa)}VU_SVT-nMdYpX<0>dQs<=x$gwks*dB^BQJ;&Hu@%sL(Hz?<|01l4cxU`CV z3s*z-HTPKmkrt?T%cB*z{HsoO{AJ@hp6{IMO1XO!l{}D}FQMOtyy|0JLcF5DO#MRV z?c#Z&S~4jq9X-;cTfL?JA;~;csne|3>UW(6rY9pkHF#ohZ(9jZj3)DOP(tw>TSc-|x{-*!? ztotvuUtsD`#=z4|Zt{I#QT>QK+i2eQb5v@|knb_pAqKNqv&Uom__O3|YRcYR#0$MT zZg>Mbm&)`!7~^M@n`l@h--GV7K0G#JK)O`J2?H4>4GtyFAhzGtFM^N@TDvH2hTNAw zf<VqAPEM?z9|Oa>Xph3u`Y zToF8@WqzH{2J4vm^C|0=z>ZVh!riHK0Xun}&QW2%+#oTEnb8&1@Nko0L6lOD$BkxV^GK(dA?*yGY7#?ydY|GZGyI18(Y@ zd#uo-{Z{Jri&-@Pgva!GRiH!q{dVx}rmFDrS=}I<*wI||%fg><*dOYDz%k#P4EPtXb4!Kj<)LRX^%W*mBqg11P zjaLM$dPiJ}ZYA!m)7(I>+RY;wH5+NlX9=7HuB$D1k~!{eb~Z~Hh}5dZw>Vk-5O$kB z-;`Lpc?0TDi!m;VXAzb%jVCLmG?b&Kvr z!Dx6Eed_UvKa$eI&w9C?{6}1N>A~oZB|Qpi;^l-A{b1JFy?@9MJJs;q9Sf}ui|lhu>DRi~SITf3 zyAP7`f$l7 z6OoE%?DOvruxT=2&kzWYfJg%0V-7Zn80RLgcKqA%y<&v`M=+^jb$IcDKAKkH8Dc!L z0)v80s;q-!ZNd#q&D($n{Vn+iF5VRyG)O7^~E$Wd> z{p4)m_8FKR-t!rO5#|gD_00!1TC)7yT8lIQ+Kb-`W_a@zwawx6azx8X1sMFd!Ca(y zE@g4QIOuV1S)Ufv>1}A9J2>D$Lj~BFP*i~MWc4T2Ge5*_V%@s&YJyD8-o%oXQ51Uw zQ${W$d+hBEB8tP87x+i6o4WKAO(1z@D6(S#Q;PA z+`EMf(clQ`0ZhRDcM1#fKWoVoI@AMtFZ2Kauzmu%`WPg95eUdO@5#zNfk4m%HP#v$3#0rerrh z4=Nsnhs_NCR0coO`$1eOK6F}HCZ;nZ!p_Y&(ftmojzT^nC#4$Fo7LRwzcA4y zh1ceknd!F`a?ci7l9*|pPXfmGTF(vv?>`9u!2Hj|gE;San0mjWcIhAYCCL2Fl(d

Xk#!QrVllL)AP6>a)eT?35+2|b&l>|a zFjzNj2DJkmKH7jZOSENrIeA~i;nTu1<>YKjtKs22fIkylOg7l^oF|c~o2GZ2y`%`d zYs1-L!tIc*g!te(bGkY+FN^>%>6Yv6q0rA@6nf(b2r4=tXk`a=xK4n!-P&ifkl5?N z(7W&>Im-T>J%w1>zJ1a(R$ibb`O3Pzx;i7P=25=XJSj8PmieAPNgc{D>|IPm%2OY) z8BN37`DSjgi(PW^p{^<%%x(;*;5o=S>DA9 zH>;U^b(;KPpZmOr9#=lLlPv|O23mZo(hbmD8OqmgSk=8g{^Ir4xN4@^BpW7U{ZPK3 zVL2Ks96|sCuE;S9zMH}Mo?f{-zGB!>FnoPIT|Es%HZU~^A{h;|3CgXF?sC> z9H2*On@~ONmW3C^gBle$0Yf*CKfj2^qIZN6C?3>Pl)UXmJZiuJ0${;-0z({NQRE}4 zOxst0Mf#L22=$f+-Z>`TK_r%bNO#A`O&U{KTJ&t1rlLc`X8z zF{GH0QUh@Wo8gTxLG~oQW(U>B}blSz8RFJlD{i=ixad-QEyVnjUY$ zDOg7F*nqf5P#a5af-R(GtD`~&qKB713VB1{)-S&;2A@HUb{u~8ay;oaxfs~#BEl2+ z*n_{klxd{Lr$O__8s$?e{yx3jhcC6i-n?4l@NeBViJL5o(GNRkuR{ zIa69+%-FkQS@bAjV4(C5{St~eBhDvk?KBuEr>L$p`vsZ!j}<%|Qji-f;Io8!UJJjn zM!1N-rUNf##kkBj)&ND6*m^rNZ;rxO7NZe?f^tXmFUnf)vQA4G%;MNRKr9xrGh~uN z+%o1;_3WlNE)5+y9r1WrF4)f?m*R*4o~%TYR*+RoR;hol4vpQIO;{}S#KHe2n!ZEc0Glr}x1Y%l$?p;}${vdQP&LaAPztS1*8>|OH#4+}^sz+#kC zA&qh@;{T^O4sPC@dXB~V)+U~;vVmR9?C!j%43g)vPben=0UX!{@*vHAl37Muewv|I zh8L#63F0xv!@NTAhl9=4aYbP^tY5~$mu$oljvYbEeEnV%-AacAq*|s}mZ0Pamb45W z=n3!${-=+>Fn9LJVng9iw`IxDESoVvS5DZ!o-1!mOi20v`cOq3P~#dFG2i}= zXf71O(Ip0kSqPrE9{s4)>2`EFawjIb$l{nVgF35Ue`wAqnZRuQDnU^KEJFd1+7_+) z#_szsAl6Q4+cnqnvD;!KLl{DR`Hs3>RCR>y11JpnW8mpU1(l&TYGXl_SHX95T=LKe z(kgXnc=e`hGoA#C$_waBdPkefBVFqtGI`RjVc+hL#M!bc=zKglk48ou=nr zj$ply@@I$9$|;s9p^(9WZx=J8ebYNia|%Bz$@cmbexDTMG04+Ys;BJr8S|x&GYwN7 zUMuT16CxnkHbshiXxKC($ds#}l%PP`0-TLy>XgZ3oXzeL5E8v|J*-lEOu*3}=mt(y zmEQ@|dix~BXkv?;cK2~zo=*_`Wq-@~zRtNL>ao6^%7xnrPs+$OnF$UIb*yHX_V*rk z1P7*s0i%ZzULAk+hqw@-$e6NV{q}z9+k;L9(@B~2pWSuZ6F#D)J}({yvwPushOM?V zXGQvc2%;g5uK|vDW0wXrnqK2Jf`#xz04BBWD$ zA#bj6a;1#>Qb})*_+}IcZNmZ>Q0M`S?yqJ&&WMp`V8FoBXs$Co?phTA)%>y%qo7}X zInLH%XW`Yds@Ir^15N=qS2X+D)@skMp5!1P#l}b)tJL0CPRh9N3!8WE3m;7#%k}P@ zK$O6kNrWhpftIP+KaEjj*W%#h@;_RPoZcaSroT7-j&#*eIe#sZg7SIPqrpIT9#1@60QLjAK^i;o^mCsAK!OL1%)7|6Y>6CpqVNm5WI^uv@W@tW0UC{-485WMh#lsJ6!qvqrIdxl=?Ud$?bEik&I>3zrv*>Xv(u?0(?Bxw&rw zJ2xN4=lyaZ48KMUZ8)BBbR*}dN2Q}Zo8vh0gpb`}#S=PpTr>#?*4;4!-`)dgAY$i^ zo!MYVL(6;&o1Mnqd_=NFzHHNL5i_I;b~Rd+uFqUwv6(|nB=>eX<@cDt%a2IQp`&`4 z)yA`fI#UZm%B15GA1@dz*k~H~ff(T&K_4JGn>Er_eaSaZ_FA-ZvuCG0TvN@&q2KzE z_i{xjOTXcVBkpcu9LgyzOhT{F>o^PSwN<3^V3xo9Uaojw=rqVH*3o&qB=BTesDeNke^bY;j?|O_D3v^snEm zb?)8tz9pD3pTa)Jd4qzvAHD#HVQA7dkx(GaGX2=iC1_P=#C=u? zr-k?n#_})f4wu3@?7Ij=Z0#Z3JLNM%NUW&YpKH&Ouf15E+wK}D{-?&A4 zx?*7fl=aTly26rNF1g3ceKARm12z|-x(&yLsgMTNqt0I#U&BRvWnA2Rn3QAQiR@U? z*i5;wmG9^tPL8W>AR#Qbl+Ql~PYs<$D074t~1TOLx>Xqg^mZhD0{qqvB zy2d?9F7R;n#3NEtb$eIJ;xI0H?a1O}C`LU}avjCy4|w0J8yS4cMX5*X6!w0%O_hI@*WqI4@Jek%qe+2f7mm5H=tyeB3s1_wXdfkujRA8*CgJVnK& z#VBGrLGox?=`PJKDOMS_8L#CyYbLUyf1r7y;5bceK0b$ejT8bC8hdHu6c}fNgX&MD zME$0^q)zjsOS!K-&_0W%e2*gVdhKc$epiIhP=)kcLdip;SU}5VCzz#c`SGgYkn!c< z#9HTxe844HY0J$%rVOFFu;0mTB#~z%4Y%{Lx-}3*n)uOz$?%1z;L9TMff{*&MTo5pmMJ<2K9};D3D2u?c66c21O!Kb>Fsw3oNj4&P zVtGHU*Jens>GJA|QQu?z|3mArX#;3@6`!0K#WXX=#h#r=f=BTaZ_OLWCc0E)J3xo+~#=1+& zD&Nfw3_!K-p`YBVgCH3l3^13~B{Z6an*f6yJ-qlUO#)2>O*py^?XxiCp9wq+#AHnh z(vO8CHQR{lyHHNdXAi?Qpzx6Cl>+h*h+S`;!7Ng;U~BsbU$a4&$M3tTQ{rv5!uADZ zy;3GNa*KkG6qr^?PDO17q=b5J>1@2wr;4SN3uv&4Sku6KZS2*(`Zj1^C!P&wxonsv zT`=~^B-kp^A`Z(#?A5W>vG7;pzd|_}{0e)q(=&PhpE1}D*-Ga63?0vZ0)77da5K6C zOy;h!(s0qXey^Xk17X9UthuA>a`Q=nm`yP1?#si7K|#Gb{ood+qG6>k(~NP#BB(K) zTr;^!t40?!Eenc!R1}CDtPtE7iidPsJMx)UX(cRiN4oH9Mg1r$)S2~^NIjokPJvE1 zZNvgDDjwDt>hh#u6Wj^!h0x(18|kg~8La#LOFMf>p6UUQOW+}Zg=GLA?F(JdK3DW$ zUEKb2c=WVTpT5SdHH(IvVLme3t}+1|&4jFE)W?@)^Y~?-e^N2d`fz2g2P>->KjSn~ zl3~l<=-;H$_9>P-#q-!QAbyeq`4iW#0eP!2(M;!lmt?zQ^zGOpnZuQE<06VqX8Cfg>yo5q|f!&jn2!J;Z?20&dGbBr$p4I}1-r*Hlsn-av|85<&@|^sQb{#;O9lhV_T9 zhJRKu!tA1|@{|dAQxA2D9w?;JXXUV}XZ-8ZCBmvCc4^{`s@q1eER^86XFO(|2Z<%( zwRvHIrzXSP7t@(};aCl40*rio#jPdSGaxwKZ(lD08{-Qp5RXuh$yvGR@5>N0Lg&31 z13$>8iWa$rY@9v98(%5>=%pVlRk+28ig%l1%ze$MRU^NXa($OJ*-Xc=afkEx^`rFp z@dVbel33}>h#j(wjDd&2QMn3ZWp{}mqM|+~y5KQQ8Tu_#iuIJ3*^4fG!A z*~ACKRRJ-O-~m#cp*@^(jwaPOaJayjg?XGj7qid4CR#D9+|imt_0lb4e1vY>C?Xjy z4Rg23%#bG)sROda{&}-1l5aJ?Iu$;i3J0Ylwx>z16BVD3TNko)FKEpXZCPugrG8#; zLHm-}?tr-iFq!P*-{HXTlo zJ+pRFcuDsMR{vO3Eon)3dsTS4UMdv$BnWvtF)%gEA2;AljJ=~uQXrY{-e9=_pI$O>45ZCK?8Q%^A4|SUg&KPAw0!n zK%`2NToZlchm=Jau6ePSGDe#04wOd+pxb-@*urD=m{7n3;r;I-!TSskfZ{*%&PW=M z2!e%w2h6{3@FxFRpo9qkIm9FgU=q&(V9}I2!ha_&g?ZfAF{}BZf@>hoXneEaIF603 zY#gVIt3Q&kq>?f3z35(tD|Tm@$@Pl_<7n$ohfM28IFG)Y&B}$prCQ0qp2x3M?;f=T z7-R;k72HEgRFzXnvuT35{?~Tkb71{9Ir5Z4@H(L1qmwIT#2~ z)52@{vtt%#V6J4~-{~+A$9CJ5>24_MdZkn1VSgh@nHCa%9KV+3Tn;D8W#Duxa|Ie$ z&9O+f02`nZ@l|a+E(XYrdU@NoF@(6)C*yn0+~?0eCp&qZmNxcQ{9eh@3mDz=Jfv_D zW=sksa0PDv;I2PEXuFAJ_*>tzNS%+TNviURC*A4k>r?H0Q#6e&A^-)g*HQN9sY}_hJhA*c-wEw2M?49UE2{8Gy zTn!^i1ROt?N7C3afN2HMQ)7(zN~-KOKKCowjr zZ0>HVUi!mY2ZqDk%i)7GWQZ$kp)ta5zmlb#80F;;Vg2u)nxe~@D>=vRqurM4NBG+Z zl|?Bow43ML7ls+8U69r-Zwzbs?)vHR(T`X~wbkZgLZ!jn-_EvWGm6OBm*$Td#2n3Y zP=7Rjc|=|Iw>>a$NF^!OL3*JRG#SIFYG{Hr_O} znTTsWIcz*ICKr(fEsAPrzlwnip0@0i$?s8km;0C+;TQDp!qpC+szg@~P*scB^x_Vt zIng|1IQ+DO3TExTO=tc1HR($8++mT_Z?@L0gxEO5$?{Sbl(J+FK^E$68jxT`v(ng(FU1C-y3jsWC^N#BuGA+1 zf$)35F&rC*LA->d#k%G}4EiWn-*(E-|uk2KY*A&TJY> zr@jgoDK~p+7wd8CO($5l+G?wyqU8sIZWU?TnP4lXOQoYzNM#}C<32$OpE(g22x^^| z%fnz{X$HfN6CPuD#Zviw1L{&e?l|Xj!|RRN_4O2A^&^81?hZ1@MtjdE@V@9ENILHx zD85WTwBqQk91}>CY)t5|8MZULZAHBOW=STs0{_}yZ~B+gv>YHm>T*ZPbZ3qs50(s1K4D-#rtI9ojh% zO)aHW0vk`FD2ND)N;N$}25iOZKZ8Sa7AOv)@wP^#6mqP`%Lg;dK8Ff~;*+y-7ZX|Q zkr@;a#pj*BiE(kk8|A#`;MS5p*8#a=+5)VjqyaJ0N+UxI(o?0ET%A!3;Tc+Pm-N9~M(FUZCHZLH2~%I%gY+K%vE{rqYv zl$AV!S$Gr{E%e-}onb(_g2A?RC!Ej{{z1BHeVtVsj$%zZw?NM4111wb}UJn3j6+Jh2ozr!ePC{1~usv`8G+ zucG2Q%Q5QPom&d>Dh}x%IrYUCg*qlK>-F!n@#7vp*YTFa`^c77y1l8%)M&1P$-1CQ z&yDH2evNlt%c~PbR)4T@0u0)0Ss3-!$nPh3JZW@Rp(lCAIcKV)1wg*z^kYJ- zy`i6#PPLlf27Fpr?Q*Wpu}4ll)+<@h@~w|k4An=(!n>jNEeks>7c<;u{?mYwt`kK4 zar*5rT(hy1;{Ez1s4CQD!Y5#kp{zwjjL%xGlU>xfn&Z(=;fiYaio0|sCF(np zr@t!~k5r%rxSrZva^K*^yyy}sZe*rG{9^!OQ$90xYOl!}6kINKSL?EKekIQ4ojyyK z;p5<~)-5@T`nc+1jC-+7%EDCkcl5yDX6UE=RJ6YCzkQh@S)%E$#H9=lZ{v8OdSr5O zGd_p&qOiJgFT5OGtl`lqlrGm-eCA14RJ^ESqm0g~hpU35g+l2UWa(+Y{xW_azjxhW z?o&)yX}~jux#ALODKQUk_>K7e(pFeXKk3UGpYh98Ki=cs05<;qQX$qj!D$5E+Y9YI z&ZubTV!)O=qzF~_buG6DTxk*vPtE%VAi8YMU zNsu@t*xw|Ph)OwC9cN5Vv@4Dkh$7$Xk>Htjj?lg7G}mZyd^>B%3V?c(TR}+_ST1q+ z#o4Pu@xfrDxzK*rba59}fzBKuFxYLq)y(4IrE}k(%C6CANnBn;fl0(t@ftz_UIoXeGKX6V_{OTw z4HX3D{F);nhdF1W$`tX%;ljozct2|7Q^5bq72=>NtS_hmtYXCK}oF;*b@VHNWX!@5{c~(wv^zcCsM-|CR zJVzC!n+pDk<8-3(*g@B*p##u_t`sGHVn7GHpE3-0VxjixAp6;%&O@7*fh#8$`W#il zj8@>=|F=cnC9XaS!;{jElGG_?N^dhGey*vGJEIt0!mP5mMpACZ6d~$@O}vsOJ<8wC z#)6S$H1EAnU1)npQW~v;Vv#9BIk1NQgP*_z5kdaT#)J_sXm!u1#AVA4sf*|O?*ho; zztN?5gHUjg$$vH9(at~s>}L}aTL=gUD1g~ke3OIMKt9JhJ^wI)`ibaI)~r((ccjG} z?qx&syRMOLsF^zAO08;>zY@a)7c!oJT!d^`?3~@DHE-Sbfw&k#fzZp!8ctmuRwCAj zX`yz%kR?*h#-X7o@ufeDoWZwIkPs1)lWMKgn^>iR(L0f)iXb^g{I)qnI1sPY9Tl4Y zyb1a@SitDcX2Nc`qLb+7vH|!8F7KJjie!j46(fzJhr>iK4jrrQ=)B$@UmbeL?_7e{ zMlI%KqB`2>V!U6^HK5T;`XRBE-k?yzs#+<=dbP2|i9W3dO6%wRGRPfemApCSj#lv} zdDldswhcj0Pq>Ctmj z_0MkE=Uk6ZWPSa;w952}`dW9b5?a%Dl6Jt1N@w0itgi9$zkT=*T5eIK!>IZo=CH1Q51C}>p4A=Y8n2fYNbMWKK~?1CrDX|Mil87-FBNV4GrJ=4kv@?;*lwjg z2tIMe)~A32P6Q+w5-I8ZS2_Yw>GbG%_#g10Pw@YB0-gq5JH;)tsdAJFaifw4J{T3L{ zfBd5n492TaJH6C*jQ@m|cfq{kCZk8t5$2gMoTT|0N!wgn27B8B*7z1K=u%ayhd>`m z;W&lJj_@0NyT1b;Y&L=7QJhwHQJPK4?z|MYrX%Go%aF!{gKEWB5VJn9KF=CkQQhH?}{AX92_*sk~|=j|N5iN*|fkAiNyq%`>L`L71C zQbU|P3M(W}y+jqLS#X#Ka68cL%7#vP3Pe#F)p$6mxuYwrEM;F5$M(i8>Sl!YS*19_ z5mb(J3;4IDSM0G5rQM%boxslr@kV>AmO6jrgl;|bf63enk?y9H!EPQkLbHC<7L!WO zSkh;I07P9)9R!Erq=dlt;?yRhaE<^oA^3N0&KRqs8Zg*}=Rx6wcQ<0Cs+Ce_XJ(8G zE2bFEsw;=|ppU)8vsp=6UHw8{1YZRYgN^wPo8@u~p?&yxIOGfwxtxyr6f%&|8nGsR z9fSol%4M&*;O$-+sJd!+n!y<9dJL#6&rGf7u`)Q=rcZbOi;1hYyyMa?+WP?!rn25_k440d4YwGy&egSkypH&k3>MTOZ0dMTH-sy_H_6hZM z&bm*E6UIXmtsn)*n4aL6n_9+lVAwF76EO3kDQ(CCdti?qpMkgwia#oL~k?;mOYxqQ%qSfbT zn~3U7NM7-j`-x8@7)2?!iI!58aQMbVZRTE}jwZ!=<@`8{LvK5dz)@0;cWfE?te1WY z7|ojGfhEyNrp8ilUs5;4+Vr~2ZTwl`?)a&cVOe1++8cjRKkrJYXr<>>Sid7JBeA{b z+?{WyFa3567wKfnBNeMSasXYI2+2M3qXP%m*XrA>=zI+eq{bh&UWVf{v_G2P-Zcm? zq}cK6qvGR4Er1n>S_?K%4%=Q7*AL|4UY4C$NBvawE(Urto~*Tz9HE2XAP9t8p>Li4 zB6Gr$4gTC~WdH)&A{lU&%zV6)ntrxtw=c2?D$51Uq&{_#i(3XsB9g$!R~6@({DWy* zEz#_w8tye2O|--t;S84GqeLd<#dZ66g9y{fUE--R7w@G6K>i~M%@4MdXh<}I6{3Lg ze|Pn+=pzsh($P4nIyLZ(Zt>kvJQD(OUX+HmwOnFV5nCY1@-JMSpDg}NZOo_Z7G$-G zGf-*=2|QQ=Mw$XF33;pp=s`KLt)6AR1Qr)C>E}0f8yw^my?0VB1i5g&!HiHD00Z_h z*!#oWu*;c|td=edDoU7+cK9WZjw#0q9C{j#lxL7}Tj)fb2Yviz6}GEvlF~gOH0IlY zN=yyy6FNxc`veRmE+&;&naA&vLP-W(IdAp`uYgPl#TOBPgePVbZxl?fZ{O5FcWrf( z&bc$DDjCMcvxUaRKM=coo5&|)d&3D3JLKTpT561oN6>6rse}N`2|OLK$4k zo=vu3EK8B>%oRE}rz$brb1k4J$Qe*Exi%K?K6_l#S z7iW`G-DG8Ab0Pkrt|)|B#_Ml&VQEZqtC?V-k8Zt)6$_FVzN0aBz)$C+so-?D%e@?C zLolmJ?qw?qPSX4Ezub1q%P$F*{zb3*B{zb`>s3!v)A#ssrKMy0Xdu~#1%JcQmN%dhy?sYVS%SL8{b3aNr)YVm0=py=Yk>=jDHW9X0uZ$ zY-Ac(!r%3)(=&4?;jwB~nf%C>6tbX5U1CP?{1OXQpYm_$ezXaTn!4A^XNa~KI&*|` z2`#hq4HxS`ii7P#8+X16*=SI@r=;F*$yYbbY{xKBo7o{6MY)y|D5RW(;vs3xis%*1 zX&UNAhK|*V4dTUpJQhFPHEk_S)*~6pYi>3k^iw4Mt&b>UN65qX?H5LH8`_PD5MonW zMRMgZXsi-rNuVcdq(pYv+&*3>?$QGVDeDEv_HprooZ^BdQ(#md(WuJE&FiOl0J9zq z{2K#Pj$X+Vn0EPE zJK%;7f3u4a2o)<}S|1?^R@4_nH0)*%Q87x7u`g5a0O_y=ABVkHmqw!XX95`^nbe3< zxm*kko-$HbrwtPE^iA<&AE~&G=u>9qXs@7I=a)6%H0(01$rjRfW%y)d&t;2DpxHc| z)a1{4R3C}00;B>)KFL&-9?edJw87|bN+QiBrzo0PED!&3r(easooZcE1?gh!l4Ogn zirkMtrwCAG`c+-AV+i!((BuZjS#mssVW+%sQsJdg;HE2W$G-Wg5>zSZ=e0m6t!QP1 zxRXhE&|&)rZpr~qt`!QhyzmJ(wrxC?3Q1ikh{=V|?vXsr`h2YmV2$g#n~opwJF5s6 zWm7ImZ-tng+Nu{NAc1#B?A;1yn*~5qK*W-ggRys0C|F-p_*|4HE>4w4@3RnjDGpnV zju;;+_b+H+l&6nXRJ^EI0jU^lfb-AH9vmjP(551z5Y5xxFeJqH$Ee4um=-UBNhTx6 zKiJtAB}3`2ID>kNaHS8E@aGO&3;#4p37G@-4@3ph)=ZVcFGV~^9N`hI`kyFIaYpMG zXs|QNuz^brQ3#@k7Ox^qta&z@aqe(`Hmt3zH0HJMg11zjIof&ML5* zg`ayf{L#i?FG$wKVNz>&08vuYr z07fGJL!tk-Vf_cg2T<&T-f`9Mh4)AYp6`j~=;FOLx;T|)TtDIO7!;#iNu8n}U&Csw zwC|nOYF!2gAJvEQb%|aY1LgyI_4doP&u2N+Qs0<&oLHZ~h2Fk}`pT-?>Y)Fgn#m^X zVYPLW`3*x+Y9pxChzJOIiF2MY$W6$kVd;;#`(A%3z|}UO!L8sea_U*#T)<=5l4HeoUvv%gJuj!MMOtmD#UbwC5)dYX$AaB7VHFKlmAEuP3@| zN18-Al5WPyXe?N2vlLYP#}zh1t1UT+rL^3*{XHhDH`3>(x9o~Lkefc|kSC83KmbZn z(%mDNQrW*!zIGZWDk*{a_5eTKs4UvTts3nKP(t2UMU7Q(Z`pV%V?>JYgQcK3QSZ`c z{W1mFq8ufz4v7@Ya_pCw*D3Iwm{r}!v ziz9+Am5-HhyLo~GAsl`LKlsQdrMqwm{i|;0b~Mi1NIoq4;R;HudBkGT230$ey}(Af zEpmogTH>9p`+4y_DN4VEMw+)FC$YcG7!NTgJac|Ua$k=Aw%^TLB`Ka-szbZ$JsZKfH4bi;v-3lc-k093?7ykOCINMl~T1_ z%I~2(B&Nf3!DL3;WD#}sMA~ntD~#2B37jPBY3%WFZd8apPd(b;?-v3SA6m)lM-*0u z8BSN`rc{+iuULv?b?(qF3J!TU!77)NlW{{)KtTLr zqx23j^3Z!&!s*4iS0iMA_^weqphVqaMZtF0ZE*8tHxVCftcqQucX*nrpy;do0BjMd zjAv=`+4hnINh6)g^TwN1JwtXt+s_4!lEy$-D!lBk&Z(8Tk#|Pp%uN47)mH|^(M8+h z?hZ+iVQ_a690r)d-7N%n4Z%IZWpD}Z?iM__dxCp#cb&&~@B8uIuIf`=-Dm#n>Ds+| zZCM)3=k@7-O@mM1DhpzAr1E*dQ!CWjRU?M={I=StgKLzVMoonBHTr+X7);^j@VQ4m zcVb(%m0gtU^W@6X_{`=pLJ&*2jM^_+K})-88{+rueu&o0-{B0b_)U--mC+v2deV~I zQaYL`?$HKX2cE6KJ}peU%#uK|d52>2y}!n+tDZO^BcpIno2X)qvF;h%-G zdejrPZ9BV^;#(koM5g!mnwXB2HTl%)9jRqC1az&Fj|KC0`WQH&*de(Z>wO94xvQ1$ zA8<5^8l#Maf~oOK`h~hs;|XlPxu}XOjf%75wp)B-RbhRJ$XFnPF#6Olzb~h?#e`QYinhuQwv{RT04RD}87`prciL3_8?BJGOI){gPwfK`3e93TB z@$a^6&N&JYg7Y3W6j1YxWJQ}b!F6QQj>vhxrt^&@kkMH2_1R6)qu>i@5fFcis@~{B zU}t<1Z~CnO@`ZEi50BnVHEkuw|^j}D?np#g+x;N>EL!XoI*G;A`6 zz50m1vu4c$r=iTX@%@aP0L5gn4{Ob9_FQmiF7%BsMdkmCUKML2K?$MDXaHE$4a zaCBY)cc7#eL;*p9?%gn?u8#;@MEf>R1y3}{ODaZfW55@6x>=mFF9aM;XBLh0%3&sF zMbLNt_j^n`c-1dgvt;&(m2jt`;bQ#Rer`0GJw&n~$?r^zCNUArumz})2Mp2&nzMoF z-u;5_p4|zug*6m3&)CK@W5npJdqWX?iF^CNO)Fc0KKA7)p%S~@Z zGdas?NRO;>eb;EsT8ZV!_IdTIoCxt>ituQ+289DG9hd=0@PLmKBUTj~MsrTp*oP2m>7Fmz)7{?B`o*?6q?>{m@U2Pq{s#yR@--y*%S3%GKtdtGN zfE914ZSY%3+c^87Rkw#Cfw>lLvwXRls2{U&dNfTXUQ@Nsg2c zc{$t~`^ioky8K5OiJ4}b+H?M09b0`89(_TeHeFu;=RJNkIFJNIzYDYL!vvasP`dhSJ!DU~!W@ltxi&>ySz%F+H0YFHSM~!f*?@T| zwx7Qw$osg=?95zQ@UIelG=Kn1mtrRuY0aXIgLa13MUD@umnw{E7z5~o!RW@n z$k7eo&p^S*X7zKC?ktS*l!tPD2bqF>(tmnX+Kl2!ljw>-W)xmm9pF|J_bS?#xOkvn zJc0V~TQ!xCA}i>XT-p-0*tyN{lD6xC&5H8vsSQGlQ zQRbUMq_s4APTqroe=%p0Xk1^*W9#(^x&xPkLCZEj-B@m(v~$_QLC19Xw7~-r!9{QI zVQ>Fbx=D!Oock&8XAyBcKxM8F zo;b8(t})K)s8`LVi$?wCxF95WJQS5T>L2d^H+ZR1I0AahFZ&cE;hZEnT-(5JfHF(#lZV^emQKLSNe~;5QcyxA;l=4Sy{}>-xEz z{GwG_=GFKqpDfR@nD#E`4;uLbC3RzY+#~BIu6E4Cin)WH?&R??>@iNiO)F61g|54p z;RozPxrq3OBxzclTU&1KF^#YIpGhWHo4pM!f2etSB;_d!rLRopmAp>M>jIlozL0{% zcz8HF3{9M|c&!G>qnu?a@xmHI%h;sMhtPC30ybP&$qTf`)q=W%+KHl*A?L13lgWdN z?*;k}9KY{BT~52W;s>VLGVvrVX8RQ;7MmNMMsloyMkQu%G-=^-l2{s2znBLf_mJl-KUklV9^2~jurKrqn;x6 z?6&%V_i%6`8+XLQvXAKTq%PeuKDT#L!=irKB>xdIC>@I=?npIKh@&BXJ*|98)$g)u4UIKd{C&# zqWMG#F81(9ao(apjb3PcHhaj?#-f=fj zDazrWu3KIXhB~c{j1RJamQ2}aV>f$ZFilZlKqGhLqFTNQseB&*%Fx67E0)zg5}mzKJ(0XS>N{yaNEcBXMc79RK=| zu}7LuG+$Ft2xnN@yu zxb$9p8w~}2wG<}s+Z1PAETiiYC@8wP8}4A|y-OLK4!3gDxBXFF$mS_Kp{ThoZdIaA zB)#sc`zPcGw7(6};_&mRF8vldz<%yL16$yA3#aCDXawgDg_DbYrA{TfG?gWaEhDMj z0uTE-qv7u-xDUS0y!8Pt4DbDp^HLK&u{+bQoX^#;(vWMW2V=@HRQ{EEhjl;E)U=o; z+pf~%^c{(=+lro2;=<3OR*;i}F}3?GwgzLpvLYBkRM8~F@fee60aDC2Bs6$rTm&GZ zS`c#(29rHM@CPGxC=>#KQb5ThknzGo0s@hNwQ^ZQP<5bI&zF&<492#S z;Gr{Ok^>%Y+WZ&7e*i@)@ERpB@;N!LV6q_9!nMDrII!nsveu-yO)hGZrpC|mMr-0u zhc+soTNo>W(+$uLvT;;MY_zA1kqOpyne~=XsAZH;E6--ymO;U{zJnc-ro^VTQU5-b zr*Yjete;~;d`(uXin`O==aM* zSK%Vz*pRKSFkto`^|Y~2e(W?Z#kUfa3hRad5eXM^akUssxTD8L2mwmp^v_am6;Z?TU%&@L)b3MciOJGK z}KY7>DZFFGIizhxG_9%sR z?e4bO%j0`NzhP>S&AedM6|Lww;Gztt`h-ysSV5VSkn2WA{$FS9N@WW9-W4x1FN2TS&a;@K1dwk?6 z2bh-nd5Ca=yE8#89xCsKC}(b}ItT4}fvIPcOEU5pKjQ`t{h>1uSndDNuY`agawL z-@D#P-g-;kEXYQrUI0wh_Sie*7G+;39J;qkZNfpMLRXXPBGO4ii;vLh?kCF_8gLj3gx*g8cEbJEH9)9*=%<CMxxX?%~6 zdd39f$v+G6YUub6>SY?7|4n}_#5>AY5K+<@6-j}<5|u4KQq%Jd=a zOk50pq4^v6*NPHutcIbx86#1l60-3x?T+13ZxJ;-QsVbB4h{kd77z|w7~zWfd(Qlp zCZc*#9c!>A>%NHESeMGsjrSL3HAF4uYW1aYt8!a!Wac`3U# z9}+!L^RG|>p`)Y??Ml9B7lR}P{j6lQvQX&6T=NwZEI75n-3B>qh9Xg)N+y-%fye?nG!ACYH+MuJl0_gf!u9=6 zNeIuPso^-y;AsE5*3JDNuT3G2&ne#hMuZ0-!66PEiNGNQz;Bnt3s=phN z8Um4`kh0@5|hfC@pNXuikHl#npCY%5H)0miWJ^yG7DIm!Hx=7vnlWzhCUWUIg& zw6L}e=JB8hMFyn3#~QPsADNNTC1^AtbuPAhSX*{dW1?s5!bkzcSE_#?NW=Kr@NA$T z+$))h5Q;-^>xQ1#}bDzEr!NsQz%{w2xiULUpO~HPurU zum0S8+@_#WlSh~+sbOQ3ZBk}ETKMBO+dK=mEs90SvkpO_Xuat5*T0TD-6$K6oe^K# z?pgaqpZ6Dl8N~*7_}g?=0U{p^O*lk}>B--y56+oVUdbs}KZ3I&wMXNtR??d;yEEu4 z*1Nv0qRl8Ux~>{NRWP};nY3qoKhYmn^erj%)}KNhA#WI#Ed{zcV@Srte>$#U7+S5b z)^Rj0N}uXYwV5*6z%j(ABcSP})SWS?{Q%UrGoTUV7S_r>to`<2}@ySnT!biTR+6kB})gl{Cb5*r3WA0)DX z8O0uPEGmXm%GJ&Su8C8X*FjXG3-$yc%H(C5Vs(RpjI$W*iRu zp|9-Me=BZNh&GE?CV|6$5&{F&w3?G{i$!I~ew7{{+cg|7$qu-A3V(c(5f=|!%Rm;^ zDvOa9RGQ%!b1Tghp>OC)H&Z=JuOsHKo2xr{{gK3Jx@tZGgG|dl#R;O-EwJYaz87WQ z>IyQjZZ?-gXg!l`ZAKtC0<2VT?mZx|YMj4?sz|gWbP2PpVd6?S5?TlJ&REuXV-S=E z4eNaikj5q)SWELcu|!H&K^24-sRm-g@Ir{7E`$(}5K))KWAYm?#+yq66o83l5lrUP zXms=jHbieb@$k(60U_WY;x1?eAt4|sOd4MdW{61=p4ywff*K89e($X8KV8i;0%TUK zy+1Rt%GdLx@z+cW8|i{iJ&!{Y+KNNXx@LPLI_Vd zKAPT*Y9hV!>5Ddr-lXwC_Eaviri?ITHxGaCNV~2d{o5+#X^s5wU0)7rUgRnNH%T6L zaF$?5gYYx$jLkKI#%8a=Nr|$upgy?j;IfF@kQVQ|<+|)q-cafQl(t&`_o!ob5*o}j z5@mHSdrd!V9hUdc>>)O+mJ({ww@)Y{Y@;)>9%~5Uql6AKd5o?ESO4Pa`UII8itdAY zKi66lWcF{*_J@U~**8SGG*lWZNk8qx(Q?plxI8=UTq*HKy6hVRHwbL=E|a@MZqqev z%1(}1b_+9bc!F*)ZL-`5+nr_t)x+5qErTEn>udH8j$6G*Y5c^;_f-E*^LM&@+Q#rb zUQemJ7Wl*#RQ=1-$N{Xb#l!JWDshwi*H7gc1Qh;$sSSA(&QT>521O^*C_I~(%JHZjvl!3NKk==z09^@nawUPG~Vr($B7sdB==8>h= zf#jzRCFbPG@GyTi+EUxl=E8pkb7x!Ezu(ud)pBw8KeL;FDZpfAdt+lSUvhz2ba_jD zxgs;Xt1Kr6wJs~_rncbjZ4sSF`I{h4ffk^AVbot11*}f}P2+hi0L#wR(Vd=zjxdt= zSXZn81AAWj@8tu1c%YiWaCJGAzkHB6`+Qv0Sk<{_R-q9hxRKsRRm?M`D>-{d3p4mn z3Oe@Qj~CX^r(YG)mFVP$r)_@8_CZg{1;qKMuZ3CFhM;S7wn8ljRy}WpCd*{b@RjQO zwrX;c8`?1bOWJ{P@IAgV_hs`t#m%2XftKc`CYWVo?;`wh=rO@C5 zx8dGP;;5-K#e$`OBC_lg6zw;cA3HzC1B;Yl;-UK5Yn+8q@9{MBPGk!%y>3ngB|ZBG-~YkT;Du zhGR1>D$pQYa>vj`X^5170cEVY%A1BW9Rt))&Q2yxf!}Z$ABO`i&t6ljEdNbbe!zKk zlP$-+9E20kK15+EoRqK${nN?+UMCS+QE~zjEZSVeZwAeLX16ip43x$;Ap6N9Pk@k<947;z?W9wjLt7J*^!sAjw~KSd5s;vUgC<4`@^p=!RFn+<@711 z_9^j#`Q<8jkJ0_yPJ9%Z60~UG@1&H|1mPlmFgajj0KK|%wEBV~1KU~gQa-I%vv6(2 z$iC8Xn*;Z)k%SziG9g9COYVj$2y|6Sr88dCx3pAL;WvtX*l78E`CD-45Y!YyR2m@aihOfP>RpXO{U8S@GM*5Vj0hpEu?1l_(I6*W^e z*K-#4ImDt;`OfNLef|*oaj-D8xxvuT(NwzAfVmWRB;}V^&91Sf*U(Q}3uJaR(EaZN zq||sEu28Z9IsH*9&Hf*hwE3}n(<-y*^keaCDAchZC!l(#PN}0x#NlOL6}jI9e7Egz zjwg3y8=ESCsPv9A;_cb$HgW;$bn3S5h`FwKDv$wWk`mQ8Ern_~in#XOPDn4hOn^lL z+f-dqV-oy>WQWgLos2b)yMVwrdPJ6lk6kH0yxwOtDL7(q*$-g}_*D^!2Ja=giuTT= z>UfofF3!%32pYov!d*~Zhm^pNg<_SeX|s#eCd0^U5R_wmfArJ7yCCbagw1TDBpKin}?=81m7)@Inxu`Y=277mU2bg=Q&di2KGx z)WrPbPDB{lg*fjXhq2^eUAEV{p zcY~twG_`@t%twD@c6q&Cx3MkRHXN_D9*;1dl2TI0>el-xugu_`&YzoF9Jk8@<|+Qs zlec{fw7u_b8ouY{>)~chXQvJyQp$HEkUp}5JLYsx3+*#?A^SWvT?=Q_Be*P{Vcxb( zsf>n!tT2-gMM$?QL;i~8qH{S{@Q#2ZK^J_Y9JuR!5+XpBF#klh)7UN>>DN%V7O7j* z8FWn};yiIeZ$afef{ZaFEYlx1d^p6M8DJ*_g$b3LcCpCi|r zenn=6Irch^JUUU>nZg%QMDI&qeQhe`tnfC_zY$=vkzbiRA!+_iS}t#~ymBBMnsSU8 z;I_xBduk_9>tFKT?~!uoXV&})Tk=P)XpQkLvpNJ_J;3y|FLhG#$SiT7yNL-G$&Hc8 z1{xXBsO`x&jsB0zE$uUe`3hCp3`$G z=8L&a+QoG&Ye0DF`*(7Pad1~?#rC3eBAh#_2+HTdFovGgP>EE? zacS-@AxQAEh&5AsDHkYx(HF%qbBcni?1ob|N}9=e(P|{!Wq5;`EvXc!?5l*6%z(sH z!7EZ1!4!dB3$+rNl62p^zgpk_3aD~*J==4S*@n)OpM=i#^Qo!V5|=3lg$k*<#cf?#7$s*I1+gG?hVC6A(6jy= z(i6|U$}zvsmHFN@KOCh=v%I^(^SszCgJ&(+MXATnZ{k)7am8Cs7Y?D znl0O3yU|6I8pj1Aus-gqmkC@qfPcz2UiA~*q;w`AN`o({wqFG8FTeo3%^l)K7ZQ;{ zNUK$Z6?UfhyNvB`W!dI>kiS-aQ0k*b0$M76mHlj{$nd78YGYO*TXKu!;Hs5F(+F$+ zEXMcs_Y+=i-V)}=rTCy%^i&+IfVUSw0{T5M5NJxE(HDv*87CL{FwJ%Wc1MJD+3?Da z5g}BeW$gRN^B8-m9_&MFO0Q;j&?FI)H^{|VuKUq+O!xMR{I`gxk>y`sCV znC__PUET;Y+bYsIilm?pbzO#sbSV^T~$>dJ@}HZ4^TPY19PNcg|EABHG^{%{x@~A>?VX&?j7TItA+sqE}j%0~%D3xH}^!+2QL&(*ySOeZno8nmcnW(mC?0cmK(@ps$0c%{pNnW3l)I@&yj)(vu8x9N7XJS7Q%E z{uQe5L&oktiEe476(4Sz*PH_ma%#AkUZj0i);jx3r(XO2z{ zvvYR2wpuprqm!_9WeFBc9bMRU>cjO?VtH%VBjSUnEo3rM*)-9uZ-$u)+xGU;a}t{a+Jo@!~NYZaP1$Oq`bPDDNF{29p_M>`aA{PkD!tyeaPLu&PDw&teMDXK1V_6>)EaPnO_O7`_-ZNt{pe& zs0gvbEOL(Zk3!mVTrsIeV++X_2d@klfKDP8O)I&okv(d7mGlm5MwsZgHLID-IAky? z?7`vD6HR^Z(N0B+DdlkhYH0w?t*x9CZA);Obcy~+WZhL{VwhWkaVfMwH;U`X8d|4+3kcoXin$P!qrV;UbWFIheDVKC=U8R+N%8aP7i)fermvrO| zVurj_blcO!#ptG3MW5c1ydT4#Ke`3_chAv0FJF%8|H(7#KUf>Om-ICCUmKrx+%;5S z>HPYetP@Qx&l6CPGQ+t}C^tQH63@@g=c|z4c{9h@XQXrR`gf1XA7uNR+q4po?Q zYr%a~v`2TOl-#dRUCi8vq}f?~R!k1;n;s0J&5f(e4EwlI*jJ`kb<>+%KQzh1WlHwJ zd*itLv;RtMx#O%FcOYxfqvfxEjc3GIHM?BDnEhcyjBQ?xM1^p>uS^J24_B zLVbU<5_2~`q2576{c>bv4-r{m52?V}KWA_1yR{!@Mbma|durEiu&}aYdGZvr0SqgH z5&Au`YY!PD|H$JCKjPa(fp_yJ3BE0gFLf=cqy_TnXyk8*X8gHf#ERFpva%++z`rWW zzR{RS4!o~WB0fW1Qa*?|I3)MYoAMNS>xdBJewj@A(N!>*B($om@b{jm2zjDnp=XDR zeEuonO1z++n|7Dt_2;i48WMoWihM5?g}zRmLG&- zKo4gm2gk+=SA&KPPK#3(ZwwLE#4PwkXOq3HS3LR{WfyMn$jMwP9MCG2lJHMAkS>J3 zthPDg3UofYTUusnA_`%w(j`8*;rH(qEMon+Es6g3U5M-W(yop>=t6Q@O2Wh=!oXUYt*>N1lF62vRTd+1 zp)&QF)tj0V)g)g)n($)M3Ji;Z#U9RqPIQ!deDzip<3K?R>EkztrL$^=#xdT1!3)8A z`#k<%ga6;O1szM@N>Er1CqB|!asuza)?zqnI5_Mt{lF9_u*6&H0v@g#4uL{YiAM@e zlbmzt?Z;G7y)t*q-SZG}frLl@YA3^#ZviF{6Xd&{^T=kA@VpSr*w ztU-e1wOahku5wx*dbLBk8Mo`uX$Ll?9e3=W*KDhaK1h`_*gl$el zi5RxaR_rielGGnKsXhvJ&#xt`Wji$75oQhzQK=0Avj?Ndo$CYsQUG2(=|RD>A(OW=VIbK|!$`k6 z(j-BJZHgSZ#=G#HDk&O^?&AQra_JF-jwra5+KNwNQu9hCqBMK^tVeEWH4cy(X7Ls- zY>^#`g8sZYb8Mp(Bx?Q_#F z@T%_H1lj8<a zLOWt4**E&_PeD3=eeGHDFwOKJq-IuACFEWw7fP6EhcT=zOxMzSW3y=IvoN}Yw-nQL z(~ak)68)&I@}4SDx%T-ZzZ=}*ar!M9vRVud@`&z-VLu}3j>&g|VeYO0#iP~KGp9j- zv6@0Y+AYp$xPW{Xr%GD;i65$>gXsq9sq2#EKQ~38)ZAhGI9K%zbpA~a_=>Iy?KM=1 zAwO$yO&@)~R(8_ML?+b;ta`COVpugk62?;ZWTPi5huxY(r|-w>%QIdrkz2(L)ZMs-Ebn~L1T(SCo$pPeKlI7enEH|M{4 z*9Q_!$GSAk{&biO5LU7BQL~#83qzVxG(7ln&RPHDP@q0CAVTNv11+BmL~d62C$>wy z!px%=2GUMYMi^qK5D%h8Xx+uvkVeE%iIDN}mpk7-@GBm2zekiFc>qSJmoORy)4mPX z7&0)|&e1P_ZFrf?klm}>H>N~}8(`}j=|3l=yWD0ijs84=J}$YL9U_-v9u1)CigRr1 zk!ip!4GSpT@6EhG_^_VB$Yj01AWG8rWlA}?65yW;zd=F})O-t$__0P}PwrR}rR86< za-N=$pBmdYIz$>Xy;bvhq?GnNQFgEmY0{TPd8&Sit}X$&C-1{#)A}QJ0~z~`RpVfw zo=9WJavg({DN#Pf>hPUzzV$N7PE-)haafoG^c;eolxK=8E@jQtV<|& zWZG1OEH$sqB-QFJHRQ683X^1pG_GD9veLvb8?5c3t$GX)Ch*Bx@vL;_sE63N!FOL) z%ybVDsCH?u=+u(-<5N~Oh=NDDJ+s@UR+%Kclogkbc#xETig3toB{SI@B$veAP)4d> zP_fFqaEWYH5BM<_CgvJp^i1K{WYgNp$Z=Fnml)OW{z|mi4@b@xbtkXH{M(R*R*-ac zDZ;9V1ZW5wR{e0mWK9;;ZgQH=lsja}`h)jUicOND5#bE;3x7~)8raMWrTxLj{#)B% zTT@w9uJDUKNyT6anJ2fH;(kb08zIG@Qf&E}xMtj?B4WjZJYvupwZK|`#;&O8Bga_V zgQbsb=R=HnEa@f8)F>Ko6SWwYB~M?dYt*HgnU|#;IV>{p^JVJJS4)fyhx&b;^)7{) z)e_Y{_ELHAtDR14VfEa)zM`)W`#GJbq~Z-z^`#XbLbH}$KT-RQX|dT~VcSQap`0*- zsBN}CM73zMGmN|A=8>(ikC{s07Yqe@VB7_|!`WmF>k5=O>!`{5 zVOn#l1}a->vD@~B&cmfuoSTLTy|K9rx9IVU$Ns655b0za<5I)<){44+vrX4A_1l{d zY3wpG)V_S>9_rOcRa5@bwVz0AbzEm8({M&{Ml@Su{g|!aJ6kWj*4PbzKnoZbtg=d} zqTJIQN8e?WVqZ!P&O8fWAr)KSBW;#n{f{Vm)chykR4f;q{q&{)7oFTHtzM(dr;q5Q zu=UIP1xxP(*&{d`)YleFxaa43Yv0XJ`1onN9dcJ)3U$eEg;_`nEaTS;;=T`ciNEv? zNqpN7+b4PRY+ht2tqCNKF4@=z?WlcX{zmOoM8yQAD6BR%Le5?$?!Jl7F8wnGCu^?Q}ow#ntvLd(EWB^HU_$5^tdO?RGx?!gZ90 z@x&#h3yBa7A>F^=R1a&^o!x3nO+{#^jbg!7sp(0lmUxQ7*0{qUO4J$;?B)M>iDzN! z_(0wj>6ZmOC9)1um_ow@6~1u7aSR=z@^txGM9;9>@}&PLCKyXC5`8IEZ=G zU~58>=1EF?A#2}Vqkl$-ko`fO6#4~A;{uxOGfc8CLm$ZtgFVTQBfM4m zBrYVM}&siBM(ZjBOWD;K{?-f;w7;JyTY=THB;29!>T8-VWKfd4m zAYLqBTdClSHlZj)97A&cU`vL-6EaZQyvSKHMrVZ*bDMF zF(Rh=)?<)w2-Ozz*Xz+r5BQmf2Pxm#EJR--b{YDZVwEv`=-XQA#HTW<% z@wZcL0qQrxiu`RZ&YPwar_6r^^@(xJZ#&`O(BBSf$HIJg`*(PNp#asEItHAfFK z$*&wcig}iV|NK#s_`NWkVke=PM z;`eQ&somsg-o>K&O%ly(s)H@|e2R*1_vj-JfH> zdg|n~2~ltV4fsdl*l%2`?V&DVdV^(2aLqSSr##i37Rmj#%I|xn=dj!Q&=`BVe>@5Q zSjnNHvXo65nB&Rgl4hDiX2pGFs%Vkfoqok#Li7hKVF+&TGe`;;eOyyFSxZO(+9%XM z)Ll)xnC`S*e;gan$qy`#(!bBwSha{{$E~nw?$n%iGdAtK)uPIeb>yIcNqJj6`PyJq zvs@z_Uz3Guwo&7&++~~89G8t!tnWMEVi*Y_o_`g!U{j@w4E|wFZhnXDz?oJ9BY|t zo7kiD)-_2phQF5s^iOB{P7;z)k^2}}E^HWlWT7vZbU|8{gzAayMZB+!L(lY<^^+b4 z#$^e$WwE%ODN04y&-LNDHEQ*QJc*;*9~$GMR_-u7dq}0+oRiI7LudEXR@yJrESx$u z!<1=n;1_D_mbvrUul<{AFHQShYE2bXPda2J4tJxkPrjjC5*Tnk;8!zN7fRIfk7o|l ze5-r~mKw8q4{J>)D!(k@-%1OkCFMPmB(k%4DwGWH8Pip&uM^2b&anpZel567ISvA* zIKA)L&PA9#0yy9d)?^(Abd|8GS<6`f2F2UK1y`{Ad|BCy!$*es>I~_4>I=Qe<(Y_I zhb~N-&%%f#gFU??Bf$ETSNyVy6z>a1ZOaLUe2&|DTcgW#{953qU6TfBY6i1h#5k0l zgd#x0jMcNrB#GYuOJ6;!5&Sg~BQSYhahw>wyCgi+vLLCm50)P(Z1}mxWj5I>^^a98 z=^yIkF&6KxQQ^pqhud&6&uPnb&IA;VXJ`4tp)j?2(HOnP>D_qdBEz%Uu71K54dD{> zH&L<+&H~ke*zj2AimsIY4wYyU;+Nb*G+s(Uo?gntSc-L`$R9T*qHeIDvH2)YsC4iX zo6f%n`{VX!jR$uh(PZCKv;(bCdeaW#kr`tyzp4bd3*wa1I^0vYS$oniB|#MfLClP~ zy>RhLIWXHu8^6PRC0OL3fWU-aU#;2S>kj?c{56B$7ikk6KQbE=pDU{kW|njE!;H|( z8brpYZJQvxihv4|ZZybSxPZ?m%?Y9o(FqEp!Gko0p>m~wyg3VTHtCduZdx}r9ZgsuZw_feISiCjVsNmquYO0RAcQ14+D#C< z3IrXUCyTrYbmi0JUpGXQc=f%5;HQS?g+;-JVvFoZ6{ge+Q=IXG%y0+lDn1e>Jazs^ zuDmib5(U}y%|IY(Q3sYY$JwZ`1ryPmQO_-#|ov;0~fr^+WpC!c(BiC{91fJ&)(+>F#M*lh7uA1FLlXO%uY;l%EC6w0f)+co~cJJvA<_v&i7@sjAVrAHc039(4aDZP+ znVSe$d{v~3&f1Ck{k#--4P{OF!i?8-GjpkdH_kHXXR+``_%vTP*wbFJlP_e^-P7P7 z$`sD7^1V=%DjwnCmWGLjx)g&=onqHHXlU0JsYb!! z6EVi+d1)0!=GyW@EeZs`9w8)Z8MlIu@z&P}>^T-z4oxyaM@Atb3<{o zMIGDRP!KIghwN{cnZEXR^P^0St{2`!&Q`YNk6ctYK8|yD)ITKU|LEY!0}*SJ-L7?+ z_GKPbZ_n;0JLk1$<|3WTKKm>P?|457%aWV!M8`=Fy>k8hiq1y$^i)kkHPjGJHH%&E z1LMD%U#bJlR$L*CkrGT#fj}}E#7X9a>NIKyXmzE27AF51|H_6Xx6~tA+}`e%%uv5Q zl%*xV8GT|fkP%V1@m$NIvT707j;3_85s#i2%b zQfz^cqSEgfHtF6Uxif|=qYV7NCMNl4SHPpKwI1ix5GV@wg>7O+jCQjU*`ED6?Pu1RZHk1h7@uklF{~NO)(r>%)Ij2OKMzAve(W1s-p) z=ea_Rv{KXN0UYA@TF*yUb|x9b9il6@RI*vAQ%$r}e+J3np-! zZ$KcL;eBH~(RXgTH&4DmYQ2GN2B}r6BEJ+(h0vR`9P(Yp<9}S}{Vof;~v#{bE5}KYAk!fY0D<5es z7wIEt7c?uguYSP?oM#+j73Q@Ul>J*Y_UTBHiz~l~@RBVA&(v4TWC|v8XvBs3A^}nm z*DMu`yZ5>g(C>Z8H-r59`aRV7p?OC&a;DY5N7I|?GYb&b6{@p}S00KvqzTR1#nEy92nev>5g7moJ95^7J|r155O zj$kq2B>wEkWfHD;l&(ZAw=l9IKi4bp72 z{-iu-Qv&O&-oU^867v`sbst2Nvk7--Rzbe=ZiK4H6 zq+}+U!TJ~TU+&pMb*;_`n@kMW=3GP;)xJ!b&y9S3K z#oevA76?#WgS!W(6pBlW6n8ILiWc`$r0vV^|K9c9weF{T@0m3pGBYb{o|DX;efHkZ zvz-eZap${)uq-;f0s(f?S0x7}izpG$mH?94UKpTsLgNzxi#_;Ue(!aANkr^D5!k8H z#P-`SMa>8^ZiAMn1H7z2^n2X*J;2D&zy-T+nBckQW>ODH0oQ!~(20YA{4}Dq@n0z& zgqC?f1r0qMLRgeKH(C@1ffq_T%Af4gzr0)DR+l79?7(IqK!s|%Q5CkGjPeumn>US{ zYiDz=9C^hX{na_(>ZQY~TD;cTEoK|B$D^pG6x+8)OQ)5z#OF z3;tt9UmS`m;GSq5nZr(dn$Z{tb}V~Kj9o6^UP}+hahwsf)<{zR9X#TSQDbI$XZ}53 zKU2jj0ey$dZ>TMWy=(7vtlkrWlV#_(Vt;96Rc0&Fo|+6f-C)-7sJ!sA{I1B)SANGt zVBX;r^ep6uN=*?#B`$3lH#tG1&B>kDP8(wz za%oRa|Mqlh;=gUkHN5ck2~LSu)sb8=-ifWDuPf5CC}H@y-NE7hb(Oag0GBv~hr8+U|bL837jFqv8u zGeu?9nCQZ1L1kD(%@WL{^wyYH0$-{rok^YN)wnwi+>Y)?mOd;Ft%6|ML&zCqqksHq}scJ)O7I$1wgYHgFz|OLjuP zjm>0tR9105;yge%9GDUafAbh;{id1}RL^^n{udjeLDTKUcM#>INL%jV`lWMEU7opa z@ktB(2l#I>ZsuR01WfTIT33;#782qllh01HdY36W>sxdLZ4)t$V#&#UMm?oM*4(j>YE7 z4QV$Afo%-eDroKu>fajQV;-bOPF^6fC6ltNdH%0)@g@15 z4~b0aY4_`982zI@&;N*#yN?I?h$j{50#~tfU;i>UnaD*d%)|D5ar!n!cxcqS13-|c zq$jzUeI3KQ_grdC7fBGjnlSQjbF3+qLG}+#_zAbq1_fd0nGmB;x-^Y_=ihvp2};&q zj~a2}F4nw^it5P(&q;Dl6<%sIPsGMwHaS5jOSk9gzdG3PYn*rmUh6UnaS*q^n|TL^ zzn+)jO#36;7Z%KRn9&qI<^kTj`k;88$Po7M_TlHFeXOX@#8Sme-x-?H5Za1VE2qHU zri(XBNY;Ubub8pY`1fTWyrxZg#~3)R@v7muxh=S8e2|upZYwiISr1PyJm(E1$;Qkg z+m!d5!vCJM0>0&1XI&IXaV{nr&U_~XEhZRm4~AtO59hQ`w+8}Qp-W-8&qV)nzDy>i zmg%nB+${XX_xTad$8L{>kX~r{jkucU-d_w+eYdlf@^3GR?>mFy;Zyht?9|rCL>HT| z2=Hc)+b-Eh`Ev%vZNiME(L-^$qk@BHg2DaN>kxiUF5+cwO`TjsMFA@#Ulk;>zSF71 z?rf7ssRO1Kra6@0B|x}oHygrTVQCI$z)25ukvp(evV+buFk|G{RVc{n{!L4bjs1LP zP=6bXUO{E~@}xE;$uSp5p)up5@iEELi3&iJi4x%P67FOf1oFpe&Q?uUsH%&bie<)@ z`#l=&1|kIYwgcmz6u^8w5nf(nF4F<=#iOPTPq%zQs)em?AKs8IEfWYy;AHl%nwlJB zEwiY3QUsj`KXWujig%?I7(9vKss9c1ac{3B5n&*@7~iBmU!PN$bI#BGt;G8|W2ie* zn5m0MIExj6#;hK;fqDve49d!U6`KERJ_phPgDHAvBi>f(pzMRc#4gY8A1SJ!Tr==# zw$hc{hip3$FW=#_8ZHxAg&I^?$Jek6-NDG?s#G;CP_yIEla(neYtky(?HBcds<#G$ zSm+s%GER7Q(zi0dbqjI2&RXS($K$X(RkTbZTPi<61k!R%1U) zLDa{Oq<8|bP9vsr$Mx@GINZEn!;Rv$0$b>iO0~RwAalk-Bc9B$?+faI2MbZ>s?@ok z4P4I_4>JR=A%cQ!tZs|1g{z?>3KuB0E7HhY+z>-f9oL+#d& z@)_LSzOgCRgx8Ta{auCbEw;Oe;>eTrmmaB1cAHR5R|d3OgGsk-HzIf?=j!i~Quoo= z`J%d!rYUmEy;|ZnIyV5(r&4>`j!g|%_cXzp_Q|+bMEtn|G9vOLeMg1!{X3ez15HXMJAnyxx#D4X>2= z(}X_Su}}_CAu=g6BFMxKfg{@W`HfV1Y5}c*G}!X{*?TJY=ZM($&k3@JbOH_53JjpE z7I$q@9r9Ss>2Z~7ks>L6YpJY1)RsEr%Fj7UK63h`>96xK%LBfN1S8Flsn9n#i$n>} z@Md6#e=IOr=i+?$GS5-{4S)bDOXX2=b&@M^N_`71t4k^;FyyuGH)b}ElkO)Pcyq!M zK4dqF^`YIhR{!fx7gIJ$0z;ez?sD2;UvLT9I8u|=^i&f!fDx%#k+k{x)Cb#K>y`Wv zQpTQK?#~N#v|=Pu)6|EGzX+84*)Y4k+b=>Zo?P7x%k|+^tNztH5r%1eZ@nsk|H^1p z$BXOvS~NK%GnTmN7!R{v%9xhuScR&4kE^%>_eruZ5V38)*czwC>Z?<~uBMDrcAx!2 zg>yg<1@LtSed)KVsFuA!3gt&esdwTL&(eTp%Wd)X2F|f_s3Bs`VW~gJ@l52?e!Tz6 z<(ys$X^3l25?I+2Mr6GJ%`+DugH?&7Npu5W1C_Z3rxH}|WAU9}_}R)=`yqL?z8vH* zC7dNcO#>OwyX|k@`LT0hKg%ak3~OZde$U-5@6zb)4H_R$@HQ&(qIyqjm1)so8!g!?ENH+gfplWu%$&mJFY z(0}iKwv}MK%tZP^mBtuj<+NOs4lvivIjRcuP#&)QDlNJc2z;T4Af^=KeqF}tkK86V zu*;Hqc)fCrU(dHGU#EW34SSmE5Z@|jc?Wx-?8^-7shH?n4}EnnX2)34I} zW9@fSYcA<1x%AJ^6*bds_NxZn7bMV_ceBoUZ0?5Lcx0zK@j^>B1m0N4hzE8yZkL&R-+*xuS zI&ZD{ST@vuO5=mk(=D9l-Wg9cpHz;H@E`XsE8%mbh$6J!vW@3*_VgKj4b1wk=x!3m zt6=|PQ9rR_GpGhnH$&-JCeVXEItu70fY`ZJj8^GHaF>+2W&{b47mQmugXqe%EniI# zRqEs>H4=tw>1G~**kR2sw4!_XvA@nkvE;7uddPKvwrf5 zGZE?gqWUC@9E$qeO($D(3>4DRa5EW~8m`{Jt{#$4{EIUCpX#{z6=ZErr`*eVNHH9g z;_^oBtx=gA=XeD;(Uu$L_$or1fFFhl%2GPh7$;MyPG!uw@QU3;;}VFd*q8t9>DwjV z_g59Ui^olm>m-ggd%YijP*r(EK__|FxM=qEsB^lRb(lqx{4ORU@9R;CzFD8Yt+Ti^ zXqZSb{6d;P)vX&Qnz!rXT|WNlMd6>?=%1A1;S#``6M4{Y114Qjrs>SL_pXLq(z=Ak zG=&;0P$b5e6vm|s$>6CQ8nTyjO(H1RQ+e~c%xHfvfLqjRONE0=ibIY0XJ;O~R{HX0 zylDu^tgLLRB{}|P%G5ZeZEnE){oy;aLi*KeL4(LoWWk-4L>L>HBz1ZWBSEp!v`rIK zI|rZM43`1F9w!a4eZdQK+_5gC(W_$!gP)DtdtV=-J&{|VD%|yK{{cf%SwfQKr5V{`*fu_d``{ zi4KA;G$7zX*GG>xuceTkO0|>YH+$V}tPKKpThpIl!r1w|VE&=y%m#x^9zhDWlr9Ac zw_-@hIjlS`A+3kg$c)sqWtE#}eX>!lXo}Gh- zZVlSrzk++r=m%rd7WtMYe4c!0JgA1L%DeNR1dw1R@Mt61sHJT8N{I#za zBI&3m)8c<0U)W&7O!NG6$=p3LlgRV-r8TARuqY(_bEPS`nu?}`lBA3PBydyc^xv+Su|bcZkB!K z6c!^R7;5#>F5zfn)0_yx274TT%l8y2#ycFRE>M#)4sYq)eS$KaUBQYUC|b%V4UE+6 zVJbNl4Niu2s(PsvwT>}>xI*}jvB77C1rs+mZUmpf!_BBCfrQV6@2%IJ@7x~>~IwzaFoLRB4_DI&4yk5J?izs=6j()}G`ZKsGpQz$J zGt-rwF66i@4o4kZpCDz7K_ZjqId#9nO*}>xH)->So&rTUVtE|w=e{K1N}hI`o>4_u<=lg-S&9AAc}=K^0>`IQ z4}m%q$JQKB#A!Dr7*^5#-XgeGrs88Ggrg?39Fd(-73p(wjTB+lgwPySz?$*ZmMm$+ z6p0Y6arg8UUoso6Kf1`ZMIfoTYX17o7Ca9oWYJ;o)wb32AX3B3Ep?Oi#0cHFUHGiX>C+#vN z6HV?_sWx%&nQcpV7E*JXW&$#Kjjge}5*I!7%1B5eCs+CXscLFw)UmIiH0IED!_ZOR z8!wQRpt`E~p%dGXr5T@jRJ=zP#aqUJl9xH_;+eTI4l=$N4wg#Ay3^gkH_f)@`M z00f8DuJ8aV$ogddN38%TL-$_>HJH$djt3a|-vuxL0JWaw+|6d3H|xcproR zFi9x{iG7JV=dK29b0;(+HJo#Hy+Nj2O4e2qY8Hh)WTlk)@_S!JzsbF{FXEBLF<*}J;08Y?82iT>C*w@GKO znpBo7L!(BFW%Jjo>>-Z0#ZR%Se546(JK{*M^(%k7)7rhr^S5cL3rX%Vt!+99M>Vi< zz(08?o@mIc9iCHaOQLpRT(|9f{+v`-%}v3f*U~KMi(aR`*^ilZ|m= zgZaXO;R1=~6Q6<`6`qKmXIT5CEr!@Wnyw9yqI#JHv3X7i+TW_wkIh-QDzhcG-@3CB zbt*ub49}E1wAXwCYO~AnSLZjk-U>SG3|vXd1MQjc1)jUp7Dp7W zegK#A+7Zd9p$ksR@EIzr^6zB}WKt2)KtxQYwiNQGu@pt!a59obsGwh2GiEzyx z)z@JHzp(68MqW#iFQyuUQP^HzKRd_mVkt0uZaGOw3r&AyjcUP9r1yxHQpwOW4na*o zT?pmq;XgLK5=R_o_`@8;t4S{qW&~ z6K~g|a(*P@6Xq96b1EyTHp^jK01&eA8G_O}8Px<@-+|un4yn$@^=sQVF%*6{p9{Kv zvT89}CP1=S@Zvm}`|4-Q4MrwfSUc1lFcY;@{v`Q2AuidZE}7}}^0fUsy~hrqqW+S1 zc($hVXQB>iWj>)`_@A=SxT_F$VT$M?%v`x6-YmvXF;moe#V!$kV+9YtHunzNW#%Yf zLY=MiLR<;UzzEc435%A@HP(GdtXeZRzkYGWx0Kme3cQ9|^_FPz9bCqR-#O$y?a}zz zWHT+VtqS?Ns#(){uq-*d=wh%`F*W5`iME11tYnH6Shw?PzLUZL%)KY<+bXk3j2pOd zD!+``NN)+fAsH3aEWfae7&asi_$qmD9WAFd{{%*~_u`+8W9@WW#)@$zaNLI%P4*HX z#{vt+Osb!MvNrEaM&2Dz8P?RQzPV#moh{9U&;aKeoPJ@i8g;96;6+Vv{a{B(NcHvxJzR-fd4#c27HpJF0>#~FsNsL zv-fd7hEq(`diA+ZY1~`72V=z=FhXmiN6J7*=nv-5S$T#EqVO>5Or>3satR%^Y@5B$5l`+Z&BI2U92jHEOC?~ve=Ur8QS5@Il-(evh2 zceBmthhB5oK8Vqd@3zAujcr-q3csNK(IK7!9cXTFpNsd)|0#Qlee4S6Nm%I>e%6pb*!J?kYm`4)gtD4{jEBT?*Du)3=@Xcjs(J^HJ?cU5*WPwVuJ}NRPF3r2j24}Hx zqB!>~X4lJ2=#}cFxi|-k2t*pfsKPO-YwXIH68xpW@AnZ3?}i62kk)3BpY}2=wZRWZ)%-*In$nInnz=>rYOyBmPYl-#$nK#zj}^{IALuemf-a58 zDOyqInx&s-7HYF3>TOkobgO;En9LFOoA&jzLRnZ26(-q3NGJy?R8$@`>OF zFz@L*?@OCPAG}!T9kb8xeFZvw-oRguW76;tOzvb|lM|DJ&cGS2wA4_y@7`HEKVM0- z1D8x*UjcqCXFi%`RfXu4yc;3H`Y3dkLq_w38uTW`@^98rn1gW!lo!7j*(k2`(?qr` zML6vWcLA!7ep%geKcrcsv}a^6Y43!jS7k3Ygu~B}q=RsIO>B*G-6as)gD&`q1WdWd zCI`vI4u#GMcjbf?-NldP#DHtCKk5uN+wv@6@%(vupM9}=IK>jO2(~1xMCe4jN z$mIR;8jjkyneAkM4 zD8+?3Nf6rBaCR;RWX=#Tl{bL~?>IFue%o|KLwe$zcJXOxguSU=AHy%L*Srr&fi!X#aA5@b>3mdTCNwMAehSTB#r z+zC%W%Yk}@4bH@O`<+f?W4U0WK%X|@c$HPKdPWml|GJhtCb}jYhDw3U&;2qLVgX#A zQs$&^*!}G^9;by#xG`47m2V#;W2_jrzr8PCJeR|Ouf=n7~+fCi-l`R!cthNo{qqPIE zArgKylktx#3_q{0ujX4B(Ty|PvPzFCgO^0Eb&VC`0b%jbgS)wErJ!|Pi zmFC|h(?(~tTvQF&nn2gJQB1&NIXc8zcsXJj<>!aA?r3FWXrZrCVF;y!1YzKKP~cBB zRr@S>z|WrkMwx2EF?7qVeAUF}CCz*%17*ok`n^HHQKb$E!od@AUsYAF@?fnancGjF z)cXJN_$w**UySJ*XZvIXEw~UXRHaww>^x~`i@@3C(R`|LPQ*O+Bv1Mh(-)~mMuJPh6iPbNHurSLWsG-`w zm{h-ac?!DW+8XproN=nCpOQ2bytPraQ348+YEEHkDi=5C3>THF@3B5a%ImW_b!9A2 zSs-&}W5EY1+CWEcH{RNpkvBGU8?8;*Pur+ncW0$pVyLT!l$&`9tVC+<-G+7OIci)J z)HBk**?EI~8TYtODcde1&-b(}LRto+kA8!QDN zVFM%;<_(t?JRWs;A1R%uYT1;(*V#4nt0RR*wWzP!&x2%4j-MtD*OF`nRL$9)1=dU& zi6-a@1iMxRuPlC-o!U}}v^$u7YmCkpOmnj=xO~waEx*skI(PAz*R%JO zg$2rgW*x6VWm1K)s%N1WbzW8{VAyQn09HOAqVL|i-Pg#_al9uXxXz0p`65kWYHzB~zy^1j+oe{Fwa}1^r|z zk0GkKtcv|eJ8u?|OS5t#Ud7?+?u=VSDyPm#`7txEwA7nwcYCPcoZ*VN`;c`EG4$H_ z_}FXbN!AgD@&q|uQ5%}&n>suH7{c5%>m z0@XAaJLEeimrd4k*QEPe%hpw952c6E@s4@!qRRZg)#q1ghEUM!*AeuF#yg*js7{qu zu!-H>* zwge;;=6mz4;hgWfyhAcE)R4#{5|Gc||80yUG;#}Z-+&NT736Sc;0S6I#4Q(QG@6zf ziAMtM*~+;VPR{JFzep*a=>N?#iap>X#-79_^mM^3mx9;iS{zv$?-JjB5>x0_NC|H2 zllsuF)ivIrHTSmj==_TjCz)B$D$SdoeXNcACp;I-VGymC+|fQ|As|PcdivUXq8nT+*b>HEsgZ6%vC9K z!gNtFJ_+9MD5b`j?u^2Vd2A|E<~|mVeM|J`C@BH|2rYo~^@s(?W6X5OwGSM~E0*-%n0Xw+$FK0Z*pHycq3Wbp7sTS58{~9e<(wx9D1-y zA{kgBEuE1$_>lJ9wc5^n)T-dh`YzgZ$*m8Dh6yh20!EL!O<6s@hu&$(P7P=5)bIT<`YqUtxf;arVP>i& zW=1fB4PgjC8r^#Z64Don35P6}V)VyYg7sRUl6 z4`a=cTdyA*IoMIfUayE@LnfOU_LdU^CHZ~97L$2hW373k?P{bPhEdmkvMv^e%vC4Z zom~dZS;Dg~v=cyV&X{&ph0&gdVZv?C^R?m^M&l6aiqW<~y5`s~i};Ma2W>|Y*8IaL zDcQ`ptp2pcpVK7vl)6zKArt@7(06veFDXXuXK~0)Or@|$^P?Qd5Z5_C#;kR)wVpez z)k|{UvXf$pKPRZE78AKmxHWy3i1$gOOJHQjt-sQe(#l&XI`S4!Ja(84J+kd(lxxlKtHyDyA~4xL+%qd8o0)1iI43{Wx!N@$lBCKg*$V=;4v{7=_y5Ff$RJ zAQsfCb+4tyVWdNyem|Q*8+ZDLkEM&*aLR^Z=*c){%UI6Bg~K+kE0Evea@gFi(CFm# zi|j8(lK5WO-b2Zke+x@ET;CU*#$rEl@%Cg&^KAsnSU1@LMv@K@xb2Lx0eyQd!fxSY?>k3kF)5XMI zTPDG#mVN@|!>an*I&RWqa|Ja8!O2NntcM7Ydg9q$+&_3qnga2w*`}k!BT#Pr+b*R5 zylqdC(3=VFnm@FN!D62uqp@)g7&DS4Hk4lRjbBPbgi22Z$8>c23LPo%Z#WhNm=Ygt z6_cp#_Ux_9;*=CKF&w)8)i7R#EihN4+#5|4r!lN3^^+*NKMX6_$9|@Zhc*|bP4Mvr z58Q?^Eg^nVKEef_gewfSUcJAV*#$*Zg#d#R@_c*Rt|Q&LR`)s zb`Jl({o4i*s4A%_0f0at0P?Z{{;dP#0T^g#=xC@I=;-K}m>5_%#JD)v*f``wukeYf zDQIb^DX6IEn7CN!7&sWIs6fJC4jx_s0RdW8QOOsLMJ|2;zW=@ih>3}bgN;Lmi%Z5w zPesr7|9SlD0}x`Mh@q$;0~r8Fgg|6M;J>c`+84`#`f|7b-SGc4fJn$FsA%XIm{`~^ z7qk)pkbua@NGQmts3oF_DiJ-eEZQp_D|7}=V!m*ADF&llQ$GoG?vjb$ z+A9JRi}W=aIR!HdD+tUcASfg(A}S`Yps1t_QBl>^(>HiyXk=_-YiIA^=;Z9}(KDX=-BxD!s62M z%D2_EA3M8y`v-?VkB+adZ*K2?-T!`g{0|opfc(E<{U2oi4_t&VxR6j#kWtY8!v#e0 zf7y`OeAhK~&t7>aZ28t(%B%qwabR)Y8nXMoC=n zev0>sp++}v86l@S^b1;O7gl<9@&&5D$9wq~JB?139Cl7A!p1k|@5vvvQBL{%f&C{_ zLWT+SBhLOnEzkH|JH-S%Ad_djHJHS*L#h`HL$x0K;+&^WdNL%aJc-A9lqZA9h0X*l z8Ym**M>5%1@_#oqzMH3QO2r)n=w`zDm>YRnMLa;fU1w`^SKYksv5BvvF>0;^k*p?5 zVhPoS==qOT{z&jSnuopTo`kSg*T{gj@ok1gn+pybgx%+6Z5hsv7J!W%Lz(?! z{Ria_$x`M{rpYC=LE6tgC4g7sdru2+Wk!Kwo__Q;4eHMZ&ytQZ;u%zgzx8Cm58*Xg zT3zL2)HOe{9oRq}gs&xWvB@Q(pFtkv%~EF!V;_Iu8v}yR{~|B63Vfsuun|}&it3ur zr2OkEg1ii)`K(J1uo~j25oMfDXIzZe#`Aof1xzBLj)e89GiMZh9C6MVMw1a8lH=3F zI_w3AvnKQZo*f{3}jVnO_f1CjG^;P#V@by-P;*32SJg2FrX-yRY+PmNY z;yykPOo?A5=_%bRH*VOAb1}M+#in@xourQGjd^&g5KLK4LnITfX7df|+3qeg1W@5V zpJf99@IsDJM_qTTYlMlmI;fqtEWgR)c@NRU3kq=N2|U}choqEZE4KqBqZCv7b_FnW z3rIwW9kAO!2Q6CVOM0&rywD#(z)6uA&EbsKeS7e42YC(GKRT=S{VeeZasb=Fk%i@C z|969c_^5o>a4id6Ex4LjLyGz=@}`0_S)1OYo+5F`#`ZjFrZSt~U6o}{d;0Zmq)dN4 zn^1B_Jf`R&O-7DG;tz^U72GroyJK+*8SWp~3-2Q(gD%+^=0E*C^Ag`}CBo;@r{+Hf zbr8J;rjRqXYEHT%xorbsYz6PnrT(C*PzJj64~r$vqFj%@zL$g?O10wc_A%{lMfCpz z1oSmg*%vT!eDS%N0$Sk&h{yFwvhh5b>>pB5cygfi_g@sNz8BJKl0c5|RL2GlIs!bj zjBzwa*oz7lJ;y&_8XWy(3#jC+QxdkrWV{D#TzcA;6_;( z1JIFMMX16sMk}~t{*<1m^cuS9!oaa)``23LRr7i1BGjNY-tVl-nHZ~yH$@qMi#|_P z)fg)HiGnkAtOUNX6L52d%Ao-uQk>a4gO&=i3NMm$=J|Fm^VjFnOSmX9rGY*g<1q3_ zl^BP5@Vh{AeSmKAPNrW3COP#_f?nW5*IdWYbf5(E3{5>*k-e-LO?UKVy4lZJFKC1C z?T!8Ar}-g#ntZ&;Eilnx@ANz&c$(vg#IFhtp+o5?0Lay6I4qOxN1WTY{^z5nkEgvi z&@59DK+r6*%rxX|zOaJ_fS0i}YE=}2;KH;H7-^+@1;F!`r3=|ozOEvn4+@m8~I1Bg6p1@T27%w1s4RYDXL`?{Ha3@9*>3wB2Lpo-)9P zPDTOT+Wr+P?rkyAnhk8G94ciyA5{G)CWnhXrF5J}L} zNF`WydG@{2~ z7%b+e2-WPkXN1@dL=v!5usT954ke4(AM2lX+Kx_4U(0)w97G{zgA|VIK`y0pClIEp z+c);p2~U`Wrq>a`Z*qQLf+7=S!BK^3Hvti>2lDJ}=U@vm(2 zOfI=Au}+T=vwfOBWn~T=aaOkk9%-Uxdh|Zc(yLJVwQrTccqj{QAOxtJFqIQo%Fwr= zAfO*_isuifoPj-mfgLqp=_uBzecPm-+X`epxiqCZJS`@V5oPcSeB(m}gL46Mc={GsO|mKR5WJ^`(89l`p0+Z=jPXZxfdn-onOc>$@& z9_BCV(H$1U``Z%O{pMg`76~s(=4f#t8%O0Re7PJdx)HSS%P#ngY8Gjmm|65xgW-|~ z55HH?aBo+Hbv{jL!%N)tu&s(1Qn^Z>b#e;4;+XsNeU5UcfTdLXmc!1|(x=xp? zCWP$y=(v1r6y;`iQGGy8?CNp;BL>>d^&tYn`0&w$`br0dSp^+Olz4ldmonJHk?evM zJu)$9Q4>EqN-|8f^;hDs_2|q8HnhPs5RxEHiMv1vQUH_p7EJGI>>1<=Z@(ZAg987` zUyU-|RY}MZAp=ME<{#!x$)HqtsLC9}GM!M*l{`zd5y14?YC_C~u?#y6Fm>z)T0nGOm@mBb$HiwLUFs~V6n%HOmm92FU@ z7yL!5keh2-+f)`skkhx{B!iHMWcJ#P?d8&MJc1X-bl{7+l*kKfh0&s>7rU7kT5O%8 z)Pa4KUp=RJ;l&LqOzw&G<&iRmaj~+I@H{6*cagC=ep&j5EFo)=N=3wXHI@ZzZt^{- z936)&3YB%G2eXXD1=do+!2P^jy&lVt;`|0f3vBaOk)A}!hi*6=-iQ09{wEqngw1@C zC$%X90sUFKUiW0fY<-tY%{+8CHdJ^mrW{^W;n&3m0~feH%QdA@_6G6wC4N61Ss-x|`1xxu>TVnQk;dUq z!aJUK_0=Mrc?FLCt|Qn{r!HNogV+RLacJ13j(614F*pTkuG#(po*76RQq>5PF(j4} zG|T}8!qTEgCRpYW6&WomLK(xMw#%eaQ}K_~!$CT%Q5+4Sjup(9eQ3FY8*`?7XRzVp#@0WxK07z5TiO)e@ofRUn~JN@x7uD!U{pmGdB+1L zQk0w4BMJ5n=RZu@+0MCV%?q=Mh|4lGWavhOi6!3+HRN|5`qTaiLK?>2G*a~37p!gk zu#G?eVFayc?p$aV5c2wAg)xwE)0v3OOwFOe-PmwL0K3bTmn!kTlt&=C(0&{eEr4Ev z9PhZ`R%wmnGE!QLZ&h7x#|jAZmwe%H$syG;uX(Qb0$eK-oWA_gLM|X&uB4zYwVc8j zmO2-yn0?FA5kAz9GwRt*wLGmi{EZrwJ+Z$S(qxALN3r_TpZLc)As}cfpGAmOsx~ZCi_C=ZVZyM z9XDE3A?J#KKu3>+2)qk*pXxDvK)87>SBw)KbBUZ53Vf}4BfwidnP^}G=W6jv&dLV1 zp%+a)cq>u`V(y?0ia&len5vd}6Y3FgOPu!G+;m6uHBD#bw`8LZ%W|?4h{)b<@<7}9 zJ6;Z_F85xA-H;s!z zc?R1+*m&x0{b!H!#RuSetg?dVku=Gg_2$xW@$mkg96SSH*EVpp@*D`Dn@il=fnhSj zPr-mc-MY+OzbdF2mlHp}Ev72Kav7G7Xy`kDA$3|~kWJBvp!keb1)(#xuLxYE7Vz$A zBSRiM6aA+^53qA|=fGinWXGd;>uM|b2m%S1KInPwWR=0x*BpafeFTxc8xiPuNJei3 zFuFQ$#OjCeLo^SVE_pS8ag0S^?+8345Lvm%XvIa}o)3b_hUxk1+%TUO`WB3uaJ_Ih z{rh~(v=%vv?`_H1dU$%#?etf_BNkSZ}5!A63dee@D`w}F+vyoSky{63b(W+!#t zm8#;A6*=YJN`k+M;CRYl&tCJD$75Ss(nucVj*3guzx5QT z2n+Jyl-_Qp9-<{cxm(i$y>VEhd8@g$envFHh{`tEQ-&~;ZIa41G8r@w1-Pr?r#c^D zNh(Q9kBkSn%Wd1R1?$E?C-!-!0xC1s)3m5H=yoLbQXPSB=$iU>lbxnolZ5Gm64S(V zV+W#9NCW`;;`&Yfl^vqca#5;9sKBrko24ahyXOT zthVwexK8g8Pv3n)ecX^KJ07)p`J;yU)%*Yctjga0;hnCz^?idF7(|K@>iVOLf-2gz z`qz=BL^l`jsS^pc%4T7!HCYWj)%#2{9bmUmV5!@)1Zjrt(Wq2!8KlV;g@A$N>obzz zpQm;0e##9jz_&R#P$GYi0ODwoG%1gb`|>12LWqVW9Rpoo&5XdI4*FV%hRuE*<;+UZPk>^9^IMtj_ruE2DrZKxkDc zWn?QGUF0xNHWD-w>aDc_-1aRY*nu^o*y7x1$W`(eTzltX(ue+Zoxh&jW0A@LENkPB z2Mn=c#EGIvFGt}FqIjNZ0KJoQ5LPe|X1}Yog4&LUX3B@zat_gociRp$i(kQHGo}Yw zjFhU#AsVa`$(pFb_j2kr(`aBIM{LPe0fkm)^53G{jhpK<{wa?BWkEXR5uLU0aO^!z~Y9VNQH>F4C_z+y!N*ao?vnM)S3&kJ>w8Wb2x4n zTlF?gD?@G7CeZsx^M_4b+vVojKugLihRCfJ#>zH+8FI-U16tR$@IjNZxM z4adQj%l+0K3xTLn5pwg0`ZllG92FfB%DWtLAvU zcl%}C5t7?a{04^g2(R+XA&U4R>D*4yqj04WoA*@9#qg0$Vh$qOuJWyf#OWuFJ`Xgf zop~AIR|~C92~L2GFp9Y7g_e(xP~?o2`g|wrJ|zCz+P`FSqgS7$G&`tIbidMT)V-qH zh4C8(;jXrKrmAGd!i#nFt*C3|DF72UgwSN~A)UXgA7zss7@v9;(BoV)dx^t>i7`f2 z_LIl;Z}>a=8IfBl)J7y|oZHS<>%YG`G02N2{zfteG+Fz|;oF@gCY-#%Ugv}20S;d{ zUW@&hflR=Zn6$OzJOh1l`)H?K{&sW7GcW4y0I}cGuMg`RdJ})4)B3;&&v-RGr@C$N zr7LYk=Or^{3J7gIqL6F+Vq)`m1ZsUQeYjZABfD{ci+XOvXvm{mWr1s@_P@=R2!AOnixvTL#z zrW9Hr*E+sp8|}@_F3a)LiFNdvN8L^qfl3$bHhUJOVRqey6rhHphZG?{WYrg=X@fB12m2MT5goRoBGOXXIl z6uLvKqVLO2{gg`sSRTpec8cRL`j(7ZrV8HXewV(pnC^lEVb$oy5j?W9hnIT zNz)Ch?ve{0@;ZAfi;d#51sTK#RB0y?B#Ye&I!)W5v6PsS}ZTev98<7`~5d zf#`aOvbQ(3??UmZHugVZWwKTV;X6BOBrkK4imc|MBQwr-(n_IN&(N8NxRfsT$YjsC z5q2GR9+^%U4oW0ih|G|kspE>%64XQA!9F6BNl$lS<65hwN65}l`87(XYe>C4S0kKF z+Sutn!;<71UlwKQ!lwfeUfd$8Df1s~{s9{F?}TOTCT4!x?S1KQCF zU&Ks#WXVUqH1LmWl-TT7@8-#&X+o;%V?+f6Ey;g@@-ILVS6ij|8tsR?C1ZyS^>MPI zXbGwM$N7!NJ&x}BavMvJtwaR69Gf9mnr!la zL8WQAw|Hg)KXm+&_&aEdjU&uxt^y&3@L|*-Do;$M(*uN|jV`Rjp=OBB^*@zs9s_+l z5ASH=-JfB9^pElFkpKLioAyp)OFD>h@R4Qzm~x(6_8vX2rYlE;Q_&(E;q3L1W$2<1?afiKQ@7#kpL;($+xuZo<69DRReDo^o2R`fVX zH~Ex6L@ERJ)*`3Crh(hqBk-pakRGY1b4s#+2AyUR!v+Z;)l#nopg~8_r?X}XRLh_z zMlQoBMsP4*+GbTolfb8yc;`ztZz5AN{757|(EtDr^Du@`@@W2PF#nBZUa*@!ityCp zg3Lw_yjT?=cgUJ(9T8wkg|~If%M_l{0J_~hb_5)6{&6JJ%5T8&?AX4V5&=1)gm;V( zvhX-)Aw`G}1xh~BW~jz|@cKK2b#@GLJv zg)PijWCl50l}8Wec?1y-S%?SVZ!)L+klUTTlmySE;z5qKa%{PtJx^q!s8s}tg`~_k z>?4#W53dm?vxLcx0ASm0RfBLCPRHSc?ls1=XP%WV{4oy=g%75QQT3zOsaHkx0a)(& z_x?zRLYIC6FMx3cL1)jJwT*)pw4mC}vR%=r3BE?vF2MsF)Who$WgG!0JLPM-9906O zoUQma!)#DSOxSkQsic#kEo^=yre6?rNg2f#; zs$7$4O%H3)z!|Wx`HWGGqVhYx-u?Ry_s*AB?YK?4I-efDmAj-9_xx|P7x$o6*6k*y z50a1neW!1$nG-AgOo{@M6e(PO)%?B8ylg@UYPnN`*!}k2sL-SAad{?HrR}F%ep6dJ zmde}ePfDU#%i34vpWi&e#%2?kLbbT?lGUpUxiZ0PEGq*WiA+73eNj1$GAy}rB~ZQa zM04&>Z*|#f0RuqXeDG9rw8DNg`irco)uOft!9d%X`RhtL4;-~(DxdvJ^_!`j(MYVo z9Ocbzuzb8ln1RMW#bKP!y_Cfr%~xcT9QNjRT|KaTu1kXo zh!`L@`Um`3yc?1gQy*8TqkKd+c6GGD$%~YC6!vRMGA^g`jvSD6F%#m6{$ikrH~Wk~ zhVxJKyUq=VmnS`>N-Uf;_S&&tJYm3}WU3YR1m*K;N`=k*`yB0#UCn2G$OO?AykGw! zne}!7fjzEW_D!0l3!O;t7PuZyXdm3x@_T94&Hp5to6azEDC~>D=lK_rENcxZUC6Hu&N`nYFpO-nCRH`u5;Oat zzJM0H-^*z?7+V~SEPBJ|30_G307YJy+|vA`P3h3^tgux1P}Qoml&p)a*}Cmpg~_ps z<-;kvH`;T<^!3yMGyVCr--PX?O*e{Lx97gJc&)5(I72Va{~#a!B20XAdcNp=>)%g7 zHs12Ty=njwGF%((Mmu|s(JH)o7sL92(|rM{<3>nHw2tECY8S*2{`jtsUj2>jND;b` zclI9hA|*cN(vk$tuc`VOdq3j3m^wT=@bYk*5Jal~vd{WA`fgADT|*h7Btt$L@Z$pY zu+}Ut?WD%-RnOCY*9Vq_708&QS)ksB+Z(C@8R~$llK#1xn1aoz3+ojvy@c2-Z$ua! zvW^I{=4r$tDjoq#-lw^C`5%d`g5XH0N3=DiS_M?cK9t zvf)gW?jlXyw2x<(s%IarT%o)#gZ(P&*>#z_s3xPWRd#)L z*^nq!`237v)@%c|b(dE~u}{Y~FBg61KLA_A1h_`tVgpYt`P{xVKr$0GJnO1#T3;H8 z3%Y-QN67P<=bL1Ijz8RMsgfN-nXJg6zv}ZtPQ=F%_7`PLwPU?*h4N1EnTZ7SY&@@hm&hFkdDEIi_)6!;?gxSp2}dQtT%OA7*z zZY-N$_+*Fu2e<+V>k{C}aGe$$6SEziR(dR!aaCAXh`%_Og>k3c{Ajhe=AkkQ zj8?5{ftKcBIy7FGUfU8IFo3DzJ>cSi9}in4NUli*TTSCbwTjd)S|XZ2w9JDTdH{ObRwCmhri;HD zmc()wIkb&KaPAmWTT#d%&Jm~(DU(=o0DjJJ~UBY5A-2JdykLm#6ZM+0C(tO)2 z^VEpEjbSTtLUY5y0&Ek51X63t26DX$@TPiWLPsA;00EK?Oj8PGa^GCX=j7&%aXjYq?KR)_oclOIYb{V1Mrav(q_=GyUFFGPYw3<_4`W^_CZ zkO*ovZxs8n_bq_yu4M_k?%(}6Ko0|gUd{kLqQ)X0ORcRmQ}rsf5L&f;t|?&zXZRN} zv-C*1>WldAhQH!;(cHI-?rF^RzMqR+u>cDOMkJU))JtdRPONvV!6M$|e8a6=?(iZ_ zb%EpIvZ~)za7Dl}&(~N)mdCV6lR=F}3)lfyK*4Qb^T>)|Re*&yO^}pQYtT33mX;6{ zIw+Qs_N_{c^3d&x&1~$K*F~}jdw(Q*EfJAd`cI(!N35m1yUYA1c6fQy!t&ch?ClCpNk30zb$|;nV4c zce!LCPJF-^0(WN^mrKra0)XlA)jf-~Wwag!esx+ljt?mQDw ztqxDr8Go%Vk8pR7to?TUd*WWqdgc?PnJV|n#~3}kgMZlf@I$M{EvBMS)M(7aut=*|!F1n=^)hATs!N7G2+7WE#1-xbY=PHE zq)#9cZsqnKL{O9`f>RZ69M?R4&YO<3CdDa_MGV*+>*y!GYIl%{ety$&(7{MDRc)({ zc!11e;tUC(`w}Bq7Mi2@?a7T^_PG0XWQH`e!Jhfmn3?+LOM^7A-=bk>^GbBC8Ll$X zE@t}DZ`a{-%x;NmRj^2U*!#)7xqKc!F-`Mkszs~J<2<}U9Wm{XWB_j+Q?2eR%r!UC zJdMTk$T5cHzP?&pqbfppb=LxDzRD0$MToPWS=)#dCe+8tZk$x;!T=NbvBwo_2tU>8 z@C+dSV~Bb-slgeFx&4N_C+<~{bRIR@X)J5%^JS|lphkzeh5pMB2CpUqr%<#en||*@ z4cP$_qtN#28d-(NA|D_4_{sW{>L#1)KJ@wf-UcHvwv4ZGS@@Bu8==~X7q%W*9!oD9 z=YFofj8Uz{SNdl;n3ijs_da(ndZYCpz^QifDMX`d;Ec$4qwb<(v=mo9y5Zd?{rXBW zY(VkTH_Mc*8&g^t)%T3_K9_dJQ|Pe?K^NGBHh$x>{~oWrjQ~3S2lyyMdHL9tRKu$MD0{DG z{2l@kS-ZM<=Mi%lIXST69eTPnnot4hP}##7K^6+Fvv*7bHi~+p^xcvn9d}%uK8Z^RD{$t@t2S#1?T=i$ z?PLpi`3uMHl9t63`3O4(UtSj1)DvEj)Thg3+Be#D`8XG1{7qf~@>sN@Y|)};x=XPb zd3(|Oh{@1B&YHL+c?dG=c>FXlYW~N45d`=SNknvkln&Be(hcPjvveQn{R8rqs901Nm6mz6hvGg!$GGNm#h6(;_k%? z2=uJZdv@P5?3FY4P_-7e_6-eI=QLh#x$A|)i;pcr)FZ2!2;}TJehk zj9$lMJNke#WUGm;(Z7poXC(I^Nws4l6+~!HtNm99j{j_HPgEtIXi3yWNr%Y|D=IMV z{Ic?7^y)>EgRJ(aupd5ERs#w52*(xfoP>C5I{kP733&J_&W{xG>i8ZB$dnAG=Bg3= z$K00Rm4dwvs>$xLlK@TTMZ=MJplFgg{!K5VynrC>52f$71}ta?e=S`8y;) z-TPudGN}m?9a+8jX%z}!7da+{e-#HB>C_*Op^*O47Qq_P!v?6_Hvr$7{Oz!Bk|6G& z>tN(q=!Iz)Yv;2Vx>%CPk_ub())VPh9=~jGSV}Ggczbf-WUJ&597V0GaUl9~lDU-Q zJliAonAX3Vt~!ddzs1f!NXNBGhy?$Y7(uI01D4G+8#*a>F7f!}`}f;xT*bNuH{Uy+ zP}iwrwutpK5-Io>Z;4$v;=c)5UNx-08R%6CDbJ2jzQ)J#B6Gz}3CWx0s`!A<17#xl z1AvsMV`vHk&{tRA-}~0M$MMT(>}1buQC|NOkuGs?`i3(E^1t-PChi{>ivOCcA0SY@g?93}O40BIloH%pl4G zmTjB2xs?GBK>Y`&mFx=OBzXI$eeL-NR^`g@P!$cF(XMT2tL5%ofsS@~?aPBZ52P-? zR6P!wcOi((Z3!x-VPT`NXGJ+0gn#W2`8PXRQ7tYJv!>Wfu`XS=pA=YfW&r4ZT4jhe zh2IzmX&>_p1`-0Ia^=~bwD_!xfGCYf=nzO<)?D~Wd$5?|rX`L_oBZl>Ps7EIE10LC z_{74aa&7!b+6)uwTHhCBXzaFVGRzj+El?;68`YrX5lX#hA4gFuQGG&u3VCF=xmE;_ zJVC+b#%OGnLk6etJ)pcvSw1Fn&}Ma{1{6*5OXW?Cn}x9zGyKld_Q)FI>R&JPNMQ+$ ze}_APomK<!8(YC-9HVm||? z8FhgJJ2qDot5-$T?+*tsb9-@Sj3FmwC03_q^j;{fOtD$Hx>ns8gGtSRj~gBtkMOv5 zleLO`m#$xhzi&;Ml5p{PIB)qOkesnwN@4Rc@e|i&nR#H;?vQN5-#Wpk|2%C%a+E!! zFc772OBEF+U>4JGFeR1~O&wMYnE&ab&!lFXoAux@xgrW0sGz*HzfRBKF5l&*)p+fb zW2VKk135C>^3PY+{{RY!?==LT-d9{VTVIRbz+xWA2j&io>fWjL%ZfgI-wT${{YZtD zf3##`%S}j-c)f5slq09`u zi)rWX!}RYNa%XBp)TSSc>cUk~DJ3@^>-ICqXWTxGXTg|{sV*y+Mc4wt7rx$7o0;Ac zRJaT5bA7-I)`>c{f((2o7UR7UH@#j#V8<%8$Qp|GnfYwMl5 zAeSu9r^!*Z41|OoeSO34yQXv@W8B62s+w5KWsc|EY&lLrW?pEQg4K$b;K?5Iw*~?u z$s(g-`Md|DJq9lTwJ)6Fd{a7Ax91G8CQu}F>sV_zeXFRyC;FB~SZu=|gAOCcCE>l& zi~Us9`Umx_PK|rWOB&tvGUbyHLQ>xfB7_6%!Tq3#A6oVvl87ifvU8qIa-q!{m0vLdZ0R>Lo6+uSN@ zPxC8|@2(YY6pNSK+VCD1P@{B=$Q2gkm8Q8W-)kn8jJE0Z$z_ml4)#0`TT8!o{9~C5 zFR=hQyvgC{22QqNx1RKwOadA`7iADM-i*Ge4T9HjyAn~lFSp4c({ zF))8|6o?=@{fJ3He2V~T4Y7fl@nyn2m-+{4IL7kQg@9wjt~b7HO=IFx18pKDpUH-Q ziKDOr++nNsZq^P__4Cu_FNWI%%UFZ&Jgxb-KJxBS7o!|s~_)c z-s;&JYPK%+^yaYMT;k!`^fq^y0m;(m%de@}gmfFSc$5L|4@`-7bLVWk6oO9@?RlHTFwoux%uFY7>_r9f)Yaw!3{?iCb!Bn)@ zEHncKUOw10yI)*02H*Q>4Pn1IRf>_A&t>^@kxACvgrd4=;|C+|k*}OUE7~G8W`w3u zG}+;N573F7lK2VmL#k8Uz4O&(0c4G1#ctN0lq5)aPT&Qk;gmnDA(cI7Mt_-WCaPNe z4GK=$Xc<5Q8|h*H0hIZRKy@diSKOhmqkF31LMdrkw|Fhoe_O~h>ZB@=8`bQknL*8} zwf#Z`yK~lsGGW&aDuDId2*_N;pZ+c(3K!Wj%j$ybvR8+YfII|)nDzAm(^FOd)V;jB zf-n2R+SA2(LJDP+WcoCiDvK>;(F4T_;m)m&%FFuzLX7sXY4p}3?7uHHms-0a>MSPz z0opLxOg#a-ApoIMZVn@t1OCX3_2wo2F8C1~#uLP${U<%j$v(qD?6J^c+aIuc+Me3 zl++NPMHnQ8OzD_>DJOnC(}vcE)4=J3)_usj9ImU+1t=RS@Dk3vo&a*n%i8;u!wvWS z0)XOmnv6!jXK`G3p)|$Y?Bw!jKo!_2B~P{Q>=L0D1eWr>d2ygQaAiZX_6r^S>3Yxn z4MmGf`St+FEt%b+hZd!%+f)sNJ%4yoWVp}~(eLEA{{6SM`5>2M&Cv>EGrVq&Bq7C?wYF3m#{NjYmJ%tb;{Wd~Txi;wGK zSv&4IX^%4A(;gsZ2)W})U4ab3cv%CgZaOfm;HPz`ENJ<_Y=iI;GI!78L552aS}e^B zti1iYr79{sWf(rtPhBi_NO}C=b1z=P#xIrqT9HE2Iy^4R9hXu{>2~mvc{AIncyfMZ zXD$Rhs~5$AOJsOpFUw2$>^xG9Pj<{l^qGmzk)`Y-5AbiyLS@xTNcED>{HMnw8=2oQ zj9lxuVV`}u%>qIpsh(6XI5c`F`rQRFzL;u)6N5&^_T)mawaSuv`Wc60*Bjlo6E8ia+IVqiO%Jf|c7^nY$u zOf8D*dIL*GV65xqL3w9|78oG!yUY7r;S+5kCQV6419QGVkHrY<8NU~RS%&ZL#(Jd2 z4x2M}7bbj*vt=0qin!yfdWjuXg@8uhudbgIV{5HH*C(`SS}Ij6YTD}e-$ z0ZqxyKJYCpoIH&;Y~XWeV%#_AL+T6tgt5pQp#` zC6j%Iz-A}q&ls(#bn7F|Pgx9l(ww6`i>jyf(?sVRN60stI`7}^x$!(%qFwN6p`Hn4 z1<)ywVM;PaO8ld>`s*}LKQ+coXH+G@pC0~AIIoN5_>uD!@l-f6^g=A7$4!f zJ+2Of9QIYJ==i(!AD|#QagOo9VTiZ-1qS^4{13c8uEFGVVpJRb_uajhVL)Av4+NWY zTUnEaThY?#4}COMg&U>9y9q^Z?yUyp#uuCj(5vd_zWXas-mVxPE+LXec-NE5GwZrGDw8k)cZ$72U zQ-xt0&4jGsa}xE7BMofp3V*%C371mXtu~I5MIqSdlXwaJ5RAc;p_HD>!tMU-59iRk;q@U z7Al*jarMJ|FIxIEQn$oQN5?zzxPFUO;AX<--d*Oys<*DanZO$F@in3B0lSePewi!BiNmEhG;xak})7Y_mlGXAPXpPwZssJG*#D< zv2DY!T~6bOgNToznsw)^b*eX8DJ2Pg@iTz_kc|UVF@iaL>2idik}T&8zMW38$M%wu z(D^$u%Z2R@#Z(ej!z;ziN})Tv1R#gE$3>ImR(rIZJa+OI;5(+$@cSTm1qd7w5=Pd}ztB}|Z^73K#Ad8i7}A4sjC}=v zzitF1F!DLR3F1*Ll>NS3?$k6qQ5s!ur}EA;1Hy8waojK|bmcHXLEF%m!mcFb*~chH zko^y!k?iiBdP~gWfUT@TitAUK*M9BJNu7Hz+%W^*N+@zlu$rG0)fWpG7{-41Cqmd_ z!YfI=uA4^fIO;e$09@}QGj~i(%k;iKU@xAy9nvKCMh?ZDyjb&gAm2}8tu(R7A~#lq z;#F=o=kO%|k)Zr0K4GUfHG4cXL6UaSvlvob-`(t+*A52amDj(O8$K67YJSTuoV@VM zkO)-W?JBXNWwemuLLsACDRs<$7Z6@rWdPYjX8OmyA)#snJ;S{L7By=wLX21+P~ZZR zU0_aO-%8G$g>DSKUa6r1`au*L+1Oai()*CV&ZS1G+i{!u*z3I9-| z0fEHNg#mF_17$8v4Y$Mr(8M2!?x6-wm@rwIJkasegv7nWE}K6>2n5`?Qw+dj00^(F z07TjA2&?XNGm;|rujwRXD9>+Fqw%;tlX|$xQ&CR~M!{?$T^u3)z>L|x4%+L0Ex~BY zqJD+N5(zytuz?#7REC{f|9Kf|3Xo%vCWUH5b8~SF#p;q8jj~C!*ZzSK0vJF6gWiDP zY0UtgQS1w%xN?)rPEPH@XEllq01WpHS2D8!3sH~_b6}KULmRW z^6p;{E=wkQO zYIh^H%1Kq`US^@fBs#?6n^GS8tZk;J%Z&g}A;v`;ZK{3qKuJPsd4k z<|&tQ5sn-9Lw@BRI6r-Vk1;f{@U=&A>UHmC<7ifdZ(Fd0#ejVHKsDuQuI}N`z&$jX zd#MS(mpY8yF+O)`r3R*bt(RaSD{a1w@yJh*U@+t7kJ)ntIveqOR0{o-$PDrgu};@G zFwvL1PG-zdFbcb?vxyS%df51e)TJe({Y4KIaCld;E;pgJTL8;(C5AQi<;k9_=F520 zLX&g1X#2f%s+Q`QXDn0mFmd=IBWEG7r@Hv9iPxso&v{?sCQ9}9ueFkI_BXO;(;U@^ z_pVH~2@4h@vZ86QT`An9%dPvQF;)BQRI%jdz3sa#t36`h^JaIPa)`_;7G)p5VlmHr zIi9g{;%wsW%-4bV$6KAg6dm`gi6=R+pL=_jUn-<5L0QOh5mkG=<|vH>si$oZCOTXf z#54qcHiZ~&biMG-GxQFArgo_I!Pu%;>S~BW$4+K!lT8OzZFH=TGxEZ?)2DeU}qR0k`$kkvYOk%-lZ9+j|fd-Nq>KD`iq(s>~zB$ zY;$qowC1qwFmLqi*-qpIYIOgEz}?wKB`-wUG~=UY`ee9r{?5BDuhru6TPbD~ogBBK zwr#zLUh1Ddapop8DvPd|V*DYC#z3HMbNdcX-LMV%+!YqMlc`1}br=Jv2;eRT7i>CZ zAjCOZ*FM4?k{DtT*OuUioO4eG0_SY~;nI(8u@}9V<-5u_I*L@w8tEPD7Q%x9=d;#D zZ|0GKJ-d#){E3tet_(C&M*q9n_Y8MrE;PvFu3GokKC>)Q>K`YB+udX-P3ct~2DqCR z^$01)jx|_1BoIHvUJf4#eA_wGcDw)oLI1@FU&&_*=T@Ah?_8Wrz(I~6Z9-AVC(C>t z9vk3lJ2%I+RB7aT!wvcoCq2RFQof2SQWrx>9msRfw#H^ML0&m+F2zZ&sI=&JUmajM zZ43l0{$e1|{^wAW@zQp7JF|9bk7f^PXdFE@Z4n?J=a~xzdlq1_5j-c2!!vt2zD83_rk|UkE`F=Yi1yg2mf}8)H@stbf_;hh>go9G>m*E z*mPg4d~-GEgF#Kq;NjTaaJGZ}srY}_+C{9Q)g{^wNm#)myBJ3hQqom@xFoUS8}7P0 z#1Sv$K)x-%rEJF#YCv1Sa;3W*iRW8&D-PN*1eew-dbxZxmM`A3gQ*5WzilsEVNnhZ zaIFYHTqCW$R`h*8;PH;#{0*fiLD#5{;=)=Cx6NdkI0FCU-qj7uNB^mfStp3%4d?1$ z8`dUv8n!NeY;PbvBuI}|@?@MqFN7o<~rzCxqX0}gxCejEf!(74ztqh6ZJt(|*5FW!o z;pja~Q=P5>=JlUjaXs9C6h2-IQ|K(dR|jUFFJTE8rzOUcQxn}Z1Ag12s!{l$C)ZifibnO_?Iub`oI30k0!(xU!t7vIWMFK6q7*|L%m?&kD z_XjroC>qs0eN2+-_6jiq{b+hh9ddJci;Avof_>$g(d+zlAuWT!X8ugyM=U>lsREku zu@T#_>e3)(Y-=<nni(}96`cs1JmES!?e2N=2V zA7IxixF3)=wp(JMv#+Z0+rs#uv;ZUPGa{?7SeSuh4EZY#hU>>gS35p5Nt+8*z&OBC z!$u(;ABOXAs513ob{o3#kuv%=U$7>X}jhNObXfUcQL3dqH^D@ zm=F2^EO8@Y=Bk>t(l%?y=N9Um^0}eR>%|zd3(ziVf0~KP?i^S(R>HzmwQ6|jIjUdZthq4(j&88r`Q_SA z-L+!1=;Phe+;Q;%!bj+cfAMb0;Q6kFMEB1|(?M9fwR_3wG1H50Vp=ZXGQ5^k zOu#pv-~Z?0HJg}vEwel^zEIf(MH(1ulYmSYpKcTp_YWD$ErYXc_%q7;gl5T z>_DSmtv62Del9N5grZMpn?ORf(9PLpu=j7z7ly|pz^yQI3h9BVA%5#}PM`|sadd6IJB#Dm z8tLhfHXUZ#IxCvBxcT-)S|0YFEl0_0EMaP3 z4l(eT!}6)(W{UPG^^1QmYoTdr)zehH>sMU)!-YT#c5MiV^{%(TXcG$T5pe(mlklt! zl{ZL~OllnvLLgT=nridHy9(y3WGf5Q<7R<;&K826`GF|kH$Q3qXQlGH?%&-8@M#5vz~+zmtG z${z*dU9X_@J*E+Y#$U7ZTUJ(|#$R8e-OqQ#`eZo$qixtw?n}G)!031Azf(Vd|LNGt z{}NSTx}|{%-ATzRJO1g&($0B^<~I<2Sf$YsX}Fnr_Xir7k6Eue3jP@FydlutZ0ZV` zbZ8INuQ;)&5-jozbYnI0`Q$mli-45AtA+8T#-^~rsWpzW^5C`Y+4;_hZ2Er`+uznQ z@AuIwPSJMQf)45kB+=4rElgjxqv$yaw$=0CFChk4OU0k8d|d?F8^3aC=D&(s{=gVb zTz3A-#IEEUiBhFCOZb24q}#L2At_yQp$4osIqc+|LK)An`Ivt;r?Z!J^B%e_TZS4= z`@l}F&245Is?QzGE)oy z&xV}+R7Gsru8LZbD*yuioSHQcobq+KdVkp-_8=c+b@oQ#@M+MMhL;G4x^+v4Wwecp z+=zOKZC>~p8KuNjBl!4`>5Ty9*{A2O)tI`S@77p{l}nu)xT`Mj)t}sMuVgVGDe3W@ zE4yyq7rfu-?5Hvn1K(%k<&&Fw99j(p;w$)Cf;0xv8fV9iX4ujrQ6sKbT!Q5}c3 z&tl!~aXUq^!h<$)ocf>>V0j6__!>(e8MAMZL?%8%x9thLseL)ZiLWz!UiQGpa5pR7 zL4=DnJ-8aN*D&7|Y7+X~<6fW;gQHf|A=~=Z3W$>w(>w7&uwJg@9>#9KmRFx zHgt>z;=n{FW#_DJ2$%}nh^ihVTd;>?Mm1F{+|8)dfvSiCa$M*!aMwUkwn8`R3|dVK zSBQ8uNnlP#B)~vsR-FZ3F_0FIj-6q#&$^Oh{8CM}8O%z(O82k4kf%{TwJwe=+aYqR#Zv~BKg!bQ(3#5JAh?Ea_wWAz z?4JTgeZ-&jo#LhD7KKTgb`^P?Kj7K}Ut*z8;MC`L8uLja-UnH@qv>t8vbvbSHx}|e z4=#?%!ng+Z_FNKcKC4eisOYebl7+y*$b>jsz5I7+1<9BlW1}xj;fs%tHa?pJwiWYo z7bHJ5T7q+#fWX(ral|Qp{8pL3I(m1{g-i%2V3$p0lABLi;K&chOM1L@UO*h5&jsq#0{;51 z(&~?9Vk$r*+T-U3CH~`^*ktxVht}8oKg5@51s^9+fD}R*2Dag^Ij(zbTO+MHDf8y5 zIBTKuclX~f&gb{DFZm>fhR@DF_gi|IEGv2Ag7Gq=b!waqQK2RDm2o~mb0_`6M$W$u z5&6gNR#di`tb&kex|6N?b(CN2ZbLon$iur?RIJnT|j0 z;PBd(>rc8z2hQittbZ-V&?X+7E;^VM0;!RPKZTpE4n*bk6X|b+`XfhLg}eyr)@dPA zm>Q9XlGsUA;q8Rt1yLBVZNU%2oWfD3~%ZM3yq52DC(zWAxevFizvIKEW zoLX+|u8;C6cu{J7uZ?N%yh4%pYYH?QT0ywpZ%CI*y5}VE= zr6dU=A8$Qejc3x{p6zgO)hPO9G|7w1>PHTwoX;GzGPanR8^1~&EbX|oZzS5g!#^7whE9F1ZasA&VI13!q8{=FRlPie6za;Bd$KWa`gE|KEc zZh}ViH;x|vd>&2z@sH$ORO?dRAr+>i@kUM~-HN^`W?$mR$6wili3w8fP71j?>rJeT zEa>XhG&x9da)@;JC+PQYbL6r7RbrQ3RukmgZ@!q6IBsNugeZ!K-{=v)zCmc^Q~SfHx5q8;UUnnN;!koJeCC=#e`di`Elz{-Fw8K8M=_Ni?6VU?`Iht z`Yj|c30dx%AJM^yKquxL5il*+CHaF<3VmEbD{9GrbAX{xnHgO=(&bi^UW9-JTA9Jv?oaC$Q#rthYyh{t2EMTStY%;sAUaUGo?08rqOkg?L| z2B^R$OT>&w^pK%`uf$u}r`}O$09^^X3V+<6OSgmBrRnyak6XEr3k10vo9pR8e6Hl$ z3eO-|HH$*31T7(H&7bN|x9XHP%9Quidd31lNlg%^BN#HJ@v*;rtXY4%5v9zeU~)a) zrdhbkdxcV79%uG6Sy&viW(8A0lsr+4sE{$(e2Uv6#!3k>*c^i)X*B?QLmp+#Bg;wu zXJI|u!O5b@au}D2heuo~{WZ!aH?QCW52h_mrB{Xl7LQEq-J&+;**>HP?>B)D4TQ&V zJZ|z*jR*G-?FGyyrB+9W_?{8)`l}`X|648r>sp>(F+c zSuJG9pjj2rv0`K)!>nA^C=Wh1MP!76{%p**P8=C35;&!0=j zTfMc^(rX`bLQjMnCZ8_dP~NhtKCWzO-CBH_gVvRU!$%vG^B!dzdCZpdt@k0_yUj11 z^@iH;wR%*1GVp;rw7vApvrf?dW-Ys}LFZ5)b$RU2B?Cl^QJPyGke1jSgS%-;J;}3J zUGp)+rkQ5)dgj&K<+b7`O8Qvh!mXed^%dK|Mgd1==O(pTIKK=9J6)sV#g*H0GVE)F zjq{7_a<>qGNM3&N+D=4jA3;#9V7u|e$`f(q7`F4R+y4XdXI*2Y9mIqxPA;{3YRWyh zrI2?{aS#6waO*{!{7VOn7JYck8s;fAAPFBgG~$6+Zu{ zo|c*e1dDLx8AH9AMT_skK$YvMq-eL}&3>5J7P3yw`=DU*(n7#)vOl6rjOOX(U(l>m zroI+5b_Zqf_gcqqua>n5{fJRq)h1hLigWB&?0<Vu=q?YG!-r$o06+>c zBlgPlV<@g#fKk7KGwnl%>faFu?D+oTYae7ROoiIu zsJkc4qAvR*3d`2{vBJUc#>WlLOr@alik+N<1uCh=&y<+=5T!&85RmI@V-%&wrku6W zxQo5xzlmfUO!_-9F(%o;>W0U`K&c2SrOFq8pw6U9Rp`oJp%-lCxsNK~d zsrneJ2@9PAcG2M1GVf9dA5WW9EPoJdd^LtR$7PLJWDP#MRlobTQ)&}b`R@$9HfwI- zf8fz=)cU;FO#Tf5-)>YOYChris3FE}+QMq$caPlI$ypP>?M$;`kD)tdMBjF>e7>QW zV6B+p_UUh&NANwsky&(s|Fq=?O4Vq;NaU_f2bb>Qa9dVrNX3tYK#gs}$2#s81v96L zfZ~mfsI9`t?HVDCHTrP>tSC|ZLBNAt!73SD%> zFPX(#7bV2cKDOV-hCStC@t}KI1~hOgg&C8w{4ZM>jo1%B=9xU!FdyF_r5gU`!5-#^|Qr zJZ*1G)mIo(A}SW9VCc+YYj&+|F}a=E0&@emMM%J3Hb;xv*fo{}Q$ge%EL> z7?FOclx{uKT-L>#ch@G)Z<*=^wi1ZAzo#e8YP$o;t|)Rz`CzOH7%ZXKy`Jn9 zb)YYIBUhdBBYx(tSfK7~jrtGb#c&L0#wx|o0TKW_8!pmUeC#G6GMr5e`5wPkPm`wOtGd3wjCmRNdXUV-5TfaKzO*?dX z&VZ|rV#rRU?ld!qks@8tHAcmjucmgZ=79m>7@joxaB~oR*lIao^%nTtg0V`RELtVa zJQYYE9jOS!OQa|#>|8+g8N4dMe#dYDZ}e(Pa>VSKeM-Y*hTq85yNUf7xUzhH4cyCu`kPde3b)Dk)Vq_fqmKT0cHMk8T&|cUbAqZu!V=%MjKLV=+e& zq^3unAV)|&7eqP@kDDGQpoUVnNBsgUurCF)&QE*=nO$@>tgGL=1<5e~(?$0mUFyM4KAu&qUW z1>Gpmoq;WxNqh6$Re$6H4<;KLw?Kdl+}-!*<^ymHe3!3 zWmE)WK;fLDl_|HqvZ4kdVVa=<3tE{^KYR8{SkP78+!~>1?rfA6DOS>sqWibpRmSPy z!;FcZa>t6FbIklfLR5{&N%iE_GK}IDl57%D1r(U`WBpT0FP$I0Gko}l*G`#VIhP-aGhI~a^WCxR^BNE`Uf8tleyq%V2O$Q26*mC ze9Cc!(Cr{=dReo$h+V577Fy%w-pgRI<~U3@qClJG4n~|?^kivECrRP&T7aOHUEr2F zULT=Vg75QhbuyzH~=Co3SFN@hdNg#X*|Y z%&c4qkJ;15(g7OrBJlGMdYTWZxgg`WC6o8)%;M+Vh7s4=)@nn_C!c%p%T3g62$E{B zF9_MnkNSM{FTs3%+qbB-drKhW=d72Umn)2_><9K0?5f!WMAMRh`)LCwb#l9_z1iUd z_1_Ky4)*>DzdZe>c`J*64!$`-;LX0r?;4sU*&!^g4>-|?sPH272}Lq&Q0EK9C6y6` z;~`ZZO_1&+SUv{&E;rOnGl0xGI%NtFWzyNkAAgsQv&L8?w(lpsYNxXXlf!*7tMaDf zb{`qG8ID@$QqfA2ZrYnG*WMi_soBv73var={JK;c?DUm_naEc=Z4w1J_!?zynj3!& zYPvII=XN9Vw1N#;(FrnZU#agwpR=Hsc6Q7cG1DLvlv$Ui-{!OLAr(wVrP8dD$K@g6 zHp%H>3f-P%MO5T#r_P6yGP2bLt4%WbzaLdjcU-FWk?ifHKWlhUvn=m-dxBtgD+DR5 zN*%LsIJbMIEZq<0=mT{~;mKET)yQ9SWQK2)%yy;Q1^0#%K-{l7?GAt=-!1$dpn@wE zp!uTyw*@8;ZRigI7272Hr)Dh_0&MuS~OGB z%S>J?)u(9com_K)_GC*A7ADooPW_&K!E_WY6M>t%dMSi?J(sKcprwCT_uAq!4nI_? zB<3Sbu|K`3S_}$)EgfDGi!m3nBGISh#iD-H>D0RLSwYa%13*~yC4jAlb^j#5t6A}z zdj#>4oW6uU_J0(edpMK-|Hn7OB!|=#nzPtca#-3Nha5KNIaHElim7B)4wKqQYRw!= ztu>P!5IP|$pQy~CoJJCo%pvFGR62Zr_wV2B+I6|y_x--#@8|3Jd_370UWD4Bn?=XI zdfq5A01TC|s&#A#Ydnymqm7>}!<_7G4oaPNrZ^J7As0XCD%%Mw9^Njy^Et(f>XmqwoI1XX3PL#Mquo|BS27@0xM#=B)vKf%p+>>K$ulg6f4Hc zS6fcc2r*440e?rYgMt-<)uqGP*o@_$o zL_CO80e3a*1`#$S5U#5k1xxE0V#kS*3T@LKM9p|75f}j1Ng3)I_o}ZdTKJf-in0um zZf}&dyf}W{iXM(3C1s?Z7JJkOwv#_s+$kT;GJ%qxpHen74tuk zqV$5dmc79RneJbaqmQT91GW9D_GZCXN3Ej%QPVd9%vO)S%LEr6F+BHmh%?@+S$H;T zX9iNId-#Vx&&cw`F6Gqip>7=gQtN)9wtVNsOw>EtNPly=*cn%cO2(7i><4$ zvwj+DX`6m!hat2X!*WxlLY*4pFE5cSf&H>;o7&?ZDnV@^p`_@mU~M5uC=-6GWC&H? zqB)KI^?V6?l}2t`Y)0#tC!_B9Sp4kiW~KPa08A7Ou?D=`z2gN+U$fJ8Rp{|D>ysls z=y&x?od$0c(5PzV4(&{}`gq%bz?{C(Br!?;K*a6PWUo^6MlVQnO?35F!iGeR&LIP4 zC8WZX498ra#3yt6EV4{@4k$i`N#1(yxuP>rS{IJ=*^&Q?u=!rX^)b=2z1l-4nhK`s zb^F@jKi&P>i8^JR+%RXG1xRkd&~e|>#y_=lGaEczjj0VCw3}#1U-0?*)hG9IJxPUW)Abk&{@ z^$=OAB5$pVzZ8_B@FSJ@dPl;4k+-6|ww$>#)HRy&(H?#d{+^{+H*hco9T&Zm;dQecgh<_jIQM{%!T+wO-1mJl??iBL z52O53&zzKrx9Hj*bI6MP*mxls%Cd6X*3aIAh(~gQt}UQtr`V1Cd!2`q8@5I5?*Z|- zF;!(}o_-oPBY$)#kU@*R{xqiUF6oKX3G~P0XD*6J`5+Los*Y zTi`f|k{y!7a31or-tE@e_^!I{^#(CN*4zNMDO{o5L6wo)t550h)RhaASJ(YU$kg$jVG&9a7T3Q3AOLWR#pk>b@RnElDTh8ZLqmJ z?6&48LFW1Ej!p}ofkQPuIN>>F;j;9ll`)n5=)*^BeJz8OpO*P22H7hckbpmqV?sI!@nca4h;P zV{hHFHjA}1kUn(sQYxy(`x1PG$Y1v|$@7e!f4#N4e>mkYAa?}0N?SGTz0Iv^y{NnY z85A7-toFKwq)oC>_z6otvce>eWW-qkafr+B4*V%|74&16W7YEYdeVro+zW+mzYaOn z@eMLR#XeUU`oaIbcfb+loh=~!4|Ik*gLJID);1vO*6DjKCOxZf84g#il-W#^SNreg z{r%}}7FDV>=$ZMyAJ!UqdrlQ_$Tj~1nV$OOG<6{c&|{_+^-z~%9wq?@3_0fgA1vsU z_i|*5?C+(JmVjr5%HXbE)WoZ&7k=H>TOS3x4r(*WDBhI4ec9`=fKHnY#-|~~LXlWpiF7)@wI|CrrQd$iIuE2+#<43vE!ubotS*R!ru_7wdv z^NsHJHji*=y4UI5r9;Zw0AJ##{KfPY)LX~a6P*;?E7!z5=q})w!{A8V`n_BP%Mtgf1r?IrZ{{wa2P{LCB0%+RNKaOhzcbF6! z94O_<+jP50o!|&yFm?tB(-I>UFZqeWNHFR;pqxex-s7x@4wm+sqV;jj z4r4IJsXz>j#t_xkS^rpsIEGyBkq$MGUliLeg~qZ44;C!sa%if zv$6>yqCG+iyLup3!lJMfluc@p7V2iGq0_a>s1uJ{<%`tsy)-R0gr8q~pwSXWs*Zs) z%^{muao+AeQW%X;KZDFW;&foojiS(iMtf4@OX7Bt>-kU&Iz;i>r34#XjzR z-RKqm?*_^|Ruu|)NDcT{Dnx$faJuW1XDqPK^N9AOch!5{;#B1eL4cvO7i%g_u*vTZ zWHO6g_PVco=&daJCUbqPBspSk1Ib6BD{Q6b9Z{R)q4*i8;1_S{XnM*ata{Y8v;&l2 zkakt+;jS)8^-4p`tS35ye(gtKKN&um|7uxqLPYFE6~TsP^o%m!hWi`cu6Cj!-k^`iIK8J@4N66**BS24ruL4Zk6#gn zUUJ5S3+uVhr8?eDmg71T7$50_t)X>f>s z0q%$jRpu9kA@?dKM0G8T*E(wGN&x-#4u8m`{A1e;U!RDH+Vf3YSSBmcUv{w~H z>mSYtBgd+I3>~w4YU7{le!dl~(R|iPnA>xy=E3QxYH2j2UPL~;9Q3{U&9RI;>%hIs zY6FK(2$Lct!^+p*)Y&JmSLKdg2ko(RcMQo>k8(sbu9coS8I7vBCeu-bwGFBcWO5Kv zK?uuSJ|wGjCnxZlS|X_BN13*tibtuS&Z7{NKFzo<_PlPpGM5N%qk)TS_o8{2?)E2-9qckiXzg;DbZeSssL8%@qz`iMiE!z@7fKj2P|7ObxF$%J%=vxqn z`0@Eg;EkB~mxv5ATeSt5{5V6wk?pkjqo{|9R~!+eez(<=f!K`{HJ{I-EBpQw#(#gx}otREm|!PGwTF-RGIzQ*^&0|{MXpqU!hWW^Y<6czws}@MpZnTS}SwUeRes?ud#Um`&*dxup7C*4wkUlpO-Rq|Q%=IGZZ~V;hao|+$yk9NL{Ss+e|8U20sP4_K zDPP>U?%T^Y)#uyX{gPHn1&?nkynfu_-M#5=Nn8oI1JAB*jQ_O3s9eJ=w+DDv(4t8H zj}4XUKg>D9{HGzx!fPrnT!UoaWwayS(foiK9LuCX2uS4cCl70lt_lCYcYX68LWlbU z;^L5-EzoVKwAQ|S{4>*w&zkJZb>|Mn`uBln1K&Q0KL8IbyMQ{Kk??1Fc#q97(+L%s z1?_lK`PzG!^Lhy;4I$n>CueXQoUsbya(KkSuKy5q@9#^B#dFjMZlOEP$ziqp*{%0Z z(FG~FJ_fG=BDMX7e<`y#{^d9!T@%y#ppxIDXRP^jntjzp=|thIDmErPy7Fx=aPMosAU?$z$J;L zmE)#q`c0#(4?)EjG*24ZBXgfXb>keTuTps%qY;KYcPZi%V z#XDujt6Y7&-yV((zG`XpQGGgUa@Nl`3ikLB0#oi4mDhI82s>dDC_5gmIKSUhqw@H| zcU6}odj-2BPj_c%e>c5CY250QWWc(2>88jbr>8bTmPuI*4BNU>NyRtjkoq;ctw*!5 zFC~B&{i$1#XbgQOuuz_-H&&3|*ZqqJ}EPk&>XS&kfNU!%VdfQx4Fyan_#9T*gXk^ywf9M?xQ_ z%zHLX2{fdJH8MNXQZB)Gxt#Sif%FyC=M&%Z=;^jS<6ksSr1t`Bf@9oFsk4RLx7_^$^70mgx!Y!VE_bCOB-i=yC)JC6DIMnzSnGd$?{(I0De&LxFQ0X9Dkbi& z0GrDlK6(n-CY4lH#FXS9wSwS^W=@CZW^;Cyu9l@;`^d^p30X!)7g)ctI1a_x|3Pphu$5;)~B_b!+ zMi+NUI)@Mrrn@#0e2`Y243`dTkisHvh@oIYQ?@@r9Ly1qMgUPHnWBlCcD)}#k-cj2 zz28U&-F$3<(hcY|OzFG)M%WpdYk3wQ9ab{Wg(GC>E3mH98@Jt%;h#djRXN2!zmz>?@zF+H02QUB- z{8kVj4$K|mr$X_v0T%6ZJ`$Yha#ZX1Ia~Kjr`_pY)Yw##P|iyD*0xursC8%gti`P0-qxs6=l*FrW2;d8$H4PwoblyxM>Aq7}J`ltY-hR&gq|@)xYje!1`8 zg}VPViR)F^jlCXr2SC4jF%CTcc>`N3$h?`VQoK!X$V3;A>B9XFq%cvaX_><5{rIL| z50d$3XC-`T$8HSef}Wknn8Psu&AUX34pilI$Jmde}lG{on04mWl8V=eFNc5fZGd7Q6w zw9C+G?45EV<_x1dNiI{oKN%Oke4<9%>9wsA@#i0aECVlp2@3rdi~+qZdL9kk|M7pI zQ`7T*AUfjgxdznI#Ja{|p4J`jqhzqW4#4iRsO%Y5 zdidpx|AFL%2Qn+J|8saX!k-#Wzz7oNygi=2cbq6u6+i3BoX=LAGd2D`7CBc?;~uvV_Bg0vtn<=u#Hxab&qZAXjGlhnyYI1 zYok{)(4%pDtE1K(vvIfCq8Od_a0fqS)KR=Vp7R$8CSP#r$x&ZqTs(BE>aFM2`4+*+ zCy(r^kWhF;j@IRqk8|>h^c*Vvt@B!L59{KEn`HQ`HL*1s{aI3y8R*CxtcYo~Mv zs*0@t0BTZG@gudvI&x?(nSEpKso2v}#~yh#_%ny7en95^})4KE3YNWsz>7h4Pkiyu~`YDbo0a5#|L1{q$O>z5T6VY&LtB_b*b~e+PRWwewv@uE6@*9*4TU`*|KFp(>58mwg|4 zJS`^Wxz|52UC^)J<4}MENnyP$unC8IfMzm$R!qj#NkPCLiTQ&Jqz}^IFIOEi;G@$1 zLip-DwoB1*8&-KS4cW4{RSHvL*-u~AeVqfHiOXO42o7^u_Umm6+{LGb*N5%c?iaa8eoiy{k9ImPuO82_dc^(=_TK|NntDS>O2| z$R7H4Im`!uEo3+X-jSqkXnA$#6qLE)x6MwvT-Lu|`?=(bQU6J0*RgwyIE_X3OGuhp zZnLpGrbH71To_PPZM2wV#fsK6(esZ}TJn4Wp?kP%pon^k8qIB}>N}81MB6unJSs(t;r={6A-z>BHhM!IE%L3guO|w4BD(Dh2 z>a7B!0r~qXT3rVqkGt)(M`-DsG-l&O3ghR#Hrs`~TGBGxZqU`BzVA~u(R;wD*+Qwa zmlK%gV_pJVe9DQB>9cMZp`o(`G2_}({3Tc7EFIuro(i>0r+1yhR~vggi3jNvWCk7_ zf8>yM^R7;sD<3Cu-=GHv;FxNK=mm=oLjG~a{zgrs3*{|uchNU(td`tzI)83&){|Ag zFCo;SA^p}YN7IR2{ldLD^FMA(#V?i;jm$z6CR7wN|Xl;Nlkq%{3zj8N7 zP_xnX$@`Y|CXOnT`MO-fg|`s?sqcqw|93 zt)Fz_`0ttWwy_AGt^5CMsyYWL))bghdKm)T<~w(@$8ee0l4$^(apmg7ZRxpZ8Wq?Q zlu8YL6Y!4r9TIPR0aF|+wQlTb*RpJW;BhsOE?!&IN^0Im8V9>*I==8RKkSI zi~TA!l$^vU*w57=?xhpIg0ZnLm)ztn5fe@cv00bm;-F*R9$dph^vORDigfx$DeeZF z?`>Jy^!b*rMELK^HI6xYjvQLQw&-nlfj^r0{z7`_GkcG=Z^~ZJ?^UD^ZybW7$F+_v zDCp&T=7hGKyn6t$9*tY$4IZwW*x~S@eedvtM#?;4@5&6C($WAg@z&ndGsi!7^R8nE z%UecXcXv+eX;mO%5|J+I_sgi)+qIbU=B8Qi$m{aNf3!ee+rCWkty{k}!O-?-ZH#s8J*e034;lI_SF{75 za^<@2&n@`+%8+n9AC!|Al*jlRm`e7;oy-5RgjLXn$C2hCpq;g*_4JS2>ZLsla~zP6 zf=VH|9*3CSyOf*C;u>0c3f9^9SP8o9j=l1M6VO}_`Ce+^5V~`aXodjaE1mc3&tKx3 zgCx>^MyMYMSRKFpLCj<2?BJ_H3SJdP%ij)VDQ^+Up6Wkw6EqI2`LQ!L2Xm|?Oy^ZS@~?j4koVU7iO1Rfg_g$e%V8=c z8~7MM%>BK&tNHjd`0rk?J$B>w1_Zjzt+0_)8$VHL3$(^BN+9Pd z^9MV1mp}FWiEqRKtS@}bXL)Nc|6wPF|LY+L^NEBAJggio1ad*O^ zXR$`#!DU;aCt92J@7qQ7^F8il3l4kdDn+DQa?|KpTimuyj!PD@pzX*at8oboQpR&e zFXA~NW?9Bn%)S8Be7B-o!CV*MQ+Q)n5YU2B6*x^=U>+QO z6@PdOdeI9Mx%w|?XV*lns?@JJQ76=v^)jL?tW!nyTv3Q%yKxWiBUx>|mRPJHg{32*yrp{6#`CV-_U^iMt;|n zTf7B!a}m3!@f+Fy6!7`mwb@0t6e+{0SG&v#;07!@q3*ePG;55}b_~)k<9$*H;ZrEk z+;2bhA5saIl&GYJ-7KbdBkK*Hq2{_}B-HcItSA>-HcN(n6VIi$LqqSRDw|N^{(T3dU&)7@?ogF)K02tUqqgDi6 znzP=mAT}5%^kODbJQ<`;s-G%wr;GwKH7B5QE~(@p)kXUSBPiY`0Muek$2Y|X)!&p? zzt)0&U_L|9|6E6(A1Tf8HUq)^+cPN%Lq|;=PK;ES^y}@ugqNkJxOagLl-yY5Ahb>pNGhZz8SN6wiU!MHcmr-()_gt?C%XNqdAHA?z9x(mP&usFFboLlLr1@of z<XB%c-C);A{&mpK<=FvhFa=F8~pBKt8=dh?Jknspl9mv zKIu39F^#Ne`BOHZ#VjzDEW#_Jz`aPuEIAJSBQZMg+`h->+L{hJk9lgo<_!Q z-F|31@SFyj?u<0isg^e#Xa>1;15GpRD_3=D&R#Dwyz&0p<1ib7CIQp_z4619d%Ecx zy;@&P^!khq04np?gX~+pNTX4uKE#|Yn~PMe^_az`zk@J{Zs4)X?F7rD(#UY%_GqHs zAjOjv;~F~2Zge&)WZDNa@vO{OZoTyP9?;*`GF@#nt2}y#jvZn!vUVvNvHwvR%eBt;YODQAKDPi5hTq z>Kl2LXXat8CuNgz@6-X6()3RIX}d+IkH>gQNXJr8z1C{lh9U*iH>mEtuP#q;CT}zCuRsn$jc7%L(xTfZ4FN?~OvoetY@*@y;MeO|< zKvndbq!~e3q}TVMjD&v$w0yhp9`-3phu%yoLMC*IDOu_ZOr9*X8>44`BRL79*nR_c z-THrBHRSIW#rUNVKuui&W6NYgr`smM43ae}I`>&R?R#Wgd>{vzPRBKSr%imT(Iom6 zvw9YTzkZAisD5m>x<89W@vz_)WtqTGozK67Wb_pp4p!{_Tro9q(rB&9%6{fx{Yg7u zNmjP1xa(V6cedG$N$oj6G_v<|9 z#XvVCctW9yz4M#dwuuw@1HEB`7^to&<`A(P$g*NpH~O-)o}nMa51ySb!qbY67iyE} zpddKo(2bad(WzYT^N3+q^^0r>W{s!NzMxI|$`CdtiR2(gjI2AJWEXJC5+3yJ&603x zgqAw3bb5&Oz~ga_Rli_ZX4%;qV~?mi{BU1`+onzn_VbzSCYciRvlxK-qOH@-VFrXM zeJ3^hn7babz4^!&pk@@9z$MA4&5BcSc9K!A+NJ=kY~b5%eE|wxl@LR*vPOsF3GLD$ z5BZ3~x@HZBg0IYY1laoK49Te(X`7)hd!boxhu*Sh2Wp!qM-gj%P|4=h16;Jx@w?fA zqsr+_LN1_MW$u6B)(G<1ZL=ZXS-0l7L#Kp!h!CNKX^{ploH@|)qv$r_6MgF0KV7yQ z>Fl^=OWWY3?|+{6TPOVChqDy+Pgicr(!@?_bWomc>c)rJ7n|ma&gAB(>U|*aS~%IS%Pc+CDUyO(cQ`dW2ZDn$@Ppt9va?^dzVVX}xi^IV;VJmXK#HN9Vm)eRy zVSjmpPrR_`&*gw=$SYF~7WL>3h><3dMuMM3H8v-Q#O-3?c+T+LT=x#Hl|%s9>;dAb zX=qLf5Uz{91}q$a*OgU-)}YU~?Ke2uDvbjvKDzZT8@Pvkg0(W*Q#Ag5Fcx|qGTJ`& z(6k%`;wLoC;yNDx7|1$Hgrdi(AL!NRHH3yG)}P-P3&YFnBS7jlw<-=)T6`jEo{}l; zDzn60TbtLpU*>(mXlk-?4c4dYkKrF@|59VURt~b^fBL056}aTK+ZAGBebk2YLtpvX zclE=0xbfxwd<}uLf#4i}Cbq|C6C*5>5k^V_DZ_~ZbX2AMy({81;qr=TdnrHe0hiyq zrLJwPIQN5(RfpS0rOI5o--|*ccC^=NwfteWmrDIcx5r9}NTw80g_!m%@^=FZ^=%mb zxRC-SMR{bi3GBjsx*`-tG|m)i?Rx%6sZ)3&N9 z4b)F*#81r!ThQ0w2)*9{S%cuWNo5EvU9;^`4j-Jd?PHECj2th_X~+~{Jq)$Ksm05; ztJnmX71~YSPdi%y{w-oW@43E>Rc$SQ9Cp(vx8RJ{jod&kZ6A!Fv}#7reyz`@V?QJy23h_qS7Oz`z(= zbdv2!qg1VHX`GzPT0!wZ)w0EhHw)V3eeoA*x%vJOF2z@)SneJUPmU7gEVy2fZ+(0dbV3vbC}Na1@QHL~#!x@B^YX>Y8}jc&N`E0g84G zHP^!+@u1sspaM-}wu&2aSaLGE_f1%=kC z%K_iJoh2btr)(Kx*)Nw(|!h=#vFw?Wg=09gNh<`N3 zpDuVMiL5A?J=W_o5AOu4OY2U;5>Ng+S-UgPdceoiDXD)Y;Pq@yhWhI?ae3DcC5a2Zspp~fh z@+*(0-72UmK#-=Qos-WD(tOxu;3$l_>$#^W`MU7_0H@Fe@A>nC4`x4Z6*#uT*_90M zn({Qu_=r13v5CZytL!l!od`EH>~^C7HkXm0Shv1jGE!(#%on?wpOHhrF2GXg9?nsH zlGR1`e%4B8gj9y9a)+k^>=`F%kY?FG4amPq%}#sX>5{!6k@1gZ)q;e#b7@w-dGmOw zHZ_QV!x)qq9Bi|X=A|KY@w^>8l>f&Z1f&wAxyqxoq7nr>teh_1!rd9k4E4u#q3+W+ zH=A5SQYmf-u(=f@1XJ=V1QeFWvPZfB4C3@$ERCqaH~cSIq@?9=pSCmq#lx7ex)M0q z+a5EIRrKIpm}CI$$tkCpY!#2i0hXs8kma z)@FbD(QKnoE2(_74l4#`l%cV6d;E~OK|ngoGUm1YjV+t$KMy&mqUMJK2OhAgd4sXa zvb4W)!OvJ24m9rNdO7ftF`h{y z*H>3?Cy`Jat#UYh_Q;({?s9edRKz7=Nvrlu-jiLAozP+=4k&8>Z-pzot+Fnk?~s;n z3|t2uC}mZkZG~eJ#sjv@Sb2Bse4z+Ra6^|E!rpHXCTY4{3kF#Byl{N1KnttUC{VJA zxchD^1-}WUlo;UITgIPl*0${iiz#@Vy|M|WGuos9gr0&$2@YTcO19sl!M_Bu(n|9! z)YTID>itICe}$KeOMmhtGJq$HMEMzr?M;V|(TrrNJwN+W%A9!69$X$(F*G|wey>Nq zrM1)k?a}f%JFW9Kr)^n%;Jn@UxkzU<9e&lS9tRz)a4j2t>)TcD>z7;_&F>(`&K)>A zb{9CK?oK^?rRjLX>>xK3x9-taF?i~Fapw(#Q3h>Lr?~9Bj$x;(C#+b!sj1Ag8S3UX z?Jc_|9js~15^JRUHQcXjXZn+2HyZthL%=Bzx(1^KoKUgWVVLQa>`x|yf2_)Cw-D)3!Ot>Dzvho=- zII|98_{5uDR9WF3o+G6hG4m;>N-fVa9wy6R{iaRAnuw2@nDbL-dd-wFeGi{gXVSIbU$AkNv1F2=y%CN z@z-nZMKSO4eU22qO8{+r#JjoMeTaJI2G|uxSM8yvyiT_|7D?)V-yrQB+A0p@-gy{s zYiRRTuYQ%vlE1|oZ*4f7wT&RR;D`zI_NI$eLPYgK_4MAWhflh@H3$5d`IQT=Sp5@K zCL#~!NXB@N9jfcP@P7R7;7Jinatb4sGcme)|5IornZZUF-CbbWdmm#pZ@GFYrjzKz zq%$&Y3)>?22`7>-k%MtTp-YTPdxd%s1Nk<)7K<@!$I6vbogq3U)d;BZTkc z;|*V}#Q5LMH%hr~1m~nGAM`vBY_cSPQ`{_*gn1^nqy6zV{+z`7w=Lpq7$@2$3sj=l zU_E+nNgb#-(i_(O^iC4(PU|GY#WQ^xyXlKTp@Rq{iE5}ReU!iKw@=Di?re>`T9;ZO~V zBa!6x$|(A*#G)HZxYZU6+zMYz?de{GW@m`av=*gT_l-`bpeeyXR$+&ch zCp$etcbfGaLV+&9{N1(XKsqZbu5fC%B?is_$%FV)LS*A_f)2n&wff~xAMVLPH_N6= z=-^TRA(U>VMyt?#5l;d+-bA8j9JN4BObYf}Dv9g{Y@ww!Ix8a{V}+PbZ+-dXF=oD- z9Adfyq9m=^XHqQu;fpFM14K0K>G+gh8%eiJy4d%tkH(^Z9##b5-lwaSJcJ5RI(;wI zKClTpudp`X!f zr9T3=nIkp#ZyLe1&h(cd#1@Nz+pY3Or`QG0A5Grbbyws=mK3*zDWF0R{SDQl0nHEtdJgI!yzd|}PdQXJ5!N4a>q^jk^8s~zXJ4-XGE3Rw2K=h^a6>dZ>dv|& zP!ANr0Qsye{1Qr7a(db={y3Z`8>@fpjYc^^9Q4EVCyH7ACKszw`26Ay()-ig%UUhK zoGxbHkJA+?UXg>hMFZ^U3N~aswTDUe6kB?mZ-e_cYj!{x@+N(LXu(*Td1@(G71dBW zJD7dOPainb|3xgiU+k%S^D4yLs%%_j5Ws95qNfy5K!jxu(*Ixm0}_6C#FqMbx8$*$ zo<;1NSEzb>D{m28DgbF3btlb^Rn3WFn8}Q* zklyH2zv&9Vj)X{Zntkmx6D+ zcVpVX(dDO>j(QH|XRyc3g73Z|_3Bd^F?ZEda=l|(Kl$hSeWi~_)O`5RWT+0$+09h@ zDQU=zNc+z=uxK~Kxb~!`Vw}Ax-10{}vP|x}7KB;$$JFYk!%c%$k1~RVd1taH?$O(P zrcUb2>+)yR<4>|`R6bslqUtl-J-VeiF_sErMU&f_cv-`}K4XtHHGzOPw6shU7|z(l zk*;Orut=E?@lTt0ycWEdBG4Gtmw^@%Yj%Kw? zA}AO>77-`L?vW1^Ve&P)Vi+{okK__q2@AoOYg^o^W4l%{T{Ys; zSYyQ7^m`?<1TdXLU~KBp+qpo(b;Wos;lYNCaDDWw$ETqjUBx4Seorrl$!w{g?1n)6o2m_HD9-B%!-B@bZK1<(vOwFnTX^LBm~K+&OC12YRu z(HJ%t_$>`GJD!=ay&`+qP!sv9=1q&ZZt}>jTeO`L)=E8JJDCr%;7FE=1h9J>z}vVB zAG*{w?cIqG#VJV}bVEP_=?|VvdUmDBYRMo?eD!*~Hgc-idlND3_SLfZ2#~?r@ z=n@G_oU@r_BOypq0nUhw5f2QaW_1uYlO0`Mov9WZ9=9{A8v$V=QmI(GR!xzQ6W1Je3rx5GZ93oaQ|mAE>eYlHe2%2z{0f*&4mr zai9U>@+NXs(5V^{vDy+7c8^MsM?d0iA-z-spiA1NTfVLcAokN>lk}hdTnmqbr2{b> zi@h!Tfkg3xE$!-$sDAzli1o;HeEXX;N3Dole33^lh~aKdIqmlGtzxs^(LvJE>_u3 ziDju`U&b32jgpromO|+3DfZ$)&64P4WEfqPa`q1?2CFW zZR+QhhZTdf5=OJd#kC%_nK9HRe5TR!^kpT z{4F5@!Jy1>gmMb}6+X<05lZc$d%d^l0BJ!h%`nZNUAkFjn-+0D13)FvdJ%ZmsZnaz zyQMeRUBX;PT|g~BJm*WbzhE%UzR!#cW2r2J%&wgqefO=p6_fm+cyL=Y=s>JZcj}8C zZnRMX4`LVId#PZ-hVA?MCSYMkHB2`~as0_yjVqHJkW3+@(#*DZi^Lqs0?!8M$diL2 zZ|?(j8yxsW4LWkNwGriMVTUaLX

4aaXE`QwTY(mae?jaY?w;NWzR2g3z;0Ym06w z6b?fL$%JZ0OWEc~s!Fwjk4?HeRiO)jCsR1fzTw*eBOK*p<-RZ^h_gW$*ID6=XX8}` z4zzt=oj^U@J0*iTV6la_HfflMBKP^}tNIk&lS40cpf>!>yLkMm1~c1nKN2k>f3UD- zuadLMZQxlGw1_5f{cH^_|5l--8=Q>?O7muM{WO*8`}s8>D)0<|mb`UC62nRa`m_01 zdAVIkP1wC?kbpn!4oDLX-ulyS-Wrp%t%VG8QtFFt8Dg%}EZ%+^7z)Lcd{L)ZE1)90 zDoQk%4<~?AB#JivD?CVzS&~pPc7s;U;ad3|uRPGO1GFZXaVRJNkKAmuukV2B{UuTI zaU(SFtS4@j$64XaFuQI1sFElNZHMIENDdJ;vU&*o6IgzXscLS~;GaAx>drjQ0~&bU z%5+pKQ$#&3ronxZ7u|f}y-u1I|YwgTGe70T9HxA)#r=f*DX^Er~*3^qxUd znn8_ParQG-&7kh>#`BFL$Z%jXdPUF%Tn#nLSBC6bX2NPYi23_NtIrPhErtn{u}P!Z z*ewaQV8Nze_ZAUR5%jF}W?8~N7;PD=2$WjpCkL=Ye3U`^?i9s5-nOoONMrKWfx%>0 z*zas&@Mew<0JwvvIdxMGJG*v;urWv6+r6U@2`IwC+4;4Kp;pFLcNfW(2J)M2ggdwV zm(~34x7Qcu&*Gn0!qX3(tU08+FGOJEtJ$Q^yDqIW`twE|BXh8&CMvtq!|3Fh^r9GN z?V6lrg1bd$|Fq8`mXB%xer=RlcK_=M4~;Q)(!Bq8OH-LzIx7j){C^yMdtB1j|Nk3M zP*b#`riQmPg>H({5-){15l|7(ZqAiyQ*hNp$_uUr(rt|J0;Lfe33#cjt+eUNO)I=q zC?eTDR%YrnGBZ=Vxa#{m{r>R39z7J^=e%F9=XG~0m&aHmGar{&k=w?rQ^^y53mQ2G zquk+@=C*ptcZ~-|q>|{Bt`P&}P5u$_F7}<_Jch2b!GrFM3^j&xMh8l-QmhFM851rw zU&m&1m-}UYxNxu-QA%FCx~iof-v74F5^aMVM$j1h741qWGA2FV=WXp$!xt$%NbM1Z z*SFhD(~%CID;nqZzJY=yg^B!v10k>@m0j4xjVEuK<9R*Hg=?2!_LQvN*dq0J*s|-s z{IrGqON` zf|P_Q1KtH|7lLkt1R(QKLJF^g;anyuhpe5!PU@ksT%lb+!cOyHVx{G4 z_-xEhYPIaKvBEZDuDVQ!E>h&+gL{dGiNa*?%&qc>iWhp^=u9SbCWk1aOd?4(-Z43` zU&457^a9gBkPO#@j!@51tv=!t!hyr0+hP*hBMj^O_9jvi1gV={#!F^sCfQ9BjMK@F z2EX$8U(GBT?s*U>nR3chhP=UPHYtQS3x%VG7wg>T&UDhDyuXPG0ed2xt45oF2B!5I zg$pf!LLYe;3ycObF1V};M`V?CfGf0+C#1}L-OiR;qm_$c9j3_>M-(ndHdV{t{|0E| zYtK2_sbW+46*^Mv-iqgSkZby{lDntLdQ^BkN;=%naYhY@me`Li-MTw{=pwS-n`e^4 zpOZ*P9ZE-Ac5~m4F6fO_goLsOQ*E=zpf-KR-ET0ixz@ya9q%NHn5WSJgb-e3?Tf=S zLX}*bcZPNNE;kOWHN1Z2F7r*G!^UIN5m=^mYkT?1BWbnXI=1z3grwBRTTIR4Jdk{M z`|@fwV!e&w`{Q%*{5j8U*`i7CSw=Yy9HPXv(%Ztt`r= z9n)TYsHQ|x60kqo+s-jv?;(rhrb zyhYymqsvOBVXG6A~k#RgrI2+e(gp$oeU>VVgpoC{GezP8wGqwzV49&L+ei!WYYnxaaLV zF%{t!23gmURdVb<)rqdBh+fWs^iSRTXAmbs-T4!t2Q=3?777F)u=m{783ysVg^WVzAk$Jy zta+{`0NB39<^Qmhaj2giJS}pX`Jg7)8K7y6tQ+C=wWZ`9J~jQ%S+Yg%OH$9PBg8Q# za2e|mZpOY&ogXGs8Hsrvti}Sp1(#d{drCa;0{0ffBme--e!>!y#bkuComBDxh5H;| zhIeE%La#QvvOrowPVf}j=U@$@*bNU5gCfTWGJxa{q1;25hxp{TTJLarkhTQ!dkG#;k@7$TMUN5sFN&n4y$^Hcy;(9vS+~cKqrYNqf zg%@JCeDK_c{d|z|ZSILZ8@^hx>R8I~QbvB%n-HbeannexEGIafeDuR;FlpK9*eZwM ztHJHzf+XKS5Eke+D3E+@W>J%dmF0p3NgAhTL?ksGt=&6*rb1NM4{)PF3E9oss|Q8Y zR4MlLCPV3&=P?&rbRFEgsQq~1QOHG4bWAS!l=b!D04{V~R$cNN)*LrAc&6o-cFZfQ zlk4-BEk*vQ3-g*(<`UY}HUj}9!{)HGk~jI7LT-* zg91-46P`XK9yl#-Q(JE`KNcB0lH(QtLk`{&4meO{oFQCZGHjZ&(16%;bU-@HULs(T zk^C4JttECqXg{xW{%C2`xZ$O^S3C+jM9K^qFR>jc76e%+Nc;c*AMr@S zh{oytd`qm|Y}M=;kdL+ivW6VM+v)M{PC-f@vP9bVNRsLcggJl3`vPdWH;arKEN<|P z$8`!eK%Ii{c()c}kqDVnpaTo$urlSag7C|{4q2|s;XKDR+wf?;$%zqu10vM3i03%N z`k+TTuammord8{K8Z_D~ysj6Bd=A%$Ix*OcGSRP9|5VFW6PTYvtkxg0{OtN;a>_`_ zBE46)t`~E>s?k0r@xKFgpDYm*rR43r;Y5%am^eix8z78&!Ni)Y@roG`7Me0KH;wSu zA;wJ#K;wa>a_iZu0B#IR2_+}asndfEZWf5AG67!@UlLiMPH)x(YhUExLGDC!SPp@` z-f`vml%%^Y!*<7r3{^n-w(=i*BQC_MQs36E4DSB4W@B@=B>?CYBtcQm?pz%45U$zw zWBp+TSUl$~(QOH7JUZUyqXkBUYDpT@ADB$H_;sF66AjL&R;&M*j_NPSJ_s@wuwvWP zsQshFxsog14UxP#wL3>pluIm|4o3fda=X`#LhQiyy^>O2&WBz^Q^p8KyQy&R*Z*Gl zUxV}I<*Z{h@tlUc+3|?q5F5Ee5hTy|G5< zd;yigaeF>7AUelT*zc^C&d|<*myG8EJ3SnvRi(@flvDvJQxG{U9g{mE9iAma|Fys+ z8wISYIY_14X>C=6uO&iSM{vGaoxAA4HLz$5Ghoysc^8OHtqK7{XT(rZ%Y+hdyQ$Hr zf61969^rL=!~>28E;Ij34^0vtz_ivQ2^1VBf=c#oScej|)g1GS=pL63DgHA7(C9aq zOw9!6r^)%PE*ov;8LU9U8`!sUgN%vXC^pE`6rQ7#R>~)1z>)}*8iaeEjt`0f+Kj$e8XT{sVVRqltlZgr^>Zl;$eqI@1KDy-Q$cCf+oQMu>AOJkC# z1UFnS)_epCu%_H@CEw`@VIK>w0rYdaTSpKrw#v+-Mntdj1?ur|+%$z#1AEkfbJij- z&)N;1_MpJA#goSX>HR>d{o{a?Jt9*;d!(+pFRL1F5zL=(-D=xYl9Gsv#>YtKu&t?p zm=Sapx*q#A?m^kA(!xVOY}%f@lKv*Nzq)153r47<`Dli8qLo&7MmX00hwEvM%Zk;3 ze?34aoUa}$JKC)ehJLm?Oo(Px9vd~9;L&(JaRO+X5_ANSpD4k_vyiQlDPZoV&@@S& zuiUxD>$smZ5k#fb(F;7F(L*kjERm(PKM~|Kiw0vla|a3RV?oMFG(2k!1kB9i;U4_?3hVCG1l9ANQxK` zo672KLRpf)P_P4Wz>Z^yUgfs11>z}#dw5g_>|1rz(RG2RD;B-tSRK?2OCqWoA&+F- zTd-z8>nWD8`cmzS~;Dl#ycC|&RzxWAv0?8H*i%o<@KzsmgX#utl zAH9qZ$Q=dGd+QA&%p?iTkP|yFPKB;az;i^m1%XkE)PW~G=L*%XLE_Sw!;Ps-Prp20 zNrG;j8{~*(;<-G4OH?*v&^Or!z>3qxjM1TL@cAEKY;W+ZycNBI0J>n-I0eNvj{Ld8 z-}VV(W9%F83&OW=4=?#$^z%<)rh;+dcnsVLsA;o*Fe87hy|8zAcd^d@?bqj|hfZx? z4eVy_J35A1@dUZ7;0nF@^}reafLrZ@_{8$|f$tL(uNta?x~gxpV_+v+G*>n}NO}MD zzkz9|u;@Ff0}dUh@_z8zcC>j~vh{n;-95u>D0d0noW&o+!erc zf^o;&zSAIFh+y#&$P|h_B1zCB)fzQaUWV5UDCFd$(|W%Fd1-X0lnK(5C#Z+&1HjS! zvkDBDL9{Z?GFrYlS{0{tYfYWj|_*tcu4`~r<4e^X~4<}6354$BAI%_oIA@xMV z`d}@x+#9P*_4IVjw$O~@Qlr;x&w0%`Iv81ZHok%zZ7j41klsE_>fuIw;I@j?auwU@ z-~A+wr;;<;ghPSw+kTy2awNwSOoD$J9sG9DqvmP|!w)87kIllHKM1x8%2t$aLx25! zez11lbwkSfmunDnL{szR4ysAry^)ga}?b@(*bEYn%FPh(xjXzGRXAlO?n5(kL z8Qe$LVgO1>)kB-}ny~KXp;im1JRHV#hPlGjsdE4)1x_gNaDcm19ySwe5|i7ci4hYz zf8vou$cGi}*8o|aOWxw?%F(+yc&_T&Kn!wz|6;Y;2iyP71VkU4$~_G6CdL0j>wdnm zgZl3Z?+xiw{*ycYY3$4>QF3~C32hgGoFl^eq=~-?OiVAaa%aLbIvHdQaH1 ziU?!}Z=y7tggN?q8>ZsPK*i!S&MH0?#y7dV+80sp+RL}7WVcT5h?R@=F<)lB#ht{V z_r5B0;mFzd50-dD#5n7;dIIz|j4cbUF8lSUSOO#N>Fd`qiz=&vYpN7~-@-ZHL`VB3 zG@$y4JXzx%mtJSRb9V=j_QkIU!TtC`HXP4^Mr4m&8FSf=MCiC@MoHCNO)(HSOvg&! zICvqYxrP9Y)DDp43L!gNzX|>(|ks~JC-&mWx}TE z*}+=PBZ<{Ix4P+w8rU>>lJ>~A{E8b6ddXN_SV-HCU2T7QIIXt-z>Qx&SaEJ&*Ln%dNSsqDX&UX%7}M6XND8;(Oqyqkc%0@|4&R$;3{b4h9D&5Y_2qKKrUso`(gYlZiq7U3oxpMP12rX{+g@2Mzww( zqznObbhM520vlND8e1(wUdnA z-fyS5d9Hfc<0RJPAxHshp>o$VLjcdPK3^U6yB_W^lIW+$=N?ZO2|&sk#c!RT@s8 z&}>^Y`!)B)(+$+@7-aRqHM4dltJ)_ej*L@w2|cbgC=d>=WeryLD;>k}_NkKzJ4rQc zaU7~oxj%kA*ZL^2S{ahVXMpckEw#^(IDlIOOuXE&j5EgmW@L=cPr$yh{lIp&VDf%sZrdW}Ew9~1G*gk*P^3C*R>*T5066oRRwB*YcU*1fHh zzPQ=6t!!HAml(Gwi2l2mU&Hr?jTIrx`>z}YQc6M-+@&)yep6LtRwO}BoHcJbZ#yMn zfOI7_Qj+#nlOKj{^t8}A0`c77mv~`jn33uh?cSjf#?U!dA8~-@I*CJI`<>3XSSS=e zxica*&RXj^Z@>|GK*Og7#)AnRqKZJar9Eu&_a><`U5LWaae1lPG!c#u6u3gjgyaBz z#QtESN-mGH4#(p_ZE)P~s&Tojxw-@lwEnG_Om9pj;JYWytf#~?@6^^K;t~*ct{D<8 zSAY(o@aMildl(rEO%pEX1>+TB?&Q{&Q>$(?Q#End+`~}=nj-I@;dHmj8?VO|*H3>g zOl?%jLhLvze*c-?KhV*a=yCJ2x8(0=jLUD;5*+mZe=h8N;k3Q;&#fzN;3iqzKdWDO z-97(ZEw=w!Q)lK6N^tDFtT8O|mmkc*_>gte^$q#Kbp`8^{a?Qy`5pQYoRbM-i_GrYLtR9ng$e7=6;6{32r z5@})#J-cKB#3$SP3b|v2iMj98dD!si(1r~OS-jCEgk7j<-a>Uur~QVYlIL~UDsHVj zx{dD0;0l!7-Ui>co&RXCCU=KmHsm8n%C9YbtPDJa7inVXI~7aW1lu{VTLC)1Ch#^D zlaqDn8oy1qLRnRU|F>>&+%G=i=+*bPw&jd8SZ~3?sGU+tnsd4o4kp6$UK9Ub^x04H zRi90}91SG_$uR?{?5-c;+UnU$(F8qQ;Trm2WfYNpfOuv)&f2f4@qqT#=44WheM;XW zIc-WAUgwl}qdz9DUxa}ae;q4v?c!)Vx%#Uy;c{lh3wDnl8FMO*dAvWKY`wdjsadDkGjL{lfO6A7Te`iSSbLl>cVS#l6^YGxwMI=~EA{l+@ zWK@d8yzfXs+2Nx4tdOSrrVn4o{2R7pTSM#*)jxiC6>w)1(Zt^RxM@Y!{d;R-8+N`n z99VI8QZ>I&xQ&&W?x4y)nVpb)+IfkUofz86XlnRNbt|}pcqGpfm52P$Na-#`yj%;i z>|e}2pZ~$qw5(vyaMf4XgO}ef_qY4~Mf4gDo^nUQie4Eh!KvY;!tXujh>c8?;{Bi9 z>o$aU-H3X733?=WSet(%?%Rt?*WWLFjQ-*N){X0$6ykp6FKdFfTv)|+T;?0Y;IpIl zd&ip&);$)2DynAd;6#LdI`QRjnh=Yc)pqqF<>A~IAdSur&jFveCuusC8c}7&n%Mmi z%1^h>H?(g$x-B_*AD}kV`l2y5;Ou2$P4Ge^;a2%16)2l>3RY?(*>W-M>Hm)n+T7ic7N$HInkL<;$n9T z>{7RtZi%4_rHPMUg-N&uB2`@5ib5(5sz)#Lrs5!@Bi7{aTdtbB;N*TrJ6`^QT{vDL z{G!=^4qnc16u(17oDgbS^XSEI6g}klZeJuR>a~#PVpy(eZRyc#-PHx)_(BQ}f zMmRzgfjRTBp5H+r!w>^!pCXzq%$+~6*$&MK4`JruoX?qxe=?G~ zG`>RgO;*1SE(0AR=00WkFAFRK0UBn-cplI+AnZMoLs{+4M0+L_zc=nrf-`AlBvb*Mt}znc3)&j3*4dFkwp6~CV8UZ49Zzaa}>o669Kerq$; z=}DO1z}0>eoXMIeUdq-M(?>45$M4$uL+;s(TV$xOg-Z%&^!d<`ERp+ztrKzAZzy6{ z|9hN%|Jonlt?H~is0iP@}qY2fzL8dOzB>EtI#=zpk)ru5iUa)9NLi{kk2O8qg1>)^6R{ z`TH{8+KbV(o=@(1{E7eeJNv1IQcZLY^M#;ws`rfD(IcvTos6cw9kFX}g-y2({pz5v zegdwhva0&U<&0A?DH%5p7go!u0SKh$#N^KYfcxtmb@_ia*l|N zk8s07yvGN%(+qFrKFCFlE$oxwT&ChsnXRPlvP0a8DP@pI8I^JL=Cf?u$!&KEJIIqp zyRL{+T@By)v6gRhKDDUhwlm-gT~U!Y7fVu8JapexaWd2T>Y0VE7br-Fi1fTY{a0;9 z&i;W>iGcAeA(=o<%_mOlmODKz$-&#M4TujOJ+B?rd6hP9cS)S4%lD3)D_gzs*KGA7 z&fQUQLdR<9-oC2Urh7LUd@=kCQv;S#oR+M%U1gIk=+7+A1g%F&-K96m z3Lh-lv||x^HSwf&a_e%>VB%|nsbcY^Z>_CmS@a)Zambmck`y5xNvjn-Hm(e`t+n># zCs@G@8?@lP_iIV3#a<|d#gDzM86B)Rajr_UVTZameD$PL=$3+vTcZO?xEw;S4v6vo zVEX;u()j7BxtG*TnFF}~eKI9%{$Qmr0`OXX#GjX2yUivEkuiz-P;vZYp58w>Ep1dn z4+Yc9TTmvUUxzYDXCkfq0a|gGd&qKJnU2Y9@(U+Wvh!;XlFmbC+{ju|SZRcx&Og|t zdf0PXrZ`@MCwHrj0mCxf=Hwum`SGm5>Q`E4awwZgxK*4L^?}vd5CGOxP;S6ea>r)a zo?~!MSJ;RG_EbsFgS;^ZYt!Ydi7H%_n@MWN!1WT_5~V;v3q)(b3N=>z1nIMm7|i_x zZuMQ8ep;&c@$UPH@PCk}4pGDZcFX;I`uG1^yQ&2%n))vMTdyxGDg6Jhqaz@f+wr?a zz1O#gB73Nb;_n))5Ccbo@7|v+tY})(ob=u4PlNN}pZ{vQ@~q*z+lw~ZKhCC&H-3z; zH~e^YC=66eZCST8LOFD>YJY3iNtOH;b81LVpu;yax1EOW3eoTD);E0{y4;o*5M|l^ z*UAUg@&tz;a<%uC7S8PDp&b_1xR=$}7{}ClKZb z_$Qc>Bv$>lIHT#H-%as>i;W{q5mtM)#vj@B{C3vp294cSUuSRz%RKxSY9_GTWIr^2 zM`yKvC}upEe7E;v*1s|&LHWjw^3d@2nNxqwCdKYpWPr!4fpsyn1kxlLDfewdbt#*bw-5$k|(daVudu`3FNX(4{?3HbD3HoM4X9Ass> z7b);N#ma0TS^7(e#g-a2U)ca7Q=)CXb}7tPe>s7vcvlOzF?fOE2S~*R>`N9{HQ%#= zF2Zj>xRlrom^x}M@#reQ@RRGPs3^Uc-XE?mAdOTUr>(r8Qr5h==Ds>=1(j<-wu2NQ ztLOz;lV@?NJ{}w!qeSZ^Or53XTM|e$r+h2#Yz*$wd%9Wvfku?~tpl1iO!ShXjtCjdaKof zBrqgRC-jKK;~4}AgJ2Q@4`~9Q(N;4W?m+kl+*Z!-faecZyz9q-qJplP10aTHzI}hA z&6C&j3xm7VCH90x&A<;8Y2{=?Lf))!tCh^1L_dGR<$aa9hjmP!{Lh*7HK#DF2rn>Y ze4&KkPBvp1r?1Y(Q{uxe9<{H0p+9zh`T6}mCy)L7%OQtQ!v6;Ub^A6#oS6NJUJ|-( zO#{aplzRS&WiX(SGXDW$Vv8n_~BT*sh){p5cO0`*%Wie2i3eR=K8c`cZ-J&lMuiFIu?fLMOt!`p%&Y{T*GvgO0 zo~*ktW*sIrwOFS;P#KmOb4P&dDlC2A%tQ4;zarP?P!_WrnE)k;=j)8W?HbF9xDCWZ zza=26ni1e-pOPqZo~wb+>p+iv|3eoGy>|0Sg5$fDQt_ZtFiNz~RioYx_YIbKB(w9| zv|c2{%JN`LWq>uNEia2qwor2f?3sZI{g*>fV~wd;6pc~bS&t7WG`-b!679no+(Lfr zoVHC1Q|?sQ;hb3SP3-w8>h7lv!Jwionblv5u?alHjrOGwXi6y25@Qm92q7a}t_SOc zUpNON6cAz_ub~faIh7rAf6bcGt^5AP-GvP+9`a6y1yXCL4 zIn7B@f6y~x>z>kW(uu)q`>{cbKR$;qFVC)Em7(K`D&VaKqJj>BBob@_q+TN1DRZ!# zm^z9XOm*>@*J*oD^gy5q_@YRwYCPlJM16&84<>>kZ1P)to`z~_?sbHtGhRCiQRo-+2e;BMw*T!BaSW^ zTRf@M-V;Cnv6FBA`-fjvUtJKh#}>C63dZF>@Iv>U)Y>^-S@vYdE#s|a74oOV9otu} z!1$V!vHu5%5UYW!o=p54yJh376s!oeNxZ!*vH8p;YTHDPMD9p2GPtZcsYZA;yJXGDTCpf1#z8$2PE zpg$6eMB*P0BdDlnlAp7zNP>|nLR{RdvBSg>zCOUsJVT)xR?dTX2D%zks`uZi=aYsY&Bn9e5>TBk6lDt7x5Ww4g*3MT!@*Vp7=3{PU}~uZYHw# z%;`bIKv1lBk{Sc#eFxO8!Qu75+^ALJ1Mpm%K*Elch~)plmZ~j{Um_`#LK-0wa_zaR|d2F`2}4WW^%JQ<02& zM&~Dqiku)ecP4YXNWR*hd_Cmprwgr{qzs}kLNuo*zgjlG(HXRM=`pFL)YM>-?y1aS zl~>pV2KxM%74N`!XFx=zV_LLe6v4UOi=dHwby&O2c8n}5pfH#u>+}TM1(s-Ea!kM*C11|2$$Z#Rm zG_G+StKyLFR?KV1GOEbE$&6YZ%lliMUlvab;-kn=M#+r9tv-h*`E99%&gBE+X57ql zgjXzZo6G?0i`C&|m%hwaQt$kladbW%B(?n5B z)LcVjDfavAuDL;3x9h4UjBA>B|eZ{Q#1yVXNRk~ zcElxJL`K*Bduk=Srwx|$O4yI?((vK?mlXtWOaLYuL)hUy=s1?FLF3Og@+jgWias0 z&en>0lP{h?g%x)w&Itk{M*mI@w#N%|qQSs}B8|wUJaXHZy=x%ZLIGd1O}GUbrjUq# zwe`oe0*25@o!)>~v*LEkJ}X!T6b7;b(mx84OCbO^!Q5dCp9~k;_r)q1A3otzP!lVa zoaw0;7j?vdIC>rM2Nx=VzWfSfP8g*36Y-IIg@m%> z$Q~7R58GW`#{>rc3QQ8QY)?@r8$VcxSH5urlc4zk9yl)B(aTHIJ5$f90~x zN+721PjgGYDeJ$J_ov{h_m7F6UL{O0;3;8569)W(pG%sI{LUM@A|9e@HGJ~rzyD*fm9=sA%SAw z3FK1bxv^s^8!M*iXf%pWgFa%FdBJTp(viyMQDrJA2HW3^QbHh&Aj=8|y{(0bO~Tfh z*xnQ#nNWZ{*+PP!m0pjgmHsmuZv%PPsj+-|3qq_6q^hkq_egVn6~JZh76KXtgBMY4 z!bYSE=s9~~1O{>x7i}+4&l20>90fbg8D(;(zrgYwBOqfA6LU3_acO;2&iNBNIhqEH za8qNNgu#^et~(s6-`!pMb26E0Il0(+)qhWxUunIu%)fCM& zvM3O9QJmICZUI?6aP=f3c-e}-ce94&L zl-Y#w$f7q=8`Cj|I3Kw}M?v`WPE3(#k&-k?Mi5ieF>NsK65Nw13IUj~xSQ=lfeFTg zj#C>65uIebV>9?7E3E^JHk}|Y!{84D=jbYPMK2&{DY+6(s$(*KbHjQVs!w`0(C; z$&0T}sO+TbNy(WL`XKK9k9k^z3)0AA?Q^OB&`JMg0oV%CRYtJ-3z#^VE)QFU`zM?` zH-vL){f!HCW-u3b*bN5){FTHzNf5@6^h1?~6 zS&1Da-2_R4<;SC+l~z^a$p$~-XECwutACiCD9J7!t#KZN%+Bgjq%JL%$(JjwuriQh zi#anH`*fh9lh==d+iJ&Vr@->nq zon{5=qoruMO2U8BPoZ5TP;TTT5QW$F5xjqJJb!W3M*9aF+B#4h_N9y}k8L@YdPT71 zuz}GdFb8(tP@WFt7X{apWMTFlw;I0$w|mWn?%M?f(GS(BA>qC0E#I?Gp4#w(gnj<_ z%8EYh(jp{db=S{=p3^}tk6Te$)XN2fF%xX$@4!Q_Qu9l9Jy3QN)cvikTrJv+7MP`p zdhB94NvpQf0aem^8Ot}rxpM7=)2MKhkUZ1+mLK(NbvpWxH- z_`&L$p4GXC{ssyq>xhfy3Q$tj3JWC=Gu#>_lG8UO|5)K@l?dA*oQz+0Lqxszr%HW5 z3x@#*$VXUQ29yXZgGtA)y+V$5X8n0Pdvc3!{LOI@rWeF+<4u{lKo{b-p?axXZ!#T8 z>eg(UyMtLwUSLH+BMLBn{{-f&M5mX$n22}~Ldk@y0LULEW8jejY?=^bazCSM@8E83 z01g2~p2m}{Oj}x;m7LJvqDNqWAItskqyB&EHmZzXhw2GaF$3}{GnA`CNf?JXlX?i3 zVvGqhWg>+@zX$~OlmwmIH6?@_b;IM_aL(CC2h88}xX%Y(dQQb;k<=z=Y6zSzK3T5~ zM#|>g6*f^%!x8}xA4(z~CyiI!=>*pQuY*%Tv>Ns`UdxYei=?{L9Oy`JH_yrxw>wwX zA%xk$-PZ6%ik_R5?lJ%5N_J`gd}_t|_^`}eu&*8GVirGL=EdMwIjo3CafLEWf}N&#UxYa1zTy88i(Vw5gS2rP|2ccsvx7B1oUq3iZ<7#{ToXvd+GJ;+aUCP_eXFV2fj8%ot!Lgu)=0E zdj33xvqh}cC~ID9Ig^miy!%b)TdC=|!75h^9jJ%)bagFr{XMa(KB0-A_)TqFdg@pN zn1f51zGK7Yx=$w&U+Jud6R%5oG)biQ=8aZKj{ACETtyM*C&_nb?j}ub*yj;G%OXa| z$XbWre;?GHTwWYzS{zwI;gaXIAUnhQ>mowLxJWn|doC+NL`g_7!FWm(1`hsOV1^o( z_NiuKua|sf2x<*ImmD>qPD?AVJ+J$!@7oVST2`ws=i*%{9P}WqRu< zZB>nJw&_D9m$~HH)C?iaq`#g2A zUYlMM&n`%gD(w(FI59Q2b;X;nE_2^JS}hCdkHjqoxNgEv$c~W2psh!+2h^e=QSse! zv4LQFj=poQlH+WEr&TEg{8(yCQvezuenfT=Sq+y<`wUj&CFl&G1N#6Zb(*^I3UoNB zrifnzMp!6QHLoTUOp3)+E{dLtpI5tc0}tVPK$G)qOoJao)z^cA#>JrFFvJMjcEN<8 z^`Mj2$Gcsl1mdkB;9?t8j5hi5;}GB<9O8yPfLd`q_!T<8-|Ar;q%hdvg0Uy`Vvh6y ztHINhgEd}<8x^&r2^~?2ZnTekeW*UzTM6i=0rkXWB&>OUT;7Ba8^wT<$rIf6v3^J7 zxkt*#mIZ+kQJBc(nKP;`o*Ewc)jnvFXcEZRRsoSi7}`PN}t|58*s_dWG3IogS7ZmSXN{XrVq`WSlnj510*AQOu^I8d*P z9vb~4ImHAbl=Xg~rL8y4G-@{4A0)05q2C&u!!4*pQEd05-V1Ev;D+EhH=-4lc+yJ& zfQ!?cfoCHI6i%8lhmMU)1#IU;VK|rEUY}%3kT@^-cIe*zpL6dZ1}^_1t?;YAH2zD; z+~!lUn6t=-b?MO~`7iKDo~h1d`@K^=LEBcQ%d&Pvs`^Fh{!r6mFPCLV8`4}o=D+?E zT{W;3uSQMUHvN`V=2%i+oO4=<@ddr)GGGsx@MDGzKyw6|Z6Kh-CDhTc?9wqV+32JE z7U^SFR6g)b4$s#bJX5*Zgm$%+&%D}RYWl?KSxrIJ(ph37Q!rAJ*@Up~|09tS@BfTG z%*oS%B<>V<1qcKE?M{z1rT4d4L*Ukbg6p>I=%HO$?7b-lek$pYWI+eP;2$L-i;wQa z+x8LxHf~=ku_De62|+{Bm28|Jm>mP5x_`z-R0Y$lQb78s`HbO%8d3aORPxu5r@Lan z$2DcV;w3a0hsb`FwNZh_H=M?@V;1|ZbVgi z41kInmq}_Xfd=HC<6>DeP@cxLdM+vMC_WEj7AqFD0i#NYBxF8}oeM&Sp;-zl3yl)Q z&Bj51;`0;48R28&W#!TgxddVXl~Irkk5{`50t2)$4g3#?m1X7E9ZHSw>X<4~6wVbaxJJ1=l*jh)WOxb+ zlj;r-m-Vp8_lY;g`oME7MqSB*SPvVZ(IT9cyJ87#f!&-E6tf>#5(X-TI4650Oa2IO zCztX6^E?PfO5kPZbb)e<5RWVlCxxdn21c)kVa~MG1UUDCK|78m`=GY&bPLvC3z?f5 zTLnBxTwEl-4RZi1Nde2$0rh%d#LIK(u94&cKyIZx7w7H6EU=J~hf_w%ePBvX?=uR& z1Lt-$%-&Sw;5nQ+OOxf`|5+O zc)HCpNMGoB7@E+ob0Iz!>(>{kt%Aekl6>q;yh|7$Se$4f8h6{a^U@=lbSsanRx3wW z_^rnEjrIGsd{@4@z&<324ue^hax4#NKx)~UQUEFzk zYC~z<-dE@Iv!L<@L<0n9O+zfCkpdQ|@mMHE(E_pe{Ks~w?x@%^0WrBMIr;cT!{AZK zK1~(E&I7O3eyRb31tUF77Vi)7<1pHhU(-7cHvG)I6=O=ZQ{;nr>FYXP$ zfCMo~*Wg)~v=fqaUw>JA6pS_y-DB2gS`9CMB8fK7usF(8I#7qnNOeb1gL7FehHwP4On(@_{j z8?VcyW&xn|K+F7PbgfpT0pn?e^bLn7RN7AHJeRt~<6hA;Kyq!5(*u`mCq~hzfSQMm zc$|eSZbektsQHoeHOHK%fXCxCKB&{TvZyV8p|7X_KubeH>N_nw&j94oEeJ{EQWZPX zjmxhx_aqS8cHNRUxlA~3GJDXG{w`Y2x6|a{VIw0S)5h%z)>);?>4H(rP^b~g5%lLy zv<6R{2eGX{f%hNt3p83gN_#4L5A=om#u6hzKw5zYyJrrx+q;CNKj#2*wJIHxRsxVR zUT1Pjp4tdg**VUt?XlzH&XpxXmQ)%1PAykDfeVAD%tkc$wGxhH+h}B+#50(i_Dmt> z9r9EQCNta`focdqsCeX_kiL=#Zwnbn-k=vGP1q++XAajf#gw{PH8UU3i$GXBMfGOYLpB#yqH~2-wcZV0U%OC?}HTD_@Za_g{zw=8z7*L(^e9P;HnV#Js z|MSM6R1`tl$#Dkb>9mBLZ}8AlBVNUWT;IMfVE9wN4s`Hz85eZ}$&&CbM$?Zurs7E; zl4Yy+U15wp33+kO^S=Qtv*_%fW6ZYFrnC1>+)3OthHxX*!d>#ct4_H{(Pk^VpdD9B zM#2k|_N)8f?dgyADiwk7{FTSu=l!#O5j_!+@1CqUD`H#+TP_x|axUU`W7dG62kxvuxs$n6uU zKYvfV_@&=B&`7HVt#%F6TF20*`c|z0M5>6?A0qT3y0!d{LfjZpNed95PcDK-@nGW4 z8Yn^!0rdg0NvB0+`tn5^>b}maGjPBXR?SP?=OExGtA+KbR` z?f-N5ft9Eep;)MgcUzAp0kdyZ%Q^$c1A|}L6u#n4m6m$jKQDBQOmjPQ{pHl=@oG#H zYr?&DB>0oG?0K#9Z~JI1HUez6kP4Az5`L?2BH9~^L4P?? zpNqg7WIP1Z5nxEcBlJ-5#EIY?1na9>^Dcv&kJT3xG!CDo?MQmxE4}sCulre#&;9;; ze!V)EAYw0TJeGa+c|=U!a(?02jT#rxi+VWUBc<%ZnQHJEnNYd)GHeQm+(?<_Z`-7e z1Y})j<|?WUM9<55&9DE3%KRD^fuOtfIf$*)&&@7-%utnC@10K=XsIcn9|8(8@(n4^6_FYPI212ImE| zS1Q*NxbZnsEC4=J$Ogb`oo08U1|1S(?v&lq7wBdH_CCUl9x{i|sFDViln`yHs++fM z+g&3iw&v%*0sZTJd}#9rt8ia5A31)hC1+`3oa4Le@d!QN$I=>*7*sK}d2F9dymLTt z^ib`N5bZ+U|F#>()L*M+I=Q`Xc3Z3N)F-WIPipniLx+!J^oc3I4W!G!cmF^iPo*WS zj9rw>#6Zia39?egS;zHX*ECCdsg$kuH$p{G~D3plsGWM%MxMiPEZO1B<*BNV1J1T#EU8L38ZF@jRL^cs{0xc zMBqCSgi6bXfjiX)Ko)puF^oNU=5BH0hao8t%EE2%)o0|W(p+-1lqGllbfnOl29zq{ zI)D%)$En3mOO#%!T&duv3ifovcD!o%3|ak!e>d$M8+k-;NQS#ZR@OMI6NEhIi|&bM zg0)T8i#tEcaF<=f`S7tmhnQNAHJb``8eow8Q5m!Oi*F?_g|0D&N*@Lv4v+C{NqqP0 z^+QE}9f>`bp*_ak@X|~ZZ%&{wr`XiE(1{5;8zf>b7vnYL-CjTGRkehu% zPrdch+|dalNP)DrQQa6Z1z~W2Ep66ua2u^bQj4brGhElH-g^8a#f|O*QUuMt$U3L5*7)|o zHKy%4clu~qM<3w{we8GRe~@Z5_j4E~i9?5G3>;XfH_Ev&V@(9s6i)oBLt6tNP!hEA zou6H!*SCYf!{_lw`j7V%pVn{j^B=F6^v?^@XjpkYJyXM0pVBLfo$qP1D{JLqmA0bs z@Qv90VV|wfe@pf3)Sfwc$(RRMPfWJ({r4wuJwAU*g~v!kwPVx#&w)Eh#G+#Fv=N<~ zwfoOzp#e%TrVSoN9k!ml@Un4PK80X>R%^Zsgv-S%%4acRGyB>y-sW7bLgB;qGa1A^ zF7n}q^t;DbeA2X4+_?!++ex9@qG-Rm2NWbkRj~(}=+CK8cECbq6KQ=E?O)8=VBaSE zEQcBa2J}nnUAzK=!#l}@IbvBA7B1WLKb;?)*4(;i?gs-iAWtARB}BL>(Q?81^r8fs z-X&_T;a;oV<~zmaKhH%j`-U7c^pFjkGsSX!CdNn&mnWk@pbSME+97>q_38JBhya#6 z`oytk^~-#JE`|p^q>PavNyxbV(>8`JQ|z57Ub62NviA4R3$6mck?ciVzOQt_=82~M zBQ+z2%OUzK2i#qg7A$FC-uCXWCwGv9aH$o3y^A?`N`E{BYsZDX9> zSf!7a$4#isp{s-xxIzbbcZS0HpIr&{?ctuMqzb3vrDci_rKY>=0 zHd@(&X&xYfz(m3;eoKW?duXWs+{ug9gUg4&ghkW^(|Sj%FY_ zyrF1ug)4bqRUCt62P7?~WaVKLQ_p{sRolILLJJ64^cl`ma6M-%)Hj8K9gPLTkLu+2 zHS%7Qq#Z&%u(%i&N0q>tI67HpawTd;tG{odFIZo6QM}8aOW9+g)pYd9YS3?d9l1sr z+w9X#ywQc0TH5S1J7)NJ-59Ml%mdQv-XXlC6_l_j{a(Bb9GIhhz)V&Mn0F&NdNw)L zVOS$Tod;p%VmypZ?VZqQM)h(vf;8g9kCld()aL`dOXlJ<@J2$B+8QO0T8q0wOI;zL z5}6b!iEw$9#+~ar3G$@PJAa*oPgR0}W>b<@4!RHYQ2w~2oj#{hXPrJt8%<&m2ccr3 z`_?mBlL)1SOl&vH`26W#Pj?aoy0^J~|?W!^N+SHquSd2kSm6|GJd=*6}Y*IiM+7?f5=1 z^r1ex3PThJd-!yWiwLMLzL!Tq5pAQEJ@|3O3CS5ouX@xyun-6$;&Xogx=%n3huO#NlA-h~z_ zl>XBg_YbwLkA~o2crk!ok%2)7m>SWj}Y2i>+V}Qw~0e zD+qQg(wEz|Hi(ln`P??U(H@1TcT)Dbe-Z1M z$2=;e-rcAvkRIIM@Zds0*p-`vH_fi-BI)yJ>e zu=bNl4GhY;}=}RmB&>n1|3@F^+IQCNyrANL7?q9IZu5J4d=qOhM7}yhuK_r{y z0EaI~7~3Sl>RmKTYbQh=R?8+~rvcmzcQY(+DRA~^tw(nsSYp7SB}i*kO1`G;ek+Ys z^IR}iSs$cEm=@}AUaYyqHc-O|`)CuwVL)%0yigC9p)`Xi)!2Q2NTH7&*Q6k|26t(2 zJ2csXA3*EMyGksKM+xMih5DZ(+1F!!aTlIB^{27<2KaU5_%rHRQtrZZ(h~}sKsJU` zh%1{gDmHU24OKZfhz0+nJxqN(xD9cn#lg^sQ&!fUzWx-67-4L#d^)b*1(gBI4S0{4 zzU}EGv#_IO&ayrdgHBV1C)v#e$pAbyt=_P=sxRD^&scBjlB?ur;b*}XG&(w~Y0jtXWW2(Dt90>>4O3kL_bC4L47`5fy0cFHYD zTQF+QLTWAJrjCe1o~ei_{@Ns%i73SgUUT(ZnA|$X4J?2+?;{gPxT1B`%^M) z6vH13teu<|`WMqgo^42#T5fQcjWzUGpT^eAUR5E8*(sF|;4$ZGF~VO8ncq0H#-U17 zwSH@a3h=_A5fyKL?!7i7B))ae}al>mFkk%#TBRXst)IE&(C8gjn+Pj)&lu$ zVr1xjf-r&qPTQ35&iPi@^$==lJ9Xq?tM!MOk<`=2Npkk`Kc2U(CA-LazgsA{5-`zp zjl{YjAO*yMRC{wPa9rd{LSg~cTsd*-jv4*3E7}p>V{@l!JGTWU4y43vK3KT3QeRs9 z+B=MXSLp z_FwpZGHuLRCI~_Fg(DNUwycPP56^HpiRqb}k3A>~EAIF9%dY?H4Cxj?fAxR{yLT_F z+^eraObKE4F=h9?QH^4dm9XOL(b}%o6~$*ApVw&qD7BnjhbZ8l8NJB98rQoPcbYn~ zxiMr~wfQr{o^yPG$Mloj={S-hrP%Z>>ihH}X=}aO1nWWh421|IZ15WtvPB2$CtsWXgESe{oevBv5m^Ud%rMxJJp?w)LA2;^Q8cs&3`KTfB-z*@{s#hWI>k}I-17up|_q1~V9|Wt| z(*nkV1w(qX+XP7%tf_o@cN1icGQ%s{wm5cxH> zQwEx7;Uj7U?3IzKnodJh^-gbij#1E`Qpk9_8S+ZW9e{s195t-N%F6U;w||?j7^7wE z0T~}M%n5p@c?GUfQ{1?lRlMR!;9rbQiA;J~!8K(eKU#!;ap)$Wn{paRUSKOSuiEgE zVbUc#bcI$W9dL&Wp!&b2HmOv7IG2937tN5u@d#5r09InpV|$)a@K1<2mQA=79Xl4x-p5jnf=%9^?*jSsfS)?P zts)^)271s9j|1Ro-7!81$J22x*hw>Lu2~$kK(h_4kh!Tqt)&38J+99a7q{aR+c)?TcHs_G?B5U zCc{HiY?W=gtlsuts_e0pi=PHcr-NbIR;JG=vh4xh=ZYJ=p*s?sT#r{56_2ESso&tO z0*$18;-1lyTKgXmc&(L>fk*nm7?a(E&eRSWoV_Hmn>Fw|8^LNs=Lzo)iPq82dOKte z)6opSl8M@1P2j;~ zY5COie~%QJvacUJ+eBKm1%8L#+qV%xE`-*OlId^He)H_QPx_9((G5TB+F?9UbA8Ke zE%gEK;*0k+NAun}vg_BFJ!kpx@&_y`q7R3OPvo6RcoO%PG5|nLZ>87tnNh^KP2C}d z^&y^MH2kl_>c#A)Bk>Mh4lyO!AJFI%Xh(r97g~J*#=TAvCXmSOfL5}5h8v;DI&Otb zF8*NqifJ&D@gSnxL-Q>DclU|j7mGIHOwafY+1ID804{CoY|^~XRFby14!aeItnmX3 zOYDQgm}->(7yi!AQVfb_SPnE4KC00Uo(BJM$czh0@safC7v=%b=P?mXE2nf(Fw zqP^m5y}q3l0aDVQ&4#cWzzc`Kq7456hxoWyD`ZXm67Ekm5laa0-F*HjHcS4|K9i1t)TM<%vVLjV%JLvva-dk+kS(1}I~~e}^xSVnKv%_iaaQ2))C!gi2=q zp(^W3Axw*}|4t85-8E$HHm|N$W9T$T#DD@4Mc&sJ2N}XYfz8YZtR>* zycc*Fs#5 z*B_OMgT9sK%rZk-dE5dL6k8&%?RC0MSYCEU<#tIAZKsaN1X<9eWvxL{#?QJ^ zwhX11FqF_Lp?NlLbr*F^Yt?xcHo$+o;GKs2dXlbv<07wX=c zcRQ2Okp1aDF-~?)^udN7_J_TyoVd2TA^TQ6B>(Wl`)8rBq_B4+2h9NTy?XZ)a%iPU_uNtAXFD&K%HeUg(4{S`fEMq&+#xFb@pZD)ZL} z0)t~0B!h$dI|Ef@Ej3@(W5)c&Ou>(-b6vu z+Z~OkX+G(W%FzH3HK3+Ag53eBh0&r+qUT<}HA_UsE1uNY=5qQC!v~?N0vS2E%#bsYVZ8)y!+ZJgr=Ga3DQCuyFFd;nT$O!`3G3mR}Uouf@lf zMFDym>i%~j_SIxdIAq^`GRUXrZDYi@$I4d4^{rL1qKABz+VGtpleIP9VU-#~mKl>b z25Z_oiCMa*7-NfzZr-@apxr@p%CrgVNw~pl#L?;sylLabUi*ZlOR+h_JFoaOGo>pA z&vdV12Ul&nq|S9sUK@qDj!0Myx0&au2=8jd$R~_WC@GPK^x^@! zVPq%%j1FOaI|RZi>@Q^8lBrF4Ds)E%CeuAufO*|XWwWHwqUSMle3v4Z%(Rk4o9Btn zK$wIp<2aLM)cF871Ih{BO1t$^ycr?rh97%kJ7ZJo^)$-0k;AozG?}|$gj!c-@Z(D?(8lYYHOg_(4@ZYaYOR6o(fTi1);xUS8RoJb z>?fhAJ>etHlx-!%q4taFFTivnMzSVN%R+yDVSRt&Pl~jWtlEq`3d%wyv!vI~1IJ{u zoidx$J4U;rrFfrAqRpJCE+!T>+~@BG!&dKSm}Q)V-=4Z?{`kStvG&s+uJ{PB=d*gI z`G2aLxqtRFtP7}Ly9Loo*2lkg+Ortw+QeUI*H_)UKF`e$ry_z`Q^}3iz>@Ba8}<&C z0P-{~)PJ9sxmqYS8&bUdbJv5b;BntT(BKLZ+h-^w88`>HYh20Yqi`zHW>L0S-!U z7nS~JQa^a|UdotkL0R`YiU2UzE*{pserf3$ui|oNH>~g~0Br<%4wd~>dMLhw21em8 zW3-6@&4^xWcz3{%7aJhHH|&+DxbdwER$a-2mOVX?$CzbfBNNFjt5cIo!GlE((uCuq zWd?V&TOAJD`#L3&>5lU0q)gP7$6nP!vCUUh_JD;O)%_IwvtsKw;CiaR7uif2a!w6Wt9mc`K)Q(Y1fkafcV`ucBOMC{8z&{oiPRZAscVu0 znoXG_>MGCAPHM9MSmbvhh<{N2-O{t{%TG@p&25XveLA#1kK57Hv;J_hCtfAScQ6`v zJn5JHT?aZ z9}>`d_DssgH=j&2zVza;$#}EPrz;l)qSXhUk1bn*tkfO@%vcTp(qdm`%lMv~|DH;k zr%qb9Fda{5M2?Gg0l_J88BX?ucS0eOxNlw9bH+LX`vE#xYuB=F9((^;&Uo5JABU%?dwwLC<2o<=;+!4tEpv#YoQVWwA7SIwuW1mnh zsrm`@YJf$eF+8^w(~f})q>%|q>5kpt_t9J#GFolRgFd}ANxL?%wT7rK_@1$rO|ioP zQdwUVsFYcXov3c2_STywRA_V_BV=>H!ukA&&8L!>&Q_0oyw)HcB~Had5XEzPD6V?b zk4OWo;wt_Kbj4dx8pl$q(pNyInR4`WPFCN;auF_^VErDc z|ET()3A6lG9yO)6XY_Q-k@OmhJEIR7_Dzw?&WZ1^X$?@81(JknUYHX0T-tvHH~M4f zr-wiB&EQo%VXxUc{MGGS|NPsMbWmMyyd8R6RVBukMr8~M^SP*|bnoA_T{TNN)EG$< zf!?iH6_~_|P-E(Vq`z2i5F@UCUOZY&CaNR5gQ|_Dl)#Q3SgwH~UU~eO}EEeZbJ*LE>&RtEAopw(5#ZU>Vpw&11l)7>lNDU6E?BLB^GqfRhqkrA~?D z(rN7=53%8}dBk1%c&|w7mAMP2p+G~ z4rNyv<`M@7kvV^XEoIR0i{|&;IzZL5?~vLvQX}3YDwR*M51MqYp+bh4U_w2s*U^cN zqjIN(L|PmlRI(nS^l^_8R&!!&t%$cQ3TSGR-*Vpxwioxbx$u?UwBKKXltH^I1%$AS zr(`@&XqKNfMl|O3bhn_YyLrji)NBeKuo;1(2aTPVVl!Uf7?dTIX^LieaU^$WO{6NR zpC#o)s(AS^^L&^8giDuwx6DwEw)x@VTYXUAK)S&8y+qW^N6WaeJEI*tvN&!`^$*)z z3MULz`RHgxT2KAay=j`W=Ps4qX%22#`bo(*M%LMN2?u07*6+SwzWJkr3w?oyJtaFf z*P3zdd6)N%(I=`R@zcY)<)0>viy7#Hx`0SwF!1#_`&On3diz$Dz_>3o3k_`;eB&Ij z8EQsV-c|j1Y1=fu+}3`Nz^g_oBDa95S+`&{w-SeJp5QG~5pRr47A7+tGpLp&2WNWC z%a?C-Rczj!)np$%KlYw;?FzPe{6LVd8{N}mdr!OpCxPpV&GzFA_}-OCnsTgteN$is z*xU6{M|DdRP`-LEW>#5uJlnt5^j~Qv7e$i{I`?Fcs*Zr5_2bO00@oNdd+paALV^jv zCAhBZ(|3^^iy#FX1GOjhMI6GwBc5`8?Y_&E=}=9k_R34k%;uo|-^o9`q)7?4*9R<^ zft1pSN-yiAj%u-HU~f%^C+sko9b!as0K|b7Esv#CkS#qQ!HEMIlf4d+clm2)l7)=a z%e7Kv0K+=2U!&M=fJ|tOd+LG(^3{vj(|nf!IA7tuYwM8Nn|g@hPi@cbh09-dLY(o% zPL6>4staoPgK#(k9pkL=w4S~M3eG#a*B^{g5{I^%XNFIz^iVD_C1HKtRB8<5vDv=0 zw65xv_1lm|U_wtvEO}YUuzYfP>RX!{Kfm1s<(&PwTlJHvll1kX*h~rDD26b%8OhgbBTlSt%R4)BNqb z#2@B`A-f@W>7n0``v2TjcPl<;@tiYrJnQTaKNZ_#9~}ZPF~d-kuY}%kuV{?*W-~Ts zTvTRoWQ*K0-*r#g;q|-YXml1R-njC@a!>0i1+|Lz`dQQ`qyc(;qZ!2I!33XC#qP?N zB0}asT)A~g7nkVBArAg$Ph7O*2cS8E@QIqWusvbAk4n<4ys8`b%b5H=eHAjRjFVqt zCL2;B_RlB%3D61t)bEmmYQF~cu)u{zd?r|x?}gO)=wu7#S$z@5gEj^t;T_|t&UOlZ zDhYsv^BJ@pts+(Pw%ZbQlywk_Ia&;0$kzEghGgOa8VNp7QKobwKeLuO;isp5WMdT~ zxp3NUW`F`J0%3r+b3cdr6%RXhM+tiirJvlXV$)`Tw>jdhNi(jFGaShi-*tcId)h5@ z1dz{wkhnjE+s(`HXhThNH+Uw8>J}^=L|~@aRLC4e#Y!|H-1DS!VU?g(Z^zfo3lraH zvW(FVZFB&5Mf!-%t`&+b>%**E&$)R&gT4M3@*F8bn>SP-ik+I+K)Y>U&hm95prmrgQAEnol}FMg1^0^U zWc>J_T*qkFZu&QZ%&$vUF5+U{q+TbQ>E>;9-F!W;;g(@sCJd?Og(vb>MSN2&>;lBn zvG(|2-}|*oXEAySabb$@V#GE^bWtHv$h=4!w#H7}uKcsj8t8~+G%$8G@!5a&^dZ`t%rDh#H6FCmfvl3O?>g?4^T4v^u1-T7V2A) zX**6qo$Ry8O`l%1V?Ede7j=I8{lm2*2X<#{%pn^_HG9Qs@F(cE@sh9!CZGGDlIuAe z1MmA&iJ6WAeTHn(AaZ^>kvORre&x;pO-j_;6M98{?#wLPlO>NMH<3tMg*qkfvGkC1 zJXKo>hW{NY^$g6jIvoG63j&O4I+3rYlU-5*V=_fAIwmwD&nVN?pke?|upae-M>*6h zJ^(3h%l4h+Vh37WGUfMmh+Yt7`YBSlxi9#ir!is#y~{O}3Z(jA5cehdVF6+2l`sal zI=dfok`I6x%;a%p?jPxuBHGDAG@FYPZ`!W?cSuQGw9v}dEJc)uqK@yZY zp!jSTZ)eGrFhwz;bB8Rp?>=wqTqEeQK@+MY?kn^X&*Jq5V;{&id~(yW_4ifkL%&3| z<0MbsS`Iz^toEgK6P_`$Qc?9V+uldQH?}VOJ(#Gj`Y1@5I3@%)U|03SOb zjU0eWJJ*StE-l-Z1_v~sZ+}eU(v&)4RQjoiOAJtwEFz;-zAwh~xeTWBrc1s&N#lpE zEb8NMl6eP8h|Zs0!WCOU$8R9?qER2AM@kyUTA+}Sz^=TmxQ3s={#HfrB&{sXrK8ka zOHcO8d1DArBK2jIap)mv0>Cvg>d6E%sDWVp$i+~B%<7Z+vXAbqNQsChI(x@lfVsky z!*pbln0`V*%-z9gITw37q7S7mA*5&GO>VGb(V9a$n~P8sPyk!;WhH#AN`N2}`T{#< zHW(J`T0u7nzcgYh^};0WpIc0DEJMFhcG6lKJ`asT9`Ac$+Wu;XdoB&s7tf~3TtgY- zsnvH3*g9pFW=4GqZJt*ge%=V?jUiEH5lnOKD1goa3j31|QKU`Zxw_Vnrm@svatN6K}U5QjHy4H=W6(jCTG9}MVXq{^$*%-;g z=je+fLG4fJ(Q83w5@o8xGMk!2>562#XN(^HKM1Tihk(&om+RyEbmyzOAn30)+j3M{ zG9X1gCA|b)4oTdquI=cexC;czbd5wKUgCWKt|d$j zTRIj@8@qK8>_Y=AYS>p~ZC#b>vB=; z0bpuyBUd}ysU*+!?pWY`EFYHuFGn825fd^fNUwfi_ zI!vz5|IL_Cw$2E?-paY!$b7wdp==3wx6-^fytqbq@IbFJZJ1fC|03~aL2S)?J~!LW zj70Us{7|n}UFuvdu5vWTxp=M*`y%YZU*O!!zQHw7ek)wr#5!&a^Lg{rsQF`*S8b-+ zC2-NSHs&G#R{}N>tkO)>CNq$RWB@J;6cYNz>aV!6d<*s%^6vGju%atyN!pP;s^Uba;au7^=y9n zw>1ZTRx6lFamR$t88=~wYlJ|r zZ!nzWsCiEDb|mt=Sd>XiXq+j_J%9A160~fZ+!E6{v_CSVorlAr{9Go`TA*=9X@rW4 z_UViHTQ_gc~S*{s|iRwMO2lD|eYGD$bXPyC9Y0oVyf zNIGrhWj(}yt=w8MjkZqR=#w3W{a$3PofCOKrc)u&8dO}o~K#3x#|9A%>s6V~k^ zBWXdXUt}g^Wb4pLG(f;XGC_zKn!2yQy(=$Y1bVSC>6x71m*5)g9#4AgvElhr5ZzIJ zA6kInRT6-gh2+dHfM(f{%kD=~Z0ibIXhl+dj% z@8!%d1^(K@Ud*u|t27)4sC%~Aft%qDCVkth1j_r@s<@B(rvH0FU#UuoL`p}|A2^Yg zb=T%?GC1+~VoO-!+Wd{CG5BWXFYr^>)Xu=zKeDf4r<4Ao2ycU3f5s$>YJRbBE-*6r z`LYTb8~!?&Fj2E`?i;9!`b&22_?+-zmUXYVX5SU{iJ3z?8eipxUy5UYRLPXk&i-6+ zeA~jf^U6=D^C%F^_uD37J$7iujA7&7`n>y#{yhG5%JN9>rEAb^bKsBFVgm+|+``Wc zVqUQ1QyW+UmtAkex{nR`Kl;cWu*edwb{3oBkcrC* ztK27t^+72S+Lq9(@Ax-nVEG@vImaEgEu+&3GeR78^c&5N3*w&ValJqpl9@DUVjV$^a_> zG9Kg!20|d_7ha6GGI*LV(_-KZ$svz!#o?jGDV{d2F_~8Wp^F3Yfattk1eC4{ z25~&?#AMm#=RiC-3)ZPIDB43!3g)-Ys1QFi51q&>{pimNqu+UQ_BxC;=h4OYe!-uM zXcSj>#^g?`^B*BhZe`jNHlHeeC7vnnm=Phh9*hdvN@|QS+LjUUv|4w}KIeSZ za6Q_{n!;iOn$PGl3PguFqHp-5Qov9KuO;+M@iE~q8eY3sGYcC&nUy88LuS+k&!dMj zC!3fcH(NcxLq{e=0l$-MN+*pGX+ezLo83u6%GKK+DDs)3$Ddiz9U$)jJPRG)*~8^J z>Ae^S4zz8wM>~9t)Q{%+!hhztlDq-a?&1`CTF(Z(HAm&VWLgR$>HcxTEKddmfJ%JB zMPbMbGl8i`2jW3zu~kj8eYD41`c&$DKb$4*Is4?#BWt;6WYW|oP#u!L zKH6u~CD<;Wxo>d55XDQyb_6c3pG;qkrH&>V>+sXcsf~^Tc=&78`25Gw+ z`N4OfyVACpww1i##WR3Z!zMPg{YO% zI|CM=WdpQlXlnVGW!0FGdg#+z2RQqul0$3rOTb3TYd{7B-=x0>S76}q_oBI)^n>6L z^5LFrIWIhti#-PPHwr6Etmbbh^pi*{$cTlTP^t;-G8UsG#4iH(+7L3=ZgAJE1Sit zMN_6aqF;(7$Wt%# z6Xo38?5~O}kdH$Td)AC_@tvgL-N99ky6u#^3+MLlO%ozU)X=g^IA=F}9U=XzwGltp zL%S7|2lZ1Q3&`87#I2gL*lYtvaR1J= z_5pY_Ukcc|y!^bwy&ewTQ6Ng5W|&_zjFH=HFZz%Wn>Gq`t_-nq(Ui5vGSH5$h7mt_ z5p4NVn?E&yjTlpbV!VH0-)v!OY?%W8kAP?l6mEdii98izLvqAcbP_OE+baWzX-GB{@6YrKt-hD3MpmJRPaMV@8A*@FPcl-71 zg~s8v!av>(*Sokl3GIyx(5oGz?3V+;@1jXZt$ped?mt`#Y~uz|rs)q8ZQIZx^mEMH_KamMg`U8m&us@Yp@UZ#yPzii} z{Ut{Y_}go|kb3(|8nm2t@+$4c7HQ_#bS;rmV z6>%7J(*`%Mc;Q`zlT8?LEUxbdQD^a*j#q0}!Oy7fpchf%JACY8?!@UoL&QkeNf`R) z4aao}g(alAmok>UQ`7O|pDmD(kW3n6vmVEm9v%ZsW1xk!M~jQeK{XNv$ep64ZujEl z>?t-j%_w!B*UK_(`l7gQK;4k;@DzkC^tmFe#P10vw{^%!{`%F){YDLzIQS-a39h#@ z;P2@~7Vxc2^B!)Ksf%}L6C#-fxzqP+4>F%|64*DE?a;ak2GaL%_o3$wH}vctlqxB%w!uwR4`AFA*T;~LKdXoK7smfMdR zuB}%qR0B;Ap8@;jEq$kI_*>nQA#gKy5^TFi0K6tR7^U`<36UCib_9aytFFa4-C)z{ zt17ijj~D~3)~SPokZky9jj&`9!x^7(04G=K+O{;1(Mrs}>rbM|QHfU6I2|5HUN#qt7}{4laUF!f#v_wcDl8 z`m#S4f0JO9I9r&f({o6#C%%E|o4DZ#2?m3E6`&g<*HA%8h4G45UdDF6_LDSxzf_2| z&dst{>=WJ4$hrB7A?SV?y`g`9o+vR-GYBF4AI++_%0MxPI+G48O@k$7kSu^sO@S&F zJqJ)eaS4%Ai7l)0DUVnc{|CK8dsYtv_1lZN{TuAoQ&cyze|Rn(sd8ITpKI*#oO}wc<|#4n);I?8*m}(4+ zTcmk=KrWgaM^d>6+Czi*zpYNB8n070Dc)Do_Hskb^~hS}dDoa0qR3aD>3?=PbEr8} zk>ZjYF>EMEh#(a*^;;82 z;KA^bT)i%!`3Y{R;>MpAC|nKMZ9X&nkpI@Jk!7k)H!TQy?=n&<7_2IZj+sgQ%D-6D zB_lboJpO)%fik#-yNo?gHT zeQHM^ZDB-&+^dH^9G}pEJ@-hl`K1|gnKi{7$lKK(V{Eksk>A~0SeMl0!M&#O;Wj{{ zx~Gg1JUF~lf^qS&HWT`o4Wa5=<;GmFfVw-gufy=oB|U~G0-DkDuiU@jV5bD+i;ao* zMkaLdz5HAC!R;UGnbz0mG)C#&&uja)AkAd;`Fi3ID9g=2k5_juBmHNUre3?760voe zY<4prz|*%3$*STTfdq4`Am0JH(e`S%U5XPfv`4EW)S@I9DlHp64zi^X zJ8p)^c9nYqjak3=ruAOewJxv?YiywKxO3{W3Hu#!a7VNapUJsJ`kVlUtx(uQYq3WzhG6r)^F4H{h zY?5}U+5UxJ?xbD>>@)^oY@s&$vR!~C#E~xXF{Bg#IEWLr?^0~7fvEc%ylXs@X-_dO z;=N9YxnQoxPw}WYDpeXI_Rdnf0bsjA4CW7hM;~)s+w22UT^*g6fSOTC*Iu!YPX^F{ z-lUZmt@RmMwANy;7s1)8vcE;d8>MJLIE)gI+>4%g@wV+4gl1I$w{SW=MfE@DPZT_i zSW*qRGYI{uN>oraj6LEadfJ`-p&htnUN6G->Y}G|Hd73}Fn@V_RONXeBW4E^Fh_Wr zjkj$sOYYZxB)Vre-!oD>BL^Mf-FXlS(NSOAFTGM&PdIZe#M3K%7gC3e5&xu*+vXAa z#2xRqi$y`k^?}<04(Jii*2>IGea^R_B(LMLc&=IxoljMgTbS$qn7U)8^_{HbWrqFq z@E=O-RecJnhf(+0O*P+jI;n5{U%|BdR{%7(XoOAx_LrysP?n&UCd1Fdsr6M=$pG(v zuz(6g@5U8(l=L$rC^E=4;4{VfF@qi``~mT>!OLIHW77uR4SvXu(!HW{Fnw*%B|L4N z*Ea6^Oz+>6VVAGR8?r1Qq`C?*p$r>o3JWN14EY8EH!WRMM#`G28t02_MOxgPvCHfQ z?#Lq}Sv3m{y&w$oSI8o*!UZQ6+|y!cuK}iTL!%|O)#};Wi1xyp?XkyJl-)UfzpMwY z;8b3uz23lTn4V#Kxr~BW0#p22jV8lC4?SoC&VP9TRrO;JNIgR-$jN}AClmGEEcpgQ z&RP<4(gA!JqBxT`1;Lv7t{~dkMk{yE?852ugJYX-bS%I-LBreEQd^MT3^+TqjI2T! zQLT?jL6@LwJ+io+B%1_mg4(G#=uXL~nLKCp9pL3p#d|lKURd8akHfl(iygCZyYld- zt~fmf>mm;K_A&M&OiDD@l2K%m9B0`4G8b**WA}BqN76qV+vgKwYY=T*X|jLb8o9&7 zmfbH^WL34{&FmyocG-PkD+QvG7>X^`$%MdM2uT8{HUBP@ix91#$#*PZL7CGOgNI$a zw9T`5{E@0n2HYN7zGVL!$K=Yx0J$Oshv6O1^?qWFc>mOzNd5-ZCa%ZoP^E8K0=gyz z89=Qh>$h0dXi#Ooe~J^Kj=!m5S3L8G(Kg==Fr@&aJ5~_MpglcvvUybLDTu)X@2{Ni z@`1oYGdQ3#-)dy~EQC|<@ouP`jWFXoKXBRm2Xq4VtyWUOa5%GQa(zp;R+m)?`@#)s z-ryOw5B)eSt-SS~zzLfRGF-A8dCk>7Y|6Do%8E2+M^Z{18 zG_J?=i~%ITk=Zo2*j+@ zsoxI3e~kyo*w=dl7V0V;x&Y3e;ah))|HFkzT!6AEG=ooEL$M~d#`yRz8hWt;Q8pW{S63iM?F08 zV&cT*TPf(VDn6bz$sDuLGWX|kJRAo{D|+!3;_f==v2bWly?z@AQ)_OG9@C=pVuAb| z+q_-NlFFtwKm?Q?n0&{a>YM{L;r>-e6wqX-KG)@?8TB=NqMk9WFJZvHm*#ro5J_Di zTR_XwLp}ZtWQS_8{+S6iXIqM#&_U6_{+ZAf)kGOnV;W6W26q=U=&UjUSfh;X`C7cB zu#f)6=>d^qL5TchG7;xQB!YOcQA&X<-M}(|=nFJKATfR?5_s&NOVM6DDhN!LUx%H* z=6LUsO?J3j9yb*?)kmwo^NsrIKaWLMvh-MFsQ?(NDFjvnaE=s@h!M3ftokji#uM}j zrC%~_Bn~!I&xkU!R6ZliZ8%?zi0CN*7&*kayJ7QJ5r&}w!ZxQm;Zg@U3ix}L%OY&s zwD`+lt;tzBrb_7CRxUf-{NVkeA=92S53_u{F(k1%JIx?Zcu%$b*A!r{dF$C+lab|$ zX^DYw;(~-#(z_eJ9N2N=FI=j@Q7TKY=X@L4$C=wnm=P0IoP6*K+LAW&|4h9HRFdx> z_YW@I6ZZ%=xN_ju!mZ>4O>^Z|%-q{FT&d(1bEc@^C^a>AS?*D8&C1kVIWp56?eW~- z|NnQ+^KcGuAK={F2QIj;>+^ZPU+<;Txv=?0@RWAeqO%;vOLm+BZlRNz0Ho4Y#>;M3 znN^M~g)#*sa&}%2tm$+Wc zd?dpN<$0Mv7OFSfa$+V#Rl-fgN~{`=ttiw|=Odv!`Dglc;I2tY(PWxLR6oG^)7xDp zdiR#n1E$1x4GAlO#2r9@$EZ^3wt#3o)q(y~gBUr%)1Or;3 zP&ktAj56bV3Pj-Xos(ypAOPAx2y5$Eake$KWlp9#)?UQ_TD+dNg<&B!VKrt-HAfnH2jtr% zI<{dVUU21grnM;P=NWk%qKk8?gU*$QR}V=V0NOfqtlNS(jM`G?7?Exn2k3Xpu|3o9 zesRK8a7~j$^7cCRN!+~B4?lj+&e%mlFfJMN3)@YDr3xVULP@M=L_o3u$SjL!P6_C7 zP(+q(bJ)$$1lGVBABffSSS?1^7t8 z69*F0?tVIxe0CA6^%@l$UN@6q^1D2F#D1OQaNGfb8 z`wWBOYX?B5`>3Q$8v}byAAkvh0vFS2SXftsH zq!0{r*z=5}H70;FKz93`f;GI}f1y&SYJ9g3FlH%$Xp%jxiu@6=y3YbqOaj<^G{0tJ z_{kGnJtWUIh`%dpvpA%}f?D^dwdnAdDfOO16cAQQ%!zfAuBw4$BOou2fQl^j6KgFu zz{4YQClQQc6NWFVOeut{6-X>}1AGR+>J*D@f%lKXyIE?5&gd$lzt*1ZF5Sf!N_d4I zS-dON8$&D5%qwh6?AuN2H5hOznT=|NnS(?SLshDLGaDGhW??_>U`jIq$cYx$#r2#6 zU40NkeMmeJa9uOf3o!928hgs5yAn5t0;oz`o#28f# zjZZ~v2x@4F2n53Y@q-9kfJuNnB{+b!Jve3x_S2e|y;9FK)@#0C#Q2lm0FX2vS$7<* z%9*5fYPp?vWDXGlV2x83yXs=Kf%?HG<}e!(ErF0r#7sRba4-g3d6uh*HrW=Y047UY z$fsCk-|8^YVgk}cO{E=$%sRZXlo^s4hGO~4>POzg{Yr4f(Q5~*n1*VOP%}nT0LkS_ zh02sv*nBd9Rw;c9uRYHiHl^(cge8mt+H$ME;VVA(`vH_vire{4xuOwrzL|a|)*h@m zjbMwlr(wrE$C`Uu0VuX$i3JDNKKO2?0M&L)UjJr(9>ZtcZ))0Ef4^-YwObJmw5XxMa0A{03*DICh?Q8M(ijrzQacyG<=^AO2n6q2 zTq1(-J4FN~J(8ZOX?5=U*V>dJ9j;P{WqZYU%KC{B6>}w^-#EPjP-eP-PnlP&^iMQp z44Kvhy0cxexQ?L1#rfPHrP-=Pr+0oV(5$8TkFAkdfg9o*fdfdIo*lBebGh4m2wD^P zJ!|7r2$p?&HGRB5y0fH$-+{S4;5(ef0mA+oK(nn3p8~=5rxaLm47#*5c$Er2;S^xz z6hRrUd1eHn7XCHw30ckztNdUbn~X}8UMTg6sf%9$!tAX;RgvWf2Ablea~*pu|~IYaiocvxxvnssLk8axKUIaQYKLsM*B)ZiB zWA^Ri>!+~HAVs$SLct{H-zA=XSif> zAfj;`po=~_=@2c@!93Tf|Fwe`Vw=J+bJ^g*`%}6&MFGHlp*_D-WL!ksGDH=UAv}`ChZ3cVFWty%p8gsb!JqZmq?+= zrjSjj88i&zQA*|jim$~}jq8{Q{;^og?{y#xAHZ&btMdX|kU*H&c|bm(vjw0PAjpL? z%F$8|@a58#Yt8!*v7k^O+D`M*S);KAd5a%_gK7DclpiBZr;yfE^90K?RwAel$f7#I zDNTWZM4wYjap>eOP$|_E!ieDdLq>!FU`%qs)MXf}AGL5jKn$kw0<^Z-IEOG}xB+;A zLJHQPtY|N=uif7Rc!qC2NF6paXvNKG6OuTO!Gyx zEYhypb10w-+yK$6E~eLoR|9A#W&vws1R^+?g_@Zf=tp)ag!I?38pEkBL7y zY&}>{7#AasoEZZ8gnNh;nlU6ohY$igp;f2Apr_f3eS51joq&M^y!t~31H$P60H<>1 zY$9ld*)1DKXM{)y)B6U<6vxF%^^T@AJVnlyraWl>PDG$pg&f#O~@+0S4Shk?y2S(yT0Im%2Za#HX z32kYlD1ysOpx4198A&-*6jP{yk?1wbk{w!i*3tNKtKZZuiP8g>ALxH-Dk;u*m+X!@N*;N-WkRI0U*p<53Ek`Amb6yg@Fr1?nH zc~h!onV5nx=;#3og6w;2HUih(ueuAsh<@XoDlCwji6D&wAnex~2f_$A8cb0$I-*%X z(y@+uSIqSVP>9j8JX3S+&7$n~O0?#AE%?X+P>X990QF90I$H69#V~X{BCP_>?p4vg zNeiN$MgSqy9+Bj&rF%(mK<5T!GMEf+J)BnMU(#p*NgFSFl`A=i1I?LGm2fYSI=LvUNMPIs~#3w=x-V2k2GA zgBY^XP$>?0j-vF_r??rupBaK?Q3)CAfJ^6~?ZLaqLEPHn(EDs$Y8nEtD1XVsqDEP? zUqithK6J_oKk#}vGr@R096)OK?3A1IftZZLEQF(VFz4GCzP`uiw<#KD z^>5n{>9#QJ(;5FP2T$Zj1NFZ|E>l{>40=+p)ac+3&JqrI{`D%(`6-@e@0xhPeYjQl zm<~3F8ZdRP{AAP|(*+!kA?T0;vm`*lp0!34iXcnj`DlTFAc4v9ti5=b!UMJfSejDwn>lWNAo9_bX@s(ck`hko%5qt^ zHB1-yMR?7!Iw7|J+}w?bDS$0QNoDwmSdr5SuigGRo6vqA2MW7_5<0K>QVX&Qz<8e3 z0j>zZ%SCfAB@E!hF{gmr0+>lH-78otW-7()qsEYZ4a}B+t)6+oOt(R08i3nJ#^_)o zkab5sMAjeu57>*3j4tv6ta@r*no~0qjhYG~fYBV`+tR4%5R3+5Bq3I4T^!)-Wex8tSPXzhwvMjR zt^bJ;0GDd+n`{{aOSJ#EZ=&Ze=Xpffc8=sRC^J}dr$`)HzU^De_Q)S(o*5cV7XNUW0v`*} z+h4+q+GOH!D?jIQ{9W4bgo{&ze~=<5x;K;r6cvn5)-Pecj0? zVt`4TF9Cu!-oIkh?@FB3s}q2CGrTMH(^)9{JkPo~K)|JjS?MBbOT++h@mL@t4(pgZ z3{b?0?j}pc?EuR?OBdIlxLmfDxHv1N;gOrSuXkV?J4>%J0wDm?9;Ns%rj~5bq@wS* z76H@k>_y-1>ipb(p|I@sIti>58vUPpy8WZxQVK|sO=lLai-@zMM?2$J7VIf3C^iWZ zBN+M66reQW9aW~`wX^*pz)Zqgs}!!=fX}2SYu2d>kAT!N6H&mMCLpPxvlhT)4s`!- zd(Q~s(1H{xq-FEpiMO7e15n*2FJk5exH^P^eX%{j>(0brw4F){3qb#EQRna?q}$ zi7elMh0lH|#J~uo8NW|o6)Pb4nLwvlfjh|bZBpt@Kz;y#LO>47`%+^vz&RLRh#m`= z?}`obr_*5f3)snvU8w93RTKs~J4)jeN8%2?=N0T16dt6csu1NBY-aWpOb+kOgcCp~5Q-|KVrlmDOX{{Ov(0PJVrf7>^JN&58l?6NfSH;O(Hf!t zdlM=?7Gp$^N}j6arF(YYuF*RVc_akA4ABf-i!;oBP)I5AsFEFY7*QVWn6mx%=GU_C zy2Zbp_j^`H;=e$kf6Ko>V5(W*hK3Qip+EQsqS43yw_7l{YF$r56D6m!ArDQj1FqX$EuBGNrUB z!-)bCWv`VBmHdJ;x@{IIQp!-w4L`k~DKo^*7cw4ckx!U=BuLmu4V$PKJGh|?3p&@K zf)Uabx+69x8~Ze8uXE^zr~DsQrp^@lkxNXK%AM_R$&^86b*-K3*=GOy$FkH->vsoW zMm6jg<)c3uwYA<*XTWoYnr1Sf@(>yl6O3`7C&_P6v9yhZf&KI1Z+6;H&~3(h+Aor} zm)xB=1lAQuM&6ROqC6l*Hsd!OKOO{D40HPpLXCUce~&jXJ9-H#bFcAYy`Eb8rM_t2 z(W^J;Jfr=DDr8De(9yF!ey@Z;H+n0fXm`poHF~Tk#8PWl;s*j)^mwKp+``a)PL^DtiUZ2KboU*{ub164_A#AsU%6NmT~g}m`F32O=Jc|D`l zmDE6@s#Mp%bc5lAy8ifWF$tE+$LLTWyb_pag2!r_n(1esv&75uA)fV!w+xqo3b)FH z3w!jf&l1EZT=$~ieVhAD%lV0`6CtVpNc``vnLnQpbBS|Dn#(w+nZom<5pv8E#veGP zLBq`ABCW31Wiiro1}XOpchD{u)a0Xs^TTI-%WX`Ayaop3EYCG@+R8}(6*}P`#8`JM zJ64{bymrrBoy)<6wI33g!AWb$f@D?ms>ieIdEu^h<@ZpF96Z0qBdJ57@_mekZLgV` zHPa~6xa6;c=Jei4+M0Jf-eG2+9tXv1g_Y}Q21>7BQpzV2jg4w9k#xHBIM!D#2lQq* z3`cJ-+=;AVoL3$#Sdlz258IZ|lh==RY~y2rf8kKBt1&ON{2bcedCQMF_y!YQOLxV_ z4duFlY8B17Wo>oohLYR4a_n1vL#f`-hgUG;L>D-fQdS0QpOxuyNr0(LM?!E?RB*y% z-B9i>ieD)aX9TwC|5SezL_-O3d~**@#|3f=NoQB0?Y>uLyf>USCChK$k83TIiuFhri-;PY699Wzv z6^(t?r+&`%FUd#Z>J4U2gY$Xa1_qzVbXt53mNq^$^bddW6$@JA<3OXH_;G3u{h_L& zbWE{Lb(%6g^}vlJM*8GOHZtJ$ezjQbxU|%pd=NSb$U%47pZWUEhR;NS0j2fpT=%ZB z$VxeN{+Q80&Si0C>GLwtPbw(4MZGKvbapp2_el2p%eeJ3HIri4$Z?A&G|20X={osq zW!MC-A}rL;&|2$*5^YL{dcV}0NAh2fFT8u-nlXijgU)GF)0Lkz{?fNeq6*e1f!*XBMQ@FETqeYwzpm8Y{DPr_c4k?HNqdbX!J<*Dnh9NQtlGJT* zoa}k@C4{~;jk-jJoPB37ukF4-dVKW-`jq$PA;nRVOC!7)4@#jeF;ojOigLYwXO=6> zANJRaCKBPy5-C~(TB~td{q!{;WHaHNdl(`6d6;0AEFAn%UCKMqwd7w~zZJUw2|Jd# zLVx|fzfEn21g(pKS}l$N%r+{E{LN56ca!?+%WaOzbZ@P(47ay5QHTF3*q7GMl{7T0o3&R%vQ zev$TWxzzg2L}N2h?AF@S-sf_o*AguFJLX(_*>25Njz7$abYZ_(<3f0tNc zXhsP$-S&UyqeTPmfLhC_%AXPT*A z4}q+2Xv6PCCp?=7uX_E>{7XBtT&=CeUB@MIU!ulvMdyMlneIY(21kvrUiWi_gL@O& zau?+Ebjx&pvEOC*aCI|Xem?Ij>~`QhjUhul_8Zn&iypn~ko+-@+}dC%YtjvGv1A7ycGgcQ4e_8h zG1~q~PLSKUT+^6{@b|*o0edJ87*yPo-*}-Hu32WtY|7}wbG5BWh$q6+FhtD*{mLQO zI_`fqEDv*DNDdccn1s*iHCjCKCN;{evlwRJnT&T9Qz;HF8SajWF(U#%wmU3e z%hI!)vb&65U*n)v=TwsdQiv&CdhZG1q|#8L(|CYV6*tAd;t1vfF*dKe5KC*g&eQzv|hj^f>fBr4RHx zIVpbGPX)p`q1|}rSmx{a9`lIz*?1cdCC0A)ksn@!usF8)-}um1X8-nIuzqe_}G1E@yTW^yi%LLttl44MjLAyfp>yA6;-)%okpdU1V71Xo| ziPDIPQTcs{XjrMyTR4x|xr*?L9mpQ`$pBL#U76Lu$7miEqhKAG{@ z5&6IC(uEa*W>Q(qVzAQi+iDSvg&3Ar5%F2 z{o!1Tyx}@l1x?yjb-lepx$wkm8mbDgen%+2geErs*XPR?siPm<@r}-x+6vY|lf8RV zq6v(W0H)aJ80pM=?*%PGrRs3o!IwlijgkY)+EHu6$iuUHC!DbJxne_yv5YmXqypZg zqDgez#s;$xE7?Y-=VZv}>$KVK6Aj&von(a(3TNsQ}KZ>z3Um+K!tbsF!}Y^##7kg?20 z3RmE)@Ha0;0Z^w&p`F_Kzc0+0u_$=#<#VPu!$)qKdB6-9Ol@i7sqwZT6w5+8T0{_p zZ`LW!L5%AMXCo)o));&A8%BrGIZ@+W?&Z($0^mo zx|?q1*c6A@)WqL{n-)vB66Y>zY;_IKbePcud-2u|EZE(|ZXq1qLT^-4=q2W1=X|5zNTHeMP0>pO&_Xmj~@L z**z7dVAV1lKcg|-NeM7IYo6MJ7@GaoxM=--JejO;SUzyNy)vy&EyG*)3}WZU)a1p* z;am8fEh0LVQ@47-T>Je1*1V{?O+v!iH#cJGY3m+|L-6uDu&j2n=BwPZnqcAMJJ|;3 zwjSMSei$dAGpU(=h3|%Rxi-~($Bp)iO_L-d3&D>(^t2U3PC8ib;8+0E^`rRa>t6?T zzw?`RhRaRVYKf)OtN)EiwKiKV(=d5`=bBYi28=%j#>l}3A@gU}T2=8B%oY)j2EX-Z zNpQ-8PZ22o4CP$T1;Z$xPmaPnAY3NZp6Mx-ol|-87qz91ttSuHKnJCA}5G?Zk-p;!O?=(ct-qx_;c7$9#Xb5l05i<}IJS&t%1W*);F2Gu(2H zn;p(X|JY!W{!8WRUdzra#cQxNO-zn}Kl>gL6VIYt_;b&)U-Kr6d!+~mpg}*qdscHo zRY+_h{Bur{*-p~A{!F~_&8NBppCy>WKW;Iaru)H-lg^uZOAn{;%>o&#Y;%vTC9w#_ z2^x#a`pyU_y;#|vQEIyQHr)#QTp1kP;7>5~mVQYuP5_0>LXMT)WsgB0oqppXnk4mG z_}@0B3d=e1bjtK0)->*KI=OX)`kVX&YKL~YPt!3^hqRvVaX({c7+?t0NNRORR#Q3u zNL6RGO7G6aj-T}sOC(#a)1=}vFgz1@o#Zs~q^v6yY$@a%%lLnZ>83n#pvb=cw`#~nJ?>krhhMZr<7(1}Tf~2k^6uB1UcTizdB(l?rvcrK>3QdTY3ccs zYvTg>6ERx9Xp|S;vcJ5ls>b+g*&{^y?Df1P{mFOEr2w%Ut(+rrhK|4Mqs|}RY!k|( z3NB}_BPuR)WbWs2hbt@(DGYer|E#87-If|i8NLmI%Zy059A3e$SA0jxwbtdRiSJLV z48xBdZwWebuP|O@^3SnGDD};BIV?Ri`lcx@E8Ig%Xq#_&?Nu=ff6{;QLq+^AQcdo6 zTL9XO(NyOb_dPvW@ek43B?r|LS2(=pW|>Y$Tf|U&2Cu_pcS%#R;ZA&&*KuO{P3|%< zZ;_s|^cE3-I_r1^$xawpy%PBN?SiW1_^X7YTf^q7#dYZxE+6E2p*<>c-}%|KWFyZd z#x6WoalGE)5NT@j^3l^)&CQ@}Uu;f{!u&#FshWb9P401M<&9)?(a+4C8(Zq38N4ieL4>1vRp*XJvr-WvsKg#u; zdp4VGRul28=>xb(ieOcgl``QhMfkL7^hLA2nt9VXM~9VT^-rDJY0$c^^BPLORlH=| zEy*xUrH)?Bi7$yH z2%3MkBhp6^7c!>l9`w<~xpE#h++H)Zo)Mb;bjb`s^YVxgU^Uv^WVhgYMTI?1ZGLRf z@b1?6OR$;6?V5ZSlTX<_9d9*V=igt;335f;?|XF6%i^_9q8rW*HQqdWY*hN9vO(!I zAtEd5LT_i@OZ$7FcRK>Mv*%GutDjqtK~b(|u#*$nX9>L%_cGewc|>GM)xQaEI1yW4 zu=g3js90~xag5)&c`3~HFsU7(-gsMYM4>6lI`A^)h4!oHy@c4$)6H+A zIu|HD7JuT%M8CIW2=m8KHZzmQh^H<=)N;61|KU7|9)2mO7Y9BrSG|_9`kifMoJ6To zUi6);-qW$%B!+!$!)IB7Pz3(GG;ji>n!)aA=AxHA-*90m&lUg}9 zSm!(jdyTzcO}tqCanz{Ov&)h1xMwc5r(>8k{sI-Ow|VvBwllZ=ss_uWMp3VskK5#& z9&do@Nelg4Xvi+^kwld)mV!a~ziJU*Je*#{H&$3*3Zto=*sH5ouBa+5sbujXY($Mz zKMxkQ5hrMD?LH>w{*q(iPfu%q9Qnd$E&|6hBz~Q?aqn%s&wZYvyT|N3oC+`dKM&;Q zhkduB!&FZlPYT-zHm)P0LT;upx(H~z*cQ=cVJOaHlyCxHlQRl;>}=0?quwj(`PKBS z)#U!GWgT%&1lE+@+z=V^_`Sr(yb!X)g74;4F@)fKsu22%@6H#5eyLcmD9>#_%0ZU~ zpVC5+U6Xd7x+0!AyftXX)=%7e|NO2zQqWBD)nB!&A4|aHThz|x=C7coShGtV@)jKK+ap9v|c zgRx~W$=T80WlcxLJua%U&+akUtA4!I%hg}EvdlN#;I@0bwO_&L@|=B_OQPtYOQPdT=H}mb4>K$~R>u{e#ED&H zzIU~`Wcb~sk*_BhpU;e2n0+yw=7Y0K+K_OPA$5o1x$ zRPKW@6$aA#-W2vWZ+}ke^g?LnTaR>jhXgFEK~mzS>K^M<}+5ng_9GG{V3> zOwebLNM$bsRl}0cQS628)&rtOlKRpuFNsdamtN^h{yY_$dw#uSOgoY~`-WksH(cnU z3a`8bYe9YxHQQBR!N6wBib@T+?AP*Q@o@52s>dptp1j5@BQMf-eBOCh^(v3bUSNOj zJN9XG(LUbBZ6S{K%~ocfVZonll@Wz^@$r+B#M#xFY(yj^UyUu~Tl$u4OZ^+kLyzxjOlRITiSl6Q9KRXtawcSyT! zo3@{W-ShS@J4h_qx05Q{>&bG>?Kc+4B1-Cbt@`IHA5^qY<=@9D5gU@Q@kOWZC-<6PYS=NEsqmvlD_wM24cYY!MM4Et zE%IU2glk@}9WWl=_K$Rs)X%9adUEYi%ZHQ$BrZ7Q0C( z>wA#`)f);GG-<2Ew;4jM@A+W3^<{5@U>cfH*6Swba7 zL#K1W@MY%w`@LVK9!gdstMUfChI8TzEn~FyGL<{!^Ou~^OHF;FI$jNLHNq}AacYck z8Ofdo({@D~<$h8LHr4SiyOh1DoKyX_R6&e5F>H_iU|u_*Z;=_2`(eUffmPqUbKB($ zmV&;)88ZbGAgs zciQ%gF-%f$u_84=-|HL?Hd{D)y*4K>(5PcG!w>x?KkKC8hL#bxJm<#xo@x-6LoRNy zJ}IIbW;ebm)c!PKG*9t6+Gfto%KxL+{Z3ioH_ojOBj3kMePDRVVB@;|$X;k^FeX?u z6iI4~;6I6ekuW@Di+K8M4SS=?#Cq%EkE%rl^oO5dN%;XvdLvnGf1>ZfJj~RfLUb4o)U~Z9)j3b) z%4?=v>6j52eH8uWq$iCwv=APibWkRAT;n2 z&t1o%#ys)t?joaVJ0I5e;>STY987U>H+;J-ng+Rs4KhBo9)b+j`0~2mgDK`OMCqSz zMGe{+Up5gAQMhY1uP$qPQ#;OjZSpDS=fWFiEgMgrGOPkxgNc5Fg=eZ^3@29w5K2)l ztu;LF3m!uB^1k9>NNY1QF;N>co)9R($k3bKOK)@hA%h=> z6%667|BF5;xdNyjo86q6GO?>DzNV1VUs}nn(QZ1>XdSSB4VzXynDnC5aZJ8}#9DTi3$osnWG_c)3;aQf& z>=_k%%Tq%3cp-^iM!{o5YZmd^f>iHl3s2Y5_p=2CF()ESpF~f+oog~rvgTl?x`&sO z!Rgy3ja-M?U|z&)J!(E*PY<{Wk@*SHjg}eUaH1);cLWs*Q;YA#+%l>cgNd1o)Iy~2 zm%61Zr&J%zaTN|`kBeGf)T+C#kjt|SirAwuBB1DVa(dsS(<#}7&`ZG0MwaMFAEY8_ zdnCkiwUSIrWED+andKbprBaug?;g}-w`thnt*HL7bI?M|wr}-<_FT-Fg11j1wdA=; zJvq1f`%sO8fl_u`&EoF+YgY6M&l?R{c>3HB<|<3?&j$o31;Zzjzmy4mi;OyngUAa) z&xCDLt0g2m6i*7MT&`29{hZ{;SN7XpsifOka{Km%x|czX;R3(h8@8-#GA`Re2`LAtEG{$l zP8T+IfdlGB7>30Qe}UW1qL1XaTow+o?wu78a0J=eNb_tMDR!T&=GO&Y2~UdPTJM2pleR2Nt|3_G=yBRubE^)%CJx`F?-y`hFm2{UtJs zi9P>uz8AszA#~2~{Gq(dl?Z$9PjXLfmGe=yI%an(X22k)k4!A}jA%M*dKwluwFEfm zZzi1gE1uDD!mo#GNm@gZj)GQq1YOYe14mhsprLu;HZk=XPBeNfP&j3CzQg@T`~`bT zVA@yZnbyl6owyDg_^%>`-*I(jm)AFZ?Uw4ZuraRQF=?t+kyPupy`F=`@xbH;l^DIAw>lv8nueS6+q+d8xf8JZMOL>}G92``osf zZz0O@=*iBBCG;ijY9M^hP(P=m{>(!!qE&B3VR6`q_%A?C=W5KFZ zU!1=>(mh_GOKF6=yT-WU4Xj0C8+r3ZmAFY^OSPz9puUk5CO|PyZ0_fZjY(3{oR7=D zi}jw))wECKA8)sdMuUx^Hn}f3y=>TP64W+d2sOWC*bBt4)7hGZ|a+ zoI}L_-4lP7t8mB>X?T~H^TI3DL|+uI{?YTRU;SS*F0aww ziH2cy$p|}(DnEg&E4KTKd1QNMomE4XKx`}Gn?aOPedhejFcG@V)0=#q`%q-|g9pXj z+&7!j`$N&YMwWLr6lN@hg4_2zwBB5|CXBu`n6PV|mHWt>>JUD|rMWE2ggEjItf{St zavhZHjnRJ*eyDQEXHChileA=Sg0f5M&d*aE#+R`~9hoz(CS7j6li%O4{PkYdtK^5M zaA}kv!={9G_o5O1cSEPox?UM#E9ke6i)+xmf0Ti2%7RvUe`AJ7Q{!P_%o%@zg9&yN6!qx>zf77i#^7#;(rQ$-j(0e($%*|GMnI z>%i>5<)h7D{8kX7U|PK5PD7Bu z;_G#D@A|ps8(}xGsP}Yo(Bu7Bs{&4z+CaCetWTuQdf@c6I<=gWwXvF$hub-~ygDdM z*Cq`s4vfQ~k49=UUs)OM z{gP}fxW$zgs2TkBzx@Xf#RsK=GgzwWE8CPA zLW?P`+19$OdI0btYs|Kx=Kc1L!IKt$(KeB{O+R>uP2y)M*DmW@?|W}hSl@}-1J@+FYTJ=%+=5RUzb9c>SJB7D_F(3U@Pi)>b{(79fzW!mZIgzQtRA} zDs$qD`?#rJXw*9;!|{TaP>BHT@;CS7YWLH8Q6*wj^3S^7-@ZLh+Y)s3-zRR?XH}B= zRo0W|^v&tg?se1UjTcXwD;9-2M{cAb_U`YS8lJ~dK;wl152#6&t_b@DH581^@r9j! z4Hy5VrCd##UoxTE^JUno0jt!p{EFY1B}EpdSXD`Kc7tSMi@&XZ?|frZJ)J%xjV18e z0*+WL5wa%2{5F-3WajGp`0E>Dorh-gZp^Qhapy8OpO45zU4zN4T9%UBkT7S`J7xK7 z@0MJRzZlUE4?d$*OU(XYn|iYX|+q~_Pfc`IF`A zb>|)m)ec$K6TISWZ5lM)VqRB|O=h-4mM9cze45lSJtn=sR;O~x?@sS?QD8U1uMy#W zE>C+!VAJ9&&wWmyTPA8|EF$Ey`bwLA%+O!;EEvrGWE`{bm?`4Jaw?AW@J?0*KP@bm zEUd4>Ihi*nfo^oNw9Q-8ndHYl_JTULh()$N;wUA&H;b*m*P5GKlXqjbO8+2z+3+C~ zI{p6AOR-@t`jY%eeq$asv5j>fK7)m+YZaSUq1u*z#0#bMV=|FizdC&CZBXB$>-1(lZV4iNR5WI$q2@do;Bopl34E?VprbSd=T@ z-QIK`b1bD2eWQXD<;Z$c4Vp|&%#_w^x+q6&RB_s3*2Tv8RMIjjiA`JYxbbKER~xhk z2aKU+G_j9NV+hf7%Y!}GNa^Uob^el*~T*{=BwAQDq#N4yJRz z5Y5-`?qbZRXY#$)ljwtu_w)km1t$@z(-6uw-VIuJ=Zx2Bit8(9#Gx$t0Tprp8 z5r$da6~8qLe0J(=AOg1Ab)yHnDfbkTgz)WbZ$xeW5@H?5BwEq#h78=Er8&G}iL zCp&jK7|vb;QfWaqQc)SKk8%w0XCz%7NSbBTSD@zXQlu+%50eX`Q%o4KC(#Zmjc3ro z+^g2(SyIhrIpk7Indw1KXGO!t#l!>X#|KCFhwKLgO*REzsIRz=nkj|nF=@Cf1f?DE z=wLLX-nxo{Jk=nCe%avuWstSNrpMJCkQj5j@sSj_nv-suhp-mA$%F5A-uZYe>4bP* z(cVi}zLRxdtb63kYfyQR&*sLqNP?mx!qP~JbM`chRb8&fq^blZWC%9p(ZZ+obJv4G zLph+@uO6*($HBt%Ufmw#OXe4oJeCGrAnHpm=&sbxY(QPjU$r)VTd)2D4BZ_Pf^>tlfHm|`(jC&>4I+YcNh2+-0!oMqD*Bu6yWaiB#6EY;-E+^} zb?@x;JfE{1`58ypmnU?mlXsy(j9U$^8>lO^v)3u%0eH<6ouEVDb1sww>FY>G_x2rr zJp^Uvy?Id&R9Cemc47EcUZ`MUvC;xwgE-L0{G`AS$BzY*%^cplG(&)t&}|0PyPVXJ z;3u?&__dF?edb|34|D1t5;Tvo$z$1NrV|+7fSTvbFS76{GO(vgZ|nP z3$~Y9Ra~0l3?{}nu~W&EMX4367f;H89`!sq{Gc*A;eHpLzDKD5y}UJ)&?U*d7MH>| z0|FCa@7WY330DlmkyB_&M2ttlW6~3Smx>NeH&+SKSGLvs87K{9-ryX!It5lW6VxP9J(o=46Tdk4hXC( zMI#X32#Un*aLeT#76C9g5>kcH2ABbcT;LK-1~Aw{B=`nr1y#Iv&3}ZsrJPcHj`OXs8#VTNEP7{Cn;p1`I($M?kN}nORuFFx0^m^-x7j=>X3u!~zNq?@U?= z=Hw=ZO`f6!P$Uvfnh2LMWk|fb1YgY6H1r8$2*4Yf1Pl@aL31GcolQD<(aC`5l$!d+ zWU&>c2a%8T5?du=U~qQ}!f9H4`(9#E@ZGoGpcr&dyL5~TKELk}1x~R@F+`BNN?Iu-Q?vKKAi>-zjHeH$1Eub(qE|6(zQmN%uz8B&9q(j(lpWab?Sd>LKZaa{uV|WueKcJMMOc8yuJPg*VO+2 z6$vh;VH#2gNCRcqoA0fQa1IQC!9qp251C&fEYc~Eg%+)Zl&$fr&g=Z405IyZRbRi(lN^Tv20pph$<2KqdUd; zlmiW?Kn~g4eJGd1Df*!uF)_XdXa;dR8f6MQ|AY})SlefeAwA1r@I@fN06vDS6c{RH zhN9;&nVQ^+;cETUSNW0{%TE+mc6xSDv=0EJ0flT4NFOgSb)-(Sv~KK65vDmh<5i=J zy%8vJbd=?UibE`LQ^A9YKG(b*{~Aa5*T78c^VHTw7;V(@ie6%F@%Ifgy9#K z=tGel8fC|71-eC$O6Cxv7@pxQDR@73D7S&W!EAH5iYQ|VK9;~HJW`#%-W7&nMMF6u zOz3SlyA^ex@5N%oU>C#>{1qSrgF93JCJ>YTn$87i3Curz{6gy3MsJ%39y z*utOa1uyM)G)qE50zc3lxq3;ivma-2=O3e)afC~chohUMb;x*43c7$k4l3Zun&=~J zyP3faKOeZ(FdF`K8S-|y#()h$q_73HoFP$wr+XYEb+eN+3g;@<;lyT_C+5J1o7~?;B&9aWX8CG zVlcYJuoI9AXbkWMh_KLMkS^#bhe`zu!4Jfhp@f46N)CwU(BTSTN05mCasV490r)Ql zfGD&Wh7bz?ke4%TH|6H9okMLQ4Gz8`&F7-ikuEua2wF}NpcMy$q4hvHK;qsykc|zP zd5ak0!FL4D{ojY6A-Hb`LVz%!|7=FY02c5AC~+hBfcy>=fQVv{APffh{}XBeHvl3` zE>>nbhp`p|WO5YunN%8`N$459ooSPahO%roLE27f2ZCo>;bKXgcMra10=>BpoEzO*~D&@U;FR77$Xkt@2$l_t&BbSs5Y zY=p`*nblKC82#AU8=ul^b-5FwI;du{9s4L|H-beiJ1Gqr1a})*jI|!gWNx^9f|f)@XUUYe_46#?zF4${|Ii)nO39CAqmc@;N*M4 zruHa~(6>q}a0q%bn&2|CIHKH1NK5N!un=dECPVttAfuK)KWD-)C#wBLwK}|8%Y|xf z9m@PM2SPr5_>)C1pFJhXY%_P+iqMw(zsZ9uT4)8mFSRaiB+ue1u*0QrK?)!T{(B~S z@-@p=B~PG8$=MDACH^nvr25~ZaGrYgng5vo~J=-E5Y&bfl`jW=m?i)BqHwRP5lhDVoW#l|KI>i*TH`iUKNcTJj7Jzp-%Cpl zf`+FMix`Q=;VRfQl4Dqs?Mlp{+ZspLDS!q!$wXVBz9oYiEC7fUs%lu2!kzR&R zRu#w`yyGYH&Ag$nB9q52+@vdQz*Ti#w;t};7wcyvA+JjN*(K9o;jW3fRB*6$9byuQ z2%5T~*<=(7%OO2An57PGh$$+_57mq(3Gxojq{~h|X{Zh~&L(;U;6V$spec0umh5h# z=__a7sClR$?c1$JgCU-K2bLl0f4}{#^SAgt#TyRE8f=Km4*pQC!}yXi(($gCeW5;s zuZ(89%H~~er2r@q-Wz_OH3hMS0yeY=eZBr+AxE0}B$=AbQ5}W(dezaABH8Cb%eQWd zg|iv21vdsi@&Dp~v`iboOHI|O?Fy4r-F3dp?-o1bbRxwqFG_oIyp*C!_Z-gy|Et*D zsya6zcHjfK%dGHDQl)XAz!!P`aUN2*3_ zVGQQiH`(KP?Z~Lg^}Bx&kEdEutcX43X+T@Z>fGC-1+&BGh=!qPPU6su8Zv)))OS*` zg*2cQNx7RnQI=gDcOPO_TkEO&|9BOol_+%5QLKRkNJMa78QEOGM+NHB&I;o@0 z8M74!zXk=Dy7}AobHx@Uh>*FHf_EX(Yg9~^sUH9f&rpR%d|cU75B+2I*hYq2HjI1m z!KiUci@&*v>kB#j1~L4kXI)-Bj`gW+igSh;CI3KAUC(rtZ6Ca?*W4>==U{CetSTHB zlw5?xMj{8|8hM3oedl}#C+t$5$1({*T!dk7JxK8~UHf5(>*{x04N|)9o&7$m$RQk> z7)0eoZ>-3>GtUZT3afNmaAi=G1v3*)Z1PmR>A;VPn(A{+{QkDa7RLtpOG*JBt0f~G z1Y8a?JWMp79zJ2x_!ln+ga1^)%lFqYTJ17A8?n1?c~8%%KA9BCeel^$-%`6iYC`?n zUs;}dcKx^PrP99pKAT-kvrt~Ict-Dh^@v`p^YgVrP zc0^!Zh}+ii{=Xo(^b~O>bhrwX#hFo6q}4xWVDVX5|CEPruXJ9j^(x4dMn;y)ZGca{=ti^b?J0S+a6h^C(usP9YuXLp!$z5Yq{S;%z6hcLJ+(#!hv1wFZ zG>xWmZW-=lvvA&2hiP`E@N$oAs+`Frrqd|9X^f-rwx^Vn@wsCg@T*viak?f)=H@+y+79Z$jRGpP7xFCYSRkKZJuVvfN}{wV#em zqP&)1WyKThaXc1*UtT|sH+8s{eTeQZA>FcB&NNFU<$?=2mjsUlRk#1q=y@LM2Lhl*vE~LR;E;q+ybZi)eAgrIU9moPgvpHsiXiT!{>FJVP02d7%C%?gQEfnR4KenjO61*Kv8RV;+8zTU)n^x zn3}aH1>xYGFHFK^kWqNW*m|^sOO&j+0Cx{@N4BuApMz00Wax*uaRFab2 zDzaDHyrHJ@G923+tx(Ri>K30|{d|4&E8hrMyX9xcv%iZ)1gPfdcy_$bp!s2e7M^0< zeH4*?01+ugpl+$^E{0StlhNzneLp{YcDMP?f}smH1*t)(-OH(UC%GZ&$YPzBKjRNMoo>2>ceQuia81YCrCzZ0abe`QsY4yihWIX)n zxxL{j!9GH3d?92#oy?WF-SbV8X4mmW+q2)Zm##u99ou&ibPmq%&#Yw)_F*}#cUJ3U zbA5g&^bA)(IOYz@6~EWL&YZLEi*u z>8;3WGBa!&#uU^qw>*3r{?pVYNxPGcXSqqp3L~l$ld_Wm%!Jp4OTC$!Be zx<8{F-X!zJ9VC9=&ecxSd-6J}A4>FxiA89e(RH-2m~*J zLOXIn$kb#tU9#Fz+|=qh#iWmr8&TYyL#sorK&#@2RCY6o2!>b6`4WOHLVUTJ6ok?X z1I4y1Bciilv2DL((O_w$$!B*%l=zj8V4UZk8q2s(rCF248HBUhazBehRdqo*`w*2T z*_Wnf76C(fWmZoH!WdaYde)4s;^NI}zRn)!^Kgwff;gTEn zNrm``_22n{ELfbh@8l~5MVqUJrBF`XZ@S!wmo#hJ)l0?xO3Kx$or=$!euU=6>zo!k zJUad;();}TuS;rrmlmhwwCmRE(s-+Y1U%MR=0-yuvz zUWk!B!{nN8M6~OfA(=kN_>i+1Rh9%@k(Gks*;*QL^X2uDUDJ!@qSIoml5M@Ck@+-o z_Wi~122=GLQv|&pjXT~*5l-A7_h5u&8L^h-{P*yc$8q)9sD2N?R!t{9J5bXguN~g^ zTUkHDvJR|;qQ06Wd(|{;aPjD8jwxnQ9D2;y zZa*pP@%Ch?M1%<*o|ghdXqQevSO}PFAAEjG9&(mxcVa<|orQK$L=7ByP+sgK4Q1$A zQxe_qRPDBchq-wewS5!F$LFJ@8FEO=+r!D*X1w9|;dGa*-#EB? zN5#b1IbCw6le{!7bCU$%Z#?X|wN|PJ!Xo9;`xS*PqJyK1bg?t^_kMPs+<rTD<`eTaFi7MvbqynZ zUlge>|0P50rP;o3-yQw2q_p9HvL@$)CyL*|iNu5+V;*XmI?G1sBo}e-l%yX#cIx1!M)gb3XWSyAOU1 z#F)0s^iiA0l|sG6zQyvOqllwY#A1GvH^!R0?;jqQZ_0!^L#`D0*fd_? z4D`5#-?crT4%7)6Bexetb(u(ENy4IRp`?lIGbV&H?;-r96XHjZ3xY3XCj}j29hL8) zfAYq1JfUcrguWQ>b$ofF%?skCGJBMfartVdqQr~-E%7Lh5REVRQn`}XU2Qms){#ot zI)Im)UVmIrnB16Wp-gRhdSO|tq|HHJxQWMKt!sBJ3Sz_$W(xt~>Gq4jFo#ALd z)PQ^4IFAdkz1EDYTfP|oj74@jf)K;=qYcJrgeQl@{c*YR@;nze{Ni~8r6t9{ zPcr%uZ(K#>redv@XJ7FfO}_9dAH)VY=2mo@uk)IlM7T$)$Dh~LH)*hT7tGi_z$oCQ zL-U6|{i$AG5$EvO4FOHR;doq7Lt$P=PcPbLo_V?wQq2qmyf&6Jopr5VBlA~W)7Us zo$N0%F12JAI4r8q7lncgmBW0H>(VwYmCeGYckpDqGy`Nvw4cu|$j2LKe0ip!_Qz=zcf%8D;!8K|3wrE-_C_*;v^-32r!X)?Fa^nL#tS{QU<` z_tG=x-eQ9)IY2;WZ-b{S!F1M~ z>)0S}Ut&#X*;(}30al`7T0qU> zq@DeS|FPLG3x#iXuWD_hElZ2S=J#y_++Nmey0sw%9OeZliPi)eLH1FD75V*fS_vEv ze!TDaA}B6rAtJz^Axg_qVGC|Y$Vs3i2Sfy>Wpd)VMRU$~bLlSkl#TrbBdL9@2-(Gb z4mq=KUE$iS|Ni~64)9b~{q4F4Pw3Rkg7K~+s^Q1qib=?~1SB?Ywq{!Pwz>MpqFMr=ua=2^%XlTRBmalK!u z9ukq5BE`02iHCY;>QkuZo;xGuqtSN6UM)4bSzM}?NvQrj%sOvn$Mh5NSc3N_ z+e(B|;ikiq(fENllI&IY>FbX~W0dE0h)A@u>={hrB~*FlTyJzLaU2TWP7bbQ zPe%6GQ&e;F$peOI55FvY!vj_RaH_lc(J^^~U!1d~hWISR{tD;X-F$W&GrRp9!)LrV z+VYYoiFo5Mjo^%bZ!4~jKt!Y>6;c*&yl`G(WT!^r>l$`+Utre>dzkMf=G%T8?lq2u ze`Ke86mcUGxSJhupH!aW$rO^tm4ipiK$Csqoge3N@oH8q96!g%7@})B*vjB?4?OeB zIistms{C_JEUC}ud5uk=Igd6IEn}3pWC{v`Tu?uAbF!a| z{G{0{I#eJ}wrO4dvu{q(aeq#}%^CIfCo<>;uSr+fAu8CcYQc>TODk#81d2nJ@;Etm z96r0$W$~n+7zktukt&worT0nK&nv$16)a-k!y&1%n z*~I9{+g8gJJ*|(Z5EnV=Zjv0&)C6pF>mvLouM;*ouiz-8IpuY=v0^oo2K52Sa6u>u z`d?2fmfk$TQ$6FmLU%2x2$@TJ+Va|qXsJ{3cpCp^m`%@8OgHR=_f0j>!-tvSDo~Ny zj=}Cu%P>YVNk`?(Zr`e-ok^*9Sgtt@@LkwDIgFnYh4nQ6pI^4j+|ephK5~2U)t~|$ zr^k+Cgs0LvOth?XHrHeBqERN5#I|W&9ky*GY>x>|EJ-2nm!~KMq`zgl_uL~=^Ub3k zvW*r!+OZI%am%xxJ|YuKPwH~)ZvMR3kjgPu6R3GG%|pWpXUNG?uHDIxe3qN$Y5JF^LV6dpuq!&r~~|Np%R#(p~X|vl(Lfev;2uxThf4N~YQHhoX{;J`R;< zwWX#;OR^Vj{t5?=k6-n4r65D`!0%#GQ)G!y=tdfeWOjJ2P}8*Bv`b**gzroajT!el zhepl9Jt1bD{htQhWeb`YY^ceg$%9ukHTiqvtmzudQKlC+zRZ+>;r(*Yi^#eL;v16Y z*H`JY4W|+{f*m29ws=&g_;jDT!!;CK@XuGAgXH2F!o-WF+I&2q5;S!~I~`1L^pU_g zuOFC?xuSes){w?HCJt^4@7mvONdGplEt^{3X}a5$DF4%Ki^|#xw&hNi2g)yeUMNMq z8$9(@a5JkFdU&O)NK?9HrCaATM3%aAxX5y4TDw%`Z5N;$ns-;8gbqQL4p;mLi?Kf+>NvBTg_7p0lgjzd|uYyCV&!CUQy_N0%^IWh9Y~dx)BJ8_uP8+i}Fjcje`rP|J6}|B}jUpmwT?DWa5#z zV{+1by5DD7lV>qE{)tAcHFG}{~s*%E#;O4p_JKw;+^-Dolh8RexCnS?20J;m3J03yDj)YA|f%llB8D3jxy~E0-=`&n?*F zUp@b3RJ`>HOG@zcOW9(>q`0?^a#{XMc`2Gr+Z-!SPc5c2R#EUt#=1SYa?tUPyLV2_ z6e-$%mgyHG6_=_?UiAH6bP3c?Ju1=7(^sB&9faYpr$3hT%vfDlulp<$ry115Q;!bm ze)w(vU6I$PrNEo3!<;da0*U?-Jf`z_g1yK~ub=5cx?JH{TaZVaQ)&#ao3CR3lmA{` z>cl^;S3L8hYC$@$l~uE|M%)(dtrt2WTw0}*>5UU`ik!*6&$r>2j{rG~fl>S+(o0W~ve{`8ZT!X8)Yz-UX_uY@PD_wb>#s=jreG?#wGK$&eW;;o7 zNDA%Z?oEx-H;v$4Z%<+F34Xo)(Mmb6Fk1Gk@etZz^s#3)r9$Po>~h25DSA|K^3KF< zqK1@&oG0xH^Rs3t!RW~}YxB=Yl8;vTcj-778H3B$Pqqvz?2^hltSP7T3>p$B)!&)| z@z95}%3r=ShhyBCiAz02{PRr`Ieo^yRUopNUHU6>DU7MhHH+Myi``r3|md1E~Q zk5@$?K5DdMK^dMBymFrRas_VnsYV_gT=Yv;I6 zGJD3}5T>fEg8s*kdG9=U!6W`|cyq)4^A}nno2;)@x)OdVsnQW6a3QI{)jMlzOk-3Q zkMQx5TcwP(q6pQK8Pn#KDxXwvaRp2T)BCUOuUdQ)C{t5~=!n+4*CEE}Mgf*lmaUA@5`Q&?TsVv$_h~ZzARjt49>U&X92G3lr3- z11C3~KtvE%;BhisW%Q-I=;r;c&Q&@KP8*MPP2#l-eTYLG<(+jbIbL>L?e(^6#aS`? zpQI0cX~o}Rgt4Q~$yyq5%uWz-=Y8ax=)xDl*37Xs5Pujj$udY-tU8}ki=kQvIhhU{ z)3G>)@+K;akg!M5&PAMiH}BbMz=pUMWiXgq0D&PI!59D<{EHvc&`tuo3VT0ZgVy+X9Dlin(O>0k2^WP`)%I2LuP|=wMNJM>r)-B2HQs0jvZQ z(c!&Kkwgz*U;}I^umgY?4Z{%Ak+uzXiy(5y0H_Fr13-YD0wRBQ0!%@}01*3km_~OH zx036*9UBIxvVhE?k$^vfSR1z)0+1fpk|3QaFcP2uq(q&d0NdY0H80Y!nZImmbWa3R<{K-q-EVpV{LFd85NDH=lzRv}l* z$y0<{0u_jtBg*$$m9jkH83Rp)FuRf+x>*bpoim-3Iw6Mg9pLCbU#F9rXYQM-w1EyN3ny+Fv@Dzyy!z`_>T@A430>_th! z0f2H?n$C`hgQk^E7(#%ylLM9e0tg6(6Cj$v2m&S|_(DJ-plS%A1EWX7DoL#%bdcLW z3<_S%cHtWU)J|jPt>U<#80dlb`n0!Tk>k-i?G~?ou=Sk-abr!RJ4wW#Q47CA%S1APfi$;13YQp`!-E&q)wu+yh%w_#$9Gv=|eJ zFk%`g03%ZX4ADD?Cz=@0!Kuk0#ZU@5rsy~fZjnHok_vWpjrFxaf|3CzKny28BoP5Q zL2RJ3R0M-)I)ED|y8-}d0EUCuLLs=90I3sTiq-`<&p^f)FPzv>1A|L~$WuzdiQA;q zcY#2#`a-6$J*p3t@K;14r*PfA=E4#9f{pRrwfUrcG}%F)`$@%Cd%R)g1@XPm={Ow& zdjjg=@`DMPV`^nTi7Iax%B?9rFFm`g;PoZD_iF0WGaM#dA@L2*jQ4NSk$0FvdBcqJ zi&9o|`Hcg%*2md_SaL?bNAsPM$!%3%q{J7*loa^v2X=C$YKXEm|H{{>Ijf5H>qxZ= zT9yZvU-mKTKieqQBTu!K+beAliL-L|HjiW08Loh8e97U82_C+8SEXjMo5ojE*(;5v z6qcQCK>Ey_j|f#=#Y{`oqD<%r_h7I7^s_?CNCT=CW!m#_by?0;PczZ4b+~=c_)rC9 z(rwn{-qq{ZnW<#|C6!5uVGv4Gr&b5yvJb`UCxyq&cYig_{V^{SHH}S^!U*TW)Y#kI z296VA&7xw+sr#f>3fT@pBlywpBH>>3$wsS=By(`?r*MkJNY3P^#n0_$NL%a)8Tdwa zddTA@CR31_$YD_syO)g>@-CCGtca$OMY+8tATAuaHM&5SUYo2< zRZ&zE-#ikS@!XIdJ3-}(n>q^Q_UJ8m&WV>)6d+dlZ@O`aYf+qT4;N8W4=Dd&VKL(3 z9RIzA;t=<^(T(R?!Z5QZnvac(|H}>lK%GR%3Xw+6!`qAmM(f(bWJcAux^7O@g0x`G_{ zC!F1rn#+~N$ez=Z#Vzy4sxO|U{~#jFGqCx(0b|mZn$j>%2+mEArPf~QVokD}^~vmI z&Y)>eB?fU+|5p+odnyUKE0F;a`PJxN)OSxnLVM{|u}DSjfX=h}tM)cS=4=Z5VZ3qF zw5Bm4b92F;mO#wl~tq04E4W1O&?-2JaM#3 zKbz9?F?NafW!V*_A73b!fIZ3s89YbOv}r5vP{c3Z7z*_}0ru({w<_e8QRlrAeh;lA zKy73~Is)Z3{)s=D9tf4#XW)t~`Wx}A{G$P$UXGz@ywZx0a)-oEWncC9;pCG?!q<(m;}R(*ei@P1&ZN0F;-a>Cc5`< z(?@)=PJHD?zCbTT0n!-Mj5TIWCr}b~F4xYddB_46FlHyX7_=er^>b3`hlUE4X_%P{ zg;h@}`)EnIaovA9F-Yumxe`q~Yg8>qd-)+!CAy%^ihS?WqYYE19jD~-tUNgJ`RV-Y z_@Zn(zh%joRrbNnqtH)8$0fpz!e5@70jp@-(a6@2c6Cs36MNn}Y59n~X6{alBPfPB zE=~29J8J^+`&-hl<15We{^M}1&-k4|Ij#Qw?nv@h{58|s1x@r{eO(MFV>U?@?^pb}6kQ>i!Vfybu z#{0B^Yf)|!!K>w1sfS_xr^dxz!6#J4*;^7xHHNJVe@?Wzw-55o>(#qnWCkw&Eqcg% z9-_qb=S9o>N2PM3`wprAjppM5O@2ekWG2gk%i#TV)NT>nd|p)la$|B_jV9?JJ0i<+ z?pC7DJn{*jjhfx-+82R|L=>gA8H%L^cU*FHUMX{M|7h51O|3Ddqm{47@~*97{$@W@ z_e|!dS1<&@StH&9K5 zwv2JQ?>`}7GE0)#KoKIAK~$9Kx)-NYA&y2C@(ki+{fn|otetf*eq%_3}6!>Phh z?s#nGL9Ul<#h&^*{tTACs@psFva-M4B=t9zhqUm8Xr`>vT$x(rNq;fNdgf@Gv(uH{ z%%Lq(C(NC$nDE907|RziAh&Fr+%lsz<)a(f9T71HQi^RI^_aSyHR2e(E}N<~J4=?eGaSTrcf zj?YT4AtrFR>Z^k)HEg84>b8xc5BH=39QPG@S9BXm!pGbu14XtZYdykW! zOye`z{*ZI)Uq*kzYoF2?3jKAGN_lV7+5@`?y!w+TS9p~?-Y`%lI8h-lRZx^Z@_r)q zSc2%B=7>5~{Y9&@X|DHlh~a(*eU#uiZcoM-E2a6&PRT#9CTK(G3&h#FqF(@Aix{^3 z;r2*%`1_=nmw$^3(%J3l$ll|%LglkZ6%QYmFDa$;#>)WfOWZ{lUK9+-HCh@ zFqQ!Q*jrVKOIO)1=e~3XXnE5?_FDe+RVd<8t;d6WYVsqpb zWrdOIGyU(s1o6NH%Z-+VgTos8v9bQGhtykj*V?CyY#pob3#4Kk-}DaMQpoY>Wo{Kt zhh;XJe&^!q^an9IxwfyognqEKGO+O!q^5dEP_q5!i_5q5^|hq3??pqFy)LckjX?yj zPQ4|;nRRybao=T*)@?l5dbrh-8VVRb{=0;@Npcv4)b&bO5pEc-*B4AKY0tC!bQDV6 znW-}FkFi#R-#+%9d_LOW`22Xa;9isXgFxLD<;5ZQ>-j#y7Iv2@M`f32?M^5v4uvt% z6U<5ib7@I6mHGGiq^|^=Av#fZsgjk8HIMls6H^(CN|;+e9jQ@D+DInv2a`;aT)ut! z(#T`r_?^}0a}r~b#c5saJr`rHq1xq5u>F8CV%cbisOx>8F<3!ovrJsi4Q>Xf~OF!Q? zvs8TUIOI+E0X=c#{UEw1Pc5t8h7+A*>X%Al4oy9Vx_Rwzi(h?<&rUNxwF!Pq$T=x5 z7;sWny{^A~ub*_7aL?9Lu}xHx#}S5py#HW zH!;Z45v1}%pSM)MYWoz^(x_Clm(-D&2vd96XoRs4trx>5_j{il<9W>xYg^7P`U znuplOVP5MOpHdUpYTQ3g%s!`i-KE$0vG_6%C2d&g%;wc@`HCjct@DC~?=e}O9|zex zD{yK;mZ8G5d3L;MJfG^DqX(Suyo=Y`d3JG+MU96V5W2&)7KSu!d|^R@(v5=OW}oKh zr#`mo-8A>CWK*4_h&vkd3Afy>$Ft1P9qqRocofIjUDRA+x6l6lw)EJ#eeRI~^Gf4a zo!USxPIGp~viwIJKbw{}f_vL|yK3C6CG!zaRBeBm&c-pC6O|@YxXjJAK6v=@UhbHJ zMEv~NV`nvLudy$tJ}<79gRO45T+b~zTTED#`yzjo=JD_gY=C#7hBy2|zU10fh<^L_ z{ptAQD#x3<4F$IaYY#pLcPyUr^|; zIb!z$CdDZMr_KU0(w(dA)i`-u@J!Oop+&6*x_Va&2BoRA4Po&fZ`ri{Ig^{~V^3mQ zeuRUnwJ5YEOD9mG!U>4xUy2mo`6{wE!Nad`@CS<0m!(-CKlY4y?-+8XmU?m7}Gm z;ZJo|&`TdEwQ4pS?4#rQf?tzO#oe_$^gK0K%D5#qw#$9tYK%v-5IBhzfRP#jm2no8@u-_I{a39X*MmZ=_0M7+w=C4<2n`gDVj49*iG4@m5`yr->eiERzYa@EXCPD7Y+ zi5yg^(&&AFx;-8`9!c|sPy!j7nsm)Gb!9~w^Y~P32PHY0+ttt_D3x7OlG^e{Tf1W& z3_95VT&OFL+5*<)>9QEZ8s zj*A0*Zmt3Ob$}RsZiD-WT1br29;c>iiMYcBZ#4_XrTFmQlz~7mF`OWTL~Y9C%g?*> z#4i`?i@oL1pPGQH6+#n8>wwYMV8SM(y8+XA&%>_e=EyS|8CTN5po4OOrUP=_Oz|$^>+1WA9` ziIT`?lC@X@?Bd3^tn3^exXJtg;#W8P-d}Zpt08{dLiyd zx$l>$dIL%3FS_zC(R-OGgz4*Vi$ly&9N%RL+U!2nN4mydxbv^lrqVH;H*a8OIQjR$ z?_KVBdRmJ<`6c`FmTbfYMq^QDvja9=X=u3}WMML46 zDBbNaV9HP!c^8kSjGOAzpOTf<{P zuN^6e9|$7@4uz-~O-#=upWp5mnS8z%t|FB#CW!IJiUz|_bx-h>RLos0du+V#f~(hv zTfDD9{V%&v$!MV zo1^gJx}3v1#_y71s0+--0h2yOv_!{8p=T|&^{4DRmk?(UkwCAdp)CwS20<2~ox zd)NJOzrEIURaZ?__gYn5-L?0#pFLV}J3Ge7=DQuML%gJMt{g#B_oG{K-~T)SzahaN z?`aQT2AEblF%j~P1kot(OYX|6WPLMvJy7goZ(C%J9(8Ep`)iMy(~ee-bdbJ&p^hm8 zX8+ng^~P*{J~|21+Lf2v47xlnZlbuT=|i$Cjd{8$ll<+uwCnn7-IT$&=rYEY`O?() z)j6Fl?Gp{B^oh+yTBGytxng@?_;n$|v=N^Q()=zO#AlZl8gO-V!^E@TY`(C`BhTkX0z-xLU(oeVPovstC z0qu(k{+?%o^yEtuD&d+DNvTYO8&Nsp$SBh;d8vNTU0COvN&%hyAK4|8L%5Foqem2i zkNADeY2A?rBrg5T1fVq(^@opnNSm`3dCmNpta&Rz41cRqU>xjSj{8hAmj0&gUf0FQ zd8VZe_x_64G;;j2`AvDc0si1`00WbJ$*v1TVtHBan=~>ch-ImON|rl(4O!Q~hPc@p zN*p~5Y*uB*CFm^{?+;u=6sqF3X9j|zkls!6t)9cUGw}|hGk#sSe)uhq1 z*0U4r6~_eTJ>IY_1^3bU=*N=T$HT+3{** z!L*N$kBj+d4r?Yc;QM9@4_;I!8h#Ik8!#(Dv<=4*AE{497})f7h-lnUgvdeZya+|a zt%-bs{!sbV&W-{Fo_b_Aa$(4v&r(Fho7~4?VaSCq!iKwil$hYifLJ7!V^N^M62rsh z!@zTj5k)G%oB^yM$ocOPBa!=y;buo^`e9fA=uQH^0LO$`06%I}1W2UQuiGx2HL+kFd@egk)l(M+1*I;g+#HuH;mK|9ED+-bQ|l9D#+amArr<)2 zf_!g+qzZb*QPhW^Q0|6Q(`trGihKjrGlYj~@s8HiYchKzGL-9y)x@2%Tq_(zb6QG+ z#eG6etYp`f;j|B)OQ>1fF}@kazokAm*(*d!yVESmc731s#9iO&%eEv-G>&b;a-AdY z4*Eyne{hKKBk`c_n^pL%t6wogLcWnU~Ev7xB1Nb-TqcD> zhhyus>yNU~ss1VBoIbKVKO>$p1FJb2q|4iZ92@vWQ=yp@qaU9anTi~3Fo|g?IAQ$f zzGn+&Vp(SVIr02jHVQU+dbDI<(T&-?Vp?rM7i z{~2WB=yzL?xiREFW$(Fn!J85b%x8bkh`t*Km97M8O;z6A@`W*89tK9WdvgQfP$!8!i;LJo; zmD;C;zTson>l2_4@HHU@i-to0p5h}r0}w@UKVXmdte-OpJfMC2qr@pIl^$caTsY9bIV0Ic@@E3@%KM#qvIWD=#+ze@4tL< zxN(=4eszJlc9Y|MO}Pg|jEB5)E8v*z>JCYm%4lcb$9iYetIKV$HtL%MpQ!jG5z>H6 zaYLVNq8K;Fr^5uAjuh3;^>?KqoOzb!?Hd9a8A8*!H4Ly6q`@Huf@S>bZjBww%_{aL zqBMYjYSsRHfC4~I4pV;x&X{fT*yRIUBCDK-SuJdC8$s*a*J5bE8g0eGR+-rP@^?4v z#kbvxe-}3MUU7~)*@^Iz$Iq%EJnGciqI$24dD&(-u-?<7Kb24vUag#^%>|0&r!mL4 zKN2T@;eCj(xtG{q?z9{OTlsP_$yW@+q$t&-h+qMD$V+)g!8CA)tnb_&0U@IwN(%Id zh*5hPzx6;q!6~eUVFd>5e2NJzkK?($4W1`7k37JpHvM&ELKfN&{B0q~<2F9J1Pz+HkQ+(h+@I_srhmz&y9x*R z7Bi+C4GVV(IUUxRf*vdqX2j$Jt%#n%07|*gwTFHSIkxH`N)~atb8fv21rn1!mQysw zFPN#sO z-lwTQ1XhZA+3*LvFzx0GXo8``f2z+RFa4X0XrO_#R}%5)-qR-n=iq&KT3FubTXbtq z9s^9FJG~3@?m}He{5nx4git`IuKsL-)A{Z5wO>%24WkBkU`@1QepqG6YOhZzW; z!NvgSDbTMA5z{pIGBG?U40l-4bqE~a>aT?333jFG(9kHpxnPt)k>cAjA8XQ6UDw52 z2gL$LiRj0dpR_w zgiENYzhq7fs=3HoI9+*P$F^3V*%UQx;~4ADc-&%BK`K&>hVgwY_pU-X%@Y^W1n}3rFn~1sv8I}Y z|Fp2EBSMJrui%Q=!{a?J2{7l6Xtis2TfP1+4zh|_JqEjCZ{1o*fuBO8EqJ*kIOE}Y z0WhynQNClV=Wztq_V0`B0eO=8aJ_?xn|-i$?2oasN>*19v!Gj?tNzV>mm`oA9-Hb| z?rTwDb?XrAQ?B3vmL=uy{F20K8Xq0h<5tu02{=@m19}GquJUl^NVyN0?aq^xT7MnC z3AF`Wmt@n1?ceb)7E&@2_jB?gqDvkAgMkF(TgI!ICS)yA1iC>=&-Iig|25l`x|q-u zJlS7j^BMmnpnTU`A(7}KqXht<1C~XHMWMY2`4TH=^hdu{>CP_=Ui=%7*fO&^*Heo} zmi@NvX4Pn9kcYKO;4QmhVDc+x(^UmRS?o`Jz_lr&-QyAF5tMcS8xJ0Q&gb3z#PUcx z_XZy;PV7N0Emwt(`umyp8_6#pc*;nq`g7W~aPJ z7r>J-vSARejWg!sq}Q!wVq7nUi6?*;JeC;$7A5o@T2v)iXOew7kZ_JDhBXSy35Z)G z$)5w1oZH@86kYr#J3wol$GIePeDjyE+VIx6!OH!2ej|)?jR1N7${-~Kx&a%93Zr0b zL<_6XlYy#IRB|P$8dwD|RLD%SVyIH0qN)UpO=@bHL*8guMkDAZnGv{!qQ5MP7Tg4b z`Ge_M+|Kms7uoUY{61-f{nppk1&8bI&S;$aBk2;?T>|C4(g? z#Po}TqrND(;ig5i?nyqi9W$FEMC=J=!R|;w!w)YytK-bVsvC*XRZz4+a*TwDZl;k; zEar9b$8!bI@Cov{&(0gw(M2-BwPJ%{zy9u^?k)m?nACwH6P|QNm2`TAM%d7WN|!X% z+f<}+u32j({T3Wg5^7zZ!?-_(o&G=7273EQm~|Y*OK`ZYw`@J9zqs1yYnHqsWhdSL zRf@rJ=fNHpE1e3EW9dbdyrL1aV(&SP$qq5q%OH9U{`lTZ7i!wB+ zw-*};gD=9w`0=`7b~i1BKe!e+ZyNkq@Uc)POjVdSPz{Y1sW4_%N9?m#U?8X&Gki*7 zH;M4wV{(BO{blqT=_pQvnSk`|@?=8iBZA_9rj@uLLJ;k9W`S+eFtAsYsNq zw%WvGBi7LxrVKZ*)$Ey>GJ4@`^0zwvv75W0+qPHUIVx`Z=bUPbu_nW~si*q1tRm?c zN~R&XI=;0k!z#^4TXpMjRp(Dc3b^i~n?l1X( z=uO*UBm0|KKmSMe?I0@G9_C2}JXf|jMOa(aWOoKSQ{~?(A&=+cJ2<{jV!@Bho0gt_ z;3{?K=tT;9i36#UdLsSriQP^@($5)ujGk85ao?ius(mIOaFLj7+plV3T2%L}H{cp? zTB`;tH^EwA7UzlvZh8tZk`V;7()Ud^^1sf%o4NBCGBPLLQP`80OVDtkPN|xE>=yA1 zAaZfz9F=P@)a5e7$e&=7YtF&T_M*6*8CZwDVnL3`2j)+UoRO;>SlXu7uG*QUtFrxAv&U~y@~yS|gLk~b0K%oLsdP8+;N4&` zTqz(8(jNDB60J^B|G@MaZ%Bc^3Omw%9WBx27;^n*&Fq0s=oz{9?ZYqpka~qQb(~^T z>F-U_IQ6nzC8H||BY{PnX=Y|zG0$%FQxkedj_RdjQ9LD|V$|Ve>!m>x>Y(5(cwG6R zniy5;-+SI{$srY(BGNRGVBgBBaOFZh)o@LN(wmAkQanDC458WS$RZuvT0MO^D$=8e zIJPJuUDleBCYmwhNgG9moCfz=3!&CdR;--D;Q=NI#X0NmBphl7Kz8tKmr5ixUNvL@ z%-u0Ve5YbMd8O*Pw7=i2*=wNDjHRD*CjiH)S!dekJZLB;=#7acRz3D`BhJvBGu%7{ z4d7?R*A&n1F$t07|35$ElxMSebDufYiaR_AJc26s`{tg9AX;9uoLsyxalC{w2`dl*OG7l0M$QC{SyW!7 zutZcDS7ShuQ#3kD3t*7R*7T1=3{j(KjHKJ=Hz^J;r>*#_(?)xOVo!QzOe#awu2q~; zU2!^04?&Hh7qyN2xO`9SC!!Mjw7S&J9-O|_alWau+c|eZ4Fm%h!tHPEIuS$$2D)pz*;}N%`yA6*CS#2!h{Bsn`e@#r;brJB z!${dclG$uQiE@e7830SIK59OMW{IQk&T1ZNBY2LzgZ0H0z$p6gI#o{Z^bjWV^oJiS z{enz;S@yj{#v~@Fq*M2IQYa<k6e&5=L5bIZ0@xq|7i$SWC+%11Ht6r5WPH4^fnd&8*E* zl#h zjagMmMhk~k)3TJ1(9hmb0WO;D7t#(dhaCi@>JOQ zH1yrYtnty1fYca!%36qBD2Jad0wr^B_p($;5o5QZFV>zWbOCZ(j^>gE%xqEkKR-{0 z7p3uAk~llIj>Uzwf+Mg8hc^3m^`~CLlSU3^7m^4q+wP}I(`exghSg2u8ltdKF6vJ) zRsSkfml|zixMksr6chQY6|1DK%RMyI)R67}u^sBXnV3z4W02NO7?m%XEQ?LiEK82p zC~6?m1%6oQZb#Xc)DGc`67@y$cds9trG8Fhx@`UlDYiN|V*P{y;@B2e`!aXl_evF5 zG2n8unP0%Q=av#vdES#hzr^71Fegq2s0B)2?;eDe9+!(xg+39|^l&ziIpZ*zQ7>!S ziOun%0*q^kfvf5gfdY1sAs=0lcyx0`#OAk}oN4*aHsalK-mSva(OMP}1NJfV6Cv8y z>CmJq9Twtbv7d@302Zj&RR{;8yZo4lY@~nN$KY-n#l@2qpK`EBPe^-}&x zA}~k1CDLBleiTN`8{+I?&6f6?c6n#l8q+VD*``gcv#c?6QcMqM15#y6teK~%R-IMz8{+A*j`C|i z>yuVgLn2@(9rGJV+SBv;$|EQ%3wU`r>L;Wcz3=$Cqpxmtom?1WEp?S`F1-?5sOM;A zQyNu0;6eW+(Nn7COaEF>v7tTqQb#mZJ^OwotJ>{3;#Ow$*ueSd%djv;pe%Gwe|IZy z(ZsUrP1X4<{UQsY{h2kLgq5X9Xz!)@)nw@qB)iLSHh|xsyq=+u_|L!@{jxo34x#fkVw{q^ldMt@jM&M-T4CJs zLU658yi%B{w7aQx;J;Rbg=*;;=Qkigbf+3B>^!aKk z@!gkNl(%%$6A-~DhsGK}1{USuEzkc#9cOfAKZlfLnUzqNHsM-Y?if=PrY}9z?;K9| z)H-x&>8i|uOYHg6WLLtXigA?9d(mzvaLk8wRXUf z#YGYal_a7<(G`81=9aq^ztL((wvv`PQ2iRAVJ+V(7*$=zgV4TW|0FY3sXAReRx1a% zn7hyA_7K|VnZUJfs)C9{=g(Z5mmelF)~%~?f;UT^ALI2;em+NLitHE6MkHKB5r9TG zXrz+4q$SW9Gii={`hOo>Zc?CaeP#e-ygt*B2L3X{U8jhV+VrUMnO_jxm8*Zc58fu4 z{aLo25F8HW*oqYj3u8&^zV4ta%vIkkWU?{YjdUqdZn52c+ueWCAHL7nHA7?E6APUvz!&1~CQ zjf!Z~ay75_mV^wq6kko&H#+jpIrZV<=abt2{cM1m;}WZvBZF8mF9$|jnsn9tO~=ov z+`rs+gU$`DI~?r(2_*imc4oYLA)KdorW05ybzlP63MW!7&{7@J-^wav=he0wUf9lb z&)zghG0o*ZGhgjRrWC{c*_yLxX+1v3N!Wez(G}VBzc-RPxSqu=Jel{B97@wn?$)c? z8D>k>5+pF7_&XHIKWWkP?y_iJL*|pSnyVOL`0P$S+k2Co%Gl?2_*N*auvBxAwk|0< zo@(rxX2*4*heF^iJ&;{0MewoQ!_C)DX>2!+fQDf9;>v|NKFaLq`R+-8`Q* zI*{$xX5#zeIMs|xgpZr}=}M_e6y4&#UWT1*UE@jFcCzN;@!DIL>Bki$e-h7ii0Sp1 zAdsDfr$ngJeEjfp3bhC}j~AF=x-vt?7>FvrVaOPWR;Zvs$O+&NymJj$Km>)#+pqPW z6eV3-X1Y0jYm`j|_Wn(87>YpXx0kBp%Q-`lxoSiONpW4=myS(IV$HBB%!Ct`7s^S- zEB`Bc?tM$d?u996CRjA~o-s?88e154py3 zy;z!=gSoBfpoY!`h2{&_sEC#t$@EzQlgx14lwGIe;u>nbn}x~0g2H4N3?%57qH%L# z;5{=iBt95xt#eqFHpb5dxM~6YjhaXYNI?Y#W~(Hc9n7R;&?ZvR=5jmtnh{Wy%7rpG zoRLV05gihPtaEg$m_Q{Z3dx10%<(YDl&HK2ve~1!+g`zqfIye@F%oS&TI9%ew_~o9 zLlrf2e+kO$WSJZ(Dk)m=3+C*pDqK&t{Y(W#7q*{|&!*H&32%DD73l0_EA!hlCp%32Zzl*c`+|mM?tr=lc*%&9x=-po4>5_qC()9D4M;6&hLvK zPohH^=ck8@of-F}1ar}cD(L$4>pQ@Xsqi~$(*#r|4=he>ley4n+63za=fH{8ueN8& z^CXQMk)M0@_HE7GVz8p52zt*)MV^!UNjY`X6TXM+53H^xe74v(6cG3|pbYYvps@!P-|9U0kW6%@|!ma_t8)3kOO=*2)s@)G$>% z0t=tEL{jRvu?~x9(+qs1Bc`7S`-`#)o=k^LP+)8pekj{-5~kgIt%~tP+2Sa2Jhfyj zRp;#rq6BzaF`~W7a9ws}sdz?oCn|bWcC~~_wV$Tp5|RB_iFrMA2bugEvf8jJ)Llf! zvo+ZZ_juw2*1u7cnr+9l5+S4T8ie3T$>L6kEenRZawN&G%+Vz&%m>W}HQFXgkt}B6 zy7QQ&v^tNH+|NzJZ7F9o=8F5e3mo|MCY{SQ&n|@_yIF#Z{7D@`(JdQfCbt zS97&no8A-}^sx{0@#%XDD+0Y#MuTsXv-&Dq_2n71^d}tZyv)Ds$h(rG<_(t-H$&H~ zwBAR6Yq}|@@0}B$Odico{p#J*+9eZY(CXdCF|kdt+Ri z@A%x}=GI_m*xduV?h;TP#!Rc@UY8(uC#Mbe&O!1(<$W;q9X2eL&0zZb6T=5eKx4Jb zZk$J$@h7C0J%)xW&;0s#@8z#KS1$4`z$tHNyy~NyB@D+*aRY}-GB6Oxco)eU-nm70 z&k>M+o}CYm)j(8~jHS*PIm0n#Sibavt*@xYWS#Z3jZfc^2K@~0 zK@rj-_)6(mEWqjbn4fKx-zDZo$`RP%vTi?wR0Hb|_~dOQPpLO|d3G)h9ciiPOvU(T z*?yim7Yd&oY+H346E9-B3mv#ftKc9Ki4Jp%* zjI(@}=233I$v-v6Cr2jqCPl(KUshUE7VWO5&@Gkr3n<@nh>%%Tghm@evLe|2xxHV#X1XQCHK*8J7*W&{ zXpEdCsj~#z`_A8Ko9Uu99H*re&a-$1?$lg0Z>)S&9o~Mrs`XzN9Zd*T+GraQAaMw9 zSjrCtf+x(T{bH09C5Yo(7AG<_#LZ&)f5~7Hr>`*yymOKhC=+9lU@9QN$1)MD{71`9 zcD6A%(Tg;*9yI9o0}hCm5tzVCMh5E*v%+o(q_qlE15%TTWrRBfe>DD427_3S%FDL{ zxQF1u5<$?90BpvH5JdDrU#xfXwY*>NW`4kbZ2kY20RPt+F5|Ovt;EQagjj>s&QUq` z+z4e|5P@MF)=DEycn5i;yI@z*m&5U>~fIZm>*C@j}{Dr z#NGy=f{;OwRQ^}5|C9bV+Ti~b_5x(;ky~L^04flfbYeP40L(DJf*p|vy&nk%h8J)R zpo;(Be|`_F@jvn(_zKrMtl>X`4v>6gWyM-N#`l2bpG4CN@)u3|h574)DF72d&u)bd z-w+4`(eIZBVpjlG@^ScK`(b_r)Qcjq!`Q*a_mAMALJ&K{+|a#c4PpW zMF6N@2M-qO{l>5W9sooB5SwVhc35_FW5hjC(EqdTe^>BhHFduGoLktflj0eEn=JBvi<02m2`139*7^3T~MRFXIj2UZpa6^- z!vKH~01(#t-8&Q!&dFGkDjwa`1qK~(WsLD(9R2_MQi%UM_g@*T_apGXW)brH5SRiu zAXor6$opOX=l5O*13@|pnKxFN48<=O;-%VR4D$SC2tnzl=0^8~iE9QBgrWhk7=!cs z|Eo9T|KN+>TmE-jtoNb)KNAIpDj$x{hXfG;8=iy+cou=Xg)Z*umT4=eitSzk+PoFm z1AE|CVsCg$Yp!d;**Lz~v=|fUCpzFFf$catQ^rkV)*fsgzi@smrz*_Tb=FbPb8Hh6 zM9|M!+U6CHOAQNl#m~ESx_$UQSYeB+!s`4QWaAbu&KX+`Ex0Owfk*s8Z5yu=7fUsN z%r)PdsG0y%gXLNpps&NLg#w1UiZW`;z-gbXyJoP-aMy;DK} z#l)%B!@-@|mB^b;^2niBS%aMAYS>7gL_H6@oD!kOM)Vuiu7zmx_uM4T{oA@9?G8rwL6 zkzGbK83KGC-TxNj|0FP2iQ+3*rrXjTptEiP3!J_3~qRA<#ut(i!hFIUv0{?(X|7vYl#Gr^atqO?}#q@NJ_NsesTpz%$q1` z2?k9sRxH(8$%*f{h1Q?rjTBiBlwdN~AS>A~?GY6=%l9WaG1$)!xT4wfF_fWGo^aJF zNpz^B+{XXny11;-?#-51zXsno3a62;nJs4tcaLl`SYKsmE1cvE_?mkke3NBj;9AzT z8XN0TpsbaO!jQT9WB)mb{+$~UBzX6ATRT2o%O+_uJfIC1A_V>RPj)`lZnZ}y6!noC zj}fblQ{Zp$m%;W5U}bD|0P=_G`wcOAW=nk{JkJj?@?PcjpM0`qZSCYJQfK2rc*;{C zav)vd;m+M+t1&%5UOFB>__J5yXa@2O&pYGTLbX+IcvI4IVS!-L4{5^8{@<`IE1rr@ z$@Mu}ax;p z20q=IY_DxvVi>4Eu)o$5X`1Volnzkd+uP7>p7N@rJNpFDrdC@p)CNcc?MgYGLJ*>|89(xp^lK?}$s`k^q0cA@wrmVkS<%o; zp=P-{aFk85)BmmDozKcV&B-B+s8J^9`^^LlcxU~{%?F#~HsqIAG%Wei3J&L9e@nU& z-knT4#BG#m-LHcEw(L>$ez)9Mmy>Eh(t<0~@0oYQsX1+|KU;Eqc(phC=F2=d4^V&BJE*7?pe67S!hj0=+EY5D!-eI{^&9yKae!Ym`-3c9`CCYh% zPlg0$4IY;OIZ=8=`5gkmlCX$xRPygwGf>Y5_@Yiy9bO=WyH{0Xznfpel_VT3kx&d( zQd<35^ca{A`~JrN3QL$%1nt{wYgTyVIW_sFObIV-qgK1odl@KCxoF`<<5vGBC=Qv!278qj$fqnxpA-=~HyYAbW^*-A%P%JFxzw`QA ze>=uN=Fig*lU^INbD78?!RkrRcDz-FgImzI{s)}O}9%A`#&J_uJL1D{m^Tr}qQsK{W;C=K6*0It*pw8h`P!h29}%f% zEa&zO-W|AJus5T0A9rG~;KIcK=E7|&!rCz-zI-n_{sP>#Q?N4Y*6}@n)=##sF^{w6t1acye9Bu;&tAW39mUWG7TD`*lyJF$N3;r5|1D*L4#%KC zwnoDt|Pe+aY$y7{=daWDw`ZsVzlvp1oQ*MTimJ2F!|b z4O#Qi`n)(S&bU=8;ih>%yJ%qQlEio*P%Dd?^jJT;TY~AbQsT*jsUm#Of?HR4g&C$2 z4?X;gAnc1jH?2DEZQ(Tv+4%{l&nB~QO;5$@N)cOvb(H`fqKJXU-J*>8Q69GCngGkP z80Fkz>WLcmdF}}3F@w@0oLR3NiXogKG3VDC78oZKKWcMa+{TBdoi}NQ)2k|WRP^#5 zWWRy^hq2%!r3$5xx1&PuvFR{80Z+FWZB6}CL=jN0ycjM{#Fq@&^wrY z;!7ic+@;_)Bi!Gpm28DU7sXadx1ntIxy6L66L_Gu2mkF zsStjH*Yp#I!`)H4YGYagC7}uAD3HAJiWKCl;_sm5)&^W`1nQ=;#eYHjRECQ2L5F#AR}+D-*iXtFNAh2hn+!Hnc@!K;D%XeVbmPc2jL&j}GJ&23Pq zAaGA<9AplAtTS9$maM+^eeJ!s{(h#)=|%izZAiaE4`{U{`t~7#bxmeZlKK z;cU}bNqP4OJ^7!N6;E4HZI?;#E_rP7Po(&d6q_^Pb#$iW!kxz3ga@Y=9e%Fj=@+jy zHYV#YxT5k>6xo{Z6=R%cG%(Im8E|x-G;EsjJIp6Y5Px8luH{}#@LI0QH^!Z_1@*WU zE@f`lE;51%^YQV*ba52_MW)T3&|n>wmREKw8q$8cI}sS>N?@xd9n*F=tvy5^)1n%y ziNQU+PzNY+v$j8HwB@vvnt^$-x7yyw|5SN4*IxG3rD*6O-89U*DP*c;6I3=_(J)cd z=}TZb+tf&VsQmu5V%sQrK{DGjoC=m={YL30LrOV;fRiU(Mt>l`Yx#|%bia#mRwK0k zd3WP@Ik70rD8+Uu%04ram;1pYZck=7GK%gUZ|5gFr-r;o_mN>arSfLK@hjab$&)>F zf4AE3;M~_C3)hWhsKOtncy0~c{5!-(I>nz*FIDc3S`DnRo08=<;gxJckz%dQiKd1h zK?m5fsL8w97mwfDeL2x`>Z5jBrMT(lnI7`B!}HwITZe82lOLP&_-5+D=YKe_jJK-@lcVCZb3Um9y8TR_h(FS6UalBV@^g3)FDr&BCYiEi;As(}x5} zw&bPMN>sokNqEc&Ip9G5;LhY&lglz$BWt33R&B^avYoq&Znm!x%`j&kU&>m{wT=uD z*45V?ilh$xqsoCVapK9|`6W$&Kucoicb|;ZX)IlzVf^P)0s@A71~r1ff7q+1?Ao#I z`nwK}_h)1-Ydwn~>7|mP);FqOV^ZrPL-A%(c4x?!8Z}I?lu{Gn-?|9{Zf(~BzKx<=IjpuEV&VSNEeb?N(b;wNT>Z=X z>9XxGszW;RqtwB+e6NebZuZCdFvnrq^N&+~6BA=_+)gi-{LH3tjnyiX3b?cnY3dgk zcqHVjW0y~!ZXybfiA_V0iVo^I)8juHoa$9O434%(vj5ofBmGhr4)iuk3Y!}P|1DN3 ztt>Ugd&spfqCht_7Xw}55@wq#*R-q%zNFJceSVWIHQmA;|F_%zmwVNlNH6!-kfplF zfCoaELr(DPO{xjBP%U$q$;V?qh9Zhp;#Q`eWhnjclYEB)!rbr{lKeMA0)0bnkCj8m++qO(7KUf>5Pc(2YEBCD8qd0hyJ`J-#_0?xiW#u zSxPk*f7ocN$+Ke@L~R2ulw?0rYj;O{jQJ-%*SMhs__sQFx87~Zqm z!lTS{`xgnH{%8IU%1<&1%WI?$_ry?4<+|VQVUc!nhTUFL+j0}FF9&xPEBWgh&KjqY z1$@;ApCWcYKCcSYjww2suiSt@Ac?41rCp<7q{J-6D@66%Ocz}BWrMsg#e-4~(;%B+ zC7u;^DQ8<1@j&Pohhefy*8Ps@C!6h|G5u+ud&Xs5!L0B{aRQCn7n_OTLdT=7&q>6p zLa8804n%QD@hH}=!MV)AbQ&!=bdV}KJ%KRU_pr7uU2#RD-tXXhj2BRQ<18c;Wt_mO z8Ibf4mz7&}-7OkI;jzl22sVIx64 z>@o#c^#Yxf_;MlU7}(pd@utUDbisx_zMBzNNePr%-HFC6&a#68D%hPG%SM_~qx&*d z7eksj(sD&yq)^}?UnYB@^!-;=Z>C?z6!oEg^5N7jA;sCVo3>=rbT0z8WRnr5Yh0dg zSADWFPF<4L6W563M3-AmRDgJ*=H24>5_`i4sTXmHzZO=8fTz2912Ple8}8tw8R}1; zD2h!@1f%{dMGAs568>2!#M^Y+RBKu+RWfaxI$?Y2!Z;cA_B_kI-Yt?DWRmqoDQm;V zZu__n%y+9TOGt<}A-ec?(hR#ejEtX(aC{4?fk;e+gvM^7GjJty#ziO# z(Tw_bA``;M1+AkAbqjt~tEyt4f*Ywg%C>u@+VPTFual@@r}ox*!(1Ktw4J5C{_FAN zfXKmoq!!b%#Si79lZ$AF0?Xh-6Dh#ID~4(N5ESQAxXl-uh+N-+{7>YNytkLUTd%d2+ozaQ*6_*6kXTH zC8tX3{i(;PC*p5Tf%Z%J$v-_K1oGPMd$t_~MNpYw4!S|!gk`uQgB9P8AR~K zIB8;x|Ex5V=@6xLYELv%I5G%{mgsO-4IjsMcS~adiNSx9EQcmqSDrU`Trta%g&!I! zA0A!T5<$E^N?{&E7P5F68X1j~Au>X`IgqG^uDoLxid7kI^g$F&bPihHM!MDlA-f@k zFJh>+Zc$6M9bcTczVbL{uHLgi8&NOLI$!c!m9;*)eZ@g@hBI6w$|#bbD5)ZZLR${! z%R@mm>$OsKwq*ZcR1Lv2T48SlA4)RxCCoA;OK<)ye=ZBmTPk5th}tVh@ZUZ2{Z}=# znNXSF>3jbaqyK8mHI#MAKL15py@F0|yd;56UHryRNb}8{YGNhyt|fJ-4(CPLEqHHW zIyQv`wl3B|xq;=MSoZ>7@7d?otsGo{0jqGNBtt6@vp zWweKYg?<%kQ7i$*DBAllrus-VA2pGsFHH5N8d{@RpUNZanbC@SqigZr(7C#<`I!TT z@>v(xjZ8DV5U(0!_2pj1vo*ZoZY={5^X1_2g1oF;)i5S1}_Fw{F3 zOB|pGjp4*<04BRdwr7T+R@vbUK9yjZ4MgC=!W9WsuzWXqK1k z*m(1iB`|o4YOvpiVqf_cgk%wlfFVe86v1(%&y@tLR!!FSsp0It8`mTBb|-zWKrS zMYG1|vzsL+x(Wgl>)qwY9ky~eeDK=m)xNcZ*;hGs z3RU;Khd*f$4rFnA{6tk`RS-OIrh`|izB_9{iyHq~DpHFKT#EHURuxKMS!`Evdi2l zP?tV2^5B}k)<{CLWb7EISR$pikHb%p5l&XZ>MxWW7%%OtZ$4p!HpK76QH7Ntl>Nyt z=^s@K%3G(PwGLLA0L3YQv(>-fxpWi6$Yx)^wsEWBa2Bi9#3${&=GJ?-?qFl}&N{9O zJISK4($fcpl<|Sb^e8ZCRf+a24RKNgsAC9eqA&|g;&o=zHz_DT;OnCN#6kH<$Z9Mf z*zC!di7X`R=N3##)ik72z?hJ!iYFM%l>GJ;$4?1$NeQps@!VU9LCOU4-iJgX)!ZOA z;+WSdBVYdktWBe%csO!Y{2RZq|KO!p-ZYRomhIKkv< z*_p&&VK;IlolJ}GEPi_k2m8J2{O}>BCA5&fFL~tFjiJ(@tmlp;O+J83flwJgeNpqP zO2I%2pU^FN$-IdB2Typu=h28%bYXq#1zW~`+MY>=d!Wrz6@<1)QAB3k$T80mp1{yK z;4jlsv1(!gvP1Pr4QXr};DP_JY4u}FWk54(DPx=i)MgIM)6j0@WQ?XFz(ai;K9Vf z>N-8X(hp+23>LbMfE)HE{RvG!-L}6|#WQtA^knd(9H=B$vKXG`(k%YYP?NRR_HUW+ zDvwep%JXvuLH7^o4m)#g0ky81Bau%_0)aX%%h7eTLU~F!id7#8{o!&9og{Xgf+OlI zZjr{(r3IXU{4BX7?mzte-4MhvGqf0-ur)SoxywA;LkI*dq(CU*GXwloSf23G%q9md zH|Ga;js~&>g&8g2vqUTYfDM}hyTenkgGytkNtdtx3 zf56!T?SFsNr+OqBJ|;+$JSK}*44RUQD{u%7OML zJhtaeg9ok;dHZ}QNc-dU;fzCx#eE*U25mHJcrxmkuCdHCT0Y4Wyii1kf?3(!V`884{eR)MeX2l!_*M!iFbu__OZ>y;MwOtZ{%O zP@|NXpF(;Mx}QO2EHzvwibI+!uC)m$KDD9XH~A4E0kTxoWg{A9Iew+_QZHs!!u1{S zxk|KMD!`mWOk|z+zO-p*rD{D7QZmDRgujlK%sI&$0U9yz!(i5N3;D_*4pD&TECW@X zktdpBrSt3@-P36u*({-~&*o@8b=uCSu8rw*4hS)O7K(Z3=JfW)$mrWWIo|oUJ$i0_ zRL=3l2z|B(W|F4*(w06^QmK}bJ6~T^yq!eeFt2%r);5)bv2Dp?-&8dOC^7s^DqBmn z?vVt!!rB^exv6-$&6uacPj=_+#eU18bs?@8l+Pb?|;!Vx4 zRIWyak@(2clL|kF21qW)f{6v^sARQ{iv(jY9qwb(akATA66(+^TzdUf&TTnNe|es0 z65X4&nA!0DL-@w$>xFjChRwJu9rv~4S<&xw5AT-IedkSxCHRXx9O{gH<+JcbedQnM zGgOTaf%`3BXX`M9oX>w&nFlh#v4<~nvdFf553n@M%8rn%|F=1 zo6AfMP_ao4f&XHY(f>*qAf^Iw-VdbpTb!_?S2tlLe#z2g96CqUJ}!}a-#(5_d%>}| zynD(NZk{(#ON^LCtd5d|1OGMuI&6+jLKINd>SVEIXo7pCsLIs}9e@{Lg<9xWXXd4D zy=|oiOU3H9kgWMK@~IZG{tO*{-?idM^y>m%n#e}ILZC58EfQgcz%BfTy-kxN4_&Vy znuEnNxOF$Bkn`y?My5izRFOiYxy4Up*1o%L>9wM@$!`be%FTb8alHd_24mO=@iZ;P zw7O)&ejLkwwiDt+tP5TaMdEN4xbIdg3HpOeZylDV@*~g+u0p8Xe)H3vN-lb0?Wv}G z&kIl>k0vrit8dONYgOt6-#iygn>jv;@yq`Q+L{9~7^W%{*!nt*Nbh`*8tXLGLGxuJ z6DoCC-26;or9rTbEu)5g*U^I($rJ*fkL7d9xU#T;^nM}D#atawe6X-;S963HCRaW zj(a5!=X}@eX?DnlDL+^=o+YRo*+b+G#O%Cn7zY<@4pd<(;YeI_PhoAN`_W78_?A4^Yfh7pIA#!D7XsaO*`8nol?v@c4=#UxWj%?S`^Fg` z-8gj7+sKX9vG;nY zm_*|P46}qqN>BK?OgoXjPXd}h@%(94&DN5*6ee)d%W4GL9A&|9s)2v>TZR?Lmbn5o z>o`(6-Wn!(=Ig$HkNj@HN$(!-@g0?EOvBiuL03Bt8|Bu|4rQ1a`9#0$*<~a0My}z< z9>1*WBnjFMwoa>{J0}84QhJIVm0kx*n`msaCb#Y7&YGW@LoAsT zZdEArWZ&kbG#IYKw5rqeUCxvm0EyED=d`}Z2S-8a9{r|H&g@?(?p-_|Bw!rb$N z8yLhNif!?Jk&wDyl&Ov-zDc6Ol(c}&CwKHgJ`OE?w8%m-;qWja7P;j4)DSk7CH(H~ zPWe`;yiPShyX=t+h3-fjwOk#C(l=96dI@r?x54bUMD~lgsEQ=^3%t4=AuQikmsw6x z%pc=das)n+pvC^TK8@*W_2<63CD|m7fqC^0F(n#1r}a#yX+PVi<$L-O=deKV+LE|0 zB;6jGsiiI8!HjAI0lqIS9J#n*-jr%=NRY0c?(u|8jVuz)QB{I}epeap4=5DXB)Xhw zZy%agMp&XuDnjOAvybh>ILpnJunSmV<;6iGq>`$cFe!#?x?7pT7%L!<$+%tCxjc}e06bGkd#w+m)&x{tIpgc-w_rL4crGQy7jXpIrGlLV|-#4ue4NlInj+$Px= zdj>uD9bH@u&=9)BJukN>BU-hjX{5~$lG8NC96UDPi)$Gpb=NX{x-GtVGwI=*v@$KL zcs4f>h1ni?X#L#@+o7O{)3`oo9NZMkc> z4(0JRLtePe9GeCu%VvTTH(`0VBAbIsr`O&2HEf-8YGBeX=sP0MlJz?#Iu}GQh&a*- zPH`;>K560ejA;$@xk*nG>Q97prom}w20=GzV}AR}RMHD{lyMD!7RoYkGNYE!FL)GI zml|v)NTL*Mdu%C=BME<5HAp%x>2NYQ@qepYXJ>;DU`eQ%{9!O=sts3xMN|r5$=m{> zJGXUNSklJONTel|IIan`nJ3&ZO|k3z-QIU%EI>Od-ay9_ANjS`8=Z$L={Uvm)3jSS zER%ngA+%*tedSLD8TZzde`02vO0@yhi-TEj$%txzwQzcbKs-t3m2_U=}3_C!XY4Afb2}BhHEJcgGHn!L+U8mH!W{)WqC0h0@j2331p4=N*bh1s_dt#5~l1#1x4y0`AHFtPrb^lX@K4niaOS} z`_5JeVb`vhFNt4`bDlOr-bB&}gWV~X{KfA2_bc%q`rI}}zGe=Xg7w0)_{EH!C@u4H z0-5w`@-hbAt-1Cohn*cA0xLi$X{!R zo*it;s!$}E0@4`Md8Ic#3+-7h>^aOjeo)Mtuu8WbU`<%3&%XDLTaB>#l2;%|@>EcC zc>ruq{2sWufjNj(l|EidX5F7g4@*Em>gFYI&qD;W(zGydA`T` zZ1}0EkV}1CLwhy;51p^X*_%(&4a-K&R|3qwwU_TTW+#{xlsbk|t5Y|VghcI0=j>)E zG`h`Y8^^v~*s~ik;G1O@D_Z)cj9UzsWa5zGeNKCczRJVICmg*}GwaO@#?&rVpw3LA zAC3X?tawIJOJE2UPf|MH8L7ofQOZ{W-@s_NYzcr@M7h zEmyX8!a%!Q+yvQS@bB@0hUQb^4Hs788ps`$2=9&18a zU)lv8#gZ%I-*MXpY~B_QcKZx`g%4e_YkfEwBX1Qog}PnSozrwia)RU9-R(0FsT>|_ zU*)?z^v@bu*{4(nUCQ!Wb$i;dIF=hzD}k{MI9)+ED?v$KUgM{FiBzQXkT?@2P#7#c ze@$n7#C5;V^WeHzDm5dbix>@awPM*%_vudeuG5ek16&*VtDE}WyFH1(#k9QxQENqV zO??x$oVNXGoQQ)_LMeFp13M?LIq$DT3I?~DhP&EljlC=Go?f%hgqhoU0O@@V@cj5U zJ%>64oKix=3mZq)IQNNt~G&Vh^rz-!kE2$Xdsr12lK*D3=b5^}V3;}%>2jibJgRYST zm*!L^#W7Ye5Bc)QIFTST&LO>5r|Xlwics$Sabu=qFmiJ&Z8$tO>w09N*SVgA!YwK( zJWeJHLzqBiQk)6VcC@7q(jntu!tR}+&EYK4)s}8@#vY3hsoXd}^}Xmzv;{g6ib_^Y zY;$w1tNTRqy-?N%Z!MOi??15u@<%nr@@+QVEbRQcl}t%Qn&J)2F1#OpcWy6*05#J) z)ze_2rjw`JW?RRO1gUe+pC;QIJkqG+!5UK;`|Dqg9>#AqkhbNyi2Ja#^^3ZfWSS*Q zQd;7Q*Ob^?%i2e(hi_TMemUHw`z)v1#luuJT2!f&60kJiRy%U%Xy>qBfSamXnHYuT zo2)+uj!4Cz(f`Dq;(597l7C;Hnnf(aHji3DvrCEud!JsB*>3!DZhy!t7z&MBqhvH;iI0AL%Jaw z$eS=-zyG3ooSgNVfLcJ4u#ers!Mj67-~laN6R!xIMxmTK^a_@sHyNUgMpz5s0&FIa z)njVKqNMop*dPHAK!_qC0sy8EOfygz;+qg5GdeEZC1j~rwJ<+3vsb|De-K$J05Sjz z{04vk1?|IeFW<}n08$g+o~_RXQ1mL0y07~eD;Gel879D*-3(yin=aLYSTQ1R7KitG z?f)`JhXL4&e!;m${@VfmZ}tDjf1vsQpkc3g+SmA>s^gm`6jUITbP&pHLe@Od3jv0S7@yF0hc*B-U|dY9bA&qpI{@?su#9^(kE%Y0s7%^~tByu@ zK64z#4M;WPX+cB)z8U&_7`q#SS%eDUbP36ZK8hkCyqAmx?n28!h+IG@Fa)(8Kn!32 zkZvK&0JXD4r%1Jc*+UYf@za1IxE&Y;j*S5LgusP}8WIJN1z52Gc@S8kv;e$)1Sr4? z2nK`>u{Xt>a+33RkXclOMNjkv@+8S65)Ab42-%LeFzt@SVteDE2PIqy;Mf7<$Mbt4 zmcB9GL@JGVg0hNO{SnKm@Hl{=5HIyNP9XDQIo2pTPox=l3MhBe8>kI`d;|hbNKzQ^ zpg1IprZ9puHtF?-`D`uxrEP=-wy2#fdNu% zz&l_Y06gSHge{9uGmOp!`i5N{0sw(tOR{^dgbyb}1Vfa8m!M=o5fl{y7{dbMAm*t9 z!MI%HEP8_44q1$t z14bQDg#>sWUP%?WfRpzaBY-fhv3l4U8y<~DC(W-(xglA z^|H}X=HU{z+T3aESTrzJpAPfhj+POk3Zt(c5%Zg<6-$Ajn!OdT9u=67VbGZ@xl1Rf ztCwx@el_QM?FH{@Z@<-$6*EWaHwD5c=a!oKp|+*Psv2kvy}jVOVb=FJkBpvEkesBcZ*9FR~jFbp8X$OwIr~ zYP}NQwL?R2a|kru8@>M!8n5UXk^XlJSg60Y<)k9MEAq&GP5xhjAf>?fhya!$gmC?D z@6dm1RLzh#T)cG1xX@RMhuP}_4ozl_J-%rIP5`{xlot)B&%BA%HePL|$!W^wU6(L0 zMnVkML0ll>nDZ2lqlGYT*D=jfH+I5ZXXnGN(tt}bI*Z6_Cug*NXzwVEU%FDMpNs(+ zO)Mve{;>Ze?#FU3L`^r3ce#rGqUSY9hAbu3BR((+1EvamVD$-ZvNMIB1@yonucy_wjIkqT32r4>0ULpozfG8qG za3`UQrdYC653C0lj;9Jy?IDzDR2l>2|7hqGin>*dbZ=$nPlcK%V6bcchMUf^%P}UOIMS&$w z^>fYbw1jw{^qDApa0-qLo=#TI0lP$!)ugfP?==BezTHhb-vPP6kp^R7L4ofVD5k-o z>*VuP0X56UB~Kx8gZ13?hfjAKbZ!nh6{$zyJDu-G4mx8`-9P#7_{egte3UBy(rz7V zMJ_Rqg2v9J8->Y))F6f8x6DAVqiTu_2DcCdGeA8qB-DIw9OkiDf=p9p!EVumMZ4=K zDutCHhsF}ebNnWR3r5C|k4!rs&7>b|Mn;uCkJ{v7f5xwNA=!Z|&ioug{AnnRWs79r zz}~a?-^f49)LV^JC@jdJI)$lpBf6)I-QEc9&H_MgIRskLAejL~z1<%^J=5QQdeND& zs_a@PNCw)|?M3{xlH@}^jqZG0-038%Di_2tOgA-~Bie2M6t#`XKQhD>s6x+|92Op7 z(n(x?!d3=kxKjoTA&{xI$#(}6Xqa^`c|=OJQpt|t(07Y1%XnmxhLTD7a$_X_?!G$V ztfkp*3AJ#$q^W8#Mkv*AB$C*BRb4PBp*jFrJq+{CD6y;}k6D)pdDk z^x6KRY0YsO@H^Vv#l5gX3^jPM@8@MUCjyo8cTFN4K;0|wwg7x$Iat;`RGdRrN&<-| z5gZi1NUyBm+KEwThI0p}G{P1h7LROf%D(e2&k1``IwuJmEPO76#7#B!<-Z}K*C0rX zq~vAgWnDyCLRyZdm!MuhubZs6Vn`>U4g(}$+avX~+4W+d89k%4?iw32lO${!K6&GVJjF3LUP45=&3=+KMQ(a4 z11&ok{crEzR2f*)ztVrjXg_Y^9L3jC=R49BWBJ-QI*6Y|c;2hCf$TqP*z&shIi-r=$Tb=xQkzW8>u)xdv9>^OTL5=U}3-bE!+Cjk7CCm z?inFZvq&@cbUOp86U^1hUs{yM`@r|N;J8q_=yDD{m37V@qQ#&j7I8Doq` z#m{!tFUsIA6ORFoOFQvxyzb09Geq#{9U8nWdWT=7MX`nAMwz}ek!D2tGlg* z>7=;1f{h7hgNr-IGJ>bBFKLJeKn8&c8NpjE^WFX50Y;*fInYga?Y^9j&t30WpAdNn zMWrs-!tGpK9NHE8%ikV_9%s0{4;u;QQ=Wrzdo!{L#*stmzMF@TskJmgLHPB?M(vaJ zz}9~x<)Xc@*@K-&fVEwDpUJ~L%tYWEuM$<*dXI%G#?Wi`#L9$`KTUj4Uu|2u22i&^ zrx5ZD^wI11rbPA0iQKg~JsCD33UM|ep=yI1AqiTdp~Hl;8O&_ zuw#2yQW2)!u?j6Bg33o>qEaG+Xu#AFwGpOrp=z+=5-?#wnEQB! z$D`G9R-LJOZj=^ng#}!McI)6BNqCpigr|=EPbw1MM8;GB+q+5(evhLVxQ2!(ae=DYyu}ufTy#1g@olyp^R`cv`R2b84WCh zj`H$^^78Tm4S8;>N0tGlW{T0#Tv{eE9}hWc>CTB1J%mDSt8u0I5kh`q4c39ymZ*s* z*O{gA3_p_7$x2OS+XGYsh6?C?+1q?0IGv;*JGoS0+=hRxoAk#ztf~rYIes{*7$zf# z5sFXs;vXnV^=;@lh!SCbv>;w@`&;<{W-snGpj8vI<-f7_eKb#TjD2N$UcO}3<$b+M?zcA@aC-T5dfm^8`}j;(vhvCL-={w) z7RQt>yH}r{&T9)I6<3VM|Dd zqo4|ld0#1K<4~m=nK!VY6`oMd=|IeaQNZ9|A6uXH4?<3<*3HI;Ru5slGB*AjwGw)N zU`KQ#no+M=6o`T{9LvOy-U->|+fJt?<>6z`9;?jxj+w~L zf!uPGt)Ckkw3SfOdPE}DTJkuA7CTi(7R8}wByWsE@zt^VE8lmMk<;6S_U`(zE;>=7 z!eeX5-Qywqzw7k^Hf0Surb*)t&;!;I5w<`BbX-4m+FU`~K32gopx2Jt$(~;QE()I^ z$(2KQ6bY$c&Y){KbA3KvNtH5}+=5Mm315eW^0Yc_ip#V*`={*)--ss9{5MCL@b@~Q zRhaW*${LDG__uny&@bQXPh(^lX)ng5ngV}6*}bRzfX_i#DD`Q4UwTrkj-@+jO`?uT z9s7aJd`q6e(N^;U%@C&s*v|!NcFlLWqahI=2I1EGu5RtemgSf9@sM%c*~J@&NUDk*u!_PBl=HWQHBT#c2*p^ z5tMUhVo=rl1QhrDVnBmydGpb!G=7Z*zZ^;9wHOl_<&JzWj1xMr3){rv&Pxwob za1lF_q-5-WUlMFp^=BHMXms=ya>xvLwYl-DVpslHCUa`mth z#mP>hIt>?h{#PLt)(;W-Jz;+c`k`wi9GybSJx;;O8nQw$LfP^QaQRX{<;9pB8q`h* zIf{B0)mN)u3`^p&Qt4?%wcBFHA-?v*$3(wht_$1~mM2ux)8O>Z2vf zoHTPinT7XWNb0SkV4cqzMTMW#Y?a_b~{hIX66kE~ECC zO+yveK(k;?3cJI`)~6(M{L#tGg>R38{!zM?0v1y!_s@_i-$5*98q$~Aaq;gvx&r?s z`BH_|_g({Ff7n?SK$Yny;!)051-J%ZVI?Gfcg#tY4RT#?H>7UgJ{bEI*SmEAfTf=k z@N%lqo8l-U`y{zyr0=AikFQ1jONVB!Z0N zxKTf@R(QDje=Opz7g6xsURUK-J`3L^bS0`xXP!bzX=JuBTFd29!(C<`kjCS3=ibq1 z9bAs5EKIZUeI$Ij4o9hc`;%8H?2oCZ385P|s$IlKiMfw7zO?u2JyJIpk`hCe;R`*# zaL-*t=llo&J{cPsJTI&grf-0d1fh#ceTTOl6ZLr~F38L`WW!rrzoBqm5eA}Ml5Uj0BJrVF0$eSW_L8%IIE1^^Vp z3PQO!>12*IbkfvO7|&IAkLoq-_{Ij|Zyx9lvP}1gvbxp($V z4Kt8et&)*NDIGnJNm?teEw$WUSjd>nx^bwCO)<>rNXHoxxCso)Ca1&V zLL}G-#Eg;3XSyDz7FH>b$Lp5^OWW40vs7_Fzx z8`dX*>UY~Uf>!A=%{B%>{&0#fil~eu)jRtS`?Pujdy89w-e0yiu||`asnnFUNb!ve z5@H8FZbVMCs`55J(|-XaaDAZoC7IFtp-FdV#mUXiXEYB77&$AX!1k3x9~V)(SZN174spY0*-{PdLT*l5RJ5yc{-+All6AiNN%XbI)X%Sj2Y=g0?uFY20)E|_ zadl^>Oye0NV4URt9kKc$3KNrbD>_L{6Ky<{bU!4izi=y#jTO5kVXx*>#vZ9l6L#A~ z<|_%m>gY1`iJA`*pgH`NyR-IEb;v@08h4yWaPaQooJ)C$5ItR#N;Y_3y0G`B=EC+S zGciXp!J#-<9~-Rp%~)r&OL->3Zn#EpT)$sD6I-g1p4~_NEy#W=joPTq@yj>umMn=Q z^zgqbzy{n6TnaWu{kDi$C(LQ0xJ?ZB&c0I;rlLkVH7y50=~5N>t{N5LWCU!03bubWv3yX$7hGqZ7BKre5Rg7`Q|zCV7-i_E>cCx>$2 z1o@rY^tOcMGQ;rMZ?NUrsvCEl80RMbIkF+Lm}GxRemLVXkZI?U5wj7>{Uw7j+Oaf| zAcvrFp%Oq-F>=j;X&2pUs0FtW##_G!&M4$MPorQe$MVR6z;#jKEdfXAsLSYa=NK8; zr^}!M8g6lsw9y7gg(GXWlqVY4X4TeEd==WCpa3^a6Hd@h$B*g@5M8AddjF3I%BeA@ z10SAe<}!*}`}}t2SMd#EuW)& z7ANGju6aNJ@DvT96z*%{|BZ=1Nc12m{C{dEZ;<~x_Rbs)HwqK?btM0FF{G_!Crz&c zpa2l3eO~6&?EaxRKl7#I?|+ir?9FUACdvOr%>eU3u=Sf_Mr^NoNo>lJj*@2QWvs1(Hn7w;`OL5l z3JT^EP+Wz&btU5eu*e_q?y?msZ>m8dvn!zqcQ=&5LY@f5ffl;tBZzOOy zbYz@X=lrJ~4MxdQc-<3^aQ35F&cNR3F-96%IjKzJM9V4mp1LuyHtL59b@=Urg{hjJ zs4~fm3EvGnH2)bW@&+8?8gQT6p&HFQO4V=zED1weGN?`|(J(EtsNoled`U76F(*Vn z%4umEIu1}*;b9^ASK={BS9*y{DucdCEpEFdsTxH!1@UGS@*~yY-7L%Xw7+v$K%<;e z%H?YEd8R7XY8MBE)9#9cFr5~i?yKEo`&8m{0>8$tk6DCJ>&d=Z*~Sei1$Nvf zG4E|dHISIsfIQ}g)(heqA_COB>E+fz!c{aB*<{I%?ERw#6dpQ)a3jo zC#n260u9Lsc79hlZzZFq$|X>NjV!T!T&L{a zJAmOfDe3AjAD|{?^FfC$8F-84h*^N0pduv^(#NpyUZ1_!+ z|6R39MRu*kCwvOn-~%lgSEL1B4+KHx#-6va_{X2zUw<{M&*)?XtKD&_^Um{Jy!I)o z!zG>&KLR1v1xJ`D&^a5g9)^Y@O1gAGI1PVqzl}RTPbNZxqIB9=#7uR}uzS-mQ4tPO zngR`hGWB-sb4IR0jaHHPil94a7Po8&k&*o*@*+n5JR5xqf+1b_D+EV8EQ?LCM)J9nYlC12xK8|A6=%P4Ea& z9g?i8!~j4sBW~zh5d8ip;IQ}VW#Rbhnu^5r#!Yl{Ph(f^r!HhTwd#o;JxxLsv{-DP z^^LmM;G?8&BgO7IW1)47`ITZb0$vtbUw0(l_sJ7dHj*}L+1Ix`FWN*K9Djmd#~Kbc z*9?;(YzDy)0AZ-`)M@ARQ7l+h3KAMpog@}L46Z%0#B3X_A=&gRSv_U6D#L(~gI>NQ zU&#uek5&Jg&vQJ6P)8{pmNvz~gI=N#h(;mlhO2`w7zim##j}UP8B{<-uf76G^kvhg z?2+vvuGv<^3K31pCOhhinDwCwOgt{D!0H4gV6`hlp6bi0&FemmvX)QQ|c z4j&_%QC$rly3D%rR(KQV%gt`bYTW9@<-uP{8vlZbzVH@e)7 zjQ~<)4Z5X3{{%#P1*``{mCcmijH3BU16Z-l8fpbXh$@I)y^Tz0-CYykFplPrP@w!b zCa)a~G(5BgFQIp6)sz-i4Ueh16jam}=<<`U?!($;2FCDBhLg=3G(}R*hL@al;_46N zd;0@e(2roHCwPoI2|?DaLP>FRLwkMJ=%8C2%!8Gm(n4%2yFgce| zLLK-xxjuW69!q`N-NHceeEN7ezP2DQ0v>UAd*btVTY2dr`|D~h`zK}9=F1aFUDXNq z*e)e63jL{firGHQxZt-()TXDug#<@GiMgz0B%smxi4;{yXC#nbMsMIx8cxW!dWP_r!*XK(+(>0d_`R}GQ>&K`?Yzb&B40(S zt`}>jn7Ma_`TO5hBslq|$oIa-B4%Us6d)7KPKl8VGmEtz&H32Q7Zaz-h3dELA~8NA zn1gTkh2c$AmpsE2YKi8GV%5E296tj~ZG19|XtOY#{PMiaA{nGt%`QC^w1fsrf%v`0 z7&PcAKP~9E;s0w)b5t&+0*J?UjH6KW7bvSTlI_$wZ1fkgC>JPG@~Ez7sG`lu%ZQ=R zk6F`<;3mY!j<>wr9X-GutZ>WBa8wk0+R}QdVE0!Hv!s2jH8Cs_Wz`k|T*oASjC-1% zh_x3yPI`TTr4Rv;fp(aRE)-A5MR7Q!^3*0GDv3z zPJC$#Fpkx%(9210pK?>sXV^5qj7|`XCRQ@AUS9^+Ead=mzvRpT+apRxndDjt>jxfB z?9ypO6!bCiVC=*nfU+#5#yQBVWJ;yqA&TSe6V_F@mJ3iUzyOUk%FHCS=JiSZwbJTc z-o(V2vTctKPy3~Mw)@L1VfAi!3)4nsq}}L&Zky)`r3y1J&|JRz0r9YDV!#fv$MZ&b zT_Mw%WRhOsiP|Ed6+ccKop*m3hs9!Qu#Ynw<4gBHcE|kS9y(sNt{4Q)kG>b;jrnAK zUx2iucrSR>_T?4wNS?_Ed?Pjr8e^6Vb89Cut#YGl1mDVFm5NL16?%r z=?z$7wZnaGI||;qr9ohv&Kh(Xe7b;WfC164rWDrOx1R3Sb+r-}vIG=7-REBw-zuu|y;$}4&Z zezQa}VNF@rt+OrhZ}}3Ad;|y~$t}uK5mGj>i@SPT)J#gn`Ajyda(@WWL86bN53(*L<2m0^Ib=JFb>=cM9NdLg zRyBldMKRYZ$IcGze;*_fvRjo4eCe9zmB1Z zI0l{6KprN>yz7T_c{KOI=ogDW0iY~}^92>lYm)#fO=g?5*~4wI^a?rHH;dbwS>*sx zc9Z8tn;HtZCifJD2(HyU@um zvlUX2boY$5$^heLf&TAp4h!DC;rmR~*joy5gF?ctekU&F<-h$M_X#R}prun+hN*28x>wf6a+3Gwb`R!+N+$ zz-b2;B!^%cUaWayw0}bzOT@ARBM-lNWkOy?WUPxi=^Mn5X~jmbd7p0b$oWOS$zJ~W6gXt|*Yo0qK{sy35>4~SNcG+Cxuw5KL8-OJNT)O<$K{*u#)Y-@&T zGU+>{dI&Mcf8j9v85TFK)sC9FufT1^-r{n$7J`gu`I0z<70##g1oK?SrV{fjj*Zz+ z{#Cl}ha?hrdFdJP(^m2sL6gMP=Oo(k{<|CPVkbF$u;>uF-2L?ZY!Lm0>(9YtaZ+}T*&8K*%;ApLx=ciLMojm{p72H0=z7_Hgwq&@p+GeX)ZA(XaNs3$!_PaEe~f5<2WvjMN=homN>ay zBZiFxs|6~Hf9k;jcs@>d4oN|`sRVoqPb<8o+rrtXJB#(O`rPbK)a&ERgDa&jI@9$y ztN(lTQTfWo41Oe`MB)v}8~Fr_!yk(qp|LP~cc&r8X2kobs@bzeD#^r)PjfIDhHL4@ z%(Oc#$nq7Sk6yu5N@y-Z6G>z7VU-G)K?Y+K6}b8iw&1MAO^4b2T|YnliYVhHaio3g zZB}Ae@f`MIF6S1n*DT|Qr)cavXU>l@WpT69(HurgPYZ~z3rYcmE~Bz2y#ybj_)nZv zmcw!odds&y5^Y>y@b3~Y8>tkzyt21g9(p>zMXfP@UE`C;5_$CR1w=XPsMM_FD9S2? zZBLgM#h?Pr02r>#O~7Kb4OAc-7oxx(V$ooxk^95>-=2NBn?IOwFQ_abj{-`t@5m6B zQM!%n`+pBf#3Td*_a9r5jl0^v?dn=8^L={D9H~;qw5eYG13}gN{DAwbOB_?-EI)~endXRa5?R&1YhnYx#R&8J`8jH5qF~4whiE*e ztkd+~=J+kmeYYyR%6FM|LaIaOSPfe%f;uJuS52is%UacavKdT@22U%b{;Y}%fNTb! zqn=>1B}eAkW$32|Alg&nqCpX$QkYqvLn9J0zkLb!QmPfFx{)$%+yqd+LS)VXy*5F3 z(p8ne?+Jf47&F%>Eqf}>-lZQ~jW?~@bF^e zQ8M1N7-T=8WewHz0he61^$q()nh?D^9pz4$%k#i~dXS7`G-~UPxWTz~>~WW}$X$e$ zI7jzB-ajQVW_4v8&sTy1XeoIv7lNaqYk2I)f}3`DE+x{2Q&JJf`*VGvM}t4i3vqO# z)yRQ2l)1ww;Jv|fU0QipHdcPR^N4s7PMRO~ZDXij;e+xFJ_v=*5LJK(Msz`K9Ne0Q zgu9`V;rA@QN+#{c!`^l2?=Helk-LjbjK%D>F1kEJZS|vcuK3n8p&t8lgL&Xdj+Qaa z2R)(9A3vGtrTQ>lXm0D`VS}bgyGu+I#;JX0J&756&ToI?dCUFIc{G3DRTmc-Fv0eW zGzX*3koK7Ic(V6M+gHLrDWxae{tqq)d`kt9w=nScE0Lk>Du#)_=WlhhD7>p=<0X>A z&2~tp(H-&ni?w`kf%3Wjdt>(dSXcs?m_P$A;y*la`@l6Di|yv8NaEaw*Z$@rS$)3s zW(zSIyHqwWS3UtJF;ZsYi8e(54Lw{Xtxy--lusb@jcBr(lYfd&JKS-LjpTyH4>Ltd z4ufoY8YSMh*g`|i+zr=+ICQ@xQ6_R2nT${0nTq_;uH-s8pODe1x1Yk%MTI=RDY#^` zM5Utu53fUsQxCx=2|aAb>>Kg78E%D`OY;vhv3bX>X6>auD}=D{>!1@v164~uGJ1m; z0tTazDmcB$UA1h?rLn#ngKK_H((Z$}a^CbKtUTk%v+nq1QrS*BIX4f#+Spa_+b&D? zs+P!#hjv98se;a)=KsgpTfoKfHEp5;gS!Qn0S0%6;4-+oySqCCcXvr}m*50_uc*O{qA>n_sp-SXZrN7`#jY>&s5dvs!}XL$Ci!X+XkonrUxH%i~f@A z_G?b6ha;+XTWemOuR3tM#ul(W8J1y(K5d~X2U%;H(zWZA+M!1C=uR< zsi|S{BDrJaO#9WS*sVGPZLOuhdEm)QxT}hL?OT}p))%R5rIa-<=zHg4|K(l(z~?vY zXj|T8*Tlhw84OuZv^EU2s!JU#MXrmEJ+Y%jm9}T{Px-o^aDSkW;!(NVPODY76~6}V zSRQC!f}MH^8~J8}=RvX^)I=-4bM*CBN>{tMM}6sAbcU)WHX^E@1(1`meS9GGg% zs>+;IoeJ?=jkGomU1B)=&Bux`4Bwt=e5v!#C6QB2NcEbPhWS*TmO&9Pv|*VVWkUd% z@ICB9*`C9@WpcX3o>ZP%mPQa>z1$ZGkJI8udlku?!PX6&Q$5v16=vqBuzad*Kv-i3 zRg49ZgOsf`gs?~}XiyPy&(|=V=6F(j84Hfz&SEUN&kuUcem1_?{)|lpImebO(!xS>g zBbSW&8$V~Vi(`s%@UW=HNp0~7_4Ko60;h_80(V;cx{AA0wK55%RG_uYK zNmF+D5dD!1L=R#|5ES>7@Y<*zGPUb97uHC#$2ADxXR942KU-fFm8QbPSR5PDJuPkQl_OnV`n&M{a=r2$D&VO8?6c;3bnXrRB2(A18R)bDVGOG zjKKVero^TKO9Kt-;XEtWdh-VanVqK*&BfuH5gO}x3Rxshf!Qty1&UFjm-@cCie*&; z1K}_@14C4b_R^v>oVc2ec2X-_x3QlAGL80&S|ZHQqhHk)RvX^*cKTKnk6&O8kfe6j ze$7scxZ!@9c+^vqUQGuSs8*IOe=i57%-T4s-R<;CUqrK$cwliqlYk3DU42aONoY9zHGzKlVL>-;iU7l=29sk5i!5Q&v(03hcPMr{tL}jMa#XAsRg^0+xXEP zTLY%YDy9O)1SMnva52tIuJbsDnWUb8E3(fg79*N<;eHwxp>74D@#H_P>#WI=pm5@g z5zkl~iQhFtO9ifr({9ORj(_V{G_hJ$gr+Zby%h+EWA0N8Q2aR-7la$WSDiA|=v4R7 zRm7CXGb;0fuxI%Ne6|%SD}_V2^t}n)^uO1aZ0*n8H~mO;jln77{9KLbKSGT%i%zO0 zE1}oOXP&xGCUu$+5L+2ePE**lC7?B1g7hWpKWEjmN^c?gc%aK6D^J8GopPZo;l7u*zS&QM<=Oz}yE zT7-P;6=s8$H)=jrS0RKM>ZpnJ5nSGRNi8LBor=hK#yua;#MFQb%jL3n4%*vY;e5II zyO0g9gR7}dtX;D@xiVx={MrM|W1g@Xqs=(#*2>T_6Fw+A$>V+yc71NEV7%-ds|ldRQ@B1e(@#;Hg}2&p_=s*Z z=Q1>JT>N;PSd}1Y!P$sjFEAjDN7xGgBM9KV& zta*$jR#*z#d=))@n8j|3g`qjxesdiExF`daHQ~?v#RjQ}Uklh)6pf4AKyQOYT{Dpu z9;azpRONlewL?BLQWQcdquCgQPhJrnNZ>1y{dawE{2nrn1DiyXHv@CAm5f8?&~rjI zDL9u48e(DB+sPa$V?OG9OMfC(n171HS<}T89#{D+eWsFDkm8e}V2gfvLziZeWW>)! zR}w0iOTsFhEHL~)p7LbfAtYXoJJYEhMJ9hKZ)ed|Eo%X$qQqv_!2;*8Yfw}3VC$x- z_C#WFx)wcU9?-A$T?LebFm#ckAW;Gpr32p;q9X73pa_j?5?wRZ6XB&PCq~)xIDJQ5 zmf+^=m0{)^94sZR8Yk&N$S0`wS`}VfDR}9ix(a8zhO~)vz9|Gx38&}BY73&oH3wDN zYyZ&5IF}gt{NXNvuV-9677B>)4U-#&ce$KHdVMp9w5(Ko0_eH7Js0&j4jI@W7Jf)qzUL<*MPNO9G#0&ndfkPdr(Jsv_cnrsEX4bZDWsj5=a=?zAD%IU>q% z=wj;7vXB%p%&+}v{xYqP;AC{E1l7hggh}UIb*8Qsma6s`!`24%6gk`b+7TT4#@0^r z^h|QoHVRF;fNiY0o>+nJmI7xJANo`isAY-T@t5_MT}#d4k<6(jicqY}DK?nE4{b#? z_#xny^LE4doQ?kJj$JkiSOCVDPW2KMM2-~E{$w^oCrpQ1E0`-238Mk6X)FpR83fn*F+xEY*B}Che5*xYMHY^xIJDa9%=~fF zK5E$P+^?yQLxx;yo@0-T5S|QM-nxgDBSnUSHH{n-o&3E@PBC5ncKrYkIUH+xy%y9R zpwiX-hl+zOJ;s%04k;(DV`*%@e3^@=+TN-3&*Bq42z88FEj~=~XNB`|<>Yjn((RjO zAW{uifK&5iL7YncsS>94o1P4zT}oV;1$OESPerAL_ULSvKdRK6{TCx@5~ZlUq4IdG zXeLS`=udg(6@?&#JU~Y2}CaKd>#1JD-H{AC2y39GQ1GWrvN>B^LSh} zM#s02IK$)HN;qiRR>w}aCEg8@otA=1(JVSX$IeO^RXEe7 zeM?RRVv(^|du|o5#mm6*qt<#E(Co9@_976hBWxIT{4fZvbxBjK4L3dGbF!=$rm$%V z?RhB`mX6v(%<$e`ds(S_n0>s(LR)0y07~ z&+f*>O#+QmkN@PyF`;a{XAHF>{gqSFi5;((i^+aGgxfMp%&#~9Rh3Y-=rfZ;Lc*gbIrw} zp|UfWrS{jpxfkeEsRpS7Xq-4ZB}OLo+7C^ay9N1r+j46*xPXTn?5nj&^T${_urM-s zOX`6uFo8e3+Zjt+^<2fzjPy5gn^a#A0?02hs%%%%#i+vU)}bEC)LK69xhKL&-iB-g zapR7P$T2QkUnioYY93cXGICA>kItdKHN2f@U%kair3kR`xQs*nyvpVC;-u%7mLek| zHKrW=%z-rxd^8_7H|Wl<`e}2WLr>?DnFde;#N)z>2(k%G{Plvr6{V6D7(J%N&UJ~v zh_f~Baf21)X|%KE^GYt%3oaC8j&UHi*yX_JRtXpZ8P*DnxC9uS%Y_Nu5gAOh(aDS} zs+t>INk&E59|@4h8o4GX`J?ioLr*`*@-iLf{^EHwgv^Bp!aq^LN&}Tb_2%hcIU>PK zYF-9^m-&E4H+PCb+;zNqWgkjCz4CREu&w(vesbT$YgGJwVku3+Yv)$}#)?ONQj?IZ zh-RO{lr@=j=a+;^)-K10vtMrwG}uV#`U~cK*OD01mrg%#`$Lto;OMXMFOC?=&Du1J zG2$Z_65L9a%ei=SGK*=2&7J<&{%ykatDv`Ujz1=8|AfV>{9!Sig!w!1s+DJB960*7 zRh9?_6IQT}>XRUBULV>i2lY$?_%=*;6}FMBI!2Sb-O7gAo>*8THhkYgML10{m-k~VLZ z%dLm8-(BR{gs1epM%xJTdMR<^W@>SoPb2YbtdNYqlX;7n3nq0`&Q8HFsu3Y*P?^d& z?S(OZILUn zEH);(LsotS6m{v0r3wiaXv|IpH*%peO3cFL0G2(oX2K7-S5e?!K$pOZ$g;R z_c3%5G9g%q5keDBhDY&%lH*c30eSmJLZ+i9fphyuSZ}qV312X=?SmTZ&U*=5-U1Y)%=UMfI!}-YMC3`Tf+JxZ3-EB zXY+6kc%|X3cejOrS|1)dG;FXw;1iJ8(pV+yj4d)}%9@ZQ81W*D7{(Zm5;OrKuQzR; zpx=g7f8?#Sg-ER9<1Vv&hZ6z7Kx^-lf|Q$sG#SAFlmmb?v7amic!xyFY_fd<42^TP5 zgh(L-6D6WDZKl&yzG?@DU5g*56cR36y^z?szYcBAjhuMDhyP-&yE$r8Tmswn;r+)j z;Xr+uBgp*(LqE-*<&l6Gb35?F$k4<~N!~DM-oeU2hZInI;^apH#E|=be`{GRRDpqu zGoY@qGbw?fgpQcWn6bkEn$NYPj0h?g2!k}J**j%E+cgCP1}fzM-wc~NO#u)DcyHuE zyg?X%5$_N70AnZ-KpQ{=pd$S~y%7ZM86-y!;j;ttTD>oeLoCMvn#9hoUrupaF)(Q4s)e(4T@RYk<5##myr@>;k; zVL~a;1tI{1a{&Z^2qFO1`+a=M0HPqG;azAY%3Tf zxD^7Wj{y{i(R=S60q9~Ti~taT09X!@EC3h^&YKbl++}=%Chaz^HiN?tvI&9;q8|dv zL-8u(Cqh49hz*80wihPjsMNzjMHaDQ4he@j*!k4=IiR3+^nr+m-hH7!s32@fpcxb< zU=Zk>g1D;u>43fBy-FJ3y-u1!&_8Q9(EA&dXvl8q`$L_?#DH@IDSO^h3HNx79Z9|d z>%W{NNrHM$euf1E6LVG+i5eeE-t!{s?3J%OGGE(iM48x>E&4Wmi=uL-$b^-)TFmf% zvAW?^GP%G~(5wtApzDT{jo*JMX!YA*a!wgA(k_FvG2jN{jaAi8DY!8EX^|x=22)3S zD}oOYtOtLH&hr`__(E($0-EjN9WLme18&1pB`TZi9dM5x+?A4i#!<);q6IUYg@|;Yl{29C-T<9T zd4KF~?GM4ujylxvQHDduWeTVKA9f@mp0LjEk`n`B08qs6!&KhI_#YYy3@bD~NaTOo zCJEpKjJ(J912EnT)=7wf0I0?Qo-nWpGKK^N0)7a9H7pKf2F-!+&KQF<4`WO}w5`an zC{e`bO$OOIXC+`C$4g=$^7zmv>6brS{k zJ(O?MO3Kb`7@s*%^Uv2OGj{l62Y|c=H3HUAWl6<`D1K~?aQv7oUNTE(`b^sgPzl$} z2g=G_BpS;^x=N>L(?tfUU(Y^Hg$<=~Dvf!R*a*x$ow6#=*ijW8xG3QS;v;5GXq{v1 zG#$pQ(BoK3-~@k1?XKN`Y-%GWeIAw>9{knhma#iru}AQdb1+qY`*d8g?OdTjh&}|r zSpsY+54qYQSx;VXVwU1g%}bP_EBt=8iv_bVma!VuEC&gGIjsFjX^trZ17bsMq92!5 zr3ogHXY}#mbWl!BJ;y|}$V`BK&`huZzTxzGBXCI(C#y4G+>%XJFJ~SqWf3>)Y#)-(r}(X$Sb=i3NT*3NQe-COTZRU}U0wI1b2iqetT;=~fog?X6-S zN;$`uW&zMX31{fyeWJEJSSwpZ|F$Ku3v z`C16U29cxUmElQB#@Be_yQo;RnvDIrxl=RN4_-_z5vw^or@xW!vTgen(pXOfwaoXm z+*_E&ZeX_C+!9o`dUZ03|F~TJI1$)oZy?5obcwoLKQey)vLf#ynEAt@>f*D`WVbu!`a|s=3s+ea@tp@inKZ)Nr6_~c42H&4 z%t{_Ir903?%}4S?Im-MwNzLGK2>TeByu&fqyG-O+|tPv%P5%mxRot!$#GKu9j( zyy~`tuC24p#E?C9r2<|^qsXBpF5A}J9)iSTiAq1*X&7eQ_F!e78q?yweISeTkqieoCsvk8m zw?q7Wf@W=a4ag!9$l}TvI|QRdf=0~7y(mL?*V!9!8st*UM0O;YvoA+z#&VLvQTCoK zGfv>X)walYo3>FJY_ey(T{5aFsV@{^IH5MK?A8*Xlm{6Hng-!3I;~`3g#e_ zu0-+X!%A(bA@4XRftQ@FGY|E8y3%~eJf({`uy~~Tj&bjk zZD|XgG4adG8O4PcRxC#(jCF`|H`%#1y3(LF$^ZT${UNvhl~}Z6FXU5xMlh+RLR3me z5e0j)+VgzNBFCYKyYx@Fj_kjK0sPf>{!Q6f$;qL#2p!p`%$jGBN#u#9!%3v2IqtLS z=zgVv5|--n%_0QJ9{b5J?E8RVCX21&A<>YGTW^G~N?#A-36$i7ogZ*b+1-IQc%5nN3-N2T2^Rbn?kwU%x$l zD|=c0f^cj#C%)-WtM-7>Ka*XZ&0t~HayKrc)mz)Z znaTAXLHl*PN9%;qMv#eGSDwt~m7=cdzTnWWFB5V!e*AbV?p`w+b#<9a5Vsx?yjcs4 z+h026%cuJGjhP)bSBFU6z5J71NdZkP6;EzD%?c~TPy9!YGr-}`D_1wfzP@e3X?;Nx zLU!XWc7h*s^YOlNeQL9UeyIjKeYy2n{*v>pgbDqP(GJ>nP~c^W^RS$vZmdpy7s+xK zE^TJgZPCA!#2nrh!C*!upDj0&<|wOh>RUHkOsf^yui%Uz`< z{(LvABRgn>1(QXUAfbCf{!C6ck^1K^F9EwRZMR?kuG(eZs&#n=xZwhM2fpw#hwWmC z9VWbL1kN!KVZ0*sZqfIqpNDq!*mSj=hxWR5kzsvy3(h(>`FV(b=WxXxN(^7xA*ZMn z*W~hU=x_yv(OUnebciTRx0@C@Lpygu|Ju}%|0&dlF>EP8uU(Fs>SluyEFm41ginqr zruv>bTBq+vCB9a0vFT@^#xP!7;7}&FQ!T8VT3KHLR!Icf<-pl|$pu6^u- zvi+{0i9zigMLG_n3};-%!iZIkM#kguzn#*3O|M| z&6svrnYw^34_GJl0m#c8$KW# zN`W$rFUy){N{c;*Bj?*_$GHFSCyG$SYJfZxF|xT{e7i#Q{VJeP;mfk6AzH^E3eIs+ zpRVfliC(JM9G@fgAqRz3t>Fe1*m4`{$u@DF8c(2*PRKWPvlHPUe`r;PD1jRQ34aUu zf1NUAXdVWDFoo=2YQt!7LrY9n$we|M{iyDFyUWY| z0p9O`6}Dt4c1j|U;v*@TKuO|tAxLll?Ju;DqN*XHPY3OpcG{Q0T4JS4?`?0(p3^!G z_ZNbP7B&xRF<) zrsX)qPeJ&@y>4ykyT{ezL`B9MBY_JOWHPw2)i?EJ6wy9q>%{``>1#RNKegj4@@RxupcD(AZK+`dnBzS4gInl0ioei3LHPX-O_bvr!wlV7V+%e zGh<2^Xz3fYO&J8U=PJfMEGr2;yt}4hxT&bSWLby89uxE6-)76)%lr8CaP5v+hDKe@lr_(4`pH!@eO zW9D2e!K#{lvB|?EQSC(eX27^Oyt-9L(kXABj^{ zo=iF2={HdM!U0elLl0|1b>{cefKKrJ0=FRDk>K)aiWkX`UE-~lp57m!jMsUnB@LF- zSNX=`7SPQgkDnQ+PjLK`+088GN>x?4AExb4(b7W1hPhHZgI9(+xJC=b*32>Z9ev!p zrYY0n+F(f$xSK16nUq_dth1x_JmQkOP26S`^uh~^lxZb4N}PaGX@0<8};mp?S1rW%*ap43Bs2?B}=)DR)q14 zo->5d!5&pL1(urKff!?i(DMcb08Qq_;6B2&`VR#W!7WApWsy*L8BG(gZM2z*5e+8z zt1D^fX|WTBp(ghDl3q}j6BfSstL=U8ds>5Y-_#~#e$Wioo{;!3U4FIl8pC{Q%MwoR zVp4o6JKHF$lIH)5?|f(F_3*h#qdB~}@Z0Q(OB!m{N1kpn}Jokp{T9^kDz{j;M_jq*>}XWn1aoQV5YEu zFmM^BVDjq?^ai5zh59S($|@@ZNjG~$5$dC0hQrDyD1JrapIQTGiy6)hGiQt6G-2`H zj6ab-f-fwFCF9qE(C?b^aRX-@rZ&EbJ6_isb$j`pI|>D^?h%;!Vfy{U(k~v?7dzg$b?v0=rS9k;Q_O?J!i) zY|1bN8JkAGvNcX)Egp+t$L?JHbkrS$d%z8s@%xY=H6tnp0}XA$b5_~Jp2yi=US#?j zbh0@SoCkDQOIn&0WL~|mjos(Z?YwN7^g&6uJ-+ml_Qf_3XH!HbO#w5yAAIKmg;dYe ziMq-AaS;Qw(Olvy4ornARkC3UucRn}yb@4PQ=x7H3#uV|jAc~!MxTpnD&|wR1f3D5 z^Jmv0gJ=juPK$ZzjbJOP!2JiWS(l&B%%YycwK*#qhVwD~v0(XF?hEyyK2wvBjGo%$ z!AW=4jt!c96=_@pDg^CPmlXy-NKNo3x9R0YBuD+p80ps;Ij-)g`qOFxL)X_q$H#wv zLetpZu;h>&z^hr>+l^I$t1S zNfqPJfh)m&T@Ha_Q0M?bKgr8=Y#clniA095KqMP}jl*HgJE%q4!g*g||Gd!{40dW$ z>AP{_H`USmLnNlDw5hJN#{5_gZAgRhn&!D5MgFv!}w+b z$bynk?i~^AM@b|=`Rv5=k=+QOra=UAo$3Y77Ri;W&!&j{e6WEl)pB(FGJ6Ki(rUZ7 z6*H&<_w??NQ4iBvq7}cubxOq@5%tDTa3!q?0XmBXRQJ2?HuhTiWiGgLNg2Rt@aTI% zaN;{RuD?8hghoTDVBTU{d$*5B6(d*+Il$?%Vi2or252UNJSf6NyG)P-o}fa@n@7uI z%y6T~ykLrlNnxJl>b=Y(7O_G62;*Y*1wl(|!4642ysrPEmEGnamyj}6D_^s|#yA4J zQRu)Xy5FyTuQ-Z2#e9&ABejE0(R64o6W*3%k1>5Y_Yd^&SGhf23mfS>8ggUiy9M9# zj)PUyJ|#|BC%O-NrAw;2^jwutD9qwh{Wzk(B%Dr%!_%&hLV>o|s{9G&PO5c0x10Jx zKzEvCL6P-Uw@!3`U(JA^Skuz0wexYxUdn~hrOSb&xO(dMt4BJWJh?5r>>6hx2amwH zpj~vV0>wePjeEM!wAZDlFcKq58Ou_;i_IwPn{LY40PvnJxk6vOCbpZ4 zKFSVsnL7ub<4q^3=+d(B13G%x1@Uh?c0Xn)E+_1Z>AJQ*2Q^ks-?9&Aw# z4V_ucs$7{@4bt$aNMi&(rwW>igVDU_ zL`nAVllNFmkOeq6lg7#mDmp4LYlzv;Wz&PqZ4pZ(2X~A61=S<=G1GerC1|Cy>9cbg zYR5B_iDborw8=J6Ehc;;Vmu==@=zTs$JZXuQ_6#=mh7I{F=k#>DdUaFQ^HMy?k7z8 z@EglPU6kR>;W!M59Kku-fL^o1D<7mrrH?--r4siXNQ0lNC~>cI zT=705{A9$Z$dNtXOxHhcN|Ce&Zvt5-E36$-Dmj<*8veNP1YF*yn>*#F^g4RY`+hsI zKKmIV_36~%jlF;5}PVHs$ZkZ_8;~x4y`=117*~arB0|1}< z{(t1o{cpMN8Em+2@L~o0s(OLXBt4kM%EeRpK|+<@kXox=D_A+iQAeK>Vr~ysg{UTc zsWXb|i9_K9id%DyIfsORv9w=T17p!>}2U5nomkleJ|&^~M;pXNcI6=3UZPpQP+hK2CVs zgiA0?QoUFQBU?N+j5-is_iqirY;KJVZ1;F_FB0lwNFMbmh!Jkh`EPZ$IEN4zMLV0% z!sg+v^uYf-^`#DBbF<==F(g2;qS#v#P5OEv0sy&sS+}0|)Tm)HHr<>Gxj!;k`yyC{ z3&L=)T#S%r<-)>9_{T+zA^u7m<{+m)NfmeOCD9D{1;%-e;?70DPFmG)7EArp#rh>G zs^YuFT=8_f7@syLY;=^3K}dcCWb$kB!bC=`f|bbT!9?-sa*Ud4^kIOsKO!&3 z8B){$W#;$NLodEz)}ab?24ybr(+7M^NDgzn+;6-Ofl__7Uobv!aW3t^$$;201)bSc znqxB7Kf5(l)~{yR7~(0pzJ;>CX3?TSI$zK?VrG4~v0L6A3};vz1DDl>0%uQv>;iQ_ zA%#wVfA}t-5T;2n!5qXzr|kDextz8w(+z{J4yn5J38E2CWDUA-Y2C za!GN5Vtp7J*z-3yDJp;t<9oz+7YZkw?BVap-aaclwxL7Jf2Aeh;b5h$&99GR_J^nc zT?5@dL-SIBq&`lgKvY zkS*%d0cO&#;8mU9T@-6ixev^}z#EXDq?dwC2$)~@j8Y`K$jpte* ztd&cp1+*f4&T%pZtwfd*g6~^o&ZAxRo89--?WHWgWv6xjnVvtrmFZ93V z=H&HUdd@lYLZxgy*29w&Zzi1`2D$uD{2H0l{r>xSPn4h6W>!>#?$91^fLsVm-T}HT z|M(||2)n2djuS;FI>n9dk>4xy%c#d=cNWueCYuCP;R176tU=0V0}kW zlmoFg3?i(X=;#0@P$~P-i=HXdUqG%`ZPB3t)-lGlTJuUh(A_7&|79O2T8_jyL zF+GfBWfOBhudnY)vS%N8E7-cIU1wuD{}!QxBoYPo;bY&76@(*L$shIa`7_^+he@s6@^I8tG5mhW>tk~>Tz8}YD$=v6vSSumW z<$B$LCECj-L3(x)g_~(kVrc;#L()WM)v|Jy(NS3_SfA!@P`N%(`F(_@=Yr-G`e?;v zgcys}&HOa;WGq-!@I}7&OG0?Vp9r(LNY*tOId?f%RK-*Izt=b_?l4uhGT#bGU^FZk zU|=XIc%mh5JLk7{T)lXM$CgObye(DT_~N=jLE%2nh?pv@XY6eYb&zKY>?G-6Wv;I_ zgNxBtc!PuZTv7R%$2=~kTjEgyBq))^Pro$K-!39|X#2>%7_S63%RPOme0~U8nM~Lh zd3kqGg<@y~SaZZxeAm%mC|^!W3zip;i=q#!H7z-P%QBHD)!xCPtR;fOBX3xN&rwxk zX5*|Ay64YY{iF7+BtfiGsn)qYKyeB73yz={-6igA->^hGo-VU*zqh8nrp>GQ-4q!q z2rAdTph1m@w^DlpJW!R650a^pDND_fqrLChwqULx7~!aNSa#2+#C=ePL}zlKfjz?NZ-k8)fMWi6@&sRj*D~Zv{Nv8;0=F97eRWl|B!)6qhE{G}1(eSQk7QG`WLf5_Y-E6mQ z{aFaSoQ|%H1PU-xoxf)t<8oxpC#WQKDegW5cydsbV^Q1TfgvxyP{8!4_?aM^?l0^~ zPP6Mw<0AzTs=7b=`b&PdebJA=Z3BD~^A^MDEQTP)OTT)#q*aFs*#nAvljYVIK8k33 zU5wiZmUV!gwe*Zvn?(cC9E>x={4sY`oS@eIs!3$==L_+*gb0i~*1ol!6zE=t=y+k5k zzrR%)YN0Jgfg}dp>fLE`B_|&p-t(A_6)<3%m-X#yUC#;;56n|}L?HBP;ipb?T3Ouv zvRS^Lvc%$cfn&_~b9N5vtLxWX0*OF)S2-rhj6;Jk37wL*MDh(w8x8bWSH7YIoc&hm zC+Xy>t6q&Q3Z1h-QXT+B?BJEt>EpxCWFQqt)k_xKRRB>B^Wi4q<5(B6o$h77aVn z{h0xwB%Q7!gMH2_+VaW@R7PcZxAl%~RdRmV>5$@JU1UGx9;P?=wGQVhIXI%4m=|E0yl^>58PEV18q zkQGDXZ}4;IsvnqUPBmm-UktRu{Q}T1oTRvwwf zr5O8&C;KK;lbmKjeW&BXkq=Up%r&Vngf;46)IkPuWEmM=?G~NP=ms?}zmP1iQFFac)A7Z5xU+hum(MC;zwqt7gR`gA`v>H2v|E2Xxj#7BYia22 ztd1+hW;lMv5VDrT$CXZl8G%79l%&T$T56yl@!gr}_O$gWcA2HcwaN4Y!DyNiT!TTay1LFiwJ5CdrHgGQQ zNHQ>BVPYyWaQ5p{Mt1|QEJtQN%fD4j?4jQqGa_Y_GGzeht5FX^UI<@!do5+6uv!?I zLW~nJwCntC3$FmBao1|Jama{;#uznG^8xz;70~nqs=oo_91T4w$@2MbG)w9SeH*pQ zAMRM#w7q~F$9DbxM(?xi#l>TFW*g%}wD*onHPCVVV&@@A{x;6C1q+85`6dj-s#$ad zrV3X*q^%DaC0fH@hL0R{LJkY_q(8y0q}pcpvRdyDIvR7absI^X)5?u_mAhYX(@h^< zWzrp&cfg!+3CEouej|VWD_HQAnP;s^kIZ7fXH(3vK9LZ&NJ9xFZo!h`sCqiT$rdHB zWy`f?2do091WP? z*M)Os?#`fEsobz?FtLKAJa6Gm1?iW!q1W4gYUyJSF=GEO@y);d;{Uqr|K^+UfAI}} zq;d?Eku3QN^$P&S!gj#k6O68_;EgHJkmH?iSn6v(xXBIMzm5;=_iUxZrg z3bX}K17*T+zmCmyPRrdz$7bs8@L6guiP@XrjysJwXSv+es7Y3t%Uj&2nq|x1Zf_`A zdnz>X?AHN*d{HBTL*8d?E>K+2&&=;!c(h=PoQkBW-V zPEJhD{=ePc`T&>+&|T2;Kqv|TG$s@f6Y6aUK=%GH80`CK{~7RqZ&1)c7+5%X1Vkj{ z_Z?a=0MJlC;CrnySXdaC_q_w&`vEYRuvp}5qHx$MCh!z4IPAg6g$R^l4gDWf=g+|$ zrmi7~NVs_T1cX%7G_-W|oLt;IynG+UB_NVg(lWAY>Kd9_+B&*s<`$M#);6|o?jD|A z-afveVc`*xQPD9escGpMnOWI6Ma3nhW#tu>RgF!}Ev?_$+B*gYhlWSq{c#fui{F=) zS60{7w|92;_74t^j!!NwudZ)y@9rNS|G@gCfN7$uv_;Nzv`*iqxQ+0Bv%QBH|ZM_ zE;#H~3h=i|Ag3xW(CCwJ7!>4KD2g)$ESPu(m3*r!bu?E3YjJBU&MCJO7}zJ2G1Ew-iZ=9hA1ecHX>T{TC2Tj) zw_T37iu{dp5zTYrD{b>kfX7Gv_K;& z4g`_F)?+=a#K{6v@G8q8C`^ngu+$i%)@I{XbE%kW^2R&6z~r@ z0Kf9|Uejb`1vKt{br4l(XYoflHhUCOKguqM2@b1mZHpi70LoDIrKnU3Am~ZBN9p6 zKwrF%Us;ggAu&WNupMs2H#(=rl;dsA4yQciV6X{Go}lJwij`f;2q(IQ{agVx?l?DL zW`c%We>`DrN=M5qLy%RFjxsr8d}m!(MjNnqt+JlV(b-56!3oH`zP&4V zCbRQTq+m%&2Fpwy*7dfC63Kw?u(Jg2gTbA~mNfxg{pI?47>I2kCzUy`-Q%24w67I< zcQioj5~wZ#QyzGjl!nkgn(mLAD!`g4tvo>mnv7p|dkH?!Ny9u@3t^0L8?I8nV*tqq zqRl}rap-D_N-R@X1O#|C0JO4fuyu+gIX=k$baQqggY$}cWhOb}1A*nJQ9%J5^nau1 z%Hx^-|M+IEoMCdGb8SkF(H4^z0em`H&*Yo{+(!|%VfL>kLDh_Jb=tTE8bXlAYm?j7;k>dXQ z!)yA*FFRL3kUdPxjO zH{105cF8o=Q^|56tH|w&2Y!_f<_S*9iu))mKW(PRm^Ow}ZoW7rdx*a_Se}!ZT~OM> zb{G_7gEF}$($Ebc0qCnu22>Hm`Sok|(GStjuleCX~R#{1d>J3H3){(U9-70-9kjutn zT(FeiWi}*t6Yrrn&+z2%W2IySsoiiR0j+(`5C=cYnP1O`CpFc*aED)Y^p2Wu&Ha@) zDx2a*UmJFNe0(hi1C_)SPOh4)t4bMIyq;5AKeAt^8(paW!&wJ?eWOOCf1vteaB2QO zz$vwwj~lLs1b_6|aDQb;Y}rq$`Zb}V?6lfo-_FBy$(aT1YfWogHirQT`VYsJ4Y6-> z`=yK}@zAu`et! zZP}6hYe&25LC|*v%ICK$W_x?3NRfbGjRcE)Hd4#_zWLK}Md*>{<5ep6AF@2K72OrssC>V`P( zT+J7U^DX+rw`6+@^z*d2aaC7>vo9>5d1ywxY2xZ8K^&6vG>jjiSXJ;+^5Mh)*_)u1 z-Sd%Lw^Kwear3Ib79rk!BfUxly71LDTnkv*1U^lqbBckcxxvafvGsJsIf#9bMs)|iBkvDYJ-`?A&ZIaK+u{4{;IBo1!XjVO}o44JLTSIeQ{rY$7uPGs` zFYRv>3LN`EK;r7txhKHLnHlfBs!wIGx-V@6O_wS?mizv$Jox81T$`y^#m)^H3%?HF zG0fvw>J#0s7Vxr2S+f%#^cSCU=}R@UcXr zdUf2Zx`+P&esRejoI{%I(Y6fZpq~t8pNgdnU1E8-0vewCKub`ayX8(9<C48OIM|E?9AXxGh2!zS9oNmmE1JMty0IV%vREU0Ae z*h$;2Pv{QcdRm=pMWSo0kjDEyBKtmL&dx(6@`cbFmq!Q4DR+zo7o~g{XN9{Ft8b)P2Ru?pvVn?eU$$&SRZ+`oUBvInvuqbiD|9+iEY(AC8ie- zyWA@XPfP9rvBZjZ38P~v4Giq~_!EJ?Aj8P=NG03Og{mrn2`E0byR~T)$bk25V2$cm>vc9MbSb9np~f^_I@W>O8vXvUV$P%OKOY#v;LOZI7a1)I z3%d<7Rve4v8s4Y0^p;hizT*Iw&n^gR9JS@H%9BXZEWdi7wZ?gPiTw8u;r2c?M!Wqn}<}CbLW)m`-^>W0)YTlxHVOK)fKl_ z6eFAy*Q+VH@Uw!mKYnQ2K2wY5Ecb(F9|}v-?h8HDMS-!YguvN|Gx9)NONz=fS)p0s;!b7&x=1&8lU2 zftg;qpcD)FY9_VX+Wy`Dy?ixP>cmy3vKDYzB={_jzTpf>gW-pZE7p7L41{~XMcHRg z&V@Rkn4bgi1giuO(01vZQE03mTe5Pcf8IN1_0HW5L+&N)?^J+EJg?+Jt$D+*I4i&D zRRVw*f2y2y0l?gNA8l(OxttPPFdPN)Axg5Cx$y(=27JRHlodiD3ZXMMBfWT^b~R^Z3_4HMLIPP;zO}Aip)7EHs;VdO>5}~Dr%QcijUkjjAKZxD zU&~DAb`H6mFS`u!xlj_!4Sl|-E=2<;o-$m6Z}eMgn)T^7DNw)a#6IhY22Xymo0(L3}6{wv3fqH^wZc$xZk02#0a30Sq z0nG+|4ECJL$$33rP%gN_ejvCwR+rhuw~kQ)-|cB)fwZQxp6Xxx89G&ddRoI!VCK|& zjVe-~^}2|}TOP;GF1Gyio5oT#-F`rY+bD)WyhtL5Nw$@{PEFX?>N@wzMylG{OH>)g zZ;!&;-7mi&a>UelFa0GEboTGc-$-p?i{Y$~JEbX!sRguVw|2Jjx8w!ZH#5S!91{h9 zGrI~ya~Ki^t2RsUoa8nuf(}`Q|P8iwjXJSV_r0DxbArU8>K_ zXI@mzIjG%xpWiWff!uE}tACxN2|nEXCiH^i=_b+m(f^wX?Va<4h{%`hQmbcnH%=&TNxJ{**XY3a% z{o~CtKe?8hW-RKdOIcaP-QGeEJ!1$0Rt*yKO9p&y;*>Ojjgm0Jy%#EB8A=ELfu&3? z1l$glyam%~Z*Bbpbyg(X2MY`XNGhT$17Y>nV3xszSG3`%l=m`zCh32FRCVe0rVQ|+ zdUX*pb1KuzNCBFxBu`-@VDEDjlbRXn0eUHgd&kK)PS2}KJ%LaDD#@g|$TDxg7_0@n zzMu4~yVDnV=o1TR$=bKt0#MUi*I{U?s=t?pNGe6LR^N>DLBQu>(oI(2>e`7>@3`9S zq)&5C`p>;O|L!lGEqRGBJ8LJ`a+Y6L%Rw)|?j}j=KkIu`N#Hf7=ZT&wzOU$-11sqi z;D-79nC1QEeoa$jUpU*qjrD?$jm@VI{K_>KQ(uqo9U5J|)`d*hl|^w>b-9!OT2#fG z*1keq`s085laJFmyynTS!L!Ju3$-u0^bWK7Ne#KC+26-8ul0ZLGK4%AwzTr6%URM_ z$T_>NRALVp%DHalW^ITyLP^+Wa}-`~CT>5u{S78o%&gVS{4BN@6r$DB7Md*b)`QgEN>TK$rIM9p?k6F4t3@t0mxY8Xj&lDQ7ZtW_0T-pJh3Ntn z3qmsotV1vrtt)XhdVJXv*V#k_&TR36y|YM-U!`5Dx{#-fb(57+h(zySlxRoqP-lSs zCwQRPkct>UDhbY$I|UrX$n?+DS(#tR%8FH?Czn00H|D`kAc)l zEK>Qop#_DPqe)qmQKPHx?%`89J+fcS?jg+{0WOFM zqBuUhNuQ68WdSb7iY*HR4Jw-Fk9XE=xC>PvQYZJuWg57t7hVtD_7$ZWeT{&RP_j%I z$;13TFi#lUNx+5ANo6wFggEh#v zy1{cg_=%J_8N^V;AeUBdB|i3|U9bJ*oUQBv?2?w%N(`V}c4f`jml9UY5uJrbLJAwD z5vVTCn83+isVV^SAo&}g%A#FS`g2-eanR!Yi75kxZ~UZO7>W;Wm9m0|*c2C^0(m`c zja_IneN7z8P3H^HxuBvAn(qF5%E4X`KT(kG$5J*$7jxz%oETeujXRugY$o-9Cya^e zJdNGH&sz1iV4>>w?$O(a-EwN@u>0nJV6Ubxre!b2G+sLiSqXXqDO@grZ6jCIY$9nB2+&vg9v0r>FdjVjCq>60DlfQRF>!q zxKp*)>v`h>LQF-}@gW>XPcLX)8`Qkw!?__B)1jZe$&w$E{48vb6(46eP^|_*kFaqw zK+oIEbZ*LBNoU79v}f{k#e8Fcxjpr59`qA#Pw^jb!EM=7G}$~xpAmXC#R+l^i?gYF z!6A0{@jdVt8aPX}%Z4#Wg=MSO1kSHtp!5S5&kMikhx2)f5sNJ?_TL18OdVKdo*a{J zx$5@4VCR68{UYG+1)4^EAc{E=!@)3A ze|?aU22qEL)JhwHTP#MZs%|F~a%3Fm zVv2Lq%i8u3vOBIYY`wk0N{e3o9*JG7{Rd!f4&bS2aohN;YgR>xo8^hd>Mh27 z{C&gB<|pg9Y9_A*dPs9255%Kxp!a^D5ebkcB@?X6hB-k#;~>OnjnvSEu} z-TE+1bAo)q%Z1no)H(#3yl%@d$cWyBx2B7DZ9C|?7o#wj7F>sNM|4Jyh7LAtEp&Th z!q08k`I6{h%A*YU6U_@V(k>f>#J==L87UWN)FIpvzp?$~`h`_fn4yT+(ETbEGq;S4 zj4shNdud=hc*J_v#?8R=3Vg1$U5XY0=%vnt#$ST5>i*!uvF^{uy6n!!^P799C(14| z@0GER7a&#*3@IaW#k*aA2KT^Y+??cmQ5?}$6F}lsaUNEx5Zy45l@rJewU0Dr7PjH7 zyIAD58Z4H=Y4~nT8HfgV=X_nyCgFH@nF{$you18M1dT*&pgoPdgJA}xM7v;7Pg`|< z@CZTI@pH7jS4y0i$)?KWQ@nj3JCWa9jnxw@&89ZaQ3>Bd(OyMX28$c4H;xIOVW)P% zizNwaERh0PU$&__-;nNOvE`+6mp!h30zaAw)7B6x=2Bx-k`)0DtB`h)*DpHoh4vP6 z@+gE=-1FdZTuvmWL2jNcHA7%GX<|JC#c6JUsv$+$H>bK(ruu6}K;{#D#|pHaVPPSK$H#h61YGR1X`inKpmI!W zb2WvxN6%5;S9F@3{U5q``;{J7xPWhf%$mosCS;6A6*1r%t;dIQ|uz?qHqCSk{xZ=xO-^D|(K6BoCq423QH8X7C z%Nu{uB|FwUj6%i`02GU|I+OehqAScd*y8E_)6DIT^H%#^I3ClAnL@7-*p2@@jn@9! zEciqAc3@Juxk6&d?Dai8wXcl*8Zv*<`7@Z67P`*Q(^u4xo}0R1b%bf_moHNFdYP_I zeoq(mlj7CSHr}dvDC0Bqv0ZH~F0J;ifZxRcAU8CJA*Qg9G2^sYFyszlK>@0Q)I6JS z%<5dNm+}uvXZy@BDlxl$Vn;gp!e}^HuN(x4tiBSJQ$^BwVL1@yhu_we&gRU->@ihp@xc7!PTX*qA2yo_KD)Cdi2^TdewS74g~CEQ7v$7Gf-*LS&^5 z_o@IdK}XTlt#xhX{>Jc)AS)t?HgLKW&RPW+7t%@ASqy=8^_YWvi>WLE(_pOR3L)&{ zngLNDp|?T~crufzzZm5ws#t?^&{Ph?uTOF`fsn=iw9)rusR;9}MaT|f2_1hMD28RX+W?wbO_-(35Y8?(Gf_BD2JV;`xn}jLFw}sT zO4C^Z2k1BYvzn4L$XV~OYv}Sc9e-6SjM4? zwa8rUj8LG2iCSba<(CNqXS`;Y7*GfcNXMC;!~zZ*sVEb<>Lb5H3lM`Wq8cMaCfI?( z6{8O2nva!>XqV2pR)R7Zbcak8Bzy!bX%;9W(qRQ5cEm!pu4MT%0%POe;D+@S)Z#$p$LB8olukzH!0 z5meT=I5Zjrq7{Q^eH*4xi@(fG*-?J?Kyj0{AQ$L&whJEI?Q4@Gn1$KwUF4d9fSzHu z7^ie;NpzS)UYhiyx<~EHl%Mxr#b^9L^L&2!4-i6l)%XuEYz`&93>t+YRfeu{c5970 z-NebY_+eBqy+OO7gD*wTbbWprEMNvZVN$vR!Wu*StDG#V^fK?OdYQa*Oh?}s%7`zT zr6cS}J=>L?d!xM#!xEMT)6xj;!p7eft(l*h81qwzJ`_i2T7Ov_YdAZ5j->2NF`rEv zK;ft9{yU|1r|YM8z4(wpaM)A%%3FgIgnxt$dxQ->X0I_H)I2=MeVptbTMgAAn+Ly9F9yL;_&- z#p|#X{beO1*Z;PeQ^k7cL&R-Z00_ zY;0%ZrcLBz@nkl<4&Rp?gvv=0!Zs!5PLYnL72wj+PzZuL!*4DOWStv(ml@?1D-M!w zjEt$EP7~aD=HmnoyePEhB7!Y{x$J3`VK=vHNzA7&CsGoV5BG{e_76d{@;N-FVKOZ! z5-?(WC|;x&J#s$;>K-QV;zGbD&Dd{>F%+0t>wa{X+u8J`*5b2R3R&~h67E67=PJ63 zd+}eMKRCTE4j`LSpVlC}`_q~UBO3FC;7c*+Hj%!8MUMhn!J7bY?6KqLl~y>bG6iq; zWSHCFVJ{>Tr}Z7TWaDY2@@dJB`xJ%gKv0*tGe)4?pJMaOFVi0{vDRuFP4fq6O@qBb z6udQe;rN0KxZ9MoIAgZ(^xZBAjwl0l8DopWi(~O12K*J9D$&QRRw>%&WH};OWxKO4 zz?quCX6ET7U2?`Io$5rA3A}2brf%4Ez6s7qx?QXE#r%o>xQADsK;S~TTraI2s(!+@ z3WOTMw|JFCqDJJB$QK9TTgftoMDc?`NTTMcIl4UV^G6s0 z=Zt_JR4r1*XBT*Mf0hw+*xZ|-IY~ggCH6IG93ZB#?@U(k323o?mnHej;`rO? zhavb`GDo=@9&I5+%B~ZU)F^Bm{4EMDmYQL~t%?n47}S|HeYy`bNi@6eZWj!}-Etb=&@8;VNd zrdz2>Iq%vVL56!&wgRGk^7QX2dWX!0eI~RWutH%bN{1vyJ%O3R+mQDjiOmnVj;M#i$ILleEo$#Ewa)ygTpnV{azLA7&8TI~r_c?dP(( zZW(_)dXmNQ9wddS!IV%v9{T{36rP*AFJL4OOqBtlKdg^*v3SI=`M1Q}!ZI~uf$#o? ziVuUUd7o*G5RggUp{lnFZ(K^ev_5(1`^=Hoe?rlo;>XQ%=_sg>V_ZnL+FMI5WZpBP zcJj`V?mxg6rG#7RYeC05y|o$7WCOAdihpH7`RK&XItB-A!y-R1)TI(%rR5K9yHz5<@GmEwF&p14AC*5Sj zSFBj&_-NZYak1|1RbwHLXQZAZ?lwH>6gTC;%d7l#9qHWX>u?fROaadt(n4))NBVAI z#(s1z{H(%nTrHZ4lw9|SSZgo-Y|snpPD0fqD#OG@l@rFqsJ(-MmVwHutzhiPe5p>e zZ^h61sp60GU3S3qn!(DFK9VQtQ&o479CBM^Do?n9H11Uq?dm|{)#}Su3nN@%k#D6= zcU^j)b@V6;OI)%N5l-G)A?P@eqUKJ(O>l!iTAQ48g!XxklH&U+^mW5te_NPWF@+p7 zLk?Fg)f8c7N&lvaK`S&PD_EnW$IKJ@D(9F%E39_G^@9mj@I*8%oY@IT8E*0~C7v16*wUco>xVNEO{-j`*CGSM)rpyKs4a>C<8eaD^pFj*7E+ zW*iW&Dw@rg1d@4*MMhFJhn6M}$vD_s7~g$d`S{&Si5B6~9owHGO5(dUBb6sga0Ljv zE-gG{1xY)-s-TFL@_&Po951T`)oLVPw^52qV-;QuwekVAnZ3@~B06woeNjq(eD7V% zx4{cp2aliUM4+*-iECv0=N3-PoFz!s!q9&hl& z`CeX8$G(t@zjq6+x-@rjDWMKOSfqg)GXhe% zD7%0wXC;=)@EhcEEAG7Mi#x3fK{L_I33a;CK>b$*wO*h#w9Sbhl>D+!!uKbj-?4pF zMRxQjY4Eh->ZAy8g>zAJAQ%&)assX6O=eI-C9pEJ`L^mh%%{%rZb zSy$FL|m>x+)@9;Vz}296wh7pQt zHgnd%K+nO_Jd!rpn9?gde)(crKDzX)mlmI<8T{R&XDpm^qnj#pVe2L8=QZbgXdS@} zzA4|(zG|gP&gCC;FCb)o`8>vQ9QLbAKyO;-K8;K9^Y6J6pO3oP^lO)UASNBRS| zJ1G6BzoN2ot$eZ*cbw8Vz-BT!&Uu3zyRc z1qTod;8%PoEAs})dp&9X!99isr>VXONUf!??Vf@oO$a$`xMpAbAMJp&J{sHr;9FR{ z!7M*R1dHH{3?0~=L?wZ%R+@`HVOOP+YFI5*K(l1Gg1)&>YXOa;FDf*8chEn8e_=`9 zy&7@`Hue7MT-G~MVU8LGT-uu}-$NNMg

%lXZ3T^X@%_{#BZ<`v>sp5KK^g8BKyA z`ZPKYHTYESyxJ#&OTF z=-2rc4@8)BQ`WinZ;{I1{aJeSKB&C7YD)dDP(dCse!j^$`jb?g0x`EM;|bT2bnp9b^)$R$LN}y`KUDYwyI%@* zxC!K5+04|>e(QS=@8ok|c1*ZA6&HQrPbWPj>} zh&vjKTTVaYY{?f{d3#tGfYkpWPZ_VjoZrJ9AKFV@!;m!0JEUJ|7PUE?-B@*Muo%)H zJHwW`S|#c`gf$1Kl9UNgh23%$54XBpP5Ac zO7HIs>$0$Xmo~QQuz;`xT*?UZ(J=gV)ENDlLI3+TG`}99sj$+Yz4%b8Q6yXh z1kB{r8;SL4H_;`)Vn>7M;0~fU8J9KUpov+gVpDwMEMYdnuy-MR{`P0$1QZOPWF0tG zS0?}*a+QM;xE&Py%PvKXXu=b}Py(eZD$t|)-`lDww<)d(JM`Y>WyWmW@6j&E z_h*w8j^cx%=L(k^B)yLgovR)V4W9CuW$bHTUvQb^jB_&lK`3a}Rk(;!kpDqXSNTD} zzkbo=>{2${G4(?2{PnPd`~uP+82d>PRnERIM21&PD5h`N3)}~+Y*#;z82*rQ-^vm3 z4XWWtqgtfzXHXUkQP9|J^NV&wr*9^VqA26xD0?=!(s?1&phf}r#G@hHL!og8`g(Um z-cpQzVP$|cofW4Z(K2a;+LacO3EDV`%u2M(7hiUh@lxp6b zTXyMH-{E)?9?9qe)M*vfsy2M$BdCxFUgf3+3+39)8%Nb<^x~ieF8;5E#4W>i$pvtq>{eh$(AK!5SKdT(WrpD2 zyK3F-3exv!HPWY6p8HcL8)4cH`Fm|IiKp)TCfqdOCBc3f*nmW<%x}{HL=`b@bIV*J zE>Mh*$!2sezW^{XW_qHi(08BXB3Rrp5HplX^`j0P*yZen4XOKU37z+6s?v+{j<{0i zf+vHo$k(E+SFRwJ%Uz*>Lk-if z6Hky-4PAR|lO7iQFud4UBd$wqw{o6r)&x3X=I>NK8=^eYiyn_CUe0-xAEY}W6XEUn zZW)RQ=G=d_IX;>(asnB~GEXEe?D{#*7D&j_)!-`T*Q_>Iiw~Z|ZUsEmpRP*^nDd#j zKTmqx%_%J52306&-ynN9_Fdoc&^U-K_wyz`?a-gkf5kx|2niXX=&~Ey?n$N{TurZt z%uLR9vHfZ~A-}h;^0cmFH=rM_H-1i{(iS(vt~nloST5%~)efe+0g{TTLs8^tHGc3r zl!O^i#mHyC(0{_7ohD_lHO|6(wT zP5q_xag;rM9lgo%{*cR8`3>~Fkos!cNe3!AiWv|Faa1PfV{J7%l!{n2t&bq~_kS@P z=a~W`1FcU$V~A%aOnrBr_I^Reu9`(v6AveMUHKzn}O5zay#zZ807 z^l2R-T=+uu@-6Mp<&*$f+X3B)z#$s^OQ+G{d0`VueY;+i!>JmgZssCp`HlXb)*;NWJ5Pd&p&9SYJHmt4ugj7KRu*B96=7E_fGa3UzRA5oO z08>N#@c`+@ZL|jFMW#69;H5pMSvk_gO8Vlsj$fu|{qbueU*i`!?@Mxnu0eK>B7203 z{1vnkEjNZv?GzhR6E|kme_Ywv4DZx;DDroe)nZ8*n#EO}kt_)&UL5tHue!___4Wpv z2|JHkh6a3Yl%CzaDUCMjoy*?ctxnNY{JZ~N7TLum9|8}nB#S6C(1Ho-NXP`Oc0E<; zcRCcM%S_%}@-k9KSw~d%s)bBgf9_&{;-SlzIZsS-ceEYdtiR?^L2ooBl4}LxKCAOk zA4zAoayclUjcWG<0Z09R3ghS)L0_0Mw8VctSw$YB+Q=%!f z0N-r_lWcJ>XU|B403`*iPMUle*S}sYRhy@%B!dB?jb6mFUomfewvs#Ud@daS9d?39 z-KvdNp1Yy)THl9SK5q9&9l~2)A>F;=`ld{Z*Ul`F`o3O&r5rZ<%#cAmZNmYMR$n=P zI|Z?wd<+eTQK-`|KN3pE9#g;oqW7W$q!qN(Ju|xAK^e`oJ)Nb7nZsLI6}p6_-{C=UIbid%d* zHwRIGz@WX-5^8c|f^5Ccmsi=ZrK}8(?S=rJ5AeH{xO>WIFgEP;BWg^(p3bqg$ohza zHGpKIw<|;-8)!2zT18^%Bjia8*AQT@D*u|3g`Dk7otc{#y(5**Jrs3hFAOx5Pe2-#6=w4Up}s9A5J!olbS}|D@=M`Q*ZJkE zJrd9e>d5A;9(WJ}vTC6K)trk(b$PSHJ_*Ca)hNqPpqR`)UwKK|45}J{M(8>HuFFa0 z!IMK399Y!(=~On!xx3~3Co1;LPcM!~DOFP6>w|**ES(i11g)dQYZY!w@M)s_?=MsN zL;+?iPQeXkdZAW&J2jb%I(>I1Es2tER!)6FxSi6ct#4nM0I@d)ICZ*p(kAl4rFTlK zHzR48@}^cM?;AKzc(NF6PdTTfnGeZ<8&hMPJLO;GsHbB)NHxzXXT_X;tN{XOXYK8h*m9Txh-ezT`k`{ww3i&bt0;6&Bi zj^mV&>th!iAoAUN^;#5rXhj6kxX>cb0SQ$WsF@cR}2mfL2VJgzQPuZh~mFu~Jy%=}zC!Ze<1q|7(1p^LRm9%Mkd^8W< zx^w2WqRs?1nuFuFm3l=H{QA92aA>=U6t6Ah+z^g&Z-z@yz~i%kD0+cAj<`@%Ya_Lm z+|HfZhC%taWV?n^MwjZwwq?pS+#9#wYr@OlJvS(=u7L(n{y>E_5%528!R<-RxEXx< zY4bWZb#I}L63M%C4oQiBkq z_Gu1X|NT#DJSk%MTm)mcviV7HCZLn2c_z*6Dllj1bw9$zc zSJy$nkemI$8c{WktoaAQke=f&=Q9|ogu z)!eLHi5H-Oapn*MHI!ZvG^B<8&*h`JPy|FZYY&!xBSPT+;F)Z+j*%$WfX0? zPd5Fei09E+k#yKXRIHrU+Dfp#Y0H3YN;j&51qyjBpW$uKnZpdS;Msh*V175iZMTbf zi?sgCSaCD(RF-t(6aYu<(q)NN0n#hxe2Oq#061|BP2+_V06}P)SAO~;-flrY3+%RF zIZE0QVKMBfwOr%r@Z;WPdBKgHrDF0W;{7FE#?D#z7%lPPr>fI?V?0c*lGZQrsGCJS z%|(u}j%XnS`Q0KsBIJt{Ys~r=)6A3f=7{%k6`*G2a`4Qk^?XAum>05c%8%0Nik%DGVX*=3UN>LJ@=(t8D1$;w(xO1u8uG{+lO=Dz{p`yj6HLa@KJeK{_HoeNBQ3M~njwvMTI z1~Y-oyT)HAsTAE9;s3G-EM!yVX$$)A%BQk(8M2qu0o!YKsAI2dBUe?D7nUF=$0wan z#%9#{Lrk<+YIRL`poN#mHnTc<$IVOezqTVs7|pLiJ>cbeZ*AX`ruP#Xv9V~k@pUm{TtUzjAb&A!#yv$L+z7@Wzk_q+O-w=g; z{#M`Tyo;Us^>R`253FZzDzl_^hPa~JI;bJ#n-Y--aY6vX^>X zVhHX$5E(&rx~J~G3(oW>eR>?oNDBfEHyMWboQ7D)o>NBtaC*UD|FV4t?4ss=wH4dq zu;@FU(G3ePoJTD9#EBw$0ed^u_O<<&OY#ySvW^;&`h@e-ni+?H!*bon~31Sbz2X}4ohBg&`nl$f%KlNE=|-4gZA3vG@n^5 zx`kJwS!0-kICds1bzjB)eiwjO>eaijI*Ar-$DT~sL@;$-3`-eZk)O^>q-)9?_*ns* zZ`~AF)N!X^rzgnGFW`Z)#!Js3PWPJ{ z^k{RNP}0rdKu6k|A;-@eIpH$Z#?4{&Qq}c{(m7+oC9aGovw3E1vV3J^{cL`B`w>vw zJf$KJ`o0Tb$*Zg9Ai`b_uw?;epiPmL8*}qSPk)1lEAY@UVW{MC0dd=ahgx|WN5xyR z_P~>Bb(=(s*#$7Og=TGXU_kamaW^PX8j7wIAY1y@>JrmR*6gW6RF9oi%N{)f?-{!L z2?1wyE;6@=5Mbuliy?k228bPS_ucCW+5%xgjjz4( z>Yy1ZcqTCu2as-jYtDu@W0JCCqnHV+23>n)#qGs+R!wysPA8$Nx^>5rto=?_S)cT= z{xNig997aMzYxD>uYsu8-7sgsSuWbgnW|qLi$(bX+}vZ}CDypf_6nAGbwfMMINoA9 zZt(nq0k7UKlAnxu7!vN`6)P+$_g?9TxwD7&j7T8Rrrb)ZF%w-1-@Xua=h#YJ{&VZT zj5$|xlysDH?8_XgoP4Um+@^i8az?f_KZlxgT&o@n_ z=OPG;Z$_tRukGD)Z@%hJAhvdi18I1mSGPrPNm?wJ-@H1eLjr2ir@(r%KWm~uv59gf zlfSup2)rX@Q*H>(6?j)(mQ$2E^V3S5<4EJR^X0H4G1*lUeq-1tw~t-=g7R@sUqjN3o4<-jOuE^?ZQI ztmLcD3|$03V{0SvD%?=rCl%}};&--mz9!JUHxU)WS-RZ9o=nOB6IR8;yra=kc%Oylo49<8{KSq5k1ABmky>1~B^4n;Zo3}PK| zqHICI{C1WaMD^LwNuRuvlcHO53t5FbkK8o)RdhCbqr7+as>&aBJhE$e<*`$}^{(Ae zYzLg^0uZGfX5y05&&IRO#FFA3FH;i>Z)8|BaD{&3*r{M83LQ<{lmb=_)IFPZ$Qvh~ zRskNQ^aVVcK}g5v`Q|X?}Yd3PGT-yFn|Juut@3b zjzR0*c)g_ezM@rof+u=95D*puJ*61@;3D23!E%k6&I@NEDz~ETZ8h?!U6)R(rEvho zj&S2$+;>vx}eGec->aR8U#-AI_rS$vO1~NRLOu?LeSKcKsm7c z<;xDyRwgN+#g9iD34MJdh+87ERE2rBtTXu*#^w>Mf8nH}!f4$Kud{o;H@;Sb7=2R%42^ z<2#ivPs$EEng7faXVCp0=Ineb(mQl`I@@_>HfXl6I2_!q&J_k_V9V7sEZL+LeckAle{vA(uI)CImBmn-t)iq+-aT(Nr2a$4i=9yP3^J@9Y=>Ji4F8)lv z{~LdA!<>bwIUhEMNpfzEjT~mqhLFmcNpi}u`izj)%p7Aa4Vz;MDI_&=&Z*JKDItSr${SPg;E|$9S8nd*g`<*pdv^9#y^zn_DDQ$@ZR9TI=!KG1hyn0V&Kxyn=TLgEOr@YaJD0Bx2iy>$vd+B=#Z_b$r0$0+4sm%=66pfla zsYvlLmibuVF)k4B;9FS2RCs~Bq{T9AGzCaz^5&_%Zu|3ow;T!9V_)g{F=E+qG;5bN_j-^D zOn*gXm+sxiu}&sA$E`cfK;l+i4>-79`d=N?>y6WM+^?vd@2}$(DnuiM>}oN#NdZ>F zE>8WVCU&~?Q)|gEmt~y{q~^?O#8MJ9L>FKm2NCsMB&Nw zADH|%fu<^#OLYeC(tf?3O_dTxzT8rFv?@t-Lq;do7h5p^i z3%GiJptgOEBmbU^tX8KKRh+V{&i?aQma@*?_B>4iFYPjUuRcftW2y?$cIzu_Z7wce zANP#?;FJOA(-&z#j(06owlI#oTRnqqqYsi0;$60geoT5pj&q??WT>k1|yI}vk)`n->bf!XP@2L z$|*b2X>@o7D&?=i)RV(w>yN<^X>Mj=oT9!{6jVv=z%Hy?7b6Z@!+MBTu-0jWRY&V! zyzZC^ONH8SG)?ri{WJ@AnnSaLtCVDq!AeI?!ZNsSY*`ZST-EJ{!=Sk5TX&As*ru<}q({{=mkH9L+3g=rGK_tNSdCR;x%5lAVmYLX8bim-~A+~^g1R3OpYPBpOks?Z@4wxY;Kn6etGNN zvLPlUZI%9Jpk?)A>5(Dlj(ZeM-m45f5tg$hv)G5p&bN&=2_9ET_>DZT`ADB~FwZgH zne)L8WGk@jeCv*=uR8bH8L(}5AbD@e3BB5U(Y*Gsw=L zG%N6uZa@fp-YDu)y3S?@3X7)5ltz9W^tr`zI#S!kH<^G`mIAT=i8~4uJbq7(2AQMC zSF(%q&765Ma-UVRRK9(>xjDen;f;PKx9{78V5uAx=a?s>9E zFwG%;G{!}E5n-kn0o+i%A>DgaGSl5?KA{3L6rBv2qh3TP1$_;-0y3U_Ba4OywYM5^ zrBj<3`*YV?>SWE*dUdl8N$bOpH50&22>3vR`WV1{^Wp?v^*(eP;Ycr?hOjrrbZU&3gSJ5t*TkHHIz-itYI zJ5hhMl+Prux_EaFRhxx9Hrxse)v~MR+$9!;kQslwYXPu*MRGv$;*f@`-n1z#TkLka zC}G6({yA5YjxL$fLZlcu>lc*G75)%RchEl`L$Z#P%kCOj{1c9R)^W4T+@8T-Vk%rv z7R{?N^-9I`AT0R5M`}0JS1{N+J;K0D5dC<#x->ZYG{Y-U>hoV zzNhfd98KcfiWayy@Bq_nV(5p{5?)+fVe-ZtONC~e!i6YAMNuZglbP5`Qn~o}wZcUw z?ggZ4qwNIq78p|@iZ#F&ZbRW*U2B54NWxT`P1fmXwDBK#TlfI=ivBtmkL7_(-Q!T* z|Dwnml|1B$H|7KYRNx}CiGv2X^r48ucx{NdkJ}-XIgQWaQ+%A4aPYRyv*iW|29|s0(MQB`_D^HMbTBtrLX*jX?d05d$;8j zPr2mVMAzkI_Pd)-I>yF2Uu$6#e)mw!Q4U749oY({EYHF2+Irn774(JLD=ptVmX?c% z^;8|*UgulS4gy47AmeVw3qz(awl6}I@&@a5W?!i^W24C@JIHTHZ?^|1$K^G(*QMJYyOCge?Tb3gJ54?B)=LH4m65VSh?KhjFxA#4dAh73|3rJN zgQ*HdKnmHK$iL3cDTzyaTM8s65kEzGYMQw2}gWJzlX=k4hsncZT$}r zB-sf~5C#=dBRW#C*MaY|wLDRI*e}0Nm-9@fA#Nyy3)!O-)Zg&v5*m}&R4W|-i6bE6q0|n&JmlYGHjKCHPy#H4>!l?Q}as(gZFZd=t95ry2CT&0p7Hl_e)E;L)0i^Zht8uHdyQQ!v^EoT#W9z zQ)JzizSR?~d%`&6Pyg0)*B3@i>4BBR97aL|ziPNGrVJA-dJ zvdwXBH!DZyVq8w}_W&#p(dtg%c*%!@4*Y(WyTeu9Q!A)Y^Z_9~fUfuy12^NK7N38Sbqq@^|GtbL?J+p3#Z-4O}3QmKk?9IWvICi?mBKpkpS_LrPi>3dX~OVm z)e3}ShFxA2xEp9S9=;Ot)PJWYUwQ8`bzi;H%=ek9Lc&p5;c8#9 z0g%4a^JX68_XC1SOHH(Xfrf z%1U{T2s2tqEmu#jyQy*#N08E0nB+VwprvM$NC_HMJUyxSC;JRh!p;L-V4*O@%>f%Q zcbf#_qPXg0JOEK=p*5;`sxz4o@FeN^uIvNNTi`;$e#F zV-A(Il)XX52uQbLYwGm4`hu#dH$804iQg}*oFPHE&+UJ)FFUA}P%mxF_Wq3riWidq z2fQ5^HitsCYX06ZB-~fcNgQ(XNSJ+lS866YUF9*kpwF92Ir&@4T~bm#o%z)zq8ZtI z6WE%w`;xrrG3bv~mtI<65fD>{(R=g$`6(0PnuoVox(`6epsD)i7z*Ka)68izaTmAj z53R>1I)StPdDF>n4_Un4XI@L$tNYqKd{g1tCdQUmEAmz7d-cs|=8psX)TgNEkb|=+ zJm*^26m+*kdwMaR{Z;?;vwp85lI)Q-{|5=AEZ$JtK?-`zE2^R@wT9`U?SpJP+FeGB zaT0R7-5R)S)|uCxN6&B@G~^ZzjI1qHUDF${z7xToH2MF5S(TMa5u1q|;G4z^*}-irDC)MPDT$?HD<2 z)p4f77CM3%e5)F0e;dAT%SM~s^Sv=_%me7UNJ_jUFH>&FTeAG%ztXw`vRrO5B$;KA11sz0J1YMu{#roa_(7Y2e&?{MG5mS#aE zU1o6|Z_|X0h9!AO*u~P=TWYS{ec%B66GfEZm@E6IA^mEtFp)WCBn1bJ@s(^jD~hi7 z*RFbzIY&eKoOL30S-mZ|S8>t@ZG9Sz(pK}C$d$yZh}Acrm8AkbJYD(EEhQSf`OW`0 zuhggNSoS+Od)M&rz?57thHg;0Y=Mwn^bU zbV2;sC;Krs4D?#z)a4V^5yjwimlQYB#be6FD%T=*>Tzh#;YS3xgeNz1R^spUpQMoTkDm>B2Te(sZiOc!?y?~Bzuw=**#?K8gHYa3)5 zcbdz&Rp}UWD6n6=iLsuCKa7xs*+_o(&5I-k1oy|w|4!I9&9PFP-Dq94AS zlh%tC=Ctwio|OLrzDvR=@zDW>`wjzqyV}=r;!GkAh|Kqo@k9pp8|rWA(r%}p{lVA(Mf?>&kEa~;FY}YvOKQ=Y5cqM&4e-NL1brxE^vaPbo4zXlP8!`6&pC z`{lt?o4c`vdb=6j47v2|giB#)iC?EGtv?nN_!+OBgitG|tc0mbhF<$3rOBE)An2FS ztP-T51~aRBX^eJ@WPfZvV!}Xhk=c0}PGsXn4E zFWvX_0o7<+N8iPh_Yv9ShVp41;gr|@$|J9|IZVh`4Kcl*Ac@9v9hS9b--i<|W>O|? z*vQ<`v}_ewoptgK3|=9PDXFTzx>Mw}Uu*sym%BDDdzAgQ@v&facCcl)xP)3cWsGfB055l@*NlwHK7 zhY`E_GUDmb&pwGy+Pi6MMeX=ViJR+EX>*M19KVP%s z&F7151UO9c9aJZ9ADHf<^D~nGFdZKL&PbIrKjt@IbZ?4gT6g=&aTdDYH*`Jh6oclMB zR;8ih-K~`<^Hu&LWr71RFC~4DW8!gdqx|&IeM*FSJoS1@y2<3;_m{}XzIkN`+I$rx zkO3HmlDaTu43n^-x8Gr;VW_p42!uNd|X3qUumIk z&@_y7aT))(8#Eg8%N=a^v{Wij7W8~y{%YM3|JRxqA@VM9rvk*}CY-ODZ~zSmFL{w` zH=Oezvr$ls9S-XZk3Yv1axD;^seZ|w_XI*thH9_UH_(t7#Yn6f6-?ubA*SvL%k;{V zJ$xv!A!ArcPX(o-m^yd_3O7v9T9mFsy?tO!(5>Kb#tW-in4VR896>|o5J!%)g(3)J zRyxh{S`DTBxUb8gPH@m~_jC~*MPENsp!~S2Sc8&!r|ESJKgLkDPlh?bcbf#%F9~YC zfw5Vms4f&{M@mU5IJ=%Q`7H&1!?`e#2`2I$Q#BLSfHSxol?rZxhz;O|5pqf}=&WUi zUB^f*8E}R@P<^jm@+(FosC*{{FI@{)S0e=q>gU-g=IFo{5irPgnsd@J(YUJ$(riD% zn+ET`Adw`^{A+$`qfAp1oD$ z$@u+RFVh$V>&={1{FI)U!ecLc&*^>tKb3NnHyG!1OhWIWrORL%LhwVF;LC@Gu!}mE zc5|*z8@vd0?P*eVS;2_upGn)cSY9VRXpSLPbMH+%EIF-QWE94Q$i4>&j_i?66BCgFgc!^6gc>rPIJPT`?uW_EW}~L1sy-P^N*f zu{!0bm56Rt|FGy)<2tvV3ABxL(0IzbLEpM z7Z!`q;nVGv|H^4PB9A3#Q~|~;CX2zlK&3fytx{P}p>QQ}zXvbMLs8mFXGh*iy-lc+ z6HnI@^L6qgl({H@aLu1?q-0AW3eMinj`wfAS}|u<`}^m*U;CEl(7ebqnJhQ(_15b1 zDc4*x4-)46^PKY*6L>M65SC_(Izoji-sTDj_dgfW=eIpUjazjG#MH|sbv)#@T(~iv zC$t!43BM-maudFRfyx5PWSNh<5IL;cU|8o;UiKKAJBA6IW%6nfC^Z8XR&CYuJ=MsA zQsyayQA~#%eViu%xaqB6->2!BGaN#uivs4WVxuuFd}F@uU4C(yZtv!(qTy=72;gvp z_`G+|aY?N^-#6($oILNoAE*Yl-=<%o>)YBR(!)WQ0$WMg-i}A znr69=F=OYPlzDW8jYpuyYj(&b?pb!8)v#!pKQw=sn++7k=Ts-;4oVth!B+}sR>@uK zwxV$u{Q;ZqLpEP1rwxx`$}11f;+mwp;I)?bxsguDVs>EdOd}0A3yHTM(OBhBh01o^-N(Tz zU~1gkLP1>&6vi=LbJ=wAcj4M!>?c&pyVmeS=vB`VSN<51*kjl|T)5Sb8Ta^Qk{*i4 zkSK2=hWE=Svu36->S>%J*QRd&dpQ3SQxsj7knm|?oz&}2Gy2^Vps%%`!%iB1(M;M1 zz&7p$Frft<>6%Y@wG#8Wz|JQs&=)tC?qo#!x-iaas5m90csJ{$*&Fl+v+jLuZ)IuM z0M>HDpfoEJEMAKLsYNlV_s7_CnIS3zr@f2xYD z3Z63D2LGV2dX2Kr1Kzw}$jTI$3Kcf@z=M_Ypq`;%owx!o{u`I>NIfc2s0P#6ArcyI z667|c>?`cGRpAL*&tH=Kt+x)y*aN*Jg+d(<#0C8y1?%=Q(%P5-Ks3(lt@qyDI#cqv zN@f0M=aYgLqQ1DmUW8{i@nQJQBaEvYL%bFHZV~msnB(l~WI`(!?QEp4Y^<20RuOf1 z{XgBJ)x87-&{AisWZR7SXhXe;lGJb_B=!bCjJrOUcK1luw<~M8El0!r-Iu>WQcA4#uksE^d&MquL_1TadXiDy{HUiJ1J6)a={eEeswvOfE#4PL7 z@OOHyG1R4rYO)zUsa?uqfCB%^n$n}h};@A+bIA)uEA0k3UmQa$i+=IvNz>pp&i3B*CD&NcVs zs@rVWBXFjH@J4k+$3>`83g@=!zRpa{0lq3E-)U&Njq5Au8H|MFHYll5#0?w|1P=w@ zyVhM#-e)01D9@i4GNaH8zAz}dnwcxPdFuL_la}49K9uN*7<(dP%YK={CHwWsuctXg zIUN^uscRh1+`FU^sz=`4w);!|s$NIiEe91I`#U-^>(ZUbho@zJ7%g8DXq^4f?xdf{%bnlXcCECPq8lvKii zmt6xa5t|dRo|6Xn6K)vESPj-#gPKhQPP9m;z55vyt35+m+&5jiScE^;QJg5%+BkpRDIYVPz;KM8o~wZS=1JXI z60Tfxw1O0?4ywyZgnJTX)5bksAPJ8vy{K{}REv2I)((>d{U6ZapxRY5+#hUX3)Wb3w8=hpu_|}0qr{rt(nN$~v z8)wjxgNm_s(h=24t`*pB1|pA6qo8Pr+1phjI>)9}W?ms23buZIN2y?~>7&=>1vcGe zS2L6kWkSqAZ)@hU(;iWQ(Hh{T;jW={cvw2>zyCfT*#-mpu>i=p<(mwy=~q1*Ma@o$y36qz>0DCvgIFTyGU2wkmkJRSUyn^?2{TepIK0W z`>_RXk6^1g!E7Mm(?{qNjYBU&uGetW1xg$>r(^D=+!_h$zFb2eAkrb5xOo??{s3~t zI^w!RRbRmj(c`%&`1;$LD;wNQQ*=Ko-q)h|?N-C5iwAHZTIVW(yl&8g3fI#~348!f zeUqyDkIdY!{U!Ri0_jU4xEpA%2=Wn@RysX9Pnkcbz@3?H!P^4;B3{W#r3Il?>C|I9%pa zjpe(~b$;USrI__{K?pvz-7CbTHB!v&R1x+)yz{we*sdWeyEnf_@{0zz`Dqq9kk`WW z2Klqt%G^DXX55FoClCGb7NZKQdEP3JL5o7--3RLJt|3aqI3g-Mz?6go zJpy3?drV!zOZnBxxk7hPGD~_4=RDcA?#R38;I!%t16)(wNf+df0jG=Xmn)=01x*Ul z+)X8PG=&?LR(KTn>#VdKF7Cz2y1af`w_CHJO0oMpe9ad`hP}QlZ2O=(V+0V>Se&A9zcKwy4q9dI-=4T;5%Q>< z@SDOc^{1&f16?yDltqXd;?@aD@yiX*M2(kX&3i)conRRKi8JSV=0U&Qf%`*6m%)0a)h2#sqE?5tMpZDgIBL z`X!yTcj4T{N2OVDYxDt?&(<#(n;gL${qb-PHk_Sj<9C zk6q02%nuoayKz`km7gg(bt#Dk58JPKDf!2d0OFbJuT01(Z*nzfZ23=hyfgE(D?M=$ zV(|S;L_WG72J8U|y_UvPH=fv~oEAPK-4`M7NfQ+4d^H>l(LO?&`aW8&KX>)!N1cnR zu~5E7KaC}b*N%Yr<=>YJHlAR9Es}uURQ-Px(6@+7DU|^l@gZ!uVWPVH1#7IN8ybzg zyzcHU<4>_Y>$S|;3U1GCE+CrVclf8S;x5eJQHiQ}Y9ByyJYo~Hp{bs&!;Kf~A{{g4#mR5w-`2)oR)5rDBV1`#R`J-NuOl2jON7&jrmktZ z6OmqhCtQ156B~eNbWOh_{wuX4n4^$&8@=x4*o{UO{H}8XlKY;>{yrD`(m2YZ$Qncz z->KcW%T1@U7tr#in%Aj~Vpe^Gja1UgoK6H5t&L#CpXR+KGIZG^fT2G*fP7!9H6j&J zGjrdWfa!V#$&EN~C4GZY!M0L}?xFt}&vW+qXC-6SWNw2^%$K~D7&oH6iHIZWllVlm zEW9|f$&2tRr32!zw221uTeX7o62?_^H&s2lP&M45S04=`1m1g;x_Ca0Z*4>tqj~$eBjY4ws zb)XS904@>V$mFq+{asbLBq#1=*2m^q^0@T)rh0=CLhgq%&!R%%uJ@l}Zjcq%@_I*c zXxqqWW-$Rh0?6Bs!ERI$0P`o#7w}FqSBRaufwWCoVs+Qc!c7zk+>?b*3LTV^cIQ6v+ z3JIWi3^rVcAVTUcbPbXh6B_PTH1>4;M2k0lDFRm#-9 zi6$T|7f*_e)qL)gC>G=tmFVxUFjp84k?%y2`yqUSqx$zS-NBY6&Uj+_(CFQMo4FTS-=)$|;M{^o4AwoC&ule)ZtA1Yk9(gs- zS_ge@lI?M)gmZqj&r<23TBRN{q$u`vncjbQv1@_EZ>2MPi{$b9nfCk+LEPv{jCF;- zu`p2-&7z15Ip9u(mDj4o_U~^e`yb~ak&BRxuTms5Ko}1%Cz5l@LY5B}j)6wfE?`+% z7VahsS=;~JidH8&nF5E>u+%Fr%S=5@D>6b(#Jqn~yWacsQvRyI$!+>iMF-Xb(ekrBkhp8vB;OJ5ryw4zaI?--F?4IRcK(% zYLWT<6G3xNI&+fkGIt+7@)IJM(rb_XI$bk`Q*S-ZBloZDO-x|$j{Bmy2H?qmGi}x5 zu@F8v2&uexSpI^|(>KX&w#Husn0*veAJQ>XyEEop%W>4yg{Q}~OjeD`yMz(aBeC}) zuK)IRxb=O4=Te?6_QCU^_2U8CL2zIZ&U`GZd-<;3M(U?yl?SmpkZUGlDYvcLp0-Z< zc5hhuoK`AJ^!W8^_7u{6dL`T#EnWA^>Dj(X?bAG5&C-(FMeED*tCPg^WR{s{wm{vx zYNM!na;sEOZQoJK52FVn?>?x+8i|z_?(Z<)BM$GWwH7k(+Q~=UIbnQ~SUoVJ^eXNn zE%ZoK%;5b#+@mZuLeBjrOt=X0PU>u+zok0lEerKHsTS-)&6(z=oSAHnU2rpTv^83!(=3nC?{(Mbr$X>IrWi-#KB`bfyJE3}E3o}+eW0JJpXNyVJ%AxG zYK()p|LN5A8G{ixumUJ(v`H}DS0O-Fz9fsq<(Vy!bvyJqSzT>dMH&uB}_Hx z+)Kkl3Xc)#7G69j%B!w&JuG6~tmLo@9yjmpW4<$jwyRcD?hsR+0PC2(XcH0;s*G8p z;n(fUQWl7kMQCo)quCGVFX);<81Q4&WndSaseQij5D?#V$kf zEEwserftH>E8-kFbCH&1fF&6BDj6Fj*1(@n*2RoZ#BJK)P9cRwv_Y$Gp@l{!9BFmL z3s|s>6MG_V)CMpkLElnOG@xKa9TRScPqM*XR0^d9=%`_`cPogBl$6(_F%C3K&SRDC zok|0RLRVdzV+P!4GAwVULB_Z-gLi441%VOAolRW91*518g`Jib{@_0N>_3Zbd8TIIkaln;goUgDqoij%+a;;JpDOC+ZImLSB`Yc0zd zfeY0E$}8d0RhDtF9J_SuWH$W3=8X6UCM9a4_2NGmPx0d08o|28>|4`_gVL%0y6?LL zMEmECQc;>`f`qxs?-6&0$k+X!EoE}pL?PXEtkz@MZ&<}?AD9l49^4mf~b|gkCtu{ z*#`)V7La8Sxn}h0S80S7wNNghJ}$~J3d8vICieA{YySKUaaxeM94 z`XXPaaVrnyuN8GWscf3YTEf{i7dO-%bx;<-o`u^KF5{XI5|z3z^dPNpx0-L@!O`x2 z>Xbc|d^tz4;pau~dNm#O$YP7W>aha$hO)qrrSzC@OjQBN-%aK$?QlR;d(eothxa7% zLW?Nd%js?Tl}7{Am-ja4o)Dupc3nLeg^2Xpau{y>~A{_LpeR9j_FM&lWt5nHps!_eU+NY^gx`Jk^ zTy56!>7QGY$)%PcIg!+PD0<(ZBY1S8xR+Pd)z%_%vW~k!6Bhdq_uwq`QvrORmG3{! z>sLF5=MWWCo`eZ0he!_wOjTk}bzF=FFXeCzMlU0^^)(xTuqRjRBtLhA8cx}%5J7UR zy#urLF*ASH4E{0Nw+@T1d9!?p3K7=tmsJu#{E!ET`DqNtbv|pLRBa=pR$O*H_k_8s|anx__bMVnlU8AseN@x|&q;9S`K`5|LZkH8+4FroE$B}ng zB5U>xd75!0rH{lX_luKmN{foI#|GaeSegseq$%yzLW12vOJsa1M==5-n&Aq0WTOfL z8EGusZcxWHpXxmBYdK~Rzd$@f5?CQc*;iJ>fO&I5+*FD8xbYfBbTo-IYQnjSasq&r z1_-(mR!It!iSbIsXOdCr6E*#fi14|$GqB>>D*tF~ zBwpMvenk7TW!`@6uyy`jhMhE$=wfLb=%Z7eC|7{#lQ>@-xsYd(jIsVz_67l*j(B+O zv58i~clywYyu0-ue^g~?an2d2%-V;)czVn0*bd9p;sg2#lztg`Ra3lX#_kXa+@!6O z@WB4h*QYPFzSRj3;EO!@gc%XrNrN@T;-T?ZDqD}RslVRXA2*c8eqtuNidqSaRl{zn z-fd}++k0q`9Uc2#u}Jw%)SjMoH{3az1XavA0=l@fh-|ww%a9IC^>EKtX$#4aM*M>! zq?v&}j+v!@V+lT`^Eu}Q8Q%#E$;SAaLRgo#|6~zc*OVRkgdBsG};fWd%72Q62d~Z0j zX}CS-<>~7P2fiz{XYHyMulp81SADbYk$EpkNi>D*8Mm+2-+a+Lsfrp$+D4nD*09>_ z($1#+{;#g;53 zE)teRi-=JV9Ls`R#SjYZ2F75!s<{hCFG|O|vv+!9ZnwTWaY6)f61kMJP}{k)FDhe< zOJ|5rm6Q{WqpAzs)MN5Xk)fZncuiLj=w4krrHzGZ%xFv-2*))9Q#{;lUq2ZH!MXFzA;f5}wxIu#uH5*R1482ba9}br zHXIZjE+%wXK#q3imVfh&*305lld`{GPnbFg9EmcS%xfsjQ+f7H);JI}pCSm@5R~yP zc1q^XsC>o35Tp6Y*AXLccfr?~Hp2!6|G-bKKG zQ4?{jtqGpETge@5Fgm-Hbo`TT8b4PJ3p3O@x;!RxcuJb6J~3BmsC6dp9qp7h?j|hD z;Nn+N&@M|#M(~=ZckhU7j#{dW2)1_-R#?dRH4Y8~-|aAv!>9hh^t6<8c894hGMIHH~E<}Xj!<0jtwUI z)+RNZ_U5lkts}6R_8J-SHPhxAIVYNA(|^!u%$^>>en7bC3yRb8ovJG9O-`e8jy4C^ zN}GjANe>#UbN9Yoa?w{UndhKt6q9kwULB~r)AF^4M=JQi^5QsNx}8VZU0-r?0=)Rqx=FJuvYhm1c!vJl zGigJO5~CF>MNO3Ackeg&yhaqTC}9X7^O!VyG2s<8<}`oHw%O*~N+IO2K$NqByJyN| zCDB7DUxACY7wq4YSK^FRh8@B5h=N?j=5ubmhXq94F?-Hwx@m|l+1!cIJTy;rF zo6`u4&({n7s!8+?c|y@?I&1d8V7Zt=H&J%!2Nr5Kh0ZNhnO7pK)eLyo;A>JRDmdCdR5TpbCDw)5@K z->S1spu{+yGzkmC_k}kOW%4VfImMf{@%)pzh!s6`^&`uCdHYaJ4lE^Y!~ugBr!QUe z_#bdwzTHsibl+*%W?^2jbT1$qedJzuSyMU&T~&k8^S;;3Jj-f!0(^1+MO`6$hO2&u zN}XM6!Wm>}wV1-U8Wp0NYkga547(P*B-|*y?wU+;X)qUb<;^{=1S}eqcq(HD$9yvy zy?DjsdvS2n;1?&kWg8Q=TN*<9c4joT8+!;M!sB+(gRNt!;lkGZ-k&d$ww`pAcu zm(&7(PMLt5x|nRYzBmUNX{0p|xJUHr$cZ&uE?%A=PSzh34+&&Gz$~=Bc>K+lbSz+k z-5xwOA$NJhE@h=qc#-9NL(VPceW@)lVv^ZaDPPBDL`p!lWWn4Oef7dY_WcH-1qOFb z$04|;Mm!`&Hr5(n_bjo}0U1$`I)m!Rxv z`?9a7a*2kg%yYq;jb)y8_iF;(rXcvb$=%uqLy&EHReOAA)Cxg}*Ap@DX| zNn1ywS0M^Fq|P?5k?DXM)h{!k%yO&DeDy`xwimV$`C-4TxYZNXjZ*YOq2 zcF%g>RXJhBg(1|oF)1|vy>5X`tKuBzAYuCf<5iqbNp6uHhseK3aqZFYjT-*%m45#f z{N7j}0K~mz{kG}8%4Q^v88aY5M7`wl@3zi!ExL~f#OoKIr%ar9B;JvqDwyOI)S`Cg z0fFDn`vs9|nvb#u+y0$-1{$@|X=Hny11;Y_dZzDm09EAKk2#{sZ>_rI5DPj-Tr0`k zqDYI}{FJ&>M*lIQ%}LsJ1$_+%x1kI5$?35X_A=_!MyvW&TAY%*kdD6#yjGQ>8$|{Q z_Af{9osN?xXBNosjR&+l#GtGiTdiDtLngg`_kWlz0SyMs-B-PH3xe>gbsNYv|5v2s zHRqWk8ZLqEhmg*a@v*gObMu z#q=j*T9MoDJ&02=IoIoQOLH;C%&yIM4aV@w`r0n2 z(gINm;oqavC12N_=04407H_?ZF}>M7#fZN8Rn`0lsaOxAYa6bZKn|sjcM`JbaZ`6_ zrv#m=in*yZ=3k&@u7s0 z(e~;n7=QHq4~H@Wv0%jXc^pPmK90mcqL$o?j&tM#(vyaVe3jU3^8GBQdcXIML5B~o z3vPFq|J77mD5pxGt1^Zb3%C})K&eI(_p+87@DbMxb6uMA`!yHOFh!N(UG|8J5^46x z1p(=PgknNTx)AiXDvP2_PG4#8lr5r&U7Nh`FrSZ=hq9!hX+H%4XQ9{#Yu-_WE4LU= zufkeLuIZbm+|uPLp6ZAuo_xC$o%2XxZj1r_`nxsfL}BzvqZCh&mS!G0AKO#^cV-^X z+%mdt3l!`_16&V=ZnYx!d#&Kbvo`D(updIUS*K&$2Y|$1llsZAng&U>eS*J!Px`$2 zQ#qG6dR{A;6(ebIW57e>h4Sy&5uYcI?FRy_LSo}w`=g?cIk1_9Cw0xYy{-+7$lS_0 zf6Q(cN}rH+4gfoB4R*#1Dzq%6-YiE+9QHH^27h^cYPd+(!UeA^dsWXk#aPG(or$+3 zqk46vMCh#l0sm>1_hHq!Vxewbt!m{qU>3?64%kK|t{_Qe-XEiWDp9TY9P}1<8T`CG zU)pa1WSOkb&sMh84@^_uWT)fcX3K`(z}&{4{896|Tg&?U$NEqV{jKWkmof$G3Z4a) zpA`*r=Max^dsV1(0Z)+MYowd)*O0I{%Is>IoWTi_wp|EE}}>;F@#7wygA&2_64E%}AKeh37LD z^K`g2o3~Z7O~TX&U`w|7P9w}n3G=XvaP_Gw(xHTb^TJ{V!q>hyP?bTc!Ssnj z_UD+x=FUzw2HnY}i)3395Pc#@_56i-K!2AZBs`9|=(#ePP?J5?zic)coE6(;wZdUy zhK*`?R>(9AWS?>f&^()NAuzZvB^UK%BGB8*$~0=#L94>AWPx9QjRsheKC*?v9uN}x zEN7+t5~UPu*IA_B6Qz6iiuOSh2E>T|cA?7X&bTS2+R{{VzF+=j$A5RW}J@oI;oR6YHTLh zmakWv-Ii~Jj*RwBaphIb+tbs^#B=iG`eNG#;eSx?bnhn$^Q3xEtu{uXZ%f|Go4ETM z0Ak!GMBKR#=BwXcXYbX?l`%Qslm89n-<2a%;P{j#XQi%%_tCz3|Tq@Yu9=<0AjtFmdbPX zFxUfkejsoW@XJFpgqm@mPs)85DQE{g(Py&hXW~fX1fX=hryDoRJ^k`{Noj*roeEdzFXjVWn z$34!?>pEsmRj$c-vVw+iVdeQ;9Jw4#Rd?kZ<*QE<{XGrXX#5ZGmCvzbO}i!JFPX)L z3d^EH0OkG=U^QgE;-1jYL#xb$Njjz#chl*CGmw+%^Z^eAVMAWg&7ZxF7zgs`I6#wDg=nm%tg?44PH1DminoUXP8ipRt zhos-`|@z0n2yV`7v#M zi~e<)@un&0GhMCqCqTB$QbA&N&A*WNW~rc7Y{ENO{Jg!)3scEZWQ0z-7yGMk55@O> z=CDEk+)$m!`DglIbSlg?izhdbfR+aBNzW-ya3;u_CP5RjQs*m4e#QU%L^T}DcRnYo zZy*P6hF}ilf`M;Us}eFEs|EU}I?6J(3{U{O4?P4G_jWMc5(|bwU@7q30>;~|$BT7Z zXEvx=K%BeMf3dgRg3Olglz*x<(5UME%vP9|NYs*33A1MKO0;;;SK}u0`MwdO!*OQ$ zgKB2&$9c~skJpI@`*}a#a@-QbK~+*{6A{1_$pVZ(c5$lpkzqShIr)Lg-F|BEXD+;8 zW_bXvdEYDDQMDsEv-B&S==seUXXAE>Oo9(qYE7tHEyT1a2hVB2SDG7}9pLlwO*_N> zwOR=6*LZ(^NRGzW4;X5l2G0%;rl?hj;n4b+_^3N=wd}=xD|iUZF;@^Dv$~0wfvxAw z*U~XUqkstUI-ERv+j%uft`nX?HQs`j4~`3Um6b5b>86`}iOYCy&iWiHKbRgU9$RUk z>+{R2T)tU-cw)2Gb!)^r4okyMZhLh9jV&-CmoDkR@PQ!=4{THfgvodJ$qQx?w?xaU z9wem?&5Yl1cp$lP1d?EVJ4p-)4=i(46SXMl7-;zePxA9_HdN{xhe2QQDt~F7UDb<5 z8pgXnA}Z;%N9$Wgovs~JxcCMKo5-3UJQPYlHysQ5^twSiRi!oIpDYMyn0{^Pfva%- zxC>fGcLOuqte!Q;>@d|Sw1dz+T1Ysz@WA}?*j3OpVKpJa0%T4zvuX&k_S5m5p}fmG zxi(_HpDYImth>Zl~CU14} zSAplO(deX4m_-2?QzR0fx@%ENa*HCPS|AB?*f>lsOgyW98>s$>@&+%W`<#X04n;70 zf)^6%UoE^wP@p3)(j-Qc!EF!ltr&2*WgB86U!Fe@#u)?0M^%HJx8GRyXHT@LtTs}b z;4V{3lf~Alqn|%RaGQm^+O^6973WY#Be7^*!H7CPQnn^MNUDf49 zMhC(AW@)01qnxotuc@@O-13C&z#MB|c&%9bPgCDx4TdNB-`&2~$2t^++5CDdWs^Jx zBU~EO(%aF-ylYkh>!LQ&d<{Gr#IiKkZRA%u3#5kF)5j)46VUUtDsCX~K|{D$v&y_c zU1sVxMbq=pLN3MDY#e5ZgGRzZRwz5&*g8Q=8t_{w9c)dan71osc*taAa>AsDELY~@ zx4vl7kP|KTH%>(FBA*y)Ze$NvI;Y)yl#~TQeGu$wjS(uSES&pFN*RKMpV^YGd*A8nNFV0;OBDJ{6WBlAL@Vznm6tSbeyD zxwFfozqnhZS@DC%jXK__1j|yPYArQ$2F_2|NprGyN9n!&3b#4-SE!{|T+g+M+LscS zTnCHhU+=@T?tj*M{y^4!BAk<_hh5MkkdN=Q&f`4my)a25=g(Pm5?a37dS4npxX2b! z2J^FOqUp<6`dhOMLqdPQNaEM34_xy^(5s6^4kKv%-yk0(E*G6L$JBOo$t+$DVArG5 z^-?IT7xRHIIk06d zrIquv=7oNL!%EVhUxtRT1uCZ_I#S-QTs6e>KH)c&^jVEuxYJvA?0%8%m%z zg*lv(i*%JQ-q%s`>~YWn;;FJ7Cy4w-zF}zaG5@WgW958zId(>!K{wvc0eU; zX^Uj5ivL)nAsq?UGx1?Rp+OTPpSSco-gx+F)m+y(%EI*@nbTyQ_WvM5TP!BTQsLP3 z%#9H9P(TtSO90r&8sRy6NS?_Bd2?87uuwz)uleWM4{aWa<=Y5i=wES-{b^us43s2( zu6nTUrDRzuXb)%IsBpM+*eu%K&9S(Yku0H;>b+ynWKDle$G=v%Yi=5gMd)C||JRQK zS-|8PT?c($mI5z<3A-_p!&}BjBYo)I!N=n#eUGbse6J z3Fagyo0#*MO`O&VYl__C13VnUM)U&k*biiADamjI#g&I<^<5|2y1AKKP;^f>3n7Tf zwsbqPrrTD*X`h&D)d2tn0PvcX0+yHw03k^VUOgqRW&XnQt;XYCk^J>`47X4WQJrdq zQ23`^Q&5NeO8rjCgff2H#3h^?s=$Kf;1GIb*KYAGOalTLaksJN_PpmO*R=TJZH^O} zI3~e0Y-{w(iBrzuHN*Avrw4o>z$$C=XVGzN9@dz-P?e#|t@RJS&a#TfKaF`jHYo=^ zI^-8*M?>UnexRw}(G*QvI(IYFghr?@MUM5#EMI{xi5|TJPTe$U;b#49*Ah9?;5$H@ zd6HmF53w`y4jk|)2T=b3IWb=hYk9^_D;YiTOLk9jmuTIuW_xbaS?SKpN?!YLG%ldR zm}~p*$D?A%+w6&?QN1sN_gj4I?^|Dgn|NUFoEiK?kdc*o=Yhw*$W6Pod_112h8DGB1t#wlHyP$P@BHy~3cd{V1o8v<3viQ}M`$yfdb<_)= z%qpes`_9=*x~p-dI=!JTY_SyanJ{@q;Nfa63n)=jz##55pT{5EbN5z&^Wna`=Dchu zh5ky9E+yf3)#Mql10b822I)WJM+a{JV; z6sp(YT>RWC%yRXdT(?JC@4@OSNq61}F;t3`y9Y%$={ze3dB$G;2@t;jF@M{+_dzj133-=eBPp2h6B8`5_4@PP3G0-lp>CCWra8rJ<8iaT zb5%4J)y43NKR9*{EDxaD-gVK+6#lgLP>>N(+IMSlj6AEK3@fDym*Em_x-F_Gkyt~L z7ecaQ@kQjL;3P zfksfmbH(5`!WwTb!cE)Zs1#h?D>zt^O@P6)NT@xfS(?YMFH7Ef%0}ryD;kK z`{Fq>kE|%_36O8(2@x=%nkOV!@z69=IS6C8#cT((ra(08aL;NFG9(6a2MXBrvx;=--A3G8v=E&_Pr+ zShC->7486zsHJo$foKY#80+?}w!)H5iGC89!C&BHozT55-DyR*0mOjXUO|CxxH{sJ zI7U64Mk&tMYp;$7hS3phzBqEmv(+ebe^(J~WRJhEHl|0Gjyfre@AIqylx5SiD30k_3prrd{Kw)ftY1Sq z>#hJ=mz$3+7-o-9**dsg84jPc6Y`gU58TdsEq0;CJ15hxQ^_L>r=O4QW@6P6&lk8A zYmXN4hy2FdGYCf21xn-Gt-@*2JV<`$;5Ro;frthYb!}#DT(?X2o}|cU8wkfGBV#01 z568M(rgc`=j+*>j8Z;T}Emd>8hY8WqB9^kJ;`ML|!ZU)NU9!AFuz(D`e(kpaeo@h@J^b0hwQXIc66~5Qcbo<{YjBy*OsS8{ zZBR>7f}e7|_%$7N(98w=Vw%xKA*J3m+C~C&;_Uc{TP}2er=z@;eeduQS#d9UZ|H40 zzUsCopMatyaLBdCe3JpMCHm7iK4>n4`ZC!bp8SK?fIe(-L5TI}tDFk^vd z9dQ<`^kZaN!Oi^N4r#LYUk{QOONp$oYXM*;o+lV)HLQw0tE7d(n$6pKb3<88wctxk z2tMzA{=sTgkLZRy^r`yG-{!W-REKh$WcF*npQ@!;K)0XLGpUTF39nnNs1bEH)S{_l z0Cq{n(go+Dlf_qVq1x#0n2pD4*5XanqE{X9tobSM;u;AdWO9W|PJ$L$Jjnu02gji4 zam@q-=p{F_VQ;H54eJ-<+eg#;Pl1ZnV#??mvaUVNY^csm>1kyqft`*%VaIB*h6mDt zok4Sj!;AM#-~%oQcsvf@M~$jBc%T4O8tz-1)%Xg?&tQ*k5qg%rdyviXCqzUX`o1NK`Vh zDOV<#iYV&sB$&*7t4~{(Y7u14bfk+4Idm*advgoF$cNNiG7~9NxLqhpyb@1kvx{w2 zTRL{BX;eD4-(abF#I9OCH{dLp>$fb?uF-(n_B=^n8iYrnT8n6uiCT9*jaa6&-h`sL zvLy}CCAusm_#~OUfHa_*#V(8tOK&;d#MAUz6h zBkRE&HP#@^a69*3^r$Ge&|M}V8R_V$ef26|f=^$*?2%U!yD zEy$$IvrS^Kia(A0qvPaDFUy;j8?qj?j5qN?!3S}pT$KWOqD%lH=~Z{lm$K_DLwi%{ z-UXl5Q9h%ZH}wZIGnuK7;t{PKTZ__*V+ozv67$u=ArlI~p}9{S7+goD3q&&dFH}})`H=m1`eSU!oOI`4y0qiPue;Bj_BPl>* z9cNs}L7c-)FBo0x$d-9}!MA2a#JPGoa);S9DZ@mD4eH(NYKW{ z%g_fNx9^|p-au?4&W%{+LHX1)5SbCHnAy_VBJUh)X>L)2kR41XfAub!(FE}e>xJjZ znp?rCTCO5N_u`%ju}wS^)^x!(Kc#3OE6k#ldbE%SPgV>-g4IWWPpCl^?7-6LQfbh` z{-c5z0-#k@sDElto0MdtczXsELr}4iw#9)RUL__~Q(O;CulRj z;*vycyeYs;wu=w(iPnTFx0dkSay6X!vCKZ7-WTSh%L9-krRA*Qj5IG~4=aE6vQWcA zmDHQF7F%i(V)WG`o%S#+4jEku-9a;&$7oXAI%n&i$#;1@I`h+{T+X2lgy+5?nZw?0{d^D8EoDtu~`N|;BKBI zJ9h-IF9#>;tYr%KWo8~Dy6Lqx3*q?@wW5QERz&TYkEkf}FhYwWwh>+lDimw&n$v2D zvLZGKn5kGayaTd>T^#tXp=^|-C~*&SfOBIwa^R%C8PIqKEE%FeZC9EeA+1Mmls|IE6za)LRxXn$-M`$s0xQ-PX=Gl&kbI?~n96`PtJe3DGa!28l81=IlDA3H=8=(8-m|q>fJRS!qcA znl&5OT&u`}!S$)3jU5hrlXj@n(t#)=7cJ%c1G5?)9OWJP2V%*bl%fLfF-cIcO8x?% zph@1Dqi%Q+vk-j6|H7+xY}rR0VvKkNdHANNwFL-?uJqiyDyE-@_4jFH&)~@kb`UdK z6754T<+OKsWh2diwvKZRf+qixher3y%<|3vD?R;{$Q0N4NX%Q_&wsw~bdzrQ;-tmQ zAn^h91E7&&CrUkMNPuzS@}!c9abH40!W8PQS8C|0n%ITXc99}bXQG^6^r9~bDv>v$ zIZzkhL!nOH;xz2=L<{Nt>va8si$UQF;?i5lA5ocGPc#R9c~!gh5eR6xklbK8X-iMw z2>se&V8&AXgws~_xHQ3DhYRn7c1KpmhS&}aBRIsD$N0`;VEXw#53l!%JZA`2Qc@;7 z{v#R!t`#N5b%MLPk02Pu%#;#5G^>Gr)&sn~XV|0?EY=_yG8a`XpWWxr{`efFD|+}- zj`iTKtz_4V;R!=5&c%l8-9!j9&sq z(*~7%LWNkta=u<#Bk!$1xxr>prCKG!gZKc^J}?Ztc>K|QNop+UbNH~5jS)P=5~!K5 z@;;x5<=D3+t7$+0c%~kb4JJD6igNP~dq2$mNp-DKxB^)vL*}3xQAqon}+85_)tOq zFxq_8-ZmOOq+)!$-lEO)qGmfdz@ES6MV6ozb8;yColXZ2PzoAu@Df22f6X+*?z;MS zD{YMi{=c&F#Cw}9KLcO@6w^i%yiBJIC!E+&t`;Dk)Pz0jM|<vrUupP5cXqI8S`7(mGSN?B% zWz~H%A)Hpt{)h{}u$kQ~;(~x^O-Lc<@YD81nw=Yj&Tf`AJLi>Q>H`V%P5ze<=;t1h>+(*eZ`T%PU$H{PK0oVSlu>Rqr7s zec4`v4TIG|t4wtE#WFCWJasvwopjF0>nI&3qGuy?*cC&~c zQAIG41h*D?B6Fz|&`kz=qa>WJADqEqwno}T2b)9ifIhZ#@gJ@8%gRqdfz}};Hy%{? z2OlTlYI~yIX|#8S&Y>cmQMo7SYssL7d8y0=>1cg+&BPiPM2#WxZiDET1DHX_Um5fLl}k(n=SDA+*?mPO)5I?*kec_n(7 z+{6po&~7!WN`qiVCA0~O5Q$?EOE*zOd4RQF%u3SnS?$48ED!;Az_~#RQG+8cd8lNl zHT`-i$+nbwV)z*cKu6%!+`_>)!%EmD>Get(5%iiyb0pbLBCf-7C`$IwU#DaW|A?jA zCZ6lLiGqn3pH{WtG{g*`o|5;`bbRY5%sie8g+1Ca0W>#AuofhGGifBYlIuN5`4Bz0 zndwIWKu!6?i7=^!0snS`JO_EjTEs9Ocbn-DAF$XuWZ)9nQzf# zQlG+NeHq0Q+@g1}tjY;zwQQbtqlaiV*g~NipI*KEt_^VfUXXfgO6{DoHz5|eNCJvD ztllMInhj71=fI4jT5B^S37$u?>8S)!;zddRl?mC+3OLnWYdKV=@Z8HDEsE8M0~*>7 z6_YV!u4C4sjcnX+4hW@ViyXOS4Hy`>G$$-!IVK?9Hn;5>n)I=0t$)`_->NoVJKq|5 zoSHB7rtK@;Q-?9{Pz75OWD?Uh6{Xh5U=&Ece0+Mq+W* z(*3;Wn2&$%niVL;Iu^r==^wm&#iPWETW>)^HVZ*x!Y96&Tb)p7l36V61?l<3m|gSO zX=N6Xd!pZ~b=SzAv&~W#>!{iiYa?(Qy#QynR5g(bGl%&SK>Nlq6mWmEHXQ67G^2ib z5t+`TRs(b$5^A9h+Hq7L43)?fvuksc5Ug35`K^+nwcLLYzD@*95?R6J$ixWpxDk-B zLmSU2P-;`J9`fQo0(`~OgqXAXLq5PVsZkVox1dOhdpN z1P=V6`jt-G;`BR>j7lTn9Z4jeX@QJ0^58Ho{>0p3*apf)`@I_eDHAKmddjpGerU^2 zL4^&#_c+k>n!Dz#h+j;`??9I37rh`9GTxu>`Dx|RgqYSU z){o!?CwXp`jje(1HGm*%{_4nl@sx`_TL7SBr_}(1PwT}ww37f;E0XmZ$+eUU`7pLw zc)oYmag#hsg9iZA!TVajettMaY7ay5#l>MlGO}acl?m3rFzD0`EGw=bX}DIzx??q1 z>xU|?TD1Tx#)*3V6M#ihM6zvW>WEIuiG^ZMfSj}vpP})u^S+a8ppVn zf$!IX`(@!&Ey_>bV7??f6jwP?C4?gC-Ht|4<9EOyW|~cs3N>e>h}{I+a%-WunpTR` z0j@S7Yf5)o371*}P}%=rK}57~(M#fyVQuL&&1|s$r2oDJ9y37?TGcUXZ4xXIPnb*u zr?tHZax}ty1UKr}Xf=LGH6F+hA%77Uv{|#fEKo=5ppD%u!1KkB!4BP5WaJhoKC()! z@U|X=!4Ld_$!H4d$W{+$K0XbN&7>yfSPKgJmQjmFI0$GH+B}QW2(s8f+%#As&<-== zTR^_A%E0>)!6a}(=u5JqQ2n5uKQt@9`+FtrdM%F4&9|^$VdWGkQ(^%&{v!QHV(Feh zcdYUVmmBSJyq-{^bRtg^n&mE4vsgw$-G$&lNK+v2L%ywFpeJf3_N8E zpc-u@T~%&DLKeJ-rica3a0eIVfS3Rbq`_j$YDBHiOhqgZh5EE_J=K3cI{>&V#3F<& zNk{d7;LZ~Y@N3p$y;-OMSThT-jmIJW;DEhSY7z!)&>vzN>gleval1v%3K7d??%_KBz&1b%Oyu1Gz@D}YMxR?^ z1?GnLCiwSvEq=_DhF8+jXHtE${Q0WENX$CN1kff}Q++_){vB1D3F&?sp_M!kI!D5c zZ6;)_raEGd-<)6?Ev6k+sRF6g- zK#!I%6#)>qfC7!T9!|NOMW<5~+!Pi(eoM1@G|N$A1KxLFTT&9&@UzVBo{ z6h1_YyskTA9&ZEXr6KtGlc6L0HNyEtb$-;Qe6dMoi_CHxofjx(ZxjIH1^GAgv!dZ; znw4}0E_yq3ik(XAr38QYp{F4|aUh~*Gq1uW0=NJtQ|-mrQ2EUjE=pz&=u~$%fKC2%A!68*mP5mL!gqGgC3< z@%4~cEHxen`3`Q=?+CWqGZuI@L#uM64yF`*Rl!+tKsdaT8bQ_-0I;eHMWM)_YlZ%@ z6O6!HE%+WGlZF-fC#n(_X84N=8os^KKb5bj8Z>LFvmHFR3(i-(?)Yj);y zdf-4+X|Sm>rlAgsri?tP%KSZJ4TblN0QN{^UI=U0d@181!SJC8`I22hC8-G+8BZhEwt8O znkH#rpjJ!2gV}y*wmrd~Cd%<8p80zXD03I9gXLpuRupPLe5(XvXTY~N90=dQCYd8D z=}@KLt2^NgsstoL4~g%onL^FjR?@9vL&01Lw~J=7L-|Bd;9yS&nnzMjnlH%33$g%f zxml+}NUh59)1?y=KnGPyjjSS4)*Hyxo%DF#to))if({ngF@YyNtfi@F=Kn_CH<1N= zeqq2ajw+ZjVLcR(223DO7EQ-LSV^@X2>C|V{YI{1VrQvJG657j1!Jl9h$rXf3+u@> zBPb>I)2jTh2r>=Fj+u)K%mK~#u^CZ0t?htDwP=%I?l?P3V@2FXGUg6=?#i z5rYaNLDnwgI(Y5C!Q25uEtLRdD$HxvG5bj+%@_Xg2i6Fd$jtvf*jqtq;Q&3r004j( z&=)8(md64BXN3U32Of#Ospu2x8HEe-3;TZtnhMc@H}|gMZmo}U{1q1cFJZOI=b_r6 z@s${{*T*;UV_C}Ok`=D->&nJCOco;ThX3N+&kV5wV{P(NS@#2(S3k|{tw%&fyxn~? zZ)foFap<~w^Oq($)7rn)*9CAn`6o@?!o~mn2v<(Ct`54Q>=)xqmN>C;DKV({_tVZ` zd8+Z#)p&RQ(aQSNZlU7Wwa#pIwqJaTTdw@|?y)`BcQyYlL9M&F#cq@Pnelw%pP|;K zRkHhKWXZeNsK80ed56uB@|;D&^?NbnH|CcfC2u?`S`inz=9q;T7S@Sn=*%zxC+&V2<%(XzwMqxUr)m=`H8TDqQHtx|_~X6I zp8Gjpy{>K<@oKqd0kiRAzp=%~X+_)Wq8MfWdV$-ewxMgc6lEn!vaR1K-%o6w?)P)n zSM>YO)<7fWMv3%Qqa*(F;*H<0ANQyeLfd>O5!x;9a8!?N`v8d8G56TdebeH0UDssuWZc${;~3&$p8gAj-75+^VGX4^whLUu4e-ha`nCWAgoSyKNzw2Oy$gZ8u>4)^Y!cJ8yZzdgI| z)N(^jF7U81p=UhzQPXRa6K`yb?M3;wXfyf1-HWW&#UJCoU1(N+^dK5pd6De-vu5z!s)AupNVmA_9DC%!`8kD72cSWmJEMUj0lfPH`)r!Fe=P$(GX+mugfs{=)`3`y8C=DE)l`J z5Yt4xm#_C0Y^9dr z|HVs+#~$4HJRQHtIdfNsQ+b;6=%?lPC=9ERPVnCJU2}1!=C2X;X;c}Wr)}&ZWn-2B z9)9=dP``+x_P)| zgC2MHPO|)*>@~4tfS8InYOtuf*?lhjGyX!E^t(MbKPpyXVqW2~o++Sa7TIPTTKs%} z55F9U?|Ep=ShHp@&gAi`O7fMnlbvI_D`KKhw}Kw(`3?GW z3_?v*)n8UUqil$WN~z_i&3}?Lib|U7{gsUPb}cs(IZyHvv*#l=qlP4G+3PToPAzs zRNG&7_>-3p)&A^7Vc3%p=2!Q#xjFewof2h(<$~kg2OiLvn5MC^=OUgMX)tJ9$l;Af zZ4U)_J4bqigp8+*ah92cryM5#3DY@Uxa@$;2-IK)>lT-PDXk^buFDghc=qq61b=h= z65@6th3m8u{@y#Nsml<4OEU2)@7wJrz4!7;CwIk;Y-j71-uZX_>9C2UWn56_CoVI5 zNjb)Zv-HL)SPbv>xCN|04kSrqbsWA1=JV#2)&m_wpUNdvs?#iBAjlf-8sh-m3(+e)coh1WqCa zOa&Z743zs8ERrJ|zgxJ^lUX|KN6)Q%>OQc_x%9Yt3di?eIb@vn+O4AzmiLFwmjSnXjtZy)vHs9yrKUZ`&J z2hw)m+4C@(RAo4q`qbC|t?y5@NZ&kqDpX+LMVoI-r_T-jC{66*D-qhPlQRDAucY)a7j|t!jw2Ixsh@3f(D-v!#}m!G zv>6u>dt$Wr{KE!+tczcKVxC;ZDwgOMruTpUwI*zoAQEKx+d#pHHe-4^)>3Kf-mKT1 zF`1{Xusg(;@vL3*zuJO>?zboA*22mB4HF|_HxdiUHRX%4@^5{o-x@rqUy@q(GLa1E}}ou5y}^!X-5R*c@)ac1-`z zf65CQDnA#Cl^Gy~a}7;9#8}z%){J0ZkiyRk-+w5zoHb&f7j!#y3leZSFDR9rN?sI8 zM(sp0JS>!2*8Z-(v-JG|+h^9)F`=LbCC}&L5-t9)i=m!f<^O(9;I4>Y0Ac+@Xf01r zf}Yor^W@yuqAq0ZgQXlA*WV6Z|E8(j+jzyUZ*?nQUqolN!!vv4D`LN~{ApktPgEdU zS@LmQnYY=ysH>?$y~MHi49e-hqVIPLa*(hXx@wXr!4KOt6HfDqeRaoOxB;da)C1k^WC>(w_c1D?moF7WaswX8p4+|!&Z0N-%VQ(D^zc6gj zh{+zY2ZsxHs3m>i-2cBHu{$;^TL*XWoO>ZRwA)_ZepfC}qdze}QoOxxeHtS5xYTBj zT%teela{oswqq(y_hsFBoA2-88@`!AMeVjKJ++kEga{v#IP=Xz5C#t3Wa&)sp6aHM z!gVgf{HgowM&Kx!D7DNgb_(9{c5zwOSj@puZRE@MCpu;$W-*wT%Og8?0`A{^x!bpx zf&B+xddgcPH0(Luzleyg;Ju!FO(f4#bSkPUS!b;=wCeP>PMcAP?@jzPE6h*7(b(+g zn4<7xGYk7=qq@KA;Wri^z<6IIt~Wqw$){=V@w#fxe)|d3!w#+s-(e{q`}NBOUNk+- zt}96Gi2PUmS2cEyV__kk)99jzolRZR?s@}cm;mYV z%TH9Rf4WUx@xyEux z>+OC_UVpJ(cbDs+GsWkIwB`QAhBCz4Dft`VFM2!zKdbpAYqw^d6_wBTi%;YT^`W2`iWj2GA|A={rHbp1^A zDHb^?+&G2aR8QxT%%#o^>6M5bZPPyvPSD?4i96`}xIAgKrG0CmswGQmqeds>Sf;Vg zB;pS0=g8Ed`w&;%J~e<;5b;37=HNK;c=@Q}ztjEw4y``iM|D>E`UT_LdL*~-<+ZP? zl@kibF$>R|cw_GMxAzv;2|ZWeg3U_x4^E#P4}>j$t-Okg(GFBR?u(QCX1x);!&5ym zTSXE)k=+gYq7mc#{83v*FGq>5jUI1BTd!{93q6k)`1lR!)mL`yA42v)Bcipz7F7+Flx;OaZ%6moC z!VIoG3*N-d&za?=&wlQ@>g-tfLr$ut#g12+s`MdsH*XkOYsQsrTPjnwKJ~`dzomEX zND6k0HTddKdhjhGK11hT;MR-qi24FHlJLr;z|CR5sg5-VM!+=TwXGeS zaz@@KyeQLh(M2xlS7L_fJju=V#vC4-#lOUNVX5(&Bvj1&r#f=#&e`v$-i5is-%_7U zIQ?xwSm~QNx3UCY<#Bj=|E{No|G(OsrMn$N+5OxvOm&!`ZK^-*;077XihJ+u4&U?n z{SfhehNDtu$bUb}1Rkf)hJP**km&uhus~^SWaSlqY*#usDZhBo@k}=CTMTK+_WiZQ zyT8&nUg!6?$NgP9jl)4B%ww){7V+JEzo}P3v3MQU9jFx&{AOzB!_H%~yyPFxGp=^? z+%YeI{@7jP$7~+s@BzW{4n>T&h-oD{)am*Yf8Z&;CMIlhft^_pw1w2drx+Vh1_zOxV zl!HWnGrSZU`ro(Be2C+Qc+>U$=&LG?=1|Hw`i=G#Y3_qqL zCv9e~YWl^T?OtVcyXhFvBA}n5%FueL->pF_kM=!ny)Ke`VAMp?HGLeycnw1tKVL7F^5p{sQCA)f23>K zqaXE}UA=c+J#DLLpe+=oi@t)|R^A>tr5^p^{(+p@ZvAh8z1eN+8y=HloP=QTv`N=X zH{%Foe`6)WMn~|5Shp#C8)WSBcOy>rAr1F;VIh*KULazk+9=qX8o|M4S8E8P8v)8Hwv4L z2314)BqKHsH)+{kL~ZD`@qRP=e0~&TqF}U|CrRv~W83mbOMQkLo2u8j`+nZf{OXKwU#9F+w{cnV@BWmjiel1TvEbWHNHOH^;f0c(Wa_x zv&!9Yk&Bm{5O&njk1MdQF(xDTNta8+slT3nOa&j1?D`DS63UF%X{+wC1^2wPa<~k1oNhIyWCHPV1+6aHR>CreEhuE6`|gDc_FTc96Q_ z+;*w9iND+2YCh{LP|zf#OuTRdTv}rb;6iJQ976x^(DZChr_BmaQzAJm@?n6%orbc% zx^DG8?1s<%E2oWv>Ne0%GG6J>-{WJJG_~fVHQ$U;QuOxl{P3nVhl?Ot(w<;uVJ`7N zp8R!Np^`madABn7LB6N%mrI@EcQ%F%`)KdEn{z$NtDdV);9X-d&G~gFEwSu3KlU8c z?+tZVC$C0J&BEt5-rlFX#{&;IbIX=rY^x0RG4wV31TKGspfZu}o&-I3Xb5cwV=Cm= zHE|A)Vom%PA;IYxu<>%^)dy9%o|OHKdxA|r)(d4X9bzsks@+U;gcxH|EujI=YP*MI z`?+=tC_n1k)Y8I)J`8TwxKLsK7(MN1v3I%e=$s+(^^c=$uZe+iv`uY}LSTkp-# zq`dk`Gu*KLzDU?7c}PF;z?j&bTBAGTh4c~?{o#@_L5PGL<7h>%TWDugh3mG6J+aCK zh@fK8m-M2Mb`(mWSFeW2h{_#WVRhriwlQk10wHkX5PX`=X);UGL|Y;~-Y(aWE!fUj zo9((>daqPjE7ODTyQ;8<8lzXv4th*vAomoT+fA3MBW*7*yd0IzRTCF(ixWTiJMO^9 z;yw4qVjdwW#wS_u)bGtsYg5kk``AHU7kSR|AO8nu?;XwNAOC+}5hO;fq6tAr)T|1M z)Cy|0wbiJ$h}oh-?IKpG1~E$!d$w9si)w3cMbX-;R<*TP&HnPa@B4i3bMC+H-|x!F zbxyA2htlQszy1sLB6K{qht6qJjp7;lH_Q+nII9OM;HudcPcWA$x z$92#8O=`MM?ENyWY3@6O><5bjJ7{`X%MLo+jow(vC)ZK(R-jGy6P~-RX$J%Di?%c= z&;G%q3OTNP1QoInw!|&7D#<~IVNei?3ZhIO!Y6ky^-hG;*TkeSR z6OqOUsy?+(yF`~+*#I#P-fWH%SnI%*X(Gbnv4-Q^)zKBxcX6B84d+aWFrgvmd7 z^m{6sOfT3c@z=yGAD!Z*ZB`}iulj*soCoX3b0pY~YOR*O#r|Eqlpe29!ulSwY z7f%-)4khn#ddK{n8_uVEul-A7PAN0(WBNI~yz^!^FnLAriP=${cE8bVQCLs**Sws| zAk>fJtGf})qSJ6+j?2x9#r0re)7&rT?l}HaJDS+Xw)edUI;P5dYsY6X*ul6&E1TQLdL-c9K!wP~ z&yv3o0ou1mu+;wJst)t6L+MV=Pt~VVC>MjVyo%0yJ?n4Uyq9;v#?&5;ZN+>RK_vG4 zVENwUaH$s{Zv#FeB5w>!Wp#9}-Fi60azi38v}>PeI4IOcp7_F%jpriRXr?i?xc=-P zx$31zssGkj{K!{Mgz(MW{fVrA`A*o+ANrreo?I*vMQet+M_=weOS7p?(NT&@Ux5@I z^(egJO0Q|&Vel^M^{q2Pc%^Y^WLaGyd!pYP(l(~7d_Axrlnftf2 zzb>b61dGg{%$}WhPuVRKzB+z0V*1Wx{rbFt9Lvworss^31ZBgwug5fH6__S>F<9CK zThai>M?{0_seGZvrX5Yz;-OFRbt6p3OtCVGN=$@u!4WFda-33S0~^{Wokrriy{@Fa ztg?w)y01Eq>hijR(w(I4=&NnM#Dw+PoV%JkHJW6u{i87ua@RqbB|%<6R_7^>lJ}4$ z@a@X&J7vgmS)H-k8$+GX3oLe$E2wcvV!vSCsfAJTM|{;{ z%qALs;GfJF_uL(I+SkmrPrMzY%_Z-Ds63)UJj{0T)?Qq4f1RmpoGv1oo7;AC@9aWu+q7k5Da-AFExAC~)ZiXIvDUN<|b$?5z zjFI|JF#4gMA)HG??yUj&Hr@X-n~~c7*@jmqx(-YONPXThms;1Dn>}Ne? zecs`L-XMnaDHNugSIM+bwGg!#U3!QV;)v20NYaq>Qt<{}BP@fv;#HWAms6Ni zo~Jd6DP=fROQ@+k$XEs3sb*6ujLST5u{(e5r?hg_6}c(V6H0?r24{Yap~mCci4`{L zvO#POD_*=Xm`uZH&J_f1#-%mFn+>Qt40-7xwe2~~r1r~aPSmchWA>G~huI<4q)zpz zYN4P;f+`8HzWBK0FE@zM(I|_SAZPhZjd^oqlc%Oooyc<-d~;g!Bk78Pze_aB#pB`; z!Bzeb-nLfhI4_gx%Y#2}cRnIdMJN)Hwnyui=-1o1?H;dd!Nd==8g{^H`{46s+hSL& z1XK=g-R+zhedRxWzcw!VZ4UDz-Tw0xS2%d^M#b+FulZjM!!N<@y6OlrmHC{RUllt8 zr4QU;(S51^C zw$J-zhxHYn@jK7-ugVEJ)FBazUj?JNN|L{)a43))K+B`q{eG?KTvgkDFHRC5Bu%VG2itUT%W5-O+Wsh0lr$UDh~eKU#faL*p(C5eZ|{J7np-Mc z^a{}Xx&9@M0(s#&Dy-kSBvp8u)ojC$?|ge7`gU#B?YQ>MfmokMZ>+mj)g_7dj_vPX z`D<8qK)`=1zI)k-M1Gk3jE(gjN!G`YZO-WK_B=VzrncPkDtBns4?<55$~fmfH-71P z={h5XdTDcW>+UU#bG_`q+h;Z669EmgW)Gzz9}RzYkN+n^U7!A+%m?FtFQ}U!aPtz= zcxfO2{P*Od9-%H_yE{6#+Ff>aw{v#HV5IJQIy(Ow`!@%$>1*q010WCxn4&&_f0KYF z0Hvpg(9=O75C{VUl#!Y995WLWGo0f*D<>b106!lO0)a$Ji6Dg}Q3!;nf|#TXoXh2{v4K0|Cj+U1C>0s*n04+Nmhag6s z{=BgrM2NsC6PB0fgQyn|%nqml^&bmp*3C}8 zgCoe^C#%{^-VF%8-UMrU1{r!Z0_EULXbGrC`KT_!ca1>~! z%PG5dS7Q(IB5@?AF2e~4rkFB; zo5J1HkBRubS4=jVOX@FS8tC2q2mBrs)Tp|X@Npga-jmSbtpOJbO|gq+&SjQ4igh*S zafo;VQ)1QJz~LoMR-f}RAQPj5Ec7rSRMo@KKr&=7+zVYKNMTmgBI3B7_R_IWl^Rieqc6YExC6e5m!EXj* zfgqW_hU<1uAxk1O;cNU%m`jv`$?xe!!0C(ySlP=(Pd@BZ4B8n*X^az0esuy8ci>;3 zFM`6a3!Z#2-`2HzdUg8(gmb>R<2&ge0R6?fpx<=!9g%kD=0xGP+Ew%VREuTORdB3d zHVFUm(0yGD7_9qAh-J22iBi)~#apPM#Ey6jh2O?&frXkSW)rMkZTQ9QBl*ST8$IfB zq5D}!z6G}EB+k?Oxah1E)laUzvdoBtRUCUvlYkg@w_S=8kIX46) z)ugSHUo{nyai7M-DWqVvY&r3B`B&Ul{(cDdHWV#n`@@;MYS5&UYRj$cur0sx`l@}Q zW%fTHKwcfcO{HD1jGVq2V+0V}1ae49v(&;nZNtY40@)Z=S6%I?dHr3D`{zY6>XJ&3 zc81;tJsI}NlOGxAST-Fd_XIzshF}*^-=z8z)!?Szq+!NXOfpkA#AZ7fx|=KM(xbnm zPqflQVSgLM1^z+X0-j?7hg1UUTU2_d)CJl(qcOKm_TJ!SH-XO0BHk|1T+F2>N>!b^ z#pixLP9f7lgr7H-%;RVsGp?(xj~@4AuQG|zUjZ)4)UWIO9sX<{OeALA*O2#{qg}D!6gQajGlEw@oG91+X}; z#0?k8RXYvjG83t!W2D1z%n zjzVLK#t)2gGCmN4dRjVdjv$$N$;{!~pJ;}cb9-Y0yx zUn)Ao6|`6DHN0!li6__N^Aqow+;DFV4MO0*XX*WXeIwTEb75epH7(U=-ga@#Z4o?p z^n*xaH;w~f1HDaH*g8>2hb2ER%<38EcX3v= zM+xaHo*^keTAiPxxRl-8yma!~1rwKUxG!zOPMQQ(4OyDw`D6!4{H|U@(u)DaM=0K^ z)6i_>VVIWP+hH}|^mG2-4rkvR7=G#8DbW#hn)p+KRSVh>co>)fs50hk*OwK6hbX6Dcvc}vZo8E%T&dr;>7gsIga@Qb7 zM&NMCgjx;=Qx{;W5UvZOg>C;L(XdPGM zU{v@C?T|z&tr`nvv~ef`=BuQ8+~#@p>!&lH6pZON>c#DpB%Cz!RdslOkyz55$xON2 zXZnU(hF!qn2n#>#nxU5tGOb+g_0s7vV9^2;?AbpiL6n|nMHm`lJs*Ep9seS6BV+2& zZWM6;A}+(-DctW*PXu3TvRR)F%UU6sWE9(xEq6vPuihMM4wGss_XMqQ?lHg8O+oC6 zB)Nc|1b}D*3aXlm58Fqca&5&ICD3P?C-i1fGIlwab!>Z}bPeun1K=SdO1!yg+k&8| zq6Zd86+)LAd~3zSAv1+^MCAK<5@;%?NF;-2F+&eUtxABpM#|DVcmHlsacxF53(3|; zGYvYWS4(-J>~)ZD@tpR0PwCA8gzck~RpLGjXNl(v*!bNp^xnXnsnNanEXYhJI+q#>f9^6U6C5hCwUq5n5_<*9Pgn!(BpSx&sjKEYeTyO(vdumdJn zxYdfFG%n!47~duvW;;*+flsuFC?VjB;8KF!spw%Wov?{K+|7$HL0%&xlHX<*WkNWC zZK&W1J^>?WX`>ZMS!B{_TL{@ z5FRk}h`os??jPV^iwrU?@fE{NKc(b2g-CkE|6=B9l;CVq5N8hqo-PgMp@O zLYoW|ShSBwWg)Uul8_uXU3KVJ0;qk!{fbch0w~I>n_M6a48*7N@6y2rgf$L!2X^E# z(;L%1u9P8c2SJyj1gj12o}E!aj;M3L{{fev=zjpQD8c@5pF$K+rP8m+#S?DjD`@vs zePhE!R)SfyrPxco|0aL}64SgtSRmpTs0~)Cs5v8{?oFwR&OhMpi`h>pN<_>Ftdn!x z!FJAL1#1rp1XRC=u8=}gIR^wAKTz=sodLk>5WDS_*{c0Q6Nf1Vx;lw462E^5LFgfh zcN2=3|8Q0_n_iuqMZE2|Fv zsR8%23vK&!#W{>mRQv)HH`H&IRdrlIE%PN*sC;loKE<_s_O3HRPS~V3F=Mhw!=5)H z@)85p@Ovek52d36xJK4jfY75~GG@&0@5qKjsZcWkhlmG2#X-WcT8_0=nl7S)3&&@+ z&68adk&xbDz=@%jqtO;Ud)3Jdxo0}NmFqCcz0~-~3i>NLIp?9ZokzHFLqbDD#9!ai zaoD*YuQ&Y$*FnEcDw=%E>n|F}z_o90?VUY>#+lNY8axicg6+!c%q2pCthZ|h(Q@GyNe3B7GR}lbO@)rpL@@lt!dWzFWUGSz6D<= zMA9NNVF24)c#9b)Iu2I6Ogb7AZ2uZ@`1IZLtn)9F8^!u^UrH&$2OuTZA=~sVziTf3 z;ny43D>R9w?J%N_OoqFEJR`X#rh1wE=@=>?tMO?2NHldUB-!|!l-tnVEZ}rJ?5<;i@wu#ac?bEQI7v7!Y`RUmFL|i-`I!WSJ=I_Q6x1 zD+4N}>;kIR5w(5bLP~a(zQ92kr)RXtxz73`EwhKI0wmioef%?D#@b86P8dqoFx5W| zZ@VZs{%bwcGUT8J?o}BAhn7=3MET?SIxrx*@toF-rL!8X;X&Qcvu-M8UGv~ z*I=5JY~n@^FS@3QSX|jGWckw<*0Vsn_S-npc;{`yWvV3^@Ta5j@Ii+B&aynskHlKt z=nw+Y(^Je}(1Fn+q3oeYO?39_aVHd!Wn(}N%0Mf6?p;^ECqw6_%Qo)3Q;#5T{+jlr z+)FPn-(PnvdX7&|=xve=WC^tfbj0Cz4zfHUMc4yXYxNeQMwSD9bkO_8RF7}oL(GR> z5kwFpr|r|iCe&Z*KrTvwT_Vy95otP6sFYFrT7HF@#lU}HY0db3$HR00q~^&SCAsPo-~f)fD}@g6O~x(T;xYAFRS#BWH3% zEwse;I0VaQ_)cosxPistXAt=u_AReGJygK2@*q#QW3x@cO9vU6u$>EboiZo3Y|hT# z#4qcbk-Ym^q*X*iVq;<%eqtv1Zt8N%+YsQ`<`utp0PUfzOdhbQf;&s;bQrHZU&GJK zXPwpG1w%Y>>Sgbz76mfKG?7?;m;|1Rf~w`an&7jiTQiY2be@~zDKY_&p~y?93usan zohealTc#a$wuJ@ab=SRd&-m{Qob1=;=gx$#{9x_+2Sjl)KQ&Ai+@UuJu^m5*uFyjV z#W(fnFvo*7j8mMPWawsqCJ~p;3M`-AH4_>R|FhM?Hc-mr9_gmJyp6T%?`4Q92X27} zrn)$zKHluQ=9Pp%n=qbk-t{T@4}Xs9&K?1yJ(XRcCf;ZxorAE#Js;Y#U#c|+(5|vc zwT6f5$H8KSY&vv&{&uT3Y_UeIF7PI_t@N%?PTXAe3b6e-$J(|>mu0ADAu(&`w}H7h zSA;|37A1P@t0#+r*-j_5=FaAFIw$yDh&?7}#h}M_0U6PQS($nMz#+A{U)460;tGN# zDx_qt7-zqNXqvEjzLcWLvcIuHrRyco6*_6HWQF_l*A?;GGV6TdpX>Xy8l$~)UZ4R# z?G<<&dqYaqBrh{!lvZHL#4ctQE^`s9F(w{d7RkV=3hxy0+qzsuErOzF5;RT$aoq+% zJjMqC@qawgELHoApH5fj0%paStpX7X4^@I!o8d4t-fP=8G3gv|tqg7WK`g|c1s*iA z=G8zj4M}P4B`n*Y1?F> zddSguUG+ABqlBrQ)A0}xD)}h4x!$r`TH+uhAb-wc@p4K}FI?mSXZMkb_AjRJOld45 zVehx8c!boom-T_7Nc?Q<1MQm~4vE${FOY_LDI2#$jRYCSSI$fFr5*lOv^^`y3J~cD ze}}jXWtC9C0x=Zx5BOD_Acj+>M@TTR5H?0*>BaRP4Y9$(NSnDNlczS1iNrsJZ>4AltY_tn7=g2ETbhe#OF{8L$3ep=M`U+xnnzfzG?mEf z{!YA2W1J75b>1s^B;417`$q1-!dhaq|K!}Dq(EWfqzmGOiQ7XSj~4B(IJPuAZan*7FYER7T3OD5 z*LCNUW1|b699@1@zlO3B+>B^+ySV{+r{AACE~vIvFehN9FD^}d3OG)KhMoDGU={Z1GpqE6bb?I1$<;Ds-!CGp+G*Yca1&WlqCy}l;T;@%a9jc8L zs@m?cU1h1q)BCZSJR!KRWp2ARd#V{HdRJPEt3bYh(dYCkL*Bc7zb!>R63r@-TZj34hC^!oce}s{Ye(5#C;eu3j1U^DC zQ~TP3t^pO70OpFC^Y!sIl;t9ZCBZ`?k_ET+%LQcYd+qRNMLkg<=rqw7Ba(5?&&spe`Tf0H$7tn}QF{VR~NT>1@xKVNmo!T*4JoB2e}h5*SOQX)G-yWyvCB3?~;zYuA|#^=y{_75njDp>9|YH;-ET(8_KUb(+++@*+otp?VQM>ygh z?n9SCQkbD4NM<&F!%dZ+DDSs)whMUzU9kkgVVT9({*S#>68^@@G=~NZz-L%RsLWLc zp*7FuMA)vqs;Tas>+=U%Qqskk?H9f?s^&8h5Q0s7aIhF0$7nXk5~IVvA_v@rIhl%y z8s1VT-@KAopq+YfHL*tRVP3w<&)E-ze}K){rt7tEg;}@@8XdAxp1AHxeAdS#k`w{K znkEdzCDeL45^9#J)`ki**f@rApC)Ww77t~N%YXb-^QpOx<=MkN-$H;k{EC)+KfU%s zcw<=cdd$nGMh{WGXBny^OXS0#MMfR30$;V3EXHc_PC;?Kdo$igrl6<-Y3^A6j;{v- zuVshAlfo@&(KJjViU(aK)$)FPuV{8j;W}=Vt3jrgDVbg$6Q2vT!$1jkIL3ol^5NI< zuXkw^JX~k&B-e-#MVcFk;6PK=!C?CBKc(YYEt1DEh9i) z;y09DLppA;D?j>kUsezZ7|kk!n;V4YT;UK-{_xVK4!vy!g_Yz~Kj%O%gfLc1qR&vZ zp8yp{Q%^R7aREQ}1@EB65pCTCXVNRuc)$Pg?7V3odyC)&;oC$F7DMj=xvs*v#fNX3 zQDpjMFZvnGcOndqHx?suhtRJ~C+UpF3Mr%j+_!{Kz;K6P`!6cn)e~oyxRGFG) zv9{N!(opVBdC9@JKT!MW0*I#0_ZT}~1DHosvt2fif89ez>|i|3sdNma7gX)3M1L0N zCO>{v^o(z8Og5oEjMX-VTLuhgVJxQC`5u+1LC4G)PxYUJl{^c$?Lsc+gdbkGltWN= z!GrC&P@mQD8$U&1Z90yOlNRwgvnAYSZskM+Dj7T>q$Ru+`!FT(z`I-Ztfu*$dI;Vg ziiL~F0rAX*1Kr3L&@21N|qvOL6eYZCQXfAG4BUIuXX= zICUJuj7jotiM`px+(}C8_V@?P-}I4cO|xMpUG5>Q{+`G=Fl7eN&UPw>Wx05E;|spG zDX;toDyf4A^dy<+9sg|5dt_)OKq*ssDdDd%to3Rs(m9KT%H3rveUo~vQ!U7Ei;)0L z|B2)4oKbnZrkNV25q?kQnP2h{Wc#Odn0&Zb+^!l2=7?~g9wyRDo91E=k;J=;trcS{2#DqRuzVvY6IwT%IhjS zQ~}B%Qx#6tm+urPX@JA>!4XZU`~<@y8u)SJ;a`DN&W)Pm%Zs9gGN?$wL9XUQGHadQ znRa&gLd1^f;$`egX(5@Br%X^Tz)Mj(5!})zfzxoD|hGCn6J|3SJkG zq{Q0Y;!a*zkB4bm$B_ELiC7rYa_wm7DIRmS8!3`!+!5T4be|I!v&9MW zhO0D};DgvePIqx?K_};s7kYU?U@uQ!3htnEUy89zvcZrUE08MHSB2?)a&Dc)@K~j+ zMMH1LOrFrybu@R73+?^r4_%LBt$&LerJCAZe7r`n`qi$@I{({5kB9tASiBI=x_wpy z62hLVhr*ZxtZ7=!0uF<}eu4jjPPAt2aYk{C@1Vc(7x>c>h7-Tgu{#(Gu{C+xi_jhq z(za+W^;3aq4tJ@ZIO4av+7~C6xmE0%JNdKkD>{)w*1die#Xh%{VK~|?n{Ecpd^b#Y zpJvVu-uh0d))Jb(a<0K(u)0*O|5;QFSi5KY;Vn_wdg+pQ%ysZY!(u?9ypBclq^V6O zv+*DQS4*h8xLARq(r$15CcKsLk@v-QC3~WXQsqtyJ9 zvnZ`91gnR#*ly*p8e5i>fj8E^OfUNFlN9~|dQq*5q`WCW1+->T;Fwa;$IRk&M+P^r z^Xg7#*0x~~+;Kyq5 zXy@);ug>4`;i=RyjN|*a{4D(jDwDYmI2myo;x_&c>D8ypV4XZX=`HxGaN*ieJ!JB5K>zJYzEaw`H1owQ5LHgT z8>?Io6Z6F`hGWa#1M0y&<%Ia}aobJ;^ zh}4vOG1vt8EE1?S>a5&T9Z9O+jxCU%I$0a`tEFbp)3+sF>Rjk)Y=a715vLQ8%*_gg zf)Sw<7hr<8hKv*ee44;=KU;goZn^Q-!KhdTn4c%gUPihVdf)iHS|)Ol^0!b>LF8a~CqH|I)$FA6 zuQ9G`8`OG$;QJ(M($l96$@79b?#gYK_mV+;tcYO?U-R2>txJllX9Qeivyy|xEmie} zQ>y{ZwGD&GWzw#XqB8LUmEiPlSXeWQ7#OZ{S_)Obm?>?g;UL}XDq3J5#Iw24KZpVj zGLibx#|Fz(dz2M%z3*9NCFt{N(_!P$E*lP52Od3MjQHuoCP}KImie3Zt8SmFl+6Z& z2JDEbNzh1#O6^XOxM91j{bFponN+hxQ0kxA98Fwvqp!x|RZ3Y&Qq}f{%}^?ghf&HhFK&S2^23MwuIk#f zJ#`+^u+w?!%%nu7OL&&IobBq-G5(XZ-~@YUU^`ARE};+D&+V>{jp>VJIIM>s2+SKw zfn^RqU-zMPDEkMnwiISKGSn#{yC(aW@V_Y|!0Z)A^=jO);nvA(*`Ka6w`E0bu)Ek> z#tEjKtLiPHJAyj56qQ)%6Y(9sZi%pyPROFb-5MZ|UoGXrOu(cdP(!0^Ng=dTGNz3=GOh#Jk6ka#$}f# zH@yrW7V+zA=m?Ip2o>j^vIGsLBRsHt^0j}z2ies16jr+-S@c#o|0q58aJ)u}Ol45H z5h`|)u>0yzSjJOhj+r%ukyIsuPI4`&kc%St|45G2w=rc)F(&a?1EL)_`F`fogzIfk z89V7K-=CA!H}u6883Cb;0?%J<0!D;(%UBtKokwU z{|Ee_vL9#oe3Dc9jUW?I;qobqIzNS)h8-1w+0dhhDU!J9#`c^it^UcMXTM|IUF$#Z;G^$^18l5Rx)LKgM^w@ zP7zutXN5!QeR1_Y#E(RsdlgtasCQg{>w4Je=Gsjep)8>Sc~9wCQR>wEjXu4;VM$h`Vd~GtG$OicyDP-X^;kTIPwywC(xe45<>-UmTY(A^8q!qY0zs%9O zLFl5Q{Gzm<+iC#V-oW7n3uSl4mjl?-;8g`kn^Dd*>0t=fI)1Md)HY8d5R$W!6ME8@ z0^(IOy0K?wNgu@J2z;%1NKaRtF3ttNy9`SSLqs~uuO`}hObTk!%@G+L?6cJ?dV6a$!FE^efWjLcaX95ao3jG)=F4pimwDHJTJNFv8GtHAGD+?c+p0AhP z8$qI0y7A!hCjFZw{qW$N)+0091d;5XFN2`b7xvsDnAgy*>Df{NeSe4_Yk0+W;;4Y} zNtxk>m$YXIDQh|XS68mB4D(3=)%e(k<}dJ2#f$mLKf0xI(hk^QDCc3YHObtI_Gn4 zSMH?2A#ZBo<@xZE6EWtSuX|XUdRTcGrl>HsWc0&nvg{`dkzZPJqE9_T4&fqL+7Ldm z=IeZ~%9GgS=cy@ff@PtNv^tqFb+`B;p7ymq5OP2@6Oj47n5t;cqVHAlN6V7Au`M>U zu45yyZts^UtflB_9MNIdX(_m~Ledp2RpGHwlieaC<4MitMD<_j1rfHNc(4v0V^1K;>m5S5Q=wXMs2vlaReXkXg;a`i#kZPDNC$b<|X zwd`9?_#}gy(hy(ry04_6iEBhG=*#6mdyZIE`V>=8T~U4-@q7hmjS-FU5akzeuLxO4 zV`3g-#dX`Wl(z!R5i44Z6p@RrxWoyhEZIYmJ5;K%UoKPS-K*MNfaFSUym`qAzy+javj>+AJ59GQ#E_7-a2UDwo3M#ivWChWCC{UQcN1$xraM>1NAg-%@ePY+9=IIV12yA>5?@R_HRLr3{b##mA;={w)qb>CP_y7L?? z&^P>eK)P!yd?RbcL$UMT{p_{A>W7Kxb6yNT3WXza>rH$NiUQ9AY1$o$Z=X8a34+o5 zsTX}qgPSj8mm7-wR1r%ue5V(uhqlFbihQQiS?aP>=x1d#qZqy!-pZwu+75r3DzY>N z=?k5a6R$K!&v~*U2$OuPtxG0Ny4Rw!JCVV`F83%VL!@I6 zcpYN`O||IHcrS9S*8T_bumT-qH%0h-Hyw?qj&|lXUhBH1TJ3}v?(!3TbLoT&pFT^| zef~G_ACP=QYGViBRz5()GWJT8&x!9%gjQf@v`o0dI^iPQ)EOeTWs0+_`?yhH@J%5x z-}wV6X{#qX^9FISss-3mwao3Ud@C+4BilOVW7a^;3+bkAjtop$M}dKREd6d*x?S)%jT8ya}XL_|v;8vZ|%@xN)cZA0SLkWr&6GbeNB! z_7LEN%-IPFE+tw+HJf37Uv>9K6uFuPm|Jv=c5@z{$@6iUwhHtEQ&fHey`5=~rZSr0 z&HNojUCB!=6h)zQ21%6XFbhkEBf;5GT2s8_SuVW@u@q~tZ-6;1xVJE_Wy5*I(4MQMX}nCJN3njua&Nji4+;_0-5@ki$4{a3viVV)cs zUG&lhxDusL$;z%MiFM(-3P}7g*UhQ=sWykbJfxe(l!?QT6KR;OzFo@u<`*d!kgID= zK9M^uiDU$dcWtG@&5GIqLG%kTg0?6~v|S2gz#IBZElL_y)FIj-syqZb$650vok8mo zJr(P#n;#3*-)GOr*x!`#^D-O^{GJ({)9)m|{z{MEEqXAJr&W(ffjOG_Do_1=a-X>f zS^RvGj-+96klC1HfhSZdw!uK7rX+dS*qE>V;4s796CRBWq+2t@bd<_VmK$vnhR6?Xg$~(y;RH_umRx*qrL@rQ{KiuamS|sMh z=VpmYV@H}?ys{87qj_#_E+p7BjIrR*-YQEdIjqiimxf}~rJ?>oPFXgw`-l=A_ZyL! z^|nWm(eUt8Ea&6%w=`-*ggaG+0ZQ%#G(JY0RZ?Y%s=Lz>POAon#t}#MS&UjJFFlV4 zG-xmHyWWk*G#-u99ArVxj6I?he$Nky@n@joUS)UiGTD=&H#A@^gcQ$eTGW> zY}B?bt-1zAC+X3;#bVVmN@?V(E(Ws5b{O1OXLkZRIJxH5X-{vWbnA>VrzqDG2j+3C zzBd~9O4w4 z$r1SG^gs(KRwmk3#@MvUnX|2>d(F#Eqtw}rO_4tAT{R{wJ5OUVfpEjYy@x^DaD(NX zQ51$&^4NP9D<1sG6_x65fvZSP>pWbh2qQYhrNMuC ze&G@qkrZ2kB3ma$R?#~pV>`^=SbLKBnIuB1Ra9J=xeD~2igPs$^vD{RiH2ytMU$s3 zwu%;L%U48(;i?@k^73q)!C0*72ynsthD?Cl7}mI+cPf5r=wu6UOr%I-)dKYPRmwQ- zyzc3{K%_-kIBHt^xeB1Jot$12hNtIbAYpuJ{?N|{Vl zx~#jspICHar|;cw8b9>7pfcbj!n?Z8-6FfGa0`~juv(Q*;#3ae#ru&;a!#2qZVU>J z7k!bH%gAL=Fs&sRI}t}-%h--I{6dbGJNVM;A`IIljjT?##50KeuyWk zjn?G97T4Lk%Gga#EfHCP!D3^qGN>2&8;$eluKPHJ+hN>7)_r(&X%U3sE4{xy^M4+8 zwzYL8E*6xa_^3*^7q$+@FEm^Whw50r2+PV*jpEpTxO`FYfiDv|U&!iuUgfXJ$iuvxyFI~RfDt=gdAb}*NTxDNTf1)3Kv(|j$(hm{tKaFpshuIyij_E@l8 zKuaj^`I%zL?Yv2zrnug)6Pw*KSSP-dqVakvz(pIfK%HTgItc%OHi6<{KFWc^BnFuI zU4N*$LIBAe?C_Bbe)6^X7gBCgT$-DrYI~GJ4B;-#WBe#A4KU zmIyVMrE<4Bf17m3JBT|@Mu9%W8gQu^H!WtJPo61|yla$amEyDVPB5O9oJ)hqTJgoT zi*+}3nNBU_4phMCstvmU_?~JF#)iugMw?v{9z38{M00T``7BUmS+rES?QA=A_N^8- zC=)6sR4GAW6}gxtu%yirfn9tJDun+Q>FEmKdwV8Fv2oMZe<=!t{XPpC1XYUf_IUd4 zByMQmVZmvzK3){4xOiYe_p!M{oex)J6vpJ>cDB7UTE*GqmsW9LCT5&m|6$}>jobF+ zp4(B3fh@bPpwI0DeHX|wH?J={ro6YjY}ZUr6x6d8VW&es>a9YA>if2JcX#{&z0>Xd zJKV!T`%G%C6&+~ivMnSohGZZ1l^s~cft7TkK>p~goRqDJ!tgs=+n9a^kqQi-!<3L$ z0nE1P{OErvOtMB_i=;;!7C0$Uo8Q27&gl|MJNclU*xaW^sbh0wL*ww!?$Xx2qQ6sl zRm4EnH-VMaqQ10`^Sryu;Jo@~0xFNIFT_3TtUOq*E^M~PElj+>>?^6IdAgMfsoZ;| zEjO4xHDq*CP_FHgf}F>XWU9k1^*+7{FLQHcDdG%&Z8>p0$OpmJaaYGpRA8mZpy+~} zis-M}A7f7e2eiz>lFHNl*T1zlgFnR!f07_vcIfPCjP|y^$`Zx$%*EU=Lum({-Vq%A z?g9S;|BgxO6t)vg6qPga&RI1>=EsULL-|CJ`~?xewM3WG;~!XVMpgXExI{DA2byC| zZDje@dY|XgepYCx+Z^Jgw`<|h;*ELG?<=2c(r9#NioBG}>WY;pQvPcj?se)X&v1LX44|bgN0yJLuMVQk@V>vDJ`VEHp;8(I)&RK|Cq-wdCe6>sJ0E?e| zXput+gp&H!T^Sh_&!W@kOB$)lCpBr+jH1)2o8i5JNDlAGS-I+lR3|Cr zkMngMRPFYs!VC>A9}|VOjWaoB_@a;Z@@oj4jvZC*w4Q?nsdwmTKuk9bq)Sb<-Mbcd zI{B#f|_N(k}mO3f<{z?9EsuaLc=r@h}I5AB7S zoXCRL(%o9XO6vUHz{Rxaz`M1{>rLHMQ1F=elkM5WB!x%C3=DM5%<6w2D+Xhk8M>DQ z5j0aq7&th&@wGo=;BXh+SH`!=W6s79%0xwg8>X<0q%(+f;IS$tDFqg06X+qY*gsA|8*|4n&I z52$0qn`#&>K{A)9^t3^Uy%>|@e$Py%E@Cj*%|RQK-@zD>Y%n=e%&&U*OFZ(TS8g2= zA8q~x#S!gE*k0tYPzlz8>5eMWc}FCliWzxnu-9yjgdGlnO1FARB>rC^t9iu3XM*QC z%(6nv3MI2ZOJtb~aH=}>ZJDvqhIaSF?}Lz(4mnz8K6IyIlahgIs!-2c)*0mL4uVDJ zlU&TAL+6)Sfi^LPI_5=YkB+6Lhdt!zcXck^q$TK7JH&W0)_KEJg6Dbdtu7YK3+7B} z%I(oQtMM>@M@2wbHjhh$$K2H{>0Ad)|LbE|IcB@k zUd!T8OtyD2NuGiKQ{Xqdhu*Nq28QK`n9f{5 zSFRgg;leP>@lZLbz!UNdhT<1#;8M<%`PiiH3(Elh#qJy0pU+$!uE3u-r`v%92%$%N ztuEGt5ufWp_ydQ~^nXA#R;?&VlJLs7T(qSWV7*@_mG5S)Pbj9OmI-ke4sd0>vXSGz zH7qKrYsw3N4lb6@-j|i*&PP0TTne*^oCrW4vE08chVrC{GGmNxzs+=MO}$*hVNv|x ze47Oa2;nkR?k@a78b%@o&zvk!MqVrN@w-0YZLNLiQ!J9+K7Jh-@5d=tB=(Dy5U$uw zmvSRH;cx9_3m5`T%V#2yRtYj6Q`P8s;qupyHB5e zB*FA>;bYZV+^>zE#|rqu&dQ|tFf^e}zlcle?=_VBC4=V#jCm2$!b3Qie>u3MoC}07KczCzaxAVRZjb=nu`rMj{y1>wLXjq7QMRzyig_R#OTQl@f=OE@RJRPbr zM?=31W0>Vsii^^_WgB8dNDWH9nL6Ux=XYSF zC}3?Wftg@X>~_BEUz~gBYYXS3uqfuzFR9r713us6{0CGioa`lRtIcak)AXY3y5RHr zryDoSJe(tV(^-Dae4ahMpBmmpObMB0(d{gGGnDxWj|xnx7**c+tqVx|-ty!c5PqJz zKR{LWCX&mVZTuEszi(jjNFSav!k&PY#%%t^*35IMj)2MZJ+sdDlI#=W(m* zh@^O52VeR4&lAwD$k9-NA%pD}#!O8R=|h#Ia(2A_+F|vv#S3NQ2@$9;aJIzXsjq9r zuV5KNqH}tlyBVlos>xf;uAqG6iTC`?Bq<~h*nO)a8$Lded*Xbj8&S)$)ltf7RDx0+ zFW+6Jr84i|Y4FZcQicuWCT`Fc562u7wqF+mN*G;AN_n3c&S%A>`1uP!UIJMX&-7A+iX)CFVOA1!}CRWa)uwmd%^G6hTAyRj-OKiy70ACb^e zzf8P;fm_Im>wpYr?}r2Y(X{7RSMQKYt2=t8VQde04Zhy(x0BmGB;`gKcOfVN8?jHG z-56;)SL3NG#^|oewXX{{fLc7jDJx!>`>hJP+f~ zS=p>upEBmM(~FgzNlSir$r@?>L-`@%Y48I%x8r?;_-ilqb?>I-hR37A3)L?j-9N>K z_sNp>3-@UQmip`^qP4K*iu8GM+e~8OG7u9bQ%t+PbYamN)o4@7RZI)RDBk{-Hsw4i zi1aNmNk}t3CqduV{o~gUsEhZ+)w@=%+}Z9p-%Yy|Bl02xby<31CZx5GKs2Mdx}1qF z(_k92O{lPgNc#gt-e7NuHy58^C+b+F7PY1QS z9kOi!Ld{6haG8D0^RdQ;O9OI`bwxU|a0h*Ay#NXe#Z-LB8qHCO#hMn%XW<65Xb0Qo zyPt$utX-J!4nXj|vK6@J8veJ^p6F0q?woCNJ*|K*3jlz}RS8-RvuH;6MjV~Zm`HLj z&+6FKy`+<7$!4urN2ptV?K69Yb99i8i_0Svbr}ptnQpm}KIwGT1O{`y-UNac2?@px zVNj~sXmP0yC?hhmw~k+zQ%O_ED^`w46>_q*n5)bEVJ=HfCs|NJr-f7&a^mYg0atl< z9<5SZyKX+$XN-Lld8T)Pw7y^NPP>Z!c6TD}(U1jgsjLt8!L0XL?YS`wWIfSRwq& zLFPI~*7%R{dOobEF{SN{-!=5C3NAY+L5Odh26#Z^*gfO}LmPdT0(^dJtv@-Z%o6o# zjhA@9mG`Rwrc9Mq(_-DPpI89F3tO@8yTnj*wsk|jj-HhSnc36nC7X)H!W?}$Z7>yv zHV*JY*zbDrJx9sI?;nZoRNe?4F|yB)MhWxmla(#xuHLE$3Jz9j-T8^WerLp5|7^*U z&x)E@sC`QLWH%FWXROr>PBpUm9Z?dOpW;M%$@nJG){d!>{6b1i5|1s z{*^CZO2T*71{)1PXay^-6Qh41F6+EbqP3G(ZYpW`?07jnNx#UZDDXCaV%6ohe(IKD z)ex|W8HgiKo7*3$R=?SEUeE?N2Be67a$G8IxD37KLi1%CUpCFUZP@FxdDciGZdV$v zUHqGM)ut(gqh)-Li|>Mx+EGHELvR{jn6wpvpXZguUu!)NPvu?YtJxU$(Bi#qK)qUF zXUX+y1Qezbh(7U;ic9hCOt-Ls2gP!~WOQ~bpj@zi3;l06!`X&UVvB1Gs^D2xlG?u# zIc06$K+9Nh1<1qEawwzwD->%-(ce(i`!tMyC14ff+Q>nhFy6eRW!%T8Z{_==wmuyekF1D($Y zKk#rPmY`k!$g zb}g>(E>^7_D--!UU>%*4&AGCkmu&cFKfalU_e6cYxShr%b>lSR(u!|Q%*OG5|3J}J zm~+a<=OtYj<@-n88>f;Ay!j>d5exr~Xji>8wF^r^4P_dxPZX#~EITKUMYCy7;p4B` zXGT0+hKWD$IkJ5|`1Z4^Lv#v1(PGGC%C$EdrWSLDb3h9@fSs(JY>i8joolLfx&} zup-*s6 z20EC>LjK;T*Nc@d3N>8KX#ji07>Fhrlgv1`lIYzLpq(@wgkrZU%$w;vs9qW{jxt!h z>=tBQM(lok4n3r%y%0j*1{ol%8-MHVB>al@Z*XdflT4-te(IM|_n3XEC)P%)%!Tyw z?EIQm`D@)YlyBLgqOP`d;hDY}TqCaSvTGdK3`X}q5Bf|mf> zXz-2D@H+_EKts=))39;ecY!xvzOO=mAcMaujP?VOl(&byG)&jnfayfe;1zktu!t9O zkeeesOx&@ZQ-pTne7!$3(5>y_vf+QN2}DZmrWt=<)muocdc~Q%Ysu1Cx&oHx5Pt-g zibfaScNA?yxleYALr?9d!-t&=pU#@6$Ay6gbkZSVjB(^T zL4kY@Hq@wcUYa}DME{}^sPSB9p$-R>XZs%ApIJZ|{=8dOyE}6f+n#7V3OHL-3x2@H zG*&8#f<3J`p7=v~u7(0R&$qqg${&l|C|+oze9-vtyVJ=;dvg`Hy1Z`qAk)|y>qT2B z5U%Jqf9r1{VMt}a+y{4g%m(DVqesmeni4JhbM^PPiTfV~U0cRxErfMer|sA@KeYKa zRi}#Yn)ryc5VA~4epR)tLTeX2ymx7c`vVB-w?e62=MfvVv5_U93a#gIrfNXW%!g(a zobb5mHq_6sE5s&6+&z5>H%zN2Il_lhg8P3yu+{b$=>rA5wLAai`{#nx>-svalC#bK z=^SYNMEK-cjxaVHjB~KozEne4HRpwN+y|7_7cw7;$<8#e*qI~I9H6^{kbxncyMHJS z|3Lp)@Fjcu!CE~Mh-DW3m}wonQhFN{{4OV6)=-|;ZgS)|T^82I6f@fS^O&)+}o=Gw%tO70u?eBUP7Z-F?@t>lvGSEg=$1NekQWnCX|@_TzXCQZ)VgiqMP5Fmv>2H_ z2Dn7L?B6N~_?#??B4;f#Yg94!NZ^6ln{B;xncQs{z8we?UG)|WM~gAOydQZrT_T_Nr-o%* zQUSN%PYwI$Wmu_vy_&bLt_DH#u!JSvo|)$4NB8nY{BKD)-np~01X5>){diSHl1%qZ z{q*r6SFKpueH(tI7rN4ogy z$*doly(`}B(0HM!%)SuK>;eg`8I;4MBc9daJzofcO-(cHrBkAG&SeBxIbNBJ=Zk%_ zbzA<%P76|Ar^ekV5@twqSl@6K+B3najLPSe#+*`@it^=|liG`ns{Ih|W2-oixlf^2 zWJ7(eRp?Blzf`)M#LI%-Do73C0u#gvE1Pml!;)DBQW=-lc>RyE!JV_scm1IEpip$W zPY+*~KCJ(p$_+ks19l>_nCLrQLiTo=sc&MT)TQ=Ys?~ zi+?8&R&uPQL;l!LGOIgU4R&)MDi;N~jb^*l4r`mvoNE-!(6+O1`*KA*)W`MVkmv)1 zXX`sZQUkVu`*Se8c*(ZVwLve6?7yL$gT)8S;~zrFVd)^*lG>80JhaV;EPh)Cuh;r*ofj@WU1T;2UyxN(>n_W+n0$+! zCNvLrw`w>D#*t@cF&@iYUKpWl%)$04o2#ld`?StiB+29m@f~{@2N+W+{T#Wr3 zakHIsl71ow6R0E+{0DkqmcgL)_KOrx$f;fOw|=^1OrOAX5? zRK2yH_{EL^(BN!O^cet9yzKn^r|K{GjIqjH_gp)xj(TiZ zsv7G~eIde{&yjlxNzuknw2&;I_BpFzBOsX6qd3^B+xMIhMvUBg(qgAtvV5RiAMegf zcmzVUUZQ6Au`jP_Cy~t_h}!!Z2D{*!JGS+7oFTWnyI-YuiFe^-p)4ZwDEo8$t!=;5 zpc2+O6twZqpHS>~MAL$s?GjHA56<%D*TJ(YWWAw{h0X*?Ld|V@tL*zv=3}bDVikuV@?# zMdxi9QUDxl#?b3%4a%;9;}o2G7C$e_Dm*CAZ>9U1vozs+`V#~~Q<cO>~`Ri2P`pK zZ$4{8_e||LT+xj69bwf7tvE^oomM^$(`~=DRO+W>?M~ppORUf2qiU&_??4P&PwzF-u}JM(=>uX%)|U$9pL6E*2V&@v93Y*fS;}O_TSDy7I>teU zN4ic+IXYRzSR(z#?E#A@N^lHN3Uk=!N_aG}O>ReZ?-%KJ+QetAe6oVr5I`9Oj?%}68wo7Qb1L<^g%qvbz$hQ^?d)`r(%|NDH506 zgMV>HzaOYYxTSawtHypdRHHL%_|9>j6=wt;((Aya`tOOD^1Zi|8^8B!lXPZFs~>rO z_=N%SI{raV{i*T5R|oh1bpS8~XMux&|E1%fX&EE2w8K*us=ho|x~K1{lbY3sg#Ojf zIXuYAB&3T=WC~>#itX)H-#R$55#M8%A)XIfl?F{BN{T)C8L0Rkymn3 zd!vDjK zv3P$J`-~F(4KQ7mXE{>8Oxtd<+qx+X9OGI=mHHR^^nuAOoOu!@IR>I?f^`|BY%a&0 zLk8iJP+}*{qCT!w!41gqk$!XvJmQ#b{wi+EuW^6BT<>N` zk`ISUCT@VvtQJ*~s_n!i&t3Z)viC;AU7ih|)tEj9+``M`L|J9EC81#S1t8GOwjn+& z_AFrb$J)>>+TuPCmaL8B0%exlV0RMUf6ms(@d>h4N)l?NVmQUc8iv21?_C`={Mo~R zonar^L|2flmKx6?LUIj``+t+qGgl*c8-Mlyk}{bl#sKC=xt0c|UJoZS&oNh}N8ueR zG@Fj5a0c*KYm;GWOSq${M_dsg7Scm2I{f>$g0%PP0v^MUPs1~g5B0&p_Tb{E*_)AB zYX3k$bP@C)=m`M@qv3z@#I#W2x;Mwn+3ht?T~7RihZBmI5|RX)eHqYVO)i%L%7a6f zL@V~|J}|=Fb=Wq>V&$6cj0r3bj14}mbo`rqfu@K#X0L~}#-BvZ6M3KJl@XB(YbY>pZf37iE5)YsjFExT$|=Pouu85{aVtP(Fc5GhzUHR&|kTeR11+$}0GP4u#Y zz5BhTek8h{=0{ZZ(cmc5J{*d%`VLwx>$NIB5K(kGr<@g)#mnWn1$ywQ{hTy5HT_-4 z7tq!HCxt^hvk44Vb?j^mDoEA&4&Sfh@ck2l&Oj2c<3?N4Yjlmvk`Vc-anjiw-kQJu;hssGOvbs(1;S4_%EHkjPf7w{o^@mtP?J@#qCVjEw zms1AE!>!ZHpl(R^s!>)rC-M6P+3%X$`CP!Q)zJH#k;6jpMe(1F2~rN(*irEVw{W|3 zX~IN7l7eu)ueWpbiWt>hJQoYsAp)`&5o_%h(eAw`5b;wcDk3ShQ#) zFTaKXzoy$E>nicR>7?nzoku}4N=aU7+J$vghhgY%UBbCv;B9Lu0d6?IfHY26>F*@( z#2Zg-Lw7w7+|o+EFF3+aWmxX$#NR6;lD^;-yIjNtKD~mp}1JMY!7WJ-q6dnJmoLthnn{H)7PdEciP#lH3R?_!-l0>;^NI) z(pucXXOtNG6@s_FzA0wb>k{d(hKosi@V5_QH~&s~qr|K`&(x;>3>VEmsMj2*Wn4P0 zdVc)=aueyr!_&eG2c|*qq4hrFkVLkJ}JDrW4G#9hNd4QVgN!|E{xu zJ)q!MsBwPk-Bl|Zzr?GxkYcwu>hJ#R#p>Cqd?6oNJ+^hbJMM%!3lY2Va)9|`OF|zl z(`VW|WUGQ5scv?GDd?ld=n^U*>AXb zSBvXs^rcId%QCYVUAIj$Mr`FZ*BTM+;nTboM1TD^c7mR%l}tgF)SZ>wF`w$KQVVv!i*~wQTe~h#F zq%!ncaK1sHRPxi!(}d2R7o&?*9p>E7Oz=8Pa6R-9G0-+V&gyt`98vaIpV0 z6MGH`8kBce8y0nQurVvKa&F-N-fiyx%V3ab_5%B`Vn()db)+X|?{1Vd!n!?F=#jFx zMau$E!6-~IX4Ka$O>bQ=q8w1QVsgGh)m^*rEHQpa{c98>Pd>_;OI^2z2+-;P<*@DQ zUUOVM?zkXge=)0zMP2A@k!LEhu+`000NoMb@l&?aF?Y^LIqU7m$P9mXzS)L4(x*X= z-aC+n8fR^;Sfn**ezKIu!|LS_;!PI+8ivCY!APtX5OkhnYtDM&J7Ppc=a*eqknl;n z#xa?pa1}H>c=V%aa<=O1-cUGzjobj#v30PkX2-8oTp0mB>L*0rQq=Bi{WrN#HMFri z#7trQxZ05t3qQERvFsgCPHG2kmIK?za36M#LgkKxOqC5A3e3=K11cn7w^SB_aeQ)d zmbnBlz`{ct8q&e=dZQ9V)sK;@uD4PCxPTrIW4C0<% zCRi)~CCdIXGbf8s^dx})33OJ(fJ2fk+ZgG7Pj(vkZPm1lgH$j)egy*4)w@9evbD>aTywqv#e zLfDS7{)yt_A7-Qs%rn`ppj0ldpE}lsHsf_bJ!Kc~AyGg+tIlKD$zvLOQ2*naW^;vLaLD)~ zpbfw{Fso*TgX4>1E;}n=ZwvvPY4>O{$YEQw*54PS{M%RuXd8NRG}kXnWGiugXp9>2 zg9#5fiN$3%F;$4>USN)wedazZ-agM6{p&de=zBrR{7G&Sh79$~Hyv2D+M%P@#N$$! zYY2DdEVxwu{vg}wiE*le%r*PaSKlEq<(!;#H-xxMM1=*~4u77}@_domdStvRj7SvX zsk>qXZ^MR{?=EwrW`^c?`qOTt_~cGSSTRH}v&?;Tn`>*D5fE|yOqTb0%>8~c&EnVJ z+F&@zn3Q>~!)Is1w&da;x%7``dr$!c;&hF3Gvb}CGAca?gWA|g!R_50t1lf{^Dsk&3 za%|J?*P;mY+RI=l;9dgv=9x*mK}JWFpE zE?VA*{+e$Lp>Z3jQB+TzY9)qcaTmu1;CHGYLJt`pFJD`>Hu#z@FN1g3jaIwRrSwbKP%vXE~6(0^wa~B=C=cc$t~xd&hGY&n~KJ zv50a0_@MEc_dk%~{7<+k<9@^UfOtu3k}>X(u?dvXUF9g{ly$9H4&s?A1hV)KVVkWm ziPgyiRW;KAF`4j~Ow$&2=F#P}btd1Q|Lj@!$Ze&+nY}X`?zvoSLK_<{u$crFei4;T zVFt{^k(4Cc>IR`p^q1MvyU-d52m!Sym8raxP2u^ktrl_Sr6=(`Nl$pBhs_^*w)vMr z1<&wH49w~%4M&6sUUPkAP(KPvNd!|a*nR(G#UAh=l4q=Jsfz!ch+PCX?n?!=zCH~N zwX+>RIas$ElmPFYL;Y%pRR=W@QW`HPO_wu-{-+SJ539Y_5Rs&pVGpIF$kx{?;?w7f z1qS=yg_C`(tGz>tMRa%eA)O%_im~AiCm%Dq6BLrJ_JMnF+2iXQmh4ok-Nti5XXXg8 z=~qUw%^8wW6!i(t?30yQ`R8&G)_Yfu=|*w=(Fog&N>CUZPyCWoN!ZuODJi zi7tuiW<4XuO8mQNdd*!n5c*4!dh1EJ6>Tz429o5R<#YN=FJt_vapzEbSkyjh5x2&y zh((TBu`RH`Ga?zfVMNvE(+{5*9lk|fmg)Y@<&Royr<*}BkMInunq}*{+J-bvkrFk! zEU5c=eRoY5uC4T?IIVL&zH|Rp&T`T)i^3=&Ucf+Pswen)ysp=a_$NWJ7hE+0%6^@; z*l2%7uciWmq;v?_VNl^o7`GDPP~_bdVi$`U!z$Self}b)mf=jnpwrk~DSrKViL5HZ zq3GmZpAu_9)}1?T3bXyzvT3`GM?0k?$q2;6v6X^lFhkOgqLo zkiru(^YE)&W~V1Z7{CW1zCoNBw-=CMqaGSebCHTbu2_(4Y|b9uS3GqnTaaISao}k3 zRVETMUbl{2i1|HUeI8t;>}IMoavqIT3nA|JKoq92_oZuo<7odIF#SM)7*MN-3sA2x z(Z|ohuVd~3Uvcj3GaNGag#sTj#pEDndn)b|NMqRG*lG>8dCK2$*!26=qU;eLgl5WL zO@#qveI(r8z@?2dVYisd`sG_mlLvCRn6ImAEOxwFIu~j!*_vxOIQI~KH08}UAJ(IM zoXX8cW}42%dCxqh=+F!|Xp~r3P^0>(tp)zdc0r{t}HGOIPC}N7IG+RYH2C6AAQ;ol+wI9LNW;Avh-%RUj} zX-+D|3qHP^e35H_h=U^7m8)X?$Hp=N2^aSVlpFS z;DAi->@t(ms&3lssAz z4!ghIS0Wk|affX58NpiPJ(g#(5YQE!@u-ETS4ZUmK&K$edN^*oc=B;*u*-jH-#TJi z{I%HZ5xyR&n`C9##l$M%kZDir@$-d9lIykmG@^@m=O%$8tgstD%k4FyzG?nW7)~G48Q!L_k}l#hgBG0N$>~SE$9|NmzDr3 zgy8Hfi`Q%>MhtJnLYB{!=W-?u2yxj&jbAM3_}HG0kOwKta-O?6;+fOD#bCO>9q-Ga zTYX~%9(ybV=yoLT-Ypy=MD>W4U16OOkYKZY-hV}Ors;{c?b02~cGkU`%tzv#Hp}96 z0VN~L?=vB(NR*3;H_wQk2RdbGO8!rw#}6s5E>SVDXmgo!=Fo`dKHdYL@ikzqp>&l6 zH4uZwpUn$ye*N;P=ak5c0 z3#Q!huy=B`+q;u}fcm)0-FvQ`5q7pShOL zR=e_0xC`<_!Z+@low?zeZ<&2yPA-0i;&U+8ee&+I_a0PnvDBGc=g8&{3eMB6Ri79@ zO0{NR05oyna}rNHEpn)T1sU>3Ghcnz2)=)^FaS!sn(^AxYfHsq4i^9F3$;#Irp?js zo?ng;lfqY4`P@0#WVTkNEL0WjxK7Vw!#e&AN0T(cbuVt?fb9EGS+5y|a%UH^3VP1o z`sg-a2*KkaA!FGBInWUaVyd5+8puDa|d(% zb5A91z8`ujKFzKPGHQ$or&$F`x%@Fs&@(~9UI$PsQrz+KR~D391$eTvAY5s;Z|2GG zmWwSFbNeqAxwX*-9AhViGM3HGAgwJjN6d9;Vt`T}3@!2W4(bxlW|9+8G7=uz6wI}9 zD4CX)s`bg?9mwlVT9qB&tx?Kso0WWx+fB-V@BByyB|S5JICL^?9UhD{cq{&9_7K4} zOLTx)ZOL^iGuvl*%@xkRQY@?1G`XLw6Lh{*aJY*u!|-}s+%jrVSw~Yw^N7b-_?f3G zCf5Th*0vCnt85gs#W+879EnH9-fH(dKeb5m)rxCRsuK7}0t0?QSFplg&!eTGq7Q8rle6QTz^CF9b@?6jEGYHoz&6~Go^KACr$Ux5ej#eJ z*#aM*Ek4GXi5t-zihUB|Wxq1XE)V`Pxa^GSD@dO(U2b1mxVMhwff`cXRod!3Fr)${ zIj7@i4<-S}phmwisGs#EqsVo=+&oU7duPoqPU;Dj@*o~n{|BSSO77C8E<%s?K5s0$&;(oEFicrEXUI^2Vm|UXn(TXB2{g44yzDbU z+NJw!_&TN+C95ad-)hs1x=2y4w4748zCR3Gp zTe*}MGG){2q+lP^d0-C#_1pQ(QQd@=4O}QCSzmo?71=1lVE{Mzejp=P=uc+xdt%!& zhA5hWMK@kh;>`OF0;!l$@SaG4R(*kvT!2C?DPcD=I%J^ULutv~N9ea;wN_$VXS%5L zwru~p`J#J6zk=tcSuefarfe9pt-Yw4Ck=j+281yvd^Aktars@7lIn1+O~i&5yZwU< z3Y*H_?J;rKH7!Y%y1wDEYy3JzU~+%r9}Vg3MH+l zS&|i17r47CIfIM{%;VpnLE(R@mFHzFhsB(ivI=2;D!Xu9X+lwRMCEX@0-3=vd4V_j zcmhV|n5}|OE^AJj{Y=Q_9XIEebqtgA%QceJ@!B?S&Pq&a<&EUdNe*xGww;*|`dXv# zQNw2_U|%{EeR9u{J-;TX1D9atAg4^qv!P=q&O906XcgMkAxkJEJWu(>TKA`1QO0%t ztQvITv~bg$8E@0-w{=ELW}`iXu(S{)%k^Ap83jNY(?CHNJ6eCo5j7_Ad-%FKsnXR3 zD`K=xNr%4);Ii(x%cz-(!nfnVuv|@5_qhj&f-AD@B~ZnJ9J#<|-TIwsLM|m^cA=?C-N5;U&GPD5_IA}$pO-6lXSQzJ5f(^nM zcSkjt`;($bO-n>z#lA}M6kwo~F!xFYRnKuace}0H_|%W0zH9BfUYTIZje~9dq+m;U zy1{mgc@L^u<2)fS;GVEy1H~N~RgfIc<$%tWA6gzfFN{0Hs?lYdoXf=B=a&*;Gh7eb zY6@*@$M5NRZ1s|-+~*5usa(W&Pt?Y#GsR7>o4!k6Awf3T;}dbtn#(i4BqA{Ai0OqG zhQ}*o9}6K3im}TDod465+(`)h6n39gOLyrwtX?%F=Vdx>AYfJW)>P-Sj}nC{AP%J8nEOelC#$Gy# z+~HXq{fP=8X)s{&T^Z3f#y#z~&x(siP77xa1VF1vo$@2RzT>EndqiOz6TS{2widXN;T$58ZS1S9l68EUtlB$H& zfx(|`N4gmfrGJ19z@>3r^%tbv)m4P>4ll)=JZLvY0#AI~e6L8P{yp2Ig>)d;SSq7> zH#!%Je~^_k*?274rm@BdWM@9w5}+s`Rl73{M(GtxfPhd+fgvxeRIIpqdT zo?(dVWGye313gn#Ta`JZk(7uF6?||b<4vhMQ>>idH+R>M0%8fRg9~Nr7JRbei4Pgk zisQd)2}I2?^dlJ1D|+s%?Bkbeq}9<8qLZbSNR!P~W2!%is6SNQwGV0g2fANioh=2v zooR#`@FI`2X z`;T-`v{$8Qp6jm3x(WB6yurpk5`be1XmbqFDw)1~-Qd__sgME2-O5F`<{M3d0`8U( zv^k%RqPt%oNhC-b*(XLr1c0u?y#)m;mh6p z=<6hVF6NOD0~k--iSM4re5cj=?rNETkfLqk{NY3Wje}8nVvm*a^W9DGq4z~#x09EF zaY%54;6bOhPZW*jFaw8V4rDkwO)L~Lp16~d<6_?cq@`&qdcA9OgPX|y7od{u9;#NG8g23wQvBd?B*yW z0~51k0%*Fli~%iHhAbm@EIezTTQ>gu-2#en7Dl=0)&uJ#31r0=>3BN}#`mKWk2rn^ zzQ}BNbf9VDB$YdSNvt%qI4{}RMS+A<<2R+W%=q8YK?t$S3nG7c#Ep}3Pfi{o{gH=0tL>emlp#g z-*dwM<=vSUlDYZ)3xqDqjQzu!UZqx!!z1xW!M-5A2I1q-BNmkO?`lhE)?nG1ypx5Z?UtD?l|M(p={HZh~p^gU5hB_1xJ%5(?ZMoY$2e_InQCc8Wwr=Jfv>LgEQJ&?FDZIR#ClO;>^&o`yf#G?!`-@kYHTLmE;#6na zT*18RAz{e|&sFRF8LlaGRwn?-4KoxC=lNaE z+aY8%o)284_{!k(>}L9FzFXY#Z5yD!6t^X{!sg?$e0@C)|I`lzR(&SR4S{ZwLBT;0 zJ_xv3z0mT0MYGiXFvt?uCYJxorTz>d~W)hE7nk{l}&EXlK zyE2r#mt(=0v_vR$g{LMXzxi|l4w?e^o7g+`0 zFl07q)zDii+x94moe|;{kuajJh(1-KCcgjfYN6Ad`3y=@?6c}(D*otsUQ(s&4L5#g z>Jm%(tK+C%>+=;o9s;~XBZn1@$G-A=#GFTvHS_7YxE_%58F}WxLUFj@<1Y{Uz+#-O zBXIcfe1o)o{@pDnLA3$h^AL*Y8)zbUGL#2l<=XB`(ROv-!)rTp%f167b}w?}XJN29 zNLFLJQzs%*CHwCLi@kEpI?({?u?r|9&Iu3eUQrhP&XZrqIVzp?ka1H}B%#_qBPeL3 z8K~A+A&PlBcUDr zhqxa%ytE*t?G@gpbdr*^ny^ldatE%?&)ufAmX%)QE^yC7MVr${t{qkD=3KVv! zcMY|@UsoEDkWOdNa}6CDIn&Q{RvbO_h`HNoF8B#YsWKQ^ zm!;FCYF_${wJmp)nXaJY@>!wsXn2{b$k^PVt`~qKDxFgpJz5AUY-kn=V9Xn zw<%O)3jz*U(xRoZ!j4Ou16;u>A5I0t9>MNBjpue0V(f>ox$fp^4GTS+H!%zsO+u^4 zEknhGO+C~G*ZYk_0{HW!km{hAfD_p`0gT-q$MZoTMUC;MD9$f+E~NMs3bM@6iHyo7 zl)UAkS}@_?z;Dj)s`N)%1`E-S@zlUM@Lx-%Crmz><-{=>U0)`O$Z0qdGOmaHOn3+e zQCOA-tB2wNbAwPZ4#UwvE$MXK>0ifWKm$z}2Z4d?H|HFpX5CMn4b$)Mag5&P?7(pJ zsE!XFlHC>@v$kN(Zk#8>$P8Opsd8?YJU^nz0QCXzYnUfdgCrd_&x}0!>zI~KuJYP# zHrP7RTvj606M^qDu$R6&QQh6o%crv^5@s?;XGY~NW#5Z?6xr0B0TfRV|FS+rq1tpY zPw&S5l5jFIi%x(xEb}l z8G}V*t~&Bn1#=V&9wP>^)AR@%LCb+24OtsHsWOgD_9;?0z^O_^`j&RD?X)79WsVJ) zFmQ={f?BNzKmRrC^ZN9rKIqDI)tLqaR)|Y@YIFPzo1Q9r;B=qH5Un5{+5a~gZAG#w zumN|pVl3+JE@QY=JcW1eFh$kgkq!Tzp&~|buj&zsQ^n5RUtLdwO@mkZ1Vh*3(Q*n* zf90^q|0v;IWbtg!v!LFcZxv4G;lqCCe}08+>V(?Mv2lfD8B!;Kp^EAXS3l1BM#f{j z7HX6O9^GJPw1pX1T?2sbrrT{bBd?5x=wEAKeBCN_(wg)Zd{n#wv&>?u z+_2MUMC~8QH{nD!#V-Q;qcw0S(rsMydZ@Q`>_h6cVy>q+xJx>0@s-Tw||CP_T~NNG$8# zs2CjaOmJM|2As0Oyt>b+$5j)>iJPLDN$qPu!rkiJZ0kTjoM_IomXp#3Aka}{t-Z>S~8B?PDY3RydWxcHyiiAx6Z?E90Uzedj=k2z)!up+YCF z%=AO4C*gwH9+BN6Ggdvqi^9j0NQhdE5TOcjgj5ZERSaewf-bDCk0LMd`Y4-Rpc2Fo zrygl`UUo8Rk-t50{fickuedFuN@`irWB8$Vxq-KBOT{rQc(=Ka>2nRG3Ck>HLLPoL z7m}nak0Mu}f_Jg3rb`$6bU9>Wj0V*xfWq~GfIS!7W=l|-_Aw9Ltu)1W3Ymyk9?fK} z+w!~0BJE#XYD58OxU821BQW*Q>{X-730lrxLGnY)6Zwep@}+{#^+mGw%Kai3Fd>0qlp2 zFrf30CJRf2`>4+-R2F?2Uk0e9^4DZ4$sVyOr&l1c zVLO+tOflNj6TchVSC4CHR{9`=ukYs}E64Q*z$;9mF~&A@(R7G4L+C${?bIduga3fH z3=^flq%-Tjk9gN&rORS62XrTJ^aknw`QU8yAs-PwPu}a-jeiF|Dyzlm%hQ*z^}iqW z*;r%2N1sRE(a+1F{{uC;RLdV^?3~(KVR*X^-*dc(02aDx=k%VHDTl?xr9*vn?T2f=m3U!& zhz;Yvua+i^Ob`$Yhz$sQ76<+D^sF0V27#U;Kp-ga3=nPY8SED37w8l6|36$&3r%_%xbrtyZ^$|RyLsDNrAUTXZ8eiy~h2Hq?H(~f8G6G^h2`e*VOry zA1y(Pnlgwh#jvcNs>1A!=vFz-7Ej%k4r62l)wQ=FXMFFcdRJ`hyET2Nk$xlUVt5~a zR6imn?9cJtyAB~r9l5Ivaq-676^|E^tPh&L=dZ`-+P+)7(ztMkqHiQ{ukU`W;@ZVJ z#YgWp)ZAP?$A4^hM%IjN3eK%njeoG8=;-#LsN5fxejASan4*=30+ufL z-^#ovIW^LYWefDzXfJb4MROCm1xr?~-Rg>NnOTFS+wqwll)(sE}MeNzU}eCJSSGcQ``7 z&D({4*`=FbrjzB6H{4IUpH9j>4!I@vInn9SIH%lH=)q6M+!UQxoU&=EV&iMC$Lu>W zt~&7$*_!%?*5@Oks%HK1-z|hX&D+OE;e;I?j}-bhiLCrz+Ks2OZD$nrcf2#H+fMyq zTVYohxZ3sVuf)VKys$hdo=0YMU2!_VMli-SUvRH_Z%SMB*X6Z(JII9US&mqlp7%mr zD|U3V{vjLH>0q#jJ}yHbuYdUbmzYA z}CG(}s_Co0Z#ju-U-3Yl9CMo3$9BL|uM3NkbtA~~R@ca44)t4>>tS*Q<+Ok{9 zp2;Eh*{<;1>5wkKtl;%K4_@{pV{Xr!ba3`vXM5qz<8E$R9Dqzn1%Jgp@4zqqG8a){ z_wDqKxljSEZ~*BWA!OsQDy}Ex2cuk1t~x)U$=Je zyPtIY@&%*H#9z-bc{bfmYj}65rO^HpGb_g$=@Gg<_d2npYan)@F zzI8A73;ZEP8BIp}FCe*gC4NQG^lIk{b zU$5ZW3%$$&R76sJPp(4QBiA&#ZGw_(p~K9i#VAWoQiO>gGk3ks6|dh(C10+)0duxn zFH7!?E8L+2_aufGG;%>8EAfvmk~h8}0vjYR)Pow*ESO=|Ck#xhCV-o3+c1g_JHCbQ zT&{Knigsr^!@~I?-nIwMoht|{K*yd7`O|OqdgDO`OUNZYdB@K9dWXM~^~KJrt-E1p zvN3QuB~@hDPYg;unh4I0_==9$--J-^+5XAcby3pU>Nn`SvsEM%0eSR-kaK~JMqjDq zd}@3D5qWe!Kc@ixjsG-c_+P*Peh$BRqu&C+zsN!^A&>u_H(YKzUUqfycD>_&M_f$w zo{P7R&TG&=dO;0y4d@ULD&q|&{+iGy%U17mF?b0Yu&BKd&oLG|9ClJy~O z#gcW>IY4eaRuwz%eoF~lZJGm;UgJ6ZZzJSaRR!C;{#j%g;V_1?8}KBa6fh%#IbmJTUrs4EV|w96zXHG3A~R_U}G zGSnF<=}J9{>j!vZOiB@fuB$#}&Jzh3*VV_7NsN%#j8AOgYmu-B*O=>A>kcjz%|NBJ z`oq5PKG8V#XF<5i`YNs7q-2_{AayWoU2H^2qwbO{LKR?J@5Yr(KVC9+q+l*Zm%#ju zzimgNkt}la6KfhyS-A3SYEUS<{GY=HF<(;-WE2gVh`W%ts^FlY!6N{nOcvuN(agtc zjUHDgXBVYFbIqse*bn}BSL)BQo693r;l4ee*+ylC-W_%%7VZvdyxjslSbH8($NQmQ zDt@3S-!rn~@q*tJ@8|G6cB#Axe*0Ut#F<&w#UvjU57-%Y+U2`y#LM+3nA zOGvz){DG~940WxK3w!PYI33F-2RP6nxU>NBi(Md+dx!M+1cWz6ML*Cng?ZdF9K=lQ z5AYle1!SP9%4-IWYhYXp&FR0DNSf0&s9eQ5mB~ z2;^>ysSS74=SKlNaPpJF0A?bgD|7sj zXVYynvXG!DR1%``I(h#o|81M<>Bk|rM^sBVET7jc-)flYd2uRXUWtCR>7o_Jr)wMV zypfVa!_xnU6Tf)ntFzcxtC=*@cF`xjw*}^i>iqM0hEG!#r0)$B2DLb|RNqre{gY(u z!=KysK96{7w;0`+B0Q11Lp_$ybg(C#O^t6IPb^*lU_3A~YT)GKA0}%73NmJ-%2(hm zkRK&!5kQ9QYHt8t?3(!P95~uii9ywwZcvy)QpxPeq7xoI*2LO#yY)J3<$w76&!7Ka z_}};XUtpMh?3+-wCKnmjy@p$eZPupoSSZ4i!K~Z);g;-7x>o}95+Lrw(s3U zQR{lXx)4wkt3D)f(lLb%{Iz?3$J6wncw|&7zBD3{B}MxUTi7{RxPRObdM9xs7%nZ+ zzBj2I*QdZ)LaUJX^BZ0wwfe%~xcJ|PsG1lHID4!MKBKQZ>g{ZJuf5h7>q)FW_+shI-bJEVcB!b_54$8%dCB#FSQxGN7M2@owE?K zdN{U$JAqM)0X4=3#sEtw)JHDg0&f3~y_mf<(!gUjRcY;~!vn~jIVG6o^$2JI#e;9k z%*L36;y0FjWvYm{j7Pz2#o(P?nPYhY6?khjNPMOJV!oA0Zfdq_%nbE}_6%K+uc6wl z*r$!=Rqi$hUoiA+!=^k*m~?@U1SG}n$fH#ju57aFaYRI#v#HU(?j>pY@evQEA%EEX zMDJ!;=+df;zu!hNRt0ixfyq8Yu#>u8F3Qp;A{Q$nVkll+5%0gr*g<&uY4uSX(SJ3b zmZ^xz=?Fe@5?k^m@teAtXw(E{TO%O(hLcgqTr5TbTPJ|_^kyodZnZ#1hO@N)D1p<( z*Jcma**#@(`cYiS&rA^1Y|#4h-o7DLr`VEa%uO%hvLG(~#{Ck>sT~O;WoZ)XWcL2} z7vry5P0O)iebCcGylUKZ_Zw4M-FIv=_gEw)OIZ4&lB8V}T_|8r^aJQ5m|Ut%27fz) zrp-M61yio|dpY z8Y*iiGMxu(uLNh9!9IwuzY`-`(fCxllMTn_wM*JQR18Rd#|&xHzA+Qw?WB6f{Y z)uzH^tjP~$yBO88^ClR^&rbIxI?I8X$Vq&xeaj?TjoFWjg@Y3M4Tb*n-rADXfXj4w ziHypLNs|p@Gz85h7>-fhvVKavi)XW_Wbg9eSxNs@%O+>@^^R+PoJ{rWm|MBI&F>@T zV-xU-D=y+jyi7VGKmDnNOfaz$3jt5~(x{RgBV*aArQ;*0bL)O*lZe*vWtKRtp9oA=M z;r({NF{s)!E4F!wZDmlYQHgMyDWJ9I#3jR}bSu6`;2}K1MuskZyEQ|nf_9n{W>Osb zGBHN}`ALMBP~MfE&NopEVJO|7!Z-_MFrC!YQEdEBhV1Ky4fOdVTd`dR9uf93Fbg3| zVa%GQu?bJIl3mlC=C8bchaOSZdd>^x6UTl}FF9(vX*im62y~4_Le$j|1QsLiWUew= zB~Z*1-QeDNex{Jj+EKbCb5kl!oS+cdS#VA_brLJWixH>^jslBnNUTGb2-&)x~EPr1?NhIk3`5Dx}SINigU9Bt-49E3> z%W3havXBdWsR9FiX;K0c0cAq_P|?7MXW?%uKda+CP~L=I79(g>uHQ5Qmuk+$?}QwV9S^t zV~N~+wbtHq*fNW+e`ic*xXufC6{qePQrPGPaK9N8%Fv}LUO@E~yk;_{k$5G|af4VH zJ{k)gTYQVFpkpphmAX$~0YNqE0{~6mAAXHuuyX9a;-GjF>ZmP+1AeV=(upa0Jm+X&hz?W z7@2$WGt4u2aj8z2BFR)&wfiF`Hz|bo%XCfNaz~u*@np7c4*A_|uC=#@a2xujSK&~o)(XpvpZNP|1pQIVs-{n_K}!Md z{2=haDlg^^AwH4BMglEjGs7U%5H>O9gb2@6ikDYrx$*!?j5k0R`6$%%0}Z&8CIUYI z5f|fd_*vJ6w!%|v$mK&R)D!C17~r`}0ckWa128z$h41GrlM56Cha7-wOQ~fAOaoD) zgSnw^>lpQfH!f~$W^>6Fel0Xuc#<5UGU3YgaB^_ncnT!<5v`c6cd|l&W33l3Y(=wk zVK~3;K2FWlA{hvx1))yBQUndS7G4Be0ueVk2G$cQbjt5IUurw z#5py)XgrD&01z9%MP$o2hhVKbVk?Gr+;M{lQV`d5Z{z`DB61g_Y6`4|Cj ztSayO5h0}bE`#4aIDYBP<*BirYkLr8HIi?k)fN}}V`$*1W@pGp^&x`8yc~ULP&RrI zmthqQ{~e!U>B-O3`HQ+YdRhRa(L{OI23M;0TC8{Ywtrznt^3|)D_6naI4QY_3eCb_ zl!a_SFJtPJY-x7P)|c|+~H-% z{S8wi=zHGPs4CZ%^w#YZ$elajS-0^^$(cP9U zA_>doBEhw`l!z>q=tqR|&*asX4&>eH4tse+bic=}Y(tyh-u9}!BEjD$RR@X1#;dC( zezMaj`1%UcsczbcTkMW^$XR?Rl2`DQzfh7xf(0I37GLCZOWV2fi@)|}XRqg`=f``Q zkH>ns9Eb@%72E53NYBd6H-24Xwbv6`SZXx@5bZ) z6zc{FnF^+Kn&!_hvJuAMGG=9_Tf^~38!>1&+%eXQPaj`5Xi{y{Ovr0%OC=>2o z4(%0ZKVi$LH;3DOjt8G8tcLyNOmtDDN1)8Ds-K#75>ivzW#rs^x*WeBRlS2Hxkotd zn6jJ=JZ+?rRwQffJb9Ds=PyQ7Fa7d88aVfHg~5@(gEEyS{Efxe^b_)1Zlm+f{U}qO zF$ljHcx61p&WiwLiUGY@$?efm6c5M@37@?bNPBYnQ8XwF;()aoO@-RHPb(&c^%#{` zJHKTP*yFK^!@S9L0)ZXimNdAd4$1rR-L4fPoP({lqY+R91@8exER9RuICZ zb+J4m{ldMFgJZD@O2RHzP&Oi`BKnF1c(mxlMr`1Nji#S#v5hQDq92f=cTOeyn-wEtYX4G3 zGN$q}Db#V4qi!A{wtnfqFGqcN`#34YsffRJs%a)NJt8>DMu;O>VnC&c7*f9P={cY) zWlifd7W-&WC#wJ2<^=^#E~UL}m8JD0lz4VJ|62r6hJ_~1viZ(s95J_4Oid+RoXJvB{s!F<#h7WP?GOAs+eHam)Dx=#PBk54G`oxM#K}{< z8v~nj91iCp-WDm+C3a?HsrtO60ln6D$SvXpIDp*@5^s7}_)*3jQ5F?HnfSTsis9E~ zv|cGMi<*(Rf{nbSzbHLzH5S>z2`4(=07upaZ1HiT^lPhoSSiJeUHG^ zKnUV(8tQ6H58Q!|R{{Ehb~Ed_EJnkb6sv;6KBg$)qTr$1wTo!Bybs+%O_bPjUYh+T zc;B>|MkcDnJRi?yM_Ugsz9J0lGRYCbf4s-^= z!{T3N;DByQLiqQYK%huVU(hV#E8TY3>m@EJM*HspPlpvWIIyx})((a$mE+BNZLPz` z5b&-18dvlR0H~uf+lW07O|TZbP**D>zX)&sshtXMTwE+g{Npf1FFA|EEI7&`)?`ZT z7n+g6LPn~89GoveAS`IDV1BwRqEXXv?5!W#`vZQ1)~>6T9Kdp{3qhsH<_RK2m+L7i z!`fda8oVEhjf_XR&}#^nhuX8>;jrk;p^)WHxkxV;L%{|(-g1d^dGt_C_|q&;tPQTU zTCQwlyV&~Y?xWOOkOAaKEeXmKx%1g3e z`O+$*ot&1ogo^iEO;spn{N`ivn{DI1malTbw_^HUk$9{~n90>Y?5muh5;h;#`3jN0 zaYAv|oXkvi-L0TbPLb>j!|dT#2G3Fx&sRn%Sk4VEWSGLy62mcfGU2t@$)UQIkACclrooVSvnO`RU)x{=#@W;Hxj71IfwS7pevoON z+dQ0dQ?V;pZt9lkWifVYA!yc@Bdo$Np16?1#;QbLPPw^>^Y}XnOd3Ux?e%(={jX(m z+Gg(rjEKi&(lNe_Gvy}yxG1cKy)^epddt%vvkV`CbgNr|7ivz4ly`-RE=z7_(h zVr2Ij^VZ5W+DeV)8k%d%VO$U6lT$#=`}=!B3V$j2fV?Almtid=R&h=|<>iM-KBM0s z00ST6)+xV;oHEs3o0;&3R|=kGoU)|xLG-O)<`e}JnKm}ETyDg&1Q6Pdytjll(eIQ@0uFD2E*0-?stGHZK)4 zyu=ud2ZYqTZORymo%)q;m&goq6}7n6DIoBr9buUq>H50i$G$IS z5|b#L^?_>inuazB;(&y*spCoXorkVhfof0&K);V)fzxM5hb9ZAvCY9Cz+>(83HYI; zCmosq_~S_+B#a19s9K@fB_<#}WECyUL$euIp-6oy|3&fU36wF!gRVch;UH6>S!Rl!@kt z;PsWpphE0Zlip?5i$8ReS3g9=HfwMFC<|lH;~(HpPY@Qc?-SOZclB1R|GD^}RQU&t z1rx2mrma1<-nG>s&t<^rID!#NJ21AtaB>#ZY+IzNW#+5jGRGf{s{CqRpc)b1YQnSS8!nu`(2p`b zemF?hp8gA9Aq)rZucGR+PgB@94;SSw%(srJEK+n^VHWnFp$im9t^*+>BT59Ibe%{X zEB6f1v346llgj`wKq9BWf2&vlXyDR6u?+!0<;kk>SMC^lJ5VfJSq!+dl`g;M1zT#IIMf-HHN(}bj_WCn3FMt(_3b~e z`fJ4a>=Bm}Jeo7U$UVQbuTW*a-=)WiOI;iikMBJer6^mRZ7v_CmTOZA`CivFES7V6 zPbZ;xLStF_+rxK}URx`9`=KUmohV)q{GLUM6UQ zO_qyq?WTK&6UdUw9pa9S-(M8@E;}lG18J(XmX@~XuKC-$2bVdu<8@UpvvMUOMIxdu zI3Y-yh0#dG*+6HUfLqf6Ry<;G2GZySBENj87?eVX#Ki+3p+t&uS9LA`2>}DcXX%8w zPJVpoKu`%C@j-zaSPJAVQV+&TL&i}MHUqL`Is+n0R}tv|#Z4Eq{50ApLcg9_Nf0_W zMZp$M@8PovFgOSH>3l`vg&iCm00McAbGuwrl z5CO(;;M4Pk9Pb#i?$>Ko zR&7I1S4v}|oa3y5D4X5m_?c$%PIPbB2PW5jUZ8#ShSp2X-}Ogxmjq0o{*?TTRIb0ehbn;vdN?nSt=c3xrC0=8H$c;w3IhUDt@ zA)}tss?Nq(fTc`M2$&d&+mk82ypdpz?79^(sK!l+RqF*E$3f}pIPAji$jq~*+N4aL z#Y_mBQ?DZW0@f`mM(EqMGUB^b5pz7O@ejHS8U2`K zorWgFzD6_YVz>f-CyNsmK_J;2(r7|SxE&5uvPLBSB+>78{z$TRe3>QqtJ>z|X#pkby@9y2BvIHKXqFpt?|y z$=d5ApRMOEeXQD>jcA@ap5^swdOg(4iO{dT)muVlo>Z5%Ug2EeGVF&PW8umTTc4?- zUyOHonfft}`=~6{h0~-v9a2z-wapK!#m#Tl!SCj+R;rwpoVrR&>Zx5g<#RZFi8%qY zXl>Ab9htF_*_wIyz=McGz%=!TK3$R!Yv5K3)r8WVf>#kK7#M7F4g*Pk2?{4o1p+U) zLi?q3)B;?w#DO|>?obvILjgRAWJYCI$Ub>&g*v2^3AZ|qJ_M+RXtXVH%;8fW`7a)0 z1;sWP)s8bZP)mLx=b}J_D!7w&SM6CJkXj% zaJn}P{^~>+7W>;0))~%AcUU0S+wck&vp9dr%;6mc9m!r_-G<;VT#zNHf5Emq&ast0 zeAJ_w$6?v|MuU~2w2sKQXAbPA^_c2>fXFfEftpc}YBLdKysC)*5gf?Hi4EW(jXz%H zKh_zTOY<^4r>OwPgYlskcy0qUu=B{ot%NkK`k;-;fyavJwD;p&Qtegs`o=_1`1?iT zY^je2Mei#%+G$z^tzg$KB0o%jqVa01G!db(ZWer%DHBDA)>G~t&&&w%EOx;x_SH`; zQ-$8re=!`!(EY;O()7{FR{)_M68|huOw@y|j6xvF0z;?AsID$}J zDLW?yC4ta)O%JPril1(2g9)e?7%2eB`IJbf2jN7I zmE~go|%C)W!nx_nG7Jp|eX66jQZc49zL5+&}7P3eV&nT=@hyaOqf~+;;-1Isq zsTMHsly2mfTiIAbKEBas`diFIt2N~n=2<9&WZ87E}I?Vp-*-|cjb9@L2|Bah<;_>`E6k1X#PGyWyqo{dVII2vfX|4kC^6{`RzR1I?SG=&uM7GR8p#PU@5sPqp?Vn&i`Sy zGe5N8rI(*=FK0KPXhN|mJNIa_D({m<;e(^o#i?B554~?(1}dZaq(cm`vARp!%bs6+ zleKDU|IC#8;dd;$%5_t{_2;)A7x(@e6UH*HlvR1yt1W&SE1Od-al`6Vx8{jW@I7Swy&8UyR~@C+X+A!c87(P$7PnX` zql`At8y;4=*yWmIN3qnmZxRyI$jEE_TT)`2!>S>>^4%oM(a^KqKc%}=l9llI`E)h;pA;`!fdG0|L@<#=G0@FyG3Npq;-cXZZXGdd@z^E6 zY{ySG9Amm!NT9=UXfSsaStWDDb+6=sXfU%-g_bI}KaKS*e1E}Z^hPA@#qL#AwKu9h)S$#% z1}&4M_yqmfPBo9!ll1cv9+8*%H_P4NX+y7HOIz*sD6`o1bTgH=0~IdA(%d{6H9*Wj zo&&erpKwWMfPD+&yGECnA#%*C`J zZ?m$8`3Y1n?i&7RQh5X7Qfa5HHDFQy5NDKumVhhL*UfgI3e0>GY&>q2hyfIhd6~4+s2^E>4h=U^j#3YkU}d6_3}V@7&7tRg>*&ak!&Ox; zqrPnH^)fMqIb%6AqUEz|z<0Xof%<`=(MP+<#+yjK3!Y9}h10Yh#WR}jB|bV0{aY(% zPbw#&zf6ui>aVn(gym~%g6wpo#;gh>bAOq0p6skguFlBgUw$7_<@)pon$c{|FI#$! zS!9bCf5LRQF>5lj5aBxXqjO-UuHk$8m{pn5xOGvS4fFX2ov@IF!{3$`GD7*c*Bt^j zHf2OxxW||Y@p3k_JN~~!W(65yy{gSGtyDt?lZ^I*IDhV>p_GHDZ*)8}V2Ncu)7)I> z-3)~F=m!}TK#$_WQ^u6D4?etmF-vJ6h1qW3c%@M!TBGRUtJw2{hW~o(g(Qqiy~(Aj z2ldOmJ&Tjn70UiUe@&$I-fi#?U>?jcVW6cnV+ml@wkpLb93-!6df!!nykC69vuJj| z@nnE_N2E>0v*qi2HikW-U zmxCqtoAwlbtA7M3)?>LrE^4B%0zjdD<;i?k+~dq=?5^Tf%G zWzSp9WgV;ch^r3~LAw4mmQ%0AahJKV$EIi0`%MF5$YTyFjD^*{_54nedn0{?12?;X z?pf`!O?p);~ewpTOSM$P~)wn3hTPBR@r}!8#?Z%4Z>Fgr*ozV28~aZuLX8pRcV^& z;MC=HQH?Z#%g~`bV|{vrG<)4)=Xyad4Z{Kt%^KOCSxq2%q6c#POPq&Q8DGk1a1fDM zpPMgTjeBe(|9ao9VMqfa!A_r$5|_#R)IvgcR04((NQ6wf4h@>SZE!X28W$rhe~iO| z>Ly%%%uniG6oQl5e^tB3qaM7D&V|0$eb6+vcA7>x_6K#Ns`(*oAcYvFD*^L1kF5Wr z8%11*aqOlm(~RRa;qjE?cU7gTMWpnheCn&_!Pi#MhsI*y?=!qu$2h+kO?B8MGpzc7 zjmkSge2#15P5X9c78|V_YzFY9CRH+WbCqSJ{pEqrdwT9BbZ#2Ek*O0 zq%t1+6}``IX_fG=;K0{+C;Fi;yQs(HWN1NYwE3ySfMR+)S5lq_l zja^`>>M$ZQ!32&)gc@RC&^5GC$WL3Q9(Qq zswTPL?BB(TUP}C?u$X+Se!byaFzQ2@1}X@?b^qo~37Pa)68Vo1U&1W=@EuQv$ZlaT zQFqmj=I-D|^e+}pmB)Qf9f(Jt)Cyi+1C%m{2$+c=s1yWYdjfcWEy1 zQwMm@AIF9|>%kaa+dX$ktu`o2b$zjE6Y8k_H}CM#OVuEdCq!2LlPQE@$jP+ha}?*0 za@*@zjhfr>T3R}?%B^G@S|V8``R^Ej;>lFO=|(!U++k2}l6!0PNq5|Kas0$h4Y`ME*1Ym;`bFv>_l3d({1frGdr_1()r@TElbO?&CiWz zTGdGey1%Uwhb3Gm(4i1!h1}q25j%ubW=}<87|anFV&xzerESb zBG4fJ{zzi;eGpe_wbR;q&(*BA$tEQxM=`Qp?#F)EGwY8M#ShB`4%@d}9$Nk|L9*96 z+3#ERx^6yjF7_@(Ply1(Gf505e zpdFx&F3z|7&Z}L2gR)r+VH(GQ5ItS9PmpJoHf`0#gM zAw^DoKgj=PGHy*|!IUgVjjWy$DoekdaKCCDb1C3l&vJcNo}*EDl{pSumK4Gr8)fUo zgDYPGYVA)#zYaZZz$1zz^S#nawD7+4Z5Ww^&(ue+P?@B|lB%_9EK+s`<6ox#SXJIZ z5Et=DDaUCs0pnwB2`#XXpB-``KYrZo+4B8_;%ZiZ)Rb=}@a|n>EW3%uV$Z@Gs=i#u zzk%iRy%p9C2IKfnI>san6;jIfN%j?7FYBLM7f1}CfxLNYcPSD0(JjE-zG(HsJ_pW z>(@J;smFLzhC9bZk?Qg-5TMyF#5x7VUHxFwz?BB3`m+zqcPyfB-z1DgY=vIeQ5L6UlRj|IPtQ963kf2`eF`7L6iff2dx3 zTPS9?v3A;Isk0Nz-8pmht!vZ@pBMw4m$82pY1$Xt*V)cGjlInAG-5&%9pmw>otygQ zz+ui>Iy>)W%<*d{bFKQ0yaGNh*-Y#26NtpnZEH`_B|m#BCk;;j>K2h)*HcM*i<)0O z1I;<#)uxFh&M55nL#k!Y%+BN&yAS0yUAhb?tRW1v28&uCf;K< zlezb^CzmhYzNfDrwbLGW#n{e%e*1UjH_eVOLn0P7!H_F%S3r3(Wfon%Cli7^xa<4F$W6>| zNkWmHOvn)(EpHBhsVA?rX-gXD5_2E{K%Cc;PNs2Fb92}Y2wMiZnSUxU*uT{y0D|<- zA+1SwlG15aUQnB31H=hn~I0}t~!Dz&54Q6~= zOfx{&vA4V_Uy=HnArJKhqrVd))c=4%Q(gQ-;aI)yjMO?n`WGQC&V#%kpgNvcRmSGF zt63c$GR=f`)jVPSLL=5NqN*XszBctzClhU~U|epc9*UuKhw~Y4G12#|SMXbY)3%1? zG~y0?y_YL~53(ataNCbnDG`wQo4ib#Yybrg_4AUDS{PJ;TBa5zAWxG*yEl^sprzN5fyM+;n^_p zoNm7S&flk0{Z`q*`n}oy`2-nIbQ3g8xKQm6u2?qjVo$tgMCi>)MegGZ&-YRX)f1}c zZ+~Y+vM8b&Tpl?s7R1Z4uB{4j*|F2|71jQDJsVf8HP-&SElfrE2IrfaEdJDud>It- zrg?i*Q}%U~;p`;N=hJ2HdddRz$G9^LD9tMDwcv{oxz#%tual-w>i= z{A=ErZUko&4)!ps2Xu)-Lc)2yaV=6J*P}lap)`V9->)Pj=NT8qFb*sU3)0jZF z=i8v=5-0gr;>*sc*#$ab#>zZPOa|VDLt9q(&}ByQ{)B~MdVKYit9YBKQ5UskUdc*? zqZSqtQVjhRC}kxUb&XWuRwwRt6x~16L&(;&@6jEQRnI*4rLHG7Vmh^5>rpu*Dx2ZFdoaHfuy9ssc z>J8QU@`BU;)nq*|n(Wo^12oi}IER^*t|CNDCqwUjw^!r2RDIWo(sTVfAw;K;T^_&o zn}?nKX6Hl=su4k-0C&v7t4pw)igEL(3B8@%4f>k-Gm(jU{p_n#lzstc2ES4M#qIbD zF@7vAD&>bJoSXG=uYB7c#`IYo%M5{@)}v&A#T)rt)|D%|qJ;5vjnMp51* zr!)XY;-i*$3P6Ql{EwVMM(Dyj{Fm`4wt3ft(g`oSC zEE_sZdZv95MR9FfV=XgcvW>l47i%;%)bzw>!=o#O;=p)^MpDd*y2%p>+>t{DsXv`> z-I=C`C}MQ+Zt+P0R$*2gbM&BCRTDGnu7l<7{?l_-ZXqCL5Jz?n?D#QeTKj zXN({^0Q@rK<)778iJh_4fQJL%Mpg;L$A&!DEhFKqNA1PDE}P=zD}2)#;CgaDy;kSe`{ zpcD&D4AszkM|u&Yi%1gz>Ag3VCL&ElL=+T!0AFfG05U}K z&l~X{(SiX837*JhnaNn$au7{7iYK#9eUG7=xR+vypHKx1iLd{zy0I7p*bBirL}myA z0R(`(m@mr99>*5b^XU2C^%WRrXA(V%0!?s{3K~MQ(Lk|DKi)aW+tZ`e+xnth8Jjx} zwBbOK@B^m3a2*R=3J-d6i%#Y-pFNJLpCLJ%(z7=5HfosjQj7w`&^`iYFMdRc2pcxa z38WO*^IVxrr$ohO7irnct3h#Nq2lRjuF)mKMyM3O8Qs?ukj$5vsl27Z7;n(lU1Ci9 zq)%B>AXBp(^Kp>!24-q6No!-%>|LKWr6J8r!HNK9Ul_x2C}(GD2TVkn0p8TZV{Wsj zPfi}p2}MIe*L-H;<_V*vh|0A`0_gSq%G!h05BZj)$*o17`j?%TuYJod95I8Q`3E{L z(r!MG{c(`|g2QNnr_*S@1X(`{z8FyGudN^VM?4VMbtrjPtJ)`?QX(=R!hlHC;@K+a z>r)k~EKT>-e&?2{FJ{q~Ve+Ogppr1zY_q8MwfYHNuy&@fe?xX2x8mWG!Jy=huk^8= zDDHbRbGA;#UpTekYSZCOjday6rKfqnG2LzuC0{YdV;s^^o?^J9)CsAss^4kC70|rU zbtW&iSWY)85OiWOrePJIITCC}sBv4+OUkO+UFE*G;0QMS^OE04>A(MytjwwDDhZlVfwJfD(l9fV!5HxvH+!u*jwif$pQ5?QYb?t z5;v_;yE|mF&;zsY>^I-!AA*f+j2rS;nm7oKLoIHDx{eHnTqyWp*Hx$8qC2U%qo#*N zZ9FM;-LISRGQDx^?IDq-#lyxzbZwX<;_c6K$>_S!Wzh(aB0dp3Y;Z7CCNhEz~&NglRe^%i~lksf!EC$C%S(pwCg*yf2>R?lkhqdwoZ4(D{XUce!Z z`(~2M9-qmx4CP5|$jLjsv!Q&WXUc5yRO&Y&=^`+wvGqlp_L4QMl~s8U*3B1yA5lGr zIeW;E6Mz9q6*hxrD3y;wxtN406Z)wrGknq13x-ecp^6+#_h{ARB1LdI!iJr9esLYM zzK|A`6&NJ&3saNcz;TgErNW_2$Ie~A2d*!BMn2{O9-m^zOy|>gUd@0mSAE;91sbHp z?FFq&3#+Dw-#0@Yv-;D_SLl7_kr~Xkm1N3if~PQ(UE{#$E8eH_ zWm~UW&wERUZxFr=zj&|mg)J?d7pi-{k~~5=pH*L*JE|s1ff{rUkSn16RnA`-M^7C$ zItXq-4{C_f5AWfOGDT_Ol{vSVtGTW2X6-raUd)dY-1fyci4D+}!Kk#RQ&`xmd>Ni4 zVZtkkc9U7}kzJGa<7TEuTXIF2?=pEsyew`tJdz#lBw8yn&#F$_jZrLinC&7AT#H?) zQs6a@AN>QzTh@1Jao#GA0&Y~2z^A{nP36i?9lOp!dG0o3yVY4*9loG4=bHt%mMbz}=<%gheS;hwrYz-+8Ed zV&8RD(%M<%H4G?>~D^pt;olXXCxETE15y${Dc$vuhKxq)8R zC*C|BWwF|Z6^@!zkR%%|^!4`S$bvFztgAK}fh9MolO{l)J_!9ChGWmY{FKnrSN@1c z*F<^X*sAwq?$fF{O$S0Fx zu>X0+k!|X_UTPSQBz#0}3Bcd^DCo=f1#@8FJ+fgbAFuM>_ zXlQ5pTXuY))!>Ir_CbT!1DO>N77$A9W%5_yY&)7O2|=LFhs1)tjs`6wDC`a|_`q8x ze8&IXbsl>yG!b(Q;FseA08~eVJwTyXLk0k!4$;W~%pkmqq5-%s{<;DH^La`m0MdQp zj-&;N>;@__i^KuYNgqH>n{tV9#u_TbyTX9j#jqgRp%Xuq#cn)S&;Sd-&jILc08AGk z#RHYy00s*ZCSWT8kOvVsp%MQtyh;iXL#>TokyoI^uci(+<=nqbZ4s0<0@kDFkrviA z)FlI`{VFabpdd;#wq+;|Yh{)?6vvXyhZoTNRAWRUU9Yl&%x_LkpRop*4W$tc4)Ni9 z&x{qTzEkyB&r@Qp8p`3E5im_Am7`(|D+`D(1&Oj8wRA2vW_4nl0U_0Ho-=FHLzFke z)L?cu%lixSq>HM2s)f{U39C^4uuSdOBxU6qGUb~4I`gV%LIlmLJx70CNQa8k0=^!$ zJb2#V>=uj3I@z6{eCGAC+Ks<>GKKdO&ndZ=I!|~^YMImYWY$uDDN~?!eGk*owP`6^!?3xWPNtUq0TROZT(cJylDoE2b*R?awZ3W*2 zi<9Ro-1+AS%!Df1E1@r3ae!qi>mS<>%L;|z5IOwSqXgtT|Kv{^=Xd%`;(j-@A@dr zB_F+6&?K0n2 z9xjnt6jkgarlUz|jyS9tsdnltGGE+*4T>$?_5I>h#&O;t3mXrf8d}?aj!-ohDWYrswKZ%@VZ10KQEY5lLJCn}M| z&pcO@Xl(`2Zw@nH96vv)wdrJBEMN&zYmtuPKYprr>H1A?hG|YaefM&Cyleb3e%S8rR?nq3x|(FePuNsb zdm*FZ*NUpO4XHN%?1NR7C9Zfit{8pm{`sn=3!E0hvtLG7H&A=nt8{;%xGS-F@a=&r zTR52+pk8_PP~i5K>WKEbETBu{ag2W;&}TUk#xC4A6i<2O@s=aqIJOm5pg2$~g&ZTjBaCQ%64?t2#1sMDM4T`@mN+5) zUn-eBU{7Q@JP_^JLmX(6h8whC4y3}$nud*Pcy)lntwro5Qb2%Ss)|!O{rj_LM)!Tc z)O@H3OGdPbpt7~pUxXvk=rFW;8cmf@%WI^NE~zjnh;_k+3aP4WgC6!bs}&`o&>}Ej z+((5Wf_QtVk{Mw_Rc}G8oU3Z~$<{Xd8C0uLfGHw%K4nQ|?tMY4;j=HGDN6_EA)Q_~ zY2Bqb)bmL2d_a()ve&g7Vta%gGbB0OO@sE+VO)8td-x+O5e=R>@mCt@IFBl{`n5Ai zO#T|`nn{qt$o;Lq>n`RN>P(cDbU}aD1L;U+OeIwY*MG`CekV&MYx}`WXtZ4EyA2`d zCzuDKA+Xs&@QnEj2-@P&}e&u(P3pL$=+A&HoC+r zyv=BY=*fQI?e(Tqx|#LPuefBFVV5? zS|0w~&RYuCn?F;UzW6SQnOHI1cgs%@xsYdz#+(Iz*iBh;Hc!p0Pg5C;M8(=nb$%4q zcGS1kW52;&8_?Y)N)FF4nuF-9+ZuFcgMkPpYJ?@F+{RNUS?qfzzQZ5X8@s>B+YXMt z3p(+QfN!1%SeP6$i3O-%i`3k~7qgk$ky&KR$nq&DZyTl{zi2*eVU=MuksGdPNp`o- z(YD7vXUdf6wNd`oz0Sr~)JKkUXJjqraeW$K{Z3N1X(OhO9vKas_cX;+Nxwp;#6KYg6Pt7IFW`PgpIa6+|6_1oU)%!_a5@%%I8hd|F{qJwT7mLQNfwor$`%^T&Nz@vN7KkpsDC2R- zZD?$;%Uy~gD3taUvPE}#pHL4Fh(#!f>_HxmIz#D0qzHsBpT#CZ88{ZK^sBJG5IgAWzSMQJMGz|AK+`y zfB7gmYWG%u&|Sq;mMBaIZw_lD+h15e>(sh#T&f*|VD*o9y6;XsB%-`Dp5FSSe13JZ zolCVp~wP`f!tzTF$5R=_2@M7vK2{Sp_9ooOyf@8^6oj*6TGJB5QCAUfrl zUXUGk_h&VZHT~;GmDb+(yoMKuK1JLW!y8rZ(mqi1n={FgnH?zsX_UD#?QOc&`nv&mmID2E-an97U`_cTaFft3UBKV;Q2T6`Fig z!sCy1*CAV3%M|n3Q4DR4Dt;gAp<_+Y$bkX<--a=-mg9>P5u|u*q2(PaDl@NJgGBKDJf2%#4&-T^d7EQVIyLcoynjUK)6pfhz5WYSD&bt z0?gr-d$&oN+B&9m+?f0APS4rde zq~G+2q2J`@IA7M+7Q0+QZe6$>AIRr8zL*3oS%UPN z(Z&u=%JVF1Hd0*bT;tn8kg*rNc}waPgd)iwy~Je@aeE#eUBt0kenv}f53{f?mDtyf zswG>Or>~HMMd3l8G`hX`sLV#QC|48OEa6mDTurO9XcWpLyPap33y&{<5hM&^eqBQ) zTu*t-9XhSusfOF>tbbANDc9=;M}fgix6I=#2@ld&B+E6m8PI5A;h zOk#5RRIRvPXCSd_t;TlzD3*vIwl#Eg<4Wyxo~H3#zAqNn;bM6#YBs6caW&JW_Nmf( z&!vp4N-~NEhKIlZc_SG8iF427&4?)P+UrJ2)q$%lpo>k%Y5E(tQVxR-P?)lgS;n`Y z>owN?26-H$#`LRbtgSTzr-5W9w38a|f{tI8$H&EqG)ir*-x!Q}Rk!%KCd5d_kc5^9kjBtctcdjY=b0xj$V@dQ zTxg5SSW#=uiQ(YcB~xX+$Ym8?VNMn>r!t>?pmTn<+q7mBXkGCMwZ_Vi#QP;l-M@gI z-(3?8kyhP0F$~D;jP9>xfZTUhCDP0E9xei;3WA(nM>3IH>r-!0sVuPU6FHPp?Z7pX zhj{Uy%;M<=P5!O%MQ8%x2>XANpAINRFf3n^HG;H`En`(wIb>ycs3l?PrPctiVNI^^q2$^joKmeXlSNOZ5w zfDD2%VbCYmMLoYw&9FCm0{X*;vMT{~i5}|p@o5cdFpP@%ea~A}Baau9Kh_yHxu!^7 z)UcvSY(Rbcr!N&uZtHwe#i3d{k&?<&)) zL6Ef7+70OHf8wZ{xGNEfm=p}qQxlb}|KiJJ#K1EE@R%H_Lm47<$f*)}m3;(i_d<3l zDKVWz=@d_C*vpLRiK$ek+JdX7;Cqhc)rG>iXO#?)FwU2?9-EoEC0Y(?%fFw|OnHzVVM5 zoR$Q;|D67n3t&ux(=l7^13!wMJ)yThPK$v3U=W!@cDz3&QKL^pUnXAL$`2p02_E}e z<$ht12`&2hwnaEkwEnk7&d7_gRnw~k`QPG9gYxx*bkl@2{5# z6l>iQ)6bOPz9IG6rO%_1Cm`&Y4}d^&c_#o}bmh*A}`RwCUFF12O$ zCX~T^d`(tAqJ52d(dB8uv91CCWW`vsGaZ-hbY{;ZLyM1smiC_#rB_>oLn@3OmREC= zbBG=UPj+f!9H^4tVLn(XbjbhwJ7F_je>$+TftYl$z}~mTSy<+P#0Gyox{2-gh@X%I zq9rH4ks=^38di3m3W@|??!0q$nG4Gwxp*s`>vQp>5r^Yk4J7P}@pE{yMl3xSC$H5Q z+6`3Sy4Xl?`x~mXvJsW`Aq`X>~jpK}OEzRDYEvE;T>V2c>O6cU`Jt>2` zl?(C%tj?I`oX}Y|3VK5Erou&EUmKH&LPW@RbVt^P)_YOqKfjd9_wQFV?U;s|C^?m- zQE}!sTm0sX#SDF|*^2%!iP1%mnMmW*n!U-rA{^|3M^yNazpG4> zm6_d)#Frc%Z|!2d>)msD$1srz!qJ!|MQN$G5;PwK1X_apOR{X7l>;Bb+l1%Nd>v-1 zf2sB7=kQH$a!;m*+Y@4s7bKgN^!1szVSeSsbMI+>l<3q+SoB>J?#r9vOvU)aBFrz? z;QkY&QTW58cJA_#KHrCr>={LtwFi{Ybhy-~3A&P9h|=ip^iIPx68v65_99(2DN zKU9wH&ReJCT3%GYmxvHY&5$4{P!J{VpYIr25(f<_6-)?JIEC9F?tMdmvYTjvfmIN2 zUC_QdOlUs&7mytZ;(>tEc>s($2?py7@JJ%aK-oMHD70T|B;gYjsZCA50szg6uRdYx z-}s{P(6Q7vyyp){Q4}4H6N@ynE?qS#u~HwyyD6^w%H$lE5OBwp6h$Mks{IJfx|Ebl ze0HHpo#l_F1G^Pe&QI-{>L&`_q6E)T)#HR|_V}HY@7`H7uh04X#l9-=)R-IoQDZap za(&iA(tACeBs?4hF^S~!ckZPtWKh0Y_Ey0cTiMHE^&aU#DUBdVex}HQIWVfZfQi^X{wD=G`r)!_}H~=ekazAc2&rYa!LFP_U zjAcKpL_MG+G`ai9t(!2LZ{+e+4S|TLl$>G}_*$*|xx6P0lMX;)j<-qa1p54Fs0E>J z5*nw^(?ifCADnL2%ppqCV__||o=mQH#pr)X{p#@?0qdya$mslvr=RKg1)}FX!ypV{ znc)Jen#|U1GU0!mX$n&vZIr?e1sBX4QS|OsWXr5GTZ?XzHF_WXcx;JU1KRC(<;SPb z)uv%(?cAM7#4Z{!W=Yb4b{$FZcXel|@m#fQ%}*-91^X|Sl=h3I2D%c$>s*Ef$RpP! zUXp0@IX-MPo~IWQV>6t%>pj5PA@~r{GH)*tdZ)$|eekP|KeF3QxnI%ps$-6e1tAdi z!u`nTfglTHlKVKMdDbSgzrJATXVQe_T>jm(E;+f`eeqIC;Za|#QC@EL*Rd?kW?O3= z+tBO%vzk^cNm=cYgRv@oh&9^S8&Q)Xsw|s@&rQU1pF`CcB)JY>@2^p}VnZtW+SI>N z)%Rb&m?YVnr)_u^>pW)0a1eZ()ng-+)5O+>aejCg7Zl#16D6zMJ23?Dk|47xnR;?d zi#%*yx(j06LmGXxqqm?N5uT)*2`_Bq0cghv=ab-pXLhw56HrGGn9~dg`o)CR+y<#m9s>ShXJWR;<@1uYaA!BrlaXTB0_R$N2c!Y&9@|vyw{N(|8NFgv086x z{$p(Lp?m4re%f|`Kf1`f+s!)OzR|JZI_EXEpxBq!m5(|L77R_wuvQutO5bb_NMr`F{jKU;p}?3X>?)-DbGu zbo>5|t=0u9Mz*(re7cq^>BlVY0Q-m(K{X4Q-Q4|bS!}y=INcsa_8CROhxJ?iY)T-= z#U?m$p$1HN+47N8N7)I2>?*$oo>`oNKB!LVX-g>sZH>?N?LJ*DUZV~{Jrc6{^oD7QEElG3dpe2;Tm~wVJo;u6& zti6EMk4c4IQxPVPiORnmruN17+4VH|Pl>GinAq2_6Pw>M;F^FY~L4~~# z^d-2H-$du4gi~)D(pg#s8aeU7)B>R{?a|8?Ne+DuRfOfEUpkp7(lNXzqmA=Rkdbzk zdo=bDXZ%H80r|j4vHowcC8R)66eibjG5advmMp{UZBG}(_w2?nYF{2IGDBbb3p#dW zpN~oplcvm?|5MTV7zXrQNo*76{XjnfhYv4U?0DH|c^K3<4%?fPF#QZXocx6s?p1WpVVU)m|De#Pic_ll zJRG#-wZa{xpLz=rr4l$q#odehT!Gr5%c*zM+;j5tl>}v;DpfQd5u8>S_>XXX;E>A` zjk1A4iHW2KMI$ylVoZal_6V2aUSv4rB7uhEs_OU1_#x!(N=wg~SlXQsLWIhYNC4FW z&QF5X;Gt>^O4BZZ^o~?E`w=2mL_jBGrbHhqhjz@4$YWr+|7vWh^wzO{#FaTkakLjv zx22Pyd41A9TUCK-9Z|A^v}NpzwU6D;x`8IhTTChS)>Yh@7g7 zW(B-iJLM^i$ao?9*HVl$Gt5kUA$sh|mRA>;al$HPDcSfRo%R^~55XYqLZ+v)75Q?{ z5{s~Jr~`|ZV3*?3->yxSWZpKNQm8Uf99ll+d312R*aRkfHgAi$(3YSw7%JPjhf}yw zcMz9hZ#4PpxpwbpY5&QP{BvYI#RtUk>63mv@t|_#dDAI&i!*rKCd}O6JUe%0@iWUU z3B1 zr$0ms&aCxfe=Oy=)#TpCJ9|{!EuAyQsa?nNgUmXcC>E!t0;x;$7TxG6W_xCsbP2gK z8N`D3xmwwD@yTH3z~&OMG_T7?dhBb8!ArUha?vj&KCjYJ@+jBt{oN!8)h-W|_||rgrq2Ext)WPrh|^ zMYf*C|KK0kD_xORD__jsR6m>EVFaG}=A~UHssl7stIYgl_D&ZhZ~6y!TBk z>og=FS48;M%v@)fK~f686$d;(%e%CP3C^q$N^vK%tHB{7f2r_b1olA7)**Xpvjk@; zESPtT;}y*Miu0pqt`+PP#i=P*bGbhm|B_yXfk|bnfSV6OOIdQP_lu~_hgqoMA>D_8 zjT(Jy_Tc`l76@MY$d&a@+4(vT%2cX5pH`E4AGQAO);Y6@>6CnvY^cOi?hQUK$V%;a z4pskrgMAn6eNu7AgKePRWXZbeQxTLB52!RYkW$^olXQ6*rapYD6Tt;HWB0iNs|&?r zEt|p6IX(P2mR4t~jmox38O-V61wzbCu!JHiL7H-c5Wv6?cqfJ@eUIlNZkGQDbPfYK zG=QV+AzT2gfjDs!Pjqo*P{+p;N99F2@8>4b1x zGC;#XJr!WBZc0&@-M5z|GG7G%0+YXK)T-j$Ib#OQ1Wl1eR0u*`@axAPF$HvIkKZV` zf5gc}KP3qNxfp;#D1>nOWdU@{-@Q^Beim>dAbi>ZBh+PE1rKf=)9jS+$it~CF0!p8 zLYqNk;3nDq!;yTSC}mXRdJKY9?FLbNTf^KD7aY+&KsdqmW;KZ)@~NlN<^H|TmYrwH zRKHSqSXJrBUxfPFM}LkP@a2K|wuo7!73O_oI;?={HhR6{Ml~-diTSA+b<(V!4;|@_ zv&-cisUV>i{Y;t!oCIP>=Zn=VqwAlGB^@0%gBTfEUL5SE+jUTV8RqzMpvT>@pdzP` z6K`=T|M2dSV=~rBuT>?#85z;tjYo`-Zmd%xj9$Q2mav;KUX|LjgggIfhnq%&%JJPDnh5Rl<1uw(fO(wz74dCp?sA%7AAo|`{ zW7LR7bh!8wH!F!I@Bl_D1wUeC9e_H3lCcyg;wpu!nurQBtVB=cP0#B#(x9mhXp*u# z3k2mOlf;3Fx!-dB_@1^>lAS1(JPoH&g<9RJNCvN_?F@7SgeQh!xi!;nj%NMrd-?GS z+uPhfmIT`uE_+f*WRAUv@ObLtgJk#8yA^!zZ}r5L;_UG-0OErX0u%X4pW0m<7>P>B zE@fchRhsi96s2l0vlw5hFgD`_0Om^WJ$`*=kp~P}GmR^xoa085?9zUi`@6-iYXK!m*;W@x4}SM$pfAveUn1wf zC`BDxtwawAh8|n&8{~{^?-p#hyX%iCYK)|$2OsksF4`Pu%bL#hz*zMeJ#GScQh@@xy9jDPUEqGmR%+BRRd+CY&Y9E&I@tW-|ZB9d< z3gK3TQ=gTG*wp6AEv~V#q9NVPPCWvs)0?x{7m~Tya&=FVI+Bz3CV@%J%8KLn4lgK8 z_99=GJP9}MW(PW#yncg)IXCU=9C(v$sL~&-7heQ>{%y?J!q3#Tqf~?YwJlEii+Kxp zb&E*^7KkX2aISnmWH-oIot_wx_GI@anIpMK-1gWKSV8!-_jPi&3Za5V1{JUkpgI9e z?O;5mfFZ1b4|paX;pNwDWD6q^29SnE;c0uvu;x{eh=;g}nFUa*XlSgXC!@(pm>)>En5x44vn3Rk7i7nqmXSVtBc z-`XkhL;GMYEl>jER73;aGNfS%n-5zmfYp@0VjS`0=YtM@b?T*pfWMM_#`V4XAb&In zp@SkeA=H}j&T{WM58<}E#*>^6F9+B$(F`a>FF2X#J9^R$`9hhV3~+Byn`2kX-Ug^I z@}jWmcJWtf--*XZo3_v^-*K^db3fzSh#TitM@l$VU2zy>fO(1?O3hA;2P@wV*9n-8 zYt0yHPnys%_-ygM=W;e#l4L18y$e%#<<0BCtC9=mf^FmT$MVM6K z(yo{n!`mjAPycrCA7;J#lykd;cjF_${UHgg>WswrGjthE8`(mZDjsuhn^Ukdt-)Nm zn`!G<_(p>&sX8Ezy}Es`(k1_M7KV>CC4FcUXL85q5b+UC6CH%v2Y+%%iR7Yn)e+## z8w>G2OQX;F_H@GVrWP*>kf%34AihM)e8D=cGo6U1vr@`v= z{(G`Ds9epb@Ir`HX#b?)yPZNtF&FXU=}0N>>t6=h-VU?|$b=3?21y?pR8d*7Bxopf z1s9f(2K^yE;~lBp0LguDqm%-t??FSJ_`xS-N6O1@F_H<7?rb`||& z&Hp6B|K|R`0|>G>MVw8Q9spoMpMrW=t4iO zlMLNr9{d&=?=urE_nWC5^i*n5dkt$8^EZ;$VoxV`Fh?mxWUEibV1aBYp9KqED}pWC znL~9=A6DMu&Vl=Ib)=ecnv2L_7-L`FPUe?1aks17-u)Z(ddgBs5_Ci%Wo&%t7dudG zVfEa>+akplC{QlYqh#xha?v6Au^|T(rQRsIyDuHU_jNJiQSqws_KlBp$J2&R-r4(x z3Y%6T2U7~8&J{gl@l`(>oZAv>0kTETH;ZOdOZl=-&Bdp+LX6bN$2Be2vN6U|7 z9=#Cq%rFvF*+oM*A|%DBLA1Q-*P&bBbGQKt1nu?#z*Uqn<))?<#I>UY5CFJx9R$Ve zKw1CEeLQi|6^P*nCP10l$kZd*^jk%4Odmc3O{wmh8X>w{{oH}k^Ci2?xMNK~&h7EN zgD(`PfWSVzqAVL-r(?g-4Ca*Gh9D z&T5N6lIe^^TESGI*`)g1bL>mfT2}C$6?Ne%H`}F&c0O1U@xF)FW zMf;UG92Sj_<*BYj7_rox4izxDJ@?! zM7at(5qmj(^_A|UL?{Fyxtx6^N-VN#{6)$q zov~6k${r7)?ya3u?Mdbp8-(wcZ*Uzn_s(g+*qKI`5xWMx7qx;AM~JD&O7fSKK@z^Gdk;LPFej;)k)G@ z!j~ozEyn*TT&!M4`L1L;zN>lR5Z9?TIrugq_i^F8YgC~v=J0TvWj>Q*f@LlEwD9VT zM@PXQSX3VQOWA_-=ML=r@{^%LKDE68!EKgT1eTCS2>ezb{->jxHcQOtYJbi5nk=&s z;V(3GY)qk}B`_|5(K7-|%C|J>{$8)RlayiJn-=J|!p|3y=W;kRDQ4te z-jAf$CT-#Jlxy;IZ7^TsS!I4o>5fc8vQa{eu*792lI*vwl>f{+E$}~&-2V?n%d14# z6IrB94qpmD=ot${Zx%lm@0=aG0TH|m1$Lq~>T-rirxMKQx?b;T*2QDcTEfQF(qI8Q zU0Bq1udxw}+rXbZgDI_J2!&BGD$E#5Vy=w3M@d9@0V9hEkG@&ZD*vvuVu+ucMq;rc z*f6>{TtuEbiPSOW&2ae#3y4j58w{;$;AGp!iCKQU996O0lCZ%;l~_$2>t4*0@jQp# zgS_`o2)}2VGssTMnkJ~nt<~1q?mt{9Fj0C8fipS412V>ppU~TCEi)uP{w{mlg6n7R z9Uo9GQ^<5P*OpxJ1Fh&AB%?5%LOQ+lMzRu#zt4CdTDYsclTJvRwdX8%`HW>er;Kl=QC8c#i`ddJ3Lw!pyGPZf zw1f`JS?0bU-Jda8q|P|F(f6b5C`e-FuW6mYmzi^^9+O{d;)ZeR@kwM&x$f@1k98hI z=}aavy&cGj(K?Camz&mogjx8AQ^;(+^}B;^tV32@^D(=fHs&&L05uymS~U5yzB9j> zT+}@-jazQ zx4S_IqKGEz1emU`Bk+JA7E5v{*G=9H*hvntbOWFx0At{Tup=f3bi>NVb;#}59`cOE z@*OHX*VOxjVvwsyxTUh#taN=VDaAt5&JBfQa-z0$%i{|8WWV2*2cJew*E2xT3wB!x z!^W}e0lsRig>=;_R$jF$Khl3Iphr^WUY+}!F06+1Un!J!(ahtPCR=u_uk{y8i;3hA z^@sCF&FmJGe%@@n)+yIFsT%<2zc~y;es^-<{Tk@8@Fy-h+IX$uP2nFsexDh`>h{fb z=2ru6Bz?%`5h&K=jqHgncqX8Uq4{O~1`x>sa_e450kuHSntKAShaA2zf& zqneSzO`jy12SV0(-@e>fwTo!LO1Ysq9dh)p*o#_-+CP#BKQT|fNkXebr7AZ&YN{zz?E;ge zKp2L#xmtjOChFP7!!7$Vz?2*y(_2D1FkwOW0DuTO0suk|-lvuille9w#Uj=sR}M*^ zF#^1#coJQEf)Kzx(g=^&0>lFgKEH2)qQd`0LH2Ih&5x3PhTewRp zwZo-nSUj$;)1dy8smQYUNb0uOpvn?MQ6n$!36Jwk3;&|0)vEcL)Zy0Qz3`Rx`LFXj z73XvEM?=?^;*hn%ClWew89coV=^r`nNC+Yp{2|#KZ)~&ZFC*PlquU*YntF^5Y9A<;MunqZ4UW~3VQ-=rymH9YX2eU&-~T()NuFXT;^+AibIQqO?ZHjk#tHe5!qD-r zq2G1^5W`m7V6R7n(&sosD#YVtPL;SVwJW8C9*`BY(3vMyXPI z7vF}Y{bcL$<7B-3RXeBMAd>3K68GhYYniEhA}!J?S@3UcpJU#cSxO8%;yQlBM*XK; zJ!{nX#e)|s;j6sjtUB5r9p!{iM%9!JyqBB%#=I8osnMOoFTce-RefP_{yK)ELQ5oA zm66Ra_eF2qiEn?xy_YeZV`Y}=em)A;wilYZgWpxYcP+T22iwIv>+*&#F6iPg9gW2g zP5IqU_J1zbr}IEO$WA!e!f}X{^3q!zXHt3u-0sh-DbCql`e)9Q9BKu#GTXm4N781p z*~jFDRH4d5&r1TxTeAac#gZzT$K*x`{praKp3_sP;ls^qNOsgSrAFuxNBDxVJ&5cjsL( z%epZM6o9+3z9tr=0sspqQD+o`!HS`R{h98-RaC;wPcoYBpu1uGYvw&c`KhhBeae z+GLl)eCvS(=$4hp72c{5l>1Zp?E<}D9KzAQti1{J^o(>VZvx7_g#!rwTyh^1?`>w` zkS+-#JbFCISuPy-b`gm{3%fi#x8wb6#+VK0`-N#XZl=36NVyA>qF!- zL(-Is=b&WxDQ8E`MSCF?oISaaOX2KMOSi~Djr~J*A`pnni+2k0Ft@)#v@%*M4DvDT zWwDxH8MxWlJfz8X)c`0<4mr7?UIBG?ZLP|&gF5({@>Y1wM2nxgZ6$bFWUqiU_Su2I2gf{3(VG?Hx%Lws&QVcCdzSkM14N-){XX*)N|b z*C<7%C%Dh8Kwyd?SMs)LX7{EcXFQBj#gH8gPnLtx{8J`8@Q|WrfTd54*eNQ!Cj&TQ zO8*j}f?xay#MC2r;-SMZjJ-!1T-PWXQWrj*5F5lm6d)IW-hpuLgO0Mf~#xCl{H+UJMrJ1QxsJSZXDzw|E&Q!J{w z2O(>lzO&g}ExaQgGb+GTs;>GTP*^p{HsaVVLG$wJg`3oT?p#m~B0>{8=oL0e2Oh^yuMR!M_qWa$mxu z*u^lj+g*QNKd)0;eA$)Cb_14uBWf!(CJ=0LlUisHkJ)$9siO1=cP__h^xgrEjIfdR!DapqZ)elKL~ zv@3i$MZ}3=-B3|u#e>Xj;7#1G;E6+nwX&pjHo?c9G4t^2n|q&326UNJ4CO4Au#zJR zP6S_AspzL{QhlPmA4M1*g?|-wt>@xKboHh9;BlAMDI)q`pKiK#KNg5#mm6}G_I%Uw zzJns}{LV=8C|6E4#YZ^70V;u0^*H&-5Av}QtPa-K~FFCsAPaL8E7D~rJ)va2L)|d z0vv_2I}T*j0FAbzT*FOa;w{D_;vJ_jnx36d^yKcs0yJf6oI{N*fxEovrB%6bv;>^m z9_$kqX0$_kn~1e9d|B{hl?+;fVthPw9Tu&y`+6$)7mf`#@;34hnZLGg0Eu%V4Y)=M}G; z-RrF_O|`+msM{6@)EhypEiw|d$u*wo8x%PWsLaEjHuW|B0-x)Nw-Fm-E zyD7ReVTq;MBBX*AYvd%Ed5=j8&!`)=UBsBesLa5mjJoB+TJX^eropK!$9wS;uf>#z z31X^3^_phP+!RnP?mg=repj|#lqz6cr5s`=dcO);M4?tMt_n?0*Z#ripp7djGc-NE zy#Q5Vj4{>}WE5r6Bb`0XHOrX(Bh39xTbbC9CljrI5r0evwEY#TExa4rEVzH`X)Am) z223CZk#IP~*MzY%ud_FNA-d61;_LlPk?J&44V8K)K8N{2t~iU#G2Nt7XB~N64SiZV zp|}8Pt{bBGIF9;Hel5;~TOLR=ldGX_eJ>f5SNrdaDGG00N`7WvN|L>ndMA7LHFw_3 z@-mCqs*})-s!g|*gw?%Uf|D8*uf5(pf7q`Q>zrWt9;fuj?OkZ&(y?8Yy3Il-V7Xi`JyaUVcaL8g+PdpnGFI%WhAM<>6{ z)jwaaJF))zf?9{}^zZQB(G*n1WzvV&nM~ILpIAzczDr|qi&)$@ADk+>BfZFTkg~mV z{5+1H*5z|>pUkui!vo4=JAT{tX_?FZ3bo3d0o9y(#yb{6j}*zD2l<^Y&%NTnyoE-` zW3rJrf+tVP?Kj-~HYqqKB*pLHg9;-TraB49fsksXfj@-9CXkpZa<>QQBi47*$E61% z zGVQ87&ASD7<>RkPw{z#NV1C5-n>5^V98A3H>m?Oxh>Q2gcPlkeuvpwtJT%Mue7%xI z?|Kau%YGu`@!jKQ>SR;pt&Z(8DNCh`Wwczop-$j@%$nHFU9ySnSgNg&44|H&dmY?; zCmEOt(M9XcfLMy2OvGzZR+C^WoWWxlm95@%S<(i1jv{Fqs6EkZM^wQ6vj~U-(R=rQ zJp})Uv-b{*qUqiSdmX6Z10YDR#Y7VDe=|EN5yY@K z|H}Uuc2UH2w_7M97pdM16dTp-Bz7C7Le1-rwQH(<K&9nWtFdyvG{PAHm$hyo_b5uoDbAhHS=f{8^DvFG9;&UrPUgNhSu9^zK46rX$l}^JNW*m;?QSI|NNOqBcJ`qEI5_abONvMtYPuTe z2SUBfC&~F0hAM$+YbohFIhRFLALap6JNHT>oXaC5VvT=o&smLxAWbAPDX0xa$o1%G z1zP=G?tE!pWWL4CD8!afA6zHNV3SA5rMhtmLvz238E}zg^L;g6G2La%P;)=S`|KT7 zDly`54Mu=H2CT$ha7bz6-?x>uNnpa#v4`O)mB9^2ji1XIyWnKeHpw*T_jmh4LVkeI zP8?z_i)4UlJg2Yr5HQeMMzdof_VeOtRe_dxwkSka0_cci_@}&(O$qGlLQ5F9`v$~H zVW3Ze295!n`V0u@--dO()3K1iR2UwA8EinjeFlnv3;`zDgJSY`R+)gSV9<0Ujst#9 zjBtb_Ih8CpqW-y&G?s4di7?5!$cTmC7$Q$5$ct53H!2!*iak*gI1+>dey*e0_0!rK zkPV<65b#ETFoqZ`@%g|I6As7(kQ8D-4Uw%H3P4bxYZ*ZGOBMh`dg%C+yGn=B6q*7_ zrO+xT=cF_ucg|MplhYMP;dZIO<1uFy+D`mE8R|7R7p%y?P-CMKTU{tbl}7v155Nc?wHl&>w|C1oTEsLGP!?>D@h(O3OH8!-4B_2d{FXUT}#Y` zttRCcs#%(6z^C*3)9}hfMji?#!ySXc$HY-%P1rO)$@+&uiX1*lKg7k~ z>AKB+s!$Ct5{f94x*U9tmg?0HDVDU7nz>|{)=d_Jm`Jo$MEdrB3ssbV-nYWToSQRr zgGV&N=YlL3pS-;8@x3X!p-bkRV_t7;;XTKj_a@SxJNCB@)pMV6rYb=rdCg+)YK+op zs)%;p8`G$yZ);ZESfTVqCP#b@f-T*C%{za8%J3Io z_mre`mQ(KKreB+%&lXr)PTWIES$9_}BHV8a(vPbR(X{EhNMtOxk$nE<_mLUI<#FeQ zOoCfXsBH10pr_0mAreRuva2aQ$;9Oi$K#Ey#{Am}4ZqTek&;rh^*B>?`Mg5je*ZE2 zw!N*~Y3X*#xbkpzdlLG!Gb`+s(yMzm&R5KPuLL(Gak04_acCd?F6U2htJ)F&%;;EG zQta6O$9d$3bbII4tc_>sf#>gGOY+u`U&9`XZ0cxAFCtq<8gGPwU5|~bYp&qM&5M#J zMx6@HZS)+{iq&Fc?Lx{@J3eJ}5jlgCm-p|s*m-~Q&Db(nTzr2vls30R*cH(y6G*)_ zna0C@TQ389(zKn@UeghB>i*<5Me~E8Fr=~n!k9G6Yg{+;dx}5El{Ze?QgzH(b5bVc z9B41&)<2y5QM_?r9RLP1q^feC!}E?UnseY0_ylC)%)A_xLU@*++HiO0r$F$n`w1=TIwGL@wu+{@)B z>iTT$Vxr$om+dTfW878(r*aKvuA}IazRK>i6y*1B2>UGssj=>n32|m>%t-HtrZ2Xm zQ`yR>ZELz==0;)FmuDIGOEp3&H_!GC2e*kSB?*vL|7I6U@0PxOkc- z$U90N=;`TcClJV_0EpIT9W}UOO;UW3$3m8z>WpCIftXO6k3AB$%u3+jOa;isJ)sn& zggt*dAPgn|OyG5JAev*s&84NKK10g6Z-P*ePD+q^`yy~n`l`acNZgSGC86tyaPZ7Kybj%mbY(!I#N4`70?giyQvFcv=KDd3GnL+=D>)D7^J5{0QrL5c|sdA z#x&L6HTB_C;dGI*;sFbjyE)+EFNXj}0{MP+* z%#C=<#3}Plbw~Ls26E4MhEl)6rABlE1*#TN-_l1N&GpRI@giw zsX|+awvly5F<+|}(L1(Adhv=hyjzu(=UwbMI z-xsB2&&!k11+PxCJcC^o^z-DlGX|6R%2!}~6qZ>MvkPq@ArGX@?{iHx22e-2Bxg5R zIpd?-2UG6l?N2;AOwbVFQv6E4b4O*OTqZrcPnD4E6qFje1u^)T4b$K^VbIZ_;p>Xy z&O{}d^8z2sKO)3biSgK%iB!;FF(`t7!B4=jQkeXv}SLnEZ9(S(k`Rs{x~0bpu& z+$w5gu$>qbMtlTINlHi}1xU-{6of{dh5s1GyT+<9at_3%^@_VVWAu!j`e>#xq>>my z3M-rpMHp?zkt2aFaK@St@J`_+2}o27L9ItFD1T4HRp{7Tn^u!Xh1c z9HzK~l73Whd?_U z5Q(?Av6CFW-@Z_mmo3er3R|E7ZF_q5QcHGvL1g_syBz0d?-0A7gTNK&UCK854;1#P$#ntpeL!LwK+x>L5}?>7 z95e={RKQ|`BNH9RoqyU^O^8**`jAm(3hzvhmTJTHp_M|RyFj64o#+jPQ~GJ;CM^xD zm=A2c04-{!VsC(VF!AfxM8%aBfLz?dL^9 zm<&nx-^BP;vgzblfsDDbv5a(@-g5FE zCf?l;M%!CXrbv1`@CocIdTBx4Wy!cmYN{)Dficr>K46mNEV_5pDYTbSwEBdT7#1Y3 ziDmJCTXE)FYS?hVti2LbCt^)rC_-nd&+Wd z={L4lk^(<}4c+Ry^ZsJrJ%|7EewVtDXM|B^*3#n{-9R4gUC4_t+u-8bEIAcD+h5bz z*axdGij-EOyZFwORTlWr1_q81Q?7dJXR|X&tI5;VbapPbSLR)Ni@ztOrX(=TT>W@Y zLO*1#$yK{!=iUdEi>pmJodT=vZy(U;&E!N4KVDHLv1>VCs#^88WZv;@x_k zfG;Hr_a%GhL<#-65~cg5Z7~l5`O34Ggzk8MN^h;`%?La_+9_x7>R2l{zjq@*s8Utk z@XI->sAywbeo;>|2cKWPqPRGx7f;>)=?A0zL;YUg!pRxNKDpkI;w_pnXDo|ETl%|DL>0>G~NO+d-O5PVEJ)^s;uC04=iB28(#@_qn!arQ0LKQsR))j8W$wM-2UVIx7hZ>ItRKz4zar9AP?YQMv zKMg^7L;P4V;DVn>&WRzyJ3yFz$yUO&;xx4Xf+x6~cIVTOUS8%}S)_F+rk$J^{~af> zp@;)u(J^eq3jl38fXaf5oD(O<{mf5$O0f9W&+n}{9NSJLU2C=}7)4&X_oiEGqj)Ke)& zjJ310qe!{gjshi5+CK_US|IO1oe3mi0MOBPSJH>`1>skr~IW_3)tF>8}Ah`^m2%U&hvd3=RC+w+p-U zx)I~rJf9ehD*id{V=ya7koJitS9yQd2P9sAa#X!O%Bt9^%{0Kw>YZleE^-P=_1;u( z>F{wH1b)q(DxUts7EX76VJMNYo_lJMF7ZnYIuSk82QKhrib7mx|9U33rStmBp!IAE zqN!ZNqB==BRmd|dSwvIyWMy2yuE)h)It9P6Y!S;$jd~#P`G=B{Uha>M;k!DLYq6d= zB{m4EDN~D}(E;WstRD;RagN%msPS}7Z+X1-K*W37xd$6I#jOfGExK#uTTWTm?4RS; z;@yS$RQ38@QLP!AXh<&q1T!-t*r{rrL!&O zQ-mxseOP}1yCTyf%;1bXI|~kngRg_^6?%!b7*@;30IcDU_LUR?Lj7hrT|m8%JZ++^ z$ZBJ{#V#vIr4(Z8Iy({*Jte&KvH0DI$yH+-WdVwfo41yylFx!`Oi@ZHD|T?WiQIu#ow9RH_~y$Jms#4pH;k$MUsoH! z6kK&JLZ+{wTDbW6XBsR}uO#H1kO8ilM6O!#tMjg0a4f+%)$B!;uoskgX4#At1eZC*Cb@swQ(rIm&aNntyoOV+tD&rp1>eYt4bzjLWryqk$?mV7%(Let$JWAfJTv%>I0gI0JS1O--iRgz!Ck*AXzx@i6>B} z`6k-vT7mJ4@Iy{+HWg@X)iZ7+%V3n{jQO@yTek)Q*=UR-jVLS8GULXR8!RuefMHQo zY${lO%cQtJIFb`SH&hw9_SFqomO-}iChYgSd_%)9dwQZhc+luw;fRM}G*eUpe~L!D zu#wPW1?HQV)O&pzCfdiLmAcahFG?+1KUow$=cF)wtWxjb7nme;JNXVT)rlA)^fR`M zD?{bRttwDwanB7et&uK^t_lg>p3f9I<32y~J%q_M;y^SB#V40E8>&@5C@ON}yQF1m z^OU6tZ+t)9LQ9uZL@3T>S8hcRby3OJ;ZwzB#b)y2qMq5UD9d2I~EBs`k4_SIAa*E$e=s)l*lH)86?> z*lF5XE0q^#Nt^n&qK0SZU#JInuih-1xiS3%t(h+KoxwLJBUq8`r=N9}!)Sk^xQOfn z&s8<4FH6iaxeku^Qso7{tn0p=+uxL)cPskdw%RTPRR!-(#eD|HgsHsvRX?QVIlQ}S z$xd4^mE}G6S^0CR zx?W1%*T^!vTl6@M*KhDWwD?O)@7)+?m)CdsAEwJn_nka>yW^uWr}(HPryyB<)y|)p z+Ek`Yye!Y1)q_Jyq%SSR$bM_~LyDr44+s0V%3BQlndszVhGfXt_sYyGB!500IzO-H zQ-3L3YHK$xPL?Fy@1ld>_H>?*xu(AU;o)HWkaz2?vUArFo%$ccmr#xB8c}INjpq+3 zjRP7sdi~m4tutROCUse}gnvE3f6jSGl#OLW;?2H~GtD<8alt z5_NxWR`{WjzFM$$=t7DJc(3Q$xGe(3lk`}9UY=D9L>D~Z8NzO)cf&mjR0h=+48t1B zaueL3>R{FTl&RPFJD2GXj0>po;ClhlY8V}!9OCqGK1re!4m!~n4U&SAQQ;v%q_;Fx zK+7AXOpM_X+O=Pk#$JU44L*;MR;_qCGv50#!!zlORRs zsCl;5-{#2SEpG$ygRVQ=(=)4mJG!}1G1x{jpr%196cKW3GGE{mbFD^-{VSV$20XE> zl}{nOUKOS{<8l-Cw-_$HOr)#&?N7n@`}3NlskChD<d~3!9h+(PW?Ga zR?;+69|ic+-;SUv}iHqGt*rGwv$m&0CGBVa9*HUL&&MaOHa{oIBp~YN`$Y(PR4|o2Rcb{&a_x z)FMB<(rqkx3HMZdI|1KI)2ijlr{b8R<{(#;XOpBXGFhfk7P|?2dbPU_yz5`w7ABvy zXJ8m*@VCjkIhs%|wZb4TDJ>h09?awrH8&Pp9MJk^OV**a>?vm=l*(yP&1d6fCp0Y= zadoCwO0E=qXwBhj#rn)|gvd_$st&?p?wr*Zt)8s09M^wYe9Dk%np|I&K}UtxGVeZ> zB3W1f`dLOPTe*P^_054C&nq=PuNL1t=}!~CihuEp?KpB;mC*#VV7BSBQ_RYTY8}aQ z*51!ru8lnR;SjdZ*W8^V`Mo-AWWE!^htFkF%8N<1dazfnY*q0gK-s9)cF>=h5F7PX9 zm*yY@h~c{11V=Bsb{6c_ri$^jx3YS3Hf|f|<7D<6aNGqL+GFPR{(%cK68 zGHohKAHJWZto9fj4qhb)&dv3ODwr~n4l?WpGXXK-pp-mC73F4N%Tx7X5NIen4^Wep zQ4(7Z7WbG1d_YK2%LyqniqxIFC!HCqB{X;f=^_~SQ#TjjvXB7l^n8bLKcIxM3{1mF z_(6@CUti0ES))#jaj-Aa0OV9o*+-e|;WfYj+jt?Dq0-uDph#jGn-eX-b45EFn7mZh zc9kXaUikssLMl*Oh(Yu97{Kz=6u5Cnkj6j|u-5?ME)Rj#Tv^-p5dDzwEDOA|(`g^V z{;ofPqMtmPGQj#}X&wYaa`AQm63CH8%d6sur_(NBb#Jqh4yP{%u8U$RQ&rUg^i^pf z7yypM0J#ldp#aC2i9tf_K&6kL1Iru_0qG=wA?pqxO*^mw6%HLC|J0NHd{meBlhyH+hyhkuN4rqr2Tq3T&NYTTXu!-h1$&XYNn#z z&O+|+uZ)%si;uY(tWKf34o%;8KgIsmn+T#9rzfe&;;-MKnrCt%RO@IVH88ey$jkZx zD4s;S%c7;;2B95`xJ zu6Ovj_>PlDPvgJRKY`~O@!YRcx|ucepgE_fC-LHml;69$FUP&1O`;Exb;TZ|jQF#G z;ZoK8Vnd5S&IQ-_N}YCvh*AIP(`TaHRoO6BT@7m;frZiPZvnm%u+wyxE?SE}vdN6^ zZn-%ND#0v1GO5^!uU}M$r~D8Sj@}-N8`Ep|@`^W~z2Y}}=rR`PkUF4bmXz*YcMHAi z&%2n|)g-k2(2lz#Nn+P;b*HfEIT3!H+^Zli4>Sp`QXd|a7OvOvs(nRyY)83MRAUZy zxYi#3rRMihY?Aav_>A*eO*toX{#(u*o$!*JM?tyccB(!KgX$a)oB5wqr}?ETi}#Ev z)Sqxn-Px-;^o)@IlQOo$C$DzOT%Fn@)o1DXABTG)5bFRFszRNE% zUp?FkV-4%MMn~h;8WOhK!$|)sC;a`zH_g{13`R%C@RmaJ{-g|ucDx0ncEi8VuVX!pueQty=l#cD| z$K?9U%OMe>i8eP!Tn9wJuM*y6nh6D716s_a*7<)q(3&q)+;(vvw&u0qqK()sSBp)~ z$;xK^?q!!UslAnaGNjt#%h|~x;@B=-{DT#IC&VxR>S_B(LQKlQY_m^<-^s$W`L789 zU+Hmk#-k5{?tDKJP#x#74(y`#Y@b2YcwJ>Mc%Qy8En-6u#)2kw0I>d?Zmf zm!I_(i9h7k_ZtKg+S_A&?Aml3^0D#*RuAxES>9CK%cwTDjR7h1#!4N{$b64r^9+!C z|iedPX!Ek^X%XEwd7*~QR0b0}?K?i{1Q;1RB#Q;ElxoxJ( zSOv2-lrR*zecfd)wxQTta?*{>Cn6P7gDZ8qI}8jYBujzr-67CL{0l1x;Es)dhwuN) z{t!_H0MdKN2}Gq5pnj7+N@sVgt?Nw9v_bm89qPO%s%vXy z0Y2XsgUd@!C2F4AkL0SfI*_}h4lbq}ET8fxp=pUR20huW@7^#eT)Z;!Mr$%UA^6Cs zOi*@L33**!>E8KZ;=L-1DaxAO-^!t&g${g3;9hUD(xK{mtwAtxI56a(MU%~(Mny$r zEu-``7+Wy&*fq29XPdZYY51JWCKUZ85@He=+p=P-UBE!c_tteU3jfICD`l0ud1Msj zmgdEl=}NMGgl72ex@NaYu(eRnT$YA!KJ)Lio0JvDOzB-i{R!{iXlP%t(yF%3qfA$| zq!1txsi~9Lkk0ag{p^x-lQxq?I)gw~8@Zbjfen=K-u#2x;6|b8-`!#tUJO@tdG23k z6ju#DNjtM6+2xoe>xd1_gRB~|nm#s;$!0LNfBpC_(#Ry5F~c`H5?FO&(8vhNpc;?8 z3!Q@q=h+A~n!gUpYO;6VO~?4Ou(v z&IVn89U2t+#aUf{hohF@gyh5>QLp>5%++SHkt3RL)MHb{75& zU0=J-Xo_d>x%7%;8lXA00ACx#UAB)$kjsXN!GA{sU^fOQl5JH390~{ha44Du3?t_U1~08xCDGV?M0*^nbF{4TZ4+!w&{UC4R@(n9bpaGS7`qBQH|?UBnx z{ajBm$>e=3(>{_%o9YmGXdn&&;xVKwp_+-j6-9-MBHA1Avw(ud=X^ktaH$J4uy@`< z-I_f&#}xHFbYAx~w>>Ym>~^{88vvC?$Zuw6xwHR2heAdyka)>!yU0-$Uge$>J7LgY2GeGkIsY9fvFES4=p z7zb4aY;iDcUP`i%4JRi!@sMK&#FGe4fxJgYCq`Dm9f7wDDFpVScyV9>_7R8Ju>+67 zcLAo<_2$NxvSFVbn-Leg94!x6Uyhd^Fai0_;-`NEk|_0OmEy%&v?`!3^(3Sf7nnJE zZZ>r03oV9;U-+wR@ z%4RO_Ok@dfE};EjdOJQpeg!^w7|NlZu|~c9?UFMZ|GwJC_4r+n_nE&dG6Al z>fhy^JdxrzpD1!HZOJt>F6e$l@?y%4N_%JeVpXn2Mk!}_ut_>H@rf}FWJ_th@!s9e z`9CBM9}6N*K558YRx8NSXX{;D-ac@6A!zfGj%{F-`Kkrqv%HifJ*O&M4l157k8(2= z?p@`O1ND&3>NcLSkaSG*W^P#DXTI)fr6OtqnDt3~jBYUQZoPFD-gEug;MY+iLVhqv zKQ2mU`0^0?06y})!R!HxQ>%60hTCmaPKJ1~JyVzM7(l|HAyM43$MbMuJK$27%4Bw? z`(zYr65`7s<4MAUwSrCiD<&Q8u{GkqJ_tFtBh@)yJ>wm2w0MTAsO4$-r7q>qm0F&J z4w5Mhbt<}a%29}w&Dq+%+4p$`nZLCdJ4`vt$vPC*q3I~N_60=anx_3T5+n38X5deH z6z@legwl|o>$$@}0^5`52Y!(WcIq@atQL_l+s&L?F||%v(?5D~FK|E$a>(JwOMGyH zw#FNnf&RT}@=s2(xBVApGqiM=N{pnMO4e9|G~9P0&^ae6Y?sk4hi{9+ZBJu69K5p= z6{-0&wIe6+!~%EJnM zz5KH`d`+rD^n~q%DP~7s-z{gdGAmD^NNy2v{xMZk+-E4c##)R+dwD-vmfwv8-1PQG z4FuIK7BRnNznuO{o4aU?>QRcQDYd&?ifpq$j*|q;+=_y~_SrScK^Pl1^xmNuX9Ldd za>H6Hwc+;)Z4=XP?Tn8BANvvd3h~P&J49JYSaS} z$6u+UebfD6e0`lN9T~a{0?2HDRNlV;a73u{ccPtWV)?%&Xf7W3i-V}=GHTSpP*Ma6 z6Zy~1P+WzQ7#FRu3MHA*n2|YcSgIOJj^sBi)nsQ8 zcPCVum4RUzNh$bSqpT$iO8d9+C>7|F%t%MqD2j9r4&JbiI_ell!?o@=WeZOdot(x$ zD;`Sh|1o;VY&80Wfj2nJX5B?Q7E!SySFSZ{M9Nc*HuPm0Is18{pzn(P{pUx8k%va% zZ{Fo`FYzy&pFMk8-c?RDXKdwtskT;Iv12_sd!&B=aqIa!%5Y|8R@eOy?&oJOZ8rC9 z^s9}UdLvsShD$RwDv^_Kx{^tSTpXLAQd2}dcxzQ)go5|=+MU$Ap8d6t` zQn}}Lf+Vbd$^zr#IFKL?RR0A-t-FLBrc`~ucdw1Y2K!QnTLp;MHm3Ipg!*rqFmY*2 zmQbzGdcS2#3*ot*x_l?3?N8a5Y=WysacvFzEv-dA^XBvh23%Xgj@6N}@kIcCyQi~u z1e@LfoJDh9|Gr?Z9@h^mkwcG}xCb{e%-3ENIU2HPS4%m4qm^(1sIp=)jBD#pt|vJ- z(CD5#J+i~x*Y~TtcbD1i@LJe-H#$}HBv%_cl(;?=*_NS~(L$AM&@P8SdXrNS+@iWS z)bbv%1j;|gwn>;cqmAY<85E6TrbZlkHot~k2foc7)*eHyG2`&MM-CrNd3X9paIl+O zZ{!;=v6VT~Gkx^wq(j#;K>8SyMU~n3)f(y;G@$AStC=9xlkmg*a=Sz_nGnzL@%HoG zC)?Phn|mqHz!DIx+I`2Zpurm8?Wy6Ok$w2t z)2}`i=fI~*AXU}gV1@=_9c>yZ2o%ELeH>?)GcHc|dcwdO!_ZDmlT~Ro`A7IeAJa$eUGd~>BhnYZ&~$(&JVOFUEiKTQ_hz7ypH?0N(pD$; z=Ws5(ozR^&tw4rjQLh{WD)9)Cak%IJY;h2p{biOwNEc+iNQ6vLq0-bTr z#a21)%it=Z0|a8Fyld1R`~BX*3aF+Q!_b#|4yijJ8jk*OqD_w{q_Q~y=O6+!)doZ2 z7J#7^;YYxBU>N`v55V5z0}3fIr}yJJO2ei|)D5Fzp^SWw9ET5UVc@Ha^BUkqn*4Jh zt2P5tcZC=5Ls>$psec1D`u+uwimw5no*s%QUF#QfZ#`jABqpqZS6aP5K65;N$%h-O7Ulyy`(n{Kd>E4%Hzu>~HZtWoHv7T~4uA!!y8ME9eg4zw+kZgD@ioWRp0C>)<0saRd0W4+L z>nea*+5lS|e4i_HP5~AN<-jWn<#kBJ*{Q0=NkIK`Z~OttPls$?G4|SHPNQDjxuHhJ z)LT3$adm8mGh~X=<$aCqkCTrUQ&s_U*I6^4Y6GW?!U-7H;!qy!FOiv(V@f6>jQ|(5 zANS6yQE=i}=nH99iQr@Jo^8qD#A-XAB*$d|het8$RGGJ*YdF)$c4#N9A3?jMoHZ(M zk%Tc1!+)bcsSO=jIm)Bln{A zei%y9)v3OoGv>ehZ+%<*6xYsa~^d_Em}V=ReQg@9b_Fe7J;d`(Q`I9f!a# zUr8%gyTo#{s81hm)fuRIt>!YB@Dp$D+xxD<$_n_-upO(L_;IVXKkOPW*3&m6FR#ZX zUNMgc6op*7!0cxS=U($3mM@Ajl+fyT7YwyT>@67_Pd>M~<=ssnrC$_CuAQYQk*&PY zTM70y`DK!N?()lcnuM#-cO&OT5p>IgX0RlAI&3jY@A_eZx_c$J^i^So7WyNjZ^KwX z%Av;oKupv7mz4`(mYs``36QGyu*gHF1bv>%J^8Ybdb-HHI8vy0V6@Z1>cVY~WJ;E} zDh)DvPct$R#zYpG*Q(aX9odQF^B@uPb$Fx86UjG^Z`|NT(Oix`#97qv6G+;I3s|{Z zb+Q;XHCIM9uhn*MmGKi47u51t=}Q z0tjG~Z~;N)KG7fp04U;y0WeUX*LZ;7$V4Ebma#NSRDXgh{5A2^zf(ZOgZ~u#7uozp zH#kxca{vXx0U(@RUe?Q~|H2t0R67nu^wcoU!u%hgg#z9Q6;lIq6G6@Y;Fd)0?9YvP z{K@|yoxhoX@sK)OKA^2XQ;Yc@Z1fi*CHG5^(y?#}S4>%A|01SMr+>t=RrOMo?j;Wg* zC@AxulL%W`t1VL<;2V=*9dL^8E9Q>A-*+Q@PGB>+J&DA0p15!$P9x6T=447IWJp%K zTwQicJV^_m!lD?Z-y3LV=37$n5_}FJOMLwydwrXhZ{O%Tg8r>)RvMbllVNUNePd4j znR7L5R^hDXb8>-jq1_}jqO5QD=@AN@h!;sZt$OxS8R@pQ1SM}VXDVoZ z`&yT?IeW-V)2}#Z)vWD{K=-3OUJr{`f}Pd5@5<{VRMt#b(5$SdWuogJ2NK0~JZ5z` zDi=;k7)6;1M`ri~A}RK>JRNxL@h%cHXe_rLabT>z8 zP7K7GC(`XZ#(RqyUM`Oi`lGSDG*GK>XK6ivDv?F;hl?9>|4&`WZw#(tx$<5_hZ^$9 z6kO@|E=*#}Di{!*6f;6|@yM=Gm0P)C-dT`(A;DPC{EAg%Vfs~?Z$hNlM{FXPdcP9c z?JG#j=HLEE#f&SO%Wws8Nh`()-H64kguF=GkFED|gGK~IU~ji{nDw)2xi$o+m0$eU zk-r)Q}|daty_vjvFzg`4gqhvtdpC$g;?zpaY^3F1Enoavm4n8%0)CjpOWwhQ6q|* zq01;iRe-e-IHQDlN>lb5`UR7G22fXUROLJQ7Kw;mox7!Vn~bULy|DL(bacuy9wYcd z%~f)j$pHf+w{se@xN^JoM%VaBQRYW<&7ULGE1c{p($_Z{t)_MY({oNTvFA?#KmdT{ z0zf$clLp8@pj|Q6U$}h+#?1kbLGeO18-u4y%=I4MAgrPHQ->_<1iG>vOyM45enXnY zey5fPWwG9Z&f!jwDcgx5ODY0XjlB zIt-yMAjd+Ex6X;l$ahXeq=A9?!m>KBWk2%Bc+)3{j4aW&rlWQ{!&%UMGM58XTj3Wp zrdECbykRjVgMRH=Sma;LOFp5?S_Sr*OQWX(8-0jUb z7-i!}x^AvwE^aRu<^>@)Wbr1*8NbAPy_0s!LWiD?((gYT%zHXfi)0bI%1 zboq6_c#gx*O2eGF4P-ncN(lPI!-g}Qa7~CBd#*TT0lbO94+58Pca%5^RsCxZQ{Y7 z;V6DapLp4=`yrymoU1Lvzuq#&hAIRVA?3?+z3JgDWQUY5{ss6309$D!Tkg$-PvWOG zBX0xHush<**Xx)#PxP!BDclP56ub}6N|ntzU`I;(ih=2bp<~C5{@swMkxFRfbJXu? z&O9a(2@Hp#QWx$%IS&GKhzIF}0b1XL3i>o#Z90`7Z|{OTCpDj%B`Clo@@?LvV#G{ zUwngb^=D2oZtxRo#mMpXhb=KJTVq-95LX?AveomeRP1SbLHt&3Zu^dBbwTY7?I@x}?D1FikIU|E?!Y5~ML& zd(&;x@<>0vhi^vpE;CGI`PZ{q6IUY%UU41a&tR?AfY0YM&uHIO*rxAvKU&bs5XvIU zDp)_;7Vv{p>S!RNNejXqe}qg&%3RkTA9VR3eTKhA=;3ju<(VqD0T z-)4YEsL@j2b~`E_b7eap7oqS}mEHChC5E%xsZZv(^mMs(l^I#4Kv7!6Yff1kg^jpXG+STl%Au6KCfK@W`s=01#myUlMQ-akAu%wJ7V zFP|zF^NSNkHi%|L(VE&U9II*GMQ=ehdTA!i6wSwKFWCq04`|V4oLG6vS-h-22zWwu zq;?7X%ktqSrjxR%i&=`t?o_H0K0>#32=Vjrd;&EyaGuNZ&S6i}f;I2c~&TDK| zR$aJ=?Jk@^z%@f~JI)i!b)`=X@UW)T9D6_@(KiRhpih5?f>**5xu1f5QyLfoWx%N zu8jFB{~B7b@qj7-O0E;2tmNVU-x$T72aXCEx9rQR!`1vZ7Za(cNr~=c{4e79$BvV$ zLX3|&-}oPk&ObZb7&*i%&_9R;k@K&$=jTAwd~U^m4L_Lj3ZN<$|IbxE&E)@-5kHrz z>m)r&!gF@Bfpo@s)ny!p8s}y?{LwVQFDiyCHRLcsZ{0pk%0C+9OJ&^X6{o0hB~LPB zf1-gjyc1-3j9A~2puQuloNonU38^{J($yoc)rk5^S}7`-t04KjXEar#QXqqNZFc+} znBoR;$!las>We7*S7(=m@LyGSq8Cha=gBjTMCdy`zjUPb=;#hIJa*b?7Cl8<0{ma9 zGOQK6ju?!fLX~+&;1P?m1-%&cgdCK7Rfs2|{0?g?+tH^W%|Q;dvYOE1fv-xV@g$%>S36;YEv_ESuNpBl9%Kj?`in&f)qH* ze<@@NS+&$T?*?45zRm8`R(-(gG~XomB*8Rq3Y&KFQiWmUKvCOVS+!ELht@Xtn4ZCz zCHZXfY3o(m#JiuMMF%9Xr&|oQE0G1a@zAW{Pzu(D!3UQMSvfRrU~5i07S25slcjQ} z8A9bwG;q?KMHd4ZtUkOyl~}M5#kI>3%pZR@Gs`8-xEQnOW+?vQJY=n)63B7>2Gu)= zB4HNCXjO6|S;^)X*r~#gMHx(f?l=Wbttqdo4rXGO3!t5zmc ziwy1in}voml56C5xu>Y0B^Sy5R*4YnG#1KT)_XUhf|euRfjog6^Rf(_NxT)Y?BBy^ zidZNMXDVQ5s0V?P|MSKJ04JdTx-ayMNJjd1qbKGDdy0BFJKeSyz3pZ1>MSlM;_l<@ z`e*si27u7j)X@Y$AQ13|n1Da80X2Xa43Pv5BPAgrAtNItr$kawQczGb)6!i+va?*~ zU}s@tLvf4nq0mBHY;6280zzWqQc_Zv`Q#L3B@{#?r6m4V0wNJ z`2Q?_2mlQ!s0q{r0igjf4G2O5`ZEArCN_UC;`BnRNQubIQc^C}rapS(nImpV2frvXat1~w zW)>b^K7Ii~sjJd5vU2ij>Kd9_+B&)>re@|hEiA1Zot#}<-EO=42L#>?3JwX4j){$n zPe@G4%FfBn%P%M_Dl4z3tg5bgT-)5z+ScCD`K;?@|G?nT@W|-c?A-jq;?nZU>gLw= z&hESSd;14pzJ5DC`TpbQ>DgbsKmg=lwf?Kw|4lC%qF!Jq6apprs}~3yMBE@WP#C8; zoL0q%#NL+LcTlG(Mtt@S7oL;Fj9t`SMq_e>D4lr&!egFU|g|*#FjR z6`+KGh(8{L22ciOa4(7?zwMfvj#=k!-wzS~Nv$lObi&nL!fL|&nj%jen>rJjl5Xd| z8iKIYx)13R>I%3WaEa*x7S?4lcR_swv^aUn2+nFAf*!IE8+|tSDY9+QDp>l zFa3Ah&6c*bvt4he*J#K)F7W?i>8qondcUuS?gr_u8A@83p&7b{7D)*K=@gg&L4=`0 zz;URdLy;DcZV870krGLfl#o*V&FA~Rf84e1dS=}}?z(&SInO@lIa`AYrA0H@>(dp^ zZolVE$RQi8iAvx{7Ej9l#U0mv=AY56{>elVPc=Xlh(94g7CgyyRiQXSVjmu$Y*yfE zS~|>|4&eJ`tSDO_i7s)$rvM)>*OA}857 zC5VmG-H{Q%Z34vGVl%=Ty&s~$cX#}|c773>>0zpd$|a2fY`mV^Hv}`v8S+Y3V4bgL zGgsnhNdzqFANjtQoL&@cC)S#AOt5KQY8G035{0JJiZ^7KLxKN9mJq^ukq|evz3zH? zk1gblwY&YZ8>c#U5_2-)U10*Qq_;j~0!oMnl9D>1YA&kO%4}UBKNqTk#8L+HgaNaJ z;fNW=V9m|ROut~%P=Jnj<>Kpuua>R&NJ`Idr_~3K?dnkq^KQ$THORwS*PW0o33{;? z1W`HZ8vVmOa^LZ#wu8Vd41&GJfG~N5Ey8&mHJo(J_`IV%rIN#g!oP|$)FofTJte*TG<>B6; zMUvM=7z?`qg5x&hAK)QA(0jm^XcaYAupFzw)MhI!+DNTO+)T{3KwdXOnUJ@9#y!%o z+_r31Pe%8qiocPHK+ONFjK#HgAYxcAnr+JY$M>1{91KRfam_{#o=uFB{MtZ|%VRtP z6omP6t}O71+)*C6cI;04+wac#Y9A#~_Yl0am&*m{tM4uqmbKIhr#Me+y|{j1xrSbt zm2LB1eQ>Cu{rit_){w`3HS7^F3{o%MqRk_!#1NiPN}0}L}j!WDc_|( zd!_7v@SfgvG>-wAj=fPH}3xf=}%C z`G7WFnZ6+eM_IF53l%q_+Ue6!H|6Qi<9)T3E2GqvS;oX)A0`O&1a-eXAN_742P7I! z(AAjMUEw+(5`11Kjt&C$dF(+Yc9J-ap?OBrW0UWKh{=(+zlw*fZXECXQS=L>@}|8b z|GlYDeSd?dR-?23aVi~xJ2Ppp7Hb6l0c=>O4wtCfQMauV;{gg{U=9^^EB~ z(Z1hfqQwA{j8SheuGZpQCaqe*dt)ITB>@mtck=edwk}i!)U_hY1db6jcRi22#Q$V` zQ0)+OXSx10uCRL|S3>8eqy60qpqBTV3j07Q2^+IGfK0%8sx~cOG?<(x$^ObQ)kv&F zC82cb3r3S}M)4zTWR@CzVaW0#vD4a|^ZODj9+N zxz^f*C8H{#`!{CzEjcEgK}~J3I|s4umR6c2*YOGk66}$L@FQdBhkW3+yXpNyhad;m zMbaN6xEQ*3GV@X44ZSwE+K$*Kn(6~R9{{F3NvH_IpTG3j8E+YZ@ciQwNm0;B){|9)mX}UVI0MGVh zvc8j&D-XKiL#u3tbmh%f@s`x!%1o(C6J}1;nta69&cx(v z$8~CvwpaY<_se5a>EKG<->)L(?Pw_Y{*-6z8OlhHOF5hKtMig{9;ehh$zk0BKk8E2 z~QXL^VNav7Y z0^U~Ag)C;v+@Nydj7Cw-O`)STFzy7(Bm1dGQoO|o!dC(P`%|WoLRWssEzb3LWix^c zVoGozc;ks)aH8p+wP*>ZIOMf7UUH!hQ$aG7* zv4VVH6P(FpHF>`8j5U>)DqCcy@>59rQsCGO2F~ouq1vKNP3c;*m^@MuVV-VOK!+rN zMPWbqb~W(KJbY7I5cst5o{lGVRe)tS5dW@DrAdUb{fsW);M;0HQ-rI7CuM0uW7sY$ zNvr2Rds?!{0SjH8Ie|Zk#924uA!7N~;id)KfqPlkp97kx zd}IO)^SM6|22|Z(i>&26x*PhFuWj;nOI7#egkHY&P*zIKgh*`^U}9 z5b&aMw4P%9N#9Kw{~{^a?lpF+@6wEHQ+-kS z5#~J)p`^vPws?RTPT?OXb}<3q=K8^UPzh7 z*ISrGL=4!hP`i2HjHn+}F6Y6UwnA0?T|yfQYZYME&-SejJyH+vQ+gQUf4U-R^uZDq znB|}p6!)Pe+7C51{V6yr(vM;bDxZrF)U>+?*cm$4qPj82Yu4p4o{j9i6bJpE{Vd$w zgDKWKUw9J&NYz^UUdfv0`~a3vLIktqLg|o$9LBP+boPIMx5q|v0^DEKf@=Q$9aj!c zZ%EO#Hl^h)reaS@lH&xA929^0OgX(IU_mlTk@YhWpDc{+6hFGzT)P9m$ zYX}r-$B%Ugrpk7Q=|XO}2ARApKxE6ms)|2=UX)(!o9wfw{=lQ+xh?!%p$cL?ayuy@ z{eCUhFL2T+XOw&G;@9a+%zkw><;+zPP*jDLc+^qALtVdt{w^~OhK~B) zF{w}+>F959Ksi;et=p+i6Qw!aPHWc1pyT{GOPS-lzQY^|weN%(H-!yqk6#l{hW%8i zpt`NtNg~|ddwpZ2a{}tB25aCxNYx6BV+fPQcwcWJWRjp?4VC9Cf4^e?Qpd7cjjV;vXxtypu+F5@>NBr~l9g^+pzXyc+FB<*sllaGVGuIr^!)5!J( zssAzD^6(o%u18^0elARZRah-9u)25a+V%|L@v)`ku$AYOtp5^C_-l;o^K=0D#gsIe z-m)||Z?2oFu?__=$yaJQ{Y7;dt4svoQ4R-(o2;#bGSBO`uf4xr&!^@OqdnAqzT4Zg zQhQwFO1|DX{k^C)pl^^?<=J5Ao(?Rm>|58%zwAABiM^PLt@B6QR;~DyQaOwB$;j)i zj1N{EQ5HX>BfdNk1qNRRwjt9};p6;^^AV&B2=^wVUDcYCrtop&4<0J<4R+z@ML> z5CQt&{X^>`G>L&5Unq{b*vc86&a)Q6m#C%w)Xs0#%t1y;SQz`7Dr91c_(n^3Vq~D$ zyf4fC)Caq#ReOk3f4GL@7R=`(!>xC!{J|E2D=CxBzD%}B`yMnc`0So)ljWWWUn^+) zfM4++;K^Fe&mcM<;$i0%`nVTsjkXD#?`r}Uoys!DS_&PT`8(C62C^g!xQnSr&`bPM^avP`<{3|2EEDcLAblKg-kdiQua z3!YX|yioNn%j11oP9!bk7U^3(}`PV8fsq~$b zlGpEJ{sAf;YYRNYca#u{KMq^iBnkKjVC#waDWRp`C*IvOe#U`^QVy+js4u&Q{Bs`v9vq#5CpT>8sQz`jqeFc>zjQq%WZ6VwSoR9UQ7dpH`NKtXvrpj@FZ(IROSdNRz%Sbajm6Db z0ew@tm{7%yQ~=6f@J(vSA=Ed3&4zW<2O_XcL91(faZx#Z+oid(HE;VmjmT+_bVO#3 z@wW4UfenH(a26Z3MFtmE*3sk7$59yyw5a{P&7P}Md}ZfVByIJ9eW~~<-;G7H3sclO zE<;t~YY!->H$aZHNT>h?ZcO~K+FC%Dm%rFpBPPh5Hj6AW$o)zZ{5U8hFS|)O# zu^8ke%Q>3xReiWlw)~CNkKO6Qm)C)#+fZTN##bMuO!fX^t2h{R;Eg6*t+WM_5CaJjRb_bKd(Gb=L3W%H-Ga$i}!0W_s-$D~APWHaKfT@x|31uh|tw z`d*Z{wYc&_C!EK#*;NDo)JAu`K}@5JvS&J~H&&O5%Ck`*##B^GoJA|-@+1%0uUdhGk|IIE9<+eze8#A$9Fv15Q< zRJrr>RmV@zoamFP>pR(@@$F0jlc|BDt<4HORy#3hyN4~cw?C@|v9y%c>LdYzra>h4 zRv`A#$~sMj1)UJEMoQ-%>&r-AfAL+z!beBDJOMC{^!Rc^te-W;9iS1A_<&y8p}p7F zs!1w)?a5;qS+p7%Q4|-v>tf%G-K)2GD;_vulDacW`z%j!J?DanXwg>vvt04}7lN$p zGh&SM=3KQ-!~Gjx#H9>yM4D_`T|`SK zJ@{tc;+j7{0`=wPy0JE>_m zOx#~5k)OhgjRHip)Xn%+qOeBpIqC6mdRcfZbXYHoz9l^pt;}oG#1Y$S{-z?3pPn(q zK8#pDqsd8k+Ef8;Cyl3SDpV4w#U%qbT8r^sv=L(sM)?Tkh-TO)qtxH%&LHk`4~z$_ zSNiodhQ;1{FyZZ)-+wrS;j*23_tLy=WVEw-B!~!fj(%kCtbi=C2*Q3g#HQd(Su$L} z3R*wC(PxG~fbYnaQX&*_R!0{V9F!Qqv|~|(LMrReC@a@jD(23DdIR#*WE&NBi8n=iRtDza@%}w)M0FeGr|_Chg^?%9 zLJozbijLt-k595FrGkR7@F}6B!l%X}JYwig;hcpMc%GaPIcrYNxlko6QvQ@>+J@B} z>bn)$STN3|buvVqOF92B&$XFsC(>7M!iSTKNbijB`^)v(^GYAf_lz&ys5S?k!W zo{$6W9{6wl!eoZtJKgXOHK%0PWpI;MWA@q`ZsJ8{U!^`bQ|D`LN?88f&YkPiFK&YQ>JyhXBbpHUfwCFpZGzI|5jtP!7;c^ zUO5;(w@|ZpQh)DxV_2I5p>u{0T8NpR&w)%};V+iG(HIyqFXw20V#)w zyj5$5dTRLt`=1Nx}oEMkqu< zLA^nW&9q>&kb4RR9yXxY zsLV0aO8sTNE0i$BNhHav;tJo_SHkQR5GfUbbaei; z4#q3_yq10rxKNmm0Wl(PKQF-z`ix}@p^rxD9oiN-Zk?g@5INxjYrc<_m4n=@;vzKy zTd>Hwa9{gF{uL+~kOe(d$DOgP%ww4h8p??eo@)@2^`7V#rBRC%@a{>(@54;v_b$rk#N!H4{Hn4O=EN! zzZg;gFCc52o07=`@GfM&+sb^Jk?t0m>tlcmH&T?I1 z#~BiSb*b;20Jrv!aatBRx9h6Ra*p3y^{g{;!BF@nYM$T!ejxm_q*_NMAGf^e^&$7) zQ?J@PozdD@-4qF_Hm~2m_t_63`MGRGN323Bil+>VrOfe5`o>4TW8uehr!|7oM0WRN zU8x@iFJrBA6^=u82wj96VWVLKPh>P+y`;LxDw52031;Olo$1|&y64;KV|fUNniBY! zM*g5ozgw>-9zx3|TYS(WozoEQ#b>#{C7)Jo-3ke0mwKt#xj1 zitWcO&)hknllc@+IqX!Wy=7&`{hp1)+%DdmhH!8|U+=m-<(Vlbg({#khMwjj8Ldgfev*i(vgpN+YZ~TV7p&|4IUk$xY zPo|6>X>d2Ul#K!_02X|O66q6!KFG>*Y`U!NcQV|(UqI-5`1OnMLcM-OCOn&%$exa= znT+BihRnYrz*yexE`3?oUUy0HV&ly{3ldjDF8wLFFQSCLN~b{|i|?9@w0lnou0I={ zj+T_AQcil`4a%As@^{_ilXv;UvNvj31UXcj3wTW58E?g&>CQA-^)bfBmQ#+!X4;Yy zOEor4{-8my`@QU^oJ0uhdNu?%z`t3RjE_0&3i)j1z}Ff6mrAd*JTL5hEl@c}j_8k! z*8Qc1BUU$0Vx3KZ8wWH$xaA0d3M2xvxpgFUuTpmg}(Mc^o)pU9=Wq>j(Z- zvz}A@4**rNa*<(u6+nTYbUUfkQyv)(f2Y3UGHlNC$^x(WBRhgi>SnIUtglIs<{6uN z1_7;L!lc_DL$lYRJlB>P_dCoBmn~H$pXxE82dn8jAnR-I^sO!_6GI5E^k2fWz`P$}_@N=g; z4vYLkL|UJ6@{D6hrA%a)hTgAYOtE`n0=|N8u!Rhi-Paj;z7lNZ+Zz*g6x>3;Qan-d z!FRwcXgWY~&$KCxu}Le_w1PnFVXh0KM8&J)2dX3uc5~&nC3tac<0w1#&R`afKd{}o zqQ$iCjt7cc5|9$|<`wQk`DCFT9ue-NOQBYN3Q8Vo08^U#>EtsulW_dS(be+?!{Q?P zRH4zQA7XPq^Vun@7frn^pa(z@IMP~9ZakJB-itJYD=I$ z=0?>1d!F9e5ruA8I(@0Pe9((J_u(3_UAUe|0NMB1xwqm(ixB?I(LiS4{@*7`I^O=_ zx@k|IDf$-Y+mB&w8!Ot}lYYG{oF?G#bGZtUHKt9mK}l|L_tIagb;xd`L{ApJWD*v} z!Fvm8Gd@muVa!+|eYpYP!y-WN3d<@}=h!6gPm%`ktnOD7<%_-exM?46ftRb@!%%^B zeNx_9vXYRX2?xS+(_JGi)-9XU_l@``Y^4z!nSh4vkCEd)y$9B%8GvH~>*@1!I%#p? zJnQE^UfRYSOD8Ee>Efip^~Sw3z>QLk`6AD$CC# zV#L{x{)a@T_{`7}Op2B!s-TK5-{`i6`w@;^`3sI z7;gN`x9vpU0R11v-bU-1x-!MzFKY8sVQbHCTuZwPTCss6`W~AK7bR4pn$u<0I44}d z??dBmy^aqsLP6R;qY5>=(0D=fH?_+1%7C-AaYbQgH+b>cQjuWM5NraKAXJv9^>ADW zvhKF@T6Uk(SRNA;05~>o)`=es3UxuEw&s)HY%LRJBjL!9y=f8sJ1eokzFj85#tAp$ zQrPzRUlBWESJJ4?QO3TvyEA{6M2_=6e#>LDrM#wv+`H1hJ_)DZC@Y@)kXV+v&H&RR zWGiK#^eprXH}o-afByF>1M^nk^Qz|iflZP>XLdz}mP6s!Hl>9&e;-bSa@#+DXzCBY z&-|&~pRgxLRDZ=cJnf4YRcm-0GiPmXlceBbvIhqXGVmW@p;DA-Y2*Qy2f9mRKV73* z4ZASey6F)c6*Fg=1;}l&NcEQb7jaZ5S6sHIO9-ugI&e8dfiB(ZGO<~O8*zFhNG^k7~!$6?~&+uvvfD5@W z<_1P;B@1$Zy}ci>#LFI7mP!5JGR}a)VwMtw3(&k2|Do!$j=1E190q1=iO)5|^#=a8 z#0Y5NBH{$urAmnfnObb~&AQhrwk|NnGL2G$ln<0T=+)}mj89S@WfKTP>iYl>8&XXTlS%Mr7O`}@)w3qo` zS!Pb{?+u$S_^oCInl0<{A*gEQ5zkt_4z`wy$bZSaIIo0d+#1jvw{Pn}?>?p8R^8o} zy&2MdoMDza)toc&VU%A%VMdn;a`&QIc$%U=baw8?K9&WOs=%xj0zpwvszQ+dvqQ~#rm^htY#R?Om03ha?~)a zCo-03@N5$G22=vlrjw)!70R5D)h_RVzEVu%F%ST?G&p2sWE8E-D+ zW<2|x?gNuL)&;UmF_KE@u#~~>r5M-~O9bkfLkvIw9D|e)RiGz*Waggo)ILJtQ3F8r zb@Xn@p3UKJbfob9dHp%-Q=cY*7tZEunba$%<1MeQd-J^G+fF3SHL z#~7oISFM78TZVn$qiE@YFetX=gcS*Bxtw9qRG8PSeLsG;Vy^R1-yINXmO z-;R`ah|6sSHg3`00Gy z%W=y{jXxUfG0z?$o9zh8b3ED~yRka)kzBbuGIMzom9#0m^s?l1P`{o(^CFakySjeL zXe)h(a0-obk5OsoNI}dzRd#iDL5BJl$UU~9)Lbdm{UM0>g(HaC8UJO24u;C$PSa`i z5uE=Pt9T*wv8MV0u%CMqnxGWOcujEiC?)r$^Jo^YhcF&Tu+fv}Iii90=Jr!u`6I_& zc1H9%syTS47iw5-yy+(N&*dmWw`c}xNHwWAFy=E2QWQlp5FG+a4CcRG=#-FGDXgVs z)@zD~v&eByM%T+F$OyAjPG#6tq$N;Ao-7B9(rl7s?5LhU^*L;PGd!!NZOThRWafUS z)u4<>V0>=l_H?}~DIT=O?83i3bgh>b_$8fed|H*H$L(80)UBz$@o;y|jyp5|HdPLM z^evNPy^U0Lg)GL$|K7b6f3GQk5&}bDhyv2Kw5(uu{zIWt3l3f6_F!N|WqM1?5U|Qq z==H2+ekMKd5^#DGwNqehOxnMuXMn$r{fmuM1&^0~efHG|QLCpoWfRG|$d^s!=vXG8 zRTrujpE=IvoQy&KSphN$kn*IZLylw?>J)CZp0h5YgQy&d!kK>5jLVMj^O9#KT&C}; z%|FK3-X56jgk6IVp?+AS9k*=AbxfkY%{Ni5tkDtEU?a_Gu#^s#ARlmMq0!?!8MA5i z9oqF~6(*>^%rnFH_8sNm=g3N4lvVMXtkt6>sVMI06laU>rub{78JE)!{{W~bD(sVl zqWof+)nfwmv3bnPPsN@k8-fWvKK?m|k>#s;r&vtiWfQQD_oTls8?Tce`0kcSVm5hPX znDkEi?2j2sXy$vE-Ka=^Tx9vhY}s0#6=&}X`f$M;5c9#x@dkUuN=EqZ=FAL*+a_t! zr%35Y5plR?jAX;ewG1IfL?tLG2&4$$_<1Quwh%4#6+I>7jm9{uhYH;wij1(1?p?KB zS?GXTGGQ1=RAYirk8&T^J<)#vh9_5~BWj=0RX^UTzuMi?w#<3=+eYx@81A<;p`2#U z(M&ZUL}W|(55Rn71O;!{n<=?e-|6_)Z0_Ay8nG$% zc=of!RwI7bw!PBc4a&&NzmW@jDIDqfD_V;1OnbxujfyX_hc83Wpw&kLE8_r862-iZ^kFKW11Yz?2yOmdq; zPP>9)^>6-qpQO!n5d`B<4if{>f&32#QrtIbWAbRG*NYoOGS5h6jy6b&EzOpSTOGS^ z(>0bzN-Cc}Y+cLW`~;9jIJ2eS#WgR{sxLr>O_A@+BAo1-9p%fbo#UHEzsSxqejLUr z3@S6bIw4MG=Vb-9Gg*F5zbl6sRCTDNj20WCR#P3+G%kLs)-pVebd3v1w6|6u$d@lRSME;(fRQ<*2n1mBu8^Ix zn4m2(n$_XiH|y)IbWq*?bMF^rcRF3fjKIdn#J2Wy%z|jd2)!J+>aUgCFNqN<@QohX zz^Q?Yn=d{8091a4F8WC(igFYCN)$hDx`~b?zQeS&tvjtL$~2_*b|g042!z&!}MYw-g9$>bDePRegY4 zg;943ED&y~hbhPqx=L`(|H$L1|EEdTRU=`L-o&(NDsX=95yQsDgaz5d`jXw!F;%s~ zxAHuQ*gV7~p>(bVn+UN2TbOrQE)?+H5VDkCkXYWzXvV9fU>S`gRa{$&7t5$+v4Qz8 zK*GoNqv`8jpX4C#^~>`;FvHVDd6eCU`Re{8+VbOegF1Zwn8QAfGi%B&je-jm9$DCH z{(xiv_;#^Q1?@>7F-ovhw>%`-7?lpGdDh2NB@RabWhsU56*iNE@N&1|N6Pcn^62O* z0u~k~gRf4JtZ0t_1r|=96A=?rQsgY3a?Nl>uPI7v%C22hq`th=NfgB5!iA~`4B9&9R9E^xzbLL z>rL+)r(VcbOK5ABYhE(m%+si$q?sXF9;zBG8IqrF6sLFiEv~w!nH)D(ux(v+wjDp$ zUyep9dm&#LR3-cFBJPUQLTV#MfLa0^T)hVQYBEL~=f~!2P8wBT4MT&z^Q8qr?jAW| zhXT3j?`MivARX+ta`*uyd1eZSqj3}6vkR!^x|zD4ma7xfgfE`2X4ZX;%`04Mdfi3H zi>@*w0{4*zlry$!lG_6-DILv-h~YT0bez+;sEVG&Z&1p#e8C7aA7$KTFTgYUU1Pb; z5rb<`76b0FsEeGAph}FcM{LScUMR4WsISTS$ZS`h5<4WCfv6Z@5ib?)ew{Nh9tan@ zTHdzq<5It&Kxt6|QG8>_Q#Q0q8!T{q1PC@!(*e*FcCgfbnakC9$}RRSnn@~GkKJfD z<2w^o%hLc0Z$O_fJl#9F*Ml^D70-;6Oh@Ypj+XRubtTxm4Yiii)+tIL{=h zbd9~D&`-?w(zEF?E@3%)*H*4~TM`HOu+6OELD}I_a^qmS{uO96TeMSlN5siDO#OH` zOH8xKZsm_f$?C17HPbHPsb!%8CeH71AG#u|3#jK+^3%HtBe~`sOF1Ld&WCsz3(ARc zuPvnu+<7JINH{Dg&PZth@~R{V)R6!Mf|Fbkfu_SOXu{}VeT#}^!}obfU}mOhLu_Nq z>#eSqO!UiZ$#b=`lCK8*70#W9_S`8Ue}e?{E676M$qcN}jVfF;MWVBZ!Nw(fbACbM$K zc-0@?cWmVT`xo)J?>a}0wH77oGK^%bvfO-!v*hkDs@VQPB<7NZ8^}G4CIP1jR9b(} z;3uhY6b>dN$=Hw`##4&fG z0d&YeU-u2#)8(^mK`NKE_Y(b1t0{V52cY_+*k4l)Px5?8bokpyjF!{$$`V-03Jry{CpS#V@FvowT!-|>l@sQ0$EBd zaGP4!dnlGfkAtX`^n4h1k&JOgiCY&gE5PkI{->3hgK;vM5q^GlKAecP3=wDq2sTha z9}WW<0pF*T)$?R;EdB!V26Iy0r)I2Ht*M$;XeM~~vAW$@C3d%pAe(-A*)}xT+P~fK-xpnK){65WYbk?2SizD0kXeuxu7Cu&Z=kSK2@Yr z75q@o^Ws?o5c~kr@dYiDY{ZDDj)#VCowy-lz8$j}7RKX|1~jhP{$~6Tnp1ivGZ`SQ z95tKtXs+S8*?J|0Oc=SlhR%ivWvYm1pG3;tj zvHf0X#}U*+VYw!5YU2EhPQa5FDm_6m*9xKTXuOqhU5wF_`}Cx=kZ{tEj^q<0-1$)9 zuM%|Z?Upwyiv(WZqQgLy?|Maf^NgX%=BtILcc^N_s{|5#bxpc4&BdI;8Q#P~`4|gc4 zqlADMNy37@F~2e6U15v*(|w_uC>fv>%Xs`Dcn#OF@4UX95rtY3`!mEnQW~#%oGo%p z$Y=>uDmDNs&^R+pfp~RvB(BIozY?>w6WgXCi|D|1&fvRf^A0|RMqI;6yuBddb^S`xejm#XjjK;| z#BTnP5&W#0UWVp_;y|MkD)`Dua;3CLfp;kVQ;^BoDU#nnHkAAb<#AIrImr?@5;d9JHVVmeV{>diRKS#Is2NcFjv#Lt9KS>7@21!Xtg zk&cv{wdDQRc%D#ko{`n^FR0d$5T>{FC{0YE6OV)Pqby`7ORcV|CbP};BHrSbYg-vs zTtd>?FD>K4`87YKmYZ6l31~&kRlW{LC~MfYmitIU6fr!l_|)KY5uxu%N%677lLxoz zIQNCo`A6K-X++fxs`Z7RP%9~E4Q~9rpL>2}V@sh%n;*CLuA!EMuNUK`6;*4JZQ2yB z!RlIOEharycUGm3@>$n|r+6ili`>&h^cnybN5VC-?l*I^1!XW}R#|{WaRsiFN%Wu0 zg+mCAGAu9voIY0hKUw}>3a}C%^PeL28KMIi{+}uaEU%EF&{f8eJDTBRX4A)l>aA`P zAm9YmM1|Ovgp39WFTAK|Y!+`=hZ7KTveEC8y4Ep*$d$w zT%J+yeD)2C&7Xa<{7vzIw8XvbT1TeB2<=pdE zeI7}*oC^&~NF04z)9^&pQ^)M#v(|qAPeQD1JF1J$vgcnGzkc{}<#@d>AA+ zID${jr!}9hL9)~=mu9xOEbG#4%6qYA^Ip)$>9iqkxAf02)4<>Nao1Om7E(~IohF}! z+Y8=7=n4YBD%kLQfh*F5Ozsq)ZJ}=H<)iyg`E`VX!nnG3vkaQn26>e;OPvx_xSgIL zv2_x!C=%1k+yU7YiriXejt*H=DqR?) zIr}8XN+@@GI}mgNV%?PZ3c~xwe&EPNHrX+b%=yZbQ6WwJ!9^|+vIhQ8bphWP{b77; z&F;`dM;IaEkR!{yusk?RiEGitP%vp+I_pCXM_$zPuPx#q|NI!{_zaFu z0hZwBrvP!~oO~P%&Gm7Yj^w=*4a5Hx(s6enAf9)y@puVNquR;Ok;QHPaFZACyuH&Jr|ySJsF%b=kAVy03?D8p{z!aNw<#bwsjij-YiTNEYA+YGIxkTYbr)!dDq3 zb@^c~wu6kGI0?J;;-%QVn#h+E%h=1d(aSY?+r&USD^|Ai0bU12*um!gU zuygh*+0Nln!AA!O;zb5p}B;R4NIGQVthj~>lU zxW&U&_QE2$Yd=?Y8M?`KBbu{g+!CvReEty8qYF$ZImy#KDBA|RAwMsXtNE#DoO(?y z9nXUO*l=sSoXxSp0)6m4g}Y;{%v&&UpE$d&eb}0m1;M#FZy`w zPM-58duN%oTwH6&x8vgJl=X0KdytPRO^Iu7`Dn%yy zU6a=A)lHzQX3(>ywYrLiEwktGwi0y2w317MznC(Q9(nNUpI)iv&a<8`+nL?%xrvYY zbs6jW`#Y!bhY6>_mvB}oYCGsVtTjqUnNp-QfgxVwoTLE&jRDPv>jg^}JMPq(yb7pd zNPs~uZ>&o@+P$(hS(#=gOj*%35WSA3`y7Xk3$s;_kf%=8$e6V3nhOf%65p~QyC z7yoI7_N{8#s2j&`(dDNj`_TaQv3}C=;Sbui?CfxPhn!3$NMvwncytW>4-mrEAV!-5 z3ybR`B}T=w%=kjMY`Hp^@Vu0@Hr{?r1IaB+nH@_vB&LCMUNVY9i7nzGVuVJIb zyPo|^C0Ttid1Xmk$d&szx0>?|0>8u6Ce1S%#PP|2I4%_z@+#}YgDbmYc z>qt3sb?51%uW9HBcP=v*AfqF@iZ>H z8fZF;6nCv)xCVDT^Q2e@+yTn1j?FC~?DmT-khoj6X2m9}dHiT~9b!2yoJJg5WcqG) zC(rfo5?6GaOp1Ql__v+*Y*R(<2#me6K;i(>Qy}yPn(DQ-<6E0+CY>&+Z=uk4G3|{e z5Ep-C#=A+cL%O2i>(QgD{&8@|@D{Ss393GDi{Z^rVZt6vLAZ+mMuK9I-cBf#Gc(Aj?5+#x9pBgip_S{}c4->P>g;o4V zR-$Gxk!jEKwU?-aI!koDiZ$PRLS<){>d4}G4Pxjwf&h9*(DQun4&MBaT-z91mR z1h0hLG?e$Yl=NrdLct|i>Y5Sp%X%Vlnx1Fs3)MooWX<$q4ysp9%E$6ad=%g2zIjVU z7oLrg7JOTRqAmEq2zxW|C9<>s<_)MIVpcU zsoMFEZ7;Nq?jXS^qoK^iGBVp6_Q_&%El1XUj!>Kti9v8x!il}gQ$R2ajCm1m>A!yf zW3CxNmwAy%3oeV;d0lMpcw>p@HSL9uB$4d{)G+hJD~v|@1NOgQ5X~I1c|7`$I<{`G zSzyN`H@G2Z$DNvKNgYr+Kr--}91O%`hM#k_Y&>hBk|0y1wIErtv)ql{eOHZP2vp=v zCb(+;vIiaq}pLJg2|Ec)+abB>Z*607I`pTd--Y?t`ECdVg z?poX>NN^3V#jUto+u#r^1SwXEI~13e;_li41&SAM3#CX~dimY?f4Da@J9B38W@l$- z-t3<982g90nS)LdB8+Ry)$k<^U9{Ec&81huL6o$aExU|!EE>trU>ed=P!pAtFh4j+O z>~jAak(6&i-6}k*OGO2@(OH}v$?Kk|eup%rZd-?MU?7#<5#6N)`8=R|>LK!S5rv&) z`!4c$>7iCU4S}dm8epAw+dG$++$m4)R|`^}!!#*x5}%`QrI@bfasL4@Em9(^C2lOd zT9A0SF(~<3rj|9aT1QTl)%Nn(R8>ogz+=qaunK)$6-!T6dH7%&&VLb`jJ9 zU(*#}KkU>uv%Jd%UNlF3AK?2fO!Jp#OSfmzl1tf&&7V>4`EjZ{Z-3$|(mFu}JAZeA z#vObnSzVNRE1D>EGL@K#RW*-w^%n(08+`kbo7AfCh8OQt8(pUzV8)Q=(xWE(t6uHG@p)ZvNvNVO>vJxud5HxYuV=OWJNJ{ z#j5&lDgIY%`_ZCEM+>y3$f&wEwmf?7#n5B==mGD>j(|g{q;ccD*rkWVxG81 z`V>%4fz;F;^$kf#s9f12z&=x}Wbjws!Vv4!>%zJiOp2T3`yo|#q#0-)f{5@Y zrc`0V8Jezo zNpc4^LrYn`$=BD{g32;+yU3C)UyF@(O@I)!Az?z<-uz^5!*5cjw#HkuZ5ypqx%Bh!r zp539e&QG(~)Rx|_h8q!{Cky@7A+_qWen;^a22Caz5HpN+LG|LC(MPKni!FC|T`|xy z`})%K8m0u@9469I!3Eyplg&NpV|uMM6Ifq1g@ip4<{pd*;-9jVx_f*1wca8o6moG?t~VK(srAC%?} zknqj{+&RpS@N+g~_!!1u-SBz3=Wf10tW$13;L>-jfth-A&z_TdDj1^{7j0K8p2XGr ziMocP^L1LtWSL?RHJrNgO0vEMfFsd_gW#hyWL9*_43V}+rcB30|3w>Er5Oj-5nPp0 z*t1Cl^lQ_V zHuuAmX)=oB!r>p_$5DUyzR}B2DJwgL27T7ZZLQU@AIvjCL$X5Hn}8FgQyr|4QN@G& z-wwH_5(@6oX}2|m&2p`jQWx>61;>%20Ht?g!3$Bo-`VJqs8P&K;xOV`H+!(Fa!~>~jN!X&Br! zzXs*c2agp@=w(` zICR3n4M~NDMRrNe?#j*sTwDp*1~KMC#QB3GR$B?nmZWDa;@3=)0Ifyk*L8~QPMA}_ z3}J%<GS2rrBG=x?rTNC^_$mGM1Y4|V95zj5VI(wP_=Nc!wi|Dr#v z9i(?ePECjI1ZU4#2XQrVmStNU3V!KD5dbvS%l-uXsi|!qj*H12zuQcoe*WT3oV`c* z_e5#|&|dUUYkv2w6F>7Bx*@%x3jYu@(oNYZvDY$1Qzo2U;B>zL!IcxulV>?A?VsM` zfJ9KldX*I|Xu*>QW@FQi7KItE0P7*?VE!@ooAT2c4wht1ZI~EFVSrwkrP{_AXMx&( z?=E0VON5~&j5g}0Vv&$)h7A29cjtve`sN(<@5Y3T4HMV*MZ$P)qo3?j-$zT$x;NCU z#$y!tND<&p-KFuWN_eq;d@8&mp|KawH2BJG-P;G`hZ>$#0*V+I@lBt{S-7J1H>1 zp)?!*XhIS|HMvFbGQ_TOyfq^#fZ8YUAK-M^RWp`zI3yKB7yYJ3Jsjr^9!79=ze*{piGu2+vePyLxhu(NKRCSIh)QgSPZ-4~sDEyi8Ieu1j|un%Y8SUw5P{ zdpM=BGqb+3|I)6(Mz}0`wNf)}LiEX7A7N4C~%C33X zxYJ)+Y(J^O*(+t3Q77Tv2omi~1L0;53Komzad~9h2y>yWDy*Vc9I>RZ(@#woNpY-5 zs%lQP_S(l;I*d8q7qxpif-t4Qy{~7~T+Em6c+JxqVeIaQtzq@%UzvE0uS-1SAwQ%- zNQzghYRc1?^72+epUb3106soEpp1cmI}N;V-%J+=D!MjV2#VuRkN?EMmHE_k7ZcBE zvb^s$3h6`Yen6WtdF;;ABwOu`!;J$x3wbzY&G!fmbL#W!`WfwEd?JU|-9fB0q;rl8nT2K3LgZ7>sK@S40gXLl`>wR(v}~7&@vqFwXp7 zyi|j-CuEwwo9vuQA-JjQ>tVWF(6}Mb)@fSwK51Fu-c=<^e^QVtIG_+5 z_jBAVaiwp z4UqTy^s!tfs5!|o48Qj0RA4bU)z6WxaE`t3WoU-3$m$qVZq0i+A`x9HN(rH6KZLq% zfIj52;9^E*RNUY^n*!f>Ifs3caa!Kvf0co^OJ+zGQn`b!@tKMPGpB689Y(&6hBV12 z;+p*mI{i)XMAfk?o{KLg1>PRp(j+n!l?JUF{>t=7m+6Hu>QfIjc~_(Yn^i47j|Q+s z!}MyA!u0A)I>xY&YGL&RXTGOXcFg(Z{z(M#14YLYT3h-= z-v~O1$G=2rmijAW1!K1|Z7RzF=iuiz%V*vj_Cmzr48;ivk)1a%Dk6A`Rke3PF8%#( zJ%}D+Ud#0&ta@fS?qzTk6^+g2300a^bUi}{$%F&0n8%Rv+#Awv?Lb1Vn(BShZ=0N7 zq1}7!!fcnDtO=ZI2dy{eCO@i5lwD*UaHaVDZdcd|vxlORBPF(_*Q?y`R}#hUtiI+r z)TJ4Q8XC^jJvOUWEO~#!pZo*Z*4;_2C(Ox`P#={=8E5dn`}8Y#Zz_sl?x>Lak9+Lq z)6B1u*^me9?U&alIOs9ml(zcvz2hk4VDAt98y)z3f5X!Oc?X7YH%Bk%!70=Q?$AG;{H z3sMkwzI7F*@I{!SqwwCP_RI0PpC?4Lt=2zw?`>bZ0->@6{pgNlRH5eYR#U?DlD|KF zsP{2bV$v&Eb>7R$COatvXw8lxTIjjD&kcsExA?8_!URKJ*12`Do$z^DE3pht#ulwr z^(cM9dcl09;iCVmuy$dLqbURhlqkd~8k0X6{$w~54_%Fq`geI^UH zJid|m#M_!KL4~cf<=cB(+W#!KxlpZ2>+!e4s|O;Ov#wry*HcZAE{(TY6k8xCRj_w(2{ zf%<)79%CEEPXatiVr-r;Xvp(oR#B#DAV(9!DU{w-P_lQiU#J;0mIFWxG6q<<1}z)r za*dCvT)U_fUMKF3x2f-2hQUqm0{t#D%3vxfnG@ntotOZWaUgXu!I$<8kt6_;`qzFl z*4}zSayLWg6pw-W28O@J{ugFRNhbA~ zeazLa7(93jufXj7)XcOrN*oBPfaErdQ)bC`M`z_j=}&VM<7F&#Y%{95et z4*+hod*A1ELn^HFnHuw0o8vq_pXjU6sF0ueCtLQeH$0wiI73~isqYP647kiDNLX5u zF0veH+J9cUs(p_;A0KU!U>V z9Tw6onfuYX}3xBTXKc61@DLKhgUS0DsYDsF|AO*|&H2 z&bg17Uxl1UgKS(|(e7(>AlJJeG zf!sud#OU$Ki3-`XUg^6ZDMk8`$`u zIW+kqy~3aHBa(;ZCuGqOCIVd~YBSWqE=BSHb{5f(v)V@z2{Y+`#iI}q;amEM(0$W> zlmtHV4D4S1Tl@dblBXwb`mV(>0RJ8TpINe-ldqdkppUd*h?B3TW)BAF(Qz0LfYE~i zfIL>=j|Z^l(TewfKEzo6PmTCr-TnAw)c@+{$2z(P|9|VPRbu|1y8nM`kdNmY_+S0( z@pAtAun%qeVCp?+H^<3`1gB0AnCTj5=o{+;AQ=6A7+n}mz8EEYlZ}lpuyVoYbHalZLB zLgIdxNUjszn`ueBGmAX>ndM_HyC{+XfTYa$OiR!sXx~|k7DoX9*zGL++qm!wqfSmO z@m=jx;UsF5l=yya;Kyi3 z*P1PT(^OWlWa(b>Za(hrkv5zp#0ZkmZTd`YI&J3G{K8gYDIM!lOc_x zm*>h}ULs7|qW;i8lJkbOoHBpM2PX|qQ?8266x*k=bYl7um_!D;H@w6(U)TSU8)Bp0m!C(lV+{vyqN1rWli+&{2Hs zPDdLV>t{mU_GF9`J?KhBs2rXy=Y7zOroY6;s?gHEDVGc#9H|RbHe>J>l#9E!igT;a4M4W2!gol-#c2j~OvD9PEZPn8Y%QQn} zHzQ-Q7>g|H(eD3{C4G5q$4rEa91_Z?i;sj zXVBu{rqzpLZRm6y_I0a!9*9{0qsqq4p;0An##@9T)>Rh=fa24Aw;y7ne$O{s@=(M+ zMKDJl-9r`EJcGHgKpF}=jx;rfxXka<)3S2yd5KyG5Zo5?Lg)#j6JlF0LR!%l0$hGc zY($BLYOI=L#K0BSYl4~8J>rBa+{(G;;*u-vk(lUrCGcf)9+o$@$sD4f)kU1_YM}Dl zd_>r2DV*f6JAeL#hl3a@Psr&DAck;+9xx}g;wikj{GM93I$lTWDVQ5EuI{un+;2?Q z(_rL^p}VWVf`?z6BF4#4*ZN{;y=Tq}jn4%f*pF^_ReNTnCe6iQO<5DU{1x zfKJI=xMUi(BT|{Sui&y?ILz6`jO0|gGJDR*Vg7>uWxTPCA-3GLn`irLcVIaPVN0#? zAr>GHSrk179H=RwV}f~@5yaN5dJ&XO)Y9? zagcdXeZRpCRHp|jSEYX-)1nTlld092d_k^tT$#EUQzn5O*Ydf6Rs@5RIbwW-4i#Boad1 zbV`;Dac}625FCzfqlZvpZ@JTVY$|nYHrf$#`mxQfK?jAbcnaPlhf-uS@KlM0)t0Ll z39?9{0s5C8aMpNIDm_vS2q(&vBUqE>eiC{#FQjO*GNM0V|9IqQW((jbW5vppG}clZ zDIA%*uF0LDWoi`JR}Ff7=?L!q6?S__#8R>HIItzT7>_h-@tvp8nlv}ch#Y4^*Q}X; zEt$YEvF}@p20E1(71cm*7jrY6welfEDk?rZa()$Cs$m3F@k?0skEvw!Pp!~RvO)f0 zxn#~b47{%@)q*u7q|BI@(ztaM&mu_ax&QP4FZwC>*+m6>0S8jLwC6(cc8RRcBy+cx zr8?SVgdd8!mCT|zl?gfUwzHxT0P&9i^;+lxp=ZmgvQmQYY7nGzrR0NsGDG!Ulha_N z1SAMxfZG?T#Sx#Su-UHEWK0(nB?#R9*7v*b_wRr244H>L4r}vjYiP|RwC4`L(DEh$ zMYN7F8FaryEtoygOd=#7r76lsHys}hoMkJ~_mQXUt78OVZB$a;s_q)ujeBe-N`QXD zyk%mE^r$DZO>(DKwdcG1E#Ls>MN`aZ3dZ{JLe7{UFCHC%-xC=~d_l36uH9hUb5@S(aejiC%P zs3^lO?bZGo+KxG^0{!S|Dq@aECq!MJPu&QHB3jXDgGd4uPM=~He9VNJS{8b{_{1r2 z#GbE$B9Zlgs(R;R8pEJoa+ggvXB52!X6c6$ehLzyOe1@3hcOFf>)*ntmSVfqcfPNKW<@(Tv3Q~`!1xV@sN?xR|o`tGWozS#N~ zELzZRwSMnzH_~YeYA`Md>+~=hUE1VT#Or_1NIjgkep5-I^ zOUPXm9@VF@7vD#gq?-kjs8W{4HjX)4W08k0xhV0yR}97XV<&oRRa&&7NjC z>gI^A_7!i7k~)=}vbeo+o(4)aiKY-MS@bZv{7=cav+AP2C3X>I?uG3Rh2_8rv;pq6uFbM%gP7MIxOe5B7zD-uP;o1M!0+r$9BXD;gT3me1cD$+e_;bebw%KUu1J z=9>b2Lpi6nCn%{UL5J457+p)0+NCjX4PP|`X?REB7hbO0iHhVodeFad_g3;t;PTb8 zdiA|^hLM#0HfZwh0<(x@ja$hiqE#i9%Ut7M5LIe01kG(ZAsFiUv5S|H4lnTZp5&`e zIFQMUv)kZ~w1NmsqW+y&J<7W4uSUUNt#}m&vj_fwnSTsH;~R&^F4MNUtV<5oXe*If zid{(3hW(M{EQo*n((aA`ZP%LVY|{MVL@1LJkfdEB<{m8yIoGSS(IsZtSCc|Xk3gy* zaKdw^^qLp*}e`fVM-o9ex`cO56DGb%je)|?;fUyMMefmqi>v^9D=GhJNR!-qFX{D&)s+2Wt+`_Xs+M|Wu=n}@nxq98|baJLdriDP;UNjrLgVuX!H(6(z=fs(0TA1_QzJCQ3D#jwQAJ?s7r<0(_`lNvbb!LTC1$nITL6M|Vw$sin3XmdS| z-gYc`UlPSv++cUpn(RzSMVnNjEbUUc4@Eqk)vxx3?(nXG5C4477*|$kc@cwfs@_>6 zA?Wif~^2EUF+WE{v%;;T9cd; zc-R6?HHgHAd(SYf%%^{~^Mg2>AQGT^eDPSZAqA>hI<>nLhD0bfA9D<_m5Y*rW+Y7m zK}MDbRH_T0YNqCxL(v|z_u}2J#5{bjj=v+3xUt zhV|(I+7^iNKOytZ$gR$9+2PKtIM#=&^8W3&YcN)78*(O{ferF)e9Jt;XpYD6iwqj!V#zM&~bB0jLio?!G zR9^??CKcY7=p#voY4XIu(eIPSk1?ow+49;{7Q>HkAIS)?YX<9*#maul5ysrUUeDQ; z=WMT+zowoQAdOKLoB0(Ut=dp(%b4XIe|VwZhhtyCkEQ9@#-(V^v+HaJoUqjM4y(2p zS%Qef0%a#6tUlY=-v&s(5V?ybu)N1B6DQM+XT&G{q@9@D3ufVrlJc6eGm3bPyhCc- z5Z$cNPncL$)s!YpC44{i(%ZMdY{_JmX%O3%azl)|Y1I?V6YzIyPycZl+iP0g#3hI%uui*JS+zAZ{rXtJF=BGI02-Xx# zP;?*q)9(kppHGl5;5<;9*W=dMt?Dl?kqIs@`)QXR$%Cv@hhFu+2QF)KVuIPyWD#wo zV*9)WvL61b8skvQfH-|GG$V}Q>rT6D_)8V3k3YtEpBIAEZ4OiQNt_Ozj|9ndY34j{ zoi~Vls>>fIWJ+&*TC+)MG{w*vmCa|wI+IsX*|aM4A@=V@N2ttTHQ0WC5bVN-P}+ z=^plFy~dv&5Jh0Q3e6{jbWh+(9AnnvAE_)kl;}t7L`WS9-#Gg>I}f(AP8T>3q!%{$ zI8^IYv$Ib?3zo1efpW;@EOdWN+*@osLhGm} z=}q_F6|$`_4$+4<8S z>RdR6H$*#`Dc8Yh@(=s0&besA!k3Mlcm!S?@z-K2$6}1IB(kB3=H8ntvkagAot|-5I}Fg z!{6NB!>%2dTP-?ULzw{VIj(FztfI4m1N=y5EgUB)((R2-H+PW5%J6_5tB^mz>>-(m zmnBanl$rp3$Yw8aG_E0c>a8Dc6CmL0MT#)v3BOb!Bq)7vHi^b)_etM_seNTJ_lFt* z!bvtii14Owhu<*@flWUcgVnBZ|N7Pix~N#|2VV{7cybZ&OW}Wsg$HY58Jzvj))m+v zlGE9bo-v(YUXee+Tb*Pi<6vI?`qm_ea+s0i?{r6;9w%%0ezcF{fN;aFdOQ#hRU7Ny zi3czy;9+)?de)?E@sqbrHFv{iZamHl=cD$8@wsHBAJfuZ!KJk68kLdsm2`1H2KFJw z?_x$r%Pa$^u#Lu)l=6;uq*Md$p?ptOSV(wgKe9N8lxD{g883#8s(ELI`k&$(K=X7- zW4rxb4gJ$UYcLyJW?=Gn%OA{h)`)1B+8nx#qe)ywBjg~X$*dkrI~-E64*d~7eo)8@ zM8<$JzBoxMSY8qfsW@+GtFqcE(}Bw5dz!2>a>!zfZ1meHFuIOd;zi~U&tNDtydJW8 zUNp@ueYa0)U^+^ip=S-e;PjrYT@$BHSx*T}~4Q){4MLll@Gp5Q7bvto^IjR~|njk~NXavzF=w{c2ft z<$0$`t;=C5vCIi-E=7!rH2>+zbMXb4s1N*(#}tU%xX9b9@mO#%Vc)yqtL|8tZq=7z zavw+IiWK=0wtJ*2F@~%C8?ABckNxcktDB6+eNBEkerLJkX}+siBXV)^UC>L7 z`menk&val`_N`WVVPteE^ok>93pghiE@~AMqm#1gt=vv>y&Wg^6Yvxy)frrs{N)* z!+RqahLeShdArWVhk4|DcPjcpxd%<7CMBGjf+!)fp6=@CqzbD>uHU%UP+T4AwXGy< z&*5IVY9e1Xu)TE_4{Z$Oxrgp)j+Lkp&v_j>1G~ViSv{2L)QnwqG^S$0Ugp{M-hyBd znUPd+;m_4Km&=5KCF>|bBk^2gW!5uOVG;8jWP41_vY7BhjqE$yV_S!UvJcc2Ipj6i z!VxDB#FX{>g2ISyU!h>8#u{!~oRCZW%`$6lqlB9#J0E0V}yI3sDlW#O}Z~ zP?9|6ZN*69zNOhXkS&^K%NyhCU6u5#V$lAxKaS%=YoSTa5il=n26UE4&dQvT z=3I{cCHxcd>|5_bYe)T|Q?U9X$7Xjmee0j|yxTqDu;JeZqm4E0wynpCw;SYV=H^%wOsAUQ-^M*^RsGKQ{^P#er%f7074CT7xZgftio=}XZkJd z_9CzVhp)~cel*Hk?Ol`~`DYZz5))_IxoD~=1!zk8ej^(*0~5keJL#@PIuLDEj2qk0LIx(^J8gm`IL zy@N#DS!bUZkH1eCCN^+0{{kdVG6T}};y(3~I_7X+qV+XB`eX(D!$3gkrJ7motb#(u zeP`R=aaMKGsEJ`fnZ;jS? zoYd`I*2pHmPIjt`&DJZCKI8Rg>1p;eX`li>K{?k z@0)X6Xy|$KDV;n&;Vrn5nea=yRsZPuJ8lBCq8V@%Cq%YDy*AN7lr?*(d~uk7UB=$# zM;jkGr%+R-1-0}l0gl9mhO2fDrausHSt5}lqc+!5X zLnd0;C0$3ypUv!JkDhF5X)l2-8W$+)Apn%tU|go!1NGncwuTG@wikHI5> zYfiQHC}k0(IQli^N%hhjA5B(f<}F;Cx@Y8y*d+r49IHSF0r9)+lMHDXk{k;a3$fts zJw?va8@aVawhFsscag4@lzaVzKgltunOLT7vW(0qpD2uVA<^Mgme)2k6^Bf{Pmpdc z&dAeb+!vtQ(PE{JbK(xJf3HjZN*TG;)C!}m+EzRJjkGfloMR_9X@;x0kNi1&O{2_b zA1Y0lnP+4Q&gV9kseJ0m((|DkL!ilQF~f)=#dF`drNq@(Q*}bYnrqXkg?$#=4U!cu z7wXc4G?pTN)4N3~`OIA`hFD23_dMJM*c5qb%~U%&v(1U42_A5GRSH5l)KF>+D%?0mtf%j<6GTq} zV{djyiEo@%VV6D6SRXRGK2@E@v258X7f5Il%HuQZaJAVumlZIJ7o8uIEgG0qMm4^{ zt%7zNJANN%b2g4NCNcf^AQRQrPQH>gH5)$E-3qTE!%4OJz#g3mPQ1{2D@aT6y+8?g z*)G=aV8W)zd9XJ4HuRW;g2d>PJ8Sg@5)b~8RV+%uRt8-a`&7isuG|!Q#BJ>c97Xf- zG)DHF@JcZcRj=F8C+Vbc7s)LeQGG{0yT+zLpky?vp{=0@F}m5YK{WfGY@ZdsiBZ6( z^F?=S>Ge1?kWswoN>AQ|!~^f+fG|GDf|KU$W7~m68K>_JG>*!b9m1>HE9O#-ICgk# zIw^j{V|uYJ_+;7j@mK$m&%ykP})m-|?l(zF~B!6$`={VJpmMi`X#CWIz zVfax8ZL)Dk9zh6J966pUe;%U)Q>_r=s)$#({haDkE~FX9yqj==`L7vW-DXM~YZyol zXjRjJ64hldC{pI!gzFn&#`?Jwb!9cW*c1#D*-rFXI6FG2GZIsr(jXTwb%7LA-HSysmjxJJSKbmeCybmk*{9)LncA268 z4F@XjOdfj($50}1c&NKz&AmETOKvsV$EDttJchx

wz4N=dj4Yp!nI39-o4I)gNU?>^cZOVA5|e_70`AS|aeo&SqcXvBRASo5hltOy{x~WN zmRYf{gW}n(Q#sR( z<0vCw-;=%-Mt>@bVP`HyfKO6ToI)35?`Gg8fAj+Sxq}9y8TybgBEZTOO2ck^5<~qC z^OA3T%9G}q+NrXpM?a}Ea|_+0XHF4nBqXZ5iwm;)6B|o8B|cT=+YVO863%Q}-&P7+}~JL2b}ARn2cl6EwVtWK> zT+BKoqR1wQ(u^ZAUd0{^TFdJA!;thb zEBEC^ZfTq$=DPJOLf=uyN`!+bX1N`7d%l(9Fg<>I`KjmKU~CH$YuShg>|kdNuQ+O`)nk^dDBu z(C`x{-_4P4{Ai3%L&u7JEeDX0yzMIZm{vFo2^VKrbYeVVsQ@OHe08QOJ@=(Lj;UHw zjtBj6=0}?gZ)|iwae{Ot;qD=QBDKF zDSnxWAGN;7J^f5viQV%<)-9DZBO>XkC=2q+$wXfyq3CY0x*C4c8L~#rc|m2wbi5+Z zty3(JX17yn?ALb%SfN7SSZW-Pf-6tu2i7EZzgQ6@8!HlGWD!9JuW2K04$h;R^b|OD zX3VVxA_IULmw+9C1w4+oPJWoFYh?LAQy%r}x7_6t{FzBr_6XVY0+@d`AOV85kdhEq zIyiHN>_U)tF59E86$M%Hfc}!RSjc$npJ^^E)#yFq@l!(PrN-) zmPS;+?aq4KS)zXC+4c}w`cdYI=o59AK~hJ7iHz2I7#Y3 zx)w~5dCsF88)Y-byxH$q$tKV*s{I}LPcvsr2TJs0w$iI8Gs>pdg4?Q-jY}v5*lnq1 zpWJ+8o->~gAVV6ZF5~o$6}H3zHILXk)==&u!*GWnyjt_`#1}3$-%Vmw*;hc7`^6ck zo#haBQD{7~>ZZUzYqUFVaZ;2n-#*RC;H70YW3ieE1cC`WoK(}9j}{#4TAbItQ0E8&WBk_&ozaJ#Hh6(OemV zQm()ab05kUL2bHh_WYLwOYBZG(Up9yz(Y>REOTNxL0+xgZP*KfenC#tLS;IUzh)1fx2Yu#B`@;_t@+ zi<%v=`v-e1ZHnSLIZIp+>Mmwgt;;~O`dy$}s`*;@WXMh615In}h(%)) zH8_&(weGl#_M&M0@j1XmEa<7&c7AAZ3euq{lStT8H6P48Jp22gxJaYbFQ^WDyxW_$&@i|_^&713%S+gZ^I(LP zUt|3~cec2b7QF2hD7>{K5EiVTTKzway?0PkPZTenga9D~OhS>+3=kmn-a$hTq4z4% zI|vBU6a$3bLhlG6AYGbBvCs)sKv0?rh=78MSg`x}zW07JzdwHO&F{?Ivv=?Aot-;( zX7`*udp@7Zxw^?~OB3QXOS>lyit=@>g*JvcJPWB6T68mR+J@gEViXs=PK^ZJ%F9v7 z%1(LtF*QLnpC(GOPzP52fZZc-eHzxHGA&8@DB?N#WyDnnJjFZT>ySFuv6b>9_tv** z=Qrg|oHt<@HU#;aj!&|d%$@c7fX5l{c!qTspbSAPmlfNxg^lg?n2dHRWOlF}st;XQ z=x*tdH$Oc&VVMbW6TNV|aCsWfMG8EWXz_{x3OFc=Ao#>XKy`?K#Ng?wysc*uvdLmj z5+4w{C?IuGWGOpNOZ-vCuoNf4@ghI85gFU3@u*c+4K;J)t4PngrkCWVMUxzpZ@bMO zXsYKF+STdb>Bome@bLNN3TP`0Bzn?&791oyQroYU?WXf4PGnY`=D&j5 zvg?={zLDR&H<;|O&_xUcE?j}W74*&ZtJZRpUMkYFHXJTl(Rx(ir<_jl&G2bfvo_h5 zIzV9sCMi}h)-uy0BcW;{>J16OisIy);>XZ_8h|fJy0w`#u34DY=4_^y(U<#Pq)uOE zL^grfH98iQf@yDsaL1wRf$$V(ErA~KeSh-8O@Dw!0^|(@QhMR3kqyMoR zAHgpN(9LM7X~|_%!|L7C@jDMLFCX6FLZh0a@IY=|A-|8F*>9rR_UEgK^qNwiP{7m03QEPCnX4MfAVQumk(Sj*zMm;kNTmfnJWU z={kaHWS&JHCxOrzIEN`p0gl_el8g2=Z>;DS4bM_)3O z<+qWzF&R+Qt8TenT7qe?gvyR#;I@RN{w`KHW1juKsx!y$mYyH<&V+3qENkFL$p@vK z7^>Mk%}c(8W|3|HkC}5=%K@p!nTYY;?dhd^&Pxc&pG!<2GQpNtmr=~ZXgKhcU2~!Y zk3CIZA7Mb-qY`bBDAD8Boh~LZ^e04RS7}#+bJ!l`E%$G;?oBICcMO_-FT`Kd>V3~L zC6HdPy|c91H1)1*Q4LY|%)5HJ_D+{r315guR}-o(Wx%7{0Wp6S%oX}QCGzo6tx99 zSrxVkPZ`*S<^|@)4Dt=_w5{ri26$ClC#v@-KIcypl=EJ*DFQ0(z_L!&%1IEPh`Omx zH}hPEH9~z#!S(Qlz@ynGw9V{A$0a;#HM>TB%KLe@c;nYTBA*e@mt`17gb+GDY?rV4 z!#BuY$oG)VsQd5q{jn5N7Q<2EI}Wndmqfz>eMc@YJ%d+aECX-bP67pfK=L~!4hs0L zvF=&q-5FZQat69q_42OQx;d_FY8s9u91^UGTF;rt@o%*dwhtI~xmv#y8I**(%aEAj zWzEH*3)P>~IvP=qZo8?ykQ98EsFG3To5CK3@cJF$2kHBbxjuU=a@;z1?{fE@3yDRl1>4;hLl5(V2a>r9AG8E`!6)g~+}AM}JEK~#{7_=7U*lJoj-ogH*V+u>a?c@q zf0s73oh8b3zL?A#M=|JKL-tT~#iulI;wHLH-BbP5v41q=E+jqx1t}iywF+HJ`VWZB;|O+ML4IgBdw# zsD20Qc_btCc*TXrDiLWDq*f9SHRp({sU5O&l3yLUjBkw%U?pGhF{$jPE~@>lDYxu3 zj4iw3q%QYrVkAAZ82L=XOacBuDAz*H1GR)M@4EH$y>}i1Gw{^9=)6(cub8Jw3WxLn z^1Cp33s%Ns}u!K4D?{iN%LK^LmX!N%neAg^BN)T-pdy zp~OGQ5u33&{G}KykTLvpAgH+{+GxJrz?zAH`ZcxYmg75k~M`m^^A=mC$&pO2ZaX_@S_ke8s z#}j@bc?pZiPIf>LjiUlL9{z-8nXL5T-JY*Nw9;R&@?w06d-pff?J=9IwYbHRGWef- zql;7vebOUIdd^Rw<+#GU{1i)aefit#6tM8KXy(3omk%VVj^Q)q#zUS~+q^vh8 zH;6`K1@~3G&8to1uGs=9iepc!)+=uYtR^WTLu+44aQd9kuuE&!&OLOZx1}cfjSVvO z0AVP$Xwx8OH3#enTwNhaG!D#uBTj0u_uxp^R*-VBfF(e* zYeNPPFx{W#Z5Jwh-iEC>AfhT@!O1^KbL`%7o>qssfIsmFZ3>T4B&bLBdWt9iMYg0D z37M8Z@K&x7oa$#B>`?V$dYm=o;s{d`FKAaWCmzi2mT{VWz{qzw&YH^MhyKJ#=&tm|b5-*T9MTW6A z5wGuCOUcSf=XizJpPz4RRP#~XK4F2#wugQx8S4Ite8S{iT9A@K*5vu&vGS0%+*4Ch z7r^pBkB-IQs^9}UYw~aQV+L!8i8%rxUM1n&>`u`VgH?!2|fk;7+Q-YnI)qd^rsz(W((^X3ta|0Wah$! zA8+M(na^T-d2_YNveXY?n^4}<7J#felF9Vf`3A9`fPf;=jdV58AF{&VY*ly6VJ2L# zZ6CbGJypat`vE0w7&n^CRz9!I-eED|3jbMxJeTtdj|#am6$wB1O-^NiY3*2YPC6)%*-XhK9AJ)leCvfo{6tYkQW?2>>{Rbncp z`d?V4v^NCi)LGGC(q{;x2nIo=od#MXld^XCPNAdNi=08^IENK%+5J2)d31Y`@is?S@)oqrKPyVTfE2e>LiziG}0mFVwwTo;Z2z2xWP+4C8`rubN zuaIyuQS+m7$H9;?i?KdBDGiKuy}MWTEI~YCnrnrlWyB;I$+v4M_>~9VmuK&L!9la6 zSGRo^{zoFx_X^TM?70-V@P$8guHJ`fEP_3l!T2DVZT$}SD4Jz4R!i2WeLyh^3sXz9 z2KxZZn*e9Rc(1vvyo`>e2X|J1(ll-r0xn|47By*<(jmPUJsWT`^LX6%6ODQ|5hu)aVK4pfi}}KPl9dI`y=Ut5cDhuyGHm6BXsJo0eqnDG6$EIqraroOhG|M9YYDEchsbO=cKn2&(NpFnN-a6h%8Qx?`!Gmzk)DYAbulwcn7d}Y~UHXl( zjx!RgFk?v|v|dFnG*dE%$CK=s?7V96#Ol{GCZLb`^sW08w)2M5 znVF}|xdED4f*xs4-|z4}pB;8+Eh_5AueovKKp%__gs29N#KC@G&_>y-Z>UA?d(-VB zwsPV-oJ}a+6NYN%+-Aj$4_Vq8)yQv{OYj}cA^cq@7_Z`}66KJBnYN@n`r!eNqz7dz zBm8^8?Y~NGpjgh%x60PGQJiG%C&hDYJ5?gWyrFP-ik+frFH&qjbH0p?CjH&mLsWs0IAh-JLL_|jTi~s1&{5f(X z@s&)tg1e{BG#4PBYpPRe7h33Lc-%sgDMu#JIs@|kZC@KjlxjhmhE@ek$d`-ex`HAp z8wDi-H=FoB8s)gkeJldp+h{H1@Ssh8GVuThmMO0gjF=TfhAV9t+S|8KQPakWFEUHT zBItk)CQ+Sv{~$MhK^zO4^YV;}i1hu1RwpT{`D*o%v-f=8>%>|)aO@I?_SoOQRh|k4 zl+z{}%0iom`8KT1om=Pe)}n=t^ZrTpl)FlU?i!@+aMk5Bs~)^Hs_~2nyv_*Z+jNfz zZ9RY3@15fu(xfofZ8vxvAbgh{$2}Z&kOU(UW=Q3#ilLdsqSaHaIEF-<=Kcf!l$Q!> zH*G5|68F4n%r5CSM#b)Hv z2T%>(RexoOjy#Vvk*B^e7SG=u`QB6bqA`qESs^dd&mOMxt+KOjQpZu-fJuYiSPftG zDZ=`pxTM^&fei3g$z}9;{gdw#C8iYXRl_8m}|n z%Y}A%i@qhlmqJd5zE2{U&vh(tcA9eVYCc!}NFwd_%xuGs#xbFjkk^pt!V2RI3xbmu zxmd!gwE zKGv?mkNG-_82p`r`s70~?rs44or!SO`h>~>nTtZVba{)J?wvWp_u2vp!?Qeq1ol52 zzh#6TO~tQ^3vsUriPQe&s-luqAu->dR&VNqvBX^F3ey{f((2jDn(4aH2`yA)aMH;$>P1amHwjmauLN zTkw-Cjw0bgWUpYbXb-@6`3_ zVm9+eNERkq3weL~s|m?qDJ|3Bh9PyW%YZjacp8L2n?{JFCD^K;L7+vHh+bBMwhnJ8 zfJFxjb55UYT^wA|=$4)onIZ@|5FK znF9|xMA!Wvcj8MDr#GkBflmHr;!WI7#77_kP&6C(4-{RXaj?1FM50raFI ztT%aoT+=ZcO*_kaEq%oz4>8qA<@X-Ngo-45X64qYAFeKntajftg3I|Va2f66ukit; z9C9^IybP3WlCnJxs-4c|P4lrNa?!aZF6Tps-MKUUH!K-sCch_@VLF+eA@mGITb9r+ zkuey3y%#sZz>sY`t4`o%K{(*^guF!R;@3d0^?mJ7`Ac+N0=?x40svZ#o>i1 zbwM&&*XUo^FIHcxp~Mz-^B=yQxE6C?)%0}mWl#b03<%9rAWp*OOpdq15c zTPs<8DBxw?TD4eWl)~c=s<938{g2l5Ee1Aqnn`-(Ivn5E$*#fdR6SeIYwHDzD!%Kr z&JK6KtrSW5q|qIG-xXtoX80$W6gOx!bu21w{;SI^D=T*f9goer3)wN&R$t;qv(NJ; zFPR%~kr!V3mGnCl0YlvcMm+T2C%1O@tx#L3JR%kF3UTwT62es`FeS-IoGhz0uOo$sotUY%f4 zu5_cBlxPG$(kJpQR(p}~yA{~nXR?Gv`a!q`N8ok!!+h5uy(UX+fHEjH!s#{oz$f+U z(-#>MMF%NxI*jcp@o$GGtGoc_Bf#K8TiacmV7K4&*%5X&fVPWv()TKzRhhw&qh-2i z>)R@-;yu}nJv+g|TOx!LAdQ`7hAK(Y1-$s`cnzT6jpM6UBC6szg&UbGShc9))IPxG z&ttQ;<~Ki+Zcvkq*mF0hy&5D~FSIlDHR9&qj0Og|Tw!XF*kSj~&B9wyoE&`&aTOj8 zeF6K5d?L-?&NixBdrkvplh%KWqQR2(SS zllAyH_F>}!w*`l6PJYmF@8VFIgOJYaMmztnd1{F@vuh@6p~OqnEStGMJ8oi0K_4&I zbj$wjR$O{9gvzg{8rToDLPl8rO7`d&h6D_l7#`n$d*%7QN&uX%u(&y0r6Sz*wa3(Y z(s6#*+sxOQVk1W`Fy0SaLL77DNhRaS`?tg98I@8@xItFWis~iw#T=wqJ{$kuwFePR z=SzCR>Cx4Zaq(*RWMVMxx+o*PeA%zIjt_ks3%|EryqbNJSt!a{;6-Kx4eYkSK>ozP zR_#b)kRb+Y6pgZjjQ|djPnH$I@%n|<>3?G)5J&+!b+o0G*Ul=EJ$d5g`b+um`7Sb~ z&juj>e?F0uA}d>Y4o@r7&7AJx`*pXu1p)+HzuBZ9m(92WzJBeKPtX>&DyG=HTv)qQ zUUK@HIpKRgc;vQA_er~G$V||(*HP~qL3e|Owh-l=aaa1D-AqxYW2>t#{V`T=(z(P7 zZ_zQWTsAm>l2V;`NbmBOwVED0Ec$@3DIM}~p4}U(Al2Px(97fr;^}GK;zFw*U0-e- zNtF{b8n|CRZxvl1VBI>*>WO!Ik(6$*eTP9i;ly8Z+vj)hJ~S5J9&-)!t76n^SA6$f zM$L2|^v9*894-R)ZoLqQmjA*Dc;C z8jpU@KJ8@>2m$8{|7t>&oA{dOIoSPB}y&uVtiMiTcdeF6yOwOpy zyYO$^Z{`B~p}0Z>k^WsKkCSjDDp`Ju?Zw{M3+hJ>&ZZXeN7e9}7gua&SY5lg(h$G{ zNHh-^kE7hH7HWGgY!5Q=Qx=S7-4>vF2}OJSF>4VEj2>*v<0SCy$y8Uhx;C-3ci2p z=x$^SrE-SVLIpI#xlyel2s-T3OnyIwKBP%53*F3{WN(p6H7pCqA0Sj!OZ9XHykYdt zFGx^*gYtLE?>fz$8NJa6CEX8y?|DruC1kJ)-7s)GkiO5~mDVY3NpJf@A5vP6=;W4+ zLoPPGNwA{gV?-yiWHNa`X}Tl z1!5mft)UM2JtAoW=0-yI{(L*HrTWcew#IDQo6KR*arvFN`iPkxdfsBBBmCr~QBVWY z%<|(_0#fCs?$!Ku3|UsOb-Ez|S+PfVbA1LRiy2>an-y9@Rkq=Xaoe&xn~Q!&Tmn%ZPF z0YR3RU+v2B9|g<@32vmA@WPDi$l(wpc&MB-Z3qnj@X*AhbKV$G5=z;*y+;55v|G^4 z!!y9}AVecVv$r={q8`)HA~wV4{_QlX<|X65BEO(O%zG9iz@K%@sDGJ*tmL3N004Gl zE9NL{%W?#mz|XS40rb+k`X8lt=465yH~Yf3xpD7(+Ii6kskTK^pGx3QuO> z-PO7(`?g}%x}4myIaow$KOk`W=})`3g|?YN8;sQ8y@_<-5p_K8DSgALV~Y;|*m%cg z?Td+Tnk3Sw+Q?GD#l`!XOX{ZevV|p>65`@j-w^OcE^EeFtnwLk079+jW1e?RX1~9U zLB-CBIQtZ_OZapGNvJeZh(xGl#s5Le^i>&LE0`|^#F!+yN> z-4}CA`8IQbG3{q5fU5NkaoAY40h?)hpV1eALB}R`zU*QugXg6 zGJi^bO%@iW5Aok^t+mMz|I|mnw5*jNXXTW%E7jekUqCC=wG$$?n51#*)H?Ct&wiEQ z_XrlL0mPlFiCjdJLtY&14J<|4xSdi}2@T))RH zt64+8VTLiy*)w|Y^prxwoRP1GM@VLwtVuNWc#gyeq^7d6Z%Vq|6iEN1dagW+f8CMb zrR?VAMbCY=RV@c!R`hz-e64u1kUg9-=1EzgrO^~GQ13ltrfor6x$Va`8oif$%yQ^T zY|C~ADgu8B+(|_galUqTsnuRCswj;Tynxsumobm()U&14Imy&|bBLm;UVH*S9Pv*q zk?Jgrj8x{9yHoZ0ZgS$*eA;H|iqh;?&*x_w58Q7 zM)(vh`daekl6UwME?#uVyhEd1AaA=%&M z%Mg!ciwDYz<|L>1EeO%S(j4UKYEP!L6(}~sX=Ok|krXpH2Gq@$>TG?xyz-(=AeNOm z6^kv8UF~|zpr}~TV45H_pw0A+pxr3R z&GiP1PO*{N#AYr?(4=vQHbop8w>eTRXq+pGDUi>g4$Jx$u{I zZBy?MO&XtMLR>1(c>a$mHmb9;f0>5F?+s{#)d#y-e zxj)IifOD5_r*Rmi8I4KnFH9gjuc&;cxyGde69FsD=kjv!nX89^Dk#I|afu zg^znez1`A0R-IbS&Y0p&ZH7IFv9A=*usI~6V3 zQC+Lk!i*dO!o`DvHY^&Xo2?vnR_;%0rWqTQFF^tyO>MsTglP!fxj_wX^g{L?^eve& z>C|bzGQQ?sE6YDuG*VDVLIT-aE20=?vt|;7HJ>LU?@NTNa{DW6CQeE(pqpz(&firn zBk#)@#bYZq@ zOJlgP?Ux0Qx~y_BeXxqYtaoZ$zw4;bFLPah1TEPOG}=na({!_F*;!f~U@4=%NM%sb1KDu0=TkFF zWPl;^h`9eiRsisoQa3+jmD@6m#H|!F{~9>G*10|mfAnZ-240wyVxZG!7pGj7Yl~J zJ6$r3!Zr>V#EneDOBw!l+)Q*s%OFyXVoitfKcr`Eg+DYJsJo}z95RUBb=M&cgz-GP zqH6Wp0l|+%sbuTb&2qCCm@3FDhyOrY+%bvF|ATAQK;TpZvh`CwFoRPkoA%a-3L9D3 zaNe5bI>xpQiX3x>Uq^vuxuEFUSAwVFdYi}R&hkx9xhzqh_yjv9!vyq~**b&Fqbq(-|!Z>wW^ntWm$#FO3{M9)2;-D` zN|ut%ya!Y`FW;ryb^RbPu@UYM{rG5#Es%jHw2d zwUu`kk_NGF4ojF-G3&`b`aMx#SKc!`47fu`2M8HywAnZBA9L(%#Jm1}V}Sm|pEaH& zP(71vmI)3a4t+|pD?jrpEV}7W#%`&5p!49#@HzoFMNZMf_h&w`E1)-6-P(A5L5v@c z%m#ACg=eLP zR=y)LBh^(q*Nh6t#?zhrzj8_ExYmXvsZQqN2I4A0#}h~0VjcsBQWbI1S6WMy6t4Hb zDwc^o=OM8wQ>K4D~&C6kepEAO`nu2esD`GpeA@G@%9eE zM&m0hokd>1;r9-k@lQn>KQ0ZHK1GkZD@`*^zeU;Y6T-FlcOpFDO)@4%A33Z`rzvxSVC$ntbIf$~Z?oP#p`V<%-VLE; z(I2)n=v=lnlKbeXc{4G!o?unxSs0ipR9kJF&1h&*Wd#-HGdJm;rC8ovIWS!b^Jb#W z%{t9OpPT;spdYPX_0j=-yV)o0vcUCN$r}Js58IA>S6c*{GMizdRz0ZV;h_ZsC;gj| zF#^K9RP_`hFAzBQ`5KLKA2=L2P&tOr4Oa!9*qvi zUQe&O8;iN*e_7>Y2Zd|DXMPltabGtal5v;l!_MvcWwf>j5}r0Qmc-l;@2Ij1_3)1spPG%a~dTeb30?&n7-wey^(FvQzjH*h65bGXT^j?YGX(X$m7Fnn1YdSfh zbc9MD`iPb`b}IV;PakU<(W>6|j?u5|ITeRTpB~i>ghlu+B$zSxiZyg?Qh~DgaJdE% z*$73Y1$PDiCAd~T36v}5WEY=uM?{acWmIVddPz;9urOM=;1M-KI<*+9Z?gQJ zO8;XO-RG_=^d;c~t2Rw_a;gk6e&b1VQsUyEEjq(BK8;y~wADh~bzy5@FXm?qL;M9> zu>lq@2x~bNz$N{wET}7q936PUsfR^zz9M(X4vKZyXhtRco?d1CoX@{LY?6Ei1qBmA z_%=VeU}?Rs{14l9ekm0Ytam|qa;WDGx;o$3`W6oJzB5scaH9r#N2Ay)2{B{ck1y3L z7|L*H?sxT(-K8_R>>nnbaJ{w3Zm`-~pe~a$o$9zWF}NZ1tXu6-pOj>qZ2-M0$xl>J zDm1LUp(#AZtJ?tN#%O9tcZ`~tJ{aEret7^TF zEV!`Ed3C$5WqbU41u)-s*o^w>oPH-v;H6Q5DR51Z(Z7eM$;$J^TQ+h3%NOK!oKW>r z$P&yfXL>r_;GBXhc!uMd=xwt%f_6L69X+~EKZ>?fY%f@?f%`CVr5|ht6n}zaR8Kkm zw=UzH6%!xE-!o+CEg}4fWFCRW(KEo+;PD;dvps5tSjjqt2JTOF#Dwk3_yX`&+Aw3X zr#6rXkY(s6o~^kI(`RZ3@zJ_Q*8ieDP=p3TWxeqp#vYY6+q#DcI~z*Zw`~6|*pm&F;82savw+g%hJ>Do}N2!YNUKoRVuITK&YNDJa{Hi^ZAJHi4T*h zjL+2=pkC0hi8w{Y;3r)NHBWW}+`Do~*&uXD$!6c<`9pN{k*0tJiZJ_Tz`o6IiJ&6?t6QYSt1Ke~G?!7+>Y( zBC>*zQ2q0-6^6xtwvbLqRgQJcHWJ<}?k&dizHwLPu3Va`$B#h+`19Gp8>4A;YH~M` z4p2W6-CUYW$L?Excgs%UtooUtrCB|G$3GjX?vS57r!%isFk%3%2M(8}#n#zZVG_0( zmpdF=KNtDOjW5!VRGU*De7hr{cs%yhB2mdz?x25J+e(zcl54QXFR2(d1jU~eJ-M*) zS@ToA6*kxJTT-C3I1&QIXmoAQq%wk{lewHC3gXt}Ahi?L65 z|B#<+_6dmNN!NJ-te`PjCH6KhmgDCNBGM=fOpm-H`ysY;z?n2#0$1#_Y6>)ILCzvh zY^I}t^W50H+JyV}igv@0`T`+f-QI`%a~~aYhkL>5<5s`|bU?mM4NWvPXX53C-9%PI z>vNhdhYH`zvj7BR(gKrRz7IOo^B^F_o%WDVjuyu#X}EmX*(HT{TtX|vIy5gbXqtIB z{|9#J{EHYp1i!5KSoj?7oW2T^2QgP&%Z za@~5_i14Go$R&a6&QYGNdrbQ4;h z0ra?Vu)r3ZSg)7bB7IlldyrcO@-Hn9`H^WckK%FMn^KPZl+loT>d>-@2YPM7v&WSn z9P5xb^^;O|Ct`rJBNBe?GGbE&NJ05)iPs5g`ao-$#BBHb2|(li-@>mI>eB-i3cVh3 z>zY{u=daz2c*+9$;_h_8^%kh!$vo5ycJ~1%ie-B&_d>O+W|(;*lt#9r58$k#jmo`T z9#o&H502`(k+`$mnBEa$>h?RlHKT8)Wg$`Z$HK9Ylf{S_sQyu1Lv+*C?1eak2kTWS zNCWJF%U^MqLJhB_r?@wj6|qEanpKU&N{{>Dy|$sX?mee@^b;R)iXdVpP5Mucse8n= z1>Tru`5SJITubVOt++6*ORApGE6cRffyea^#J+qusk@clLW77h7wMYoWG~6OllPlP zPFY-zG+VLM(mISg8kz8;m|`iWDm(yz=(|KZs?zy}fvjM& zAPWTgzHlUr#7+l>0rbx1Uu#(y7XaXP220<&kymAmqZ2V6B1GuPJzIG1K8F31w{=<* zz>X->4XS8NLzbh^r%q%VF5HIXHcTWE0Zh{aHfeh-K&&7}4-J`}1%Y9x(*Nf6vkNvK ztljvZ%Y{3u{4b#coQ?JWEuhWULx3S!HxNt*UaEX{=}tQ}$N0hlO3SN2rd{1}5zlDM?#5hve?2#>VP2Yvzqa`1P@RWvgIa!OJ! zs#oVFz+)kNVE#l#o?~3tv}kzH$u5B; z5az$Qtve8f#Ga@UENh6vexIl`ir&fADIwF0L#QkLE@EZfBr|?c@ijg}A7N?!AV6ve zSF|X>li0YG^crq}eQhv@N~;~w-uj{>F2y~73HS9Hz|3G5+3$i{-8$-YEqg3kh4ydf zy84@Pdg>)Zn=Y<^f$A1VWL=@0?MagDAxSwn>p_ zc0YPIW6CBcyAre%u4?C&V1R_BD6)GAz8?x@J%C|_vL+Om2gmE4W(^otu)AKV6{$p~ zbKB+akjn)avQ)=V5aBxJ5m!xdVR41fA}lh6a_vE5zWcF{!Xh)n-)OX=A3r_CG9*)U zvXry46j^vqkswfV+~VkOsz2Kk^yAY?G!{8AMN7-3?=v_ss0!o?_-82d2kK#t@S~uM z`cx+CR>TW;QhWs9hN zrTZ0WN1y0etX(HK0PG+WF!Gb^KG+@3t7526Oa@thbL78WdDfulB$tAIS#hT=RMvr% zXvl7v=2AOZ%Z}r%65NGnaaZ>&4Q1NOM;78;eLWSj`(x zO~2Eg84GmorY!oaHVrPp@2@F%Sv^Xs<2%2aKk}FztOP7P3H{MhJxm<*1109W=tCt~o2K0iY0%u~NrZ6S)ez!0%?a9bFk9VwO3CML*= zyAP%tEWdKUKLlXYTv%9kVQ-V)!mE^0DObF9F;meC7J9W3(V1O9OsbjY^r(;drZro^ zThQN4n5b#=a-}uH!f?_ptL5gi&+{Ji+HiX7FJFf@SiG1C)@%1xt0Ic7 ze)SJsnP7kI)yX{8HBm=FRD3oLdswm=`?cUvp4CMP1$CaMPAEk@Bg{Z;>R9lQ{)LrD zFIUYHM?sR>t@Xt0;}jjEEhQ-?++e!9t=dmoJZA@#V%LY#Yw_885zKKG5IR&62BK_2 z+kGs{70Brce;;`8+UZe6&3&2QBwSW`x@&c=P(RKa1T_Sp$ft541_8iM^LzJRw5?#~ zzUcK2lmLq}?^>+JjHcC`_lG4oY`a*al8!o`CyVRGdsraq-H{49+AShNJZ4;FXvMJ_ zCBW*r$$^ChY!Ym~pK(2PDjB9(#?xKwL8p|p>-`eS>6mahLb8fDl5LO2K!A&Hbw;B8 z#h6~6XTkeZKYyFM!lF6Bo^AWXx{H!^ma-pVITJ0e%Td(smiVxK#^w7px<>VIe~ccd z4#Th`+j&DZb>bNQ-5Z2vqB0}k2z3pgyFi!E|1@d0! z<$$1Hf-Q}VOA6lDkGmGS9xYq4`jffvC?;n_33`wX}oyX^e7LouNnTz{)_-vUO(q}hbv^uFK*2q_f7G5*y26C(imE{BR zuRkRsQ}<4V?Y0?`m-^6#CWzRuFx!j2{7A9MTQWXvj^jEUBBf(- zZnJ2cfmvjU5Zxf*YV2=lJ+PYrKvCT0WFFPnE9pc0xQVTL@Ir3%;?Ads1uQz~FVyA| z=@X_0g@@CMs0_=Y zD~heQ-dkMK9b68N>P7nZcDhH}WXmNyH(xQehn5uF+v$Qd*jx=-M^JP9C6YQA$ETjh%tG_5tW2{+Gf# z_qiGkc{eUKdYBT5vG1>Ii<5PMG^1vuQrRtb*%f%zr|z+LY1e~3WKVDHDw5y+hR!IR z6zAuUo^fSg4*?sE{!GBHv6t&Xn@A}JQ-@bU#>G!Ehm2@D+<}wtk1YZFE>=-nTd2Zt z1)d8WW_W0XnnrmQ-#LXcQ4B1}YM=waJgyL@|kB=f@Gy=8{?KK0DM8?ZT}a_V)I3u z>x9{8$2g;3&nkrD^>ok~g{Z1FZ2)jMX~^}SE83~GFi?Dq!D+E%Yv-sXQ zI@IeO`Ur8*=kW%_b`aDHimRa(llM3w*?2Ey`*P&nJN02kz}m{8w5;!?i*KGsh%m62 z4vHMezDss`W@c+qT!~PemF3kp!DawlPC{$nQ!K5=6q8NvC3>~_gAef{ zP9L;n>T!3jgW^w&@buQ3u#drx-teB>`pnkWpwE}n`56J}W*<3|uq$;D%~q_an$czf ziRGonBV7{)x6df<=3xIT!nX`JWp}*u$Q_36XVDkI8h(nL0gA3vrLEO1*Xp`4)o09B zNALKlox!aTif4u!so788#*bZ`8vwA3qp+I7UuZLxin`T|pg_%YQ%L|sc^)B8jck23 zvz2QWBwexK2%`NfgZHp{)KySzd@vJ)${hx*X zzXkpO-25L)g+N&#mmmNj?B)R{{U3Y%*8rp&I@8aRozb-!oL6x*nMTNl*`J{HY0?%> zj6C@%j~gifF-fLFBxHcvgwgtjvYp|eHcSXwWRz{#vr?siJEzCl-k)uOm7d>t|5X(g zX+cQR2943dtU#S0R%fxrS|k0&JFK2t$8dFsmpC1lMJ(nLKgTXNfohA#fWa zGlJwHiKPapEsHlkfBa4%w_X?$9RJ|mPM(DK8xNt|&XLkQ~-#1n_ z3u2P&5)3!a&+`Do&!1>uF$UEh72GJOe_BTlkbSLdkwD5hmP<8A?K1UTN2I=2e*saqzWp@jgV3Bm0G0R_a?eX6^{iGL~ zU%otdd@<`lumWbMzy;_sQ6UTD1Q1LPj`u;447hamrG>dk$N+)V6q0sc^2HCw%K`?H z@-VDFtTv5znVvq2)3V%NXX=+FVa6$i4XShp2&$d^S}vn{+ivTnabvYlv2IhU&^Jfr zC$9TBX$?q)F|&ZNJJO_sfQX2o0YdLhs!A6S=?GZqQWX$T6zM2f5D*cpC--yq zdEdRyZ$JB#`EXscW@hEnS}SwS{AUe|{UZ;7OMI*Nk3aEbML9iEl5S4@9phx~7Y5BX zvr3XdlV8B4`DRjf0-9km7oX}CQ!1g;aet>Sq(2-^nO?4hYTvD^?XWL{lEA`kqL)+I zype+K$Nkp~TWGo@g8}UBk>FenWmMG~Wo}Wdf#ly9E;bfO4R&j9s(d*U;@A29m43Ob zp`ZK^qsFXEN@l}Vv7U=uac1r9qigen$>Nu@QNwaE-ucPwbjOI zYZYg(HDyUL<1z=2frHrYb)4^IV=1$cR{?D>b}q%JzuFE0f@c z2l~mIgpWf3xt&W7zrhe@D{sF$Jh<_;wSJLhU+D;$$fV!TcPGQT;@skv_LWd-+G&s1 znH~}%w!joV;%v6=%`*#mU|Zc$H{)`H%RK136Ya{Dh6^~apJ)T~&>+F^i&!iIl~Th0>G>(c8YAS|&V46>_H>&2_N7nQ6tWg2tv*C? z1>3d!SH$%`Ih5OiEXgEYk<7_x^!3f7Oy5tHH0ccJbc=GGl)n1U@altcms`}}DJK0# znnLGD7GAb78V<&P@S&`=DJcEZ+YahOY&U2LX#u-#6&xHFRntsrbw7M9srd$A)P9D@ zbd8&%`YiT74NuIK@3TZdXnop!QC{&PDr5RKy@0P*wm$A_U~gwb{qsAibzI---ipQD z3APyLcK-2s&L#sMWPRt#Z;)}r9wkeBh^xn>t$5Y8V9stzs{VLRkYU#(i}d&IA`g5H z+);u^d-DhkqF;_G zd@qO}L66C^_>B`Ksm;LH9C|1Sz*^*Cd6bk;u7+67G)emY^`e{qW3`-QGq1qzy%&=^ z^KlQ9K!_?#E*e0EZ7>JWTNN@jq}6Pap&(#p*ExtgfXEz{JB_waV6}C=<6b8mk>V6Xq|NFex%zL$-Xnd|?-Q9&6X9PsZ#rb8-@HIBE(*02UhYE3E4nSS@0MtVN?${~Dgp64;eh)>k=r+pI9 z3L;}D{_u}{7n0kg1(H;-RMA>_#Qdt?ma4xj46RAL(~w(}^642&|Hg1Uy%_{5H(${# z(x)QjKJD_K+Fr7xBlVS)*DGSH%+1>#lhtYMicSiWGj1gJkn&zx7G6b2VBeOfuVUF{ zz}qL;NR^I6ajkM@skWF_Hy5M?_SJ%5vE1Nuih}pa7x2ZXcfM()ciE3BB?T0qC69Le zRdbECu=q6Y$%479W+Sykgqz)IP=>Cm4*p3vzP@Uhde&Dw+bPyBxwGaT+c%TOU@J_1 z^)02)86OT8UYoUZ7Y+HjN+Z@H9(Ecf9Pp7Qds&^;xKb4|Zp_O**47dX`+fKgMa-zP z{vgA+d~)?>rQeBra_h&7s!PeM;npSt1Yg2+h3>9$`K*}quW$3186OvfcWn~o)sOw! zCx843LLJDpjWhILPBNAJurHp9H~f&d4|!=*=?vU{>-ENXX8UV@a6;%xgqzn-#qUpz zdSmi=3oH1lo(3unW?9wkI06n=*NtaZh$by7Vwe3@41ru*SFCxpogFNwTchaDrLAeX z8!85`Y!u;}JW3sY>DuOMC}gdPUalm6^&Gnc$9*1Gp_P;;8Mn49`1Esl#aWR{aJ8{t zC8U_~jJs$Zk@V+3kOOXO2jCnr@Y~~f--q>kr9mcf>;p!fdao4? zDEB=D+>vkY1G|@B`-pg#IE$sY^XK%9*W~7D-h5{?g(Ma>8J{z)8_}1I)|LMmtWh4K zQXBbMym3Ju(Phy5n#R*ux3syqs(t5b3OI(~VUDg{-kLk9yPWGK^tGCjfSWJ1oak8= zH&rYNtcW93U>m;fb$(+H6Z(C>AJ)c+ddNC(TFWuG7Fkc`Ysa-|@L7pUWwuG}HM8*% zl5uX@Wd!CJ1y0*h1p*b>zo2V$1#t6-Ym2 z{u@$D;jh1>=*jFp*+=-tq>n%^f2PN$LH~{IKOzaycr@Jt9df{fffE0b{Qo4l0~7*? z%iHVwALolx0ln`)Na|`-vaSg_2{{(tkoIO%Is~oeE(PL=S3U*TE9J#*Vgc<@Cp5OS z`jrvTj~L62SDOS%BK9LQuNecS+SZU6JgCbV&S|a!WUGgwVNm8+l=|3{?D?LT@vtai zP-xQo0fw2s@5hF)FO6@GF7gkds|E+m^%Eo=L|e3fMimGhrlkisJx9%Sy))ErZ7y>7 z>0U;*j&gADuhpy?&&nEI$E3+Y@KspOj``Wzq}w%3yET72&lpC4GBAU5Q+m#AUOtdC7utTu{ZZ7&EafHLmDbQzxe=|Ib=T zm6Wzs;_133Mq`$Ux|#=F{S0WL7>+DQ8^F)_cBH9}v+AbEG4U&ZDHt&D%CKZ5jGS8G z(UgAH=@32AJs$XFId85rx5`yf>81J6Ui@_Y8B=o@xUB#aeSJc_3C+Cxt6~j7x z%%X&odkPL7-7ih)Zhv%rU61s7r?IfWu7ZenNEX-(tM)uk@UblPvge7ND1Tz2a^Jc6 zH*Wy*DLbBLfg(QO61lYQ8 zXjF|49*wS?{q z^0gIPH9_ys_dfpiM9T{PuINS}cx2V~bN>=vwLM+z|Fm@d=*h<)uFOAYZ)aJynmDR0Le+{DWKG6~ z+Lu4cTmPiZv|#n88dHt&``*%Z(_lrUVpvb@Hu(B=cnUvn&0c! zORty{Zm#U?ABgF0ztXCN)ks^U-pH>l5PD)wY^lC=r#fsp za|LYkjTp*U*0hrujs?a)7uYuEa^~AYw5WGnhD37hr#wnFZxNbhX}tW)whN`kX5KE1 zbyuAq`EE#!=$QxB%q5erjPl@b+wV=f%N+}Y{^GBCq$uu&M+Z3U?_||XUoQs{+yTJ& zf3kF-E(jQngmNJ&B}(Y0Gbpm)$HKPSNxVe8-R&3=oSxq2XJDcm9~{VF|1dwQCq>CJ zoQzDQfUxwC02BQOs6Zss6#;A`oC1(n`zN%JDPRM+^&|lH)X=bm8y+W=lN)@#j3YfL zZG#6CxEIaD!ugq?=5Lnepgd8T3Ebe}pt{H}H;Dn5JvI~aFX>Z{rlFe&7od++B0;(k zH9_pxw>c*4y82IF-RP02j39#PcN&X}wB=<8F|-D!u8Rz5Laz z!D*fE7+BgM?iqVrLcPwP<*Nn!Q+hQ#;>YZ72jp;nX#$Zq6#0y^l_d+R5+S%5|5835{>VVyq&8Q!)#1CL8R_#Dk1TkYKvOM{hZ%(c36Co}V;)$ABISg4=z z!$Xw#v9JCdO6}L!?}@%f@GPGI1F2#(UNVN zfWbNU1E;&Yb>%lLr!*EK`!^ZLWl8zboAzKN+KU6RJ1gq#scz0JjM0WLdMz<}d;gWa zT~j~5*`s5z`fz+PVM1Z<0;s*}sz>#c%K+Ymw%_0Tto1pWsof48Sg-O|Pm?Y_(-(iC zYP%TR8^-2w*Vt&%P2%eN^8Vm!Hx}(D)7hK7DQ&R3pFhi<$$H2tS-14oaAdTylE8VuBjvE79X0EO^iY+fMEy2G*&#o=N z&8=rsVUQ*xS}A5Bz-IKHfvX1Y&{?hgObz%ErrCPrObQ+vGtK?qL{%L{C#(blXXhXK0%?NwOI>8YpJs}CDW6q8yGu4qbhRhm+Q*W6*lhc{2eIwmVD2rW zj6T8$DlV7q+VodI$Oc4usSuP3K-)Cl;ZEl_ni@s4!_fu-;p~O1n+O!$-STGbN6VGwZp#SUm-;e129T*bzj~>DN@2%(>5crcH{Y1$U zv|S}2Y|SqfnZ$I_^|nEvU11i(OPbvzHj{=wjay|fxl&8US+&`lphX1=%_ z>yPOWjFIS|k?OUc90#~YOXj{DrcQbzpB0K36qGZ}sQ&!EG&RO{vUQVX3T7TL?WCxA zbT{zjr%h{i0|T@00aq(8tO&E5%?-t^q)L!xJYN9Un=y#R2gjY3WH}Fwfe{vRO_f!D zYLZ-09S*2iQDkjB&I3p^l&rqL61#B!x`Jn;6xXe(vtyQz@|ATy#>OvE8BTTBMPpP0 zxzCWRX7J5O<&4XrlF>`Ps3DxHXYxV0o-m3AAnc_ipfgm@m)mI);+PQ-JQ*H`N`#W0 zGX^j&74GHB6n8=e(Yku9WWF`HXCgE%l=vmVN@FL`s3rUco;ZnhZ}XB%$^H z_MJ7TBF(ha&~Dy!Xw4@ocPZi;eABzi*$IIg#+q{nFE8WO)D`C#jb=|-(O8F*00=M$ z-k+kYN0`XJ$$xysptzngDRbE$uj^Z?_|l2z+H!?B^J)iaL{abfww>y&&8B>O0 zsWRM0u;5}Y-mh5zHK0e2M3&O_y0_ZaFgav?1lR+LK%~o*7uJ@iaj7M<3rgFoX<%V6 z^eC2nwdk(xgtMJ24mTjr68Qa{Pfcp;CdQlJ0&Oa%P)t@9^RVdU{$pB`PN>vN^wj@Y zvc(Zw$sxeb#m8D$Er8Bdz(VpG73DJUp*f>wzgUeTxnG;P5lW^ahHwr(NRg!0m?B0s z3BJhJbN4V#KI`!<4{MPx_02YN7vl6kp2LIWn_?hDV?D|%l0BM6{-vI!Yvf0t-G?{^Wplo7I#HtXO{~f z0TMvD)310-mOHmjEcjM@h?B?(&BKrtFXV+h7F1MBRkC@QKrXa;X-V?B7BaWRI$$&! zbR02ckK}6_8e<{M9$9m;@t5$1x0}T(yz_ulswy1g*sht6tTnJZ+eE=Q>A{r z8GSQ^-srkUza*zREicXyK(q~HN@Z$#S^IWZ=s8tXy0^ZB@e<{tD zOyu^x&e*7|k$o?`gyWdGgK@NKEVM`l^13RvBg{sASehQE6X9lUM<&pbOCVCCLMc(6 zL~t|sKtJFBIeVLD;A)@cB;25Vd)}jr%^R;?>4r@Thh3~)ns_&z!ZfTVw zgb=a_dfHo9AqGqWq86F;I_}Z-YkaK4EG2epLDx@}=Y>v*GLC1nN1J1LIwRj1o8`sz zegSiNY&MGF1$H)3K2uq&nzy46*|D?>-f{feliqfqoM#p!wSk)`tOD=h=T z-{kq*Pxp-JFO^|HFu`Cmlr%H04@=2=*6EHYF9YWRc_^7Rj!^S0>g zJ5weJjCNA~lYPl|$lTO(`<4xsljFj7MPA?SvBbyxX##iX>PjGLrIXQW;<7`tixMy8 zgg?w|GFhB&UOI<-EfO1bRNR9-+&|$|L>yzG}f~Npn+5Xu`kJp(JYLE~QuCb`0mD16ZdIYvxw?)>_5dTNQUylF^s z1}x0LAf)gfmVqBm&AN-H&UFi$u>0^T3M<@x9tPs3YytI5KVf$z`v1r{GsNWZp-pF^ z!usM%7Ju?rLd{wI$fz6xLB-1oV88KAT8(u(4j;OuUsKUg4H!6kv0B^=1mj?RKf^Wj zXHAq%v+AAYkjr%pCWQ|`hWGP%BNEx(iwxuyhbtW8wdCy{@#QK6$}5A^omp8$SQAKs zs+2qq%$*)-%ug^A6sHl-or?7IVEbd#c4!!Cnvc~`T!;6j7`bC|A$%B6s?ncJgHS)_ zi%yP}XLxxirj8@165MQ7 zo1(`S|7@ z13U`ozLYZfiI1xZ-(fWUrmOS-7LhkB?SWyI*Uu)r0P0wc34(S^FtYdLM&BWsq^|yMG@IyFG#bzA3+;$02@M5I@f6=YjW zv=gU>JomGo@pNMWL(`3lmo@9-g5`=?JL~$E{fTCYIf|YSn2h7aa@I(RkOCRoO+|UL zQsJ$%`x&>+(tVrPUN#j~1HsG&LR_u9)ty_=)anH7zC-2>kHI{dHPuchIkj9hgNk%V z_Fq|Px8I@k&wMoP((_!_?b{4ucvBPO4Q}sK3KJ3xY`@2-C~-B^MD?i!jSpu#6odKb z3%Vo4aIs?J>GUe*j#@y{mUmA4a9(+gDV7z;D@(Ok22D!F7$=^(SokU1{p+~IEzbe< ztOB{>n`d}ZC1*;0phI;M6)yaW2LxNTG#0HU`}Io{uwGMXWh8VDQWe5Y~!o7+f(6=E?@YXyASJ*D#}Y^ZCJwP*+90@u0C8~rlU8= zyRlq3f#Rm*e!+ZC?Jv;)}U?3#~lC#GD|U2jL9!L0|TUfD^W0~v}n`lg4p!CGumUld}w)ElgT-V2bBSDutqOKmGd6O z_<`LKz`%&{5jr4@S&z}=M@}o#+elh>qUK53$yd>x&dB!jZ+Dg#8leTrcs4k!zn?FW zkD)heIZ&~fcSiLZQc_A@O@VMavs5h7a>p=;d+*_1n@n#RmF2_g!3;B)UxnSQ;k${4 zhTQ2+R{Y3We%H5JPz)c0|!SJ!nSf0$wko;d{yMfG#vLR&pOZ1UTx!wMFnP~Tzv zB+RxI$7u6U;`j@=!DvKL76^BdVRv}07i}H42{WE4PNOZ)yp67c(k0P z(QZtQzgeW5&7#C)9aI6$3J}RfvG{I1q|Js_1^6Keb!N5xOhIlI*At^bt!RTUAK1ue zt`>#Ld>&dd&j-L6SNSewM3Oz6^-=XQNn^Tp zjJZ|x1u|KY<5Hf1T~tNHmNh1kBvF)`*lk(Qzu4;6EL%mMgE<~~N)+~eyo!-)C3FB7 zPWgHh;ziMRA1HP+XH`A|vy9`-o8<`cV|mq%(>`7T_elGd1_#APHCZ~GSfnk`q(lUs z6UKOIoWb1xE>2OKdZh>D`JnM0sbskg-}Ie>J;(B7-rCAGzPNSqT5!`f|07WNB*U3& zPq{cYANv7~ADIz5Y@_T0ym%Kj%v|xq59HChmPRI`ich@8BGpKUa3)2TFYTlmbv2XL z;jPPrwSGkBql`WSKSH??K%i{$D+WRyok9GrK5zIs-k9OWpo0(hwtinpY+J3jy0G^h zZW9||M2BOZVN!xU*FIX(Dk1mWErf}f0>5O|dIqHu>@S~~MqD@hTiNQ`LsLvhub2rJ z9pfK`KM9I#T_cCU@7{lHs%$7*aT~TdG+B&>#_VqvNDAPvjin{U5MaD(5-VFjs2Hsa z025Q#M^_ff^i(mbw4|Y=n2%UOwIfuZKvrk~nw8O&sM3=vk-`UYhZ6wk|NP(jzj?_T z$iHF?I|N|LKL8=>|5p8f<)~PC#1aq}%7^|RXCmjR01@QpFNF7D&_K~U4NZTy%^WvD z;3bO|N1J!L5?tI|;j2IZ>C?QrpEL$yk-Z58h_xHB>0R13B7AtPL(=`qlng&}E(0@z z{s6@-C(cx~!l9xtaIJ}Awrd>a-mof>$%jkTnq7P~t`9Bw;?9IODz}8sE|>DsiezF! zYcD2lUpe(k5L*r`%y}KEc^ZrbgZr2p(%dl8vry7cOgdpy^#Tm@2FYp(PSTA76a2jS zY9}2JcM3%4*bkp{w)CG)VRD|c9C!P^?Aex(6*`dGaFf0xh9@J|Pq>5hypSlcf!7w{ zDRhvJ{#V3`lvZFB&;MR|g}$mGv?SeuUlr3stObNPF%*Z!t@;|xQuQb!ZwtOSc$%P2 zgeOha00B{@BtkP3@%p~m@rT7ZG$^qeDTs+FcVSgDbM{>4WF3`J)qTG_Y6uO@iO*#^ zR3^VDIN&ts(PU#yT4_D#vBz#~OY|C+s()&J@M-S>VkCLw&2C75{*;%hE-4A`gG4Z` zshm8+dxB|bZ@~n;Yduj+PO|6UZf1sU=ID;*3?_N7qrkc(G_B{Au#w=WH;X!M^%vaH zynR{lxSR{jDAVU<47M|BUkesVTpGn^7n#}Scri=!@lTYvdObQFSs{2Cbe z<~ekuY^0~^+lO$e#*6WMy@{S*d+pB-Bj!b>u<(={*BxCaJ_fU+_>94W^7u7AZ@xIP zbUY!$;&Qcy2P;_+hf}p;H~%W8l$prxL4N(H^8zQmdrlgXnbq~+GLN7<7wy*0uEWSg*M{;Kzs+8;reHXE$m#D)a+CR!QDGTv$*}FPSx!Z1SV@_dR^L@9#9NXzceY z5v+R1_rR3393KQCsr0^?{v~XZ=ScMr_K;@(p0yM?jM+{0FS17|E98i5W}(|(&fuTM z6+Q}B??^8eLPorbwkpC@*c=*e=ht(PS$hqj%-!2b$fz6yZM#F zI2~_PTCu%YQ!pd=vo*!Q+-ntmpI;;b;o~MzN9|l+c%C~(6NoKxfWw!8IOu%fw!?P zWu$P0vxz8oj&xdz5^b0AbrdHdKXUiIO&k7z1N7VGLe(sW=2W#U-?cuNs&_{aot~ zHN@9?imlh#e@rvL9F&HApB=e=*YX6DZ(8!=gxw_5;QI;n!ZR_J*4#7IzbVc)r6%f5 ze!vnpcsVr|``yvTjhE#LwNoG0qsw9di|0f7gGc!#l+Vcxq`g9(sqiW?d1JzhIrCRv z?o*X-qO~AfnZc%kqW?8o1EgBw4R5tG!b^%v;1PjJN0gWx%y6VFe{azf2y%;XALS#*uPQy*gm~qPFSGdRB&B-zJ_NF%S zpD#$XXCD3b6*LgC(PB;;&wiPr^C;9t{6LbDCS|MClf z0@T@D@WsCT&jJ#1ggTl;9hEt_0Op1j`OE+j-im@@Y>!a8!f8twi_Z;BN~w zBC8K@c3WA{0=bYt5rX^l%*aQkyD$zbF24e3e#mnD=QxUc!h;K7dHE3mJHTYX0rEc>n9=JORB~AP=%5KY^)VU&t&|GXQ2!eJn+Mk!be@1|KVu)+fGbm% z0UZ}1o1+AX%Rv*VxPLPRfbedotH1!ZqdN)*gAe8Lz?em(0`Jl~>U#CyHs1njB%N!}z0>Iu$XaAS2D4|V6t|{V zZS8U)Ie#}3e>XYXRnBvBMRoCxDGhK@k3y_B5gJJ~xu*8eDV;@_q2=e3qXZYV1iW7+ zW1>33@X7CGxBKT)x2vn(6sY~#9Ww>|>N4?MlDfQnvG@@!U+;bH_Ahr7m5Nx) zd7gSE+0kE8`z!4CJGHnt{Bb2U1AtCXH6IqRc@nfIN1H9J?zXz{PQiU zBUCe(&uM813yIdvZ7s0>89hBaV2cx=La4^lLCEJB1bPDJUj#|ImoeY)ip%W+=-XtF z)Ws$quHE=@ft8}Igpz^(umPQBqyCHS`47Q={{l`$uDWK*Y5|52`Dz`9lBP@IO(4ZMST!6PA%j+D9&WnN(7J&O3w!T+?zM#mk&Yj=lVVLAWwdGCjlV+z;)+fhOA*yg&8@akhd}@wbFs zqys~k5NCFWKW+T}`1|l8&wGYeO?IOWE&uW_MVbA6)Bf>%_pe^q`6Eq7Q0Ir+tdZkRRvvsKkd}W!k;asGNQ??oPPvsYe5wcUFtlE&xxJUDjWvxeThSSKZ=* zDb)m^CaC8NO0-}OS z$J&9-C{!Yb5t^uvor}R$0ET)7^o|SQTactJchPQ4Q3u>&NYB#<+(ey@YxnZBg-`)R zKGh^OPXctbuP0}ez9ZSL8PSpvbM^ULMX7HM8Zoo5R1;6oqDSS$yPv~m^C(=Y!}0Xh zoU0Jt1|*|XNk($Fes$vDb1)lg!Xl9^zn>zdsb&qADZp>|r9ERkV5epc)FH+mQGg<< zvF3V-G$mZ~m%+DsxsUtu`!0F$xK7lE>S4?^XgZY9IP)r1NZs+8Y0Pq$Ri6Y)IMJI$ z#hG;!aJurz&GQ*4X&uQ}o$vzxvOXFK-yAXnfR&1=?kbG(ZcW4H zF@5a15WvpZfSriVq928R-CaDS!CUCj-ljqvmyKU^RLhVU8h&t#&M1oRp&_4$;6u0h$nJob8Jh&_R)s%$nQi?ie9>; z;Nr53F27{PF{GdHk|vt73qydsxLhiZhXy2bv};Y`O3G@m_&MM&BKNW6aK7gy9qk;B zzP>nmvM>h5by9w@&F^mcph<@S24XDxJqD${+omXS!!5WqO&n9q#pZVUG_kN%-^;`b zd+wkn8GYe0^qREeRhzvf5$0!xp|{0X!poYP&-KH;$|g<+0mRBcwF%v}jdsZM4o;P} zsb&*`a;M>;v>x}czP>2N$yN2*4V0KE3p8IlpD7AzX+824E?_4>qbMv9Ralb)LrJx}^qR-mG zGKJ5RR`!PT-bF@;y@{fYXF|KzZt{K_vF07Kg)ScrPX+V8atMQ(Hzl+Y26BtS+7r5g zW~yLMbHpTojR*!{(G@8AKKb87{9h~|*c}D%cK_EHOwTp^FU5b$0G(U^B{$UjZ`J=V zg-X(30-OO&cKEOMU;xngzewK45E(i@#l4tfq+u;3P)?QkdpS_q<6uXY&>RPHSVe|= z##aw6XXqvUc#d0B0CdxD5KkK;2%ePg`a0Hm;jdKtCB-*V2lG*SYN&TGf|i%r@_L2A zX(&{|n3Whl`RB|x0qZE@g~#&!J_KCu=GtRyas&?P7x%XVJ1Lt^HqfrXBs^Q+Slx>{ zCKA--E_lBGx?Ug}gO1YGt~`yH`uSiblV8cUVOEH5A8R%q@rH5qrgQnr=lYoiuVGK9 zjKOV4SPv@$)|90J5TQLA{{>xeV`Ey#@eC1vcux$Tf|VNSgu6Ws_!9_FWw;#QKCK)6 zNIi1=+G_H7y_L%LD`z(5*0yd(I;gEC1iZ>Ea5?IZE!ty6%RRWT-aAzj+VhJ4VeIqP z8=up6SE+rgRE;BtlTgmm2hVvK<9Jd$!m8|AA9h{79xnbI2Tw_g#&ttNPKCqvc`lv$ z(~_?*tFd)4w%M+%S-3uJL@M^BPrHgT+4_%Z(VvAEc5fDm_4@cJn0I))@=~dAe005@1z$6tMU&Xk|If1rh)V}G`M-;4q*TO5VPbc-O z-WFe_5<@(9bk|&YlK)7b__5tKejb-X;`P4MySHj7YgmQi%;f|e)NGec{v69L;>Vdd zA1_Ib-apSH?)h`z)|F#yNUKBW%CDGnr}p+GU+gYVfP_|@GQMFOOT@Lof@k@TMLp!_ zv+4MV!0lIJPhD`buOm;EuW=kdzGFz6P|lO!c*!+%63@_N<6cW4@?3!-D^fkU;NscY zF~!6h4DmPT6h_SP?7hCQ@Zw_rkNWb1oWS&3cG2UXRlbDkqN(TFvjvtTbW$~c7AfLn zjoy}=?H=wwaULCTj`%t}5)bSu@&2ntdG4lY^!T1%PfeE5G_fkk;bP8k?PJ-Xvt~g< z)~Kr%`4fKEqW91L^bfluw95`$+Kvc65&$N)-+cZvC^%&n$;Do63X6)bpgnixAkT#>KUmPW4>}84jeDC%zqS&@`lIDYo}!|Y6|a9@3?uXnT<;|b1)XU`nfz| z`|_gS@1*9{jBh+3^6u7~57PAP_T}brnWvwVmYFP2m=62TAfJsM;}^a`r?)R{sO?LK z%)7a1tk0;8Y3`(+KW+J-)U11V52DA+eAr1F1+nBw4DA}TW>iHiJad3+$~&&UViG<) zJ%78EwSLCkwxxCw#tq02)Z%Psw1TXj{ZvDwCyKT&;Dq`c6WXo*IcC)%!aZz^D(nj^ zH5=Pui>i~^{!)ug4DWF~StpS7N5@*?P>b<1~B zfLb^}PS&t+Q;2WE5qDPlEd*s}dJYH!M

-%sfU$%jk{r`W|_eR-5Ejo@@LqM2X`r zs|4C1)&-X4mCA`|>c!AlyLuk9=5@<0+!JLDny8FjGj9r7cPh>#I<1#moZv0o=8E^O6;=*oQKIwkqBRWWRaOi>6fDh+ z^92-gxvAa%)z^&y#*p;Xg&Y!e6Q^HH-di?}(ye|7n1;Zn4}b!eZjQo!nyPvh$X(i= zyMcS9_P1aH84}n*V`-lvRlRAN!i0Q`*NO@M$`$_3=JlRMBgjUpu)|+uI>57TS8sPq z-)~iF)mAn?yI%u(;u%%n>>X~F4gm^HIjPwWJmQE5FPr!s_S)Zw-SJaQ8mAQ* zXwsK?CvvPNo7MTeEj}jSWZ{A24^da6jx(U1A?TNGV?S}x@Nz15`NE4~2M?!pMj4$r zzi#j4)?Avlex`W$F94_%v4%LS;2OM!wpX0TUlkX)lu92%je z@QNRxIEP0<=!^0LASo3oJm312X^=%;Ny0h+EGKc$$I}X^LU39?OWAyOwh7c@WJ@X* zv9kd-1yDdHMDlxovmtUE;D(gE4pubBF`1d6So>x@0g| zx;H&r;EBlc8ba${P^4#kO59tQI0+vzW={?)C>p7pn>?Qdjv41ZEIkGDLdDmKF%u;l z=_gL3Ch@(W#yu)O>gOSEJgy?`e|wp`sdpGL0N4f`ERjlcmPk*_iPvhVUs?A-Wbotx z?6_>X@zU4(w{ANxFwE|jtp#}udQb|MKotqanLOYP%?)XT>_mP3mh1NTh+;I#Lmshh zasiCdJ$Pvy#D6*b?50?`INN(64~_}yHcgg$sC8n&$nLw)x(BQLSV3~nz_yOe$L~)p zQ+k{5jdMRdzi9M&s2M!}&@7VHouPzBHhZrU_(&UlI*o5WMmv1G75U=iL4C{Stbt^; zsZXLs$2U@Z0+q*4U}~aG21p$Vh12f@02Tn(AYehvc>n`LA7BJdyRbS0lcRcnTLE}< z!_Ca#z!3l-3cz$7a9V8u?4BkmB-y9O(z6^St%wNR?zstOoCd`J*n2r%b_e}dSCRWG z>vAh~x1(a&N<-nmNX_&`!IdhP=c9iKw~qT&GJ%}#Tg%}xLQ}JHu%3u|Kfrc?MoS1( z7#@_P5xu@-z49ptKawlFVyO3mNCg1Y94SQl0ztaaAOAtZx<{;i|L}zW5P%q&xxj=f zhMX}{g{uBAiWXzi_(hLfz6(zwx@rwkufhlX&JodQ3Nv83LkJFC7@fh0`J1a|Y9tI2 zBCYh9#Cm_Gp6qqzC%xVOyXK-O`$N(Hx5Zw8mw#W5XT(RnmoILrR7rFE{P9I~^>Rux z%s|$?^~;^yWbMuJn{(7E;lB#&gy0c?Wr`Sovg6ij_2wV{njdx1Hx3NOV83#eoZlO; zR1x=Zf=~M;wi{ehHbWE54yF46QyhRp_~fmMVZs9?e&Y69?u4Vn*aoMJ`DRYK5 z>05NZ&M!*&IsT)}j)u?>Hwoc4m&5NwbSVvn;p*ka?T-fQT)3u-_5YrYb>LvQ#G+B> zs6)g<@%I<7(XQW#@xPd=vhLWXqWk)6+8>*tw~V!08#EJ5XS6)Xcg$*94dd=C0QrG} z$z{YX?stL7PKm-EJIFeopG~8K&--ZKpWdsr&u1Fo&@Cv|Bd|Zqr0)ZFIQ#Xtg-a3* zB>?w-YAylEt#c&(4UCt1GL_lKD@3Mc_QjV$ug}sl%?#=coo!3V+!v`i$oIfoq?$YbtF_c>Zo-cQpSctH zHFxN07~xzc_oNu^dEd6~Dl2(-23&0BcqaE&B4GBH`eEg4KITY=7G7Py_)&5@e5|Wc z0ohRg|I`Rur~OZ!Xm4%y@G-MhDT4U9Y0nR$p(e`$+j z1D;ZgGhO3t*O+|vazTK)c!|=kdIR!@aON;}OChIVv9XV%7Ba z*lgjm%GobvghAm>eh#ssaO$s_`Sb1$MvUtqT`?vytljZlc>&c;q`#RJk{VxOo55H3uDFK+|6q5KIo@z-MN!*@P<=RH@*+=arv z5&J(y6`YFZY#)IC+6U%!{cWpG@Igt!Ma@ndH|Ehm8mX`;u>)x5|H0UMM>Q2KeZvU^ z2t7c6&_f8l_pTxI-jO05qzDM86j2NzKnY z%pF~f0RT{cnSUDs2!j~idl(d;hnjSO2q;PXU+Vv+L0{N=73ut&;6IT0!zlK;cftuV zZ2M62240RQuDZk@8;x#BBw}=Cb%@M2dc_)3tThN~5||!%OfTJgk~A<=`1yv_d}L9L zE+qDB8z=WRlANLGAqVS}G}Q4(a)0PR27!TLD#T#wQ7*@?8CncdwE&)JtbXPkE+*X&zLqQ2e}U2vcV8?0gL z9#_+fd&>)ZG>2WJ{rNb*Yc;IN@eB&NE@ohpZX~Vr>D--sV7RO3Hv`MX*0B_W|Qb@G~_GYhyE6dh3zyL-#j* z5NIu`^V$P8Zkz(DIMS}nS~1lUc?y?JDcA0UPQ!9lwXMM)`zqAZxH3#+!nd6UuZ=iEPRv>jXF3T*kdQ= zFr0sWA@Ne-DR&_|a$r}d6(Ynq`eD~RNeLADml(LkyP)vlFjb1eLeE!pG(NgW?LcmRhE6ktirI~=b zOX`Q^!z;G;Ze#dskqR>7ZK&1mFG!;-HtwfP!d-6*?c?(t)}4XLiQr>y=-L|qlu&T9$73n=3`)()%Rj-`&!RN(;@>-!YewHaSIG97U)!bsB590E^g`r_Tj_+) z^W3Y^oT|&){*`xa7o>N|L)XDTa^Rn(w)w1yehplh;r$`S*T%tovifO!&EgxT;^aD0 zUi8-kx^I%^^eF>3^JbEsd@}ofe?LT!{iUVOo64D6ETUCq4=of8h<9q<>i=Y-tIJ{w z{$4G761(L)4;}F-V_)cUt?Gr)mEsFF%2;G2+AM54WLQ;Oco!!-yBREv{Cq=E zw~dIsh;8&{kB^}imbVwOu1^O#VAgVEZ+{e#x=9*q)0!%{l~6KL@4z`bZ|58o!%VDc zYiQ8y^zpflb#2|P28Fk@qhG6;vU(;0H(JjY@IF2&UbW@+sb4}m=%y>*RO(*OFZsn2 z+{~i;nNDAt=V6}Ie0s6nJ)=6d=Gq-Ct`E;Ywcm;_q7irm-Id1%z*4o1rNxnvl(Huk z4?MeXo!%UvzVCmL_qcEHU9^bEWjCvelF*mu?sz_h9w0`;?RrUqZh5wro9b1Pkxs$u zb5~$O$~O*4$MnYYucV9*Ydzp#?la7nP`_O|63eK0qFBYm!e^*zzeL4E-#H9OVgt<= zgKW^64%E;S$R+}qM_$~1XX23O4{xeGxLr{<7E*NE3_{FTqEkq7G$8~YVL>iest&-0 zkwY$veo;PxNg3LO*N%T}HBmf&YzLIM_s*$>2j5VS& zr;GbGQNLF}Jf!u2Xx?Cu^ayCU&f#%wWFNUg1^>d@W3D$0?eVvY5;fgLQfnb05&X(A zZcpf3)6}C@?sKDDz}AQe-5ab7q(Wsc1$I(zeR+x5W_a+Xhv=qnP2saBUIUs!G9LbW zXzFVyZtYer_yM)a?imPQ0}>iYD;VJHY~H88-pGum{V1evz=oMWV+b+1hHwk1G*W9E zOOqDaXfe&)hPI+C!n5wT5eW*_bfgJ(e8Tqd8Z27e>FuL|P&JVBtcIWnUokh2baEtK zXG&!5*Ilm7WU?y)21c7#y-z)E0uDfgf}a&kilNJ5U(?m(kjg8P1cB5B)Z$C3nQ!TQ zLXD_HJ8iy4YJB=4bujgqv1mgI)88>*ehF%#514#8XN+_;s2uD9dye3B0~@2(nbW(vFsVh z#J`ykVn7c7G+TLqG;#ZfhsXTm`hQ=b+DwJ?#Yk{5T_g`LIt|5&Se{OM&qe?NcmRp0 z|6BjBg!#!8s>)S3@=okO-~az51wyZ?SplT>CjXz>M0WuI+>PSLl*S$_l9^Z8#$nLF zS*#nzN|pqH_i}ksLT?Gsn0M=?{{!v^&w}&7&%q!_HAoDSm@hZT{v!M#6E~b@tmIne zOFLIp&$y<9pAGTl=bfSoPSFZX5b9U2PaGg?c7HlwD2|9f`?H<&^jD~A_LyX@=wO|s zCX%#2o7af{)GrW%b zJ=NWPZVV;zI;&#LQ*E_B*HeI(&Bq*(S%oWb2iXxLJh$7Q{wl`^-HN`KZvesXfBDrc zGW(+42Uvk-*&DSnU%K<>mE&*s2Zv=6PzUfh&_vjkbkRJ}vk!IovHtg%MyWm5&?pX> z#H3M2kYxfRSNs7Wkra(c`i|?@(BZ_avC-+py@F5zD5AEaf!Xuk`!6NBc-ed+o?__j zO;RkM-r6cKDwZ0@a2JL!qz7Rl{X>KZxVH6(2JLh>mB=u<=7g_gprLQGsHrXOgPh-6Y;#O+{zJ)k4G+-tlRTXn?dCej)neNtQJ&K=2|{A+Po$3?f7&2O-}k^YLkjT>u$+e zB)fa#Mk9MS;Z3T5XAerl>}nNC9DTG?#Wlh}tSS&kAQnOEJdV^C{jl0IwnwzjL1Y|;MS034~ zZ^!-6C~pslRAY#uNvGHMIe6vN(orzDP|p{er#?_R!#-M9$;VMER8v>2_H85Z@lWQx zu|b5AW74&*6X)BV1GKkf@dyG&(j`*fJy zS(MZ2OW<*e$>}Z%60-7Gymos*-e~;9+9V^+puWV0`Yr85a5@iDEelIn`FN=6QR(0e zbTO@PM>JpTSDB6+57_*VAumjhCw;+p0b`yvA#csS=B*Rpi|s4>%Ex1e}I{WfSm zf7@1?Grz*AN0>h2We96%UA1tF$xf;F&Xe_+38C8SsXBt@Z!)$^5PPqy=-o3dli$c6 zI$o3tidTX&g&EpSYnES>Ts3k^2y%iYxTiDHsVTsLxH>?zB-RNh*8>omsu1Cl>^gWI zG_!eaO-c+@yMH1zU;JJ&Mtx)cT8LW)tJaFU8c7mSEVs;)t14d2ai3)E2Y!|CEB7du zo*;6|&FQq;&48ENV_7fK*|tQ?Z+9+QRP)MNIj1r3nnLNbc%-)(WmL z&j~a+JX~tz2-UKq^HF^roS;>G`1uBc4nQKmFG!}y&oQ@uo5|kqcZ$_qjGAsHFMHjq zOP`qs9u&!tpoBxs+) z0OFm2S@0DdOv*K%ENF5E{Mpq32a(kYct9v6=0mi_n|PX%t<`ldy;tgGFiCPG2%QOL zoT0@tM-Y$ENj2UV#PllR1R8$Vm#hprBEPzgASVGY^JR3B@K3kKC}g*VQF>Cs_CQej zxJF4pFUZApb;DWRoW$wKdt-J_QD5rj43=*HZmm2Hpy-W`Z>e%~a*ya;$1Pp;*li{i zEF#Qsaf>|e+bL*c+TK(%8Rs>KfI9P)vyDMmj5GYUV;N11V6Uf1aq0css!+CQ?&2Gn z3^FiQnMH+_6#g~h4Kgm+#un`lbv0ULEB~jJd!Pah^T!X>5*SEdk~;)8ok^tVcLf0t#Hs01Csl0XCiA)*=)y0-auSMW-WlGx2ANUd`_S-RqVI)SHrkuJW67*k6l8eAPFs zs3bf!8Q}Mlmqie9+VPVZ2EiRdszsK8d5r&|7{Qt3oh9FaaQA&#~Q{I~g;3M2JTE;zoIpvKS&0&ALF zHESX=bSkl)2T+pS{Wb!{xofF&Yv6Fmhz`0)KmyUh&ROQsAjNrfx-ob&)_lBSi$*%;%eY_HPSBFk6H~otpV>iiJPm z%QJcj63D)g4kk`uR(P|WXKipIeC&Mi)hk^MVG$@rFO>hggb~T{V3zpoA#;pUd6kH5 z$kH2eOTY4{uOEmY z@4$9GX?s9KnZgWVkZ$Q$|Iid>YUg~`_1H>9M(?+oz+joA+}gT}>&8Nh@wJ>1(m_b6 z&Kb8h%khsNS&zjAeSLOgvly$`6w@^ny7Ild`FMqv*Y&@9u2%Kl5{%B&iJ(ti{Ke;F7?ZaqF3(8KzEW&{TpZtWgW`2XVGj2<4h#37KzRP&}ory05Zf~!ZBGg$%^;jPJh*vODJW0{!2T-=>fpa`EpTI!Ykcf@sM2b{Q=m zI1}+*H9_=7sxN$9NKb)!VzeY?iV6?xfZtu)^twM2Q~LbOJY7C%eiY!crjf|D7nL9| z?hH>VTKVAB6%v8s2i(UkNg61?eG@rsJrrxJlBr6o$i|9TeSO4m#m;;TB=)JN6!1+EEiJ zxv3+fAxVbylE#huesdSsNYQsa3vXs)q7ji!;#d;S$sv^HY>&2aA3yOpIp8hJ)paa0 zUGrtK7JDS|&}c9v-CHn{JAZx_DJAdBq|4&ey>-cy&x8YHP)Vzlo=p1;jDR4urctS-lUOx~m43q~dsBTJd0^CEUI5VWqa< zic%^muzQkTM!?Zi1s^@LW`|C(Ab*nj#x*nY7jAxC&q4m<7^>MGDQFV{S^eGW=B&t) z(ec7QY}j;Q#n)=dC0Q#VgF-SDlXS9>FhJrn1DLP^Y4!JG`c&eIzx5gYYXN4ewE-yw_M#)-dc97xbr>2 z8r?yxllkpudhMPhQ+1>p|4Br8Xmjy7gqWbg*$Sg$wQh*ErWjovS*loACc(hSZpiJm2JwB0qx$Sjy=_?`l+F9k0= zW>WW1KQu}*3J|XDUy7YcW&kFfoIH2%^c;3qI)tWdOkg7hs9rsCVnV62JteS#P-x6O zXy6dgy5POOVo2i47Ed5C9KMP=6)Ek$+B6&g%6+PmU`lFIEUBs{O|8w&g}-khfo;b0 z_?uy>aKsBZASX>SSw!ANLX3wIuh1eu=WZlLGzVOTgMP+H5AS*hW}e1wSx?2FY)fGy zSYk?nnR74s)0jfxfq@o*Z=?AYAn~C)9F02Y%&CD#(KWt=WT~0<2QGv{4k7FT2hmH$X8JC;J@RL!yEQ)TxuwXLEz zAa+Put9U909XNfSy*OdPrt~FmXGzo3X*81~Qx2eB^K}}ZN%+$3G+Rpo`#AX;3fv;Y z)`lZui!Y;Qclsm}FQdi+hlBstGDoBXX}AbZ8yenD85TWK5-{3KX5*3s9eutiihIVe z=vpdN z04XpfCF3XL_u#+Xf&>0LK=}J-{;^>}1hl={w4RiMdjW<9?w%P4nk^P`M@(siq7dHEP5Y zeoH@%-U@O$jgtT9ll4Pt%`}v`_cjEVSU$`8VoP9w|3=`;k-SFE>{70!mzhZ80l%m$ zXC2R!vR=dt?w164ZPiaEo>txK#(L~$H@nuD*C3{Ju9Aeqfjuh^wl%zIY^b&XmOK*b z0(Pd6xh3fqy6&FPX#dZ~0yR%gE*0Fw|kHlwb#xMzKsF31- z-cE4i^H^zQa@^bg!NUA0`$g1*)t|SH&*sH^jNPWjV-oX?xFD|+p{@xKIx1;8s(}YT z-3AgvCvFaJ{)$yVQ6~)G)u^QC+ny<;h(iOC;QhYslCJD7_<$H#>D7VOKZ95jo4b%U z9tf7ZTzts_g{9#J3C6O-|JKElZdDh}@)-^})C1NS+gf^)W7#wW)+9X>Y%T)?u2Zey ze;cYsC4`Te>R2bZFfzSY7%h5kv)B-xrFlx6$d0Cvg5F80-90JQNYTVThFRLVGVi;#$sFUf+aS^Zajv%9C1>xXQd z=sU)@an64J01f2CRU?6gB9}pUfVV;9`h7Udt%iKDX?~~wLBew%(Kou{!5C= zxWbx9COx~ij?PI2VCMmbSfce$_a4UlDaq!~Cka%R&}zSYU7hSbo54f|v(m)`*Ut9qP|UK~ z-Zge#G<%ZOr?L(*w}`iSG;tUc`tv!h+8Zv3)uQP9=|$PCy0Mtj40D;}W*a_P9r4fs zP5R!Vw`#p+N>^US$swftY6$=+w+9PxxAB-*v^rSN`Q|P$JQr zo(qDRApV{n_l3CT^s0aTo~PaTnm^N>T>I|~rV~lJAi&JBkcF%ON^Hx|1ufx(1zSYU zxrJACa%>}U$8qFBz7GbOW}|`11o-rZ8M=>vF2CxP_B%mAok|9PRhwOoQb!E|-(n$5 zH@iW4Gt&Y$-nsk5qTt_Q4vatxBi%S}T^CR}(MT`MDW#WWl1-h>#+idTj*a?uA`ZYd z*?1->FMF2F{?w&;xPLv-^>;+6OWi}!0V#E*v}@{eoe~uF3apVVYJ=qn4UKYk6Tuhp zAmeqHGXOLm$l`QnE9hN3t1k2SvtWqq@xyVr-S>O07o$$ICc3j zvXs&N=zwjsMv;fOM^>NSuD=(+@!-#NKH&qarCmwCoGwR*Pb34WhRnwnFq1x;b0LIK zQV_)=@J@lG;96O5<4!eTUqX5lHXK|)r_nu%x!Los(xl|~3 zO6M}Ej%Ke+B#=5Xc-O1oC?l`%Lmh_$iBdT?4e@sZ=taFyO>8wnP06Sb;P9KBE`)Y;rRk@b@KYKTM^b&1 z$E#s4$Uc7Ot)7Azb(75t6A;$KkikJZ)svG2tnI|5Rb$tQZ12x!DLTF<2~y)y9H_Z0 zb2kD%xvSFXlRr@+6APyo54`B@-61pt&KuPbY2P~1I|0bi6QXrWCa7;g=106OHtsGr zP<^E^*{`gN6e%u&3iPdP?7q*XElv~D8%`!U@+9Wh+B44#wBb<~H!>8!U)Odf!zET{ zpiF?NW?zh~Bl$W8R9eYfV5b#1z;tG;`E z1XD!*-dXlr zDc%35g7`;j;lDNh{!)}zQlYKpp62`+8dxM9){y4uSySEj!jR7v!CP6T~p_j zC@L&M;zUNvKr&JqY*K=kL1c_k{^qvcM@vKq_*j#3^%*>z*2$LQgNgKCitx?33gXnb zZ@=*9g-{7*4@Db=&hhyqxza$9Qb}UIvEhkLYY&!AH(QY+*YP0(F_a?m50L17uofM; z1S~2Q1a$xJWb^%{Z93gbyqlNI;80g*)WM;#WRdQHpK${-%!EPplmZ8NM}0E z8PcJ;=s`CJf8tx#4MO+9;Jp;=S1_O{@;C~o2p8KKW#5@cRU>ikRM;zg4QPM0`-eu6 z6mAdsPs$n%!O%F^DwvxGfK$+bndiQ89E?pP$(vpKDa>3_w(-%;oN`d*bjYNahzb=0 zHX&@W;1(Bc=`ROI3SYPc$j9c1tj($1aZ6+NVEDm(7i}S?6w6`1K1bejzy?Nbu#jXC zT|DRO@4r<}=a2QVj}AE!5~~-11TRX*!6I0qan51PV1tm;b_?S_;h&eJ-bi`~{0uk> zUvy%Xuz2CEaa%AukQz2iLt^N6-YN1zsY=6|={vn()9Mw#SVO1zpBXfwTl+Lrr6!P|G6e4DlaVq+Y}jFWvjWF5}L)SaCXMngXtbBBLik zC*>xI+73KIpqql3adMZy7w0-lm_9S7M5bF|ZDyz?jbU8z`Dkk$Wcp zum(>eUVgx9B3W4w8MPloa^Cdc+}shHIzo7qKhC2qe5DPa@%*j#V~LcRUXL{Z8mCcZ zkd)G%n8Wl`~&6bFE%ND z>&=V{dtqr6Yo|b|t}|)D3vvP?P|u3!m%0?gKgXEqXV4XHvWmM%nt>{Q1&T6%W-mF0 zf|vRknvE-8Sw{@|0fO@mmCqKvh8R0zBQ=Y7^Q@A&153-8YC!V(hD63Ozp=Do3(0af`28Hq>@))n0<8^TO)9!(N>*-R#edC z7#J_XF zYfYv-&zC*o-J+w{mQdnq4&sDL-JlhE0=qxhSfXuOqaj2-{FUNb7^k;?%yzGuq3>^0 zRHK7hf66w>dx zsP@#l%_FL1dkkl_BRXDby&uZyPU$h+Gx_LUdLuB>W$+u0B=CNzK~7*At-TnnHKX@# z(dGnwF)ZnZ34S{z74>j4&3vLvzcf=@E=ZZ1oCL=z(2!(R8Ld7iVG1Pu@Y$uU4IdBB zeMa}WxWc;#T@fVK`pHbgjt^l@U#;-YZB@HeArQ<y@>jGjFny*AR8fpTk=zDiHk!v5W$S}9tRvmq&4nxPc_Y*JV+;-~JbqCmJtqIk z^cKOvi)JZoTvWyS2k>KE^m04a+!eusdnv?OV;=VF@=Bz3Y3v0qIc%jxGGslXusRI^ zZ4AY_WIG+m63mzo0ZUV|RB0&jWa*8}88hJq64dK%`8jFm;QTXRrt4#R3FLi#MI|P& z^pqntkby`FWI=kLf;mxNV;s14G0hG=N~5-C#z(|10p`&RAkZZdaT)SDk;}X@e(jd2 zO45CfHYJ?qK~n#^h`$3hEkpIMaO@wVzu^wZwdU3qnS*3(Wi=Ixg>bfQ#a%{^D8{Ov z)nsNv|Iqr^Wv-8iY61S2htW0tk0Un!()lM9rGat-VgLY#&Uw_ZAYr}!iUvG&r6Zy$ z1;I(xK7lhuuO}giA*IynSuY~M?T->N0~%X^(+ROvE>MN zmoRI>Is>Ypn8Nq{PD$ngtai?l;jPGxRfEBJuSHW^2sjr4o)ejf{#x`sGgON8Svxh@ zc3k9`!C_m+(^DrfuwEUGmk}^CkCGo=)tnNQ8zsn^`H-R!!UeEr%%x-;?BZsi;!X-x zPpIBW$J4i+x{W+%RPCl)ni>(*!x{m^-CA`%p}ea&PXW7JHt;owO51#d8Xz`rw|BZ* z=?06`0`kXXyN934`xkSA+Yd*PQ}}g-P`i8D#*rFvDoKhn6x<;AARSc<^yW{G9_`q; zW{uV_{!N=srt92zLD3z5=K+a7a&bZ(J}$9X$zB7i{@3k_pkb? z1KD+kUGcbB*6Z?McSye$zeXZ=_%c$Eg~~aBdq6$m?tR4NU?NLGbt?1Ol=aXQd$eF3 zzx;QK&VV1@7+W7-^9vyvjmEW#B}yep zv&eF|^dMq?XwxyN(0=uk3S#%gayQ#mY5 zugwytun^NY4?g9r?%UhjHBeKj9;MfRn$7B-{AucN^7j?4ERnOTzt!;^!7A?s4JVck z>CE)_WF{ahekV|%)%6$QE+JaNFOgmf7O55g&7^8DfGPwBiR2DOS@xWMgyA{_-n(0D z)G%7)dw(rct=iH#yzQWqZkP3LGP!{P>r*;ji-{n1%Mf#PD~->A$#DAl2epAqZ4rWG zuKhdr$v-OCkJ!crs1))OKKzir`vwudJiIb=H~B4jM``t!H{fO8@~inml>XIf2;5vzy;Tjkf(gByob@i z?!G~id|%BMA`^v2k{?YqUPPM&TmU~KG3(=9eT{6u!d zT5r(~R8y4VMpWBQoo@8hdVe;C9Yrx;(Y{ni5Gbl+4vfIhMGSu~Dewr+?E?@yOXxO9 zjY(HL+vs0;>%ACFRb^`ppo(Ur1xT@>SxC0@qF5kgIwW~>Wc*+u=VRQXZ&rI+qXfhJ zH^{?9ic3O4?`(#7PtUJ*#wucl5u~AT}9hB+s)gp@?74FkhLqlOW0ZKY4VcsOC5c$ zuDLpMP^U6+`QpI|L!`m|blt-cwp5mep^6_)RnP35%gPWe95%Y6Pv&hSW#4T!2KlG^ z$&}{X*}i~AywJ#F5B2EbN__bw5b9YP_o0K++I-lQ>0<)C%_@22>G(}C4Q_e$ds7lo z%;)y;w8599Ai3!|U*nm(Od_Nz#A*Wzw~xj@(w5#x+4>U+5#7Uz)O(fe)xLkDFR|PC z@Il*!t#zh<)5?Cw*J8=TFJst6RgoGz!cxe>F5CR*LLQqBEPI%Kg`$i!sL!M*3h!Tz z3^mLQ?GbXzd)QYtTw85#=!)l)sU;K>T1xu-oD zaHJ1IW?^cNdXzO<7U*57%Q07RXcMS^P3OAZD;N7Yi9^0NLYtD4N=+c9nk!Q@z}dVx zX}qLF+I}#+NVSj>O#S!c9QQT$au~i(sw5dRa=bU+U$VQYzLn>O@Xd;O#^rF1pq1lE2EE zm9DiONS|~Cf2r;V^}k-nxM0GdzAp*tS0|U*ItVF9ZL6=ylo%9~gE4v{<8j{A4DUZa zFr6?fd=^nZRq zKQ`iFSJ0xC#pstx!n$~Ja-Ip@n^St}cFVv;OLokM?91}2qPRMnFG2#DSB?3Q^#vS& zym_iLXR6WoB|EM8UedV#e%pWi1^WAT?6ias-Z8XU;a*2B^$4)cLimgit%L0AtjKMA z`4p(H%7w2QYYlGT_rx&61M5x_)ZUC}L&)Fovtv&X3x;F@5GefLcmF4EdIY~RK}ISc$puFP$Y03f6Oo9RP5H1R~i)w4`=MGGA6A9a)J6re00JT3opYe*Rz~!>eEu zh8z|B)bDS8sN{lfn_tG*FI*re}=|4ZY49E%&*Nq=?5Gnx7EtO#)=ij z7x6b=WH0c*QYNlzEM(K}nipM|ws=g?%ha4Kjh$+=_-ZE~seB;)**N)#dW^R_U*rZd zfJzmH#n%VLw+DLrJ*9rtEw26j6VLID&pUmLlJB!$YROUQu}btqJWIJLB(T877mdvd z!?%zD*)xRq>)Gs{3sR6R^N9~45PR-J7xHcu3YGdAom!}pMSIX0$)@t3OF{}Hj!k6Y ze(~}B?hVaW6GwGL>#CVpy(B?q!5Iznz0%0k>ZxE|7rZm{(^!Vqi#KAGWvLLOljwxv zneAcYe2;qf@{A{G6;S=}bH4FUX9TNYt^ zA@ysai}eXzUQRn_C)cruQV|=7h;i+EB-sr_&W8w{mwL56rTPs|`Q&Svgm6_e5B#mZ z>P%-}&trIg=99yU9{O#TA8r04U+ujGSVc z`J(3z^GUkwJ@%?Zw`rvk58{MZX}C{oiNbwR0YBPfDEoIRvM~KIhglmhSPGq%kjff z$EGY}^>SJbZ5M~K($yaEr_Dk48<%f9Dy3dfHrZEiRE-c<_e~g#((klg^U!NoWD`X8 z???6#Wr+LV`piX`MlIDCbW-|C8NB1V*^){l%qPfabMyV8-zslYb)#K^nD_>np3A!q zsmHfy%XH5*zVsufe;kCH|IyPVyhXT6j6@2_Qf>s}0+2tgwFv2vE$Q%9CWn{CCTSht z9^XiZ7EC^K*mLOR(*A85v!iFFFS*GlILi4DWd1dIDQhh~t^)J@HK8h7+fur5l8}3S zieIs$t(8~RQhILBmFYf9lfD<0cfB%A_PXphi8=OH>@ejCBU?9%a7tE4idDL0bYF&x zRHecs97UnU)r%ILTFPO7w)8{Y$n;H9GD|mbsccW+L~=_8so=gz4c@MYV6M z2x7n<+(g3(PGpeq*RASaA?A+LWh2a3BCj|~o~!}gXB_;wYOHViSanVxOC9u#Ld@be zG7-af#GA#d532}$6vkdQ>CyU-*ypB_y0v{lT`Ihe+VPrzqJYQ%ckv0i-bfN!4f`lw zeIme*M^IUp;K|6UkMsAd1DuGt^kp8hB7Vh!bd=*|pwlLFtvOF5NN~Ta%YcXG6b2BK zw=IC$MoapEXJvY-BL>lYzqF8JqW!;wHUtKZexf+NIB%$iIgN_y$pxm9AS;r^tG z%BQ9mJjBZJ?j*>H;bf*g`rw_%u4mQwl7|Rmv+Xd}M^(YW)|ni-;ubr@uk5s)Iu)Ll zZ}M}j@o(hR>1+8lEHH@dq+eHJ}*Y2x* zjqwmn4D0OJ_|q@?0yEwkC#5^=JBG?ia!MWb*fT~%IjhapH-SG;5vpggBkHD1$Dr-q zkxgI&UEe`^qXo{Jh#q;|0u__&K_z-yOE(fUtxa2-G+pmRx--9w>k!P1mJSc3{*Lb@ zv}~nkINnnzn!~3WDyA#bN9({_NcWm_oODip8S*A|nUhff(m8EXHVa0}9^ep!SLHdA zQCc-$jVaFcSZtsba_MM{l~Nd(A}1zMf(Yx)>=O5Wi#zz4xUkGC8WQ=EZyC5Br@)J6}DxLXc2 z1fE6vJh9annhz!4r02$D4B@iis*<{~;cbbP+LLycCj*jk#Ydq8?t2Ey+F#ePM6gAmO9Mi)TK&1?w51|(Zfr(cD6`FQklGB<^qkRE`I-#3H4C z$TR`MP=5GtnY);QVL1@B70+0?boqr^S68ES10P2KOn)Nrscq50)5OIuRwbT#39At7np}T06o)6@l`wFzx#^}P z_$^Y_;TprRWW%g)pAD`B%rzR@Le?5UrO9iRcu0MdQxJsaBN*!3Az~MJ)Kw|1O0GhH zNU^af4J?sqN#XHjr709DQDKo6#Q0oFj$UFqO5f=@Fp?P9SO>$P$T4D;AR-_b^fzVt z?}Ik`Je@iHZStK8G1HzEzclZzP%Zs|2g-9Ci*{;eqXQJZ7FR2OfD<6q;g;#B0BJ5r z6?K7;?fl(wt6X^eb{@-~CAaAM@fEcrD=7c2-$l>W(jH%N1`=~)sBpj1B|LVfo zI&)U@w8Q{PE=d$2HmzVHfL?l%*B2x3M(tXZXVmz7Ff^YD^HA95dAw*5#u4PCQRFH9 zVZ}R@?w081F}rtN0)1+kU&rm6_Cpl1Wj;CB?9B{9A|Y-9&$}$|4MNHk6lPopdFg17 zuHb>0q1Um=nGKrkrm&d_2z72FDwh>Ai-}Q>GQyxE`(v5gvh9k}?Ke2@wMO+0S(rAy z{$d_lCDd~#_qL~p6)YORk`(7+&_1u5YD!qw@^FB_7z#&KSyHr*R*41@e=4MXeFGu` z#3kHi@GScbB4sUo^>87IlXhT5%M>pWDVaUkOejo8y5Qk60NM?6*%ibW=oksB__ZEk zqlZhA^NvhJ32LOUNE(G<7pmmF6Ml_t9qk8RX3LZA?b1e?X+oVBVNo9`^tI{0xM4mY z+V|;~9tX(8xQLPUjh_!5yvoSIsc6`wAH4U}+ej0k1DC|o*{(c2beZTMOn%GNj( zk7r6KlHArbf%j1BMq{eGwXqAh%ij+TDU-R0W~y6yitp(q8lH)S-m&6FlR|%*nckP9 zYIZT|247@n?GUvr9#%Adf5cEwaTlEVB;A6hX;OTzi@rNRU>!1OW@kg;6NtHI+;>$n zSK!1@DB3bhm60)L(7h(IN`d-6OuYqMTTRmknuGwsLvV-S?k)`wT#7q1xEFV6@Zhe+ z9f}tyP)dQ~?oJ=HP^3jlTdJ4mecyZUH+yo<%Gu54B)`e*?9BYDl`0wRY66|qYinE> zh`g|Apv)n(Z${`ptH@8B;#P*J_7~+=l^AD!ob)ns(ob|eea6!pliHiBLZ#ja};Fj6`pWcBH(0DG|z ztK!8cGLV87x_B#`432{KN*2~!iy9s7@F>FZ?*=JXD{Q0)UvnMeY5K7ZHVK;+Z-OjS zom@E0&+sLGPT7t)N1oRbUJ|6nggMzwAwsn*^uuV*JIR}1WewhwX{B;wV^;a#gd_ke zm0q|}eLDIY>~wK_g)q+9Er>khZ9A1cYri+>(Sf0c%DH{eWb?pGcY|DdCY1qPnzS z-ie7TVfC!M2im3TE5?VIt}Vg=Du|ft0mTs8iUED4$*h1x*oaDXTf3_APz6r|MSDX< zNNxOgiMQKx!mqZC%u#VT+ComS?6QCE$CB;&iW4>d-d}*y~_q)vuQ&- z6Bcfy14q3VIg0>u-agK`?hS-F){4KLw7=?aj^Ig-zPH#WuK)PBK+Omp1=V=V&gV8J zEqRCrpsycUwsR`Bf6vnD+yDTqa{BL|Yz@TPQg_vgG?{rBh11X63nRqhS}H7spM7DD8n`RbA=8YZVd&{dhBtrW1+a=xL~p^U zHD*Z6r5!||FMpM%kJ5NZ36n#nlW01Z8l)6k%Ta`Jdk{~lF!=mFE&z#tgS=_xv z12c4;=#XcEXy%mnFBql(OsP)N*A|3mm~H=ip@@zKz18erm=cx&8_7eQ7+SqeX^x@i zs3ZviVfQs4VQjf)VMR9~XD^QLxeGt5VbUl5l;3Tajy{%D@Xt^o1TfBye5sEVYJl|S zcnuNpaupdWyANuwk>ML{RC>*7@qkcl*l0;CtVS1OP?IR|1!t3dU8me-9p^oxexaOE2*D7lj7RIrvn{UwLpS@UAC5Da#>{i6i$M_s7l)a7$xhlz@+6Knx0V&uX zfvaBAe4UlU$>!GN$4t_qRy0O?&p7|oP4t+qc)f}~n4Z%&G3;A!_HB!SpU) z)D8#N_mt=Rx7E~fT%#v)#pGQvL|w`fd1Xud+&x_)5(XqjH|)%hghzSgT~k{XtD5>u zRwbdMYVeTi{P*N^wu?G6FB?fy)z~pgHz&lh9=W|ix!ARdE)pZghTAIG8Y<)trny`J zpF7nAIt0}yPk+yW5cxPciZLHxc<)VjpZ^kk2({6`zI>NclV$uP@8`3sBqNBWh1%~X zy;BoF>h~vmiaEF03{=oJedzsEmx{j!9oP*^j{1QmxUv$^@qM0f^OX9wC6j`74Liz~ zrqjaj9kw!NbI8rV{E3lV)h(%iXDaRdg!$chHD`d6(O7?Vg1Hmng zxAjhDy8*l*6v?M5K~)KdQ9V_^<$efWhI9T()AKMWHSGkjqE7#+Y+Gd;uzji9Y1V%; zu_xl@itsDSn^B%+6d39l8;l_Tn8z{M;@TN){G?he&&tutk&&duHu=7gs6$NJ*YUdj z#@#>EQd)lQr$3Au5y8T7tW8ZqNHE2oLWleGX3ibg&-q0moL6AIP5K*Lqixm{9#UB_ zY|gDLY3HUPOq~U&3?Sg1S>2(zeH^3#?ZHB!{h1t_Cmts(N zvII+7I=B4=cd0><=DY3X4-TZH7Rp;L@@eP{?wS!*3vI<{bsZ!XNN93&kW7G{2S@qx zc7+!k54%+FGyzyRj%5VEvS(vFCbZp4(}(@Um}}!BU)zKb$C6I-W>po^K~4fGow=t( z?T`&i7o*Z-WZ(zk1_ETBedPwFCLV+EDYegD7*eyaSoI1$g%}Rrq+#F)&|`u_nLYf6^?S z`7m~_c)|mbfwb}it%|pmYiQ`cM56q)A*mRgMHRl8ln2_9HSN*5mCM{D)i z66_2QH%gQJXeYgE;)F(hEV#ZFJVMD?E=!hkZL#F8*MZXZ%RHh6DnfsG!iWTt~;lpoYKxlecUo>VnCj+7*?p?I?bOp&ClPd zej5EBO+Wgj?iztTOj{&)q>FbdP@I~z`{Rg=3EmzE7@EhHKWYos;2%S2|$ zKZTzMH)A8B5&v6`pn*aU0DJ#GJ?QrTC5JyR<%zj*R`^@N3t-|rX@mDA#BTc}6B?8= z+XT6d(*cHKhnWjxxk79-gk$gd5;+A{E6{N=`c1js(0A<#2}np}H$YgAc0;C7rHicj_Vs(id-czn8E$ zZVxN?5ML~AE9LeqvQk-x?E%QeCe`=RJ zPTb7*DC9}f=Oi^81P_fp{h^0Tsq|pBOgcGvg;siN86oS0gO&Jq^n*#bwg^OoN6>au zl}(j3T8lCvcA~>(>!*ihm}IS*G$-w~iJ zM9gP|`5-vysh#FZY1x%I3ekJ9ayVk7A;w4h@LWQ!suhMWlYZ0tn)9lzycWo3eNJvq$x5#N*Jt7Y!ZMa3gh3*ob3ZFoO=EL{Qxc`G!UUcmtv>yHH6nuX zp`K6!CnJ@EhH*+Gljkm)j0kdW);zkMriY=)?uFkVAp6f(WZfc`TUV4&97tyu=FhuX z#E%&n6%WRWt%B!D!eG+V*(yrQhTtl$4(n%X$n%QtZ>7q(x%05tVnw=(#17bS`95Sm z?ONHZ*Pp3Yd44q4bZ19obGCNMrIUc(Z)(uY4_TK9)itNKOK${oh!CFU`2)?HxqU|J5FFxwt# zDZ)qx!;hn5CDWUr>D>0`u!U=h$?*pd_8(65drO&pG-n@HFS5Gdt2OtlLD2EqT=#D_S35 zLAbuI%+7uHu<;OvVMzSC0jd*`wX5`H&RfjhMOfn5id5u1@eaH=H|@K};I(0MSb!`! zaZZ^>oQg8SBMwOxY%W&ctcbF&Tz!BHvDV!Q!QVVhwpdlq!CMI!>1dF&_PA=d?MOkt z$~hHT2S*k1wR6*5nWC!sOD)t`RNnJQOFftK^PtT*3s7{4{JYQ5f3H52I`^rgZw12CklczA~uH3L6{YDpHpruT6lZTmXHZN|tuQSc(%-Z8}13KfuT@;xjgeuk<4yd%@yV>%$9xy3~_wTDaovFUnmPJ_s0PS zzqtvOOyuw_YJ==#X#$14?1Z}cNp*5HqoR@g%)>I+q@Y3**T*rG#Bf@6EIe}x86F`n zcya;nG$6KN(!JJL&1IN5B?EKEeHNF4qrF?C+0h$cAV5Z;$1h_Cr(MQAo=6bnfv?T@ zX%RWJSSJa{N%--z5Z5w5vfD;#PN2{s_;2|F9b86~fb0EhbyXa1K$votxj?nkbRuAH z5*rA_(k)jvLrhtt%PpzZlr`H3GgD%oM%64t89FCAY>df0e_+Q|%pBBi|4AFO0w2=_KCYlk#qP`SwgfMTQvw##OwkggICx?E7UB7o zx)&62V8_SI4wd$nd*7aIedB%jJT~l(ov+Z5bbx5$h*SKU%=3U$wl`lCAk5WoV zKZy`IGy)gY-{%-=UI=0%^Tf6g;`e9Gjp-M;dlHoPf}<6+l(PvUEP}PMx%kdvE7iV> z>l&SY06CwRLhTfhbe25+>%^VjfSeMyXXf)@Y!YH2?8H_*p=PoI>pueDGW-zPs;Zc0 zS~p!q?d6pFzyn?OcDAL@G0su-AL{m^Ki3Y81yhsSB|R#_^~dCwFAR#;}ayiNq4Pom+(PJyXu=t(qN`LLcC1bgcz} z*W5N1SbiDOexFMkJU0!)Dq>cR`3lzAyBC69-^O?0eRKri%U+_qY!@f}vaSsYz;@Rx z`2}_c<+n#ae)+oLrRlZR?+1AXR82F)>5=5Y5#oX78q4R8HjMaOg7Ew}J>ru;<*EW&d)tzz$prgvnIbTlbRthC9IO=?Vs?HK}>78LjaS*Un z<->6q*JJ=83^<@|9NapE@F6s|$iO2YX0{UMbwfoSEFEloRj|@}MbyAb_7Mns;)?a` ze&gp#QYph@w(D$SsS_mwAdn57gp38_U?E^Ah)8+4kT~K2U!V^Q0D@ql z0OWXo%(|hP106OECw|sg6)eT?qo?`aM`L!#uZ*R&WV+D$eD6LJW#Bvd2BLxBUui~_ z9+LJzj)fI+0xDb5KdN;M0JME&wP0O@p;wbbvf$YPx<&64M!qL{Igw;5!5%T{5TAI>2>es zvfH}>I;S%(uCqIZa$n3c8qo!P;WF>rY%gNf*&q{!jn|WvowM+hKP`!=lfji|yq5;~ zeJTo3TW?F4kpG~oH!O+B*BH7!I;+|x##bisMKg>xI$2o9Y-Y25n9){Hm-x2h4diRE zFV&aT){?iKy4CLWiTJ4+4_EH-#zc8w<^9crS)U8dJLWAyxL!X`{w23?C;6r`_qAt> z#$cSL#N{DjHTL=;RE0BaOMl&Tu zg!gG5z_!m;^DiuF#qxXJj31$+NkQHEdu|;q5>N3Kp<`O9y5I;0wqy4XlSzsPy{KNF z+sBEqJfhHuY&mUmdfDfVsVxj9jFP|FOyItPK4APH23c2ffa)^=zid~WjYz6Bjg6^K zvn;QF&KXnjfGEl&zXyy&8yS)Lu$n0*Ypzq8btJCI7kp^saZ~&=oFV@G+UQTTrd%|9 zI*9pg&(*v=j%oj(n0hUlCyBD84pZORdEJ1&S9H1Uj=> zec$|B=$=$$&M(my4ztzK^<=~!gLG+yGalMH9v{AI%nR)Fb-qfW`%@>fqo_Znc_tdX z$}zgz6Q^m6g%=3@MCyhWg+tFNFmcC4eK z`+jz_RGBG#oP4CqBxrYQEwY;F=kq%UHF|Nt^UB zwa`3Fg$w8Uo63>`oC4?ljQkyAjrg+-XxYgJg$lXu<>Z3!$mGA35H0>;!UvlLClg<=RBa$&bbhla7GCcEjosPA~A>!(Q`KL9N z$r~d2ylHX=Dw)7DqZg6C(pAK&4W>*fn8n?H@T`f2GcSuqm;VwGNrp7rO5`_ga>!BQ zQ@5O*?;JXLS%{G;=~t>Vg0yyjmvCF@dc{=wHPa#{^#;77mf`Z`<#pB``s0;lWdM)g zjXYZP&g$Nnm>T3=S6In;#AB?olL(NC*p@0T2Z4r4aSWMF^SZn94ui%}etvSLSIs3q zL>Qb%H(?#DD4d-Pum1I+#Zl7)Pf0@fj?dG>k;5m`=Vd`r8d;U_QivT&98Y@aUI&_as6qJj8ao;%c=2_ zYDnHB%kZaKV7kYS9y%!FCC747k%3Sg-p!Pb|Nh+in)!wt-zR8S(te-UexfO%?%CqB zVa!1KluTM!t;{Ni#MJKNpY~}<0Sw;)oR&oVIzsnlfG{kBAtZa49NMdgp5|NjX~Fkn zu77X>4|uJ~H<#;6!~hF9Ku5TJtVkS>{=30tFZ>S2pM&(0AC?lsPI1;W_^8M{aV#zQ ze!1GNY|}@|cj$d}q~f}53JouOY+W3wam`g}@|{|!oOs0G4QxE?BbGhiaZecEH%+g( z$%`)^3)B+?k|z|>jd(1$eVxunOX{>olvP%B91JHQEqKYFj@Wi{mdcDjW@39hAtHZ` zKOTh4Aa%LA&n*ATKJj9m3@7A%{{W+?#e$<}@cNZeWKO3fGrJhwo$$Pkq0*c4SAjQ= zH32OU!ACc=`WhV7>eUO9ysDtdv{@VwD>l`rC;K{#gM{N^Y{=b_#8K+q$o$wImDM|` z7pjIu;*I9HOP?o?+o#UDznn9@EQ``PyN90WB)N);P*t^lc^&kOe!+T^n(pec8+~{c zy@CI$0(HhU^fW!q2cr?&k4?`NlLEq@V0XTxeAC(;&I7m7c+sqBIndQv0Fja8C|+4m z{UlT$?_|M975GfRRXdbfjhtLX85NaRyfZ`l>XU?2sHl zR%$7C!1G!@zo+K1!t6hC&czZQTq9YA!npIRk|%xen<{mmX(cqb+V*7P9R7XRO2|_T zYLuSyeL}sssFc*&O0KV>TY)fD3jdI7qc=ZwmSTuo|9i$gRU$OMelKDD;80IJ%aYOV zJ`Xa6pSGRLt1^`StUl}&7p*YAhUao-Xn(7-A>uvLO7TsxI;Ev1WzyO%W|F2q;q|eR zr7v+ZL0)qTJuZFt?&wtC8FHrLxcl2j`?2^5t2c}JmTsbs=)NwN@oh>Qk$K_DRDtAg z*z{69L#J<7R}fPA8QJw8&NNt)*olZv(EFogLji=mL z^W~v9LMuhYmPv~IIHMl}0JJpT%?9|vSaDJo(@w`q7NASCT8At5qQV$Nx#yu z)5LsbN{VU3hi3OG4HV~^5>q_XF{~PGBGUL77tDZcbxIFLTR1IM28~q6Bg~j#{4L4x zbA=I_mr5*Kdu0OYuZ%%X&5pG7s3PZ}BIldIP^bJj@=|_>r4p|j9;vn`fNF*T` zCmyQD3llLJE-dTDqjSf+#@;OrcTBHRB}8*FTdmiU3tOp6vC3;=5?Fs(8$xeCe|P!9 znX7TMF_rTpYWk?>VxrW9Pc$}~CcW%1rYijSMrO@$biL9NBoy?y_&oDq>%DITyI|## zKt*!G=;ka?oZsbRlC)Ke@J+NP3OrNZL^HCnxi`eJ%|!^m4n9bo$&Q~ z2DxkJCv=*2Bf=I_eBfzZ0+sAe?dkAuz7lffO2KjrPvw2G&!c>PeQv$*{gRQMO*v$f zDZ+7nF2NmK{>kQ*cM!{a8-&$iEK|CG0hcAKqxsG3qBkKF+Q7(v!0~<0fk>C87%AZP zo$r%+RTmOoJ{ zV&z0k6B}vB8r**+aI27qalhm7R2!FUs7_;83n4`*XvkO-k{M^|9FzK*@uU@+(DfM; z0_Ykj-#p&|1PaNb%#7XY>G;BS&R#$rrYy<=yPZy6)0#e48lkaM?oV6WNmyK$o793S z)L}pCJT^nDyXxVXSXs7{USy$ezRSYYv3DTfh)1Z2OxFLDo?LeCF?-@MpSg4L`-M;X8D^N z0PqYD!n$nKrSr5???xB>%152hMNmtvjaiYjM3!Uzr)s3WQoJ-_ybbNgnApzaGcmjy zZ5r;r-&lLp5}tcn(fxbvEs1~1quXnZqYPW692XCQ5k+m+*q=BjbdAUhD72{52BP(Z zcd=YaiJPg*G?BgwMG4Q!R4Kb-0+Na}*x)kDvdj*i#lMiO2;r>Y8|-kcN>6zkVA$!m z=6#;RoVHY-n>DY_D+Sb1VxesjCRWrWx$g}-0_oMydtt)N_c)14Z(jFxmX`Nv)5 ziJeHEt5>V;RXMr9_X9f@JpIw`Fz?8EM;N4;a__jnE%)Q^&%MK2q+M(b1FMj?T=CPA zukuFF51?ZQt2llI+A_Gi)+}}t{9UMJP2YZDUk|ZPWO!E&h>|aKB2FRACLcGNpPx(NX`iLqpT4eb$4;3Jt+Ugbfz|B0j8pFPoNAAHZ)p!PbU zi5D2D#kGXy@KnvOl|t)fEfEtcapiR7cm)zgX*=3HX`} z-Eu;NV4~xGu`Rk!dcFe6ng^K*l|JB#_Kh=q>lNj;%5<2+84*o}slt3DOuut=IVB?)PP0q@o=^$>OP_sCOrkCSZ=Y(WDW!fEdv_*kxXD}8))xV&rY4^1ss{N zL6hNu5aK=rViDkS6!tOFylD5qVh2u)53PB)>iV0kkU>Y*8>8gr^q`pk_!#18}X4>qE4-H;Er{yzWThI>zn{J|#ngEb{kA6694wjv>() z94r|$c9Ee!8owE9uu-EQjjd?<+y3AiZW3;mmF-{8n(2sLZm(*U(+0L(ve|^zkeZLP6 z{(YQ2|BWwc{w@P!W_f6(MSm?Sb3AgHo*(p2gg{I`f{#TRscxm4mrJ!cGWzl!(%kW_ zY4b%k$2PY7pHg1s&5q|IDv@uk)aX3~w*Ay9Q^&(cM5W}V=U=I2eGhjn)zvU^7YxqJ zEf5-ic5P`s+Tu8+9)aL`(Qch3``ptm~5{}e4`f#orS(6{uq$!H3Q=eJ+x{3a&W3x=H z+|sV)6(H~lvz$#8=!4VOwj0}(g!bAy%$7ddVC32oNUgenWr@GcshrOpx$V$$jO=S2 zhneNd0coa!np|m-hOp_q#h$Nu@YXoW1*H`j8Nj5d?3;0= zHT&3S#J^a&M-E=lY0lg!4@%7nOm6T$^)ixupW;ur5a1GL%E5;( zRuX}iO3krXlpKvqX!ZJ!|rH)R11Q&=x4g(xvv&rgBy1V{49H|lxd(Ne` zB@S8FFOxfYQ+S#C#BR@D5l{Y*_}gZ0nYEfTH(JhRRjPNisZYRXZ7JM2nk1;q^Y=-I zb(>+&pV1B*$3H8Y4f&(F-Z29(I?RZTs%*F+09<%cOL5u@|D(MuUUTzj#cQi=U)V)858sFvVB>tj`(*T9f+mQtyv( z1Q{v#MRXb2vL1=5^$_ZqL(@3&xSM|Wk;kuY*<1_LettoEZC`eMrJ+)@{nBMR?@6;8 z?Ck4XBtNA*kXAN|*siv@-*4ob)@w9L_^ZKD&O-$%=vc;)x4oq4R3gh=Y5FAQrNle( zYsZjPZ3)?41~TI7Fjutau?C)nw7fZdam9Y|Z|p%nQ8qnOa^LZ(t)3WpjXQYdj5?($ zIZ>DXQ>b8_>B+oP0n!O|u@=y!G`+Xrs`>P-ihYG5Ne;|(S|QYN$?mAy$Th>bYH=kx zgNkVWG0$2Wvb+lKk5Dr$*CzDBzcVP%JT=m}{x@abM19?(uYa1;xu}V+iVjTi zZ0xLdbj43cYe9R@q1l@3=dM(-d-Z$NUPI#L{DSc#dG>HME!#3)%fDq(YgrDUc*FWYjNS^5RE5 zz9#YgTaHM+C$HT_=sq|}9MxbLi^L-TR8Z4kjIP5{6p!{uik}u1Ee?0T?KuB@JZCm6 z1^S(fY%~09Adw_E4#Y8k)S8kE?1;>4xZZuA@lU!XGhePMhayW4^--y}RT`9~RdG@C zY2JoK7VL)nTw%YH0wY+LhJRan&wMDJ_CCMbLG-WVVwJ$TYeUB$ z??glUyDQ~NqrwR`SK`P!A_-mh1g7J^pV5L^p^G4)1r1}Nds=%Dv%Q0j+U$v$O7@$s zj>BJgh-y0ZZMEW8pU;+D+wug6Ip}P@G%{Q2=Ykf=@>Woyr=p?On+ko?;;|~eM>Lrm zv9&X^M8ysfjEqOCL_3^jm?ebdlP7dLeD)K1Gpg=q99feG8RT>utb#OUo4FHZN6H+D z;h%BUQ~Z!0@d@LtGQorSSgcM26wsvW9rhlzhuc@2iD30RY7;cUqM zS?SjnzfrRPZR#HI-W@ucc=H7QngzwQaP!80kdvSiJZGDc#x7o2jBJE%Tl z*Za8Y8{HmXDY<`ax(W|Vsz<*Rn>w+5Y+wkdtg=3i!gut3KX_CMVPZZYfws5%t6P$7 zF{-F5Z8|-Rd-lG=H~J*Le&w0^2dH{Tn#OmulD`!%+2I|j-<+mHDgj)))reiHt6^t`^|j}|FP ziORJts1rG86OeOeS9=*c{Xx<&0L$w`MX$8gPbO7FI-BXAv{2{R0@{aqp|myV^XZcQRA;>D?3WUN=VbN)b}S}T-H)dNo65Lpg<=Iha1r5wUb@5+FDH*7l1?#AA&|QiDuBjYM?u2Pvq88uOd@vlEo>coy!Z3=HT4K&Fc>Ab6JeA;$1L3_FZw zAvYqe7h2HE;b2nVN38WjLu_sLZxGLeb(?=g-s7+x0FNiRRj5M9Ux0)fU2+FM$jyx} z!a34b<{#HI;fCUA9deK;+~N-bvF-bK5D;+#?ZHUQRh1v;e+z1y;ZiRQsLW6&B*(iu z;2H?{;Nyy)Kk`+|QI+I?`LH(Ok(aQD?_6Qy|1lQQMXSd=n?MkglnwM0T zYJ~Dq_jb5sFJY$>BTIPf`62{rNRpd4{*Scz$RCg}%+XadS+8kq55 z>?{1Wk&nFE&>=txbJ8G+6^82~1m;b_Ap}7=9-{dXEvk{Y<*1@82E(RZcQ}`-MoUJ z{9vXHTn|9&6{|CYcFzL=dht0~SgQbR05Gss;DyiQ{$L&c(s(BqoR!v>LlhjPzmBl^ z?UV=}xseN1Xqxl@+KHnPK-GY*N=N`F6!dG5&{zb3zX2F|*!cW^6T>%*kY)Ccb!Isk z<-nt@4K8TcOT7ia+rbBDUjzV*8(75*Zd9HU)`Hn|;{Xsi|8``4@IKK4LLP#4y~v^s zrGvKT3Nv6yfby+km7^~mxQs{%Z52Z)S9 z*pb?mt0y57*|O9h+^{ia6j9WSDp(H-$A>tWU^pox5vBoE1VbP5uoND@->lZD?z;JD za6pUPK8husTfgwrOyVof->q0J;`xeq zsQ!Y_&8RGy;K+KPb0$0COb$B*JPA@%FhDHX?!+Yxy3*L`+e%?_c4?_j{ZXmF6hG5F z?B~~hgPo~+`>MsgSC7p!D*5Rn`fgj&m%OiB;KF>$-3uqUB79H^53rwR19S;a`MXZGMWMeVadNvSgSy82aL5bu$h> zrzZc_zgRz#fpMArHs{HDz?d;pVn6ibC7tpJ<@WVo1}XWt&Q0Z?W68bO8@Rrc1Ce)Y zcNq7Z&R#-6B0Y_Rrt(K$_1j5V&Kn{DH+xUG@bK1BGI$bgn29Dr*sb=4XH46F z)T_vaoU}Ov6g#oRN1Dx4Nac^EwuLzs&9>wwl9j}$CXg3kFvD|t8Ud2>qwUy5au>E9 z+w+T6C1sg!Qe@JkFdK)i16e}FL-dxeAUp97Y?F)Q=aF=v+z)IkVhJNh2;WS#{())P z!a!JnI!UGsTUAunDckbzRf>}ck|Ur~X5lK7HJ7<&h7{8(wXx8I0&^N;zFq5$EPrCX z@{2S0bR?*7)8Qu2`{+zJfWeOI7a`A<&*lMrT~Rr{(X^4T=gaiq`bs4^&1a{43g7KKmOIXaK*bT;(Y{GNnjS8Y(YZ(nciCaX)30^I z7rWAGMdrfz?}}zREvq)tte)#^165L9Xx-A)*&+B0Z{JAiVpzDy5{!7={oNYB`$w{C zQ4sK~*jf{%08{4NM)tC(CqCW$m~%#<$%c8^l-_eKDHUSHgazvGEG=H8{pSVkv;J-asuO(C@aB%m05EZMr)Jy7@#rkdN&mAQ)EN5^k{v@ zkvgu-L4;kmG1fH^a(7+c9~#JY8>CW+WzO{a#H=HLvN8%K&~_}$qga-n zs>nBbE>8D+Ql=Q;ZhMh8=)~`^@6nN#nwzSYNwbK|yqRLoJJ$r#VL1v3!H)I zoz95TgE4siWy+lvXZm<6xYIvLWH_dL&|+^(?v~Pfj9P=@7cpo4gUDUZ(%jfZ6~r1M z0UJB&`7ehNZKE2WOxgXiMfrJ^>6*dlAN)9PzckA4RGa<*#|$j+2f?-`?-(H*f(KxJ zo!A$02Au(3dEgDH_us!nkZKwsI1Y;I+U>|Sedx_x&CZ$E5GBU_lu;w%2Qyi};-<32 z8zAh@miB^;g$Pc)2wyaksR2rRLC;bKhx-DcgzCCi&?(`m&)B+|hE&lneQUvHT!1Ao z5J8Oxc*0U9l&jo5h4lD$cAwfL#|dJzYE-RsN}CtMlf%pGMN7>1T8| z>z7(HQ^V0E8qvPRd|4|woARNph1muX11$fm*I8fWCiKJ1iaNT1_Ak=(+tLh9MabCup z_=I|3t;r~ztY`U)70JGF>~G)*>>2b?68s#e$4nm7MT5Z`GQ($!?zBj9ffFx8&NV4> zaZu$Ff&q_|L{h;^w}H!KL}r6904uRTqoduaZao`d46l|4_<57|i$cQ&DPhvgna!<1 z#?vaq0V%dNCG4h0u;#W7HkM}nm>+aoM8Y& z@f0b603|w$%vewt1T#4^q?{1Kv2f4?1{GwM6QV0%iLRt*u5S&D$dXeq%B zZBYcb`&pFW51&E%46m3$BruKfv@4Js5D-+p5GR%q{c_Po*tK7sW%k_SiXmwCnLNdQ z(lTaJ1F}e_J(x;mz|~Pzr>vp_<y2?%LcYvsQTXJ&Ujj9q`n|@ zJftjYB-ol`B3P9U^XQ>nsKgj$v+CcOMgeE1AhH0wpYu3p8Gv?qoeUhwd)q5~!LiE+ zm1A-e02c+IXagu!qd`~y8h`^Ev}(Wbeg1y%gXSwl_0! zDYnqC#{+~_1DZuCYX#tJR{#+700=!O;-L@SAK;V!lTcXag#Ha2orVAaIGYq=5xT*) z?GmfR0>vQVr1%sRYAo2ngDhem>QGz|w-y|k0!yoTSW}d<83BdmO*zPNR9!|i+VV8` zt+K5;RM@gK*s_$SqNC&>!e|H~uKqONgNTNR8^$m{$araTU#d5zR6FrQSgD!Wz?lyS z4qPA&ga-8xNZlTa$Wq6U!Z{AlA?-j!aUnX383P1E6`>#qiz7x#D{Tw-UM+m1AF-s4 zU{pJ24@U|d@-VB87HXCS#VX~S)R}1=Mc@ai>^4?Mf@Q*@YH`(43a$w(REj>lJ?{KJ z@4*r0nc5@xeX2raclzTWS1m?&A2v-%qMV&md&cAlLKxS;O==n!E4|BCwpeoEMYH{| zk2p1t?eX|AUCr(mYx#`rTxkEMQ+GV|)eP~|h#;}?0M;3r+!w?_&!5mr=2_@Feh`i; zQA^VjG&@S^CYh%8Ap4OpPGeJ%aE@F+sxs6*GoZd&U>C39wJ^!4aknt&Z0YaoV{MEb zb~PuDjed#|U@ShrH-Vp}_*lDY$X-wV5X$@bseT*_Bz}&16m>qGpjjLJ~9((HaAq~ zZj-XmKeJDym2y?{|H@v2dJ>nn9gd`byA!gwF!_4SCLgzbG*C>ByU1ij@^NYWJ}f=v z5Sv1S^RH%J7k}HgRO1Ar1WZ$8vxbfDLZ-W-4 zqd78>Z>P(X*W&_9N>Z)c#Gz)byBXdd8nM}eF;E!1kl>oCafzaq9eo*K{Z8>p8Q^M4 zXVl*59=hZH?H`jzBKb~VzBUJ+EwXp&JPnvDe#4qy`ebXc6=K64xIU(rU_`w#X&kUz zzWa~axUl?XzN?7iSkqv_ip8@pFEg2}!)CW(e4*(SO#`8og5tXaeDXxR%yr2oj#VvX zoFk1+f=5;>RyA$p8qte{p)s#^4~v}Gg$M@G?DhvgOtcd7nk_irl;FISLw=tBHTqrf z67$)mO0&f{DbYV7t^KsyWlO&0MN7%j7TNdW=k338Wpe@;&MH+K6$VbqG##g9AR>*y zh&4w-1FAqtMy~ypQU=P%=u(m2>qc*DepDtsDrpi=3c@`*`G z8lU5OI;sL%Z~6SGi=D{`$AGYgz=W;MnOBlJmLMGreKkic$NOM<=ITzQu`L&BW%gFS zOEkM`J!!kTYSV1z5xt*WtBEK3r1zC(t8#Hcu&WFGC9^GWu@|0Z%Y&ocOv}dafPfpr zy-17>MBC9oHuv1Ho&RenZAh5+zNCYuiTQMk^8J8ob6;*!m-K)fuW}8v?0EmPAh{Uv zTbB%JS;S#DqVn+F!TR-po{w1YwD^LRmwD1M?<5K1ktCLby1602&wR%v4Swr4W^gyf zd6h>u-^~I_wTQs1pI^YFO2+;!#m1Vd#L*xHJ`G%aRbFU!YLJk!R+d-x6kV4Q7Bg^} z61&PPX&yx(1X{7DcrI^(gSmx*FGpyTT}s*h#|Q~jxvGtU+Jg^F5>c8Hv}m>})deC~ zVj+ECcx3M6bT05H<{apeD~2DH^DhfTWdU-4Y%}llYien!%lFW`stw32v~)8M2S>dT zC<*~b*J?`%0K`6lGXVAY@C*nxC`xhfKipHJK_5K`L|_na{b27ofm)nAxB zu+je=Bx_(OW*q6**;M(!13^^y4-IgZr^6>0144R300S=hAZ}nH1sA;m1g0*WD)Qjr z)X8lOB3LMoL0QGlNCd|*OH-PkgE9XSwFfuFvjVGYLO3iQ`7c2vuyN?{k%SWD)E>P1 zECvM3FV{NYJo==hAOd_940ojO0q}o)p=JjBox>-+`wzfissHJWh*7$yWcw-98!eKl zei!}U0r|LLfio=W@sxjg=4Fh-9sR4JOKt;5l!z8@g5?k+wF~dOU2UH)NW9h zil~v>8XUroq&0m99~=V10zi0lIYHbX3P10DOjjn>W#q$m!pHUS z#1PTL(F6nlW(hMEC0aC!1i`rNf(4=^w||rEcHk6i3LuQ7mi6r31`^<_wTGg7s>ujp z=lSO6xDRzG7TdroyqHvPHlcB@yO{26&o*e=YfBtK=U7ErwC;n}Zcu4Bih!UE+FlQF zSv`DpS4yP>ZU4`3MEGDafk9=ZC?fo=fF~JALa4JC?*PR&-O+d8!MNvN96O;)Gm3DL zNqN*D<-1Y5>NbPu`$tZ*{0 zAL{g2Y`tj_RM99sEi5qpztYYFu>fukY@BQ1K)}B*%7>a@4?#~y2UlA`7YA<_ zFMls#VSykAZw-z92gMWsfcFrT5cnTiC-k8N>IeUS_!{8 zk3ew0aRIOauy6sP;z8@?v{hB3he6>I8z#>l97KtO z!$i@iAiNqaqGTsZqM*nt?W0EgD2OixL2)A5IB4HphZP=zz6~8=i$=oI$kDP2BxMpI z1&7IvgL9F?hEAImm~>G1wSvN^==>})i^KRfP@$}J6Qa>T0Kp-~Fdc=hJUx!U000I6 z00RI32mk=LQkI`vRmTZl*t^&pd)L$w)4yh^XyD=kmz$ly1cUzz&akdsbP;R*hH(=J zuUEMbfGEwhOJPsrJ`y&qN~y}$yfR1CaVI*%(XR;(~(e)P301g&_fC57~MIaujNUn0R1~s8Xug?U)za_Mf z$QIMCFNg8PA+-o!Ecq+#f=FZNlhm54D4TMZ*j!FT*E9yk;3YPT2o1=x-{uN2;9ILo zZ^E*ETFI>jp-|ZV>jI`em2=2ZwbEjf-e9m~AOLM#Tl@1!9ius(005YP2)>Sns2Wgr zK>>vz=R6gNXUrPbQJ}^QhhU3!1_)sb2^!}x*m=bWsA@2kp@NC9Qu%3=xemGMm=GXg3Ej*6?tv(Qd_219c4F_$b4JEy&bY z!zea@64PXZV}WH*n2V51^p+(q124joxZDC&;4iTxgV+7+w1@&^RG|zOqalLOdwhe)gi!2*k%Q zkO__XU}_;vXi^YxG|dHU8FUGhie0pTfbCcqCO|O{HpI#%&TV&hb9+tG%Vp$5taqjR z@C^V%%-&&FxCDvmYUl*$a%{P<)d@{cSxZNV069rEw_enkQdGTo3N$NslE{Ch#_m#= zkl2YNe2d62UuJe80e$OUUnQ65TE;}z()ET2-%Iqbkb{^+lb7Iq0%T_6z2b?;h^Ep= z*4sPlVs|sl-vf7dFIqvlhE0Aw(Dl@^S!UBfHCck+v{-4jVW&?ZpxU8+@UYvYenzBQ zB!vuFDSV4w9_7w=tXW|XvQW0|9ME^rd4Moj_+DHs3T%!g+Lzd74`!`pL2k8 zge)$hAeaEBpcDwf2w}7fkH{vX0Hhs`v~~(T7bQuI1DS_oMK$6}G>d4EfWr7n$)=)U zOf`fAk^nLwCT@!qKpVb_{W$E}LEHt-c7)g#NUYK%#n#Qr_C-$vL=|2WH0u`dA!!6U zBs9PPWAQ}9fC0v8iU0)J_9VswLNZ7O5;3t10Ew}KOh62>34#Cv%Zu0{Heud?B1wiJ zLGa~Z65k>jc*PF5qjr!3f#YIn4=}h?V^Oe74Fdtd#XuE0S5KFV;uHmlP+?wcLZID9 zrhq40An*#>1|z@#YCHhK089u2d=HxdMitJ00gz5Wr@{zgL)+Yke>IOi9cGp_;?N%8 zfwQBEV_=LPU}gP!3V~>2Mz>xdc<&Z4^-xNwP+I4pP;KA>2xKOo00B4T0I&ijfDghR zQPc;(VETdaSA4&usSKmY?iHV{#0!L)DP+Xk^Q#}MAc z0UwhIUN zpf3OcuwVh=m;jPSO6LbKUI3z#2y%9(7zKpS3(X4Oo&oK7ZqE*@-CO$!1s*|E)pdl* zkWsbJJwTQ!RHTE=O8^{yLce$U2*pAT9+nfZdaC7Olu4?(y6+)nMA|ILDx_F;mqJ9n zZ6pE6CmK5#d$Bdu!V;MEq)y$;yy`FqDnt3D}(ie;W{ z0#0?dj~6q?86|!H@ykxmK{;MP7 zjU<+YCE?Z&m&6FxgjG=`mJTQYZ2QXwjc&HCKxBd{scT_CIBd24L&q}7TJuN_vS+Iv zS+E=H8MM*^dR1XdX2Ew<@!!@k`lp;l?l15VV5GTtU4-;v@lV|g8K0ny*t}9^uMX(A zp>d#6KIj@GomuesJ@{NQ9~MiMDx>XBlc1E_0677Ae0aO|-g4x%A)4F)#kNHmyVx+&7X^2uU<<{cTwB#5BCwKO6 zUnkLVlMEL4prmFsfJ_#zxd*jaFH|L}QXJAJXrD{J?ZUPZSt;+OV1%*7wFVXj_j{9` zCO2R{2QMU9P{I2XYbzAhLo!)EB|ZFR9*eT3R{?aH((b1ENHKhI$CiU~&>5o31-%n_ zo>rX|CI1@T8>8o?H9sv6bHk%;#|}%%6wTKsxkcE}AfZP@31dyiR`Hi|APb!37^#pn zfp8tYEz3+DK`@H?5n_9X25}ih?kMbthhqMWfi!9l#2gNI6U(M2EAY z?YuG{BBo56j66d{7!_8VTvei=RG%`C5*a1cp_KTOOu4F+K19vN*V!3ZRTqM54`3s@ z47%GtUI|--R5a6Z^fDTx7ZOU6{8*a%Kp;|w_*ylkL^YLM$ntEHl|zlK$gIx1a*2v| z?8l&7=f8nFU0BfG`okhEF4S3r<$N0nVwik;l>Y2!&UG=RB|<$HjHIHSLpgRDo>-`C zuATAIGQ}1NyenNVkzXIEdMp)FIDk`-_6M1DX6!aAl@cF$8a;?d0cjPMq9(*e z9*vw}h|>R}$v@sm1;KkGWoksSl_(qyC=U}yDk^L=PIOT#aV{U{`tW1JPR*58^Eb1_ z?dsaFQ~k49?Y0QleNW@qZ7gvmp0X^EQzfvt?C6uTO%_d%6gg(8B@}~#uUH~6U|P19 zbtZ;XszHR22Jk5xMF1;rt{z2PO)L~O5XD=L9^@A{*7Y$(O|sRwYz zh*cGwYJ)`s9pW%_hp1pkCc%bkp`3IQ6F|o^78ya(r%Uu+RPelHb`qx`NLOECGp>Pi zBr>1@SjMBYG!o=6w$w@F4*wL6TE;j9Rwp0!S~D0eHiU(RYzmm}Org}kAkkEl5V)AU z3W;$ccIsdwzQT6CZ`h_kngVa43_qib%D%s?Xy1ByPLKfKi)PBepv?c6 zF+t#Vc%t&PM1`|WJQsCUNPbn}n_O zc7>EmMdGhizPo$j=7Q3}JV?BUj>|s^UT+fN-Yo2gQp)sw*7PTVIT25hV0e-C7u_m> zy*4r_4`?N&ZixOQd+9k&B+vaEQNikh8Y7nSfq@8=fH`QR!RfpFX*btIw~w@aJyoU( zl6r|M1T%B$z4b_$I(5v-OT@vvC|{|e@^pU{RS)FGmBg*+@Z}=xxuM8pkrF+?VS;X(lJL4&JE*GpEeKqLn%Xp}GDJ_* z5?FJ0+?t%(cZ!O|Y9P!~mF4FCgyaoC#(Q;n@JlF5z9$t&5?L{vs{ddbbA6Op>NlO# zjboY2pAc;{D}=9>sA46QTQ6)zd0Ah1r}^hQh2o5b#>?lHt&jzRg0v{|LY-~oYdO*? zv36yai6z%1@8Z2!m@WH@SjWFh9RG}9&vqvFJgc%42YS`9wjPo3MwjPp`LIC7WLuFpv_+4@j>Q1dlO&izyd zL63?ZY1QK;RCkx|K49`>_qd-eyVN#DY)bFMxDIKcT|222cJLr28LCtM57}&|iVG;^ zw?PP2>A~`46kxruSdu}#L{EHL&9V|6TpvETK-*kL$M2rnVkvLZew)itGRsjlx`OiR z(vpqwc|3dvyY0+x@MU&#k7f*3+kI6ioc9VXV3MgoVVIjLK?R8l1E%JCwqJy<3ZAk` zprFOXv>x=;uqOWK8YtN(d;ug0iJiTU55-Rfq(I~q8%>nOvZfBi5h52#Fmw>D?leds zz%BV!2D@Lz?^p<~O~i-nVXzR{0OzxSu|U8rNzzN`<(t15J?I4*WYc{-D1Ne-Y}^x{ zC$fe`Xo8F3iy5jaU^ak}kThQxDigjqtxe5!bKJ_Zs_+t+%B3$-ELKR#XaZ&svkn~L zO%X7X$Y>^x5rC8%#0LSEG&I160-$IV7J`y)XbmdSawggo8F@tZI0)d2Rrfbfj8Wd5 zD>Z7~LG!l$U6GK)wOqV)0_Pd0+1pjeB@My%0m1% zJeKTT2JNDVh0%1CXuj75XY@S@S7bo?n3c~uyPaEow-xYam7?zUuE+?KDj!ynBqJ;?ba$EF%41miPNt#*F zDD^HP3cxu>4_T6mvftW^^~0(sE+v{xUXEF>f!dpCS1g}3m`xK&)?yAievO?Kh^r!( z@_X8LgU395fvH1`{wf3vsi5W@&VoHk>YuYJ=FFAp0HGXC8OAVBAQkLMx{}l>-HZj- zAApJhJ`hYRaAm7ZBm$97Sdajk#>tI`XgMS{i>0YBq5+IR;Hn8D>L@fJpo$HEmQz14 z^cYl|1y(#N2+%>9j7&d*(`tKCbbi~s2ik4o6+k!HCBUVlU<4NhloPEm5t~jh z05B$GAmHB%igz7CfVpIhBWSG*BkY64qUhOEn2&BQjm-soOxjcPFJ1n+2}`vl{r)6;%lT7r_XVc zDDvaQvS+h;ngPPMKN3AWJejlUYC%jz3fi;9tB#=i$-xByyZ4gWHE{F~K6SqyTU&Qv zvPr$MPC}l-j8f>+`>D;r(;}SIIs)1E8x)DWrP=JX3sn?x<}9}9EzU_UB-WOSIPpY` zn*TbQHd(lddq@_S)K>5oQZ{uH7NQgvs)Z__7az5Xxq&`JRI<^_T6S|UnvXQRS@2!< zC^kh2bS20BYm;p7TJXa_-pVSl8bs)}$e+w-Zd-b)I-=ag-9YRh@%Ojb#R#Ok*(y8? z7scJZc2sYX@O*Bui-AboX|P{;0>RxBSxzFh)@FmG@}uL9Ran>t+l#7nN+hKPmSAp4 zA;D#VlaB@^UI*E8){&R z>;huv%CpTUQH38U@y6^8lpyiUidPd*-w22qV_-#f?4_cB2`PG_fKANs^$&^44?j($ zIHi+noPS!??9Yp~$~kIhLFlxreJrMx8%H-mZC!Nxh+L{cU-EWdbiz#I=X-R;GjD~m zP1uk5-7SKNJYNsL8X9uJHg=p{8dmEnD$&5A(AsKr`N;l{A;udt*$^HcBQq`CH-tKE0|t z&itICya~xLkN9)9Cht%yiU^;Snb!_+RlfW_7RAj8PnV~t1q)RF<({%`iNRd6%9e`k zv3^18>i2lvr73ShS|*W-ES7J66dp`n5mquvR`PWfV{~Td2IYq-ZKvoTENrsVnCI-} zg=N?%uW=zEsPE49RIB_sa#Dc3ckyG}`T8yQjpXCMzcQLNmS9V0vTH9py-I)J#bXPz#5xl(Abh`O@XsZ!lA6F ziOpbAkxB>_(WVsOD(?^gQcu}-N+!gxG@?u%6e8C2v_|{tLQr8^co%696BtM_w+vv? zLTj-CVg!i@lHm^HQVp9hq%}f7;(IXJApy|8Y=atBCt>2C0P~z*V**HZ@!-E$;1(a# zfiWdgw#>^Yz(1XWZd4}h$M&5lXX^rKzr;MGLLy7WV-A2)5xJ9LW zG%DgWd{HX$Pf5{pC6xh*@^*HzWkiuvO0tW#zm}V3tTDL-E{&4DWSX-799fi59q&3j zTmf^Gagg*EkZ3cp_nqR#t&tKqF)52E|7>G|Ancgu;{n5O^{bWnU{tZ=osz%LZ4B%L zi)BxR_IE8WyuH?9(bydlN_4L3n&-ns98qZU2Sg{HS3ygp<88eUYUIxM+~Op1q?^X{ zj-}R7?7C@q;G=Coc58DSrVz<|Vk;>oa00)Fx?+hL6_Pb#5i%piv9t7$ZKnl&Y|N3u z{EwHJXjE*-D*_l=UM(pl!m#EILa*=%=#rLP9E`5XJyS7KGWq2Lafk6v4b#mLib;x_ z01yE)%vLhN4JX@$YA65`uG!`Q0000g03ZMW005z$1ONdG@M8b~00000003YBNoD~c zgc!sacrqoToAl`7mj@hBc5n!Eams0N?eU*Y5aniBWy!Dgk)HiM{`#_&OLCg-j*3(X zv~%QkOoIqX)o+s#k-y-*Uuz2QoUB7?Etz}b>KLB~#}ulC)X6R>G!LUd@9r;-DX`>) z?2cXia~x4mAL}=%lE76G&5ZatsJX*{?96W!pBiS6ku#P18YT~5q{lBdR`EMJ#OTsoBDY*$ zD^*)MEo^W!3CpF9mA@Wfp{#lWQI$tHgfK_LASY^Sd z**bv;13&v2t^;*`k5w)T`COkicx;+oN<6a~r*-<(O8K&5mxX6(Nk&{*7Y0iJiVD;~ zz$$@Nyo)xF6YeFElbJ?<&jNTk7~7~K#u2361G3f_6$XuhrU*no(l_4#B$gAiNdUFjH=pEdnt%R1NdRBm~3OGNs^9GzK~~=)h0FK%%JPHi~%tGxV4xyi9?KA{2Gw zO2X;Oq!VhebeUAc#Y*fGSkM*(YBtnJlUcXGP!L6ssHg%9tkp3(5&`SKOaKrxm{+18 z2ohXkUiktR>|VGomGn`xTFbwp!ia^9Q?gC zF&oh`Mj8f8iX?I;BF!@!bXz+ba!9r&lU-jEalu6I!8O?wuAbUnMrzj?O3|gC&ME=b z%&4VHi||kq>R?p#1W!68gH^Zf69>)(+0V91H~k|8K5L`Mc5!+!Y;yW2`Pj{EZN33< zh*il8=%htmV#@oCv^}K@-i{}&IdM{9B}++^LIV;U zCXfpQRqL^^yZf<=94Ju)rOs_5b&$ci_40{43;?14 zVy+B8Uk)$DqmHZ-t zrI8zLp(6WK9I0<*)DITJ_C~M?uB&%_Ffx@pWIR}%5V56}WsmehsZSDmEAa<>a)n<# zecQ5BLsAxA?zAs6YDjA?3Qbd3%L}nrjn39zy$zVsBM`hrx3oL!T<@>^ik1d`m8kyE zyu4Qx4Q_;$X+?ZaUE)h5IZ=Y5CUX6hY&IMAhu9r^5=Mn9A_@388bk(`WyYM+L3G`s zu?SO zU|_X_(QAJm18{m)$2Nu~&x_Gjg`(MYlNV!MZ5*S5b`!>p79RTcN=k_n3we0nx=qUBk~fno9r;N|}@G3J*ye1}sKzvOt)e4Nz^Ln zLZYIsYHC><#8=)1G7b8WAhzuq_P`kgW>Ke`j4RYiDugfs7D}N^b_D}K$g5of7}%w0 zfTB8sb&UkkriXgc66>w4dC$ON6#7(ggY~C%JqTeBuY$^?F^O{ zhOk;DZ`P}d>Cw52H4B*2UzWDBLP^>Ci`cCnIpH3-azMf;1P;`$gTt(uKW(f~L_B&e zB}C!&)izkNYcdlYp<<6`5tp2O@4xZ>a7Ap`q5K|14M{iVfY8oaYWgozfK*%Aj8$k@ zD;AIZvu}}ckLelc1l^b2qqnH=`_V;>!36519_~jKM-ZqspTebmk=UNjOm;1Nv^bD> zMBe~T0SEnApn(Ee0-+`(37F@-K&~-KTxk=YECv$C1O1h<#N3~)Ks1H&gIZEeR~N*_ zY}v&{fS`ha+y`{aHvypanDl_CVK3!{vQYqkJ1MM=33wG9)1U(h)hb8$&X?T_dTud{ zc&ajFn{R4@rfSV3^L~cr2J;u(s zuU?eS+d_jlmP1^=*+k*w@KU0QRssxSxl$-Ja1?Sd2%6|4ZLA1Lf;mp7 zTLDSbL%c4C!;u1Ddipf>Xk*~%1Z_kxkGyv+Y#284GrEdko+|hv~%@(GJ+X4cptxD)nc$G4{Vn`tc zji?17bO8`rL4VlHaUpPVppnOFU^w7KwL;-y4Wb@ZAheulhnqY|JOP)!z>1Ut?Tr{cWN@KJwvL=ca1l1dY z`kWa=mzQ<;LuAecbsLz}zpf14hT_a;`x5L#IkW2Hy%Wvc8?^Ogo$a+RI-aegL>>qfR4p8OY#2i!EM>U{AoOFbetkpBJ>v^zg>I5 z%No!gk9`8Xj`)~F3u9(2zEr*z}exw$Z^5EqYhe zd$KTnfr!8B;BlmcT3Q3i9p>1N;5C*O;X{ktmQM(ynWL5NONlk^Phl1v{l3)}qEU7i zu*GQ@AQvhDm|zea12<&~#8@K<(a-=!0094+jZA9L0000ZzyJUOf&>E4_7+3{08KN% zb)U*2Gl4-47xIKe8QZ*Xn0& zk&H0kFW|cQ8nrRMmY;P>DLN$5^iZ?iw@zG+e%l$g`ZRk0A|QHY zw-5Aj#osuZ!AfG@S;I=*$m+3W%A_n`Md{3qm2uhL%h$OzEScrfloL58$|r)g<5O-9 zDE*H9C=Yw^S9mdX;1Abo&lWBCZL=HTFZ02sh366pChjGdPXp)t#ib>n-WWo~A*vMA zG&-(r>1CGsUFBaSw$qUfT1lc=KL72r-cmr~yQA4pf}^?cwoXK`l^$fxQ!@r))q7eW zK;k14k4?rB60Bky#la)@+T)*n3|ht6cn)gGdwu;5Cp23eU%MI11WaCLUJ_pkRurQ+ z@ZjKhpc=`QT{gUdGUKtN=~#wTbHP|IlBf^?CXXo;c@fN#=`&*(*;X1Hqy(7QvKnw? z1`FLQI1Ubp0%o|D2LfuC;nFe+S~2=64<Di@~^ z!AnpvM)XKyCR|_vBCnwqv#-Zw1_P98gJhym_7DcNeJs)epp7vNf$b$)&lLj(>pl>z zV+7fioa{hTaX%)91Rv^HrL0Y)Q3zaUpdy{uvLG&YSXo?xVGKkjVil?Kfq6DeL=0_u z$jz^6I2;S0s)1aBB_YS@aYq91GvfubM*WfKvepkKBcc_yzXbHyr})qyg4mMDDD255 zaWvnfr;%*KIdi`xnSTGhh7Qz-2L(( zOe73ake*XH;{|qBN+ayEF6(5piZ(Q0>$l*Ge-Z&&v*k(A)(iZmA~fNXkj zqh+8rHl4ytk${&exesSD#>{bZqq|Ve8wIdWoTuVwl5C})&KO3lmU&^7wd)zqf;W>c zAy@u3IVXCxU4d&@J(mfmoK$6c*YuR?Jm`aE98zZEtqexw zT;+Qk%-6I3E$hK5-Q4(~n~{>%nR4Y;9rLDU#5rW>+j+be0kec37qj~4kzkQaj#MP6 z4|D6(TC^pQ{Jzpamv<+q_&Ycn69(K;UG1rbZ5sC)P=^3+18T^-I4Xm)(Y6Glz!y_Qvfh);`)a|!cEmR4m4113{5311OO3p?S2i$Rvc;r0vfCI zD7=7NyFDuozg(4Wcn0FZ$a6fx#Fz(B0>jZ`F(psEO^2+}%IeAL+EjX$V1&aC{87-<#YK)Q9K z{FO|Y@BnSa?9b2@3DWfT2|F+{us=g@6} zY|}d9Y1J0&BOtLdrm2I6a-d+Mp=*aV8sH6zpt7vxgAgO!?PLibXl$*8PNhh=Ko-w5 z(`}Qt+T4TykYY`ceT5h<5mSF|L9`AGYx@&V;1oFp^MlXexi~tG(SSxb{m3Q8JMF2t z*vX}+uSVR7U0EP$v_nn0G;mq%c!sNxBF&~R1}r5pe$B{I@f(85G|n}tHK z!~$Q{D4_TUaEch}o)m1?mKt>I0)On|QGgA?;pUDr^QAsvbPRCY`=$ zCN|Ij!J@^kdSR%c(k`0_+&N}BLe*HhlIuXET-}4OH{3!wQIjwqeqsw00CR7V(n3Ie zK621d7(rVh)$4kbuZ|JKrP!GkQ9!^H;6f_Ffq#~`C2&+&&E0p%Mz>RBDRUD9ATAa} zV8;`~8LF~T8Yii~*0Q44JH!DjpZ?ctCxoFZ_*9Vq<;39Z*2}1C0|2G~Y!rr#MBhQJ z`=nMxD4IK2K!j^VlS3+yZW5nA-^o*(K_B&i1V9&EsvsJGK%XR&7%*#~`CQa!(*tfa zhQ{!$Kwp+z%uguBKf+vFNRZl?99|BBIUIIs)Xq!j7|Ebx0nU{as4LIeR^Bo5rj zqO?`S)v2xFG9(A?THFg-2^veaT+t>lWyDdg2P;@3r5aYrinmI5n@k-iG>Afs5Zf@c za#pGos`#_2FfF1;wg?h$c|B317y>Drg_O|>kSYlWfqAB=4nW`PNkO#8f?w+p6e+fbKU{uZ(wP|+Phoc4 z?BtZQ4o?^@$VjPFRkrlGiOg2q-4HD*?aDaAQVB9^pP*v0+iR3aWyn)8i2{p37VTvL zKDBlz62MRv?KxILB$FsIT0xE4%@{jWpeprJny85&ufroY&rw?lpArDgnwN^|ZQfElDlR{^?R{@*g#Ogpek$t2-+K9^-k49}iHB(gLQG^llO=hH0Q#q%VxvrL zVGS{iU6wN>X!tSe>UlmQ)p_YCqEAA9UX3C`aH{D|1niY^7#Eb}vx*uV>5$PuO8n<8 zr1t?)Y3OgVfNo45gAGJ7x;E( z!8Bzq*x}?cjH&mWCHu^!Hzfl-{+j%UDj6k)+a;XisRfT`J&|a1z|KcWMHY7x%7<)- z40Yjo^P;Sf5}e(>*(hq^{inLC6Gj_xfbRkXxwUdE}pAl z=gmCTsPG$Qb|EBozi76fsX;}J|C_nAZxUm(bl;{ljqx|*ML;Knyv~9O1CxK8N|qQY z(8)8_2%rSfebN3r3@;%1JGhzP{1SdEvm}QpN5$PPPKezbZ|e#oTbZZuV3!%2T=mMT zxI2_oTcl=-d2n|-1Cx$+BWN5_BcJGVzDJpTX+H3NZa3rnx{RfDVwj!aSn6;eE>1~X z)9N|%5UYR(NN0L=K>P{uyeOL|}GY^k{%umz$|EXX;-r zSms`QYV@dRjDgQF6drfyAbCCvu$Vv)S)`>S1pHT>U1K-tC8!4M?BeF)>wjdYXtC@^ z;cB=hq2Yx-%Y>@HiJB?(jHhFfed}sEe+m$?lsQCnb`ihB@|WLu2G&h~AX6FU(ISHYCNg*Jzlc z*pmkptsb)ONI69we_Mr0ELE8@%K6l6RUPoMJtKu}9}{LcjlpOvn=~3Lmo$jL$1Irt zPJ8;CwI#`b_{(lSo55Ztw zH-pkvfr7dIFAN<5Q#~OHv2x_Ig0{3L@VIFRfJ_UgyAeS&lr__2_O}pRl8__B!6mQ& z3AjeUCa0EZ1b_ry}-bm_@F+75+ zFgna&AOgw+KvWc!7NXhWi;NPZP}vv~i0UU6qDZ4q9D_&?JWrx@9|Q_qT2z=o0jYtp zKy8mSp>(fhOhB#pQ^%VnBrRo-t~S`cNG0}w1~X!mh>ZgzTGyZgm&fuug#JGwWr36%QXplWxD% z5?aOx1KG`ihO8=vjjeOSROq2C>(Zza2Eekbg>Azii{mPS0wV)eeK^1bL6+VCmj=NA zup3Mm0B1_q&mn+1V9>6|4F$DxEYQlwjUs zExLzSq5wzsF#sY6K>(G>?|=_jc3#!#pwJlrWn#<`v;hNhf^_3xsRccHoe+Ra86*-& z00}6Q)-X)3kb9gv8mS1Xjb;2lBt+uni!P3TOTz_TS`*?S!{L_xa)XSh8=3UDl0pQK z9dQT)^BoD^DOACw{dCg>90ue$RZt-4AmmN%Xw@8TREuu6ta2I$=PacX=_aB^UvT=I zAOU>6?}8ejU(MVXoyE;5M6c93C@PCyO{~;1XiDu!btPPB->lFrKH*3>EAbHN@Q9eb|sGqOG^eYqqDEA@Gd3ML9=v4nfL0WsdizXa-oxvC(8drdMCaVC=_y1i$XpI!< zcCZz|Wk7$1C7Evulpt;nPL>I)Lf3J_;$tE5+b(F!5<%jw_ffiTH1b-7u}tsOd}^$b7X!ds$Y3 zBgKfLnShGLnQ#-g}x z*%1t{%Zj=dfLvawx;09TIMFpB#9ST=<^y_!?SlpRSP*JV%rp9yfIKk=F5+SP1PcOE zEA-oFWQd$`k=>pRfDiX7*cCn`6TiN{4;NsOeQO*#2f)j!F(NBbgg$=14AwBM)!AFg z45*L~+PtVhI0U_nh}J`36YruMRA{Ub)cH_(1dXt~?c{*(4(tI?0#H3+LcX$l%CV@* zgOlyvB z1pz7AqHqS6E(+AZdd-4jtbkPtZ!bx)9}nKVDA8g`uf5$JgJ?RR0(TSu7&+p4j09{8 zM7Z=zfFOppMT3zr2I>?X1%#_%P{iZ~%)-6ZuBN~4K$FB4kn3?_t3W8Vy5CXK10_|q0 zD{O=S7$N4s6Hg)pXsX?soT`CX6f{(P46#ctX;2Ctm+j3snGC+58lkTQ^NmHZBhgh+ zNs56YSOh#a4~CeNAShP!!j6aZpbbU9ZKMrr+I!Z}2XVQ!O0x(9m=>O$6@zJw%Jqv9 z3b_ZCC1o5PLrGJwcQ8m_;ZF|)17G1yV2+VjBdNkvk39>MNXF@P5cb;OT;Xv6E(_W) zTXtZ~Je4j#5DXP}Jcx$4MG-6#WJr55x@(Ri2y7Cx01%-*Y*K^eQ33>rTr83cg(oy& zS<8L^o)fCXtzpry9lScY%rB{U8(f0A4i!7TvFs|dYd*>4F*iwPhB3S%x0p?c#J zC1CI-67>p<0BN^CC5DLs&{81J+CwLa-mgVK849>qkG{lsrZ-w#m>I`Y@_Zt2D};k6 zDjBj~6^)N4!2}y9KEPds>cZ=BP-NDjc!Zr0DdU`VlngUO;v56;Yhs4yVFC9Ff%Oqa zcT`O>9Id7oIEWOSbZkk>_!d{Wq&fq*us&FM%>Xj0hsI=()%$=oX|2R%M;CD_qiX0n za5mK~Y#;T;YY!1XeN$7nQN5E*GDqetjddiEev9FzaP972eC~y$Yu^36X;Iz`)fyKpM4Fec)>3AzKJgAs(c}t2FKpdABmX9*CR5BlTe1``>gf= zlvc9R%1V2nF~N%Fs8x^!8iD~ZDu@kP0U8RysWJ|n005y2)9ip1KmY&$00008@B#r- zOb|c-g7iCajsO4v0f2x22mk_D$(;emQJZslBjC4{9PtW5#WpVf=8@*do-)G;KnUXy zap8>{yjQd&!Xl0=84WMx^m-zviccFBZ$}Xip^h|UA|41$6dT4uF)+)c$MII_)m+nE z%^nF(?%~<=UHq9v97W^z5so4nGd5yA(t%87vZXXh#;0tGE{`k4MuX8~NxChUe7`z0 zICf%0Q%{7ju4eai|2nLg6weN2MlG91*oAinW9e?W%m+&;;6c&#u}2;p+CrpL_F@kG zK`$UVlN&e_nygK_khRfGYoPlIPUNDZyu&|wk%1bdQ{fBM8U$JY zaF3pBDY$hu0l#}^RzF<)^3=8f!^-C`|G}L(5pLHZfX$z36*|LjOO*yN6||Qp5}al# z^Qe8N|7FtDmTHubJ95|+t2Y*Ot3$qzF{$=ZDrq8dlaspTjDP-gY^&H{1*VpE}wQblj3@TOIaau^*G5)>*~0i^(% z=xRA&fYt{FO85{D)ODa5G{RK}%FBTgqyqP^hC^L@JI6Zh;a~ zvPT+_VtsT(NxB)!Zv>GL3QV;2X_r(1jiEsq1OsZS^ba?x4WVzu^YflSC3w`21QiY$71Mlt9AXZW6p& zB;u*(;P~=p#Lnm;93^oJMQvyg^cRivWJ2IFoK6URHF((R1V~~IwGr+tAh5&hz=bMK ziO!fhC=-Z)KxwW8q(Ve5L;Q;509iP}%S}qs744d=fdZG*C+quokG@yzlql z|J-x#IcJWsm+hUMG4|eTuDRw~^LeJ9B;)Cuu^Bv>DFiiRz$5ACA@E}v^JBN%mhnYB zIVs)+y#s1{$~Ya$hJtko2J%twooo9xZROIq90nv^05$}R{YBQ`3LA{v(l*kNmpJ_I zmAD)XP$qux^0+x+JAx7MB@$TJ2K-~^8P`{X#z%5RNZ=1luh$@!?!j)#5H0Pa6>FK! zjcWJ=ZEi3xKb#gxUg)Tt2&RRc1JhO@qQScxFF?{vTL#Bz5n>y0Ez*dq;07`^5FZoh zP(c3BZenLj0A}YUqs2_s%Zj)$F)iyqTXu{H4?rystQQ_(@f1ee+DNwRpXj59Xt47a=bf zFhfhR#1kw03XgUe>Vx7xB17ar#qwP9qH;Msk^;5aTEsLSyPP|=8N;8g{p0O31qIE; zO!BKCkN)N#e>_py1#5ZOrh`<*EeC03Tkf2}4a4QfIvmw8-1@y~q|bTZy#IokaO;(Zq}8 z>L0m}`*b^#;4Z+U)YTt8f<7qDIqGdhF;Di*z)~9W7;oc~Ko3d#y&JMvo{e}&l1i8- zHgHc*Dt?aPwb$)i6B-iDj<`W5koZvV3#pvuSN;BC`O8xJt&)PCd6i@}O~jFa(7N8@Z50X+tD2W68U9o-V=Wl}D1KC94PE@Y_D`D(+>@xB>hnoevB z%AoMppR|(1Q}hr`j{~4pvNQHe5=+=DQy{vrY`)FI_8t8kV?@Dr(~S zR_`RIQc-mhHN;KFO((_8Xx6*mn?SKmYJUga&kv|uA!sRm7zPJB(rIZvE5g{ZI2zNu zBF(D#FvPOSVd}YGAKQB8tux7~v_9(V%U}78E7_1vG{!t?#IvrVg<~WSDfl;H!WWiC?~Fe$z0h>jh1TRmrFz zNt5+&OE>GVWTgn}H!OpotISE7;Zk8KLNP6e2JM*3Ot!^mD|0ZZEaw0o&ICIKwe2b7 zFOEpPinA$8m-z0tx%29SZVBXK1M|q5&aS1Zr1HnA6K>rGEDX5JGTVFOlY?D zeuQ2#z%oE1a$n3z>7faY3zQ=BOM~AWo)nC=Lj^{!L2(9L?f(2qu01Ns$-l>lfFO;c z>jCd6<^B>QqRdKM{NXxG7gaIVKoX^^RxZw$>k?C&FMFoVYMhDkhIG&lMFJjzF&gyG zBT*JkoFDq`c)Z}Ao>hYVfh;rLmvGCz5}7#2?1RYz96gQ^!LuJ7V@PL`zP@@fDLp=- zFYBunrF=zXqS1!qG{a4@###2Bq7i0-1wND_q!W+dn&8%lDdbVu{*E6z9!L1+=$!H5 zrq8L}Z5JpKh46zL>zTd#w!AjY6DW+Vd9-t$=p=1zlrE!^{}zbQ&OdiXN=T^`N91`1 zoR(&itQ+BO7bijce`ZmNSQwX+Cj<4Eh@grMZKrz_HayyG>8>g z4t3=y*dbnm>phO}0$^nBkKp<4)N{UpI;HKK%*CUh_6s_;o$+q1x*k6^Y_@YT57$b0i53L2 z>G2IhyvF=vAF3U>zHQ=D2NZAJTUo_9@HOe_f3P*e`kgR2+K;0xaJazk4P%J&rhL;e z-7`2U+k=bD227|-gg*v>iz`-d?Pz#{qKntzgnwj{DK1+8~an(2EihA0#`wj(r{6B^A=H;!UBIn$rfG z)$x_hej)ly>LvPR$5mh#^sTrn;A7Nl0J!;}_onx!;o=Oic-G8Q1o~Vs{fqFQFsqQ4 zQr&_;;tGXQSo`#fhCGG6Pd5-0+540cZWbWNO-9W^L_l3e8y4-#fB2zV4a7omlU-yM zCHnwu!`#Rzo$hnp4xrFD3|CP5968^t{z$G)Cz~weoge9DnF@z>9=-*{%Zdm{fEVwq zNjpr09agZT2o9b#8UTPTV#kz!R%?h+SgflWY$2j%1polk0K^z@H?Y-KgctyK99yu( zUSNnlMUaNASj%A7cl_P9Dgr%49L|_L<->id0EiafkxzaxzZ>jKq#mi&)^(IjUPert z{aRQcA54%-dd~Qq&Ys!3)1Xtde-npy;`WD`k*tbcJ@oaK?1si-hCNYQqG6en#Iq!YVTb>5w#FqxlX?)bNbK}$}-A5fAxmi z47h$UMfzUZE9)NL+ttP;WX6QR!mO@J0RDt6eIEs1zdYjV&1CiKuO6SgI-=7WVs9I5 z7g81;ZT&PqZ{mHMEL^*SRBaK-Kg5WnDD0S>RQe{ve&s zt%-qQH35?YP6rfe^sOJ~N3lBov;hbAHx?a0lM-96jSWhXEC3wGHC84F=f*j`J-rkM(6yM}s}ZN<8Pr)) zN3{Ni#i0QZJ#Hx)Y?N=Lb4_?O;20ZS)So{8C5|Gm@oBmFJ($%Bsl>Ji4UQKr9*(8@ zntP2*b&Iu=i9qc)738e8Uv)@kpj&}Y;G@=2d&KV-ZmmxEwF9(2(GO|pZ#93NCoAa( z{%LPbl*PX!iOOoQE!!e5Rs=Kt>?^8Fel&$t@`7YDR#kq!wbI!f);XxOB`^9_%hyMN z@=ffG7c+YJhmgh8P>Ic|^Oq*{Wc2D;`uc(b!4qZne4JgA+Gi(Zx)&8Y%C(%1jT@Hw zdpW4{wzjDtbtnaC}X1f zb2mE@nmA9n&puwv1dqx>%YHNl4Hkk!O6FYFGICFAYpIw5gIKJ)y|NudbI8;Zjn1u& zEEg{t%+VKU`m=+EA)RuB<2p5dbkK^KK=VwJ2Eh3-pY@gMnzA2XROF1-98{TNC=F-X zzL3j8^n^w5+X1hQ?MCM|KfXpzt(SZ{eoc*_X5|rsS<~g^bPVlfqM>>-_tZm)%(TW9 zy3?IFX)}+riC-CY=8SGuRx`aiiN1DIGXqN&>Eb;LGVF;cQ)jDhHAKYPD|s>EIk-y3 zAziBi>V2^0>eN~srmflu!X%^H&^Mu_Ii+TWrWdKDCxGlQg%+OUC_Uj|n1Ic7V-t=( zmAxb<;DGiWT?guM*fGb=z?{POUrBklIHjzHlGT!1!d{FPO(kr?CL$OBW$ zKr|&dQ7z8NqgTSEkU+S6nK)+IfD}usk?r^%2Nyvru-06queUjKpX2bHoWI#};iCW( zaO$`AU)_p9_~x=ks#+vhNfS!h4^*37C+WwMCCH~i$3bR9a(r4VM@|OJSvG2q<|3yT z&p9@Bz&mJs|9Xc}bNC+qix|zG${KeQcKh5LXND1GmAEzzz2`E7-pBKtW}IpVa3~;P zT2EaE#OtWn%!e|>(KF#nN$f`%-PF0|wG-glOW10i5YCZHKQ^an@t3-EUUX5x!LmoP z>i2=XNtT#7$q=9lHUdrt2x5f{NVl8KlO!TKg8#N*+~M@wcKI~Okb>W5el(r>012mp ztM|1ntOR3t-rrE+a(%$`t;tb%LkVjd2>t={>&G6t#DIvhW~|;M0%2=dz1`ch$x5k3keZ94^EmG z1n_M@81ColsX20+Lo;fUrf9svPe(@v)9d7b>S9EvA;zDP-}u9yB?x462oMYUs^+^m{vn zlsVodT4FAmNiWcAG{xCT&2#icHaCiatTMkaW1wVhHNimX9b_8$EfZy)7gQu5b+TmR zW7+ZQ+mbj2uG5Hi_^Iu@N{O9_fCLY)Mf465m8A_E2L$>*I5iz&B@R zLQmtk!{PHT=%85(J<~?+r>)p2XR97j$2^N*;C9EMfT*kqQy32;x z?d5-60f)%me|gNJ?oA(8@FwrqR^r}bCDYAD)hmk2knXxajj3WDI^PF(t+XgcWKnm| zyBzsachMI!pM|{H;&r8Es+=to-}DAeznMC7q3n|1X@~-4u)p(nmt(oI<*`Bxo{PZ1F$@EB- zxM#@P;{oj$+RBul*!a*uq%!6_j|mAKA9Ej({$4I|ojiEEX%acRQ4sgmbOukNTBp12 zkuTrH+w8ym6#|@@kC%*$dMmyVrg>}H$k2b6(+AZ?PSAgPed$1qJL@FlvoWP!^Lk0M zvgdk`Cch+n>e7k|JD`h zCD+3uH-Kym8uzuu^>=*&(AEO7wlD8`OL0u%?sbS^jH1l7?=za~p5k|kca05k)Iab8 zkyT&Du@n+YlEVPM)fZ&|Y}suvVA=WYx52#JtW9H|5&oal=*>e!y2E@xwde z&BKd~PLwqn(zY7Zf8@k)n(1SK31oWdhW-+CJkIyF{PznCfW(uwk63QLWUzdt&BNy2`kcbRQr5 zyoIwRPHOcXeoHuqGpo#P-<;LQ^CZj%n_}QIo@&k;EVmpV7PQ`Yd&jwQFZ5OZ3HtfT z{f0x$dOw43@=xoep{SdE%ZTDy`n2lhpVucJ3wLLR8K4>Y`-N^Q?-af14|LDF8!o#S zxB1V}i5{uKw(@l{L{*NQZBnfzoINJq-Z>)2az#wS85ZJB5>u;ob`c_3Q z0n0VgD-0>t(e$cmm1=6~(8U|BPv0!bP8f}vS*;e4u5v5+117F=8J^P{{2B~;fA!7@ zG-cpwPbXImM_1_jYlbuU;w@2$X-}?*HGTH~bSmMc@xRE)s!+FNY~+`LX`c+G7vpEf zNGD*JaL#|GGdpV~T#Av|F+`2_m%if!P~p>}@%~lH0D^vOF7`iZWB?qC!%9L1(4l6) zwvz~;nEp}z|4IZ_^J4`k607)cyt%9uDMT;c5Da~BO^AIxLaki$T`iUi^RuHFv@+j1 z@eoEMtmrnsJ`XHc3nS4xkaAoyVGtJOTwk=G;$#d8WE_Z{=R~%f!aX_CGZy?#!eKI^ zgP#_CuPM5@(LQ9jjJxJV8fx@!>Bx2l$SPE>hc$@wbfy3EM3I*=BPvqc8MTd#ocX}D6y zetftCNo{dHGxa0yUlzDXB|(1k<;;7vH2u;0jBGVr0^RpVypzZw*|c5!jBr#eh?iIL znT9SaP%b8?&th~qvz7{7X@4!U>0OuJHQ`tTFA#W-zl=&WSHo|%#HGeLsKYfU1;yzh zq5Bi#v4o;c1WO-(%W*Y3La+z5Ea@@1xh?2F;kNo_bs{A6UatFSM?3pe zo>Cy@p*)$i(0rTh{BcPCSzTB3+;B#iGoq(Re0ihXTl-5K!GbUuafiCl!QvIGs$Dq2 zP-&$I#nbCK%%sRg2zY($=#7n@2k4n4)|z1s`95o=t%`)0Wqft+I&7E|BePOU>K{x0 zD(L3ch~B8O^FO^f?hRibQAFQzM%WcsLxY;qnSVSu?E@bBi&pQgR@qP_Nj|kE-+pwe z=n??$)&2GQXmi$jR@h>4T(x49-7QiCvFVO@my!I_c~(CCbgeDlNU~_|{=WKw65rk1 zm6_JX-@vmjS4|?HGZU8iL?P3I<%dAR&n3qvrvYJ@MAqd2iMX0~4vB;scT%P*I}*h# z@hm?QDpPVKCiYedn2p|W{H-7RanQxtscLKiKWrT za;_EQ&s#5(CYW1;6xy#d;ocw zCoCs$o_3`v(d+4PHp?|ue$&21Mcv$9wEXZ(e4x;<1p%G(4RTrMnP2|i(7BUHrXp0G+_RnTqpux}6^*7m$A3Bp;_F&d#K&L-bfrIvlxD8as z25=&m4_`@M(PDC3^wCg-5xh}K0b@3U^CLYAr1XRIEPMpfF4#t{*+cY2nVGmtpuZ$P z?kJ^SRX5jxrpd9SQt8Lac%Gj*`k~4*=ssNlGixt}0O3_e#bu6ud|1@N;mS5Ot@QJ$ zvFw*?s+t4RezQZ|MmnJx?k=D9+CDH>njVfj2-qpz<`;`Vf8R|@RlBzoz`x&@cOwrT zSI2J=YJv9_=2(fewD3`F1j6RG{~m{$yfPH2_>8}^`nAI`kBEi=$;G*hr=yj3}&T& zkXqT47G{>f=y86wS)RRf6mhtr{Z0+fH^pme=)N!XLk`r!ck#kp3=zDWsGEEy#Ikzc zq|10xop9$YQUq6W_@=V>4LxEi)E$;)TE*DcTPD6n+(9aN3ZqRG9~xnY!Qu#3)F0r8 zf3%qiz%DlU))kjk%vUyjOuz+c7C4(P^frerwQRVf2t>NkR#8+3%VI;Ixv}WIzK?Rl z1>03nDK84rf>=CoA=BL4XXDtnwKDlzmFXVk(b8hD@@M$;eX?fv+Ch%iKlNIi(m1rv zaFWq)+`2(f$pL)^%lloCgqTZr^qBg76>k*-$$ZT*H9Um~ZvA^ayG0_Sb38|jMe<(o z1A89uHn*Sc9!&60uZ~4J9{Ti?GKZjxpjo_J-f(%G6P<9@%ucLxhEYUL9`z$59Ad?| zPAJ|l%W5_3JAWnhL}Z+h-DI%hrpR2AV-}^0mg(;pgk_b|HyUXguuxHqz!<1p zp6}Ejv9@%ptVNoZc$=;vlIJ*kOs}~RCY<{Dyb(no$QIp!6o!OC2gR>As~SA{br}D4 zhc=sPZYx9tY$XA4a0BH8V0fa$@&ru4MrmB)oM%m&CL;0Ki(aL4%HKc9n)A%XqS`R_hn`Yly zsU|Rb_|7>TvG7gMi-^vK*OD&pjz@yRbmnxw&gXTTm0@Go=#19M<G%1$-`&hp zC!-#LPu(JcC_n~~tPF=1-Kc7_5`thLpIQTFCTh1lwAEbZ6w0~k; zano1|+pg$ZTid*wAytDjs^YVch+TbW9)R`*^!UWn=D=}LQ%h>w1YfkdtMF}4v?1!Y z6VU455|Me#Ran#z8#g{Fx%Z_08BAxFSr&IM64{*6P#QOQR-@ zO%u29ZWv*pj@Q=*(iEDZ6!10W{CVR7OCI0r#Pa@?%`eM03~nv&z%)a1MXS%=Q@}5; zrwJ3s=*v0>P4(Gjjp0Ju!(l70I8*zAKg-SEyh?PM`bt_cQI}R$!+7$P&GdFRnVgNL zhcTCB%S}{T^(Ojjt=6$`VB_AeqTZ{xuKFCc`HlT%2YpUNtgAiy91Jf+k){H571%!f zW=&K!FS#qa+xV0Muln0ZY33g2)!SkeF22vY+i^~krVv{tix9DBPV1FKSa)fv@$lHX zs0gDxWIiN_ofKv{dClitZTduoym%q9vb1|>z=FY1`bK1bYiE% zIz2cV0(C}swHRp~KWK(9=i+}r{H4axljF~a*k zh(U@AtV@io7B-RH(}TGn&Ao<`qr)lJHlRrR*hciP&#G8sJw^egK4 ziuJHcu8;_?43tQb5pe}g-2=x`M5xvcTXxh+6blY2j3-K=wV*c?cdgDf!3jyk{_R(?!zGK4es(LoPa4yBsn?Yba1{Tz0?yj{EAy` z?!D6oyDlkY>A*u1lU^}JyV}ae3ZP7V2a*i;11&SM9rV`F%ngNPE=|0%Z0Xo4nPo2H zL`9bAOGLUbqW8(_bjeokw8`2YYsa+}+Hz*F62Q;|Uvdl1F#-_I( zRKU3n4Q`fu5+N&JO3zF!+zVnJt(G5U7~Eg1@0m9i1n!iEpg!K?)a{@{ntXU=Ai=1S zgxTx7TR`?SMMjm!%fFmW`eM8cZL{ZrDMjMxY$Y1BC?1B7QdRLp4GRg0e z>~0_cF%B6PcP%pOeMm*aH7}+!tXIBf$MSR|{uRIFT$fn})6p+uT<3oBGJ^^Wb-aWO zD@Y|;2v+_?M?Q*YnB*QV*Jm|c+-EPjG&t@W4AfUBvdJmXR2s{a1m$U6cC*RRV(B`B zU#LqaGFIkOl-Y7OVn^uy1nOBFwNx`qtg!5a%NVCP8Y|~$4z&}@B|y_X z)b~ti=bHLvZ&&u#a$47cWEqLKJs;!j#+<7H!Rgh%ZfPLFF?zT)cdi$ zd_sP%k*;&r?D71cwkM4p)%iv?St%*yJyc?nduih~aL-tk!}@TAy;D-wcKzq`)Tzal z>k^}{6Ipup|0K3Wz{>^%k*U)8)!H*3Q-$g0tw^C5gN|X1N6jB>+~CWDM}7RxT>A-tKl1qz8OytJQD*J>G|{N1n@DM6P1`&k zrinA2rCiNB4ijt6{Rw9g)oVkkyn8_TkiP=0fQRKY$C5dWuqN3qS`r-?!WVq{A#I3- zfzeGPf-j9j*KNLjkasJBdXXs74eVkL64?zlf|5vWdOuhZr@HE-vyleGD*c{|)UhAV zSF*T|Dk>;X?_5O>zpn&nB`Yc6lJsrzcxzC2n|AEhpmpS<_cfXl1V}B;X4H8DnG%C+ z9HJ>;rA*`KuWc0@+ol9`NDS~TH333AK0zP_A~3p9BiH2v9r#X;)=i=Waqoc%EPOx+ zd;uRRUf2X^J)VP8HbZN9rjRDOVGlG-U`SpE+Lo|%bZ68hQAVF% zzU`gTw}og?*_Wxx37#= zw0`@{jUJ`17Oc-s-@eO}_a~8hwt7@S#j~|KtE2 zVvjtmP2U+`8Lto>o3QXmB%q^YL`|&ho+Nm&=#)QM8Y3~6{N$TOTl)6vw@|OZ%Vyh! z(%@D1<7d0m_X?m_PYL7>ciyh&?HINX_`)88AN%nTl;MG?){wi zBvr-8eJmbDpPl3RfK~017}Um2NegJ-(LMXZWpIO#vcPmDTD9fh;wL=ovIPv6h|_ZZU`}Cam?jE zTN0D%ZO*pnXG6tinG%R}(s(D2*TH@^6ICnGU~!bo?Z4bc)C=T$d8=@^NNV15@T^rA z4?3_ke>(hrYF)QYSbd+S&BYB*(il`iBqrY~XSPw<*D!YJ-~O;9Jej=qT}-_(TgC7F z_xm*5`NA=HBCFocrTjXj!y^|Xx0O@xd{zwOC+QnJ*}4h)h`6pd(9E%P3?DB)MJGRT!ti!fK0qj1}x0SSq@wp$(_ZDA_L�&wW6u)Xd7CwTwY zQ6HdP;fTU+Klt}&z<*QFf8XN2OVnAKc>q?2LG1y@`?&WAspw6If|vP^rXSSNxBd{S zj0NR`q2|$Inf-oGtOq3Nc5f=|WSe1+`3EQ?sJ7FsI85+~K9Hk1h9dx@Rz`AqiRG0R z`lc*URQ<-SCL{muLF&SAzH2O+(zRp1^Bj?Q-Icdn3+CmBrz7Y3u^qK>pX63_#p#EP zc9l+h@UoCBekyd8>Xwj>oGolZkr-s*M#H_W z99%J+z{zOFylcQbH0%GxYX0!cujgzl_DKG2k6%r;#nI>;4hw6>hq;C<@5avPBkvkB zB(+Si&k>KKRGyqcTEBn$zaCKNs3kuV|vb7_)Ulz#V{5D}2Nw9F+^pT}imTTRHM zuK0yX=9o(bgGR^1%B?%JOIS(Y|9dQC&EqGjH2B^$?AvU3 z(O`GEHDxyNr-spZEb6;5W!$J(oHJRBiI&jhiMs%|2W2diou=sso7$%>9_w8v8M_od zIpq1dPCAJ`U5)TToW2NNR4OD+C-E%dfRZHZ!^ul%YyO0cuHScwKy@;;4w~D+ayA)I zOT|Dxm4VQpex|S;e+x$I80_bjRC?vM3$@7QAQjCHQr`=8WQI>_6@0t#e8(IRe{}xn z9F!i%q0MLoUGx8;B)Fm{_mxPPN)1kxxa05Q8+A@0m#6ZFN=AuA=j!Qd#k)v@W~HaM z`W+(7w0Es%rfUt0lIy~B{#D?XasiKY=kZCIBaGLc8NW-26_;c(*f(AJU_Wp29eC>x zRXqEsqpk>gBD}y!N6>lU&^Yn}2X|xRc$z`o1gvy`nBd=QTiX|04hydJ~njDJmY=uIAdQx7Tsdbq%( zF>i*pL-xE6{2gJ>jHoSVKAYDaQ&s{Nex$eQ9CJ>ANP4$h+bA?gO@Zyq%sB$J1;Uq9m8w%%$&Nc{;8G7WJZtylFUn8n z;W#UqJ;amWV|JIPa|!52-ENV(jGiQUvu@p`trhMmz5AJxW$$RJms!Ux`TFF(xN}Q> z4$Epje&!2)a9`|~QcoWgaOr2#ukcqlb7pSZBBIYSb*Vxq=qllNb2G|f4D0>&BmgEE zSKe^r)oc6;k)l3qiL0n8KUBnQb9Neqe0!8rK79Wv`}a{8uZ4Lj9?+uMYG>TlPM7fs z$B^iR`OkpSxWnD}EU|ifnz>mcF7qbY`S7WtD?X~RCp-0}PCa4yt#!e=d+A0cIWRWA zgo#zUNW%$caoQ*H_J#E2BWJfBlRoc=Pb8MDd4>(h6;&Q*y{gwh)WRkBP-QcD+oCqb zkKK%xTFTpn{FOI|;`~E~dAs!&7x-JEG`}j1Ojm*WikoJK)TXE@cL>vM*cm_cjOif{ zKt&nTj>vVbcojc0p&p-$9Fq>Nyzgp$yjf6LPIs@1HI1wId6&rIw0I#4u_vnidf#wi zsB)J)&gNh-dUvcn1e}ou{X1<#V0&;sPPxB`E943Wpn8A<>&LdNVGlAuJMfwAl9v0Q z3&Hcpkc@@feThvhVLbjbtr!}p>~5;ZD5WTyES2@}W_OE>pV}u=NPMlh;^z-mM)KlM zyIG$YUPRHUzB~!Vjcp)JxoMiO2|J6+p(~rxVC6oCvI>T4$>Y-hu z^oOQax@qTLN$0OH&+k{Eg6Bb#lvAi;Uim=tJ*8%@BZZtv{=HNsM;)kaaJu20KeY_Y zH=at~hkMMvp>HL z+)Sf-^7rK}?tNepD&_*Nm;?OG6z>^OUkhruDE9dNQCpI^KS+gdl>bpy0{`=hR@~hu zwc>4FHTiNyru*F{S8)yDvZ}Mv(Bhsm0dcqFSEX(`VfD zLbf}Lk4zrF+KszZ`&cP>I)4~T(?DTRB0?yBkT62Gt;$%6mP!<&teiFYPDTLjPW%jP zofMKM?P4uT@@$u=%@(LlQ1#T`nPZnHf6-uiot;XyVZKf5s{Vza=+UTiI^z2pkuXJH z0Qh{d#8Dh-CHSma!(nzDK*lt%3~ebOSd97bdAOg1Us3uQFW|u-v^YuqaV1U`Y#tE1 zOUD4qy9wNOB}tpuwg5&D5D1e5iPN6alc!+0#qFGrlMsXga&JJE3BPno+Y=uW7}=cQ zqfrS75b{A5E&>zH_mg$=Kc$kStl_!PyIqTp6P&zmZ`VwHdb%9cPb7lq|uwpiy zCcP3tz5&FCSR8_#NC4&l02C|_AO-;tHKb~AW4)VLcZeE30^583kAh>7<6hbi0KAHg z&(S=y(`^t7cN&hX!-JURn^H4b8IF#uD>Y{K*)S!?QSL2Uc=|o{aC@UCV?=a*ZjLG! zXYzh(!V%r)2NTl*LGn0>o{Ffj;j``d-JUgP^W=6`Bj+)Oo9P;`su_Q#D;2r{`VmMb zwIsE$nf+#CQ-mET&fv9fTv;46I zf**u>tXxSPw8m{TuG*>NJVK92Zb=WL&Nrwqvmvi9qlPJPaB!xNY$P)P*^nK| zc>d!mT1Y75H4)4R8<%pi$ebno9G#YDZS6JkXn4fb)JvRV*QD)$0i;9~!-mg}%OQ<2 zE!&>!wCY=1?2d0?98OiDVNP#Dlcy&#$$H+l#nnWyr9Mo3;Vl0oDTrGu5&BEb@dZuD z>%6AzsOu;ES{P=k_;&x|bW%a^gUsAU)S;9MX98zV>%D+69;$2wriQvKPAiaWTp+pr zkEIZ`@1qr*aOV<>T9bER^S~fAJ0%q{te+xOD{sn+qlsLD2y6D}mKXX=ph9`EFFn}x z+<8|Ez)V*(z4e=(NK0w(4-tjXNK_t7`Y$fiv+i<=PRSJHyE z-*$=u8^fJ(c+{=gdTL{%asHf~e|f}{B$+tKlc)XlUB{TXt?zF$x=xo*T6v14%UG=h zyA;_+jfF&;=fKmu?7@$wKxl1G(l1z!cj4xIQto{-{+cA@UxFCEIQ5Cb@}HMrtJD-e z;UW!UY7Xr*E8!SA;)`KVnnwR0Jj~A?ka(3!ZP})&BnISGL)v}&8&=X|h2*H;{~e;M ziAioZb+b(*XX$>Gvd)=ZK5<;aG&&&3RUAqu(dA9~OFsGaa4P>P0VUIm=Y4LlTsTYd zT5>$Q@bST74~!|CB>-Im*w@_bA7~^wW24mT;uPhY*OpfZecn(Y`CDKNl)y#S@%M`y z9X|c3Bh5?8KwVv7|H*8Tj~?YTW86JL#RHg>z^f&394&lIQS0if64ks`YR)BcfbZq92+L z5)mK&do+LiBGWtrVLA=?vocb@Np_P|!~gT4x{%LduxtSDOhl+SP1$+~9!@>l#iO=jr;6V{RNq(9%xX9>5-miYW428DE@b1SMmTRx=Y(A{~4)-yv`aHiSR{iS2ScIRHb$;x!mGdIysL!f5JQ}pg z{eifmioajL)&B8hnI!mXu$}Fb{7VHK0a-DQl&KSvvrm;Y*UgH9c4)|$rm}Wh0GQSH zduUx535dF$6k$@MPb{-RtyNRrBn2wqL#5-%EAVf(EI=jp?=zh07dh&nXj9->>#Szg zj+OyCkLC$ok{qIn4FnZXhGYyOccQ}p;IRBXca$(Hs-JA%l4JlKVupjAIAEQ{qzWh) zXk220G0`ZvSXMFDV>l>I3h6V_kP z&k4NU*uqR|NYN(s^{M-`DOaQ=sMM59Yd7*L|S=IUaK zcs6rLu0<|=F(Yxfb&C*wL+X(Fz3iOmcJoB)>z70~+Vug0VxEH<6(ae30^e2gM3F+} z#F_EI?~o%lBnl8sV+OK3H#fbRoaQ7aWG zhtyie_`TH0TsGN!e6_Eqt35gvlxdL9&Nj(hZ%u4BDBCkw6j@6#@xQyO7V!S$m}OPs zHlf_!TSJ2Rnp0FX#$t`v7?lDB^z$Cnq zES`;2+J0)a*+5~ODXM_;(^LlGEXm?Ym$1ICAo5R^LUE$+NjxraTxH(9yg^hZDuc zD|&Zahl_yplsC(O`&Sc}ahZA`YTw7*+$outK1X zE2kUehIrsGPr2VBOgMifBNhXd&x7&~(E=p^MDEdu6cP^YyQn1-b=@wGI3{9MHBr2zT2&Ro7hB!&aX2ih5e(HzAH5pmaMIJJ%(e3LS2XaEOIjPH}fE%e+8^cc;o z^TM|PQxlhfs>0)2$jNvrx#$`^ph|7eoh zh;vLX&(8U>lzgX=*a>z#EGUj~twl&PwS<@8MI2e7U!?O^R-(WfW zvn~Z-z;Yp4NXa9RncD3cngzG(W+}ce&BNy8Jb)9WWo9F+wB7nuvP6amILHi&;&w*8 zlJLuQ4ye|*SZm4DNJ|7ju?7c#GER$#*p%{-n_f1!)-6FOKrV_X+$@jb&a%vJAIyWXu0bKbUkYP#RSIYPa7PaxYcQOg-X)P(*IfRg zknM6!lw&9^!4bY3MX-)ZW?O;oT_ZqpyiAl}`W#7?P!T$zi;zL1uR%#5{gDX9XC7`m z8eAN1pPN<^|MLy~_lJd}r42$s80LLcS|fuaqx%1I0!Jwa0ssQMSmXL~ocfzl1b`5G zGJDx*Ndyb`5ya>V)2oRIp>rP*`=`k9U15wk99r@OcXuZsW`=hJxzfIWlS9uk`NUTK ztGLVW1Sds=oBD}Z6|HA}vj)vV^8n-CIKIuNq=bIi=3Kdp3ezk*i~0%wyGJb}FQFyx zx9A5+I3V*<7BayY&!U!gT^sJ)oTRG@_xueZE>=ZfL2JSAFYVXLv!e>5%%`eWF| zIm5|?Bf%)$l3ngehU~l}yWzY(8!?MH-OZ8-T2sIN)x-H$UyFnI_!AsIEHUiWUeo1x z-kXyr7DJ~eI|7i4LkCoG@l47uokX>?gsrRxN0-yv{~Ai9`cp`x9XO4!r5aO@{W7gE zb^6-!VGm zhrnqqQ?0Y|ZlnjH-1+b{({cr9tH-HUoG7zAXNy9`E9ESviff1f5v}R)MZ+JcES$dA z1`V74Q$R4J>9)+}Lnu5!+dBy>7*_KCbRYE{%RTWGXgjx>z37UZv{?V3c}7z@eBGLS z{?ZEp-P)Zy*AVib;fZs$7Bgk&t?^?tU;XIv)Z2qXa0!x=n3FxNAO8sGdLwfe0S4P@ z%XgWY2{MV4j1x*|%H8aerZ6P6mMr|uY~&Q${xdZ}u2m$^GXk7kZ$g_Zcw5O%3I7_~ zvRF3hLwLaDDc<{t)3bOwkHI<`#g7{0-u7N}9|1t~7mw>9go)b2eZ5a`)uJUuAJbY3 zTDh+pL7A+0r_MMo9iP{F$ZGGhXDf_Izfbp8-J5hgLz0a7BJCr+^7yXlh1x_fEJqu! zR6@=$t9t4uPcCvU&7+?-^rmFb@?&BbF2i1N39wpp4716Dti-{qi|X-;ed(T)znlOz zv3jX-&bm%?jZa#w&u+3lGrH&1!@V9mJsfu3Z~Gj7Ju-XI6TM2|_3N^M9uzN>yDo!!dHB07Du_fOEcHoh2%iGU z^qXL+=T;@T^xoEjao#_8N;^6yULRMD@dK~+)A)e@4`Xi`5Y^lDjZQHPJ#-2~cXv7i z4BaIy9ZCxb2spsd-Q8VEiGZSjbSNz)($W$tii&6a-}n8V=Y8HdXMMPO&zIS2?ccgq zt%tL5{Jh?W`bN=tmvxwZt&L+|IO9(u(()DL5ixA`Cv2M@0Wvs!Qcj$O-$+kmFlQxk|EwdI=hnI$;QVn#`8~MG<#~lX#JM$yqQO3IW2p#-+Ep0s2+V~EBkhKV&T3dUY^zp*XunD=vqc2wF4{@+ z5gtiANEuJ&sFD`>)dAvdAfgMB(P<>%phJe43?vK4nm^O=V3E{TgL9^a~5)$P|En5k>e7Ei$9ZvzW}cSd|GA znmcBcqD+Hx%C>*nbnv;@h84I-Z)J`_|gJe$*~|^KLF2ZnI|@|xO_k2^EQ58 zi}EoGvX9~5F$!;#Q>t~<9YT#fpfhEKEIF3-AX!Nfz=-NW;?DPeP%j?XvC)?;7DJ1H zl8QhiKLj4KEEJJIs05>QvJ>%mI6ZF)pT;4j6}$h+8o05<9q2zR5PJrk2k!q%xM!07&p!q*U3zHvgBlLnHd5hihe)!G@DE9X5Vj-&<*bVw2pi zEYU_6p((k!tGOts)l#OCIg<=A#|VB|A$SO75xh2WSVaPlqmP6fe>HWWi9NRaU=n04<~%g;V?>Ke5F+i> zSVmpo^RjK#84x&$Z%sZd?*2jW^p6KXXoXJcl@bMYkP1PvoZ9x!;V9)?!kEaOiKfO9 zB_SGS2D|(%W#;7R=PGCvSFz$=>gg8#%xdkaH4n?5`CA_XbRAS;#&Bu(s2Hetd=89D z{Om9~SK@@^R2M^o6HYIZOfIcbe6MMkT2N051c1)TnLS&*wS ziK=2^*1oHx^I>E-e$Vo*N6IU|5Wi)9>M#Ci<9#=iw<>Aq_Tf^Yusb5-Oy-;v(zid1 zw+^i)*hunQ`#YA&0Q#UUKswA$FwvEuWzQg+p_@82-PolZ=&6qD<}^>o_Yge%E-iC0 zI#3@Fi!*q#Ib*0mIFSzA#Nc#V3=jkF1N7nMxY=J(PlRj#_PC&I=A!LqD99L)HNG&S zsiJ7&(J@O|6_p{Hj>}Qmh?OD7z(;^)6LrAmk~=BI!HAaBmf?jCl-&`55*R5)Ch#;C z7>dp`_1RzIMYtFn!v0t+>~96#P8|}CH&LodJ^V(mYOZ*1a#5PTQ9gXRAU#)3AZp{u zNkeazYrs*+yR$9;d7|YE8MZg-V*}d@r9SqJ2p$AZ4MEiSHT@Z52d1N15YLFp^4OTZ zHl7Rg3Z7K+Wsx{)WBGTKsi{k%gD~IFlkb!bwX$#3X>lyx_@X%Om5UP>Gk+mBdplxB51JG?#?c|JU=dmc}cBgAPkeeIdN0POAhL3>*IYSa6PgG&a@ zeCKWNuji-ann&w#;-b$r>n)m4YJOprTLB-pBm}4n(Kk^VRUQ=7+3&-z$9Ej4-nbn6 zL_fc?x?3fs5A7&BbR0Je2^+slyB0w4s^Md)RFb91xmo_wWr$@CXLwic0qwy;{bEKr zlfEY;%*I`<*u+TvaDJ_7cqz{(^>sA4M~g8fgR!nQEn{$1$HZrPdOc9k)A7X*xv33f z1aoh(jkoyMqAw3P^xD$|8$Znu?COg@XI^_Mhv4W{F`@`QU58o`y}?8`Fni$bT+V-{~OPU-#yiCWjoG7o{gH!k7P zn?nRfkSGKyl-6ppBo?!;iOw&vfX%JfdaG=3;EnHsR|lQ9cFdIjR4jX2;is{Yj9M}p zEPY&WYH^jmSaxh-DR$A-LamHH-@Z5poGXYMUv3@$X$$>cQ6557O7uA=($-GZJ;;C(!2u{H> z-34`oK2d1i3KTL{;(z${Oz2Mk#X5rinREuDFh+yqAls;inp;OoLyQcvTunJ|F^!nP z4;Vb=w0@uCA4Y=BBwqXcMI?Z6ceAskwX*ME;MpdIxl~F!03rLptY)A zHDhN#q&W6nPQ1Xk;)A#W8BvP8J*C_WT9bZZ!k1-KEpN01l)41ej$++-9}73e#GHpn zEW77!8tus?bM;}Y=QQfdD>j!sH2cUI;JxxznJWTQRYGj6g z{>!+6czdV{n_l`#u115S#!_a#MYGefqlXg6uPSDNv<+Ag$J8sDrkw{cNDlQP=YkI$vN!lw*^>0c zz`In3DYlmpWs4&2pl=p(bu3lsqU8}|*p|*J({eO4qq2#C-x*u$(FZ5dXS!o)$`3DSY701O0(B_ky-}s@yP!P zNq37lLU~bfN5nHyP{}N_)oDzZafQ!Od92ysQ{R-+(-;95)hpnMAAJF#CA-!3*~0x; zV7%Ta9I(}bPiGwoW)E*nqn3bz#G?8=Av4fSC_SCZQ>sM#;ZGnMQ+62!=M?;hcRaEB z8bCDXw}|-zfVm`RMGMYmM&7ylFDDa(#(&da{>2j_MeMi%l$ccd0QuM981rvd`A>IF z2Y^9g*V)c}|5^Fp_QW;Bsz7Q5G%A78coP+c63F4p$$1qG-2?~;uf2-+f&86WV&>qq zhj<{A#TvN~ivKFinf6buhOlFbdQRTUnmfuUhideLQ}=wMa3Gq>23c@reZ?d-!mW%V zR_21pGfKx9jLfyIhGFWpW*J-P(kh6);~-l_9Vmg98e&8VNmVXl8y=h%^n8*sdu1h6 zItbhZuOWlP_@|(=Qn}ba;~>SNWccW46)wEGrS$hcc%~9XEjm$tB+|Xw?_PqvA^~;=fezVuO5?MIy|$ z$e?bErFx;(#GBwrl`XGO5Z%z4oS4a`k@b$~JOzkM#8RMbq3dv2#3YP5;nS9l&3edS_7LUj)NA^o=8wZR+Cz;QK=Z%OA+pL;Que_O(Mf6KBc| zahWXm?Mh%SZD5Ew6#$AikU|dndkrX1W}uJqU`r61CCTDuC+OlRWfAM*xEXx=$P2gI zt?_B?C}(NT$5aC3u1Rv0|2V|xPx{WINvlJiir)lr0%FuE#vxXlO^T6tS^3Yl9*OEZ zvGs$dSj#F@<0`V+#*z6_0w71u&*TnS?8y!=*bV`whT$c%3{i#xB@Jy=Hd^zMIYKq> zPETYa$~kdW-};GOaHD2GoUANy%pOWg>M8%Sh@1t$+q|=2e*}L#Pel~GJK;(Us$Sz!g|58i2oBR}UnL3vS+Uqcxm?upJFnZ3C^j`P)ctrq`y zMV)bp#Vlw~o&69Tg6Qcld@7f^Y8#jn{Z8jBi<$Aa>CV{o5KUb3=~XKYVX(1BdzU0d zw%z@oo-+O#lK#;zOzCT!N_4!v4aL{T6p>A4tX*%~__R1i1eZm<5sR8_d5<4e>>a6Q zYe*sh$xc>N&Oh7I%H~5>n4ck%DnvjiPcqMa(C8tZxww72-sJplXw%gZC zQ=Z`F_R5}K_u`gGT2Ebp)s)26eywrs!srODP^Et@E1$6+={KvLtWL~;+DmlXlURJo zhCzV~PVh32_F=u;R2KtvkH_WTVq@DdQJ=bQeAQIKc@!fbH;2X#>QT9L$6*C<~}9WSv$l(`9)m#{1Fdx8d^TS zhDw#jLopaTHXP6`=+8DG*=1TSHxLp`PRlv02HN%>+ zZ?|d@Yl*rfM*!Y$zgNYErmG<#rT0|KeOyfIh0cjAzksHr7B;G9#yVEJzp*RYz6%@+ zvloi{qDxzyQgzKge*4YtT4GzK06S+lywO};FZ-G1H?y{sl0ITzfIp#*_xw zDHa4P*r1If9zhfyz9ZhMvf@}`+A{aN=a;rNjOx}njYLQ4HX(olXE@2Sfg?R`{26{?+}3 zIW~YVI5qq)&N1j<{HqH6Lky6A4{$0FD$@DIlpFE;DBtG$o>{^VXNB9}82r@Bf6eJ3 zI-^nRtn454GUh3&U8vbpdeUgu|^~7~pwRNrk{!bMDOl?4lSc(6(Sx->=r^o6yy;-m&(?V9Q+c6Wmj z()@T16@3`gt$U>mXy9oxB8<658pQrW&tHqhKBWT5 zJ$!k&(WhGCH!q~djMKQyiz2OyJ2}8iFcyXC83KhkR(OsfS3U=ra{-EtDVubWVP$VJ zU~$jbK^o;bGhl$5L%mdVMK+#t^5aD4rh%A_QDtc0E?a_*rzJ7MH8%|q=Rqg!uK}G_ia>}0 zfZSyc?$>4#vMTp;^4BX1@%-JVF@!=UsKq6`@R!VXS*#q2qtwi{PD>;tCIli#P8|sh z;0swl8xLT1^dKJ0K%>He@d+=oCX_S z-1)@KYS&xYuJCU3_El4ZzfEVyo|Y_0eNv0H1m(+)puiW7OuZRz#2+TFT>!VW1xkXq zKdG5spGHd09(FWN%2>`=*w_`EuBIJm+;XXuTuJQcXx?qUG9`NShuJ@xTz`o!>2B8h zT}Aw&tB3s+73Y>8Ya)ils>_UkrcY83@~-bBDDPl&lXi+QGI)U@>4=l?TYQz00FY?H z(zONbu=mTxM0&bE&YU!(S}Wa7?X$+hZ+B?Uq}RzvKjRLXPrS<5mrN(J zZO(Jnl2~m!eUExUC`Ritp5(Rx8I#1)AI|1tdj@mH^7>nGDjztNnO<=>Nj6Z{^9-;> z!g#q*xEm)33{b!uOFoE67M%fz{tuq`*8rFX(;!`er@;VG4s@{w#DC2||1$~u_SxYw zeF8J?y*BxucmDfK$f4{E1aQMj?JXu$0^DimZK7Eb+To8P25vzdBVz_cBMnzz+duqJ zvz z3xaAzJGV5RHq+8Frn+L=gMc70%I_Eh=15>i{an;)m+5b`g<%d4B_e|&xRi@yyMoz< zO^=5>+Ef_;+h9)M#$9jF7&HP5(bNVU z=!FKE=JFns`R|6ANd&9o4;FPXuaAzlhnS~f&1qT@*CtywUn@qKClkp8_x^C!%e-#% zxIYn3$zfT&l<=s&<!2`0+#- zr3<`v!gt@UO6)#=I=B^pZw%pz6~E`48xlMGyD*#gP`2aH`_Am*SbaFYu!wdf6;(h# zJ;DvCdHwCg5#GboltzH{Nz~l^$Uy=I*6GB@!Kij5d^ON<`Kff6;7-&dczd|hZor8( znU9HN3U}GtSL|bPEz-GturLZ-j(iV3`QtDk=u#r80haZh5Q}d@fziXXLtip5v|~i!Jc3zE_am|3l^h zX*>n5{l`61jTiA<`BN^kb1nn3_;0mEnt=Of!MgE-S=GV#AI8Z1vRvIq@+YjgmJbHh z_qGP}ErVwt(0fiAh{Q-G`U*SIB|2e83dt1GkNmUv&$gTQPnZvw{wUo@Wp;8?!#yW94rPe_o2EjRT7uSnlRnj-_=EX79aLxKL>-yEsCc5k{h$)x!^(C+HkmrQNTkU^nT9G?*6DOlFrO+FSbb(|p}R8(G}P z>#ym0#QTVvbgf~wU`1OCY508Hpz!&|{)OdT&Y7u}@1H(}l9(gkcY`JKx?jvQ)&N3` z0aZNo77fJZgUrJ;VRH_Aa21CoT;|Olt77 z4q{**I~iXcMl~ASdVXfL2uzCK2Op0Nq6>*$>qpbBw|o~J3d!&r0)5|>`y~eMAyBPI z!)uszO~RI~UIJb{p2b^*UwC%L;8ATp4~KVr(y;EcZa@0Ipe@B}>};x`Y8%UPN>Q3z zTTv1!`6erQUw{WIxZtJIFgc!|nHCf$H<_D6{j4fm{b`w=e4s9PUxi0Q>EyMrZMl=R z@s$UQhPmQoS-EG_rBZ;1Z@O3O%1bOKP}lncL;IaMKWmRb)OU<+D-5h!Mzib?#a6VBsiej=HuSY=CetO=&?wJjZK2v`csU(*z;dMp`r*!#_0#9jw_Gu3P zPO>{d{*XJR^juu)@%%Q|t&q-ZhV$K&*~W2uVj7li&6i~Dp}JVxI=R3(XI^TL$f{}C ze&7202BWu?Ial*TDE79Bj@rxjH1L<7_?j|`w`*2pcr}HvB1l!383Mb?sT4%#R zdfe7*!6fbdIfe(fiSqA}7&f4Yct}k(uuh^HSTmO;1DpPKXMdhW2>JW+=`}RBk?<3Y zZYGJ-f+BJ6{P+*Z5od*L7*8O%XnT*PdohglcrJUOi1MZ=`A%&%LGvkP+M$uacI1$q zC1~OOZQbt|iNGOCPC!vL8VYbVHe{%iBuV)6oB}S!-;hkq$ka#HIxjJ#R*RTAx~QF{ zVv3ujD+oZmaq8nlsRs3H#AVIVtrD?`JFQmv6FjimNE1h?NRei+DVjU%?+rCY5@V75 zof;TE8qumF3Ku;=>Bn3d!YI~FP~&0HB$af5dksZdduEjuhm_U9 z0JId;DO~K>F@V6xX$@fyNRhysGDiJ69zfYbmf<+|Zqteeu!bD0%a7q%S2?nCr8qfF zm;;tk*&(1nOZ!vFho%~Q-JCCTHhP*+@#n54T$h7v*@v@q7 z+pPpZpQAnO9W!h|>;hM-w|N@1h`+z)zhEr6CdvoEk=Su+A(60hL zYFy}?hLN*p#6-SA!Y9lDVrf#bNIOIqCVLau8plpVUdJ)2P~Jo8d8g0O_&0>!IBJr{ za14Au^uSEk4_M0@-%0EQ<$N?h2miA}ylru7!vw+hFzE^4j?E%wpo~y0lLtHUG71zm zDhg_SrZz<9p8h1m=0iWm*lZ-nHEQf6z&cOaob4&Adc5hl82(}qmlPf!bR$Fxp+IQ? z!SwyZ5IDWz-+fbHrb!+}bVEW953vzgueF8HN14R~iQC2bHUR);7}kzM97ZCD@Q+9Q z1yE39R-9+lf2@7Dh5rrVf$i!L018<3yrHO3C!Az#ld|{fT!@Q>VNmD|1PV)TEsqcq z73pCnLpnIv2yyDK+(b>NmCaEYJ!jgMn?_hNCplNE);4QZG+Vb9a+`Uq-sJ_Tx0RCO z<;bCPGB{u|?&H+bVvj^A{|Q3RYP?T4ZcGE{~U7zH9u=mevqT z?dmPpM_G)JwamS^_vMKc!7)}w^1-AW5}+l@eapO`Yz5#C5Yl|<)506eN8<9;wv{gm zQ(kVqrJ_^$I+d3%@Xa_gtDKIMGh%j-{~c>OtJ*Eo*gSO|a}p70Yu&dg^jjJHSG^h| z3C%wji|^!TOI?#)la*XX=pbUg-UB-qPMvTVGivFy)9AjZZKHR@i+2BW11Yc$hj?o1 zLPyf00Qe<hMEfJT)GQIQADW{ z2Db9U6ZBtXAVKBC_82=j2s~;hPDeZl20&Q>0CFEdc_osNR1jn0kun25={1f{$_NS$)m1prmWyz~CP z!#DzIk|P0d5hM^VxZ3%x+i?V%$B?d%4glrwOZBBQoW(MchCHIU7zg5^T2HOnwANZ$ zV5_MCv=dlwy5Qm_9Ua~ePsWr#9@?J=3p&s7Ke>7~z8rJgiR)>;)i}2hnPy`yWgK*3 zrJA+eQJD1cT$@)|Y~sX%EOj>-F^74l`joKFkn z7oL<#vkMd_l{Dh`dSCG+PQ)%0p+hr>xBJ7hsUfvD563j=ZHH)Jlk9zqHwWU7p4 zM!#gV{^|?Tlu`hG0$Y2VKyeK_U_tmo!Su&JO%NzFqaTM_hBPL1fh`I@hbZ z_`Bb9w)-i5m*%wFQ{0;`E7H>m)%xx3R<=Mdyb7+OAam$>BQ&YGMZnG+Dy9Gkg}o{p zJtghPgb)Q5K5;06-zAz?BDWJPpeR&-8aDU-8O2jikhoal=#l37sm1Cx`r(3L=Syp~mugC*0=y#T+&VsPZIoH1yG{D;#7i8uS4DRb} zvizb!hfCGhBRQ48%@6Y|8}BV-+{$8zEaKb#lZF7}YZj3w#f|a#GG91_-}v$-uxpx* z1_uL0C1j&GayFC{$M*q)okB^yuT^@#eV*kNQZZl9F%*>jjmwF#9J)k9wOV~&y^8BY z=IO?pkL3#P)f^twuW#axeCawgHO#u=xdDxGNq`;r>Qy>!&ASgK)HEslW+#ImfR zDG*;B4z7yBfRgdb>onZZ<2mSK$~#*i`GHH{_VpIiJH&m^G%rcx^dgSvpR$gD9iVCF zZ4bnwJs>oj1VJ7|ai1Kc)NEA5iROw#Q`7WB`tpuC6Vb)=vF<#fVUKKap!9GA0Fb!v zhAsmBAI1dOA^!3p0N??D0OTp`MCcH>$t4uvQ1(yd+`n7>Wq(^-nn@%8nC93m|5Iyz z<<}i!SF?Z0>#K*;yPYqH2NHPKkj!S>W>xE{9(dI`*0v_(II-V1puqNGp!soG zkrA6@z`j6eGJ&AKkYRqfNTZoPi;<9CMPv<-+u{K?4kCVaZYHdC^2p<*uLt7E9_>~tt>HeiB00&?>W#W*T7!PgB^ z-uf_K1wt~+Dy{53mzBc`2=E;9}#I6()#Px>8AdKO26IrH02WUJL1PM$ zG9`r9Q~aOyJ!3C+f1EW>no9E>HTqI#`UZhU&p)=MURIMtjpE9#yo8iANu6bHyz zVAA?Zjj{RF71uU9o%(6q^$N=5F3Kv7TAYtwz3*uhMGTxYdR_~Cq%q!PFKPP7)~i(a zM9B7;kdpkdZR+Z_;;Hw1lrcfdTP5@K^4?yC7pZN624U>ZIj`nh)%yFt7Mef5_1fmp zNY+*46*l?t(;e53&G8ijVqQt*U0?dauRt(-=?qbx;BHMCIqv0oxKQuiZaX+P1c|8)MRFpKsE32)R#_c=bfQ{rJ>|8^pP4oP#d~hMpGS{s;h=^j>#BL7E=c zkQIV5FSL^)<_UkwGw5i}7Kf;=15suJYe4u}3yA4i9sImE1IAB=1DOo*j)@*7_8FmX zHP2R#CJfwuc<%8u5Eu4F-1Yih_iK{3@P^WgsswB1F&A6wn1WgiVmCTo*8( z%v)AVMW@Y&{rMJ!Uya6qFuHMIFv&0D}{6r~3=>fX!Z zH{WdEJ+t)FQI_34I37Bwbd~=3IIK16!7mn&%6$%wy)rwd5vCwXVdLqY)XUY_SIidg za~THN*LJG`{K9&kga=Pq)R~Lbh>;nAJ*!ozyW>(tB22Y`*%sZDM+pS3VSyR84k9wJ z%Xz-CGrQfwADmDn>zyw*K2rX46vqSKqW8Knp+D47=Re5ZwjYMo3=4f&ZLaA~r&jtJ zBSo*2)Dxo|mDY}B$aTn!@=A#O)I^tW_=)c)TOql}jN5awpyzx0`RIHW zwJGT-EE*M`A--IzqB@!N@jp@+0!)dxR7=Avk#WB!{)Bj!-*(iTxj5h1e*}{XYqC*{ zyQ5b=!em_bw20uPOjTCmM}E4Bz=XI++Lh=&`}gO1acPK#L(y-oS<1H){?7 zTOJuMS{=p+UA_qIhVX}jq6h;vG^ ziB}a2ty-C4Jr5EP(u{9%Xlk`ATcKvfOHy9ybE~zm{hkQ=o|KP5A`Kll=`Ns3ob=`* ze4`|Op2z`9Y#vxF3s;Y1qqj50zN`Qu6eKG4FoF$e0@C3N*3sRw z1Yo1vdM&wwRlgnV}p8C8pQTM64K*?`*S z9!thL@MP+?9BsY1*3KaoM4GzBy{e>WuOD;%Z6RcfKcz(PCi!Vkr%LyWv07KvRa*8Y z8KZV4i8W|K&?$^a%l2;hqx6&~Aw}`{dn(=(-er=@_!yew6so*GDWU8FnMn0b-~-3K zY%u%SuYQXMV6iz0=c4o~8tElLs?-(+=$rksR|&;k`L_-HBAu>HZ8F>hzC?fcpp3CW z{xS>JkY~gHMdVF0h(;(q#!GCwpiC}9StIb(P+HHUzwIz{Q#%-?GoT(pH|e%zW`Om^ zjFzEU$Q$}#{e(}=CsRMh`e=b7E|b+*oL{R(Wb?E4(gJ1Qq1>%9z`);n1;xZ4J4XES zr@M@#if3L?Q~-9n7s=wMj}#{(pOLwzhxZ*X)+V|~>b-O`Q@7jmEH$`}Ap08GVIK3w zN)gN7?fpqD16zLY<27?Lrwbcx9~F|+fXH(uP3vv{cgOE((_>s!npA2jQ#RVHKjlnb zMyojT%$~5KFUB@2E%x%={1X5TJ%Cd2wA|f2b@dkZFvPC9{xoy+Tzhr>WF)aq4SVyx zdLNO|k3>bX(Cr_(U}U7mI5*WfXMsQ@jcy z{sbMjeaX0*F`@7okS%`qN^G)*4>bR_Vyd33MAX%(uFn0z@IftC0Z=Rb%NmDj>@8ju zQ;Q;B3GU8?=hbCM<$EKof+3)?1J@>Lr*{2p==Zv^&_+#@)@z8HU}Tw?(#${ZPvCvt zuly=@RLZviI%PP9`me+X ziYQXiOTvGxHEn_?`6EkBXb=aByk9FS|F=Lv%zypq{~zNB1nv-QZLkd2{htYvfB;aN zHds=8EpCYH#%F`5xQwQaRl?IYs4n2N%i!PR3zp7-O~vmf5-w4`-`YS#+BrwbCnF*k z0?ZsjzjOuZij8LXil1LvE0ie!n5n?=o{*&JG9s_4Xa>CCZb8cmoG+YFPIVBmw}=VPg6dV@^phfu6{j&!_q@3=d8+PEN1s%bXfIr3!-T~w%5 zfoO{9(4_4AV8!=Uy55Z`f3#AYnds=5DC?+3CB@G{)+%}8GruXzN4MiTk-^(zUj}o5 zLukLLbq?t*d#G9UB-0j<#D8B&+m^qpjmSwR#*keepF;n`rC`2MfFu9)yD(HE&4M2z zRK-n6ELnVJ@{PjlxY!EOTlD>U=E)B`&VM_mt5>S!XRkH$FV>{qq1P?m(H^dDWm&a^ zRyH;ARKU$Se_zpPI51dgSM#OPwOIbi9MS1eg`T;0KNrz_Jj7S!1o$QWS?+;*--!P2 z@jpLXlyr*6J-QT?ya#dyVZ|ltXnSk1e0_=mUb4X%w_;P{(c;Qfb^E@A+sQKY>m8b! z5;jG~8@$<{7j>u8Nu}N#CRtwYsi!(lNHGY;M&-(6#|wLDuhK8!~qSv!XEb;=R$HbP6?u4spX=&yYArqoBj&Zbx|Cz!7U z{AR}9?JP8bTU#{BHm9LpH~hhpsGn+_ka3R&uDw)7fB3qS@rP%qRJN?tdrk88Q+#dV zLtH}K;=^#-U~dz`5at}21P=fE4T}nQc(xqv+IEo_eR18|S`Rs!Lzcwj2zDzjzDV5# z39T46lxY;tMn~AKfA3i4Y0IX?zSYMw&WUm4;%(&o^5)ZN)Uy_*_m16fN|iI)`$B!+ zeLd45enfDOvnX0w#ruqav_#z>%G^)a!zhr&P;s0{Cd$EWbx&)Bmn|WijDSCg*1W`{ z%GyXWxlgh3XR;6Rz08iLm};PWj}=UUKr?lZ14uv-o_V|{_`$DbIqNv;9Ko9 z@r1pN*&flBZdg~S-?!_ctwg-`r=2|c)#!OK1u0=iOgJ-JM!~&jvjrywa}j_(yy}am z#eh{^-2}fP;uv=g-ng)~?yc9HdEV8lHx5L)bfB@4%dFDWgo8WqgTM;MZ$-BczTQ9A zk{NX-kvhZ5+N3t%f5?lDkG&o8rt#eEd68i+MoI9-dYr>dL{>&Yz3tHq#(^lcH+YQa zE|o_z9pFp*@u7G^c)t8aYzphlaMG@@5a-4Py|vZAE4Fk303+@a6&J}bd1@cG(M0jX z$^!u8z#)ZLBRb-L>0kdtc;Esh01(LcJOo4nH=;ZQ^m+Ve&+%VM+FxrLktvf--Hgb~ zQcD62pLbfXC%71-@hl_)+ZA9Vwcf@z8i6*IC{@{P^i7qumV2iB3)T7N;?vF(Dp$@ZP$Oi z!)^i3A5^~DXEn|%%E+TSeX-Zuyhlc*W;buBAOT$PTR(K51e*7ZnUijVB-fhb-TuN zM4~oZ_3y3TSM&6bbMV)!1>nzRF=tWW-;w*q1S0`i z@e>iC(8;&4T>!3y$TFb)eM(QvG1c;^j6^?^WyUQANT=hjhle3mbg6Ki2$x5gK4LL_ zAp3a;t+rR{qBc$E%}N~Fr{;dU43Dz|49y`U*sB!Wfy`Z*bMHY*hID-qBWm9 zGtp8b_Ytc=NBpT@-=t&~2q41CvYDl3C{>$5dws4YcdJlE-wk}HlGE~nM0=gQyq7go zfi1Z`11~DAbcWprz)BUF7~l_a9ipdBb%^MQZ~8UTBiYToY-gMK2aP3}9A8XnUXU?_&psRGnCNGEdpOB@))O70p^rL{d& zPk9ED@Rgd#A_;Z%)H~Gn(d-OLkr@rkGSj|eYvhpER4V^Ph!gaI-VokOdHB}KSf%DQ zt5sEZCmy!coNI>=53Y)%ZJA|7Z80Q=gg4pSsy0<0iscG~hOu0~G3FH{ubKUnp z3da3^+4_LD{swF?*F1AFB*BP%THJ?wrcs9lC_J;^+E9ivca$oV1QexbcH4rRI-e)< zs|;bfv*FqmgpUjL&}=~a&>bg%JeVMfnkQC1(nY2&;2S6`p-ZbjZsj}w=CS|e*npj)0G&gv4v zr2u8?n9>zwdar&i8Yj~d{1C;?3X{_94xBVs~?<`AwgOCw-*0{;rLoQ`=@=Yqjy8l>v3J zV5QhoN$)yC`mdWc6M6%`%h^PS;m#Zt;iZCwR%j+ew+0t?Me+w`F+bv&9+Am9xNU33 zB|o)ARKT69e?7`vspzQYtpOLcrVYIknoB<%oz$4SVTuuAAv^IsymB{`rB&)qN7E-L zB-|EM2;4i_!X{otpfY&)dW` z`tJ-L|5ofzF8Hyv>?ZewjB8dCR8AizZHp59)SQxTy>)Ojso-z1BihhD z@vAJeR?WAgnGpmpdJ6FtFNcTZ=RK$UImm)T&N;?sceG;$&Ym-p2WC|CK{BuJy$Q#Y z&Ulpvp!8y8%vV#OPkm`;E5u<`1|8X@vdX&^uXKqTpLV-&3_hZBuKk3<{E~S7P<5pU zD==9TKH{E!&73INrWqi>WvJ?rQ7d4NYZeq6PBA-_AZl(w{pyH{02E`7(p)yL)onGS8@c)9`rB*i? zTpVolR6SambyH(!3!9HjnFqTAR_R~_mtRfv1_;rEeJvS)$H}P9QH3h*1AGM6WJ*o3 z?&@2G@A#T?4>}sa6=}MRRjR{K^aG~KtO)#^_pbJ$fV3e#!X?BBL28s|%r_H7S$`hd zT4oQ1Y=&aX3LQccIn_Kk>*@N8c^U%Yu+WGJAdN~jssv2@ak=O<(EJG+H`<4YXWaMH zS)+f*$i{$?M_xRUh20_Ib4crN>y>6zN(Eva^~ zJ~N?t^cR_ufYr;o%I7nB=jMf9arIvKc)rCnrEEzBUC~uhye+TDA`MnITK%qfKd@d@ zDwWTfJwj}+hk9(C_9T;+BHTm?V%#q|cUpL0tmEJn6+C>4pKDMu)3e$HtEy24RfYB4 z+8~_-#%%*1^)+8J?%@E?jlv~P00H%3IA|jR+)T6kjsk!yx$^q{iZJ7UoIXK^?#bRi z!<|<9<=x-}IV}8g#4C#H?2l_bJ(fPb^#GQv`WY$7H;vK@)=t&vTeydjdtSOM8$Nf3 z--h;4f66tK^s1au`?xD2BT&ezA>mFlC?9UJ8KsyB=VgWFRp{m#Mu7(7Z@O~qo*3ku zozU2;z$>EBEK92QwM~-LnsTxa%|p`Iei`oX#BGI=ce&p?+|oZEnW0IXRd};VIcENP z<|Bd-(RbHF9iaP`;7+HVcE)G3c8m9(iqdWQ^jn(akI12_N>K*KMnD&^p`nMWNxHv??QJ4i}f_THz_< zs!sS`1>f8DA1EYOHy0<#_OVbXvT>?LoZPjl{HhA~11m>6*KG~C>fQciR0kXA{+61s zt2l|rcY7ByEEi+pU2kysf$9gnZZkOxuhYXVj-D$^I_|H)GuuyA4Y>nslU`^&xRtB4 zu*ER@uyEC?b`ZlB9^nArkGdvvk?@q;_4A^T$sI@4O&b+g(EM_hr5qVYaxdknA;DH) zs$4oZp1;_m>D-13joIdAtK+Jn!}}p(aSbk>(O-(&wb~ueN59fcHQ!C08Cr^!R_f5< zh>};|dh4l;nUHGtcY0Y0tIJUd1?fsCU*7DyEd|9bwM7*}bjBYx(qLE^$EHHtUJDDS zTSpD0HTRT(rD>`3*Rr85o=SsWNfu}^tU>B=1%NNjW<_kiu6o5eM3VQw$fxcJ0pG+Tgjsi0l%k%qQq-C9yo@%OgsCP zW_CUMJPhvcT0xu}UY(2^1<&hAz1|@S(zNk!dvIU;g3r-UPL}EipQtBe`Z320UDP%? zlS59(b>LO@a-kW5Bw40AVkB>d@G;Nt7N?jQ9ld}T7e(0g^Ll{jmtQreXBRc)+WCE{ zX8Bofm=aq9+`;6P$MHT6^0llUkE=&x?q!p=@iG6t$57s3sJ?LGO~MfReDPQ_`D&!# z(|MHqKv4#MMDQH*nHK-89kCaU-NipL2CZa$q&+7yc`9#=`t2Nl3EUG!Z_4b|O0Mb9 ziYxT&XbolAP}TfDTzyqg99?(PI<7+ixp1P!ji-QC^Y-7P?H_uwG}55e8# z^8I!1%RLXLyH9m>bwBj3eb(MZhziStWa409>@8 zAsRG5KG)4SfQWDrZV`YL6^4ztVFR14>>EmDME=won5U>I0Dn?sBoIuc(#Bm4o{tdt z1sXK!&JStDumQ^j_706h9i)L$O8|2ewT1W!_%ZlXa)-8v-80Mq+lQqGLp~uPxne_- z<*2ti6D*5VVm3zs?IRk>t5tB&5a@O+vCpw(eauPtO(qHeaNkF$0RRY1ieo-X-E#m) z>oW;HdF`55>@qNg$pld>GEAEVA14MVwV&)CV+32NLT(9hL~e-(i{(O^VSA7YZhD*< z;2vp1_#}{|?F~|#wu%a22>-t(EBML%h+23mv%JC3D>bHcRhC@pO(gOU4m_|-=PLlH z9}utn-Z~Ml>-RAvG$$1=8Lp$Pqei4nfSL7y zOg%7Cbo^V<@uZr1GT1ES6w_R9{Z8|4s*OVUJacR}_FtRg8nZU1hvr^m(P!xCFJ+NV z9@m26(eU4UrQ7y8Q@S(TEGIaNY(}SPw|bSdu-+FiB^RzkKEVc2xRE;Z7vs|JQLEa@ zfa?AGfW-5b*mWTPBNH|yY|lby225%SSAQ)E^F?@CZhhE{Iz^Hf#ibz70;bTB8a7MV z+*p_4v}?%cQJtQHii)U)fcWaKExJQ&7dxLbDz&cDdFMY6OU}G9Px&fnf*9>RbC$0e zw35Wy2E(tC*qoW%QL{FQ*N7V5lIOPeOKS{c9y%C)T0VdMx+n7#DuM3HqEPxPBJi;E zhNNXVq3bfVaHJ^xIc9J~X z@@(xXQ7&iTZZ1^j-|CWWxd^t7!37nkq=z>n?ih8p)KXDAAiBcP@5Q%{2BBM%E~UUp zlx8xzc*dJ?yGI?hEaT4PuIj13=~8ed%wpUf2opjrn@dW{cY+X@$&91gP$@i1Up0j7 zFli$IpjMB#4dIiq^}Q=%Q+=N2nsW={~v^Tl&Lw;b0sU+2Kzo3?PnmTrzT4<+Ag^&OYRz zK4q0s`olPAAAc?fXUwf~gpzrsQ0^viWlK9aBWPuiZ2jV&tpF-ZtTPxBFsqpd@&gu` z`#h0#Vgl`IUmtHqF`Z&(b$CC{x~c6%W4M< z#BtE)Nbc*KY{Ie}U(1TZ=#ZuU{I#^{-SlyIrPW+{6U|^Evu8fEZwpl#DCiinVwx&K8Te9S*d%Kf}f^PBZtLC=(0_A(C z=fDLMGPg6Gv>W z$KETHInuI*u(Yz(Cdj=(Qm zFu5`(Q$xnHjI0=OP+C9;J1O`>{?f1@&;U@{G6xMB`cKvpKp%N=_(ApgFZO+mBFq0J zfFDg00RX7TwvV0i$08*r3;_E7b}OKKP^14FK=4P0_*kNX#X><@f%!Xq#Hy?HIQ?xH zj7#C7E_fYV*72AeqL)-TLVu?#pn)Q=t~Sm|ld4W9(^2^_c(i_s6GNh*;M{VO%kz-q%( zq!|A8k7ws+pmq{U6q`ixu5!%`W$LLVZ2L+7VHM$(#`KS4NOvox7T z&iM)M3qs}MJh1*0J6c;U+=OksVp2;*V+jy&w}Cc{4&WSX2AW7JTO))pTM%gly@i?WX9=)qKKg z27euhPmW^^x>5O!bCTouY`Lb<-*?LERq>MM{>dEBF8|bRyq$|-G7<2*2XyU!O1^}S znOfY7->;aTTu~)srut*~Y_~8{9G$s`jOhF&bGat*4{<8{09;d^TkT>@Bt`N1J9{vP zr>=PD(&8gDEn>!m(EWWD$P2>oIhXqH)^~yqGsoKx5->enmq^_6N=;L|IJmr%HfG* zagDnoS&^T;NH}eqY=Q&ji%Oe2DF&3_0JHa-nHX@B< zhfaR~R0k0gi7eYNF^R<%_mwCpQgtQ3MCzN_FU(}Hhj!b~=aRnikI&3FDS(bI7X0|9 z{3=1uD3PjMim=+U$SL0VHJorsIBXBuM0NGfG8N+343|4_fpXoY{s%orDA z2$d=YM#wrs?q$F^zk4&g3XGSb9j$}T&7@pA`alx*6&X2?l|yd05|^N1AsDpbbKO1K zF@Ok*nU^F4$P-1d5)=er+*kk8mXvT2nQ-B%X7Y`;L~fT6V<9>77y()gqal?Mn*6P) ziY~~WfJy$_wHihY|M53+&QK|xpIKm;rXUzx^FL7`R|JXsXipje)Q(nFv~oN0vR9Q7 z2=b3;WBY;W^1TsXM{?34B>EQdX;qr>E(O+Bk*-4&$cMPp6`)VM`X*%K;`%UA(j`qO zlu!V~I4Uj~sN_L6V4PG%GtvTl!8sn7#6-Z;$*Tz}aTrt(uS~89mc`dkVF30zwkz1ez=A;dz@e&K?|)$?C%scrue=g`GX}3uYwXzhH{4Ss>Z=H3O;uZ2zIvgw#$_gbDB; zUEFmhbA^j093KP*5UX+Bk<-Tp`J3BQbJ|J~QqyBA42`sO!@)Ehbtkqc!8i#_pa4Bl z$08NcWP(%v=)ivTKm0e0ND`z-9bAC>pt`O9EqqM0A$|Wl_tp%l1G6F3cU zUiiZaE|@bQTk4Q?5ewzs*0Tx#DQsr|fHVwtwrS8{5s5187Z_l(TpB>35TA{b@<<)I z6M{gg{Qn;Oe~;V2e1LH1*+UQh{Zd73nFs(JoWi{HwqZ7vF0H_b(RO(Rf9!dH85?!+ zxYCIXLP_h5AN2ssg8sasw2=Ik?1w`i0e&K$=Afr`Wh9ey^2C{OF$K)0iX%y*xuC%GCRo-+H9TzCyyINy?2oQr}LSk>j z3r7j&C#yebp9xN8Dn$}55RycDzJ4I~SIPumk2d0OyzzI{Z*m6c=ZOE_UP2NQ(=x~j zY-n9Fiq?MA+qfR!Ji+*|E!b*wJrhVCVvhZ_yw0TBxOLe_a%^oRAJefP(YFZS>X4*h01|sYfWv&XGLvy zjp+RR8|UBkVj+t>J?Y{9<-kl*AdV6GM{5;8Wf2Pm#2AHTo*{9{H2GBh8y%MjUJ=BT zUX|-eZ-OZRK`<$F-wYM|gSPZaJEFT};gL?A72a0+CN z^2CCovCTswCews0rFPL(bexGksS0^eVeWO5ijDok$Y}IUT@8<6|HLFDseonVvxa7P z3x6i|c1n+Dp=dFfjc4Z_Lb@!N0WiytuCvCuezfWNW9N;+^U97(Rc!jL+m!G^duS16 zgEkCTG`r&1D^nqaAhptp4KkY*QIYe3ymBW&4ZdUi6Y$Q&74jj~{`nwsdEwtx$pkfNgkPbSfGDW4V26+iC1k(Nn5ch3n$ZGP7rL*rGks$dY8`nkx7 zTm)*eY;M$9oirORmbiLMY?zYmln>Vkc7L&n^5Q;ncdMu9uA=p*N@ViMbe699Wc`g^ zg+G!Co>j=8k}Yin_KA{kVcgWX-EWA8&&>p|Bx`0C2|}INPSOxMJdG)9B1e&1d%ZV; zQGQTBzzOw%1mYTj)V8DvW9r00adqcXL9qHts)IX3$e{&PTLJ9ln{|Bv2oV2g1>V>d zC5))2XWY+V#l=Ssux%Y3YD;Y-))8Mhn{3(d+o{xOdjJx=vnz=GQ^0Vgc;QL~qMPh% zr0tJ2r(yjmrRoUSqn6pF|1*g0%@GWc?PCrUnpgee&E%3bi!;&oav+}C_{7mcD{eL%B%4)ZmIYEBG zo;DZ z#@Srb`j^-(_6gk&d|nja^Mg#7X!s8C(z4OkcjtuvGY;@Gqv40$5afLE8R}!Ss90Vt znaH59{H_ioq*IbjhF76uSN6A-4Tzx6GsaPr6l!AHaBjVKxvgqPS+FEabjb-JSz5Gr z4f+#{)8!-F0IZoWvP~smhfCk-=m;p4PcnY{z~_Sh@#JQ~>?@jKwY<(RUSJ z_B#eGjvQm)vz5t8lk7B4kw|MkT&Ew@sivP#Ie>$+H4`8x^jY;P^~D*uRYkFgBJDh> z32z_W@~y_GN1#P9@pu_2(a%M*l|Ni!zHe3RQfi=bK`yCGVTYAI2iymCk*UFniD8t1 z20-2Q{TJn-jXtJ6@d^~!Gynh%{BiLitkL&B046fR^@z-H!ua&F(IMZaW@XsI+S^|< z^Arhc2^RbiR)ntVBHg89_d{g5_08RTMed%> zOl0=&*t(rBB^d_6t5@y<-0?dwEKHnP#X=iMS6ntk$Nx=gV38FdKcqS| zw#d@Ev2QUdQ>&b-$%GMpb1Vi&%Cd~0x`_<^4KLLQ-IE^o47oHB9BxTf50sofNOoL| zHb)1I!qGx5Zv~Nn zta!?obA?Q&Pf%(!xAElGoNl#h(x$PN^XLf*qV%|RxD)$5fEWsS;_x31+#)n&(uyok zt*LxPZ_rB2)VV@WAv^0dc&TU_o#QPn{1uEz@{|^Ze>-VaEPEP3b2yg83KB7sMPD4> z6jtTR?(KD16vh&hm@&L%%+r}()dh?W&CMsA>Ay>j7ba%ia-8P#NpgR6{J>YARf9hS zAYHZ^sNxKQ2iC;(%xcNJ`qCL5lZP3W@}sa-PTJ?xJ$Q%1%|f2GvoS&=FPA+XN$Dix zEd!)%Qw74rP-te) z2vP>>P4yx)CiN?mdO&q$eB^>9GKmbBLM1{R1~ICm3XFQfx(=U26FcAsjn$ z1YnLG(FHdb{~5rRw4W!7OAfVTn_K|`s(tJ^Rz0m2vd)fqHB=bV%}P)yBkfRseb?sR zJ?G2*lx0UnJezC63EMwxnDceJyW}8FBVbGssS}4$?n9*I^uUP&SJz6N=oVN07-< z9kCu3+Yd1BZ6y#&W}un^Q5kI!2<-UEGJ26apY78XE<3_FiLPH1VaQ1*y;d0C~g^1nbF+<<*MMm#H9>dt0 zXU?}yOBY!IrR)ncGl**8M$rL1tWA4ev`%VkF{k-Ybi$>(j=>>IB-!o>J@I_0WTF9U zIQKbx`k3T#d}-cA8~Gl^&h-oQc->{G5V@xU;`CLeq3&$SwMgS@NQ;!{XEZ>9`Xch+ zHZ~v&C>X5^L$PBAPnK{xXCyJ_mrWqBfH2LD%A#zT>(`xe}aVRH*?Ipnsnd=3v_5>31*S!D4DW)%cMccI9b0PlXS^=xd z)9yku+6ki2Doc!Um1QKv=|R6_enN6xJNkhUxkeueA_7LDFd0e1aZ}=L&RJrDwsPFI zp~Txl9%2Ce)aDx-r;_xsz44SfLKErtK8KK-Hp*Jq$V_}Mq_TDZ2>ll1m}&x@T!@9_ z9|u4!H^p5|a6vU4{RRg}Alk93!0R)rwp4;CFhQ{eARZe6LJ$z>e9Arp!`Q%C3fOsN zs~iDnQH?GU#sVMEEQ1=lQYIXE!3Y#<xOeQo~iJcx005Z8bQ{t>$2|U z*!NfLEtyhUWlonPXjsCRLsE@q{+d-+D-yb$&NYoau_p$>hyt9fwougP1IZd}AcWyhrVzK(WZCvc);FxO)whK~pzg1I=09JIp| zwQj}wI~WAmMxnW<<}Ywc!boD@P00ZM(1!c2k4VdkJK?{kfNrym$x7u`MF$NIoIdp< zAQ5gx*H(bNnE?!b z)}#8&*zU1z4Og;@L}IqZq0_g?Kh=LdDt3id99vwu^VQCiTAR#pVnI8Q}N6Yi7bl@|4#V?(xHMS%pr%2_R?Fkmw(!Lq$P^`{aK1h?1Pq4;4SB_nPTIr z)CZJZv{y`DC8>X&!kdp}2*|Dg|9x@ihBR!)atT}tbCimodu{vnw)pPNS6$3mcT(#_ zFxTwbl^{Coq7w@BHpCXGC3HEgoHmEAFW9G&V zbcW<-9bM}74P*Vq-QGE@)Nva?`Y_&o@z)O2eB8QB{iZ<(m`=g4*<)fh)d(F_WYGOT z&Mb;EV;=l>;&?|RqLiqONk1sul5YMcGev{SE%upGkO_TFX5ETJHz}BiPR$i|`^J=M z2M056du>jEiQ0L-h!hsh!^f8fyaBlhyk{KZUQrloh0J=2x9s8~LR(Z?QcYe8f z90F>X(07PD=swmQCPll*vo=*R{5W%uRttccHkjf~jCIkX+FN_$!GC>xOGvJIU@c=w zVq-p5^SGx;UmV%S9WQ)E$eH}g3V}~1MQy)H4e(LH`0XQ>TAoQ6q+6J8yhJt{{da85 zSG*gQS`s&Ptn8vL-Z{0-N&o##90iKfx`1#FjE~c$T-2b6K%GV|^Pi3?z%>-W2p0g; z_un4jLs>=}K>pv+#L@_W1f-@w_}@J;VgY^st^PM)D*jh=000UA92r=mg5S47R zZ@sNnQab8~dF(Ldqz=bP)k3*j*VUJQU+?D&rI><~g*t}G^0I%5FRJ(w-$ui@4l$}xn9kM@XI3~3)v;V`(>3`; z-&zNxj&hhueDHQvJYnDP4h5(tRhdMVRKLf8|?nq#Cw?dP1dvhw= z(c0$ikbb|T5g3n^m`t7zR(~HQeN7b&m^SKuW{rM@NQ(bJ%D8bDB zGilv3I?=Q*jdhY3XN|@hXY7>xp7JKo4^=_ z#6}!@@E=AKq5qR*3W#?wd(Vbr+`-ZjNwWp4^JPec98|PtF|8cBsQg?YH@}kO^F2$)Qnm_yYrg;DyR{yN~A;74rW7mhjd zp(gWI+sIOt{-u&GSR%CA;1bPSq{P2>yF7*wVbV(dj;ctKTHVfvCadf7?fU91!PpMa z#1=u{oL2{6q4qwQKbDp2^001x6$~f&%6Nei$)xx5eGt3a81#6cZWN_x3@)vPR?dUz z-uY;uxRI&?d-+|%%haO3bvO>J#ENGliLV&k;u%UY06mehK~Ye-Dcbfk&?V8>HfKz; z%XFK{@#6E5TutTRZ1(N@(^e#;-`Z!SyRBi$i($M1HzZNF zg5aU}UNh5@q3>y*V0W~1|Kb6WGRpfr7um##Bu%R3Q3kw~?UJyTx76vwfQVAOK}0NT zv9Dc&Uu^W3nhr|mQw`al?8~1=`B-rK@(z)XhCeC@FbMlcZ`{Cn3c8PT``x$k`W0@X zPp2_)yk3lIwGrs&YkyA zyN~K?!{t=06cj5*(`Jq6jccleV`s;#%4WlB6UF?*eQX;+JDX_QNoXaRQ>J4Dyd`;2 zS?(V{PUOih#@NfH{*$b!yC0vii3gk3$ZA%P^!G{9x)mqoTN=VI;$NFXGQ60UUl@PP zFDG3v)e_H2?9t{y!%Jb1rCF^MEC24UQpFwqS;pKZ-_g)8YLjfWH1SJMU>)GhU#8b2 z^%tMDmEKL*_b(>;d7x-XvQ{j|G%iA?=a<-N;vcIC+ii!JD2AxNAw9HC?+j2XRNgck zuPPPj-PDq`3XJX8tgxr}# zY)}+MCn&Xuezzsx3s<}XU%*s>bhd!p0(O5)p!s?Pn(%bsssKv;3{#9rL^>#L95Eor z60D}k2DYwqA!_>vAeZuO3-6$HZLx1zHqmiS0uDQr-3$^pG;kiW7=l2K22_E~hL^#> z22z=raSH$(LrN+Dn5)PFePYheLGbu$DldfiEHs}%&g8s7aNh1sFt`iKaIn51r7-=t zw7y^;m%j0SS-z0@RTfHHBBO8}W{+G~a^e|1Rit29ONR~+IYJtWc>q4fB7hbxFm?`e zQy@$@0>a=S1%y}SW6d#6uB|bE#RrBYASnmn2VxrqU&7+0iF0rj)I^?IO-O&(xPI~= z{c$1D3BMv$aeJw6e}!mX@LPfNyXaM$V}=o)rpuTa)Q@kU2UeX^X=-0pdzXo>!V^>K zpoW0!7UTYx%66u_&iC1TePcP-W78Xoxw;deF-Ga!M}n56sVB-wgwYC-dX|gY zqYJ*PCa=q#q}Iu$wjowf!C}iJ{f-jRKIxopK-0_8;1({u7-BppxLLc+D5tc@fx(f; z;8n4X4OGM75zZ=@H7;Bqh-Zzm4vd2(hM39$6?9!K{bHO@+RoZO?Ll%_H-;hBK;aty zBMdpkrj>>F5 z;NKYpIj|U}_u1dpgG+N6gsF(lD$if2ZJNX`7v~b99T-{WH=tcBi$ai#H-erMNLRZu z!ezMlHYMf-c}PJNQ0WbuR}0uoUyzrfIBAg(AU64z0e z=@)ma#uFH2SaF6&*}z?Wx%@EsC~whgrL;+iJp1B8dN5qyYWb3F%VclaHKHG8 zu7gkF9#>?jLs;mWd=fyeM?`e{#ofS|JX~;z2AVJru7s#%^DX{_ zlN<+s9NLBl z^2$>#1Y+N3%Tz=JZ7AbxQrw!&LtAF@B;awsV7n!tQE0N8&@`%~hlZaP2`nCHj~?U| zZ?p%VW4-d5HJ|M2tm@qg5lEjV_u`}y>!9#~&3eA}(EnpgUqag=1Z;haygs})nL-%r z60o}xO?Q7*LqpVz<`bh-!^6b?yk`ZWWLATX`y@gAW&q;pWVN-_F`ure9?LYuppjpm z=Kt{q=`XgU4&aFyr$bDRu4(kC8-lG8S#)qRHiWibG|LYPkSMruk{#v~l(Wi`iGD2N zO5=r9e>P-hA%<8~nBKinl;4k}G`0$pRZe!WBLPqR28+jFfex7KY)N@74nd1`|%mq8Pg8PQy-Ecl`7$RnMTg#NbT~PeC|W z(x(V6^{$^CfoTn=Am-wECY2nBm{!uxk@#M|U+QuyKxu_s4K7m?8;~PiaUR(6X1<~r zG8KG%Q7?5SBt-GhX#6kRVQ8P_Yp*mdI{>@awqWzh5fD;5cTv``Ia~(8=CtU;uqiOE z8(+fOfRfc{rMkY9#`d+{YNma)wHTTdpzj@2JM21$K#BOAKS2b8Ha|PB&TC8JFxc1=c13{&5pOScZ4}6g2sp2Z?9d_n> z7?GT;@UOy*x*5Q@gOj`^AzdTRVbC+TZ77?6ttr4?J9(-WAT;FXy2KQ|O8ud2gy==Cpv|_y>^1IAjp!S7nKC~w$J{cKX_F^TmFq2&bJBd@|C>IxthXq+J}%28{M1nw0N1<@k@buL8^rdu%vulgf?!iYfR zj~k0~MjNoF*^E+!*!R8XSl8n-9y5!Uh@UBC@fn(qHXk9PWO6#)GvZ}tR6 zb9_a}i@zKe9~H)y5sc#;7gGWMVQykhQgWDYRzO;`eT0|E7~#7)=>85+xf_vYh5O8U zHx^I#eQFp-8e!Odt?ny`LP^AZ9(tr}iXPvjn_8H@xO}lyV_H0XwO}{wF^IRUo1I!3 z{Kw4H^bYtTTT;}bz)j;KF0nfFwz!SpY&4RRZG7wONB5wJ8E+%CL|42M)UFIibxD1K z*7sF0*;O2lUmAD(EP^w$?Ct~5p`?`DyR&8wIq||`f7o$5vI&JL_IE9!nnh%MaVJ2K zIUy5oR_U0Cel8S!T zdCyp<=L2Lw!99j+17qqLZLq0i_?z~+-EQ2gQ?*g>aZ%= z@e%SFW}u8{B_TLjh016sm_T-Frv@Bl@k4iImoNZaJSj&5Kz)BzAOr}uX)uDOj5~gN zVJw)Q_(2gZDF_vK2lHEk-2_devLG}X%F&RGg$SGgcJkRG2A7*eCs_|=S^c)Q%!+}K zJW za#O=1i4sO7eF5n-85>txhBmZ%5oSUy+~Y%%|Doveel+OtGa; zh(3*Qzb)EJ&@rgRQ1dsjH>Oa%-Vmk@tZ4ixfWtc(983Eno5n%cD*$gA`emgr00(?L z9R(d#=6eV3E>UOytpgsbcShK}hZ#94)eVzpG97{b_6!I*^?`nIp7^G3##yv@pir}@ zG@AGtBpp=KSE04m7k}}A3}vn2{DOIJEZhAN>M2u2VUlWJgMtR-7E2Jk9qoiU^>5+Z zn85ko0VGOAZi(cjgBZd%TO3yq9#zeGnyU^t^vQK_l}Fz8Wif6m-ls0hzVGfzWm)EB;;AC8R;t-(#QmFP3~8|A3fH+MM@;CpqvR`v9L*EzI^W-5 z64I4KQO~ueX_Oin0U!c3BX@|)Z}VCGpHsyn0b)9T4?8~-qp~9TvVg;pZuSZ5@J~FX zXKFPh3C|dN*eoe&ql>#vIfU~q}PDC5BWM^1rV(PMa!FsrZIz2(wji(IEZMFkmD;3^U(ZN z_badOm2J&KqBZ>swr@e4Ug26P6FDK`c)9hd4=#;sr+tS{&uy3$>aXTMspdsYvFC=u z(e9B2;;hU={1LyolJ6ozQ_g|7Bl8&@%(p5K$C7j=-~-3pK`DdAx!^GvXq$gvt;FlD zD2TlZcNf#bpQpgo-tOG`g80&W^I$4g$&<;z3oPt*cpr;%Pr!ckQQjuNFpS& zYIsoGXt;;NRWQc}jJ!}4P66$L+Z8bOWcPZjPRLLS6s40>ADYXxzTtG~sj;=lej$x! z9{kSDO!Zd!kQUVx=T=>VLl&scnV%>BVA3dx`iu$#%pQ5$mk+_4iXC#q`|2qRa4IWn z4=H(;3mWv4)RJW(W95mlQV81gr2EO7oQ5#VaM;lA@IDd(`L_o~C96FpmpL zPV-PWN}O+_31&@gNiS&`Ci8Y!%`K_nNPWPr^ScN8xfa zS*H8SimzRz|Mq)ix1lA*yGYCl8DJBC5!`A2DMjH*iZPx)v+~D;H+}>Bs$QK?&?eGI zbm#OA%xkA@3sDHVC8eT?f*W_G)x~;n5!pFw~R;XIZ;k=S9~9JXDX%9zt8- zn3yNhO;#0u$Q^axX)>yF$7u>}dRuKm<;XBw32H*YQA0|-YgWmCtF`f^5TNr%8 zA7-i2hF7I`zG^~L-UpuZN0wFRQ6Jj>#QBYE^kdQ{xUyDIU9gUQZ}C{%Pyb6E{KK@- zepn#pL6{9TUW7xSy4fTFZhge@axzzD;baV{2BXj)O?Kw>rC)0!nJH3{D8|m~+%k0ihE2U1I!v3H^1h1P%gifuS+^|m4YO3P*!3SQ+1O11x! zAId@ffKB3wda!c?ZZovmLvX!anK;n}c~1=X5(6Wi?nH5p)BMgBvyg4;Q?!8GkjvY8 z6!V@7?;!}kR{1bxJmx=tpkc3{IHir)-a3Q(u?S2TH9@11+AQ_ds^0!_qK}Y@M^ylO zwiolaPcg^lIUkfUmWz(R(?KHv9@z9HQL^2Dktq_oR<}PIT$6%~`-=lcJ@^ZD?0d}*L zP`RYVH#&vXYBJkC515mvCl%j*9E1~E!3gpptEHSp)xWj1`s`Aw`r;AO5K>}x?Z&M_ zCzVIQD?z};$1CYPT33c)>H&tn?vyDtau13^!;c7w;guzKC6y%mt3BOU+t6oQSIh5Urx*lt zWj&tv`BgF4_lfu+B+KPhaEr~8nWdg>i;~TlVOdi`$<1Bh*Deozp@r~km z7tr@?=3=9=zg>h}tlw~JP&sS3m(mFX;tdG(@6>q_7D=J!1F5;K)ObY6@#8ywF~bep z8hdL~d(;KuohZ2mK2D}B?0R>Is=@_zhx%C^a{CBp{7AAvh|j zFYOEZedA#>35a}q9?<+qQ9)RyzH0J$IFZRFdr0hCI=>>`Z9P6(>!XyVj(wT*Wi<>= zJdHITd`}D877&D%`2z0BTl&ojgi=MgM&TQ9h$pErsFmoHh#Qt}2P9K9i3EYCwW^A(F1vh@A&B)Yc& z*rk!^TZh^3%}e1q`u)EVqEXO$FSgO3bhu4Ka8)l!auX{tu;Znr(NAGnlSz-{h3~vX z?%-HbXH6h7Uo4urPWQ4q`z?$+wzeUkj2C54cow5FL@cxqo7g~=m)Z+c_h2MjHj>8W zzA?|k2q{i+%6iELLfrEhsAr>D*XeJusbs9a1=h;Kd+{6i@m(9O5xI?=t7((Jbo&#! zT*2fh)db2TNo@)Ph!(h>;J`y3?5!^}9oz{?^~h{OiP+t)%ud#gtGrn8u8b;~3sh@j zk^BhOLOI0#d=~UsZk&==UBCFTWD?*lccuz*!l}o2 z#-}zprA^vYTwXM4ZhTHLD7Z&NyZzTRuFvt6^zZNW*Lt`G zN$fafDR0%ltY0b4U&)MW9J1OqEP3PEj&u!CE@iTUpuHWSZXQpDI0%>5e@B?Z#M*d2D|REbdC4U+Z$#!p4h+`vGH5AM zFc&N49LPag%^*-}{<$FHz+ohS`S(2)xJruG(9&oYdZ1Fy^E8l@PZyLR{SN_eO=4u4 z7rjGd_b<2Wj>uuP+;*^cZD7oYBd9t_2$hQi_o4~rw}2?QF((1tvY22MQq;NCqscfH zQr*Q;;o+`N%N%0_s^9S%1L#`T$As;c&1+bouaacSrJIXVw>A<(_+4MgPtq<#&7&g8 zdIJK6K5_kFL0I}bSTHL#kjGbaJ8Tmsm(Qah*IZF7zZJ>uC71hrCT#zIID6}$IGXTX zbOmQ|TYQn=5L|-0I|NVAAi*KH?BcSx1a~LFHG~AW#UTWDCnR`+C718sQ@>kv|GMY& zR8LiRPj&TEGt>P__w$-$Pd=i%N-Jb+z zOMsNe5CC8sRfWOxRQxab_Q))jT&Ut;c{X@&cVEwqmq?%-_G3x?0$OUes=LY_>=k-# zE4Cwyw9JP(Y2)H%+0*P|i6Ak?Im{M;Y9`jXBJ6nhQhY3Ysa|Dblr_;@RKJe7-?5^kA;|a=<3# zghG0+MkP_~?AS>4y)8Mk9Ang&F#lLDc7KP+!=Ej9)#HJ7Iv|1ZE}SUREsA-=Uutg) z%idhEUBYde z^L;Z};nIA<)$(}6*C0c-L?|Q}X?Dw>fOYx8=3L@x1PZ*dYw7-$A>E%)L^?H?DXNNu zlY}o)I9#dxtx=fCr zOweHlFpHu>Zil2;tBl5HnFC$^g1TPsPuQ%WWLz%WYuBfcqb?Q;SFx+My$r0QG8;~Q1+9Yvp;c5BJqQ>C0U4Rfsg#q4ThiB4u) zduw!AJoxiYBl1_CN@h;^%Ebp=u3COPG{lo%XTZZr!Do@$d~h{B&e!CwX=|sfzfO^D zFa5WRLiTW*_WYZysZa`@-n22Z)e}#jVZp;iL?RWBQRb=#i;(gkfdOOB^q#LjNL}MI zMBfw7x;0y%Kk^ovUu6`c_KZ)r;6rb7g z33GQs&H8*(Uy{W{riXrG;ZnW1S z$=g4aqiuLQA?)-y4~8+#La>{K@Og&aMhzpzghyN=2eUe#(-j?>)yfz=1WO@)?Bzz6 zN|~iD0$8vy0O=Qs8Yf_XcQ=`Q&q==(C%kkue&hT2yd_-92%hGogjh}5#Pl_L zIfaZwuDZ;BG6ebeB|U2jP%BMq2i1j9CJJvf+;}b7ryu=(7M17h()}9ON_TI)sKeg$ z+t=5Ts{hDH0hK#@VV_KHB<$%F;dyJGWVf>$T+nJQMY*D)^V_dLZqnZ>4Y&Ir^HI-xESX z_ClfK^KTpJuPhkoA)WaOO=YT!?L~NY;1AJgsl+=2%c6Gtz~WDzuxT$keeE#x5769# zi{!b-^`ecvTLWBfgoqEftZde=AN)EJmL@1J!b;jQ>{okZ+fUA1yr>6$aIB3*I2mq? zC6?qP#@{D+5jBiZC#7(vjO-n2+lw9UnVcf)|teEaPz+w-;RA1>D_KtmY2am+?nwCvlm(C zC`Xsb6Ih-X5f+dY1SCf9<%$5~VcDjqniAbp+-Vzvz78qp%oNGLBhx@?eZCA4((Hss znem6I^Xfmp7$$wePw@aVV3QXboUrLP!hV1qZazeVNdssgG8W#Hz-Of%{!B^(+g4da zdaD7cz2^jp*&o4m{=qy9+;UL9tad(Zy zEvj_Mxs3NhX(=twnFAUKym{ojz4?+Pwp~k9TRVf!c%y2G2o=7pciifxf6{ZAN!cOs zlXI{7Tg}j@mEOi~THz%**crN;OB$d)VWCB#^8#;6290r8wMEf5)qsd~2n$PXk(`oe zp#w`Dqs0wl?V}Qe_*LUWkvjXgMY!k9nh$eNlkObVg49%l{0I8R6Gnvbl@WTsi&By> z-%M}hr>lf&s9U8yZG;;qkuB&d{4=CMNs=*clugRcCPy*->y<1)-b^37k5s7vZKQPs z1hIHWPIs@>0kj6G4ngN)wt6%j?rStxpL^GCWhBjZ;8*TJQ}!PH4R;qxZ4xY0q6T#4 z97Fg9raoP+HGD9;xFRElk1=p=oYk2+2{*}nskWQX^tcs=9R=`DLlif(V)$5}f+T71 zgEe1o!7r{6SyRKtX=NO)tZR;v=+1k`;v>-d*z1H=m*taPg&gf}LyNHOWCQo(;Vlad zLa>%0WAcDb+m&#yLS_OdiL{@&cJdP7tHHucwM@!a1j6X;)Bj#1a&0&h6jjsK@Q%mg zXd3}?%b!JKXxRoU_`rnTilUpHaOMeH6mZ`x*zR_dl-z%-5K1)}FSQ>tBTfz zKGt@cO-QL4Ag1CUK9@##+})-n9jo8l*p(LNhcw^HKU3%apz$R#;km6HY)r~*RfXgZ z>B-x*RE^J1CU&xnq)bx0dd-9t7gF|GDQZ&RbQW3J`+iSrp}8#R{9R^;7lmM%2H z6g5*>aveQJa^vd~$P??m5Lx<6P%eD4to)&m&YDukwKX^DXLCU2;qgBL9#zx+NznRW zgLRqDO9jeq<^!5}ho04SH#Ox*i4WCnDw&npV#;$UIU?BVXwRYqNwB)gPgC<$Sci5? z`Ky3FX*F_K?+lBG+0YN1K)W{nrNiI{jc*$`U0R32&3Won7M~Nx-+^@P^geG`IhZCk z{5XxAS=~oZ`p&aa`10zXb#>Y6FDxUg@yTVML=Q}a9V>P#N2wj5AN-t6wBG`7QdHkw zKW#o+(a$n?xiD63KcEz*7PCk#e1DBjx!s{pUW(<`=+=DfkQu%XTr-r599H%_56e(U zMt6KCdnK&X$bhAaRH6SMk4Z;dpP@3m#}O6c3VAC8G>Jl&V1H!{_%gZuOg|yP0$pz= zA*|^IlWsV0eHP*kSo%y?O|C$y*=4R(^bUX>J55C~k4S(4ls?+af+z{+izA6Ofuy+m zx`e!N(X{W)b*3b-W7qw0pn%zuNpaiQ-Gq&Ho7gM$;6uB*~F&)t`vFFMHz>gb6mw8f24c&p15ot{jjBdva7Gc6y zrSITy#fhicQGpD*6eGBiu1GwBCp|K7%ml$ImayUzY!S?OR+93o566(Tz}R!rv}_6U zFN)fSm(o+qj#q$-q%14HKQj9(yqu?Xt%&-4T>~M??S>5#(+glwcPMnxrh1ec8J+o8 zkAswHpEdKa6?q%OzDM|ltzpA2wZ<%t^H7{L@odhKK%6|kql8bG@1kC=OZgG{y}112 zE#TS9=bA1=DcGsFHnh#;oOV^`<7&Jg|4oh~9HmBW*mJ2st161D9^&5bBDqXHm$8$^ z#rT!!%60=1vF9Xcpj~O&1GA>_qOF!ZKOhQuF)w^cBDcYo&UD37FJd*oMC!zChXm3^ zJw9}HjRRd_AIZ0MWl6ro@7KL+v+mCfRl;mH(Re<1mgo{eDSt z)b~rMEL&M7YGE5^$jR|rK04LC524YwjG03wWvcO^=sA%7G_+tLgm^ix++h?pqz92>Z!z zm)-H)-~PCR@Mc^bC`-$xq3*PVo=80hENXDEDn2KcasD4C2tWmZ4@7-FeHAznIDw15cIqbGGUhyR?ri-9g4 z`~1yF>C%H5v4lWu*eJYIT)~FXz1B6aKQy1=FfN~sQ{&QqQqWk}PHBdW$vKV>En5ji zQ$0b}*Hup0(5K(YTB1x{(_G%eCts;W#wz7pZLLU2&Ytck$q^Ot0Z#XCR9Ed^P~hob zMrsC=Pk+f;y%Gc$(Z2~iV&{{GG=2VDxyVhw{Ud^ODQKyjuysFCEs<{cvb zOUuNUZ=U5!k&RJ1LS!OJ?+f%ZG)2aWf`3jFX)eSrIK-gnQR0DZud&mcyE?vnakBjy zD+F)%nj+`Hiq$g78E7JDs+dxIF2N!|sbz?yruF#p>4d?Jqh=HD2d7PFJr!5fQY`fA z7Zee59ltJzFq$K4F#?Jlp8H#*V^e-Nle@({GCW^rEHLn{p8><(ZMgj%X(LUgX&xC7 zsY4T;I5(iH)4_&evvp-BN-H(ZI`+Z5p@NmgL^}tERo$cm8Z+W@-?fUPz=8cKfP#^4 z7#ap%-S$4w9>e`?tCv?PI?$p>}lzE`odcB3-PFRUHIA#VI@n5QaG)LH!!uJr-u zZ{v^K%!R)LdmU#Kj~Xl%bxs2QUs1m4pRzqXFz(o{&MQzPjl-YAc=glk)JO_li?^V$ zYWNhuvdPy+Y5*I>l3pE$1)_qk8HnnscUryIr2JrNOxvC$ZGeoApfOY(DMI7j6&+PG zvKNV@{@$a2X&_J96jHezqdSx^Gf1W(+$XE!jCyu&2XKs!>S79R(QAS=;zJZ7`iG_X z%q&ZhhkHHDRbjZjrtl$pl8%ONQzfn}lQzTHW1h%ghfQ8oEQD|QAFkLOa@t>^XMC~j z5%N74-zE$1S)JyYvHVo`zU3*Vh$hNqaT7p7<+u6Eembl5J*DMTu%JhZZGJQ>!{hcy z%l*f!exa@zbNv&4I5W4DXk+-4HEw%T+0=_af2OVsop*7DJNNK)ur&L=wYjqv(%#tO zGIu?$az~ai)@6)6zLThw<;D$duyLj%Wgx;Y%%yvm19xmOFm8KoDni3C+d}o}Vz`i! zYmNNnr9-Y&IgO!_ZQoc#>pDId-PaS?G=-TLrEkM5CM1-``)t3b>M|`h1Y?;_%F?7- zivgWe%(_Z&Bhb;8xRRk{#`>QL&T&vh^`_CmY&+Ys=(9H!(;$SMv{)&Sx67qZOoz10 zkB80jglxGB)4MRvFca{kc@+mozl+~z+y4dE_ zVfkZ-*Y6a_@gQCIQ~uWA*1@y8`=o=HglLn^PAOKynux%_gDL(~XYMOTyRgj23|#hR zmsJ&wnG@taie+%B>QzpDP5VW(OG=Saiu%1iaIM+=d)jhp}bYG zfB76Wf?l7hQX8EWh`7CPzUeU0Hj%UrlY1~ugrnZQbyrBDxnOxUENg7m-fcW0U#(8~ zph(ZBzmPLBRal#Bl%i_t`R#4y!Yd-p8pQ1ivz!cwSAuI=c>0LMPbBAFuH8;Tr}isw zkVXB26^V&v<(VV_c9xJZN-YPo~yT;!eRUH1zCiS zLhkDy!6`)4{w1n|hcI?Y$t!sf-ilNZK6mrQ&9CWLsAqrV!FN^< zdUZGBL2Gucpc(oGMkclOhMcL9f*_{QzuE2Ic!=azwQX2#vOEpFGvG?#`Nbetwfu| z9o%=$0v*mBjWJf=HG-VSKjTBWQXKx(OMVpk*zPuaHoJ-HqklWI_uT{{{ zr?o-pV|qurL_D%xmCnK_d)>1u@xp72L^~1hwK;pn)kl^=l^cl+)dZfK8ZM+6mESp0 z1o3ls8VHL)$!}`gKXKbDEPv#v=c-efaZeNP?gu0M)ua~@&=U%hrF1`=ME*>Rq_3sGwcx$-!zKS#i1Z-3osaY)PbQTSv8hWb)m?%q^_o7xrI z9mnt)N?OfHLl*JRe7GY-vw2pE%WM@3ROay@?@gAxY*5Dq&LF0Z6q|5#_dSE{Oj;YC z4p{`T#j)}s>EiB(dM1n+=SDr4>DtCfpVFYC#@@Q=?3a3jL&HYvS_!x3`dobY9hkjS zfyH^`alN%Nw(l=pGi5#n$L=@aj99s|D_T9k5vB0vn2fILBCXkE%kTO@@2)*B`B_I4L+T3V7O1wkw`WD z(P+)~*p0Y;w)OV+F-H0v^_jB$kN9gqar2wb2;iE+FVBQBHU`3X5tB^?2`kMLYKh`A zoYuz7K7%s(C&4b^+ZkrHDomG%JB%n)ZPW(4G75~%a))X$Q=|hgZGHK$2tk&C$XY|yk@8)7Hb1@>?f9F9D~7X zHoK~+OzhT%Ps)R4{Ie*5%8ip83Y@~c_Y%7=b}$9qvDbPvLKg+K*Vb^iSC+U{K3d0` z)D&C1?=<}fQi#WG?UI^o015U(a!!+38+=-*VmAQROhj z&VmJYUN|QzMg3)kjzda0b}S@xrRH@PM-F z&)W#ZG~-j5ER7JuPTnCO(rQ^3nBI(1Go#|t;Nc~Nu`=!e*=NL{0V;O=ZJ0>YJ4iCu zXKU=X4ZpNyc4tOO1e)bkPsXXX0uLduITzguu1R>KD#WMI%MV+g*4##e6oBy=>>=Y` zl)C#e-fK-NBs~=8w<5vsr(@B!*)(>GnaB9kd}oaLW&=N^p>bfAG+|j+8CqMHr-lg= z4feF`_p1*#-M=5Z=W7)u<_*{a@)_u$B^%JFZM2QZIN`nFV@?$&mXK!iCZ;J6d_6(( zaR$%pDPVDr4CBJ}?vv$HRt5w(WHZr7E(`knYD$ar2px{4tfz>3^HNH`2xmrfOe&)K z4<37}V{1++KHMzBl1ui(p_ujnL}B$4_3b>PYESxuYH(o=)%fmya3mn;JB(hRXbm2L z!2oMc)r3S*3JEr11UN8I6Ux5YQ(O)EPH0~p{v2vM0n<$0f72kl{3$I>TE1?Ypvon> zpSF$Js82o` zpO%Q;G(8@~?I~cOPFK_jCfoL0_#iVKDN8I4l51ca&+xwFZ08E_g~ zjt`$^ylBXF3m7Y5DWXUfVy2=KqUvbKW&9`CDvODaBl`TezBP7|jw9-L!tXk_fxWs( zq7)CK`r(dkgttjKYngCNM9_FkGF;ff2~VhDiFUC}5GezDK`6=*$yoC*7*j|3AZHtFzyv4#Fx!d3A`EoD2gZ&4ZaqW8MB;=FlG=9>DsW}3G@f8!y`V`6(Yw&QPCtaP z{7Hsj}|E8D4_*4qV zc;hjRI-F0ZI3W12CB2TDe~tNf(}3Pg6K9#&hUxFrqOSm!A%AQ|?Iyx`oNYxddlRgR z`jstp)WK*t|Lb370GO1j8C8S>0RLsOr&>Sf=Pq`(j#kedU99Zw`1pC8-0kfDE&kgC z5UMGuDgl5%AYk?B0{mM6$UlWe!N9~o$HK(K#Ky+Lfso=saB(4Tfyv{dwTv{W=S zFlHWB7$X-G4Go(JI~OmXpr9Z?r_ z0T5vU8-a~rAR_=o1OyWS{|x}>pEkXrKaKXk0spTA1cA}eF)*>Pad4j=Xe9)IfM75P z4UCSC_B0m)gP+;~Xhi7541BT}B)V3Zj2@)?h?HV1Cb`C5GQF8IW&vx@Fl-!h3MeJj zGZt1hb`C)yVG&WW7xD^cIERxa8X8&^8ylR=-?A(JVN$913IZ`0m~Kly;yNyqgY>=>Ne6W5s`}q1dS`XuXU0_ zQg%aIV(C%%KdE86n{l@HHp>*44n0g_Q{NX#bKe|BIDhp9DStHXO!(Z%D^lgsJN(sr z8Z;b3Hj3Up08I-0Xe7Sy&H+WfO#LL+Ni7%<4}^0-Pm>SAH9Js*mE646m8(93yvzlH z7u2K9HEmL_d;{m6$2expr*#9Tw$yhim()s`KwVht=H_jdvk1u?vN~K6 z6MBAKSHnCw)M-AVg2uFecTcEtDD4YmQ(}&oIjsHQGmO#;U5grV#t}2uK!lA$+q6TAI8`7rRb(7U? z1G~{3#Fb!ttc~C5-?QKzEq20i5}B<5_&FjE$5Os)j7_5Z1HP){Bm3UpP3g}}`9&V# z%cJqEVV2Ae-)0IPpS7`+=A@r3S&j2-`~nTimL&M7Wrd&!6d>#`!7n{O(oFT+ zvgNIu6hlu``3Il^7{sL7ro^|~NovoLQLEXFl@Kb+em~K~zu3!lU=t4KVqW>|+a)~_-Cq{848%U|1W$U;ME59-P!8L`dQulR|5MdrB6Vr?R29tjm4A%(~3WZN-^(^x4_%+D?>)e8px`HB4#U6$E7 z*CbIsq5sH;JDgch-~dM$QGmzGX|8766x6}<8g@|MErsq+7S|LGhvQcYu7s5+zy2(Z zKy2dVtn-qYJ452e{lspHa0}mP{|w!kHw>P7T>1xKQiL%oLgjpUaZ`(jt9M9I13JF& zTUJ&W5UD3O!ob8q?I*S}LT{S6Plh5(iAyPv`lZ+A)gLA*FhGEH zx`2dQ@jNH!V}$gpHOFN22qt%Ju4tMI{{zw|@syGtEGp?PV8lW+!VGKRDjt$O=4cr# z>fE5Vk>*c1bebZT$+n!pLJ_!~$i!(RP^ZIUfv3wK`abN<XuiX`zYNU12wtSCZC%;n!2; z%#j6n_v&y^bGuG3Iv<)<1;?8-Pk`}Ol%jD{es)mt=rJyxqE4*mz$W46WG#M<`8Z#S zB1nLScNlxbjF)+qzExwfeJx@p@2e&`2D^K*EWN?W+CnsEKiv3~WQNh+ zl|?D<`!}YZ!#4}~zJrSF@NvnleJv@j{$>cqHRGK(V{-ov(ECte!>>^}Az?cQYE}S) za$lx;XG4cMF9Z@XPZEb_3Xo7Ugv5vr zuQ@+`h!Gs<&yev`V_lx?HCtIs#3ZZ$oAB#$6LXBn?Cbzw7d+Sjq#?>><2TCm3u7p_ zQ6+T@wD~YVlHXsBVabb?B>gUGo%aPDyOrPN-eW%V?n94Pk`urRHUdhR#0F}QvyX(k z@evza+E;dSnnOq$<@m-C4mV)KPYMO_KRX(6k%g4tkMY-L@EP3dhcdOdi6bd zJ+tmJrfzc`aj+kbrWu#qHXH?Ige;YG@_fewnxBbBr0f8ysF zecjPJ*b{{vBnALwfID!$jYBr`pL+g(kA`0dXfCeXL6sqsCt$x#Vd9^JU<7NyG@M>;%MAWO#g#O z)#i}yFq8NPNMN=$P=dJ_z52KsXjp69#*pTU>wTw#HtxPSjGD`-y!gB#LoK_RljDQ) zrIO}+Hk)v{TnT?0C;Uhi$oROC4kr*jHRPf8K1~cyR5Z;PcWxkccI4O4S5PAy5Z?>*=ri=jBOaRNWf-cUyYQS(tyvfR;z~xqYAP({_hoJXBp0E1_&DZ zD@dJIsMX3flX^ky^C8RX(n|UJ_ihpVi^pJY6Te^F7W3~PJ>x7SV>+|63L zZ6m!*Xh_JVZc9ph{!CIzmav*_l4-R7bsmJ$Lci(G%On&iA#k`k^Q=IKkhH|PE_KZ(yVPF$X zefmas^tEYZif)duJ7CWkaxhyNJ1d^P*QUa&k#)2v^@(D{}c zftcD->`nPb8}7nH?+ZSZbi6E!f8wVegBul3si76PC8s4cGAwHg4k$BY6AuJUuY5ZF z!6D1|qQ&t*B4H*LDwU`Af{W>AV?uAgrC0cTfWdRLl)8P3Qqg@lSEn+D?Ims~(Mpey z6DNXkTZ`bg?2$pylY?T<+9wZr=KsiUi|pECavwOzoH|gkt1iNRk8BG#pAaI*84!Iu zs1jv*P~`4j2QwjUs#$Xa6>0m((JTv!&U4Iw0Q`im)c$1I-;eAy)+wJGBk50lADsGz zW@v)O#Yt8U9V4yZKbu4QeW)mopid=zA6$pMnRj_>fJb*=w`dUd!W;AfTK4jJM-|i0 ztL=>JREzPXIfo&FiwbnR1f+9hL(%R-EA?=*>%v;sG*#E9NTuMf z6X}86Jt#EIW1;Za>(*w;Q6~m?YQ12a5JwZG?5A5Q19hc@X99dMa~v!tYmvWKw2X6M zr@hz1f(JRGq;Og15N`l+GRrNm?VX_spuE5xQ-mWdFjfIq|;#|-H@$BaNQ7v%X=r;xU(B^0^bCaEQ|VN(vR z=7o^HC&v1YqBe=SjhO%#b$T%mGeI|Tnq3PN-uP0AE!QZUMqw!+v8}Fz1k@6E_#%)& zrQpKJtSGD*DkFb>gR58jS^ogM3OIk=#1UjnK&r;!HA#WIw39yuI%TP9IN(bfcL&M< zL1Sw>0_a9xqokx$L=8Zx2R%xKOmdyhP~{saDMM^Xx&A;`rfUy^>Lj&8T#*8;p-ZHc zSc*eG?$YLjsJ|>2X=jnI14fu=3_hS}IP!KM#sH#I$Jajg8ITD?FWh=)~qZU^M^4l?1RKYHDhWkq#LYVN2P~;wk*YB+FF>S|1C&(^Qozx zB%3ByM8GDDz-nbZnRu#2eV_f!Bu#2~eE|2GJT``mY-^0}oDhRN7eiK+xhv4qoq+bv zx_W>h%Zdx&73MVv(1fuKl5ReqEcc&aMw8Ck6vYnz-GO_gZB4bRvLhrX2aWWM36(R2cQ`d#vb}b1{Vz$252{b~+~VGbn94@ocCICzW9~paE*j>bl&<)VqFh%A+ayPY?eMvaLl74y**c1 z=w9@gK%U4yz$-+&>%hJ+5>0I7@7dLqX}xDw@Fwr7Dnk^nL;L%&TIEH3ALHek|teu~6&0)HwUa=nS0NU}aNvEo3u9Pe*dCsUXpZocm`sRRU z>8tQLQeXgQ zOxal1CgMSvWOU^llHT3 zO0<4r)JhzD@3>srjBhqQLo-CzhQq(Ze9PZ}V^XwEJElA)+16P42wlN>bXQ;B#(;n} z$1-Ii!p9w~_4lkfLO?PLI433GYCnlZkFSUFBuD8>3_*%nV&1zlkzq{2Hm}w5I3bW> zxP$=T4JN67vNEMxS~xPXqV{w13ye!LOuL^R8|8cqdI0ySv|fEU`yw{gzA6~&`yLY@ zEzvQihz4)`babQ#T9u>dYt`;B1faQ8Ks>adllc!}>IDz-GWl*GBB4*}%tuirkp>ge zO?ydpJ*NFgOVPc~Q*F5ml`a5)<~a?)B!WQZNWx5yf7b?ZAhll^#fRfX$xrt;ol&Vt zsz0^cQ`%GnEx7B8CqFwxbps{C?^^(WnhI?>z>U`C?7QIP;qOP9I8kzY<5{pIufJph z?U^Me1g}38?ZjC!P3%_l$fiUC18~aXY?FEXC6C$oUJ+6>s$S3=wKq1|YG7v|~ z<}W(^dA3PIrFb+=>^^qTU7HI~s>g`6tUYxifwof)TZl|KG+CYxT-gfH-dzcu5_~%D zza8hhOmScO_mA|JB0#20P*Hscrs6L4n+&a?%(YVVrOp_EbiO9qSSnte(yy#!fj^c8 z`U;-wrgr-I{jT)h<3pU7wc4w0*5L9{84`?QE!fjWKL zB2M)CKcmuX4~Ni2YR?ZLT8z&1W1b-urKzM?1L0XKZ+DQ1s|G&zBD~f`I~-=BcLqOa zTCC-iC$ZAPR3xi_Xz|Sc{<<2`js`U6bCQi3oshX5cl`L#Nldy79A_mD4*ITPYdkGO z9+GkDvxwUSWU@H@kxZ=f9>8BsY3QiKJIGzrAXTyk+CHg@?lHHXPg9_GYfJRCPFY)y zV->~KkWd@#c3s(iD+u{uQq~6GKnCv=XqU64$|$`4M00v;KyqDWfI>^4TjkrVh0I@8 z;rDdtLxG)pw?%U55M32IF^s3Rd^cPbuh-FCh9QblwMTH%w>G>(35$pHfa%0=5$ct$ zN8^!_7kYgNa{QR?>IDN_e5MLxu}v{nAw8(xuZxXns1YCDCj;Dd%U*&Pr=J1%sh~TlG|S6P9%FuH6vZrb_@hQR zGntWp>8=K}_o~L7znCY?r0>$7)%?I~L4FoEUt#>nJfcHs2oJK19<{kD&!8<8yOo&| z|8!4fL}|jqj8(fk9JNW?G4*E_s_(DMvea)`4W$j#uY>J)o3-7%`kJBm+uowOqkbL# z#oc~Zti^&d-|7~WBZq;Pm+!nLAz7nc;Y>+PnFdLXHez&sme59*oI$8 zYr$*mugyn*;V5|8w=&Z)pOh7b4pcVH;YYbrjOj7ELJMwxEvKRQ$JIVDy>pd=2crY< zSbqf#VpfjhoOM_4cGx+P-XReB{ABID6ZRQYvMpIfbGyMO?lBc>I}1KnH-B ztXySZp}%BC#}T%Sg0WCSP@->$5Rs4l8}3V+cIdELETbb7h)5aon^33mBH(8r|H;2< zi#U}*7?Z$aH6rTQLrNENnFL_=$$YN;cXQi`{79Oi;!gr1oPTfbSZm-|OnMuXvL%p`ruvBtvRU;C{(EY+_+Ci{OH1IA=sW#vGO?y8^|l^=z#Wcd z>@xr9Mc&20HT^=20fwEP>XlWPB8CET56<=3<%;P}2b4)PG^w`r#j@j}qoz!7))tsH zjX!_dWIkeip&evcrt*v(Up#%u@-pa)k^%d1FuR(Yy+5--G6G5eiElQC z5?MB4Ac_|Lm0G!6K@BdCmn&uW5|hgTI6j`jnuP_u6>bx|zMHcq@ZjIXaOEcm4M-rX zNTWoN^jz2ejDJhhPz%53KP`BS1Ss=SlT-VhMT=ScyP4Kd1V-v!A4n%inS|Fw9xGuD z1AIUgEeUF(OyEC@mxx2jLy*c001TDACh+H* z2_Wh~+_%CDd8S;hO7ec?qGI)QSyc3I3p^f0JwuBF_i4uWbeiX)=lg-9jCRl#@Rtm& zMvhpxkZUXU*y~g?(PdDCB!aecWa>x;l1G{gyYSzxQ<#94qp$(}1;Y!u?)A)eGF-B~ zJ(~eE-vWJf)SfsURPN@0rX>3#Z`Q{P{Rp(p{~B`XbtooRu_q+*4M_$&B)2r)Himt` zSmF=(Cc7^q+iQUuQr2+*nN^K-T5m;D2Y+vsT6km6H>R9<(vo?4=;V;~LQtJ;y_CbK zLsDi!FQoyXYFv$Gc|&<5Lt@^a&1|`w9Eh~_o_K)?;vS(G*YW4fyAQoSHl81KMm7;h zl4gh7iN$6wyW(el!Qx<{Y75h(0FNdy4Ycsh%vGJ7aR2NKmN+PSXV57$unz zmy|=ex7aZU^0=qYSY%9$wz~>+j&~EYbxVL{7T@nzVE}SDe_#k> zZ}`i{RJv?=`*hSJdj8)M0@pBSw^ATB!#Od6nq(| z=k^Zx(qid;-0Nvl#n<^UNKVt{>6@3TsWIa+_G=T#&qhX&wKY>lz4$ntXW!=da$Ql+ zRt}daY&dBM&P+hH6V|b_PdO+uk*UN$83vq>GtdD%`__ODy8JU=)S)xcCiSA=tD20F ziVn{aC27I#)y<&#S1g(>-A@fPIdSR{dW#mb_EC7fck?0Ub6YVC*gaRIJ%Jk7L<9U< zQr0hWoPFxKBKUf*PxM=KR?rh}K1Vkp_tW_Kx1!%;Q)1;i0?wNl_6F~VDN%IcM+Gf? zaik5){Z*b~ZdNK-+s|aC@|?x`?(e_3uWJ-C7>V{WhjLh|Gos5}jA00aav*T5} zxCDA8q|h8KM64#YN7nd$>0_f84H!R5TpN~nd=j3tR&4cze@b&9@v&<3`1g7Y#A6r` zqomDP2um?nG5w3bpXZa!Qnjv`HwiH{0t@D`%mRJ?0Zckc6GL447s@j&DNuScI{;$U z>q;@pEL&TeOtgzthynh-=#VPqmTo8KFPR~g3q{J9)7#Dwv7OmM8fx=ciexd&3cg{f zmXTuX;xSjupUCU~EZIfq?fiUip0)c2HUKbb?xukf^+XK#>x)wozExz4BOj`8@fRn9 zk9Kd>%siV%y0OGeQztOaf+i9JY<-4J0rqLE50|0$`*F?h{{adr|K5@60pA0roRPJ2 z1&@LAgd#t4Ep<6)dmAUk=NH-uV4O^RlD=shvqiats~Gy}5)Ym9x^hHf#``OsCVgka zd7Hog0i;?jpey5JFL;Ol7?da)T8{Nm+@|wAnTVH4amnXl^&51R{{Y`KaIrb6I84Ou z2WY}1rEw~~fbeSWj&?E9!)!B@Zl^5(S%*pXmT#0&^ABb*E2~>8j3G*u*@}tHVPtue zz8j&t`lR}>?YKMV5goD@<$CU5G6$8>FI2v~EPm^w%^kKUcCwyDXr{_EN-7IqUeZ%m z%keY(>)vH@3p*p7$J_5qfZj(UMri-G@}*3FWymwOjdWT=KAh#2(?$}E%AS&o>H+)*{|dc(vpMh=Bm%JOCSjF7sF67=ABsMxxjOBZ0tyy3wQ@EPK81dZZu zOCq)0jp}EM^C3uN*=-s5vqUXPPxflAn3;covh#LHEzHIuxgUfhLHTnw^ulw9W2`du zC|k=tUJ9`L@0;3$-29C%hRI1^Dsk2~OlyU{j*y<3=y(>{FnwR0<`2StI%LcNX)ute zzXp|bsO+IQF?(>jl<33($+g{cGVKVV&kb18CS@Cj;n zHwfcjTV_~NIF5*N@MFGhjyULO=`?C0mmo23r=ygJ02!Uj5nfT5siy&CV zsj5D;N;SAQ62W}S`5BAY3FZa-U)cqFERBaGzDWlri%NRPfceiLU>__fxW1BfcIIdD zV<8}!(B<^{RLg_`s@$2O3K{)T55%+R=BhZA=F(eRHZN1U9KaQ&V)WZNzQeVTPPt8yUl~a#mg`F|4K1g) zO=9>w)N{oo#9FHSmcd$#pAbk}1$yQmAF>Ckm+=!Fe4@?J|D=i`{ts|nby>bV`4m*e zU3BzLkAEoIhEpJ8YSJCEo0m)?1IIsA<06ii{f*<0Nsl4;C)*@CzdD?>tw$FD20M~& z2&siLPh{d{=+2#-$lxbArR(@WT*X7)?0hHv?oSRJ_gnV_+ZI+`RmK0pN~v4xR*@(S z$m9&(ZMK{A7z&k`Mtj@6=>N8v$q}|A^hPvOkk|${(W2`SU9?6X_;`?GbJ*P}{ZW~D zf_)rL{284RE#Uk}1zT!9lE%e`UR&cn%}_lO#zYQ#_&7zcCL&Px&7v_p?Jvs*E|tb4 z4%t-y&|d_yM;d5hjFjDxoNP(S8t?*dR2K;hO3xH8igf2yibNMhg^I~YIon7`Sbvq|Dd_x2n{H}I{sQe)?b ziwLhRZ7H`q0h~QrbVlxr`}S11WT%R%$lV9BaXnJu0Qca_<$R`MqKrjdB{gDyv0Z(l zpdo8Qv`Key0=55(rK^l<^8NZ7qdR4jksCD-DPbdrbV#S5Kf0trItB;`4%ldrl5Qyl z6s0=_RJubXB}77e_WyjIcYCuJyLVmZKIeQ3087kE!^j* zQNlf&Fb#z(T*Gf}X=VPprX_BR0uKKHoUx2yyMTP#hzXXPG3I}O#ty;;RSeWd!p^&P zX-z5`@-_R8Y*u!xww?2$9@+O_6~ISzw#tL!``9{}FT^npV)C+?zhkubIj{G0 ze!8_gcY#+Aw30u)Ydud~<0n;7{lXCBGVEu)TRryumr3j@0on{&clj-oSK)h-dZ8<0 zOd;NzW!Trsm5;foTz9K9oV(>r4?jM?N{HH)lUg0UZd*zsKQALmAsMw*`8(%uIZ5|v z!ocK?<~{pi(V?rm!CH1)u}+y#;NU{CYmT<_HxdU$A?y*{D~u2jX92r&z{70w$^6{t zM;L-)1CM@Ee(`LGEWtQCp4ZOGZX2*6Up0d`DY3QHvLoM{-Fb6fLM*Cx7tOl0G)^$H zq+Lmbf2(L{Qg4f6v;1D5l@!|Noo?7D#Pn0X$}*&16)ATzz<R zTDe$$e!jh|NUXAH5Z{4V{lXh6u~~(kc?xV9OsH(Hi#`w=B zC_@zF{DQ?^4|0P2(HBJ0xp^J^?KMK^l6=4W0hF;7DYvs|V&d3R5b8!@=wA;Z#oU{4 zV}H^U)e(q#s~G9qf<=%`csBrAVRS-R&(-78Hxd{SwYhWQ}+?ZE%>=S zh7IJ|=GE^)@>0K3ab8FGbK}l3PO(h|ONkgOB6Vc7i?t}rt*IShPu)+(m5^4VUsO{A z(dax$jXr$D%AlpO6VSV_1mcpuTraicFvj)K`Sw53X%X@`yhE3*7T~d{_X&L=TiKQkiC+aE*kzKNn&VoyH=et8dLMp5_NQNR^o#{0GjuAhE@;q zuYAKm7fj5FUNuLy$N@sGrvtJM?I|E>2fMkE$&Vv9TqrfvR+q?p6idYnts2$9*wYp~ z8jwEQL?MMk?!2upf6&BJeTQw9h&h-uICcL^7ASF+*kM5Jitce}qcZfVsTJ^xs6>Hb zL@59mt#Z^on>6ruLe1v-aB$Jkn-t$HHBtDhWxE zNCKd5&}(nY3IXvy2+MXWGVABtakVQPFnXl=EU^Ep@Ramn*V72j;|dYuBb_4`utU~` z!VI}v~>im#w2MjY9Ox% z9{T6dnJ7YGFk_+cY{*fXPZG-8I2gzLV6&3fCMQ26Z*!rlGCwZ`_Z5}TbzE#RBjI! z@=2XCkvw9i;oejxv8P<*E}^?F0r5OHlxwzb9W+x6bS!EmA!@Aq3hC;n_+0@)a+osv z&K!qlpH;tnY`#2~=}2mcLSF0?7Ls=MB@nxRq&4DCkw@rBjJYtR6;=F10h?|TjdK{^ zrs)EPI^~SxeLtf|wKaN(p(F}XSq!6z?%rv#diua|`Kn%tev1+@G3C(&QYFQy=(~gQ z41(=UO`b**$|fZi!aJ9mMo9{3K;F@Cef5|0i79oY5(he}YjV2~yM5V>8Oo+-+}7qr zFMY92hq=#Ls3&E(ghK}}=Z9vmCyDDNG)`!GDM)AV1N`hw`hQcL)3it-dMzAhc(N4s zXcChaQCQ)5wQes@^&5LKLD3&1AR$$M7)*?GoPe44%$%sS5b9$rxgsW?b#dmA1ID6E z-^>3v+_O~GMXr97*n`QtYiasdp-Ry6e(-AW-8Qytn-e2%Gp<4N9Y6%aFUbipMBl%0 z-La~u_qfO)wQTLD7@A2;bg>~m9wh7K8~KQpmem?g8#uvn_DUAirEghDl+(*JwDbKN zhHMCzYbUp!BbM*do*)3cp3s@p;Mzfz8BPLKne~BaIRjN9>Ky;0V3#5cd;7)Cp6;nc zZseu0pJQaIaF*h8z4wCsPZl(d;Smk`G>hxl{AQAos1uVX6;higRU}lwqm)ewC&3vT zEPBKjm3JQSAAtxA!H~s|YT_$M{=$7#BI~=NR3mpI)55bW83}Jd0#%B?<6F%D^aoM3 zO73dtC*)oZpqkl8&f$dv4irPve0tL-PG!6Lk!~reoXaF_KDB5}Wcw*P*6e_ig{G!zpH+ZQb3G!?q5Ane7n z07{wF=U0cs3!+bC&Sg&HZKol zW?UF+KAUuBO;oNXAuFZgtyfyysPm)MAa+?JFhqpmFkJ@TaVsYg6;BMcExO4 zh3zL$NI>w+XxAjm;<63fF%qWmxw+HUiZw$sONDgN&F=fI9$${^Cs097(f>Z4SE^@<7l|6m zcz`^P?2e3`R@j1^kclrL1m?h+_=-!+?Wq@QtvZu7=tY`TH?2YI;O|QAR!235dmWrI z7=Vp#3Owgd2Hk7UK!)MJ0$^o{!EN49E(qJeXor^lvC8|OKP_JQu-&+#>`CV4avTk% z8lIA0lq5NlU3eJ8Uw=yErdbm9zO=uI!zb^k=S(?;5GLB-$!n{I|1#T*^zD<X9pAqwpTF>Q3Oq_4JmFaYhmr+SZwF@c5|$n&UCO6PeQ zQ=e1@ru9vOE~EE2#RYR0_H-(C^%r^wn~fC-Jebh(#&LnE4KRZfq}7qR#uyQCbwHBD z5KT>=Y zjiUOfm0X4-vYD?KTSi2ZIZd>O%->)`id7X#WgRtwwMqr2mS;|{1S(#iX1J7`?hsH& zA@?rHwieOZ6|P_Yc4nF_^!=ZBU5d*t#l8c5O>t3fBmV2L%jxf<`6ek=Qo3l*^>qvz z8)wsC{2k5youO67T>U0>p)zG0IfzBlbe-2M?UHL}8~K;4l+(q~n-l0A7e26yX8cfE z6Y}Ky)({YBw`=UwCP8ANs`3;QaCJ46?E_aab;KoS<$LeyCQLT;QHrlJ{y4J99O zK~#}^bq}LtZBK0lCPpv{PB&Nje_AL`g&X;~=|igzy_c&;ymz>l3x~&2cBUtT^+C&9 zvjsxIMPXmr0T&e;FEm(XTL?%OWK5HqkwdPuUz*i!;JvF!R@AQrx&oKwpX$g%iAjA> zR9G5w^nKZ5a=vB&mkL=(<*&;#iyi>%SC*YX}fW6 zb0XJ=Od$3vE1yZYAl@F6QpXBLvwj>iYG3TU=4&iTGQ7aMQ`Umz?m+9pBKoVfJq#Y3c;cj{WawRfu~1V7 z!5xfA6j2ukIwT=MYpMd5n++5<@Q`WSPq~Y6i*H^6@>wH|y0+c?PG(b9#A(IO&aaFE z?)=J7u=F3-+bhrl_|>!k_7#kfB#~eX`91>y<6FtC^t1yF2>R=em$eGtfc zl6*(9M>9v5`?9pmF;kKx&Ttx7ItGw4yeNy-Wv0gUu5HBTsovGw5*Hu-LYtQ+i0SqrRSqCH7_(7Srf$EuzT zF76+6p*H>j-ab-YL<6?V&3X6(vLhEcZ{LB~KD*cokRA3@k$|BAlE0q8UvRn4TGgRA zl?-21+Z&@f9+kgYd&KlaoBE~QNfgU99*U8tCuenunh7|xGEaz{#F0x z;84%C&V$#sE33^Waa7#6om4w* z!}#ACC^t*}gsiI-$f?QjmxZ~?rsyR9jy^qLGoe+BC?(?j9d-Qj`(_MkXtSWZvPEQ6 zBFY(dwDf|v~ zuUelu2mMWA(N^{DR<+%Er&`s3C=K+Cg#fG`5AUlp#>aXR!5aFnVFu;lfy zwpvY@wG|uS9Ihhqql1humy<;v84W(!#N$Ztbt+H|T|5VWkY)R}GEiyUDV z;&pUsOX@}C@n~P;RBPt+XMz%mc8sYX242ENeEf4|v>4|o8{bOPBM2lwBAubX;I54T zb6kLszrs64O)E0sO2W&JbNTQ$sLRmx$!t!y;u zaQeZXVQLdBVtk30oqRwmMLXi2cF=29XG)WZv-?^TvS~L<1Q^!|Q1RrWIqg5dR5ebi z{En4Z$XVGP_=zu?@)4h}W{wuAtfb@X9Gyu}llF(~90@d|V{M5bZ+*JGQ1d~mP+rNI zoWJ6DRd3alfKM02X2sAAS@6-#gVmt)vGJnW$k=HQvrP7&vmIvKzR9skj+NDamQBJ9 z?Y#fFSci#4$?sKm9M3QJxe#e?DnILWnV|)Y%d0==fQl*M@ABAh9snGp6s*3|4luYM z->7n>JW+a*ws}7VqW7IYr;RmgJ&so-7V}oF8V1Z52OUE|ItIARiyk^qOX?pJXdtbu_ZoLr*?mDx%;h+7gd-mf0AEprP7^G}F zQ}vI!D2r6@&rHK*(B&pVaSpvui|(Ao%E;pA>glEL~tu#C+E4VtkJ z|6Or?$JVHG#BBZwTj`N~G$y{ih&oN5rk23?PLwkPkP*_ruZ|}CK3EU%#Ewp4m!TPV z{AJo1PfnTq$o3r{W1n8E@3cZ1>Rue##p`%#z2!oRomas_y!9r;Cm7#9AtuHg-X;KH z%x0U%JJB?W@UzBYI{2>~i`oq9C;t7NVJkKy=1RURX3LLVsrd@L3$v4m5uwP0& zb$Ux^e%>UegJ9Ky9@2gTYs=-_3GVYiyIAK1*^g(16f_@3sqrFEju+l%JeA2}oFmp7 zsWDG!U3=Xnr4g77Sc>ASm7L~l{&-WRIFwM7xI%13mu;FE8LCmhu#w-Vidnw@5$YK*>If21hBH*~YW+P9etysglJO)9bQD;7_qAMQ@t6jG zAg{-p6roq@Uvg8H*NlkyUv>!XR|q_p@=c;0HvjBJ)`vTEm&y4_T!90TE`*B;{9nS?4gq9^_V>S|*7vHrWNoj7`pop<-;60G~SS@G`EsmV)A*Z=5ZTWwnW#)`FWx0 z*`2iw^pR|2Gx3u*x?#aH5{rY(FYqv{13^yeurV{-;7y$r_WrOajm~?x$djnkWY0Qh zaE}jcou!kE>oY}JiLGAtw(8JfkYdc!cn(fL9ekOri3wQ?T(2%@hlWO4p}!WUibF8)#0xU;;7bvrTNWmnRSIMGi6xrBD}8a>PKirl zD2KM_?%qU1DS8T-xItY*Me99ccV!eFM1KHQ9T=8(UDV)G^(U_)4Zt2slE3*Ao@TPr zto-92;9{@{(_qz*;Ji(S81Mqvk#(>LS5nvRsJ9K6vJ-X;xHuFJX%$hUs#q(s9cv_P z9i$^s(2wC_7=S0yD^OfYN5FLT8!8+`!tFlX_vkMRoHByrr4D`cX~_wtGv0oF^ruuh zyVA}ybP|*=nM3o_(yJ3BM`x$6b_B8Ktycn*m4DK$E6L_wJ-#b3q)=j%d#~HmU|gnh zGlT(6-US8a#UU*;A)ap^klP#85B}(MUp*xIhL1muY7XKDW2uRaPUR@0dyh181ejwjnvksq^->#HYexD0knfFw(i(S7vFusx7yP3s$}?9XX9rKU zOXk`y3{c&@_T;)0{BrbwolhZsAINJr5`ABwi{%5ECnryI5fb@&@8mxi>uT_y^Z~>s zM$E%`>T`Z~n>7#2GlZ);&|Gmy7(IKOxP=vyZwF?=f`kDBp|>m#-pxOqFB!tsk?MvY zwX7-Ispkhx!;d5zG@kMcYzooFaplssU->?{6J4=4H9{Bi_ITc9vIiUF_68tdj!Bte2QV zF8U1Mtv3qkT=EDOH@p#Of?WcQy$^m|IuKh|;+&$%^`DqD^})WzjnDubZ1?o9q^2CB zD%Y?~y3PKxo}-#3Kl8}3rL&8-~+YIF4 zJKEbvjOwFBE%G1g0SVxv%v&~k4N406u}AO)3iE6eS|k}scCLrEw|Iy!Y$D;`=|04Aqdox^y2^({Po)*#Ot-brF<+VmVkmqO^ z>OjA?heuqksxZYzO;=v<%X~J^BE`KK;57S5hzX86(Hu}yPF%4`R~->UB&7Zfj;-p9 z3Ib5)nq(b(0h&3n0+d=3399wr|2fZQM7_(tC;WxyHv`^K3Fz1piS zi7)ehVHNIJoHklt#NJSS9|@k=Sgvj=5J!7mZlI7?3893jmAvbqe$+OGS;x@Snaby* zrpF@%A?xcGG3i%lKjeQpuP5*$x-2w0ySDM{JC`gOqMFpJn+@y)h9Xv-$&Hp5hXv$G z{C%W0B^l!Acwf--!xAfdgO-B|xOgmAOq# zYetF@8cnIbJxwf+;V)GiYrPIOnR8HMqY@JG(Kx>)a7Q}X(xN1$KN0aL%q*TJ1ZcSw z63a~)=D33x6O2^3GyQNY^Y6>#;!e#-)bt)-oNuZB_i<(SDd*al0@YtNF;s>?F>u}l zN2^SWVm~3{DEjn4nB0tAD)JEx<$zqs3{!@{t@(&ulK0ijru_`75WHSSWu${s#F;2} z=>3=C%+LhZ?G-FO|B;XA(|56@_tW+#rH|MhJj_AKnfYyX{a?psNb!;i1 zY2Fl$uj|2!lkZEuXQ;mMg;f)_>7vg)KONxIH=oVb@oPVGaY|c9rhSC^gZSDd3_gS` zWb<9NH|{vgN21EK5o1D+xbac3^8OVDmy`*)F3sc$&4gkl;^N~X*y)R=HGyLYoQYm~ zxgIy|wwDB1S$r9+PNpjNd?D9(L~5VCQEOnv`%<4cYFQE>mZ(eWf3x{l9$`3Gy?soS z0?16A@G34f)r{^}mR|PA6AeQX#g}0>_$=V2m#?58^qr?l2wW{JJv1_@dSAv^VghO1 zLcCEGMT$OWuae3S`Y)KM-F=v#VMg7%t8seT{KCPQZYPIW6}~z4LCThFNrcp8gt|#; zXX%t_2m=3#sYo!E>DRdQ{vObF@Nh)3Pp;WvzLi7|eziGC#QOpEMuZ+qdMjM8t7k!- z#K_!fsD#Vcl>fZ;PxlBBdVEb(``U!fUz7yg}WQ$Id`QQ(1-=;K)T zuC0BIqrZZ&X5P4l7b`K8vjbCwPX^h0U43Y!ebDEHRGglzgz^+Io>03p@(-X$clia) zD74lB%BNNKk_irTnE-!;VBcnuJAEIBS{rE}O)p=PcU1R%RyHh?{u)SNMI<#c}zibOSq4OJOzZH({ZYhcOB+g&^ z&Oir?+R0db1I*AlN7|q?cwx%|uwnQ7M)21-gOuiJZx4W@__#D<7Tjam0J|>S;s1uY zoAeV9AKg!@6L^_*jL zER6l#;xS)8@C7Prc|8x9BYN2b6=(EP|6^R~Me%q25TCs4L7(83!9C>s5&{9CIP*Y4 zTNZ=Kl(MlNij?sa{9avWecG_W>MgBk?DMDU8#-=jV93+l4N3C&1|1&4Q77r;d94SN z%qp}K6r3$eh4}Pe?AzLG!autba}R;pqP>%XBcFa+UD9ROR^tJR4E{I5;c3u`oCq~b zwtUUqJTB6-GBTI^?c+ZH)t{(uQ>u+o0NjC@35e!Yyw0+MpPHhK{7hnZIcw3cyqZ+M z^Vp?4DX#(oiIFB!hvD}HYocvB&niPsf~Wm&W(&!)m8?U~`W|G0a?&w_%rQ!w%2Sa= z?f9GPh8Z*d%9STSWh$rrE^*|;i9NXuZFi{|so1mBZ}xtCsL{Ead+v7q4}jQ8B>to#IsaITn3>kO zlo?=%oid7*Ju4&=B9SLk_*CWG*W39**w_~nSn=gOt)j3=MLbL(=6yLakvEz;>1+09 zQ%9~OdXD_I2iC$2jJl96cqW8ECYfp+fonOY+nJ(>^W$de_Vo8#;qwX)u zz62pFZ--j$%VL68p*z3I+kd*x**>Ynk>U7?!*6g?Rhnn^{=m zY>AKJ*4yzvBwF>ISJzWR!kPEBDhBzvtnCYY4Qq>fOGbyy{q#d_nSq@7iaTkF7kw~#%1$hGD zR6IK!4b0^AjbeXCym>Yp+1{L2-qjzrYrSl`&|v=uC{_L-0l@-nuNUfl;#R)pR=$5= z_Nc3$CEB|nBA8U{V4i3WF|4j1p~dY!B`jd^_391MYUa!EWKA}yMknwTyEDCLtoLkN z4IZQSVTTU`HPKOtH3fclo>=}5O&6R16NLAEG=9E={Rhx;WD7pDVH04}Rm{_F*JMK} zST=MbycF*O%tRMILz_L2i%S!qV1g~f?b=aDyFod>^%V0iZZL7^DpEG>R`SnIpuv=h zS@Pj~QZHv13YNQ*__RMnzgAqcku->>|6%@mhPGb@?=$OOCt{|_8SN~7hB17T zyewxohJS^n^Q8S#VoTzp35v(fUW62R!Q#j&;jX5{Q;FgVojtEG|DdJf*}8GUOkJIz zRlh0AxF{VimJ^@K+^bGNFr(FwCFCy5S!0UKwvkvW(}M>T?jpp)h4qi(QpAyGKLVj& zy-+26-1!}AEA)MQdCyp;m8f3;9(GXRw6G~Y8pPkVzb~3ah81~fp1u|y-i%&SqPlea z7zP>;?}PfcINQ7b8Dv-L7fZUlIn~{eXa2h$wyVTT(3U~JjK>sND~-zr^vUKeiOT-~ zlAp=TyQqofTGKY?50rUp6C79oM&K+^xwkGT@<4OO>7Dw$ubvp7>>kEp2ydn4T+Y*@c}s{r=6;m#UF5Bq9QD z%NpX7rU!D_A=zE;60STixU`QMuxL14FGvnqo#Z0Q71Pu;c0}rH7E+*r(!~4)?dm7x z@#fX3LPUUt*n#l0nFK?So!pt?c)6vIeZ~ zj?61QAF3w*R=-MOz=IX@eC_@FK$ni&Fd)dety9kX>}pc{e!Yf<%OXFOd+=;m;C1rjoUM0Je3iG`*@_0{bqF)%(<1TlXSg6}jF7hLmJ?_okpI?ShOjU0m z$7D?n>ij@|TXQk(q2&U6z3h&q+U4ea;RzWZhUb2VnA!{MP1|Nd_C4`ozDrX7HFfyk z5aTFS)dja~{^?qHVh4|AcRy;DE*S9SkMK)ok#G~v?*v>+hnIGmi_egBvbd$AR%Pl1 zHG}1dkIXOpa?VNO&=xD38jwGSXp^8}{Rb%UyopgYS(2_P$S%UP3EYFm*$96O1`%8q z*by3A%50z(JJ7{z@B<1i6&BKUTHncJgQTPk!cSp%g{Tkj=%wg5@kb`q`ckPz z*1wR8qE)I?-g>B$CERAp|F%pX@t?RkP*XAF&f-3$;(r9)i6#->?3_RTH15#ZJQrh! zO$+yDO7ZS@Rez_MCf^23HYWJn6q8t~3=VgF4&~4|D+5KTF)=g=cls&b*W1y(Ha6pe zA4hX{o&x)%xBNv84;Q+*XkuBA1Xi29@W+?b=*7?N0fpoxO|sxlWv;DAm{-;44v^Of zgWPu|c;c77!T$%Uo9;Y+Ahg)uml3EG4)px*xRA0Ype)cfLd<~ShYw=#z0*i%XXGHH ztLo2CA^DF1=6!<%67SYxLJT>XHxV^c&ZFji!*xt+=R03rG1U<0)cdcm#DRa;Ngv+w zRYz*0t-iH=JDdlHevGw{zASeFigg#Vcm531tfi6dpU*2Q@g3SJbZe?7Nw{DcGnkKD z%Ex_{j*-mrfG5IRJ5OQQ4Hx;g8&VhdP*1A4zhytc>wo9EKGGX2tbTLRk_NEVVFbZX$Bs+5mEc z`LemsCMQL*#&%2`WIF~BtzxcuOVnba-Ek$!_pH{|`&>tZHv+(FK!WNLBI73usaJ@T zoN>vaVYmE00GGAJ=iLc@j&$JeEQHsa{XP z_RR$X6Yu06_pnaDU;i4P6wBdl&C%Bay#okqoR_P-{N?E+GRLit1)=FIw2Rd}IdqZT z#|mXd*0%anTGDmK{W7FgPG_<>Ng%GQi1m$Ti+S5&`z8-52~-lR!3?m&#z|Oa{$AiUV@56e%lh<#mkn`w$PJi`LU9TRF>_XB@ z?N6%hFPflk-cgFB++oGfRK#UA{mRAoX?u0pX4aZ+cF6^|g{)cJ+&m%x&O~>NQ4Yx8 zlB4v9fMlBmuGtVG1Po7TCLO?~lKNbwB}Euk$>#aTKq_>}n20mD+0ZcoARw7tTBxMv zTof6@C+H#o=;M{a>Vv$s6TA-kv}yv4A8HwEy2nYrmB9=6@0|i0wM&Pv*8XMPLm4C0u9r3Uxu_V1CADZH zm<+PD?l?~z&Lx2u3I+(=5g~hrA!-fE@+h&rN2cbl+y&wwB(eK{X^|D(dcv_PY7@)D zSlcp7UeLufA{P|1b6Th(K3G>`ow=yHPY?@BA?)w)=X1McaWDc=g1|~zH_jO+!ozTE)OO( zJ@HU%oiXW`&1$)flptAFn!BS+@ks7LDfw6`WIovkE@Xo zWe{%|5MxA7R8(D4#!}X3ad>$tU64j;el<9D*S$TU%D?+Ytbg-T`+8jY;nL?c#Z1^o z+4Ri!UHCtQVO|4nN+i^261Rk-Mc+14M?G-Nq)zH1l}a1pjM1{y3_q#S&V``4oTiyC zd)VJfj~9a`UcKGW*GM6V+4OSS)&|GJiz3}*h3klOD-_`+P}<;x+)Ja}!N?CFo`R=@ z>A;vN1E|RlKco(PAWf+h-`&*E-7}Ok7~L2*VConxmAMPRxZ85*#QAoj38tmBqi-IjErEYN^fuXw zHGki#5BTvT_zQzINNC@7K-lt1pX3GC*oUR>F`V4HNjJYM?>cX}S@rcx6+2yh^=H^N z!^6pPW&9>SX;5Jq8dWAnZJ`^}%zzCCXjR$L@jz3-p20BxL)%u$wjX2DdpY>Wgjt9G zaMR`_Yl8Eoyx^}91iwn2M9K!g=geJYK?;a|VQBPs$?jHbjlF4?>cjU&pGoc9oM4fc zcVjIfc0Js*6dMg?Ld=7Qg5(3P`1I*GL-|C>o!m+8G()_qC}V<^0h&Vf9=L>C(76ah zNw}wAUsa+^W@;@GB=uCx&_FQ2GdPtJM(h+GL9GviT)t-BN~B}EwqM8GEs4Yh9f}zS zRdq#Yo?CIm<}p50AJs(d=H%XMWO~nvOHI-kn2JnaZ#`+T(e|){zT+u*Js1y(rUo@# zI@WAa7rVD>)u=JVd2S<2LvYvr#IOD&+;q~pqV+Ac1_TT#Q=6y`FWaRH}Z#T@iarsUx=$}w^Zzu zFLKnOQw-_W7i{U?z1j-|SkEz!0PoDf7P7py)iPCly^TBHRf6SyXtk{x4g`ZA(*0Ko@>812 z^r06A`zRD_JW2|P)S!l&a{8T!9m*P4)2HF@X2>GrU;hIrp$bXWC3>G~I{`IER3b8D zXBxyI(hC|5gKCrvC-0Q*oI7>8RrGsDb$tJZRoy08iOh!^gmmTUjqke^T6XVD2zP+qFR1iQ2E@bY9*k>Jh2)ndmTA;Cyu1sHfA zVw46IY!P0xuI5ns{k!DkjeoC&h1jUi)wQ9gbHsCahz3euA_w4S_Vh6e=SMD%Y?Q)f z`3EKbQG?jv!MH6_>}6?tA0tybxhQ+k-jP96Xm0N)zB~T zaD}uPeC_zRr|KO%r52N#DY4?lfX?UVd}W?zI6}V!|GT-G91M8nmFXOove8JF6@|K~ zEE4FxoYZJF7}g4!I4^ysl-ni1kEC1?GQJ0ir<7S6>RS9nRv`(LOFXU2=QC*D@EWIc z4Rqr?FZTzs#jX|nK!8iqEi;8*hW`V=X=ipaV4t!{Et2M7NZ9dNq5YI5qLK|}PwZhc z9zhwIK_HB$5B-oe>Mhe`eMSMB;6npBjsCjSY)QvcbfG$dkvA?t3JhoK+Na7ywhEH8 zQ&SLHiEWl?f-HGBXZQy>@hU+n{Je~(4N_DiwH|IS9JCv4famm0?#48*1|y8_W`I5D zHZ-?#q5g#`e$Ay2P2zB4cUT4NxX{)>ow*3Zm`fTALSIcqCl!klCRzzgOzIrRT z0NGpiT_vpDPU_+nLDWa7(fM)*wQKm=Wl`XSXhSZAG`xN4j@nC`f;t69c7j>do%1Kd zq-OFIV*ra2Cx(4b5yjUCZH%fEczlX_xG*UIgbDFAAb?&(3j!!&+<;NZ`vf)wV)lmn>SLIbU@%!ED4K88siSFWBGjr4&SO z9TAwTFBY>-F4Y|kBYF8Ff=MsQk#_LpbKehJgT04c#9ELY5xV1|^HM<%svs{(EUj3I zGZEvkc$r)Zoj7BJuu-vgG{k%ZAr|Xq$90uzN~L`wK!|8i@WzG-TD6S6Mg9X|-s;Pb zaq(D2+~=_W0=uu{qZ{6wkny93A^SD5-$z0zMT~2XK5b*i|FT0jDt|dpm~{3_P(OO$ zJ2PP0iPF+`fI}ufra{MpJoij1FNFIaBQmAr}bOqB;tY?3|3ht6f=LtBd=6KsL!eE?;aM&cDo z3~lG#EDwa~vN(PxMUS*d0&eNgpUwZ|Fd`kEu*-d|gaD@)&?)~FfZWgi2hel6{rg4V zar!o><1c|v@T~|(ZnE0lcz{jPK&_lzloIzR$Bc%Y{Ol3#h%eNGx-yHH6&KUqE~m-K z$Q1$otMHp+Y=zrKR|6Cch(WLG#nE;pcr^P(~zEG z)gB4A>Du7L-5LWbg`g!HJ5O0UUUKf~Kt7~U>!)SCzKEcj~gWqFRw5;5v5m`vNCzBoz2{;Cl$vX#{JV}7Stku2>{Z-fUP7v#&aT}Ep6|Vg=Z7M+}XuAL$ z^t;TI1Z?N48Z-4nceWxty9=PD9sVuk#!_gUmqI#N2)sg7kL<$v4V}MvnXUc7Qx33D zKTx21MxFi*FyJlv*}F}K&R6G-o`fQ9SGrP;v-W{cjVS~JSyX9qcL zw^qz_B^Isi`_S&rhDebP?f8~9Jj`;h%fv31bW!u7QuQ0lP30i6a~ajA)%8?D_}dQD zmz5b)4b%FeQzUNew7vFWD)vRo@RS<)589*d{CfvGB*kgP5zmu?uBK_QKYLsrZZx*= zWKkN-kczag9)#0yi}P7bd+|GSZ92`zQ~#isl=aVl6Eb7dMe8r%(MASF9iYkmY38tz z3p}~RkA|D*lnQ>8YHB>GDtW_+ye*!}xc93+Tq6gi*fA~um~B7s-)MU(SW!m{5|j_l z@$+P}mqgHAM5lw6$441grlOw)YJZy0UZ88RIxn>J8AWx339 z2g{~G!%)mM00UuPrqn^f1X5(l>+okvC)fsn(N~`*W3Rnw*kxlG2iH;)p2a@*3aZeS?FH#E{vP6oKi|e3sp&ht zB6c6&ARu+1QFb>|(E-Ybglq-Wqn^Yva*S?C`s2F3i-Tub-zn(?)K4qYJ7>#$G1_6{ zz@pBlryfMjRo2N7w!z^2W(e zr;)^hp$E|OAA%Grxs@;9DxQ2#QD{ai$yAV=pb_B2j#`x462^rWP4`)|kTmr(y)?}L zQsevOt?^8@fmZ_z`rIbpRV8VWWhlikxXS;5q?_ItvuM9A8Cm&xp@U!S+O#uu!%hcL z{x^KLgj^fPtMBKP94h1XAADAN>22R=VlqWl$QPnpoqkD@XNbRTwd`f_GV}Guc`xS) zRY@O-um$Kh_;DtpeSXvmzp-0taiz`rU24F%TC~a9-CmyDOGzq&f~RNO#7ON_f(JGp z3AQ_;4_6N;qg%e=w@9o|59j)cuy)@tjf0x{Dq&Py$U>ll5F59wk*rsco0Ha($+y=<)j{?D0Nx#9s-OlT z2Fb|97peZl(T6PrUTQI7kK2h?+oy(B;!lDfUI*z@CU^LxcuR5Zq38m~SL%=P0`2Kn zM(_|h!!(!iZ=fwadgyGh>Oyo7zHFk^@i31@{(W&q%-x5bTkPUy%PD*~TSx%+`MmdC+ zm&CXt#~Dz#kny@xI|c$o-q1XNXMFWx^ZBroq;wVih#~5+TH-8Sdrc7N|CqY!s5XLr zn-JUy?iSn~iUrr=Zbgd}C|=y%-HU4r6!#W)*Fte^ad&(9-uM1^o0Hwi?q<)NIcI0? zZ|2_nYi3#+;fCb+*4@!vUsE)qYjetnsb{mF0JnGK6~G8)g;;Ld*g#AvS6LldjNRPym9(>a@A)JJyeliU z-lfAXPKH&D9E}i<+1F&5seKFptA>2x1w-~X)lo!Snq+Wkv31bM@fXJDck{A5!L-Jc zNb8akpkFf7UpxiGGhil}0P#1#w?H~K^sqGi4I!}X>feJU4Zp9kp(Xjh4t;wX6P$de z2^stv!>Qxrp_8HmeET`3`sSk*n?Yy4c>z-#@Hxq&q+fen6s{)(dG&NKS717+cUVUQ zdT|;1Hm6yH^}_;iOk(5uByTO?>FIr!IPVEplzkk5f*;EE|#cyJlZqK$|Hfj>d0)c4{24dXe z6bnRJn3`V76snSbew9bue)Dur^6y7UqXB8`wcIUI5ZKh23({gKcb!u`D=zviDCvd| zt^T4p^b8n)4(NJ}c`QQQQ(oJoiN z>UGIjCR3sEs+ETN3#r;cVopXJqsBcb_9lxpoY-}23wI4VMxcwwK&*e7Wn&VjYO^eq z3j6y6zkoJE_C@VbE{7Bpr%_jrD5{|WK2%inAc&nnM$C}F1W}id)gk%Yos~ea3f98_ z^E+0H$&R!XBGj@#BDR{~M1L7aCnNM%ynM4<3Xh2rJH)poL2%pXelu)~`WoWBHwZdmrrJ`9jS( zZcKMyF1_#$N?k+t!5xZmApjqrS-<=*8PCcRlb9~98b#8PGNWz{!VN!9jAjfoPid`fiDtRB}P*s)DVxM zxDJOFR9UHcbp+9p%WY}M@mt`;m5HB@Ov60sW%}zs$8|Pi+zpKa%0|&B*H4D+iSgWb zegcGw6^OjRoB`W$374V=KZ5v|wQv81xwtTmkC!TkDrfGc{skTU$+N}`^6hs6%|HbcSuZB68;ows>&}e{2bG3=xM;$erP!6kz?@uv@`ITb$V8iUToe(izXnrHvh=C3(6PR2 z$_*^BgFc;kbUh2cIlu1)(@j|vwdQ5Rph6GwD%OW;S*ffb9U_Ks%?`ZVtTbegc$H3W zvxcJyfYP2Uai|JRHI*dvd@zMt0WXUm9ZW($#iyMvkYOXM!z#9836w9qv&XduIFas6 z07OsJMw*3s7@lDHHs$PLs`yqlg+Ciy&&=j`L5iWeprpo-=(sW=)^0dqXy{eF&~PFE%dv4kiC8{)6W2&XktrxXudEa{w3t)bTzWpW^3Gvp2Fx?DbR*wWRs(3?g+T=2 zb1PYX9}VzwLxf4>ms7uXXbL^sNx|hlq|cr1(DS47T;m0=Svd4KPRCb)69@VKGSyMB z_c?b{{yi^)lLxKx%T|MvqlWWdk3*(b!tCfqD?x< zwv<61a-2_~dLBi2X4VR`c-iC_d619I^<$bb!~|6pX-?7Fn0QaabC1sgz5rzL7>z73 z_tSQ%hW3MXg@=hK(?krJWL^$OXc}pKvp_;O3{9}y zIpmo2w~+my5_hor@!6>C~C9rLh6|;hN(V_Pen)g zjAGug7VM;VBj&~)@AeRD=E1QC7{H4(($K6cICghXV9hmAL%NZ2$C0FaKzPei#2Pxn z+7A!$+rq9IACWWJ=Y)t?MuuS4mAgvxX5o^uu#A`hf4rA^md_vmtmf8^X?8B>cF-@) zQRH|&Gl{#%4z+z5nY+VhQ$@RFUjW={lp|iVSa}LSo=s0wTK6o zkKP*3T|9teyc=dB;KogXMY9Y{!Yudl0`pc;m&>8NvwQ>mVk|(0E9?!|-gM3V?&rs3 z^#Hgac7JWW$c-uH9E_hyi`$pMRm?)!+866lCKG8Hx9uFPgem*( zV*M-WR8zFrvuU0er6TC#M>@Qq1)@g}#9WUlst0l-bSK&4$83O;CwtvKBA9HqVsPfr z&jx40t{Nh(ghN(;`?%m&5Aj-(^;+A&hq$!&*1$cNFgk1$k`I7d>so}1v?FnX$NRTa znH6w}@lz`f11)&>xfG49NHcLFLfvl%7{j&V7Fj2V{{atf@B+;r-T*wY?zrP-Tp3Sc0l!RtHRpxh^YRSi`q#sqI5d0jtj8F1IZuN0FFgethG#{_skN{ zOcZ*%(r_O~1Wk_;3m(-;6(`35Nvf1?VA%l0PmyR2%oc(xapgi&nozJ`wtVf35~+1U zvWlJ`2EQID^Q;U_-d0AepA4UcyAEo1>R(&HT)JWAXa(Cq5Z{2; zw%Q}kRzsoPGxfJiiZzqhM1};VvJIEOZ<-WYAf-$Xi%aA&e)+W}h42tA?umj}K!+`G zM&rTC6~5_DRPhGz7zSR>zX5z0c)J^8yh!UiI3T#~>Ir}4FF4mpY=ENBl*a{W#u^u# zKqTTx3`Iq3#jrPk8?~qn-1`Dqk4bJ%WZ=~AXjAMk)Vbj$GE?X4@~~_L0qH7rRjmZd zQo)i@BH0GGiIGHv6DYb>)SeX4$5r{4zYj->6;7y7N{dbFuEnGi2q|}-$-C1O@q{L! zZFDhBbUWc-7a1yQ_A*HWK8#q`;i(^dJXzh4(M@)|<4NSlcqYmIxF&1&sK7DiyJy>9 z4z)m!(M@#Usr=bMuySn375;9z=@+ct6yIcgoVbC8%g}#*LZ$klrbH(T@>}stTc_4h z3e12h$jQ`CPLk%6eg0kPo?&pa;3HY|a+4-ix@W)!R#*!$`7qZz9xc*Xy zzBb~A)r-k@YQSF`g5fIx9pHY=&apO&%P}vD3d%2HebMOkB}HU%6tYMY-Ot~I@Unsl zuXw(ekQeg;Av3JbKeC*Z@VhB8k7b0=gVc*+J|T?!1tC4mn^`F6;cHuT6R$PGNCOEz zpRUAE6lKRGgU4r zXlo@Y8d1O##`T8LynRWSjVIm!A{p1P2#^u3QP%+#&?;hDIiWA{GmC9BsppbxS72`T zn>}X1_e!;Z1>7rtipExbc~nX6Ya$pcEKZ%!DnfqGoa}+U;PvGGIZoGoV3wsS{#}{~ zKeKkuotYyri8OHuCV*sqNT58mywX-ViHG&ZQY`%thjkO~;!~V-qO&PQTfP0n3W(6I z$JB2=fizNCX$j>5OBVh`${n?QPFk-SuUMayD~?h)qNh1_iM3oL&|HWL`su*n7f^mu zYdK&`vj5d=t=A&a|LY+WF|lhhMAQk!P=uRKW=ZWI{@&z88xC`)F2M-eHL?^WMoO40 zVtyX(#z{&JwLXX@e^pJEeNeq{vO!BG9Njh_MHw1}v5k((o8JJPq~qvbtZjmi8ZU*N zb?xd5AQr}>>jB>WC`L;&Tu`EGs|Hc`x4Ny);iW=BhH!C3f5oyr35X)lBL3YR35xz$ zx~}#^lxALIu=LkJPeXD%S&xLppoH+hci(DRWDUasrx^DniTLbzeTjk_1ajhId?@ZZ z(hl`QEdUDyubZ3Femzq3B#JhjRdGshxZNE1Lg_D{GeQ$M5IwO9pY5+g?s~T{d3cUgz5iz8l#oZO>BjkA!gxUGpgjYBR zEVgv$54Y^$o&TuuFE-+(>h`t(g$R0qC>WQ(Ky`H#Kd(UEF0bhp4LucpoZVCRh(d$w ztRU^mSJY106Vv#XI)#2PDLMg=z2HaDVM|bf<;X<-qq^=@_uV-Vlj($ipij0ue@pP> zxiU}dBPA!KP|1RLiu_3pu&?d1burTS9kz6ZPowJk7f-VzJ}2nKHo9_em$wH|2^}+Q zGa3c+sXw`B*xw?4BcB&Y-QLb!flyzbSfFWexLfIh0)Pd4VySBvVNQ_LHUQHg*8_dYf1#L!nqD!@tc)Mp)%@M^?b}@NtTM^SD)x)73^N2sOEhD>6V&Wv zQoX3tW#Ret@Xijh0SIe*wb^cRUssLyEG^IcD6WctIVXxF!T}Mg!T;wOl-Q>&ipr&rOgn zmk`!fiEj$vx#SDYy;9K~yJ^M0QauUUH%=bJBS~TvR_q|pI-tz`@_T&Mh9r442&c>6 zuL8&{&IRS&>*6Qk7AeA4MPr1QIU-o2@RGLF&wzWM@PK&<- z&?gaDt(DmCG95f%rk0i`xsp6^S>z@~+kU3wd9D0#ujL|+J0U$@4$mSi;IjO}2)s8w zBDN4HAOi$c3s1T$K&7>55umiRi-}S$7TT<1KoP=CKRelYuN58PD$!J)qqS2K?*Ij^r-=fHA^Ad~%@L+wgp){%Bedw|Nwm8G*>^CEeE0++q%dO6WmC+X$ZlaY;?NxLX?>yjn-UYFNJ4eJXKqwKb>Bn-ip>NMJ=^-vaeQbfE$6Xlwj zNZ`ILr2r$KZAdG;MywJfN_%HOWjpzvGnih=9=i^TBz170coD`rF48=y`+2RzY=3f! z#StpIulo8EAh?Fby5%9X!?a$aAW)$j=7`4#`3tXwL1uqh->MCNV&o#%B(Sfi$9*k0 zB9dUQM#$=glWtl+8sB;1cJQDX%2Q(bJwr`QBQC#UKsV~*E))2=7?5w5%u_pPfm*X_ zWtjh3SE9CH6*I0Q4TDV<;m^$PFNOADGI0P)?5>ZGX7Wjv9tA zchPZKfP|D5!pJ$=ArIi^I-8K`<VdUpO&~&>Rg#p^Fuv!ML0VSHwiF1!jXC*i6|?Dsvlk)Gk4!A;r+n`ZtR1Z3d}_~( zvfXzDDB-he?=iPEzbOPmcYg8?CSw$`hcG_=M7iK5r4(uu%KnRl{6L4U}?RDzv>Zf~`K^zHGagVEsi1C8LH5*AUE=bn!R( zijMq~?75rRN3yhZ` zjeik0u=}$b4(8>ETf3iRR^_MHHm~Qg0PTOC`cW-QLJ!Hz+{C?dq{^QRgj_ntD?2xu z=5CVt^Ueov#jA@w=AJoERhG%(yJlt$3WI*Hr^*p02H}lEr&eE60ej6!dPp{sKN#4> zOBt3!%68mQIn=@u@Y&~>jP$#Z_SFglO8L@tO+}j2N&v>)JuucV4izfuszNI$uFfLA z8UxS5uHML!U9lMfPR`M|NPa$1H$d}o4q3WY&RVi6qhg+AOI!V$O6{u?#ixOwSP35cN=+T zhTw1qp<~fHC+qS?7Esaa>58BORWe<|aPy(W*3tD@#&jo(%hI6JmMEAt2) zF#|}d+vw0|1wkTYR)<`1H3Xc?gD8iLXzBFswlR!X&0rT7!JCTZyTCz7qL-}%mDCML z5myq7^M&Z+Jzp0n1#djo^8Fb$FdHDW>E?e}jQ&}#YWVr-z^1^1h2a_2O?hh8yuJaR zF}l9uX=59TAF*{ECA~JO1=PF&nqy?}Fi^0b{luR(7IVa(17J2&##mQH(eSE%cSF2TG_4!AtGhJyAKiro`#sc|;4?pj*j62*M#y16wVdr6fRgh?ycAE9 znB%!c^=?9J=T&s&pZHhUe|-E~#Lp=AZL4AZIdRuf8lDO5f!73-; zb+IKd9l)jELV0BUI3okNCH_x6m~P6A{9pq1%@32&j8rxLCm$OB&8tIa^kKek$Mbjj zhcu5^dopw(N+5Vtz<)Ptz%e0RI0g$4@SiUM?4+kXhl7=+tr>@nrIXEP zx6fSM>|ZRM6cjpv$gry@0AME&fDJ2o!@h8x@Bkp}_@52_|CIy(uUrSa81(iE|9vu~Z|yTkR5LV(ck;M_leYPXU)1_@AmF0sx#u-S7a|XI};t%xg=) z=-f0z^Qa*Palo_Dlb@05_u^{g5RWVylkO@0zD29h=OVXNWSTU1S`~-K>y%_>F!cn# z(sb{%WuR`rpiLY)gI#gH#JuE<7K5%Noq&Ps*pA1HCc*1g$7GIgGb0)f0kgY#W-d$a zdU`q)()P-n7W?|xEFb}aDFGROc6SKWql-FCu{qIU&4wNcYfZXJS!)DArep((mNHgV z;h-v<*tCLbARNiUE-4P{XPdhMwbRI=8$dq&tYLtEUsaLeCx#Qib5ZNTr@3u75 zt3_Pbp!&RiB6^M|1OvDQ!0g%n!Xg{a1$XmBvL0PZ0-%<%UR6LI$JuEHpaK92p-?Cp zAvl*q0?9u@{$HCkl{Ws5qTqKUvuu*PzM<@svfU%tk%!+7&uP?9da-4&+fR7mcZjbR zIS{e7L9=?1Ak)x1WmQ0PB?( zhyRq)!*yhgpgl?H`fM4At=artnyIQgV@0}hzFl^dQ5{_< z=f}vn=9`4#ZsIR3FccJ6V66sMFTm$5T;0QsWD2}f!&m;3K@}aTsW?_ZFt&In1h-(C z;_BH+q5%I^B5ic9QY|qF{Zpk2I%dg(eZH>`9o9fG<+?5-D;)5FPY*>g)B)@3Ooq~8G5w?j? zNjHdFD%Enx*%tz`QJI~erUn8|hv2B>v0jz+j&yT7DnjG$4>pJtr0Uc4S2LYiGIhu% zmsKtZj1KLTD=b9J__scpF*?PPUN#^mBP;!l2?L2_|NE*Qc&;l{!LII+=&@~TCS3<7 z;9_Muub(`&_{>d6K2x~xkrn~62tJc=ZS8YPIfcxApC)#{{w;=htVz8hN2OK6-T0FY zb;pU>S}cSCB|bLq-ia=h`@3Ezl>#E)X0Ko<@Xafdw9Q^A=CIyJ)RYRUb>{>Zn_$9~ z^kE*?GFFAJpKR6K!1{2}5)!KZ;)X@Cc*E+4yUQ9E@lM?zj*N#keg%1Lo}pohmGKkl z_l)pyP@DE4^cOF;q}(U*!taDObq(LqaEJ;1jd6FQZOV_(B$7^tYhy1NGf0BTqZ)_t z5JVD#P*5?{)Cy41eg(^bQd!JOLW0oL3%P{Q&%&%Y`$VA<@OVAAbt(JpiFf>X%{%Nor$nJUAxSUF5Li2|$|?DxYpE91%Tl4>Ac6Cq{6yNMWRGsMdOM ztwQ9MNJwv7+`n@gh)n-(v4=^VBE)eUj7Kw_C;~7y4YVCZmXhEo(DntVl8jenMRQ?L z7mx#E0EWR)&wwBBYo>`ni5qenbX1NwgU~)nO9_JbzyjG5wV+tkZZOz3kj#9B2;kC; z6D*0)3o5Wj43^0yfgd8#j`vUYcefE|Z%qBW*RQ94&qQhW2d(6oZS6Q3GkRd&{hm{k z20K24m3<<`!A)3S(6Sm!p(Vz#TG15vh2Xt)0cetbNFwAYlZwLMUOHx7vfxM#`mmVZ z&wkjD2#7@U4#}ZIO{O;)CJ&lmrrHSKVsO>!mds=tvY|9ESmLooYS@d%<-`7M$?AE^ zMfC@ky7FQZsk~UF(G6T9Df6&#Fma4F)=hBg2_F89?GDRF0NJR$-nEi{l^AQ{4(jO$ zJY#fYVsez^YeSrpYHkg-qMA6usZbR7<%(o3;ca4TPF|%Yz%+Uqg&t&_+XHsUp_zFk zdQWWpNhcQ?N1YVaKCI)!o8O)3v}XR*;%ZpN-u&x7ENySPe(kT*M2@!RG7j>JXD%Nc zHWB&?HR$eMh;z8Khco%BGZ(=UwYoYQhym@hvutz!$mWKjE#fqVwLdi1OGNp)0SjR1 z2Wv-DytQIAfxgk7iyc)63Bbu+=4V-9TY2`}PME_Fu_XtwK}I5(Jc4M%!7lf=-LpO6 zX-;@sG`*fmEMj(hWTI@#JO`>l>J*y;(`fF#rbnVM^LgcDlyoSwq8hbPy+^Y2NLJPY z)dxxa&bbr`)ehx67XJ;Q`8HoAAx^6=h1L37kB>b@suG5c8Pxhfv`>UojRp1B7lgROYxgNK*cI+G&=eZ;Jp z+`uv?#NvSG--u6`vIeXrlwyHi)XSXStFa1R>;tM=4(P9-ozPEMXEAblVs!W^Gl_bM zfcr<*r5FHtBTqVd+HrraukpB+mW|Al<*!G0q^$Qba_MS4eTGZEw`;A@o-3S2gH&`Z z21CO`@orv`lTQ^tu(2Zr;M2?- zmn8eG+@M@5!uD2XIP{BCusk!mzhSwnH9nZ8c)~a>meD9Bxg|kmKkKLpq$C1qP%+t% zJFzjjftgebyBJYX^rSz{XmS0hYzxD9-L%}&-V@FDdQjF2fjM~+nfLW5&$Bg-(XlevVQ{!>dj5eKvaYtl!VTvf7xw#EwO7uma~(o1cT^&}xqmKz z!zswcA`#AA9nL*(fiWB2wB8FZWWm;Z`1ca2{#44&A1(`{Z_7);nhWjoM}Us^AR!S} zko_op*2g1ExYSfnI1%&-I|^kdoUZO;SwK4d@EXSV2ZKK%xjmhPnrN;j;;G-tO|2)~ z-siIgeTyXklSP$ZI=rQWt~Sf3K10e#loc<9#>_si@4kKNqAI=ZM!IjP@k~^_FPcK{ zf(YY!)JoJP7X|+)B9m-53ub-Q8jG~v#Lb?>!O4_qL8S~pjrl~2jMT5;YBhGLN-NdC zspo5ISiq1qS{hu_-&&_KZKCg2ic{|vpgbNbk6JTLHFl7Q<1hR}l*D0|TcsguxLM4L zmuWI~$T*woX+L6EZOhi?+MfY4NS0O|CP=3YLZ<9w3nB|`k9c8g##5z$P?St>&3%?i zh9BNLi(PmexeG!@MbrtX0*H?Bz#P!ZUbky5y&$AY`)mcv88bBp0V5mC9jb-Lqzr{X zO577O4v;)v?r`yJ(qiPean31Mfiu>d?om)@(y?iC(49g_$uA=*#rO5&F(evbNp!cM zo(2tWJo07o7&3!9f}iGeX}CXc+r2p(g=|#r%M6!mMmiP2k(L>Z)z*QU)KD&UZ?t!T zM7OBI7XLhOl}exWFC zevKD#umRq8N6^0DZ$Ld1jIYn(L|A62G9zo(em8DosOBf0>h;UU)dkEEC4Z$nahw5# z?h6mjdOJQY;lzQGu^Ci}%rE;dlUug+IqAP!0Y|p_+&w0g(_$sXveajZ)l}@l+ujd>UC_Ul=z_*wA|ccS3l=?M>*TeY7<0F(T24l zQS_Vm+f0|^*M&}cv8Ri7!&ZOP>W7yp==}EK5_Jh|Z8C@;b?A zIl0P4>G7^#p1}SABdhIbxQ^wf-JB<_vzoQuo$7uD`736j`Lee9ThHDYo-{PvAT$W2{{x zK8rylVpD54_6JQ!w?8r>r9!aW^L#U)Ne^42ROxnJYXG^PlbRONIe&k!sKfh%?l!`? zE+c9$gwh1;*xdJ)hXwYh$9Q>u@1!{}=nTK!Ybx;cV&bT-&p4?q08gi2QxqQ*^=aVm z87tm#vEp(3&n(B;bdwN3t-`^D)huW!j4L`xP&A})mAhi^l)71!E2d7^si#6Fcroj_ zHWoRG#gDlbp)N2yE|c-D6M0ZOGp2)^$y$S7R*CmeNGgKKi!@O3oVVkNujW8i{aa#$ zrjDUZgU!~K6l8Rp`)NKLcWtDHD7Ky^%ctO>t8uK^IFAe>5;$|7v&5&LZq}2fM3bn7 z&FSSYkeQ5JQ_Wg{3TkCt9m62NPjaXRN3&6oJ3C1l(k_Y1DF*tL5_iNbxJ=n!wG&rd z>*9J?&+#T!i{kiI80748Ce;_3UbN z2aM-xjz8k+$5c63y29x!xJne$Aw1egG0YQkw8L*R$Md&?1=Q6ZwbwR@)%i8PKWTX6 z2zD3p@eJ6@LKXyfJnju*3OZHe^*(mzWVN$-SxD-n@<-8CTQ_%ImzI5>dJ)zW2|chg zNrQAKYKrk$9wC=)Jh@L53{YNaB&7J(2S@=HCR(khp4 z0;65+lXjtLyjmOsK&hzh%zR94(fc$jem@5hwG_OPJluVj)ws4j?!gf0C0@LlZ-{>A z1UWuS=1KgY@g#!vu7ZrAyaVE3i#4ll6&j6y>7tB;qX;3%ESrINoPn2@k|RQ0_(!`m z7`ELq<9ADFkzW*@8P8PlYbxZ5Rc_+53MUBXHvnz4Q=Zkn|;DuR!EtHp7=a3VX=;NNVzrd3gT z48c49hBp)MTrd@p=9s(6uB?>0gEMg~?=J7kJ70I@M-I6wAU|27p1yVq1_4;z+Z*CL zY<s^yJlB1o;MlRIo%xR6M{wVg-r)Hc@w4;&Ms;X_o?IcU-G`(@uKC%22{4z=^Or= z71~!?$0n$JGv0t9McC%_A}$-yCaOh z=`-684ifIOqsX)2Z^Ab zWF=)3zwZG;8{=x!KRG`)3n#CUZS-Y-URhAn{=|o`lXcc=c-ug{wz&xX2AB1x z+BtQbe7-VP7M*@k9lrU;zL99FoI~pJuPST>1LQ914`l?cc^vA)LGnlIo>I$LWFruu!-7Mg|vls{UH1(%F1 z`k2JY`_&(~+W5gFs)a<3oO^ld6Ih2c%=XuBZ+l|YSC-|`(F}`V{Qc)h>0A{||F1(E zJ(^bPV?w84`!2)Vhr3*6CwucgnwZ7|m>qh+hdwGBKyosZ+zuQ78DbECTYgVk98=tA zd0zY--E_U8m`X!v6Tu22kqq!5{lH-G`0n@|zo-*YpN>VI;O;>$&JXDxgkVMCx`0Ls zC#1B%hIcd+vZ9?)r?*3!DBKWxRcrED*^q_}l9PY#(kVmt*rYHzXXmW3pN5ext$Y<8 zN05xPIXWtx^X{c&=FYhxZ2|1k`#E1UNe@%9$OpipG?|hv_wcXTG8Ve70Ny1r7RzJ9 z9Ile#E$r~{5Dy{73K_4PP#;VC3ANt(?9UloHEB~OOm>xu?MH$-Q%79(W-7<&xM~`s!Yn-K@yHn|LWD!2U!*< zOUE64S#Z6R&7L9d{Cu?f&qrBx!$>@85-bSn*A8Pfd9ZT=>Y&psenoV5dajkC-E)1R~dHp zKlA>x0C?UOOC{Tl+2uF}D2AkZlLF%3gwKxci06DbSgUpq&xi?5k;P&ZYgwE}3JV0a zN!;mjR$}NXx40hjfC2UyRi_X&21XnAEfN2;#Z(-z(w_PCFAi{L-oMdhxIW$aCojG5 z{`Qss*jZ325y%9uPq9zq;ee^ksG1Cz1}gaBR;Ps276IhmR9fl=0l!A7zH@IUEqe;g zW!T*Evwl3V7L}8X_$DK~7-kn#SK=su=Max;F;0!+LQqyBlPuVl-T+~!*B>kDFkfl* z`m%r`W>~b{qUglZoKF@8^tIVeoyly7A`Aq|IXM4hCL2ek@{ksu$ox=hT6hoVZ+0%q zez;Wa(^&FB#KboXTkPA^zm`ZHVQ|%Q-Hn2@wDPfs(Pe+EQGx(7lE8e4J7M3S8%6OmB?>O*z{$kgJR`Ev1aSfDa|8&!~T99k;Pa{{f`F zmHs>C#-33^*hMtYa%+LlKm-fs2d;mROroKd_AO7saQmHtVczqE5mQyty~n?2?mx1g z)@H?F0`1wp{&F!#H}=z&MoE8{mGes~S<$kU(`M1Xn7dW`5XKaCx5n+fc~xad-ecFDRsUY*Mv6^5SJm0o^ ze6Zd`>ad_#;iK2)%>w6M5IR-wb7%t+k;=EuKtnm)wwG_4CIw2K{-i}Kii=?IMu|PK z`xe8LEV>roYr?JdC6mtJ#7$=wRg3l*VRzsUzfRsj=v~=xTFvjlm>!qb8Pj+ZTXl)5 z*JaWU2UKxP%^c?JvzFEma+E*dQp*HuwOxYkYMAZ%lH)B+ru=nV2)!iynWoGxe*hJt z=_w5EopHaa*9&rejuJ%~9Jmgm40glzx`(8#Ha?A;xTnJ;{SjBG4z;+_I&e}>YDw6m z>hFGVqTQD1t}z>F=V#gbbDU~L-s|by7GYJTHOjnQf5AR(bmA(md&ih$PgoJnF=-vS zX33MrqJ-epX4W|^gglt^l*(=CzwH@RPo+r|Sek=mQf*UDe}u}Rd$NKL^n9t^#+aX| zW?ay~zh$Niju$h^>CbHA__YcWtC^q}{&Ok6#c@5jr=GWLV}K#d`kTrq+bh|!|4JPg z!?@RXS_CW@A-VroeV*kJ2Z#0)wW3%lmgMsAV}(;})wzs`fI;tEg^HWi-p5BueqnXG zVuf4)VJ}I+sPTPpxF5yAcu|<$-{y9XSHbe6}sk=b?x&dE-=yz(VCq{V^wg>by-=eNuK^ zoT|P>w$PsgUN^k=?>@*dtCiMBQ;73JLVY=CUfBtA<;H?DQ*g*4hm>uu20-40mk63yN-cURSKd97)MVae?ueU#?B`Vvy-=+~rOXMq= zixs5wz3bWjNTo-J^;)Dp3d>P_9%T;^z@|iE@sQzzH)w7m>f}|TaC9Fy(2ytF7d><< z&DLQgiDCOKmKQjT_=vK&SvcQCgcQ_O0Pm4nTx7{R#lfk#jaG^?5l~xs<)cKkK=s>@ zUpFSF13-Hw)lj4uJTVxRNRpt2)mPjL?Lnkax}hVnWDr*a!+lVJKY-K52U1th6st0mT#p1j{E7evj?6g zaeiB1PO=cCGO-}zyeJ!SSp8qdRAobB9nk<4Ze`V*)!Lqpe}QB4wbPu|+rRmz@bNH| zR#9yU4A2|#`$7nBZ^7Qee}R#Wnvo4p!#?j(`?%DW{ETv)o+7^+GVS!YG)y~olq>ZW zv=os>+hJpm=&TX`)uG;u=1^R`5^4_~b|Iv@^8Wf;TERRXb$%a-gL!g4kp(hG`d&7; z+_B98ZmVl8kUnl7V!c~ZNh};d}11K7Fy{e zT-Y1aqbBYWkyYrX*Ru^p*wN)cgwS(N*H4t7f9W7DPd0E`oV`VcqCcV_}ft{sGbD8=Wf4#?d zFu@C~`cKaYy5HIKa`QUn+=Vg`0-n;Ph-7y=)z%WyD3bDs9z?gA3FX>u-c6vRDsO{M zkPQ7$5DxcorE;(5@O`J&JZY!#9>#sAJq1PtX`xy*EtF1jv0`WGb7uJx$P6Sn8cCw3 zKeN5#%;L;{491}R+>=Wxd-F#yHZ;Z~B?!?)r^56x!Cn)Y$HSkP zFN!q%(eZp4(I&JAS#dJC3JMPx@jjOcma{xHGy-{0FlG@~_0TC|aol1#zl_5HTV5;K z@z|=#G+zo$5jjSET}f9)D7NQ~zyzt)8w#^qk#t4Ndw@bdMvoG5(~7`$ZPj5vBV0FZ)A`EFK<7 zelr<+>Ilp0Og)J50YQx0>nh5}4DpQh0`&0BH@W$3kJ>;xugBzH)GKwSH#>47`;7=_ z(I!}BtSR&wWc+_6KH(13Q&_s@yVcAW(dbhmGlx{p+o zL62-r5LUeUfy|IdG3hJD=jro8lXO=#iO^*FnaNM0DqE#%E)qY7e{WP0O;_v!N{EY%25~yz-Ab724wzc_rDto)qjt`g8${D03fiRJ^QojlZV^2m(7IU`{mox)9*Qm55kJ4%r8nZL-9(?-9cOtl|4Xz_y8V(gw>m` z+CeAUOn;5rngR3H8FrcvA(=@^9)@sK2ocm5)V zr9`<&j;ijz*<{G9w$mK2wwy|!@F(R(@hlM#kUC1&O5)LTu4u*7((5`M%196Pi^eC= zw&Pa>A^&-GS(${fX6HT?v}mVPg`Q?Zz8V$mahQ4T&&ZEyx)0O#w&p2uP!bxhe}7a4 zJ*u(ZnyvKv3-?)Plg`|#QiNDvLLUI%G!x;qj9sxj?VnbTPNZ4)*gR6Agf8gBo9upz zfD})a(bC?UZ$ymRCxel(%_XI(OpymZ>n%BG6;KM`egx4;knz`;+X8Yi9)r4m4CtYH z7(Bv-=j^sCm(nup(_Bi?SJ5!@#y4VMkQ{qw5*5sMFMmCRj~Z!)BLVUAlgkUlPyl8K zv>;!rB`aLq=ejSFXK*tj=@SvhE0Ht(Ro?sWNN(iF|2@+(P5QHxj__U`!0?aOodN(2 zlYmI4n)V!f)|^1)qv~`cr(@mY{|B-_O~15~006x(kW6g^k#TepbrpdQr^5KNQ6Ovx%7Munce+7eH zWRShPqqNv&uS|`AKkXXgzzq?Hd8=fOR0+Z?NVL>bP$sC6FX-D1Ub^&nv?e-eT|zlo zUd2T?csLSH418b!Oc@o2;z$BtTQ%Xj3<(19%-vyL$cm`UA_mDAh5&h3!itd&0RcSu z-XW=7iUUkzv_g#dh!mC7#Bf3c%4&o0#tlJ86|o=*EACND6mU>obPB{9pjVhUG{Q^Q zQt6ygARKix%ya}>^@*`nNI^wlt3iW6tC}D~!)!zWod_|=1$RNBuIK}ASZf87gAprB zEJzr`@dhSO+=?KiQs|)hQ!2J8(vk?Ob~b^ih`nS;haq`Yc*X~EL8JQRJuSidnf%(G ziNp&YuqZp1fbNmT#m6THde*;?_c_cwvHRVYAonL}S!JJPDvf_z5lig#xPVt1Rtdj} z#Y_ZO=3?>Y{#a190$2|S`A<00&6#u{A5kT3)@IW&S$*jLl{d9~oJt!VKE%o>xR>Be zRU37XVDKcRepOIqn_A4tY|`W;#YG+}8x9OnOFnkBCkBnuRF|%SxeQ_-W}k378Uy{tr#Uh6AjnY zt!ra#z*lI@Bshgw(8j?v0Slt1Y8jt!T?~u?IF~Oj)*OsC_teA$N=6Tce~x;90gVZO zkSmafSh|D(pC>d^kN^pC^9}<70lvtn&Uy%SP6pVZGwYl27e0jn`;cfcMGlTCEeJtoB3oxF zH}Tmu?k!ee_Bx3ma88jY1vJAM@wUvnF?3iwC#Bo!uH(b9V`<@4BT0y|8BYr&Uq(%3 z_)$%ZU-adlaPL0 zz5kf++=>N_R-1~pCiX}?k6S~(=8qi)gus)vFSjb?LbQ$Pas;4R5R23$(6%V%CKZ;u_xq{(!LF! zf{zl_u(J7CBfiikoY)E!IZH=48B}v#WS9;RFHU^;!azwq*P*APkKcXJgDm>Irvthu z*e|0&0+uAZ=zksQkFb4Fw6qwueMLWkg5&gw|BOwDo^6a8dd=~pz*ma|(#P;nqeLNa zeh0K9icHW}N@IvwP2i4ZB>;vxX$s*3JTP+0BrU{@4$8yzE(~~noDAdgLCF-Y9sDq9 znszB2fNdY{y`BheEp4D(2=FgB$<`$WJv{)VNCZ)_VCd=aNOSmG-3ScgoLli?@B$

yk5BTNZG=X=tFrdJ@IBzkpn~Dr!(ml zpAvyMvHkZPlS?{1j3BWq^P#3%F7kA8?gz$D@1#bPWTA0#hU1yoEs%9qwmCJ*DIlj| z*sQJC#oiVaY~#&bh-ZXHrHqhgHx|7!SP@*4$^ ztNZczgTzXCJWV%C?6Y3Yn#_kkITOshYTpqz@b0WhsU^~DlAtye5!(Q#d{B6oaYPbe z3AtkTheZXiq3um$$~ds(sG>xtz`a=U-ya~i?H%g^E@?6B1F{EDfaq6N;ft z;EG=IP%YW_z1EF~yrNFmjOSY%XPsyaMq}qIUK@z>%8JQNv!+?BD}5TLg(&{P$_6ss zt>5pgpsfd40}luwWX#O+Ve`RTThy44_jjy3bP*T1TX-?#z#|01FaUr7?k6aW4aBOH zkPLf_@I3Ygb|`mJE+v=9OYhjq^x~h)^GS+1`+;g{YBz7D?LBK?)CE}zx;!>4*A<3k z8Al#bSW2d?4t|f|nWDGU?b#d0Htcge#>}m68 zY>>(L;)P7Pvts@yIAexq@mX%81|AxTdx}Hg)G*&Acc=p5Y{>JnU}}tAYic zb*ZW6Q~7kpH!VRTDa@X+Vc{6DlboCIRVY!Y{%g6ZKCzjJeSZ!%64c0Q#GvQvn{&yC zukvR^$Lw$jgGUxjsc9f-F^MXxh|!-qEf39HK{qrdbiw*9*@j05|b3kVv0R% zsfou)&m20n$l-@A3{*fWX{jGvX*V@R%Z2o#xS#1JLVii9Xsn%vVl@C2-7<@J-MTZ;y^U4Q%-^(wm(4TXN5c}Cdnd=V z0qbbCkLsw@muW(fQxk#U6im0kdr7H=TdT(C}PYE z<)RS;@=fc0+QG-0%!WQ>fJ=lgn)i^as!gE$a#iseKGKDN&RO*D{Pms4XfpPmcQTE` z#{#MI3tgA^9@~(Hm5INaf#35~fZ?wTva~^FiK6eNG%)zI$gj9as3yVrGv9hSM&q;N zy~xFGpDm8rDba2z67(ZHl02xLLG@L?DdNn_4pC1ijDZmmBP;VEpsP+~dMJ_T>Naq7 z!nW?0pb8=4oUNHxObl?IAXX$sI7cpTwUT+fYw{YDCfYcnroMt+PDkkNRI|Yl3`)fL z>6RSniP4uJOJ;+Pu6`(wQ|6qetp?9k?!GLmnM%N!5o19^7uZwdbZrlu17cm>Ew+4N z&*F|!sS(Sfc5-vyyh)G4kapRzAFeg`hB>p}>lpvXgJxGMo^6i-0f~)>tFVLT`cz}W zeS1789~M|F%h!|AS#8i3qK+wY$p>SY17j8nOEqG~0&U2m2Unn2-PFrfm1OyYBgm(#@kTrE^zE-oE z7@x@nn1P-~@2eI8EbJ=$nZf%|Hn@GwEf-cOzWJ8WdrK<{-YKB3T*eYV295WMM=lc7 zcBZC+-HE&7ncYja>N|7$7WFR5s$vAGX-GRjOUYxOJV2qqmz@9Xs0S_t(a+U^K={Twn=jqCq`rZF(gH zz!-!8sOsI&1`Pu`B>{j!&#(-}0Xtr6LGj|>X z6EY400!ls+gNy<(&>8?e1AXP6uR&cNY}QL(wkP#Aucca+78@j%E|fQ6OW4`i=c-O2 zX2FaAJ(~dD!>o&+uem7(r3(sqK5Wyf*iOU4PC3Yk#}*gs9#bhsp|MjawKW0CFN0G? z*v*+~S*$bu639s;9=j}aiaQ_GFeFjl;Q~otBq>4wL{)7LjI0~gJo1@uCzFYVww{?+ zFgQF!D7g<#A_g1L?L8%LEIS`X{!{PUR!ra3+rxQFhxRXFkwvtmTX;+sZ)aocqdv8{ zu|VDo+qKkw2p>NZN`f^P{?b|1X;ZSL+1wt%$LcC@8!^xHBT+F4f{r!HX#7xXNS*xD zOaUA6_0H|08Ib)^fqUUcuzL^w%OMY|+yQd{X5w7W5tcao{w-&XaU_&jret>ejY0258*wK(@%6L+o3ed}z zpinx8T#T%5fg!YilDA|9vh;gZNWpD)n&~@(qw1xuS$D$Gzrr}zrOXDRmd1$@IEtiB#12ThV zi7ZvI1Jrj8HM1L=jfkuk{CkpFEc<}mCPOFNHE;ai!6{2;~mSM^A%N%l$$rZo^a){(CWE)XYCd4o#P9Ss}2EhP;VFZB~QEXanY!i#hQkPo-jD&s>4%}|p72Eh7osmv6I7(f@2aKsP+XLpV;pdcWd00U8^Vt7RXD?j$4 zOe?&X)v@Lv2l+;Z4=Bb3EDg2*01=S}ll$PCObsQeSR#PY)KToYs-&i7^yf2F_UK09 zX5!F2cSxmrfjh+{FP~jpoo-b|#Vc5=3y8^%LnGK;&Kg`KC!z>6Mq}==2q5Y?{7s>q zM;mf8GEW7s_AromC*3m8rUN=F!rKK0l*TUw#+{1o9A941i&K9ui_>`%ZJs>AaR~R^ z@|j|{X7-x3JJ)B}mYPC?P84$t@Op*}fEOp#DKp1{$?hX8v0p3vY_nE;c}$-YIVJA; zy{|FJ__0qQ6tdsGT)76F9*obzJfMm$k%{=_qOmJpb-J>C$yZpqb%AQTB-$*~q{ zIPNbk4w0OLx>t2&a3q|Ljt{}U<{NrY5fYgMl= zRMpF9Ac4S%$ORHblL%OIOkkxTn;yWFCH7jKA; zZctFQ-qgY)qmz*HzU`g*ynWd#ny}oW{p2NS!^&}k!SyZgpWOH2Iu>%m+q!a8=kWNx zBPyur#wbz9^^t%t2K#!pHES3*VgubA3~1!9)H)HrE=E{voW)Sny>s#i|nKNp9U^XJBDwhhJl)yLyY6j_a9 z2S<{Wn>nI6%_n`$6V21$?V!s{)UUY{@JxK2pW4Zkq(wVCUlF9D-N3}iJXB@X+Bk~M zcJoo-W2tj5*gW95j{egAk2)B(tw~%_&^-?QuolCT{jgN_p|_CPC$Y^mg*XA{o>RjF z9Vmd9ee6?O9D}knB_~+X- zS`UkEl18;DICjoiZNxl$K8u?c6&Uo9cbK_Sb|{jLdxLYpPD(Ag$*zR)7=yve$mhR7 zGbHf$$#0UjH_J$i&ZLAX$;xm#m9dcU%#b8R8L0{?a{~cmYmy<`30V*vzhgBSxgcUD#j0qaMBvg(Zlmm0KCr7*?>9c%&48g%$X1tDfKDt$mF zKO2LFD_%_NE}BbXnn2)2Ezp3XNGl|eZh~V0UmDjsDvCEMb7Lu7Y%Ohut^h=~4ggRE z0MAA`&>R|vf-koNa9La%LZB;X12u)Ij1{(4lLW)!?ypE0Nl?bSjE4a@E~G>R3q$Xc zuBeX~A`vu2{ronE^T3$`Z9XSoU%_+!*CPJ(UG~)?$B0c;Zj+Wti+^(bk%x*Y`IX-L zlQTOPLp=XCvCVGKpnGhg3x_#ev#o1$Ei}R(5zBGf!atbVwC1L3vGcIFSx`NYS(-z3 zOvMQ5ogk&tYZ`U=P@sfQjTY-tI4zHTJ+`52Nc*vY zB|2D$@#>6zy`J3bXZ^BwCq5yu0sRpUSJhBd8>2@gm~AwQ_c3efB7GZbqM-Z5E{j$9 zptd;lO&3-P@?&QGddaNy#4_X^LI4;501E?&g0N^@5{ZOBtN;^do&W#<0So{D03ZQ$ zq{2Ah005c*000004gdfE1ON%>n!a0;kzoet^9!eo5>FCeApb^1(h_byNs`0l@a1=9 z)n;I@k@`7##-mD=VU{c=qjbE=B=hTviA1BQnIUeid{#-u)^6W*NiN^N5-s3} zS%J@sek^3besmYN2+sCkXH#PxofB6L>vu~#mTWdzOEz*(5zeT>>2qaIV!^Y3_f$lm>J245OB2-D-rg;_j5#!b^X5V6oPBSVm zFk|0R*rLcN!mkzHa3d$<>yLx5Sf}f+`9do@q^M@$qb0 zG;CFH3rt%n{%q)M-6WBGup(qTCE#ggG2~r8HY~r2>OKa46U^PclT|nwo0v-j%h z?^4oHvS(Ud0iLj!n(Hc1Pi>|a5s5zQuCeW&<2eUA)^(JOms^E^qLm_7o7+v4_w}UB z8#*-iFKQITRBYV8hKO4CcKgcXKs22%HM7Zt zb<^h9i@O74AM;#r`(rmJW`Yzd1t+~>B>l$N4D7S9#)CL9>Q0uDr0(E6y%TY#!!qSc zvD{raV$zhc=-`CEd*)m>cBh1ssKk%8Q|L?O zr-p$rzmRoyFA)qDs`x zaZ5;#QM+w41th-ZY?8hLRFlfb#Av6z_Xdmdw!8-8nG0~CQfH_wRHu)IJs#1= z>1p(J-#?{P+SbcS9|yq+r88%{%SuHcW1pu(SZyY5o&xT8PVcG0i;2sJL)@*jHQN~4 zU}!t^eH}U__^hWQa)97^>@vth1QnSY3N!(j(*rqD04$pIZC?mrrS8MHOb^QgwS*I) zyh_csT$}-%P~OrJS_^T)C18LtCp0>!T8(Hbb}I%kg8?7_UP^O9h+q*g7=Q#op>SXT zEM>WMEmbfrI%m)feFu9lppK;(c`MVSE0hXEJnySkAp-&fVn8bbm^7;rLLtbH zTvIeAn_*NKWc=Gq5uu;!T+UB8GIzWN9UvD<25EZo}3$$&6YM@{M z<#>5BV(3k_px7o2ZL6PO!ENQdC|0ijTz45a6hh(7yGOD-CNnWJ!0;L7)(E-kUV)W_ z9m2|eg&l6$WDKIT;G+j!La8lviz3vOqZ@dbFaXtLAFSO1*yY5|Q@C zltjg{ic(J@AvBmOOu?U$S`LN*f^Yu5V#+D-mGnFTWkuabk77&WQGJi6Y%1AA@hs8} zpF_j3Iy7^r)r3=qwyn_dwYa5She&|jyb8ct2jsPsc7n_#;DDV22QY&b8gr>}z~R!_ zA{KH5mX}JPBC*S0xy!=j1qM$5obfszxceha=p$QT@5yA5tTu+12$&l%?Sk-`-A!fk zLw}M|jvr@}8+lWHaQI~!mlW)It;Sx~Orvh%6~v-VExBIU+JCdtp%x2aOTx0H^N}gl z9m+hvYmX;&_hx}sWuD=IinLSpa!p$^%tKM#dwaOeosUqaqn;?cB18wDxtuil+10%H zD){5yjHdX{`6gS$ifqbn@|}wa*gP$u;9JCekC$rb{jgP_6{YdT!Y)`~^h_TeU1<)_ zKH8rB#3?Po{vaos<=l+>!duV!Z6&8H7WWuQ7-pVDe$$mvn3s*D!Yp@F&SLfFv}4Pc1WI69v?^ z1W_5Hr}sAA_*G034Pk6^2JsCa6P90Ru&xK0t)AR5C>$!9wXM z{FC*pdWdL*Y%)hL1gS42Q2E$Y2|L=gAPzJ^bZCvS3S5}NJ>a46Gqjf zlo)S5z3>kLXl+qagBl`w^IWRLP*j=ydxj{)+D!r_b45Xb)PUP|jiRQ?D^~(!Jk|HY zi=1L}^ur4t+m0qN9vpogBJ9;;YT{JFkzml-;8Q>}yZ|48C~44T(8p5XmH6t_GqL2D(&I z>X;a{Qi%>7APA<5U%2qGI-^|5Ym1Zj#r%G;mjljRqCyFe#41g}ns#rdPe{cz5X#f^evLJ@)UH^D#yqP0de#kkU3QE!EpHHU{QPIO_0q4RpG}opC}PPU z>f*Aq-@3q26D=nu+r%`#XjAv{s8VUuc5kd0CMxuN$Nmq=D*-}L zS4GeKtk=e0H4{qWn>ZFsjD2FiDdd$Z3IyO-g(hh=tF(SuOtfk=QDD754<=Gr7gLx)cESC+ z7NIJZ0M{@V*vr5LnKfiy3^zx9^Ok-seQSU|IJv8VK+Ml^DGXdY9~OFtBh7^p{-(O{ zv(xh)#^y(F_0QQ@Vx=m(cg@lu+KFk`RW^^8^b_C?`YHAfz*rdmPq+i@TFIy46~kpW zlN?yYp6Gq^ND2%PVQ{T*?aYL*{WpGxFGlF}5sXJ{=#_Sa5XqfWuC2_N`^}vO&E5pe z=n>ZW^&Ai}Bv|vTFFZS3{pJC257(wtZq!v*r~$;PUz8nx%fUK5ixanIFOUwsy94{L znAE3`!@7G6Ohi^l>f#lblBQr;mvwJ&vl5o-OgJ1iwB98|Ve(ZrDOa}o0rAAmuE4iC zM>mOVwn%J5bmq1H@?jsru1jJkVw)OU30YD|esN@7+`pIrng+?!0cmdM!I@NJSUhJN1^$(dDA3 zAWyQg`AX#82>_hqlmrYsJL|zrfj2VESlQ@M(CU9+3Z4{36IG zVaiDm0Nb;$PQdFh6Q_y@8o@s3kJh)-7UJG5b#<_t3oW!{g-K6S)M zr7~N=G9HOoeyY58tz$rTuWfiYL{t6hI`=13c}r?$EKc)gn6Tae_5M&f$0F@1DL~71 zApfQASHhN7`oR}@={1{dRZPy4IF&CiNTlYA)qwNJc(SHaOzI{gBmA)x1GF|`5qjes zVTgyB{XgUc)Q50g9WZCJ`Rf={m)pfY85BuCb3Y}Tl9Nw5BH2!*K%vr5{m5JM;H!ZF z9nzIx3^Js$o>;I?bG<^So_d?wBOkDB-lgaC(_?&Pm1yaTPIw``2(005u?h@g%N$@Aj?1i`@o00000KmY&%fCXhB|G*0X1F?(% z0003-0000W0E81Hcq3I=B_pqUknP@vevF}#20W*U>Qi{ffaQqb4UCSNYBK~b%j|5k zhK#73*S9hd&OGNl5Z(y4g*-VIqJB-2PE#@Q7K06N4}#0RM!!Ie^WYx*9TKn&VDx#e z9)KRfN4bnpq}04|?Q;o7AiH1?62acYl=VcVD0sm#%-G@BqTR)e{t)bDdC>N#P|{tw z^+5DdoB%NOE_2xy~g zsV%_er3Gy4T581;yeMW>+RH5VHgO5w7>ueLsB;94f6=|7Gnf#*nGTrbdD2SxvtkZ~L0~56@t#U*AX}^<$7uO3jZ1)rlTLO1)rB%6*I9M2u z$O>*zuH$O{It`43j$gHhKUSCv6AHV$ZrDcmQ{{tM!u9}*D9C8H%+fqERPPe(On2}j48Nh7A`!#t`8jOgbiB#oS<&2rw)E`MZ2Mb<~ zfrt;Jr)tB^0HQIYk?d%%BX`!REcfRJqpn7g*3KDur18^hc`vu#)TPeBP3ZE z)zIY}_t(-vMTEwTMx@8O`2a|E{!oY9A1}weM9#$)CdbgrI9&g3RYDD|k#BWWVJ!4g zk?)08Q*tns;4{n8H~OD5N7!l3r0<-l6vA42`rgFiZ!BDUbzdZl?`h!IfVzog9)-#x;;&%a>l>p z8<}7(u5x*Hc=TJSa@<8VN0luGfGCo3avoRktUh<~A4sU5zOZ$hu*%UEGMFZZ!g0~2 zm&l0PnMC}{FfDF_(HnAJWKwEqZGdG)0^k7=|A}~t^N+}{l?bHk>NC|Ser%Sq5dj7a zJ`UC@-YsB7i43w=jHXl1C1r_$=%h<02=-ZL*|pr)5hf^-GkgUCk zn=DygbMVX>Jh4bdfO6j~Ix?&Xx^6c0$V2p97toBv)2LA+)o9VQ?NEVWY(gL0u9=yz zn{g?i$qM1I{k#+g$UPKSfdWWq&SzNv&>(s4phUz)j2S2+j`=ds7YL;3rQuH#WPkv< z6g-ttiICQ=7=lqHByCjO3QtEbUaHll6KNL8rc@*)Zlx>dnEa>8O~-d>utF_6Tsyf@ zG+d}3NbMqW&G+^JGtC1+r=u-dR|M=XjxE@Zbpm+VMWu(4>MUxj3SYg;f%^txp5+G{ z8frIsj~v>ZkE_19iDJ>$^}_N1Z*|Yhbh4n%6(?nTgcDzFO-^XsW*|4#mCVKU3xs*h zY>iB>KIE|@i!7*6*V`gA0OoxgBZUq6DIuaFx2rpvu~wGtwfv)h4quZ@pG0f6QW*&)G!svqyd89zPK?^`Z?rr=*5tU$U4Okh#Rm~m@q$7T2#{& z2+)DX2rHBt1D6`82IG}b)+T_U(Y64P1eHe(&P1R%5lG`F)S%)Rg%Fsu$3~olh6MSY zeQ-jyfPqOW0N9poGg7`(tgVHEeTgE7vOc>d#vkaxtR+uz-fFML__FEj05-cs+-I zIS*st8jQE812_!47Wjd$E@H~;O0a)zmtWHsTJnaiB6KI_Yr~JrEQuav_w*6$m6I-&Bb1(Zjl;GiFNHS8H!$uUCM0i889(I10Us&vIa&H&-X}8 zl#Y4&^7(*8^)F)2f6U}V&Rs2iM%u*BIYhZW50g^Sm#U~_#kN}X+-aZiSzl2OD>;S0 zSS^n)HC}-O<3!$~pxTtXMf4;&Ie5z>B)P5V^m;F}5ZPRi|3Zb68+706gSUyKrzHwR zpQ6v=d13~c`UlxxWxgCmA`+}mYGP_J6lwlxKX^?N;~*mU)OtB|mDI<^Dbe9SQ@kNt zKEb>XD-|VetC9jHD|)0r9PFi-f*D3K1>|$) zl|p7Bk|o~X9^zif4X9YK&JToV?Z)?NWiU1*=?BTkuD^#@UiTJUZd86xU^$0n#RX0? zVO`gfAG-r^mZ_44#OC^tJEED<==#AyocwuGQKK6r6U}m%+b&*?lGgX@evO?&1@f`7 zXJSmNW#7F)f-fg_3m3FZLVj4-&Mp+jngsKZ%u#=?M?Wmnsd8_k%6kk9BAj_WoO?JI zpD(d)$W4v&$xYEEV*{YrnQxr=-H^{dX;vDm6qKEzqNI+~GK&W+c*@dAm;95NFmiOB ziJs)f6%P=tkO~!ccaw4}h&6z~a^l$gmk(ei{qZBkD1iK zWE2caN?ZQ!z+9N<_W@5ki|NfEGL+<000P-@#)Vt5IK%Uny1svD zbA_ef#u0S$>iJ@4TW3nS;BfjrN!@$>j8{Lw)={r2wr;4bX(2JCct-5liQ|qYwf+=4 zqbgPW4Nrwmy&pj;eQI!Q(rRXb+f`9FToi11`{KVgrdG=R2p??ePTC8 zlx?p#kCsoiw1RM@|CXEYF|F!Yt3gSfv>O|vj|F}vGqr=mtLb+MNx!qmOZAQ2P8ZPc zy#cmg-`_{DGV%c3e^*qKIUYoM+MGC*@i?_Dq%f!drkPV5@3rsN|CNX}cz_5$kN}Lx00S!n zG2n^~oPJ4~%LG6G|Lc4+$N&HU7=Qo(0sssE001r&(0~{K000mG002M$5@xQFKU^nB zpwjKRN6H_v5>KKu{p{!6+DcOtY82?YLw?-Vv2Z?u^ zc5XiT&pA#k&aNH!3GAG!?AqB$!+4X^06Aq72TuU--v8L2d@%NS%1?;a6Vz4~D)wW~ zt=T9rW#X~PBi`?M5@e^V!8G#K8|BmqLt%PQRYOG&J`Xb4=tzqVMXvC`JcL5yf5A1G z8wI}Tep{!K@Sm4!lGL0&#!wKLqSAR&LE+hg<9wqH0Xi$DBW0U*w=9xy%sH&-#Ad~Y z@FFxr;s26*ZGQGhfaCuR=2aqrCKDj*V8tT6*EH#Pwt)dwhN6AVQL}kWJb*6;cjSO# z-05}5AA-d3BJeJe#Fb7_JhzijeeTfBFo2pV`B{1%)XWlsM z>9Us*?mN-OiChwper4)S!J2Or&|`=CV_=iI(pQ)qls*`vTBfGKgaMe_*gQoK%3?l` zavUQMl4B|p{lT#ru%={JC7{tu#(S_u!9<%>cLCju#btp}9x|1|&&Zj<1>RsKk^G}C zM{465iXxY{RMreRM;1eqogo_Uj>&vtOPl;NrG&3$GE@@1Xw;w8)d1B}wvB%00vG6zx96irlF_ zEL<$v7f*^+?;;2upweS$v)YECyo)avFB_)7O!&-X0wE8(QW(^wi;q#XVf3s^R)M5o z%JF!V&WwS69fW7kDN;#a|_zMEo?P9MpUd(}sGESXGtT%53&bQr5ndTvmNiaiG%CBYCCnU66K9q4` zIL;AWxdQ6^a+mboQ}`}7u0dJ^x`=tJVar+HvE~x2w4@1e9Eph^;t$&{(F+vq^h-i! z?KE|GfID=hXlsBKjJ&T~8=$M@l&rp{CBkSl{q!WKC=t7e`t`}^2}4EJY6?I`zD?CX zSa)s_SUtwY+lGO(5%lj-^qUEy{7_|S$K!-lg|^U_$;@Aq3GD*ouSEPYgV?O%Fm;$$kAY*?crD04A23Xe&QBe$bBqjg?Djx9w z=kqTk7|mq@Xs3q$yyIdS2C}vixJzI(Gj>LWHiAjPq|?21>}`ZW4zPg%nC!413>e0& zx{cn_0&YtvjROakC+^Zu2q4hN+&CZ@Oq~? z0MI~1GNNFH(wM{wt=E(mLua#?p*e zjB)}$Nr66s+!4E(oLpmUU z;sTfkOJHQglE!xy0hWdw2E^h~t zTRBwf1k8Awng0v`K2QLqH~6k(OJ zD8Df=5XgEq{cQ#%`zikyS1B$*8G)6|I<0r7Ei!g6_I%8;k^!3yr)X*^^g8zFU?8Re z^o!$l57=KM-dW1jFIJ=G@`=ai?*3wHy{9{pCP;>4aPG@z z#~gfOM)@ZL!o|Uyn#(uiY1}2U*Mcov8AI-{Qu?yKkNXr;ARnstM1TA?k4UYBe@FbR z1ZQIlWIpx87chz2Y>R3Lodp{Y`|QJGfb_o8o;HV*fE4PyNloi#`eDz zVoJ=`naGQKGPWLOIotTK4dUPV)}~ELOX?4tk2~~yukXa$l%tJ2N*rAHzTLSeKG)}| z!pu#}>24EsGQ~c`AqAVIxl&-vbW?qoW5HnM1#-(D7Xz;4+6&$Rjvi+F!ypkK7&lqY zTj-pdkz%NvCssW>dLI;4B}+dXjDX86!T z_H1ai256G)y5Jl9%`OxA;Y?1E&W;x)+}4XX;!ds}A}3DPSqC}RJr-)GVi73Lbx^Q8 z_Z#3autcdM1l0gH)OchE%EG_FMl!@f1d)L0( zPSX%}Wk{Do6Noa#3~`|}5Y&?iBq)M~D9!;u0mvqwj1WYjVneLS0Kce6nVmX-d8CI( zVE`)B0+*tVfh6lWdTb@B;gX_^8<}0d@&v#+`}f&EW&xrW%Yr2hfb7X)VB9Ls$x=Dh zaIJaxFC2i6*U`=4rXU5JI!KNP z?x6OkRVu=RCZl3(VLxj;wZg!i%7=MXsK5lQqgDYR?Y7%sk`q!a=%6Hn^`cao)PV3e zAPzhsWY$+*rr+Gw+xW~?$>43Wbo)^7c<{ct211+|3+T~C zM3hVhm?ADVcHPCXq9dqE?a@hOmvJ;g8=kT8(jqbJ&ebr1Zt22P>^yk*%yg1iH?bvN zbRYTy5-ghF=8&iy#UZz_lad6uY6)y~jKw^9dcsGO{-H6dDoReB5uRm(ix;FLFijN=l{dB7?f0rGhw?GE%$DZkB^v%B*xQTb4XQQa zNsHX{_&|`zwZLeEnni85rvP3!-QfDdl3B~|F&I&Y)zPRSqfP2*l@l)QVUE1_Wc2Fb zmHJ$g{bcsr4(k+~#1#l&2bZ}ZfUc1VHjvmHuB|dnn`=vg#3MXdwhTmO#UI7iLkPD9 zLMSIxgbO&xWGn_!c}z@#l1pPO8bTJ?T{2)iL^)!Xx_Uwa4^)T+P5>exKmlL&sg01R@uBuzdF@Bjb-oB#j-h5%z0Pyv7dQVR6J00008U;qFC00c(Mk@~hPv`)}m zLpT(4S{pY9klSM^IFd1ZG_2$dOI;fl8?7btbd#a1q9m!bYr!Yf46FC2cR#Fh4-}~^ zP-m?gQe$)MAcV>+S&AeKf;Yj*P(rpeM{zrb1jL>xzU%+F4UA%&GzCy@DUnABHcQ75 z4Id;*Y&AYy2S&?&MEA|D_w{`s=}@W#-%4X>BQZ%bwCWrnYH4HDQBgZSL1puXrSmi} za-MyaQl>JcE+{%PoT;IWE7j!G!L!AOk88Dz*VuXI(AqA-KFNB9Rv?bRVe^(!$AP)7 z*oX7wF_%NgZn44H7LWEp_h`#9bZ^ z%c7lauMRenPk)4ykVD}VdoE$dVm9Z6^Ql#Tm$lc+&75QTOVg4?4r!q;`L*+mU*1QS zM&7EdB(&VVqNFxWnMrF@v7xAv`me<+}qeYBNHN?GaWLl^+=eR%d`U*q-k6&?;ybWs!=>13Y#jr zm{zeG9ALnreb#5K-?pq%VViTV^aO{%IBjJf{9VVNcO-yiX`G zO^t$XS7;5a&NQp;{|fYRaW5KXxB>t8a61`vx$a(Zy9<=H@e@2gRDW~QUMq)xR7?TU zOJp+H;j6+YuPqG^+pY*`^ikJ3BwN7mR%R%h9Qz`T;vOOw=JLn~?qrbL%P5);ZJq%t zbWmcG&Q@gRrU@gm^SfVBD)z78c0IHp%uhvqx~;78-PGT#=gTS7Qhu2?Z04(`zUZ!?Wh;46m2~)YQtHlbplOYnZCujtz8$h|*0hhL(@l^E~ zJj-JiSUzu@Wz6%NGGt{XY=JwlQZfcLc9qN4TO{>Xz}7u%9}@a`6eLmnc+;;ktWBd3 zp|^6z`!N2l7w|15af|kVf&78*F-%Z|bZ!y@Z;&!zQ4uBQ9UNITXJkh}%XaeYj z7(*>R#RBuje`jd%AjUBuN|>I`#)N*JhB zqYGGG?Z@6G9NFYig~_ohMnoKiz*0t1*=sbiw_Am&&B}93WUtv)%H~ZVULLhc`M646 zIK2`2KbFPZc!8{Q#KH0^w?>Gsjy2Qok5nRU97U8wLS!gdR0We7Vc_NKa=MWbMS5wf zOQjn}W5FgF4<424$<|ro{Zz{qjyx1yY@#w}k9;01Cs>mkD8HCZN@#W_h*Db*po$Wc zLWH&d(DISdPwT#jhp?JX)-D}L(y?@RgMf6SsC23{5+W@~35WC=nLP- z#d z^QIMCok)i2v@fug&4-6`Rid85|p4> zdy%ajsw#F(V`O5-^MFp>#RdM(hH2C1Z>#%@5ulsy7nIA0krIRs<54 z29{Gu4C{1skK3%g^(!?uB-hS3p^j~?h9h>TeX zJaVIcxNxrl`Ha;tX2cRaAM7PTj_Y2VxkoANtR5JM(MyOvPE2Q+|7^T-47=)x(cjNl~%ci@0LEc9@7Jq!HLX3fyjC4T9lGay)q(O zSUh4*g8T)0IcuE7>*SmARn`_Q5hI=Z<&2)F+$HC@L_N5@IXxv)-09Tv5V?^v{S)gt zuH-6>(;)RnrkfE}rT6Bc*YB#ay-Vi)!j4(6$Lutwtg#6ToJX3k95NMLSbB9ckzPsY z)mZ?;3*g00bjsAVX{QA6q5Q=Fx`PB9{*(BAu0bpT&=8|tCvcvQcDbSxIRJ_#jIzE> z_4z$yd?Pa0V_EU1m@>y+p4|JO*sVDuH?UaYFuc*h*^YXH$5%BmYtw7GcTM?wAa@%y zY0jzWMk8S~?(ZV1v*4ziPZ?izT8-BBJiSS6epMrt!5nhfIhFk4l(lN`u+r(WjfcD@yV$N5OqbfjwBFcETRJMq#OFzcq(PeQs_>s#_o|aNw^u#AIb_q~ zmBsbxLG@R|mM^trKPA)AhsxjU8Blv3ZnoFm;`FMoAZt?&5^A!V&iP^Vs~DGucYNVR zIR50urxCB?LL?+S19H`xx(`Jvr`&ZP8a^IwSzB3_+B0Lbe=x)Q3FC+Fs%qvrETz@i zH_20KG;5WEKrP*KZ4UFq3I;Q=DMG>gf>^YTGvbt1qps!4pD`y_=OSL%$BfGG z75+vz;A8dVJrc|9@sw#9Cp#7hnSb(@OIA3wd-Ar_j(@_M-esZ8sEh;q!-5XyC4}wB z$RATLgNLR*WYx>4IHN;OQG?txA0s9+4=JK(r4hY=?aLGxMNJut&u9)opx)F|vXPnB zd0XViEq7ZpqR+@kMheKoQ^gE0GksH{nqIA1pu+}VDX)KMgv?!iIMu?LirL>Lh^#Sn z%Z4yeAo0UB!6dKvEl3_=bUY~PM_MC^p1)G53Jc@HgxK_H0OiQwWB?nxyv@yT3))!U zfMiv))qq9E(k+`VP$H5fLwB?)C1H&NlXywi*6&}xgZuDlPMt2Y0mQZtN=vtXN{v_XD;K5h!=0cel!B|Dq*{6)7B?oNqsS|(+>+Uq0<7dbW2 z><8^8OBg90q{Mq8@JDk(8fg4<#=xmuL9 zy-Vv(W;8Dp#V0adFSv{fsoKkk2Hrm@z-s}~jlR2HR&%6irmY#v+=Thd9mIul5<`<@mHtrQ#$FwNXTeuo~|Vy2UWUo zVAW3>eU;%82@!TPK}|1B3|1wQj-Npsel5NU+E;$$F2k{i&xqf(H0no!WSQUJNYV03 z?<(WvZDI}nv6Gr7`Ql`k9KxfbUVP9)Fvv=gZRGpTh(o*H(a?orDhG_m>ww7%CC%OP zj=N|!XO2{bFdp@gxx8JfLLdQ>6AWgw+`%m&895IU+4q2b#83$<+c=p8P>&JDL*GK6 zy9NOGx6$*zOoa`m^7(}DfKe>E&nx_>?^rdy*W^^|$5#cm0O>z8W#`+;Z0R#O=Nr7+ z8SZ@Q{xqCCIeLq-SnNCxWOW0CmSn~nN=SZXzD8beRA|CttAlV=aZkI0D#%BzWBsSE zv*hBjedo)|xQQZCHREzoJ7a;)SZBta{Kr8fC~{S}VD_ia&be;~c!=KG;_I7E@saVr zpqgVF9M{h3_tfC!2%E7x)6P&mpJN%XQvM99H9BF8dvbatN~G=2^8K(#B%V_#!%9Z7 z*dmijOG%Zz6vH&-B># z+Gk2W)vSvX*49>4A~@Xr*6&wD`inKmR>$+*QEvWCOetZ(dKNeK4FVd_!j3AE#U7SwC{b5_@iZ5ZLF*I8lNVLPFQuGMD=swTe&>OLlN>= z;lj`tOAPPNx?fU&321aPDraoljIg3kW`nT4hD|2S5e$vOEae9ry(KJ-MmvR~3^W*; z)E!JR0;zxH5;fTLi!YQ!$Yaj)oLtFnLm3oICD@r0inYqALmrWPvN!_dU*17h7{%nV zAZelkJ4!1`K89_8vwxP~l0SeQw{CCNKA>V~LM?!;3&$!^da;i09DkwO zh`>Y|A>JT-Jhz5q=rg>atLa(l4vsv*++s`a_c+5--uRY1?!Xb24=qhar3FdyJ$;|) z;3}U=0xmWZud9X$`!KxoOurf!SaByTH*Z41qRTB1OP6%dVo~N?Jom1B$n_+7N-lALrRMfcQhf5LG5>S=2W*4gqtBVVKQal z2R7sL@y%($<7Md%>dxhgLmW(Z!vL{w! ztybNS<1{9&@`fRz9B{63@LZu`duog1%8cx5rK`F1+JvCQEc0RHHr1kwRzACDj@l0xH^? zw$eS5%YKM`NIaRFe}Eb;rRATum+Bj(h1h^fiN@i2bFV)g&i8w-(|QRRtYJ9~*i9<_ zU7g7{Q?H6FSk=zcdPMZM+$}%)s+U4sAH(0ECVElC`H#7da9nsdHm5VboxbjrZ|m;k zW9b#iwoYujb(w3wMAIV7LA!SUX38mVA>^mJ)g4?|X)F)@2B!@_NV;G94?S)IT15a% z^dztTA?E-9V0ohdZ}gN9or3_pvp5V;IWWXp5#^VL_J9Zey#UZrC-3AqrvIgUC0w-V zNgNwvcv*o@V(c;GU`<{^Ed9D!nDutX1s89hbMz53x|H2XdS^T-SwBf$rnmJ%BbS|R zafMo=6l$bVIq@n)voCGJZG=>+R9)#ZRk}cLabT2aAK!iZ48=hw&>RMv?Y?0$D~1hO*2ZVE@agzXK+QAYby64BJ9O=q1!36*WXv6Xgp)`9uPS9-nX0#I zvS3j}voa+p`=f-*0yC4?9+mhOc_giogI z|4ycrY)V;d7b>_i6?<+ZyzTN(hFTdcE*o`oo4(6fMc1f0q8uiORTrzCWE@7zcVEiu z9+ecaIKVbLC6eo_mggLtL@UoHF+bHwxOI^mzIZI-j$1ubU}2hUGs!r7|2ZSTiOHaA zCqTGNgK?TQo8UVvqvn7)m#?zuZ;A?n;Qcf_)k^6DEB%+h^a!$syIeI_gX;^7rCCk8 zcysnAS}Q^Ec+agd_SH+e(sYs_*}DFL2Wq9{JcEAuchBr8u{jIhPm4yoO~`Ss;%cqz zPCS0qP@OFuwAP|Be;Jf5>r&jpHIA`aoX4+AnLmt?mkAYM8cU5Ha5opQt(||{%mMZ# z%DZb4nGKSQW;uIQh{fr>jlcf2jdq8UUuwYN-qQapm`%z2dW|<~crR5j#OcRoxs^U~ zu+VPh!L5#VqpirK$wtzO`GZUoJKQdjGye1dn&k0HZnlJs7u@&)J&Pp`shp4YtPctG zux1&GA#{(xZ2Jrkq+-R7EsUu%b_zft&{15Q+mWdvRvr{eQpVFNDO2**?Bou&YQ`kb zw6~;ahC#G>?5fyYjkEYij(Hd2km z0ri^lCz0&~OdgZtXU2Zo4q1~YsdiaeMsW^F5>jVk z8n2ihv53QH@!B`u$*t_|xl?j;?*`Mi(p%d!jCwNNJFuTAEh9!oHK&CV^o^cF69jjp zlzsoWNH>?=#M(RHk}1SKSj@y-@fa_rs{FJMmlC^w-~kxTgtpL*CeKPx@?xYo7oB$p9TXkQ91EEfvR-B20kR82Na|j+F7CyaRYxI)y-(j$nYaQk>VZ zQ-Jb~m;|c?)E$CHg-mC5u$fQ5WCLgl;`g<#S-=P-2mvt+2@If#-7)sinEfxorGE}I zsQ(#wH=i27fS`Djb7JLL{IG;$Fl#`v`Bm>T*QCqea>kuKA{x!qG8g#K38m&>v|s)@ zC?Jwj70?JvG9;uvFL0Jkq$+bY%bDFleeHG|1S$tH2;BxTb9os!rSjQmVM%i$@6k*i z9o(O`+B}%sR58_I7ZNvx@~64B%C2|=#B%M(ER>d<0wXOxR@n@7dZ>G1T!Yu4R2}0m z`;16*-)2AtDePX~8+!|ny0&VKJ(T^i|41qa9b?&v6||0Ym4Ad@66$*5b4>0OqtJ$F zcg%! zV^Q!H42#~?CIkV#p^T}G&}w0gmsfsc?6hKj;=3{NNz!a6d=*FaTr)q1m8E;i^TGoI zfyWB#SEu3Rdl&wTbxgaA`3aX@<9pXddW%D++U z|8%`Mu?qXnLE=qBAbx@szla^lwR;EI1?No88+sFyOyV>@bn=qAu(f&wqM; ze=PjU|C{=RE4R~(w+#jz&DxBxXnrLxr@s%!yYNhK-NQDmFg=0tKBxCC{2a~ni|=~h zc6W4vo=0k4ZDwX1zBc&rt)e?EmF+rkU-MO%>PZ&i^8#z>g*O6My3$>tqYw>Add{1@ z^=wex8*UdxZ58{1oNz!Xs%@0@j z=|ZW+0i2JlS_Xu43T-SYK1|aY;ET*}5Hn+Qb-9=wxFpGYOtjc48Oub?@Yx*mTN;Ht zP10Ee#5+}t9=lQXh*3LN#bcC5);*vURvOfIY3!`!!6+ijx_ez{+y8xZRLPs4LWj~n zJww^hf^#xFz$y=jw(M#;eCun0U5yw(DmP}IjqIJg6)-^8DA92SO*y5P+p5?^9H z<&%*@L6|X4$*-e`9ImO}6YJbEocHw;Hjuu~+Sgn~4Q^?C*t~rntm*1i{#C7yX8JzVAs#-^Qmt)e{cN(CsFzY<_raQa+xfYc zTO(ARiABQsr!Ns8`-b4HY-#^8<&c)+XSbi#AWLj5Vj^D@#*s*Tfqmj%1ZRmO6Kj##CNnmh zTXhWk{X$5c{O2xC`N@=_krg}l`qsjX1(e28*J~~&=8tjQZcj{rG)`{oChU!rn*w6b z`AVzV+m?@hkLfK!=1X07L>7M8!Y;1%jMehz+tgLkJ~!ry7jP3lr`9J?Vg8GXy_y^$|>*&QHV<=%la{p(W7*py;rqa{>{fde91pH?-ZTV{gWj{ul zgOa*h3HD5K^|Yr-5}YJ=N$wbann;4&4jK3{oi2h#J~2Vd;_IQUoDP{B2kCO3WCU9> z{3i3RrFZaVj?_=iWsiyo7&s)gMvz2$*a}ZPR(;c@v}-s{O_vRW-~DblYi%zxxq-T6 z{0@yBHS42Q*&dk?+fYz>kXB9-twJna{5l(_|G<`lYiM z|J&9L6nfm0A$5X{UU5Wnl;>&`BhFyEieE=g4t;h=vcEKX&fRjHtHI~HAoUn z#o`DF5Mck~so0!jg<^O@pES;}Ge<#~(VqXGVW6)N|2+Q&6&T@;a12~>RogvBAv_KY zLQ7w@e3o9ee3Ew%TZkA$03v)2rDi*a;6m##8dJ2gQpR)ldASb^Q$=2K9gN4ujgzZD zV%y6~F%dC-G0WnwoCKzl-#I0j@a+>4QcBP#u|bD6`B$Kt0ytDR24$<#zil1HgyyQC&Mr61c3{eY zq5J}MsNvHs>Wsm0s1ZY)gR?;)|5EiHv{G1eSGe;dm0{}#5hsh27ZlxX)@2lp-@Z&+ z$J(1LhPt5Ej}R@J@e={STOztASX)|V8?Kp$dbAH&&Bt5LtQ=ICD_N4o{LM#hwfQgC zd=6gZ^PSIHlPINks%gIZHXQ(S;EQsLjUsv6a$zmKEs2P#u>To_Rh#OjBnJ^=i8%-T zEC-to*qb=jQcInemE>-)2?|zWGUXD(dnFF^nV8DMSn}Z)t^@GaJZ`m>fEV1mN^)#_TIbSB)tCilXZQLN6LcDK~d`;?+=M@M+NQv zTcF2eM>k|vH7Gjl@}GS+Fo`JtPwoGfk)ovp{@r6^kWS>;hI|@>QQyI4chlpE+b_5k zVm`-IdM5fqK6O8{0>KT*Rmc?z?s(z!NzK*ibdOHD2`JLDt~XXB%n5y8TG}^VnCci+ zr)M+La*#f~W>mSy>O3h?Yo8BW&FL&P>wg*{ua{0ww*!t zXH2$Ea;@B{2t;>+!L(>(h&|+nmH_>GzKf1^& zUUILZH{YBE+a!;w6jQ%iym&2lQn`Z76J{!8R# zh>b(bcyi|p3+q%0C3^yQE=TV!)-L|Q%ul#q9pb2T=#`j7m3{=5mB)~Yn{rvOJd=Yz z5(*%#e0#neLZuIFL*mTyE)$NGf5`S9lrG5f%wde~Kf9>*#c7R_KD@mKpWnq6!-ap_ z9xZVwVl!c&{C*Ddm&0wYOl>vgHoq(1;77i@h1EJAdrRmphi`DNU#3gLIxX(6MCD9= zB6l@ayzQA!92qGM-&nrYkrFVd;1hdlJ3P^#vqf*8$Dn`JX$K#64&tvSzcDZHa|`Nk z%Gjawhs!U5g&4$P15v~W=Z;qPli3haeBeabrxuf127O@tN`vi4k}~KbsA+TPXq(y4 zp)(7YN-hwYPEEk9fX|96(&5RH;%71Y?EKO>C}y>k55>{?Q;b>Qck8l3L3k&gTllvx zQLh%}R}TQahaTMDr31E|*_a#l4r!V_9gg8FJ2+lmYxq(k^Q9`<%8N!gXa-03d3ro} z?dH-&uyzUK*XF!UIf_TK| zMYz-;gP32;9J`d(smw&{wD;o2i1Ah|A|tE|Ff#`$&Ec!_<}BQL0#M;EgsV132$fcI zhj?3co6g+MSnXb&M0A8vX|v00IgsPrGO@&dpH7Z#L&r=0YZja7eQTMz8%}s)3vWMG z)eE`+?rw(d;P&jEigriL7wkXczf`(sly9bH(Z)XCBcQt8UuWzCoP8V){&EBTW7o+o z&j#sHqIu~gA-+ydXpluKS;$3sKw}3$m!kL!10+cFI1q}4-WK|-0yQiSz)FWlrv4*a zf};~TAgB$KAl7c>{xVs&!gqW@^@gKVPsg{1P7cL>yW#b;eLd_LMQQ1IzOv%PDWIT3 zU`xhxVayQ8IwZn3RpZle8HE-E&k=va+WPzzYsu6}n5y_9b$@76fxSRC86^G)^;K^n ze@Of6SNvFsk1@Fy`V?~aEQf3k-mTuDL#N$ zHm;Cp6@rtUH@7Qmz%kdONKq`5j&C}I?0rJV-jqX?7NOvLGy%z12R5vQK~N$$Ge@To zC1wOPQ;9U${qV8z?6&#{%uj!pgf6~)5nKnt=OA<6~JDne+>E6>rB`5rO;KQB$D~<0sQ!CuEXnE!xeA>fI$hfd4 z>T(?)2UuI-a4au=@(U{yxwioPFkrg9=Odei^ev^|x5`UJwPFRFcpga7MnIS6{}>dF zD(T>-e9kxp%Ys-jDWAp4^To*hN?X#>G;+JI3-8%#XLh$eCWs#=6l`kEy4bhJe!fq} z-Uo`6duSejZ+L*}!W&L9qs(-Vzb50cVd2xqPWPchMo~j9Vpf?=q7CERkV9w7n-)=c zg9eSj05&NS0wB@rQAuc^aR5T-5uRM|3d_IaKxi8P#J`Y&g_F5rt5u;&SmxX80A9O( zX9!p+iYAI{kZd4oAemVO0skH|2q;E^Mpg4VTr9KNaE2)lOoDXPnf=Kp;)lYmf?{^l zns|y=%s*Q$Oh*7i7Hw^k>}tI`bQ6NSflSPleT1 z4!kc$IwC~3-bb17tZN+pf#Qj5da``Gf(ZjpzZ1O3cbzqg?hsWJTzD}b_;QPln^eCd zRy9WMHg+eKJ!gwS1(UTyAyi1@*u|||Z##XBS70%rVmRq;Mns!@m&FMa+ zp3S(R4MZ_!cM|tIpZx{{)?TvzMb(b-o%*$ur=h`+a!3MZANZ~xy2`&*4@3P$-o?+(Ryho@`J=VbRcS*rZgS`-#0C_X zkHEVPouFUeTIot-9(DW~lyXtJHf#`MdY*{a=`4-lfAL+M7-gr~fH`F29gQs1|CByr6Q62HH#uzlMC z#%5&N;SDTQX!DDE0yj#uh-!?8O^ELMvTJl?g^nO-0y6xm`vn5B&5YCyS)*nvxdWI4 zf*4#tF;RaHc=U!Y6oBYZ0jgcCz~*8{%@@9v^DSP=g3r{#Y>h3f5L=5Wf zywakiGHx7u(fm@OYc{pGPfuO!o)k@aP$Z!>chC(EtHbwSyZgTy1Xe!6{GYpYwwh7C z)j%<68x4RNvU2_1p1_F}sm89mSKJpoK4#XNLyoXWNUK@?iMvW&U6ol}K3~Jk^cm-X z`-p3@=VkSXhD_hC^F%@k#r131?xwBJMkGWNQZI6jN4A|QLSkvO*vT*B=L*Pn3X?uW z9FsrhBsFzQa8{!aHQN(SVk6g_%VE?eo~umarzGC`pcD4hu^@zFBhops;Y|(2bJUZf z?N^^8f+Z}TgWen$NfIV)MSkC}Z4Ei5ZX;robi%RZ^pml4((}crWUBO0JIVX4&0*EB z982$IY9T^h1%0-ZIih;iRiwGMFE3~*8$^sz5WOL}l#6n1yA1f9UdT$TSm1FMPb-J# zGU9|AoVLhWg$ua)v|qK0Kp?^FveqysxA`ynZQG|%lWVSYxAah;$|3m+XK zxPMSRRqVC*WmUT${ha?i%QT z>Jhf>(Bx@bYoG&Nk2NIL%6P8zhPqoB>V0a2?HnhVF9Xu@$O+m{UVgG5JnX~%%t}ax zB@(2PX|T>`<+M55M>Wg$R;qXD*Lp3>i+Xe3tudY zMs_n*N&T62g1VV8WK&0GbI-m~HSvhuJMS9~_a|kinx~BUR0Z#{sCXD(a>0VC^IMkl z6YtF5DDGZltKGcd{t@4_Eg%q#P9h=;H zxfd0!xP&E5Z&ELBdJ5aqhzo0pXSQ>Ae(9vU?aRn?w^KH1)U-=;h;q!iCXIDROYB>? zmMch(#y_V`Msp3-VBoHwL^luXA7f|Y^)W2{*dkuYF8}Q7su_dx3sdxJWrRAtLyhJ4 z$V&)P2m%nQ$l0scU3eh~a8L6G2Fi6WmzNQ_Kw?keg5v=?oVRtyeu1D+gf zce`H|r1{|`7NdQe2)a+>1)s{jeh6xxw`AgVJP_X_Ai$~3aA#JnN7=}H!GLovPDMbp zojSM)K+0utqqposBF3KaTzB`Wd^n2inM}(~`ag(~1GZltb<-i~P{6x0p}VzJ)zV&! zKWdwS&4!xatA3jNh=_-Z_w3mI-Zla5PK zjI8wGGU07=Y~y{`odWnBRr^?PlP^%0Cx+5L>x}NUdL#SGb}UQmyzs>ZcBk_PxQRW| z>)S-0okm@w*b3pyYyoZy#v+3t>!P+|9@wnU(~I1Uv3f&Or4cSOK=9ZI6N6_-#55F- z=t?G_97BEX0S&-Ws zXs>2#Yfm_@z}~T^g8niVa#~4X-$6i|DoJ4^8M*2ZAnMw%=qM2L89&k4SUz&E0+1!( z#rsJXT{sNFZT3wDv%q&J|$k~O7qja$RHJXUuFD7 z5Tr4d*h1-8J<*P9$^waJEkymKHS%IA6keU`D_hh~`Ld`sNjP|JL-E|egSBjlF6~IQ z%P|!<3Lgm=AL)UN{~_(XRgf{{H!w zH~xhsOzH>t_(=y`+&zJ(3jUOXTTgwv3nrY&KZ#uGxb)ZK$6)uXk<4Wa_uc(5u`Fs` z`TabzI@ZDl>!<&%m+JoH#kmo?7Z$1X$yWSUv?s)c65||9MY%17e@9|+#;@ss$k^Jz z;|pK;*~Z3S;fr$HA=mt}uc^0iOS9ve6yXBALutBQ(=k?SzhzCBsAQvhv$2SK$y7q6 zf51LSCo-qOuiv|2i5#VYY)z;>oR+citAgrJ_gtS{doWMUA9+`n7{1vVtztPSCwn{+ zkf6a5P46U1LeU<}wtASj!rEyq5JD@KLDl=N;@NnL0&4Cz;Jz{!bpPt}PwAOwzY}?~ zqJiJzEXl=1AQ_>e$A@oxRy_r)pl-Ba&J`g5svZgd?dDgGSOee?FfIf!)Qy`%hylkc zZ@?x@iH6s4s!!$Dv6~Yh08ETl5ZJSkngB<8U;t#X2GH?fM+zm9z&+hep{gXZi5Rf- z$|nQL77*s*0T58?005!@2niVg)c`aA6oDxR2r^Tr!7#w+_6uTt-AiQ1dI(Okr-eA# z;2$vb2vaR4Y$S90Y^o)aK6#Q3e@-hPr&VN7w&d-5P!9~qZL(=l_q!H6<_w?L&!qig zC*Dm$f;E_tFvs&mTeodl{X_NSU#A*XF0>+9`=5&jj%*xLX>x}T&tz825q{Jo)Y;CQ zE8(h(+3v~qMDkw$jTZDqHX1hn=KbhzD>HZyV)38qzl`|@_AF$SCTa&yvCk%6EI@@N zK)Dgt3Q*vApN)>A-qxz69LBF2%~`2OP|ySlo-uEjh^!NudJQcTSw8imf;tMi2WYJw zkpAAKu{m7e1=ubEbKE)mMToV&c6AfCn=XU|3~$C1IKEu#NEkb;r)`Qgf6|^vpcljD zl%#ADsB0A{686lrX=z8HTQwDP_t~#M6r=0XqJgIc!A;+2RP`rya3(&vD~IX*y$)L` z;+L)ucc=R(S>{#$QH)qN@zQF{b82NJKuwb1ny}?@A=@YmS50Viq*zP#NYC~+-NG}oDB8C(JKBD=g9lR!DHcp!xQ+)$#<82^3E9 z?a6+6Qn@brgx6cEu)?7EP6yr^__)M>8Y}kwR33CrH4EQC<&U-77bF&>i@!0g@e(J% z*e&!?jK9TTp|ksNAGaIjjIo7=Rz*nEMuj8c-&Aih9PM-%wrZts&uhBdM;*2dMR=0f zPRH%pI5HMTrC($$8HZsyTuAJQ-qM;yVizy(B|%X5Gvyk-SDx)l5H}jT2W>%1M=s@0 zX%uGNsBx7C%F?6bhG&k6d18DzJhB1dOoexR^7N;jiw;P(4h@pyxfx9edl2K-s%h}3 z@4JZPVTSjt`am?lvBjD+ zlGb5*9NVo=N@Mm97fo0Mr6y+Z(@lQt=OC-%sExT{Fq+=GY9?~2PSd&=Q!i(WkqN1^ zyDx#EIqYaMd-I*6J!`@+Vr8|fVla95&i{NCE&fyBPC+n^eZ>kEIR8=tYmO21RB&Ex zLDjlp>_7}mJiYb$=+2g{misKa%pp8yc78UosWF~CDN3zC1jX?!9;NDM9X`yet=9(} z%rqUnW$v6bs^ubpR0dg#O)ZNsQK2@!)Qye`A)Rw^RGTT5&tC{%lk1IdOpgA_vkD7| zry^HmeP~rAeo9#qV;;~UFbD{{y6dOKf0Fnk_JZHDB>lKzIOs z4M(q%4`6y5B%EmBc{+SSd3c*@j|O$d#~cGOFr)71JNJL z{UW3<@y3b8PvA=66?scwXn@gs7>S*ETX)NxcwC^Co?H zbw8y3@C|yFGpzf1&*`-C&#UmqHBOWq#dSMy_2Y9b#~jv<7d{e^2n7j+u;^?LSao)w z8ImKy$`VgoScdHg`+=6%%TYN~Mo!s8dkAwyxBOqHX7HISGzgp>OV z?ww}>*nD=()fjJ_pAc8O1Tl217#bDMJ1r{>hqM@OrKgTws#=9_hOmAnv{%A1`^4HZ z@VXXjV~#00$6!q)GlEDj*>WxuvS3P>-G-IWzAjoCs}PY|79ck~aU=HCjeTdfTiKtu zg2poUDMH0GR@Q$7_73_rScb~?jaY_OP-_PE*K9={jLCT|^K zSd;kid*Khj&~|(fZ-UjsF2W%2hCxZ&#h%>jcs{$sXAj}fQ0KH_WGS25$2&al{D*l} zuOSMgNKB#cWn%yU|) z_Yn1N(c&Qz;40l_3X=0-LRt6Q3(yTk^Gw7%lsQCLR6fY>iFdC?ksozh&9>7MAfMkm z@^y_-*dnCC>D2D>O0RN_RO6K~oHMYPx$FFE5{TX-KRuc0(pQHaRcufGcU zKaT%hGXKv7Mc?rd76h-7EbaAxgL5JngA7uIRaPE5G>ErF&CEVSs#Wt!cK%9dCiB-) z1Y?y^p8bNKba=x>e7nli*i>h4<}z?sp#iDc1>SoL>Y#?x#W6!XbMr*U!IcM zE7$xQ*gDs#U)0pFFUl$9v94-PYa#zZ~6oq1R8x3okL4=^pEw+UY+--<_8Pc1XjHEI62U#V zZf=}b{Y9ri`1^u=1)hdRP3J-S7Ad42PtQ$WDvlE=-}42U=IvGxPOCfqMWF+y`dC6ntWUwbdx*B+G8K@ zskG8L4)yS|H53yXm?OSai<5`6U2Xm^SoYvirLVwQa^nUdbl=Lz9x%W$7}PpuHf{_@f; zdTd(gb0|>ye(NJGNMeU3t`}juviHsG2_VhHAdFh-Q7m3lvj0sgYMM5c% zpe+o5dW0Z6M>lOkEO~IgNn_r{bOyts3Bt28>e*fsb#7~l`|f&3x*XyKNRS9&bd}T7 zB5u??b8Q zz=Z&FECjAEijAYf85eHLIA(8xk}0{}CiuvIm7%_WW5bSf%Yf6Fv?e&b@Uj2-yA1En z=I-xA8E0J$`SqK<*OjzY%d_`A&P~|!KY6%qnkMDm7(85ROkCI0Owap`YQqV5YC>u1 zB>$S~qMKs!v3qGmxpW_Ei1q8?jog?7VTbqTOJ^R<``lgP?{w=n)}6EIJH;k1wqe8j z`H2ZFDec71@dR8vdWv-e0>5xheH$N&R!$ZjU4!0@7N_aHG$BGYJzqBO+0EGfsBXS& zc7*z3At$P^9@KUX68|KF!&dR7snUI{k|LhQsEEk9R`HJTP`u`1iGBOn9H=1bOJ!Fm zU=VODINLGaxo7b-qSLHNvU&>FcY26dS!60!*epRpY4PZ9Nct62F|*qkF;Gm*2duBL zzZVmVS#af`t5eGZFqSf23aB`Bx;V@9=~zf-#aQQKF& zcZWqQYnjqb9iN3cLv?+H_C=QNz)8#=ra2SjrbUh0_!So^1^nKTYuazh&3EGq+`*H{ zADS52v^%Z5xfHRU%S#qY25c)*k}q3JAZ6Bs-6xG@=@sS`Jgq9zshU#E3tP@xWY6qB zRJ_VHf|jiwJh;W_3BU~^)0cX1XXAvm{0b-FcQ1WV00Haln zd81BKJwI?lObB{_3CUixn7qVX%fB0mrP+_IWXV9XEyz$uBEw=U_6oH@58URsvf)xB z%Pvaw`J6eFv;;I6=sBqp;d6^dif9lvD>`}sjX8{67y|CFBA@fvy=Qd&;l?pIwWIz6^Y_7&=>z67xt|8s zVY8(dwIA5H^0s0+Sk(fbS5Re=oTssD#>er?F-1FE`6WB65<${7{M9;&iV#U{cuE4#5yZ?%W|EU<*0~W zEMFYugV%5B_q2&nVK!t4>5cm+@Y&4X3pf*uWVY%lIBOzV@x*WUllcwa9}&sgeGIaQ z7zDRoCVAB{7dM`$$3vLVwP$a36raonGd2E>IlV1XCSUG<>pnq4X?#hIP;mee_kYb19mY)BD!O^x=WqyX(@8P<#(*(4Qq;Pg{p8K+0GCM)p znGi2WfhqgYo(-Z1fpw#@ZysC(s5pQj4>MP&1|dOU_Kg!Sb`WvY@M$#WlR7M16IX;u z6y4_p8qUGPyUMuq1q??tT_XENiW9v&FdIwcMANTF|Hl7=Y*_pEC- zW-mcbk?eS0sV2DK)uIV<)@x{^Q%x$p(xB=kxCEA?0$=g6zp86PPJRyyVOPrVb9+)K zp*^d*V(lj6Q~sl}-wK^8CapCMyFS{4#a>xYK$*oWSv(Dc-kaxy3$+^+oELW#0`>DlZo9Q!U^ z$#bA`Velx1AOVctIA&bDOi%(t4Uzxg1pk-)$B_SB{&yjn?dw2|RQNJr^u~}hT9y37 z0tq6N8jIxYMkH+|zJw@{P-?Q1lL(LyVd7H6aFR{F*dRQMOGlszSuN#u#v<407(2F- z6=GpUP2743p`B`#FU|6NTZ*nFppd!7i}yo52f=X>AARA^`74L`dY7wvepZaKG;zIs z)-j>+!f4Xo8cB)Zb52>1>pyYT@GXTQA*cJv`j`1P39mA=F{ zvSg8dvT;^@h7%LTFvxkCM5xXT{Js)|Fh0b+pOxz*vauS(S=v${6qR^- zs2nY*9F8Y}i+hg;CgTgij*m%AC!4dwXC^&Kx-#uPDk2szkT>aQtiG~rhC8nEFcEci z7;Cqi{TXF^_H5qiMQL&_n)U5cNnO?oO9m$o9uX*dMk>F-9sWYi#Yb#u<2O$6^xsDd z-^jXuT$ra#sAo^gMcF*z@%UoB6zJ8jgYkLNt^Hw6I(13U++yI&BSXE*H@N(GVlsy^ zJZ^mH?ui3R;K=`vuJ?|HE9%>ZXBeY1dS~=eqjxbz8@-Dj-4GH4(ITT}^e%cQdh`|& zJxa9bEfJlNAW8`F&3!-5`>pk^^?iG-v(Gtu&iQA~-q-%s>({T}ppAE%!bS_23YZrD zWPiAA1f+n_+R`LT1SA7gN8kDtagJ+`m$^y#I(91(+cz_GECD>0TkwKYGQ#K=pZ!X4 ztg@yyH?SV#f>2c+r6cf8=~IFpe_z`h&%%{5%Ofijbj z0=VE{66RYJIbqlyl3K0M%|HPIOl6prDF2>D@S;|FDVjh>L24i*NYwlFrgKh@R?Xhe z<$uGE3Aj`ZE;mWOl+}sq_ML~aa#j((CtS3Yc&*N}z_os6HvQm`%HL<_)CA>uTnM(I3{|$M?pJe^-%>I9syZ?J`|DU@E z6gwIX@Zs6k`K5}%*#xLJTMVie!TPu|qb`yXV3NiqJvQs8nyxPbDZe+&+5_F;EH=6T zxdo@j;1>(6sg^htm-5srRb79R6DhkB4m@fWd&pu;94;CrZ+Zg6lH&k0($8`^7kBQH zO4zbKZ0D4@PL?k7Iu?A^J>s-qPKtaJO?^_U7XSc+9u(C)_A3AizSs_@{1<5Do7ZS|1^Q_Kf>w2qhSy z7lfZrd15ugUHJn?V%_y=;a9v^@Qv{yrw0sCiDiEwsh%k;_Louo~!vu0;A~79W5v0ddXnt~q|w&KpZE%G>gprqYtqV#cxaPNtwR`~Cm)2L_cu9LwKz63 zK5?ci^6~zt(MVxB0qn0htOd>JWZ7&At+&Zxsw>>6TshqYthix1@9p!lBEta!a@IUA zbJVR##SsUHf`=8Vjc$7bla8lj?S=;I0F<*$I?1nq2$AT zHi(@9&an4IEu4bOhW5!+$#tZpAJuM2w#grV0Q11A+xSAD@icq;*>3rW~K9 zJBZd&UPsc98pSx)d3x#u=0VB^Zry`N$gG+v*h2u?Bt2}A+(7cAVd9*SLnHkoAt^CY zNd0_;Ts#BEh(Mi+0Vhnfx|zdNUCmk)W(G+ ztBJR@H!q6|%9#q^1+Jq)qFP5x3q1jRrTE=|K_4{M+W;VdlEAT297vqlEEf%62jHWz zfw})NL!v>+JC=|QfT1jnpU;2Rmk9PyLz9Ym4m@|$?6va;_SI)-C-Fb)v>T@9Bh1!Q z`?-{sgEV3JXxaXan6-$wYf8D{Gug$ncVuM@n|#6kL?_)(j1*rC;P$^2?h`xunEWmM z&(ncDWb7{=NUS1*J}1urNnFv#Xon+i3K5@U{H+p$;CsN52Wy|Eao*;G=~#Xc6uEfw z=n29+K)v9=!2$e);))DufKy5%wL*#ziL_jW;ZndyyW)Im85AAT25OC3IIik|B8P&% z{kTcz&Ts{2<8ZaiMP02<%v%H(->F1_1!T3{ME-mZ@?9n+=Lvg9HubyMS1`r-%}DT> zq%e7nZ%ys^Bc#V(^RqM)Ewb`yiYU}P<~9;TA}{Ejo2xljLA$_jqbLNH#7T&>{rTGK zR*0PUYjpAVciGMB#P2gfDcu%+%h_}<*yU1&N}NaL3JdOQRP#@$;V-4iU-#K&KsTNP zM!U~thQ2Gpz7vkcdv9?>ImHnj@$BB_4}RkDyNSx+1$@prT(7s6T6wc5dqdV^_se)L z8h{Z8&z59Fqt(C-Y)^|0Uei7&a-}+=Abt8x*>^tkn>SHu%^7nJuC{c9yuf%rij=S4 z6#_NRX=mUaw+j5!cT@3U+6NjTVfHCr;HZZFG>yO-vez zIUOMQ4f?4;Bzu%KMyaT=ZzSZtQ#oL!WmJP1Jq%j)*ryv!kW5@Vw40>bH3U4_OYwP> z{RASY@6?uYcerm%UDw?}{+!$S)XMXYWv*3p6j5Ab_2r0JtCXQwBg4j4m+JTEBLv~< zguKI)*nwIZjn0sa?)5tHN4se5^mgSHk729S;tp2r6cf6?VX49*g7w~2yz;%`Nt%U8 zA8VOJqedQ{0UYX;!{rD_jI|*K>0aX7J%rX9{(ho?B&p;qxw@Riut0^8x&VGCt^S(w zmU2$yP-W(VN4CcUNA}3>z!1qENzZek$*hpVm*`}{rz1#`_sI1&29p!!;(0Bc6_BfW z{v7EmO4=pyXuD5ki{F6`9g9ml+cj@ism)S}q&H-LN;>n<<-|w*xK$zW;Nzn4&;kqQ zUjv|7d4AhOGJCX68a?MEQM6%3j}w>*2UHD=i0QG*C=;t4{hyso0B<)61X4|}@dj)- z{zs4U$7)j$P$~8bU0axrO#_jzW8O!z&E=&DW)cKS^a;I7A`a{4jH8u+FwyVscKr({ zS`;t#&d9k^JR9o)Q)&2C;!#qZ1Qv4R2QLnW5*lrJTY9~7_GlaAimF`WAmIGrpiE*; ztw5;Ke?^Ts7Wi3y@F?%kpTfYB!I6>2n7h=6^&Z4Hun)zO-{I!-alL|r+u_En_ zoPM0kD;hnWt1JgUvRX}D-d2>=>NimbIj{I-P*w^_h?@~-n%Efm1Mi4VSZloaD>OY3 zjc5!hk+87l{k_HWUe>r}d^MXvsk-(NlO2q3GPP?yc?NNuhKc+>n|UKim&qORKTDEh z&K$gjYu13Zg%p$Fg5Qfu={^u+5KYZ0djggmao0!rS6;e8C$Kvo*X@J7f0l*~Q4d7I z0{D`s@x={U%vWWvbE2%`-4sZkmndYV@9+asn}woZf948`a{rN+y)jx>vob7P|CVFd!Fx}q z%2nkJHNiSpqoSM*$D;YGbgRhAz6zgle4aI(Tr8>nPoaHpB}7`1b3LoE_DJo%jxZfC zdr&&mpm{e>=W;tMfCzIv-9>WYdnkBG(jD_gvxiKq@9|f&bZEbNjQ2dvDrvrt@W9xX zw(*KgH^|EAif$Z+4<|8wYWZO){o06`UcLTv%ey0{Q2OAiH{+7))oUvLefFod{ZX)H zzK?eb^Q$UfxVaxbF`6FrKX)2IF>~9&mdm2%79W30u0A3Cmpf)B2Tap8OGMbuT4>&o zwGjM$sRFm&9WzS7)eHj_~7Kt)zz)Rxqg2$ow65u{ot>2#cRAZ zJYuc)y-afK`nBo6pLa6HpRS5~k_q^v5Lkwu8r=>Rj|W0F@4o3zYgC1c2F{sMo72C( z`;(mqaJQW+3EWrO{x@N$`Abl{&$SBX6YCJ`Y-WVQ{dfGEO34%NOUkz@rcqFSirmDQ zZp5_ebj9vtjc5407Io)*8*j9qu1?>klX7-I|0zTqrJhaGHAM6#KlnoY3{I681wod0 zTPK@#@yr6>*0Veple5>{o=I|JQI?=ptW;0FdNc8kuuSS+ESIL|j;2KD&L3qqMZz8( z>?ht!TK}agJ&15LjQr`M0USiW%b590F7|bwqnt9uNp#8x?STDnc?@`1#Zz_cbuOHh zot$#$5hZ_Bvt1JT6DbGT(DTOGLgn=bWJ8b6XsCQx0D6_wk7WTrNXYJenF@}GuRk+; zeRsY_%I-89%X3`deG+Lpr=AKi%Tz7|yuF@IhbVHdY=>3DU8BQ)qO~b?T7U-V3!XGY zWuX*{5ZTQMW#ryxq!5dw0B_Cm@mgqR5Fl!a<^V=ml=kH!?34-T5pSajU!;E2?Q8b; z_s61C_N4v!id_vd@2$jm4H!y&Rw;2(|`l~ zidAmx{(BF__HbM@Z&rKP3$Iy-p|PrD?1mpjr~AdTqwMlpJ3E#W)>7@Xk>H#M=`Ww# z6VCAjE;}p`OwYek{=6VFIwDz^rZ83z5t;e=XKFIlQLRtORql@6Z@sXfGTuZDiHab%t*KZwX(f}Hd zqie!DJA>xg9hoCl_2oeAhOb^t8B(t(C|E5!2tP$oUQd+WM3%$X+q`fF;$mF1*)jYN z4089?Xkw}&<(<&t)FKK`rk@cloNh^kmP*y7|C@s2pG))7&TPE70`s^G}5P@~`YbvQPk8YDs;nV_&_^b+8yV?po`| zaza4Dr&LIUlln+P3CcxMXO;{z@F?rsmFCn%v38eg)1-|NU$V6qC(f7Q5&fn9}d{n zdJ)Ch^;`Z^q1|ZNQfeppI=J<$D>be3WqS-kSFf|hv-HN~5QiBXws?G7P7b1NV~TL` z6@I>q`#&GOQW9dWUh;iKZt}a?8zi3OY?Jm=z7JX=7JIG!*PMW^_&>o*T*Uww0JoP2 zHS%ejI!qk)axnZU{F;Eow&5oLunB-J;hWp#Is!OTy(r;m;4hTpnlc6}h++LqB-rS| z|1_Nc_WxJslMHSHhTZBYkmx{^`5*~`%zJ;|y_Gne>r{?y)n^x=ETT3e5N}9c{rRpXqTS7m>TbZU0ljzWp?v5lV~zj4IEcUN$K&$p>b1Wedfy)N z6pSzXpFY8l>ug~7+RJg=!G0e{#iP??BX9JB_s4wTGQUsox1U$ipTN|Vv0Bt+`8P^W ziXe{!I19QKJ^TkX@Ge0ewB8vXkly*M9;?PG1DNV%{<$rE6S1pI3O=#JK7+up7M|=m(Z8E%%Q`n zyxiN@!lMsol!w}blH&FyDSqv2E7vsAglQGG zoX}OtgU$IWTNd}m#AZ>Q_B$ykc)V(^OddvAN2b(RXoryu2C zDpK|*H?QCa#hJ|IFf8zm~g!yTQfTReB_r=18{1Dme3T*PLAZySbX{iv&}~-pk#1x z3{kSszQ(agH!@3AW*Hn;^ziykOVZ!h zM*z*tU~8#GKc2!b{tz_PO2mHKcSq9(JuYfUB0IzLhTNo-h3C8Fq^>T=unlmhf*F3| zB3p$tnPmRw zX8+#ywomY9X5gx@zr3)>7A+V#Or|q|RAB_6u z{+#gGI9V>I&}#)x&iuAd+esfOM3g0V+_9RrQQdHQyL6%y#iCMDnv0OuVxL<>cseK@ zl=&^p9*wS&*g_|_tncF@xb`KLzo4>L+OxOQD=j|$s;Q&KDFH)cR!&MuV@Xf!OiS8B z(L`X98i~HPkO~(UH9R8{Ln$A$d@oDxh7)6!M~~zP$qC@RhNwnbXt<|9dEXvfhW~Yb zh=%$UB&kXL7*RZ)5YLQm)(HIgG_e_`2F&+Z+71GF7meEiR`yh(Y*Q}57Sk?{iHPnd zkm}Iv9r-Y!lxi2Xv$lm+y`6_?e06~?5y4aPyj-1qTzzf(^Lsl=w;c7hC}qBE%NOjK zZgZQlc2`e0xAyv}E@9ed{hvuh;%V*603vqu0LtG)3N#Th2&h>WycR$k34mZ%FM!_; z8`WBbgJ4X=g#$}CrYmH2u*2A(asVDHV9u$*lWgdtFOkF1rN68-ZaL^jr@6z-PsTX) zqY!-=P)@ng0-*1pvweZkg7SP!jN1vzrF>C0sLq`h*M_#({T!oLLDeY!XYjaR;d2Qj zhn?_Uk}(VIS_hJJMwq7Zwyam-H%I*xnOv)W?K-PZu>}oFq~E)__?Vv>JCU>$hd?BmnUy%l)JR(QPUAYL&6Rm>l@LTX3x|&n=IognBDfr5NXf zdF0Jj!P|2#etdFwb-i~0Z!@!(_0+THyu|CoayU-suZlIwUed&ubqZw>JtcI8o_^n) z;+ZcPGN`%G&^yOnW>5IH1H1`92yZ3-C@W23O2}``tv#fM9)%h^4nFZWLDD*rQ9fHL>>K;k%|fZo-_TnuF149pUY^4u?lyra+^ns61wy(N5u&3Xg@GW-|NH#^&k3Xj0GQF(Cu0IwH7 zP!Nz2aQq$@chLmnnx3V6O1G&tPM>-1p#N{brM*Hofwj-6hNpT9OWt~BFx4_9m8M7l z4JSEd4#>dNtf#|1{M(TNW`5O#-3?jp<)CO@#q2!f8H1gyF`B73K8=NqYX^#(j>d{9 z)NH}BOVSozm54g$$lG&LyKt})L?#Nd$@~@DuBafh{@SuWHMd2uO zG0#A{)cK%nFbO#L_kdGPZrc#j7T+zuU|}fT z>JcWzI5$8)S=c}IETYJtd_!)M+ z`We;5Iq%uIZ%iB?ia&hB!bbdiERD66K4E!1RrtXU%5+AOCR1^cgezJ^d^U2+;pk9h z0+Zd>=yF&wJS+YtS~IxsW!)bJN?;QVWO^n)hK9bPWUVlb(u&LIYw9ZZR!!9N+)>C z?OhQ;Y}EUV*l$z0;YTbV@sS_muG}%wv|nU)US{uPlb{2iq!g8DDV|P`(GxbcsIh3> zXvG)XVW>`@_#%H`%Oa-QiOjZ+{Q(*m_9{<{-UcV%3})c!gQ4_TVz$mB10Kn^(1sgmP3@6pD#2`;D zkO^}$0WdrYRiXnTDX+xvA$SqVI!(4{o&yh#M81Ei zvZb+Hma51r*E16@Mp}`3G#D#)0B~ELHku3I0eZ0XYXEl(Cny#}{-a6u0vdcIplBc$ z9CzM1trzPSz-lfy^f<8o;MoEFAmlbBzUFJgS8GA+gMIWVYOJ_~)BzHn)aD%c#%or> zKF(nOGF4&kIEB&pq9vtO!iVc=4(wBR929D$RB8<5q@LOpm?u67)Q$uyz8<_+)*iVJ zi`7`q?HVx>4pcv1XUfLLP@gt6Wno#JX~~_YWDeG|HNpcvg^Lo1y(QYcppdg@REfut z6mnr0IeL3OKF{m-Z-*pIW~t^Gg&|T3M6bFWL?lz5oK*Wm8OqaBSsjS~_rzjXC=+zd z8k50nP}!kRnMWXatB_V^=aBPbOW!yq{Is1S_dfQ72>zKXTlf%+>5J@2g$kOnxyR%C$suk|;u6HgCRrMTw6mLuqX1Gb5ryYGsjG>$Q&iB9NrHuoQW7Dsp0U)z-BRWKCZ>*j`MOY{b!E$2y>MRf2Tz8DRU3faS)~GNTgq~+NZWLNT5c`QiqPdLQ`#T z;58$K^CQNbh>MmhRF&IG0>dT|D@nLs<6c~#eP?j(MoI_Z30ea_$oQrKCpA*1R!Kw@ za3;v(1|oJvK;iL4V?yUtbzC)da7TNVEi{QT{LHF50}_oUI;NaSrih#Fyu$bmztk}H zU?)UZ$qjGdnKBQ8=3KnTzpQ*2A%)2GO#>eXP__UwRzzt3%fYZC3$4HccLWR?rePwAYH{q$atuffzFLD+J;&l|EwNv&nT{H|!a`bq$Ky1e>J`UGKma>sk+D2?s03 z$l-Q)`U&ulM~c6QX^&@1E^nbJieSBuBu_?7TFmvEAa8Fp%xKd%vNc)H#h)kaK2?&# zn>pR{H^TGX6uA-12W*dcOE#U8D%yv}@=OA+o`D{7e?(F#aHX*@MfNpk(4W^X8#I)$ zKJ?{O z3=UO21}wr<0ud2Fm4bkdrK)xS>A{XKcEtR#qG;efM+-fgnaY);s*ER+Sm|AQP}&w<5r`sO)GArYITR7Y*^A>lMj{ zbj306#(otMaj`E`=;Mh>DCVn^DE17aQCRS+JM%gV*b8vFZ75o4{c^_>o`3B2b%CHT z+`t6sb+}f>lYQnOyO&%NAGKn+cIdEk9T%f(86y14pi?{y#-gTi^zNzkD1S;*>^x8O zuev{|j|m3BstIK~D9M|>Ho;}*xb@V@F~#RzueF<9dCa?`3iisM7ybG%SEfhva8*92 z3`LtU)kUc##OBatJM&MTmKVqL?m_MBFUK$6*mo?=# z`JKmM@0+*6Wn zm?54h&g(v3@*#y|`aU;TEbhwIqr#AjJ&DfeTMpYd!E!6h%2D}+x6O2>gOIEpt;N?r z^eSdqyqN!%5Hhj}T7T86u-c$AudsQ~hew=qK+g6dMfwNNb%CAg%OpjW-|Cv#fyVXE zQu`m+0k29SbfeQuZKRlz1cevh9KaT{^N~BPrj-_AyWpe4Mb6FEi<|u}o;s|I&yowrV?yw+I32X6K9b1>q=64Qoryooy<#s*alH-h{q_YRWSi3S zuhI1Jr*pUQ;}>sLH(OG5+nqz2H}>X5KLs_I zPUofHS|;=D<}iC}Es%vZFMs))E>K~S8KYS0Xe-ZDk=b>=eV`nwBsF|e-hWf86qWN} zEgD83&*Y2_3m%F=T6|B{Byx@pOZyf6k%72XotsuWFT=P->1|=m4@q@rEvk}syK2*!HCPLxMi9*PCF$%BjSDH3s5!x zQ21%owM}`J*Zrsz(`~r_Gh=x4T=RQrK1d9>z#oLb^t3(g%&5b(dfk!-RiW^65pfwy zcKfAj=U`THonhL-dP`?qJ_7tB!<&nk{268b;%-c-KAn$*y7Eq_yo7kGfF{(NeNY;o zuA|BvK_t@+FRZYVkk{JMbE7^q9biFxrHRJ`#>06;6`M0kYI~H=m8s5RgI>#0r%Y)D zbr)~$Q9j3Y$&zMAW-6~)Mb0>0d-)_RJr$8}8qzh9Chm0U3UfTTh4zZ>da#H_TLFylWq>?iQsZE!oy;GT42kT*wZ6<@~l74SLd;{zs zxS80|UCP%QnkW%9q#JC-6nEON>Xv;0Afp;^7>U5CUfm$|6S11gfh-M1*aUqIJNL^8 z);(wxo>)o4AP5Jyp?3v5$U0wyzYRuapsxhM6hg>ha zBV0!JlFy0$()B?_*eqI9^cvGh+u)hv#neh-c(@MoOT>R&g~y*!k;WjR)anbst2m5g z)ZwMYO`RYFq=!A+pH9%GYJB_#55{Gx+O!~TUdaeO%iyncMGS_3fi&*k04SCAToFJT zf-I>12Bkqai)f3DQnK)NZ@{Dt-`5GGE)(<_ibUv3Z9#mkQp^KxL$&?Cs|su4iM>-m+M zDkvNcAjIKm+Y!J8woUl9j+wyOGHd&!DCBUp3=J5k)={*Kx)gNrAU6Jg`&=X{W8kn9 z4uTmuTiidp)J=f$uV4p2vJ?YkHEwIWUp=MLtOJjq*EYtyZws=d$HjlL;-NyC{Tsk+ zY}H2&-W&&7-`^rGfinp6gt@1mqu`8$BJ^2(L~&@Mr3yye%OEOu+(X-KAkVm+A*~+X zsneF;Duv3#MLS0-oF&jNZA2Xh`qdB4qV8V2Z>Lae0Kx5eB!g==U0jDhX0}4=Ytd`B zr2L-lL2sh?xnF$jNi()W1SQ&jbpGUol)U4^ zDHq}Ek=(%3k0e0-xPi(X9k@O=FN`E~qEaq1e#4lGftV7Ao9QN4QZ%|JnDkvz2LFpm z5ke-pL#XFxV`I$1qwC7#d0c^NchPqV&&uI4Z&PVRM6>0uAAJoENpMsw(JD6-pc#AC zG2Q#o=X-Am9aPnJ=*MehIUb!gV`)4J@;q2tT!N_ zdXiB*nhn9T18eZA0mIe&aP9xqr&-}(OjsgUB?JK4I-@QyX2ldybCRFK&?-&BA5m!! zjglQ^ea0#&=Jx5JxYc91P!XbfSj-`>N{l;(+@al=@9ZYWf8QyvWn1MP7(xR zTD^1BbgAXTn~&?)u0&L%nx1(j%Y9<>0KDy(b`zmK^yGFRK)-P16=Q(EvPrQnHloHm z{J9|-&eI5z!T~;z*IAO1RQ5C89blmG3}Sb$zdgGb>2`l>;IbMZ_su_zX?Nh^k; z*Pbv;WZ=3+$oxF+*1ScE0>iQs9|rBF!6Al`k(^}#6G7oV8+KxY{nC{F<8EjgRY6jI<)kN#(_*q7LoP6(Zw;V+1nXgJGm>coYc~q;v-!PUe?HVr=d`hP-!T9#6jg z)oBcBa=TPBs4q}3+sj>568_@e>c95B{#4@8kL{0fRC-s5g+|EW=ZW^EVy+thcp2GR zSF7j!-s@Y%kvWu78;-t`9sSr7+$nNPJ9goo(k_!%!+A=pA`;EBJKPldZ^G;9zT`)% zyI>OrqfXUed55iKC-?o_nGdD+!lYE9zKzk2LG&8+L7%)Xv+TMaZ_tu$^!+Yhx%l9q zDYZ}xkDiiqf}yjt8k1H3C*R5j-IcVu&%t`Olf1cEOK+1JP5nPKR-7}*CImEbjW}OZ zbbWgycWl{12j8Td zG`f2shTpKJt_m=_=&Qplf>)fR87N8GfRnfgh4EC+swT&yQJ2$svt2>1bC%-j$|})c zs@qCN9=`r$V2Q{9yKDRbbYbPwUp#;MjYn`q6b$0BvctxDL!@Y`Is{o( z9x4=t*^d0{p`N&C@f)~j9CZ07_{b%(f@00zS)A9p0teElai_(!SunzN7=*)5zBf%! z4TB(pWh(nfhc_L~RCMzeOT_*x!PbHYnJtA3019TU!#cP3V{%IqEqb`*OGM@+V@26X zJ1OZk#dL4>j%%{)Rx6ym{@~^FDE(Nwm0%uwac9A)9vc_aX8O&U+WW;2IQnIc#y`AD zRIdjb;`PZc>*$9C*Gcsl^97shF(cy4YvbXB@EL7qMQ<>fjryuMJM+(u)--#O;OM%J zY*8?6T1pN}J&oAIqQcOB2w6>%r=2FDj~4Vngk6VhZF<(xc;!kMF7MDep8SYl*c}aZ zhx_hDwDTqvRB+d~G;xMpScPx*B2kDr)L0?Brs1~ij`gn)X`_DF-2v-xmV6z#eAmD} z%go5ZJ?#xF$^Mn~DHY{5%0zi-a`m25FS>%GJ!=PsXz!r?D` zk8|gUMFQUYpMBmW5D~PdI2B-N!wtO%6=4o{vG^K^DJ}fa!Q^bH?l_SYIXIe`o1rjB z9Y}m#wM$=cG^ScQ^)x@%u#vOC@$XQ>(_tdlgZ*jnkqOJFtYdlT$P}UX3u9K=Q!iNa ziQ#E=MiTL>VcF6c(!?TGC%{ z?9FpG&_@4^qS@t?M*_a^#xPB+N+?8}N>BlPd+o3?D?qSv+KjAk6PrHC^d{yxK~WhN zE*Y?B$&O}@OcMr}1E8y{KoV5xRFsMp>no;+;0Opia}Cu&rj*7snizsmBZj|e9*DlD9%nzK{}q(0 z;G@-Tk$g(^)1vI{r*$DM7s9x1){tgLll`9HTW?HNK0hHB;mo2x8WSORr=K4>=xaZHjPjBXmSiWR=EExhQuH{t>HlytNu!ZFb^htjQuYS zZFZ9{k=0!KyL``V3gWU%F(VVILnW9nV3V5p^N@447~>L7!qh!W3MnVvUk|2(bdybq%w5h@1PfOBK_pT_EVOIr!FNg@EefhVSmrYZ5WSD&7H zXB3f|Ai?V}=P!;PB!G1WioghP8!8#$l1X_boVsE8m*ECC1fXGmSsW1AVb@3zfHX7S zoieVE5+6@6Oc#bnHGA527RI3J2oPsVCrEb$u(DXb7??XE496 zhY+7i^Wf3Pg0<+8jAASzT#o>DYe;KOpfv%vuv`=XKW%eJy-LJ7T-nI(R5-GXkz~N? zGlPX{*zuS;x=s~Dqj(ZTilK34OZ4ALvOi;QRm+Thh%FB}4x@*XiX(OGdVzJri?lG) zilK};7<-W#4haW6am{!pJ&EJA3CBVtN29|}Lp&gbWy62F5MpM#KBLG5Q zG=umDFywJ=UReOOc9(bv@GatH4RSvVW2{E;PRJ>1>SIJls&dt zCTUzH?^6$;Y*+WrP5-0Hik~)TI06UG_O4KaKW*pndKLA@rxEsku8MEWC4|U9@s$mY zDAaF+HiE(ZGxak0jDDEG?lVdGl5mCRy)f#3?yhZJWL4CIg?>4stPG zUU)<4<1DEbRdqBZ4DC^x5DVwY;&n*dX>HstpT+n5j^(IC*zv1Viejg1OZIC;!tZMC z1ZU%ILguqBw6-N=p4)A~O?-)hgBU&d;OqW*n_ylwKa1ks1U3!ur*spFYjMeoq68L> zw!!3qtu;%9w9PK3v#8Bj*?;8|jF7#`sy|#GkH@{h8bWRIPM@8H->Qlvz@G-!Et zM>)63LRfM`jUNea;EnXW)rui@?TPiIzWdG30dyo|dFlVcSjSob$0v+!t%sG98K;q3 zDumYAe|$p74|lvUW>+~jIdT3QXgDP6B|_HM&2dMvl!#*y?^BZCvB``TWg*YJTIuqe z1gcbk#?tI3dApt~c0Mv}-Z+^)JN{}1>w)_>Hv1J3l zBuS@9G@8R_J6)vF!CtAioWY;A%m{~j_?GJi7( zHQ(W}837IUefrw4OK587u$)ByCWGqROOnE{#u{ZG?M1veybOTq@1&|WjzBD(reR-) z^c9`TfD;{|Yj%80$zPa@d7~L3{QXr|#SiwU1$?81UgH{_&#gqCJmu2&ow2!5$QPvYxnNDzrel%P%@R5-}J8Fez;kEEkEs%M{b18gcc(Oo> z|2Osa6jQZ~i_3#at)GlejAAaK9G~u036iW(G`t;|T`5Id!19te-5yDbpQy9iisBdY zqKyn~#_2P8$ftUUmGe@q$NoSeBk)igA*#m$ltA%k?f3R`WsTH34@&5bRLrC)+3Z`7 zk6+bQZOZ?EV0Qk#q5I7iEbye5U7Kx)pSZzR?d`KJxuWZGgG$+;iKe5AaM&#DdLkrD zLj9vhNGeoKE^XAKT8Ke^TGN*{&7I*iZzHfS#2^qNeN>Wp1t5Z5MLp$*x5@_{DO3JD z8q+4`y*Ch~f7#l%y{XJJ`8^fsR?CYI2e^%1k%81O(kJICy&grRPn;yEao{lqVzIq0 zStoj2KrPVkjuF}-ST};p>{BlN7=V;8qtj6i>NZ;)L1P4s;HrGF3kPW7 zE*1u2YsOn*JP5@Sx4LzY=AQtawsuK#!bJ3{qJD1tlL8d zN-+03Rmm@^(BsRRhf-iFYA31q5x~#1w=i@3n{;L-c;Ak|%<{%~^1B*!*tB`roQY2> zFcRhWDz*!w^b+I51leQ)ty1eO6OC%!qs%94s7*h-$2>W1-`a8JOuu<>N@lHdgFi}n z+mvE+HilK?>ti1ZPy{YESUfbt<6-vMeS~i<*zgyht|}}2<6T{-Fx~#SrxiywwGsa} zae}xw4mtkjPmb=;4}@)hlm5nxt`dMRj6R3is9ckk@SB+CvM+b9$K@NP8boHi6&4K8 zRNnY@#a#WvEh>c~Z(iGn6fb=4P9UR{)?;mGwhuN%QaJfuJRC$tQDT?x4h(NNIE0Tr z^ubSmN{7~-hOtw)yx`bhI((H8`j761>W2bThB%-x{gP5cFD^mj%RG`v8P;!k3y~gw zWKOH;V`$FHGe`ccG&x?ozfyh-u<+Y;OLrIUu;R=xfQ2WER~+P(mHO_czBNw8bmez< zdD)mQlbVz}`>RO#%;bG{lNPUpdR0V~fW@L(gy~duS|)-zzU9cff5&lBPJHzJsg{6P zRLRv>g|MWnd20ou<}=LZZ^{_Adi>9x^s3J6?dFrQ?lwN=PlhyeXMWY{@a@qybA0RJ zptRId?niW9DywYR;;pJb<74C32J-60|9Muy)r7FAn{gDKPlUaC)QHQSlXwt~8OhN2 zwncrT7%IC_Fvwqp*Ww(0(XK|Bv|LTx;$(8YTzB{3uQZ-c$5E}iQ22eNaC-2}ki|gy zIkc^rS<|cjbt4~3VylwEN4cY!{dOUGg8W_!A1-ey2j7R<$DDT&FLN5RqGr1_t(iwd zV^-%W(hXIo=GQo8TBX0@hIk*A-p+m(=AIeS3-~1|tVT%`eck@jA}EG-=mp(zP_?FCEXaA$jV;qb8<4j@~&)Q@;!aiIUb=|4J6cw6b)#Q-q_j?s3Cqi znZ1|5QCih4@+VcFdi6WfqTEw+5e~JY_NESh&P;WpY$vd@@L7ZBv}}zcsb|5ZsCx~G zjz2?WOFT8a6GR{szT1Bx=hHvZNc?mxQL6Bjlc-Nuuzrg^;i&NeByRS>uf|cIuZ)mt zZX3KWWUWMxG;~(e`E7&1i=7N+D?ab+S zUOfMQc>3z7sKV~+nPGsThaP(9ZWuz8p@)=aNQVJwkd%-Zx{+?AkyJ`R8l+1~T0jIu zLP-@B`FP*=x4yI1z2~{{&%Nte>)!pGz4z&3bbfuM%W*p!{CPxZLAV}R^R~Z|{d31` z&$p!bcV_L8ujS}aZCmlGBx1)6;^xVo~iWbIM*!2)!a7qZDIilV!^Zq zq4oAdyXC5nRI8%$OTO&Aukc$XmG2f6F8Z1eXdc3kwc`_VC)!=3Y7VbF4&ua=We761 zlGcuSy@yHtlfD<4OT$lh_;N>sF_68kRSV)^?CO;>hY+T41IlwnrH*91;t~_BZ22^# z21c!r%vUmC zVuj2m&X0jgiCGAPfDenb-(65#ZM zCfZhA5Or7o&&Lqb*2#E&CY->3M_>l9h$1^B#pBG^rmhC-e&<1+E+yf8s6e`l>4uT3 zuU8X|)U)e*a6hW|Z-4_V3Czh#FhU`Rlu0OZPSv(d9KU>i^$W-wSJ!a2dxzQmm^wxp z#u|{s+_W%32TA@iQr8`rZ6Q5{)0B@LXD}v^^6+^U3ld{~JJfv)z(@pS#28*0M~GHT z=%bzFSH-H~vZAYwMe6hg4y^;NK(LP;(h962g&!rj^rwrGM>byTYNrz5x<;CK*E;9bM3%I+%xb%1PJMk|zT=}NiL4p^{Zps!al3(|QnVGQ==7NDdi zA?(K*U-`-jLyU`u_GdK+Tq4mb|;KLygAb8@Vya@o8uR2RM^1ytloGB9a zAi_qzEoz`Ws|N}LwkY-q1~AMU>qc-OrB*ud|E-AK7#$LTb>b-QF*BHu6|{ub0|1F% z)6pM+{_J@ZZmR?HZ*=@s`*8wBv?gRAhSSY@lWP*Lkq?cfis?f?3fJzdV|iLW|MrQc z%N&2tzu((kk|WzA{wiAHWG>@xKNrOL(NFp zP)uuDnv|~|Z%G%xD=T8bG^?>dMnk3sjc0)RoyLzR?(~-5RjnBrk@wgm-u!zqzd)&@ zI7o3J)!xl5`B&#w3r%7gH|)h~uC?4ATruXNDEnGa>z;(YipSes{6c>%^IZJR z?RGd;(m6cf(bzM&tL}9zE76+n1xmDC8=C&(I>tXRjxolR-bN zo6}`AJnWyw>Z^A9kuHa%?!P)@z+JosS1K&R&)t{A*DDE}B0!|?3z$=tYn-qS3Xe8`5DpuRrP_yc(Vo!1f;nyMF1txd`$^K0aQsX^@PaCG|?rUT5+JQ zlo3vrB!}4V^fXv3#ZCMu8QI+P4XujO_%J$W4PV6eP6}MbtkTo4#I?^HYs@1QmoDM38XoVBdyfDvs#{2J3}}R z&{`1883^ahLGX-rz7&nrjdN}T#1~+OOJA_-Z`R|TX`_`OznijZ4BhO#I!2UHHPMb2 ze)vDLJwXG_R%#edD;6ryYzG;2MOl77(!r!38}0T^cd#Qn!Xx$pREukY%~(ED&m`nf z5VXW!G2psJ*F(p?;`Z#O!$$N&XpFrkdDcs^mf7_?@<5yAVT+V#>kYG{h+X>ZsMtul z`eszNvIDvQ!Y!xxXxZ}#6K=3w{BU@NXa19?iM@C2N#3;IXwmgV`-b8_;)f{zdfK`% zm9VqxNje<%yUH>8Q;6t;_;zgKf9yf)FZpKwWsz13xk$dheuT^UKa zln6&d`uCINgwem~Zv__`iHGLiS_KAXR@`Rue9uLdsof?g|09#R2`I)jC&-pLeNW$D z+ivunrFQGJSz?Qs5Bo5L*(omGMBl3!O;ifuJbbxGEp-oFv4fzcjT_Y+e`2cGs9Du=~#1u57A_aynB&&b@Jt(N%2(3Dv&O3xVS+!GsRs| z>;7hg+{XZ#;kTooD~iHx*G$S=22#vJl1|KfDQF)OOT3n(?45`uA`^A$9skr8#KE*( zH$4!rS<@kwtV?3wPqytK5}d^L(~{J>#< zu4R+>$_S{<8_`DhhQ=q*jL(Yd>{$(@5Bpt4zAVa=ghqF`xu2dl3|z z7$5@b?aPgiu2^7fsa3jXIrF*Yz?hwb~_dhlqiMA;XtKB$D`90-*I-Uh0D>Jyj+&= z@gC9$8(|}mtE%z*4|rChHCQQXTl`+Xdl|XHMJ!x=^@t=-6Q1G>&Q8~DU13m&VUXL( z)U>9#4y0lpw4eMb?V-tIbM%I2FXv^Qfz(W}Q*$R{7oUYEeMEq4Rm_3G`0uW?i{*g) zsa~RXMt?OPAWD&rO=yl(BY zCyvfqAMU|kDjf%exR()RD*EMDOPe>_jTsK3^=;<#D^SzIs*{78>?wG*jVO;+Rc5TY@OXZtG$~oBZve5$Z;pXiahyb#98`YdtW(DNy{V(N@9m^ zTRhdRD^{|ya-s%G|LWs~bIf|qVC77x!>x92Er~v4dJ;f2 zKcp3h1(w{EA~Xnau>W$H|8o%o|IZ#kFp>%YG%FiOZn$@LvSZRx!k%TeNsQ^#23xN2 z2US@b+f8%T1%gQ--cgiW;}T1RI%o|Qd3kpRD)0PUz6aBH4S(szCMpwnLXvnVkAj0g znX|_5};a)IDtPBb(;*CsWp&XcrZz znfv6?+gHS&Eb`WH=Mu(W0cPIJ*S3d6II|TIb7yZ$HT%Pp3b1x$VPse~zx_ART#*u1 zO}^N>yUwo~;M0!MM_&%M6wy?K?e>qSu6MI_U=!&czG~4@D^$M&6(Mj)Jg~8Sg zqgry885vIgj*k3@?wH}}nl515Gt;M>T5r8Z6OGi(y$pJ(KUgmE-SkO;aMquRXs|Zt zzt`8@dE&-Wznp#o`$oKIh15HAc%3(uY(b@-d$~21s29HqvQ78*Wz&89(UtyhHJG>p zc~%6}JqG#N|tmgl7l zjXCCXV!UOFe*LoFV>bx}>-)}6^91~ND{K5;k7uD7gJTE-s2b_;bhUSN>gx%HO#NzWYf_ha6pBsR>&ZB9t;+O~ zugg+VLlj2|@N*pG?N$G-FF`b#zev_b01v_8I)sZDa~x^!2SNc;qAIrAe`vx7UV%P1 z85)Cw91JF?1bq6%3Bjl2k(GpcOc~f7;*pVoU$EeKa#diEyXyoJKUipFB?dZ79I6RW zx>{by++<>T+-<@jXh*Q@&sR=0T^J;ES)j=tG#3#{z{K6fWI7ZtQ+!^K1;(f@A4(PG z5Qn$bI|C4f`<85{jWC#&@1>rqEpJ(Y)z16tD^Z@eQc6dH{^gaC2EA7{cz~K+VHkpZ z*lV2-W-Md6k=EFd)%sb0T1BE-ISyq<*jjZXf;7chJvrxKIfe=<&$~^72_2VxwoJjB-eDz=1v-@1X`Q%0Oz8pF|Pn!1avpBbZfjx-WkE zKm^VSz>^<{_vy!7#QQjvDI=eJgO)kjbx9|c+C%$Alu~k$3=WN`l5{Bi&stA4lDc}V zrmZNBVek3hwUYT~rEeP6z{{u9WETDXEr>3je&Bq1dqoD@ge8=T7D#31&{H~h6;qb$ zR0(htQYkFbh+gg6>_w5Sp!e*2QfIsnS#-WgZ(@V6n~i1bf~Q&n{T@`1iHCDD+{>Rf ztN+UJ{?Id8l}XxVlh4@8ZQJgXP@^+Y-}e*u&$BKMrNy*BEWOv%mVn4mQ^K!YQrz6A;I43J!t2@bmPH(WsR0yg5gFDSgK3Z#j;y)&~VEX6L{jXM%8d967dXBph%bsgybl&N5cRD@ z>b^71r)|-zfVe@&{zBXo414UkkHLdVKS8&Km)yg<{vK5U-IA(UBZT({IA)xxgr!?} z)`N)+?;kkCk%5>a9T{ljTfS!&un4Q-#DUi&q`uqk4TT}=rV z^r9NYgemEYx5r}e8M8*27+Jl}QVf~G>0cc%W|qrkk0mw!mck3XUkd=qrxt6rfnXB$ z4-#a~@#+~Rt3~csm;ZMGs&*xQF zFc~r)-g5^6&86sYK(;+L!BiK55>pKwlTt`sN0lCrWMiAJhO$y%W9A-~N=sA0RRsee zTN2Nr5F2N2Q%26#ll{a$6qS&y_dmGtQ8FBee%?>FV@TCJur#H~8FzpKSkYRwh!@;PEm0^j?U3eGb^0iM>i))CC$ zdW%3Xu=}&Y)jJ;4_3j%n0vu~Z6#%zcyA(7$F*H2Kw|L%E%rB<<`2vh_+m@`Zz86Q| zn)3%_AQ&%rs9jIysHq=>|kFT{c*%P#=Z^go0-!EDtT0+%MS9_SdrpzMcG_B#u+ z7jCIe>;QISsn(}?0Hhpe1U{ah43{$cP$&*6*IK|4h6UC88Lua{+scd)LaY2^h+&su)Iav^P+8zkE> z+fC!Czglq8J37&S1nD0|BTAZm_*WDOho@3i)mRf-glQn`DBH6dvo01rA0fo!KDIz5 zhx9e!@Xnsl$3j6SrtL5hIO`RS!t3iLTvD7RX_Bbs?Wvt3a8fx0jiNVp0wv zbP*-Gn_~O!_ymy;bS;|a>R?b|cZS0nR%Id?YV4Jdjj0-rxSbQ0iu2!oTOp3i@~R;O z=5wV(!o!*LKyI1PlU;4B7w+{z9cc}Y&8B`N1H(dla5ND`{CI6~%Cz8B=%MCy3l1_Onw)JX0!&LWRA8~Rq zht@@Iwsd_L>@RT##D80vuyP+ANG|6u$+#ar+EQzx?x5%QV|%P>-qM0VoWIJm&4B2u z8-EAmkb#W2WM5oT!wOsT2fgO|0+(9vbkw|ovDZ7X&od>O?Z%CeD%=;g-_I)O|73(_ z?ixPTHQ6(aVdLKO={v{Tq;h(``o=pJN0IC%?wYQP`(ZmuV=h!)`dn=H$Avk41eJR$ zr4`ueRq2GX(RxB7Br31yt-q~brlD+N#@!<56Tjdm*X>$9os-W7x+X1N>CybPe<^|5 znKAL=qLf7^R$Jg~>BpIvsS*^p^hlHM9W8-42xSd-wuF`bOr4Z{M7LhC`R7VJPYL1} zfp+jXZkD%b{x~-K)+lSPt7}1Gy98ejkP1=eDbslv`BFC?q;&p74C_* zSG4Ga*0-l@yJ?W@9}}^kW2k@TPtVW9Y;$h0WMcA>6xub{&Za;C`Gi zKtoGlfCGS#cdAHoKN^Dn4>-Vp{|4S2D~g4v1o|I_KL9BY1(4pUw*MRb|4U%Vo%oXG z^qKHcG#BoRSbzXGeGjRl8mnIH(?GkN?C(Zx6(xP6o2+wU-rl0EVs`V2?bQ9M&KHgo zZ03ahdpFg2Lj&K^t)9w=i=kRieukw9edI8(UvoGp=rnB66?yfA*<5YzYAm-(N>$PK z-a=~I?nbltV-h_PIgJqI_v!`oS{3jw=be+Bc!Ft?s{u>z@d)0H>8rjyVNwclQ$RYR zZ=KFQ`J&GipE}6-OW$6ZOIYRP%ob>8gz_JVgIv0v2+RX~62rJFxT;KK3;cc$-ct8& zY#^Io1plb-qe#BEwW_GG8|0hQ5HhZ&Y~wkhTVL!$2^hCyb@6>~)-Etb93-I; zj&Pl2Y?5_B>&CK-8*ArvU-ck3eV$Ez`^FXt-%x$g+qn_5$M+z9nt2N1z`hHCHx4`E1hRzP}!36ehPT(g`mSxZ~G*^H3QB z^JiVMNXIIUqzn|QIz$|IvU4jv-2jtjxwt8_7%cvQ1JP=KBQateznm2sj7dBDEpnB0 z?r;5Aflkxtr~pX%qw~p|L*dPw{bG11r7RAz=e(6Yvl0j@lx}3Q{J^6sd$_-0n!5md zJbD>ya>mUjA09XEz0O9~Z;6mCKhb25Gv22*WWazty@nN=;{c?`tv_qM#f1g-)tiWg zu;U;BSEsHgl?OgVIvlxr~m3cZs6H{Is_fCJ2CCQ9+`- zNk2FrxB3me^z27VR3VqG%^PS|o%skW1lzm* z^)9c<*(qGyq8v8vorkDH)fe21A7q>d^}&T8J$6J7oobe4}of}l~zt&!gl^jY@0j3^T7IbL7RmlJO4IxWa7)PzW{!l}wmKdDGj0W(k z&2O}F3!)gGAV0zJo+uW1a1un>;a$rqy|jauvq1G3T(dT4(sK2Ld>>vh#q2n^B&ov1 zE7-O8G5{Ves^^>uhgpTSNcOVzc2ux?$#|U-!eTG7u%~&gBH@@AWuQ!?o^Y6I6h)1L zFpV4XsY|Vqq?uw}qHa_)wcwhZjo%5HG5Dz|912)B^|p3`Gxb#Rx7sB6CImymTXU*_ z2f2Tk>vyO#-jtf@i-oya@o#gDeVJo*Csn};N9%h#S>+5e zmIF%=O4*)-3~Fdr%+TwH;R7^+DYzm-*WO}zy7++P)SRps7k3iE+ z{b1WZ>Hy&PDSGFpresz$ii5(GALEZMUr91%Nv8akTWzf?yLXdB;X9hiH!}O$#aYJy zFwv>q$67+_{izmAuDj+~t&Ev<5-%Zs;ERDJZpvn&T>#o02ld!YFF#6fl|KuJ<{3pK zs&cR60W%cmAEqV7NMx1;u62X1TMd(rM}-?wZtT~syXuveZAm;u7&r_XkKptOzN3fq zN{7R_?V)4_DUq6Zx<%Qe-mFdjmQFs_6}0H5**8BUD&Hp&`CNbO&3Zm_U}#wSIehq&IXKVTC2siU%{ zF%hz;zZ@~Nd7JuTT9a!0u$OEtuCU5Jciy|H2jX_dJH*NH$KNW(tOBiRD%8%aN9RFE z?mhHD$u;fuZGc}o^!=MW4-j+VFMkglgz zAuLdAyZGjB_-NbvvXCkwX3nqAI6~?mYV*2)m&%q4ncCTE?T#rddb`eDx}5JKGb#5` zMurX3h3GLo!b(-n1zwhim*}ZtTA4nX56*_yk5uvUtnbSpF@5`>gkaL*rTYpi0nRs(+-@(or8!;Y4f&Ib?a90uRxb z682Bi>vTxJL)$G87!JOY?Z%O^sl^lXUH6@8)d7~loH0ZMt9rVPXgLdC@C0QRHE;&A*YPjO;&|Ab&acwvyh@~`56 zi)TTAUEpg4J-L1rKlp{4YBf6mS*K#sa#;?IiN|}>n@Oc$gfk*Ouavo$S=mSkgNQM} zs*z2Ues%T(E~KM+g9-9PTX!Ng-J}dpGBFtV-s>UCQ9&o1KF>p()YTEEp(zsaC$*H* z0I?#APD9N*B3}e?kSa&SGh{OExtx44fvE4X#-*tg8Z<@90#fUYoyNx)nrS~B2jx8I zDG~{7s!CpO&9KP)T)?!7c$q!<(JnEEV{hWC1kXgOXrJHXL=WRc9=EX`TC6NV(io4s+JGiP~4=njpzu4@;)KVByEZ2R9b3yJWD&*n7g zCi>^aR~Z5Qy*kHQMxQQsqg!B0jtRLV-_DJ}6iy>UdwpuedSdoD&+LJeggZYtnK)D; zv$+o%)TJ_6yb!s=L4y1JAs=YQYkxAw=puNR$K!@g5Wi@mh77K_EBVtbl8;KFVH@Be z9pVA|1E9vK@2gUfCHZOG*s=YQ|Kvf5G3Dd1j|7o$FN97M*z&8TCVBaiR%!vRVY>OH zrBs8xZ2Io(AKduLB9-&K{NJxI#PRc&t83eouOYwwp87pMh<_sagARx#VrgsCse-l2_vw!NO?b z3JvdANQq_@6S3j+LcsRg=Y}K!5`h96N8(Kc86NB$C)u=iHNfmdS<(@GK8OjktF~W+ z*wZ$feKwLM&(O4Z<(`l>`V|_HtUgBk?EMA}AW+GnDh%GJ)Q+QV=xc@BUvJYoZbZPO5z<<FOfClahBn4*Hs4gl4kRaj#8X9us9sbC@!yJ4Fz}?^S z|AHXqe;IxUO721bH`c60{om;SZu-AOwmTt`V`tH6AR?7#>vukJgy4A$+gxe*^)kUP z(S=5>X!5Dl1ZPnk^}gUR8v3rVRz*X4U%o@N$XwV9{qmbJot0l1w6FsxH9oDG7vTHo z#r36w_0KxjUk{qp`#7Gm()K3HXQ_K$g#T(#)jdj6LXAoEzMGe$xkk@x>Zp!bvKVl# z&50uV7%D&SgwF$S@3{<(BE}yyINY(md?ZxdVUu`c8^13^D9?V^v28VVre!82q`E%Zag9;tdrp1wCU7`& z{W28IP^yV{&sCu-+Pyl!@Yio4gRZjYSH#|rzQOty^xfop^+iV$T!sx{b=ZKm7C_jNo*5U zppI|(^utwGYkeK3!XhgxvJ9`#trmn@nSf#1lK3?B*3SgWr-7osKY{HhJV=<(Z8i@c z=bv%8@Z^kJgpL|}6Pg=tpOGXmnCY@Uu)E0X3R%to5AIMqw7WR88M2A`CFls;1DTH8 z7jMhoNr=1A^cSDHyf&MAnVsWA&zdQONlROe?qd8N85FGz=OXu=E-N~O*fo#Dy%8V!rucr5A@Yaqg39p3^Y|YVtNGP{0&|Vd8(h+THy^F1&(gd+hn@#C;DAjl zVNNex`_3NVb!&%s_j-g>i7wU_!Ri(k{tC~k1$IN z%cBwxM=2@n7=#?!0``yk4|Bc474;9855DOTwjHdby#=-zoY=YFYjMQ9b|Vnfc(xRd z??s{DE}H(D?h`FD`a#2KN+jffJIgua57{dgqwd<~;|L9{M^o30sM8;S&=ViT8|lSc zg)m&7edD0p@Igc^yBu>BC0~EgZT^KC@<)%X>}v z@pzF--{bKzD~-+~QX!YMk}F+Hd*Og=EgaALk5g192|VO|5}L{O>EcPhH8+T5>|KYD z(==^RdN&4F_bLhrQK%Z9=Sod=O$QP2Af#AJK=q_w^bjD;vy0i?5FUjhX=SPsin03c zAd^f%D@+{SMY>HhqU}+#4*q0?_?KFq;H3&YzYJ<1M@-PrxBxAN+$G+v2`5x7=NAXo zLu!(62*9`#%McLC9uJ-44KK=RI}@cu=xl*INCc)AlcqKA!kE1l&49kP=^^)1N+Zoz z9)fa37+g&=mui5L4}Z**HS9$w9L4b_`voi-ejSQfg5Ps$h`=fA=+$!YfWC3*z-Or` z@?6X2%Sxb?kZmsBVx#w*N;rmzdkkLU;a-s<%J;Z_&aqz+#6=|Tftwh-kV$VCsgz~EFBm5t(a%xul{lG7 z;pmt8_=l-&sqpVnk~4{@dVQ7M-)bJ|KK3~+kH@=Gn>i~@i}-oXmwXwUvCAZ6Mw1_M;} zZtaI`a>?A73H8N4Xm6LAj2EzNZ~zJKGfM31O7rOiQJ_HNq;;b(w)DMXva7_XEuHM& z!gV_xr_W=iGAQsRMbCiEP)wV|Wi-RllN+`S#`kw}GmOhIu*4gD-P^CK3{TqsJ$!-! zn93DyskoiGzXjRpOw7Dd(0)mcttlL+8%q&T@hxn&dmB$pO|Ag$y}{9UEtP5 zyb=eSLB5x-UH|rI;5k)MUU?fFEcf_*YlIY4K-?bJ!5^9lK$N|kTzWL?JPEYvO0wF{ zDWw}Y*hv6;y|#xHo-tQs6J<4YD7Y9_sR(VHEIU^P&!~_7({>d;qyddOvO0bdM>H^` zeQQ4PW{~-?J+2Kam#Fq^oK-<7489g?3kiJD!XQU=o8-mIajJ-?BxrPLRqbe(?)(kS zOgYgVU*zYDN|?&{QLgZ{;Mw2j-qiAfrIi*TF4ald`b=OVJDlilf03QUN^ znFoc)LXeKa-L!B^=Day{D)kY1;)C%zHi3Jgc5_L-eoEE#A>^&u#`yy+vWE)sW1l)o zr;a1iZ<_`-6r)C&HfD__uTSfGm{2>Q4VI!T1L;Q@LAvOKGs(Aac_pV=1ugtAP4;|v?n}xec1wv?ij=ACAkaHe`5hp++i(DJ5hoxVAlq?QwEoYD|5$Ml^8xgxa|Pyh6UqjHln5}L8Bzvy z1?IUb+mVUFOskn*j$J}!rIt_EpE|wFdBUed@4h%GxY3Z6T3a0|HO`N%c}B&_-iLo# z>EKp?5S?m_ASe?E{+^uA!E?c5^a3zV=Vmhi^-kbxqt$d}J(!cA4)sx%@ls$}{dMW3 zac#2Kq3!_Hs;a^m|1OdVJoswkEgu+n_GxjUwfM6}#=~G0;L?eZKR2ULWv{b0Xvk!< zzcDzlKbAz=QDoUU5%Qk-4~f&ckRyI$C&Bicfo9ra%FQB)5{rBA`x4myl07gtwriwTuu=bS0LV-`=NEXz~FoxOjU4wYFR8nTpsSg+|LH`sS5vFAhN-DkE4aDJ~(T~(I-NM`*z z=gXVnv+e?_VRU{1YO0h#jz7_}LhtY9UZjMep#?YPTc#bKdv?^xpawW zdNZt^qum0GgOsenfxt)0-tbwN7w{fEH4v|A$Nsg_Q*R1c?kk}IvJXLTYDwc70Z1sV zkt1_G5^KlRo>oqCUm(Kc&5fVSr9h;p)_P`hmE_uzbC=WOY24bONfrLRwx~Gg?hNL3 z;?E1*H7})f;SPvk`Ua655hj5WnRd_w=!Xq5oS~iL;^4`6zW@<|+E>3~H z_&q9p@X-LF|CXHKRia*EEtT9f%R=op9mI!T%;c@wXEhm$v~1AAf}v_bY>MPE-QJ6X z%R?g*B=pg?sYgK0w<_wQk7|+xq{{66YTC1Dd?{Ztt}dqZRa@NL?ngt`d$U<7I7E+V zoz(7_3S)kaEJ=n{t4`mHuvL1We?cH@wLUK`-L0%9Ll1zmoiftahtdCp1Ab9?KX<`x zx$_49t7{<2A-D#A0661u8_Hx6XdT^{6gzFzHin<(@ogvZ$Z;9c-!O|m+54u5wfr+~ zTtvXhSH9yVy)&qU-G~yjx77*z&B|{7eUrrA-H4KnU&$_@>i%+SMWL3EudZi^b8`g= z5}0#qko2F8@Pi`)EX))ASoq*anWTBymc#(B%XK1&({Ev9aJc zeC8-FB;Cj}!>5@PC~+p!(&H|s{$Ltl%P9nX11#)L@Tm4FM>bRrM6|c zme^i~telK+HU*Bp-O?UDCR=ab()wf(s7?4Xoz(36w+Ed0PgonJW?%89L_Py`N_6P| z_1x2t$*n~ky1Yj_>I#1EP3TV#iJ;gUm!1|-mUxt7iQF`>#>elMmQ>sQdKoS z$9KZi}L|Gc>2_aE}z>VQ1MgP&BvvomTU z-BE=WMi^Z+e&7l53fXRHj-5%$7P=(jE?FL`J+~qJXJwEW`;*Ap{-1t z*SAlcKmU#HV%l+|@2bxNx0!45z-NrJMnhgD2GfZeqajl-7}p!|=UbofXYtoS7=L3O zTyI4~plp=Gj!GiGFQ7T;0p#MuPKU?E34&TBmYO!~hv!rb{M|D)`~5q^%%)06MbW}H zgV`5>r>>HxA}P=Ks%W>>#&0x+i_e;_V#4HpdpNcZ+e7BPnaw(Sp>vtB8)DShOGi?# zzq?1-?~TuH8ShA1kaMhc^{5Q~CCd=et^Os3#v^gOaSdpuv%sKJp1HH{6LoNm+_Cq4 zOzswCiXP4mQNep5e11ghz3Q;dKNpwmKa5r0_z}qTT1_N#vC_1Tldi$)ePsx+P|&WT z`^=oRq`t!SVUUOatRIdeOsQqZUdjUFEz8LvsA#fz8nE6*Hx;86>;LwXif&k2&r$!q zuX~U3_tnQaBCML@^Bj(ck=suuL_wdYxbHn?Hvm?|eA54eD%DG-qqpqku+W)j6^BGi zngoq3j#OgD>Qudmz$nDS*Jr-|AlOY^hyV=!fUozv;(p}?SOJc`r`-eg5 z@}O9aukm^Y<7*6ik1P7Im{Ofn@&l69$Qg>Y9PLxT{Q(@8;p$`{aeU z&29@cg2pk=(M#L)@pdAJ&ug zga-**$6Ay#dK$~c-^A90p3{#tn5fQsW=!yA8av+3sO|zU5%+o;f6AtD{=<5jCaQ*v z>{(DD%&{Yf@0h(0o4@l7Gp)LiAjXL@UtG{Le~E8?>_u?jP|>0ae_IWX;oNz_vHA}! zY^O{0;HH{@zE=0C@tKNj4SL~IBy7(5(~|*@;oni&@b0SVWpZYBUaETQ+Vi0*5i3mY z_sk;~ddSu${?9#mKF)_{CxcQjw{J6~ zv@Ro4kDj0I+}60yBxmahhVVU%UG0yT5$OqI81a2&-{+!WCUtTCCwC(?^$)KSG_A`3 zboX%_A4qn>wI0Jq2|pQs*Wxc?bCT>w^XJojB6117(O0{Y#CUi^y#g5gNm3i$+o1sU97 zNIZ#_G3B>@i5U5}y7z2K50HtT7UB?<@elmw`chJDpvv*INV|8Fj&b&u%Irg@g6aft zDs~RlsDUTgG*e=5I57N=FE|%yWJf@fomsb{&RG%;?zIPS2%dY(h~>OG9@@quK_r-s zuJJV>JPD#gxvgU51;Y_47<&+43I}jP>A~u0BN!U*JX8svi~Xl)@gLF^1YlIUxS#|e z$m5S%xI6w&5Do!ssbF&Pl%#`{aS`#v_;_(G?mv1s;M3`i_Gu(t4DyH=NvsqlL&=~m z6ZU8T0*Qw}EAFbJg9V?Eu5qA0YCL?cf&V@o7Czmp21+uceWk-C5m?Ux^9LvwB8ewG zdEt6?<${E>KpH9-JbJs5G=FO%O!vv9z7o7fMU%VE;cws~c~o?nwOuV21H6U;+L+=r zl=4mqtb9Q41+d{8R?XA;;&}DiMuF>u>s@}kEjUl5bcdsNe_%9Hi@ii@Ko#E+EgTU^ z^W~lOM=(?Y>(DfN4RK$Y)MCptHScI*|D?Gs5| z6M%b&5-~+=Qd{m?BNMvx88flvrBVP;W#)>VD|oNwggbZvrxX?UoxpIJ+BHV`v8vjD z6tHj>A@8s8L^@8-iX(VJIAu|%lc~Jvm*9YTU`?JcLBLgj5x2IAgJgtRcV$%nd#hxw>oO!&8uD~S?|2&Xe(jJl;DC6iRafq#$!xvoae z5rI5?{dfz{_`SaEVg(#tgm}Qup1{q8dM?#MF6F$@_&WF83?h>v2RG%ss3EZ#w0nGR z7Lp~FCHMW+JGGolviFJEZ!62Qke)T;(GpLz?Rb^*pz5?lTkDUx+%XYEuRY2fpH*{$ zq51^6UJZ97Ddm`wZ#lXb@XsLq030_<^O;fpRbGaiTQZSs$%-O=D-~&G>)*6*Vy;zeBDt4Yjr<~W4oNEn_U#F zmkSXBz=o$)bsf3f_fL4rSOrT$5X-l0oNBS$?o~c{ZhK;TkZGAcHDd!CMhKso@)6*`j-8=nuxj)xs2iLnjd^8 zI{-h^S)(MBd&A!rG;G&6yGGk9Jb_Eddecr5&8 zeZTaY?1PyVSIy{^_#VBW_qDPO)Q6Hl(bHON%G;p%7G&UZRrrg5b$i6Fb>-H(P3`OZ z_dUjG4@3U7gczRf-EkC`rZsB0cKYP_8G3Ch3&HJr3u0}nd>aa`Q(7-<{&BX?2ZjxVj@jFcvyKVHV zgOxcz&!WCM*JTLQk+xChm%KfnZ|o<@?@Il?b)~v$v_{h};Q61M#QU2{$L44E-#0(i zoFu%~kU7eguAtQaqxL4BzcyQm#q>#YcJ)!2(N=imRZWW(iwh!FGwP*76XuY);iP)r z>DBkNtuJ>q98VKKnQ3uX4tY)GKh-CoA4jb4u@b;<4}ovcq8O_blCT?g7hOc2TNZqV z%uV?%-je^BS5#9*4tga%aG3I%W>rG#xmGObSS!jEMC9~=PD{4kbByt8({C@d6t1)2 zNPpJe!TMpW1K|DoU$3;R+uww}3n+^R#)5{3UcYD-_txVM4bl(vMj-g@JBDb?&mbp` z1lZGy$CeB?gZYOPoTk7RE>_J zlH0mFoAywP2-_ibPlprubtJAz+_i)p^8T&7bq2NhwAWcu=K zm4Jl-un};^7&-NAEK#U`b<${~$L?FxusV>pm*9MWPrw=*{ynYi_ny8}cikANvYtC9 z$*0y>&;UT1NPxDHB(X`_m;ARm$p&99os#UqZ~DzKu$%4hyG;(?+qhDu=U`dcecQY2 zxm_PkT#g(WBGb1_O>CiqFIVqk4O0h+ z$hJkRKFBgaLJRM`H9R75*@@&Ph`LiMMuBI_;fXi-P~j8qpiTx!1Me5U5VGB$cph3t z5`mKRs+f{b+8D@oS7Z!U?J*;LoNxKgKx)=s6nze^%;N26QU*d~f zQ;gJzsS)Q8?Zn8B(9mHNL-dv)I2ytzkNW=sq~`f~6iYWDhEet?`(OJ%MkduY;b3OB zA4A!OdqVYwi-Xbw9~frlD#@g(qAKaAPx}W6oxid_vlYDrJNLsc*F=`v(?u!mkQ)k| zAn5n&ac=$X5Ty^F(8Kl;BRpIhc5&!qH-lVw zcKfniR)B6Wi(f(Eyi%->42Xy|qzpqY%biuj%g>LOVdtjtvBI!g@pRb!B4rt>!?P_0 z<5zKLA0sLVSzqgIVYFdq6-~S&@HdI*wl4dbc((|48$rJhpX!o%by$*Wt;XzOFssPv zA@fre(qWVeGv$tFk*xZB79`i8Ba96tRL4~C+J+J1MRQA}j{LL%86yGfVaNxZxsaIB zUzsV4ME5Y`*QHI!kohU^a@ghLQLVJrumYu7#8_T`Sd5w`_9T;D+96o_Z)8p^Ykh)M zQc)046>IdVf`cKIQKL$#0DNSr!85J1jSPKQ%#xHM@SUs&6yz?VR;T<)9!%<2Eg()i zpZW`ogA?3F#)^QtBog5S<1d9nSReWvF7)u<{l9=Q9`2u(_Hm7>VQk`S1uR72o!sV$ zGJ}hbKHdBbS*3)(f75q{L(+b(Sq<-%H3G*u5xduEX$$MpkhW^2L|qed&RWw4p3Mkm z#~)tX^4^0?eZZ9anOt%krvaS=G6ua5ZA3~wBlA+R69n2$?FtpW9WlK*E%HBE&K&zw z$jb^6In!~ijVcC437s>k24ZYbORVWPD}y>IV>(OhRHE^X)6&wGIbI@$^tYk@8zK9% zylAu!?3v1Yy-?oyb2H%4NlEmD2!d*HWTbE83#RR`N@?I`Vy0BAYUwuXB}psE97ROT z4y0@xcuEnuCX-oFM^Go(A0SP;@bix&FS721L1)#O|4`hF(s5wkLS+H^oxrn=BdmSJ zr9KPIbAiX>m12^O*t@fl#R7r;y?@O1s3h;)-^m0#k;5D6Tb6p(n?PM(CDwiXtlfdY zW}#_y+JNdeZEy~L#xRp6IW5dnWqNC7A{^8N_Xu3uBAaNjJDIS&eY+vMUWPySJvnhQ z1ZMz0sTOb!CA4&$O;#ZSyibV6(D6!L_qL`jRR%nd@Ub&an$N3)-z4OrJ?!wXec+9x zmfxvEK5#T999oY9C4@-`i|W|5RMep&F)(rx+~Z6E8s{Ko$JtdSlD`JGw$zpj(!2hQ!4bjThSvEYYA?0S_L+PC@8FMq|r2h?}n-SL{w#OABEegVbk6N@bS zIhgc}!@t{yActSdoR`zE%<@_N#5_*Poo)riC@i!bD-M4qIeLkr;LzIiGEYG#*i_Jg zTpduZtnQpzWkMd?{&WnEnknC&V+j=p@~?57chl#5^X{DXaVPs8T4QatOuS@ai|2%Y zNsS1~R1fs+%*gK55jHv+SXylt;?wdnC&2(XVy#kj5yy%=DR@Z0(OM4sWMYJNc-_ zEb94(wT zd}KY%xK?VF=W&hFpT^moZ6eEh{gT_SC~a`X(ii5t67xbnBe$eAedPTzLo$qgA~GSC z%tCC4e0GFwy7@GIUcLNQ@ynzH5)%5!Op@=G0gpw$lNb>FotAfK@P|K6BNKoH0j@No z53?{fnp2@oR-gL#Qwrni=~k?wrQaLdAA~c%ijmAE(LPHlcD1mjRIw|xrHpMY^|#W( zct?89ih6p=($d)%EhV@mRiuFrgdGhKL;nF%Y~C>UjVNdHg<7z`qVW|qKNtB#YGPFB z)_sNCD304Se|lKPvMc5V}K}4f8NuDi;|x%CxL=2ejYxgr_g&QIX~&^eW=w zV^nUyGUK&;{`3Yl`MIvOy478bxCEVmr>1?`hs(YLG#;t81H-Zf>HD>HUEJ=79~}Na zdRl9{vi>3B zY%8XKWF*`^4`!bqb%pupqqf0|P*-lxFJrfIA0>z?hpAU2lx3pv^b_<)yb4e8NnjlK zDfaUpak`&xPe*tQ{7mR2I4Uw(d!-jB8w63{&g_31z{WrK*DvZw&~CG4>?=nc(Tpqt zn}h-3rRB0-Hn?2Vy|Zm}NB^iYjjTLZzvsb6(rhD)fcsEK}8>8>ETcwXp?69fE(i zh5OFUCz6wMmXKwCRqWA&pKDXUv$??-&dAfGa6iO8P->3&EeST0IZ->x1Di>in?3fT z2?cttk#yoe5#JXfk~3{4c3vG_4%3-v$L6xVAzuUU&pG>&i}!!NvHfzW z`v^eI*&e10EPTagGtoimZLNmzc!wu@=*_nTuJa*$y8m zYbyJz%zmQZ4-T@V`BPj)9qlGKjWf_rjp2pADOA_Gm3V&oJEvyS@t{Gtx_hkV|L>!A2&CuLpW zm#7RfytbY$U-RhO<<)lk%TeB~@4L-FqVo(dqurz(;oa|;RiJr2(xU>X7Ik4*C@mxM zv#e*mUeL*4<_$uaNfAuY&23B)^(l@wT;dM8&jD9f12mNj@y9+RmnrJj;`$vC(-aQD_+`ptdpqOcLihUV97GYZYGE#+si%C-SfMMI zOq(n2IAK|7f0KU6 z*|*d)(@h7+ow10=*~Ynia~&RW&l<@+4g=2SC;l8gLA@n7zZGet+%PL)((bWuwQqin zeZ@bO)x0(Tms^IOA)01Sr=fbu!a$YC_^Sdvnsu%*dUi{({zLB^xViy+ViB1 z+cm!9ndF;L#x_|ywPt7TH8L2nJ<%)Jc_A<`165+T{k~^hIj#NTmxqqJxj;*?RTm*K zYxIpxgdpSYbOJnq}5BGDf~Ul@mW3zg7MA?q_v9>RTHx9(yT|eJ|zVM2|^g8v5kX z=K$ubZ3CvoS;F#Hmnl*((_jwU>N^*mbbcy_Bd>~($O|=$fGb2ay;}i)g(wn|EXwh zoUJz?MK2m8r)LlY)@1IlL2>M%mM%5h=QjCua(6V#s18`f-Z@VqnK%-}18p*J|73Bl+hWF7DtC z{zaOST0dZl(+M-7Bvy9Nmky^NjjbOV!ii(Alyo`gYt8$_60A=f_j$SA(N%{+sA7|< zTUrbxGA@MNe(WFG>s9(L?lnhe&d(6*J{*1(usbd>Yx z;vY-Pzd6lMGMx07z0HPwWW5iJ7&?#?1{|?+9ee1#W51qbY!gNkmKyInXmmOK_k=I0 z?16`3se;%}S4B%P#Ac0psnhaHih(J|s~XXvu8yHmn}VLwn+;?vrxrcFagT*R@IE~% zmiVqbz(JCa2qgUv7=VZ-5x7|Na6eo4j1M=4KH}@u>iYQT>oXS=qvnUesK$@rN7>vUiUA>UIl7YbNo0q_e=>x3AkZ)3eZP-_3&!WtWnV{yT%zucowG|oS13m9YwAn<5l%iycR~pZV<|fz*FdY1db@v_WvYSr4XS0#G z9mxg718={~1vyQ{%@}HlH$!dUd7Q%ie>T%O*h+=|q&yDSr#ab*yx_QJt-&?xa(^oS zn)O*o5QbG&brV+|gJ8!q4nttaVHjk6%q@E?zak#is$EjW?pXZ3FrY{*_C>Rs!QKy^ z)3fd$Lyi=FvFva}IyDM6neAb{G`5Bi{|`(H+Kw(QZmu|2T(?!#Rz(^HKiCB~V`Uuq z7r&}H9hCGHigC*iJ!<1xMl-RAbpc;!@+qXhM*^KEH{BiexiCS0@gAmR2y5P+6@4J(vp6=XX!x?Rtw@o1fGmJQ%{h^1?X@+Z-$hyDIKHd+hQCnvo$YV$!)-s0A4nC4Pe*M_P z`q{|a<@j#*VDm80_Zx6v?o^}W1aJGN8sMbI_9Y=!D%zXh7!B}E7%r2;Jz;6VX1r*<%RM+cLcUV9U6Ez~Ciwj1P1>BX{ z7P;7yHO9FyrKH~;?QKW^6hd(gj*65M|Z55f%CcXpOZQ3nG4c_<$~d2p1tJhyeQ;$`g8_(JZXHkV90QD+u*(v?>4q{Wp{qfbsGrtHV19BV_X9 zqcG+aRyA5z0=$OvWMY$E9a)F*gC}a*?~!_zV%J}+Z4h&PQGXLi#ZuFD$&{iZBEFbN zJI!2Zmp=quHjF(HF+x_W_e6UnA&XkHzK*aE^`_vG`cSqj4HtaZ{cg}BjyV90d`hct z3S$Y6p$*=T8n>^dd%Y7~Ud-9>#p-3zqJRK34%^(bFF2Ok%>hZtsDFN`Fc^gf0NCEQ zgmt+DE-kValoL(Gd31`Y(PEFi^>=Bbi5Te0*3d-%nGp9r;Ep`Xpnh9FDm(Z(TT$SiM>?jYDbIZUSU-8%Ina9Gvb*ea0|}W) ztwJ~{)&?yx#V1k2D6Wg$~>+g+&}-cD&{A=7#AyW(GjA zPbB%}z$8ybHlTr&$@@to_TyXofqsrR#LqMj0naR`C94Od&E;5{BW2JfXHC&Jg`U@)nZo88gBhDgZmuRNb>ak;9Mi@}Ja7Hb{fzt*vmF3y-sRD#jRm3f|P&1G8A7N0vCa|5s4+LfRHVXu;E51C!)E*k; zjPT6_7jqdvT@{NN?dF*CAF)GzNWcsR?53H&Ip>91$foK?!?P{?K|}ZjE#Dx?oJ*me z5dxXh)J1C3d01N{BLXsa)+6j>7J(lou`a5~3qIpO)%0*G^jvrtQ7|q}m|85GqUN)( z3vJ~)<9eQOt083_CEo07vrT&u*3xZuVyUn~qaXT(7zBw9z!Yb&aB>*2?sF~jEkfLa zPn?28el`Gnv9kUvQrSb<`?QI@vPZW;hGhZ;;6re4!*GCI{^ z(xEEr$1tzij7j3Z1=S#dNxU)uP(^_l^K{rb8@D#}5Nd1`f*ZnQgfMo+VHF4!$;gVp zLJF~E%El{86y)-|KUQ*0#w@_81fOCRFQ#hE$jMG_DF_^*mEE=o$Zql8m1*V>q>Cty z$-mS=LggVux-?MF*BYUYK>WO^Z3=({r%L30#(bJ{lLM_k)_`6`CVlrV1L>O%Yb(Va zHEV~crydc_H9KZ%`%u;cyjVS=8UoZ8;5O*xUP%m!mJ7$a4-R<5>0rRsLO`qBa1#_$ zC~rqQ-BF7*G^-4-4`CAcLIAS{*y|j6{r0Ch3sEaUVt|2C#g8Q$#H=+NW-CP&C0rE1 zp5focrxjKx452*y%NTNv6dOQez%*z^SZ;uI03Rz<0&a-W+F&hEQedgB7*J?v2yFuc zl%ezA?2)OQ?*3y32tc*OOo{+0(q-ON!(NV;0IDJ15zU2_3CLCl09NQm%zXgM)Tj_k z5zMvo@xBbKpb(rsSuS}$3~Obv9!sS$uQ%}-)WpJ~Z6tADKBbO1N=+g#>Pl>deGrs6 z)9_PPjTJZ?q8YXfv^)?9E6UWdMH$?s;QC%_u^RHLN>V~FUH|~gQF>I`q#=C%VTbdK zTr6v_h!=FV!sL<}pKNoG&kN}2n_?pKkh9u~1N{~UZ>p(7v0klx%ki*HqIf6hGc{Q8 zF0zxDc!rA7%Vb}?pJ~{kP8KAjE2(BPV#&c(?IB469r)0@ofuSKZjkk%BQQ}w$U4tl zqo5{ZR5Eq|Rd5zY9Mj>jJUGE7IC6Gc^DdINf{)uZ=GV4{iH{~+)+N5>@%xxZ)Ey%_ zQhF|+ZAZu40^-D$iS4UDSd2Fj;_-SSWG>AMpO?T@An(=+iUXk2CK*amzizj>^GP^v zkLr^SGjOYiz5tb9D)ma$$HHe=o}Cq00=oCUy5-hW@;%+ysp|9D(H!G6PR2W@O)fSi z?Ptwae8vIqKk%YW2HyKoR_6VkD0owa@nfk7cU6zV?m7a6KG=e4HAwXkkH$AtVK!_H zRN2E3czUFk;oLydvMoJy*pu`SZ1g&5WNng#GVm&i47eC8ASUnNWIMaqw{n0X1jzv$ zkAT7pX^Zqrl8n?lThyqAwwd&sdZ)EenP_I!FNlW7W!rOXWeMqUsUqd0OhY6s&zvl1 z@hl#PHVGThsIqO_I~2E#wbR8^*Ioz`a8%4ZrB;h~drMAIj_DN95e-F7wH}jlju(K0 zzRX}K2VgkTT$|FsYx(W$tfZVD9ko?=f_{M4G+uz2aUs{Qrb_SUM(PpfP7QvE0#nyKemZXUZll&Y1Vu}$qOVV|j9$)ADP~}Tvd>n>5 zD+Y7{A&p|&l=cq&zZd7r+n1pP?5Z@lI!0~+43CRSxjvBR6>V4I@GgqmuB&*U7gyL7 zov4IPFN3jaaa#H8%4)wb>_uj!$etfgCKi#5{rW)fFWh0CChwe^^;8X5o+wDCU9d0h zbqipy)kx0zn_ThYacf@ue!}F$c3D!7DQsewlHI|8SI{lYOTqT62jPA86vzI6)#K=6 z=&s%$n;kC?p_#AhdD9;kZb54%kf*Ig#Y(BXX*nj*rmUD>1D3KpnPQ*4Ti9Wi@!DNd z`=G4h1MIueJfh$`JA zfkM+lG2-;%vsoEq>7qht59kW#M#)+2pP^rZhTcX(<>VZqQ8tG0zopadgE~2VC`6tP zQJe!7dZO*G$9lcY_WEzbW?=+FTMsw6e@@Drtr5c;*MbhRu4|hh4|}^XAziuO?qY-E zM$_$PpZ}~#HaoMXL!BdR7EsQ>wtoEysTf*tZkm)|*ca=CQ)i-qym1qN!BguVV(X|O zL4p_4aHU^flf7{qrAbJFc>Jwp9X*HTgKNdwm~vIpD=3Yg^OJdzq(?JVR44nh-J{Hi z`d$(9v>BEh*)y{3Bn`U#2LeEfUuJ6jH7A4Co){rKklPo!bwv;oi*4gVQ?drXPz{lx zeySg8{RQkO;ZLjJI^i>tL4OZ1O!dA4B;#)h04&r zLO)El+sv^c37J%#Y+f#uRaV;vz<3l&K4A~D38J0Xy6`5tHYLG|(E-kr8*?uexiIk! zXX-SrWX|$Q*bm4tVP#aMCY&A9SSeh>V1#y9isa(p&hq?xz(vSt&b0&Vi z6LGe;{xs30pDjwu7f(CGjqu@vd}}mWmp4#+;g4ILf{wvkvD9zH73nS9i?2E*TRhlt z;arN2%IFSc$WX?TR$GX#3B>AXoI$oxCv!V(s~Ed6Fi6p!d_vU@HJxdw7_CHHUjC_* z4uSBrvxBH@m4^*+dg5S&Lbn(~Kt79zdCq9B+xOW&FfrbA95s;_R?ZP|;Oo4H6L^@^ zaB-3*Ya39ufJUB_#2kBfygV#Fo`phCrP*f7a(I;WL+XcSOy^9`2W2@ffag(UzL1|9un5#6-(!(##`-aO+`G4lOVU~>)?P)3AMubRwfqlEI8weJivUjabU z@^Dn=r-)XW&Wps}zyQWX5_9sBW?Sp12J^I48W#>MrHOK_+glLuqJdXay4D;_OJn}Gf3*rNo<$%M-65VKzJ2%}3Y z+QW^3>3*zdN&ah(DW#2g16W;Co4)y}i?{nCL!=bh^%1@s@HtZXIMb9S3ETBKRxBVs zJU*T?RP)WV>vyeE=2xlf`iYp+)b--2jxa6{yz&{pT4y+=1Htxj$9os4$ou{7xQ#Uo zzQAN|MHM2Ab_R_L_7>VWnTOz6Q z5+jy3@;R<+*-^-gz(1EoL^>#K-YhsZpeh+k53e)&fH@>St!X4#To*_g5&jNe9oXzG z5~0+m15fDF+5(Z(Et4EA;@P+BPXiiR)d2>dfeai{g%PD-)J!lfks`u{jVUqUB)3VQ z(1_6#{$|?^9~*PV19!-Yz;;)@Xv(i3q9rViJvpGV?~2XqZ2;V5vEvE`ENl_7s5Fq=#e_y9W0dPMEfy5QZMDxMk zP%n(r;SSVl{Zai`*VJO$4AIR}vMWDBxLYsaJA~D-Z9Fb$jqN~vsp}2*W*9c1d!yrV zXrW%njMT$X@lcZO@W#@KT)^las_IjAjMQIXaFg4F|HbZ1ZLr6W*KIqNKLO5WXc*d$ z3M-d!N#Qg+r>cqtjoNWFuMM7>r95!DL^OaSHHX_x@Cdw+^UYaXI$N-MB;OLrwjQ5} zs=o7_8V(!Zf=JW=%amtaWv3WG^d)x8EQ&XbO+?+m{`E?-Wgr_GRP9m(j z;S#9=36V4}CFYv(ncqK2GfGvJ_PwCKz}<9kLO;)Bk#3%W@!o?bLcX)!`UU!@GQ}e4{GODqF#AblxzEx zRHfPhrmtL!b1Dn}*g`4?M4?5AtmGb3>o(3z>;qq~;2H5YmeW#f>eL247Dzg3G&-Vy z79o~mw}?q7tfS!<*>6dqHu5rR*>Xt)QF#;xGmDQyN{;S)2>>AlKACeU6xMVSHle{M z)`>tyrvoMy2jS(wp^Wd1BOPRt>2a*YPbWcR*cf@NKi8?zrF>CpxF1n^p+Egf!LA1QSH_X>mx4q}J^%Nkhna7_ub*VL?#)RVWr05d!c zA~B7HIBaY-lqf*%rn0y0f>uT<0YW1kYs8Uge;WyN(}i43V%SrtMs0;--R0+49sz0z zZp30s2`Wm464!>YWF2HCy(dQ9RO?P%*AT9~uJ!0P6(9KbTbf%Q*g@0BYW#1bk_L?v zdSO4~Kq;(7{LHyjA>*7WLA&}*d&x}#Ylcde)f7_(Q4)*PYxvtWUdgL1x>-}3;~v8{ zR&UKN6Gklf6r9tTg66thkJKwOhXK= zII~nOQxvOy2lg0+@XoSKUJ4o*ALLV|D+fVqbvFcVZ>ImdW{X23me!<_P<|Pda%g&D zkMSD)AQ2>8v10zQdbR+87RY*>{E;|{{6EeAzZClKOW4@AMR^-Lu`PLuwTOmd+x%NIusth3-itMzS@l0gg>(x8rYcX7FUdL(T$hh>s+tkkSBDr;D^Gic~Yz2m?2O1*^z)6>& zYtcSU^NOxq;x$O(gIRLfG!`HB_>)6CD0!IH2GA|O<6~l&?Zt5P4y8reZZ9x zo661Zuqy$qu6~|xx~3%$DNqrtVE2?R_|*KF*|MqMgijy_J3v(LmfW--Epn{@B%t)R z$04PD+|}BH$tFshZb)mHDL5x>;(~K8FKf?CAr|onQjCdmUVhbe%!#g(R4kJuAv2tO zG(8GLd43QMrSU~ctUX+nedk{ROAbeMoUA&=6p=jNE$QB>3dNT+;nAlgZo4Rda!LHM z&ebupwc@s4mU})S6MsL*=`i~wG;Hr)r(k4A!)%5Q`ITF>qOE zC??d#w6-T^qISK&>FQ~yej=8#HoU{;l9MLf%5Z#KfcX%ZsYUJotU)j6|W=&3Z z!kHQqGd|QF0fdbQNqp}`=N>OQ{mdrzf@SfmY^o!4T&hxH4mio#M-Nb6ygB0}On-gx zsix6;XEhLT%A;WHj|HD@=ZQ3uQeVeaR2bAbHdyLLqF!poFAAbx@~WehN}-8l z*=8M91$J>%px8Fg;O zo@7bVoMSwJfolEYAGrnCZLLByHgOaR3T1`!%w}5C^>x?EB!6BOVMAIhp!=i}m zfdHX$p2R?iP^mA8fR`0I21yT3d$4S0URMeDL4Y;0wFET81N|?lJYSRvkXaBYlR$%) zeYg_yh-*tqf-iixLr5}mfR@j5(*$6Zb5AIqm;feAwnzQ+sT*phTCmeiYQbm?i{T2D zp`GF20(NLwf3U}-gK%%N#t|4Sb$2b9fXQ^7Gw@Ak=p&Wbuj$gN^JL_g194OSkFlK% z5b;s%WOcD=*v+hpRUxyy&PYFXcj47*&;Y>tOalN21ptWVAEvp7@;?Gz{Z9^%06>6jEg3t#LiuthGVIq=NjD@f z-hNavfY@!?7TYKdCS}GZ=-8xNovU-t-{~aN!e(}jZ(fqlu`5&ZQw|u7#WR_a)gj7foYR`gyD}--t-=t`_nB{Y+4Nb8(=&u* zVueQgh^!7+wsuZDF9m5s)>kYNo~LrO>G{MGaXnwJ10yHQNQA;xJ4C?;^6a26&oK$; z$osYqU)VP^TV3tY7i`O63jMY>(OX&dpF4{k!NX^57y%X3r40>&QSb^-L2NHUU0aOa zQUx)eNmxyVP)0+C0l~D+GdCib4lz?)!<>DMeLZYI91v`&&HF;_nANcg0|t(~1c!Wn z!^yl{1s`P4cDXsQR;?g1kezUIQHyvoU}X@)Y!0Q5X}KO6Knr^Z$tt8x3&x#B)i&aa zPJCFD8yZ-_t>=8p7Sv0$n%mQ_%%Z(McQI*wKo|ZgEB@SFnOIq>LJtFm(>TgX3&_{b z4kaO_(&`ib84JBKAZ$7)!?5FCKRrQ2Vh+LmUI*Hww{U7!XUq680xt~awd3N$tzQ_I ztq49)dfvs!k}iAjF^8*)ydUV*QgZO<17u5BmZfUXku=S}rT#LlvS#3 z!9%$bo*}e_zIF=Ew8vFm9#N@MFJy1m6$(BVh_0@hkC1a@=7QYt-)in@-pCsoeQoa0 zij$)RDWm)pc)~SK@t|lTDZ}Mzg<(sNsiAqr=;VCVv}ji7Qf|Z*xQBuxEaTXt_l#yq z%S*HB!Py(;)bi6q7RQrci|a*Snc>vWX2c>If^n4RY%>D2@LE-)f+@ziRWY39w7{&B zF?u-4tc5`Aef_R+~G6-J4^ zHzz3B#a9+I5K12UPQG8Au9&3k7?GBi0;KSUZ+5cB<&`9NTm5d}P6O3r)Wnh71LZwn z{B|~Zk9=4MAW@1_ECa@+_~CeSx;06N*19^jy;utBrEGg*&!)~CNpOkj(Gwa1ss4?h zCiwR>G=lq1A!bbjXk+9?lp$LE<+wXUWjX*-4db!RT68H7c%`^fl~zX@ zrt-B8COafX9Wm~BwO>T{WQ73FPIsutd#rw_W%}#VIkbh_#Q1MfJ@Jg)nHnso3AbHR z*9$WxG}<8mvMv}V_KJD9nG+7V*j}UbD}b*t{yec{ui^Sy88kv2!ub_Q^&=P;>~TBt z*^I%)fiK0~Fx7*KQ<6B<@NYkL2$&%bSY!*1X8FNDfr*@zrK3Q+|E>7IPEe2n;JAKj zJk9Yylz=l}Yil<+D6H27Y@P152|a;4xtVsuqe_9T`g-&1Vx6arv(d0=Lo*DHxcu- zLMl{5%}AXAAG6bR8hZhSQ(_oemYIzlvI@yi8dL6QcWTLq7ZCX&h4R_&#mH^e5zIf` z6~Tmr46!9NtZ%5e*trYNPVZ_ktCzt-N2h3G;+^7GFEd}=_gr*S6}{8I?37VsnZYHu z>RZg{qs|@s5>ZH~u9gfvx)b^cO$p+g!8Te5XF2PN0+uJGGDrRRzHmgihd-H%qnA7` zz-+pTcb^)ANNEI4?YNy86#COaS7<7N`LL3wW6hZ*pQe={Dv0zANYn*G@cGt>-Lamx z-~Cp8Q(#R@nj2S^h3Od+NPHq!Z_cgsS)^i{E>xPGVObch`QcCvv*8ha)rpB~0XaU= zQc{65k!#lh9IH5D9e{cA5J^Wa|1`(&ro?JnaS4gYhz&8UK3<>Lb5y zA@6oe^nwibi5rth25?>GY{&0;xi=cf?o!a1-`1+815mi52F8k% z8vvLAN}oh&E4oVG%8I6OXBRZmsjsA{F6pOyZr2gY7U;0)5%`O2?M2uUv~yXcC5P-z zdiy}YPm&44(gJrxEKRIOeK3M2Uoy_S2D& zl5(z{4S3}0g(@j)E@zc;e1jA2SWU!W(!u(q60*=8C#wE!Ul)_T$RhXTC>G?AbkH2B zm13pmTP{mfdtrz(BeTGamlshK#02y$9#k0$SR$cBtYCqoUE&+zcu@^Der+i6G<*;8 zk?CkNv4S6AAj;Wzxv{o6cYd30*Y8W#>`an4mc>H2NbxyK3d?JAp8f0))L2N1ZsDkG z>_p~fwRB!W7}KTrACW$2FU0{wQw#!yE!*PQ#_R;$&w7DVQ)>HU+b=%ER$Y24xqgt! zeAUz;QXX@}3=!8nm(8=5wj?!kem$T%r8!9#0W=9ySNm-Pd?OGjA&|YL%e1MX!VJQU-!jPJ|6s=Xhi2ekvHuSOO8PJFmKFdTl1f|jYGTqxP+ATjg)nqlfaj7n zkAG@uYXjf{wA4T)eH--xNp8WqIVH7`?ds(K$ zY-R>IWAbW%2)XZr#%Mn4El=V;ylFV|ZgcL5C|g&QM}Us-)cnEwoORwmGPLGa)mWs$ z_n(q73DPLPl24BmKH1kMRWNVXtRJr`>foz%Q{`HBK9CWSB-E%V5p#Sc~OAxi+m30lo8nG>A%LEVecc}0mG&$p>I z$Yd)OeWlEzxIZhmlYO}Tue4}_*;jtbp_ig##jaa>fBFO~RK9A!{zP8l|BbC{oW62w zbD2qaAf8n{(N%5)Y(T)hZS3lIKx|k()Z;aBp}q*0J|LURpHNtRXI>)%V8m zrcxSj7k=SE5H$UWi|ujMz4nVs8s#Aa=WwCx*V5rCMY6c`EhDi%@geZr19%p4kAo#e zj`!FcIn_ITy5%=PQtlXvA~3+gaAJRVlWaL>#pFZ4&3d!*yDWvCfa>*v!dC^r`X6QQ zUI0vDTi|EMV9V5CP;sdVIE-unR?2Ez94M~#`N^$Rf<66d{Y~#k{By9hKX? z!+zP*wW=P|%xm=rD+Kquls|AqTjpsnFXZwO8Q02U2;C#2o7T?gLQ2z!*ST}Wiq~5p z?O?hBY%93(i!QwtO&W}FBBTg+V4|`b!e07&2BpqX3{I;wP2jd8Q zi)?r)UiEXCOs&d8KO=RCV0%^W-c}38UiKh2b;Ul`og=PV+UUK+fN{@VqN5%rjLKHK zfop_&@&H`tiK?`uXt2R8I+{Z@FUfxMo*=o%7vx@)#MIhW9?Q;olkye0xTC3@8H1q9 z1t);E?OoX>W2o6d*u=SgSRTL>(&UZ<2hEQT&&!_RL6t+U7Uo4nshfTcqc5AJW^i3L ztz>E>SJFAPYoawjGAT&1>jn4D2uYc|C8M2dsh(EO%ET$qsZ)%&l`vsd%gl@;+$I#z zxcJ$lWhrrzF%HKp{b7*FWg%h;;!>8vttQWaGj3uu0^!MfJJ-w4CnM6BN+0F?(i>We z2t@=99A2c+V>*|hNqDenDZKMs7YZTmI$P;bd;^q-M5%$G%U%qTabZzyuk}l#mF)b^ zlf@=kr^LE3`&((v zG&S^&p?3+r2uK%DkS;~(T~Gu;x*#HgD1V-N@9!PsT_4Wb`|LCFAs^O0YtOmn{9Snm zjq=s;0o=U~kyaS8ANTw|v`)oIu`H-F;wZRk?rYk!Uk^WlkTjI*NwRnA3^06X&?k)R zdY$9&2rjv(^IFA~SbgB1RrX&@qgcYYZ5!8d581mBR2kd2_ID0^N7ajD3Q0+tG7j2e zKBiSErH4=tS{>rdXxI_3Dojk+Z~&CqwOs8;74uLCt#+=8EMCcRc#dc@6~jgm3=a?j z^k71`=7iB04M`M|BZmDcaTs%9&(24ZX!lqE*9hC?D2oE z{3pq97kAED08k|?=}uDa@9!W^&RDmF)bs|f6sky1jyO8h)nTu0y31733NZxmd#v?% zIp6<<1|_kwo1+RDLL^wvMQls!j)E8M(`Cc{#HQc}U7ym`7_*k1v3k*}uSVU7wCqpx z)**M)p_9y$Vwz-5`9LYMHI(iHmQKm>{F3KF^5ZMY{A03dF-4b81?RrO`#>Virz*)c zj9@Y_O0Tdpge#fqJdBijEWAHEWXQ49QyUW!4M)Am`()aM?N`ii^YCid|J(1Fztmq> z5&9g%7CWZtC&+at>rQQ~x$KgdNb@fnO~chD{+Fl7V@a{PCr78RnVQ)57B;fR@Vcp6 zb>e0&oIv~i^5~REg}WDBl9t{?JrQbzNn8K23E-7a+v5F|npvlnWJS`)r5Rnk7f;L~ z|9<=hA6FVxu3jV=5F`!oha-G;V>O9-F*d~RDA!KHFb+l7pHImHs56*k@#vJ#`Zwd+ zm2%XYQE*N-l_L+)V%~EEKK^K!zRli8T>9#AXPqV1v!{|qLT@Nd!!{YIZXy5!apVzQ zAG8{5Vx03_@|Lin$iPyjazg-re3)exx1J|nA3AvcHGA8@;>0dB?mVnYO16Qid%3*# zhAWBfw|u{wdA8)HRu88Kwa;hBl^~P(K$^UVB0}lLFt#PUkU1=Q>Td^sn3s*u=347q zRP5Cj6z@uf5~6neOtLcq77YZ(|27r_edwztiq~ThYkg8Slf=iJcW5J>bZmq{Cl4r( z?+5u=G$s2>^4GjiTA9M>IsIHPWvhh=3Lu9Zcmf#JX_QAGlsfE751uxaFJcMFHk|Pc z{WeK7DL~v`j}^QIJ$;!_Z>VlJg{PC!`@Y`l z(NrqE=D)f&&MmK-`r|8oG|DII#QO_zc=>mn~21PmJz*_sdlpaVWQ`MgVR`_ zw`uDDj?OVJOzL?NkqzBPYck`39o zAE~6P%Hqj$yXIBi8(;d80OxOzD}EvL&a}9#uMN`*oNmjp(Iq2PQ{?7e@=@$c?yN~j z%$gXT&_dmv)?idu!i=hRJ0Fp1`6yy8K;pMg;vVY8*uZ7-A}(IR?@PMgwFc-kDB_ivEVIXmrYCgz$%s zS?}lCN8n;d^U_Zqnz35G0c@WM@A!2Lk41rVU6@=ap4&})Z{PV4W8xX%NJ$nmmPk56 zvH9x6R5mqY00WCKL5EkpT}c6@fA+qDBYDrJgITOXk(K0+_$Zu;Crfl=cNlS(dFbG& zHr>%7`1iAnv9;qUp42I>+q=rp%&L5Cz;#+)8 z%4GbvZ$F#8D~M&LvZ*ptA5si!WRJI#eRmMFrLQ?2>7&Dm zl9W3itQ6r8sHJ$cPFZWqr`1p(2k+Czb7oY0xQHd^3F~UWZQ!@`gd87}%a%9Oe4Lmk z7ZUJ+9QFGGYVDPbxZgg#T0sT;l4TPZ?(%L&vqQUrwYH1U?Y8SApCXI;+rBM}aE&rb7tPq8p)T{;2szkMzuPCX0cJeun zAD^pVS=z@xUawv4$J5H34~!ql;#M;LWt*WUyj&Y!x)yOY%ziN=`qoO2{)}@A9+Z|; zYIXywZ(z@Pct9{Vua=EV8pD%-oWgY1N`jyBD_&~Wt(r7i-gB1b7J9oEds5EGT+c=A zIN0$@R>-aL2zF1GzNvI)CW(aIS+}xb(^%}~V@b7_PYF|B@+8ahhKanZK@Z1bJz8V< z5HoR)RRxQmYJiiFac(N5KjQktEIsfj%DjF&`QhSLJ=kw8k(4ed&NIs1t@LxC=uIdn zs?F(J0cZjbZh!%>y%GxPLn?xP_lZKMI8i^q^NR!u3Z8I9RD+r0qq>!0TRS3+P;E32 zGe8{rASQAPWx=?`Ut)X$SD zuFAqENYc_SSLJIG7oZbocF2}$iuFZpM;{$1A%&k+uQSQjs}Wl~J!VByP2)J99YvZR z)eSUViXZCzO?YyEmPer_-$uZ2wvK5W|6w%|WaG?>#XmA6{hQ3zcga}X8uOuK1gDNT zbKOxvZ5DBc&m;3YfdB*Io#OYzV|jrB#n@*ZGcP19xDc2WEY$5Q4a38h`x*+mMva0r za-+r|g15P~CWTmnZ;ywp-25Ax4q(FD@or9Rd~ z+Wmo%@So+xmTX(r4#~#bnM!A{g#f{rD2J-kIk~-K`yx;(L70BWq6Tl74+gAe+7x=&!?!lYNN4-D+45Zc6IGL_Kg8WBS~^U z4n8@WkjMookT8G?Btb1bH1uJP%+y?c_D@)?(mbL=*8P5sQ|f|_&an83mf$$fWK6I! zPm;Ud1ciH*k;duqyQoXORI>7~-$qr}`ZMYHIXj{WU8cIm+$m1$`H7U^fY=9HDT_m? zL7bQx-yHH@=Ky{IKE$JUvodztauNC|W1)#L9;=v8k~-}^Fqj;x^rib=ZR*vPC!p3^ zL*zq~Pct#bQpmR^y9`P?a*Q%j99SR+#N+r1xsniqSF#`Ph zXJ)dWDw07$99PRIuU% zhmP-K6d`1R3eB9rmMZ~FF(irA(D|(F{R&({Hr|cynMdDxRX^tzc@3ya?@pbNw#qk^ zi9r6=8j-64Mj#~%@01(aik~H7SUivIKqb*W!Hd2Wq|nJ@rZ;u@KxddI;8R>#f0~&( z)3tVrL+9JmC)FSf4O~e?NRyBSz@k2F@4FT=O-~H~`leF1F%6pk(l0+rPZ_8+rqTXd zYyl8P`PT-6_!yNg^BL#pnxxXF@3jE%1%k1W_~=ZCOyNW)N0t_T8f$UyIppD>55^k;A2LJkeFzo;lkCEi&#Jf{lDjaD|L|Eut zt>3?4&URQKUeBeRA{!G$@n zn*>F{h{Wd;INF`VH&k~=Q)_;&Q{+{P0!{p&rNjH zdPC~Pas`+uX(;pY;G$-&kuCIr4%r)fg^fSb4Ep-Q1rIg*kFjj{qFcP%{oX8hy$Kns zhODqxS}ao|mwb6NpZuVCs+ytC@C*{&zUJCm4?r4M!Gzada1aI*jHa{-HiK-BK(u8> z0c6CFqfNE%1tB@8>rrcU%kQK*OxktdH(k!z5C?=Ln7R^;!g+#EgsjanTfVOUBq!yn z>tryZ@fr&S{g|-1JKvM&%%*X5Q0LL`g7N$;#ura5A^1M0=v!W#M-4P`qH+1bL0K0+ zuCL`2ESdj}A@KfuYn*?5YtR=v;B|pqYGJZFdaJD)NO7sX|aWGGqp({D(ngM4QA^l9G+M&FPU28yWT^MvyPX&C{7f+1Dugh z5>h_Kx|dYXrQgOUpC|Y|OVwT{p05)F(V zR`QCZoqXj4Z#Iu#_ig7;zlt!X+$ z_ZWCJZl>uGUZ%AgSCwzd{!Lr?#AVxtR7~#LdlZsm3m95A$~cLAPkU zKxdx(66pyz(@p9*`B(Oos~2;6Ji>o(?FypZA5V{K6)%s|i)#pL#E&92uK$fkLiyLF zpxZ^j^DS)J6Ha9CqwiAH*>TNb@6foqa^0&ik}%8MBdGOzu@>c9i*UGg_WUFN7t&XZ z#w~iX!Sb$1Q^YgMC7#L&!6c*a%$V^`&8%mszER3}l$Z;BF$Kc|9c}<5?(gqC!zd8Z zn4Jbx7FuT2+I6lA*LcQ(13*cMugMviJT&#g$galV}&zt&&V0pP@#I zeb5Fi-gcQ3+fO=yVM(EphEI}jON)vTw;DcW56H0hAk}a$m#1$v6M_b7+Eq1D_V`*MEA3C(Eb>1;~{&Sd9 zgCU4A+rK*dX?f9Bl`YsI5OY@yEpG}kPw6Y0BTxP0tZCivJIgY&*ayExeccTp=SY4_ z_QN$z#hj_E^tGQsOVgN$)WsOBc}nOC%l4T&HNTgorp}m8_bWQPR9-TkwHhBscAp<^ z#&)FmkRgG>C|CwcEYo)^$-0GLd?^Dq<ULKG&}k|#}Rmv$^iv?%q@?Uw-A zUoHV{F7xMj{x!+43US)<(XH*!Tj;HdpFYqB%Ti5tcH*n=Z3s9vWZbT4s~=SKXfB_X z9(%mAq3!&ATG^JDpyOoMa8N#L7tNGfGzcgSaL_CIxUajTRr`(p;lVfOWYSZs@0LP! z3BsQZ#hzerN`(qz*>9{2Y>WgAzJoIOM1Dd4#aB4~{nb<-DFZy;KktcuLPt&3-}rMB zYX9pI4PQ9Mf{Egn&FDNeG(+8%LsCW92&i*F28BZ~O#ija0;tWCY%b51&UreRXV}^u zkcJYvVNZYiG>W$OntYM1x4RYQYTangw}Tb^8=#Y=&Oyz(gFG%C5{nVV(hetezWWAX zbSR<|Q03CZ>2)Ze+OE3Y#gS{k7)Ln3@y=uOYT)R3hKU{Bwdm(T$1Lqt@nm&sh%ihWdl4 zaT~Uz!WRz^{F+uTNj#RqYWM|7j(`!r`bo1v`4o>`j)hoWH2+iyiF%UYLfvXKaJcTM zf|*p7=#>Buy;3~IvrGG=i7b!S5GM|ZI#qkf+9I6D7@PHUJYLz*YLrp^6hFP1hhpi| zNy`Q(&++acl1$!%=qB&q`#cH07CzMjNB_C5&L=lF6~ep0QC^`&;2L|Dy=4Ful0UyA zUo(eQW6!?KWBM_<^&1BWMCiqs1GJsCG*=kKZUZrEVrk6*JKeYRCWILg=gBbtd+?MW z`})QUR8HAvz|W}%VfPPK>c^_mT$=}vsFp?RI+5*hkYsqAKtXX|9v;Wr88LQ@*#yK+st1i~NM>UMzV_!hl z6WIy z4i52t2Bsv|O7!Bg7vJJfI&KmYM$(j|Zl_YX{##p}M_d-oPbC_$zUyWsVI8U#ORLcR zp6-ACwYJ~VFJhx9c}40QCpI&l=?>w$^zMlcv~ZAS>O!vkY-otIvA4e@=O1)t;l_8X zv4qQnw~Nj*j5^Yi@$YB1w>6Pm-~Og)R`UX+OyxGsQ-LDUL(Cr#T@>8@(Oom^sgKm- zh!eIp(L1pon-OOr9Dfp?*`?;b6eH0C_##K=Z*y7DWUiF!5=g;FTv!t@u9Nh}G?$hpH7NF*%HDLGb%%D+3x z%fwcyMP3Zx?*?%d1G1SEwA0uph0U0%{PBJ`t0sDD!Dap|1IV`#aSr|TuU@bubQP1* zZNlW_=CUm0Cwh4YaevJd5sIS=MKjtbBqi-4FibSlx-lV!_OiP)kW^Fs{P9*9AHc7* z&nmsaq}cu{?+i)qtbX(cJhyxVJ38;_12p8Y+v8};xng5e z%B}|(#2{|duU@1#G6c7r%Wa^rFTGitp*k4p)75B6H=X2ngVmrV%Ac12+H)S{THbc&t~m_`A1=Aj_O@zN$!qd>R201Bl=-!e>r=M3%aTxa zFHPxu``$DI0H^2^L_-jO7WHu-?vP0uk<@6AqK@*MYL)MnL>fjlhqTRnXhSA`0Yp`% zLS^nPO%o!Y(>yFJ&rH&^v{%D7+6HsYDn~X+s>&H~_|1;8#Yze*>x8H6QG>lVWUKYZ zMvqTzJ^*ci+Z)4;fD(MBC~C`_mQ0k#(`}A6hZuD&@*9o^C>6)Q(GnO(b=;Mn>@`5i$vW#d1xIGyO^$RUhr)Qh##;E1#1u776zy76b0ko(pE)kyRMn&kS0Vs|KQHEk_*bF1~dhAoOmEf)rje6i|I0rPY{TUmT|=_m2DpJrqM z$l#jRIqHKTw2T_96(%H-{aRyLSi!Z8d<(_nu9B8BdihN3?AFXkeF9|iLxXX5JB_GY z?YaSC!T%X^Dk$DM^S16+83HOCRxw)X1F?&3XM0ej$D#O8_AT{Ag4F;c zpU4iGpDI1@?c}aPaUxhRkh(%gQY0GR*`VI=+vPNwSqn;a0brV?-+_G(;fHDC!%Wg6raA`VaS+w{@B;SWFr~QWholD^o84Xq75a& zik5VEXNu=D!Jix0`Ls0I%Z=?!t6pHFGyRD@3Hjl(Bqn#fFX+VgpOw?J|D>b;3B`Q1 zaN2f3O?+-P+j$Ty>%bxyX=vJ*WTg8@NiQ^9pp(&ZyO#YmhTyUYMX47>ID)Y5nYQu_ zxS;kmhMQkzR*=Tx3ag`;?FM*>+diceF<7yQv<{AQU{#b~XghmILy2;lt%+E1CukBr?rYVcYhod96^rGcAfr+>zrF6UCRKor^GSp| z^#cURSMnofl~jKM{N(I0rNHKZSjTu!_xqK2Z#W9x90O#+egCR1y zUq9QrVB?;BaQd}%3b~XZpsJR$gQ{0$!yoNco#sArWblY-&AABlUn)gyU+gm!+E#eH zY@chY;QWI|2KgXw154s+Y4zh@7|A4VK-D3{Wz__OwG?YC!*QEC-7Zv3qR+UfmnO(t zbThZL4S*=pS5vaV!{Ge4?rXnGkieI?ZA$v7(aHVgY{AZX>b}_8PcA5v61IfOKcE9Y{O_TEY4+!_DA0E>#rO*ww25p@P}ugcE?;+nqmeAEugCW@Q+^(B|`(Sp@* zyQJ*D;Vp3yJI0pa7x*#xJo6qeSbXcr7()@!%{!~icUIH3meb)W(bYDQCCNfM6B+PT ztN2(Yn|w{P*%?MRT~U(A9VhWe@6ZiM!Kv%W*4Zg3+`}e(>^oeM6m0W}0ekY$# z{=v;L?HJRpf!FGnsc41|%J^_tw>f4{yYA3YklM>zY(=?X=|A)a!er)d+M=Vqhx7N* z+2>vY(CxW+>)I^-f;uwVAr=Y=oKUkpZ(Mv}`6VG`+o5W`rX$n;auy1a07z%&CDkDZ zgnYnFlFx`5JV7>iomB63gn5%Dk7cKKN|)-$+^Xe!^S2Hr!`esmt+`nI6cv^Gl>G?!EJnc&kt)(5hCAO?Yd zbo+JS$4%3bpsUkF)+&|&Y#vR>FD}qDUIJ^R&kj`Mxi-WQ6RrIiz2=Ge)sOJ>km%Z1 zxX|{cO~=Iwdj9#WcZZ+osCL_;{<_~g;{up3BKcyejAd9F<*arZb0oHrq7DQ^MuvP= z-UP6W4#>A70d4jlnlYozo{ZDh+!SDToe>RwLI6a4Emal5H+q-uX7GSoj-PKX*cL78 z6UT^YyA>ZnZC+9Bv^o3gX@)1VG-|9OLBBAdeXclQ-tY$Lf&~!4`uM!1JWRy5|cI1q>XU-!kZCTWozB6)=*&RV@EB%pp4z7 zf2kCl0DwF2J)z5q)eE)%l6CV!m2RH)k0%Dr)_8QE8dke&g(v^k=0W#gCwH_2x z<@kF@ipL-L$;WGnxZwxUP0mYw2{PU>gf9q z4+~TaJX<){`^@-vjmJK-TG`Z-CB|#59{xNr8RLin=!OAZd* ztqL?uJ#$_8HLg>Q`_x9o&gqxGnbkg%37D(gVxr%KmPuMG^RVZEj~)k=TdNC( z<{?TVAFZEnQ_eFjCq++SiX77RUn?WO0pOwdnv*Yi(0Ck$;Lm*z+u;F zROu|%&kZ(H4zqwl)2o-~Ikwznh#a-PbV5yE`Q!-A_mAwMPoC#Gd%b7!{)g=tTJ};} zVNSN=ypEHd#A@c#K2s?K$rWe#7)wjX?hq-t_EH^|xfxN6sQZF2vp5iS=hL`2F4^Fnvx7QR4+-@e!piC3*=_s^iLR8IonS#(z>6=*{_Y41wDQi7$wwhO&l6D4N+Wu+wf({1d#UgWFB7bm!jxO>$vcG{>6M2Lh8#E zxi0?}_zoS67KTK>J>2#fo(I)*qmR$)%>J2vT26Na$5mR&V)hYF>jgp0$q63W(eLQ^ zKR%kdWr!xLahD{aseaKGU{$Epdy09QEu1JB=K=V2(&Piqgx*O}s44()zCWn*(^8|I z8#^EB<*%m($ACq-IOJ*RED;)kv*xvvuIY+<2HWPM32^EL|PhWyv1j7uH9kgw)I&>M9q^k;y@60z!oSu zG#OtO{?Qh2w>#X$KSxrv|L*?fC&Koj~qzm_}|L^MgRXB06@D=yCzl> zqq<)!nT09LQWEDB#nXM0Gb-(H=aR863pCn)&5*wNEy&s-esl0p>S=Nf#dh^{!mVaX zX2pQVw?9UjV5^E`359zsD@R_Tt?soI;?KvmvJc1zIvRV~OcM6yccLy01<0(fRO0Fr zXhM&4sLXmoES49ea{ZplP5zBOvbQL)8~@}z?j~&l7xl?Dmht+5$sZ7Hw({tAjLPnW zOKpp!0G6%w^CF+0Xqt~5L)cQoKwyIA*OG@3=BU2s$u-e~O~Nd3@X&XiLP8G70|k>l$5LIARo z+Jg{4^JRS0NN(ZRHX&*fFT0jC&f@it|CldnQ>fkdw1YqE3HU*o*8+52l=@;TbT($3 zP2+}D5bS0g$u>nx68WJBu>Aa^YM8?@0Pm^tE~ktVz|*NJoLe&1{mh$L+3?P^)%URw zrAfT3#nLr8Zo>YWc-RQnI?YV2j`!ERmKr6$_E8D3_M@HqpnuV|1Ap-YS4Au5@AQRagu^yzHK z*MO`S9H!(g{V|`cf5u3aq;=|a%H7kh%o-N+NfW*1Y(5xVt6#&O?2pHshOSzX>5XMh zbXxz@3h0~Bb-O67&}E93Zgh4^CKnMo^42k9G!);;?TxSd__cUEA42@C>(elhbews< z-om{9I(sB$%hHB}P@i|}<#D7LD{3JO_*?L_RXo0X-eGz* zyS3Pulb{+=Db>(OxGJuy?5m-u8+{p2Tv<2yZyG`gbQ4smOeR{;JNCC6Whx+xbq`{sRIC&xL%79&lk){a+wM?5M;pQkt_ZMr2_*lNGA!z%A z=+GIUYo<*+C)^?`{n`S+w&$r(1x$p^M8O5vCwA3*;^a>naTqgJ`B7YvgmEWTJBWJH zQFh@$s+0Bno$ehNosY%(#sz0G!6EuR&XyxJ4k9g3b(Hw>U>@uCGQ3&5N+=WFLnvI0p&$v!`|3#KYomnJl9{QLX8Ajgv>0RA>B=J#*DP{k2)D)c=M z@^G#*L(fF0@A@xtv+X}L`4ao8+NF!l*t)=rWHK-mD=U6}lajQnnL{w+4rZbA!4;~C zjGL{B_J0x3@%jpiBQ^Rmf!u!f!&tcXRW;SaYU}P4ufLd=Ifm1K+P@d&0NwE{gj#`TV-4oV~CM`DgzU(8+q`k!s+#W?&3e{c*OZ%}e| z|CdSp^g+Y)XT-Qz`(D|PXk(`?(_06s6f2I(M;45bR9dyVncr|)9*JnV#}G3=&%IA! z&*EyxW!$DcZF3?loK)jPCmN&>5^(`V!fyr>B&hg$O20ci@P0EloWG_>0FD{zdG$nr zWifI&qVc^$Jb4y8kI=}aKNf%#rc6ct|F*^GI?|YI31L&BD4A|DHpE^%gDMjNikF~zWmbdK^&A(GYB;cq|NG)1x55Y|~r2PP-5AwegNMb=OzMd`b8#pHi zYb9BR5L?HQ;aUkMqyJa39y8%Pjgb7uq_AIF)NLqi452Q9XK> zZTuzVIDe?o9i zjx+$8s@I#|rDQz9K$^f>HHXh^EYJ6v-UvJ#0shqW^8rJHpFheXU+33BL=`wxSg-$Q z8{p==Pi|4ACQIwp-t2B}C$mmZLf+c_x? zICxZE`gBI)7&|}2^MEV`=uE8&WBs3PnCXz_H4yh484isC13h8hJK@re^OY9z(bu|p zkSpU_CRwb#r9Q@t&nUr%eN0=&AMe(BzeK1oHd1r~c3S*vx&kGnYmQsW| zJ8;^1faABZsh7r2xx59@VmU?R-gDX zR1EL3EowgnMGubOk=}8=RtHiCLv1sT@wv=a+UtTr-TTt(wN)TJ z`e;XcIk-ph1CSDCM)rpz>uXE-A!;1=kLBvUr3$rAbOWmQ^?=RSTA9$hJ{W5G?6Pty z()rdVBIgQ4g7sSV^)t1RKPQVSP%p~B@Fcee3~S_Y6!Wn{1=^U!e;1kKcuaG9o_D!@#DEaY*(SQU7aN&LR=bfl% z5Co5uQ7Y?>*AMt~w5O!}3jKg9p0v9WFMjyRsCYn$fkSo5E^qo1HRyauU7gFec9tBk ztU~-Dv0eymF{2oHP0T)Pd?VU=kIU$-nA@i?p$%27#C{3%A-SPSpn zCr=i0gexUm0FEzh7LWCFBnZudBxtNG5O0qd9!R5!&(G@n%IW-h^LYupEo2&#+{=#< z=C9nQ)fCNL2)h=YimN}df6uJu`|701O7cYrC2mcT6GU(nwB+;gNFgj_h9`02YU*W- zFX;tGpnYYeoYG&WCkm*^LdkGD|NDphpA=$)@;>NqxP`!F%nWkW1rvjQHRwOWBU+n# zB*E<>#vzQ|Wv{@saDvcRhLk8Pr6Uj${$G({g1gI*dUu2Wg8VL-|6j2CpfW(n|0aRl z82}9O|H=;lasM6H;V!1&K;Y2Wt3TT8FD;)s#0kaNE#N^huUcO^8t+b*&mZV<(U87y z$o;9#Gj%}P`-vmlpoxv9^gGIzb67>^w(;kLb3wA8EkTO~q%uJ!{6|i|M5eLN20Yjb zJy?QB#xm6CgdDlH>bq#?O~{LB+{Xq+HQo-heSb4_kyH?odNgJoEyLIwYZJCunUrx7 zNf8M77x-$OqvA^8{tt3Jj;@W#JL#HV(*xC2F~nlmW!w_{AVz}o$&pu<#yjZ|q=^@G z{d80!vyVM?;w(Mk4LoY@_n2#Ja~SGBlwRAwPVlx03nbgSH4%!NsDZL=9oY3(b>B9{ z&-EN*E*#Qp(q6;!<`jfwLiY^>&ld8lwb|F@4@r8Buq0f{%Ld}9H-@`N>~M5;m%1?n zuib;L*V*ynAq^^oa1duzH}wS$;9{Biff3c4n)FO6)aln0jxum)4?!mCnbfL7B3?iV zt`qC!J**9BxBm|P$&F788!K`0*%zAHRwf3hE`145 zvxM*jD3aLQbc#0D6gVa3a#=8Yn$~woeHtADrsorVYtva3m67F=n5$JTlP5pberrju zxkN_lPra=TNqI6IYIbA_RSpn%JEmLUe|E7?LI4~fH~U(MX^m4$hr2YTEV;Emb}f{7 z?0LJF`q4^PBkSdVqawmYzpnUGNP5Fg-531ZO*|f7&we_nSv$1`WXN}Sf2b$=W zLYVNQtS+P8?3~L9Y5%ewv|QZzQ>@6hm#^Zp$6=o}W?;X1Cuz8u2Vzg`9(h0tnctKO z2#Mk_HFO7xZ&pT~E)mzuMsFTa9Xy<2?5o{z&p8N~2llj1)KF4hD(3f=Be6^e+0E7c z?3=#%U(`3v6Ki#ty_&hw_@tbv9FoVbk&wP=#Kc3Uj4T;;JI+oxg zcKv|Ymq|a{77(68Hu~pj}Lr49`tThAdtP7PGPfR^DeGW<~VDgh5EBf`JIhFw* zDSl77fLlXHn)(t!7>}leLSgLG%T!5sVnLdBwwS)CC>n#E+WlmEMleNy;!-7kxu`-{ zX`MKvQ~OvESZ=JI%STZ0OPcZv$;J7yJBWXR;O6H$Y7L4I+=%-K#cEzWW!^whajMZ5 z+KlZNEXC?Vj4JR~q>yh`{YLe3mUSX9`87`=KbQ}{_`m}zGB{_&PkY0IuWS)iq+y}1 zXhwhiN(Kqe81+Z!6Jj}=TXCxtKGcEp_lA@w+@BUA1nH=AR~Y5#jQ4e3?LUe9q!#3l zFAA3CYo27w2XfdYndk{QO}?Nz@(GLhCCa8l=`UUa6x#xN00qARKrUY`bG0`-e}U{e z>L&@*P3Z<~cRd&-s6_t6E2xlyHE04(`U-0$(QYxwj66L(O{LbQ(LQ4hCVXY(1JG7K z#ZGoc`-2dTWv`x8qcR;0UfTCgrmD`GMjA@90OSfjHlGNQ!O;a8;wHXcp=aY;*F}&n zuT+S0(RYF+7Bd`GZchPy+ES1$5cY_a^L~>2z8)m-4JA?SKuHw?I^4iXtUk^JgTZ&Y ze^=iC03=lcZzRz?On;@stx-t8|0X-KUM;9%sEZ%eewG0CLY=z-dWQmh$3ZeiiXok5 z{ZolIMW1v391_+Z-m{?8ytmW&Od@tUKTNR8_h;}#HZnn z%!mY;BcUyQkM>#F0zt!K*eEt5J4SP5RW;Iar^)b)SUxjkk!}JjgBoKtHV%K%hlXN~xbSe*A!!mpasxTmP=D zhwtZ&CHl9#^fjz9TW|02;YP4Y&#AZF?%VsH{(3<$oO`hWx-s;#T0IL}!v(XP)A;TT z_kQmAyNh-b15kJWVA({G8AZCB9ibDaXc;xNG~X%dV3M=D5ZYD?(qA(_P3QzR`00W! zYWRKgl=QfRaD~7D62=GHXQKOImQ2nag3_vJ@Zyp6&n$p2hr;r!M=r5*WXVtKT8YNi zsrdgLyOYj|QO=q5%c!djU34}A?m?4$`qeWbgJz9=Ev#gzu2_VI`}{5>0AgdBm1+{9 zqq;C!fUSvnIyfpJ1Y&Pqk)alI&Iqr35+KT?Qch$VWVK6>Uq#L2e9V)SkNh9Vg-H3emVlweM}Usy>(yy6ieV=YO?=E z{vlrXDy{ruGMH1g@lQLFu~~)si`I{f&1y!8+$>VQ+%b^!4qA*b|2}|lblou^qr9O3 zpj$t&MkL6!D!cZeR?IHmBky5$bH4yQUsW=66nQp(ASVBr)Y5T8A|N~lb|(!Bf@AJ< z%!%+GGa=f<%3lU-A`AQAKfhH?TSN4(N*#R73_t0G}={ZQv%WzmS7J>&f zW%<1CISn3}+xr|?*{!N*R5sjj2u(QumioGZq_a*`7%w?vJEb8LmBm9;9&Y_`OC(+J zn7kV<&cW>Vfq9agzXh8bviu1m#QcDF&NIno$wVH1OYdbOlA*?Pq&B`;I(|iDR4L&m zT%F%NeTpYJf0!=iH-ebKYD=r4E~SzyV=#+=3*^~KgEeFEYr~rq;{`7UezZLFXAi0zup02X-gLyqi}I_Uy9hrT=w7bK1tG$7gXE zWhN>;<4iSRu~zwAH59D2aGqp0R?X(OY8o zvwup@D2e5k=#A^L1C+OR{-$>krWqeTC*gNfFJic-UJg%qlr@%!LGwSF6$-a?)~YIT zA#p_Eg{-VO0+)6P^qBRZtUtISEJuuV$Ug5haElIG&@7fu5-sg-eKz=cY%*iEK4vkA zZU;Y!Ab>oEk(Uw8C#%^rAJ*o^CImF_2U{}NkVchAc{Gv22%suCd;7(TG^}>(9`|uX zg?aL(rU;?v2L79j)-a^ha`~wG`VxL6F6QCemh@WI(fgDqlJq%Ks0zwdCy&_W&IE7n zMCmd;BzMq=2oVqdEG4NI9Mr3HV(xZA+>xPK)!~Q8& zpJ4|N6m;~e)fXx_kY*gK*ExCB6A}8#58vfV?Qc@S2^b=G2V-su`Rv?(^cbUmqe5*5J8MpsjYLfk3{b%-HAlx*+LyO{zY}3=c>zIvsAIR z3UnYA@Ev_BCg4OLop*-&(LAP?{Izv2W7cZ_J^v$q-xH{T%blRDJIL0R_k!D((6P!= zzsf}Q^Te|g_RM{@rT=5zr2nzMyZ>#Q)D zFH)Maw|t!GWyHZm-2sWfvVPJ#VF3+m4;!-RyNnFP-Ch1K{!cRia0fY)>O?m;{5LnZ z!7xDvn*aab;F1Oq66U<*ju`s?nEDQ|CZeX@4TKONKteP0&^tot2pD?rMVc6@R238i zq=epkuhOL|9R$RH^xmZiB27S1kRoEc@%z93-aC1+=j`U}*(ZD2%$%8dWxKPVmlNM2 zF%zB6tbX52RIE<4&5^a*z?mwi9WT2zZOWOH9(cW1JnwchRn4?o4sn~RPE&3fm&_LI zX;Cs)>a7D6L(TT+6uyXKH(J3Gh3I72F=_*AkC!(n3q;ihATzmJ_k>#M;A?flwJk5! z*}twC$7L}?Ox4Z;Ppg?wtpco>70iD|aDQ%7ULNo6@oltnYitVDQ00$Ss-B`6!lF;L zHew}s>B$#<59H9`wkG*WKO=+3m6J^*sRza%QJ01(kw)Hjyyq~@*P7ce0am&wOK9A} z3f_F@6t9pKhrW<7*X3d~FT90AMA9Ti+6^uL!5fGTQ!y{%-H+apMAS1d5f z%k5Q(JKh>!$`#^Le7Pm{u~oA9oQxt;)j+*9{8&CVNzr%cFiEUVSTRYj1jlr>hLCt` zDU(;bAhhEQ1!%4@+xW*T+ZfV)#>6>mwU_g!^BVD(T2&J~mn>7;7&SF>q&NuxbfBLJ zOJ@8fHj3@P(d~X@)8M5NwIL##xeeb$J{*78-``2;U2#)1cQ`>V`)kU-<1BD=4JjML zdls}sM@FH%4&o6vxV?{K9Bfm4eBO?h)QJDJH+B;Q%$F)x-FRlMO<57wZ-+nL2pIw1 z37Xz1p~~QUBC@sDAVOyzi`XtQlV16ZtZs~UePI0&x55@ad#jNuIQ^y9IV%%A3zq8#-8joJp?3>nwV2q*n5b zGT?$;r``!`Mb!gEO!%^N(z1B%@G^Z5qoo7HlcV@vY4!0w{J|wgK2nsB{>~zX8N4S_ zX?`Ec<`*R|Zax1}RSK9*V9}%BJ=KzUyKZ^zBrOA6KFuGvM$+ig{d%t!_Z+JH701zP zF_^d1qHUR)7P$4@;GMdEg`Qay9xu~bK)MopcU#+b0C2!rT`jQqi4)rl*p4 zJ+~?`qLQ~-ZQdO-KZR1V@g)?CR&!7`lgscz`RS=oWf&uJ@(OW*51;;HJ%jeRqSf@{>eWE ztzY~8?g+7bH^rREXEaVifo#jI38Bu0V6Lb<^2-=V$e0)s5Y}NJZTb4rPeQ6?Fs5Xv z4@azhmPgd%k-3X@=Q3CAm!YKDyef?x<9}okCUyb5e*YQ3lY6>#ntKJd%=(r_4}7dk zi?-*I5Vw78{zmHWc*!bPo>LKH{&`Sa;E!Tm*&^X>qEQxY{Q?S_KNjL)hjzq@Q0R?K zHaRAm-2L|eTbt){ukGVyLn|$7$1MJ*MK3a9Op1Ny{_6a9?jo`da5V4?<;Bs+cezm0 z85u&YP{IsJAQTY+8e|6mydMHVKgxW9&VqcRwFBR=ls3tWl8;|+T5+b(yv!J- zYpSVVw6^zY`SPVKe(&Rnv~5Zyzmu%bGfwc=t+r&>NEYK}Hfy7{OuxjRZjS3yJlnEp zWckyVDL0)j^b>SHJ(w{p`wE)K>pRe4|Cpo8&KZ_68OR{*-;Dp*^VO~|uL-`LIFKyO zl#!i(c^S8akXK;c5*_0mdvY^0%-h}~fh1fy`09@5`?wLx`1Js8Hzg)N3O@&pTP`u+ ziN%B;^>xoWVcW^04Rz4Q$tLI6M9`_n-?(pI3b*X#!t>a)*uh7aWi$o1*q?r4*vt*e z&b2f!Wb@K`UxJPWiOERwoWYr+#u^&&E`U5xNyhw;%I$uL@WT+R*vFWQe8M!&uc;gT^+J3NQ6VC5F_?ni;^ zzYM(AG5oSodhByk^?fd>fP;OuChmfbTfck&hYVS8bBpqB5c>WZR|I7yCjMxg`CF-; zf`vyi6^2%LCW75r%pXbTVA^l-1~ym8%UU`qzjD)$GaZh+yc;1M$n8x#xWwYBVMwfl zBWZ)vrX*;e-qIUhGErSWa1qoPh=#&nG>rW{ajv|-l?L779o>Gcm0{O;^M~E+pbM>M zPG)ew7RuU`SUfVF0RgJ&-2+N)dL9$3wcTO+Tk39*a1T%6D6`Dh_Vwf+^lkr3J9hcT;>0Q-=V{7qY1YLdj^K7o8 zy9G)0c}kXij_{NM9)4R~IZrpjPqodWuO~A~Iw+{<)!1eVQCr|kdW+VTN0#GaGzSJ> z+v})B$(WTg=rOcvmj2+7P~iq7{_~wnY0W!fA1Dyi-~^6Kq8=Nz+0-&o=ZAV4H{vVi zKV2VHjy1pCGI`CJHz^Hl>6Qn-W;;H!x*dZ}(S6qQLPBh>Wy07bo0vkdC38q-<(XDS zT!1JwDYtDVi(ilW*>|nn(noLKxISZz(q?0mM9!+SEcK{XXFL=YR6(~qiNq#y8MI+41ONI7vdji;5@b|L#b8|)ZfiktFYe1 z!6%cibk;nC6fp!B1|RvQ-0t*!CLLls4NlV5;74pre7S;0TJQY$JB!j(AKJ0TzjYWQ zR>Q24#KtK!NZdWli(X;p2tfZSW1_t`i_wpxao^V{({IwyI3cgblT9D$msvD|g|f=Q z0FpHAGlUEa{ACeprM8!&$e!%(rMJnb>MV)1g`t=3H{=o%sV=u=Hhq`_+-3kLBk_Te zSh(U`ryg8wDo^m9!B5i;cSel=7-m4QzZI3FuidDn!nE!4hC2Er(c+7q9T^Atd7f7E z&3W!B5Z;K-%Z?Z-fc+YFA!!kZA)(nEAO|;~M@c1S<`gBzdKziY8S&&KAEmcw@byZn z-w+1GaH-%Z$D($gyd!7u#*^Qm8R&Z20Rs=O=0y_|LQeixhv) zyC5rLQ0E(I-9)NGoS0uc4qtyE_JY11C)Y;7Pc+~vWLo>clL?{_TI6OG>bu+V@_M4M zmF4=iR3<+6oy($R{9gfui&_m)bS}@^a1KaE?((6$Bh8_`qDrjXwzBnE-9dWsq7x^t z8uL$MFX~5uP{$id72JpD%`pu8dv=SWs>Y^vh|Hflvs@mqQhg6eN3Et##5xoD88UAr zTYSGC;Eb=Iqo@67lmY`SY;`7+_jM9hYJiBq7K6M9d@})%9 zm0dGdF-=Q4w-_fGps@$-_r`v^tWjVy3%P#lIln}DU%O{bA-kOU%Icrt*$XYHy@{|) z)9Lq4nJSDUVO(z`?vEdc2Op-o-DLA1Arjc~;jQ@!TWLDGY?dw04jBwNT8p>g_1WU* z(GP7!vI%B%m`gP)ZZA($)>-zXHg(SQKFM=?9l?Zo9^wON?3(;Z5o)K;AjPKyv!XcP7-A`} zE(y|9?iZqQ81Z0Go>9>}imhApMm^@^o68oHhc@y3dcl&)+7m)!t2jnv&>k1=E0Nw6 zPaP8&S-@5g&S;B1ifR#(b!-UuadeA*onh-4iRl((x1OW7-9DA~i+2LwN(3&HrzC5W ze|oug0 zsHRV=g_n%etDBP|Rz7B$A6mosPJD5zo*40P8bHv)8e6Fj9?AuP#K-(q82t5b)q4DZ zHwy%iOcev<`Mm{{+blV}6M5k9K8p(GGpy+|o7_1SIvM4zpC#h_&^=POUZVH5A2jo~ zzIj!Gn096k)2c~4YsA}+S$F2?{Gsd&55uEtV*#q6Dj3lyhMi7AfEx;TQ zPC~}H%+`y%b-p}90t|;JuQa6knnnOC8r-#l(nJuV5Z@GGA-Yy5qHXzB$58f(MPn zbtPN1e!YT_-pJMo5$+N|zUZuq#pJ?W8|;Ax#BEZ;&gT@PW*O$~;Psc9XRj>p zACtp`D3BcgD_IljMA(BOP5&c<6KqPvNJyug8Z`{-1pA{z!aKWOlqZm|f7UH_Pas7o z4<6l>-u2xut!vdXkCKW$Aaz^GtnPX-TNWgxd4Jsi&a*r6>B)ev0wfv-iVpIp5P(OS zQQs1H@gl$(xRtTyHgI!6ChlMx$)|BhDJh{`r}^Df0-dXEt#fyHSu6 zI@8BVM_Ks$6JrYrPWxho-lF38!B}cktg3jd3V%S>z}iL1gCln7r{a}S`g*)8?|S5m zG1^Cpwho1N<*KFu6~IH52%{o*9~6 z%ZAMdCLV6nX!!tWvTI8SS^smf0*aiu_pMoLtzlEV#@e&PvDe)UE56ITAegrM7?t>n z*0)>%e5ea5ogFn@ri}8D3bNR5lR013O1y=1|I8Tt>YY6NQQx&{YEQYj>vh@t=*6YD z-mG-rE>1l*`b_Ji-}v#)O&T(biPi(ticLccnrab)KTYKvA5q@3^imoICQIL2GeWGk z<_S?|quk$4)zd)2&Egf?j;9WcM<;DmEE=sM*Z!QRsUapx!RpZ5ZBq9&5H51D(^!yzQ!m2m1NGGn>T0d^?QZmOuwM z-*2=^+Jivtp2i;Kjl@VY?m-3)kAI!*9})Gw+g03olf7LeTb0E?=>0^Zc#%}nNCF0v zCmsO7F@7zD?&eTw@d=$8GAB_x2gWi+`};EY2%ZCM>Vysk5@nZ)yY?xxa`gE^hKl^H zZ&7-gHo=?MsIpum$Lb#u#hHUe{8qaT`&A;+<2{3x9D}@Fim8{p#ys5X{e`7i)Gov{ zxm_+(b-3M=1Sk^Kf82Ix@=(G|@(?Y$1$Z65B`?J`CR09nM z8>@yXlN-g)H|O27tPs?ss=^GxN-|ZY{Mm&<%>JDZZ`jLW?>*{}<;py}DE$Kq;J7wO zug%F!)mnvIKCT&=rV#S*i6OB=)4d$~;5V+(!TjD+1>EeIzxpgpmF|g1mXsoM<#MbA ztv&4xZ=DKmgshRsR9<_W<@j*b)2M8RVNPFr-!HO6A;EGg#w;m&6dE8%iaAB%o&(O%l|49^qKq?M8`yxyG#IV|! zHOILO3~8G7Uk&lJJ^eyc94Y4VX1$?2lvDN+%2|qPVCZ4UY^C|ro!&!>3-!IKswJvu zBXuhCk&g)MiOF#agSFa1-eI;r)L1-xy8h7RTC1RMV%}SG2`B5!O1iWmQPn$#ELp&5 zl)y=8oLKIuiN-mnKh>rb`KMCrq3^b7lVk53xIw8zaZq`|u0}z-KC*7HV*OY!6W{>w ztTS{Hu?AH9+?L*?i2aU>y22oS)Hsw`D-oonHy5eo!#B@=;c%((h>_n)pPAK{B9u9; zX68Tq(Wj4y^AXqPT~KI}%-z%a;QK~?=xb&XofSJhNoR9dNjZRAj1BNM_qy&_yvOg; zRw<&+?##dD#bXwXjK`0(yPvgVtUH0j3nEjG#m5IyC`TFV+@}ublo!f zRo0{L<9D5>T)RB1S)mD+8{1IKF_YO76gtaxA$yD3l_UBif zolJ*YkLt8;Xy75WZk9tRCXXn0ced6=Kh!>v+8$nQM(e#$_{KeiWH$h*Nf=)df{P*X zo+jQ`J2?pKkJ2A|SaV7-((Mg0S^pcx>R0>B@LKyV}B6dvEEMl3gB z94nI7+G%PL;r@;3|3?zB0ERT|nBc(*#SmaFERP*AGyh8eqoJAqN&9gC?tMy0MO*W= z49XgW0QP_~%ki4)$H=O4zcFdfsy_9OI!O7(eukKVmq$~c&NbmzR*+4^8>Rg^(9CR5|RuCCINHgnj>lEiPu z4p@|)H{$X9pH|DszfXTn*S4|P)>%$-y(*OcN}?=%12@?WM&b0I=`|s(e$ir?XSeTWD{4e=GxSRZCB65 z(T|HYE!Q=AOr5Q-=_3Y$##Dtxbwt$}61%2mPTp@(NpIb=4eszXCZkCQ%x5aFbP;X+ zVK%C{!)hV(g4d&N*EY(yRF%?5dLIs8B47Ez_bl zz|6sz8WK02(q26Au9!&l_|?s3nJMDurC z0bGQdasBn8j$xp**E*=ng}H6?Pf zUsB|7MG-pTKliqOTCe}`Cxlc?i*NvdzD`TBsH`zDa_F-3BiUt8NI9Mu9MSYZ-!-!y z6j@W73P=)zftyJtup;$I?tY4)TABXn$MJu%M87z0wallF*2I?_=RPJun)I#*mVU8TT2)nQR`)k8vk}& zp7AXDeXtCR@r>~4oLI#E>?@=G@E_*hyLTaa!lpV5=DhFjPK-R|L^))}MjRc4%cW9P zqRvg)n@62`&-5V6ahaX58BFt6F#Hy5mip@=Ga9 zElBHd!-(*zh_kEPNip8|J`i!D_1A=@oLQ6uYna%t#Z3pw#8rXZK~h}s>dBCb0Vdt| zD19K!yM-Z?v(@CaoyaluO;UGyD5V(H+f*zL#pU>f{zZI}Ek6D0(|A`~Gw`4>1N*?%+|OOHf%0Cjiro?I)VYP}%nr9N*b6|61-Ju~_~SODU-Y zavg_RAQY-5IJ#}$D7ECVK&2)d`q}z2p-21=Zh3rEpGNenezw%VxBSg4d1bP0{UtX6 zTg&vsVC9#SU<2KT&KnA{xH$CnWPvyBck>pGmX*l8n|Os^#01{nS_t219M7w0`4G68 zbKlu_+tFTd)II#t_3vfS>NXDj-{cU4WrCEm6eYX!h*mM%`fzDmA zBM{iYar2YJ*vl58b@gPvFTWCgo${rXt%=9E?JVfcW7vHXd%kTiV83WX_$TIm`xwT* zsPU8CBQ{Tp;E>dcwG>X3f!**5&pG@97bu{EJ-H{8CT+rHL&OMYAm+l8dB^fRw;r3T!FMLZ!4nt5A4=gD5xOLOBT#QLY3`XE`%PvQXo9E6&PqoGkeZu`=_8iT_55K)E z`NhUmm>~MI2khXl#=3xsk5ro~f#!ycOr zKlSOR9e16r^l`mxG*SE_$^30#+*8|UD~|0cZOQEY@0XYHALFb)S-d5K#j*DSBdtyJ?32`(Uxo_Y&AvJEFlLZN zy_`c=o5mqj7(FcWU>NfiL?)tfrA6>{sZ{rNSs7z=(;*$BU z{nd3L(+oj&c0tod`Z#vL_PQI7(`%kK>8P22gFYiQt1uHF6Nz;?UgHY-0T+kLrqE9`=_d^O{Pd0J8eoAC= z@Meo#?`~6y#FF#u6I!as^aKZkf-HU{zH{~=yPVN3SKla~Cd>7%x&yJ6fOpUI4Hv!{ z3YX2Q72TsuKGE1u`xP9rOziot-dMmyr+f`nh~$>o{D^`C7f*@u$hhhToOfe{|P%D9r%&`@)%G!A!*7*gg; zYH4B^K+_f$6?MN*m9}Ef&m6(6Ka{CCZ5A2Z4iyhkcOS)G0aS`R=i|uT$?v<`P4+3v zll5-{wQ9NtDxaGBR(rnR`97nJy8Pizdd)8@3 zkbfG8>@z%rp4#Y86AcKmmYNiaVSI?*L}UWkLs^s_2B%3O|A1f8iztZll#sO|sws z*dJRj;?l*~X)7?}dOj#X0#E@QBFRy$SOSg#fdd&S4kO0R5Ta@R|3u6WKtWbsu19g^z&&tnk*xP_`fLC;<8@?{rc!c_>Ddjg zukQmbgVotJhpXPiJab|RDZ%~RS$bk_q9~MA7dx=5$irU1EyDo6(sui@=ED2kS(Q2dqQ~ zj9jnM3)YmH=gU>-KjE5YxUN^qs;SN!^rU}1#dN!1ftz&8kEg=e8u4H~j`SAA@DDB< z_fHDxlsT3dwTp|oA+ruh-}n8da7MM7!sWk7rLG&!*U5*z*`wcT{x-U}rd9Y`f0sBj zA+O09STK3y`Y}OB9~BTN9=L{)kY7F;CDSH0D_7Gjf2rIqnN$&4iZgnwwP0(?1LH^* zE#ciZL!8x>^^*j-W)$DEvNiZ(DZg-C8L?vBoT{~A=WagHpVZ$HlC;&3!23%rG`Yg4 zDABd>Ceyh4pe53L_aqVA+O+}oD+Jb%(>0V1J-yaNLt7m8Jf3HbF!Q{F z)MNdM_3r-_v0NXa1v$r!lMK=sHNTM@NC(=CO@3J=>oZP)b&?Lt%J6%5*_*z$0H z7!b8?fFS_|MtTzlAfqX9ARDK2R!|fbYOhUG-;7zA_IK$k{fn_L-kQw zfQmi`0fL+n3SGdLEJ6sF0nSlfWev^$oK!6;< z6oFVe%4Q)BLYkR>m?ObN>fSG;2gaWoRM~r$kX+SwSgs(A2*v{#{sHs_pbvufB zJA5b^Mnc;*nUBJf(wE?o)NXwJ2ZEQatnTtYXooT{nmCk(5yd|pwp0VI)Nwvo*z36HEAG;uun@#4ZG zxDit+na>LD+*}U;0ONudjc`ka0{JzY&>J!sAPl4xge5!!`k64uto(K>IBy^_PrR*0 z8pE8H$(MOUag3h}`m^QgcblwjcoMmr)^!H6Ri>=da&lK(er5G#6H^Ln`mm7B@o)EO z&KSR|31s{sMOTq3|197)S&`Rf^d>k?J(6Q-D&62TmePsO{c zepOf$F`e3PJ_eG;fBzK_BTN|t<=B7n0B~#VzZpV8IZbW=y$v=7SCnu(pvoeCnSV?r zp3t85?#8sj2!F2FuYtO<8$xg1>6yruaZDz$SKUZgvgx)H1)3g4zs+i>vxo7fdJLINP^J2Rq+Co^kdhOO8fEvi%S5&A2+pPHH?7;A4C^ zoHxSR(wq5YN$u~n=|(d&0B^`2y&rRPX*x`FP7``bAwFkBRkfSYbMY+jnVSoJn9O3z#NR zQ>=wutxmR<5W=%r(&9wQTe#T5{7J^6D={KRwYaZU)S0Z#X>`V}<=;<_>EoTeTeVIN zY0$#1WxqUW@BO&TpnXm`xZCpqYB`YtNvik_4fWAYz;7e9DieRXHioDxtqC}!Un&uk zjH(4tGQ#?|<2mp_BM0tJ+RRPOG$31l$ z2dAHQ4>O<3S)XiuWFJ-3l9^)b}Cx^2{;)!GY7U#VuU)!kE z?O`w@o4EZd>qq)x%X-@D`30naiZeI`exe&Zb^BQo-Fb)QkBi|!hCA9%rA{OwjcqHr z-U_ujnJbT0t2LAs$W0iobh-t6S-QC%>)=-1RZZ`czTPZAA+=CJ*D-hLbLD5iX!FFX-q9?umkHGS@$e|9MpK{K&s+nQj*cWh&g^7$0@`t@EJqVPf>U znw?hvK(ZXAf=e zaf10+ZgkEKd^U+Trw}5AyPW1Zj|`qu-v!!6Ezm3)T%!Jr$O%LU+CX*kbF$U?v$AOJ z{fp`w;5Q}JjNcxdabbw$74ljb!!-G{K%*O{`C~9=*)_>D zF;dajv+CB;=hb&>dT(o9p~$By>$H4+We8t3FOfS+$i6GxYszqpttf)f+oV2E-{st{ zVi!I2d01$#AFCQJCRMSuq<4>3xNE^?dSajPd#@KQjdR)Cbbi;nx-&n#7?lJ)5poHr zSmRKmcrL@T^=d}s3S9!nIBB=LY~zEXw;!EfGV{uLm-JAl85GO+W2&yU=VJ_mJ=d1% zSGgrHr%ew(R}L0!Dj3s0Q(%ToeR3n`n^Nc9*e)LOsuz1-T)1N?M%^dJvcvSD+JrIW z>WLSqOdL6;`wC=M@mhLP5zU0$i;`?5mn-x>=f#3eP7@zU5!3Rdy92m=bfD7h}B{)$`{ex#hJ_)ZpK9P$oCA~Ui@&bxz z$QFn@$+U{SK;oKGPS5r8D^~$TR^kvH{_4+w+fcnvdZ-y+l zISPMJef@meSS|dS_=9-M-CpzB-+LpzYhaaG(8^Y?*kqZ5=aURG)#aNn$7ksD8{jn+ zoO+)iX($(C6C4!GF@Vty7s%iSTdaYhaBc&lnlNf}7uNxl9Nmk7ida?>hQCJL{S@1J zgT?}z@^e&aN(f^J7LhAPO2dzH*5ScgtdlC25ayN=00;i>J|rmOzjMt$-B|r7%E;|s zE3h^~I4b^EkDK-%MGIk>!~vjsOo2s_C`R~iXa8X(QTC`J6qY=>n3$4~8eBKed?Y73+CE{o zH!%m^d$B6?IJ^M4rFtUP&DqhCB&RIW<#&KG#XJ*PK;G&?UUWriq!+hbf+kYOeC zv=YX#TJxRh#Tk#?8K+oPjI?#cZ#JM~z#D?G=z6M8WIye~Hh6Zyv|g+kEcvzMsM0$5GF%J)1X6jAgNF`Nf}`%NNTyOI^CL+Ras4*#(lhWAO+j1ANsD zNZNJ)@%yWz;usUkfn%HoM47x#yq%}qrTD|XFs(h*QIBANf&s)R2)$0M%nV!*0Rd20 z;U*!*iO6W;y{p8w4Rjco7y$Sa2C~3FsFfQ!V@4*ZvyGm^p(c{&%^P&|e|5S47$yjU zaDagUfCC5%%ce}ZyD4VxDh;D%r!`_6gGm`!qA={>rD~xD2__Dw?+HxGMvkB+!a}PB zA~hwx6T2`ePHx*DP82#1SjZQB(f+3XkW5x%;r8AxDcXMl_hp&{x-UjgqVkggYE&T| z?KJ?ACc*gMCopSe7#IMiJ2S#Jt6#2u1b25kGW*DWy16IBY;)ZctZA59B9h&o$U|Ka zguaRfP7={sApFlUt_Oo_^!X{_M^H5z|9f#H#yn2EYeO>oEXG z*Byr?s5r?Ns7LZ7oGohq@c&6wQWi;hmbZelSn--#II2xMkZewDhC)<;l@BdYFhk@q z;Z6J_kX4i4awhYG2-KIcM;A_mgY*lrn*=`_5RMQSgRAGA%}T~=I!f>Xy<`Um?mu^6 zZxHxUa7FlkPW~N8kC8IkcBr33nx8z=Tzm18CaJZYD`PcS#tbr`V5*485YNCYXNzxAF zzRlK)$SWZ1^e)xFOH z21={r=bs3TdW#()Zpb!M2^bVb8N%!xSTxk(9b>c%%uF;;*+_9NT8R%>g`kpnU|2y- z_USa3k12yjoD^9Z`+59fP*{!u;$)L(a=jt%+w75BH+R#4P-7;YD9?p zBScUbh96gg0>zT0VKWXKS}jfx-TehM#5n^O44TM{kcTA6vBQkn=&Fk57qJ8n9_v2j z+@FuzA+O>hkOdmT=~|MS5GW2HTO{DB%|{Dw<;$Z+jx)=%pEB?q$ z?TjP{7+Aocumv&|!!bV{>CmNV*98t6Ydxnh)vRexHo7YxZU?49_7920`b+xre0!$8rUqJ|CPFEz-aJmQ9gr!tjpInRh#dP&93x*hHyEw z^WZn(k1i8;mHGQf-emjleR!n!d;WgF*+@kCB1hNN(ZxYZnxHVnX}VQy()`8n{BZk` zQ?`Xt307ku_?vCjC+Vf;k5*wj!2!a5iK~m40}f_t2b<^5wQv7!8%j{4zw|$n8dtGy zzxmplSFSL!?@%B{DdA?+wN>AGQX1-|4B2mK_aXz4fBR?ahU2s3dIz0cPX#lfZaAlH4PB`Z`SbTsg8hgmx=oFV9MKyR$pP#Lp!@9M_S zMFHaIQP0;-pJ%*-f3K#6h>BijIyq;`JF%%PF=T?w2+S!SH&D{pX+w`*`D%1;{L=eL$~*uUomC!b>3fETR+v!*|nPr z1xp(tYt`YB?YvZICWR)m#Q7efPUo!TcXxK1b*7pvOo`)OrAXXXiT$C|$?*Emp0Ix9 z-#mWuAQo%?uCTz-pPbyr*c|9d_Ya#Is*((S*9vRyw)j(0W@qM8Gb3>CB=*!^v)rpL z=S>}thiJ^a*1_o~+FqlTP|-N);JNXE4=Msk=%DJf?i@zmJa z9m!c!x`)*@exA2!(CZhmPG4r%+xCUqGyj^YnWevwRG>3UARcusj&CSwXfW9?Vol`q zto2N7v2#x!-_k5x{Da5)Jmbf*cX#PF0&o(9K& z`jMYq{NFqVex8c=Y#mP%DXC&k0C(dxpTn-$rFm8zs%?x~5fj{#wwm$wV*Sq)r_G2j ziz;Ikz2*khmhp|Aq*+ZSDvwI?njP$1^_jJ)|8ALfxj>bI1$kdO#Kcvf zn823;G|H#ys1eYA7ca0l!7PtJ%=|boF%xA|1rZ=ZI87(_lHaaCrvA5776HA8kOj36 zY#7u_*T#b~Jw@sNzNRoBQ;9L+nG1M{d2}z?E!Y-ozX3e7Ai@6`QG5AKi1}dDKy_Lr zt{_hBsEZkOns)r-8=LjJ1f;TJsU`#Ub8x`w-tBCo(J$mFPnRPeN&7w(*t{sL_U4>L zzP{amqm51Fs4GDUE(mCvxIQeTR@km*;d0=NpJ7^M@!4N{D*$RhPwk-( zNl)S$wf@pp*8TD>U%s=Y_QwPLic&kD!JN5lyVTdn)WI-fP1oB}BkP^TJ@}m_F^_ov zlPR_N$c(nj>iY@>gTEbYjhmW1k9jlv^&jyl(U`V}(Uq&`a)HgM=-CB)k};o4(2&{dW- z>er^Uiyk~W*6g!b*x%Iyvl#T19AbyW-zJM|*i|`lQi#77S7K@=1}T(A#L8!ypP%aK zHzLc|%-rCnz9lt|w>7}5U{}%kOo#20kkJh$x-KHt>Mn(u=3cn5yL)wdFr(CjhfW3! z>ow&u}aSp~{*PoJv}+OiC`nTZJYV|b4I z?Ru0g=u(rZN{lG79)$SgF*m;WnyV7r+o^f9qxP#qm)e;!Js_6P&NIi3<2vrtp1+NU zQUdh~jVMcRT_%xO!FqAuC!Z6|m|PL5WbY-8$w_}zb(2t3BXfCW0mAnE5V4?OawHy1 z=s^^^v))9>5fHPfB8cWOn=vQc#X#9-2T2lHLP8E@8u7bjf zQ+@HTWa-LIoX7FcuYsLFcJ186T13x0R?U3f$P#G)J$^EjSD0t8qwvg?Bcj~1oyrX* zxZ7{b-$$D3=Fjy71@|Y|$)bpMK_H_7MF5oDR;i+gy?vFgF%h8!8WB&_Y-mg;h;L!B zz?{7Nagx)%jit&DFpd50?Hchx#g7&T@qZqjyDw*k&Ym5j$N34(ao7MyQTakWZ&vI*gW;GNbiR* zy_4T-+aa@1Gi+vNH;hzSD1|0Rn5n*$))W{G!ZXzuqK+JuwP>RIZv>iSJhIs@;r*W&k# zW~CfL7ZG1wDE6ilL-RNosS$R@D?xni`~3<2MX&zGlPhRBy_Fskr;&ZiOu9}6C!e$< zFDI8Bkl@seqDFYGr=Jh!XR$dHb4Q<~2MBBri2Wh*A>ywSVN4uGmJ9KCPwX5k%RpgQ zGpu)Q$1oC~Zj7dTX=uw-qH;N(`QDw28S(!y+~6#LMy)W%oaQe|-f3aydEWh-oU>zl zU0wXlJSm%G?XjYp%DbDVYlp)6Rp%3M;k+M6tu!@Z_J!YlfhRfp&rHYX5w^W>+0<@# z?{o9QpKtnzdtJLdo9?!Ed8!0v^YO>`9kGsaWvdDcj%NG(+{*s_*gJp_DcYG5RrNSF zBx$ZJ>4mTxpV{zw>+9n(PDWakPEd0Cufqox-@bm;>kwAfKFvHiI^l{pmFN4FPsgK~ z`ITIgagr?_U1E4745!S^yKzCo6RnC^Cx$SA?-$)AuWg6 z%Jbi26+ly)!lEAMDaL_(!jbP=BlRz{hyLQ8u@Y%RO&>>$?Z;Z%jJd?Gtf0%Fw>(k!j$6 zg))$c9ZLfEcLtjp=0$JGCsuI@1Z4|Bko^zc;16qj0F7d(@rUb`ed5{sxH>A88Goj~ zzT@^lgoW+xZO$(qI|fh={cB`l`4)b|315oW^I2@>$7RaSy!2!~Y5lnu_z9_4ED|y5 zDofoisw(~IdsE0!h;)4!TpgQC#`eYct9jkjvqxZB-e9r&=t==CGpUoo<#+in9j^lQ z<0aeMOr5NqoZg$aYg7ItlF{r^B#Y~foo0y0AVVla(W&|hLo6uo}j9(IwS~LmO8_@}DUdN~X60ts!=HS|pB7 zt|EnR!Cok0GxWxd=|TOeLWzYqSu&qv$YZ@ywM=YdYP)|6M-kt!bvok}`5CfN=x0UF zRO4q-zLBe0Kp;`&-m{_4J8vc<&)Z00YK9%xnG}_(d@84@lm~%faUsx9e>fQ%KWW8ce-x z>I3S~?I+@V1{O`trdQ}x8ULZ#tsg(sS0XZ3mi@%*QpX9l-GYNANo!t>i!Bso3H~N8 zjtAD=2w`S<`C}_V#y&LEfv+mwNwm5n^1J&Y3qDeQ;V${|o&i)B(nd!2QkVC3rp8^_ z?6c7Clyco!74vDsB~xRAOS;WeF-nwv$<8A;U@obhS+}THEogC*$-NSb&4{VdPPy-N z1JHvC{?;dO&B3OdI;!1+5BYx!={iXv4ouF76s zNa%1BwHBv8pnS*}rW2o>sU6<*IHUYn4=0@XDk^5dWB6gx&)aS;D{RHfaA&YOPXd27 z-Yp(q=W$SExo5vM3>raWqGWkhzB*_w@^Ba8>Rvvctnher2EmLH5vQ8!^`2?jmxs}} z9yx~x3ogp8yGkW zl<1G2N_CHFev1tMX7H(%$MyDx!Ac7jZ_Hd^Y(FkIG+h4X{Rml>1<8)Y;E2O3T2`2f zS#4GBH3`XKrn`}{l`80g!%jO5znQWzTISRXW-|@1Ppv9#U;* z(G0M+$99DNjH`2{8MtNvfbj!h^-dOgH<&6xg9gCUwMI&5XfVtFGpWG-t7aoJ#zDz+ zFs=CnJUA=>&?iEc|62k8vX}`IC4mU5F(Ghz!(PA`UG3Zt7`ee>^Y$*gIA4_j$C>&M zlStB$6Q}f;tzzGR6b@|5=I^Aq@}yt4!i_I_Wyq--lZN^XS={RSHm$ga5m=U6K8on} zq7aTB4qj|oy9#|>IXy9F_t3e|;sk>3v4NHo4?fo3tS_gaRcF|Lyl8qT`Zp%&F=Y0@ zQPT(3$sFC~{kX%3IZE>Z4|Xvo>eUFDQGuE(%hFf}KO7xtoBrqCR*^g`0tAGUNAMIw ziEY#|N5DK}ExGIe5cM8VO*G&Ca2g?m79jK%dM|-U2Se{j=-p5S1O%k37Mf})^r{64?;{O>uLnaxf%yL;}PxpT{B&~n$l$nzJlWOB$iPQEg2 zCZkPA`Xox2=%2BTSk7Rxc($lGZI-&8t8L~$i(gK{@Vpi{?Qx_vW!M8~h{DKu#RvgU{r$3XPaO0|B8ZltNHp|A_if+VWqvT9^}Ho1~MJnz1!vIuY+9Zetv9f zElX-(s`=}VMO*l@3@;HsS%q|=>K#lx5Nuv#u3-caXu(g&It;}k#k>+kDC*;HNzw?e zFM*$n38_K`sg`{_k(0O1MQ_qi3YlnKt9YDMS%6Obp|r?iad3c=Yymfzviy9c{M;gh zO<#m*R zVqE>6$)>dc%kTg!^$olwfThj?45#32K}fShsb~d(GH(b3?4&e6psM>CXOey3p!g1j z&v*h}2ObElp(sxXoF?UDix%>S~B1KfN75P9eD z-{qh{D3Trv_Tqj2y{Oui{AL!m_XpdqO1D(25I{S%{@I#p{=51Lu@c*l!R9XU3}N9{ zpM7HA%g$>nfPLKhy%_c}l^(_u`h=&@;0cO^q+g^`%-A7#*t-V9V}an>uo%Bl0r5ML z96}G02?0<&>!&&Y{uEINB&i)F6E2ZRvec>z_Lf1u*UcD+&m^E7*kp?A>`uY~Qqq0m zuF?gh-ac4T0YKPO0pOe7SJzvOzl6bb060A?ppU$}$BmAFL8momt)XhuNQ7Io{ZB&o@^IH;65nO^_aR({5azOoOHu3Xc+bX$MCCaibMzk*yB4I! zNHPW|d_?w2kt;oMU%FeJia%W@kD6}ySa)0-IaaZBpMXHkev$@lLk9bK)D?jt{n!Rb zy=4Xo2oy*!5S%`NO=uTUWejJ;dJTFN;v4lbAUIXiE%RThMts%w)}`CZ;3v; z=Jxj+mqg&@%FlQhL<5FP=HYH)?@M%T(UR;SLsTf(4AAvzxia?`L%8_OUErwCJQ>3p zg*#_nz3N-IZFlB=_bIp3rz@|LYKFoJ_|3lL z=w^Ec)|UNv%?p(ye~iZDw$OFbabD6!9DjwfTn1lYLB()6?} zI`AFx*?s5L?DJFO>b(`)_6YK`u}hkJ$?^@xe6D|nHu4`Y=CIOj$65LdCuf{^-uhVd ztfTJH2OJOhO;%668JEF(@Iq<@kIVzVxs|c}@RsA{W6_f6biUd*ZcVjGl|`3ZBP>ZA zK5FL6*VBFW_x{|}9tgxn}m5N?i{Cb0(1P5|*nEv}laj=K=#@ z-84W3vhH;9O@{TwKTv_+yoq&I?_&ZFS|k_=@}%tw9M{^CB^Ih*^*MUhcFMN=Woe<08|6q)&o8^3%pV{ec3H2R<7L+n$p5nGR0j_@jz2zo)(JhfrJFYyN`1Xo z&;lKriu|q1&*z6A0{(U-yru%^ZuTc_AIr<^)Kl=Wh`GQy?+K_p1 zVl3%!Hei63JWpVw+H*d$?b9r-{iJTK@;W63H{c&mXV1hbHO-x$IZ%;<_{?k0J3`Lo zMxVo8v8D`M_N!)Y5W$iC?%O+)n) zMu0GY8pHZ^?Y?b}dS_knyePTWd^A=eRmgT@P@js7dPAwCPR~d3`UsFEQF^?rjV}nZ zB6;9nYmlU-(4kQChQB$O1$_2~bG5zWhLq)_-sx59;|IZdzaBfU5Q{b8c0oF7X2=zC z-WwBEI&~~S-Tr6#X5R&iUrmAcc^yTcw9I1BB_ef=@d-)@J8^1I<8KYN<&9r8!i!{3 zF$QC!F$lkyOm=ellzup-`g=Vb_NHOKvsdSva$l({2Cb%(bl6Otd~zi`EY?49R~D*X zRfhoKuj3%<7R){OfiWIfA8E}Hnryzp>L46t4S7$x7 zIZZ=tH8~MjrJoOD1Y}YoG`ZvO&!}@a9 zsHzHr*E~Et0HBFAw@G)Jb`BDHD~{~K(Ovm{$G z@qZ@(fW!^}{r{RIA1qaBwjO6skMZ2|(_v*!F$O^ZpR-Yd(xlLzs+{ZG6B4f15pR92 z|2n54UkTixGW3-*&;6b!g*3l|a30oC9opSZQ)D*gjx_klqsQM`Z9_iM?D^NAj(7ct zf|ibg*)+fHSet7(@+GEDh>LcfCR;5SOxv{{5@N^H!D=w^9xW@Lnzr$qT z!d%9ZKRjK9FU7bzEJL$rK2fGzV8;<3g+90IxQ6P5;_MmKfhYO7!Yx3JmwC|| zZL5O`C3?a{utASR znCehe;w8@@Zvf;?^ZXfrSONe-$GFl60Dxk@A^0dN*z(t40g>85fN_KjI*22f z#*{#M2^P5qpRtzNr@7ih}7>^v0pZ%cni*5sB+6U#r>Od5Bd?;6uRv zJ*3@Qp+^r#yQ2>A^^#)gxsqUtchzQ(SiLk!h8!dSbXb52QIz2x62p?u*E{srlwX5t zDZg%$+nH|X#m!iNGB)3b_wh9QqmVFLvd#8owcR`->sYb~@_vi|9*AtmfoW+{cH=j8k(+Lwk7e@!5U}o92pAx9HFD@p^@Oq$~e;JnDz}aPRE~ zTT@ZpTh9x6lK~o7GRBDn5A}S}cBPj=Z!E?KkjX*A>?#Yj%}Zil{0264dR+lxiJ}4G zuRO@NyFbtjqFTm%%SWb0yY$4=W(JC%t4UMGORMJ16M z2AF)JG4M~n{{Qupf2|hM`r^t3o}8fzPl|f|NBCq4vQ}dHVRu*<#`I^{r&m&W0#({o z)#sxcBH}EHNP5lHtac82kp^Ue%F|lqim{i{94Opb_rL?KkjSx-W1ZB6+lcN48bmiS z3NNpq_}4~!<`LoTfbQFLS_VPn5bA1EmWOUTnv_(r*$X7Tk#XJ7)GWy#lT{hKwEOea zsg1(**SeED1BYYlTFhrI)a+8XaI)<9%IRMw*++qPGxwXToKkuopHPIOZ ztklYcKY_^#9qz4w*yBD#36mUBSQct|HnCxqXu z?S}go^wB+#tfH1Q~f zE-404@}S*S3bySTII8J8~wD+TM@CpHDL z^a?|CRPm_HlzbpavIGBa3~HvPKKtbDI;Z&3z=X^@Gw8$m!k0D4 zzjPa~tj=^sJlV*XUf+)7*izBbH=l>a@cS4|^T%5Al;|baO-&^Ei!J`v(nynW?ql~# z)Yxv(;x`TW0{oflc;kls9^>uD-Z_M54@#MUH*@g6DqN#_0KT^)`LCHc0qB0|%_O>S zPPr?6i@3pzcHx~x^#fK~76#sd(|Q6R_)QcTFi=R%PM#q>qYhoo0-SXGIL8vDiT`6M z06>2NYF2XkBPE-IqU=M&mzyK`&`8)rw-+z7)DuCY8EEI|&gA`QETdfi> zvE!1*$J}qxx{EWpPW!kjLglTJk&a2?4*k2Os^gqn?dcXD1mrgbJYPE)Z_wYne{;Tv{;!2XI#sojsLS&ky$5;oar2MwOPISF+taU*wrS{}y7t7#Yjyed zMu*`yDFM{?BhN#lVa(9ffaDOr;@KYs$FpYlF3i>Kl$9{iq!j;(bk_Bu zUYkeVsj1be`puwqmEXpYQl$0AV|9uOH^(%uRfMl5Jy568r_krY@$LzTdn@PKKIp-( zygT!T*mtQwu+mnFxr*k%b3>x%O%eUbzvjkkKl&UP@cRrOs>R7^Yydz3enJ_Z3Ls;g z2-M}G^|N8&VRu<~f6>}8I5m1r5g@+)qiJWJyd7Nh%2277uPrP+>{+qD(?=x{E1t6b z0s{GcvKq7meW2+uNnhM#&S?W()ux$49%onSmA|-ZOGvW}ut5!Xb2kL+(+`7{FU6^+ z%IQmUwY$-y*9Njwz^+Lg$1f$$2j1J)lSet1(%ZDHFL!v)j&|jAQPsnC7=7i;r9{%RCHEa(&M%gsa8YwJ)@v5K?YKkc@9ecFD+4hs~TQzi)xy4ND?&aMT^PX{m>tS(A5f#=Gqok zicACOUr~Rb0-f?0jIIpl-*wsL;n$&7#HHTsSd?2NA5c}NZP$`>`~5g_jev=IZG&#n zcVk2WjpKRsLH_CK`&#N*Ua!LA(>@)=r+MXDHx0s~CsRQHGUcuoL~prZaiXh2uNoL~ zWpEInxnLrvMn$HS?j2x;0Yl{k;Yov^t7D!o$8k7~8$Fa#SFDR#eqcP|$;}nC+h4L6^xt4YW~r`)BYAEABjSG*$?yye zHLw{Z5J(L}+Z-q~HCnd{sKO_UoE{0+5N$#&v8|~@%Uy{iVg~lt$ zYQgJc_`i9yOW8g#XM*R?t@*E7TED+-SFpYUClvo)7n`;H@NOdMC!=yClX1#i`_#+M z$@LbU%j~?jvzsN_t><*`zb3a?5(m?1ADic4yacv&Imm|uZ4Zj}uZ(t1bA;_@aC-4u z&-w(}Op|AZ5k$KIZQR`V+);Yu+U|lP6a`QVH$yiPX}a_sS4w$eeq5&!@KV-<{&kQg+!4NM#g zd>l-<=YJ3MiF4QF!S1e<{hgCK8quU|g>|i*22d&k7W_W$_Zr{Fi`XeAlRU&Xc~1{7 z0TBQXqWJ;eB6|ccqq?53nx+7g3MXZ=i}!f(ywFeO5V? z3Gy%Wyg}bYFyr$l2NC2Sb;=k{x?pK_dRczW9!Wh{E9b8J$R2>0dch=YylcL{<5n4b zBvC#J%rzieaT36d9xuj+<4MnhAbtLiK+!DDNfUG&`JW4MaBi5Fgrkna}|4Mx-AZOdiO`-D3Z_Q)D{ z8pm4D^G+4vm5O7|2cEApOdxl(C?P_l52C29;-d&}5y1}CrCEpEBXUY88%hN^*>HP9 zGaIs|8qdU}(IeM*2s;G`94CDWX6B<;q+Q^f|8>5j8oIDLm!F}4dK7R_k&2QL5)(EF zu%3zr2#@Qf;s%S~!K93julv;e3FioVo2U+;8$`HJ>VBfJ*I8_*5Bc$I-K=J7sS|0G zfY#I{i}ATrw5a_Mty&7C(?XJWYz zR)oD9qHg18WgHy$JS#T6D6)2?NeBY0THNjG3H3T{iEh(3L6Z{&YqX`{E9N5OB@u(I zEjQfr-bH@p%upxm*$Dq@?437h&X#w$JDj(0)S9fO^FGFo_SgGO!%5r2aD@*+`jTzS zu0kxOpqu@EOrXbR#wpit=pNm*spLNi5m8MGNqS(MZ<`$1eMfvQbK*R7T1d?6k+_{h z{y1*CKyqGYF4XI#Q>=EZhyo8}L)Q20#BOU?$IYZ1g9o8j9{1%#cW=G={7fNpEt!+M z%hsno>f9sb%-}eDpChzjEuywchiqdFI_I7FL&rG>*FXa+0?3lvN zulwC*hhvK^VxD(b-zYlSG7`p<>E~Tuf%}@wp?erLgfW6svIF{-?uE#FmSO{4GMf5{ z+cudSm!Z_=F2XHdAw!CM-faH7n#&Fq!M>IBNh!4V?4c3Yp6^tvXjR!>@vcIK4C0Z$ zJP1iK6nFq&4bX)f85XvO8Anu|S*|JOAFXZ|En%)+%2pm{oZ`s4N(#lD@4dX=1>KL( z@`}txm{cvyhMLY-E)6|mpew!Y=N~9*%s!BO_dE#{$qxac6aV(-Xq^y`t(RFj^{Krr zWZC~ZyF!s7Hw?nILL-0;fy8xcK#F`k^VX2mVl$p~MSYJAB3GVapRcvazDOHwB(3Dz zPP71UT@0FnA(%2?G#8KnCNLXTl)82CxSi898k{4u8+>XLhvKjEp|V+HEQtS;$SXvG z+=m_H^&}VY5@i-`o5*D@@ejsPcsc)(sJdgP=Ha`EV)oPYR>o7>vF)Bz z{r5GDcja<83PnRg)QQ$fLaFh#6x{fxYYYP>7iLys>r6^b6JIgXg&8hLHIsCNYW?r9 zm#qc5Az{Krf}B301P3is_7q!+2gw*M-bLjJoQ1Cpam790J#S(hQY#Byws2FWcGyPY zsqN$e()F@H!B!-U9#952By&vjVTO$?L~ zH)CJz3AXdmbN7Z1HBCpO8a1(~%CjZiOcE&3$o=k%7mX%*HNwrLXf6onJ+brR@}JM{@#M#p~Y;Dn)I{SoG-*3`dGri zFs{Z@#)K}V(nK0zldV4qon({zef9zxf!qR1IL*-SZvQ}a*ZwS^c^lJYV^QH^ml%oS zrNh8;9HSPmiei684<1J*x`BMjXOm4ImRMK1GO(EFm(ozW1P`|0$i!@_#_IVXhC(jb z#Brl^Hn}0t=%X7?~AR!vEMDfC%}Yla^#U`R|xi0u4#?(!c25|B>{6)xTryUz*BkAUhB&y(=G$efaGl z^X)q(xiU~_)hzC}EsgU@r^n87JIR#qqAIM-9hkp!jPC0p>K9fvviF>@f=`U@+DS0k zO~Q(pQU_Xs!{E_AEddL8;jg8(WM;sK#o_1glPO~lUm~3rc=i`QN(2@lqjT)U*~23l z*&Q$EtBmzRG)JSH#RPR3JaQb1oqX!-(<0>93fgr3X+x<-ua}`J{8dc^|^vS zEXLe*wAFYd_fpSL9F!NpRc8=ZSHwnTT7g?%V|#di57l7s))I9#Fq+M}o*l^6pa-Ch z+eoE7n~?XY^_d1Mt>Eiwe5Ue5>cY5hz|V)NBR37&H+&BOHAniTR=h#1 zgQB1W@#z3&BJ_DD#kID36n2_zaLxgGc?(d?FQTA=g4QoH16KYVbNW;-@XOt!N&Rn# z5?(UfhmgA|4i%CzAmk%RSVv48R!3m>@y+0Qt3YqL3ZJPD#SmV83xksTO_U9pNs@^l zI0RaJicktwNSDnCLUT*${bO@*_V>4k*^j~4c7p*9gcksTRi1>~JY~!GbYU5o$_-ln zJ&tS$tP4=8N^uP~wSC8`6C)qcU}^^RHp7fWdg%_X#sAmw4fwklVd`jdwbfsD7qpNqu)Iw+w>>nH$Flma-IaJ% zlUXFeypmWKdNZ8!6UcxtEW(^kMK=%Q8*3OAEx2Jb^Qc@vsbI>e+0SXnq&)D`Jv%)k zDf!bXU~;IEQuy~m`_}NeoTe9i8Ry-APvgTV(U{O(DLkUorOW+{lpy9PX|Qp{obrPrkz=z zjbAig)HNb|t^LdXH*}E#O$Rh4uog2(11= zENp3LX@H&)Dcj3n5)geP9ZY~nTp)X4P^dNwQNG#F@d=XrUx<98D~cZow;7~PRR1zq zD`yPDr)zfLSaY%XC|*ulc1HjTGIkT87_5|j>hu2YC-{$k5qlWBLdADk-`1qhjIvSE zi>|-!_J*VLn7ry6YGm)g)lLH$DPG%DFfC}X`#_|Vu(AvLmDn=amVCB|FRTF41bX_#_Yn99zCB(14 z81D0PR91be_lGeDU40*8uOg(dL~J&;<$jv0_6oz#eL(k^zxIp)S8gn~4LWm!JkR_I zOkjT3c6E&RmWY~{x^`wt&s}vlKBStz;KXaEYkGp3h9_w#EmA;cW_^lks@!LX z3UOW){zQSO%pts#IU188%k{JX&a zBP3R#1|mMdE`QTawqvUODPSa)&9yi-+rZkvdTNMs$rl|j1AtkBeRBwU4CHj8l|RI; zX>o?;<__bI&a#cDvR!k;G%`8eWGrp>dv1GiH6iX+T|HsD|M%7VO(s*FE37iWw-UR; z_m742bGb1U^wb$*s}OICP5xbBrD>3GKRn5-?1OjM^=ZlxOk3ed-!tA?8_Z$-PBJ7; z_4rQi^lWD(b8YB6ea*Yymt0kX5)5u3=4~m#-y`3ptHiC7Q=oYfX=n1ExAwox+B|)_ z_bJHds`gD)kBxId^ue9OO5L25gmxbH2lsZb^M;CpMEaZQjl7afcdoUR=WM8*%k6d? zX^YF!{d_1XHr}Kg9hWDpd_zu^O@@JAN5@6?wJQfmfVO!|BQ?>i_xaT6$W?x(1tVU+HdGtMEqwON|V>%HXm@4hG+vPx8YNs!F$Xi(X_=E7(F_iAIE0Rh{|#?-rHYhtEZcteR_FVRx~d)PN2To~}7kV47tu{2h0LT0Ic zhP)t>Rg2$aUeNDJ2)w+JO~<(z`(w#N$FZSoIi5+O>$6>N`)FWj!xafF4Rpa0qA$}> z$HMboDd?NG!{$zrZh(-{=h?qK9a%s@LhA6yHQsQb00BKPIHD}=+Ae$dK&C2%_DK9WfsK8@Zj$X)@wsh&wAKMq8|3=&#Qh(uSxp zPtf~({zl|a=|`hHcX7LqIeRlg$=%8p)2pRN&tD0&ARgs3dYS|w>8SwT zp~|JS0)oqe^DQpa03e#kn7*4)gg=zJW&o%&vfuUP6b*v}z=E=b|GN*#9R%TO~ zbBlCl)Ioz%rm)$%A88NxD4V8PDZM9_Yh`>0)6y^K#>#&67lr0j`Ro`W!t2cbECUMc zr`vxuio4lz*(~{2EOhJiSZlSDl0a#Dns^E;sw0UD;0@G+hus5ZK!AVN_cwer(ZD** z6jXnr7yd^}>~BwXxA`t6U3+YLlD6+bGL6o#G`;hhC>hrjEcTO`o{ZZkNlnGE-(3-9 z*gpM|W>KRO?I0J50TO!HuVg-@jJ716`Gj0R<_KjoUD0%=peOtat2D{s zK7Dc=KLxCVW&p-XfQ&_+hz7cS3dlA876veS=4fV+DunV8!R%A^w=&nAsm1t#Z{kbT zt)xxv41)c|_Zt63BlGl>`Ej0#(coRfhQIwxf(L`(NlEsR`69`+tF}Gd0*}kOhI?*ERJu z%{uH(sUAhAJ3bcGtl6lQXl=o+*#?h?spR-OH&!tBK$%>qbp(H7EF!kt<5Kp+dXugU zq{H5h9VpJ0at4e4uDX_8+4sJtikpq!ynrugQob@7V<)V-a1o?^d@wEHuk$_GMvwwG z`*h$_XS;^ENJQ{l|A|S^WuF9CK<{|hml)?n z8;=*$B95kWKR`UMLua>&gA*GRv9F_ATa1S#I|qX035}-PGa3Up@$c8LcLX0xy`k9C z;P^U! zxaga2f`WSS--C~PB154a4%c#K*F5e(`#(=cHb~*kK4$ukaM$FYvVQ*wu2$(e8R@2C zGxA4_Ytb|FnYTR_eVkt*?U@|kCV~0h*30JB%4t!zDSo@fymUM{;m}H2sM)bRHootr zf$1lNrC8I9^kxt}#n1eY8RDoTLuw`+mNW{(XOR^NM0$hjtVE2tXLwCTN0?J99Z$Xg zlVfYSP5%HgetE&FuGR@N&L}%q85n!Guryz+NdHq0lxB$1IZu*`N+h>eQ0osuET3nw zhbB8Hn$Zd%PZDW*l7h&{pK(2_^Y=4#^O`o{ox>hN>x8$2sG3W+@~{%DCQa>MS$ z1qN(3rBs(1l!(pdxo{$bOXNDW9!~H|>=q!#Bgz~=S9{|eJELN$P2!|>pTQsiKx`lU z#p?%|AhzJvXCM+Q1M~+BG5`!$q@2HJ(Z|h|38S+fTYp>TX}NpRB=eH|CI6v9utze6@NtfE{4rs@PMy|Q$Jkup=sh{ zAD5;KRBcm_nqJX&*=fN{b$lJXnAW_;cm+wv{$y4r2gla}&GM24N^2s-$c1+yv#;&6 z1W%d&E#u(Qhzx)boiO3w9Re=GUtxQzPSyw`#ymQdys=*L95(?az)?$%c$;ayAO*5% z#Rb*(Fg4#l0{(X&Tuh&N7Aa%yxQgPnYFZ*eT!alHeLQaX%Zy&Wgxd020y;#Dm=2AbAVBIIga5E+YHjF z?xX&_tp5nSi6=GKh%ndzL4Bx&BO^SoW4lQ!mm_-cFL_a>hs!3f+U?3|KLczg8=vHz zJHMZ8n!!-oE=4cRM|hG=$4O>%0F^SW(p`1yVO}a~^{6y}OpB^R7UXKn&FiwkurN!h zc7Sv0+nS|sPogkJcxafP3Hd5RZrPR!jJPdi+H!lX;)M$x>x>P?o{UAnG2-;ZB)Y-K z_@ZupS90o}blP5Kq`j(eOv+6EX{rXjDEG9Xp>x2dxqmZW05Q&CDMI;m!+~B=_T5%E zCa>*%*ZUFE$rjPO*ssx(s-*mx>W_~VWj^L}JKocu@|=5WKWN15a@{MZb$|`?ad`3T z$f>%6L+^_wNtdbnQa!ApyM7;TkJ0i}9!KtOF6O>;^}qE5^n;wxwwkIY_eBQn->%UxX8@W`b;0#@yZMsb;$*SiJ`hT@7kB+~_svluJgCXKi~zTvG2Cni~^7 zVYDzWtm4NWC8yg>D>j*r)aq#F*r)Zr6+Y5tS3-5l}g%Yms4hD=vEf45OO*>ET9I@GZ*cSylHE z@+e>>c3;Z}xMG$0XSG>5azD_$>r2tDJYCajUPki;STb9=s3vnQEr|Ck1$xL`ac75E z1PH`Y{|=Xg+Z2jY9lWk8sYp$@gY+MF*LsLKZj?)VbFvPjelI4v@6r;@w=0`ZE?>Ug z;S>L$M~~Gq$3hzmRmfxkf_eq2M5RS+wQ28MuXT8KQnf3L-74_F@$gp`CG(#MQ;VozT34Ah;h}9$O>&dmK>UNrX|tQO%5`2M6Ym8nR(XUFF}c{`A?3Wu4fXxAn+(b{|tH4;bLB z?85S7jI)_{{BfX^jkG6TnhiPvApw9ix+;H3MR(<6OSos`k~lq7I_nc|YGbsne+Zfd)vnDl(;xjzJV~5wE+t z&juZ5(52iMG%Z}(-}W@I22Wq_1b8y0W|X@c93@)0oBWiAL``>M>?JiDgES+1@BA7e z^P;Cs7Rj741My^;N`=y~wC}SWs%#%k#Y-*K^=+#>^b@j&0Bta+lqD|fT^C?##i`5; z9uajc2&E3kn92|I(5M$JO_gpHM+FK3(Z@AopPn8@8PV+9$wVj3Db$obw1amxpu*Y!kwJa_3^c*gr1D(+-I*XW<8EhYU zGgaVU;R8_DnEj+7Np2eE9kk!t;o~-WfaG$v;};@dHil+!__iuUl~W5&E=E~(0Cp+P z&CHB)##a&KBFWv&cqHIm)SN**W0@Eyk0TSRFGz&JGXSRM=|`&Zq%SI=0Kh-50nC;F0s<*X##2xYsoM;x3xbr~ zO8P#PgeKYL@tNG(s?%!T-)n6r-Wa5kCQ>_A-+Ya>vfO)xhTpRVC-fjV-pVcfBLDJg zk%MmbKs_v$J7y|lbE=okEc(ULPT|i>S^ne8KL20BXT4vBTlm(_LxOhh6 z{@~a!qJR`d>-GulQ*13>l1DqH%Kf0Ii;`1_X8%~+F zcP0jGFV+!(QC?+K6bv1I;tMOcTs4xLPX?0MBuu2Ey~uBmSX9&^o5ZUI!X<@HtTr3u zV;EG5FHV>EYN`U<8~acFfMc###LGHd@au{x(5Dp%Qxk5x_%yOu*$>~GLtjwI85(oA zA=E6iW54hXZ{%&DfV@4E2`u$q>%qE6K2KFDbReziH}MWDk3<%hclQE#B+sLy$=z}t z+j7Z!!$BsoEaRufqP#Ca)T6Izzh{@JrWTEb*0ByZn7`l7^d22TaS#OUILDy8NP>P~ zNxrB7!nm;9bX19_2aA)x42dSo?D-h#V*oRw&aQWG)BBN)cVdSqp1S6n%Dsh4v__JzD(ZloWX^Ek8Ekzo0LQV@lsfcl-< zO3*88OpQ9`H~FYH+uA#=kVdHr@9}*L^v5cWwFK9<(OOSsTE0Ep<7q^r53xT-)P<*jD>x|l-16R45pP;Vg!RL8D{Fi=#|l0k%3oYT z02Zn{ckz>~-{2&IcPjKNRT`T0HWl+q-;1JcuI3%5imZq(}TT!f^u2!pOQAW&B_lFhVbMW$ACNl}lG0ZF%480!1uzFIhwwj|gp z63h~AaD$7C<&^VVcIMXg{&g1?hP!SLX&$8@2mm4@Mqp*5n?M8rGpKabq#>?102Bh6 zf0m;YVj9|A?o55DYHtY3x9eRV<&(`jUIf=AMs`61v}&SMa9bx44xev4_)>RVC1S{N z_o)W1p2A;BBD+7IdtFw` zGwXB-M$zP*iJn+QnDi$@?kPDA4y2=gCZ{`$?Wl@>t%+{mNwXBugVf-mC=lY&C)Cmd z;qC?i39XJnDFsI!9L)Xg?D@lcM+3~gu_`JZi;I>Z8jiSRdHUMm+V7ih(-;@Wc-@&i zclHkzQWCM#`x}iQ9c%e`Z{d!E@&@38)L0Lk1e_kJ> z`e1PlXv!O&iF|vW&mh)_#~M@;<1s|iQw7(YGN!=LEvpHHn+UQsqFAK^w{pOwL!P4v zg{c2MF8z8@Rql^stPe*8qhCz|1mjnKE(Wr^#;oP~#r$4*>|X33v(=_nGkLmjQKi#*FWS-h{kwi+rcwV%MVmVh{khAJ-bG z0sxUI>&W~PN%>}xXcPe$q+`QS?zhuzx_+pNQ*>jc4jDP37*4%7OK^xBSov`7 zID>eDmy!lhk!CQ6RBL@p){2k__Iv|Q1yOxT=lp5qxts6qG$uwEI^*YRP-|nM2|$KX zy>D~n6MbFImUD~mw`w;K>a6F=i|mLs-~8Sz>!3hW1t-_9Kv$}#tWXLqeFGz}zS#9g zrD!gVs1<*ra`Wfj&7p3KwwH&~o*c@^Zk1_VHc%Btme&a`*JS~6`jDm*)LY;O zHSx@>sYi2NcKC68hV)CA$iD)GR#ba17316fX! zF!oe3=m&rloo|SZDpBK}Fc9lL z#kuiv2CO{(o^ZwUqU=5#c7L#adKbhg-WxCHA;ZcwzOQO57Dt(56_Eps zxl$$IgV&4-z1~+&m)iv1wB?F%`cao%J_EY|4SRhl-d2GW@w=KJ*UC30e}ZBdke@?^ zjI8XQsy?-2u+mHTz?p0a;#aAIjd-nazJDUtrobV_G~QXUwg~td^;u~yDvGk8Fh96v zaOSOb<~RvI?UuXqTd6l-SFq!VWB*?8i^%M^xL&py`q2KvH_k(-+jNKAjqtEtNo#w> zw;mMGt@^emY^;ufSJ7RJ-!g&=MG-6>W=q<`$=^~poKa}M$qt-i2K@S$Zcn<~%3%+slD)T2!f$Bsli*}x9 zUj%h(PAyMeLQoN3~92rC<6yEfS zyLfo3wk{o+F{QBA^*nfbF7Ay1zxBnbxhkFch{|BGmY|3^v4Vu93Wk8~X8UwDZR@t* z2{^&1Scr0h*Nf(oXVO?pO-0t#hlPgBKRAah=v1FebLbw@85Bn0Dn9$`NB6!N%o_&cObTsn7sj1=)>IHpVJK z=;g4_%}hZFY5ERph!zzKP~I^PA58&cncP+)ZTm~YJ`4F*{vYB0s}o2Ta#2DQ(UWux zjPNC4nJ)f!f`ke2&ut5UlE!7~mi^K4yH6eBP9zNZ-{00QINiw(Y41&?TVbX2tipXF z)N}KC{*)ydvw|_81*4%rk zf8@D!`8K~(cRYPs{mzt%ysV{qvV`pN5!p?qhkP6XTQN7^@W`kw&4tS(tI$y%f0QN{ zTT-$4P7hZada@w$jAtfZNuy{!N93udurzL7-jqjSy(X`j@5raDIZqu`_v-pknTo6K*S-Pp`=?Gx{;Pr>6Qi&1nCkG5EN1L<@5c$&sz7Kd(S=V{&Uy5 z=kDk1XKyNK_1lDGB9Yd@S3QLB=$47YVomCFY26A*0TtrYf^YXJ8J5PDDNGJ&#+JU# zJupY$b*YbvNIYvfz&VB|eUNVT%7RliChm`MzF2_kGr=oN^sz9>K>O}dX78IEfo7Ys zt&CZ5ODw7N72{j9FCdiRsns0~4@BrNrizV}icMXYLsG0V^e0k_St%*DD6w8KavA0n z51jrUhG%#1j4K>^zv{BMol(N3FEvZ9l3a7^eCtU^0M*jG6OVV}(kx=i05zfsPdwZO z*t;Rw3q?1Y9#Mr+T?P$uj;=p>v7_SlWGo(xnJA2yYOiKNv@$nez`zb=Af+Lfd(l}4 zV2Pfw{TK)UyL7+#FfP|*{fSDK}tt}{?<@xBJB zF1@JdtsJ0HzX8&KP6jl0dKtpXfF-9vc!pf)F6Dz zR|;_bCdo0|1BmCoxq!<^PFU;m1ry1X2{sM#9k53TNV9*2Rm%u<${Cck(*f_Ztai$? zAtJlwOmGbg%uz(jvpXbn=k~Kx$P?UU45NR3)tmFmactf~-ba~g(0;83OCj<|nf4)@ zHwl61;U-9!yi%2jNm-~YNZGp@U=@N09O-&!@->=~Ho>0_L7@muFt(u;{6i6_uwHp& z!sLif0aTyDjoMh1V!~B=v-r@M^R>ckJQ>|X!-hUd`9Ri;45$fz1B~JQ2;cgt%0y-Y})=f1x(C_0nB327-GYjqweF_ zt!Idk^JQJl0j~c*!=^=ILl7;@*EzJA-w&V`MBc#okyyEb!;Vyf6D9Z5xX4zzJUBxq z@$5u%wDplLa!We7LT{e$MGN_5ZI&RmJ7nzK#Y=TULYx2xDWw{Tq58${vtV|4W0DtovZY}aDz0J_Uyle z8C<_h9tm&%5-ER(fm^OGk>6M`5e#65?V$o_8IKBWr(u>TVP1IFZF`DGZkDa zZ^A?=s;0xw^iY4;mV--jVwcJ=JF7F8OcJcZhANefq7-5z)?W99W0wh2Qircs2`N?@ zg(ddp0u8>Zl@z#sF>4v5f($p@4TavDj$w6nGMEtH<|ZCX5Xx8^WER-A)>|c5} zQ?r_El%Pt3q=&sm3PV`Tw!=#I%_gfNC)Kk7GpF)_Omn6EuTAj1Xtt=0IUac38^G_Y zHIC+ohOCi{teqOv9sFPb*_YcyB4~pDhLMY3!0y+L=E!$;E%&}k=0U1Q0*m7JkR8p) zn?M{z-g%qaBJlfFncZgl$C1^l#Qa9L&4b|RrjI^Z$MgZ=*x2Nr~MyoOG^pf z%%+DIB>(#2l;64Cd-ld)Y@=W0q{1#7-}aR7T_u^mV0K946h9{F|DN-|*6uca=XNB> zNE)PyVd6uH&WBI)TOt!sZ>n)a-{Dte|C(p*Fz`6|9FxA3lUP~v$TO;xfNi1p_)1;CERBm_oE?YeX{Has{aLts@#I= zJ+EfN;zHjz0L}S7;y-zl`1n28DWI_VbvvCmGh#Kc5waCI1J#A@C7H*XGC zTUoX!@sieEV};v?!9)F@AcS_bwkqWPS6Hzu!B>K^rY=oDT>WRRP{R)`kxLFUQ&GVk z;?QYklec?UA73c?q``?*3|ekuQ7~EZj&rWoixRs%cH9%<^WihqC;ABoG!{~6ue4`N zM8=sdjtEq%1d^)z^PvG@t%)S?otfWDM@ce+{8j-?_J?%rcNnuY_NvEQ5krsoD?j$G z?26F;NKS+FS8O>kRLK_xd=KcSELbYOCZ@l>jbBxsjh=2fZeWTb#-~jd|C+wI(HM2W zH>9nKc&dcKn87R>4^NZOv6vj>={O&}@&pw z7wG4Tt4+}rXQ3&3Izvj&^jXKc@^F)kJnW2992C@>C})uwP=-K_Bk#mk`VP$ zxv-9702AC9hvVdCO}tl>qas=*Q4}agJ<d=-O?B{Fh7GiL(q@z@iGFL(aF`a=j0&lN662UjXe}j|jL{=$m*gJb zA3VPeP1Rz~nzGWfah#EFG6ZTF!n5%BK@~hJd$$8SqLK2w?QfVER?bH#9Lhkzo1Sbq z>38Y)&b>ZVBT(<=YyVg75~lq>t@TSoDa7gZXB`gJ{VDCaNyl>l2Ze?zYaL*|;QZA@ zPqc=}D{FeIQt!!aY*LDQcA3y_#l!IwrBAnr7BKRhyg5Zv+|^`cIT11M;`mS1l_k0i zwnvR_fbWA|r=8 zHX$v!>%0)i$4D`om*}7}XGgI+*FX{zmq!5vu=m<-d4|Bj$-Xxt9|Iz48{e*9P@@u~ zq^bjm%k0GQpcP#dVSrzZqypONHXXQ`lz@0E-sMba$X*$C|=NVM!rO4bO zuFjY$v;UaN_uE_){2|Jj@)1HE{;Q>!2I9#q^*vC}iTqv6lrwi4Q^(lp?qq!I)wZY9 zJw2DhhcppkT1fJr;tsUr=BL0cOlu4GG+wrYM_ z2`A+v+;@ji)~3U3YL}S69-_(!4@iw;Cj=P$?1}FM{UOGZ3;>pv{sSPuoEUZ(y66AC zYm8Do|4Ze8=x_T>I}q@H!w(5p+q ztb~#6XzH7q^YfNWpS_P&2A-~lV6_kG{h1~ph>|y2Ylj-^tO?BB`a2)E zOcO6TV6kDAm+-cb&GA*b2K4BzR{bIe{TPYgl&nZo6h!1Js76JSp0s~UL~7)hdY6zTVi zO!KKE?+mA4ZPPPU4FBX|cGf`9d@PT?Zi|Fqj z4lR(rZ_462Vx8av9$0mxC-jPj?x4bA&~;*1L{nG6Q*Ex{VQu zWQ4saekLuZB%UeGXH-4VUkg9`C8h$cVV5Cz8m8N_RB?h@+m0HX?@pyUJ|8N4jwtw) zAo*<6Xs|C~Gp1!hm3@Ley6wq>?~EVeb!(w5qfGbTFBYv0MKQDG@ZHj)$le&lJ$gr( z&fDB}?IS{-^z>2O=w&n5ftv*E=m4wV*C|D>@yg@^r>|X3$?kC(;l+YEY6A0^?pIXI z=+>HLVJ^h{G*~oMB97=`j!xn0<`jwIVki-j)Z2_!KDFa4fNW8vyw$3lAN#8q8D4(Gnb!OHd5t4KsIoWOH&{wu z+_J}L*ruIt2abRX+egGvF3ba?C%^t$!mHoIejR$iQMfp({Pszt6vlA;PuY+TP@Kz) z67X68p;*yrXhy`0Q7M^5L$!RmJVO)jG(I`LpK+!Kl+}9nJ`R{)CUhZ208RiyEz`Y3*mblP2e^uZea;vPZ{E&MqHm}?0Q}?n>)fXCR(T< zofAb!x;VV>kYI9=K88TFtz(!GJqi+B`fQH7j z9Xy|KVkt&%Cy2N}6+K6(*r2Ww)T*|T2H{J4Cq)Ll@H1VPV8r*fnb8mr4m`)Humjka z@&FpN2BYT`ivehN%&;FZ5X89-5KTnWvx#^wV(9s&fK_m20ialLSTEu4V_$2$?z3%l)@H zKSTjw)TmUvu*AON9eMTb@=)+}7)y8R)=vgoR_U-;Iz~G>LzR3^4y5S5x{eoXpvAfY z2!N3D553&dNVle!3v&sQ^a&8XMg^w_Kp)Qw^C#c_TobdsDQlHjhb6ska-*3KnA$5z zG`gjIe0Cp5G<3tdhCh5X5Gx)d)e=C(>N2W0M=0k0N3yNOcZgW@rI!+}}nO^7wI6XS#J z{ZxK*PWJ1}ZY`RZ1x>xX7W{-RQ%oFlScfFumlFnYljZdicDdFkqIsTwJ$qgV^yVx{ z$|=r$4K(C>RVzJ{BmK;bZ80w}Pawy{)BPS2sr2rV5j%PMzN0FodU6*X@p}6<@(qV( z8nqhkY@s!IyDDVHs}X8M7QjGgMmgX`zz8gq^a>)sFC(*A)1ZP`+TYhI+cqNi>IEgn z1vPnTo^eGjOXP;3Wyvr8;!201i{$Tsdi-nLy&PEQ$DFn4dH_Ut zysj-VAkPeI^*9QzHvcg0NsG+O(pMFEjfWo#Gs9MG&uhf)vINlWo|0mLs1BB=Y>A&1g;qGO^Z(5Pf7dW&ewTvdyJCbG%GO0JL#0ca{lva4`arZ3?+J~B(v1FK43`-v(9Umgx*toP z?Cj-cM}Ky?p~n+9lf^Dtz>zE5AoN_X--e^F_tpg>pHqA5Wd|0OQcaOCZ}p%&62w&b zLgXTb7t6a44U$DjCjRl7ebC3~GMQA62G(t(Yq_kl5y#Pbrhi&{-F!(Fc%WJIE_o|DnE@X7P@rD0X$+ zc^d^Uvu+UvJ)VA0lxQOMFxDx3oo7JtHJtQq=(A9%XIb+CLUPqoBkH;kdrj4scETVY z>I?6tXMa9sN*B$vb%Z`3!XLsBW=5RT+8H8U?JJ;1c@v~nr`1orZ{>+iq0?lQqmWbR;v0iWSbVU`qf+C)@QM0kxs37FPw{m?11oclhYG3ISox*~+@#h( zO8NEZ%rzr)F*n-#*Js{im+ zmkoxEA*)ie1@lwzU)SaCxPd6jAJ`+SR!daI@{6fCGEb3Qh~C~XtRIy{^Y>j7WBYF( zx;Tf?ZTBxO6yHh}x2IIEM_AMbFodR(lztc=x6Up4m4WcOqJ}3pDr0kix)X*7zGW^GO3fvf;%dl3izs8I#`&Fv=e{EMBwx;Jm4dL~Tj84x z<{-(+-DOs-^7R{D885q3SlC9iJAhi2ydYYW=~tjmy&=T3$J!g8@69CkMbk{5nEkat zL|pNY>!-AqQ1sSJ#K)uE%C)!T5&_JmKahmHkykex`V?k$oQl5kTZym#QAJ%lC~yw# z5xuC2TFe4zac|C&ZVOpx21g^7pcvMpr&$1eE3|p&jC$rZ9fzi zSqbLo52~1+_42K*xEA#WDa3`>J?LtxshoBT64DitkFuxi6z@eTB(T>Y?=3~vJ5|l{ zl2zm1o}K?HXKqwQY!6%?tiwq5@;z5<%YZU+vQ?PiHat_wi69RiaVR$K5bB6CB>xn@ z-@jv5{++b?AQMc*{>=ex;P%LCF!o-TEY{=JTZ&m3^yK3f36h&K9XXmCGYf{z2paAc z|EA6VP`vlH@bRllm8ELDlP_WGi{L0SO>0&~hd zkSW2+gx6t6Y4}%`3qpj|8^(Z?Mpkj7kldkSd#?Q_>OAxVg3P^?Md^Qw?mnjpK#Mf| z)YB%{^wVT_NWSS|taPV;Z+zWks_gU;T6u^z%_nZutvMPla$zQ450#L%>kZY7oUdi} zue&+}I}IHQ?*BUE#)F89`4X~P<{T^AVU1`n?__ItqJRl6xP*soawYBzO+;+D)PMdl zsfqkBp)4bbRQUzh)@2|A!A~HPYa+LD$?r0v#ti(|m;cU03!&1*Qj-Zi8y5k%*V)^J zm`Ul8`X@8xt00xJCuakX&*jubM$h8^MVYOAdQiuduV|KH;}P{tQJ_q58BcwKpKHa3 zL}j^|_6xQAu?;mlSBkN_KTz{pkH*PLmCE5!s+iNshH~I;Wi?us7Rj!!);`^&TKLDp7cv4RDStK$l%M=D!`@GmdHYhP^s##p zbnL0CK@UCGz(Ge^kE2mWc1<=ySh46?ropg|JW}??S9#_F__ob?%uHvSxI@p&CkM0M zG*4`x{}u8Cof8MaspfKQ;wY{hoSWz0LKlpxd@M-*lzkvI82B(~DAPzuRDdp49N?X! z2eI-3Kx(OX@70eXFz}H@eLoG}$iM+^VFcg3pLX{_B9CvCofPmpg{Df-#J4)|Q5wxJ z7hl~3l@-O0xm6?kDXEox4_e-v8%O4$Bt`X@Y%$rHI@kfUD?XkS&C*Ip&@ z(5ur$=(24y#nnqs#&n~rQJ|MxywvcJ^;I;t(^rq?a~ZMU`|v)8Xo}1FooGH~%|J6U z!1S!OIMh-LDr95a90cP?I$yba;rLyt-Oe)a+FNS#=Dk3`&)00AbgbeU_jacQM#Vos ztBXDdpEOTn*y5my4)Bf9Jxdo1a z>-X*P<4pNY>cHl3))lu!OcqCk5hoa&bZ{9*w<{6+9q%BlHY^*38&!K;=v9qyre*2k z=-f~_&;NF0^HcH*cqfSut1sREpd0JJsQNnr>9gCDn0Wr}!JU>l8vZ=?ya&=R{cw9Y zV*LRxpm|EG+*d>XA{OSSKgYwT*@^w_*=`rq?jTQ$jsfv9HQf*;-LoH`dRb}^NP zzwgb3W~lQ8ao&w~@?<@5(QFu^g`h={MiL7Ya>_+0m`-PE!Dl*qLe6%a7R;{o+cA(0hG zFl(W2?pAH*e&c92g32ov++KWH$+J6K1oF%rF#(x`#bSZtamcoPH)=J*5Hg zd#sGv8C013pWM1-i*%CvE0omItYsJT&wHM7&XL$i?mJPr(O~X)1-lz5 zW`|zV)2rnfdo>QVLjgM)c5*p%`A}MIK^1SQ1jJf&7a=%=_x3R)>NTW% zGY8fj5497|qluFj=WUtCzhYQR7*~ z*>JHcfrS&FDX+OUe=0s7RF#RlfSUHn0hxrf}@zZrTPBKWmb$%SOuxRNf!QNAC3M)cVmW@Np3OBVr_H$ao)5|-63oj4_iicX-tz-2oP;23VF ziUZ`P25O(qnX=XrPjN(of8Kd5R1R;47PkWR=q?z;KZ%D;q*67YRU3nPt?O68?&?=-fz_iA!7 za39n|z8ooV-K!hPiu_xnS%wm4;M#3Blw^to`2G@skMKu0YH~?HwoW#(G0@!&Q1~cS zJbf<3ipKqF0pm7J<_AuUy?5M=#?s;=&MaBT)7Qz{xZI(X6CvlsS2W8z^U8ocUb{~V zDp>WKh$&!-J%zlhB1^2rr^yw!CDMC#WRR`2{2nyRjY`%-RLVN-c|~`u{ht*@T0&qu zamgG?MEC?Twh0d!MxmByG#FZ#7nouteX&WaRi_oppXt`GNHMgi+kLjhObxW~=j-zf z(b7IvjpK{hw&(FCIaU0y`-iN->7fJ%rm9aFi|e1x)6xw!N-0OVJvW^Gvt1l%=;y`M z99kOX--3Cf%+C3=57dB-QN+zizP_uq9g8MeL?ZK35NP__+Hj62L=RzagWWAmBR&~e z*2OIUf51lge?1W`1_Uq@DFpy9w}@_a$!uup|3f-3)Bm4&i~UH;wur+otnweVdpX3G zRR;qjCVmhd*)_yee1kk)376o>YW6UDwdSSbPA2r|Y*EhOup*QNr=7^D+Z)FE?pao2 zOT;n@iJ0!orjc)Z!^F*k5z@UB9(`=d!ba(7E8k*BhY})5> zd0H?8T;sH2LjE^ZcxG!YNFl|CSdG%$i1 zTI5DT5m9qpz2%m=o;*@DNlaG-5L8wo-`!Zgi({DX`!6`|_1^kSE4yHD1AlvZNqP(^ zgNY+Ult3A2QHl6fSR&I$;@{ghhlc8g#P!O%jC&CrX@-9CJ>K>|e1tRqv>03YCHqltX*5n@=8mK9@i~H3Tuxr(m6hTOtIJK2M z=pf>Ewe$~Jnq&1E5hZ?TD@>Z8{E8Si@$n2LCC-*#O+j_1_)W{wu0v)|<=w%WaTS9_ zsv4-1gEK1~zW52X>bxS$ue2g^XcB%S2j%;lR%f7(0J(aijwAdWC>`jS!NC0>`yEFh0Ot*xFw;)LO)jc5@B@S#9Z4k8TJ zzD|3^R$Ylka>kC=CHc_Y8YQ_hb19F`2Y~@Zf9%lg7(gcV5db;-l?&}9kNz9Bi8e9$ zKn7)&Li?cv*AJJYoB%b zS<at zwk}ljp5?<{fF*HceIGI5rrLr92q?ySO{C*84jp1hLJg-WwpOi6w;mrnuvlvEFaifl zLejqk4-S{O)_e$SluC2yzm{!qnocfrjvm>;Fp5MLta_6vZEt-B{PKCpC?JIEdgrfH zGRc}r;{-InP9;P*Y&x!bs~G71AP<1yPxN~p#Vozlv6uc?l?%6Dh^km;7=_3TuzY6! zy0;2^ju5{Id(D5iW8_zdX8QB+ngb64?SCWzKwmzRqcQ+Ck%tdOKlnO*37exi9+*qd z+N_QX`X2MzN<-b(p$A60_$mEXn{?#z&5oHmD=hk#%yZS{R*6p;oaSgK*$-G{OuGJe zKYBzNezFHu4%&~_T9r=whE@&{?un6p{tdrgf5SDcaN1Cp61P9KZ4?pUt6`URwXkW= z87KBCs%wa<@*3NohM{G&WfD7MxHyVNHkpj| z1M?*%`#s8>);Vi-l9e(5r=rJx=S(=P#Fs#x+l=^eI+ zX5%GM*5)NeRL=Jc+Ps`w<}>ia)nFIyBgk5b`)EJ4DYSY1h<+G6oa<^a9hnmWV%vYj zSnMBf`{PQKxk9G!PZceO&r4#Tgi=KBkl8GcKt;2HFyn}i#QsT;u-D-bE_+;5_~$tF zf%UaoDp#S)vt-5w==j%vu3==wf`$%e^1mb?>aQ%ck-?$=6ib@1`?5@bJT{nw-MF?d z_Fgpv>eV;AF|;7o`d}f~S8e7SdS3?TRB(60mhM|XwCs+BjIdHIv3E_3Xk!O|n~fz_ zE8alIK|IDUM3{$4aW?yW_R(i;h-|1+3|>Vo=5rkpZ5#WS{^EWN=Ce4Q5B1Oc@}oO zQuPpXg9$xpM;!|fJb#>ay43r{xNb2f$t2F>X)U#cPBZ~zdX=yjZ%ha2Az-Kkxjo<{ z6Ck-07+G6F+%=x#vAhqy)`i#k87k2iMB%C5eQWZVY?B?aZvtJ-(9lscY0dnbM^~pL z;;$;M+ghoz6YhkHn2Lj>R|nNu{3|);zGz6wYUH}h9XGyh^1A8HfsvB4>+sN^)4UsQ z%O`)kn6swro6#Ib5L*EZA(-bEDfT@pGJf8Sg!`d6Iw z)q}zhU;N>oO)YexZFxNKq1U^j7C!=y0?QW$!R9OQ$dGM{oue63yb9@UqMJ}=>6`!k zaaGL`;`e!ccChDnzI-JQ%hX4wTjj9l1 zT!q6?AyKOX-omfP>#xtg<6Cil4g%t#G=TT*>&fxFPGmG8UPE%#>7K0ojKQd!dIe@< zBs+)Rx@8Q}qb|Q7%=0HL-e3<+Uaf;BJG0>{%qMREDAz)?h}5jGYIK7O_{@<^tV4XD zY020j0Y+}4&v-N6z#LUDX2kBn%@<2dpv7uY;6g zmtba*EfG5RROm0?KYz>#m+#K2Q)c@^O$b5uebRki*-qUP-u)J>JFTojzzAqerIgz= z`OwoOYRi}R3KKWQOk>EF48*zNd(b^{1@|K9vFx|HvTWFWQc&^N1%Gxu+hAIO2jQYOYpj%hK3E|6|Te@ZMe^=12&im-p;_g*?k+7ola8x*<2WT>D$35;w>k zneH5YXD{wImT+61%Gzn(m_U^!Kn*G`<<5E>#t}Gq&&m$*{`Vf?eXbLv^RvD)Ubm*B zrQ%D|6I?z`$CI1&!*&g~Ll_!>x2TM98q zgdT#(;}Eoyr6wY>DxBE5@=aHk+I$3cZl8(ko=ikLa!AsxYq z$c(UE*OX(~!5ZB7VEzoC8IZKUY2+>^?(?}7M~+N0P6t)u^1`isXXE9SvJF--V;@!Y zY^lfy(_j%)IUZ0Tak0#gEM|JJE8Q6#T1T_}6aP|cvGOO@L_bAp``z{sS&YtW+oL66 zK&uMR{Ay!yWR|%}T3v&eUf2_TJyuwhmxN2TWTLNF%3a5RV*iM-PpQyj9jwCFyKCh{ zBie*)1`qlxqfF?I4fd)_L;bm&iKytGfipwJTWW=6j_8!~;S>jxNQ62*oh&tOSZyD_ z7;Lf26RxCr>m=~9a+rMca^vOLscd%+r4yBjA@hBzV(ew-@Uj~e%wN!KF20o+GA)ik zMN2gg^OcI#E{|we5lGus8l3fBzCV68K*mXKLhZ-AhvxH#{rckn?bdfppo!`SE>T({ zqg5yNG*Q!y-Tpzy87@muSP2;4Q4VXf#Ft%zxAXZ46z~5svjeHpv;N{|a;e zKj!+Ms=t|2hTT`-xn$f+xAY=bo{P{H)sq+To@ImFmxaa+aBmGA4%#JuGHNCEYCcS1r}2 zu>*oU&0Er9$JxutRW!atzo;|ze|I9SP)0N)wV3%3MCYtH4l7>OvQ%#gCPunm4&`zM z>++OZ_WS6jvWOPIE_69^(=wEjY2A-C9`heANBj;csU(F=${cW3rhpd3WI7E#Fg827 zYmURGt^%w}m4w|ZS7FUw%D->yny4HJ3ML2Y5!KAO%UGWZ76wL38zG5TROU?_Ady7; zRIEI0<|%zQZ?HY1l53{>ce;k8)^Pqt2dPVM%EOcynsx2YaTOEOGj8Ygw;1;K`bVnH ziOcyi3%BK5@BPwT?1{&BBfUhRF&zqJ@o?{XlFhpaJe;;eZ5BZD4|tnmJ5*E>*2Jw7 zG`rhp#SeT~BiK zraN`Xh_gPZP46D)XGcMwG;Ofb4=7S6DPi?!{aa5KH+V-*Khph5q|kTxA)DyN5b)~9 zGk@a->u_R3`Ywzy)A%}zCMct`Jm#wq$NPW);u-mjg!+7S+`KF8r4%)D%ZwvZgclb)RlccRpJfpbJ|=;` zkZeTlSeDin-+drbAZ+6jGUDY0KF|k%9D)koBcl#a+;n_RSpqs&e9A_@LL6FI*h{TD zL3X~=RjsG53ynHt(r!hK+S2Z7!s~#jX3Q&>Kh%s~ih4#UK!(_C73LX>8vM(pT|tMy zF$uYajCi!akI8{SpU?A`m-|bYKZkjEuIqQ!@PfiVwtp~T2;53J#BpR z_^<$t@-Xvx?A-w68a{r5$1Aec+YI5o*mY}B>?g}-qJNfhg_V!w!XF+}D&VPFj9lN| zg?S;WxY<#Vgif17&ILm}nSPp4#s@HED-N(fwxW7P!LneG5w(1n8CI#RIyJ*(U)7dy zJk}-xS_?Rh;H4WXTPybEci5tztK+1R3~N23($&BkU=39YXcfG;{@}d`rY~OEhG|C! zZs3e<0PObG5Q5VZP!bBrcZ2m8Mm=DIH7AO^Pe|PfYWU?D6DX29QItMl2z( z$UWP7$1+O;MlUMrn*r%te$Jkd5vdw1>O^wM%v~i%J3nA-o%?QfT@1C2aLRWRhO8OT z&|n*Z32bdk$GxH)pc$yhp1a+Q4&96us;0JWX9!Dktzp|=Lrt@Gx_Jiy~iN&~SxLxw%nhGr)nYb%@~i4nc-Yp3|}_b;9p(4#tnu z#}(cry(Bo(PIXhteGy`!sM3Alm`pm5CD@XIYHOkY)zwU4U*1bt_~qRNiF1@%a~90( z?{E48HHF%+x1F_2(RWfk8Kh#6un}$(q>hdmtb|>&nT{b4RHBIE$WqBvSiGYR$Jd%4-gX&oT zL?AULR_%FC@b*1(f{3v)VbBJVO^{Sqjy+LZaJWqvfs{ffM{{WZXY!| zxljuR&J)PfpvEvHU!x!hsQXd$da<@GXP6UpP~=@gz7ojzyJLYWWY;UCv$sXAWU+_` z6x|{*HD6No963Oy@u~#=z(Y-RE*1Cn+qF`yvTOI6UHXIGcUx5gbvwaefeOWNN?Y+XcKh*9FTIm{8(q!8!5&z6nUBv~Sm^NN7rfa&L5OHYJ{4C9t%4qZB ziHb`5HNaLpF@e;0_mEEdmE&{m!cQYR#y>~a5-RGD2e`J!wb(#?IdUPjJAk9_Pp9Gk zhGGZ@at6vA?|a?xYI`-s77u9`87YtpH?0G|yL#Xg^JY8}T8M1)m!cXKL}hLNFCE-SvIyrwX24vsH$4wRk&Pjy7y5JT)?vO{4 z)p?~kDhKI5D%>90PC+Gnld}q0!x83x2I7{UbAtDXcLPcF85Y))ibTPh`>)uwK6>l# z%e_YZ*yhj+`sJsq{)R($=+D9DPXT?%&8q`HHUn*naRq75Fbj*;5nI(!{RGm+)R6ZD zv^L8z!<<~Den7XBMXmhovB{2IL;bs-h_eP%)2>%dcG*uwOQ{5(eD)8u9dE4I49$J*kjn8@j`Q zrm3~v7b_1b1UB`>B+`E!sD37h4hd(sK-|kMEW4^(bYN^Mpw_UlG0%3F)d%YEz5wFg z)UMKhn0bA&NK%*0>eAND@{rs(k>2ZKC; zc)d@W)NMkRa)c}@yy9Sv_?1oJPh-$$n%5ME`}7Gx)wR@SxKPjSp*Vc>skYb32o;b< z_uoVGDe&K`hBJMZK$6koYf@4(kXPezIq`$-yXR7P8AcGB4weSJ|Ni~4tDy$0dP0Mj z>HtkRFeZ$-*`4&uQkfxLN|pqr><=>FjCCstAlH+TTz|Vp7$*n00R|1S2ku>!8Y=81 z_!?74|9JN;3yW0ToB`aPvzLhE>weQHYsnc0Hf7}5m608yK83bC8wF*)0| zn@Fhk6C|yL_M5cn(*(_WEfTZ{c=6rpUIzv`+)KiN74}SxoNrYFuH$DneauwM@ToOS z>yfZDLUHJx*86Bo#AC}oM?0$N&TX7gtO*j~1|nW|>f;33Ufv>u2QbrfQ`IS=EyYc0 zy#{BC7}cL5o8Pg4^-6K6e!ZBy*~b`aQqRA6hbGBw6QdkbKN3094k^p^xT8Mbm_j(} zQ&}5zC;9VT6IRi>i1_Cxb;~=cqMPH_Nz=3cV9ztEbvh#dF~=K zGLaVOauqms0yrI@#Kx}#C%lB+@)B=hlhYll+t%*?0MzZ?BK*HIHnaan*jEO{)dcPC zE{nT6Ebi{^?k>UIEkMw)XmEFTC%D_9L4&)5Ab|u49wZ@`_r32|_1#~0sq_FgS{%i6Raxt>v~qc(N5 zl*w=OFtIw~xMNG7MV%sS|mb zn`$l0{soxf)wdH-z`?_HQTcrrBbY``w>bACY1!Atpt-V* z^ceW7ww9Bka+pY%p6kQLGz&SA4FG&&7`Fw-PZ@fehNDL<`>u3+k$PWR>hcXvBGD-A zT=rerYrf3K-YL9qkVuSkvBKK~N^_smbbmgwJnCkavR(v?1@Mg4i!?7X zlm$LF=@O6Yo5|f?I1E9|(4qKE*uD}Fn{Q`lXPbMHw?MtkxB<&SIVZ&H_X9J5a_dI< zMcdyMD7vMeUQh3!FTxwyX3TQD)3b}F%L!{rJ(XLXF8K0>RK_omCFn+;uqT}iUxpqlGOXLbfzM11fOHZ4{@d$y6hb+?IkufOOr2+9q z`n&drjM05L@+dB2^HXOFE)otuL%z^)!)aL>>MJe~`kjXcvuhIpZa0+}wy@OMk5K^= zII%auv)##Q z!{28isxm|3C$A2MbDN57J7o?^O$;l9>!{|?YthO15qsLjW&{1-Z`&=tP+~U42?pNH;cxo!%Srvg3Vb zCMOqNDw1Q+Lxdr}gy#rL#d`xn4AI`$k>{Oc>vjCoF?K!Yq>9(bO8hK-219hMh4#QZ zH#Enm`odaVPl|e%9UW-VBP4omO5Nb{PLlQ4hA=|2<=Vp(_4F5yRf#Qi5I7yxgY=N! zcI!yMQ?-%kdJ_`_ui&6bCp8}8<}`=DO-tS(If3icy@*m?k49j)rabA(p|ny(#sS<1 zT;*&7?(|b7*sL}pu7W_+;s%NUCyp<82)6S%r&kdvK=*u`C zIlqy@Fu$!ilie3czm$YzD}P4NUjy1G!tH;v2qt{u=TgACA3_iAS2#XOeJ`7@D*Y?; zO7(Ay>S^1&*syp^Xz30jHv5l#%%X-%7YuVvTC<*SDO`s?qthWj*L!q6(tMIeUI?fL?>sKYuOUZWZ`4XCEEcz&DV}c zW+0hhb z4kYP(QyVSwRmmO{>fCCoG$NXnjZlYB@H+qNCi!F9ps@UU2mIKdRiV|J(lQLMe((e-TBzpv^t ziV1gT^2%llXO@)^zeIU>E+@)&^>IOAnvO~GBQwK|XCPB&W`;w(y|g0T6989$mM|1hP`xfqL?w{^|MVH0cpw zW-x+OsGZ`ZT9Js3ohE1Q)X>xwgIV8`3=$F&ZwCW4OS}sS9iAnk@NXp@jO#Fbs{+}} z8?a2mthLh8vQ)J-?zxT(VqJffE@al(UEisenKmTNBeApQ22ITu4oeGO{;Nt#E^gm? zgVM?Bhu-w9A4wKrS8Fz+O2$Z|@I>RYaf%bGHvCM9-93DY`lbOv3lZqZATh7=fM$#m zrVy)BWaZTQIR`E346<-$XD3cj7-5=Zdjdq#SI_MiEqAC_OEJK&2ur4bkDwUKIcJ;+ zN3y$7gN{)XOC&?Om~-_hvU^f}!9z~=8TiJyo?BU4b{=IUiJ5$)8Dm0Ox0`S&@~Y1% zQm~gBcz(ddM(xQ>ixoZR<3>;F3g+8YzXkRh#`@|3x}x;ysnvPCNr8djTYBC3?Xm5O zH>3SOvP8iy3%BxB6?6d9CqQtAPj=Yey|e>_mKVvY0>~*>QzIoC#c`TJ4^jeGM6J>Y zj!6|OvfKNUi1&_u#5J=`@k_+z$F2{ocCChw%K8ye(8_O}^{8x90l>0it~To_hd=0H+7w%`SRi{wUB;-u_2(rbUlphC4tOrOu@kn>h_U@iq`BPEIIaE#2t=}Q|` zs1gyE(lQd4jAErK$QNhJH_p#k1EaM#NdfF<*F!YHgO59S>gSt~!`41YfTHHhOL@cS z9~r8LM|JyO{?@x+JpUkpRiykgqZM7?q!I5D=;5h7%P;e=6p-k^e}KYc)WFd@$8fB* z9#Uptm8RQ(8ZcVvX=0L@7Rd!^DNXSJY`8rktNd#W<4Iiru(Ml@h)Um+rm9$O@?`hJ zs(`Rq|F3rE?3v+V|8i}3cp>@IbaUz5pBgxbG){?raKYlE8&`QU?(nzOnbJ5E(-PDb zSBw`e(e8Vb;%S}?rN`s(=(TL=sr+O9IHl>)tR_F5g@oZ$`A_xD_I%3g>;}ZT2_0^% z^m%BCZQUoiPeP-@WL@DXgY&HbsmB@qW6nSE_lfaQ>TgL!UBFUkXP^_$QDaqYSgLPZK)|5@U(llyE8_*fSb6x>>GGEsGq%f3X=Jw zvm5ZpwU{Y%a%64^RLfZlf(Riz!r|v5*9ggYH7RT|D3pJ3r$*i|k{`A>p^;ZhiWYDo z9ki*G=(`F+6u-&0;*)Wqo;b{(N+KKbCPY!mmT?%815}-g@mcRA`;#=#jr$K0h@Ol{*mjW2Le9!vSdxHg?o3LMOmc*JR8V+40k#PP|b} z9U$>}?Xv2;N9A`FhL$nt# ziv1E=+Wc7FgAM{|mPsOs!aYfoc&2=`Sk}yi1gqZ^)ALRZX@(#Ht-x)L5Ek+$kxcm& z;1XZ7aCso{A?&Z|w*GF)iYd?&^LSe7e=ZOF?+0k%EAzlW(WhCZ0zk#-P$++vs1ZrSekXvUxl zO9hL=2_>hz5^62&Y%y^m`|sAWdUf?Ezk|{_jMNa+A(bFH$v$&$g`XWITSfBFl@wNz z9V+hs)rIbKk01BmX)6JrRPE*1TxI*ozAbtPr>p(#_9jz;s47?eo=v+NbJentw#pd9 zaxpnxGGc73!S<7;W@6ZZS(oo8#nK&LDJE$oo>7I1%4KC7Q;zfQYQ!*xe(RvDORR=)hk)NVJzv;?Nm&I=w0gA9~SOreRUp(X-3p z9<`#nF+&v;QfyL9w@tR4Xeqe(?Tt@7n5p*h?1d%H>r2*~Bze4<0lc20d{49Qr(C9v zX>%=MY8PdnSJ6(y#W|V*)&f3TU=hfV;AJdFSUe{TKak7n-MD7zD05~%8h4f!n-t*s zRtaO@hF8V{PA}pd87ErivAbM7g&!bBJ!;$yb}*>SFp`whi6#WGUeGPk%+c|D;ZC7l|e7>aOnPP{!>ds=txaw4~8P zBJ!!h2@|K*+nZxf1)dhASIpu-D!Q5Sw3oC=B?3Yo*lQY+u_pfGmMJZ*?U{ zqPy7JK_8)tz;7^%c?qn=Yg73_6>0Nh*Cw^2zQ~pNN~*qHW+GUgd4y1=tdq~552>8=R~7GIufoD z$CHiMzfw-MVCR@VYSUF}C3qt{rm37Br`RnO=JNBomL%L-;m|I};eN7F(&^3T6$2>+9qIKfS;a0y}j^4XG!>(IDv2gVi|9+lU zST&C^Y@v@XnJ#G|BMY%9Xu_4)Oz!beDj1u!Y$U;gk^FvmA;n(&6QNQ}gYd{k{{uvW zyMC$D>?kjCUknh}HbmdovSOIU*SBB+Lo$(-<)K|(M$oPAMGY6avZ{`rVq3vs(q2fp zk_@}saN&>-+{pqdoE`F*S6knX^pMAOa}VAr!J)8O>68L2O7L~?ET~IV6@S55C{mN3 zg%|AOx7)}^@Z`etFKFpcBcC87U^vf+A;Rvlqkhr2jQ=j#| zkVsv{oeMX|R)?bPje_6?(=^@he;>6BIam2Vl!|It$>MjWI7$T~)%)mBSIKSOdRv6r z>^Z_=@cNpL-WW)+9OB}ndf3sjuci3QW(lL#_75ZZ>-z&Yl-?4)xe88F#iy-ROkrZnJUwe`WmMy zcFD|2Bb_E8mqk7iCQAkn0_3~U_5R{ea~szEK~oQbqhb$kKmD; zAa0748u-!2xDJs!60+M=uUBki$Z>~>1v28I(o!+Gzt-0+_poT7NGYpabkT2if{Jj+ zW6mjdIMgi`g@+FlnF+E-HZRGrt4%i5<0vRAlkVV1MrHAG7k&$r`e<4h0ay9Ccq`lt z&GqRQe_W=4WI?ZK1r})`LfoAhG9o!O*OB;?aTif|9x2{mK8o~}r(Fq5C&-I=bD6A* z;^boU03A#cr{?ff13dw;@AKe!L>LvfPvUaGM;mx09uZ8XVnm+cF&Pg{a~#Fwly~0R zVOXF=VX9BmT$bz%R+?-GZ;XRXGbmMhyp>UlvGJtjL!s38_1`-<`7o)#v=W69i`}^O zKDOFy+pw9TP*96H!uSWBa$<*k4+s1HTREt!j?luCY9G)S0<2qtE@Fvi*JH0j!=-6r zpJ4DhssIb-9!`EFAc3GTnj#R(SGx_3r2%W{9pWhC-H|$xKo-JxPz*j5eewcQd z>&~@yq!*<^(npQp!;H_@YG*82E9;g3pK?r_ZWDIuB!JjOwW5vRCix19^hGNMmrlMj z0l-*4A~~(2n|*!}3(n%rP97jX`T_S_Hk}IP8!vgo=qDmQQORmN=A659Rp7_^-Absi zgEqmD)O}cr84iF2QP`Gk8GEe`>Qk`ALbDgX5Sv+$BV+XxQYZgc8@zAdr@@g{XQ1ct z16wu5LB=)ouc~1YHUbT3qPb()5ifI@pSaiXPM;_mb1XT_3X3t+)sPkC8oBNIh(g0E zUP@AB5l51LYWgy$Td5fu5?qD0C(6xbk0=!mRyCnT=>2K89r_LX7Zasdj%Qy=f*aQ+ zzxjRkmTs|>rKJYlmQqG46f{Sd4MAQIK0-zxL&S2Kd zjY!YG$|yl{p-=l{&tmiYYw?#au~S0lwW2HJ!Jkzekn!$RPtd-1XhO?^=44ltHpe-o z7p=J@+X;e;D8_%}JNRdY?xS7ClD(P2vpi6>ba22z2K20ZKdmfc-MLV)$N*aIdkhxK z!-RCG@3na2RQA(wQ(G@LvfN29@s=6H%*E-Dq-S7f?jC8GkbzV2hpmj!-ctW%maFBvjUk~A7tSBZwhEWYF4iNwvS z$0M^;{kzt5-Dx?^ZQ1v7=yUJ#V@UkU8a4==C5b+j-fmZCEt`uzmMwoAKz(y|I}&we zPq0gD=7}CF&>k(P!}@;4ob>|%hiLM1zLrhv@#)xkf6mm{p&P+ZIt_27xB384mFzd2 z!a`H3GgdL%y`k{>Ml9q*VknF5HZMtL8Ykx;N4>}lS!>uhiOQ7!Tn4>V@-WEZRntf@ z&<{|aS~JdSyRMs&0`0dPfykNb|pw}+z#DoDHv_m zJKf7;BSxCl zeB5_XI=nJ`BdaQb18-ftD-A3Za`&j7;*>FE(=^T95mx)GpO0mCUBSKhL z3UhHI;Y3)D(I+v031U9MmsrOnpeTL-|0z?*&!b|!O2-k%N-^>`k^Ea=fK-BkDL2te z7mVS_FpEf4#rY#asA)(=@uzOW#0(YToF8Dr8UziC#-Rr4e9nPc-x*X%3iCr47)fB@hISd2*H0qr>3lC8lcBUXXJpNHqh^L#3oal({#!T z)f?~SWrH(d3vi+{VxD+L#ghg?qYa@ED`Bh#3s5wKv{$?eLevpE-1HxCg)sh~kPSeB zC+BvN!2-QvS%6hZfW`k*07b8a{L3N;hbswyR(jCN#-Cb)L0qA-I!IASG)=1SGfKWr z9I7+^wfzSb^DjsI8?H({J6bdZ&q)N71pi~72_Fhieef@o27+j_0BC1{vBXFu-WD*~ z6CjczRw=nOGXH&(9{~7DXo&KK3EHgnD=iF$26zSK{-4Hd0$?S}r?-TKBHU6%WbUN^ zv|RErSaWYRUHrbJJ3J*b(N1pnIs2+qTJ|fGRtOnLSGqs<6`0`e%pZUAvHlKQSEN z(F9U&6q5IkTMQQjg%6c`2TNZVL;{BFb=Q4Ny_Tckj1a(x5k$q+g6cM(N*BLiYcU_q z8KFc)k5c)SX6#OA7iP^V<{s{84L6~RlAxutO13q7y2>1u1j471{nAI3*Ii6KZojX_ zO&FY(KR+-8`!NN52;791?#vciYRsrs8j}M~-r^`({F#|*OGZ4|5zej_24COeQV*s6 zD31*dGe8M50J*cdf|1H4p;(e~qLq|N{Gd_NeDbVc$VZ4d!HO_M+2|fbRHW$EYNK73 zjYrE0r7XiV6szQLOLVy@?P6#%!Z+)&(gm?&GV(FyL~q*YKlG~bpHF+D8;jCiDUPBt zly4uQ#qeGDUI5~n)mPh1Oje8jOB%#ZlEYoQ^hQ4;L|E^sPabmarjD1z^gN^;u8PA2 zMs>9IaR_~^;#($5v7J#Yzbm0>QKtd%;+QaL#iExSO$RXud9nV?A@37dEU7lz?C>LF z&_UyZzgp9)*He(`sAxZFmP+9Ax+pfB%D!(Ku>*q;sz4@fQx+T?Ru!oVI65fw3Aq@V zJY`83O_Pt0+GT(6q8k$JL?xw8vH2LQpv<2a^qpZtTZVLeN^H+3!auOd`>n<^ZX;+V z-x_K~%$I=o3GG~+;Fq7hbQn}u!AepH(9kqGhp*Ry%otR$T;N!?^?OUg(C?N>83iWw zJLHcplIMsHH`kGe<($gd5T4(^CX4GOF-mcky3T`3c-9>}ST$tpd{!`E1PNY0jtxR535qc1 zrr_^#zvJKW52cw{+wWJcZM_LpdPIdwH95mkt2smO&G4l+~KX@+^LVJ5$lZyys` ze^{8w-j&+)cV52>AEuz5@UKMpHBL$V-#qwWo zIshs_?uONA&nuuWB=|2=5x~!d8{8E>q_fyNMt(aByg;MPNs zqm8%k<>|gIfGLFPL9<0G3jMq_}znk;mwxw~%=N`R0y8-2$Yr`1t z5)jAjIyZn9Dd`)l3eN{@A-GX0{_Sj|+l%!xNnV8ltw%0b_W^I9$R0a=QDVC@{4aVv z12ACdZ~LLbHwV3I7mqj3mFq8Nx@eiG1U=If7eYoYs@0fS?&7evBZ z)?FV_QNb6{|Hany{=Vny90eFVyP|;yP3bSn1MCwaGkIBd>B3Z?__<{OS50P9q0vFPd>KDmFH|#r~RC%Ev|mjZZS})!-BhE*Wg{ zLyD6g?*S>ms?b+>BJ(P@7AZ!P1iofig>9&m${T1jk_czzq#M$88to+tEq1IZG%+h) zjtM(O1mu5{=+I8oR&akw<&9`R%HnP(WuyKDGjsJekS)4x$QG{1se-*>k9*NLf?MCr z8QB_%U%)nnTEiH#!~-LXzIVmL9D6cmIhHzK1UzU*cVJ>UT6&LF3KhoJiU5^zb=C4) zpL|MJrfx4~B#@O6&b=oZ)woZ8S;g(nE0WsRxqNjw{!uVebCkD;>SvDZ|a6ysBR zM`+k#`bUdE$En|v?XMzV>_|(te-$-L>jR3bwc+aZr_n5@P1A;G)fGQ1k@dtnsmpgV z(^>w7+vOg*>m(JF*L2rjjGoLu0q5T1S!;H zYVS@hUT-TuEy=_a+wGV;f_K7}otntcXiq!vQji+5_}SPAI(I?;hLZn2Tzm zT5lVQ(9^Kk*eZl!l*-oJxwtM>iN#O1;bw|$7smBtay5`!E7viQ8dYk%u1_1Tet$8C zfgO2w+qH9P8?O-ySSMj05{GYBiiN7%PA&Iyag(23StX5J$TjJ;f5ncurNwIjCD<`C zkeWgbcA;~=V(rXbL-Nk`J*b{oCq?h>11*O{%c>A|C-3^l2I2bg0+(hx)iM3mB7B54 zb+gm;7awfJ_T3KW={g<03mXwjVpJ2`8BA9G80{q&g+h;>czE1QuF%NHAyuRo2br>E z-mMgde0J;0dM9oTEJOY+7<=tMstuIyYNCj%B0PqL>6_$T&X{Mc6VpaNxQswnAr{R{7a>VIce-6Ne7!g_&vnobEJQ5XP)*xe?-e>SoN~_@ z85oJO7*q|XrH#rR2GC`CubJBm8~SxL_~J)8a93OA^`@!6w3wE@dZDH6F;pK<2zU4^ zK+w`3*U&dN+90!zURh1UBAs46t8*pdNX=ry~?>CW2~?~wmk8pxX1@LBHQ8kRZ6Q#1&zj4yfMFU%tm38O1Wi9U8P zM1LEZPRMv7SLhh6YsdFfYLw4(P&E!U&Bk;q^NaRU-mHz=r%N7E%@ht&SsK(-)|ZuE zsPC~Yo79$Fh>kBc@)?s)6DlmlCYEcx9!Q|q5t5_fj;Yu=gpt1 zYKWIGfn;n$-^`UulNc#_m5+Vu4mcy(4ndG;{lbR6U zxYq%4n)f7W-g8iP$p3S~(4!c8(BNO4|DX8z6DTu1H!t$Gc;`W^ zds{4dq#0VgO)EKuu(d{-e}+G{2F8seB}_1GJ{rOh(f+5;oF-xZbq)nd@IiSz(yxyB ziW6KCKmVr~9rI<{u=w9jtNmXnul{X51+hk3vJh1N-`~)dTi~>INPeqgbzoi4&ekUHRs!eNuMETtw6q-HNsBhadQ}|$EUiA+BBYlFm-yJz>`b7*|?7P9vKMie=eEv2Txu9oG@pQTL%C( znNP)dAAIF7c5;&Xel)G%exdf};PckfCll7v%j4X2#9XXot!3!a3^8CGN~W8WQ@EHt zBS2eyafYj0CvY{j<4~5BeEJ@`>S5b6S6dL=fFs-(#YysUz@(3ggvm5;kX$?H}s_;fc5@g7?Ql5&EmV&-JYJ zuqU+HA77|CZ3;{FWog;pi+u4sdFy_kzd`G6w9rw{#673!NiAJTWEU**;j_1(6rkV~ z>&|-@uDs@8l=kX+U=oARy_Fg6I0&kPBqKdkBEX5z`8*B_2|!=VP3uxR-U7|x;#IT@ zI!;;^g#Nw)bZRlHC(?Q)D~|cX!Nt)e_J`3R7h~R#Q1>!b<4ZKPOz2%-mWRbr3>1@O z9{nnfoM7i3@$R1pSKNP8`ScD=9Z|4Ev2EKH;1dx}SP^5V*bmqC>xN8v3RymkHZmhp zC{dd#CD43h%~~(|7Eti>^ZH09=ZLq?ZlA7d>990OYlpmgC3jH1$lgwHPoOU> zrBkp9^;z|y#3&T?C;xT3{G=l)_~~$6^xVH2f0EwbC)0XyXllWog%Y$@NU{Ll{KA4 z{#OF>mm#;{pqT0FbvDs$WjAk|AJ7}kZ!-!qdz7fI659&lYU1{@AFGWUZIYVC%s27mT$IZ?Ui%t^NgsiI9C*Jud$N8T|1@LCB<{17B0Q~bIcMK|CbE= zPbc=(&d`6d;Ol(;X|y9d?r`caD$S8%?|c&`(G1iy6*Y7wxlLxTmV2VPt z(@5WQ>5E4ijlo!gZONJANnv`6v za~ahL2+Ay0y0*|0TER{Xe;zziwN}whz zZ$Zl`)n4c5dhL6cDTB2`(T7aI6eK{_Yd}C}0i!f)wpq3%95kUx6B9XhU7)LN2rRCn zEpch&rkWM4i=gz3*3gjC-9{2%K^Xg5W(NWTR!b~4;Fc?)MW~o<(oEG08Ah15 zJN8_uN7$Ff7kc2Fp*pFVPqK^rh9$Tca7h)5QX%&&nW9S7M?es=r{4v|_ygSTe~)Ct zrCNkXJVV^!zZ?EcYx8|&{wUw8qC+VRavA7M#AhI#i$tHhz}M)IG0GH>?vdIafgX#` zD9A+fIbxAH3f=-RRNI@5Xf5>qFGQ3`j$;V8J2W*QgYjm^b2N-R-^`o?QCyjS&WIxF zfSr;2z0qdpr+HP9{IN-Q&<2edWjq;lm`Qr!dG7w_Zn$?|F7GmXWtLPABHg1Afl?ri z^1M8Lm%wNXX|n~&@mkZWBp43|%+%j683sk)9mIsgivN{~g{S>?g3E!*Q)Hg19A$i9 zR+`T*o6D~_1Pi-(xb*fnbUV7X8)|otI*~xmu-l>+BRz@mEQeAZ-By1_dGlydBFOFu zaM(m4nLNs)a6xz0zBPwXf{|jC0J09BZ>!)l|fbrrqI!T*=uvIZvtIyp` zQe=f#wo#+^v#~~*VdMdeTjKzo#Sh=~noj9Va&6QYRX2DbZA4eu=$?A3ffwNlg5d`< zSW0ieMQ z(mjufZ6mjc2i7$Z9ZDuoSQXkM`NUb@nE(g$)6f3ep@`)Pf?YFHuHYx>N9tsb&T&Q+ zF_N=}pE_%i{sqzlKV!nNqWZxJRpa!IBS^b&kx8BW;ge(cxGLwnd7G}pi1WrG$9|2oSg832D#VY-Uv%&Txw@@2kh|57)T;~=4qRF2C;+z#oxnhChIEzlD#{qS) z;=+G(io$&L;0HR1+bC^WsBOYqa%4;=JZ?axszgmde0ZZAD`MG%npJc7 zgcmI;wjp3kXzY*!b87>5`FOL2?k5bx6tQ9VMDhZa-Oz9;+5M~>(_yf}JX&zqiDa$# zM=;h}5TLNR*xYyzw36d}ZHblVWsw;u6)lnj4iW;jotnJ6{Ie|1gn+W@x8$SsK7vGY zWq3%7$SPH`sUDx>awkKOd+r0#EsB2fyvi;V-UgjMOX}WmMZywCab^j?{XQ(K7^@N1 zyEA`86uk+=V>HtOj3;Xoh`ykqMlBp5_}ZbLMU1JxM|U+)3HwHG<-Oa$j6D$FSr}1W zK#WBhS3DgD6+7aL(3xdJP|}_Jct0g+a0$wR^Ud>nFM^rvR%*rYQ%1Z+hTr@B_a?6Z z^ci+i_Xu_karLuWOH%h)JI5I?f@QKj^~UPwN~G!Ah{a1E{B5+e3YIy_wFX?tHRE}T zuZX49w8wiANWBh1Cw}K2^n4?}U<8Fy3<66)xL=^_B)XEa3smIJigzWfGQa@_GW6M$ zcM4L|uoy|>lLop7kOu+9hEk}gCPtkoa9ZI5K-TXnQ#CuLIhC$PJp~gDwa>BDq5|tp zjI1VJ(T(&S(wHx=BWqi+DJep8o{;-sYP7$R)6bZ%1!*?~;$*^R46IFrNo;Q1Tslm( zQSY_i4`q@5?aOD5wnugSAY>jeKN)(cmxE_D`r;Dj_bDPEI@Z#}p;oSp>cdBSoJ|Q% z{;KPGXVcBh!R_YB;rwYHo}K%WWR3}|OGsdz7IEk=6n*-Tb%gPW5JaT-?4t)r0q81) zzWuD4a>GO?5q+Wvi(LEu$?rTzm^7Qf|LEsnmLrY{wnABpJMK5@4n_Kh1s7~K!BeB) zA9*6lDIF%+FPx=h0zpPAf*T~QmFPU}m0AT1?u;0{^vNx6>mS3(Ei9=|*O+}pJp=w$ za#~HpL8v*l?@Vx!@IzCs-h3zCBR(N+1cg1%B?^D= z@g485Mkd$3d`Kxzw*Tt5^Q90a(9hbGifLBiLx5J)u=T#!emJ>WR~?)#V{@MUX7q#W z%UlpzoL!RvE;GhRRqsv5bO{j7wAPfHE zy-{}vx+AzGm_|b!BNT0>S#BNK)^SH+n2?>{H%kH)FzLe_SqR>Ueda=sdx{xGpwX*! zp)!Y$X@NthCW&~ZkpjT)IYd&kN~Nbi#!CXwt`WkD|A__=AOHY78UTb0!Uh1Y)ofmQ zg#T?o0BE)#lBsu$fyciTX~4^+P0RU?nqF$(<2P?WS8>>0WjB_n;=@9LKJT}HF0ebP6+^a+k;&U z2E3mkr?MmNH1By>hx^Q84O_JX=3?ng3GM=jC_8~AXxPHqGRBg^S{f+p*466K_eKKE zQ#TIX4jteWU6XUSomj*|?du#-HDNuc_x=d1;hCL@CD1EL0Y0XBC49Uohu-unYzmDZ ze>e@?tPWLe7oI+3QVsa)n=+g5$7yzQB9)8T+5uedvA5VVHO16`QZsUbAOuBA6!Mt+ z@J+LD>Dx|uYy5IxL|=oo9p_i_^U+Ubc;7dPmZe-dF~r#Nu|`0g-W@|jf$gonc~pL!JK#85VUx1l;c9ko1`zBp!h zFzXln$eAyO-MQ8~+F=q{@g@b$ok5!@u3(7b2fciLkpZeM$8Ey(u~6E#1BS93$UuR5 zLyx{D^_r#2T=SqgQ1*LBsQSXl7fY~DeR$Mi;4Vg16!iP9DcJLHj*Ji~xz|NuEL!f7 zq{XyQ#H}$}Dd8PUMSX8-#eO+Tb>let^!M7z zpXczH)nCN*vOqiJvwX=vWp2WaOyv)!u`)HxCqsPz@{p?TVz^Qr`gQbAk?;YSnyE^d z9Z}jFZ0`wAxZvFWMw?f1Yh)3@&|e>HJkcEf9OU`VNI}S0j=2J#ew&7-)t_#VosN}; z!YgUB?W{~H%Q&QXTA8RqrY%Gw3?2p<48@k4B#4V*zB%Jg-R)lI3!5?Ku)%MBw(jr% z5RoDL-0BcZ(gx#v8B?-Me-bSIJR`FjlX=hWzDQ=u&>wj>g(K1uwiNy&Vk*}jpUMm| z=*vy6rRiY^+Gci*Kz6}FRo=%JA1e>MpN36nEosP2VyZUg8l^3F%t`Muu@ESK{GMVZ zHa4->jTh%&MIW*Psn*?=|E6Tn;TJFO4fgSeIi`$tn~j!H9cS_JTicTP!uU(6xXmON z2k$X5WvkyVD1c?w5NGX;?CnAZ&4gX^TqE$l5Bw<&axeI!M{m=&Q?Rl@Lmu5HPuG!5 zYdm$l`lO0QGz~}V=}$NeUN)Q=XzKUkjJbNq9+ktP9{h2EGvgt9k!a*Q>$cJ0(M4#~ z?B3_X|K8|oK*DJX4W&^*A*KPvq`wrqB_+V?JI`fVEdU^9k1oDxLr1I zLWsZ?>y;0tQC*~EUrq(NF~goP!VshN^3bz}*F_(XJUQsz)lHM>R(v3y5MCktYR0ZlZVjKZ$&pXLv_{3iv#nXFAhvLXX=2r zhi3&7&S+Fa*SwOTE3%ItvYgvpuj}@wJv69(%q5peng4{(V1Y*!j^PkB076x1)-GF0 z{I@uWTPh2qYaEXmQFv+O60AkInZNHa7w7N|{_Xj}`U&Yutz??D0E)WxnGUaV^+^wS zq!i~7Gj0K%tN$RWd(&H+ACVCD;ewlQTUydl>?6DgE9-tYg)#%5pGDNCy%^Ag4!-DB zR2?|pkGq2DsM9W>+YhdZje-8{z7Z3>fPiRY!&Fmh>7NLyL(luAk__=`F^x=wdElyP z;VQ6n6e@=^qkQ>yaj&`Q_}xuQ**Rl$#ZB%~uO7m!xrlC|)P63@5Sd*Y@EIJHZEo~tHp;BO8%LD71Q)IF z4jgOX?U@aCK*XCUHWW~u09G5ZwJ`B~2|t}F1?LhOQlehwbm%0v7^S&&YXrt~U+%}> z(}5O_3)h|XGd=8y;-ds3pWbB+`v2Yxy4ug<#3ZbM`*s1-tvtdV9+AsyKWvR+iIL#` z%6QCIZ%EFh-8I&eZPZTX=ycJ>U&pg6^xQQ+wF72e1E+0xpTdZgz>p!2M`_NSWfY*;!!HP_RXkSwCO~7NilRbok4HZHXrCdfvItVsXY~ zH=~)8zce>DW;kY$kh!3V!(;5~9#s#B7WS6sz8fD2Y0T~%`evGsmNR9H*GHwABe$iO z13Bu;)QM_@7kB<99jKtPHD*fimoE(idh_hGPqFm1$bG?lf!ckYy=G}<$$BG(aN+BE z8zw)SP+y=q<8dnP#gm1HxuxVwAWww5Z;eW*Nddbjt$g+m|4lnD-h`#*-jLL1at!TU zQSZvPOHtod=!3_{Rqnz@Hl}0s8wqrNAAWCZpO#1+le5?sB&9e+{DXr=vTxQGBvqc* zNnTyngMOXs;{ZqV&RaTHj`TXz*>+AP*=jw{*rx)?&9OD&5;fsJhrr?|as zKWz8BLaPFf&Piu9ZG`tMM-7PclVebe`3DH()>{ulD7BLSpO@3RECWJkqdbE8OlaAu zaj`M!$p<25b29U23T02~42okc&`1MD#~&1YjT}iMPn#HG0eop|ETFQ9JI#?ObEo`q zzfM$g5*n<%VB}c&BtC*T;*3diP~-|$R@O{XhSOc`aGanCfphN=jcJmR+DdwL zoTj|`%NVkbQ-X^J9!Ppgb+Icr8~7cyKgAtVXr?FWSfu^o{nfVg!B|3sW! zvvNVvi5*k_OsE-hHxXNM#@S-%s|rAJVyJSCR=Pw;Z98OYz!OcK4T0`6Rms!pJU1!y zssI%Gf7p_+MPIaV%@zf+!s%e+rJ6|Ng#ySEd&>$E;3(dgJ<~(t-0xOzB%#Ve1Q^cU zuV9Hqmc|HSVk6{{N%CGm;bvMrGa-^)x76YYpDON<)u?*=AMC0Za6tv=5{j0zLY zxd;Z))kPMkCq3bA{pcD1V_T>yL{J?d0uTd+#IY74flUYi00X=L000007ytkPkN_rt z00014F@OvJ0000000000jL?;`$xlV8d%y?s|L%k3Qp*^kk8&(1N!1;%5s#7|vvKSZ z!mTad=M73UpX7DqQ*hFsUv^~?5>Ok)lNp^ByQc3Zq;f&3#L8?Hr4sF}9nHeYh^4a4`h72a}y}HVKV%+5O6!TZ&A{~X7>qVD9ihI*5R*rd!;{`gj^e?TWORBHi|I zXhT~nB+Q0)KAVyDRnmxDJ7Gv(Dn;eJc8JNbj^Lpj!cRt^z>wz(2AMyE`M~u{kSTtl z!j?4db)v&z93MNLYoK9z^-XY>P7nNn`s!HNG^^-f8AkUtLrl)avi8&tmKIO50jWEW z-k%Xk8fCwl2>@r5p?6;JfzHh@6xQ}mvF5;Mk!gIJOfy(%ph1)1`L79?$g~?<6B ztEnK#_kK8F4Y3jVdE;}{kK$~&3+s~Tpqs*(bBzN72j#$e;h_>D_L`^^@}MmKz6>!P zwJ9JjAk@3;KB7G}yw{~X%UXIja1k!9SYzjwL&Rp;ua|ipn-BoG(1j`3jVzGyL2UO- ztLI`755~~;!Xtx`MX>0{FcC;A?9hg^+zOJQhDTWt8qfHZ&(n-qM$PQ>!G9Vu@mPXDcL z9uMv$(Me}1dCD&W0Pqy|5{E5N|C|kITsoTGYWrX`MI}=T#{Tv!pufsU`MfQXaRBg% zBAaATQ zw|S9vQ}F6IGutepREw5#)#!#NQ7D{IZCAlEtmyx0;lnQ0C{l}U~ufn77P~+uZc1C}T z^VNi=1<$hmVz0u*9#kIXAe^ozzFV-~DF}HDHwxWNM0~O)Qdkigc4%h1448{HIns(U^7oz>kGM0MDoSL#;?_>MqGbowV=pFTfPigl8U>Qa zQVHcdeFg`^>5(8!EhQfiq+N$J5!lr7y~rYODE!EH(w|auV4Doa2C$%9E2K;O-POVL zbzDwcs0F1CqXh6hiCf<#$Zc&Rt~Y&pQlN;;jVkCK_6{fi`d_H-;Buj;kw&?r+#`6n zRoW=SNGFf` z_tWU|+ZRj48`-KvS5L+mH(14aKIA0pC>(s_ovf#F%lZLCVpZh8h)t8{CGsUK;*tdB zD#BdwKI4YfO@L=P@ULqXQwaIh%K}H5vYh?Np(Ry3%3ip^WTqdUaJHxg4^bv{Q`ght zMuJJ4w=Mw)`-_(gHCHg6SLBye&gGB)c#Q`>Su36bTBpVDIL>^4(v(zP6j~;i>%0r` zHdTg&g=N;c0wj-)aqu2I*`G%b(Lc$2ef?|RQC2m96!GH)Udl(I9ohNR>mmB-=U z;HeFPbe(IL{ydk}r8q>Ndf!O~*~@h;UW=PsSo@c%2&dR0i0e;H=I`b7+Vft)MB)o_ zfj5P0NyB-DyU)a(-9W5>r|$_4n$7m5KqbFtP$96Mi3HEj%zNURVmfp5IY*G2R@(HH zLFNWP(vfJ3mukDSMSQjEH*qt`9HX)hFg#fjz4vS=m3z%t!UIQ!t5Kp4KNE`a#_t2l zS7D-4zgERdfwaEbuO+Vmj!vQDG4H!q9b_4+SJ?$AXJ04fm+Zc zQ-MvPpUHCj#O?#@JPqZs|1EPW zEQ^T~b<#|G@#49G4OqY;oKFozAyN9MoncGzJQB{$Xfnb*qr`*ln$wmK(KH!}?@_@} z88R<;B4@aPSF^X*2-JZK6Nq3;1)!2)t%4w*c>y6eRokkVf!ha^UJR1b_{N}E@$t4g zJ~1rql4+NOOR!l77FA9XZ^ytw`(}kL#TI%6->)JN>%ts1|Y)3_ZbgBLCC!3$(>k75OKHD71=2>jm6d`|TU-7anj_6|PN&5a&l z1%n-D2wPvB)({zMaURhTo=>E;FG&--i@tzBZOiO`X@Txj*4l{nKQMrGKh#?+@GqM_ zbkVcvF+05b+$7jXJl4=L;})QTNgBeWOTxPHM}ohyyDIRsTR-X4WJGKJ(CfsJZ_5Vl z@GC!m)`r-gi(X(nMKV_x^aOiPh9CR|)?=JP;rp-Hfy!4j#By!7faR8RrtxCJ5FM!C z5m={3#WE}pi+#f}6(NlBiSyy9J$7e>qiGg+6WiM3O^>p5yWyp1zQN;~gR>R1xkqjZ z&QqzQDaYjIib4ke=AduLm!j>?mfKUSGn+38J1FH)tFSbEo)`g{Cgj_|C;+6him}$~ z(9|?0{8)o9)?F{pQxsmMIX8LeZQC(Bv;A-#0d-%YZ+l=&hhjm%90o zaK*|f(rg7S%_Vd22h)g0Kc#s@zqYIT)_3U5^l&8#z?pccoE9vQDBA0P>^8 zvMC(<_?p(k5VXe`6y{RKMD}KXuj{~Bi`z2eAF(PIc;%LlN|pjf%7v29WeKHq?AUg; zl4V=RBb@z_s9_F^jes;VOi@&6thYz9b}8r7u><l+LXW&ch#mRo&)!M9=8jOOv zD7r~H0cp^gn7nzREzf0kwrq+?>G1>5i5Bt8L%^^`x<~-XnfnulB2p0hHu2ZkmLbu_ zn;t*{pKmvNa9H``X1eEOQ)Mo$Ej}&KasDjTVYYz>Q0ngkIzR7X2r4Y@ezC~&E#!Hw z-yYAR!d8soBRZ8{IauRzTN$PvB1GMpA^XCxEr%PwUo?{3#d&vjNoybZLD})N7~ysg zXsZ&)rJY7_3b3VObJ7RQYq4B|<9=^qU^*(o&TZ%~pD1*fy)innl+*$+ZWfOtj?HHJ zoH!5{!5i4zzA0001B0000O02<_{Q~!W$)%D`UcB&YfD56A; zH=@e_`S9l~{jjWh>v45YYFbRc7TXv799u1x874UJOcq~pUDVjf`6N~g3JD5Z2G-+p zkiS$+$%Bd1W@5f999qU=IC%CRY(r7c6Gs+N3`nDiyH9zHOYwUma^RK5i52FWGRlfW zvGt}KBtmdA^O2;(49FwZZYD7Cl{{FjMJSg;9ODMV>I1SEiHxsoo>u=b#r*rz`~{$| zKY6qL0E|h@c{o<_drn-MJ+xn<|1^9cl^=kpnS_64R5r-gkvXPy`q!f*De($o%!Zt$ zlsJmX?=&>@%(mj>;V=_`HsZ?$Lox@V5ZgK8<$hz)uQeEM6YE}@xTi}Te6noN))LK% z0&rARP|vgA)Bi*a37?L)#}%}loejw6vM)rFht7MByS*pR@Tgtebij84SlQlD1wPU}*nr9Y&!0F*` zQ~bk=eGc!!{(|-+XBgcD1@2KI!AEf$ClYJWS@p1ymFG$d{V2ounr*rFv8-SCHH+y; zbO28w#J|m~Wch#`@pww1nDJin>e$8!3@h%a=@HV{Vj<2uU1Q`nvy93WN z+=YN!%|?hBK2of}C>yN4SrB2Yy>=hoO6}Zjsjji{fl4i_SLj|jS=2BPdh_+HS&Gyv z08~0uh;o;+*rs9T#GiwDI@7iUmDuQvVnUK*SIaXA-;DTxh4iULbQ3;324J$80Sk2Q z5zQ9>n{1!M1mk^XeU}r7YH?WvzOW>41{gd@EPu#KT70rp!a&{KnOSpES7cqE5r`Q8 zU~(*Ir}I?uk_XMfsG&nuM0!$9DSj(12qqBnq@TcZvvIVPpcG``8C2V*%9gGlrtbAFoiJfami5yPXMd7TXM?7%g)QLP^q6i4U zN1TE2ZmbBPQ-J$#o}n$a4}Isd5fG7D6rBDF;4SfPcwLOv*vM32*V+^ zq%s=M9%{6N01zRtxvDXqC3^ukkP(3}9#wHX>QT`v7l}6RN&hIr{oN zL^YM!Xrgo)d0HA{c&AE0)tm%+-x(lz9bVu;r&+m8I$WZ|^$mXYIdaY>;NO%jUlHi( zNe=OfiuK~~hmD2rgL9*Rs8^7dM34HOYiKx72flq-7X80JE+hdJ6yK$6yIn&LHOVD- z$^ybcHnz984N>!?Vkb_*a~a~7oL@pf?LJLG)24A=OEOCsi`Suu<$rmwUP24%CDe12 z(sYXl=Po|iRmE0oX&>EX09fHhB)N|Be9HOAwBJHedW|K6fD7Pemci8YCi)B^nuiZT z%ai4#`D9nu=|~uj&CAgiih5rH2~MLn*wn;oC*e+4X4Pc zNsgq>y8vri%9$P;Z4U+vxTeK;5>NDF0bV%4{y_`)w>Ob^nT^6VvB><&sgW^WKtWE+ zMW|X3nXmZs@y~&J@p3!FN|P9wL)Lr_OB6o(z z8^i-(DxHGeX^9KP+{Z7qkW#p7lqts-hf9$ME| z$CgE28`^ynYHZfBDafCd1PmEEJiuG+oWzSu7D(F}EsrF;xZyC;-I24&*bMRL4*|;N8?5y@$l!0#W{7x1TKQ(u7G>#RvHL+zwPs|RPHrq zCX1l=%eBk|oEKU-ps7)C+zxggx6g6f=_^3n1T`WUJaKG{;SBE6?k#R>@0v;ab9Wh2 zBJ0g@c?*JTOl$&IdiOIC6f3Rq0ANII?o|*arXh~`CG|3A7UEcft%WfNez<r6FqF?r$M zXNIMON$Po6>>bOGs`{O6}g?2Kqwb;>A*mf zc#0$LSbSnxlIPj%2efM2F^5-N1 z9LQz-`J@!YPeFSSkg&L)wU0n;Bg&^^-8THBfZeAgmvYF<`ORZ-Vlv*3N=yBr3$|8` z$i#~m{wX3dCg;I}^BE*<$hAzhZelXd+{mvHj7@yp`i9`gqIVKpTdr2i+2Er0+RTaO zyys>%81W_D{kWHrQAh;8W&O&N?8s>vtk#G6)cjR^Q`~#Pc)D#{oB3VvscHR)YF!y= zrMk=!l!7K@uzW|-lr>*!qDSQDw!rzpuYA>mGbJeatC;Pq>+g|jBvHpdg1oL97jdAG z0R}6e`w!2)MJJ;e5@Z}z3;kVfuo(-+IW9};76>yI6evgt= zUh@P6yki$yhz0-y8icV3Oq!qoU;qfyCXE#+*Z=?kKmY&$OaK4?00F_Kn*aa+0ssI2 z1OOq2rG0#=tM=wYz>1|Z-?M9{-l6EFiToY z8=5_f)hk9xR+YHRc9iNlXqiNaho-sZFsl==aTll4E{TGVY4N7obGKBKM2mb`8*-07 zwYB3Vq}SJ^04l3M#WCSnX%D=MZtw-fu#Ki47YLrk42ahic*IdEp0fe5B~A`g8N?55EQvPdHaZ8Ij_pdBeN?+(JiDX5)4B7W`&L$4e^}qnW6V@#dC!v%pCwlNf zXG^wwk%&sPwJAW&)9xzkB*QTEqZBkuy6zMXwO+^RoI38*6cZYcSN!_eBV@?L#U}^b zs!d=Hp9agi=&Y4TaNv1tU0UWcem7&VyaN;N;ut><#E-N#&d*oOGD}eziaN!W+^}{; zOXb1{aY}P81&B(3U?pbCg%SE41eEoeiOGHA?{^V#Luz(c?^vjTvKV z0EG)K%NUr^&Q18VI$bE^rdOL{F^Z`ikrRQ0JLvTwa~CJufs2^_%|EeN@KN4}0KA2IIETaF|7h%auDrQHV&a!mATLUevr~Szv3p4BDhWc&wsj1e4cKzl7~b zLQ8J71G2yYkP_D@;>bnV`6$Asm$b?;B=o8PL5LqxlNP-TD7+G<@+O8Ohiq`H%}OMf zue*aPk9?}MT$=Cl@Z=$*?Onn^(Q(CufLoX`XyB1W2Oy{m1wbh{5d8WNwv3^zs=_0A z@1|}*teE!@emfFkM4le5ikPhReMBNY-OG23IY&O|49k8$Um%N9qJH}`P-#g*C3=q| zk@p&yfS&B!3>1@Qk^2-5-m8fHb@DLeOlaNTPpumHM&-m33cjJsWJFam;#ewxv%^#afy3mT<{X(q`qDD+en$S zG7LvQ3Q{Uex;aQ{zb~_>I09l}Y4i1(!T8CDoQi`&eEEO1?_C8ytVfhvAgI&`E--+b z!2JltoKu%Aw9-1$Pc?W-n`etz0@yryNm*Y^AgOIke_?!^-&cNND>rDYt^mTH2Y8TK z6s0Y6#_yZoS%X~LOl0eI)G`K2;u=(!R|4j&%d#$9LF@wnDE2WStXvF|_`V zbrc%UJ|EO=Kn$hkDtx9QHxkMC#7O{NN)QC45U%A&hz$QW#@Z9JON^!F|e@n#g+Zv?Eoms}qPc#c^&Q|uuc|Mn0TG_gS_goM(F&y;~U zrbPt_@L&H~^FAP9D1KqChcrQ&{oKBav&4G4kG@B*>@t2>Z(pYAi0n<(9OCA5gMIf;X0)>QEb zI3-0&qB+5GYa~q@4Ip&8M`_z4XX_oH4qj9k`ExCUIr=N`-kyr?}dueJSD{`SXB%iLL^N`nz1xsV)7%S+9KCyrzoX85(Rh@c~ zAfnF_d~J1~Fy1Wvly#m(65aF&!N(~&1=BZe#*Z-Ux#v}l0Pp_jb~zzmeem?-<>#qx z!W$%kBhg$cx|NkWxCwBd?^xEMU9u0=J3|d}nub8A;=+A0#iW}A<*ALL!qH1!YG%?F z&XpdUCbJYz#r1HIqbfH^-(IJQ_~by?@!Z(Vr{9mT4n|C?M1e766P3`I=IK;pXa>Gb zS%yD6A=yc{EIQ%tr^&U9z^_lW&+x{(!A_eQe2Fv!NLqOSX(1VrOu10ZF7E5Nb)7a} zAsbfmB}N1W!gFh(C$93wp4JUyNoMNE$_se6)JE*|(JP>@oBYEIV-)O_Z2o1Gvw_HDGxsYUkQ*UvbK4SPZKH-j1PHtPl*kBa7?zi(WpqWFw4$Vqz(M&JzHWfz=F8dAQ z72c!(1bzo`FkfY7OMI$58s?5EMT6okdRdD!l4I;vXuAQd0?@(bz>BMNo__xRPReJi*mjf+lW%ys3%~QrfO~H1Zw?0y1pU6=>d+!yhp7{eq%1l z5TC#s2xC1~3OM!G4@#~TBHp#T5#PdhBmyf#`cC`W2Z6Z%BRGUG_}#5p+&WH!eu1-< z%FQ;7y8iS$T<0mf>C$U=wHKiL#Buv2*0`g=IMTzuo*0cT%MFmtP4rOZ3VWe(%tH}VF z8#>a(GOX`noMGgty{xR|mnff>3l#H&)l5+NqjoO}p^GDOd~3gs8J<7wYo>drmjBHa z9k%YL%LcZ4aO#Vqo;*hMY1wn*HBU$S!s0%fE}7F znLv?-a96r#0;K_-qj%SM%v3o;)42FGgh30-1BDB+PwIAnL~Q-_Gsy~jA1utN2dmh# zTDkG5%B?*b!OH7w2q<+b;b();o6Tsk{7YDj&~sK;JPd3rHsq z9I(zKis!Ss-eDTjE(?lJfX#*LfRDRo+G`3qHJg5`?b*a-%m&;qVTrd+`UilR;=#*3 z>k`)|WLr>-G74KCx%MKB%U}WK24fn2z1nzk_t-qlH;vnZ7Dl`+;baKu=j)&bzw z+1XaBS7=aHq&EkS2oC5p|E?>LU81amg8G*8oFkOh^89R%u2JLiqF616toqkR#xqjh zHU3z#P)rYlOPmYU9;G@dWBkg+4p9RG-NUneR=`qt`ybck7^Du$^(It#N{!%O0EGPf zYn}=&&QXK_qQP+_sMBnrZHgc^R*UH(xW|!u*Vw-S$hxdOB9g?sp(Zw7iHWH3YU`GI zL;Y`~-m@m4W-Pe80xfJ>Tz{zuk3onBG3Y=xfCB-LA{<4CEYLy&00MkqFaQ7m2mk;8 z5CA8D0000*BT3bs zZ?*F#&U^**S|e_)qLA_(-@OKVNIg5c9)B2Qi8b_bB^qs%P- zD&Zu9QBbn}YMA_Sz5-tvF}aHe7e<0xZuAxo(3ELhu`+R{%H@i;4?43H1Mr6NA_o8B zSx|yr;{^|MIz{G|Qedo@Z35{%yqpl^Je{NUK`#V6;Mlx-K@R5{?{DjZ;|68f*0|;$ zMYof_;!jOi^H;tIJe&cCc`Q-U$6sH0xC5vfh+}wBN%bLl$8pHHKw~g^byG*9*@m-vWDMrGeZHVQPzEx$%qxJz&tAp z4qP+fHuK{)1?$#_sOX6Lat!fF(~}28 zj~4z{`)X@*rMAshT9+p@L~>^yJ+-J%3Tomp? z))P+J3nnN?)bUqkT(-Gc194C9V53mm5&0 z2`KVmEBk7Ii_z;WV~EfGt(#0TPLk7$=6Sti6mpA@OVG(K5&WLe3H2nZ0m2WkkO%jI ztSp*3+7Ll$h_o=t0Q&muem=NHWMu&jw%uK%QBUTEGR&1lMW*^%rj#X?k2oHN0^H^6 z7^lrHS!J6Zv*~dXZ6n32L)Z-1<)E6z$&`A=Clu`zp4a&ahn6j4GzcN}J2VBrSWOr+ z8YULNU~D)=ol_tSO8pBKU&Xz^G9Wb|qSIuS#uaU72s*WHvgf0?9E4m~lG8di7m&X? zxxuMsf4PLdljLhBUyaY8QRVYleWPk~|kJ*8&w&j3BEb`e_ zH;|TJOAdtMUIZ4vATeSPdcgnyNpOj!6rHdc=Z?wBB7dpl>qqIs?{6_x&uUx&zg%%_eKf)Ms67TT*OC>mB@q&Guq0iz2-0Bh|ff7QYI!h-k@+ zh*2ZOi0v5!ZQk0MRmwaZOoP-n2OQ-GL;q;q<$PZ5Dk*h}+o>B|h0k_n6&5=ZIFX~l z5T$DVl+cAEW(!T6>L9m7II@(PH1|MsP<8#Y#;R1YN0!XEq|1s+yIHevya;5r%S70X z_{dSliGm{Qw5@!UQTXh7d3t>>7K=rakGiCnx{splu0%S&Y)KdPTOM6u($N*wv(Ywf zPyHU$x!g-K+&1jR2~6e!D+q~BK&6`Bp&n5vc(&MEQj)N!B`s$pUGT;tuFa8$n;%rC z+{OX9d4cbUT;yWBSeG#HU0utJAcDu>OvNHu4R{G6IjtQ_Mp(1WF*pIKaF^B&e`=vZ@P5-mp3uM9}Ac(TB$d}eLrH$QgjsW=LFN*nK4Ns2hNHzQj^y=kcEwUu35#p81%u>W{aWcnT9ozKmcg1oSkT1ObA1Ww)HqYT zDDvPC&j#qkr0C_pxcKP{MTbh_PsMh8c!>n=r!KWKV+P}obagBO6iDZ^KJIZxj@LZc zPfNDp`z3IQLAhopG=IzG9_7doF*hkB48QkZVAL*taQf1NDUuPz)V9J0H zlu-WM!4ocCtcpEjB<)$<+>T!_*x?tex)~D@V#@(bC09NxCcwwMue8t-&q|`R%X`{8 z(!mbr&b88xtfn993O0La?yid@nQV@%jB+R5ehrDJmWja1KH^X(Fljo`JfhLFSYPIS ze}93m<^gQF**_(3iUG$byl_9{i1OM7S=j)Y?4S zXeP!?d5!Hr#pgqte;EwqgWwKZX6!RKv$f(8};d(sEVQGL^;u zZ$T)8W;REuj*w#{fUwQFs`x<=j&=pxCOzv9h7u7JUxmdoh>bp9)q?j2{$p5P8_M@K zrBu<}{2dkfp|}cUhz;BPs^}-d|N94UB}1g?&_PsSo@Av$pF#M1G}@b66!NtamZ2)o zX$ZBKWT+zum%lpTC1*0eM?I<+?>AJYl3qZy+xB(aftW_l-n}rhX5U|x`a7lU)SZuG z@9u?MN^X>{oIv19bK>_c<3=hYt*sRVc6t52r#ucLQl2W@0OwE7*Y*uOiwz1evO}!L z>4Pn5jg*Io2{EKEx!^<+h(d+g@u^5egFGIXn7DRZky-8aRIb=dYn>7;RFvA1)VJ>Y z4PSqOFcE5TODSa>Z5H?302qD;vRoZX%12eOaycrjM+0K+kCqsKts2jAT43MJ^;bv+ zl30|oW)LPEK+>Po-Qd9QlYv4GDI5cyb-h6ckm4Y#;R==_M~dMIhjC-<3c#e*8)Eu2F+`soQwj_$AdEWWRYEtsbTNguXqL?LU-CwXvA;tCo1FW z$M+iag}rOiUi>B1K_K(}PsroD0uT}r6$T850B~~51|^8GCYd4UjS2t&85l4C0001P z0001F00ppcfB*r>PR0d*0001h000Dl0U0ncDbKKQ-w5RL48?h?Cq)``wfb@qR%{kg z#@pT0hqnk1et3UYc3B6h6+TCc0F9J~8_@YreoEHtvM1`w?k0HO6W^>qD8w0f@6|68 zGJ1O`;QkUJ>(9QiL-?{BA<;{4?rJkjVA!Y2>2i<;==Xgj#skS+m|%u)g9eYDXsBkc z3rouujw00p*hWEhf+cep#W>Zm-Fzg2)QL0F%$^H9+^vRv(y_7E2CZCq1B&U}}J=HK+t zKMzb~0P8tZ_*)q|n-piztfXlq5*lMxjvY(>E?G(gF zR=n>}+DsC)(WG{^`*H@9LXIilf8iS*C%~sgi&kG$?HO(gItLpb!EL=Gy>Vm)G-<+Q;~7{WPWYr+PNJUo^_>`jx2h@M#pXBZD~*y+j#e3W#8z=+zz5IK{CGMx1= zYzImA!icvGV|7;#77t=L?8RzL{|ILu8h9V5IMPz&a4F)Cm8T4Es=Eu!!j?>3eDN3=WwhfArlN;T443DJ1Lq%=%+(LA?wL`m&YYd2(LdzJ&M)Pw@c8#qTWeSAjCf{uIHx-pBR5P5X# znCzo{+maI@9a(Oj5i%&EtLx7kzH(TxybVIIOy1?9nDp!No7#b?LC8f?v5I`ZuseoD z_ifiOk~f|vF+x%5{ZMg#PH#*&4DmhD8AN^!{hk`hj~?D$R$fnB_&Bd3xk=bt@kL`V zxIgyYMvx19D|YM$!E3!%1IS#rf0w;-V^b1Kn{#p0X|B{8$7nm5qgy#hX!zNFYV@q@xL)rYg# z3Th8wlbG5p5VY7~l#COnH>6R86KTN%k<=G`6j{jitwbgBAF4cu4TIkmQ|aK+l=h?f zTRj!`E;F`|QX!#FSuxbo*%tSkAb~U6 zN9Db96F&o2Q5cwry#^CcEkzR!OdAAe$iV^_&qz1pLR6fE1-ry+YO-U=5mGm*-b(1r z?#twbeK^mJEUbt@G{vXh#xy)1NQhX5xFyQXclvNdc%#`=HNjI)%UvS@(Y<@$VwaDn zv<{DN*=sF`38If?rX&N;Ia-owkUt9jNSPwBIxej^F$m-Z3<@ILx@d%cu0)NxC}&q% zI#he;S|B=U8KDQK3q_L~!nnDVVlM0}S5m5WU89vmM$-|_p5e`i8=Mgz)+R2^iwP9P zibP!ziEysKfM7gm`-$N93XhZeiX|ZUv(s)vSdsR{Gi-Waj6Ndf{}Q!Ccg6Jx)$|T_ z#j4+K`zd^cjM-%$b&(M>+>oL79?IP6@W$Zi$T1^7@{a4LFmO~ z0YQKT0kGie62w@7Btyz5h5!O1GPwg9X^;Q_04Tr!02#mp&a(^$fB;Z$JU{>d03ZMW z06+nDN;Y2$LN1kW@NF$PRYFTu4w`-WfaHJxdjxPHIvO%y8n!ZMs&hai!C}E78`X0> z0ows8f0MZr|V0av`wnE3hX{6PqK#>v1CkOkiNz{Jd+)-(GmUHz>JtCacrsQW&yHl*}Q8{m2gFJEg@DuONc|zV_wq`mPWB@x{2_?KUo)Dp*p^Hh6$Rrg@T7A-ikNf?t zrIxayggDCqru!F+$g4NCbD%{Z*AHxR%;tg8laqJUc^W}JdI)w=I35TIFZHPKKLxNu z0pwtBU?<@$&x!qh%z$isWG2}0ocYJ3a;)*p}f47oupdLY|en`i5y6@6D>re(Y2>y)OgVl($mMG=0ut;Z`XQQT4|@&?=`f$_M;`uVI%(HxQo!%2f{8#Cu}DJh7L8=Fu1VJ>tP! z3Z(&!R>L@a=)9Yd!B=X-afuTPixq*1Q61c22_DvR#cPS!JwWMamW(w508L8Ky~N+3 z8R8nIk`7jY0OhX?jCrIA|B_~^6ou+^F}uygyI_Y_Bw~K?1HeTlLj(bbt~Nz9O@P3L zAc#W$h!8wvqiYxd48iAs0000000000000000000000000000-EoJb7dPa(mv5CRpn zC+dj+07(HGlp{?+$-&Po#3&s+y;Uztw@|i0B@lT{{G%8Z;z+@|T=4;wd+~MCGx6{N z(oT?JsI-uU5QT5)RD$wlkN^o>NdrB-Z|5GBCkTi95hC&jQFLq!L?XqmGjnnP^ijl; zQ}dU%{!8KP8)P&6)ge4oQj~I+VRDVI>qL4l$>H|{D5c3pdu;`6@>?e~h|Lc9B4IB=$R z#mnfqKXd9E^mgr;eth7r??V#wfAl_RZtVbg;@OB8Xr*wT zOM8e&M;u;A!bBBU2Z^wyQVs(kxA?|8(NKd1)Vawe9*a_V{jz}yN?x-u2f3w=G@9mI zEfQ`PFynB8AL&`>qiQYIb$mV|VIs*M5A|mCPZ7wkshN?onu^-D04JJG`<$6PXusEu z02bq8ihSfo&G%b-MTKwwD(pyM4a)UGBey9xiiFe++9)zWi?CM%~ap^qzgEM!3; zPwNfs?og~;kMq)2y^{`<7HX+L1}HWdt38jaW-4BRdUBMl)k5_Va>#J5gPMJ^yExNT zBg*9P!5H#Vwj`kiI7(lm91#tQeZIz9HSlHU;>8S-qvp8)2G-i{t}F^7JTX$6zD~qG zEDl(1vf*rw01-*}V7A#>ezkC_BhNM>N`bAsqPs_{s5ZpgXSj^kcrAfM zJnZd6j%GPo+rH$nh9dP+(H|Q?)5P<8gBHxDA_@+tC7I&(s(422V&7{B4<|3pSB4uD zBjCOnJo|1l$74L<8(o&zNjih9eD$5pI-K&eu2Izo^04F*j2tV^<`TD4Z<2 z4wG2EGM%!hFDXr_i*i`5JEALA$3VI{qbWJJ+3g(jQSl(4c!w!tjMx&3U-6qG2BHB; zMvuO%Vn1yp@_`MCnJy%?#21K2Kffth!Z_qc!SfkL00$yLNDNjaia_AN1PA~EhJ()# z000080001B00|;Uga&{DP|ME%gkS&w0ssI220#E|3YU05MO~N*5(x1(@O})oRsMZ( zF99ESGNG}?+-aqDy^MLkQfh(k71~FBw}HShD8v83_P5-=Soov3gZ_0ijrwdHsBJy? z^Tj1q=Op*lRMEABF41ml*)K&sIm@(a#E*sl#I2Lkuaqr1T-SNoiE6XWd|K0P2DMYA zjlW*YO`W>OIHaPEeMiAhquFZbKhomSubl{=a)!OvEyR=K?zV~HsMF`6c7v!}GJkB6a!VQq;%32$oo*jJ%|4d1ur(kK)f z+k2|#z*4?Jj zIiV7ynQFKPi0+*pzfXl}WF#ro9Y-sQ1{>7@mQE-9f;TY)Jx9;H!`S{GZqu!myp}$*#gybo~WX zn@`X;3^5zk+8vNWmM8%zvNv$MVE^NeBIE`zM^zF1hB0FR@c409Mp)=7)tUbV z_x!)*{}bc>ABlD1U)Q3m#)8KM1P~dbk@T?ESvsMfm*sP?GOX&1x%twA`T@f8i84X8 z&}pjB3zZ&~YPBfS67COQ1uuJ`QN*#4eB5>G_r=psh$IKJV_X4<^heW(6Fz)ROt z@}mWeNoW?i0+V(%i?C2LB>A?nY#`{Pi7i~gAMBq zXW9PxUjx4a?BJ>PIW>99i478Z{cB0s1LbvXK?1A#m52O>WqKZ!WnDX#X84k4n*C1e zta)nK|td%&e)za;Ie4#zRW3}OX zk~WVQlEEBr(i`ADCfGvn`d`ZhY$mS?a{BGPbk#`484i=tbyHurF1b`8keo7Ch^wKT z?Rs+{X>-d@N`{Y2<1Z=p*qRh z5~oB&medhk(PKqyrkuFB@D~triXC zS8|w*va9Cn;(JX;RDAO4f^9Jb;yE_;-$<{x_c`!LG!Nf?CVq}jrDFxlYpj-Jk!5e2 z_RCsjdo(ceiW}oTZ_lb5c_cbL_Z_DoVDq5T!CX@BwN=cAfNc%JgHF^ZN%`qtXZug7 zd;_N=gO@_W5L7OS`w1zbzORpQ_$?U!AX#^EM_9Jh+)np@7Fm2BT1jIeNsMwxGc@b) z9OcxkI1kg6+i~M*=Q(6b6R;KVM~mxGTCv1w@WA?c^(UKm*bO6l?xg}K>)o-f>E~a! zb5hnLzRPS)$65F2tZbA2HI9R{%@$9MfF8ZD`PDl{$s{5uR+zr~2zwAS!1UhQIzZbb zidJo@@`_J)na`+Wq+PJ)g^#jvak?+YN|ZrAcE>q0!jAdZ_ui<^ze{tvR1gOJ^dD>6 zI9t`>>YBa;F!hLyG?F=WIJlOOVp84)@pEi5s#`5E#M?51lTTf704Yos+>)B;38VHX zmX3P%PC>bLYVFj`$$@3DwB4CJO2t3UPm0t$Gv4Lk4=Wc%Bimn}`c98rztf68*wMLO z6oZ0J`7VbQ8F(dN+$krIcp{dK2tE{1uW|miD>ZaOut*1r;1h)Pnc;GpZf`ZoVV4-K zq4u?P`v*SZEMz>M!CGd>>v-udp?KW?=kZNOy{8>j>Or%uoo7SeO#HWJn{U(&MxtMT zfAHA5ZPCQ`l?N1leljJHnqHQMWkO`K%4>>C_xb6b+w$hXBbhV_hu`FzM;|SNyna?x z>8k1fF!2TO(XCeU&~hHdR%g^5sf+keA3%j=%Q`6ftUA|ZI=2Vx5P3ui>7Yn<5D1Hm ziwtg_Oh$x2O9Er@gnt6zU%>?6b)6#@=m8ip0f5+lF@c2W%7VZuRPp^dkmmTQKfBn- zeA3U;^vlN;iI-DOl;2-QZ5MyhRsT~g!-G9#X_R45%xM8DT~q8)7+qCq$kZyUCgU|y zq{@?UQm4lk=**u-*8K1V?=BZv9SSNOFmooEesdpew5OaUWyU%uGWg&5SO6`&T zz|0$}$5A|kpCx}8_Xa6iYTU3#^nBoFBU3wkJpdrympEOx$PSo5B!)HyelQ;OZ=}#i zyT`=V1wfmRNXHXu78QY#@+sNgzi*pxexH{VAGuLdZQ%8FhRBJt@4VMT)p;y-n5=qz z=9zvb%*r#(Q=vwxdx255c~Pv#oH0UIqFFTwe4rT}EV|$-5_7$#joQ+(DMiG1S;rb& zL|X5Osr@}EwDz00EUVElQamjF;jCzKNiR^TATi4&&iFH6T70gQ76$I|@#nk-9_LP{ zesBjjJ+|z6(3VNgdX+KG*`)LymkBUo;=smAn^91SY~V-1r5OR`g`0Y_iFGvxrRm+6 z{+jF-`q?Fs)H9si)yZew2)QJj@7;t!LQR&^+TR=knu7NnJ-c2B#R)ppJxyHN7GM?L z&DqUFE|0owzP2JYIJYAfoI!PZ<+5gMY>X>Z2Y+`1kOV5m`PjEMk#{rg-n`G0!4f7? z6^QDq{RG_qHlP{@zbNb3(|mBU2efk{m=EIMG=TFf*AQx!XeSUK89aQiil4BF2*k6I z+5%WO{l{qNl41`5060L1e~OmyKLW7je|9AT6XSSZc~o{RgtyA?X3@z1k^IWnM7TuS zb9_kdpgqh^TY+4dgZkkqCCN4xwiZD7gla-Ol>fCG@8;{-c#;Z}WKstIuOU;ZEj=cD zzHCza-`@`z7d)$gfvbJ08HvWZplFDXrkTug1v6IVp#7@?ot+q;{OX!E9^nyYgfd=? zI(>&uhx-Fn_nqY+Y%J8$Vw#35)AktP?;uYz|gJmsE|o+jXahQOkP5j{QdKyw3pxZ6AQ

KyN7ngQX^k?tjBd+r+zrW<(V1mkfx1|6q*Jku=Tvxc)xCK@-vH#Gw>Y&mTyTPG-2+Tqty9pY=t#k?x2~ zjgO!@h$nrc{2I?BP<+GtcoQR_<_dpa(g>EAFN)*kGH%rD~-HqJ1XAUDuxoak0_D)ZPANZ3QS>& z5|b-Lt;9ksz35HpRV2EzNb_(m#^oOU%EH`7<_2zkBNhOvQb{##CuWJUceksG=&4g4 ze=yEWjtbhrcP82@D{4&~tu=z^`@VJrl=rde82&uopH!vC#hdAZ#b&JkIky;;vFD(1 zs5pfi3AhQ4&uwSDi!c`gueO z8ODHlmzMtH-=eA09L-&Kv(^=Q7S`jb)xS=X=#6J+6LTk+C>%`{hU{H+a59qa2y{I4 zs(g;c+LHGcr_YpkWfB>}VJRKeVc#6}x&}?#Iac5!MlJmcH&eSMU42O-T5373?zRuq zi>s23ZeLl+t!`&N3k!VVBh+_k-SHCW{v;dKR>$2p*viV!Dg z%h`GOy*dgdXlZ&wTT0mI^LMozAxLQ@aVF%PU*Rd;Ui37)G(*01@ApQ!Y+8C^gQ)%P zjgFDu_xKv+I)RlxzGq(9i@l*F^ZdUi(!12mmmWW+1m(`Ni3OK>)3)|8-gfT@aZ_^B zP&2BNc-mICglW&DlVL!Js^XIT?eO6*`9pum!nGunu{gvR-fU1Su>G$kg<%ol@DPW| zBu#{!l>@{@AZRcUcxcwZ@B0@AMi5Dcr}B?c(DnaPFyG4p=v%B^>Z3u-9TmO+I(K$c zuFcr4?6YnRejRD{dmwp~s&e_l7F!{5LFJGENRoW5*H$w0*Gm2=>sQ~@wqs3rzd(28 z<`e(a^EBy9w!!dZOey`6lPC??Eyn@@2c3hSE{yTh^%DG^4d?Q8^C#`gGd&Tcwgtd~5PK#z$1ZTKz~vHF2CofZnOw zVTAA#ZvzHLQDXkV9jiCkeY8a5uNQaJsxjHo7nusVY2d_S4st$T33ppO)*OQ}d`yd? zH0Q9R(;WF&Vghm)V;)xC+EGgfGgqU%^?}VPxEGn%W9`RssF1;W^ojzkXaP z8=6I7mFPxd+n^voa*eQul1Es0*<>tU^zSn-XBP_>dSAdt>)B&9>#&ItFw-_WO}`w7 zAw)BTm4oa$@sODx0HVRHq#+^z2xF2U>`*iSb60>o2G4ShlPbe7~kg<;-I2&xvzs&>@2;o ze3EQnW<$N=bZ#Go_?P$v^AqAf=0kI#FrYQ&y(il*mWSl64{IWEX}aEzy9rOIB#Mt> zWbwE;{V=lQWS^;rB@|BHA>FUXs>0btKkMAsBH0ZI6BwMKCj3_22ud-;Q+q1%oUZ{MK zw6&$Ys=GgKl*`PkS@|er&9cv>(tcJ z{aPcUAKN4QsEVhKbfL$oCmc6t@E^LLe?aL4UHOLa&+}Dp{EMpQ^?$`Pl|3$jKmB$? zDwaXBvje@)5r;u*ZBkqqgI)!@wT~I+S{mnQ`3CcCl{-Fpz@Fl4l7ZPMwLF0?YPpYc zWlTLcm2FagNAiS&?0Xu~f^eeP{0D@+3oQjX`|09OQtk0|+tTE%q6QFHyK+wXPLIP$ z0jpJ;nk>Q$S#gwAE+cFli4RHBnmoKm$d29G1qw+@jeub72EXcdo!YO-iXk-l-Y`&q zqE@Ha442#&SNu3ACosRrOWwbmj*Y^+h$&lR2Ly9T=3Plah=8ZGmbd90>3~fGwngic zuz(mDTODTniIcQ5_ zaT+;uLN%5(sb-DPw?%}{)0PXCNOe7Sh@2dWi;W2><9Bk0_c%Gyu6UMr47={}J7nry zS#_yO0(su4CEkuiYtD@ZAn1vYPb-pS0+1E0I}-K)TZGePoR3jKl*g~XXfk&`Ka0+Vim-}GM_CZz0Dz!B+<19xzY`B% zIH&*sH7R(I|MTkLiornu0Eu%9f9wB}hyaAz(~S}(4opr4#6R#2aphXizDct)PE7|eeMeHkYn^OqX*r7CX4GHpYP>pu2bbQ z9SO3Zk51hty=b3^FrRbXG8)tZyEcL*`xy1U)ka@r;ZV%(w+reDe9%emRa2c*GDQ^P zsRCwLsdfB5GM7KpPkI1Yerk;G8rxJQ#L~}#p zvgRB`yka`wKfQZEr1o~i{Nr$#{b^#@`YC&-SW`$RGA^sJlQDB7up3kr@zq%(1)rux=A)!@)2 zrzI@`^@2)3DP$yg$w0G6yO^)OkQNnReyQYGx*zR(FW4PjN5La%Ea87bw!8}3>BL>P zP9F_#cO}4`q}4{a-Wz*5&&r4v5i0g_Bq9BVPF0_6M)1DKT(dovT=KgsGbH7v#KEeV zVPC{Z?Jk1-(b(7h^3Vjjv6s1H@DcYKU5WCF-bj`6w`#uES?kN}EBW~P%Tvja!?Pa& zR;Lz0QBdj>M|xUWu`>^;yARE+Av~Wa^A2;OBdp@)=T`o(S1%q*UWFZcxWaa3v`CQ+ zC)DM+KX_QM&1m6fd4xlif<}^TE)Uo9{4yu4Gx`D3a&oUalXi~3FqH{-<#$1CZ<+Fo z3NBNkqfXaYpXvHS{fXwwB?@5!xk^C|o)53xwBwLZt7VkFi;$l&j(#serGDyne8coS zXMIFlNqmiif_L1Yfb16@37%CXAX>R?69;b^Y~o|Iao&*eB3L)1jN;tG7LSC&^Xmj> zlK5X}Pk$dA3IBXIv;}%miJ}`Azk&XMzGWDvf#HI7Flb5D{2u#{^dBfH3b8)pGv%_H zuDdxHpJSxkKOCX#&B~T(&|FFdWEtGfQzz4*!Vw`cVj#yWM<3XQ zpJ1}EL;mA1y#M7h0FIusFakgs2v08BXSx#_WiDF`=C6HX+U2jXk-DkNkZBx@w@<@KB_&6nTlTHUx-6Z+AW8*n3LSuY;3g1}xf zQSY4cC}O@DBdzI#1<{!{B+}hFjaObsNt#6Y%)2M1z9WPtiBW~oGs>r!_b9HG(feEx z$T1AME)S^+wI?-iF%LxRy?} zl#(~@_E|iyO=PfQJ)rFgHE$C0Pwe>YaHFBEZkL)#!p2sfjX5oS&Hj`A zp6+Gk%VV-Ae<|_(a!Xu3gZf2wGXZ|GPh@w&H|8XB4(Z+;JS=S)nM(||L#89ToGcTr zNVfhX7UXQ(MurIe6HlL!_Fj^&{T9kgGCW)Zx%%87<7uGxWr(j=Nu8wn!_$+pV5m^^ z%LX2j4x_&oyJ4$B0F{W7z&KXw+Sa?snt=c&0ME47QAJjniFS5!gZP*br&XcBlzIhP zyj?zzO(dPkwz&mrbi6RQggde0p2r|%17+QqqkojtsuWD>EZ^@(UtaU9uwgytn*N~D z=Q;5eQvY$q)*1<23EVmQ7Gz5VQoyM$JaQ2npWLR73oV=M(dW*gYR-zC7(s@f%HZzm`Dc%V^E#2V+PQop#cBq-9Q^~=uP^DL;N2BZS$i+q{MsFb`oCSsRMKzDI{Az z{0{R)ysM_QZVcA!cn0?Fh5_JMyDqpK+49jDzC`UHqCKz&K)J%{_z4x^?Zu_?pZ6kE zW*M6etg7jtz7ID&oxIRYLX0GOw`mYe{k;)FRIePs9fRS8PHXPx0o$fHmL14ZNkAfw z!;rZ;x$EJt=m5VzJj7!!Erl>t5&8Zk-`dAL@GH@@pLHh8b8xAe!ccp>ZK%?^UWsX= zwiXQeWCM8p{2CMSdc2S<(nyD6SmQm*7Z#*J-cxkg$`wOBKu*U#(Zvi@os@yXa?FZn zl&7ml!NUr&CxgKPR^Ub;XwT+NLcb*+`k#mX5y`~PZ8h2AW4$#y-2T*GUpP{;L&>|a z5Yq@!0gfZSGRx9}V|hGiY#s?+L@v6UO#h%hJf6BCdl-4J+t;bAtAdFQA1cP{DXRn| z{Pz69>iT@G@j==QTWQhtO_W_&0cIKIgR2bPCa_2OT(jm>11{j|zB&Epei}>e-Bk=l8fzZdRcZ=* zNh$&@%k5(VH}?>#V9<%Fb@DR*NL$}2t$N5@rZ!LOGq-0Eixrc zC+ADb*Zk4GYbUV1c74!q{a$hk{Fdk>cGt>&JOKo9WSV@Fjf&>E$W;BJzdbyaEF~u8 zFlFNFCyHXk$IP1zUd4>o1Q9hAHSVj+71hJVEqM^FXi5lBm3&$LCiL&Y7e<2aq9=FI zc4R(&yl;^Rjzo|IA zCU4`$!Cs13aygPO>gjm+LE+458~i|3tOZ#-Vtic0Gp(t+Y+>EXN<4);+>2lmfC-|r;LTfgM8y|`CbSDdTF#HATd1gny; z#PNtEev8By9(ofCVergm=FQC?SkckMed!b%AitGB9N`amLpVm6j-dg7X zMVIH535~(368v={U-e0NK-xw?F;~mjV6#1e7%aCA*2KG1p(LqK&?{@qFsQH9m*zy^kGYK0q{J}SB;0b!PvJW zmo|3!Bz+{~P&LZ}n;aujvIILCkT8rI1E>{Wr795T5~MH(3M975&QMHI+7Wuj>;Sk+ zJV1YlP?F^p@f~ddBWHlPr3T9*Q?YRTYIP)?=k!OZMo)_~*=uIuCca(y%?sU z6!sk&=?r8l!pD@{<+|zsT3?Ow41GQ*l_{ zB6QW-t_meR9?u+UmKBW_zWzAQ7*U_jXK&fo=Mae4T>~8`){GA3TCPu}?;1Tds$xpE z^d>v8p1M2jFHog!^2RejNf#rPDFt*4zAGwxY|+u@a|4Dm@Yc(alH0zkT z6MmJZ4Fkb*SuW+>-ayJ9FR|+Hv!znxjuy_1MR@@bzK+n+s4_eg(>+(sETEbipqF_$ z>-W-x@B7KBfkDu$oZKV{z@4H>*W`1&cI3XT4srgh0zc=m&Nk5k1+RvrI!$n1pp>r# z)1VebrM7PV=jZ__voCmxSGfp@js-f$wHMdRyR?n1lYY4N6xMz77VwzAN(BNw&2%*k zHjnbfFfqhf*XEa)A0W{^b=mHj@aJZb{<;_8;>#LGJ~7E4ce0kc2(Z>U)%UHbK-Yqn<4iH-Km5k|n-o6v+^jj&booXqP+Ea6^7zK{KJ^ z?ewXHlfurt54S*a*xbE>bM#&t0!}CICcJ|Jvz6GN_j3jh5U~*_t2C{UJ*C+G_(@rs z-Mqo;OIW?3^`af>pq8od5Hz<=DrM3(L>2Rn`LFKt*H1`@%li0R{$@P8h+`LVW!Vaw-VQ8X91W(8RVFZBaiU$z; z%;<}tqpUFbW{>4HT8^dOBq?oXGmFTlBNex8piRc*Mk#~ z0Zt_b3&__}7^(~a*x;Yy))1aio_iYQyv~>ka-8Q2Sd-|F*6GkQ_if4wD6+WJLyXn( zNXE1&k{mk{34+++#~@#uV>0MC!QxPzYLQ#kTbq33e5B0uYjb-(GVeSdHi6F*$CUz^ zvSa@^)GfQ9fK#?L7(^}|5tgnMBu(;-0^Ic-Mx6$Ae$Jillx=4PXZk8QNXF z-ceS?*U>Z)=X;JSWu$(&ci!+-)l@cc29>S6_7lAsZKpu0L}_~H-3v_C5=ZNn zUU0eSLL~@MuvQVnmuK(87+~D|Ro~n1#_^Zcu>>H|l(>y&KmE`_*I7%%6o4zpNpfCJ zM(5NYWk|NcUG0l;0kg*4KG!tQ+;V@Ceing_KCLk7?QT;>NrGGPpyiu18gehl2-q_u zt*{E}#7;$~EK8`v8(-23R%~wE=&61R?Kv#Xnu-*&{IkK8H|q;_yGa4w{OL>;hHzRW zWVxbkNNhlY3i=?6=KnP((QA$_KtsfT{lA8S-wyn9z&qXQ7%XC_oEI7Rdzngp_WL3g z>efO0=v&*z<$wZ+I{;x4y?(P%;1ovcHOnYHPX>e13s6vL7ON4Yhj2m`<2P9qVi4-% ziS&5v2c16HwV|19b)5OVjj&E)vgJSWARz~%`C(_jMsK$&n5zUMJ38dGZSEFK2 z*q6&sj6A=EdY%Q=BBU~xsI0f@gFiWATQvrk9sXG?d+9pkmkMG42DjRUTd1d{ zF5<_QsJJ)S&XS~N^%Z`qYb!8#pQPW|c8~=%V9W^`UjL{)l4cfSk}ii3W~f2s3K?t% z{YzMnDh%k^Ai6R^&Cuh0AhetRwn{A9RktQ|p5=)#Jarg$!W+r3;ZN!-Qk5dZ z(UmmPW|opCb@MO}5w4;U#{y2>J+l-4WC#Hm5^1)sVR9F9=}Jq_8u?Xi2_rR0Iq^WM z9RLI^S}gs?sSp4_J4u-+3X=#&6wmJ2oTZCk-3S6mEZPEL{)cbkG#x=;AQsTvi^2fZ zZ2)M9B_J4)CVXgy|442JV74>-Pr8vXB80g>!Z?6I^i4LIBA7H}UZ|u+?jxE>lL~Hi zK8OKC*dlNOKN(SuieW=7v_?Wq4RKBdr`3nqW7CI%ii79FkY_^?1o zU%jP#6kc6WXVX^ec8SmikxD(lmy8{de;IgtE(+gzE)v5C?rzuWd*Bs40qh@Daq zzU8TFDfubQVK4*fV@cha*dH%lxJ_PsC@HhEG~Fb9+BLl@Zc%UC8;ta{!n$S?O{J4= z!`P$pf6V_&`fS7~C7w4VW<#R6}sb9b&@L2fiqkpuiJpOcb{UTrU_PpgBC1hd$A z%Ioo%^xRz1>8*FdY~E~Vpdf6U1*0jBAC7(PBgh!$(ED`QS)S>Lo-DUAaZysndTj)3 z+>n?ILTXl)HTR_RsJLH_{#YFjzI|0iB+(LZ**-W!Bacr{Aete|U8pr0i@3;tAFHP9 z+hl>~F1XhG-PgZX;`fyscU4}cX?DrobK^&dMcGMvsS`Z8 zE%jfX1a^$0#Lck+dOw|!(eHNhZ>DuJD=fH>BWWZwzP*mU5ozXc$U&{Sv){bl(pWI0zOniwv?kS1ftECD2DKn{`LL;ozGY(3#CM z+)WztA-Q`+VISLQ632y|lwRE0de@uimrpe=r|7pw_O^pAQ18|%r`V$fOnU0r#}4Zj z*6)~7WRsNo27~gxJx!+KlO#;S`f>Sz&EcEYa8O{B`trjA#SC_&@nCfAXqgu&S4~-qFEU3hf>FbVUr=yK1rI` zOaz()L01G8Kn$&yN2f8PAO2_O;!M>)kXI3mI{uwkYT?>@wVf!){(Jk=OVS>x#xHMq zep7sN*-}(@{e5*4)^H zWo4Fj_k*GYLGN-;{WzWpChOS9BosfPHs^@SZ?aE6dLi1@PXn9OTgHCPwMRf!INs#? z*R^ku=CHv%J^|p`(XFm@Zic?n^A=bnc+OgP$Qa3T#cdH6ck*R@$nR`K`7Z(93n7?Z7e&h}OHAuz&;Y5IY`MHgVp*OVs+9>G@z;P8$D)s3r}xxm%Fr<15A zQ)Aq>c=0VU00K4i+DLRVWYSDk(WVy7u5FZPS3YCvM41SQ6QkYvXh5W28BK;zYcMbV zN18D_K=ukN=$|C~KWqBm5CFge6#UN!f}ZFW1{k*34zTCfnM4R&<3V9lkVZ0<8hX5b zd?B>|JD-kSGeh0{`ezgd&f_cI!Vzt@v=s|aw|+hZi>bUgETo=D-sWANjM_6j+H~)+ zDR$Sz4iz$$2Ju=mpfa%J{s|{)Gxe{duFh`i5s%2+@mKf|gj9%NrfLSOXSlw*kOCK< z>Ru48Awib9lN^OBT)?osmTl?>P&GPf{RY?bM)PXKk2i`wmGir0yYUZlL~-9sZdl4B zxYqL(!IJW6QnxkoJ|U8TC(>#_*-)PfvMt^f@mOF_k+F<7V_(6kxJpO>>gE0_Xq9-6bulyLD$0Yw;AzR)B z6GNJrm)l4h$*6408UuxDmJ1AEd z_j$ISH%ETA$5iVy9x6KiLJ7PdB|G5f(8WwYlN6}v{8Br&guJ!ZZqTMnEKc0l zx$oMJ1f21vbkX5#U)R;qmd4mu?Te zWIA@tI}KaopO(^>7k~OxIkM79^Rp{;9A-G&LzUd@GJlL2i~e4Z&wZ5A0Xi~i?v&1a z)|cw+x3aKvySJ_r7yEZpL)B^Rsle(>OF>6e^i^K5rPhe(?Avh-purI!yqxhUBSBH@A|0@2Qw zLE*a)^{`ki(uX=?NtwxfK)lnYd7Mo{WrTp79HqI9Y;fh~F`si}_qmswz0rAhZXq76 z<6QvJJHX9lxFw6$7nX3LTtIj-t~H|VWtQa)izJ_P(g@A&-euKDgsay{aE%kwQ6+AN z{!*Pq`LgQXS-X~-xz|f2dZ8t}=lZO>b>9>DBX)nsgI;*aaDB>J(Y!>XKKKZ%FrK7- z6rd0kpdk+v>aloI9xA@OJ!D~_Qv{W<-~4Ot%r7BD`unkIJ#>%y4PMmd>%))SJJ+pY zHI6IlJ->*=LPLrtl=KbHbWldKmO?8Gz3U5I@6x6;w%+6fvbRJ;aSIRN^qi2haisaS zk55pf8ADH~l*dWy>7(*o1eo8$Ht`mpcMor4mvP_b%i5A8gcb+yFTX~VMm~QOmqbS zFr9K1(dY`Be-!lNKj|N+9KDc?w7?8?W_}%zH!WyhYw>r!K|z)8?O&av4~$VTuPOQ4 z@xM|=bV=+X7*l^*cqVZ_S+c5=w2Y0Cv%B^^WA|jdJ^C=}0B7x~yL=V%hS7jI`tGZf z94CRrgg~_S zUAY)|wd4_y%q#!&`FDJEIzJrVSI_#SVu0#8YnM=}+vl13-}0TyHzXf@gp1KL-$89? zQejG*MOW7A=XIq5Bky;2Wjuooeg#FelKhymlDyxuOgZByTnYQGDSbCdoG6+s;fI;j zpqoek@;X}5C6TmDF;3PDIz7)|^LB=UKr=7%6zh%Pv-M9v8XnU_dMp0g$F3EvOM*U@s zH4CM%VpJj$J#j9M_c@7wl@qW`SDr=_rd|z57(c_4$7S813_@S!$q~vtm5@k@Hi?3 z(G-pr_>O|2>&ZJx>UVwdctB7W0PM(87aI-DPA%1C*N~2(({&v%8p=Z1MUjD8lYlQD zjftE;;M7)VYx(`bBKr#)**jn9-%ONx@FAdgB(L4pWLEkxxv2iTFk#0T;XV&7u#C3) z@s-I{zWa@BvRbLz4sqUyqCY6S9zlTg+$zS;^GUfI-Bcf z<=71eJEX$15eblTY08*OQUoLW@)eSHOS*djQ+k9pfqQ07y0`G;9mZ#zYblU^p$h$k)zz&>4`;=LYTc%Vs;h<|TVAXSi-IEp}rl z54gatDA6lF;^wP|jz`?0Yh|+iVSV48L`q^4!YBr4muv9*`baMP|i5#T$$R&Tytf*b($ zHT~6NA<`fe(MPn&K!gYCZv}W35OhioSKXqpK!B4&`*y$!mlo*GC4A2(ecFBzXA$pm z842o9($eWI_?l5)Vw+O!@5eM8=OG`q-Np+55AQdw9_$j0}5Uxhk2ztJiXWbz&c z8H5Z`{(S$B-|^XCK)?b<4gd!rT&2JE_avbs4Sfdi|8orYKX1l=EiDf3|2)-(k0RLr z4YN)YawFbjtmlMfi4nftKb(m#cD%M7*Qtb62!J(#UV^TH0)Laa+_ffaKP9Q8SvZkh zrZ?AFcy?B0J#X-&CN3$?`m=wf+$P;9fp!gdk5I$`kI2JBkolD_m_N61lP znV_n#jp4INPAPu}Z5pStUMlYk5f6BX`$iKFCP&!0WnF_uYxR(fyZP~B9^J%D_>BRh z*`e?`clP+5$IMBcf5vLxaN#q{o(S6Z0{QmLN|&{+2PpVVhgfN`h?eA+Ys~kSpyH6u zKf~L$%mY2)&-e#KNycf*fJROHi6DcTkU&`7Ku{gyYU zS(YFZLHS1-%WumgL>PSdaj5$@r{jIyG64^KC(%O`7P|k=Q;3(*!>?R4a@#TOji_Y( z81gN5(%xE?vypDZC>=WwlLsKrQ#Y)ashWWWMM|QrBqk@hYDIy8Y|YR-5^erru-+Y+ z^U0-P^5RUk#o{vY)GMq-DnvpB!09OzmME*G`wlZPCqk<~YmYiMx-!L1FY(7`3W=y~ zsymrVk_>UZj!;CF>C+qNj00IS+n({!vgQqcwr#@1nG5rs6y$T{9tvk{afn`xt$`xK z?2Qyj08Z(>pp%jdiJVtBKppNNQb9n8;uUakjOW#o1Qg8gqzFRX1 zHX&*#b#qoVK6TxOpGUi(5uXeYs4uqrjr}9O7|gsse_Ca<+8fuuTv^= zr^M+SUipBvSzP%H3dRZm$NFMEERi4%)luFca}*+*aIf}V?i&$!enB}n6ECB7I;M>n zyO3?VvHB87u>gU9Yvwdnh_(~ia5ObXwFTlDz4zCy=!J=ejb5(KXD0UUx)!eGl7}^B z-PNhGEnd`>*?Eff54{*`R?`YbsPTMF8DIBw4=av(RYauvH=C4;DA`~)Hg9S!S%L;7 zpm17*Q_%VGMF@XzzQt>{bj7~)x1!X_&nrax@irZA z?$>{M(s3DlxUR!HjPQXKC~|*Ma$i%vH4-#@205z^9G5^Udg?#%#e8C>L3_I1zXF=L zndq`4_PzUij1~q*r3&M-#HW4>o*$|R2o>^%JLLB?k2Q0F5L!^~gNOPpebic=w)?rE zXI|8_g}Qhj6dblZOhC2;z)Ao_A}~?dAM~T?b*(<29XO$m?`5$>BXfHqAFr|uJg7%t_2&rT48+rm?k64zU9q*;K(6cIMIf@6`jsSS1nXSQhbmrn z#ou;cF@Gzw4*=OtyDwIwNQWoY%r$IAtG2WSDlM%j&ND8&w<@ z4NNVxR6a!aIH&YHIV#`qSfhjfttvL zB?|)-N+wb=s-Un>xAZc%^f^s1K-KG)CJb{c=Cg`@QR(wPt3|?Em)K zGjq)k*HvQ8byUz*8_j;t$mZDc9Dh*40{=^*+F}kFoF9D6y$M} zIi@|X)zzOLaAdc;TZ^FLfXco$8Xw^BAk{rBpRXTED`!;o=9qGHWf57hy!I{ko?dP9 zvUi(F(=xXgNF_kK!N#qNV`Tlg@=}}E`nbg4xiX?VE%oV6q7Ry)MSDsZ7{#@WS5N_s z+)ur+!3!lEUD{lno8`Gn!cHW=A9alczfIaZbGHpkql>Rm`Q*{@wh^DAm%@oe*` zk&~+x%aTx}bc)b#;`wc@d0TOk>|wTokYO8DwrKOh*ovGLn>Px!~KS&hZR? z$P|suqIus41PiL$Ml>hsNSB@~AVf)Nn4fNgPHif-8lm8R@vR3&|DsmyXY%6SVIBDG z112D2kh$smSI?vLO?`ZyXoVore?$>PiyDX;$#5 z%FCT(X#9(@5xXG+Q+ViY!;y4gyx=YVx}@hYxA_-)+L1kx0%ZP1a!pHw+Xs+G)^60SLP6T?_0Or7}PY%!~DyaFt#P&%l^12?qo zn~00W-ZM_@EmSGFV~%AoXU5O*h$CboZ@%0GmMJEDeFq;!4XHVIN@zk~fynm4*c^dB z3kD%dAi2Z0pdI?hgk|ZH1(`TplWKZ>;aVMGD^3=C3le&hZ(Y?;Gh&C{>ySd}XMFb~ zMVgf$=2SK!wqx#Y$z3bloV|G(;FVMPmZPse#lwZ`30km#h;4Nwa6dyQ zZ;0itBPPDI0Nu9Besi~0A<4JT74RAFHF9#`Q_BAQrRRsAUi%YwkBa71UYxqFbnu6M zCR662xU9kX^*U=xDI03M4W?(De{vb^b_h0PodUa=>{ubRP*oGApcqjQ=N>$LBoZIF zt^yBqNO3|_j(J+Vo(y!>H|99A`N*glsf~eT^-H@Qq}-4!U)ux&g2!{bsJLAs5pvu^ z*+KYyQS7@|kGL1u`^*dn8Y;7splUOm)Ij550{uwg+L^0MHe4fF7Eu56yo0Wps?CQ% z&!Dy=6`E&mtN<3~1Os~MXi&0wxK$enTFG314cCX9NjkD>(&RHHLFUt0`q_ULHsC@U zcz_C)RH(|g(FB10A87oq)K?Y&AokeNLdkw75{s0pvPk0k0CV&{=1rg=v0Kp1VCo|C z^_fZs>A!fwWl512;%feC0@}%=OOdlljbRWvyyddX^`zrNl~b(SDXY&abr~Ry{hh$y ztt+r66PpsmGJrVi9B5kXi(EouDA#z1n$NroZ#Q68#9E7?l~C9EIFyV0sUVm(;!d#G zOp%r>Z-YQ#ey^g-0J*D?aU=1;RtW!jC+qOi*izKsijuaZ_a{Q(886!VvtXW#@7i7I zwZ7M(x5A!ksrD8zA(|s9Us$WlePxjD7yBI(GvKMIn0#j8@zuE@d6V#u*O}aIGyC1y zKY?efBh32--i9xIuw~JF#Y2ZeHm$DGB=U$DTvoEAlB4Yj)a~QfwP`|1zU3Z6K>Y$R zM}!6eZw~V!L;jmocDf%*lP$G9>focduy+my)uq@?ch~G9N>wPniI8 z4t{HEOhkf-B?2-LaE9cQ&B3l%EKwW@OA{(a=0fqHR!*W#4%BqRFqwnF(8Y-}c>h6X zdS>w<#@Ki*wkK*ORxYm5cS%XS>Fm?Pc_*cU`oiqUVWU*DvP+F=`E6j!dqD`5J=ItC z@8Jb-%Qyido_Q$CSf#a>!@)>{Bm5pj?@+C!vz(XPN6At~A6Npue-a>LBpKk@&+VN^ z5>?+2o4%J{Z&?|45pPLelA&v6%FrZ=%u4RDOhQo!Bgosz>~=G_wsJ#9d)Jj=*TCXH zqR_0@JiPO1%4Q!zx@MZnuZvNrbq1Ygk>zM@&kZV91zD2nQL#Rw=cZnPX#_+dVW?E~ z$MQ)@D@|TEq&J_sr?~a#Y_sC#ZwWcQ`@xf++^IJsi2Nk!IZ!L}TAq{FIr2q~Ua0_( zvvzH$dOE@`c0n=nKBVOpx0!Drmzl?ezK21?Ti0G((p2YI!I9DNmx6utipwm$9Tu?V z6m(l{A1OwhhApq2d8LTioNU;@AmkXit+S53j9jfCB#B_lZc>ZC*w-Q89U1dxlNc8S zdo;^f?>v6pyj^k(B)T2|3ez`o=RpN_g*^~}`_$+f`?+?ZJ}VqR`S~;76$*Lizsul% z1rh*NXKP^e#n$@t_BX90zvwe*8LI6OIb#@~PFQ4vgzE2P2Ka?^dun!soP%`9bbeB`h;l)oxzUTKzt!@!VJ(t!I^71^ z&fGVR91~_wO1;BEO^&^FB5}EMeT5YQ$H#Awk!zdz1QpEw%{AEb{>kN2~Fc0ZWkqmCX;ZO%+81*?>v zr9GP8(_`QDGZo5dkn5JmX@`>^lFuBIE@Jtg`z3xvXI&f40mH;EV5>FPdtHgZgN=$# zDESYLqACPk@E21^U-S-+vDTWDG;E1|d<>92t&xyTzFQAjZ?ogi5U&~RIz-gRW1rW_ z{FSreXHlh8v9z(c0*>ITQG(wy!4~%=(dPDuFw4-2w{n6frw1IGh*5LlGphkE`K@r8awPi ze*6U1`lr^i5-xzbKiDgPkv97hRKpob{>oesFhOX+k^lQA|GzCz?Ej2DduY927FxbScy|XpM_Ext4T1>l7a3jVTB?DN3-C*eyHLff$2Sl{Aj-7FOx& z#{@P+5jdY@s8H)0xeYT>mBX1FMZacnqc~P+y=Cz)&*( z@5*iJz$J#Zbs=P}_5(B!HKzMuZStb)O#wt}SIrlz!_qd?MY|!Bf#ITBieB=x%?+Jr zoe+3EbVt|y!#?X!|)=3z$RqQO_P z(0A7AnsG#=*Q5xxp}@f^A-998Zr=W87f3j$O&K*+{)56x^LZ{xt2G5O#^UD!?o<1C z9FeQhhkaW7`iE}|D=SlU9`fZ{gYc2LnLclbm~9eAX%=z!|(ulUNvx*TZjG&qVP zuA&cfmabp<288jU_SCtc(hZo3pv}kxFjIe$UpADzkfqk*JV& z-O0^~A{}maucqg3U*9d`s;P@CW(~ezS2?)KsL4Mn=}5?pA+*xUSc0wXQ`JDSBqeJD z?)t^8{xi*_86Bf$v@eiqRZt6XMzPRUhReSvMtAx3hCX!F^}_9H+&b>v2mlj~8|a^m zrOlCJgCZydf>XY1<&Y9fa>Zkg&SuXQB_2N|$l{GEe?{^_>2VoHwP?5ioIA}u3>0%LIWc!Jr)zJcJO8KOg0aN zb9Ozfael9O(T`e2Ns6ghI7Oj}U|s9Li{$xpOJ#S{rVmjP!^{AT7aO3^$q5fOsV0j^hn5 zI5EExK^J46+5dfo5&zf|2_dniTA4u6%cigXXT~^veRg?OrKTG$7uB>kW zMxW^JPpO7R#~w4mlA6wXm92xXRxOEyryd=-d#J{d_FA87)zJ^LUu4_Y=`p)VAZ>-G zW&%=Sie1_U0A0?67^|>6@D+Z94_QINEUuClPoz<(+i$#kT6btu(kpJyiuul-fB=pR zX0W!}BUUaR4w5-qcTH6+@7c3<@k4n_**>Ebrl!$nrzkGej{+w* zP7Z?Vt!{$z z=f$hg=wb5x<+c$X*F1r(Ck zjtaG#!ae-3karjJGP*+n&oz-6SxF@Oy7L$uuZgE|B}4hK55v(xY1M}2PQ6JsR-`$_ zr1&7SN)~p5I<vHH(wHo$M37bFx#>ob1aEo zk~+*o7He?U6r^sL5J^&PA%%;NL!3BNgYS^|oUxa>G$bnnoQ0k+RXm#2~Qq_mFu^1Isq<=>gRTYI`?ROEX8TqCihQ zXeqO9hDz2j-+MmnK;&{Su(j%k)dcJ|Fcy7uUQTN1YY7{4Uyw?0HCaN z0A&BYpv5u;*Z>eL*ip#gB-Lmr0BYsyl$mL|BQU~WYynHABDMD`K?rKLa4PmSR@HDW zXW)X+VuX9NTTkwYZe-6ikKVu{w+U&o$KfCEU{^YgWFhe|Ufr3wrq$Ze*dvirD(2D2 zWG+E+mN>b8P2e4d5-AC^c<6JsFRI*7EVLt~GM3RXM-^$P(GN#9a85CY(k;V0?;}sw zHQo)F4yw8jHV30oIfNz?83t%wf-g&;^G7Ma+dI6|-1?X(7LAkZ?A{m)T8n%tLyvJq zpZc{Q_KKI_&YWzznz%BP>0cXPHw>Cdm?9=UBX)7jO_wLv!lnxkFuYF}%MPP0B17X5 zEL6lBZ#r47%9F7Dm;0JBwq#!q|Ki7UeQRXj#`zXbE}cCU>X0D!7jFLHyMH}z`j>+6 zjFW~Kz|F5H8F{GDmTCqd7-as4Kd+f)bb8(A>+JbI4W zaCqw=wo!d3@KbF-%J0Fbnw85Ha!1HhA-Sd%!Y>Yw!igWOX5sCYh@w+YxuKz`Da*sE zQIQo*#e8M*Mw^B+xD%7@%7LL_uSRdo(AaJ=i_E7lbAi>|Cl_O0uJNMJ2qQE9gCfC# zw9$@c`j}*$U*`IPvD-lRw;rQipw}svYoi@eGrK(zLtHzKEV!87iDxLLiU7+MghiL7 z403C}pLJgHj(*2oN{tr+y=jS;z3hPT>&N+8CBe?fPJS3s&w0io9d{mYc z>q=#2Q%qYUYdo+cIhS9ANThaO|3%9FKzkUsOC#|nrgP@XEBd!EJn;7Qf^jd_5|Z=7 zE@pPve0_quLN#eIX+Ocp&c%3yBuxkEe)r5 z#9aby2u;tYakjtn`?ZKP8r36>31tGhVut$Y75sJj8 z+|}K!hO0FPRri2_XDqVDK^BLs(&pH%yT}CxyG^kx%OW}q7$fl3e8F;LDbn^jN=V7m z(?UgsHWjXZ(q?wWi`}7Fqj@xn1Z=1Yhpv{&qpf`AozPfz+($4Q09^?>DVc?irO=|g zKWU|+ev~CCv!vUay6o;*ZSR^Og=QBN`no8ui_=Zh-RqKo7~4UTBGmL16sdV8uM9v& zW_@e*o?gU|$1s9zO|Vvu*7Sd&O|mYVM~8(@n&xw8d>tQrW_9O`WR#?czkv@Ro$SL} zCj_`}J%%)HL=&sWRx>DBile zc-xHUizt?yM3gHra@}qe3pBx<{{9q*-W*ZGRIPJpc&=@Uhu{7WL9Ea*V@+#VklVpI z5{_yB?i3$??k5`zn(sEb0RGoInk<}+gk%<3*?4&rO{JG?OMI0C$NGF=aSWni4TOsm zC;&}weG*HIA|UF|9yxZFqPszRq$KNxr@`NDDp0WiV&Qki$=hhhDw}~&%n--UdHhW8 zoqPLKZuW8hrSfsXWHYbLNFdm(!hkMQF1@vLiC`RmGiqQZlNm<6R2~C!_j}swDDe{9 zO>(0G4ENXA6(x{w>Ga@ld&AK}&BROYRtLhCxDq%qAHEUg`HE0;cj3?+W-x&Zk)L{s z$ryUJwdUhb`grDP@A>Imr4%gZ&0Ffc0_nwP$qx|KtW(XM!4QfM_KTi&_< z7pNz4qq6YGgQWxlut>G*oUMALK+uBow(*>mM6*KCI}GNda91=o`^h=qBM0L`igA$Q z*S3HJ(X^CTN$P09LBFYP5U_{n((?kL+-Ec`SJw8am>^W|+1dh#X(n7@6l8qZK!E@+8||uBglYugNPO zS(IW48Rn^huykAZayfus(^curg=8&;yHEoL%1ao9@ldH{v2ub6`&~ng1;SBbPk`N? zfku>txz)%&2>sF%H^4(%qvk{;vx{N}FqtebfG%svA`c}F%dcfg4p&g1ii_umOizvz znVtXxQJsTp`dk{HD~bYz2J1v5WcCTjX)jH;&WN{A3F0AV-h{I2k_<-B0STg=`z8bk z3=E9CHHED;k)DH2i7LC|OaT>q@ePGdr`m3WqWFOFp7eT3^mGEgTwgrXXdLZgtT3U`{{w<;F{6cgx$N+3{~wL7}o1&<`%**Vc|OJLxp*iy!* zm9fF4+;%H)R-whGpS#J6s*aE4%pnP(kxF3YK@hy#tj$p3>KI}$pkr54iqDRxXN$2V zr+U4VgT1p?bWU5Cg6CCSwcpc0*2F%j2ez*?*-=6QmuyoVHbe64i&&{!D$yE^a{Uer%`?()i6w6k}4v}ymT`dn}}p|0lT%Yss|>Dx(Ue@ZAw8j#}->vD(*_sg2`I8 zWThUnbYI`hGe6Re349#cMM9Eis|{9!if}u5*GWPP4W^@sz(O?0;Ej7_10e|KqDs#m zdGy+}7W&Bm0=};Zu!S6TCSyXH#oJL1RQa0^9)7Dlkj~hW0}3cYk6ag4zH3s6G3~y+ z$?rVLO$>|_OtB}3vtlr?t&B{5913vx8T}0;qb1k7a;#2=c<9S`chvvG9XPtwq16vX z$kJa(Vkg^4QLW0oqCwE1CJUEYx}3WRb8LV!%(S3ZH=0scZo=+;5jNhHHa~uA>7p4# z&ZMGm>nXKhp$4e%A!#MhopR0rgnr45=%<}{mQp@PSdtTOQFycL#kHT53izN)9BAJ- z&6@NwB>!QNy=W7s@h3SGlWBw4gd-}1KQ7-+I=>JlK~tDPnjF6g?P~8#cRGP#up_tn zIDMdSnQ>-F`xu_X+t7)4eJb`VS^pRA~M+20Ed=G-E?pQ;d^iuSsX5~tF z$&tcyou=vpT)MU!)4GEtz`<|D&YLx)4j}eNIM2+~lvsLClInhM=>+Uy-xOAo^CSQX zhu^OPDY~V3{l&C6CU3b0A*6V(?h3_IeZ})6a)X0=Fpl-b(a?_MeK*LKk8#=~nL#L;H{I0?Y_qWQ^l0}&$ zChN(*c09fVmrdvyS>YAam);Uq0*OJzBWYqpL^62@IqS4~_&TaYIi#14_wSNF8$-yd zhjkjzsZ7ed(4iA%2y4b-v?EtgQ|pW*ZET?8-Wj@iWD{i#WlFA^ZXeLyke4HBQe6P(926I4wn0N-rN0PssOvy^5ifOd8rEpm+lD1wxx} z=y@RV!~hnOc!0pq&29d_4GxGFml*x&tXg^<_?!cNW@7^r0fx9Q+Km8RwmvRqT(=s_ z;qf~Q_6+9P@fUWF`UDDHmm1cR;0^<@%rk**+~(SrQ3u4_z>~khd{pfL$RNJWkx1D zZf+6x>&hEOb8oo$W1UCiGM4Ci?+OG(`}}bkWp?1hLBm=L-A&l=ty4=WSOA#@X??6Y@)9k z-Aevd zF?76@d}C-IhapqDqR@4a-9=vqwepLz$w0+Amk)7ejg;*{Y-h5N$)UUWnWXXa@MZK_ z0A=;*>DM^hjvAerq2t!lKxmQI1v$-sSFdH}%yLoIo6z!2lEJ?ItCP^2i8!%oew^|M3Ws>AEGLDXp zVZU2ZZdt$6=b9NKUKR-1srAVP>)8&*q)njF`7Zc93|@FoOi4p}P$VlNN4G{d+MKM! z@>y$2NTAvA!Qe1EMM+t~1xtcD;PP*uE_P}-RiQ|dq>+Pdpk(7_v=S9l63+evvJGpS zcKU}lv6zC$Xk#%a<6UzHlXv*$9h5><|JZy|d9m5YZTqha2sPs2?l>*E%4XOW>xc`h zQ-(^i+&Y?7W9ylVaY7gI$Vp^vF@CcvMZSSRk+4Ie=Z63iGtU%FI&|B3co&)jo~a(l zt>=~7y+5u1FnK0L$7w)__Rz(vwS1;2? zWA5MXg+|~-LR_J-5f$c^BnQPa+^XSh(JjJyZ=oV%o-%_o+NnQxAQu1t7KbcY5CL*f zjQX~`dtRCVq8#PK`#X8q5W1riD*hWRp8*C+1g`WPnx-fb)h8GnScgChf-d3LKD zgaaU%&5x6z&B7R10xP~Z%|iET-szZieC-lX1V~Y~=z@KY@hA?cRWermzaZm%zyRus zX5=h@jW78xl_N#hQ*k5?o~Q6vTZ)7=9W)Irso7~y>U_dqYw1+zSrH-D+^Eo9AYYtM|{*DD|-OX$skYdtdyLWR)B zo0z@VC4=1SP1-ud>sgM4B5K4d3lzd+Awz_vxDefe$gt(6;d?Pa9TIAKIxRk?>JA@T zb=%?eJ}cc-Z}wQgfP+K@NO!Vw4dyyNemnET(wyZ)`&gx_V#i<<{FCP5GmWs>hy*r} zk?65(#pn4g6MrN&&P-Y-lBvM_l9rA-XFscRd{~i77L26K|8cmj^Og@AiL9U0-@@F_ z<(aMndu{3JG6@Q(t(y>NCgES?PO|1rT>G8yQp+8AldK!90Tem><_+-cZ3Q$_Zg`Nm zWri8d$1S)eCh{0L+h?9m>UzyEa6=#_TpV8!M*09*LIL?; zFUcl!SJ-m;I)lHzyi(?{&3-jS>~E105!)Yhc!**akaCX0(Ku8ca-7 zPe?;-wqVl}sNqpwdarR7=~Ow*54T&3$Y-9%BD#gW(cvHI6S>xY*UxzrQ+p_fMk6ST zv3Ra8!-q%=giF#{1N zS_(&A_VrQ+mS4Gdnfv$dB}&(6;M(J4BaDRzwA1A7e#s~Q`;inxdTCL$<{8TZ3y-FH z3g1WzEE|pc74w+(G})whJSD(rL0!2KMUc!?J`~8f#(Ho*J=HbxzKiF;m-a*XJEbZp z6+j4c*`#B-v`wTF7VKe`aEBZ@={y>JIR6G3Z2oz)%!F`rARam*bJIrcA|+sZCZ@;R z4MnnY{zDT>`}?`^*NWL)EZ09Ls{`BI!A;_;^TCP-Q9$jSv6v{I)~0%e5j4EsA1wHCC>Of;s4=31i8vlb-y_F1s|~dV#Lpex zEFdcXs#EJCZZl$7#TzrVg=m>n{p#uNWEeW@?JEZa6^(%^YQ273U!Q_zI?;%=NDG693rRim%?oAV6qM3OO#LB0hzrmROhr= zjT`QsA8CG>{g~h%RAifb23`XE-QLV?puyOEie$7Z=K{cd5~e4Li1;qD5$;I|j|@<% zLzv_iX2v8VWitp+HvweB{f`g==<^(a0+4inn(F}&xgnpB^^-#56PT6)sySuh2Y1UU zcL<*=qD7jwt&?QP+L2DRZGD~OJf(~LYdca zy49|QD)^pyZncD0Y7M(@O2knwFR8gPuLRBju`53d@^>a8&pV%Fv!B;`3% zEH_NM!vu;TNK-uGtvZoYFEIFIL8MS#OoD9J>4~K5CyV3_+`jKVy$n#*<6GkIDPQF2 zn~zp(Y>6eDpUoumlYCZt{;;QR{w`+U`0g2SLro2R60jC756>gB0k5CP36POYQT_(( zUa{w}vyEkX$&QI0@iJkI$DK`99b&>hOK|nHF@_2+5|HuviU7@G3N zCqJUSVUeh$Y0aV|_n;1N+jEcxMul zO`|t8{a#&yjhG#^dQGWyvCBPRuoDbAm|;>OOJ*qZg`FYxrM8leT8#c@Wx}DVRRSZE z@KLB@k?|wWP!R5|!^1!X&>}wFH+x%lzL%Hsvk;%%vGGL?2bp4pN zLSPou>)^2GD{2U@Ulvf`epzPvYsVm%WIN;lQc2M@6y;^SnK6g5V!iC?fjs7PP7Sjj z7bOU#!!3n8!FtpS@GgQAB?Kj3C=DC!rWhLb=d}{;zM~d_=UW68wOuj?HIFy9yF28G zC%9-B1npERRM``oDq~w@OA)furdg*P8G^l$#$cuPo04>@yU=8vj2eO*4H!=^8mDja zDpfCr{+MfF&kipgKs?O}6+bO*^1KauG@ylnI_-S;69_vyxpc@~OiBIG zj|3`EGC1;Sq+v>Ef8uO~yzzLCmQv7J&IDD(J){~!LhMu%w$UbMmr*TXR27{|nWwem>Ra@Iz;R5-ZL#$4{h9taom8Vc$a}$(_*Wp^?B)3D!^StW zWGhCRUsL#xKqXc_Os-r!$&t1az3M2ap8Cjk$rK?g&H-RkK)o0n7XtZ3Jiv{>q#c`$ z0v~_r(vy&`vP(`uO;Kh=$+f#0?$m-USFIvEaKdwS$d}t`;Yp_8XJF=T{`! z<8x``w7;@YxJL^~D;uWoXdy4$^05<*m80toL3}(srRMCk zlF(pjk3YjfU_mz$7Iahy^_i8C=y?7K&mro~G=#5_;5|7qNGC~(5|SQswgJDz<`WSx zq~H?~X5@nM(!bO>hwg#UNEOh!IaJ93=mW9`IIf1b3Mb_kdBrWGB3;mq^@sh{ZJE79 z7ORoo?*`JD@SuL?Im#0+vqFj-B>_>4Dp>mF24$8AG4DcZP{HpI@oKPibXKcluw|Kg z^7zNDhQXGf(SbCb1fzIQGlOS_KBN8K;(pJAeNWCZ#vid=s>-VMVZMJs9Nxi%sEguYxf&-7nq)!?__zJ2= zHKqxk+V8z@5vs(@a6$iyL$n)V{7gi@Imp97GT!6xoJy}CNKhmdLnYT>PKu}KPUN!0 zVD|A<`TKgd8!I^_i+%XS?ZlXJsgUve?Jc2`_D4#EK0aNY!+kM2&QhK@uLs!oCQ^y} z;gAg*MAIX7f*El@7`lUaW4#I5J%AMrmdQFS6JzwM#R7Eg&g%Nqw8K2tQDFQ_f`;v7L|N z%A$`Ps&I&8BgRR5XF6F+)@z@Y2rZXgc+pG71Ax$7Bj7-iYBV@AblNApyF*;f-pHf0 z^phl*DWMtb&L-W<2`*NHV>p7dx7@#1@>@lCeUGpfX@XR#!<1H&o*gwjJvPNO&}~lV zEmt1hgXgn8#&evctWGbEp-25<3~yp~EEO%Z`ibB}R{Vl`i zVvo_{cGV3Qwv+(6l!0HK<)(bGy)c1j^+!JY!`=!?UY+5r)uopb8Qp>0Is*gD=EhbA z$e?tGQO60z(W@~1@gMz8e0_reN~Vk9f1~L!Hv0n}i9LN1)8ncfAEgxH(`puY)*O2i zavw2#IYFOcX#0V_!0RR)iobR1;pg%*V17}eNBD>iAD(zKUh?o(9KfNV*)aRxN>Bcs zXkurFwe+1o;J-K}AyB$FS^LP0oZS;+rI>`qqI_o`nEMXn4vc zT0Xk&uF+2VfksF)o1azVjwGULda1^LtMTW|+=B>gCSv||`RETG3K2n2zzj{1Q*uZy zE5auCJr8a$7T??Yv}$g@Fr!ZVT2%GthO z3wBypH;76d(A1`=%S0|8Zlt0NFgpzjp?yL+8M}U{6O!_6;9HR46sv?obXRVJg5V}A z!HuB$;$2BK)T;^D<9O_`3l5~#im|?=qZ3tBLE>-g5u{!*bNM|y`XqAA$j)^kADQpa zs)v#%lE=`3rRx0eS1aDo_J9LJ*NWE2U`lS1M+gN|6wEFycJxR9wCl=xZqn92_# zGTb;Lv4s#Ueyl1TFqK??eCdunAY5F_N6*L{eu)ZYavj}h2PC+`yvA3-GR1FqpHSPf z%s-91<>~UDUN*p_Ma%01rbk$n<~d9cd{5iN1zR9TcH!dvBH3Jvb(UySY}pYuC;H9O z#3PfC{O*BlH5Oz2rWQC|b$9l{4DCdk12bM)c6O&KzZ*-u&{DZR5ZIr@jjndTnrm`A z%aB$ay6~qYJz2dK6aG@Rhe;~*5bkn|<>W78{rJx?{}+M*!c~!!3`eGordbrllb@?t zWI3oMHC2rwbF0alz`Bmq?~k0TgO(S!Aa;G@2HkK!XKKNpL#fq3iG`oXM!{%FBk;Q8 zJH57vO*3_7md*#DJk+y#F`d>odzV@V{Be)a((|YrUc@MZp?ET8~A$ zdeyL?TFDrjIa$oE1DT}51+-fWpHy)k6zdAmSS;wf1B(&nOvnbkgfdAVrHs1v7DDwE z7?wm_@$FqZ>l)L;K1`*~X4hd+j^c zK}+`gTeztCxq8(f*E`fn(be_dsoVNPJ7Qo{Y7 zA*KDW7r2;Z$xJ*#X-<*4^6xIH*-Vo{Ei*M(MtT5h!>N<&YnuEMc_apG;WR=sThaXY zJFE8w0D?pyRAW~@Oz=6J2AD-{Cv6FZV52GOKuT}Y5b8){1l>JyoGHFB zHi_SZ`vZl!FgS+2>Sv^27Aztpefnb?o$6PsUhm>DaBur;D&6$c88&c|%r6`v-aWK3 z)C&rvj=BVKOkk`m(gM&GrPZIUogxfE)s{*s@tXe<#yLP(K5r&AGa}IRKRY{z!K<_XOM_t zH@9{Lhpx0bupPD}eNdq}?kfYGn+VtK5SaXXASFjC7=A#>{cDJNoXO9e2Vq{$Bzr#Z zO8R6pLOh0lyc!u4mm1JLHa5)VRL3l*RX9U&O){l zg|rGE5NGZXu(?#%2=mRAqshULNm*QKkv)NDl~n*$ca2~uyBULe$`=pt`Y7uv($%`z z(L~{zusw+z$wL_&mIAEI4Dk9Biv<**Rv zEZ`*PdRP0W>FJz#OOdTk7>Xmsoz)-xcD2mZR|Fja0QHn{DvjDslUVmEj0 z6gNOr4WoUyV=!sHo!jhI31_!q9jWkErqS#TA=4(^dL{Bu>GphTk>x%tnO7yC#zN)#Bdrx1PFxsC35EuCq|TO3@!I2_0B%_ABuQ7MqJFl5vfa$vT@1g!>Z+&wE7k9poJi zjbI%E{k%A_3jUt+YOiF_IeXBpBvDta1q z@G-|DVloxV|^C`ffE9M42MIBnAa;(K`0r>&3 z4dK-bW{YPq!v73ebmqaQi1B^Thd(PfQjf3-;0w4_f)afE=9n$KpDX~p0Ft~eCyGN4kAsORtsRu<*^2zw{q~eSt%D?7&rD!o}a2h zx7A|%jorE&zV>M|lEsVfxCp{C@r4UhGczgqg7wHdxbFt47bTh>%<|~|1oyYK%U;4l z``eim)G?_njG3pEk5_pqnsrMXiWO<7+lUTUng8ZDq+H1$n_}Fr!`|W~>nkr=ggY}z zknt}-{2q3!+OH;Q90Fgqx?Cotqn>veB608;)K`HlDEh@ds*>{!k)HYqd1~ChR$OPA z+$CUC56|OSq6fb4zOg%T6j&;p$RUNE?wSBJ1YD|)0(Z{WilMFvMTwe z!y>}itZ<31f~AX?ES0u^LJ^TxW0PF2ZIBEx>GI2+p;Um?tmP3c zQI6fGnhmt-gs((dMbsyi5*5{pBdEL|?I1!xjg>v$Na$!H4bmpE-*wRon9jeodIpDk zs$XPhJ?;~zqJ4vz|8=3OlAJs=+)11Ll?Op7UthxafZ{mD@d!oZW#P_1*i8{%%%kaV zt&yQ$I963h7?g*qXPHwj(oo9e6`1q#<23 zHStMo2}+LSXkoBm6wFr=m?EiY2G~xnl^qZXFw0nN&vyW0SRy95~AU4pwi0fM{C;O?3b+}(qO z1cF0wf(Q2i2_6E0m+x=idbeu-+TGjLUEMuXUH9p(u0H41xz9(>F53_Qiqf@wIR^0l zw*h!-sr4)?J|qN$?++FiusAH&KGu#mVbktQ0q~k{MRb2#J|rc^N7jB~81&HS5EQe` z!03Ck^vmATpy%|A`_+mYRGDx!dF)pn*gn|X8OD1ZtVsnHG2JvEvepi|u&?S_E{4STH<8WHNz-60E`hsW&`g1tpuVIsLvf27VP1h-ZI*+yXc=^Cdc*VT@I{{v0c<85rcJ`dqp~APBOS- zc$HG=oMndILT-UsuWh;pXJ#SVZ~ooyk37^r72EnHf6hBM=PoYNHCLMnKjN5aHcxXzoVzKmB7+=jo-+Q_`WNexIjLN6J5lK<9T&$EDE6=pI{?IhnPj_8 zgMbMQI`|tj#d8L-8s}<_-OZ|2qeQw)tBwyUU>6eXx^j;z0|Uon+Et`rmladx+IU%Q zIRZD9DjGiZ^f*%TxxTDWOL$|3^I5==P!VWoug;q)i9|9G%OCUTe(RkzNx5?wbCt$& zie#7DzNIcD4;>!S8y-@NZ;mdXhIeefYjha0=x|MqAJH+S+9%MFO9n)S3mCjUN)>6w z+BT7(M)|;jC!P5oW)x;kP=i>ZzCZ08d?BQB65QI4z*pD6 zRiAR-ekSU-kb;WKe>CL!! zN`}UpcmbTYwp&BoE-GPvfP+4+jME@AolKn`M?LU)h%O|2o{htAVURSmM7`-T%Z+Th zcIfmg9i`Ah1>Tj9% zopa~X$;P4Av?Q|`+uuLR*^nXKBS06$YDgI*Z;ld()O4j;R~nW>X_}h=pn}+XBJPN> zL8^gN{fmi_!hquEFiFdjS31_~Xl+JfBpuRS!pR%oKdXQ!)8^Q9Z*dBQJetD$9)D)> zMu=WfLRLXn2y|XKyW7HzK$m+=-G4V-R82^&GN&mwEd5Wb;ft>a= z-7$G!gm)Iwg}Jl1=pPigJ&8)AL1(L%3;OTq(S++ojDXR)^!nFvB|Ak2`wl ztS`?L8SS0SZIN={P{HR)k<-?HNAN}V(+ZYNZ0B#s+`)l<)9kqUa;MT@a0zph@0@%XwwgsBn#dQMr9xE zq=e6wkUsE-80lBQ(V;|ehu)tncr4wsxzQ{t#%4du_Jri)?IHqi$xFsWPMMlb-h9G) zt@Wdoa=dXEKFtHjIN(j=)kFC{+u+o|)TNP(+r<{ka{DDu8vXsB?jO5T;rh0zMsIeV z9`FgBkvvJ9bZg8McFOv^u8$MmB3ZU)7kYk8ao@17mn*SjyfaxR+vK{r>B7GB{i)r9 z6EEmYd7rH{B<|^URZ{uuo;HWsQGD5RAx-OhSo(Ep-~GaOUbI=_zYT|CQ3-s3r6QKk zLYffq`p$HtrfTMCvu8wt+@lfPwq5mHON=ZgMN#CPHL#PV`+GF@d*-ba9%u*M9K~cV zwos7{vvz|5TgN;A53ge2&8JoD!3k;I*5Q%C6!{|<9b?mL9u5{2?T9fCzUgneky$~F zj`XBT)8ijL2j1tatw}yXY(=idW(}1VYoj?)%lf{P^nA7cT67Qj?JVq^`Hj+rI#7pg ztMq(vbU>0>=u4o0lD}fEjDD0lXMQUcuXV7Wf?dmswPT01m!s#+VYffYe5U6E^0j}D zwPJ)%u>Xu2+Ao1C#n>NNT>8o4LHaR%&BRC*b`OfnNxs0b9V>7e{d0>+`US(z&CgsK zUqiS6CMQj>8tfYTV_{F9{FUw~fLJ#+M3k3pX~WJ_P1S6yq8_PtE4I{;C)xg{1u|%~ zI;X{Mms0%G$K~?#L4#9a_LUK!GB|YSQED52MWP{0#InL+=1JavAesq4((GFh2N{oc zr{|7weKt|BKl319a;TOq0u~8if1jcDOHeg@j1CuhU`ar%99O6g9`OySjGd5^JCnpO zD7|_RjTunZZ-H=3FT?AioKH+RAF*=?*>G_S3^?`UZ~#^0rR0v~6XpeFLzJeyq9f5C zn9-0u;ML0(9#VfE**O6Fwzj6mU+K)AF>S4MtZH~k82M(2r<1-)?Hg!tFJsY$!m!Yl z0Iw>YU4n5t;;I-Rp7NdPLA(5|z{D~6Rj#&NG|r*!a+c$$zMrleUii$Kc6VXbp;S?Z z=bu6tbZU&9sjQ8C@VUyBAcu`{MU(Wv4 z&OZRn(o5-XQ%7>eL$*H`ql;Wg6oOu{{Xc9#9IYaA0UEvs({*w7keCeVNGYZQ32UZ4 ztQV7vT|6Y437V(I9QXkWhs~%^9EI zDz&oOr&`^`%ZflWvB3v#L47jW+F*p)yzBk|+wd|w;q=qovX%e&6BNgb{KMvclRDan z=D`^k&6hxDqzoNb#~H=$#IAGG#Cp#%jfdoVez}+Fyv0_6ZU!~F-XpD-R0jU{pVSuM zJ)Y*B#7GafP>j!mUi-(U4iVZ>+LF8_j83dy+><3e!rbx8lbp+aF1U!aU4lx`f-Cv@ zKg~67rQO@@5SM;Z65SGKMAaGJ<9=MNO#M-BbkV(Jw<&W7`Qf958avVXVcAsMEIH`> zt>&xKrRufV1l27+HSq$d-Ev@W7&kvlRkNTWb`Cf(^pQPTZS{8~@4t~l=m+dbcJQ#? z9ZSJFugZtMHyGz~3BYs4&lhl03>?`pru`CD=BVFV>9u7;_ErQxBvOagGMtI##_2~ww#9SvNFw8 z(vE2We_$imwv9Qhnb-2m{F78^5mY1?;P=B}9c!zD>PN|+D)!HQxeez5(8Q6|vA3T7 z7&73P0`2d`18CEm*6zjZ!fSFti-|rk+765d8{DHxX9)*J4dN zrTTBvN9-e>QCo9lAeG}^;-z29joMp@_l)m9H9_h$r={*{sKg=czB0djsHZhqb*xNRz7ZbC#9qrEYR*;)E%y>l7#o)sa>3#V%;t<0@QTh%N~UooBOS`JFiP zhnoWH-@`&qICVUBmG9?Xl7bQpiuFyF9o|%nvCaXhB`Vtw2$|ntS`9;*KP`;UTX|K$ zD#l^#_)M4$PR?CKjMt)`y%@0(kj>nBe{1X5wpUAxuFgEb<*jGDDn#^A+1x0F4cl>m zG7<8uy3Wg4!F|M$o>ikQBTl^_QT)^{pe4TF*Z>-9BL7%YP%Z@25J?dkQ6_W*S+o+`6duK{8$xVNpj+Kt&Sj?h@-xw$6WlBabs^) z9k)dBtG8P6OF|e`Zra^`<6B>W-V74X&$eBeuaxNRa$|ma4oXP<{Ul$8F->;A5>jHB zJW_HR1SHLhSU`P)WqN|2lvW^I{6O$B+#oti2e*zmB)ov2K(lZb(qZ0oq5DE#yAD42 z1<}4ASj^g(T=Y)oM(g-Br9)!4s_-mx^!f8Cl2n`fs-%$vJn)y&qiWbe!00blS0}@E z{B^^)oi~HRNtJ&;NvFKnG*|t8o54pgfZuQ44A$6R$dp=T`touU=Mh35`lQ|q&C|o{ zK#n_sNWybNrjQ^8KDLMme1Vxq08N3e9^p`28H!U$rSuu1*fOBpet4CLon(>o_o7UH z`1DSR8nAi);N)@WvA_!;-gMR+S6;MyyQpk1s)|oq1DsWx7kK*p#TGwNsprP(HJT?0 z>))-;4V#2WW%I8pZ$5YK!U6qrLSy9D!@gpMN^O_Ywl5XV*MfWdfcFr;}STt_) zpMPo+Q7-SN{^OD!Brdz-|3d`#HCC8p!Z!xiCrvKH?+arPW91p+DHKzxMgP`Q>CRAl z3dQLC?E5~|!g@k($R3{D7#qgq>jdJYDlzO2BEM!vo%`=idwIZkAmWIN(iboYsG{YW zImQh4D9Yh7ewRn_Z(v&orsY*`|GzL9&YQt}9c22izCJ^-^tz2EMett)IK>e#4m(92 zyZ1~!?8o$ys;Fc$VK;-utQ81@7AV5NB!LP6& zp>bG1x1Ji)f}hurvr$&UOR*iX{QfXSRD1gkrx)Jwq|uS$8>m<$v8quC*--Oc5@3;4 zeQTiET2m<|1g7?vrU{EsL}!6h=k1%|p8BtVQfz=-wtw%*kHWsUQ`{2jn{rvPq2cra zbJicm2lxB;pZ^VSt+kP;8i4YE>t8|+#xC*d5FE9 zm}pTWB({`d7WwCs>U2B#Gx`BlGu;dp)p=U;^ROM6U;a&e=k%v-L26b>_)V1xg=s=pstmS? zDS3O``!%1w+&1mc{Wfco`1QO$7rO1_h)M6-Mf+MSAU@`fK3X(Ws|Tnmc(VDi!^-Fe zyeoMkf)Csa)y6^aWtcir>vNb|VZ2ovWA4lj&7l;G6>873JvLhsE0Z#99Ml%IXe0J+-oulqzvPjgw zmv+XD$D8`n4_3y##|%xTTYi)3=u#{_xYO0STqkM&G)N1VL9o4Ju#Vekt&?N@d1ZAn zvG{M3MaP>X(DDKn|B0;dju^)QkF%|%R|1k%82b(!E5(+_oZ0wM7Ih-FaQQ3UAgOMb z9xmt7WIl;KT&#cdTg@Ri%-`G(4n0ZCK$hLIQ<-XNo?}0{LXyCtI!7wZjMg^$eKN%} z|BW--*dLLG51;)_+r$WiYD;*1uoQ{emybvJmdUu%XT8}vcoxNKFgOP_9psDrxZh?D z)f1*3U%k=}ZDIGZBVgw774Ba6i@&9`;hHC>&!iSE7pfBr|S`t!TFy2OY5>~ zBzqiY?Rc&*4skvzm2sEUy^bEv8#?2(N&cDl7i)GKK0_?|@O3TBoP@l2e?(-qyjM&J?4olb8PT&l8`jomk9`}qQgv5;a&XHR2$-`4Yx3K z2pAV-9ufosWTTUj-p#WRcBsIW2KmN{=hb%7R2NnJ*Pm6pZ>cfdZp95!hnT0$<${2} zp>wYx{j&gMJRQ6e4k-W>fP?hrzlipK8U(=o-z?mw{{eC!zwChlYR>wmS==?nyOgUc zqHRGX20o`$th?Uvd~eLU-6lO|St%*RqS%CNj$XWRl80663q@`+#+DghJuPcG%di2A6kBwjb&@c=_;4d=EDuA(9 zHihsmcQgFganCT3t*I%9B7U_&LL&C|jP1x0s9P1rx*qgJ@7-jL1jkTpVt!%5SPfCQ zYv+$+5+zE`B9Xe;MCV&BZwgptGp652w&b~91d3>T^Os0o_ab6D%wJ{W8BsoZm}T$Y zEn~P16tJtmVQ+dxD7gV@x<5S0i9|M`slAH%2}tx=(RH7UwS;Fdvg^=T8@YwebP6-d z7z&1tfBTIJYlNSo?Nd+Cq6MKTB@b|D{Wzd1Mtt4WC$N7K%Ax!uRZtfAhSbzdz)3)h zLulu3F?=nGnLbj@>^^(h2A`;;ClOKC<azpR%jpI%>ND zZtVclQq8NVA$_kPE9Z$~028t?PLdZP#XGzc9P<{ppy{0btjuGt|6p?D`cn7Pnf3k~ z1v4Ule22+*WQ-+?zPa7|N#D1W>n%rD?CBb!*)2d;Qd&c9K(76dSM#1_n)Dme=5$#Z zQpHvjtd6)iPq_9be9+KW0;_)LRl__K+Xv5hC3+6hg-h|=qrDwOH{Y#g47?ydK?>xZ+$ zl{vO!A47si35nPKQR}U3$+Of6O$WAUKsD#m$svq|CHjsK370)=yH4CwiSf-`v8(J4 zj@DwVniM!qJ7m;tfD2IkHW&|8MyKm-^AFr($!UjRm!J_=kAZZg3J`uNWrzh(Nbuhy=7VRx?G+6LZH_lz84(eb6Z$-C269uj<+ zh=!7cjN8V^mjdihh2(Uf%SCauH;WE$1>_E(aQ7)QCuN~2Qk$=59f5?NcP-{OkyL2j zAqj$TqX1(kpmNSzgG8X)&YLG&?lJl4FX|vG*6A;mnKCdhcF&qs(?0F-jc2XHNN|6I zWJfDlEzH?)d%G(aBX@nYE(U1KMCGxWvPvP zbDQTp9ANq9ptynEhB3#jJy2q0HB2{>zR{@0>f4Z@HH4~F?{&pB$v!0+AJHZt#O0lg>{6^?^#Qs6_?W0)e5JwU2D$DbC&o~O<$9X^CyH9rp zDM0*Qlr%X{L)?T=g2~H$MHHq0SWF?RfA97xq4`j`RcL*kI7$uqJL+WrLFY&vm}vcv z8r;37=vRb)h$D^SKKd>xk+Jk4CN2m0?TKEivf=2H;ui~wj)eobykRbQd+k3~tR^w= zBAuMZV(_8yPB|+9M$_mJ9?hIBxj+mH#ox3y;WbcB&o2a81`dNcr%*wzzrF_Z9Tw}1 zxwa0clwZRmaRusa|0%ml3mR$DQcg6y8|}_o4E8ize@w2nI1WcjqgY;Emw5Z83J-T( zonX22F1?axzg7vl9{1cdV4j*4q7KHb*u`c*#PznHE2b>v4T4tY<6h-X!l)N8rj%z} z?JW24^7-+TerT>&gKfv9FCbU@Ld~<|=(9*@@+6n?OU3vhe>TF;1P~g#;L|caO6dN_ zfUh{<&9cnbc!E~>o6gIRS;4kSR+H(09C;HF20z|={52r_p)lk?(EN_|Qg!?lKlt9f z7{M@>7_ByCtv!a5BY0|>LSHgVq)pI8!z;VpKjtR|L(JSyElJ{$&) zOLVlTtoa&hmFZ;XchnqUFDm00%;Pdmhg+JzIuHr1ex#~|vStoD1|!}Tz-$esq$}uV3hh|$ubpZa#tM_`)+q~0b<$hK{57* z^tUl(Zo@h%*;L@CVzix#vJ z1M1tk8^nN5X2uV~1H3L&C$#j8FCH2^WO;&&p1+MW?{%YU-`&q>y>FhM{vIG=J>Mhu z?iZiEpTT zIviInaRcs4;~S-f&rI3oHJv>90mfSZ8+$3{C7Y04-XJpxl%1QBS&&GA6#5TGI7ubz z@q8KL7rxyOVdczTY?)Wvs^v(SC`rwaZ%e}=Sd5o=2|ma+7#qHJ2w~NA^$pMDY(}O5 zVjI`_*7tjZ5= zzE>DV5~1UbIMx)xM1GaKVR8R{VrQe?>bD$cQjtBm3^AS8@?%`YFEY|C37OQDuE;>& zv~H~nd#1a0w(*I|%)PM**v_^Uc33)dsQ}W_iPM$N%!Z=)U|JaNt4bU+p&#v`2My8o z^l10?pD}y-gBN@WEjxNyf?v51dA^j}2F>*302wwQc*I8mV%_%ojRb(cyi8~_?;-G>Adry2G&R6)rm5t@lcSQ?1c;3^$Op8> zV!epvrXXG68i`V_fFrWV(u;`4p)w#opf`HrEAj$5*7yJRqvIElwtuP5WqloZ{D4S6 zo`_OhU)0g$)7qBSrEfz;J8QicA9-s^K$kiy$FzcJNr3el-3|VQ0V22jQ#Nu3f4osZ zmf5kpZY*A{t_7{QB6H7PmKX+u`bSxBQlN<0F&E#t)!>6A3s;#4atwKhhNe{g{x7W%*@UO)$5g@1_NTv456h8^Z+K zF<2SNXkpFOM+1nN%!2Z@SqfQoD&niGaz#40iYn*lXm_k?CO0h;43$fY($sh#(5gme zon`2t#8~iIs5^~`V6?kMNlBWm0Zh!#ytS@GOuvN9-pnfQ6&)bto%BMkpY2A}Z* zue%KT4!R|eE|qBwmH=K=Ig}e+1^oUEmGPxDi<0uY!%Ue=9#gzlwo!G%+|n2GKMkkf zzvI5CzRAs`zo=?fZ^Ma9-(F(G$N2TaLqc$1y}^M0MhIs`KHr=<@qmkAA&pLRn=*s~ zGQbj;Oe)>4V3gZFq)6Hdy5L0S`*k^@FLZWv1_U2WU;l0+I=oPiZ!?jkBF$iR%>^FW0Xy*%4YoLL~bwE@Fp#T z%2o>Dj-(9XknX~3?(ngSEjf{DY#y1sr%4-1*H_tbOvfC<$8s>m1IuDb*VE8JcwVsG zs;xii1UuVpwVo_YBnzeZMn5m53qmzCjJd7=#gHm#upAv&OX{^M2pQvlzqWLMSFL-u zbuanpe=G6JS$`L9S36rLD{d!OD+fDXelBNsJBR1x=Pdx9ih{Dji$f$3u>P_Dp4R}f z05B>l8Y&7H4Gj$)9gKlRgpGxXiA7F8h)YCGK}$nTK}7|Daxp{bIT)y@ScF(Pcz6W_ z1ZbII;=+7lT>Juj|6K%#j*gCniA9EuO~yw@MaTF5xjpv*@WH@lU^56v4?w~Pg7AUQ zg80xOi4-u~C&|J{H{AY>F&G%z{_=F1=2Ul5r<5C{nwgo1+nl8OUEUVaB4we*OW05s^{RF|l#+=^2?>**Up+?@CI`$}1|X zs%u(W+uA!mc6N1t9T*%M9vK}QpPOI!zPPl!vbw#qySIOEcyxSnad~xpb9?va{_lUf zUM5idU$Xv>vj2xJ{1;tF$jBgMwEuJgk^Ej(5I!;r9WN?@v=*9`2O&Kl0!$>6R@~f= z&cLtzo7mcO7J~#Tu+4b!pS1r`_Ww>;`2R0u|3}#Wt!ov41p>Z2JPQiiA29)? z@)LLV&V*_5;};aC$g1-;=3UwxpwUD;vXSt)0Ar|O#Kmb=MZ%n)kUaU5amx*+7TA6+ zr8>=uRYk$aK~svvygaJ3W2u42Zkw`F__Y#04!wp;-_DguL1khN%-t2=UR0=3LKx9m z&?HL5lU|wdDUBlqmqq=E2S6k6^B7=S{RhR!wMZiIZRz}<`??&?3b2KT2+1*P&qu~d zmp0exUkoLL$@EPRg^x6yQxhe>X-+&UHa`QzPd=}AnVx}|kr!&&()&Mp3PTUy0X!6x zRZ{iB?+$$kWi(XwQl&6(+<8@ShV4!OBg~>sIM>5C=wzGA$qQHw$zz?M#6*gAstTo! zQQ!zLuIh)49Y@00R>WF4FZG10*q&?u4uY_2?ZdqlTzN!R?E_^XqO+B@TSPalr4wHm z!~iJNQnR+9G-(z!#Cgh$mMdgZMw_9P)z{ihqlSitged-5(8v!D-KN^Ds(>aml~y9V zE86^2FQ(U`=pmb++6^CxkMp7wa9PIcJl3Z+N?`2|-ScE)Vp7Vb8OaCcKLeuZ(r9^o zJN(U~E2b`)weG@V#GTT<WwP7@`pGsgA`Yx1~B9C)tN5d?6*eG)1HA83Bih@=XS@X2`iFh9kDKeIO(BFBa zvE8~{^27DO1$CNxvS_X8JvMnJsR7QkHL^z*%X)J1v0;OEQZj~JfGTTYv{!C2b_pEr zQW%5D9tEYxdJ4Xg!c+5!|C~nm)Z%e4!Yi2}4>~{@6o)wYDDt70!)h8C65r#N_jR>> zLU0g*OrC7F>KP!WixJ#r0LmzM2Gm11d9SoC+V*y#3moxWWDQae<0OUX6MQaYeN*$Y z?8=mQDp}-^IkLfwiE-Z5@%4hPn`+|Vgrs~|kNzp)S0sCO20mEQba1hcy`oO(o5+Gs zMga5DUL=-w@A&UsjKAsE$cM)?^{H|GL(?-Bb}FlsjiUU0Y@Rn=k=dl){Un2 zg-$@%zO3P1TH?-j6~ z_{kXg+mX{0dnM}f@pBP6V&+FA60iVI`c%q8O@9wG2^^$2V(6kye?wCs|M`y<$1c@X z7=oN0L)&-W-ZX$lHuWk_Y_hCaY|-vP*} zZBBT^S!+Ps(yM(w%+*g>VxA0GplGd82H0P10jn0nt4&baO%bw5MIY`MHTbFRew*z$H0Irr1{iNLOtwh%1%Hj>0gk=2TP0$C3}Gc zi)m*j?Oee|e5WCQbxn|6KzrdhxNqwLn)Dps%EIbKww!C(v!M+l`PLOO<5FpH3J(q9 zH3k*}C=QfYiOJU;NMx1dz%jEf*5rsaqT1B;$5}*Aa>Of4h%Q=c-&TZK0R%(?Ihtyqu_1&$y4)q0_EE)weSy^T%U$Ys@78b%eg%O%A_$(H4C66L+5pvHNY zoyj-pF5N($UwU?0A4ba!?kT)o#`&kvKn0OAbf-efqh@`+WRt=p=~cg?Kp2`fOQ>b6 zy`D-qF@^Q~ju{wRT$f631G#u>SD#4(!g=_I#cSH~44@y*(qhhZ z-x;|nPDweNjmH?Iz-w90i3rIzd-xRV z8VSx6TWY6@NA8glcC6I@!?z_|k^Vhf(S4~TEA5_c1Oc)SV=RCN6%KLSP*~^9J{2yH zS1(rUX2tRKh`EB)zQ71=VM%oC?eH8|xMSPhY=FEkB5p4%b zB}|((-_v!gp>%R#z0YcX2jP>uKYHJqF$C-Lk2R0??7Wuz7YK+0>sd>mz;0@xnMsBy z0QVKxSe2ChHq;so5K0V{ONIZ%3&T*u$BGNjBhy*OQJRzxToK#?3ZpT=Om)goW_JJZ zC+aA(rHi7XL<7;p4svmKFw-Y8@b6REY9P(NW4{aBBp)Z=x7=deTFE9c|F*(jtmXXv1wFl3h`v=NytS3KkfLHKA)i!^ z19E|_d%cTO;kDQvg^dK}q5fGRVyAN8a0gUnHfEDae)}?zxaB7R_X3nhgExBIOMB^+ z{Dx(-tOYxVB%x?G9!vMSR(^u$Sm$3@sbkO7(3A{NLhW>I+V0qbw5{ykzEgDZadAiC z-Uuh<609YbyAbskrl;Fmjl4eU8{ghj#u+|}) zYG`?};83qHIKp-=+Hp;@kqKmX1#5;B*^uw~RNdtuP@}ucaaRN_Om%aiFZI_W*`C*1Xq4bbOTk1*YvaU@v~)bc_bI?)aGt5 zb4237khLEtI^@}V{q3m#9g!_*a{gX%e4y}@%wF@`qrzL+3fd_jc~9Am$heCZ(S-;= zBa#w5@*OV9kgte4(NJWQBd-}Aom&-1#Ln*{tYZG?#&0XktYrv;#10n%b@o%HB>905 zs)re552ZoyE$ShlV5K^TGRqE4ocJNWs>aX7eq|bVro$1fx2kZ=zfe$;8&gxr!Jd|` z)c;Gb5PH7SMw5GN0KWH{x*^Asj16H$Cx9a2ATOW(GCrdBmRNvwQR|942HqI`VHm*s zt|pyp%t*oimGy?5JjMzn-)0U@1Y*F=Pb&3HE;O!NmgIRT%SQ^RjpS3}Wghn!sh6e0 zYvT1tyRvn72gu`xni%enM-=?2XsPAS?)#hQS5<0Y@Y;|*9rklA{sY{dib_bBp}Fi9U+I&E-X(L>7lFu+495t-uk9Y5U_D00|8BImpVBAO6i#r8urB z86}?CJvKHB9QJqy{H(&#CLr(mn?FOpCJ3b+>d8nkj&^J@yTbwwiBqX8Pw_}tIA_?O zP0a9|1Y(#e=<$(aFkp9L*}!({Ogdf@S>(Zn1Kt|fh53ARlf7YwsXTASctrORoiO zVi2PS23CIIzIGgW4jLeC>-StF_jBJ|xg(x5>%UZ4J<@N+$m7tA)6xr9~;S61duHvoJ&w!c&>JldZu33i6_HDbPb=!@?Zfe4^vD={Y!aHugmh;G8-{-GEW7t?#}cCOKX&&DTX4 zhlL9X!>e+Db9|vAgET>(GE)g^(E(O)Pk&JH$YtfZsL@)g23Yc|bDegXos!yb*}a>? zkL4P^a0>CMvf#eEXTZ&Ckge1xrcYw@%49WQmo+4s~X-(FmTH*$c7S7&;FW$9@gPvWdb8P85VFR z#L)+fG?a{WUz2<%9f>FvH8E)f`IqqVyARQ1ThY@D;{R$ou^z^Y*p!fyQ4AwlCYslkkiCA*y-z=#bB{gy=yB-uQ@cZkuY$}5jrnKF{_AR8Mk>@_Y3e|0 z@wv5V>%K}fP*DYs9u_Tja^bEj=-$&V)^Tq59k`cbMh)@};IkY|9gGP?H$I$II`&GAe48ozb# zSuM7k5(to{Xmh%xB4uFg_By^U^PyHrwca}HJo~HTnZs3ixu+Qh=zU$Q;AyomdrFtZ7@$(P3Vy*iX?b3tzPD(hAOxZ z$0;yzm)d(cD0a8Wplk`;)4h~aP3=zrB_>DS3M@%OJ@S(d>Ee#1Fh5J)-)B7Cm(-q? zz=;}>dHZSoX68$?O2&mzLatY!sH_-tchzNKv^-Rw0I3X$Xcmi43Y2gcp^xk zAeIBbI;^~@jB!l9aXlKr;_a_&iDOtVMK37YYix&5W=Gy@Ta}7Mq%4;CK=|=++@(j* z7EAEY*2@xau*9qN)gwTR7I3dk@sKJYHI}UiRjoI*q=;#oi(N_-XJU|UC&Y~bt0-b- zPuIa4znZ~QcmoddB>HjZBxq z&rvA6pF>v5cFdMT#_$J0#rn$JY89 z>N3?fBTb)zr#Y+7H7P&s!vIxSlr{&6_ACM5p|TfX@`M6(e+KyT9=G`p0d+k5#|HK; zR#W+j4PH`Mk&E`2Kl95qRqU6g4GNkH)AXt1>BH}3i$|w;G++7tm;n^+8!2P{n_t%@ z)v~RAU6zrOllaa>PM$S3UDl?O(xhDi4#OPY2NA3xBvl#(iN}e75mW_vwdtY1M|jBA zF2`O1)Xu~~Q+G_lRQ?ndLVOM!wL}IKclW-6O%)HUjC|I9VdR3Cb{#%oI$6$-4^Jia zN*kVpqvEZ~NqAXG4QZXWZ{MTc>wM~`j01Z!i(!QlWzY)QPt}M!;qRtVxNJ7JT!6|i1v-L_fG}Qrx~LvGG_}* zLhmyQ~sDLmuWNY*Ru_yDxQSjOL_<2JoCtLr^;|V zCJhY;hLbLvHG5M+v#9%ikii&pQpKGWZrPJIdyG5@5%W|S-F+G_m7-)J+si3W?NUgt zoD6PLD!XYJtL1HJ<;kW^Q0zXO<%+@hLnk@pZB@@d$3qh9Tf%+2)eP;h9ejeqn=y%(G>8=dZB91D9!UOiQk=@iBJL3};@rL5=cz1H3J(Ak*96D7Z*duu!Z@x4HtQ32}N)t*T(i!u};=DKQ?9Hx_--v}g6PLHxL}9g3OL z=Q?qmINxVPAFfThFG|ULIVt$cY-=pM$f|3~t3aLyZT%-(?E%Ek``590?Bg2Qxq^8} zXL*u@9`>ElZ8~K;RMFCtTm$`HGf;{n59mIW3>JR65wIP+D8}N?&j@!q#Q2qn#S1xH z2)n87(Ti1MnMP@z37kjzd@tE6ufE6pc$ac1@EWA|&AC5X_c!YlpF)7_LbAs%b(t4`tdimk6C}7mq zD%x}g`K0Q&E072BH{z$>pmSsUazlXr2(r#D6LlF}uak2*MJ3zLAWklfZx5jP)>)Pk z6TzHqNQFbDv&kZucyBboDvnz(LsWG+HM1-pnDW%CibEOb%Au$~$pnvl>`9B>m*iRX z|GSXda%$KbJ**J)N8;4#q9o0Y3}jSfy_gO{8|f z!3B;>uCcGKuRX;ljh9=7e}>C)?TtMS(Ot7Cin6zKaZmyZ9=&TB6)qb9xEbkRyua(p zG{;F{@koyzIUOC2lfBJv>XRrfu9!)qS29;5VBt>WrJbwc( z;&X0`2l3vO!9P;Z_=>_Qqn!b3I17vl0e^KpI*%rYal})csXqcn=03oaVzs5n(aKe^ zdQ9mK#cU~}V#$UCgcz0loT(wW;HS8>- zWUuWnw%cwn+Bd}Yh&W+El4T%a{{0Hd{V-XyM+jH0xgU0t#g`)4W6TUMs-~5FonD4B zcnv!{R?Ic>42+je_N=Uel?-sMoEh;>e-q4l$vw?htUqmq^CxG?L)WsMRJVk-Xm%t=EfS3s(JM>=1<5a$+8 zs}KRv>RJhAVO1~>;`}fMqf=LF&~YO#qnJd%i?=c_|4jn(XPcPY-z3;Z+Jr!UtpVG~ z8YsTIdf9pPRQtNbdL4A=mHAy5t2cmu99ttbu*w4BFcL3eOtQp`6w(najOU-HC}OK~ ziQj?4647D-jvv@%I4k(6n*X4~(BO~lImMTb?fF&jN(R|>WQ`T0lZw*GFsgbAJZpz* zX5}fuY_v0AIqde2+6nHqVfHMsUrfbNCs9hRP5|rUU~9Z;Vwwz z550-Jk*lHY2OW(D;i~kxVzZrmNKd`K(^Fx81AnwrL@VB6^mNNTb6tEkwB(|a z-PYhefJ~kaY~~)633R#dV^>DrO&Z?X!f`oBynHSf9@><3)hvI(a8=jzJZuOuU5&!( zvwEl71otd;O*A6#qmm_BcT3{HB0Bw|MDsI)p{t!5xiM^&Wamta^SxywjKiNNbs^pU zzw9`U3pSSPy#Y`1&lcb6s$KFf@ER>#0l@sSVl%ywkAJYAYW1xQU#ku;`SKrt-*G&A zxJVGG{phkS?$_k#hE=M!xTA{EbNP3p;?pl5W4Cu4-+fT2S4}F`+;#E{hks+T<6_4;^=iS-U}6AtKn-Tt$hglc~E=AA&m6NJ%EQ6#nY+{n?uw|p-BrwY03&o%2_k9-qkZbHn0nTHEKRy?&DiYuT>)QcwRp z-OKyEZ})1__41_~lKk_L|5|~11(AOb{{y_r&v<+CwUmRA#-(zgbE__0%E9AP>NBgx zUs={}uwZsJ$e32z<8bOp))P%w?jxfYwnLO_8liSq+?E5&&1p_Fe;Vux(IlT9|cZ5 z77`fjzPb#Gj^%gEEv&Xvu}vEq(*=zZJdw#PiNGC07PSxxEF(+V1N@2nUQ=^|!(yKV zFY?~pQhwk`L1*K?A?{!G=X5TG+llwC@kql!>YV!E7e}=p)nn{gP!&udD{vIm^4&>} z%)aB8dskLNqBA?}6xjrBlaPad_moS0ay^lE!!ei7;vB@CMDv)Tn7$Ge0pzZR+m6S- z#j_8BpQuUkn2ZQ@2iG8UP=b5K^E#{ws1`Oc-l_{()i1!1TbIee*h_)JVi9Wu+CF*%$G-RHH?2D zVdDg?KQkUfA;vvJwp7eS{AA&MPbbbv!IFXoFU)@cOl=kW-8#o!!b^{=SXa@v&%9uO z5bapbh~9X#7XM5b7TXU-^~03<$?9H-n)`PBh2L{Ei$!ZZxG#`i-!{A(nurtAoJry; zBq=N@H?~7h!@ywp}2Zo-)FiVzI1?VAX{mbV33Ha`e zXCc=(R6svdxhhPRs`q>5P4fG~GAT6unH0 z+sXNcMhKxMDWeo=0WclBS{PB)#x+%#NYg{;5RVQ@Bkd``osEpZJT0PUe{S+tKfq%C zR8t>*Aetwpeu&y~ADWQAV0ys^uBP=P4m@#tpj>ga{d~zeD|m$D6q~u|qs`53MTy+v zX99}tdm2e3ns{Fnbn8aGt0YovFzKN3LA)>4SiQJ30@5W6>VFF4+n@lp9BAARc@90p zX_;O1!9&!C8BpaRI8nz{D;!8Rd37)E!46Sl;IYPu?N1%wew~kN&y+Ybpfrd-ELI51zrNS z-^i>6O3dS#Ltv2nQyL)F^Nbxk;*~3&T`67F!P@;Ff);)l+Zf>6% zDWOxwVSA|V`S-iZj-KdFF_XX`vVg43DAkd8WxgsCW+;VN(>(x`=p7+XY8yUXZ~G5W z-0(m7f(7SAue$2zV}ouviKR)DfQMN%jYu1|1>>75wv!`)OscGi zW)ECQf*GEMY)C8JpJ)RH(U28OUxdD=qZuny&4Ye5>b}4bxOlzvsFdUNd%R$>t6&tb zmqplfkULdED?u(XZYJo-8ZtF-y=;PI=BZSk7kj&13_>h!k|kUd2rdP_$(-MCs!lRvHCOopP<|v?WO|TD}A?jx3c~NTvj5%Qoz{D zeKUb}%EFT08QJr(_O|1ooaqej%n(t;)C04R);jxmc|du_|Np2>Td7Usy)0!FX6mcR z5ZOw;C0i%Pa~F@y2eKyHUlmGxa)t%Dt9aq??8EY2pCG&U^FiX9ve$#B@JZ)|MFwlv zOKRLo{y=Q^%5uK7cwX(?E7pA(`fGaiTDZL3QA6~Z$g#=?e#tpZEc_&pL(+drLoc#t zu#E@(?^b|o0{>BEzZPu$nVdZylo2|h&+G8{z7@AOgEfCP;e>l6U6s@*OLc? z4C*gbA$(@vh>Si4*p4|8o0gQ-i#z`11-yzd=CU4Fod{y$1?ciuv#LY&V=(uY^|pY{ z8H*M_!q*;SJ&}^^4ac+*Ng(l0 z)e9a}TqIkVzT8^|lSCe>byra$@o9$Q!)J z#Xq=#?*_q}{iu@0dgnJR!5ru{OkS8lXlsO8J|ouyteP*8&n@aQ)R}hNqHKaag61Cw z;3O1*q^vc6{?i+JFYfFVp_pAY>+Q^IkbkMSGMdx2Nk`R=!tJQUS+Tw*X7cP3i}DIN zSJ}{%)i^YJ=FhZ6GK@Fg+pcLvs^?s2(Y2r^y=dt|9x7%gb+tv67_g|XM6cc{2&F?S z*(?;p*o+k(XbgPFE_|%Q{-;7sQbacXIg2`nSo;`K>)~bn8+oQS+~%UF^6Ua1q!(Op zAzKwj$|0KCnFReTWfk>OmO#6ZI+ns-n>cn}(wvcH^bXO{txuUZ@kHv-6@@IDqDoE0-{~UGo>1wI7lp@d@b1wS*9ajxSc%_xBq~2 z8J|rHRxC05pv2xUkA+VvieGMw*Xn8$_kAGwA}unrof3Y0hH*ow>ghu|Rm1WTZmC_4 zt?NHPm*>{9Xvw9mY`$$e zfrz#pOq{{wxmwi9 z7Od+$9>#VHIB`%paJM5=uwQb*0HV_~q5F)harJas^-7H0E$i6)O}T7Oqie0+$#So- z^`UiC2Yae1nA|EER{&Pd2iV3S)ip`eNFx=?f;W%Z#f&v?N02yj(Qke)khzH(vC=p<$6V3P-0sYBbgL$~+&ZMd%4dTmX`liZgqb}n~N9+L6Oax4np zH6`q~Z2NnhfGzzA2Wr34dbGkIZ>=={2C6YvFPMc9dlq!|^PNtKRiksC{|z$aOF4m2 z0A64!R!E8KrqhJQoOyUvpWqSk98f!BT^7XAQhLCMDnC+aVE?5efcseT=01s*P2m7l zc4OtJricq79?+!48l6o_I(@M{bdlw^gSWir%kLh>`phZPc!frd88@j>YmqpcAjkP( zU2N0XU>`|SmN$_&9~)k7B2VGZ?5;1dwl^9a6~>)0Y~P)tu81H^|1|Z898`l>hhFUW zDi|2#6l*#f52Dzt=tDbB-vutViF<}w-GqbZ-(Q%poogOblf|aLp^*!_s}CzgSQvKp zeC_l`Xl^S}zN(zaW%n+_jSaS*<9zlJ{ULqtQVA*?FTfgj@5OqIFQUvkDD@(y~9nNIE_X^*1{$8({5HnJP$4*`ne-;Jn&}|Jt z76&{a`=2d&5^vA9Gex3zDX&ASGzj+N{-EGbX%&RS!OymAfc59IG$yBWhu?@8bqimm z9cHN!rNs%9n}!12e!f{g<{O3WBd}xxtl_uoLnoHigEgB)orar}i?X@75|B@d}k;p;kgge0FwI_I$QR&~AkQ1%IHk zRtmRSA6*U$Aw|?C^wcCh?46sX^gxHR+qv5}Zv`&-m(L^$ry!zYe*~8A@r38YU^;&{ zKe0hcb^MC*p4M_3rkSU7xy&ZcYr}z?Iw)EGN44%m%o6lZWX)yLrNLfo& zpI0r6B{a)SfUSSv*TdYz4pxW%031U#m-9ZgH-MWGQYLf{L5leS>_C^#DFofTK+nWY zWtaLR)UDI7VtsiSF^+yTs9ca-xYKh~`*R#O5WZCuhIi80tdYqD7QZ~>fn)cy z)$o&p==EBD!S;-=Izcv3F8^GGfW6*{jxie+dAdxe4C|GL?WGrsJ!4CTY;BL_{*3+y zxMgd>vu zM24RW|JRtctovRmRhd$Q7G29uukTuC0T2z*|{QIM?^51f_G+p6!b}`M- z($KAS+QRc|-ltE~TPF<$%zd<-sK?_MCP*KQJ!=iSYJ#uKnBdfhT!AymI+(+lXAjDRs1T&g8+mP&xZI zJ=FdLPvF*#M)r@NF9l2o9$$>{U_ywLusd!CtcqE=Ne0mdaXDeuRtlzAG1Vn|pqRrM zdzw9P{;0MlS@!wON~6fo#77vl{o=UkQ_zsYQeNcjcg+09v$sgG6 zN6!3wTs~dzU-vm1GLz4PzX%twDD@KPS^Hz*7iWVvB`d2cnK1@t3LIqSw`$N#RktUO zo@8tP2Tq3)V^9#q@i@nR+ax0X*vx}|SZ__O@69_nXmF8THu+QQpllPMl5^U+=tKM) zo+XMZIkl$Cu)UqDX~m1(BqY2fwlL>x`HB}shYi(Sg`kG)x1{MImZqytIUM?eTNa-;8OsX?h@VkD#XpWs4;k=L06 z+rNK5T|ryjWy|Y3-& z!>8$XV~98rcgArD9FWbg#>4S$4sf@&RF;wxzvOL zYoias8kFvY&Aab**N?c2K8HA5|_u#6CsTE&?Pkjoj5%-S!%?mgTwC3HFm{++~E zahB;Xt8}T32|)Zm+^yROT?QUhi?N01`Qdn$+F^PI;Wpw)Vt<&}QY0HRRG!m?E1Rmb zsSuic>c|A}=SXexz7RCJJc0GB42Z}aI|N)?Ol7G|Kx%O>Wat~ZIDl21ra2|@`t!Y^ zM~D7ywhBuZuQxZT;32x@T{lRFV>e&rZ=S1g6{9MT^w0QRgCrenUwKEOk-~@S)A|sv zH0|*#t9MY8$nBkewOW8T43?c@HBayT?EzgUb#GR<=m#p0IddJ9D-psM(z>Wy7&) z*#*2A*bTV!%HcDy`%2Ps&KV@&)bpzM33g+s^hIqFVX+h9|4pG;3lC+4ASBQeX1N%r zdvPGcBN5DDB@66MYp^`q_oU{*SZ7Y-b%?L7vqaWmr4u^O_s{6~j($;4Wv2-d>Ji+J z=DFu#3iQN_ajry`YnU*L0}vq)ciL1>_RoZN^g_&p+eI5efOjwp**Lt&<3fTTKY%Y} zH7<$VIxD~|*D4I|9t<`9aaD1z33Ihd0X#OJ%0d(l=$`08^9NtGKejb*`g1$NhGjo~ zcb%w$z2MI0>khyk*44=H!H;Uo?bnE-G;;XKMp+9!#k@_~RQtF6eDY?D7``&?S~Rev zFzZcpK&pW4TwBm9z* z`y+>XSKWS!F)LEe@=R@*J%uj(`qrCt1(lg1^i_}d0yNFCsx_m3_&%tla~g5-`;6d> zUo<%e{>L5LSz$w`S6_HDA^ zk6(~A{kB})j4NmPFEu~o2w?!YZia4}PCUL|Gk4nh+puI;q$%E|wdCf4J3?}GIn5DMQ4ubhd{%#RsK7A<{%+O|D5W_ABcJ@_VJeU_efZzMc5>g5B|YwU4Zg^c-Q~JDnDh zr%p`v$~t)lX`9cv+Sgac9WQmGIeO z_coviWlyI?(;@U>y8%S;ILS`Hk#1Lb?K$G{&BK4WeM%BYyFAG}_jNH2=!_l3G?nF~ zQevFe>9pXt*nS$JTb%nAnogcHQ+D?wc}z-%J&+DlG1dU-9?@;yhW$xQ9vTPMO$v2; z4vxyTIo_q6LC2WcUP2^T$J>p- z2+Dw+c{`)=Fmy&7T%vcs>^r*VuP3OV&%4byv?v1?pJp!9jTzd?xZe{1OWh`UL<}f2 zSB5PS8@ks6Hb^$0@hDk%^QTW@MvlJjd>uM1aqlYzzKGaJDOE@$>W4b2A<~X{%DRrn;Pe0>^Gc4ujqY#Ej(P_Qknn7B@8$pMbUl8yZ^*->hO|| z=WxiQs!t*-iOLSY`4<||Dzi)QX;^d}e!@N@z(!{?hiPuoy}~=&@L5_bqwgVp9J1;X zoBN`1Z2HmZqkGUWjo)pnO%ND8qf8?8u;IS$^y^V1p};~z>JT;&c(lCeq5kS}FbD_xng#Y1>nPa^5h&}?hq*<#bh?77!d z2^q9JJI!6Dpg0kO%mgmJ1QxGrXQU0dRP{l(Zwa$z!eGn-Snqy^NvLC=iuQy1b8j)2ac*|lV<-;7(Vj=2 zJ3$3Z6rf0ei}COkGPeHDZO1wH^YgA?VQ!B`fxtk>_*q%1>Q(}J+jLGbEE(f#-1I15tZpbkNG zsw@oPYhVzv;wUM`82e`=bYt|!@s1Fbm2`B>ptF>i6@*-o37zC4pkN8S(^;$brK7@! zJC+HuJGssD=gi^$ICn+tRnlRdgs3{>H!aq|{}LI%LT;rDQ-a-Z7w4`bqIh+7aS{sS z#%$;vi}QKMT2q_od)a^>i7u-3hBdBg!AA_xb2M0m&Zs3gP#`scnd~|jHUdGzBN{sY z;%=vjsG))s$4>vnO;h|kobz!%w(wCph0xHMw6%PXpgo~X9brn+dk!i}L)2G3hYpx- zJMJdgFTpK@S_}@w*Nc*kzZLPJTkW2+6)6x~ZH)kDrOGLjV3!&1eY-QH8FcBmqVvV~ z-&-3#wO+DZeYM0F!+j{Wg-}bbkMa>8F8{SDAsWaGIH{`uMHI*eYt>|0EgyHOlYN=D)Mk5$#Ac=H#GzN;B?;_ zO3V(_wI9Gx9XnX4UnbyO+ex z-x-F25$T$*Q6F()$*#`Xk0rS?A2G<`wAdNj8-EOjO84%PXhp?RZ4NdkNS|SF4df&M zU4ANGex%22n5q$*fg6{#MgvfVjHpAk97U~jI|U3bj)N+y#R~=jl;Q))3S^o8@tDQz zwoM0EqW_Z`m9jr#SYN^O(aPE^tbRB)gME01j1e<39)0D7;3^AJ)@I`K5WnTGrD0KI zEMnn-Vh|Tr>6qn@FH`m}yOKQqUbpq`zcsr{QQv^%q>_Kn&^*{nE;prIs7r@O<+v91 z0ba;XEcv*Kw$0CmwMm7lfBEV{;Pd9SlLyIq;@=EpH2qtB}>Nti1mTCvj(jN&li ztVV_7TdK1Un0`tnbFTW&1f9T(IP|y`<^mt^LH3N_1A zd8$ow5hqXfG6zecME7f?%F{Aop?lkP<+xzF$nnRP?wO0n)MI^@l|A5AMo|>13Yox{b^XB&o<%~OU&)5W0t;eh-zr~++Src$(96GcRMSG@uAnNbS{V7kZUhF@ z3<0EWV#MkS$CNqE;q<*Boy~luqsr-( z;tWWa3(&H!l!xbNDWM#?V9dl<)s;{Y2Y>9^UV9s;te*1}(IN5g z#eJLbjyWXXrQ&}bwV#hk=qEO-Pmk{;3k#*6yA=83*wBNuTMZNR`mM-JGEeBta#(<_uH+GSqisA_sT0hw?&OVy6y zod69KRT>>zS9sU`Hmp*g)I2odWf`UQbWRSOVeJGKi3V}NU~)5@)?I0nbr4d*FetAn zyV%(Jx$Hyn)pVlm8oC=0Q3}aPYb(PdLUe8gYOFd4q?WSK#O0|LXm8){&pJ9|7gE2| zAtD5x&`BGX+1(pn>HvtAL+n(CDH6$u!BKm+%%v{f^F{mPw#XL}6I6FS55 zhB7S0@;$VpAe5cge#bKJWt)5aVuzktfs_N6cd*>4g|Y__Q5Qa(D4t{ zQ_#6*>=e-U*OtsMRsFC^t@Pyt^9)wByN$vO(VkfT1{ztziNkhpS;67v71r$cSP?ZP@(t|$;D(j!)%4)t)QhQFkVYtCG=GDX#} zuvwMl;eYLU{TWf6s5$;per*l39Ac2!t-RjI9&~&AoiIxCU^8^*qD#KxIuIcTey*b+ zo1;uiG^eG&Ll3GPZG0)poEZQ~@!Pp~rJF;gJbw*`aKoHjrsYJA3D}bj=?L|2A~z-a zVz6p=V|)yK0C4p1#482jutuE$V?D(9ma4UJRHD;@XgI*SIuPq>3N%-Shv@WMB%Een zgoqvq(jvr|#+wK4Uu!CKrXHoP8wmp&TLGmsuVQpjd}z*5i&ZQq{>%CIO|Md?s96DV zj5|&ZBZz?kJ{+fo;h7Cd)5{5EkNySS#5x?+grtA5%PU16kha*N8fPJG@s<=Iz1|h5b?H@txuGaWlS%W(1e17cJ_l z8{Ruxk@b2i>}+@Umr_bh3rccWgdwgIxW;e+D=+YQ{iQpMI|*!yv!t#f78}`NeOJ-L zUmkm5zmQa&5YSk+_`PW4nDUv}X-nOr0QP|D z=}Z}b1~m7ZeJHN4|C~aou>zW#`3&#}^vhR3Te}tBQ0$xW5KcFJD-j(O(MG-oIF&Rk zmqCF>jk)rFnT+oi&C_cLi zUek`ObqsqV8-2>94$;h8iiuwUSY|JKb z>>D@NUORe`)N`VcsK#?~9QW@ueAh0&H%k=&9MJMBe)Wt`lEEq$o>`$cUdSznOq-UF zhy2(KbjP~P>aAQc-59$_aMw^`P~X(#Vsd#4Rz-2+1kHc$Qy`uEB>6b$~RsB_YrB1hXZ#77!;glntI zTYNGYzxk&Mw6eIAO#%V7t;*+&f!&bl*}~qCe%t-uN5Acw0p58^FTM9f=N+;U{Og!# zFc3{!>?Od@^2t5yA8TSr*|=*p8#aGhE7Ck)P8uLuVpSg(8__4}V4p>V1S;f@*KsSp@C$6qQo$G(@6 zDNC532>&f{yDm3QdGgVQi}ZT7IxjbV@%A-J-S)hlM_P?N@*bC$^o3E6e-T4croQoL zwB$#smOVCEc|-$WmgGl4eUV=5tN)HiL}Wlh-lUceg|P2|a{Ea7TjN>|7-xUFMcrbG zTt}V6Sw$;zRKlLb?e{V-vG$5=!|Q56Nnr{$(q0JzycZl4^z@w`x9qXcNys18dfC5> zK0wSC&0jPk#6XuEQ$%bk8pPKs2GIqkp{9723g`)e zTb(G7%j4fK4+Yr0GiP?p)NtA;D@48X0NRybGncSJp@)TnO!muFO6~*#aHZb-(;1oe za%J62uBYTYKf{AfJ3J>N=w7p9Xrl3@-O3cV=Mpc6Cf;_49E_=3h>W!4{|E3c{=0cy z$kFE8BZ#qFwdSs)dfl=ME&ol&#*TUIuw$as(j#GHX-N3C9nnlu=4mmJIr;@%r`!$_ zSDmd|J|(=+eI6MxR5^g#tNs~ATC@V&dw8zSm1+}ptf3^mNeUaIS<6UM!~vz=lY8)2 zfojg)P4R+fR^HKk1b@~?jp^h?N?Z+W8nKh1kW^&#k7{iV+GS3`6WQ0d4A`V7+Ww`g zsAgoWZ*{t(hFF!Wb5SyqzrfL8g+|IUi*3$$=Tdw*9lK*moHh2SB?_$TnK_7Do}!=6 z>8xYs8rk#b%OTd+;U(5JvkzMb;iUAj&U*Nw_A5qE!u>ihDz9tr4=o0w$< z;6Ee;KU&m3gm&XO1i1VliMZ|MstK7a*J|0a^VN}I1on;De1k?oz`U4AHFMRZ zGA)wV57Zn!`F9*h9F0MN{8}mRl4xGgLz}xEJP&Vuo!3AwVFs-9@*wBCG4{h^6CKr{ zr&`RUNA%prUxkYAKDof7=4mx^+Kx_^_(45OWoLXTZ=T6*f0#6c!8pG>pf&YsL-vEn zs8=m!uu)L2&`f$Y%kt%}?W$qjF)e%FkL=G!PrS(Qt$@YqSRap>^?EqC6L`l;YSdVi zK?JMV-7&dc_zKOh_zPtqv3cN8x8NL0SRnfOY7q4sUXl!`Ll}9jjo`1$Ll3y7L>K_S zJmz8it~5g_gw@4o=r60Wk84O6o}CRW&J^^XF~86Dk;tb%F=NlWV?h|47W=i{b$XM9 z^0{Uox%}=4Cw}}EtIp_gij=^~Ti8*Rt9Dw{ccg+==)0^&oVe{8mU|j`Fc3EdGU{t& zB>ZU#A7p!k@8?TiP@O^dt8=6^%I?5U1{!MCxJ5#ZT;dRNN1yox;tS;U1Aie8gD~8^~4x)siWy|C$cObT(RKuY&9UImYC9;9l|(8NZ7j zjouA7C4cQ-sKGVQr(hb~+uqSsuL_%+DtY+(ePOwzS0ZqzAEej>XF3Cv>$DS`5SE+Y zN1~dL5@wlRzM|bDTm%dPqr0odoa&i(6Oog{+lfNkiV-}MLQqYZ)_HxV>8|v^T@X$t z{b%L;lqAsNZLPx(5H-%;yumCrg|)@`h8YRpekUx76gxB9XRgdu5zfCK#cX9)8nJL% zbtx7u#vtEoMXH#keUPugOn|Ch`o>)1EndZKnC!4ryApl>wA;uVdf#g@Uo+0YBAGh( zu%sKy;UupoQ0Z4i zPfcAVDKWjBZP5B(d-dI(hiS*RokG|T5Be=5!X8)X$pWGC;fQ3cT@rzbjG9_x7SMU3 zR^n_xtggb^$?kL={NR&kD$ZIUDjvh6fp0o4J8*ZO2mI7MKnqw>0qkA8v4D7DrIeL( z7`@oETH!;mG}YW2z`l`0)yvb}TAi=hp$Vv(a7b@^gzv+Dm$(7$z4cIDS0tNgOT_w% zis-Y78OQ8wm@Phx>E>d<3A}WR2eQ75HVg}Gn#H27?ShhPbYwSOEatC*W8S>ruxz7^YUG6lbrwHGdK26Hlw}=w+}#|l7ib|Oi%Ma2mAQ`f8XvrWEPSrtmN#G2TQ9H z8}h>+_LhDrLL!xW7|he85*IGd6*{OR-wvuid3ug5On5eNJ&I{DD8+o&{l@qW%dx2 zz`&dmGeZz=G=DT9F|@lD7gMr|0F#RKG-I?z$|XLoi{BSNNYJ3xzD6gpf=LS(MBMvmpD<`^Kj8Ky9089wj*|!^ z<201~g~7j4?=-r3PU12K31B!+ZlSaWlFb2C&mlLrnD3EtMShe2%X!xALay1 zL>A7VkJ9OLP~sExN4aGstus%3_(dL+!OsN(q0}MO%!z%+4OdV7guU7YNF$ejhSO?_ zK67fNUvOLZ1fC&I5M5KBJTp(?6lRBso63>9P-U#?K^}h30|f-VRvbTeFzW<(?VbES z@?CTn`#6`gV`mgnTE;Gvd+h-;RPX!_FbubnaC}%%d&vNcBcH8^t`UEAc!tuOArwgwAbQusZmE$+R-(Zzuf}t5<*yD{%6{hUnM}KC2(n zMNWyI5GtDLDGHuF`bx%kcn&0e@&GkKIn$FofEqOVF%TlAuVWH>(a6A6HE+GfexX3- z-@4v8DE)Pnxror4T>ZR|n_O|fr;PYMr*VSJlmtOLetJrh&+RRNA(fT0g8;xm_M6a^QZp%0*&&81P=z*F>cs z1&W}D)@2`Esz<4nC}38*{=E0SQ-oM8!^kBaJ>7DuzJpq-1CvV$s@pg|^wNOyXJzNt zZ$qtE)YuDq2Jlyw^C0&hL}smxhlSl7yyhe=^Knhe#LoGclSM#`%<(6!<4SnWj%`ed z67>c5p1Q;D*o^qbKlwc}l|d03mN8<0^ce+`2bT>Iaklx>sP=yLAgG!J88k*UV+JMJ zEJCT_QUI`yEZRVRgUIOlTTRf<}wz}StvV4NDVkP8Oz?WA0gFdGXM}K3Xiii?3Fe3Rf?5} z1%y$+aF5^7h>YOZZ!a&>D0*%YNt{+|BW+9TZ3^%5@D)LX*YV7>i)*9qjO^8d#dgxJ zp{kTe!=B)g)$MBrx3@1R^eFD_j>p=WjaN{y%smX#54dpoV!MZvvgv?|5#K2$p}oyDyCY>rBjQ#q`ZU^!Bn$FAUxb_w8M-P@4`_sBID z(9%NPlIJw(Ir^sr(8k9mp0P6sRiDMXSFClIH%ZFC0LKRtJ3F$+oL!vZmn5fF7T2jFD z#sr!D{dvCZWK7pp`wapC91zy27xthGWftqY3|i>~aFJK{goGaE3YhAsZku0k-vKtE zY5cUJkl{1RkLF=Z8F7rCbt{=(PVs`pSTUV|w77OBm!5x09+9=Oj`q!kC(B*+mh^F@ zl~Tm&jga@8C7M^!sQ@CBr{)E>?8dXiS?a*~4MS~e^y=m!{gsD#GY+*C^N%)GN#HeZ1t=KO5$dk_NP9l#Ltr^$ZButu3dNS(|7+-jVi$ zvSul(k9XxoWB=-)UZfW0A%kqGvEZz=03V8%d|&W?OpC;{NK{((xI<F2w}29NtK2w*Pm@vxg4wo0KLd#M=MZ$D;;C!)zYFOea?X}xL)B=fJ!n_m+y)8RHq z9ou(pa!qCVy_VaOHb;=jlAD8m?eVy~&3>Q2JIA!gS#Wqd5AdkeJ8&JGjK?pFitID%NsDVBat-KP$OzN_|3z>MvA?DGW6zWmM!{p&dYz@o3g- z-69k4>Fn2$FXPL|Kydc9g`un>vd>Ei#}GegEV!*}$IEgHZD|7r^h7`^yZP5nV4d=1`zk1sXV@Q`*x@ubeL1e?jrRM)=`FhsCQ z8Kd76bDxIQN9RyYueP_Z?Ayzq%Sw0-QMywFG(;mfW4*8oI(3)deekluOGJQ=vSt%_ zl*FQ`9h_10-!rPF$@6F`+ZVk&M5n;+VU(2V2AL^b0~tsTOZ1Zjal=Bc?GeM09yuh= zrfjFbG#O52$f!39@yCpu07CU(UtC@OeA`>O>)e{I1@ zsJJWcM{=eJgm@UA5xzK4_Prt{aKFHtEiVIZJIlOA08CO8%~(j)g(si=b{tB8$kF7H zLvN>N0GCl0*{))r6-a3KBBCQ>_iq{eXf7*6&a_#IJB9g7jmg06#4!aTE_0eHM2~Z8 z%{}*Qbfdbi7eqDFe8!0#A1*9&R`RHEQXo-hkPulba}8U#?e0zd;CyDvS5OcOmZAW& z|K+#K4bF&0F^J`RDot^lY!IiqA{PgGSz-|GLDu@dEIK20kU>yXS=183XRfJd*pCsH z)u(9w-vj03 z0bs0+$=hw);YD%wV_h%gVyV3*so7p#^V7}QA!0cJ=T@56lzvc(;Q;K+8O{4e;*BQA0zu_E*>u%PA`K=OzsORW2;w87M zZ6g-A@P91C=w8`>DdKu>lFBaDTmhWnLGD`MmEgXx8KNSXP_*YmoXrQcKK)R=XnjBZ z0F+>YDUrhCOZ*Xr=SfoWoed5g2|a`9L8%eoH6zeWd@pL|)Jl_B;%yrN2KMgB>=8$j z$sGv8r1J;Bhjwzo;iruHH?d(4PPu>QBAT7gs+<{}P{AqS&KJQF?^B^PC%l?_QQKD7 z>yXPt5y$)h=`0A+E;n4dZXV&yf9Jp!s5UtdC(!)yQ39jvR~(;w28peYmCG3-AhBsK zFy_;w_9b9J3YjaFL0lotFh(AWEJL8(eeiThZUl(xq@0NZ?qD!$=}1n)Xz=hVC&1hg zaTBbiOopsahouoVKIb2h z^_HZnoR_22q+LHOFcx_vT~hPD$+A+1A8zcSypW9@?pX=k5L&mzWqj1S5u6^{ zQJNAJ3QeRkih>R@9@?rw3IP%IJ5MebW(ER7{g5>>fS|jgv0;QYB4r^KRd6J@yx!iN zi{?DOG~emQv>_+B~aJvyajcsp>;s$VQJKd}x{x0qaFbe6h-uv~zy)6Yj>`0w)v=qonQ2T%e~Y zV^XCAV4N^3StJnm0hRm+aB?BRDN#h(>Fg)6K)ETc;i^93vJovx{$-2K=sM-WX%0V` z(z1Umxa?UqksLDh`)5P|_j6X7u+)M(7!4)yKsF>W&D~ZA)+p$mV+9iJAW*9V>^MP2 zNqVx#m2dA`VS)2$!B;17+!-ExP)W8yPE-;(;$~|q%bzbp9PI#au`y?6db`tAa=53PruH%X%JuMm}>ndn>oea%J$%*v#}89(Ce4CP1dZlp_79 z)3qN|Y!W}6*FPw0*Y9akg{Pk(cv8~E`$cXZVe{qBlT)~ z45>6SVs9_k>K9HCz!-WAcnYcDe)3aS4 z7ZI@U9*CflG^U5^d61U9UBu(!N7@d7O!L&6_CfV8y}5AonwYTJdcU?LvW>v z0<+eLBz#c~H@22YWd$rWC`T_E8}9}OAtx!msfK|TNG>PbXB zf(8_A*`5bg0|QRO!8rrWM%Wa*l?~C-CD(Q+0Pr~g9d5iCyl$9gP}*X`_+p~hNwnCc zQ3jOUuRt8MDX!lB79%>)8~CPQrb=xdR2bUo^P<_mzOA2X(BD ztgyJ#ijegAd`0nn3k7iyjKzem>k?kWjB#E07YS)j%Q1nqX}EIr_U`q^a<-IQBfCQu z?KH1+WrzeW#9X^?d&hEYDWBmnAT0Mlc`2fwubo2*a7Sg*xggG9cq1nR8hBOZ%r0fI zlV(>ER5d6GV1+!wA&}k$76I5I!N4?#TjE~r(Dt7w1QM)@_D#PH;|{_m?ge_^tgXpe ztq34~_vy|-r~$$yNmD{%?<>dw{*SwrZ%Y*IrJ?9VLq?#h7|bUsH_?%8f8`@uuv)Sh zu%H{balxO;l@xWO08m|_Vj;bEqt5t4+zK&Do{V_l<{ZQvw8vLM7R5` zNGAlkT6_ovC~9+}ibhRjeBB!*VUXYt#U{B9*H1M&1zb2*>_fv5WH+rRy<7r#;bJ2S zD1@9yLBO+4;nM9}bBg z^qT1qeBQY-E_&V43aFlEgEsglO-`kZ}3kmKr|%oy?d zl>Y;Ab_-is5ZT<=QQ(qJQAyw#z2^t23XyeN^3dD;vrBXljL}*{`uAHUkWfw}R zf&S58`+3&RziFkBa@$9rekTFzEC`vGxcd>krb(g9v``z)Ah__3tf69jOdO9pK|NXV zKY?{VKk$RHN8}>!rP_``clCq|;G|QgP|`H{RgkukmHR>8x;)Cyu5QwgV^#MP!_^>D z7Kl?}#f;b1kqLs&#;FUKnl}z$g3A(?OKs^BPlXACi+W2$ajAtAxw(I5jBD~pHpMbr z<9r9oj9MuVFk;GC+tp+yVV`p44F8yaU>33%@Gg z5;!~*fWBRr)qC~4b3t+_jwQml3gVpE$I5~`f_G!e;6Pg@LT_1^8@Y<=@)9k2ot-@#vkM*AnAS7rFU36y{? zj>#%&_5o0*dD&UcW_d380QfvBi^JN+3wG_CXEpSm=)AXo0Ay&3DMd+Mea7D}L4#S+ zc@w-h0cF!>vD`g?O6keJSCTwf76yW{Hq z`g%(+RnRm@dO^Q994NO6KY|AOwWfD(z@SDFMe;eCwv;R-U=;LkpoLJ8eXkMRGB^>( zM05@KWBvhf{Qv-!@*W=)Z#F^2TgVHe>4HAi{%Y@q34jJQmIeUG03?RcOf%2`K%*7_ zK=B{#y*wP8ZCotP%v@bq44lnuU0D9#htJHOcDBraJ@4zvJ8W>FcC*xdkX;%%)c2Hl zwkjn3HbKi*h#A_d>XT}kt`URB{KoTkM?@EIBdee;%>hN#&F!9flzH>JJCkgu+hF*| z4~XA%My`CU;m^CU3xQ#wGov9a3srk5{mS&HNXkRB#3;m0Je~p1ha?yFPN9&mWv;@> zx3C%o$DVbl;p z{E6_FcP*bY`f9)H=S-VZ_TeyUj$}mh_loND$?%ciGB8Fz62?q70O7(t@$%L70}hEK z_%w6a>A7Oar`$y|k?oAc*UJ-`J1xYS*=4|kPEosgMu#yQ&nVV?x z26#2bUH}8018;7l*y+dKJl}pX_k(GT?3wI6&1To3=Ds>pv6j)|Te28J8mR05!E@+Y z*=`;Jj8l8NNUaj#DaeCw8xz2M%bH1 z!;p+B604RKc2SBr!5(9g##%$H0`u*4%$C4Zi(qk$e?nJ-Ea) znX!bzD!yK|$E4b{kO&Iajya?gswFCAh7^yem%IRFH&Y_CIB3V%u#o$%s|g+5XAdEwhCS1Y;eLGs#q^dr@fLCj7uC`TKoJX@c3aAmIq-U zR2yelhKa%3eW&{V5UO;y#e@+XMx@xm-6z;<*>#}4_dDE0jW~CYz`S0!FucpN`Cyr8 z{K`^>I}~i0L;OqnR6Y$1WxY& zj5f!m_Dd0is>SNX{Z68QFsv6ht9eJH#}z%F1|LzIKdd$6!$oc$ z@EKm&zRaD&8KuQM?p0{5vudrv!jHB*Pb5{xuW`IWApPOSI|b!H17Y=uRZXcd^sHkCZe=llT}K6V^1m$y{byeP1@&?NwOgc zb9RAD-cD+V?+I$pCb(@2vB=K*i#!8{{?6-DFKb~8sTS6&m+FgCA#FD{IasYBqUNJ7 zTv3ETtn>@1yl`$Qe`tE zY+P$yTy>JpT=t#Fv|4cqGM-JEeQ8tDdN!V_@=CetX3no|>xAqQscQG=?4MXZyXb+c zl&&angw@|5u8dU}XR{Yg*gG9$9+MGVrK)TnPkX`w?e+Zf?HXxW3fJ zFaAejeVaRGd}ZD!Wkdl#Sz&gzS>1enzP-geYWcWybuLGjIVsyWbgt80@~^w`n;9wN3E9c~6<$O@{`ApA&La-w;s5|5W4cj36*D z)h9A~n9j_zkUYCz1eIMb@4<4z)Ka!GKD5pp7={i)(IMYtlHK>f=g6Ttr~cw*IwqUd zP8^mIed{zDrPotm_hPPA06zjbQH!+7PFVjv=u@Y}(6OF4YIG1?Y}>iBg5Q7}mKKav zXtq4cfXi2fZ=Co^*Bw9OLs0EXM(p&S)J!3Z?b7IIMvt8tL^z>tVi^!o;=Mk#xk{qh z5VLKmd7m{TRDVsuvRaJ?(wFXgaVPiDm8mur4 z4l{`K^6u;cdX-9PQ7p%BsBm@sKya62uQ&-UqzW(W!2OYnZ|sb_(`lKQ3w?$%1Y2$AbwPTfiv}t{C3w~vURR4T?WZle_}Ox3HulicOi)sZ8&Frsi> zU{_ta%6w2U%DhzZF`Vi=tKegCWyKdspF(u60_{);&e*Og^2dfc``S{vUEQ&hbg=?v zz!6gdDymi{+>CeG0e9YJ(TMfD%>!~HM(?Ca{O{*uD<+o^m* z!A5zZej*ohhhdU*oviGy2WcAAQaI*#r9CP;m2X!r}Va}mZpYprfs;~C&EBr90(KiN3?^H}UgNm)o1jXV6djDcO#xUduO;u=9g z`Sa^gEafi{n=0JNlFod!!X?l6i5tZ!%Nj<5F=9gblPV7%4!);|j?;GG6yMh+ZuxjQ zOLE1iceqw`(uyc97yWUe6UQP24(>7#>IPT!X=I1hybe79_6<3PTwvI_+g2`^GZ#i` z?DV5+G!mu}L4wLcIkcUufu!jJYa9=LKJLM&#MOf3;uT_e+#v5N^)E6dzBA>|N+~Qw z?Wf7>njoo2duaoceC0EaxrcTS>H72q%?vifu&VyvLN$hO@ND^UEw zFQG770hPRECm>}gM}-Bo%+GHX}pubzvc7V{dP-6hc8NR2dh;8kQIrhz!SO z5A$W9?bY4MU+{Y2aG-6{7&W?%gt=QE7sqpeQacg%r8ePl`M20E5u zC9TWipX5A)w`@Za-HVqCycUjKMMSOI{}q5_>V?>mRsNkVCQyz6?Q+j9M$^pr!w61t zG&o-i3|YP!6iEFHIW$0yBAM&u%JfK|5MCD5^LwrjA(4Cj(8W+kU`!}4kepmCvF}hb zQ4Jq@6|ghCxHvnGC9nKZ7ky4CStuh?9AXKd_=h`@nH|cO!294L%4SJK7Nd5;s0617 zoPotcDZTX4Nhvl*zcrW0D!JnY(yFZMq>Vea;cK%DWO}@%I--U*(cG1DTbhfIP70(z zwcSCZzTbwkfQVyjw*u3iGly~|A$PTYQRg?K32a4RdSe-^4B{UfCVADB%ye(+p8^x< z-%6uS5Rx75B?^YEA0`-RTCEzqBZVbZ&oR1Q5y0#Y;I3JyS4G!`RUCj+UsRsr_NmhVf&0gM}Kvec+xn>_!4H4lUO5Bj^IcSD4c!$XW^1tB(&)66_6+{OoXk3{c=mCJeU+Lj zm4wzceqh#`flIa3^|>{(&^V;Pt@NNB^4Dp7HQNNMN;bO2D2_cT%d8Q_FlHk!9uq6{ zrWeFA-Y2;&ZZ3J{y?k8mFmU^Jk>Ul8&(AR0u}~xp8(7}u-%6zm$$lRrp2dR^wq66` zt18+m8H?k`Fj*E(wJ9{{V_ZLlshaVAfQw=)p^zI*``M`YPTczq51AgnDPe_7phjz{ z?PJDUWn+cc@yY*Ez#|M8G~^9_O(Ec|)TaD_iHefVdgiV7GeL;{RH6H)_lYR3N{^IE zyyse0@|nOlI}5V$>ub`b+Q`+c{R`nBhFF|M(CG0;@r=;xC`DWuI@JrG6&5^aEadVY z7U3Q6N897a?SH85Ee4eiG_lP*sH@A)*=bunfkP$)qOWuAuo&>2SQpYv2wWpAH7@&9 z71>~wD15<4P!9(~1SgDn8j^u*-!rrrAU_2i|n*@ z-Hzgc@uOpf7~^?6N?)GLIxiMxd4_hXbNWOfm+t%AOS>wh{lcFN3fvQ6pA$5%ti>?4 z2Z4m~hfQvtD!u0Tf~a4Fiw1vk0duCL5yM9Z8ex@<#Od?Ab#MU4J*%~L~-;pw=xC@i%Xx*#|pXeb* z3BSur&GIKjxb3g9hBmE(c3Wyi$=ydcH4F>jHGy)g3oZ4z_i8)Lmlq|Do zqIG922@E2BS_$_k1iILoY*s}O*ZCWV1$$GtZv`Se+@QCV|JV7So%LTHt1DSvagY@; z{6gwAf*!`+rbAv1HeKEq(JI2pa8K6^B;0S7PA#r}d1zybv_o_fCOqr%Ivc(B)cz`d z3B4>`gL@o-1}6mfO)3p|-Qazym(=I=9bMlND)zK5>3ILu_7xH8;c@(6z73$4YC`$2 zt*iP+44KNKfHVJ+YN=(PSTtLCa5&sT2u7Ks(0wOF4w)~+YasF)jVOAxJ2b<`dCh_v zyysjYz3>wTRe8ONSDox7F&L4yOLmY2C1S!({GJi!_Y(43*RLVHr)-k?I#SI~e=Z>W zJGa7>;Ld${<;sZyglc77yCv=IA##=NGWq7p*_u*GW2r`Q zoW7M4pH>wd*XZoizS?kh{3$E}Bdbcj!+*Rd@0pDzCVbr|`n#q2d5>+{1P%bug4(eE zpG(E|-^hjLj>9@Ds()V72iSp;!w?*lc1vkF1iiX;RmI%lSToD+r+SJF%#L1vNy`?_ zCRtU~KMk#qk~8;*7d@RfP63%ialCU9w0K-SC)`Mha!zDrK`#8G|MP#ZYez~vR$ZLS!TFmj&#nA zHWkKQG-CcjXqLys23@&kn_s*{A1{oN;?^c8w_auoB@{^gg+_PwRV?Lp@=FH17c(~_ z1j|VqYHSQ`-=~J(2Yl^d-MMpGvs`H!n~-Nkw!S&w7&nxb&rbp@n3Av(vIyGqt7Nk# z2PBKIjF6`nhELrg;M!Usxh}g#NY1*J8>EL!s~SSoXHICFA9-^AnL&FU#jF~(t={Kx zi7a}z0_S*s#`T(f_fb+qLSE#Qz^o+5w*38<%c;a4ce}29a9{Sqbjhos3A-R{6#^KJ621R?uq5PJ|-f zIV4?eDY#8vcKTd~=n?xDiZ4u&5b>@o%kjR6)}C}jg$E#p1xelA5FV)?_6g8l+M`cS z>sDlGK32&!Fj5S~{`#=5`}^a@@lv-(-MY?o zm%I)_Yw`pygA}y@9Snb4ReD3(EE_Hnw3&v(Z7p>#r$E1c8 zJy#B$z@+dxl1?I>%zS2|2W{#x+$v4|!^4BX6c>AofH^&zp)@lHQYnP!{bRF@2%<9% z&@@HBn%_w6-_Z>5=JuUbMWGXCn&`!m)uxVjuqI8EhcYCDadj)&4JePVDMizEsb)b4 zZ-dU%*p*nIZlH_Hir z?H)^HfWpCRz*ti33Z_(cg8KHQsh(d?tRP!*3l3q`BShWAIwV&@OT#B?WJ_)z8Ue?9 zp(op^n2Q%oW6`ZhD^6=oGlrjCr(oZ#{0ofpPyacDj#|>+t>NIB(~rSL9>D=H&BB7Q z!InN8B9ir^_L``rmdtGAIEKx{OFYp5_$Jvwv`sSX>TK_f$cS(6_vQybS!mq1d-3 zI1^ULnxN)XIRDT$Kb9iXowI!*+d)=;(|(XvE>iCW_aR<=A_!_;_4+jSm~bY&Lu2D| zvUk+ii`8I_n{2_qRwVehCZu;7ILZPtA#vh=GNJ!=$^So1sHp^GLjE#RMcK5cpZ?2) z3bqV-Z6*@X-CW7~D|dg?pPcyhyqxp;cm!mX)aWQ>$)fRq90wDs+=yc>M{{@tDFIYspj9rMxiyVku8Uf+_be9N+WNh%a_BR=nhny>1J$g;BW)=%?QQ+? z75G73oA>AEGhuK=>zD!TKk4SU_JS>krJ#Xj`-fK*)HGitVFo8H1!~8|g8=em(HC*n zY>D*J2dQk#Y#BfM9cX)QnZ2j-a3b_S0hbLG#CVPnnB4gOm203n{Q4Vv4`QUy?014$9Y?NZ4 zwuYl2j2_)qwGhL(Sp~)in0ht+r#>x61mR`^{i`DLN>_)T6#NX$5W6mWx1zR<)P=8|HM z%}exASar$ao_T}qG(xDGD6{QK4UUT`8<|!#c`i{5qnx(&q9t8pmkg^s+Cuwxt5{VS zWQCl=MEB-nqyoea5uTm`c;-~Tb4sX3kiJi;EWYPlVJ_V#BNLBp^xbqHaSmwgVKtda zm#j+hHeERfopcGW8~HrwLk?)aTEj!iYFE}*^Zw$74^^+R==CntnrIx!5rp~FYa7Ve z;V_q{eG~BlFwL>wzw5TUz?xWZ#YEzaw5Vw~Z#qetD>}cLfMz&`Bfy~Bj*Hf({ zVnop}d69PFE&j>!*x!Vr&-%eeIq4(mRzZIK{^cT~WhK4MzI_PGNaLhsO=Za@cAUjC z80UWMVDb&m-AwsM{+nTGhjkOCaGdZZk^L8j-}Y`hezJ!SA?ZIPl2AT;t1I*d8TCLN zfHXhZXwDs}o5a^LJpSQ=G`WoWA}EzG=cK2S#gGt^>oYz4TA$44^Sbqd@OMmYYKy~( zA7pSdB>!Y^oc|)#`&xP+pM~iMVroi%F|{Zi_$}DTT6w7u`KG@NPW~i`E9p#RvUbN# z6R)_Ak)xsGzUI3s@5Ak;OYc20wbgtFREan>#Ha^<8C0@GQsQ7=JHGGsx|{YoD_%Wi z3M!ZC+)V%bi-*tGMAi_&d5WYH>|AoU-PqW1LG;2WSe4Q(MwlpGr&1Mj$BJ-Di`Q_Z zAf?$8^t)R`i;uO;nnqg3MXk^Wlv3_(T|am1(cnSpkx@FSn*l7-P?`#{F#^8S3bKq* z6V-k_T$fV$tE{qNNtx$9OcElC`Eo{SAv8VTpYMxLV0-K@5PVMNyMrktnppun!3BvH zY{AmISOz%=#8F&*ywL~4T;0%jmwoqx7!mW4C;1D^_b=RzK!p&dfcLCJtx(t;1w`6$ z^oTCRv>kntYSh|ZlLL}Q{o7&4$_NcU2);dw2tp?Qssr909izw%h=pqui zjf4vwHW$kh70(O}DP+rwl`P7{3cSyM>-?IOF-&;mlfKyi zw89Tmj#cCy`3(CZ*6$?^jBzMe(Vs0N_6w1zQJzp6&w-k)8Yg5FTcM&WAF?K+E00Jk zd947l@M5=5{G!aRb4H%4x=>5^tpx4`u-euZFC3<;uGBiTI~)hJqKz@=nbvRC9#S-! zNGjs*jekKDe$XN>9OXHYA5JSVEde(68Xm@z5y%XKA$8}j_=O~BHtd8asNq0QucR-k zWE)dm77=MzR^yjrui#tZj+^Ot+=o5_rA_ zM^*I`V;X1fLx)memikwiZCc0K^Oa>vc_Ztzw!XZd>}LH>Z%;|Ev6F>9XRf@-w_bUO zijv=;`Dw=Oun9J+pwpg6F$!KV!Kef(=!pd!4E@dvR@s;6lr8ePgyx zq-kn0X*-b6cz&Hk!%RF;A6ax}%ELU|mF2J`cDs+KKs_3rum~1&LARV-oTcdJICpeT zS+r^eR`C%LVaF*EiCdnK3JGz0Ju5Rj{X~i7X?Hv6P(3hp(a26HOzyj#v>&XUFrpcT zHo$7gDSOopX>sF6ti4zCDHF<_O_H1+-vKKx~%I)iP@2NAPXAP!x!?6RDVD>bt9G;uMl{qt|l0Lk6j#)7zGp!dP zB2l~lu>pTVgZOq**+EWuXl!k@(>^t>m~4OO#Hj^Oe;niake#h(53^sb*X6r6v979` ze^`LK;iDf@7y?5b1j)*wJt6MH+ahcgj_MBM@Uwn{MtxwSjlkJPa z`ukhAz`n}t@q2sApV^aJP$!dJ`7aH5%N7nqxIPBBI!HTD#JQ)wGuUY;J`s3xXWuxNyU&XT~<}1^Ck3RIK zx5b@YF2VRJK=q_}17aH1NG=ZICT4HMn4#~laYV6btl0uBSOU5-ELIwPJwskDn^yl`+fC&6?=ed1`=N-_%y>h4rp1B~1eiPdTP1+N>9 zj^i-&(s+_Osm$i=31do0h(kjO-{@oS*0lWlm+3wnzIaDx=Z5PpM%o1JxSGAXnXMU{ za?;)LeszO_API?H+{pAvnp=CUkuv@0IK8#na(&L?k1uKEa`C<0@3`tCs1&1{=J(=G z8+lY1T$^l(uY!_i!d!31{3s7Zsp?S3afwYmTXo&NrbfQ|EX0VxYUxsF5Qsa4BL^m4O&Smy4biCi4lCfiG{f)V* zFHZfh17SxkRl|}xk{GhgC(F8V zpzWt0THQ-<+7f{l+ZM@26c7R)*(6n()_|SmL!)(Z{Gq~Q^D`5Zj#4Ib()~3Ol~b;a z2P7Faa4Ae3DNiKSB@;sxrzm1`cJj?4jn&~+lM+6EWDl2~vuf8|0)r`GO+(ep$5;Dd9q@J{tTKSWT<^9cRNpu|ry zN$P3=w3~XfvNIS|g-M=g|8eamW-XW(?6Y{by92G^4yJ5k)L~A$KdfqASJn$q1(~GF z+g$nBa0e$=U}EDBeV+)>>7suqQEzvAvkT89|cP~J0eSGL^(D!LNhbhaf{v7E1O_&@jFLxsoCW}r3Bv*CbDyM zOGU8G=;;nFBY%^ZCPp)|R2m&QuZ*&@d|u z-Ql{a#`meiep8q$Zwr!ZMMyIb3YFgOQJz+kWc*`!g1xc~Z$U@9wry677o&&I*R_WM@vTO#cr zYu-2Dt&W<~z641Qct1Eq<=O6ZF+t9Y)}(e-Ap(1o{fJ!0UPN2GD>(rWaYq>nirj{c zp8WUT952NHo_Sbk(|-ez1wAT-KBoKD2<(lYGch-vDTOx*#nHN!^|zbYk79EVbul0p0NepluZW?K?p~M z2z1cb1AsDw{m%w^(m&j5<7CDB3E~b3b;wAKhnt@c6;(3_y>Chn@7;cNtb{FMcDg0d zvM-f>I>fu(@pU-Xe}RL}qlH_dPKYV=t+$*vKOlq7?Wf{W~X0pagJD-CfQ)s(onG#h@e zE}yc4EE#fHV6UX3NPLlc&RF%%WQjMF8aQaBoyRG0#G*rrgf?+37jf zxAW1Fky4|W$JUtnjkO6$m|&F3;kEwI*#+6Q#pXgzhTDv@PldOMcvMD3zKUF(>qfUw zLZqSkscQQjbXNM`v2+-mkMJkZ8!V=O^8M`p^8Jh2dWz&gP%z!}10vJo5W{ILas+BC zBNBhu@7rP~GKa#3v<~X)oezv7*8@N{*DmJ;?7D z9OY7`6GL@-e2C1*{#;0Qky6skP-k51mERUpE_UKCEEN!6r4uv@2w0=%h%8Lyt`=@w z*$Q(kzhJBNrO45P-l~b#l8$5Gsj%F>rI%@pIw~xW*y@%NN$QnezV}xLehv_5nPN+y z%at3+fp0v(+J==-;l@y8rBxQSt~AQa%hTggh~&JnGG{EKJdpF$rXnt*qu92)5b-%g z*=l?d))iRU-Xa7`Uf|N}QS;Huk`^tEU3fgZI>|8xa3R0-^`>LAN;R%n-I~Fp~T7nR%du zsX5?07LG-lPn})@%uQ8q5I{EyM2xnv)|>%@aZ<8_gXPcpI{17gDQ|jZAk5^M#4THO zRI}WTM;`N%B}|kdvir*bvjD5F%paSO45CO8$1U)3OFbB%Bcbbj&n+K)YK7iX+?H-_ zA$E+q7LKb_G?q-~S55lrj{0o$c8zM3g37Ow0p;_&PKRcc0?*J?AN{H>pzSPfYj%YK zMq}KcvqK827o!U7qyGBrJkgTcH`km9OXkT_&X~HhyPe1l)c*;2Kg2auihH3c;i(KC z()@@sqwJfK@$A+cB~SRxX%(z9J#tkDS1EmroW__5qne(y1>BRjP(;DP@N4Y72@d3H z@=sm72E{Z~;~SJ`xv@7iGh0)u{QLt$iH5+7JCmY!D>NgF*g03An4LC#t$e0ugKZ}V z#3jzj;Ey4Rd>O8N3I;&Z=NP(eTao5hTKI-%M?=-cR>SXs#km{PFyUQelF5Kx-8D)B z*IWqONZlV%n}y8a4|V>Wp+|&J`B*-@oFcZIgPXB4Bhj!FE1IQgI3z|znM!n{h9h6M zyg8p%?Hlb@O?bJyRhYgVbyf=M5fLowdD}j}#5R_B$a|l(5ORKV0xmO}Nh87*Gg#~= zi#(;j4=M~pIqHIaF*~mSIx0$sbT@ZR?R9LAG*0g*?+dV9{Xok8Hgheg%efvS8*JA( zGyZ|Fe=6`@*Jv`*e*C%Bxw8eTRg@<9pol!1D1?P;bk)_7Br8It4pR)7wzsu3iYRk% zM8CrjV9ABnL&(L+?_n?p`OANWp;7yuno}5NW+jNYmeKp*B{heNE4Z^H??~I>jO}Lp z?@xd?oF!N&pc7y-X#1e}kEo`pvyq3Dy~TfNn*a0h-!X%xlxc+_QcQ^l>K@TSeM`v= zp!tz)?6~dpBLLD~r^yj+ceblL0iIHlPYgo4jRgT*8brcpTG za=35x;piqCjT)wIEQXLnNSbKp<5lk!syuW{i?|*}Ub5OZj#|`d!Z-#N3yVp#%5gkL zfVS}CVG8bv+}p6K!8YULoAA1{dA(}RyxxYo+B}edt2!=%56-H#sB`tVa`t#L|Ti6JKX6=7(#UF0-MZ};t z-H`tw!`Zn?x`!X%kog0oi2d;K0ek zdYwTWCfu$>iG_iSZ|s^73JDDS4Wiw|=U_fOTy+hmbRJYz>SJHyJ|p6;*XMsn4sHDew>cV&SaR_{G1<;Os8Hx<*cI ztl+(5TJ|C;YWP~RI#H7;^N8n>ac?ic_i`V(ke-|bam0|SL+|?{6v!eJ;JqL)hBDvR zO$6rDMtE05yu`jid6(n(ShA5Go)qxh2~p=My!@@FQ=B2%e+9v`3KZS_KjF&pujvIf zP5LjmLbUr75XJHQH@MPiw?ST7Z0k==4N%uGyTX0Wxw+~$fB7kSA5O;$kFLE97|b7U zGo<1>BVo1=Iw%ZQrhrOy>_gl*f3>}dETX?tBG#R%RuM^OO+~*59rG5dWh;v;Q1F(~ zPwSA=5GyfA6|c9>vPtS;&(CIE1GRVIb%C=Dh+KN*&3@jt>Y{o315CvWbL{D0P@;+v z2R|Gra{AM@!}-cx2n8fDZAKm9{YI;5&_>M?kJq#LdEq3ge<%okdQ~yyQ^04Z@onZ+ z3;K5xq!SXIHtn%12d2d@TuY?X2GuVh^!;ya-iwA)5&mWC|AftdvxKhHX={+JhdqS# zh&mcf%Vm>~2pms~!7JXTKpW66RipW7_j@7XkbLe}h>lgrP&V3Iy!@z;G zHkV^+2q|Os9Nv|adv2Zl)EBo;fp0m6$H(2&`uW8I*DEsNHNSecF!~A!Po$1_qzhNb zMe#>)R0{I9-(Ui{3d%BC zp>tBMDXp|kbngpP4(lWq5v4T)L32e~Ua*A9cKc1>r$EXn%ulr8PG}5saJCYYYrMos zKWPJ|Te|o^J6wOn+HEY7GE5gWs_V^<#86%*;#V={o z)-r(%f5HE6k$LSpD*FFxa{qn(@;@fmz#^P&+*Zb@#q1eS_&Lh%HhMkJ>t!M}sC1}W zYbJvu!l?(_C5&60zJ2>+GO~vShUP5QgVfTa+u&ED9x+K=)4u$iY9AKnRAH9 z>{jrbo$Gs1O`79TJ%U=k`Kp_Yu3D?AI;Rw`VPE-x9!ddODjSl@)k$$_-aI=a-Z1O>FrNN;ZG?knD9$I_b%(#b-13MDe-;Iqd^hqx5L~u@Z>#%Xw*C@y z1pFoFcrtQ`lh#yVAHP7B`8-U~Dd!9ooV{FwFgpop8ym&dJ( z^PEN_t^IF1hSf@Jlszj{M2Wh?BBf;Qxdw!OWJD(!v0C3LLrsy=5n)IKbM%B~2;axe zMK+MNlQ=0eU7i_A(k+x&Pw0@)KSi-YxzJ{%T8}tr!gCzCE0%j%h9DBJoyzScW?03( zAKJv_K5S@6lXJyl8DNucVK7^Ur^_+#BjKA-LwQ)ZH*0&kPl@gK{SuL~Mk<3E z3jUF|hagL{QgpM%w|>ObU5RSQEp|mxmOj&uH?l(5E#w+tgrgpcDw*NCgVGUHwr7en zUJ?x)mp<;3O2>HSz<)m!9Vm!PJaT}ZG3q{JPEGVAt~vhWJa>aFB7pN-xX8E1GHe$m zhO^=i&Kw@=U}IA9OgSHnsGZyHTZ8x5V|WwUyy4))*|cKy+)j@u{l40WQux-NU6o5s zO0swQtI-C{z%~6NJBJ)u8tk7}Rwa2>yT)3flKxcjVF$~2i4~KVwlHUtmA>9%z3Wqf=voKljYB_Be-6dgwb%7m?kh& zQdpS&E@XvhBA4Hvu3-{DH-02^HuqHz97<9<&e8H+WLIJJA2b&lAYG;MUI_Pi?EAgT z7scn7yZfA?9>nmm)*_?YZ&dt94r7(489enPc_y?=xJYicZ##P$>cOZ#v;K}#@uZdv z4`RVrKyBVS%`88v!r;+B-f76w?H!g$1EwqcDgI!%3?l>1iy4EqDBs_S%#(Z`R`71` zfIKg_C%ew&^PZ+QFs{XtUw}C=z&wtceCIaTjh^}SX5A3XKcjd_nb#x;i$Tk*N~%FPkRNacOsL_&Q+i~eIpU^1<| zq*nABVg@yCZ~qj>1elbFJN0AW2+ebUA{X98S+J5a)Cm6Xd>X zqLLN^CYu!vlYNwFp2nk__(b=8Ay2HI!9(EJ4Yvbj^xBDj*>&KRIS*(MxkQs$A!=724x&0t)Iswy2Yr4kN6rmpH4!JAgNXj)M3PLs^cvf1V$mMSy6NjZmA8_ zdTNC<92nni_SD+HjRl_N$`fb8d9;&!m~tJY8jB%@+URsrzn#E_2$|OB6&Sa34$3wzu|>sr)?F@Ea zuj*mJ4DtQL+q5ZQKKrggMSxM8;if*-NOwOKWl6HvhvxM14eK1OijVo7unCiRgf+=i z$JnH^n;-y}IoWu8mPLgs+WTolP4OXaWj5_D=ahy9@4f zlp#gr60!djKd^; zc;(HXRuxc~g9jAw>lnS>+cdFos)W=v&j*UMQ^%6Bi?c<{KEjSpV6Jg5slt)K_f%D^ z5rT0WyC+y#)C0i8Z0~zMjcMdFJHhEcq+X3J8Pgl<_5SLz?{hWOwFkQjnt$BBXK-Xax8G(rrrkQv?An zX;ALF@b^BsXUh+ZGYQ|7UM%d1|BZceBn^c{@BQ6|Rp~l#jmsdjs?)T64A!LVHY?|- zlZ?kK+}XR`Z=%%jz_BP`r9V$uQ`bwN?%p$@s5iA$UBw=MGc;au)bb>B4T{Yj^Hj0+ zQ@>}932~W5seqIUM5pVa>KGW3)~V-A0Yg=mJ=rxkU(K-Yt)sV2h+w&xY| zdrsE!RQB_QQkk|)-)*nPZSOU8O6mO9-ClA*_9N`F7wkjV*P{Brms|ATBuBZgg{W-( zUyfha|2cm5^j7V^0=T~n48H=neO&|SZcXl|*j7wY-{iCb7hUkt;;U;i`J^Ldb2XQm zlLHCaf6$MOvLA{ZE9nld9nB}VXYMB2y)p>b>ht%=2_Ar(XGFCO=&VyzeH(`}%iCWq zE_IG5D{?ljv-P_A$BXk^zm7IzxT-CZWR;v$7{}DguPKOX$)9$(W*la;jIZPtcpdE6 z5;F9jTC&kuk_Jb?cqvxil6Bs38><$N0z7eHojU@}9UDDIOkoC{?+3;L2Wb3gGYn>0 zP1_#0Dy=FBS7!)oN!S?bf*V}>O1Tr{+Uoa*9p;VU#Y5y3@CkrQmeCiO_s_96q8Mxh zlHP1=dL8{|9JyP+jRv@>$%eFvF!T2y1mXc7f#9Eu%*+s!oQ=VW21NSw=6cvND^pedDpSU6nP0tWOxVpc843`<0L;K{ zowCAtZS!o+=Hk2NgaibR{ybP$=w8W+d!QA@lAK|&lcrcTN%cutgC!62l=^2W$w?sl zeMbmE)^hRx*FvN7mQFK7-f43Y$fvbZY_@U^VTihA8z$K-P<8BYw&e_F078V6AwYrM zMjRgEtf2cHye|e$^6>Jj;9CEd)9Hm<;Acbw&3n>cnktGeU9h_Z&+Ph6zaD=k3xUuJ zH1DyJ$vTz4xTLHoW)*+;YG2x(oX`No0pHJENYQa)FvBxn7>2B_YQubPT@ZsvIpMWM zoCRp383da!x#MlelEEWLDfK%8#0y#KdEc8cd)wjcEk?RP)TDstq6K zSq9MW<}spHEN%~&RG7l1F%c020UMDvj#6ty5_=vZ_jm9;4~Q^qQPm`&g*3inD|j$!vI5ih!=Ww!o=m7sWbAgp%A^?M|pC#@)RMw@ z>`+Rc%qBDXdBEgC6zc2ZVbV8SJK~A@NvI?UeDBl}h@G7=B0AHFLc)ISb8fEx2!lyK zIdl$38A>ApSOPE`u`!42`RG=Zeg!6pH3fn2e&eYPLjZo%8dm5`C?6Q{L zWlT0hRpmBX|Eo-e4My5xi4v%za+T33B?Qq9l(}GX3i`Py++i72@54K}P3DAb_Iw0h z{twzAdj9h2t|2bTH;K`=pZZJ)Z|t~T2wg<6`KCb&uGb8+S6ZqgUrrzz9`3uO8jJxU zI)q}VXw_ElQsrSEDKS*W>Q5d*@HrK}?!1!4#a+x>N)l7V`11PMB{XhWk zy|b^pb@Rf4jQb#@NO@g`2#A6kTN!Qv9#q*mF{_f6yt3NNhNs0|_73kntDezezn*e9 zGWlWUIu_=Z9ILp-t#{E_dgPv0|LRf#89`tpHx7tb`9kEP|HcBWg7`(9<6U{oWUcx= z0XMT@@x_fkM>+2H{v72JawP=@*fo2WMn6kY8Kh6ib10%P{S_ z02XfJcXf&hNdy>;&LNzM}yMdZp!vou*bij4;P^!9ATeH6HfyCfoeOp|1$TV-xTD=-teL< z7ZeT{La7r0F_y^8b7fp59~yjS8F{C%DP6h+k00|HQaC-OsrrzibNu+_@hX!-1wP=TW?e^b4$UYo9+!JdwDf%^btF~%+%x*UGJ?r|G*$W( zd>U|l3cnlgQfQVfEzc=@h!i{<_%+bRG4J>@N_jsIQa(Zm;q|QSk5x#x4$YR3)aLr` z04AT;hq*=%TU-uqB{=w~PUAe%A!~2r#<=yX{;-J?KoyBYbd_p(y)~Rg zgemAgpEetC3^5&Gdmy3UQTZ;UuuvPQ^n4R-;hR#zkaN&5XfZCzXWafzOvkBWB!$O5 zHiE)oR&|axbMKA-#k0TTvfRc_Rp#CFNc^wNMJ7EBOyzM8Jq=qeeF+Me9{y@>gSi+2 z48RKAWx$!Zw{8FW+9OEvCA6gd&zvqW^djfnZ@gsO?=C>S?(jVb&!NjjG(I}9vE~CH zlX5i>R{Mx!3hgSEN8a%&s?+G7hmf?$LPW+W;>rpAY;sJ2i(egN*rsqH`V$3As^kpR zX?vd^PEVyw1$t0Im{mjta1J3qwx);ThSWXA+jHc#aYRdX%CS*V6`tFy`)hV&Fh2@7;Xa3DN);{(-^GoWz#06AZO+^u{m`I@G?Zl zCojO&(E5i(B3)(X>QhmdnK}UYoh&SYzO$&us?reKfE@$+m%?9Z-65(-k_^%-7tDBj z%ErXg4sd(mITTRmKBhR*KY*)(rUK+CQy|_q#y?(xrn1R=bW~`&TaXcfv``VP#-w;a zI#pU=F(s@rj;{Vrn&h@oc*4m6`2nP3$jU`jS1?+!P+AWmN<4e~6W7me(o zfvV2oLWP+W^7k22k6>Rf*I+`t_ve+z>V56gAL@}`C5iz4)q=%3lPJa&e z#S+Yz{Ky>GBo-Tvm8rSICtv<$rKn4JEIDh!NiEp-i+z1}kEv)LA1>ex2{fPbu%1gr zHg%(cMP4;Zpob`i=&rdkhyVfhx*@)r5ha+gS_pnzh?@~)uZ5iJm{Aq;R=Rj;lWZ}+ z*nhTp{Zy4h4me&batdnl8>h9a>-eVLRIeNzPCp2$)t*ZVR5g)4b$N0jLV*U+sz##W zAqF2cFGIzcss%MpK#qvBRYgKc*Fw}IZ2OA&!W70}4yO#RR`WJmigl_fdAK7A{u&{2 zwI5>;c8SklkcrE*6iPj^#%#%G&D=*PqnC2!q|-&xhUjTTBLn`?&5-}IqX^jsslfN4 zX2BOf>pQFGX4Qy^h?{Wz>LRhA6mn2O{q6esMyk7+)N~$Dk^-3aE z0;4Av?D;b^@&a9qJEMURXT<+UP{E#0qJ+$@Kv}qW)G_Ksm(m71-&C$M^_1ZEsvAk+ zh=60F7ffEK?QX8`mue79B<@63uBq866s(RS90%E=8YRge`tJ zN;|rI!<{{PoQVdY)MrjsMB+{hTb9U-p%jJf|Y51uTkN(k20_2+X{#m;rzQXz2ni7Ty@{d z)i=!dZNG7TD^raZWO((+_?4tzQ#c@tF@PG+&*<*wfFiR$fJc)z1ruH>$;}G{Bk=Xj{*&(B{EwB#Tibi;(7yP6=5(MS@={{Pw z--IMCHH&O*qA*qV)vCge=U1!KNmVgbVPEH1jgw7l zf&NR=;OSw8QhaQeb~NPrqr9wcE#$5+&{esNG(GSZXM!nb*fPht01;8*X(71H$=zLpoO98()s>EV{VM$3Z#?NAd1BDL=CH! zjU}*zo+0MKtk;dzM7-v3)=k|I^P| z(_3|30iyngPXU92@@if<12t_A96cRNsR&Gr9O)__oHaBrK%j(!IXrEl+!XFrmt?<# zeB0^Wsym#X`}N}bcy-Z77aMz_nR3g4_xK;Rp$-5P%UO&4X;6YQRIs6>KMg2U%BXd^ z%-Qcmx%B%yU&q0o0r#cNy_N8VtN=W>ax+H`31-$I>VVQvMo^8x=9^ zjBslvnYUDW>T?~4>`b=dOn*P1^gsV>H@o+Wz z-Lm89)WLl$aSUKuQK$88*c%i-HCXF@e`SrgS$nn(baK^?=I&N|~E zF=KU(j;|l@uP<;}*WoiP2N4Mt0cZ{JD!aGK682esf`V;1FZ;J`*G0~v9LBy+o@Xw* z2JplTT_~PA7E=m3zh(`B+3Q^P5uKX5ejLu(v$?Hr8ft%;GUcZ%ox)FbXflKr-+7ZIcw)o7k!|c40kk|2;eQZTSTxT+}XJA?(1tG^8 z28#mDE2xjTFHV&~-lF#0a!uy9xtEGAnJvlr7%aP<8=g*+zG~znh9|CM%z~u>M zr$3>wYsa%eSQp3Ereek=QKYQd8G>Xcdm{rJKTyCF;gxOl&;PN46e{3Arwi7){Vs*D zi6P?6oIxB(;3GocG&a1!_3o*sg}wzY$Le(AlU=qE0z@2B!|JhGB(bEx?1AX{>T74- zq7-qN?GDzvkaT`UFR~^fFSlJ~u@+W?dFJCgb|959fefNZ9tePBHN)n6qnew0zso8a zI)-xdE$v^kxbzQ~{c4qcv+yKCn$_n4wy^piTVi!&x?i(5v2Z?B6vO|1QUL1nkwZ9g zIq6#BaF@Q+nH^k0;kV!=U8w%WRjHF}71?^+uL&@t#BLZyqYLS*s=H-2Kr&oMHnj`_rXk3Y2r};Tb5EE4>e~!+h z*$%!l4>`}d-@E=Tf`@i@1>-1tHGfCz9T|S`TZA_K>KhilCnQ%-;_jgjrgs?sV=TE7 zk=g5KuLTRzzoV~NZP^#4dtibBPtU|slhUoPR3^VdwWXi~9kd>JL%Uw@psB`G7yLqj zWl8mk?Ay|R8sz_?Df9hCjIn}#UmOt7>wcWb@NX4jpY1#T0+ki+P%!W5GqgWE#0;mp z@E;=?bXT7Ih^jQmUBydlmNVaJ-lg4tFr0vsZP0JX_b1zZJI=;?{8GRkbl+L)z7#Mo zJ6P;vxw#*O`$(=@?Kq$2OK3Q3JE z^*bpg@uqMai+8=8dRGn6VPZ+sTiuP&%}}Q$Yl!h~H+M zkh}&A-=cxOS>RY`y#~JRz2%9 zxRa-J;}PWU-+%c1uhKDnoLNf#f!v+poTD338u>-HBJ z>X=7xWqDYIkMr7RZuJ^J7jNuI?-o65VdV&wcUziL$kjNUG?%W=#%~4KcUvwOrF~qZ z*yVAvW25VY{y+Fs)bY{j+wOJd3>r>&D2+L$g4APL+{WM6+qf1D9!YTDaAxVzI76(_ zl7b@Cyfx090rEzE>(xpjughIBd4L@Vg(qsF3td-7>?46hq)zYxv(P~lNKmmPyN2q`7e zkeazWa1&>As=_ zY*Idg<@r9iE)x>$azvllt-E5azNAtX+y2Tmtm}x|9*_6$-zwB`Z#8WxwmKZ zG<0(xadCpQ6KO|h9`8qnKn}F!&+Es{41qc!0j#Rne!4KQVXncT{;2z`WIq!6mJnfd zV*bm8$3NM$KY4O;h!Ttiql!%&ioQ)eC~Jo&((V((v&REF@d{3#W3;FmAiT0{_c`p@ z2vcczy7dxTl<6ImbRq+uN~!3pzvZHmh%kB1on4~tfEygS*sT?uTlFpIwfooy{4P{c z9{hV>)}8=!H$LHMAbw}G1#lFOQsL+ygyH!PGD)FD%5jSB@8XzHk>7oUI1W2aY$yP_I-jSNVeYC>NdVf(!<$T0u_<5Bh&#rZ)(0)53&w-B7^ za+>=<@3{D}ML7F-4Up|Z3t3KWr$BxVr@4K)ke<8--$vrPP#V;)vVQZx^;|{JD{r3P z%R_x?c+fz}_beAl@{){wwmvnqlkxYm8siq2KFEeXM5rwGj47E_BWx$KNlHqAHj7DF zhp~e^S@|rE~+a1xB2vn3x|JpPYWzG(8rI?x*U+8{gIK=F(?@}CNk~JAwvU-A+8nM z&9MHeG=e>a^}1ehVsEV>bQxhnLD1{X$IGCrC%y2Gt|=*-+E+fcn=bd%LkB z3_X82$ke8xSTCLLl?@W!NZPn3wtN>Qb7ZGIa*&I`UT}09W6OU@7eOb*zgt>TAG^Sm zW|}KWpp$;lPq9>(jge;`GHT?lT-WAHEyI_11xG}ZOhpj&L!=-*gC^#irEN&XOynC= zwqW>aT9tVf?KgN>jPafV5S~lN653upB)B7JlwB#WYrG%?tRUa-2fE%d0gm@+$0Rbbfi9PmZn zL^@)iz@hjfOyGfVqri^T@~j9UVA;pDb**=wUcfC|ctkl19z-L0*fYe?_{-U!8e-qY zv&$#~0m-C_+nawxN!f>SS;pRKs&O>}9fW%Gn`>nbfP83WcbJ!Z>HELlX}`k|md@e6 zeM2hwZ+F`N(5cS!bX?|mFnu@E-%+v!&U8%1QUT_0h>f*VDs`s~#O9NIo3OZHaJ z_dj>2miuMUn)eEtIy;0jw$u&cx^A#PuffXP7fYlt8d?z)*7_gLtDHii4On z92BU75*Z$M+eoNbvyq7{xjdhD9yfFR^7C^0{63c5L}H51vobjZAw$lD=HB z>KvgS*wXmVydAO*(a9t}w+^L7=?BBW$6QuVr>pTqkK1F?U)(K{L5US%SUxt_eTf5s zP z_t`b|jDW4|M_jiwJlh?9l=VC~blZ}CeK59MF{ROP|C)YX=J?YWXmJ};FcMuO^fZ1% zW_Zo8-f4$4;>c;xtqiYlYa=TJ?iVEj98K}fDMVZoh%x^JZ@BMfpJSIYN5Z6%A5&~K z=H~E(71o;02J=rV|9H*ywA1k#CC^|^#Cq$rcx%E|2q#v!EuQ|B5) zT=qKM?$R#UftqI5$4si(33+Oer}K*nvVgxu3?@#4>Q>HsiwdFoG5b2e@p9Ye8mqTm zvfw17G+|h{sLtQ-Y;9lf^~sBFV(UGo@R0uBqqRH*QEQ()2l2f;DP7>0<~G9LQt?x^ z8)LAU@i5yj65Y^GsV$>n-^w7ul=HJnK0Hd5>;>OkSqSknYs^;tc*JOggw)tvoNjEj z8^Eh|Px^z59owB}KIr^p`z{4^7|Czrqs8#zI_2sIia);T;NH~vCI$cO?;>McZ5+o( z9}>N}(teEOq=nMcv3_p)6Ehz$jCsY(@+6%p%FC&W1b~sI=d=R$!j8F*R??Fg@dA5g zm>o}?2%6*q^^~vy71MDju3nuo^~#<1uDeNW)DKh>??W;-#T&kbzhy(+&-2;HypKu} zPV(bJ3oD`^BV3Y}r=ad8t01)f{vtCH%&q_t^OL>cG)$5`wE87?a;Xx6ED$i!!gM($ zIIMKS-I8@neB0*Ad>-qF8tkj%JfhtlVDn_~*2GC2T7chkbjOUJ@d>8RY3 zt0M?jEpB|?E{YY>5ZHeZbgEn2|Ao0$oA%+ezWz2KlD0D^Z$ogi!VH;U4ZaJwBRE>5 zP=~pZ7X=;oR}}Y$hwR}epEDkDw}oIwxwXT!ze>kROvGZyo!5Dzuf=L0yYDrnge1kz z(Z{rcn>E=Ty8cc#pxJA4|K_#p%rAT_x`q!+C`DxX9c_0odnT2;l@&dc)+O#Te?n=; z9KPG65c4;i08`?fWp2Gn=eu(tW(BRzD;B2q+eE@iNiygdZLHC{d#1Vc?A#98ZnOt6 zmSG%aOkN`F=1eSJL#jvYW^XilN3fAfY&%Azc#$X0zK91EvglrqBs4V7Gqo#(LyjI9V@R$4g~&S8^Qr zOqJyTJfcJ)(}}++ql>%{0?va>=3$p``wxa2tjG?NS)0EG8m8iW9FuT9xfzQvE$_&C zev;2!R?_%hAhP&p?=OnwH`5lT-g99M;stS}D!wQJWttkCH6c~SOx#Sa6DW*P+HfTj zXAaPY@mllA=}&JDA93{<-K$o+riH&-H>e~&!ez7S9-=Fd(sVS5Uw!v?F_&bI!f7=; z{M;q*3-|5HZ6$-n%61B<;!&2ROyr zCm=j7Yo<5js>rq-3qyE2vZXIQwVgP;ePT}l2Df!mT(v2veJeH@mnra7 z_Lk7xzH9lpR4#sKM4?p19g`@@_`X{6)%%M7cR^=~G6-zZeiWFR z(1cytVy{UPV%miBBsTA02BP^FMHHy6)o<71T0{ zqx-##!zfsw&7kTWe=wX@=vJGx=KkOHVsOODmm<>WNARp>Dn>-G>cRc}azqJ-lsq&r z)?IQXz8M{5g(!fDm_3#BdmKv8;TF%vV#g387XxUY&DEvcR#o`RJ zDa76HA{!Vgu^sn3d_}WBnhxHR>J%|N3N`N}yIO<{s-3!X`}4YUV&z*9oA5$aYkcnh zMNo~KI*!#frF+jhD>jat>MEP2$?v&=+?n z99m)}Yi$lTkqbjq;YUWR@6T-ZJef4&m`*wQBPL$p*P ze2(8@72x|K%qfQ7!l*8w)1pd9G1y=fB z+8anvD5TF{?v3wp|E*m7KLQncI$sh9rmun3C&Xx97uru->R1o%DwT?YHytFSmcYYJU>zLSr-&o-7k+tYu#vqfSoh>odRcV^?)e z>-^dU0H4;U*&3!C4#)Qq{5)m3{%)x81Z3tiV_-x5JGE?QCGWQf1NI;P$TKZ0CH@0I z`+*D?Tk?w+-iJIf--o3A={0D=El-ZUM%^$=XG!D_4exY{H|lhn$#e7Y^wes%QL<*@ zx^pWWMWJ!K9ISHwx-3zd{mCQPMietQWpYk+>-f)PcVwlcf5ijYJ@?NV1haG2^x+lq z8rc2N%$P?_AB-6F%aak}MI(Q%>~?5+&2t*-Wzf(7i^?eKb8p}wHHxmFL0&#`WI&UJ zV%CiprhKO(95}k|w(uW$FA-dxpYE@I{;o<}d~Fp3ChIe=`KVq2n!3gEBnBxCFg}9$(>%eK!7U4T!Jjb2{2X`?^zln2Mz^3 zQkB+`3L12;=KgMjyu5Fg^NO_t1@1Sxie*gGRCXH<6CcuL2KN@WK184`bmrQwebMk{ zGkdymz16wrhC)4BrP2^`Fy-p4yf+q5Kd!$YT&>kB=nv&=S`)!KTa^Lt7#}R2ZXWj} z=#sm}QU0^dkF&u2TdYDUaX-ierVt6!T92htn}Q?0Riwau0W?O8XBX~NrMBHxPM8j? zE>+?sm+zWw+U6&z*iHj}lpDo|W0uv$A9-h!!kO^x?1_LBQZ!{Eez7yMif+Ld>k_vR zD}zbkMRjbeSklvB{;Q`034I(;?HBY4p{pr}_B`St^zJ84fwTlA4t(ixn;D0q&masX zjS~|U{*Gi4=2Og2n!UJ79*)qFP~)|pz;p)$lZ(N77YUmWgP~H8>fxbZYCsb5Mv23s zBPbVZQTw(+8su=r+BHE-yGNlVeH`It{BhxU5jaie;#iYB7GYK>8G|whvL*Jx<4`QK zDPMl`mJAMERow))Z6WKEv~80aG`xIL#1$EG=zdEL6?#~iN#)`?!LoLN0N59fd;Bs( zX@AxJxi6*&6R|Qk+-Z89bv z;@CT*1XXj$Xod?88;6ur!c_`gONxLP6NrVuVXi*iWNCHCC2mGzMwN_0D|Ek^HTRHe zJ#YO6NCKHUm3Tqf>=NYz{~{7th8g&{p3e+X%5?LhnPbUwupLA#(bsZ7mHl|HKz-Te z{kaI1mvQQEJ+FBXGh}d@Le8XoAV&3wL2!J16_%&3Pa<8``;yFquU$1RUHB+1PeSe0 zQQ@7xg{lGX!YK~(BI+E>9BcE3u8rvrHe?GeREqjT1yn;+5m}SG6Q#vT@_2pvQtCIZ z?tj)be?+Z^#IRi62ND36d-${h6g?T+EElaMyu0GLl)AIxUAyGB(Us-btC4$U=;loX<>Z9Xj44C64L1O9QGFcWvEuY?FI|Eve_vrK-rQ z+&jKIx49u$%*kPy@q~ZaZu#IZ$un|)rQlwOMrtOle@6B!nRipyzQH|obTp2r={!O< zWOt{cEzHukf4JeE>pGdLg{wPN>r+!;%)XOTtoBQhWKxRE#+tLzRVLAdp;Jl>AYn_hA=f7z%x5G}7**%R4}%mq?;fhU*^Sqb z4vCRAIKD*YA34v zWb+Bx)U^pRjQ=@fSSkL>%j)+*1EWRKL$jseuoln8PdNDt4b|{SHKsjV3+#0Ot3 zf&YNZ`%;Sa`S%mGWKij&TdkV?(}}0Cd7=DXI^92XnCYt*0+8NO%gic5h@6P@g8KDf%dtNyAMKyEbb83x0Ci&PIYWdVxD#NBV_Y-merQw|;H1=~}>u*=i*h zWJd_~$*>D0LJ%ERDj&U`Dgz*$a}VwXcwNnA0D}UFopY~b^?mwVga}>V z&T8z9z_B_WJzyd&+niiG6DZkuo|coSL%1mw$&o}mhl4G!c-x%?h9060Jy7&_W9z-* z9E#*Lc-B5G^UmRl1ltA5x7m~ zUQkGA(5#EaU#7XN0pADAK*GTy)tOv$KrkRjX&zxIFsFPAr8JpPQt-%~6P##AsQ?JI z=6Uthy9$ts{c;qZV~Nt_BS7hrn?#lh3d%>Er3r6HiiPoL#P#v~e08|&n&qL{j*H~g z!TidhG~%Khn6*8r%tboNC;rAYN66@)M6@`~$u{eOcf zgF$ZsY*{@$d-h1Kd zFIgHK!+p`tLh| zA!wPg+Z*%y`)qB+&+i0huO5U&lsCLC}o}QWNVN-nn&{^d`Ukm?) zD!hMvBr1gIUoketYmY<2RY@en%OX=trLKgHVku z*wamg0E6yxTi@8Qe|e;hvO=X~n2!|rhmKz-{OatiZdtM!8&^&B@p3QvsvXiwTI_p= zstSLeCf~rOSr`2B-M}}RS4doOb2`E|eH{^J26I6@B;CMem%?VKHf@>>rMDfG{Di>r zh?v#20E%!Uw#O-Jppr)GT57qjBijY#pHJ6Io51c$Mj91Fk8Gks?TcX zn%KF(ZM+`Kqf> z43~-m$$re>21M5eVpfU%QLRTz9|`4hWC#QF#-E;f|Av~fcE1Mm>z&uhV+aaXLEe=E zax=-3J>ur!2CJ;9z^nAS_&jQRawc>VmFAbfd9mpJ1&1m2Pk&1IcTP#jir7aN{6>C% zugwU;EF^c46V#Vc}eN9{Ayx{!E z;OVnT=~DMu4RS?r_qX(8x!GDh*+D0T$(9 z585ZC_Q5JQH_DN(9%)fx`35E_ctj--9XX%CkPA0^(Y-^gGhw8ny32@$<35UyPw|j|JX&$Y2;JvOMQv6DOht1ZM*yDz?DA=5QAlQ^+is1bOf{d$*w4nhlqo1fKcT;H|0Fm*G5tdM$HM0Gx93N!*TLifUYHcY{c@1V@?qD}tpsL+lTlgkSFGawrXJ8W1n90Uo4Phe2oVjjY6eWqRjMXp5y}&Op zT1cRrLHj6?7YNE1FTvsjc#9Iov7?Gl;tu*kq$VviIOp0MjyF7g9ToXAv7s)7&F@6~D7A9E$;78+c4zL>+=#wecQmJ!kVbWkxqW3JkVi zcI=X8llRsJT*+Ux6w<_^@jLb=cD_(1m(+<8g&@a2SM7(c)& zd2C^y{ah@5M9o0%S;AqbJG1zzwvse4Pd>%DjF~Hh@_C1I6itbLZ2=-#?UN8)E5OjI#lJRQS5VPLQ_9!@pTSD^3WD?J zgG*jO>8N@KKfz&KNxu2fiF57a1kINE`99c`FJ$JwufWp1c(6S&)vP8Y6+t8p=~fMC z5~+ZeBpxw=)Qh2tFeMeR{^>bK^ZW0-{bQlR&bo>I#svHYbniM-a4QHmgap$8c-qYq zObX@1(*Cn>(tX41K)|}lUzql)1lq-5SFe0oSHMlTxp5-|x?6gKq zW?+eX&f495CchnG;hW{sf5FN$L4X@i_DiBmHXqC4Kf;w|Yk@Xt9*B>qW4h-ZG1!?r z4xh-QZGG}q*KwQEJht!i*3=!8K$}|PQa7u*u-2Owe~L4f@4bonN)h9TYJ@(I_@%hz z*sw}6ei}+`z0qF*>3nCJM`Zz~-N1G6M}jPQ=#a=yAxId31UB|kxiaDM@V95^twGF0B#bxF^; z#k9Sw(seAF@@$^e<^lug`Zo#byH^CnXmiaBn|r4=uJT+90<96=M7|hgB`z$UquUC9 z|MEnc;Ddf(%PWIMxIaR9Lz6v48yvm_AqsMhv0@I6VL-oV%I6_Oj{u=Tt*mnjAUHGs zE#SIlSiwmXcOxhne(WIk4Wi`P;LudOA(Mf;AxG`ww?bd|prB^Ej~BmmSn$;Mt%>hW zDbjprZBqNMD7-f6$1w#sRM3@dH}v!oZck1JmitI) zHgFDpwJke|23pp227AfZAC~M59QoG>xsDY#hg2Hk3j^`IFfR|_4_nQuj~eh|Fu3~2 zCKlEV2_`QFR|hUW|4O})t%Q5-;V5*B13ww}h&197Bjal*HLF|uQRx6k*iQH8N@KxD zbvuv?b^AJ&k9xZ+j4s2Qiuo+6p)vj<_l#C zHMTl<07JU7bwvv~@=2{^NJOz(@8J=)$mQ)9;liuIrS7fH$@>E)0fyK>=j~BsW_gwC ziW97IrNilm$V%21JgnijuuxzPyhxtZl}*xMTQz#DXvVB%fskl5`Qm(%E`b}!I&;Ea zhrFwRCFPsmQa+p?Omyh$GTar*azCaW9;Kk@r&M=J(R z{vXcX0;sL%{T2-bhhl{m2_D=%xI=JvDemqRDN?i$q(E`k;_fX_+})vgaEccxJbw4S zcmH?ZyEFH_w=-uZ$;q5KYqGPywZDAdTFZX5q3rpUYF~LSQe-`%3y01EmGPlY9Qzs3 zzSE^ZVIT>Oihg~nJYePBI@4f%6@~>l^zEpF=VYFT*G!`H7i|@-&7SqO(R0tvlZFwKJR{A>Y5ATdeEO@{Td_C3Q~R_y z8Q3mIMAL(8lAN#@w0h4>RzIs!*1ffrA_S+Z=>8h;ievaof#41q((JX`E6)j}uzK)9 zsqY$>QtnVGvmarP+vc7RajbFDSh&)$A+ZvI@43q2|_!YP!9rX%4VqBOyBn^E+&2B2t&&_~49Vy0l=fa{PR zU~5;p`wb=lIl4{Q_UXZ%&|`?t(zckI*GU zYTo%rKYrb}wa38Io9LWd_oOW8ra&#gH;#2xl zMts`-BS`!<$3`xvdH@uH!OY9$iL_Bj**g9U3`RS6yE^LyLVa8Qf%;a$<=$PJg14?h z5JIFC#w>AnfM!!rUTWF4p`iiFJv8h$r}bFf=-Yw_NzkLyo{bT00=um&AJiDKH# z%wvy9fjhxmwtY8Gu0s6@-x-JeS0mT_=t*E|tbbL_uhrRx1$j0oenJ#|zrTmlNS1hv zX;!;rkDtbQRnJ0Am^&~N<^_q_H2%(t{e<91?aw-#saj-2iG2E%)}2xxMf-cR08FY` z*X20&#Fza5en0wh6`eGed+kTfMJ~g`eYuCT^0I%3eDNjxZd0LuL?`zttncuHuIE@% z2RQF4r|qdH_#Oe%-}Q8F^wCbZVEG6*arE|Ev}qxE{rVnij>b`g-I|b0=8H==Q14;f zXo`hOebkp8>iSI!>G1yEj~`0)g#q0>mB??Ol=BS{CwaAt$IiaP%cb1`;W>O@hf5VI z-DMhRe)=f ze1X@7)+&8zHjCRgi1lB{%i=^D9NHsmHU=`Pg2eNgXjy`l09t{_Qwnz*XSU4`W&`F- zbi(21^4+|kB5huV1r>{_N)86wld8QVll(0f`C@$pYQpkZ>$~}tfwByq z!P*)Y7P~VBg`!a3-Q_fve>EwDw=A(e#-Dustb|QSkrM$uJ)u>bWzvFm&IS#tQfxyY z>A^=GBrb^%iirXinWh##6@g8Ucd`K{GaIc=+IpST?mDa6kpanx=i$0ms}lUD0!XVN z0cp%O%=m>(#ZnZt9H?E?rxFKrEG~ZJXWW$CNiwO?;~09Ib4>KV&oAeEuIw28Miozy zePqQn8P1cfw$o=229X#Ob}~e&7)J~9?TlrmyN^iWxh9(z>+G)TjdV)N;n65E$?EZg z$i*94ZPDkK(RGDCwy1BI-b(r2!$k6oA0B;9=>YZl$Aaw^~2m^_zX+OQr+HCS5n2`MMty6XY}@|MSnE zyZX(ut>i%s^@-!_xaSBDE+qWwzEI{z*>?T1QQ~3Oj6~@_8dyvmCWb;+$wlV#!>jEP zDb|7@nIJoKl1w{YuLPsq9&Kqc`!Fa`tJrv{5SL#CE@nuS;AWk!D;B|NipEIU>59Id zGtc7mxCWw}8HNqfg=j*Rr5`H7!Lk{;LivZe2=@i+GQ^%#J zUEazag-a#os7_wJn#I7EGkZj0pX)?pQ!~Xhq0CeZDs7_@lQLdC@BrGpEa2A+0j^S_vLXxJ{0l6AX$LHM-{D^Qk721OHQRt zzUOp}?VBQn!mB#iC+;4s)-iQX2c%I6Y8$afsZo>`{>52+qb@_fa_(;KsJ)+gsc}8T zRce=F8E4}Yp&G~Uxt3AL9puwcm{Daf#w_l_enPnaa4ShvB3lu859K0vdRTWy7Ry9a z?<4M+P495nB46Na<(T~Y!y`YWexmsaV=bybPN#2&1^CM`aOx!VDAt<&!GPo;9%u9{Z+zI$7EiD19Z-)f|4(7*?@<2vVxHo{uIcGCDEU zKYMp$>t5~5}rh^kT=g30Q%4;Q*)ZgjYi4ha4e$98mvzY(7*2ngSAuDUp`Th*U zs_+nRV@Dh){WtM#YwtCgLOG6x17(1m`snbSW`SPr2O|whlCYi`v+E!t!Ro#%=VSFO z&#OF|pJZv0NT^Fd6H3zfiCEZQ%ZcBiH`cry7;3+KEH6$8GrG{(bcJC(#+k9bMtP(I47RX5CN0$`2ggZoVS%13da4 zHmhqOd&H!7bzfpI&&-b+{N}`@a!<-<3gal$!u(R?E#UPQjQ7@FupQpkJyc)yt&==2MJ+O-oXAR z?m{CLUA%GY3S4&%N<7IKQjst>)^|&i3$~o0$sfq@R;RHNRXwTb^7ZheqFIR&wsdkk z!+0~Fg59=i0-^wdA5GZet+?WY@sfAQd*4-u$m(+QI4>jFd*y(<5vc|N@A_=SDqta) zmGTuxoJx8*AZe_hKI&zhe!30ApNgKgoMs9Zv30u`Y?=Ay-E~S^tZTglDoUdo_;j?* zra>iFReP6ENDNj?d#cTR8C}ebO~vIvonjUNmu&uzAeD7b(!CD}SCF!Dp$scZ_u0Xk znRB8DeL-DOSrLn|zjxAU)CN;W*?m@C7ihmH*X6HCp|!gGoiwF;bUc|JZK+NJWe8g;6WM`CUt*jwV?wR7{d24e*JU>%F6X2BguxUw zrV{KZdQeAefV8j}n6WD=RP;NJy;*m=Bm7RA{_ScEk-bH5mh8zfW^QTq9o&}wv>!q> z{oT=JF6XE7(JPCy_@ysSj^x`r3A16%oz(^(kbe1R6dP8F#}3Sk7(G5JnflTW_}6Y+ zcqL!L&KKSzv3adsgOx*lF{8(^>l(%R1tAeGD8O|8W2nKARQda_dwpnPckYxFCEn(E83 zHA)cTA?5%o=I;I}qe5a_Rj^{B3SSB8l2~m^xHNTuJj4;x(A#Tek1@$DuE&ivX@CJP zWXqLbZDeSuUgemgwxp-hNF^gvq@4h2bEaLWTEp6O3pbkMDYvSn_FA;hYlS6SSs&}< zvM0rMZWL9jsynSSU5m3U=itZ1kzDspkBgH@#=|<-VV*MN_7;w(SZMwj#vR5#46;kw z+wTiX@hU@0a+NPus7P4-%#sX02@}rohRaDR&Nq`a!dTkg_{88VqBHleKI~DtdtFUT z$Y)h$0|iE<)!#Vt@;M5m#}W)@>To6nB|nM`Q8T#fNr8AhRSv2HSgf1c0IGxv-jsV zhW{$kNCrj1VifU~bmFb6!lvE(X4|Kb_cdfX8!%unY`3}JQyZN4VUWH2j{%bhJlu5f z_y01z{%LchC-gNW6iNQ?Lc)I;9PAqDyX^4c2C+}QnEuUoNt9No-|^0-%q&E!oj@UV z`G9Ot;KYZ|s8(-rUULo=wXaaoB+FL-vxmT@a<)Lf1GvXZN3{vOQ?=-n{+PWd)@hOY zPeic!b#`~LzU>(g!y&_yojvIJaF(AWiQt(by#aFA%_L0h4YwnCvCoJW zE5(z?!qdc7Es>N3hbszjTWpJcCFZTOx>53LmA%`x9iIr~I2m~aEU!=alKqnV+0~k+ zlCJ9V`DYY^s%k)lKxB&L&|hvAh27YaM=P3rQqQfg;PIdEx3n|4A24$i@FKJ_u1Xd{I}`g55tS?YBEO71d4X=|Hy#A95gPuAAx^Mc9Skl4R=LylNaIEp-;*%&sI1 z@5BqO1X=(j6OOW~4lPDqVW>g!&r8Q2FsGJpWFtYmtqhrGW*3_P$w}1Oj^Pa?$?#-< zAqt{MlV}?E;dvVb)^Q|>Ar#mMa$MT;+33kY7qjL*stH5`cv2uTJ9W%1DqWJ|mr~!| ze+=yi)^2pabr3X$*4{^bbUgf*{oW^-_RGB=%4Zg}4WN-Ox0f)QU+-h$R`R#5MF!|+ z(=h~Bk!c=eqO4$p7PV=PvEGJlUO|4k*q;%z1b+4%Y76DaR)paf-rAOn8h9F?Jq_m* zPg|RkKYJ-+f5K(x_yQ#&Eeqi2YbQkDm*g_Vu=Ql3w+;{1mcWF07Xy@Om#KR-W0rz} z4#BnIqom;##%|(PvJ@fej?16F`VNm{_A}j1YbM)a6jK``I3<5{N0^I3ZOlMb18&Op z2B^+_w$jQ}9VgrU8-E>7vbkt4+KpYEf+H$9;dvy%Uc_MDY%e!-IA2dwX$T7ZJcr>& zTS_viaVez~{KGlf!;wBghd#GPpQV3z#6wNAW+leHU6Q1n?ceznG1X=$@=+Jl&e1_c zgIw$vA1Qs9Gia;{4Z(xJF<)}0$0<43uS;<;jdU&AvYoXh?-wdaI9l3wtlLH_%gL+) zk@WOvA;I4?FPxAFSX#44UKY7o8W5|sOK`d!6D0BjF%XG%OG4zN*f60jCiwKXcum-p zM#JD2uP>}qw}7?b(8_bS`ly=e>srEjueiPJiYSry57|RySU)^19_kU^i<7==3NZ7E z8n5Tw#pzZ3e)I8GOY0mR%ZG60#7UGpT)7FT31|DBqL5HfU!2F%q~Jbrdz*pGk86g}z5G^M36+Ooxro_lEccG|ULCu3s;(|J7&PNd&XYbHG+X8VOI(j%QYuu{WwfmBIt&v@e?pgFf zLq7+pi3ubEArlu7+-Y(zhTGfh|I-?d@%sEfg9>nI-H2J00s#EyAb5S}btma$Woc)| zZs%lXV7d z7A7VZG5%W|0x}W`axxMSh!V_3Pf5)}0|GJdGqP}S^6>Cb&T>qcPOE&-y4WSO94TwMuK*U1;;vu~B0bWb<5s+W+_CGiLe+~ph zAQCbPDjGTl=IaNVZ~=%2Kp-L#5E&WiHT{YZ_^IS~_|LMkXF!K7NRRpp>+XtQ=HcK~qaxM^{hZz{1kX z+Q!z--ow+&+sD`MW7y~Lh{&kun53`CDXHJm(lZJQi;7E1%gVpkH#9aix3spk_x|eZ z9~c}O9+{b)n_pO5T3*@O-r3#ThaVgsU0hyW-`w8)y?^)*E(8GZzr*?;$o_A*@Lq8t zA|U~hQ2&Dq0nz960OBDbQ*ol;OQ@roxxJ<43PB@~Ow6zAL8sx?_(N#!K8^7X%(F#% z@gHda4cY%YV4?rNko^x}|AlJ>fCWT&{qlf#05QNqgw($V7q0J>RebxNKnLd6d>Q0; zaiPMV?(ZWg69L& z<;!<)7W9deW-ipJm{4eAUj6EksF5jM4>dEWY%?sUZQ!FO3*Q@+<$@Ts9xZOcO%xhu z9Md0>3vnoV6ICpfWf8WS80c!)+#xys=85@z4B5WI6Yu23Jp2UDK*YJ<=yoS zIhM##+qq6Is5_hp74kqa@NL3&WnfE-D-E3?j~SmJWHw9dn;Qtc?4% zBFS5cCuHTi47&6+Ef0M1+>%7K@PT1HNY|6XUU_I$p~Q4enR`<1go!wRvS5Ry)d+_Q z=8x9jz;XhQt}atH)f7X^TD^Twc37 z(<7WKphR4XP%HwKCj$FwvVeHUsUp}|6O3QvzI>j0X$QWFJ473qbR%(ru;zXfAVWa_ zUVUE)sLRY;8gr_b_U?@h7UA0wi^K0TkLnR_{w}ViNwO~o+Nn_u%0@;6g;cFXN^$^{v zoBq>^dXD9Fcug?dnvU?ORCyITai%AVt#^?M_8Jhnt|Ij>*V$*4Mb|c=Ma)dG}; zx_k5he{QJ@75BN1+n<6Sp(&(5_fP)d8e)6OBW~2Yb@~ys2^6OB>=R{gXZ>Q>4ly@FFXPZj zq43pY`Jq9)ANf$>99}icYO)_xW4!UQlxFXGXp&bj|ICW^px#rep1+BPGd@jW$7j4t zjx6wyrA6gjfbW=CR~)7#gk@7Lc!{D~r7Dv8&5H|D@dia6;c`Qyk~=o;S1fiHW0J4? z-YV|rkyr><1Zn8*CT#HP*|XmqGfsrEUE2*KGN4G*`F7CC8ie&Q(@WVjR;HSb$H)X0 zwg0~Rw3@c_SlFcJZ)`4yt4ihOS|WpxaLyP@?l!2v+PLN8;aNWkz6!>S%3^A;d{dMo z_zZHB=?+~hAZUj9w6(a7?-ePw$rDYGLInPaFkL0uSb#4lDAd)Pw7vIfzNQ`@c3&T= zWoEj8N0BhGX{=xxU-qF-SZt8v!%2hhiK>K^8y5Tzib!^R@0faE+8yx23_#4$vsH%& zR%|4K{(M_PSoYx83AfpqBAW;yMoTC;H^)6vd@E!amAv&h*8s|T$I;$lJZP3^CdQtT z=e0uw3RJZZ6{in|8rrEXp~wtwpkj1snLg8{;l++=puH7Jb3#H~jT+#$C~flmvnp>> zT4c`SFgmbw^d;hQF+SO1%ImIjokkIQ7Cw;2X-6(^y9;VDMH9X{G)#(?XQr#j0a4?XE+L2V4rE2&aJ)FBbp^cMgiw?i zE`lr;^1kr16VNRe;$~MSS(cokh{)5^zW^$k9LhoBN2heoWTA*5(e!OdcLyR3;!!!W zKikBsH>FiRK26BccymC`Z$y}E&kSUJpgVlEbgsC~Dnvd23;HWU66bpP)4Z&{tz=o4 zcCgE~P+izeJ`BBD&#*(12xkL=r2zQ&b^@I;w{I4~sg5idjpIaut<5DD$s!i-`pN#) z;^&9}W?HwYFrD8mcQZKKVl@46p~UoaV?sApT;pb_JS8LXgx~JNP3iI|iIhhpF+#BucAB5E}$4C!(mhhTFOx%l7ju?j)Pc)J@Gfx(&l7MVtQ z%N$dz)%SLq9s7G7uxuQ$evJ*oM)OJKD5=&E_Ke`&96zK-kDELhJ4&7A*g>|xSU;d6 zPNcz)Yi}pT{@EwFu&nhkrc&0i7=~^I-5Ixve1GUmvJaOOIHe|d?G8pi4t5m^={eNO z`J;HdTEp%jHl&!KGSE$gTFrM`>dN|yMbX92eL6)tyfAv&mxfgG(vNt*TyJdHTuE)P z6I!;3l}>O4Q&k_7$O-)Jr~OSTW|>}2|HB>;(;zX;o|s9OpjXkXQ<7(}^i0kPmML&( z4HKu6yX8iAl|rEji)}dI5^aXg277?>v0ecd$bs$3 zgc*TyX4kxODjQfJy&~VOzM2yW%OX#CKTHm5U?EB#Ds)A49Z(6xRxK0FE<-dVvcM`P z__1$V8KcO!i$eccN^@CoBD>Oc@{<$&XYiU}H44tXm_nWNsLS_)`+B0PDHKUpN#r%( zGk%X#E$_P8lnraAu@FCt*tju4i=^HJ{3GD#49j+cMjnTZ+zRxDD+=} zW3jlu^6%?%A|WD>{oERP)((Td28iv{k$_quL~5hDOnFjdD^|R3nRVRcEK8LqZrD3p564{d0zYUQs`K1( zA>a?`rvT(I8+<6Q2mENNec{FOl^wiu2-6vms_ujYqH@O@5q@`uBOuFLr>s)%owm1@ z_Q3c|$T0cO(JIG4*x++u=JTW2j-I+f2Mgj{atHoXkANB%0ok$uTrAuB1+Y|pBzAuI z0@yyVwcR?SNnV8p%QaaaeP(k1nZFqnFn^o4^G;)stXrRQb+6EahLEPkF@7OV-n^+b zEdtGirSKh%H&ND`A4|tEhFppNuLTQQyo4@SAYT+>T}nk+wkZknV>mm@Q)6h6R9Ed1y}L%oU6$1x@Cms$3%H zvA_XEPtg-j;VIc8>exDU9{6j;lBf{4K@A!Z@ z&BL)O-s&Cfo&7w>%BHJ|3g@KQ^LIef4NZ=ob2V76YRs%)rBVetDQt0WorK8l&c@dTL!UF25jhK;w+lr*8fHRSsfwuezj49@ACtCixWO$7+P(WS@*QYuJ>yi-*6B4Uu9}pC(Fya)hpr@2^YSF>U)ZJDg*Mq^12skOJ2% za@>Z`RT>gA=o@WQC7icH$HUU%$y*_t7YB^NE%Hp!)G2ooT?EaT@|2T~HsooC8LSrU zcoE`LpG|KkwBCCP^v2%20A8E68Yk#hqFOk!>$&;3er^mO4*^%n_fswH*vvEDUdf{D zt0_>askpz=)yMsWQT4_G!e*FR9g3J=FW+X6c_7*(nMVu^THvL~o9dd&wK~~C3h9Zx z9)ed%;X}<}dr^{w)b!u%(5FJzT~+V*3o~|Qw-43(RQT4YjGPZ|dd_o;0XB**Y`N~l z`X*2)dm}!-o$u22u-no^sPW>~B#d@6{y!dt^o!14;*-oUj5`ZLr9FWcRH zyvRvWQRc!kr;j?1Ta9##P@g~m(j;++jBA+F#C9eDJ@}XRc8l`eX-(xeD0gDL2H{#i zroo?>>d$0Jttfm=EdUSN35yw?=R$@9{M8FOUv_&=<9}V3tSTci6)FtvK{paZ;+By( zkHmLM%S(_VHa}E+1-Xr&JN2Xhj4Wz&MCXnx{_NozLv=kmpkE^B6H1AQcGhmbZ-ZNY zit`O4kS10Wg`jcK|*(3DpXNkaEOzO6G;A@ zv-R%5Jey}>lp4A_$~X2@%78;EP9{e@DNGV`wC#`xT1v4{U9aE?Z#(i6IY6LI)gvsF z*Pot4pfdT+C92^EtN{fw?L}nV2^E-Oxej!Xdt|S<1>-3F6C+8Tm`|lOR>Z^uj>;hy znf0uM{gs$BSmct}t#ls*;mO^Z2_T45TJE}gg#E5kOqd~yqK?)aN+NYIHv*{W)d^%fZA=Qc#D))uY7EyBMss;|(9nE+*suKk!T7gxQ%iy$l9SL^d#voXVIXQtP~*}m z626=VPo)b6IYnVk`i-!~VlizVm!fS|pFpQ&pw4{DzUA+pDGa znk*4Tzz*f7n?vg>-Y?diMP-N;$(Mr@JCuo&N*2E}k}G5g-f@VHOkgVMIa6Zc3T}Eo z1vPeC-eLWbXGx6EL-W0>C+p5t6Qd|4J4_&sQTFtv87p)&eN);>MBcrdIQx_53rQ!V z%iHH80R|4Lhd0x`!J)&W4$b3B@pmWhLWxk&t$AfmIM+!Y|T2k!8S1VpXh-zl zVT+i>qqO(76|P~eP5|ec?=X_*Vf;jKgcM%K+?F|F*d;SJ;xYhVRXy|*leqT0Ugm`j z(HfOTa6u{y6kb!R+S^#z+Q6mAB=ycr9n6`JWV!1o>;=AxSD0wYGMM-#q5t_y*cDTD zADp>o(^Jeyd$}lMQL&{7w{V=skurM+kmGTt@(BZhfO2VOsG(ZAl19gKMGFPFE3&l7 z_DH4t6Ove4D4|yDDNW0G5{gg?TqNEAPf3^aUkL&h-?ZcXa{Tz*j)(+B#2bnB1wGlz zf^EB)`|46oIMP!WDm?)L*y6;yh5zkmbtXUM2HJ?Nq|UEX*g4m$4rZ)3)#Iy0q8_EG zXn=p51B~p_m#eGYY{6-iY*}>re+P*MM;EI4z0g{J{OH6NuEkA6a#{^+h{emf#wv9E z_C8~;JAA`RsYC_$^nrZ2qDGYEoX9T`J=;9C{d2bf@y_giL)|aY^SWS2g3Uw~d6|yMI#nReJ?*!wVa$*h>|5 z^%D+R43h- z!H`#?(D0^IL@*@lapC*^Uw3*7XSt>De2r{d*I<$QNwUo0=I#UNLcSz`6PxL z{$??zPG4ocMKLESP}k$&o%ed2PXV6GrepXN80K`lGJT+=87Leb}Y`d7V_TX5Y#Dd$6md^E_(_*a$%(RCh1 z^PRWa2XNhLJgrZ(_Nvf)bT@no?_TRlw!C~8S6gqS3>%6z9vd+rutVv#kr#&$T?HR= zL!2bxYSz16AKV!HJ9j(tuTTY@#gWaaj+z5hpYxX{%j+%=U14pw5RLeAkcp-6*IJkE z!yHr*zwLbYmgWOT_}4V9WOAxT@GkH~ zq7fsT$%Z4b8eStK7$z~?b1se}m!t@FKHVLw+v@$vngUMD$phUUe?3%daBPg%(gb-B zV^4ia=yI>hH7Tf)@$j*qQ872eY)x`X+yMfZ8R>t1cmWvebnxA_aQP`ze`RMwIcJTA zn9UNC|6@Q@Tq-)H8r?BIq+ztkDlz6~C{c1#auECT>F^el&M<0 zae^n{ z72;|V{j$WCMZGMcVB@N>H_*1!ivBEsB~L+PX+c9~m$>wM^(K^}fQ0TnxB5rZ7fcqVyEwAv}nv{$Wnd4N2CGrmX^UIrrK7%TS{;Np^p}^|8^z`pa~}8r_>FMW*|A! z^(j*h zK$U^)kw57|^nzhtMQ2K^C202#HrlRMfuh6a_@05nRR9br1jIJwcBJB)&lfr%{UDus zA=!)WY?J^u8%Y6zU2&?pb9*ZgSidW>e6njw&q9_+xmOiYrB7h?X2yh)Knl7#nmv-J z^@CY|L!MKFt!)x0P8G`nerFX9c7BJKKsVta|LL)J0_m*P@75~KjWc^Y9XXV;u1)?P zW~7SHsCOhcM)knBF2Bb2T~9iCRUK5HlIXjY8J*F1v|A!9hIRLdJkI+ncd96SDYqE5 zGfnJSg=r62z(R95^orVPE4d0xepfp0o<>k?h}G`IE~Na(SvUylx1~(itIavbTK)LZ z6eGg$o1!`ko(!&X6)2`e68N@zf^!IPQ~PRM?@-d6*fS z(0tF&NGSTkABhJ-Wgvp?}Zijk~Xuk5qweQuvm}K3i`0j$ZswT;&NdsWmd`skt=oALb zkLX@iVDN{4=na9#sQakH+YvK!Zk{0&$gW$KH!)IB<4tP}dYU-R>xDf@hZ$M{dB<03 zR5M~3WvRI~FxPN>LPPsD?u& z*fCu~IBoQ<4d{BOmG`6FsNyXHVRqqameapQ2qn(;@#Ky;A^gKBX|pP)4$&~nwoA{LqywWK>`8!O0J!CO&Cx@x?Lf)h7A50)%DMevRTZ@rcNP=kM z4O?F7#IcJ_awtVc0A6ED*`#LdvlfEUsK zrN!#kLDxqBwEomUBFT;$Rj3FzMU<)D7Lq;1$5C)nBTVI|YPF2#1RInqC9NCaU^9 zhmrdizu^}Qb$nstrvsR5v_j6f^=s1Ua<;dM^$XW}rBc|I5yVkT1n=?@e3UuX?)fhJ zDLFYt+t%8Mcc#4PDNgRni+(;z$+MOvI8G2*?5S~ZPMU~yElq|US>|1=)XZ8zyh`6J$t&*kXl2uCD6{LtubWL#a>x%tg$X;SpT(X zI@P#8q(=lMm~|2JnhzdHJ*HOake`GU4yD z-?kwlZp~w{&-!xVT728C8(JH!byxF|HsX_L~3@Ttic;W3p}^exB44 z&yDP=ONFq4?a@L63g*=9oUdC@f&X^g8QF*-V0WAHhLo%gMuKI)nMBWfbsZMK1XRd? z5H`0sN1JwMWBr^JTaRQvr|>mBcy~7m?Vr8gTzKlZxD@sMG#kSDWGT^_ka@+S&7_~_ z{T!1q)un{vi7U3ybFKn3$vWMJt8mr_{cyh$!qzGFm28DGSWmJyyJ%?EfbkM^B zjH@alR;fcggwE3`0kJ~ zL98=mQ+c=*zF{dzMCo9of???cemCTeXi0NTw`peKEedgsev_#^aM#0FSNqOqt6skt zXj^k&W@7!=a_>d1^K$75VST3^+!P$bK_kZL)zdvG5&;=tyee+WUhg3F4TvTnFqbk@ zQ7r}A5Z@9|l6miMF9?;8Qrtb%gD<+?N^Kn8jJ-Q;Yzs`V-KV`lXc;eu?0z==RX8}in2y5>v`C}rXfc1(YfdV=_XnCRM7OwFFi!m50W z-&S*~k4rA3hXyro_;ewd_Um|)?`8(0b)+rA@QN-)q|&pgzgokO%+MCB1v3~;bO>h> zMBtff?xWW2qQ*pX?~x3fE*=!_t*QiaC-VM2ZpWG>v@}+hnf;DW<6xP>zfChZu#A}7 zVCYWKgRr%gn}RcXfQ&oKi6-nHLyTWZi?%##8jlQ}TIoj%2+?Mi|3^(Hy7pR5d3&*i zI?u4N$q`hGqd?R>wNWG=?&9%+eObx|+||T;a8{_`3xElbvyJ5M-lJgTl4zMuP=UyO z7q8s;td+0+ro*VxF$5!eI&|PC8!GXwShg}!(twq6ym(IbQXD10%{)Pp6CfB!kxCUatUF0r%39vvA? z5E%6`3(1jy&sJ$VL_}w^x?s>)0zL;z0EHm_;;1SUiP2aHQ>PJ?8F z!|mr2p0qjwg})Qf0I{I3Mes+hgx@A_nlBrr7&vH;$J032ZiEZ^Ox7e&lSPEdy*(#By z9i~sbXof9qCLt0}yhEmJt?WhH9jl;~JV9!E=CM-rJe7-999HDFRE>Z+zD+cNN%kK{6ld@aznCFWM=tHbK|-i}wEkrh7qCN?OjwUXO|QE$;3(Z&|! zb^LUo827_wL}gncdvH&*6PH_#!Dy-TvahYJy=B7^KVXP#a)b*T1(jwtqls|r^0ZM= za#{|Tsi++M@#_$3>6V`L(FVUxOB3l;(rok7Mc5#)hL>mc zTO{Hq8yaxG9iqvp=M+dA{>kHqbRlL2Mav<~MfU{3+rtcl5RSGhXW_KbAq@U(w=7GX zvtThLo0#hAS)$G6G&yweeaMfaKi)V}zpDgj{m!+F`chrXkbc1+0>?1H=M<5Rf|B96 zqPo$hhVU1F4T#;vTP&O^d|PNGvN4#LCLjSoP0i&hB0t1yz*v~L|2!$qmc!nOK7d9% z7VWlfU48@&E1^mjUPW65rmu1j#%dk`^NUpP{>{Y>-0psi4WS4 zt+*yer^KQ}dD>9f4j{q+s*+87=|U!ph7?&>ros!rHfy)pS4MzT&Ld~@0i%UxxX3V5 z$P()^b>jn#{p&_7SoMYgt>TlnRW^0Y;8#cQh6uoW$GByY$l1Jd7Al9R-9~-ym6A=% z$7N?YY-vqyp?p=gE>(Ve)pbu_N*3d@a2BkvnRAl2*o((IHR150f!GQ#N>Y>Fkf7~v zQ$A@BB(9rW^_1hM4t_UfW4?O|_=BUe?ssM{KHFbX?Ojwa03{LWtKB)f>OMei5*%1J zpdCQc+3^=*Fz)ZT$_dULQU}U=mC-IK-+EsnDF?p^qh#~H-cLY(^IgDDD6fV)?w50r zth0)WE9U{SobMlbu%rOnkFluf@-6K`le|}{?fH81x|#hP>WzSIDKv?MwcyFsvI!gm zm>!tb#qqS=#_Wg43xHbg5|;bx!0*YHn1r!u=Ird97=!BPC=lqAKdf*{+cUyJNZv$> za>={@GbJiycpX+q^u%Or;QdvTTp_w@$59q_q8eT<+9ozqxgwT<i1@U4gX1=Dtf2wr2(d;Vu*mj@M7zcV&oVJOim;Rm^mu=9cudLEf7d zsMSJ`3-L>+#ozwD092o;^XjAFP#U=~xR>WrFb{o=^J}qBpp4P;{InQ6=K0gVk5bS= z7GizM1PE@$NCyo)Z9DKVLM)LGJKi-($l$#f*Wk2XSf}M9wj4#AGJJLYuy$hTY>Gd1 z3l-TPK1+l8r*d`a$G9sAZ(!M%y5(obTNk$hF)H!M5Bcg`INW0z{O^R*9%8R19WM@b z;eMs{%Hs0xGtoGe!b3C%O+;Kpo9q>nJL)6VsABS|wPkx&rz3nP@4jQ|JDp_MTDC3I z@Fz=1^zJagFM%^D1EwRn*6l8=Ef)JQC4xI7j3pZ#PWwb=Ijk1|>jKIqc94tP(lamN zeC|ZEMg#ZvZ_%M1RFMCJskaVm`v2noM@UP@fYGBvN?|T@ZcrK#0ci>G-sgMYzw7$_@xI1(?JusK^E$8dd_2#=b`t}8{tAh5t0y?Q z1w0-qJd9FZ_?yxkW=a!8Bih5*nyL5hgnk~^eetXMMhk|OiNkf zVEW4RU6zeY?nok6>+5ygIv^$p&u?bPMU@-3S<>D8$tca!cw@vR$eCt5!ax8o+b|eT zhHcPf(A5%OAVF*)ev|fm3v;W5F%BnR7)oAwCe0m4#yG(Tricx0X^d^Ik^{iau`Z@D%fv+fDgH)g?ct7VgE6xd>On zYvFxN`Ig7W@B`_dj^|W3%z8D)`>9d7`k^1yv8-v~#^%1cHPBm%-aW~QP*aW45JDI| zt{1DPQD^CCVJM=`!hcGV4DKexv0~o-=y0=NpY$uziD;dBOP|^JMWaJ8a*C~T)%7c? z)hYZ&>~>oY)!Ia|zeAL+`X91yEPz`C{sBBxUthx8R0pW41~-*rQoEl#YQYn0ftnCp z#4QCK?x%{2`;Ritr)$?$rmWQQ?ng;M5p6Q_+^7f?TA+)$YK>Lcs!0y#C1!^r)R zKifAudMI3Jt*u@iT>VM`z=O;n$=w}6=p5Uram)WQr#gulfnlD;2-QsYW!39@i7n^f zoqaHcK=!^D>Xh0Qxh1n%84`X}GwwvLt4VNa0{Dy0s_T+D4&*+MgC0?MnUvC{8h+Hf zJ~ktq62r&#XsR%;nT3`V)G*=q?W99Wk^ln#JvasxpGDBUh_ECp2_PBn`|{a#?Ny7z zDEqEyrmydJy=!xM32k!M;{rT4hoPHp44eE7x-j$k8|=>O8a{2$S%Z_Qh~u73W`dj5 z_xaLg3za5)l?S;Z3VD%BuzQuC8krvzNhf1Q^UpVlzc1xE*Q<)8jqG)$8T=@Or_!My zYeC>bonn_jwoe^Ue9h&XPx)Tn10R<)JVaY_-u|t1=1j?qI#Vz-{v~MLZJk8osh<7~ z#<7eQi!n|^`)WB-DwE}oo99BD9)P55$Kuu#@G0}r-FVkK)q~p_^dqRI{>j&x^f5uP z^A!XwY(h^(SfCPJBVMA*1Kk1+k3h#~Y++`IB=zR$gU$A~xQAzmU$3c#=M#7kWX^h7 z+2XqXH~s0mk^`2sArS07@-2J*j3GrfmFVnk{Q+l5D`cgcsy!@1QGPDD^x33nuaE9S z^MwxtpPGFEJ;2SYTnA31qP%kB*qaMfxm?d>E4MZoKEC_o`a7n9b}wN5qYq}jQOH> z&fesl*^=5ES2&+6>xf`SaM|Q!Ah}GD8KQq#S#GtFa{>^?W9ILxO{7v;zo;6?4C@{MIy+N$i z58A`_F)gYlHX?c-{l&9%!#$XJ-Vh%7*!!am&#OyzwD3w=zFle?llp4=ML7LbBnl@3 zOiW*Dc+by3da&`lVO!q+Bf)-p6j z1edkMm$ykCIe|TPw1Z=cKb;U1o{m2Qk;&F=89!M{z|UxbDMehGetoC0;}N&!2)oD$-pJp;$Yg-5TF!bq0`j-NcWpqT zk-hH}1NC2+Nyo@ZSw$5`J5(=nbSN?vY7%g)o3SX19h*$rz84Plew;(UTi>lX@bbNj zbCND$2i@?_awXNa%*G<-+Za4QBD9obY|{DUBe>x$J_?ny`n8#4{|H<0#DzQeUOGJP z^}yq!2bX@~NICYLN}m#xW&F=U9v?4^9Pn&FQCX+8ZMJ4AWQM$T3=BnKeAtw`rlJVL z-{g6nXb%UwN-odyeFD!jK zmFOIb8*~a+^wOmVt9>H^3xgTFM&GA{=e5dl!l^3L(Q z{1p?&#x+@UCk8*O=S1>s35E3Hc70~3?B70o#G2#jX0>jm=Y+4yIdIq+P7zQG6J2kP zvm-HD(o@T3g(0?{`Wh;oQB;W*3|zRFNeqh3vb)aoY>D@5@?V){g=SL7()?;+*4}ah za2+Mcf!!u%CKNmC^JtIXQk0cAc2*w^kSeNPj0rK`*ln*fF`v$MwoZI71-$6>mY611 z{Ii)$s5IpPb_-DMe6{^%Xic)^_7fOgpm=?1(!BUt2iPlG6h-%+=Ye(l)o*L zCG`p?OE`JUr#)OQ$pqN+m6O}3igdTL(HY~h^d5dX!8c)aI?eIXK7+z%iNgBLFsm*_ zbOx#2qvX{~s)(k_)Y^mM&K8>fz)mS1b^6=Ynb=D|g&7Kp-=h6_kQRQ)Vn>~PC*sOA zb}9xI+@MH7_zsMjJb5a0K%8{wfEgUHTZ_+yS{V0YT%^a+iyZEc=ura3)H+V9{-I$8Y1pny%e8kw|3b8_bgs`}5E>izD5 znXVMFhw$j0Z$-%gpUzbe`hzQZ9Ay$jr}GOV%1Z{JL8aAoF-ZbNsv7i0;w4D}0Ng`u ztU*s9P?8lzM{hD^#EJU^m|+YX6=#y(_N!sWSt3n61PCma?nLDo#D%&hw>rek728k0 zpH^7CADS|RH#~pgYW^UBN4fVqVov*gmaIgt!0GHa(Vo|8F(ikIfBJRRWIc;wIAk`Q z-HTMTDYnE&uT*w%;NI->ocMk0Cz1m%t|vkdiGA;c6O%Pjj}UG;W>!`ouCduoBXX6B5$1ScMj#$ zM;;HG4;6Ip{swZgha2GwYdCpPAoU)fz8vI*q^Wj`z^`3%FZ``-yE2}E+fz9*ZClml z#vwp{j#^18cJ&**;@t2|J{gHk$R-E{07YZeax*s>Eoyu9E614Chx&t#)AP~aKFes*im@c!JF>STPyqy)a z38^Go0|}UNK`~_i@dx(sa38_WHlK=@2d6|ras-v*N~?mek>PB zzc6_8pV@wtf&%|%_YKRQK9X0yauEB@oAe(g#dQs*b`k(zQY)<7f@X+`p)i6VW#24N zH~w?0c1^a-@!>)eg#W$7=9d%tS39cCE*+oUp2wui@>$sRRt`db2)j$e6LLegEgh1n z@wG;X)Cgi{>M#a5)i8R=8u70`z8Y^I8aJh>f{$!Z3_a1aL{$)SHiW~y*H7!wHvHRL zr!8{j+`6x1e|n1cA^E2;8$}taOnJ?DN$*b0L1EVBvq@QqWzt-=b#waiD@1a7^Dm!tQK#>)WD2Pe! zHIoV9Z{?HGo>~w*sYsO?Ui!`33xjXhe1T^*mhFK*f9WP2!J_@P0z1mj)Sjjf>v zpZmcLURr(LDg?sV-F$X*C&#moP&dX)K^6^()b~_YvH>_7mUL7L+@GG}7{hAF(7l3? zS8&P%{*e0nEVFd*>C1KqIS-b;n^M(YbqpS(;B2yY`2bGX9;(24)J^YvL_s;Z_x)RG zyS7`4E1H9En}_w%cXUh_@91b>h330mFH?aP6h9m>X~cK0oqo8>G=`%f1i}@mB9BnS}uF2@7p7ipIq0 zrcd$Hp|4i0eZ0jPe=e*e5#h3Fi-urq>7t|2R1Y5;biDp5awzLV_Ne0@U|1<1J|;C@ zS>^56_u4t9^H0H}6!G_Z1hh)Y6T21C6d$*Sp?WtZ$U{hj=+|g2Ao0hKY)VZ&0l~V` z2ETdxVrf1hNTY5l*ivTvVR$K~`Bz@ecRU%MsZ;skzu|w}ma12mJ14pZ{*+{zDO9qm zqvQQ&qro%>+N9pr&#jz=Nsz9-$-o|3#3qnqtm1PHzm;n>9^yaVC=8^>6 zsWXf<0QAPW0zh0Q2K@Js36wUlU#Gr}he^yGp_~rg8ShQtXdB@KT@_l`WO-`U$mc!h1MKq0D#Ao&~uE8W5Mf{5J*I~u)Tm>kkc)u0<0y{Vad7Kik2e_1w`)zT9>5__1{jKGrf`%{#?7BxX6rA{A z^E<24R^renN(^!HOGP0om*+5wmgch6bjBzF2lQFwP zpqn5?Ct3E}n?!H+)%sT`b@&bl5!JSdd_`ZKQic6ADk+tgCAn=*P17y6bvjPW_N>2C zW}oKE7jw&m*?5{y-OL1Rcja#r=?7^?!<864n1-Ust2RGEF4xkIjMcr9n*S_d&EoOZ z+GTKDBSw$HZR#yydUo!a^e0mM8kJ*ND3u{jCfim+5<{Y zc3xKBmtQFx(Z3lqwjBsvP9%ZwD7L$u9_VYz7SqCF>nXZrn7IwYj(c`ne1&FTh^@_!Cf{23R2U9T8mK#@rC=Wwt!kl%Y#vDR}B&gU& z5dQ!qY}Y5SjrR(=FIYTyxh))TWH|C>VibveRITgnY%G^+Di7*=Bu;|cwrCAPwy4IU zc)C3JLy8kL9d0`3Kt=pn81MYq$cBG_8QF86%FK#58yArE>Fc5qRN46nfc<(8P=3Skb?OBQP22h5}{c~%*NbP zt|x*C5Y2J9^KtusfMl`OaFdjmzGp{J5A?8aL=~HFvS@^ zdjaWrwZ)~Rm7SLFo13~3LeE9u;eCK%#B%MFX6BdBQ_Z4XcYFLo`1r$O@1yrNrATVK zKC?ub7!XAi6*L%o_Cs($J>>QVg4dF#6yW)8TW)Lf>Kr>*GraZOOJi62wlzzI{_Cw9 z$l)IVedf(dXKRzg9N!rt5#?+-14u@aUGg9^9lr(6th4UeynG~c&jv^#@elBG^Y}eq zU{{OOa&=i>NGP|EztF+iA(fBL7!9~Z`FS*2W{K?X2ZNOyt2ROOpWq@Vu{9Xj!`dMw zJCs|_;xUi1SQt_$9F}gD=;^cA-`#^WMHXbsUA`9|X)pO(vLf_dE5?cV-bsYdAF7kv z=Ze;(an0Y|BBgdtGHw3agb^Tf?#xIU=Bl$zFfYN0@H%-(2PU2<$d7QGk18O})&}Ud zl-&a?MYIwU4B;Wa#6OO?hP>0YQ(g8jClzK}CbmW4TJ{R&FZErKKnvIl?3kWY#6}T( zp6y4SZLuF4pCI>v%hxnSK&6M>;&E#_lE|aUkzxv0L~?lultkf@SQMGH&i~D7WPqI{ z+iN2(K@Wi<$4Qv3N(?Fs_1{;b^7W6~6I|ll?U*E>!cnQ!5v`@StRBdV}KX4doy9zsI`1r$1?P%7T`(vO(}-(E&;b``^ei zj~e6t`|no!cHEaeEq-o_Nnq5j3TwHLH+pGmyocqq#*!Rj47LfFr^^J)U<>+_;YxW; zc0t~>j9uVQae8N8;%$Q)8+$v6fR%`!DpbRD0jkmH*1bIoubQPf%M!_m6X&M_dbhD3 zWGPND>$y+c9u_ouNG@@=nU61(n~;J0ap4@`R#>L>QsVQ8iDa#J0|Sy!E?9AyEg>x2 zM0(>;kduj(Q;(F7CZ(OU8{o8kep%rG*PdrL(PEW;bJOB>ufzb3`3MazSSa@yVqgK6$_v z(YB%(Req)WVqCJjh~339S_B3G-~$epZ@wma^R~M*Y0nzJHf&_1z##orDShv|+iEw% zi|Cj%X+2STM5{6Wf6&TgV)s0}Cb1`s?%N@kOd0p6CDNATY%Y2l_g9VyN` zy1hY8YDG#9Z_zA=qCsF2B0FWfhqx+PyL-2?LdD)}ogG%vdzBaAMqIqhiSY9u-&Rxq z_QF}H+NC*%IZE?xN0k}Zc~O|)?)q>fDV-s0R4;M(y&m%<18Oe z%&VICkz)6rb#&RB*XL=%1NyqO9Zuk`@;A`tK1_(WQTfNTBY904x7bwjL_Qwwe~XxV zzM_~p^6@Dc9_RILnDEGSKR-t4b0aSQtt3($_|uWN#FDAH5Q8s?K@OW=40T$b`+HQc z!2~~b=>3vF1JR{Ud(+>_UyC&{6}awuiQ8(|#&!@)x9)=G^m5%TPPu6lQuv&;al-r> zr7Az#!&@=tiq@nKL)XiVxOy;|2yM74c+Oku*Fnx!bawV$Huxyu{Z5pN>BzhHFP{}y zgAL9qa&-h>|JPpC5hyFd|1YI5qM~*GUp_HOBI2cQ%pegclg7Zh&JIo_V`Y^!*Sg{>BqmSCj#pG&RCNCrM-Ec&a5HE>kPJTFDO%4Z{s1z;+d+|_5Yg( zY-~u@ALioU0S`!^Aj;ti_2Xe)+f#d{p>Nub?1-TAB96AcR4UJ9=2q+tX?n|_1bpi7 z4RZss`4^5wQ#DLiq#8;D#dE1RXUhoz12AmQO-^7aAX%n`Kz$W?dYzlcfE+~e4zYtv0Xx^W)X*JJ)@!D9`2l;RMU`So|^rLp76HEQxe?3e&>IXtAs2?_ha zV^#3^x9xfZ&fx)Yf>fkG?2EYw%)^@KDQI1P{n8g6c5Not@g+$*X*mS~+8UJ6}jaToE#n{0mi;$d4L0zo?#e4d=ovk(JSG>M}KBI&N;5O z{{c{w{{ZpwBymzOkd`~=(UNa3A>J5~cqo4{rb+*T7kAe?`+nIw-I^5r;(c_YJwtLm z4jKpf^@0HKlz#wwp>Y;ezmk*hcahZFY6de9AZ(X;=at5nrtoYxo6aj-yQr?FcG!ea9jBhAgH=9t|Z2P0y zmpI>RAQz(nQ#mWrKwIhUdurfEhX6?i7+6!7xt9W7@VV1J#mL>5?bmB7dL1T(vO&rY zLxaU0!pmLmDB-0MZ-(_i7jqN*t2nI==-~yFvWd4>XDMvC;a*y)Gg2QLJnwQ{1Nea>a&-FL!L?BU#HbRCLz0pWy>{VWkXEsgg?chu9}%$=4Nq>lz9z4 zRe{==wg__LaP2hXZTK!svzI=0}X#thuGNff{En3W+W&X=(g47yO@6X93qteV7)tp) ziW!@)ED4^z28K$8IYIvl^LKgdJyH!qAh4v1JNJk^ZapMQ&TBtu1-#$Z611x{qY!F& zk_VLv1fExY_^>v$;VwG-aDt!kEJZQo{Nk5Kc6)|Q(u8GQXx?AXZ=2IIH?vd?pKu$n zEKIX~b#q9ec!;QH!7H_|EWi4wC+>Kq#PKGA3>VXG9SJ}p&A3CrGL20O(AC|BJH^$8`0 zs(8c;)DGF7u*dqRY62h_|2fp|!P61(hGEH=k)Lt$;=ujy&}h9>@wQAez$Knu(xNF7 z2xUfr;J9m2EN*OxgZWD**-4hmu;#ImZhrg+u$hYD&vh3OK}a#*W&9bqL5AabBbjhIuvRIC;qYa#3A4yPwkD3yM6i-r6CZF=Wfp9$e;rcQ3#p zGA=UwRzvoeS14f%;|QwN3HtlAra<3GH5sv3Re9=W(7dd!b(L)whQ_SBShU zUEdeYdt;$%vEwSrnHSI<7APuo0Ju{4AWVIX?e!qWK?_8gKkd|&MmTpl z)XnwPdmOtee{p?YMA7D57USyfk^>fQ(8~|NQBpYc*AXmsApG+0w=dRNSA@YP0&vdz zy|MWzy|rc!wN+u7?&Wy6b~D%iRM7vch7yU=Q~0ODatTH0$pl*aOOkAj@Nj|J50ItD z(Wto7TqlrM{D1ccT$dvzNnuj&sRq3XwaI_6iVNy{mPscYB;XdLem&N24R3tYyh?*W zy5`QZv$r70SI^mpEi9Oz;^7y0j1S<%`u;FWwN%A*G0M<*=FYWk;n3yeqMrrF0R`F{ zMnnqDH#Z3e;3(n^Uxr1ralNF}JR+aq3|r~KNz(EdCcGW2be5RW43Ex|yLmT#Wj3F- z(!<$=|3JxzVp@=x98Cpq2;9gRV}a3%G|&>~p8O{L8M4)^=_|;-K~n4L8aqT%#zm|w zL70-4-wZ!1l^CV9S|a5YsxK&BoJkiS93S4FX5KO7^=%{PXc~2*BXA`I)=VdQxaoY1YsP)=08h8*qtTJ6$UD`*3A?zNb7oOi4`G{{=*{Ip)S6yiSH)I7x3>wzoh+UwFz%ckA&pn>f_)4cY+lic)$HT~9Q!95=WaaqEmZ40UQP z5^0kZOiZa8GmKTfCJ74Q`D=Q}o47_XNxSCd>P-W0lVr(K0=b?6(gVeQz6um{un{6* zkJ~A$cUksuHXG3ppcP zC&xzD%Vb@Y+Uc*JN1(-Jn3i~{JoSMC|EC8XBgx341Crj@wEW!(x3iCWoMiw#Q;CmoOsPj1B5(h%6U5=w|Fx!>SeVJq7#u5t*cT82jw_z7kp8Y-#8Q-?wd~ zF8`|2p>kzOkJF$f0}l@~b9uUT?oN(Ub|72ldP_|R#5R&<@2BG5ea74lpumxSZd%kSKzCb+la^X%P$b(i24?qs}KJn zGX6`Z(gtsXc3G$1l|!h+J1@w&C$5d2zY`_K@j&a%SZi{u>@bL1Wwhf4^Bu?Fkqx(m zx_qY7o6>C~1*TT&QEPkOXlU`+vX-^C5_teg)zb=k0OQ2XQi$1oOHl;f%4+ZSpy%6f zTPfn3B}j}M;O~8WM)A4oOW6k~w{OFr+%sj4VfpoToPU5_T-7e8{3pr5MW3AY&o`d>oF0T1fPtU9kzkxn!!|S9G{MTA z5xJ+b%7PGS9Vhr4$v%_9W8240%1z)p$%4sBjuQO`z}pI{6f3p_P&mYxJ&}ZPiv+KQ zpM&qr06ie;u}`YdGzpQQ*LNY=#QDz0*R#JztN62_K0Z=>v%;-B`M+Nh^HhXIvoD+G zhc-0QR?z6Cow66vETjMalu4oaTacJMnIWI}8wg_CgztYpKG3ECH&2!Nbi8jyI3KhUO1XMuK$Yroh0SigK00v-+;3Y!q=;?|=lsX}m2C=#~$ z@w7spRkP#@KSSaJzA8qomtclHr-;aY`C-kolZPDxyKZcXekxnxG-s8rtpl{~?Am?d z=_5Cru``!!r%N?jvKKFQl*NalEg3+SgCMS>dEiBLcKtHRrA?(v5CuREPi1eMbL%dH zQ|iNEX?viggyTCvdiwlB>-?2mkN4CGNdl#uB`LO(dX7f=TpQ`q06JK%pdf;@JY83x zFACqIbV6S;9dEIgjmbd%!+S4R%1PmPQFLru%{qcEE%%J-6*c*)##VU1vS;3HH)O>R zaQo@X?6CWcjYF$xvc_U*QU;4VdDWcs_KcVQ`+P131Ai>B+(vox$wkDE zVq?r80)AHY(`2DJKc!5sA~!x_Zxfj*Gz}g&wvTz(#oOofSBR@!grnqC>Cc}u}lLoIS z{(p4{#nhCsN_+__D~d5m#~OfUO?>*;a;3Wcz%!WPlUqe&{c<$OC!0h5#Zbk^v510r zCmU)$lQDBYNi8GA_b>S!l*UQZI31yxz?IOSQiJ2nXQOI@jNWbutR>C+-lysxP})vH z48Gx%5@U+`szhj%8cQ`a3CJOk+>v-Ef;0~~(#iG5udhp@j(eZ&Fx*27A>Q#0W0!l# zJ64q1?b!5+8%EYN;hAGt(d<9JlxF`9q*~TJNaOKGDK03<(tPL z^omojPK1%k$ntbd(tq6g3pT z%8?$z=Udjz{s9^t{{adaZpZ)3zG)8GV4~3p+9ksWbW#KY$4$G(6!%&AqS`(jJFf5W zcn#fOC&rdioDe~P`|11olHM9=>-uHba9gh>QV;?O!9Yz%ET(GepWY4QiB!>Uoz6C_ ze);+?SfVDuB10QkoasmiIz_IW$Y19haSP|c1#Z-YhZ+P=zKKITQ)PF{<$cBBFt!;V z$GLeDKP~LGfz{=%P8^5QyjN z0%$D|xE5|ikk~59I#hpET2eFVf+a_QC_5=X@8l3K7pLLW5uNQMT6%G|p1qliv+}Z; zk_R%bRy=7jU&c>PI@4A-Y~c$t(@?7CyEcqyK*V#mAU+8MzQi=>6n&PU_-GWMYm=dy zV8m>&-gqweQx$vAQ}d?(5ktB}ovr*QH-5#Av~knNAHX)RMa!&E5b})mD1o?qH}+Nc zju~$B@-Nf?^2g}*aK|?0BL{BMO^@_aS^}lqzFxmEk9%2Z5w7%3cuV3T2rHikQibW@ zT4!qd(wq9yfPwPqWSO$4lCI!&gppWsu(Yc~Dcv8nNti`azS|HZ=shQ#@_bYw*cNPK;?7kx!f< z0h-B34g`^9h5*bY70QfU z9F$D7UXB;V=ti1t4}t3n+ryxmQZ+j5_I<&mb6_Vzdy9Xm6{Og}#$ zSDGZSiCRl<)L`F21TK#=gU&$a=J6l=#MJ&4XGd%=REjFKe&@oSR?zJt;87(S{orI%(1z(48a8E9HN$H*n5bi>^07T{neoE+b z^_&WXK5xS(bu|%qdZr00#{*?C&4@zVseU}kn4ZoF!lbDD_BBv&H+z$pR}om(ccfCA z3>$A9p|o+ijNF}z;*P;j1Wy^@w<|!?)=EP$WRgnWv!)~UxaenAescVNTyXhjQRd!; z^piEh!nBaBi*e6WqkjO$)qj8q=s&>sW0hCpttM$$NfcgvY=&{{I1qbzZKA0L;xELOb0+g9CdC&YSN z1XmM;jt>jRlFSWPTNFYA0BPd{z5_6xLTkT4FE4uILEr+3F;pG@st5cJz$pLMgWa*; z-Yk>%KuGK#AiITg?b?ZB9d_~dc3vXRV)dqW@-}5Y?T0}GZXnOpvIZwd2YyJK*Vfx* zMJy+Th9>fMp-rJNq(5+c;I=ti`3GoOJ@Db zBj;PnA!fcPMC&WlqV%p7pvJ1f+ko*+bn`_(+u(zW(PuzqorF8ylejqb+OMSC93uG? zXi2&ADn9b9#;Ct_(n-Eow3Iht&ItCBlBA!{1(xJ;AqQ_>OtzojUi~+g3;Q%S$qU9O zm4<04(=vaMvOIvUbRdL+ko z{4s$}rGJu`nO`TUm^`_J=idQ|e}4$}Qi8BE6Ta@Z4B*b{e#xTE^O1elVu$3AGsKk@ zr6Dx@^S)mM;jzS*Mmza~K{QuJkXL{9_dUBb9?slK^qa%@)CV1! zR&=~5uP7&|OT)8kM6kU3;}&)ePX9dmAAms7aH@VH)sIrawQ*g$x9_;=ll%aTRbPnIGO2a22XZSkV&PZycUUk~73u5&jEVeg6aBqBd?wQ6 zhQ;Q)K7Fc;8r#R%bhNmfQRuaqOP0!=>(e^XCZ0!6;N!+eJ-BLKjYE3y{`(&9apgno zscjSy)d)i*i%R{KByVRjpj*V1&~4&@|K%(1jIH_%b(-7$H{tSMJ8^2mj?-l%`>b40 zVqCM3Yo^)yaU4#WtfMjsbA3xt0~Ze^&b_k{H;1>L=C^_13lYFdK93QJK`>%m?D&hf zv-xs2K@spad_pEaF8|fa^41Fn)c3yL!rr~4x7pkqzyW8sUdVvuO*9q=#3=p%xG^rX z6R!IHFryzIQo+mi4mn>n3ibF0P-02hdN$nXTT`kJNayHmq{{gUO zB=FebRye2?5!DBPcjUiRjKWF4?C@rb^neBuGadoIvL~Qa|5PG4PM)WN@MMu^i>y&2 z-W}mI9nkp&&v7LfG1k9h(zC26)xnYaA8SbVw1t;U~U^Ux+GB zN6MHEXtYUaSUtE0jrXFz$BuVNjKraMob!aSgaeD<*cQ+^0msM;yzC8{$EWeb0k#wm z-6w0%l?*WSCm%sJ>^LVIOb{R8VFrn_6kmpnmr43l zI@-MP5%GqkLe{RE{Z!ZB2H&RYJ)8q1S~5UlE0k2D=(e68%Fro%xgtcUMqk~ErwFQd zvPeu4Spp3I^iuR&e*qY?+WV-8le32mcAqUyb=%aqpcy>G->OXiLzKjEvYEk5 z9512Cq@I&|g<}%_hGRPYPYD%@epZh^@91sCw3?GM`2^uAeF-p5zheoD0RjT-2aMYB z`8KMQCFW&01M7>PySfPe*p!p!DcxlN6LRzyuZ>m49nP=Ua*5-^vO}6eM;AL;Mrl=6 zYySY#f&Tz3$JSB?>;7|xw=VA%%Oj@TobpMCe%&c5TW>!6!uI5+`^55tMNTMnZPwF6 z_-*~4c`*Y`L4j5oo==crP(I#x(MFzOKcAqbnuMm{!aI7vipkUl!U*43S63xrYEnZY z9!FVm7Ulo1DPXK4i03`FU@PV0P+z$+V)%6aC)|cSsG3E9TYJ^OQ3|Ea59~e|fIQ4} ztm5$u`KH-J@>&A*Qr~OATDw+6=U9iBs&UQhu;%Yw?DSN+Aj5)!y#}4l-KAg6hsRt% zKVQ||C`0SKU(axJmQPD8u|fP;3oqvr3cI z{>j|~)8o_+ene7ZNSMGHUa7% zJE`gxV6*zQ`#(5_cTtpnq2tQdS&nHS>8ISTpq8Q0?;@*V0XPqA$&-v4wCmLqB3bh* zGxX2W@W4&Q>hSy}&062%Jlu+dhbCsSPl};;^xg6AD5qdju=~X(>m)r9!48PKCpvEq zSb}eFzD0f))C7Od*N4`Z^ueCejBh|NN}p%>FEYn(e|P=^d|tj4puxAXdw6^@YggYz zW1HF=dy+mD7M_F>B;>*NEK!YSUlot}BPrpr*o&%PTYuNw(~5F6DU1qARQ!i_r$1;- zRdZ|5e+u;y3{WUo@IHA9@>70O1py@y8G=XVeq)nA3(`~J#*>k3cch3sWG zSH^BK^&Ql~jUT1;(bmYeBvj{!4&r$Lq}VLB4fq+t{&u4x$+GtF9fe9ZD>!ik6wzFcGc#UflGRZCWQC67m&C0?Cpj(M+^u z*7Z|!WHWC?CwHHYTfgp<84=S?_x}4{NN_7~a11^cGGN#R(83SZnH;%S-L_zM+!ZoL z${`yOnf1)seNIqxkowT>BdB6K6(Al=>kFUC^)^#4chAxdm8p*M&3k3RPv8@QE)e|a zU7{=`vD5FneKH!GHbFc{{DnAI#iXs-IjR#SU=%wHU?g-aQZ8_1Z|d5%h3(e(iNE~v z)7ePri4m1y(d|C1xzI`#i1NNTPbp45$LVYufd9mFfH969$K41TNd!s|6B6#FB~gso z(o5C=Ye9jcdnKqOfbG=(Rn$2DgM04L2bH}24`BT7gv2q9FcoqW&9b*bNJD^`W9_m{ z&Se3%I#$GTGi6`fwYC(0iLPNy@1%H@LLFa$dUU~Te(sWHS(9De@+}cL>1H`#AasmK zpOIAZ9s+Ff?&(wLn;6wi;Qrp7zWOwbwSHkrzfQq`4BHcSzbpG6;G?!nG|2`X{oHY) z-iqW^&Va-`XW-V1uwPAHv`xrjG?{Jkg7Tlc(5+*`IOaO0NOX0N`74qLQ_gA%7#PN4}5DymM?LGp6}^}~TdRV=TAGMB7oXi@<;xZk@x zU@E-TiA&TO##%ZycybbcC$|<<4Ht~BV~2oWB$w%C?IFUbruX$gCfF8Mb#~EAX=?Wmb3Nkyn>3IP%#)GF|~N-(V&elvTd`Rxi2tvjOCKc0g4KIw|6(yHlB#BR-s>k3mpSn3>q{F6V5L z(tU*ma{~NAR*~qq>nVJNG{(93okS{NJ|(4Z80D+)6D)D`xhra9x=m7zPF%->OE1Ix zBzpGrX?4qSJ5^oMcb9s%csP2|e>MFr2(BjMl0vyM2L(_C^#`J9J=iglJr$aVGu5 z2fJBwik{D{;*C+9T!n;8s$?WrcBe<97mw1fCJ0KTY&6Ka`x!9ftkf_b$Qn`(qiTrq z{cNiF;;lV&SBT2?0tgjgf5-iH{#0$daU7J?n;@X}QFG9Kv!edJ2VJ654zpQ%dIreB zEqEv#4Pno~qb^{lXp_{;8%j{9A3W4lUGtx62n6yZtY`7N0tfktKeoQ#CXL~z^_jmlCWs6KNsI84 zbfo&l8Igi*@1)5#rjynP_VtOfA^R$n#@5$Qg5+&Q}`8BBbZ{*5MKEdS0D9;U+7Y%T=FiyY;pQob)ze+Hu1qV)AwKUVC{3e`)8 zT+stCkRMw9=MTX$pXA?Lzl#qLBgKTU zjmewep+Y>bz?=i{j$-eEYcew`JR>#>e!mZ{a^rH)STt^ipLs?5k|j^43I$_oI?oxD zvirQ8@YJsJG0pND4Y9a5jTg}~0c@21xus5N1-=_5)!M?RLe6N#u*)jiA*;^HG9txM zRJ`wE_uxt-W!I=(vS{sNr?+2gaN{!a;*6@2}aTq*0k)}c9m8k<)PMYx2Ns5U#`!(Q5NQHr}Tsc zmc==$H0k@(oHqd_;cc65F~LCOwlBkM=*1zCd{7lQmQLRjrCrOl!z~H!-lYiNmEJvB z(rihj$XaiCiGI8&FrX>*XP3m-F#IDc>+dh zud!i6#tpt~n)F`0ws_cBI3_1@anL)UW$ShwVb0t2$0N9xKC%PB__`8M@5$Er`{f>< zz3?7r%$hiBHNv>{7Axs1wX&5GA@oFKoN&}j5Y6k^Nb4+LdA3{F7gW)xkkkR8t$P}^ zCLfKxN+CqR_szVY<|-~{x+vM}y^fPas;;KZqtEbywAb7I&IpQBmsz$W8qgg$Rl9rR z{ZLN@YK{4`BfhjZIX{PtO7}jpwJP_jj7FoI84w3*v9Z7OKE?TEdpU5gT zg&m)qy-8#bNZX)l;Ux6Db~^qcEa@9#u~1WmCJ4mOrBjzS?&p=T#R0TMVxr8YmnG3} zbSMSeq;UsslHO#l8e>+T20oK?Tlu6Ov1^hSb1BXSB)ueYgnNgWVv)jC=aacQIsmw| z2^@xY$Lp`c1$hQ(z56IHJ?`wrWri?8*KWc>6~WlrC(W|dVn2*xldphKg8Z~SmC1Ju zjWP3oxwjcqS4xw|qWpZNqC%>6a;3d4hA%SGeR6+cw!7E7p#71w6&R85*G^{%0Hd!f<6DGkPe&wjx?R())=s!SCR~G0SA9LDdkUZWIfE( z$=6~zk{o28Y(%R(F)UYVJjEB8Lai@JwD_+bkg0OL-Yi!%?2>2#T9z8s=U_RB{Hg(a zC=B`^pbP+EVGa2_lh#=BP=QML#5pCeZddN`S!er~L0WZ&Ue0@#PwD>wq*APtHefz5 z4-l$8TOzv2*wC=*dN#XBs?-Nuc~SjCR=j69W%~D#!D@FE*hl1(bXlp(Rj?A^erz}4 z-4laMxTkDe`k1;wP$fd@fV~KJUO#EF?%@{uv!nrh%;Og$H--b`sluWU#l)<(LTP8M z`G0CU+spMF9jVYM)TCWmtP^P8eC6c&{A25KKQ;=|ud!Wf3R#(_mFJM;1B*B~-5WD} zM9cs>E_pH88FY-Lx_`M`d=+(5bYnJQIT~WOeo|Xu_L!`+aw!ya*LkW(_80gi?2>$f)1dRweQ@O;@4&IwzDR@~4MqZV0H50jr<=6yXg z-_GMtVBV|%MKC;5NT>5`vs`z$Y4I9LA5b}yQ~V;NV&q<$I9w>Ny#a54rw&1WkZ#WZ zAI{!0s;M^m_D$$rdJQ$97irQv5}MMhf&!rnNben~1_)J}bfk!M1q7uhp$JItQUZuH zX(9@E_Iu79|2xM0bngu#Ur5-=0tTpFvRzDBbP5IV&24yqueO6`DX!%x6L(m z5E&)n33k6%e&5LU(~4BSRgDzw{XPCaeaK6>@7ngp zC9TTKAz2|_-|=+4zVRIdcx@GzNAqQ_af32p_N+}eKk(ATeI|#n4 zl;D9k62ln4bMW-hYq2+NITq{MFv#^!kls4Nn>}f(h${Q{!%stb18>=fDnp0`i+$Oe z_fT>>D2Auzxvn#-jrm0l>v~dx`^AHtd!|D;8*y>{?8Fc}xR4pGL_51Gs@BVMqk~sB z^`*edDSHbPF&_btTs~C`*fglB-@SjU>79uD7pz(K`8Vq#y zGh)59qe8!QzPF3cUKpS`ynxmMqtaUY?vKr$rxkKpbz^tNBo;qjRu908+MIWol6wi{ z_{(5GE{YlpMThjr?2N~Kopx$$%K*2W(-!1>vn5rUkC)!W6c!jf#LG)h@#v8!ODW+O zmdYnYsn+vJVT%m^Kj2ZWUL}q>W5k>5lS6rT<`#Q>L#UzF>%fWdg6+R z5a$Qso#=?Y{Hm3}oC8;In2B?ibbcwZ382?`AxfWZ+C;8aSqn|B^bpuV4co_8IY2cA zDT)F)-nTnBZGWu5)}+;K-oJ{GzkuSEHg}{feKqKvipv4vVR#C8zsyJ^&4xE)SG30@ zLpcVfOD`&oYo_WwCRmnPZ+{vJ;4=DzLQAU5GtclWQVE)xRVAK^(*MHvhJ3LYn6#mzstu)sr`fYOrXFh*kEaYbyus|&d zD+-%AdCZ?BZK@KU)z&#aIE?d~1X}t#??Q5uy?pEQ*^(lGGYge?MOx7e?S$`FnSY>c zk}*TRuL;ZFF^$I4MW%Rs5ePD7^a5*HLg){InwT5S7^oVcbvZ#4|OmbmCIw z6U^>Z`RgsqwN3q3;hs5t=5ov%z)N#yT1xWh3i-RiXN;&o%b2S}HBx+%l~H}zYFCzb~y%5 zds3gz_iy&()^K(}(#pEex20&o$II|0K_{zig00XJiPqjN2uQo-qTQ^5TEEb`5flw<3?r$J^xwm>tCD%gx}ZWbSy*0qWVRH63_*Uw`&UNzX=ODw zr80$xq|}tk2AeyLRkDBCqjrI|#W(1+`(U82Qi$vHE{hLR1`hX*Jc3JI92)-RiHe** z19Wkd1hp_r{T;NQ;KPRA>%l)Xlj%R}Of*@`hj~h0{$^ypwcu|BkZ}R$`^KMI;Dx0n zkt^XR&A3c)ai8fK=W3>8wvCj-1NiDUL9FvG!EJQ`s1fqelR5v96!UzX2r=eFmc@hHgV*glzE_)Uh$X1mU!fSw+ zfsQ<4E8Uw;TQLDM3b02%3rv%a7zP@OXhS2lKYj&`qL~IY_)SnD4l$$5V79Q(A|K8XKc-b5w)qokQ6RZ=WN8fr(hsA%#kpe82HHE6lFxj* z-XtkP@jvJQV8R^!H1FVxDsN%tMh9)i)0>7>y<=p0Ud$xDQrdY$qu=AQ1c9wy9$m{Z zdF90F=`>I+f9%uttN2{+Qek~Y*D6)c+bv6rp;~=Q zKZ@4fMM)qp-@-QzxoB1vDVv4fO8Yuelj3J!*~9)A*Nm7f8G5Uqz8V{6ptdip-R=1Y zYG@@HzV{Uq;szZN#nCc8(Tp|xe22L7@{J~eNiVC`%J`OqxG72-#6g0N(i0Pg0L<)n ziZ2;FC-7qHBwl#nE{+d}&+F*!+vij`kUsh0E0pY-1Q?Q>0rl?}`U5cBO$zQ74J?H6 z%TZKBNMNQvH14`t2zN^gbp0Zeivq+#55LfZ4yK$lk<(y5Ej~a-bXQMMN{c(K)P(Aj zeC<&Ew(OM$)6B{BcZLLkx5m~h`gFPwksqIQ4lV1?7c92f4j=cjB}}}ckjTiIM5eU< zdigAvL!0|3v{N*9JmRO~IfJawAmdl=`!9sC^>ALKC&t5nw^8ZDqPjI6%p_I9YZc8z zkO{^T6x|tpC;oKRHsQ2f70b{~7|%}? zR3Bz~qVkzv*ExG;G?p>1dn-gK|S}=lDM$DSzPTgEHJg`bN~oxbK_`<`B7b$O&n4hvL!( zKwIg0iLy+>J2t5&mq~bd>t|UD>t-iI9-auDxMcEdZ#WJeOrbNeePtf6vrf$-Q(h(y z+fbh{k~-t)*-!%lckX`>`$-{1OJ3`U4h#COkkYOs_-sd?Z8LCymS}}4k!9W6z3j6a zeIJ5mFY^$I3{Z)izh@JYwW?HsNdMfIV5%(cO5^*i>DL6zPnGCj|3L5zCILDE#8_E%dDrtw_qz5e_}oSf=5M^f*MTX(BhiF!0g?g!8o zpa^23(b*2tcua}RrBVZ!`#opB-cq~Mv>)MwAuF-Hc!^D0JsXzJZ43GXLI8)!v+rh& zw3nDc?Xe-7&EV*^5)#Dbn8izC@Xr!jeVimLjO)xrYgK$2}J-wFV{-N~j&{oMVBEXHKtkXII)=hLZ1@os*Hcsj-R2Q)0?J2y&JQjPv?U>`d${!*jV zdD9NCeuOC(UHgC55N%|7OPN-kI8t4;!@?UjUK@~(lk8s2d>vq=wa*UmFkIzIx(TAH znBE&w|HUscJbv!QVw~J}d#S7t`Cf#yVr8SMgS+%^j~EGYS`d}`4@EQDmm%N~%R_Qj zy!C1rBCe}3D%7pjb@;S39F zPuG!GAtP6Q(Wd-IM|M=f6V-F&FQh3ppatAHYn~H%Y+OZ$e>;F{m3eyGqY0mXAWoXW zjkruT7A^!qdiDvBqSGe$nIIr1-72qcYd(!iaD~iwh5W6~moXXx1lG5wD;Q&wF*);$ zC3Y|N8#4$x!X#J}H*RR8@;+dL#sII)el*%!rkTJyh-&bxDDVx57!B>c5FS%va-jqh zNl9IHh2ruU>b5L+Q~jjKTd1QF6}jXekV=lBhoz+6+z)P=59%4wy?sCKgwK{S>*ozh zpf?moJ^3eq2LJEHP6~qN+QD8(`2@<+bX2_4frvpVy z(tWG4O#n56e)8v0T@UlgiYa&=PobuS611`ugKCteQf5=8jX%m~5covPcL3Hkviq5z*9Vci#StBqk_7E37NWev9j~z? z{Vz~{H(R~6b|`pSsU{=Z*;Mch@@sFBGd!^LamaLH&bQG3lU~7x*QhX`^r}Zz4!VP= z(PzWlj~G|>F_4m{)$U>hlFhlAz7Cnry{o*_1RMhp7iQHBgM@w=;?bN2>evUa;-y;+ zIvB{WFON^-B2RLjKvU7$t9{B53P3Nw>uzb9$-^0BpNvo`VJPPVGElg2Z{J<$2P5cAvhi*^S>>fF&fJA=Raj}BNS@4&Cze`3?kedJ z_)wv_Q_VB-%}LZ&TrzzDJ^A|I*&KC9nb=T=(~>N9fH2Ib`-xF@Yo({RMdW&cYdvke*Nq@ zv@y4rI&nv50W?sopWYyJ4lpoh%I^2tCG~rWwH z+(hIuMOt#rJ&2xwFd&MkM>(@*xd>LwrMlB@kb~mc7pd^p4F^pQorPm0ASH2%P<@0q zFoOZ3nwMeG0ydCyWg=fH)Vh)W%=2gF` zqJR;4Ainw|8RU?(XePP%glVzFxZhOPaNe<1(Swp8FP(6Iw9mx!c}-d88IMq+Z?Vj9 zQR8pZEu^3+qlt#$i1vs&Gp1+Lwd0P^S4Xj*x|{spRf_(B9%Ya48MPoNybpG{3)!W9 zpV!0{jA|<_|Kgt0J>lSiAs;7dje|hJ zaVm)tO+!(Nnv7mgECI3q)#Kxcqdbfk(88nf2^7t!Y&pwGAV`kxYY(I9j=9eoAH9+Q zr9-%B!|?o8($9tr{p?;))2bG}B}uq;{A1@69co7E$R*S=$mcrDt9xf}T=7P(s&tfx z_oEe35I@BIhm49h2FP}$4L;sKHmWLrJaTexu!UsVHyKJOwJbbyzCUDA{M7+=7?pAP zv2+O!(HM?Qf0Q*gGc*b6E_@ZZI0+H+R-g_0YRCV~su=E>ED|ob^gGHlT9VLG#w)k7 zmyb^9Dm{BOD^sH6Y_90zi+A*!u8~e`X9RiVX;fT%+M~_Xai2(;%K|w(|6z6hJ@IHc@zBvd2RoJl3bcW zj#IkqpT_4?hMaR8!7Jc2gN`mh$g@NeuYdXn>d!$Vl6c(+9Awr)1)1-`j2NB3^ToP<7yfL1q>md* zuznNI?f5jW<0=_iTpAhhWX+XFYpK+kYv?IiDh?NIg`|BcJA{Sgf((P4Dd+ zvd$X1Q17tb!sVjc#bIxOue3GKwey;)%*CVXYlD|;kANweq+grMQu(t*<5!-|sWa=O z$#&iAbXbgug2@cI$`Tz>|G?<}CJbP_uAG`7o#3Xl* z?&-+sNbbpFxLN9A-|h_6&EKFm%T~iM$z+oa6D=e0Lb%$5nxuC`-IxUNx93EgniMX%p;9ux_&Yc^fQ{a9J>YWRLX@!k0RgR|BKvn^`k32c?6~reQ8ob_ z&8RdKiJ!&&q}y*QpLZoSsiIjlQzkJTbfKKiuKHSBr0$D9sp4eKk}-*3ao5L;-e7+*%dPDrLa7nL@|UBo{mm2yK}~(P z$Iq)kHU+m2YnAlAcj;YKIu^@8PG$n|>XIU-da*}i>Ua`6d3XROh zF~^LS!HW%T!>Y%O9RgNunZwZuhLP3uHWXOTvAG|aERXJEwYJ>TI&T9?n;4P8@FS=P ze!IuB{Va0Hs63p`nRp!#t=~PS?N^Fo{0uTvm1vjCApQ_k;3j%K6A|OYL-J zi7yhYUjIM>Ov0H58b^OSw=&ZHJFz75j3K{Ibhao036jT+HYu_4eK5g4Z_`hzi|k?_ ziHoblvExyi$6AAGLx(nXDl61=RNj$!%Ktzd@7>u3c57Vq?arUP#gwUhep8UnoqC!1 zqc^oLf$e5p^))Sq{C;6dLNCr`8^@7Ygy^B~&AwMP`BY9=XMiODhyPub<2}I~k7~jA zQ$byv*HwgHN70PmvMy^Y`tKE+9*Pvd1GbyC>Q;WcHLTduC9WD=6tH*rt?FTP!`x|K z5QJF(#?MQf$KscPF_AkqiYOWx+k*)TY#7m|7ySvnjeY-lp^(nwaiJG+u5SoCz_I#M z^SovJFL*Vh^K05P*988Xu*fz-WH7GytKs63LsxGGARnmSEePGGt&lDBq~TBC4lMb3 zBdqm~8*9avNk>Nv?ldR~rn)dM?Vx(aVJ4aDa2PYLD66bWCJi1AsvgtG)Loo17oAq3 zD{0&_sn>l^*+DBDD@D=EIKdw`+=pQ({xP>o+Uy?#89bjK^I6-7m;kbQDO4~NKkK5xh{ON)>KqMC(1TViLWl(ajofa} zrcgoofH%=j&Ye+uR1@4t5e42QYGBtq_-pY@&>lrOm@IQdyl}Ba-?PLhiieLc!Zway zYG2%w?yf2PkoT}$x;UWUS50KOJpkkz(M3l4R*Z!ia%Brs$00{1gQ*>#c(wZgm| z!ugOlHl7H2X&^POt$O25Ic74*!|0b^vHL81@N7AyXo);zrj>6Xqm6Nk8MmwSYq#kh z#7J~7rH@O>_vLnG#VLmKku;u6SMyo>z3jegw0r=I=*^1Reh54IR~Sn(HCD^06Q5&c z^VPv9q}XG@8To=@EGk$Vgr~lxbhef|^@T!{kA>wWKmXC?RR`{DE?T(qCrV~vRXV;& z`+*}4k?vJI)BFV9TKe)~PM$yQ@XS{6+IiF9sQ3dkALdIll{!n`cV)jT)49b*!hu)p zn$$Hv=$n}*45PNys3YF^$8SAUHj3+bje}5$OCYz154K{#ZF+2JWEy1_MfP zD+@^90Wn4m$n6(^s_wOUkJrMwST)GII#((<#rKARUAox`R393mQ?I_#VClm}D_)f* zv48QFX5tylV3KzGu^)RL*KPw4AaYuFSX=v2y#KF6Q@+hs)^yD8i^B(`hn`DTMJ<~! zr{`jDlDZ$>p^lIkv9hP4);}`kAW7K}-`noC# z#Yb;PH6XWDC0yE^%-)4*y2)qG?$cOKo;X3YGrxsC^lhj+YG&jYS@HR{vUN3A>0Qoc zd|HGevkSvTnnPX%Hs8rdHHb5KW8_u3onOW$ZA@3_AbIoWy+ul6;?l1DEH>NIckDO;- zcsXBTOpCIH?$6s=NSw=+Z}O95#Oi}W{QZm1=zwsu&Z*7GdI*l(-ESM$mtjk>{O8Puh?leH%2Ozp8(CI?S7LhAQZ zt!cu$%rJko-!Tad?d_7uuIi`%Qpe3cJ=9md+Kf^_XIkdGRHOxFXQd=x7ukH934$0J zT{cNK*!Vd-BF^TTYk-Z>($d<}D&<`3mEoGqJ>PF89nGjTwWBag5OXaS#%cVBacOo8 zBrKa(oT|o=^K6skHQw+ai|yAxq=g(J7ICr9M#_8II=B+Vu~9;^?LD1wL{dB8)rWY^ zdoO)hl()h!i2uw~4R$P<4+f*}aHVXBcAFvofvkL^mKff>aYv0PeOV?|+Kg`gDy$@= zRQs6Q`~GV~l@93yZOP{!ZT}jA8lRTQ4;jmTlTopJQhkqq8LBnxjC83s26lDTK6Kp{ zjXTm0emvf_)Uer7KEqyr&y^u5k1`l$bfE1q-I0_T!j*65{3@<%6i6;O?1<9Kdm_jU;eMWPb$2-ZL0r-K-otOco{LOT zxw==`$9)%2In}9hggaLTQV+HiECe`3zGm)r~c&Eh&^t=sh9=v0U$^(w`hsH)XVhXsBTt;GkWRh$DZi?9Ge!!F|;I4lC+zbS~01A}$db zQ_NEu;WeYLPL~1lrvGN1=#flo|Ir8z=J)|Lq0${1d9Umjn}ycR$RWS0;LPQT)NrcvHC`2=(PVFxaPSU^m-^Dg}Ob{YWl}`t&KC!i5WEYu&eg zv6a?SEv+BsKi#JKeDL9Ak&D|_QFIZ=Kj@a4(;MSI=oDh(B|U_1L7XN;xNVh{-)G9&d-{oMMb9z2NBOS4`l+6SQ_w3 zHc2A?f#&k=2^$uv@nuYmw()IR?k~M;UU+$clQU+ow_zMKPP9MJcbR&_Xuool3r7mm z*89vC`Je?$meNiH5@sYkJpK55t|IR28h6i+rr?9&ocLLle(+Pm`_|2Z z8LeWxkC8qQE>K+(FbgqiEiOG+s^%{$XqXRrpii(+rai_iGZpGccb(uafHU$V;I)+7 zMN;`)sH_sg95!Zity|cd<+o;jO?+Zh_chJR@@LgZpUFztQYIzviJP1}1{aYy0LDT- zB42SLdCn&@eYDU7A?EZ#QIwRyS$R6eas-tEYY;Vej$RCxxrsc>O2nT(X2@E>GhW-{ zmF9gTU0+>7xUWJ%&E;1v702qJ@-tv#RDPz-;R_-z66mcv3=ZKZ`!p=q5V`v_4Rk+v zJVaTy-tFRXSN)ZH;6G6CPl1jD|8~})HnwC0G;l)Q%CeZNqbS73F{T%<$)#9sd_Vb8 z_R^xp@U6-eN+31j2oVDoS$~yu5M8%{;1*Fi|N#(cdB%v=lY~{rP)Ru(3WXR@(cmGlH$4>!z6!O*km0@>a*CV#)o(7iJc-th5Wa;{{Jr9$IZK z)au>eja)k$@kd8| zjEEYp!OKNCn~hU3doioDAscud9G@77SDmC!RIw5c4-I`yP0XBVf88J%5mhD8aAb>> zsiY3!Cc!kiyM@GvIBSe`2%q`r=-buEY&_0-PlDfWIQZ33F-vrHN$dfbDSlL7{LWkf z-=_!BDew?^3*1jXBSNSjvD!7b?Y*jhy{=mV>8=1(#Gio63UwRv;=`|OLX|4wI?T#| zh4SKX(#Ya_7OY)-!+`l3vv)0z_7!}=sMw93Fv6QDG%gr6b?GhF3gCHtg6G1XQ#K;N#bTL?Ci$-e)$^&X;$|Ye0&bPO)Th z8P?Ejxr*!X(%vfB)2R1Jf8~A>mv*6{|Ggj2k>C=q?qU5h+^-7;ISsz9>98(z4v@bU zyPkROs}3P#KC~J9%!B0-Q|{e8tE2t#sNKtn}hS{%2nBkDLj6=^r&P-d#B@;zkd1MlOMRE&$G(8HO47{3>Ze(soNV= zktwT@g0T;ksBw25GyS*xFUkn^?<}-$+R=w91g-aF8FDlelGMoC5l4`$%)JrqNXN z;_a5u*AjQ^kSLdIIZE}<+Xmpwpyd|=R#dY;w81=ZsMOsy?1J7wzXZ=x`tHaQ&i)j_ zMM6yg?CfSI!HgHv@79aAD?O+Nu7|-D+y1JWdhM3GO{zb+fx~V38ju=E{0E^`+F4P< zkF&As>VX`nUd|HTUP3DH57n&M^Yi{tT$W-N`CTtJJBDT&KVEr6wo&R`7bEP|>H%!C z)FfvWhhJ#Sl_f9l;W4VdCWzxb+3Hhl$kq?H__W?}HTjGv1ykP`9k*9<>qiaBxUOR% z@a=_#+Z)O=o6^!i#k(Ig*!b*JfKZ&e$Aa>&PMI6Ds*=)6jPSn;5f=|h73M?!lHpx?Gt~v31Y7_tkwPd+Pa+8LftgLdYJnsRRw?O? zcObZX9V3w>!|56JZ zY93#nl36^|(Nm@K=|6JVd@av+;Ab>!Zu-m&^#tA!(E8sq{$8FZN%yck#WjJw=1_}4 z1Ai*(J-rDKi6IybC>KGz_iq6D7`Ao~V6=npiPD??PgsT^a45ibK@a}7Xrzx%KnD6h zH*S!gWIP^gHVE|JodNh}u*Y3bCr3B?yKbKLE>05CV(#8fF8>z(t%Iob;JR=S7z_rj z0AHYg%OFh<2@w%75g`dNF)=AA2^j@FB?UP-1q&_R9eQ?FP7Zcf2!snJ#?Qqg0);>X zWCcaUC8VXLIr)KL0ZAn>DQU_74gw}6C8Z#zV5X#GmISs*lK-D?|9U|*B;aOnGd`FH zghvC$rvd*P1aX2uU_#*C{`ZFeuNxQ-pMa2vn1qy!9C*TeY7ib6A0LkZpOBD%0C;u; z@HmKohLDz9LY;`t*q)fjhh8!!ql^Tq(cH&i^7SW7%E335l#G#ynT3^?k6%DgNcx_P ztem`p=6x-=wvMizshPQjrIqy~grk$Qi>sTvpMOALP;f|S+>7{x#H8eu%&hF3+*f(| z1?3e$wpMjbZCy)i+xrjg9i1Qh2L^}G80_%K)bz~k-2B4g(#GZ%ZhL3<``(X})3fu7 zUzfkH{`^-L7=-_S%KD$m{vUPG0CnLJ5a1IK|5q0nF9^8f(-07HOAyhj8x!06(D6vd zkkD&nlr{H}LZwW8GC25tC1Zq1Z}6V{SK9xs?EhV1vH!m+`=7%8@4A*i6!>7^kB3hK zQU%RqH>U_P`7E9$KvSMIyE;S)IiYwylsE!vwokTuCp(MWPw|>~!$i>x@!Hnjh3q zcqRzQ_Y(I2p+Odz;s?}+s!$0wc!b&?6MOTxa=hBM&x@pxU(%@RVk8-ROv}?iy*m$r z-hdKjG2E?~iaRHzq}IGyc7EJsde;?i6hL7G)Iy$?8O=i1g8-mfwMv2KR6|n&Rz%=& zIxsysqal+u3TN?3(TqFt%NhbH2nXX(*l?m7yny|Gq`jV}~{mnUjuaaln=X24|{fyWqQup6>b(y-B_vBwY6C1K%-h z1iF^O6(PPn66$SUESP&@6uyerJK|I;{G97Vu6W(wjXzv(GsSehf5<*!FZ)XV@4~wO zJz?n}8f=*wjItDx>4%OGDr)K$O(14ZN2oD5r8*{|QJZ`sD~Ibta%`gKMUr%<#!LDqGxIOK3-9l2r1SD^wYzp6lb z_u|ruObbUXnFCUpIZAi;e@}z;oi#HLz>q+W0cj#w4GEPt*noHoSPQ<%=YG+0$W@X@ z)p1^G@O0Z~N@k^`Fa{$Bafqg`d!sZ^QYg27=28s^S6@qo=t4gPWfH$}EB1FAJ+cIC z_zYPVJ3E<)yrA-ZeYUSgLDyl@Nx-n=tLSo%`Et)N#Zb&VqHf_}AkIWv{C*Z$P&1(p znt0;@IjI;mmd-6I$3kkHxc#CQicHLi1Eolz4L2ix2;Y;$VqDF!3*`BK6} z5Al$32;_CA2aq(eYkobXGi>G7GgRp1Z;wbqT_# zzSg!NzG$9~TwYCTs+I71D+EBUsf?c-5R_k!n8yCP+<(BkW|C*_*@c%eS746IkMrG9 z>>&faCw&%NB&I0=jna&knyUCfs}yhI#q8xlkyc#Xrepa`z&b^sA5W?ss{F~Fg~q{Y zVX(*%X;*t*N{ktH;}wx74!onZo>D-6hA*#}c(;v8Zm;BL&638T5KV$=zwYvHQ?%b% znOuKN)?^?CIBQYKayww}2y%QX>o6v5|?#y z8b&1!k#Hl{oabCCC0kCv)MAj$;=KN)3b>S?q=0;}6nlKQiKtic#52>5t3>dNVZ!ik zf6nRmJn;hGlLkb}lD*=l*{`Z?JaSA73&S9c!tos6Mt~6BLmDl~BQ|dmx$#iHJzesH zB4;>aHbE*=G3w%b2dyp-ypM@fz{`wtygbA@SCX1YBhp*t5}39|^WV4kh6oOJ_NR3j zPL&7ATa&`cqnT7zqyAh7-=6YGbjiP@cv=czNT1#Xr09BZi6%$d|IU8#-PbyQZ4`$FGB=m)krj;A#3P2GzRwHR?pdfAcTPNQG|0YR%iC%E-kIQIlM-MjBZ1PWC|!HV zW4{A9e;-*+iJ0E5$8gPm;`iDM1zOXji#QlD5Y`b3W`qVH6J#C6nN ziB9Nb)z2W)3%c7M6P?l|>5nFq{)CyHL7D}%%mO{)(oz>9gk+qeGGu56neJk~6tB&I zg}UUOGTN!v-0i$)*;+Lr>D2xDryneHRI;BxmG7@Urjlqr>zd~))_X{rb1BYGRhCW+ zOw00c!M&%$zKbiNMdz1?CR&0V2pl{yv-H&PgBw2eQ9BD;aGz3|#MEop7owr`Qr;%G zWr-fh;%4*MX{EjzmS)LO+_o^%?Z&aEAvh`-4Faa@PpU{bFP-GkTixp}3o}|QI*dbU z8@YX45dt7)CMcgvy0#4kS8S9TfihIIJ2GE-dt*igHi5R(r<*x%VuQ1Ro; zBOFD7QAIF8j1d4INOY)7VLyH+uW+dQc`N%`)8-%Y?Mbxs@a?wzp0XN zrz>qXWw3C;+v;aE10De?nVHcUmUFF|BSY`TV1&Yw^2*xHCi5W0Gc6qLh$#~Q4pclo z%l6yw^}Gu60qTedK;#ifi%nV1z}pDEahpy9NTpZUK&+|v+Pq%; zbIViF;ZdH$M*X_drE%j>jik<)Lql80ryZrzv1btSdBbiQ;=AIdn*PR(&mx{eSHNFY zmK>0(CRNzwWZSEANl7E(IX0ttQ%RhQHAs~*!|vFm-PG3dgk(KOuyOoY;M996h@hyH zT6fBUt4isZ>)MTxSCi#o(aOzh(cJ2P^I-vqBB5p$mbc;rR--5>>NR~TUqifd(nLYl zwu}!Xo}FBwGp$5!_uUVCySBIFq04`a2zjL+9ZQ~ll=i>_Vg$gk{v>Cu(rU0?S3iS{Rnot#Zk9w<>i5t?KO zq$jbXphGLOVmRKpKY#5u`uQ8lk1uT8hgkN1AR&a<_8BxazeQZ12#74X7ChxDSQx3w zgGL+xnFWAz+;m%~#)062tS|@3;e#|kI!TmIQFJ1+>La6JR(WLXQ{ndsIvj01!u9&p zH|uiCY1Q-6y%8fH4ZLJB>wU@X&h{|$g^cnT#r7M3*^`CbqTeRGo};;5r#9PS>jK2+ zP}$rQxrhxo%SVCR>}XV}HJR)%)q!8ag1c}$%_}ms;U!Dz&f_5m zg4^3s8Dw4cjv$rVAbSaoU>Ec!dXe|rQ9BOLRjW3)f>GQ0iB+^O&(GEpi1bT;r+D`i zHr#9(*ZkSRFr17x-4%r%I68C)x$^@a3a}SA7zIgkAcF(s9rn#YxW_09i?tdh(i6fy zoc<_Uc!V0#`SSQJl4iot#)Rl}ek_T9m>aMmVkUo;5_YuPNTDk|v+UK#}PACf?cJTXRIZCo+SqXqB=bNBg93rUUp%XXLVG4$)S zB#<$Dh}DCnH@@flm9itHl)qGQRFuOW|Co*eB-Qw5EC34ys#DV$iS)?f=hf}K=g#s{ zN};U`ixZSHUb#^)tHm3p`bqv-s^jl$;D>b&4<}LxXW=#Q>Bv~kg>HZ2mSe{M2YP4d zV!>k9SS&7XpfHP|pNu^rauQNk3=KsF)-c$%80+@JZUpevm+&QPjXOJpn2>3&B{Z-v zTb~{F_EJ>LzcbYmQNrBe;zvo9H24@upsD&{YoHZvs66i0%!>3LE!uqeN^KqgYF5M? zOAc?K^Rexvg$~>Qo>9?n=H;>LR1O0cQAuPHmORaFP!k=K6=bo@pP9E#Brh*Z69}$1 z&?LXg*InY3iB)Eu*S_wqM1FsAaOa+UXDqeWXC3qP_;KBfd&En8T@k5*M(Vxnlpw48 z?iyQr;dpsipnQ#!XQsTr@1U?SH5g*dOvy~A(_H!luZO>Amwk`UE~yKMef8|WWANhd zBxv#V_`Hjwk$J`){HiDp(>%1TndA4J0_$E4t3v`#k6XEF>0+Y=QY6B?41@~H+B07*5(Igj zQCX*)8isS~fmn3XsZ70eDM}$96iiq&w}nYHlDvB zaCTiR7s^|&K_A?C1TriTuVZtwGfwunJl-?aNKi@~!TDPL?p(j4IV3}o&@brZwA!{+ zGqGnVnamtLgon~dll7S|00oIEiqvg^AfCH{iZedP@hsnj1_baM)G@{f?$Q>hgvC!- zxs_GJcREQ$lgX4)Yg^w#p98RPO!YnO}|Utfht`N|-|Iq`kw zC%X8tGdk4b$+9$)gyFFfQGaH@tao#yhRV`EMsxS2^>_YeQVV{sTd8>5T|lDllB$HqaC9 zUgevPH}+K-MlIQaqLcW)|ClE&baOmWabgx?#zFpp^xpEYAZP_(ac!}^C0+t}t|_e# z=^eX;WI>@Bdsj0$GB(g|EAXk$@npbeQuh$juzOP~{;BbbSp$t3_U$JU5ikJ~7cc=R zqquV{v~sJA8U5g?sV^K6q^|9%^`cNWZCyJFuFh3}hKhvQZk$ zeY%OlMAM{;jRM<6Wi3)+=#@ubg~U1?nyHcF9LKXA{+a44`ZyaeVvn6P-oe}wMGeO1 zUoj$h&f2FSAu=-HE#HT~Z(>NxAk0Ge)%V~Ig>q!uJ1*<)Zs^az;+Q+(DK5DTO0h3G zpJyccp|wErw(4*bhUjHMt#vANA`N-Akd>5Oi6+2MxN-Nd#l6)h<9?zU-ii4@33ql) z+fJnr2_^{Gs-BAG*wEpzG-peLf-)25G6u7>;%&TGNJ<5IaYaFYri9xhLq0z~_2D_} z<%lg2N)|WKvieEj5gKygvB}Er)wL%CZPMk+p&(W9XyOZ?mL&hK={xSK1^}MG4%rfIRymV#oFH^j{|GR zTzOuOQx6*aaF{z)|kIoL> z;p9OBWGLk$Qga?@kpxr8Pi#z;8l7~#eNKlUPhbXwDs`2XT0FWNzD9@N#SQ;j15}Ah z)^k9@ zK@S#b9UQ?Y6_;q%INZ7x+;Mags=YL0!Y*R~Eblw%QLe=7>>|qF{pmI-*5RY5q~BWh zIlS#u3Oms->wYxM990*qyF^US_A1gEA~U7tS5#sr)aK2;W|Kv*OQgJVYb%HoqIXkw z`djRhkNvgz613;YoxE23SE{{wy0+#+eYGpqXhyTnfCO~Dz{-|!QFF9)_bSr%Tk73B zr$hnJlA4VKq0h=BXjt)n^IK2&x)^9Rt#Zau#N7aD-&88MtNP%!?J$$Y@xC2ZZ-?rj zTrDh?j(ctFU7H;th%N<`Vjg1YE|CqF^hqO94x7H6XyGLefyJu*39RLS3DesLzU5HE z75hBQxV)3W{=XGC(>;jg9UQRJx>5S{y0hh>Z{sMoS1v zDIloi7>$64l;8+SC6&j6E{CaUW-jfLwzc+%5oX7B+&y=J)Wv z?FP1cOaaT)w-HkM=elClGnV0edYi;{AaHkbF7FdGO$m92fKZ))^$Y^S#HUg%bVdPN zGQ(Q`W)Y222N<>Ze@%503i!n7stiMZhm1eYt4fce$OGKPXUN{e0il-hV%FKytt)X* zX3Zp)0P-LTMEF2n3yc&I7fJTlH|y8z!=q?EmJJHLmt{w$4+N@0pcjwPwUE&!c;#l# zTBr|&wE#X8O6k%M^WUOW+!z>1%{Z!^*CQ3<`^pR3b3wYb7VIHKtvus5*tPDSW{EXh zFopb?qA1iT7`e7^4s=q|D@R_Xf-;jf9c_I1H(w-uR!zC%d^>Rg@z8A6XV*xYcy3D!e5uvGMoIK^z+B5!-Pf% z(bVdx@*WsI7zaDBZS-2J|iL5Rz3Y~$fO@o->M;% zC1UH;JgLEa{AY&L_rz|&-Nn&9f^sG2cQer)x@MCdo+9|Lwt_W4%iF4lDI|Vr>RNs< zhV|TzW+OHk!WZ|3N~BUyE=V$vzMLC!%Yz{L)c5F!E57N*%%8NAdJEyUa^nE8gKP!z zrxhDY8x5yeH87AV<`39gb)=A!Y)2@fZWOu7nDxd8M`nK)<9i1I_iZEAO3#e-Rj`zM zXeP73Xf>dpBuiLf&$daO95d7mvvZ_uw#OV$rs$mGyN@kpe=OXRZ+p2Oj4Y# zz!FaPU`dA<`bKz-@3Ou=R*y7{=}RKaSA$zq2TWhHZT(x@an~1Kc5$lGzUa0 zxLxWISI(>rwNHWkFs-zcsD9w%+ZgzGsdUOhc^XYMaL=2O$s;2vmOZTG!^q=Fqm0Hv zZ>FX;Y;k6H^N?u4QCk3C|227KA*EHu5aLUiQFVbjLZduCM2!EV_)j?detV^C9|I>* zZ_@mpk)x17$D>yL3Zbsx$%$wTr9D5Zv=f9&@0c6J?fxY@iqEeho0uG1sJBM6WmKkw z(?0PJ)Kk)EX;@3+%@T~UA#Mxgk2VEajp>Xf;)_pJ>%~}`X}@ZCU@<(1@CX?pY1FV- zUDKtioz`^1K8CzHRYoWWlScs~fmP)vK8AwRFxL{owzWX|lD|a`ws1cKVTlDc_{S z*S>PA7rHgUd@($Lep`_o-&(+85AA60>7>?dl#%1Jao7uad+r^DDeHfqdHh#yTesJS zcAWjbm?=8A$)=r8$p&19+$gDKqXnOCExva^&N*^383A`}GOF+;$*Kno zM5yNzAh36Wv_F?8Taldz8R97xH^>UHBp-)cBnQ`J$(Qn_&%B`m2(8==ghF7hG*(50 zk$ls4Gkz}!^ju!w^je~CQ3Y2-fep;p|9ncMPb<+=`O(?CxFZfqwI2z< zxgg|W*(lA)=@Quu5$B3-2eI{D|Jg9zj-DdMgh-lNf-jD1K{1%!1HE+B&ySx4q!Gy9 zM&IS?=@Yt}CeJtVZcoRs;dvIwYnkS?q+hp0IYS#(U9*#ie}Mi<(6SPr9(8xDef{Sg zO%GrToU-dvmE8qok>v2nt=kVK?zCW{=!Zn&eG6lX*4S^q0ZS-zoVX8B~9Z(Nx_aNZ46 zffyd9AK$&I1yS&(eNJe9Hs8D+KZkn^TOvufz#jhI;;!nDw9`;B+K4MY+_z$Lqcv&h zu;8eK9&m4cWC!u2Rc2HyP;V|g3fs2saDXt%wKB0&<_lyQx!6h{`G>L}rwIJ_*4$dR zMK$ULriJ9UPXG-?1BNyk6rvxYM!HpN8d zA5Q+U{@xBH^t$)GRhWelqR8x*NtySxFSYzX9uI5Zsz8fxaDR-RzD5tjn~Ja0Hu7++ zH-*Oi0^6kTx!Pr<{Fz!OfgcRLS5kQTSRrDZ_1v&lGpdY^@D*E?6(tTkCQ(H{l59dc zT{GsZ3=5@x1XRB%v?6VuTW0A@Xi7#s$$>0^I8i+&-u(Y&0pd8pZ2MWTwtRaW-PX~I zB?!y3ET<}M-)mJ;qrAm0VhbX)W29-_eY%vdZ=(?V*$F~BZ;8!1ECbpw&nd*y{w&>q z#($ebryw$n3C%C4$^8s}V?Kohy|rknLc8Ol1nyNc(0A*wS*#x+f?2k>w`bUa6PNSk zJjV-IgsMOJYfwYDkzu^Q93)hhOYiAf4l5YJ9eP!4mu`|hGB#c1IWQv*=hDI^B-a6X zerEp^f78lv#o(@P-DwSOT5?I3n>+Yrf*i0~l&POL9J*%t!7{%`Fch|LcK>OrzCef( zFpOr3YXb?R&XRq&b$*0lvtvjLY1an3n>%ym%g9OaWa5i@XgMDfZ}5M@TaxDOb4i67 z<=~L^A|zvpo%!o(K=CFV+rx<7m{?y+J( zr(FBUuH@GX92GsnN|@mJQ}TmTUqBwP(`h10OZXwpf4Ot%#_rO0z5331Z~hFH*QWRB zOeOXQ>M;g}WZ;uPD+TQ>skj@@2*Ktn!zY?PAUa>@+QxHn_LA-_|A-gzZ$9Rm(SP9e z{a1l^$IDHVts4Oiiy!=pG9B0RD3FUyVK~*YYlfI-;iAgY^m%-mzOl16-cEaL(LoNg zqLUDp4EyRjy(-^}53i*`*@Tv_1dl%625=#l1YJ&)@#6;T-m@CbW)vHz9ZC(Rfx+iC z9mGhW4crRO3qSlgV^1I1VLd2@Tp!Py9G|zKd~RMSB7S+3GTfNatvn*P533Z;WW#En zsqgcd0qSvu3HQj3*?f^N%32mhf(0wy)UR;MqSnnx8jy(0Vr0y?NJFRWve zSrrsVT7*;)J8`)^NoUoRMeR_w#%$YuarMlb*g-}3vug&OZauMUzsL@E5chH8I?ZOr z;SksA6xDrDklat1jDr22CZQX@_8c=F+i`#HeXU4(jGumv{ zlJ3=L`lw^O&w1`4bW|AwjBL@Dho(_p`9lvfyKK>bm{`{B#EBrN0by*bMiec>^}GHc z*@nuc;uaLAPM$A!kfa2uC*GkzzeHTe>eemxu=D09KhGOmzun{k%8#+rjw7*?5`85- zuQqp2CSBp2{78~JSkh@sy`3Nad+0Wr_=TRw&|DT)(g4GU5LAV+n;GBpm@LRYQ`tJb z2hmfzlE~&dS}uPorPVM@Iw0Di$2L%pGIj<52aXIGLB>9_^e zh%8=$&i`p1@1{c?mHrdi)TmW~bVBedWz+|w>fG$2@@De1Cq2JwDG`UXIFVI0VHsg)$6S6RYh0{BVim;@9LO2q|qR1i= z*Ctq6eC-`el7EoSE=oL8$qD9re2mw2sq--l?_b zwF!>F zA!S9Q2d32)3x&^}0>jsuGnvVIm2@F~C)1LhMqc-<^0WG(*n1Bhjc^Sljm_c~$$_bM zMtKlDli#Bj4Qh#ACRkJc&v|m30LJz5U^Lx@@zfwZBJ;v{iR>ezWYt$~4feKu|p~^vUHc zV6a(eW$|h&JZyNl1~%T4AGw6sGgI^4HbZkA=v$9M>8sXXyQh1R6cbd%gcT>IN#wQV zZIPUDrx;A%%kC%YVgE!c95@llkZjI4rUQzi3~m-2@f8fizjEqzbf%gzUv5zbFfbRP zC5hF1x!J+N!9KQLRQ1h0!$YoSN&3_A3b|%`H*cv8N^|Z%z~HStsiUzcW%M0CGc|pW zrTzY-o00@#xHgN&6=7UXQoL(ThWGT4(5Jt3%Gct~X`YqQ+#cFAF1b`nSZv0@%zV8v zJv(#mcPDBqF~vNn9WWPe9l8+}rJbzcD=25(c32!yMpt%|0i4sH{j#6G{}uq{3AURb z2%Lv?WabtO0=FF+GZKwVR(w`Njy4NyWsO9-MI5a+w|??(7I4RnHz6?7r$l~IG^6HBX=8iaG+K{&U$&{f5(#(Z_YS9MV21QSY?k{xvKn0+ntZzuR+ zUB1-A`MZyLS2rlKddcUR~#{%NJY#Od);?JhHkqhR6QzZw9M>NIF|d4ro18C zX5RVBjDsuKFie+D7-RCs!zDaWb?bsBv^Kjg6A?8*u^K>`ne_V>G{2=K&15?XXm_d6 zq-g{UK*H9YMnS*8MG){}0XQcE75hBIpeNJq&c%(y+1YW;HQZ z#JQ_HAfKD4GSKlRglI3KC+xmKh>o$w>+=?VrIi^o#%ms%K3EEluR^E`hX)y9-5kD* zglBjR^TsbRH=kTgQF4e1PC~VOAnL_i=hiqS3$}=b=8n~@F6!Rn%$k4Qrm$-&@$J14;!R1(0EI zW9ix!Ig|U&dF>9j4z!q`?zHx{m#a9=TjrBZ=7*1F2^mLKA&Ai>4G(-S@V%?jBSg4` zF<;}zd>b!OUYJ|enri^KFdp=(484xVn?Aeis)Dkw6NAi9&Q(M>W(!?|V)&h=n63eG zG%4N|)$4-Ef)S@L1?kp~Lpk*|_U{_j?AmS=IoEoD&{Ql@SKC4^p7y>1G1}u<=2kwS zX}!0%MCMK8jZR6L29ixM1*7z_=vLIRz>y?TPvgGi)oY@FQmCe+BAdpbHzr8xvKuti zL{_1MCD}fqSeSI?kCX$KCAu7ykv}GnJd5jgXZSj{O}H{uU3@tlNEHVY>fUdRo{Z>c zdU3nw#dR?UlYM)xd7;80i<=pLVPE*)NLL{@j5u7-3G-GcRp`ZOjY(FJV9|}#*?)Vg zlQavZE!1f>y?F(s`%1i;zi9k`B;;96i&26_C&;0s3V+hhvY7WRi2S?`(IZPnB3%!c z8ZU{9^_`P5haB9Pb6pF2Zh`{wN*wsRKAkL5I0-Jo!ua~1rew<}fDl`nofT3wH-#Oc zfe7vth4g!JI(cb0{SX{?SQhyzlGo?uAfc380=<6R&hD-p$!pR5+t&|Ck3FU_u<@dg z^7$W-B;c1s+~8nfd->^+IB4gvtILE7N5}gpCXRhuCMpTGu{lsy`5hnUA_9n8{xzPMF|6I5Iz2WTo zk)NRj#aru5KK7G~8BlN4`72R)b%%lf6?NzW=3KC?ATo z`L|bJm834ny_lI$g0tuhLL~7PtIHt3Ypy$xle25JTzI{gZ9>!&prL`V1K--**1R&I zrtfcZvp)@!jKVtw9BZ9POa`@l7CUBnqB74sM(&~7$$=2|dJ>X68Ug#=xvEIKX4eyG zWk&EJiY{xM+G0`rY0&M+T!UbbcE-xL2d02Ar~_{=X}g@A;2b~n#xZ{cIVO~jgmt$i zCG&qBx6Z&jy@6Hv?JY50uRN}^CZ<2UG&>J=ioM^nyhxTA+F5CfR4R`xVte*`^!`2a z<2xMXx}SCHd3HP!u*o1NE?B<{lKk{}H>r+5XB-Rz&1=ucfYoHrUe|Bi@Ec7&tLImV z8yNOsMulFk)88+8ua8hvvc8o4zNiOwKi;-{=LFiMTKT3i;5Lv=S zmVw|=o&ir`7F=@Y_LOyls!2+u(6QIWEWq&U#n}r2(@$ZU7p6lpUz?|_%8s5(+lsKc zbPC1~RRhxK)--39F2iSeS1Ic09-Zm>GGrKhJ&5c$P!nR>bIz00p~99_&PLl*h!wD~ zaKhPhGHL1{b!D_U-U~N|nYQ@2RyP|qgqNlG;e<~!?Rustp*LAnFO^pqZ$d9)Y)l#J zD-0zqfJOO8stcxEAo(}4QBH(*q)zMaHZIw%0{Vjjrv^K%`4H&oKXPZ*6~%Q8UMFOm zr>}FzA?taNnPwRLdZF^80d8J6_xY1QfBl@&{!Jde;L(*Ei_YqwOL_R_Tt1cnutiB~ zHyQ@k!$L%n%j9Ib)`t_2dGJ|9%_8&F@1V=?>41Qnl*Hm@@`4Wc@T7%rg#t9>?RO^; zct~>3R-<#Cer-eg6ZBU?FnrtgxldtLrp|kvM_s|7D<292GMT|MUzv(U4HNyaoa8I) z%i`vY6{XwaYqmh%Ag-i$stjKrDK&|EBWz|;eKpgWOYKYJ|BzUA&09XUUn>+`XESsc zDYlTv7)U=jmfYN-#Lhfa^qe6ycD^JcqyyIDKD+r+oer;X4ACChA0|I#4SauRI1@l;KO@=qbu2 z>EJeA8zh{YQoVCW!a`Ae`|OQ{y%1cQcX9r6frz8KoYCl}JA|gR=j;}*Avox*1NY%b z!lFGN!4xn&OHMB9hs3{`cUL#BmcNtJ-Ky`Tp0*a9@aUaoSeB#&1S9P&WVR$wep-D$ z+2V-KVOT!4mwKvZW(6%ZypjFk?iFcsd3WDr-JK(vGsP!FIBSUz{XzaweZ!~JK2~9^ zjpZXeo`9x%q3~f--x|YL$^E-#!APhy24>lYNv1iu#rHAqEcNOaLE~yM`umHL55uu5 zh9L7%d}JAQK+yv#(G5(%$ZPXP2*kH6$e>1pY~cT7n($PKVO+Ps{b z9WeUmfms)q4oe2pXYb+o{?J-n>q|V2$yrGIY+MdUze~`48}%=@_wub>Uoroa(g`#a zOP35CKz6KBpJ!?AFj^I}n8~58#0h}vIK_>S9;?WmYsl9Vb6%{?yl0smwHL)R&G3G1 zF+O##Y!aVp4Q!MRPBZWJ9G(mmv={zvu>)k5W8AV{47Fb=~q5<??_jHEPR+?ZUj6o6!_XlYabWtF+6-$ zou*$eqXd-nH$j@;{Kob**fKulwe2~IZrC~b%#*KxO&ubf(F z=5qCTlD%_XK1{QNNwd~>KyM9^j&K$4Nk-p3^|bGI>c@G!gUU|JXxHaOT)9O+tJn!~ zkI0dHJ7>(RNaAVb7{B?mjaU0$zkS;_gN;M^L)5Xf&N(v+Xnse2S%x>gIqL5Xzq|^w z(|DStP0ZIr7rNq&F6bNiW`+V?ZA}7~J6@Ta*p?ir9o$b!*0O%XM-vCzG$l6Gb(fiImNRsX~>X{|67C6_sTdKP<)4o);(t-O@I>mpu<_Ri&k2;27t&}Q`(oW15C4>ib$pz2YUasMp$NGl;5m}c@o1ZkXFY| zEeMHbJP)=`lcKPE@U+qM#b zm&&YBmmUUe?$GSGU-eHpU4442#oZjkj{yF*ACEt+pQkvir7)8+#X%XV^QH{@f+XLa zn!_E(nfU1YWL%f)H5FxBVyWKT%ft||!f+;vVm4;;pz2#K?9SwdAFw2b z91WkMnq<)UG)R|&VH4TmI*L5`UMOWMCAq{`@4WH$f54OK+d^Jc6^d3Z2Q(2-{*RV} z@L%ONn7(1z=}2v|P*Q9`C9*K>edNJN+mjPyxnI4)6wH&+xH@K1z{4QV$5T0V>{tprY_5#}aA=d3=o;Az}$_!9H`FN!H% zAojQGdf7Et>%ZmR8I>VmBl({CFtS}b&4_DG$=3O8Z2!Eqr!C6Sw!c<|QGNEAu*0+p z^r2*BXtE$l>(rUYO~y$NJhJwJwL?Hqlc&OG**?U&U1fQ`v=IjP0z!BdN~=Cg`lQ74sLmrE9uJ^&8biDch{=`O}OpO&*L)Hg3MlP_%u zRpKlUFuZe(H~0_qAt7u~$~E-8SumMkMS*(bz`@Anj$b*IcdBYFAeB%gPi(C|*fycZ zAuFJdyNJ>XGeu7u0d=v!<)I*F@ATNvy-a;^-ryc+>9cK9{(HHL?NP-6Lnaa9hH$1{ zLdZ~~;MrAuA4>hJhEZo4)27O{?eR2PhFj!q@_uzPJOtYjsyV2;iK4^CLw^sk|M)$r z_LEt;mIfMcy+H8nIO^}VR63xl)=Xr}Pp5HQ=n2q4ZokA;31Pt%`d}F?w;k{~m5!=rP z!RszjMvqI_+F+Dtz9?C9t{J$-cS0$HCmoRXqY18b0?Uz<^3Eg9+)(FB^uoCS_(+*@^DQUq)>2 zoKKL7FWk_gmsF+4$25QcvRlWElrG=9BzwRc4FF~NwgStyUR-^}AsCi0i;R|~j7v8= zjeRZ#d)|OaaxE0*wVT$5Z$_^cZGrn??-Y(%BK^sWgMb>j5glkHSZSqZ+j>d&)k{Sm zz2CYuoAqaVQFcqhV$yIi-_shI(Lq?ixUhG|md4{uaiAv(TZxfIZ&dD+$*a<0*ii$) z>#8y)c&OZsBro}CTTsmvUJfJIdpdf#_O#x( zs1ad`I!7Sco5{q}daH(d8zU}oNY`}Dkw^M}xR8&&0p%Twdoh2>_SUI$OGEZ2f4Q_` zdq+iM+-lpTEvpcAaQUe9u&jxO>Yj`N9mbtMEAhuU`=&7u3lne0|JGw)#mANH%yqW2(_e_i5=|K*k@oN37Wv ze*JJvhAyhs@f`TlA7C@5*u%)b(3#cXmlRwNY2GMP9Zy^{^FY12?buXyHE6^C=zSg3 z3!_#UPbU2FYJ`sqa)tAaVXV3Oa&V7)q8P4O=`i%D^xk3}u9mdsrt$ z#t-ZIsMR*pmsvVjDIZM3#XmbE0+@gS`OYif*iWVJBtPs}px9qs>)61kFeOi&f|?#v z>WO}avKZDx``d+~G(w>MN7~C43fa+a?5*j&cWxNC>ai-dRCsGfB$g6kiJ%BdL|G!!G|Kmhks7uYN~#+ z`RU{9a7Rw1EEk!sCzC4zk=${^O2k(Wgwro$ruyYC-Z`l`>Sg zv{tmafDDx2c{FV|@%bDMLHoV+v(35>8G9w#<*c_z9nzX^Pg~zezKz4{dnO)uGkjJXXCs zQ9hNGVsR?lb2*d9(Ao{_`z+9Vd7UJmS~jI3ZTawA1T}l|5|cXF89BEe2y^NIyvR1x zo2xO_{LA^u*e{)2;l0*h4pm+RrNZVjX`z*zSFPr>f7rC3jLPyk#4T<@lp>I&U_@ov zb?(9_MQW<6Kv?Z0DZ0jA$M(CYJLHG|<79Q&2aet&6c!t$h)r$xc`E9hU*?kso6{d4 zV?^ohXw>tTayo%$W%Wms9a~`ubc>m=)6*)Us~=;!mI~LuDLY@rSmZpek{aa!K$8c@ zrTy;#Ix1YBlCZmUgm+G61x`U@a^q!j-s13{x&==}l5m1MLR#sy-f3NfMZP}`)nNza z)Rgdlt*@`n%qPD8PTgja)5u#@^cYN#oRNMtd55{Harz z=5VCDh;2I+IDXuCOJSp2<|ymbgA?+FJS|YUS`UXpo@q-sAD^C%BUWO6T`ev$I^Ym0 zgHHU;+g+oKUje?F(ie~ObVr2=bJIt#f+jV58|aQF(o4$;rbF}xmSJ{BvMvtu0shng zWB%zaikFM~2>MR-q%P&~?Tcw?QE0kXxP4xS?OmgbtY2ljC6uut*yL=^F!5i~(O zFm++NKeOxv8ll-)SJ81?gX5&HJtrK@{}AtZldm#_n{FBYo%70vqVW@dAUXX5NOy3P zE66eZ&ok%Ba&nc#mkHRGdOzzJ&kXNlXu$Fuh zP;bT%&3wCyug!Ylr}=666G>)k{Kq^i*4Fj<`~~@7HF_86UOPM152rLKL%02KOosQO z^~@L(guCR|*R>83XV_Et?-%4Nslr34)vP@qsOz>CGsZ4|z|Vehv4uOc&R)z=Gez(( zJ@R4U(IZxka|o(DXbiZC%yD?<;Pwy!ZVocH+;z+@i(tUN*;%>yiTatFNS@(>2vB-v zKXc_3g+;ETuUOb+zJbq8=>w(Kn zyJ_8!6f0GLys9}`4m0NQ+)L%q_xu=fypH{r*{}6RhL%WkpF%Cuhe=24N$qLHb0nSP zc`z&BAMzz=x`cUR(HZ%v7MisG(;}jps#Zk|FA?ui&pQQ`pAyb+Usr?2gPl7|@mxd_x>;8wKK2xM1L?U3Hr6)o9_J-{=vW zM?ddX>nX0dOW4}b%5@=_H2?kp{aP4SY`i&w=`Ps{l=P`im(!Xe1WD&Pe0;KV-HJP6 zSQUDNs`GBgEumLkKWtlP`+#;MggFTGQXW!_SwnNV&+;MAmMe7jO^vPjXmU6O;^xS4 zMB8s0e*?v~C+!Y*NKv`?j^>~4r_ESh7;md%l8^h4P(nXRdHu+kZIz$d`Cn;?*w@&e zQLv|@lgQJAE;3ESvcWR&cvOt4S;hQN5$H)17t~)Y6&uS*V2aXwBnihl33})F_qa>b ziTzN2Q$VakpLcO#RK^K|| z5LZD~vgd1>y=V7I}k5ha=tdtbLL7(NgBr(+c z3u&^R>5poH^;KvGGGUp1s@^dvlw6ePifa9N+H8a;)IC@%XTAt{neuP#ug^;X-_pxj z3o0-1nZU11T%Mj}u2SUChS`JMF%P{b*Ys#7RkaFg?!d!;S}7$aa&7t6cNq!BVs6Z6 zky&!kte_&JXR=)T2!XM!^p02D6s`KK@x9lvC#M{YQw=y+x=im=&kc43)mm$%f5ro6@ljZmp};@H^#9p8v~}X67AC7)r!dqZTK1 zc1@3zncI3s3bq&xEw4W0f*ks)9X}tzvSE|{f5|7iarG^4)22=_-;zyd3TZ>~(})>q zG5Cc0-x~&bnU{lk_Edq49~HnCXM=zl8$p8R})|@O;ktBq?AhI2V8M}pP<#-Pau`0g5mfU0ATi?

|;(?k*6j~S72S`-;Hr0tjgjN81u_FPb%f8f4`3nUYj9A zXZCYYsbPS%Vu=pLfu;e2w;F|tR@i3{m9OBLg&E8R=U|uctKGRvd){CFW(|WPR0Uw3 zCR>m%7hk;mzEheiUQCx7r7cO~20%N$8I&#c`Cb4M>a5=G;!WOcX7)tG4qOvHNjkaZ zlkF~+@S;QNxo_j?k*7V^c?)7#7Pv(<6ThP{-5H?m)F}Wxdo_X* zq%5R36ML(1uE0>)zoG+r_anKY#@N6_=a;BTK&O`B}~trPxum2nV;u#}(?ev~^|^3(B@hIQcVyt5rpa?d5RKISK z%5vb6*;CH6@&O%w@!38!VFg~x#oXP93)$VaM2-qAH%Xk(qyrythG6|`K}t#kICVz% z8jAAF(7iE_0d(9?Rc-Xuj)>K-0Hh%?bQ(0F`M2Ih=*^Ozp}L$TF!BGLA~Ns06URj5 z;MW{cKvtaJHPM?Y3j?p@nL@DpE7i{?ie!!s=&SrKy2H$E)nhw25tt_FJ8Gl_G>gtw zeXBW+2D+ZiwQAw6`-3lBf$=Ko8YMWct>qnjkVdfCpFoPo4!zMHzhTU7>A$dSnF3s3 z=i;fJ!6Z9ih=ZZTSsC~@pDw}T51-mYRzauL4wa0P3h4Ss+kdh#(KhvK@iqljCdm1I zuC3-WcQ+~?GZqMgoAFs*j^r&iJbt}7(bPOz$OJMBjPb;D&M+#Yd z?O9TbD7$v4@^70A;2ydXuhZUdyZ47>)`I%Z`>|{#opaPWzhD2*^}ciLD<1yTG;u zM=&<^Q_898kjQ)A!%?VCdLc=B4Eb6q3itaMkGoZ}Vx%hA!LC($RmdW)xTHtAP zAM>>yeUVK2qYx}Oj&6?1GgBy~;RgnKsA z5fH?MrPR*RK}3oKZUNi)#9uFxaTG^&wh$T@RbDcs{`R>n9ViV87fjiR-1Fm2@mR`< zSBkQqG#@>;b}uk$m6ZJoRke89OXg2~GuU9y*+``w%}r zdWzaK<;)fRbH%h=@4q4I7&bYzFJ||#zZegnJH2$x7#S7gqlE}ezdHgNIeQGG6QI7l z2ep$M4(;uSE4NYC8osNyROc(Nb&zTr16oohqWR|=Wc2h`YY3$Z(A=RWE_#h2SC*>yJ4Wb?ed zN~tzd{N%m9w`+NxI>IWRnzX9aXzAd{YA}zBY7NsHU4BXY>l>z(D~Q6SsV1%q+h&_v zyQM8ZBCM$wdgYiqRmu#pMzq-Y)y>LVnq%V{`;g?NAzUT5*2mk4Z{XK=jkgB{ca2ZV z=qQG{m>QH}Qs}6wx=od@B%5dX0;(bC7nRFt%H^(!*{H4KYJ;d!zl~zDULocVh7p8a zyr`P7bfksUSL;chtmL-h?mqdrJaC0{*^?-h^Y+Iv3;4IMDiv7SQs@`oW%U)X7V2gyEQt06)TT zP()nZqrW>g$@z@1k!R7FX6`Dm8|YVMcM^d8-R-$Tp{1em0!ob9k=&yv z(Llb}13OrKJrL^j=Q3Eb!c=%@LsluLIDl%po^#>y^BE>P>?ocL^_i<7q-T0~2}Q(q zsStl2h*R8a>E8__@7T$xa%-)5?XLg+{tF@}ba=4itk_fs!V*|X8|;-sL(g|xw+ur{ zzT3&i%)SPVxMmg0xtQ$1y*`~6nZsBaNWRg89Nf7SL3ReLrU@%9VEnga=k~$_Xy}@W zL$CGZ%x-#;E{}qc_#)EcCOX<%?69^-zC{8f7ivZm_&zHdXqJtA!;0i$%D6I|=Rc*Y z*BYg}md0(x@Zf@J_Rp(8-FIcu=@D{6%Uh+@4s=1$#t0=X6)RZI?oT)i>xU`sVxd%5 zcCoRr8LiK@qzAnof?$@AxmOcV(Af5SGCi)0bUbKC8$#P3r56`V5Ti`co@58{aw(O6 zgJOt!i3H}rnAx|lL2qE=LK%*o3!#rCU+ks`x~!5QIoDL3!)4esCd)2Ru9ri(pVu9^z_^N|%X`uABcXVz! zLq}F_u{Yl~zi_$3{{R-^);D(0b@5#zga5d|;J=Y|loh`M%g@XX1mMe^3tP}GDuZ`w}Cw#jwabf-Dr9jckt zb|(30YR>}%llJW$53EpH6*i%QV$9t2u4$v6=}SMWC1r+^=ESdtI)8mU3X^8k&T5JR zL#!y=@YOon;w}ie<@ehKie-;{K*35|AFIVrYdEOkfFu*`w?X3|fkHK0>WCAsaRAkY zH3g`6rqewK7n5UW_tnxPifB<)YY_B2;*T{{uA$bAH&E5b(FZMwh4e$MouQ+9H-r>NG1K&~B z3=bHQZfKc46cMv-O>T-}bT*pSTB>*%8X7hHFV9stn~2IS{@{>IsRDLS2O65WH-ccu z&`$3+b)_xy;?tfz*!(oX-E*u%J^{62K0XwNn7b|t^$K6j?s=u2@F=nx+Cn^_R3Jr+ zj>Vo`iBm932iPrR5~66hPkz_63J2J?yKO{@g(HUql98OoPmTu4db>h`J1FpXWXeV9 z_zFs@kEb#t%jiFPJ^vRud~Rv|_ucWoxF>(f2Yrs5D&(81&&;fP_ZwVy<#*rF)9376 zR5LXZeBja+G2V|ceaJH zMr7V`5Q(I37;;#CNq)q{+ZB3kG`3!wr{w#kuB_#!gthR$b6c+-Z8O%i0sjIw!g=#D zqkjI`tcmcjgzQNV$Y1{`t4^9(DM^F4Q?wI@7#pZpHM3@>%V8>c=D9!l_ayQEmMpH- z28tDNGgQ9ASJSS7X4tm_dXlP4`h$m4&q%dDZDl!OX@V#SuokZ&6-{Z`Ff*{x|E`q@ zwPU~u>ib4JE+IJ*>aGFfuT)ItbeuwkFK(!wUbwx4Nr#T1PDRml zZmhp1^Y;MKaqWaIW46xKpo1Mz_K0mqt~_NgYujSKjMiw{twt(c>CmW0pInregYV~f zS#jUm=XZibio1q}H@T>=VZU%2)mj9c#V}k37<~>5sA76jdr&hqyZ*g9$9PV*t+0F1 zTdK6XCNJbb>XU!0!HaJOH!qB!4O$*hjB?E_6lRt$#89k=Mlh@w?3Rs}lR(dDusZUT zjE*wqpA~oXcv(*{X&tB^|FIit-?f!F8I5rq%PynbT!1Z|YMrFm%$($Bs_^Xk`sCIc zY<-B*ynGbmc_VRn9SVcAsh zLF$lQne0<{eNcQkAW`q5R4s&+oW74S;eHh`!E{hVQNq<_DKS1UF!MBQWdddeB z0pptFB8Xo{_kUT*wjvk$IErHVA~<;wd&fPsJ%eT`w(V|$*8EYSr7wKbYd4;%U|jG? z|JZvBGRQNOI;ht_SYkdywAbx0aTx4jg&5(}qxLyc7AG5`%TcAQ8oqdrcjb!dx?ae8BsX7+pU4NhDDL@s{8P+konjy^%A`s~JG>@|i(>50JnF8TLmW-D9JgTh zAol{N(ptzjKH_PWTz4ch_b8b0;p(xux?>`;O6XpmyQbEMJPEQI^^}#s%kNjb^-U4P zP8=6K#yk1gyLP+JRUe7We^QXM>7@jN@o{alsUx=JULUl)0HNVcoiF9s`Mou>Q1du( z3XUvUD}jOp`nM~<&(et(M{a0^rB;-fUK^gq%Ah;ibCR_N z(+Fh%AqqIQ9@u?w`KsVq5SE^W_Tti-LWDduL~P|55aig`v+h0q_XcP)JtBG}J(L)t z`7)jBlo#%;{qBbVAL6kQ<*=W}LU>PBV+_ z&(61#@Nb?l!3A5~_)YWikIn1nZD}R)#xC#BwEQRA!dTb55g|#fBXp>mN8-#boc)tX z;d*4QEVWVH5DkVt;T5s|?VfOma0g>-S#VYKth~}xGaH{}oQ1tF)#)VpFN1u==8&XJ zf5dJDp%lxp_*?jILXgQh;Z%LCyG$9;9Z zqN!eau}vr#VzJ3yFlP3-TY)5j0xQa6r$W?JDWgBaO@m)dGr^Fba&5%~3)A|* z+o|d^iXnjvg|WzZczxA|0|_Ti!DyM@B;#>BW@0J84a&Nm^b1+0i?-A3efHYyWLmjQW4Fvj&vxswVK4Sh8PEuTPo(@{L z5jcZZz{OR?Av$9}6#+Zdht+dSdW?b>EqLwQV_k=$br0fA7ZK_WF8}S$wb*14FvoD` z`<(9iZUd*#O)LXqE%*N@I_t2e9xse^glADiU03FL817a`RBpo5IqgF0D zHdLvj?euUwt)ys^f+K&7@>1C+JLD{w?Y(l7qd#j)D|sf<2T@`d+SJcB+>8<#XtHqMX{Jo~IKv;mK)s z|B1>fB|?0uNbIB*eE^X|7sqCeE_Mo1;zc-CE|tyh#DX;n1IvSi`X}}xT(+K^-c1E( zFXvqr5nR_aLaP+HRg@GCk~zSYwu$DuJ~-BQKUkOt$`gYpvt~zkRZ67rC2*YbY!NUQ z)jVS*96{aA>nE}mkgZ}fdsqqRPrd1g#LEU67dNLgm=8n=&j<7nrs4V#iIbS^<=uf^ zK-fz-U`bqJVeK^a-$@w^_xNv!USi|+er;gc{+7#stI_Oc_XJ*z=Ocyr>b#A1z#tNQ z%sNK5*AV<454e}&n=~-gEU5kSY6lLX_$;xh4I!C*g=*0_3Jo2iLFu>QIux-9!s1w_ zk*NjV1zF|T!3d(`r!m+zgqKyHTN5J~yPq}Eajq;}xnKnn_Ki&z<<5F_-AGNTOR^l@qI zAAUu|VV<7AZQ>+{CyA7rX#1{jI;m(>TuyL<>Ykgi&~|yOGg>pupC7SZiyktgmZexI@(UpU?f{pj)nmV!+bF}ULgEf0}7ps|}A zqPL-yJi}iF_>>WI5>&NCLYtkVa^F&h(T@|O^x}opjTvVY=b}+|sk=x`;sTP7UJ^(8 z@dlWrUn16-D-4A?l@%eG9_$R9aPqMd=4g;2eG2glElnh8*6q5EtLZU`D;ujVN*y=u z=qJ2VkBSnl?tW#DpJ$jf&E_DuOEHA!(9igG7B};Cdb1B@*f;5y-2MB7RxTd=p(@sE z&OR@vuzj~7Sb&OBTsY|q6Yg~&y34aWtt#p`EmgxLPqKhhQ*^$cm*T$Utc!(E)WRZyRR18*&&8s7I^ zH7N~);I;HEzeGmF(l#^)mO7Q{ZKO9(B&5G0Jhl&!d&ah@rbTs8gkL*r&ZiF#9ye11 zl*nk=h2hTUbFH(m+6|EU$Wk4WK2XKTm`9;~mGdKr&!rzj0SWb_?8vZ1k;LM8&o`^J)Aft@-`TLCN`FXzsZJxh6Ju%u=w z*o4bs4MD5V7{Dp!_E@|m&QCNB5(eFJ!%td~`c$a)Mrm(&1UeI+QKE<>G8IWC{H#y| zk5hwdUm1(Y;$mMNz7M28s%tJ&^JKUYfi$>=sX?_qF0HM)*xP+l?a@5KB_2K@+_i6n zIIDK^rj%?*tnKob14YZ)o|s}L8v7-HqLYXv-a?I-YQhe6VoWc@{-MpxC?3iQ0-vnC zzm>cdFEAy~CHgosS2yScYwHl3h!%cB72`RL;8xnA6Q}(qA0fEPwGP-!1H*b&(bq@& z39W2xrl4#ycH)k^A*!PUhq{q|OnMxi9B;>M!8w@3OOvNXl|j&|gC@Y`w8w?7iH}E+ zd?sS>=1ujSl?5Fk6$N}bjTSHGQovH9#j9gb?0D@Q@u{X_sjI!fegj=}Om~!%WC8hr4cTP6ve@(xA0kN8aH?co4u!Nj&9WYwAb$o&Mt>P(QeQi>2bp+$9E zDrh5&Cs>6|?R2rvtr~+?tzgdA;4ekl6D1(0K%f+YQTapdfNizyTh*-kntm%E8R2K4 zq6pJVH3FlQ?U)rck7wZIAm|6;+eLAN4w10h&78~-S!E^B@3xe0r`iqK zIf0Kk3@u#Kg~*~EG>bLT`ze*%z zddcp8(vdGaKAeW8>HVDyyZ$SePi=uWa>T~xR(S;_Qc(;-=qPG@+YqzP+7%X}B1xC~ zhE$a_u`FK3pO9hLPl`==H$|D>yu;w{Q?mPV^dm^cZfzOWgv2BL{>G{x?HW(1{tXZ5qYl6DIPSI>I&pPkP32uGsAT8>oVT+AF^A844wJ* z(S82X9O`#7hiZiaizteeQOuGlNz4K(-eu5lu2IRJWfJvu*!VE4a;HP;F^%79hIpr4+@p>~96 zcFq!q)1m1e$NyyriK;)^RM}(z$vu4$BjqWYg2pPcM^^xV0o5HW=ptK-AgtkeZ@!YN zXUmk`8XLR+F^mjU9I4)=oa{>C_lgnt*qZozoHlMLt1x_qC2BMCHN6r4$;)Rj$Xj)8)z%EWo|K*ohb zaF5${Oa9`~zIOC`V}70|w41)+g+WMqE-aM{Rh%boc94R#beo3svLyLeWRGN`z56dK zF$qGiAXOZudBRL3>-)O?yWz<$mMGn(rP6e(fiyY~b|Sj`*=6pbL6cSd;$FH z&Jz4d1GTA;dOIpdX=Dov?aTUSbHtL5Kpr^WNpwCxY$eYhTK_mi4U zljr7BDr4D3_>}`_8PG*Fx^0X6L?lVEAO^v&8AQz*Z-5&JH0TR@anc{q#(ayCaP5#P z=HM@?Z4zBaVEidbw}8Z<>6ND;P0sn zsd<8O7aO;tCy|dPNuh^pqp4P0?P!BQ=bc1ZsK{=W7XudDD`@X*Sdg7dA-dh?mO;Xr zI`Vu*^lBG8|7fIEg%EUfL%DpY%Re}BFjYG~{rTRzV5FRs`ic+1i{0%3#__%DnxiFc z-UBIIO`mV-e9Pt&ZbeLI8PT#!PRos?mk17-yEr!?uB1~B$j>WEkq&*C?%57d3qD}B6X0@o_n3XAxuYRJA+(|`mu{F~MxL{bQ-tjF=(t&! z?UH&lcl|UkajkRX_CXY(?sja1&G6bDvLlySXM$RuG+pc`(tgtQwbBUqHGCMQQ;hsw?gDgv?7#w{y@RU#2QatJAt;kJEX> zF`OLz`V^YL9?-`uH{~_@EsxV|JBbd*)zDgFaf9qf^^Qgp2?4ZHG>s&?P5DhWmPYnC zWghltfLZLjCTn$<+aGnnIBDFlC1zhrc6@gSnE7u3;PE7OcQi%L2clzsUW z3Gvo#X$jfoLYf_4*85qb8Apxt;op|)>4Z+Fbu%3@AUE6kdSahJy!xs88AsW4Rx zUWkn&$!TYBQ>*ushT0|(s@r)+MoJicGu`< zXH`+^RM%68*Fd*WjQ)h&KnP?t^GpkVBH6d( zL-@Cf9`}^i-CNq}GCU4MWbZx68puW~lsL3UTTVJRdDg_9%m*-pq9zWr)4G$p7VpVF zn5XKI61fXBj|dilTleZ!=c>yZPIBn5V_1I4;4@wy8C>%;{xXz*)@ZveN&H->Lcyk_7M8~oPKie$zA}%Gy_i3)v#nl+|(q61;yZ0$nwXJ z`{C3nqHlu)J-bxH2FeWm6tv`DaF8s*#N-C@iianTL^_Cis_zD8edlx1%qOm0OkoI2 zOPi1H`aTdMcw41~?0-;uFxJ=Bsrt-EG>1{Ctp<&~+=5E)eb8QaFxVYG>lTN8U&sDH z>{HAzk;Iikb@uq=97wy+4Ae}8;xG@v8JZq~=Eqyx?BWL1j|p##EH^X#PKBV+^6Q5x zT0<~Fa1vZsGn4}X3oKtvpJ16t>?48r@JLc_`Z?jYKV|60*k<#LSuQ5sL0ZUEp36dl z=hQQn1bfBEju-lz-#L>)f69#^=>ld{$omTNHw+^mzKDhW4$%WZl@ZbI@M5C7A^^VETW_0=*AK+gk zv9>(@DF1WA{!LYRT&-UH=M6uUBx8_ngEtA9$7vT5LkkPR4+2HAXFN9HghF^B5zma; zj0(Am)%|dq$)bV){Je3r%D|Ti)cB=F@BiZ_$SIAuXi~4zE{cfdVeQ6H9FhoCSivY` zrMi-^4YM^AdX@Q8)m5z&ElSn(2)ts+yoJK93u)h$Mmauyn5^Ne{Y3+N%qV`GM|f@V=vo&? z6XK)L@56yFrQ`jR+XGvxKOI>w&mQZAU*Xz}j?cYB5kex~cp-rVSe_(JZ>S9i&xF5Q zZiGxT7uJ6XhNizCOjkmEwjDR;%hbEJxHKDWOE5mbmvRKG1J6*Sx^hdGiUS<<746ED zK2tEHQ=BNK8%r1*!pW4A+;}?7)E;E<8S&okX8DgORE2RP1cW84U`bnQ`8!5ZSP|x6 z#3&63FCj^D3omomDjZm&7|Pi9nPL@IT!d`QkGBgK2b3Zn&rAe8b#q$FGS|#!(YA2*@r#NTRqvS_QP&o0f&Trz(Q;QbTidS= z3ld~fdD?R>c!6Cy4u!}X;<0An`;?JCf?i%KB6{NZ_>n6{+pm4GY71S==#}>u8a$`p zXZ+c1H!V%1jr_mw7fz}1rHRSnEeJ%Jhq+nkb<%0PFPX92Y}&c3SYc47G5+ChJ17xX` zr^TNWt%!lZv)1NAwge0b{S!wEzDhKA3aO(XOZ0nY zcgS>CL=tqhJ3I~5w2)9_WcAxWUiap)g6K;AId@rGNtsV$0?w1fkM@lOl6 zj20?l$DAOeKkQM0thW*=1yM;AHwHPUn{T3966pw}boj{YWdY+Q--*6x!?Zq}B8E4iG-jn4X6YX6&LiGv31&nQaWZ~J74=-+ zc_I{YIlfhLtDL4J>J{7{F!t~o8_klSoXST?x8ftYowV={){HOo{(ef9+7I~I%Du`^ zgYm>QkrD7GJy(5(dIVLo;F_7Jz;XKi5uPhnEsEfUv^`;WUT?L@Qlk@;wLAR>D%7x+ z&eAG-pP0cWhTirUxp#Rv-Igwn!xxEwOWe$7^=wn7wj|!+>b}+gG^VLEGcuEFbG!Ee zq_``9@z?)FW@h?Z)ka^XxKxqo?CZ!jf^c6uhK|USf~OvI2H7suE8w0aVUHN+?(pjM zmjz)j%;HFSGqB)%`h_UUOUUczr8v8O)fwJr(e$^kO8R@E1{k7=jE>BZ>8!qecSfHL zBh8=>bFkC&yN3XaFS;S9-o0b;+h1ScG$gf1)@&n`tiGT~vYp}pEAE_% z-0CPvuijFHd0fQ`JFB7{kMFGCbu|>vqV*BxV(HHN;#for^~DPPBUfUCQ17$ZkGdG+ z6*#T!P$lPjQ}u)GO0>HC8EtCTD9devo9;vs(-Z61s{w#CjwiF}oNWQMM|xU;r2Q%f z17U)b%BdeLeMjq`8KTyA;C|OFmtB!pVbMA;7q;XqZm3VId-@%~TPZd8>;~7FB7WwF z&DeDYw|z%}GJ{J+a)A3EK1jEnd6FDLBE8u&d%tB3jXwUVkoGh+U8W0*oEr3_)PBkE zI>B^H`mQgO`9~+LAl+C!2hwv&1&)FINMCJdGxs_7$q(_gfHSyXNK$M% z;o0xEuMeMR=>BY~WO|YMAz`Di4y2G^7Ew9L1Y+E`PuxPGzP}4o zkg;p;WWDEmzonuMtdhSDrlcNIaY1&bc_Mkh^?*W z|5rYBM#4!}{M}|I^S0MgM989&e0Ws7ekMSbmseiPy>P@Y!{*EmE>BQiGg^?FnciM| zA6TF`K7dK7>7zR@%bc{8ZsqELJf0E#+zPsSAJSxYKd8A^68uy4CsSwT zmh+q>_5h@D03CXyLWm722#}C*0rR)OJcd_OsG&P2N4k055kbECG+2VeodCu-C}_7Z z{*-8IW@-2iH$9| zC$B)T$d3BlIgOIUN1Wy1=N@wfBQW&_h!Q+%%aIwAUe9c^h)IaFk{kr!u;eZ>a^HPT zCe4mGmFgAQ`GN3tj_R={0i&1Rkcf{AaubCgqC3n86bmz1Fv&VLYY6I@7y^tY#BPVd zi|~Rihr#bHl!T%8bM&wnJVqYiwj~D@D0*S@@|@5~yKlS!uwdj|2iPaeV@o>tOJy1A z>^yW?!I3B4Is6+PK_?y^9VR7Zsnlg%Bdb_#`6Mpse4H4s_y^~D@qY6+B=2L&ts+?A;##bDp zD}4fU5m#?2F~v+Pa`o?z27|RsG4I?`#>mu0M)qW*3=h2_m=Qw?-$aZ+2p$}$uS$iw zXoNIgC}BhFJm>Gua`0epI^=pt2&J37bT;Q|Q{BDfi9h!C#FAbc*%mjaD&dswB@vz! z>bTk|(>b0(1SN=jHY>3L`CsT0fdx#e^Ta~bWL!Tj#N)GblK2GD(pJfSg|Qo9TnIMP zejDE4Raxyy>J?{o706!UGbge@*LL72>XAVrVkhUn(kLwh3Oks9?Q1|n$GIFfdu4j* zNIjyW@~2aEORny}Eh5uN(2vm=Bqk}a$X@SpvJbNB^kDxx61i~>`9h&g^vUjS{|uyp zFLN*B0tLTGOC=t(^YH!-DxAv}$tDy=u#=80e?Qz$0DYht6rG}sLYjt0w$I~V|E*k8 z!^G2}M9{>-mxoEu?p+d46BBl3Y`z0Wl91Pz<(X+O5+@2?vikJoU0&YI;>IR@?UQh@ z_K%KlcbccJbAqV~N%%m5%Ni$>i>n{p9;wkAra?kB7H{-X^jdI7budeZB=a_$D)g2; z2bLmhN&&`skg0laiQZ7jmyi(J*j~$Ha?S_E<30HypuTaVe_veg@PslRPKPCwLgpom zf4!SRZeC?0J^hn>)tGg30jM;kS8B6`?~{!Bfs)G>e_wCxce5bM&Uk|o2}xQkHGNQo z_)fMLFUcEmHf%=1$w`T&Vp`g5;n%h)d#Op}8cAw(beCBIHd-4SRTz@3Qq!QWRRQ@W z5n4P8McVkjDNx+aP-Ow_kv1r;v6} z+72i#pV>xfR&IkI>sJ%I4dj2y2E^p(_v4N4mVGcAcC@yDwXj6sxvZjf^;Xi=!5`z?K}Uy45Z;6&P%&snJZl3+EVO&D?6)TJnzIaZ4(=|_Yj*QqsWCTR=NlNmT5{03}BXRuw&N_!T2 zSE%+bVeb^xi&$SE&Oj;I39{B$fPHdJD1E8wK46WUxvCLbvSVnkUEG2 zoKfjLT8RthBw#d^n@QBC24@yz7JzTlmA-oIQ`5~q!}TVVQ-=G66VAj`tq~kM(1ZMw z3tFq-W!m)Vc8Yx8w49YQmQlo-_;t)?dx@B^GqRa4Fp31iTREZ{sx4V*CoHw0`oRZ6 zi7hD%3mnWS99h{BZdj;*m;+DsDSe1quC?qNMxddglC(Gdon_EJdiI}aIQn`0#CE8bt4_s>JoDu$ zsieOS5+HYM#(mr=Ar2@qdRkLO=B@oK_6yJuc?L_VP3{RKi0pjB29fca;kS>e_1^vZ zp)TPuyOb`ZJron-qW$$Su3bR(Wv*;z5uw$t0+>fv9n~!7Q+uRXp-WGrZ7? zM_9=@IK!Yj!gr=&)1a2tZda1X;1eYL;z)}?3@|hS(}6z|JkqMbZcH)}7x=-M0llMC z1z77?LPfVJ9bU4;8+ZgauO!6rWn8n9fuxfZLqaNbd-=kn1k?wgu6hoBz)5^wT}G47 zA>-ROTJb_n15MMWA~Y4tnOqUn=-?5$NHo^%RgWK5#}bZ-*CJ_tkHKN_&H>f`O6H~# zyhID#bB{S7DXFUsQ!3s-wr7D2Q^y_4e$x@PC6h{yf|oOi?ZpCW_gm#*0CnAdL)EKV z4eFh;C(|L9C|QRpo$`o_vi9y^E;I38x&7Py9zozC=zXLemra`$S<)~?qiq=KN8-yj z%Z8T-gZp0k9%(T<`7JHKe{DrTM-p<+qvlCFAzUlcf7+FU>d8e?A$-rQZ9an(F*Bfb zDs=2s%G|qAoz2-QwT(O7=*~S_PJsRD;f_fb22IPw z$dCWU(fu|%7XGzVKL~Xeelcupx{*Gi0+YS-J5kbW1{?@JE58wY$T_UAW(_ElnySp3 z8tVn0Y94HucJeHjG-g3uxEHmBr|Rr)6$KF z5;%La0OjBxNLW2SEXB=BV#c-bb$UNvAHH2=WV>9x=%UgXiT<;ivoj8FfHBlS*$N|k zWVB&l%t@2g)_^osbZj$LL1+&j5tlNH;~&xa{t=6z zi|yB-59vm<)j;{9kK7B)=!8-!gkAE&S*cs;-L9D$JhtjqIy*AY{5qe?#HhgP}YSx~K~Cr9TlA z*i6n)m7Hk=SV$ih%H`?ay{d5sTh#Ns6f?;Xp=2{O=zL*0P$l>-C3j^n0uN8>k48Bq z3y=Lfy76h9Mru>S&-3x@JacM>_Cit-dBBh?ZDqP?SF1P_?-(y=uR=RrOD>}+E-&Mt zFC2Meu%mD5bJ~mJVLZBicP}-EwUJ|MW~uos{vR0kf&35$5UYW zHA|3q1THbNxt1Y9JJ5=5z(Ifdl=Z&P%w<-nK(mjb*J4}dnT+t=%ZZ>&ZfKNMK z&V{6V@-}V)<2^3(DQ${H{_?I5a9D)9n?)SGc+WG&yb;p z;X`PRe;`K_{Wp-NiR3ycj=2vB5t+itv`z!i8Wk53q0oy5_#9>Ndrr7)WRubOPOEzf ze(!|%o79w`$KC*Md7TE^!ywV82Ca}#gh{HO@bfVZxP}|h{&wdj3I2X?WRGw+DA1Y_{ zcK&l|e_A+%^L^qqN7<|Y(!U2!FF#3n0s{XC(#3s}I(6E=X{2z$k)MAGrk5ItEgA7trNT@9oOax&fqEmXaFJin{;E4J!q zkDu&?UPXH84{c%ib>Qgi+{bS8XBYw$_qAYavoX$^VvZ%idQ16R4?bJ$@E6^0s8~UWTtmt+3Z$0Y-UKV;Ytr)OZ)^mHyNMq#MoT_`j{_O)Hi&Ai2n zPU4vO5fF)BXn8mi7fPBD;J7;BzD;-c(~H0)>quox0TFbDx>`uB{ZkAoomfFrL#O~9 zM3Fi#Fbf$T@m`Q{>|8ojl)#SKAkGpqKJv}#eR;;bdBUV0IHHIs7yl}65 zy3;Ksy3GY2@^9t0ZtVT1KdhP5$5$`TiwJgjHvzZZnfyddqV>@GoBfIF_; zXN|)DzA@qi3n61M+fC&m*-%??Zrrd$b>?vDnE#x5`h%sSAsH4M`ek?7llJYlw8&8E z2GWBKZhywme<1wdqRb+fQ|<^5!XJ6#J$hE8w7$e+>WL4sODCP#f9~Rz$L&BqO>V?u zsG?~nWYVr1lvwYr8y#M@lTT5owV`K|Lpl5kx>4{WDh; z2X!=hqL){oj$<8`sM098q!d@V7hw_l9w8vpGJ>pPF|_vaXHwmnOX;)A3^mpT1mf>u zxqm(zEx&F|nQ0X8?Z&3Q|DF<_8SF>P^2M6t@#*#OxRvT%i+hJ$w4`l^@uVu1m?XpB z_U{*!B$wW)Xdh~-bbPGTBcEUEUBc=t_5HvENV2w!537>a>WzeiT&$~iTXstKNYqgu z`1)qS(0e`s4?`FL)Wb#-tHc= zP#^v+!tT5z1k?OPN3dy|#TLOA67e!uWbX|hjm`o0){ikEShJ9{_{5V64aBg(UHr>e zziE5J!ZZ^3-Bm7Pc(0F0HheqQQ5GPqS@BP6v7g@TlAWQ-eqQw6N}v zkOcxAdWs@pTvtzW>)o(P^e%!g_p90$wl)9cT-T$q(S5z~AbI`94OC(FIR0tnyJCL6 z+;WQ}{h7#QZ-t3p=40(dIx5&j0PUx2c%j=^R_J~h`=Xo{V{h_?S)9nML$+5V$FN)W zC5-4~$0Gux)nO18R|!v@gx5b%fQm@u5683~Z&oZJwiwAr%vmA0 zJpBZ#9UME-HIf@-ceHJ~RNr?0>?_ntpj?5$?!rWen ze(MY*PGA0@s{RbMKl8%vmxDa-Sd4;qQwSH$wQ`emPimOeD$!Q~kDqz}| zZrcqshS<9*BtljDXGrX0mt)H06Z`8%tY}*7Kj+j#D((8wlqa$;FI8k*P1>E5ga*b0 zeWu{6GmQ7#1%b#wJ(|AlpbGxysILwX{N?Xn(uH0C`h(EHC`n=Z$3%GFO-?|^GMz#( z!<(BSpkle)4TrRNI&UvyGjCtRWn15KVez@nSx89o(hVell6UelC_7l;*LXf}(a+_^ zQ8dqoigg=dWEKX<2ZJ8|xGj7s8%*j&WzR1EZ5q$0q}xt%9q7ebUD)2i;raVY_b`>a z$|4iyCI|d+9IWbE0wC)`hKKyZ?MF&1KDMU>C(|SPR7Wkx|>>D+#Y8(83(y^3oadt;zMyw<<=URMK{wj%hjiz--1g zG1Cr++8|TsSP?c7I!S}` zGID99Y(?Qq24R9CJf+#1T}k@KGoe6i`v<$v(iw@IGXWz3jQ4LB7;OCIDcIn`W_Vse zbD)$mBX$jCDNvVcbOB2ZJMeC@JLldv4Kv%PzYycGM?RIXmILdFB28g+-5`%gBu;-I zbC14!P8OL2Q0`)zNAO2dz^O2M9~@!Yeo-OS`iiZzNevn9LoV?bzu*I#rq^VYkXB7z z_+{>Tj$N+7P-BnImqsD@h>)=ofLLPAV zD4oFm=$e5Lh!2O4vLNpPUat6LlX}QuKU8u=idh3ypBBEWusE$c4gb46mkUPrEx&hU zL8x)k%6_csE;%zG8&3c9=NiG-$b~g=z_Ziyb+nw?`{+<9%!!wqm(U`D5M~E0s>}{G z@%s7mYQ-G1*FanT{0s|jvf`Ckm<2w9Kc;!K{)&*!oHLZx$wLaDXVDpY26M5SBEXEH z6?MjsPiTcTsc@}Ek!N$c1KhANbQl4&`rZXBvg|oI%GM-(L|~HON2%HK#JZZglKoHQ zzOE`S%VcY~mw(a_FfKB7LBjBDE9FOoaRvF}jtN;NAgO0tZXUE7`l4@MiTdEW6;Q|E zAI`m3&$aeL3vN)DI75QY7Ur$Y%&;j4-8R#F!_W8Ch*_*?PzFRD*C}?eP(~N>C6ui? zKA$&}skL3xJ!8BYlthZd?S2=Yc0>>&HYo^KNQddbk^X2D}l zrCCDTEa60e9KW&pgxh^{K++myjn8OqrY8Zp+mqkBe)L$&?clN5sDz6pLcylR@vf~amU4CO_UfVtS0Rtz1(R6pk{uGK;f z*IZL0#rNpZ6m?ttPZHJd@!fE6bCF2D8I4y0vtwgQh|}j_pSjPEKtNBXt>lfg`*Wy` zz7nPZk8z?$^LyuNhTdVio3x|2V0*y$G9a6_WpbB7vp}%VHv#0*rNF5hbdSuQ{B~s*^rc`D8$|P-E)Ea?fmui9W7GKC1%Pb zc+JD;k7;dAQ)BQ^7v+-zwuaVsh((x>j=qbAj;I=HKutdH2zosWsv_n-gLulxZUh11 z0@)7HyPZleavY}o@gtpA@VeailIUb9d{@)C1@d%QUXu2ga3IeluxP57-FCU$1$%1D$bGh+sM#+>4#1tANjX+vvbIqdxGhHv73JCBK_o*p8O!D)S zgdlb&Oe^y_+hb|(M;e)q4?BD5!*|ezgtSaAtncEH^a1TctS%PZ&|{1}03RedY<>I` zR@~B=%R8#gOYB(yqoIwV24kB=Fs{g^6|%?zP}nC_^AE5EPA2rbmvm zOpAO7y4crIMb%?3j~FK5GfElmyG8{c?YaXyCq??|(&|wbZS#n@P=lE|u!{!*u~ExQE1W@Yxjhm#~zX@>$8}7K-WYfleYANq|W3A1tnoI z^5djX&tqUXf~LvgWW)2(h{1O52X5%deo=49_`9+AexWw`n}kFs2mZc6-&PV(h_d!6 zi_;_gsK$Sw446A-@qes|_9|#2v$U{DH8uP{)L<~LXpGWWaD;Z?OMMxaxxl6oOnN$u zIY1oRE3f3`Gw>wIJ3?cR6bX1(H0oGTrm*6)%07~3L?D2wVht6hk+%LF`ay0@d33U1sgVM7DbEc;PYoPNeYBh}j!5 z{K|dZ{8}ruZ5~66sGC^wp?)@paUc^TvLa7{IqO7kN`Ldc+7A$z;fFhOA{O%w);bKO zQL8Q~!Lo6AsF&FpONgH66Vw+cG5n+?rB?#kmXm-{0;jQgS(EOOkctF2sIYGqn{nH{ z4)zL7PI*_#92Bgd&N-1`nu!fN6}iWSP8rSQJC~*q!YF`zY~1!YBM!I-Rui13SAXDC z9|v)-zpZWi;~8#ToR_DEtDo_+ze@^AkvVA3nA2i2)_+n$CUH@PwK8OW>FbFN4wnEX z>J~xD?osyLLZ1ThBX|^PmUoIf%@o?a2oBGyk9>lgcG$?8y|KOTW5f30{=bNImi$&d)K-T7!?1q10X?USV+&#+lal)3Y z$oS8YO0b=ya2%5;D$NFt-SGWS8EN#C?xy^br8e!Ku|uul+_o1kX$57OqFa2WEOb98 z!}GJYPm91-k}w;HDU1S~b}m}r2Yw+Q#aMd8a(0ztK$`R`q^kEM`Qd|#~axE8Jj4kZsqwotj67c$@!7_XRTn11@-EpZ)#HS3vW%6kY#}% zd%Fz(H*tZ)Kd*mc-H97~45&=f8wD=CuBY*a;1sG4o%nd=rtZsL=IR0c;AD<;Lx}AJ z!Cz!5bo);cK@%jrEzeV`?U7NBSEh4?IU~df%>`S>hX?X=+niLnb3+qMXPF2 z*QqRnSbEeEVGvy$|9zjy9RkZf$sZ=z1w94nP(_|cS}0`(EPUy=TQ#{6v&hdvDNK@m z)PX1-Zi@R?X=VXjli_yda#9@|vW zo+{i|EY&c}eOo{)!q^=@2v+X5gs#Y4L5Z6{isV?ewpX0wjE5AFVSt@h5lLTUCggTQzm}q5 z&46W8fB|G!ZXX5mrcXsz3afrYP+hj*{iuND*9%78-Rge(RXue^1vK`3&?N3;|5`~p zQgo2GOxJnk+JPC2q!dY^0BCE({QO-G+wclp!>ZksmCU?oLr#45!bqd&o|(=#&};T2 z?$e?b9OQBu)*>|gr;IakBKfX*tg!^}B~|<~?O< zl1|RMK+S(3i_x=M;+em zeG_mLd2)ZJOS*4=-^*AOc9>m@r-SZIK^q;$O6%p2jVtP-Ex?(2%*bT?d%p1x1Ob6g4e^KkIhcLDgE z{`l-VA59xDI-9vNPhp!yYfM2Kgf@x-0%X z1d12R9KR#4GuhtX-`@$4G51jUN+Vm(>?Y7$a1{DBF!Zv~Qf`K9@^;5H@XFZgm0xq{ z)z$pGV|VUqL*GI}>e*sshyQh{_w~i8P5Y|nlUU{rpY0>trr<2`x*qzMiJKbj-`^eW zHp&J5_~b^`Xk2lU{B+goC(s`_&>d>hK^}yQ zwsDMsM=?KiypVP0Av$_lz=~n^pWIVy;@JdgYxuZg^|`GP3%^$|_4eot%nQqxQ?R(Q zY&U%?^|Rn`$zvx?r&r;Zs+hO3jzm^X>RAN+bbZ?6tB{^X;L@+4X?QyC@!xXD3ms=3 zgDh<2`ug=zntz|VhV~X+1AEOMYl|=IS_}zPF4dVMbb1rGb!fan47=pE;^{RM$Ibgq z61+t1^hW_(9LC0~Q&jyDTPujP88v^p1GpN~f#y_n&_rA5%Yc zcJmHZ%Di-|?^~YuGFzZ_w~nrP`K;kZNULB)s4P20N0-s^Bnx?47gJl)3q84GZk5MR zjBMZ6a$s9@P>%SSt$MxZ?5@%`tL-XeA{<~9XSz0y-Wubi_=7GXCf58|U-i3$PYAn% z^5yx&axEU6XwKSufzhO=Ci5!a(gdBuqVH|m@7&2Obg#DD;;zmybFZ3qMirxlII2G) zbH5wMUp|&M^bwhAev;{$l4ih{{CGvSH@&~S))001vZ6h#@Px@J*Q}q$_se@r-kB5w ziOo#Uqi;*|vUE6=O22=nD{T4Pr|CKF-W#9dT9M+x|FB~cTj#r)F-JqMT;-B>8+hG6OvjOZZzUsn$RT>@ z`#$`|U}pz`S{>udQN)v zqPi|b<-L1XxpRaxzLGg-8jhGbNK+lbk}x)IpR z+wT)J;WQuDkC`?bW2F84z+TngJsM2ThQW_L+kv4!2)kF5~xL$KON+~eP- z$%_d^rco0(S8p!*t-m`xje4ZQ$6$!8RgU}hTU`K}@b1;q+b*TbGICi*)BW#-B7tXF z6|6^cQzkVp6YlQXqo?lYdDZ4$KH<#GyjZ>YO_ld9YI|vT-1ZN}M9uaf&y0yqpY(xZ zDxn4ZUsdYj+1bJJ%a`9S&sHr1`djMPznkq_=T4G-^kJ5?UKS}5BtK^a zLS$bbpB0M~lIPF=RX$I$>0cv>$c1T$>4PuY6g+tie{$6PkEwGElH_@#_1NZ)ZSHtx z$F^RM+qP}nwr!iYfA{`B+>FSl-qTgl-I38<=*~JPz)pc&5h#glTlLf?xVx#6 zWt-!1IFB7cB}%Z<^P6rw1kD81h=FxD%3`TFAK~e1Eln-L^WG)zMrEcZ*MZBmRjC~B zFM0DjH}`C_Eku8%aaa; zh8mma8W^_L8O@E*0X@0!s<|AmeSZo59Q#g+O(KKPu@EjoWbNMyQ(>Ct_c@;{w$Gmz zpH>n^@;VI+lyFLWFn(}V{bUg2SmZo|EO{Y9Wde8Y$D*V7u&p@q)PVrw=fr+6`7vV{ zAyFes`MiSPP;&}PavWoA`V@IUGN|=;H#PExPk93KW#mDA2J8@;&?+CL; zYY}Zlj`4-S^8&C*#t}aj0{n(%Emek%wHpq1Wzl@S`;fGZ>SppVNI;^ndhQunDfUko z5ILsm=7n5Eu5lF2f{oD&yws+i;c$o_l;%us{Y-_US(XC5@eB)S1M56_rd7a)9RDig z(?zrE>`;k#9*|feVSq?Pw*OgH+MJ~ddHa7N0E+^lG~J8(Gg3^X0PFt&ggcf$=)urV@PW9CiJm%AP%eC2R?KuALQIK-vq1M8hFpLfob5)Rr+gu$IE?#J0B zrQ@d62NE!Tu15e>v&L*H zesKjtkWs@G>5M}Z)@UQRcP-s>i%Gxk-j?;x&J2cRy$gu`L7JN(hHmw4UlVVDe3DZ%e(bCKvIQWhNDqEPrr9_lV2 ziUivm_Yj^C(PPXtS!1nn5;DN#qi$+l-DVAoC}n$nV%;RoRXOUEKqS4qC!nB0?WPcc9;6kl_Q{J-td4YNp3D_?z0wkTCRMRy}beMZLMCY%iH zN1_!BI5-35<<9~)^8;Bq;t)Z=eEst75(hv=LXhocy}HW|YWH=<41&m$R@0T!dfkgIG1sm^j znADQ(Q{Kq2eV1wzmZj6Nu$SL+B><~U5P-V!RdD!ZPgoM31=NrIC}yCb;)S?ysOGpu!q2L|g&lUgKcgF>ZDl_S6shSi;E{9Jpi9^&a#=|bJ=k+a7VuSQ11Y;$wlD9( z;YIi0dgV7mYlTrD%tS~xw&Mg-+&+kWH|EaNUMWlAkB?4A34cRKH`VA@8A+pqR(bBZ z6F1lmv{!!0J3nh$>o=d`hW~4)>x5u(U=J!t*QjKv583Z%6gBQOx9D%+?X}K>N!JCl zVeAe%Cm(ATp)c7DlDWh}&(CM`!Qlt8eT0aj!Yc4@8YvL97UoN(9We-(`Dd~6<@&<0 zgU&~KB|;17VJ*gt%H99l)VbWKzBgb?xCo4afh-^IK7ti@iS7*EtRX$tVCmN1yPlGa z(P4Zv6Lj$-rBNDlnSEHpOvp2BleR%TGvHBI z;ux30f%@SipR@B5gHS2L%PN*K5csj3GJxW|u)&D+GJ;~~R3nlSWGvk0?WSK;NJiF| zU?umIFTf7d=p%D`!UgwU8H++E5%X=de2<(MgjWl!lnBDwvjxpUwrc-xB88(QWCb=T zO0ocbfP;wzb&Eb+IjlEbbXCzeh8DYmusv3>V4r9q9{z~4*jZtO!7AFHkT#3~Wbh=< zhrfG;)rW*ihJPV{A0|1$CvP4^UKF~fTrFDd-mZ3nOv5U}LM-$aGut2}WGWqeb$VEW zM!Dou+Diu#6?oYz!lSA!77{hFTLu%V;m^c4RbeUr>dZBgPPB658Ys0;-(*8%*9du;u+Ewm8cn^#Nzd)zK?>} zalD)J$;E_o6T9_`AOE}z%U+eu%kF(SB87((Y8e=V^P>f^!Rdly!77+)E+{bN%8f;{Id~>FJIKLX+F9S094_JeRrY-1qevT51h?jzFSfo&twMkc;77p{j?j@av?+Qptz;_TXS zw?u87-_~LMoBW2@`J3ju*5i}TyBLh`L zt$xB_5R@8c8oVdT2a4-lr4T1@ED;{68sJK0p@<4Rwrcguhbr!*I!UOQIU4K={J~tu zgesng80#bZkg~Zwc4af#tF|z+*ug5qsuJs?{ea=8s@Gf-dRH$V`1H<{)};0M%#K?B zTz=$9Ej%LY)V*Uu%}8P!*38}f_+^x_ORFUdO(pit0o+>n+$9u|=~UfQNZv3;*OA+b zJHTZ7jg7+6p6?9gies2Eku_pvd+Y2Tk^>xH zK|fs-D2Ef3)j%kyt~9cbi-{F;I_RIqC7}i04%EOax_m|Xft~<~@g#^}X?m0xRz8u! z^)5D*UV@2NJtlvx6$_d71pYJ~ZmRwZghFbL8A&?Fk`fCb%qsw^$F6Ylagl{qam(%p zK8}FunEuA};d0fvDkhP(LFtnp)q9EE2Hv7PC^e!q%~|U|h?yXRVfrISq(hKffW#$9 zf-ONaYRm!GA|AsMc`bAL>Q2hox{S`F%C1;i6!DJoO^Q;s021aF#If>c{qQg4AO^?n zwksL7NU~{si|ns~FN_>2a2bfeD85l2h^SIWu(O42iho1tmjO@l5t>n2={t(YEaOFv zE^d;>!@>v@iIe;a;WL|9I0z;y;0VCA1jX5? ze3H&U8XexxyGDo+P2F^HaSYdN6g^0d#cAjFg$?-c@^s-~3Tn=3G%gxFint1{z$XX>QLqbRXYrxMjNv0mXAPV6YWmPm=CoxEw?Rurfs6Z3;UCP(J~ z-C>NosuOSz@hxIPrb)WB8}L&dEQ#HcRP+nX2%2>TLU&D^4jsV}CY?5=7riW|9gG8z zUm)I_-wv2XJPuTREgXX*r*Kvz9P3;hn(KRuR*C+FCZ!Y?o^PVqJ+?wlj0yMkG~L@Q zQOBR33i4x~D8yKEkgE8AHNvC%gOYbjSY9tOY}KL5U7v5@1u0tnQ5)ckh2a6bQSJuX zd9GIg(ewnG2;}WhLnf5232ud97!O59c~+`H0sAMBIi8O3U(hbMOc-3bIQy{ z1<5izW`>E@L^D`wPX1iOp84Gt28S#|MrbTwBou1dT~mV@T{3zd8|K@x8h5%B}hX(OZmb9gQS|G3Ctii6S#M+NYs{e zl*=hoE$*U!Erq`RhC9-pMGl6M8WTZU$kTZ;jRbuO|BauNyQWm))~DPV<0NLQ=SrmR zu%iKjpo{*O>&UE2Qx8*SJ?|R6#mKsG$5AzUDygSI6j zKWGH}m~lXAf{WHo{3Yfhf~;xWk8VAd=U=ZBMa zAjdbM|AZzhVTNhyi{HGzQYrl2kLf87ifK#1Qr-G z)kM->=VcfaTw!6GY|ef>-9TGFL#r_orvHVrC5d~AhcfBWrEigfEp*@~zRH)ab(`6O zV^a)5$MQ$#+qLCB47)}X7rZMY;|>N!W5qb&?+j9^B62|yctL$1QmhU)xp31x#WjZt zJj;pWJ*w*O9$TmehMB|>FBqfUlFsk?-9v1Z$xVLwAv;Tp0p|zl^snIKD?vi-ETadv zJa$ zi}{eFYNBe5|BmV4B}3tWOGMy~z!n&Kh+@T$_m=jatnmM_%Hw=c@l~8sO^EbXg`@x;j77J0=J7@%Ceh_LI*}j&=5&2 z_sDR@m0#QLOddkZ`MdsVRuHVo%?HDMDs?`DY0G>L;fw!G2>O@)`=z$3T;%J~r0CC`^*O zq*}4{RtjO!Q$g_hzotVSj1RFB+2@Up&*}IE6hea6KvdOtigdD;G9OZdCrzH-TDH>Z zsem?)K~%kRzWciRtY$?|7e$Qmq+^WP%A*itCz^B$Mgb=$0_+8QdwD@j&~sJn-J zAs8Do;$u*qlT*0gnl9^;v|Yx?08X$wvPl0z(}T9J-b4Z=B0=7U6^8_>f%ZL;=1#5P zW#vs_2HVeTu^}6hY7eQs7teATZr-Smv>azlxiJ`O2HZ=RrRpn{SA%t_4psQA-o}8? z_y*=mgv*eTr0A7SQUy|!YIdv*i#0P=6Fk;QGI7X2py(CA36K8XO&Yp0y)f2mlOWd6RobdFHtB9h!7wX4EttOE3pK#J{ZPC+(&OwE15xD)~)rM@~MAC z{t|*rzw?x|{)5}wr>eGRnz?vn9Nj1O;Y~*ca^aJ#$=QWM6=dS zB==P}h>-}y#e%0%hm+ooVOY!q%ttCKIvh;glj3!ypK*L#Is)VVWkqK-X!KAN+wrYt z{=GsT5Wa(n$!|Z1Y11gWt{NR)+NQ;Bh{Z;U1<0P?yUILy#0myshfPSPN`qJ#aP&!F z5W;iadj5>4cf8U2Bv@npVt8syohPf5LfeYX4k1V;;fPe67PIw61nsH?{QPlM8sdW0 ze?o#R-ncy0$-ePDWpOMe?DFCjnJ^Ix z)322MWb;}>y6%PyP{s^_N|}suOKK(LyYVm`v{haF4yndAU1R5snZv~}C-lr%U_7f` zNR`-VUVAP{U0w87l!-&X&j0wYmCAUYNZ&5}ebWgORbUp5B@E>`sR*VpNdmu->9Set zt}0}*{do(2fC|2!O8NI*;#c4Td)(jagEkLo7w%Xh!YbW&>1R%yRK)K~5C?tQAd%V~ z*)+E%A$uJO-S`__TK)KKUwBS~o8{XvsWjj^ks!|QH^Z){X88$zBBdfBq>7#rp;J6e z&pS3a61bvmOBj%3DQcB~;zLBHA(Q_vMMkIa@lXJy^ioxuBt=;@E@rv^{aQ4=%`{}j zAI}v055x_ul9DESPu7}6=7f-pcVa_`N8{g!pEmd6KhRczjzE!30dGF?Y%lrze{gFZ z^sceyan!GU3Sk-b^?XR?^p}(bIJKXY^`G^46jTx}A#|?g@wZJMD&*@D<6Fih#*jb8)h)anX=)giEs&(|(04;Fdh%$QjwrBXTGoWw-a5J7A>zC7oCo z51*RyCgu;XT7xDmdPZSSTaX+|LU-$p9cNrUctUHv$PzT0^IschHv4~3XxER&r$$!P9f21eeR z%@slXII!EJG*B=-cwq~nO?d20!6L}l7&&dQZ##l=WhYgFE<|AzwDR^BmwhJCO$XsMl6!c;oy131cjzwVoPq(mwL{s;dTM@YU+79UYHex%K971@tk2rBR zD?TwTI5S1RXiyreiI2g$ar~x;>YuA-;N%2Qm!oKmU*UX?6%x@9yHj72zgB&QW+nfO z{adNPpaD(oI9f;~$oyQ^fm?q^0EtNcC#U09QBm`X^eIW9>zaX0RoekPm%jM?AF{%KVLZh@KV+^cuqf)V(mb=8A1gT^Ad$sEa@~{fzs=WiJ(w4CIXg!#}%xPkNN-tpB&w&*$Ik_HBVpW_K%UDs_%ol!-M z5c>}-NI4||uiWs1CuKM}KSgn*%6@*cCLukxZWn8k#^_1rC6AD@#xGo~of6F=X2tAF zD_rc|GP+m&w`>|6a#F1({Z;puS5F5k!IRBo%>$RdtZEI6mAwbvzr8f@e3O12OqKb* zCq5nC>O*>YyDv_TZZ?EG!ZH-TUT22BEbJ>w#D_MPTp^+Ty1d@Jz16#&>%H3led>NY zxsdHp>2`P0e#;#k?GMf5;4tL$^DT9ZoZdtZ?Sv?i_-zx|*6j6AFmxPEo%Z}Zo_#IF z__b$rf7rjD4Rky-ybX0!M9A@VcX0fCo&l`yt7S_{a(*Dy>vV0N33_Cw?L_qu{++}e z+GSaSqT zg4aGg@CCnF$HV+=_3v4%*@~P^u!M#!G-B*{cY`(rgccO*0d^xFKOlg)U_U>gK>y7a zg8|h4H6kFdydK0K9uT1aIy&GHz-%!a6JrYl26JP3b311{W_mYcdkKk7;QuC!7;1}y(;VEbv zf3*wX?flnB2e#}$Wxu8Bf_dCrqsHLWWaP!=l;wbs2YVgBOu$Tm_`whn5D@;KL&h;U6x8e zF3fKD0UAF^IVq~S#6NX`4Pu>&KU2cfB}>6STirWmr-(n#JTI*ufZ6SA9+QtDGNd8YR0shVaUVa2%E9yUe90Mkf?6x1Csh!T;A(ErdQ3jUv?ZD5qpA&T00Rk!O6>Lcw})}X zUZpv@NN|F*YeGSTVmv5E#@)=6JyHls5Y3~znYGw@U!N{~_*kUTn7Nc*Zzdp=JK*g7 zC9T14TwB0TUK}Kep%+D=_-rBZvZy{NgmKNwC|IT>ZLh5e>cFg#b?GT13vaO(MyiR^ zZ_pdM9*UZrU84fWGyVgcen;2el}B_(vNU40{N0DcaX#73y54o3Nd?u&G-%-@pNpIr z*>OSbX4*J83k{P6gN*+9y*jSp`b_;RAAC=)Ta=AF9kMt{O2K`)_d(%)5Pf(IPA z02e+Iqd(Rj=aHL*LND6enFP0vQTkfjB$GvE=tPv+AMj}gK~zv2iiHq}j_63)r340+0ig<|+d+0&)qX~7a-&DnAueYCrYzz?{xucmIGHsABCROi!@cbkUxFTr9)*CPpC=` zilhikWUN^hR_52%=0YkXO^Ymxe8wtZHkm>%@7r514=8i zk>6}7Ql{120f{uz{^JEFXbTVew=v$lx_YTCF$^MTQV&CJ(hvmK=5TVn+z(9dks(Au zi;Nl$@Ew)&_HO0>!z@st8qrntcUHQr1x3@>(y@40_mGjFEC38(^IH@ut&%^UIx+Fg z@a}58!}hu196bgl{^azVp+6z#)9p^Ujx6Kkdk9VbAvah$$4IQDwD=D?w*1(i-=1Qk z5Q9(zid}(d{9KGX&jOb8`%yNdK$H8aB-kd!!V!)ExM4c&Y#aNP(+6#?p+kmKE)Pn2 zIjY1;wCbS>(@M|@EEElE^NK!N{p7M(^`C!#Igef;uil)rWjVk_dMEawKThhC8AZE9Cr&x5B2H*UcLNjrE_*qXKHM5wa3qId z2)pC15cQRJD+OyJE6aF7axl3;_bxXRBuk!T8jjHqA|X_)=zP3bKqQgm(tfb@s znpaO(wyylN5kRkjwfzR0tVKE(3C@UAC7Oop%4mb+yr_-Id-gr&R+1cs!64Q35qz#& z#>G+RyI;%?Aa|C968={C?t)Tabi`}VZL}t|KR2f{RG&EM=fX~_u&VT#FhNml$a4)K zFoQkdeFX%0no~Qcg*#v_7q^MNG6;6K?-Arfi9Xu=AfV++mX1B_0nShe2| zrJWvV^Eo9)VT#nR-!^*v-CLTY8OaVh8b{pwF5JgyaDN*lqbBY^yJ;9X0J=)wDk$pW4NQ+`_Ns9i} zxNDgEB>Zs$Q|k^<7!D~lGHV;(ZDHM-Z$KD~(h|~6w0x@4D*J<`5d$@YP-}>6af?ER zePNlT>F`kF&Of;GA*pO8kDC16WSmgtW$B+wXMu*WJ%al9DeQ3CLOGCu88M&rvNWoW zI&@6DIvyhc8LHbcZkB=f+LxIVxlQ`jJhr@Vz#F_ky7_BSS%=CvRN$JbR0G(F5|hdQ zw~sW9Y)pMvQuMm2RHFy4Z(Q?LOJd4h5WIrE9U~p;04(n@O2OQ720_PA1SC@$G4biQ z|Ec2$nz06&h~jwsh@gW352ZqA@H1fuE+oWom(r!M)eSPNW=ZTsh&JFCxPoUrrpuwG z+Ul|SA^I3Rus{^D^_<0=NGRJAAayX1-|k0Y-!Ix~0hLw+6c~Nx&&fqLG<1$BM<@Ov zrBZt73k;}b2lR)jwdJAWu-us3)?1hd_!_xJ72ssbGW*``9Ut|@EETsDPS|{|RnRF40$1P7`S6`_KwH`!6(eXzNnB5;C zN2U2re2P;|PT{df9?@di7mgas;hqU%)0!CyTC#h!_12H}M8>Y-0<%t4#C@6gL&`_G+E5zIo%(V7yc&qQ^(xjdh8-7sUogW7xCioAqM z8Me7QhD{OHkM8(k1Z3|f^idqxn$f^bU^`VwLiX7yp2btGkSEM(;~e=<=^mkD+q1{d zMO5Np>w<=U#C!i>f)@!ZE09pq**IeI^i=@Ck}F-*fu3k?4gh*1%@~C5vCZR;N@xm%Dc@qC}7EaP=x0T_~SJ`l#IoH^IyF`ucY|So>R7gg|&A?5M zHZ)!|A~^ILAg$Hg>o@E6%p*TNNWh`cAX}&gv(Dz(mzxUp(~mY^!;0Y&AD0W4LfA{c zeMMdPNG>l8=O_d0RoD8mjnR_G07qV6Q1H?C5)9Ere%j2PSK3<{)cEsm+Y{8+rETbn z7f;DSB>x0gVJmde8P%HN^GW{27CMb)){pX}YnYbGtM+kS><^`D9V<+o9_P)`$j*GVL*R9%;%e}UZRDjsm^^#m@>A= z&242s)vr>7J$)t1%z+4;Iu;(YJGrdK9bfAbi}M!?&h3Uerw4IKl`al(i<{o@*E|N# zbh+EM3|EQZ$F|ZKdUU>acU0!ufl4)-B5@7-8cK2g7;S?Rp#py+|LSs@Nj!;p8CKpe z#xV8#B%}rfbU<`2ej}763Cx6y>WhMOo$>~mN;$N+6pNy8o2f=vcd$=|$h_6OniOAq z`ncEBcRIq;$_x?J>4gNQN5c#^-N26VwQI~#I3IYjlDu5F5ZVqKMkB1g&gdS!clFVgE;N#)bG-#dJ~qXS_@g&I>djA>eOVc&0l$ zJs2GuNB)NSbXf0$*-Z&B#LL8sNdd`!51;CJ(^ZO+%O3_iKzbn6uKXavN$*62@s&P2 z7&P-27#jEdHcL$&KWpd|d*T^-(~y;`g^j(z5&4&Cv|HVSOq zJ_Ww(_XB?P&3z7xD^hizA=a*!zF&mW5|6$#^?!HLQ{~@lqxyASllQL@cSfv8lq0;DodEp zN(9hyKD;ul4aofmFL2EEo*fPoBfYDYL-R-&?as3JL{xjgamWQS!G?vB49=Y`r0AM>R#cXM9t@@*y&Hp? zG*o-c^~eP(>rU^>1J24S>x&V!=%gM7n&hY1-h$-{&AJBCww|8^Bg{TmWG{u@s&xk;4U=T41Qd3sWi z7{R+=QGypeF+CpNw2J?pD>(<|CeoJ?>-TqZ9oXh{Tg9S>C}svLYwqy2FTS@4fyGZH z3Ygtj&3E_%7U7l{E_fxTs09jS0(M1Ji5;S-S>dFTLhuq~%ZoP4?cK`555=G&Y}}e2 zMs;~=P}`xXsEA)7v5`{c4Z0EefTOMdgjaLNSBDK4*{d zf=7|W*SIJ#RaI&&NBAi03Qwu!dRgI@V_^*Ye+2szLGGS!DC_5lzVF)xp4J=H0^}1o zhP)P4FCKeWHJYy`YZ3yxGYq_iJqKFve+B*X_I65-WbM@xK0W6t{cqgHIpXsdspI$- zAImB*Ps%l?2;0yvo<_r56~AgkY`#c)#M5fddYTW5j5PkZz&Oz7_Vi z#PMnM&zZ-P58VzIZ6-F9Cg#}HVLEzbd>cXC-jzA2-_y6^oS_c{boLqeB|5110I~<& z)06X~VO2YZ1WGc)Qv`M}6889`2{CtB4>Br0xyS5dQ5BC!piLPkqSTFE`NbK1EN6F9 zqG+;uNFC4pNhs<0Q{Hd_7CH3yHqU3=UrKJh4qk_ZAg+fT;PjOAXs5{lHeZGm}9Df^wOt;6^R`EI@j~hZ)GeOUS9;F}X zM#wMfz8t^ZdWvZ5aNgy<8wTo>U2caun5%of-Tcw7BL;%!Tip^f#jH;HoX$4;4)%GF z?Q=yY#g9R;Qf~)t7Bz-5{6F*&^$F%U5ycwJ6o+9dT+K2hB~mY_BGUJ>Uv@lX8hg)D zE4xg5A~D(;u?WDd2#;F$d=F04E2Nzb-$mi+CT+KGBz*X^qKkEKleD;JS7Q@D>4rbl zzWC@%b^@-_jdZ1$TG7#KeA5LK7P9Z(F-|BfBx~>~D~<9?!}x$73&< zoTrDZ+ML5sk@ND=uUK2|Dvgo_j2#6O zd|Qb1P+WsPX|?G2NQmXzv9=d`lq}DVF6d7b37@l)*r_SQBG8J|dlbjWP>4;`Q?`ae zCy&qK0Jn|dwb50ic2yS%>wBl=BIo(KMee_!`j*d2QzctZU zJ|@y0T?uE4nsmoy>|;kvhB=-6QeP3AJ^0+nJ_;+;QaaiDs(M=-r&upI5%HF){N$UE z!JtVVMw=^kc@8IGkmlbKs-aiM(U6+mmHjw?sRp`g*WocNjPHJ{nW(Ykuy{*)k2^m@ z>Q=jkl#8d;PL30Mm?!D-U;>=*LT3;vaVsOh(t=^g1FgU_M>&2#Q!mAu;DXKK!Sd>#>X-TYTKL}|7 zwVHmNk~Hgj^JP|eb(KO5`52~NB2pj29bOk@<~yLEa~zu>XCzFFl!a&FB zIndS-1G6DI10mNf_;>c72-r#xK~H1%nAUqM$`LAJ6YI-GQD|20p9e}eIGL<0%evzj z)e+M2VA75698$$?iCX6p(4#{%*)$JgrnTqWK#EF<>jYELsGB};TnbO09r1=DgJ@^b zMoyCW#d8ZJI1R)>Qz`3tipcQ$Ybv_A-T8}^Wf3Fc_&vxaOkyh0 zy6YTBD&Y`gt#C4q9eEnfC^Wg0ZN{{9Gqrafh`YG0)ZniVIfT3pIea{=;Zg6p_k6z^ zBd5enmWf|xnR}#l&tQuM@{`ExC_BbwnQ|!^asv|Ef!>_xgyxp<;UW6ml^wa>kmFn; z>1rC!RoY=Q6Z-HQK@AzWh)0A`euJ-s+D!kRwmo>)_fnD&>`twGnf7d4qcaMNCZ=Fh zwT5GZKggrK67}xy+z(Rgs6Y3zYlApTMq?i>m@fNQ$`+%JlUl>*O9cy0e**K?eyJ}( zRuqWen`aZr%^6yUY_mD2s91;=Pq-amh5IL?4w+B&S|5mG2QP}fRC1*Ct=`v=Fsvg` z;@qRPSKnnrR6w+hW!u&Sy!|!{teMfrg^6)>40@t{9!JCXss?GrF4>O>4|nTQxas42 zJQ{MQ!Ay3L$hECDv!fOjSkd8lPc5G3AE+Lnis_rqfx5M8*gQ6>S9S@d}(nR!dKUZ+>ZU z{*9!zoYXPrw0f9L`HKIYei?Ym4jLEdCNd{kx<7(%ONNHx*1Zh@(XUCexsr;C*@MZ4%vcFzHcrTEt*l#E$8E(6s!FjM`=5xU0T% zUBnrs8{f=^?jO;3XAUi`gC7r(@00)8M1uOSJjeyf{ev`N-M!(#PR8#Gs2vKXX!pveIv+->}It z)B3kw{nhAh@z>N*yWNzl;StMt`sEsW(8|V+!|Awxz*;$QzIrWbI>KQK1qq9rTz$vn z`czi3Rw>za=tM3{BEa?~Ti>?MnPP_nm+^4QW!uo_?-ZBx15Gs`QiSK5`)9N{rvx4Z zny^)zSJTX!3Nd&;vHV#hg!z(7)+Fx1iCYKNKBfW{4`sMbkZk%!9|ok=a7|`Zo+b## z!IW0XNUdcjn&ZvNt6#lwCO(q9H?a<7l*yaM&K0N}%rtWP5^@mH(4xRASP2duZ}(*J zzAM0h^{>)-Xws?7gl?0$l8w?gc%W%D17#zOSM3=onI5af23yf893HKUE??_Jr;&B+ zgY-bU!G+9=?w@pl9Pu%o0*sXG3moK1lmvKqfS*C-v%^WRSLUUmYvR@@iz5$gMD@dy zx0Zpz*to){ZM!RJR{T#{^;f0xF6w|wYkzaGjPMNU1D`r29zjv`_)>2|Iw7ueXxviX zkDxi+Tv^3%rZSt^CJLM}N*Imq3mnPW{!^w<+|@CGNspC zUqp&Ot*aF#eV_xqRW!f&N9iF_Bn`n#^1{rN^2U~_!6 z#9Jw@!$#hu)W;^^D@tq4*IzD1p6tjC4$X(AQ+>a4xcZ=Aj9}eI*PD2G8PufzRGc}4 zi3l0SLuzw3?U>F?C6FH}00K!mC&pDHNN#pY6R93d1k?V2l1qMcD}M+d@=vfHsiqaA zt^f=ZA)pde1WTY%BuTS)wwPBvFpk283k%u8(<`dk^FC3}ILo$UvWlrQt{k%vkrNUa z0Su9pDgI0#R7hY5ES0M;RA%<03qCW7x*KpjgN2QdKq(S*-XLxYRd!{iTn3NcYT3|C zu40vF`Vk{tN7nk}g=C?Bxw@j1ltjN#?5{v|yW}CZ0&&AoStnwtA^1d@3~v(~hazEE0VFUl$djyI z+~fqv+9CW4w9ctOT!G|<%>OPqRa17G4`mN5g;q#pM@nSYyrw~_h;&NJ7@RB~QCdi3 zSR0@$kBnA`+A3d~vPjD`+uCHAAxtbnDP^3ZGzL|9KOrZq`V>wXzJy9&Mp{`)tEd3v*4e9pvL z_rFjW`NfB36ZjF#b8TIwbCpsh^3;rAs>8-@mmq7KVI{1-Gk|g@II2Z}^e1r69+#^3%+^?lca)hxo>4MuLN6 zB|9T7%lM5%I#-P|vd) z;bHtTl1}|U0Hi=$zp6ELJ{h0*jR+(fw=J7jA}wR6)ud;8qCv}OfNdL9cOpi0& zj#b*wq;OZFh^FP7aV>&%TO33Ow2KJtoLkq&`RAlwo+XK-ObJ#$%69a|N)3|s#$|gR zJ>bU{CB-5yXWJomRsjJ^*D}i)q56N6lhSD%l1iHzX1RKicS96+L0Lgjs^CP~VNDY&%r4Rl7k+5Lp=bol!3GD=wR^_Xg-d!`TFgX`@ z9y$d;i&xhaOQ(zekbK!oF@HRynQ-c6Puu&QGQ53Re?}QC^FQ)5=Nv$jVJ%Ja@P<#_+c#`L(Z-^6Y2jZNEKJn#Uo#&nkEBzw*y<`lJ6$xiTEr zsh@W`$wKneO-d)>ePgN%+*Z}f+JlQEUCuVOE@biJK`wR$IbyD#y8r^y)~T)ywk484=+JwB^KU;!Rd-9SHPXmAUph|Wv3rJOM5i~x7X7G`L!pA zk>ln4$@0K?CI8ptbYG?IV?ng`+W#-oY9a3OK3nI2lGJIZ4spb_$hy{e6UzVJ(o5bJ zj(nE?(A_1uI1gA`Yo2;#iuWQw-wQ1qU2}q-RK#Z&;av+ISMOse>}*3pofkdlWtnfj zi%jW=|Ks&@CorO#E=Eg{YQQ=UARBOhW4>fujmQoUg)61%UV2Xu)pJbJ3ma6*@-rmk zr_Gs;HF8L&*-z%nF^7B>Ea;vGtQfaAfLa#r!UV~(;VG; z-N&hxrjiK?AS&jVA4?J9(~4GEa_nFCf@L9G_Yy$_&-HvoUxPT+sG55+iFA>aox3s> zJBn}SL~oiQex1Il!S}xyJhgbS;@9Dqm!0#=9U_CKy_TB)MP$}u7b|o;xosA=Z!SpP zItpBqRGtr%Q0$mRVkVMT3u6CL)80s0P+*eeL2gynB%3V~q#VAPTccnlx=n1#luP0# zD7hArS@^wRvddVj0mzz9JPSuEgB~E1Ti>4ox+>-T^YWrTVYri~cv`I6{@WaP;$0GA zFU84o<{qEj4=o84u_Iz$Z69SBu|FKUSz1JY?MX(DOs-zyK=S0f9<27CJGlMvDm<}% ziuCCP^aG;FtU-v9A#x)1yz(0^echo&k!nsrCtpDsXcD>#=p{N4(O@f66JJ1R7eup> zn`kqXm}Ze}a-xG3&h-b`Xx_xW@??r>;%d8DNRrX~w0sIxlp#sF{K(XDlsu;>_Twrj zDW_82FKCv9zxfj1`-nXG)RLml^F?pjN}L1a$VAS6GRy}u^(_OK7oXzyor}62H3`Nr z_tPylGOl=%V`O^KeNVb;Bm}No=vW3t-3tS5)L6IPMX7OHsc8`-=u<^32hkw{yeptt zCcsWSdu6Caq$jckpmmb2*k0X|GK5KNlz>6@s;*p}GEOm8_J^4)L{k!Gg@VFsAZ&>( zq1!qXIZnvyC}yX<;8A^NA=RA@OFC|QqFLytImQT+zff%)s;9F~qEl@U@pxDL$Rc=l z1!|q+Y_}oK2XfsA=M*_krC{Xyk(~21dD4%lFzlv}fT&TX$dz=`e1UdC?2#1Eu`7~N zJe}*A=Z{NGS=Jx?S}p!xWpBJ_E~I|6@)lL2`6aW0?;6Z&36UY#< zksJtF@~ZBlhYkmIgHZQSiM}B>n46((4iu&#y;;nMMJO~I&=Nq*2swB;UmoNgB?WFg zw;)vp7xy5L;6X6pT*N@05eID0C_fEFG<+z5n(T)&lNTVF3w^{2JUU=@98x1$T#m-A z=s2mSh(2&Smt`yf+cXM=fJzJD_K}{%7kCJULWMN$MpTzI1`mUc76{pPxkKbL)H&#> zjKe50PXe(IDx3&LlR45PT0G>|>9C;hG9E`M$Z5<$rzv0n009w$pwt`;1`!MZOacKM zM3~A|tJiWHW~xn5FXD0~KQg6CeSWQy@Cad z31L!MGgF4bC%Irc&tM{E%ss!LPKRZ>eg)fEYb#Ed4~|M$F{FgT z{%qR*;EW`1kg@&0TRA~^F#&oHNsV-+& zA0^MD0Z-vAXT)U2LvtwQQBp{R$+g=3WF&@F0LmuiJ5L~^X5|3^AifnVUZcv3NDUP! z{zgNA6LmI^GG;k3=X1v^M>WR^*@!1n$Vskrwgoeg0003J0w@%qF$_QiC;$M)00000 z0Ahf~000000CE5T$PLT@0T2KH00uya0{{R4Tdqn10)qhn03ZPX0p$*siTIoV0w@4J zG)4MUZK6UEM11M4Ycd4_xe#B2!Q$p3&`JxSU7L}iV`r!mN|gs*lj}^TiZmf;8uu$#ZK@&&n!?z|vFZ`iE?Qu?4MvZJkSZ1i4J6K`VhorlD0)NlT;A zL)W0u)(Jb1I&klDXrs-C>Bl3IyFhG%O>efZ%~~pr6~!OV5KoAU7E$l%hH0v|$qxfq z?>J`@gf3@u8MZg(yWniU5!RY`8?(KBQmf7pP1x|o0R7I89wep+%6--zm zm+--Jll=w=7#`$wm z%j14kicO;O;gl z77vb3Br3%Dcjpi$`jvry!Da}9ZV$C7yRc~8=QY)uBu>fP)2k%c^EDnJ1^4F9d1md= z!RVI>iaZ=d4|h5Fz&boUI0ShvZ}P0S&l&Xe1{ zR|wOU=Wv7sc=vxbWrhIRVEa=dE7eD_nhJrH*46p$ro5@VTP4k{A__qA6YU;TfM18i z+xf3bz|F+qh}Wu>>%Pgum&Y&g`BYdbyb#0H{-QwF2+_>9zBr)+rUhw+j-Q8Vg>%Bb zTUnSx0cMF?*W;}smC8BY#jBO^8Vx%RJDZy2o*>C3Fc6g4=3V=gp;}0}_FH|D@{<;O zQ%z{Q)(qngVA1iTP4}hjw=0GcG-$l8q3p3sd>fv_7|{$S*=G^`JUYrgmP&Hd#IQ1v zQbR}GWt9;fOPB!U5{qk5ZEn&o2Kdw+VS-pzWh6cl2+rfk4dj9zKBb=mfg3CIdTDeA zU|c$7P}7ug>RCi6k-OEAHmc1lhb@uEt_w5nu=8 zF-`=tnFW&fLG3};(2zyX~^XB2tMoj5mxGafDU*#1Luh?6i(JflWY1{3K1 za2~t`AQ80XwuEgQkb`O0qHRQm!7Htu%}Arj?nSh^FC^4_5YZP6sjD3pDKMr! zQkZNJgC!Q65U~-lu6O~8(8lpa9Xn2ob$ve!1Za=A9uE;}0V5@OBV$oj2UHyqL`VCm z9mb+0nJu0y8EndfCbFjha{wEM4_w0JhV0}H+t-`{i|9^JMT06;+MU!^H9;9GN*QLS zeM{*nRslK9LDU&xkjD*Igu<1e87QfggEQg=2{{MUNaU|@y~_+9VohnNEl@)x2?pTH z$x~+~_mDir=p})??HbNU>)L%FFe5lJ+?`AOaO_UF7SWj?e=#G`3VKXUZ$XGIgRboq zfZ}K8m#5=Lx>{PvPoFSQE$44%C90FAxr%--`D`$Kkkt)D z(+;vkMWP5Gf`H*xR;g7+%>Jk_ib?O%_Ykc`hTPsOS-d<~`5Kh2SoNQRFW2(R9-2KL zB}X>&M#nT+yvj1oddr`hc!|^93l%4f8M2!=9q_s%NQ{ih)zN?L>wq&zlrDYJNTyj2 ztG;O3Mlp2veGywMk^fJz$7Q2M3n)NKKwg=VA5k01Ma3&7`bKV8Hi5si;BH9}5}Oh8 ze581lACYNgjyhHQ%9!^_I(D%Te2nO_MVEbF9x89-vSb?@kl z5FgNA?G#3mYrcO=63HRi{Bi6|xJjLz!QG1=DrBdalpE3unSLaY9m=<3MTs(wY*>)> zph0nIX(Qd#%*!vHLHTc)J(PRfI4p60)6#iqSD6_XOschty2+*HKvD~mgvxu~4No13 zFh3-00qA?FI+RlIDH=Vhd(Quhjin&0CRjx#co)a zwzKMVmn~^Z2dt42=RR80szgWW+h30z>RUm;Nb*Z5NO>MZ?NoYX7sc%LE?p!`+&Z`Q zd0Wn$mi;x7lnhDJmQy1z_lMEZe93aeTgwn^hFzU~t^zlqSh-^5ix(~Mh+dyeJacX3 zd&;J|y!yvQY+R>WtG^SoJm2#-aBf7G>bEoG@FS}vBKgu(w0rq8C^ay(u8eO#|k zAdn@wQ(d-KLx6s+g(IuQxheejR4RY&^*P#L*MfPuHma)a@ z!NMSz%Ms?CJaLrn_VWLVJN(%Qm}zNNz%pxBQWWo`XNZee6eXAC=w5PcQzF&8%!oc2 zRgEiD{tYRVaQkGn^G81*m^LLX0!3%cu@RO{rDQ}0>2k!nRLW#NW^=Elsi|g>R0)xM ze}_6g+MPqGbjRyWu}^fhk?~{iX;%rcdy5cKGtqf!PziTd{hq*MD33ay?{cs7?vwNG zCH3?Sq`7bTk(yG4|LX>!X|KGEJza2OUl&ZJ?8i(FS|7Sac$DL={XnJuzTht%u9%$S zUE?W~sJsm~mrI`b27Bv!G6zDBh$E&t<|`RnEMc$F%awn`L>^Qqr6y>)50W&)<^E*H zSi{d3=v#G*(Fn7jSg7Mnv((j z$EV-Z)?*MpR>o#ni(D5d<-8@tu|xz1?A?FZ;!N18KF+tS zM~Pk~IWHHnh08RnnKfYWe0M7Da88|7dtN2>mQVs#-|89nkO~8% zt-^4BBFYQpl21#Ndsk;jPXhR*w0CgTw-J8%BwT?2wCxJ;t;m~!DgvP20o05Qa66zJ z3ej1J3o{{hgn?yYS)y45z!-2K`tnFY+l5Xnm3F1-tIUmNL!5!HG9Hf&)KkKAH|)<>Ck;lk2wZpE_J}U0=#?g8|cbpo*c?hrGZ)+L{b4{W!%Y5a|nTe zZiI{6h0Z|U7kQmils*pcpg+96B@My-MKT{(_!x(3D7pdE4!Z?-0j;e85ikQf$JT*R zARA>ewMJP)r-O1S;8aA)Iu>}|qs|B3rf_%-8|wQoC!k$SvAG7c*~kUq8+9e!5$L%L z7@6%2SRXpF4t(d1bHld-Cr7|L!&iBn3RlZH<0!BgEEu)5(e#k| zP8X1Qh$}gWdA0;=1MbO|gPhmd4Mmddfa?=~Z_Ps@!0P#d!r)0X|3$!-=(Q0^T@{LD zElYO(2?g>UT`+o%(VQy7l?FkvOHtyM z8A0+Kmj{!Cd|Z--WVP#bHBVQC<|%xL;Pz38G0*Ya!w`!*uaG6s$xrc{sAgt&Anm+) z;`C+H@Y93?fnu_BubT_dq-!X@?tvteY0DK#6Kekg7xLRje4E&ZlIj96!KjmvLNt=z zGEY4^jQ>iK$JUaiz3&FHjFXh$B|irTESSC#pvK`9&ohasT^3fd@$Y?;3K=A-y7lUj$L61^@ zi8w7WB2O)Lg2Yh?fe%VT5Hb@-2AVm;wen0j{};Yf&uS;ajPfjw#pw7^6_3rGwWoY3 zmFy;w;G`|>vP2*$NduWAOX7klqq2s^5GCKNt z5BXpK009|-;Im8?02(?76nLW77%gyy#-gIaq*-uoL5prrH8f#9pbf;?+e&c7?`mSSBG{ZNkgkY2FRwEfgf#WG1tT8fyY*LQ}1Vte*$` z;#O1WlmvK5(jS4;m!2us1@K33m`n_SI0NM9o)Q+^Yu=&MN%1(97xKrVK?@}#LL2P_ zYuF7*aC*NF7ym$7!Eu`?e9F0#;lz9in-)^P6gntqGotVZIw!ILJpJft!5PtUV+eQi z*jVTfCMlA0000401Ti200002B?bu)7%%~Y00000A%Xw^ z002qDTT?1Y3>F#^000Vw000ATEhLT9CNsbQDgX!Hl28c93?QRcg^TTjF%HLh0MB}h z{3WDxXz6GARj31a->pQP_!uo7a3RG3QQqbAlkS$WD4*oQTI7#Lf{Q-Fc`aMgwU`JX zy~t&Yd|h$6tE0HuRzU2dd$b{1w;>q>Fp=9Vsq|J@^aRuvD4q~Z8(ULp5LO9;INlQ0 zlCt0Nzo@r~pDgWO+#bO~+ytrRhR_7AiQP5WiS$kqjT$ydxmq2}MF35-&hX==B( z6h%2zT8NbryLftcsbN5ERG7wT!MFmb--s)c3RJ;2pgIWZ96vww(%U#v&L}`cUR*XS z^M*ilN?h1*d;)=2C>Vn0UFu?sqnybbfhU*rvU1Q+;z6Xga7gwT1AHUoL5;9dJ*oXf`{ZDg5~eC zw+N>Q5|N8Q6t+#tzq=h~2Kep%r3xy6RqgAL9u};@s_G-4}={GhHPQWs^yy3T zzpPDD$FtqpwEz)wC>t#N-sRu`T;Q9J9Ms@afnP@E_f|a!$xvGyA3C8sWP>MQ>FSn3hd zo}nl0c{y?{Z<(FiiSzl<=!uqM91!Ot5m&jjUf?A_7kXGd+lzppc@^#a+Bwt8#?g+; zpR@kui!)+u)h(yN;IKioF?zfykVh({T1gqiiMA*J3Dlx&ytZU)i(4apqbS$Kf|d-m z)0Ok;%RNV=Ya%&b(`}tWItrJTRZCE5!BC_Wd%J2^x`;eqm!&&+G4QGZ`SJV7edGBj2!4G+;B`80Qsew8m2QfK3%#FfV| zA1q>c%N@FnAU;*Qiaq8O3#ao#?1KWibvWS1&mkpyfoo6peXX*7g2cgTTpn#y*9%!x z2sAQoltv%CRx6}Z%GYM^?8L-ItpUK?O$LI3fw#9POGmCus*)`4@u)-98r?>>15`?M z9C|u4&Vim(FVGS*r_t<~2U%qYgqQqk3R@EQn($d() zBQBuh!Twh?wn2VcF3JC)cb5{+C9>u`xic)EWankF@ss{mEgt}7%mA;AjQVqO3n|;W zTwn49*V)EZfg(6vax3?eWL53BO2FfxzVoO&6ml;)`zW zsp|1$*##4(E;k1(xCUY9&Q3vE8V=m|6NCDiiAkEnI4=SQysN!nVLvoo%)PnpcHr3r z8dP?dO18;#vCCL$P(k$ZV)xPNws~e-T4eSFTV2iMmUfr`viQ+@Rqz#*;^jdgis)s#1@a}mr zrpnCLsh<$82@AP<#m!F9YQ5rbE+%6HwF3;9floSvaEuy*L^Dz>rJ8xb{G^DnD-Ew8 zI)9c4@6r@KzdW%o(Vj@nx9_g^kHmTZez>)xOp_^-;4Wcc?*a>sAqiMsMY{=AVVgNk984^GxI&UKg4WNk$(F431_M^7 zlQq?aOCzNbt1>+Z15z>6y1PR9r*71UGXhccC>o<&sjW%W@zpo>5vYKl3M6ZD_dy2SnV8p_voWX@S627zUdqj6^y#x z#ap`HV@MP`6>N$X4EYEd=2 zvNXy@kLzl3$lViSCuD6CLZ8+(N=O)05$vo}V$z{boQSeT5J+Q1H!tQR<3B&@BR?QI z*Wq((%=MJ2%OggpMo6OnbjY~~$sT{I>2g-J8+!W=P}h|g@(yuUIleqVWF-d5kn^!k z(B7e$cO-cd27#ji(baSeAMAu5_mreH{TG0JNBX~!kV9Al(MEuvZ3+XUL**Kf{2kAA zp!;0)0@+YAp3yQPw8F1|m7{TB?BG`d? zl@bg30S)$@b1MB*i$&$jkz+akCBYNHsIFIr<>AVo-7+Nnh|jagE~%q~@dqsT%fPxj z+ZQAHUEW>i`c{@4t8`2;Pfu41*8etvP@JEC$c;l*v2Z8h+mb)>Lh2&w)rI@}zOTaU zQ~^q~eu-4v)g$s=`{)Ou)JAxHl=>?u+t1Z&x_o z-^ZTr@t^1!PzndqBjp^Qr9%VXApX`OMOX^4jUTAV5pS217J@8&Fdy<{MohjLYrLz- zie6;aqZ4=kbhjVTNFMcM9m>bayrL9BP@rc|z|x7dO$VPs$$tfDi$%K#fKp+dvcIw;YR zQ9*W@1R}&!lt_^=)5#eZ`aj>+3MZ^c$s^`mw^X=4YZo$4l_N%sKjham^0xE6Uy?NZ z&87k-k}OvA=*f*w8T$X)$ctVORp~0S)uQrBi8FhEoHRsbWtbJu##rpWbHKi!%e5I} zJG_nD$Nkc%(v7Uu0iAKgXFUK)|0~5BlQR;KhH8XtC5F-{_uhyGfQcb z$rGkq5m|q^BBR|{+VVVPM-t4*I|xR0#E4>Z-95z)ba93caDO1TGuKB2b%XX*vH5z+ z5qy!9MV@=+7Yf}l^FZk3nN~ienl71E)KpRnO^I~+Rj8!? znACzsA2d{1Ma!1~-zJ?_oPX&a-X?$4JG;wy=YLmp#mf=bWfO|qh9~@3lg3AgrP9P? z8GYJ4^7KbEDwPykcJpg~R^em}FeV#ONqB#HeQ^l{BFqYxGv8)P2lu38l28xji)ryF zbk#hx?zScG zAL;7M`j^j~+iUn7!2itpjqneW6rC}i#~BXQ>&jhX(zY~+=JcK<5g#u^$*i(rvU?6E z%tG>9Ci6aY-hRXck9p!FAS)UxeRTEb@053)m-DUHXyF6WZeH}KBH8`JaNo(~RKf~V&hm!LgKb7&Aom$9HINbwRy$xivQ7Vx|i)cng{Slv(Q zZ&Fh(eM?Cun21!?Sb9H0^_l^rpXgdY*I6!O>6utMrdTS|b4b|^GVz)%w#EK!D?*bp z^)FJuDZ2(i>)$eqXZy9kQH*?H*Zm0cOpNt*9k>?35EjE95n!BB)K#Yw#t`sz2QI0*@}Qpn@F|bM!#%xbH-p&=1d#@=g{ExcbQ^l zDGW*DBQIvECGP&h<&q%r*cA39%_xYu|1>{M851icU$JlJ+Py-lEytxj@y^MDpH>;lDEcwx38>8 z$~Lw%%`l2a{Jo}n9?+C>t$!CPZ^olg=ek_!i$BeMB^u~pK(`d?*i?+3Qa zi@Rw?RzCGR-J|)Fii-%p^#7FGSR>iof0H%$^*w3kx+w7;l0LWU%Q2H>7jrf`E*;f) zIUKKeslB<)0oT6EJXLW9)@zgHnKSl zyd{CsR={i1fuZ$osmr5UQ+jfuk;)elC|r~3oN8FBtRJn2(?eKTG5NA`%^yCJkuR7I z0nDP$wMq{@Ve6NEv9-+%)pIcLUr!PgY+=V7yw+dK-52803HpDltwl6tV*AN@GM4h? ziz`AYUr)o9W_ZnsI5@cx&8)raSmF)7c*#x=P&e?yteK@)+=J^Wx2=lx&j5ke`F4l1 z^LYI*KJK1`J1DZX;^b}kmt|nEl%u`Xk0F~|D0iC=OiKf4NGrtk3S|0{)v?7FX6NTTJs0003Yx!{rPx&{e12pSXt?8apt%W87y+*ANS zAcRH}C`GV{X0h$QHS8_mG+K=|ZqTCYMomg8Q2-zy`BY6d5CJv=^A|4NN-@%~C8aCL z(e_FDopB)h0#A&90M!y+BPuCWQ=4xvop?GS?G@1SF!9#sqPa+@4njpm2zajz07;2W zj#e_AgyK3fM|H`nMVdKoGLYlc;6y?)k}j4LsFobavJ2}88D_oSh=Ml>>Z2anx&xo} z5GTBastaKCU=&;;a_ssu5Y2m3j~r%3fhP$yLdEzxR3{vEV*V=;x+={^1uFz~8%Px5 zF36$pTYg|5>HABTVYY6~>8icW4rzu@2 zSQ}FSM_DR!?4FnJfGG$mfzCDmd||s^Q>1YtqB2B8OSMKt6d*M&;(?3uU{VL(B*pKl zt-a>4;SM_Y-98WrWv{|`SvNAalLVTU+vr`YVA^Foub4rspeZXtagCx_+Z5xoG2cOjpfC6jdVtT5y(nHVy0002GNk0Gp00007 zfB*mi-~a^08O9*d3NS;5sF4t^Kf)%ugfavgw3Mnfs&PG@zn(B47Nm?KEfq%kXf&q# z)En>dB&<|>*Frg_jaydNQ6mtT*mRJco`fxHfV9Z_C7xS{J)^}Eu8oC8jZV4@5rP3! zM?FZhVsSi7_<*AXvh)QBz1klm5cokz+FgEI|i(^G0@X?}bAZow> z0000N#FOv<00000cmMzZ9smRIgFq{{&<@uUk}OW^&%C;fN&6TpaNqI_)8bY?)iak< z40%bd*@KPJgbXiEYZrDntZ~tFD81WR3{KCFxdM#pk{J|gL@E*0QL*exFZLKV2Y<(R&dyiESUd^0zXk0vEvj+2iT|s>pr1U zEpVAOiHbU4C?0~ZIY5aG`n;QU8e#_8L;?`XG--0wO;Laof|>-6YFh?{eeZ}Y5s#cU zS|Na8*{|Ja%DMhy2eGtaSB9aXl4luaB2L!BNJeRpCd!j zkaF$LOd!OEJ2|uf6^CHGY4YySxS9sv+mylsX|u>eMT32zn-GJO9HSvQUl3xdbY?rz zNIqhD$Q*f~x_~m!a?n%cg@fNlGfGjlSW$Ke|#N_m(VY z7Mas9BKc(eQF#P~n=TOZUZ#XtAZ7vV)v!!=xn8EQf5S-iL}AROhIk5e-At)lMEq(b z4%_M$3z4*5cDZLS4h6#I79lSYB zfr|Zen(%;a{27jcyzzw0{3&KAnUk>D!P6}ApzB)^j($| z=OF0BM?|AKA-~NX>XW^HNHrL~Ehsr$+-jF(Muh7dl<`5@^jUM5%rFz5#6865hWL5y zff>X0`o0n@(BH^k199-M@KLa0Hs-H~F+8V~QIv_CJPMV=G5hnhR!4DMLY%&+7Yg9P zpI6AS6~iI+VTcu>0|PL9)MQd_Oi^%!8U}+<*__m6<|U0RbWvzyTz6z@6Dyutos(%5 zxeo-Ebu9o8lF-h3pVoKFIh!eqj4mZz2%%+=Ze|itLP1CyH4onI)L;{7vc=x;QG+t0 zMhsj=*^o41C2TjIMDPzLTU?QL`{ZYE8Kd=jG-2;`D0lTBWHpYo#mZui=XvtF+Gr;d zkA3?|9%eSK2H4A7eO-_9jav~$0ujU@7PM*eN1F(IKa+}!@M!34N`CKkmL#n5r|T$G z>fo}RCvkT{)1lHxuzFZqzE+`PI|F_^BI61v1_$szu!x9mlK$7drH(0Miw^t^{_TBr z9h0C_wFW=$3aOk&$B#Iu4}v30BN{E2)^n*XNA>8C7xO~_*@3YXWGXILCv;#zAC6Xt zVu1ixgdZu)yy!6%fq zL+lY|j+D`R#A#xj)3TUq3WG+b7}TFUi2TcvV*eK-pBN&2col{K00ARTO>~=u!7s$l zZ}B$Na>V>9SJI6sxBSHU1jcvjr6#Y$*Vvt5y9v2}(a6y}ni};Q)KHt%u#-N6&rCc^fN|MT7ubd8R7%5;RP8lSz94_(?V+&3r9>I+@jMNvwaB zk}(8Aunx#-t;NL?M8(W4O<%-;^h_Fr5eO)zzYzrxhx=elKvDL6{fkT`Y_N2C!U{{; z$OI?cXN(V-Z==T5CIeONoX8ON_Ey3Tb~fR#;9OBISr1NWHnrP>Vi!t5LFJ)*ide7q zc8R!DB;94s_DwBEbBQ7b_*Pr9MdB4APG`;ii79W1?7k?=BoGph;$*zyf>!7Fph)fJ zeMNNGFvWPVEOOUH;`f3&$j&$lf5NBpEKHQyjGCEMF_|(i+GZsJwuT3c`Rl#XNY4 zMem-a09tL)dE-s;ytbR}f}!Bp>QF_ghJ!((y40PD&YgtHS;8XLQUDB;D=04C`%nvI zAa_zA4E~n6)UwEMl|W^M^qJ)13JkCJX@F$OelyNuhc;Lx3Y3mp(kV*|@Fz~vmOd#S zwt?FPQ%o7pP6heeq`HyAk)BE{_Znns@JNAyjZ4eTvL8Zd?^+2GH2qV{$Ao#A`0DDC z4j~=Gm(=pn2Vq%o5+==ieBiAcFk`=wup$T|6+khQd>+al3PQ*^o7hNF(qY0vLvodW z2q1_;6!fez6A)Q>;M4%ba3JUv0BPo2TvtJaANJh5GX@M8OHK>Bful-%u#l?BoEa%O z;K=o6=K@Hj1WOQ~?gvhRa$qa1;ISbSyBGq(c3ZuOwmj{T;uG5~Vse~hpgu|m;&clUb0f$_p?wyDB<_s3rg$5en-W}8 zaS&zh^cXD?{Ae9Ak!0MeHr4a;yK4A>o$SZOd6TW>-$Yhoif*T(lB{tGBz}Xy1Y&&p zQwNrZM;=)&YpDFIF+w~!vX981+JG1M2#n5TR#JzIA`@*`0Em0%xJYr!#Su|N(Z`G$ zi#H6h1nrC@*#*qrSX#tHBnx8nQOcIeIatCmA4!{K9(h}%lRk1tfde6!WKTdL&LUJ% zL~a$5=TA(vSPZhLRRID=xeN0^R|eeB0xuMGd%OUBK#_xV;QXFE#RIuD_sY(C%XE-r z`3Ev1{vKr_3!roa9s@!kr`{d>WQW|-U{nH$=G51aJ{z-PbOfMK3*zbq>L}M1n7Yt% zK|r8aikztb7nmocriQPy2nKI8?GAfb1FRnh&^NyM&D^-kLgOHZ_=EsO4pe#p0)&>0 z?Ru~$oaHDhtFoE`w7}64Uuvuz&J|3jxlU4C=`xd-XHX*FKod@{K+xo6kYb`LPC;z*d!+ob8^~sjkWbq77ou0id_A99&2br!gjUM?7PeQ^xiv|L-r# z&39#D$nI0KFbx98j1Pcw;k?o!CNcpOl8xExtN*j)q%3?WCuAS993-i7p+2NI?9oG^(YqE3O)x*49 zku5tx7Vu|<3R$H|T&abe-8`VY)B~L@s5mXkBOZ*@(9yJZCUg|2q)LbMK58So=Q#+D z_o;S~)`DFr%4c#ch3Wh$;<=KW2y`wOP0Gl~EbmR#BsPoNiOz8;${&&nRAbt)YRqlcCQ8W^n$4aYsz} z<8?vL6+7^D*2!nHdrQj$@C<~O@ih@ByPdWZwk2nrS#N8kVH#7>ga=7xPFzv26BvaHuvmoX(d`PFpXPQ(!%QA$RQx^^T7#YDA=p{|b}ALHbB zi5sE;)fo}Q>?0*eg=4Wghd(*Wb60XX&BZzLp?V<+@T^Koq~e@3Isaz64v!-FoOua0WQadm>k zgJLw~1C$4fRs0AGLBFBD~ z{s*g2OrqF=lo3{2%S@uR8_mF^zv5`97>NH8NDQk{Z9Qr7NQpk9$iE^Fp(2U;npMn; z*?uqie*q`)?L$=MPb=5Xo{P4b%x)ri)6?Rjv2Xu!o|tHUg_it~c=yz_DNjD+Ym&$ViRzK65>sU!!UGB=%+M`iO=)$+V` zRzk($yzhkJPxUD>yZrU!iNE8t`5f_S`^pXwP=m1BWfuRDWAq3Q#-MdpEuxoAWwOte zvx!SUwk=*f0JwF~pk{*^w3VjN=eeskuJSHLp%Qbx86(^k!kY%4p znBR}fB$8){6L~1nb&@`0mP6g8Wy&QB?F;6o`>IC+tmy`lna7%f$yXu_0s&7p!F0h#Z}>eqH?2 z`WCZ1mh{#o^o3^x*v{BLsRywj^1Wc&Qd56NJTFav6JRE?Hi$htZ{7@Fh?hw+J_0Vp zLFxsVpZ%i4+0!?M1bLOWmoSR(D0zZ5Spb5zrAM^-#f%HUvEYT|M)Wkw`RZrf z^&=%^@qB)n7pz^+BOG483%AtOinPStk zsPbmCibu=H?7o^)$3Ix2P z5Olw!moz(jrM|@Au5G`87fV6>QF*f+Gb-G*AJ43(@4p1kX{9W%vG-9*oAaXeHVDL| z$zQiU4>Ss+#Yy(dXcUPvM#}+64Kg4A00AkEpydn@1P==kJ}9x`Byr$rLuJ#eU`Pvg z23h3T5xP+&lv+Nj?+DPWJnbZ#CwT$UjuXUKa{rGLc9E_!^nCb~*PaK62ZYy(^@e9y zVR~t>R+h=3PIl7`6BYCsCHXEE3bX%91{-9~WR1Mu$hMY*WJOF`N z1`Tu>l=zCuv%Rl`ri~oaDTN^qk36(cmCzX`TUqRJbC*@HG_F{*fm0Ka1f^}r#BQEi z=_P%2hL(6@h(%%&x!9D$qSgp5nD~Lr0%u7sNB(QIoeIoD>lOxTVp^!RT2kC$`r zh%t}=000000000000000000?K85jT?wc9vEKr=zJC?=aodIld@77bbSyC!=?%~Bk-m)kV#D=!EIil#lv zsS5U*$;9Q*<%PPkC)%>{vOR7E5Yn68EGs}NBaIJI+Y4A|PFpJJg}q0hl^;h4Sd`RZ zItkOH`{Kfi4ZESBlDc~+k+U>ep{}&_j_ueu^dFg8KPbnlfI#V3%zP}l!Zpg~yVpga zX<9MS#%eOpVJ#QrIwVwb#9BC4jw}>WNfb3a5%m!QW6v`gr_T2S&~)N1O4^i83%ZTM zJ*Xrk5hf8Bk7aQ7z)~qBy5L!Y9iX(X3f9rD8b+~RW&QfQ-hmw!51N_)ZvY&{-dGkf zF#MyPh1|y!!WxhrIyP*alioKFqaHAseMd z#=xd&GX{J2?sIza1~{*r9m&nXQc0 zM#8KFg2Hi~wSW{LJ;M(7-y&3+a7BXh{&R>&h&8+bSmiE3qJd4(aphH62{0;D9lUJD9>ZMZF{{CXrE}Gt zrIvaq_&4TYw4SK1JC6uwbZmp?k+&ytylOjyLM4p*y=%5orbQ_BM@(ee{H)PF<$li6 zwlS3|nE!$4rgTQX4(B#1v^eh$%B(CC$JlW@EhECQMMhIQo{c?O0Z`a_8fim7qk2cp zGi52|M7YRa5ukdrI`2Y`S@{5Q1hJb9tH9YhU)OrlNFd?vuFNdd68Z|ny&Ln$i2ZzickPq-p6Ruv$r zRe9k^>##ht!^b$Y11f7lVupCF?daqRd22x)ck{5~m_$kC9E3D;+~F+^m!_5iZ^ZOe zq)q!yi3x9fZdFrK)xmSE*o6f8g)ra=t6(@hw$G!WwZowgH;Cdv_iK%Xs2VMPVCND1g7?ikLJA5o1dlaL-y(HH5cF zADO~HxW+6(k?k@o+p|p-3)&=PI~l~nFcRq@C1>DzmFCbe4TfveomK=eDGEx~1ArYSyz=`IU&gJHX{Cl8OVT6m0Q*SRq*Zg*9B2H=? zXg9cL}h2X5xVxXTMMJjwAZ4k64!c|X*Qr(e_jw~C=4_|OBEy~L`K6v(!;qgXQ z(ep^AlEC<2!!(CS5sE>Lqus!&IM^sV2XbzHus)iKKZ)X&;DbjneEQOS4Ed>#LX#4kAtZBMU@v}&_#d$ib6d6kGVIF=(L0AXOu{%D*)`YX2N0M(^Oi<4eeKIJ7y?)1IY2r}2| z%!|)`r7JC@u2{_kK02+c)3=u5UxMlz`hBl$^jZa2lqjoISuTI$Ub1n}pE@~AVtC<%wEDQxs zC+~CdE9|~{z5$Vh3F>>mSu;(a67;_se;ta-#8{cd3z*}ti7ixtQVq!s4mH7 zrB=RvO>3$1+@X2Y#Vp~lezoqA73x3C$=p5N&Ys;J6Qos(@%0PG(16 zL=ZtAPU%s3&yqwSPG9-xU)n!bu1j;tldu#nSnAvEOKB;6%iynhOZ2j5=uSrJKtK7B z854VdRI;MJFQMeO_w_Xg%@U#VY+{+TaggAnObe{&R7IiPv$bU{d zfL!RY+^0P4!uSz(DCA|oc!K(p$H8xR_ey8EOxmRWTWpA>?pN=XZbk#FOfM{@Ub6dL zcZy_?G+n!)PD^o;Cs-R~7mW!oWe{beZ$TE{+v+DW z7h(y{(EHsedEUt%X{PqeLPb2puwAjA#imlwFuU=6bZ9N|OtNOh7mex69{a+MT$e91 zpR)NANa7xW&r4JGJWz(6=&@Gh2U{CTQZ9$NC^FA|3sTk(?WHDWb0pYFsUj>6c{#BV ze#>0z<^NKiCGj44fM>pYnOqnVFJf91SGQ}R5G_+BPQ=KF1q#qBQ?+E9rGwy5_9^ko zu5-;4fD#FXoe2sScu9d!SgN4unqTa2MHbFm%sIx@65Y&_2G5{TEE}H}MAtG~#@lH?jL&95iIUo~ z0ot;VDtJBtf^P%)i}(}@#9I~*;D0fAlN{qG)xNh-K@X#KOVmO8E{DADe`>QM@yZ(0AjblxyI|aj(pj7J9Y-o+?LBdxO z@+Dr5w^Hn|@qNlLEi;y^!aMfskY0n9s%DZBYGkL@%BrL3>^|1GC?#cbOdjxssyXQ7$%??m?&5pM-koeY-07n)V2JT(Jz z3`cd|F=oqAlFMeAdaSe1wKtpmu7**8)!9=ziTvGg%9|q`BtbH)Sf}ID^FO{|hk?*c z*9C34N8-KsxguK|=g7X?ktcAk8nZ?fJ1nE7vi_X-iVuWQVY3}++?DxzIw#V$B}aSj zRJEW?N`jr3a-?Le>vt!w&sX=WYI4=FC;Al5MHW9Im;sUj0-z>nfG`XXdW$HTb~4an z&RMg>RxMVcUvAFqtp|QmmgOhPTWD+Wgi=K0R&yqAID%|WVm${R1bd1{H(EUKLC4H= z-diBFy}YeAkqm}O;SQR)i)#kN>2{ROqCo={axe&(Uy?UcRBc~|Z_ ze5CSf_K|P@3PctwkN@grd>+;|xzYvFIqNUL=S@YaDqb+JrEucZYgmilFAVe4MFYzb z4*BfLLVmWg21_7xGvXD=TP%zNI!e#}KStW&$ zK*!98Npk`VRKU+EZv|`6z0z1KWdzfFL0=k2E4u3)^nm7EsL-~CqTXVy!@#;J<79U; z)>@Lto}RFVZ0r=-K)XHSkE9KVQ9QCTHi6*r^JPk+;c^RqGHVm3_xJSxi#Iv&F8Wj{ znVu=Ou{vR^Jw3KBR9WsKH2+Oq9mp(b-&#(Ki&6jR++!|Wk3+qm^UDwvQY$+71poi& z8np?cKA@=*X-w{&($&_cq(V}XH4Ol=1<(iv#0WOxS-I9BYxR=ls06+i#ElC~Q9Z<^ zC?97CJ(EDZdDs<_?jXg|DdTx=g>-ElD_iRs9=wgCpmz_T+StZ)Tw5bLFRsYWbJ;N} z-C2uQ>3NFVP>NBDZkAm5hlWHFa3^rkJ1vD72tyJ3uX8jf?)*WFe*b4&5}j_rpzE9kycy85b-m8 zj6+&@aw(#TmPn`bX-&;e9TojCaBQv)H3CQ_B#4X1 zAfk+?r5dJEj!;EzL}U1K!X7*#H%ks}XC!okeYCov0ts6)bf$tW_zSR^`N;{-OPmKZ?+ZW~^F%&EY|NHT>)^@34t5YbRXh(rMi^&~G=z0oN|lK-=ovTWD*gA88Xfx{OlA zCilc#`Q!X$TZ%;n22EE&X&8y-7uHCKs^(qc_2;q6W+(bzRClnV|#Bxs?c zhVV9sD$cXft;!)sgpSOQj>Uy-R7^^vvbH7&seW^CWM6oru-;T?(8_0|zS6U)xyi~Z z>KT*~3DCBZrMR4s<_H2ZAP=|*4ikC!=nJQjH4a#t!zCM6A0p#-$`40G`VhY7WK5l6 z0YRa(Lq#Ku-1bGVRI;TCT4s)DXR+~FawITz9&*S?%uEbl$^&gf)nX~xqjIc%IKmRI zx`*rOl(gXB(S%6c)=GKlN3XZuILk*`2>Tlb<`O!BLMAd}7u$M5;MDrfWX!$-IwA~a z8<586J-k|w*y<28C}tZN#f=p3J(P->u|Ooeb<*H0!%Va|D5Qy*Q$PWGD;juEwWI$B{s~_1*7lw_9rZjNLjA1V#edc*ohyLdwA{U=U z_JhHuWUsbHNFWAyJb=-X23p@9l-fojh(b7smCY;@qgI{he;Xgdfoc$_g_1!zB##?C zS@AcpNM}hQxnGY9Q`;?B?^do=u=g)e2Qt-)GmpS0S{ahT3IH5PzQlZp25^K6LOTtWw&LZUl5-}f_uGI_Icq$;#5KdHJJQ!j8yRy?G0=9Ss)Id>-45FJF$plRCvXsUs z&=TH_tIaVLek}kDysOd4oWE3N_D>j8B?v4?fR-J@N7||KL>o5pkXdwv1j?W$jhhGL z4AA0iF*@lz%w}pzz^{PUM{L~)v#$kg9cf-!>-SO!3_kkXvV}n%A#=oCUmC{P^wg0Sv07-F0ap*!DluooCiK~FgVr76ZJx644Tk)7l25}kqrm( z{*Q_Z^tig8BHw(_UfBgv=mU)$lE_4WBFfAVimv?jglVhaATT)6aY`B>QO%T3)X11U zN1n#rqW!CY_(ktcg@iK*f+LN0LeWmao*O5;Nu-Bj$Gk!)n)iAKwBkHAcf%&9xy?KVn-O1NePMx zRYDPCfk6Y_DS>e-hKN*Q`gpO?NO*{Z#lv%RnzC)M-s3<>Lc$g(-#~=8#~8s;&Z$=r z^VAk|N-|mUjF~X1%3P7o`i}BKy|3a9|CQUUOd+pwj2xpZHjf{SccnDy*ors&|GYHikcgjm zb*oPyhz?JYstBHPIDD2AW;c`ROWf`TmIQ4$#=6S^EIa-EeK8=QOTT>&;iEdB)OPYP?(XI z;%@pbOIS^5hev}e-JA9my;+`UbApo}_@YCg0DS<5XT)?a6zg~y8E=&eDc!VsJfrv| zf*zA37bvF)E3>SJbjHEGbk|F2vzlBsIV-ez&ws=hB8qb*ny@T zObO~N3qHrs?&cP0)!2_KOenrV0*FLL{V<%n44_uZQ#oXLWSZpzqLiE96#Ei+aCjck zH=yNt<5*^yo!Dqp!YdRi@o6qW)W=zOT#ymDN*_X3HU|t8HjRrbmNskv0&}$}1VjQD z9F|p-F;M}C1Z2`saa~H{+{~B%wWA<+W-SDIlF)WhA)GNFSVWjXARct$c=R{|?8VTK zhbNfL@vVak@JES{j{;pM2MMMv5|4^x16*=4U}5E6GPyPs2hZ?ycvQ31_w-0{2anC zIuZj!Krh5Hwg?{8Cs3^2Qa`MB89;Vw5La>}KvfV?zNaT5Br=i-h?Uyxk^~JtT$H4s z#y>?fJTWsxqrz1X&k`hrGPX?4^-~!zfS7jEmyl)1AT+I?jR+7uSNct=K-35#^%;~x zh}?qwDd?~W(|dl~TOffM>jY);2i4gYMTX*R&kdHzwI`r5!jz(#VSTQP3rH>U07?i( zb8y^`^0s;i z6Ri{0+|%p|)uzL$WYAGek}?*ygU83y4KO}f7{;KtCbVNaRC4FiXVl|nswa4 za{^$IN8D8zh`5Cggq1Epw@&^8Q5QLdrm6kKkp7jYJ`}iEDT|IJ&sVqiMFC~Bo*5C|6uz9GCK^I_S_y~q#s|Z8_1(N|1Hvb@?zhm!ep;|x@md$VS z?CxNxg)Wi^pa{{#DB~m!I3diTAS-luFaQ7nGYf?U6o4vfI-;GWQ((~|#E^w3Ld1(I zdKPI|f~6o6eGx2#dn#EXmLwAeN-TzG7^ST$jjVsRvc;OCQ~3 zLw{Yyo^dSJY}dHaw^_?xg7aw_G!C?uvy=g6G$9x&$(S64DP^IyASX&`I@oaqIuxXB zf50_T`xR}(#aK6eL~7qctsdm5oM`QNk*KseY1UGD-(~FdKa^KP-tzP()e~Ou2_%z7 zqN6Dwki8b}P<6`4zH)+OHEUL;b!;W=fRIJE+E<}%0=m5!G;~Wi9w5N&5;=Q5pq%xP zis)n(Obz4z3ME5Sl*hI zV;1r$pu9y|RDYYr=KPP#=kzgwE%GobfuIsXAP+z^K;6(PZdEyRu@VQ+eIx-@`Qn*e z@{t$ppfUtZDT}5wEat>cgjR4NX2+C<%K>2GRebA!aI*fRs2LZnbiDSUAEhYxc`X|dg zdMGXh7Y{`m*R@(PC!>50h-=+rME3}dWqQ?y_;bYVf zi!JGz2ELLDwusGkkqC%HLN5?*B8el&E!kBCltk6VDXw&=k(1EX$UqK#1;p^b?=z zc2mln59Qp_MS*GE0+7i>C!kb~U*T;2Ba-3qX3rc+BK-%lOxYPM;lN=Pa+2cq9nPYo zyev0u>CVYW^^rH(bch6yOCWSr|AcWi_CppyOYA;UAk~F4&bi8K<}NH)&~AJ|XdYml zIv`dzp3c}%oawW1m56O|4|tlJ*08Of+(H4AE_pS)oI+a^aVEjIh`7Rs6Gv+i-w{Hf ze8MoD3xcmZqP=KJAS*-#`trpGAqozC%qU38bUMjwTtQ)?OEX>ZlV5bT{TUNgXw`_1 zEc-!To&wQ~#a%-jgCvsYJG9-)_B3_I8jf^wC z)d%kna{4kAz2*14NwJxeq(7XvHDh2ch=s~jn}~@N6ntz7_R(g)rx8S+wY*g7i5Z4&2Zcf>P3yzMMR}$!r!*bS#m8@~2mz*pzO(4q8L=WE-;D zstARWy^oj9G~`z=>p2&jF>R+#SA_YwR7V@4%hyN)%F&a#vAYbo_~CbtU3N zFKOno(X7QO`ev$9l3dK*M%{;o=g#ZqwGrGOsf!ecth;a_YBR#_fDx%KT+fz3q6T!QqG}LDugn%w!(D$QBdb(o*~mp z1MD|IsnaMo%RtaP-y(YucugDTR3wVX(ZXc=C#Fv}R^z5SVamUX);hI>}GG zIfRlbg(1}06Vo?&09h7DT5N&D6Dj;$yordv;wj`D;fhSJ6y+nbl)Rpi639Z6%d+QN z@wyUt-!)h-D_0_G+*f=-B38nCWLUS(=`l^!k?R1glCUqeq~*0d>1KYSA5!)_iGD%( zZvTv$w@pu1?xOpi$`o6BF&|&Y^0$U?YG${z;Mg=VHYuI_oV)luI8 zx*vO5x+JWgo@v9C?_{Tper;Iahr zY}<8e&&#@=RM9xaXUL~1OMyy4GUX-ARHpqUqHLiSBu99lraP{hE&cB#u%sy|G^G5_ zO1DMD?#d+kdLaD%DX}F$Oo$F;dpC+ipzz(k?QF{U%kzZ|<>DgaWLo9o zQ$?N^vP6r9$HN|C6Q|sge<8+Cjl;2 z4vjMrhXa(>tCT5P{5w2^iR$L(vXUZXw3)~RO3PTK#vzL&_l}Ab88k@6MoJ8+T^EfM zmMeQw#@v)cQBQxLtp929-;{elrTZ}-xF4}i7ghv_-u8+rQJ+s!#r`p(=uJaYU3P+|Yf)KUWp8)if3T707`Gbq`tpDJvUEBBn3@=*#?ERY)K zj;%jzYjCzsTEyOY8N$uNxbh`GP&1GU5$j8E&5^Ny)%G0T_4fN0gaSTD| zsQ`I{(N+?QZNTodtSHmetT6Kxg%FXTlI;_?ed5O4+oo^1Pf-@=lm>+0Tx3#w(k~eD zJ19|Gn9+2;e7+!KoY%%;NcHcdbpA!qotDVau}RCPr*Lq6G1CfOjQZzj%Uk0a<<5)i zt+Pg2UFEJ{pcz0=mU+q8-brV=W6DB4Y2xY0sU%A*Ezs;LGhy|LK)kN}k39CHVRx1) zS6R`PM0x*ovbDFn1sVC0Ch?$?fN z3ppbP*nS}hh9cA`hE3uniXd0vMNfF;lLWdcvW<;Jl%om|;@D)2vKa`06oE5T65}eB zd!S#bVDgBN&XjH_3*RUR+SxY35ou*LP(aVDi{uqcEv|=_coc)*_aWo+Z|x;0eL($@ za{5mLsH4rxuJ)hL`9HD(4qDNdD^%c1aV?jgHJ{2{pQo|7{c%!+}F zMFdb(tb;hxgJr0!D$UqDUN|cRGfQ)nxO$PwHx~LDnRROb?u~-t-ZGIoH_>iqlP%N0 zyy!Q#gq{=}z2hR_UwCi7e#SNV%;cTK-PY=I7nD7B>%*h_`fkKIQIxA??qo{Qn(ks# zkc`~1hwCUVh+%C?R(J{Gj}o^?ODP%Ul10!usk6YVMYahsa<)dC%iOW!#F((CvE$Z< zURx7S*y?8G|F`uM%9rQNIrIz-C3=Ahuy=#${eQo)*pgki&V5HNb00g1ZgLrNoQ85B z^QI|4?oxzjjo1~k)a<6K8sD5iu6=#Xdah@h?ArtZ&q+p-Y$1bWjO$Wv))VlW_~F8DSU=ppXPS4rbTliF3gJLDE^#&w<3j=`;u`%F5*g>BI+!xf1+Cozk3gs{P?nmqzn! z7Jur&XJ_*={xVa-%75d@XcGKSX?#Lt-buJ!m&6yY!Vh%m{vw&?o#0S-s$PwOI9FRqDm0`{2vnMKWUVg?O0+p?GMOD z$rsy@aSpfU%TLPBxjuc7T&afV`Mt1r4QJowA= zKVl--qIuZm2T70-yHe zqdiWn9X0x8E2AX}jzdZOMYa;u^y>L)5OTySd{R)g?)?@elXmEp&I2r%>ID@yQ9*5P zZtOFVAB8SK@bn)PgiOH9G?xWZls4}n5&45Dw!pBP@{o#da>_wDyrkYV-DRz3{&QOj zV7f{IqsbSwUx zoHtO7%HKD_f(ekdgCw3^Z3ZD^V~dJ>V#c)INQN>gCKWuF!ikC)V~kj1j?0gh0#dkW z1!`&OK9>pEOr$vxxd(FrAoC3l6`2{!1InJ`^FHjXXxV7>YfO`D*QEX`(A5uD<>BE? zZL}EGomig?o(=(r4xk45>lOOT3g-$$pr)a;3I%CQBFbxl8D3VhNKgP+w*cZV&upMX zBBD7&))D5XUnt$BLr;V7nm~nF+IdZ7?2H^JMnN77nOL>>cgDcLqHw?CG5gCDiz8ig z3Wl%^o^k*glZlgNZ=J!QQ*}rpYbG=ZR0vf7HsCl=(2z)il>mSWEN9(LMAHFG>W~r; zP!a>1$uf%C+Qy$5)0ndfaQu{>Ri3_c%Cqd~VmTwDA_CG z=)h-WZ*B;%E8*G821$q9>nRB~=s%i~ub&Q0jb+R$%uaGMl45{9IZ#}JT6oB*^hb&- zPc1Z~IEBQiIJrFXeBNxiGLMkl%V884dNGO)g@hn-GA%)f&PK7cQ%ayfJ6ei%B!MNh`O>LsCF~%$=fL8M2F{hGdN5eCif$qS z0)R4>$7PPbZ3UK6A|dpgTrzp+vXr*j@Zb=U&t>qmQx+A=HY9|(cuHznPrbhhzx4+S z;j!awEqtbxJMV0CR;)OKmOds7Ued8#xAhd%%ED4Pz{bYXu!BG*r%g}(TNaaBTs6`MIuxx6Qdf|DA)q}Q!#H0ce0G&3E^KP6ntgzg3(w{1( z9%nQ8SN_$$_8@+1*6)*-*rdXyPa-un-W*>ml!#{q)vMk65b{=o@I{_%qSQswFVbyg z0QyN6*h*#Ws^tV>CXNZkIcr+oxIZdDYP;2uzr{QW>B(omrJxoYt=dH|of+u?mAIky z4%O+wob$n(b9k<6&*wxfKNExIb-zvzn0SjnzUz~t+Kv7B6V9pk<+)K50`V~&$`(tx z+=#F8h)r$GiuYl=1wcw7J_w5PlO}J9e%26u$#zdx0IKQ+e0b`GjA?VtIQ}GO%2Gr5 zN{+ez<4YgNizQzm4=zh{^KvTC5<@c2JuhEumyW0nbnQME9un$V!{N?NiQaZ2rx{F2 z;+(i#AP15LpOp|*?77OuWJPHNECUqyhKw@OP=$&i@Vpbz z0yL4(N1L8{0uCgERij$cr1+imShC-k_kR@~*)`QmJ$YdZA8~8p&mhs|khQQQdQt=3 zD%uWtViX6a1H=CBb={gDS~lyhQh&5BtBDIVi|U$5q4_~A3dU6vb4fDCBoYcy zLh6x2&pgUeE~wzFNn{EskR%;jW>x8n>@bD3d1vXvT`~=2R7+A&`Os5d)INid&}0(N zD?o(lOm32t^;JzKqiAaZKT#9SCq%2W`&M;M#*pU_hYMl)Bv2`+2U;*prI@J@jHyzm zABa)9-BHmxn2~BAv;pA46L3N0Uxu=8OJby&0Ro`6P?8EB7^6%>hcJZ= z1R@VBp>_)p2-(%Ux-gBn6{tdjrKf>{Wtrp}A^~1AsHypYiA*IHtws=}Fd&vnV2+QO z0th?}1O_6`iB?9T6>`&RroulI27*5`*;J?(u~I(hTuEv}2>>rxBGoDa$#f7V3n2yy zK0745;Mk`cf&#-PfM|nmfvQ2bv5PoCgcs6?AU-wIoea>65?0*-H#aiGm0enC!uiVlhyc zl5}Moe_zi_IcP>zaxExPwl-o0$QV$eh=QAeRN4$S?0zWYs?_O1bZ_eD{^=x@v0%KY zE1Cr{OJ9!G97yodcv?EZvjMcLFiw!RCOFJIBDn+SJPAgz+w0a^jIqX{T_z|bMhcnJPlG;FJ$2-!&jSYM-H09ES9KHC`Z zv(RsNf$Q3f>3t&1LPSBM!b*RRJjt{l1}zp>*2;g)$j`J{N;*eurTKp$UhY(33mQWBB2k ze)HHT51XXfqGqAKpA^ys#gYR70h!u2p4J(*U%un70- z9};mI4!1(XW187AE~Yo@?%)1WoL#g4&377-&;H7q?iKewR(XF`bnE$p>| z)%^fO3~{Cc!Va;1MQ5|{W!oBLpGix)vMiFw%<+Jsr*%MD2se%CGOfWc$#N#@W9ASv za#_tuVuY5Fe66(hE;_9<--4GzOa=0a4kLS!;>wA)X^k)X(n_PCI}DPcEde+WrHyRNWKBm zV=_S$%55M)=5)iczD>HLmkcJlc}rshr3jS-1*ewuLK<-uQqj5%HIQxP_-oJfH+UII z7I~y9dK0uQ+|f#>2ga1XX_%gofrvf{SrJ%pBt-o%zIUr9W=BNNB$S5i99)eO>HYnj zK=LogpQl1QucANXzH$_cFZ5^{iwoVYaoVRe7rP zp-Rlb?_@P-LHPmDMUoX*gdZRj5HbrCcrqMVQ`hnXL>>5-B@m7aPDq7;NeY~SfxL0( z8apB=3Uj;&2@u8vvfLBB7S znB$+QX4&|p+O!3;LXH=dbGlO8_=y!0YkpN~%P=I>dqk02doJTs{fe9-F6MiUzk-P5 z1rY=ZVlhR!gj%?w>}U!F4;vCCr`H=TLvO1GsocX zEvr$X^~n{NOQV}DTLTv<6omP}@JY{)WNc>YI};mqv8=s@2~x@xKFGA_`Soi8IS{<# zUDQ?9Kuib(NW%!IzgP&9GWHerG&2dw&_Gr755byXSs0zjVPQe7Q)F1VLU#`UB+^aw zt7@_A5F$hhU;+d-GI2`x|JU!XJbqCycOUIO1_Qeh;sOj>GtAbIAK?KDSVJvMt*_ zV)+xg05l39Ed&8h?wabw46w0Rf6Q1&7!t}y(3Ka)!SV=BvuGP2gm2LZ8y3)G6T*!) zaKwp(oSD=uKq-km;O*ho%49A-1L{HhctIsrkXVtwDUluYi~~4qC@{FDEUUbWq5o)nJc8t+dE^O@cdH5=aLzUNbwmE> zJQV6qo}XHic$EvncZU zT1eQoW~Xy>UzFLP1*YW?3Ng98GWlto`TK@@TROW9Zgk7Pnu3oIPya8*rNTFmP<0@= zb{p~lNe-O)nwSxi?=YC=@q#6rm!=ArB?l(kn+hd730>bfDMud&3?}`hjgD+i#in`Y zkPrX>0Xt4rG@i$wt0GCQ4>JKKy@tr+0HpO(uca}lWEmn;Yr`zH^em*sVI@o9NTp_| z*V|Ir)S+nu5Cc{LqBFH;UWJ~;&(aHEER}#wlUUmTy+A_0jUcPZDQfVD@=&9SePurr)!}(f zwJQ(?Y@5s~5~LTSck%^h;z+2~3K2di$*fME%}Uii3a z9lF$PT?^B%zQ_AI)Ndu@+wsU61u34)O_DF72C4@5N)#GgS~5u`HT=9Sjd&M9#PorKxm*mVt3k#|3eaOp*a(lCXkT4tbr*Ymkew9M81)dm!RE=MBAx-?>2eza2s z;xn?RIJKcJVh(9~ezvvsSb86OtcOmPp@&8sQVkv^n|tl=tT@jy@)T6ObznpZ#=l=o ztziUI%gP3WI({78p}0p7cjk*go_Rm9I)ewR?%6SVN61r#VGNJ zi8j+&SV9S^|4&rQ!~C9GcyaN0nkrEph6> z*XttkN$FjP9bK_gStGP3nvvus&CAGL$QG@_BQD|r$^1v@V8>mtkCqhWM4RcAwoIjD z>(19h%E{2?;B@PiitS_$63cDkKL=!xF|uzY2c*5vT$HkcScRw+Z|mZa2Pabx#2^og zY#=gDF&RJ)j^Eh((HYuBFd=pEnITJ1ANG?YI<)51wk9N0);!i04{c+)70kGLnsOzW zrgh`fOu>~@2*Q-6O{Am^AHT$^0@%FiHXhXn%$EGBo^bzSJ-dq12M~TtBB*BZ;vhdQ z$m6n4d4q<8{nE7#Q`Q6zCbPe44LD|>@Y)7!_tcp!k@ms8@;(#P-mk`eh{|SCw=6M0 z>PC9x&JwV#gh8WjceIiXC;IcvJS)d>uabd5}5!*meIu$Lz<%3c*T;OmXPwM4!gq*HiZKgEP>ib5=` zJM7`Kw^&&xt9LFjP6%2>p))%qe@KfDok>Y}d7vFgD+ zWtF=!Uxn>tiTMJ2LLkVEa~2ohmoXxUB;%VK;p&5i7LFbI8c)P2!(>(9NRy=W1pbo? z{&P3LCjJwg_ut50RtC=SNk(NsKb#@@ic%HHleJv$d2&-&9yR>2mk`a4w^jwm#p%SS z$@+l;N`zG38t9v8JoE|9_1(F*8dZo zHo1Jwqtd*eQ$T-D?5Frk-QC(Y!h8yWD1zc_ws18=*~!Y@!q<^*_2ZG?}G>Y9$bisf^4mvg$D8_&+f%8MfX3EW%DU_ZzuGruk+;klKuiC8#heU z-%G`1q`*1gIICd;`K!xBVcLZ|7CV!^p1dmOP!?FNO6*hSE21UXsE z2)!`gMHg(LIt+gCQ_(;vk(tuMn+5gEAEy-5@|9wcX-UhHDGC@*E0$D6s7Jg#vv3&|d-qsq*S6CgO_)APr1OJz&dVI&eK2>+4#wenn38mjw+f zI2x^Tw%ZJ(Mc(|WN$qi&P#D~jh*^Pxu2E^5owIbUJLKM`{zjy8+RNy4+tOa-rTd?w z$>oEE)j#k5p}ttRl(qLd#8{}?BSwt_rdDgsY3@-XBF$PH7goGCS_kI`Wqe<1lG(qG z>t5#yy~Uh5NT`))ibayF4pJ_z8*5vs^tvQiL42q=ack@Si*2e>HU3E%BeMo4{?p{W zKJ((H##5dhV=?(8RmLRpDH`E*1@HB`f41kO9qEZ;)dslfVvvzL;*Ae28vg*@u0Wd0 zNQ`l`xl9I+wjgtOfE!<(Dreq3&*BJ&5?Sgfy@>;#U-*vH$Jc$fX8ERA`4V0CQ+4z-Xio&1Bj$@pli_$kzCeRupQ6LjgAXP*NP0*H7CFB(*+9GHnJ?3xBo%1MYu?sWM zki8W>CiX2wAzvbVIav_aj~)<02&RL^M-?^F#F#|fayPe;E|-Xf`QfuaqM$(O zCB^i+9i zd_%^SAWok~jXwn?0jX#UlT`X>x@Tfqt1C;zu4vj@2FpPo$bu_$LWsBVHgBRcC~~x2 zTO}_dPxQ0UsoEh#P@9l2IuWEDmIYH`G$peKvMoC#cixya+WuCu+T(M6Gxx>qYqnRjvD%K?&oK#y{Mgq#x^ncPb z>_a=wqo+$&M%5(6DIX->SIBB)Uu?BXnLnM>H?od^m!n^A{uD(t8XO#!y_2l}l#irXq45<&`Ez9>51VYC zR5CN0?rHZT{C9J=L}%V1A{+co+Zf2@XPu03M|m~M)^>JT8rFqL%cX=hI}6k6hAG%m zP`wLEXfJI?D7}%95hMS@Xzs}~dl@nVh)#22B9yn&np1kl2a3mi-f|TFd=J$^Uo1z6oi80y^tcx?A&^IiJ zL@eb1)I#5Y79x~{RPV?u$b~sW7s!VmN;=50UkU}uBfRi)IcxK5B(y~|MSr@abLH;k zGF?K!9A}1{3a%JJq7@;Q_)#I%ti_0jIFTFADFY^PXT>aNlhZooMVZa&#YtK@oY<%g zhQBH;M~*DNMLEPGlsJol_a~MfRop@t-r95Uaua(`Zcg4wYKu?gsiLdOn@ZTAC`uJl z=7Ogp2bY&4vC7z_sEJkNh*+Yp#gvI8i6_h0hE~?r5cMofm3L)g(a1V+hi{JHK!|wm zuuOGNQKt_iTzeuRM!wpbb+O%L_ciRM@EW7PO5+qMgS$5asIoTlZmAMl+sH+b2rC)Y z#X|ihXdpH1tr*;(Q4Q&i$hv-!e1L?}6=~P>k~>5p&O#|!AxYpG-L2caCeW&$A~b{e zmWfC$%-2>@EJ6^cbopyq)7jF{8Q|nICmrLlxdarJ#tPi_T=zt5jE29r3Sx;Z-dZ4V zKJkc6@KU10ArHx8G_n(R1H(_gTR(n6mYAm7i5T};YhB=@<9f>jvEwBhL$NT1>WBm5 zr-<5enQxQAmomfIt|PLPiIdYhO5w^0xQIB4adE$c;Z=ajLi?K=>UT2NAgg(a3CT;Oclb6b}`c<{fR!Z%tG-ABMMJintKhoxv3fA-Vl>NQ7KLvRpL_(W!=j- zMIxe~oja(jy2Wgbj7MT&1lt=TML>>uD0Wf;wnCoKI#?GS$}pz6JoTtO@2aDd>DH6M z6T!)47BEb(oEBRJhb?SKKfRqa#l^XE51uvbZMaUaq=W;aS$4pqlD5BSq8EUNBUX$SE zhbQqZtr2$X3R2b3yq-#n;eSMEz$(zyC5v?YV7S+A4uvDjpFV|x$^Xdh{>wiA;m9k* z0?}sCY-^RR{+a&(ae>4Jol$wwKynY3`5Dy1kwNvv!DaK`{Jme)`zS9`z1pXncQ$th z=Q8QF+weylmygK`d;Ilac<+nT2kSP1$?K&@j~XS);F>Sx!4X}FT#1VkAh2(BgQiK| z=5Yj_(uWGXmc(^(^%pCxzsxGXs?~kG=PqjgL0gz|bE4zJ+2{|Pck$vn)|t7+d|rNK za2AI(nk?Q8?#_rXmdDXAqUKnQeDbZ}K2&1tky@X6{e%wHXQ}wIg5;VcUI=G&E!z1= zt&9sCi0f*8g7F~e2!26DmlF{7;+Zg3RNTid!2D+9N z@UnNi;Zb1s#WRA${3|cLRI&Isr0_0^4tfI@y5@g6${KM!w~FbuBIOWM3z*&RPj3Vxs6 z&o4g!&_2;gRxquHvt{Q{JC&xWg`HVYRMKXPo+>$CBXAXa9<9 zlsHOFZoTkQZdM6qBIi$pX>v1@1Ft$@tgy@7Un_k#qVyud8FW;&*%(y(!G9H(&&@hP zCxOEL89=(q4W(dA77+2!2>CdTFpeb4fIs4^?XiV*`URH&0003&j^ISBVjLaPzy(GY z9oWsPAJAMSE;Ghw19cw~)X~@`1G0z)qllFfUai?!N)Zq#DO3|6MG6)ZE5^!!ij5NV z5u-CCaSc@rDDqJjRLYr*PbvuU1|rh(i8B$_CnT1+m?ar;3Q9o%Imieq>Lynqp=6mn zM2Klv>cZb-#+f?_3Y9`9j$&*^E-w}^fdP)ii6Ti+*k#*RO)@p(5`c_#G=pWgaT%pn`Uek=v-MI$vVBhgJpXeXTNpXU_)c_l#-H#>U>U z6)Ff71W-Wb8ljR1b;)Uj<9wypxf@YgfNxaj)U2n(92{y0%A!;ek_EjB{#>ej)OhD9 zRi)fA`W4a!?GOQB=`poM@R{2AS&A_)LYn?g;HAfzD_$(scraN|sSqX;Egk}-tQpX; zYo#dnQEx;^Widc$clxVb(F1_ksO~k7p;;!`#V8>x*gCo5QCfV$E;u60Xwi^*=pio< zM|kLRnDDk~LesXNFIFs(M@bDae^RDyZ7xlcK_FF`$U3H0P=FPnRI@7|WuYPNf_*1M zyzc{wBAwVQXIwm|8p(kmnAuf80003(B001Ug zH-=5E$VR3J7ytkO01z+$0005pM50R6RB}nHTp(fq000;O001=^XRK}p_Cb8egl514 z0iUZRq2r*^!6MCh6|dqA3Ns{yV349aQ%)*n0UNDvrTmIc^rTt=#lekgF+qAC*v31X zq@1?}Hr5yclZl81Ewyhzmj*fRCtw>wj-C_!B^fRf(zXaliZpSTm?%$Z@g(ebWlRw) z*757Quv7wHAT3I0q*JIRkE1H5zrC?3Zd;YsGAl|zoqQ#;b!F33F2QIqLwdSOpOqcp zT*h+6V2x58jY%@#2MG$owfj<}QPe!FLNXL>SR5|_v9GyQ%V#gBZ!rvR^W;9;22jsh zK{%-zp2pkwn81BaI1|9Y%duY25Pj8Xjw+J){WvQJ>mNFhcjmnp>_sRlC+TK^aon zaBrU3M};Hm~ z()7O#ET%73TM5fA`EuiDk=>L^az~N!m>~@}Yd0;0%zq__VQLXL>Mz5&wMaSdlnNmU zkTrr_6L3&tKv>>7a1IKvHe0r7@?2a{Z02Wn=#eq1!-AH(iF^lY2aTK)B&*46obPZ2 zH5i!@4do(_yctQo!NTRuX+?`Yk~)@H8RS6NmNK6*pf-!!s0JqFDFbdeoUtOVd#+IV z*SzJ1p2upFDkZ~UO&af`+A{3W*8xQ?*aSdti=v6~{gN~D-G=4?TKCDZSByDOXl?BT;M7#YOk4d%e+)% zN6!Zp2P=*V1u#PI@7UCsE`8k){{8e2XB`hlQMGBtk+crfRq!ql3?P#i?d_?dF|uzW zv?kWW!t6z1OreiKjAVj(3H{OB%}@?LXMFzRRS>~-O0u%Stl0I&N$V}W9i}GNg4QR9 zcqpVb05WwmI3DE#&oxrC*QX~;wvQQ4&eD(OP*{W?xJBiY5ul?>Gp{Ou&yCaU-C6k)YjSjr7Uhqs1kkwH+#yB?BtneDjyQzGGltg5pzsx@_3V1@(Fc zI|#iOolu{ z)x0?5qT~r8{kI-Ru@-wvH+C~p$@_an!)sU~Uv_zYN@il{kcQZen7UYQW3g~aGk-8p zoyQycq)tl4AuTUKCFmd-XpSlNM9)yHLz-oMB}@9JN=>Y*%pu}sdX9*2AWrn^h6zRm z8(>2$3+7SDej(9XJ_?#){EDMnM--_mj)0Xt6Z!D&FUP6E)w$5=FL@f|HE|$YTU3or zgKBITA|e1)GKsh^f)fBLqjy$PAs0p>Jm+WR(Ic}6PBD~4AsN-K)YD8J`as$7JFMP} zrUfi{m=qNvM=^Kxhs9#*)<&mtEr?Oa?u*_yJs`cEJQL(zq{hM1{rmVT@o*Bxt0y2p205SeesY zg~4RSY~aWcWqVgq*=|f{W8&ix87Vq4K)(bJO*CfpCNEHYlOc&GkO&tzlgtI0AVwqM zZkqBzN~tM;asoC4Y*DZ(o)CfU>D@fGWW3V>&~)&m(KHopAfi=hwA)nxTu6@~zFUYv zgGADzNdW?dj!?w66yqy0kqC@Q_vC2PQOgU5ZZF!Zl*Q>&%`zA^^qGslKE&gahmTOjwM#R2l{C zq&-wOi#IhpEv(xb+yeo}7Hzd~gYeU;G!K$vzGL}nMAC8{0@ljE27*ddGj^#=Dj!fO zmlKw@$#Ibf6ZFcIE@HvklO7VH0y6->Q3XkK9C9mcNKY}S?AS6MLdGD*>j863y@?H1 zaO~JY7k;?NEIi@V2J^-sJKs%m3_}Fh`0@tCfv;*T>I9$%NC(VT)iQ})8FDK{dmy%~ z2-OGb)sB+^Y!@k_%fJ?E-AJ5xyU=P)VzM0|G;$y)+o<@+`QR*9x7#5cN3NKZ1Oy6` zFPHjE3?LAVvc^dn`V-m>m~eYAIunYXhbj|`7iK;mS$pcayiq>_d&?_6CP2Ud00Bb} zfe0ZGmsvTHlG;DoxLSJ<6P%|*amQSjwQ70={ZPEIMOf5J1tOr8qHj5SiPSMMjiOgX z|B~xUqK_DmvL;%H_o1d~kGDRsYvP&$4At$9` zg)D&;o{F7nrDn1x##%81C_#1pb9C{bf&~QhO6wFtEZJ6SeyWfiCZHuX=1agBAy+{OLqRh9 z#91amH8ZHDmG{*sn$d%Pr6E?qNt_H)sP>iDAi?@2g`mOJoh_U-u)1?PQyDO_ez&wi zgI*cGNl6wg|7(c~cdO06hgqQ}*|U0EMp(Y1Y5{0C`KMiFn?v5@wdli^Z5fKwry+}d zwF<7*w-oc+2?n`<>c7i- zO0j48xC!NEL2~npRLovvuoPUAYB>W66rkF!&k0)SKXtudAsI4wcz=AG8ZtGGC72Q{ zqRd7_1#Cu(9^<0bXgAOPY1EccOAd2HK!frqr}~EQ*2{53Hs(eU^&g{TWH`LB6(+hG zRVSd-+QT`fm4KNoh;I(XmpKjW!>FQQUQAusw`7ypg`l(qg@ss8V$f+|X_eT@lpM8^ zwelmxhAvY+coN9i&}FRaOKFHA6_SSKcCs?qjO&PtxbB?lgWRrqS0qhsnRr`PV@y>u zB5PvVE}bMipePiwe$&fOEjzW*NEi~)yRth&VBw%578mDBn5c2Zz=qSBzh2Q}qtFxBapm=qZk_3;1n zx&^mbi$rEpM+V%D8YOi9w04$jv#TwQ`NFpa=ww*;-h-O->d+qs$`gJ~eQT8Q?m(m# z=eBv3SNiA}a4IytMt?aB?d7@|C-K(V_|%Vbu{(P?jTBg%$MT%LO?M-bcWGV4A2ONo zzU5zba}(FGA8OId|Q!Aa}%2f)y-Yvr6D5pm8=z=>J{2)PY{QZ#nJqz>Xk&;$duKHQui?Id*^w@wu(92c4uPO@)Db~ch zBc;MpUHXH>bdB6qdcjX zl@i$qc=Rj_tye{S>lQybvA8;s<6+1Pvyc=7XC`}_7=?|TtPfrJob$Z0pDY!*5l#?5 zh#yoGwbR1mokhBh%!sFmlx3uC7K)HX83bCSKp40Y+L5N<+uj?)&+m6Uvesl~3f+?0 z*oI+<60NTy&c+M_tZ&s9>~;v zl=6KB`QZ01W+V0Np=UkOGPM;lYI{c1n}KeUQh^A7sa@ir4bgX9o_SAmoz;v3)k>(~ z-_SoTbiE^4V!X00N|AaJFtH!%FCeq&RP;w$C93o3<|{+cuy4H4mHWgjfvWPIWR|dP zcs-9&Y_oN(nR|le=(TI|i)-m%QEHaRqSIidfx^AXu6;!pDmrDKf4zsC=5fu4g@d_t z{0%i-x4PRlWaSRFB}!hkX8xtB*oN}i9;RCf*a(=@6hg@GU(Ix}q4ql?_jbf5I~SIj ztF*{7ZTSZ9Ov3w-PR-ngQa3-IeD(%zTSQr(d{1E^%3>i`(1kgL5(py}a5JtHg3d(C zaxOt{W@$@uBYTIT%A1FG=9JdSp4m3?kvqsR5`SOk-}sEoB4w zM(TGl%6JQL?bXM*8R1-hk}pOapt#CJdz8CkXlmE-!P?)I<1(%VS8rMSa!<;>Y4W|* zsee>My4U3GtHo?*ii$FemYyP$YGAi!RxqBXcH8CS(w~(w=|Rl$+);R*5}ds-zTM)l z`~Cmm4U42XBd5R)2FrOSsfb0}?RG5>NptGh2f-c$b`SR9XDbk2LiYS;7{z;vS43eN8(NSBpl zd|M+E@O>$aZl1{VGZC`bhaCwok}7uhWBs2wi@O(Xyd|?{;dPv$uw$~py~UdR1GL#s zgH+&5&H!QVA)LsdQm1t3!_4q^kk<9U-rS}+MfCh4pBrRL$|d==BUeet2T(FHGTEiy z3+jrL6-^9XF0-xi1;~^b9aPv4ebpWo`29`1v7_?z4P0`A+=qd=Tl!4)bgmO;fo*kf zzPRs|&j+j;x@VnxcGQyYuHjU?Vd$N;Wx*-0uzENN09;JY_ahJ`P-?66OaITg@WD`QZ7%u6(D4 z=n=P1}qDr78Y`e#B-u->^vy}s(N(4gXc7E?HZeWu%=ipEE~&~yW-#HWW;tW z`zDs(Ga}QJ(LKa0Ud$KF8xfL<5eTJQw^a7AFy$fPC1ezvPL?9U{I7C?aQzml^q25{MI?WXMHL~lwiyTV zc2GZkPJu=F_^}6Dbg{0u8lv37xrK8Xc@*S1So_MfO|82oaF$5_>lR2M#Mfl;(5Y(kWe{h^C#?G3G=met21GXt;m@|Mp(w$~sn zL80lRUR26yy_@Ni<}l8j0fcoHA_RhSvMjO0X_k$M%Cz(m_=23eP=uuQGa@Msl21{T z{Q_?olb)u06}l`vV-8AM9&D?!cp|MUEJG0Bl=6^hr|gVDwl5|wehI3by!|L_iwn4- zaY3{3$rpi|rLQ-KdfAU;2%3{EO&g7nqRYX3|Y+?+apn( zpruM08_+qkOjN1LZztL^)zIMCGj^FR_jhy~lJb$Et_5g#s$8WCk?1`6Jmmicx0FvP zun$2R$+7`L;3P~|Xe~%0RC7d52;O8?(q%GU$k^(;Cy{J-&Oj0sfrOTsnCSOQ5Ri$S zlPXwqckQj9L@hXo;XbOcn7L|XaqP?{6wR{95G!DmZt4;TJoGfUD_z^T2~~mKjX_b9 zt2`C_KzQ03E7Qa#gL-sM?v+fU)bSAKN(2(GE`u;A2Ba;gJVMr>5ExA-8!&Dk`>iYv zqPFEWz;6+bzbEj1E)l|8x`?oCnv;qTv@5Qif?T9bn!g=SJ)5lztE z4kQ~wu?&se!Y9`?O$KR^Bj+MV*s2edOhYWpTKX_6KF$%$bC{bIshd+D%+!gC<`P_0 zsgfeu7FOAQX%Qx3Ax-8;MB6OIG+%jykqDtcvo3Z;7Pje0u`Z-3Y?QE#{6u$(j}0!e z)pv|pS)Z?v5z?&mI#IpBaxr(+ykg~bA41@zXT1LUo_{1CXcOZSR?fs12dGA8e*9fXDPY$8ZZj~3(qVY9D#$8MLkOv{TbBKMqk`fLLoylqpV92 z2&+ir{E1D)H0-xzmUk%{)z6(_O+}CeAsm7{+@dmcN-hdY*1ELICUH{0wGufK>$y!W zwJQe_N%q^fHxZi5JK=Q9l;wxwZ&}w82&3eO5Dz{mU#y_Jf+;9n(={H+)x=PLt1oMVopyT!T+!hy@OlYEK4l0^ zX7p*wE0*?tRp%@%w0}fHL+B`mEIc_PHZI$M#5YlD_rp4=b4L}PGWEmGOOTbT0C!7$UFuOyi{ zuvYD@<%+<1b<)SlJ|Z>P)~a0plHqd#tBAW4gc7hitgu>9_-~>E$L*4!<>i=*lNXTRddr@sv+<8ViU!a@cA`IJc!Z zvqGHc%hz)0E~9-{;vFgDQ!?!+bFP9pV-l6zh3DLf9vznGt_Typ-O&)y{&{<%Q=&y5 zXE76W7m3A_bB{Is|Mgb66FyvP-R(}%%C&!VWd%+lh($a5rl&f7@RPzK8K5sT;2lGD z>z9inDT+68T@yJFp=f;*@Ti>e{A6foTIP@ZvC8{PL%0jk zyADz(x-lS~hV&mN5p(`xOYzuaWcT+XEg~W{y7L@<{yMn<>OT)TZs30pwSz&ygYQZLAKmBFQ3J=7~`=&B~HPmVwE7^nLMU z2wo?uo5>_yXJitB)=&*a_jyQ{0)SAd$RgMDLXZCO+w}+!2wU_b-Y$VG)Cv|EblKR; zHdaL!9ik$|KWDR$S-bHPzyJUNNs%E1JQfBG1^@^F0!Rjk5P&qe)THr)n%i z7D%D^AC(-5KBj0?cTV)hY|S*|s3MD4U{+@O(#OW6Hv3_T7|CBxraiGF=oLoi0H;A5 zi${1wxv=!olZ8Cwz-JC#V8V9c<9Pl>r3R4^_@+dJ#$vpnfihyDEPD~fumbVjhnDJeQ|V0e-uSI;uqCdCb|7DEMaM2XFm$?FbL!gGd^VZ<^7Odtj{ z4vovrjAO-z3Y7N}soVyLjDSW!ikwhk)GVr^jMC81$(bHiZjNK04!EDmE(y1C2TBjV zA>+UZ1MKB20003>1R=m=5EQ@y5QYE%0000003ZQ~000000HFbxQZxW50000000sa6 z0000JLEQxmfB*mh00002#CGBe6aWH%0doBEOO?Uck+g8I(|5@7k_qMaJMP(ip%Y?0 zlG(T%v92H7u<0+fJf-4v4I0fF{V3ymHXKcn8zM|d=>(JWX;Pt|;&S0H6h*E=i7FsL zQJ70ZF7_%x<(uO2!=lKCP$jJIpa80HRzLd9{jxd=i_MKSqs5jaMEcdLy+@(ZXwmFb z)k0K%9Z$mSFG%5a0^#2j{ZCOJNHl2FL8h`(@*1-v4DXIU&9oL4c#c&%VWmP2c1}}J z15av=>gCfy7c`qkTa@2csNg?c6`@|4%Zng%pvZaAbbBLm`}klu5Kb+U*Q!~{=g2P* z*?~_nOL7;Q?=@;A4Lxj4#GabxTnJ}U_NGxi+4?Q;rwh07@{qamQP%vE}}Jw@~vZ5w~DfmNHjUi zq+kd@cTBg$vu9ayVIl|g-OyYeDMGpt}$9J)lK?8?WNfMJ#934h}+Cv)m*BlmE9}vCdyzX zY?Tj}>kwdCyS1mTgbe9j?r^U^kgo~Tzn6+iz`1YUobbj&OaR;1#_<-k9sTcA^70XvpzF@_03d)$7gZwPOt(c)Oe|wH+Oj>X zwpxoCSyHrp?zJKfI3^;n@)KbRO9rp;mXT7K9(u}4&5nX?moO? zW)GI2?^1=GI%C_J%Xq~>^i+?j9{5w!KoKR4P~{+_#X)<=(0WaSX|*a}g1C#fhp($3 zTONiaYWKkn%2c!#GPFzU70=)$u?sS@y3RpVMINT}p}B={ad>gNm*)G(3FqwOmG5*u zm$gq&=Qe87&k7VZsgzq}``5_1P)Px8ZbkT$setfIws-Mhh@YEmO|cV$($tA-Dje#E zIcF%3Z_!L)$Qynvlkn!&{b!rWJq&{tz6EcfLzD2*V>mo2cqVEzv9Q-pvvgQGyVYF2 zAOm!tq4zyl6243mfTcq@HN8M4(ZNBer*SU^!gm&EHL8Y}H1I8|4!%*h*S%K_m!MXl zD}kU800)$|n^e7>)mkLi&R;v8S>Ayj9f)_+{a81-`K<^n{fz)J7w=T^NHB%RImj)Fdk14O7tl zDB@fbX{EUVwX?<|8N>I1pzd#Qg=1)6%tXNGFR`ib^*&3Kk9n7Fs z9E)SBJd))S#-O0pFaCle_k+TbJhoXAEkfml4lu?~T-1OxXSYuyCgJDewPp~`IEvie zASD#;==%`Mf|C+Xw%2JOXj#TLsf%zL5Gla6@Kae+LpU)uO^!pBilZt;)QjkTLb-Vb zuzv<@YIQ)2aNMxV4<_%Mv2aSOQj?iOmX=iPB*|Ri*OTV?dFcFIe|s9{!ciJEUY-92 zRP`L$C5~B~ z;)!rmxTVD`@|?Yd{5j+N8dpeoRi4w)uX3sWG+QPnV5D9l{J1Vzk^|_hV|V=yaHXsQ zms4WSq`|G!6gaucAt%fWA;)RHgUH>ZPrJh~mNaa6Z4q!x&m0My5~wk zI={}%Vvssu3ThFCBBQnnR`ky_pLCyT)J5bX(dg+^E`R6xsK=CeIevN;=Nhec4sIz3 z(aKDho-nwuYm#?v1ki2#nA;UBacG&|TexM53R;~be40OZNi-TB&TcoO{MgTzb75~R zE!GN^C<%fXrHWck^VeQXppxW{AfEHUq81$@rj(7kz+%9OhRFx)IMfs<7Yl|f%K(wY zY!x3r7z89zWoy znG(pu^@~++ql{{SoBF-Q_~zZpmtkI~A-X#B;HF$bq-jW?nR)-T8ip%$E-i~t}iRP{w(wuAl{Axs{Qh;Ya<|CG6M9uEVAECMY}Mi{(Q)~ z$J!D1(@BUblv;jEdAK@|L_s;4>1Wu+F{^G|xpat{zd0kGG{{@}9%hMy4U~@jI(70UhCy%$9dEEKaow=^J zc>&%;Ny_+>372%6#}N}&9-4vIUk1xQT$sh`#z1p2HHezO8`+8<-&-!lmBYM;+M0C8 zrxN1L-0>3Hoj&=I6dk5SZXgji7N$$-`8c(d@?}kk3X#$GDWPjhRgDid{G6i#9RB%H zW#k0_$}!(RHP!*k^pbat*UEnmHHw+j|03nIRrAT?ZB@RoNy#m3>7vGyLdQFniOlT3 zX;3tbH>3UW>4I|yEm{Mtza$1z|Ea#Dim+Qu)?D@FG^U?TJu4`K<=4y$rjIP$N>{fP`!Aszkc`Ga!`U)}@#^z&$wU7Gst&@;*x2($@wO zl5^aX5Bg@(Mm?3bUoE23O-o3KKc~g1{+j(e%tZo^@&)Xlhs~9@!k)IreysU(u70;N z@bMshuN@4&dl&V;e;Wg{CM;!b&qYl}{4bn9aN9b;!wkO9sejBO zvs0MDjyai`;rG0R#$D4kjfbMcm;LAdVg2@@ zeeRJO+Q|ukay>=LeL?cQ)XSmy_+@put)-_@_46S$I@PqazuKYv`g9p%h&8;D276YnugX5J6b_)eRyiFX2)jIiRyA~MMU-!rZiCHiA##(-547a*4@fLPQ|_r}@0YSrcH~JmJqzWT zN*)bg+yAQ2QVV&1^W?`ML^IR>GA599Ow-9l)v?z@DQQY;ppU$XWq`DlP1??vfy~bx zRvQ1%d=Ir1il$T1PnA31ZTZ`Q*fN$Pwm9{RHM++&i@s&cmQVdcYGz1_vxv*=rX`6p z)cr7>K>4|JM{A^Wi7&@cLm%b6{y(m#u*TfgR(?@0bZK|v=<`;s9IMA_%11pqmCWNVs1UbyX-CM{Tk)!N1D00XxZ?ZzzA)0B1$4iIPMEEh z);eb9W|oFlGAjN{AE2_ezL^qWpTjF-x$c?g^^)bPb!9(G`A6bMroqo@ADMnrF96nW ziK$*~JvoQF{sW=vQyn!?$o|d1a#%iIsv^r5n%W-l_+6n0rM^PTSg;f1YFysSkQPIc zK>IG6L7;dX?QrvmbbP<-^Zb9PDMfL0RiUm(d2vP(1B2=`cUPU z#6?Zt`Z;vw`-vrsnVksR=G5p9{S3U%Py5P3H~X{ZX11n`3IjsPGE6qk^C-&?8&9+8 zh6SBQtg!AM1u8jMAez_?VB*N8Mt3cc=K_@jgTSuoH3bFAP_R?ge>!vnQ-f!PjDzOt zR~CAG)xdl~^2;SbNQ$OUJSi!0BEx=K0jOmUsJTa>YKfg#JRJD7PR?uH;z0<52&k9& z_6eZ5X_rqdUNX~%|45PcfTE17X=gp>lO&e0lDOiTUOnEK#n3C9Vc$%s?F%ltox9a9 z#5#Sy-g@PmeV+=mTr?8IW2(w>BehH`tTO05Gf|$jF4GQ*R@^{RWhQV|h3_YoQn*$t z<;X6#BO_wNNB{V5=9mvm1M)aUmFL8C^w_pOvg=PQaaC8tW2Qd->~V$IBJ_GcU2i_3 z#Q7tKk8|L^q)Qa}YCt@@7BWI|(B+qKfxNv*Yb^0>^H8IU|3|@M(qiypT-VwtwRp6> zttNWCW1r-qWL&iGk^boynGvR?k&%D^00B{pp(l(600ayGA;64e1x%(i154^?k^!?K z5#o_3*C%daHfdEfwQ{!T9T!Ylup+%4_ve$XEEMa<23A^QHqFtjX()oYZM;VH!&HJ7 z;|PRJh#HYgJ%0R(?8G2ZBgrsLr*KURK>4z)$u*ivvJzT%C6|iwB!q^oDl3gGA$SFE zU-23z=~RF2;P&n z1_*4IYSM)GNJ3bQg3H?0XqIHPdk8Vzge|5o4FnKTl1)O5uf-3WH5v|jWoi;N7&7Rr zTqCGIqcDNmMp2UxLfeVJ)}kw>MFIr`K%ls$)aYVcNjb9UYfKoF&^m@d0003}08t#G7{Eg?3;+NC00000 z00000000000f+?w4M0Nx0000000000001C?N{|Ty000000000Fx4Sn1Hz5%t010FO zeCegZS=ElU=EJr0q=|{VM3Qhwc-yfE01d0CerGM^)rT@rUQJ0R7@s&5(I#ak*V7O| z0vvBeh3%~aD7^xsG#W`TZY`oh*}SNhUgS<%S|n?1EF`o@+*D@jw1vChU!Hv|^X3&# z^kzWV7qIjSOsX`)#ex%?5d_mqJU}I2f`ZwRj`*Cr%4SR= zqaHZ{rfF>%2JpeXeHJwHv6Wy$Jz5YANWKv=Y<8k0a8a7))lM33xjUt=gjlk>S zYQa;i41aqv9ndLw?pn6M$b{>aOhyh%63>(f6mc+7kdf(jOXYp#I0_CokX$@S(do$7 zi~9`?=mN2{Yx?Ene$OaeE*B%1)BtlpjK7yk6!h=W^@>dBKc?;LG;fVTRi1c{TF5dV z6D+w((BncS3|fxOS{;nubRfWBoD@r$fixG;Zvavu9F1&ssgW*?#p)Xxsz7Qu8-q8C z0jb7L=05~fsZMdtnM%lZREXt^QchJyvr)}v#K+~VKd93el>HS5vCF z{JHz27k=?~01i!h$EK22lCt$|pZ6s&VmdGBStSyUNyS*_Y>~$mWS!ynMdzrtQN9*Y zkc_`R#%pkFwbE?F!Vim*9yD32d9P2(_mTIJObXd|{@7z zRl;j1{Z8^1>EfhzJ!2R%KO(AgHDQxN_#|N&BbeD2Ld@p+hgRU(a?GJ!VGsC7egU8e zVFCjJ^CA>YPzv%T7Zw^xOwk7sIKTouWm!an2F@tYN?FJR4Fxjp5*cmX8sp=qu~`De zDpG?Mp0Z8oH=!xzH~I@utPQYwvxGY}vu3`el!XgbAgagCEPU|@NTVXYg8kBj3o235 z12c%>xugvSnOz**xIk?Yp}Ye9whs)I#whil^V9va5gvdBU))XE$q#KD5Tw--(@yM- zqCoKrM#Rg|G%c|r!2}PM`DaUdu;!Lh%c@xKKB$Zp2!hj`+ih~T0{ zK7}&?tWm@xtUWT>)>HW+#6bNO_oBXYY;%zLn3-vjAU8P2jPcGmv*`*jO+UI>M<`mR zB+vsrr=n~u3mWfuza%vd^~B^z4cie36)t?v9U>cnzv&l zYaY2$-5yPd!71cgw@~;nWP0lCt`Hi|r{&>)&+&U7S_ zkxe4s_Vy53or~#W&y&YQ?upd-V`v|V9Y8}7{2=*{_jJL9yU_VjoU<$yygFjDd@vw! zh&Yn%w~6JKBiny8lD;WQ1OXU^TudOQx|`lZ<4`UKx#eFQmzX{| z;zk{q2!T6-5$OPkWEVI-SG1uTATVrTTR)k#94n+98;cXugu;A7u`S+#$c$0rVwhy5=o&q|0?{Rr_;~^oCIxORsNsLh)I20Tv&2BguCo`N<^7$4Ld@ zbrzK-+yL`aV@C|g76K6!1DdF(_%IBDg9Z#lM!}>I3kxjZH1Eb?VyDYuq?;K|k}j1C zB2-0+MFSD#1}Np#=EjqP-xVn$Sg_RS@}3m7&v}VB5iUJhZ3R*dV{&-pDZNVWvLL%L zCfcV-%5djevMb~FFRbomHix^}naKsxna*sT<8*iVHq-AT#oAE=40zEL#;S?+BTzO! zvP*1iL^399aofF7_7ygF`gh_IiLr5 zIpg{Y(w9q@thPlOF3mk7-CxWqSvo7Z77bA&qCa{)MT@7x!`3BAw(EaWmTy-eB_-Af z1VO|I0KklBgVAWne$~Z7(N&3U_#ig2V*Kl4sGn4%GYnlvA&d1*HbhLBVnPM%O}>K4 z1bRVnL0CfR|9SpOWYOba zFN}vS3O1sTDpT~7M~36=OgTeM?)B!HW6M~id0@c>#2}Hd&*HHd|9fucuvkgLA!NoW zDPh(T5sUK>fw2Y=T^abS#_1t|k!Uu<%xKu0YYv7JM*N{B6&)~y-2SN{+6q9?g0-fz z^s2%gj1XFa<$mlm?J6P~3;+NDQxoWbK_ay(R!myTicvs>AVLvTzS~I3l*Cme#1NqY zD2lR6Jryj#!3s>#C$dxtB{gK0Ac6u&kkuASa$uoAp1~xFEMtvws8p<`L{TK5i4;QK zXi-Heo`ron-Jv3vt~%vHl+Ltv(&`XNP^6-kD1;#(EJBe8jTVWZ4Y-I5iz5;Ul4+Kj zz%Z>+upUAfn4MV@>pGC7Qb`SYtq)Ronpt_Q{^h8t0E1Wc3blw-8`i9EHLGDzx79i| zR?YRWpBj@X1rkiElXT5lF~pBgv0W3BQe{%aWxrAr_EM8_vZA7-4RNCaD5feQ2v1gZ ziW5?!)xAi>6rdFdB(+NC?kK5D-D=OME~M3S$LF+^3f1W8pC$gh*#C2k5lHb|rAo{@ z>xk=nbZPMI5O&;;@9yLLNQ`Xk6 zSt`%!-!FsJFH>9MQ8hwV|$ng5~2=!;ZnG%6vR6 z1cD7p2#S3#?u%6D@lSZ*-5G0l!{Zh~DF)>#Y7XZ6vofqV(dA$*%&j*WthXkd?1%1& z8`;rqte1F<;BA4LSwU!eR_hAO#JZR-SiTFMu@S|TH9&RTsgIs<3WbP*V*oqMqlzjQq)ANt# z`J#&k$IOU1l@zM=jZ`hmCXph;$KCvym!F-)!VicnML$ey8Y3@AsywUIZAWwC^wqR2 zMo2opr(udccAAK)vYsfdL{^j_P}Lsdh|4AbZdZp6wm#t7yuBT{!@zU8G#k_Wqg`*! zzrQ#|2(T2A>{zrG{ubEaW6x5cKnn7g5xQEsmOiwznU-MITZqD^GX>~_|0a`EYj+Vxpwkz-w z0Tpy7bX4f?OZA90N_r|OptXsyLsRe^2e($cPH-ph%hgXh~;h|h@}H| zP%+ldWGt6a?Dzn%l*&RSvpcbqJp^)Y(G(8^v(S1M3!|c2hMzix;X41*{aBUgCb&MT z&F2o5nyvHG3wnyAjF0hZbsW+2o2v_7$EZN!2gwoXTmG)ichWz~#8=TK!GC|6qWS6W zhbf4Iiq48EbZo~IRbg`@^{PVZAolJKd&~p%Mc4zSI=aID3lavO)IOrM7Z$S@25nb> zHA1B}?TN@`wydjhIyjW#3|*W-vth`OBICQfCJNtf=q0jw?HLrc8*j)rb*0PP6z{TY zr#TJxiAp28g5j$$k+6rX$hnwK8HFm!aw0OGCd|%2T!baQRy}zwWsPh?E9an;#RUzN zyL04<(||j_zc-`Mq33a;&qC4mMW;g7Gg+dd#g~I`ax3uw>U@>Q&-{G&^jeb^O2WVT zQ9F{%cvIWun&IYw6VvcNX^eyO|EP)jc|SHK#%q7GzgIicq_>%VlF&Rj$iA2Vm{}Cc zV9{rjQllh9h?P+wCAO3Y0P3(OBx;lqaY_pbsV!+qm;z3iw<&w5$I_P(`)r-j0*0%$ zK_m6E2sCJ-kEJlc6 zL41+97d%BubD~?wq{<5q_aGajA!~{RE<{aP923%{#lx`&)dy_iL@oVBTj;{z8(r5X zc@(5yWw>Cg!2Ut<48O=OP<#Q9>TptrYJ$cBGw(2;nMcqkJmB?HSaT}3Cyor}R76HYcBIzFGCBOTL zl>6?DDM8tGMNBY|(XoxhxOH2uL_~1ZSwrU`JDkdK08V7(0_G-eCdB^Gea{N!55iN$ z`R&CK%{A^FN%cq`nFwkqA3&HcWjKQzQBNS#breb0J%kt_LeZlssIEdWZw_3TL4_HK z7C}X97-I`hQ7oQ;u?-nanH-=hRX}~#cLB|aS>1@~Y$(WD8Xu*J17fY3v=GS@SS$#C zl7K)>N<^DvO_tFZHk3FfX$St?t*%zz$cUsO=jx4F8&ChLixYr|CM*BD`e$j!9X+Cc z%P`#^GE}cnUU0@sEO70MO_%7sU|+|Lh>Vi1tEBd5%+pYSF3%-gi}@M`oVb+eQ&6h5 zu~`9R@8WBxa4A)8Xw1%>w->jJ<`#5XlN`EVCGPS6P}Di+m%ZA16QE9KHlo4)9#m`F z2l#A-Vl$F051G6h5ta0k#KvTq%xxnAwYH`{gJ{l|Cp;9UdB#Cq;ENt)dP#qx*VCbi zGB?mc?*z))tu1?U42q}jGk_l)6P<1zcZ zWj+RVsIp(J-8|M=&QrpX%0={MzycD$47}QD2^@#a`*|<0JE0$wn_kc%qk&DH)R8iu*hbE3NHk4*koB z1cTnFkNNXdq>8fFuXyMe`Jy1N2n5mSgYkN3^?9zN)U7J};GV|O3B)s=fw`p(1KKIA zMLtf=B@5qUn~vnr*yVF}7PlfUfL=tv&43ER2?eB1$OvGjkrd=2Y*Y2h?;@V)i714z zsD-hJO4B)<;+(5Ckz1h?f)9D35T&q!DV=1}f+dn$_;t7*5^@;1BGhImy8?~W#iG#0 zg->yWFwsQaJwy;l$aBkFuH+*5OV&oDGG{n~7Ss!mZvf!pOtwsj&p~cyAs_6F*s;6u zRzfN$T+Td@evx%u;xS~}Sndc?DbuG`Z>z$d1GLNzopP*4>l8)eueFTv%2otA+Q^|5^}A(?!dFNn6OOvelmT-$>OTBHV3yh>OG6v!r=yU0qJlodHI!+w#<4 za$4KSg7_yRW7HAfW5GGe7OH~m`i%|q+8I$1tG^~k?c)+Ym3x^6tsJ%Up+`Hjd2#&w35Xy=U9HtiQlqpw` zGa#e)D$S+|J_$O5;Gg+-D}RM>u6 zS^ex?f=C~BiVpW8(}<6xUa47^nj$U`b1I6b3tJ05@gOU)ZG54s+}zZ}3sXU4UD``D zPI%x>crnjQ7*~epM2^mLov!l)@7nfN6|0LQ5(2W4D0=dg$( zn^m(I$jY#1Gndb6+f)PvVj_cni~Smpx=Pq_qUvQlYWq(IQ(fBy#W@t$ZwwE=-UVtG zAT3BIc0pnj`fyAjx2G_$df4Ean8=-oSeh!+yiJ}?#kr8rD6mRHUuOBX7rhzczU&sfA{I@FS$|AL1|N1mp^YpCEQ78AW z^a`;B`1}W=U0q)#Mx>ZCY<<(BiGDvMb%L&>c?OkPJMz*p=?0D9)f;@9A{{F8Uv%x( zMQLL162i`l6O_2JPE)y*6{rlJ+)U0W30tudak%%+Rw`L>^K)_+^ry}!gp$_ch=&#= z=RShz(@yE^{P<<7u7b^S+BoyF7K>gP#o5id*^3y{MZSA*yO}HQDHTt%OVdAXB+T6< z>3w~a=-E!U9oK(#yJ{X zDw+w_NrmKdMiNM_LPA88yc8i){7J?TU!V*Uuz`BJ2nZmx6Ges{!Xc4$$y`x$4j44? z)QxT41|}p-vm()^N~IoFtrn%3YSVNWj(}+?;&PX;IFle>mf<=p2r8uUb*$E8Xyrdd z)JiZC3es`fI%Pu|n-q~@iDaTN?M;@NIR-~WWU)v}z?B5qt%P0Hr5*BIwN9=hX}=4N zy(~Ms@EMOeP)WKJLJW0b3Ku!kD2CBaPy8f^q$iTL5i9f&JfVb85IaCeOp=(S0R)AM zLdANYX`C^pVGCx*suX)vsiP$ej>vE#V=~#zd8&*M1@b`(8)!(Nn9@>+X=x-+O7wYU zvAa0E026S}XLQI2hdH8EKu~?!Z!>E zp27s^7@-*=%`ku!aTA~~^vAtG2oC@N0a_qQ?LnMDNzf>UU>E?v06+i$05A#w0Kfo1 z08_0ppsdVrJqmL1IH=h`s*kvp zjb( zhZ0q5+%0Dt*ZInRVFHT?vU0*wBSBL2kZPb#CiRy?+Ef|bKg&{OkgJmsw9av{^UWueP!_HKLZAQB0IBqGue0O&w zj#dr1(w71w1j0G9>1WLSf6rcr9+Bqw zIvB!BL)WS&t-=eHooet(?$L&0nQte87~BWcV$6^Q6lsfJD8RsS~m9^!$Hps_R?D43o5e&-WS2K zGXwP+;9(i`TIwi;1`xS(>q|#9qWE6}DUg$p)B4a@A&>|mSO}D2NC%^N3J*C&zszR{ zop+#u4lI9fQx1fATA&i{#4?E&#g8k(yP!lH=8F<4NWPjWI}_K|;pG$r+#5);OqH2O znZ{c|^qwfX2kiUAs&1@AD5GGc?*H~yv@Tp=jlwI!2Lu`jC4V!*0Tx@K8%+zLMHA&3Ert3 za-ovO$e41NTqPC}9ub609pHlJfOX>pCJu|pRj>b95m`P)haXa3{3P@sJu8cawc!I? zD5xI+tr5)GUOc!ZzK$NtYv8ehlupGn(zRYhRR6R|)9%L0z`>l?IIlW*2g83i4hzBbXFP;F2O8 z{At!sAYNA>-l8X;^Baa$y8Ai6b*9>P!EtEOwhA;dJ?A1v+ffR1e6#w5^0dx+9^27B zWkdnxHwX_x*B&&*iYCb&sZ;6f5H64J8Afn$rF!Ljwa|6218vF3JE}`g8Jwnc9Lf?|3O3Gz6v9usGGl@ORON9SJDiF#py0r z!&kPQIg8+8OdX}1g)nDm5h=j1Ia=JmGY+s&o_>$H<8`V93xpa7BZ3IANPP;-XOgJG zX~vRf(6iyC!r0-l5uEg5FUCA60Vt_gnX+yG`W0*=uHf4u`X z5TbPU4=!b92##aV=|vU^$1dS7E3Zcn>YUq{g7DHG7N8C?4|iu{W-w7qTZ^hY0)m$( zuq2EkLT(Gax&h#TxJ9r<7)0c7`cy7UFdV2@Ov3U zgAf#JgF8`>^Nu6~DA%>(8s=QY6uuOO5f)j=6khelhC~;S=ksJu+8dZ&BG4xp&jPHC zD<3Y_+bM8@@v=9ZRbMFk_Hbyf3HN3+02Bx#u1ZH5z-JK!SXd=&5hM|05Ue25vDD!O z`v1;-(1djeM>+J>6J=s|{)LakMd5BEb-pIi2Yf&~eU?kpqhFk~yXnhhxPpV|joV7D zX!?5SKgAgKXE2aWHN2?z%azt)w}fy~abI7}=jJ~-{F7QapQ}_9C|wD@Q-oX`;XYkG zf*3i18bk;%G4D%1s$mJV+zi>1mX&6)rC++|1{pYEeeEBoVEFEeO zVYn|pmt+2x$21?8tpOY!$2b=*uF<3aZRVyu@8$JpuF8Knv0He8zR6|cgs?GQjPchN zL(iB&c6jGq$ADrRq7Y&U@jh7iMW2#UBXcssUsTfZTw^^bpd@ReGEy& zl4Wm2GwWRAe^EFOqe%<+d;9JIM`=!V{yIOO*4O{8Me)1uptEABp8Ie5 zN3jW1jHy_i3IT}aWC6*Z(Hf7$?bSX@DCC7bzO&X)5b}twLZ0G^5d~^WDkWHy-ux>Q zYNx=&n<8!}7Re_-Q;1ryOlHJwWdo`uYatNPMO#2uD{Mo2S7YdE1aTs6L!NHB3Fpmzw}kexNQEBKSbDqEbxkO4MfJJVv>ox;EOBBgLw-b|NQL=kywr66w{O;7^2*t z(4;f%MHrH&aSfG-Ocp{R5gt9rmz31s8ShNC{aVC zxU$~7NQUBwcZ%d?fk*HTa@3-a+HH+kQCp!Yyry_5E+lT)^FYrsGTkaL+V4D(SrvM< z=ktJisdiP~<`abUA`Yco=c#)#OwS084n?t{75^bB792i8r$gyp1Yg(&QqY%AE6Rfu}h(GEwtQ@^fU=pCk z6+CBlc*Y!)&~%}xq14dcL_|a#JUfMD+>@C_?6dS??-9^L9!&%NF|Os_rL06-5dPWN z)U@}urK1)c*B^+ii!x^BZPvsinmIi-#gQUmvUny0LOSL|naqA}KO&1;(wV+*T?cRUnGRWSRI%zK^E>-8<=X9^@j52cJq zXh?Dox_Iy|9D~C`n!+io2JRIyA|_#3z;4(j>7aFu6eWUt#oRSY9LowhYE0g0T&qb7 zz&%3blB^I7oWRWd;DTV!Z)pO8Y@`Cxx^BYBP&3SA!?{3Kmo!A0C&SE%@aCXcgduKZ z1(6WCIcea3IY zjC(GMBdi}XSCoy#7=R?0gI1f*iz6*HKL|e+tQ=w2=nnkUltkD$_|iSHlX32`Dm+$N z&OPS0##}h}4M-EE@oHQ=NT@MjvED4it zBR6DNw>GsJj3DB-p8HK*=1y4Ugh;C-TkZrbIe}@Zlok)tjsrzyyMOn@X=p@Ukz!;} z*vl!D!U_G1sw$+ILS7RIvvBfGP`D^rGXMYo!)V)M2$>YU0WnDMn02xB7zJh(*PvGS z6)UU!+p%C27NtBCpo_At&>8rB-&&uAyp!)$i3-nr!k%D#n;o|}eobY6Z~3oVytx9j z<4(%Ns-zmpDHD#Xc6h{MWtwQI=(FR-=p+QHdTjR$q4&>ny0$ zmJw_8xHhRp+WLuUbDO}uS5otb7zl+W zBQt^YDH$2gLj)H_RSnz_BMAbI|bnxi0ZP!8BN3OTlxJ@2e*%C*b?0V5jn&9sC4Uvqb~#qx_TzJQf80c5=AR zBgIpar>sqry%*!(`#5#_!F*O<(Pcr?ZNGdhj1S71dyr_WSdq>0A4ZaXufj;XBahuX z1zBGq(vVu(hr*W+{Hbw?RETSz5I>O`&(WTX(!F>0CD7#eE!Frux#5v>ZRgx)lQ6n< z^1$3xM3pC4vyf0(X!FJ;H)z+ z7a@vgAd;?mIMis2WHfwKVDMx!r|u~U4iqFK3awc6N$=<}=P0tJAu`PBz;SN+o=XA= zD(5+iD{)Hikt=jo7co_1iES<%=xw%xTQF73#!mSWg+`5oxscX2+bOl;uNM zSgG?ZF;@;2Mc(otP6yl;<>7Fi=(srKTPe`VZvCBLT8FiC7tI|8jcFbp5cwK8kvtZ~aH08~$DO-uSt(S89JAo$M3I2-^ zPizzIvdxe_?(#>bNj@IPSkcY@x`Z`djZW%cY4feIYu zJhk3nG6e{)k zToknawZGYFTF;(Br!(MGLkT+X`B$D7|dig zaxKIe3)#X!oxB@@1R%mhFs5N#Hwqy{DV$rdQ8y;7n+Snf5++Q| zu4tB#S7u_D78O79E1K!0hK^WFz2_>tatUgqr!5Zp5?bd}EFLzz@Qk|$V5uo6E5DY) zUC~_yT|cFne}voO#Z z2(cCrVGkWehlLG;P*SRJYh=685jh!53}D7lap9t%(!-FQKsiK~W=`SBSaseNJ)OmJ z=ZNj*^w#RR8Q)PrU&YND<_n{v&k>k8dCB`K+(~*KGgRr?IVb7|7;N3~j=Y81p5dd9mL9S5I2?vP&xk)-_SygyJ@B?{C1XA?{k8$k|iscwc^R z-4182%6XJQaQVCNDcG&>X_FqjG0Zn5jcN&iiLXeI*|+&w z=D)6yc_KN!)kWj-_0Atx*5r6(`C?t2n=0-*bZO-O2$EN%Ke{J1y2_>YaPLQ>4LKg;M?j^#ODgBd`R6I(DJJE9$|VlU z@ax&9p40QjWJ8&EseIJj8ZV``_vUgG@Y2FB-OLN=-tyJWRQ2{x!FO6O6Q`oC@0>_5 z&`G9xcIRjEo#av7`)G5PNP;<>uBywRNm4JD!_zwR-7CB4%BAu;2C^j@*_B3Bf@W7z z-B;6g>Q%~@)mwmkv2rk#ksGHsMv3?p@A`ZC+f>LQU!KShic;X1O$ewls6{yN@?1?E zo)5t@n%x#RDT;SbNhNHPCRE-4*0bvmYEOqNZsni2gxF;hq+6s_XE}+pt(Wwbyh!=M zysc`WeV13-$mvZ>o#cp!?{{j;0QBd>o+ND?JMMcxLJ!`T%`FOF1!t?qZ)a{^mO>T=-2c1h%%y{)V7Z(Vz zsTp3efZ<9WkIKycW*^Ty{cyB+0004D)_71m0AQey8~`C; zlaLlPAP^@ww2(s>+K~nsH?9wz`Q3ykKU8jdL6nZ_Mi3loMu4{;Z6WRKB%1el;Q`#Mvp1&}q8ttbt-xUs`h)BD`7n9_ zL>xIP45WS0KtHuCe-!n@d83uma|rq&t%eo zQbj~Gt`Y#H0SmE^Q`absk<^%wt~Gv0m_m*`5_@$Vg)TyTf+1dO2nf(ZSkQq3?;*b=`f&mCD zxMSnBEFogg!UtMbXeE1lc3cNhlT%_H`9lIys)CwARY8vw-~a#tVgmsfVi8Iq0DwRs z000000007j0000000I!mIkGbunS%fT0000G000001SePnim}Rp0001i0005M4if~8 zZz&mw0EvtN|A{&~XyRMak`ZmDuc=^>2#0Kt;zWJO){Gt4Vx_q{{Vc#m`JU@z=#Ziq z;&6*MDhUm%r1YKqM0)imD`bugR|fG@kb4MuSKY>wgs1{vlLds&*}&ip`NMkDm2^Gk zhF0~uWxFN1&u7FH`cGvzMFR*Rf)pYRqXH~$9(0B3+Y1eWxG|Jifa4U|Pbd|{V@^vC zpqjr4P+O z5sTt-%EPqR%7$b{an(j#W*!I6}QLI4y^0f?jKIk(49Y1_Vq#{xglxc zZG2+afd>PLaV^3b2cr;J$ck8*ZwJJuu^zU3r(p178Ytq3g&XW$yn!JbQSj}QZS0}! zHBK3X0w^U18jj`Ue$waz0f?moi~vIsF9m2uhH41S$PpPBGBJ@z?q?sCcLN3HiISWo zwh|@*1W^P6A3no-2nxmGP1iIm?S*-6O#j92Yvwp%PIc{}V6;%|fWm7cA^?B}v$Y!% z2o^u;#4eq}3<$7WEe%3SUlSLHz$>drFQDvUMv1FbO=Z9kPnp42Ic+bnLkOl8EMq>F zcrdFCCW_<(Ty`&0S4@Y7*89ON117`p0P_0`Bj6@q*Goo-%BU&SgP|QikMabn& zM}C8QFT z`X^!4Uv-fXw&bK)mylp8L&^fmxd#|9!x%6C zAc5H`QzwWp0SE<2$RUW`JhK&H4NMstI72cZfVejy6lw>sfP%u&$^dRYRba3;%jsp* zP6)38^xB~uBpwh5@BwMiL8!1b0fi32HeS`M3W+FQ!W~(#c?+V~N*okpL=qOvcz6~( zDj<~;CZW1mm=M8_x_C>lfr3vmmIBiGRB{k1CA_& zPQ#u5G+Q8kDh3=AaTIMZiZP77(g);_@lb$392uZg1Ms9CF#|~?0lozhv;eOrWH_Ay z(btF2^$mS@Vwp=|In-t&^eckQ){4d-tRGO4?n)T30<80H7P*=6@JsQLDcs`lBypru{$XO7$l7>L$Q&I-yq~an7sP7r4 z;9Ab4@S=G^0b_$Uue(?r3mh z2!g@J5Mu}|hCz@R2ubcRP&5@m9$^;aKwyX=;8;Q+gJ84ZvhkuOkkp_nu>j=>x*wXQE=t zS|qO@OIcSA3(UpvI5;~X&5ebdNBawZPJ64gsIgGG0ue_x226<34>A~>*kn~;jSa#X z<1-`RqXs!d1ZW2gfdT@g!l#pQ$B_`MD@5x#sNjSkDquX%hA@(0h@emy5L0?9$8{%m zQZt7H3Jy?FkQ@YpSG{MFI#j(%Ae0JaI^PzL*J9?={=(vh94a=Wl*WKY%N8z1ZXG^qNl~Y@bcq?V^G1z>aokoy zV3e91eK0O-h6MjanWH)K_Oxn40XvXJhb5?9c1*1bl}QyA{3M}6CEiC)Hn&E3H%&5{ zj)jX03_wOqnBkpxtkih63Lq#RR%jA28;CQQJGN0>tmZ$J_qd${G2y^N zSG@vsN;rfgN+dV(cZ*fD9b@NBVjkjy05o^S8Fl1`ty>esfR?O{8=YAYAC@d6vKXEa{SXUkTTxK!5CL5Pl1?hW zgv9ejl4|rPdkqrQOl33(9E&epkwiBwJ!it@ix;x?K^Z|VAcv459Rx!Jpn$<>Au~h5 z<_%2S!`1#h2IGo9gvfABAScgJ!=4)u1Opz7Lb*^>HENwgrCM4E5rl1oZvKh*dVw?Ho=F~VS7Y;!9w7HcmmYng_2?}tcU$qoz2|HC0r7N2%;Bo ziQ-`s+tHwdM&N*8f&9bp{I^HpJ&9z}26L2|jTN@St+Wu|3gvwRiLjh45$i@5ML1lkityi9o`57gs}^Os34RK*iQ`1$wT#-hKhk( z2pIwmpopp66o$Ax6Q6((Jq966JCgLmnK=)@%!A7%g&>A3q;LHlGG!fsb|9!G7ErhG zI8Pt~g=sKM0d~cbMiA~Ri+ith5NIGcL2)opun3Tua%HZaLMXzoWD$V^9fewS5O(30 z504@0Sq;GbdJ__? zAUI(jfs`?&$YO8;neQY&NU*92Ez75taIO8&HqStzvt!1IA1%ARX}cM^?l$1iMfgDA zf@afjdL=R~DHF|Htf{2XX;gF=q4Yzj#!9?iOu&id1kMWOmPhpY%dq(bnq(vUB|z0| zQml!vp>Y)plo?JBmx@E!32|XTouPDVN_k8jW1ZBk%wK0b>h+2tQ(2)sZ4A zv{_LigU!*%XMDv-NU_eh8T@Jr?5d5? zAQW0IhUyJ2Yce!Y7myr}FM%ATI|${litIZ_SDInTIE$_*kkb7783L!?`YMEdSIW@cN6 zJSbI~c*4wIFy~_BPRZw_iP>n>;t4G~Q`d23S9o!$7UK?rCxu8i;)MzGOxVdYI4L{$ zHiLGC+O9=WTJX`LQ{hGK5Nj#XtkB^)MyHG|5jSLU)g6>^lxm0;ZJ8}Hly`b$Rgl+C z7|@e>(bP}R8&ay}s9{5fnL`7Qa|YBBela7FgL=d&O^{J_27Fmpyr;DF@ui@fJEXdQ zyjiVfxB(c7Wxt4aOpok?s&EI}kS@wqHR|Zl2)f<+wmZERgW^N?3S49$M2s zqRTD8iwYh*8yHC8;j#j@{O>7`sfWoGEn%>D&rMjecsa|Qk}kBLKy&n7B$e=csIi3W zl*yd8#)^b?No%JMTJ!-Ww|(O! z%$$t}`liVlPI^2@Sa8sbaDiG!LuVG1*3Q)n>M^KSImy|}Zys`m%Uyl%4jk?r>md7L`fA71RKPNWGjb~8oU`=K zT<(g1%<>=;A;g(Ug~3596U%*_%NAI9!UY*Pznl$=3Ui)D%sb9$mxt}S4QHe81XcUc zS8+1KnZDpi0udR9BA+R)RgFPCY1HA#Gx8*i8-j;qQw|iTlg{=%#eyr_NC76D#fPlz z#eu-U3dNa6bSBrqxxwIV)4emV7ipZ8R$HWhR2t#k4{;Tx1bqBiPq|;4AP$!OhN_a` zUgbpvg7-&YQ5)mv;Lbix^$Kqn^a_W0{SoG`^M2pQ5J=(;R{2vXgTa)4sTa?b<#9lF z-MfIILa46~zr2|^eZ-*xYSCzFWhPIp(TcNvQ;Fe3$4sXP9S8|wAxtDVeZm7m2O8Q= zRTa%meQMiab5mNiZLm8~fs(ff9TJelk%X8RDVZrA{M5@@^WOf;Cs=oMI|ft|0QO~R z7L!@}fF;O3AS429Ogp4d$byR_*bEw$)I7ugW z((A7>mYx)_(bEgK_KYuwA~Td)D|Hw(2@K0&Vl-|RMv4@&Y*gmy`ADS!Jfr4Yj}0|d zbh}ClNiLTB#9h5jnMt@on6WxR@iJ2G5F!g3aG+eWEvW8N2?&QxGl7LwuRy%C@amvn z!Xsw1VNps|QSYH1Nf(_jxw!UU~@yd3IiP4gIU1F`;nw3?EU?nt)aQnnef=6QUwXBFyK(!}AT1jucXjnC zlxiB@KS(G%B0v!l6+WOOLF;%nN|s)% z$BzRQ?>tTyKFnT8sJfiEE7E2r*J0u}m~F3{atp8W{&5jQEF6 ztEC6v%1gx7tX!CL1*OPTE{2o=FQho)*g2EDzaG~J~1--SZ z=hG`*t$fYqJS`!lEap4_V$DaC#e9caWXHC_`6DkijS zw>3QeWdQDHTl~xvu}DOK*YgO3z=G}>g=){zif*A~z$$5+kdd)Z1St?pgJ_s#EEmjD zoRmX2_ko46w8d^`9^_FanBLgsAyNq~>1BchDv_pg!rq9gZ*lB2H;{4;QqM8B0>V3^ zBF$7S0ccPu7T3%zGflA&a$q^elulcENvz`Rg5ykO9UZv~4>m1eUp80J_f|5-h#(Z1 z%N&JVNh84nOoVWid=L&n!?H*`6fh|k3Ij0Y2h;ZVjF@c+HwR)e%Pf&^Zf$L1!?RIP zuy+wKK!vASqaL2^5-eqKmQq`uY+ACtaRd=Zykay(vge`RxSU$m{EX?t|fM}yso3`YvN2tFF*7a8TS@JNtW z!^yp1j-OMf3u>N-nxI)=2i61bn%6h5L95x(;-r|eG+hOO=89tw)YoOan;GaV^B?#p z0OZ0WHtF_Cc&W#ylyReA>9(Qd$mxM);w&6U$Xc0VVqq{>dYw7}>QulmJBrjw49Me{Xi}ChbrGvL&xlBo;Ezx(01Gu5TF}7 z0If4>eop-Kz>Ad9KxoH`BWB|neF5qrMHMN(8`S-eiMdQt7ix3+#@eu5(0s@%FF~N_ znD*&R7*q&RWt;67+TmCgSfb0ysFLbY?Z880^^0I3Tnm7UI>AxUxe|b4xSE1fCRu}x z#F)>+T7hw(utBnU&2wx9w$z6{MB>&&&)V3~{rw|4>YSh$&NJD~Fdu2-Zu~gx?C9L4 zE&~H~OCxlG!Bx6|peZ{|0d<0UtYSUelrv3_4;1wQRV;c?Z&JhNgLT<3t$v*RYZlwiXfy$Wa(U3fRId3gp^V* zAmyeAnFRqXK?EQHMB#98mP!n?jMLZkjvStI(CX7M0^;_4H! zB!$1F8h0D3MS7I;3)b_OqY`lC#kCu?j&a48$x>f#&5;oKNJyAiy{p$!x3b%p;qD4wi7oS2} zcTy78=;40~_JRYFWg)AAfkkNvXzRS#KX9g-_w;||t70Zp4pp=u*tB-$wh`151_XjB z)r|xPHd?QXMG-R^*1`v2rkW_D0pNh)096r?kt5JYbVAX_n+F#b{%MZG1P3zt%UdD- zY8bbWtssFKLW}Pt2p|Q@Swk$>;rJz7&_SL@Y8w|MEsvt@4OaOZ7soI}5g3FK4H5l~ zczbAk`SNzQdF@T#WvD(kChJkJZ&N$21hd&9ikM3%{JgL*Kv9&$Nr`L{c>R6#Xx3VS zUPioitbHz4^M4RlmA_D8M5T1luO&5sJW~=~9-DsY7IH*cCjfY=HT&WwZ65P^xBjoE zj^;sMiZY(yE0NL15WU0V1NJ!v^Ad&qR>m(ItS(ij~14rq68vUxYCQ5J3eH zos~pnWTY6RL_|KW^s1u!g;*3*D8+-(I3g)t=LQ9q^OgBnT^ez%X^5>d3sgKD(ygq& zhKgkzPL7;>5fn(Gosm~qztja0L{%|yCai36VqB-s3d6v%r{ygG#exFQ@nX0@amZMr zF*XJc2oEUan{wp;G0*F4^m-=dwgG_p6xf`=E#D|62m~+kc00OT}Cg< zOf(L)%=Cz?NDPW01h?4;;**~mO;nM^DhrmKnmY>ZqZ??Bk1-q|I6%cBiKF5i&^9^l zL|BkpCp6dIfarjjkruIJ>K0Z_O;kd~+hcQjXG4OsE>MIjTVfk&t$^p_JmjB>J)J|T zu)@30sv9F?d%m!uD_fI49w?l3d-~2*dmoO;df(9cdtrYjMutb!Jrm>EHW&JncEb7) zk;kQ=M>la?;0BIsn_SnB=oQ8Rkxog87qn)Xs-;L+n6*UDiS}Dc9k`1^wu!sUUa@<6Z_ zeB7b5z{d<^6o6X+ac@AIp5C%Ui&M!lYpBRroLaZV3fYV7U1>REt8QCf z!41j(?Qvquhx*SJY@D#mCeYdLrs0%Pa?KD^N_7019kRDi6Rp^Z%3H&vs!C)4wx~^l zxs_4sGBpc7;9t6sUuXd`nCu%|H+X~8jA{krWGMGQ`O>q0X6N>&CP&cnBw)L^Q-~mh zC{Th3AcRB=N`WsWMI==;37UdESrCfYAW%RvA;lb2AyKjl*ab&~vnMEQXwZt)H6R0i zj{$VlPlCBtp?2$S+F0cx(*zp`9860^wp}t}$jLC6jv)JH#o`ho6Vdv?81f#0!33rw z4O$o=xHI||CCzREml0F$qe-uV2o^Y^7M==UriYWT`Y ztP~JWjJjl{!UQ>pMy>u`8rRNH4HzK0HV+4CV1c7@!qrmlVqu*8L`7~idQ?0;HR|0O zSTA4KlJ{zG1SCc%it1p1;POHiSkcM1@8yp+F@Pc=ZLRG;ZB8yS-=+vZ#ajdn!Xh%q zqED+8%$WE%qR(69-Y2>BgfKwkL@k3Td~#2>N!l+#A&nF1v$6dxpr>1# zF7V%8p!)*!LuG9Rl!dK{k=S_~SOu*#HJ5NMK$!6-5+f@cc<-AYCLD?^Jq=q^U;%Bh zJdN$(gXU@l5Kig}k?i0nd_x6eo9?ttzC z6w5`|;rh(w(xtI0+`t241XCP^jB>@T>C&I4a(PBBx0vvIOJS|h5rE4;xhTbr6htva zf^S(Xd)vnv8aV}-VB>->B8{WQJ2eM!$H>n*VJSyJt75X9sQRN_Kp30P>FNxSPuF!; zXLhUtI08}-6#)>5LXIez08+%rB~TK?RZ0X9K?p)1C=5JITJ)Fb?8C z3V-- zIW;&D3{gcbK`r5+Jq1A&QAJQi6j4D76tY!|dbI>W^BkZHG{$Qd2$dN7=(0-YSQ|(8 zIV`u21Q>?wf`^X;3669eXiBvFQCL^=s|b=b^`0JQb+PI($$_YHP!?D_Rih-j&P`l^ zLr`9{01-jRjfa|1Et@?RWSL~c*O8i#HEn{TG+Q1>LqWcal|`9|p_W8e0EGok3(UpO zeFcq#79}<~-GHz`Fo9rd70TVweTjhJBm0`2NhKH_(tr+qGt)iOH%1}M&rfvS1Wv7 zJgnbM$#G!M-I;6<7$G?MKQ2`h2{1sQgK-I?C@dBvQ3R5un6%?r7A84on@rh^@GJ%h zjyVU8IEoD!3OraKFhqEn*Z)?%xai6z!9~*gQ?AdoI=W7$-r||ov?%(O`RhPEE};A< zJd$N$RIz%(T7n*R2e;hTpr}1N-a&PQvDH~$E42qgr35}D!(dZ1l9jl*Y``(^`ufVl>yn}6l3gD^MuDhU9?pP>~=8RrjQ--hMONLYRBe@ zY=o##r)(Z64?cd>w;z$k_=3fR&AzqKW7fe3f)9iX*%vhl7P5IO9tZ?)#)#GVS9_?2 z&Ao#J9ta)}FXr-#m)gR>aWZwPWwxNf1A)NdBHCa>P(YY+e?MT$Wo! z;l_;=eIKkHz3hHv6|u2`6A1vA1GL8c@GnwYiWQlcW1?vBK}+q>1*HV+k6>ztZii8| zOVn7N7$3fm#v!*RgCsq0v1p(enab%W<|mT%PKxMy-M;hwRJSC}M*1*CxtmMXg>$CLP4uPc`Br)UZR8w>B4Ka0*<%jA|8 zt?;~(fGMN`>Xp(2Q50^D9aE#_I#^)3wRUPm4XQO%Xb-wnL(IvC_uaK9$z2)(&0znf zz4thAs5!8Hi9>euLlGuwUZ#40}^I{pa-F0wCk7kpb$%ICQ^1tDqw-*;vZm> zv=&<)cPv>uE^S|A{+eHDMi50iScBWlRtZ&L@Y4>R>vu zCnT2JXNMns2nHlV%@edX2qtb{cDOCGvFg8KpnC-O>`6OkEGrYpbG1B+9}@#mRj8;y zgB+kH!;7#j5*@_f`ddS`C3lmOmd3?J!Y-!7Q6f5QS{tS#FM^SE2$MUdAr!Ga6q#a- z=<(Bgi)KZ(9?1ASm>}MqQ{fhMbF~!?WxXv_9`s^XPx|(f$Miv>F$^ftMq-=%vAByq zb+OD?qah>HtQ@<4<7{pZpt}SPAmfaSHY#&#iuI;7BxyuNmhrDNKY}j&nXQ5+Tw}$g z%k{K8!(Yp2_Qkgxu}o>x*rsIfRzHCkXWn=y_Wu$O?Sks zp3!@||6E(3KSF!^}uSSQ+4F#KTX*!G+1Tm!x zWJQ{LT%-_&I0+G$vRstxVm)Dx6ax>_!q7!Q48%|o07JoyoJM3gV^nyHk^_-o1%d-$ zmP>d5vP>fCDTVBQS$$;(-6HwGUPA_r?GOm#khCz2U7!FU05X_DAOVqp2pJa!VDNw}rI<`J5fH!xKwuL95x@Wd00000 z5C8-K7yu!F5C8xG000009smOXU|$A(#=y7_LF;bOnJC0Er2Pj9~eIo&W$q2>=Ed#90gm zVjFxg)*u0`We^YqgfIXxYyt;()S2tD$OR#o2@;TCHvq?j6TkuB10VsA0JSlQMgxF| zU<3dF3;+NC000;OJfbYXkNV3um=%l?V8eeL=J*6d0fP21y-pE8X68BXNEZ}fOQ3R6 zdBg;&M~JXaNGLu-5+DHF2IByMfYC4zP=g$By8tQC1r9N}(v4BToKcjOa6(fEWD^@e z00G2MF&sny(#i!gMu0nwjk!$U4|Jv-dOu{uF)=gt1O*1ZK55Kj!Nvk38^$mJ6EHN) z1RyRTuxyA~1J?nOi(mj?0x$qD03Do2U}O>@x^pl9FaR(Cm;itP00000002V)sel*& z9KZko00Ec)zyQDi5r_-~0ALA3U_lU|{f` z4;eEP7O+#2V$q}sN5)_+fXwXyN8^Lz7~e!hZcGHw&b~B=W{|k@2t#9zI55RSj8v2s zVTZu8Ar}i7W+Gz?%GpqegzZ#U4@4m8JXqPDwv5jrFO7rE9stHOzzk*pa2Nw82eueD zgEYWKcmOZ~m;e9(FaQ7mU;qFBz(61X1_A&e003YBU;r=z02lxfki`;#U^5snfVTh) zfB*s(=NM>U0AOQ)0N4Nk0009300000V8Ai}AOI!+GQbD`0So}Z06+l!0Kfo@00IC* z0001G02$x_0004L*0@Mh0>LFQs0Zo5EnZFr6^3Vvg=SQUpR74A;c)`0q)-`@+Fqvk z_VP2>ijXNf=FXOAh@!)bTP(CMTQM$lr$oZnQ);LMlvC4zJS^4^rRBR zGGdFNDc(1{L&DU@EFcf1mqsf9-{&qdHftvrD^nS?BwU3`I@NCG8a(4A8`p84HNE=D zQq2^`q*0X}Es7u@Q7cG=5Yb%Thr$VDS#u5N$e|RF)>-)4%4_8D@ zaTfI|7jwkGRCvz8K6#Xt=~5&DNQd)4tFD}Ju$oI9g}_3Dl9{QMjpafCBEbo#oTdWT zl26rPP3Q5TgDEYXxwTDc-$X=$mz%N%XdO~W7J?C|-3|^;vlg(xUY2E3jGb7!!p{8~ z3b0I516FVV00C+QAPhqo2mk~y7=S002lB z06+i$-G+10@lA0t50h&O$=3bZP|wL@*6jKx2lg^rI-$j5#;s zV1Q)*K-J9P_ZsTr9#bPAktF3$1ZsalP1M-r=Me=N61S3avKqi4sR8^^<1c+JhBXv3NWGrWB$h#9#ir1o$c2k~&1l@wy zMFuM(hc6Ib)Jk&3Vusf$7v9|T`Hdn0jA~H7EQ(GcU-F3`5(SGf07Ny*DC4JzLqkK{ zlz3|to6Q`eL>c}QV^AO@Vi8^@n<4wqbOnzYu7pR)?6LP69QC6l3LwA6kcOKBz@-w` z-4yW9R`N1na|YC0M?`_(75!&cP%rJ%wejyO-c!hv)Q@rFVeq~){*S{A86=j9zQPGx zkpz|^@IynH)Kwg{Hll7@28)qm6z^yhy3|-OPll{WpQ8bR0*oNy%O2$r;JlkKeD#qe z4B~7(QIeIMHH$D*ZGuLeNhSq?3RIfgE<;Q}2^6SxExgi6x)UJmfHl$$4j0aL5Ngne z-wP;DFA^u%=sLnHB0H+r3LFMZj0fRNL5Su=hs#kT-=h6dc$mVEW{QNM)m`FxR52vP ziyTR!tNYF?WDr#!*rZ#Z9Y3y4m}Ed$6$128C8VJ&p#|?7*g$z`h&=$0>g@C3=|ngab=4Nh6DVNx5AlkqzGOm!+(RF!28c(5hY zYoP?$&6E*VpfS3_5e+h%?DGK3LXY(69+0d&$k+=l;Dchk?265&TA=eI z8uQcnbyl!Yd)e$$vRlLgQy!yQvGiDT0YgCqiGYte2I16gT+LVU0dvsHss1QLD@TyX@pBRSp~Y z*ee8WODTVDj#u$G&gM2`3~c5Qj3GPe>sO?xfyaEDS{BTq`C2uQTSN>-kG z-idW!IGzh+afNU7gY*u@d(Ig9oWh)exlmhJohaCG?sqc{U+N1SlN_@YCEoa}u=fa3 zX$#$8zu%(fo9*a--7S>E_*xH7qDiqUScC=2Y6C(Y54+CTU`9w553Mj7M<8Bj=q{1A zi%mxTmk4yKDjN>^g8dNzY8hitOLC-*B2A{&aXG((2AJ3%fjDc@^!$W03PUVVOoHu8 zjrQoRkJWFMR|yxw3*;fotn8-7|5xJNYYY0;Aq^4^wD%7W<$vOjLOZh`k>Xkz_leBy zr!pE8E!J&2{3yEiPF)O(Cxh9JVn-Q^GW3p;xyy8e{XCNK-iRpT&1>Db;OrVeHkOWI z^kRx}3n+E2RwLr{|-$i!wNpiw%vom z6U@R~I$C`$tmoNTg^I`&e$t@whj=BGat%zKn=uJqlklrvmlWu|vT_X*Jjp|o=M3cm z?)FVK{CXX_Q~Dj|7eFyIS!wv9Ye=5)uXzDB6v@>DC4j}KbUH6=hiL?z^-wDt8HrU$ zC-P!Z<0!iE7~~y;6(VMKnn4FwjgA@z5wN5U=R>Nt}Px=tWT75i(tB*5iZIL{SlH zf}to7?KVsk>@t%*E4#)cqW@Y6OHeF}0?(QfqGd5AxlT``KN4082qJO0773@YCZYro zIJvVc>NS-3#n1yIL@kP^H^P4^yFRi|-?>s|Yf#~z%?qG_>GVGupBjnjHLulD?^VJn>?1JfcN&q)Z!0q3Z}{5H2BP#C#f?X2pqn7c#~oA)_JP+p!|xl5~nv zK3#r7@hBYRC&GI1Ds*>YoJUOzn#1I3vnL-L5HM}Fs&POl5D3JbA{cHdWpb!34A3un zX=%b|`k1Z~gIWs02a{3Aa74XiVSxnEmWV?}AhcX#x%m1u$o&?15T!ybWTO}m@a&kg z6o-uA`Agm!ni()|!UqAYxZ7i$&adA900CZe%0ZHVBduR9ZjKV; zK(F0hm3Ont=9c}ccLXZ?G;vo_ycNWl` zc(&rgO)R7*8bkou6Unv}+f#1!HYdq97Lt5Iik3E(^$m75!fqrq;|Q2})`@b&l=T^; z*__r89>%ZNSfQ%Kos!qZb-u+L{N+Ct+VQ7RyRAx%X`Z!{5)$b&_EV(VpsWFaRRZJ} zi9tUU6chP1EnwdY=&}T|>*{3yFeM3VXA%n7f^xyB>}-q4ji8Ck;|AQu(1`0|3Q;uB znH8*|V$|5O!pW%sg+Q$>8i^clA4007tr14BGU%qI?$(SyB@N<}fB@ zebgtZeFwckT2vKy(`ePAJqTozdDESRG1K|6*l9Ws=+n?AZe$h?(NpLP(3h zJ`*TdrMuF$939?hZ*C+PBQ)zld=f#)N7Z_`?D)=^;kt`@&7Tc#j=*N<`grWq4qu&qnW(drKwalm>oVuApEGgGTim1RS!vo=^;pW-lemJT#kIOX z8q`y$(IY{&H0~)&&aijQ-)%a3I6q77UY}y)%J!=*cZ;iZkx$j}CG0bfzU2>|n5gXe zYRS^mmi-sD5irgaqB=pcTn;=n)@@gS^<{{qyjY29ItE9LmG0(j&G|WLe4|FoMsrI` zPIDN_b`nnsg?)(geK{MJQL;$QY$CyW#Gjr_`d~C@ zZAOpU*=-t-D?IUc*KW+VU;mY{y@+_ls^~fEvw0t3?_WXV6uZ6@D|g^YzKZ|&XRY)E z1Bv%#P4iqjER_W^`k&A}emXbSrL~5gkhb+zmc7#Oq|UgD^=ld_cyv`Og*?6TIl3z+ z#0<_c$@ zl6IgwoJ!DTYYH5uBU0Kw&SENo3Rw4)1&%voM2H*n>IM6$GX|u(0u0hV=xO)5V&3^LE}?>S{_n3rmDKCN+DrX-iuH2I=}io?FYee(BPIf97x()&2l`Rp-^V zZDL`y&Wy@QY)M6J=Sot<-dOXf`0I{ZLBqAO7I~19BZGMim3^&e_iY*R%$S*@Q%sqV zlH`mz7lTQ^|KK{-mZd4kj6Kjirk>?g%1MjdOImZXxV=XgD2ZB!l5pmyR6G$8Q^$x> zEL(T$$szu0ljiB1HGUMi!Tal7(MdUR%jQQWyc%atYX;!DWt&d@)`HY{L|rF_)~%N7 zin(dpq(DQCwp^KNrm~Z=o_En)5i43K-B>D?9nPaH)d2KV{;w%3QE_-S@6_;0Jjze?Glj zBt1h%>1igs|?hLxYrk5}N+Mh=`ceml$ zoDP`Ee)giN$9vTP$SQjJ%NHSWCuzUWJri?TN%{}UT;vN@#N*a7$4#Pi<+AD{gL{ z#Ty_I2W53b8%Me3S~eh+Co$B< z%=9Tr-a7MBm6&tEyhrPHMNuDtTPdXlb1X?=rvvINADS&J?LeDcA2V_e{N;S5tJM3pzJ?XeW!lF1uKOq%Rwl*B)R zi7W~uuEqL96^qcU+3Apt9g<#B2w5ku$DYxB%0e?KrC}?`UVvD{_d?{%P@q9_u>zEnrX$@R zr82sA5M+C=J7+VP5b_x&`^M2*$Ls1ctpc}lJG-68?lZpRFS6b&ZesrCBE`J_TGtlo z6z~l}J-@U{Z!N?T;A1FO(^ew)i2DLLL_fLDCG>y!sM-UoM;X(^K!5&1xzRV~af4^l z^1D8hgG&vJkr=VXY#Fe0QfFM{4$_`NCD|EI&l}uG`XbKCxAS{=bGPnvdQ|Oz{PDHC zaZ{rz)MS)pV@a*m(YG_BbGuC=+=s`wnr`^TNoOPBwpa;X8vX-={MFH=Icj0^kS=7N z^3HOfx=L}sV>c|8>0Wi_Xn8I7ILHjG}ifBG@@#BmX3Ic>_SSSMoH*b6}-cVzT_!BANT37y}0Fkcw@Y zn6`-eWgDbV$6l&@@@mEUVKJ=iMaoj13fW1^Lfg#bk3Gf{{gr%(zw^(2q5QdO^E{W9 zE>p_wDz6c$x~uMYMJ>^uGu(|1sETwrBkjs(3_?yRVgE8rChQ}Xz~`bRlu;B=#S=}tq+oQK)bpDEGn z1E_CqLBF^efvUjcYcG`*7}d4Ck%w7Yuw8W?wSQ>or($SqjYtt16a}<2Xxh@$tr?j+ z%#(w+bj+pDVK}H-lLr5;SQ|yBbA-Di6DKr&$P!~SvcdPh(cL8@XxQ4&f7s2;)8>C+ zjp^obu5{(Dlzj%=F5BF5moQiodfvu!Mb4$_{FN$SgUC6(dmsNd0Rj%oK+yHj$=Hn`WBH|ZlOlW+?Dm`*507NXG*4;6GBfp9Ngkjxav<_v4$4XLUDx7* zT#VoM*LK9|uH}mvQ*_>B%^TkuDk6Zd3ecnQ^AJ{RV>GrdzyJUNai?Jfte^}(paiXt z2__6N%!H43cKY*nJ8B{6Lb1Kp;D_}euI#X+S!K|G$N+Y zrnW_;6)wyVGb&vJ^w(um5y+Tg6F^v!i$0i-=~-O=;E|A)-iZO5qXtCxkRK4M;kFLN zff^q)2rLjotWr}}ja`Ha_>o8ltie2p|ow!t8-) z=L&ve_E*@1-MO~J$Fk0yWxK^0vwDW>WlJ30O*#rp3O|4Wl$_R8!bjND7Z&W@JiIw^ zl6e~uH$Z}Zobb|6u$v3UP3l^X{sgZWk`3AjGpi=2)YyH1jt_;tQwtv~1YoLKctX*H z2E?{OJrdU8ngsTfS<`8hPH8Di00001ay<$tB`l%P7$l<*h64Zq7ytkO#sVM!3;+NC ziDgKpL8u5p97Iq6FaQ7mpg{lt002-b4agZFEet3?7ytl3AOI1~=)mPP3`l?gCcp!V zSVlC=NPv667YXK@?i%=R+Sj$Io-mjy3w15jwC?3IE>x;krh&s)CKg!TH$;y}B+w?J zh&=u;b0~t<6hZIP|)(_@v5DiGl<; zLXVN6>GBL}1#Lw(Ohv=Rr!NCK8i2Th1)^dZV@#jqE*u9;LRLBd{dbU?qI46jnj~rS4X44K69FlnC0svKT|r3E zGPy&=(X|x2VJFIcvZoRP5l&!LP86(>mDo*q^?8~1%f9OzFZiTH;6JG z`Ma%0)P`tnD+H}87Pi4O(Gz>Vcf>f_jEn<#xg!R|saID!X9S0Da?WQjP03x|jg$<; zn7SjuPQ*BhIWKN$W{z04<|lf_t0BZwPJkE?NaG<2ew3Tvdo7XZ(Q9!iAv0PMu&F(g zFk*>E`^ySU&kiTbr*P1O?0@jJPGNxgCTs#?qE2se(6l^YKVdR zV)#5!cf**BS&Mff%+Ct^{nv^=j#dgiT%y`K$kbIO$$U4-Vfbsa-UNL+F25GGl?og& z2^fMQ$bGzNcA?;(6rxZ->li0s+b(>?0AQ7xQg1JzAVw9Vj&Ms}t8fDV31p?(USM!$ zj;Su!4be{i0c)`&wCq1Q)B^(9`fzC7n5U2*00}k>h1=MWVF7W^d{co;l_Q_x>B~0g zP3Luk(l~cV-pYA2vCwkP>O8fwMzk$O?p4(igoLyvkbMAljD;#uu6Qmz0dNN4JXBXq*OvJm zjV*t`$Q#7`6o;x&yuggJP4WZY1*d46(Py-&D>n&5k0_&;pmT~}W(vZRMUkwHWi&%L zMiJw%Lg+c|3w4(?Y9$)7{gzvD5-5mK7`+5fl05$njhx4fy~;3xJrM-h)LOPiReo`l zY^g6nLT$yI#A#YNc+Dy6+M+H^WiD_zrJp%B@DU@eler(3U?x=lfYt)k#_qe=s7udu zyOOM?h=~isH@sCi-G)T|N1y5gEEolvA^#!N(mL`fty+m}h0!Hu@AslclC};UK%L4P z3Og)9v49{z5F*{01`s7kG=WokKod=_!}10C4TtwF&ajp82w*|=p^2N7*G&uUlCEnD zn9`SM?8y1+(E-`lBKi<*$Ss}J{{g`j23i5(yi=i?)?jNmiipOOqRD4Y(m>o?Aisr+ z5e*ylcrhR-0)C$+cP>*V06!j^va605Xs@Lov?R(>r&2{Fp#n~p*vjxq zt01dGK{hwrTkUZREs?yW`9DAkq3aM=1yk4}s|xVqnidVG$ZVoeg*#Ms(lm`ToZdQP zMNG0ZgAnuy^@&C-cre3J4^=&gg>@ykr0gL0H;2mxXtHh(1j%Hg)U^=q%;p%&@kLnX zcSDu{z!*#vQ6ry9x=Ad3W1-NIZ=N~gMvinY)}B~^Wo{=@R3K}wEu*(iGkr^m^09%V z*4X$IyO!zp-|IwaVrcX-+#;4lcBhG2$M(VDkTm?~-^fA#x3v72^Fe1_{oK>qe2Kbl z2W1*TB(h~3@syU+x{<`bYl)wl1B4$eXzwbKP4Yuq*=Tu{Hauh>y+Cndy4J{;C4q_X zjX(i_$Q2BZm#l)3Nuhy7RGgcp?xB`1Yd)JnVl;F4{6r_Eti}1rxY)c*_Ew3Rd_E|& zab@6D8A>!rlcU2ntjfz}BWEhU8C^Q~Z!}F$Fe$$mnT#Av0vSLsn0Qw>i^4cs17(5k9eI)s>^bvz0J1qZ21 zNnCgXu@h|9`GK zm4W$7(%Vi@c2a0t7)iDO00DC+3qBzK8jm3D+NJcqzBPRsHmmF=7o$<~wHoDMXq2Re zB6}ed)H7s|yBdjPia?4zEJnLYCpBrIMe0>FC?FJ(3R6W@2%T|a3iSv@31w!B6hb1F zC}0E;th7XyA!UmMq?nuWC8^}isFn6erKY7t&6Y^1NFgf}w95vHNRw%-rm+ej6dghk zp=gDD5QPvBwU;EyqA5bjL`i7L6)XgbAfkvNN)#xus8d$6Su&wtLW&`3=E)V7prQ&P zFri3fFhZdM3Q{bR$U#^i#N;g`TcY~8pb!e^qjRN>PIBi2_yMXyvZbw`ps_Tm@rIqW z?15&WC<&XT)6m=w@}iUi{VPG&_~)|SuZ4ERut;8ehykvasxN;joD^k1{}QtWA{j=2VO-fO52#78*mAPb-eMM4bB9~uyk2FBDM{g9gebreVzz) z?dT0KIwLSP+;393m{4XHUC&*y+X2Jq+Q};;J_}@e#x4Oq8)aT8j^^4QeK0V3vSi-D+k$;)dp6%Du zK=iyMwa(9b&xg#+q7UW&|M~sj^613ag3C^hoiWO;>-#0P2KC;F!_~7-PIs$hPC+58 z|2;xe>ffAfJn7~xaRu`_(_5iPwADOFR;|CRN8DVRJ4E$v6A`?alYC%w*w2#0iypKn zalcPL%lgMmrAbHn$P_{?3w%5KR9hbp*S8{zr+Bw=!Tu0s@Bf~)p<)??Rh(u=Wojac zQQ6UhGu2#<6!jgsl7)yMxOj_sX6?_VLBd&Yoi2E@O-x1FaxPr25f=N9g$jagV1mNc ztGhl-!Dm20I+c_})E7ugU8az znS4ZT@)i&8EpKLC)~tSJV(!b^5yF-|>ZRWl@y{B6+@*Y@<=oF9|KZPCIO3Kq^9yKC zV3ehUz4OKH^q>Rj|8f?t9(SobUw0-Q6t#!!2Rv_yvobOU|;Cqg$C(ZUEj~1)cvhcS&V(!H49z0?*pim@Fd0lfhR3$J(GEZ zM?rw#o&a%gv|of|T^tSK2hzb5R%jV`9@H5>slj!Em_8uofQ_2Bz^;{FkuJC8lVobmsM)#d`P0*u81v@_IxUV zd%K~}(26Xw+K3923lNUBC8*_{63eMkWtPw_8=-#-=E^-RsTZYPN}c8ie8_Z zCGDt*BP{^`(qH#V)X&d-;wyUxBTSlTq(4$hPJ;uXX8?Ae;6C{aAcmgjEZGD?l;oJW zo|Z7Q&I0*CWzQE0JR(~=esj+F?fk&a)ae&=6fTcYV=TNY?_ai9^wqq%Qm{8SYysXR z?F#xdQEv>hKE(N)*Eayso}9f(3s^d^g;pBz(G7?BZp6Epu0u;lW^R`JDYv(lvL8^!FRWB{g65 zR9wi)TqX^MdA6+KoyZ z+O_4s;?~z-De0M?O<55cG>W7F=(6XDQY$Z2CNCc%G><@_a@pi&M=$Mfp8$$Lb-%D& zC7&`@7oJeC^y|~DLCO!HJIla5d{iobmLt!qqL0fiqrivqwnrR^A2p2=8C^a}Dt_9F zXuVx}eS@lh%~yrhPndEki~m+p_?7B*G~q!De=j~u6n%6k)+DC*m9SiE zUwjp)6>^-;ay6Wd`c_er0~F3doCrIj$893whXw-BKOH5Ye5n(nX}Cb?q*NT&DY#f-1iy;d3w5z<#;7x|z-XZI7Sl=%m`ev|{) zMNvjw3ZCNThbaXH96X8Oims}!T-MI3FML2Q9?W}2f@^S6n0Z|9bT}UaH4bg=ZNtId zeIpKPBqRW_h>H4NOw?0p8E?jb+9w+&c7NyM7Ysnve&N9&PY3Gq*DOqCE z2(0v3t0ZAJlh(4v7dp+-w;4dl{pb( zPjs5(8rzX)gJx2|KKl?+h>nx-7ek-v22-Yz=@}CIogt@b%bb58T#7;bUNVp&?D$`9 z`dLqv7G^yU55KKN-T~HB*KOF!t>o(9zOf%Qn)>EBxo3Yv!LpVU7HlFf!~nj0z*q~S zfs3cXi-C)$=gZQ8Y+nv@42aElxfJHzR`9#QUKu{f#NhgUL$b$PFYbiO7gAl|C^gIZ zv|fQ|_Lgzk^znDlJ^`KL0{f!XpPELn_`Bd8V`m`oA91E+x2t-7M0m)*rMn-M@}A@L z0-Rivp9|v)6WnrJJLHM~Oj6jW!XD>L+BuKQ9C?~&epi`CVY~x13b7~phn9KM8YkY8 zoEMa&IT!NO%i5^OD*VFA%HZ_VMlhRs(R5uF3GrpsNDnuz+2|Y_mht<ZeMX%_9xY9*7SY0 zBP?{+2A-XFmiZdi=pO|7%!q4let(Lxc=54NvH zxT*BTP(0BQIX z3T8S>;GX*kh6j2?ZNjHgQT!p{z3IfOZIz2$2(nBY?nY zZdJZ8BCvs+zJN$cr7NAF7B!@lDj_ja@oI7=yD;Pk2x2KS*azbgmjSv)sRu4_5SFq# z$jlXKN~i${5}cAiHcofHDXf}=WDBskwm!N~eING$xphYQ5OvMp%jkpgpkho@io4jK1LK{ZN%Z zBn-smY!Q4Rqgc5#aPxX6N#Fng0eS@i2nrz#1_Bts000000000000000000a`0RsqZ zh5!Hn000000000017CsLQGfsd003YR01?X)7P(*m7yu*$oJh(kNe}QI?bMW?0$sV^ zeVRCJ6*of^!`lA{0aMZ8qeTf5Diu@`{|gU^B5@+IKe~1W4(L`0Ac!=0XBR7NxFHH= zwHY86D9kuSA!Up!^*Zx+chDD|7KZjQXP5}2!jxc#i^oVLLeboU7JR*sDkwG>QH5KRQwq`=JjIU068g33iE zLw}-Mi##kPJ<2sI*fv~Pyu*`p6ulDhq+;?2dV{>rCw*SVS}FVGM)3Z_J)o)At56po_X1;FkBB9^o8v;y@Jv^A%c*1lyjyX#6DpI8`41Ol1zWc9zZtOvev&egr~d_IxGG< zTWy{gn~9X$5+k`IQ4UeKgItsxE>1>qZFVDP|ga-x@@i<3~Tvv`Zy(#RA z#J!b`2{t1Q$Kl=PfGs!?5CHRGb@#zd0?wn652r&Q^yU9nS%;YMDf1Ru;N?=F!Sht7 z-k@2jo>Mfuq!;)HOgn{)ATaepDe)%Ov2%go{U#^`oUSzY_c%9GXQb(@hHEQsy_I z1R>^t3M>)f>J(A&dY%l|)Yu$t_g?I*?YG;PT)x~OP(Vx&9L5O_-=9=SI>LDuc!3{} z_8rl`w4;hvMdZ{72849s8eC54Y_ih1Unx4A3=c14%1!H?rr%*PpULLVCBGv=H39&F zB8-0J2SJcX-wc2dSfOnTI7}4Zk))dHUvx$O^t)Fnf=OFxRjjBZK}N$&M!^_Ig)=}b z$_w()=hPdnOCqAq)s7=*gwH$Pl&qBE`YG-fWp1g&IZXwE0h8tfi>09qjLC6~^}dAZ zts1l$7bws~4(Ul9;Q|wDO&ET~^4_qqcPEI(BA>+T?vMX$=poSeI0zz)?zk4`KL6i$n^ptyQc6Vhl%cp``YA%7LZZkPyTHj)mXalqj_#0i%mjLGZ-OnNwWQbp8Y$#%Y9$Dv;;+Nf!zf@MceW z@N^%UX*0M0jet9YxIkWXfON8&G_|?zDwDIH!r7YV(A}R8F^s3?IHnqH1p6&S`gRBp z^G3Ak=Px#vq zQA9iM3&@pjp6f_es&A3C9|MS>n+tR|Mqa<55x^7_Y0nUgE1W2W9XFi`k|VP#P0j~H z9&#sS5|mczXpK;{rW~fra(>1qc2XW%8ISVQBCw~_;R~hgED$cm{LV=h-BhClvqFCb zz(@u-n$0UQnsX-fxttEo&0M7V)gUKj>0OGn*+hWYp7z>!>`4%RzRwFw?BPTp{FVyF zA`1}{O&~#z+`W@NK|Y`jSbP=cz2q`>mliObI68jPTmcQy>qxV~hE{l3vTDSWr9Rja zb~O&+1cii(ld?bWp^8k4+<5!as6|YyMX4d!_iVOb-*BR)?|mydZ>_nb)^vF{yG8 zBc>xNk6H$OnnZ}YHv|J}3BDhO?<3Ipo2S38LL6c$9|R!A;IeU{1kJ0F4c9`i$`mh$ z;>niOQ9Q>qOKlSvWVwQ>=j`qsizI8)1kfL)dW)o&ywKLLt>!K;l;?;prEx?L-O=SaNiZGH3aXAsuBu63gx|x}b+z~MiKU*^ z>b&DJvVScI0n~tv`4z4-O1`Va0!aj|eLf=*;wd6xl!rkU?rgJl0Q+kJV9vZtLMxH8Sue7yJ`qzStptfrjl}WgsM?(j*pp0}>u7GK#{E7SiX=8^b4)`M z&#j1BG?1oRjjSwwZh?5QHOpMFrOBH%UQ8=l8WU{bs+TUb9Bh@kTgkm;C2BJ7C)bDk zDkLI2kUr?FwuE2gg_uhlqoC35wG?kLv5e8i?MNt+)F3Gc4aC>-yoRYjg=G_0RJ~TQ z#TLpUo1zKl^woZ}3JFc@yk@MTT=ZQV9YS9sHG8&|_L)zhMMM@XBeV`W@inXwfA@D3 z-QxFn7j^ISSL%Iiq^xoaaC0Plrq*<Mc+)=L2k{Obm499cO5EP2#G=E!aiLwn2w}pDZrEhDHcpae##VC>b;mn|?}VO-Y87!L zi)hY7ZhDK^=2D3k9<)<#Hp%M%Zrsk~<-a%)326ACv`S(a@z5@djU^)j{7|8^yd)%z zLFhY;n}c`4l-3~EY@`OwkO&q)v1igKy*h8(F3ZQE^VTAbSo$B{@M6aqY3KykIs}S~ zP^IktRK*U&W+{G~dq%+e0~eNmI#cHy0RDLbd=}~i0a3=ipj?z3yf4g;&>C_?=e}S2 zWd)*Lo#{}VvS3tT0{@*dc0uT(E-MKrawnuh)@E2#xscFdSV@0UJ|Qc35{MwYPAQR&q&HXvPJ|Fi}#wn0x?-t+fuzE{VCVBN>+lVGAd{f>a{2_G`aJ|jFo>%DRpW_ zKMJueUyreG^^y^7J414I^a&8NyfI(`D#qCLxnfg%LDD8jh>wM zm7lVk@zr}uViWiqTALF@{>d}gQpnet!eLa3CJmNaV^aw!hY4IirZp-W1H@-7Ha!W1&i0^~PmLm827nH0hf zDs;`8Wvn=T%p`7mI}o$R?56SGP&P4%uO!}*ef^L<50*pX$Y#upt7((5kM&)6_9JBW z1!fS-w>t=ak%(25I3Fhf846~F?8Q}UibV$p3I}@TFTvCXx zWf!~1(Qh3RiY$!Lc|I*G%u!5VMUT!d9x_6K8+^CTsqyB}|L&{LSP9U+Amy4zsLI1r zA0joaApG3X7FYCUk@a-s0}`A!KlI%J$!YbUU#P1&m~QO&jYlvn83SWB4MJRm2DMDdA?Hht;Zm+5VhH zS-J6Kc)2Z+D3_PGy&9xz7e7BzM8(yM(JD{-OnM~mT&Cabm2{2;^dA#+S;6r zpn<3S)grCSI+cS_#Onl^=)OnYVl2coXs5qJD9NcwSM)EPu4Vq>~K5E=vS3Ap{wcpCJvb2*sZShOj)m6;@Kl|Zs>p^uF z?Ul|TvA-rQ@S6KYWE8U^R?#u}o-Tjn$DVX5|DoTlPt!~vnS<=p*YO`irjMilPrdYE zp{53FnROJES3S@VKrUYE=8xLxTsgVUVOl;#t=nk$jg0qEEAv0_DgUc0l{7(R>d$u z+3Z;lTN&bXdS<($P3Gi$`JN98;@(TLSCRkY^ao3U$**Mw&Qt-PJ&w+rCsB4VPqMRt z%R<_%K@YqevNd#`39^M|noyPI5K;di4F$1^TS|C0+AXKevn4ajx{Eydng|n%|B!nh z_o3trG4_(8-*`S;tA(DR(>$s+HAnvKu?5y5aa>HFbGi3m;~FD8^E~-62K%3cov5}HTwX}|$-jroztNA)u z|4k8=ihXC(l1HR|c%R^_zy7by$%Ox=J>N*MJ&rdV@fm+~&6*Sm7+c9%dn92(-QWGo z7(o?`ySw<0*oq<5^aH)C6X+$8qu7-aiLE9kvdLNv3dopd-{rx zM?bAOY20+at51Uw@@0@Y1X0YQ-Tqqg2dImeq6XVOpYnBLjW*M??rQdXpT7l1dCh>L zag|F|Q`7dOgZ`NNJWlYav+igEaCf*6_31mXQ&tWAgidFUhi6(pQqM^DRsSV7Gh&ynn!~{~H#9 zz5n0y)}_-`q((>Oyv@WN`YC*)#GX)0WLK6XKOj6^I~rQ7y1Yu7D$Nlp$^BzM!=+lP zbmecH-`G7%J^d~ADob|te-@l_me)y2(Zs&1$ouGv^+R}AlU2S&rhAq`LL&g$kr7!{ z(kC@|@m^Q{y^UFi!m}M-`6Kj5jQic(nRodfBge$9+%IJ+%-Fdj#z^Z=AGyzb1b zc_t~KTPxL`qstI+g~##7x3{$L0fB?!2Ht^#5gkbM6dnw;3;-Yw34(X4cDAa2UQIvj%NgAQNQuJ(r|i0`fg@7L48&R4)KS6_@vvRv2kxYk6h z8n{@LOJ1nSdS{ZE(m_U;(?kLg%@=U$6Ac~=%3vxYL9ESIaM~zrbhJRA$WSw-T&KXw zrzTkn9ujz^+6WeHX2#7B^76-vp-W6!LeyKAJN9Le<6lGyOkA zrfDxtR#uP*GD3Wo!o^W5V^kw~Eb!28Tf=or+(mv8nFzHh7D)7E+GL_coYFk7#1Ju7 zf`n6GHYW;(O0}_4rvk;PsV*;5nw1cmy%b`{In-#MsS;!^zS?%Ul*a)=Lq$?gPcDnC zN_$ZzA%Jo`>CkN>sL4bWDtu=a%5hZy)=VHx9-8U8!D}w1AjG3bmM*1+*e5dgWqFn1 z`Ia6QYHgOiSbw3)Oe{;XQA5vfBK*Jr00Dv`n8jff8X*lt7=$1Ji~s-t00bZq#sB~S z02M@iG?Mvh9`a^WH84PekN^N%5P*Uh00C<$wl;!GL`4XgzyJVNGC@E94z$cf5S5JK z00Dpilt(7O6jT}bM{DSHfS6x7S;-z>brw4|`HE>INZJoz#pQokC!>uj60R;MFw}7|#jkYT zN5l9@GNG_QhErrwCN2pr%Z1dDTDgRha59m4DPoI-0g=gSPM!*Mt#J>U76M4gG^OY& z(PPU$lDqIxW3tU@eHs~Rde|(f5|0gnx2sR|%uglOo^LB1T)h*N{CGqXEI4>=kp{bN z-bj(D!O<6x^&jkR5^)22Yy#D;>BVKjYQyq?!JS3Y!@dn%YR=n z3p_Of1t3Brl!w+z!&d}L;gH&4BQ&Rkl9;`H5ucHKG7Ypc3-Db$l597u{Hqg%6CAU1@1iOX2$Zj_ub7Bt>7 z#O~9i4DUkgmM0Lv)5(pC>A6`j3{P?!8q58)SwoJ%!k(#Z#Dld|o~q!-M*9Tu1|fKx z9uhG&HWguvI9Se&i}CT!0F1C^0XZU+^VG3sl@1*Vap<8-BGbWKut4_NGzljqlNY=` zOeEQMowW<5pvqL~WLKVVRKJ=G_jVx&S@OBRh8}9#AdV0WA`j(CBOFkDU3NtOks68R zKQ`I*g|^-GkF-{O9h@GEsW2K9=-C12*&8MnB+hNkYDHRxHhx7)3cJ-B*z$~IOo+7_ zI>_6`(X2?twKJvk#epPOX+Y9u`~?G8F4$>!2~YjS zfq~$jz?QYLF&w#_WhpWps0J?3@Ni~Mfu}Qxdj6J;u$$Yn%L07(r7$j-kudc1&Fynn zYWd6#BN$waZA$B}_Q@Bpu&NU) zHM*f_!!WAW;u%6m%n)rhIJScCZXyJ_4g$IEy>FaFCJ@ufhB7qD`=mC9+GS!;=o4D8* zdW+xY#ZenH&5J8kcL*7jWPaRDOSwm3ZG0@vVx0EQMH!1S+VeWahPr#h0=>SS&@c(jE z?J66A4cx3e|D?VH!r~K0koMa3pxqy^G49HG~eb_5rNTL5AYKTLlMWz;|nIZFFztOM+ zd4f&YljC7j;h0r8)&7FT>%`lYQRS~nL&IczCUQGze-A)}!17%rD)D1kAdHqOE7`J_ zsTk!#FpqWy649Eh<5YvC1j3UNq(Kdhk=i3nHn>L;z+6Hk9c3XjNFiJPW?&F!TN@y0 zLoEd5x|ISIrN5JU2ZO9RnXp4e^`hBMi3Goq0lYhBj8IVFHK~9Nf-;q(O$g3i`eUbY zW%!LJamCF7?#}nA13?0U2?PQzRgxOaS?-1)4Zo__YN@M8 zxJ@j{<4@fyrpy#F2vmvpL#1pvs{jM#BdvmF8zbt>d?Ap#3Qe{}(B7^=->|B)WrLg!BRRtMc*W$@K9wzi=!UrI+3VJA@ zs%B4U5{X@8bCRL-{=L+mA4?5ZVlwRjVUM)D6z3xH4k9H7t3zi2Z$}4egCDh?37m-y z1Tr5AZkn#f$VeTM=6WlF6L6ciP&f$L52utUzBqAtXkp4lkPDm32DO+hX4LkQF$sJ3 z_K1;NM8k_6Y!k`@q{6bp?19HNJJ3jK0y1Za{FITX)rXpb3y360==1XM3u~a0WK^!0>9~*&580UK6tQZPe#E3#st9@ z78oHF7)SSd(>gyuWw~Gj3vjn$V|noGJi6=j)6G)Xu?VCsz={KxPWK@)t5FcIU2cqd zKpm;H;(-7%;QBo}f!_ffC1Q5&avK7jcs8?ZBU{#i{~I}JO}?EGE^lc}ScDRp`18H> zRC%2%5nO5%v?ed((kCAbSKF6ioo)OiPUoyGP%`1bssM9pO9-tn*a8XCfEbot$fkWZ z%jg_X$X!*)9<^Qxa|<-U&hD9=(5_&lQY@k&dRUDPfD+R=gaf0Gb9#@Ctd2J1-iXUN z1GMZwu7#+F-T*pem=&d*fJ{_pwxj@656oDE41q$(21J^BX7I`vl8TH3)U%f|HHjo; z0JxPErXpeLVHQ3K3QLRrGgoG`Vj%5dtewA7*fl}!HQ)uFiK1o3Z9k6IfpfoGFDY4T!%0z8%db8tyU94#I#M>Nr2YL z0CFm|3?-+NfUd^olQi=(8{3gpo}ZBPbp;V0GJi33ek-zAvYdIS!zqd!Yw7rEV9KGZ`6d7OExq8krb4VIs_A+%0Ml-fhkK zghWeJMBny6Jdv8tr;{O(NFyJt{;BoDTB3m5rD^C_sN~5Z1U|)T=_XlZDa0hTsFws3 z@Bk5cr>v)Ml35`%Ac^cnWl;zFZ4(r4>YwUK94SdAzkNel@wD6U3;L=0jq801Wg6YL z(Q(vMo3%oek60%Zs8bVVWFn-MCP_{rOB660^cHF@GL?qc-np{OO?t%<(EB1%Ua7QF zr2;7Cb(G*as-Bql|-bq9GOC^T8WDzFT^AgLAgft&)Q|Bon=ap zAd_QWRbO$W<)-OGu)9~gX&2}e2{SMnS_X*{D(DImWdjMKksyuEK`j8ZFUoEuG*HMQ zM93`65C8o9&;0E{x!`b3Wwx(K=oOdG7iqvS;-{E_aS`H7$?cN72;g zw7J9R?CMGi+#6)&xpImZix@XfJdO4GR|-`1{Z07=eGi4TI&!02Tj`EMdS>>lFRtmM2Gw%s* zKojyW*Tud$$?5Z|xyQO5SLt-+EONSHh|r}t@n)Xniq9$0cEEH!7Frjl>CNqoA(Psi zMn!}5D#;YlZtc=(S0r5)JctX5c%`PYmpf21K+yv~cIGe>X3RomP3&56V2JKcV#UsW z9FDjADU#&>hgSidWuQ8aisTKp-&PuZOvlQ2$111duD@cZZb8Vku}%YtV+&1_`qaz! zAg0;2p%*3`UxcH#!`Cy%w>8Z}?AsyC@Y2?23gx55ys_&0kZz4mn>>q1jBDDHmi(5c zl$k7v%IF$N_YnLa2IM-sr*BB{$jWBg8)n30WsOCZzI>8N7*4gVU{^StVJv*)DtzyN z;t3zKsEON&<0PX+6*?8;DxPG#M?2sYk=z1KiasS54-NXcRkQ!PNCKH zV03YNKg@2xn5DWz>L;gNGmyVI0_kAhMLpE;Ks5rTK&USxBfV>Nm2f1ArC%X2r^L6@ zu#C&6ymvk?tqTU8WmM*NPnp-LPsa+UYUu1|uaMN+xP_5ExE-n0X8wfPGPTVUktI4J z?&cx|$U=ojS~KUAo}^@$8)P8^JVHMNI>ER9|B-Yn*^lt4-}7q+)YL^7SC=&=Q{<^T z2mJ27E~V7VTH>2B_*2&vW?7aXX1nPmcP7i;kBMng-q_+$H|UgH0nu0#dfZs0kJjc6 zoq0=&7P+;cYSC_EM7NKNavNKi%Yu28p5!*2hhKCzM~%)4F>YSZa<{wBm-qEzA|fIu zH%F~esoE0I*IUZUeSKN2Ks#V}nI5jUoYB)lKsyoo28{ztP!*w5yljEFY{<%~@HEg7 z=L+CUUsbHQq|{PGV6{+H{K@e?H3bx|fa5nd&m&0DwWe`sq)31^irQ1!Ev*4;MhjzX zVNYd5DA%CdSqb6>e&aL%gg)@%nI!fkGB7}6tj5Zfu|gvv9Nr@cKhPWmH`k+24$ zVB1G*Ahg*Q<{*QMbyKtStmGtL+P3(2s zpr9$T6~VP_P0Vg@W6Hb@%42L%sS)l(XDEfVxzR+n6Oxp|i0?Ut$(fYXNR|X@igZSM zwie=^84`2ywe61)%GB91oi9%=YrfX`dU|K6-XRN{jWJE3fg()7w77~~UfhjC3ifMCW1i=14xT{1dGC3GmIIWdXDg?K% zq<$@G46~f(74%PQ8e-A^BOvf?SC`gyEr}H(J(MZ&HcI@Z1*M)VO+RHzVlHfto?0njL&6*e5xZR_h0`7+f~-X((Q-%VK>eLUd0{%c?0z1o%hWo;3A)FhMSOyyz`U+Wa? zLY|tAXss3t_7qI3BB|cX$b`4HM2fN`S=t$9C{^jnb#h547ImBwB;L~qysAwEEqEL%i;^^`HA1NH$+UNQt?zyMy`zuGkXx(HbLx< zM9SArU#^ycaS!W6jF*aas*+CjUe2O)ONxk*3n(9_kkyDFBX~?4(#ax-LMm!$m&!WM z1+}kkJSkpmEf9V)DKFD7>sp!FYgb}Xh(EqLR`H9AQ$A2H>S;+zQsbagQ}(4C>?k^= z>>Jahu@gHQp+Uja9|5U7Vj@b!qT0|B0h-J~q^0Tg3o-NX-Zosa`JFJNZ;z3@gN`ni zmf&#mMIib}uYjOyuM#tgL@jHy2QT;{9F}e&5x(P`w{(}5ZX!*~mlRSZR!LG&hG6*t zAs0NRM6=2)tV;#D%V??Pl-lCU5>p|gDUl&S#AAYl%(dy{3oLGp+%B>aKz5Q0-Ljd_ zo|aG6{)re2Q)LX@+X$s$OBc2#MY5(bI)1iT>C_8Ir?Clb5wsH$?IW9HCIyiek#3T` za?bxI%_=E)*R<1&ioB>_D_m689*MQGs+rZfoLw`HrY+Rq8H;7ZZ)+`BRRXD4dRu!l zTpuLmXxm(eDtnRR;j&YKN@P=(m3=hzh&w~L-{Fl#LD!gS2+Y`UiEOwHq3Rtw@`=6{3nP{i-3E($I>|LT1Wggq?YeibCE=x0>4! zo(v|dG(wLfK@gaur*8!J*u;pWS{p`qQ^%r}EY5ZHGc8nBGY@Xh=`2ji%A~lKsap9! zZ$g`4Wu7qTy9R4(Z)WkVIdyl`<&29CZSF-nc5wzp&M~P&5Q4SgoXrz~aV*EUmd;vg zdU&}(H_kApVkR9sh%KD87K0f9aYR=56$G}NlhWUiw>n%BvU&GA7*W!Y zQD|r^zlYNUb@^6CvPa>t52<-ogW+Jy1?Nj5+8YQ3j7eppWJMD06s&2oPmx2>kTJB% z_mEiuMx8}x3F1~GSdTgZ_Vr;DtSnU^uxTDifNWb8K!*kttEO1nQ?oKlnYAvP@0BZc zLd+n{VhWP}lXen_n?_z!5aWWw41q7AsQ8v2Yqf0lqiS%?gZo}%wq-a;rxhtdq~J#Q zlq}s29N9^-n!{#FMJ$8;8KmqZwv3BlsfH2h8O%c9Q$@%waMI?AR1x5L&sBC(4yJf~ zyF$v+IZM6x^z@@FE*)@npmj-9ZTh81<4*VSZ#cQl&9S*fff}B+NZw|gqb^&R&sGZp zvw}?a+bU6>C6LVZ7)fzK&3ZApqI7O|N4qT?FgSFcqlQ0Ain=XZ%6KkMyy;2d_nfay zS-Kr=f!vd^8#YrTGWIj%GCUueIY!?!ZDnnf<7mqe!uuDMRj@K>-?@zS}gN{%lcy@(er+jMyU&K#(@2GHiPLFlER zw)V8O_*HaLZ`q}Y>q{ZggOG(QACQdfs3AOOl#h&_k)<@siAo6`_!Z<|kEMT=%8I;Z zR_T`FTbtii?>adRTuZ+~U)zpVmB>Y3nUUW;4b5`JGG3V1ai&V!S% zy&-7jN+T^dh`llJ9EM(lNagd&0U#2J$q{cVJ_Uu$S5ZFPT1_5At$fHXI5B6 zka5b$ypG6`khG;Ubv39}9g0)zD7j6xPvEIxFr<+3u?q^lhY-Tw4zfyU0Fa3I@*~gN zUC&3)8OwiF2}GQ=?$g9;3PL(4wM3Fq1x?9Z!m3@=8j)^9?U5{BEK&>PkD#x`OF3&$ z1FwFPR53CCgvTrVr|;k~QKrq=e;yoS;aQYvXd7y&08tRlWe>c!nHEhs1VdrvLR)~1bw1) zUczcMu!M3WL~@jZqCJ%>T#8FvO?Xe(ES!&<3D=n;IPwZclmB@Uth1i%q#t*+K^pnX zkX}9C^-tt99{5z>()pRx$i6H(onzOUc@oofjgtG6Tu0ZSe1z&O&?|ZK4yOf^;FU2& zB|%V0B#{k)&$V-uiIdCGD3DjMDmZe|zB8UsXz50BE@CU-)p+CSLo!ZTNK@@=S{$?A zbdSF$XyVtmx=P6;PC~J?&m;WymPB4<`$Tu-Rkp<>(6AnT`i_uv4rbHb!Ip+aM7M3= zBf)R_Gd|(OAjm~*dMJ^wdew`&UC%OKn1WI0yC%2zyhaa8`XW5;D3r9NAQ?!Z1sn7q zne5DPyaz^AWa!$c|6PK$7Eip>bvLMBkh+}D!aj@vmH52G% zBQ-xGA@cY%N=hOb6Y|6<8=}@`io)~SET)#QKcd8gqcX-H{9{GY!15WKJ2iO>#gZ;V zG38wtoTWATY>c_0hxvi=`}F^#WJ}9iT8A!GDQzTwiMRek+};A|6prvvMQ3j!NG>PM z);=JMO>ROX(grEVOW1G!0oO#3V%T;-#z=PEmiWzn=(L z9c*&F5|eoOpIHMwDIa7K0o{-}7ly5d$unnBSS=<@qw{hCgr{kCf`T|Kb1-@$nt6yX zgckSAkxRU#H!0gTib0KK|HRx;)KD_D4fz>~ewP8(Yk}Z2D1W@MA$of_k0aOP7&b=yc6EnU3 zUl7KuhRY20{KvZksLD6r9gvj1V>&kOr;A?-F<{z$p>uBKv_`n_XuO1j%tJo|(G4Pl z+E$^sVee)%5ZZLn-l%uFTozhPTJPijVuIOP0F?a-vyV|vxs=;>(bme(DF)iCXi`si z`a2Dx;aHdt$Wb1dfx=Pmd?=%hqV2^agqmR5y{dsF`3(k~7&xLnQU_TUgVrH+EEOqA za>$CJ@IpP_NR&m@wL|GosX(C#j#M^C!3_|GB0wMuKo(eP72_{TQsX6 zYhgTzHWHG4vRloL+d(0eLLamm1`~>=DW(x;#=fBp>|5a?mz|1KODh)92_@BrSrP9p z$A_w2Ql^o|z8=s;)UwEdvoPVsC|5`a}|PgdkDQcQ*hVllDBC|x^v5|Km&`%5FV6j}VX$cZCEpo=RF z8sTIdkxF>iFBnpeg@=kC*OeI5+-Pkg>_ppb6HEG8m@^E=W`C zwHgQsQg5MI47TXCZ>CKpSc(-CrJ0?WBR!3b)Fd_tGS-<~B!uCTN|DFblqPuvoMp+V znj%P(Q6{Tj&|ra^J}7-hVpkVg(Pa=SI_SI0V*V76R+dV_6mT|12(f6+s2Iqcp*4pB ziNFMNWUX=7`W8V;nqDfH;!2XeNN+TpvXUdcFju6MP3V<8hC2yRf~m>`$^nB-q^h)7 zRid>7jF6c^@a)Y@T3d?= z6=3EGB823+p=yw-iGvZQ*|lMZiRJCiy_u9q?LxtfeJgTMC7I@JRn)+-r4&Grq!AOt zVcRCpmXw6)2si)$0g3_v3}7(~hA@ONfB*mh00008000000001_5WxUJjDY|E00000 z0000008enyV+WW300000009SMM2Q+E4HD_J00000dJ78)l4T!P=v=CH3HdLh=0yiD zial*@s4zCAmFSfMHBrF{@wojwQWzFfl3TsK0x`YeO1jd-yeqmkS#P@{6v@&{i&80J zBxxuR%-8i$w~~!PJ2dI{iJNaSi5fkaurw`^OH!epGPQe*_F3eAIJ#nSSr1CUScSLBo@Qpo~a}g~2v4M>=0x6enClNUZ?r zEM{HYVS0ZqI&sP=o>wi$lST?~TP3vl1M*G9Nl&@pvpPmuC5@()u62qi+w@Bw(l%$L zxuWmF!9%GSC@%=!83zq7pxsU<%&a5}SOY)8}_^iZaCg?NJ9u>_>b{XY6q{8Fqa> z^Fko!eLl&6na>Nz3mSH!9$$s-f1~Py&&RYFkjPF1D1byK2jWTPs)S@YVtuHac6!*q zF`{Y>3_FbyBv)yi=(_^gfY%`~yM1CL1Ve;=0;#f0mgl6y%t;&~N6=&$0tAI!=QxsX z;Nh8rRYeHMXo8>|4m^Y+yMOK&4U9s^Il>B?8LtI6L;=vg4TZ?1FbMX{CvPpf-MGS^ ze?%e%L?{#*1_0`Foy+auIV{%jf&i~%Y*Ah6M9F}tdK4)}^Y+w4MhVVHx`4?5+HrLe z2}w+c?OjmULXVxSq>T+&S`u5R3ANgIgh99*Ak&HM-W^s$KzF`E=OyaAhdc;;#8`O( zgI$e{Q5%#n;F0M&s@>~}%_LrfkZ=a_Xaj-3#V(7!Ig>z}3o=FrZz|n;4Y38x8ZN2Y zNBqv?iVE!Yx&f$jVN$A;=7IwzW-Hp-*D^TTpj<^o?m#hy>rs&8!{oEX7bA9=xHQb; z63b4AQndQz<8%rar{xG=Ou2HPnLx8Ui0rX-=|h}(L__OXGd<#rxY(Dh5RAIA+tjB- z2>(AO919IinGmqB*CZ&Ny=s@SBSapnLr*&~+RI&CY}UX!P)SJLVkr=tMDq5LVqK?s zVADKyMuDgY1f>q;WVQBOT&jfbb&Dl6*jZyCPzuWv1ybyCPQVBcbgbOyF#8MXR(tbN zPesEe3g>8M=)t|=J=Rs7&^ptQjp#js*3NST18xz01r{Pq&CG%78IIX4=0AlsP^${h zDANfPrXJt3>l9}VP2>fVm(16%5Y*tz*cb>Go%cC`A>#ML>1`Z{a@@6x6p#jA_Z zB7?|Zi*VXs=e1Z;mzGII$UaACQYIc>&Zh8;Epi5Fje+UI;?8M-;|5>QHC31B(NTw} zD>pFo@iU{A8f4oVN?paUiNre8P(s;ATPd0dgL4V2Go=Jrp9iWmbOif_TB^c5OjOg4 zgAB0XV1x~b0A8G#EJD9}02eDgt61fJ&&VQwmDQN>EIqitC)#+$M)i*^_iQZWP;~i` zL@$@<9BfVsdJIxoEEX;b&)wW@<%Ee;qbfv4N`3;BX_X?3KvzKkP77KgZp7v6e39Ps zoeXb4zEa2oXCu02A_A!FXc9$v#+`{5tC9i-05?shg~|Exc0OM@oY~(;oTjpn?xTB=-f~ zuJqW6zF$*_P%Ky=74G6OeL8!iA!EZs%R-RWk=6?c5R8P@THJuDt08nb1A;J2dSBJA z(dVTpP}?f8dCd3EFF>!NhAQx-p0>FlG8dX5>C7U$##0w?LnK;)KN3EIS7qGide~H# zh?q2(O1E2?9RywKU(^>BeKC@;5+C!>+)b2B>5*YOiT-Qn&{PE#`Fuu5kn1zhnd~B5 zAUvYo#?tX>AKjYx@QN>Tn4bH79*IG!o&YfntD)mt|#+m{XjrI2_4p{1O0j|wq zf1ck!Wk9#6@wbXER#*$+Hj!)^%%~Pz2CU02+{=c1G@elGDSZK9rf*q|?z&6>R5;KGOXJL0_17Mp?NGJcLu`N}&`82H?Gm zL1LnKqfgc}DS<}4?p%sTX-@Xe?fbao#4)ksBCA-`?KBY(K8xNJTXql!k)G^7d0M`N zHbvs3!l(>W5~_%Z6H2(X7h7RkMwmcDDPasW1K52!VIk%(oes=+o*&mp=pfh8rB%O4=&HVF7s%(a*%LlW^Cc zh0{#DJ|tB7i$^f~J>i?z?b{C%;08aZ!BPhE6rlS#Pby3lce)^C0m^{WvSNBd|Iy2n z^CmYje3a2)vNlR5svcT)3!FaRwbQ%EqCW?oL z8F1vtPxzQO7$BQJ@&*Oq=+CCeA((_0MbwUi!$Z0rc0VN|5{1px@|Zj9YjQmZAF>1h z00D~y_!x-dX0imbkx6wt(Gdk-Y7;kV_ttxw`OMMdE({(Jiz#KcuvUY#mLtY-Q7(0@ z)Bq)wzd9iQYIKRD-fLxdO6yinEEmE?lT1-UK!kZnB?%-unvuKfmOl=<$O>^Z6}rKh zp|*pd7e=s&^Uc^hPQDcRsbA=xPj~_^2vCtZEefHnF)B{*|#wcYFO$W;H=?wlJ^7gIrus zzIB6~I<)qdO1+eBj7u68P_ifwS0n265y4ho-a!{Uxj5kvI*Jd%tsnLZ68_m`i8s41 zmnRt&6tSh1l5cp@C9MT*sxGJjCk{n+x>cMPwR*dy_&g#H;?xIP@1i8DA3Vo`=Zz?h zRfxizh$%oAH#gI=Fj^Hr6_j`mO_@08~Xp2RlxO&SeLy57u?UhY0KG{%zmVRe6JO5eDCAR zwCQVPjYh}|k(7x!FD@b6&@xQi+_-Qu8c4C4ivwaA#Vn0+sReVIde@pyM`dC~!U?qX zJuq9DA31XTrGu<$J1yVboV|5fXHQKk)rTy*&X@58`%typH4jG(=5bYTyI`0Xu0O0m ziXJ|r3%q6q9`T5K{GVgG-CvYtdFX1+LpjZ=*xt7xkZKx^o*IX4zEs>7H-pVQ@K(4! zzW=#t7MO%AYu!ORD}2f5f~3(eZAKPMQ*3mp+&S;-6KUqFoR(dGPjv0FcwXbvqSbAs z1tt8}zIIeFd>vP!Cu#$JAq`D-^zX@p?EWM*pt;VUYoG z4=SCM5mVFCDU>VEJTliOForZJQ1amGMaPUp*<;y17eScuDQTj4?X5){EMU7|tEtTy zNu~d%!uBfKWR+G^7{ni-Th`*{F_5F=rYTvOp4YVg)n62z47zPd#P&Y|$@7^Fa(P6Y9y!8-)E2agRtl5Bv$^Dw>=zH#5!A4L@K-JQ z*i$Ko*oImy@cRfeI}c4q-hVsx1crfO2Ni{7B@{TMbtgI^g_f6-%>Nrp3~J}rMNe#% zqkqQ7Y0~vZTR9AhoaoQ8nI>DE_+>NR8~w7IF}((~82Sp+SwgHp?bfkjv{2jQv!{0< zDbWybCESRoy_%o8S5n}!pq}4Uxt@EZQam}3S%_pj#W2$u(hi3KZelImghSa9iLt1L z#Ufa-9k#YL?RbQgy7Lw+bfp$2<|kL}u~URt=rLRGzP8-y%E8#4@ty`5EQTrf)+y{) zVbI4B+=)}D!b`2n&@@g)X&&WI)Wnpw3Y6qJ&Qb(|b+vzD8cpm09zw%y1? zy53a@!QBJLH}f(}wU^<_Q+rEB(W#TqZE4G59#PPUranWI#$pmFnu!<{kMfj zJpcdy@TscnrLieXRBY+g35%la*oqHY=b5id_p>Ej)Z6SLiFWC^^v6U^E zl*~ffe1a}dG)E@w5sM{EWru+zVP&mjH4vH>2gs(2McBg8&D}?{%Wgb7N)8m;F5YNr zp{q;gixDp*?-`C>->gRM`=PcPzJb6zo_k!e0xSKz_)x2=nUGnZbxeGqOU!;EI3yLPr zUp#Jd4-yq!bhk@A{!_YgfZHXl$eU-7vLC)RyuCZqmTivNWkpOP6Av+)?!9offmh{G zJXGk7IFn6q=5Ib&+Fyxc3d;(sCS|*={7J!-zDEWiktgVE*AIt%H;HS?Fs&<{E?V=B zck!>y@nb%wX!8pixAvmMcfoYPn*V7B)h{_D&YQ2`?vsL;6)BvSeVg?n!1CP?fl!AA z$sPU#(xr(ar`v8;Sz?Sfr-)rGMpKv+6W&q^m~Gj6toO^@ve^WT>FcK&&jG0FB`qh} zh()QAml|3RVo0DHX_lcC6C9Gy3rcx$4~Rx&bMYjhdY6YvHa&53n;NL4m8SelkMnAG z6T;{=#se)rM_6|$VN$OkqqdG@UBYM-X#DjbW%hXa^VBt{P|L^BW3tEF1D3O4YCgi$ zHD#29EdrFwDoGO1-P?od@_S>?Rkm92hE+K6TgSzMNQ!O_hq~CI&*R$puyHZURS7W@ z5Cdn;GSuw)8br!%PtKC8`f}fm*Qc!nD6UlerkLaBvSunMdp#?Bq{lAhA}uLkB*T>~ zky8-1YYJ-WJ266^GnRf?AVK+brCM^RDO_HA0h|^o3{it+E|is1N>%_TCP@0~R|B5{ z66RQNV07{hb5oF~GM1h7=u~}O-hl*JJsOOe;n$hj&va>XnWZ@l=acap+tS1X&W{1xP`!GJXt%S9 zKD+HTGnU-)O;cwNMLwdi#E3QM|1eiG^;O~a?TRxbDbD$^~z@&{cLo^&DK#XPH+^~;#zwU zHj(e?OM@rlf^sv3MWhX>Wo(YhlB8{#23#nnlqOB{k3s#`0 zb|%y;QmsvMF#OzlWgnM7^!i`YPF5=`haS&r-PMLpZ0sdCY7s=c*!;&=PDO<{I>G62 zCg!mK>fVbGeKPXgQ4(kMHOJBUQm245Fj2W`s44ySzFrRe%ukH!OYV- zX{T~BCEYgrnCatwebPP1*BM97N1D#owl`^V-d#h^nJ)vC*Yw?GZ5$BkpWW_u%KZ&Y zx0QH1XgOq0xd^;hk94;w$V*b3WB;O~dtql3G|*DPhD^k}SJ;jqMPQ=3VTc zRrv*#mA{Uh;Y3|7tfw5QS6Tb07g0MIyaebKPZPnwpmi$%W*1eeDpcqR;80eeK{zg$ z+}+xo5*;;pHcxnYiNR69GK&!4)*!riCPcdRb-=3-ceI5*A2h3?($`+(aABnS(*E2s z@0q@{5Aa4+Ta@h{9XHkUPWohu@-Pgvexv!n^9l^H^u=H{jHDFPx?)F~@6k_l(8)OV zbMQ2*c{1b>E)YV)WMJ)m&JLPQ7B=`HS8)U+mN@Gd@SJ(+pSags-X$U};&TFQ7&eYl zX95yE5fjW;a43l>3h^y8@Ir?zqDT3RlUb1nTP=knso~5gvZG1N5MDG_~l&6Tdy z#o8@-XZWX-eOlEPCxCD)nO?&@lVY3|z;v%`^jTdNR{%V8w-nDs!k77&zP(IT);ThgGj`9WT? zwuq}gF`#XOE1sbJOdS@sX>LOzl;VvkX5=+;d5t1Pxs02}w~f7*%Bdo*F!ClVe76{J zwXUc(YCg$?v{As)uJL4|p-sQh_&}6j0n@IG|RU$VF!1&U~Gn6N-FlCO46j zo}!+!$+V9`7Ik&|YMv2A%nw*OWr}@dmArRJmuyR>Rh@vGq%kHWuw2NDzDnTyYJ4@^ zn~|9m=JZ+)*oN-N*;0?1$#FEc7W&ZGsP~lRgSm*Tzp^sdn5#jfir7hW*)1Fo%Tm$Y zOi+CC865I+_fj-g1Sy5xIiHo%R;ol;N9E=zTXlq!K=9h)&>;M@&*!Sv;W%ACY=f^#fYJ5I8I zW(k^u2jpY24CiK=PYZ>f!cpKA7Dzi`2bCz}z#38p_eIX5DK~WGx@)}6!CvnBr!N|kOZi`2JIq#LP2A$h1EgtcSVD|G|Rh;99AcgSZM7XGOI1b3A z;=-cqHcPG^^HzEfx->igf;}cKjhA*%6_MKvH&Ze8WMnK!FJ_msnW$XbvK7Or(C^tu z5_2B)bvi`+WNCpO(PlUol-cSMn=Yln*)7nMcoE3Vp_4jf?wfA<-5gpXc8d>B5nYQ^Z;v)@f}y1nvL;0g=>* zIFkavqW4%$+K@H%*p!m?x=j*{$|*xkv|pXs`%)}s;6@-_K$5Q3K}m_hE=7p2jX&`r z%|%IG9FSEK!7sPbn-vr?Xy&Yss+(KEA~7671&W?w`4jCHGu80_qCpKJZm|Mfo%0Gx zbr3+spl)gm?O?$X@1b&mg`qTv1T;`(uZU)go;lhVP{Nf+O9%Qfv|-}WT_LEu!q8$8 z9YxI0jh@aNRXpQNwb1gTZcyJ{F$HN_!Bx~GR7wjJMKcf}2xA~YbQ@>-2?pVRl^CHG z)ixcPQoD_hhY5m6N0bRej0k%QBBCOO5Ifd{h8_q6lIFAYy1y3r5QkbK#RJjAozyCG zZwa+Iw9MKd)gthu4LA{XX?l1T-f5)?DD5xVLqs#AY)NsQial8*hDT*}`YQBXg5#z= z2XhTkX3s<285!o&kcwzDPv}aD{v#q}KxGD%QI#{Run6*O^u^;JKmq)VEAZa2m2z@O zWs2x$C1*jdktw(#6C&>HM3IH$xT*{Qf#^oH;DRs^Zk9BiL6~(CtFnN5Mm2AD$!1}s zN}+SBEStkeK@Wi;aYcG>Q?0@d#R0>*bHLINM7@bKQvI-fC^DH1XXeEU6*Ey-=)y9P zvRw-DjdfxG00EK@8BS6hMgS-bVi*iy000000vHT{000005IU4WO+X03RY+Dc2mk;8 z05lX}C;$L7505CyErHl3NNgAY1m-Lt02(smT}?-6(Vm%s6`o*xFo-ilWXW2>DK-ht z>hR4VmBIsw7KE+70tD-2^xX>Sc*)VAm|69>kaBdRc{VuAA_%l-*fc2CA!9Vi9~SdY z5CaDsErd>p&`h57;}&082yb1K2gauc6l|ulI2mn61#eyKY>1GRkFj=;1bwae;X-KQ zeQx3+ad~xTS7VA93d*;0Q*ga)?E3MO$(sxvF-g-kROFx2&zk6JOLbUv1Xqc4GU zg%G#)thvx&(2Lk*qF`ZOn~R=~}VB52{Q`LRy~Z=@3zn*`=0gm{>xMySI3 z__$nPO1}kBDOt1LST9+X%eRYo;?VTMNELMozK)*Il-Uvpn*rn- z94FMYIwL6pC!V*YyG4wU z5I7MD9B9jTNWTrn6&l}~oY-_&F#8o^6Jm?yuaFsOP|{F#nrCd%3FIxe!AwwS!i|c- zW&IXp+AE@u6gw_*0fZ_xf01C!xsZxcv-(9iL|{;b-x{$$Sb_w4M_wYCffNIjZO}{Y z8MjorMIqtKK%jiQ|0+-vl&F}dn*Z78ysZkxO5v8Gt0^J$L*(<)*SfYT7C<0VvPqz_ z?x6Uo05}Echz`(bii0Z?--yb-7$b;K_!V?f5s?^V27%QhIFJ%9LU~=YRR|)BVI-4{Eckr35CKFW;FK*2nv(uc{jl&0Nq{aKcV8ew#X%783u>)D|~flLtv@#?z8;X-kf z-W+)c4*4K)2&Q^l)kGrcF;b9fKj?x;qJATc6qI`pmGo;+2JGir9ow8?sp^0+6xf(n zAvDo}0D#Hnd|HVK(Mwudul$pU2^vWAz>x~zHprM=EZ85$i6+Xtnj%?TR)x|F*$kx5 za+4&9(4U#S83rZlT}FsuyYF<-Rnn+PW0{nZOf-Tiz#BV*A#vqw{B1wDdMx%9a%Q!- ziG>pi2mz@?;WrnE{3{5bJ-SP@Qhj%#JMm%`U#{dk#i6LmlRk-%6c7H5y27<2l-r$V zccyF%n2|JugKFtDwBQUaWi9NAXx-~!5iy8{@rt|sYC~!db-h%H1caCsv*eyen_mkg zxY>FUIhI-k-ISt2Nx$}-x5IhrhXzq$LPqKZAhdu;A|2!dN-z>3(5KV;WL0)Wn2tm! z{ro#1L9#zFRS5?CIa0x+7s+kVI3SoSTV!$Mr^~cl3dcay0-epHX;nl&d~^z;+SMdf zg*{89&?#3@*DwggGhp+j_6*Th_j|nr3R3W+>KkrFIF>+}fgUdd@jYnhMD#Es2+Afm z={OOEMF>G}u^W^{?4p(iDedfcW#$_FC@zK;)t zJVfwsMerV&31d=EM(A0AhaM*BVbTKZ6iPLQYRU)Dy-bOW#F?J*LJP<-O|oG)l9Md@ zjzEKo6*37b6iURD{q4+pO2PvR*lh~QbBf1M|cEIB?Pt5XasA{ULP&Wi1jHz zN&Sfx`pZG1?>dSq&&^r_BzfPlWL7e)1~uJJg$QXZxQJrXk~Ye08IxmLbUCs_+-rqX zFs{)EqM9RPNG}eCd(|tAnhGFd0l`3oWf+q5Q{RPl1T-zZMyb#!YB7e0Q40iRW;3}fs0l666=sKOKM2`E0!n~b+KDE@GL}=4(5}n$ za%<}9+N-PSw7JH^zTQ{hvn`d)iAmxhK}k;eHS zSTekJLt?@@;bv2Wya+IVIs~8D3sjWkh}qmHP)5or6Ylw|>CXw>&@REYfsAFTxp3=A z6_8Cu1tRdvL8NminE|TF%$w~y{9noLwv$zjx-e| zYzx#!rs~YJZ&XLA0)v$^Rh1u6tH>5}V~IMLiCVtwh!qsUVn*A7NeFuG1uVIl6e2|| z8^UTK7(4cl?1o1xXhhP|C)RNqm*I`Mg9x{9hB>fFH074V1ye%V@qGq0*K1i zV|C}90yshkPO}}KJTSVfx3Frp?Pyho`XK^~1j`hVF4|VOn)aeZWk%7@+MULR^AP?U zLV(^jHSqvX+LFAwLyg~Bw??HJ!P>#@`ar00uok^)z*u%FS{E+5rRsMY zTxvFcJfZET6wg{_eqjg3jSwS#}H@UlQP z6V#ZPM%D#V^a$P56}&4@e?itHmoAvtqm5IeN>eSWHXy!`Pbz}$Rp%z_WC)vXOR2eQ zWV2I3@i7Jd`bbP_Zc@dmp;0GTBSJ~g6Q=1|4wKb^2CR6od^+7g`$%#74`O^LmcLU{XaT1*2D^1A&@Y35N>YZ?UuqWW z1iR=Mo?As*LX)Gb9$4`(YYO%>>0M{F8k~+-HOtHCUdW&5lf9TOB#OwMwzzrX+JBVs ze3Xt5K?IVEkhhkiAma8AV)+)6Cl1V(=@KjSL@mfa%YK#}p!+P14VBDCeKg0%wzQ!5 z9-O>{&~CtV4>iKJN9SWPY=EQ4$UXmVpN!cTiIOOyihEk#A>V2TgrFO|ls{rBnFr$S zpgIcEMNd+#g%n0_1#J5CBA1dD&KaOcAryQlv`@W^0$~WBB9^uj*2g2x$ySLkAse02f|Q~Vt#LJ+vJ=Wj zB@&MS?P*|pC@te6mh#IblhNm0WA%WjqBXQupZ>XGew!<#Nj3{vK_1R8ccXk;0~9_+M(>!arh=4xc{45C?>7UZ{8L`@h1*&)TDI7Xo!Y_}w4VE@)1n{pJd znvY#hx)-8`wyZw3M1N9_fy;Tqi}eGm`-%g-i>N&;|10@-F&4J*EGD-Y_zaR&c#HKA zh$5}VJHxu_GN;jr6yhZp(Lxd-A|SF+o0|$$6pB^-=cAsEDIAZ0`7=t-=p9p*ehzAN zyG-PEQUlNJL1L8csTCDV1MO%ti6SSm#MwlKck$OkfZo+>OWna$OqUm0=g4cgCu@Gt zK~S^I&&aKNX1tbmm*h=Z5T~-S37qU=8y}T#LQOddLk8E5$a{$4E)lV z`Ld5*3j?YVB}KGW&Us)ZaY|j zQIwI9zxjx*qp`)2YJ3MYv^RLn@M?3s&O`tB4$fZc88*=J5!4@7|b~2rY5f-`$$7qkb z2<`2XI8yNtkg`ohXoyiN=9y{%B|P$gl|)3J;_Xt4@#5&>#mr>nil(wwd|0wljc9DO z8I<%hpQgXOLof7u6W^gF^Fmw6K@uYD`gsB=$la|+n zvH+@MmaIuASjNwudBh+xB&L!wqKrC^kIIsp%MmOp*Efq9p3rtW`qKRT?@L)$CgiVw^m#qtNBtWsLa#TwGZN1r~m$^`@i5djP3ZEZvBWBHVy z>&0?fbNlBMBHl-&Sjm!~MQ2(Ir9Wl0{qYcE94qU}J-U%g8_6;8(Lh@oYzxs)=7a2y?2Yq=TbwDJ?&ZV*CSPWGO8;?PuFxnix2K`fO*5P(`# zb|OL){IXZ&LI(=YM&2z?5X_;I3Fo#f53i^z`@M-Fh(avYiISBgUx>)Ogu_0>WRZBk zq>s(73H@Z<4sm9{oL`;=BK``95rxm)*vbjl@k$DX_e-3e?4>Sn+`ea*!V^o`BWy(k zg5;u2iIl4;FVAjApJG?!r7MUj_c3(5mLBk4vVchCAp_fxwXSCIb-`wIpAwar=BKYH zsZ?sjuROFO-_Y%obe|luBsnTPVpZ^!-iWO1`%c^s#OM4CPm2`o8lc6r7WjCU%@qoN z$3*?tiaV#cGf*{MwL7HpB|ihC zMV>yon?_kB^!L>hdH?rZcAd3dDp`D~Vk+lHRtKCZG7Bmn%IsuH7wMX2yvbr&=iaE0 zQ3LrRA|#aTS#M!I`EPf*?bXgEN)Z@4#&XvsrQKpiA+boR2C3XboOj|PJ^zu2%anwZ z+mpzl3P!*zV~gui>5lWnArUKSq?SD7u9E}H6u%-r&_W9Ef+1+^Cn_9vXDcGy5BomcY~1cc z>u>d1qgRaTLltg2TvCxpZ_^ad(Urb_jE}Jlyr=rFP>+gf^(S;fZqHB{45-4-Pq!8j zm%@q{3M8;<0SJ01qKb}R-y!UCB>!iAhXsPK#Sn;Hm6Egc*aq~9i+@+(CUC3r`qiE@ z0t*-p{|y^31Z;fJ*Mva-u7b43NiSyca(HOspd<}2hyMSAF*W%#roT!jDN zEs>)HzAU6`c1|@H3z=k;&2;58yx~C_sRgPlt0`8GO0IeBii4gM?NQr1a5r(2eloM! z{(39NE3I6HC5xC|EtT|kqv`2NUA7rjOY;Z^Xj_2`5^7#qGXZhxvkh)(KPqOWA zDg77en&-{rXv$=-*0-N4=*~sbTcaz#N3W3B{4a+{+^LBEE{fKZ{Tn-T8BW}TQJb-pFFWGqBIg?` z%Rt2d>RWzhOI7+sKGdx{(+_ldt=%N+WvMRY{i~ze-`ADVMa>F(G?{-a#n$kEFka{I z5g!qqyiYi_5#x%OoDXE8)fBx60pZ!rd$Cz_Wh_0*GI!RjNacz|vfIRDNK!2va?RBv zL@lk6x54~zA$IB_m8l8(SMeQwn~4R&9#2zc({Sg06L3;&W6KrP*h67oUme9-kb2-X zWMZ~Frh-ga@jL;El&w{?x$>yuHOWL)*4`w7b9L1RYp?xk(TIYhPtxWh$RnldDzbd6 z{Jjg2<>i7*!YUw2c|vTifiHSKV!b^7ePHMc*z+HQWi{lblCeo}9Fa%Y(f;4cLi$OI zBt$EzPS=h39bstbF7k;=M_ePof$eh^S}O3`!C z7L{#{Oy{8`syrxAKGm0Uif3ulC$`*t&n!@N__D8XIHihoqzc>IQA;FINlbapEp(zl zN|07Cf{GzzG(u4zFzr@ORwA~Ov5V4>oP=1AT>;?;qT6B@QFNJHD7I%x(oDHSY% zwba=FqiTuv$VSRd6omCBV-={6U(qpMQ};~g^dzGtkeZEp61f5NoC)%ObNOp?AxOUw zR2fRiu=Y%?v5&pMDJF4Polr?aHFOQ?#!WP6j&g{(!E#S3$XoCtQN{T~jPM+Ur8*V@P7#Dzbj%G7tG7Oad$gJZ-LJG_Ivlxb&6{kaUcK&$>C{(D*9Ufjpt zg5#Ir&d-1!w|<7EXxo_t+&9B3?)HJUdp2jk> zzC*$t*0RUQ@|T0;NHUN@OZ`-G*FGV&Oy#Jq6zTIGzA@U2L2k&G?J;I=sL8c8<5!B# z`6@cZ{3e@aplZNi>*bsC8iay&spUg1k;d-KZx-DE9YnIAl>OxEQtaxj6vji-YcMprI7S7&KFSEulJGT;KwV- zYEgD?RsJbRvKa6|L!P?-Bjc z7h80QmyTaVEkJ&Vqv#g#o}??bx{$$?d-hG7rW~pX}C?a5x9!h41vTX4qCBdimXz=;QoGCrLB!$ zhEhf%pInx|79gUP6cHi?hY+Mv5fG(_C|dCjN`PbxV%vyCA&_*n(Fi0tC5ot2IHC}V z6r@uul8~}ZT?H>rkNm))O~T8eSy+Y?W>N#0GkBXhWfCy6zHcPusT_#UI}{#@{aUtC zr!3q>CD0EtFvtpszEKTF#SBv^1TUO0va(jH+LS^JaPs&-=^dX15)?WgE}AHV0AI zr0pu*c6oeKTaxbn1d3LEfU@8^Rq&hqMN*x-g<)6p&MMS|A;dHhmn>v2H+ax~j^=MP zuK5-|(m&z`mS3J%eDxgx)r!B}%?e53tgMARwfInVYSk+g4v-ECe5|nkE!?qB#1cw6 zMhYo18nk*cXM=^rAwgF5^5=d9Mn%qDi^B^ED|8U(U9BedQL@?c&BIehO#44jGEY zkKYBN1{UaI>-)A%#;xOKbaTLrk4cBzY`h$tCH$sL$;v$h?(dg+`j0RlxkI znpb%E;SzYBpiw^H^C2seN2wd+^xa;{~V1`M{bfB*minhij^goP$TEC6Ew z00000000mG0000000ijZsFZ^c3cvsWkQ5LA z39@QZvXKH{0AK*?yH;7H5;z+p9gUBvV!}0;4Wv*h1n3Q%ND?5BLMrh;=^`$CF#kvD zVjDIj*H|2wM6Wo4yiyMDLU^a42pwn5&V{FOco)OF%HT%&!OTp>)@bN%FhU^9;uJA; zC7VGvxZ9L;6`EzpYN$*10c5+4IP^)bE-+n_BX!rh`$KHh=W0xT;FOsGl#^(0j}mMQ zRExsUcukusSNrJI6i@$g2?efoPA=T#jR+mCQk7q97xW8Aj!5jEW+~UCG;&S-!dWqj z5ZMR~^G~4agM_7+#K=6M+VeHI<{^v5oh^VDa?;%#XHM{L=*;WMY;x53?SKq|8jNFd z><+3sN$Do0axA&BI(VRk3C*{vd=8qx<>s$Jv0(7@UZ1JQIJ>2eCvq!{Sa5ntp&otx zIWG`#S${#xI03C2J>1!V9Q+b5gU;($FwSY=84afH*kBNB%gwUp14{ZjW1$*h{pR4f z`b#|R1-xcjja!%?bdSDdN4X#H4R*J_eHKKK-lbk{%^W3L;xdigtTIK@^h2(Dup?A+7+M-=Uh-C?VNHJ#03x zZhY$BpM=X%F|v!cZ?lkaI5|)^gHwx;OIp{>3dGxZbi!}p6ctMR+ZkYf>KCHQgnxe^ z%9kHKIy&;?zf{s0%>iUbsrSX_k^7B;YYm=IVFSJJ-AoIlTvIPZ__n&=0!C7U<-Y|| zmnl$pR&cnPLz|>a4;yztLTg8pW|DOO#0a<<#+-^`;c#csu;m_U&jxI3R~Zci!o*i zDz2RR>Lq7#xIej|`mcC?mM&vGu*AvMqB!1x0*uBQi5Rd>pYvXO;ZaqS{}=MES}+Uk zk`Bb>LTN`NqFXd?%{9>wTk^?J{Ekz{GmVX86TeQ;z5Qun2%``}iWGVbxiRs{*TGdYxa;9{s4&Mple{&KK<{A#nF>v#hqzx@9VMDSip^I<0G=L$um$ zVvbMih$2zPE=)ntSdO;wyE!8!&n}`qVb~__av>~h9X33U)-FOMt$cEEEqQ=YQX>4R z*_WXZq_rAWO^$FT`#0^ky<%2pX0nKy3F~H}@&z-i-7;t5&0LF9nAMn8ZZwj(RM2Q0 zF5H8RmUkm@Nq`{5*OzBg#q4!fgx(9#b zw)GcsIR)J=u*Jn@7#v!KA`{`9KVq0jDG->GaH8(OJp3sTky=1(&cqT+*%id21fBvx zhI>Scb5J4)BS_rmKQ#bYEK3(cJr>+SDUTep%Vb8E`e~)NTC6$EPu8pjFP=%M+ z)vr-&)V|8JpQu#|dsYns-myh}El0mHz$t4`saT~V;F`E62Es@H2qL0SO3Q*_03hY4 zmQz`+QDr4UfZ!5DlkKKK+y>h zKxt%%QWc;`kS~X5SoBLy8NltU)5zap5l)K$7-cz9=cRnILr@^L--00QS9#% z9KkAYMd;DH2N2P6#k=n0?f>OY9=0XZ(}m_ntpVT4t@6}iLEJz*{-d}3n>=INFLCUC z>F6oq@D2~}LBUeW)v1sQ8N%o03+O4_?zr*u&!{}0-e?M~o`1YQ{(cxAX|u;~GD}W7 z$tMMaCza3lTpD5}w3ARMQsK_FaNwOS>22iukh@siv@Oz1)ne%$y^UDFt0(AuSihuk zO)ADl(e*b<9=DPPQi#fmJ@uLaKtDzE$tZ#G)nTF^ZJ(B-M`a{R2} zUjo^9<=ov>UQ;>b+6pBgAg5T+8tMv@9-Y47wlq2h{>tz5KD)Kl?2;!v9>6GL1_h480H1B~MDRhsjDzg526k!{yRo zjxvPb(ye7U`_oI1WZyyIC))Ia9wQOv*eg ztfJ4&J>Gtg7KU1^3;P6eu;&UO4nSYuE`aHmsc=yKh?Kmb z8l@G#fMy{bEBvtq+67;t^X5&+i2=O{dyi1whkdrGF1x}m=wFos$7N*6X^ZtqoV=eh zC5r{872yjRCt%5G`eds8Op2_c3AtiSjQKUE4u=5q+op$!YIdBP_?2#Edy?FR@vqCv z7U|hWgq`)@|Cy{ygCl@1HvgMN|4gH+C2BiL*x=>*M|`!2bP{Mhqv%rlp1dVjaiVR; zMv}ZT)K)FGFVHF$m8M=rJ*FNkx$%0(K+A;7^y`>6J*=th`zYw7{4J#C;wJT!b|SeK zz5JSb`2s4-P5CTmO;4)pKp){WBV5V(ldz zY)=ADD2j_eAv3bjur4f~=D(`S1se*b>UfLvkPoDcyJon9CHW~lvNX4%wC2QbpEbE` z{Q9|DyQv|8-~A$^mQDKy2r>S{7<3Dr7p1(T*T%9vx$kzH`A2T**qZ3T zI>B>p#03c=J^Vpi1x}IZRvB|ovM4@D;@iOc z8fft@sIdqSYH5Pcc6?At_gKb6u@S1%a|HC!_`PPasHDHjQi@i90>TPa9igq zO!GnF?ovuVe4m`y#n+zh@Ypb=TNnTIFPeW?Qq09HQv44tAT$jkaS5M{3cCA@=(@=i zSYUYWN(als!4$I)zj{QalWh6dqt8zZ0=}3&6N6>T+I93!y2ug>pt<_K_sqz>b(H!2 z@cv6^v?9#;oy;50r;nNGet>XWlfxISJs17vexQAst}UCiv_;LoL%=(N;=D&%*g57G zqV!Vo0RsD-%1Z~O#SSC?V;C3ki?NER2L7^))Kz?~-Y$NZmqdznFe6{Y%qJdVvAj zrHA5L$=22QCRFeQFQ&EiB=se#e0sP%+@&ZfO%BSkk%!3ozo}^wLHm50>$o!Uf02+5 zb^$a%Nq zOdPagt#AJ@+(|gX!sz;=1 z+)>J(nNfV^Y)t? z*IUY_e!3Bgt!LA1)iE0?&E~wAyc$o3GW$%a35Qxu?iYW+x@25+V((m5+~!PaT-&Ju za}7m0+Mc&aGOQnM%KA97%NvebjZdY7Mu^IaRJl z(oz5b00E)~F$@L(D1c)a00000000003;+NC0000Ua^oE?$!N+HpZ}Pu!qDX9k##UMS~ud`R6JYy5&li4$m{ zJ_`C@N0hd)$AXKs+mF#oQdtgGlipV(t73hpgUZVrw=oQ1yHg#(V)taj>CNt- zK$1}+WRakm_a01gyC)n`@tqMc(B z-pm#W`AKfqZa9usrlb7A0r4_D*U_Uz8))*#_V9;o8ZJ{F-os5n7+Ye*L8r_ z{CnO8&$Ylve=K$C&5E42VZ5>GxueYosU>`T7ZLz+fxi17CJm8ut_p5OuWv51R?Aen zm&e(Ojbc%A@ouV-00#%-Jh?$KP@?s@Kp`KcXL(D-4woKNrAI%lU#r*`0`8gxw&ENwVV4%G-%lO3S&#w|L zaF{gr`Ou*#8yvE=k6GO7oyzaNU6#FuX<4)2G%%OeUz@pFOAXde2Dm3Ax}*7 z(%JD(=U?ltCFEIoOF309cLCInVsjOBdG*x+pSHC+j}(t^fv9XQtM#{KxtdO@Y$u#~ z#rycuPwB`S1~4@zQ~~&YF>rw&U#0zj>}8HK(PYu@?zl@z-VPZDd*|Mqna9#0?B2a{ z&-01ic6U4Hlv${Q_c{ng?Fc7HjwhQC!v|Eqfz|O{^895(TRY||l!9emuARNL?RrK3 zzLMH6sIbY5H-Mn^>!4m|Yf;Ia(r z6eyN3!i{}A_&)VI(zxi6N45nKQTwcF78%|rJ!LlLFV(G%6Xg58y{O?Wt!=1dm_%Ed zkn#FTNr7(AukHP*A>+HJn$v=Qkw;JFb33)=iBp%&g&qu&M8tAuICxf<(#0AmCBbzJ zHI#f2c37+7Y!^@LJ5}aY(La|rx5&@nnNus6Tt%TZSJrbgBxtlzZdJA=wl1t$g)!nI zZIU|3?LU6_X-wjcXcy9Z>n23tueNF$fcm;p%)`N~xciGdR)`lf$CL%uTs*e>Em(gW zfv+}nV?~;N5Ok@zyz^6Gsd`^mCN6hg8X#W}T%;2{A|yOQvVA$Qsm2ct%= zOUo52oLbhj|2RoL4Hi!#!P@r@gOBsLurTW7!2Lm!y6wql5Fjobm@#tQF6G(%#0?YI z4b!D^%NVx}N6!QpnYjUs*LOZBzL!TUxGt70l=vKc()O=3i=`u2Yci>Ar`as4vh2II zNc9A$K@UB%CADzUe!aR~oHhG=pP)?52`dAP-4FB2`Pa|H_ucsBJ_^Vex-jowxGF49iIpo$r@<@atk&M=A`Z=ZvX9y`o+rz+~1+DqPXm}IA zhsCywpSP@Q7&Y^)0%9UxFXLcE`Z6a+Df7TkUfgUjRqa~`8!tA&P*CM_107^5z2BVo zhj4p+%z|Q+UDJvtlfhExitdw|)y2%Vt)P`9)Y7go3!*&COhm?yd1NY8iOPQtuzQH9 z+Ga|CmHC?gm7XfS1u&(3dz|c+nd(>Vg@UR0GCb;u5Njq;3H*Ea*Ykq50vnyka&PK? z@Bjb-qc@8w2^JzmR76IpSgRVMNI)eDjU1gPvNQ7#iYZvJ5!=b}1PT}V&laLDL|OG+ z#1J8sh&6z(BcQ4R17d6y6b?*E1sCVMxo_#f4z60M zIl=>%Gzy zg-K}amC>stT1|LUB#Y1InB+e5FZ~OitoG02E&bLqO6Xg^t8gGtLA*hHmg;>nB0u~IDPTmM(`pJJs3MOkxp zM3$^+e(qTylgQ6+O@naqgb_#5Ni3GfrKwk%jl;)nLfg&yRMbXL}rSjdj{qr^@9(hlj zGRDRjMG`jsk|6SP0b`u zNos`a3y=dtrru%T_4{K}kY*<&$UEkFH1wLqIsORZR@%%rE+?o}BmE;JY<-{4Fo;@v z|G7Wj=Mgi+dS6YGSeZF~1}ctv$thU^aT=h=Dr3a4k))sRxFRasP37iXk9v>sGj2o2 z)sJyMS7!Fuj=m#1$Bdua{k3{!DzSez)8Jq09?um!ZjmHf0QVhlSubf)`d+%{H?oxU z;^({j`~21T;$BdmW>x;>Rs{77uupT2@_KrD6D}xmka*AaG>|?RnTRb-`R;3TY8-8z z`h6|bgU(^3TcxB^;94&kkuX-cQR%PMjdX&{;ug#W%Kk&+52^It#=~BIeOWBeg>L3e z=9)G#^oJ7UV*2Y|Ox8$)(`GscAIL4|r{7u;|I^dH7D;9z7DvCIUl~zMXr!(ClhZd-4LQnK zi6HPc-p*l)EO+t$@~mdp5D8nE7cC;jQuB~H`08>pxgLj)^^%0-O7@jK=lp`{u?Ik# zt9f___n5H@{P)l=;EvCdNfLe4vZt2`B)-d%^RL52d<|=GP0MLd(bDN-zxmY-$k;>VX$eqjB%A z_`dqZf+uIn!DT%>hrI8h#S@3jJq`=s1nm#*RJ29aGXzo6US(zGJJSasfA-jvqC?Fy zPc!>`o$|@<^^NRbNR0G}F<_C?mr_EDSBp)xmKyL7a<9*7zSYN4U#aBDD>U#DLG=p} zdr;;+(P^3QuOb0-y!MLEn?R8`^pY&w?k)4MiyF!gzG)KQ>`+rmA2(C6mX=N6MiFz4 z@c->~!o|wnG@|)k3L`W?=soqI(m88@bk)MZUPtMr$j-Sf=gm$hi2&%iSgn z!xFvwyZp?EYg;-2#keMckG}KAV>2U^by|AZ^%qB>!E*NxEY5g?_ED{~?Rs8Iex-=C z%_IM%Pemz4N97Xw?4xSu$bi0n6Y5W-)R82fEPtfUNG@mQU|xT*cBq5g)o;i8gYU}+ z2_o4o(n&s4+fL#~T*}nX`O$uWVb$oJV5cwp%NA+c?v&iP7xN49|1kPVRXYvlNZSJl z(=v*aLVP@{uT2v7PxXnx84Jgn#v77!=-D`WzV0smmLvDXu=oFb(pZf*M}tk{EA?Vy zj(WjEWW^0y!=*TnbW|?V1TEpbnl+vxMA!Jv=!ScaE zikKY%m z*Ypd%7msG0z&&3#-o5@{QnH=}OIX5`K@}JM+(!3?7Bb#{@y1?>*^Dmrx65%um(d2Cq7`EVkhMIBCPu@Rb(EIslwA|w+#k#Qbx3$F{0Cy)RD0jZUt zCw#I50#pnn@P&3)4FvK4LiRX?Yc`hRLXeds)^Sk5A!wjo17!A8?P-@8=$`rnD0k?B zec4T=60?fWZP~(t$w?i=#x$H9c~s|=CwmB}x0|4U4>mniH*K_0 zA)nB*n7+)j^)z;)IEEZW8)!pS4f0dAk>^Ce7%IU5qH+}z;8II6exn>qWF)3q60TS^*PxzCF>)@ZG`kVC zBme*bsuVhn5fvr@5nuoS00000000000000001(Pb{j^l52xI^N000000000008hQ! zAz_FD2w{T(000GGfB^jEqord6hE*T|7T5slR0?Xsu9O6nE=JVajyD9_SK8Uk*&1DJ zS|(|}C(uARW+>fVHZ?e+pvX9uIS@1^=T7~39)g6%-VGE?*q?ew7)rsf*KX0x@Zk`c z-||Mzj3JDN8mtr>M`|}>H!gBBV7w1LX*R|rcwDHFwaZI|&gDpx-!zfXcRJRUgklVx z0`!y#1${^8paZ!GGF?kVi9^$yhzpHPRtYHDl8vaWDpZ3283l2v9;9%LkxUt>7y_%R z;|E08P!c4G*vsd55Y6$bL#f6gv~&MFQ;V6SUS#1+#?oI(6~u=PQXdgxrum?gsW!wf z3P7$4MH)D=sSNH2N5iDmiaO0~JqQJ_YOR!v2CXJIC-{=sVx_R%7TSiOV5({hkfq5s zUk~pQ0}N6rD5DUII@cbUQkX)NY)UpZ z^@(Hf+69wx*zl;GXcR*{2Gwg|9AOqgcqjnThH~P{D}XsL6-Jgg(k*xBLH5+Ky(ogT zp3s?G%W>~6bF?E#51uEKc}*OS=^D>LKNZ{zKgLZtvM>#wWLZM&+U=DTSDk~do#7KChQ`!g0EOwYxf=0AFJYv!? zW};|hQi!F9B)hRsmq}6t5wBTVkBFpE=gDB=wzRRkam_%1rPS_khzP6hp}k5m zWi#e~UzZQ3RI*2M-4mZO$EGQfpJkL$Q1s$!&2VLy!M9P`TPjhqp)br#V-$!Oj^>vB z0}C4oN)I#1T(R1~Y2%R$ppz;btP0I014$7da~uPsih;ai?6+2c596}IswK6QPtJ>k z*KkA1>xrN9t6P0Ll9B9(4u^w{!}^vL$a35ylm_Y%%(7c1jSZsiS_!}|=8xM_*0ji{ z%(1@qH`3=d~PH1 z%FPI!leY_J-)tUplRM7fwHkzI|Jv*8YJx# zyLYMbUAWV)KFXqj7YOrs8w9~HoP79_tdahl$CJJs!g;#;ha20*+;i9<8d}|kS0e=p z>oW0Zk?pN)EuJ@XD0>&??-B=1q|U7+&8X6dH;tZOvSmU^>RNXqUu0}M1sD;+148&_ zX=leh?TWjf-8swrkZ*2Wg$EkRh(NZ;T-A915J9=b=-5qsrSgX^ZaSpF3RO`DU0wb@ zL|l$Cp*e+Ll`xxV<~qK-?~^ehpLyo&NdJe9ESJpaoKmy!DXI+`i%E+$yWkp}(kYG;vJ$&LxoDn{ZkT>$q%#OF-!BE03F5-qwe$C*4wgMSb>DRZh+ z;XY#uW0{wbYqF2%AcU#C5;^p~f{V{2tPJX0!B`=f@{8RH5p~{x0gs zAR(QTmC6^VoPH!QOmY6-=fTKFmW{T$>?D%suq)J;F1;=g=kkD1JyHEA@B~DZ^HREk z0;PWWe^-Er000526SNMbl38L1NhF~*nQ%&xfHEZ1h#A&d0-|CiY1E@vy2P|Byq~RJ zzSJt3uovq8kgY)wU@aJQgIJnIM6Dk9Vl_HxUIhCgQl{|8P=|tyn%DKQedDEp zwoi057KTF7>rgYMY`W7?7Bx^-4#{{6L^>u|p0?Ly&Gb*p`K8Nvo#cb%AEQ zN3)jv^Cqx&{*jO)ENV8O zFOhIO2ewz<9^~`!Q{Y|$t*K+&k*#iInM*eqh*Bz&!7@*q6iatYCDQpDXlJ17`zA*+ zYu)yH)7f?nVsuu!cOa_=XLz>bX!8pAwOtBxLRaZuMC7$T$G>X_N%{|t6BFVnz42ua zE3+y$o)f!}ll%j=vPlyruZM2P)Ag`#b?n^9f-T4=;S!S8r-_?(a@n8IlvV2SBx;Rz z2)FAg7zSzn?iH zl(S?jL*@w0vmCx#5QG=cx1M4tk!UvdRVL%bsn7D7E{akJtY}qUSXs|Cd5CX0N2;7H zoJ4H2^z||+Nal(L&S?mukP!7Bs&!2EaWokiX~F(sam_d}bTsfnvX82gSDj>d- zBBJv$@J_~yP@U=4q&k7C{*YK)<}!r+QR5SPp7Ct>$QhI>7#{a?Eg6>caGRQ~dFgG=Z7j_xbM! z8tr)cfeu>)!?W#6uo?&Ovb{w*wSi2`pS-;`Bj#+&oGqqzTYTP+K<^dn_;G^Y`_l9O zW+$LfrTw|$FJe@yQ{`X#s}ReSc6lQud*l^ntM5Pm?&3%4)<%G?48HI@`hPi3%a|3a z92QWc-9SLCn?sXh`f|n`9l*BCy>HkQ=;8(m!V``=$ zmgy0m*>4IYGw4a)O0j7Yv&9~YZfDg&6juLbIk-L4O3sQ-%i9ucNP;BGqoedT0OI(F z0}FpCwf4A$@ZzPmJXxjn`pf4z<)^Q!@TtSL51u})aV*s%qs|*9Ec|kdc^>X0dd3n@ z`s6F_q>j5

nPF)7!>MmNeVDdn&1suAYAvCyoh-iZ5Hsb17NjXOyq}-_r{EO#9*S z{LKA|vE!^siw;i^t$h?(&c6#{{@H!RN2ytsKlktR3C|XmNg4BEA0sfzEJR1K@%1e2 zG117tG({Ii0hMl84c4TQ2 z)t}==0qF*Zq!#sGwCKFOehU0Pm69VLV$_udqtHDK*!v$NSGbCJ*#aQpbXd7Zek0-8 zYCrj0+D38vj~PKs+}1n6R_Z=`oSIsXzxI1kdMuh^)lE8`+1LJg2Kt70$}Qj<8bxmE z+T*fbZIQEaz)kGfYb6xV{ z$t0*Uzt3KW&&!_%{PbFZ#NhU*DADNj{Mv0dGp7x}KjrOk;`vMZGsJN7ATFJVjz38I zeOYs%W!|HE|nCIn{7 zM5D&+TFk#*L{aE}aan7!l}pYXTmGfNPVae@7Z?5YTD=lpSePY9@gFlM)C&JgY4(`F zbQ)*vC2C5ujEvC|WJl69W?an!k`;yT=@$Pd=z=?5{a2pdIh?4Ckg-$2 zdA2-#?~qLXs0-$|>XKtnf7^Xoj*-8gOFv~2;XD4^mm>3y|JrTkti?%q4wo*WluN`M z5llc)@fumv#Ib)`4PR6}`m|Wt+#!(`p?Dg>96|XSo`2|hliYJ|T9)1_a?4Zaz%`5c z5FI~a2x(T;;#z7HwCgK%H=Ypyh52xK?GzcwX*+1hRkuRQi|2kELGdmYLhblE4}HoA zm;JidQbo*W7Y6+noLKC>NK{Ym4j}VPEC2QBuaOroabzx$e#OtKJTN}}(EjhOX(;gb zV$*NbTjSc-CX&VbtD!=wWgWD=B>zmJa>j&x!HB;%y7)XqyeBM1U!i=QFVKGnE~ovU zGL)Xw)FwskG|T^{M~~N65ZU2uND!6aa10mFvU!wbpn=oWh=`L$FVmppWNI;p(@#j1 z0OpYa$PPqHB-$wP85tQF86aD62kgDxeEISrmgKE~;B`|iPt1sm7jYhvotLXy-vEoHl~Cq6wR@`SR6fTw$y zk~AaDI2jbPHide-TgpYTV04r$Q?6q#s~FnXkhx6NF*jCsBylrZWi8w^5j-Ho(Rb$> zpx2b!&pF-+Y=OE*ENp`6G<7y2a-b4cEuRB&CRcjCEKVXCY*!?RoU}TnIT|3ks=r9| zIV>tRK#!7XZ^K1>N`A4n>w8^U6>YQ$%c_;(`4iU&6D?4zqsMIQqqA}XowAb+1C_azglfB*mivLQ7Q zVyh({!wx2@pce0ssI203ZwiPyql5c}#%| zf<_}mga7~l$N~TY;m634&MU#w#hH!(TLS~|0x;VIp8a@=Luhew)8HRlYtABBiG?MJ z!*MnUE{TWl0#KGc5wa0EUe$HBlx}!k96vt`bRplu?rk)npDL%6~0yu;c=UHK*iy>N%bSFpja~W2L(Tbco^YcG&1c$aGCH`x2BfRzzo;l(0CldcEm4p;B=`ViX=s-@Fw zn*nh>xj1A3kPM*Ag;08sGZVJ{06CGIfHr}AEO-}S)SkW$2DuE(4jZ^{$}w z;zpT+NjQ=m!^R-R9C1UrFZ6~h$gYXmn<615awgdLB;1($o1jr|=x>QRL>k7vPHC6Y zSY_FYX|@AkOEXUVTS^vrNkul89`8z0>MaGPdJk$Yp02PVlzBwc>$*rzFDcm*vH_O6 zxfiUQZ73cXvXhpAZSd!^$sw975(;Rii!NFgC7mSOoyh>)Wwj5!<0nKVW)&f{7@gXz zp4Tq`x&$YwvxhxpFRr_d2F&%VVG}JN zZC;7Af!KTqS_L^ehdNS$D5hH6owM9gkj|S0&s_K5F#Su4G9~MbYUZl#OyRTKnwcGu zCBnAfy)s9W#UbRaT&b-SLCec%0~1YXQ1B2SHD)_iA*C^*K*%y?dMS=`|5SLqK{;<- zA`zmnLBvCeo*710qd<3UolvzVt7r}Go+T^j)?SM#FBmKaf^}nqKOr=)xp%JAse?_0 zmP;3#66p?=sI47>IKTf52NLoqHLC>)CR2`ac|o%}t?7Q{;4}ZCgiWEIXYA4mJ)-YX z>D$+QlQ1>$ZS$_sZpgo_m-$2*4_Jrdi@QDtSq|B)D`H5I_#n#55cm$im>Ib8r8zbz8EB)yqYjhlqG!Tp^nGxU_)o-dS96&5jodo#A71uVHr z3w=<)0q+8#g95T?TG-DvB z;9>TW;p5FRN;|jG+&~MlsM$GPbPim@UuQB^Ufzb z%@JD{#6iB(d?x-SD^SXE^lbkFJ6<#=2t%zsZ?wp-V5JmiXrqrZDh6G6wPT{2tCqaB zJsd@dSqCvpg6klbF@KeED%8w8qG;8|%ZLqKmD2uLIQG@V2OToWI^*Sqv3Y}u2QH(O zB~8os7XfIZR~-5KG}k_k1^uspI7kh~Ph6tQuzUWwF>3m;z*n9%NV^{jL7HD>&>m3o ziZ1a2e1K}=Mh_a+IFnCMgmx&Aejli#@oX1%ewHiKp|u{5 z^!mzu7K%KwO_nfKtrdYk31q1hCPlPaM?Pv}C*Y1SBgs^mr!Hqq?$&Z(!}~LZL3rml zw45UlygR)5_1i`-5ATbj&7c8+AmX-lI-PDbwUSm<{}a02VpL3r(Z}cmFMeg#4jCj4 zzhdPU$XKSQ=$8+o{FaqV7aB)<@GCb5=LN(j3R|A}@82HTr6k_Gqj;nJn9Y|It)^tl zO{#YWaixC;?u8>NbV$4FxKwG>0Hxq;7-2}vPZMvlbY-OtelLUVv~~(YAxhqWd(^Kr zj2#U)^(4imdzz`+G0r`ObV{{uT5Ge;RQp~=n)|&9w&lOpxZC$=8#HLP#SWH-$Cc1@>+VFfpl;rG)D=Px^^UX<|v*`}tP+Aw>{DM4H%u(oW?$)YNJ; z)gLWOtWpq)OUb)&z+^d%XmHyS-IY(TLyG%Bwk-_y2@0PYG-!(*V5#i}Nk`=Les$sx z{ko_Wu=VQ^t7@64R^IdR=xht4UqGnuC7Cb1#GT}$TPi|HWQ&I0v*`8Eqmq;^h@ML} z0mK*8Sdt8tpyja3y0SdTwJ2V-HFH+$DXT9v6rc=9u^CEAfKyQ3^SGJ~SrInZxY4^( zL>Kj-h-#EY?xY@qWLpTrW;fySDr?EA%@friXig*q+)EJqsZCOkQLRn->IW-cuo43E z887q8Vm@AF%!(9-Rv7r9FRB5UXlVsJOeNgu9Yts5SNbWRJmrb_sJ#gnDcqgkBvvC{ zM|6#U+lUW0VsBq)s7bI_zRn{mlv%w+uadrA~0m< zsm=`WmS42_Xxo&7@&yP#O4EDFmE!$(EPTsecPS`7!n=9mY@v!5^R9%I=(kdadEsC0 z;sHs4l(mCc5H&rPKvnN2ln}*BYbRk9M)RVLKnDJPF}!Do8vcIo4BIHI$16>IB83zeiQ;`4GZ}qVFL6>GGH{EP15dGl>oTLwwa{tCJzi}_v`*J5Q$?5m!@f6PKU{r~HckB@L)U2L# z&wkoRgp&Ans(a#&%(hDA^BzWDBW3cgdpmwq*VaXGR$Q>wKE+GQ#>;ys7(yww#!UQ6 zYpVbGH?uYQK7W%5PY`}ePIod|F~E@Z0YX>(L$+@fr)7kge5%{0b}|L&U3;L52V!XpxN6ZbOyrp2RMV0_$D3A&?O}TPUN9d;ke9PkIT(dK*Tf; z%Da=zqy+yXP!L`!L9sq3zgT`Z>ci7r?x&xK#3jSt2>y%U7vv`Ul7JsbLi#dG4o6Ri zWLHNlyvOrxNdde;+ z5sjf8)Cz7~5k!iB6dd!wOROnu5O6MrtP1ulrv*Vrm4d+_i$SG2ppXz*4FX9B12;Bq zZ6$)(*?ao|Nf*-s@~5qb*go?#vM=fs#hkpzbpb@H2Y?(^y*lK5+#W+-UoLjAskM_% zsq#@#WagG4umhk^=AGcVBHqQd%AOWb_*I5pZOntlwBcotFo)188R!yA1`S`X>JWbl zuoR8af=?9xrIm!FDI3ca^N3`M($|zJGDRf#rfPB;&QWoQl@=4h#TKMB%;&uRSxmL8 zvP(W-{5xDxZd$WnELZYXe|Ndss&dnXyJzi;t#PH#2ZkvgvzJ|pbA%QCtvH4#hMotO zP4xQmKCtBj!y^_RT(CIVK@ift&MRJ2*;z;(=r+E1i((Z&mk_^V0m9IGvi=TOIbxDZ z=SK2yqAX$_d9?8-ij2%GV}}Go&g%cgB(pR4H59VN7G4~tA!H(|g5786iAI~2EcdxC zMYI}#Su8}9kt1njCeIM5WVZR3fHaHo|A}mRWGImF0{QeTi%07BJVzTP8)+7%m*cJ~ zQjllgLhA*I&}4MRNn4SujmV7zBt2{0{mF;xA%1xfQl#R&wN09|12)~kC$c);Z z6t5!t`O#2|2l1AsOBzMzs;{ILBIK+7a}Dew#)M|MGBx=e@lX8elDuyWMK#jt78g&(R-WW%F#&yW*IZ4&IgdKBZ=jKv{s}k zA8kBZmohW`5$&bC&p>&UKpsNgX^mT>-QjlMDe+YkWc%c1Mhww1SGPTzg@C!;TZY?PMUL`JQ?f`g8^~K6+bSh=Hmb`=&>`_$j!3$a|r%Soa>2B8cyr z7yG_TW%bHL9x|+C;N?AQz)0;lX_G>FfJ=mm}t#?$)ekffEuy^}YOF zMr8P-^3&#p<#ss3V?RiUomWX2V|n^X^Zv8kQXsH%tt+YTv)hG(^{AsVSgKd)e&^k* zS!o%fX}2bkAUUtR{DYomWBD@zh10Bj)a~=!M_QJ3LG;Npz0Q)p)0CkH;GQH3ab(GG z57o@KofcG8<*22n)lLtwNKt~f?n^(?W@e+`Jx7f!y@#4)nnB|~;8H)YQlF$oTFiV~ zMQVQ!##+P~24n>+pP%UgKlM%g9Y-rl-K2q;>Ser$l&t$3Dwl=-KmAf_$R_eV^1heq zR8=CZzW@&CCHU&zRX1Kqws zWcdNeslfE$asm%ac@c8t!5C8ABQ|8Ae51UHWIX}Q%*e>ifm8CtA6(_lVESnhkr^2g1h|a7Vr}$D-P4n2{o8 z2y-P3Cf1H}79%v!q)G+#dPt-@QFG0xg+DZL!k#hqBO7SbQV%2^xD_=4*Qg1jb1P8L zSzR3Cl9?+#LR&9CA%d_{0q-zEBpF0Vj=`o`B)`d0rw)(%DKcadY)mJfEW!vUP&)Ik zMJ^v!M$=!sjSJjLd;-eUcs`gu%B6)8rJ3n<8%08MP(#GX0D0~45h{>8)zpW3W)h10 zi^4>GQKU!59)WaPtipy`=ptWcCS4Y^mu9+h5f$8ZJc#Z~03SM(tt390t9B4Mh3{6+ zdhlL4e(HWZ8q+yVN%mJE%2_-^nE9uwJ&)-9qIZ+~ua*A#tDdlqMtkkE+q+z~tgPO5@ePgq>NG``zuii=`723& z`l~gb*giJX!)y(x<4XVacv{H|l@ZS1sIvYvd%DfDQ2bmppS-Y^qiP~}0M+Z|8D5Ux z`;kZ-9bLwT|A3{ib4%hF@BbGx^$5CDu#%bENuM{wEeMxQ=T{ZPp{L9mNksj`jc;gF zXk18Zy3I4=(F7^a(-rnQ_e%msCc|i#@t0I7YE7e;|=}} zOzjOH?qC@q=|f{wnAoO6uUxG>5^$gkYh@0 zT;;PITZN&^h%{pe6Xg;gyteT}T*WdO{!=xHEi|bvz_$Naha!cN$RfG)or)q_$Ps}8 zjUo{UqwL!Q8+>hc+5Gt=EGk5TiMTOEQO#uX(t5CM(q!S-rIjJLkhiHHt&~(Jzce>w zF>Qe{W#tYqN0zoTlg>OdBP)DX%kEHY$k}BeOWS_D02TCtLuNofZPE-H*iZ=PeCoBe^V$4w$uYT-VlG|F^p2Eb=njB$Mw|uD z1ET7r`4z=Bd4FDy7$&15jVyVaELs43=%vgAeC7z;siIhoqHGj;F9eYJT!LrH6;+Fz zdKorDDSWhivw+}?&g8vXE{FD6-U$bK5E*j+K3G*XK{s5|Ey!+Pi2RctY4G@!Uv?ya zZi~;8faPq@cL#5Vy%skVj$X^Exfh+-hcM*v=$c-(?r|z~X2?bT*|mHI6|d$_Qg@g~ zC0c&DP#o@Oe*xP)2w9bgwIIovIfns1MX6oEnQkF&Vytld5Sz;u4JWe<-r$g*7^-%g zXcEzd^W@B6pD{LK%Ev*X(&%G;JS&8!V73tFhdgE>$fr9vmc|!9+dGs2g_65>)9jii z+AJF*Fk8BbFk=k7)WPM9xfbV$XmS_f|Gt+K(kNNupTe%#nlqiohT-^}P2kcJ205IU z{8Hl4Y+dyciTT*DKgilGt+4iMlk|PtsnW#_bAD}m`^a9D%k+Mw8@LV?oYCV^HW@}Bx-F@v=A~w$ zrojUc0T?KjMu}&W+?N-jVjU^?X@iTA$00FxSND#FUlV5FteisAqo0eU= z$bS`I37KjtTK$*Ne*^g(^(|$Jf)rcX5vbO)(5X=^vaqxD7lUWmmbvOf$`3->G|>Qp7-Jw5#TY{i z9aIz)6ckhlMLMD)A`k=-QF;}<{O-GR-%K9;iCs4*?Pt3NJ{75B%jkE-D=W-HOXfzfMGp2H z;yINCss*&eHYY{GA9oxPuEU-ReN00vx-`bvOQ!SZ<&?Nxy8%hph#cD$m%2@M=XEZ@ zl!_-5c{OGtL{1mkV{oGBM~)rE8QO><76P@fE>4dfk2@aKeg+w_Q&s-11|urwwO#As z$%1t%N~8w8M^Jd2VfUsk%b)VDd3)FY(^Ip4qp%p!*Ds0^Uw9vXve>k<} z^|@!dB}(E!SA-kv-IRtPI&CjXd9AgW=MNO&ld45@&X2y)9+}qm4|s)!p6_e~RbOd@8Vp_U8J`^gOS!3Q=^3A_q%;>GXC?c{ zXhU+NdYSK|M7&1OU;o58i2;_R`|)J+?&@=K&DA22iiT$@=E<36fr<#WxyHnM;mkad zt4LeW%%?7<-~xMJQi9=-xsTW5tbK?)nSI2dMB=zAI9xdF1I{T&Ssz zx?nMF{hRzR$3Xat2d^x>6!$m&yi1V1>v(rM<`2qESn0Gm|-O zU$&YWUQ}+a=Ceefln1Vf9lQKX0Zz2UYxpYKMn2oBsEzR;gN4qR`%N1uhsKy7F)ORe zVYu%l8^;_J{+erE9iiwLW{H=dOb&ctC$X!Qr+*DI)bTKBD}QL|4kL0{UVr2A%#ys? z#?e3FJI|ipor$-iPB`{cCLEtX+{t=73{Nu^)N9rK| z8FxwN#Y266@(+VQ{_*%Cc;eHEBoXQS6Ee{+^`ritzVhc9^#}7CP5<34*Vn|?N2?K%fX zJl@@Y(p{hOX8rHo@=vewLKP)2&swcPidt*OZSw8Yei6@L)<$+tGC>hvFoiJzkHb#n z=eu9^x$&rLUeoas3GvuGNVTv~(Q+S`*V*KLhJEWqwZhy}pG^Nx;qS8YRV?+)Q>^aq zH2AnHdA=KC_IxNMCT|ZE?r9iQe4M@Cs-S&OHux}WUyWM)B``HJ7nJNT~Eh z_Lsqz;AXE7tB5K7hV1$GFEzAoDR#l$EjkLXb=^@r$P%X2YT|Z4s1(2-rl<8Jc)ghW zA=dCW!j{3%3^t7-q_gpI zvMg6Z`L^!ge_PFjThCt+a=Z;~X0O;%>-)~EON_sCMlm*H$|FUT;6A5YC02WqM}AF} z)}*J8vh3t76AsDfjR^aE{nlUGQkZj|bEG^(>R<7n2emkknZCTdQ%Ar3xEV3?sUa>l zll=WAnH1Zhv%RMK7035m^;ie&w&zX!rNY$yqp5idl=~(+a*Iw=e;l%YJbuLmk@^ZJ# zy?>)qo_y5g?HN}WZS3*MD6<#e1$2g8UBC9;GQX(F%{MzdPS88WP&{>kk8tGQ3Co9> z=~K~1a@SPG9Cp@5zW&YiI{j>dnsE2Z+C`o@kKUb}(15_VNwfEZc$d`-4$pjzf0|@o zp;D)?gg(PSw+Pwdr*`A1}w8kA(a&nYCHzn!H&NS{fuBTBCihGGXz0sRV~w{qKUX#%{=s?1 zUPDR_M<{91BDpF!uEeY^3;_NiG! z)zbk+NoWw+xa`$m5$BL6km2SFES(=WPG5i6+w!UgQEsWKu%px36&shJ75w&NvXA8+ zzZWYrCk1lzDyum0Tu{kh10@V!$d|ac4x*>Oj?Ue2d4<+Ls&d1iq-tlY0CqX8hwz~I zmA9b$jk#029)9g>y&{RP*Iylv-3~c~HaQZqD_{G)3QE;x6lyF45o&|y^Y<~S8ifO1 z>ZY%|qNCuKJoEO2PCuwmkr+DUNb@Iz4ULDb&SuV-r6fu`y*tpO>LB~6UNQ_i#!mBfv zExh432yq|z=!Z^p6{M9{f3f7aYsJnW!il+;(5Gyam*|TmQ5*w$+@w)!X^A9BA^XyMM`Z1e12+1v@`9miQ9DXc1 zNHrWLmp`~An&EXGs+IjCu=y%^)A^!xK0)K+%|IcswI8v_0pEw%6_Zod_f1L*BJO=w z{I|Bfbnf6$yygOoNl?kRoWj=ttN+OcaR0A-w4mnb|{sd;lbv3QfcAP+b1HrUbZNHv0LsM6=h-_E#x9!3({G!sV z@;Tc$PvXgrqiI`S z6rs_tmgjktpwmVu2N>T2bXg?jHMGT)t6#G-yM`+%4JqJ&@1>z9k{>Z}=PQn6+(yll znx;N(G#_!Os4C_Kp;wj{p=Rc^FA>_mG^Lxk8`qlB{$Xy4;VkbF2G|yXA{w$X?#E9d zr@ohw?z}maeeWhnF?nR#IS;(zldvJv({w^jOt-HtQcbU?-cnO@`-i7U^N_~aM|}4W zo;@RltA@xYsy71uDNEOsO`Ts-SJ*y!m`gP(deo2fx8%lC0VxTUuXe}(Y4{-pu5-UJ z`1a&m-o?H-UATP8)tj4n4Gh$s_B?0#lrpI6ZFfsK!9QT>6BZuXgZ?9=eD0OHPDs7P zF$ce@d6n&fFwYsy{8w4cWkR{1wZq4|{eNNeYaUr#<~Wq>FVmZLSkd;_C(%-!c8(&^ zNu?k0+`m$VSQhIs@XfVvu8jJxO&s$8huLxNSjq1krl&wA{J8a(a$)Lu5;JDoFE1~#mY^xDIor+^$?U$C1TcFU)HB(WXBN4~=c ze?C=jNK|(BpV_FO&(DpYzzWLC>9v%n?p!xLyZwwTEBp8X#?q3@b&%8bt?bJ2){{Q> zVqY=K+Lx7b!1<1!2$J2-+x2R?2WQ+)v@rc^P3R|L)LO4At%aSCD0)<7_#|lS<>_9X z1ku07KYxXA!g}v>74M#U&hzBc${W4Q=WoxMZC-dD?DX6*LH!`RbwYnz0nukQDZE^y z_1|f){9GdruYj2rCH988ll_(Rd%L!@H^DrSj_#*db2Lxuoj-eaUaRxLG<-q*`uR^o zL(09WF-hg_=HuS;Cg`7Ez&a9_;IPp#_tWvupQ(G91zj~7^{K9B|D5Pe`dMwU^h9z0 z#+8RBFj-SiRt3Y}i7Ym4?<74kII}*6 zRsQx4)iJj(@bgkuD(yzpU;ahk+WXh?OiSNz+}#}B9xjGv7jWrrx(5|0)Jxq)m_oOd zKlX}5@+-*sdX!i4bI>XF^OeUY(62M5WmlV?RDK-kD6xN+dnqsk?fqdkcgik{wi%f5 zK=U6vx?&Hw;_ z9nVNRGFDmC@A=8hfvask$K#LJ{9fNTdGlz{r!vDfv7kXY@Z0A5dQ^eO%|L z`99w^wqnEN_1}W{SCvG?#~j26+4K7v4?q67d`;loL0%WGXGLbuZ^f?Zcgs|1^6cVK zzf0bKdwo3Ih~tsjrMR(@ci=56|MHNFECl@I;za{0lq@3K!BC>!(V)MOP}p{RGWY02 zP-ECIB<<~u{R@3}7GiJN{n8eROS<>P?n%Jar9U|fj}5`~ zPv?hQLNBO43aOaHesjLL(W_(ce~=6U$2B0d6jBy_#or!E7IgUV_jyD<{GsGI=D&36 zotsZR)p9>!rf;+dnyq?{83048(b4B#h6@xZrZ4P(oX-*$md>x8o<`GHefhELt-L-LUPf`cYJOwd%c-v{KR=qa z``O5`ymso`s*;wyYE($Y0=Zi&|M#Yu;Tvr3Sa& z2(hRdiNPA|D?Rc^2pIcSbJ_E?CCAN93C@u#mDY!}>h@lRs9fpwYm#Dn+yA*0bMNrk z`_Jl(cPRS>fv*!L+aiz9kM!L2M}Ydy7VgT`4OYxsWLmCu=NwhLq5uzTMZ z(JZCHd);Q|lVf$T`nztX6@TB#kK>Q;6q{7c_xJvu{N*WkAGVu#6;Z9T0^l#Gu^9T# zvRe(G^xkQCp4(>m%Dgf)qAdMfMohNHTh|-s%|6&f-YK@s@CicJz6|_=WfmN4BU_f@ zGJkjP7y&p7DJ)G zOw7V>bn@M}A^+@%>IGkn%m{1K*WaQxUM+p!Ytz^xW`91r_JMFsHdp<`=GWV^qiaH& zn+5L0z1`GbhA}y-r39UptP=BSFLC`Xk@R;Ko%Vs2N^c!V-V3Lh_w#M8%>OK_J{-~( zePPL@yY|%V4*!uxakJw^Bkre?eH5i+3CPsj8E9WStXi+jhnvq`Xc<4Y;qcO>clw{S z2-iy;d3(KVqMcvNRX#BZ$vr9i_(pdaRk}0vO8Tphq(KX4w`_cD^2P2{)C|E=fiH)r z#v;Nc|L5jP%0kUyv~W+#Zno${;mCNoXP5iJC8Q6jjIp{Cb~coUBWi+w=RZyVb0ox) z?3VlUp+eb}4W5~?Jf_@K;PA*gwE6L1PZh@2IN<6Tvy2{-1x87K;h~VAg_#jU9fdB- z@-HgO&^zZmwzM;4m z@qC;bQuQ`eUNh$C;XS68PvOp5_>JO3=<(g{^?|;sW3?k~|B$PeW);fM1J1n0rlJ<> zkGfqXZ>tVEQ6ud3AXfO_7AMa1O4!Vtg4LHU?4&JbG+B2`s^Fxr>8^5?0UWd@m1=`=4>HhPz^6{NZ zT33y?SH1gR{lIu=(Jvym|6S#V$uIPdVZraWGpta@ zg`3}8F!pn}nL|puI@+E0PYxX)EAcs_yp`G<3CXk|hRd1j80es>msi;2Rj+RnS%qF* z_m7D?j#=OSi;+L$=-we8=+|R;^VK00bE)s&fNhoEN02?eO2e+AxOyi1vH4xA3!TT8 zzX2|Bg@m~1}HvyP(qi$NgB$znSe<)cJF>{VFG+x3Ly!g}0Az z{8biM=8~^?7uUF9Fw7{iOv!$4xx9D8{gO>A-!AQ%SluYeQR)IQFBM}q`M1t)LMev&56io z1+I=)29>LSo@`{;de!*DpT@6`L@35MN@#o6$IRw=imO-d3Z(7jiCnbniP7~e)0C(T zw*IW4}SS5ywbH!P?|+AYU~drJ$G{i zLwNu53=i62z&}2N=Jf~!{3o!3U*gZ{oDT_(2+)Z*9}pH|pdA?<687)ozbQc2!Pedu z0D(XN=HLSUeFlyJ++18xE>3PJ6w1TH&C3rH;OFDxml72dg2_tD%gIW^;R?#yY6^;4 zN^rQk5kgB>4~ay|s~MZ4^v$#lkoy010^;G};pgL*6cCWqKMX&t|NpuDYXd~MAz_eE zFh~*L5CI+3!2I_XkUucFI1fhq-+=#D195;MoLo?D9$vnK8ybZH4iFg30ReMzLLdis zCm;L|Ktwo259?WRiMa6vB zr*Olpsm1l}JW2-GW%0n6A>KpE$Z3_8|DgR(WdHAgrT+gy_P>GspSZ>WelY0Z<$*;2 zOJL_ODTZx%6u*S!mRf5FgMkFZ1I~Sm!nD<7FKkEIMXiJGeS2xpFjMYm4-XbJU&Nw% z1e&JyJc_TJMnfCH_4hVy`t?m>G+uwM=44sCH_8)vyuUCz70s1|QoFnRcetxWUapC!h;Y~VljgG=|=rOI(HW&ao<#qyJ(1mdO9uOX|SV(h>pxo8;s zm?|38=PXdKbE|FTgt%BDJt?+E_vD>W3on?QG*RQGn^?HnR)tDQ3Hw#hNfDpl^1AFs zpDf4uOIKQOU~a1yDIXTR0_&;Qd-Tm0FUHP7O(Q2REj*L#ICNk}G`#xq=M8}x$fc(&u9~@kyFaxAa{lAgMPjIs<)c$s4Ab7(|Pw{c$&7}lt44`gFllKylAB) zxw+sJ@ZzCl5hwo}dMI-epKYmeQ}VY<7Z`Bkc#$D_P(13ALI!(xwEFI8SLCn|8j*H9 zh?rnp)^7zNkP^$|&1kl_-iT2+IqId_%wk4Y^??oxLGY%PDg;# zo|w?p#st9B_LAuUHbCe@8kr-|Eaf?(QH-sgO-F#PD`e2Fm*p#yYK};xs5g0&Qx6_T znLV`7;a-#-5-`XezL}m;T`#4!TuyDiF<0i^Z|5@l!uC&{1mrl#eZXS$8a-Oi)oj%+ z5evB6bQ(wk^pRbD+68lUs4>^gG!9fTw9b^gih%mzM6I)31Y`tFMlvO5XpVv<`JFQ8 zDMo{M8w=-vPw7zq72Z^8WS_3KJx3W|CjnD!vQ@%TE>)>h4+e&oF% z+hLCZ%)d8z2S8y>EXW9na(6CQnSUtyQ33R~v=gDNIEF=a=`1Z=4w(&CfRgo8xx1EUMs~N6OjiwUtZ<>X*iWNuD87WNw$`8 zYn8X?Dfa%!^(Xn#MsZzUa9)mi%Wt~u!bE8!O(IIZ?p%X|tJ8=R-^b)|5z51c^9mzt ztMigISRbz3m}T`nx!-xgQ*Np_!3rXRMNR2iFK^%{XF_BGY3P}Z`ATFZv zS?{}m(!&eB)w_XgZb0sRC{GI8IO;tjpXx~M00O(2)Z0))zfUHD?3ZUtNuK!zWWwNR zId{P-RPiQfzln8^pp}|=#8B4>2L6=t?q$)e=lTL3xsE(*>VFWREQBrKPjEA*>A%pZ zLe;E#KYuwz_efHEb$J@?>p-l`50(|@G@f?yA?$G4slpT%WTKtyUnY)o~8ymMRFz1 z&^L!QrjzyD6&*qIC{_Sk{K2{*^_cBH!07UOnOmah7is*vC#)$Qad3ulmEdqSW}x*D zSM=(5FLy73Rd?*v{HN(VsVGD1`8PxI4BaO4dYfx89$pPJ_{y(93#;KL-=4)kPa~m^ z*+^RCxq)n8|Bu4i(WptB&vF>1aNe?J(=SzB1N>3)zFyhTuG!d`?4KeJxUqx<7mdrW zxfk8dW93K2+rlc)8Ol7ZLexUc_Wu($kLbl#G zX}*v62c+8_2DPz#X-AcerPi7HqHmAtIX1AKd7V4sv(kpMZ>#Q?3E>dng5jd16S zv0`%Q$;V4$dHm!WjXvE3fU3)>rI5c!T}^$_f`iSHfYri@F}wjj^#%2CnRyJo-&i7ZN}79#?siDwBh)vMj;D`gD$J5c z@cq;1TGS&m&?NK6D+e;awta4uvRH(8hRnkW%@c=&*n`)69m75ds({R z{2fy!e_w(R^yLL`1u5IHpN^Q2FrHy>*%E9zkuhH)cotnkJ`WCy_e>3gP%I=|WSHKj zL2#1Sogu>O(zl9^NMCD*=fR@&t{tVy*%5ZZh&n(V|8yLWi|2K6@MqGNl+h?5oKa$xdE zGnj)Y@M((V7cA!dSB%mS%w8^nMz`eJ8aSI*vB1TD)PV_^GHB#HDI7k#Rm3lsc&Uho zOV5gxc&-;HA)9)!Hr z$<39P?r$EkW6lX6;pKR{(X~Ve;JX+8VFdMYBCG@GORraY8+Ka%c2IM`rwk`R5 zb+FlbQ4@|NEZ`~geB_>KJbXB{c_#1A1h~(X^advUa=lgCFv$P96poP z;$n(hX=k>%kEKKz`LmGhMjM3z2P_DMe5<=ZLAo#rOpWwRCm^S|CItW_zZip44b{aS zXT;CaF5u82+2NCJVe-BSQk@76j)_4?@NF}GUMi2x6xN>uJ>`a4q5(n2>xPmSO2m)Q z18XlraEa2ugRvboalX$+4y}`E1CfxB#wSX_{A8S2xfvt>A;p-fSLON~kwTs-l7iiP zz3LokA1Rw4?(H4&gig}twA2&RF12Xb$}h_@9yd3S?DbwDwqEtEQ4SG2I>qa+c$8b= zpm;N5yZXml`RA7gYyGGLzMO$Sv3LAtgFSLwilbd4OYc`m{i&Kxi@s{YrDV2IQY(vqz4=KGLFh-)O2pm4Ht8xov5GF;L;xHK2g92fRTJSHg!EWl($1l^f~|5YuZ zoON4%^5S9cY6)dyz_rW|?QJqeTA$0;>t6hRR&GU+cJ;m$tIQF7cb<|i1Cj5%ck2Gw z9muWKYVx{rY;A9ym~r?^H>i^AmAnkXx@Xl-W;!9&Zn#F+&K+H=0&_=m{$E6vNBK6p z&R8*2USTI`v^UC8PUEL;J?M~r(}rxMLud@TMpaVmd*oZMMGCC2?0iSLrpE2gAI+S# z;YXLiNN?@Hj&rjQ+M<)BpNSVkIrV5`q)#66#vB!x6Lori#R929_rR3*!6z#&f=La4 z0C|pqGp|bVP^6&St1b^w3RsH{UFe-=^D1#nX981`TOL1iM_KMZ;^PnQ4t@)#(3_mZ z=!D;xVM3#wMWa+un{4HTV{G{$IUbhk{U*WnAsHi7)p6q`5^ufOYW$+33_RPa>MeZU zP&r!9VwC>@EO$+3IE^RtG^$Pr0W5SOXOHDXBly#gu=#Sw?sR`X$W++|hPa^?`}BAu zr%1WsJlR|k`X+$~seqhQM9@$_X&y5Vx*YdhE_q+QNkBG6Xe_Vro@#zQ`EOntB$(`` zX9cY+HEvVPg%r9v=%sZbxle7I@p^Tl%9lU2&80(hkiZi2!BuIAU$Yy1>U&J=d3G8N zIO7(M61rwJW;6bwALG3A$$h$ug9BJ*SwxZ;TdFuF0V)35tF0P$DUdmosvi>!G%spDp z6)Ek)n>73n5JLI^>)=*{`yY`8@M$|_%T^I55GJ+Qrw+`~nkO)&cr}Hf@eFYNvqnT` zf6|EG{eyXO4Gv-;fMy^@UtKv!k!Du`yT(txSQH+w%+Icq`elni9U)l@Mkj}JIKMGh zpD-99IbD9aKC#yRN1e-lFqYMd3{s0OdKzEOR#Qy@SgppG{sRMA4xwwOL<6u%yVx+L zEMGJa6v-4u{R1{|AkQqkLo(hO*ebf+1qmd=&BOZ>U_y!39!K@iLY*#n3}^uPR_zj@ z14Wh-08Ha94^}X2Y+f)p5qY^pbq=hRY*mX~-d(m@9rDl-dbB!U4qW6<72zMSSlJ)L zT>;Kb4R7Lgu@#bAzYEUtjj+^(mZ8oULHRHCNzNm$ftS!~<>5fcFGLv>x8M-NrH5vr z!vV=op?Sw_6P%S4tIQG@1YEeH1=OcPZ#C_@e;@%7K`%Hmw*FLo*`A>i;lzmV92^of zo&^W6%RF%Z&gTcRxgFuWameVF|L|`HcDm;w9k91v*z8>gQwP5zMs|0t^~Mu z^OAL-q;URJ7DrlFr^cV#?b$@#NKp9Od2@9RWsUo2aevvVphi!sq(CimZ}{YI>tkY1 z3l4!5bA)_7sK;9s47W>RKR+r z?|bjdrFFmwnrBc-fAU%L?I3arZTNOyYLMAxM;J0DsvQzkrl1fT*pcOg_xu$7slB`E z%cR=)8|AI?-+saSKL_>ii85<~`#M)Fo&b>U_=RRqA(KU@z>$&eKPg&%%gmWrX*AlR*m z$8(rJJcw3H9$%g9vpcIT@RYn-gMrEi*Rjj%Pg#5-|A2Tet*5!xm{=v*2;R3acN^e8 zNsNs6j;FR6*Wi7Z%-~tpCLY_eKWyOsa-$^a`n}jPjZ*TO3-mnS8lCYnukBXiYGg<| z`@sAmT1tzfrTPFAKRg;S{dB|3;~W%fdCTwy?jV{DQp)#tA&~r|PbiEU&*o?xzd=u) zR0qZ7n1s^ea)~XTx!fMC%O3URZlOd4$8*|ABk2{F30{IwfPh12a774q=tvNhp$0E_`%R}TXy(*g?M}0dXXTDy1MZ!FWM4GVkdCX4t!%p=Xo0~h{HGF^g9|BrX8BBFmz6hPG zOp%-oB&VSVSLZ)0+S4t2?ek>?>~8B2Q5!`(ag2f@y+73o^PKpBI?(1klDnYZjOIs| zEid%}^QSmA3C9-$OnP9hS`lia{Q6Ek$?cPx8BUUY*v-`!EUKUIH;;a>IY~DwFSh7- z`VIJShF=W9?H44h)d;U7S;Pl=gesHjOnM)6UjT*a%z*U$3ZF2UDZ!)-VcY@W^oWzv_TNwxB}iO-ZTY*16)25$bD*8hoX|m)Mvcmwrz{sZs066 zN}hij-TlQ=JuBt7B2Kl6UaGB?8O{ny#G_>rDxxK7hQ&I~)wS?eN@+H2rzi8G=Bak4 zT^(RsiurARsd&fSVVWL&IKLZ;1X{w7!xaa!O!#eX8xytY3>2den5E*BPEduQkXoAa zPuEsmVGwn9Fmc5p8pE1*aP2v1=0Q9U1oKAttxe_~wT(a@-dQi!RSduJ9q;%IzKp37 zG?6~`LHu}q1t(9R;iE%LUc1N$W616$=0Qc2Ymb0wylY#hfcnBfBCcm@1NKW=oS7+y zcV4w}1LX64rv&q*{MIX?>+P4moJ0)_({S|=uWa|NEQesK=KW7aUI+Vf%J zhB^mS8do2f!$68p z{v-P(oGU!jh;!gVnGO7%;K=qGS~2(aP(ApWZ*t2Ezu>8~6T!g&Z9g=MQjXuvrH*G0 zH84D?t+1R&vIEGB4UuN}juAhvOGTR9>@-5yZE5j+ucM=ej?RO?@`FeId z&Iq70h_Me(#-~WCKG8vTouLc7ot1ZR<{Z!n(THwK`)v~!cSVkJVp7B>3wKbX-;QgUtVI#6`8(m2DlmuOrb7T1gB`gN3DylCtA4ZYx+q3@zM zS(iCTR-em-U`5R6L4e223*_0gg%ihvwFMEc4IyIao*R*^u7*ZA0Ko6DjT&&cfcjQ7 zp=H4Lb-73=D(@$+8`Nqt|8*Nj+KW0=PDBwuyVX>Q#C6yW=rc{}L*{(3V`CEFG$0qR zRA!`nR0tUs-d3id*Kb?|QEEbdQy|ZmsV%SnL0p?!My)d;z1{4GiD!SocSpd&F@gqT z48Qz704W#EX=)Z*p7o+>qkPrHSpjA$Lh?&RG}Hp88{Q&Nvh`?-R2nx6S@8`9#JD;L z6~nIK$H*(_4)A35d@E;)l>Dv3#=u+(Z!*9h%a}^#MCOi@SGtQhyGzXxMoCz?f==U- zDN7Ovm=~8)GQY~}mu)h4zb#4n>{KP6(-(Rw0!&`R*bDikEjjRT*5_irP~yua5TEP7 zD*cE$y0lBF@m%f*eJC2vlzVjxHN{W5#x}!VS0JG=LdM7-I;BzM2z?~6aM6h;Mj|Jn z_+G0`8Y3Kz#{|9q8%cQ7CRu5ZoX(hH~1JrZG(yyln+ z?dvL2i1s212d@;q&Q&I3SLh_YwBKj}#rq9xh5c}T1F~D98`ve0y;8w}Rx(e-`m;$+ z^OW^#W+Idbo((1-jugg^lmRF?lbP(7cB(XU?lQiwmhNalev^w8QIJHB;PY|~eYM6A z>Vi#M0SbPpYz?S<@);IHY3Rg+d{4sG{F03Xu1j*=&m9!Zd!Tr_CD(x&+aD=>DJMBx zXfTD2YwCrpv@wm>E60v~ZADyOqd^dtmrX|YVj}t1SUAkvl!uDm3z* z$7@>O@SWni?2N3ph6$m~z{!EeTuSldADZjcn+U#X|CDQ;8rZloCPuh@9E! z;D9HGt7NjvbaRAGBPQhXfGMFe6o-sbnO%+`Vj?Kb2`Xx*fKAoQL1eb!9pGXlAPy-m z+0E1frUoS`t?Etu3Q=uv5j&613od`P(yV9KXlO%QL5(057tQJ?9&P5oh6aI+k)oik z1uI!SXD|(j4s`Xk0Ux1`-Fjn&OZd_ONJ5qdEE>v^Mkqp2h}w=s-f%DBw8?Cu9jt{8 z$7Yr3HfG!^#$(W6)J%RR?Arb7W`d*Kk!)i#(plSPGq)H(s`NtN3(IsZFf{lTHlC2^(-M=iR!4*67?!NIJSu2{EMz&WPAuP zMQc=fq?STT#T-o@q7NQY_9qkC%Z=4r;GSMOGXC_Dx22)d1>TE@vd&8R-t$=5N{$|v*8cEnA9MQ-SVq(B8NoG!H)OrWe$9E|89Aa3NqE`gVPb4sS;409AAcVndB) zjw;SXNzJ8D+BL^Y$1!tEN%boY*Zijv2@Y+lBeu>ME)Sfm0y|Y5a3|LnXZ}PO!6^h6 zNi~H*4nW8~4Z}SvvOSz51o<<14UR|i5mCsZ=_c49$dBeG6bS^VJs`M%@pIY!!EqIo zd$*MJxVY@D`tm3M#;~O#!dM3IfKyMv4d@jrL(B$~j-PLlwpDlrEd%)Vzr=S)ooZ5I zbRI&UH5K(Mt!AzMLn**rN(D-PalNL=Yz&i)ACaE41bFo5*`+t9ShlqK|Y zDuBCp-6kj|Gk1)oSiVkj&A*)iaKpucI>|3>6~d)7r|D)G5DU-h%${9yHGL(NXf;we zOayfGoE5fUt+vkE_-->d4w2PVlaWVIU}Mo)S)@bFxIY|(k;U70nc;TKosB4YfZ!`% zyrnjxX(~0sR*!l>KB~q8(WWC5j*W6g;_xdTqPk>UXSg!>z($Vd?$e$$0xa@?`_I>0 zSh5iy*@dsKb=5)oSAJjc4TqMQLdYU181B=Yx-cRaXb~+NzR(RLCkrTWc(~!o^SSn` zl!lv>zb$UyjAR5_nSkNxX7*1exq)wJFfWx)Q6gNT4ea~X0m=0;V3XO!kwWbk0JLpU z@L_T^-nr9-fL1Vf-d))RVu6}6NiU^O=Uf`*t1qBOb3>b95pA6b zMF(_*_EbCzIe8uV`wk2q1g1K32p9T>4nlF=6+~C1vcpodBV1}``w=d@Q*@d;c^At- z!3r{$+rrFvqw{{1fsF@_*^k_68E#6~&uu>l)XHicsX!J<#~}_*vUZ6p_}iIz$Yjo5 zEQ37iF4oJrzyfe-aqE?Ky_0!zCLqIj4(BUWUH}pQx zoIgpzKst8^9HL`{D(bAQAi@YoYPY-t#3dSiK&1Fh1&Iq4bl@qil~5>s4J}qPe-Lpm zk9=M)1(h4Eyu@e#p^PmZE?UDy6RN@+Gx#b(2tHq@$Njm9cB+kG5=fK)2s9_b zh9J!a7s=0LHxOlqInbBV2f5rVpD)QeMjljtW88%-g#-;})8z_p9qxkp1+wXZd25{} z*eF>}_y%%B%v!%j+SZc|$7Mo-rOj_i@QFNPDU3!jR|O-n%oP&ei67)7s^G_d=x}Am zHWBxyH8Hv~ z_qUoBmz<=C%iZ$Rj{M(*dhq*aea|MpkzDj}E|%ruVJf;uKL#-jItSs0w@#?;0=< z2i*!*wtj&&zvaegr`m!R$DamfACQm3WtVK*;g2?p1bwEdE=T7`-_;sKmx63Gb&;O& z=MI7l_zvTQ#mPJ(%8>K=IVvgQ^nuw{$tqKr^&g6cfrthNvmypz$3bS(0G9~KXr7IV zWM>71G%SbzQirTDbkVsJ#8OOk^au4xNPd}E8K?VEFdgb>LCgZ?m8otAAZ6|mN}igR ztm2)HhmV}tFGh1zM!8PAbV6ajP`s!j`ew-#k|?n=EJ%0j>*OvE-W`$Bkx5=KUK(k& z^(NZrb|vz!V2<4s_y{Y0bhXSt>47n`--Hp~BzR;Ecc6^<2+nGQe_?(+;9rs~q!`O- zZ`6M!#ZD6~*ac^E<`4X-twEkVqKI22I}2PGC;yqL>`S z^0f8R=nh1`!6F(^u0T!z>dI5tIN5Yv3HsEo8+SjHZJQ+R1R5s7sB|n{E|u1HpdfS) z9D2#lk+D1~85^8CM$t<(UO)@5C-1_DtgK$#};vd zpQ`^5bOtNLSW4S&B7xEhUx@?PwVX`tFjc--gw{7k7CN|hFLr=st2of+5d;Q8Fp1ZR z9^0XJGrNLx;q-Ny8^P9e6Grr-cEetzt0v)M>?@+>TWC-v`iSXr#J(+P?&d-0J;ly* zcF?K=5}d3K(p&69z=MU=;SZexbKwV3v;@{#1;6;hFb!qt>y+)Rs~qSm*=LwCz(w0xWogdFT;-JTJ@~VbCdbC9jCuj_lNd z5F@x{Z^45|y6R1SwxBH8DgjgYii2?646$jj*-V=ICn5&MmMVj5}X72ZA?jTRqUlYM1qeJa3a)><4Wy|liA*Q3M z{~j;(Ga`jFzyJnX5h(bYmq7993PVU{_lLD2Epyl2{L`)Y@%*@7{Tkd~sLxkU6y={( zptLTeNe7$S#+MW-3UVWH91GoUdXsrE2@4LB4g4bXF$pbesMT<)9@)K3ZuFX1o8>JD zkTXE6xTyMWi>Z(g^8>3bmjy9WiA_HuzJ!DBnq4Y2o5GD=9Jt^M>^%R^KnAY`NtVJ> z1&xcczaBAc>O>S5&k_a_FRYyJQ(cZXuI!dl8qU!7|B@vxb(w)GCuf^4#P=ikBhEcj z&6|xae`zTV=7pHz6=?~OG%F=2*S!=G?Ek=9%6FeY}|=z+ix>^xX*bm&%d5d*|>X~>XmDlKN0X$Aq5 z_3=PhjF1_xb&S5Hbhz32OkSlDuo}UCx-_ew_y(m)rR6lVk}_fx>6Z@kOhYEM?hlBrY_Ep5ry2s zQ7~?-Rgr(4(Qkh2H}q#T)B$(@m4m@&MY3Clf>~G{KS)vu39l-X{VrS}DK{FH<$G!9 zn}&l~E{Bv`5L$(R)r=M|8s zXkR9mA27p+BxwK~nM}+Z7ja6FoV!{`p&C_1B3^zXVIJ6%US-&a_h#@?B-|OA;m;)F z*rDV+&=WEbrRw91wjRLQs-?{3QKW9nf0>Y+AZB^kSZq;$ zq+d+gXce;e0~uv&NX^7(7ZV{upgOEBdjU198RiR78I0^A;E;d zq7*RDRTQT1z5KKEIVf=W!hNN(2rZ%wt{fHh2h&U&;^p1FmT3Z7U<$kjN@rR=A!-f( zZ_$6%^^0iCnwB71J-mlS-{9bpzM7*wan@?g$dj(|u*67GF-DM?NHnw}=6!g2rSYe* z@-FtPZpt5O@^}?(1~ia(1D1|P6G@CbcNDv)17cZDdy`aeG zM;S}SUF2>LQ#AR~z3P$J#~4|B|x8{uHmyJQ5g)jXpT4T7Y=fa||8_%C|@ zPWjZ$xCbfb4Q?gr%7T@L1RD-v4)xTXgh5|vKXSsrdCFF*4mFczXAq0gcnLs(A7 zf>hnvl=bN8m>v@TFbW^Az7?^Z4o)+}v7Y`RWn! zOfdaR6(t><5-hJH;FX?z`XM8>te$o&r)xww0t=4whQh(pv5B}+nXv>&k**EW;1L<9 z$z%&b%xNghcv7&L4U~F|@av7!Yn-biJg+%OF$Hqt1GAyGoK8DGk%S{Mb|)`VO|bvW zKbI(VAVza$0-~+5&wt%cWi~@Bpg?Sw;hu#Y1KSQ=}zkn@I}e7xDEI;=weXU1Chd|9~fQr6IM! z)Rh&sKzT$nfkI0d091kD#hgEjG6;Nz?nZ-$vt7y=8fCVh$dA@3&=VYboG9!<5vWaD zeQ(AWIxFmZl76+^SxAD)`bM;0-n)FzUw>|-G}%wqJ4@>lmX!Lgr<5A>PV&uj;NBab zba;3YN@*?t+4;E;*;dDmm?)4ztDn}T@dhKgkz?Rz6iJ96zSr{(eK0bh2T{2=kQBe- z&bIIn*GL)p~w=0kUNgpjyhv>vMCvkO1CWKJZjaSZsr>)6Sfab?+z?nt3$SLP} zfFCp0wxxqaeM>=RLP$F!NWG|!kR6P@fKw=A`*{Y_tG(N0`}bPNp~b0IXZ!2;(4?}k z$N&6_1I|T8B?2E<-(Y3ood`G|4qh-*8gW|>e~$w`2TZhH@IDk02m6pCB`t3Ga61^6zVXhhTo1NLu=bREk?s$x^LU1F?? zKr>WPrw!1(3TSnubZjhLjI_NogoGoAS|k}&2Nc6y%vRd}bATv448xq@8BCSN3`{8i zk8y7)^LIziaK#%O-{98)N||$Wfb}yh9ib$&Q^1bLI(%p{orEd!aLtV zLC;M5;||u3&mfES6EjpygGa=ZUUXA1#sm5X*`q__g_D;(im0s4e&z>(jR&Tn%o|SQ$){xhKHxIJYAsH(c^SL z^c@ha1N;tCB)dZ{T*uS4J(~-_VajOc&Gvt5%S66;4PNN~Tz0{Js#`rBg3dR(o-L z_!-9|6i&oQRH6s;*cbH!khw-3OiueMpALsoVv(E*MwCoG!sX*VEpf<7sm}SMteQjb ze}MuNFQ6L^t>-wM#t5~k2tB^F7fTI;jGjgi%@905@6G232X^74)bNFt@8tqP8px*j z9n`lyY6cAs9xRn+c>k{&T0g`4CP~qDaCP{B?=}8IZ3q;mx)K+}rsCru6_P+gC>pm& zR5{~xO{`E^t*~U{t5pI4>1z#Xg3Y@9p`W+CmT#h596wD$-3?{1m1t^&-(N`+IpC|n zE>fcg0x*NuO8OZvG_^-zG8^GQIS`j)O5`WahdO?u(=;xiHX;Sdhw*dATaq(~z}dDw z7c6&Urv~?+$fOB z%Afc|GkkvHZlwz~ieWHIgG0v8iSWRO%sFtSKm;*pv!UQ3=b!+bsHQ}3uSEqmhbJ)v zz%R8IxLQf8gK^&v2czK!^$t%dta^wXkv^IPP8QVqpZLNBnGOq@v+D!2=Q?M?-yA`; z11Wrz&Q4p#M)I_uBtAOu*YZA-DBRe@Ifw;ZwIY+RHp)vNfZ zT)E@Cwvs!f1>XiZ?tj3lVzNTTGSLGf_cy#evZ|yPEl)PFstYNA#<0Y-g6xxUfs`c&1bns%D zI1B(cd&i9VI$Jtg-C>OMMCfQ;IB9eU9P*O|%nm)OzEuyi?;CY-HBF3pA_(y;q-I*1 z0W~M?R@;a&m1=N66M}{eG}|%Nc3~|4QA+_OmJTe)f|?1v^7KAJSQwuyOZ}_oOC987 zzrucJi|O{EGv5#UMLW4Rfbx->RD^Uv2z4lSD8mp?qa8lU-xXds>VQfYh`@Qn`A-Ep zrNxv>GkMu@-jrNRsx-k-fofd!1X2?tOHjC64+m%C4=t zfLW+;o-Vk z?#qN_SS>{Z+%RQg;8WeaOgAqFfAbW|3~%6Y2al>QnU^7QXK3RU2#h28 z+ny-fOFSqV(z9?hE(?MVNsw&hK5aHp%_dQJkA#>4g&H?`cx>|6p-w({s37-e!J~-n zK=Od+m;|KV066PbNKTZtI24moG4ouYhKtL0pqli|HcsT%3#Uty*T&2JB|8oDN}k2$Q;E^TT$XB)*cXfx3SZWzLrJNvg0qs{phU zf3>ayXCLY6r9&&+{UpHYkMi1VHL*Hp3N`?%f>zLa+(1_D#c z>8}MBjQuV^AFGYrGaID}$;1*QG^Y_!k$ehWXJ#-qNSi{-VBjw5hq34;mb@z6!Gk%+ zPcYNie=<0IBspo0Hjr^X%U6VF6S{FTpazCvhj8ft;{OD<@C*r>%w5#^aQF34XBfBz zp{igRinThr*^w8m*kGu1QY0%0PpLlVT^duSaUyh13ae)qWH2for1~QrPJliFrxXYm z3aT?_w8D%s8in&s3%IhqziR~oL4OB=WVL}o+Xtl`^?oY+pLA18#C=wBq&mGtDy&_-ZWy zK{R}9c@~XEb;0&tw`s&HS0DpsqDI0%cheM$k88l?5)Vdu)>e=C{jTZkUiX(Bo-*+8 z9y>FsV1^zZp3Hj`goz36VqWWAiV-Q(#pzNn2(Z}T!WyxIG0#U67 zcv~RVCYw|UCE4R}uJ+s$kUprErB}eoMM+Bo^cTXxn4=^I)IqS+Ez_*Vq2!gqg@o#e z-%8ZSRDh;Qb2roq+~BY*+J$y=vkC9 z{gVc-69&)o2<6_OZ$GH~QX}>bL2|0~VeAmraRcNBQ`GIL>5VsS7uv=JLf5dd!E43d zAvDY<4fY$#p1`4Z6jJe#+(3aO#bjjck!ma$NAAZ?(`5)`WP}q5M658@fgpngc^T!b zK-4*xvT&uTBy5C}0mngBm#vN|nTdb?I>*z$)na7s_evdN{sL~zX=SaID|X_h(;0hm z4<=Uc{zHPc=10IQ(Y?okTeT7ZCbgE_Q)_R<^FnI zepZpaJ$EVId-;_!C{$#6%7YR$muXd*cS#s1az&hJW*1@W+pKr?b|ORz*}(kw$Bu0y zm;1AW8M{oBJ01?`m$~dL>n5)@9Ga+zyZv|`%vL3ybtMN$ZCQtooqd2Qg)Sc{>rR-5 zSgkXcx@CZjh~@1un@micpt6aCnAsATvbmY0&MM1B_xSD`Y_s+|5(JV^hc892gL1O+ zD!q~WqG5`^yIp>?XaiOWPf=Mw9oActO;St`3&Gh9%PA$p`JCsXp98?l2K4e!V#iWU zrwpblL`k)?uH4YrMH#GjK|b>WbvwPX0u&R0D)bDU#~F&fQ9iOL*9~^qC;5Ylzu|(c z+>e<*^|_Yd$*TzHw9=~tGagGkP-S}o8XX5g?{J0V1XFNwsuUnmU6k)wg;+8eV^IG7 z;Fgul%us>L?vZx`_C4VFfUUnaCII_Q2HSJP`?(OzZeY^I3$;Kbf}*u}3ff`DMy%KE zasZyWOj=x6XBr#cPsx>q2k|{wU1j`2nXW{s81b%9%3x#rM_b+`hi>1Ghpr9RCOdEj zzRH5;tM}v2Hglg4)A%92TKEE5hB$F%zoCK*q=;`q9ZJ~_t)9l#zB=Nov*bQ}n6l3| z8YJO<+&brCPLkaxJooq zdP|`T3YD(}!;x}l!Wt@uIGcpY2pBG?&CY`6PFJ)=P zU^N>eC(qLC){(&YFnHalsIo>Byq+@lweCNCqSN|2VRgCSmRe~`tHr(ZH3y}e!7V-5 zOO_mv<@a&)Ftw`H12ahp9z3Hza%|-j(e@v{Vd9pPp^ifndWITiyMswFFB-;tDC71M zA9+}^Hw46OIfhw^i^7LmrQU3$+m!XyQm#!ADX;tQldi<(2NokkcmxFNmRDn_nO2t?aqgIXy#L-p>P` zyZP_adlu_62#bG@CXs#d9O!H{|9i%BGkcvXS>j)YQYyq>MJX zn%iJ$Q!%;o*E(bQzazgZ<87FO*iz)~tiIl`-XAZgKe$<4?TBqM-7`dpI-^{3VrH9( zrqtInW*)M6F6HuC+>e0)&DP{P1T|~v>VtVC^|I^B$8;-)6}1&L^(x=_xPxRJ^LD|N z2Y(e~TpBIUn2ED$&J(WdTUu4H-vq}W^LkLsUAQa}{>IgKN758Wf%({5=ug?bB2q0V z=Db+ZTzcKbv0!$~^W*iOd*f%Oe%ta_d~DMiu3j6)_Z|@ji2Gkdu@N@*Bw1d$O^wUoZ%oVRpRPMF1fsU29g(*ubfD$afDdXQhy3HGG}hQ!0$j|vbS zj5~MhgPk81UMBQVLo%&=4Cgi~yFu2$IwdCHL0c$#iG{0S|t8ShqvkVmA~$FmSlU|uWn?tC9%2~pRf?ndIL9LHig z^EsJ74^$vwCfF{dVjH}xY185Qu-R@q26_5L2MpW`0LT+!JGyq_nyzf)I~Tw)1KR*3 zjr~Hkk5H%E9mlH|r%jvflm&{aX66E`Jqu+RXDo{iO!Ax4rhrK)x;y~&vWt>88xVWq&n#d&O`XV; zi&!Nk!%}p$;iTX%FEHS&qEGVo`)V<|?}HHkSY@5vE#)-5!#Aa}+_YZy+b(cKHKUEi z9l==8$M*KfF0MnMv;T9YF+NFxf7Fx)Ro9A*JWZ+Zf*oY_-s%n#cx(OpmF{}MYjNop z66U~7;KkQ8@Bylwu!2`432n=-tWD1CtQq{GEZjk*UqTUxzRARLbU71^N zd{*@6MS~oAm1y87z6>T?n&z7+8Itnf?3blsHYMHMXNc39@2!2_<}5k1w$kEBsbcDk zr89UjRKs5PGp;V-nc81k2tl+ztD)WEj%U%8@2gI3rA*|(YX_gUjFFW6vB6Kh1DCD! z{NPZ!clgv;cKplPtb4}p%O%Z_^wyJ(aO}-SFxNhR>CGU~HJt21zleeCt?Qna#P+yxI zeIiC%6QAFych22Z6fmU~dskQe`ZktZkAAH#Bt&YheFK=SZ$`iTd>pPkW1{MCE%CWL1rGeK5p7yu%ezkI@q5~(m zNkau*s>nfM-eq67!ay{>4(J-FY%{pDm+u2!*pBBT0tJo6p_Q4(qM*RMEe@S8o0Gt*JA zH_3BxalXR;0hW#Q3bPkGq+ey5JTjofgJ!obd45BUjeS~*hF+8Gw(prL{S&R28Ekce z?IMjC1r&Ri7CBH#g9f1;0Fh_JgtIfp*nW=&KC^(kMV(~%)YU9-o)LtJ0kkYLJB)at zd1N3iW0g2}`kQsKvf1fmAq8U;Z+kgRxNz~VCA5j9_lXfg2r1GSnB~pUunpj+Lt3cS z12|#NO9o4~j|_NDti`^?h*+K+kOvkS$^w%?lhO7zQ>sIq0lnWE>a^bTI6Bb12o0WPLg7Q2(C9zNTHkd!TV-~G!hxJ%=b(Nb4NaYnf|imU^iF3II}N<05;l2^iCMEYG8k&@b65?g z&rc}qm(qn3sU1#w(*4g_W1>O@&K7TqfQz9yqz%V$2-(zVF@S~_bNNV@AWQTZcP<1D z>MVKz zN}7Hy1_2qn5)n%d=1w~Rsj*SC|DH!|i*ipFv;(>>BNJCp1N$^mnwpY|sZil*c58`` zdZuo|rNH7+Y}=teJ5uen=#U7TzhLnxFT*rW;DtNIrZLgPBdpoc3h83~M4xFbUT(Rn zT!#^y&pH^nK8GE#sqIWEdTz_#k=&EnS^Q^Ps}2e_<~7`_|Gq3~!NSUJlCm`X=1PRH zbe+Y@POH&>0xZ+&!S@r_SXieJ(%Z+vn-d{FO{ zTozoRNe;291M`hfHWt{OGX(Ok#N9OOEBHcTUJL2Cf?HKh?cVP5`WuE5y`^&3QvCI? z9M28bX@C1~CFXaccSdfE3lM_d@^>^*YF(C;0sA6%@SlkaiB;|PeXOr|uIF2QQoG!T zAHhw$tbdkG`9j>hvMwa;_-ZKI!K!<+=#3}$TY}x*hC2gIBMoCy^^KeJ&@b0#TP@U@ zY<|IdlFg}z3CoGgz+Sdmj5O#Y%x%%W`ya56mA&#i?aI-) z+Yh1TuG`i}e@-7!PrMCwdq+j8RysG2H@TnpFxmMcJj|rp5QM)n<-({$vsFXodIZU2 zUKpavaDxY%yS03!JKXo{6-{6d=}itu{HlC4x|OntWb2_rLxNxH9uyDDKIT7ux()~E zAKn++=3P{U@7cKkuitUY;DL}c7jGAR%*xn%OTu$m=Cf3?PC5`)#v9Gmv@&JuXeNx)68!wuUYhE^zuxnrDRU2Cb*6mbz&)IT|(x{$QAAaBZkoScW z-{~~wMZVB^I1+`w=4!pByk{oz_z{P7zeS=xbvCR_zGv6RUz=>+Svw}s1Wy|4*12?E977v} zIi6JG^@;h0@e7^4HDczFi;Jqvi*MwZWvO1qq|5?@}(Y)gs;hen#p z`vab&iqi7QeT5gtT$D+Y-+6_dpkumZ8I)|hkT**= z)kIER1LH|k#Rvu%^|nFx^ZW)N5j}5RCNPrirjaf8a1`xpdN(W;oa%s16tI7^_^^Wv z1^ql;Y`Q}$fUY1ZyD<`^7EmyGQv%x4(YlI$1&O2LY139ZiRy?35&!ylN2RJ!%BOo$ zC0+q!P~Ro!YP};UF1XJugS*C}%=n}UX^L1~4ky)MQirQ-ig29LXf~&M$Yhx?mv{^5 zEeR0Xa%muqoO+!Hk?ho~tdKU;ur)x)fgM?{Nt}6Z@Jh(bAKEXI;`3)k1W?+Bbk%x? zY^9Rqv!$LFPd0VQDp}9Piy$09yg5(`TrYh0o7Ht zkY9y0LQcT6G};rgs=~~U6ZUfpr8GJ$No&D3ZM2tt4^ZJl9ZEA^M_RpgvAyV%<2`za zG^H&m_I`p&r69e*k7U%?#EtF6qUmfa^HnZwP0-1tvgZ;WC*(k&-=w%i#p26e7x|B9 z&49_`c7*dZ4T|M5m9cNBE-)}kcA(`ph{+xy%T6Ndh;7aaD2)5OKGVx@0CDqmD0L}c z=0jSXqi?bloPQJ17v=C-VH7s;i}=2&P>y@+tIco*<|DzUpA4;_4Y+`6X&q8FDItM! z`W@eR=!$DC6JKk+529@=6)KKow?|~CLeIfH%5iAt(md0Lrks@Zz_gGb0t9tmd`8(n zkVr>Su=ky?@kU5l?$!1Vw>3i(pLbu*Of4(wPJU-*kaIuBP!;TF^k!euQCdIzmJR0y z@qa+3v9->gROvZ^Y<(WeF+N4;Io>y7J{_p{GYul>t$8S0mxvq@N#&IUk-Eq=T>9jr|XLS7Zv4e>)_N6!f?m>C>z~wEc+vGTQSLM;X zI<;faP5;NZDe|h{ibBFM@XE-k+ucnmx-7?Ydv0;XLKoN3*?$5@Krasz8ReLvNSx6fPC@ z`sAME;o{$9dcls(`0x^%u=j(WbCP)ycu(uOzrHHFv);w{9^N%Ilk{TF!UD7i2HuW4 z1p}BL)^~2i>g#)X56iWCg;yu-?*2o%@ZCqU+~QQ7T^{BUKJ`3L;Q-#w`#oW6LH4c9 z=1+J9);C|w&u%B+n9`l!D{?pBB54)ZGrDfB`FZZZfs}F?=n_(5Ah1@ae zApPu#P3~0=)iTM`f&8;$>y4K-xwfx4vLQUa&B?Q^u#GeDXm7}wmu`++AhKv`MbQqn z^UaQ&#QZvUVfg!7^D2|98y69gAyn4Mfk$nwUfx5SU_B=NNy&rfV*~Fk-|ETmIM8N3|*@^Fr2ruLb`9byAAZe7Mil}9RkJJNX|BsmNzLX&TIrO z^(7>!ELx@X3C+5GAa8p3q5&dEdstxM_VZc)>rFK&JkD&KA!#hOgx@tRe()XmoY@zW zwPH_lb*pPL5dis=+-XLnzL6maxH(A6B5>uNv<3reKeoXD$dyCkex-negpC<9@(P9X zZQkQU0y=+A(_#DZO<|a5i1d?m@PwNn0;Us$7&tUH(AHAYepp9(3nF($yat)d=z)=) z|BRou*{8ie@q?MRoa#+OBG{leGwQ1a`vt(M|Ac~oz%6I-@@J;Q_#r0fUD(3eaD7z~ zwSLVD)R}1sNTdEAT!(63K#lx}8RB&7T}S?$EQX*_M{r2*0E#t0Blof5!N6{l2`p7O z;OTgzZ)C99H&?U1{MlQ4ABScHQqWQ)o=|PdBfQ9WG0|Tm8Y(dfN;YYqtcry5qMdg} zIgeH@%+fvSs2B9$#RTcV)$5W z0Aw5OJ$#Vju2}p4k)Fq}HbacqI#?=8mbvvoY4DB7$Z)mc ze`?Cq9zPuqr@4nvO+rtD>9K*P+%G%{`SqRcql?#!UwrF-AaXlc3f=^LJ7JrGe5!lf z5ly-GOi%zfah=my>Oc2y^CQ9xlai~mHvLD<@`x9u{CfGC93b74@mwC2vioZL&G`g0 zdff?5&6_(+yb1d4-%&V(bok_*Q`jPO*3G@OS2nBN_b+XlZN0AJ z(u8~6=}p%&Ez#=i$0zouI7U?nW1G>T%w6sW7v|y=w@%SEOTWy-?$}xsb<>JEE#7>) z=76W{5&PPvk!$C(4X2!LZAJX2Em5!N4^L^1g<7iWc~g)jQ4uTFdNX=?56 zb!&ls954EJ!`_UyWYmYSt#NLm!tIOde%HVMhNw8(Z0ickm9ckrSN-AfT59}>X2V-C z?(Tj|HT$$XmoU;0UQV6ihi2~J+3pUchC~}?5cfD-{I}zH>K^=_f`z8Q{nr^9(f7;n z>4_2O$1VlIzR2h!+gBRHd3q%Z9V2<9rCSSk4xQ_Q&M?)rW-prW+1^f(i+ab}w|GS& zLtLywci0$Ix$%^lnwpWe(ljF_BFifr(VIn2-7)!#26CX-FG zuHTYl*4nllx4=$XIDL+41KVW>-36yl_OH6QF(c2h0W)~~-$=%Pt{~d>_t1)^YQIe_ z>k({bp&H&+<&kKN?_C$+5}#C3kgbe2s=-sXj}v~-jQL}q2G>>O zawPN>eBU;c7P6<~!8Ha%eZW{tX)8^L?#R{cyv`|5XuiF7gd0k=oDy>>3^Lj54m zNvrtkNzD8VgWAt<*FPlQ3*ilSG>$SZfDKH;W;=yb)0>zPm*jY`WMWm>)4QD&j+#ZJ=RvZx&Y>vHMYql|GBj2?;B{Z;Ka^Y%xMGA3rrZBrpR_+K zcqp1ytCJ31Q-Ny^(Ks89G|gfG)g~mn;R?*8*yOE&Jen~@{0u>z3)MRaaD@^Yo4drE zFsIYzhO6u$J#~2)qe#Mn9P`=5Rww8Li#ZV`>JBG^pDa#aR1`z+uGm+b=Xn19>E`Zr zCrEGiXRhD_ksog7%9EqA3U#(1OFO9NgWhqrV~t-idtWT0*}pOgT1=h|f!HOos0}>i z|8==~kltrL521k_hUzTl{e}vf0e~?|%0Qhj6x|gAHso5p#XZ*H7X1pmiZ?(58JuN( zta~e`2T{2?)S%i)pjSOKmXnDF%&oys~4)A zE7YynKNSE%D#m*vEhz&RZY{`;H&$QdVL_&Vr{GwfEi>g%e1b; z81i=C06}?v7(|tJFajeBiH4<~nMx`P!LSh%=w`@vg&L!U@L67l8c$0ShM7TpUou*O zXaskSuX0M>^u|)w)CnHVW0W+_08NuM#3{^z43X+k7T}0sCdr@dN3!?tL65eiZw z&6A~Zo@%j&Y{x4u^n>iu>VI-kcMU1lnLd`2P*Lr1bq9iKf`*pvNfh-O(Q8jBduu6t zPIRva(nW8J_U~5A9>@LQeQw_>GU0PIc$FIij#_M#{(b!aVv2( z@N0!)nV!_HF@2m_@Y@ge?IDZb@~2iLlN?sSK2Pk$F!3wKqR#uDtV2BDySb7Ne+cz| z+>qUQc)X}CxjmB~U9KNpZ8jn(ZP{^k9kb{#GAeTD0~|Zs%*u(geVn7}G?>t%x?288 z_*>+ic&h5RFT}&9d#%l2MYeYvGz5t{cA^ z$LEBQ*R@`D*{0-&z1{D2;#Ao3O$pQ026Mp&6RT5nj+2+t+WJZTS?jaWzjFD%^dx4B z4jfg!VDu0~g!CB#16Bj1VD^{2rK?K4(a`Z(gvmgiolpy6eP zeAckWOr3hF({62t&&Jge_pV~UHS*ybjMB=E?3fN#<(&3WIXNOb+&p%lx(U8`7Sq~) zW?mfdO>f6CpPi`!i?n|`2HqOt6V({(Q;RV}hH^G|1&wR^MQBU=5A%ONis*KJ;K_*8oo(zX_C3VlnS_ZG(d3r6faFy_MfH~?bOJND&5 zNFk!bN{2wbNs@w@$jXrQ0GT{_qh-dVi@zf5l8?D+@OYO)N8YBgkiR^s(@CxMJ-M^D z3E)fav)>Dojs7}*!#?7HR=)DmlyO^s*0Fa)k;h#4b3SJ z$T70~zJ)l4^E9@(!jet-6-U^U!}%7=Lw02T{twt406hKtG)8d#uKalK@zWQpRTt5_ znD`fmL#?2#D`A>h|2NDL`#rO|6}Nup-teb&Vs{@6%f~8n-}?ky-5^mhk_ z&lZu#o7edbkH{>BFP~K{>!gTWD=b<5DO;(oX?~WobA99Ov)$Rx`>yJhyPevMjpXr` zyM+wDc^z?3+xD#8b!rlQX~x6GYHrKy0YzJOmg7I8YS?lU2$!=&_v*18XI3nQevtXK5(CuqTYbO=|j#81JvQp<`{r^;XDV0K5i_Bmm)6K$NQZw z8x|cKmH;~i-Rps-A`OMx3D!BcdRia&pieTtDQc@J#@}jFq7IT$G1mD7=UOdeC56y> zvj31l;J-fjl`BoEFGsyn8OV(T$E4Bgn}-8SM3pa4ogu*QLs ze!2lcMggV@lm%F-eoWwu%dIoEW{piO%rcC0O|HS|FtKOhjzlj)Cy4XsDfIueM&qcY z8mo7ljV~lDYEJ|D-_Bwd@FAEqCL0$$t!q{-P7JU+g4beQ9M}rZ(YBKFiENe2n2-rj zGusZK<$zY2W;>MXOjd)Tl`*ig2zyH_Ho=W?X+~^7ofR&o_BVRukiaf<(E`r0tdsIp zf!-<9=1*|LL@p3R$1!dcx|_%@R6tQ;0Q+~O!HnSgeeiL&PhG=3D?RrM7?tFm}_cs-8BHj-HMV@fkl+(Di(Z6l+aI}jS=rlzi{%S zaI@`6dfB1A_a(9RDFIl&$1WT8IYX~D?(IzTTxN?uT9uGy7zYu4U1+KZFz>JP6=uiw zH(Xl({LeEsK*w&s$lDd+cW7Z_pX=Ic(h+pw0|&Q!O5BJUUD3Yz;^smD{nQv~HDQ-|NVGquoxGyZ%CVcKfY) zQyzsH;QxF&r*V08Tlh!&Y+zuUMspM86j;tnZ(J7Q?6^4HO_;TI`hFBd*z{8%$weB6 zjORjjVn-_Y2GgZ`hr`Q&vp*4uw7wuD35 zpLU&GY<#6{2EofZMfLP{0`SDn_L$*u$si zvZtVLDAuDbL*kDR^4qY6@C@ea9yF<5Q33V)hg+)t^{B@PNr-nGdP?tdgvXAhnH`3zIOXcmr{Knf~8eF^TjCNN%Ig=W)Y)G0AOnhPC_+)hx}4J^dk?%Cbw-DW+&IJ4pczk2S4V`){~4Tu!EM5bcg-4*tBj87f`8vVNqd8WGiKzd%g6 z)wMYHE&gp2zhbq>RIwB9O0zqj7)JHuhKEMM-rr09*?RFho9cGD_^m)yG?z%&Zice` zwLoyliwylYE9gnxI;K_UFZai?E-U9o$I`%xZX9s_uIOj3A{x?5Bpl@FX5rk&IGZEPV!?dF%ketpnKd*2BRu7FkrFEm^6M&VCV*RSfcw(QOB*+l<|YOVya7MI~gCM<~vynJa<+&)Rf?}*q1q0@&no=-u3f8iJlH0d^Rm=v+!04DM8pW*+ z#;aI7Fk0^SLz^nKW}3zfi|U;CmbR636;e)w^P4ek69Ft!g3zO~7v4_+63-yGg911# z1R>oM+>N~{5pE_Ao}f^x#ugONHN#?{2GEuWXeF5lhx3UDheoT;p1A7Q%d{->OU|0oaM|Nqzu-GK`r>;=HN{vb<}W8d+QpzWrNbk zRi(}MwG8#iKK*S6A8w2%yiDc?Q0BK8G3xlc&)lkfk@R~2_-LK#5B?9h@_-i`m=VNT z-`hE1Ym&oz__RGFd!)48N6wHAn=GitX-}tBnIj>Z+UpNi4y#6$)vj}2BzyElRQT@l zgD2nZZo_#okdR?yNR@+5q9u(0u;+CaSXo>nDSl> z636fL%q+mK?ae=x#I4ZYitu06&>tRq&GBfm@Ivt~^rh319P~52|2{1KYsRcnGY-Fo zBF{6-Fl)Nc+}IHwzw5 z`GEmw2t$mBtbA?tL;XMCF>Obc`HaT-lX(v?S*5!9>Q`W8F&hkLs)4j|;m;$|(m=So zLoWpc!8=v{El>VD83s#{vO}GP(RzCk;;=9MjNeQSWAOu=Clpm&{52lXmiymoq z2e5FPKS|C;G{-KNf*We?sZ&Q=upQJ(?wP_^*e(C*rPAV=C~;_eUjkM?Kc$J@D;>C&cO4at8^Tw26N#57+w_3(Zr2uyW2+*$3(<7$#3 zFrH&+Pl8!#db7ZRRZaUVvLPz!Axr47v*E7yQqMEw1C+FepZWy}K8&vX=jx8XtpMa` z90Mh9cGVH$-Ia~LV9TPQ}!$Z1j= zQLULdl{AZ-b1p)1H|1D4gb>oQv5-SK-8y}L*Y6+j@bI`UpX>8}zh2KLtWrzHS~Fmy zL`H}jIHV0CF|1eQcPm6?B%mXH{PYE(;_#T6Y`71v%B21B?A`pfz+!uE$%j_qn(`3H z6)hf~;xIU@k4nl>%q8!%?XPjlX|kXG>vJ5uK}X4V4YaixhSA!+a%Cr?*2<+J!;c=M zbr+iK3fR`DK`2l8(4m7=|LH}Gu^W(D8EfqEGc(@FPt2)1YOFM(7uM;ECgQrmka=e) z9-85fQie2|9>Z+e)*Ey|%>~;CF)~*TbjeigV4#eMM|yemgYVZiN|(3nR|FZt4nBO$ zST_8K<5?;3@|NP{C3c)^n^+!rx}yquS2MB0@bSR1^2rsS8}2gTQutHtzbf+9(%0%3 z^CE4_FpRtMM029w({GFK`vZi7J!2_?Wm{cpfA$*$>khqEN45C8m_h%wT5c4UjcX@i zbf4|svT|ilWjMX(UX~ixAN9RG3M|s1et8k5Ah-T*NUu2Dn*O4rm>b)Ey6(nXT?{Y6 z(L873H5!9Yf<|F+J2#P3xwer&7Ov^VP>3pAE} zcO;XfJ+AU2+yfwB`x@wg>8+G{8@)6#4G%Gr zoThcaB;;N@s<-8jZHEary@U22x|RvzGO;@p5iEMjPzO#Kbtx~6M>!tgzgDyl%1rT(pB}Ph_WEE_zitM?_8>SkX3T=mveD>KofEIsL(e&sw`gFv*?|GwhW9X;g8|D`O1N4Or`0}zVdNQfO)2%Dh zTBq@rijLzo3IAx_Rfh8dhn9 zd?CE6BPpgniSGq3#N1+DYm~pGrc% zLugiwR{AO>DaM0Gdv{f)u9teq{WGW5nY@Gejbew#&j!pBa8lfzbN4JBOtfB2lmKx3yyokFtMUBl%pmGK}O%6v!%$4QnMW4tg~ zlVNTKM>c+zZL9C4b0v>g4v>F0 z){qP4M4TFPh+x{>bwXb*rmyJmyY4P*vGZ&y{SI5QRQd7OU)i#8n@4VG3`IBZ=eIqD zH2#|7NKmFm<4p1E+NR(KUN}j;k5Ht&{CHig+#6d?u%o8>A@}yiRD_h?-mmCAskgN! z@XX!@toN4!%&r|eNYsgz+RZTgfifN6nC{xj2Qxjf>E~7=Sl>){SQd-Y4O3q1PhAO%8)O=vmzmrn9mucOTL0A~9z=lo z(>m%$1vBR7oY5|?UktP!mW?o|!mkxKb$qaDq4sRVfRFxbs5Y`Vz%cMKqUdI|RpzG> zPRtTfajbwR9R8bXj@|EZ6$DmDzR&j+oodMCato_u^up{TL-fo)?@Kr~S z4;@`5W9BCtw3_XFB&H9rcAb2Z_CR?{>!)Ou#}~dwFldXxTdE8C-hKL+BYQj+C*L!% zY{>m^9;(BZB=&>^tJcx<-W)ybYcX=jawhOCPb>ik0LgYnC!Z{Db9i{It|!rIGP4QF zdZN;@Q(7|lAh#r_8>}d`K#<}bN<9y_=8G?c0y?`c(#9CE^Qo26vgf!|5}a(W=?dVN zdNjK&*NeUyp^4i@pe$c3*X68ziFd=La7wa>U++S7brkwnw^-_uuP0|9`)#k5C!AI` z{G9Qs;eWu{n#=?#$#R)LOix;P;^O;@XMRzZ_MiL(ZfO>^du4?<>9vaHINd9~1JRyc z7tg>x=^A_%NISxue@3*tJ?x)o3{pR(qjE(x``L){Jwl8AD^qx#X_Zx5>^yukb zlctf&R++&vgPN_lA{YU!I!0`gj9_o?M0Z^l^zU7T<#p;-l`h74%H5tU{P6cEbi4(6 zw6VjEYQIMx@#A$UQ1YnyETjwxADp%JEnyB9YiisqvLU;Gae|$RIaCp9u*OC_fP#S4 zAJ<=`R#R=GIfH{dc@v`iI|mWAeS(Z}p^WhgH;RpqX&#i*7}}vozf9*i$n(J18H?q5 z-{+^hY*+Ub&qtiI!p^IkKQrSBd z@5dVuvaz4q^h@%k{cZ?ukMLinVA;O%ywX`#0L$+GDR`H!s`>=x1j&F_8xgDpFj8Ql z+k`?l;%#HhpzJ+x3O8pYV?hOchcXXKYf$ZdH28Iefu)7Lid!8Rxqr$WL`+Axb@9M< z-z)0qaAF4)z?Ud7yTH>S&OPnNiX&d^j!H`;%EFKZU~C)A&$bIX?1M=_I+OkYx zG*8Px-p+O-b?tQA@3}ojLh;|snXtE=h%P|{!`4EMMLa2lzxaMK`s-pu0uZ__vi9|J zD|_9?pHAL%T0lj3`i{=jjsNqRwvoM7^>6Q}j&I=n$>&%1TC`6REgGxRHIR=qiK;11XHT>IVD){c?#vWSAy%Wfz zx$en^2N63-(TAY3u8-Nd^W9(L4JcVEdQ3OoGm~~>=?)h{*|$V6Z84Ub<>JI5+70$y z(}#o$M5rr0CPBRjzWGoIQtbf}A+Wj#*zi|@6z%wa7wqTebd?#NKp~x~6w!(Y+x8{e zkl3X}XYtB=W|@&4e%|>S?ChUXusfQ5EjUm+OEjEmHnH7=FR4FhDIkf4vy-DHCSSPP zmmrHeyGM$kw6mZnO+g^St+wMZuze2d+YagF&7_@r-Y<2@AZB*f(Yi~!Qt#}R)&<9L zmdLUndirjMd32FW+D2gNa3(`e0wy)CzVKkruEw7=p{@s>y=izlssYfTE%e0x#M@7l zpiUH3Rn6C*p6%J2_DQWsm_V4rAAFU+S=$}~JE3{C;Cs(ev&R9HyS*~bHzSU^zMROG z{{Gq2^iDZZ$8vi}8vo09ZYTdkaG$Gwxf%wK-4%Toq;=QFhvGUgKJB@4IBBsz>-}!E z|D=bWnRu4qz5z?8q7MU75kphlcdbzwX{S_gNTg*22%i%NZN3yiQm4IZn$+jh8=B=m z!qNtwZw=|`0;@R*9dEh?`^uhnCkdB>Z#SQnLwSUs*@e{Od@4(NvmsXLHJ8-W=y`YE z{SPRl4uT@4_7vXu4?By)c>w;hJ++m!l5SoW{s18e2;Ip-Z&M zI!!Y23DsfWO-EvQL>hBcRX$;Y#$WBwHHxvM)bi;RJLshj8ribi@PEK?o(yRG%(UtU z#6MkeWbh-P0N>}h{dT(hp41j^v#|%4M(uz_L&N2wK*1-rf2ASfeqE%d;(?rU)4$~C ztDl$^18qNWqDoVEj2>?3c&68${Wp&o^)9Y$7YfVf-D^+^-^a1TFl`v(n^pyUu|%Wp zhf#q}gp$} zx+-_uTbF)!sFw#1y2uFR;q(m8D_uXL&0xdNPal(mY5p3z*U#UIRoMi^tm~sk45s64 z9j#taGIw^+hn{I0PqjI++s=az&f)d)u8R`o@op||Vb*7|!sz3eehumwy>!mtPf|n9 zM|E4bd2O!6@V}W|7Qz{D_8S#cE29a-_R(vGSu*CbK88EF*BzgiXf;h`#ey5(dkoaQyGHghZkS)>-h_GmJ&JEEGf!z>iG zQnmpd$vHY214~Ei*t}*sRuz<%ED&5=f@N)7Z%As2pMXjjvV%4dPc=ys0b!EbafZKiYjw4Em`MK!0>}NwQ`* z`mxk%{?nm;>HJh5nmgph+GCLpWkkCYAW?XcOHRJDoTw>~ZKalMU2LHQ2W2$w4&a@e zw9}F=W1388-+NS>J+O9>zFJ!2FvZ&fw(hXT#71EbcvZjAdQq}c0^w6{RasMd^t;3! zRW}CZceYM(<$V;QrtVpW(FYxczJIUWQ0~OOdR>D_bkdgs8|!>$l2NzKR^^*#Gd=!; z)+1JduQ7z#HngQi=76!utRrO3(1Njp#+)m=X~jyzoy2WI)cd6zZ<{#qu7mH0upef)IJu?faQh!dgMGeLM1B~VdMvQY z7An(6>Ctm@KZqfbzRCa{sW!L*z${`ck)MmEN9LW_F1~`DM$X!+%p?&?LHw3cnC(H3 zfzo-68Z+lCcLM$?7?#1)$kOt|wR<*l(~Vww`>v|(XFayzWt@64aS^4O9{4&;v9@A7 zuYIe(^p(d-TK~F+xtN9zOqt=NBWIePg+p}CmHD;=1qcHPWhLiw2OPaErOelgT?`hq zEt#9c3g(TT$TLkFrB(HQ*81f5;40$TGqJmmYicJ>R$Eu;l;6~*tyY~_oUST*eONuh z&90N?IX`cG!s7D6_Sx=USa4rU);lLxrL=)Z1DEb7PaF@dHf{V#$Lh#froLfn#2mkU z5{K902EV#0gsxWIbREd@3fIH^c8(CHp>2#_m#*eRhoX84fQ@;l^L?RN+S>|rzB}ka zaoXBBGJYT#_#~~KB z--!wY{Y9+y^F-@zWi`V~IE{~GVdKkonBl~gjdr7BfRW0PTxns1yE&(GxmZSXM^C#{ zjo_mS6rlGPG6lkcRSL50YV?k?|j@0>sHnxYB&_Sr7g?K<5h{%2J zckiotKf~Ymnb6$r)_(^YFBI-E;24|q$ZQn_i(N;xnr%3E^)kCyl?AW-+6(MjpI;uy zf{d5vDNr^a-OdK!h*18@>Bw8_`;k?XPYt_Bn`Jbnn=XtLcsw-KtEg$8FkL z4a<-=eds4L9i?cLd^^f`4a`!?(Cp`XZ%gJ{6(?X4uReFyN4XS6!pl~+ zmzpcP|L3!kQ~UVTm)^-!HPP${ED$XDPsmi+?Q<4fn!p=tvif^R9>15CiWF+N~fz; z)1#~*&;2sM6?i|O5{TF(z+0-?gue#c38M- zHR)+1f4*;(Sgy8fH{^q^fS1#R#yprfv0v3fEPiP1$g&atjBsAy{lzkla>Kp8qQ{9c zw_A&o6~dcVXA)d216-lIC|%l?t7Ri_kZ9dsYCaz9;w@Ke%S!t+myXFeCS)>05fq&OQy9{T*CKmHo19>YWl>n3vv?DvE-O|!HndjsCuz*rh zkM{O3+FD5%8B**EI?}X+vTl7?eL!-=@tmj#=Zor>=K1Ax^3hvFpqm|v%sYx?xQCci znJRiPQ@_AoVnz2oMSflX1Jtym2z#I`D@?HVdk(jSY9=zR4f3ek!wxfezrXzf$-P9o z`nsc}>f+=i<l4_BA=*38oPsy!%(>P(_ zo-BQyvrSWp(MPT$Di@B=lG*~Jw2;{VCC5u{eqqPuE)n(WW6^`AL=8-9FGk?*I|bv;drE{Rhejrq?v*^mj7rtx_#Znw{wIYTCQPU~fy zvJBK-t{QP|_`I_Wb*0K?O7Uq=9pA!p=Nsai(e8O?&Da2=c^5o*n6lF&=0_>VjE(JN zWu&j<-Ng&K7J~o{BWG6#SAU#EtXN2=bt-GQHBjg1aqf>8FV+g>*kWGb^sLLCLr2@y zXx+unFunFITBCRMpTyw1XHTD?pY(f)?k1EUInF+A&Wo;kGw?YSGe4Zw!S$Yf^EkXw z#M>y_S7U#x)a7pd2_s4sjjWGh3YI9e(V2&2Pd4L-qhzTLluJh(q)X<{Og#JJxUz8S z@ZIvg4eBx$DLmB8P><#KS-Ah7vmQ{0Qza((Ic&z{p$%8o5KTC#oC!F6 zP(|7I0kLS0fpBG(gv@5d{6D`=BM6cQ-eehJVXv)Le_V4dSyDBkU#kNju~=+gI6Q(x zI?zCXVH5Fv*2J6J9oo?-HYc-ZLKvCHtA4j7Pi00M1#bMq0H`{emc1-%Rp-AI#Oq4~ zNd(vz5U2_B-oAVs{FsyrwRc*}^M$?TB=eN-p#niY;1<1yj$!AxGRLJ)-`@IWy8>%= z{{c_eU8rhY#c8Rlea$@8xl0UTRwruc$=#ySyiXcmMyd$GClb*qk8-yNV0nGY;ilc) zOO$YS=Z)%%@&z=NqiG!>*Md^LyBlw;q@|4|u!V7frq`sk%N9K340Yi~hBhCcGDpLm zbr^NpZ%$k&ko%bR&p^FGA}Ye8dY@M+@GCy}cF>n4C3d0l)Z=BiaqN0k=BV23``Hnr zl>Y%wq_}Mg8U={G(pS+c^<#MEUqvsY&PY-M7{jrvC--4-v0Z}-Y;L@0X2Ko z`Oy1~Px7VPtg%4WX z>cI||yEL+%_TX^-?Ppb(oO{qE2q_-|E@vY8<(=Sl-}rTa6kW;MaE!YnqFu9l&fplx z&)BA|zaL)&MDEGL{s@9JW74-BKG&%p{7+u-z42j&mS$qz;7R!XveW5s^TB{rHnXn? z;wJ?HPPaZ8WIc2Y6?o-9{f=d9O?39_8F($Z?0)f<*NCvI8oZwH?e|j-bxOx z*V$B2rQNdX%ZN&zY}TR-hKb6_j6!@nL=TdKyr!%2tf(m(Gq8aN35qqvd);Nh3L!V9 z7zuRXOJKmCAXyWbN;~39Vg`TJeY+IwatHga&>hSxOT%r6ufc+8Vm}!7rF)#3pb>Wj zB*x`HWX~?EI{0gt(-a>xj=@-G&HWKlHVYy>maIc(Fm)RklhVVl&J#NZR#Kk=XDSs`1IhetBy)YOqm#Wq}A&YeXova4`-;wBgJE_Mv&=RuG*)9*A&0uN4bU zfT5Z@f*>!T_ApB~4&5!?1>~Hl+|1$lZ4aP~F8J^birQWt@>aPo{Zx5rq{zJ~i_y1< z*d$wb|MWC0L;7!$G}pjnz+jQ=nit_m2=x}nXT8_nv~BZAXjk~ZQwib=uZV4KOkpTCW@r@l;S$zEqisSxO_B z;!f3ly!5np`tJ^qxV#s&BZ3!k=EJ8a;LYfd;lswk_vaN}F}bHYEIW9u)?pRVc1^QF6LYn+z5d!UfU>M?UnY4Ql*uMHoU3m6OA7SMNjns2K>Rhlgc z;iYDykITG!RZ$AP@im0v8T)8>w-e=fftHr!%RE{t2l31LRG9!=2t>#4=OqO;+ z*#RTU<%#R*Qh!Z9o*`R4^R;*KYiv1jA=Y7nV35&&_x(fe?i}TyVpLI2ioG8?Lf^MCw1-Q{zo)B9PDs}t(#$C>9Ar-3vEpgmS)ns8~;4&>j9bOy6` z@^7|K;!Y{oHl%tlUZ_8l6qQ^%PYPck3_X^wi7|2$;GrJFqS#jJ{SM63Lac_ zTn{$uQNLBqT$(zw>-?|!(awe-&A6PYRoNrdAEV3koH_ppwPzxMrAI9_;=-=8P+Cq} zvZ6A1%dy*OW0lAn*_bkYBSr6?<`fSzyfRHP7K8FsyNxJ7fgdUYv1w&_GPF#5;u>%F z!kx~42C738sxw$6zy_rRb(?Nt-99emiCnGRrJ&}&o7nD`1pmsL$ z(RFe!D%xGt(W(6x3Vx9Q27T~Cu47niY3(rz!@4T!@7JRpA%1fgkG6KiD7OdSvk;%- zk6QLWGUR?bgS;ap87m8D(D9!o&*An^to86HMaTDs+eatDVLp^(xplW>4Sl<)Xi4S6%yzvv0*muxK>wqF10uaf(nOK9>J+ta< zkwR}i3j$+2zR|_`Dwh5TU@A%~Mu&qoR*130sOxK;23l(A#fBk1Wzzxrp$9Y?&0H?*(&d?&lrJv+@DdvMb- zF=H~#dLPG}<&O$G30g{oYiB>r@)o~sBQ@zsyZZ)HZ^A3!;jw+e^9yp88N3k~_3%C2 zZ&wI}kjlX-yZ3!(!7$#xFEr>;wEZ_*{L+lp|S)KJ4&KQkz zf=}?m-~9I6+VoVZ`!O;jA{=T4$Cq8YJXEa4j{X*+==N}j{~pJ}djn)D?uss3yPp1CD@1wr zd*tazhAXv9_Rb7qjDNDGBh{>>);4Q-Ua@9_33$LuuS#>@Z54uy6n+gl@;{)`8f4ys zN`pj=Kei=5nS5adv z)$bdMEzW4I%u2Z*9$N_g(5h0t-GQ0vSoN4v9a{J2f51U|Z`qWS52GgJvs89zrsFH- zV{43Ef*aMi`siJ;F!eI}`Yh=Ntv8K_%g1R@*;EA-KqZ05bR@oA%W^z46QtL^w%6uw6=(&d~&Q24kC>ei!d0^Ub+Wk@wY*vw8Axy zg*N$Pk3jJpM;|Pk4=Oh(T)3%oNH*Jti}4?n%K50RQNQD^<%J@Z^Br_oBh92&pwkH@ zK@ByDfWdGY5xA%jreB=27*xD#dpaB_oTM|`b)$cnZO+T;;4*7n)-WLPZRapLQ`}OJVm~K}Khh zK6K9jL&=(e%i95y%B^Fzwrlwl0kKFbBY)Pxz6e0Cp(rEjO&i6_E}!yGL(_=x@y1B8 zJ3tby=4r%Wn_c`#G8PHqh@|5pV1VU%ec3>_ z;b!N3P6kAfRpQyx|G1nN;i7=?e4QSKZtZd0z8TiNT46Dxb}wy2r9G&J){UGUu31y# z7VaQw>oN<--3;8qSbfH{Y;ENuLn>nP*V~+ClvrPaFP3}pKOj28^8#^B=J-p^3(Um` zcavQ|hLR@mhGY53*Y(BK!Q*_by<%4Ti(8KZAj4c^|Lg2a+Um$@2v4tP2~?n z(%EjU^RCCQo`>qe#>%#+Hat%#HGGL&;AizZ9M10foTHm||CuN%ZpgJ`pm*<9Hixuu z+-=vw0o4;-uu%GlSIKE0Pbo{?AUEYc=>u@Y$IJdQKpK%^K5COA&N2-8Z97d>#qk6K zrzk}Ifs+B;0yxIw;DMooiuC?I9O3bcIXTfo@9jaf=j|CgqI5kJ(tIWr&esamVMS5& zC(k3-)=~9MvfE*eXZS<#+KWry8Qm5EsYq z5jJN}-ZOuC@l^nLhNXX*{vU8MW`VPMGSoWa$_U&66_`q|Y>H^qu*Hwl7=dfFnq1*ClIg%ODJ zM2xH&+b zhQsXaac(D*gO<|9k0-?Td50I{b-7{*AJcBI-C9yY_m>eMVN3zye1ihZn)`x2m>AIx zpf2Jq16d)8_enSv38GoxvmO27Y6-|(p0@dHW)2p&8`Zz++?`Ji1~waInTdhdtUJ}I z4xs0`^57Oqk9{Hs*I5bRIIQ^V=E#4qrnPHnTk>)!Nw4@I0Q|9IIwG=Q-*^Vwbv#@S zhP?^m=~=)v7qy$-T(R=_e?zCqUKuQq_@3B-Hd0S7(JrC4P~)Z>Px#N-x=s`%#A08m z?CB^B`c@fv?8+OSf3@l1^@OL1jqFH``u4&fc5?r`syHwocBZS-2CXnRJtR208$WyM z>D=e%nvs@q^6epI$Z(&UJ~!9h`)It>qr~pO#z}JQIoBP9(7|Y_2V6S}`#WeZ5}a$D zV(!S70DOGU#ZeyvzoC>Ryl0$_S2c)vmA-N>7+FzS&=?t8kZbVt9Z7!;GUaamJa$)h*eyomLzduGOLZ4 zh*Vi3BUgJ4+8udyk1Eh!{51f9p_J!sIv@bQ1Ye@>Bj#i-ny@8Dil7H)YoTVMe%e|U zA1B+|?{&!ExE&;E_7z>>p2;WUyH@jor}oojz4-Z4zy1xEagGizswqH4^qin%aOrFL znH8rPZ2!+?m2wZEX#-F0l0QyWz527lH}~L7FN;x}tRp&!o__v=$Z`w{lyn&Savgr7 zKhagsX}st!^ylb*wSaen3M{bQo&UXeo4yvup->7Q(*uP(U(J)KeA}kgDxJ3Jia8!J zz%d~ea%2pjdEsV>%s1aTbvMK!LYc{DM5BT+sA((F^sh7!L8TJ8IE|rfP55NJE&K>( z*6n#TDvq)N6<`-tlvvUf-?*sj-JxOVHs8hKA1|20 zdBqmv)kV4vxE{F}T@XYBJcfii0~~(tSMa&B1rCPCg6<5t1&1FZCdmQxmg-+B+~|?v zgv)|1!gh2w=ykS<=q|tm?lr;-4~SbG9dNTCzcQ8Lz+OiCY=M9v^0OBE&BfW$1;7RD9oQecq;l3nfl0; zPD^x7cTd!NNpnhjZ%`(w{O3-C>FxFQZ3)-GOi!uq#9_U9xoyZF+e@b!E3Z#qO=N3? z6g+S7NBWwpPMe-mm4s=dW~#)ad5nvoWi!k8;k^=Tw+^BwEDxo6j|PPrfF{(7k$cjP5{*O5E?hn5X3|A;!tGZk}B4v#gI z|Ct0TmcI$^BEg@S?%Qd}|6@y~y26@3Ob_UCwXSSYlk(L35mcjorZCPQ`Fk6+lL5?o z9ALmgG!jko3T3(ok59Sn;TY>r+Tjb`rThuOhqdepXapVs|t_yU=rUW9QInktQH(m8sa=Rh*`Mx(ZHK47N^p03|_& zmpZIx5>AHUWGgPQP6`!V@zOug%o-7o#l`8QdOID;>pS0inNDl<;Vae_i?%jutd=te zK_#nZHvvqe9z;wrWDi4{%HFiGKPXUziRm(EkqTaxXZ~>7DHLcGfhtsx{tC#>vV4H1 z_2SE~xG+$AAZ6v`-(u)16tak?^CWz#iwv)iI) zIbZ~UPHWU_p3-Mf6^N4_kh*?nB_Gr`65*N)Q`r+j|K*aM%*57W2`b^Z`}RI!y~n*qv+Y1nko+*SOGLeDZ=W=-oqaIm72kXi)aY)Q#?rQng@%58PiGK zQ-w%9JhFXnYKC+mV(n~OBto!7WR*+Zx~l`fT7)!Q(HC*_m3UIJ#%SPwfKgfK6a|T(ylTX4**%)t!-)c6RAKk(66v)1e;_jdk4Y-s#st)KtgyqWX6)}S z#Ksq(oHt@&)+TXcBfk-sCxa){x^2c@{OQ5?IT(Hv#Yg)b#Ee|V{SMYu|IVs$QR$!- zMT{ff@4NJ3CIhEpYRI4~zR8}G1C;+(wEH0rEt1 z3G1i=`1?6x(t3mNdK{XQP55bKA?`psZke!6vm>@pKa8lITi z%l0oVIY{aZCMNT*o$biRnd%OH#TT6G#dz%1)kg8-Jn=ugENWTJ##JUf)i-x9-)9Oh z+yMp+swutZo^f{)r)f_2v%3_Rryd1~vy5I)YU)g8!eb`viwy&v8jMe)Eir^SwM!T$ z);p8LuFCmHxyCVAP4Oecv3YoUkutBJ(Tm ztD%WBcWYdtb5!@3i&dRWFJ~JS^5y>1frkf6&m7)C7s)o=(8KqI$`zX}NDg+s)J>N@ z)7%`p&%$Ns!?93uY!9$Yyh1jh^-ZoJ-t0t*!wH7&uTSPo#OL;&BkX$W&;?xS#g+Jn z974j_1OMhln*HQ_XpIzqXuWE-Xe`x|L}T8v+}XP1UiSl%(ut7i%{jg1mj1`t-{&6_ zSv8JH+NsH_>@9i?^gGu)R*2H6GocgaLynCqFl-T16YgwqX+N#CSgXPX>HU7-(5~U{ zs;&yBBx9vJn=L&qzgUpBvtUI_)AtW{YRe`i52O65T8(}T9X^}f7~*`aF!+X;$v#o} ztOok!-=(7tqd{}XWRtZ2RLd=yWMmUap6kwVciM3iI)7>%-rpYD4ta!O3eGi!wp)Ht7=JdMANCtHX==p6Six_+3w;%3iNnw`wD?`Z}>cHh{H zl6jkBwNcWoka`}kV3C9U4y#6t;DQ+%rcKvlry`25wz_6Y$cl`N4%^L}f zb%Te3rqb3LQmX-1kom0-rc<{^Zr^kE0NM%SSpP#c9n&@ri3v_B9kO^Hf~ zk>$bzUI{hK`^z)<_f?7|)7_yF13XN#COGwWy5tUZXZXL?i0IL@>jvj*lZh>uJUuR5 zm8#Wf8DZ_#WP1qGYp*T?$hfFr3za%zitnm@AEG=#f`HI=z!0sc)mZ2YhLRp{QK9@` z4nO24f_c~-4zMZ$I{HfY&;Fx3h?eeG^Vj(zWS-38Nq!4@ix#a1$OM#y(RsDn+Tb)j zaS$sdC%*bByCOXPmsJ$U1v05>0b+&2V zVFj8%MC38(37=Ac!wqMzXBqBjj&Lm6oFKFoz74EZFEfIFB+LqYBS7bk;Ua$4Zi~*L zU=l28pRqSLA#67?@6vc3pIVkRhM8FLfZl(730f6fHf$WllMH!~4&yp-tK|+Uqeqg6 z{gVztCCa`+4pd>a$EUs~cG-R_zqsK*-5Ti)12dWC;4?io;LGept)w}{Ajv0bbA~l> zn)7v~f(6fxDCaMIu^zCC?6BceO+gz9U>*L%K~ zNMRTzPF`JIsP!H~bRaKqh+?CQ-1_^^V_WG3AQ0PA_$-3Q8XEj|hx;x@msw~J=luZT zyIsL=XAc4(RpYsZnun5boq+Lje*Wy*KcTi-g*4;Y3ag90CqmlJU9+B`=d2!=VMyT&a);*w<@yK-$^B|XnYtv zHTt+C?~ud;Tbi{jh#%~^5|s#3FtSjUwqBQe>nj;&mB;%fn`FX1s~hGY>%=KL?jWbWr#>*w;lmTc8}%7PnE6Yc9F) zflQju8HcMwI%E{iIOP44DP(ymZ_D=lX+oA0`O|{KU-Lg~j%cxp6vKQT_@b z-7IFd2R#ppF|_1jX4t}j)DDih(rO84vN8cJ7NN1TcJb&o@frenMH4Jp;|i^cvzm}l z?C44B1WXR)EhHz%z3{?4O+Fc&Ckr7Hi&cJD6Pz7BG>P4Jf{9Zlg|r0;>n6<7bFjX# z6Z8k^%PS(W$=09;nZgnZ-@CZ(UtC~?(vA`6K6>!S0);Z+juG4Xs?>{v@YA^1<>IR@;d z+bNUAZA~uk%=b7B4KBLdZgLjQS@|ZEw{o~W-j}lxGrWB=R&FB$PfXRmLz7^sm%aUJ z>z-Ck3{iYaRl2%2szQF9qMPjGY|eXznp*2vc4X8Q=U16Qj6^|&E&Nf_|Ean|<6 zea)7O3+JtdhQmAgb+0o71pTh9iNnkZr|U5*V_Bq6e0$4*z%fQx_=M+{J4xN08kryV zk&R%L=p$(GTM{opw4ptFPii#vT=^-bb2r^M?S%$y)~8XccDVB6+3pJ`wKPGQ1Y@Z} z3^8g8EIO^2mhqn#x?~Rh+b1q(&^&wVkD9&Qy?@%?DA&YR8G5DZ@c8jPXPQ6!4Ya+8 zimbo~u4GR?C3aa`MDQ&r$rB7Xfm+t8$&nLMZm9@VHj2~sE~{xX=>5WszAvO05$J25 zL3alGLJ$1lB(`Y23(O#yboL}IxmcV|pu0nq@8!Gk*7Bb=V;{iW+7Ak4&HJU2bj0a0 zYQ`=glnUI{QpJDtAti>L6f%l$Yx>0JuuE_RYC*FfDu)Ez6JP-7ch!c?EDfX-#t-ND zEsV9$?9UF}EbZ>4l3GE!e+^oITNvi%w)u(&lr_cCMFLO_u3owo(6g|9!zAiRz*$B% zSn>Wj80Mv;(L%lDYVujeUgD5oM$ zTplXta9}#2ln9`BzEeCGR}0R+nG6OQ{hDJzId`s~k-EAkH^{qv<~b^K|7gXxa}ChW zlFBRIme%=Qf{Jki{f{-a;|**mYv^?R=Yg`ZJT;PX_15!b7c=^npvlA9yaY>RFqnHFIRRasC44-4;=;>F`IV z{OuYM16;Mc5*~zoB7s*;&U&C>4K$eMVHy&LGq5MNXsbmGKUw-ByO*{SS!w6HGo#0y zZ{6zxtHQ}>@bM>`+jJMautEjFo_W#h|0bLHgvGb(;K2I-_jEog!pCjb`U0s3&HFqLV ztE-i_TEVKTyY$-)fwaHrRTRfL&^HvwX;P#0Xg&HC$fggqV+NJow!o}%4Mz8kXijCN zm@94n*ot^yAK@}Sw6jMSz!e&96VpLZ#sq}itEN)es+mqBx1I|FZ`KjKJ+D%l)Tu=` zrzdk?iE1KPHW)$Swv~v@!ECm~bgv2-oGa<#q&2qLbFv9vA&H`TNC3&WvxNM&Zn%@y zgKX`@F1AqfM=uzUVt+F`&>#ef?#_XE`|4TzTXzG}gEPX0k?DTv%EDL zt83n47hLMQLyc0}aHdefEhBA=G0Lv)=~32`eou-%c4f*a7yTmD58eLM9SYtmyYlwj zD<)8_h5R9<)DDKidXXr){&0gMc{5K&FCrX=Fa$>R5ck!ow7VKv+SUzvsop?qYYD31 zi!&YuTh0eWtwMJm2e*M>`198DfNOPCT5uB=8+r~^V@L{Qx{ksX9JHumr>oC7Zzjw6 z$VWL?ez#G9%N*4bWw@`-AgBbBrIq^ZNTtX2SBd!2PZoEZr*Bbce?M}!YF zJm#!z4UFFg(Ly}ctbXwG#UQiqvp!jg zH+T_g8U0?DOBRjtJLK{?Gj$m0F6|=&g`*I0JUY$F#pyzk)rSWMwjaNUJPfbzn=|`W z5Q^dayEb^QQ~73vrjp6d{y>nQ)YSIw+J#P)ufe7Y-Hj;!oa3*0OfIQ71$aC=v9v!C zRp}{6ANyE^gYq}a(`Ew>Mg=xFjz1mzkWiyu%k-}Kc*BC0wunyAPXGH3H+|ipY8@9} zaKwAzJk!Hh9|oG^GKWvTHHcrVw-nIA+umcgCAbtB-Br=~e){KKKGS&jj8#_O^NTV^ zQGpq(@>>yCMO;G4G0$3#q~*voDuShU7m9t?1^=K42X%;l+NBq+UaRZNzS_B*5C77E zLo^AaJ1cdCMzsH2<@^&c9)R`7M$jb)kJs-8O2tuy!b9&s50w@K<;$^<_hDS4Jgn41 zP5|qI!k?-D_qhI|ty6=$3_hGNSE~2Y+pSArxdE>K=U!{>y6g@z$dS0;1oQ+z6d|&G zW4{Ces4BS`u7th1RBZgXr_)fxZ(8EpMJa|=H^ZH*^-&9ouM>}-2=|#Bkng-*@X$(SO&oCh&MTrwnGOe zemIa90EktOk}f#R(MV09uxdJm3(m52V^($VBqccAoKG9zs~CuI>&40zF-XE!oG`V6 z+gfv)@XI}=%{OhWcw;J46U|#Te;>Ae`WYY8;LUHk#;6o_tJ@FU5Gd;Da^peJJ@8zF zYc2BI$)+@EJ60pVlpQRI~^bI>NU;yoWpYa{vz6k8$9OQSW&N3G~73 z!q=D2)`32zzAr@J2TWwYEFpYF%i>`pYehPIBcqtkqQkKNBK{(L;Wu^Gu-P|vKssF< zoxZc(;nx+tUGcrPSYU!LLwf8WpBM0R&|f7YgKyx*1@%Cmn*u~9|pr! zxSo2N$a)&IBt6?3G5qwrt$KU21g6sG*a9{Bid!_4|38Y({gLVR|Kpos&T^_@4w)OH zm;Q#O>DO3^n<)KBM|w|g5K*50mo5~nKr=vZ0ljGx?FQ~ zBja#Zf1++|Wlk*iMHk%BoRJf*2Eop5MWzb45?s9#&4 zb=k`9Kt=fc#f8RejYA`zR57#pd&q7;4V1HTn`mV&Hh9lVPzVa&q&z~G=P>dzf~1iuU?^M z=lK}%z9!%{Wl)2!N#sCs#;lT-^H0}A}> za!%s82_+x7sHwRcl_+v!!R0pK76_{Evj}q+MyQU0$dE~D+#Ca48bR!m|I8*%m)sHU zAJoyJ$)@n)q*3aTL=e5T^q$@X2dla@2EnM^5jd1>%yPvUPBUav00y5ufclf8DLHKp z9u6r&u)x~v&`}S)g4n$)mF$(JiRuQu?n<*0D_xd+8N%%GKhL~PCUep_fAsvA&6nTZ zij&~6FG3YdCFZIF}*%XxAkp~rPNESZt;7aGee~oAQ{tWg*V?4`=zcO@rgoD`O1v?7*?LX zi{mQeqTfm^-kfA_6-y4I+CFlUJLfAofJv z=^Fkw+AM;Mgc6xR@7;~Tmg@YYi)UbZIMQ~`@U7oZ-F1R|XnZBr82pzMsV1c!uH|O$ zxv10Hts9#C;lIjM&eb&i=;D~#groodM2<&rt_yOC6pR|&{ZgeIYUlnQxTSfef|)Z) z{h%fl69@`4a!@mrz(ptf;Wu*g@o?H=iSrkH$dT6QZTxd(zcp8cF7*7x8rW~4C>gPO zq?=1#Zc^psM~CY&@HvfIt^Bx9=l}wqeeT0BB`Eaz9oubz2c(($uL5<5TAeR)mN79* z1jfd!RL^pC`qD9zZ%U8IWxw#*le(#tfQ6?suXi7BhI+JHl63=otK$zFefWMw*R9EO z{$kndlIclP%{w^|ZL3O4+3`MXg}CGgt|n>3Lo8;eqHhchXHJ&b9|MpwAq@vY?-bES zKE|E4bmyoo02GdL=paYZP$bSLjo*nB9!BLW!h#H&rKAhg7o)TYrWuP9x#`lDyz{P87fbrPf#t+?!Sv*n ziFE2KLq4!({&r2th)93FRV_I7O`M^7mIlRW?u*sQ9k}W)6!oF+$uoA?=#!DDPU_evvPKS)5Ey^<=zqoo`rdI``+Ewxv>u zRV}|YRN?5slRsAqpF}CU-F`ha$RB;DJgQSY+1g8LF{3+RiOaa+<_iJQZ)poyV?L|9 zqiqwGmNTVPvXETRu);^_1Ql@3omdUm68-Xw-vjxCE_?z)526g9%z?@ihBGQJWyT&1 zkaE}w^7$8z#eUyp0}>qsU8nx=2fYj_`zAm7XY%J^!uDyw1Mz@R-7csORua;7+jih8 z8qnLP%wLJh?}sOrfPipheSkZ()^N$OcqYAT-(7z$TN*H{9L-XvW^cMj6CdbPX zgwPUjR#xJ)y&XZ4uW?_hdk9$oqy+}q5vX^Ahf5KX9}g|#eJn$Y7ca^4b3U;k#OpF+ ztns5u9uW`;B)xzR?G#W#$F>$nNrSJMOKXCA%^q^&x>P!&$e;7(**PvA92ftarm0tu zZD;_NM|+e8bYgeM|eQk^!LZe(gxTf6)6%GLP+HS29BWhK_OAN)D~49*%t}9d-T4Rqm1&kUOq9Kp3AcJRk}B{ z2PwIrVJuP4HBsqfJ(0LEzg?Om!*xt-eoJ=NnuWT&s{3Y&QxrF%Njtugh>w1IBzYTk zBg=Lymn~g$VvTOG*o4A9021$*HD@%WuvhSZAQANudC2HrR9CR%h(wK`To+8G(xv^8 zlL!7NWh9~0K&m@Y00UrJY$i(Z^->FP;I1P;4dt#&Z7~^gqrBjF@4G%d7Qe@rCW@w$ z0>Rd~Gy_AC6~C9OnjsXL z=M!ea`VHtr-T*`%xz{GY@gUPNee9)UQkj5@`~y51MVeqKO7uK8_x@)pm?HOyrZjmM zP;9*Z4|KYnnQiWMf>WlD@IVuxviGxcaJil7@$ZoH+x{*D)05*41j%^whJ)#(eV#s# z2xMrS%cxk8xAm5+)z6>H&H?ncUNiLH#)2885G7x_MT+}|^?9Cv=w6niLZ%}q4sjun za*!v+5{)n=)@h*rz3l7U$0zy2Vn(7I*3!}c0MeU9N! znr(iu05qpKB(k#XSjF%SVIcn=E3YUFSgbWXu9Bt^{v|24j5^9gwQb+(xamcKWSl4Z zPak?4{!TN2D(eHAwioCmy-=08?Qo|>e@X4GX2QN#`IMBn?QUxPd)*z`Jdvwsin7m* zeMd2cp5c~vaOM|lB5NK~Zn$1qce&;oy%PNR7C-po!-A{wn*zm`!C57~+SFU0zVt;Z z$;e-XY!=5A@4Lr#&F~?BilwmI^CCo^R@LQ!7a2xfm>}T=lOS-0^k*;q#@%A4^Kg2B zSIPN?(uTzvaOmApOGBYiry5vza5}!$bn)|cXVC>${7@XG&cAET)zYyCB;8lqA2H-V zlxLMu@awUL>91ZG}ndRNR4wOc9gdza)Z8DTe<4L5SA}u*V(>9SFpIA$%ueP@Wq%zvZ`!y36YZ9J$ zmM0dRpC2`P`*uQjqx-6eithJlUjg*Cf~{hU&dQWG`&2{9LLo~G8l>B?PNZF0Uh+;` zqnBFg5vPC`$@TVps2_HbLDA^!SG z2o6&g3J-$sdw^umwk^5qfrxZT+<_p@-`wrK?lgCywDf!~D%5)P?ZdW`fHg=C=YFx< z5t*m`apvB|{zT-fjgQ~@9!4vG`v}SXHM=3o#xzgbf||45Z9rv_n2BPVYagwI1kGCpqyfDE`lqw4);RlhCp3kbN=hgYj{ zm?&roXtC1mNw1-Kg5HR^8{s6;612DJIw~)1QWcAygGx6}vl2o3EJ0+y;-JAid!9(p z3f?T@|AJfNV$%Z#jFT%L-}O zuUIBS&mcnv`gDpF2jxLwst(1PamKs6ZR=5XD6^MPBE_vyL<8tsyp_W&BNU@{L+Pdz zxa)T$28u4y+{DeI<@p#nH(rvu;iIuUA55#YvoetI^r_Vy^K=5 zw2AHLDx-swG*%Jf;$oVUe|F(8y236!u4sA1ugbh=1)4MHNBv^R%t|TlYWlJY8}x~E zb!gqLQjLdgK6+6(fc`{9$rQ#GL9&LbW0aqTRM^H9gUsLE(tH7V^tZ_qJ3P8l6n9Gh z%1Poq@BVxL09(Niv(J9r&eQ4Uw4H0ncaVIP(rAao%nM+5iXkdeBtim|+=H453Qb#c zdLS8OoNZ*kZ0q%5DuV5iiKs)d>7{9sM~IxHV*8km&0)tl;8nE<D6xooVAKJZ`0E)*unPs&oaR>n^xe{Lw5snzFA}}xjHcXqi_wE;oeT?Gb5n?uF>@7^B{Z+`9|E{+0)qG!f6{`7b ztK8%SZC*moi?%zzKT0B)u6CO^OfK>)S=f^5PrR(yHV?RHQ?B6b|A0LL5 zNq(@p0Z*e08j2nk++6AvygDyuYnf2&y#zqU$m|12g&+t>j088uuHi`8NYI@|w#=Y% zz3|)NPIV#d5u^_YpbJYEETkvTcw`O^VM-fpE&-V=bin4L=*WNun;IP`tU~=(Y3@nb zYt_-djPlo^im~@=dtO+p{(b+SsAgE70RgITuP7<{m&bp;q3%ZG+A2az#AXo9Z94}Z_!5;*+ss4_)&Owu9viYNw=@XtS?s=dfqMNL-zgW+i3?mD#L}FIW zDMVtWyS333q~Unt2EjE?992Wbv63;4jb!#n0}c*0CErM;3rtZ6E8RHpLntj*UAp2c5_5Qb z4YE^qZ}#cYW3%loevjkc{-=AzzQ!5#*FQEyAPqpvtBP*h!-bLRX?BNIi%bk{TrTU#FydML`;u& zCrb?!K_3yCjL!6Ng>s3@Zk_Wd>&p_YbY$)C?dEi!lmGtnt&FNDdb?I?|K&t~WxR5! z$a3JHWYjT5k96NKfpg^dTVAbxir8rf^^nJIt+mPLLN z&*<7I_r3fv`osuGN))|Qnv((87=|H}k7|(LM3*P7~Vd0@FQTHLw?Mrl#f_)tQlggbxcIx8%-8N>fDg@3S zs~ame=8|n!JYypung%w6(Pjw3^`;_ma_rGrQ5;-4)Ghh%?_McT?3%aci2=)Z5pila z4hf!q(j=?$a#7(4L(n5_?8#O|{5*P+Io)yy1UF3;3-SRWbgY}M9*J4%(|w>|6hv*2 zQ6|!Ll#adtf;a>&!^Onkx^<8+JQAt^4t4+@{f>mBH7BU%x{F|FnzKZ32*Hr*!A%Ju zIWW)&78Y>(xX+FLK`LwH&^woC0TR6UWI#AR9Kg$2o@Rido5diG2!IbOQS2{(@eC(7 z3Uh%K)DtO?A|U-w*@qZyR-K{`GexwY}Llql!y|X zR5D^6ux+SD3fK)h{fR7{{~suY3c3^+X$i>h9MRe}8fkGjkrga3NlmjwQ73JS4|5f} ziZxUIME#ev?l_JXZm#71@Bq>KCR-?)|loOrX3Vwn% zx!CQ-Dl!&GIxmq>D(v~nPFB+B)0;~#7VAtxg3MEYME}hXXIoMU00v$3Is*=+enZ!n+^6;l;TD=s!1>19F62a{Fd0uO$Y}hKy${?Bp)wZeevD7l8{muQp0=y2ZjDvp9U5GZHv$M_IeB5J@0OmE&`n>1C#jB-3rs9`Gkdh zP35@GB>Ap_`JAnaGmda@uYv6KFPB^m+a$1DM_2I(OX(CGs6v~AmR`)wpSRL;O6g+MiD~4P%KAENh__Vu@^e}1rqyGb4kchK+NJJVJ z(G0tGDvH`enc0M-;*mXi<(#`nyYJ4D-#w)Y8{JE*sooY-{o{hGPMbMyme)5##3!fe zZc|UKrm{8`H7cI3lRpI_KiUHpI;L}9GK2lgOVfE(eS67a%jy^Zx$7>((mfPC6I*)N zK`3odkX&Znm?=s=1X#ij_}u75f!<`JA@Xy>>c9^a0t&Uc0eNnv14df{1FBZ6A?tz` z<-MjWXr2~>DNR3Aqo-gQ^p^I+hz5WBk5QSs_UMh#Qs<_C3eTW zsWl6t50T?Njj>5l1ZcUFNor2i)vd=8uMCJ^jmKD15e-S_dg}W!W^|O>)6PT}oDegY zLOzSB8{gUu`sS5faZ{n>Wj;8V;+n&WcCZ+Anvv4It)4r_deiYhrp2o2xVr_buN|?V z($2bzy8L$lycHg@t9rhAC z-YhJPh1mGJKnH%Fo{L{<)dmq+-8IhUN(Xk&c`I>tXFbHFxGWyO!>Yo*9M7NBG9(ju zwcK^#zM;+jyC2vQf@HnQrm^p<3p6dCH=k|$NYtvs(Sa1#Gjeu*zydZ-YfdEHxKcVB>6 z;D5bjsfD53pFDXsTEm*BkU^d!Abza8PJmLUc(<6wCuqUGvHHpPfgP z1UmCW<%<^bp|+DttWEKc8p|i1w>}Av;cA(xa6<#jKHtdn{P89(z{s&1&;&5R-y;e8 zhV8M*+}~QyiW8~LEk_zO=Ata_FOL4K98)zL`))Z({qpc^-^`-s6)Qd7z0X6pL@u3< z_oejBr3Ly``SqNu4mkY+bVoUsG{TGSYC<&~lmGPbP3(y$I4`WHgA{3s)%H0{!Np|p z!&<44WldV=(=_V%h_%Z2a>@zgj-d_1*RUZduj!cep`3pzKgdYm{Sc0@d3BvL-wyvD z==K&8i7_Jo5b}iuEeRu?{?!uU*X^)GH@N}UmduO&IdVl!)y?FZ;u&7#QwC43@ zbu=0Sv^uEK%{cqdgs%nRB?ojlBr4A0mxqfcd~ToL2C>Ni#3+=mg?rgXJvCaq4l|F5 zT+%1lcCq@;HNe$c(U-dKF0p8x8+w$@$LdKRy`-94nv=Wrvn(QAbdHyw6@6YmI!f+{ zdqXU`_Qk89Z`F0Jm$)gL+gIpqnki%3H-3)StHDeT>MllSm%~uoxj9^ynh^WT&jbC^ z<|@h_%uk3lU-{*U@@JNr456VDPwVu@P!vP+diNk>b@HqCHbhJALF#LEjPX7Q(B=P3& zM3NzBZl@WbVmjV$M^D+F&1E+ehoaOqvDQJtwko>L1u>u*4+JI_XBF*=zZ|NE6?2%0 z`5hJKLTFpY23=EPR3Os!Jn!bcK6pxt%d6c&3!+y6mPR398C3YZMS9p()eiqYBE$I#CSVtq>rn3IqoD$ z`k77Vd#iI#+HN|iSuS>xe11-Q)B~3sa`6-M=9N!*=O+V_nfl=VHQyz*lIYVqSdccS z@$lmrOl%mnL6{hh!imjANX&3a+(2Udd1F0EW?z?~WId1q~5w-Ef zMc}><0PX`=1%`BDUnKSxU?QAnYIHKzof$ zP{FW2xcgTl-uSQlb^FFS6b}rmkZA^P22b>TP+-xn0FOg!#3lEb7xSzrC;gd7Fl>`K zMs=eMpj-vX!1D4?nZLOhHa;$ugfEy^O?5ZWT%Tr3&9MR&$vWTyP<)iM9?RR^{I6%3 z;EWh3B#fQ2RWc|TO4bSNL<)e}A?z}a{hVz-3e1(T3K+clhYuPSOpfeCUVA0Tf|vk9l9WJ4^4*7z_OS3 zHY|*}LC-IbJ?4e;4N6(8@w(M^+B4>@Y!PR#_PD3}cdYs%YwG!^AhX`va!WOD=(Qdw z?rP{Lzg0%)2>xs1W6QYH*14Zs8TK0`be`Y8R=6vX#}#R2cH3n}AacxW)!mxZ7=>H? z1L`E7{~B&VEQ#GF_#-6ScX1*MrEtKp_GK)0iJA6I(!;PLEOs`{SClKvYO}%$Jmj4r8+Tn&G$4k9|)#Y6vnao^T*b=a!iV@MPVa3tOwh?63X zu@1=2rO{la2+DMGS1eSB=s=dj4;Pdgz9G*+eW!99dm@dZL5pcxt4E3bJO z7UPNA^5hwr;Zax6DG<)s79!@*jRMoRI_(ilcu=~O^rExs!=yEr*dEJKruj;U{UGoD z+qRh%-J?FfqFRaNUr7I++&$N0nvx)Hge&ZyQ>l9STnRBad)@c*i)WWtCh2)wcRG&4 zWT3&`jmLB9KX>(_w#wk6=RYnLoV>K`Y7JFwvWTDBS#o{V3Wx=se89y!^oD(dca5XD z+S5%XuT}N5-2he~@vVz$lSJ|5rm8;$%dFduiVm%$)^&zx*YB#D9|!X{#XLk zDmsw<I(V<=nJ zwU))7A4=_=XuLCrR1kaeGTo|^INknV<_|mzwX$hULDRg?Ip`{^hn*<|gW z^4){MJDDyid+*(irlK#U`D!h(2Y}rj12Oho+G((Gs`e62Tm6dOsDj9x$(MhH{r+pH z^-w#;CJ@Iuqo9LcD%W=q9nF3*0Wo{zI?>&%;C~)&1b_tNKf}NPd}U{ylhLs`n{nsp z&l^YXeic7%wgUO5VchMgYu162x>IVoi517oEpE37ysPjb4dZ>HWE zLQn3FB)j$iGK|B`_x4EGp|$&ebn3}fa@i?jri=1&92@EbKIi$UZ=ynmvUbxktku59 zi)@kMMJLE5=;N)jAc4#{Kw!Do&Lbyg+uNl%4Eu-Oe)dofHW_Dy1Onhf2$f>HYujq8X1IjIla#Q*8RyrNLXsxpt`fhaHbJOjKk2!Uy4 z^<7V&6%eaOEIEQe;GH`fm3QaYM_GySTG8=0G#X&$g{(4JuEK_FR{=1y z>o>p*fkWOGmS_vcz&*0WvjRsM0SVZr@uc2UG?_n9Oa-r4!(r=p=H=lNB8yDy*!&Ow z zUh(25>Dz`b(^)0Cns#->wOm9&+|wP$8%W4-49hg zYYnLbqcs$R&`&i{Cyfryb^bFhWTEtg5ccvgYFVcF~wxkr| z`86>crP%MpPYorD@&T75C?jus;fcR1s?8zT0Ky$M|0x^nKsNk;Z;ibMxlQ}Bs{>R! z&B-Gz$3+_`3KVN0Nd3!rVH^p^!wf_oiI--0v?lBk1fE#&5C0#*dMLn2Bo=sq65w8sEmBh6X*%@2MvZMS98}2V zUq;o!c}7<|#3shhzmNT*lH41=3PoE+Fr6U7#|GB+JfvV7=n}9!G>tG(aIx1N>}Do& znq^fOn|Qf++vJXH_A6tui^=#B@}@xAhzI^;>(P2&o#BcqweW$jhHLIPVYG>QUtDDC z_p=}Us#Me4{@A;8&5%iF63E8!*1^1|Yr#IW)!%=R0g3ifT^VOBS4xet(TWwTb23BS zr-7QU_ytV1lkgnuz@tr2LvA_sruiK6vcl=9Xld!NH{30DJ-aoIFXiC%yMO2+fzvN zyru06p_o`iLggDnUUiFOS|{>lxs1$o;r(zUA*bpOBgIQHj`q8!UJdG)*7_zjYYHN+8S?^CXv*q*u z?tJKzmTwe)8r$R0+(0|xcAZ;LBLu0;8e;jX`Tz}clSfx7ZOga|0geq?#JlK$tx|+T z(ew=xjTYYV+IKfX^BFB?!ZFlOG@Ogku1Of4i?KH8&W+s~JRik5%wPL?e-U>+zF@<; z@!|b#X~Er#moY`$aAi`q-~D|~(}%|gj9C@XdtWL%7&wy8NLc9D{p(%TgR$dNQGDE; zW}ICkz@Pm0b@xDJN^#6j`?HX=JrCi_4HpH+E|E^VkiX3@mL{X5>;;M59mm5|)jNNk zq8KpJhP{RrY|R(d{9oqF0w=yq0g;!xNnzQ&hm|#GfU1;~;G%yKU^SLvelO!axOs&6|;sdHC@U z62N9TcIEAzX1+(I2^*P*=cu=-%K)`lS1A&39;Z3{xLUkA6JKICa zydCNR(@EhpJ&nou^^*2puk=iE#D$a4&IH$hqGQl9$04V;N_L@e2=DPD>An=tD5D*< zJF@t)v}xvPrr;uMZLI8s)0|>CA2Uz%C>?3fR1gsT{N^$-;BV2v@$pb#*nURt`Inh7 z;qvbxv8nuen8fFdx69PS%#|+#U!%J1gYmcx&pCmImS**#@;0pFT? zCtK+snDNpRZ~a7G!n$Hm)6+i^AWo)9FpFw4MSK5RII{LsbKfJB4j1y+xW1uxxp{_VTWCe%T>FRO&evQU-CVnI!^aaIi|-N?rL zTzcxG5^-i9xA>O_Q?hq+d5;&Q4Cc#v6 zAY~~2d!RldA@VBQ*#dF)Fa}oK^%c;vfm}SCzb4CHf7In3))F1*Bo6l5yq_9;bBWb6bH$FtdSt9& z^NY&Pl>hsH{cfQR);IBGYasuu4#4+)2Ahp(e^9vOecfa9diL>2g6LWRd)+by7`{Gk z|140i+f!bBZpDO!RZPM8r^hhg?V~pz#gY73xE52E0z?jGIluo-OXRyoe-5jG!jTLCc)u9t+wNg) zg+c}1eDISf!<>G@k#~CUtQ~@vJYH+f#u-HC-q9?7J>ppk{pYG^Zo0)*C0kD?@XD2{ z=wD8`&wr45!yKe@KOoBd8?|t6#8(3TTtT)@j_@z7Xl@T$P`cFopTNe{B^Ih$Ud?cH z!v!S-jNMF6(P(@*rPjUsw0&uRv)I4~BHtwSQsF7?aYmy19tS988f=HIIYbGVAgc9% zLbp%?1z?Vw0clPIuJhV zD&bm0g1h6)7gz-FPH_mRt1L(cE7>;$QKFG2~ou}+jC7IGr>)+N(G6++~wtA zW@ebqZW}59bjvVvsxOt-uZYF;qcYiYj)Qkv)o!SRZp_7Et*Yz@>7wHZT12|Ne}NRv zFvs8D5!!j{ep=I0YGmX-^fQNjUj4zso}cjBuX-crZv8NM@k9ZlSpfRw6XS)@I;>c^ z0f&20cvY_l(f4Fcdrzc{wv~@x>h&uO^hop6n&0%-jJ49e!<#EPB}fWXH@;&%_kHHx z#*pEA^vb_z`?Be1Gn~k5zIK!da~`Vw$bUcnYo&g`&TMOpkN4Z}`r(>|OoFdOT*|0J zK;xT-dM^_1`Ugar?>*6Z{q+5#-Rz->Pd*36pFB0wuVNpw(kpy-Im)_v@LaIW9b)>S zEUwAmlDTlHES7k})n2Gz5ao4-v75TGVKyE$&H>r#y|h^f~K zJ@#tWyMObR7Ei_4IFJAL;(GffOP~8+f50x@_WKO6PM+W7xGXzoH(5xEcNr}0wzcLj zv?Azn!dL85zI2=l*1tWQAcA+m%?Ee)*G14FKTX16N80KPcF6-j+fjK98riQYLpo8u zj*AhW|HPiElja)#nJL?l_Wgr|CgoM zi@*FHU+dKOz2btZMbX0L51+rNKl`km-;{dOjV7r$0s5BKq z>p#yhKvEs%+4S7mLqv#XD!)x5PDFiu;$HTL*^J57vnlTQHtvpnG}Z#MKhm*fW#L+2 zrdSrLXaz?^wuFmWbB@xhF$F9D_($ z*PNhgq$Z6)TBAxSdMqgCvbj`>~T;1wW~W9@5_0q;Laz=}^WfCuGAIWaQ&?Af z1Z^eLhVK~+*cC5@i@s!GcPSOR_B zP*pIxdU8)msA~;tm_7Z-gn7mMo%qe^i{~Sz3%xhB1$UNDHhgS=Uy`eZs`-11Yv*P1@6oO{9d~*x-DGTIDBrf1tcdDiknrF(*x=!l zT+}LP*gXoZErH(WA2_~%u@3m77b0r5$$J{qqMkF^6xr1}C!Z1BW!rn&?cQ982RZ0s z6_cS{;(%|qUNz(~vQL*qAIB;VYP1f2c7j5NM1Du5(SL{MJ`Kggn0$;L*;L;ShU~API_7DE#4+gsUh5 z{d=jJfL@fJ?E&!)sIvLOmm+L#NO5g$7|3E^zas_COU;s9qG`r*{Q|{-nFyeUHkTeB zg~#;&Mv4priAHx4@EVrp!r3fjW=^lX?-Ap=K&0qmonnbi5(Hp+CX~bAA@tu=^A>^J zi@hKi*Q$bmBcO{`cM3Ml`8uEpqvV1|_m&-2aH0qnQ(f&Nv9#Uld@{G zb}DWa83kOJ38@;$zSEvFQ9DIWQgGPhrTY;CKg3<94Ajy;4B!-(cu&={9<>h!-f)C3 zDlU7;95SAg;H`Wdy_$RLuBGQU5zD_#PB`Z;>93^XY{b4aS%k)ZP*nL-)%r*qqoSw# z?adieJPg8!lA3_W59CPzRvO!&mto#-o@uRgiwY&f6c}UQvzs0MKd%-Y^)w9~@UV5p z$00V292_uoPbMnKfB9$#lE(ikl8?|Njd4OpSwjY@RkfqblD_3OYLWIt2DXjPpNG zo*=nZatJ9Rfdxq|P%{Je@@u@5OLP#>suEIu@grH7j5C;GK_nO_K{{N^i(iG*J=)7qpVN!?6Hr&C3>Hx! z_QAgIM8_m~vR3l1(OKKC=mOzdVGEW=>z`@qPS~*R?#Ku9(O17*1tLm;3!s!sCz2bC z)l4i9&W?BS7fuXqNx_O>JU+2`?5cP)N&;%V1*hEotpjbHr3Y-7Clo*tmp|xDH*LZ4 zn!*H`t*V_>@Eks7tIG5#{(e|Y4d1F41$}!>>Ut2K6YJ-ruC%4Jek{X(@lnMj?v-!e zWUJa@;G}1N^cy=~AtRyU8&U{OKT-{NI6CGO%bJb5O3f6)DWcu86(55t&{dh7cm5|O zfak!g=l|?x%$=;y&^xP@nsHcUg}NSP&A)Uwf9Gk-r*NC0=eO5~uNST#yx+h$@mBUN zzSHx6AkMol%RfH(-7M#PT2V~W9bK0V+;DPs&5+=tu_>Ho3U};~=8}2js@crKR z&v}`imH+;z+zy!x+&Vw3SN}hd<-6t|LVudaUmSx|I7rRz@$c#nFV>ja$*3!I54YCA zsNx^hd?NKBIvD`Baa&>4T5)9INrOiCKllGkc}vqSixaOIpYdyzYeCR9*9Z>dr{b-Q z`&>`OeCgHn&cw;WYltQ;{f9ZKD|cjkxG zKc$O=fL()p@^)W$rI6p%##X04NWEp*=W5{de!Fz+`qWb6Bl$@cQT>uUZ-Y*0cOtKY z@AWLk<@DX%mRIJ+sv!AWWdV~|_sB061lc3-@a9G}(6{}mU-}`xteTB*$;Fc?@_FhP`eN3QBp)&IZq3$KM}VtU>NQWlmBJH-03S zN$19*R>87n?&hPjhM(B(2#Gk-BVI9R^=tAnRvoR!Z?erhlDsrslk5a%UoKAZ^7Dz} z0v;rB(H!>5GB4*622jO>2Z61Suh15iWN+zFwHG&}a3sn!xtO*H1E6!qi7YHa77*27 zfOiiN|OAkM6~(3mmY-DY0_`0e_I>%xuj3-#m2~g5P-p zYNZ=weLl3s|9I$VDEs2l%Bk$r3$R|X@x3Us*ky+&j9KHXX#0Vc?K0hizaAGK!2850 zt~kz}uou*q9&6fa5k7kdhn^ohf0w5Lp$wXjg-SfQW$F23XksGBpj9wJ;j%+o3(d#m z?A5ZOV|6B1EoMHwv=L+AI5-{h?y8*wG- zj>1b}lNsXgiXVjofY?a`{7DvMaZN1o&@wQ4(JT1wgjLn-w^bZYVXJG-RDSPvpyk3f9NyE{+xn1#u}O0u7Qh;z=zl zoigHAGf)d57d*97kOnO8YNLfwkOiWVu%k>agYl63hgJzn?E;EU?8o!V1wol(9k=YzH?-Q-f_wWo&J zG`arrKC>WqQx^b9hE;^3XB&-`d~$~8PPOX5AzMY|>ZVqmQ3i>?7yPD?-%}bZWp%Dh z{!KZe&g!etUT>s-h7c%_5NDq9=%DVB#eT*h#$!Y%LS7iKY zK^E3#OT~`A#7+DtDfosQV%80EId+Huu58E1)YU(oOOP2wJpQbiaK`B zmUGWmzsM%(y}I16Lfv=A9Q3_=@>jKy9*{E>&p&d}_kxjud>ZE+u&3#8xlrThd|qo) z>(;>XNXpfWssyL@hc&n!RyJb;so|m9EFR>6->y)#d7!~c0R|N{csR+m-&`#JDJQB{ zcslY(g|2`BE;_#j+#;k{qtQWf&6{C85Ey+N!`P6I7%R#i{8v#eP|sFK2xo{@oc$1T zrV@Ea|S^e_$v24gOC$X`XCj7lGu13k+lx7bUu45#_#6v|0 ze}JF9$>X>JOeOHf{Lk8RT%U@V&nmW0Gi3lU=F*v$QG-c4y~hqzmW_MSxv!Ytt}K~_ zLGPRv+Hk>L`DE->EB3{Htl*ZP2Mm16QYtT4M7+P+O;)ww{stgtofci%b4O~!}k-LTLnivF8=z ze|K+4KPWlz5F1Jz=fzNDlLmkj zQqHKD?QMmeOQkXMMAnJ~HeICB%=@db>7rG;YmdjR*C)H@w*2;Ac{Krb=3;63=oSJwkK-kD_yNXY&95_zsw}WNKqHhcHSG!{$)KCq~ZaP&tLE zWG2UwbG2p;BU&S6bEXp^sYwjwkU51U=v6`FM2wtQ8)B z_a_d`3tE{~JVkns_rj(BYKAnpIWkrpZxuEvm@N<3Pck}Gg=F8F%m%J{8A%s9=-`)_ z-_+9}1VoL!?R(=J6Tjl!y{sf1&AV4EnspV%`s3vz$@IS@PNHwI*`me46K_o-wIX{w zG5m^d+5E6-)nqTS_lDY(#RknO!z)A;yaJdyQadCk^85lJ_mF{Ym4V05XtHO3Wuxja z?iLR{{1$&!2qT_z6R7=~hUAiL)M?vgIrMtaWR7h)Gp-$A35`w5MT-eLs-Gy*xJYw_ zA^VjJPGCUSFv1puWfFHI7ihK+RC2mXf!c*fgtY_4y#G5r@56mtJp#AHVul7D_>g_P zK17`f(lMXUelDe)q!a%S-pm7N-Qs|j$KAvM0Ds$j>NR-k2nW^Xau?v=Ckm$ScCVc3 z)DgrA`_4Xi$aoZn0j04*;GpI$b})Jte($NyNgIn?{kHjnaKlY|u~a4_g@Dz80yj^- znBOe?1|GMF;ngL?4Pv{fN~a3{2S9k^6dLxc9` z0GD&;u1~3hbzMbCRgop?0cj2@wZUUY`= zilr3u9sVgl)|axSes+HE)xFhg8F&59Q_c;8hZguveB*t<^mM^P;=CKJIF;G<0@Twx z!n{EPfLQ1d^W%@xf(#vuJydh+f9SVJf3rU>hChsRPI1Inm!4FjeAP#7msoBUgGRs4-yw41Mq+~&@l*(CC@7^FCriB3wIf5Jm9tWUH4}}l6b+1zesFQ);IbE)-07kf^<0tG}aZA+J&$86? z{tdaaHjb!_M5B-{@8YD{aL>#XN>2@zs;eJ1KdEQ`9&TGV?8DO6e1zY^;w5~<` zDoqh`9Lxuy7aC3ZAk!HZ2vtmK4lkk5F*?ydPRM~ob0aZ5Ed`*xk7e|PVhJ1z=x&4F zGqjCYfioCxZV*hHr47zy{cC_iX{&orP93;92_3B?!86}JD))}ut7VL&33a_7<~w_# z#DiZPOOLG;M%H>n1Jmu{aEoNG*E)>Jm>xRpip*&nIKy0FQ&sv)2S#^ z>6|SnH3W|p_{5dfPcn9?fHDdHRanFIXl`T34z+PP2&kz%ZI;To9I0tea}qF*z?Z@X z*(%J7@Pg9S3he6dN)y6#2<2X@Qm1(_FEgJ1Lzy{-AlN zaau?Po0bvAKSFzpVw?_b0u>MKoa?>DW4T!035P*zmDATp?tfkPJ@ke>Uf74RaXKOA z_g{rn4-dhS4lGw0DQZM^^<$?`IYgV?rZ1Tk`;oWPR;n?WM*%1jd zwQp}+SEu$iP*nX}TRigg&f`0+TWzk1`G66!wz10tIppkk_qZSn;eKxcN@Hb4u*#B+ z-)9}}^c8H_(A@3c;o&wAddZa@bEHr{ot!%05foDzdfabm#qLkyw|`qfQ6&;y z+|LYGaeyX&etdF$CpE;ZYRf^mFZA&{J%4_=S+(9be|cP|$?!;%^Uz3isqxLg)Y z`e5Ex7YC}2TO|OWjW$lb)u>{{0q7kwL}8U!!Os0AET%w`q7aF=1`E6K`-PM80P@V+ ztDmY&zr6CNLRX>qUX%5p;(Boh-3|+^c zwThGGp92~Q=DQ(V#277@sjr(j)Z-w9toWMGF*VT1X#%Fg;xRg4vPY7Aa)HDMry0VGS$Sa0=(Wwb5h63EywTf)18i&EY1%KqUT9j)ZEE2 z{`-Le?3ByZMyz}nn(8q`6I z>Rxp)iJc-ZVwTyt*NyF~S;a%#+X~k(ryxx#>Sm-NMAiHw!8Ybp^gg$Yi4b%YA zcDITU0pbI5bPDi8b2K{?Fr_P&B`JagWKyZ&R+P~(CyNYdh1nuH1eA#7M%(VQh7W>P zN0O|}I!;7%fOMWu#{A@%etE4+)O*CouLCe#ENH-L+VPQXoYqj(s(B|2H8t z7a@$~ad37&En8pk=G_UgQC=7JL=MO0@M-{eOUy8eb?X=`2F{>!#` z)ew-1S?2{^U1?$<56ZzmPZ7a3tEQY#BmrEwfl?Hdz+LJOG-pVH%k{x;Vpa$u$=!$Y zH7<&S%r@=ka+VwyoAxr%5HMc-kS!Eo<}6JyvURNSoG&)8S`a8pKU&wexAoa%H1K@y zNuUKbvud?&MobSqfs`yXvz?^Cag`~_fT#xB0R=J4#|bMr<}lgPkg~re;Q?`5oXDEs z6dTh+J&a=R<{42EdQR{}rlI{24X%X)oediE|%89;%ztL;VA* z`0Kpfs&j}HpHp%Bmd6A_4BFcD|Fbq#d^P+)VKe$GDS7N#GZAE@IP7s@8;KH+A2qyk zP$C^So8zwjGUg&{b|ksr@}u$7cMm>TcY;V=jUPU5l2wz@2q^S@irY{Q=%y(hDX zE$sUw{JPZ_+6VuF)%CZQ$la0LWpte-dC7MoWZiWnWLz&^&hPRoc2zS>^`FJFx^?Ck z$SlIZZJ#H8#o4FPpRU)mAczs}^oA*{a%r5MdlI zr{?LcN>I3ufLm<4-&UoAO}004p$V@1*eJYclS(q>@0Z;B0R&B6 zorI?usk&0eMC~UdF`mddw>+g;=Gmz&9R(7Qb19)E5lZggLv~^SjG-RM-O(w2o2^@p zTydCfVxPw&5Nz>CFkJM_b4QSC@+_Q1Ps#UG8BC_*AbEZ?QPLJiL8=y{7N1Ovt3B3T(bjg<+=$c(~dU95QM2+b{ym!Di;vx&8LwMc$>3vPwVYiZIZ z?@|Y{T+(SFhnMob4YmGX}N^v+M7PPH1;lMq0;?>Dr20#Y;?Sx+xZJD1K#1~@T- zuh!3Q{SMaAjrigi2HHAxSNiZ_#37DJ@0;rISy|r1%KoYp-$TC454T-TyJh&Vj1>A# zaw+miE~Hp5QvWv}s9Qsm$joTTI5SN4z;|wZysIdX!~_Db=xh_G8(O2-w;B$G zX3etDy)RFjc&+vsWN9g zvqaEcvBX6OKfN%L|Ja8{-sQ(>WdkcRI7%GF-)Q^_eN+ogQgFa6*)-p6Itz%SfxtNI z{*w6;w-gi^KVXhfY1NVFsZM2uG#EtRS;WjLJtg*YbQ?wRzPkYo@FabRpV@qs_7h$W zu+#s@x%fWmGo%l3?I3zmaP}ViK39}9N5^rxP)tx%taeL=XH#`kqga#p%(L%e^w@G; zZd>;@FAVhLX#WXqcwm`k_4^t;Py%5(X9&!qT_uGuC037a?43;b((9u2PF*YORmpej z!B>Uf3vN$u2(cKt?hMf5NlB^S@t!?Od8pLXGe_cwds&8q-hKXW(t}|YE4{wn%M!l3 z-KWpQU<4Fra?)cBZ*1f(c`P5xS(nKdLCi_>P5){Qy)>Eam3e#MaYO5vJ~5egQOB*g zx}Urg@6zZWSs!&CW61w7VxAAMxF$%G_?x19QTL3qn8GT%24#hpE`CuRc5ezjnXpLZ zhxf9=@@lb}t@e4i3mY0Wn~^$5@|JD>b7?N3MJn$=_la~cCCtX{ zm;iZ{`Nh;`cGa-&RHh-ayH(Wvw6RuTE7|x)hfzzb&c~93$cd}HWBp%7UXFZk8m^;c z_v+i0t3SY3&llIqFB@IDaxF51@htd>HykF$lDxa(TK)9kLi8+y2uyFxR&))~ z2spTpfTGt&tHeNC)h4q)E)mk(P{rg?IAtXD*DF^m^6+a>Kh10(C4HN{xQS#d+ee_R z_~Sb;eC0AE*F;j++!Va)oD#dV%>jkCy9=M;DvT`*77976*>KuSXOkVoxf?rfPi}H& z8O*zGjrgvL2;@^r5{3F0Jdv#+7&#>Z?dvz3}sdvqf=y#}f<^=Z)vr=iaUvz_3{oVQh2qO@&e#RhPdcSI3Xq>!sYw)fU3X9r7t!MBdohXULua2mcAC5 znD-^KX=Q~8=7C(&4?hJg>;J{J*BQIte^B9-+%{8AFkHZjReYD)pb)Lrz@3=*EjAiV z5Ebsku;<95W|jE<1`Tx7%1Lex`4?r~@+x;#!I;lI(|jU!fM~Z0P-K1UcEhTlLCKdt` zA7kca)j?o@g$8e?T1~y>BY^WsK`a#b4?zN}XeaY^7g>RD0XIT%TrX5btRD*D*lj5% z=^1Yl!7%*K5|}u&afB78VC<^9>Bn@H;}OE*eVi1-o^lr^86!*X6-S#nr-Fgut5ve6oa-);{z?tvi%U?C{$tlQm$l@?J&{?XJ0mSvo1k_UZoqoLx6v#AZKSNa;Z*|aOCqR*-=h~u#nI- zQs)PA0rlP$%K>ZQi)$k7W%8!r4s?q9MLpCg`DlvnI}Ni9w<)fEIJeVS&Qr!(B?ETk zx@ZLS&^g<&*L?jP1mI@wD9{zZ1o*LoysQvPN%Pq{{lEG7w-#^)GRGa&nGbZ&b6w15 zNP@5g1vs}T6iz^JKan_?lwwK>KSckb^+(;(86&3S~IH_XP z%NlBi=IRrjnz|G!_Hp&%x7KZ?dRYVDwl@oO(!`0Fl9|X%(mq`%B=h6+74}l&L<6jtOb~91fxuK!UD^Kw zwdgjgG+3}@)sdwsdZCCPTt(Q$2rbJ~!)sBMva4$2OTWP15=KJ1lnW!P87Tmbvq`b# zOBS`UC-Xo_&->#`=6fs8J|to$&c0LjJ^A$^?S?w?5o@(PRBb;v#Uy^Dr%Su^m^2>x zEUJus;P~wm`>@5CYWf4I%%{crgQlBI#r){DfbQMq#0Qc zWV?Q6Y_D%mBuCD>6Cec(4d(uO6L|m6t$LLCUR9cPukEhnm!PWffH_S}zwF`7>+GFd zDZ<>nWyJSVD4*&;9Cw6rlnjleXuvcFaA$hKd5@NyX=|OhZ8q^Gcyxu(8NUUOkPwEa zj$$PstSyddHeeOMVnUcNHV4Af5*Ozr>%Y>p30=V6*xlu`p)EB+piZPOUXGxntC|uE zzjq3i^P4}iuQvC(XyPDwOfppA<`}>b`^nM7`8#sOf%uo;@71a7nv)p;wnNK(Zdz`{ za`hKml>w?O>3&;Jx&JmUTQHj3f3$~ZepO$RU{#t5vw7E0v3K##Y=J!|8wuD~>xTfi3pcHj0#9h-d z?EPVHb9!eHIcmbuR4xT$Zt8c)8#F-GdHILz8u&^RQ5ZPCvbWrZ{{GU>$;SIjY^T`@ zYa~$doH}yl4E$*Zt}el+{Xg=+mFgi$r$_6e3)u;7)Mhh>_`jij-(;s}9-ThD)5pow zqMf>S+{WFD1zquQxc4~FBr9yPvEF?rKKq2`hXYhs`2>ocwX|Vzn~hnk=HautUC@yi zKpH4IdebZBCoN6y7;>HgN%9|{PysZh2`H<@4lk7=3FxfkpY&mR#1!+90+JUT9WoCg z7qH3MY^g>vO7vE@=x6UGk5AEoP_-upVwci^p4|ZT=i9iIrVZv&E%|XkvyQiZ&X5PE z?!j~2;)hHqutcU+8e~SevA~vLVZTAeF9#g{2fC+F5x95+`dzkM(%QQ}GgkJ2$W9pI zoit1CsZN~iX(6C*YOdDS#Wo~bmVLD!C|`Bowsn6;O-TIm-7;_okkyukn)ZI3_`+bk&*TW zH+pGq9PmYE;I-Ktg0Q>*wBrO~WfbKWgbIN-E8$B5XA!9F(g)KqYy`I1e@K)7TX*^h zDODXx%51{EwK@gmKD;sgJ+vgSU#$2pd$rd@9YrO85837fA5*-z7v}4?(;3vS&Hp_@c|F{-|~#0uPsmCikWW;czf+a#WTZ| zfLxgTv+nI`?_0U)Z~Va2N91rMk>@;8m%YmgoH9yNNooLeN!zkZCuQuW zT%Luu@stbGQ1ts*91WZwj;-_rNatsRkbqtXhw`IL<$X2BuM%MwQN=@FzZB{$Y9KWF z)dvd#8j&g!*tE>n&;`&eygee^7-*z?by!10YKZ0S+ywfsmsa=+Pf4Qfu7@1~*H;p5 z&CxslK^wSf-9b8uOn*6`ckCXHcc?GTEOv%9m&)zMX&+1mcIYtEfBBlJ&j!;hUb5UK zBEX%Y5K{mPw{9+g;g;{Wq~o?rC1}vmR_GIvqsc(lczfB5cldd6Y^P?V=nu)0*2=p^ z=WMmrGJ*nu>muI=1@1H>jZG*bXuJGVLE>43PN2wkMqfPt7CHi4R?Hi1IHr;$2!iG0 zz8qAP7f9e|A+R*51%eo@Q7AjTAIkd0!HvIaF8i^dQb#6$k$=W!?!#-PO(X~6lc$(4 z+;Tjb0B{}$1Rh0ne(vc5<9CPs?;EKC`nDaj7cPOX;(9^0K}Vu1$6xo9?9&KnAK{#R z^=VO~G{5iKBE-P%hc)&k{pC>MKcyY#-OmGx71#wq=SNu}ZB!R(Abe7cEbJxZEIK1F|% z2DSJz?Lu1!UBr-6QymFn2iC`25!-0AZxDYJnu}+6<#?Am?& z@gb_U>m|{r5ZHSy58*b`kxTc!>;4{j>4iIdUCypWM!F015B@O#$#c*oBwm~;GXdza z9~jEADA7lUc?F7;6wSX}tsLKxY7^^h*yWzvg5BCz;Jo+CCa#w*dnW2hP+V+%r+;Af ze<|&fNH#Yz8LPWdke#qye!HU^wJ_u!ZX&Pmu`U`^oI^CN(*3|== z9+Yls)GQTPFr|5%tu!|FV<|RQ-wItW0Rvze|BD$a6Yw$GcS@f*$1ZxsKEM(s?%sm4 ztRo6Oo67Dy2`>)zN%oFliHn*h;rqY1v@7EJ6Su^l>?ilv`rZ=3nQ7uiAE1VR2kz*v zxb!I0`}qMrg9fvIzf>BGV*D^*x3dYGE2CIb5Vgpb7 z4f6$7xe@Y}C4!5_E|(TNnTRcpYDzOIglPvejQv@{;Bl1jI6zRE!#kTN?n>W!0}CXm zx_}wo9UukFmuFPcbX1494%oG=MDQqsXDgdQ1TM&^RGMqST5(*7;OCs&c-QB-&1I{I zUhU0iLd<?p6t-O1q9rZ3{;s*K%T?{TvQz)rg60z4 zv#Kq8pMhz|WE&KPVcS)WIn|vX_cZT3oct6e9{^vD1SHsI$qIb+KfEm9fdXl zcjLFq(ta9cuw7|6#rbEKch70i63v#k?=V$q2T=6++IO5zAZ|7+6G)9#{kqv-8~!`S zg*v{p|LV?V?gFmrMc=)-FG+h^$_F$i6+Jm3%lboWt1jqgRy!VZ2~;AA!J6|BDw;7j zV0zoW*3%FLaM3&FT)$I_~G)V zhFdkb&=|$xfS=p&rwo7#GjSgu9U^P19Bh|ndOs$~m@lFfJ59Y8qo8Tje!t*;*ii4< zf1YCZy$xCWBrpO%q_R}~!QK++z~Sfx)RnT#HZm>C+qFGNTvV_9#2^#YH-lG!-#qQ$ zlT(}*cp{;W#LJj{+>6ycO;{w==9U7)2IILaz>S{;1aD^!hF)q$yN(>~DnI@=Ovl_b zrgC;-Xk(oy@bMY?eyzYhJPjo+?#yuikU z?6WK7h-9#FRLzadf!WKm4l@V`DQw!lF+f?z4n{he_s4s3O;N5g%K3TwTJ5odFb0d? z)dnP2X@Mxw0F=-OFkKgU7nBIU7K(7#nNJeeHT~!I;FMx)+ls9ZE45c2ShH9@Zg%pb zur^M0;&9kY$ZmCP;b98TJ3!)|gZ1c&6%jrAz5L1{ozC&FFE4hlupvKu1g3Xgt-c+y zjdpt_vVd}l>QY%GCEZT{cdT%z$_OaX-=^2kL|8(5LBuC4p!%-~4^F>&-|@0{o&*>vnw@AfEDka`XfVybF!#UlDt(ChzR!|rxTX=+vWRUQ{f4&HvIx2lP)0Dg`DR} zR{WOloXJwnxZ`;bGVn;O@MQr%mlQoPjw4Fp1GxgfwYF6||4zzSV*O%c0T`2wA90sjL9gB68QZZf3WXJDak+jTXBGzdIl zh%%me7ut$#&-)VcJQlh?vB72h%a@|l#=$SDYmMGZY(~VV`nLAo^Ra8jAxor(Nxw{n zWK9`99~?ltSLz_08zuP;R^v-YugLoEx&+z*j~A_?S4#g9cXuSS0 zgfZh5MUD@3qbC}!i(b6YLI(Jj(F;@A8VY|t_*v@qePVBn+;0ip6@}{toV33XHmaQv zJ?G@Xw#=4{A8AO-FmmS8=4&QM@}2_F-)_89QT~n8oKjn{H2;yh+Nlok%^H}E-?Egf z%Ng5~6vik`acB*8>hQ9p<00G5;VU4kq3{dG{#aT5SUBNbYZ8~)R2G{Fg1INA8#9d-;@c0lnqd((9T|yW@ zM|k=EG$apF_qP@@ty8noe09E)(jmTIXO7UWTvmT1ld&uJ>UpT={MlhK@3cg)nCk`c z=l6}*DwTa-n^oZo<~qC^Em_5RhI&1~#Lz-n)SZ|Ys8ViQU#hSKmuv>=QrgBjE)0g9 z(n+O#b8F)gIN%IQ_2A+m_v*K?0|S16vho4Y}U%3z^{pOmZJx=RkPRrhJURIRcA3>D0>R;V)F7wWOo zyhH_M=UQPT$?1C}bAb@-ppcH#ECDQuQ&DF2P}(YC>PWU90JHAAqXJ>s@UUrqKS<4> zAEcWx4kx@da6BQZwk{A14DE}>W~D@Es0wyhBGMLGF{T?!1pmL|I@W4QaPjZgH2ic~ z1N!zyz`RX17j(i~(rn2bH0LC;xA<6?yw21wF6C&n0X{LJI^;HJhUjEQ61!Te5E?F- z;F49iNoW%>HN*Jpbz?(es zevqWFIojY_q&GDj_aeCDipMvSNL~^TQrhGP-yM3Il9kip=HF!Ks7kiqM;Rp`Z_7-T z@k>2lIF+gu#f7dNcc$L6z1`h(hPzfxxDo+TL9V*4?!?Hn%{;uxk_yk)eW#6^9_R?v zcY7`c?#Ic#eId}~XDs=!UUQibPQxLM};{@@Km z!|7d@ra>_cX2>VHU{v&hDet)~j@w|VB2fVJvG%v}4xsuC&BYnj!D+?yh^sGC%#y1$ zIi6n+WkS_cS8Tr){@Qn=C+E&~jmbL@H5NABBJ$9Mo$OUGpwO(4Wm_Nop}o6Vm20-^ z<|4ylwpMmZ|4OFEd&J?xjotV0!UK%=9x~(i>c8t2>obFAZb%Fi3+hTDdA64=hE2H@>32*g0>8V zOyDs0QMvC4d)cM$H8}lZh)u5hg>tLn(n-BW(6og+RjlmFm_Gndz`A>G6 zsZ`6*fIx9tG)L1005Ch<1cK!G{Dw9S{_qo?TAjz+9p`2Kvb>9D|h@M+wRs=9?F=ECGK`<@t%81v#d0% z^^}}yrj0vlyIM`DvADHL_#RX>MAnFDILBlgIyX1^>TIw3CN>L6QU+!f8zy}B+D~Lg z%6)VyU&-+Z>Ld9a(gQqhH76;`QCDN2BbAl-!wH)%lysGKId-;DpyeMc*W@Pg?J}E+ zQ(u2j`UIW*b25jbpr!)@b#~`TUX=b;Gtc?C1$zD&bB~_cy7=KCQF2$W7BsN*);$^s zW2fi$MN%uoq0ush;P0*XQOn9A3F8%_3>Cy9uv~|@TAvjof(?F_=HX9ElCrd&^~p-V z-DGh*|AUuLQiWmCR72m#*Sof~pat2{kI7#_v-ABzOl0YPaX)H7_t7r+qLX01^O6Ud zCU->0?R!LI^Gx%q?MHYxDxSGAkJ_q{IICN~(Q!a^9&Bdvvt;4Hy6tDJfI>&pe{iqB z7yI??uXL^ShdE~~##NRc`rP&ajYgamSvDS?Fv-oywyCi5zXzr)Q4ffKciaZ_-hI}~ zDnR}!KmF+-L*ktrNBQv|?)FyY#enNZ5whs02fZtaH+sRU!) zu_%Lh+&_YOuV;oHTxh%cgT`5yEn?tz;G2I2IDeX}Pz0zXn?lWD<77sdo=3SW7O7JO zxJA-fv~r}=rbU_gLGYjQk)9BG$)swWgFUs=8tZ( z_4LRCuG}-MZR~2{MW%&(V=c&}OvhyKIi|*53HAUxAlhz5O7!(}Q54ePj$jlUm8Pt{M0$y?r(vq3;lWk#RLGH<^0ErtZpCipE1^JD8kdezzYv`UijuC%w^%Q?63^qYW7B1EOi3vPAkzQ(%mPS3vPuH*Ti z!jkQRW}0r72)3!9Wvt%no#3f7n9`E_&C+!;pZGmGn~`oB6ckWl0iPt(6t}KTm2#kA znR|1Cxu+zDKnf)(I{Nl~=M*+-Op% zyma(^?%L%R`pGLEhPH4BXqFR1vVAI^%-gJc_)!ObsZUc*TlGoZF!-e7SBcj;NbKTF zo4T3(Y3WDtj8n+SiKH~i)(eKqL&o7+gD)(Fl^$#9#Zu=Kw@skBM`dRsgm)4=EknO# zzZgu}jZq_(?gKbXGJRN&H5UjefeC~#?+V4Ke=m{N z{N60Ydc=Eed(v)`KVG2lTj+Mu=rlwZKue)>MHcb!B@hnD!?WAwLYA23PY&qJ1wK!# zA27RKz;aIH&0S1nrhd>F&}$9Ft#vbE--Y{U{sY(NY?mvz=-gOn zE6X+{ImR>q+NqVCkw>TO)BOQ$?yvY~K{va3@tq94#zHH~fg)!=tOz)NRjYS zP2hPEBq|u*{b3K-^9lNI>zgCzdNPHoC*3`D<>VE=McQe=wsw>T=Y{(tU!7$n#_+SU3R5-Gl*#Q5 zzy7PEdRGGUhX!n9!uxDiJJ53g*FmXWVtN7PUhU&ibOT1hCM83`P4s*XKjQ48_)$4m zSsW^mT1pA^iy#kX=zU6m9F43^f9ArzxOc(iRQ5i&Vm!lV@f}SxAml`X-@a$pH8~;4 zYLi>|x>VP3l`hj?vfWr3L-+rW5b+A4({z&|YHEr^@SAm2+sKn7ABd}3_J?Q#7_wTc zZ91xI<9l=E@KZBQuMapsV|x8P;W=iw#dPEGyoYw*PpZ0D%+d4icW_s%M36!$@zEVl z+;kO2uT_tfw=d-5lKm0k72BC+`C$Df%8D(jxZY3-3EY?5lRHU*Jf_tgV7AA%t(wCg zmjs0*r`rE%edZbzh3y8JghKQZ7!IDWvM^H!#bMb@LW}x#R$zubQ(YPq#JpoD@Pjn@ zUm*fmaE_p(;G6Wk-gZ-|T8IjM513o);Yvvp9Y)Kc3LWVAf;%WhYwW#73e}ls-d!SK zx;aG^S%5acQ)XC<9GmQyzc^w)7(gxW+SEy<3>y?Z6x4VYBZLY1q^j&)>PCkxkIBn+|iq$GdaN3&F|AVnX6IaKGO_M^lekgA+rit+Ry_-%40nK%gq-VLvQA^}=-~mYaYmK z<-a8+o^4$b{O~X*Z)^3;r#DA(^d2Abp4}$yHFMAI1s5LNGdiNXtkRDb^40iN_b~E_ z?^U`kJ%8cmstlxj9+v9;WVttezwQxZId;d;w>$2b(FW@yJ=GHi)E8Whk}C?=mN53%m97;Gy4{>Z_a4{NF@(fm61(mpb;mP}qgPq5hOAR0V;trBBEg6R%)N9Yjn(A*0L)}1=- z9J^LmPRGclwN5lfnD(1wmYnr$1yl_(D_#mgRd%HF!ku4#y-B6UAd#4`ERwxA;*%C?Vh4^DZhJkk)j0qBTgoNO*>3E`b5W6JL8sl=cv zRg@og3K8a_;Axp}cegm_UPLB_4@av8?Dt|pJZmp}T+YlpEeTpbZDQ>{J33XA{ObwR z139K$LTh>XUdkyl~1( ztogI5uk<9dy*27KNFDSyOzXB&yC#l@P1>AD8W~LP@15eL{3LdACp}(0yLit?aHn9T z`JtDt>NU*a3f~Xc>|Y3dT5%6C{#g)!EsKGOM;oJ|h%R6Fy(;DV!a{Wf1#%VXYgQi-}HIk~nmJ>nga)Bv@ITH>) zpjwAtI`h0T;t8RbR@^?)^pRzwy;fMJX7SXnI3s#T29h1|x9 zJaw6)Eo_&C9A!n76mwlzfmDGTy##^AF!rITRv;rV{rxU0b5cS@2HoF6MCY|Ugd_zg(x-8E8@)Y*)@VjjbWHUP{XmEeJ_h%mbu z{rbNom@P@(4On6%xi5eQY!)$I`@kiNx-8T{r-Cah9Ge901{~w^R9}b<44#3@1_|X& zi}OXgyUP_zn4toy#iTFKxTb>;~RE&-YoH*X`kI82|9-eOOU0iT>hd~lkYQb7EW zj1oGqdC8R)B2>6@s7M$2)Vf;$sK~{N*eSeDC$8k$!1?KL(T>HkuDRJ2hq&uNdPXZ@BZ7zpB zfaI{;Q$-;{5~l*K)qi^2vT;8#QggBbix77lYz%(xaWQ>&!)x^Cc?b8nZzMx(==d_Z z%Ym}pOFBA;*nBBlhb)@C7_~>*2-|=1(Egy1GSb7kX#FWPXzgdsy@|iIO*kjx&5gO?b>3in~`iZkDpD7VGDp;;A`kJJ;#4u)AS*}Er62uKoviP z7YWtzerg+JZa;F}k`VR$z~bYSeYvrU!!3}DXbQ_+{=}zO{Lv<}YLDY@nHeNFv82(t z0|(F%iu1O)bBS&n*)~vy(-~UzP1t+g-bm(Kso{gTl`}6_x^Z(JTY;QLDEywRK zzc*^&Rp8lt?)c=(6KFu^y7+C|K%=^)e1#}k5Oei>e2`mYkF?`f&HSsLtF87P1ul-5 z$Degdke=R`^Bes(IxpmCpLq(49~o+ZMjFy7Lmot+$(g)j?X-A8{k5%mZloYm!FT{j zmoK>~>4+==kwRKv5=KPz>X7z~6bCJSz!%7Yb!*=3JE^Y{e!@HAqBgM6RKxQcEo~Z6 z0VzCF@xe8dS9v`$A*zhQ3}0=^Z>PxKHy`>P^a;Lph8r-nzsBcmAg!TB4=0rDg2w7e9T(Y z;Sy5c&iK(@Z1>I+x3v}M$lF#XIU>+eL6$KWD*^lWOZdz;h{6N1SH2oF4x$Jez zwqC2R;tORuwJb`}X7R4D!+)q9A_cexgQAM>FL2G89q!svl0~p@(j{Y>wv-+-*+a3E z#sVM~4a5bPmK~?Vpp4BblahlzpuQ~>{LYAdQ)>UT!-3u*>E_UWRoZ3s?!(zjXcjGF zdGgUzm)-NURYG`}BnI-xi!jymYk9Lu?S_gd7lH`veJc+_y(^TAt6T|+@&7xk`&bN) zWGJ^wo-}^1aqa=)2sSgIsL^Pej2vmV#jFPQVO{Moe!VNcgsYEpdUcM}y7?wid=C|7 z`RJbMgLTl0;{M<6K5!7df-ADq5z%D~A^0^jvZAY}jyXpR28m#^y$u)riMf239& z3or~>=>mlGlDJTp>85}x@NI&?A{mRfS*?5qq?czH14DwbZ6g_W1ZCdZ22yVAYPJUMzxQSLa4m&}*=EIqMU@QF`dinvRX<#{BlJGs zV5m;t;aWyb*_((Rri_G@ekZy-aAKqIl;w9mvFlnfS+}~77B{NCa8J%=k>5+ z47a)oN3+!7J*JFfq?y~Kz9o8cj6%!i&obEqx~hFojngr8{V%8YyFd!VXYRl=I?dKQ zYf}$btzQNnixs@8Q~RRt<6iEJ&ebv){~@knj-Rh`c1t-A8R2>EfKD!aMXi@_|xqfY@PS3!yy zom6qJlbpMK7Iv#I52uSwY^W&w(u)8Ib|v`3Az8*H-C;$Z4L z;J9oNQ499VFBOi{4A)1=(n_^Q>O6p`j?j+bw>HI--;aC?xEmery1mMUV5y_sRzp0C z1~im|w}gBK4<f?PFmS&+Z!jvR7E32< zlanQt5>JQEk{!$jPM7>>k+?v@-+BJsCS_4j)ONe#ymnaSTKInrWXS^?ic%ga=L6zW zzorg(Ed7npkGS5R)6pMr`_dfFzN~w9d{*i9F8VvBZUqQQ z==Ug<<&}k#(^5C9Z`*{$X5}oO2)=cn=x!~)&AY94G16vdG&~i3=cawQ>b(rtIEz@F z=LEsXc$8HDwnC57AF?qUj0TDYQgk#iUGET)1rnerbum`l_F58)mHMKl; z#V;>Z8cW>!i*P3Th?=M!FuYJl9-m09N69=?yIqheo=?S9ov;95P1Q)FKOBWl@FDG& z9IKo*o{1leO7Z=8)xJGmLnr=4Y=6t#vrJ7_Pz;p5l+^1nTKG?JSY)*`XS>p*6`_03 zik`dJ7jhUzwhA6qiZDe~NkY6*(KiXN;$D|S)flkq0yoU!v-ae#5I(Z6E@YvvQCoJ% z(~=QDaK{NMx`MTF#qS@`Xx}$}C(QwG3|2N~)#;h{kPHbx!0>~5YliZ^t7^%OA@(tIg2KS$eRj!j{l%FfMciA~uQ+(HX0-4Swy z4hLoV5=c249iF;m3_qT~h0!lmRSbxg7w76m{wzmJ7ZMG$62SWQz*DcU5MRiM=GG~} zmwpXH3P&$CrWnq{o+~!?piwe}`?t-#`XWZZ#u7=mL1d1jEbGe=Ii+wFfR(q@bPyuH zBuJFjb98g3MiK1SP`^pN6}_MhwsNkrkE|dkpEF$363dQ+#|(gcG(UkxZiBuj?u(ic z$n))`6KFH>f=F$upJT2nlHpHA4xkxqX&a4#9AdAb-@VWXnU0Dc;8=@?hRR}u%Pt5L z{oBpnAge-8>;P!pCxIvnRDhzvn$PgkzFMYA1APG2Q3`ZK%4c^wnlo#`gWN{}k{Nj^ z?GipGRiFprjCcrl#PC=!JyF#IJ;(m{#`k#jK`Sp6lVx#McDi)2&tB;wgj^I!>HU8J z&(DCiP**1zy9Yp$F~H2LLjVH)Gzbeyl~tCY{&06%I!q|b?^Zs7Aj zaTaE`)RLGzHQpS&H~sa|t9jyv6jidD)ns$(Wjhj=U-drhI-Zrm&ng*D>~Yo0oO@OY zGpka6*ru6s?bd$Tfux=eH{{A>RnjqI)!B7Ypx}8RqJF+A!53!HbQ5o6K$mc;`wP2wX--T|r4psop*Tab_gI8-Hb~ouHPh znwBpVR5zfF4W2f+KbR{nwkMnw2wDxNJYT6?{;i%J+xMjcAqDdY7<^BEq?Ppk^r%9|B}D|#@hMv ztyOQ$XNX0ha_0Kd{)hsOLddB6U<1-%kxwR}MJ5Qw?d9veQ<-ljYq zyAU~yEY%`;SyJTz@N;0_ER$O_VJI{MnYbduqwF|a*ebFo?Ojj8^D_{;ks_rwZhNKk z?z3;_H7}U@NUVblze^qYrxl1XyrC)SE}=S{1z;*9$e_LDnxxw=j}H6d6JdXc!mIMK za@dYHi^e8of?jRU&f+I)R+C7}1JR6RhloZC!1?>tM5}M%*{PB}ebAW)eSqomoB;+n zYeAR1(hSWRKQ>}&Eg}_LQCFrg##!$Bt%N`MMv6YO-sj@CXU;tC%PZm*XY~zcbf;*T z?T%$=ENQ5ON!xy#MJEreeaTo9SjMY9a#@;F-n zlyxCT>GxJsR#*I0)@jn%D~``OaS}ZEs$8F+kwy#m0UTpobZSmqPxo)dtsXb)QtnE& zlVjtiw3I&j!BPUHF8*{`b_`iguI!@Ma!H(^@%J@c1&U4J_v?-h&KJzn|8j%&JIxDf zQO8=f{yghbv47C2$x1G4= za(x#7&I@g9furg|auJ6j5`k*-SXl?t6`9Q~3U?)6jA$J8Jm1;w`HHdBezfb5i@CoeYO?#)40jm<2^tVR&&c(_N6;N3>YDjgynD)_+&WHwLV&cI7N^2^f2I# ziXnu;&-RUqKyAeh*t16FaK!RUImfuzW!mLgIjj5}PieP=hn;B1k1|JTCE zjbTI#r1HVGrpv^-kGq<7C+E?U&sPArBGD-0Q$fOem0-FdSN7Ws^8c=%pVE7k)#BQ4H z&bWDN{=27`HE+WPT|i8d1)wxL;(JlrJP#h8#Q3@9iI2m6VX@&bsh$LAm4GD!@(+nU zs0q@JKYG7{M!f)B5T&V4YrSHoTb&C1EF0r=7t&ziyYPc=?jb|2Lv_b_br0*l#GaeU zWHt?nOboeAmMoFM|3G7ogH0*1<{h1JT8Zk```&f+nwRc=c6hk!+blrVf6YLD!7gVX zc%P_v5jT}<#~D+e>WdLBcOM*fBXKwNXR~e6%F;j*08zMi=|0xSH_@AElmGi>bI~_IX>mHcFuFTsVnkfWs7ma>DxiT zbR3PYZau7XB^-o-wo5rhcFe=J{GM?CYm|9~h(jZyvt&NEIrS}U@pnHls9Yt~+Y;SJ zCLf?cTO!2y_GQhrN(N*IQ!x$ghdT7LGbFV&n@zt$?kt|o`OdGS?q=EGEnt9fid&?s zyuhI2L5OwV&qm-e3tdsz=I17YM@wML-Z}0+IRF|KqRnOw;?i z(u3~pMln0br)%~^50nQ)h4?FKtP1EO>IzfOM-nO z2J7yOxI#P`~AjioDN+z-my1zwhH27OM{t^ip| zC50rcn)$%SnrkmgI14G!m{qxQ0RaYvo>OlRHHet@C>3Imvv(tXB9S z_H(b~Sq!>dKK60D-XZi~V%`2YN=fPvY z*!V@#E#$qZ+3t^cj<58Q3(6PF8#D;NLi~hSbDNc8_z6E|Pre7-vx|u}3%Ggr#j@Hd zbA4mbI&6bJ^Q1AHQ7Ph^hVQ35=yCR$4Q5(}YNW8PTxfuifm-<Xj$z!4ehIhnH$~4dtoP>=2a!)Kl23rL+myQ8ISK zkbx2EcoL2vP8HsZa0OkHD@p=7kO&C7X!X=@OeId2!?eZY%YMHn`Jel2){2Im#X!ZE zI~oIG43%nwFKX7>c^)UG^H=)@<9F)|q3SEg3S{hyl${2EWfU#qSS*n7!x-oI%*GiK zzB@{=!8VG%C|cwKXV^`4vEse6k#&t^zGXw&%LU1FS(mIQKY)0NZ7QAgY z#U~oDhA5+98>$^biuBC@xfmguIlO8A~h0G2n$dKXL1qShVN%Q@>v zAI!WYL6wT%1Lkf<#?2JM;rh3ycp${jId<0q=wjo1HjWEwjjy-=Igx z0xJb5OoqHp#e*f6ct$=JCeyyqjS8gmmT-|VKf{=3Q9QT+Dk?i;5P6JIRS}bwKLBo+ z`d&dpPBPz#U}YyC#~bF;%xGD|DO!mY9reGdV{=v`wa!0sreHFiqbip#9r9m3enS?R zbNm!PJK~(KU((zQa4bD6PAR=Bd9nIpf_K5*HGI|j&4FhH_I`wC((sczWBg;SBIW*! z9Xw9!l16*wR0X*}K!4D2$e3>%D0@>B1Z9kfm5{kkgOs4J54-MrAdt038hZP+1Lk^kOPuZ=Orgn7+0BKTvF;d=Ahj zjaPixmwg|N82hAq5PO5tiE-FicY zTulK^&6zeZG*XMvsf57)BurhEWENe0D?s%bl&~x_N8Piwsum^zyN_ds>DEuap3RYu zPJIzjpBI}go$`pqA^@2tA0^+Z8za8EUM$oJb^Zr?X=gNcCvJ3@W;A*jDu(5oGft_E2|Du*F>X;VG!XY$D zB|`VB%+ zoZB6VX&U?AIXxpP$}O>1_RqQ+B&ZF1e)a5QrxNMJ$$B_Qk%A{ow<64JVi)-#?>@SF z21FFcN|d92SM8w}cC-vceYw?Dg@zc^ne)g>l0hl!P&WbqzD_jC7#lS*FBDED-0_`( z&__mzh(qDpi8rKXHFyn@G5e65B|($vpv5IQ84=YPr?bSakQcuxG)TZ;22a;D-&llB zw*0|##YS#$i{DMW<^_*3ixlGH_eUyH$1*+=u4eUaR`p2%oKd4oh4mdP9*nNjB+Ugy zhr5YWZvS6{w?FPwWKId)^G_fMku{hAPQfdJS3K;T-l7-M1m*H^oBSu)K-cPquEkoK zqxugP)*PE+jhLNpj~Md^Je4%BWnOej?{SzqM(w~&tusyUPDzn^Yq)2BWx2!^1c{bz%6fP~(WqL$KC`goeTEor+`fZ~d~a7zk=(u^%^(>?DPn8+U&^ zhKSBlyKlV_uz+2Qq5t#OWC7%Utqe@f7cXupf*-5010CqOS=yZJs`9f9oKN!>ke(D-u zG6U;vi(MWp=ecLwY-%Nd5KHU?;gXi^=v659J<_lDD(H|WC_@Nh6QnI%Q5HQiJA@aW z^C++iUP+qnMv$=|#Y_EQ%)^GIGs+}g+2A0;=*%SCAHF0Nt>RgT?UdV$QXj zgQg`&c|9B=rs9=iQEbB&Un1Lzm1}i}zVE{<9P6s^NE2gad*s%%Z1i`(RH#-GX<*P?tiCM~SN*_Id zh&*X}1PnIZU+!26*-ZK{8{v8v9Bz_Na&&&e7H?CN`{cf|6OTd?@qY1`Nv50e{I7)IBxVkg*=0-|*qWSYtgX1y% zoFlcQy>0jJW?_Ev&DGvn5Ws3OwncRrTU9uROs#4J?H}V?%U(e+ZK9H|n6C)NtS}p2 zpV=I$1-Iom?mhG9d3%|JMW)7!XPw}Juy>0M*F`@6jmdu6zJ-BgO|nX#?X(p|BJL%P zdk=gaT1PN8fbY8#7M20CKL^}Aj2EFKJAx$0^cSvEqZBMjdv7Cl1t(bS-R}@8zUo2I z{xM?ruV1w~UaJ!>Y7roX=Boptr}r@SI8&zR{Jm$7zxe6mZPB2qs^pVhE>9T(jpgb! zv`Ap9)t!bAkN{lwO17f}M{Y?zeVboA5814cloYOh0F39*_e0u$KKJ;5%GJS{F&l!q z!z@J~fR?DFmr1x~QB{a^#&gluY1#gExqTlSqO9!y9j<-8T&$TqyG z5hzm*+Oi)TUfu@dBjwZ358DswdKjK;`!_i3)IDS0+i=*O1Nykt{N0jrc<#A=_g7!d zrb$s$|Lv$wW38Kdo5*j;pG;|P6b^T6C~;4irQ=*%sji};5|C`D-_j%+7)EmDVQk3t zCBxl}RDlUpGUu!5PYboysDFlQ{(Zh!QlgD49KTDmz*7CCbqZ_(a>~v&4quiP8ZPVv zcqtBh7<1jsgov}htM{k_=olD;<>Tu~1S$K@`#{ugTCz$tFy6|(}io^VCRLp1lm<7^zTIfY-AhH`o2P< z8`!Y0W0Q}Vx1}um_5uI3o-yn1mPY+Gj^;nngZKC@hixC>BVQ@rm95Kgb5|em;$7GN z>j1Z?4jT5SB9+upDHwye(lFRBcbjU8K{-RAEjuA9JBzn?2N;x#FXs>Z3R*4xdX^se zU)lJ9_qkmdc$BzGWaW(33HPhlx;N#n7sfmKQ;4x+tW&}pUa(A-&NWj<9<;E7g&67L zt~cibo@Z1;6X-PdAL(X=cG!Pd@**?wxH7>k<{NhP9RktH&dJ-5+c=qq9XWO-! zDP~u(N}kb2+sIO(Sr#QL1IJ>V8gH%m8=AR0+_jVX;t*OaYmh~E42u8V)VGYobPR-^ zoF4MwDDVk*hs3JDGJW8MK14RtOfz+__!>jP6$zl&bcD{NT@QHqKzL1et7SD?6vHB;# zkum}=L*OhjV85(xzRY5v2OUDayKP3u$hUuclI#}l@gy6*TIJAdO*&&Yw`=4EI2PT9 z1LcWQNVVaD-*P1+p|$40@ormP;3`#8_*7D?G6+Dn+=TA-O$KKS^lAD@TiqtTb{aAU z+4e-IG(1vorjt5lw z1v#LnV={zV0#wo40Ala}H=#nU`{4I<)Ld5EFv{v|#*jYOM*hEm7&(az&k3zcuo4tA zSNPg#bi?NtsoPEH(c=~`;q-gC0Kq5!Z<%3z7${{h2tS3hgmtiPmUoeCItpaN*z|Z5XZBCEdZOew~~HBUG2@UG-u|h z45O-g{Se+Y4Bb~b;e-JU)G+!w(acmiHxHs@3&N;-89# z*Y>!K(9H1V2*pHc+PA^PLc{kr-$o9ZGiCTV%4T)y>xCpp)=XWRkS`;8kzbfPZYTF? z!sRvj!pf8OE9aZBLx~GZH%`8aji%XrP>?Yam&9gVqXu#IA9UR0nd*^O`Yr za6D_3g7U?4B8CCpHO--32~JM2lDzW zUB*28b7m@zc2a+g7g!LjM3q%A30W;ui24%_;37$tXoU~8JHWLPk)2wioXH#4yai}2 z)7Q{fTxhL&pAqxMv+RN+zwPt;PX?)X47#3sDbgb`lGS<>ZXbwC*7B9N=xj>f^R_bX zQ`Y<89eilq(Uy0z^GsJcC!-o(SCWMdca!(euMm>wykT6&e9rN-|ACSVER_=3nGEHS zEbdle)fcn;W`x=*9kkeFB)t*6{UuRSm+0+IT=XbyDCCHl0mxo`Rw)oTmsU*Zc6&X~ zb33AP*=w=F_L<6Lm8yZZ`^cl(qg}TK9puvdZ?^0V!wvysdC-{Mdb$84GZc|YPyn3u zWI&s$bk!!@P3*KqUU3145gU|nU>3B1!&3|yqZ#EXG2t3J?iS%wR;FQ+Zv&GVR-9#`6+gbNUFy% zu_2yUw>K4C2|4JaND*2a?kC_AkXpO~3EF&Ze1>PIr2MId6w%ki9+r(fSc?wpoveaLTmLEGrxZj9)YZ&Tz` zFf}%%wyjNiAsL_?796+aRQ_D{;9F7qM$16kRVVeLb;q6CTxpi3iyN6qd~@X!-I_?_ z+!en`-Jo6`Il}Gz5WMO@54r+%<9@Eqe`FAb zdJOb&&-!|e)&XFiYXJ0BZyJiwpmKoE!c!e24=yrBN%f^;tF!>rz_Pcx1Xl+5!Ps~( zjS-`BQ<7%$9|}nSu+O?X$15*59RBEURRy=(?I*7x^NLKxBZF-pn|a0M;L7vqnI?$E z%e1$^l(Oz!Coei>gr4 zfNgdQN+$95OKu6oc)b$ffSdLb-&?UGy)MT7n}LyHm3gYIOPB9mx?{ zVFzN71BRl@VlSuh3qS)h?~F-vcdr;|nJ7cr7zCD*Pm{6~X-fcAVwLBwID=aZYGD@V z+PRH*$$wyTJ|F|wRS@0g4{*QYUN9NZGlm0k^*Fm>K#6D7?O*(gqbRENSy0pEHhD+u zey0q8jt8E?Cq}9FI91Ngrc~k3i&@hcXqG3O`JC;S)rY!#egdXAAA&eL00slUmjO=> zgpF6e+1q{4O$sF8Q4RsTBRQ#{B^1MUv1mREN4_Kn3NU;mz<%!eW;^1f8_8jabN;+> z6frN!IlYQxM-4jKDTNZ;EN$p=(ts%DtdFIQUk?W0+RPOy&jyfIX0pZ$LEq7WAI`g# z=Mi$=9kVfPSwjvUATdM(2W^Sl=}@NYL3A0D2Iy-!XVm%M%MIx8g;|aGSN0~rCW{?D zo6Pge@!)n18@V&dnWL6RGr>VPgvRNzubKGEahA%R^i$Hm>sQ3JxVCzvxU|7ZeRlB% z)XE4 z+_0==-^RgDWlwB`M8L!j-ohtLAOzgTTpZ_xlxd^x`V zcHg<%2UbtOn95{Q$mA3Asl%EI0bL~DXZq7I^|1RM;q?nUsRFgvU9lXBugq(Yvslm? z!C&8ODr<_9R(Hem=9R}BRgXSVVpsZ5%vN1t=UcgEOUJLf3R#(RmtBsm%EYQ;&6Wev z-LaGC;3Py|=&*--?Xl_Me3~DPbo};b`PfH55NGr@XgBw?{gu>>IKgF#UiD)T8f&LX%Ie|SDDH?!5qdsQ4W^JadMg_8v_m8jBZ!&deim_ZG; zsxCDRANHJQ%wtb;(jebB^Horu+g}ugiT94*lES}qUpN2ok8fh%>Fcql6#5JA@vMuk z^v!cOyAjHbQeAL`Z0cBBm}#64^2nEZvQgsn6@tUg*x1DJhn_7uUW7>hr^DMy&mbxV zvICxz1QphE=7VR3E{$aDpvk(>IDToI=Ds(B-@0g@v3fifMfg}W8=Of=k~{3EGv0bL zXw)dY9%@JOnLBk{_QN`?1hl!j;;|S>gGOwYNuPO-+Z2#OTsUBQfvNgF7X~dsz$J~; z*W7A8pnvYhVDtovxRq#KMiNlqs_g`j3*ZPJC6E)P#J0(GG7$}gt32Bm-S(ljqoH#O3bMyWs zjixi8UBf9WL8G8{n?OAT|9&LVahAC?WYg$h@-BJ##Gg&G>G{fqw`!Gno3&*rYcA^k z5I7>P9TUE15R$bqmkNAKOS#!nTrnoSHGjUm39 z>ekb|wO4o#NUB=bKi&28may)yshvQ_ULh=O`z(0S_D!au$m`z|0PP)ro8S(LejNFC zoTTanDZ4?ZN#A*I3)dTkEs@&A$MvK7{_45As7iG8srKCPXn1!sdPtw2ySoh$(BRIs z8aU3hb}2{<)6g~$h2B**nH_Qe8&!7CGZ;Rnpl;k!aSAJiib2V}eBps0@S6wF~Kpb;8TpQYd(z5JJ*PefkgGgu`mge+~^rJY?Nog@iV1M;+IoT|XOkzx*P zu_Vd0@Y&r(Qez5V{tzneo~JZcW~kk?!!T>Wtz{^brF_xf%Z2PY(wZc9&aDG=)-VQZ zJBDRJz1f7UA;K7s!@H zbGG@m5ZXZU~L>@ zVGPh^&e{O%z4H`D=A_Y`x0T%>TQs05)Y=^B>)=74C)GFtrX}3)asiRf(2@ zVxELt(@Q8b-DNzLbF(S6Z;u72WAWh?%tA`#gmdhek^bT*f7Z*IaQ(hPcOXSJkp*0X zQ(E><7(-@ChFy2p;rz3XkqpdY3&o9ofx&8kYlA^r>khmUbL-ZpiT;IrHtkB(Eg(Wy zu*YNi%rvFjd5ZPBBg;efTI=XOe4}L5#O~a* z4R+s)XQ#7U@*gWX&D6wRScHqHQ708xzT?#k?-I2irW?*x5PV%o`9r5+IM|x z)%6@o%AnsIu6QIynDb&+I2T-x3MlgO2jZ8T|2yAj95^VYcjrxVP=xFXp(?7c*BTYn z6~l;Ob2>sKMC%nD6&?oa*2Pu7Zm3Mkig?MF;^4+x)xoKsU(qf;C#ZMe;QhOHckrJY zV?k==m*l!$`_@?<|Ma-cNzxx2_$P6!>B&Ij?3E#>z-WKeG8_S+ub}>QIA{%p(&Odw z~w(4xwrRgi53~TIxcIb>S`q=3hG=2iT7B;>u*H^52A)(pN;EWGgO}sxQb=D?%t`wNn<-g?t`2lE3{DDDIUQ!^w z3z5HB_sH*w^Yg9EIzq@KX2PSNIWvayO1i8v^gmEtIp73Cvhf+q^gx5O_wPlpcN%O& zMhn?z5#r!X@Q9JRmq%r$*T#K%XNUhX1qaE5>mWoLpsmKU)hm10d zkt4r(4o4z7g1yfrp~+z2l5mrgM46^AM@2D3jg3a8uIav}cN1T2 zq8~cx-+SS>3P6ioLMKilHg|&dRGkVu#-wA-D{YbMb5GV@KAX)S&T(u;6Xr>f`#N`% zZCtxtypMKFKO|!@4^2mRW#>R(pHIbKpAyxX-anhxEM}FH=9|Jc-p2WbUuk~KJB-71 zROQxoN?zh8Tqzw6e}A<87B;KS=v$QaD@#VI_Ez*-Kt`-=8-tS7?HU8|HphHc0*RBP z_m%hd%Wc)#h8^1Xz2EYJd4#653J3&WVf%p?OOIfR3&<%Gw83WO(um&?<@Ut+!*AN` zM$b{yBYYIVG0e8BCx={U3HbaDxUsl45qkcYPO^66t?jP6OFUfP{^7NK!fm6*@qNaE z&@+u-Dr1Qkfg>Zkk!rVeZw}dyMJeZVqIv7i>!$sGA4d9*HVpH9tz!}yo7Nf$b5{~qg4hDhQ(ncd$ z-b<;OnE|xycNdGq(~)=x+1G$hOp;&vUik|ueU~8yf)ay136|98lFJ5{Y*_3_y%X~w zir<;2(PZ8XC4Z7D8%Z{iFu3PM$b}S`zHXftmu5pzBGO9s#Hy#8Vx~s)R-fROB*?)` z8ffNwroEpfsBoS5-xlH+c*xtr0ncD-lDA!=CsP!Lt{sH z&h}7n;1}D_L^JPdrCJ!+f~CmOh%zwbHde%N`~g%a9h3l6pdO**H}c&eKM0bWWznjn zK~qIr!fauW2_P_(fDs)HF#LkHs-a;}MtPYKF)X173<7+hPB}O%2KEh0aU34_NX_;r zLmC@5nIlpw-WT_nXi9j5LVz@Rg!d6ivTbUa%MSn{BMVNj^fmPNNQxYmNf@+*qHc67 zjO3C!%3@$Jb1>~ff)gl<*?4skV!%6iA$}j-5u}21175&uh8pCpIHMA%e*x86DW z-}2Qj5LzkdxuWPXyIFPF^WIHlZt${eceEeUFWYL(J5FH(!c7zmWII(IxV_ki3Rl-{ zmb%`tGgtFIq~<=@-D|N4#vq%S-wwIIRFljvc}QB-DSG{4vqJl_|C;5=a0$#}`K)$h z-!Z&hiaH-&?{e$qj{opCa+^o3`31Y)w&@>S7(H#5x{s{p#+320pJ`wJ{15A=hl`ss z=83BzX%^V0GX!a3 z0Gqz^d(GPbD$uKy%=2%<v5G300r?YiA3xx^6Hzhb-AXFm2# zTs@!{=&BCIo-Q7is}tyy(ylVn22va!S``Dc&s*7F!UKY|YyxINAlglc^rYS0Uf+Nn zz@GgzcDkaGT8hoh`VC8InT5R24sr223B(HIjC-P=M=O%CL9o7z%8v_@0Ytb0z>vw!bD0sj3t zigN!r+2tUKSz5Vozp#Nb+8hL2nSQnQc>lF0>)AZ}D93g6#vk5-a3OUy;P>OJMs1mQ zF=+_0dBKaP@n`AzLR83U^0P`gC+sgl0Z|T^m{9-qXRUp)9f4mtb_Tl4mWuA5X$(3NO3xPmpbBsP^J=) zaIJ))pN^11;JUtb_HMiZXO8t}7Ws>?$1cn9>Y?yC7I&%1LYWA%)`P%?6%bqnsQF9I zj+p2k8W>LDjO>y_EPa4oUF1!YTC@|adfX#674!rKu-OZy58-U+fwxT%LrDD&TV}}6 z-${3|XdCm}L^-F{gF*2tyv19Yp|u{KXBNH8LHsNODC*?%oratDL1VvsVPeG$onmxn zJ}YBDx1a0#(NU$?w*CRvXRmq%<#$zC!Mh%5n_(jpG%!kNi#~PgEPI(zTADNFfc3=+PFAR^GBwG1w3twCNF3$mlD$Djo(HUzFouK{0Ja() zlMhsvlqlV>ZlaH76AWw`>7#HEJz$aNN&e9df-rGBNv@Qs9Ue3p4+d)&Nmx+ab(70D z%pwrosdor9Kdj=-^PfV2b{C7NJ~?oKM5BdBpQbD?2-lF9CC5wtM3n-|pdj;i!#1&O zFUUBHu>t7TPN9W-RZ2kuf^110VS+@V(pQ3nfKCYS3+HKB-Ful=^s}tY%yH!yAPdL+ zj-RB^WusW>5T20}y4z%hZo`4l0V=)-Mz(n~l zX(dQ6cqm6ac&INm-%y@_7LXWAMkNI>30u;N6K45X0nk2+b7A0Z6~os}-E8DcmS7T^ zIenGKcP&<6jKv(Z2sYf$m)M)tTRnL5-g4*_-0#Ha4Y|Y%wg8>h8h}=>9c$EG83;>% z{7)rUj{_;h?Ke~1ySQ0-u(;ydmGGY{K?b0MaLP=1w5^;hrb@5$-Ga7{MdEJF9^$L7 z=9R~iPrW)6%AEJPmhD*WRjBEe^ZHJPR{G+zJDH@HmD>M}T|F!Hu)F!^@0C>X$(S}> zRa5@nQ7$exUX$$Z+28(Hk=QHy#nSxb!iiFdz$Ji72-}~KMccvU3k~v*uZKQY{f74$ zpQQ$eDuaBmU!H$=H!BG6iwf^<8a2HB*w??$sJSpWIPlE8`0#i(smN9C8Cat z#{}-tl*S*pJy)K(m7Hvyd;D#Gy@xswd5_HdG>=H>-YrzWNzdcZE3PNa>5w^bpA$07 zWZ~8a231p?+ZEhIjKX_~$_o8}SDi|CE0jm0d9y5EPs`d7L9P5jZ-x1zEd)2}XdZRl zNQ~3wS5^P$7ylU(qH^V9V>T$?%>8}a4}WQ09e+Y97Ofo9#t4^qnhIKDwf(&yf1z5E zr@(%!cQX8W$dGyHn=grOavRHRWsP96$@N@{$a6tC&fh&!(fbVcLuuQtyq+hf z_7P<}{*a5kG@QTi%LQ{+#HB0b=G%{CL?f$`RF(5}Ix|vQrw%QS^ z%53u`0HwXp!n^@J5B+aBYR|9q6x{ zXHPHceHUOQHzoV(a}L)FVXqf9yAMwPA5(80mSpc(lQ`v#Sr0A84*&7R5P|rR<<~UnOmh2I%Z`>Vv?DaTl-A!-S_wT z(!h_?FBUyuT-op+9M! zJ#JA00oc?`vNhd-BU~wkd3zp;RLM!N0MX8_GDprDPPqKG-SZ?_u?A^yK&DHfSyaoI zc4J8)FzmLzJ*eclwJ=^0;fwEHyU%T1AQ^t9WOOo5Jpq=qP&--~@dp;sb@nXe&d_eU z%Ok=xMR+OCc8#hhV+O+Sy><;%9|rv3#&_jvAXFS-qw%DSgdC5CSJ(|mSLINiL_#q^ zDoL*@K%P%N6-9AB>n~{ZJVd}VUlA?avMhM%GMQoCw12pvUpZTS-g7^V_9O&Y_oFCS zSkY{SMHhpcj_RhvK44EA7BF-2$(l`Buqbq5WlXF`okVUkpk}t9$#z_%KnbvQHNBcJ z_4HE${4L&Yv*H4(91}<+Olcfy7Sj+J z{CkFhVgVjj;xKEyE^ly1`LocY_!tj#J3UoHn$moPk{;!N6(4j#E1~>$%IrdG3--i; z5oUpf3|(()3ojxc&Q6qDj<6I+~;7wPOVQ2Ts@=Bv=l`*`N zD|X+qh<>T4KY4=3*@^GDm_kc+Dmg4%I5R|K!kiSU)={$cqp zjQ=$$atd}J>djP#m(SIJ$&O&Fj84HTqT8+emEWONaBRjB8{odXM?iA!~DdC zU506iP`l+qc1p2T)SixDKZN(vBR)2k`)8^ypu~N<{ev85T}$a!K9VS^Cu{HhGG`^^ zP=Sg2>8tAnpS|U8Y+Popp8p*RavDvJYLpIMd$H!!!IdJcLw5ZoFVh#}#m@DXxEBX} zGFE%HY}{I{`f&cgp@+HoIO=dpan&}?`e?#Haq(s-KqYvWoV;VO_e2SA)phEO9*S#w*Wqst3!n!y z2-W49(Lp6U1jhOpO*42s*=Z`=(@gT)`)iC-r@y@yWzdyQ$vowrMdOjqy*!9Eo@~cU zvryM)uISj0rl_Xz3Tzt@%>y?psF8J|&}+2TBz! z_P$JQE7@q>DdfyK?0x-J7NT1le5eX*;>VuyX`C^$z-+9Z8^69>;}Em_&%i;GxVx5S zfBSehk30ySrIM}PcqZGF!hmP00F`qr1;gH3ZWpm~&pUnhXBt?FbbLzc>_6PAK!0tL zatTYL**zM5ufk;7ECOo0-2E5)hU5J%VU3UrT!cpnza&-VtQ0pdcfZCdZ4y7Lux6Tg| z#YLBz?vq3b1B;rJC@NK>4tRFVmS@vA8Z!&6L=o^AM(2s7gD%ZMXNE)(_>WUsfGFu2`3Q#Un?;AMTv*XMcl`9MtPjF4_R@bE>n1Lia-j*qM`$g!I)+=PY9Xb+z zEEd<0U!@i>H-zWrkWfrbgr&jdEwze*Ba4c@L$(m51vh!-F`F`&Fb*$p&!!c-abcc5 zgUTZ)p)_0Gcea>~3ZO&al7sDQ$$BCWiup7b8XczF>urOc9hHG|40|$GLk{)R2}ANU zlN#sND+ou6MCKWj*gZ6;j3}7T?Zdl5Q6tizPU04oBPk>SuCkP|hsDzE1i`aoJMT%M zMERsn9h$Tg7!_X203-~)AyI7u7d7GBvpV^7QO5abbIgo`Bg~Lg%;bxQXelBsIMTlT zTsP$W?;r283w&T*$>+u`Ktv#6w(8G{br|87-ncto`_6Q&Z@I8xe;yJZy*>Mn8@o&G z`<_f`j!MUVZg*9AWK%P_dpG;+U7X9UR%I&r#{4FaP-$AAKVlngb9v!f$GELaN^Nrj z9b)rp7AmCyg#jagXne%gh3%9h=!p4H3N>xc@BAh2S$kqoOZ;xo)06qLYM^56OWNNR ze92_>w2P*XVIwuaFeg4@SFviH&p-Q?Fq8PxlL8$@UmKviJ*GMzf1c!Z;1q7)LLm%+ zeOuTPI!wnG{yJBE_hH+XBZIjEb!~QlrV_WQPdFA~&l;E}lRT`QcSGEoxN4@UYFAQ5 zy-&tr;m&EUtF?@ls9nmN;+r|+HP_p=i;k6ur)r5;@aGY*DXeekEZcB)5-awkGg-idgqtk-PXmMJ`2iz-gN&L zLgSlx4sQlR^=q_*#arhW*6`*I9(^^o@z^!g@9W~_pzicXSpP0|@>%E28~c+Fbg_Yt z@zsP!Z?o@oAJ4FeLUui{`P@_1_>Q@$ZHqxSuOsPZ_qSVh(P!Ihb5jqXNbE;ZVWh&% z$XU}PzC$EG_j6A+peUXFQ@VKTs8IC!D=86fpMG^+?`<<@(bF?ttk&cldN5yF z>f^;jdrU1lCMn}g!54^y_?~m2o}GsmY`vyhW^8iu%UG2Hl9CenMbjBZGwNl z2Z@Or%!HRsQ+WuOpI71Z&5&ZBYIBhv_PCp%$0$dw-MbRIFn>tl(KjG!K7sA^%Oi>2 z3z&muIX75D)tX0`PL6jkjjm|rP<8(HPp}n)R1PtJ%bB5ysE~vpHJj8h2E4D~l6%f8 zZqiDkcnw6$nHoDrSsS(@)jIr0C?INhE3B!SWx)`SbWg7PJJ~vA8~g|l&F<#_7xMVO zV?uJcnoVboc22-zV5YJlF=jtOv9}KI(R0^TpeC6KmarR1{_(;kX5gY8q0X;v-8)$& zk0Wgv-{qPPvEL|{wd*o6J?fVJ<1wVD=ub6TP-Tk1EUI7FnQ7t?WkmlD9p0%UYSwj4 z#B^bIll%422#v*C5~tYeNdodJl3j+q+i!*Ls97lNo=}HKp;!bUxH|)maAF;-HG6Zx z)6Yrph#bLa2i{3vjZ0wLL!V8jnD}>O}Gy7;AC}5>eoE*Syp{|m*jA>y=L@t&abdI&Mreh zA9Ba(GFpZ!spvNyuG)+4-m!@0)T``}NIFA|j>b?Wo!{u9lWpzVkj)LdBt;b=D{lg} z;@c4=Jwlz;PBS2WQ&b~jIf5>-_Oc9<)s9zB+V;W&gPtjzr!S3^6(xaR^3@GC`_!ipx^KpAp} zE>$Aq;HP{zjyXKWa5Jvew@B-!=1Sb!-Zg6B^2xuRlC1p&30=M@?6-fG(Bm5_lmGbS zqcR}p96tasAHux$8quC?Mz>!BM01RG&yKsZFm5@vOfffBm1=;j{bs8mZ{UQ;SAFG- zQxQuip|`&klJ<%In!G;xY(HVFzZ>Zr&xlShYp)qRtMfRHDl9y9W4#s>n*57ShX;(5?t*6=U zI)%fE*8-T&c_%^0xgIK<8dNxmf6G0Kay zyi1j{1JdhE|9tgL^S^`V%ttPo_gtwYN{_bq?@HwNU8J%lwVa#R)>Ketq%Oq3!egSN zHa0J5PFu%X5-s9Iu9I7+7Hxu@&@kNBIP%$c4TAAj>^aXPc4u5BW9@(Ox7?k$GjRO+fgHaZdBM&*8j^LDXsU@#c*4Akqh%1 zO<>v1qcnzvk)9NTf$5w+6~+h;j@SCb@07^vB*=^*Im2Vp*vuxv7%pJ(+8M=f4p?`U z^g492qItE?mn7V`7KJ(=NK&hkreQj%WGOiKb-Ql3#RYE?d}>4k$=vQgW(2xE;k?N(xD}rTJtV4Ye8g z@)`EaoMHqj=VrJgFG${_15iR#pimkSF>X&LlXvekpVCe5Gx3=X`C7kehkGlU?C2Ux zO+l5SV3^&)-R2e48g^EH=sLN@OpxX=pafWJVhpvDyQI`VASPz=-7=Jy-zjqMT%6sM zmhz4n?|zBNXvz010^%f%r2?rxnhXu_0?L-zT|meuok~gpyT_5znhYKA|JpEjd8z|K zy5+Z$lDMQkTj)65VlakSkhxfqB4n}(ty0(BA+}Qx@3rA16Nf|?v<0k1r|=>K#>Qk) zTI)^!k@uL5;SAw%Px@_9liitoMH!oIf~8wiQlbsKJSoh1NjGiN$`)32@%Nm zklfjiA%BqQuDCW{ol?{iVk`#Vz^%|4vaIw5%sC;8o&_gX!(AEs?Ysy4+TT=#&f4kcg5iT8Ghd3cSbtTWq75x-IE9S>8 z^a`!-fS>^7lB@Z6*Y%&sR{D?4WDm^;E!xt&2v-d&MNd@=4z#;-@A9bc5^vf8=eWcC zO%`b+R2W|y%%!#pk~H7|)BTBl=|!y^u3#5uU@Ms>mj_% zHI?8Q>@8KOFqGz~rElp~d2j1PJD*Xz$j^l-7<)gL7E&RGUl@sd(v=)V0b10)M_PGc zv69G)Pme>ppnenkvVbzqpL}UhDcsO?<+|q)|N0YqvOJTMy2B#Lf#OmsR#dXm>;pLn zQ_ND?(rEV^E2CC7;xx;iMLsRe4!rZ8VwtGf*0q4$NU?a6p>v3<*59%jj!&MDKlQ*= z98Fb>VpA6PvXBNnVVk0ayaW0@)9w$&4 z3#~h;cn<8zMds|Xr9Jy5fEDYC7nFBKv6THn-$DWj1n|l0v>y6RG=tKP?T7WMfZ*X(u9TwvK>Q};%m>(=!$S%6Ph*iMmg5rz7-`9JKo@WsZP>;L1Gq@a8Ls~QX<}P*+3Kr> z!i1GO5Lml&8&{7kV_Yh?$fwfNrm*80Rf5&*xSzFCf>R`gm z^clEtZ>gaMLfA19 zq2 zz9b-+&>%wY1>ejaph;Y{KT*Rh}(aE+OzZlL16$)KZ zi`IvBH@?OM#d<4KeF9LTIS4{oyLQwlE3Ahr`*}jo7!)OwmT+&FX^jVRw1Y}y%h5OJ z*`mn&9RprQ=nAzZll_Fx_v z??0)5RDu{*EBhbE`52pFW3?UY8X^_X>G#MGzJ*~>l_ z3>qN4xR7gO%kaAr>f&jRC9>Md&;|Lv9r(nX8qbsS#?g2)wg+$ek^q<2>vowdg71I(0PWPKG0wb=L&k zm(>N@xuN*(7|#^fRa+LZvv4`+m z&08FPbNP9SZ&}t8{gB8>a7*1Y(YnPbgT>`A$<|Vqzu>v?^z>P;Lpd|xkN5!`*IWLMYh3JoP?q>r9k}hn;kji>ND=h(To~>-n!e=DaciJOm zsereXieZ98UCsRr%Lgs#onuVIU$B8AJ)@q<(3?;X?)|1(e^({~F<$K!?{elN$>hPU zB211j(a!RJ=LYFJ^E+bBmX&gukQoaZV0cVeHlxoBaqzh)g@=D66wZGZ^h{0hBkP-J zKy(E-VDF7iNn*V?;7+=E%@$|c@ueHKs@ynOR9^3{F*} zhy2E|YprM#9YmU7MY~H4P-tj|<0-TUAg9e5DyD=NL8L7iWzAlex5}&^rb!Fm9ivz- zY7qQaamcCm5o5VbEPh-Og|bIrPgW5Owq>d`g@O;12A~Q0^lgYEF7PrM9#bchJU-cy z6Kzz$2&NKaS(!A7W+p!<1+?5kge-NegV@E0>HqMBgD>l?cVU|HGNKHTm-m|APDpuS_Hc;bTRc)K7-sT& zz8F37I}on?YjO;?>8MLh1`5Bqvff!{AhgYAkTuhR;I-LvkvaaW#uX(p0r60>$c-9C zx-+=BL>%_&((<1y`0n2_64ub z-2=II6akNwMc}&IljZo|5FPC9Y5U0#KS z5xq(a{ZZWOQ69xIm1!KL(o^L6cGHJ5pFj=-yw=e@n~!;yF}CGnGiBzbJ&@=l{BXs1 z=nhRL%~<7l->n{u>^A9=6(0{93;pwTnKJ)xXP~?CIu6e~90{!_Y(?57p<)#MNtF;p zsRp;9h~LHTsa%vm)%rn>;kI!NuVBo!_L_gWEblWNm?(5MKp$B(W$n-yvuT?H(0H2o zk`NFe4`Smn1xxE-lCl+a>-d~3nkunG<+_*gI*4xX(u|ybyo;RSngonWt4#?GKyv#v zDFhFwf4kpvn?&}$Fr@8HLJkQ!jxXfO9^tSYAFzae)=P7_TX%GOaCyNaS%yg~mw=O)Gpf`=rERyBS3Rx)#pr_!ua`b_&~X z!5jC3`CS3?rj^h!EhtmAi%l39*z>+Ee0II&h@Ui-EMksM>c&x|yA`ytW;C@KnrjEj zZ7P-00iQ|LkZ4l63-o^Ovcg-o+gADH@2hpqT{WjigB}b-c}21o48T%j(Yq zdjRGW*@P4}AEfXEZ-YeQ_zEYs;w0Z1-uDKDwhE*iY!P(q@a;w zbn8~t=5oa>b-Bv9t@??)$KcQk87N z@_lZd{#+JXQ5XtJh^$$myeOUh#BFJfEMjFc|wDb)w}8{N_O1GA>VfP2(> zmgNdT?{)Ch{tnf9?pmwP0(WAIRe%_2^|fKR$;V8#YSLKBqH-vsF)J~D7X?EJ&`*Wq zq&}EH&82Q^*T`hK8b|$ofXn>m*^ypZ#x7g#7Q9EXsD5mM7jLW( zJXWCGhuQInF|b%YQRnI=K ze!foeRco(K4b$&Dm*|HX8+#J?&l`fhfVQI0Fbfa7z(SH(W{Kq6D=J9}H@VqYCbHLK z_#OVK>2fZE+KljRrO;$a!i>aQGCSvYOo2KMx-+8pJY;=0P6wB)Bk1)D2*mjUMR zFk&_G-z?3v{X@86R*OFn$iTJ6Y-Vgz{YdskCN-BPJACshk4Y2d>@3)=vY6*Yz?AT} z)GoehDWN+ZU5)U=4KH7Qbrb-hX7!q3I^^6E#7xx;s>a@}0JBZmM1~1aeZcLO^G9I5 z)~wUwXAF1zDBcg`@ULO}CyXU05MoAW0KK)WKCNobWj)~0R8=O^DZ-N8;ey^j{NjsOCjh0_iV~Ono(c@Gk~#vKky50KSWaV{|BW z4Z2s!j`t%6AjB&~IHykr_$gCDlfyN<$7F^ufq}@&g4(*SM7Ip=`k$Aed<2 ziYw>3&~5L09FFmiPKE;1lMMyF@+x;CHl23|(E(iqUBgRLJC1xwSehuC z(f~90>+aSXWZ$Zw&qfO&^O6=_NNNBq5X41Tr_j*AswTk0&eFa8z|#=!edH<^YIUoS z0}JCGI@rP^e!j*dg+8c^L86O65Bjg6{Jw4$=#w?V!HCWG#&uX-esE-yoBL)ffb_e_M%bm_o@^j{S7 zKGM%S^l)M5LYXneW&#|ZeS1qT1y?g$8^(oai$$q3yrDHl`)}{RXXnm z_^fAg)<`ok>@fMhqVL-o*x;eM`f#AdYiie{Cy z{OZck4;pjOe$vD)GUO3O99)DoL;Q5Q7MdhU*L09cw94D6HST}ABJm%volrAvW3>A#6F~6K6^|m`YJgL$#zDdzlWPgfjtH|~-ilWjitzL&GS1Aq<{x=!84z9sdJH46 zX(C+a_^JIa+Rj;!pwD>KcH)!K@j;K>Ub04J+{79&Dim0gfiuVAxxRe=H)S@p4RvG? zr+>qhE$db8L^PU>mB2L!*sa=_|BkUqlf{;xG-yDvUy72?*4F94&F< z!COTHfpWX|75kFAl>mTfiGyQ3f+82+7?45@g$)yN`VJ=DTW;^~g%r@y>;FDp-Qp(C z^2zO>U@FMaEzjhGl36aaq(L;zRfbnp-WJP|3cBfo=I}ebGFCRF!y_J&;m#CJKwJxI zS9gWH=R|&W0Mm+FPt|!ON!b!_WtuZ#60Gmg@2j!<3!`5$5q?y75w6|4me?wY$#>D9 zuJU`U<_eR3vlCjhi-R*u=n#QNT3INN4HWJZNQ2rC(uK(VxHjy*7hnyS!I6C&64_V1 z%hV#&lNIivt_VkeD+uqwHFHx2jyH19$ym=t>gyV-jqhUZC&W_0rQwItEHnY|bt&U! zl%n#4y8QT@%M2h$2mu0^3N%Y_gXGq_>0ux}60zf7FgsfU?Y(G&d$AQjVm5Z6FMa(U zV$!%tLWibwcAiH?ZsKklf{lcUNFn?f$`?bZeLt&JO9hoWp#3Re3e(B^C?zL#%8iYB zNSY+>aND0mM{mnQtHgAw<>3`HxC%t+kfoL~!y916*Bd*zHiQgYdN^|8`BhSVTl*>N zX7WS5Q{96ENvotO~NTdqLI8sKBEN&A4NVez0H#~Dnap}YKBLO5nIu*Zq| zH6~cx4AIPlT}dpx$w+cR*OI_QfFdFuDwj1j6Izql3&h>zcHr053@bbzzh=T3yD6ZR%E-6)!|+my554-OvnsuHmjx-J0$X)szQfRY6|1;M`K6( zGrC>vrU%^g=*guij_#H=Dq6%BF?*3Y5~)(ZyzLhH*)J7_bO| za2g0;H?j=QRT!eyOaBh!_V%)&@*m61GSDs+M7L((otc3Y&BFNP1lA9b-X!TB)1_WR zmHFgptu85{P!ng$Y*fJ6z#=UU@~B6=ukyR3h4D+64e?kY>@}c_z8};s~Oa z$-sNmVFoKnCRf|S5To6WW(sD~S~fPNMatv%lA3o4q*;FT8g#n16h$AB@8Z}^&K9AN z@55bxsZ^@ip&SgA42jub`n|ODic5};{OwzV&;UKEQl_3uNA+3Oa2 zL0~RESD#`)2+ATUiyE-7+)c;I7!*pYnaNkw?Gqes5zQh5&sMELCIv#s!YtrpKS4)e zNMakRw?}z~ldN0Z-U0+cbe@Ar^>DdJe9!rzQ30ebkZ4(woZ@5LHJxa(+lkfFnHKy` z9Ri$7Bcg?rC(?X1Sa0L;rBRTAD^xmc%W^Lk308FaN7^@zH2W9hC2B5oqJG#|Ms*oF z(uh{_zTUD$5~#00mIH=J9^|K8T+m5`ki^EJ^5XuR@%Nr7;12gmrcxk9@5&4d<=~x^ zc@dS#+k#YwwGhEv(n5S%5~G(1n5cY!bCE!XqrN38i?v0HHmmZ}r!=to@I~tMv@{JJzWm!0@4T-6f*anR-IPrcBlu>*MU4q1%WAe?$WyBW=ajLyNodjF5buG9wg|2T$FSX4H@$W${j-t@Wa{MPN8vn^rSY{ zsf-RwT_ZN0kf?6~arn_^Wo3Ybs&EhnwBCy_y$9~A0LAvBM^Uw3lmQYTa_q8YsKSBZ z!D=Ra?L(FPwFO*170nREe2QA#xi=Z=wDPtCz*e8F?y%NtFcUBX3Uy_ScAApzxf4jc zc1DtO_+7oAS&$5Aq#>Nl>)7hCQX;J2Er|l)lx`ImvmNP^HE?(XSmnkGfKY#UvbC4c z;8p#D5Sw9_bRE~$ftd4WB!tWqEv?&MGP*)_)h0YUy%l=2aG~xpCl_dwY!;zjF#JmOo?1K{Sg? z&F{`nluJsU9m#)9g!+RDG29g(v#k1bu!{^6KO{ph33i+vRA9sY9hynf^BV_UAr2}a zQ3Q>A?l}(F?*Uhjb`oKaZUZO{Zx%nVC8UB=1W8l|#D|x_Gc{oUy;7>Kg~eflkJv_r z42@AS|B{$bCDE(AJ%hIxgy%{CYCAt<>yRQbfVZ>3sHmm9~>QJ>0c95ayuZJ zXG{v*di(9;DmyXTj9Xd`83GH!LX!4(^3^>jq7#`gL`jbUaeaLiwig#h)eRnLcenDp zAH@bOil-y|16W=O{X4P8{U9YLs3$|N?tu(B^}Z*^%`d~wR^i&TNFlJ<1wa#Mywsxx zs>1X%DQdsBz*xP;R=62R3b)Ph@9dX67DWt7j1>%;vrL)CregQMooI%dtlT6qpGTxw zZ3Jh)xj`Dda;$4qXIirp?((l)+n($|kU}yU5c4F_^@E9pyAoiMR_tFrnz0`g5Dl^g z6(EIqU1qM6XQfO6{}4LMrMgwnK|t61I+ug#Pk>v(0-^yZ6SCa&ercV?xm%tE>+=Dg z73fps>tXiZj#Wwsc3L6JJuO;zo+s!no5PNyirmAO#lD46fN-nK!}`qei#)EyTk9`k zvrfsItj#_~4eYWs4~AFH(vcM~H>jm6w{1`|*qJ8n@Tor>S_e<`X%M_gw?x^$I`1wW(| z{3Sv(;@@*0>DxdR_1f7E(k93i;`&UFf5~KSZg(+{>pa$B?{BRCwr3dl!5Mh*VP{&? zN0d1EZLuv6xHuI&jv_|l@hgiiVrEu2Aq;!#sztmI1B5rkhaU1el#>(o3Oeed8D~@} zf|L>1GhvZP6Xz<1IyhNV2Bgvg@}H=HXhnY5ux3IM<)4$~mNs+@DJx;}to-IghrMz% zRk?JK$BFafp$9-#9rjSgIZP+Ts4}EfP#xXxbuqvCBN+LjDQ!P!nvyB4ovY&fTcDk} zBnvkL*mMcJsAw`2ylplpIYXL=oY2kkfHJxnEG0X^Y@2%jI%JEYx(@@fj_aebvD~fw zo69{X;5`bguuJ*vYekNbZ+D87E{M zJNcyMO9HIyOH#x&7oBrgZ(%_PgqKgsti6h}ymtyyR0AS-P}@jcTKqD)&kii0;6o=J zVmSE&Vntva=`|5XMUd@EI&j{aDlXc`K(_0{3tkiLpJP>$5=I9UTJ-W}H>+t=*6Y66 z<&zYwHFwSlCr*hnX%$S(8mmvNBA{R{!z*3}=Hq2MzuLf6Pd zmAvi^A`V$50_e`oR9C8>5{>uxci6@!15*zD$5(QZA9Y@K)KmMfK;(=)Zztd9H`YKx zi!L!90_OYi%K zq`{a9jT&U8S(|s+9$CA!ak6H5z(YV21J@;@u^$lj((eMV>OX>0rNJ2{6&Qp{g=6eS zZ)F7k9dku)7uK3i-<=L}+=80XM%2lcEa-WC?l9eFqI-5BWeb=?s^pcmkS$}&=0XTu zW7tFAWPCPdo?c_!x09UfqV*o?B=G`N2KYRPihXkwcoVhZ)!7LkWwvF!;j>-5hnWC; zS=nw5BjW5p$)eQ{b>hKg>5|KMhh*rNZSH>(&(1-bFg*#ghYV-My(RQ^zYDbiIUVh~ zvtWWjq-9{D&9PmH?8hjU*$*_Zc#r}P6zH);YMZuy36F}M2RUS?<92Qv+wlxTN*_{G%p5tbqCWLZfZE#r$4-l(_qmh&5{(KKL$T@RFY zSL*=-#V6PDOrm-_yrK{D*QAKo#h21yfTgD3aT#6IVY;o&7T`yg)%NtEOO-dJ#+v)I ztz{1hXA-apU;bNp-)_vPz_^J&H2c0e+)}PeonXQ`nVPhPOoB8eT|psNOp?zt=fX5N zNlvg|?Lz;8u&l->?bT)+==0x~)-cRMSH{o_EElW&$WX>LzgiN(b8nAk)T8>tWQ~7& zdrfhX{z;oQ#UrMY!D@-FrDPuI0_(@saCf1{Q_?xz*=!D5P+1$S+hSM}>TNvHu!r~z z&5)vNy)fo5K(fGI_X5LfMnF4Olqhq^&Z1DUu25qaV8;0jg3k+&W>4~?=Lik(fG(tg z(TqmaQV=}`II(RoSBt|dBl=7qHG_8G@3Z`BkpqSG`qLsz192&6w2a4TG5~Ok-fbaY zZ=+OmZ1mbUkyh4g{P;B6WrYRUb1<~udrcuK`XysFJSc`8eK*9Inob!i9|z@t;J;^| zEKy${IHBe>H7tVN$g6>ulyq5`Fi=mw?nM4_88Fpx0XdYS6d>cI|YI~H6QiqPP*;%e`?KIBBvty+> zAxZJi+Q}_ty|)tuOBp4UYE<5u*7<4PMJ#G6JQrWw|i9p>_&DCsAhrHp)%;?9|9%B z%fmahUI9H+vhF-}0nofNIYvU!G7pChMwPYqg>0@*03h%qL0kJ3`m`nw2Zr&O*BU8= z7>>(?-V@;wOsFJw`t*40b)U^jy&R-*fS7lzEMT}4 z?gXviu>e91KLXKG`EiY%dq}9A86Zm;w}%iq-!e*QP>jUy3n%d9Ck?8sxE=eg^j1=g z$<)mVy-0-JG4P`C#u5NvP(XRFzAOH&s`{wQsg!xna(*1zUI`T}JuTw#1YJTHbug*# zWCN%uqVWi({wSyBm<;qg3n8w|(`O>mH?V-ramr11X&)$IetnX4TKs1aDD2V)O%Eaw z_-J_9r>jb$2H6TaJ9eCwqP#``?3x(qg-HZlMdrU*rz_C7nztWLOJTn?0t#5H|BGF& zL=EGO&{%{ccz{>4#xT)WLJI}Yq(qWECrCbd4wfE?wK;I-KpSPC3VHEeB(}I{kyx)$ z>3oKyL=@iSnrDrF5D9lFJ;$7?+WfMOoJhAR^|$x7`5ARz$8{$XBy}Ef*o0zV zqXbLQx04ei@3g3L&%!?QBeDC4F0rl~L*r*li4e})_n4*wn*b-8Dw6^ACy@>V&HVs= zJq^mB)WL3X7dG(+e8S1Fs3#NY)7mv-;>S`V46N7m)tqR*T5LkX*u>dt7kA?6!nGNhoXrkUe?Bcm`Z9ozEGj4x>m{Y6eAL*T)SU&t^%^)94qgL} zkQWz!?E`P>AMIll^gM_R_)YIlOnm<1yVaRTqVj=8N#ZgX3s>Fd4VRLv844y!N<3x9 z3u{K2#v-xSJEI1a1>5Qp=?I9vv^>?R8JmEJjsTqO%G=;;`eB_*#F1F&_@J=+;2R2f zpPwb$b`6{`JczWj@=3b%#CDV70Ahk|@kOz-PD>-gzduS?fk4_q|L?~O8eDa&b=3|y z^yA+Q@XP!yi?(jc;BH)$mBGu}p1VD8;m!;mi**ZT4gP2Y!EV7IN3bOX|KPWf5DfhP z;|KZw+ZO$A+l+)D@&C35!FJ)TY5#k?B0}>2+t&Z@F;eh4jsM%emka;D*Y#<7x*fs( zZ^fmeu$_5_+U?fFB{1Vx#zRhb^nBz1(hSj&j{p1NLAMdEWP}_3S0f#A7S5b zuDCVSy!QJ)Zy#=ZHuZgEGWB-j1gwf9+Ox*|jaM&aWh*u!kzyGoCRSJSP4TO1wANz}$AS@XLAsqW- zf5lM{;_x7>6#v-YFbu-Ra1b*4zeC6f(f=JbSQR}{Rg6pWu)Rt{f4_Jo+@&*SO^x?i zr{7afv`!s4{m%1&-v(^4>5P>u>u12_w7Etl`tVNtu3LZV>YWU$Diq-yd2!4vhoPeH z<(L;Xvo8HK3p#M#A>w=MAGUG6cdk%o--cpxo2yqx=S?;Z2JD;KS+P#G{(xhj->2QS zD@R#Bo%LUJzT~mv#o4!)9c9knzvX#B7V7Gw&z%{pujxM%-OuKp{>f^tRU{(zmm2Ne zfQ~eHvYj&4*{${5gyPGI zY#PxR#q+-Y6->+*U3yu;-f+WQ{AVn@^x!WQYhKb0j?}O7Dw5_tVfoq|c*nS5w}WlF zY11YzQ+~q{gY?j&TtEvWB%a*i%qz5baC{R;Hfp|X7We?gwT!(&BTdU(ICT7|t`^vf^O z{23JIP1l!K-(55(j9%-|=Wy?d9Ti;oa9gNkxiyK2z}fxZT?9d?|L=CPW}oq8Fd;jq zLI?+>&F&CU5DJ-ig0=7lq`TomSqVXy=@5i^vn=m~&?|G}?0mo+M4Z3%OWd55F5e7q z|61|>%%M}de~##XZW4b<{JHpQQozvS`X%{K-Y{!)J}a$iSI1qPIXo|1miIc%X1dQ7 z1@m;(Dt*D6XvQbM?Bj|&vLsO*_19_V)SuGIF8XPXmNXz6y|MXl{8*))+Gw}HveKdT&m~IpM&gMbUNbJ`u)n%U7OO)>D`;$zR@s`%2xiiT7Vj zk?(e@?yZY-Uf%x8g3>kzj(zj&KYpJ4W%a>N#y@v|#1rGX87Cgi1HAfeGtJg1Lo;uz znI@z~qSU1Gcqs>RsYKtJ${h6t?|ywAgiJ|2XAJ#^@V+UiXJ1D+8Q^l@jRS&y8-ss z)Wa42_Dg(!x;&xVKOf8Dv}n67PtEzz*s4m|%YP+ZAR*4(whb3Lk8|$9^svy}_)8x9 zPX7I{-Z$;HaksktkLRD36`gtFY=Qr__{9{d`uWy(xyqYxnCqO7`zr>oG#FOKuN`Zh zzwM7{7yK*>ODrjk0}BwziGz#P7r(8zbK~Opo$h0-7!E1E%?-r;FX)8jAkWmOXwH66P8_nCS6fXragKYbzezOj>@V z)3Jo13P!ySu6HaX6zS7#=!MQ(=Jp5r>=(yPBh(bm3~rA3tH(GSv8?yEUlYF#5v|ds zojvFSeY5nUncx1bCWfyG+NuhTJLtA)0Y1vV-lm`}$@tTTxdREQrp6B?b^Mn0jL{9+ zokeR_;4e-4vv(*tqnZxw7yk$enZ5p2rH#huM! z-i`FlN_PzmKJa^_Vdoph0k31d02VHN4!if8s#YOoEda{#mJb8uL`bzzGbe#r{J{|cg%ka9<<6M5=;v@>Y=hg)^YtY2=?_u!GVe0bec+}y zc$wEb@qRBr`Aco7EtE7K6~W*BY;8?sggW+TT@(i#p>r!fv)4$*dHtbS@Npv1 z$0#5zA_SB7 zlwY_~Ky9Pw=?^>xbjv?C!NYXhnvMK!nC+3qJl7pXB@s~&-9M;B zd`Ys8g8e*D4qh;qKynQQ^C0C3$sMhyzI>z>BDsz(2}N5Dye})4--cM8SXq4!Q8l?+ z|7HT7LS8Q2yB;Imk*1JXnT~DO9OmaBr`h$#jz?tegTYQFXI4d{ZUZf~t$g&-h_mN4 zX$}~G1d(9{6Va8e426XTHnZG&M~1ow%Sa0=f@?!R)LCWa%{qEnc}0`1rEehoADM*H zSfydU$R@)5?SsoJUfPUAp@eQCoxRV~y8^2pfK@1P`1YcR4tuUd_?O#z00xiqnobthPW94ST59zP*0l9WaJsP_?Q zVbTp(@91?_u?YYz9n;U~D<~m!@?Js!DP3OO64XkIwL~ZpVD5)rtzSdNdO(Cyu`-r2 z=n`N0MdC?mCv*N(rC^d+C8k0NMG^S(cir(UFeoga`SBUMWds7sL_}Lis2we~BGWj7 zIC<}Zodp~JP2Jr6oWQ39{F_Y)=tU!K)}-58sgz+--(Z6kj~=fb9=?&yngv1jJM=C3 zWbuU}{HU)_QZgb~=|=tiESgJreSBehSv?{P2aRH%G)QCqiGDI1U4vmpF6t z)+kQ((n7ts1|6J$-@IgP>3)Tevv|81Yu?`6`KGyQlwx|fB*Vm5@sr9%>F=2*w%)l! zNpCYRGAcjE<4fvzQi-Q2{M6%&zdOp0Ka%ynuS2o;1R$7#Vm85aGK$;d`G=TI7t-e7y{q04y|l1KDw5U$C-#09cQaJ`i5%uCgD{UeMqrRn{2 z+OjN%`bp^|Xsmlh&zdvil$vGI#fXk})&JTA5KQ+wi2RZvN-I#xLn5pZqy@?<#1EPg zM@0pVbdujx8p2%z#z`yMmoHz~vQG)WIJ!PXE0O9VQe}*Y!^xVT{ILbdt^F2Nf(sN=%Cu@=W#4scuL4L;8~)9_n4q`h02g z);auMWJSv-2zpve8g%+WGG>7?qVHuuA*bgKtG}Wc)HUGX0|_@C;CBr z`Akp0z7|KZE94isN>`qt!r^THKs>AEyoy58reta9ce|fUcvaaTvtPxD>qP4YMLau! z_QG4isqU<>6^yY<5QTx>@uGG)jXMwt*R+ZYu9+5=)qPXRR+f-h$cUWD1~?}P|B)6g zZqg*_c06!M^QspG|2aSZG>su-FZsXA$v1%-;`Cl`AIty0>EHbFS?<#Zs(zBqVwO6_ zoPKg-ZJIWLa88>NX%(D=ohWbyv&9wnr;E@UZ z9i*^%4=yE7>r1w)S4-@nT>T;lg!JCQJ=ta5CF);;7Pev)+H)lp;4004q|iFr>;;aA zt^cQ`sdk-6wEz5kt7ogEWo(+fMjl;_4}~m7*4Xuk<27rH3O4?)tx7>O1n zWOL?fxn0r@P*cc_A2bLE{Imj727NCom5HCC*1nNeE?Tjw?5Z!2d)7)Pgi8+dyK3}D z2So=(=6ryl7_EI|ENM3j=zBW9(ohDEq-2fcWMl!H`l5}PswB^AOuY*hh11p#LUQUv zN3q767l}=6T%X%NAUPdrfhNgmmspAdfk=?FmJEgKA~`cSoU(h1`6q9P`WN4)Ee~54 zRxLmMGAqoKINLv*M^3*kNl6@dem_6mQJzbl?n`L9YHdo4axL@4ihFT&<3KpN+%2Sz zUjLl4I_nTk$S#&Cu_rv@*ULhjQ!emFPk})8^VH^!oh>gaD;c;dw{IkSzkxYTTcdGj z$G}jyd(WU67mvVwQn74hQDAe%7jXK$;p~sYs-bI^~QBouR z&8e^&uKHSQf3=8vLod>w=hh`pw#Z!9u1Z|SWRZuw$oF)Xv~7Pt^Zg|UK$2bam%Ebk zCb0!kAMJBO&@7WBatS!8u{b&vpYH!d-0J<8_RcM2mNhv6mzON#a9FH>_sJqH|5Es6 zHM3oM{SQJ{%i?)fB*q`gN2PlZFN&;d;_*Ddh;qQ>%s^Evhh`I7sS_!PQi_Vk#xo)` z0v7sx)%~P$8+9|^0s4x2SR*L0ZdX077R#LjV$>)+x2gS`QFyTwL|!hPZ1g>-M+fs9 zrx-DJbg^=&Q_4{(BQJmNlyFRGV#Pei^itne+JNONctR;)iFCDMDSk-O>8T0Fx@Ru_ zrh^oZA5$fWuLZB1A*LVDZhjzbmhNjQ^Zbku5zRmr1_ER zWNDwVj9+*zo^#Lrj)VLBvz;Z_=|ugTZhDmprI#YvcIhDmea!uJ<;K*wj$6x5er}*# z8E9Msi({gu`enYYoa>=%LEgpXjEId3dUiv}5e6RIYmk2+8vmZG4V;&88ZG~w{A*VI zDRx~Ksa&$Ld4W~16v-k1M<5E8fj($iEDOeVbWvhR1D^rO1$y~L>M%&ZC4y8B5fV}~ zv#E^9WQ%{=jRlkQ59^UCpE$~*qUkSPt8Tw-rdd(j$>q)#JtF!4ELV%Fs~mv4{YZ~f z;c0q69KJ4Iu_2M9Wo3|MHE`tkeT$4zTXI~2;p^zh;GLf`HT5J@yUWr?jbzC8-1>#j zJ+0=Fyrq?;1+MbPknk~)MZ%mOOHddO9j9m$iRgK5`5G(@>S0z`Pi)K`>nBB#5fdcJ ziKwKmRU)`haFyGxsxTq$k=Lz7*=%$mZ!IKz+J^uAK+#04?Yt~O_m*oiENhw}axzGa z%aTT+0i~tWYr)Fe;moSxORSS#4|?UgOZg+2wuhGA-149NqxFZet;rsOz#h|w@nZHc z;$u5UtPxgyc{q64bfat@|$X~;2lzL$lj(sbd!5L?Oh2H%| zknY^SVhB*Dv!BJJ)y|O;_=4bHE&o`90*&jSt`)RP=co^%ZlZ1GTl;vFAxmw+`IR8%VT6BjuLQ^(PC`H zx=vb7lbHs8{Zj9hJTLBKi)ngtmOt&;Fy8dAT>(vB`Dz8fZpK-ZB#uOhGmQIToq}b> z6G7Jd2CCr37{LVcvz_Od_E12=)@xWcuBs&I$HIRIJwB|q%#9FXr$mTJ*=HdI8JReO z$VyVLie(GJsUNvbDHJMVHPH@ck}rl9v1t)rDM^i-@SePyCcnq^jLOlVCIUo(n6{$H zN>b8=#S2mtG(;{dNdjbZlx9ULC~q!C1LlSl46#v?M0$h}$Yw9FLQa~bgvM6a0ivU{ zAUiG~ha}k;tS}sreWeTmCiqTrthFDJ{ zsM4LR^fWzi$420G!Y_eHn%-+lF}V6cF&A<5DeBt_QZav+_oUw1m-dJdr`}xBgM3R{qW?;8`1?n|fST-Udh z@sa%=_E6e?E13sE!s3Hy+4vzn2HPn>P)m??(ZWQL<${hT(1ndf#M>rF6%Qfyuoy)z zfuzA{u@Nk>3VYV24uws@4h>hL&WbjPoUwtJrF3jbsV1(Df@P^opT@%+xycQ}>9J>c z+sipYAzmo@u~sbJ38JNgM$nN+24Z6%rFI8XO3~Dq2t+fg?ZqY4nO?ro_y4fM6bRPP zrThTLF-FUmnv+aHIU~jICBMmZ^)$iyh?V!IXJo4931`WQ5rbQac0E)T^ z#(p_sX;g_j#egvK)k^vwJ{@oHKxsx+`@L0lon0cDR@@tJJgyd+A-O0?t)h?GAdSKL zmKnY}9CSVopYIc_8*>wgJP!57nnbQ!wB4qGZi|xL61V;KGQTaKejRX#=>8Y|cl{G@ z5!9qOKF8To+!VqmQHmi_ev5fvc94WPws*78qymSPE{bc!7nXwJ+PW>LTP!vvx*}#S z>Z90>oUBB5$`g;cGOetoM>Wo5S&?!gIJS!<-JHCYX_WnD>o+kLt-<%-iu_h3rjt_pl9gPz5zIA`N6RRp zo?Ca>xT0(+h_mIDDvOQ|w%4|{Bvf(E6E`KKvZ=Ru5ff4fT+1i@{N;}?&io`i^Uq}y zqulVUEm&A$zn-!aIH8ho6f*8+BN2dTH3ys!guv=mNp22rHHVq$A}!Q}2wwEwG`lgB zBOWD_}Y1)kvkZVP6(Z0$9?<9gVX#>Z(OuBHw=mLus)`7KY5A`OyzoSOAK=w?!J_ znTbkUqV|`r?#hSq%|bkCH_z-i35Kj9QbHR+KP=Z2_3B}(+dyr2JK zvppe^&UTA`#PCNgF0~VE#|OGCW>c29gK-!5qjq5M)}O!QvAWZ7BI22zqKh>KF!nKI z03Q(8=r5cfJ z;<`M@H)9t*eH?gXy#~a?z|?BmFP7jf4X@)eYq1avj%Cv=1nO6yeq~I<&=@?%7AiD< zq(C3{D00LxLMkCtIAs|R-31mHDJgurvw6AgHSaQlg)NF4DN0gIErI=!8efuvD*yv> zTX6u=GYLAgSM)4PU|lO2hALaQmcWr2d9oGp~|9jYuEZKP*gb)cd=HlgF zBM{r7iK0gt3SCwXmt!SjZuKAVFn98@TFNCcV6~b@vjSZ@r6+-zjy?Kk377^3hcR&8 zPf$2jPV;BD^gKI6e#6>j@Kp?wB_6j41JMsMmj&ip+j>N~6>C7MK~NbYkVl-Rox~4H zBDY|JnQ^W}#gTe9G^U%ai35TV`y`2NZ(1ypA7a0z)bQ8F39=@DptDQLPmttpQqkzj zRzWGzuoU;^T=x7=V7_D6j$SP3jn}D=@~~RBxWicdBATJCVIjH zGCF7rm)mP&pDe;^DH#Gb9a%nPkt;@-VbE34ASgmL9&{?w57dt$u@DYIud2Jc*{DDOI2s-ETG1oj z5Ca4#qeNgymZF`C!W0kZdKD4!O+uugGA&2T)fR_JZYugINittsqDgFM`ETeGbSes< z3zYA}*n_;});MfbS{LP1Xv0-kdsU>YRDl49j_bV1r38fUBP|O>^cBi)9(f=`GfO|G zIn(@?_w@F`@{i?+n8V@hrM$3OSzy@L&r(ram*t>Rx@dCR7gNcu@eb#OSd8&3S*^Jh zHY@$71G6M%Nf6WhE1kysP|KPZr&Zarj63Hqc_f|ie5!8`eb?){ zPE%pub}W`XNIYFfK`;^Ne;Jv>lB8CLK&&?%@k#LS8xHo>ztz0d9DKdhWO#iFy zLae^`@$B1tnORF#GV)mcTN4Cq0Yc~fFXVa8M0pc#O85C`u?Sh8Jl{68h`jPHkXmiw zc*;tK5WMZkj|X^CCc$vNcW1*WkHgcwlmo;vJbFPRdK+~!!~H-kLt09wWlQCu9hQzOEshM`3*StSl098Z3Dq>kiEL_R&z9zY%Mfb8Ig3RfGL}QP z!sqyqu=MW$WuHL1$uPH5GyC1{Ra7uvLaqJ{$1CUCN@Se4_} zfq40q@8VO)x7-nE$bYc-?O~)GTf19vl{tg@xj*SH7Q|e!M|xX` z15ko(o<99Ov21=LRnJEW`z|CRmE+pPYIz|^6p&z9?K0Bv`9;-j#8%o7TE)gO_sgba zjJSCDV<_++vRM&-&^URC#~(uF-AQgojNv-z64(Deg%zLYjnrtF?X@rm=mjvVI-T!R zZ&C2ImSp)2f-Zk2PD*htOvXXzmuGn%{J6EQD-ztxn&2F9ZlCVSZ`8{F@{j*nd}AQ7 znQo)?P7{yRo=V$NKO^*#`zZo#_W!uc8v9OQbeP+6r`@vB%Kc!-tl}=NvGXmbKa6|n zVlpI6liY8Nuu}6R(Y}}RI1BewUChp&MY{#5%WS2L4nnxKp7l>NPm+e-SM`EJtH0&5 z#DRF`Sw2M6HPy({Pae~jFV;1K0q4kzeI+bKZY|}g5N=rKjP!{li6fLZOHWepc^k*SUaO8VNVJF z)=L(&%$n1cZ{;`l#~fg-!=~Ovix={LB)L;!TkZTkF6S9x1uvq4`mwSME`WTIl%TPL z>SDq=N(Z=h9iBG;nxeV)=u5sT8V+;@+K zO_UyEm#0^X@+Mys1-x=H-4A?mYJj!tKMk=K>x3uMk5<7<>L~&1A+c$0>R)B7h-oX( z@VOyd`ovKgA4^F2&yzHgliXN>#o<|b3#L)|Pu90f|9NRwY0zWmwO*Mfu?F6y*K9<7 zOckL7Q+{}g(y;+ps7U&Vw3019i@AnCd-Y#%_?B9?(Em|3J@ZS{FsPoyu?LlKo`YC? zmb0p!Sh{7MH`CCWg^SR=3pt9N6np4)q=Zmg|4_VIZ?9j_Dz`^37b^OcT3n7TxjHKP zN+9_GY^WxK=1o|450aGPkYRl0ELSa(;;gbG)NhZ4O|V@Ym5BL)PkCi1=p~6G-_jyt z6#bi_E*|UpD4rcqE{9LXs57Zc^P&rUI*?bE|VHN$SHAc4|;cr>^fm?;#5&$ z(D5&EKlIFte5N^{pJ|IordK5xxVLqZ)Udrt;P70PU_S0}8DSMJG?LmXnRH}#HP^pI zS5b05lW7F0fM|E}R{!fV6m-{gXP5dO?ki+3shZAg_H7oy!6J*97B&yE%PQrQ#8{frh!)xJ)Wd9BixBb! zH0sWW!^=8atmRF+i{IlUa@H%s^wBh5arNk-G_1I^+VX$ti&^J?!zi)-BzQa>w0PUo zQouUf<_FSf6f6$O8RE0AnM?wPSj!%>kGxaQHgieKHJZs|>ZS_ZTP~xOK$t>Bv@9jq zrXdufrMpPA6ChKVkxYv{gbL0PNH3NmQ{udw6B{@OtSS;yJt_kopMKz&1oA7$y{> zGd%|{4`^g~cF(36NIe%Eq&P2&N;OZz zV&`?r-k%?=jAGP}JM_W$x7Iz28h=&t-0y_jtKw@FbNwW@obfDZTR@T^d2B|WB|LzX z)5^(kv@k;77FLBR2zFu;pV3l;P^B^w@Dp5C71L--bqnADAlo(TPPJtNwI#sZBb34g z4>Vit3Pmy$DJ(3C#-w^wSE#LcDL0~C?TrQqw$W;BmlCd)AjzCa7bK*&2BO}Um_H~R zt}YzNyO9)_q`ea2!@&8>qPaaZ%DbL?i0&YXBbt-wyrB_U#)ZVRFZuHn8ia-G@)V?% zmbLHmaYl_YCf(j#`K3_-e3k%hO5H>B*n(e=7LgxU_H_0ZnCPJhLYMzJiynn5t{8A zf{_7YG7h~vMZUrXCD=j>?GoWdIwhjLp(<1tGdZ&|1pu)H3nxh|q^m|-Sx{LOI8t)> z1E$Ai8wdOvbueu{`q`x^l#)J3Q>UT*w3emfHL?StYZRrI&VkBY+A_H#)=?cLMdLl5 z7IRDrkK)PuQE*!t65$g=PmH@un$)4>Jh8=RSp_C8hhwsgG@{v5;7cqtQQBEdD*l zhab=9BB-MRn_^3q7KT@((4=!r$rRB;4+ArrB41<+Q-d^!3nEWK3k7|aSpyvOQuHUX zswI-%ypvP3G757{jshVQjv_A3vRYD-#b1D@E*2xc70;<6@F_Ctcm#v3XJd|?vYB|m zJVTtheA*|i>z6RNX5wJjvpFs$C2GA^lKo&xW zni3SIgq1Hndg`(TB4sgZ75lY<*D^N2;bp&OR$@CDP{ z`Y0(D9v}9Sz-TL-5z3k2OyaWn!v{d{a8?ic7iFXt2Hu`NaB-X@jtN?|N}0%;Ji0;I zOCFP2X41|FnzHe&a*C z009w~;;38(6dMBw9tZ%0byqRGBL`n{^JN}dIHJIBlr_Wx_2Zia=17&8jjN3s%nG=A z@KaXTSxv^Ki|KQbRnTgU-DYm5XiC*3)E>|(VRdfx0%P>OB@)_Ay;9+XRXiDU77rWL zUK+_urj=AXBi`E)B`gE&$To-n*j@qfl-urSk`1o4Rd++hTk=%V6d;zA(0#$b8zfSX z?>D+|6NO$_c|yG%wlDuY5p}u^+Is=EM3kcKj;`GSoGuZ{xBbu_(n`S`>T3gG-1Yl? zvfpZqQOpqQ9Dtm09uSr1hR`KKT(E5NMMuA&)rb-mb!dgM%&f2hA6N|NM8q7-74WJA z2!Jz6i9<^fPVo!$Nb;jK1`vay#b{}%+fo^rQiQI8DdBb48RBE6>|D8mJTgoW>>(Q@ z5!-UesES7$7^&S(3Z|^IrW8!MQ^8FnrE=J`IFc{vw7$btCBQonn8YvT3(CS8Owo6pH<-R@r$us&hcJQ%xlV z%d(|j=Q(IP9TgSMn478t4j5BH(=Y`Cmu)Au{=|}b{k#iAu+0wwHZUPcDaoX~WNS4>ymX0^_M@nzQLGC6#b1&&b5Qhrf?Gyp%J>5F<=>8v* zyFvFQvFDU{c7lb?@6Mq}o5&Y;5GTC#fi21;6*SR=mEC|a3>AhC_@zgd?J}18B|J@| zW&LsD;Pl}66uF&xnzzq~#LRL?cSM<#f<{8)(bknWzM!uQdMVSipOoo?Sh)OeX$fv< zzXs^yW)~@Pkc;sbyrb&>MauzY6mKhEpnen%hZ`>a%w&n0B|Lo zFjQ@Y)}FZTAwDV$dmyt<8#;w$hea5;+nv01Mb#E@7cS`5wQEXkH~)HcKUCr3$@zbm z$C7Q?T6>=5a9}t(N^*F?))3x^c1au7q<(Xw$f7~VESfY?Xz;ia=qm<-z(_eW34w6! z&I)CfKqf%N>&F@>a194?{Tx}8F2B?>2lyys+}cee=jhpiP|WbmJ>QhErH+l^ z=mO0QIsBM`@1EbsQf#@bhnd{(mg`b)5I`#3{PW}iU3dpQ(EU|zz!(eWBf@Q%8<0ra zCsB4zxEA~O)IkZ*|1cZ?7DT%ozmQW<1;E@3Iei8md|bPi!AW?7E*b=A!ZpdFf=0g< zBsePFrLA12974<8Pu~(V@7Hzgx1`eDEs-EEXpSAzXk-G_$g+8+vqQBs722= zOM<~t!BOIniVQqnJYUdT3ZXx3oZL1`(#0BskU+m^vX5YjTG`Zk3lnfBFg0L${T<@2 zZ3gHT$;TtaNiDzPU+2rSh!G2XP5sh@z|(#=GlZx;N8>&ZK_a65bdXnoFdGx30rPp@ zxOo~RE2Jy(AAxo$ad4?FO3fLW(spHAyW0++P&9rAI5gsbY&Jx}am4yS)WeAXR8`7R z$)3GIke7-c(rC$Av)dxgnQ=11ruf$?9%FyoqMke}E&RZ|VR*o#dtIb#F>y&DI9>5P zy99D!k|By7XP5=4@a{b&Nh;-v#!qmpT1qbK=<@>K6DZ=2Ud}ui%LxLlR~|lE3OxBx zC>aK0o+jgXEI7GtL9%5OXq=wv3vd@#%@j^b#lx9_!Up7*5AAjSd9Q56q?49w@#v*B zUqNyxR)^uZ!U|Ztaym}IML&irM6_)ey3~($*w_%d8Uh7FCsIB`sZJ=P;@FcZeIG;y zO0xp!(~vh^wenrhb*X0{Q0RcDd6EqRvXCw)5W)jV@GBj~!KMzw-(*OHzcE1YR$|6m z3D1$f__7bV48|-3I~mO+4#m}pT0o^J;8w>iuvTaU2)h`FMnBGF>*9lmRxkzzEI{Q# zVMYKhxHm-I2E)^W(}cSiO{wD$0Nhw+=P1I!*LflG;}+jyE3(-a6hG#9RSk_t7Kg|d z&d$?$Y=|sjs51dVg+2RypT}&gk4J1#jAsIHjomzswIk`~%;H9{LU-0}#?O5>_j0I??5bF0dr)f1&75Ny1my6PHH!$m8Qla|G3 zCnJ}S&^@JHLCh{+wh-1sol#aTco}j~tUqsk<^AxAs&S|M2lkT82OTp=Y1eSIE&gJ0n$8Wb8#Q3^~$tVIg)NODmzISRp17 zD4!BikY)cr{OZKRuzuH}PbxGCU_9L#B^yTT`e_HXAj(A65kLqTb4B#=Mu`X#bP#FD zDl%9o@oWK7(A$CzrpPTFulX~T;IPs*D!f>-<(V2t&kq#)+~;Sco&y5RMC+TYSk`}Q z9Q@Jfy2)TB@%PHl#cf7~#+L{3qm)@0=Nv(ILsAZ`W%L##pNZ;g#dZWD3j!v=1KeA% zzw?U{#K4G5k+*3&!&1HNVidvRfF=zhiS7G~{h6I*GsS?D1Hq1KsQ$TIO^$)v!fD^; zfnU;iR`1vMYL0ZFR@6cQ`C|rwf9ZIXr{1O4wt!Rmnm#<1d}WhgMdRJ zkcCdNL?H+nYg3Uq3Lt?50Fgo{p@#@b1S^%00wN+*h^1gG1*kGJ*&rB_vLKbJNs%fb z1PqeNEVkl`J+{hXSW?7EjW)|ED_A=?KG{r@*p?4?U!zMhn<8SlXyixQ-hUQdGq@v?X0_|!9;Qdh zFL5hc7m612g35dQWI1l~jz#G0E=XDzirYb5`b(I9ZTT_uQ54D}-^v8=h|iE*JdtMF zm{-V;dPcl)mCgw`M=Qrs!D7T=e4TWXGx+=+#T;0th&{`^l*(g4mu2uNDU<@8Dfm&hUG_4z*okx?Vba(F~4)a)|Aot9?%z&3fKhAEaX1OQ&OCe4z;l0Hpt7(c!t{x4q zIi$PXv#CjCht%Et#naa*eu}=Rzb?aG!S^BdDn?PkY};TW>T~H78a%YgOY;u9SfAu4 z<+^g3vy_>8bscsGq1Da*&X|2?p=S9>GYSdOd zSq^&DKkTdOTFU@ZgVofC?m780)sOuY>nY`=jt@k$E23drB=J*;}V~bQ5GSvA6JoK2Np0be2 z-geIksTNT%C;jlK{2_LB4izL&?vmZIxg`^=3x)abGfW@*v|YcoB12QbKjQOX{S;2U zK1d|Y_q(fYa=p~y*G1=@x&Gdl9T$yiN^~>5Z4ZTy8y!g=p0vtBqt@lsl*DEitfUGl z;y#uvpR@~CPZrMETcJ1pvWlq(xDI}tBDb0rESC}K#<)IK_t@(*R@>Xhy{W{t@yyH$ zc!1zm4l*_RT1%t{WJ-#1BF!txe|34{X9q9jT(M$H)68%3B$pSKKy=}4{qiEd2P7ta zPf}Pvsi}J6u903pPk(xqh$g0oAM`!?rGhOsd#Au2yr0<=Pnq4s8~*Pn5DIln2eF?1Km^e6rjJhFlgX179TMV!A@(lD}hEzR)%P^_UVJYD`@q#1ezbV>Q@WPkcc zsWOExm!Bh1k$*4jUz-|a$8O~y9aEvoT*`J1d$Vk68wWBuVhZcglmJ5DR!dSWIbrfY zDf#A;C{gLr9TfGv4n&;~WUJ1+n#Ydx+qL7G)kpq#w-+O#h@2KxvHzx#HLGGm`GnN| z{TUpuaM=D{43q*3UdVEZ{1d+MD%StZla zB*Nqrvc+tBUbfd_j|{iEhi4|GK7y8ksgm9G(Glo&4HTvLZ7!>YT~qi^eLb|JJxTqU z`;Llg5NyyYU;ul0KE7LCmLV&s;r zNJkQ%V~n*uKgQNaJhOO%#m_8hckhvr^>n>uD<{7 zGvr>Bp?;X{y^l*%ed&5c%k#d4fcZMHK*QZ*&}&htREW_!!A%*o;tG3B6=IcQv24gEtxeof z;pWVXJW54~rLrak0#jCE2#Dq(M@61xL0hFx{sR4|;uwIju*U2Ow;W ziU!EwBt}@GiYTI?O`$+7)PiCHwBc(Dkm~H2Jl6s!qKfSbKJvvK9#M2{MI)^e!M3a7 zipEe=0dJd2je6QBs)ksth=YCK#L;^q%=RNWq|%s-IRRy)`t-qRlcW zl|>(4{Cde?PPn)2eJwOU7*-Q0j+$g=gLmtFy|DsQl#Z3}A?X!Xe6rFiodU^LrTQ!v zBC!KKsuzwABIuq=gvbmNPNw$k-K?Qyshx9_q$38& zC#_TKUwVtF<6O$h>_JQmNibCKPV+Naqu!~MkQV^J>hGgJA#2z{mAI^|`1n< zgt2=n@Uj=gpnmz8fnLDDFR~Q&N9eOho@QgT`1Pl*4X_Uu zYK5<}x1UTa>>oceg zIZ&478#-?PyfZK_4LRYNoakh`%=87xmyaal%W(|Fp5qCx5i^)X6l~ktOyxJhz0E>0 z)Jm8Un$HMKHBaD@%D%#NC83!?cd5ukcd5Tchlk$xAy9QXaw~ZSv07kJ7l1@!LYGo5 zb*_JPO&v@Y*doK5FD78|b4AmMYNUEeucgiIfOnDoJ#yd;<|@ld$!r40tvhG;IMO^+ zm!!OUI_G@8F0-ViCKKS$FF(f;)s$)9+i@`QDM0e|AzXecQr777fR7OF#?g41*0yMT z(LGxsSj;l=z7_tRs|${;W!mk7vVyME=9TT`$I2`5z&I|kjVnmT%;>lQZYbql@rXrE zc;_{zg*+47K%?8CZiqzn2$ZVfaAwFWSq8)!WCRK$n`VzXq*Fp5^r_7jZ?Y7^uF*3j zP&1JlW{%6EI4VxPTa3Ra5KBFsp2)58FW9ind+(SJR*Yr3znfy=uVEXQ`bQwNk1vHa=j&& z|3c4i8FOA-d5;35MDNfYb3A&Pl=g(dI$>3Y+m7PG)=9mg`7vn_0+iKQ|Myh)iKkLR(E!op4KyN|YM^P*}kwPh^V}h5~=+$>W zQk;fWx-6~HJ;S+9a(vT6RL9fwS% z#ewGTMLssi_y>!EepYUWLDlqrYJwuBRcj{CVm3v!i26$faVfrFQ!o{gUKMpAL?Se zH^v@`gGtLf4hg?_Jb0|Qxm)D%qx*ZfC8)1|J^eCFtsXS<*JZVYlwn>pm841h?~`?z zsnc-2@-(r}2FqX3Yd0<2zmnEb-+PdHW#DrpFG%zLmm&{uETd9wM^Byu&2y5*9XLH@ zmc)#l#YCVwIk@JT3*zCQY8l(%8vb|b|F8ph`DVQ185lPDW#N(GXI~GEk+|P{>KG- zs8yb4iw1PT7m7EKue}I`B{;(ep~>%q@_uDe=AFw-CeZS-FeEc&gvbx3Ntzm`|}vCPmm}(0?TB$NINPd~7b1I1BrT(TxKIxzYz$4GpPgG&E~@+_70U`lH}-*Ab4Y3>$uzB4BAY7^6Qf&fWE(|9hEQiAJgvXn_@L$hS+YP> z=u$-l?hKY~K+P5j+_%9oCMdJk!@=y!E>L7;sN~`(g2%D7I;?=Kc2G+ZIPuiUA>~d2+a23&s)61PCZ)gy`x71PYft@Hf(EBu32< zUe>p8;XJXpSDYY*CSim$nnlMqLxbl0006=Fc^9!j+DEW$)X{gQx^kTQ7|bhWy2-U`Ao6| z5T$7{B%ZA#q|Uz7f=0dy%4ivalB2-Al9Ae)hD2KdnLfp;x} zMu{F45+;dV3I5z^!qN?7@3+?a>l*=x`*h zY)LLm=9^d*(ANyY2jFE&TV6Mmcrt&M?_qjhPs=EguzeI*bNIkFP7HVCi)Qdq?w2T$ zX!Lm+)r#!vv7yM95@#~Vz1?Mo5Ne=7qR=LjD9wz`ne$4NxW;fN9WIMMBOgfX$lP&${(<|F`8UG+wR@X-P&z8r_JM8 zKIm3C@|1@!9v}XEx)8I1%eN6I@$=p(7FNeUxU$k=qBQpj zIM{_Ap=X!z0vpkZo!Yt=-k?wiH!lWocvu-F%sK;n{+gM7aNZ(woyNc4{kE&1IwUs$ zIJG2dJ;LQY#N~9Sp8YGiDKa@s1ZZ9>Z<6wmm)`zlPz!{I#>?ILi>@^JK0Esf=29{>*~&!Yp!geJ!UHkqQs4rH-)&?|BJGv7 zQ{}7mUcJa}6t)*ue8iKQ2>C%DZ`O9@)cHz?e$u#}f;8(+}0S_~j zW~F0g$|tIIo{T#W!9roXXvN=^oO)~_vP-4(X zHbH5YD*fO8@rH=t6plm*Ww&VQ{)af4V0;s$=72mDodws(CU9v2SSRl?P1AG(5EaTW zC2M+8kR+4V$w(;C^ovHQe}1f%Ru;^QO_%EKOU(N0SEVfiN7l%36J@mh{;KE+Qpd%J z2vMZNrLvdtGa}AuaYSIeU_gvaR1vj#&)P^8rf`Dv8;7haDcuysKBHq4a4Qm`jz|WE zS6!J{|IdO32-V?-_Yy#ue1f%uBE%X#`FDe7mFg&j6UBmTu&GBHf5et@fm-my@06d$ zFj2PW`SKlVW<_fTir?UXD>I*t4fOj1r~L_|`IPJ82L)3pE)4E}5Jfv@XwiT*BI|=% zqJ~oVP0Fv{K<*7jy(mcuAGEmKdI$^}08va_3i|!2L0f@n%%RBpg9(Pf1obgpPz*iR3J6GXE7Xu>2sIWIFJ8iuQ-jEE2q`RIpO4S+FY`j5uo zFaiM5KvFsV`c-w=^u+O?|_GS#-&N2f5S0+gE&g7ySiVajZp*n*y)EnK=Rumsc8 zJoG8FND15!2y_Yp0^=8TjFS0GUxdRz(8Y`j$fNf^$6BWP5^O7?m!7i!>ckP%GbfLn z;FLm09931S{-C)LY}*jBVTr4U1pNkz`MfAfpvo$Ny>VrZ*&n;UrSY#;3YzeT50J-f zj^Po58GM@lmTEyt2<6Lf0KO3JOQ*i+$tL-M-QbgHu`@T!F?WQYv+s=cX9*yx|Jzxh zz^ZThVFvjFTjnntmG6|P5@4)7ZbAeBsge$n2%^x`HYx~pHs?B09h>FP6SFW73N6s^ z;S}4qlyyh68=~q#w8hkjkbIZnAP8Bq1~zDcSTxv75x$a1H@k_I+$AZEohk`{(VUeX zEEuy{a0P^PX+6Z2^4LobSU>_=`$J-sDM0ZZaJfF1+zm;h#^MeOp%FhE{%@g93V&iux+V4WO7DpU#OoMZ@8|`9SR_#(=&tWn zZ1iCGkx%%~_Gn^puz`6NLyZdT)+Qq*&_?;SDDu{ zuB#G6mV@OZEQ~C^AesAqdGvrh?tWY|mCYG;yo(V-ySp5G4z88!xp#;yiH#7l?spfir6hE9oWvb)kN>Og;-% zUR%77tNQ4?`WEHdF5bR=J&>GJI^4Hwdgk4!s1%eMc{zUjG9>Ql!u}UoG%Smjua6gf zXwuIE;xse<7r+mLZ(l5RE35^J^FxKpb^0pvtl_O4BOJFyU2-CI*~W} z=3k0C9{R?M$3<`1U)h!Ftf8bAX^juj_Ks3x}4DAs{XKx;(4V=!*fmfkkG8DhuLMDgmSs zM!%2!J8Pdh-kGkUJw{TI6g;d`>+lj6G^pv;PJIaJDEq)VVV$A8STe~;G&jb2uOY`J zk|cv+#IDidH&tv!pX*iy7=k`{Kb_tWxkR)BbLJZnNpdw#Im+abXCZI+xL516q_Jl> zt5>7AF&424B>g`vBlnPwW?9+w`?)HQJ?;kr!Sd1zd7ONT*!LANZt9k+;ryZawzt3A z*U7Q#=@$J;O1OC>I4_=|l#S#|UL~*J1^@FxHo?f=r(K|5H8NK_bk+3J0Y*=9kK&ge zIdbI-qa)qxTW3(b@MBKWxDgbqbHqkQvylp1E=p2IrRMm99{HY>cju@R`+oHf)Qcyi z9w+ddC(l0losd{Mo* zp&eK)&mq302v40AcjU4x79=ebB*zjIekr=Ys_;{$+xckmWtroq#6e$MC~=vhAhH>J zv28eh(pwP(;bkyrTE>s2T*JY8mXLXR{G1d;-%o#Zm?V*xvZ$+iO41FNWF}spHGdf+ z<@DfH0z(x2I9X0D^(`t1)%tSZ+xuE&KB1zf4C2Iph_QQ$<(_;Mufwnl!^Xq@>c5MW zOTeva!DFKFtkzqOKEAG8mR&N}0Wkw|o-<6-nH@(3MWm3g(%N8uf03FXvpGS9Wvkd6 zty^Zr!PWebZ^vnnYu}Aq9^(Tzh->)`1uA5gW4y~xG+R}ctR}G`0m!@$}MT2tpZ5=)XV3(B*3S!7V#;+2!b^0%Yb~HMy1}DlE^CPu0$X^YWWx zLiBx}%3GSwWs5xT-Yb09EVPLT&>1b&D>|9i3ut>+KPl`)ZS|mWDaW7|mVrzNawsfo znCF+M8ec`f{xY`9KxWoI;pI1r5`45d-@%DvKzC}lpN?AkzaYwG<)8HEzG)f{|0(0k zQHkv8C#;s`h&GEcAurdD3(cZmk;R(JvN`3c8i7u%Yp!YNU-i&M_|H)`*;8-nJ#tYp zWvLW#1(ePtiVBXHBCc0-J+2Ho@uF;ZSxfVd+2GjOF_ty`6KVdU$I9~|GCa*Q3z6#S zoP-hL#(R&HSiu+Y=c4^36{~Ndaq})b167bZ&Y4WvYu3|Pu_N>DbO}GmUHLw$W1AnV z#mda^TD=`dV$-HPQD&~&ghP0UpZ2*zFN{X$Yug8)vOdu7)#l=gwZ_6F(j%#ZZkiir znf40g*^G?eYjIcTS7|I6Sq!ySz*?s|;=F{zM!XZRUq6Gw7BdA$F9zgVy|j5(e+mrF z7AblCxE=J}T~4bz%Z9YorMfsd1+L;Z^?0$M{BA!eczBEtI z=l6YrsR%Mb5vaKW2X!9AgRh1a3;A0SzP{>*F1|x!7@CGol3Z+1t~%D z0qHN26`S(wI~)y`4en|!K&X=Glvm54n4aVvGl(;F7*5Dy29k9R*l^Mw`RzcmEO)>Q zxlk&;lOf)sf}H3Iip7>#sas$c+bKAD4)HCB8*&0$iYm@EEUBk{wz84lxo8EF+C~Hl z6t}rTh}GaT`UT5Jy*_5sH#(xTHcD{5?IG7s{my^b#y zGbENWYNbDxBTT%-4B`a`|5iY0>8)a-nn{suH9jtdh(E|*^r6~L2|tF?4wZRo(Z^IgSK)FC0*f>8SX~-@!-m^8llPM z3Y?8XrdbBPIvec|>cXc2dBP*~ET(q;sw!ouUaEO~@=6hz8FJq=U7`)KZkZWTQ`)$Z z5B86HpUnWJSA%1TL>`MG^u`ws_Hk{OKC$A*I-M8Ah{+>Yxi#JedFgLg5B|w$E=kk> zEK3J+gPZt^!euIf@X=3Xz@0F zLc;eVIne2zV|?6fK}t}e3>)RADZj3f6`8lKxxZvgP*(`U>_RJcRH@4b&IDwg1=Ocd z^UNtv47V`IIl%w_zENKq$}Z5jz06zh-42<=2|N*xISgLn1d9&>sV+sQ+Wkn6$azaZ z?6!kOb4OshlAQFMs(OSp)7x^k|JA%V=1jUN(P-H8w?oi>a8Xb)SiXH5%l7eks%RHW zFqgHmzS@30yUClfn!Q1yMet8okGZ0;5*KW;$nyM$GN-nfjU9g5NWpXV5C1}I1uuuM zuC4*&o6#RKp_k5Wfd#_zddi}3_BngiVNV4A4vO4HEn#k+1~UiSacoPk=_(loGnC?| z;WQpcMLk;fuClfYaPMU(c)dxN4d|AQ2R;{5wXYc-ywfME`jkMqT>K{VDQUK54t?Nc z==?j*tMR<_z6OBqVxIc*(Q6k)EEi3x6|=-t&j^+TJHKo7Y{{O~?GZzsffDRNO}j+G z)`Ui5qiUe9qWMongFkq$H90&nG=oX#eeD{+qJDy}HJ$@7|6CzFoKSZ@U3vL`z zk*7-Hl#bdmSqm@ciO{7hXCSR9LNKAh=iIs^UbOni%g3ust#E%9$2Zg~61MUR-5E!! znpi8V+v|RXU1j@|MCfG|R?5bGNv2<_YudbAK82R-@3QJOBUz zA)evK%n}9yVgNV*1R;xIaH_;1Cg2B9&c;QmL_#zopfDO^Skgxg7K4*QoU(xuT=pa1{?A_6GDq%g_@0003100000000000000005~%{s+t@T5C8xG z000000000197T96Y0F~<000000003eggI(3Ow>RC004i(q~}1Hlcp+h57G_4;B|2L zL2oBEZp~b?j4C0+xR&f*;?WYj)+(>xy`X2T`8{E^lf4V99HpA3s*}=7fL50M6Fs?( zDqWM_z4VIq@XCYSKlX zYc@D`v)0_n?TYgWE&%7EXONOxH)f*4RIZ2I3?!m71KWxqo9B7snAFrF7))gesQy0uuM2&a1JK2jiiRUxN zG~+M ziEs`@p-C6PHq(&xTq+xrzm@^PrwZo3p?KTF;Cbz{6zaxsSey(!(em1=H(QvwS@IF= z5?wl!WHPf2*pamjlvBqGw}i>2^J&x|J*vd+CGyWr*sednuf>)GBEp#GHxyn2hlslg zQWX^YVr8^SqJW1S0UoLsA`?5w;)2LB_nP%R01H@@$Ly)#kW1(v4fj@(+TSeo^YbFr z$z7Sr6usU9kmfG%rsE@|i@mXMIe>3Z`1^FwSePD*oFzJUL;kjRN4A`YyJbNZszk~( z2M-Z)hV@|32|k`MBmg1O|%{|C3XY7%Cg#44sQXTxy&cf61ef#->NJ=4>4++xSe zxf{Xx_$}?%1mNe->!aYQip|cGfB?mcjim|OPw8IFXUvGUKlNuma}*0Gw{yR{eG}em zB#(pq2shvHA>okAor_7CK2Oq5Zg0Mr-_5%$n68{FvTFpRxrm2T%VBri!iuse+4MPP z5g*^qBnLT^i(?5Fb>D~ZH=yoKIiiz^$`lNV1AqSO zOR{l5%W;c}e3#fe9$utcMI}oafa;!enhy#Ljh2Y)u;fdI>HjN&fC7!27@;`9OM=en zN>0EP4Ii>eo(NQ1M>vCE$mu9cgt6Xy5$YJ%YoC6mRq1(tDNq1s7wPh8djffctOQp^ zPl~B_qsYLg*XG&4)s&<*=PE&q+mwU*qo8@*FJ%sx?-U2m?$8hY_=sGK7wS!^Ege?2T04?c3tM@aF6jvooWqzY79{7(R^`zqy=g>m@gMw*o5lh|p z$v^wtjksM8B!B?K22=UmZ(q3lkLA(6xwug#Cv6k@QQFky+ztS!M#q!5IX@qpS(9Wg z>Rr;KbZK^nVTolQ_NBT`^xR?8Pa;a-EBO&aP#4 z%1o5;9YdMfFAT!L8#}R^7QirGvxuOPCGX|G7Vc)1H~zlN8@&GH4p93C-QM9rbZR^M zK^e2~I0Ql$khca#Rz`FigK`eJnNe=p4f6rS3`Zx=vdSH>kbPsdrm4JGS6mmf>)>p79XuMB_apXzbwf4BJnP4s*TC zb&Cy;`FMoVy8Ew}^}VIUY~_@}R-0?S_e`j#E*U8SIoB7V{M@OzPd}2|yi;vyYew{3 zKTX-Oedv?X{m1uN=+@6Ilbp#~;{uvM-ImVx3N!KA$0lJ_>fweqUW zq-&TU7q^NwS{9)4Wf3aemO`h9iz1BH*uKcg8?3DtmH3C$y0CeHmtf2T0vhQ z1yva#Cff(KUZkj`z9c#Fk|-Z%*czCiB#I>#&;H_@(LjZH=P^PH#vPfekbnk&pa1{? zBNO<7mRVAn8L%!F1cW4zz%3ZhHT4=w!^NUix``1`u&+X?tyPk;T;io<$uthh1jTkx zfo7s5NnK=0rmv2vtx!dvJu!D5Cr0vBSC5qSnvLX@m?0EV^%|i5@hULw7Kvz5;<{Eo zLE5y-o9mHK8Q==U9WhkZvtDeME>l)8tVz1$Lq}CM>WS7x~po0`oB|99=MBak6 zYr53SBL!i^x7Cwexzz0GU&zSd3;pSJ7Wo>X2%zBp>R03uG9^ZYF21au#R?x#JEhjI z!n*1LMwYB)O6@{ae6bNC5_ZWV=vBz-$YfTunwWH}o`trps+cUNgw);#cgS~#;b4j- zF&mNMFkj8Ls@eQYr1}P$3jVM2j?GHMw-PUI~{fb*?C{g}_i#fkUx=z z+sw-Omn?tZBIhL|m(s+g7+aPqc3`~v)++IMZB2^Z4!#p|FIiLGRGm$n8f9leim%2^V;Q2{Jik!(Tk)Z^+|0nA@k)K&vHNmjN95|Z%c zJpulQS&Iy#uXu8UwmQJMlonzsXtJ07g}nD6^_2ckvwY#~G}72|0Lr zjOBLs)Exq)yUA=ql+w$hy~~xgC(c=022d8tX?&G#s6iLbJd~>_F36{kPhf~YWfNFA z1h_Z)1r(}lEB979>Kn-z5-ti-92>1ZfpYStU{Nl2%HTtXd1JhFWntCs2wTqy@eeQ zhEX4LO2HRwNhfMbrt%}^_0$^H2t6zLlo667I?7(TBW*f%h0Y}@eil>KOB-P=SPDi( zr^z&mv~oS0)#Jn?&)4AmWl!F zuiFPRyzyY$V5Iav9lW^@?dYQ98pSzER{1T=_)8ju!j8d7^)iFD3tz|OIn-7?Dn2T5 zG;a(K=!;&y&tlo)Of2}7by;a}cGO);FHk-nKER+}*}GF5#RlJkNil9NPy$mtM4iC{-I$>5`uM&mox)Sr`T>e*->3D1rXbo?y zMHe!Nj7fiKvU4lH=vcoZ$#T^3Drn>eg?B!(WW-)V)w7R7-;2DkT2i7q+g!{%T9IKD z(vUT^C7G_j4=S(8Ah>ws#lw7iSq=k$`1C1Bv0=*4{{IP=E?R{w zdO2?(f8F2-(sUliW&4Q)K0x@Hjy9 zQ^Un6(`oRjmi?YW1iFPknpmm}UqSl&uZ{VnA;qt-QX9PaxS~`cX-KkM1O$ z84I@$Z}g6xdv+=j3Om-i{uc}6w9M$Ka$9@i<_YEI#hHBCOu3an(Ax%?VKsubr9SDT z%bDLmd*ngjKQ(M0F?1?tng9E^1{()}83mIErZ1n4Q->pi%pi$uYo=Upn0V4kOk3e0{XlU)?N~5W%AIu zB66bd1uQmq#$Bt6j9!Ml<^6k^z;j(!NlVmSrv5c}%JG`w^_;*{G>>q9nOkC?4E1GT za3p&0^96(XBj3%oFTSbLiSy4FQ$v!-1rM%2%H$lfwB2?2a>dDfZfe{j!`+U`-bRw( zgQ6>I2eIrEXk5bJOEF4nDfp8jXb>tcu%$(pQ;4}A9E_wFZDp$PCY);7>Td`68t42$ zcSyZlbYf4<0IMIIGj(Ghu z^(=9f?>)tf7ROD^tWz6nsmrVCyVnny6tr0M;TE7~SX-bN2c0RluGtP6*Y84q&A;c@ z+w@RrPgMxKcdN#?RIK1vW~1dDxkgv%q(`G-3UMJtPNk9;wVOuR=tr{yI^ok*<8-BY z6t#HQBRS!x*L!8R@?*B*HP1$>z7R0@aRk?efA5njHz52@u_V$~*4 zB}@<22=c%~VnOun<-L3QAJo@qT=B3TZERuv6_lLifjT=kId&fAvY*KX-HU1k^-4uu zu9HBCVotS`?gO2a7g|Kyx0RfCeC)sQwuh7H>ZhCE4z*=7sJMN#_xQvLCyb>`eXM*N zixj&VkYvF%R>oOuy2w~^x{bofZG+KaC1O5wTy`Sv=#57x912wG_R}hDRHAoE-Fj|O z#J8WgM-=nMK~K&-OfTk>E@Z10?k-!+a42rZnRWT4=vQ@eMl9^nol2C5s6M7%e z`S&4xGr=C*Db+hEpszR9mmUQ~>l{;}&@1Ryhpo`d1FLg0XMURJk0H5!PpdD8B4hkP z6jaty7e(#YPa5`=UOF}l1YH$d*WWtj1(@Q?k0w;YmWvN5TjH_?RAzz6f%{ykwDkAO z#QE;hobXaoxlu}HYvQD-JaYesyI!v@6u-`e!fW{iwpEVH5B8VmqTg&ggbM=8+`*3^HqcCeYJIq2<)N)nmrXQTahM(p%xccnVIxX zskLJxJqULku9E3?s~otynC2xy)`Rm_-Kj|D>gVK2;^)p~QR#%ruoQ#l@+cmZ1VxaS z^*wFj50U{R_2HH32iCV!rO15W9-3ki>-~FRxN;@5)bqthuE&slo2n|e%Ia;oq<$Aa z2)}Wm!Amgsc^Tmm9)ska28;6j#)k*gE`e6y3$&$8Bhl>NxpeX^}njbHJWJBm0vn3s~S*U@V}O9vY-+s%yq$AH#jGGy|DgKF5RXMkMu1U zxj}98I0I`G6`|XE)dJ2|=jLo#;1PwwV7JHTK>0*`_HC(NQtAX!j5+q!a7+A+W?`K; z4icGFKXX>b8)AAWkjht@#uxKEbI*_23KT#IG2|`1L+fe*LdBF>WtPT`pB{lgI!kZ1kMA*Xtr_FF1Kn zU4AsJ-Yzr~!3->{u`PL1k44lQ^x88D(Mr?-id6&%rN-LCXK~9Z;&rbCua?`!OHjvC zav6yZ*i|hO3utwJ2AG$%@+a@6m_c}e*qtU7>lhnpbT<*&BGB}D29x@p^O?-i-ppY% z#cZ}y2s4p#GtZ)u$b(8jIMBr-*fp&o*bRj1Vq(bfGw9Rx%)nPN7a<_Gb4mb+x}Y)2o_jnB!bqw^`XrN`vsh!1 zykc))hArlH7p0ZJ$Xs6B0EP`}6_|#2lM6BRv7--XiZuboWd&BARB%AND9V#}ODoXB zK6J-@n71mjO@unyHIU>QF%R{W(hHR&k>}-C=X8YF;9+r+lktK(F<$~Ds8FHYjiX+a zSf+VFcOWh?3&O~NTPUtaf+SE)MtH59<0*rVQjr z0V*V*Lcx$uC>cW-iU3d$000006ab(g000004r;^+NYO|e7%~6=00E2{00000W`lxB z1886{02~+$00_VbpXb&B7zTy|+#qnFj{?9yOLI=qHyM>?RkZEdENsGEP>1OzNdmi} z7k%g7#iQ9VZP7pS+D1ywsu!Kavx6$e@pO|F)PtK~piV%X25BuWCMHn-2gGe<8K>zn zBSgt9x6;cX6Ug&mI+jn+$OADU!<9GBQu!} zR;L0+XOozxtGu$2z$hs=lh-|Rilbz_A?s^NBT~cf^U&;;r8s}l^tB$6E6#(O{+o4A z6T9NKHB8A9onM>x1IeEzra?B`5ME+pE zC2 zpS$_GU(}H@n4z2POvqkskXi^KCpH&h!BkG&g_@{NH}$BBUj5Fn#5g%}`$AsKV(lO4!s3WEnC zeEWN8Vi4c&7>Ds_PlC$vC3`RKd|Bp}`;;Mwkr#r-ZzU#2)@5{Ywj69%M%?IP#2XW- zQA-pwsVG)v61&_+Ox8~Qic+dS7smc9xCkFe$E>r^_w%hYL}s6=6tCg}v8KVPKb9 zSkJ}r&?m;|76E}_K$W^aopMDbMdy2V?mE z_Sie?dH=Yc*PyFB%}7(Y)G`8uI3IsUkHi&33|{I)F&;VB7X*hQDo4qSmsuu>L=i;< zNUl_#*e>}na|@l!2SmfsaC>D;#nP!|m2tVaf#f$u><9q{MA4<>9tnmE%+4GX7DDVs zQV0980Xn*42|8%>%`&RYQ6hZ<_>aJr1_+aCKOP6((iCF!T&XchR{J<>83KZ*JFCST z3P#dfxvmb=StRl$cvKBrU-WpSa*jCnH55j+-=Du9ksb3-+~vpo>bC`Z1-oOiYbKV1>xkt)B{wRcL z;H7bpQz4|DQoN%SA3vAJ7VVHxdhySa_R&$xko*L+%TFzit}<>913dFeRyeyM$hLuz zNI+j-BZ3M%eI9ozuC@dU0MIIQc)?=?@!CuaqjXZ(EEWu25dSBau9A?y>dw-bjAb|xRnI;i~r;v1?#v+J{tl6BvgPdTn2Ho6vqD_1>Uq*L4 zEXIX~i7~|#a=XwLOL%^qN-z(|)@&=`+@(AT^)xwffx+&aiHH{7AN9B|2!Ym2TK35S9ly;_B>47my_r6~mW(6Y! zmKC-0HAYf{gL+vludxy>J@hXCRiIFQ2u#Sqf2gAoQIJTLij<;k zrZE&(QlG%4a)!)jV@Ts>_RdLSw`q#U26>qEk6LXjgO$Lxr1@~!m#cI!Vp*s?wppqS zGNQHleg&Sk_KpwFdXJp)tz(N67E`OEP@-0m27X_iVrG(TK~WuN zD6&je*g!?nY?ErQmv;BKMnEMY;%2ceOb|GH^^#1oQ{ey8F2%fB7Dx#y8b5-TOiaz+ z6Tm>Trpjs?s!H32P{P%Rn#*(=gpnAv+{&X5G zw>eUHQCFK1=6U!OuU)Ef0MMTCD7Hg0?#d;joN^VeIs?HhDar~$aEx@m#^!@TO-R7i zta9VIzysjaoF+vtpRjsdecL`Z*-;7F4brvkRV_kjtV1JAWL?zFc`o>rTWy3{I(vNk zby%Hwfpew!34w#LMCyBOIG|Q7zZxZMWxCMg^GSaVjlg1%AQ28Ucr&%*o05S~0>;P4 zkMh;EhV3;M%RF5g%fbzTO%$&4j)(O6NCHpQJbM>1oq~{<9Ao)hQH# z8HYY_I7V}W3TA$QUaJsgpzbGox&M~F#tupC83PDGib_H8kg|ErWM|t8lr>57EM&L< zM3>Z`eeAOdfl~RHQU9!x+>OEw1Qurkh)B$F895@nxSXS^V#B>j=sA6ZoUu0V{ZcQJ z1}dWpmzb3Uvzxo7ma&H^tel3ip%SMFd;!MDx;>!J zG6z&lu;qNvTquNszi=vOG^~>+Vs54wCoiN^K5H=s34o0SovSsfcatvbk>G>DAF!vW zYf_ai3sDuaQO8Z&Hg0)r5e?5bO*Tang*TSjQ#vS)V6cR~<(pP#gOk~)UPTFtUR61j z1n4jij^_4a`?1$^#Uu1TmTRhewzEnA00Aoq{t&8^4TT6KtU^yp$cRD`h$IZ;@#$$) zf+Nx{Thw^6Vc7&264i#k?jzD8(I^ngO+nG`o{)%y2lFlPLjtl`mcIf(lzM!z1{5Jx zi*%3<(N(J%1wvAi0pr~g0tPELj}`K?xfZ&Q>aYlc>LeP{M~T;Dw~(ZuiH-f5AeBVF zac(HkmIA^~wsokAtCla&!l1a?>_-h#>l&&iQCTh~acclNicG7!w2L#OXQ`IH`HBK0 zxY%@y|3O+s)oAf+GJ$FNq(X9>H`k`OGI&%9k$0A_&0|SRqAEHv!!EkU7sO_=8Eez$ z1m|y@0%PAL#IijT&)6xu=aW+Vh|^GpkG&+;%C&SUN;5cYf4GZuv%UcI5iIyu`$_6o zn%(9nr<(?zIw!C0r>cJbfjM}67D72?v7`d^Qnm?`2Tpv60#-FQljMi0o{@x8I;YZ` z7NzEt{pXgTFMUP1cNTh>1I=~v7c7=65ni!<6uAI0N4JOq&|o=tx$`14L%^ODaP|J+ znxLwxF07@sWTE@#ruxgx(aP@ZU$JTM96rVo7?a$ra_m9p=%38A10&t?Dg``Sink=R z>*!C*lM8EAD*HP~?dT(%q9h-L$H)k)2Qh=vb2eU{WQR z`V}!Ba-Jiw+^Nj7Q;9QLn2iEt8ZGOWnH7f)b^uT*;#ic3u=n3T%HC#oJ;FH@ekAjV z{K@ae#swufKBduG9#AVB{)(sb?nx;zNejK9H}VPkjO0#Je?;`!W?qGbo*5*CV&4n? z@A7ImWwhs{Wo-7!U-vIAW8_V6j~SNZ|1DWAE8EQ^0#)PL2`!K;fU<)$r7&QSh>7`u zDOkXslH^6E!5@npS=>Z^kvWyZN>3DJAD`>hApCsyBR)%{QDK=DEUJ_u#mX%rq7lX$vdy5`<6JENpT^`X=+(YPghv9uM*qc_MTI_gQqoR1_Xe9q~hmH zwmO}=h`FjF)v`{1>Y0DtG(K(NR#?LBeCL}NaaShInF0W%CV@pZQ$6q(n!iUR=@8f}UL$PfYbKFhjQK6366q(#fDisTK}WGPMrV$-F|K z_w_W9vH25{FU7uHSIHFtT3n0$bdpFZXesDhLZZt67QLiovJv9Q zibb0=j%ETxt1$$=fk-GZB=lVo^~)@1ND0NwR>AI~VMrK0aFPZcvXM|sVi%xXM~l&Q ztD8zpk>Yy6^B}TBX%?j`DJ*#-#-tgMo}QXXF_Ix}=lW|YchWc~%`SzInY<@5SQH6p6ncw%Rg)x&1ZrUMAr^%nK)t<80!HO5iv+7@mP6_ISen7& zfp3u-l&Bc4W=xha=3WIeHnSdIN;*4tyuFJ&$@z05TXfc7QY{xxdu8rV$d!~^%fsPw z4|FM%SjmxUNBi_2Pl#ANWcw#T{veZry zMp-3;Xx3{+*YVL=^9iH15$jMU1-T$xsRH>KS#|u(+R%=fa>NwkNXuGvl=;c9Q8I_W zlHpIUzPNge}ru5)i6Lb<& zDUc^(3&iF~FLQW+l$nC)iY%Z5n6jFuB`pHco*q7>l+3{aM%HwEx;3;tQ#g4X9hXLU zNm!VG>T1fV^x)rAMWHLvL*I$&aS~t-ah#c}UE|DD1DUNh$^X zrxn{V0TVqT7GeU-)Ke?6EG$Hi9W19#K{}?MQn_Cubcwp0=yU33OFA`qN0|5C9o_eX z4tV#1mg$!9^O!XZoNjpMPuB|cI_Nv-N$ii9#K^WV$-4|;rrcVu3VOiWxSPDfjzuvF z>}0tA54@mmJB7^`Sp!@on(!`eZIC;ILvXUQr7cPt0>lM6b-tgUs&uPn`vpl)@A(o-4 z2Zy?g5|!&m7l;|$@7Q4^ETMQ>_?C$;5cP>`Wm-9*`qJ*jl3t+*8Wwm%kd(_w(1;i&2LVKL z&?8P3{kOyknReAUYmJl%nE3=inh{K48ElI)+5{;;8$~a9R$HT8NQ$yW0a3~Wu8ECo zSk*J$tNzxd)e_1p9A6j)0fRY2)4o4Z5s`MD8(Zn=n-_D+v6?Pc#nTHJBkzbPmeT*k zYmuiY%|FHc-w*w7aRNgnvW4ilyUmD^{eN3yh?+JTD|CY4?^AztwM!V0oQZ!q=uJJr zjSl|n>ZSPN-RxbHnPsA2u?xVdGz)6NLr>Hw%NbHvE@4Xm_i-Eu-G@_L z{)dqtqRK#}0n@if{;*y-LVB)LN~zWI7OixbkdFNq*~(h3pgS)(f-5Ny za-%JJpA7e`TXc{;MUYa|w!LqDKU&koDD6-6^sRrT$g?juM4$J%(IFr2Eb9FVR+^JU z&QS7>j>Z0Fg_UQ^A3geSFFiee_i;t(@J?TgchdHW@OUltI(j_L38}bIg+}lmKBdao zv;m6+fwu(k3>ojN59Y;}hn_Mm&$G_-S>BU0h^chP<@$a`(yEe2gKdu@ zB2dXi7mH4cjx$RiGf;_2QRB8W`5vvQyM-1lOjN{N$bjU7i`-Li`aSaS_Dj-8Wrvjh z_nCAD=Tg&tQ3l*~J||TbgMfkW|Hq5ZZwG$6K(%13;O_u3o z*4L>1p8&2vQNOvtqKu1qAl@mSm{(Yec^?C`9Q>jn}ul2V1o`!_FA(~Bf{ zx%VaIZRrGLV#Vfu9xR!@l!`|;^Y8LCmEu1r|926GJqrq2aHtQ3(+e&2(4_o}ClZi| zs+m@FJqzXsqWhK4`&R z5iRT7ep(Xr`jNhRH85Jicz7=p;F<}-*4#FxAOHXXF_GhDY!V0?2?z^!K19Qu2z>_R z!(6#x+gX%mtPt&_T8Jt_YH}i4#|g0-T}8JqAH>6!Hbj8)RH;?v7p{aQLQz!=#^okX z({>VXVzgrcwFJQOK5Vhm{-X;2vxYB%JW zBcQ8k?{GXlkpHqm+5?hWQA5+T)!ay`1Jw<{RQR~!0pFfljRa9Kf(Rd4ExajT%qpzV z9C9Cwj}Ge+y&wXh3sp&?-dQ*-EBZlwGz z6qQ8V@`;i^K9b(S}7icKGXD9SA>@8_I!ws8UqG40}4sw99(rJ(aIcMR58 z=S8jUm*69zUuY=`OW(9ci*PeYs7Dgi`(W2*YhcM6x7qbnEq6Hs&zUKX6Ak~23j(<$ zqb~4!T+s_BggX=c_IiNiU?#8t00A-s7#ILxFaQ|D+D^n|V-A%>?{{w-GJwuwaNEqBRH6`twV$U09q;07L$I|7m$1VcQ9YQ-m^DHO8=OjKoLP9;EfN&DY48)Y{z~i!5(#BW+HMAh#YHqPf zn6Zc0`!^&O+Xng{416)qeEp^VhzOp|dv_;AIUuzK-!b2G!qWhd@uz6BYukQoqnBTe zf|pvd@t30~R7sW7b)=>4C&1cxPb@bC3j`}46?i0B(kS)P2S@Ev0|1y<%SRLc(}uOe zv2`i|NGzw98f5LT3oS+lpfzCzC7}1L`v{h3jC578E$mmoVM%sJ*!=Hgl#e+jb6NSrM*uk7j z=$B_uZd)&9RU|~opJFjxO=CHU`l*^=-w+8mk|f*zOT z5V&3^rxdT~$_6lr7DZetc8)p!NlbMJ#Qsz++1^u^vzUNVzt!Fw%)Wx`pd25FDxXnV z$&wqi$rpToh>x=AXvc54#{`kiF+bKXNKsNPVi540l2nfzFELKhF-W3k?p+%JC9Nf( zkbjum$t@$yHyzI;S)@fB%s4ZEDGtqP64p6oind=QttDtjkbc9#?jQIx*f}SVc+nzk zP6jh;Vzc@ta1&GOGWH^mNl22E~9N1!(i%tH5IqDINoZ|XPvWEa~bh%3+xAVisYL=kz(t?2{@r}vzRK!7b}{>py= zbFn4CT$+co7IawSI6MnJ$C-ZXt{NIJ`aGwp!iqu$KnIKrTzmB;3Np%+iyQzP03RGf zuo@hFyMCttM7mN|NafY){B?j6wL48A5SOnR3w#kvESU2jlJz)&PkZzV z+NhiGxxOir304_RD^ILZITvG1!ItcJ*f`6g{cl?JLPwEHW5Q%%^MmJ^q$sZxRHcDD zQe9h{3L~g^J~=r=uS{4xEVI6dUFD!fqb!sd+6LU+LBZR!DWb7K(dEkwxQ{tsDH;Ip z8|6N+HA|IKg&Ve{tflqtsqlaI+tN=Ge|<57H-B-gQ$&nbM{guF4* z|9Q+LB)Uz+ftS-Ea(+eanE}KBuqD33>iYUz-N({m9A1-?mFKbpvWc>1n_K!+%uUSq zxVn;9<}H{QAqOJSHe!OGml>GW9KsL3ZAXEuu}tt$X$pP_1|mGB2X=C@OB*qAT6aYc zoY`bk>LlV*;~~w*h`)%R88P{OFFDO8c8AVtqxfM~lF4sz1$Irrehrn4zvBC9XN!S` z6~ZV!ez*Gy3otxD4gAu$&BYT;(cs~Dc=&)UV<+4(3C)?gtEBUJ zQ4y)4lxU?H10^BqD<*Dlqsc@=Wl(ef(=-S9;7`qd|EiHvbQ*up{sMgLI_NWn$e>40 zvd*Dk{mI*Z)|njYh_S?Mu2+Ox!;j09p=w^wg{^*!u`lTWP$E;3Yy}XSF6f#m^eGUJ z+-wk{YTx+pcxg~XTy7$_q0stbW=-Iby)u$`?eJP5h_JHH2l9R8Oy;tE4M5tgN*Y{S zcqaYb&HaTyQv@`%9Z?l!xl*a)WfMn{?yuW;fE8!T*Lo=-Rf;+aYOl zVJR+DA*ex1BvNLNY|xfa+)wnVlC$6RNmxr1!quw()ha&3#shF1~cWU?>z|ssmG+GDZ0hS17*au)`sC1%p-= zAV#{YbALflbOOXUltLixYQzNIus4u&j5Guy%UE|z*Uyr6AZEvm@dQoMOl^*Pc&M(hzVp1Q*OB>JAk_y%b*T3OgThwQh^B^D+)8dlL@ zEFxnSCUjWRSKOjKFRd#@|AKY#?~xH3k|QN>{A*e%KQ6FhY@*6|ljTcN6{f|XrVWCa9H9j{99nD^ z?I)wTYb|~a>AY#c^*D;R=9{ZnWn(n>WQhFyN~Yb5^Rg>~M7xFBD`+6kfN2;`6%+{B zY*77@o{+5A8|ETu;mPF%d2=IODmxnHqKaLMAYD>0<*Zy5^jD`Vk;Y|$*OX|rUvW^D zy(U|uD8@|YJf2&KY|VE?w$=(HB!ZUl$8I3Sx9h&%dT)Yj9EA<#Os63ft;mX>1@QHw zZlI_bp7LElV4I%uF7nDVNs&qaJXH32GB7&n(R@@{EL}YjnUdy@%i;ph-SlX@hQQth z*TC|pTbV`f6NS~)vDO-$nt|M)dwdgE!cORJisem$ow_RWS6-a%RWkCYZ$~HG3I12G z9eeG|(Rgm5_Ambal3hjRAt`N>Y^*^0?ek5O^^R^8X&=?KK6D35^+?L-Qtjr{TGX<* zPl07q#Vvl^f!F2P9eCwJXP!FuB7^hA=bjL_bWsKz!=0gXM4Y7DEJ(x zi3ZZ=mbr2qI%pPe?H@YHSU&->tmGb_GZZS#1&~<+fF_o^5R&M#5@eZ3FZC*F(N;WR zOl{J+gkL!GC&z7D$R1cXrwb(8vpTA{Uq85nq%I31vCebXHC*^DjJPV%pJ}`uR}ZQv zy4ZufL@cgA*=eaw7L~J7!1U_Laam55v@Q+5_n$nWQ}P4!HNAtPIZnJoB2dxa{^~?| z=CPg29W}KwRea0H@nSxEDmhcXVoCc)sXKJ_G^nu!cQ86_oA|)=-3Y4T9uh?#7op{8 z9W|Z}egBl8Zkbx9Lay_o(NwVSr2QRu?45Vk4!k&kC{lwegG-S@^Ccq0#crm-C7rT;&#AVS6&8il zonWy&0Z8M?Sa6l~v3c*MYOLx!Bf`z6`T?uXJbBSgyH#e7z)FI?WOFDgUqvFrOyH#a ztshc9{YP-Nf_(C8wBB#L3)nB}+EHLVm;c;xXfJQuRz|WSd;c7Yzovc1oi$U~pLd-y z=jS${-@E)iwNvkxhE?ovq~{y#argu52tT8@PdF? z?3tEwl%noFMT*=Dw11*w#bUIy^TJoTlkfKU61~^p1;~mEmn(;%9h$xYJJwV7r$IwT zf{LxgX`hrxwWoTXE+_Z!iVx3QSww^FcycvJ=_SK#928i=ExL~+9E$r&NWpTK9W`tI zSj3ghMWWjyI*L#1=-~Wo-D6)U%lcQ0>h*#RCDQ*IXnB4j#Mwjxrhk0hKH5oqK{)d= zlYQ@^fHW4=6X#Qu68Km?p!BOBvOH%t0?|esvhC|^UX3hVI-RP6@c#VTilV1DD#}88 z*+jZH&l+aLc#}3dsq@J8-enm~sv^xZGs@Z?0PhxSkW(&fEl*rFXm?g zV6x@eJOQM|hbTW_v8HUl^FV{`soMSSc6C}v)U9KKuB;0ARNEdZo5A60Vi)=;cfOHk zE{D{ua(vU3eRQQ|=%TGD^6A*f*Rs`5T6_~CEIMj0#zvZDr<8GEJ}}rHSLHMeWm3hs z_V8y=D+P+mTV5dXk}A64A7rwo`$SMSU6!nu{1gYw!o^ArJJLXGsF#yQn)O`pZvx9A z0m+p#-}+JB0m!;w8BZ#osU1wZy7G?F902EnDt&fJlV7B}m&iP3W!CXwLEfLT{dcEX z1yhz657lC)uE*SJyP9tPdP|<}-Fn60l@{$Dc@G6MWhbX-?tGT=im1J|Byr}Ua9L5m zwjy1pFH)_S2Su#9&DlFefWJORKJ|gfwko31qR0l8ck24ehr_skK?5v|*Oe}dOVQH+ z@W6v@PgS5%;^iM}kF6*v?DMt)ju;J8B81!7v$kZ=$O# zj@&KS>;U zS;!dhb)v5m{w3GHf#=oyS+4n-y4IX{_NAs^83XO%ur^x6RUj|q9h4Kcevy^0);~`u z0YQCH%c%7^NFSgkgQ9JeEp=hvRM(zBHC3dy4LPcKfZp|3`5G@*b2`0acRXeKb*dK) z?r==Ir!N_@g~RhG=kFlPnDas(W*}|Ss;M1gfYiNQCVKrUg9z)GLff! z(vDxsl;L&NI4a8YVyBr_#*Y^xvhCN+RLitqlw0=}f5j8At!OXTH|V6PR9z;#vxL11uCB^NjS}An(?#c$!;l9VqKbr(y?q*@RCbF>V z-@p}~i!9{?eJ#Uvv2cp&qkVH!%Of&MKGq3XL`bpHT9b+;aAkj&f!ASu=TfmRnZd29 z%Q?4w@j*Dfu^*;7x4P0^I!n*4ltDns>HVeS(MXIZvRM*mo)jAUV@lUL{Dp5RVxr@| zf2v#$+hfbogLvGS%T}=kmay)yHlL8V9*WPOR*Ll5XWB`pbKfUstVu#VTVuiZ4)lC< zcvAj(sZl{nGoqr!A5~cC^D?geH!5UC9z2p@4P9WTCC|$k zQ+R?RsEbVW_=tI0eJ?+z5Be$U2D*J2&!^AoMvI5(_oaYOIRN3#nP0W1mzQ3PI@pXA z9E13xSJvP3k1437^pSXuJ7fQRK8}P_tzNEdUKigo*g+|#bh9}z!F+Om7*mKoR8ji{ z%9H(HV_h_hMaU^|S{_9->7;9RM56c_E-zJhE4&>_X6a{YwS?JM%qiHC?h#jIkY4Do zIeR6`{Sa6?D-kC=IlT`)#ChQb^uH}tzju-@^9@7+;-cSnzl!G+@V5Epxu)nb6p!*o z4eDzyY>n0)3d^*pEuqNaQ>%rEbfEb6R_7fug5|B#ht!md6!d4TWemHn9dPf}`0y#B z>SFgMyPCkar01=_aSG@97V~%Rb~NE%!LUk~l# zcOhO^wpKr{&cR0qijSvGnlsbhjq`5CKtCWKf_niN#JyiYYR!=t4ghOZpbm{E*0&l^ z=|@O3ifqc{s1lSNmJawg0_gP1I+@HUF!>TiyV1V1StUj})zfral5VIitJxZ>(CrFK zrIISc>y?5nI{q}Mjy&uY`Xc8kYM**4BMD6%Z!+m4`4Zjp9-6Vq{miW{i>Io@W{=hB z3sTn=MU~lU*-B7zT?e4|m_>OI2RTdF8~Yp_>pVH+wfd-xx^V8J&j$j&O|}0Hwvl?G zi*rt%Y!(8?_S=!-q~+|03b`jgL_j&>N&NK7;J3;)_STn>>I@71f6bv+c^e zPgW^hjWg`^Wm`X_i776gL6)gstJ`FlwEn>uTq#~0yj{+5er0?GOUQwxOr%jQFKB#U zynKpd7!nQJM; z%Ik4U<)VpMGCH!6q<4~QfdAjc;TOKOp6KP3qbDxy8ENE5@PS~;4I<;u=8UF`$0YZGTqt*QWFtJH< z=Wd0}8h0dok$*+^T~REJ#IJ?>GOupW@FyGT_OyvI7Vx&v~nzW>L5?T!Cj7Cb`DMKVPz~OrH9E>7UFPCiBM;UVY zQ~L2_^RZpW+hfFdsvgi5@_H@x&A)OTX!#WrFsRGioro}jZytH>Z#l-By$hR)6>X!G zmlIhGsrQ64Pws(~hF{vxmHJGJq8(khZqQom5tC3^@{0lNl$jzqTN0$$AEv0J%OE`$ z>q*{ry8EPMs8O5)$r?$)00BA%APA!w#8Q~R zGXMxc000000~iQE000000#FlOB!L+R03iSX00S_fzyJUQRKQ6#fkXoU00Kh*00ED? zMGZ!!p@1(D0QW{NX*H!nT43kXAp}yepKm=G?qou@mwA5ekX4)#OO>dG2$KheC?i@Y zDfxB=Ftf>}OCy}^+cZw_sC&g;dGGLnd8B#G*G)1nrSpFLY9s90~VoT&Z~6r$ZdG-_`~F^nzWBlo0dOa4*B=y*Vo&R$)JPX+V2iKVtjjK$3Q%?XRAO-GXZwOWHQ z6{C4U$3T!TbWIdIH{h^-5bw`r^Jes+s3M^qBbX-_?610?(^JsftlUZn4xeIJ5vy!kjLDEzW2 z0ZLeCqLr9X4bwGT%h-0&Pqb$x;;^b=o?9Rx2A|}CKE-sP2S`{nJklW_)mPL`youwA zIMRMN%#1PuM(om&;>kg^hTb%@?4UTsK#MS-qtJKbKTcUbt1?CQ8wP$)p1K79$)G|_ zpjAii28F9CE14c`$AX5r(BM(;$#5{~0fid^V%*-4jCcls<1%WlKg|ansqx_XYp}c= zgN4WM`n1V=Mfx0!nu<_6{RN3ds5A!ymecV@$}*s$O#*W&`x-S02+AH z%@vB?QsE5Xf}Yu)7^b73A!< zd8CcPUJIUNPq@#;nI|vshe%io2OBo)IN|BX^bT?rtPij3gHJ1MrW$oaAEky ziYR3Yaps0uMqzN9gDSiyHhPc8<2 z_}GwK`N&sZ>uzZ=7LHbmKiXOjmV>Ag{8}MRNB3}>y#r?@#mh&#FTCc@2Zj{f$xZxt zSwkG8^Ids@x^S2}(Gy_IT74WyquJEQF7J-%!_NSD;Yk(ifw<0%A4eGy0a=h(IS>*gmGXm+Bt8R7 zTnF*~*jsUJ%fo?jO@8UnY(9d?U(x)w?QIqh>FyM3i;Y~;T9pdkkF%?ESSE{mDNRy1 zTh}DS8Vdqr1d{`~#XRJSS@m@}fs5&23Si zx9VOtnzXW;f(a{63JLoU5+stcJ?p}9Ov-f>RD#9GO!?jwGGTQYdQlGz^8&&Qb7N2Q z&cS!*BafQ;+E&6yYUXHhX2zra&{VCe#VyIG`;3*gy>s#Hy5 zQxv+RiOad#>?}g+DSZ{j@+tapIE-QgKp7q03QrIdc!}@{b4ld%kZ9#hhX&FSwXLS6 z<+=3Anj@jf?FF1SbKe4&Abc0#{wIrKMFJa0=D>JQG9NYk6QGUX_{ZD)Fe&1WNLD7V z!DbqR(kwIHgRS*9jPeN_3kMEV;o>N(jKZbtJo)3x^#((uzoed?pR))T8@_iSN0>Tk zw~$!^AyXQ#6wxga65DA$(FSPvyk%nkpkvT|jS9_tvm+mOIj7we0#69Psanq0EEGw|Hxc^Q~n3n0#^3PdkSZ4BD#K8$4mCJXWvy_j& zj98vQ`M?Z(ZA2_!UpkQ7cN-ijMx+|nVz2KMpPaUi8(mLv^c;hZG5ybV5#XIlgYQ0q z2O9L1r4^grMGu(3`m}QJY7~(yxPhb-5bl=NA{{x4feF>(39FLN1Sp}J@h;@F<`@kC zW`H;k9Qn_01;&%4Z}wJuYnsA_f2}ScPoMvMji;Bp00001I|qe@6tbDsJ#ws?ZY+dZ zB+qldM2jR=YGm`!?1e<26q=~oqTYN6z#8?5VbXxF`Bkbsew|?;7OE0AX zsP%QlcDs2qP>y7Dt0u1g^gXW~tAcf8f(R5oaEVRl?yAv*qY%qd5`b$U2Fz zkO4thTuR_l@_CsxjEo83y^DYlfUcLzBS{9Uy{ej>WfcG&NQo;buZcz0QCM2_YO-J{ zfhsu)78n(L0F7B!%T~GtVQLapyTkEo=8ZIx3#nk}`nV_V;Q3m7eW}%^OAM_f-Cp|}CU1~z6WLu|(f1^M zKqnek-mA(YhkoS6gU-t5jImVm z*3({+W$hB`_W-k=>XY%2XL2Y%>mPt<9O7>td&@beUj64}^2JIyaN1WO)v;RyUofS0 z9WN~ci5wDF;|YVDesx97lM%VC!Hqr894u*?Xj$vrsb2RYJ1mPnn#7$p{@e8r$pyJ; z;c{zESa>P(*r&6UF7g={+@2wX$bV}GOo+2G)F`BC`Znp1xa%16BJxMijy~&4gZa5Z zut`M+(4BvO-uRBTLo1!vM$4s4d0N?PnM}fH>y*BSHQ{QmfXqG6+7?|;BRV-Pn{B|{ z8XuJ|V`iCZ-u+(H6tH$t0anGyd2);9SGp6;`7RMxuhRV-RZx~%kzGTzOX31wFqvWjF?WR%S^*AR|=E^zJWds6-wKV@2RddTdqvs}JP%fOQ4tHSoI zdKMm1yfzN}a6Uyu>{HZV0a8)u$bCx-cGE3jDjjbf>-3S8DJ&OlzrGhtF3B$(9}xSH z_e1Gayod8;ccCYmBEaT__b7Br@U?z!oB81YfYh+P&a7+DF5u!8eo>VR1z6&Uwj=7n zAVaQ-o_H(B`Vrm4V)YlBVBh1D6uItJUm{5;S`n0}y6VoE%Fj`9oE}HKA0bD_W(WN5=)mt+2?MT z&3RGk{xBb}=_LHm3iR0#`T5q+yh_!k?5~*o9ZSw@~p8hW4(3{gTMa_QeY*>}H zk!eh;D7tcw9h8^y=4zAkivwRNvPth|-?dF12P_92k#RXN4A2bs1+j&Sd_SH_zsD8) zr89%(iMjFch30Z!f!LI>E?k9gBVGlcxrctLojEN)=H{Ktn`oknVSAnv1t!Rs@hdnf zx3|16jc~A6`i%T?lorI8q_!YEXzoDYwKAtMFs5CUr-j1R{$&L#5hQOiDbKl?Vb)WF z{}-~TtDRYVZ+~}AuLM?yxxHXryV%ksdT)SfSz*q|HdT~W%w6T0-3wM$-b5Z3@_9vl zEOnoSgZj5|rC;5*@+#q1*tEQlDB67 zdL26}@SGt)(_yC5-e*pGtjWKQn@Lu z;^*t*=Z&pm-TQM|eLplsVnRjD`DaOPqvWI}8Bb^@1LZCo7b_@>*r%-Qc*Ac?(w^xO zP`Istx1e*Q!`WP3#6+ECeJKzU@!Jq?M&~8s)cN!+djDhKx?nn%onDVsw!HhLA)A)h zCF0hUqMf~Pa?7K#2P{RNb!7!Sr0`5^JJV@!s1i|`z!;NO2Rf`ucS;ecKMvh3{>E)JPF!APlkX6Ds^ZR=wu6Rwf4NvtY z)c$MMbSC@ZN=J_tBt?fjJ)un4FVOINJdlac=0C(lk<%aB8tN+eKTL*6sH|RvC3#fW zxuTWrO=BR7AuAS1b!8%Q=4UQYvXmb$fLpETMNw$ECHTXZbv!&FcrK^WMSh=jDfCj5 zV7XzKhjbmnC_ENZI62iXZ{SwQ=MxY`XjtZ1ZavRv94?J)Tb?|J!rbr_E7X3iJ}72Y zgCqNhyUQdQJ-pZMhjp%aRlQ_?ch!_B4Swynb%%X2a%$4Fia!i7rk8&NXrN`2C zujg{m%fvcYBzWJ~#bw{qrwi=2fcNPrnC7$+^=_*xo_e*4dBr`y@!OKRVg$PR#F1jO zzmKA##eXl+b~wr|Q}bft;|-a65h{Vh>kA}vD*+J`U^o*WOHbYimrPm+t;~u~ zhk7^laF+WiL|CzG91|&}ESxQUQ5`3@D;6)$u`dE`pi1VZib}ppDRxf_sVClbC;i_K zLxDX{*16YY@N;~Z;2_MPpTql{Z)rP4Z>d7HmB5`fPKi-`ygZUzA1!@5DIZJ1l6-ig z=F937xcIfX_a&iCuyC!^r9GI0yb3bc!3?^7Q7$R*R_2c=YAsd|>b2r1<%^OWJ^@tv zWvcHIt<4PaN_-!!xmeK28D$<>eii?+^DZy9uOS!FZ zQ)SUyqSTd*E@efmp!+{%DpPY0az1>*O6JV@Qh0aa$xc^5st3`sx#G8*;yP9!IZF0- zveOV(inmd+g;`G}s%3+B-@cNI^L)9h)RshwS(PMV?e3B%*N>>IW-SGbK12uGJyVCk zC*e&r69P$Y2zYz~Nc>*gxz+lF1g6Lw#nklu8F%r~Sji}wnO53!Op0eM+tZb-5jy!t zV&$Zc^+|rs?4&Et#iSCv`Bur|#FVdQ{7d@$kcf*Ya^O1fU27K|owUkIx--`feq@^= z1DRz}2U@05)SefGf%*H6v`gd*pDuOz*~ruBxrM6#{mNfylkNfiWjq_4K)D^|9lAuv zvScs$%wWUkisqPC#6cFcaeAuuM>PoS5(_tM56$sXJ*IU->O$6I@z%doR1BZ6Rk$b} z12gVaf!rA;yUB72vX#zr_tS+&PqO;RE2t_rqPD#j6QrOeV3JRk3|u?#y;@jH@y%#K z8XRHX&-${WUn2mXgxVSMSg();4h%0cI4aobE7rKQYSE_v`Sd+(Jgj;2jL~w?h~Vef z$tr9d9Voe#J|!byvNxM|nvs!s6Uw+x$s43iYlqaRTb#?rvL6=H91O2iP*>6j^f*6& zc{ELv7jMycjDXx<($C{8Kx)x}nN`D9Bwo+th4bWJJ~VBY5{0k%I^dWWo>&j+&yeZ^m3Kd%a;V1!TUIZnJ>efqOO^OAj`o&(eUo(8j;eMI(Yi03bFMVf-2r@i;}55_g=ImA0W^VdG4!q79#5Sh52U~bAdlV^$2gfL&6d$RQCPX$YGI75T~hIO`?lV#9o7b7 zk;(GTKbcF^#S$VYWuB*{2c+o3ctHT-TFoP1ZiEy)3Wp0FJWmS&m-*qz4vDA=ANB{o zE7j};#L27crZK57oZz+NK#HwM#E|p9@C#~AXbSezPS!Vs5%}#?mi9LU*iB;+dvCsQRA|<^GbrY?%RwgNMU6d1Ue2Yt zjBsX>E+dUe^hhGe6<*pXN9r^P%g{8NO2TWL1l}|}q*IWoKM}8vC(JJ*o*(X^LFB|m zw6@n$cTfhHpP{UZXchi8F}}zxU63W)T4)9PS$#cKyHDsV0I7ve?Ec6i^2oO&fJs%B zG{q82A}O4S%NNr&M)w?9IOJdb7P@?WI5OmFA6IU!`d9z}0YU&U5P%8*A%F;A0vG@Q z0002M1TX*q0000ZLo`4{fk6PE000020e}Di003hskTxKIAOIUE3;+n_)f!Ng01N;R zhZ7SlOIBBK!vG=-3>n3Vi;rxO8~G7M#2}p%G}nNhK_&)m2(P%crw-gn) zf;fmcUWpqjO;85~w*ItxlN}3kDs^;qefkUHKxm)dk|INL0d`h0*n*0nZm>dXvjmMs z_Vq_V09Y(4-5hAFTIR26Lokn3+ zhriam0F-%$IrU2#m^I*J!z`Wu+-s5$& z5^o~MP=b6qTyB>^5VkzLZ%=14`k&O!$$x9UWZI{!kMkz^dJ9JDLAP9DfHXB)ax~n; z7~EJDqEv9lEkbMzBUbfsqm$FIJ0|gqv74sG%Ld9bv|H5K&1EiO)B7=MiKn3lVLDd` z0Wd&Q!DQ9;dlEJiYG%FPR>=^a`|XklQb_}m8r^@Z=H8~%Acx5WTR&S+ne;xw`w%6K zjfvn&(7(koT909%L@3Ou1yT$@Qyv5-=6r*5>2Db}s#i>&Q zwiJ{+PmgD4qO&7o+Dj)`NGxZfBRJ4c1^pxsS;Pzw8BH9~5!$GEO?!F}QPRH-q>|sG6ZP9N+0dyEPkU_fq zrv;h@`YjYXLfTs#tu1Szv?u|=lR3RWB0Q+$<`-~+Lfu50)O|d;^3wR1#HWs~hC9My zrgpz4gZ88BvIC;!zz7mvU&&nl7b(7%oN#4fdjpul2x6bVgkD0Pp$4|me!)Wk;E$M{MtuFmZ~Sl^#7jd) zD9q!hh6D+dB`XUgtjt8-2{1q?%l6yx7??yXGpGA4zvWcnJ<=?g4BN?hDu@92VaC82gBn~q-I2)!Lg zR<*p^a0>Bco;C*hMG9dox|YB*EqAE)8pvRu0)XlU{H(RvRKP(X^4~PAZjVPOHwQG; z=oV>-5;<RXmDe&1*5tDdgVw3MpmY>6)-@s9!CR01GpE*HNXU{ zxAgvc_cV$yhd{+a1;WcYzr)4j0;PG(^}RmF+*i|^wGIBR;Gc4{)$<0 zEZVIWOIa&-DshY>wVS5(@0`HHPlh_D+^mv#Q)<|s=LauqfI#Md`t?pAqdXuT)^Fl2 zRh2hyH5eF|x^-g|t0VE(pM_m%+o0(Ofld|IPh9wRBKSX%?S(>6a;IZ$-2Qdv@L6`b z&`q30g$f1GH6PCOB3Cq2Jo#`_CZ66ntO8Dx7>)Y`UjUJ2SKT~#YE!s(yu|?1k$kn0 zc+_Uzn!AM+r8%3x0_ClpUsisKYZwd;&=uj^nw3l)wtBi10uA8v0B|Cq!J`TGP$2jq z_!hMq`2k2zXlnz@1PbATC>WqjWCe6TN)oE&63Pu7oy=cbN+OnF41%y;RzPh#{6JK9 z=U4fVFr}?3?5e3X_Z5FJ;O)J_wiW-8(@zC7lf4UK^FSoby!d*vkPwIscn8D{ zS1O%H<-4}()%d4ZcR&HsfC;!<_S!(K_n`7Fq;Zw<4F_Wa(0EWiEefDqVH^#(>pAkv z1w*8VI4TBMz6Gc}3=i*c4XEJD^+E}QYNo#s++-V4edGh5`fWPCd`yE)<=$A}@r@kd zozQh4E0OR#K(Sci)g|Hi$k_qB^2DFDCO9y=3o(*_6ah?7jgD%d@pWhXQ;qFt%i#}8 z;XrG;6y<&>#)h8B%dP@TkX;uEV5D9O@JiG{K-Iv}C zbS{K)lJX4J^3gu%qu!1wf%F(}W#FtV_Y<7^%4jy^WB!6U4!nTg$VPIWMI)A_g=iNk z4Z=_2mCEq=N*?OyIGo(7Bf7;VXBM3DCxoR!S(-AOgd7MQ*A8ofx$mX|KuqZT6awLb zK&X19gaNZ7>Hkh9b1RiRN$`#e3(1Iu;lkxo2SUq!x|3?{IFAE>YI1%SzVy}n{KvRbYVz;00d45|np|(IsSyjZ-+l`vPst1NomjQq0zXb@`+p;OiPS>cs2| z;5m^fIjz8)$PDH{cxS$BowKBE%6D6or)-U~K6r8tKN*eAFplh?E>a5|ZYYL@K$9cC z<)-B}Mc2x|Z1k>x0003)40J7Gl%$(hd}SkJUu&#Vl30j6~bZKND0^r$Voq zrc}hYETmE{Z2F@;BW;mwALtTUBAi-}j!6^->uq+lh*y$gfp6SVSfN6TQn<6*R9n>_ zXp*UYCs_(Bkx!)ct)7psz}+lMwT#@T>MDo>BvfaqK{8=d)TLluP3qBf4rE;wu_{zR zwB5~0)M|7k&~HlThH zP9%bLx!dXVCrFcUFGSwFkzHE@1kJqMRH;((jB;pG*QJP`3Ph;d*V$-?b*VO_)UldE zjAVeL_{HELbe0=`ZU`Ry(&k@%8~bwThm|X<;=dyvcnKT@%*``ZT?spRKI@rcCxu$k(e;P*2c(nmb0`Q5OOF-HBn-DifO8+f!=K1o80Z z{}ZrN7QR+Ac%RCOTm1W$ViAi`R`q5`j?ebFEBa`{OPgw|Dw(&FapF& z7NHT@*F5&mYT%5wkycY}kL6pTMUTFn(W}slcNodratLz})oZfZ#YQeM8kVo$WhM%=RFu)r_hMx(TM|Ty@q8DIP4* zMTqn@&kIZx>6Rp6^Jmx5=yR|VBzAWNbc$vH)U5jMbPt-b?ss`6FY*}|vr6F#RfCyZ zdQ#Z%Rjlv27Ki^LwhN=F!re5@)Mbm)w+Hgln+>(4JZf6>v8&@Wsh%~|743JchI8@m zprOfkh)E@7ym1T8>?H-f`9C_Me-cZa+f{aLh>Q^zh>agsRh(mj#|{jlDV98cd@PHg z8Gj1de!r#bO{%@uvM&{#h&Cdku8KfbBuUj;V~J!zSVa8Z;`qJl^}Zhq z2KfthTY#d`_TRu0mew4qz&|@>(<}G6h2LGu&MXlg$`LHJVg`IdNIjLBN4E-c*;`l*Uk8-^%8sU4QpovH;dfDBQ!6o@glwOzo2{@g2`UVi zY0e7OaCetHocK+O9g{3YK)99GMx>>6Bv0{1y2@b2PEGdMvzry>$0y9S##av1?hHEogLfJ zlyc2E(R(M+>G(udIy)%QELnod7-jOO=cKN@KbJr>;Zeyk>)1Y>%br)dEmcRFA_2F^ zK6)UrbRwe1;+M}a2rl)p`PomZ%Q=20%M@s5i)Lvwrk~eaZQ>!YVU) zbux74Zi6c@8ja{LpQt{Ta%b2R_mVW#)raRQ zo*ZJf<#kw>>|cpxK}z+~id+^cp6GQcD%$3MluF7pMz6_IGbFCpgOs%~?bpKPZFn+@ zij4n!%wAZhrPD>rif$}~xyyH@DOKuv;>MXrb$-*5H|JFJZi`yQA$E(s-9&zY{$BK5 zCvsP}i*nR$BIRtC35(D$Zcs-gSI>~r$BCtp9)j8UYhdZ7!Er$@N<@BIbGb@cN$EVi z>A1AVW#dJaEMEtzSNt#O8kc{r^i@w(S_yN3e8cLft4poaWtEJz9ai;7g6P$JxHct= z5RbzBj|z&pc(0-l2S1sh(60=>3O;|Z?uJ@Ue;MR zmTJfjP-yn^owuy%UMv?*+`#*Zeq*3$pMQ4kC=QD!|5lqUN%C$7Z+lGnXN2EV(>Oic ztg{zTURX)$K1!oLZ59ilDc?vt!SY4&nG_QRMWt7N`3K7ZbEm=IOjr_*XBclA^&{86 zEylki3Vni!!^J?BVvHyd{rWi>WXo?-Jn~ciYaF~iIY8X5ojUpU)j0l=#rYs?ur)!H zv()X)eyj&v;r~~P%gu7`OBR^&2Fo<(zHX{*n)ijAEj!SC+IyZ-JtOsA3767AkARIL zsrFRbl7c9~w@QazJLF)P6tR^T@afN2z@JNiyoYgxPo=1R4@+4XU9qL?w|Q`~0{4{C z?M@5nQgv{Rvr<5JVP&TZ^Iq^{IeNiknL-bZL1d9YF}H;wB^&J3T&4o9|9JOIy!T0e$u31@qr z4i0F#{&mNw``>m@P<{bo!Bb^aANBIW#UnthN z^9o))$wF8+Zc6XyNgq$c7!s*KAP01Kj_%t%FHrGJX>%rWo!ld}8 z_Ui}ElRJPk-m>=-QA(o0l(1~-2Xs+h`FWisxow$#7c^Oq^sn_&csnhz;tTy1&tr@V z{a&n{S}l>=A8S%TW9KEOcr|w~3&pCdgpq$Xwl6(1q~~ejmoBN7OaaXJJ#(STIz+LC zgqA<;aQ}LatJB}N?fRBa4;JJ-7n%O3GlG_^Hvy$evurL_FFr}-*2*PdrJB`6+*G-o z4&?D1I(J5;H3MG99cR2SS?2j0t1^0l4}WsrCie=h;Ts1VzRQo(pEXxokm>%A`v22i9W zr#W%lA$qQtZ#nyY#)vw=BSrLsJ`$4XLkj!31P7pmjs33Lc2w#CqaLk1W-;Y~6Q z!c6e1Dvf$qEYT|m@KuA&jCmAnw)cwkFGhU3x={L}=6ue>()!b7g1Ml3Ts{qFuaBo} z8F4;mLS12XN2wp}%bo@Bm{Nn~z6F7M9t)H8C*OY0V4XVfRKXEg7#h3lQa#5O3X7T9 ziyapIK?5opP|`r%`wdKczA$mplzEQkNfPO@eVx6!?12=$4N)1u@~#N$soi zTD?V&G+05OT-Z5D9>*^$&qsm23!>-LRvhiQ zM-;F;7UTsic(ttqMN|!v`W)cu^mN@F$$n~gRvh(HriIA$TsNmVF&}_R?ZMAJ8>c;F z&vH)}0>z&ixV2eVd=HM#jc-Vbc~a&jKE{s~>QB>t71kyEKA5yYtpIG=%~=f2aX@A=nRyXM@nTvv%yN6N`O@bEt*J?m;<_58;x9pbB5=L`O_CbU9#)*^FZlpcKDZ&r|>Q* zIz`9x4Q*H}Em2b5Zc+tdsn{u2v+FgQMNU+3fYwYOHFoHqef>b-%>CShI) zD{L1&r9k`7055XZtDWI+zJ5IOTGb1qSSj4gA-rBzLYMW?stL;VO^+RyW&S%Q@AIP5 z5%>mASF94n1oG*F)S}^ZqY7#0IG}X`K>_CxOJ?s`oxO09tAcBS30__eCg6d%xJ6BsDGT=T@#F) z4lhXVQZrA$Fz=O7XRA|2#ihHnpJf(I?Gn7@V~6$<@lj`kWbjg70G8El@F-`>(O#3* z>X!VX#)7nGk2YmgzId@8EB#2(hhjuW%;+A6!>xN1>jrt9JKDyLBE23SvcqD}4{$&L z00Bv$qNdyo1_=)uJ}|Q3koFR~q0vJsIfORI;_mBix4{eR)j}4HL`jj)g9=wfpt8-q zUgVbTa)Oj9G|@Y`Dd{4O0Oi6dqc=L$XBP!iliHETnQ3lt3DvXurxc|4dv3CY4_$Ll zd!wi5uoYZBaY#gv<+_AX6}3@Cr8ubLS%^xSreDA};*Jb>?62hZvAXlh$cP9e$&`;%ozLTC_(%C_o6D!S;1 z()3cMLw*)-G4~xd?VE-DP#2+O*N`uW@)cx!LLXp>s^T#&^C>VkszH%#5Skkl-ed}p z6&Q$9<&GDjI!I&@+(pZ9q9ADZ(IlveG9E7^X3ohFNdqziiWC(tc9f`veLq z+v^EY5UCH(WeMJLKz&3spjGxhE@7lV!Cze%-PA<*n(@McjD9ymGsQ?f}+cG zHpw877l9p{lmfy0gKK*%WcvUB00Bw>0C9)}G5`>O0000000000AOHXW0000Q69Xe7 z2ByFO000001^@s600KaiCi8XzDgpq200IDjKsrq+Vr`%R000j@a^)bsg2G{P*wMe1 zwU)oe5;$5@PANA7!o$^ijNAAeW{icr(hkPGM^k*Ru}JFH0}6t!3rx_*40Hp$S^avB zqbAV{vzW}MY^1xrpzKgvZoMax%EaQ$;$|c);{Z~5qtBCrEd4BLW9cu%iX+y2Kov)A3Y-wVX)tGRF9j_dwiYXOL) zLMHzM3wvuhwdRUvPJGedL`uI08eAGIKRhA(M3;xP${z$$^A#pHRVtE2asGd6({s*Z zA#0@(e`KAzHad$3Oqpt6*l>P))a6Q!>&@iB0o*=PEWZRnm_7J_yXH;Pc5BnAhds3` zp;$g?qyPd@LGxd}!5ERm$~NoEQucD$ZrFd@G4UR7OTxK{nxqV`GP6!Ghso;jU@)*^ zi;_TbpCV!h`z4U>QXweP9EfWWP94fP{59;=##?v4PG~z3T9)1S#G`Y0xX+c6t8Ubg zcN|ZS$p^4|73Xsl{xMWYI*A9@$&K!diBX)P^(X(tdO!HgTp|#u$ew;>h|Ny189;u2 zSfcFczBnL_@I^aJjlohUNF_u7Bo2+6c*G+w5XyCB9DXwPw_GF64(cUJA2fx#{>U57 zPF-_j;V(xj+_m&~3Z@vUTqP8DdV$|8i6 zwTaW1lymIdk8TH*UMzL z@5Yii4u6P&M=y;OsH0?uyr`b(DY)~yx4Q!#xy(hgyNcS2qdRkuOWBzbe)8yobI0J5 zTr^CvEJio*R%0L@=Oj5s*{K?R+KM>_gHByDlR%*4w%aa!9aANw2c&?2_NjBWX4K@z z6id;xiji5y=5@kv>!a=bXr0x?K3-fNGWZqWgQ4(dnSXeX4&E=mq!ZlnT z>wo~vmLe>#+FVl(L!kMdW1!p)4nk=h9yg z6zj-<1CRmc;r!X&i5)HsMb6jD%6}?aU_!DAX*{*uW6s7o`!Q{9hF%7H+Q%Yq{57ay zAuW~y_*A0kv(%!)@|T?`3Zb$2@Ir_H`Y>+}!n#vMhXlKcU-QX8t(pWd@vw{Vvq$@Rd0GShx zCWqHvY0`PXaekY)-g`E-QVmCtPJV_H^cLSsH8sr4MOETS9WGJ#_o`Mr;k@9Dl57A0 zA@*=M4P9l{9?fP82=m#PVG#dERlwlu=*Xm@_(6m+LD1sl#F?geMUWmG>g0L8P!qQY z#)>G>Nza4w@%-m~OfHo{+*{R_4k_?*phb<&R&x4Ggk%>an~xjQb^_i!;ALR^4{r3s zb9KGVj_{jO)n%zn8~^~csP5sYAP@=<3DGFDYEa_}R~{V}9*;;!`0(3}vx0Pcat_`0 zMye`c>Qr{3?P`Im0YP15IawWI6Lj}+y0&t-%?#it{Us+Z(acXMf^9@8lg`EZHeMN| zo|ZQIHFCYvV^90KR2jK0viB+)GVXNdI#{;OO31i3L4W`NKN&lY5PJ&l5^?5mb+Bv- zB$xaLR6wRXi*+>BGnOZlH0tbGaR_qp2MHP(tzQlIDiB2N4WzbaJ>^;Oq6^E9oW))2 zIbxZ5pcpyJiB*Y@oWjNAh=`dIHo@8gJT z0aAZ|G$3E)*k}>8Duq*2u_I?y9$gK`igAphd0G&}terw7cv%IuMEY9igG?VyUeAK(H~{^0|z8?aREHkj*tk6ia*rM`aj+I zr(}M@D5LsFCjbG^PMfxmwizrB8~(APy+nZ1y|duIyi{dC)GBI|XLc$j7VvClB6|4` z-DNb+CR2W!f$odCnW>3=;@Hs4LPnAEA~3p?z2gAnd^8f$<0ZRzvKm-s{6hR776hQ(=Bm_ji7NU}%n5R_K zd!d8~tzBVN6Q^2kuj$2g$}VMEf2y(V`k}_J$SeMZT?J`g1gk`9s?x3WdEXBZ0IUFa zOKO6-);c7N)y{z$NWhaq7Oa4yNZTr<>s>;%vLuz=Vx0(Z>Ps;qKegXiZuY3fK@eCQ zdhWSdBlE_5DwT?Y0IYE*`6Y2y;+ZU*weUe+?PJ7sXvV#W%!07UB`1AZ4$FBgp7Bqp zEnX^72r%y`s=6I@opDk}SCf_vE9r43$njCG1&P}K5knK?V?khKh>XxBI^nq&ng!Si zsb_zD>uN*jhJ35$d#VB(1;43?#!umU+=Azl{NkraLhPOabPOx$(OyN%>Gl6?aV59X zu2qltJlI*|k}jnwnZRy8UzYg_E1%E3sj2wOOwuZUq(BaQkeO4G(_m)W#Ot{Con$?B7U{0eWzq9zrQ9FQMxy%E~sDtROP5P(<`nt`=RttsO)(^9NXwR8-XZ|~Uep#+nSN^Z@`z_;mQm!#$7RjvwY|j^ z7awT6Sc3StaT^hR9i|FbIxi-BU$~luAaD^D1>g?)_SVl1EZ<-H7f67pQLdP@T%|Lx zXcRqLnN0g-j&hO!n5d-(7azBZ4DY~((5_Rd4Q4(`RK%N|OXHF(Ng`C|y9R>9>>P-ta5 zv>?LaVgs5osa;#=L+pxCc=~%0;+uszqY5@@tys4>kmR@C<8ZC;2?A1jkHPof=4NI+ zE#;M~5g9u~6B!3uy4dlVZmyBIXJ`<5!Dvm3mwU-R!?NhRFY$f&a$nszL}{dGpGzJi zDE*?^q5&eC*>+mJY1USn4|F5>1tO8#{+;ZR!bMHb&Wp~YbaLYJe14G-v^&*4HR!LK za^{46r3HNNlA9$?7E{1?#vL)K=vuf{r~92iA=m1X*W%1X3uSvM_NTp2f-fi2BK0eM z{)Wz%R(T&ItZOtyt0qD7Kr6A;0`I zg14@Pa<}f8hr{f2#hl92C#bwi@m2=p1S`-oVE10E0A={9|!5+pe(o1Nvx*6 zDf%kf>+^ipT_ClW7FCN7Y!<*Kh>Uthu@x3*Jdj?pkUPTdD=+yMjHRdcz5);U0U+|` z(BQau2MT{AZoO5p5D&|7er?`3c2RGnMr9p7Sffav?cHGSsP9ewfWUJDqG1!kAN3<6 z-bhg{V1R;WgUdJ8qpHOLn&Wj|c~XVd%jMR0V= ziqF0>QKz5V>Q8d?m1U`GNcj+Q`3Cz%SR`lJM9?JRbSvzt<_)&}6o($Q4xW6QYClap zPb+?|waIKx0u0}tfId_0CD05#od?*^bJ&>*=moaHx+xC>Ug?=L2l=&TR7yj&wazqJ z+Y&C3*F5*)dcCDtr<#Pw2l~tE|5&YWYuJ?UVgs+7dRfPyory|DzaW7uyQy(KIw3}spRusF`Qh~ta zoqcQ(FNEZWhmbC!>Mazo%g6;$@D2x1f-Z^#<6Hef)&6#J#Gq5e1tp7kOs)ByPF0G# z;kPNk#|aoHE<|52t(_#`yyj0-(_#xeRN%VmEcE&^naFZJfXlU@D7PbGac#VPG+#4#xOqmLmH4w&ITP`g7?VIjF`UikJO8Jrq`) zq)r{u8kM9fcwGq3Qi7D7vTG?%$dD(E zym?pul=v>$qL(*K8x&5KrGqnwi)ko>$LsN6TVex|vKA3?RQU|K;zJ{&hbR*%?FCoR z8a|j6A4q`XvUC1;7IlNX1EIXob5EH_Yx|*ao81dJ7kHgtA}(onLdoWmxk_YJY&vEAZ*z}@}=RDKwTRqeC58gjZwT~Y@a`P^ot{w@q-%CTRSfePZ#UrNA!DT0Y zeY!!*s-HCA?<9lDr&T{bwLkw`*72gI+7f_~%eD*u``dr3DNN%mfIM;Dy`1-LWjO~e z*OfcZl4mhzp_b^q*=Im74v>mg3lW(<(DD&tQ_%Dl`$Saj2+wGW*^aD)w@z+vzoFpg z4a(<@nLv4Vp;qc5XF`#KK;^p;Kf>?oy+7Vh)=-m_ExpntUNM(0OYF|TqV+(PIQ4a+ z(_r_hYvT*;%R47gdYxJ`MRPmlZu^9NZU{v^^b0Lf5I9#r{11LiDz zkC&);3FbQ?{72a9XUG&!b}j?&?vl1RK{-+cvp*O4yJ2n(FY4xxCA`x;4=Q4% zWN?+SGRsM=C`ofFwH1mq_==PA5$FUSfh7kiFN@%QKHgbdNVJr$2T*DZ2b-rlW%Z#8oV@;?%Pc`-=F2S>=Zedl76z-X@R1zx_st{w z>2`Q0MqV_?`JG-_4*<)Wu8w!Y`#zO#J9>L^^{!7e^NC9`Lu`g$Lc!g1=h zMu{Bd;yIsuSwU6;srFIgOn~I8f2|Hm@}7}ZcIQ(zGQ6IdVmTvR3GrW_m*!bPCVjO` zqq46Z>JGuH2kKfj^6BVz?~oNy=*KO9G4FT|hPV!mjB7NZ{+fX%I+UDv?p{B=KW~fr`q4bM(l7mL2JhXr z(D4QTkkD18a7Xv^iEhVuUMxvi>EEQI)J&>W`(7!F7F4~wc2#@|D=lb54ssQ@h>-ko zWBC0~poRAJX|F4sD=wNrY+U!fO921Cpi?p)!;H8(`| ziK#>sjZ*-D_VqoZh?gUV6phyq%7@SkY{cHrd9 zkYR$7QND%}LI^ND2*VmEb5SUlXc-C*Nx9udoD@-IsaVwDX90!1*b<$V8fv9G%pfSE zKY&G30@Y?KonJx-^IlO2T0JQ7V35Xw>_e3hbbHyicd1^kRJsI&m%q#O54eyoGSrM@j zDi*uwjsgWQt!)j^#hB|%maXGtM@&3|^kzc!f=Nk8j;ji5ZekuKv1FxBW+00B}VH37@*ND4qoFvb7?AOHXW0096bKm-5)002}90w^E`Fc=5` z0001>0|0;q0B``zqD@H*z%&2>fB*vl00C_pLBpkktbh;(!lCXIH8R)}AsO0*r(h#fkb(Z|!hG zKZH4Cb#*`Yi0^lzWL+&lgi)dd%&8`P83C$IaJavX5c$n#AgcS4#MR(n9>Vd$`heB& z2Z11`hxQah$g9YGpLufbtUDx#7T)B7k3S>aT-59T!4bef&E|ljp6BudoOv_O!0Pw1 z5A+`Z!00Sk9Ck>RBS4;3blnAqcxMPa(V86G8{^NaGj9%FDdE6LRD96nI$(zi-W#I? zpfYw1{rGV>F!YWXvz5ql+zAdW#{=3s_gRK0oJ0w(1KH!5h6<5jh%BQ;pT{gwdagQS z)Eo3&9?Yz=NiW&D7HMaNgWLp5i4k1~B4icQ!nnH7q6x61NT&Wq&W?PfN{KN1cG2eZQsnVsadA9Q3kKDT7{pwc=_}p2Aaz9< zSW;PSyjPPPatStK9wZ^1iL`D*C()Smbgw=OKAJs6wfNdraV;tbL4NM2&jM;BF_y|q z@|YIvZjKr#HUjAmm!W8u8NWL^K-|<&NksS<16ho$wzdg6HW`&v1A%Phu{w&|R%F28 z>e6jCcw$1&mcbxzn4K-A?Z?e_EYuNyzL}OLrKz^;q?to`E)K}jF5ol7F4UfmvmW6I zI~}vY#<=9(EWo*!^N>7cLPCuM?R7X2P)AKP0NIQmv*UfqTM3DZo1niv3dYsS4)3la ze|w;}y1@v5b6GIhEcLz01T zg49nUDWq7e7MJGYpwJU1l>A#SvX&%IiI5df0Y)7ld@rkV)rTTLR#4BEibF0{$|#HH z>u9S1AkgN)rL+2hBn#*_VSyrs&k|O%b`#yAoRXG)RC9r;;qLNXnhffhO0b@i+d*FC z60{LP#~kp{)BOMEl+s^I5=Z-ifp(2FO7JOhJoNL~M!1;PjEv{haG2a8r3(=8BNTFH z=Qt$v5(T*1hX=%6_SF-7ckwr7f!O5 zHY&VBmy^sDCgX}A6dkOXLXzFM{x*!YV7=W`hC`1d-0QfQt@E0c&^@gpK-$e_Dq|%R z71fChoI0Hbs1a1MA%lZ84yG2tzi!sb1pq+}M9~#cX{6azOS<}j$hU8)6t)Oe{$g^i zt%jG*+MZw&1RE|8m_bG;ha5>_b!xah$Y^dsIvEYADO7_J_HBM5L=e0xjRb&>tUxq} zcB`s6cc1Z{Z8=7Kro47ontEq+LG+gOsWhb0hb{(-mov~k&fyKmiRcxrlFnGr+n#!u zk)DfqL$QF3S7AsHh{#0*V~+$@KukG}3Pl%t><^bE;MAcQ36T<5hZa637 z7$00{;o#w+Q@y?i&=Eb?8qe!7+@j@N94o+S5{Z&pO@*yAk!U2iwG~F>vp~YdXoV^fHBHa(a@rxl{!zfK zpdP5 zs!a~M$7&E>jOFcUbf`U(RElQ;lz!C}Tk$ci5v~we-2^jpW>UpyB)_y>iFMP|+P7i; zo1$a&0%}7#woB0zM=VC5DB}_Wm(hqouT}JtBME5cyEBkct3aUrC3&bP@SUNa?<^)5 z92SS^a>?zX3{;Z@D?dRtTpT7AL0L zeHH4tX%^dyDhy#H85m>~IFuR5xZo;1_{xL9^Hv}T*d~&-jZch5B9^w}Sw3IwpqrSF zS0Y9lS}0hCSqP3?Sf)^_&sYl( zrBM*TG8m|ciX;LcgtfWa`g;-)rVu?RwIH3e1w-eNIkeN_XB&_sY0Ybzf4)rCmJwhUi63Q(ljM*8)QazNw zwyM>LsF6tl#8`!tBnXVsvPD4$(F^^?79#4cY*mQB z7=@?0-_$7ls0u;?K%%k&)X3nX&!;4ro6d#D!V*Uqu7y32+PVQ`86t8(qW4nJw?%2` ziSsysaBYIEq1TCCe4)2^0p^7d=5koel-W6%iJ5SwawhlA>8sVsxc2In>AksIQOp$8O=I>p_+(lp#s z2HJluOu2uo6o`C}bd%~?V2xoBTi#E)X48mXN4vlKu81jb`C{%QlR4)a!Ip*UH!|gj z*K4T@aJVmhQ}-E1q$~=Wp4HgfOy@RNM zUFzLQ`s#L2yvLE0S<%6%2dJuS2(~H*ih&Cv>Tp}Vx@08gaPv6i3xw;lkQe=L;sEjv{owqQ1-6fy<2k*(zmE?Km_X3!ni&NTyeciP4_Wwq4+ZX_?2$GUM^{U; zmN%fTF*gwK!@U&MTdixe{8$! zg=n?o%aQUAh05eu6fF1%*mFz=1#VvchS%M4!mPi|=YVS-OaY|PEEX*b)@A64YH1mP zNk*g>B#msU36!Ki$Le+0;CWXdW)%}f>qj{lIXmvbS?l9f|WKTF(!HM({}2iiOHKvY~9OM@NIJfNT~4owbRSk}de zkR~EP^$riEmJm071R@hIy>6Q-k;wd$&#cKG>bhwXxmvprY6)_W@-J%;?uYi9f3=cQ znR3g5nm7MKDt1Ze)3h%7f9u_I>D)$yyreB)MqF*>>YUnLmJQQTG&Q5+*$I$Q z<-FDlVo-Ei5uVW!d5Q%LlgT>gjQo~j47Hb9HSgBkwHHP6ANaI7UHYDtZ2aqBN7v?_ z4?1s(cMTPDg_ZoRk{_=ha)bBc-iMkI=7t4IYu7y1jj%52@atgf0P6WZK(CM$LWLk} zs%t2S$f0Z$Mi3iti8qp9Q7e`W&U86G(euEoz`VJUwVGy{enIlpMWDK;*4_OxK)*wk zuYQ%UVohyiY6o=4^w^bkBUr+}TUYeCF0uE@_fnJe+6QjQM&JIdr9Bg!qb}O!Pc)uV zzrNAg;Mj`|PWJHX$1!e_aLg)DcvyNXq`^61Yl~B7Nsll2g_X zs;_`sXW$%UrbqNPKS&DGrc#r3k>Nt{w*uN*2@fOm8<2Tm<#2t_6{B1}(Yr{9jspDF zvPMrajU$Jm?#n}v-%Pz;$R`Hgq+i`)in980Fb-@MLZS^Fl?3=LL;c#pYx;g)h|;15 zbv$L1>!z#6osT`fSpJ(r%6DV+3lNOID=u2cUPhh06lG0kZ~`8e)X{9Y^&oX;9DNp; zXc;$r=y0g0ilJwdz(qXJ6GkxCusAlVV`I|OT} zXN{Rp3q7^WJG|G_AIW+uy)vh*y$9u}a)C9wYnc6z_;Q&BDOw{b4?{V-R{}(L16W5; zILq)#!M^U>q2E41&b)TYNzvokXW$C^4#((ggq0J|U&cz#pi7nH>SX>RII_$NqkvX{ zY(`3$474KE@Ai=#3;TVFClf4@_IAu$LsuJt+YGx1XMtEy*j}M9HIpj%0XthJ+=(_P zR{tW?J!(}KXV>3iMRZK5sH}C}$`^i{5hvBh*nmQipjli=P|oyw%jxnLOJ zz;yuz`*2TqT+$}#gw{y5Ag{71Y(h$DSq9rdxLuNid`kZ;M$$5b>MUtdT70V`>Pv0y zn}7OR7F$oqB3l%}9}!93JJTQ(mG&cGU$v#_>yTWZ0B8QWEmSlCsuy$zEJ0>4d1K$c zc&-Mp!A$izgbYwAYn$5}R}$b_oP|~-6@_*n#12qIRxmHq|FNz?b0c4z_L^^qGDy?> zL`&mEtyNT)qGMXNU2j zd2VfHv6S8b)-9j^vbx3=^T)mi)g*h6|N52E2#qs@B!52Xgv8g((Aj9S!{}_GZ-*%i zDasOzXfEBy&vI%?e^X-ScRIY1ex&$H=x|o^=w+Ih7jlB}`e8q)Tq$Z95tN2$?apqo zfn7f7q0xT}sT8=s&zKz1K5VAQ+4QAUsn%6fmj<(^dVkE_EnDhvYip#Ybb6ov?zXv( zR=JdZ>3E+wfhJR=TbhA#aAXG{JCZrY2!fmALAiwuEBdOrw>2A@<|7(&7;*~QB0fzjdiBO@az<`p=J2Ix~1riV1jM7t4(4!H7e3d~)9XD*?_^%BD4>CRFaydC1t zzg7?I&mz^B7ygl_7T>H7uza>WxorRLgz1GAS*kyK?gjdzC}yqB8+#bECJf>!Z$QUcR2l{${k1;1s(tPhs!XG2PK zWXdr+qfSP?@Y5~fyP?WQAKAb;+lc_DGAW}u=xS3C$$@i`=0Sl_AGTw72!u|`$1foH z4@J;TbF;M>K>w=LS1|c5Eo~>2G9BrJc9%#4R?~D`*{^6^CbH;{Pyeb?ah;EoNs^1v z?xV@Du-Zb|rx}~Ysq<*da$mbHK$1j(B&MpWg3-B&X)Y;8$EfLudc+}2Vv0OtCU~51 zMX_LRiW|&Gl9-2v&T%D;jAe0uBD5kQ*dv>mk(FXf>laJ+NN7dnh`x&4pd0=_=Gci< zI-B5Y*K5F1ywauO?lChD133rZEKdRxYLPmTJpx=%RXhU# zU<@aqEfpaY_C%(OD-xW5CZqzJb5JJ|sPt%BP@C=U`O#6nl>_XpD3}VV8X)jb)IPSY z|3wmboq5|DbXHW}(zCX~v7&r+B#w$LYxHE+6$ll$T9FXaucObUdsQj1xuwcR_!Nm4SSHPu+JgEh&DXa^OrLx{J#FA2VrIwbKxC`?}Sfo9=HnzPIS}+}& z*%*z5ANDe=p)!*P|NW4|`fNz~2ZHIE+?tlO(B2+d6YOP zrJf|Y%_HtK70IuwFWSGpmu}r?W$02V16;@n_-Xo;*=qY&T{9_UAnnk$fpLfb1SUkN z5I?e9Gw0&g2r{RylDd>1`JC2-4h8biDIjJpwJd>b*3%F40>r9-LGCnM7`JnefE zuKF!Tc|r3=7KeZE&7B6yDSlG$lCNX zqS3X7@qGig=4uZ5FvBh7i&D~0!`IM$l=~IY!1-+6*E#MeApJM`FZ4(sODs|m1aw*N z$MXt%u`}aLv#?U+w3p>n=_ld1Y`ne73wkt;+e7&Ow0y3*xfA4?s{~RyL9RJHVC=hO zQ!fFnAgs>5)9KBCsL`~_ltzxS#igriHyy-IpXS;|cik2c-LKb8@Fo#xSH4iS=fAg!*P19Gn=_i+o zy;v2QQD!mzM-Rpo$2QYekCqUa9CM}!x~*BC zL*8ry<&s9#{X9qrw$@BWyFcC6Y260ci$%=&>`9+3i^)7IxpZ$KN(!gP>4#i6uyr-% z&|8EDOmI~LJ>BMvJ{ASfO+9&7(ft;_PXJ6wUV!P3U3e)1&C;;X34%@Va>M;LAUscM zP($U2AM?Qy^Exu7gX)%u6KAHf>@la)b>BhxanbyvfB*miS-oN*d<*~z5(qpPpq2-y z&xl;p)gsHS-gTBsZz2!kCXX=G(mPOkl?0{{nyPOihyqpyQSQmQP;pZrRy#zSOL?@} zSoaBFQ!(-ZP~;RI9E(U}ifo0I_l6*VTL*t_9f|{V^35fJx=0_}aT~vd7H2TfO7Wy< zYN_|AGpz!HF{=#;kQ}TxW2Va%UHD9&z_gm!tINp5Wd)hd#~BNw?_iZU9~Y-A(wJM( zZ8Yo%tQ0N0L@d(o-dQt@XFK#7-z1gFcT>Efc2ZIuW2Wz*XKxfp*)tb_BJ>1>UZb(X)5_Uj@Bt~w1uEW}0^2ly@4%A; z{tgy`Fpu0)hGeTz9?!l2000461t5q60f+!#05O07000000LB0S000001amV44M6|_ z001BW00IC2U;qGxGz{oy)wBr!00V6x004$5yqY%0F`xjb06jY_$3%Ym6hWqldgSpE z)P|@pPx)|-M?b-2i=6LMQ=IqZ;>kQ`QJzbk`Mqm26$+Foq4aXtKo|$hqHXa)sH;ku zF5LVUgTRIffyn;PEZ<|j%mO8Fh&DAkjW5PK`E?SgUo87{Uu7>B%u(={R-{7$Ot)d6 z)_NuibMCMtQM-Z*XF?z&S^FVsWlE*IA9JSo@`VCJrqGH9SoDryKU&W=kp} z`p{7fKy2kveG?emLr)g?n`pcDTJkpR$gV&s26MJd|WykjZL zh=@gb!@j}hH!d#s6lE0XZQYFR(E0$9L2@qq{e{qyd3g!D&3N(1qiurG6aivz`mqqS zWSf3-?vcbavrFSYw#O`}M3*ft6q=ZWd#K#T31O6djN0FUNxQFJo>>5PK#9MxIV_S( zAS0bJmPZzp2#;4Ob3P*e5L1@tt&4Y#Z?lb!$A6wJg_LJ*DD0GS&xynugOOmO)2F>>6G&l=^F@|pT_JI=|WGwIzt!v=VlEbuHQj_56M8Ty1+Ei0sS!l#7Tyo=3 zNaP7PI)P#TZDkY6hR2tfg44^C;v5+z-JC{GQ-iTQseK37Xf2n?wI7VQ2WOITZ19)X<97krzwAX9uQU z%bfg}oQ7)PYX;Cx9}sK1hf?lvd~$NwE{oknyz?&c1qyi*w1XC5j{t+w5H%5>7qL(} zJbcV*Jx8PsLx9tBI7aLts$EMkSowymi4vT@=R}pHs!HSZd2NHixYC!3e-b+=bK{Zt z{NAxgBmB!y801djBwS=cK3(~D_!kwGj)LWSUk6O#iEAN$I@6q@1BM(CZYOD(K;7y$H+EeY2wbJ~=6~h8>8>g}jQ!1BX2Xsn{1k_H zqx4LsiXM?)$Iw_r?-aS-rSpivHWxo|RUW5fK+D1C!wIadC28(^{rG1zlBANXOyW6a zglYW&&1h1c;l12e!Y$x)Ls~9KICd=*QQ^WIjk(U9P$#pk%RmSVMk0_oTK71PM4G{F zB);U_cHn->E-_?PaunAb3Y}+Bhvw!}`J{Q`!0#Cx+#;jFVNrOz&z`lTtDfG_ofdWB zQw$|u=P&H~)udN1HDaU&l(Glb%5L>@tl3^bb`<+7p}d^K3_kPa{s=MxoE|djZ8bj} zRpZMg7Ra?VayH+=aazcn!BqAqIMMdccU1$8vh;i|0igi?2ns)lIcF*!)v6B4tB+xz z%)B@`U^$cVDF95xBV1Y~|1Lk~K|kH6^ip=8)Uhm&n%;e3ox#q0Q$BjWobuvT>?FA5 zHqW5+kVhNK+4z$n>^j&UdW%EM4L_E$m%4wE>@TuNthqYwB88y^l6hF}+K@*{gnxk* z(;jj;FUD~7&X4A_yYtQ3Cldp@>OIdK;ZIK8<%5@;Ix8bM_gJWR23-tuWcl=$JZ&?` zK7uRUjF`R1@oq{%2997BucVhaqYs;5&1kY7Khdg_NUip~rR5BZ-@w{3hW7{Da*W8c z(?R*MZY)G1U^k19yMx1__jDKbcqQnArc!Z&VVr!xvfM{ z>02D!3yeg;xmgkZL1^C*P#+k>O8X$(ZtS_=yX)we{MU6hj|x&Is)@IsRLskQ1ZHS zCV@>rj$--Gz32vPetlMJBJ;@a8qdNlZ5^W+9qbl-8jWyns~b7qpxCW~RjL$=H-@TH zLrZe{;#_>ixy!EW5h~~eIcTzb`u!+vS1DlS;CUuGTk^zLQ}#i#XtpGgCGCRN4lN&b zJUIhN0F2!XVL#^l@N0it`FR~}eXTiir%y+f5`@i16z`-xo?Yx<000476Qm_!N@%2+ zREV;XQ3(*hf(&c!mngg|PelP7wq)$lrd6&wv11_XnSiw>4#e+T{fR6KWWLED)E%Xj zOJnaEu?7MXjZjw2*9xrOE@5U| z^I0xfdXp2PX;L+Loy&-7)f8ZPiopb|Mw3<2weG6oXV}myO4WTUlKT#+cZ)&a zR5e=TdKh#fNoyky5DG{pwN@6-I*}UMya}I@0b&qbOa*r7WJaE;iyra}AVm#O5(I`? zk%Kz5*!1BtD&wA-BDxNqeXz-`6{-zsk~USfQQ1A$B0@k0tU;qXyE0o z`3tC^<%K;<9^$t3cdD}HT_e)ZE*`EQlZ7I-R9w+bjy(bVUV-@3M~kGma)`q8o~czF zn1zKnH1%=nD_;1McF!1%v%1+SwY(y|nQfmXTxwnjSgW~0c>8tfYoOT{{SJ*101)!Uaxb2r5B zFzQ$8MQBpFBx%cCBeAw3x%>PSr{M;!8U<}zGpBNbOH=A4)^dO*uvOv6mt|!>bex-``swwZWe3dGput}TYz?&2yf1$P z7&or#-4}=l4hl`yn_6XsB7)fTczF;eQrM@HaOSasg^HdeddD`7`vpBk3pUAf4WgD- zB~6kqvb-yN5)?ZYBJES5 z>CaU~sw%tha$7plY1WU$i@_gFshT&R%BS9`suXiwPaF4456(mvy&vj6)I$5+EiAIj z6jit7=&I`Er>G#Al|B|%$dea5SpGt5^I+MlZeA#z%o~@g)t|&wR#H|OX`UZt@(GaV zVB=rMOhFW~r9r+jqEvO=0C0nVFiYwA6XUh$$88enlDDw_#jJrO4E_d;J`$vGQ+ZspB@bsX?C*G zJ`|k0opl3dSpj{I1m*KtS#Bk>x>h~mWK{8i^(S#^CqDu0x$;jD8jdPQhG*GeTPqT_ zob$k-SUADJ+TO2$c6vCxzrBuC(j`s%@qY;@J{|D)gi#zdyEn`1l@B`FWWiT(oUDoH%mn_8ar{=M(6!J=4vRMy=Qg&20 z-=|E|w%tFU#2>^`?ph5NJ1=sY$%l}x^6;xEydF_HWkd3N)2-SsB)iyZl>a5eoJ49* zNpA`^51+^8Gs}^eAbo=UXQOaHq&&Is+!lFOsaC9{MJy@F zZdCN+ewO}y_y}pNwQi59+=Kf+PQ7Tkl43f+SwRu#UDsc6Q5V37;JK^4`Uh#f2~ti< zD=A86)YBkUv@1bdYSOMxC?AIKchb`eWlGmfW{@L!s%&6eddJAxV7JQn z(#F#*P4GsrXNPzqmv+yTWhx@nDNi1lg>_$T-6XdX`#RBj zd%^yYtTtHsoiLvgpGni*$|iD6&q#uqPnMlzb;rRznPD`Q{S2`2VhT%=VUck?QdP0= zKph1>pYBVCHR!4;jPh4|ONPc5tdYI40o2a!b4_(B5gY7SA zt@H;6{7+Vy4@zE%KDIc@&TOx=$|PHZl%aGyDPilf>2Ks6WLbXuMIo&j*z`TBig_lf zKZ!==6NUK(iQ)N5MLgo<1L_tF(RBmNEONz}e~Nm~KfvFQdZ`G{H8V_yY+H8Ukz%$j zm6GK^=TFLR2P1;(+{m>oBQFs3veC~itU%nTpG__CQj1a6WhbFJ12UatcmppfQV#=s zJ>hUK=}vOKtGp%qA8KsU-Ezrv^iEYbns{}>YrkOdel2)Vambn>()COQrdO9My|tE$ z8)1w7q})07(We82DFt7Wo;>6unO$5;58&q|;ZzAL;8M3B7l!3?wJ4n*{DYPp^dpqh zA#}_wZDmeU3f)2fC3A_?PDHp^a+SFPZ-Va<6jjeGp>f$%QsSNs{$2yTf`Ln``BvM` z%JAQiZFse&ayP0fQu!&lRg3Wlxdq<@Q#9xHE~S+c$f_uz)Ra1#7$#?cP|Lq`SiCF3 z%hi=9kd_O*)<#>>bTieRB=_dhmL2)%o+uVX_gIXj`CUmplrOiUJAmO<1O48KdL3f` z@t!gmCS0tfEkePuVyrqSE3&X5c&2=;8d@jWwff!9S3K<>n4m+M2(|mg$s}(MMU6Fv zmq*jQn}xxC<%aJwPKf+?&c$DlTc#=S{~)Gx&xZw(zEoEMvXNjL5&@z_g`x+9(53d0Q16dB&xn zvZ%Q!L0Gix9p&~U3!`P2nOW_SPrhT3BbFY2~1iZ1n-XRY=_j~_*0;=7Q2~s zf98@i=5QRF7%l2W9!TfTeUbK7I&kq)obA-RFep1#L|$ukO!YO47bz)W9EaY=JW1jX zRB#R{ijKsntZ20q7pPLPo%`6Le(RUr)(t8%=Qoc$K*2PsaR-l=@+trElF62LI)9V&gTovv!F>-PjNda!CNDSML( z@7{@Ao0zO`JP1H22L`p1HwC_LBEgDv4|ITL2d~k-W$n5yAH< zOm>a&NW4>R;8J)Fje?dISLVu@5kFw}Qq2+LwH|%RaI@)8!r^ef2Gf90@IQ^PDR903 za$fHR$SL7&1ME&%^K-pFb?#rK0J{I8r*M*$(gXe`O%7h3i+Wij&Cxs6C?J zB4jsvFMkOQdg{L~B_fD?E%(^;IZTgI^gO3_D)BoQFAFUIfxvbDH~A}Iq(xe_@W{MT zl|CMe9eLNfaE=YP?}Yoxid&J@At#04{e1~8Z!Eew6IS4+9tGB(0Mv-2Jr*Tj!22AR z&y>G@eF*x<9|^;7-4kbd9df&D!_30S^nR!FXzWBO+vunB`1-D`{0|j>^EFdmi^s?! zkvZ}}D9T+6AmB$~=y*j%@F@7Z@h(IBSyTFFo@=Kb9|)zALoR+&tou`d0004D(YSzr z06_roAZU0Llj8;)N@&e1u0ZF$*_o_XMG?gg(UOGVtH4x#+O@1up28v8eGij8;f<^( zLr~hNfRZgCEm{+AZET|IZsQ1cJVk_J%a8;W(V3QTqkirL-PWoTM+Rd8-KcIP&fe{BtLRMw$P5I~&2qNMT{?_wB8|Ng2 zqf<@E9%Cy_^9l?iM4#kAmpCETK;?)k3K<+NR0f#<;DEJdciJn*!Y%VQQ|JttAi9MD zSu4CgMG<1K+c!}`5y;Y-8w)^Vk^&5%AEJecAMmeX1IMD~A)+9WMV0E1PN4iYH(^^ai~O}$M{x&)vFvAxN*0FiYFAzm3l1E)eRM;uvX zma|c_!k!UJtQ8K1v^oSL1P(MHkkkn-J3g#1feBH9ZE6@1y-*%VSxT2Jk!BH1NQ$%| z#zZYNj)_nSs)QPwUF9p3W)M!U&FnRLl1wR>%*ZB^rf4#z(*V7d)XpZDXy7mY$RgB; z6-^~}P^;Kn790Qo0b&9W8~{Qngdq%L01yBG000080AK(B00000kjxSU0LXv<00003 z0000003k}RuTF`b0|0;k0ssI303{`wmH+?%2dtw`lNBxqIgH<#!@A#q0QLj=-MlHs z&B6p4%r&(WpG{>AZnuAtuC=-rHWNu9G`BHu8|Y4~!8gmD~e9gHl??c#bt0bikBCKScRC2H&Q)@gU2ha61lY0U*#{+Q#M*vrwZVP7*e$ z#`skmZ4=`mX_uIsgW^O%;_Vesc*rKSEx19(5+Femh#<02i$*B$mS!5rr?9$mj37he zgq}m9vdw5)*pVgn@XBIDCyA?h%Cu@&pzH zV+%zy(W3|5PAlL5`wx_Mo}2H0m|_&P;i`5k4#Wh$T0&_n{93pZV|K) zNFta_1|$A>m-U1k7m+e5$fpR?2+J1;uLu{n8!8sQtp|bizA-K=1(8G202vr$wqD|I zIg1OB&k9Ss)m5&pP#1wAfU`zz5yMIp>=+tR@Nky|^l8|O2z@+5OFs-&9=nYyDxf1P zy;!8f-3EGgR8(>y6r3QJMnsMj=40Mbnu+pSnwf)OfM8+se*Nm=#qBgQG2tRY%2N;6 zw<6ElQ+)?X15pZ`_+P}h0rBG)6bb|dfeYIKTA)xshyZ4SR@#&T+7bobQOq5aHtR(p-&JorTMi8%I8WG@HGzwe~>|svVFPwO$0tJm!bpQrugT#%B zAt)mpTGrcYW(kz5K!>8y=phOm5(LpIRLO8mw;aI)(3B8JECex7u$|5!T)j8YD(cuY>LZ0acJu{8}{bi5-u29}!xg-wTrsj3=>f z5|x(3gTlE0Oqqg3Q0#6QLVJDI)(Vod9S6~BH^Z5%?%2K%_DQJdfmYW~gRtk4q}fKq-R~wsLE+$hc^RjA&(;NMVd904O#A3W5L(XaNX=lCN4Bp&^4a1jG_n zqhg69*pxy;Wgcg+jj&Y&4hWZ?3kIvL-Fuu*zNjMaZb%vQ;T<12ehS_0cyX=*P@n(+ zD2bOsh=>4@*+`;p>35(^e78g{luTUP=QY@vd0EZEC4vEj7Zw{G+DixCH9lO^yBh%v zV1P7g7VfFDH9wR42GHoFR8U<_k=3KZGXM6wX{8W&GlsGXxw6hqL-jkxU>AYY_t0-hvU!tbC<%6|qYZr2{^cw(!JB z7%>0_nMaZ6=h+_+O<(*$sPY>QlG4G50MYye0McQAzzJv}W595xqzu6tAI^{*OQz#g zu<*k^yL!Q7fYS&>Q9uBIfTW-mj(`9GL{`so97qP%@itX#zQR=D0f1nz zgux6TEgIm4d*Zr~C?k9h5F$FEAOtA8_QV1)FqE1FO@(L{Y*_J4(ng*TmkBpeqGk0a zK1GLkKq|{h!TkW_mn7cQdgkpSfmtGd(F(5pi&umPM| zotT~QA;mT_VA+^ba_o%;33v#v%Qmx#56_hQ@|QLFz`TNg}-|g za+GWl3owPiFn}+@UIt=l^I3>k?9uH`^pwH||LZHocN15H!wlK_?7bb&axTb22}PnJ zAYY*K*p^#1`Eo_14gc(8Q7|RKs>2$bPLq6q#Zik=DOc&I6~+M+2m-!HVU`$SmKcDN z<;SG}otMC@XH8lTsFgkpWf%a=U>Srk(kvQ+15z>ph=3r@>(=r1#abm0`vlyAD$N8p z2!0T#&6hSa^;@Dp!ODe%x z@oD{fWW;O?S9#`C0uF*I#1k~G$%rk<9qB?TmR0?|I9al%)bU20zYazvRh(O#44g@a z3W4d*OzPZG-1L1~7I7D1C`m;kpkWGWBLrB$00#gjTJBm(<=N1!Go9*wFjW*Kr69B* z$ngkb5Xv!t$bCD-Lt+GSL5PEAzGxUZ2W9nz3 zIKjTdjz?ae!~+!iU9%ijy(|GXMY%*|`FFAA$$~00Htprq*E!8vy_? zkif*jsSZQr?NnlL164GxphN5!vxT?(t^z`HpA}Esz(jGN0i%WfAkUZx1qsJ5B*4x* z&+Y7nTL2bdB8fmCgl57Igc=?e2nJct;ZJWp&v^=39|)G9Ce#+z|J52JUpjYgO!^|6 zm<|CYm@GV~*~nO$0R3tjHqZA(wH&)BF+qP!j17ZziEvP+K^Wl@?h!l@)I0+=5G%m~ z+x~`wETBTeg{d2n+Vl1OcsUU`SP-Y+x_GN3YFHDWL}vBZv?!B@~j{j zMZ12Ra{%;gUfwl`GXW!tplT&-Gdv7*V$kB9J1u^q50eGGykZ>~9){dULK#GyOg;CN z9tK@#C2r0TUee=d9Tfp=g-<~lVH04YPQe1jz{PVv^2N^6oUW^4pIAWs6DL1gT*#jE zEhW|lma?#8PBI7p002M$Qu!c(ka(Z~0RtTu`5ZV8jYI+>3q<^jB^wIifQz%MGG&7+ zNr)oc=yp;yak#-_H+Bb|rKC~`Cj^JW1%wwC2tE)D*d%cD$VKoE%Ic6-NGK#e5q1%z5f;`E*dMW{b8!eb^24(df}n?C z0E%FU_W=N-9iRd$q(nTGX3}TIt2GFj*hM+v$Du5PF(cBpbyM7hkQ-q}Aqg}+LSr{& zAOKxubw=Hht>YIMd46iw_kwnxl5Qo?L*Q7r2hL_FwWVb9m*ZGGOpPOvEfy)H@4~k^ z#Z}RH6@!sZn%P7WMIxeIRHe+9t0qh49*-Q2NC0F?>MsrqxW<|uw$_yTSTf*3{Uz-K z+ECeQBWV$27yhgLd*zUEJxDAugMb&sBTm%rSMZw=1CT`R!mCw4c zw^|;CFo}sKBw!y`PUNqWpx7%}*16wwU;DVpJ4hPsA!=C5 z?U3Nbjl0MVF^g=$(HtIL8eNvY5?#>X7THKba06r`@w6u!VqnXdGBr9!2Najy!}JQRRYscQhBv57D|V15FMUF^-apoN&q zcht;gG9&(CwWUG_U{SKgl&c#GSgj7R@l^mxYA*o*GHFw-{7LXIvwLaB{=W(1&~XL4 zvhZy%Fkn}tOQHsxI`HZg#OxL?sLut{u>$;)A!9zD`-l{NG+TfN>F@!wu+FjfcP>w z<4mG_6sU*1MBivl!$Hd6{isB?0yNizb>4eLfuUaj1zgZv=Tqqh?v^Drm|)1isfO*oz`sM4Z%`6&$R_fly+_T8I)zLYZYE%0g1m zq*>P2S*(E}6@41WfP@HyCTNi(6j&vs#U&YF*~t>*sHANqKtmIHn5^JwzfrZH)hHQT zmQ$r-5<(#(5UEniMOC^@5>qLXO11SG<6G)=9c?z+r>N6OoE<9^E)XWM1r(%0C3aZZ zu@D3;KPkA0S1J}3R1nD~zU13}&qXKDPL&GhLKM>17>cAqliIsY5D3MBYwT3ZO8Wrz zhX!9P~(ojGaT=UVu8 zBDu`FlVCBSCdG~1_`-ZqE1z#@3o+-X!gAVfVg2N@VEiBQzj}TWo#E59iTI)7kv`%K zL179gZ5qfT!(D5oda}5HgEP+)9!;D<@j~KlV+0;EnuB46NM$ze3~-Trk>g>A8W}XU zN63r|5UIYBLD$(;bnaRtP25sa$0gkwQrQ-RSiu5@VZxAkiaIfi9%}-Wl6bLtOmnvt zQI*bxz3_=L8@WY?3umXPr*e(GAc|;FBw@RN8{`Q$54(PIv#RJ2*i@?&aUPk78V;xuHp?L zq#Szg*$-LTSd&j*eKu?~cHo$#55c>4!mPQ$+9^&DQEE5M_8dr#GYyvfFp(J?JR~S- z1#H6@k_u})By1DmS==B4gi#Psnk#m~0wbD+M&j~b5p5jHoxX2{HHVQJ%QHU_gpAZk zux$yR6FcDMOAp79MjTG5VJ+8!B%0hJa?+vXeahjeTr$H`8Zp*Jot3X)XJ%)D)W&TR zV(yr+U*O(T>#^qTh%ENCaGSj}#o$?8=TB$MsFr=TJYIMDA6Gx2O6C_Jv9_zL*SG@K z=@i<3q1QxRDd4@4RXZ{A?g*7qh^*_y>)v1=#l1ktH_uZ#S}PZ(#2m>M_07y|86`_6 zWTBE3DJ{YVVWA2Tgeqhoa1<7WUvS!au#AGvd#7pbkCvWK7CbIuz)65f(^-V2rR5t(Z@A9wOp@c7fE>=^zV1 z$xl&-L0k{sK+|b?6x8%s9HL*u4ph)yPiMs6(xZZzc$5v?ATak$Seu+25~gt1heEmT zX&)?Qbkb*;%(j!v;Q)rFhO})|m>eK5XqfQG$g_M>_43T*g}PQvfpfYF;#fEb<+5hE7KyvnJtUO$O4N|eaa>3um{u#3P9V1^ci`E>)WAVvZNKwGK{If z>(Dx_14BaQKwD8*MPS|?VXn@He-|zbF4Dr)Pl)P!IJmlb;TO!8>HxN!%+Lr5$B5_; zP+9u(OS861cP%8QO@?xx*-XDzqE~1aXqBw7HhpmD#$so)0vup+075}DjD%6^B3ee>f)=PK z#&&oY2H=rrt~QqHxQr>7^ji|vmY8*kVG$rVQM@lPa~_hCN?a32)Fqyq(>96#oJA;$ zNCRXHq_J(IdDW(Ax*~?T1zMG5l7rw{l~zm`v@2p(r9!J_e3)iJ$OU#l5ZWj_5!%bb zVN|1q5R;fyO5&ADoR~x`l(7hh3Q4L}BvZt!ic)~36~>3U8nub*I6xpe($w)Z?v_k5 zo*J_^x(T*vJpwE{fl|&~TNY|-oPqU!Xq6=N~Mrjw90Zpqe}?c@IGKsL6nRbMJ%AA zmN{su(&Z}Cc>xJY+JPu-%WzUpUW&zSQucP%pTapv3S!{U4~-VS%SF80IrSrnJ1=0N z&eaWI^Kdvxx1jF*+2|&`7M@UGATbA*V!Q#b1ZWcm+A_l5I-@Dq6iOWMTsyOzmwHH^ z056-tO7a#)dxRc}LP#PAjLe6s^n#6(iLMZ8Yokf-H#rPMIX8CIVSL(PaC89)2tbgC z!;IkETdQ?_!{Y=JV#qm|<#RS^W?~2+tcXB4fTRnlVk#+ENfzctMss^>T_a$aAk_5m zNux~)$(RbQSKr1?>dL@jkp+YX;Q$b*E72w~VN_o8yP?A~PQlOBy|TnoA_CP0qXcbr*X9E;33U&+L1;icV#9=COtm~Y4@y@& z9L0nbGcfLQz=T~(I+83t3M?syAmub=at_dLkRpi$7$iDCsRAoPA_f1v>ZHoS|CEr(%YT%DiG|3QGU;*so3j&C(EStEy=!BIZZYb#v9VAtqoLDFd% zLPRwa^MxUBlojGbyzEK@C`z6&B2IQOiadVeQkhIH4ig}x-FeNcQQBobxgTA*i%B&u zlB~f1y_F#Ei&fdLicOf6tU?81S)BHap(9elY{3U~tGO z1vnkJ!2yOiaON_FCEQ4A-&GWfowVveRB__4BOsd^jX?oI99hf;v$Y{htTa4`RY!xm zBt@zq}ZHu&~;T%xIk&=iY6)@*Ya%Xq2A&M7_R}ax7yg$Z?lH z2ZA^}#s~yu@OG__Z@x_Z+R!S;WLiWJV1jW3l?w_ID1;!Q>(0CnQ!4IPSBSDzv|H&K zZ{JspbZp8Sg9+j>7T33%Vp+Hzv}F+u90ZjpSRbdx#EHwZ!^H`!YGqL? z-K;l+7SXTLlGF&`g2av{j}MB)$z{>s2n;?fYBylY3!fW;MWem|TRBUy;RUs^=BF=L z*a%>SBrNfqydT+_$DF|lh{POdijFfJQEc@!C`B#QgBmH%ybXW_tbBZtm4_aVJ{+F) z7}1cUDsbRC<}}%)Et3r>@gN4p7T>OlPMqTBf(=x)X;wIi3&$LqQ8n{JNQ%ID;4VD< z{0~ae>Gg8OTE{*D67W@lgoW;5h+I!vn;jqnlzkVH#>j6@Pl`e|3sP4JbR!1(#}YH} zIFeZ^e-bk)TJVEN>O>BpGJpC2Kppu}U)qHfs$Hifz2buMGY}{BLu{@V%Oq%fusJ6+e$K%E(P+(LaYJFQa}t zK><&}T0^bkdq(OTcRqYy_x#%iz1*W_&g(PT%Qc_^We(l&E#a~})wL)b4hT=y?pXLtLA8ne5e5Hl zV~=9~F*;hZA&4Ypi{^pkmDXHs1ayB{CiyKdWq{{hWucspY#{M+-fq$Wz|~)4&Jh0? zRB({sgyDr?XoS4;7jnWcc}>P*f4N>x2PhSlqgEun8lK@t(nS^SH;bMl)`tb2w6NR;SJ4qr0aO7+ zKzN7F<>7m$Wue{NytF)cxg%?#YcyFR#J?nrxqm%q6+5X8%BSzAq}bZDSESnui=PAD z(mYklIQ>B-V}gSv8-HIFUq@ux^At^8C2yi&~Z^<2DE&f`BjZD?|`cL?c~71QbFMVhAiqu>m_3 znVh&Gu`<>_Ra%a_F;)mZ1_4GaWF$-sK?D&;`6OCDJ#HfBJ=K>>_K9LgwkJWpYDf0p*0$PWvI10VY*$>DyOicXK0 zf)N0Xk>ocrxQy6}*llouM%yff1$}XB2aT4Ju;&8}V-jYAlQcX?J&`!|ij$Lr?H_GiDV0r?!n(#vvJfng0z)K=!q1|+l@bmVeVB8cQ)vdK`Pk!sVi*y!ql^!3Oqp!R@?TiOU+`yr~#e-IQ{;&Gqgve;3($-)#5jJC>;i|UG}N(YNgGoMeM1PbL5Hx z8kEE+3nF`#Fi|IzMh%rCEvcl~C`iSq0w^S$swJv9u4sruxOI%i>|frI*T$yWU~qz3 za}QtnXuCtOLK7z9@;5=5tZ0f!T4DIG9VHxnkAxBk7fwn)EB@MNHDRJirFzWB%(8l~ z+tsU)ZwLxT9itZ780dn!bz%x2f{O@%myl@B^GC4362hhbcZlOL3T|{Z4Z1H?0uvNL zeu%c{faGL>cJ#E{8F&s5(iS+(Q6ohZGw@X>fP~qmMG`4u#6KtK>+ep^in(0LNO1Y~ zrjtI`%L$mVjZR+Cc&PAHWPGeP5Wmhy0hW#r(1u8dJZDu*>rDfj9&$oprPchs*Tk-` zc{sakdg5nB&)>?i&daZVK>{4c=&>viomp%+q3X@^J0s;vHr$G8|A}taQ&`%JPf1?| zX(vXT_qW-vHRA+Bf_{%E>~KS6h+LmXUF}2YZ+Qp7VDVKGX{n(hhl)alzb%nxp^7pr zc(4rIr-?^Sg>uHG%Ui;8J|W(MKcvpRzaxJu5WuiV%2}we+t;kekmzH-AyA{1P{%L6 zAYW*tB!1jUH^^c|5?!y9&MELe^`D-s2wd8`qO5#cHQBHHlE@+#iIt-D7Wzglx+8@I3niF8m2^R{0XE|MHBb=wmUC^;*|Y-*>XM~@Or@& zF|%hR5ChCsH&R4nbzpEo{^z(=gn|fJv6K~Sn;dzUn75TSEl(9|6(42Ur(lE3MWvQI z#(?B8GD34yq9#gOLdO;*AL1Bj@bJivD;DL?LqCC%YdtFhe=96m*rb$Nu%iX5DX58= zwxn{wv<&Z9f+|2NY!Et%g+DBYek36LjFCwYRbZAVK?$H|{Srz6PrZssY6zuEQPE}yg47bl2(KhAVm@L}rB7zt+VNn3 zy*FlFWwwRhm|_GfAp~PaLX(~ic_2Wgi(s#7_C~Cb*N#AhPaIL!AqkcWP`4H6|>n?Nek_1HB;-g2{*V3R5Uc3auId^jQKcB+k%<4NApEG|itA zb>wP=b&QcGCRmYg@hK_^iIStCVQ4y3frTBc>nWEJ;3@(fV9j#lRU^N6jVr9t|bcC8)x;_yxJI_Q0#lXce(#_ytfMEkhQ*dN(GqT&1(D9-}<*^4XDC3VC zd~~SPdMyo)ga+nuMnj89rYH68jn=?0fOV={lsgt-G2{4e&`7zgRTR_*!=pAaks5$z z#u*twJ@Yd*LkbFjW@c&&T8vcy-2qq^XWce35}i;~3nrj`zL9yKnX@bqPBbqP!nUqI zET#w?5f(XwjLpFaN1e^5Q!_|Ss|f^85_{c|_?8T@X!yFJCneOu0fHCtMq?0BV3fl{ znQaN8i`@jCIBI# z8my38uH3Cbo6Hh|0-IJ;0PKd*!lr8oomfj9VNe_^#fp{cSi}{Xj!U?a1NRmr8qgcC z?Mo_%Rg5Lo9h$Rw_~PUpNzfy#ZAgn~(rgtPdQCNLw@aFxCMkTXbm{-9Hw|(@)$Vm5 zvg?GF5Ou5&O!z9PnP~RFA+ev$$UX*Ng%om{*cL8ojgm;uoD2|10fH3~h;fjTVs~Gp zSraLa?${nC5IZR&k3ZH3d|YLowzUhc0uLa_U6qMVukPNY+5v(g+#tJG%*{oMd;fcB zHeF8i#4(%x^Qt$;8X1w11xcG(^UgEPV`3d0Em9)@67VJgi2&|NAgoWv?H5xX&_XXq z$ivTxf&=Jj?#L|G!2swWoqR)LlceOtcBsVQwl+10ut>2nW(8c>3@Wz~u{5PA3t{gP zl%xY`i#j?BV3`#nZcqY-wUX^hI};+7$19YDD6cVtHaua^s4lVlCLIT?6Mb1|4ipZ8 zwP1&fmAO|{tzrnY1TUy@k=ZZj3d*v(-&c(btI7gbQC;3@!1Sxepshfz#js$+VeAEXL64K zus{(vFV)9u*JdpX68`gm1Pf?~pjx{@E7va_0G`M8`m^FX5#(G6puW_)LP0`x!T# zGDKSsTj{=$rN#7j-MY$Dl9MZ4+Q-|l z7{K4Zb}3fy=H_rg%ZQD?hn+Y(>G)>D6(pa1K#2%X5!J$)7=hhj8KWSdTFt0j4AVd4 zmah)wO@noSq13y#@KQrV?~ zIj28%3u3ooCS7lbFg+~}eCtx~LVluw9}n)TqH>oV&Tq4m;GABHgxl&l((D(-EYV7? zXLvIt=s}|ol|~#tSKTVdd#oN0(crAaRJPL&W-RT=JkeR616~%L0_&HXh9gl-Zoaa1 z#;p>;H0JB6LL!s)q@B-s25ZcR9*`1I5$VQP{iC-0M8Ya#s*>5&X(Zu9uW!l5LH+fs9 z=z+FM;ET-3EaiQ$MI;Dx8(LlIDHJt$h!;IQwFbjiY8mx4CSeaS=|Kb4QK<0gG__mM znE2NrUp<#l%b5Fn;hoEGnC2V|NE$$*X9#iT@m@vg$Ba_rOnN&j{Iyw5T)M&qi!P(% zPL@u(MVIbW!Gz~w z>>+AmD!9+B$8xsNAc=bU-WQLGl)#=EA^USy@zMpr6Q7l#^uUMB8*64~DF6|FN&Odc ztFjy9jv*Cv|6fC9VosBF7FqM016OC8vLoY=u1Ty-;z?uq$>+xu<|q78^CK3zgElg= zTj@}WKb7lLFja(z+8%sXa&@8ovx?rNi8?|P)|i*tKINE=$%&2(NJd^Iq9u;s@=5nE z38UZd`BJzzfQGNOgE*3z-2V#rpb%_Vti9etEb0vNnT>vVZr33wU9n!P34A7v&3DkC z(4CCYT@X}&@C_WQ5Ok5mB10nH_dh%jD3*68rD<(`1^eJp05T(eO9plyNw$Na1E;rz z7xPUUzk>JD0SSTOtQJ22NRY;;cW@mn3yHr1MsP++HNugnfYpJ4_xhk9CV-^1xm1cn zeV&s5667|65FD)2B=gs;{)sZUeKzI(PtgY^(b3;#co5obdJjmLwZCaGfc~F6FYi8v%r3x;b<|FlvBj})F2xCZ$G_eD<3lLnXo7l;Ia>4y=4 z{P9@>9QjEhV+vpl2OvVA0nmWkfI9$NBoYDyFz_d!zu%}WPzwO}g#TGj{Ga+^3?tIG zaCA8MzfiLP+;)H?6f_V9Nt9633P*ig*dpXnga>MNdMp`e7zmvx(Z5ag2p~Y7rcwC! zw8;wV1V>KlNNFrSE)r=h0zktf{XAnJ01$Zx+-D00jE@s)1AYu2&k|4O%K-q!GQd>9;f^&LpHqf-3IUbBC9J zOgFfwHFAyPbJT>x18{AdK!m1KPeXR8WKh7?{w0`oO`3Bc;^ag`P6zz_uZf=>)aT{> zXZ}B%MgB7nL`@yO0!~S=zhTDWA+Rd>LQ4aEc_l8&>FWd0#D*aHfxkq00XTE>_jRW0 zao9>nAZlc2NWj05hbuxcWiI$wJYY3|g!Qu7*24(i2Bw7U`r<1ca~Hb5?C^ECB0ZdIS;k-nN(8*mL;P>6%;>Egb9IYMyJ>&sc1s1}7kfcDD8n zai#N&UTzaWyG}tCVQ&mRnQt=BXN-{Sa&Ft5N4PDxAg+#x{K9Os!-7!7aK+K*8$P2EZjw zw|7g}a%IclAHr~vFhQEknp6^)5cB==FPo6W=r`ROQ-TZ9* zva&p=PJN%rS%YxZ@?e}@NnBTtaT>vydd;gBF49BdXMoalV&Zfw*(x*1!2Zto=_FeS z01)kSW3m0O`2T-?`cID{5+;&A_rIO?KcB&oN@3w8lm2%B07&IE*nPUy6o`N6r0GQS zdthW0p}sMoNHRH-I*X{)LUQ?tnWPwv=U>W=0vC;&$Lsg~4AyWlUHM;G)cLfCquKN1 zi<0X*L#HWAgJN0c?7yrbHB6dufZ)YQtq*sTqt`F{% zf`(J=MhtkT7nX9nJi~rfsPW7-|4oYQt36|b%%4rbt(vy zW)+pGY3K&l)nG$7Cr{6x)v>s;Oj!4iYdaJJQ)rXBqlJ6WWPkUWW0U=Yx>0YxWMoKH zpKyKZ#8Ll+L}HkYmve>yKpG6E^Pd{nXoB5*BFXzPh+SxMZ5R*eBw}(vN&=tDI6K;t<+iSn6c7cm#f}L*^+xd5hY>4xH{RA!ff? z6Fbs0(B+mMf)gwNfS7WVoF!|Y?Ph3H+^7?9@|1hjikR}93jA20Y`83N?8!F$T2^ZU z_DFm`dRD5Y>Z->1+W#FX*rRl!m@+G8@8G$HGbTmAwig5A=|Z9KuiF>f`Pi-b?J-hje5@Np;yi%WV!{IA-ugAn@RnRJbUAO_R?QWM{fuUb- zy~__YlA=7{2>b{>`BH*^Utr&l{2^$o+ToaSha&NCM)X~jL`v{@{@59w5#g)TmI55^ zHifTo5Rzc!DIu$hz~2p-$r_I(U_bS$%e!`t(%f2WQkYA61Vn{t{luz6S4H}8<5&7- z)pk%Q@B}jz-qMP8ip_C&J3-lQ5tr}TIF1^GripaLvBh*t%zTccDK@q+lSw=@?P3YZ6p;<^14?nsyjYMO3|>pyTmL=;L4FRw6Tl<{d7 zQ{(URvx=)+90&`S)Zs)?4W-S%Z6_TMrw$?Nuw$d2a6U7tplF{hZbs(dlOdVZtxX-ad9Zs2bRM?1~SJ*DQ*Pm2EdQ>e1Q~d z@Zc&U*wj<(IX3nCWY9E9UB#_uKEj30fqhyUPbUjsv7ogp;lKy-#Ax|vNvN$eCQ(i< z8@5ifkE(M?ZsDbETOc|GtFt064VHlpzaIy|k)e5IvZCQQ3VfQ~g^vg)&62FdeT?=| zZ!L`@zegI5P|a0A?3s2jKVdQ&j49ww*bpyW$84c*&IXg)Ce-!uTHlD@VT){l-i+ck zzP>=D9u)W{mD>z`e6Tr&()R; zY7>LMrXL?xsLdUqcJ(0;p!?6rB|dsS0rOQ;|NxKR53KcU)y>6 z+Fe`sLhfpY2Kr^Kga@EVY#)&{t>lGr?bg1wl7vdMlBAD2VsI$}6k&CvPF~d`&n#QPqE`eht~BnOMOsqWE)vMSPm6I>fJi*vh@wvx zBfEMG$*iR$5{+V*^gw^mI9{cx^toH2rG0Vd4tn|^L|0my1&0UF5JT*o9KL<^>0~6y z>Sh_8gxb7>$(_B0l0}&6{Fdk3k6T`%e)j^EsX~aw^rL4O7K#6YZGO8Ug0Woy_0EU{ zF@A(m=UBc0z4%r59cJ`XspED|E}lFDE~w~T^;%AN_}2!uw8~pS0Ig-=_23ztBjN20 z#SZDw8|-#n{*tnF2}QIQ(3Sv}A|tgo4s2$D$nmT#J5ys%r7$fU4vYAWJg)I&-E5Mw zbPu!l-8qgUMrmmC^UHaMDX%fi$o~Dey5kpb6m=qGNZ-)$?R{EOVp`{gH-n707MJpU zVPcEcw`sC1nfgJHyYOWG&i3c)-HzertM#yiKMhCkqy+WbWNw#6DlH;oQ*WAE*3uVS z_T@$A;`@yxDXt9dTjMnqunv2X(Cz^Huxd0`I(N(dvT9SU*gg}MtxfU0FG!`vG}0SO zmm-U-h)RcMt!6(B<6Bz=W+hKn%FI>!o&2ILlXqg~OKM5X*W1Hbu_?Y`avgL;O&|IN zM-@cbF8y+8yA+Zrnii?@v#=g9ckdJ|_F>9=Y)+%vW6CbA>AbXnc$%0 zAI>aHPXNNv(X*%EP|mBW*rm!?Bt)B&%a*AEB~mSB%k!bIiYqKzB-H8D=#iV$tb-3? z8J5%ykEB?XKIIpc#nQ{N4%I*MFCc1b;!AW_lZABhv}W$v=LH27|LEaD ze#9s@lPuLAKwecgGYOn*6I2bXhE4ZqzZ>W8p z#)}r^QeCQ=t>rAtWg&x@Icrgx`!t-H@lB<=#EUopf=9>#Zb63|owu9jt6NKv!-uJSeG|DZZvA9n%L0FKnK7b zVPK!j&wbG+5z7HDBI${<_i0c3OfNP1eD!`pc3jE#pE3;zN{f!kKPqt1QIuhH-{Do; z81{a`yeE*j3g&lJ=)}BK&C(QW_wDLMNLpm;J~Nwp#C0d+#j4t^YU}trcEnMqdN=$>h5$N1Z=(djQzkw2W)+XnUO>Qh=e=(r-AplOAb;xvdq*E~4Uu&;)~ zDh%b$I$nu};*XPR`dnh{AxpZjo{*?SHITspCs#p!w^n(O%=d^X#l27-a_88SjP3nS zsCF_B#JL%svj-pwAF~C72z#6;jpyKJHPZGKtmS(1+i_=U`Hs4w)HLT9d}Q+!cKzTj zNB>sZ&LzdrCz|W)qcxmj4cFyXN+#6n@H;Yv0F*TuLwDB8# zdHv9ise~KZ5nuL>shj8(RY~g(=)tXWl&s?xir~e4U*_}QFf|7$%d9vpiR0CJ52bI{ z&$faSK6HXJYJ(QKjrvvZoGC<;#W`|QXGfH>R=28tO0?~&25Ji>3yvA&=zSKwA zuF5XpXc-dqPz~^xM1{PHJg+T0jnWlm&}Bpdp6-WT%4^linja34n-Vvb%PaqgD$?F|1wjK_%PEni#Xn&PU8JQx z>20sB$7v6j)TyPi#>ltmv7-qJ*;@EJJ3%RCK6~I_Ma0LupRT{kTgWS~?e2dkq=JOW zSUqO21xM_qRllZo6Zm>3swCaNHZZuUMStFuV$qqOn;s_#&PCqOmV~(}T^1o0QcBKa z<5QN(XUp0*?bbYL>~sp)vWt)I_Aw%-_5Qq5Eg;w$&hwV?{BEi`-tmoTazWi8?yg|Iea|hg+AuJi54BQ*|T~5lgXn z#@f@%)~q9`mbgOJYfObb#V6bfRF4t16gTdC7IrV*bq&_$tA!fL!G+pBZawxe@Ab*_ z@A>&|(&kkmO_U0waVg}R*vF2bi}-i~{Il642CfM~^j0^Jw&;-McPzwTvWFHQqj zW0aoeEz{uwZ}Aw3p25heB+}a)2=#ipZKsCsI>$Cm(Wp@O$GI=nB3etiA~T8JJzhxp zjlHh=e-QRXcl-L-gDWf}u!)3(`n2woMUEJ^_VD z+x3QI`X?rPt|;t)l|MC>=1r`dRH?T$k^x7SbovFr7IhhTM(#dG822OSj-%I_CgZZ`?)k zRI60iIy{ynQ6oPt<_YOdBcJhGH%?hj#Tv&Snz;(zms0KiUA09R1>RA+SWF2s>da2+ zc+@S-`6l`SSb?dfvm-m*`f7=`G}AvxBdMMmqcDzos|dZsMY?~R6UUTgRL1OIm&5+g zQ9kpaqh6m6xf3F+a41c!EQtMRz(<<@nVu1ufwJBl`QoP3W|!~mB(i@zqf)4JO)Y@+ z3Ddj7dkYjgT9@bVAuf09@>J6I4D_;ez5jzaFG9fYXgg&_-|5Q5V-hB#98I zaq3VzCXaoIZ}Fa*>zAiP>OV}Cp`_=KHiIH#hSq3qCi!jHJT6L{@KNLSgH9OynJ9zzsGamMkh1JSc&mnN=^Kch^-H{p+V<3jl!u=B( z%WaFT_iCYbFdV6V#Ph?#s{ti@4`xG(j*_2_^mT3ttS3S*AMNhHe*+hgKW=DZ?ak{0 zU5ey#bT|x$d)YC9-#hAotB;BC8iS0gFa2{Z_YQG<53-=&%r-+|`Wu%2=dZvYT}W^Av&T zG41UwK(|;rUfh!%>Wy!wkh*|M<+}dmNqX_HaU= zBQX(P3g z^@_n&Hendoo5SB>qpi+GE!Z6`zS_CG`efgY6^uI&x_i@V8|u`m_Ia8T7Qh)MGe<}M z=?t~8h7Yqah;%vfsi{w7#&2cf3DH2~&)EL^q9^MVus`rxgcjpEt@OHVfLtEWEDrk1 zvkX!d3wq)$Z^t$n$@y@6km)OBu7>>An<(zK`*6l3!o--Y*|n)hUg}spQA>*IS=t4+ z!EXBZ*W0tLoiZ z7VC0-;ITIxjA=gli3SA5&c2uhRA2~m+Gdl~g&T&4Igmztcft~{mWf`uCeRQMo>o?F zB*|NLpkk5%s}{73JnY>&Vmf=HND4=wYfhTfEWRP3F@XYq4%yj!Pvtr;U1m;skuc#2 z82zH042eX%!TfJ1xg4y{*d(1JD!p3GGwp-edX%YrYTHe>%q*0+_JP9trmy>HpYP?H5v zbo}fVkhZrRyWMvCCvURkh7_B;)yC&^8lgft>=-H)FSfJ)BFw)Ig+MO^` znpSPbem>kOm@+F+_k2R+#|0M>x?nz1{iV6sd8lWD`huFzgjD-CkT<~~15i&vsp$6g zh;W%ykU)WyrE89s+JvSradpn!uiac^w$y}_Mt-X*Y%dA}G#%jQ0uLGH+(a3x%K-JX z+bauc=e*ALf%A*rh9OHU8q9X?eQqs+{n7iFrB>rVF=m-aKZA zb74=Ua#AKTZ2|l^Viq(4(nMD;{E|ihpL!evPvlL+>)^FcG`;#@(bfD=l z+a8(Q9m4KM0c_|W#P6jP{A`jLC%}W7ry%RZ8+K@SjPw8)Dc%-6cPf%if0lNmUvh&G zQZfD(>d?0!84UhN9&8gUQiee!lCgU!9M5YVR)696F)*cA7}}iKJIVSYud9DRT<-31 zt|+m@$2&GW(i?uR<2Y^j(!v9U|UICxcPt z0%kiNVM@%nmJ?!;3lfrv+9E$RSXr?4Iyp*KY`4Wzh%lU!VL;#i+v(5Lc?77q_A|pE zc`|fpi`-|x)$VbAu_mRWJgmze zm~9TUG?A^d0wkt4>8zNp0t{0JBim=x*2Dcf2nVwan(fDnLFy3&HlNAtwc)+gkCF{6G}Rd)u#a>-hx2U7ADEPPx@z~EFQ zJyZsa6ztwR>a>7CLDZ)%8kgbJuWTjxZ(P73lW;HfU?I-8fUCE2Pnfz~q_$bDE$V3J zz(Bt?tnq%hEJ9B?;q8qV@+M~yu@r66KBWQ(@sJ+Z<}SoH z)xN}hXoqJUq9nseyH3$Bf!qJ|ev*o*OMQVRVi!93cH+u>`#3)X?a8{DGp;_t3U&Jnt>u&4y_XJ$GCAUJc-mwwwR<{SQv;)QBS>#9s^?*UF`3pvR) z5O{(sH1~A?DX<9Z{d~&AD|5ymy*_6RvS|5hx?17Zt*&2vL<1GK;~oMkjY`!tB?AHHrpzA$rc>fGr(9ttUjA{n{eWqqAD@41ek@MyBgZIVusS7XLiuj5!CN<!sL@ zac1n9vWh8HxnSAf7zR<}&KW_Eb`!2GVh{m<6sb?`VGE$h_u{h0<0jQ$3@4+Hp_blA z1tHgsR0a2i#B>s((V-CaNn2M13}Z*4ju+aZ0Y&TAHPi(66iO+%B!zQk0ayFyp#(?I zE1#Rq3uCwrA$Pk(EOM&byT?gaw!Pa)JlS4Ked(6USbf$5q>>1@KTH^yLH0Ddt~I>E z(3TmCN3;nq{j@0UDOnMVn9$?yxabU&3NCDDEoMYzcdf=Za0&-*98Fjv**M$!x5G>? z+zMmGk1^i=_E!O0RU5U^vg$|v-8XJO)lKu;iMWD^M5jr;CM%E+s|VBDcIgfBeG#3V zm=76*!>^g7;DCzzIXs$uu*#|nGftwkr1GJ06a-|WvFoOgYiqb_JkkOY7A)f$X!HLTgiw~?(vU~iyhm>LTrn_Q&KRf4RziXFucM{#Bq3NdZ>d8h1V`XKzE7VFW&mjS)}$XLm@r;4Ud~PgHMOp%1A|VPZLpw$rhA|0kM@|$&LXtLga$LqqkukcdTvgV3GU;IiU>ZD#CPsyh z4*V(sVtm9)z*3zeuh?KLrBl-mHAS!>7_rTY3|Ey@pJbF)pGys1BEuM_15-&rOpzMO zYLAG5wTn3|BGt$uWlR&;(Gvn+_6ieSG=nOo97!gO#N9C7U`n~2?r3pUD`c%N5w+rv zi6CJH4ixefnF=pm)&=`oZ@&_2lVG<9vgfJ~1`}%sCw7$qc-<;8*}lf^{UIySoh3=zI-PYG5r4y`h|#%9dxkJJ&)AXgI? ztcmxxB@}I1P*J^9IJAJVW+28YQz66kg)v$c_T4C*NIhwmoM*X%bL;3vTcekh710@s z$G~BDa*x@ZLV4fm$Qwy^FyA;75X@nb;`r@Op7Pvqw;w$I`{JdS#AP^PZj z6Cd%iy&^o^n~=%zWg-*_Ynv-1f|c`_P`HsS8G&R9IJVPO=al{amudjjQP;sy`E8-S zM1c=iiit3EK+IGC?HB{GtV&^YfCV@9Fv{p#%7qUpnb^I##Tn0VRX@NPogMt5s=V7#wK+VoXVhe6p8C^&Pb2q<8Ah8uGBKwt0bC3 z+LX_W$yKkahMPu`w;xIqLScGFd?#~u2qA-~TM`0OgvX5#Gz0SLALJno< z(h#?upo>b3tH@IJaqfD=%9b0oD`wT+M(mbXd7M;mqnJjxF3rA{@e^w@!s28Q@}g2` z(f)|Ts)!RH+2B(CYJBB1C*V1y35@9K4H#f`)m!)o{)jFkyo{bp#duKLrnAndHg@G2 zSk&p4wmUU%Coc7~OBKevAy4BK&^Y0hCDZ3t?U1N2M0wrJA=bzs z38E1QE6QItEzEo-%iKga=0Sm2d<+q@0q02zgQ;~17-mxr8}X!SFi`Lj))(E=fLj&{rbp#)F1KzoqUpPvjPt$6pyOR37vnD9YI1S14Y?ryCn=w^w*k8yl)C3=4W`?zERH&)TV!hB-@!~W`v}3MBU35w^fiUQcEtUw!pR+`6TR0Q*|pKc|YHeVw0Q z>(|lEr~4SrUz5PyPhr@vnl%FDrFl9Keb%Y)F|;~U+U8a(cswx>KtP6t)*q=AM+eCH zc9>?ZIVn+|SC>cW6d5&`QUz42bZE&YeuV!kPw`6qDWMvqBo{4FLJJFhaDh{Fs4i5R z%`msuBmbb}J}G?iZ51-G%a6U;gYP#T^H?JAFC)5kJ+%hI3`lN4`rnQ~N)k-P&YB}W z`Dh2|*AIs60~M#C{w~1}(^$)!jq_-i*X6QAQLL~Ezgbp8*17<9qEF0Iwr}G5*zHs$ zdO&pc_!|bxL$P|Ty-M2b3=22^W(%@x>o%GJ0VozY`uZyun_i&<9Y;YATkcJrCNJy7<$dykUMN!hxma}$>q$WwnlI&8(CFsnqSrMjdt2CgLKo>%+QJ9M(KP_HBH zdvYg(L(RdyyK0R{?6XF0;h~pdtAgm4-2TmS`U!;FD+?@d_NDLUiz!KAxEWS9%Q{+L zZx%Eu-vVqn%jYu)YVK21EJs5M2%4zsa1yA$zl^3gtf2U>#DsO~H_Dx%d(gl8z6!>Z zxTZlx5!>NM7zSPCU=_##5*!LsUOE! z+!>P{g=3D=08qz7J>UY-#0d`skH9m-81_yQjXW2bpi_F}gZ>ZbbD(VH_V<5p4MP>m zL?1YNWqfoFBlyXoGTkKlYZL#VU0*~UlxAtxdW+4_?h%C_bx%M=!k0tKj%fm}>PBXH zy3&ocZ@kcT2g)k{^aK$p)GP3H99#(>wVx?+0jte_*i6tGxrO|UL%YK zOqQ$pVp90xS{!QqJ?>i92&VE0Hdp5ySy}S(lyl{qBwQ^&c@o&++dorn%qT86nSW?M zFO>uh=BT;Mc65Kaz5U8pjRGqlS0!Fu_0N}De(8--R)b+xSZf+{aaY?ce8BF3S8mb} zQjDdI{B?a7UCCbRI72n#OxBszLG2lqcRA9+OK8F#0O-vigf&;Iygdn7ExK0?lAv5`xGhtyLjl8g~DZ!bFSJv zg$UELU7c@4``Xv3Mlm_8sVP)lfc{ZqbL?7o*!S&9o8GqZOw5oS8BIra3#+d@^SrB? zgwa-@`g<9xgx1VontgjZgA5t6>Y@W^pjkBX{6!AR>+H$iQ*U}h47 zN@b1VXdah>Q>jH~=*iPAGg3!S*rcuA7)NquJ$iqc;KomFJE2990_n~Yx8r6KbZ37n z{dj$n)MLtm3|!T0k!?eK=uLc~V_%f~x$eav?WQ1!jEk>JJlrCS1o*_GyvOK5;|g`R zLIhm5qa>^)iJ7_n9h`N}i^7}}t%YPZzq^avY*j?NLlV=+fj^G3eF-!wY$_limZY_SeJhZqg&FVYQU== zh-*oYfp`PBzSP%!(G*28VgXxo&zMUVF}R_KEfg_S%WLuwxPLt!|A|BZdbI^Q!K>qi zQ=^2;Og47L89H}sZP7r?f~%Dbj;xpw z9u-$IKE@Tcm<1Z0>LuOj1st~7$Y&bj@n~C018@AdUQ%hQoY^s;LeU$`GX(uYXbRi; zEvBF=8Z>;7!O(*`Fi`kIkWuXSpBJ=m=towqNj7i=Vf2Np(dO(FjB5ELY(>mhChH2C z!Hw=)Sxw=BLgn3&YwCOILvT(NP?BQyz^2V&NQc(F=aF!UaO?+$!6-Gi{Ru`9G4rBk zTZ*D!x#OQw>b8S~Rhx3V(+}IKd=JQ|2hmodjxaCg)g$37Q5v}vu3>*&@OEes%^|LPFnS7IGkC zNKd-^fTr>&QfT%;;Gztz0`+fV1ODv#g6J@=@Qmnq&}8Kxru)bU6eTq70!TG*A<~#< z+}BO&q)tOVo;oSrQsi@kctep^4#VevM+-yi|3u$>Hi%D|1gy`IOqi?#zXAgfPNe@6 zJoBl?@!2C!H?moBla>GaT+o&%1AxF|0rFTpc&aVsJ5*&9$*vjz1U&bj)uo7lP&3nx z3X6_3GMmbws8E2lMe?t}!4g4ECrKnUm>zq;Ct3*+#6`(LPVtGdB2^DWp;IvrR0d)O zOdKAD;S`P&K_nUc5V5;K&^4cLl=ooAKKx4_Ikc}COU*F{mVGd%PgXT`hze4Ju0tqH zchkrSk$D)MpqYH>!lT|XxiEp4aMYk^Nqp+{9!>H?$%CM(h@=+r)oFy_w*2D-s&GKP z!64d5CxZ(@4EaIFhQL2<&YX_Q8dfBo(3AxAW$YQ2R=(0Zg{3&?+*o<{CqAe#PX2?xC*oOAr?xuBmA=2QJl8r0b9$B2>dj9%@ouW0H6il!h2k4jUGH zY5R`xe1=+n<3ss!j%@7Ddpp#UIjt;(9;EZt1OF0PMuSb^yra90Vot+M^6!eKjMld@Z88=s+l!mvY+6LScz*Lc z0cmu*9+h^-8yYbm0f*g*YBg#HK`7yeJULL61=nWqW=<*Su!jeHDvO|8fB~#?U(Y7x zAc7MQB&z+MHj+u7uIU5sTOIqy`hYy(qT?VaSY16w$I0Mfyfi15%J<*G=sc*=Vwe&u z5>%Rn2XeU1x%-nVB(p+59NQf0t+ON{ zQz7ajylf?P;rKBhFu}o#SIIIbnLx3X9uU=1E{0u!;7$n9B8ts0E=(V|KM3qU{YI#n zjv)i>SNH_S<6kBgqMsm+h>sxH>4-Q}uA*#hX^@c-zzERUIYM%2>18)tM?7LaS)Ddk z)c!~kRvMhrP4;%=qcAi4ZW8!O#{!>Og$_qhy}+ALEpg~#-_3^H$rM+cybTar)OA4>yIuc^1rbfo)-^_jJXAdhZdki z_BAw%(MJCkci=%<6lTg#FqjD?j%vwm9QP;)c_`M**nLSXz+h;RN0r%Ee_+T_vXKAb z;RFRIj(|A1?tPzCWwh*eWFM#S4}u1Z+oHk3fnNt!wLQ9!ixLfXVc2T$9iGlPbw1EU zRvw2$zZ@Zu1X?4$vA)u*m*U|Y*=6u*pG&4RLw0|`s~FqeJA*Dqm2<Fc`v^2<%ml70;cI zO#l8()O~9~4voX$*E4hrDXYLW!nD=*J!$zM361;}s%9cFM2(RoXVP+sVGIIk+g~cA z6g5Gtn|T`{Hn7*7BUQ*vn_{qJ>@uK*hm!QcPuWmv^SP#EU|JzH-AmXlPA^P-zIMjA z0`_l=%Y)@F;}5V)czC~)3RGN}ZHFVp<#l9On=xpVYJKbr7!ffm={nV5L(Mlfh8~T= z*fj^9m8JO>J}WZ3-<7#U$cQimH95lKc2Iw%30;}vR?is6Iz^(~6>yV1rD#OunkPw)UYZbn+Hs#C*>GhZgtcn1MpsaC%W zQwE`9Gw1zU4r-9eviO_LcSiyHc%7X?cC$f+JOQVT@hJUAcPt~8WnBTn2BL9j>ngs= z88;OB9Q_d0)@ZL{D4hd{G{{;jDr);(9;k+DcDgo1h-L5Jl~!)U?Y~Ahib@xlp+6@$ToU>rVE?$Kx+t^A_*-Q8Lc$Jt?r)K z??Fx3=vx>Nz)d9aStN-7696T-fDdDE4PW_}om%Jx4jIH^FK$(jE<3VCYA*KeQ#b|7 zUS4kNCjMLI8!1^`s|rFqJYTqeD$aNvC?EK}0ty;a>ZK-Wv|6+WrYfQvFHU$a=1F4| z=s6MSH@T3)hUCt4F6}^uc>67wAtD$UZ-F@_Z~qioV3plwfc8gK=ZJ#Y;-@5c0xNYS zheTGPs8zB=D0cymS80A1m{UX+hHv)_#gBpd+_hNqndFm%NbBhYBmFH{s@s1XmM<4h-}ZwpvLAa!cbQ*IX8 zgaT({4}CENSIJ1w7yWWvY3kf|pnXbqNru4ABq;2}Omrz(6ktnzAu`PV_B`J#JPJ2r_g=^&62 zI*PXNKIkwEC`OZ5)3J?XMW9?Lcp6`tC!sHt0*LLiq2;rJprZjSazy|dyG~?%Gd2&f zfkWh>-Q_*F#Gb2jtvLiXZMK=SV5FiBfmbF5gq~PW>oTy*kg5im07#}ZphWwECWkU* zM2;w-ELJ}#&_bn%I2_Wd0zj2vqlTCUL+*K;dCa-nnMuC62ln> z_T-y>5RRnTQbxXf96gCmm>};2{-y)SXHr3=4!pr=>sGWnBF(*GJFaDd`@pkB8l{TU zVL-8=JYyi|LE4%kB~0x{^vs}Mgk zAWkE~*jME!G*30%?Ns;E)s=X;dkOtrg5yGag|Y|)V-pE-Og>_IM#D0g@nBxhch$bGVx?L5HT0l%!MJVcA;?8k$bz zvd4|(Ot4TsI?S$85?VHSOvsY@ku#{G4yu9j5TrU_N3Q)<1ryHM8_Wv@C~XxP^HdO0 zkTsf&C&n4S03i@rBuHua7%@nxPyhe{dmaQKMWaR{fqK_0v^0||df{k28(5t}e;%ZHL@b@OPrRj?#S~FR6|E~InX*L|l1(=R)rp>>#74|Q!~n!BlEf4u!6g|lG}7mP!RZ zFI1?g1eF+)C?u5#aKTAUh=xqrR=(Aia!ITOtdR&p6xJuGgn?)1kqD%3B@tZ9)73_1 zqzs;9jXuOgPVi8VO88ic^4ccmrBTj7S;vEF-<=ZKN-13G(7K>4${r2TB7eJbFC+Cd zO)V_l+mG%aXS;FXtu1VE+0)aq+Dx{ODZg3L&xK}03n2u=@?9XFmYPff`|#fe(`a*||xl^l^$HHgFdX&g%<^J_7&#&SJ9 ziJsfVoZF?ec}geO#YJcpuJqtbM`U7nNkhWSsGXS9^YpbDD-`wnH1SG@JCK@pe#n30 zu?2hs3bQ0D?o+J@7gmlwopr0Z1wrmw=r`ggsl;DyHXe_(tc@PqA){_>Cfujugq_l4_RKwrzRsirpb`|iJ?A_pBXAglsM7!{w|w=g#b+;m{Hmwi@O3vv#fRRX0r zYwL?dYhWrB6Q43g%9FYEFPXvRiX{hg%p(QAw#ee-c##qEUyjgxA9$P;y**U;PQmmE zPx_-!$f~k`$jw%{X?c3GM&c%?*-j;Io_+1-s|Z^;HygrNzUE#Eq}o9g3iBg5G6| zDH>Z6U7)PVWMXe-3v3ro>`!viUn!q8njIEpWTA^Ji9O!)?l{F4O8oC2H}2LHZ|RRmtE-)6Z;;-vVzSI>!ICS()kSo~(Jvu_}!9Q5K%5 zDa1fkL_}Fg73f(}`5l2hcGXIV>KYVYFr8D&6JO#NC@)5-*np$Bcq?O$qH4<@!imTv zYCzOXY4an*Q#pz;?yd{%uB-~j)!3HjlgUqCk*)bWq(`~`qLnq#SN>HwHqw0w7oR$P z-|nnKeAT#|3F<~{+|!@>jTupy8ka)O`EB+gvUGXMPaqLlK+v13{FeJQvGtGY3~lg^y4Gc``3xmkhP zsCs&8&5MvB2ZQ8Wpj2eU6wgubk~?AqFf`UTSaY2PVqK3Cpu51VPR3m|nJZ;6Ox3~q zX1w;t$iR@Lgu3skj4U6@)~O>a`2=5p=+T$O zwHpL;1$|(3POs{%H&U(K zZi}_2zi=nIsPS|6s?pM{Mq%pYaU;nqi|#Ta4}Y5%0b~Nrs+J%>;u|>VL2B@NW=*)g zO#1Zn1;|zHIzT`$lxS-CPaS{n#B+lr#takABTS9%W|kqZ(p*_DkB(!4t6 zQ9gxD(kcGq)nDwVA}xy+NufkGd@XI;+pbfnx6$6d7WK?iJ!h=7(lVYi|KBV?4&R9z zM@&a8K56Zz%^5V(k+;hV+CAAoOhHiD+`EWJAhgw(`5xMP*~F}zQiReao4IF7zoB6- zp>OaV`M~eaMO@#qrArc^(JIwIbw*~!FhM;$?(VvB5f_p+B`LakXu#<1?_*k#(REgu zt9PYdYZw}D1i&wux!I)5>IF{3G77?2kxtn?`YE41h<};xAtqLt*Bo0vnRlb*_`MP# z3!lXu(&zEve3qb2HgOqKVvf0$Sh7e?GbLra@!n||iY>8v-RI^?pW;}r*?xcbMVzGp zePl?NXXyvKV9_4u%Sc(bK(OPNik!r6euR<0{WCsj#Ibz;$Z%YOiPa1T&7tLnG^(meQ+=f)D+orq$I zh=A|br7 zzQuwe8Y0p#DI+$<(H3TYQEGF=ywILh;C@}+X!Oyqa%$rLmmR61eHMSYNT|etvT0!ckfl7fHJi&Wj^{IFSdM8wkmfv9c0tonTh7 z|Iga`9Ps#jiSb5(KYDk(y{;@>yhMYdkMRFJW2S3dyH;>va>+JXPhex_5=<_nM@aVzON>Dv|q z=E}9J40=RoiIT}5%+a2{1vLWdp#JYwXjrydtik;iz+Gf}r{xs1i3dj>0qT{*>I$Vu zv!Aj&%+}V|T&Bp{7`~I(gQTKsN|=hwYuctj9IxBA9PKO?^O@BU*)Y&Q@}ojDN?eCgg-!0pkA^U z{=VFdw~5T9Wfif8>O`v_uFBm;v1$>iDz-24ObJmEr*5>wU+Re(KlZ9H7tKE}E&aro z7CUk3qZ=~brR(P?D--kTsHjl^D8$b}TL^N&b&8tO+HPYqO5djsx>EghB%zkJV|TEe=!CHDm6^39i%RH=udyGz|jyKeMk)>V@14 zT!3_}JgxMoVU4Q5PLgjpBDLL|Um)-XJuN z3vpQLZFE?P>mx|Hu?3v=PVH>`za@}}SL6Tx#)G|NVigzlk2n>wOoqdkRenOYqriL2 za=M!qLcT^H($q!>johEbx5C9X``$&wsxB0?#jj4ZleRM(`^Tv)Vcr5|W|Y z5qUB@)*-vHGOL<5x&bmIi!4MB(dBDINc`?J%1&5G#%Sx&S{D59y^s%<_VLdm0nRx( zeL~yZt4RAwp9k0~%6noT#EV^ivOc(!c+{Dd4@kR<1@TIp8xl;{TuVFVvL`5-2MxI-z~_3~Hx2iI?{w7tUf3T|GOd48C#=)Kglp{vXP%E6B+i zoVB?ioMciBqKq?j_969ID5acmXgWS}t-^BPi zzlWeCO}5_LsF~l&yQ#LV=BCxZ2Tj!VV$;_-S~o9D!dL~TVq_|A1L9+|6xEj|lW8$< zu5y?zX<~27Rp!MYObxJpIt~=oMc2>;OWLU+O|IM>k=b{SY0=41#(>*y>c zNkdTic;hw6%?Js0AykQ2U-jJf}m{2vx}AhzvH# z%jl4dL|)i!dv7HouCMW>6gNN0h&hn6r5Y{&E>U`*KmY&$00Mvj00001 zo)`lFh>cJH0000000000004$3M3ZIyKmq^&zyJUM0u)1f5}A?oH~+Ah{4h`{`e@Ri7waYKX{lyS;XyKPtG+_sGpBuL^(G(DQ? zv+m&0kTQ`GznmO=W(YRA=Mnods-49AbuVu&V4t`0I24@M22HT|Tb@&tyc;`bXQvUx z=W~O>g#&8bInXSX#r(Ory20)zNEXN=+94w$MHbVxBa*_c%%wuFy?xZCuw&*H2d|+D z(fP2$PT8{zDM# zp}enKLb;^wxy^ZE(V(cjlP*kfV|NU-Xn{+97q~29(J=XQExD-d=4u18{(7dF`Fn;e4bK)R*%{=#U>W3hw#!lfG34l>K+TJft~knk9aDP2Rs~8qJGOt z4J~d9Dfd(KQG$Ugvy0yQWn6n+fJcDL0%ZF!y1lxk-6|vQcU=z3TmboG&Sd!mWD?}W z?j3?P&T3VZ-_gR6NCNg~f6A8iR!mr%2jxeX<=Vkku&6y5?bnfegm##VpKZAKwYR@K z?luWK*`T*{tvgMKpN<_LDF$9*zEe2kl^@tGQhb&mq+$BQQRuYa-0cxvi1icjrR)Iq zn>}NzVHUtKMIxH=u zSS7ubCJoGrDMaMAz>%;`-mfbLj06}~UpP&H_)ceeG|(fX_$Zvt4LS0xi9~Q$B8;fJDz!F}-6W9aEaEe-skV88S#1Y|f#ZR)a=WpgpX;NE9C2u} zamSPJ8>-}>ixQmSDD60InhI>-QD(9pW-f1&S0+B(G_ypc0hm z(UyYxjV7-GHhE5b4NfAR*Ey%otu4ZUzjLXBxVRZe7sv9zL=O8T6>>L$xB$T_K>0zy zK5k;$tTAzi>keF`eVo_9q*UUS)1Gp~+OWiedJyKu#L-tX?8c`}ks$e8mhn**o0Pfe z5p+}W%HjB`**>UDfT*Fc6#;=ASHtQqCDYDZwjC&GD9tP56^T>sR1-!{!J3%mo`1j! zf25HuXJuvgP^rJ(oR_)Lo$zzparI!LoF4W_bY0#KjmWTD@+Dwm)Bll&drb3w{1xTovWLzK^Ubh&+d0CX;r+3Bbs!^##Ga8}a(2G5sTRMZ-n zdIk~XxnIB2!;9V(vlbTV;;N-kq4ah0LncK!*9VEujHY&6*o`nbZ08`Gk1or|=Qiw< zLA8Qq6Z?yxj77eHlxh{plkwdqa^{^d0gC8f@@s>k9COSgP|udFgiB}cbCD7@$^vki z0qgh1LYj^*QWU*ByEwW{H)o%HgTln9lJf8fADdF*@)H$4g#+(;N z609W=$(Pu-Bpw$M8y<}_oSD3BznO%76+n=mRjbjjWNvy6U(K9(uwvu+PfonP++w^+ z@``=XBP)t?baWdPxNntxe2umaOEG|SfHT=a{8InWg#-4<{%M*5_&CLarS!N^vrF`p z6Bwh-ouZviX6qw%edY=TqYswZ*maT#Qu!dNZL=1ZOP%)Flre0H-)!vNcEj^wk;uFJ zE+jS>Ti%3kc25V;$P3%x94xR%ggB+kFLC94?k2Bm9#+@D@ zXzN4`XAS2uA9ZR-wWOqjSGyb`j*T7ia?XP(uqr1YYt)iq+l%|6d4HYm~c zEQ`9D=Zb2hXDJTiK^qBnvYN)wJ9Se4p(O2yKDpvV6_B#DNh8_ZG?gi;y41>O?iHuS+hRzLTgmbOb6$$n5eLr~BFt;oD}4#RXQ;f!u>`+NZi!7> z^rex9)~VBhcg_Hex`F)9J|9K&K9HQ z-%n*u@^r3bZcXyJ>0Wu_#&*1s%lw?y{T4mW%)C_pIaRi6!fxh3rozC8R>5Z z0=jBz`Vmi9N<8d))04q%;jal?_I@2C&Az`t=dX9wP(4`Wn>JT+ zX^xwqaQ@BV<~sE?A2$QvdgoN=%h0t;)rkJ5YhABtQg}U6x*VvnZmo3nI3HpzYqw^~ zs2(Wn;?tG3K4GiX^0GNmkZyXJt$UE$13H!ZsV^?Ys?ipX7nzP)BFrx`kgQsrDk?8h zKj!*oun*i|+j*t8!f?R`lnJh~Wm?Kc=FrM=&-ETc%_=T?Q0XQP3F%YA+Ea4u`Y#-; zfJ4}{mgiZ#(ht4;6HYNo6)wUaX0s+SPjhdW+77P$AocX-Lkl1zB=cT*|bs#YIt3_m7fR z_T?%8=y_xh(OC-1Ms&MzJaDM{>YSv`kjyjq)8!mwWwcK4&of0^A7vuL16GbE^3g?swOl*F&1lxM<(!$dN=~3>gn~qPKi(?8<4~ombuXw#T~3F} z>S3OE(2numHt}AG_D>>Yl#zDJRZ5OWD_7{QjG&~nmkhb!IAxzhky#I*ta$2Lo)-zQ zT4kN1T?IX)=(9!0B_~qa-rFxUcOtpmiAVxLPn7Vay?ux<+Y}|<>fz&&F~zwm|5J~p zq3@S=KbIvx()*uKyGXmebLQE;7aHYjDFavV(AKu1^8ZE*zrBrPBnJZ}HIZrLE2qkvOHI zmOs+Pv-9^@vZuw1MQA95+`_?nD<2?CJGNM@;vg__M z+|Q6$4zIy@EA)q!xDe%B$~tlY;cV{T3SBR4ay8{>%O0gE?})k|O;v6|ByrE~Dr=GV zfI5UESo+S{mo|*C(#F=GSUIS0GgWsz>reJ5DzTITyjuT+Tu=>T)~f zO7%9r7$EC3nt#^ysmU@$!Hc}HM6mXeo=6&wi+2@j{y7vKJyYx##0F2`P7Ck`!F*vS z#o;JBt;yhB0j+L?`gcBM7A2$aqpq&8WL5ebBH_-S1H`lgpF&>}SmTn(Kzm2RUFWPk z)s%t*y?x)Q&Rvq?4x5PZEy+qp%Slz=vF=JXjk( zRQ&?3cm%6IZGJ6O*7PGNg4fFTDn8g7*wUW2EJ7>z!>A<-JQ=xm2LGwaALe4-E(RV^kHeL}a?nGf_eFbC+2P%A7Yin)LE``W7 zT}Z2u{n8IC1EGr+1Qzr3Q;|BoN1c?=bdh#&YTr_Wz65AxBV%17Kzq8aSfc7d*zg`7e5o!Tv`U=r zgtP;x_O_-vUXAh%>9BA@C~%SQN73*rPC$66l%fxMM@GhtpG7sg4464QhC5re&q3WA z(QM$p%fL9U>CiqcJ|sCy0ny@~2)k=?7fkIqye-sUmubVcLQZ%!O=-&RBtLiZ8Gc*B ze=0u^<%Hd>T3!cec+X5ZimP=dx8?sQ7Y&=0PL{8A|mq+h8i- zRan=qt3E7CpPf&{6qKN;@pmWGSrmlwvW0Xt)ZegeC-=ggMa1#l^=Xyfb@`#uDx}}T zvbzs8B9{T;2LCFpD+NC4RU`0jx}di^;d%6@tIfAkcw@#zl19P(O@83zCv2$j{eoO4 z?+th+ym*Mep7LES?m}u~_G-c0?zUusfUiJq?;|}Hb#eKU(<6taUP`_wq^vf~;7vegzjd$WknFvD45jmrfKvhfuHjvXHbT;k_MT_(cNx zU7JmegQrGULp^mOZb#0kJyLqV%S<0m4%rt*$~$)wCWG}TQZm3Y2XAvc6MX=;{kp_a zd#pMM`H9MppZKwX!*IUkHANE5*q4iY`vGt*=G}aHm zJOGG}qw2S1Dx#Lg(#M--Ln3*Q?;(Z5Tib*F6VjiirpiJz=t<*xa)}GuDKjBV+Hud( zo`!U|C=*>9R$rK0l_$$6{dD_zJ(9|MVA8=#C@{B5oHElevNP1rBh4Y;9b_l(*F~c9 z=-e{TzqVSNmkg@1p($GhRq`LA)R}z9v#m^~*)_5q>*AIfb4v%xsCfv0qHYA)d#z8* zGSlUYZeNtP{kvItG(T5fT}4NtONnvuwdqw0~XNcck1b&6OE4mb=B21+$2UVt3 zY$_Ld9i*y&CFE zRPoqZgF+&d3q*yX(`{ZZroD1$iUnW~(B9OnxVbK}R3hhPC*4E3NFfK3G9sJ$QStje zyHK!gnov@}a);@srp#|ug86bz@*ir6ca&w9fx7x|@nsUq7X?{`nm~;1(;&TtwbH!>Q`RAz-fu zT8g492E^e?dOsoelGQHf@+yn9PvsdzE8uQTuX=IO%|MExDEV>AiEy%Mrff|)TcxB% z`H!iPeuqn_t76uuHt4QlYw6ZBlQ?6?$si2Cr#G9S<^?q-7gSW;s_#!A|RFd_0oe%xlamZUkN6~Bw=!+b`;w)!s?$7nuVY*|q4xh4#IJ;|hN zhW6nyW)*P#lmGw$iO~pvX8@o;a0ob9BmqGNnAm`syy|YbeJ3aIl5-lg6GxR>ds*vS zK_&$6b&Ip1q+oYA*xw;gmOm;oVjV32MA39v)`{v2Q(qgHkgX_`x^2pzBrALi8}+I=*roIuuCW%c4!k93v-rVwv%!quyyvDAw>j1ruaxS9M7PZ66vO&pHX;dB!_`?fm&UraRU#xhH&wVyqXdmbN^=SoWxOr& zj0Uq)fBYIQ8d3D*HXbXHw32@5Syd`!jiyzyNhI(ZJKaqM4@OKjtYi}*l!LOb5t@|7 z)!0~Mpzal(^bsxA4{PK22s?Ao+W3`6C4Jawxthrx{Zs>Hzoqi{o#`UC@BF7-hn z%6;1K0004s0HUlwkN^NE#sB~S1ONa4000005C8xG71W!?q3c8KntI!PLn;{0XiO9B4x41TVav zBXhtVB%La3NSkv(0kl4j7V$mSLhTBpiRWl8cvb1}oM8l%1d+IJrB1;jheMJDl={dU zEk`Wo-lSTRRF)*A-1mU{v^5N;(pX0EDG)6ew}A9|EberE3l|-4mL}Mc&_hp>{p%GJ zS!DV7aC|GNbsBg^e6h1)?1?^Ga+fGfeRNRVE2AImk8lIXLwV2OV@s3B-P=esaS4mzbie}(}z0D-Qz z{*|878_0e9Lg8aG{B10JQ6lT3i$@k{$f3Q@5x_ivU^>4zu4U-9!7-QMj9AHlGqZ&C70!qJE zeGT76E6S~}M%Z1L@^Y|A;*Qz1_uGH*q{YR@o`q3D!RG@1Ym_-{6BJXnv>`fZ#lm z%YU&?9_dRLT5GPtiC|L3BTnCZkdUb`HOWZvY&Q-Ufon&7eX*3A8hGJLPzW6bWe{mns(|Y&YPHYl2*JNm2r<%)cW!?v<4&=U~~hv?@pXD^N4mbLgn0`-vR_Q zm)^|1WG6eWPxaUxq>r-~u%ydeA>V8SG@N z$Sk*aUjI#mPAy;M1y0AOHGvQtLKZ2Sy*j=f6@?O_QF4wD+i7xMUAmr~U^bj3w>IeR zHDkmekHvS|hkMXK#atj#0yXewD0MLi7; z`z{MkTHaqB&aF-GQ4Z7O4>04VopEL~zJZia!;&uWrP%Rz` z*3Fgk$^hs+Lu$i91#n1Ly=Nm8=J5gzJo*&5El(}9ZOIl}r!o7`Pk7jwL6G87ib{g{ zg1Hs_7VQV8;}K41kglg|XH<&t@g+e`0_3k}75tM=;an@Me}5%T{Ht-StmDX+Z5*(e zH1O98=ShEtzmC!$DE4lg-wWk$7Xv)dp?;Ehv7mVah%s=QZbhoxe!6oP5DDfmnEQ%u z%mN5pdz2L+$pe67T>H>Bo1ZTG?gYku2^(aC%!9wS^m(Vs~C3M9GU! zmY;N2Am+N{$NiOfD+W1KK8_%Q*Y4A@WHboH|DdH$5Pk8SOe2ud$;o~}epPQ;EuxMX z1Au71{qR}B0l^{y{F(3^5;rU{oAbWCi0ZL0Slp%H>xqP7s$^*=gGsV;kMuXy0Y%7; zBcj8Bdba{-G!ylNq(Hzp4~$mj`auXI9FHs$3Dpu-lCk=;tp&koN|J%80{ldl2T~ls z=sM>3ly;O#<2hP`&UjKw0dV*-C}?UkxY#kBypudy!%hOS%fp9_&b^RcZJjM8E!4bZ zyewj%UNQ~~ZUewAA@!A5$Ke!5OwwC|LIE8*_lQH0w0$KdnJwqwpqNwem2E5VTn~fr zhb^fftpxai02yelAgup)kWeythlo`Ymhm8|>k??DfmWx3*o1HhMtPd6+pi5Sc$EYQ zOP(v7%Oc;or-JEDZnj$8WJAa(=srhw+FyLC)I2e8fw@Hm;lv~iJO){loP<7R0H%t6 zIWNG{<4&JtJ8WkXC@6=|Ed``1=e9Eph$(T|wM8;|ekjxaybK1m`WfHC%K+Yfl%Kday_y7O_ zix=XO71|N1EK(7P5XfXA;)w-oAy*_=jPa-(Q`TN#q>yK6SQ9oSa@`XLWTH%!99pp! zK3Muk72=MhXUvE!CM*H~eKhxNOB6Jb-I$dl3`i?<{}Ldz((+leT#PMv%sQf2<4*V1 zJ?vLs3LPjAP!NnkT7e53I@PUs&dF+hN?Pi=op4p3uEehep0L!JT9q1wX8M2wH>V&j?k^vf3_XbPyY_nPtyUS)5ELX{A^w|<{A9=9Zyw-nrot~DQK9v zW>eYSE+Fn57eC0bU0FU*-slt?L4xZ|Dl5|cLV@=RTAOH=9@A_dM8SPDW%EN<)cWvG zTqU+qhF2#naNbF!$d@bVUgnga-}P~V%jLViJX9lELRrNMQAZuB+j+h(k~fenXc zQz_xLLtJw$Un9p!(`scc4p66z0$8H0}g5$V9d3@ihLosS&Z ze0|B@sWOAEE>dO1t?}J-d$H3g9z?DeK#g8gdwz$@Jj_MWNe=)CWlBh+3iZT-k)hcc2PG|R7n75*5d7dXEy*=iir z;HF1K#i014XM}XliJl$)VJ7)rSHd&@=g2ly^c zg33nRgLGRyW*Z|e3$%adQhwPF&hpASZi!sFWw-|q`OmlhZ;NHMFms|^-iKqCV8vMB zk!7~wl4C-C=hMxtP91bUZpZY0+DdvTzKSrh)jFu+Z;@N*2atWw6$f*)%N2j$G%cbf zwr#upve4Iyt>;{q_m-3NN8p5Zqk6mQNWQBokKI69@#$*uCc%_o9k=aw>KBTG-ji`iI}w=6+EDm`6g*?XafEZ!XS9t2IEiZrWg z1{w{2DB!RT9X%@m+N#NhODgb|)YgLsz8df3#Uqr?zAID=&~ZzSg8G-!4Hqxgq%0L= zg49~7dIs|&#g$*NV}Yt+`;}k$?WG4llv*WV(N>D((D5w}+=Sg#=X;nE?X0JSHCnNKCb z_C2!No4C>@1T)hg%YsTSpfe*rG)$f^DarLG?SM2}FK1XLk(8SMEzZsP7<(0ZEo&_p zp+eEdphKRCd?Kw|q>QCa;{CGr-u3nC<66bbhF30g(Zn9E9hH*C#Y27x=pPPBE!AXF zNM+lqpU9CSCkHGo=0T+zCJUVr6rCzqW_b8plHW7J^a{(a2Zgv3$BhNbih^LUpv%>s zO9wd#bFvhi`JNXFRCj=LwRWR^ccxyKY<;#PXnq?=|}nQp!UEVC8#MxvCt!s+HvBxLOvVQ z_Eu}5mr>nO*$_dEgl06}h_0W;*e{>ZE5t0oE7_Irt1CiuPl-+n(ETftbN=6>fGkQz zUB&Tm_!Gz$pUT&&-3vVdwp=rbPP)H#S%V;Z|4A24c&nph{&keINmNu`oek+q-m)%| z3ZL{lDi76_Q;!A6go0(!>*ENj%2#XZN24a1Cwg=;-u-a4RQ^a(OJj?L)nu0LBFw+q z)Ugr0H*d!(SB_VU2KNig2W4|4v4xE@#96Vau0!UzO4$PHm_6LW$Mk!!O}x~ZXq!AJ za`u#AO6Fd;pB4QNNqRq@mz{ovjS&`A@Q#*!K4Enzl(YkZ!K_R?4J*0H;-jIS6><-( zkV#Yz9fGPZoDLIqTqJtPPW$%DUy#d1DToJ9|n*+CjN) zd6?I7>VJmW3qK(M3q{@ zgugZiyc?9qP6ud-GyxETcI)ycSe{4zZBA zjPAOsb!Smoys%#rT3JLou7@fxah8bi=TIe);^j?Ut{_ZdYNEp|`A6H%Rg^ml0$y*s6>4d*IfvChu&bf6gHu-j)Aj65hjb`b^S7hy>{Sb2l)Ow7QsBgb>_r##TYT^xJ^ixhdu*!m=y^=j(97UN^O4}5f#qdHvN!V36sl)|lhZqF?gFg4 z(;P}veI#7fm)hs04qB+N%SF^Y4$x{*2kfVwTea6Ep<-{(s<$ltd>C~T<(e-O!@g*b zj>ODy_z|IY}G${TgRq7|h_!4+3>7pXmYg2jrUU{HcR1DPLu2ujd|`31ZFR$$aN5 zX%cWv$fmq>Q$Vh#2f?=vc1)MVK3u8J9uZ^K`Q&f-(YWCPiEx+PMfkCKQ?WG{^DZow zHl`>ht7bZu3I2zVaeCJfR@#eV9(PoI8z}`>6~gvQd7^Dx{YbA#4!ITO)~QhAjIIw7 z5lQ1ED^rUje5zMNWu29X{S!Q18ETw%u2gi+Bo4lB_`al3*+_j%i&RmBoydc7SgT6n zx>3ja!b{80vMxcM0)$OsKqR;O;;e7ZmcR)9Me99-e{K^koBNb#QOup0oR&XZ{G5K)rW82P(W; zE)AZY`^0#?(4Q1l=By3m3J0AQMe1iq+>c2p)Sz78@C&Y?F`|?aTnHVO@rw{Y)Hu;6 zSyAQ@T5%%r2W6L}^l>k=RlHoqgIlH(YG)SkspiVlw2^zcUlr_K(4}*gk=8;o;oy^M zD!R(reWKIbD7tKqsV=XPQ!flI-F=5I!DMo)bjuoH6Bu(%$T?H!eLrzvQuZoHk5sKM zI^0Qe#CB8quSi`ML$ePxH@7BV52Ay?)70fys`4MrCHFZ=k1%K*E$o8X-uaSr2OZZ& z!KEevcHO1hdGNfLOCj|Fc1t4tzst8gDe6v>mBEO}8*a61@=zg7vt96APC=|vTqLSf zqP|JQ|0Max1c>o22b9Lo+zldnyXGMyTf3h<4<7Ua0?uT1p0Zb^o~gz)E- zIYf&{IrH0!pA>I|&vLHo+VpOGPrs+p-sguZGtisTwGm*OoTS}ZQu*V#>MJLYpY6U( zDQEdzsS9^|H@a@q+T~J2cGCj>&R$+*1zWiXgGkR)EF{-dMY#_t$Yjn~8Z79|kld$& z!krgmA`LUJ88Fb1`m^D8ih4m#XfWh(XdM8t1|bI*vKbM9emm9?ra8i@ifC6cQkaF1 zPK_^Yyk?Zl{+F-1fcSE0L3C9ms!sG$e&>SpI_)V^Tu(3zBC->mksZl$wQjr}6@wkZ z6XJA5#7Co;5qiC(xA*`60g=*pK&Joz0YCx4Kw%9J5#dqbAhghXo61{4z#>+;$QHD1 zk60}j2%iO38UYEeqqEY1OA}4i6su9cMAq|B$|mAVghl4ePBo>4km8}I_ebnX2s{a* z513&l+UPKbTObql!S$Pxu)-*)5w`+A{x6H3Ll=nM@tH-N+04!hjaME|DU7bO<&%U= zR9!^Ea#-?^tle!@5fe@d$-|-Yak*<$Io@cE5Uh5oNGFDy<_1PidB0Y|zkyK{)=k#8 z5$qDDL}flADoE5y-ZSL*+wHXV(Do2kpa?(ZJf3mrjjQ4-fD+-`A-G8^W72(XSHl!q z(d%%HwEzQY6Gc!!(-@jb)L>H{KG?m!9&a*})Kr|IT1C`(lx|Z)VioU)*d>Te80%rG z>wZx#`!evylagA>LX<>BS0@tNC-IG_7-l5uQ6)*3T|XV_E$pRxC$owdp`wmbr0g=u zC=n%XHklbDx^>{%3&JQ85oCjDhFukePY7khN-pxT2I>M3|4zaMERH6%N^~%iQm#zv z*r91~(KbHFGH5X%3`xcBFVRzzMiOrt#|49Erj1!jqGIz?n}!i!T1Z=r>7^5y^@vJ| z|Ks_AYZFtUGtxe|u)N&+nidM8;(Z0!nKRzNiU0rsk^lffj0PbHhY-L3KmY&$00003 z0096100072AYjSJlmGw#0000000000GNd>(gaH6RZ~y>607et{3sHao2ml&wB`K#{>@YHr0wJc`*{Jhn3wQBg!jBCtFwb9 z6bvGk*f)5fOF~468(@=TM%+rM6~3_uoF%WWGqd7Q=7EmP*Pxhz!XtqcQH!d@(bzoq z>ljGw(oC8$;iQ??l6BMBa|NvgKrQc*nGmRdS)dgNTM%84UW@QH>ox0}v;W(^0_Z#U%#~!)4x6D^Kc! zL#!H|?gNJzbah0i@8$AzzvKrc7|Zo6>U%U_gqI-1f#Rs*9DR}L=Svr_cN5E_*&xfk zDcp;i-32Ap^bdIt-no)Sf#~l&*KL9|)=qUY`IPE=spG~Y{#>(7JY0Ly?Am3{)o1l0 z`dbs$l$!2Uhsh3Yl1aEjsOnct(K20)QsDJ6n~>3nQuJ)f3g^`v%cbWIGj?#cGicSE0D&Fgk!?`o5ld9SW_*4 z#+BXhy7|Bzm*-{uf&&5tO${@tVqnerlnPfrjVKO|0nQ9m)wzZu_JOaFAaNjQ%^%Ab z6l<^|>^xCQ01OH3Sn;%ZMoi?-yWitp1#Fi$Z@Ol z;)|VFjuW5d`r35jRMmNxtpfimPn;6rV>@17Y2ue1RXkJoV28I6dE@~ z{8yHpWJuQ{J|m$97{rQTRdrjy@`-S`T&sXAe;x|BRrrV5(+AP_ZIeuOLE-Ckq0cn_2E5{Amm*4qIW6Q?rtCr%6!FmUA=_JJiL+rspe8;+*D9=jvu-ej-*{tK zdI6(WgqG!OM!Sj&rl)V_)+Xmj6eeN8;)D9zz&}*JEV)RP4ws%G*@?EZr)A&t=d`r~ z9=Fj|+O}U!k=5#+RTC`@mcXTLBhG<{)Y524SBsn8WQ1f}OH58i=0_y`-AbEdAoD?S zsGYdAgHd#Fqc!B@k%MA(pJ926h({FQ1q5Ixo~4x`(2kpOiL}og`_P<3Xom$3w5;eW zrX*0*r2Cc>>TskTBm`r~;Q5*%XF`EN??Jl);z=vxJE}@&pmyY55Zyq!A%+fMaLjEJ@}Jx};Rk0LAwnOsxyvU2!lQ z|LD|D3oEU}K_F#pb^SnO7cuvA_ktL}1Ow!gYHY3+Pf2r(@ZA0nEPIuYAmE(fDx@D9 z9Hf+6*M&z0$^_tl^VhFvkxK`7zFLmZQYR zF36yAEAoiG7PAm=g^*l)1dvALYAc8f#1RI!{?GRGs-$R4viA}wi2M2WF4FV@&P#b* z1%n9MlUo-l0vRD_xjj2K~fB|hE)KG$Td|aagodt9c1TeSeYs3v!tDYRz{Fg zLO0-wiw*P}MKV#YFVJ=U>FW|iJ6WovkI1C3kNDJyU1kiV#Tq%JD2RG3wPa0hCM`!z zv%}&$HEqv|B8j=&PxfPe9V)5u!%hmMaFFjRmfpt97TSbM=S}9Ek1XjkGHM) z4o0%4*n%LTB^Zd4EMOqexDM+PdKG4NM8rMJ1xWQQqFiJ@_$YB0!M8d5$GA_w1c{sl zLvZ7u3lA;H`^|ISE`bTLAe4ezgg`ig4B*ldIG7$r%=y~wSPI;Npm(y`39X4BK&Bl@ zV1*J20YNh&TCOqI9m3vLCJoaLh=;TFj-Fy3#4P22#1a=oh{rp;3$dn;LO7?fJ($Fa zv}_ub0G=Ddig1NQOfF|?L(G89ND4v84m#Hm08W$P$UFSYonX;OtYSBz)r_{(w$zgQ zjDewXltDysi@dK5G?y`Yn^I1|Xmp}s0`9)6Q(`?mgY*=bS^vDGN9ePZBKaFN+kID6 z5}siw3h=?7aD(rH#f@?uiD3F|@1k;Z={#sVTD@ZuthvyoYA7G%+cu#&cxDi?# z%aN31KEYyg0%8Nv$Cojj6$PFm;777Y1?7$SU8il=*dQ`E%&rCHxn)T&HgVf6#CzY%`cU5U?!XY#W1ut_g!+HM?5m*)U+8}}iBNseD)-0x2eQ`D# zuB}U|5|xE@R=B?Cn0mYNk_UH)OA-=oXZm#~H4}M7O8JtBK41%Uwc9=N57@IbwW%iR znHo;FhgE;}4C-dE0iGh{j(D*ZX{>auSgNa9YrxtC zj8bf)ub_bF3U-{>1BtM9shYkeO=!8CwMTy_ARzdVbfQ>T(A$Z)lfA03tj$ygK_O__ z-0wGac24XK3$daOklGcjl-@m!hO4FgrK_B3=#4E%$!jo_wZ@|AkE|vxa8_ZDF8oWf zDOL_R%=`qzdUA}&jJe5rC-^>RMEEU9@LtT|m6IMTqYPwa>VrHfqVmub$?7+yR4&b^ zz%O`FaI2s}Gf+-I@A6WY9a$2pY#&Y0uIhlxUze6q!M8ha4VF7U9;shYpRGqRZTCAf=#$b&EV0BTNJJEE4eSMh}E?bF~6 z%SKV@xd)Dr@he1h#2M9Ih!}G}l**|$O3#$;Ee@}BjENXmFO}Si=B}iC-mdkxz*|?IM4Mcja5BK>7mTv4R+gW7mCB_pQ<2KGc6UoS zPOc}S+IgL+%7yqXEItWJ7E_gLZcC33k*+&St#M5%z6@*qAIfv3!OErXL)Lo_>A;MY zp8cMdyL_VajTZNLCUEKZ^*LaS|EEhq2DbANSwN zxt$IJ`c%QHikTw)5#O@CQq>;OF3T$AIYui_1nRk?7JAL!m{j-Z@g;c88KroGDXqIA zTI10GeVTk{gYR<}BHvuxJT?l{#%dhPInE1UTZZyoXDKylU zS;`MWSaZ3>`DxTiuvYY)$`%qGFf{}+!rmSUf6@nesID*kwfV!{wi7{m%J1p_NQqXF zW_ft8!lr*xdEm2*Gr zj!2OJ=Ll4%u<|WO%e~422|?DW zx5plve*r^NDrCpgtw0@hs(~>^qV@peC>5>F20T)tRjGuUg}M5|P0)RxYo8<$rjcYNJQ%W@x&s}|LZ3CzqWNFL-4AfVaOS0Fd_e>XK_`$E z+I7M!L4R?56n7tf&ZEQlw6SPk!cd&6X9g!G(D-@uv3v`YkAO3Ro{nWBo&d}yUwhS> z<_&%+b9lX9=ik(K)x$YZ>haziq+!uf;h(ly(PvsMbsng+Zxnc^$#vyj@bC^mK8)pv z4>Z5BTr0oZ1{Ie!2k>%DOca-^YIShkbgI=O)?)kfPfG4fBZa$X1g!z6Dy$2hY0F%E zxii$XuUEKRD&MWOFCvm>;o!5b%Z)nMg4y%oa`UNyHd*MHlEkeAsYgljpo+wHm8-Hq zq29(VWfBiHoV7_B#7cqvUp8{;BHa^y*{2~Ti%>hr_rE9hXDwWm9Hh;TKkYwXveffg zEZiTE7c*FBFq<2~jice-SN;1Lvs?m^f-Rb?`&icP zF5G@L^k+lSXtjJw{pcw{h3@2xJOPI=`l6Xrl$@x@v+l2&aR7gmXKWwb+n1Y86ut55 z^v($Uf0}#KYGk)GPFv0Ff$yS&qPNq$69pocHn1O=VS;r!cMg0k6Ni<}!oN2)jWXir z{&HJsIUHRJxd3xMZadK~MeuB|J;$*)z%e`$@7x!BpB+bf-0Ou!U*r_4r^R?8tCtHt ziB+`IsIbeeW%qO?C-d;n{$YD;034}(w{xd0c+&Vwrj?65=y_l@KDC0mqsvl^NE@U6 zqMV^!krX`oM{yK1ixi>YSV|}%(MlSc!9c7FY6XLM=%kE|Wb6@9VDXt1WAg&V&^$&v z(fEuVr5w5!Nfh4iuVM%51ilTH9L(snTqL0!*S%hJ=IGwR7-G;JRQYnmVGf_iBuUGn0 zz{p}qrK=!KeO1it-1;KjYR)#87)(f^U;8rV~2FeNX zh6@I|(v%b`cwZGCfoB~!K3H01^?6mPT(huT4y*OQ_#>w1v?8!@5f_jgFz!nze+T!VF)=srOF-~O8ryU58Fn!lk)?#1BtJ0p{7EAJ@$ zq{q3v?sYo~PrQ!z9-atCm zuq!(^+g!c@el$gG{E^aD?w#?5_fLUE{~>MC=KHO@>%vOKgQzP;qviz7`!4ULh%MFU z9|*?_SDsz@4$)#qZ_5?3C$v_MoL2Plb^6N17guF_&l7u@^%!_{W!fnHY?YV(?&@meG}sQuY-B+QB^=3e2^! z5QVUWMYaMai?riHwA-r5akhPur&_gc>kxO%;a)P*oxG#0c-&A93SIqpA8_$Kqw|%K zs4n|)b0uCxAK)t1;h#17}e|HBU7`x$ZG+N&LR`R`BLer(fPv zmlKwP0r)SVuj+nvdRSkWClp*A>yb*%3q+_YG`Z2UXZh|!D*KmyUiZ(oStAr%iVBOr z|MXGw#+Tr^h){Og9{xy;MO4!(5f^RA*SDLc_#&zHsuvnXS?$G;<|3jkSbK$Qut6mX zzCGr~rRAPEzbiPuQ|plw8v}LG9oG$ro0IgJ?2emJWW@y* zT7nmwPbAXENTKDMPPRCegOKY=Q3o!bUo6kLEDfG2Kz-%3)KvOUUT1VTrG1~4g#M2* zx~qDh7DhUHcXvrWw*2|5OXXYJnu3w1{fawR*2jyp!_LLC!Cy6L)QFDvY@#5Gutb%% zw*Jw1^)jAnJ}7!E?c*qv$;aoq2E9f|9Qj<`LQakB=<&DkR(LK)qq4*4RXAI9G%Lc7 zOum*~HxKG1 zYOE1XTJq%8s>;E=54zkKp}#$4?9mrgpEyF4{z?J0OE&!!Kg zc3Piila0lqoul)juoIuRPqcDH=2GvMCa2O2?yEZO_;;fZ7`fu3O*)DICSA9@GB_6yy=xnQ{^2zFCx-9=O*^)`0i)w9sJM9eIekQ+$r(J^VaF~mjkD6Kp#pC z<%%A=`PMLgbtPg#?w#coL+<@DPG1L8mHUm_G1Roqtodo<=)N+Ba`_w-j*j~&F=1q3 z92f18$+cctqUO`e4SxPI6?(b#se-b_zXZk=myF-O!~!YsT!9(j^i7t#(<{o=PqVNAcm zzK ztKVCSe8u8RV_90DMm9m{)8$UZT?f9QY=d;^8){nUqq%Afbe=89>D{8mOK{{a1ly-7 zA;i&cMEz8OdPrPb)#N|3WP@(rntz%K+#9c2!hjQlTtErp= z+Tmr{qqkM^qTZUT>x)aWC~=-;WBjAJNgea79_@R}sYU$$=QypcD3L6Tjb83cmn8c0 zAtG-F@0D#wY*XF(@i@#re1^7-t)*dPaunbUHLw=i60a4XY!O&1TwmR`<6EUKJ=4!vybgmXk*MuE zM&ATxyOx7;#XQF%nHw{Q9ofGL>{E7^Ke`mWX7S?^DLu3HKFtdmMULHUs4q!DWnM6HgXtGLZ-?{; zRqoEP+R}pL5=&VvMOHG`A~abZhxEzzHhoGBrpp&1-rfnADOwLdUbil>QH>UzVE(LJ z(eA&57k8ojlk@ol^VRFa3Hw{}B9uDZNid9(74h2}f%`>wE$vl*F8f=_ayGc)ERE4RH?8O(=`iEW--AWUv(gl-6%Z z7KYKTh$q<(5ZN+Z5$Rz2YMDc#oFs&U$KtAX>zT>JNGBZ|Kd_@BN0YO*kwmL4LF9sY zY2vfl`om8W_Dn}=C-1g2->@r>P%OKDY)XzAag~*^cB)5p#y{mFRi5RyT80iBL#tpg zxo8gSnAFLHsed+7mhTn#=MoiGfCWGVI&D(I^c`6if7~%OquCL?w2T{qe`%^9Y@Cyp z=>`#hEsW2=0004+C6!>t zfLKQvRs;Y6fB*mh0000e00000018_|^a2+#z*7JNAOV0t00kHbfB*qnCKFU2J56d* z5Nu!o03>Jt01;r?-E0^_Bcvb=SAZZ$P?a)*LI`aqts5Cc&Eh%VdNUoD9u%3Ap{0WM zp2uc0ee@OlQ&d(7Xd7S5QGmjT=|7h}CwKBos$NMRc3hY2bZkb%ksVk{PYN#sBLD*; z1Uw{Xr5NL9GE~hm;L@H10LqAkM-N7RNj0_w4iFgOqpr~~Pj*>EC3+Sc0LYD#paG4L zOV;dTH+e0A2Lzz8Bcz^V*#(J1i5bo)@LRMh6nXOFIKKpvq>`b}VucyNk~Tu)` zfpPp3)*d=@Ic$r_4$^tYy{^EqtbAZ|u?b?lsm2Caz$rLEpg?HwdP(b8&2%Kci$mDb zoZg}nV8k48U^zSa9fU;f2B;TVD-wwE&`D*PtgjLiylp%8*+)F%Pe{sqYgy)b%f42A zEkmE%IjRy34c6j~IsH~PA3l$j9&2fQsei&ik28b7zbCDZN~&7tNE9NhVP&A!tjo?IN8 zXj@Y?pq`b89f^xe%NV0@t%#;mFr!xe&jm6VZp$p(0x$74U&}&ujRlMH{A>S;2m;T~ z&#En&&pl;D9`enp1R_e7SIoPC`KF_c^2bS`3!3<`arioRSk*%R2}+cpX%j#IAII75 z5iSr5>}bBdxM)Jj6sE<|Me#m7bKDx9e@U1U3xUhzLIJ>wZAolGApCKu8f19<&tOe{S_XR$K*6d*k){Bb743(r57 zBhnlxT*RaIa)%Hm1~&I2XXeIuJQTz-ST!yCps`L51HCEH2r1(VNZKglp9I^{Gp}PL z41fUK)0>YDR?7Lok$omtI_w9}mSa9syqB45Kvd@hdVLvQb>$2lBbphOXL$IF7d#M2QGNfcubIpU0*jx<=h+FXDmdx zWWmTlm`5=Q8Km=V+FRsCJAUEWXveG+ZNfoAa{TWAjGo!98F8x{~XBGjISJ8DO`g-=J_)lblrlSgTdB zpLPRIgoP}FF6u-bxTH~*dX6dCP;~}I*x7IiAA&Vq<~eh{Nys-G9dkyuxOZt^#ZwdS zpiLggu~Wcv+nm|dL}7ETenS#G&h_z3OdqC4Y3@M`Q|^p2udC0_asWO62l-t501=9n z7%u6KoC>vAcW^Y_M@XbnDjUf*I%R0O(PN1zZ3DY1PcoNeI*YT2tWvluYHT73u^lVk zDf5s3&BhT_c*fxM<#NkwNz3DBlt{Uy9d0{5ff=k~6Eh*1)kyKQBGG^|Pyz_YfASa6OTtOW(6H0j?%_#j5F z@}i~$n6z?PHX+-f=7#s0p`E)*ui$eb<*6>-2x}cF+6v^e+@?P|yC(+{0?#sx-T(n$ z;W)mys?Nt|Q)%|gx}`?=SYas|Q+F+jAhb7p_wfd0P9`50AM}bKogiQB(d!G9>#VPr6yr+>~dy#ltNtmB`>G zXaFP^6r3W8PZF@ujsk;X+9Xj&f{M#VGrKv9D;4*5*-D&Hb>#uYH+hxAe@qI+gLJh+ zoV(?w!ioWIFpCb99cn^nZ5l*4gZ!xQdkU;;d*a4Yaf(U4w}UWtRhNPH_VrH)iRg0h za|h52Xg%Tl9*~)~l~z+o2q-8300El}?GQlyY+@p#u{z`n2v#}bq1mz>4 z;8^$C^HbH)HJ~hxNcJ*Ks*`Nrt0HJr&5I)2UbeQ>g(m|R+E%=tMCrFB9pYD%nMYIB zAgMrs*ET9NiBSlIM3BP;EI~|8Rv@xU2}LVBDxm<7g_hM7W|kpD5U8Ra7_v&X(LuGc zL_{zF!%=G~kfxQ8 z#43tu7^0P_C7=~)wW=&qPhyaYfCwlhQOTzMaSrgWJS zWYFh<*&!i1l9@uEz=dnfi5s;@wbBZ6vNZFB$30WmuTHYNEQ=``D&*=K$Qs05J>|&} z?m8pgthK@L{oShOnGlacGHMv-#7jTVuS zutpJkV2}I%6Z)X6SveK5J-7P*r#)Pwmg+LATd*XKv%PiBAc$NXmj!P+WbH946GH{V zio&^#jhKZfr6hsbXfbS)^*4w}#Jb4a%F`6${E@(vuq03d}^W3wqWh$GM7ZyUi_LrHfLKZT`)xQhk z`>7GvV{+)Nw~{_o4)k&=z;l7MB{^?=R+L*n)g~;$(SGtk;vl&mFE6Zm(wwhU7FJ!( zp0!i4+Et?Duk7@$b(WtRMZZu8WJ1Y*fMsBTNT%8R^+y z`Qb+z;vx#Nt`L5Dyc+tQy*n>bt)H82uG$AxB=_3Iypv0!sljsTl^A_KC6Yw&*u(p| zPqW(m+SY~mdwOP5b(+e-Bg(xq>27GQy9iR7ePwE>qh%{zf5?Ke)18TSeNP3h_rz{n4p1w@kT+V7UZEn0 zxVtMF;-<^;=G04zz3Cdb$_%ydcf;!K zDKlAUn$^bL(&xyQpzqN}kJIse0d~m1KSYt5BW0HWeUHS79!SpF=m)-=JClVV)eqsTqYDnoGR5!wdv zdS#!0Xt4wAtOxKY9i#re$~XP*ncQgO%7;v+DZ!MlD0!p#(?^mx-k$VWy=2Q*{6+|# zM6sA(>ueXjKK|%jg7~p5awxL7(QOlq9=4f8w`07G{bCV5q*A}y*Yz_q+R^9{YmQdw zQDs`#@13|`tb|5fvB~6ZoOtGV^KF#qjznpt>mg)&siZ~DR_BQ|?eTw_RhITGA&&Yi zbIEpX9?&8Y>2jaMbXw)ROlMgUhU34GMPuCo)7FC9Dy4n8CL+_KtCsR5`4NIGbk{S` zxAX5Ls~Wh9)1ue5Mz3RJ+a;8k2d`L6P6F7DOMwo)(#<(ZJK7SsLwvA zXtjgLoIG?}d+&g`(>kxuXVLsq$n;XH?=8`?xJ(Q=qk`<5_AWNwpu?h;d zkQIy}RSO}%`~QtPD{|J5YR!=2(us6O-k)NUXRTivQ*z3yaPJ9z4}aFI9sXe4?hInD z7v~xT$j7UZf9=05OI{uhA1;N?dqS=K4=BVG=Gu^WmP$C7;#HUbEk<=}-BXC!3WD6r zjR^H9JcN5s3RyYrzT4Y}y#G;_rYl-lrIqWxT$Mj@-#~~xPT2f8(bnZ`NvEY|wL;`n zwyG{T)4}8$yd)6k!mq!Iu#jq{Ju$HX>CoIZuu(30?|R2JM>?+ne;l0e23>Ce=)D}X zl2Kv^_un+8mnH6TYN~t{rD*#9=tOrlI?F?h6E8HD;>Siox2a?qdv1pn7Phg(6PYU5 zxd7llE=e+(jv`6s+L>UR`BR}~9X%x_l&MNUp!-?2ygMlhtc*Nd$c-zUg@EwxNN*u+ zY7);|_#6+rl11?>Nlu)Mld|!AdI3YNgM3Td`CA+yJ@|ZExPobQmuC^yPpR3lX^{uj zI`+n}Mx~rYSg{y<)o!gr6}BSK%g9=JQQ-O5(^1GSx_SV2_V+{SV=_Rf2c9ZxElQ3|GP*~l9SN&f?n2&wi_o>N zQI}^D#Qr7Pu$8tkw8XTobzcg$RqdWb$sn?;AUn?}ocVf7LLp=y zouQq8l`&JQRnJ_sBk8QVEY>8osdTY|9-Gj@)hrelRzP0+nTl_MBL3L zuCb=dMU`{jTllA#;*XC!jOo!f&sQR$mg+^~X=(vM@{~Dc<{5SC01da@XZikp$_ z*omNVN3N?k{Cl08{!4{&r1)JEnmwVHi6m$|Wf>j+D0lBrK3c{XtXr{t%f1)ldf}vA zERc7?V6w+rsO7^aikUJDu*rUh$i1tNYm|Ba#U)=GU>*1%Nz zL|b1mq5b-DT6>blkz*rDO!q^^nb#}n1nOE*>lHqvx@rcQPCZc5Xn4wBcpvlIsAO83 z=`<-cH=e0mkoh00pC19=sY{|hC*z`~U7g-sqQ&BdhX(3U4w+>CoVU5!oeNkqmKW+A ziGXm5sbPFya@q$RLoWf+GB852u@NrwC%P9kBI&&#J^~hKi*nppt?REv23Ac`BxPRq z>K?w1S>)Q6eBb=qu()#nxYkqkl>F%{m1*T{5^>vO(^AO$q+io?tDFY|lo2Zxvzngz z9Ce z7En_-7bA~K@`rD}#8TmaWu01l@8YAG&B>&HP~dC&v!{BKdF?_6pdZDz_KM%rH9j)W zxhki!tJcc%zOGkG>1Q6}iyksbdM>eoc~-7T8K4}#c#w|!Z%dahL{7k}1(SBmnpSaItnC0RW+JI+M+l zejOd>i=8oEDkp#d00E)W2pAOvz~ON)05os_oq!R9$QnpQlBOVrk<7?iYLhaw)kLSa zS}uta2Ks@7wqfte=BU&z3FF};%4*tOiKLwWYjl^D9f|^7EJDl_Lt4xbYA}SAT4Dl) znyVPyp(4_zR@zc3%t(tiOYRZyQ>-ck7S||P$TyQPfopUyg84^qyzm__Lyt|-gZ(NV z6Th7J!3mmXWkR>m$L~ZyWfY~N;!m|+`8Q6Zk zw*Vo-h0B5u@B@V(J2hHEx%i0+(!b$Q+3r zQW+9R_|c+^Ds+UlaEFq}{}Q1fdQZ{1I1~W{sCi--q$wcYR|xW;dGztJRft{OSjoDm z%56BiO$?+&cfu9gg_wXs)5$VQR9-&1(zE-RKyK8Egx}a%*x{i0qmW2`#C@Ea0u7{t zuH|llG$TUjL@;V+g^O6^MM58>Z7BlL;Kczm3}dMEZWIAALeI9_TQ!+{6<*}$9_|8irE04&z9PWiHpcfTLx{K8NJksCLg;ja zwJoXLQNJBxiY;h0uJeAW8xxk;{OgY6QcK5B#d4JgO%$EQ zvEG|uzgu6*V$)e>4mz$K$%^_Wv=ou#mcy)WK6JG;(xEY=Ot+E;+v!r&{EK>N;MEfa zATlb#Lu#-hkQq5P=g0Ks29xyvzJUQTq6#4g9*#DO$ieQ)C)=8}+Ymu#J1_mJi&~vp zc#b!^!e+U)fKdw&6t0BbV$DawAlnAeF^Y|ra%-&$gwXI1UTwgOz;LCAJzKIbulGlP zbLX=Xh?9vG&p?85re!fM@_DyPy9`8&F?(@2d_bvE(w-!uL~>y#X-+`%L?*CjJ>+Ci zQDjseEjgRXAZszKP$ph2iV3F4wLmCyKBk-akns@v0}5E!I}D3M7zOf)HK<_AM9Zfp8uvn9zn;Jsd^k&t|{ZagxNJj~0viHQZC; z6y1{}n_{baxZLGDSX6)-7b)V*o;`i8cpM!c1q2faepTp2*2?i9y4)N5#T2l@0t5WLV}Fxe8QPc;dD{O;&JHQ7X|T7U!}seXpCV4f$c*R7}P=; z#8f{SL?Lk*%D|#(tkCLOr!I|?i>4GrR11~gy@aG%+=kc!l_bVAfh9>$Qr%2x{LIrt z&QoG~_SSngJy?Wz!r`WB_8$|0vP97o@w`hQRc0Y$IYx_Mk?5Oi_7S`X)dUOl&l5&p zI{=fpO#;c0T8`1Ac=v~Bid8BA6cbyk#L1Z%q4FOQHZVk}Qo&&|--cF~(m*(JUSE?& zZfxy^XMJ7LQmY){u-qC9lr{*5(VRLh9u$4$wSvXsABvBwq*2JO=GzatkQ5 zND#C^23{!ee4H)hFg5$YKcCWHkr%~JCe;xk&z3I-god~!HA^E)BLsX+VH6PqbTXMt zZ*UhqMmE=&UJI4=?kQsJ=7}Pk%7>eh7*u#30Y|>895_l?K^bFTc&;mfpv&2x^RYxi z_g8a{p+jS*Ry&O{K&s1qQ97?C3(4m4&q z4k(0=zq5t}%|#9#IXpaP>%ZmaiP}6inEt;dLo>ZgbHem5^s0I z>IS7-Wg4HK1{j(#$ACSp%`=Bkv<_w=_W|I6`4~qsvSj@iUVP$x9)1pAP!0KE@WkY zO!1bD?zMvEL>ghK=`IRQo}rdnqgo#ROs*#^VVHE&GB7>~30Q@Z4fWJuJ> zmLC^+4J^>x0|L7|$RTcyE=3Gs7@t+`^en0A9ViBl9y-f0lCJxn`fC7*g+iakt z#Jv=l_r(5J-6EiX$1;ev3(NuFTMovL5ZyWXQVV@5Du8n55jlKCk&Qn9*14Ljg{sfv zs};c3XoQ;ei@BHwF^Rl9kj_Yu?M?&6tP~nS9T`a+?kQ&EAuZ`9dI+6oJW&wh<~Xy( zILdPfBn#1&BeI?Dglnk?OIvZ;uwMr3j_-qqH&Y`ksMsk-`#wX zc8#KG#U}PdNQ83SF8M@L6S};*jLzBOWCa`5@xFTmU)AeBhqk?x2pCcm#0eFkfD?Pz zz*11AN>Z_ENQi`}J!>c0gkH5_FGA9%XXq6enZ|Vv4zoA(ngxU+2nK?9`;K&Q|0ve^n-2wV`j9uOf^DXD9|kSHcm@x>^Xb=QADEYMF(1tS9W6+vLV zj}HGuSd+q);jYY$nJ6jp^qx!!>SFT7(v2MOufbyrMlv*5H3|Ks45A>8`ASz%PtEXQ z)EXcKz#svE99nIoI06HJz=Z0JFj@hKrZ9^JnUbWz& zd(0GrWmfP2L;+g>Yyd6b0004_EAcVJ(%iWu=R#6#rsrcXH&m`^Q5^DW5fWDOntGef z&@=);v3Q)6ZF7$WGDpOtln4d|nb-Ynm9CUTvVkKnHEH=7ZPm|**Jb2x1_{I&F&^iT zDh45-);@yh*@EsDW1Ui(RXH{ttVF41m)QD^#&KxCv_Peh`jrdhA!L}ceVKXI+Z;kg z6dEaF^(yccM5+`J5(tEYL?l-7$t_TaAOgupmP+m*f>8t{ilGZYrGi9CB?O3|RV-zr z5Qw6ZbJ zVd=eybd@xAgDAtI)a--4Xc`6fgqjts6tRT3vjxhI;Z|ga?U5yRaaH`Wfau!5t!=Cd zl_LU&T~6WlhAR;YCch*NAD8F~9XRId|H!;Z8juZ9>Z8#e1fMRE?xQ|0|NR-IZD{88 zEWGq(7QJYzL{B`(=_^O1jgZlpBGBxY?6vd$`_jjZ1Jq)Gc*I=u($9$v1pVD>MSEpE z&w*0biY-N{(xrumw*!`b?6Z+lqxScr%npTgHWoDfI$4gCf3|_~qJsWWpzi9KgKKCOcyHiY-Rt(u**?UX^)6NHdJFeQTACLB^b7UX?-)L!6 z`+K7m*pRFu3(uYkE{li<{W|>V7KM#ohmZ7lqY0?-p6Lj%Rr1B=0rY)6d%Aale3RFa z1&B;&NV(CESuS3`0A5FCk0mV~bb9nq(72K!t+MmVWY{ zy(*?gQ~WYBOwknc1`pKf&1;z8B8Q)y zZHV8Y>ne(8F!hr%i=P~3N8l{ZVnr8wk@P$gQQxA!Lh+^wiU@(Wgxu7giA76_Or923 z6K`?JI%~ICE-vCHBD41D`-K@`4t61KE81*rJ~H$Sflut0`f~v8)p-giv^}CnV#XKngwN$pcY*sCuo0cR?_w{N_Jg z;CJ_*QS4zSuE{Myrz(8SM}$Ph@(n3*70D9SjQNCTVg&w15ijDNPFmmWr_5V)rOXlI z)&OIIPat+ri>GHwg9@-x$0Y*d5yzJ4Gr=^R4b~RYrM{(ii_1%spCmy{Q^RK#3tL*m zZX~Yao$ zhYlWKqteG_lOW~|gcy{HOF>w3cod>&XYY0Tv6el}L?!*N)0T}H5I^qD2}tU6Nwb)`;^3-EN8BXLJUq!s znFX@jCd0^-=Sxy4X#Lk9R8)Y1G+ULPU4o2Jv{B2JOw1_ASt0Wf(dLujrxq zj?Ru%=gB@`!#GUAYHvfDBylilTxAiZh zGd(AS0^h$#k)sjhiaF^k+bvV;6m3QS&p)`KmI&L-`Lf?BlV5=cvNS#Wtiz095(UZR zNzPJlTrap>In4$cqg-smg&{73ouOo!N7)BD zN$vO&i)B82n^A9;>1|e(6Wh<4z6eR4y355CC=r8fh##BEE?~~GJ#Tb;y$dD7ZCNzy zyVV9VxvYsj&$3x`DQUXd&UoYbNjh4Kss(*!%Npb1C>x#E;SRw<333#Ul;wzamx5{6 zK+_JXK$$Omz1&~JqeSH}@hOW; z4OvM;cfz{My95|PB1B?#Q6pu!Guaw1DS$>2QDM`@v?~N!Pa*Y5wyGSyXi96thH^Ix z%_N?cq>cAzCk1>zn~`I3P}rugHy};){1ToE^Yz4w;Z(G{2Am(Nz;N${*pDzZ3)nNR z7m#-;EUJh)*G5KMHzL$R7pZ!J0i!C`76kQ9 zsOO@}H3by$`l{pr#d6ebMd%#c$=ov0wWUOzh>@do!C4S^_x*TM(^T|Y7FFhj7{{f$ zL{;RqgZBc)Gx9Uo?emz-h<-`rur5SKdf6*M&whho@+cydVo{cNAv;Z{3Q%ihxtu}> zhYcer6HYc^MRycLOv)Eh3Ep@5=rp){o+094L!87i99+rB8wfE;kTGLY#}P2p zd1?eJl6rH4wo9c$d2(&8l3jah3hx48Op0Bpw5P`&WI(c~f%+Gs(&B@%;Iw62o}aS0 zM)>_weVNxe0}ardmfh{s-^V$?zvg20q`=ymtt=(Tq*lt?{ZAHI+bZRV5D%|QEZIfN zC@GYpm1J7Tu63mcUl`&hi%NJv?qc#xq*ET5XRBw4$)*OSuV)aK;aG>1qPHyzII_)# zQcma>6ha)Mmb)nW7eLk~+K4Duk*YA$TC^@;4M6Al?kD|`*$c`=x0RZ+Fb>LoWdaO8 zvb9;_dn{xB@**T{3R+qjADM@VsR%N;tP({9!^JcAL~qcLE<&3r-`s@5&T|liQOKvB zK_t7J8>DYJ2th~E!L=O7$SWAgvn_-%Og__Q9MNqs&>?Sf&J63eTk@7gAlniR71X9i z_ZdP=r{X!2!Mi1*#_ygKJiDo72~l8ZEp5?qU0KBt;!76=X!YDd6!He-AjU~KXccm= z)Ol?l4_ii-L%W!V7rjTW@x+hHxgN+IDF@nEq=R|L&4o(6c11l2b`lKD7Y1;y&tZm) zCPITzGE#13TFdV&p^TV#CVWb7D4L<^{3MSS?E7b$dj;1Q!K}} zi9yGFSU8(D3Dz`V%A4v8@oxnY{ui%uD-?0)ai*m;f z#?#?5cspeo6r^bwPSN9H8|ANVg=|9@O_f@65X@zniisY^jT=WyV;ag8lOj2zBg274 zz1bZh`XP#~QC?T4JV?(+FVtW?7S;r-0;FQIQtI%fx4T0D%C8_u2S$N{xIWAk?No@5 zri>uRrKYQY*HHudpRYM2qrX=(<>*5Frt3I@6weNkof-2g;RFIlA+udYgDePT4nd?n zcN~Mmorsym1y7S^8gh$Fc7h~WOdsOyS- zN4dbdt~HhlI!)4#i%$uGSaVaI>+OPO?T|NM@uz_VVOkE+#6w4H05OIxg&UqE=db|8 z5tx!PhD2J<>M}P{Q++yEe>}40VT?<38rVuAAIHpaadmD<;`xJapY~PDdIu~cA$v<) z6Xuwbh>wD=sv^aYj@5Bwb*C#Cy-cjGOXeO#Wy??MJQ?=6V-kRLPXI)vEpVMX{DJFJPrIAZtQI>(eM3PecnV)F57#DhY>4d)AWfDKZzh z(JYI8g$Xb&ELsMvusV@G%6w{t19;gI?KbB)q%sm)acQLnrV@)N8<2U%^Dw2kMSkTC zXLBO7_ULYj?v+R@ZG=mtQaBq(r%Nj0rM)1qS}`&-T|-Dx?oBKgXnFF>DF;XTsb?wb zpmG)&R%u#GmYFlyB^MDVW13ahnVQMvyD?TMBM8HG-6vGQmp5G`%o>GFCI`Z-=)I1V zby0zFi7E0$HtZ6FrwvS?jKE>~rrHARvghI5F=^G;y_A;-_)T^r$X*=KB+@d~0#*d# z>u6m{<_(r>5zzc>nI68=P`eVk!~y!qJlLz)U)0cr;J{pP)mted@YEljq?mG={kv+IY)Q}UK4OWmrn*wrO@)f@VFbgSQa!>zJ5Z+Gg}3geTa*?o^v)z1 z@_{un-{x>jch$X;BWlAf7SlO9v={xQ!2M^%062LN0kwJC2}Yyo1cUhsY;-=!FSJ@LAZ%VpjtQ= z$wx5qesZfr;_xTiU|d=RsgQAdH9%m2Ob8^#NGL2qNhFHy;zVk3NTwi#GLs(KEHucW zQOa?lSI71wB-_y-ZEf+~ZQxVLnJd&Q*#Zf>P6rV3E2>~{6*?j;Gzbrt2Y6^^5rF%S z;D-jMQlyVoz$}yKS*}Sc7sA^W+tdeqc~1$ifTcmogMgqZhF+JQ#AG8NNmL}*@+)bX;Gpo+1}KV3E4YPuVgLXD z0jYq(BTNPqFA)eXR5JA72JnoRn9-F|ksaB0s>v2miJ5Sg)Kd`-lF>y?3{1dtt6vy+ zzItS@LK#_7DPlJED~eOop2^2u?qQ zx+MFka#;`=!5jh9P?oaT=b!{Hl=etd)(h0cg*<{#kbp#^Xg&vy4JhjIPGCP2{Y2Zu z91h(Rv}qZkviTZ#&A${fuasLbjXkImxc~;5d%B`RoFC-fpuo}H4H4u3oDDkP@qW$-$V-6h!)H8wAx?Na7u^0F0*3fJC*1;-p~Z})>`B-axP{6 zCM3l#*qeG)K_*mI1Nko&L5Q;^%uq?6sKn;#wsZ6<+Qistip(x#lYg|gQadL*Lx{nC zFInRYL>grR3T|hq@Mc4twDqKt-0X`<*;_`s@kB%;<6xBuU{WGVnayBqyhN6p9jg(E z$8GUWk7DOV000511Q-Ya0Am0d000I600000001BW00000DVRVM87M#iFaZDn004jl z000JD#Q8M1Dm0pW=rqx}=&CzZd)g=oLW! z)KK9@ zszs%85tkA%FePbRn@;z2@xNI#)Chd19h7QG{YQtbXhV9jcEoZ7%PGAeSy`oyE(H^k zHGxH3OFMn~4NpXrdO5S;dqC9S{x%mVX+0-XRm&l-7=n_e6X{;wNuEnxVDO^^3>+4q z9ldIY>2yet=qx#Dn*=dI?#8|(TVSfUrns46?MH6O@f0a&3TNXuFD3_Eq@*n|9Qr1=opcB3 zK7B{4ASo2xLs=RPs5wh4xOV|^vU@qb%jJ+$ut?G}9Ol>AL?+3xJ7wn3OqK@)t@6r3GZfH|e!*i|I@YclS67LFL6PCy9&lU^vc(p3upJpw}xEOABpT`g+b zb+Hi6B`tOgq*w|4;7rJita5@L;Eyar$VS<1bigqH3+On)jMObEy-^RBcFkrxHH zx`9VmN`2)~6eS4sH9S0rL!Y`lSx#FBg?y~F8@sr_qUus9IV%+s#8k6NO6hVOJg6fH zElFx2y}c@%)Z0(ewrbWVni`iR^(>Y7r2y|^2q&PvVK!PWAJrDF&E9klcMy<)hj8Q|V(OJcAF z*Tcnv-fBVr#al(SYqb=~wJZ($9aXFsyyX!pLrt(-;@Z)3x)JkEd4n^2;SuBhfP3do zEENpI^jI!O3>*}1i(yoke|Y)LEULy6FY zvf{yf%~4b8e^Ruot`X_Y2fy|bomEh0#yy))9=pgj zrNJND-CWwL#eA3~t?{R~`E_h$H2l_F&4b^m{voq&c@jXM?&@$mn#6;*yHD!`;*XKR z^1iXtmDG4;Kl}~(a#=H(C($wm2;TCKGRsfO=!M?KOdynQBp=_O)QS# z(D@npOhSN!Qt2x6tEZKjHzMa?;I)q9(P2J2@N?30OM=V6AhoqyIbH{1LK9zcdi$*y z923dU>q9`Ce<^+-ne>9fEZBX;mZPI5-D<`Lo1vW9WH;M2zDfB~I^?Cjt%1uy%rzU8 z6fCxqEM!?X7)Qwfz|wyaSH6-b|K~_Qq@ZwA?D3~^r;pQ?Sh>+7{U3`XOHwx9#hQ#I z+kXX~P`pZ+d1{p4TU2Y`-`Z(osvTY)!R^4gKhO2SAXkKMJX}p>h>_<3O0tBg=vnNZ zeAC`+^547QBun{J3_BHTZFvH~RiaA{B%qs*APp7?XFbe?W(S4igiqA+yQL{|ld)bM ztmjf2*e%)d#TK}Rwyec_=} z2T0E^8kSjPD&jQH_c>7^U5v&oSc4vLidxi9;*TO{q`FY}e*Dj)4G4)?hrQb$GSGV0 zMvV=BL-Og-@;I;s(V@~@zqahP9HWCHO=8*G6y^iu;08nSBgrKi&e@M-*601rDu>xk zpvV>PJqsuH?DFLKwU1f=|Htnp)*1>a`uUt~9zurp-A$J;sTmv6*`G5KMwX?PaWLNK z;2ek8LluSRZ4;+J70Q2TGBP!7XOVsb%Q^NfPw8_p^@u;I+=vSE#O0i6MlXeP`?YCA zqEF+Itnh;2pr{*P{NiG)2wM3)_9M>r#WBR-7#8HE2m4B4L`LVj-3gn4klnQHrPK`o zES}9ydWzYf6Y@Q2FV?xb$x<>@;LCg#MxCR!vi^14)VX4AVQ8y#R*YunO%h;dYHQ`J zAcQ9sJMYrQwH|Slc}$xp{D>q_@H#4%NsVl;HX>4*pLfN8*&@#}ZVp*3%FE=!v<*_Z zo`g2%+3)qmE*T@FqJR#lSd2s!1uTmwXb%brsKPV?kf=WkD*sA} zXlVsxK+h0W`x;acG;vr&sW`G+v2y9b5=H`og~}?s<#-F}U0td?g6m@N>)AC(!^VSh z(EvX+cTCz{f>@qMcXka_=pg6~=J7DEM6oPl2m~M`R}Guxp)K(~qk9vTMGmo~wO9Bh zZly}pl4DAt%6cJKb)s&ih!x^N60$%o*f-o?TD%Iv)-cHoR(J7*aaorHsu3Xo?Jp{A zj@E*gE=gWFl2%}4g?!Z3t_rZIyNzO<0zYuAj*k&rdb6Ga%dr!SLH|GL$zKBJT#TJ5 zHPn+6eK>zQD%`nsBnG9Wbj*XUDSYUtau4^xeK7M^6@6Hf{IsZfTLZ(#<$Q^mwrX^i z+<4>s|4V8bjIE1RVog(SGK;l!Ah$dDue38W(4I%YdZ$6zPe9fBlH9KnL@tk9&PQ$z z%0c9K=KwT#GLdg|6`(pPNLzDzLEAW-gSv#x2M*wwH)L~zqW*o5*#;%dv<8f_NmN?b zrSSSP<#aALg@+@enZTk#hdHo($b)`p9AdhUnlMvEA|fpraF@anpKt066`6Cu9xQ0w zl9aM38OUYI=4L_PGpF)npr)TBUcrMX)ncCAGxu~=zLB&DloBm0qfY%v{7Y$xLhe;8 z`@8$K*y)SaT#Z)!vEt-UA$D!H-3X;Ybb6?@m=`1SMvJ*H=Y`X4R9>4Zmuj8);two% zg52~u>p+O#?(BGevHDd^vZI!bO+Plg2Tj*E{^U88F07+Kys5FF$e^gWwrr~5{F(hx zx1XfyJt_yf$>gia87xNmK)pHYY|d$^a@VoKi{13`DV}uqc^UG=c9Ycd_0LvX|0IzY92L4q zTJRMRD|fd2{|_G2zPNl(+MkuO@D(#GCMs*l5o#rc7u@$PLc!zI7+_^2LPgPGK_Hq^QuQZonql!hL z=S5D2U$I0O9C*toOX*%?of>~kr;N!oEvq0O{8ZWhP{N76UPNG@5fbIZaR-Sqwz*wW z_@pWL6)hg7(Mu2PIh5G@hzFiQUp&Eks7^2NI(i?p38LFYdqSi%sr)?9eU1UjnPz1Y zy2bmeh18-7SdvGA`O4^LA4zEwBJ(L9Fy(eQ(;h{Ca)px9|MixArn7=W!PDLJv9x?$ zVty`~Hi!E7%gwIhM}yy<^&oA)tFu&GyD1XbnnmTjj`dk|4%)x-Hfr5hx5XF4thE+& zip$c7BG?)JYXSE_yVoWod7VA6Jtj-%&wU~{!6iqY`%+ew zJSvu{*yBQ2*2ZU&*tKOToKY9@K36C&O`x3w)}}DtY=t0weMs?XhFe+T54*hRvtL-D zY@5qcE%ENHsho;D)}8>*Ksd1|)6+)F>!}$Ae@=N!HRtzGp0Hkw0{ zW_--g*zjGasNYq&q*|?#IYZ-zMY~0oBxNAC!^#B;=^nG{DC4KOkYw+bzC8C3T*G>D zNr|Xj1dgL*2XT#)69(!_$fjs{an$h2lsRT+#a*sPo#CclOfAryh3nmZX zA6Bt;|1PC_kyH47n-Y;zpD)x8XYnkgX`%33pqIEiUb56yJiXwR?gsqZ87`j3k=147 zqqVol{ilh$^K3>R{bG>mEi%NK21ZhrH3ECTs~W^g&-N{XpO=>mPsW?L$F2Q8)20Zf zndjd0mI<4x1oZ2^y?@mTxR_pexk_ID>lBnPu3WJvp>C`Z#v=U>C8qikzb*YV5)rvl zl>JVzdU~7qmCgP%ZB38SIA0w)KE26wkILm3Tr6It&+Aik?^GH$#my7)LziF`JPK)| z%U2>MDlh#d(@6i)IM$#1x7fp>W=WR$5Wgv%$hi_W@cIX*(MWV%9uLL3wLT@$g{D*S z^S**y=izm34ds@sg@wy2Bg!3f=oI?g4~c$6ZGX@6(;^Em_1MLM^^Zfwv#R7|SvxPx z;>=!RX{FvTGzLKKgTDq1N3v%jN4+YZJrLUOn{p1xnMZcAv zX{g=F?jw#sXSlI61-KT(nHt)4)-z>A1n8sP_0JIt7FG`!eG~69HZlgJc$Qmw`27nl zua;8dyw6zW@?=N&LGR*c#aC}HzdfPybhS9Y^s;0ZPN3scc_eIqtU-h=BKWlD7cfso z>_Z?+7UETsG>H+rIbWeK;1XEOk|uXNeW2SS`{WX#<=T~a6mgKYVp?v%k$zw?T*eMY7)(etKxvg;2 z4y~YjtKPDeWDGyIm&WhEYl`7kABEyj>uokSMec8sR>oCWF8aa7T3^%iOB)}bh%yU# zpQ8A<6SwIZ_qqIkzf6+oz2S1n^3+X@0u8s$uhC>`RwZqWCr*QJh4HKt64qTSR#K7( zizyrv@=n{cb3G2&C{vME546b)h?hfycUKR~Y58fPSeEvVXv)`&4rS!lGSqsv>C+{q z7k`NtG}qF_`D1B}{cSY}fsI1fz%mOLD|9czU2Dd+h0J`j9ZEm@DPuJ~AhEn4JU&t9 zPD?FsZfC5w_u`j~8!ybXq@zOn4hgz?T}QXfNGMuhojuF-gGD7M$p4jlVlEtv2fEzm zfmkN$7e&R4zW(jt-3?_D&mx!PE(&J_qS)L7qrg@p(*#;fw2%CNRic#!AVZ1~sbkzA zjFeS?HGnV-#F7TcA22ChT_6t^A~GyeFp>eu9+?>#nWB+iu4GOk+IY_ynd3Z6m2Y_% z00058y<%f*1ON^IX`L{ZHK2unkz?VM;GQ?lp9WAmtZDTLr55-Wd@3r!@zJrRUc95&4gGZXa*)~!uuW;az%LpMw|FH|lae&0KdvWSC8^pF-` zY$lRzTWm;{cy^3LC=64bEsZEl<5gr_@@FW7f;koF%7kwq5kw)`R~&n>66Fg~k|@A* z54R-zpDZcYG$u}28bl8Nzpn&9WG1{ckjCC>4d>7fL;^SuT3LZ*rC6BRC2WzWLIxIT zb%PV(64-&&TCNB~iN2t+g==-XMAAX>7LB@@sUdU^B%-+*6^VG~c?1{V2QCG*S$Bv} zdg_iyDLFIcCLfDr_Y245UXP$Dq38UNHAeRH5k|Sk$g<$F_ z?N{;VAOHXXvH}1A7yyJK2n+xK00000000000000005AX|1Y~Xq0KfwP000311^^%g zD48^3$7v`7Qmmo? z8G6&apO8l$#RSuB1kflY`fuacO0%>DLh?!z__d0iA$5*0CU~_i8jdJ^5+o}G7*WyV zvI(h&vn_#pE+*j#5yVI><^?Hc2n+}u^t0MLUZ7FL^oh#_a7h;D zc}zGN#a5dOa5o184Xe3Pd9g<7AZ!LFIjLDON;LVb`bs2|TAM9uHKej?3}-vGSn&a; z%5O8tSWqfm!5SrW>omWn#!oZgzL+LQniHLF?TDm+4O+3s@;ZUbhMYc4rZoL_y6@2| z5OwTsa@D`k*H$ReEy4|XiJ~il*XL#VVic;yg2C>X&Nz|C-?1m98Z;NAkB?1$WL2G_ zT2U-O+@&xU70cDDsN8j_=NYrQ=_{+u{Dy`q%V8-dt^e~|;PMNj>d(lDh1o0N;8%|B z`wigco)QEGK#&Z?PVDd|Y!kF7#i zFM;0T+?2*$m-=SZ^xj#n1&doAKLUu6EAui9LTK|xKi|vpYxWj!0-Xe696&^h*_^J; zWkD?5pSj}on`}(sSRfBVL4GCX@a_o)LT86#_p2O0>}^c=Hk4etHZ7zLCNJzmU|g%D z4C3XJYKCZpzOkoW%AsMPCI=u~%H-gkYhwI^LD=5yj}%C@+>y}4wZxWW=H|!X6~xS! z=>)YLXwmy)63YQgKzqe;Ne!N~4b+l2g#yR}XHGs#HfyR{a43)yqG-_Lp_$aIcbJib zJQ}Y9aSM>SKIgm_bI?&jZAu7(LlIy7DH2U8Rhj8(r4^LAbDbcva+$9(ain0O3baZ zuPDZN30U(?E}s;<&9c~<9Wp^Fa`fzAA`$UCf64V@lOTYlO)&}y^Qg3PS~)HWZNmBo zbsN3+>8$iB5+b{8=o;x`b7kPnfu_dEEa4@=^_NOrDLfRdx`q8nxW$0*83MqS-52^a zltRyxlnba^2hnDP4VWn4m5{cz25$NzvVqE5Zb0DhY# zf^&HO&J;u2t?`m`bK^g)9(zs{QqLXf_0B@~;G&aMTIOu^q&fZGhn898DDau^P1ACT zonf=5$Bz0ZCGiO_5jg~PFa7zHZ}GwWeki;z1Eo*ZzD<%+Z%}RE2Ovf*!YCAZF2C`- zrCc#@D8Qakfm>lr;EQ{^}p$xznCY{`Ua-|?d@hNu_J7jxq;UwL7{%v@@vGG#VDZS7izVejWGMNC+Mll6X!LPK7yNpocqU>lBtM_w1agKe zL++>>P(4t7Eg4H6rOP`Cbix}3P@E;ax2QdE&>T~BVkopVOUFOQ+;tQz*k@$17N2x& zto zASxD@j6=8zc|xnuW%(iCj)FFs)WhJEx@N_L-xP88C@s)vDTz@JBs?sxhYkUcgOl<~ z>*!knji#ZwZRbZMGq?*pwC!+Q4-(E+O&yZO-)(iEKG1**`lLV_lC>5!96?@oi5je>m{(dS) z56>iJkMI)og9aDlO&qad08M}lF1IHll13R$l9L)&x;p%=C}YNqreLy;Nytt0++Pq< zCqRr6mP&?42s>FHe(F5im-XCpfSAexno#di`a_-Na#?m@1Lthg@Xqb@>;V^% z!E$>%T^PLjT(u=^Q9e?%dh8-|MM0!Ywkm=RsW3Dg9|(175&?4>S>X@83R-tt`PZqA z(OS~=rQ(UGko1WW4-{z9dq*8_dbcrO$4{^rMR~8e}wP%7FSa3ZR!Ol%lyrdNRM<1y z!gxg7g@bUEvl1<=0005A3xWw0W+>jX)GVy5hRq2IAtMMP)}EjVcat*8LfU@QdgFC1 zG~6t)Lj)mjB$$~`INAjfWV(;^NEYSVOQEMEeICm2<#xuSeTbpKwE=k@)b-?Str1j5 zvc2`7m*8%Ru>|kMdW0Iv(l+bKM)oPMMX@MjsWG6f4DEKB%-Zw>#*NApri{0!P$h&l zG?Ud%YE?F^mBFaC+DO1zU@Wmk5>!$YsPt5c7t<;D;G1YitTy_3)^c)aL_)nvgq)PI z9EqTw#tpn)yBET)T3PjU-=~@-XP}wB#IdMCL8CcX29o?kUP~g{x>hwLl7U2pjp$Zd zB}yL@PURec*2zt5$k{QrgWDqV1s#3|ah;q)8MuXtERe zVk-==NGc)JQXqk5qm6<^Tx>xhVbXdkSfVP0N{D9qAXw?qHVmw2uOnHU6HGyu=oos+ zwg^I#>kwQvO|E_lFVBHR zkyYcpLN{X}5-x1pIO=Sc z1goKQ&+MdCAgcn%pgOllFLdrIEtU<(1Q|C$82a(s%j**V@Lrv9U4qN7c-7LSNh}1F zVwj!4JwZ1yr-f42&7v5Gu+_iuEE0TJ#l8eu2S~`fcE$Kp=-9}ifo|v z+S-4pDq4XzJQb!?A8sE|Q#D{8PS_{vG}Y%Li4Zwc6(uU!oEg_9^ubT>=mjoM8Vg#q zOC>?!_L7QK8Cu)obd!**$bQ%x`vbLf zw{UaGa2byxj!dLKWMwEQI#K6qqia^JP5SX1ND2tQVjrMbNO*iqrqsq<$cZ#vg-GB& zYt&X0-UKV*NL&T38=)|#hbN=7Iqz?hp#)5o$CzvvJ*(7}Wd>4ajxZcX?d{6BS5=j9 z(eZ08ID`=7z@M3O^WU&hwjx@`=GM!}YsIFWi0$W>a(KS#mQ)!#z`tV+OI??;DC9t}G^@&jsJHP2Pf+=#;T%bdGM*+wg0 z^<~czZ#|EY3Wz&wS;zjVSbDtCZRd_$qOf18#xErX%Pd@g@L{#b^Xdpv+<~^=3n($> zP_JbH$HK5&mDxc~U&wNc8SCSMcFFUQ@i|}J$2|8a4Fe-JYP|iFr@EFmw;b_ zb*)+QK)cnd9jgtI7QS*HIVvd;(NlZWSsUkmq<4K*Q{-S)iq)uLaya12wmWAiDsmot zt^L$**9YJ}fydrz*q85Dj1IMyc5lfuW9TA^g;H9N-_&LmRVpaDSoaxa79;&CDlLOs z^)&OF(~+2hIt>w$sqi4zQ|sKe9l0_gh({!N@p3eD zS5_hjKPCNV$bh!fm6xh6&>&%y)^FTd%8~yqO|2`=6=Lkm-kFkNc4#r zh3`j}SmrwSLH-sBep2TTnoVHho~_XL>rjdU?0EaJok?Cq=lLEGu0A>7zM*OVj*7=+ zXs>Q&q>iLve^iJ)yY|uK!mn;e=uRdC$DUlncdt9B+ilhAwQS}x7{X$JL?Bq7z&=2xxhghqH_Tgl6rm0as7*ju3 z|19_XjFc%Xt<7t`eu)}lrF~4sizn0k2$oyFs|0JMzGt(>NWG4v`}^yY!#X}WLV;u- zL)6%pe}34%Q7S7FAy@!^toPl|;1L|JM+V3Z*F*!SeEK$_DmkAtT3q?_OyMWu3!|lG z)uHV#M<2)zkFP_KO24SLJuC`+$kTZm)|;LFLFE+(FYJo-388l}`}p}5mrp6@z@T=z z$BiDBEe)8tBI*95UG=XOch(4$mH!{7p%>RUG|bTwqv4=(PwA_LPK!}D(DBc5n_RO> z3Pq{)H9YdZnPZ12Q%;%ga?I2}RUY}5nismVF57Znm0sj?Vp!)%ar4HT>Z}&25%|I? zEWLwjdF^Y@R5FqmR36Z*z2=O)Q+m457kU@K`0oOc9UUv#%=UzzPZ>vV263nUAIBCi z=CS_XRa?+}r7bGDD}XBUa0lJuh?(AO$u6j zetR{Mm^VE^Rdab}wZ0-#9E>mb+JCyv} zTNAq^z@~NY(u!Jy5H0puZGZL2d*M$3-8zh`SE`ZU+|-|cDQ0Qhk*;X4Y?{TJ8Wt7| zy$W33vg;Z}?`T=?_+LI3SrZ{ktb{U1k4+X2{_61B%B@^{L2vD!HoMVfph@_@QZT(Y zk(v67q_JBZbXy*Wlvzx{AMV=r@=9zTFo+etg>74Y-9=^etfek{8yX>aj>_8k)u^TK z8cj&#cA3_`cjDV+77pU`ethGPk{jz=FzG5Xo&eP5*^tf1RVD=BnZU>~f(7>M;r;H#3>$3GFN$OwvzxSF4>NC64ajZb!OBU-K5fWkQ`mZCvR0IC$qFybs%*o$Uc)lgd!DZ(E zT-zUYDh&TL7?(?5+G&;uQt&P1D>tsoP8d?gXnrhsx|XeS-YWDDLP=QSt1a+PH3)3L+`Y5pz1idp%KK36Q)?nC!G7bx;I1s(xC1^D9UiMT>6jA^7yxM7DFig6s9&p zjY#fViSs<zxP8s|OhG1oyN(45TlzgRG2d2O*a4w@x}wI5#++k1b~T+wvn*F93l z1!5`cDvF0qv5__0l~8(C`Bid@d_l2cKC8Pa*V4qkrTwhUSYZE=fM=MwlXEz_Ij+kN|LFye&%}@EwUP~gTY&Ld zT3t%2@!43=x-CN2eQG~FoAo1$Q^fUn@CXa%Sx`G{OmY-JEZV-;z1@pNjgcQj%H?i) zc(Hg7q>@a(g};&Xw~|Tf?j%sYvZclTR_YY8D+E-ERgCpy4=f)-kpO-2`p8Qn4%TZdjF&P%(=Vh%Ep;(P@Z~s$5GOtsc{B-{>3Uu~&1N@kR z-4}~$*y7oImn-Lg)-5icqm+*SBJ)^~jEQI#kr^smq(V;V?yW-2Sct|Fpn-vU;W5lH$&zwT;pI6l zX=pvHda3LRU2wAqXn=t$Bg90gl|}U7$f^e`SQ-;7T3?$JAkOTBqidCdNhxz-dNB^W z0fu;XxXiET@D=rJYCD|#h9W(ZT%hj!2r^0c0;ff}-kMEldP#Z|#p$(^E0Gi(45UrL zxS&pj<)+_Uc?VW4SH%q#%BGcVRHm7@gY8MolG^v%Gl>Y)+c1G}_?*3WP!n(TH@YD} z=rvSBM|vk>=mDhn08$mC2q?XGLQxTs-U%UeQBgp8QHpda1_Y%j(tDRC!kh2!zVqIh z``5kq$?PQA&Ft)FH_thr^O^IUqfPY+Qjo}fS9mJ<5H;*T*_IApy7BhmM#l5Mqq-Xh zE9-flnQlaxMlrX0asC@dX2vbe@y<=A`cE56jT{FuYkD8@VykB9-<^x=eY^u~Z+u)! zFg31yFIW+jF?Mg(iMCBBzP*es;LS&ALl^ApezG*J*BcgS%_pBW-om!uJ?14bi(7l~ z49dECv$&sv*Dv;oFO_(z?#90OqKQkUnqK_(FW(ZtPDn4KMtE%c`Ma0*HYG^#6ROBmM7~Aop+0P$@`E&{MOJ}7+NHc9#djBq=sJZE<&dELvc8Fy!@-0@;a44jrneyq$;q4BnwT&n2# z6JzMhQ##?+kQvU$>uch@UoBfF(rxsTC>nK`sdZ%&JBQ^;Gs-LQ)I=rfRf%<0a^&Ez zeCT96wB;ZB-B&jZRW)!rAmnJU%#|1ql74`f_BqqiSBsaTrjqQHB!RacTZ>eS{v-Rq z*c-dwX!boi@E#;4kQf(Bceh}t;wxE-{Jz(-R}Ix5Ge*R72izBSR`;V9LpKYTGxVQx zFnkhlsZS@pKl`ZO$Lt;NyBw|v&&n7Yj}Oi($N4ks>Dz+mmYKRn?*bDg#%GRRF_XN| zYoC9Z!VtXDPP&tuezRdeNFM+@!`?N^7i5)6C=v#d$^Pk6s1d_zpKmdKApKWN`Es*=>2BWX~w+p8ZPzBjXN~S zc=uJ2zzeaWN5ngde0pp!F=~vslAvx>7IK@HkiY2p`ZWA~dv-uc zrdo#T0q*!W83O{l^m%k3$CcUi(uhC)>Bq1+4^;)rwTNK`xv#l3ZOY!Nqm>;sIaF3) z6A9!diPRI5au$X%XMtgt>zp@Cu91Z5-Wpj_iBrWQ?yT~sS=4xz<;BhYV5 z{bJ!?REPq66gkQ13wGX88B%Y7)FQr2hl1Yf+O3N7qj;EQRC@~q)w{oUOM80tfMOyX z;E_z5C#Kp3E_!$Ps8zesC?3sc5AR8QYOty6@5{dTx-8woI#K1F;!hSoD=4Hw?(F*g z-%lmOruoLOmF(%7ht65dPxSJv1j+Y)Jz|5}Up%Ec{B?5ajq>h)&r|^J7ApO5T#`E) z8bp>-v6SjVUUjdq=Kez}GmtIAn)ce7%;9cdraHeyAiIvGL}jA;-Dl3e-U)j#u+n?; zj1Mxch1E#b=zO0{udZK{EV}v#qoeQ_Xvy1}&^z$jU(`JvtEdk!Fr{9X-uc{uV4i|X%>)r!h6uq4cXdpGu6C*J*$ ze=ou`G)6x9{a~5w9gX=dl7t_v%bp~1_C%I4tJVBAW=h_WoFC?_pq6U^F>k0t%k>Sc zDGu~EwCq6P7@s{e&>Cy~nUEB&a!5sHSoYkLI$#aaLa{GdBQz^%lEPZ>{v}aQ`6AOY zk9j&g&7Zlau9KKpYhs1D6l+ZSl0-W242;aR1xp z>brsLSoPwS4K!L$#uYUlZvvoL3H} zxi5BUOie^0UbheXhm^dFUDBi~e(rxRnc=Sv|30Fl zX1WQxrS@KR%`v8vYA@Vv>0~i^<;f4RrpIFk;_Pn9gFnMJ48BEjZ`$4~sBEX^4z`;< z90BUq8&5^p7G7woeIfex`r#*CM_YLi$(n*a^Y?LUvz^1#HrMJPfl9GDKT75oV@rsS zTO|W;)Bj=6JCM4czs=}POnmk6wk73H@2}2W z-s2Pzy>$U}E$^4@YWvYWh@@bho`WT}#Sew!5(^>&+%2Pac|LH>Vl4`qlwlD{qw5kiD4ZKd7pEWqLhlam?zIJl++^^GS=GElKo!W$w zzr>x9c}n&rZjEGU@+0N7#EA}{Q?0L`jw0Sqh7J4LQ=@R?M`b_${&S7pMmGP&e9(?> zB?%yFlN}mNaQH~M{u`lDtTSut8OZ&)%U+I4UflmHZiSk6DA~k!h52DRl!ISLt}yQG z;;Ufn~skF^D#V)_g=?+TM6gr#PluLL9F@>n-t;(sk?I9OcZf>CQEl{rl z%j`tyb?flc?b=^%U+es8*Rsu<*DS3K?BZ(|lI59KnS zrbF*@V`NZnM%;I%)bO%_zeN%Cm{3n7!O6C<@B(60WDF>NLT8+YsTsX^BttB(B+Ao; zD5_XbQ)ROui96cH8*eC-Zeu=LrnETop~)1bn1$!vxRGP=^e43`73mu@ao&- zu+yyw^DWm%Vo0;pxlnhcODm=JOtGe4$-hM-9w%6+< z95>IYPZdMmGx>WiD8S>&-`nWVPkvs7Vbh_zsJflEug_p?8VI?`H?kHPMpSjZ>sYSh zQJZ*cdJa+N+bJUApdV^M@}>T(+MgOREN{QlGIxe3 z2)Cth8frDwf_ZNDXt}y23@^7AJZ0PZV9C%0a-|PB_m>~)t95n?c-@g1{*sF`XjF4#^OJ%@1vn_`q&7Ss2hY|RR&=WsZrwYOfwONw7Tx%AZ^DUeBlipf| z`iw&5tJhx=YEG03%5GdN8;kJ%^J17}aefI;%-D7O-uUMI_?F{~CmFhAWq4?c8Sh&{ zA>|{XkIzn3?m%vS(#V7^bBTMn$#ByH?RTpF1l4-3#5;Ed2OvZ*O}nHYjW`coC`k z1z!IyuR-C9bMUjYWFk~I$000E*$ZY|Sd)iB z+q0GQj_)VN_MXPB_Yj3w{m{R=m$eR4H6CW}=i(mPfRxPh>c6{(edoHJ(XwqFlGA*d-J)!*m%hhSH2c|EKW6e4=0!B$ z#WODpg|)-vhx}2uvR8| z9lCNdvnFi2jjxINXehgTJTq0&E8ApvqqiY={G;2!T8oHSoc}{|@f!icOf3EDMl_zI z^7hu?nU8`+d;M;H7mSA{qP?x<`TmwoIbv=>-hWAaQX=_D^M{|#(JLR2azyg#EPifP z)2zw>4%lIll*|HTL#j7}OYR?9WLsk1+!&TtUUgAW(y^+zA3l6u@MLByI2*!UH94}< zohiB>+M#9?P5h_qitvd6J$Q_FEbU;g>0IT84Y z(Ps7_d+}fIi+?y9a`%5z@9jh;XS(-@ri(d~QFf<)c$?<&Tsw`FMy+1u1Ip2{$(>4N zsEy*TKyltqiU8$Xb`m>We3Dyhsn+&7OmCYz7{})>y2X1{Yepn99<$nYoYX z9>uDvXnBSxeaQ2Fb{$;2B^jYgIrn<6+&;%p=+Jzl%9`U~kwY<^UjNjeW9n{b6P9ne z*_Qs$o%!9z^IRMGM4|HQ=awQ_i~Yy%{MM}m71muNFTD-dNzY|jAKbdHVqJ~NVB_Q1 z(>ozutR~6FrzFJXsrk#8pQUd7s_ebYSvKz(tRGdsKb%~oF>Q> zC&GR+&3yf2x?IU<_V@0cJ9nT5qG3W}xZsZ~JavJ{QZ_(d5nV!zAz_XU%|ar4CwmQle`|RdUA2Os^R{fHI*U{lw}0hpC>u5PM;xS|wjQE@;WBwD z5EyY!vIE)uwgK!Yn#}c~b1fx|31L@7Xuoh@BKSHtaJ@V(!ce65s_cID&0JjW6@vH7 zH($8&4-Hbj?xF#V8Z1#`-nL2_FRB~M*V6NxyoyMf>f_wZrmB!p5K0~{Nth~`TR)o2 zG;@L*hMy5(%5;mxxn6yZ0RNLo`Q&jgXLMSs7P2vL5L`+cBf6Q4mleVq?!z+$^=F;> zf=vA-^sal(Ydj%o+WLnNepMfjiNpr3?K$z$G-NSrAJ>Y{as2+LO1ZO&Sp3z?@WRlA z|2q1626aS9$7)`I5s$t>LZkPHI=SGh`Ua_@h}{5ve*UpSmf^7+-s9IunuEFHgXHz^ znI#S9eyFyI$vI=Ali`vE*$D}q=a(m^28nie#&wtNrYkICJ0pd9Gw=qRO>kLZ-N3Q3 zm>Bij>ik#q*0$bXHD59RI>t{--Q*W=#m0FNijhCr&1ĝr}kX?5sHjn)x85C=~m zr`L^=;_vn*7DUv)cf7k%>>O*?p%hlR(`^lhZ_IG1% z6T=?sO?!hZ57+vPm6u1QW>qJ%2WKaK2^p6^BRV4$A6UyS$$#N~XBzqke>7U{KA{ zfi8K*o9*9Reh57t&VD$9?^I$ZCV$IVXJ@yPbt^la!*ed=Iv@CHr93F~A6(!Cg}nG*7g+kYcTO{9|S3uH}#8yI2{MSY*?ts~3}U;orf!JC-WX zy8BtEhhtCMBtPo%1ZUeb8&)6uLN+KgRc2N!pl*qI&#`?H-md!CI#YZ1wyHRO2pky_ z+a2*%{8kSypDeGpi*?uyXwY_mA4KF?Xf`k0QKpM5yQ!Xyk>NATN6VperB>U2)B^*V z?#n5H>Ac)iWFPRdCbTgqh8f)99o_v;Is-|mo&uVlmFW*dS%em){@nH^k%@9$<5uy< z5QHjFSLtsZDq>PvdQu9i5?*otI^Bn_YEGr=+8(eJ)WNK#Y^u}?ZDdimbmFHsnjY)l z1(KFB)ok2K@=_=Yricj&<$qrdd<)g9|P1PT9% zj%TM$;8kMxl>~B!s6_0^A~5kX=STt0dG~kDferqqcHv+7vb!qGUVw{@M@~c1<+Ean zPqj??xsl;N7>qvL2{9YDbL%w?RA9LI@j1c*cx$E8CRmWF3IW|C-CWS&nDyz#({|XT z%s5bd@~Y9v)d&?XW>J5g4ehcc`SKgv3!H!eVg3 zQg6V74gko2GXo~7%v4rV!jAtv7(g7|V|Tb62w(rpKkdss#C?VXM05bHfsGY&kS>us zKhu@>Lt7XfN^Uo&hlA_?yOHt?e=mfGBxJPXDcFkYj&aD+ht>0nq}Qwb}S1U zXJhX*V$IgE!pqQBde*nw)_tEc(Zuo|R7F|%Yk#@^)4r4|$x$s$g%23DtKQVZb3ZaY z?zfV!$5hrxf2NhkX&qmnXE+JPk8Je5scbl%ojHN#cC(cvSt@S6pabCQAXezmZtY0y z6fLr~cIby@shY5pLz)~@2b|;U*-G|L(tl!qQ`y#=2i`qBaXJoi-gBQ`JVUTMfS1%s z;GHt6(JZ8Elw)|I>VxkFoP5Pw5^P$#H$KbT$zHv$#1EhEw*@Xbt6aR=0syriDkPS& ze#5QQBNOvEuPnct`w7%_2!k}#Ql%@Aq*LnIpY@{Ber0#& z{nTbw)21I{S%X#>THCyYKG8l8dceItAz`pI+#X7_h}FyfYW_nGU*cyJe@_45Dl0n~ zv6Nr1B4q@Xd#%zpI!9F76Nh1WuXM{@U_;cRM&#TdwGta#s)%k^%xYkv{;e?a+^PO( z5D>A*_TkO3wH^F>TSSd~EksW?;h8F;U#kWdW4GC>I=*V1^8-j42uB0!kN*W+L+^1? zhVE(|7InQeAQ@>j`=~Dw@=K2Xo0$3zyF0MjYd_*SKP`jL8lkWM_^yyZc;8l(Z(mGD zQF*feZ4>)x&U2&s>-7V5^1pt(&wi~vM?{y;UQ;H$iaH;DT{V-JLoJ^3FUNvyxDQiE z6X)~rIS#nW$+~L%cR_vgO}n43kEw0@i<)=Fe?=JGl}ELCEM%FThHUS$?fE9J5npyI zH?%+Ulo*cYz|b6>6zwS;?D|1=0e*6gn9Sed%`}juwye_|ts6_9=$Xnm&T<{Mu5-vP z@}39=|569hOQ8gp@2v+3Y#f`OeTpi6vNQS+N$*X~NMbXd1EQ>s4FEbx*9yqKC zajr+XrPZ_?^GA?~6oUo>#hl@hj1-5Sy|Ho&zjgA%2kH_}bTr2pHgn_wDQd2*)3H3k z7@evcS9WFK1Ta$as3k?j2LJYP^BL{Hn2e5k3`50zcl|T)nJml`Hr?A5TNi93%=Ez8 zkNSLu>83)RjS67%N@jx8kB;>0_OSV>RQS7*7CcGj?g9bk2r}@{BFI4WMvIA4I zB#=E)UMQ{C zdJEu~-mQ(~d0Y-xLfTP#2??{eKaeO1D^XvmIxjpvJvo;hgK`Xfzuw;LroHl$pKf@v zhn&>jJu#JMWTO^(t>m~(YsJ|l8EUMK>lm8#ZgRjeuUjP%ta95xFUnAhR=?}_H8goOFH6X%?!=YZ=GZ|i0jmK;67GnTC7UF7? z=Uh4^JG0;P%e3(w|83L2eS3J}k?bv}^!b0ubnl55f>Ar} z*(@e53@H?EOM%d9?rgM2hfT6L#m&lc7yWWEyVd3b%IDddH#5<%_Sm(@vqL^^OLZm6 z$iTmNrRy?OMB6_l0$bmV{`-jit#7~cb?Rerp@AH+Nl)t?#;0F7Y7e2QY631P-~5!2 z<$A(jvCcXR}P2(-0P` zFu}ep>tu@|y=%!DxOT5MAHUq~>;7AkZd6A|U5Ub4|7oN3BRN#~ z+4wPE#ZbicW9z8$+`?6s6w%R2p}LO=#p+;^-6;=t zDG}x*tBK~UgbdRi^jVGuE%qkKe@jwtuJrahJuU0Ijas3Q1cig9TjF!JYk&OW%Z4(EfQ{v;9FHI@)&juP?s8Zr;BtW|k$t3TNT239mMb_22Js z3OPljdE4AvVAE!2{)k?haD!H$B!@%o;rZ3&<(D6aCwC*ax>_9%c5e|q@c+{0F5*7N z;nbCK&9YYkxq9o?P`mbKsj&W68Jpz@#2{ge8HhH`>a1msE&0b^8Mo?Z7#^>Z_L*lfjL-EUvv&O?&hf!!qw z`!2W@;(>%e@)MI*pW1?BD`R5f=ywg#8PBWwhx?Yd(-4$>jAevYbS4Bl- zB@QEW3-sJJbeYxHGrl}uKz^buT#zuH5PR(SIrHF6Jazp)>8F!}cWv%K*smU;oJscI z-^@B7zB5x}%W`J9x@^^ckm^#I{@0Jc^HuZoeez;=L3>}@$kqpPdWouHm!CXikL_&i zI8_3bcX<31L#D4MBdno#C9`wV5XOW^Bh3vP{Wnvlr%aj2D>E}ME_2>xWKuT=*%S>D z{cfzfUmlQ7HkYmZ;csOZnoIF#wk1~<%=!7`&wG?QV_P=44fekpwj;i5>8F#6J6XPk zmZzn^?z97ud&>W^TRcmgI6UoOR(5MKd*qO3e$oHJk4toFfnnYbcM2bQ6l2!o)4*lW z+Q0IoZ8Y(7KJT|2^uD}G`n3FXBLqKg|Nc%85$Kjo@{0nl{)+{rp-YNr)Sd%qN|6u3 z1X-lO&U74H=$As`c@KXzZJf_u`I2jCom$X}O4P8>tvTq&)VC}f=(YC6Em!5-YqB?3 ztI>6&7`4}&(#X-(11}9kosGjB z3hbrjey}jHZqKml+^h-rnRmAz?mkDm65amWk9v1WmP#jm7-iNuRi84%9t}dWm45Wf zDT>me#D+pd&(h>krIK<~vHT87R+7qh+1HCL2>n0uo;oXab~rJs`f)&6Rd;q$L=PNI z%9w`q9f-SjlGX0rq_sHBy4~hWQS>8=lGu-q?)VzMj{U9Po41L|j;Ty~J^bO-#k-E< zgIOsNCCZ;5+&#L#jh$jkdioc4xMRr(H(-tVtM={56U2cRuhkp679ORPEA=f7Pm#AB zdaCNOlQ>mNk#%E@50i&_vPXFF{Znx@7luZK&`;YlFHCrjix}fR6*I-!4#;~m&2TA; z>S1Tqhp73(87CfL9TIe<4)xO=d=!%RIQm1g(9Sm5YECJ@Ah=i$6L^bdY&WvWtxW_W zZ$y&-L50@}h0n0`Xa6o2&8A**lwoQ6!9DZCtXS(~-mx|#Q=Ho)%=mVmW+EkRITJSPkE5p@qOZ8{uix63j#KXN3Mrm^rjeW@w0 zz9?TlDzkdYXjoZ0y{uCMDXWsC7kuZY>1Ng)I_pn!44ng8}1nEM!u_0?;`&Yr9HzHeLj7_Nf8Xwo-nh&wc9e7z*QMt+n;K7qgbZ=X9}335dpr)N9vN_!h(Pw~MYCCYIZS78T4iLzpt& z4Ugc|zdJ1VT=Sgmz@<+1u<~vFd>6mx`%@;j)=Rqd)9Qq>1}Vq-FD@KcOdssyb`vRm zhJHb>U%Ln#-V+kL+ZE=Z6pg)-(1-no-dn7*R&N{N`gbe0-Mn-#J0q~Mi_!Y1WSYAB zmy5VNYyC+9Q=~2XvQSk)9<2HH(?M*n@ctQsDFs!cDE7=n`>zfx0Bh-AbbNBK>CB;fsFEwTj*4Vb_N4l6DKR z&H3|)X`SQ8gGE&`ljn^k!%XE2n1kNcR!Ekr0XVA#GAa1FWh7le;zqyrlXWi7*Jh9h z<8L~{K9U?Yx?zy*DEw-E=(YNv>o=Pi-WNp7rPJ`CH&$cky}uKW7~sV8Kg0x?KKJqe6WOHhxp?cd@f3)&QJ)V-xahr2G^UcwJE?X5Bz z6g96zpNTt?y|gtE?lM}9*c-XbRz0@cmtRuO$wpayTeTJ`Z5O_fhuI!D9#9Rx4nPQh z>v=S0#OT-<$Q)udghwy7%vc0k-EDPA;QbpR79XZIOlel-a*@s)OBs2#>BsG5@@NWs z=S;;f6MXpD7T3`*_Bws8E-PYLf`u}4?vAI!9;Hj>zwU(}oznp~GNEs(znv-Ee_{9U zJ_Ez&SSQLQq0Ep2W?m)joWvi-;8R^U5DJ(Scay!cwN?mNwGi;^N6C1@@8cZBdz{e(zyYJp( zuB8{#r>B=EO&`*lJ>WXe^C;prA(V`!Ac#Ky4IY3|Tly??9|ZijK?!?8JS06`oZTNt zx_drwb&-*HBn&*#YNU*&4KhuHnp;}Cdp`H}^$!dV z;U^})O-+CQG4p$IX?bOJZGB_&;PB}9&&lc8`Ne;@Kmhpvg7trp{XcNg6L1j`6N8B% z|KS1=1rs(fJuwN7G%16cDdd4KBd<&h8B{&3xVDR&PZqV$6OYTBT1&c|WDkF{c z#TSec^5HXd_mJZs+wl~#qv2-F%j3ZJF=%0(f?2b0|B`9CLQq+s;1}hM;_&=v`HlWZ z>N=1PezcZ|71h4*`>qSKJ_vkD@q)r2h%G%V-*n)lyf36zmcOthMu2Vk!0^H>Hx&UD zLX5i8EQNy8^ppI;@XKp)x*1sQshA2LHV?2-Cr1_TsIwB(XIw4)l23^yGk&Eu5v3LS zr))3LAX`Enm;4#;KPto~FOW*ZrqZ2*TgnHqo|Xo)DzO{Tjgz|T^c&T$u)zWq%QGO9*}`fQcgm;F&xM#yEemVP~N#Si(uZ1?NQ)V2JCC1(~l#je%pFV=TnG zT9G@cS~?7m&D}tbC%p|NO?0@%0yRb zF;>c*Yyi?+4pBPYLp}>yss_@!xLyh@`1u~8h;&xbM4^jlK(V6=SjI1bGmun{gw9lk z+yks-PT53BwD&X7NYx^n)KqPQ2`REZceN1#K*5z2mn@6TWYE^oP4>msqwSo*`E-D8 zDL+!0&q$zX*IHC*L&RfbMFL7o%=O3_h<8WbO zSfZAoe3=J~&P{MyH46+=**h#-57|I=ZAZRTBt;H!ox_P->w9-*z4qQdwl%76w+WA=K9(?Q@ZL%`Y39q@=% z4lU;hg_Z(q4N`!XF4q(8PC?Zt2n+@^lZ-jVktStr=^2p)QS^NS9F3NphMxnGrpoQi$4D?d=9o~H1+8iAL|B^ zEEECXCa9LI5bSXh2tg>+yv7aI9gJ}LnE^vbEBKzM+5j3cqwchP`5J{i$<(4?3>Zl& z18I;n)u!wVDf8e|+e1?9wXIxGZZuHf(eFu$X6iQ?4`Zor1y_jGblRWDu(o zigDB&72Nm8tPtb>6U{w1#y_!7PE57nYlPH4-WgFHUIHdSi68`=J|&kT_0@fUL#JlP zT=Hhv!MS;X)NRJuL`R3fDwWgwlc`@>5srpJO2-40zT-5l3`@y6a^ix9*dS z@mo9t4+}DpK)qeK0s`MQ&V;;{Y@FoYXre-99O%_nG5E~=uF&in_emxDO zuChW<1)XoY@aIJgIrk}POj`PFr*YF}&g15ufC@Rb=KKDrS&-~us{d5RUcknlkyu#F zpHk%uJmvGG;L=CQY6K%AJ2~N}Kmm|L-noMTU#xH?=7?~Q7Y<9IXjZh0a9Fa+4m@rW zzYOZcF#@F0=P25+d+n}>^50rQ&AZa*QFkr5BZKp!S?Hg&l+p61OQA5DOot?gKb3z0 zX>EW;h?NdR%o&bf6D+@7Eg3~k1SL{a$^3HEE4n*-hzY|xwUhy@N7(vY#gULnS{C4 z;^@LC0HiL=L`wmM*5*e!q~!xd`?{)GQqtmMYIv*>X=J2ue9ZWf4uIC?aO?M}XLj#IIq=j9|VJJ{@ziJ^Y z3R*dPP=@G-zU`D!9Pghf=ean>Elhx9(_&BnP_aZEgXG2}Pj(V~8)H9Tj5b%Hq}tdP zl6v9Q+9zns2=U8i)8kit=0|5H;9TmtDEM1|wUnDGpVW6?1Q4{~jsGp1QsIugkx<48 z@dSu{_q51i<6&1Y6xCWBl5)_Ft2-&lF{AK1FIq<_xt@rW7^@gq`Of#qOdi6vrKh$| z&5K_4?-jl;1dGc#wJ9S4U&q!Sa(v(;<2f;0o6Sd0oJ8g#Q0^A3{yJ&Sof7a zJT;5Jl0R0HKP4vVpL^bth_OwQ=to_I-8c*N_DCEaD`gxORuYHt)!^3XrJ}RBtl7C#ve0iAym1{@vS__=@3_6=`NJZs-Xr6d4vF`{xEuR$xY1z=D<-9uf zlZP^sbe>cYCDX!JxUt{ZuK^n$Rru62ACIn7G?*c$yb$1rb8v-^8%bYo{E}ESgkyZP zB83>Kj(S1Q`S{8uzQLA?^h`Saw4r@GgGyls$a7<(s(`pD-~-qylbqn`kv~N{Fl7P;R1}On&3jV?Xf0}e*5SmF z?3bc;J8b1`k!dh?oe%ZCGp{zOGm=iLxYRRLM@Eoy4a6C}x04>m3kWJU!{aZ%_rgHa z)iiz(_@I+jMl7{}k(40>F|@Ryo2`^8Vy&Ykm_#G|nNupHY#4m@wa7+{8=Ow+#@U^e zszdsOpSJG>%~G?V@n%m87-T#@VhXY$?_IHw$kLvazGY< z1yunzbh`T7z!^Vd+5A8Y25TIQD+(w?WbFLFnd(7mYfR>0yn_H zc8i%DbNJu>iRKF^5ZPi9k&F;x;j|*z9g3!cxyI?x&`9^P$}b#fFqy`jjWg4bj|yKt zsn`!+L`Txad{V%>OG=j*C7>A)j8iuDcyE)hhPVK_UJ1NI`v1+()j`Wc%UQttgsqH=;t7$X)?l$5DP zBtm0$Yzk=<&ED3dWM48H^cw=5Z9Z|&*p`m`jo)!&RnP>*)%Djy3#~3RPc-cV<53ox!oNspJpcdlCs^N%7-2g7T zamYxT9yuFi3Qf1BEUW!ROAY7AkC|xRK=J@$^(#mPR5~e8zFGEn+~gUDFeT&U8WijJ zhd`C*x1-kkr_j(PCC&!6Q6pnLO7Mu*^3K2?T(+p;;fi8lMXcR275??hvZZPzX&6X{ zSTt>-TnG$H%y{goTF9e%o39)$%0qUpCENo9RuIjes|uHQ_K{FMXycBVG}Br8iBZ

cT-HE69NcvSQdr zqqAXz02~4<>1ZJEPFlVgtp!VBKLrz`5Dx8fI2{cMKe#oShMKHW5TSC+fMnft0vaNUz=)_P*tkIP+)u62@3e9hu~lsC)VN~CrTvfhFOY@8!Jbs%JDV> zi(sV<8;B66fRxtY3#DFR`EuI}oU}If#W**wo)|r0OT?fOo=!hJ7{`jE@zq#zU>#J+ zbO4Y4ov3MRas|xjX;tdY5{Y!7C~yn-XJ!=}_i8N8RUoy7^|&`!7c-DlwJ>>7n?9E; z90$p7^Jvpl3lao_Q}p^LL394ox8C!(pnR=zBwYL+sb#TBY#M;@&jjUpGbKp<&2{j& zSOqg3R@g*}l4E|S6BO+YYDG~Ig)C(;a=sTRd1{0R%T!)yIZ0#BDCg~y;G9=~p zP|0gCwU$r?JG1?^K+Jb<4}5ZF?pmTRx38KwdEXpZw@E4PPdPsg35C`KY6uD16eee@ zl<VZ<7F;?jqT}EbWSkn-9iGLOr-;z&iiw_Fr?D z47NMRT`)t(r$a09l>_S%Ha4Gp3|h8)4d}7l=-fg55mNtr72q7$zoMr8_J?wq36cuZ z00s^A$>wWh?dYj>t+7?S>fAK02IPIB*~ye*-Iif^fLytX{N;+Kbc{G=A~%*0M-ZZB z0O16SGM^e;%(+Qu20XXCif+d3EI5bZT`@~XJSAdYP5nJv&BxdVKEQ!6T-|6Q3WB<@lB4!2+o?u%n!0Zbf8{4?U#(^-;5eRG7YF4XrqMK60r)mJ6 z1xXBM8-X#7*&x6KItt7kWEg>y7SSL($4pMCXa&Fp5W2FVp!&!UG4Kp<|j7T%axdEV4!aN=D`2uI`wn;Pu6oR|ii8CT){ z9ax(x^-syU#ly|1y=0n7er_D)1|ldA$CYc!)I4^RiNO6#Ah+`r2h7DyR7?2llsR$8 zPMQFr>rt7maYcBvZ?7<7U8n|F@Nru>(oaityT8^U3i!ur0*#~56v1YRv`qxkjW*P4DK$#fusiKMjL zC%u9{Sq1Y=07azADw-}O45h81pWK&htS$tqOfE^5&bK6aN-d-=L>zBUyarNuqWc(|kL&C^4L{bo^ESl5SrOAu0t?tD&d;Y~&C^=fyd5TBOGQznw?abe{-kE?kp-l{?5 zFD9CtJ-MpEoL)>J1obF(OK^8-?pw5Ieke*y!Ks7D`Iozyz_@$Fq*K!IYc+lWY^@ya zX^I*0MU>;;ucjmsrby2Ce$gaz@l;J!-@#YI;F-2E|2qK=yC=6Qi8xx`uE)&D+UNyU zl9pB#b4>Oj2KEwr(sFkN>b>XM7T8BU-m{Jvo65k@^0>4OJ#(i14(S?#qM)2_!u(yl9#nmq)-T z5PaZRcfEz=)!27@fC4+fx|EM9t>)oga5$PX`TYGQ0RS4X!&YPfoQCphePM~}>H*-b znap$=WCaF^Cr{!m{Zq-KtV|GDq(>y@36%c^ z|AVTQequ9B@W^ekIe@^=X0`nD$%!3Ka3qw2W&E7d$p1yrx%ee{zi<3O5Y!MYaiOB3 zIDw8Hs6eG4eIBwJ#8O)n5|%3C>Y_@VciHgp$fR&&MQkS&3(A6A z>H|XsICQwYi^EyOF89UAEOb+dgtQYt7OP-k$cf{A;)$BQaUsqT0FFBSF3ui{j0;wz zD`J0)3sigQM8j?>lQNcUJ1K-*l5U{8Fcf=iy;9>7dn6kE7W=KV~A|PAyG0R zz?k!_o$E|rLp#>-2C@59fOFoKYDFaa)Qtv}k_cFf5aFyFP@0}ib=33i1_57Dja-4w zg0$)2MC=td0E8YPOl^}CMD^x;H!)3z(@6P<+vA2nXlLZrwH1NNdWcWjN@(Z*c~|6@ zR~;8P(YS}ILK#bOP}kc5_o?k+&2>>$GVCsmJJ<^r1b`dUY$G^f?P^^SDq=;=(CzqH zkHlZN;VG>|vUmNDfA%~Bv=0PaW^8g$h`1o;OM#yQ5XWS_ZCwGGY=(LDaP?mnyuEmE z6|l9NIwOxZ&3vaPziKa=mQYW6b%@yE@o)JYhj z{VR+7cxaU)dHI7eVc=;9WqPW*+-U4vc4PnSU}!6?R25#F(TV=_=zo9)4SDc;pqxty zb4X>VGNpmvUZhUMg*=o`Kr z0K0{gm>rTBpW6;0k_g09bhw?bjMBQ1Zq{tVy~>7coExjMO0rkc`^h4F4-PuJO*|(L z|9R%oaqz>-V0dgE@p<4jv3O~JYZ_#jzc<59+bm9(w0026S799YUDcBXip+%L0~Bw8 zMmvvY~N-jd-0LdNi+znua5M1p4@2~eQwOG^ekNuXbXQA3N&f`V=RHX^Z% z83pZ9L7{jNc++IbDQ^B^QH2v)n{&Z}s-JC?uB>*%4O7XDBg@66IQx5sdKcxvkj;DN z4ALqw1bhgaY$97V6sU;R%L%66fX(a4X&Jr>fh}4Rto=lEWWJr*rlhoFC>-(@264!= zMKxt6e2*lU-Cyh>TWE#DChC6x#EWX^KJt$2q7f?EaNyZmnJC7Dl(EuZMUZ)lh1L~; z;f3f!H@-ZK9!FKxUkOXvtEZxYmytl?4(lt;)~JUcr~KTo&W^yQqR`K90WI_&0n2ZX z0^+As)(airG5!GuNH@*YEy??Mdas3B&|^2Kr?p`TFMF|bvrI-#boBSTj*}0)E>-8* zPth^SENAnx2t0}cCEFCujmb+b@(lNU{zw3V{98T(jj{y@kiRtRnBX0Qt>E6HQB**F zV2wenC{$T5fHh%H6;L`+lN0)i6fBm}mt7URM+-j@O(Vgh=KBI?h5J^9TQj1V-0T6~ z??HigrrDrBhemyRrgIlS`zM68VmXy?Uxq7c9Z6TB3YZfdl6pn3gp?O3r?2CU)q71! zGtgdeC$b%;Lc3I`hIW(HiUqZna9@rQ{P5X5HAe6fo(eA^0<}H)0)cBiUc0rUZlL7=8y-oc#Q^n6il(Ny9l@_`(Bl+%A|0} zSPAUk!j5MK1jKmVjDvE30kjGl1(xC+wZ^9^z#R6uej~*E7d!B>I9|XFt<-ucN4sBg z0~p$m?NQLS)4*ZRz){18bjj#-wQSfN4Tb&glvAAQ=pSYJ41Qx3A#u=1H^i&fJf_{G zNEiuvBz}d>wq4}^j%U~i$VIR0@EjucV&y3Q8x>#^narC4ivzasG_&+$8-%BeaGMlM zizJsb3w^5q#-9Ey$;bMSUE&l2dF6ZOw!hk8u}s#bdEA>{Y+oKwine{w`!Vpo`UWrB zPG>5CtD#sqb1&BEyIX=ySP>l_WpV28cH&s`1y!0musJRWRP=qN60ICz-#ZC%|Dipl8W`zi3?X!Gijy>)xJU*@ zcD$X6(v`Xq4C-;fRMWBP@3`QPNx+PvED=*HE^7OGNNbun{YWq1WZOh}6aIPyW7 zHNDun!d^RLP_V}B^=xjuGy;ltUI_!6NCJ?M$KeeUF;uuG>RW zm=7GJOe#2V2w5B4KNX8z3%)y3IBLwZ$IVY|`;-lZiQ@ni1%F@uZYW|kb|WJB`}|v~ zg7J}+E`N2mwox8%@CbRfWsZ*0o{=i~pX=igIrotH2UjIMsj{CoD8}W5X}Or`>2K=- zB)WQ!BC*3yag?JM5}8r)wbh#T6j)5dmu`sSM~f}4R$1)hF7MRQacNM5pFdM8VYHa> z)YgqWhFfx`*sq4iDs|Hl^*x(F69)}ot+H*B5JUcrumtQPRD(lXJ2$;ISZWmqxV@#8 zgbc==IS@1mtG3%*pU>#qXafW)4E|K8+^NSufPx(jJVM7VsLtymlT)C*EsFX3>TtJ9 z1Lzl-x#&}6=hz9_FQM+msKX-GJG{SQhwZ@ZNTNOR#@ard3+9;L=aHv2QgI8EVDM>e;2+Ty=YH@oi9$sKYJ?=FXYI3RMKOA%Yc>}WytB6Td$0@wF ztg@#?5T{slz>uE4B7iZ=g8!o^2zOx2gY8VEIrqR);*Mghp;o{Z?CvHzqT&Jv`fwD? za}q7KhhnN>L*VdW3GsOzhiDfyl#N%$*uqP7l*Q($m@qHL^?aE23W!^@=}21~f^{UD zl{kOyA!|n{AkSsy*+OmTUJH%={c5*0sF1{N>gOc;qe|XX47QHRje38ez58J;{aXpb zMo>CLQSUpB?wFpTrxZnypPX`2JrN)@n}9-O7IBd#ek(y`FU@ccyw0r2ag_eHYDQ{gTKDY8HgB;0k=k2M_W?|)8F175LwIygE5>m{UuS}Dmc z;T}5c_iR8*3+eEoTI30lyO{PWVEG+%<{MR}S4nFo*fkUIa0$qBKqawk2rRQ44LGIj zUu^#6LtHG~(I+mJ+_+3os_`xc3e`XnjW{qvcfbIw2}x{nZZIf8iLoO#3b0Kvqv2Gr z|BJJ;lC?SJ?$%5cSB%Ic#x)_+t zBT?<63Q)uK;6~Bxr(#kh$yK|t@)*I2ZHeE^3zgifuQz4*N>FyE1Ke*PAMT`4a<3g+ zMOW|Fe07^AjuVuZsvjzl2JfCeXaxkV<;8JAM>aQwfFJ4MR8a6KK9C2X5N<6B>r#TO zRvK#9|C|WCKR{v($8YPMewScF2WN3599_UVFf|Sy!Y|wg0m|-09UcRl!?!=fuc#=+9Sv8Ewyzxwr7R@?IuAU!LZ8sS*dq3-P_PyT$pDLnD9_&2l~B<=Fs;nq`^A4+t-UzS z0eEAj#ef?AM^eXC6}68HJ#jH_O9*vlBw>AWIRk^Jr2`g)fe33L^!QpVvf-TgiY|YF z>zo*MfTYeeC0;Np>w#Yt;Asg6Obt$W)7I}<5c^QiA-dZHk1T+GlR;spPY(G+gfwxU z-0AUM^i@FCo*Jq@7b-;C1=seGyiPTdSCpk!?4(RI!kzMo&A6g7QqM>5RecxNm3+!M zug|%Xt0v_<-(z=C|8(ek|HW&1s^_na{=nDYuS<7(M|RCWX@hYNj9Dv^C3a)lI7Q$k zv~}Tx^kyt?mvV6Q%BQyzWLXRmOZOj0k1c_0Baesl8Ne7^B~=pGqtHDojqk&eW>gKP9OdJe?EA?nO@s7>fNWa~t~6 z0lx8)#7P59KZtVtlHy$Qf~z)JJAHg^-Q9PiI#^b>x!wyLIHzOK>)>48a58sVTGEVn zgG(E``tYt$@Mt;hm8WSfBX$X&>rZH*)pSOf1INx{MpVPs(FX>7(yuLQ`d<*Y6w84< zy!-V9j4kU8$Irz-sD|Bq#_hdm=PQQ{(TEtV9D)MHwwxS6DXo1|+U^L_c-ekc5we2P z?1p{QQb(ttp?Wgzd^2uOQ3gp>r(>Hw7<+R%SRVh+l%+?*wk^GD$j&#PWmgj-ZW{p(kt0_PK4L<6d7(aSlC_pC3Vb(!HRvou&^njALRT zfQu>x*({p{^4PT0iR}c1*Mp=EWJJV9m8!raN~gN1;1|BU#2Ml-tWxe>3S0nDq@NUu zCAy}^9oUx>0(Zzm8Jjia^n_WAO|Lg^UO0q>ipE5e6Dl)^PFSpDq|;v-LZVS#6x0ou zy{sKh&e&?<$B&w7bP}gzr)cOMjZGRebc7G3_lKE%s|etnZ#yAHE;b|cc7oTa9u5lp z4v-mn92XUuE^2(hUh_()>1%wtllB(|KC2T=hPOk0Pm zk%SHerk{LLfB|nS%>%7>CG+N$AIs7k%{;$4>NF>AquKAn2<{OAv*f~tfD4#8cWo?4 z$>>Q*(OXr<)){O@bzIb>QgLo@I_lWXHw$Vg({7dnT`j5iVg|o6z&$RU(ltW93acQ| zJ%dLKX0Z_hD4d24K^xZvg~$`dS@)$j%#b<804_ta5a8m66h@sIQ`l{}B`b$-TsRE? ze92`sr2jcrrATjTx-Bl8jz*AXgo`aQNreCr{YGU0y@%;&DAlY%JjH;xWGfYGK(C=p zNbM^=iXrmjRE&)*`(6e2YTmEnFm7R zY|LQg>`&wB709=$3E{Gu4)melOVEkXD=B+APUG@(t6DCF)LoLNBTdQJ15In>UQPggeyq{<>xeX^%$(e7ki9%Sxn6L^$8Mcu+A9RQo zof-pA@gAw*N?fQh>OnsmSlL5K^Xgoaol&@fu2Wn<72@IYlSBfQu-FT|iQ%X1N1l6mDKG|)IqzV^d# zEIT`mqR9ocOCvT}7pCYB9=}$nMtvgP1cGe+x4AqeV3raTs6%qbG3^M4iWX4T8a3e5H*Hwh6J=4(Cl*=U7jJc!$`AK^A-u71s{>SkJM`Bgj$?f)AHI3I-ux z@EU*$$E0P3Rc}0NufR|0s2V>=WISDlbkVltYIPxrmtx%D645Sc;04F%?X!hg zYo}S95_koIQ=$RQb|S`bAR7klKYe64mD_EG3sJ)q&#BM}X#mb}mNEFnvKq=uV%RI< zXRHC6AskS_bRpFNfsuRTB>|+n>7eB613Qa~2o>>cr~M)QCOKLPb|PZ1ZBAGp z=2i7mfK90e49&C9*CYTs#|Hbe?y*h+3~?bivu8Gi0PPF_{k(~$ik-Bpi40osn1o-R z1h@{diKT$!3hx;yz$uZ`~o0o3Kj0gz>Vc#&l_ z$ci{Xi_~6UJ}NN1CPGXAC)5z2vG7>I3gn2581-kpI!joc9TzN;$K`=P%GW4h>7U1^ zhU9i@M?V<*d;7`Itybk_LtZHrjfB)B+j%+y>j@HNl}uWSMm3TJf}6|fmHi00gr2|A zI0Q_^x2AG;tnrm>&ZPx&{C;f4P9CqwD~qoINdlRXiZ;*mk*$(YV`E-0eW|(?JE@?C z$O?3*CG}SCP3T5X@EhY4y$sz^QLntCZG08puEy2paKX3M26%=51 zNm$~mNGQ~BQu#k%=#(@9KuD=mEW3wVuh9&Ja-kIfjjt8J(o!OGt4Ur2SPE%e3e~&8 z0}wK1myAc^0s^CRd405`{ljSBgdgvnAr15eW70R7)*}p+DirfYVAOn;ccs6L_nS*2 z#sTVmIBiNW6jEk*JGh>JlYiUg35qZLxlIHfC&3FWN`phB^HbBOCi8(TLMUiR}MvNQe-*+C0a{CluTjBy?>aN{V1?5un)?p za7wnP>Rvi-c<+X&rknPYkqvYxXvoDzPn`J%LTO!j;|Jf0Zvya8`KoR_IT89-CF951 zzHjx|!nV_l%kCF}2lD3utlNJOikxzqiO>zXpZ+@VT0VThG@>JW->N;Tht~rozH*)d z!lF|=Ng+tlSd&s!ox91ahv;lnc2Asq><>2fYJJWce~flo9)tixx-GSmlD=)2x$ARL zRS)GUA4TND!ZG0yI3%nfCM-W96zo`pF?(x;tZn=%c2L0<_W*{<7Az6@v1hsY z1$`KTN@YuZ&L0UX*<3HczUH#-cdMZ27pMw3kG_96b@T=}y%C_I^EUGRSV&_b1!IwdS)W=zn}>4Hx?c*4E|3c1oLT z?$I z)0s~yH^+6i*y%mFH!uUVU#aVDow|uMw0gtM zKC$p~%EB-4U5aC)4Q!Ls&Cvnrc=h$_nPF5xFU&4ArkfZW#7F^)487yYE6s)a}IoYtRkJ$qV z>c?kO11ekHqo%0>k+Bmhp$;O>l7L6C@loQUR-rN$Eoun;%OTANKrRPy2#_ZhNw|zP zJRuA2#plh!CEn6Dxt}NM7Ydf&!MaG6tZmaKRO+R(zUUXfd7FQuJg~ zABwI*5Ud+%o?-K!_ zg09BP4?g4^SheBHZuB7%PHGDZyOx9>;z|ce2r7D{&uoxm5T-;ydJw5MxS}i(*gl>g zNmgeX%C(Br0GH;>BK3IGL`9?@L>99~WyLJ2Au`3N zK&c+}0Q(fT{_&#qgeFw)3} zGut3O7Yk%;bI;(4M>ksem6jI~8x%4<=&}4(iieG?bnE^DX&n8%G%VrBFxV%`Zkc_h zDQWtYk==XZC8L!)-n6c=^&|;$_azg17d~aHoZ^4Nx3zz%J$mF!kj;YC)$#VnF4unx zJWd1!&U+B5g_76}YsP;b?)Z93;$T3TBdvh-KsY_7&y3vwEh`DL2tRGD)TT4180K;TH6sn6~y8hnr}M777yVBEosh0s${p;?_sCQqL7A@Sgmm+G5Ds8Q||8@&ideL&(MpE?K` zwVRMl_V$Hx!XWBjzo<_0<(h9-SLLJZ`dT@T?DYf+q|EpyV&69q$lIwE5NggNyrH7u_9$xI=ure3aOQK^#+G0=2ZFs)|rqCk77C-IeJh3jy+$$0)O2w&mmSwWG>RZ$Hd z=h))ZR-e$f%?*;LT6h34ftmBi-$fsFiuqsCWRa^qZv&_<^G9ibW(nR|B1vzgx~3;!J{TKPO+t&doNf0UQ7bs&L+Sq{b%}J*7g-n>&jE# zw^vSbO!l6uH{~H?x3EiaXPLZbtJZ|dZx_Xe5BIG2&el87ZNar+QmLPBdnf@ja4&36 z{-g^dn!DP{zrL|z6I4t41zt3aURXW47JH_<9rn^0vDd6go*zNh1<&mGHBdLg{WD`< z@4ouQ#pe3rkT3Jl4QXYs_=&GEnR9(<|2OI150Xa1$rq1Ts-GiTa*~(H_m%>uG^`tM zGdu?qqZ(=`gzjHgF;bn_KRE^#eVAiCJj~AX(Lq`Q?~fNmoj#T^BhNNjj9T2n^tLMm zznUB>v+Czn`Eag9*zXy!DFZ&Rg`JY-To7BIMkQxBUg-cptWz`yDo6F2^Kiu2$z#KJ zG}xE8&xODW7KPFZf}k=yM&oyms)BlNBs$j7XJQ7zOa_w!u$@5lumAMY(T768Cgkk| zDGn@)2GNkmWkVDV{;!O(RH2Hjs$}y;Q-ji?N^?YeRH%G=h{R019B~2t+lnmuwV{g1!99 z!&J4S(h+(#>LU?{Vl{)?2vKDt_6uqn!$!ftd4p}dgv0O^l=e@tA#3kEC7({>Ny-u~ zIUBk?v)zWAqW8CN^lGW!Z*kJKJ6s1=UWw;~%}a>8bdhZCKABq!nOwIMFmB5dAK*5R z8^!$yxKv++J2lk2ZY5>|^0%87tdTj1p$(%U1o<+PI4O5qzN4dy6pUhMfC@0}esh@G ze)QIi=hP!s-@3muJlky0DZe{9*-urUg4D$7l+F0s;T**2=<9ShZ*~KIIH%P1C+J9F z>o1PilnZwIevX=9J4-tK!4PEVz8s)tm$uJ`&=OkQdj7$;3D`;!+JIK|#dPAFoMH4$)R` zoOt@MYNz;>?be+Lo}cynFD(0~-B~8(f%abm5f6I4&iHwt-}6GOV}m}r_!rjKYd)Qp zS_0p+;~QRLGI!S`w;k)gbk{4YW2Y05z3e>Z%ysuS`G-&(#==ZemaV;8|Jhol(?mT) z(s;J$lRzp6cbST9*zbBvVFeaEN&N*nuJ9t$masKy_HKL{_V3~!$B~OI7pxU5Jvl=O zBAkXze|I7NB9Gkc-EJyY&G+whAGu^qeYQT7v0=|Xr^}fa(*Aj~*n;=WW4XD3##)ud zrTXWx^_Mo`&$)V0o_5X9_27$(6tdCnU3)Y45BQbUMkru^SRA|0{%lu^$GCkYsr~=< zH~1xuZ{9ck%|-gNr#p5X&iGcLLdP4h*w?ea)J?L;63XGvX1_MR}h3v6r<+8(H zc1<3iB;c#*H#*nlZ>|TH4@H_ej*q1ITbdA5ph&gB`>HtMrS_JYY_R?zd;x}?enOrc z;@w)9O}tU`yyyakup#a|V0v8^X9t}gc3p?>*1Wlf3h`Q4JNwt>$+ng8udP&9xBFmT z72kc%^IiFOS6qW`Ny-zIi$`n4rcV(ujym1+F#Duq@ZJ>!UR0m}u5PK;;Gm{h-9IBex4u%K=&uQ|beZa8J|>{iI>qd!6n zrxexE!pC4m(FCmYLqhcj`O%6rq#?6*Ypo&+qt>R>1x0w|)3VK2d45yJi)?owa%)L5 z1vBWMS29J%<&t|Z#HO6$5c5}Z5$EEkm_eJHh+jr}#(d#y6A-0BHu#E#y`B-Pe%=Kd zdM9ip*#wnUzO|HKXn=a3+*0WeIHQ^s2I_T_dzmwwKiT}`FsI(f(eB=G4jd7GU*Rli zZS`$BweNbB9YsfP{+$btwW$|faRaL16q6vv&CQc)pFT960DAYciEt5G}l~jw(C8DGcB|uBaZlu-hOsnfR_ZpW46FHMufG60g+=0L56ozfX9F? z@^9{=)Kc=y&DRJ%7WukF1;d}$+_e$Kd|pS=*5zfpq%rN@YG5vdV4X%QOIAQvTYf1;#-ztg!A8@DHhgVBS&_EK9GATBXRSvnFh_MSQu_2AU?`d73zlX4ONEb#8DvN&pL48|&Bq#!4%d{Dpx(PE3F z6{-oPfaTyGmd6OU_d|lfL|8`8>SABHIj}(43tpvdjfi{!JaSK}jQ*xOT z^6iJi+4sDUk%j<&i7324IEY=Y0Cl35YI7F0fCW8=KExZ787g=~q=2o(lcHnY(6E2N zvw-_BDINJ(J1|jS$3c*9C`9rEW{Jsgx7bmoF#Lc&{kAppjout36C1ixmRUV2H&H#f zTFZQlZju5bvQ<|QpaaN!q>u;BrzHdo|Cla3g8D)hrsT##C0ta9()J4%ug#NAWaRSc z_?HMsvhrHtmdfpi4kLxp+^^^KIeY8Qtj^sM|IPfvwzyk)s(*GJx4qt)IM)30TWDJD zf$x2H{+s>C7K|n%Bin?Vu2!G*qSx05J^@e3>SQmHY@BF@~ zZ3i4$eGuV!%;v)C@jzgI|Md0&0(CeUV=?1jsh&iF+3ak1K^;X+-u3(IY<+YhMlJ0j z%@Oz7kSc4UliGc6GPYFWLVgILo#(xm|JB3(f%4nQAGU`z#Hl{~TlGg`KX&_yq|q~9 zMN0z}iZPd8a(yt%?^KWWT!U2-Uj3#}r5C+bzX;x{OS`n{%0a^)U-@o`bBdRx>9JGzZ(R(;KT@TqU*rq%K8<;nF_M*1v)w&w`VN)M!)`v?FUcZ+HIR)M4~S@{!3K z*sO}uHjwDg2U+z&SO(QWi!6Csx@_-_fiVp)F#uI{+mcXSAS z#0l9Q^0=gDDrtT;qUxv6d4<WP zNN`426gn1($9oXqEtq$c0zhHCBsG$OXq?&xEfab zZe*pmvDzstUAFnMs%!*$q}OC*St+fr4sa=0@ra+>i$JFRP%PW7cZ%UQ6ahtgjhc8{ zk6pf_Pl?lR4dO2>fPsdkI5o7ZJZaMJwXGk(DWzrOWJVhWi;A(LwN4M6-W$_GF<}l{ zH}9>ZHVYp$-lOHMBnuAW1+nP;7=ny`1LX*;;3*lW0rmW7!hY&Nb4`aE9t>;UFHSS+ z08=9W_sHavfPb=JIej-2eGQ+XT5PErUX^W8U_XFxr5t;Rnj4$*eSqgdhjXj3X&`g- zKFfh8PyhXi;$NNzRd4<3pMYy1Lc#RtQri`0iu%|9qBW=ZgKy)=I5P8Xvv5jvS&4wy`3n`$ihzwl4pbJ?zU6aEd*n1@hzR`k}11Voj-yPW@ z5?mIx|9!9lz`>NZ>p-^08*$1Y{lf}wIe?VlJ1{AU_Wfp0E($$Oa!weO{b>;PkR+M5?w*6uMu$S`&&Io9} zkr2-JzUj+c440qcvNoJtWphxo{}OsTIM2!VFlej3dZ4H^G*hW~4bVTZCJ({ph-gz5 zp^kLejeG(Rcw9AJ+_bfY$_TjiSdW( z0%sYR#OjbS*O zno!tlddqTAuSV530KyZQ^LG;&T2Q+KV+QAufKEnmLmT@wO9`%3lTDX1zzpzyg8cAM zYQgASlJo?Axw~}(r}R1raw&>ec!c)JcK795@BNm`jDK>~E7#oMf3-E`$8PPf2|0mn zIG37aJ=gx3I^#}{7nf?5JnGy=UmIKKd7&<{<0~%Y{m#vuE;2;{Xn08h>-1J|JsqYZ zFxszuz`G&zrDFXctCW^A0PP(rAwOygHAn+%rXzhQXdufE^dMEkf0FE}!_f)SSTHYY zqYNk*iF3OoyDwdS$4#{&KWb_OM9?s%{oV~^FPfvr#jrkoz>LgHe#(z4xG!mwbP89^bR7|@q5(yrM)O{`$@9n#3GbliT= zsTrO>CFAngb*_i8H0+HldzMpcx8IW!K>9|=kXXlWD&DFIHga5(tGF55ECoI|i4~3H zck6=ta6je;z`4z}!&5Q$hHP!XHwl3>5fx_nM7kS#F@ztlSo9>iXT;K85#10}^Pky! zGY}dm7K~-MCIyDpz-!)sE$4w4eABtQ@PW5c5=2M2=+k6poLc>Wqc+nn7`xWa#$p4LQJY-PW=Q5EK$Tug|6 z8%#QJL}zbyh0ivc|I!3DnkB7c(iI-akV19B8vVLQ1%uR=r4zsY?4TZvxEQ=-aKjJ1 z_#Y5R*|3JL1b43`1?YDF&|H(a^UX%PuaD1+$-Z{qy))~6d0J%W&L~$&B>Ku1AIe{b zY^Q(NVHv#~Gz&9jk)0y~*c&a1xp&6bPT>im0+aY{Yw_esT~LfS8{X-?pt8CR`fn8* zDxCa<&uq^}PH_kb|62OPF3EV}HmsDTX+!0=%IMUIlUMV4(ZASDPchcSzpl{`sbLE< zEZ!CJ3FbVX&2ChcvQd+V1w7xYq)uMfjHovzaOGEh zYdhB1<@o-@Q4J&#n2=hq&=F(T9u-_9b_yR1&C`SU?uC)+XdBARG#yFRdsl{HQe!tS zw0hbGfaMRuwq!s%R@Ev{T`i4wv2R*`sf|V~ubhx0Jo&~sa2ZYS5YYt#c{plHI)u#f zPPQXo<@G-!!kA3+2ya`}=0>khAKW=k!F_ow2Csp73ad#czDopW3;2tM8fDjS*Z(eE z0N<9@*G_zhElr*j^a)!8CoB z*dg)O#7RN3P+q%;(XYwRCO}1fB-|oesZD@k5a7}>(`)-?zfAY&AIxNJ(UxScU(pmB zq$%duzDA0yfhxp zT2}k0F>0|j?{vmS3LfvMS>2kL~sdemBbb@U?eGbb%4O-J`oYFLJDoerrB8s0w<8 zf9B5K-ulAD*(h?mKU+CI@k{PNuV>Eno6o-KTB}g5TKu!o=pWk=zB|`X>Y{c1=U(@* zq8X0^&(9pCK6n_yQbWpL2HDRfSrV!t&{t=FpT6C|+KqLXJa>A>A1>m5DMy1EZU5Z6 zFvCRgKPS1=)@^afcB7Ry_@*nVSkwY2$3jI01(PSzKF>A*E9ENpnoR|oyr5Gz9^i8nCj8) zU$urq(Q871p0B~UMmJuNoeF{RSOCInJkCaf$ccW5i8p}4YleTl3G%TWIOG*{aFvIM zfm0Z}q2k0e+sI^4@STm^{=%t;z-g{Y9TgN4C^M{ls^_O{PrD&oNLAqdMg&1wPom;M z(;78yf-W}0{s%0!+aPE5b&y~SWTO|xxl}{z;U1HWL!f_>HaXk5ZAp#*l>9du1XjYE zW^KjRG@iQNbel*Or8<+n``#+-k3BJk=O5kg zZ;S-Yg71Gm@PIyqS!mVutwfwkq?eky!hYB)l;>}53%Yx}l+MatpgNm%TMBvocs=k6N? zm$KhZTyD+KG2cH!eV~|Q+k+NC<3uduU4lp&ImOZnx@Mz9R}oj(nKjW6aj|*;dMfqu2|tUn z>UbRs%mAuTmyhWH@8lpC;iD#**dfA44b^_)-n!>OpJJt~2bWX9DW3d)an3+ebx|br zeyx4)Fn`Noyo~-5`&9UG)s|qz{yy64*dAsi*)HLxvfgl_6(}<{#O9=J$e@R$H%Z~P zq4=&oveG=SLhPqdTP{p0_<3aobN~q&{;x}>`qr5Of)`blx%OmX>>QH#EIW+|KH#40 z`+!#Ej4EIS4a(`TDi2okF6)w^5@UMp=%hqw$TsU%!m3jpEXV>Dq@VD*HDj$f4oU~H zfHWca0}t4|-Mb0%-yTgZUfACZTf|n!h1irWwgv)VoZWy3@wewHM~70kz+?ncPlvIR|W!?$-gUl;ytkH;S1s;!#v$xEovC1Wu*4NQ%#0YXHN zH5-}=^c`P+DYTdp(j=c3Am8Ihf%0{w&gFD-9$ z8`k_^9u@u3T*Lp~nd15EOL1Dr+ZJ$ZSM5>HizM|@vHIpsY#{Bxr0 z%6$P9%thXh%-Lvp3GUsu>J@aBw8JyRU*qYkyi*y3i7k+FZl8 znaD647f{fs6B?5;0*cp%iRjkOFtfs|Eb-tWlX*05B~)Da-}1KoFiZ8WH?+2{lsx=q zf=Oxe()oy%{5U}05%`N&Px%C=z2ay2;Unr#fn$_kya%?ArE7u`{2Xk z<#2G9=P+h40PEy;Obf`2)<(mkZ%L=imk z&e-8@2XvNfth=u#6HJeMKjoLGH#EM?PJJwFNL1=BG+JcJRAQAGD-^Rv>KsA}_t zAx9qs6<&WnC-}--%Sx9len9CbV&bTGic!Mq-&^)inmc58vm#wm`bNc@)hB=3x*Lc0 zy0^v9q#LTg1_6!3Y1!k>P(aj1(D;M0$UM0FWZ$mHNB!~d{z*g5D{ASu*WgmfXmH<^ zZsf5h0J$m04ly~)*#pZ&kygUMqXQs9^GME)H~bPC3k2K_0iY|dZ$!;T^=}>(?g+qZ zkg*0SWEv#R1k3Llnr;f03>lt7q?b0YZYvV@o8Ofg1=@j`sM?BBDi|%d;r5o*uyaQO z?uEV4Oo0(oz@EC~5cmEGGdQaI57YrJ$KC?^yM@@-wD!|ggV(FpKB%TV(5KAPA$#Y+ za5t}3M&D~=rx{vFRcpUH9;T#`f}H#kM4ePUZR(osKr(~J`MT*^(PTxj@OgwklNpQd z@@!jHwc}iBWXCEiP8Kr+FZ)MVK!5q|73g5%?6+9rnE=L2%D?K$Oo)!=xUV+=4;LOE zK{}6D50CoXYPtaw4)g!m9T)T)!gF=#_MWeR&u|(2Y{84WUFrJM?+>g_xRr4Q$)H{O zCiknT*r~64zNDCa8>%<<_9O7<8W1o+Ji3_r66AY%egAjo*!j9BvK*Sh%g~b-^(kfB zciPuVs}7!QbKRS+IU{pV0(sC2vj#<;Q)*8oUXYaFHDNiI_&z}arew4T%nW5 z;Ix!JqOKs?O`0h#GY+`vQs_vAG0(wC5g<; z)Q;Bgckf@X%ggKH!teLKKcDye^#b^qrhszM#@ZiO9xH{s1Ov4ju5vT9fa3~AvQ`a@ zy?{9?sd&fLo#d4=THul?di4<{n3fH>Om$O&AM{ckT=ax?k0dRd@ZUXEWwp@D;ycf> z-C(rE;3XGumWCPu5>!4o9>HyZJG@chE1P1ZT?W_cjBCD)1N(#k5`SxhJ}b1RtYi#=Et%op@>UM_uV%E5{?E|#QiQg z-VvPJ4vFg)N2=Ygj52|LXNBpKqEx{R1r?@L5^T8V-abv;hr&;C zr<|M4aPo%EwIj_71d<_L7#G6ESY4iG!w&19+WJj{RTrWr&IS<@5EpPW9lrBu(sLf0 zI;rvxWpsi28YWW-8a)Hm9dPXgCLKT=b@L;;|6*mk+0r%ip|bM4rA1 z32tA7zK!+%MTRj?kXxw{fK>vtbhKJDd9r26UCmcZD$&c;3F;+Xj)b}O3eDMd=8s_= zpF+pKgG;upYTlPFTxd8Rwu*oMOz)?miHxnPbKK)!?FE;TmgQ1IUP465l~y7R|KZ`84L(fxNsX)cLr!%O`I6U(S7Xu0j9p zU$LuIxYGRp`KO(G3W}NwpCHDfVu^gKF$*!K)h%#~HlB<0;7NL)x_#2N~}H} zH`9NaXCNO2@K2Bw^ARe%Ibm7=kur5alx56EZ~B{tyAd7$Ol5f_kEciTx2TFx@&pTZ znswU5@25y7nsa#(dAw`u3;j|HA2*Lz=Tf{lbTdidltr^+>uj<&vmAt%>AYyq1-~kp za-{#~HO?_7Lk<8AcFyONqbi7MSepmck<()_3vD2R1qc=G|ETk+oPzJ?G1czo zlD`|zP~Rm9kel%#`0+~Y(Ew%hq!zZM3(#>PMZa*4zZKq6E{gZkU#w|;5~Ol*j2a+_ zDePERtrH$|BnGv{N`+Ujz3b@E(x9k!Tv=tT5l-ay8lmNPucbnMhdXB+bTj7EO#lL+ znk1!c;dHjlLcH=Wp zv!xf?E5N<&1-W273G z>c&`l2oGj1Z2P#??|dA>f)0wGn_=CIkPRv-!!!&F#<>F?{bNc3^?}4PsHII{4*ziD z7{)y$=t2P1_;%w0zHdY)Gp_Qw0(Y>*O%nn2FAbgqUQ1r8bzy^& z{y+fW453-ZvO5W2QoaLT_V;`~c(2WU3i8HQFFw6%YvlUzA;QJ&yITqeGXDp=zFs;jQ?`}JGqCqT3D29^wA?( zB$27R5pvgIZHj=yTl5N3g(d6;l?YffYpU1i@6Q;U2kkRmOhmDh1r(80Ep0d_apBlR zP{qb0c)uPgD*0_+$i$W0`D-K)uEuM@A*~8;$AoyT1aMeDVr-?w;`_I(E;B3`oTRdb zcS+Xso1+F2FX&;-fbi3r2YX%PT4{T^!z#vS%0CfSZjMqY+&*8U7(y{PNs0TGCgK%) z$_!fWrcHDU?rC<^m`AJ#J2nA`v3MESL+n|`=v=5Tup8GgpUo;3FpB^YC5}H8mm8WF z>)ZGT;5f|HDRRvTP^4H8(ZA)>=t9iwkzIiIM2;?}>7f@wZU504!kKj=9J1wX+)g<5 zx3OTy-TB{sZQLVYi~5fIMO*aKhL~{cA5Gui7LNW-ZJ+$_Z3HdKe%5~iyg;>@ShqwB z)c^X=hzv>}3y=Q5n||UG2!eaKU6MOLz! z-PB;Ft~?t)OtvS0uO;@q5MY)x0{JaKlX9 z(Ae+LWRH|&boGMP#(HeJgx+Tjxkq?n$M>;Ust$>^{}_XgU^VFd)q_1?GP2j6Y|?&xTMaqsA^ zw<+JZ1rQqQ-d4b(NvV$n&t5ONLi=N;v2x7g@LW>V?b|}L$gOOrV)@qEyuCwLlRZ|H zr`GZX_}z(wr{%w@wm5;_QVXeKfWMV)$+PPoxKo}_X$sPgLvD)oO!g}bfNNEnPgc^P zj0OF&o3V(Ll3Y;Oas7(@$vbr_?~k-ZD+paZ(`j;HJDj?X7xbkjxO89 zGyPAOg{N%$;ktfIkh6+r>x17qVFL`u%nu$Uy@IP%{niOqMcPlWOXer3T~iNTLIK(JvKv z?k7ZvcJf4Yi>$++oTSk9ft5&u((<}BmliOW+0%$G!Khm4i6R??uw-xU5E~bTq3MjlBc%FMpfyR z43s=RJ*>;TnG}^Sk6&ue4!B%|IqV;V`NaeQ>|EX!;X^nDfLLjGUeg=;u}SJhLey3tfD0Ywq-4qOVZJ^J^;IP%C+ ziDp-XT}?j>$cd`;SjEf8B!-2f?OT6gBsTf3RlHH59H>Y0WrNi&#EMf4P1;4QZD0Wl zfl%e58z=TMi5Uq>9fYzZ7XfFZUD^1HyQC2?L!Z+e600J zME=IV;L6`r>Mz@culcWq*2am7Z}RGK;}@#NGU08%hm1HoIuhjTq5Dl!a?jh%gw>U4 z&uKy0ZHHAlPY3r-wwlmN65yJ_aff?VJI76jsGkI|uoDUm-Q#)ih-wUJ^4?) zn%#m(KWI>SJqTkjM7^qU$sgyq)=M|qCvNzmiKpf$21~(FVpsu8Xt}foa*E z>^ysoV^GS7&IXBRT~&HW8zFd!Yb8erBq!S?8n@Q~U3}_#jSNrjZ>ZDlP;g(urdc9T z$fcvsQ}C-_imVGbN{_H-buJ}5x+Pgx>lc>~-bmV0=2Eji74Lc0ABXFXQOqV^j^uic zqeO?#fMJ=1XwT<``?4@-2u`*23ty^d=sz5sN)RMM+$KO4kni?6wV`TqT1Iy)o+jLg zdO@w@U-4~xmTCReHp?pTMuNuuTc5((bM6!bDo|6fL}^oaJK3q2WiH*ppXD6z>ca~3 zDV;O1w+m6Nr~p|!@~@>^*BW#43V-L)k`lLB;yV9Z-L!|An%{&86gdSkFpKw_pXr}*tbT9s)a{@_@-;6s)Nw!>FE+w^K@$$mmb9{vrJJ{}b;u2!)CD`Z?m(`vP4~khwaZ*nMh>Bm}N2IO* z)^f?`Pa0G#|9oW>se-;xzo7s?uj7)Oq@3_#uJ87s`b&{6^c{Xc@8EwLyLl{Yip4B+ zs`li1VhwFUfqnYb6W2uXkN={(d`r6`v2dip2ermx7G+6f8iuwKq+m5H?vmT0@OQX=ULEKY)75V($On9s5@Ww&hEqpni(10{quG-H=Ae!z}N&x=paD zZT0T@EXv_o-FzR+{^m4x(rrgDZJ~ZQYvOd>;%^D}Ea2KM0?`KQDse4=$#bQmdP4Paus4>-=)AJLE7@*x3hJb^Ff-lN=`91eQgNXCRnBI z$C70;EE;#q0Yeg!-+u|VTk!SA-O32J?6i~Z7aSa1kB}2kS6D}`e?BQ~3Lr!W?`>v50=HH;A`A727a*loEmi*md|rEISXjY5 zJyMIC)FVRPH#NY2xaxNnT@ZxkCb1nuU)_dO_1JYsmLI9u@ey~n+PFQ5x#1Z4yUSCG zxu?9Mv5bI0jpv2>$X7w|`!&C>;Nv}H*HUxGkzw#8)`7jY3275-C=g>KyE!~6wG z9+=oM(t)psdDAx-^pF^V>GS#;P#Zyi--dyZn_W-dvy2y8rQyrz)q|^J>!L{tb~=CX zMC1eUbYhuDCRk^*JOQc$yey#Kv4aR;`7ZAz7KK4Lf=dTp!PFD6|MdmVnOfHd;4BJOrqd(0&_c7?X1y5 z5N&4gq!wSnmMKq?Ois;Fhq7UY=S0s`zsEGnWceD^kKW(@mk#7Cy?G?iFSIVuoTPNX ziG)_u;j}uP$HPIx=P}-!`p>TV)aS~eJpXC%62cEReEHkn25B?}osOgz%*_Y2(-nUw zA~g~GK|>C20dr%hCvF~dJ+#@rZWZIL*w7V31tJ^SXZ&*TazlIP!(P?dJUm78qnVNq zJpM=uzbWrWw;vf?vl-yMAx4{HlT8_2RI4{YiCyI)9vn`{e&2pyk!AG%36_$Odo|@R ziF|MIxEiANz$Slfd`(%D^@_?Yd{+7mG-y_oiY<_a2`k?PEK~h=<++KiQPL(;-Q)k* z<%pmhPV-7F+f1rI3wN)_WH?prm1cXRGr2HkUc?*K%TwHd`l3K9;N72Se7vrYfKL{*KeE-!x zq+pFoKDpx|ykdHL<-##`(D|I-S>jp!y>f419;n`(=e2)nytQzw_Y65ADleV93Z)0?LK{6pLg%$@{yz= z_~cU_GK9=>?(DsFtGKTjIGHpInT|AMNzou>CxIy~+Tk-v4VYry1#CB>I92kqM4px| zOX#6@8fg}==l;&rJ17ki>Z;C~;50y12f!!jYWTe28`JmuTQ$2zUhq8Wo1s;r7tH9` z)Uc*ZZY68#tu-rv5Ejo6!@!Q5W*f^lZfhg<;TU!`%gdmZC}UDndSC`_T;|6E+6B0x zfTza*+U4;lYFe725=heq*Y8Z7!lb|ATHIR`l2C=~q8I-E^$SrLBIc zm<;Yqb<&;Eu$lO5@-ckYU{zUXWKvUrR?ZBNr+19T;xk6okE1;5s>*-GE;quVPig-A|l0y&s zXAO-a2;(?;&QRF-l9RmlV<1bTK5Y!N0mxDj+>96eOmG z=rh!D5lJC!QE+;%h#Nc&7=t{#&F}gNkkRRh$iQR(4s&uN8b4>1LKBoD(ntI^eI4xK zJ`Hw9;WzCFg|GI1@3RVHiQli=>~*>qv31IS3E1nd!IUjOa3*xM=Vh``xA3p7x%AiI zsb82Y;wSZWv-aLf_jON8lSm8ySW+}RjrBW#9(=a;&seP-h=qDNF%cZ`WR(Xp>?3CB z6l0?l0)xWnq8YY|y0S9FlD`>>gNUk=@=Dzok}q|Sc%2}6(H9>hHXC|WP~XA<#JUFb)ilyJjH2j zdizF?TIT#Et_w2?N<`Kk_J`o*POkf3CBUWmceH5Vgmu4aGjMvZWkPB2Qmsul|0~-v zXbAkoEwP(!0!*d^w~@)J+$i|NvurU)B2$pP-Tjw>_aI$nww#Ldaf7{{1XRI)WF=aK zFK-hG*DK<{x?K>xwBAQ?NY2Y2SN}UtI28vYTw9GwN7&`mnNe9~a4(J$!gwg(wKzWm z%peM`Oi4G8*^f+1-?A<-^E{p-3 zfO-mpjPO7q%XyI`h*a{fN@Q^@d3hx9w63&PfP!BlIqpK+*mk$NpJAWaYMkZ(paH)B3nPY&-n9EXOEKT4cTh@xk#d*!X{@T(6R;Neez3*dQc)pp)Liz7|VKLH0NQ*rRzWRt4B2m zfM5(7t%87lFFJt`dkMPH8AK?y>LRTCUXVYAW1NQaaQ5hIbJz!7v)R)@|H7eN=!QrE zRItnu<6qZn-zDW0qNZ5Tg+0*?K8WVG)ndZ`QC2q9*>##IWTZooHj<%!(F4yaU@ z2j_<1+U!v&&0wke9{gc+a2x7{5e2v(s}o~B?rEp(MyF*V5eV5%$LCp<2#D$J**-|+)z4O%$)@8MJ(Cu_D zA$FbU{%o>%pRCWVRNmYyrurR0M`UR-xzY`nRuvR)#gw9Lm83Sg1|qn;&NcZqRbQHOO%D3ZFCS&p`jS4Dq(&~dv`aMdYfQH(VGfS9XlLoP zx@F{N-E{oZ@sR~tI0L4xKw7LR9kWzS3q0CdK(Y6y{c1@Pk2hi zoI_>brQNaw&fc%n9bEe~Oq=EOmu=t0eXl0Zu5q*N8N!g^W$ZvbKpza z4-2$lqj_Q}NO9(K0LViQOPkaz`=m71&xpV)GUP50_fr!b_-3w86b4=n?!x;PO~oO@ z=$$k|FcJ$4IN^|RW{Yk!w7aXPq!Bv#Q?#qWgbDvY=!{s{1yU|e-9*4S6Ck(t`8@85 zenM#HWy~?a%c^W)lBekUo<3-);4L}A>(nt4i@VqTw*cQMBbS@$A2#env=OhBEl&xNF@ zv0yJNJy3ZlJ19UI%@c(ONO?FxN&O`Vmbm}Aq-)~zlm?EW`d-~DwvEkqLpUyAaA3dx zG4IfD*xMRT&5*q92Qxfn#NHD%X7Iwclr-8vMb7*46+Vj0%#6#C z{iqxGmj*-;QgS~5kS>Vfw0UFRM!Vuvs*i9P zIoA0?WYUdg(Bfve7m2{(9iAKh#6K_uJJ!ELC=Q11ug?^?BOZZR`D$|cSyG@E(3A*u z^SO9s7&st+1BmH?Zb-izbFe3jVF&Ts75*HU@hcOY(g&Fk@@UxNVQ$8f5Cu~u!>AU8M` z9n9zR=#=(M`~9*Z>cpsYX!oMS#itoz2fNpZ`MSTRV?tJHOPVGt+Lt$KWngp>JFN^$ zoYJKGGfY9qQ`-C~tI7ka+Atul=*#pj+;Hs}b0_LtFl-C|%0o)u)^Pqpt<)8HLL8Bq zL|)9FNk}q(XX--9SfRHnxbVgWP8Soz@c!cXUDrf@=qba{Zo>f>0jE$tcu@?tp*wAEX&)Ep>3(UE`)oMRz@u8KrFfPdEqG4EKW5^P#sjD ziVowF>j@1<{V(3vc7sUL%LE9a8?W{K?PL>7*?8Ea)++Yi^nKgu+51)MZXZd2GUw|} ztj-QfB@;!N=rm2SbrBg3E}TB4X5T*%b4tW%&4w)e*vM8Mqpi(Aqitw(Daj)z?0rkc z_aA-mE+z2o2?}v@tPs?Of0*-HEcrwvJd(a!{ z)+bIRl$7NB?t*mE&Ve|>HIk7wU$;Iw_>&H*XKx(|!oR|ZWnJCSF~kCJ@@zzZnKEod z%xSH*UvuBAJcAmrx31-PtP05^MF?^dcDVw)?tP+Xq*= zNu~g?;Ff%o1u=Vh&oELFJ4Ddm* z_wO$of`S4MW#gU{&exTxch-q3*Sbf=zD0II!}Aym62MYo~xu#~S@9`9_9jmpsMg|FxE zhT1bfZvACq*1>X)%CIUo34*(xWP`oo&1w|kC?+Ea7nS_izq4rImQABh(U&NMve;zV zpxEcVso2}Ktxb=BUwqE`8vGLF3%ft@(H+vU#{(g zXg2U#kSRVM@ZAaeQ#sh*(IM@kK8T9fxZ3NehT-zG1LG%Z#_Usc7?u`&`WBgsL<#}) zRQ9G{>0&N&0{i$m*8nxh{^(j8>H{9rdXqK>?_u_XN2r@3-EYQ>A3u-UeMN}vUMji=xu>nMD z`cd}>+gtqubyo{&D}ny?j}2*AmBCBOu)XmEPYUo`119malJ1p1D4T-RaqZ2b$nwvw zSG@h|kNq#DtUo@lEPy}M3|#(EjjZ|Y=c(iS>X{tJ+VI9`^8gla#CLHoIh&m?2%PaA4?xISB!}|z&#~Td zfAk7WzGYFH-9bRRP>-r;ku$_#;CjBiYHo%BZ-{;ZGlfL;BOj?e`zhnFCkdcRBKBr( z*xzHo4(qDK6$y{4$MS+U@ms&1`6g=(wh%;$i>5fjxeSbMyt>rMYvR%> zM!j%U!-h-PKXF~5e)3$(>rbJ*s)Lha4}M2f<_jMA39tCah_47Yh~aT=szax_pz(oU zgMV!Z4T0Gy?aF~gi3x1}<}qSkG8iuaweM18ReM(l$FvGL>Pa!($lRmjgiR;s22LKk ziIKD!Iu~j`E2sS8EGjUpz$k?sK{@dgk}bUq`e8?9L|^Tk(L()rpxUOa3Pf)#Tv>f% zdM2@RN#(yIUOqYV2tf7>;_pTzDEF@gVY!_RxLf!Z;Y>X3KKsmtbIe5AqT}3f>5s=~ zM{zUp4IU!pPP9Pi5DP;y=c;%aUoUkj_Dv5)I00ByjL?jjV@R$+a3ARYsYw(=F zGoKIX=MoTF;g(8{vlC3SN!2_>2h2U?{I&JZess03lKjL;!A5~vsH_do)!JT$Yz8(w zCrR4BRqb%h;d!i4AUbWk)AHCpb3hLVJ{+Mg)=7<@D2R3}dboB&A+MdpY^N&xGBW$_ z`I0Kk+SudFk-0%dW`>dQcZvy^nHeDN?VirBNVxfe6_p}(d($(_ zpX<`a7XoLnBz~=j^QX29WTI1OJ&YMnpgqu5oK(G}tUYKREUVzp?&}F61wnkR;p}&IM13TM}EHHri|%XIC*0S-OGxsB{3X>F)>fi6p__6KBJr z^Qrva_(ME>x+;PTV-Y-!{%I3_@m9qZ;(>8lKkZ!-bmKrw@#rtUdF(boY5%sG41#fB zoqV`LYn7=YlEJ=IE2U!~gTk(6ONC%Iry7|ze9^g5>>Pk!sKp<2Yc4&X=X(waVGkfvj5|G)6YqaepQc2?wg=w_zkKb4vLqH zNBTswZ&EI6-ve_tG<#pX9Nsjwr75po?{_k&=d1###gB)Ejvi6Ij9E~J1Y@h-e7>*@e|iDG~6(VFBPCwB~?o+Sy7S>IJ^yr zew>RZH1OkC>PRs5f$Bk_o-qK(2`_|kf?C3%C#C?vHru@uVW$v`|GQ|dN(at&VD|yU zd#^3a5(y3XiYxLoL19Ob9yV7EgMH8-K4v|8^xtD%49UPi{%KL0dX%oDe1i}-i>^nQ2qnW-Q5(0@9%Ys zCV5F|RLbEwDM?%-C|nGN!150Chj}L7MJud{N}FN9Jj-tyzP}0p&FC>83Pl7?z>TY= zC}5ax`$AcD?LYW*Lp9|$yDZCR9AF*zRb(Kpz<9c85A!>uZKPb^a9@((Bl z)@Cn{Tdxb@%Uy9mqy~9BQ)|+e_F}Fdq8iO9YM{^P+LxZfczZG7vlHrG%B;ec0)bx( zS5yEHza#k~&6G-~{;9TtfrlViUl3upP5y?zy!tD`Tzmjt{xp{I)9hW$NQN;=dp>n9 zx$gt7GGJLzorlP+2uB6h0T%Ki9Pk*ePOf%qm8?ZsT2ZWQgw_Z-rXCWNaGDmdQu4Ec z+)Zu<5dFjrRZRin)y$u|+QzGQT){RZ2IvNEXH~FVdiY%wt5Em9RURI^rjZcd4wpHF z=I5w^b9#a2hN|luzAd@*1tuViX6(E-!@fE$e$Y+y@VC!qMmO!kOad`D?VEkn>8}MBd5JM3Le7IbXx%ZbZT<|aw5`gyN5}xkvkp{c z*gNiJ=AqSUb)YjG;SUvoXsJ?m z8!hB%gl(Pc<9@fjPB?n3^zm??HRwcn5wCUI1k_1kr&7cDQq&_>XfanJQxxb?dhX(DgW$~Y<^Zi%EJoql4$~m~sgAp? zRO$Bf{|BY2QBj^}gB~2ZH__J@(q$%FPvHI!a*Mw#RM_ucTKhN%w24<>qxlTD^IU)H zy1!&{=%z&3i2fHOO$-_=t0#K)R7vZNh|3R;i?MIbu(n>xc*N5Czp6k5Y5vjcJleZH z3K1O(g1i##2NIKixxD2$7?Nl`YbK?6p^>lZb31z;YJOFm^PuV_P3eVG94Z3VO>|c~ zX0|ka--$uTz8~4E<~@mVgM1PLt>*&>-H?Zi>0`i_>vIY%S8x>l;7#|J#Kn5`paxc7 z#|H5C>?btPD2W8Ssz?TQhAxJ^-l?8q32L!3W**G{XcdRg}HOutowfP*0RR4n3=GMa?sh&b0>G&vkO?!i)O+N2l*z3J1(zUg6W?*ZNsg1J(*b@VR2Hc;iHL zk&$YH&H2usT;B)l&3Kdi5L?p}`Im+s20B{MVI33sPb8xBc}HR%EJc|OePpT&QCN#{?MyN~XvX(Y z@QS2Y(b++>6n4`D1dN}=pvco$56>m+ljo%|-tgrTppy~Y;1Be{+4g7{WkMQ4Y7syg z9Aeg4ijyb3q%jYPGQvlamFp{B>gL59o@c#~xrp~PpHyi3>0uCGW<5a!%%%+JBjqUU z^1`^vZ70@3Gwjom1Wj$2r82P~Isx*Le%Y-amX~c=cF!+9zkdBjdo(E)MbjhjnG;j7 z)c3!saX(B}Y4IM}5M=i~*}Vq+0yV)d1y5Jf4Ru?99NLYb&Cn-gar)AX`$`XHNfnxG zzQfop-n@?O4uI6pJp-h{kfX9tpQR5Nru0jjdq^h9Vifp5v-T6+JWpc|L3jFc7i^PN3NUop8BmWsLx=FWAavpMeqQf|ai*LUxzU4hRQval`GcnEQB59_ zL-(y}N->M9FeLd{G|vK%Zcu)?wW=m&H6Y|lXk9_d0qygNYpE$8`r|^<0PV5#HQ+c6jCXDW>RauOc_(RpLtwIMyM_+>#-Y3>;^c{ddP*&p2<%Si zmkGe>$gW?O$T>+m1KXGWz7KxXpF?WbY{uJHX{oR4oSevQ;6t5ZZTLS3{QO*)Rpm}p z&+FfLj_aK~82DEd79h|XU7<1+SxlcwnA@K3X(Qp6cSdh!UVQxb{@Y227TJr&vBL%W z;AF|e*5K>fc5^5QNFI5vJ$C_1}N{>a^aY>GaCl=nYk`I)kjWrs;23 z_6z}-cPK%$PSy|ZVRrfM-Sriw$%_BF2_BbGZ(fcwmMUd9-jAj~nx{d^zrR!D%}m*^Icy}hjH39nwJ=r51U5D38;I=uj%urIgM z*!fhLK!h*ob0%DI-64v(3Qh^qIZW2GddH1GNI)}Ab^ANINj-f+u9J?*+h`lhw0cC^ z*R3Cg%}j4SX5k}O1VsIB$vuI=HvG$)x12(APH54LBQ?cQ zhW!kyjMx_RpJOE%bT6r^z1|p%x6judZ_mUFb&>s&nI3oe3L2MQ3&(*3XecZS`S=6#bpju__LUJt@_<-6+(A%^Lbw{vrz4@LISm&O zG9bS8K&{fSphwsiYTlU4!Z?xO-fLsj`Uowbo|ao^CLv?tQ*pwPB1X(?Q>ptm zwQab5QUO|v1%lW?iAy~#pgheg79?K5+>xoZDM#1zCXb3Yv7>in#TX+WM{_`LLrI=W zz-^}P%HDLL_z`jv2&e9AT;0Xg1w+zy>XV4cs^ib7HSVzY*HYt!-D}w> z@C@ZNn%4ot*&OhARe-WF3L$GVteHD#gB=RIn#G=Ru(qSonRxZ6Dr?4r zO))GsecXCx`xUA_JDd0lyw!a8TPl6(Z)Ss}Viu>!eilmz5hgxmM1e}kq0=xiAKV=* z%HS?U=KKEt*n?*ENUyMpK{d*!{M$G_j%vXf_JpVRIei+Ha@0+j(B@w8ns-A6PWa&u zz>O0~?|ZgGZXpa1L56@LB{i*5WEId>R(TYF@DW^DrxZy5hWOCT{ zm(vKI7-*c1@ZMFf9rOP81>A%CvXj4CZrxW|^4J-j2Clx8(7hHA1>dEx!M&ouRxqyf z40Ho*sHpTT-0NeACk{2fttgwTfKQ^TwaoPo$p-5k!Z5HU51&?vE{B ze|-w|;_OdtDXQYH_7!}-w5|JJW8a%|IJLxAbu{O^2suOGZ>nJg1Zcnj_fAhp#NG-P z#xCn$=WmLFC(nW&qvvgs-cNP~VfFIFO|!5U%^}g*2$%{?sneZADS)ymfO=b3SF%Al zq76s%B>^WQ*mK)4&Tm^=pTH7V{@MqwU|PPSWUC+rO%fljn5WdEunUu_FWq2{A@JN; z5eKbTF7{KS;AWl$P;|=H6#`!e?328L{AotO>FKy{-yC{dM@GCTNv3;bjf9ZEW4&uS zUifli@L1*qSYaXJeO9|8ldi%}iH;6wlIT=Kzf;0JJB52BEjfOBBrU`P6|io{*yYtX zZ(^^M>ek|TdN8vhY2nJ-KrqBnH-yZBe=`>6{8x)l!lA&j}nj$3;WAOstH*< zt*e((x@w7N&o2Y2L)7|A($r}6j^jZu_1PH*?2hF39s__%{v#|tK$||xHHB~(4i34|x~kDt&*M1z>)yZ;ea{#WH3mb(3O&iGEp*B(AX!VSAI zl=U#sHY?xe^A;h~fb{d+RH9_(?M^svN@ECM_S|*X)#BcH-#xNo_Y?15c4zmm;`e2a z*T3B}fwOD&_}G58R{-*t{nF0ZGVJsFsFZJTy8$G7F!#*X+Oi(S#z3gj}R8 z(@r2K6e6*6?S5-A-D?N5YwYMEEPmpU&bPmJbySu(qld~he<^#0?ahwUBASZ z>$tDU%be+OLMw}mmLEX1b%p)GsJ30X8A4yRpU22yKIMpf18!J1Df=f$U6Q_oduSR6 z$*XGbTyqO)4&>_^oxB-s$g;y51R_DOITopPHBm|_j{t#=_}+~VYU)W37^&(0#5qMj zzoNw$wfc+}zbt##n34zepS-Fen-c-2OW=76oZZAfdPCt}8~(1+XUX2mJs1;%>c}ln z5yb?wsThHaY0Qm-WcOa8O8z3+2gTSMa7${u_D+S86gf~8NnA)<%5H>rlM>ojm11)R zn?sq3gWwJ+9NBslk#Wi2oEPyS8xf)v0-xP85SwTwjwM$zS?~IiWS@`7`GD>YRLYd* zcDHmab-V%q2j1q_3r`M^clS#GEqJ+iJFj!MI>Bv=@V?e#rs{kN&*eVa0APEj75X~cVEI5{sh{5al zDxT}jQyCq>@AbM3RnXygZr{`#1#>hdDmB?;JMc6cvVo{M@1t+4qy9($=GuXS4mzw2 zgNLcWsI+akMFCvmQww#_5Ydb0mZ1W8r7t>t@*B0a+t&DUwi zfDrEB42T6$EvaelwZ2#TYWD+Gs55bF`J4VCsB%Nvx3Wn|L0Nw}F6xJD4%SwR7chUqy+*z5V3JR-OoeOE=!5#vEB2o@vV>@Y&{( z_p@xJaQGZ)2+;*pq(V?bz}h}mS*ar^nt@ydwhi26z#ofd3T4xAE0)OUE`|Ft&ZoMd zu05J!77&4)h}rgCSDTaA-JtG`<0DSCo_?U##khHF+hj$lXV6^DPt-Q!Q^UdBdwN7?kiG-4ELLya1t3SXaU_i0WQYGB zbT&RF{I)Yy*jt~21VeSzSRT!AYiT9YdG$mzuWZRbe8FqQrycBh1Fk1*@R+!;Bk1OK z_@IikMDdb@3HdzsT#-ILFHqqd{ls0NY>x5{bwOd)x{iZ5ney7v9MyjG)epQC=Y+k+ zb$8ugD>t(@8-DzvUDz9Uw{+vIQsmZNUNLxnC#%bx6Nof_{Dlg)8ajtnvFj4{jzF&` z|6rPAs*u%4&>aGGYkPTO9Dc6f!3qW2X=i^1ZsK$Ua>txpvBwafkx!~onvuoHpgqsP zB2Pp?BuEbx&9Kb2NY;mJsB`b+$!i1N@uW0m<2Wmc+zk=22>aPpFFkX1 zp+vjZYb9z>*H>9EhV(R3*kKjE??N)+pQZkN~P-R}WyW7l7|B`h+dI@HFn{ za01GhunL#3x$Jj~5eoO{R`(S&R0#)xeBgV6dsxZfy9NEfW-Ov?Vt8u#hV+>ZH`m-m z3_P=?>*H!t3(AQ3BcLUkwc%1)rBC#k{tLI3%m4U4DBS){_Wx6K?r}+;?;n2<6*Uzr zTA+v+&O>eGff78TeN#MvVyBra3zuSLBIN}9j$a`X{BhJV$eEy zh=epVH4}51_50oXYk%zZT9Y1m?)$nvpZB}x7Nt=g!l9ke!scav8+mcm@^qtb+<)u}0(R`F_}@T1aolnKnAhgY z>-wT6Qm{!FkNT?oCf<4?9q+j$sg)-3D2)pF08c!siDast{%Ev+pV^;VRAw7w29^uSl#lEj=@GNmrViVed&A4yV$ zv3JvmKpRL_$`mdViDh3p+#UO6PG;gFgBR|0DQYnJ3$hbt+K;u_4?Tm9e+Iy#$hl=>CRJ4I(Q! z)b#9LGq5i&euaReE}TmDC=C9W+#9v}Gk_3S!mH}*Z2Vc2w%yW3b|)v0*&xHu?_^&8@Ds5Blu<4Rdt~6RL0~^k7|+Y+VL9psdP$(kmqQz^jpBYs_o*vx-!Yb{CL;nLmv` z@a7vg7?sa3C!TmA9t$BW$V*B(JWiSuO!InN@YB7lu>PWRU~J{`H+?^&Gzb7Z{O*Q( z2}i5I6)a%?NS>&y$w`1f;hInofUnMt`SO1kZ7n!1W1suD@(j#P=M$$ zcynUUAoyTpZz_0&5ULMjKmyUjkvp>yS;m~gHOrRfeM|0QivQhHZr+06K{W{9TUFta zsg9KKE(M{q)q|Qq#g2+YOg%v&@DdCI%D7y(g!!Cr_2UlVvG6nmwkWl6K;W~S1~DPP z{semKVh}IraEj z7^>N5vUZ`5VO@t=hz1h-;7t2RV}(oBPROw8CTp!_URVou>A&E1Od(cn;1ohwp&+Zn zAAumafVrtI!)$JX_Wtqg#01p@D<#d!bl92K=K=<*VyIr%C$V{*zUn5ksx{VGm#NBH z_U6vT(G{z)THDCIm5qg2E+x+!ZSwA_ZxDVu-L$o`<(x37VdKV41^aPj@F*uyD=WmJ znBK#P2K$D>EI1a&i81m?7;TMgf`hEs&eJ?ZIAGb+`!qKSBX!r96tl-?I&+)k?f>fn z5eh&4Y>m@e4~kjPk_f>-5`fSx5tk+hX7MRYijk4J20R+$LLj5w3Ytl^TJd)PH%`mK z+HM_t4k{jg(XZri3R?S(Lv7=?%f3d3b*f#BjLh~|gqa4lukfpR*NxT{Uh-b5;!vz2 zEy#mPa(!^o+r{Li`cVZQy#!gFOR#6bb_+sd>Bg{<1&tstPn5jk_&_LXb5lUx=ReA~ zPsoK+q}hu<_I}(lR@6K64`Yk*==$eE>Eo>ZdYng;pQg(<#nWseXcb3@4Bwm9WY2nR zu~Cv_?`D1)0mmm1`^-soN%pQl{_02>&7*aar-m-%wNKI7dpTj2F+D^98MTz(J|g%? z4?OL7GOTmc|9W~;qM=d$6z9hhpp1|~r&0b`+A(j61 zJK*D#PLKOKp&s2yaXAYhbVm6~$qFXp@5FVt6~G}1qAUR4nIk)^j_58jQ%+|<S%{S zsD+~?T?+r8S&&YDl)#RH)<%G&S_OHum=#9Ar$>RY0Z5}m$Yy@`WHJdHuk(zL+)Gs3 zfK)8>W!E`>D=(96^E2T}U+M>c7M;PNm{AE5WcW4*Jf^lxwf|}Rf&~N;BtWkew5F3& zr53t@`{Z&yzXx(9e|;#l<^beauV*Ogg%fBCLZn0CsELa zKXuc!!shw<{%vR?FR>3MwDDz>DDB5&%QY`rSL+K#A%o0BFY;xa`3v{3A`Cq`PBWfG z5TRbbzb}q;vZ$S2ebGU9$sS%nOfT5a+h`4dU(e$GgUO-##)X4vTU2I4a6h~P=uvBF~QQdO*mXqovWguBp3ad`)@VHkK}02sG< zO@y^$+7$t#73sQEA2qBc9l1)3kVqPg6C@y;vn^0zXOTdv7T%^DR ztB)Zpc~KG6y=QPN2oF$6UVM=u@5fUrRIBJ1mT@Q^W{|=Cvln!?iIxxE3M;apT;f1N zDN@Y?0#ivJ-9FnOx5$LQmW0?jMLVPSwB88nb#HXlPx$5Zaf(fdWSC{;!-1jm>sz0EQfY=igWmz)m`&7kI z#brX@*JiJM9SkVQ6PhTcZo)CR0@OZRoI&w8wYglqL4QoSPWT-yMqBWw`4Z6FL zVwQ;uG7=1i(1{B8Z=s`MU9VvPXarvE@S>DZKaR*pb0e=wQW#W_`w}b}v@3Yv_;>)* z8yJ^N$TT{KMi5#dL|)7DO3{36zRGF3B7@qlFHELnE#^GE>x5+_frnQ_3rU9BK?%5h zq^z>l6D%iZ+Gd9Z#d#ST&1;d@*c3>Bp{6d5@GK>7Zxn9Gun%ZFItfBTiK3wK=W+yF zJg^XL=EpRi3BR0I(#w(^c|ygN!B(XvfGiR}+`T<-x%8Q8cs_e#oA!F?rmlE>^eP?! z4_{F0Mu)HV)HM>;EhT?jUC(epYYih}Tjx+G_{-;~o4&nTb+h;j{GI959k&qp<%Id4Y6$-Y;omlOjZu`P!FpRtgd_eCk@pVdrzZh8 zKOZ>fK{QI9kd|x=@HZsvoXoU%gEYI^?Db{Fejc{e^Kyi3hd%w?*2mP_?=y;q5OGYxjJD&J`)5@S4Is?zwgJ0nRCAMu=z|=o(kj7N(XN>oF|f*7uicj6~hpjalz*Q zO)-K7IAftb|Hj%3NMKU7m}oFTgJQrLf^|z zx0C}ni*XX(p;N?GF+^B1Uk#!*32($NeTZuauxezl~6qlZ`>?qKzTkp!q!94>q-@^1mOdx2iv<~yf_o|c;XpY~2eNH<}Z<`aw6_QjW_u9(+m zQ&A+)BcruLd&{@O;y;lmSw4E}vg3f@*jgWCmnAc4^J9mJJcPPdJS@9f^mgnu|J2-r z-#;nl{{$cZh9fUsrfVjp>B+E6tcc`4Mz-oqR*{UvF6fV7t)sJw>gSh)hf;iPy(E&k zYF?!sc@+TvmxOP|ai|a=1i&~|-&-9C*zaXR3n|B-P*OtUpq(CoOMP5>EIh=}iAY)T z6e>D7e z=%sQr#5A3CB^y^$U*|jwEY!wJN|X(RK$z-R4b|P^@Dd|8)BH z?Z7Vo#q;@N-fwA9el{lmqr`TQ+~3pVOsNk%h9ygu3J($6(y|oYF5tFhJwzcqXf-L4 zUF;lw>7S$dZ~x^<0Z>K3<~|>6p>-ylVru=`;<*#Izt;8i(cr#vBj@D>6WGz~y=RD7M)z8jemSITX10-59S(Tm1{~ zg9+UDuxzcb@l{tR9je@=n9E2gDH-B5T{w-(MMbaly&&skASfxfgx>2FnMGc;Ucby( zdaroV*FO2bw#ih!o_22Iy~Dsf6rTndyPy9}es^-~T<>^lA6pRU#hK2D@-|_1|9IM#s1L zhC0Ot`yh(ldMEe!e4(B@Ekp|i6j_aY}W{i!Tk`9+4KkF#S74920ifTpGUBh!@ca-`{Ktx8c`DmEj?swky zSuLZgg%9Q*fP7;Ebu9wouw|CLuNq3Xa_t1ZP+w6pY#Xrjm>lz=an*Y8p+d6su!X(F zqZh}9D%+-tx#|PmZA9qAeK)iiwDR4$!N+;N*Bssexjy`=xj#o58!Cp-sZ+H6#!~b4 z35r>rM#6n61%+<;1ZZ9f(mlXCa4#)_aiIURi1iWyif<%@!co+_?V!T`#B(8NU~Ig5 zl~WWB)+Ez!uFKJD1lcwD??hpWZo)fV0Q%xr5hz};`B?a4 zFuzTErP{xj-{mrkf{qt}>&F)CM2}05cs?2c$)Lw>^f6kb~oXm!u>%{-yR;8Zk)h?s6D>yA1U$dFeQLOCfu`3 znAw;?CVD`SYeEMfWtNE$R&n=P)nP`?@CUzV$rFN%mr@=%je;n>3j|l63osTqkwwV^0FJU^&GquL4SkOy8t7GU3>&1{Zvi0d*-zRX;^B7r(j7W$RPzSssmv zb23Ygl%4{as{oUbS0X9)3io_Gik=9v2WMmA^pFINsUAL*$L-!;26;+gOx7>G!%LQ z5(KbFD$_GmY$g%P>>*C~zByYdx-4aFwDBkc;EOZ;JU4f*=fbz!tDam~4E))#NRLCl zjp*dYW)pDVz<&xcU2C>evQ(L3O*Lku4%A3=4X%V#1W+xMzN2YnUaS{Rbig6gPju{Ni78_JQf3?cL0tN8<&vYTx35~H zMXWU+dw$IsEIro;zdY2F^4K~n@aK)2s`Xe44?vD!&akQG1WiS0zC+F`2@)9B0A}SW zST)GZmoPz(#6wK!96Gj|^by$b5?0iT0R$kg6WzyU`X@tv-!wgrUA;Md){ivA4oVtcQ=8Vk-2`!e{PF{3jeqApdQ1@~ zk^7u^+4e(-<&`#o^u%&#Olj*TXDv4tAGz#a#qnn31mlK%{e^6>)+e;O9K>|Rtka@1j%@iPMn#s@D@_Htzc$tBAa-FwflV9dmu)8w@t}S2d8+kA z9OrI3zlB&+$~0fOamy~(QSylVYzVug{n8as3`{wN?alnQ$>Y}T6LHqwiJ*%?HUUp= z5o-;o$}+4uv$9gUe?56kNieKge~0GF_)I%iAfUusCaEhjQTPqkZo(z|{lIKf;dJb@ zS8<+8F&Q-(I`n=MN!g0TJgOOWb>dx8%GG>+J-r6uw zAvIemOseosIH25FD`@Q=kHU*0*ke)9$LYKd7uq1p)7K)?H^^n23caNxKFd{cX-i&a z^mtTmDG1?gYK#BPzuv2tuD~c%SdbMmMW-WB2}^^qcQHzZeGbz;8S122xsXWU{^>Oy z{ySJX+8Q+*1G(*0dg`;M$9qF_lea!GD8c;VB+U;XRAfxv>~ zpxuxQFIxe@UI3IPx#rRgrLWmImZQ90XR<5Tp9N#k0^=x%ectvgcVD4pG!n>Vg_Q~p zHF9HHSIz39oUj>7tffWFjMac;?20xW7I~EgV#x}Vo3M|`?G_$=2H9Fy2wU{L%u+Z? z97rn4ZB&~bu`a_medpcD(Z+)O3#q!EAW~A;A#sKd9r(45!JQJTX?>jg2`qj zs6Jgq5V1FT$W;<=rt#dc_&&S80WyX_^9p5bM2m8`_WTSzwamzx#|~?oqFISWjZM*E ztIo6)3BaaDIIT*F4p{u8ZtswFW$_U$VK%Lr1F32i(o_?Lj=LAqn^xe;@!BVOhct?e;#5 zrsMG&!oQQ{pnvuKSGTqq)w{w}v!k-v6&tZVGl?1YZm87W5uLi&Z7YCK6}0;yJ9%~= zt>D<{+3GZ;e`q*(g2yTO&-Fp~ zRix;i8d(sGrNSZL@m zS`NO>jU_X$3yi^AC-3fL(rwFXWPBb4@!+`#aeJNJjiKTz7@d(Ae;8FwAF_YnuewJ5 zLx)0{x5@hpfXIV3uEC&=XM(=|%8|(|WeU9&SQJ9crhtNSA$kpx-qJnK?~-jG^|D$& zrFjIkJN)eUpS84;HN8Po6qo!FWC*kwi-XCS^pzOQ`UbdZWZu79u_;T0h6dMNR_*n+ z>#)mTNM^!AQxcpiA8&p+ID>q0E9b1cSj1|BzbRxUwUTVMt>U55vL{)3si#kFWBWq` zg7`7huMc{RGjVJi`AqyPKPWD>jq_WQcOI>B^<0nXwudt`VtSWiX4e+qpN4zW7Z+>V_XI>WO+nmoUm zNtW{{bS5%IB&?{E^>#SGBnjDr1S#XDN!BaV^TIT9GSPic z+RBF2)}Aa90;PrF9v(Nd4jTtFb5%-e5P(IN@F^By6OrH79(8*O-o9YhpM3hp%V$~I zGl)OGFns8J|elYF%iUalO&w63MlQ>Fb~UlwqQ^gHyaVT}!f{)D%5`!cGrEy=IgBi!SzpMF8Jy`=7qe<#9KXsBHe{&nq&2mQV)$TvW}rX)=55&yIUqr1a$w_UQF-)ZIM!jJeY$ewSB4dXn~T7Nf~ zpL~UY*pydq8bCpTtJ#6T3uii<9liSJHK$;};5YQBMEXo-)qfJaI$LjP92%V2?Ni~o z%&Oe7sv9UG^%jz0s><6M8vC3+rEGD`-A+@nk>|;cz4f9F6bT}y|5Z0R5jPBl;x!T0m0@E+gZ-$1W$BI9 zT^SidhriT$&fCyaKt;g>D5x39gk4Uo{RuI@IEMq|k_{nt!r^mMoHluMUEwCU@2R$l zFah1^0BYDcPhje6YqDE@Y*_`%X}0b_Ct{4+mM7L+lm#EEy-VSaD%_mFb&ZFN?{hqE zV@=03%J#>LXe0&U#&CsMdv~{g{z{vHJ6S}nr>BWCGWI1qG^Sv8n5jwjUtkHNM4qi* z8OuU*LEzK;C5Th0j;M{b*uvPq;9-`geh<0RVFGi~u#lrlVFY0_XKV4853Vj4XFixu z*BDEdYQX;xv^lBO4Zq&4ZD$B)EI8kffleqvD2X36-rDJ zx-Xg-i-m_|#q%fiBVsttplE(IPW1t3lEV;d>i5qYlXlEDH*G+ezYtSE$j(J=D zFsB&33J7PY9D}St^_QA2VFQI8U;IoB-j^=pg+7)GUlecxSo5)tOVe`;3g9RFLs;S0 zh7gGB@)%`oj~~#0mQaCG;3%sEOW{1c+3e*TRq}$59t}pKA|Wr8I2Xwb`QjIL~knbu%ftP z54hrgoEH9UonFWUvXfui(vy2f+E6x>8mtf-ZM1NW8);otxo)FsH2ew--0S!+y&APx zjhWraDcYR9n|mnHb!_M9S($rifFPiBbZ51;mU@a~?wcE_B%zov??g#Y@_ z9>&l8H`km?e0=qG-<~JeRQ^_*#G)wBCCysD1R`I;Z{%@?{umuu@0d!n@12jIuwj3Em6s zy?#~xTl14r{}0^*cb)rMqN2|oOxb_)?CY?Lf1iIJXuAjfnBU`_F8Oq{sZQ^`Q)&SH zZ#+8vFQHBHPH48yCTxKbZGhe5@KxNMz$|k}rmIckM3DhqZmkD`Pz=63xD0Eb!dTva zR@}hfG5T4#V_Fa~sR@8s?o5LHWByyZ={ZhPNkvEkY1i|D{p;)jYQXqT@<8~VAX$@z z`OZ*N+w7x5vTwf8VZFn?YL6dhDEVt? zQ18)t@@PeT<)C|V|Fb+wU*%mJub`Ng%+Ct^#H`#H2X5CsMQ6`txRMZg6aaGc2N(%U zL<}`x=P#!~I6C%&m6FtvjOa+hErI@4zG}rtr z6x9i1)2ZmdO7gZ5jLU$?V8rwgS%=lZ3OYGTat(WcMzSA!u*SV#noXAbiqP*p#F6B! zz!P!gvaA35qYrW%Jp2kx*q%+j0gVZ;ZpHqj!hoHyanM`ykc^H+NP~9Kl9fRV6|7zm zMTu>>_J9cHi=oFF9LX5M=bC72Iku#$E>B!C7TNn&cxWo3vJO4``)TV=))vZsZ(?D@ z1|tdgpNl{LCjG6z^_8BJAMK-A-NF9+1uQEAbBzA%4}|Y({IK?k*}`J$_$|#MqOJpe z@9g;u^Zi;Hzns2KZj0U7b5Q$Nvf^=Cr#Du2aDBu7L1u;F zh$p}E2M*ViC8>fjgI|;fy~G-`6sF>XYs+c*o5|zd*JKHwN_X6UcRIAm=t?C9a&q?X zswpN09Nd?ECUgD0c21XT%7(MX!C{bf^`9^Lie!(K%R-Ck#uiT=e8N>`37u}9K7}6G zRzcn#KaDtxFKjOuIAlMzbWYFPW{-?~QT@TeYE^-==;ghGQmiFEzVc1};mh{DUl>ug zpK8~JEfhvskA#-{2#^h~kB+>YiWwO8I>pR-lY#jqZBta^#9PWJpW(sjM8<#G8JzZ@yEq)0|?uO!Yc33HAVXxSaDK0d|w`0)SnFt|B>IQ#P zXU)o8GBG_Xp=gS(x|-T;T2}kd*JtHg*qc_OyS*#Hg*v+jH7N>AGi{(DIj}O zx3^92*;7$a{pfUE;wLcDN9U1yAYBDpCph|^kPZmw3D9=rXi(eypChLq)ukG$ate*K z^i3{e(1Q-sT4X~TLOeqNYb5ZVD=f|X;G_u=yvbY>EN1<)WjD}pz?p8Ukv@~ad*C3Y z1;Hy2>>89@$QddI<9BsFMxQavkKdrzMSJt#H|8n#lCkyW8m-2o8d*t`UZ;Q;6vqcA-m}6U4D)v52X8mX59OBs? zOQ**L(>{tjoTFW56dSyGV^YT*X6yCbHQ7n0k-8aB+un5h-$=>xunuJBja z&^|V6O79KpdHWj9Bgj+n(rPoo?EO7Kvr{|Hd)5fHt-5^IPkKA?v!~DIpPDf%{_rB; z^Yve9ji7oY*?4oJMS{0~kpe(spi$=%9_TeYn$c5O-TN65Sl;t8EHJSWT3x#_reZ8Z zZ*77HR!rh?(L*U6jr!X%@jn~^8caR$lOH@HME7FAPk;KQQmna6NNbv)<8_$Yt`HOI zs>&|thk!FD*tZ9+2U7N>P6oZxT2{1G-f+~lCa+pv%8hx7L@j-R7z0HsaKA6l14$@{ zxFn3r?KK9hehvTvtgX!8PM>o$G;1K9ymts;sKG9C;|(oIl)8QZc8Je^RYvH8Zf%PrEj(Hq9SwJCujf-2t8FOWOqQ{#F)Y>2&mPnf{ZR zl1stpmV|g)DIHsei2T7PGuAqcihnUhE z5Fmo(Zja10!Ti_@Ls_(etZDUp_ZXll;7&+cMp_-lPzzsjHol}!Qw(`gw963i+pDw^ z98B)+xA-qe>roeHh6+f&o3Xam!P76^+=dWfYTkIFnCA1egx>)KkvjX<_cq6@t$Z^; zw|(RSFVtyNec^0}8MA!CWk`(K>7ya6iR&8+`j;wqaaRZ%r z_+s~n1Pu$5*{yG6l?Jvcpf;}x|-_Kl%w}m;<(^B@^VNF}L{bCm=C`*sup`&%mpQv5N|*SH+OOLxRH!?*!VaYI?X9h|E~Y%>o~hYGqXzsF=%hiR zMPARQ>C0S4XR6IIWBHNz(PY#|VbXIU4{S6P?wH2B7tRGvhF(NGhuz$3`SiYRy z-?jL@m#rkI%Wk|MScqk-XaS9V7F6GmfW`|H7jmat?k23HD#e_v0#7Ay=h^h`aO-_ieC<4k8!0&qx{*6ZSz@vBhuD+)Ky3H+K*acMh$*LXb{l(^#-{V z#i3_-q`I_~Es^Ym&`&YrhQE6 z6Z`#BJJuG39Vvhl{45}J0z|H{429U?kFD^N1FWW&ts1!kLCs*?}Mzj^GFjFnd;)h zU#bh69!`tGK&(*`Th1em;u;^e9YX^7oM{l8EHi!Aa!p4ElYGz32~z)hN|#LT3{>02 z$mELvS(pLgod31+cNAa5J4tKp7JP1^4zebIiE4?uxx^|mv zZT9WxMbgVl;C!Cu4$53v@prhK`Dd5^f|NY&v(+K)ftJsv-`=E-Q)|Ni5hkSW*(~+i z*5;(gtZi=9W_~>wKM0LXYt!M-KV;Gzvb#bELVJTdz?pQ z{=U2&Rp?WQ+=5W7Nw|Xuhe8fk`ejsmsf>zs@hl$|+!9v)}*XM*RUj<}2-qZSjO z3N&J?URObxAM3;2Z*1Xfg|TQ|J}Q4t{L$n~-xF(iR;cY;{a+u#ddI);ZFnqt(w4ra z_H)=Krx$?@t|ya*{`5iLsyf59;FZEw5VdDi@3!>wOS2o6!nt2+zpo&;`Hj?&4Km}m zO-l72c+(zgkPCS%itL|kqvnJlQW8M2y2c(@eY9UXz(0^F8AnYZJRB^yrwTJDPE4YZ z2L5Frpn8>QeJg^uAA&~s{I9o-KQ1-*lm0^{WB>6jc(ROz5BasHn`I#`tXb>ON?#ks zo7q`+BDVVd!X&MbdcMlo6cwQuus zrLje%DgUhAFc!M8O#ufa+6|me0Q^hteN#VD^tO$-Hq=>S{&O2xl-LPcPr1}92yh6O z{L>?zX>xZzph4&l`GFuSsSDKI^F)g|>S81jI(}pzHl6NV)i*h7xY*tfx_~S5hD0lc zhpKslMbDzm%>b`dz_XNcl(nviHT>u2#6@44I@Vv80HIJP30qS2u=sRq?gTzwI67h~ zv9_iYk9!+eHp)@MfDi0b5n1LZ&8skVu}@C}Q=Qjh$pW1AeY4dK&y7o~6qt5!kTy;z z5jECGn{+bSM(TVZ&Y*U`&^q?A%Wrf%B)Aq@jDp*?eWGC1VhP0JUUaD@q0~UJAvGAG z1b+$G)XW5{L04!_(VGs94gGHN*dj&BDc$i&kzh?(eawg5O?J7B z@3c+^3C{v1c^pjm0f?SKsuedK()m5zJz$P~w%?5GxB2QNQ?JNQ-8iLSrm57c@YcS) zbDq1ml;4G5v14ZilUl;33)eeaLmveq_ugsxCH2mIGhK&UuSigKSTd{S?$-0w1T|)oz%?H8hzSotqeFi8SdeEII$IqG1EPK21 z*)xaNTgR2JSE*{>R-kR)wqrM+Z@cnx>W7%m?qAyL1D>Ag)D}hLre9+LvlBVHO#y%@lN4#-2K}hht@pZ^WeHTMey%D z)#1s#l;qcLL$81H)$K9&+nRCx=l{hot$NOHI)pvkv-MhsT8VB%K2-vU&L+Ol zmB(p_o;QV&*wZx?X}~1VgI2G+Ys*y51fxGm6HBzd;>hB33%Sj$8~Z^Z)F9}8%nV5YMC#Y{C|*gNwg ze{JK@Q3+5Q4XMDt%aE2iwB-BG%iYOnmj^+V4^gB8?JAe&<>vZzgl16Txi!R78awQC z3$jcjfxPZH2)79$0Wb%yyjD0lUmt4KHXgO?ktO0U&Cr<(e!5SnBw~6^Z8G|B)Q~|< z)B1CVB{HpeKIY|t(J=}hp3vVvBu=wL65X9fN}53j3@fgpvAm7E#?|@V-4hyAUpC&_ zi-K^%v1mR?#7U|S#TzAQxm-2mS0WraC*|q<+0-DbQY2A!alh_jn=FCTN$w!c%tu4; zYQ>~=R)?DUB!dE(RUfhP;--Gd04ckxZEiEpe>4c5et?*0HCuU4A z;s##bg+qqRIUyRc;nLYl!N0YLOm@J9wr3eHVfbhd5OF%>SIF8gt@?TIli+;J@Hs+L zZQe{GqsgUun72PVEkhi@sIt=jTsZI$`1!kaJi!ShwGG2y=+X~sh(8S??btpKRL>f8A z3Uv2lB#n%PL+0&MLEd&k30R8h6zgFdmDh+m)i9e9zjtn8(^|Dp3?+W9OK%ErRte)J zKk!dt8X~;zuWeo3I&THIn+>UVJO^}7Y|igiU%ol1x47$Tnqk4Uy{Nq5_m6UqEnyF( zt+q7dGmDC7b$m_V)!-SD?(-~>-{UtEg3Tr_OsfhXMWI4$NL3A6njKbS@Is6RP z`iWoURx^7FjQJeZ7&Q|%D-*x$gAqzyVb-B2BTmn1q0rW=mpu_C+>K4N6};srp_2J6 z=epjnzTM@NI19fa=RIt8*xv=iaN;s#qK;DLkr9lrzoiB8<->9W@z^AI6@VzCv-)I)pi)m z578AyU#iLLR&-_~r2onwpQj17^wd9i*%rR)l9^P@aPgg>fJ)cogdkW!I?LVY?TNT} zPBB|*7*u8w_+bABC>1&dhBR0aZ{Ivt6-NmHTb^VnUJ8~D-D^sUxEntUnPdfgM4KVU zBY21a!wDy?T6-9QYmz&GhKdT~7fVG5vM0j7mz{@>x-1E|U9zabD<#AME1LfeE(*i#e|$)VEu?>m`E{`IfgJ7M+L&F1|P0nd;v zUERdP2-ExtanBDhWc3t4@`4oHgKKf|mT8TUF#Ha;ViW#`%ala`!!ydw0ulKAPsDEX zb`|#f=D;P=Z~4#<6X0kG2cLXwEUvV;729lm)gkU$}pA{8W?Z2QoZ<-7>o z(Xp16bqyXCVFXd@*pftu4#o|OTuoYLQeYf}Bxq3B1EY0u3=WUvQn;Hm&jv$tUGQ*6} zotN(h{Nsg7!H|3R{VxUJM4gkKPUhdMb+e3I@z3?3FY9Nlo0lJL>3Mc==WwKca{u=& zh8L#_?SD8-en;E)?#-%!ZgP{@b+6-=esSI}n~A3~gKnSwJ{)>O5M*n)c>dcyn$@~! z>D-a$FMjHBSKKu9zkK;q-6=zqZ^Y+-zrS>#&N-%;fAJsR6yTf{a+q8}J*68tITPlz z((B&(-*Ubf3ejszVjeAv&qrUK+xlD_ta&}6;}nykJ)>gP_afwjq28}jV-~M3f!ss5 ziQ6#4ML(<`T)cB*$1SI$zy7)9WBz6G&$~LfSMTP|#qNradsJ0Ah~^>YjjkU|T|1e& z;_S%xQhJMR?nC0==|a9C+0bq2c&C>eMfe#zy9>y4~g-`wbyg;|8D5~{Aw0W*seHbJ|6;W z({7VydB>IZE_g?-X*rMt(71d3|N1{@*?RxztWxjN;Z1k9SeX$l%*NZsyQY3wqFc9g z@F9Gk=4$UFqt>gVj}|iSltdg$5ho;?Vma}5A0sW_pN)gZzZxqJbxLkqy|&MMN*Nov zW`HFgKoX!oL6E zQ-Alxb{zSyd~6kWa?xA+>zapO6#Hv3&fj0W3JP;4f8t*+ThRr_Gh5fN>h0;!=U0Sn z2hSZt6YuFrgL$v3IH>6%)xpD$3-v++-q7K0iZz1PmwV8j+x=3u1fC{8<~W zy^SoXli5>7@|rH<4;d7L?e@2*=A$KrKjF!#oF0th=S^6hvv^vsapf$RWUM-W7lFHP zm<(#4zcn5s$pfORU?*b>B%1KqP$OCAe-WRjF1Pj*Ax$qVZeMg8%)&LU=$1jI#?w?! zu=cI{ks~T=R;IEkW?{+{BvN8PE$?yy#wVf1MhF(6W+9rEt64Q@f11A=)ER+PK+4j9 zPm8STCWO6D;g-F>=`EuE{Rnb##VvUW!dW>av4ZV7>~#3!GhHOqRS!(t?lTL+ z`A_tsZ}rG0Y{^$ma~D7&n*12l<1KjQ&tfk+9j={tH0uI5+w49yM`+2wg|!c#y82Zgsd2rr1Yfn+YS|eyD`p1pIMjO*|a6Mz>uE*!8&JA?}HBT8C~`(T~q9#oRFF&c3r?g{fiv$pVP|6bFDEjwswbf+yf0<^pK z`P4>25%cS)p(prln64ptXK;NQ{h%W0I#{$_@?F+7BSo&jz-22O$HC=)OQ}~?`0g&$ z7pF86F9cS-)DCA@mcxzh^^hvRp!oL0df43g!n@7$ab+ddZnJg}FL3dr;QWT>Z zqi34jl2%>{ESr}86LvEDeado89=+EmHjCU#sx^)T(^K-!u!X0F9?US`T&ZwQr}b5seuDjOY$alF) zs=f*76eRJjcUaB#-`tg-Wu}r@hlX{315vjE?(mJfaa=8i(N_l<0#A%xD8aLGw87uB^l=-rSX{?NQVEALIsfr8YaV60!Z7e0DGd0-= z<7kS@>*CV`O#Tob_AVQUUzQA&NpMxJpmf0_bvW|vPIXU2wK?Rw`TxnNx4dUv$>I$h z)C!}`Fzt(D+vjHG`!|>(;SKne{`DuOm~Se6eV~u!wW;a=)&1MlIUdU$2``GXHXkjF zenf&3dC}}n(%7#q`9GJ=Z4oWUQT*w_`zp?{@p==(wg3IQFJX@RcWV0YKUfbOT`W{D ziD@m`_w>ppQ5804^9J&oIFz-i397%jd~;|+M9c8?w4*VDJ44(HE!s2{sl zkD^yddRArNR(>k8?JZTu`~H2pjgq#qe{9Rtee2%2pMO5{YcdJse!crup``}WIYh1CBD}( zy7X{U!fjZ~4dsJ(f=l2!k`>C``{k5N5r@>*6ud>vu5TUFH7)Gl^Ix<2OAjgZGzo3L zxVZqmd&>ykDFg~%4t=q?=()><)i=<$lmHQEZ_pI;A?tXHGn=heQunc<=30L3!qp3N zM^5J0b?iD@qEJTISA?E+KjUmE2|K#IXoJiOT@p3I3RSN?fSOq9y1Db`sfu3m^+Gqy z@k(aU=)?TZD+F;yR44hGL(3U9qIvK#cO0IJsyFn9)jIg9`TFJ+yd_+|z(CEl*Z}{U zP@^DETncpoe<%UF8gzr+`nD5jPT4QHbLDY~ zj8vCBbQLrHH>cp!y|`nK7F1llU7nTaeD)(i{+{v0LglXB_yu*3ku8V*qACXf#9k74 zyne_qh49oGHZm``R0|4kgC$X7>&IsZ4@)HVlWaZi=J#O={KJGQ1K~m?6Yk_s2OY#{ z7VWT+Cm1(>?r;NJ$`~Q|6QUu1&01+GWgiHpO=R_hKtLOW0gD*PyFcc7rxt|jGQkLK zzEBA=`11$vq&?DS)7xOyEt>vg4!vzkUJ~Yr768W=RLQDvQKSyYQf5t(@$e3bGgR@Y zrx}=st$B-LyJZE`Kzfh1G=2fQPL)H!^QN$>58Gnqs?3fUmf9l^EX%iSk^=QSXr~avfXGwD>(qp~X z())7~rI)%$68-uF77q`_6!B`_4f0EdBeldq~EmIl1l+A!WMk(A4M^{WNUwH<)@N?-ksQ zv*kda(*eN_Z1P*f1CgHH z!D{3YmbMyD7Jq5%9M^-si-=jlQ=Jk8#gOb_f_dGG zbESCL^k(j{7s+JH;4WA~`XB+hEz>dqzp{YYs&D{zfvL_w)5C}Y|1ilx-AVcLD%`e{%$srKlJ$#US6NX4!^K8J;~flW0}Tx47a z40TXXYHwKYKwx&K%Sk$9w{1~t^EkOqIpJn=_m)S+ePoN6H}Y}A&2dTp1{ER*eJF2S z6e|0une@6>o5bhL06#*vLMz`+Os~#!3*GX>(&D}XY_XzoYL_Cf%nzbDJwW2K6-NJj zPA`e&iT7RvfhBhQCJ`t{^VBqro7>FI9$6UWgU0=ed+(pcss->Ez#mY}HN-`9ZLU z*AKFt2YD*Z$Gw>YAYkgfRt%_}lfRKuSgQQlIlwPOJ^jxjPo zXnhJ33|#thAR?+D zXa%TtPERbXMScVN>T^*k$DjTXKE1X4;twHQ@TZOb#OUtpp?=#PnMedHnHrVV0a?q5 z@4DouV?*-NG>d=_+nw#J^P=TJf#fq~GCg3F*L?NwHkm;cf$2Q%I zE+t=oAHNVC80y33%%9Yw=g*wKPD z2n5P2;EOlC(H4@wI`x{pJ6?OwW_4SYPX~+df6F<`Jlg+!zaDmi8+rd1LgzBmgc%{%*hBh=oA&MhgZ_It z=X}Q|Rz2|cuY^-^d5J)loc|^LiaIx|)H~G73SUDnH%H zgCRM)&Nl8Xab0OOYhAd(GR$>+vGiPF$F45%&Zu7ai1aY>#llt%Q?b;3M}rZimaU~W z)Ds9PBdAm1;xl8XnjUSsh;NUB!$02a==LWunNiy0jL<8el4FE)kWyG!rSEs7@ZH0X!%xhN z?MFSRfzW>(wo=;vpqxjzu!GF2U6`E1?XIn|qNzO`)s5(V!==qsr}I%`HHJ15$#uqu zB|7^TI7b&G4kfX@9@EH{LJDgMGDaI9s}!#*#&3h)l$OG*9mdTHs6>6f&-Wr%@H|pbx8K3s(qR}pGz%d zxI-=sXKg>rcL4<9;jcZU%A!sXy@=4`&Qrr>Yor%U)R}`>pJ9{iHMqQ5AC+HVV$*H7 znL!b90NvRu(n>|b^d~w`%=y0iepKE@)L!yW1EvpU$K`%@r+ymvPl;qHl_Wzq3c_uv zUTw0N$NEOk2-JY=%!H(B@%uJ0D>5J6ITN4~kicA)>gUu+%s{ep_EKjBWn;cg*48Hu zX52mn{504=negMso75@J0`o&F74AlPlHWU5=&<2LntPmFIMLU4FL@61w6Y!2%nAaA z-iSd-kBZwM`n~RDK{&8<%5_fzd8pFw^6@_R82(ZRWzuqF>2ArXCFob2)&S> zfQKtE+)a)6;BY~MtrLu>=blZ`kAn#cIH8%1<2Rdr&4hYA~@9?Sb*W&R^_nmy8meLY(gGPQ`2>36Wuu+Y=~VJ&8Wo zd!822!i{!aq11d&c+2dzxeb}MUi;@8;Rd43UF}!lG0C?EVkG5R)Z%0*uFvb9`(1r< z+*&w#Vd0wk+Y5?wxsg|FI?WX7)ZY#r>p;X4MZ_D&2PDQYKn|R?a;;nZaU*_WEM~#9 zNY`>Z|(IT-~=R!2(v0A>`|dIZ>?FI5qb|vcrzn) zit22Rg8Bx&oS)(b?^yYR4?qx?Ih3Zg+&Qu1WNF5}4m?H9M4*8^i>IP*jvh%*t|Y^L zi!%+OOuLz_Tqt2nBQ!XUCcu_X1H$~B;|a%4I+Q((YJlKhK}m{-_cCJ1$tTg|bX~tH zEF9Pek9&_5>vSpbR3=h{R!Glr3Jif!Jdn8x`8Z5_riUWy^PcH|Ol?8O&z0BkUdmTN zgJF8#+)5p+3dTmf&fNnW$M!u=QQ}M%#husRQmpQq9(>wa%UlxSu76)(u60Qz!LiiC z&=M%q>PB~Z9veG%?SWb8Dpv^oA;$svsASeq)ynxfzS7q*@8P@Gyppl~RGMA|W~}Xk ztkK48U+T6GBbn5NYp1Jke{KwNSKjAK#t#g~#-91ym?f}yo^(~3*b!!bCTtJPUYy#p zyH^;e{YKo)c&U?jFk&Jv?90dTtewpoC}#7;kPr`VvWu>7rCbyFGx(|PyDOJXPiopa zH!P12wnhD38<4ei*TK3%_mE#_If2uU>|YWdG&av?7x^$0qp^mp4@vLW#IdUW2kk#K zaeD5a-TAn(b=$B1H(2=0Q0vbH|2IFZU7OFR_8fe7m7ieHIyCJhpLYMapT4DG8}r;esE5F2~Jz_K2UNuBcJ?+^b`2#;{s-M?6EJi&F9^}-3M*l+;VZM< zdL7@>R+Z%KGr=<69enu8zOLaIY2&vIPvW88W1;Xdr=$xVwmHW6qzRmtO2Qn+p&K~XPY>SsG`IER zojY~gJH`H%q9mvJlpF7yy{_09g&2-5-HiCTeg6e_x=*C-5LU{Q{UBTDK(9{XmfbBYQ|x13kk*zU@osU283 z86^1N?FIvuhr=Vv_r__Whqpv|c-UlprNHDhEE>c>dVKZS<1n$>9A`HR{~U|{z{lnS zMq+Io37ahO0ije_z$29^QYXap0v0cy-PgCx_vc1x-_FGAlruW@Jf{OhWO_^2c(wIf zf!k3s-U)Th~B)muu4ckB7cr~ z`>{+Eg@TD&|B+r@bDr?^-dZPRioNNTikb~T>!aiDjUd)<)IHymk}@53Q9pgqdG#Sk zKH5~7e;?oBhDXZesQ3311vXp7UWCK&Le{q8lY1CXnp|A)ktfv7r2s#C^+-Z$RgM$= z5EMrhNmysqQ{i*9`6rBgA!b*NAeB(*#PoW|1EtjvT3RLA#lZ(YK3u#%N2U88$Z(T! zZ5%g?-~U#C0`#QVHM&%6sav6~h9!f+3ihW0@YpFM+{bhFtx?N?wh5j-TJfDT6yT@w z4D-dxrRChDn#}6kV0O-(cQ>8HM&?=}>RNg<0^$;J^0rXiQhfx?>+SBMkq+HE+yLH;_bzbtkC-$rloB2@LbGYHd_>;^BJDOp$!Lcny!}46AJD`(y(=^#7FhOLMU|4DJ09$d<4xL2;Fj* zIDw6-w%vNl1^;!*f9!Te`cZ{uqFKvzJM-kO75aCZeT_x^(}5hG%}-F`P(#vdZzOIV z;FnjUMdPK)1jEa@De>-zct@IGWKkH39+4vi|K)?q!64rgmwUwQq)V7GzCGTWZr5cD z4p9gUq4FgQe6y<`g>QsXBw@|rT|I+j?*x+qR&>wm`gCtax!9RoGb^eYYpUjQ> zq(_NlaV(5gKhoyzFst8Maq+R6CkAjKwOWIUq(wm6i3anh%9w9eup(|u?!GOjZel9w zJycm~Fb`x8;82BpvStA?aA~mAucmzUvMG~*Y{f^aVicimEsjCQZ2O~GjbHU~2Gb1@ z7Q68g0pyboJuVV14k_-?fCn zVnCwlqSQwLA!wr&3;UcQVr z!zmZqMQJu|l3`ONR0Xt~M!qW#OMJ2x(R zoxbLKYW)xZtu3_v)uemO)tm}^aLO#(L#F9Zm#$d8997I#R%ajB9@SDX&4mlnBku;q zO6A%Pye2}SN@S|rKkdX{9<0f>H365JjvG~pGiX(L;lUgKu8n1gJ;WGiHnVhUp-lI^ zZ`1D$7;WUG$@;x@mp!|62SUS;4fc0EUUn9)^=3sUw}0Igbj34elUbdq- z`9#>V(|?ZUeG9P-Yj0sBQ3C_IYqJOq{{#^>cge@U7L<$cpS}X0t0_4XKhd>xI~cMn zjI$5N_E$a2s}9;Qc`W4GuBpwdd!4jU3jp)chEx5s;wQRNXB;tFdK3vlz_NkVX-H1WlM>cETX4X+B^?uz0b$ zYjEFBs0AWND{o?iGDG=Se@Pv1C}|}~jGH#S3--?3#r*@gLoSZ7Zq#7zk6OU+SgFIo z+LsSxB0qFMxbS%|2C=J$o-9aSSgMjUOxY+cq!aDId-hH(#pC^6@L$wM7^oD}Y zDO$A7h;pLe2VMYN%BfIR>7AmANmGNFwPkI;`|Qdd0w|kmdymu6&MM4e?Y;-w1J5HTeE4yy#Ob=kpXV*bzl z|4BD$nB{%kIuMak^F6i03A8!AB00T?X@6r-#n09;Tdai%Rz;-u!(c(}Rp@seR(eE{ zB+8Q{3$)}QNI=@B>6=SK1dYs7Ap;E<^V0r9$<;jpWb;GvjX!DX%v^=BvWFagdVhjr z@PlP3Xt5=CD4+pJnmQAJHX{?mtViz>V;)*2+&0d_T|=6bM4O? z`A4gBT?-X7ea=yjJWNF`;#}4}h>rT_P`mk%njlW&UrdzAU(^s*p(1^tx!~E4hL1PA zbIt6cKwoh_1y+~CN2p@`-2MOC>tQi(D#h0GzxXr^0|7CL{ zg75O97Hh`grE7t>P05TqE+~$^*tw49kW_Jc_=FGC@o4YpKOIs2Z%k5dWPVdfo62o( zq3k>@jNZ!KclRf4v&)uZGdIC#V~g^o4FNV6&b3PX<7{7ylvoPh)Z4r#))ek!DJ14< zY0DAQqxnU=(SfmtE7y;An0?IM0B3l25o!zCtM~Qgx^cSU@PVkgst>!I(`l9p5)?N< z6v!C^blKhq0V>b%ggl&-iP((D%l+u$%02I5`+PBg=)Zs)$PPY*#(-Eq; zlc(ahH0CRV6*7}A2%!4+P$0Pg(13c~drg=qLkHFId`087)h~h`KE`+|^IaK1$*e)oT%xz%ueYu>+>uqe(tKg?QEi zKy45Pmj(E7*_kNb3O{6K%S^+~5BszWwl0tBc<-=~mG@LP9>_gnZ9Ohrs42_cQuS?d z=;6zaRZ6y6_z;&A{c~}lIV+pzoQC862OVfB%eLJtt@?HxctDr5s1PrwVaYD;KPl~{ zm&)Y^Yo0}96Gn%A{?b|<^-5!lElm-*T&{t;?QD?EMD(i^wgD@u#?nhtB&sXjz=*x= zu9GeBkJ~LwzNSanQ#PfxW`K4}J0UbT{t2(dJp7xI4?08$JLt(x5lvBK8x~r#aN{d1>BHBgj&IxHm8+^dQ?o4DM#(B#ApATRjd9X z29iv#Tl}~YB?*(pF6-T+rfu2gKUpG9bKu#x^oR2C%I+9-mZn>{D&q^<=0Fr*uy`== ze&OH0yUtvg+{a@@UOhbi@ss7+I-BR`KBg`A-)=5FkjS?C8GJEcX`MSpQcIpx4EvQE})U*)-MMc>a|Xmon-X7Y(&(pkF{`=7g2vPv-r6Lm}+E# z3VgHxT#iakoS#9B5iu@4Zm7c~a9LMRf6o%>16TB%RN&#E+M%HLXEf1cSK@JEl_&-Mugr$9hQSEnt8t3|EJ>gsL68OK{QK>AT`BIP*> z7T~b1u`;&56!e`$s-I%X4pHBP8;F??kxC9lJ#^j<^{I%6FUl5|mH)gl}qqtev^JkuAbZ zn_NHHvFoaUc^=R`y*2+1M66QrEhqr}g%id;iA#6+(qj^10!pJ(50aN zoeA3fQCtJhHk*KM(UxDeNB5+WZ+k^wK8=>3vIO!5J7JfZF+cd#qwpo6YT&sc(;Bao z&PtsSRg6!S5ncvwBz*p#(CbN(O3m6s)!ba6<2LKEV;MLZdJpvMHI|LAAH;IIsb6hQpGmyB1&L@ zP>6mg$5dH3mC}jFcyYG7m>Wx#B3(t_oRX@nl&rIWq#Dtn5PbjV^ye-l`JU4^7^6!d2X5X|&rg_^<2 zMP;J{{45`TP5bv7gSywac3)uSEZ!(5z!%<`b^cKc7v zr5|rA4{@8L!oR#fp&@-hjx;)G8MWT9bo|DTrso#ilq>4G7G-Uoaqbg9l~6xTG2FPz zHfrz9usq`iGN;DiA}ZT#RF2{z!f0Ny+^98=_3PnE#=^x~IX@U7Eo(O(2=?{XG~)&$ zmFa8LnY_jo;NDWohUe0p#;1HzYgccU{UvB%UO#iy=Iw~QwLhG}TDnm^U+q1PGQ13?&|3b~QI zj~L(d*)3F`%qo+t%bLo&+@M&Y>{C>JsLy|`{uJuyXLm~lJ<_8-mk3MDJkd5>6faYi z<#bzZZVp?;@R|^qQ}lAIfwJVH(H&28&CQYLhH)v>_j5I{0lD)Di`^9$Kn$DN|B>*8 zJN~^J%Hi;ARhKHxAV~5-4);gZzMoQ98lk0qy4MGSl9r`2zv$`*0BvV1|9{Yf4oiiR zql8PHzc^Erlj{Q-Af+xv*~|CvEejPsyvJpb{ps=lCxs~6Y7U-KOafbBXj6PFEFl1h z-t}S2{kifA&;)VVV-Bm*E`>S)uA$odQyL0(vK=reY*o;xEK=v<*R4zb+s3k|i{7^x z4f&SeXZDgRI3Y5bU?DrI1SkEz?U-otEL#fH^i|;{5eRaJftX)A@rhV-@t?-u7ue#R zD~~tiY@b!RS@Y2Ty4$rW>-*kqgZ3lGQ*U1Qu$QpeBNV%4&pFv%l7Oh0FjDq2U27x=LPZz#k3LHNS#a}t{Z9~H5T&O_TwA?~ zDh?PIG<|xny%Mti#)b7wdA1Ms4Q<|>7x(SW#V)(sfoOi|vjAb=+KpBxvgdPy2J#&T zcHpuKEoe{Tj~}#AX9CK$P)FAP=u@v5`5bQVWeeN5><$qe1As@+BBn}YR?xjJKY*p^ zGC2({I87>7isgKtD5Sq3K|lWAFm|NcD7*wzdp`^3fx2}T(!usA?7uBqp&vgL-&!pu zE>-pJ1xGQpP^LN(qz+WRZfy_ejlif~!_=weeg&8R7ewU4U?+69i!;jTs)&N0ed@`o z)0|v5oR44bBdyS>YRCZpOpcLt3-Ab8BUbr1PDBAoksX$o$vM3(XR@sMc9k)MM5;pY zlYk!Lftqi$jCSkOND^qK^MCh+h_IG1pyuK^MklkoHwE`|qy@%4^S$r7VLHJWl35!z z`Zhq9<%h;jzb1T9h|>4mGH~f_JIFB79I&%su=!l@xXdUEi(FglLwiH)@yB~&MBNUM zoo=L71Xj>k6;nvT$U#yuJ@}g*7m0`ZJgHuxnwg0mFl$0G$`2+JDL*`Uz^K6HWHKD*|cHDftxFDTkJ1em^?#R zJ|Heu7TO|w&Xx@<1~>Ah7EkVqP_@m!UEA6I969t zTrdx$7$?)Z5#;;Z_}W>N)0YB*yh2mRITv6d0dFgrL>%91ZZ0)yc zEz^Yu54`vL*SGnj|84f+18=!UuYH1He_ZwQ*fyx9eXqiJ^p2I$_m-s_t)f-)p-%N| zG^mDS6tBdP{nq6xkwge5@2YX&!h&Nre*vi|1__9u&5r#=b%W>&IH88+?Bwh=7g z&<#C)&PW?Ubq%A1l)L=$NX?5u|MIGH%}l`_pnH0j@J zeBj0a)Baf6)A?>}e-4?rSi{M2xg>Ngv<~r5Ce^w#*ByWLU%jj-_uT1~-+lf)&^QSw zSv{}(^c*9LbN;au^}jj)t5~}=qhyBV(QvR~>gD^LchOZnaCI%ux|_v%OP7<2culWU z4@yd#b7VV=qR&HbVn-5=(?`eSej9qe+_6V@&cA$YmrkiPV!xX6Q)4B+_&&pQ@ zVzjPrA}zAio$$<;o8=YSw)Gx2Bs^suoQG%nzx8rot1lkQY+QDugwq!)<72nf6il8| z85O0MDsO^94af6VYpn52&dwsC0rGqa2n=;ssJji^@7_7{E^oPuB1>1B*VInEHuLS5 z&-JYdFW$wiH>!$`W4&04T6!;jS|};)oamHblh+mG@!$5oaDw}w4tKib9JG$|SAkdR zg63k%JAHs5a9#}CV(%>bVPuAubXMo9Cxmp#(y-6rf zO_~}mX&$$*^HNd;S(qkueI}m9l2vt5x7Kmp#+I4I6* zLGst%Yh&sb2&0wvfI-FT3#8I+S_D_j3$s-<{$3^fb^_dDRjBdrLy3;4T|DP#FJJez;gB|=3&Uo3l?LEt6~9eEL`;))cF()OVf7{^=jgzhMnB8MT107OUxum(j)t7OD(4MJD>d zoENKXkTwsT4Sf=__^f_qQh0<~z7=wN{>5rr1`D}p;&yQEeYJg#GPAT$z4MJRLRy4B zwD+Fkxu<_ij`Dxl?-`0G>R*+9W9~#{!7jWX zja``D%1=NHazIkXkIFiBOUr_@^q%Yd;AJt3*SI=ykR4fXa_oHx zz(e|(tPw0|nd^uO0}PYP_&>%*nXfIqsQF?CaNn6nO96oYE0=u2QQnTH#f`$Qu^iZd3I#zSs zOrm|?R4D0eR3dM&d~DTvYfPn~gUO)k`9&gKJMp{VROw04%=R*scYQ4n8RMhcqNKaH@{x%w;OI62WvX&4y@Lb6dD~|BVm5Ve%B& z#5O^i%hA6_XD#(EI8Z}#deXPszw0bc9v`kqyTj-nymp&7-lV}E?2>~fsAQdBM{}IQ zd0DP-T}G>6i9>yt82^I3+2e$x>y|wwID4;|a&i8IR=^3LJupciNNlBo^PPWyzjC_t za69%p2#hGE2Zy9=2A*)0fH}C7k97$0Qr3Lz<}dn$@NWbu`o*mas_ zLr*s;MoXiNOLxCZNYlp)BeDdK8by29e~UQ*!BU?7qv9>8fHVc2f$|DiiY9IeFhPOU3~hKbO;&y#zpsF#9;@g^XoaZQ!UXz*E``Yq01)o1`tg`4(3Rl&_%0iE*eR2bxI@MbKN zQHub!lz4>iybqIC<`f85?W7UE#LD1V{2zqbG8T<7q9kUOLT;JRl!R~*_YGP=RYE#{ zVi6WYh-u0ywyh`2?b*0#A=#7m7+hx<+h-01n2fVt~wTWTQFvM*meEM+>d-0%*w$h8U1(> z?lAUfbrjbcH^=i}x<*L1+-w~9a-=|a_%q&tTNjEko_gK3>t;#gd#$}gBOd$qum1OK z#gSQqkiyckW}^(hS=1(uZQT3@-6Yz`Lm?X%bz5t5U7cR**QJhYdH+xuvooJEj@A@~BE}5$ zr(gSQeEOftvz195apLgV;v#a~Qpmk#k5v|S<2YsIR=pXY$(8Z$4~hTrGm^$7PnQ9F zWi08tr{2ZFR~Z_~A9Ln54@!&zbevyX4Q@<*^l58+-?hWV4$3X(c$LVH;>4m|7cSsg zU%q7QmotgiLm9ga|MR!dTg62~e~3aQNPA#W$Z1~X4;_}xQ?jnyUa7yTs>mDTL(Zih zQ(*lJaUa~Cp$3;26kkO;_A%a&#OA9w^2cE*zDRn*64juwl2fuMH_cYy8zjEZjZYKm zd}>Rdyughby{JNx^=T4&30kmDf?*&K0cbq@E#>L}R5Xxz#S%fyE}(8wfIv&ey=*$G zyWX}773Byfg0LwZ2rd2F30i!--eW`|;Dx#99Y2Gxn(*D$9HXWw z@76mbGgt{^K0vtmL|7pc=pY+a5YU@|SD{rTc2yAwGUjJW8~rX{SBw~*_6_83zcA2iH$na2G=E;!2K23o=wo# zK2~)NKa#XrdCS0OQP%IkS)}4#W=Y77{dZjXN5M;;n4gv9rK)dEz8e4?McnjJBmlD) z-4QSd#muR}3uYJy_LZUxk(5tuAi~=q8K|?_CKlvE@#uN4#C&&RzAgSCNClXFNk}uz zhg3Uj51Smwf8>lbyB~97y=rN>xG_(PH|8MFqYUz(NkXD$igh z=KWMCwd2^ad_e+T<$xVudQ^6_+lhR_C*BsB-lrf_OPxsc#lZFJFt}jMy28|Il4+^k z*3QX%8&_F$$U)BUd&?o$f7mODo$nb8yxj0HI{$1=ClNPr2$>Q?x|Tw}eVex!(sp_Y zmE+-o0)mSQr8|g00kg4?H4r_HMro{e*;r`DD;Ap>6bl8wAV^@R%D>fQ+n?E2g6>c( zY*D_Tbb1d0C3T(4DzCOt4>uR5RhrnKbjAr%DzW#Y7ec!i(PYyqhQR&(*SAJg7kK~g z=&{9T*EvVC`dhk8^T#pb*fo(v#1ZE#0e;s@f4n9I5-nCQRj69)QL6P*QHK#l-fuq& z_dQ5aOdP%>NR=xKDvdGA!LDqtc&ACWYY{vBK&e-Ji%3{rjwX`vdTKxkh@ORsKpOQV ziJXdRRkC$j?%xasKVOW|ro~YQ73gRKd0w0=>=WI3Ez^nN$n+W7$elcC?37;MWo_+` zsBOb35swu}nlMlyVnAwR%uSjsD{6*fq?gq5PaKZ7|N>~gL3K+6(t0*>sLs-BonAT>Yu zcWMB-iGA;po_rOx^CmQIGU1)jidx-?KzG1zaY9LvX@x(u7GW>rJir| zGq`+~%X5;d&xoeHGa-^0xeoROU8BV;@OjfY>=@hvpQgNA69XRlP38zt7rAHd%$HXi z8(t`v=G*+*u*0AX{}5Kvg&Qvo`9*2(q1(cUiv7NdZaGe=TNWy3{|7bFm37);_?3J?bpA`rSD8m zit?=^H2p0a`7^)r^lgHiGmdOHVPO^0)6+lZ@ffyYrwMnyH)_Ur&^hhu!Q?4z!PXtG zzgo2F{cV|<3BU5e7}Dl+sIM}T9iI9ca4GlG3}Iv1`Xd(fo;lHTtZwu5>8XPUZF64a zKHkJE{jhQ9sgnYdit@H}noaOFbAI_keD3V=l*sG-`=cc|WYguO`hX-${h7ueSLIPl zHFFQ3zw1hdW=%tQns8|~_ZPx=c6pm0cYdk<&D#O_aMi!Rm#(R=1{qE2vjTD4j`#a| z7#gkX$imXwOY(Ta*dR^w9m zIM}8;@sw;}TjVJ9q_10h9QV^Jm0G)@te z$rZAI47kA8H6|ef**4WdH9Uz!yvEG9K~Lyrr3zyO-+|P95WP?0qp~WiJdPoYF)0Gn zW&|1)-|3tP-0Q@e*{)9gx>YJa!EmC(CBu`rOk*i9$n@4=KxMH~D749XU#)j5nad4k zh!lWJ!B%q#46iiUPw3NbA2Z?~&QlR;0Sy?rNqPhgt|URrUMmOe`~}e6D)`y1$6xtnTQ2;prBZ{9s3n^vJC@cR~Z4o-{14ky$Z7t%a2v-9MCEF&; z4>OxSR=)B%-bn-0DT!}4ZT0- zjQtiD)>l{bX7$6O-6c7%n>51zjfZCm?7EY}HdI{M_rO@%T6))>bwxkqAJI;MS5ZA!_76U;M5*>;^9aJGI4}fq7O9$+e9DcFV=O5 z1Ey%VOk~@9Pod4KA-(3K=;eMEmL@lY#tQD(dJ-$3O=cho($d3V;BEa?QORQ$S6_pD zA1iy!AE3;$U38OWNE>hV>>v6a)48JI@;s`Ca$1Gz#pbzvw#=W~@#1m8NT~Y>3>Nmf zdY{f)V?2gj&(Wr|Dbus~@^7{GsPf!+;@@pMl*f5=R74>?Z578GP$~l9-U#8!r!F`` zkrhjGlQP;}vsN4lSZqQ0A=Z$r|h2p?{*Ls0u~|JPJVbKbp-Ra2cPRcjehmrc-SzNA)0MMq2=U{}cne>4dzNI zp>WcLG=2Z+u%F{(`jKxP$LDUwA``vOsi?`(5?1os<|z-I%Pvoq&6k1VK;)4?t;Ij% zb63-MA?hbN{G(Sy&bMO4sU6l?{JNFc^$A4hJP{3>&xl`$YO z2Ca+JlGXAqzSPlC;VYrH$h zOVu)M{p~2qj5qoZqY5qu@Mho?ugO$kMSkzQ3Kjy29<@LN!>;g%*rRC*oNQt6v#$}k?L^1bXLg=4$K-?lX?l2iZR$^U@S}`JYgpQL{6Ha zRVeBrbXce;drYqHeho>r?7EhNdgDRHIihHgjkFV+D{50$N$Q2ip@|t$4_*j@*-gaN z#7_v8Yiov|sZoN8h*)#%%{#%*TI7RWgX|U(pj&}LEYXyAu3#(p2iwiF0ttBM2|=TD zR|;0TW(ep2Q)x;@xv)=uP8iI((&R#b$f&ly3!ia=QAYx>$i;PYJ;&JZ9V129@z&sp!Rep~8D#5!eB}1QK~Ey%=qRPD3jAP1y-z`44yjLG z(4Pa3;XD8X1^u^b&Q!OP33l#lX>9wU+z5S5_?E^ok68_~LvXJ&V}<sufGA4O;4kW~7%;e(K_20IiK|TgcKxG=T^PzWDLL(H>SRZJdE} z<$(AnIn3>(d1ev8BKHleO}cBY-^+f@`ixnXQ;sudo9LRw8QC!YlN!ZsM%Ffvs0RFN zaUUWQNrN{mcH=|RQfWG7$dcWTNK;0?%AH)>Z)+QOfH)Y_j08UlI|Vs#wgO4diKHyg z)Vb(UGcGycJ9lM3Dse&HSd2hzr43_iL}^MsuWbR>j@zGqP6YS~_uSI8H()Hk*9uG` z4Id?WsjTpTg+8lt)Wz=cb+Ue~#&*CE!bpq>6b8nNJNy*fh&KbL`r$9DNmL+g!CK7V zdU)Mk&(MSVT^6>h+)56kdf~vSxY_N>{Js_s+Dte6A3D#LOdXc>J0Tx*yXrVxiSzxl zd9THzf-!E2AIcbYR7)Kx&P3DA@Ey_vYx{fA;L~;WMFEch+k7P%TIW`hmKPX{erL#a zm)uSed?RU$X&@(pgifhjC+F&)x*4y$2}0oR8%$=l_1n!w zu@SfZk75j=aK%oGoRM<7XuEBV?_?|*W^f-IOB*W)OZd}2bBvvR|7#yuWu}jD43wHQ zj=x<`S-i~p#YAWc6OmbS)V9MHge~DpS=o_m@5mF}SDU4gt+sA3xlierXmQ24ZM?-! zO(SLK+xFpB2|3DwIDvS!();2xnpp*xE|f6Pt4<4vIniJ{D!0J@$P6B_XI!;zz?SgJZ(fm`hF!70w^+MDt_wvx^eF{i` zBVwJ(L^qS;(saud+{Fb5(ikv%yX=)FD55b3aKnmqOK+}Wku08s6?bCZfR1+!^di*s z_*q$eNIQHnA3t*9>Y%tos9!W+_ND5loACF5=MWm%tP}E|F_y_MoPbYN?^f9InF z9F|pJj|d~sbi4Klo{9M2l@g{j5gK4S9>~~QjNKVpH>pFIU}nF_ME%zXyI`43Ypu;7 zysY*$_g94byUkEUFvohez4cBnp-uEK0zXoW>`9aPEwS{JFZRz;uhmL=h0&s4xOT%V zJFFw=xK-pD)5tf{mINN*3Z@W56zelY&4_Q-DobezFoop>JE^(w z`&Tbj7mGz}p!hycWdJz8+N+FwShr{Xs#)WPt3l`AV|6K>#viz2y`~#}J*~!5*?}J4 zeoOgrYQwGrY9H52(t}M{Er;N=6{>>kZ>-w$`*4S);FnI{tAQteK3a(2x8>d-xuQds zsiX;4V$W`dN<7y`FspAmkyM6hW`NYL!5_qk@pdgk%C=P?0qKL!3n!UwrZhsgm^5TT z3b}K3EW*Xfzt4JphaFf(lU%0F1Cq11GgS%B<5AOmD?lPWJ@1;C-Bzk}zN^L}i=UlQ zerktczhg1Y+T6xUh9fPYm(RC_SfR*oibw$K8NOL(4u4*egn%lzr1{0gTu+UH7p--P z^hfQL$bA?AF%PZx?$VcafVa>usMdfDyFcNbPOR0d7f_eUS!xAyrxX2c{aod!hiZlJ z?|2S4$st?|he`*m$?|&X$1Us8KKI3H;=RSlhPc9*NW)?Z3S&CcYRRy1J)e zydwMJQ%Y*%@wMA#WpDCkMsCsLRy{3GPz=v$dYE&|*$!@-hjJbQ`FIZLrB?X+pG&Kw z%BR4#mC?efuP_aoNTEIZ(qJo7(>)A$sg=RlpQ195XNE?vT$6#^&DtPLqlqN*X-@b&3{v+fb_S*ADTx|p=#s`WSW0KE$ zLn3aOyaWacM19a+*_Un~VzXJVY*WHQ8(}5uys+HRkt(9gt^@TpB25EDL?af2S&q}R zR~oR-U{(7Ab7~uGpUgVd$jMm*Xs*BS9snsxjSIYzR?MHGYGZ#ce8UpzV}*oh#<{IhKf z^&+3gAG)#8nM)XSvC&+p$;X3vFHQJsCaa~KgdFcsWc zm~RAyK*9eok+L^?77D80uTE^!>pcdMtL`d0`}m3U2U;UvL7ECC}9lIe=`0N}kl z7gESH9df#|6OjSbaY({|tO^n7nhFtHd;_MndNnNQTv%Uft%yYNmjYmOs%npND^f&e z+gGR)dV5_%!YWJ!VI@!CLsCJJ&^zcPU`CT~7v96`XP{ybpf=TMF-?xNIg+h)tI6?e zr0)T6L)(XR8(!OZ>&{N^Lv_K6?<}2};37Y>DKPLJ#v2zhte*U&oT-xa=MpFnOHw^x zPuxE6*v<{Ey5aTjA^>rrq39mHe(U83K{v9vV;&OFC}9JIV>sg;1^3ZdHwhO2-aaa0 zB38%Q|Bo;idEZBWMlv8TKMfb5c~(F20St^bHltd=hS#Z*XwQrOjgmL%EXqodVUm8m z7lZ}|T9K(`?|L&}lFR~u*WI~9UKS(B=Aa2L6=(-2Lb z_vg|N)zR$M|C(OQWosjWZK~?TobX}3HeipqNw#h!%WACMYay~XC#NrTw_(`KvW|Oi z(w{i?psNe4gx358O!6v})9oUT&)te|b@w2C;1bKw5*D@F1sPy+I-0L>T-(^}miR@F zmC`D?ROq$*TyUu(LzrIEDhhag>6zx2&)a)07>v6z$2aegyQ9N{;i?MjB{wT|fdt&l#SgC0-f5Au z9)B&<7$S}1?bJizLUE#?3|#yj)iQ&ooZl(>Yq8I~LKthBIsc6_}OFK&m$ym~~ImLe^>>y{!WJci&R{xxpcCZH>xvd5kjU5KTSSS&Ons zN$ZUirGUTmrdBZjncGti0B9O-^#?9*l$-~0GIY|Iq*G--S=^IV4V0%C>B*1`{_2pZivTDKLBENEXLT#yy8IZCLyGIKe@h&Y%~lH?Hep_UdfQz;yG zndI_=hjCSWGobrfczgZF=zPc90_#uX;5JuwQ}9J+TD@l?xg?1jT*AdYx0-!_klq}RC(;}58x*g%ow&jnno&d#-EyH>S$ z#M5>#tk#In_4i%Zaa-tSGz4rn(eP3o;(!{~YXpJjPlSQ8ABeWy{-UN?l_eCx?H_RS z+D)BZM1-cO-AJ5y1_O0#l=>2327twWd|h+~H#W{_TVY{X5{92(6n*(urg1o8D<(+d{t7QJzo=?1gR%ylG=> z7VCYP)f#{hR-2ksO64jha}SlyRwb-YsL1}PT6nWS{_SP?A)c5;R+jemS{Gy<(6p+Z zJv8(~yxiJq%5=Zr88Cyb-HavFa`+kzC}(~GSI^W`Dh9Qwa~MF2i{g6O@PPOzk!E2l z{ViUwiW1O~Ei%Xd6f-v-KjtIH~wF0vU}QU31z z4FHm1_1$T z-O@ZufVxU;|0Uz5k=L-|eAp?XY@{mj`80X>AI#-5d4JzL+*4Wh>&>8FLh*_LDeTFn zeO3GLX`B021fyr?x&2~Leoe2z|DaJ>8l0%0`4B|}+`fft}*nkAUvc2b? zQg%6XTO`Hh@z~wIm4=vdL)zC!L^e`!IJfLfXw>uGXr)Xt#^_k&+Da(Mc9}7Uc7ccG z5a`GfirHy}FL>|UQb~T*kPmfx1JI-DMZEQ>!oel;1hCfUUm`b1v_f=Rh>Nk;YbZoW zIwG9`DLyZJ+9pCOYu)Ce;;|U*3F`Q^O3fB$U|PVj{QAUN(CC?aEk03=C=T!Ovnifz zt(jCNlqBQW`rxMnxv){W&-4NFZUH|67!Ht4vlPv) zW1dJZK-~yrbo0Bk{D5<@DSb*1vAt~T`nF>wzcb(|JQc z32X68%_0{;w}+z_piuvKrwkIkr&f0wjR3ewb&ieBm{VnR)$$!=iy;ts=c9V*iL#NkLt%s|gOqc8oZHb8$AoRcbYfEQ8x z%y`(Y#f3;CPzDIe;6gdqLIZ|KxL7hc%^Cvn=IE4wQlMJIy3HE;u9a#zUgVSCNVn%& z_(`w_lE)1|MEQopn6FF=i2-(7hLu-HKx8xgiZGhR&~mmF_PNZ0o{tX9SA0s%+~oi@ zM(&>HYH<{7f3gGM`U=MX4ij;CeyK^=L62byJJpQ+=-z3S`+OS7>jQFU#m%Ia39@~?f| z;CN7%4Z(=4aGeH+ZZCOLm#&(|>KAU@@@5wY%&l&_+r#yF1O#V^Qu17z&hTck17~(CZH==WkBm zi5u3}$nNi=g3-5aa02_}vjAV>R0H)1Ol0TWusP4`Vjem<=>wDUlN@Y7oP$SED`t^U|^avd!?0tTm^atFdk?rGZus5 zq2eMep}{lHE1aUS3`$8kuV9aJws-;Pw+=_K7U5`J>J@2u9z#~<$Ca2fcXEYJWfu6` zH-iqnB@)0R_>)K&Y5j3TEYkwt54bn7NY=1s6~dp58{_aT$=$1)0`H$yiWP|7!4vdw zq+(I@Ji#p zPaC*ivU0`S17D`6Oa(XBc+E@uSW^C!k^HpF)0%cUWAEud8lL~Wb2_k~dEdD#yV&vf z!wafNi@JWjXB_mF`D}JPUgGnz9x+9#s^y#>?$QbW_zhlgePtCtVzm=>NAxa-c8ZwM zxj8UHX{FN_s;*HapdQoWx**E85D#9C>w322(+4?2re_DZn#r#7iFE zSoNS-@}(DUDVQqY@3{U?>^3x$PEuJk=}Zh;mtwhKy=IiR$E<29(8=Su67}%Y_F68fvd~1Ecy{WlP8gGy1s-N3E!iH~ zfTY_AKmo-~5VDl^HBuCKtf;5V`BcHLRVjAxt2KD|$&{9PE_h5LR#m~)I=&@{LWE() z@tEm7B50UunygVuN;`NN%F=eyUX&LO^q^sj9|!am1*FszR$uQq^p@^ZI;)De40$jh z|BGuCm`~d4*g}8%t43}&%xH^xUaS*FW*!*60na4dY=Cje#SGh>iwT!KP}Q_i9*`FV ze4;c(>0&?}+@Tkw2?Hd(xsCc%Dz+VV?J*!c7o7rg{(ah4-2J!Yfi`iga6OC~*Qy`c zj$iwNpos2L8L4e5f0hp;C7EFxAeHr};{YeKsrso*DEI<+(KZ>= zV;m|GGxWrS8J1|LRT&U>(5^>{+9fB^G+4t25(jS(9ZGV#D+os>EC`Ivf;*L+y;ec8 z;g{Cr1Da24B`UsHL2e7Ah?JH zo2impBP+hB=3b!ZAt6}UriBpTU$e0|?G0b&H4(`%pHkPk{sA_AchTAAXBCXKPsiAT zG5sG%Catx#27(#*yl?Y}VW}i9a52VquY4s#AL2ovoT--`zALsp=#XifKFqwU<~ZKK{1uhy5ad_pFD!TkrbP`7uIfhJsD`)O}X$bD{T^M93@;k`p;DnTj z*s!8)Egt5V?&7%ZueynMNW%1LEK-&PQ;pLc&4a*n^aiO&o7ORh{;*hj`vZCXr=lAx zE&U#LSgFnjnEnao{2F0#>dp33c*Xv!j&C7A%TN#YzpqtM@_hn_1B4Cse!AvY}UqVZ|rn~l)?d3YrF8+!k;WV>j@p`WUIjq zU0oF0`Fcg0)A@=j_hPxM@o2#pTtM`-_jJ;h_{s2|SCRL_4iZQ3(~7|x0=IZ4t4mfN z>$@gm|32`~+P=PltG~tk9NXlAg3Vt3E#?c}xT|8e|Gv`jebI^fUw&8lhx|Klp3lji z9FzW{SA1K)=rt>*15LUzdx7;+GRrRbnfxXqe?tHha!Rt;^GYouHVQB&0)gCk}UWYbCkvW7>%h^*I?n;!_(;bTx<1z4KFb;{OA^A z=A~Ot5PvB7{+k}+e!W}Y^iu^*w@j2snY=)bQvUadf9%@Z-!?~zCHtcu--rzK2sk)Y z*2dEEZ~=YLs3p56x9r1zN4MleJ2@OThgm8Yxu7c=dmv41Nfh#6Uly_&f?sB+u|&l1 z7)J|S5X)_!>?jDviF_mq>8`1J)$9B8r^Q`}UPPA3yuQ!??zOM&5Z@_BocJCvyErG( zn#rl*wPmkLr@<*O)I`?_A@t%aF^ruLzIPgWBdDr)+l!&1bG{p$e_Dx6y+?Q^KhW;+ z;(4_zFkV}n%3x)EjoC7(sY$f)_UpqMvF>$r}BK6a%6LZkzphuQ)f=cXd( z=e4}my2$cG4xdd8?kpe;XtOP+TdS#0MSw7BQ!GnUgdpUhAFCrV@wttUyIgV)K+=Cs z@-p+R%)xo}vSB$7x|`NJ-R(~HI()2{b59CoqQjwt5gkGh^k&Po_hk0Gj$ZVjBIRzI zT$4DUOhu4a$utmszb99rDD2LCb~4j~EI##HNwg0Io@?!RG&3sz{Xj8ClqTY_=^2xupI8uJ$1+I73=Dj>3c~LxtmGOZYAOGsPuJL@ zu|}~*wP^nAc<6J-y1giyHTL)nd}JycAJt_BWJj>Icnj$=dY(mQ)0}@=T_!GkYO1DY zbX#GEo*IFNWm%p;=7E^j;Z%Mw0s`KJ(VdbOHLQ9V(X2)+lt#x(QcGn?Se+0V2P*(m zR0}7&!+HfDlvHG(8SfbhnLlqtrA!2K*x=**MTAMXLu+>h%O*!~w7r@&e1q!bO_HYG zo~0BpFp_iI8kGz9wAoszS4U2a*P_3_d0;(ksQ6OJ1ZTtlK{*!EskA=5O!>VG$?*U6 z=0d$hv%-ox9x6MA{~Ea&4_kL+FD>LUhWtQuU>XD%uXRb{>yRK-0_vnFz2?fk%M^O!<@+5@dvcqVC%$~^8s$6)U0ce;i$8-sWVZ|EuU2LrN8|j#F3V8hc)Bjfw$eJ+exk9!ywGp!b{gHof><6Iw^+J#$F1}ZKQB8enbhi zuSSp19R0vmn3lX0Srp6(X(4zZCC`o^_6;hy$8IiDFPBU^-<5xRmoQo5estgWw-`e+ zmU8g6D2dtuQ*E;F0w?jSqbv{S&gkR!4r*srD?*w|`-);SLY-qvlVJdjHW2+w#x#>1 z_DWEYRO&RlTm_eO|4cAtB*88PFA#8JriKSjY^Jqa_k_*?%jw-&$5EWy7m%CV62G)g zJ+<)^QTb6lFU$Dm7zoFc_kyD|TfUF(uP^T`CF;fAc&FC|*NZ+TsY145RH3mar}pDF zvF?_vr2ocwGHwdkTqigshdgyIHWzAJ!knp&_2Qjt5VN&`tI>AJat9gD%e7RjKd)O9 z0HVxRAbPRo?xoh1k2JFvRQUM5Kbg>y4%QzDDc1kqrj57zMXqu9 z2h5e*x&D?wFODxi+*J>C@(7S zM254O6XBgP(v7%Ti>5_Om3GTG$j4lvfd%#lv@m+s%;G=KFo7%@*muijO3pWK$Mx%T5!b`mTUW?Ft?x7^ahY)vBCQw!k z$Xx{$!kyy$&YpMQ%Oq0eq>NcLZ}VjzMtkQruhgVgfLf-UIg`;#o-lKaCg(a80?K2} zbKQwXHu&R==O)#f(H1}oShc@D5}8nR_q6l}ddR@p{(Ah*KSb$YA~5IDi{8>n+LLg{ zBFdm_2Cex&$QM}c-3{9NIo!)m!R^Td1>nGxJa|4cb{*)F&z$;F;VIqKo; zORO9zb-b?qA39$Hx+OKskq;jKMIz@}(`i*#+m|O0G4qbNZYfb0SPo8psw19Q{`sL; z5o}*EzFt1eCs-E6rcepkuaWRhgHx4RU(WKM;CcQ{;B{LGXID zb+m*o*ozR@k<(}Itv!Z$%}?bX;$=ZL2-kRFFZbd5Bq*f=lw3^6J`jhq%*|Csl?YJ| z1B&~hnt)y(<$DmszjeKTcAPDgf>@w6`0VrT=ymp9tyqc@jr&tOQ~j3NO{wf*0(XN7 z)psXKJX9`Bv^?cD3ABP5@X}Jia5P;Dl-a!!7Sl>;bJ4{;?EF#WTYh8M+kV9S0nGLXOy097b z5GKJf%i_fRnwc*wRmoEifVRuuD=KW9{;3)Uup zuu-0C;rJ9ys&@t{3zAmdLS-$J|Bkj>uB}v?K$K4xXSaiGH5!7einOra<{wF}7;3Dt zedpl<>+lI3OhR74sD23OO9iE_7TR_x%2{aX(eo~$AlFBUw@Hb3#l`#X`=_TAv90kq zrC`yqwKuN&p2EjD6ziL>`#AjfCmjB)_ILHpTTgEG_YWrB{>T47VC-LY$XAhV7h91d z6EP(|1xKUtYJ8sXK=lfn=_s(^<9AT&J>u|_OlWdQYDnvL*GI%fLM$|_nji(r8J9>T z(!B!OMk?9?=?Ik9{<7T0-v4Ce0`xj4zjg0PEI87o0ShS-AZgW7K@hfQz6oqmE6$QK zOwy=vX+i_p3k*J%+OTqFs(17aoYe|SpNR{*-jPCoWRXq>jHo-8x4Xs#q5W)toCY}- znn%Mdcz#v5#PTOf0u@t>12F<7B%P@#x0XovD6EO%zJUrpI$~|v>8@oW*sXd3<_zP% zMj%YyCX6-_=spYxVRXKGCa-oyc6C=kVzsMH&LV>yE7`lo>NU`s zx2jQ0NeDT=j7iz{5DpQ z3x0nLx2%@EIS3~GI5Q_Cki&g4@k{6rr+31Sb~R+3{)Oeg2_Lq>@b%G?-Cw5c7Fiy@ zv&(hs>VHQwJWH|*(n|GzlNg@R#4oXh>O$xHp|3@W0ftpAKY#A9y2$cYnJSVSMMn*3 z8;+MOBNp%i#1XWK0TGNw=au-t5wLLA<6VoEUkUt)l}Q>AOA+>2)o@j}4Me0|l#a;J zt8QZ6&p9=AbkNNkCc}cSb*}{R{|+9bwR^oiTQ!wjcHwe0H+;MCLr%Z<&#K)a6kGh8 zL8q+?sJdj;eLFY&aI~b@BO(dBPZrmF2h*Wr#r92iv@Y&n0Cp?4YU`Szzkv zKA6h>8dJW&&xv#!Wl#H5Bcj1wCe7<59iY*WPObS11fj@JtZ>E;{(WnZw5~l3_k*^=_VKAdVIJ<0?+ZkNCr~YcrI(oS}R-w%l9eK z)^g$w)GpeY*7z+aN(zOe>p8^+G@+8pmy zkeO~PEp22om*KQlI#26N?m$+%!f#;X;uS#vwcoqtJ4KnIi}#O~3L`C?Lfwq|gD=lr zNfu~8UQ;DdrrJWTF|9gGA^~9&Q90+)(Km3S9J>FPfVmT!i2sP$B|Z6;6xuV00u2{j zW;%fqf34Ffj0uH`x&PGd?MiC zIn9GumRQM91q=y?51mTkzQ1?F7uVIQ)@&jmB<(&pfNJTxx@I!C4meFPmnpt3kk2_Y z7yF);RObtF!*>_F5T?qN^ za?m-x)#7vmvOm_#H{cx@R(wHdVA+E|lr$ZK(9RT87UhWJ^JB^27i@9q+PiQ-Zeui9 zfDkIkE@=+i4J)iW{7aI>B162sSc`ZlYgWVlgj7Kb*zGG>8e39843|rtMp=Dr;0rSAov1!l!84AznktAdJxqA#)F(K&|D6P|6*db9JDU zoNP&5P<5_F5d{uIH*gcr0Rdhis;c~j>B#dJ$PV!~ z6iSdpy^`@3$y~n!a-00BPq-R*c0Fe0H{@#4jWX%HoqKK2>=aRu#l zm9=#EafAED{LbZazl>@d2&)D-ESkHL8pwgLMX!5EYW~)n)$H88i7oTi<6-Bj-L3Yz zj1MA(Eh*CNz$hP{_vkE(d2w>ngR!;osVIBZ)nUnlxtS>OrnNISEL{yo{d=Nx zS8o<=j7g(m+Ljgx!P&~wo0)>%l8%{r5|CbrepQiW4%5*v@9ow$4$*lcLr5&w_k%5o zK*jWxv|fd&5@gm@#oFW`Oa5V-Usd?`x*Hb3r?2woQHrk<10qAUn3QK^M%y-^eWnqe zIbo<2%&`%CCTPS#yBwZ3P>M@I>=K(|m%_Vb_X_X^MuqwX$nE;lbFasltswIJRQE3l z8tfMh7sSY{0G;QvE}2x3Ec03CFCH+U7c2EEcCC%zWI;~InBdDfkJbEB4H*)#{)!Y< zyk+vvT`T%>E-v7qoF`fF{{AHJuWhP|kxoWigha6np%on^+z>!4Pg7)f3?V7yi?-~e z(nr@&%`x|H{hbym_xAQ&f=wK%%|A|EZH=k_)Y|p>dXnD#5|<-3uXp!KO}_2D<9c-S zpvKg|Or+QU^<3$q(FSaEXMW1xKRVEA7*c^r)FM%C)(5-Q?30`1Z<-v<-k~GPhX#W& zW(~U89QH4o&O>L+)-JGPhWr1mhpBgDjpPS7k+|&PqSzfhek1aBH&CHEY69K#EK>m( zDV97LzIB;5ET`x6XT8_1URF|t{6`puRGKJ*IZGm~D5?r|A1-!FhZlXh=TxuXWb1@t zXh*SfW9a!obO^KErCB?u`8c%$O)`}P#%+Ai8KGz^)w)%j*o?&0EG_H_L4K&@rk%Sl zPm`R}D~0xDTU_Kf!SlNLbx zIlm?HiSB2`vO}c#`^L^yuROmb3(#(SQ`VNfwgzS_!Q&(xhC*(p`#P)C=FVD79Lba! z6MFXPb1h{HoaXF{hz7enFaPGT@a2vF3s$|pZ?zqu!K8_pW6o_@%0@v8vSi2ytDv{k%*9M^AyjExIX<$(opg=8L4S+@wpmduZ66f0yXa_Ee<(o z>0IauYcfs`_F4hM_+0&M0cWdn_)Rr+d4&iRW$f+FAS=h%cHKqXGL^mHR#0(e@8i;2Q3)Yz2W@`Du?~MZpOa=S?YoJGK*EClu+qFyRQ zm&GR%D0dB9gHP-GBv22*FBIkIE2zm#!J1jiGt=1>Pio^$k|_o3OA}4C(gO%vUwYvt z*dfvW(GD}6KpEI3_kyXE;+xWFl(@8y@=l4B3O!#LoZ~Fk8JRU zbG6l>qP2|=r>2KQO{%Z@1%k(BHrD`it$qVWEQp)#P81J zPK;{z1L`!krD}EDdH?Dx zqZtvc+(*THw{EB0$*SA!MoDO)RD7Rlim3>PQ1KaRui-0ixB+QT^t+Z=b!x`Kp!xvx zya1;)uSb(nt9P@u%4|!1W(fC9&J0y5;w#FKbSL*Q&IuH$dVtERI_l-!l zTz~GA%dU^zlyM~SvVZh!^dYcg(M$nLK-?mnE;d?Sz%15bs;9E3Dn#HaeVKHM>Qp8f z!Q!XaD;*d}7lZz0EbmaaB-{-&SMjM?fNJA)h*z;=$2-4=&))!^vFnquf*>-JxF4?I z32x@i2lxkkqUwBc?%Qq*>{+Qq9OfpKa5qg8P#{e1mw6@fHCTF%$F3>7SwHrR?y)&K zgt%P7INexc`zU_RWoV-J{=MpCV!)-`ITdi}rBEZW&4W#>61_{q%<;`wtIsk@vxH|LA)1?KO0@bh(NioGxadpY&J zE9PI!j-1V5-~8+v5=KWC!3ed%;i&fA#H!qMw4Qb`&Ov{kYEo3KStph%_4WcytxTw} zi(A-kL1=xhR21b|(dr@1@(Q0Ymm(p<_x!_WrI~RBQ4{TCviCan)=XqyanvNh?tp^z z0x0LJAVP~>jiuYA%zPVV{;wi_j`JJXZGWe{n`~b-kBxzoCw{uwzU)KVz*UsfrVS-e z=!ceHBVQi4wDmb(T?R*_k_K6RE;!hqIr<9=z6oPGP1upM4v{Z_IiYgxzot@Y%)v{f zj&(`$g61B2@{yiPsdkHgmKW!@Iv1|HIr8H%cr_=4_Tuw~-BW_+digzC*iMD;O?LH{ zB5VgeiRLD{#XBBk$;1seEEAU;;>{%}5{Y;Lz$C(cCtktyVo=W88m9{WAA`+`n~I3opEZs?vsHY{j=_&07^D9<|DSpbw%o$Fe>BhbfiDKA*)Ekd@)jRP_V8T1l7NNJoI=XM5sjq2J9dv+922Y;-9d@2Aa7_VG4#=ciMJ|wls z2K^B9)9J(4*^C|iuchcCiVUjDk_2oB7kFg+W~#(_>rk+coCB&bJEUNu-S_>$wsbQm zH-(?2Hlm_Otu_I8X0?CbhjqSSUr(#G)V9EO(4rxiJ@WT2PSC)v_^)>ds$-sjG14XY z)%lk~RR^0iEwXba6I5`Q|T?7OC^_@lG?hPE`|o1pp5~ zT;Zpm)mTaZlt=OeWTCCnURESgmzU7Y-B^urdajN}MHaIyGaK#nd$1u-WolFTokW8TRM$f5Z!Dqfc#{rbHuWj7qJ zh?!n^F4o$H;g+*Ak5$rU9CknT`M9ZK#)~Mk(HAv`L*;b;=#Q=}TYNke4(E5Q^I9mI zS%ak0%|2SE+r3*nWnbzOn7tnYmk7ED#2dtbc%u-!)ZFuq4kvX5Hn`e;>cY;{zG8Rc zhYP$SqWV-SOJfBqjf<#gdVRJ8Nv#oCW&v&*f;^$Ypn%>IHZjIT7{2!Yu;dbqHoPpa zs&XvaLOtbE5av)qQ{TPo3cbpXY2OlhWCg9AQF#sM<+fF!e7<=yUjBJ2Zth=t*2O=! zU5sB2fjm}8ArRh@D$XeI<5!rQKiQuuj^A zB^CzhK3Y{q&a{~cfyXgo)sQ?nP~3^pdwbhbPHj8K*%mTWL$;z@<7$d~=$=enR5zuL zNU{E-#!gsq|h9$y&^pw^Fseeb|elLumsQ zGAn|krv?8Wf6N@wneM{RiSz~}I+LQPRJ$VxwbHuV^}Y$To<1;#ZxEmmfY-2lP01Gj zi2;?@rIGP)jwZ1nSvf7?U|}Up6%yst-yz+XaBEiW4S8qPNiQt@F?2>{UA!5iw)eWR zfSh3}$bwMsC&n1o5)DBS^hZURdb*pXMMB1JJQ(qTEPRnuOw)Oh-!0lr7nhH(FV!P| zEKD$ef@cK@#6y2wt%lL*zx7jD#Zsej$`{1`S-D?W}bE>MWW27mt^z_hwSMRnb>FpP)YQu)DK|F(1d~>Mz|(Vb`o*Vwv5&UWsxD+jjfFc*I~% zf8qS1Gr%kHZn7IWf>o_tT#*EOf_<&*_6IMqjZO9`lA6>N`3qJr$ z8_HMVZ@f5jsru-;jT@%A+`gyxN7!_#y~YQwULKG2{lfGV_8z@IPVnl;TD=r?8JV2T zupVpwxlI;gAx3vjM0MUaJqA}hZ_>BFigh3w?k`(MqV2U$qVti%>bwPGAky@5 zCHnRrC3hi0qD$WY!G0Y?9=!gcd3&r?*97-%6|y#YQ_o;8VlTs~WilM@3HTLY=Eo08 zz=-0F&eIAmqZ6nf^M4%#ew2M^#)lf+jHLyqg``~n6wd>wg(8-Ina=df?r0U6;>rJp{qTHw%^@DkU ziHfW>F>HkY2VG~0K4%ZmQDBPq-vSpOcQs_ZbB8C1^Bt9x60UcId4O#syp~n_wa4b(;N9 zVkRKjDGmSiJ~0fxCEe@&kOZ^)e~QjNp6UI6$;xT9tS&kUyd)QOG5nPT+3V%>>rObywqn-vm`q*DUg?mE%^JGyrdQ+EGJ#SP<&)B2(m^4DR@_rGl+7bT(ljK*hrQl z1ZNJ$Gd_oH`NxyjG;UAtADCY}FkBQ;bKEFYQwTc7(+3(h2NGwCd|8i~yyqK(ep}FS zrjID?o7j@IUSqQ{4AaZn5d%_}7Z65~EVtyjgAJwtDu53+ATiTEE2BkgIh;~@gthK_ z;?{Lsc)3695xir|mp{=E3)U?GpMr|6Dix8$-(i9{JRoa^Yz|=3AUIKata9xW_N8lS z-t|QCe-*ETG*V`*dQ(3)OuHUt)Tc-k8xCKx_z*?}IJw?J7>SI~y%5o7f{;;gi*M3VN+P4Mk_8KA% zlhp#KG2z<{q}BB0pSJXkttKgSrv!9e;<5y8N@@6*L&w}o54A7-_a#Q9`5p;9R5vE+ z8%0!u#vUkq#0n^a`=5jMgV~2g)J+v17ZyDKh?&`2X$?`dncK>~rFc^gN(K(RS$ME* zdFymdfxzRdqq}~F%e{Im?5jo=u)r-3M*5FTVV`%cwKcys#OLsnJMOa#%BdF2(tBGI zNZ1{A9;fc?wj!<#inq2DWyv^#(^G9kGXd2LVIW|48TN#FZ-{U)SPZNv#E+u9^j-VN zN|au^_~z`_L6`E43U!M1Z>Ki955<_0>>Ktp^RI&OPURVb@2Bu@Tbd@+MekM-D@%v5 z!@sR_Hb)jc9NakC6$@bM{*jG(b@QV91{w!)x-xemXNPguE0Bk$O>MNZjBBrf6`8I1?tW;>>B@<6)4dml62zL;(Q{3gpkUe+rUe*UANV}^ry0jvEF9!I(F{PSI!q0ghW zxq@9f>0dIYY?D^5i25!d=XL(V*C5NBJNEWjC;pHXF-~9k08cfvwdvh;J*ToT*EFyG zLhjV(D_Sn7R0dO__dWbgc;5Ryj2BC+!-75y3qt=7`Wa6I=}0W|s{l&L>PDOD_L4j+ zTKde#1>UB)s0zr5q#r=3gWHqdyVJ{Z%7Mo8F9TB01ML?icA}a)f!&=Agn51v?EdN= z_&Ykyo;<)>w=tuJXihGIO3tQu#bo+8*g0!7wQ6ihFUzX8mnc5`W9o(kIV|1m4~*C- z+EWAiHfCpRxLaJl>r9|1>r*hCGX$!+FYsoi7sa9qSuO4P?)3Z|i&#}0%0p>%VaD61yjNGHxwQRo94M^i)*)}!@~(j^ zN9k@%7q~o)y10%+M)7m#Oo9H|5q?_8dSr0=>x<2RZtGmd`7c{s`VS4%O|2xb}GDkBTS^pGtE8>JB59JgIv8A*+U;{UOO# z$Yc7uWTBx0So#4nuR=11EvcfTyxggXi9}Fzs|Nc4BTHfAlU>Uhe#u&c7MitBQ?aJH zq}u#+s{Zyw=IcrpTo4P~P*qlWcqiy8S81}Ci0w}W%G!0fJs}ouXQ0tY4w=kQ$qu#+ z(6Lb%H=LF9mia#CS=U4+xgWAe4im8Ts(m3&=!yS4D|QXl%1*6(dxeJI#!L_=XrIo?nIfUik$(jza)p!BjV0(8FH z9Nmzg`u9Z-2ahOwN?xcl)?d*A_xKz!MIbcTHA3 z?{IW&|2}yRPPD(Xe(dpqqSRNzgeNzIM-V@hC3`!M4fwGB_fI@T6;;u02UZwSTABOL z4{R82^AJnmH{6R#_huVe3!fo!=S7t_wXfg+1nsP%RCLy1mpyq$-L>aYfxF6nMp|Zd z7(m~$zVAFd$}mYp*LSgu=z5;Cfq1y}Y_g^evp0?4{)cHB9gg;uBQMfyWg6O z8G-ulQ-F$b!M+G`XBOcNIOGT_nz%|h)Oe9uTwh%^+G&gcF_`KLk?~Hzz#E4 zoc%&QJiq13mAfu~Dn|d?%Dn7sP#Wxgd&2(GrubpR8p8E2Qo_<5Y7)MtIf>sI{lyg>&Z@{frV{qk#13;(NNC1MBv zaaToUcSeFv$3NiG=zynMVL`0VgDY&_^K#mA*TCo}ZOQoIR5doz=G-5?bmM5v%&)H^ zs+yhHE$m@I&k-DR<*N7|=bfE}qLeo3@nhhZrifmY5!yI}GHj1ak5Kdej*(D@?8*P3 zAL@~|;@{=ni`2hC2KfEc+|L>8*B1vTV1WYy0GAys)=x7+$DsmO>eF;5`Oq#lRo6eD zz8(qbClSpRAs&=ESni_o94mVcFXOO*{`=}SErErZ`AR=*mm9eX)EzZrk5}S+?Xo;> zm%pqFJY?P+-?ZJ7^e=-ej)ea_%QA=b>wj*1NF()aZMI9`@b3Ip)8`%HbhFRNvc>9q zWN21jdV7P%nKV7emTO;p8Uv?ZRu$%hdFdx#)n;v+W|9l%>-9Jp=Z)^?W4R_uAq#Ce~Ebgl&@4H#O^T8khJ!qp9e_ifwMGS$TfQn2-E&qfa@N}=Kgrrv_G#cvAhSZS&m7w>sFRKV#!Bys-k0(YJ4RHH5glXW#la{nE8TSRQi7Y%xOyMX5<& zB)Fe`>uk_6V~~$bae}^qHZUc?N*_l{uyMjkmhs_zz5R@uQoeI2CZhSydfh!I^g~7v zKSp!t3!X8tFlCk3>E+p=cPPu-pz7`zFM!-HFU`-TXN-hViq{yc7g5na^uvxt=3|#s zN9$g&dXri@4N{grCM5uXRkqmci3`zc8b#|;IJ7|R-DuDmnxs1NDPY|hRswodI0Xl# zX!TB=b>9MFHftru!Q06LMW^16;q|n0(*2_hgvu8ERHBu02O;m{>J>(I?+M3)W`pxD zi`#K_YUoG}-vyO~HJGZ&N-8vG`wA^oi!^iYH_br~pPx+P4pns&D~+B3*sRh<(eH#YJe0Dydh ze&_ziRK}c#R>=j}&DWI=zWn~Avf}#`dNeLIXJEua%Vl(Juke0qE*;-KS%F36DhG|t zx(QYL^BcbjXS%Y<7oShAm;MrH!vmA$CF8Q=6S1CA8u>I38$eiq<``L+61hS4glo@ zT_1n&sEzyQIegHoJu)4fP@$Uq6SB8`XR9oJ3{fZg)f)h#Pmk3g!awbr5e^uCS1l7h zs#r#7y^rQN^}14DgR-3En(N6KE-iqYmf!<*zOI=6v?MW~%dwz)i{s;qf^(nI^!F;1 zhIXOwoc&igY~W{2yJ>HART*H?&uCWY6$U)z)&8Yj)o1-N-y^=|RkmlW^&RC%aN*BB zsnlA7{yl%^itF99bhWPTJ(FUEf5apb9tUDCSl^ASASV<(miu9x2_OA9AWOJ-R6-@m7A+_nq4ReVtUi z-cVzk+5dd^)vbbU|9zegTs@h7sK$CyeCS9=Oxa66K1bnrZ@q$a#WgVxShv4fCDV0W zBW@MH=zHt^6UJW~t11n{Z6Vch^0SauUnKy5s9q4OteYgDr1sE~7(v=YVR#ce;F}bn zbrQJ!?I+1fvvT%Ov5Z*1tys+Iu_=Z>aIiZf>DHBRU8gZ%=*CWQg2~0T)q_(Q@qDj? zxe46%<%M;H(;dX}@6Y(&my&er9XHral}0z8{d7@&boGO$bKg0v(J(o7> z*-P<#UavJ*GkXr}ib;5F>)7Z~hOA_1>kOwEU=+l+}r%Ru4I>p`E)ff7P zczaJj77O=>aOJ}dT9*9@B*Oip3T*=!RJ7(DJ#2!(Vsl*6fvjVX?bk!(yARxbmpwx@ zfc=^lHpJy|xJP6V3DaSYgae-o>`nVDO~*6bOFxy~=Dz>;x9$8*e}!IGBn4a zA%%-nUFxQ@KOWUObZ-JjzytLXJ2+d((&@70KD)8hrTQZ6>IB^}f4Q&s}+B#X!PERpYGHg~Semb*gh{yQBMj$lDXA zuIE6paXBS1!AH!$_t)6ge+M4a7BRHcJ-vO2!VoV(lND}YR;L1XDNc*2m%dShRdx?# zMWPrwN41Y2$G7pZp%<_mSD0Pe84~6i zZ`mMvS`rKEYjBtbip(lSpcO+_sG=IVQTg4ATovbQRN)}IrCPk&^0TD$ zE4}3-f#;cWN=mVDNv$;9Tjdb9fv&{0yd+UV!km=ro9-?Yn&&*9y#&mVrTJzeqaa3n zD3ZEi+tZ+jx675l2e91XU~k@G)0pzHk#@vp;mU=~Sle0^;T=&;|E9r*udVJ=aeD9$6BrTm~akEo0_u z0lF-^WBZ+7b0U%0qvDMaujym)eUk|Oi%#Tp(2PQNmU?ou{k9-uJU8mV&qVYDNyV#x z#^nYEKb}n*ws|Im?Cb7Avr_W_WZ2~XRA%z;vfp!3{E1=_2d!JlLsFP8&lgUKnx4I} zzaE6SOYI?q-#-8?Pv#>V+-hkv0q>|rk)_J>g_}VA#o9<}ITE+O%1FKkD5~7Mt|9R~ zix$UWXt~9^EL3VjWzVCrM+qGL{6vq5b%J<0Je;IDGd(O)`| zc7y1Dp1x;)TP*70Ymvyq0qHvLdHz|A89UYm$Msj8CSs4)szf!@^uPG6t1T1b>(~W> zm|8WkaRUyXlj?i;x^;%@xI9A-*eR>Oiqcp_G;2RH$OVb4#fKs7#`CE?IAhbWnDD1Q zaq!Uy7C>!;qP%r3avLEP-82p5u90q}%F)gotbzVsyL>}@_j*D5sr8ZsRMG?p63$J8 z?=EhV?{^ghfPGlDmo+scbaCxNpJmZo&ZIeY?CXa6qn>@+xmc%Qf<%r54rGI!55<{` zln81z3|oEpx8st3msRfbonaSv&uQkdH<6f2x3cV5jNU4%(7b7J`Cz|I^pQ?)kRqPv z0%f1ReQhlsV|vjkFX<4>C2L*9yRe`X6!eLza0(6Cz`9=+aK}v$>D@H}zLAt)*?TzT z@J#&E^zER|J%PZYI=RwZLIY(vY#IqnOPzBk1x%sf_k?nuhQkWMSw8=}l5}IFGlCjx zBG7pq;FHwSwb&i`vclNkg)!;0mLu>%TRocYSOaSzsY;{>t@}r74%iC~lzd}Tm*Y(e z+{Appz8^j9b)gW=^Zt-yp=Xy+0_5Bp@RQtndh9>64wwh*VFVafPgC{9hr5@?c@X8B zL_xKi7tm9))^14-VHp7C-^Q@FG)uS=U|JW;gVa7S;Y3+3eZDn)WYO1b1^2(BeIfHB z1G?6+8!okZ1O-aEyOv~z4I<}Y@Af?&k=}N1PhrN-rI30lfS%l8bIB=vVYvpkA~`Z0 zcotb+BHi-&KY}*qI|?T_|aQ#eHKVP#y!U;I|LHB&Uq~L$=?a zHB(M_1!>9Od@PE+*z(_z^Y2}+$^b^BaaC6C%2?vByL^H_l0Y+dDA+XS@v6m@X zE?JlwBx1fZC@JN|%6nKg5?mWFs)6Ntz>B!BDDu#VgLR3$esE9W7ilA#ep z)H`YAcq^vq=h8oYK4*38A5(BE2gXfP^kF@}>D_>|Y43|30p__tHT*loOZIP zf_3bLrgn`1Ul)C)DpsIpdCOfX@`yySsC$Re1zDKcp$aH8P$Cc2o1qrGs=nTUEboAp z0Cm~L!NHfSI*$GXsuvHGR|jPuIywcMjWBPk=~f8)Y++WdxkM#bKVipG(}*&Sx)oiu zr=~=TiC8?2)-sbJl&kl!s&ir?lFZ?ModpK*3Oz*l3-XWgYL*f5bFHVh+-e%SZ&Wc5 z#Fkqnk?h%FW1Nzdrd7-W=PzNnNL|}9cR@uf5|KXZ{ZvzHVRERwW3!Kp@X@SYi~~x$ z32KE`Ep-?hz7v%2t(6?{PMCl;ipO;_)q>cx^srZK&@HZtV^Wj1wkqB{InTv@AG}BV zcH7sXQ>)lV4czOfB$v%Jti?9=z_fS7Jz`CGD+b45e^X8fVVw=+0|N^+3`&ymD4T}L zmaUEp-NjR|&c6pZiVJ<|e%8@Tmsy~C3b&B7L-8vwuO8|`TDeb3);i&i_5jX?UGc9v zNR{K@vCW|SvplNv=`iW4IoR_)x+Xt)|JXk*L(|AJN6cSU-(|)ox>UYIUSI#$Z`e5tA7*;jINuby_R(N|X4m1d@O>pp zzJ)W&^-bG$KC`F+EzwLz=7+5l7`q4u>-qPWYq{2p039}Op8;ugjNhXP{ac{{F~#3j z@J_#2wshtMWA_(ogRGXiRCzmj@^o}B@#>9cSn_F)-9=~dE-z+(y>*7GhiSi-=kvU> zncbQ5`q!O1I(CVizJVkK_7R7xU(kN_%h_4WvcEI8h7`I-QlEh#cmu$C*dvP=6BA3d zr-6YVfJX|Z>ZQ2Sk|D1CZb%8wSV_X6bS0GI^lTX%G~7Xe-u%@_rzd*qX`B=eYGBHOP-%I|G=XkUHB=Vll7dA6;2 z9~iC{a5tP*IKRGHXO}S0mK^)a`Os9`j@%5;w>Na&1AS)o;TD-$YxdQ(2S}C$)cKXK zU@jt0i83gsktUAFZdkh0bsnl<|ML)axY;92s)Mrjb|q5-Rr-+Y$zFU-DppOI-i5ni z->_N72>3b5{F#BT&*2;<3n4Cm@88#8(|hnxwG?(wpPG5B4Q~imx^DyLkx257$P6$V zX;RW={R(Y}U1Y9C?AE(W47^;uUZ<66B(r0EAq-Q}*4Gx$jHo{}$PFD;dj;*?m*PzG zu?|`+%c0kegjlAziiG{1amNqk0I=cG`)nzeS21Z5<$xRKTpR^$v(~vL@|r7Uxz_j& zB#{I_Q$VzFEu~TI>!+0$xj=I5Z_c3-$~d;7>>g~~EEo@zTnr6Bzj+I=2^OhqCTCuu zQ`8ulHBmlU0ps3vfax0Yn(o6uk#MvzO55oaGKn;2sGAha?lrnYc%bgVPs!B2>K1_5 z_Bdw z3jCO4W-J7A!%{v?V!oH33cyLnQ<98Ztm?2!XqNSVO;ToW64VYPVg(Iu+eWnZtay#g zfsj3Y?*c;gda%n9+v?*QE#op5U4?rDKg;$Gt&TSOsK}>^s79l0ppr1A|0t1C-~nlO zruQJ?&f3pVt03K1B@gd>EDg&4bMc7h(m4~*IQ1#!r{PubeI@9^BgXG^07z)zfo=RF zmg}!?4p~RXFdSF{#dpcy}P!;Ctqk^%DNvAx=qhNKO4}H`u)# zV~|)N#|!-Z{eHXA?E2RY%Tu-P;o2Ez^vN&Yo>=`ElQuueJGiM^2r@ zj2y)+)$En*4s%T(cBjSfj7FasD#RJ*R& zAgbow_o!`jUpWN%C&i27c!Q_3kKe%@&$uD)@q0J~=ZPb_CQ78*J~zktWozK|1n6P_ zB?N1&H$9BL2kMu^4&a@Xq<)f*gYYTnu;kSg(bqKQSkMxD_({px@=5k$8gklSPS_kq zaSW^Y@;y>V6)3(=Io{OKPhVrDO#oHqVz#h62xZiq9B+`QicE`Ap6#_l4;qc14)U5 z&}rmI`M7{cnwj;cq^2d81n|U7kp^?}Z#Wlkj?FHgDmc>l~GWpxjQzY zT6%EAlliaeAjav(gUS@WpwcpbuNcPZ+4%Av&O0)1PCp_2oj)=2WzgHLc63?Z+p@-5W?guVi6EfFtReeE`owM8|+K7V=60IfVL3e zC$U?Sz}c4BGr?F>Lx;F99oAz&$1b97*^^GoOYduQQ01BhQG0>-K(oqou-slw%NYj) zbz1yk=x(k?vQG^s%nzVXvX%UG1}B!Le{J3dlnirVOCXs{k_i%j%+&T&{j>`mj#z zS*x0~`Y&658vQbLm+^s6DDrGNIp5*6m%L5e35z`v`;1Aj*@(o9b5E`OPu^8zTBMAU zaG$|2X;o)LQJBB2)B%G5Og&+|jHw^!r98h9-8aslO<*U>x!<3~7hpEc6vcwUdTOfK zg4onQ%zTy#e;XR8e#s~HZRk{177lQ_2-c7lb&_wmHVd?%P_d{7Q8da2bTP@DwDH$S|8G*x+IVJ&_!f3jEvIdg_8@?FqHJASWD!XCMr z%9#Ac?msP7>&5)6wZ$8>+OB$ED=O2ket3m&m`{?6O^od=>poDX4Gx8d1#8fgNHKi0 z-yq~#0MS}=^(5lJdcNr@JiPje=t`Iv-T=9h6H)ju2&-IsPH5~vv?UUthY(5H1u=)g zY_?Pg`~*$<$kexgWz@&Bx@NlDXCoBtCAJ9W?hNBCPiWoJK}1n|a2Edc#cgFjpDchy z8&!DgkDH2REA4 zfj5wqYijNWihX7=YVrWh7Qq7%noL0Ypr5r{6x~<0LYW=c8?&WMZc9_#mDS8oJ2y&yx_KohPdyXyH1%UfJ*L)?P(0lk6iO|iRC}xXYwlRk6jUV4Pe{M z9`oOQDDUO)nV~{B22?I1Goa6Yh)OJqk%j4dEg_fXE{mzD{tnuAOL>};C=@;&97buR zX}`^CKj-&pPg@qk)`@mo89G7Pk@6*(>InHjTh33!Wjpg9FQfrFRNcBtjN3n{HErY; zA6=}dkbTx?--2$v+pU!sV>`UzlcX&HmZ0r4pyP>6z$-xIWU!O-f*?9$>U(4(U`OmpiTa)!dsaLLfdj%c& z1{4VQoOa(+-cjb|TqwdzYZEwA8zzDL7L$B6!+< zg}md@MH8?cSP;?tKHi)%`*ic$FE^umPdcNV{B(m^AnAU`-#_HIo|nB41*E?@NGD&z5}SP_=`P|^NkSLqa(Av zd~H_>}U%JZEnbg-KmimZpP;Fg;uT34o5yc&m$aI7|g3@z*ZmY%dq#Yb?Kl zfa{rMeo8s}^||dhFa+UI&?!|>6XEhW<67?3xEC9i#_ygv zRxB#KdA)Im4*Cbvm&*Oq3D;RpWxe|kNEQL$A13@9lU!`FNGG-%bbbWp4PW8)nLe) zd0}w-C*n+0AZe@pk6%}MoK(&BfcjJXKiycG=DDY-1zy_qF~lLZF`Zf%2aYA)$agE# za+G|429g4BSbs!mzjETIzMzo5x21;|tja+#UUXqptK@yUDJZjw1E0Y^_*IDOvtHe+woUG-IO&}-aovSl8P)@IT z3Pq%GH3q-4XmH_OfHIK>2H+ujgfHC9``)8)xC|)v+YzrXiD)b|T6L?ikSatN;hL`(jY|Y+oA= zGetN>hM1xX-R!idi>M0aqYUTv>7ZA~@5f)bhmB{m=~+nhN}S4~I8@K8lE_Lz;Blyn z@4Ye!&*MUsxl5Ng8*;;Ov20E#EKoiZ()UF76M)TwHpw{Hx(a+8wBj1bZ@b;0eItDY zc+Jc-HEmn0jB<2bJ5wqkla{#S=(l}Os~c=^Jfn5R;%$N7`{99)*r61_WvMkgJE~2h z+S@HsR{^X+)znPLMw6RE#qW3-K*`X*#T6bECobfMPpxOIfFG7!{-hjy*7_tG>9GCci}%{=KBww1`y*j5U&w4oeKS-e z=!WHA2gLQ>dR^oMsZZMP9HsDg_KYAd+66WCVOH{%I3xI{`-9Qjow!5RMoPBT&(ikt zclLr|Hr!xJ77^QVP5K)!D2wl8EG#(k&wOZ&Rky7(Fl%`>Y05&4CA*BV`3a_1(0CKVx{XtKmWLG?Lgbsyu5Z%$)o@i-+=yHVB%mD!}y6V2ZGrVBi2aP|JXv zx`J6l_V|A=B3wiKib(hF)zP*$2dQG7V+`KZpSdgHC{E{!erQ%bXKHQl?WDo8 z8Rlwf{A)$ptj>lV0+V&h8<;+0#jdR=-4BjG9^Ja?j*YX>+n1Kgr1^)%q;pXq zJun(>Bhktdm*Jxq<&vLo79j{X?JS(!^kWY+`-Xhjo*r0O^JCthI9X0UQZola#Hew$ zVs3D3aAjW>flVdV!|wC){)!kLAV`c~EZ5$;OB5%DRN50B`Wvm@3?8bq_`y#xt{LzO-LEEayhtcj_ZE z{T?UBzM;*>fljig`(4b+gMPay{On#7XLG^Pp~WV{G!r`|1C(VXi}_k~>1G!Ztt#lH zl8;_i?Xut0gmUe{z{O;dUW3Cm3*SmG%RJAl-Hy)v(=HP%!3X}GgG~=r=Jn$Bzd-Y$ zuNJsVm(@4=RryBYjA+PJpkF#v_-e5F;ThJJ&{nCUKNZ|hu_x{o`Oq*r{DL^zsFC+e zL7&2TF_W-F--S~TvD-IL4JR(G;~OktBYCu!9s|)PIJ?itpx`7u#NjXF!t`d0q-*a0 zlAuaWi`IZh=?$d>rKi4wlBoWp_GeMDKW*o7CogvFJ;_a>)V*(A$1&dvC~%>UR3HiV zehd!qYU*%600mt%O=rlDStwnD)&-?mLTG>(f>t zw!Ql=uFdh~uj*mZ^LPh&Fnpk>LhIDve(9|;3qGi&j=Be%=~Na!B2p*}40|D;5qn7u zoOb+6F%UOFS!Q+e zkVtqOeJOWpp@y_4>9^K)8PmpNf-drRh~NN#!wHKV18UokaP|K|4ckYx3C3X{W?84l zdm(|7l@l-_$h7KsJ>)~-B=Hn_>~+QL3jpOS)9q#GxDFJp(tdbdO|_Q=Wx`HW)&7K= z7${^`#~i!_%1$-;^61rwqm-m>WGnC^f;PXX@Ba~=*@iQ5m5}&JVc^p~!rADZ&8aRh(2PU$qh1y0fGjP=ts}cm}-m$zUmMN*jS;vW3 zlM+=rbg}El7(>Pu!1rE}7wWa?moB3&)G9@na`~9ISYr6mjBW z0ieklwp}~a7;P=TRL^s zy)wpy2dReSr5;$_QtY-s4^U`dAFDb#8@}(!lJ$744^*pD(DbaPctX>7F1R$v6y@FM zRFCCU2fY~BVlf)m442&@v|s!cn-ADAtMa|g=d>dWRXyFLFRSC%$BLX@FZtMQxXGN^ zp5o@2nR!XE)IJ+r^6rp6H0o!$OGmagQ@Z~ZFsog=aD%8*b!N{bKeNN9%oIlX5Yg3x zvm4c&=^=1t0_BI|Mb6xQ?KC8TB}}k#^l8hUiLf?YUs$y=C3S2?!rKDM0<_M_5R2i@ z7-x6f7+Eirr)g7*%ezQ2Uiz=Mo-~`3%UApL^Ry2(?Q2~fI*xPYEM0>8A39B)j=-95 z(|1Z@xt#Ft^WJv$oX%LfX^vV@S{TYW38Pj$E5p+|Pc$HLsf>%r7#|p0!T1_EC}2Pu zsZ|oB7S|A``x?yArzq6Ra->HR@^wYs2g5D!T9o6Va0T|Wa|Az(q;RCC1D7}hjv*BK zJjqQDX`d+NbO z&1BY+_C?y;Ut?9*_atlb9FlD9(XW-+N4TGW<2e9JD!vt(wJn0u%5oBPxCP$=`v{5F z96}sXv#v^i)aY}qFaaslNGG@g2%7KLNGQ4^Q*}ryd|9nZk~cTF&@#>$Ky&&F1`BGR z>btX9Ml+Et7gy!Q%HC}tCZts!Q?J^bmmaw6x2IZ{{>Jib3`GV8E}yS%%-^L@+u z`a3s9y@}t47R8A9vYZ{ePHptQtm2-yO~fEQ3uW82!kvD+E^Mk{X-^?vUcuT9Mh z@rifH);W`(=qG;<9>G1SFpLbV#^n*k#iJ%YYcRb?-+`O;X4>gR-aM9m>6&3F&d%?* z)=hnv>fc68I>e?WHLQ1qZzn%Jm1lKRT;6fZFf=6Mb@i@FITT7wds9Qp5b=w4)`&+ zbSI%36Epn7bKp)+Mm>E~O^PdRf6R+13=w`Oc$3cY_nkQpZgMBaE5uebY3j`&k0||A z@nX zIbp$2%(>HVbRcCzoG+mC$4);Bi4|$849WVLhd2RGOJbvvXonv&1%4aAR(L2b|qiJ7F*A&i8SWv3|{rzlb zj5b+qT_NN{D|K&6D1YtGr~UZ5cx%g{4eK3d^YKQ#DY&fGc?D2_Q#7& zdK~P9MLI+{;4I1)%l!lVCAL<{(I`3j2i@R0*}_+@NDsQ^Jwb=wm7tZoGsC1rlNMm) z=B0C1r~}k>`R*bx&cs!pEmmFZ8M?qiQD=gECR`J)H(&uy#qw!9D|?(}9eqUWvK_mt z-V&ktfJaeZl6suXg{q}>!kmd`Tqc*k*o+2VABLWtszjOJItAui`rPB>ejH@dC4mfJ z1C;3iWcg6#Eq5m|giSPR3r4mARf=R^PSYDr2MKHhKT9L^a*}@P!Ol+ItcCH7&{b1* z=|MU3U+Mf&A<#|^ME2&@DTn~tMG^c{VC~P{Fz(wi1g1f?$?+4TKh~n}%OndL5(Nkmxw0>=6MF7ox7m4@tsOW+|7pqbCdK$XIo^ba{&yd2@cG~u zrf?Pb+)uQC8eJSx?x!(&I%DEG_CNLIV72gXd(#EQB^3M<=4|-0%#HP39ex{eoPMQZ zEKufZ^stP2zS8AzSI3UjZ9dC;entTpDC9ylZfu=#M8bf5@T zoToW4d)AZM&1=XjkChXN;}RWy08#z2%4cf56xrJIi~sJI>_6Fpy&qEDqpDA#FMekR zihoHIAzVssQ|)#j6>rzq|N z8O85dg!}3SS^;zb($v_w4V_~_gaNKVfH;X)Xm55QO3aa^f{eGq(hkV^TqXpBAjGP7s*)-}g_C|z5hLvp zn`%PVH?ys~a_b@X*u(4p2N{Jjq?ud`9d71b+c`~-|7Ry+=hhp>*3QbRXPdL91ir3& zZylIu)Q+es0% z!*_Y(-N}`!zrgQSqz{g>%_sY(v?^jyCliMX|2abHjG#sFsAwZ!>+P{x(3OWh-#}35 z!86+oLc1xz=CNoGjfDw^DVs8dE~2)pjD~(Utx6mHz)mIqeuY{iO(cStj>7F zgs9@ljnS#eb)5WG(CQ;P8P8|!;tf_6bYeQuC*$bbs9h9BrzM!26sJIasw7+?=Di={ zfcbm;3$-I7)(4DWm8FBJ|AbN;x{yT~E-wB_n7A$QHk&E&^!DzUh{9l=BEQfL(}8yk zAczghM=f*_6Gf1VY?@ZX?2ZGz8u?z8jZAhiOfL z2{ze!@S}ryACB($sU4I!UqAu68=R;Jp}}zZ%-~n$r7u|)F1tM|gx0OH!z65K(#rsl z3ryeq)4*<&+hB`1bz5(>$hSwDH!fAbw=)uP~} z=`OF{iZo}DLkmi=yW}2C*N{Vv_g=2qa1W$c5nRpmYr*edsZ-YpONSP+)l%(3UuFvm zf62w^1ql!o;WG4drdblmGC3{%Yh)S|I18EP z#PNI`W)b9eV7?{=nk-PHGBVP8xAkk8RCd+PcZMeWE&yDSEtV}BdvE;D0Z5SP4?2Gh z`3{~BSq2mPIeZsCVm($feu2Zw2AQt2eL)d?=J!ZW!aA0(LCF)A;pqHpLEmD0v8+y9 zDhjZA4`Xr@kE2iKkF4Efc~0yVq>ESt7A9{sP}RE0$D6Ek)o85%U#i~UV3MLYrB$Sp zw&t!vv79x2dfav3X5Gogf3BJPlq>I1j(6|o zjpSKd`>HK1EcAJ_v8CN&b=$~umYh2gRnU3ZsO*|9oK#=+I{9=&9SkLL~KF(l$X@q{MWU}>+v1~Ca)hK8~H`NtVUna`;dLD$8pv! zoP7fs9&&KCPwUQ}=)$Qj%{uw|i-Jn6%9+K;K+8hrC+eDO?;x0{;a{bI;Q z4ZE1-bOp|qJaC#~6ci`zUSIpjw}9-1sbkv~

Q1U4Pkf*0nr*^cVdyM|m7$Eu(8) zxj9cIwq0AWGcIasZ9!6xjzTTeTq$d`6#U}y_r@$K?g(LdTtLF|l1$986Ba~8Qk=H} zUqhLORLI!KthwBI?=ExDBVAHq>HrJu1V7up|AVd+j~uerJZP$V+_MFdKsetGiZ8>~ zN#e_b22y<%gWha7DvJX;9)jw2yaMYCN*W`3T|kaITdaHD8>_z`c|0#Uc$U~1qkq7T zNlUa_jtQkr3|?cUY5Sx9pR;$5N-_=OwO%LuEvU3YwLj#wML|1}jg^cnBS9%p4Qb%(3#+xn@7J_g;Ii_5JmI zpKG~Rt60PXtoMDM`@VnIRhHeQ>0qa!(7_b35u^0h;i#i!6s5vHl?;1-Jy3tDoHYhU zi=)DaY~{csrdss1DF>z?tjt}=gV=1asUFe9mS`E-W9jWwl`M60g)y_m0N5yD49^fp zi4z@bC?Ec@P;wk+*I-dc2?EskAas6`(RneUjLTZoni+R#bk9k|6S@vQ=I+f%Sa&b~ zNlV=c+v_CcrS+Ws1}O|_-()qK&%~OU^cquzf2-?cspK5=;~T_Pwyh08+Ys^!@yRX_ zdhtGtUA_k5FpRu#zSdISy($$i@rL6+cw8rSY~-U&%B%f)d#;iDNaRTFTw z8m?h~rV()s;!{k&#r^?d_h<4BJk)Q#tUnh_E2kQfCdNMPl;+`fr~rjLT;ZQy#Vw$3O+}=)Jp>TwFh9sE3^LsBX%)>a;c$TYd|x@L8AXlQASERAGYiK>85t6DV9FtK-4U3qEW9?rFU;>`Y3fD&v_ zPwW$WE~(LOGC+~$=HOm&ovr1n$TUiU>Or%@y6^p@is|~gZoQy$#vjfVO8K%>NQGgX ze^Z;!`kaIx5dsfm@!bJx;o<$JkpL;0PVdjzMmh)UN3V*WV7nfj%RC|I>h& z!T)R9o?ES6u@(w|C)@5kr_*%%g5FNk%lrD}xI_lI+Pyoni(Z@kYq~sTzy1~ znzf#CA=6^wXOn3TNUlpBQVVYq3YZp10Mk;MIJ*?ry;?5~I4u`aReTzRB+y zv+Viob_jhLs)zoA;ikOs!l)N#lu!%+A>7? zbr|8pMhNemj;*hPI-BcGhTm2JBJ$c!-!DE_tlU z8~YTeTxMIk5@E&-6P=4CCiLIC{*uXfr?%v@hl|g52)8#rT7#P1cIGl^Io39hgox=Y z6(@5>rj*_JTXqqLR3I*Q{Km@wN7rkbkuby!q=boiB8`tPp9$O!X8N#|R`Cae_i>y} zD=sH*itM6FLn8X3Gr4&Ut*b`Q3{)+xTb0ITH6Y0N)zv_xB9UcmT)FHAmu2ab=R;c3 z1ksGBxoys&pUD*bJnFeopeiBjVn|{3g?GdWJ<^LFlXboeY~+70RUSk)!uC{6mJ6I= zqi5xJ#7y(j1=F=FZNidcWW1-rWb~B?Hd?d=rgPpWdkdOwOLg}j=Zu$~PnIy^PlL&~e`m8r~@!-T#)nbC@)}| zeDaOV{1Dj{W67Ee+17a`D%*$zp_4L|s zW&eP}+mux%lvzx1hr{U89I5G8c_~K?R3vLTI_%S`!%dn*CGwH#3ab2IL;aLIVDfMNfIy8$prOaXmJ`42=yRV7eg^+p(xfA5B@%%tmH+A{lx}fL$%J;%^I$o8qjDFb9!wt#Ye~yB}7P5*9^2eyHFF- z_gJA`=I505SEftLR| z_!4TP_UEQAsZlaX&xRE8z4R$9!CI$5Fp<1+C5%COAxc+6r8299efg=N{?#&O!`<|> z&>eySI1fdI=<&ggSKs*CZw$g81&{PUfBF?`+b} z6B6gD3)_+L@Nz+~5hPQ9xQ{$roy0ZG=+=VgIGd}V@(V^mV{xa5viP}L=cL- z;cLZ0rFTZ1!lbW0I4*9=wcfx%iS$#9Uz?T(vfhQSDJ_B>-#-CtpQ)4?CNT}Lg6NsO z6lVW8>jep?!;XG3g^2Sa{fI66FPfc?-s~n$OM*Uj&MZ zd8&6fgod9jIa6})K_}~d|4N+T(HCrGR|h5RLrI51L3cQ7Q&@Bq zbb&gg>ss=ZP`22a4DAbyd^nVUIEDNO*JdY*5ChRGAMvwrRQaA<*ojaI;@F`2UL9q) zEK)+Tt_ZsqtOBv|TkWvP^t*88cfXLJZbCv-3d@x`iAZ%0=PVnb!Z3PU=fNN4HD|?a zK`@5a4tWU{Yt9yKZVE?kKV^8mJRy4MdpzDPE4H9(cE?z=XW5U_ z-F?xE54z&M-?Y!C);XEyk;c4KxA*U7ovZ#}2e~$8yxo2=V}HMoWf&f>zX)UOxWRM z>fXrb0%_<}m3PKur3KDhC8;8<5$h18;Mhq-wK zJTI$Ww|C)Uclu=W_xv{E>|M;UpdfvZ}lj34cp{xY}`+BpQ!#|>=YGt^%6xAcE3~-Wl;IS>&&Hbt{tRTp<9fBvF>9y zBn-)LPKdmlS)aC2>}CnZK-P6`^esp|Z%iB;^iYhku=RA^`Rk$r9{RcY)&R$??&GCJ z-dVL*4r(0_2j1XVQL~*^U$_nUK$DZz=}x80`|EUd6j+X3@*l?qs`Ly0coF)M&i3m5 zRW#SeATanUPMCP3x!3i2TeDq~tDVTcX&UypZ8{Y1RL*mxlmKIu@Lf2JV9ml$itS;( zqJE~YRnUUHr<9H!4CfI95A7O`IVpKL9Z74Awn9%Hx4JMyyt%=MUb+SmJXLc4bP*vo z>eywsOF&Cm*rz4&yq}G{GV{n(iMcbZKhnhZC*>(qmO=Y9WG+2fgj>rd zIRPXhZ6Y2nKl)J*Ut9W6OM7XqyFadwsca$vStZ=qzn2o?y$Zu4yj5O)ZnzY>Bg|B-mgr zIknIxcfo8R{?42fewSmKm-pP)in~A2N$$-%VghWkv471-W4rteJU6@B2(f=46D(m_P%>GPmExW%)r3ie1^lFp9r0h?-sa6ZB+Fi^C= zD(a(6W@--Beiz-KSHds@gZgx=A)oZP!$hNtrFV7qY+b4ja>8|x1JPh!ZBOSFtsCWW zJ`mjUk)@*w3a}vlK4h{cEkIhf=A{(L)HVR?Uoi_ zU@C`oQ|+4#N>(gPm@k<2UvFWTJ1G;>KRx%WO2QE)gi=p2i=a<*mZi@I@4ANVw%Yuv zapMoO?;&g?`n%Ip6nf4==^e+zXM3 zPWIojy!J&PHu0I!`9~%byg8M9ex+{S!_SHnrbSwJ)v09taAnvjoa>cjt_Va4c4xtq zMuNkkw<9y377b^@oXdNt@xFvfg=rK*l`*RfyH)jxmjLT?=Bd1>&QSBR{LT3l)@6{! znKY@|RptE_Kp4ZTTJw@(cU*}aRv8cH%&@s>KH)az_P=S72`^uT`7Vqq+|dq=aNJ14 z>Jvx)G}w`xQM&q-?>#nGY7n^#{tyRR*jn~`57BQ^m@5^s(wVC!E6nor6mTQT)z3Wx z9yVC2pp;2ef#&VFyE*dZjO0~_5lQ%PvF23jmnAGr^$&>5XV&0->kQRjGK@6cS*A?~ zO1W`e6Y;JDi|9qUe}daDYZ~6S7Vdd>hQnX!bKLvN`rM(y!nwwFWq@1~~DCaM8BD29~-#Aama?>xa8mbvxyfc@McO@Loh_T#-fE{jqfuh|s@5mlA zEyaJG=brbXWvvPdVF?}$`a8-Ri`^?o4+hst=`P>^GZ%rO%dQpNR9~& z`F56T3)I}5Sf|ySjDL^60-V*Ux0ef*vFl%o%y=>@9Wm>CTbu3iF2=2afbuk6-=6JF@6cJmUpPJ7VnQIyi8xIkw;ExE3A`Yux5XB2Hcfszixw z+s7QqftHQT2kMe4^Pq=XwmPH7*M0Y*aX7uJKHk?l6ea1N=0LIy(M1tuZXNyJgDGlh z$oeQ(6;Iwmz0MX66*t@QcWTz>k$3jHqXeN7QZtBY}gjBbRJEK~Ufj>a23FWb`3cWu707HjoTgfT+wt|3<9@E>_bJS-uB@?|XFzad9Rr zB`2lgNedcK`9jT;*&ewdcrDFFrejBiCDH!2gA+VOmOz>X8K_4gp%UVECw5As84>w%4r1oz!@E$IG-jQa9YV6j}T7D!P6&&qQ9g-S)0 z&w#t1&030S;lu+_nX1q5Rq}Pd1S!(?N0Lr$&zRmOcW09rc?~9Jy&eLtY0yaYsREs5 zzeTTjPq~a|X%U>d)b8b*PR%E>*%ZzW1iS*UAFrWHSu7Qh0VW}?zTgJ~VhusYyKZCo zj7vhsS2Z=$iHmiM*qwHTXjiP>gl6Al=<3oq%PbE!QHVtO*#<_4lWnBSSwsYMEb$CwFj14x-e zbQW%f87dGPe*-yJ5*Cb=9|av4Qb^VZp1pzAK+^#b zgwKk>X1hux^{;wD7D;$i7k5e@HeR;SZZ`69AdSP|S3f7w@z@N!CUPD?nxAoi=iNBd zb4V##tdE5tDxwnzS77BMhp~ELcfGynjmFTp20Fv(Fl?2Kr1|KvZQTHmId^X8M<^qu zX&my+s!dr1fLr;3a~;Zlqds6u>Wj|8>m1Hf7lL&NsGm;P>ejrP2@+e3J~7GeCh zQ@iXWyeb^qy;KKCq$`)n5vsV#-{lpxxG|-PT@clo(XkSU)anyTWpNb~bMGTl1>I`P z0<%CW;RCo;jqxP&^L&}*RJs0~4rESCU}5(y5Ut3>NdVLL??cx+N3y0$S^MYtEc4DI zB4lBwa9GLMUU3cmX@TSU5R1`qe5aJmu&2{Atj@@xqf_M}TMF8GJ;+SwG(m*Hyi=4- ztjbZZx9#}HhX3q3tH(V5FG!znn=j&B#n7Gn?#^=FIT7uX&x;Z3K(CAdi%&NN?DImGbpd?PT}i$OP~pklAk76?dIq?Yo#-`Ux}W*(FJFwK;1=;6YZ_aA*qMJz zw4;*0P?_TYl4vNH{`S|?=NkuE%f7s`=S)i%%jwZ;sl`@z-puT>-2A+tp(A%_ZOeLp z`R#;l7lVG@f`Ltoj)y(QQ@{rVubn4rP4bi41|nox8uAl^2+v@pKs zp{g`!mXPvD`_nPC7oRY{AT`P;rdwtJBBUKgQA#{IK%Vds*AS8{fl z`)}^=OZJ4HYI`ha*2@woGo#AbAF@#B{8iYCRmUVtb+wnI!B=|$`eZp;6pLI?&C|6D z+rI3beJG_xf<)x9j)=4{Dr|LrU{6)@&Rq$op}CpxG~-@2!#hgS((AdXHs8uWzTf&` z)%V)#dz`=7vPo(fKXq+p_~)iG0|z%vetVyd+ve!0Eh%jKFgPa`WnTD_#>sMuwa>11 z9wQ)@E?9XIuHmLyH~;zivnVQdqI@RQ)#8LX~=(A0p?Y3Y2v)bisDkeK{Yt=^qsj)J=Y5v~%j6l<{95v`;qI5Nw(S004HYD0#oF zCAbD&HP(INH_j`=?`SK$hQ(k=ePwqKb?Syc*+ep|d=V2*T^_ibpOsk7ls1~UHh$f; zL$z%jHXYv8vYQVJm&v5Z^OLvZXg!`t1n28mOG?!uTx27_;ju#>0l@*3YDThvXCre- z>zh7V*}uuS#}P7{Jk_B4BxD(`V2kJ$;Q=^&FA2F~O#em$7fP8XU>RutpnTBsjCaQa zut0T}!&yK^jI=I8@G5M)Lm9?aC(&zX0ZkkVCyZ6HO0ERI5J{qp*3I>2( zG+sx2V|y%xtip7ZTaEy%ZVY57s=QF2ciCeDfq%H?h9koM zCVZ-IbnG}>RH0a9H;p^gGBX?MD4zN)dW$=Ac4n)jq+0uePIb5HT44hwMG&P0!CEGQ zpoijE-IMw6XM?)_g-kKHRG)szkz)|g>~$DcBPh$&#{-ld)SJ_eE$#~&Dn~;~1&8NB z4rD2rX&Cbj3~wb0&nPCG*xWRN0Hhs)#WOI7C;;=G;V{q&zKdz?AtTKiCdFou$?R}B zA(d8JmScDy(d7(uEsljP)8HJdb^4jn?gIha4Kt6wGd9)MO|+z?bp%l#6m$cuuU)6C z1eDD0XVdE;NJl+jltXw>DuXf6&7YD zjIRFG+{tW@xbMaqvu2Q~>>rsc^VX{*=c2<|F$7-1%g1s?auE(dqxj&;a<_0|V5g*O zV$gUC8psl}(Nbah_!(Kobd>w!zgulNu1W#%vXKkM+d;^Lmehm=CDYrK@+chf(~Bfs zC;YU^mHPQptXVi5Q%MzD(k3hV0caGK3c5E1A0lrFIpUYD54G-QbNbTbT_DA3fwUhi z7JGy-8X!0{wg8;USvE8$SL{G3sCL`_h!JIKXuP1$xWmN{v%G_q@KPT`+0OwBL^u!F`IwezG+D}&Gy<9W(cbOR&m04!df!TwaV)8 zDZMW@U(ZBW4LbWMt~rZg_3lpE^+9;`guFt>9Z~X~>z>dL;s-a3p|6DpL=BcjvUKv{|_ITr?|zWW>z{r1dcB zNLdh7`)iCT6n;BFrBCTpzX3EAf9nkojrE3>2aS2giG01@`>k@$m)I?IBk$ zh-r03aku9Jf=4KLEYGflxP6#wl=98DYtziH$AVUL>}T`n8+pYGv6n?3AFAc?{eN%| z)b8o-;GF+!^K<-v;*{-|7cAVuJs${0wqIr2%IUt_M9X*mq~P3&kzEn&a1N+KAC0Gt zUmJ_JouWYt(f#gDqS9N8WQE-2C4Oz4ahJz;$heC~_f`HxAWutYZsekFt#d0JrRy%U z_pMyGer-%p65LaB42!2BMY#hKXR|l|_zWOV@1J@GhJ=jc-|JUuE;fztkZG)dgx4dDvMRl!Z)!9GG*7D#V z`;q4j*^`%djqLv_=Y#doc}M3&!lY*V?*#iDjZpf}(LWSt9N zWgs(rABJh3tUkd$cxtGTVjDD{v5~xNFp5_^B0p9d+_I*-9sbp~tvx%xd64S4cp;aa zLzSvIp8d+$BzRC4Bl!j5W_eV^ox>~mJKaY-mC&_w$uPi0_%k+eBdIeQN+ravur)Ky zCD@ZqM(Aq1_4&P%YBaiZ`_FSjH3~%6%%>M@_f3Fsyak;cQkF($2Thg-xVTqqj9C+d zXE>1Fx;KE?VL(XZ^Ru<Pm)8u^oHWBRyeB9*U^|5a@kl1QUzyPoH040CD&j`2K}q@#nrc5p}<2?2H+ z>NnH`gOpEH#n06zUe&lm8P&jj1GhkqD?866hZwm6@6>BB7E$FP;@LO%II00KTy8=~ zo$cjo9D>mTS$!7QM<1WsP~x{CSw?PKU0v+4kudS5TKuVp7LTS5^&x;@fX_HS7U{w2 zB|l5kO@YDOGUjs3o|{+3q+EZ;Gk?cIcdsDwm)5#qW#+s`KKR#&$sEif$lTb(7& zJ_(irfZxt{t-R6yVM0v9k;8Jzzc>U)L`Uuuz^xW1)+Oh@!%|Q&ZA9Hp+6Ma(OF=_ z!A5xkm4=fm=tw6vQ)LsSC0u^3+|MRr0Qt6N3_)wR&2F3eFHWc>RwXTyJr@argWqcV z9HKYLHR14t{e2*dUE4^rlEo<$Y)syHm@z^X0TSJk1^bFxK`^Zsaw-1(@s0H(;!tYpE^zO)N3pRP1fZnL=QDkQcM%AU zbf%k|9=7cXBOaJ)bP;skr0U{pTKaAfd0=3874WEwQMieOe#AGc01j`~7yy-LfqO92 zEpy_gKNI#zS?M3|ytvV^dqNr`=+g8%p6=@Y6zT)6w$ndzYVMf6gQMPS$6GyDf$?YevQ#Y1=HgVPC*ep|;(rR`OWt1#R(D|q3yJz)Xf8Y6zP<3(sX@3qD#@hBW7DvCuyF@pTzz#!d5iF( zVQ|}uJM(|;4ob^rJVzXG#iVjB3a)mblc#38zk&7a-!dT{G`nudir&*19Qv^jdnU;n&w1B$4x*Uj>OrmOpxFgt>L9AXxB_I#5-kaLh)S zv)s@Co{PQ$!oyGH;=}1?lzG5W_2(S-8F$RjWTr$wO^|1KdEoEm zqY5Bf=jUB(cgZs%Onp|GG+PS#8bL-z^hUd`1C2Fc-EM9exe& ziHS6X6bGgGMKiY*0eVcf?nR&>_%0~x<;E#*r{zW+{TK2MNss}=*Um9HStl0Fv7zUo zw%6UE3!EL6<|BaLJ7S-NEMt!Grk-^+`WW5Q^{rL{4$_*@UZTdmG^ft?*%gzKr3H_bAy&^p0$br7S<>LEkA;=7!;&HVxWpLk z+wZA*Gpmd#eW&!#PtCPKnQ>@N;QDQjv~&-(%SKdnRGPOUIAu2-gll)VH|eDe zi=nzHhZ9hNP8}QgM-aGy-ZyTisd)C7v?Hd_7D0D)2`G>OGi-$_5haEK22 z$b|v$AcOIvXBB+hLffb35HeosF0$reAjD9=In``>55A3tg{)M9QH4TN=4Z+ls;tBI8l=!3!7WK=a%R|}JaTQxDg0Y)r*BDz z7(-DBw;<%9$g@w#VN|SR*9#KeRG?Sncha@stlkdCL7lsk{EA6Lm4r1h<*SE5xEW?Z z2e{I_=d@v~YUkCc{8cjEn7u$wSHrm`K%uo>6bX}{f)F#@HKpPjS$zKCnhFBJhFJsz zmBKA*t*c5hdZHPe6D(Cz5SWPA4Z~9npxM%YI7Rg_+|exIXGl9NvTvT|;$G&=vV)Q# z8FUvt*Fz&N6Cb`ka21>4q)dvD8LlvrAXAGqEQEtU7jck2GhF1xw%{c}U5hp4>t+Mo zeShErVKluSQK*Ba8l5hW#6HaF-K3H3kZ()s9kQF2J{ERHqYw2LWmVY^?cx{B@4tpK z^ZByk2K98z{C$zlf)78MY}n)468&nik+r_DD-A&!Kl^fPzhLw-W#-+GYW+9tzi%_l zdFk7H9)ER4HYLrtR7BoMvE3zMGJ-N5QwN*=!biTHy9_qIKSX6)`6GU5g}E(n+@$@f-2q*n~h7Ir-h4b7yX1 zb-B>0b#F_8OL82%LNe4ReS)SR59cE!ox!-}j;@pcLN1yh6I|a$L<-Uzh-7G60B3r~ zir?LP@84UVl~^KrPM!U_#^}(`FEP10sGfywxb_%nT4h)FtW?v{`*L{CTBbzdGdSZh zCY@}W{rb*Fi;r~t?U<04>b|H9XENRFf&+`K3TIy zey*67Z%gdI>)N_<*@>=pn55x&mv8#{V1);Hr>33e62(!bIjUfZa*Y52e3FKB7J(97Ldcz{y>ZV$j z>X(b;6@{@hCzM!NIvu3I1dU5nr2x}9VfIFCf7f@we}9}geXxq9*0`9G*9?_zs){)@ zcqxyMn?m5!af%gJbM<4^1tG&(f}RaWMBAY@H0}cspncis7zdFfS$H*pjLaizWD@CiCRup%TyzMqrdqvVGUT;q zJLzdQgD)!4hCaIIgqCcTUF|e%RiIei8vEu8Oh?`>Fhn&05;A6{`z&Gxa4$_<^`}pw zk+CBEyyiiErxF5$M#ghL_nA>SM5Ags5dcU5rpd8S(?*+GCKcsX0UT)JK}m3`E2D^f z*<`;o589Huul%4B_Q|`3O1 z{fZqA21BW<3#wWGoYe1*5+h{7db17Gghb`$-5SuEv(_uVW9eW+rxY|zH_-;A&wXSyLoM98d*&9Sj z=7lpXoDMzNg9Bp;zMDi3&YKzt{p^>1(Iz8JcW|#kTMQcW3%2m1Xd>J2>MBV6Es|K3 z8zG+nsIgd^gU;YCzswXJBUz%RaVg!}{gNgOW4gAW2WqE1&&|*ns(VSG-!P=YmU%t~ ztWUVg@K6d)xx7tYd-&jb2K)dC5h0I4vEupg)Dc;~=pzpv7`*w$=xOn@VK8}yJ$iEg zgK24`>_EFae4q7oE2Zl~`*HKXn=e^(TpIrM?#X@2R3PwF5_+?2&6&8io3RTo z+-eCv@SX9c%3956joXEDrv{f?Znz|#IM#&)DMHHX?{iO{bcZ43RZDRk-j^rpir9j0 zk}t`=VL`%ne%l76q!UA{c2AmETIc&HxUJI7y11hOdtfr)RJvmt`}-Szjvb3^GL8HF zO2kO+LsO@+(b>k)O~tH_N7Ir-aJ#e5+}V1csEDeKkzCfpn}!c)(1J!E{AWzSz-eC(J{Yx{6feaKdSqu;u;giA?#$3p<2O%pCr!2)0Z57{>Qr$7hOP3yJcLc10 z&*%F@9i5O3c!|9*eC>~rD6+-5{Z@bd73#=@kj(^f?=^*;@ef;_NNe)>?66=AMK5+F z!rDCrh}GJ>TItaxCtn_!a(|EjdLU8qq$lN4Ff_CVXcbDU$T8+4JgbfXj`3YVoxZIO zJzSnjF!h(nc&R9sro$(b1}~&f^kc2cl6=ifnP3Zw9rN(uTU@Pm5o61lPFE)@>&=0w zPsl;X``XAR>`?(hs*J_DmoL;&vM^!0`%Pbq%lr|me3B`oV?4*{04WH80Ts&Eznx2t zkNtFGow;$B#UW8th^Zp^;M0lpy5$zXf7-mb)A-G&zs%b=Am<)8`k`NII?y*(;`G9{ zx_IA2X%5|YPRd6LI;m6yMb~CvJSQ41hiQFMP|UH6>Yeel=@}kkbG$4vf1*H{x$Rm> zM`hbj^HqybbKIvlb*FiPC}(;qDGuMBe%wa8Ku&yw$$yZitJAzw8xF zo-*6{FO+V|^C@VzGeREwDrZqMJ9GjEAg!ThG-vrDwx}#*IUmo1m*8QiEVxZxu>+8|3(AjRF9n0GyX_+ z&NQ3R@W5g}$(4P{xvzxoGDpB?jih-$W(ubsZ zr3B=U=lic%Bbf=tWTTXVDwEBFV-O*dsWWd4rIx<7`+|%@I*) zshr+vU^!b_Y+f|Fi^jFn@qpZ>dmv*&MT!EioC zsPun(?N$2*Zk@u6SS1_`hjolLsS^zI8lZ6nAD#=*EUHYDSyymNJzn+RjP+^SouaF) zfQl=uO7*HR9QDtX)Z7QL@an+e6@h!WZ+eiDHop@Hrv!XQQYxgIkynh-dobFTPO5R? zPfaAPgWFu#C+~1<$^;Kd+z+a>l%e8UxSkMmdkW!%+S%4$P8j1V{21(Nl1pC0~jksn;sJo%eh>XWO z5BQsX_8zaSwCq%Pf2kNZ303P~_b3Fz%Aj5}VM)EkO%^-%lK(g`W}b}h4ZA@AC2%M_ zyQVyLsYdLZt$$nlx@W~`EcUh@!_UDQAE19*t~CnVJqQlMK{60fkcM1(`6#lpHB%X| zm}O}^QsO0;sN!6PyDU>!OzoJ>F#6$ci(|#y7OUq!-I1x;^!9Di?_8LeEmh`$dmEZg zzK8-Ql(UWBP^9P}uRcJ#F6%S`~iOffz#qetw}nIp8`o;BRpT-lG=s&`uMR`we zmok5N-B@)SBi!17)_NMzw*%4V(w=jbLTN1Nt00MEBf2p=kMAkObL z-?nXpiPE?sFh@*dlQb_xs`2{m=3TzqxldJcw+YWHBaG)(+3tWarl#VU6LuH=4sz4{LCs82XPU3o-7C-dcM1I#t?Dqttrq_6^ZCy_4i(1%t zZP{x2?63m+#sH4~wK%87&_dT~&hNcR$gi_;SaHGNz@vBt8U2fNtr_!hN|TpG$sxUh z(vBZjIC@aZnQgP}8*rd?A(Z+Pb{^ABbGJ|3aB=s@eIN~q-N7Jh>?vHHJ4=VHg`W^7 z{qBxlPzSaV-?o$bo`xC~5Yjb1$3=0tdU}3gqD#_r0XU796ZjxC-8?OZNCD2+lRSBIkkkKAhY_To}Nr zQYQ16G^!blk(We66tJ9d?Km19jHYpVNu52voI<81ZEh+MXl6HeH)l{|2Ej2v#8$~wVS*O*-s`e)mwwMyau;!A)^j~4jHJhJMB8Xb(Uqoz2YE|7vmX8 ziFX#d->4N~yDJ9Dbdvr7xPO;JFxR%xF|{5gekvIz!8*}bu3!_+gJ|JtLscjv5Wlpf zUf(fslm3e3d^-vhOQ3=dkm)$>2{=Q0MsYvSJ43>jcB*frM3!&O`&H(p`~_; z`{R?{Y6Z&pL&Pn(I8bENFK}>uc!MoDMvSUNPr4|L!-M<^U8qoE$vnx)d1^sTNF(W9 zjVd}`gJ|U5t6^7y1qhibU1!d$?6)Nj9A8pTWr45c`wnwwmlRt zb?#2eJvv%DiAGRH9-CoWja@Uel5u{)*|d<@T;8F-z5^#U&#DSbt;BgyoG@OAO7ncz zk3c9=Mf)_)SBGnrEX(KY+{sI<MB@_&u66|SfLn*D1!mzJ|`Q&6O_1qcf#d^fwerE%T_?e{|cR}A%=4JX1zNVS; zTpA%V2r_^hRTy1;pbUfsPNnt{XU}s5e^Wo-gX*d6f_w78l&%i4mspayR0sDTbI`)l z_KxND|HIUEM;_KWU z^YsaGb6ZGzt=GuCD#wout{z>pEJ$j!M+bRfD&~5F5X0&XIqHlVJrbhbexlm3}^_#R!O3BA@s`30Vz>%sw4|8zId(Mq9C22Y`Hxo)v9}T@P zgVr2ASo&xK!j4o^cvZUppJQ&Rti~jh`L>ryH4P@^$(GK;Q7_(q)Fjw{-&cCLPcTtS zi8*4`T_gPgS}3Z_r?q>BHMd@UG%h6_uf+Td1@HWF=;ag|8xe(+`+SJ3O?$8~6M#M1 zZLMh0c6Q~|NaJjds>sv&bANK))<{jiD(=l`Gqmnn?h(75L8@thU8&>F^%T-jH@&Xy z4ik~;tvm)X0%;}G=^}L#Q)B}biofiVYQ+0w%PC{Zrb_|X@U6~v{Ikz%B-JhNukp^~ zYNWX1n(2@|^HP$Aha(3DlQfh--^ggG8}5O1#HXD#QWVm>uC$1Wl9Ejnx0A6~34f;M zP$M{&N7Kl4QWAXiy?AsZ?enWUQWCCNM{W0g5Wq2MJ~c5Qp|@jsxME%XxutJj1z_9E zkteXH$MTYD)UjaHv%ZW}BepsGh9BtsAOPgIy|Di+T)c;o>~T0UULT>Kf^m+~eqEb~s)z@*n_`eBdQMLrF;_pTK?^Fi(BRb+Cwm|X@JTc+7%z|D&Z&Dqc;@7x-e3g@43N%fV zAnfx3eFH2wVQ#7J+7vb-glRI(4gzbEKBrRJ8Bz8%Qc~P;FFTS$rj(3b{kFOUUn51f z@1|=~0;v&9N6jZ)CWtc5fyH{gekCpp)9JE;83$s-(ZT9#^1i-QC zu`kr855fP`?n^Kw)kqxv{VRMc0%;2UuOCN2Uj|S=Ha{Elj`x`lfX<&Ow5*< z;mpl(9*zV@kN?j<|LPzsVw6N~?{Xwp?pl!F%x9 z*)uLJ-^6s~DjeSCD;HN1*^Rn!lNXKd?f-QEJCG9;92vE3`;ML8M8_xW-ItiePZp+U zWM*aOhzgDt79BhOgS4!?;>5{Qm8X?8wHj?*{rQFq*MDld@$=2*mS67Nz1QB++0}ht zKQQ>`(8EW64L=<>Ogx*MdOrPPZhm2L>CM}B??3#vE*OOPU(5PGEBk+}%L=Rujzl7m z=>OIQgJ*$XgcZ`rk%C&zia_rXSg-bw7-P4TR$pr~aq{H7UJ;k}z;vZE_32l0|1Ir* zuI&Ha!t(!rt?d6S?EkK77&1e^z=wyhg8ZPax0*)+R-1v=fMU}7?A+Mv`@Z{Ke3I_$?U8Lddys~Bm7M2Gz30nqC9f!+*}THKBF%=N1bhBT<}Ho z5V0it#TRJ%!P|*L3ag(3p>xqucA<#!bJ1YH;}sM0cmTL zoSESw9_oKQ?(R*{PnDdk$XcYHZRLwI3D!Yv==1FxXfys}(39hnVy6_eAp~(QKCBbJ zG#wbx3zxmw(m{-dwgUcLHepM+Oo)C$Io^t zX#3D_L7NF-Eu!SL^;27`ydMmJ%@)EJ)`vat)vuAg{2ZsMmUcT#pn-|;Ewczd$oN71 zt3{*hoIqjj4&v(Zn^Af?_LHPa_$vJ7hKJJaumD=R;aqYGZ7ieyH42r+=I@N7*ossi z2J@0KX}YPQ6JP{qErp5uFz^d(nmq!yh~CXMae6FW3pQC!h}T+8%)|$T^tY|&ffY*w)K9}h;T>*k3Eg3^NSUNDPf$R{89QH`~)h%r9fZO0|qc>sN(hiKm^ zIir;y10fy_bmaaEeQ3CC{pq}`31Ab&N3+h>t{X0mDo|OSi)Lz0CX4EkKXdFnnWncd z8~NPCLYoZs?-pyH`?-M$i_YM~X&zBBefrpxGMv_ty{O(257aa_qbV}k$<2$csXlM( z-~vSsfP5{~IuX8r(3M0t9fGj)WC#A%>JaTe%P~S1l+;Ii&OB^&1-3%5vD*KehJx~? zdU=jr?!u5PH{87owE9fwc+GTJ3~a&Spq2=yov$ntaMueZQl)6&n15+fxM=@|(X-Q%tl9>sbkNe&G1AM&{`F`)u{kg8|eHHhphovILqS8U1jdYc+ zTg$wK70r|H0}PcZp+@Zc`%`H#wvkw#kM{;}2}98aJ6bhkJ@{@5guNH*x|1eyTq!n^ zYXwk}y!hRcArZK7(sD37qqOB8FsfsTpFOW$SZPFtY;h%JQ&8>>>kMa-aW3%QJHF>z zW>0XfKxt8SJIH@H-^2OMYiF(PN@qaMg9xmaofM_Z(xYFhZ7ixT#TAW;2j+psVBVm# z*dJtJLKK40&H)(>EdJ&c7g48oiS}DLE1=g9)t(GDRKpFmrQG{s|2R&N@mKeBR@*0G z9&vfHN^!0=_B`3GD$yE_`gb=K-sX=<^Z2lQePu;)T}m2eIa{+}eOeu|D%uIx;UtOI zwSZ9xrLhUZ>;111XikLOrR5laqETc- z?%Vry!677Zgr}IO5)PL#cY+3#Odwj|;;CcB3Idd#7gJ)8u>hso&)l@_+rkUD0E|Jw zM32wOxF`C`kr-LpIB3E2sd_a#6SdBRL+#wlSTfw?gltJ}#~5Mxq*2*dzs%1R4OZfS z6|=>!FB$fLVjh&~MvFL(Uh-egr9;J|pZFnKH6IoY2Rr;gFG-@8?_ZCZkUflE(C!M= z$Ce|BWxo}7ET}^`0wORWz-SW^VVFlO@04imeI_c==vsB`WG5!+>c)@UzrtX$Q~;QP zfiLoUY)qmDrRT~IMbgvJe!dY$yUIn!D^bv_etWr?8^fd*M(lTtFDRWCCeAo}fn{=2 z*#GXN5stW=G(!?2L>)Ka17;sP8d*FW02+Ub+)bUoJe=Iop+~*!3gn8!FKQYQ#T869 zSC5wP|4acx$^6=(l|(JMA6kBF2RqZgphv|r58ENwAFa!6Q3QW1ffkL-D^TNs=FAb{`G#X?X!RG@+f zVBDEzX$t{FRbcAtf_j&q>+YYWrbBA5d(2g?-z?rONEc1WsFWFQXCPAU7Np?53?tgY zsAhRT#J!GtdWyqb6|6JMB9n$u>vH|-L^NOo;UM#Ad?zkHSL39ps-^fdtT~{MQ|?m_ zI@NCU;*4qpBTv+y4KEIN4uAtD!?B9qZCa!bB}TwY_hrcYsUfQ=Cs|60()F*$^P5VE z1ymW&oqLP`Wdoma$K1I$t~_voV+pGW48MqD#!?qF+x8S0%8o<_O#s{vwWGa{ko(vp z(jfV_sbV$Rrf-4BZw~y8;2@94lZqq1EE8>2(q~z5&GpwJ`?uwGcTb$JE+=T4oHo|e zOL@`(E!9@UuBdG*Y1;Pv=-uRniK5{q1R8h`w+I3}MC(7ST-*W`!8?+ zo+!Ol@9h{Xo3pFo5)&|=Y$tV*A`tZXdfZ!bNx*~{4$zKK`j7~oZS4U6`Wb%&)$|C^ zbd567qyS39eJEY;y}i0&tr?U#DB;%de1Zj*pAogaR-Bq_D&3dHAlz;vKtH|frtfXg z;=8Cl^oc7A6w7l(0iQY@iAa*nPxEFhMWO$G@VpW$aF1i-7>!Qm^Mw256>>M1FHP~8 zsG4ck@{?Xlk`QjFIUJe2Fjh6YMpijdKrEzvkwpf;AGekOd;pX0 za;iA!WdxD6xxovbr!uF{oa9eQjeCX_cMlCY~hGZQ>I!2*6~#DnNldm z8i~73R*mPyuwoN1%4y$Pd>0|_m?6pEXk{W8A+=6L*69dD1QTy7jU$OO*wP?}#teU{ zbm{KtP=jbZYY4-a3fx0GDeiMC))0?DIoD8g7L#}{HpGn&#F(Fi3ZO55k7@HY(5#SW z{MD;x>5$~88g8q*UpYj6(LHX2uxVigZZslgcivtrTMjl``HN0f?w+Azl_(Pd!pyQA z_5S1}6m&0w*vBZ02#Gxc5yYA1t2=g&jF$>Ss$0Uw!O1@f3tbd~F=N3tSnqA+yJbT& ztVC9u&sx%}o?b4gR+rtjSHr{EyH|BBUw$2hS* z@!ukzm5L9IJ^-ZgKQKvji~1w4;g)dslisF6$0Xz&iqCs7k+t627Ua4zl1NE8)^zn%p z-6R_y3KGhBm7$D4Bp!=Lw>6#_rtl#h`Ksu6O>hd79Q{91rB!y(D>eBDTsp8;ypr51 zc7P0!MjCrTWNCrLLyC;D6waT}i-Sdy1(kIq+G&|T9+OMy5^Q}rMSxUNOIc(L6mVmT z)alk)U8ht7ZQ$td(t+1i@?%0)2Jm@-7%%JxTj|MMhpHV1BL88B<#xM6>l5mKeTF#| zidMc^hbx6Rpi_GTMhsiATC}L=b!7nNbe9`(5(X{_p<6Q)f;1;7TM3uHA!x6OPOi5a zWX!(xN*9bPBbnOX-s|%xbOtD2?7wrZ5eMH3UA}t?#8*?qAwhp3xP00O>rTQjkJ>fw z5hHODzPBGRaHlPD-x*n0PO^2zp{aS8^p{c53e$^{d+C{ASWFLfHXv&SoCCN>q+J}8 zPJjY@MLB$s7Y?etCKk8MQ=Na+AvC&#X&vf+qcGjQ-Y5y=vzL3{9t;9l?Hl1 zl7jD@!$pVTuWy*7^`{XiT_hPIP9VNgrhB7$)<48c_loRCdoVW zBV^^_;?Ao3@+8Zjz2~1vPpAm=fJ?IL(~g^4D45xBghU7sVuuTFTiG3bg7ysSsz9g%N4M3W!x!iXNNg{!*ts4HT3^L3O~!wrd`>IXq> zbw%?@h5))qb#{wp9KiN^Lzzm~RQeAMJr;zT?RUiImIhY&o6Hrzy|#-=M%I;)TmQNY z-BdKcwAz)@`_-7GC8K9s4jDEbI$AnMoQ7f6fe%Kq42`-&M)u}Y_CkA@myQPNg zBQD!X980pL?I1*Tjux3K*mWWVWqUac`>VSVQ#8zI90!-UD~Wxs9!<1wL;460?zQ-N zW08V_HazTM!^_)Q^9`2*-V_|Qa1s^5cQKy>l>!lYQfp+veJ`rbfPl6^CqhIj3f1s8 zppqH#&6zV)k4T&I!wRah$C}oW6fDvHep$9H99$?A#dW-ctsf;_^Il2zb0E+Svi&0- ze>J{7RNNw8&RHOL>SMsIT2b5R&Y7rvEaIDx0@W!F;jn9K0DRwy?r(0Zf~htSpMjO6 z=b#m^DFj|7WRE_r^0M}lVa6sLWO6@Vdx}8I5Blr~{Cx5xwH|&VaxRn#R^H;;NifyX z>MRHKk$~SymIM6gbRI`;62St8&@S(4)nwf}a)5bPuuYorkp`^+%JWNx46=|M1u zrE8-FrgYd2O+d6zz__QoziEn{R?KP$tbdt@eCRoK(hsxV|W#D!2t!d5}`tz3y zONPzuR)hQr{VItUU)j6Ot-cU&)oDH@>K#(5<8mJ@>&gQpgCGQPkjipWsn9`w1<&nJ zQ4r1^ATABk^IhEDUI_ZYOy`@E=TWXtOUf<^Hl*bp7o+5xh5(qPAez`4*f2@Ukfot5 zO`Bn0)O%ZxaayO+|1Xb!o+dJ&ee%!2wQYMx$*tZKMQ(ZgY;`vkGtTQIu0tdq>;#^) zCTzwKb*$*|ez^!RabB(pxX!|If_G~NsvW%jV|Np7nWCwhZ5drIpZu2-mQHxQ^ax0s zpTqXZ&vOv5arr@pimnV}(_S175n?#kMf+u)kNwi;%cE*M&Uf%!lkI@`eOA*)#CEt* z&Nsi*(=*3pBF~^dj#QvP$A-$Of(75MK>P_^6+^CJLB?vjg`SCuUxGX8%aOvtns%U@ zeejo+S#16M6+-ZF2ns4IUG_E-l@ zTftR#04iXazel8KvqH7AVR=FsW1T8h(bnL!JwOpfk741KVs1zh)!V-BE3C!OYi4g_ z4A(+lL?ZI~Jy1SG9r?Kiu+8r(Gs5f31)`*1k|Fc#l}pd7>Z%!?koSt!($c;>umekUf;S@aHwPGnxXdW6f4etmXc1CrD@6v`+#{uiCW@g5~(V%31a*=3PSs6 zs&5*q%YFyu7Q3qbggda&@}#*|R(cxA79JJ8e%qRtd?5b4TyU%ze7@MOiq1HnavBfL zfKK-`#C{v6&x3od<-oSZRuj0i#D7@K1seyH7_%HRtH^2BDqVy4k_A+TL*3CC-k!)1 zAmT(zMrn|YvtocIq(Qs`v7X1=^Nfez2r`Tefd?=>Z@PW%c1ABVO=KJ?E@#?0$vbmq z`0(li8)qqfl1$WEtE;mT;d&+ zxQkhXsxOPAtxJ!JMzu{lU#}F9Prr93+a^oi&&4&4Rr%xqQOjA1_g-PWjNIu*{}YOd z2(CJPED4pD^!|sNp~5rUOvjAB$^mw@V)$kgwAV+@PsCc^S?CFu|IVg5!y*$D1ywUb z7J7Mv*9Bl_@Sj0KfSvRN^PT1g^QBj&M{^GLwQ@8B+ywaSbaU>=Z zj%}#FiMr@mY5bO!1b-^kNJLA9Y#rF*^chYXgnG0crM)VY;qj5nS<0onjBtCgI&d?_ zU>;I$JsSk(p$=yucmq(B?r!T;Gy6R270q{73`lS?*!IIb24(q-12pU+xz-B7=Mp8b z!CKv20pNihT z%?0i-s2(Sykol=j<+{Y{>UkS)@uG8r9G#_0VG=NQ%`{beOvaIyX$ap&z7gC`-<@|- zt-FTG)+;sQ(6{p9@WZC**Ph8j~uKUla(AOCbEm&pZbt0m4;4E$m z-xWrT*gOI91zo_gmLUzV2eT#UtZ_HxE%TQvqjpB86X4O#r{#GA@kuu$jwo)`!!P@OOMdP2 zZ^n&x26>iu50=0-!>6jltvsPi{l>CEp2=K-`Lf3_v5mBpk3~V$(LrMaB`pY zAQ3-U2pnC-bupmIqg{CLX*DJj13G6x)w|XgPtS{~a$m~hBe`JB`oP;Fg95`%rP23@ z`V_ZQVc~#R4l~Qaw40B|l^#tCar^hSQbsznlPH~0(-6jM-xx6_p){Z1a+d0CGJY-- z_-Aw4&V=6?5SxOM)cEmuMb##0Gpt_>uu-ptr2-wm;Pr{&rXR)7hp?6;aTam_R1_$A(IikN3R$ObnvAz-Fp7St$MC$?4TZ0!PQ^-+`x ztTuw8iFdVEpMLv`DCv`rZXN2~FTZ~Ix)@*z zf$M59hunW=$?XL1)kXp~5Omi{`-TZxo9n z85R~8Mv5rB;8bp!9c|f$7?M%ywQXoDEygp`0$Q?wncBa|uDNMr>gE?znqxEF_Latw z3sb?(;z)R}&%nJ0`X=094b&dZOS1ov)`YPqPb9!JQ$t zg??FMR{|!^b+(dCAn+F@PHF6-Rd$BAi8AXEg>eH}eoI*@SRFHW5>Jz#ZBbKCrmW^fPr0ASw{ z2$6EYv??+#XD;!NW!r2A+LM=z*YgQs`S{`RbzKL)X%jqum^i>ket``nnEvmEe5}Ru zrS}RjS@EJUtAbEn8?^I~ZzSJKir@+l$}NEBUeOnnP+qbt(ucsd8fR6$O&@PYmpslG zMh#jWCgbvWh1B7dbdpqYpdA7B>8}XT%+p$3+`v_*0#tny?!?iQXqvPNYQE!hF?ir) zJtM~!1z3B@7))i4YQdr)uwu8ugvAGY@hY;I*rPcwI+kGrBRZ$hO~7amzSa1(t3sTl z6(R14k{54%sPeg6D{zOc+-yVlGy#H1mZzj_)!p0 zcBs3xkBfS|I4+UQH@3pXIgZQg1m1pzCAnu58c`b8`r~!TOd+>++lr%RSaG_RM zpiIp%1PB+visdkQ%&&E7G+3QJt@i$LpGV?B);EUueDKx_WjZTzR8xXbi}Z`<rT=9!Tn2GU?&1RyLBt|+?8?WTe(!&Ke7KhwwsqhnIip{e)@||;^%I#>+?Np? zD8S?EnCc%ar*e8fwE!m6wvxY#W=FP^6E^mRYy2Px(H2#qxD)LZpK9+!+m%T^&l*K; z310rLQs!7S-OK>PDLnhw_=39qX;=_{Znz1{DU9&kXev@%skS|>^5~O3Jl?SHJ(?TG z-sVC+kH9vdePj29iHzB<-2f}_Tanx|SLIZ;)`sC#D1!PyrNcg9Z&*PBWv26^^vABX z%|(Nt`UiP&UR$h-Xja_e*K_I!QxnZWN_0D<5j6O)2kS=&Kl7q^eVJn_!w&hqstLu?6(NS&e zQD&Y2>Z0f)_ICs~U+ghg*uqEy{cvt%wyo27wx4&3=2HdJy)!~HbuT&Xbdv?7Ye7gc zaVQ&*k;;C%vTT7%vee`9()6oAW}Iv%1fgCBQtNLC!+gm4Q%iTMb&p(}Yt3=-;$l z%V6bYKrhQ$&;V)|?S>{XJEoH=TF`n}A|ZS<0Pth)#yxK?F_dRbMSTE!md8&*-2#NQ zfUFe)L_1@$G$EhRk@+bM)k>FYSch$J`dD4IFF)loCgMol%Y!#T86(%)2?e@Kt6oTs z@mB?;E=UQabzpmZjh>Etrgx}_E9S*V6;lMNXxa;Z1&YaILLV z6vhsYmtgXEYZt~dv35P+6NKg8+ag-~SL6FR7TL)h-&iKXFOgikB#Qxa zGI+FrYpA(~%3xSmEb^t&o$$h@t-19>b~VTaUTEK)8y9r4;n-rOHx-+*FKqYj;MyO9 zS2Ognkl*ze$HWoREnXu&$xxNgr07^j3vIAcj!6@UYn*ulS@ri?KG8o%ci1%_5`Z2gAAqsD{l;bB;nlcMcBbVvdhd{i z86`+Tc4|T%KR$^8n~q@Q<2`TLdwpXgm-!20O@SUwXk`+vqLe51Nk-S5L&%6W_R!6O zyH!UZDSLGX?rWl(Xh4z{$jNEwVq-w|k2OTmLL$pteT!?k`^l-C6~bom7gv+LpGgjV zKV)MfL%81cX3ykym8XBS}x?x^XKHZ2lld*ekEDyhF_cNAl*l zaGcx#BPwbqaqse$N=Z7tkSz|1@dPQ~`fH->&|cipKcUZ{z0xO|AC`>Y`9_@ic0uI? z7BZWU*e%+o56do9mI~>nOjH+*YS!RQQb9fW^}uOAP!)B+TZdiFGrR>Xx?4WY##5k~ zCsZMf#GMy*lHq;AC{qFGrSb+%Kyf3+>s>dU-9a@Jtr)ECo-L}-OLd}so3Hsri#!Ia zTgdXfrGBTKOpAJFj#>6)FCMh~LMyYS6dfH9#Hc#Rx5;nQC5$A`t>nC}DdbcRCeK*q zNvZ>HI~U(wb4pYETm%P>JUy@RtrasG#VhA&%Y5Hh7(j?TZ<=y}2*CsGumY{(O4V6s zaUswV%f880B9I_o{lzZ_+^7?B1VRBuEb6r3R9b$6O`eIxJ9K2|w8R(_aBQtv1@EN5 z2Q2<-C-+3Hd4}CfYx7>X>`s7n+bwOhqSdI~4K8Me^`gc0>FF~8@#Yq{-6W}C4?Im& zHYisjZ%tIeK|Wub)G$%Lj^ZmpAr)GYa5_pq zj`zkE2F267(RNkW0XzW6uc5>qxUz_^%8?oE7(->pH1BR8Mb8if!hesy@l^264bmSm zvZ7jbZ6R=Ftm|G1S{W}H_eeRig?IZZ?G5lr;J|em-oR)~%P}`?C!|2@Uq|gq6_Bh4 zpO+&i5!bE~xX`qoTz768fE4jY2aDOpYvfFQixYVERt3Zn@W`CFBzY5LkfbrdPWZv1 z!N`J=F3)hVfZYFODKJ@NVex-Ll*?j~&`>RAOs*X|B#!3#p8K0`Or&!HBjvsHKm0NC zV;9RJ&>O^pZU~#~8#z(STo?2fs1zImcFk=~>C6vm1trtSs+|Q`Ej!Zc3N- z-d&trwa@cfLem@wb$uwGV-4_^6V+i)hJn8T_7e+^_Ey6I?n{y$T${ps7wu$<&nDmB z;HCIuJJZ`w6hqQE6`ea^VT4bpEW-dSINeF0`-&jJ!pu`i(hV&JRK@h@IRj_W_E*3r zBnuQerXzq(a`m)Ro^-9bR=~E?>ry!P@|uW<$fP$7<6nDpsY0@S9RIo`uXtVq{G;#Q z0LVoRR%A4kzgJXYiz;wkKdvBzG2zsC0Q~~$Cb0vp*6}z{5=t!WgVr+FMaKMEfSm+5 zPk8gyuw=+?MwMKPjms$I0V<&QIBDpnh<^Z4#I9rRIE}^%C}7h@Uox_L=GAGNspCA* z7x+kV(Y7BWagS-;*h6X8?hFUT7tlC=TBmJsPf&2ysr=;@;3ShQ$<95_oJ4#XO%y2z z9bw^s%NFh7-x3j2cn*ROs}Zv+`1$&~d7o|DxR_V87)`iAMNDTedL%yoE#lwR?~g~L1$0J<0)Y5x%uMYsRJ%KO88At_H}Ed z4n_ReZ+AfDa}d86Fk$J8ej`(18)pA9&O;tM$@!|VB_Xp+8ZJ2$c)E)K3)igpER@;cVa(4WD;!`g0zs6Y9x zyQ4#!L`6tj!oF|dlgLvyu z&H?z#NTS-$8yLO(oXrE7YFou%7~oH7)9*2qqzPF(N#jd-gxzj2S#+|x_l zsrGvn8jE~E1<^`N`9ev-C;q0SjlE&JxtuEZWHk0xBjC;*v!m{1<{_IQUFt0iJObE9 z`nX5$t1x9T%uXN{;^)=At0}6}xX|;6Uy_H7zOg3*8Owa3QT@S&l2}r&vq*NrP`*L# zVW^x1k%j}?!@x&$es99P+R)nyfhAy5k7cmt&_bu5Pdx>@e5eRf*mu!Mj;Rw>)8ic) zv0$Pq(?PDy7S6ey3~ZYlF8z<+X80&*P^r>_Mdl*^`UdGhVNl2xie35lT@f^X)>!#@ zFNQ!&1ophKOQY&tUp^iy9<1~<6mEf0y9mnvdjmQ~5VDFQ-L(N;hiQ|sEG0GPFQ1ou z4S?IsfxFpQJj>XyG_J8p^G3nBad``*=k0~oT@j_iDJIjwl_K8m{4|f))tY53>^omdPpp( zk7jtoJ<(NOd7zynWu6uKnXi*Dhib;e-o>S9Yt5T_F{ZI{ zH!gi%Q>XhB<0?g&F^aMd}PGvfKBR|4*h>8Kvt(;_$E z4Si?a1K=45>dHnM#@O1v3r^NHpdl}IWo3Ctkl<@O2FP(!uH1fu6RD3N`Te$=F1V^) z7=K4(6un7a_wZ%oGAF2#c^ckA&-C`zq2fIXMR8T9cbKt+pPnuK#jY-BzF$xK4&1Wt zC;%HRjY<|H2VSoj&^3rTRRTjF=VTk9x*#I6wR+01VmhO zYj^KPehaRz?q_Stpszz^X8v&C{&dlOttShjZ0g6FV1DE)4tGf2kXHJ zoVfkS4Ma=iZdX$2ImGYno%AKQa?~odeu)p0WjmeT<}oOJurgMCS3pz{#99{$BWOaI zIQ&ZrAJMW;S5_!uvQ}8ql>g%s7YDuwr_RW(dteOcY;_m6f!`B0hlcH@MGhKZxO)&>dKQK+W?9- zJ0wE=B_dU@Ta@IFs?oulybAf9w3L9({*lu%DaHN$9LQ-brspJO5VUpT5AS2--k zR2cNl6NmQwNufg(7wCcOH|n*Pa2Hr~A{LmnJi6pZEIw6#ycV7pT=qDZCR7j>O>@s> z=~V1;LiMfA&)SbR?Xb+&PdJ?dS+(yaagSBKfIWWFp@b_2N`~t~IUUnw4~_ZBFh+yg zb^!LJ2i;BJlHW;hp!-G$FeV?uI!Vk>*%6-cOjn*kkqex8yF+$14^mBA1k^skkF>;D zC8B6reyDVJ^9bM-QFVjl`5GIBDy2ym}y4ptvWxC{e4_jlg&c} zS0B4aY%IjE1|q?a6s>A>C%~THi-m2v zJN9IXD2rwQno8J4tW^?M%pmq+L*sXN{`Am^6C}G>gG9tlloxv=N{vep25NH5CELWTc4 z8|aDz3+FpA`~EuK*Gg7q!{JY>Z?>U<0tzTBuv2ZUHa`Hfbc>vuek%DnEx6eUsl@=7 z&!=t-_6&ztDbLmx5+mbL=8s2}Y8}pS?g?DDB9J~vO@?K|!oMh$-0;`nksh%SpL>;n zz_n4FM8+EuMXL(7B-<;u6ipwL?hc7PcWR9>2{VC}vLGE1!-F^HtqL9*_c;}$R)Nc4 zc>2RJ#eXDavGLm(xoRhQ2q}z1aVq*&luy`tlcJ_zBr#j-eScFqQ(vbO_LhaRL7xQk z`@$yTcYRDN7dQH0O~Jx9|4@l7*J9I9VBSuW748pr2`)COKYa(k494clcXwOXFMjL% zri~bhfP@M~)t^u*@VwW{$Ex4uuL4ZV&A5SA?}w0>| zsy@J4!6q>Yn9rePTYE1B`EHzF1g^7Txyl5|qt_d;!Bt4Phk85wI&I5FbhNM+E2UnB zM&{MswjOd~MJY1(%9!U|@BZf3AYUAjt1&me%HMJLA>6N^>eaYnG{Th&biS$=a~=_% zuCFjlh7Z6}fU+uRwdr0&tvkt$YVeFUWs*b_lWm%z=4k$z>d z0>46F0&ggU0I~tTV|t;%R`FDficWs*f?Xb~X_t!NtbkdT*-*ZzFBvi&%U1fVF7fRX zvYa@?fB}}y$gQWKyE1sV=ktwu(N1|VhiYm){UoY&CMxx`sNb3Lb&}H2_&zc}-@56G z5m9Ls{8SJho!QYxP#rU#U1uuDtZlQ3@lb}Nm-a3n51Ehyu))S{@Jw&8POyxYX5R$J zAxvS=7T6tFIG|1if$3!D(~5HdJC`%P$SVzQeh6iB*q)y9D6qFR!q5&Buswx#g>7_} zB+2`OM61cyyB5Z3rB&HFZj6oDm#dBU^7qR-wq@(J!Rn&ky*J6HeLF!Z4{%5ZBx(ff zX$8&VBX3F1FP-OV)#P!L&%mG1{<4%r6koO*5z`xX_y--w^yteC^7F**8BPbN8~Tre z8(WYwnS33FBlp>NpQVp4@x+W0^#?#kloD#c0L+eG0k<2|@8q7v*oZg377K`dkToI* z3>2Q)vc8&UIj@6^Jrh?_;%R=cvaZ_Fc<&EYmRY4UPGXp!3DpS~`D>Yw;qkxkK32YI z#Wv8vJ!#`-r$55XhEYv?P;1YrJpk>cfVH9joa&pouKXRJxO2fv*qbm(IBj3C-WFC= zERHa>f>Jnz^l z{=NlJzfmKKwOhbcjxF<6Zy2gGRAVFy+Id@~s|&Ej7~clRM0M-whE%sFT~QGIy6*SL zgx!Qo|7BYvc83wWRS-x#k0kl57ze-&F~lulYqM9e>^OeZo35MI;{w;sRy%Qgo z=cwRwWnFTr#=X*@KpxnP)?O{#0gbQXfrGC87Wl@FL^Fh;^S^a8Ga_pLatfA@-L3y0ouwgyL62_({ZZE2r1nw9HTU;564?R=QHhkprDe8C-vOWjLaMlMMSU_x>ra=qpTdhpT+I z_FCM)eX1=yLCsbGVMltZ`d)@z^AY5DRyooS%xR}YSz6@yHUB{|e1<(VRJt3K|9J;L z03n251R+~MCIu;Qr(%PQSUvCEgd%*(Bcf=ORzik(dy{{xzZOf?7o;3E;`|n@Ok{N6 zI=!Ku4j7fH)LW?H<<2~#r}B7hSqjfq8nPt;tooG46qFSLi-K)r0XbWtShYSt1LX%S zk33TT0b8eQ!Of9XYgMPqV*lgL-&K%zutH0 z@^|Mv&`Ou{ii;}BXt&uoK)JL<`E9;N8Iwq>T6=7v-B_3Cvz2y@BFf)~>TGFp!?*Uo zu2X7fx@Z$1qm}kJVt=3@eftfHRE*@_^2KSWuQ_u-b3e zH?kA|%f)UaTl~BRYuv(B{)}^b@6ra^3h6PeXYJ!zOFW=XJ^&s-QWM;_PG<{^2fIO) zxy_G?g6`a~YtM9BWhhK0uz1_aVh&?>GCheN^WD=siWJ;8KDT;5f{f?6msQYM#ihmQ z(>{yf;Wde3x*%U524||eL5sn8V(<10eTo3%#Ek(4UA^*@*}Z z9?Tr;E{@M~J34V#D`|4Qa(~bCh>^=_7RxPymE?ee%zmVgLT;F-;cz2)@A^Odhkt;` zCn~&wP~6Jkels90_$1qNrl6|CTa6mLVhZCL35UPv#VF|Xt6wFu=ZU>xGOiVjWC=>1rT>vv}Qq@ z`PXrD|>h#Ymp+g#5aKGF8*EY~G+u0NX0xg*n-9 zcP>MRG1e^1M9s*U;Yy#jU)@A+JigAriHZ*F|e?1XRyg!E*8S4kc?X!GE`-mh{|tqV%C21E<_C#{C+7H{t^ z!Hsi$F-1cyJGnPe+O0tg4bR#U{_6d(zkP#r&3Ilzx;^|<#`yyGMvLQfQ!36EIn)eN z>1W>F8j|~_AuQqY#^qjv3f|hY&|rjdLiK|hT_Nvtr8qsq${y9m#!UBT)qA7dxkoZl zFl$5(;<=0kpZHLW?P3VDS~yC0yYwr}T0S0zWZQJHX&q>5=>bs7{&3l?++!jcF7GGR zH4*HZ8dqvP8ZbG}i^@_M`e1u|Ds}l;veHaZ>3kz1T{`N0V|hkzT@wz(Aem2$nECp5 z$-N|{%^>z2NNlxMM)i{Syr_6*NDYZd@Rcm_$7Cd9SyPDix-wx?)Qg{u#hd_m|3ozy zX5zC~3DVtnGPuFbXUo5R!v*;YIR`&|5QxD0+%4)IrX*++H2%aKpMA`qs0bN!FsQD; zaZj}IuPmTkY@O_3D6iisu^9YI{IY;WQH>~yN)YOXF890pa8fI8Mp7~Q79vAlo@l(6F>|`MPj>JOKUJuUFg~^U*0S=) zD+0?^!WpT^K5Ywk#xkrNCfcs%iNh)LDt~_)b0bwh)TrG#8o{Kt>rk^@l%*J$Noc5= z?ey!8YksY}r6Sh&+%cHpLqoD7*e6p$aN9};RBmz_D8DqwXNy^JRh}NLop3LTGdP&# z>7wQ6QEkdsoAm0T_G4Yj!dgge5q@42KedZ zkUiIh4+m#GYPk z5YM{wNdMwMyGH@xr!W$L(WCVd(*1ode%?iW>`uR!q0-Ns?;+4Le0MkKGjv?@;PPYr z_BsVcW1)N32&?rv7MCP&vroQ#7j?vZJYZ2$(K-Lo$S+aa~+jWe9%W25_&2 z>>iEZWJc6Kp6904HmXa$d}knFX3q=u><%p+_PKykSriPx{{ZWfHn1~2LoTa0`#QHV z`kOmR?|(tJ|7Sxj@U5x0y_b6b_52La>o(?_XHnD|fLgyfbWaV1%i(o{s@^al98=+t zPo5F>;+}s*&}<|#SLaln%^-{*=BX+MO!I@e$=Sl#1Cpy}%0S&?s{5Z1o~lZGDp$=h zJ)F%$;J6qo&nG-P=jWcjaTk!P3Q)D8f=oz-*;K5jYHqBw5uOEAE*b#$CO)t{cT8fM z?S;QKEm#kh?MwEoad>x+1B3eGgxX3+-4i{=m&r2V3aOFiIwOWi7@pjJF-e3-3^@Dl(x@xf`z0wIWNQJl}) z+|yf?`?E8ltWW$LwrSoOKPLo$Zk4AAnI0o9uf;2rOBRxyCSRlh(d2;^RqPzU0RBnd`Wrt61R)Q63Y+s#YP%^IQ-86) zmV6kR4ddh`KCK4l>9v>44R#EFehExYz&1nuB(Yz}n0b6=h?FRyTcBRWa zDp4UQsDgC{!rE1nZThBNh4(9O9w|Tp6x)5No5T@pSG=>3y{1Uvt~6nt;Yz^I$Firn z0h@T|xnD=`{xlA>uBZ^s8G|)cI=@l}EGp7;OK|h#pU~~aLpiv+DW6V}m?ds$K&h#E z1=;}iQS?^e9JOFq@pL&bACRFJa^pY0?Q?N?6Lcu@3AHy6wYO>Ktn^mHcb%k@yYu>; z&)fv}0UyZc&Oij)3U0_ufxTgHQAX z|M5?lKiEZ2(3tQ>W#a$-qsZtPQ^oX!#QvB_(#a|T?Kb9jq2_>rub=!MZ@?XV z3;jwX_lypa-EZ8fs7n!iX{>A7OUGn4{BHL1X?_^VZ5%7V89Bh54QGS=*Ib=W9j<~% zwa+hj_ApwtYySi$r1j^M+VIqN)bkM^J5tE(A<2_uX#nYQ@wOr)cCQe4ui-T>3NP%% zrRFDZv@S+7b_>=K^$s-(nLHU}gr?3bqrj#_!-f53cIk z7RLdBrvw#ZqG8U~>%MOjaNfb+E%Sz-R^L(u`r{hwfu*1ASV`^~-vY64pg!%%U%hZ9 ziqG9D@ew}kX>|i#$kh0)ZL%?!3_dX1yBPZaJefXr7|twtB*`|DpFN?*3!Vg5xd-CS z;62ASTBpOq;qUL;99%*^J*$6zlN!KDe+Sl2lUKKTex>oD?^@fZPizX7+HW%z9h=H+ z3~pA+k8SxX3tSuHy@7{g+Rs6L)YDiMAKm5mFQr#I!>VJ1_T>xK$Jca)YAR;{OXcHJ zh$iB&yrAl$8Cw>+89u0Tg}5m>aWJ|Cc)7+ZDO;JK&Rx6}i{M5u8tMPLrV+r8fxG8r z;s{Ltl3mKv`@wrdR#pY#V&L!%4fubG&i;|<_5b7VnG9)Et0tS9IGFB?sSRUt+%1No z8#x`}#C%F-Bd=eTWPIPc7xK*IVw&$O~vTMw26)+HJOnllSqBP*ZBwhFnjNP zU9Z>k`FKRICPEXAxsRCdCpstYJ6=_Z}gFxR9dh_%+efA7s{cZPAZHitL3!-uXzJ8k2$YBqvl zWctQ@z@1@#3P3v~Syx=_)OGE)4HSP1>IS z>Ut$*%QlZNaL}VX6A(J!4}Q^K`D<9k-}6Zl4_7-LhpK1V-HY7IOBk+Z$)c)Q<_M@u zB863tD)iQRPGo;SswL3(oGrGs8oZTYi_wXn#n_pl%K+@oJ@clZD=@sLhzT;A7u&(8 z==C3LMKX zo0Exz(V_X^Z*}Z>buaeNjtT0U4z-_xTx)Pd7d%<0M8WU61v@N6u|(jLh5$5UPNvRf zfmA)gI6wPKO(tM@6a>>yT3Kp*NRu_g#QF|&=+gI6+GbHpv)G`F#jBD@T&IIE=jXfy zR_D7QYzyvsE^x$U>IA=!j`=M_7;;J{+X#PK)k+dS=db#u$?BAbvf>my9Q~y>y!++H z@Yon$3C+Yu|F!1|CXF0^hro%kLY2|NA$s1A$K-(Z_nhDow=F-lbghT|?`!^{_R3uu z@C>i0-F#DS-$kW;AGg@jJ5f;HliWba{c`2aA#WCVyfzpwWY%VQa{V$q7xY&s6I0PA zyc6%(P6X3D^;1+UZ$0V>aVw#BUd z-%4Gt+V9zA6R{hGom4=FwGg8E12cLK4Isb5#XJX zJvDU2Cbu6U3AKWADKKSzfv_mDpbS;qK(GjZmaUg1s~yY%9Agh}?eAsTXw=$hY;F;{ zP41&VEVDjU{PbdzzRlL`$gEz{I;&A}%n3CB-f84BhLRD%5uS|)VgZ(jjPqK{oB-Xt zF_^53*;f)YldPA0(alQaknl5T&oQThv$4wnv(m;*IASAN4Qn1b=7MB`7z>y)rxg9} zfJqi)LUR&RHh6OD_`Ty4yPsN^e(<`u>51*#xxE=%OymnJim{>zjHT(zKTiXy?$hvl z9_yT}MHO+0YAd#B77gDqNs*7t>bSviV3nmHI^EJm+#VL7zeQ!RloP>AWEy^BuaYF| zfd=(}cXs-k`w>M0Kzy_5&QO%aLB06jrX)32A!Q5}F0!L6IPs8?Ih%>#mM|A07`(}D zujfqu27Ftfq6AEx9?^y>YlLgJp_aX7M;CDW1U0@K3E8It`gbc799JC6&_ZUMR2pnb ziBeC7Ca~0Z2#bn`s9_T?j$Gz4jC8heIY?~Jo1smqiz4NO6N}Aq@H&&vwt1XJAb@Vc z8g~k0(Bc0Az?*_lAVU0?3r)`(v$%$y5S^CPF34Fk;e0I zj~gIo-K;DhXfl$xex&Lp8{9)$!F8z0Z#z$gZuu*M!7BQ%^<1;g3{XF;NrZa+mjdjDzB?k4w zn}*s;KDjxa=JrE zV)E3L!=?S}_!&mXR7xgZCHPkZ9}?U1!|=@t-$DrcDM%X*#~_#3wzGyR0Kf!~=Yc=5 zmr^rBh%hJyWBIAWI`FpEKD+}t9qKEh<^SE7Sq*)S5(ClyL6?0!R%~|S<6grY zzT-IBZ#9QlUAFCP)>JUkMEglrXqC0~J;nIh8eUed9MZ~es%p+}OZOa}*>)SJ_?2zZ z#;E*6w4p}YExrE=^}s~qI*pn<7ZXzbSWaLPlhIA;gPhbF~>Bb$yhe4mrvuD@A zt8%~MOZ}?|$yhcw^87exW{^YRrTs0g*t4&Z;Vn4p7Tu*!pcZ`(+{`yX&!BGiU=#1> z9a9v;Bh`qT>j&Q*XMv&F>$s$R!ZYnnO;o(KY+0v_AGG(J#jF0$ZDeDBpxOX$XRFVA z$OBgw-MlJ|q`@5N@-ogxvZMOpeOKdzTQb~L5{Dy`{{Bt8|FqDtjMjKx&vL7s*zrJH z?|3+v)<$BcMy4m}H$Z0l%2F;^S`sWkMhLV;PKURbl*-Y-yKK+x)J*|U7g=XUaqk?a z57Q^LWJD~U@2-##INN-xk&nvFekI%op1-ItCyf58952+OjV{i(AMTu>wFhZvHtUlj z;5lf+d{p7n>D!lvL^(edlL%@(NeumpKs_!q3e01KnKpyC8bz^ga)N)(5z$w&89~NV zgFmDr5`%ZbThm;&3?G@GuUpqe`PMH$Wp42Hx$A!I4XOba9IP)P-B4yLNv4Xih@l40~M^~U&dv4rUQWQs7)dC6ShgJMGSD2 z({ziL;s$qwN@8lPZQ1lfPx!E;eC|)t3pAM`^L1g=lWeFx{)&hD0)rZy_C5pvjGPHN z{&g@|=O|)R`Ce*;mSURA56@tDn(+fRQ`~R>5jfFf$5IPb-&FC5S0oCfbMjwa673tT zH3dOYWo$EMFc|PrHSkvL|3Up>8$TC!^SeZ#o)hfk{Vg&bY9fM&p07?d^kCUN(1(OBa7a~>s z0znqc$i0xLAamX`II0t+{KXi#0g~qGa-GyURlWl~Q_v}^ zJ^j1EcfUCuO}WZuv;7L9#O`lEf!JjdUH%ndL~cz*JT9SyIJJZbpd5Ql{t@*5LA%dB z`L_1VKOAExhP3YBlacQXvphuv({B)Jcw8`r|vBO}QMy(Q8ltO`yRXe>XcBbZ9FYjvX7h+zeU}4{|Qf zjTZ1mj`%e0^8YL!J~AumbRy$JtWxavtB=+p;N)ey&&op&lUZSBvbMZvPnDleQ=%1w zUB*X8N7D1ggZ~u*((2i@u#&;#I?28GXHQBC(WrLsf`{`_+<6*akd}?s8VLeF41-mm zo#n~!D;n!r&yh{8OQO+l6vWZ%*G7^tqDHeUC^rHN1de-n`%BDtNqJ1VJTU$req(&n z3Uk80sLfzhULZua9CM-Up3m2Lug#uN^i?l8+8sbMR(Pu^_IKZ^iQYYchAg$NPPTj} zp-^<8{#^LLxl8tzQfqhRL}dAS5KD-Kd1AJ>f=V%+A9PQ$Q)w-ZF4DBvT^TkLohtfO z#txGgg)R=gt`oy=xgTc~-WJkDf$VoR?YTYj>@h@K)K>*Hp{~vMJSZ7n=FU#|jm)AR zBnZB~;(;`$l@u?^u08X*PdIe7#7qOJVA1T)xWWC$DcG4XhlOD}G+Cu8j`jN3p=3^k zZB&9>K;>&&#AgrZC?RsFvB$ml@FZvlK+O3-U(YlAkSk|KW~DZl7MBp9J#fN$jZiBv+In+u#oOQzC0bUm1>tVU zWh5D(LJTw#XT8Dk5TE1R<;}Loje_cGZ!rtybFx2ICwOv$*&3ph6L{$2PRm*1JCR#W zSze*3nD2X;^yk+E4mxg{+vb=(%1i3WNg#?1AWuy(I}7XP>*C+cZ&d;6>`l0JBai@m zi~3_r{91f>27WShW5L8^sDHDfw#$PHMFDlU5I-`bs^rX0(cnDpw)h)CHnBPADFL*t zl|~|PxrVILE<8WmP^cOR#p)tDqklAhB0{rb z?<3Vqq#qAa1Jjmm6(npV{)0>pfWM!c^gA#;6&@u=d(@s3nzxtV`?VYJi@a5}9S;0E zaLiQ^Vo2jy!j3uvVK7xxLs;uPQ&rxhX|Pr1H$LD1qR5w;Pc;LV>GDH}iJ=nBO+v$G zUfF*xpvkG=#9fOI0H!jWwuIdB$)}>=W&=n}f%LJ+cWst+BW8uU1TrNlue=lHK~vO+ zze<4Q0iU}-|28YtPpX7}H^vz%YsCOk1KRGy*{j3&j&X(Hgz%n|hyB){*qXkYMQ4Mb zM`rp&rriFU-s+X)xRnXJQFt5m$|Dk)FL9H-(3mq*!iQlLarQhS$EU*&PT5 z+JSjbzP#hYJ9aZ0VFQ&`qo5^F`+2K|s6dN1HqFd2c5MpYLxhIEsn3T32^v4uzKjS8 zuP1~@G*@K%kb}=&71MgZzOmE}hOEXj@3pY1WJMgLbD0vk3be?%NDPhzf`q3^~?hyy8rBIgYkx9TmU3e9~vXVTQpM z`Ba1f+d9C|Y}Tqo0sMqeG~nXT;YRl3w_ zMPAXoo$=ZFiI|JQY3$@X)>+DOklwKTsRgl*`q+ub?Dzh}Qc0aKN9JnRDVkb!6H(Sp z?e3u6cK?-=OhOHRnpcQV53s*ir|F4+?{4)5ma{Ht1HiUK#Slt${iyPrL*F_BX zF5i;+%kU>(Pw0}9JKq5A_&;c`U{|KBB(L60 z$~Ebfz=bnmopmSxx!R_;to;XbM5&kE)_{P;Z7C=Dp#)P@A|kyD$6Q~P{laiv7iSlkw_1vMo=_J`zzT#6I?8+{lMv!~k32hTgCoglI0lz7JHkz=+ z{;DVR)ehE-=EY?OkcqAO%iMQd1jhOel?0y%H3T>tMz^ci7YS(8JS`{feOI|`OpY1l z&2;BTyoIJQ{`c*{%4;2eD@NVRo zN1!F384h|zZpTdH_Lsi`{r*z~Ahdtgg1yCNt6(hv7e}yQQK8Acg8qi!<$sk8J>pIY zGMBC_Zoec#q*kxK0OMeF&1jij2ap{bu_G6EEBknF)59FiZ;9oIzZu6Q*3IKf;QS>N zBWB2=L$2!ENMehf?^*adW~)Q;K#l)>(qz<@W9^kqh`!3sh<$%e7wt7^)sk`5Su*5B zY+jfFtbc$f9AQodnvl?7*$)hqD`@!@&EyXIfs${L<-7#W8vez1<;T5-Bl&>a+&?3R z|I*Yk&Q_yf0+z6Hv?wC!(*1E+M^flh7$ag{ie6G-|6j;*+|HF0-3coY{ z1qiE2bupVkw3ImAW1p$21sC|T428$?5fO|q>a7k$8~|m_nK#yVmIHfw%ULj>lf+R;7jEudGn5}O7K}zdu^MgODRWIBvsDj4Qj4jD?bk_;$+vG%w)AA z!ysDsF9v17KVod&epPD%<3aY0y{#!;JPR`Z?ZMq%^aGt5K|0YYeTic`pff>6uFWv6 zlgP!c)BX~JoL_glL((4j;TE|1Xy-Xn0T}pCidC?@B+Ee~tcm_+8{&?;Wh&xR?sLF5utku_%YHfTW7U%|F zG#zZk2n~quu1yyRHRNmC4hG^f*VXbJU=#%bhACZFr-<$H%{%p}pe?rfFB%jdo_eEN z!vs1wXqgTmA{YPUus=?Q9w@#5w9&U7c_2npFF-xJE5My;uFhg9DRQOLx+`pjcNDG7^sAJD$VV?H%hQ{^|n zNq@i$o9u$N`bG&3#hOfplo(@X+6=JA!)poe;dfzD_{@=x+3I_~g{uvIdFoz7n?;WA za40yAry$XAgGxVJP2H@-o|yJkgQ~yZOhU%v#@rGY?G^y|6_T02qiOO7HPs%QW(~ehhd2tn0>ug-=q_wP0VE1J2AWFvZe6SI2`t}%LI@hfTNdx5h)I;=;vD5&t39$J7ELV+) zi~oTdoeGA*3#ue=EDy+tm{a9_MOg>*3qA0>nIeX5?hk_I(Qv6~v3J9uwvU5}D`CTi zt~!+~sS*Dw;~ACnXHd|iuj5E^At_EHpao&x6$pnxIoY9wG)8(?AMAIO7jp)%9>-Hf z$d3WWCeb6`T{^sC{_J^?ePM-JDKAU*kF6!C!}?tC&-A zyGfWAwKZ0VxbpIWllZu!)m!sN>z`f@R$#|Jx?F#}q($fG1}hV@>C?TKg1|N2pP602 zW)NKoNFLAIHlmF4{>r)7wV?@vS&`=z1+x{#N4y^3tSIijaPN-Ya59#hT5_@s&ZW9P zPA(3m!)DR|QRG9sw(ley{qd+!-;E231KDVD*d{Ml*LqHiagB8^XVzi(TaVSvs8EyD zZVKPWA8<;G4&TRb2C9}8QZoG7T^W4EmD##PEGF^LwmcIlHSl9^gPme8Oc!%ze_CZE z#oXbbcfn+2?Ti&sg4hr;T*O{~5DkWhoEmqeCv!)QqOv|PPuDacAFX+P-g{;ubm-+coXnb=#ARk}c_%vvaA0%08ma(!}nAwfH8iPpt7#6VMMot$K`o^^Cf&ySjw!R596+){P3Y`-|E9$eT=ZEnUT_g!6~S=w8)^y3(d_6TE??cs#6 zek1_ItDrlMoTy%K1hkx@vcjBhAn|nD2&3HIA|wo4r74tlH*#t`)HxX%pALObHTw1h zPG6%@)sQx@^HEz2V4_^riG(-VRR`$2WDzL$6K>$EvH&fkCyVHi6jf=~W8~Wac}!2V zPKLp~H4V7;Knc&Tm1`$Lx78O~I$_UxG~4_G5P&W`QST+LH?sH1&ue&}S+s#&8sD>4 zTy33RvLnJ*0$;Urv{gHFe6S>Nna3@V_Zlc%v{np{bzS3dtkC_Cha;>1v-H+_&}NbvCLtA)&ECnilYS$bEPvY1KV^`7V=YVz zc&d?2fw(6;YXc#xh$k$jIp2b@K%E3cEj(<0BH|S53RkV;9hPz;xIx|mVnohdjXi`! zAL-f_4oH!5R)#!nq6=*^Bz1$^6+J=KQ+8c~Y1?mB=}A_8E{%5E<ySvdyTI6XNe5PmYsI~xM9a+N3GMSI_PY@*@$ zd1I4&0BWe72x*;C@qND^ZUGC;r6Q!S>5guudPqQQC9GhUyou{^#Uj}YQC2eBJlqH; z2i#U@fb0?g&DKGKIlkvS0&}Cjw%OV{xgDdX+g#q7<}gSkBN=jtEuh#r^{*@U-3%^G z$C(P0dd!96ueO}4RnjW7`_zI^pw|Z7RE!?q`7v8d1d;4CE6?)OZnzhB-KIzM3IR2tLqQ=M6c zz6See5#m7BYz;5bS4Q=})q+5=`cav{;ezx`#@1R~&RHjT41H0qyY66j+VF^;P^P$d z5|dmIZ3vxzB>dswM4FW*ZVH!B3*feVHgIAcIz~PF*KFPXeFbj@t`!V%93p3ueW{lm zHj(Qcw6_Tl%5rB^oK=;HZ-%ZaqsCL|#@ZV$wp;E3B$@e8Tku6ow4z$NnckKGb_E>> znFMlthh*_oH#Zk|mke)oDY25`maScWW0jw6F8vk&>oBfVY}zABP2#(TM*)Yo;mYr? zA0#)|`Xli?)7?qSB5(s>C{$;+W_kM?s)^T0W7~xn>GHY`C!bk2{D5T5-*}pQ_ZUk7 zm)PYuIbLPp=lIY>q&pND{?9+F8J z22*5T7iKH58#mrWB!5#u6ui2~DvcdosX@2-+fBZVfO`SP>J@L(IMoU!U)Uqh^dsZ8 z$D6ZPF~3F(YizT`uEY9CKV7IY64Z3gPxJ#nDgrX`{y~^g75-9ldsh0V#`eW}<3R5( z3sGQUD(-yEJEA2d-UiKzJesF!xPCihpekwt(Jcf;BKE@&Sr zYLzX}MrXL{l5koO@e(BmTAQiL+sZIRM9lw2f;UVfxh= zBLuY~143Og*g_6x)7YxJZWQtCJK$3wan*8?u1`{4KKR`QLNWnJ z*UfBhRI2qrWutz8xKqkvO1Dt}hS^VmPL%-Ei6077Q)^nVL8|kWCbOegA)}5s(_HHZ z%ZpMbhBz29W7k4HYEuwVi7HDz7`zNII`X4JJe+HqI-{JCc9vAaN!1%R`GFPa5McOy z9yZIR3zNB_Mu|=hKY86De8zDu*1lYP=_m|OJ#+z>|0dmh6? zv{S&1yloD{q=jD~$+5b>|68TLB6Z3T)gj)DdSB8e($+TH_-|H#oFB&k1eW9Ow?i3&06o6$S*l?W&tpf)Jug1FZtuv< z9a!gV{fE&I82MDFUUt~FW6?|XQFAjkLM-H}TRcv_xrD9#Yq{0UXSDotYZ^jxES0ed zbxz)SAkkiJk0@@JorQJNjL9y4TI@=edYWEh!a=X`q|d&_wbyAua9J#iv>`}_W!$gG zU`H6t@B>JG8;BYZgv$^ghmBtMM{jKYlar0AG@uw;B1oMwZ)ySWeetRkWEY{^`B3h#3jM? z*G{`#PEY;gCN+0o&`>MLhn+e6Dl&xp-Sb6E2Vzh?cnIBTYdtF2wS5yiH~Q9cb6>p2 zez$O2ZBy4yc&f&-^WF6)CN!eYIa^!;$)~aX03hD}JU+AsN)Hcj*csXsbEt*S*!3Gv z@368c+xLNdWVuiUUg?_8d|__Xtuw1yb-@aeOh!G6#t0Kp@3chJb+=tFS7BD99#QxW zUAqy!$|rk5F2?_ISBTLLT>0seFc0@3WZ#|QzZv4gZO~Rr>@rfc4RZ_!vm`B!Q(P|> zuCa*E3!16cd_4^^1H_V}|DD z`;dDMiL%&z4xsy15_HFPjW>Ozs@!`7iF;a~Gcps9ZE_)wLaY4BDzTb&7V zbV|$WEx9qLGY0|7Rbg`&@H-_ErZG&im;GfjWRL}bG7|yq2A6~JMNBe&qEB+WkRb9& z{2Cb?POOV32=mF#+5&)EbI{z9AuFC3#*Y?X=mE7{N_9dldTM+BH0lT{$?Pz2fP2}T zvzzFUXkX2UiS1r07>=CZ>9U02Rk&@=FnF0AtT7snssH6&@F91JHQ6imc; zJf5EN1uUebFd;q9xfA4*xj(W2UVqq}eF#0G9)m~<)Coc7+|NH)de>> z6`9A)h$`xd1Wsv?^~o9_XZz$E%i6MXpk@ORd%wp(Yv17U7bvxh)gdF`I?^-BD~@|E z`tH-%N3>ML8ajS34dt;{zEl&HhJfzk+zKEz?Rmf7x10>VfiWPZ%}c2?&&6uJRPm3N zxUP1oRi)X;boBf9E*?xIYuWB@@Fo{M8Pm?}WlhjJ{56>A-dT^N(mxHEF%|JM-JYtB zZ>Ma!FLR;XPHIGWdV6}dW!KML zO*i`_g)ba-l>ZduU}_Y*@5JkImu0UiMh;76j&_=0O~&$YyO!+OH^gxfrfIkoC>ezJ zK#en9r}U$oum$xf(4u9vzB>*msL-3Ekpq`S55PJP9O}kuZ18a2yNk|>xICA^IXqby z;j(<)mffenyOfs=&WU{rj6CxXj}xsMqbwkHCLw-KgPN>2b}A1Go~x3@ZZcRxW(p#B z%Cj=d(d+Ym(dr2JRt&p1wzT@Q>jMMEN&DlZYl-vGVXae?Ra-7Mx2H3yw{Kel;cPo` zLa4Iz&9ne0eXg}DQ{YbN=uC$QNtxAtoS=0a@D@ms)!#Z$N?H9bV3!|LDcMo^(Z*Tf z9kn;ec6CCqE^G$E2rAaCng6eSJ4>8Um3D6Cs_zhQroD)V>)teY^^TSvvmX%E2&2$_ zHaHF8HiiF`G9s#IP}npqzmKz`Az8soe=|G)w`nhXWoE_F7+v!sVZ$}S?tGIuNj%|1 z2h5Z;TmMIsS4(cfwfU-b9Ar>zQQ(108)_zW;7=gkVSSBS!>x*qTYL=o@*ffGXoPR~ z#lhhpt1_HhUv+klo|GpP@P;+I$fxhS$u5hsWp{GT^8V+x*UEDK&n|~{7k%3`)*WBFVM)bfBme^a(u6szudmx=+zR)O{&sH@peKtBS(jgjC?r7^UQLmLBabs(| zvhz=e`Q%g&T@}?#eDp!C3TOU*kiEcDkLp-p6egRd+#(Ptf!?zQXf~}SSXR6e+-a&I;D0syjjA# zVDH1Sc!0WJDS!eefL@jT>sztZRoCAFubb%djkiByCnqVb8|8lLhRt`-8t<8q@*XMrm3arlNEyNI6MO_E^r-&0z>BMdU%iAd6P z5~$a{?G;?&W%;X$d_AMU@GNJ+G_d_+g{Fhh=cC_cWZ|0spojeDWYEK7vGkld04k!) z))ein8RD$D108*xTA6C#H=ut8*g zQXP^a<0{@piYjNtc04j8=pRL7$QwcA9JdSd=w6kPO?XxUV4YKRl6-jowZ+#aSLLLa z8aNtsMYJ>0yV-5d-&&SI-ic+j0K5N#Y*m>6y`Qs1beZvT+d1qmFt_R_w)>oOq@ZiX z4*IE3BjVHH<;ti?MOnHhau#!HlsGCnv1AF~y&ZRjU+NR_Qq!`{GqcV*p|kNYCOY0M zX|&d_@z10qH8w+&1JY=#t>yQ~_4acubzBec#qZzeAb=PGDY&Vetj@q9@(R zsll=fGR3}G&JU3{SY12xho`u#COGIBO7C&015pOXh~b%=-oO6c{YXL%flT@BaY;Hm znlzHjqPckTQ(6_?KTr;KO`S>&75uVi%GV5C;%B6CG6DSM-mvx_8+h;vomfSi@Pi%y z>Sg=>;(k>}W-Tx1^p5#dbBLU)>iNyltm%ieCS+_@_$@IsJ>n%Z`z$pj>|S6X$stxR zEp0-Su=*sgMJ&Nti>#>rqBr5%JxrqI@c!$zkK!$uQz5qy z4mV6j7NU1K3BN^ic+a_QaID4rR?H6%Vw&gjh-ygV;ryj8CGq~}W1D(At)!k&_i{}W zXWe`x2j4#J=1qQBd-OAgH8yU;W3XEAA@u1 z+&i(ZbGW<+O5BPK)=FGw)LiOIgiW3Ji_{kL3HOiM5txNOWgBpd!uLhqLhxzGblelL z81Ws6WS;5h!eQ}B!o|sOGX${{Q?$u8Ud|m$-F(5JbV&5Cq4h;_-Kp~=fKZGZnF;o! zTZ60GBks~6-j~i{(7bn_@3Gs(?12xJmprf@jL1gYTqZ2=8_nV{Nvt8ENw?KRm*pI2 zMhSo9S8$kVM3N&*vqG)8*MgAkP(hdfae1C7|L^wCn;!+u-4A% z?}K34icUHQl`%XuK8?cCeu946%WmhU6Ywj0k5|pB?!M>@1w2vE#K^q-WY6m{Mi8)_ zF;Mx3-@bCXBDH%tp-45J>t>{<({iLYb|tCM58HrSwT~-YpsUaiKC!_6q!3~Tk*fXP zU{klqb@Y{!k7T~0AeQMVOuo}fU!Dc$Yx-eZ&~K`>J9|~)RMlQhh}83 z@(*4;`0(&pUo({|b1FDNi>=jSQzq0^5(Ih}upv%Kz0@HeJ)??mi_^@}+6KrL3wtL_ z&lYQadO>f>q%4>InP~H)9$yfoDW@zQx-b#oXdb0*fe=#|3!ghyTA3!?o7YRrQL-Vw zLkwNtwWp;^A7KZ(+uP1qtB6CCjRleBfpMlDg z!+II+;J@g_6a|?TNYYAdF(3BWZcU9xqk)!_ok5hK#Rf=Ea2+AdO4=EoxhnMgV&;go zdFs(OEJ!1Aas5b);w`Adqm;uqj^uaexXUeVj_@tPlXAkvkp*Pq`}s>(+BQN4(~&|; z_c7A7pO+P&JBDAdjz3{h5UI%5Rr`r%;&po3-%TUBYR(Yr?dz6dVtN)1bsTeGdHQJ@E zT~NcGtOijcYWPob65`V}*LG6_*-a;p^=6yzQK7Db9qED0kWwC7*js*c3RLoEwr#Px zv&L|H>a>Ds)%mop6EzQr{ytmMNTzqCi z6eyd21Phw?(2LVONB>n&uZO%+q}{jw$7hK7-mZASGHo*Pu+u!og~zCaN*Hj zTXbz~M17!V(u;|byK>w3-9aAIfbVaH+RY;)S7&x+Zcx+_1?(QDW=@;F|tx+p>&2M>9(Mcg+Zg;-D1088MoY1{DAic&S=(Rrl|Y#1LLvD20q|9)UJ4I0 zs;G)h%l=V;KLh%iJP=t$*!1xiG2CFdcRZ`;Py~3>jx6lw7~Gk(9cCgYpS4vosqDj@(h(7v)Mdx7xi=%80th%q&gybr zE?wWAI};oRZB9*Nvi#BPv*UEUmX0t20Mn85}b$+EIkR=O`e( z6Q!p!f$q<0oILKQmi1M-iE9HXn+`{+Ly5kmb*;!{&wos?|m z4vYhY27ZBWIF-?5fbon}pur`=ykRp@*JW$Af>n|-C5MV|0g!bsQ>dMo3d;AX$eOE8 z3>+-&HfNuh^?9*A!<6qn5pkEr1NFRrgb`hL09u;2kR>_Re23=VMOd> z^k=K|^bm}If?QlK#LNhiv8S(w3qRqfCZZJRf$qFh>q-jm`rp5zscTz-)s)Le1^W-r zM+5S5;mFLIrUNn6Yh79Vf(E#71OJ(As9Chc zTNLI9!+9r#sqHwHMw$x&A(XUupFFeN9~Tz&Uwxnrn&z%OJHg z!@c>)6xhSqy`EY@_@fKZ7csu&4>EK61XxZPxl<6}Wk4Nv;Z5@cwi}$<5PFIE3iX6S z1A{`HMM>sux@T1^^gq|Bp2Hqi7CT9`;{A_q8qN|vGK*6o1}WYgJwb;>7EFOjp&a4( zJLlsf@7oTZp?5AjQJ{nhKx=TPZ31wrI;avIT}OmJR>c)xyodBMy|L7Wc=ud~# z+mm2>W%k>KG6lg`?Q_ndX!-nD?*6OYA2h`cFs95qaYmMr8wJc}oAYxc_aVD!?!v4( zw_y21Xnqx0P4|o~b`<#o}15Hi^MTtUy@W!xUG%YZYxg+uJ zfWd9Fhat%c4HrBt2_)C;=I+QgI606#86CHT`No4yhdBtYPF@&9JWcg57zvha#mk)< z+yd>=UHx|Wu@4@*Eo zu9je2n(-2#h0g_fte934r=pIN=f&{93|NsiEmdi${%55%&6eTsfjQr z9@sg-m8>HF^7fQrAnXLe(FU;jt}wu{GZ$-NCUIuK`IW~&v^b_fU#jy+U5J|vo1l>h zct016R(VDr-JCneQsx{hK~a8z&INpt)L$OUd}FWr-6EpY3j5|RoDN*kSGZET;A^}i z(QEkL3$`V%;K+qhjHdL{niz=RA zzF00iFaQ43*jrmdX5ejP6V%59k_M}rZ+%rn5ob-RDzfSw%n_oNI)L9Xv({g%&Pzd0 ztJhtC+w5(8VI%P>4>ep^n-)U!z3lx1;K9oQo$P3Gi{tYS;GpEOg0H8CjEtV+_!oyh zFM=r$1{aEd+;KIR5HkUSrB^-OW_LyuqV%cIC}IOz4=k^WHBS`H+M<|KMX-s|F6&CM zK|y-}&b!B)w5WUdtj8c%6+hRuDMboIw9nPNne79`sT5!vEb{zPgMzHreEiWUIw6SC zadO5PUJ0DFUk8jxA5+)4nzW||k!n9@<@Uh2weRf_-(H_3=JvYZg;};@oeef+gn-MI zco?MJmsnM<+~Em<@Hb3b8r)S#s3CR(F%NHTe4r1*Er@n*laXiit|vt~wnye<+ue@; zk{{D;P!1p}Hyu}pR{&{H+1nv}PkdquHgz>ABS$=jO<}Yc_sD>=*H4H>k4S9{ldMOni9|4o;+F#gvC9*{>;F% zxb9kJmZM7Z%+$vIT_w_Ch+n$+!%DNd_|6OQa`+5sg`Ang@z8Agj^JK$I z_mwl4=y9^y_o^)&)8*lNmJ@z@-;LO}XYKw|4u#@`8oo(G!1F$@V;e3%5ti$s%m3#` zM!J0d*FNSq^dQ^%PApNBcn5VJ!~CVK{}la4_UqTBiJ@kPJ!)iQU%muoIKSp4qk4ah zXx483ZSyb93R&uEgwyHHMX!FzjY}yGj8N(?Kc?HL8zvtc+;&z}Uwgk)lw*A^v-RTD zJaOi#=ES$7@HtKam$SYh8g8F5Dnztw+Fmqjwty+S`tx;rzklM7)L#&-2)T0Bu6$qI zd1Cj>FFTyumsxkeTB7tkWHxR)(!PaHtWEAYWP5rw1>d1$>z_sK_Sa^2XV+A0%2{gU ze_U3anuRcE*)kDw_b;=xt}rxlRd=e-O0Vs^i!XU^Vyhzeu`W8-*N{3_EjLB7nO$+s zjep%Lf7*1SV78v_P8#9C<&u4+TlU-`l+#*4t9hK0Bm%XVggV=F%0g6#zrw)b# zZr$GAzaz7(ZUy4Q2q#vbF-!YQ{nsx0-MNtv3%7!TiGgb^e{xIMW>u*tR>(k_pS)`& zHG9M$h<*M4DLVIfrv5*UZ-zy331w{VVY<0YZJ0~SWit0Jk}$iavt|NY^yJF+n6{qic_Z|TS)^x}sQDp`>D?32IKLl(EhM23<1ZI#(TQo4X8{@c< zvPVA$g|!^{E=*+*LN}ka+sjx2yXyXg@$sb+vF5Ux&aU-RCbN{KZ#_r%119V$WA~{M z*c0k}RLVir;0dgMlc3N>1x}#wykF$&A2iqA3GtFHYYBt)=Ty|LJ6%&_@eU&|xEM zz!DVjG%JejmwwWCf(9x#Z)ui6fE0I_;rE(vumLToUXAo2+yr67L^%Z>5bx2*_Pq4} z;5%rfM?W%r51)3M;h~-UA1HP>SDw^5<>qVqo}4=q-L9km;RIKSzv+3y?>T>o1)=c& zpQ;HBK4jI(>Vk()r#sOrq5!u5Knp!R#7zx-uf>^5e?7tT*4-4L^f~&#zvU3jMh+ zKkJ-QXL+`jyP1IpxS?xye~8j~&9n<*IsTlE;p+1T4jX2)Xr#$&CxhJIC&mQ0IIz`v z%J-``h#`{AlpYnFv_TSydZ0zeRGb&c%L`}fBEoaECEhU{&Q@rgPWAO@s!d%mdaABX zh0rdi4{RezDz{&#`Wx&^l(ts<7QvdaHRX{`%4o@Da6`4erXUOO#y)A4Gnqbb=M{pV zGRd^kruB0w_lWO5%DfN7o1XHnQn-^?gEfeeY*a#bAFn{vNLYG31>mA{i*7%SFycQf ztK73JAF_kw1_+8$l^IaNkixCNPWCzGw_QhJ0HBL`=It*qK;5#!R9b;ZIH*n@MFQK5 z{M9BdJrTVvOn|}Th()`}!c#x2mnjX3lEnw>!tBgl_Q-1~4M&&4nFjH>7qhjPk4jE# zHYy=jtj;)VG&PTg8N1Yc3AICa6FW81tZ3&q=V`eQ4M(F8rgW>LPk{A!(x~#8fm>p) za}SVGdO2)$%{1Fkbfs%+QjgtWey42qe7l7Xz&ik}S`>sddeJ${rHI^aym-i})Dbr9 z%mIc5$NtoaWOm~^k7KlcRrGzV?P^R2zVRaH-NM?&qZZx!0C2L?VlBMbfNC(6?)9ju zX$rDA@Gw6^MR(~@%NeDeTvu1d^;sv45Ta{MTha(yBU>|r^nY?~+Sj$B&?d5zb|_dp zV|OKqkb#b2cKhpR*8`U+VEa!Ia|}&%CHx}3o{PMWkX7Xt#(Xj0gi=i zdsE9O4=->w0PbbgzNhW6LnOIqS^ zkt?MchVy_1w=LeI+13mIECS4}ld5m33?<1~aWU?AiK0~)AJA9;?_8yspv7*p&2<*{ zwH`>xoHvD7pdZ2Pt?Lh98Wm|nFsGhw$*Ok@!NZwK4eo52H_b@!-(750qT$}F+?9>ZXx^t#$$ zUbC^Tu6fL-P`Nu3Qtmr%j9>ptJOcr!l>qcMHSsFwnOuOlY z4v7Vl2;i^NR6wlsWts+> z0LI5F?PhOm>L1PugNu1bVw0Wwb6-O_vKoW=`ZeObZZ zd37Ie;9+2M_E*JN4+2i+xf zf6MkTCXgzh%K6zT087ky+niN$Jf4?rJ^gOyI_p+HS?wnU_{l}xw7 z10V`$CEdMGCr)VA5B|#THYzyL;$`L**bJL2XoEiSVn=dX!ycc!-2C#n>1V(qJZC!* z{jZ$m$obeKo8Q^#i>{E1Ywcfpf}@KzP}|ktzjzY--2`j?^?YZlgw^O#!Woa``V%^? z>X|cU^yJQOt(6)w-+CnAhpRmEV3vmrT~bazoWAz95|ZuqJ}io#ns)iPhEhR;klvTL zH8$MIig@2|_+y-jtw;)_O2;Z^5|pMwO4pR0b-yyRhLh>%qEGEvF@U`U5mU@*MkkCJ zDvA_7{oWM4jTXjPkjy76b6eg2MA%tnPAatseui~(lo zRQgGYXXzdJ;)cDJIQRZ4b#>nrH^Ui>kXMQ~9vDCZ%W0Q*_xUXV63k(1NpTmy^ih@K z^ln^jf$5I10?xpo#R`p`K>1K->?_9?oM11in;Hnj|CEE~PX2#~jCiALU}V1rWN9I* zMN4*mbo|#MF*P@R1RcZn{o->yH2F{aZ6$0X2#9yM>6pz;YcScES9ti#$IkW(utHNzI2(ihZa~i$* z#*tBYAsD^-7kOu3W*6#D0B_08=fs(0M2cyD3TgQNzahqsi&pLM6>HXfM>Kn}vs+y` zW);;>4WJP>*GrG8GvrfGgA)rVfEhuqwH*e;DZp=&5xsnS8PqQ%g}}=RZ40Cg$XT^0 zs+;{{0r0`R>bSB+Kz5v~5-XXrwY2E^#-Ddrk4`#b(>4ahYXBi zg@1vLnDcwQ6^cQi{T0SgR~2IAtVFiR?Pg1V^}PACTYYhNi$t|o6%}rQ%(C6+DbCI5 zI2+9yzJHc%#T9PuD5e>Zf4gn)m)L%CP6e;5gs$alFwV(1D1?3`zPa0zayfTOb+x;J zI98a^?LK zQJ!m!>~rDH-45Rd=po-8Oayq)Y@wo&lf}BaK&GDvk$%T);-%vBv$P}eJ0@wA$!yF9 zn`@CXEaHxoRYZ{6ZB`=9!>9AA5OyXKhrqEC89>_SL7PIBSfB?|p__{!PAsfcfI|HvpklZk2-sN#%?9CYz*&l*d-qGQz9pr5fwIv>%IQ%vPG$f) zpShazfHi8&ojVET0i`maC<|cj3*Y9MUoW!>;13qOVYrC^?)b8IkiNgfiGHw?N7K`k zWzDQ=>%~*g?1^_)=8q}OKbg8CUndJiWed{|ScF;h#e~35JKrqv>NWj18;R_(iz#{B z^hHwwk8_!O zC5!#kFvHYCT`|-YM6!IlcGr0;qx06z%%|ne({%C$ml)4e^ooL!m zGfX5ZNE;3_oIlVS*}i)Y$;9U#6}?m>y2>>%3ZqQklai!fN4>q-S&laVM$qN$P81@1 zGW#m}FWCY384f|S);V#O%J|sN>hf>~Bh`mboy=HemulD^aVL_yH3VbXU{eO!4yCF$ z-(R(#dU9)N-cF%llRd|)n3RWUOZr&Mh^};t%J>9vf%Y*0;oRri5xrKT_U|S3jj0tB zVeI5WcARh5T#iCfLg4`I>hEl%C*ag3z}>;7%SbfG|KT_Sbd*e;T7tznR6m?~$v=u&m4vExt?iw|o*6x^0n4D^Dz zVL?DV?y#tf0YU~Qf+xZjA)p=EGjLbBj3eBt?oeKUn!J zvRD0=ev44(IbPn221w-9q;B)Lu@Y3<40iVa0zt$`s@{auC))VkB1o~Y9iA}1TEa^J znEr^(7WTg!%FXN(5S5?7dn^rA>n)FADi-GkrYV}bMOZQPHs?oK7fher%1K`i5`j7E zB4mPtx2|h4z8vflDWFR6g{l6UT2ON`4$U#mz$~5wdIbsxX3NuhNZscK4tl-6@N99n zX^}1>o$Z=2wWfs#4%#p{WDN|Tej1k7_Z=Diqa4895hV~hXTA?L{QddT0WJVJWP!PW zhObpP5YuM_w1a#Y^rvSS*`1Ga3T?9OAV8ijXG^jw5laFec>k0mtsW;5Z9#^WEpX-yZtA<1=u(rbIYz@0g%r2n2P~M_ik}BrY zrD=Dx)cuQfe_$pgp9T0{E^Au8QSdI_bTZ+-Je)-P8vdn)J>Xsr_Q# zvj(PBg;V&>BjL3@Pi?CkCEsbG)~`sHD2nLjiJV}}EA>`g9GfKy>UNA)Oid=2J;45J zymnFj-eMz+Uw`pM>cEE|(dx3sLshOXUR))3Tsw$+TYf(yX3JyHV(-OQ^y%qi)=Hk; zNCzFsLmkPbuXS?jG8L?v0+uiP47sKV6-!9jh4&jD&g;y5$mF|I(2y$Mk=ZcfQ6bIne53w=R!{__$FWU0|4$oZ;IW;Zzz&HglmtEf%C{@#?^u_WXwz4W& z)Kwd2AnPl6$DxZhsDmInq1-FoY-Od%qo>s-Sr@;`U9D}b{-FB#_T+i=g)br!r|wL} z_FuC?+aLVCTh2JdrC~GH{iDGNRoNqk1576iM?WGM0ia^0&?k<8Cu{XsTnxGcSyoJQ z4t`LAL1RzYKIn4YXinaraNvyE$^NEAea}q$QBI;h^gSp>P+Ot}gU7mveOzpTfh6OzDLWkJpK3HZ<%nzRn^r_vRQ_&Lv6Z`I4Es%d6n{wuU%IweH_)f2dsKg zkHy5-iU{WYY^u~0LFih%*=X*0ry#yQ8ZVzo(?{pY1tj$10-j_Tg$5}-^-k6o4|Ucl z$+{GAg+Qm&LR42jcbW$>AKly0m$+y7oq>jZXZMjCSEr<*3T=(qLC4}fXP_~uXQlF? z8K#n_MAW&6|3GiqFUYTSn~$HSA(ui{JOV}Xl^rRDL#QesSCV?T;7&PAMDRolPS4DY z{`*GXs;y=nQ|#{B`p7^!S^*sR0ueMtBU{gB+8f|8MF9^TAe;+c0GA##;Tb+`Dy<)` z1piB%Q4g^*k^A#`zbXbBEM0<8JOGU>4ev&Ft#y{J3f&C00kIk~2y9B_(HdBMg%aQ% zexgldRp>Cn%MoCS;x|n}xRY5VyjFSp(I*y7Zc1-@DA*uaFIG>rBR`p6rVz8`3XlV5 zDaM5%M9iXn&@2+<8zI++4`s)ppz_3nEWS1}%1W;+9&OFNArR`bklR})C3lOTW-6-iJ6nC*KZ5;bW z*hTVB)R{ypE%77(>_f5_1wKuQ@AHx+w)Pazrx=QQ_qovKZFM zmF&W*{kyTkJCXqj^vjxjbt-MOdnyhn*`@(eMilsLpCO!}n|->vUTGZnqAulI?&qfq z_()G8dcM%w#-c^$N$^3ELXYF_==Ig2>)3LVov3sXFsEZt4BKHX{QAS%OteA)iTZg5 zp35YXvmKH$dw)2NquW7B5TLz$j1SRb8~^G)d{PxiYk)V_EBBE1)lWsrsO8K5285xi zUs&2Jy}0`*rvvk-kDEVe_6X$hv+?f`#9EPVUUkKGgJt_rYOh~zQ|$~^?8KBGAmyH{ z!};Br0r6A)thmFsTDsL~n``A-(1?X1Y4Y(hg{e@x;NUDv2pu9U%mRT`?7*cl7fo_5YCy{R+BRwxM<|D z(8a~?ict*vHl3A@>Ze!KCv@S_N*dsYYo^a;UGa{HjitLr&2@+1Njy zqE_X~%g^64gYE0Vv}_F(?3?c?zF8jzoUEo_70RA#9(*{}VRdz4h1a-K1yh&iD%Jvx zR$5mW;dSmF6p%SzxrE@_BJiCLYVN1X_bzO6EFN%ngIM>Icg=TI6MXuMQd$YEr=*^G|Poxr_*`SHSZDEs5?}kDXjnugfTj@To0A}s){ypD2;#cGWFp@|pASsbOvo?q8 zgdY3i`_VXwUKbe6)k@`TTu?0LoWp*6C12as%hq{G^?&#yst;pgknuzF zl3QpCpB?zk{%Dz&4%;j_rS9>2E2Unx!J!2s2iA=KnLDnpOneQC1!^?n;L`0I1X@Em zqM-xYJ$C1!$Eo+*ZJ|M+`{>Uxa;s(cHTil*SmDp9g0`v1$~|S~r8la1Q3}=V{)`L- zUx~SH6L;NmMgL3QtNYS%$3sEdv2G1}4h+B)&(<=3SLQ{`hrEAm?faC zH36dZ(~deDTCnwU;&Y?D{K%Tp8HiWl93 zoC6wCMf92ywcO(+Q1$Tg+eMQZDcSR@Wer-`3cD*=P*6DPtzn;=5-&8q&NqSuJJ@~L z$N7gFBs5aSW-#xGYBR8J+`R+z7qG=AWOnHFh|7?MA9kSU`^WOod?f&rC-;iFx>iyx z!#+HL#C8^|OT}i|^{6M0h^=;j~0xyNwC66c-7y~&1{3uq+k4uFre zn202=75yE{Xlvgpz1(fdaL#~3c-qPH_auvDxR&B35qF7|WXW+A`@{h0Qp^XxQ_FbUB>dhU2o z3*Q9%XQb9c1Rj_eG~W&XhXQl)^;Q~P-XZ+K9D)*Gb$|o?A>jBqX$LAPwCSxYl#EoN z!YBG`uw`Idk`T!8s@R4BwVM}Jy74(Jwo|`IbQMILrMq1SAf6#pJ!%fMb}9)V^hPCq z;oIU*R{{qPwYjQ75B}7j|LJ<}f`h1gbg|_KSVrLeCV(gwdFOcD%i75k6r#{Z;0Qrv9yPX|a06l^Ge)i5H&CQKHcwuxg zit7b4uSaa}pgmj7KqqJ&F^~0^9 zgT-fi*VhWNgZZUqr%xwzpUCY{FIsVI*AS_At5IOyxt`#CsYLYAFUS3clA+-F^Q{}^ zry`0uc2UXk!k;HlKScrY{j~$GZQc?WDD}lzGU`LHLzy=(>wnA?6y}r*-5$Ogao9V* z8?9T=P~PA@msB0bg_sZRn%tQ{erz#5#=aZv+^h&T(zmV6C=&cI(aF3RZSp-V z5&bpv{b|cI?|?`3B0YC6?)TGM0q7Jue2#=o*d`+D`w zw$oW&N}`5~5u$>pe=iqLO`W!!G>g2i?kD!J*gK-~T-G8%4Hwwl>}=r%d)8R_l6s?r zF%e#^<(PKqf&7Pnuuxlc^$&$)So{8OxqUhA?S{eD9vTD9LS&HarHn#><8VelWdHeF z-6f;RzB{~EeEbiNp6GRJ ztvgSaWCn|K&wW*Lb2Qle{iX1$Cxf@M+lj*Z&Oro3WRIMm9n`wvt?Z_Xr2+JD?n! zlM(?;TiCbOwK?1Qj}oFwgZU5I&pF1ui}(-3OA|jmYqiEnR3y>tgl-NZQ=V5xPV3gP zNqaQKZM9cY&x%yYCAipy`eVG|>!>HlYzCM)0OEy3&tQ?SFN?LH6*#ccGQipldo+Qu zu{X`e8=8udv$NaJKd0v3LyBA6N^riGYoJ7Os67*~a~i5k5htpk`HE)?l6JGoOb&!N zK+eUJ07j<;z;taz!Wp@c5|w34p~n zYfByjLd}P@UIzg}SwK?W%CaadfM)ZOsMi-yiq6yC0`4?RWt*hcjS{9US%{xN2fjdY zn9W$ECC*avkcetic*zssK;NvZP zKMZ6rLp&4>cd_2qL$@rZ8i+dwi$X=Rw^wju1wyk}_XePPL$>oy=qkaMn*p_pzb$jL zIyj+TbBnOV7Ui1*U8GhmIBy%Ebzg7Yp5c#WbRY0*n4fd(16t+z^TQ0NyN5;;M2S6% zG+mj)0qz+-jJ3`N1Udv}t~zR&cpJ1jOLCJNF;R1$`|a^Xti!mUj@6q^7(xNLTHydt zAL%!-f?$R38s;6was*1ffF-9>4PRFzV!BoW|CuSOd#1#{x^It1!Q;S#w9&cS@IJPgm~f^&YX^uxPZA3=U7`2+{g7`8G?!%S z7z0jDaY29cQ4Asl`7OFfT8~>+DO(&CTI9aYh#U2tq_YC6&W0(9=nT z1SavVrj@QPHrc5qZ(g)mtWnNdZ{UvzRi4Mndhw5+8a;;HOcdXyki-4`>J zeLC6q_od4ZABxf4^E==EQ*1(7pWStDI2CE!9;8v4H1FtOC8bq$DywI2_QwFRbXcWr zetb@wt*rWR(#{z%4W%^>Q|wgMg3_1Uxe)0c-<;I8c=Rt3JSe@ZYiR(Y?% zDRd;o@2OYO&^(=5O7eGFzeln3O$R4a&Bp`!Dw8J$GxP%Ta>VYM7n8zyGydd z!oV<)G1`SFFQq8I3(KS~c}qVl?YB%DJu>V+(ACX=ZHknq*UTY; zcV-`9tSHgabP~NRJq=0^zS?%H(W1%M!w--)9xZ$P)7bxKt7xgHMk>wT93ni+>n#|+ zZ(VkDx3o28&WYcbdJ5EascVWhor`xEjqWxcP&FLOG~j9jzJ{8+q3zET==Ydw7hzg9 z%h|fWwmi@W95nMkctze1+=+Cl>Nre27+tmigdhqBSOWJ~Kmut3^{YWiRYZEKZmT{*j zAP}Jn6}Ignb_>(tFv&Jg5V}^A=G_Q1Bv^i>(1qAUB~W4{V>eWrkOt@O6yaKNPch1@KuX*vEAvw}U`4mbuVW3AiiJ z3n4CA_XLGJSeleo z&|+v6V#{r69T=ee3Fx;sr$;ROW@$yj_=7Bh^D+yfwZ!2=HvfD|$NASpLQprOfF7+a zM);d9BRDBrk~?bm9Y1Q>SsEsOQ^T?G%}Yytabi4b0!W7gusxuKlLUdUaY)qlRThWP zpK2w#QMwNAr^z6abzSZK4rpF=nBpdAlWPV|#pPoc@`1E}2ot%QN?XNTt$U=XfmfuAi7P(=Hlm zm>p(4=PIqDg#sIeDX2Qz;Acoq*7t?k&JeYCbYH!{M46#ftfiMv!~Aa-i1QeK4(~p) z%=$^9htd9hLrS@4E;?UMt%%ZIIQON2p_%Zzy(xXtDK^w{%Rt(^u*EZLE5)6 za3^fa)Ahb?YV!fhi*KLZ`0_yp*DG2Xn7M!)^SfaTuVt4>b~o^=WxPNWf03!uar$ls z56rh*MD9KCG-qoc4mIn?=rY^_03s$Yxiz#=OX$)nZ*}XnvoqV ztm@If`h9ZIHw15*HPQ=X>Yoihy2xjcPPA~e?TEc>x7-~*Q1o=YO2YhLMa?k@trzO_ zNI7~_QsxMnW3AjpQm%P>AJ*-tdBsOTYPEDEaNZEU)F2OFhK&cWes_$GnoJWZgM;+_ zgswK~^fBGeAJ(EV9s~RugAxT-FAWKM626q~uS~qX%GoFd>S) z`l-M|39S!}3(nZ*tA8&W%{e#lM#KYMEat>JF27KpHzP4Os{`BI>>~Wr&P}K5LYnpF z8V~NLzdYF8-BBPvng~xCh^X4#>QOsmI=J`tzkc=TeY@)PJiCL(Yn5+&(LVAn(G2cc zW&06v)BC>hdTc)%xZv4YD@+tVAo6{;@7Cq<(+YPR!`I@lkfflAZE#xxK+p ztlf|FKNZcTnYqz7oHN-Ua(kk&m1LXGgUg1n(6;N??z5i{W=+5MeZMn#pHrBr=g0eb zzkYgCM$QmQiI^j|>adVSM14~E>|^i8+Bx^kD17=rLyjF$`{DC>x3J4uPhX~<@A|Qs z`7!hi?S#p`4-vXwQg&QhYi#P|k0@adaf=?^tQ#&dX$zq&W%FL0yBt+j<*K37GON#g z7MvI3*@i#saQ-WVmvtq=_E6^JDLcn#+dtuu-I1!Fhi$)t*3E}WIlpotT>x`0Md@M8$fs=7i1hUYll;v}4t$jbRWC)DY;4|-!$@h8Ol@qpmLEy1&zo3AROVP)u5=cAJDcR{4yqI`f@nG#ul`?*9 zsaOLa6rf5;6$K~%Te$gmxA4#RIg zdQHW{pRpH0_t&0pZC&H&9J%zZl>6c+-QSi<3)6?>rZ z6G9$PHcqnU#!Ik-6zL$@#kW~0U68_RBp2NUyei0mb|i8!$uX1J44iHP3tL>N|IV^| z%t#Il=?DDOBB_Z4T3wh7xks-TMF6>5LFgCW(weRV+xnLIb`Z3b82f1)QQlZ2YJS*t z6?I*$&n4#i;vj8v&J83(W|~SypnGBl2&8|iX8kRbWnwd=IeWVh=4t~F=re-qP-OME zK0(7{tHs2Keh4nT3gN6!2daB>TXkUU-@tb!7e(=jiFLa^omYg26LJPNSR%5!3=YMF zBhoCXf#}{~>(S33SNq6NfMN&(RB4jN{mo{D!JxGcVk|ty1w!gETQ5ls6)bn}vjOq3 zW@KEHE6r-rVPuIty9;Ek{z1OS$uL^i#5kc9fZ)~e70y7*LB2B8#CNou&s+$vkY>mX zQfgkAvjZBe3Wc1iBO?8;mWCfN!-#;G=)TBqD8BACwmf#3*o<9i-z##ob3r;-Q#=eC zT^`V}VCE4(U9tjz!#;$rf5#rL_g=u=;y1K|j@`Sxs~2bWL+7-M!>Q2|IBA#6UbY>x zQ3+F0c30|LoRROVP>W#eefJQuxIoFn+l{A{F$KG4LkMkc^FcIj8-zD;Pi8StGF zWCWkS^J<|L6bh{}|AqalpP{%;{o@u2hEFrLk6-}(V|x$CSuPz2KT9y|4pd zA_54E9W>7cvQ_V?{vH25Jm+qRok#2n6qYE*J(u_auAHnegCOi;^eT_-&fqcnoeX!7 zQwfA+jxs^2U&JVuVB!{AHgPJ@QlEwo#^U~&`TZz~UrM)l+la7p$@)%*Y44X@DO_}a z;nEoEJ~aKn`AY%~(t0B-7_r}pDZI6uUAKB^wc;P*x$@(%&CN3!8494ab&Jnm(lX0- zQtAuVo+4h}lDnfRSJa}KD_x>a>p9j^)9URp`~Be$^L18%O{?Cud_`<9uZCuW_jJ1S zCD9IJ@%ELfbi~%b@OM=|BVrimzQ81=z#FGt*@tL0+;Nn9U(>l!5@C^`e>-g;i&fsL z$n7>lI}lEQ1BTClvo5ngFY-P(We!`>T9Q>u8xKkwlTi_Ka=zV-=`PrrAANT2RoDJ? z7RW^!bE)x)+@PyQ?R$Qp1J!q%lFxseHK@t8`Y^A4T28U`xk|wM8gmh(-S?Vsv+s%b zX!(4Fk>Yz1+6*z1bNJ?zWu7JS>6g|u#XT=7tV_?B;Ub?&>C>W1AB`oDQ9W`5i7K-QNdtNO*Sy|+&9+x4w!eMHAf0)wtzv_Ih}>Ip?Wv$-lgtgMBawLd{T^^b2QR?5BPAIRbuG(cP%=Axx z%yB0B3b_~ceI7qDK1h{qT5@wWw<08W#0)&xHpG9qD=GWEASHtK8Ba`PATcNk`NIl{ zi&`?gsA5+i*xB3aO&&s2c!riQGia-i#cw$@hdJ39xJdGM&AHj#c(gD5gL}e&s*|;L z*%T0Y2nHQ=ztJX@&5(+y%+CGxV^JLlL>xQ%#Q`s|u*>AzhpAfKX2<~>74OkUnuh+Q zb|-`7$iv=hUX=>H@^>{a*&&oviCI}6VRsMMX%BoI-I0EP#8BR04ryI2sy3t%y#u5% zYgMv$e)q=geWK8SDw66Gsh(~fsy9vK1i;5U|Es4F?p*W_=v=Ib@k$| zZFV~FL89W_qziPT~Y*O*T)Qn-4KP6C*A>Du0w!J@GnxvI|30T zc!SS@lPNKMB7txKS!(D6E%O`9`z1i7AQke3?MOkhZhT$a;a`8;ogoTEe7b~oAk_sz zF8swtM3t^v2vRWsdKTfBjz<~`x7JHI&4xQ)yg5~*iV@EV#KyXxOB6HM8@j>XjB^$^ zL3Fc%T3F&4+J#7#T^@XpZeu6|6vWk~tGN*~Oioe>mq7<}ex4**|?+?kr+ zLBchYws>I1r=e7`e~>1Bh{JCXOy+^|4J$JPQ1lZz8tcGv}IjVEJ^FV9JtL=|}Exa*?a}PGY3G zV4pG9GytGwYI?+Yj({E{njNzC9|&D8n`Iy!Us~C?@3pXtqsNaFo}lDph3*}q-|qn5 zEVsG(D#g+m(&y;_pVv3iR}4$b>BM%s9Xt5VD)YRv)U{^U_bJ$4!LO+P1@aZe-auK< z5zqlv`f9ak%{kKImT+N4z-2NWzq+8l%IYnDl#n*MTC__K)x~Uof}0e(B2Q0#`*YKS zv8Hq12{-L{{29?XqpCp%-F+(JKqr)$87F6~H|ZEXCL;-AzuiKmOyL2*C5N z+gx561^y0-;itxyp4KT>AE?+13IuTX7=5&Eak(Tltpp)_0Ln6?gXUMOf+5;RN+)D1 zz@n=rpEab4Z>z8PI9|eeUmGsIt?{>V0M*qrZ(&4kkb?K+)*-8QHnLf&b*JuRXwr!T zx7mhr^ve(cag6E*3gn?%6))D=AKw48IA6hvc)T~gC-;=|OGfV66Ngv*^9v8Je@fBz zFG)XHpKNb0U$`D!{M<}6{F?mmepHwx;x=et>4G;3U!|S!=60XtVs~=m#M=V1RAT>C z=k3}H?~Bg|?`hq1i(c z%r(0ZH@DPb*6(%jL%O^0`YiWDA%41HheOam z->}P%madNhUxW6Yybzfxzj7rMYfD0|(bIjIx?b^kQnP#2(E7hN-ZAqpMF45~-bb;yr(gs?#XT`eckoItj($hoto{glO7 zl0%DbDz^D1&PE$137W@|n5zjXqw=<7dkFTX;6s|Vf=AmKv8 zkd=&8l;D(kpN30FhB_BJYdg#UDgF5z+I9rgx>jz`LmJCpz?{GP4ldo~(UOH`rHsD3 zjTsS+J>JxB02+S}!I>S@v}WfjtgFli%IjPGCzCzoH{H?K9xj((33w{j;v`a zB>+sKTsB^Dsh+YjhGEi zM3)9G>m>k^g_qe|ilh|Ywe+&?hm^6q5wk7Vnh{VhU+$#U~BXf?BXh8ORfS150GfO)i}cl3I?vlm`eQrTl5ec5AF|kdDlAq8;Z+44#v) z#^!zmsLDE4t%5!tvuVBLFWr=88#klWh-sZ4%*LR(cw@UOB4|{;Wg)7~oc#OKi{XrL z1f|@?pAe@+*Ey&Ekxv9-=76@S=>0n=|PZ3mmf`LM12XZcN zf;Wzt81NP_ogfOCJ);9R7Wk!@^5@${fPC3pjo`FHdV-_4=i{&VdaVo(@?d_b1jzlE zawxW2(s)FZ!DTWgOHLA+4V32YcTVTa)^?bF&WK4(E5J>Ka;u&8iby34VT0}SZo2pL zivM&AyB$?T&lgRkhtw^ICX;$C-c~+0dIyThbZh$R1JwdfC`(M@EO?Oin_U9HYHz_> z))XST)uGcuoVYX+B_g#1*a|O(hE@RGkbVPlhxPoiU++kkUiS?f_}FqX@9~vWmWQ0< zbFO^6K_h3nwFF7lUVOdbeW{qhjDnS)M+-3K%E>7zqCAM>iE~;J-SOj%9{VU2RqD}d zPqTA-*{9v>pGq4KW+0k?{lfL4?3P}WJ(#I@k8MO#?Odic|2Y}YS3GxF+Vpz$o3~rk zmGdZF9fL+ouOEJQp3$TY2kTMyR!Y6^T8cv(ifc>yRu&ySt3n7blP{({Rbiyon0mI4 z-aqVx1hXq;b4JN{6mSJSsm0hR-=)zDR9;)z+$xJyXc)FGf10J$SORy^cnDm4mmJ0@ zTJ2^Ebqzq}dejZbGp|3Q$it^xX(T)X5EZr?DDR~zhpMhhtrdZ-#11OtfLw>u-)5s) zBoO<}&J0*StNR-0ng@|!KB)W|B{1oXdgGGtnDZKQD9h zfO8DRQR6}$WX?tNnVL5_wO0GYX-MMR;x7k|pAkg5#SD&`n(%_SZkxwNCm;iVv6Z`A zww6r?GX|=spQg4?UrNzAa1UVp#@%}V%vJ_~%$^DuZrgp?bLq!IOOK)FF>&*R?6HJg zpzz~nbo3fNH?)nCH1G221|LFuz$SeuuSpD*L6jde^aq)Qpj-C+A8;eG;A_EAXesq5 z>w>$R{ffrwkGAM10Jo6y2HM|*Cq=(3w0eXqytYZ!ruu%K$v6rk4L;uCamdUA1IF!- z2V+oQ<48esTv!R66-K6YjO>JCk>F2Oyca{|m5KYjRgLFxshJhIx>AkP`75B% z7~m`@+KFF?iQpKHlBrvshtc;%nao^+2dT2wTJ>fiT)Z!+C&nXI0)h}81)f%{(@Bt| z?XURUgJ9*hvmG&>85J@yX=hS%t#z6Ia#49lDkXmhYPtHkq@=k4**hB&0k6AWNdHR}Tc z%KxM2+~b+-|3AK&3^_M7np51EPR6Q@%`xVUEjYw{DHZy&*%Mqy`InWq_djj`AM>ytyNqh$60)~ zL)ryz2Cc8ZVkGA{X*%E&`W3ZqKxYTXu508&YyPWiG!H`g$cv&z#NJfmXFz(0nKlJB zo>EWmbOqWmdc`wUihhd1Mb8yO&#o)#Hr^-&KM~{v5Zr`98}b9sUA-}rulcmqx3g=D zJ%k4yaE-sm-|}i`P41^IB4)p0&jNfquLKJMzG>=B{ZI7Mh?0CEY;a^bM+e!k7J5S~ z_B}qc2TiVluZPCg+k(F%V&|E`Yazj0`vGSyI?v1bHVEE7AE=tqK$~aovHzq--v|a+ zz9E#H`#zo&VEug&4Ol_GklL-i_S*CE1m-4w_$!VNaT}6+9M?G7`H4N!vF3S0m-8ma z`DB%Pm(P%#I6qn(oo9}u=MQQJY0D&*U25eDJO)qMSy(cdcvK(d`r~+j>30DD-_Mc5 z=J-%kjOy%&Lws%1ub4r*?U7v8hD61_6ApNlc^8)&0Ia;m>`awbbjHb>dsk3uf^Ju! z@c!pTOV-IM9jys_XU)PSqK14u^hcAX;+J~?;Golkc}^FiA#56_nrkatZXUS$nP7sv zp$-)o3A^Y0d5)WnL$To&c$&X&sjrL$s6C2jQ)^>3OuM|GaQ+ZZQ5)Z7v2`e^O{-9Z z6O$|a5xNnT4wHTdtNF``Ifb`DJs#)kjz1a^{2%De0WI}o?)}OGQC@vQ2)4xlQFCWk z-5>@0D@EkzaZv&py=4Fz1RENaWE&EeuFMK?vp*_#5kpF$+?G$C{?|U)O0bXZo^tuKI)>#iJ;iM&+<1^90 zga{7%w!6cEge0IX?zDk0a)sgz;t1;+|RQ4}wbHFky>WxL>}!9@8lczIZ!Bsl1|^GV@_cIGZ1p zk(M&%@HOT(32RwG{(R(0c9VZHt)08jKL{0sORW?#0rtROs<$I0t(*@vNiOb{15VR7 z?}JA|_5N8(8u!^d22)(&d#8kXC~dmpN8&WqCx1nZ{K-R}1C0-04vL}V@gUV@7gX6q zL*jK(HsxG>{F}Qcj^Goy-F%}yBdOtUWiQiC+ar> z-^nL6!;P(uk<$6g<5!e+-nW3>vBHpAzU#l6RWOw-{(cYV^^uyBZymB!1Uoa5d(ze>c{3*WY?mz(CcpCF>duEUti z00o16d)0OQGbKDL*}qqyI!y0BU+mNHRp>d?I2 z^0EP&sB`gRc1o7)UIVpYn1DzVh!7m2<7o8@xHR8KeX~oR#m9WbHg#<6o+Xo})|GX@ zXVO*7f%9grVh|~gQ><7lZapNn!z#U5Z#soO$I1{{vuTTjC?KHKcm{F zT=fT$BmgK_kTvgf`0(99;F6;TjU-=zFau&-C-F-`cg<&G8gMH3L<8)n6g*PvkL@P+ zPOLn(vB8i_2$w>%3ji_F8Ux1@VKmb&`IYLE9feTB!dQXAcdECpdN zY=d;1z(BcfNr6^D4gW-&dZ9EH{G5K4b5HVF+M7STJmFcfPb0szY~A5f)v(JJr$sFz z+I-yTRPcpG=313zSIo;7Vw^+CCU0;$<2_CX`n&Oe8;667_Cr1bcRl}T)5LgINzwBI zp-R!bpAczrSJ$r;^Vh9ByDRQlDvd9VM<4&?l&Y6?E=wGrLf72mXy>!pu~OjE*sIAP z9N6)R@^9<$&kYkt zRJZgCzu=MYYVlD2CmV5l{I#0q+Q37kXC1ru1{`&CXgbBNcr7=+G!nDNUVY=axGm&w zwZ!x~^tB$t!|X*45}5$HSqk6~LQLCEGNa*j5ZL25aYn7$Ol7$^wH6feN?gi-cv;+J z?08!^RV+Tq*nvK`6qVgqB!76T=6L*t5P7w$xi_TdX%+2X&@kwE~Rp9c4PSP;&o2ZH&dCZ$iPh9%bsM?c#hdvIs9$k>v7K9? z31cB}cfZkRO*7YNBhz)bE`Y{yB*+;4(sEK{}_2(z7(dWc66@yysT3vd) zp`~fZVnCk>LFx%!+V-@tdp_I^`d{;_I6#jT9z-q3p5w=MC>pDlgzF<+-y40qXG0nB z6R?X@SId6Fa$#CYj@~5cy#Gi%>_RaZfQcm|N$7Jws6G&AmstdAo&Zy~-P{5-p-sTZ zAb_@HJ7D4zl3ovRzHzy2W-_<_xnhm{qE_gn?7v#603n8};BBRygHBo@*{Q(C2cI>= zaWW<^4A>~^Erf{p5%DVDrrkQ3!ieV<`H}mjI7x!l|G4BIM*f#Pto;u=gzpx}nENbr z|E0a}+6Tn1>hdKx@!9A3{fh(kzmPv8lb;mSh07)ZYJB>KkS!m|idLAJ%6b-$@(zq? z?zqTODg{zZcYRTkwi6(!GePPcDH&cD*W9r#&gZxtxE}~gYB+Sq&t0fQYdH_AL%0Tn z2oyl75_|&W!eP+U7{v_d8sa#GCW2juPvf^hK{Lh4j=qIF=u_+ZnH{aRKs(JZ0Z@y( z{#hHNRPYza9=2K_LekblwnDowdCH|glb_|y>P7$ynwi%M6w%V^fEv{k+fC}cuS8ru zylvjc<782=m&N=9XV0#KAg+RMR;@i&!i2@6kH*}Ux(dAdrA98jf|!G=iblECh3Is4 zrxJaSq3cFj)}DIm7ft4}M=W#}dJbF!=_qEhY*y-Zt7h|@qCx3Bs18IZH}~<1ug$x@ zFO*A-GSygMd4Oy2?u_x&c~ie&v5fNhDmM8y#b@ryVbn{JQtYyr}k@ zAhS#+X3J9!`Ft5TCTi0+FfctFO<1-{X zVyKFOmOMF$(D~l%SsJ)|HosH{i+FW>yGgJ6km0c>0IT!N-VvDuU3<2}rOkqQD|FU0 z+xTqR%R>&2eBMvR@{r{cqR?oMt1(c*u7EW7IcM;PHR+ljxu;SEQn<`iaYgu!9Br7@ zVhh{FJ>HdY)Z>MqB0tHS(#m-1m;a}8iP6OBqp<4T;nzuNCA3e%Rl}pVsU5N6YkT}c zc{%c0{LX;aH=nX%cQX31^AXPX6?gVYZkrlCxDkz7JK}zN25ZS6SRa)whBvh&_B-3t z{HN}pI-veF)IfM3p|Du@4l$7t`D)R(CNYv3ZPMf%A`Sxkzbys0f)UQa-U(nN#Z}V} z&KCCMPI)CT3ojB^r65xO@HLK#Pmwx z#qxNgUi#RfmP`ivu$x<-d0FIS>DAfd_vA3y>B+(&!R|MVVr}tSrWQ3nykP=vN5V8e zxNUxQ;H?hS^X+xZHP&w(leB@8$`il4!wP&i6Gt?uyyka~VPwdEU;YT+{mQQQFID|s zd&48Jqnf4er4yOhA-_V^94TjbpL!nxGS&ERvPg#DZ9(nWYqj&iy`9vNk^2G7-`|P+ z23K?uOY9L5tq^dFb_=5S3^>%CxX&Ee+jTh&EjyVEE6x64dnGp+^_HX8coA1t7#?ee zu`)|cFgbtpQhD^|=Hub74)3or97V0cf1eolIa6hPY~M9LwG?{lTl3eRL6TSysorhP zpZzb-PCxfJkJjBnNqXdtm34)6!%RBy{yLp4;RA;%+I@GA88zN6Gx!?5Awq<`L&cyf zD+5k1_x>HqQh z;5U z=33u?miLSs{}eZNsR@2gg--JwiF?J9F4eK67`fLu3!EmZ*Qf4|xagzY>w--p5Kk6Z zD1hnD;}xN3w6t)MFj{;r>Hk3g6sIA?ye^ju#adKg_Q%IN@)AsJUBwI?4;GV%8Y_ES z$c;yv&7lArjSf-+JLv5if%-1iFII=w#sK%r;F{-C3}<8YZrP27;~Idwe5XPngWD+T zCPq1KX2fy{m%J3P_`~*YB+#%D89`e2Cq_M&?11`dEi;He@z_=Ut>buUcZKluqjz$irt?qO3rsSVXnmcB^7m0) z^T8JJA zcH$z0rIq}k*ncdTt{emb%9)Jzqtdc79B-d_X5@3nyb2pA01r*_acN5% zs%@ZZ9~XA_>_a*!Hj&v&J~1K2RQbT6Qip5_uvLa)jQCg)9+|nYCeiD(O6^7dw|2%Z z>zaOx%J@992&WJL16uei`qyvHf4=NhFSF#v`@^r9b10%~q%QhxkAKy?rKW ze;mc8+dLf?;-0-H;I`Fsq^jN@URK10rmr(slW*^u=vf6n=-11&NA>((*h9hbelHFC zu}&sVr*0I{55+V4PDj8$9I5ywdyrMHo%=G$bM{s8!R|U-Ea%zP7o#PO7Do5RL$}U! z_}aYOU9!B07Jhn3wz_8d+u#IkeatdViVc3&t)lpxHTRcUByWAj(YYh^)U+{r@`&>_ zB_`IxGZn{sU2XH{>A)7JhyOZh&MEPy;~5igtw-{n_zdpWRYOP7*Tr+t+zXZMw*s32 z#`m=Fz}T6;{-*k6I2t4#4ji}PQGFkv&o7Tl5jyQKrgz@6HjiZ;RPa#y*pkTaI_oBQ zvCLB|#XB(#?D+Jlq1NMj8o)lzL+5f$1l_cdjfDOS!Y9567o`KWaE)y)zvG()&sM5m zet-S!#*s6$Fq^Rcp(ztvFw+675S;kMXJY8AWMKpmSE?Ij_tIR0mA2?N$}g5&=WYv` z=sjB6z@E9$>vgm}y0)|n1I1IoR`;$vBGM)deTNl>cTQ_`UQJs1{@TCqh1RQL2i;h5 zGV;!G-X9)Y-FIEEv~zw93QhKQUyP_6^G>}mafyL>w?GQkulkPpjUQ4#EgQWZh@jY1 z-g%snnBOazFBF$0BwRAcM1T1v_YtN+?{wJ;ElmPPA=&xDKK00qt|h9tM0nYEU4;ebo{$0QfSh_@c;FL4B!1o?Rt~@SRL$E1m`u zj9l6n|1;$1xZ~X#v`)tcs3~fhQO_rXe4qeKUqqznWNRj6&hok%f0|+eB-dY{RRR8@ z0G(IjrybP&i0ZBsm{-UHWdKEPpM_|&DyPX8+qVgfD2B*`6m@)~2%(c;`t-{F{}gj& z@M{1wxb9A?(VF|>yuU=P7z*P`8|YCZ`h}s4fN$t84_A8}Z^*sLBNE6Fu5zYa*F8|y zBqstdf_OxlLIBiw7DrMA3qGp-QvCNi6E=AwwJJ*dg3!rOrsQozHJw>@E9tY->!>8NY)LlqOc zAn#i(F0+vhtk|&?!O&BM((s@v8tfhO)&KSOf>?4PESSgafIyTBg& zex7j3m^cpLk!+TfXvQD$h&;RCG4!bHDXddij}lqe^^(y42RhCu@yJ-uzGAWQd=w+8EJmr?d5neVEM8V%H35d-HSj0b)3DSV*?3F;2-hZNT z#7K%oQlWqd4HlWmj{%c@zOY$s%Jy5YZAo5MwF zQJ%eqx!+xC#VU?Nuu0S8ECC+h*n?I{lL5>CA1)JAm$mcM|iq^Ho>t zRHa6nNWA=IXF4FD@>4rARKN8%wcXc}$O9#R-CLbF`js{|hAvqv(-TxP0ZkH(t-dO3 z^qtJuwW9J=HMKX;f#O-OA|00aJl7vH+_~+pZm#xkjNm@uCWY|+lfAR#$c=`$4S)t% z8&g<7h!op?JhDz+S?n=$A*yd(A6B{dR^{T*9oVO1mn%0qKGA|xh8Ty;{5tO^ygj0t zu4sxe$cjo2x7utlH%@X8t_}vO(tL=}r|$ki_l`5~&9wZr!{|)Jp%jNa~aK6(FF{@pZi4#$~EPy?ndKw8CSL>Teyr8lRC*jzBvMjmq-@r|N>!V2&66 zsN33(JtWTsuikiA_af=Rn{RxBX!Gc!HGX%OzU*tQmKLbX!S#&Fj@!4ROQ+Y| zPMe^nn*aF(i{1Uh&axtSLLLwUP%v6Ud^~nwXOm3ZUX{{^VafqSJg3(BJj7{r=nP$4 zy5sz2XJ}o1pQRvNe7ooT`ec^Br7h-&QN*wBh`-KXvo6Vx$4y6TUd_Jr$AjU4L9gJF z<;_(=>5<%qw{?J6G#agtocZW?^3>9@tx2HQo{rz@9!6aFC2VJJmi+Lwlb|&GAI^VJ z^*SkL5W^iyajfjH4@o^)8_zk+Uz1ylGZzOEs`S!bBPEZd=wZTvm?_IW&9EF=sKfqU z#Eu`xbB0n(>p@epq3WH{#sHn4b*&nc8W!jJF52Y#Tbb*HM!&wS4}DWDNZ;}+m_QA& z+Hdb{c@pwBE8n;4l;weZsC?uVSQME|=X6?Wf^8b-k1ea*@_Q&Bt(5NVKiKc-JuYo* z{@4E?39$DTpZymr!~+EeragGijk_51G4Np>ZfeujtZv}W_*V>+6Z%{00*NCe?RgIdUD9cT9xT5O0-7rU($>A!_^j0?Fm?zR z+>IFa70!ldi2K@eh!tNV z_phO2Y%JlT-{~M{Dj>+LE2a5%8_E6qY`D^Ph>p{W`z+Oe@GDg2jkSa?hC=c#^D=9H z%niZ1TwCF5_kGmpyt>h=@&SuaBy{>91@z&km&yGR&0uePe!Tg55CiksX_(6NWaELC zg7m-HFp$`#Z8F=K+J~mi`)Eg|*gKIgq`2`-NJ$hr(A{^{Oh+db>hu-g z@2^UDBqC4oINeIzp>=AV42$LzOHfl4!gSOCe36wML%?1WZsxEV<2p1@!Qu8+;XU z#=5wS={b^7>!u5UNzyl%Nj?IYmea70WfOnX(VwvcnCKaMs}Yg4tAZH19ukskBzF_# z!m58zo?Dl(fDnr5xRLdBHuiu8 zzue#NoR!=J6}(t^%lRUjB!fFatF^qF*Ma@vzs}*s>bY$QoqFCs;BG}@-_Co5oalYX z6sjBaZS|(*SeO0YUwgFDub|mRLz=bAc8_lvIgOmv$(GP~q=;}ZL9$dEBE4I`jJ%X) zGuCd?zTe1*FAU0(-B|RQO@(!B7%noC9NeO^nvATdXZrD5ECzjkro~1xT{L8O=(h)t z-4D>%`;|BDBGmcGXR>_*F3thsw?ps6*K6o|%s*i;FmdhbI=TC0h@OLe_6n!+ACFyX z7?C?^H^YIZXgbcp+&q4N4^iV=BmY!c(IdIvw7J}m0D-~^%|l*;zFRHB|6;odXZQwJ zor|#ZVQZ^BzWReSx%fiypLa>Y0aP}fLoZd+FjT#zKIvFYB_IFu(cb*G0@c%25AjVU zUR_7O1(ywArE4G)6tC^5`iT;sw@y;dr3|U!M)&(Z6DLj3Kp1eDj^jKPB#Pz#P6bV~ z4ieNF4?P9mp%>uF=8r0KD|^mY-8&g`RKkplJ6Sn8!2y%Qs`8R>0hInmXVY6kArt3|INr za@IA19et3iX!2MK+I??u(eDnfxn;~oe7*zr(BNMZD6GZ5#;SB%diGqC!QlqiRw7Kl zTKLm2N7diz<9KP-5NyveY_A=9<42coOVX><@WCwrmAOU5X&qut}gEQ~J6%{R=gN+cs|}?)%I1Ap<@>U=$dS|0X3v1i zv!``NEKUq|NDP}TllL5k;=TN;;EgdR?3$*g7@4^O(zWZ(-T6_TBm22YX6+VoQC-Lb ztm0e!_D{4v47}liFW{3@^8#R2z!?lr!2)NF3>msB#eKlW!@-e5x^DFoMD930Waj5N z0Bt}Q-bNloWhn)-JUVa(C*)Eoa_H5}V+4M>DmXcBRi&X8x}qIc$^54hKX)NYwN?-OHy8q7g4ckoF6WJCO@ zlf&vmyNY#t&@qe@`!=)3IgccIUzU8wHf@b2IL-(OxWnpX(Rah$@oYs*v2mRde#p~* z43}EZ&Z~CjVTTTQ>=<4}n>E0ab&&5g)`7L36QaytF?UtYJkx5f$9CkkP2H@x7!~Mf zP6vVsuL9qR@J(5kcYwhL1JS^w4&o^-EJ+8@*}O>ZF}XkQ=kn3U%LoC?s`r^Ml(^5a zH3UB`hfK@cz&g+;z`!!<2N>U9U$z#6$}K-xhK0q?yKSu@4YJ#GbF*I!wVHz^!0lwD zo0E~$2C7?3tt%WYEX_d?ngC{GZXsfw>E)b-UfpPzs;c9FN>FV}1xRPbz&;|X#9ax% z0wG{FlFspDw{<`_6Tn?y*NVg6;fRq2PAqa^sCDn*!#Yx7t?Zsz1W4qfcw>KLR}*;W z+4qr>ONe!{H@L3}vwKLb#oh2DPSN}WN_^5D<6ag9gsYR(tMD-mel$2!wr;p&f>6fjWddvud`!nMCkt|engN4@^C!?35VP#w`UfZxvec{3Nae<-z;;RzCB*DB z{+6nwgU@0#Yq#}_tp7CoXr9`9{Z7WWEarn7z}Qp0VQV6D?VVgE@9?@9i<0 z$Z?OVewmTsb`X%%Dznvu>2P0rxZ{7e4eyAle%$zBPk@{3M8KE7Ox3ov2YF-7$jlCL z&qwosuRrbfKukbD(XZQ3NBV!D&rOO6Y?|}X{TI^*#WK9TozVjgIHUu@bURRGr<9rm zk}FT~97z?uo7u63s@#3)rN~<2$EB{u6;S%0JN5u`!3u~$Ewy8{epiAN$h&;i^T zh1{+0(gM33_nVpnD&XW4@TZ(O3QEp1b|c1tc*!V=?a+X zrgA=nf$D4gby$fQ8CRX2VLk9c{KO-%edsj#M5~25)@4MW*h}iN%#kbvsGgdoYZ4m@ zeT60z*J=>-&S=qS0U?Rv4*Lq80D#yL(Qv6rla7XPj;)aN=ExZxGT^D$>8d4pYaa-m4K!e96q=58>Q~*+?_7LFowq=<3_Gpi}Rv=`YXb^W*V0HZd z+v_!VOpqB=o}-sA668P+iA5U_th6`*v#BC+g)js&bDap(OIj@^J$(qfu3E9XfjE~R;snl>9DzZ=zo{)3_? zS43y%>E4-}@_Rb?%pVEBXqD8uA9lgURAG>SPO$~EVBAn#A-U#bFfR{S>Q_^y*H4z6 z!HA?pqkcg&LKmT#SD%PtCiep!K^dCmvs#N--9*BNg+V!uU$R3$0F7!rl%+%MHZ=R? zzFZy>`}U^m*#gkFddNzJf}iw!nJ@Ucr$)>$`7Zsh?uo5P07qYdqi3-Fz3*i{kD0Ef zwqPM*c9kzPQVL8k({wQc!rJyZ0nE+~pO_uYN^ctq8q-{?BRF_Q^~sLc%XPm6wU&y=(q8*|OaLJFPHkv_9L^tJ{v=Wyu9N z`+|v%X_Y{8(bLx7+Ai9^bbit|JgrN1)BE%A_U~qA0eHU005@(Wgw)1!Ghb0Of_fd^ zC~gX&SfhF0sp@VlA8s=?Rs0;j=Bg+E{WkWF59wr3ReR(N1unO6J2p z7O~HX0gy@RS-+bkW!9{;9b}N~9OSOSx;wrr&4)o!rd^nQXB)D^P>x+P)Lvbjly=mvD`} zH#)X*dF7E?!!uU5Z_658_$%;HhE8Uqv9He2QeW%=BOHqv#cQ+Ihdr+P+$$(W>mzt> z-LMDZOV%su+9D%E*sUR+8p&p=_>w+>mxCgw)D^CcWR5%0+-)8tfH&AafDGF2tI_YH zm9~d(VSA!BFrlsoX$wAD-OGqW)-}q8$-{=1_1Sq&m$Ps|_PgJ=Izr9-sx2M#P+ZMx ztrfAVYyvraSH7Z-o7Ui?w&(}gT{CMv6MbglH@cd=E@I3J+V@b;or+IDGf2BnWx7<` z9bJ!O5W0{dg#R@z^ZOC)m9&*=Uv+e=Kh_o>|{FoKPQnOSx95=X)D#mfwC;+JZR?Q6MAPpdwWt6zTKimt$Ct?w;?sMJSDyR1U{ zp%M|T9@HsSOvP)Wte%N z*hj%{^9yJt14c%okAdp0)fRFflhpP&ULFcO(V#F!HJ^ySLxgFy5+WBX*? zSaE*QJmL2UH-utWp@{x_y)E9G0upBqQAf*XmmYqixkHk)tx>$SdKEK(^;bmdWuOXK z;?*I+c9Z8%Xoc=d6Po`>9GO0=)77LNMa0bezGWOOlAvP~rA;>NAZv$YXYxHIe|`)- z8Q-N2&4qPJ&Er`i5Q6*YEjMCj-9v$@IBmgA_~S#r+?2-9o*4besOi#~X&H|-~^ z>ep0%>OVgPBG=Q zp{KxqeCu|-$7;ewg1h+od+X}g?oIH9ddI*)Ob^ub|A2+Q7?iXFyJ@%o#$X}=*q0V1 zM*mC&?~_v~Vofzd16o?s>c|DW2w>CK+tg$# z0_jxU@e)z1`R=}k+fHJw*kK7fbo$#30>Tu@5dB`+^bb&XM!c4Ng0_ZLcuRWKoAq^c zgOGl9D_q$_fnC8nC&+-$C#RC)E%v*}y^=wvljT}0X<=a0W8G1~7m(ad3j*P!|ElGX z&Kt4H+ixYgBvgpn(JwrXJpG)|2NY#X4cxk?>7geyZEh23#80Z9QAACY1jg(%*HK72 zr~qU?$Uvy0Ot*RqC06*^yF+i=&7QK)X+A1K^|)J1pM9e+bUcJH(LQp0ONs^{=e?`% z5xe4ky#lnf=!^bIvDmSdZMPkQ#Z%m56ToS7$NQ%OBz^#~9$Z#Z5^6ym4_yL3gxoN@ z;$C#k&8(VuFgkxNNXY!X%rZT5Iy6qZu%2*sSmqFq{;(4>oqNFi@S04_bxNk(w=^Hb z@L98398lTLzq$1Ak6i_#o2{E{m9|HE87@j@r)63A?fr8dZ1rk(-;o#{VQ72uzJtjr z6J43jga43l>)D~&xT5!_9gWAvOC3w?PNA0jI;LfYAXaCeNmdV5Ez%%c(UR>3+0|rk za3HijvZhLDS`iWs)Wej=@AWGUAs!iVCeIqL-&?BiS&c1q8qwOggim$~`MW|Y*mY$b zJ|wOZ#dZ!N3!zwp!d5`~xFPKyYbHI5*Y^FzIy6 zUoVi@Va&)%nO`Mpib4U9DVSCN1_`UU2vPu zE$?O(WHqTQ|ARQy`|c(eCT(|^q;h9XQQ_()peA@PPkrCJjatq8)f|BE?k{!fcJtnKdb-z z=F@98Yz4T0)ZcfQ$Qj>06Y?TLKzr1v0YiCbLs_&#Cf)Tl0PB0S>?v>3iz-b(mD5Hs9`^3Zb@BDpUckIbt;_M+Za_5Q$PV6}SHDZ*6# zao%?sCn{@>vE#F?5g!**$dc9qf#hiFcLiU%EZBKu^!gZ&#%lv0{bWiKv zCio>Ui2S1WCn=s*L$DAfIxe2$xt%@I1;~XP+Et7RQSIBR>#Wi~*@ZY4_IR21kzLK7o`3PSVIxLtcAq)Vy+rhG#}WvI>Uvf&yO82x1Qv+={!DJ zJ=P!##K_%VSm_r|)dBUOSTTRoDKv2P=?k*n(*N>&3xOe24p5%EKpA;8PeKHlo7fHs zpu;kkHX6{$-HV=H2E0kRPev~C#%tA&c>_j-6_h<0rewS*gwBE9#XB;-nU2s^xwX zC{}RnY&wpUUtF3gow|G}hDCm`QZy=H+8?oE4bPuX0-rDvHP%C{;@mI2$EEVwfraV* z>5asxW>+UDSdcyfVx1si74;8}9>1H-2E2pi$Dc%I zv`DP<+_#CWzZ6wz-t-xy4q{E)wog7`B-9AB=92)DiJ=L37W_XV^0^0SBG>!D=7 zC$SEYhd9lAVP9W2VkCh0WgW5POZc@=?RZJI%bQl@E+$6*)nB)qM}xa@`*H^Mb3Ps{ zTP_qgzqq%mvvcRKE;p}f*ly&nH5Hce+G?8;Tfi~D{%L*s-#0Ew%@&k7(xtx4YBoBp zMX&1hF|HIau^v59wRqd&;UAgfTWBlXwC2B*IC4a&&1&@0e4xV)V5^R1h1d{}Shnup z+nZZKv4jt10?3y~7OJHU_`pC-ZjuP*^AD_)DvBtNdTvrmfbYCtY15@*WV;4H??Qz* z%~D_Y;I?EsvlO$8g~KA%cia_O3S5qk+d3z^v|DcJk332)pvx_K-qc4{W%FJy@H-)FFe1$N=%M4?Eg{JmQG1Z; z{Tliam7EE}KZ#le3!m-cSQR!#>mldB_rH_D@?tPfH?it2=WH#zW5%<7;m`egCCMDJpmI{-9_ay9nIyurBk zRZWN5<5V|`FwUb_g4d*gdG~h0VxhNf2NYf14W(m3BF z0sbg+UJ3icEt6Qn3gPlG4yIWz`dgj0Z+<^|@=#;5{_UUdoH)=i^p$_o_)$IpPgS%! zuWVq65!*!q=LT|7E64OJxfH zx}#@b)~7AzrYOab+%L;iA*6-u->s-eVJ%fdl!FwXAtT7VH)g;eP}+WSaOMPc4XFTB zyY(g#P!!&Sx>z!L)8_60lo8bA@38dU5}Q_gtH_b+!~-@p@(|799S`x1vU#^f|Dh&6 zgz^u--ShKs>8y<@)&;zqm_dzMNhd$4j=K^Nqn9O$xFQ;_Ev=!Jd=Zpp(;72xwhZYXD$}CipX5GwK>&6g&W9phOYQsdKDVo3~fH zEUrZBlHcC!e)rk#tj?zFE`K*~ z78;x=(CpINGG#-maALI4BLjeQAFMc2rEDn{Jv}cnLAIL3jtq|*{vD_6AzHY`8_Y(p zho$ea>V}I9cl*uh!#@xbBl2~0#C1;-yI>AEmk0HW>k0taXRV!mq}fsnEpgAO*fyWu zp3^UQ_4yT%bDj&n#@Eb%zvNWamlUGYw^kDeRTK%wIL%5O#MXaPxn4W*sGi^+eCQow z8+qX1hvnmh8_hx;N+N`CR^r}2Q`6U9kJ@<;i2sNTbcu7-LfjpjE_21t)Sn7anjL07 zV#nLd?=DGVZXWK?ym^1AvtYI1ujn`~Pw^1U{>a7(zcuu<0ZJQ@q1k5Jx}=Wv;CG&m zc32zS?}b4!Dy)~LY>E$^T^X$dX{q7y$V>J#p?OhaNY0Ay1+3!UQ88X(H%pIdg{ZZ13CSh>6S| z$@&G@shewPQ2PcBcR)>fuaRcRPl1P>*2AoKy=x0Z-_RL$;w5Gwzzm{$cQdoc`-`b= zY~X&bflK64;Ahp_YnVazMSrVP_fB+o3&bZJz^Z%;b$u zAYt|ANJvcstUSF|P3cmu@0SH6MAh=uy#x2371QM2nLtR&X`7#J2Ol&24P9IFXe|Wn zxS~JGS{aTVWtrj|=ck%L8EBn0v!CsjDi}-HSI9+3D|8H~glXv{AUJ`HShe!pwrjw{ zTD(#;XA9NC8uUAQ}TMyx7FZsTo_itn<5yp}G z2(GO*0vni69a=zf;^du*Z$E^H=1RF7kW(zWQ+AuuiI>yl0b4c`q~h}bAt4eGwnOB_ zz{qs8RN^W)kom<{CE#P$TsfFKUDL!jamWr))@GnM(MTrFD{e2=F3<{`jgvpA zWryh1rV0@0e4*pGvE%Tz@9V?#SL~dw&uSL3q9|>TBS!G)(9gi`&`Xk=;~KFK5(Iit zI4byAVUS-^sBEGIcwQ72(MbZ6>>zs#Zd)N&9G8>e>IW8yi$##{9AX_i5HgZhKg)Ik zCQN@?X@!Ou_`;j$l3y*wRr;%a%++-8S4u)D9vRXeHWTCI<+r6004*h)2aJ~TfAqywz(7WaNQJY2A zthD`BIrQ$!$Sfw78`AfJ_Nd4&1042!f*UJ1=<)7u4)QMdQS@wV2R}NQum%&h?u!VR zsf6iFazo=7<2D@5xY;56J-030AXBH*#=MJ0n~A@k|7pn$Ju2nIn5pVI7P~}ukpz1f z`Xe$NGa=ngXaGs321aGotE>+_@n9DX^;1%LwqVSYO2R(!;>dd{388_ds8Vff38nc|x3`8=dMu%S!24R98H)c+|e zFU?#aVtTRbVdtZ$Om->=1#LIC*q9^>XDY4sIHk&&*+`f~FaIDTyT-HUNVnFnchKLG zp7Wf^>0B*fy@CT}$6FV4d_wkV^y;7hH>%|l-$C{AzQ+ojf<-#R*k_uo?VnRrk*YlN}Fz=w9QSs0$oA-LR04hlU&;V^O0Ke3aXA`PskPg zAa|Kfd*H*5mYe`BCMb%h_$aioVV;SIHGPK!o1eM9^B$8b-AshRZ91DApl8Kk*UMvX zxwL@wvUzcN&RaG6AB#DzuReSl;YI`eHCjcU1RHLd8@>qz&=lVmZ!LCx zmM>Y8WJ2E$OCD|;n1ndf)y_iz1EdUJDKpU?aKdihi_Pi?>JtqT3vr{2$cGE|mq z(xR)*VYleBGh)BxkE$8ryrFBI;|YxLyr>JI$g;GgB30y@ESGZ03bLGbjAkE9Omg8-4K z+yg)wI2U=<5h;~ZoEwCD^6CyZu;DISYQcyzQ^FQgWoDvkhe*)dfQpnzP2TkS zDU+5U_UhaF;gg;(4D7JX+EGL=szUx)S$L(k6U%4(6w0ek+`_kD@zHT{?>sEPkwjy{#qp z7>wWCa&HeL{&tDnpEx9ibD`A!u}W7qdtTF6>n~r}Ks8DGcYQ z2hA<-xRc-GDVD-NxG$F|935xik14$2$}4E7!`)QnA@Y&aTxtaMG=_fajZ9)~x(#4!Rt^03K0oFvu!H4sbL-Dl}r1@ypV~Y-oz57Jb zG_FPX@+vPRA>@+qROKAyI9kZM4Vcmad01SqjX9$wZpL1Pj%9t4*MhQ1;X{BjI=%Let{fZR3Fp%=&X@9r) z&G~_?dvtp+KI%PydswG`^?3y;a@{!Lc2F!~(XmO0Fg-QM$zh-4{*29qaE0irB`r`x z`8u~~CI+e9S@n}%kg+GSO}hxliKM2M9&oxe(R|72e8q-Yb^QO!P{{MqAf9m3mawtq z=}@g>of}yTWmwdRG2?`yFp7D26G(v;*qH)ZsPv}>HBt%!s_f9SR3X!Pjd=ylrjJtx?mYF76Z%~&raL!o59Ysq6wBIjkRWez_b~(Chtib(!g=8 zR<&S?V$#rccHv&`lUO>jZZ50cm1KXaMhdwlp11unJ%N@b=2gBH(ZFFmvhJ+CHNuK= z!??MG8^sQ+TlPhAUl0H}VAjIA0;B0IbHx&~kcZ9W#{tT6XcyL)g=qc2UL%RTy(jIT z0J-Gy4=t&Wd7(ycNmgvH`gKUI^%y0>f>x_Q(W`I21lGBh@?&Mj{`*|#U3oU(UGzE3 z^|T+VAlaiKz@gmhfvovKa^73rLGHB~>w4PgogEddyAAwHZ2m(Wip z5d0c(Kbnx(C1OYQMA_QRY<1YYEUTYOzY)~_mSj{gxMs9U;|{_K@ecW-EDGg}BvG?J z0CkGBmT&nz6Ch1kkjWX5#R665JCkG!dWo`T&Rmp^$aUbm32&L3viQlwx!fsvfnV!R z2k3-$K!J_x1hbMiB7Jq9IJe`%#jtq4T#mBk7k-as?@PgCdG!~tc915chqU&wUxb4sf_sZu-_Z2`Pn1|o&8Bc#1j7j;e2WT?~ z&05Lxm-O?yyfN&uG{bvMfBWucaz*y;$7iVU??y#^zF*y%IteYSA*+HFmU7d((f#_b zZ4;>4tDj=A=09EH5V8xYp))|sC2r!7-Vk)CQ0Yhi_$pcSVb7c^xU(yq(nI~-`SJgb z7Nc?rqW3!d;lP?idm_d=e*OqLW4KLlr}@c3&ms1OxS>yCrCp(@#EX$!y;CkN(jhGN z0b;~3-!hMcj(_Gdt?IA}J@&QvCrmqOTJytMf4SfH-RHl-S2RRdpYT6+?GGO$rhnH* zb6fA!U&A)zvd=V!DIisShxkPyj*!HcTxm2R{+2`KqW_2`2&XZtv1M-PFHTte^U+^) zOn)2fj@oED_x@f_v+==O^CK0JC!y}F(rAno4f8rHf19UxOnh-hUh~lxt&h@*`g}V` zozJr=_%`RB(YdLbS()JbTT7FTS5N-tnU+TvpI%ZrAGHnZVt+kraWao8!-XBXsK%HGXd-7*d&rUSD5j|)t`Ex|xZg1ur(2;>g^sgyXylLxI3spbyZ3NW8fWqZRL zba59y1*f%$MW!dPN|_NC!3!YjJDg1mGVgc$b~r%l=#-6~V#sE-fqG7KFLof7C+5-P zB~jZ#Lgl5zPn@3^h{aYrBjR{_U&Mv02~e05PeCY_04=&(xRe1_GHF5|MM=;sSc0Tt z`8JyWabNJERRK~N@5V@`ZQMf5)N=`m{7QQ0{qRI(E{#~<*W`| zG5hosIE9dV^rhzZU7h`=`1_#7akspFVae!dz*w^mqUp~5xJ+39@L)O2F zYzmgZ2un1z2J&b`{JA<0Qa_|#)xA?LSzYJy=GRP!PkaOiHl5-D6M!JU$nhY zfN#KsiP_6jY>a7R32}pWsQe;LH9J&ZeJ8~%OL{_@7TKkh;SE{=Bqa_YkFeTy^W{d% z3k~8j#x6tA3`;7XOM6(gu7^WqQQ@9ZmziN>N$?4;=qWbB@MQY(3stD@4flehKiqu& zWgpS8X7YmhT#6EjO9)!v3C1;V{xcIuX-|^%mc+xW9g|n&*wQxl>e9LSdfo;k_sy|})BM^9T5%H?ZDpKR#*FQ3c-Qu4_`+ehBHi6>Ir zrmQ;X0FuW-_*>Ns+FMd%^$im4?51*djNzH_+Q_C~O9nr}p56E1k5h{u^WH@tE#@1q zNh#O`8|%)A8)LbI|KzBWb`0*G>Q&X;PnU$02nM|);4jf~DI3j3LglocU$#`_gpRSj z&bxaird`z%zrdXakG<<}f8&s?ks|fSBhfR3-&FS9zEx;o#->Z^0*x{_u}WUOH#|l4 z#qa*^X5m?qeLk7g**Q@b{@qr7yGWA#Np;U-YvsT0CmTxt>mO75eM>hzo5o6Q?xf_Q zoq@^D9@pz9Viun88otfwI$9mt>7w+#(rx;)B>3}wYH@1TY3mOqEy}-W^K9ss z_b<|kf9Nks8~{LTo29)aE?zTMzb^tsYcMVC+JhXaJL6W6!$M{k??SC_G0MR^H!QAP zu_>~<&OP)Z&EIR7c>U_f6@(}J1Sro6PGjGO^_RJE|M93sj4e<63^6Q&hY$h!HoG(o z1m?G^nP0yY9}lSBw5=qYb`K_r3Bt@)mce*N;dTifgRg~29A5T5xdX|X9f`KsXd*CH zB%1(isu)!(ur8{J=M{ti_!I}bfgb<)c;(^HX#4u}8}KgxXD{Lc&d{h-xayBEArvwV zwaK2)AAzt(`-9W(wTC!Ku_-6AEmr_8J|sQU1t6HWvBQ_uxNu`Nb#+>ZiLe^Q$NdGy zYFK~Jd^Ibwwj->jGD@V#nr-NoO4|N}zd+vJVJ{yr-9P4;9om5bXAyP=(JlSBc*~*L zr$g0NWJ5>lE%ed|=vagyMlLt^t`iE1Q)t11{mE#5xaNH%%k9Hf!GwlXS~m`#mC{f-cMi zAfpXFjRf(1sd$6fgy~e~gaG%SI^^8|>A1v<<%p`%{tc7o*_mMpNW9}&)r%I$r&y{_ z~fD-JS27(urs8?B>SOZ zDIlJIz<5&Ox|VX)yT>+O^IiSVFS%v$AO(y)P668VVX(^*=EIwOid$j4=cuC2NFjS= zvO3>-+sRTv5Y8p+@u?3v-b`LrdtA&7ods)i9l9i_yLciA&Ni}_(9o5s#W=A=3RcuqTT^)uS z+=-XqGN8`@^{AiN?&V#3EC--Y6z3(7iGz-VZSd?C}F+98*UG2RTc=o%0{AcLj?{iWACrL~<{a$)3 z+z9tY(zaL;54Qbmy>X&+G>LXGj=wi#A+7+ff)N(edpj`fzu4<%!OCiV_e zo6LY2d|CsB0-p{kS{8FrgfVBIJ!KE2T*FRHQs_&^o2=lHaAUjIX4jd7x5Sf*Sh_k) z%K~XrejgPitkiBUgX8t1z+_857&ofPvYx_q?V3sgquV}$cY0aykuN${`keScuM+1Ie#q@ot#iqugThyph##Y6^HITz}X)O#)YqN}x>Igv2x2Ns#< z?@r5I*NnF&rSL7_Bi;n@qv)@W+zkPH^V>+Qo8uD`KGxaE*B_P+|BYXf^x;Z_Cr=Y`5d z7JsB1`K%_|icPK=xqJ&qb;41xQ9wyZ$IR2MG!JT6!U*3yVS1%m{vULl+I;ZcCND|& z=hdh}pVmOk>-LqtJ&=1oHGAMZU%tRd#1(?3+oE_|I1om5dq=5#s?uOno@u8eQbV>6 zBaGq_E^m?JbFebK;fPU4G+&H*c+SwW-g5ok7DX6~;+QJ_5b7L8>f)Z>d{%ifhXgnSTn$@g7v3Of()m=nRJ4>SbVqw5dcj$>b^jMfbQ54ss|4XixM zdqncKGxt*O>ue-HxTsza6cc(+!QtP1F70pZ)cz0hWYr4e-4|Ec8D3S%LzkaA(3XMJ zTNtIW>R_~OG}7UYV%We6zUHTLQ)|Sk&yY;u!-V$dO;_n{@yp6`6R|srB8=q<3zkI<>JHjRgEFhBVN60e*6LEr z(eN4YYKOYV#t;-JUBQDPx(TjgvDo9%%BmOBLVRd-?j|+IVbO(rK|)p*MeRXULRs0> zK9`M+9-=f|FUL}qM+M0_JA=X}>&24uKK&r@wwfZGeXM9pcS;7}gg>NuL9`DQKrOF78ub8($cg_>9}t-Lg39iG z>_SWj!xNW%vZSc_SkiWpS~y7G7anx6!(glj z)YR)z(}>W!b84{RFd@;NKn)WcF@G*RCtT@+Htx5bISpC~FJMyxH29ena)3NGhV6wz zYa7&|K;Q$DDAxx2_T101G2j(s8*P1NMTMxfXd>Gta_@IHX#+JmgvYS&33V;rv6hBk ziI2cKL^XgE5JC-Pb&BYY&ef?~Fe!|f7F7raQ+@4X`@|G3`a*KES3vlFTW47HOm?ChaJ?1ym8#I9D)j@M>Aj; zl6FgcuO3iZt=jf!btCFYcL+CZHm;w%?)=^^*mdo6H(?#XNFwjAYEh-xW@OH%6t-k) zTh>gL)p$vmMCzSqhU_i#i~GqjSwD)9GL9X`_|$t-ZH0bOX9J`4DU1Ve6V8vBz=bzf zu-FIf!4V$g;${dfHhVN%AWwnmT^joLCWPI*LC;REreU~!= z_Bc7}7x9`z$1OW@6nu?@^F~CHpr|yD5I-wPc4q7|@!}|2bh9;L zczsg1MRM(`;!#x^Z=zX$LdF8Ta8KsRB5koL!a82vWsg63drxvD2NmUZU|VF{H|I!5 zgxUPbYIiI(8+ha557I&YvX$Z^lhOSKQqGk`)^rr_t!|cm=|rQbstCWtm7**Dqj;SHzCBU$PeQ;4nkLmrRDREs=0`}Ru84K}vRR+Q1led`RrqVXuj|1>? zk?m+Xr{HiFfHvd`U^NV9U_`qcebK(4^xOUwU`Nz{T)vn}CH0b8qAmEQ z)*WAUoa|Xrr=?W5B#YG;KU&-i-$gas3SjbN#ZK2W}D zp7?NwE1DQ`xG zSH&N6PAdx80y9lM1*fZ-Pr{d4+I#->v)ny{ov)(24=hKyVg<}bLmh^+JVt1x2Y8mU z{KQ@fP7aPiO_`7jDxq>=e+c)%Bh#Yx{##H)3jF|e1{TH4Aw||+SmBE*(Tknywy&fM z(~Z>`Q@I}Tu&&sSw+r|-hO3$1@KBXvY7e+_%Nk75AK<30-xIqJAS7WM#4GMp9`kqP zwD+>g$y&MDy*t8~huiNyP{NJE-=^)D$|>w~dI_niQEJRgw09Ted&0}co@3{@`nxYA z!*dd6xEqP(3ze{VkwCTC@)R8=H8h?<%$N5cT7zk zyQ*N2x)9{)uVI89{|toPo?Ig}M6*4wl8Kv3_%XsWub0*HHA9!a4>y)#u5|<+X;JkL zE^etxEATcDuSR1ifEW(UQv5?Ebp81#W<*(9Mo`a;U~sq6QvEp6w;0b+O>yz9^}kL*klm zbuZaixbVtQ1JTsuKo7Vj#(U|rxl@kWSY&Cfwt_E8g>!^V8O$b2xfpJ-#cc?Z;EPMd z<0F?PR`h3O57yYXwgunINgObX)Ca5e0GT+U5dDxXYbr;fvcVtL3 zqV8DGOF5DM9BhpyFP$SJ?2IteOC=(*cJ9Hmc*wG#U68XeKDz1zG^#Cc9=r-q3QV5q z%hZ;QZmDhuWK)>M;UJgaq42eJPvG}*pK-N7K1SB&{o@g38N}P25vxf*TLK$3 z|F)w4++hW9#YK9C=V1ptoL!*z2SG+2Gc-yB-IMiUr%j22v5vDxFR8`9k?}q0=1~m-FZb5($hyO9>}KM zcp7pN7)udneV8BP?oOEa-6Z9v|I`^MrjIrJL*A>bxJXBRNYpmf&JV4cB6W{X!Eh8a zyCGgyCVzGZB%0XewKUdwL2Jb}0%`%Vyg_f6^_ElYkvB~`g z%sO2TkSEck)S6kmMp^JMV$-A@hN1tD1;(R}|x&Fn^UVvEhuhg4P@{QUhKdgeE zkdc+nhJEsdw_l594qDRR-X$_`rt3n4biZkhQ_C;a{F-QNu~D4Aq+Dcm_*xsft7~lI zm#O?@so@oSvsZ)CMtj|HT8mO#@}77Z1nV!fRdbsvTyeH&lC3MC$k7$zPYsiCAYg=U ziC*O$dLByiuzIVgxrER6E478OqX=vgQ*<4PX!gXZS<($QVI!J!fRdX>2#uH20e9}nIxg`dsQ%FU4Qfw?i&~Pd(yo?F4EOutG zF?rQ2c{W~)B6Y_=+YXB`jc$`Usl@~IXRlJeT2jqqcd#C-db<9;qXVySK!~mY*wnHT zdk3>-#65XI0MQRhhC|&ug)i|4Yw;%jX@otRtC~;NpM27C7enDQS!71IluC2dAYqO@=^#z zR0(~Ai8mquq#pFh|Bb+++Msr_`gtK*B$DTFqo-;NI*62KJJfz0-&W7nqR&N0YR~Jy zua-yqs-JHVkdqzL=W&s3PxKh2%lUrBlLj6;HiWj$Z8DKtAn-EbEDrlo7HIy`xT?e4 zlD>B!%G3lH4x{Kq9jJQ)jj6HDEio`a^wTZP3)Fb`<@%q^KkVIa`;+johL^xmXwFhy zijxpMeS2Pr2HZ#>gVBtf0n$OdM?m;%qoUoRTc}~q56{E z8{hVI&u1IEHB#9BpfJ?O@FqO~XNLGrt(m`IAiGPC80#fZ5_!otPqw#^10x-C@P(=q z#^NbiJlGR8If2PZ``ISq*wl+cw9b>VcmS45>f86P&JN_an?61}d^O;oKn~RtP;U>TBPW&6bOWEhvTsRAk}R z#b8k@TI38h9Z9e7pm=qK_yEyTlN=w;M)dg{Zma8BQcP<=b~dMu6cM25U z+Rm@Cx13wgdSajygH1~LP`%#0NfX=ATM#k5O*)TdnYrNb5L@xNTLHY8u5cX6=Lt>~N zh?@bIzth0~!b!H+XAgCcStoVwNBJ2CO0b{hN*JwoS9M z3D+jL{Lz~)wat1^p!gSNr3Ed9wOQ@)A3QjmwXu@{^m99$EV$e{ogf*k@uP;cnl-Nkq@pYhiidcjd1j6) zX1xzN{X7AEj+Ea;nvi85H(qWAJM2lReZ3{8I2rVSH^cW9lILT?YV53eMoAdE`-4|D z(+f?D&xLSWF-S3nu(IHvk#Q}tg--dJ-HeW|-8r$j09_6&C*k7c?%W`Q0JBMdj2lfo zyJHy*GMnix4MX(}w5Z^Jq6)EY>GBEF<|=*m*ROso-TIdvz-7X^q|Whor|C(cl0icM z_j6=*XV@4d+z?bmGVqLAw2SIKfB5p0 zDUssEB$0uZ&h{0j+0W;frj6a%oC;54qyI4}Jbp3Z)D6!xw3YnVFXgyTTFqBi^uGyY z(x|R}j}KtagO3=`guvx4X!h|&ztIICYF(PF6X6QGoD0>K2Tay^ymo1xMsx zYd(+>0`4?nz0;S=%_3V|_gr{G8bqgLfXn9fpVl~}nQT30CL;Ck!x)RsA3-zVm-Z*m z&wi+HZyA&jgh6^2d3e62Ml^h%8*OkXky94HAacv1mT&>5zRw%@BzG+J;UWf)ekIrj zdpISYzI=yy3g-z}YM%zS*o;c@46iG3og$uWEGrG|L4z99#-*cW;n(kB&rz1Yaf^)r zVL5LDf1XL2Jygw#NUl7+d5pi*JbK@mS!iEN%|+2umQ)?+;~4vV!mK!78$h<)^kJrZ zsFEtT-OF(%O-KrtH9nXA!}4hNyi5iUVx~Y~ys`f@{;qcK;XeT5v=Vad=qIZtG|@A;K}W|NODd#vl-TjlvfINW zwb=4u_@&zXZm`9iSW#vPB)_XN7^J96WLh_spoB^v`zcdPEwGRnXmN}mgX76Ekihoa zA>>t*){fUVYn)n#{d6Dj6x@!AaQ6QAV?s=B@x+>mDW1sF`ec**o{m?009j!scCgYJ zitv?Z8jrX7x#R0p%hqurzEx5m96!ZNDj8(&m`L*7DdTmcvSTqw60x7!B91?;@i{>F zYYD&k{SA`RWxccfU^~jKW~komX!1^XZ)kO@e|oU%9SCRped1U(LLx%nf5TOx1Z&Av z>1=pec)DEh-%k#3klua1R)6*sth3M8$)|M})DT4F$HoRx6LGJTTu^l8fp>v4Lir~F z`BIxlTF=5Xv?6Lc?DKI7M;Vj0JDTdk)spRp=IN6>nn#a54KR~!AlL;fHqi)8@`XbZ zM+Jw5d`TWl4r8Z*#56ItCkx^5#q58XhY+kq7fF0Ks%pW8`bCvBAI zWy$7aaxN;DZecyd*N4tCi_!tk_2Z|q{9RBcqVn)#;`jsz);vhVp!&)E+(%XE`2S*T zfBny(BkAA_x&Y8KDW8I%=?Tt*SEUcjgR@GqW&t1Kd1>w38$Q_cIc$A<4lb#Cy)8tM zdASAV+UJYg6i`1R5n%`51y7P0VIAZ?W)3|)_2geiKSYgqvR)FJEHV&Z&|4Z^bL^6h zwx!n(4x0^=Q@r^^sF36pwH{2sNhuxuR07oG z#6hC#SJigCJ)R@#AmeOfH2SaeBaIpS#mqOsxpCeTy!g)|auansYEX3>`N40-IAnYB zUvCzhMH^TNoeUAw{FzN-U|(`?M4sSOr6s>gc}s%ZxVx-YZD0k-a_c}6e8JF4tiK*6 zpRP9>FT=Z+E0F<8n6?GcLJrMLi%-G25#(mdK zctmXm?x~^btz(;`0lRkx_@4MD#CTFKYUn=W5AvgzeiRtN;$p5z`z!&8bmG(AM%A`m z(K~H}VOEsR^Brmu`ie#7iFitcuJ|o#@UUKM>#jF|0#_Cu+vN-CPXf|Xckc<11t}zx z5G4D--Py4R2VRtIySR6gH4uM$`_gm5a|Y$VzJGf`gGSE;enb!P!V_rY&b zmm-EP-#&y9Le!Q`{ZaJ@f8%$nT$r~N7&ML<`q~|{36zz! zCXB{?x*Qc)-najLxbX!@vW+%q11<@xVJr(q<%EhO&UvyNe>(kLZyGa^4EuI@Uaje( zOQuTE9R-KMF|Z-NidjgSu#PmHjM&0JHsw2+zK8V0PJOy(Ym^gI)T?p&!gN!R*vjBl zwbCo@`hS)M|A5qkj5H5{BKH8OaAn*M@m7GLyys1ywB*Hn?F6Smy$gnqVtTUfB|Y-! zoi6X_+6A4SUuwFg7a-xa3;LUajKG7#m6t2DSZKw}+q4*)EPB=mz6}&bY6x7kGE339S)0!kBWTYq`&_`RXBm8D(CG;xVaN0GAK@Z500fIz&Y z#nZu|nEd*lDW3M%B{HlkE!@+ZU@3@4FtU=6D;G$mwS&F-?1Gbm*KEv{31L}ySi?f2 zuy?6R8y#~d0uOGxx415emN`GD;~6VLyGeZj^9y}>OV7+LAGxg5H1<3hGi`oBQo^JlzC4rF`Ddc>Tqpxs zl@@Utt+}c%dszKe0@aXxItX<6cL-6dM6pZ6lpy6RA0~H(;QrOpJnJybKwj1~964gV z6i4-BI*}Zz$;&_*S4hUDz~k%3l7|Da15MMB^)@aDsVG=c-)>rGKwXb& zyAX1pmYoOM&4UWh?5~9+%5>e=Zn@-nHn!%&nhN>K){HzGXs>=cXC>woPlG_ITow&n zgWY>Dy_1&XNgRjLIzNZBkS{WeH!W@nNPZk-eCuW&))EJisVzOO(cTHT%fG!}!J$f;rVyBiLF|g3R%~Af=y_0}@k%fp z9I3te091w$h!;vEiW_0UaYOWt*yLfb^#|rLM&dCSZdv7J+)qY0#rk63&T0~(@+6X^ zV$-u#!b`W1xP&n7-!}?dkR;nIqj29xFkx|No*c}tE%KTKJHY8@AQVEkgJ61=M6v=1 z2dCE$*WwBLS0oaTV#6^aV^4eq#vl& z7apeanXxe;;@65g@bA(&? z7?B^t7$8!_A)zau2C2vBAkfkGVMng0idjaBcx~R*+e{hHaywRTC%7^S>y@!v=GUz-N)*z6;JR1&fpun= z(-$Ot3Nxx#1Fq_x=!w|yB_+!2yj`#$bBdyr%n=~{P2xTLgI^@;M$8b|;v^WLa-VR& zjV;1~aa0A|V;LTDQ|;o#L}T5Sw>>dRuO*e* zCoO}}0)RWA=0J@k0Z9cVcqB<}Aa)dLQ#j!M=)*+%Ih7Jos-?c5sn4rj3%zkM zyZJrH1vFk%b%VPpuyO4e_)`!|Honh0^a^xZ+)Z=er6lCN5AFv*Eh=gpS9Y_(1zlu$yyh znBOzLa($vafNs>p_D)^Qz5y4b9=C)kPzkY5dNE)DmUH?$VU24h`P@t*Hd_-}V&L@!E_r~&Rdi)_QM{(|2Mud4i1dtcNM_*xvxvi~z zSobf#$lIxF66b_X`qF#bpj$56{moy9FX)hIWsSJ!?*x*j)#X9mBtwhF;y*3>mgYz0 z{wz37JQGGj-&@w?vchDSPlj7CN=^upV*1{-!*7P$3IZh;g8Xz45hUqM{yTa;0Y@@sRO_%s{o?ZRb6BVP=se<1(jd>?)S5?L9DO?ObY_lzJa7Jk|cMN@T7zq~y-~D*G3wdj~Ymc9polkiY1BFO`va!;wAhvTLWYdz` z_9h6{eN{YIGkSY>Y)CLItg=iOTNtTPs7~$zGbC|F*oHxkL#FY1oxqf>7=Qb~Ho?>e zMvaSV-SM1ci|&pU6ek~j3%uV$C19!f7nRawQ)KP8@MZl%%BMGfjm^F54dz8;e_jvP zL?Z)s+eW~ZMVOGMX!}XR0O4sk7NF+4OLYVmf!d7O>QmhCu%=4AyBI}Kot|a8#$%0D z@ow>K$&WjCXznLxINHpaarJaFMXZJ(cWrw!ds~TKAyJO(kFgd;r@3Pm~ zH$?(Uo_L3_?4YECtR@b`MwnK?0(Eo#MlDC;xQA$ak=3CWxWqmJNrYhr5~COV-(KVq zbwHVCwo|wiYkWIucg5vE5UKlREK{7UpD32abWCL$7s|Um4r0pEVxJRo%eEZ|l{lc% zS}YXTNo}5uc69mrQrLR}6c#`fqj`6MS0&)JrP3}k{6H!z5lL+kT2=~4)RwSA!;LC3 zwfO`B-&A>+Kvo-c4EGE!-H!x%`42q+D+(B%@k1eaB z)Ilrz{4kG1amEHct!OR9)2Z^`DS-}EC^R+YprmyAi4y!)KR-JK0k!F3uWCK32e3>?Z?a$=YYw8%m4eK{K4haN zH0tZeNg>4r%Js*yfLsj&Xe5g1{c1sFk>zG-g-CvSEolegLS@-BLGsgA(1axG*4D=m zMg;KtksulB5Vr@^$+5=)(0DeZmIT38o6uLL zJnc+A%>yy*Yf40D(HmFROrK)91*Th_kt?{!TJhaL+}Z#sxsSA=aC{O|kgVW-C&y`P z6x{jMJFT&skWgtJ?1a}tN$rr++O`vk)v=(HqW2>io-sJFe89w&ibRT%;1E(T7~B>8 z>Z4Tc47tl+Hn@M&WR*wPgE~hybeP^v>Erl+CP9jrSJ^cib@X|PrR%XOie+*?9y$n?6eV@t& z+j4LT5Q4ZkSaxZ@eJ z*d!LV){rKxi8mY_sx1JHJJ#M!6K=H9V<1GiLeebT;$ZI|gc%Myy4MC!E)i}ieMw*a z584t-B3gRw4BqH%4`HU)uyiejcg_HG@^V43DRHO9g2v{6hi#*+Qw}1ez1kd@*eD5$ z)5qt}$FONkZSEaha9D%=fE3KjV+E!jm))*-^S%r}1I5T6xs2v0Zu=4i;3EOiwW?E({sI&T3X8!~%8H?8dvyg{ zo$$3k?*dawRo67ecmAV|K1`%&SLpZ@EwpoY$@a>K zLDlKeV0CntysS_AaAlt6I>CvmrxhZN-|pYpC>4ow3pK**TZ>5Q^^-Jf9rC ziXf9GYu2pTylWHD!#aj;vAZ}0!@l_-&52Z%o!k$&IAGq-BnY1$VEBoR((a%+=XYT_ zL6+NlP6 zGX*|^Sje3RrV)(HRxv21PE{uNkjYD$93TaON1Gyb1bU0+#`}vS^^2$B?KvuDV~@AOF?#RiCNkd9>*9H2 zLq~nzQc3&3^1zxTKMDGVmp-R~<;RDkk!`TOK6U(288327V0Qg^p^FusQQ9Vi^%&F< zc>N1a=9Hx>yM}KE6O+;?CQ0wD>cgUbt}%ZugYiI4S_5XcPwmmRsx+0;KVD(>?fj0y z$=OJK7_l~>Ld?fI=^(LF+`?oxV1L9LtH+U8j|v;Eap@BoSe#@Qb-6*FWf`IJ$_FwVxGkD*BP!dw(nN2NT zICRIqW?WWi_|llM$4St@Og~O-xoZH72?_FWTgBvxGCzvNb>Ve00%|4MX9&w0sR>^@ z|4gsj(G`G5)CKZc*a{lR8<%eN!<2bBh!2V>fUq9o?b9z|G(yj2irq-Fapo5u@3CQH z)>hJHR#crPMTB??MwaX*%9eyq+eQo{u_sorW@2=cLGAn0QM=g$f`ipn*+;Rj2jI;X z?SOH=-OjRgKj%(aTHgV2&l}`xwXe%x8H)$tlDq3R{=C^l1OH}YRbm>HL<<`3Y7fmi@vdn8w~4gK?U?EYAQ??Ks6_ z6-=xEP@IVG*!i;wN4r7gd0PmJ#foC4gGN}qfl`_u5DO^CQQLA~7TMKcjiKIcv<9e`X9yA(GV(b=8T{SP zS4M}&HSwE0qw0y}s{+$y5NtvM4=KXX8unBd>;sh4!U6#*RHBir63;w~>r@T6kU)#( zC0~X-zz2O49ULW#3K?ybG63GXC2i z+h`si`5&)Z&{`G2k>{yhR9+3(`(Z8f$pecZcD$r40cpHBt)!uquzLQ>&!vvf6l?6@tAZ(eHl`@|bJoAj-ujHL<7|D)?GqoNAG zcZVE0lVcM8g}bD{iC9>BfgrT}K+~cNJ|HD(QtI6;=Dx3H zS;?CXs+X`G+S1O&5qA{Y);(X_D8(RNq6FaJR5+{<9E0q|$#$j?U@e0H0%ZUIm6QOB z;$MQlxaW|E+X;gz-$aVe82eAK8lg~JmMmYDT^?rp?TYCtp(dz3@#XIBtMK?uV1sFL zsjIP2&ou80Yc%0G3&>$QcCiS9fMU^&=X|ab8_ud{ShfQx!&ND=_i!N+vY^>UD#b-O zkmS(32WT{w`KAmrAYnk>rL%u#UsKYTI!-S5hEksU1)^ul2Z>Z_OMi-4du8UGjk4~w z{9XbClKqrnC?&TBYa7g^p&K~;(I%7~cZ=l)IgBVcm;xCH!Vi=|U2Q6VL_oKI=B>^^CNCCi@ zY_|YpH_}~-Actif)=(Tp@$!S791YaOOjwPl^r31uCCi{fA*wH+HM2x1swE}P8j#>9 zOP(*h|0})}4)|WeCCMz2V4KnAxAcIRg7iW)b1($qPzph8lh0SY0)Z4@5nUFqaUQve zK;YIplg@UB3V_gRq0Pl!fVLZs%9(O=Qol$%(EpFM#PWi1odD{J=rnFX&xQ{anP8sk zz5nY2E+8*Vu}Swq7&&RuMCd4l4Gbm)TodELy2@>?&0oAn7gjX?-Fv5brMB) zQm+SHO}>0`+m^oG$wprZUw)ShqeLreB|Tl9Az5=jJ=Da`4yAaRa?^qe1JeLY9jKtU zA2jnlzG2k?1dMq!8ekbpiSpXT9zl`Xd^W1qQ*|jx2?Fql$~whx2U6`Qysk>3@$m7a zyEgKYZgsfs>H)#2LhA(cf=3AVELCLAr1ok7z*F}KYX;@BOp=yT_#CR|WC; z8sOpr7Rw$RUm!#(@c}}nTCfLrQ{y=Ii7zUDHWSM{Krb9dv5_qd1Cls|k9fY2gxlsLgf~K3#n(The)`Z@WlFrs7@U=$pp%4y~9b_e#PJUC`z#KP<7gm zLEQOibZeKA8W26%NLYM6aIhDppopDTY+2Jzng?16_J9!5%lw}(toX-pEJ)qc* zCA7&mHvpK)R1@LTPWX`);yCaQ2EwNhpHSmdJqt9U;95YRB$v$W=?ylsi~RtQQK1jI zk1ITbxQFSZ-3QI=qU~G(C?w_r!RZFLj->3;8KReoR0sf;*z3U6s@S87$cf<}QxIAv zRU9Z%_7|c*|#gslCCfJttmY13ZIAm9+zr)4Kv=f(xm zmAItOiqtK)DD!euN#X(}ng571awrupo+s z=OSqW1#do}9L(fduw{>TJ?OlXlk6c1-%R*ZI_TlXs|2(2AlX<#z^&!) zFr{>677LViM&@u=hyAv$n;U7diWkFat#I@_v6js?vfE2*R&_=1XN_>z*=Wcee$ zQeX|dkI4@E2Y&(>%>A-#%^Dd151oj>lSS`!0eB{05owUvFT8bq*iS+-1ORw@tN8~5 zy$X?-@^MhrWjy>TX1eK5y{`*p6A-ig2hDt8Yg8SXW!Fe9EC?-|lyR>?c0eM0tmLno z29!^f81ADTbd!G1=ekvL-@VIA)BsIFEaj&j9l-3N(*4R!*^1&QswAtA>aQWv@$DCi z8myoLp+n`FY_s?v(HYROI?Xk~(b`rxJP`{IaEIuUjm1D8X3A*RKw;uNRtIGXjk5}G zCc2MPo=b{I=jP7H5by6tt9Q&6X8`jK<>6t46^Dzp-%-*9NXsN|TMhvha&UWlC1DrC zO$ERmvE=pBong@Hx+!nP9#rwNj&H!qU=~&C2iI^b;b>B&egwAgcAywOPD9lReeD6s z-6a66Pi<|)_u&B!EuQ%v4!>1E(gRX_M;Bci0M0ePp#h<~i!PIUl8|0tc8^UA2f!!5 z5K{x-fC7Bz;|VMqlt``Ott!SR{xt5WNDMd7mW0yBV@Gg)f}^daDhHZ;^D*|=gK9F1P&yU%|JA(OuG z18UQkr%EW|ib$(r@ypZs4yejEm7gM>@*8Gm_y9em+&Lf;6$Jjm1^IHf06(}DO@d6k zM8J0=DOfk@=9^BlxuZn>Y~nDE>0xwiSl8N1jma8yzQ<*1lOkL*{9$Hz1~ogvtS-UT zfV%SCMj{#*CR|bth>DniO{55XO2WDba9a34`2&eqR9OVA*Cmv~_cL|afe4AB{}AJ7 zUhdmO>JR$?#9n~*N3(#TrldU2sTj`M^uLMv*g012;9$$gR`pIg(mn?f&)itFd@ zp9+%Q1eLcG5XeTv7Ell32I$D~4v#H`DPjHe-u)o18@@bG4RIW4s#JKeb3z}y1&0z0 zgVI|I9jkQYl@I9IHJixbYY43sHNXs0AVnE~3dDEvMUB21iJ}XCApsKQf~%5Bov|aSqTX^iH3cfY z-^gEN?U$b^ui!zu>_;SB_yeVnoiSVg1M%T|D#^FEA``jdJ1MEK`J?)7zxyc^UfWNC|57@#P>s~G)-gyz#vrU z@4FPh(4l`axCQn?CYGw*p&bP&T%}8>Xr+yxYO1B1Av;x23uw6Yf|ITYx-1<12a$cs zAw~3JdS5=2?5oLYy0PM_B@E>Hi9G?Lu|eesxZ8X769l^j5cA;FtUJIvq|oX_EL!c} zGJG`?*F3-~7xmw^-sM0ug-a1GEj+<8d^`lya@ekhAL39#g*LP0sal|uu8x*W9`5tG z+}ZYf-17<5NC+uIr;29p02#4O05ydhGM~^jrQk1__WHbxrnInNkRa!=oV0wkti*Y< zd=QdC6Cc7ByGgyNr}R5GjV-U2pV*~gd-JRiEQlKMzCB=SkUkW|w;CnpU5Gv?eLTS; zF^~;Q@YDd9d$q_rxx(G3*(?4qn^;dJlz+S(EbG{v#2|;CgKFAth(W?PrN=;}hqTN( zf3}7jRsccU&z)(z97l$DKj~#g=IZ*SOzGC614v;mVeHr$1nH|uzLP~jl_mB>co&{8 zi6e?3OU(BJ;4WT|lkRo`Wfx5~>jD$)_`yRJsa~odUZo^Ui%4p*|!iCG;1J+$p6bRbX z?YYzL(cwsuYg&-ArFOcrp+gNz6&=tZOvPNhd;%8=h6$A-{?VLid>yD4FsOmUx^`9e zkyD~9aqAw#3=Wh=)nD3 z80Nh;9S@uqHfO4V{``Di{9_Pn%kWlk1E~AAxV<Z^}6AET;TLiS};l;zllh*NRyj#hrLRaOXLPE?n>Ri;b zy5#Zg6(fGY;Z2d!fje<`d-Dn^v9e#qrLGjdy_=+iqznqk2HfM?g?6bmii;U`!d?h! zt1nIRReBCmio%nUmf~5G!uf+o1|a@n(~3+3>95vtU}9Wfj2WUvMc zAp8IKH+VDLP`kPm1!2Y2XtnzLBfd= zxS9~@Zu(pwn2j^N&~7`g*qZ05d>^|f;BF-h1NuNJrAP}Y2@oeN=1xa1zX|R^h$jpE zuSk?Y&-kD_SeP`qf+rx=q`*dk(TCHz56{{Q@`vRM0frx96jZ6SQNa$&NyqA4gA_Zt z;zDJJfWLy-Mbhs^CNyL?{)8kMvM6aO&1STgf)s$#GSG3K+?E=;drB<{kH$3@(e(`k z*u)eNGU=;+(xIJ{7J$onIKu}^CP=6#JqXT)hs{2N{H8#VCJ}rM>97Px2Z>pVlc8Mz zw|tE9Enc42VZtLwsRC7$4C8E4#ZrFQTmfKlySbmLPS`V3P}w7J1GZ$@rj&}Cs(|_o z+R!1qRK_ESdm&n3D`8(nSTahebZ{J)1Lz4Ou`^LXhX8-FkqZa%@@|R?l~+l0v&;bk zCn@xW-s^cYJ29k0B}d|)L4~E} zm+k#p=pRIR#uXZ+do$+wW8@(L;!z-K#X?L<_~cOSnRM zD+OLm+0k%zlbslGQ@H6GG7>)u0L=*ysD$bAg;CS)b$m_i!Pa6rVTqb1Z~p@8G@$v7 zN}@EH4Bj{5FIPS$S#Mx2z8Qz&d>6Ko&|*LtVpeKB(te z)(>M~8?(8y5IQur=y4nXs?yXxzprLPL>v$}uId`TbDb``r(ak0L(UxoPH!Iz9yhfG zWv|LxhRzj7=RXXRjDt_JHP;+PJ~^>Y1WZNc;*ceMpMLO~!gX!ymr)2IOMU#^QzG7x zYJ_4&fi*Kp50z_YlYXixMedpe7@{?#?t4KFQKz_2wkv)aB%r9n<33y}8JyC3KSRo? zAuN2V&Tw+Ww|?U&aL{Q2vd|vBE@eYs^MY!WrG|Xr1BI8N(60FwLEzV}MS#RVAi9E; zv|4f`k;Z%rgk3f1vEo@ZHeikI)^Y=LWhUJREhk-%^cO~QEPU!eb<1oXcQ)ESd@H{jbR=HX`acd-bqcQm1?7b26v4;5iZ|`bw zqqtY=M~9%e*n@qCHqI2s$M3Ik?Kn$0eZTNtO13*EFtfhz>`+(^)(;65f2ymwR{V6^ zu=0NLcjlCfU1vVgWK^Yj(66H37U6!4>GeOsiVwkUHD7eEygI^Ls0?S1FG>aXrQw^8 z?_#JDe~NnFT~6hp%+OK!1|-~!Nj?8cx6p`t_SJYjmtot!@?agn^7eh~%&C6kbBp=$ zNWt)cXskIkOWY`|@?H%w8XKRses^eWu_drvH0Rvm>bvOc%9YOMoQqLeUk~EG$G1Xz zBgGb#ul-wtf`v;W{#Zbwd4-JgYnEJ1tsLSz5?Z9+i9{jKx7>{R-d8__A92X zY__rT0a?M1J|w3v*M3uNcK_+PA#bEpLSgPdEAJ+YN9sQ)@`oa!HdP>%CVzO0vVwA^wobt#Jc!w_hW0#ce2ib` z365**ABsmms|goDp+bQ!iTK_?_H;?UTj89a}@K6vQ|T|omCd9i>)-)`5b}C z$eH?GYez%s??nX3Q5f`c_NQ_dANKc@NPMWh*88D zuM2_Y=gR;pceo|otmoyD7UuAVc4%23U6EF;Awpc-gpt6cjrh0jufja4!*J}K7jSH% zdg%v!@z_X{bZ*A4`DF7cFC(;glG83bAr>Ep7Z)3r?J_P7*Zpn}Tmz*sK|7X30Upv&arl{J?&s7x!itGVBK@|Ty4&qZ>OQGKPPCBtLOuCW8RfF@s&&(o+F#l~9SgyFC^^GBRzzA=W><7>g?$k^2q<5DWV8CPm?xq9NXjScgfDtq zx_`aXWCaH;sAYl0-eb4&eKj(Bg)i13KlePVD|lh4ikqHuK4z|kxVVRcinwd~6uLsz z<45NZ!DV+r_9<{CnkjwPlqH*LK<=$bcIk^YyqFw%vb=9n9%)3?Wd# z6+B7`t5&95arAtFvO9|vRRlfDZ5+&Pdri@l&h%Zc)e|9N+}X|MSer-s1LW7n*TzX> zbJ-C>Wi~A(Kiot6IFMf`BZ*no#;5c?6Bij1Y2-*^DP&wnN}p4QrD zzoM+TZ-G1MM%`ONySnqp1(@^DmH1+ZFN_#7=Avmv0p*FW*d=}z$xQ$6KwuFXG--Sr zwYF%*EH1IpihcPitT777{1ncq6z%BSTTz&`F4f>hOL2Qum+KUqM->6@eTl=;%^yT$ zD<@cOlFu$!5*F0Lhbs)*&r5xi!%DoHQR3I$FoleYcV zQe&zqlQc~E8Bcoc%MyN)u`z}iA!VtWwEg@4y=zmS`I+g6u;Z?= zoq`7Brg@xK@qbP@aT?)2B;X29_{BvEYTv7c<=nftPmUFh?Mz32JPc;?%PJ~h2? zQ$04+rub1OrB*s+6pS#eb-d85`39YPrz%z*-=HL}1ff~1{~D*lI``B(^jBTnIY-^_ z@NKH9#7w)351}?yGo#{p-`HBFoT!Za>*Op4!qTEL{Oh3LQFZ?vKkfP3_&VaVSDuTm z6NiiE1D@UA8-8jvD9q|+;z(8W{VK_~dGiSpT}D1mSVqpl;A1<>n_@+H<#(>KlkDkA z?Rl=jJua{yx-@GD!g-kH$(h-m3XSd&R zCV;llwzX@5br2M$5~GmM@uew% zVz~aY4ps8MSIt9rEB4dyaaZvH%VNumcM|s0RFf$C*qXB@*?T(sBsvJ|xslM>d2Mf| zXz-844k42!;@$5?O@>3)VwxTshn^D0pEeF>UmG{PIPFLqVd-(Fgi-!2=;W<(ash`moRcqBSl4(?$?IWKoFTqJcpFCC;a zo@p)Wa+ccY^GJ_ky>IPjCgs;j80C*j`ia?2uFkA=mu`PBy48MrNb_juq3i^RC<&{2 zdNglk?%_S(qdi*zF7e$_-$gQS}n10nvY!E$(1Dp5`5idl{wM0t){W(j`t|jih!5U*rK>TOV*V& zh>A?=+QT46Rs{F2w=h8cXBtOkkFKXWoSdX#lfC;9p2``$EJCWXCjfj#x;e{GFxOK< z*A*Q{ZyLu`E`6R<#lsa{Bg7JE=Vi6X;#Sc|=)A%3D=IZRqlTJ!w@qCSb{F(Oj*f{f zc4-w+=<;lJO3}v`O3ldAVDG@D2`!n9)oR}G22u~IW@KZohU+vM{fPOFWYQ|$3lp%Y zM{Ghfj77Q5+lPNhONRV?vyDLR#$0EN-KN8YMrQ8UupX*l?)(jeCU!d_xf#;@t5!z8 z24QGalnc7KfyO>-p(zi!rd@{t{ER?z>djN2SU-6P@!&V%hP6XM^D>S7&lRT3vgqwd z-l{u)K$m5M9K%{NxUO1o-N?S1Me`2IQAo3Rpv#lRcNzxbD=*Av17dQ&`tfV8^ zmG=qWR}Eh}YUY=aa(Go@%T>q?^wX+^bEFg62*a=X-_l&Np^_uzNVn1VTY8SX<+J5t zU&4weP(fXS8O8cf71TFhL`Q&%)o45JKfjh*O{+be+YeNjsIu z!}C9}ubm+QpL`ogURxhnRR$$+np4$HZzJ^58+yTn;~d(~VMiKxxUX-(xCz_{aqH5> z_u}`S{;1~MVx*CF4mh~i-610&A5@KDX%|iwn}Bk zSBfq+(kT6srs-oVwIlnEBe5rv&*sPb;aw~n8h<4Qm2^P%=brr!Cv#rB7bwDJ z=juNx^J``=_XA}uZBV=k-v2*O7|{uHs6OcH%sdbYn8( zo3V6@ORH-dKOqSo+{JyTaGI5~&nindE?JX5T42DRJf>@BD6tMI4k2FOWxIcz_9M6n z?`9eB)e_-&In!C7bXGg>|M1K0NXR0hmU@fZeq7OQl zY!stA1aD0_SDgn;0)NyBke^w+d$L&Uq&^8C>packcXJRJoNNv>01MbdIz@ie_+Xj; z(WQXQomV_97d^gc=hBsYi(vXe-A=mUPN#?JwE2>peVeKJuyUYHOS4Ey#m(+y)2-|hVIc1%Ek zRwAa*(~>+U!A{4~=f3eFx}rPHr4m&=;DFeT>KP0IJwGFX{_kY}bpyAwBsvJBLHGYp z_WA#l?3;`xZwL{sX!bpXhxZ?0)FF_IDI5IZTKjYoA3c&iIPW00!D-FiR55l?Tj0s4 zD!_xj3MD_SfBD^Bl~5kZpuz zNr828vEd?xFmEy;B=+rbN2y$z=) zID5QsOq0xh;&pED?_eHKS4)e<{DNbtN zHkq`%&{FSkPfT)T+fwI`&kn(ab;dM=RSRKBs+FX2-H~%flv@ zWo7jSZ)PV$+#Gcr0=NA>X`3t9Ufw2N7-C{#An8)jo8&ho`1O%|c!|fLD1-Zo$wm!> z7oO=uAs2PVN%M5J7kd=7ihHgTCWB5UWRA2Q@1%!&;*CYJ_ztV?M4I7o)IrIe?fGNA zj{;8d9D-l(us`U6Og<$E(V{_Km6gn|Ce!{S#;;<1(*~Cqf%n>eOd^NpYd=P>;Qkpt zaJ+^uPakz;C}u!{=>1;yFW9PX`bPp6#46N8U8s?2jlJJ2Sn3x!b`ZUvuIB*mlJ?^B zpMJDz=ny`svXTIYG7FeZajEIO2aR?K`h01C#YYb=)x!szr)oXJD-a;aj4O~_6ar<`R# zy!7-o3D$Q(-+sJG5~k{Yup@cZa4aO~I0@CZK>@~mm5BDV^J266y?Si-=myT1jKo@W!>FKHJ$;qXf}`ATJAgwBTFCXrJnF||z`UsrbdCkDkdoAQN)Vn*X8 zhOpGdUdVbC8@`Vv;oWzRUk&na8GE?0ShJcAMMcr{8-*s>`as9uyp=meeOx&| z9MgE<@ejl2UwSi{^0!wUvgMgaWUT?_VJ=fmEx1k2U3!v898UG7`u4qF8mb!)^cTwz zbj^EJ6pmzk4C)ulEhJSKE7n4#4X&Ks6co<5h|~N1mBWvcjJKDOOdJyrv zS}T7kj&Cgc#L-XQbIz72u-+8Cc(aj$F@UR~Zfu<$h%=^M{()bqd0cn-!$=@mj#D8N zwE_o4<(#tseneWZgYWZ(v=!smEX}r1935}dh&=~TUd3EbhjgneA`k-6g%yxqX)rmnkk{u z4bQ5?t=z^C6CA-U;2gdS{qW{@9TG6$f7$fww0A4!m6eKOg<`{&Sr)H^WGEHe+}t?z z>dxc;tmw9AAvD`XgmeG8!0>W%YWp`{vphHrRmwG0wa4V9IR@<=jr^7)PDaBDDLe1@ zNao3Ve!3|3r?rl_epO{-YEx+EC-#|~sj(&}-`Jp<(h1kYMPjV*xaeAxG1UM2Q+a`u zylwEm$LlR4nR*}Lyl~D9aVr)7_2$`*sipiEh4Y9_NFyy3{<3!{fLg22dX&%qVEF<(tF}I-Q!G^PEic z-hhqCM6O?CdpO^{h6Ob;ga2rZ_QCiTn*@A=%vu_^*%t=ejZEWZziQevn;O^`(c8D7 z{H67hgYz007e)9KG)*|~ZSH*I80`4S-8%b{f{BaCM)hcGvd2CzwRqv*&T+ubK-=CZs=Q*bPs8{rV5;btwpK zGgglf&!+dqzp^CUWI}BxW>UA?WzfEN5)V!$84>CBsn!O)xNF{Xd-$8%&S0GR{^wG| zYvfL*Gl8G#>#~85$6kK#T9IQJtkTy>T|_SB{>~)z5ASn5dR4ss@>P>q@B3?`)er@X zsRG<<`K}CQd}7;)dg33gZ;q(r8J<2k`mV@2lYNgmml!26&t(X7*O+3{T42)%QQ)1K z%39)FF0`5#xvlbEb>Hk!*F}k_HE2D0r;ugbh9~IyjwXIH=8a;B)|UO3XU%UjS{_E)C}*9)fea$a8MpNy4zRJ3_Gh)+-yzH;5ke+FP!N4!pxFK&l6@=@R-$I?E;%a|WuDQ4Vz8P4pb4~cM zPI4%jQ9Db#q!P?fP4=65P3piZOzh%?EBrKbd6O6ui#Uqp2c;qkjRc)o^xo$*7=0yz z*D>oI((7d}g(9&35AWU+&f%DIOgEl!X*7B<%|C4@XPyxb%qTClgzA~zZw#1ze}kTo zfE(CWEfM|sM*rdQeCo?~p(=7E-;4Wg#3fY!3C}+Z4~~S-_>7T@n6Jz6tKg7^QhQ7(U(frb)Z`&5@)e&}yk_PS84g+ipzV$qrpGT-rW<9DLJm5x5w7)9hSl zM7DB}Aou9gzPu21zwU?RO)0>)Eq1IXI(2!UMi%A!mmSOJ>d-1i;(XjHO??<)c9)#r z;{wub!tQa=|L(3&?zE#!m&CoIwg9x&Ng?#P!9ClIvji4SL% zWG0DDdYbAa0(tU5nJ%$xI@(#$tEI)%y3EL(H zkB-*Ub4;R+XdfOLkg}BEpnZ}H#fBT@+|u2yGzvn5RqIc>j2+~DWNU{KSCr4vsaf^j z#!0u*Ja7}XtIOY1?7{RdJ!vo$5M&7xdX$-QvgzaXR^B8GSi7QXe19o=@A!Qi$98B^ zS34p<7~%_&c8P~)Q}C5 z6MdpPty!_RD@E|9_U6hb8{S=8Cl*z(RUC> zdu2lGYWjk2_NZilkq@x-*z=Aum!aeYD<{xy7yb&IhHK{W4NP6qAP8<5ILE$G3e|J1^eh4OqS9ju&>KqJ5Sj zf|pwDL+w4*38!)u*7K~b@Kud$jNhe{$L3-dn%5Fv@MTkIrhgKvn1Hb6n|+f{I@|$@`Ns{fCah_{GP|E5^6jS(P_$t&Otl4HB5lKsNKN9U?&mFEI z+J2MrTBQ|rG>WO-F>)0yJaYbG`R!{S=tSQ=UyOedv(^)meVNZ86*05*$wM@WMd2Fy zDY=s6+hu@uT!vjN#{9D1$vBEuEj7m&@C^A?rd!Gp@_SnQ7*l$-as5aOEMcx>p`cakrU3N?&cf=#PsL68;O(X)87i znNzVPtD4szY#F0-a}UmhP6vr=F9ZsEK8*cIHKD67OTY`uTI+nm`LI!fUnwE1`MHF$`P1j=U!Eq;ZPe}jOcFPT>9}1UMIzo#nrpTw zq4_H`%CA~$(MS0IyK(&PK2OB8t@%iS8GR^hU&!!R31NixDxGd=xlWASq*ior5n;r) zpgQlGf8d=D{n1aG=8+O;)3L|VQmF>+OGP04tf-dnRsOCymrxlY z@bP11SDSHv8=uN)E3^{3+>K^1ii1Q04z1KAg~#*@1PWC|8gs{t3PW#S(dG^05bgCi zczkThQ({qhevhW?Akm?8+N^x>@4mtkRc2c+p?3m-&LY13)xME|3z9D1udtQ+;eF^l0G#oI;w2E3V|3`8h=HV3OZfx92)ENCZmd=S}P*T!>o}o z`GT{SYDh(`I#id)Foeu&z_+RbA9%a*2~AQPF9~rQo+K80bK&2TIzM44xM%TAas3K$ zax*8_Ti^GvX@!!MXBZM8<;{mjFt}5NlRfe*WRpq%8x|O5jI^H71Lf|%*XiGy-!beg zb8r2kc=CLz(51cLZ4q;uM){nAsHv^(mk+*1$!xzQ6y)C z1~J{`M;P^I4xVPm7b_75*qb9NCE4hW2!uE`=nm6(8Dohk3q7(QZ=oN{KdZbb3paB> zZ?fJo**a}6E!K%CZ6_W{&oCJu%0DFVKc8Fqei z$kVFU2lG=cj@;!*OW1js^)iWRCIT-6B%@NV#TFWjwY`F&j1o+B%e`@uXItxX=2#GlYUhI|QeBAsmvy$w?xqp$Z z#+5OEO#3FDQ}eV^St}QKVT7;?J-z?Dv$o8V(U+}`FN_CT#p_<-6Mip>Vrx`tcr`LO zng1&{sJ9}|_6$0v#JtaYYG9Np*{rS`;^JgH+Df^7+{xSQEpf&E=DU+-Z`86ido2s^ zBx5XBb7PsOXU^M=<@jVsPV4*RX1gc8;KU4bX2y6D-%;+Ln-2e`vHJV>-Fl3bYdWds zkLMZNM1guKe&1-!EBVT^H2>oqR|;~4<#8E|IgCl6Mx>S$Njqy*npyY#bhfK!8v*D<@&jJ z*fz~9rjD#tf|QZ4=aTFWI*Mm!UpuMekaUx`mjvlVYBK0Bp4W3=7k7u|K|6Sb=Q>}g zT6oX?iqsW!i%9d|UmW@cwbpavUf50lrJ}Fr=wxgylFsEIB2dn|Z`51rr3PlXb$S0S z6K!88SdhgKG6~)M_tKWdEHM=xMEtmJm@;72a||XFDK{K^jw%)w@&qmBjKNZHDVN&KLR3?3!%mf*sKGWsi0fA9qam3F(n1YPOyMz2kV-H)UzyGb=yn#@nxIZ6=ZPxFz z%FY!80@umDeQx^hi9z;J^r_i8*UYJ@i-2geylw|SpGUdeEWgry1N8Ir_UNyl3Dnm! znFG=V|Au92Z%>V5swghq{w@=da?m)(5Iv3UmChww3FEIrMPlpL$fB2+DnI5Cb&X=7 z6^zLXT3M)krUXWn%3F>0ZA=T9?`r?8cED{O;utw`diJ;PO!?6-^6>rdG-4hCGl1PU z`F!Q_T&*fwF1^*1)icmJvh+{z>$@AvtnLA=we8&<87R1s1^R}#^vudpi@=8{&78tG zb95Jogo-I35@gJ}2K5SZFw)qp4sk+88mqVoRWkVq$!4?k?BkSDz%|E6mG5^rE%d-S ziX}opEbY6T@xMYbz&uGNj?-@09rb*1IsxPoxyiB;XF=T1n^y$_!z)14wyfX{(;COJ z7@PZyQk4|*6c@ZuJZlGGpC3+p)z<&p{1l_G@%FXqeo8C4E)$1sK6$thfSQ&f^$rSsm-;TYU8fKqf8i)FZvrQj`TRU%2ywyZKb0a z&0E-L%FD5dY-&4rcsjdY*pOJc#CZNdHZ5NMO&4bK#_=VA@m{#C4ymGIF-l--HASO3 z`FIse4Yc0;z)a)kt^iS$1i{#V=bti%qd8rJ#hSvA@2TrQys2XgOtrt(l$Y}K3}mYy zL*>&V@+vB^G=9C6;>1R8#-Ps={0dr3vn4ontluerv2Q!g_?n2ufM{$N8Fkkr(_Ki$ za7lV8e**8+tit|ULAaeYds3`7Qa5)_jSM+~JU;3STGX8v5M9lP)7$lU-TouOeM*^n z2|An%jo-dN{2mu_r5)V8q)_rPTY+B`NAX~KwWpPUCCB3YG zkY#rt+WGB=kufjUk5^-x&|~1L0dRGqPvW&6{d5zx`L)wJx=A0|nbj9fZHk!WFO3~+tU7eTTmIqC&CXlP<9`JXKHDu0@tjKVIIGzJ zwbURz+x?I6=fNp)al*#bDa0qPmxIG1E^c-{LOd~^<_MxSoRN#K&U@rAO?Pa($5vwe zY$NT)XDQH{gk$T3nGe$ul!k^;eK?s-W#Ot0R}VM+PN5xqgIEm}ZizKNV;v<#BL5D) z$1gSf!oHdp;Z)5z`AwnBibk#Tz^yIAgWm4xkGQs2Q^6~LvIQyRZ|7oY&e%irqs91U zc@yyRdHXaUZx`PSFgwC%-<(RG#4fgdj)Y#$9){HDmIRBwe~?%}V-Xu!T<;vJ;nmkc ztdnI&Yj>B1=rN4PxdAlO8i9s(B5o#ZSk3H;ejp@Pz09lM5M)B~ieZ{-?W1|#oAqE( zl!&>3u8C@adAzrc+EGIhoIa&+&wy<6_Q}gIuh~5Qwt_L0IE)(#IPKcj%BK&b93$## z9KC{mr7w9Uh->Fcrz@732~Tz3-7kt9Ea@Z=tKX*Sqv%`5BC^JuD}8llAdEYs^{ZCe zXP{_d3udRp4XKx&JL1x3AxQhiOn?vXY1; zv7RL%HA%TNKdJYM)?1=t%N}$Tz^Y06WigFzCG$N3B4f$0bswF3o)&oS%^p)wOWq_) z4#WSU>m7h33A%ponc1;z@7T6&8#}hW!yVhUZQJIKZQJ(O`+V<>cp~n7E24g#|EkQ& z%IfNltjd$;C`%Rm1=Yh*iQ`N(GBNSbIjKeBe@VAYbb9BK!pJ7;Gqmz%P7`}JyOSCC zn~6UU58khX6UP?A2xG$EkHfdmMqR-7_wVyQ;VSV=u9I!y)pR9`zKJ3}<+uL12yu95$4!aAS{D%Tx=ftFassG>oh`Qszj{NC}iJB>OScmb*Z>?V+@ z`o&*X@X+?#?2ICcOFW_jbiBZX3Vyd-Hp{?`l2-1CV`=cg&sW;m9(3ZQIStrwL)pM0 zXzmIDsr&a1r$Y!j8I#6n{b;`mButY+V=PlSj_{{7@tS=xS`E{wmV|Y|e8xfy7oP0N zNM-?9GZb@BlWdME*;+CDbNt(Gk&LY{jQ>I~26P*oEPEN8yl`7oM(}_(*PO4s+UNt4 zf+G$z=M}kifv_Sj`(4XIF%kR%C%;lgFvpGDJCu!8=nof`sF@hPdNJG|F6NO7V&sMv zu$}Y9AnVwFL;BcjNB4`Tf5q82IUqjGBSM@xBZeW=xH$5Y?+Fl05Vde3K^*DBI&5rs zAl_L34y6?^SOTaZ4N52@xB->PCEf2o6-ojFDtr{^(xY#(&_GzAzW7(a0)2|K4fbBI z=Q+>s53jNoV9;$=C2V_sAL+uiGF#TXh8{ETQpW5Ne0{>wMP+DZeVlYL)k zJ&8%UbCcl|nM(Wha{ z`$(k49qvBL zR%;}GTBMz{PdND-2|E~=?ju!~Z3+G|$6exiN?c1u2Uxl^ca_t}KkpifkNRJk0 z6`425)$8qK3i>(uqg5NqN2URd>DsdFW(x9L`cX3!7R1AWb*wE+WEMZ8Fe}?#lt^{T z7C+r0^JUlq{s9%V#;6@enzep%bLDUw(^?y{HMW4}v`V;a%2(g~(Fu-92y_X)0Y(e+ zpV2stQ^q!}K|nRP%sCG7tz%)+_Sf_#5nYm?Xq%2w{25XDxrFp(a9;_XECre&--V$$ zirgRMO#}P+hML)#hQ3_kXy4z_mR=U$Zdx_HM&>XZ*=^c+8}lG^Y;Zno*PZS3!?&v}f+d91 zCGMKBd|IYZy{*b^nX@+jo{l-MgIH`fb1Wj|3wo!e*aXJaMO{g+vN27aLmc+l5F>!Z z-L?^yt)o+&8PTl*(dzfG!gT&^^hHC5!_a)F8C|6s&F5Rd__>Du;JdO)mddW1?%dlR z>;w5xzoq(TG2>ARyM^dOnEbG<*oUN4BSvO&*^@K1W_8b?phJ*8i>@HJBTpDyj0O#iV-$7w7|3~!>cF zeXTBz>1rIh^sMU>{-R&}g&1{c%)3^3=aiEx`cWCcHrFA_; zOo|Bz8%kskN4kAHfJ7Av1WvBi({W&F<|pmnrw z@IJ2Inr*S$Nx?tk4<7!vpH9%;GdyJ^8wutsLB!?$pX0@m$19(f^6pKSq@A4eL(5P5 z7G3(qoE|WRweAnIAZmC2px^|u8K1u7? zRW3#R?bw^jQ~qMi>H7YZfBTquwGlMxSW)>?eReqCyoQH>*JS7|oYY$J<(z}@cF*6C zah20W$Ch||edO>+7*}W|W4BQlL`|?~806Z6S9T8^^UPn046Bue;QmK+W?9d*Det^y zXyhy>g4giWzNrk~{QR_-|1zdy^VXQ>#B|`+7oTgRhJS7VV$W>kEsoFO#g-pO#vEF;X)&kc99)CEx z0g+#DYux-zy7UGD#*5sRGlpz~z+;m52YGB%TkKR~YV;N>lD<@@!nPN_uYb8@eyE1P zvC=+0E_>8y(yYng{p}kJFfHx>wq*-;eJGj+Sh+>u{O_ZxO#enzGc~mn3fNG*zsv6kDDdyl zoo>O_>&Q)dGi2&l*VZ;kreTMT>UBPVx6;OHrY$5P{Z{JO>AM@{THYKNkPYwWowBj? z;>+bG46V3O)>-0-=@2Y#TUozf08#&nEEZ%{aPuo^;;UZc7mnoJwmX}LebmUGw%Jx4-qIf3mA-j#ej}#5Vv*s`(b)V-Rh%E)fBZC3 zRGSqJZq3QkL~UtaC7ANc9#+*%88HQMLU&V%aW|==(P&?<<>{<}CE<3*I7}Uw&JUP? z7I5k|NP`*Qi>=@Br--2EnW?hKSlT>_C5BMpD3FTQb~>)yZl}i9FaDNEDA9VgStz+X zJ*MLAl#Kv=>=*e?H2GqTu0Oz=O3M3UD^ytxssE4xzd|silWrLM6b1@8z|^fLqiE=v z6LwlluLxsqz_{A54&h6b?;$zeFYAN78q7$DaY*aq_QH0TniTFYFnjtOtddbjnXXe; z?(OTvpz=4Om-*SfAe$CZhHDUx;{cd>qvoh{jEa}@cjdk=EMSnP&2 z(wVc35xqus)Uf?x4~sRxT8k&EQo>+C#4V%Ti>Wq$$ILt0+?&e^;?;mvLkTX{3*-W_ zj#anPDX}E@Wg@GgmVF7Mo=Tt_h;fav$yXX3UntQdqG)~@h8s00^Jx891brj1yT2>D z#(p9o@;Gfi3d9nR{ADRK;4TYd%X;y-_gbL}0vJPf*Ml0`W%d_F*Q_Z2dA^?WY!}^| zD#mAV#MYBYm$B@lv25I$LH+N()qE5qN78YTc*V4wflAW z3r^^uOH>hZ%x4$Q<@E_HEl2S!uzNAnq|v-d)u8PZ3!JQcQzW_`@IMxuQj?=1 zNXK}WlqFuO+Uym8+pyJ~EHW6kk8@w4B2;gpE-qSM;9*d1~OLQQfr4ABaG-lr4t2)kN)bU`TaVJlcYr)Nt-$1I6x*d z&tSv6BWNsbu#^;z4nb*pByYB?bjdUz2D`wvBb6blPIN(CZ>e7|mG(@=PJGC68^(9X za<%Fn-(rlE+eUW@>H%RB(+^3{Q-e+FgB5&Fkt&E5?KFXm9XDLYdPv$qSD+A#AE`QE zBj#S<3jx+OW5V0&){SUiS2%BaI&Zv0lykLmTxE5OlLhXW^V7DXP8zE!A3tzaa|Y!+ zSI?*w-mHczw=$N2#V*y(jO~&$o;6%l;}tUYYZo(y$022E>iBEpntkG881gKvet2sr zps45T!GmuL(FZwt3(g8lTDpJB&T1@vIjT?2ji_fe`k=xl)318fVaboq+$ClhOiorx zk`3445YgUm0Hw@9V*(wby=t?W8eVyjXEQ9rvr`+}HNMLj`F9u4*nv5yPnO;Csn)8% zwFoTznFx%40e^ac0nD=JEp4uXKS@Z?U|SVNhb4V?+5iw$Q%Bs(!d`F%!PK6WICM(O z;Flm~3-q1+AWogHF1M0Is?=Vb*v6hM2_tI<9hs!z)(=l|Xsv1vqAs~Tq)Esyurus1 zPU}jfd6f3OCt3to854V{rR*5@XBEv$Sc3c?1}Cb3%ZpdhcKIrGX|BghH6QTN0xm)I z31qfbe~7vG9B1PBgTfeo&!Ev08YTWUT$l7FfWL=wKZRj0y2d&__39?lNoBe97q|6P zZwA;+7M;Q>sqE_wJ40v?TNDRnJ{9dMKMAvZ`3Q+bedVypZV@3E0>ZV@WX<Rouj!VEmNNK|W9yJ!;jy`CNOX;2;yzDC|N6oE z@G#rcH zJ-hen5AsMDZWZKB78Pc%dQe&E%ygL7Ol*BYTfQrF_ir4Z+hayOv{Te$=+G)rsJTM0 zP6zJQtNwu&!21!qbWG#Xw|O<#S9k`xQF<-2e9-A_vQ;_Ruj!nI+QWUnaK zXZrtVFQ5zeLz^97(au2fzxM)||MdbowX~h~xR8DR*;divKiL4`Fzmpk?L}AoO-oOo zyyD{)1I=MfZJHus?(ykKrWs4dBh)VAArWw^u(R~G9P57na15==p_$4*;ILS|w4E>< zVOSL#DUm$a+g8sJqotk**k=n(_?gk@Q&;);`gQ%M!&7dKU^TmL!#~)F&EoR@?X33>n?T%|K~2haSuN%Ddrxme`^E3*6(_YfTa)(#_bjn>{`{W< zUIxW~$j5exU=5#wtcOy+=}K7|VkGYZP+!*j)k=z$UqXPItuZq9y|M?t!ScMUp}SA?QEuHO)^~FY`9>o(ZF&KSUE4 z9JSSc|Ghg<(5Q!z6$(*4Ir#~mXY`_mRy(xWYnEsDpoVr6SJB)5`lkyMgX)G-HPXs< z<>$eL5Sz73kwn=#&S~Pw*sSD`v-6>0bTM)|L^etlQpCnTZ^bt9f}4#X#N*C(j}f`>^?8m*EvA_yYqg_r+q zDfEudZUl$VRECFrH!4c^FGk|IWWv`|pcrAvISe#>nt&p`+^?P!*^r#L%s)~E+04$yi4&kKQf976 zKzEs|m(!9&eom~=gNYw-h*D-_4X3AILr;Bjsw8hmW(u5)Eqf6`T5OQq8}*CgQf(jk zQ4kzB15`#0)izMRpd$rkosX?05nnJ-PKcCG86YgYC>33SjjIY*U6jby8b@L?LoZQq z$937JrB3QOszT}MScH@mU)b~)v`qb%=VrO*z0e@-#ENhWz;2_^Jn!7g8Lq4-7CX{; zw-TGDHbhSKy?qtp=VnHR*G&<^{u)z(+E}1e_hy%tD+@?OD{6zLlaL|DL91ou*emIg z5F@Do4cJh%Z|x@Ykrio?SikYK#G%QPSVNJfUaStIMG}*+WGABm3&@V$4``LN2RIBf zp_8OcT|+ulWv(6?ST#pB7T1;}R4OG?mCH9K&w|yta(W3mbZUvD#Mx>eqrVI)SG%$q zFNfnKB!x0=oLlO;xi*uf_tGoSortZ9;LF`{1DZrGaJosUVjV&G7W!IJYbL%)O5lZ7 zDySI=$n#?C;l)vJ@vb4B9hvdzFc8AdN~F&~xa9Xr)QQidmMoi*;&J zSU#!x)I)UdyVU$=_R@sI>TGMAa@}Ibb@v;Yq_Wkfe5umo1^kmw@I32lpG!C zi%`5R`+T<6$$+H!v@Ew|GVC3LdMIy;Wc2{SC4&B{4?FshMv;o-x$aE`n4hzN>w?0! zEhf)yVJ*fMATp!ZDcU=wI}xtwS7O`>%{~zSl3GJMh+U(5HdWFbI}w|0RMeZZ6@gz< zav?@@49#+7K!&ikrnKkkV70-fJP|q{)=2^HsvELT*MikCRrOrfByz19Q7|MeRAA{cPl@Irq-9Rj7MubW=0P5$dX%&w6|=7! z+%1m8d;On#OjS=y)GD`fn}sbY=`}0g?UGBJoCV=C}SSN=5_6U;9%ZK0_dMesi7dYp;Ln0cuybnEE zuPt)9X99uFarHyRMfHwlE{O~eO5~Dgka*XK2Ui9KulHt6*K^@qi=$kDvbO5uendW@ zNBx@C55aD3&qCu^P+jEYi0f+^me93ZV=+ASXf?5%Iq+zG1@0<94j93B*CS6Jp1l=+ z?T}cpyqN9deZ5<$fkcR0yTAq4+$tV1LZFct;KhGAus|N6xirq4 z`J(3bhX1`OuOEe93N`izG-RIN?1GZ(ZG_e{&6#s|nqot&1M2H#n*Mm;r*u%SfP_rU z?>W|2W2diyu%Ovj28Y4L3h2^OcV}ZNkY7^4z19~~6N(@Xd`wctH+cCvtKN39QCZMv z+x$$C&uKK7+Ppqgss=zB|B+D^CS)A-SfU}_8274l+_=MhOf%2v^fcL0m>M<&Si|p= z7}!vDvYtIu+>?{y!MAb^ehj|{iu!XamSQ6Jy^D>`en0psi7RgXPNrWGbUa_@G))Ui z;iCCYJ+uh?qiF7Jq$yJ45jgoKM^9+nxQQigrjeyxJ_mc8c^=#`Us^GeA*!reLV zn?v7sO=9YGtkPbqo$XKlWEN|9KVF%7ITPWs&dYOg?HW>G&|`%V{E5Vtpwh`YGdhug z5;b?XnY~HS0n{}@GQtf~Q@XK_hZ=`>US7QyaK3Y$JO{7j$cWcrka6D9N9j`&@BOPKF=G>XT8ANjOy1Aj zw=y3)55*Z1sYM)!vJsgAk#t52MTc9J!NrWicS>RzKTWYP{lAVs*L`Wcjc3p9%-Z-^HExt4-`sW*+zUs1n35>Qcgo%Dzf_u zSrhLjBcbm`uVIMvehA=9IzYYLXR%{%Jn<(e2!?ZxJu`%bvu3x4FOHa7N=%w~OGxAZ z?KR&OiCd1{hVfoU@lceA$Oki%rdzZv&}jJtViZfq`E zV^zUiI1a9gbdbeFZqt4g@5LHn-rCxR0v)kAamkrY5oMhL`v}lGxP%Yv7@P~%Z$O}( zfx*{9#LIT7OHSfzh*JuwVV1-0+hv{8pq@&}HonCadkR6mOOz%Cmc3Pm<6so2GU++; zoiEnH8JqiIOIipK3C2=&ZStqmgp~(gezB9>?PuNr39ZW*QBOC2)J-jNqC?ic+_3CV zp}u_m+)qXZ4J5OuVvn{eZ5Dg-U&?RAx)1}K>lMzSMexj4PW?@+HMjQTcY8x7;=F*@ z4s01#(adC+Djh>N<7d!vr5sEmVz>?=kNUfB!xvSm{NbO~yLGZ==W0#kj7HIs#g8^@ z>ADhV8VuVfa%XE*xMsq@*cG27iXL)IWRsJSFz93%Knh#22YSY1y5HO*jTY} zTGG_2wJ1IsE(vUAB*zD~O?pjlwEC;+on~9bsx8L~iN-&PAm5%bAHNPO>A|FDavR;q zy4|a>PdFF>M-|hwu%{5HysGglVW@bPejP$eAD~CeqBUFg^`p}$VMa{SVAY@%AKGZu z+Q6VoTU&~Iv{V&a>9I1%s;#TsV@g+5kU6+V8KaVlLH>eX(pC-2Kcym4NtHW^8*GO` z8Do+n(v`hYQkZ?n)ebrpGz!yI&upFYP*5X>WgAEFb6FyfzZdf(wy;y7@L!@(G+q{y ztF=TOV|rjX@}#!d^ca+iNgk3e%B_Qcy?-C#8aiAw;@xOfE8fWzD`R5H=2a6?Ag5d) z!NMR0R@}<%vILy71*_@yfG%7@yY z!OxeX$mfO&$;?0bX~4>`;DW_uec%A++!pi`SQi?rJ;b%ntRr>V0}hUMNo^v&U2D;z?-u*T=N(s0}@#FyasYOZXCK3xnlH3S*TO_MC+k!(^ znE|zigOfVnHA|10BCdkhR_B+2m*228CG6AC8UBY#C$kxj=B-{Xc(j$Xg_3cDBJmB` zL!zEW`JHvQgWVP;X~(qMQ}F|U+AFTQlII@#-vT)lujinSlOo!e%8EEn$KCO3xWt@c zt4&SJ1NVxIyW;LptCH_fiyP!g>aG&WHHUM>5H|qclAJ3Tc+F|*sFi;;NGVdr=!-;^ z@zra@d-}PQ@bob%MeQCdgrCW=#^tgq|B66=63oW!of(jF7t(0KubV3%J=E2!rQ8mm zukyew!>hexHugvXF*8DF$>Miu4sKVyT9pupxHLwMGC1{SS2z!Y!=Bxp75L@Y(;18mWXA)-iKbqk*|7Q-XSVA=5HK$oz} zNJm0rO$(D7uOP9Yw0~(R6dqu`!X&o-wVZv9J}++RDsQ@W~tO5I)9rRxYNz+{Y12 z4}71kSSS4*)#j`V(Q#%XY4yZ~L!3U7P9D9kS-vNf+}8~R2MNpx9WSY9azhVc%Vfk^ zw^X^x#(Em~_pcB-QV&bb!xHb|!h3Drd3`@NCGp3O4&LG+<#s8Akh#@Edh*CH4ZVQ2 zgWuRQiac*r-R3v;>X0U0+Awbd$(!|<5HQ6dMAX<2zc(%K_Z@uIbJ@D>Lux~ll8Q+h zMXG2yUV=z%ywR^{GJ+Mu4y2R$e@Ct=H{4At6shdWs;lPF6N;HT&tE zi_KapXN4f_Tw$_{{1K;#T_><<9}Wy#2rD2GvoDibwJ1XJi)xbL=wf;Q@Rke_aeJ44 z(><$BQ~JYZG=x4|V^A=WSC#;GrK;hg;=fn&5X9GIV-Jia|! zC|zXNDOV8lSJ!pHdZj)S{J}$S)j#v*r?p>CcK~gJ zeo(sLs(RNgjd0wVP%Lj0aIZjX~XXy&J6OIZfqy z&eB#9H~h*3l?k)jRZQ(s$3-VtmJgM*`6-pM+G^V<0m7?Q{e)cAEGp|z@hU;T${&Ze z_hYD12D3$$V~E3$YnFzYU(+S*1DOWS-56Sp!#?LMx=`=Rl z^j{46@}1@EU2-4p%P^A$(=%(CIbZFfj`S!wo+wbq6$MxwmWx+yRnKKRA zu$1iNExs_B3UtiZ4iQ$X}U#SUAES&Y$>dJJG z0ixeD`?H6FZk-h0-P$J!almIPs@Vk*v;4(zC9X0W0ZTwucO7@s^&>MJ{W zM7IIy+V=kQ*T;DAYgc;RtT~-*BuB zH|Yd|$P8f8Irbm2>QM3*V<+9jZ4q}yZ{e$l`%6VewcT&U7gs(1^&kTcNdH@ifczcz zYldKc0R3Ch09ycFPi;($Eez<*jqT0tob4Ft+>GrdB|CxtIZ1^A0`3F`LIk8d04qo* zC=f8<^WOscUuoa}N$UcJtNs2f?cWLWKlxdN1O6-B`#*WY0mte4pENh%bp9WfdgkRpfz?274XAbij0g6aYgc@bK{efjvL=n$@({a%cu?KvMQHeLmvwUlx>FOEHeA_75Zn$E6`=p|SvgVFCbU`JeuY4*>j{wmC}uE9YejfcGr`LDBzo z{4fBC1^{F-{nKSR095>|x8C%h?zsV=PYHmLntyuE2Y~rg0M?)YIB@)jHUN%<0l50} zFVENII}ivEAR`E*06>GFH35LZ0017yKTQ?|0EIjNjNkvXNC5z1k^sna{L^~z02q)0 zU=i?7|MmjF<6rrJtA9Ev5rE`J05bnw3y`8I07|F;s0{k28}9*VHUXeh?VldX2Veve zfT^5+dc_}rRY1c)cBcO6^K1Yvb^y42_@`g{0eDAv2l@fz^$i3nP$&_%EP@hHC#K{wMH-qJwqC5T1iy4I98g_vjYiMNj*byOHE7r zuI@m)V7&y62wGzA=MWi~^{;VqlD~xhHW%Lhu|ElWkR@yc$%lTThyR923h8uc<4J(3 z7@u_LnmVCUBj!+0od~2dBie?aj~=H#M4n1!5O23^U5M(C&!@pCO+DB{i-nGIm&-OG zwy3TQ%&DLhY6v^eOA4h|k$e@BU5!e3?_qpEf#?5U22qInM<+ zrl)vFl#eJKa2a6NpQ930^a@D^QzU^?#k6%Z1Qj=+cuI;N@F!Fsj-7ABv%#D_^TcF; ztHEEo``uC4suMG+un?-Mg3wwv#oZJ!2MP`XU#BSGd(qNgsH-@7Brl3fD5jb-A16OW zLdh##Eh1wnAPHv;Nw0ARWWXXLs8W_i{VIDfIFyHC!85Aw--)OZVva_AJYLuu|3pmc z5G0JjNKkIW1A?-RCfqMOHA=!yhR34*pv9`348;kiRokz#wNc7WNG%WuCNe2cDZg7) z32>~~dJ}g(V?AFY`2$&rPAolpuQ1jha)?MD@M{I!feWJGKoQJ{`b3ce3_w7bK*NNX zfIl8kU`jdx;r7%-b68GH0U%HyLQE+{TnvT=)=$5ghh>niCA0ErE?_xn|icTzw zU_{cl+N)aG?hWr?(qw|NNi=abk-^YXQT-w8@xQ(7YCPchfYDH^L`q-a>*Q&Qg}oB{ z`ia5m2?^2S)uB<4ZG6*Gg@1>U=IG8bQz?%9Wx_#82fHD)xX!oq;!uQQNI+&3p$xng zWMbtuubpjc*zM{j%jtNGNF%KMjeO8Ol2i7&e{wdmoiEpH$ESztfYLLa?=8jRLO%A3 zoU@v;gVOwGJcFa6{8{0`Qu6f!BoO0KTwjc$1wdULf+;RuhBB8mW6qlbyfxSQ8VkOm;tHAqx zdu7T?KC*PHEN4~f*e^s>GqlY$cba{zpkNEo;?W;b%;#vLztS#Uc8jJ2bbo_jznN=q zE89f^$$6{2Ul^BQe0Mckhx(?>?>|BYPP*i#NG@wb(0xlY%z@v3c8@e-s`83eIgPGMR`dE5KAa^CseW#FSA&hYthLvx*+ySFQv&v zis*TyoR+UH2gw!#Lx*!4UK*V*Sn`?DVf@UVR89#)@zX;0IDw^%$*yD29lY_;?|HyV z!@Q$KYbaETKK#z0rXFqLLYG}>Ezw{rgJi&}pjg0~M)wut6FmqV0*A!Sv{s`u)#;JZ&H*>`p6H zblOQt=^Pk(dNXE9*eAgUi{8VUBkT!xmLb5xn);;--t z7B8N7B%nZCY8;PQVwH`~Bodec*47$?@G7`Y1+NtN45AC%~u z=MhlL3H{@>$iN#c1B($U5M`(8Hs;{NCw#tomYXmprpAXFpHT=CIKyO##G)Ocm$;;s zZ@BlSQWa`%>%u7VpTp@d-&n(^8%b_LVt@C$B|u@X6H*%st8CyDr3MCJpA*kh+c1fZ zj}_UgG)8}dX2L)UV?yeR8st$;|DaX@0!;`!{~k2_yK6>`!RTdoiC2S+g?uE(MHD2< zY_gbdpZK2am5m*|am%z*-U)a9ozFQp6h%NDW-gJYk50A6_dI~M?LuVT-2Nk!F)Bbr z3B(VxozaFm@4Ehc6Guuq5F4m57qfkV3^=x4eunR(uFf=^V!s+uYgU!2K2lsnG+{9N z*}ufS+cHgT%i5ssKE+d=jPzK2>=s7F_&pdb^J%_A1Txe7aYO6)(CM<4Ja{CU=>SQWGV-R z=st1pq*;W2q_tD*HwI*QHaY^20qK5ul!dVO9nzvB88L%{U6q242(*pu8dX1(bSOkd z1;PNxFf>vwut%wBo1cnj0XF_KrW`NXe3^mW^j~O@fO6x?wSEsDMoJX*xVGjuKvbFz z2Q|bpGl_ZT&3==c)X6EFZZe^UGDl3(wOEOa@kr zNdVfRfP^x4`dx&zmSoIdOg@$a8&t&u{dm5c{HLK~7Nt#X^{nKMLVdGFCrJW5yV%~U zB05h;W+I7{8e4?JVtW4dlaWxhoI=+*i0TKu_o9gZ9P(YuZ%wV_L8F;4C3mXblASyO z*B}o6Oi~4JGsMeRk{uN=-l;AdMJ;?cEznFgrjt8`8gLo98Nz(K!}x;42_h8z=X%Ks zq{C^|-s^CS1%b-TY9vebvtXOmbU%)}gP`l>;23(h*{o?k7+GIHALfUgRFLW7Sng?a z8JyNvOARgZ_%Y$N5v%x`aZFTU>0yy5YpH2UnK*niQTExXa_MlW_;rQ*6IzTV4K)s- zdb$Y#Uk@Hxz?~!|dl*UeCUiV-QS0WRrNn|e9?4dOSaglBtiA3vmu1yxItHwK7cm{EYH#$4^0(ZRD z2bJYw;I{bG3Ir*Nk0OmLABV)8N`AChrJ&)(xu5}SOH=p4mU8JuDA{m=v4ou1P#moM zJC*@k2%!;S`3LWUG7;@ldW=jU5^wHH6G%yzvv$JCQ5&oh-N=(uF4 zY%;0qT0ats{KN#BG6wTPC6mME`()a388GO}%v3fg`iAphN`+{6wd(hKt(D5ZgO4@d zjjL-*Z=_m5P#MgwY6JHvCE(LsARCUVmF(Zfn-Yi!_x&$7-MxVmHKt* zDk-B=bAFC_dCGyiK5A6X`Q^Dk5RxEOLJt{<|RooRG894-V>hSY|I z{V~Yk6p8X}T^qA#Hs_T>f=mvjCQ~c8u**k$L);DxBx(~o;qv$KXFe#bYkgPW$jvG& zNiOoXc4yKgb#(mIf4&BC=m|DXcQ0sho?gBLF9iO04*uYv8l(+nU-x21bzNP1_dvZs zga%m|bgNd3zP$E8dn+_UylCG%=f{d6%BOPBvQl?6?;V={P(dWF0Q&}&hMsGPIB!Tr z1Pv9{x+hJ6K{W``nEu!kAQabu4XS?b?{oRK9qk~6J1bXC5E4@HO6s#iqbO>@NL>n| zG;NZEn2VS?c$p?ZAvFa}NM!=4De3rk-~2v_gUL~pA)eQ8mMtZkHFDme>nOHRl0r+N zCNWS9yixmc6c7U20q4S^h1q1w+c?YCxj>HZS7%j_2P^_;*97UIIh@{2=s}AWaGN>( z8<{3pFj44DiOl>`!U3`?j$9rh{}kyrbvHVbI^mXkPvT;2y#w9t1P{aB z=x-eYGiCxPN6lx6M;aVt>uqk5q9h;!(cbqT1&9BW|zH3x= zA)PH-sBG(JwGk8EkJfHYZlb6DKiO$c*}Po)#`{SLYaRVZd23G+d8-?|62HHTT^T*V z^^){(adTufxFj$2s5nV^`+9)D+_hV4%-Gi8 zm{|l2Mwhxk*NB~sdy~e}$VW^la$K?XKpI_rq8jLKiNefnPjCN-H0rg{r+vI-zndL!A8i)*)q+^=rL4e!G+>PtF$U?dHR>#rL%ZzW{YdRie z9dkDX^ZL{s4Woc5DAzQ|STBkFxD6rn1dU|`m+Oi8WxAio(_`X}AB0I9CntqQmxGXM9jSxZ3r>pn#+XgB5Y2I=&4CKV zOihX0n!!w=USB$)9eAK;P&s=nu+r+0*}vbYDBD->r39JCkF}{nsec}IDudcezR9N7 z>3fb0Rmx@mzN7W@8)^9*`|h6FJfwwXAO2eA2S%o{R+(}-KQI~dEcC)XDU3c17{`VU z`zemElw=l^6!d9InXGBF+Vwd!rX^UA>dp@p`VM1wxM``NtnKnk1fLc5sns!j8K_RX zE=~4Mm0!@&qdT=AEr-l))yK@Bs;o}B=d#Aay#G`N1EWdZRCGECcV&!3Ktf3`=et7vTg`R0 z8Jp;L2UDFTSaahVEe}FcOh7P9SH3y|q z|9Nbz8x3}_zFZgza7QCuw4%s&ktP59aR|?!65X3jh?d*MwjiPxalasF_)f~tbRlj? z1{H_S5$Cj35v#+pZfK5?^8KgzL9~(1>(`H2jXS}edXv8%WeZS+msEY;mECIG!-Kfj zEN1uFO?L`o5R;|RKk7zdve6m&{LacQ)TYZV)6w8)i4;u-1v|MN-(R0Z8f$D! zaH&P+g~sI81hQdafM)5ZpGIWp4-p9IieGBzUYSI<%fR$^f?`bvHK>Qs=gCvXU8+UlBy=Ws~4ycec#sX+nKQCL{Kf0a?J$A_uPyd~Svr zDe*k5xea5=lHrxs;o@pD4P^pdz#_;lEG*CDIwd8g=hVEn@~Qr>v?rrQ+9?W>(bQ7} zsxXNJEI0B8+P7C{*Z1?Y{|yY{kh9RkU+t3^yX&{#!)Vs-bOslPdi;i@TCdC7%x1%F z2^D516Bn!lUK)5eHOBkcW|z~&q+t#gTHITb{gHapyfi?c{#_^2dJRwE!??AptZxuv zDx_&c%=NVX?i-)gj^l-gKc-3xT}brDLEoxt ziEZab1v;hw(jmrpht10!;Obmc{*89yCht9^Pokxjg`O9gBIPz;Pe%`$=rDUJEMoOF zYQK!6I5Qw{M28xJJm9=cZ5sBVWdCYvPEL-bNkjm0elp=Xim)wW&z4|sQ&@sH8nzLdTwrA(KrKM_CFcP=W_m^I2EglG9V z;+H4c(v}p*9sYg{76W}tRygr?=vxI+d3|2?-N2QCh&nYhURw`4 zjkmzY5kf=gu(hRaQfc?aGH##G;Ccv_j&Dv}P&=uOluKs>RQQsiUtku9qI>fKgPdu` z%V;z8#exBke$Io)NpDm!iA{GD75B$sLga}D&7WwotpI1DmP|alCngGX*r1DMLnfjH zA4>lp0FFR$zp`yLQ{^j96lH|2L7r^*G|^wCno>uO_YVbGYXrx@#uIe?;r53I`l!l_ z6ynrLgn;DSIj8cwDw~GyV>5coo*W)03B|-ivF)yOCCcm-MBtY6$Z$c|idd!EQghTY zgvW%V&NRvAfR*#pTB67xQRivh=iFG%1wl*aeDjrvKMj0V==Bw4QBi1~8DZ;uTkDA{ zZw;o$u@U#__4SGH4wyH>V0v4mB0#q=YSEvEKTvO9{H^|5s^^qo4Df#yhw zKC74NuOif1SPN3|MSQtqJzSR`$uayJ2}`=AT+K#ZT~_>FfsDgn-hybnTaTTWX~&3M zAsNYZuf>nu982DkbNxfFaM&;SUwQKRmbIlAte;lM5wY?yW_By{6O^MDW z*>^k@$A_S&eD8z|DIbkO3BGL)z&KUv{~+zI@$&YIbX)drY5h0t8!bzlloqq*_{^jI zBwvCZd`S>tqFOm#3t4w1tRH{n=ooWafO(O@G16J)%Eag55%ZLy+2TG`Kl}gy0SShH za0m<_J~k*^fB^`t(jG=EzDaDlpzeX@uS2Vp>wLi#l`BQ*2KXCyjZ!&CaR9~Dl z|0+!3R4ZY-f`x1xYeL|sm7iuQ*A z6Vr&&ZIO!-H}1p>4vOU6Y2aFfCNR5$J0hgoEK*V7HUu_aY#=DiUk#T zoF#;zoJ&wROA0)Niy=J)F>-U5z$lbMjQK{gA6*Ruw3?$vO?8giy>LhkYay0UpJy12 z@ZY7=D8A0yHH<8tq!pb={4Pi~#~wCSWWarmb-3KksxTu`X*2LW2;f4JSAz@}J?NDi zbUoP*HIyAnS}@C~g_FfOt1k~05G+|AGLjTkkwijG9?MEef-J5f000013KM9Cv5*8X z7y(2800000000020000000<{zWdO(;nS%j9000040vG@Q01yIIYgP>dU;qFBAOHXW zpAD9x1n~d?fC25pV0KbQCpB{#azx6ylW|MFqHiBiX2$^MV4&-j2ArjspE9hHnY)VOEjJx5M zW(DPgMv|s%ift>M*KBd9Rc#bE6i1ojblEEKsl86k!nG0@px^zw#j9nLyP@ykkZt-c zlBr()$l}rth80T(I0ta3Pv zX!Ef#M^V3oa-7qtBrgREHI^{j3K~e}9#B(UPmsillsrwccWy&P89aOZz5+KTR#KQj zJN$#(@JQ12$F0sGZYpRvS5ZhL%KXY~dueU&nP1QAbPNLsa3!;hy)DvtNd!ql+x8lYttw zD2BdB?Lr(;`}B19lb0_C8z{`hFj$diB!V*)?gd!xtl7%6 zT9hG=kOOabRyD5WGM_g)n!E&D;!(*a1JYAqd`P>px)`^x69>W{5$&DTLpgKsH780x z&mWkEAbDGC7LR7lO$H)^)$u|JG0IlvprO@A!Fg^$g6-BMUyTWS-4|rcO)o`VwIxp) z-x>1vWI;#&q?U@>Fz_LyQhC)SJPeD3tmNFu8~B*=&xOmjt+Mz%DnG}!PrrE);53go zA5xui+hUaAJJ%6I21byl%oa#vR=~k>ldhEW{8Q0n7DC{*QNoCqs2Fv;XRlIazBfC! zoen`w)8>7MpNNOeD4!*yg4CFb(~J^K<-Mu2D-eAMi($c03Rdu&_bfyK2b4{>kXy?O zK;O40Mfj_2w`UZ8z_X3*?BMzz*>TFK5rjxTv9EDc!{fJa6@?JB=FgZDs(=dm2ZTp2 zkK5J0-dsHZzkcRLBT-CPu}KRX^A49mU|C{ba;nng=bNw zB8LuXPUQ7~_SRBA#G;h2Kocw%II&K>-l`o@xlT3(y6v>i5 zvu;yl19Wm~eF&^ZH5+0fviWr1as4!uynpQ$ItNoe55p8-t_=Mz5o`?y4SZ}KQps)9 zB>-G)v4n@-mR=A9*7G`-aSTDn2f}O>4&)a{_lOx{jK#f(tnS)Q+a8AJf0lsA^ZOzo z!fiVz#hZgW+a#5mFj8|&44*bHSTR;r16~-jz1{>0fD>|l{1XRXM^NqwDeU3|8~11U ztNOh2IOF}iA*F{SmFTx!mYP$&+x(3S&68&;YYSL##Ti<=-BFC!$!hL$;@+dUD68Y6XUZ*YSSWnW#w4iX@31 zL46aN>y75Xk%aDE3Q$-JN6sBMRh6X%Gyryl?yoYDU zb2g(CtsSA)D*=g^vV|aPtuP&a1z*`X$*7N_WLGR}`(U&B);YTgKqnAv8Vg!ofTrA9 ztjbz=9bhOVWg7qBu&g&0jZQNSvSYzQg!CJ8av?P7Ra7Rb*&J1n+k^h40)W8DWMAq*y#ocKe`n%~Krp@CQ|3Fc^` z--_NOTH`mEJQW!*Q5CgbvdCGoo_ItlWG6Sy03gntC8)73=Sb>fHJ}vOktTr}L-MR! z>1pK)7oe-E2&!X10#GZ5m}!DI+)0=FA)f-QuipRw0SgC-2zs@0ZERW8ENc*{45lGc z3R+BtZlcMIXHo7k1PLXat8A}E?@rU_$Q(c-;C zGOYa(OUbL6Rw#l9A(2&;=csaztc5ESp&<(u*9##CAcBGsx&#!YW;g?tiY(ePCQyQh zZQ)>@sioC2Tc-(r`xhkm-V-+*s3e(b)awm2=eP z%sfOyObU-{z^pJQc%z2STsujycGghRm2ZM%Et8DMh=~yqduzZn0>^+!_D~vg_vYvV z1mh%Z79t`uGh@t;De$-xK(SS|JxJzmuq$v6w18xgNn%uZdC-%k?Fo8jN}y(DYRt^d zVL&t?R4f9iWRMaCOsoLQ&I0CUW@cpo!bujI+{3xwkl7;&M_3~=Q)^HWDd956dgm@F z;GSi2#TGI&Cv-)!?fR-_b~R5#|CiovfJrW75Gu~YY&QD-9W7N(`N8E*-B@-u8Se-ofrFUmeX91xkK*qFfaKkZsOh2rWVN*{#B{1_mGfp zsI|Bj0;-kw%+%|!CA~?w1e#RRuhWW9pzi_im+qG2+=0NBwhOle;%pz@fB)70`)(To z1g2XW8L&YqzaBmF|78|xbW#1si-y5bSSO3Jl0ZW+^8eq&53&OV104PZ2gQi@$^liU zEfcRX8l@i-`9-FEANbfH00HL*C%ZSh_u9f14HXmbLuKI5jXVWc_nF0&frJ%?3;1Xo zQ&3`=`DUgy8FcW+PeJv}`F%?YNz~7xGN_`WEl62)Kd;%nrmN`9i9R`%nvqpSBh5$F z63GVhI4alszs+bfeB?rdNL~dZt_7vDV*LNQ`thUyR-&*PmD;*g2*3P5kW}FU7u>Ms zn!obqw>9F)Ekp%)=;Pc`>@g(-g7)RSsj?jP*6La52MZ~-qoHWV)U9-8a4gO^X z?f5j1vcrZ@UuXZ3Y5ziBWEN0D=lJ5`C#jjdo1x{ zy6NAP{t^K%q^=B8_dc2R3`K~}JNHsiS(4;*4Ja2(^*)P|lo%+dC$p!;yr||U6mQ0V z%4f@rDe43g=cWzm%%cp?YMAImM{1CDeBlIb8UY=KWW;9 zh*6ZJm^PjwIh62|%;Ut-FxWW)g;n()4E|~mt}~aRqUA2HDHNX-$hupcP?n=KPo>Un zzrpr#U^q52DYU%H*5yyhj71fd7gsZ(FXnpvF#eg#Md9rAHch{VIv>lkKXP`yGvGX1 zK!aOFKOI>?Rp5>)E}4udDEz6mnpAh={L{4zGAKXWhERGMpB=UfF9#OC1MBDlKM@{>!RdDz0xZBK%!X+uAnCGSZOcCl*ya*~Gsi zu)m3{aRsvezVL)m;>5>D`yDkky}721|AwC@Wngezt{hK7J9E; zrYM66M@jX%pDY7~(=NchlE*Tr?tT$)_4=WZH9fRS&m$^pbF9f|@=phj3o3o{#g)o- zWgW}ZWQklhEPfWOTT5^(i{}mKONaR`riFMv2hSgbaqw{gT)YEFlx$z2{et|lysK*? ziYaaC_WkFSJUxGxLzKZVOu*)SER(t?C4xp4LJFx=0AT`82HN^~;M?}3UM>}k%<-XP zjoW@z+afQ^bKr~c#Qp^S-`B=+S}A;#l&h?AEY8#YEO9I@6WfPu8PANBXMStJ6~2*D zCnQ99Os%6kZmV^`c!j^fj*vrrugX@-6qK`ve3whe{gp&40E#1`{}tqzsR~O(*F%E@ z6yiVfX;vCi=lS+{`6p9T^zU#?s0RK`RBiq{D(BnyDcL2`z|0%q2ewzlzBE2XbCCi< z!{6;3VdIxp(Jfhc9D_X$#_EtH*v`4*35i3w%ubmOguZ;%vZm$Oi)Idk96=1_*5cD;F}U7@mJqcu2>!Cv7(X~DSphXSxC|`UR#p>fBnbi zK5>=$r*}bnmGa6n?5?vBGyE5e0W#7<+R-wb(f2O?_lL{2a;H~5t0^WmP0#22_jLKb zJ`nIy=dhK6xG3>Hc2*5Bp1IRY5gSPZAhj2BzfuUQEmPoyciq6=3u`YC(cxQ%k-HFL z7ncRz=X%e%zl*ths&a$-;mot;Kkpsj{_G`NU6skK6A@z1EiB_C8x|_Ta|&4|5ho6t z)br6Ot-^Jrgy)R&%aBX>+GsPBy*}p`J;ctHJaX%u^$64bUS(Xd*`v-uLO zuR$zJK3K~UZ3D87PD+$IyA7gN`qz zP6A_>Qt4|KEXhyjSF7o5XOJWd4qB!P4GyLW$s$5nVgqx-C<6xF74js2JwUpml^%?- zL-6T%U$^rv$%QN>ePfb;?kSeG=TnFtSm>bJs6s8RgPo78ZmIl>p*{!Wa8GTpibKcC zIfW}r5vD@#ab4v*8$k%Y=ll1hnaiR46Ywmoq?!d*&M1_!Nfjh|p+oN~EV1)jDTQUD zISNU5O-Wm%niZ{?3TLF)328^3MC_->MDts;i)kXzmSk3HXp|~T;u0!#6xTT(6sC_S zxeiA()U_?6^mz^OR_u)}SKT6pPsvJnUg=#+n|LEF1&|aGy(yfC+^{hPW%4|% z{~z3F5{ByT9GhuS=wsOu4d3;FZnO$lVSR}%As}fwQ?{%W4P$Ech2iDTywlwdkkh4<=<~_R`Bv;~SL|!8e`C> z7DCz`$qNchRG&~?SsH}fCnwnsZJE)14T^DDAXd8+_+aL96#1o&sxq6%lvL4TL}l8z zz?5vkEo+UWEn6}e4*3i zYSO`K5l-7A5ltj0jFyz0(fQF4*4uJ&p-KhL;RrjUP?a|aKP3poRf7J001DRamY3TG)XqV04owm01c41sc%2f0H9TX9$z(b&Iu;!O18FQ zV2|Vz$`+*aLIYR*^`b`UB^t9^Xm@$=WyvRo?Vorv8r19>YcCNsPPT;K{N?RQ4JJ<& z#jIs#Vs>7Q#>lcsNhLz(_##P^-eI7`73p%l*(Fjk)!`JBQ|`4`{jNt$H^vieiHyN)*U#)Gql_lY~I!2hHj|RrA6Vaq|mZn3;v#Xvpc5f>nMvSv| z{^1`bqO-CSc(rfO*<%aPOCNjmE;GyK1NgEpiJdd^c3ys$;PztGAZ}ZqoX|djzil4^ zx9bA2GxpjWRVeHiBUZST9(YQT_jaGWNlL+J++-({dTwLyO0A2s<8|dl31R5$?y@T( z-IZF4yTG*Skc>kE`1vllVf^FKwdr!6YHffBSz{HD0RE~2~W4B`};-7T{38E-jY z->6!B(4`XV+flTS_u6y%6yvD@>2>!KgYx%{7jhdZ;s9?6uIm&$vCh+a5Zkx-$Ih3q_q%Q8+IRq%YY2u&_~Qh!zb^2@NkU=vGiZ*-jclK)3Wcs*vlNywjO**%l)}9 zL8$f$Ph=MIfk5mMRhtsEEn8EpveI=$Yg^hKWiNHaMzd0^m}KBN*u7-l;LJ&(UFNC7 zxf1Em{;4$-xn-=-{lGj(8UwbbA|e`4J~JGlCWyx_hsE9YFTf3b6nRUhx@67;hX%n+ z7#3!rfgl!OVJP-E^HK4@uULqlB7QqDZo1ud*aj)za?6@6JHKa1i5t)0V!HGPVzmw= zbM#x71Qb)b+_E%w%R4b#;@wx-7u{zI4jmFGXcG^rx(w9-g7=oE~No(jyJ92*wV_gvF**ed6TOQB83@X|6j3nEk>O;Bi7 zLYxg0M+FlzIyC5HZe#_1AYS{?Vfq2Ev~-IW8Wf1mSV)8#BlA6?De>0-EJQMeB3GDE z#iQ6+Y$cvI{8@-1_D^6H*v%V99$K7OM+m|o;ZJgVh&#)P1Qx=WTbvz0RC@;rfKyxo z>LuvNA(egv43M$@1VkdHQYavVNr(Uk;4mLj)OjPuP=R2M8{tPo&IK8RQB0U5(IAJA zz#6asl4PebXk;XY!tN|%wLxvqq-hp8i;|dD>_Z`t;)p?!Swl@QE3D}S>8J@%=%+F% zG#gnSNp%A1Oy(GnRIU=vxM-N!;nzXzfLg&pT}&T}CJcKLAq>Ne5k^u_P;H}Kw1`{a z`eCFzw$^QbL&MmI5JA!!dxvOQL}TcuhAR&gfkX^AfCge9QKGE3#rR@wWoQE-1nwgi zMrg2ykp&KB6qsz5v?fk~!~{Qb5k$q2p5oDo2b5TYVa#D1)T5{%f=1s4=*1S!T?o*^ zM1+t7fZ-uH)S;#c0z!gOril)QrAqAzYGmcUi{xQU;Xs6F1Yk%K2?c{dg!FXV(c#&V z6bexYxrUL+fj=r`1HnM_8G>YzEy!^qp5U>!q%=Z^OI6opG!Ta;reaHh>}CnMDL|zN zQY6C1r%hX%nGGRVQdCk$yh$*j!c{?vlL*pkok#CBczvWK|1Agy_~ym-I==pg}3SJ=`!3 z%L@lPEL|K?MfpQT1cfk2MB-SbifxBp|B95K%)RbrQm^ZPK}HS9lfiiw36Pi z0K{KkmFR#m9e$R#wP?nX05@-~_ZWZx009#P=+asuPO)aE)t%Pcj71`_vJ-8vGvtL3 zp%>96?P#-1R%-&dpG-aLz`+8v5JcY!YO?gP9TPjU&P5bkV}4NpN#ey<-Wyd~J((dy zDiysY%gt+4OKK8GX*$WOH7c?Khz?gpf!m_G=gKSazyuOiHS!`5R00bZl+|KZWPp>` zJW)0oF)am!D61B8k4}mC2}n>j^;P(AvC8pV>jcb844{?;`WYg{yu!Pp5|XiC8DLly zc`$>5Uj#IL3lUoMGhhZnChJ*hT-P=Cf$@@DzqdH?^Rku4T}re17wPn$R9IwX?w+** zp&*(PjL-S*u}~s1b_|Vq#f!uncQE|Hc`vYAlzs)8)J@d1>>R;9FArva9Dga4Ppm`) z)+R1i*}x#}!;{J0Rw_}drd{>^y#wH)t8_bHwkOcF*dtDH@(!^SC3@hynddm-d3%Tu zvyXEZ;G*KP+SFsLt`fOSsFCMQ{z(}MT{EWr%ycYCe=4k}VHw59;tB}9BNq`zOqQTP zEsk)0{ws8LQD9N#m^L~-CC$2Y2*c-C>dIdjP7mSG!K2NCv$4@!+)e8kOf>E8w@`59t#VJ{%gPXEC_4w+K9qbHvN zW6|J-S0IY^EL6{MGlPpCJbHhY47ueUr%Sxcmpn)xqLlqy{Q2|58T^&$wJt8d_qeRN zxtR=K*_FYAk2s4Gt6NhwjCmIf9u4v0+ajGYHU|NJO^&P%;@W*Y!r8{=w%(q@5ybIM zV?_CCA`}c68GzLqu>UEFfhig$GU-`JKVgn*8#xJULR8!H=2w zX*Carz~_R074!5>sXj{|1YVws3E0A*k(3<0c><0TQ*6$Qj{X%V_0h20zj;{|%BAsG*syI=%p<2Iwu&@( zwo>A*;uG`0iafw|=P#{uY#Yaq9xPmgD6z-1ppQA8+iylvxkv8Jx>y{bp6s>^UFX_- zR&mq1wBosTS^DYu;# zu{0E%^JUYolwHS}WhPHXZ|tz&1dEp=^zqZrikZoe#o-ngJO)rsk00VXjXnIe;~2UP zxNkNNrz%H~zAlu~Wu6G|9&+rSTPDHQxuw4O1wZIggRkA1{y!u8qSPpY_Yr>u6dw?XMg{#Hj20PaDi#-QKWQi8CbEE{pNn~tLk`dTOR7N zm244s02p%do-A&Dl)n*bSo^zti9!f0UwDXrE}kf{b=4M$>TIL!?Jk}_4D5dr^)Q>3 zPC9-pl#0G+S!Wx#dLJz8FAiW1GY8s54&OoX}jB+6wtf}Pxr zy4yv~!p0vqLkq$L9!GnTV1(SQKAk3G#|JC-7fmwfXJGFy#u>7RCTiSt%3exE#k9X6 zx<|m>{0Q`3oicqZg-_0GT4+bSAB#GKcw|=K*UWOF(fks(dyg76g^>~H_fcxbrs$yI znM%?si$uqqQD5$o@X830;hi7Kt5KY*l~2kN_EQ*hUo*yb*4y1kqVo;&lV27+<(5|5 zWF0;LT#`r9iMjQty!2Aanwd0>K2Ir7ytgJ5|E9%P(-6L)rsY$7h^p8tz6BO_YB{M) za?n)uUW+8sM?ix)2fQ6>Yv9@7Ox(Lge9niGEQySrHR!ZI7v!bY==$gsv2_#^viOpK zG^nL0xd_fkQp1t>gw&5yNhd8eHo&boE<{~HtcH-_9qLuEe-OHo(bV9*T2Lk|%T1dT zMAZ62ydq6`(XXL|c2i=}Fz>^FIrO8D zk!m#uH^->rmW|}Hj&XlRui$<_&GZ?(&Oqt>8O?^~p;C%*0~{epBO5c{P(&etdMq0( z#&UI?BV~*VVWy!j`@&2(Q!{2C1#aj_ax&cxN>QGXdc=lENV-=I;hgoyW$S^!=X;Ei zyu6Uq9h?s(Ubs^&%rJo%W-Lc;GKUN(b8;iy3LXtJlpz9!s5gr<&f#3p;KX3CS7mlZ zspc&w1#_+(bDYC4gb0E|Lwt=%cN`%D5F{yu+A^55SchREP%2pNYXWjcv=6p2)pWGcBvMnq&_#SLQKbnT2;;+3P6lAujb zNiD22t`ObDc9wXgc$=9`wj@hrZ_>ohVm4k9hY*8wbB2IeW!Y*yyNjyQ#u6sXurl}S}I zrr;R^Zm8!r>jm7c6sw-%cwz!!-R5Cp%)Iu>hbs3WkfL*#^{O1qE}Zo`m^7%*Va8(= zL@3~caBx|Aw9jzk7*V4rMI+r5Xtw#0V42}pWK9jXUO7=3!HvCx2_Yd0;UUTJ=E``H z(g~EOGG5}6xEP&jGt(Z0WHgSVBGKF+x(g3Ie3pz{?dg`t#iB99$~4kAltNL2 z85T&7vsZlX;Y2BmBNvS&zuPuB%uuqRRe&29!;Hi*;zYsB&?})tue{lk41xg>jxri7 zfhQ|-0_Kl`D!dkWAdLAoL6ElW9rL3u;2NZSyBC3*ITH#eM&+bVzy+J2Ew#m`2#z+yII)_O49qLcH6H77HHrwP2~xtj=d`nfq=RVJn?e{D zBY|=X7jQuF^4A!urB?xfzB9y)om!?E8Y>*mjyPZ#4`t?JDn*&Igur!~#3Uz8OnJcp zgt2POP`;N-cAe3SW;n^t)`SdmV6XzEa6utLAf!4i$2ORm!m~MqnDQychWVz%ijSxq zx&z65oN8tW-aQ_SWdan%WgR*+1I<=M4gDa~Ii}`{ur6THTf*#c`1yQ!Ly-Y^p~9H* zeSk8&&NI1S+?7fMa0eO7Bfb}TJQHb@2;T~FN2km9IA7Lb<>7CVM>%SDZ|!kch@M{6FkZcsR zr7K#}mFJm*``R4=rMLwK$mVZc7Dt%anTP>p7N{AkqDcUNbhEs;HVL!URo+%{8HG$9 z&*SE6P+HPUckn5?P*^0cyYEq=lrhUTOZcHEb+ubt9fbrkLlJiYhg)%qLa_8&D}qw8 z$4O!0M-jq8<529TXi7RfD`cJ?h_>_?t?Y#sDV^F{bmwVGTM@0z7zY?MW*p6PvZDzo z=}hy556z@geHsWcSP5pqaHb!Ww)HYa0=a)^9RPzrW>PJJ+0!o&?4q)VYAJ4Z`n=kv z9ANFx*xiGZUwB;KaqlV1mZ_4%K%6}Z1n{9Mz~SKZ+}SYXg@&Th9Br;8fF>QnRc&y8 zw&WK|Pj2A7ksKI=Oyrk=BEg!L*nkU8>?vp*5nun0!jL{vhn&Pseo%jT2me@E2M}=? zEF!FR1I+yu10Oz7-3t~8^D5(9PWj>7Ugr;ppR!=KzZinNGbAXT)#7kc0Bu? zVDtR;R}J&ww*RP881eGxIby4%PzZs3A}UV}+_?~?xq0q#$VrWd0x?j~kl`*{-gh}c za!fT%zBt*7!_?U#cmn5KmbH=e`iwSn(0k7Ww6X0U3nhLL3$h4+8*H5avS}WN6cH zo3Z&W)ma5DrBZcmJy0e-l9*!3&IsZPyfrG8Q9I?Srils|RZYjHgxQX7VD!7FmvP-p z{Flb~xRnz>L<;bf{H|{0*Q}T*OL_H;+<2NucP_G59ZGR1f_X?WWHx7&w9*l~)gBn7jTcN1h&<|e39L`_=yqXH$`(S7GG z&h|n|ZW${7!c|29rj!J*EuNzSNrj1Rh;_SvMXgkc?>v=DIF0x#3u&$08@UL+5BaHw6009~Y7{CMoA%F+~1Oov8000003;+fI000062u1(~2mlNK00000AOHXW z00K}=fon_v0001>001RfKmY-N0X#NbUuHbwIu;2O^^3C{Ctt(-(pIs5iwfYiUrxcP zeYV4;IZVZyo~q2x{Nu&&ya*_5}Z6Gto%&&%8i>ZD~X ze0abQmB?i~ib$qOXK;lTDW~KVU*IAN7S2bOg6Hngt-Hj7FA!i*KOw%!*}|EBKY>y% zcqcZ8_OIGDW30MSPv*nrWX7oE@N{WivoIn@Z}S$#!!bv{_yMiMl4X0nSH;yu(dUmK zVBInRz6Uu3e~TUslnF8Ek5A=gQ&=RJlZN!Nv8ZbssImU+zt*iX14^}SvwJ@gUH$yI zAXKxTGXEApXOq_+EHCRI}{q#d|t2}eAv2e4+ z#nKo5FobQ-&itVe&B@PzAGN*7-E2e)vRQ>wXN&f4%iSE6w}s!LCmI9*btOyxK}6nJ zUfB-c2*=1M_Q`=#d=We-7bvi-5|)13unQ^e0x^q)_7-;9UOU+56&EKhYS4F9EUg}k zK2O#OaHYho_D_r_v)571G&!q0rs=n7G))q-JHEA<3*R~+e6ZEr!4z}PXo z*(biM7=bWF#T!qsR>30y7FLE(?uL!m$5BC9BG?cLaL?1CmGLu%*6wDI(Gdqnz>+KS zGC_fGp`&CKJCqhYghzHWc8chsVUdZPwlQs*TFF^vr^^oF#Hj|nL?^n5frt`_8N$AY zhgd%hi61@yi5&c1XcyKnq=WAlz(!<~6+Dnp5)h_Rk8QQE)Srso72~43PAhjwhHNr$ zZYGQhg3%FOXNz*X4Cz91O;)v6{jfT81V;`ODF%fz4o6X(gF}Z24q-w=lqkfsEWPW?A+WM1_~D*!#;T*h(TIdAd-=;e+d>!N#0p z02^x2f!Q-(2h>!-utMQ*FHw|D7HUc&IjAPGXJ@J+jy6C^@MBA-&0C43MeNXVH=A`=EBhH$w! zjkr7tJy3r1wGNEsdiTOe=8ir;z^RB6KqOSDAOtX+Hg6KL*Xk#&+^U6GDKahV1oS$A zauAUm6DgE=08;S*Y6_WTYgc@g8>W?fQetQj1Y#y zh$9M%CkS2;d;|vw3?<`VBqo1w9`N-OX74M+W9IhCC*z9lfjNcFrm zARuWF0003S2z(I>%?L=OFdtE^w^J9|`@iJ!;rAJv zfTHxUR)JGxhyRzef~Jey*?a)Qu#8N_yAvc zanVD0>F`_dDD$2yc&cl8q-D%pzIY|POAE9JFX2A(3GdNM9FbvSJaA;1r^W5!*|J!_ zv21Uy$$6YUJkRm&@T@}zPQE)%sxDHi+F9v8&ob+x2(AuTvGD$^V@K+oR1A$v$CGtA zC%1lz#9ncCpdz%)96wr>UErVD=S%HCbhC1)&9RQ4-Mg|=5LwF!lb7){Ta*(_@kEWb-O&kQKuN4e`1k~TiguG-9sUMW$|jwcO_ z`31|AFUzT)QTPYIk%#lZW@a8(@l<~}cve=yJ~N3{RN7}oQzRA4m&S8tfY?&&sK?um z7taQ4=_dEEo1K1Ic~n*}Bz4?Z>(}Lja^3Prbk!S?7SbT1@cvB6Vl^vEg3K0W|NZ?i zv8tzo&x%T?EO;34B?bAoF%~`9Z|9w4x*3#pPC1;gMeljjDkw9z@3KVmKWWsPQT;Fz z1Xf={{pB5BmVGD{U)nBy-Ki25DsjYL%X4_U&73gy86&(w~hv3$=)Nc=c5wl$9xR{v|mXJT8pEPZxwe6p`tI4#&K zFFWi-@u(ks@2Qt^i?WyOVPH4Q9C$^|(mt_nAAlfJ(Q+;VuaeXz=(@Zc(%F0p5M|`hQ z3ZvTrS830Ko*qhm3T0E#9W$~8pki|&Tz(I;M^0!qpM&!JS`^BQR!CaPJn<4H&jObsNWiO->nhDXdi5w4Q{(t@A(}x*w4Wi_x zye>H|h-*|7C9S!) z0t!ufc6SoKm*#rnto75>;x%5go{(r2HQ2HoZU=Tf zaz?|TO;)Sa&5v>rl5U_@_%?kz(!aHzW6N|}EV2|p#dj!#)VB#hVB|=%T_xtOH#^WZ7@+DVA(R4-4x3WCU_Dj5t*8NSW3?&crwtNa0aP? zBp?1d(p?Jq@J7p0Wa*SE>o4Fv6d6az@D68mz8C7A@|PAwpUQze^g5F$82lODQpmrz z%WL=2z{%FZO`d?z4U*fU+FHmN;2g}15oC_1El-DC$AAvBTk+%dD4kbJV2UtG$*?V| z3#FdPY~X)f-#pyrfdl8dL<66gZAbQTcABy7RPF<M zf{_tPU7BsD?aGwJeReAhLCRFhL=zRC+S%@M8{rIfD&zGErU;+HuYRfxDe!m%w9T{U z+oHH-{QEA&*uD$=LgG1o5z80tHhQM^Y}~6Z@GgpRk>g=aGwH*I@0{~fXQ`iU0=Ql| zNbM(>4(6_8QIgMId&mZ1%${XM$tr0iuAHSgasgTF(ofq>n@y&Gzp=T_*LlbzsJ6Tq zLQ7~_=|{8;4B1-*%1)VS^h?B^RD)S#5)?E{C3g~>(dUuRVzg@wTdsy&@o`K0%P0w) z6pQB@bq}LqWdBW^=nn_n%E|>@pBz;+k>q^2EipU?v>iy}FFS{Z!P4j4-o?P7z+;6k zo&IhJ3axCZEiqHmNITUAY;kIVcmZYkSn;c%`dFdT4?> zZk&L5~#qshl)?ukd$VdJkuV=}e9vT1YER z(P^ohIS`5*ByGzF&CCB66+uLeQnQ8&*DCn=r^(zooZQW6he4Sf76L)Epl%(M(kZ{# z6=+g7ZfW~-ChU_=#8DCfl-mf8)fb5iE1{Hg_7*LWb>#wyGmv_wME4a=%d_p^2AAY3 zWW2oS7#&yZKi3gE}@b zH5Y^gz?DH5PTRKP#y(HTDW8<6w*B0YGbVE4xr+5Ft#Z#069S#4tfp3Kq(Pb#FvfwzC4}5l6a`(eWY(n9Y;O09E2buWuJ762$Z|HV=F4xLWOo4nE})M8pAl&Qw-^OHzCS{ac%K#%3jTnnDj)Gdq zodO6FgbLEsfcF|1idu*pFowAabLLRMBSJ$sr0001GSeODENMIlU zIuH~95763gc#x$KPsYGaDr^VUgLkv#4T(~n-5aS3V42E=|9>Dbh{{5!sign^1Mus+ z&BXI@HM_F7GBDrW>db>g?CN?=oDYlx;k0a!lOFboHYo4VB@!ZE`F0VY%u068C37F5 za!SCXlcqEPt&4Bsz8WpI;*`xTj;mHA3^(K!j8|IVp7UCEVHDj82_3BQAwYaEx+AX{ zEVTFwwU{X3bki38YTG0mqT*9k()BY$+9sXyhOo<3*$%h|=#P5JEK^9?syFvqA1}rm zypAFImdo`dO12blaFs3IMV8H&t|TJS@uo1*ke=;sgL0{VFMYJ;gWAQ6QBCGlR5_`O z_W5fZif)N-#B$HtRg+-Ex8R}Q!kTi6iM<^$92Ke?Z$YT=R(eZ=pP_DmZ*ti*0w6j|cZ!20*Mv-4XMRoxb23KyX za1?PH0#2{`keYm+XZe3tnREV;{NEz#=%m)hR;i>)Mq6A?&+L>v_`oN=kj855&Q z#2~!ikKG+mX9wh|{F7_?rLL?`Ir8WVL3D=)cr{I{{A0@!Le0LL(!VT$i5!`$ggs)J z2nQ;_;(Cwj0|P=F+_1K?6wOpS32EGHU?=cV=2Ey3D^=4`d+nuU;QNc{Ct9312GMNUZGrM~#N)-G=Wc-p;^WFGKfhsf zHnKrWEgvvsnvfq}fCVSr^V7jpIck=RF?f(Rmz}nJY^4W^JbX+UC;yV|{Yk$K(=#00 zg^miYdSg!UC2MfEn*Gd+OCEORS|B%W z!noRU+(ehzZ}iH7z89EiG;X_rgH*jmrDWn0epEfXyOZhf^Q_%TsoP}_KzAwCEQ&k} zM72iJ@v?AAv>BXA&vf5DtKo_)7^ThILXd#=Xuz#Ng;+Akc}y6eWccW(h(Uj#%E^mm zH{UqC|K$}$Jzy8&hHgBR94H&8+N#Ehzb4u*ORLD1J_|#&ayh2Upj?x}Z6i7StgDE; zP1%WMWsDEo2cFi<2!aKH85C)r4+g|M<%o}D$sax}pk|@8_kCcrQ_68D)O#YrE#R2x zYnrAUfVnY3x{P23MZY?1K|wGbO6=KudIwBJF}k;-!i+Gs@OzDKank{!TBD_gniozr5S^9C=C`I5}X=08gA@Rg62jkY9}Nd z-fB|>4Inll&Kt3jLiWQJDTKRLjVgU zNVi`Dw=k2C6n8ZEDNSLfB*miBL(On>B=Z3O)5@lDu6PX zWtnWMN;Cx~$%1EEepv{s9Vc8YhABu3!k3;(U24HIRNPeREy{!xQLnEG-3t(b5J4Vp zHHw~X0$C;~qKYV>HgjcYg`1WjhEYkilp$cII+9Y>SfY|BtXT>*iw$z2B87rMvPtb+ zbqFYF3>Z=vqQzy2Bm`Be5E2a`7D$;ikfLwRI~&YsG7zhYs(>Oi*&-4sq6jFW3LqeW zXQ>QCl_ErlG?5jHK2NhX2q1x!3rtdsW>GJxsiFcZGm|Vrl#)tCF$hHoKvESWgK$Vf z+Mx)wEVNdvhV=;qmPH&)`(juW&0r8(N|=DkizT|rAupn+-L;Y=8R879PsP&gG=SC6%vYIe5&AH z`Tp|=>OBe*bONnVw6AC|2@5x|?c*XA4vDPx*7d`9%U$Uumr+y zcLG8$nj|!$BQrD@)dqq$jo#@yp|ZSQ*Gg$H$IX1>Q^xT1_YDFRlPFb>=nIAq~}u|a8UI; zxc{$XJ^iA&Wz-Kpmgf5*$A$iIPd7-=N$yJd!u`NMA`+&=GQGln542iRsQdQDhI(RtnEBq|`!CO%E-JQx$DfuW^$O8N6}-7fkL{A(^P@WgrdSk! zQiZ{|5N;0eN#mBWqcZ<64}oq1%G@e?*tg9+6;Es`%MW-~U*D+$BL!D1XS}g(UnaO^ zkMo@KA|%R<-9<9WGc114xzT=H;|aUMlRNT$0yCo1J%cv?i;=Ah86WV|oVc~oe6S^* z7Y@qAU$~9#W6QCb5LsrdiysFpWyt$|iZaJM1Lw~hQV4zU=&w|$wIgtM8NDJ{V=KGfU#iW86G4dtY?jZ~fh{Pe0U9A?&oPXTH4jgTS_m6EEb`JjdS%RtfpR)8x!LS}%N;OWY3ctnR9}6f!4H3%9RmY0yzv&T zHDh>0i_XjQv!VPN<}37i*yeZ4coHK1vndDPS*x$pP~#7~eO2&8>+WL^B?YW8F; z|C1_bzEi(U-&cOnO0dA z3LCDT;(TKV<nQ#>&t^`r@=VhREi~YdBD1x0% z%w0+_|Af>J$z&y)ZgPAxy*WIEBub`3_hmb|_wo=Cbs zjSlaV9B#cL%##J6zc9HUmnErxm#RH1LxTaK@V^Q&u`|+;U$9@2%cOd)M=~oBqndb* zLBF}Up*Jb$(?Kb$iX_o&RJWPb37L+lOH%Rw30V|G;G5?Wq*N4f^2EKrVsJGsROVYuZayEX9f)&-x!8Fe|hdUCMtdB^K|>t>r#4U*fdLo>fe_;PG1EBIjHdF)4Z_wIip zh$^gS%o}?y)9A3bApKJuH3|80GQr^goTKKBBntuhe9Xrw?jFYw5>thV6IK$T1 zwkpSN1)`eqRw7a?&3S6YrolxMA3S`k2eZoBdGUeYrdmvWEx1V$`W+H@CZnK~{Nu4} zBDP<+IZmerTCe>0X6&%=;>FJ;i0Q|nvZ%agZVNd1g)^qrDN{K*wCa_4)I8{#b=r`eoJ+{?n`c)bhfGLeXaaQ#;4CBhzj8b0&7e)?oxPI(9gO0|AQ zL}bOMd3+PCxH&yUKNg=u{pHK`<==@`GA{G7mq6nQlQZRI@-blT-ZG^AM0wR0xXeUm(z$N$d}bcl(Epxqu3}D0w zCpm~Y20_S?roi})LpU26vpT^5od!*>4GAI*+HIV|Mo^O#>O?unX8P563@#fqCG=0- z`C8B~jSOJZ2!z%4hOo^D!XV~TO%pg9Ek&v=koa<*E+0*pna>VHvnuDjj!v=gs(43r zKy7~9bg8-nK)RxZg->Ng)X!j4>um>hQA$u>DkrF0UM72?K=za8AN&RF&0`*-tiE6KJBEs~=6GzyBu(a6%g#y9$iU?89(O#-x}xw3A7%R# zVb`8|f=3F>r4^fNDFy4wJuxEgVoFQss;^X%SQz9|A_y;VlE*}aohF;8 zpo(Umzj~bT=mI3PmK#&B_}Y*1WP%3l%)taggaOL3p{qn=udZ7Q93rBFXaT92N|@Uv zz$v!U62kh$%Q(1_$uVy|7QLbS!ntx$L``1%eNyTo>81@qTO<^-3Mj#lk_CJM?8dm< zY9#69ggYbs)w)UjQk9ShnwT)HqG~}?nvkgra7;qg8n&f6uk;2-&L<|VR-`SV9OocO zv@*FLqp4d4-ihfIigxf|xed5w=UJG*$XUACdvqYE&E*w+Xx+&nb0cLUZZ@$p&Xw7r z-Wr`bW?=;41cFB-1*Vorl{l@qpk?nA(E|4*>rLr8-`JZ zPyhe{Dg{U=g&+XHKmY&(7yy6(002M&00961zyb;(ftUaQ3;+xOpa1|M006)M0U#}g zU;rinfB*nUYybc&RSgpa0cfTnjzBv={LL0$=9}jII!Ph20F2#M^>=sE#Qcy&7^6v@ z8(`82FI{m-iKBA{)Ha2hvvDJYEZrPcgO9eT*^@g0;IT?u1k&s2rIl8zw1Utm0yh#m zM^Z%A$lBZnlYukl#PW3UN|ON+joO3VPV^e6ZKm1yhnO{7NVQ?XYEwMhFY+Zwd1X~6 zx4%_2MHEYxWuD6v-6We+M@_mbZn>0E^JP+i=m%-n@o}pwC0RA-Y8u#JBXHSap&~mq z@YRvxM-n7AKKYd7Qf<{`&eeoO=_Vtlnt@#HJoVC-jEIr-ZM~MY0&{+oIKdXNg)A;bcZ< zKc|eO6zUOU{2(Qoo!OR?GF+bQZ?S!Nu{@1Ti{r3Njo!T&R+%wuy%(=R9qk91q4e=J zJVJJhhav94jeXUO%=t^tB5)OiWPIi#|LQFn;dq}^L&Av}9QB2wGSLXIZ*g(kc<9mI zh>LO#AdsWTIUHc~QlqGn3IwCoCpZy9g!pq(k-lySzE5je%bQ8zoJ@l=BT#IjB}#qx zKx0Em6NmylD0dagi*-9D*NvxPvE)XxL-bK*X8BN;f7475<)ltfg@!@QjNljpQ|yX4Wr>!>*3@J|eW1Rv5mz$sF0=(kEWpy2&X0uMV=8cR z@gfamRo=Yv${lqwF$s%QMn3Bsy`M1@uVY`k=`9vt_l9pSzQv?hC|eY47}Q9SMkgck z?ltuGnEOUip?pq}>GV)z5H!?#ZoUQ)HCZ*O8*&pA;B>a|q`lc!&U;RDXz{RRiKENV z!xWauRRV>L8w!Ccxa^o&CX^gT%Z=kZ|4OqTsFLMr3AJa7>dPU4OdT6w!BP&Yz;B3m zp*jj7?iD`zhEO10Qg+$A$s`(M`S!tdH-!a-)Sy{8XiTDy8vv9f4@c!&Ak*ZSoVNBA ziuzCNX+>r0UbM0C3jcXQ}61KY6AsCNu)euTS?@kEisE@>b|^!(;G**sKNo< zs0RUEa*#L_8A!r504MUm2tSqpP}W=D5=kKcd@`ZPZJ011IW~=VPX{1g2Uj^u)i;#R zd{Hi)(Mnv<>h3}z@8+c*l`D3FhzCrmVkWtKX2^7V?5R3sXuLhI`5z`hLVApuvA>-) zKRXvO36cz~@KO7TAw!t#-r28-C|j5rC**88S_uK3Esqkjn1+}Nu;yI@KD=n3%<8~t zEgHwPRyMtm0YHO-X4CTSKrlu}>r0&AAiPkyVKa`EIcR5z za-a?p!$<{a3OsN9wo+G+(CdL`Vfexlrsf9En>_i6HUpLsn3^FiIqg$vG>~yIPqyEdocY&Y6m*;ec;R8|bh|VUtlrjm>Pv)Kvu%e6i*r2L4g5B${ zn&hsTER1Dxki4P!_0c(jA~7N{iQq}pmR56&vQ&3HY7_zOm!)Wd=qQ-G53{`uRGP%g zfkqI%Ey(%*l%Uoeo$3*MM!1(PH`NgE;CUbL+n|B(!GeR9>}gyIRbfqJsq3UNY_lGV zM#QCt8Yv8(<$mbS5dpzwzt#!K->(Kl)~uc<46#*`D+uvOCAlIb5R%F zDoAHo1JIzSk$t-00%H0|2_*iV9kzw-7X$TZvX$Tzh|}KpsGdn}2n-|T^%Xsd?47bP zOG+LKsaQt!7^B1cxHigFo)_smavUme3(<%k6$aE|9sqSIE@h?SyklLZErvrI81Mo2*<=7{%O`Y$Leq0gNj98KA zqeZ1)l?`q_BjmdERz+W4RxB1FWiae#)+^VA2A(Xl3HlU0wFz;7^hHB!Fdi}6WSHbMT)Sl@l+)dRsW%4{cpMSZN7pYNmn4U#0003i7vU*H&@@nLIV46DBv6n* zk|>Jcl&n@ICb&^Z1c0IuN$o!wOJmt>ncq zCnc1kmy#v6DF{$_0w85ViXbTgD>f)6pK_%4JwytqBp@qMVA(3fmGq_}5TX{9LXRx3 zDWZU;?NV$T*(wyW8*wlxE05TTBayvCB>Pl<*gD@QZX%GqMN%&At6Bw9buXn8HBS>s zt3BqrCe{v*T$&lmvTSW(7LtL-l1WkV_SCsThWd+bFR@H5OsiKCTurxsihK3 z)FdscI*Nh?w;r!0QMjQ67L~6qNRCbA2{}+CMncoP%N8TP_PTJT3SS~K_`l_*IJNne z+HIW!;Q43bM_BRcuIVv$2=l&VT!bqDOy+ny{u|?`iR(1t#~6dm??rT92TtdeAj16c zPSc57^I2Ko#n1s1#ClNR>PIRs@kILcQAglpcAE8{0{wB>W-TZ*lswJ^-E2X+m3YujVE@GFOt*S`C53axs9vnUUE6I! zl=)SbcUsz(WbSJ1facnRy1`CjAGSd0bFsj)g%l}Ff|mVU(><0cKTSH_4s+OoiXz#t z7xWFo%eGKa4qfbXXtv!lEJQ@Wudo-;EC)N><36y~bz}_(lf1OVjEI~V3xX8e&LHhA z+5D452k6Ls#H z?V@N*fw{m==oJGde+%lRN{v#c(S&{qK&y(%XS(@Z!1E&fPj8uL=0;>^?R)|lRrsv& z%fMt>l=44i%60>^^V)LEl@_EeMFOP*Y^BXBMc=dL@pfh^inbzPUhzP!05K36=}+pl zN6B#>?wmwO(UVsSkqC>daF*yWOd~hs>k$SJ`{cW9JS7v zkHw8z=d#0lC?xZIQPvq>*zSdw&uUo9$wgm%f>N3J5>DW9nbZ8S`kH}qxNwSQ7nXl9 zBn6Y)GDi~Ykuy+>BTjvkURU*{M3W32--mE#19clRP(D-~ zmMzl*nFL3P8F$jOwx}++wCAY+%Gz^%+)-^vt4{|H`aVa?D-~53Qf-eBmA%%}PFeph zmh-?p%E39`v+|)9KMiG-az$m#M3yyWeArRU;sEFs=89iBW=>Olqfh*iaIbuKo~8sy z_rZG8&6bDQkIMzNRTJ2*%tQ7{tRKAgTwRXB@GOB+1yqSx!)Hq=$@58Nb9zI*&6Xu> z{8M-DduUb#^|9rhw`}s4fcTXw{#MRKEj*VEskP4}D_Ya-WKPSvX<-x+{ZFK5C*$5G zyN(-Rhbk}Fm(tt2o6=ejR;OwD@*tm`G!x6Iihs1kp@b0ky_ag?o1$Qa9XriVcE_uMvzCQd>OqDY9WW`{29sV(QFDpyz|O|{xju` zX;`2dXtiNw^7a-j$pYkL(vajtSZAg0mLsPDPK$ea@6ccw0^sOn=};)IH z{@Yqci;~?%uZVe$#{F=9FPrmP>R?oSXn-Th+6JosxlUKAa>b2-SJvB`skq=(J)I=% zq5Uf=UBh651%r|$Y-nKMgLo?7HW|UIV#H+P#6V|}AG9ec3&AxX%)*-Iz-wDfQIIZ* z#08t`sk~lpf-|+fGIk)SxxXNaN0ls9=9_VO%(C)DGgy?NQmc1jf7x3+^417Uzv9eK zBH%Tp1%YR9bp4nXRqUUk)vY|Nx$4Omb{8!HE`hRj;O{ny(jfSm!4zA7Pdt~rcGrdT zP%37`!c@_aG^|@LPfvr%h|wn=GPASpH0d-=tYAlDAP~&*N=HYGvL|>J1-fW zOYQ;iTN^ox9xDWQi`^7;d1p+_(ZnkD=gOGrv%yuD`af}UiTy4PtYntkQB><7v z4c(W(MPTqT@G=^YoD5uyuCWLGkm8SLhDY$8%`7M2hp7WzWzUD1=aQy0q-v_lgrmpY zpiLqER_hr%oc8l$6354k%kX)m5pYFs;;D8Tin76TSd&&Zg=GaV%Y|+!qU*GI9kr9n zs;^Z`xt$ETWhEo~Wb)A()*e64!;J|TTnyRw$nlz~F6iSY2Zpv!Zk@qYuEEdPgXML2hd=sy9jd5v9K!a>rvCO57>lccTJxJiB zH|T$-$e$SmUy69~P&v2TC#Ww>^_=#KCf?({d4aAFofp-V^R#tkVl5AIOjB?W! zrztt>j-sr#OQ&C%uPc5v;{9}BN-nE;>GG$?WfzW_Zu!c_jJYJ`^2K43D@AzU;|dS!P(V_R1`P0003og&{!<90mml1{N?t;1T1zh%9Zd3`57S%GQ-J1y|7o z-vWVU=&uUHg`(P8C#c{-VTHDGTS2m0VHd1QQo*jbqpWT!dOc^nGELqM#8I>)N(h~o z+l4;mLD^O{_#&mtf0^YSB`lj<&1V*UIwm))gk~yGaa`@xy=kGeSt86u#xhD2UJw9X zr&)VK;W0EP;>U;*2V5kBSUDH{@D|hv**uP)M1@ZX|WBuE~Sx?GA~oRiy%!4Cy|YC)Tz7My6z; zOdugq9NvF$0003p2OuN{L6Ber5kLR{0000006+r(000000U5X;05D*{0000000000 z000H4pc^RC1_J;900aO8UIq`ucmMzZHnh^HX(^7Av_$oVi$6PLwAYQC6MN%ifV&LB zvib(q{EB*cCWLCeeBM2TLyQ37k6sr@^zK*I6QgAv`Vh)NIj!s=q9hw(v9rBi7H_dO--Fgi4g^NRA#3ud+>uiW%yu`@z!jGz(CO;D{sc(K)o` zb&@U-FNF8(_Da)r8yOEp-0%Yd#p{?iKreU1Us?9}nt)ICw1#P6irGTP~=Hu!=Z(jrH0lOSJm$^Y60iMl027DzG=` zZDz6RO1uo@Y0fE&$h`TAmd_ZmqsV-TS|gKB`vmu7N@X;+KUOrV zoQ8e&Td(|uJAojq%pPgFycg;hcI_|mODd>c@s^xgCoR(6XKw`e&<$TE|H&2X>4}h0 zN0j~{-Agz=dzu4k(4|PHfM1YIb#fDnv(_v>1y8esaxc4|LHPy$nyf~Ln<$Z&-|iCL zb;%#Y;%nP>|<~Pb*jm-7bid$TAz>nPNGzM zm%H4Lg(^R%7L~6l@jJ*pY-iq!cAV4_=$S1URO^jR5GJ4U!s@Ld`#am6d+AQ`^D^Xo~9J}C&6O;R_ z!oyBy#d5dXX^d*Jc(VL2)}w459l&WyEmtFQ+Yhf=DNJnIG78-!F}SqJWv9TY8iv)? zw(w|?cOrGFT!A!zhlZ#qR`SZ%LExeb1qFwf6(7N68R&)NSbtDOa#Z2}SBnl+VQ*V>M0Hw{I^qTzh(>TG(38JPj4xh5Ob=lxT z(}_$e%xB70lRygiP_q5T763smY?yF5CJ*K)^3b_9hhQ6i=@?vnbk}#!y8lVapB=)k+CX$F87re2m!~@uMp)LrZg` zOE8y8Fm=4-Lp)4mqv&&T3KwG$o)E^N$I=J`02ze@6gPtgga}|0^qCE9_PZ2kr;ug? z9+78R-hHi`Zaf*|A1gkgX)AP@mMJ~L%gFaXBa5dw;#Zhi#@304;jn1t4~zdRT?D9-xJWKK+R zdFVc@8iPnQhv(al+QhFdcqESKQfR!Qxh-lbwT}xVBOa#G?~KAc!l2F3qG_Ge9Gm;r=G!!;n%V#!!&VBqYqkoX13^ z7*p5F!|+<)7+Q>VOVFGE7A3eKec_iXj87N&gul zm0Og}$s&MJMG#0KGE9UiB9S5}mLfYB1LK~PLn82jJUa@)RHJsl`Qa7 zTUAIMy=g9~CKFT>U1T98WH3P}8CiCkF|lUFA+gg|a$y!2BgqiTL^2r?ghB*TnPCPj z63H!FS0sroP^>DJLMR9bBqRZf$x6i_3nk`>HI-VLK}7;hd!sX($$ocQ)5Gj!t_RB2 z$rASqudPW%OLs-9>DgV>yLD@eMT2BYBSn$natyH7wb2=ac?~-0hzf_u`JNjKer0=a{4MeOCFyxO!+228n7K zSexAK$kCXPW_~_@i<}c+2A&-^a5J8>e-1St5!;}9F>|$Gwn#V1J&WKmNoC9; zxn~i0eKzXFO^116?epXqJ8-yJX{fv5JY^VVVnP=wO`py~FF2nCUmoMhL*dI($p08m ziX~$B`uqmsIOH7Q|Ct)QEZR*-#cr=X%4*TGXw^C;q9ttV)ovi(-F zxOp{U2Ha)UeIh3iM0$5jjacvUY{kpP%fg%=3CpG*n8hnm;IOAO%k6%NZ4cba_h z^MY)9PT+=Xl3$gRIe8h}e4#%V4TzK-m({QQ+-V8>Y5bS`?oXf4COT?=B@^hR-5oY< z&ll#~7bE0Klxn^fw5xWWGEDhXU^C?co&WQ591~v@@pI&7m2HER5>Plj+{un3Az zPVh|lgN=x%yZ%J1tn06jk=a;P6)0?I%Se``pCdYMMT5(@vDEf~5Rb*feisViIu3sIC@tQ^39Bt<#@PF=5eG{?bj4)BB%5&W~zi6gtKsE znzj17Dp&sF>b|MIePhLkKk*hzsabY+`T^qaAfFjY=D4x2H+d-=M;`JokH~#lQ{y9< zMGx@if9C_9E);Yex+e#UKAV(Wip$g0&mp){>UHiO&)?4{dLVq`w@$chgaVDlnke{t z%}dfRL=GN%zDdwc!L5y8iYXVzWhj(i)O(3hn*AOMXX!kPZA`X46UDxeMgE%mAA-kR zELr^WYBNQ>1Le*w%OABS489D@=Dcn9In=0OI(;%WG)TPf5p@2GP^(C0R7k#_0R>p_ zIluF#W$%`(mX1_e1XyfXzl0;q*)O2~V#mwYkwxB9eo#-(1m~&Z>_iKu zRxTVtK7`w(c<9bQut&4HM&eK+`26*PAyWPCtY@m@!a}k9%AesleF{ps+?!&iplne_Mm&5IV`j1EOEU7oIL^uRXul8p`Y-rC{{@vd3b(OO ze4XV-m{{~b4Qxzx!H*ep44#MSv%nlJWwL)NYkpz=K_}9@7v*;CV$%uc|I9U<9wWge zf&uxYg|i~{vGoFU2_wJ?h_Of%R(ya!8zODOi!i_$vjDqvTOdU}s+Z{NFHk6QkXZMsm=g<1 z`evXi38kZSQ#y|wA}}mKzy^j>Frct#X$t{Zav;0G10doG4- zE^>;@kP{-)B}M)u8g!Y)Ok6Vj(SiaeLa0`;%t6FM z5NOjVbj=V!3`vDx{r&Je0NxaP0>)6zQ-m0T5QT=3j(B8y<}JdCB-D#|;zY^H7)W9a zqGvF}j3C7sjW#Ucp%9um%ap++6i>8O1t??@24p~9Hv8=vU?(yoASe`!&rQ@^WLoH# zW7P>_?8`u-dBVGgZJ`1Pi{*>B>G6cOHXt-;mzq4Vbn%*v6aSmy%jL_5xYRxoNE1da z4{l7DxN^sj&I{u>p2aLD{x7nMgiNhO6-AE_Ur4z$gJE+)LVVHMr~uva1uGi5g(PrS zEwiNqcV#DqoJuv2uM-jFqrb z4^@;oa+(R_s7b+5ckV zq)fBivV+s*w0UEvJvKOkFBp9P#=ShtW|>FXr>AC#uQ1Z|`OAzpXL!ZRZXQluoMdfr z9YPz2zs`Gypc0}k%A?r8p?p2v2KGa;iE1A1EP7aoCAKe~Ps;8GPfV5!3VQuORL`P1 zrFv|Omdejkh4Qe8KWz&@&RR4BiAxMe3T9#EYKf0*;Aw4hQEXH&Kp~-wW5>M4q^B&# z)?z|l?JY-QMp4=FtbCYFpbM!je}xI0YGNHpv>P6Yee|_Qg*m86)TJN*FkS+!diHDd zrIJ#6GueU}ESZ@CV~{fKKs10HS!fAXQ~ENhk!P@%H*u(R;KxETF?dlhGIwiRp*ONM zE4emd6^Waof|obcl?|UXPT>(dK7zSO5S4Ifeou>>Lsu5(GvN zQDKoJ`Ca6`QYX_=2Bw_UguuZG?^!GNA-LXKkohaE3lL3_)>)PLIW5&NT~?oBwTV<_ zR){IuwZ2wFr&4D|?2?Hdl4lxU%qghS8ies0F%q>|wPEtK(SZ(SM0$vA!HS@M;zwAc zPWsW*7sU>yvBPm(svD5;I4o0y)l#!MtW#T07pIjuEtz1pl5WaG$E-@$l+!O8FG@Ek zSz@XcG|y}9vMtm-dk{k@;$Z_VYu)9ZxV0#VY+!}t7Yv@3Zx%Lesy&+bq(1xb&WxalN1rTt=IFJ!4 zG^e|-#STzc#Aqa9xg@E%T~N239=uwDA!4BmUR_gm+$2l9&;xA23QegL5d8-whjf<4 zYN4#TRGv}eR42(2Aan1SmPwkCN)oa0NM^zDeS_E`#cDK6@}dYc@oce~Zb7RW5~Xy| zZLA7zh?FCNQUbwnBGN?dhAD_)pZrzIf@!2eJ5qAxVw34Gi^Z#LO21H}8Au?tNF;a2 zvS_|07T$-Nu?Gx#)toy#_Hivnf>J2;6WSaVLQsyob?EK1l!1>U+`s?;0Xhu<6oM!aKrsNo000000000000000000VP=7eptZ>qqJ9qujCt#y;>TW1)`Z#Zm6V0PC-A3q0*>e7(q^$u(`I!Jg z5D_i{?*sD$fX%=nAS7fR8W6%Dnj&|AGgT+75K;#7_P3!nf7U&_u?=nhKN8xuEG$oR z6IT|#lynm>rZE9kO_N|q>S$VxzPScyDr#7oG%|qzQ$kr)?y@7BMA1TMpJSFz4-FDG zP<~39RWFT`(%&_$+@nd!$K!BmGI%aX!pTi6%K{Rc8Zm-ogyN@0%5K*6ty`8<*{c8v zxhsAB8)3Xl5JeWHZ$p{yAnqLk)+@UQAijK*C7_;Cxfyfv?L{hQLAe@`ACUDK4y2k^^nA3bgbGV5tgTyV5)~g65!zY{m&k zf;zyjOXpN<6jQTSQMxG6O^Vo(xm_1q7w}|yoDb{m%-7hhkh=wKO*~dD2N&B@$50~2 zaxPcy%g3IcB4y63iIw61Wt!sU4r>;x=PHPRq7CYBL~do+l6kLtjd5xut)Ni)o|j<( znkvQR{Yy1uW`fMo1mi-v-%v>!lviWrq`BsT`bQvNIKiuw01uUYl3jRvrb_nLrqf5E z3Bn>|lHLz1E#@OXb;_^+YCx60H6N%9AR;gT82|tP0Pk*!p`o-2i%s{6fhSP`R74~g z)=-`%hkp5tW5ZrOhJLXLppU zF=qK~cgV7@5jBrw^x$H{>!R0IB-YVB!+f9u0W{?xZIdb5O5-5iM%A>s!xVH}LBt^6 z&FKAoCk6TOG=zkfN7C~GBof8dYxVM#eWpu5D7G=MYm8@1s^qD$p<;k!K~w_(fkEYD zVgM3X`hsA80D2U(NoNX_3j~@-G$I3{5R>;(9g5#<*a!>}Bo7Ee!W9m(#^}LM8o3WV zNVM_6M*Y6k4Kni^?xIg!lP!Qn9no%x5;gV?f`R{s`|!n*)>tESTCGPg`(+RuBwagjjT&hh*0nUXED%T9c6RJ5xCca)(b1 zVheiWy`sE&O&dux>Rgx?@2G?{-}8OhaVZ*Y%K*?cjq2|hWtJU&^3(k!SRy8Rb5U62v#hS|h78fBr% zi5=_xvdTy$@F8tq3DE}97phEUtRaEji_x((-=77oQctzq0-+`V1&L!K0t~=jq|Hi# z1)8b|ADiVMI4RxjLzG_@2H0saETsrK*AdI#TC+;O?E{M!qjC_BxP_IuT#d%Xn^A-Y znkzyCTo^(J=kmi65Pdn60CmVzs!IrhAOs&Zqf&67)r~(ZnQ$+!FO_HpTu6A4K7~zC zbVP2+b$;bm()P(a`M8?Wgk>tFpwGF%=`yp_KTrMfGb8oes9KS8MXa5(i0fLOS#X+r z)6EKt;gsGaKnkO^R#9mzyFy(%s`1W--T+iYO0kUqR)Gr}F+1!b`jvU5uz<`01Fx23 z90((b;y_{pw#1_V?T6DM5>(U_3|TI1Wg4TBfdQ+i0F}Tc0u1CB0cemxDZ%cIm_pnW zxpWT$aio}UBff~aqMJ(lmr_eWV`Y;WjBe95jakSZTTG+S*&_X3{rQnsn>O(|cF{4_ z9*YGSwHVh5I#3#UgUy(S(RR=Gv2L~T|8hqRL*(>`VoX!gHChmi>Qj zmhBfCq4Er=&`f0V15^;3)-@z*CVZgrUz4!*HURh_fsg@~z}W=8Cj`YrO%1{$-#mMVG$c!B9gI0Y^YvLfAmCaN7fOl*GX) zQtZ}Bw#C>;wrNQkaWfX2{fSdL zvqGik+88r0YL@WCSQxuWAgL5Yl@?233=TsO(>R!e5H?W-Vc3C1=85?@FTP_c&3 zq_@jK$mjFP>j4{MFCZBJIT^7+fIPGI>;eOgpC*zabffa%5h%Ckw9<=5*BJ0a2tSN( zz=-f-1P23CFqz{}-La%j3MJ5*DAA{mg%%l_PgrVTE~`D&NiAR4&ObpEG|F$q@Zf{f z4H;3g!FOM+3W)S^x_(|#QUb|L#$kMx%&cc$^WA~~1Pl-q32$VE@i6<`ae{M3Rd~zD ztz9UOAjo@A$-Q12ua~U+5@J&zj3CJ24Ki)nhqx=Jxs3KIxdu@+J#(uA32jQ?H46}$uK%j`JI3N?30kZLHlTqCIbg=k;jZQ^AL#RbLNH`2w;Rs?7AaNIIDT2xh&@sWx@{@djF@szxggOwmi2K zvTbUfE+@sMDw8iDrX^_|Fg&agwlS^7hht&mEkm;fXKZYCwgc!Q z0Rj_gAtaEPeGOV9x(xlXAX`ceXMj;D8mTW>RJ7<6cLD9YUhedg%xP1`?O%8}uxHyk z2wbVHXr;YqOa!NL(l@+k$2tvAf0HU3*6<4+BEcjA7e5Pe-3_#9=gMSnRCqYMd?Rp8X zH6-YQDTULAzbCK1g+IV8JXaM5U_@RLD&V9jo^th z;0l8Q3GXpl)*qy0z$Jo^cb1hB(hML%;-uD%B28OMNn%7LY^+R`y2u$6X`wBWO|y-( zNi^K1N~Dno*YOKwU$SN@g%*vMV_8JOH?KqLnILzdN)UjY zu*=aJ*)g{;@VJ|D-KNCP%U1BIt|8^l*d*Q-4+@+QK%Y0o%wMle)~?Ru{UHJSR_o51TC(q#ejvg1F8<$6f|H4 zdTxV-%eExyWlE=ZY8_6M%UHwN>E6{53_%J|0>``%RfEg90R@FUFTyxhVuEBxUGdaW zFQ0k;p0q(f<3A3vOhjq#0s+PR$_x9`fn^Q)LF+4QyC|Z|jyABTLuQbq+9eCnTDA(x z)@McS6cZvo8{oDzZLDD}%%c{{7c;wMB*M&I`EV*U8Z8n>xOu4&2B%hljB!dE3PrFW zl#GbOnB)*3kgnm$mDKvrTj{(+W=3XYT3~-$=6=*etBtkyX3|J0<*dB|3K|%Jju_!Z zn6YExr%}z)b0$e(lL*L%U`7%>@os^!bPMN}yQEXtWeRbTnblVx<%0yzPtXF>)b#bD2q+ojH0Jh#W!wK}$5T4r zYj=Ez(|~QFc3V=k*_`qX^muiJJ{`M+f|{8T4*FV2tu0vJi!YXPO-T_qmB7jJ&{PTq z#RjRTQ4*H95r6wNh&{JM+#YOCVPrpNa_O2c)(Xo!4&{iTPlJcmgQQ`)qAl|;P(oVC z{-oy%N?HM+aiI%vEOKJ;APGUKx)+6!d3uDDiG(W0Im&)>dpl8d@RK5tA#e>8gcPE) zl6G@}nQkQsE@KyGxDU*hW(!J{9P$n=RyM8)Q`0GcLWYo&+@&JKpg{scLL(zb<;dGr zmCTCQI9dY+iQ!BugScrf;h@zchYUp@Hj1e!Kx@q5=!7IAA?LAm5pEU)qq#z@)e;Se ziJLNj&4HN)*VCO5N^3Q^yx#UcwK| z3k_P_*mdN!)nzQFMQr2>lqbLiJCzz0UPVt~Xr?0VmRzQS%ws63oPoqjm~+dQm!c{8 z%6xUVfqJx~;gpoiX4dHwNc*1nbHOPm)@1XknSCl<8fqwxbN~8+ov2C#6cYy6dD$xZ z3exDF36+Yk^FQn@SgLG+3poYE1KGnQDTQmo$$)3M|DP^6hi%-~F|Y@`kU^PK&J3?O+K;C+0s!VZq)`S1K+CP1h666->#a6A zg{u~&DpH<>eRbyYGv2Sk)Q@%IpE$aLtDR+nsh$j38Q_^XI_j58$0L1AmwdFnB24*4 zi>Wdv+L{a3^pbi}ZkNABaDURJr#TFg0`ISmbf5-);YI4e;i<-pMSTK>l3-t9Xy$SW z4y!Y3%-&U|756yNA~-#mr97xs?U_=AsisB02hv?vZDA9APpr-M7)wI0PUkOnKCL{= zt-u)b9<%NCLBeerJ&@qHAkOU_+aBC~n!x3rk%R)&*kB#UJ8TJ<2A?H(}Fb z-`FH1NsmwjRxT4jvd{oeE?hr@7sSgXrE|y*p++82Y~Tl!N>WkNZc+Mx#TWY0-k?cU zTqQ?ix9{@R1~c4Tf+s@U0sTN=1-2)1)Id-oKVVjY4#vHd5|vl=7b&H7$Popk!{I{W z+r5!YJDE+R8AXL1O5lK6vKA~kC1GfgM^(~lm8V+!%Gb8Cwsf@4-YE!(8imVXT+U>( z!MIn|;+A|UHI^5Gk7r1kc+$1D=IyREN3CGdn%iIow0ji^MxxddW$p(DF=31&kq~gD zw0!0S1_XlEYjtT`h4f)b+talMk6KndL3MUgQ2hhNz8Xk167el{??YmVODS}AwBVT{ z^z^D1m9ecNuW}5as<}JMECpW^XV03g1D2%&b3DR@3VV^zl2hMURaH80jzgjJI5sK* z(cz&|7G}Oi6x8?LVd27%Q0uv88zjm>;RtO&F+w3BNksttYnjaXP2gXeiB!-UWy78= zS4Z=G_JlAyRjiDby(%`+#N!ZbPbvXV$~4o8C4^M#Q4|T;-8pN<6Zk$?;^(rxADFyerzK@Oz|d^sS1(?e8a3vK_K$7VtSfs+hPHr0X15BoM5-keo z1Z)U-%=LAxX=T~VSg@*75%>pDR8}D=8*Czk$rs!Jt;)ip*<8iDDVjq32%oJ4(7C6T=IKDk${&Ts4HGMwCix&K6gKQFAH#ybhkyp%@JOq#>s151jkLg-~ zxl0Ski13eH!MW-ONs7_v2~wV{4X{c~>!-o!2 z>qwgDRN?QvK z8Y6`YP%h3;C23rhtxY42+BMt~GIgrak&g({iog(cN{H=90RqS~3L4kCfV9iIf89Ve zdkS`7wz2PSFB9))67;2frPNr^7WJlECQHIAC(_H*(C&0-Eh8wZ&MX?0d^oI^WkaWp zBJN#Mbd{iEgcZM!AZ|8oKa_HOfkqaj z3(NQ%y$Cr)`s?b$%LkeSO1a{fLRKuwQ(D*ZR+m=)=gFFgxtS5FK<2?njKsB-@*uWQ zbS(53yL5=_U$*v9Fd=H8E~`h>4^qpVEFQiY3hylUavBCwf}tCWP7fGWrQ}L5^gSNn zk<&6n8?Nvg_%)|rC2NwErI}mWia{a6G99IGLW-W-zbO_js!X@I#%%J~sFWnaQE%64 zos~Pe(v~X`lqg+ePAY99-C^KD8WhEt^U%zS0^it~h7MIzx5J*WT^}`1d9Th+1Sr}q ziWG9*Gs5qq!-6`dY?N_mAd2e*UM*C|J8>X(ib(ay?s|1#z zaU$Y;@UYR6R`@BaR&l&wy-OXM>$cW9N355MPzXsG9@>=Cs5yl)o8f)*v4qcpQdx|p zvBh9bhbUVrq?nKy57VaK^%F}}Bg2`jhF4MQs?p;{xcMCW%MKr!odA{Rqf87XTd*>C z+Eiug#%~C*X99ovrvIz^Q z5Fgb4>tdEgY;ZuS-6~fyzxluPAf1 zMQYiiCBUWI@jG*GzLwQ)3!^~g49NCU$|z?ea)FAOXuywlDLl?vs7HyO^!EVGB9L8z zXwDftzNffW>k2dN>sr%Ih@FoJRqiYTqcbSj_X5H|Kp_y3!VYs_snTN^iDhgncF_Wq zN126co4H636M@!4p*e02hPb9SQN%ztl-)nGh^^mMbzT0H$VP!rg14F z=R|%FWb+jyVZ8OVIane#H8kVdwmy9Sk+T@aAop`6re1hZ1^JH)98qn65$I6MlIu=T zQ-h*?$D%K3LILwqtB03 zyW}*LurJ|3vTtU#>EPvV!^W z%8B@hmbi@c_9S+rV6BKQpdL~Ny2MZZ@NPqS=A#pxKYRGIEBWM)+*ap2S`t?|^$ZHR z;DKwzi{a%G&wa5Gh%`0`1{sGA83!9k79JERCPhwtwmsN4OvtM&7a?K8nUO;%XhvZt z%UQ;ZX;CUm1K75EE{Ci*raCwll@d!pjlMlXl~wONl&!6AYeJhophA|5mZ4U{oTO+l z;6sO9c^;&6&3w&JV$G^}9eUQl9u}woBE>)HiUj1vsa}Dy7ALlB_3~<8w}?>}Yh0Nr zmnAssSzY!ONU{VeoXqe1?|q~xm%cfF|L=c3(jn3hS$w}&aNf?~dx8%BFFnR*O!kQ9 zJ+pQDW^#Zn-3S#FxG*s{P<;LHm|HDV_N-oqMJI^uaKFd-H}}~ zdXsJl-4v4FKCB_uRt1{a*9&>H#m)1DQmKPpuuoM~eyw$Uf`o~f`R4mORO-SpqL$`I zl75U4svfQjs5vL1uxkuhnWBbMEO05yj$GK?B&CRHqmDj*_nA1?x3po?+fmpNBa|;# zvKNG_?)H{iV%EA(HF9-2`=0VTJ=fIiYHQY{>Pu2vUIqE1Xn^;h7MyIydnbmI&c)-L z(-}ydyC*G$nrhb0rD(d8^_j0ftjqeVZdv2rVN#eThn{In{o=L|>MwA2=)7%zZe$dr zKDpAI;MLJd=5-dGj&IO>y=pZe>At~wg5AW9COUFH&Df~7k?@D{RP1KjHumXMGoMN2;BC-}57e}+Ygn6At-($D*nID1*?XN!cut|=)VOHS0pELozFv=p$nX$w%iO^nn?HqC_p25c$f zreIp+Ac9AdEto~F%sifzt$NndBB2t4Fi+E9Sl};Jv`E1I#{TYWLBDhZv*cwwiEWi# zs->-=t_VCKJWWHi!YLk--zl9lOrlgsG4n`Sk?fMTW0l<&fl5;I>sTM_Tc{LqZ9NbQ zZx8iBT1z`VnxBPSCOe;rwO~MU$SpMsqI{Ql_JjB(%Ok&dbUHZS4bk ze_20bPp~&Vq*Hx`Ep*g!OB5*z&xN@EfY&SAYu2_W2F9KcVN9kk6ihoeuMtL&MF}rdm?k zHi?RLQ=rtK7oZ;bc?%(Jld1Vu& z9V@uhz4DlP4VO!8M)tL%U3j0cdS|K5=rQ;q%%4=kC^g3`*@$^d^sQ@Or3%SoOi?Km z##|P`M1w+aB+Yt!`k>(}CHlUlW6W7*B17CKyFMPX$9{8a=mv|Vq5cd}E@gR;O9p;K z#z%n_K&SneRX+=K0003&nxFtZ3Klt#qf<^Hp#oCjl!XmMW|BaeKRRA(q;m2I4^!4A z<_>;w;Y6U=|DId2XnY|VtxNDLZCwcp6lW9{O^8g*nj^@!?=;5Gtr_IB(BvlaQWBqm zUgQ~4`Dh}=TvJ;-lS?)bype^A!geH%Xq+I0*hK>b>`N3lL}>>CSeZtP8@D9-dISYz z*qA-r0qPbtaB9?!G;DUaJ6*jtmEgA0+)7&tR>VPRW5oyF(d~^<8Z}Le$kHjQ1J3Zo z8@conXQo1>;hNc2+)+Y1TEHi#VWI1D-rC**ZI#xIQBUZctWek>kpVOr(h!^2$!Hxd z#5R-!izfKV+G02%#nbkYiGvoEw`u%mGEFm%LPWMERtP(%C~40lnHpe#ED>P`&O>2X z1HLc3I5$lu^jV273-u{`mK=LOFSkmD2gFaQ7nLIMK3XcLG~IEWws0004i000aCKmaiS002a~Zp;405+Mez zvm`-Kf`9>l>IziS5CQ{!7H@xv6~+k&`x6HkAk9($B|yW$F^LGl0st5gU;rF|0hj{> zW&i+zLnO2W(@ldBCD|wDk#>xfT=-yK!7_>2fh(viG*IK%D0r;+6PW$1*Y8G4p6Vbk z0+MJ&%&M(VQ(X&(e4Ab651bqAi;q*yELAf4 z`}+f@-Uvg2vsf^dU@b3rY#RK<{@uMiB%MJQyB zm(M{C!HtO`{9_m}$phyauy@TmtOYZvJj4L6*z}vmWil;VOD^j-2H52SDk39;=Q_v= z28w%PpA`R4IM?(m1uB7$R=ANl3lCLB|9FB28q?2^5S%9YVN634y8;wY>2^`!Yd>d2 zUE(_F-k6wiT#}m}0fYX$&Zq0bv4VR@nLvd3RjNx)|K3UNB;I)2gY_c&5O%fxsyZ?Z zP}^T+^ngFOpxv_RTg5C2Mnq<~E@Wmz^<-H|Ed?3H0q?GHa0MEl>F&U-Hzm_QT5ZRc zBumc#0E^3dY5p=YD=LvOZhtwBqa~Gk)Ha+$fLVh_BZUHBZAgu?;bzo*9a5Z}`hx|C z0CzBiQ0nNttG2@v&~kryGr+0N{iK6;r%o*8rNunk(OP|+mGJ~kwRHJpdZ^E~snUc1 zNEJ{t2l8E%OWi>&Zl)x@@U0mb+j_fGDG|%ps=K-_15ON|%YaO~%0=ibQy;C5a#`CUV)z_JW`q+K zbj3f@Pk=G16Q_iQf*Vq9wmjgf#-i^f$YQb-lH~@7=XG>)-0&o|o?T+%>y9Zd`)Hj` z$zkIh7bP}Jv^t3`6U;*vV1Z$x_h{rFWO^9^XGP%*0r(-xY8+>kIoc30Al)&71|S5e zM!*k9K2dP$Fan&*i2;}&`+)E4%$~6`=+tu8s2bCk-7P+q*g|ONcojE_`{~tUq}xnR z=JzC)^9U!5N3O>f#=2<&fa;W@FQs+( zT*y*PZ-khXg_a6^7l!rZ(Ao}&sbkC>g8-m_610n)C@J^`lo&qS8giK@ZKb{*g;{#C z@o^=Hs$HJ_MB+76g+c}nt9AUbtbR!%7mWpi9uV{jCvX8BA1CU6`JUx9zLoLDj1jAu z^XlIPWen$t42KvB7=nIklyvSw)LT6HNa_f<_f*%Oe^USfKO-WnR0n;eWBN~1NrI_t z>6g}0Ectji3~ps3_{LhfcjaL*X^vw zR>q!zrQ4Cy5rP6NvcJk!v+5RB8(5F_(C}C2>(}XRP*#D@(Ak2O&BuyP$k(7GAFVk0qMK+D0IPib$f02qc)vTY9F%EV3!dp2UFZ4kPuH#ez>Y1jG

L4;KB-NOaOx8p|O94bECMgI@1cZ?x7F4EKDhd(n zcF7<`DHcMBr`EVBAXz2$>t!rr|vzc$S+#^6gXF1krvBx?o`DlA_2P!A}<@6G1l#`u% z1deREeH548e5tIUuZNh?YCpjVUpc_%e|sJBwr z5R5;CMDLPw4|Yo(G&(amh_R2Kow(Z9=gSx@~5IJ}M<6 z+@A2`P8SzGa6sdchQxfeK3;uK0`I=*wujw3$jRnLj__m276-)0_}wQtp`HkXgpu_& zY>u{ai`rt`h#2su**cAAXrsWe4OfLLUmkPpot&(k;Ok*HjY%q}D72_2{r~gSEo!2G z_Q{_%{7G;z7x8J|j}ONbdhA(p@d)KF8C&qDJO4oJWpc&*9F92fLBPPW=%ykE*e5yL z%rd9(FJvAX4}CPh^6ETi!g>%F0lB9~$$E9AQ()QF467C3yY5&cx zaBSdhxI6aef=bVmQsMRwVEoRzFCI6%8+paM2exbli`mKB&SIlmvPDmjJc@dWJ-}Zo zkiMLGgLmqMOwFqRSywOuuTyqtSJ`Q z*~)d^Ni%SV@v@cNg==)c*3@W>l99*WM}ZlZYR^yD!=ldoWdv|wq1f^pCUAVJ?1ePq z!9NaG+I9<4kh4ac(SIpG7;0&qZqd@Ka;l@?y6fnJqOcO2Z9>XUS9lr;LiUoUv4>?N zSNJ>$eibvKt(O-IcL$JFp)OF;lJ5+HB@+!xP}KoU|Cv&KVh;OZ;o%~ssxLH-Jimm& zQFA}zskj$E_)2UQWyoGtut%c6iCMvie3RqENfZ-U=(;IYd|2iEI}1~UNq8FDz=LwC zn738S=oz1U%8FV=+#U{hZAl;a8ILu=BrD_ zLA1Ua(WB=g_o2mLk1GZ5|9ux|zF&*t(bHyk4qI5YW!%sFf#Ov-Y?BwONX47MrB$Wb zMb-#|%_4{N`NJ-XuiZr{WXSmR6G6t9xo1^9N$wAc(!L}fCMd9p1xTTy?5uo0Hlm=v za4|&nr6;iwqJpB#^*i!3^`d(iZ%YN-C?HrT!!!6~%1WipwF8#;AN<(8N%w-~(enFD zu$EFURD)1&%+xX=^0vegL>ic@|HA!yd-PQOow0t1eo=dob0Yc5+yohQ>bm_zuf()3 z{SR}S^zp?$e(+o;HY_s?zF_>bR*&&R&yqg9<#S+znr{uGC=yhcG74;^U3@{{f4{MQ znSY>UZdg1td7<^>?ipeGB0G^{LzENTj|TQ2sJVg+unx8bY6ke?$!8SG3FeiKHP=tF zFDey3Lgkzp?>=S2KEEw-TemXFJJBwf_@6!BGU&OJH3A5h3x=0F(`r34s^z`L|61(m zJ{lL{4_l6Gpq^ShEpN>889(V7;yQlSE1iBttxDJb5M3>HSSI=45P7aFXf2e*$Azx4 zOL6eZ=h8CemLy!U*>lHUO@OeLkvH)EDm_k}3kH1_yDLPztE$8OIJt*SGpM_GCgLG; zqW7Dlbo0CXKg%o<8)Negw=-rUOdf~4{~6Q6dNdw>((!UH1oEG@v$0RASnE|6r&6~Y zoRwd>B3-az=~eu!k#kDNjUx_Crsp;e_C92OlPLt+z;Wtw4c`g3uzb22U#euNFZLaU zU3uF@@dq+GmU^PrV)|cuwg>2HokzxmYo!;RUtDl96W6UrsI zAUvkrHCb`t_2*(@1I3r;p4_UEESfrcI^W1L&+&rgVjDZ9cp!5>``aStc#9r2(bYZS z&_ulOr-~;9VB(y{K15uAO$E z=V3!D8CSb;$kqtE+&ua7=PpBP6)f<#=<}ZoPEKU15Bc-CksL?1V&`O4JrVUHc?Auk zFVKoBB*j&GLcW4hNR|2lTAPxi>WU8aza!*%hP`Q?w=jMWQ+R9?&kC_~$3??~mVHr` zrB?0W*w=99hnR|}`l7;>&dbJs70+ZhPUDA0o*s<{s3L*-YogR3vnu!sr*kd?=F>Ul zd3?5kbvHIJf+wF(nP5p~2;z^~Egw8ZWgo35EToj$~7*R%%W6&qBGbYa<`&<} z9>rN)%Q)e4FwgoaDMuDj)?_VRg3nQ7-j&|WprU$(2WDp~w+$?&r&bknZN*_MQy^u2 z^3x(vqK_pmEq#2s+nmY<>)>{87G$gOW)Jd;w&J1-a}%e(0s!APWM^U#(> z)K+n*MMDPV(;hRTi#t7KB`C9Oz5Tk)!@(UT&lNg`N_aRuZ~LLnIG0kNP^$?u|Ccp* z*vSpj9ps z{}QM4yC>lMPrxHY2cmfw4@GGw_RbB~m1DW_c(`@!jw(L&1NA45FV*ay2Qt4Ie?LTw zoq?h5UHq5%6jJ6~zZ6gB^}}c^91Pc#vAx??4XEsKKRhz&vk+lct55Vf;gnPA5EXYP zGAm+{>`{6Z`2{->;X5$=JosKn=;cm!QJ;zfn;7bLEVz1Wp5%Fc5R`D05eLZ2D=<#x$#+~B(M#V~RuOIUGfy^zAsQIM+?lmRa%;Si zV4{-9C*E3=>zMIry0b;Z(DHyH3oseo2<0d%ScSO4LM!Y-#%LfPVp%b`z^?-c)eJJT zRl6dHib+1hID#1^g0N+TB0!B1U4@fwLWtzeI*ha`P@bC@Oe)Geggk>F*=2FIkbNkb zO$J0rtRi*Lj-&)h451@$#@3?%{Pn9-RCeopC~+ljR}soo;Z)ffM5*8$+~gLHA8WnS zh9&MM^i_o};}>p?HN`is-&s|A8q_xEx}I6pMnlwm*PS&N1lHY#B4U$Ds%d({hYq6mYnT zI7r$(Bk;C{l;)I@xZCk_x4SAOqm^Kv3GX=f8<~4jgwaeD2d0H?wf}KdaUfs-0X+&G z%m*z9H1zOU*~yk)t|fm`PF93yvE-Y286(KF5_VDViH~LLL8C^A+^XzNNsU7_h~>fL z?THbgpaN*4>+5NcH(n+;fN!F^2i_TAn6uOyF6Dx`JADxuvYoJ3eqlP)Oku(c7ZBqh z!U7;;AgD8s2%Mu@OTP1H(n{3c0I6u<()gwMY9}Xi;(&?{9e~rI5?SUO5O8V|@_06Y zV1z(`&{3kzWR>KZ3iAVK5Ep%_mXmCQY~Q@1T11v8*+ldX105d01(j>s{)IpYOenA9 zuuZBpD8{NOMWwhwsPIV85CvQ{J@-~9lo1bm6 zMDrU{78)jjG@w6S=Ma?MobTMV>=_Y+cRjc7>(t4|?xG8?VTw~MQWQ5o)%0u=zMX4V zLbnVDx2tBAc%D^$C;&j9fB=9M&fowq0fQ7n1}t3!o;R|C`vC^(1YIi|L^6yRgdwOP zN#YA}2bkL^N#O~sg$2cdgaQaO5Nrqk7iL+M64{lS#J>7;K1)|=DhVe+WPHDtm&UF; z)b{xeZ%PobPVOh8?ovLsPyuRJMCgbtYxBkCr;0Y3tU$&|$lKFjT19KFm_+Ae)2?cR z8W9kNs=o>_fEDi%6bJ$MfDv<)REmvdqqC`p#U{ym$zHc9=Dm85b5?@b8yPlK7M}AZ5Qh_j(W6XyqL?-`B37%fj4%hf zJJb+CAz;FY8Chlh1QE29oZ#q@M_}}qUkes27|I~PeQBuIcXweFLTJhlsE|J?W9=7d zxX?^6%r)`pDoTf+Yxs5UHlmnG76C z)3%RFcNT=b_ZNHygaa8U60t?@v=u@_?~i+{%RrJOw<2V+R9v!N zl_NnD5S5exXYoSGAn?BzDME-8W;mzO{fR}l`+wd{*K6`=CMXm&LwVqtl2EAB08Weq z`+T~EN^?<*{Vw)+Pvjm~r7R}c3<@9) z0iK6aPg%>*<|Ii)1Ibo zQ8vP{`e)EU9PtZ-i}!m_YB(LGjhRL?n!7SNGxgFCY9S29XkESLfKkgM1#{wzRV;Y$ zT;BIl@}Wg5qn}Ug-Ze`?loG3aR8dIr2Iei}=Z~Cf%VNy`gk=`ZEWUXJ)uBn8P)bMv zyw|7=808SQMpS~{WeB~Vqf7g;)bxF$+dqP3yc>1F-*-mhp%`NN)AuslZBHcx0zAFQ z&|w_yg7ib_be-{O~s z-<~hzY(Q@WR^K0uWF3UHERUE$a%OM-$hbioDdH2gmF&%_VF78+Btr|^48ML(Pf|M%nj3IRDXh=wrktG1f^a~7 zREFk#maX0Sf}2Jw^MI?ASUv=Only){2Lgg{#?lGAtZ2G+cH)Z2(M1+cw9R7|SRSS< z4^gM6ZDp+u1MCkJ40q_6- z0ZRz}5J3XxWk^LL#UfKaBCzEYgehbOJVm5_5i3t3nX5IaiJcpov7QZUR^%rtnHy{9 ze7pTZYMisjjPOdjgIEY5EfS*d^ZGZ8!U&*Ik#YqjE-S@PCrS*pKrg%}Wb26#WQGSi z89llMN((bd-)PY0#a7o?tbP9@))fTSn^2;ul1iXwh!w1S5p{&+>3{$Wpt=e(OMNaU zh|rhwzbCMCHH}Tiyq*p$8CKBCM{0gPI9v;%T0I@+sG0M6V0(YI<(KWg)+OKs362PKaOAF00I`su?jHA3ytVZrt6U4HXf7~2>=z?MVR)6?T zc2a_!qiP~u-3}+T%AA)6znD8pbdrAckxXc32)uKy2AZ^=P%c?WgB9dOmMLmlw>2ZL-e2tb zqrD<<6@%%g`->J1BrDU<-{C63aPwF-c<@edWdU(V*C5L{b^v%H_Xqi;gheJt;P`(@ z@j*$TVP)lV2it*DOjxJ6u5dFMZm&8r#={`h1L_C#WoT%g9Tl2L#`_Z@Y6kpaa11E^ zPl7Tzl4kodLdsbOJX<^p8;VvT9y|^&=3(CFH?n-_rh!LREPSzVK5=eNEX*okw-1ns zHSjb!>!c2vYtEKwosX`fyD!e*d!W`k`KL;BMuqg9#K3?UEiU3EAneJ(oW>ap5jOlvlmZ=Iz-}>9zmfC|*%6q?{ zRC#J8` zeg}n#t;x^CQDRrt2Q#JrFN$iw-vf(L_*P&gg*9t?aC zlo7Wj=Yaib*jk@uB0yaEIqB|^OPmBlE7?HmuoL)ckEO}R=-6OyA+Rq%hPe3e>&VMe zDP#1~h?YwV50P2imoPJQB|HIzA}K`%%XFom|E3JGQ)F;;)q;-)-hYw+!Y(o|g3a=M zEESpI>V1L?qzZC`>nV$}bzr>}Zk!LPqp&FbFZ0Kb1X7cgv4)(lYe`$Yrv}bNIIWYp zaE9(mET23`8Tjiw@DoKx@+Ao$LzcJ^&^(-Ej3GeL{2e*m3`)Vk?QhX1gZQdVTUpYa z5dp;oJJo{}pL|MWbaCmJ-H&yYzPzRQU_*N`@q4YF3A1-Wvk`+;!%*?<>e0C zY*Z{wBC@wug^jSkF4biQJ{5VY_*UQ*gD|^~21wwH?LdS3x}m)77iCx_4)VwO^@=X6 zM;DG?Gbrzb-iy7p<3%Lxrx)11Ph+z9@p!+S^iIk2fUI$>(#4F8W2Izxw;w-M_6166 zvvlin3Voe}`>kRme&C)m|9(*^!!D2g%9b(#yh*)q9W{GT1k|mCX2LRIeu|9j1RxQQnxeYpG?<0CGgt8>>myI1Hs#o zuB;wiGLq~;iGLDh;*x#^U_MLN;xIW=V&7#6aejP@+%%ppNDuBvrN+`+ROhCf=A5-* z=4`C04p+PR?G=N(MLOWZW_9ely-pU-4}TKYu{maCm+#=r?1kF$dC|ekiD#aL)G*kN z$$AHZ7MIPjq7rea3LDrz*HAd$9g93hAeqU^$cymnMK2gw&XqgYWG!D$9VeT@pg{jF zSh?f0%9&f228puCLYT7hdJSgy!&6_Zp;xP*$P+!)O#(lkGLL!Zor2*WNxvTimYj-= zt4e~+Y1*CqtG7_#AQQ@_IxIX-aYyKS$_wZR7QhcdYG$;{<@~u!t_r{Snio-LaNs6S ziD8%S2u05#zUXobAmEav>*HsxAW@9OyPoX=&O}a;cH4yf?}H+8ZSy#AU$ZI_&vi1v3#Yg_nG8~7YT!= z9^ucA-7Zd#2U*&rvg-GDx25YlFA5B+2A%3{xu@&v1v7X8;|{X;mu7MU9^`5j%+2R! z+3I^87}P1d$pnQ?kVd9w4NUc`=sV*^BMOQZY2)^L>;+61HV>D^oi}KtE_{?f!ywDb zFlFO4=Vum$ch4VrU}Zv1c?_SfuWn_n7jm-0Y;;rpVB|;7FWkaP=9>CB*q#eujG(KA zS#a6a$$pzewknjYR$pw2w3G8dn^KN&1PlO-Ky$x2+kuQJ_|*VZ<~NDjTg^DrF@JOF zInS40GlA%SJn3)kvCFO9I4Eq)E~PHxwa{CugDUIw^hXYpbO*#YrC2JiJCq!Y(SUPtx>pL7c1H6)d}ax@uHi6=hHTf|6<@f-I)Ia*Dz7!9}L8 z`57c~AHTS;Db8)r8^$QXGTy;d;O&CgvEwYBCl2cZWN%U4oQmK(?t(6^pO~{ttmHKeog9&HY^f!DLy-Jc8*fb z9$4|1zvZhP)fLc+=MUr)h3a@*)NuZ5p51ySv&=f+vaLBfV9Ul^|Gl7LJP}9Sq=n~G z_9xDY`aZ)+6@h{iCuxsm`Ivc}n6v(0FEC}*X-crHnY;DN>85=b32v@s*)J<>yuo0Y zBQN{7mohG=Q>XD`3Q#^D>9Uf%20CGe*Z&_4&I&KA9p4Rn(6do;x-SQzH_YUVT_G@E z9}WI^jwL^bJH^n`{(++2S#l8gs*1*d|5of6C_l{z!%jzp+!#3QzvmwwoP z{`Q{|wIIkdqTxS2d?9>X@KT%SnCcExwqI{nWVq31!)?9hQtcFM||LplHZ|-bF>1Iy3Msx$P^KDk$LuGO~Ce z`xf9M=ls12ZJF~cY0V14;`?kX5NR(PDsF0tQ$Q{SsJLmvO8q<# z`SB2k3+d>=ho+g!eK&8FFj7pI9KqX1qd6ygA1lZH8hjISTkM; zJ|%^#JUmpb-j_pgrg~NyUPuQ@@1|WffjKU4T;9L(w-IzxO4cD-e+9mi)+aLWmEf^* zURuhth&KQL0a2QufSd>z7eo+lol~KRY~1F)aEmxHd*ky2^3qe}QwW4dY9|M7iYjKPMBTwN7@Jc;1CNv?>=%En5>v~KuGD)t`^I@nV@SguN!S8kApMip zA3}_kife@Qf_}9Trnf06L5Vkr>_+gQqQ(X6LKSQo84F|)ARBjMiXFQ9^Ke_Jpi(wy zm?T;kLecdvUh*~FA{wl**HQiUT@0>at!y__eW?o&s|`~JB|Z9g;V$Z^=#vf8Ju3qk zCq)k4{l_by>b-Nfq#}vXihk*y!Knq1kMSn>_5nAgfpsrk& zg;bA0n5cnE5s)Q&c`QZDl0_L6OL~EdY#|14!d$aSGW#A2%2#ko&wy0003}6v5DE846McFadxJ z00bZa0000002sgk03urRaO*1(9&f+^fCc~nAOxTS001YcbD86G#%Dnrz|@i$0Y#f! zKo$@C8rM#k*$l!6CHa5_cEBH0E|J+bLOGEwQMPBRkWh#!-^*+`4c#`F!HZHx`SHpC z0LyVFx7wX-X9twv`YckykXF+))RH6!l-pL_lfT7an#2|IZ;rjlmU1Xfmh3(!AL$b45Kj7qvWC@YSU+%cWm|HGWeTyl=H-suu*5Z za3~b8MsQ-J8-_SzormrF&2!6{}>=s=;YwzDd^UlgyyU$fLbh4 zsr#_B5FxqM(swR6A+8KeJ%H3j1kuU%h*|hj7ZV6!B90>SH%JqN9bnwlGn8BN+v#n! zAT4^p26mjH+6fzN4Txk~=zXvTP~}&*TU-V4bPb8OFg4Bs7l4APilhS%xYM-&`mMem z;^rcXLZk2Hh$%kMv;N|%I+>t>_-$P*2C9_IPde7~WmQU2k}3`UR4i$v07f8@8g6IU z@6nI`?oiYF2eb;Bve%!!$g@QFG5+$F;E*gi1M7Yl1t%M8b30N&L#ztDyLSt zB)Lj260HCP9HC&&K_174FjNc%B{nP;!waboU=2dKOdz;HNDv(w3s?aP6=+N2&21O* zZFrEhk0)Y51d{{<4(5is!khQ%HAP=Fr)P=?;F8d!lD}%u#KeLIB*!R$><~d5moJeU zP1CZI*m{q%R5|Q7P(}o$q7Wj30yPt2!D4LKL@^))6G}AAke}P;KBSrR%SX&P`W|o4 zr|+rV*cvGWkgTcOsu-DBF-Lc$v@Sa-Znir189AK0KFG zO6Xuf3yMd)w0cUBI@2;lTtk1*(k3pG$->-q0SGb9#Mjs5HP4v z?8qz#$_06*AORd_C6w`2wn3Go3DS_vhb>6FnvVfoA+azdOK*8NsYx3m1X*N^GhxRP zkth*_@&do$vvDMRm|^H$YJSC_xjQUrE$B%F~EU|lSfeAEJp6{W{VgF-PshSaJL`5`0 ztfjH}za0>sFzO@B-C-NKU1_eQksPoH`Dgt|HI7)8$i#-T=A1}?{=Kah6XAp*K@0+^ z^@Ca(65U|MP>gyHhJUH@Yt2T#5ChhUFGX7F^IKFN2uI=j0cKL_Of$rgl@=E)YBfOXBAIWfF3EBOa8s zs>HU0p3JX>IGEJv2LU(}Jg$pkDOMC2)CS{CUfn>ECV?232wYL50_A2&dt3I3AdhiB z3NVq)8Dw(D%CpOa(gBhd6DM+wBiKPx zN|(J_$tD!hYC@E%glSV=#FhNk$q-b^S+3491c073s{Y5lHjF-{ zOgHn*I;dK>UkNGKFyh;U{o<->u?e1zsN(a()by~hFT0x=nG*~m&*o8k{W485E zCu5YDWJ6&lqL(9R=yLd&c)g01RCrL-t2uvb zfTT>yS_Ofy7z#{gW7;GU2;hA7U=HAEAd*a-ILwIUfdqdDj937HfI!F?j~s0`BZ7pw zZAM^*2ZU8x{;8=NM8UOZ-l+5@Zt2;rOe%VqdaU&*MRkd}VR3{?Cz8jh()g;eVq!oE zfRA=jsNpoyZd$eWpoSu->4vCuSz`|ujerrv=wk+EM9R$-O2n2EJD@>`khF;cK6@lY zdndiFzXr8y%vf;dr1mAng(DuhhK)%5vdRIa!E#n@ZYlXFy2w-aA_m-0{-n_D6{3g~ z0RS;&@&720ksZu7^8;UUS!FtJQe5pwLyOdM!XTuDi6`2Hz&422^-91;{87{dB=Fgr>L=&Y}Cnbj%enH^DLY&+{0AhhFG$CX~ zAfXHhRWm}8R6%8BipW4!WkeKEX-tt*DD)(dfKBw%ZrK3!PN&f)gjsK>S!eu4sLMJ_T6 z4TO+ZWKi3Z5lSVgX(CE2wq_!Ug>a@uuP)b_sq--fk@a)wPf5HG6)OM+M8J0!6;F93 zJ=gOx{Q`=kR(70- zXgir`7OECQa-9;(1=OMEm95t5G6V6)*)quDik)GPF$-k1I~+{ zt&Xziq>F>qf0zrK6;}_C$g}Eqo>Uy!_y8FWXN@yxA9OXD=KksKpK}ReuOzvandHoU zP$A+jT)9K~z_sno6HV56fNlE*p&0^QOyWaY*T%ZL#S=D+T$*1}!39fo61=5I1Vo69 zAOD<%pFuM()DDtV`pkpUDD_M$C!U?JvJ@-hI%jeF(km%BW+j4y3bNvnL_Cq{{$b3a zcD#!U6=_%{xKo+3dnxItw9F5&(P@udl{(;WqQP?0Q-kxlf@Hn`O4FcCFM^#_+OCnw z%Syb=*L@RFQ$Y!xlFoQ6x85gWD`43IyDYkT6r_)0At)DFJk|&sKZ5nMBhw=bM=bz> zsJP%q-wKLA@Q`xXoSl#;4`@X)=Ua#I5f+xz#muD-uB5G1F``~02(a>p9RqWXNI#Vf z2!WSpC?o8u2abm*=YvU{p82L=rh6>-B}zoQ`sa!Vx1Thu5xS>>2H1=9E0O-46P=DP z4qgWLo+tVTK6DOpsobf;MJ>w{W{oxkTW0C0$C7`+a%>eSIYFMM$Yn;>A}>1L8DmhO zM@k+xy^=c{{JT?(uf2xkfgADQax*g`Bf1c1UUHDKnJ3h}w50;$-<7hV1Q0zRP8kQ?djks>`o&!2Sr66EHv|&@1_t11=^(n|I{6+V-B_k&jIE6LAz5d_8l7`Q z>_^T$juZgxvtwas=5WZxnH1vDp}Iv*f1vCoI(1fgQ7%^jV7l#X0Su{%Qk6U_+uY!_ zmicBT6evjr6_*1A-zdHyYoM^a6VU-N%`E@VX=wsQ!JLnMOv%#v)Zb<&iv-0w}=qEG}45+=)FKg)hy*D(o6_ zkSM|nks2y%rhK-4Q>L5^$`uJS`j-s@T&bwE z`UW)w=6J5W)w5qtMDGWY&VC`cQ`4&2`qI^b+C_r0U2g_o!rJ;mg0b=&WjK{ADeg3D z*(U-dGYg47o0WqHEL-mEO)be;$)5-2jNoXMqyo1Fz+M-?W@sl}Uz zeu?S_51C2d6&4QIrgwzRzRAl7hDqBWuKd1=Bpec+tUW-fKjS{NK^3G%XbzlR=C&6K zSY+~BVT7b?0#ncvPol6Bwqg~7i@*)s;T3{rPyjHcW8F&EyIMv`@+bLCDqbb&MfmR% zCDj)r#BuD55pZy9zvn4R6?C=7DQC-^-hnt-tkauUrLWAq6G$2pN3Tc1doLpW%gz6w%Zgrm!tM#Jk) zkz^@sQcTxo2&-)RTQiodD%095o^m~jy+4Cq$ud&0u$@?-0%luNL2f-5CV_hHg}{X+ z;fF4xz_<-5RHjp(+@{iBF!Y*Qrdu3j=2n%ZD@xMVwaxtKMJqAH@;Q2#7lMgQ@Yy}P zZ8n+;Gyx%lx%Nw94Zq{GQ*Sqx38&rj^5oXqF29FESEerYsAK7ao z8@m&Q*4!Ce{$I^WLj6Lzy%Op@+Vx8C<gVdm5ZzT;Dfl6Ur6-Ajz=)C(= zUG>-D56>yP5Iai5e_gD2dQx~i- zrKSASmdQ`4!ikeKJE{zmwZd-oDpD-XJBD>btRpx#;K|W+U!k;bMDs~g2&DQ>)Uwr} zj>^tNa)YS+7$p=P%Sia{r9P#iVKXal!O(WCcd-L=x&q|1a%t=O9FE3;tR3nr9ym)) zjue5;o^7|C9^PQS-Wb1NSzbLtfL z^+0Ey}9_j}MSRxo_*x5MX7CAk-n|D(Vygr)BOuuyCoszos6?`^_Ut z9X6ixJ5h0d-cri)-tUIW0ITBQJ>V)wpm-|6OWztkR-HZ#oD`((;(L`E7f4#{-6US( zrpujHfF_bzsW8K=^j(qmp*>4&?d=d<2a*i@nb7gGXplCbUtKjK6L3qwssQAx_FYE4C!NQ1LF6ReJjKabsr8v{NbJX}NE(0INV z#a8ppc?+%HlH#=s8BxN5<;wueX84(iwEWpvAc5FD)9OSATmE<-B;Qbn%0HBK%0kEb zaZfjj*dq7z%4<8Ozp4XFuAQj@B=GgqE0#7f9j}iN z=Rq|V5ndkQK`nVa3UmRiL6ypUj`vn$C(C&&KrYZcNP%;j2axfFcq5K(6=-{L;dl$C zPI9!%PLxLd)2^uknkD}L{c%36Y^%$h-VU_MQWy4TVtzg7Jh@`z_@dlLkMZ*?VY+Pu z4_$ddRv=yP3qR9NDPUWyme4%MtwJSVMeRN;aU{$68x&rCtQfDHrOtNnXITuicX7{h zJ=cw98b?8%Tlo3)LRIMnE`IsS;qF9;9*;NBWx&Gx@Ph>xoL}~v%a#c*B|$52aQIYR zYwnp9N6@BGvJgKF=2hRi$a0l`%^QWJ{Q0{G=egUhU~d5(@^ zLPDwTG!l&D(+XP&0>M1Pm~%1kPs~~8JfI3v;x7G^waKLN)+W>nSO^NuuoFJmp~Mu{ zPP_!80~Gt{4UC?+z2NXi_nf8r2O55XOq4#THM~7Gq~O}l$ha>BHPsFcdgcb-|2H3= z1)Th&)qaE|A>GKz(>@@@HQs3|GukRexb<}Cq|7N4?Kosn;moC_B5V7K!3NVRH^SaF zi(b6pp}KJAL*fcUA_E0C+M6jr{LV<{w=n45Pc6J@&|~EQSFz&_f|ne%7>8P%&?p3K zIcLGNzroO}dCmMUZ!(@Gg&n7l+e+?AU2)Z)3Te}8R=Bhs%I$)P1y0@r+>JZ$TQ4~! ze!UJ*QXno=1`(7ZGI3Ro4Ma(xxX?W}8dBe?#YKWf=2pPPbco>MUZtgHvvme$txjU^u02Y*RtsJep*=KQj7J0Q3eZJDcJ+kVT`V483YQZo&%t7a06 zow|jzOGT6PRyIwVbiY}~g4akz4rYT743095y8+DUpHkU8e-;sCr75Jh?=!e5nQwWg zw_G9nicMHL&KdYn&&fr5`47;Roh&XaxpmtVeSgE^C>VSbtQu1}LLm;zUZ7N!?J$nthw{ST; zGa!-*EcIXo%}_H7h1`~YsXbP0w(4w(7LDk0CCb_kj8xHT+TC2(bM8B{(pn%YxY> z|0t*yOFteunP-;y(#}?OqVTXLYJ2Gm;x)~b0Oa%H=Vy|fxa|sy2Hs&;0e%Wl4hpRk zn1CdyvX=U0ic?8utqVoJ_2iaAksaQUPM`8n@V+4FvOF~Kigr&2XSeKl%}oc%R9&xBQ{cOhKX_1*RJv<%!L`pP3@s>UPKww)2*rP40L>2{t zH0$}+NZ9%EB@Zlc{;;+7_^2JCHo?^Ccv7UF6m7PmEt(W2P91<7UZQqjH?gvW_cy$Wb6*sB+AMaagBIQ@5o`4dG6^5=B7k5(&O zwaT=Jr1>k3VqY`(7&b$kE<#Ew8yu~oX%uNxJu6mti5sZ=sI%{8;_=5lA{?Y8*9-46 z(JrFG-e42FOD1skbyEzNN%!#C$P!M-bu^P59SmqpH|1=mC6Zah))yk)iYelqqZ1lL z?Y74gkL>B7hL@p}_1;RsLb75j9TP^x?=C!yjfsB(TNh}f=xGd;zR#+YU zH2Jb~izom90a^k<2mk^Y01QGX0KfnM06+jh0ssJj0AK)#kVHX97&8C>0e}Di000C4 z00=DcnqVXd5DWkY01yBV`xm@C)CeNL7K4C(VBNWWu(l0_-A~WrEhVul`OZrfs6YJ{tMMmBiQT}&j!m_sLK`lPfk=eU zHw~4@GW9gy>*$VwWg+3eM}-@-y4+Bq={Zk{E2vw;4uId6o&*<&ex@(l)o@`cuQX&! zrv~0SCfW@ymM_^GCYxKh-zGOKxu#7J)1lmhiu0^p$|OEP^VHeyC)$$9CAQOq_lYLr zO0Fu$K7h_B7c!G^+0kQ8J0}iY@`x1YosCjyDEDg8X~k&lSv4p}O+F*WmK@o!@?D(C z3xaPi5;KyQCL~XZlG?aXrvl9Bjw;uWDFo@0>Nm+X0=}ot8s)hhS^h41V(02LN@MW~SsO5{K48En~YSqOq*h`5{3=;T?Wq?GUkY^!XWKdil3x+B9oS>UV zxxsX)ha#qVYsLK^UZX%cYF&Z+Z}|%y6czN#;w*g2i}d*_npk87-MFG7EVi;Y961p6fq%0KlgaIwY3)80+N9<1UPnPT_^{0&|8#%ksQRO)UnELan1f;M<7V2S^5fnDDKFgsfZ7dF}-9xvyr z;nqZJp0qd&8B$WVzXo_%jqc|GiqD68y@?z5p`Dv=y;Q#6X4OhkmNnRrt2=h&_odI> z?cv|9VGPTj{&?70G*UhvkIXdc*BZ3jZxjy#$v8rbP9v;#2%{`329ZDUFgh|zI_HC8 zHQOwk11wH8WLP36;m?7ulY&y&V>L;ErzAv#)vHR@!2JB+Sm8*&sc_^B?NlJWMCN&L z;kD{?4PI0Mh0sqN*C_7(9G;j{7ezjbBDTsvzJzgSePCZ5&WIRT57=Fq{AbEVDeq~Z znT*f8WpX^FoZ1u9Hs!8<GE(}C>B6I}SuRU;#t%5#ZI{_p z=_#*?`j*1>1O@<7HZmT;a{;jvL}yNO8OPP&Dm`uOl=1%C2~YgzPA6kJnA4)$2n9=xu` zWa5a5IyUB7Z8296-9(}K;?R>Dg3%jMjmH!CDOAYXP$9>KFsVIbL?j$|J=6}uDiO)Z z$6%(U;=K-iw|#B;%2Vc!g*~GxV*+jUkQh;dfyoskeN9F4`$e-HlG)vhCU}Tn>Q;z3 zVgD|M}*pV2I#uX(O2q?ZuOT$kO6}SEKFaj&y{u3ttp{YLYn>kqSA0dwhd8p z!4Yf~sw*?wVwu%tkX{j12=cQvvaa*sR5Iif8F%Mi*Ul%`OI;bkxkSg1=0#$XXw$B? z=Td*O*oc@hJl9X&WNiXaO*zVsnNe4gpmw99lQD(~^ZlaA7f;cUA!Pa`oL|ATI4K@{ zu8JE)=hd94=Dur6@xeH5o$E?G@|U!1spn=xQV8@#kxjKx;gRrIr6=c&5NPW4B=p!6 z%8S{Rie=F)st`ql*0Q<5KQ++spON-^o*$8W-HMf(^=? z{Gxv>?jVX5+MaqICEZgr-!}c+#|wbCm(5#+`7NR2Fr`hD`LiS=<6Nz8Q?j<3KqLM~ z&msJ{Lr#3E%BSj-8{)4=XMsx@RDIb;+(_81<*$q{4q74XJ{L3a-?;xLLb+k*d49zF zN9B`PGD25AQTgOw$SW@v2RkfYY1x85h6{$-FtvTaEJ)c4L5VyK;x$2kb5**wk}Nh{ zsJ|%d2zdahu{= z4=w=R8m(~pC;ao@_6X2U;^usoD4&8~+*JeoEJ!@X&R@YU3Ay9T$5Y)p1x_DAxfN)- zewHK4psa4LT1s#R>c#X~!TecA5{Ggt6dn$^TfYae5Z&zwKb`E_H_JQ$A2z>ou@blO z`?e{zJPw^J(M8Cm*aX`X-B+7-X_KY!N^T6as^!%Bq$F4~qbIk}Lcb_~O1&sOG^rut? zZuSdrHV??kGXEMI;p98M#RU-UxfSev*eBc!uXLZyWls{lFLU8Ba^O8OG;U!PT#<}r zv1FCAqOyvjtcu5oE@IVoRwzBefpUVk&oE8RF}hQ}UBz0iSU}W~W~bR*nb@(ht(X*4 zUz!mgd^>RJXB6LQKmRVENv$tJY2}Cuw@ed;=c0zKq03D?gvm^+OsP-h!ofmre>2FQ zukt8yAat*25L(YO4R6h$O>;axz&-9(Q$=vNv)HVz#g;&hA1oBly15L?mMlw6y@U3q z$IA93+MWQYyT3)cP#<}6ba;*)dyAcJ&^`JoiaOGeMefl&e6qD3Y7uA(y&q*w!uO9F zURbys7Z6OSu&u&53J9p_+hdF7%SfiU^vbXE!Pv6Kj!_x+ux-sGGnP4z<{MCqizb;r zVocEf2rW}?5oxg^5fZzA6Ypj0ffVPlC%P8EM-Wr*BEA0LJK_t|X_1`oPb?mAQ&Ga* zuxR!6D)DaH#QiSyEbyQ24+wVQ(@kXtbiWbch4h+CmX-oX-d!tPprmISVwMETjqc!K zOVZu1DCS>zDIcNCqc|+gV+Vgj|BCWX4G~2OXCu=fc5!n6=lKN5N)b76Pg_qJFKuPw zJ7#Fu=KcLYEVxF4dPHNB=ZicAGnADNlL-F}iG!+t0CqlD`D!!6X0dnm_n2>GtYy3^ zFF>Mc=skhYOe6XSYROdI%ait}Q(l2`{(0?|aM{*HLcVd=I^4EtY4hJq`8){vKl>T_ z2jqA$rwx)w;hYPv34X1X4T#bU0aPORZedMe-!@tviPinI@Xz36A$?bfIpMx0v&+UE z{&Sz%+bE^?nZ0&8l)gb7kUyHepXM5T%Ed)fH7r$Q$ZlA|-Wf<39vR#F%jSQ0i(+V^ z^McfgFP+FH4=IA@-t5x=oEV;ldM_tRQELDDezT3+F0*f>Su;hCW|7- zP~ytn3X9;xW)z^XSt=18VZJ0&l9aBksAmWDB&-%NoUkF-kQsyQ8ANm}#s8J1Z!UQ8 zs!PUfSn387xr=_xtOHc$<~A$U+c<$Cra|N&p(~wrk~ymA`*YK^?Pqq~$G}`Y;N_Mu zE4;(9kHZJUmZS?$7k4}xp=9Cte(OXQe=H1e53w$bbV!5!`M9LKq4=yvi(H(`mgkn! zsR~?6qtixxg2x}Sl<$+7k%X6Lhka<`?Gbc!-U?Qx5k>ecj9FG%ECJ&xE-$#*f~hm5 zFH^G2`aHv#bk}`Aj_#7+ZAzYmv~OU?OIg&sQkSiKD=(Uve`=N(E(e*)UnG?Ghx0#L z9*O>+=k=qE3RVofv2w+vlIMyi_7D8hl{ODkWzxTWjxvTX?~erS zXM$+C)(^*`E#Zhn>!4|2;p<)J5lQ3@Mh+|ES^}Z0^$uDGzlNHY;El6zZRcO?{!Mjj z#UFu3hEc02U2Ja{fb|(wULKz38Zjdml+OLlVEF*HOGo18O?6o1zl*s~PVz=~@Y_#h zHiBeyTocM$;N@a6-RHuXX#TY|7E@^h_S1ix!G_+81{02gqmL?7*3p_-T;?Y2v87vEh zDH9-m&?2P;qQLH@RzoQPuc&5FxIPcM&Wc4SMf*`!#RSFqxk^E54q;`fc zm0wSiSI)|BH;qb#x*2BtEUo6>-!uX$qWQqJG2#mMRFf0=2H(zE6y7d;gTeMP#uFj7 zq1twLS(ub3SkEZS3fk*?1n!G-x3|v9+~Vj`Bz(P7^ZNw03fRJI2DK{Z9#7Md&huFy z>4GR5UqUg;huVLxT=xSEK#0N=SaT1GNP!ZzBxMi151xCwE)3@Z2@J_p!psyT zIU7h70!~v&XhMc$Gaek*J46kAFn7Lo4=DPFCBvS`@T0+_EP5-3*ZPaJO9^bPI*q!I z&Gg%*#1w?bZW{(=5#kG}McV`4K!cY*+~l1ZNn9IjLFsvhbQ7?&69O1MpJ#x*&;Bt` zB7rqcNy}E)?=DCX$K{Z#e?79|BMDocq*FPgHS}N zZDP?f3N$Q~Nz~L3pEKh+S~J7Ua;-?7##e;-IhXk95kC46KGom(96Y`!1%38A9 zoZH)^RcAX>6ij$ZX6l{6x{wLP-v<84P#dV%Q{F^5P7&CiC$X@T{M(mz$=eXs3{^PN zo+b_LA{=COp;kVl$vp{F8u&Mx_M|tmLBdfqiEWTsg#f{lV=(8f0cz8goe_SqZw*`D00001Vg~>z z2m=5B0RR9D0000000000000000E!hrBO_7<00000000005C8xP0zd$O1ONa40000G zg9?WR00FcB_2r7o2QpI5OV96ki0}1g@AX<|W;e`|^d?UEu7x3IDA7Vh=$U>pq$zkb zdJ<`17Asc31Q21Ed`A`>IthYKp|swKsB=l$G)PuNL17qWB1a0NO8u{xDl|+TKh{ek zX8UwyF*H!ooJgS}!v6gt+VOnH5<{Sw6eIp5N4C)7h=qtqH-+#bEO^vf8Y=XxN-~dP z8Dv@jA^?GaU=!db3;~9Y5g}s})bhmw2C`pr0TlPCa4{{3czcZEYlf_P_SZsLB&%Ba z3BE-lWIsx^g}_6gz4F>+SC$zD7vNYrnlk-UOKL=lb5 zq`Kt!9%+x;SD~ROK!gA>D&$EZOb%^BDr~|7h3afoTg4#&fJIDSEY3n9Ix_@Jk&uwJ zWAq?4m+^r>KoUe<@RUkmwrtq`R3(vb0B=SGlwcjE0cen!dE8Y>_0uY^I^6IapLm(D zc(DDj4)CmuFE0JEEW4_{$x{h47uylqBR?>nLC8m)xSi$PN$`}k0l{hrh!qMJTd!)C zef8kTC;$*J2Y}leL0Lc>U9M?8QtG6INuZX{?rT7RIRY9WMHuoSS;{Lbb7i}Bo`&9@ z4k2V8{eV#y9j=r*kd>eygTsFs*2${Y)$3iW*GYO*L`96OfYyOf`uBUR;$c!Io%pe% ztv>DRk~@^^L~@Q`3vF6GvM8;-lGY|Hkw2bhZU%WK(sX;jYffE1cyc8@Sib|!M4un@nb|R z6Fh%Oa&%gEbb7|I<~_0NKG|9}+kfCbIUHChibLwz52<513uZ`4qPJKK*jHZw9CsjU z!kO?>Vh0%#48XN^?3fo!H%9{9!-NA}YVtVu;d`zjH z*Y|=~5Ghme3L$tE6w%4H{u5Y5%fQg2i`*o6SgkYEbKB#_z_xER^pFG_bmL!9ogtuR68*Fcu;?%;Y-0P%C0Hk>yQzOR5I_M}g z4zOYkbo3Aszz6BzBNQ$EP-<&lpb5}n{_@fZ3naF`5DUnd!u>>)XY$)m zY(ZJVTlJ`92@@zup|Z#qLGHv_`+pY@x>PL^PlXS$9N_(HMLYMP;>r@{=c~w7oVI~L z`zoJFZJvx#w0wdYb+|YNFIAte*u*rGNKgb9m|)D*`x~>@C;)<^ktBs_$_QZw1qK0! z&|(737le)`ywJ%t>oJ8pbx1|l!djC(HGyI_`b>UZmZ*fL6jf<3e`v*|6ykrXChfZY z#T5~c8n+<)+)ZlK02m-UCIp7Ug$@O>RWpaEeA3UPJOQolL$*g3&GEq5Ham9DNKv+<+RHZIazxXa0elAO#pgGne4NMqc>Es0XZFP=Hu^Q@`Zs%`Wo?Cnd7yP zJ?Ln-S9()wA$L7sTV9=T&ndXPzL`W;Lers7RabenMe)5)@@lOI7RgF4Ll8mJ=AiuJ zl}(OghRl#P&kPdg&+&+WB)8dO;!KidxS0kp7~Czl!B{{6uO6NiDnT#bRwd3Q8QxEb zEPA>%QPrxiG+EhPrtCR?ypp8aU2PFJ?$D(~>jf716FxLZ&_FSaW^)rf=YJEUk7RZv zX{fRfQ%p8A>ZZw)&z+>g+Cozb)k@qo#rBY;@XjV>zn5D0NE?S=t zZiUlbYe1%|4PZ+o#`Q@Zw-m7xEHT)ik|hk94V>5Jcrq7MBMN}Q06-Mf)I)@<$AE&sw5T5^ zqg|aQq?aK99lZXHS0b>csNCXI_30Ao_S?E}VF-T_xQ z6oeAeZQWwKXQW}0SW?A#B3_|F0}@FXqnEKnDiB1iQ9}gUvXKn-ZPd!ha#AP)3@|_h zC0M1959=a*Pg!D=!&($jl|7Xdpt8#$k|C`v3wD8bjhC6%tj4sGQ`)X;hOFz<>(01u zqI4$xUDH%3qLu?EI$*R10wNhBr<1D;E?PKm{BqjWCH1$xKI<#+6co`LzOqWto%SGt ziYSQ76&Yh1Ih!z~7;LZ=H%_iF#SzOrI&ARL+{FD|tJ{ePS!9x|)<_0OqLPe4PPx3}jv0hf zVuwPt;tPw47B0^;;6g`+b7Db$empzca3iS%jd7drqD70MiRvk@@VSjz_E#fj>l8uz zv`B-JCP6QUzIjZeV)@>rVM|N+dq7w+Rm>5nQNiv9E#w#xn-EGo@k>#)zGyB9w}HAL$4+v zA`j1gD#R-_t>rcouiP!={lin|KXwxaGW zD5(GuDs9zTft|$Kbu_xdLl2Y;T949vbk|ggf|ZmuW_JQR@?c}cQ}0ufmKj1_qtVmq zdL-A|{FJ1q%@k7SU+uMgFA&+YP;^NlkUCTm=vTT#+LF1*s6C12G6OWdpv=)X{~EQMQe-rB4%jl27`X zDw?mv59D3_`y^gzv?lvRkSiHw0?S~<*0Gd9DEq;Tmnf5>hZ1l~KYgunV0NRQe_&^Oc< zDG)jHs_NxB-y28{=pJE2z>9r(Q6R3Ck@b?@A$1D3zK5D?T^Qo0&dj0X^@IGzkLS3P zP3lrBQ6coC#}M|OrN*{Lj%XT`UO+Qr%+xa>Cw69s=5yno)_VNPEc{qNKA3mt`lJ`q`Mxnvlty z#HE^%kxX(+oS0}r5SYlA#=fvxN2W#`+^A4$e(zCFO*=d|uzX17wOsaVSLGyMDYlv1 zk$IbIfT;cji8;?j0&Ef{VE z%)Df&fGzzvFv^$3`P}ox`1v&e*gz-0iGjzzT1&}jL@peNjJ9aBluBtx^v*mjbTU(Uy%|YF@lY>UBssd~hqaR? zO0OlPrah^V9(Z+MFr>4lOsDNx z{@C_YIg153u0_Pj^y~`H3OFqr1kC%Y>8pY>ZWQ2bH54Z3t#&ch*Da{?@8yN!R0vop zE`UC*rixgxA_Nncl+J1JxBI-*D57lOVDsn07xpas_6d+_Np6=va}fP3ea%}!U9qv0 zNWOvmU&*Z0H!=;#s$TG*8F6pOLcHdN}Qtg_Zs+9s$owWkTI<0 zo|aKZvpULKwklgzu`_uL=4iBQsFJdlQQjqfrq2CqOG38u$=9i3C@GZe{<)fn@EIe0 zguljse&Gp}A=J067^nNF>t&cEW*6c8^S3pOwSOt^cx4Mrd=&qrp{&7~c%`lZ9Dyw0V1MTWfH+Q$Z!| zD^dBSlM-*}7-(zftzBd5G$0bCzEaZv7`Ksf|7u@`xwjQImX}e5#zC>pWEeL*5Txv^ zV7Wn=He|F3SyEDgSvgN97mIRJMkF+B@!iWgG2yPedInDNvqonmFtRU2@}NlKqd7oxgt+OmTD;P{k@IC)Gl6p=xLCbv(C{C5>hp`A zPDegrHD(~CvFVwqJn(TIB?v<*2^W%tg@Ap^fel>QS)Ql6I3$y$c4Q*KjVHK(rh1&` zYPn6l^eH~MyJ0jfYFgF>MZMiMk5E=L7Lrtzu7r>kOb&ySAVQ_H*V!xFrb8Rf`N0uX zKTBHT@T}6r5ks63_KcxSc$nq~(m|56SyQtt;3V#|mZw7JC5gIsqwhDZiJuzS+z-bs zD^>tjIZgb+uFqGO37M>nr7WuS814wdkgz1a^yd0obR8*lAp<#a&L1?9N@|bq*}Q6G!JuVnU$_*SG19D?u#s0ye#&oquq3xO@hcNDZcJj zs6ZjZFwo&m@Z@T9Ew=Xs! zXSQ*v6e*YxT-AaUf}YGuzOnb)H`18{i8Uf76pViEkug>hXj|y1B$_{kY&woq7t?7R zr6S-7FP;k{s8Hu7W=yVG_04>*@&e*%ghG}aEb3?uO8K5MthT+NYtf)Y=Esxmqo=Zh z%s|+uiL4P-#$+6)(Mb*xv|MJ87ts%|T_Bb$cX8t*SN{$FKVDz%^e?>mAbOxCJm-#X zeaY&7AN(v&;AaW<#c^dM3io$D_rvn#{SP{^50@-Oiys64vnliEre!gI8g&mzIJYik z3j0i~E{YWYMW*Q{ntvqr)Yo*g+gi z2)6;(Oq3v{HvA%`|1#-?@iA0^I&|FG0zLidV&s<=7icY8rmL zI+3>D%Z0Qh$E_K_-OGzdfmz{*s$Kir z$7qFdl*ph)Q@PSn&B+i~l%U`N!MHRp1^!L2F9#GGOOk3LkPM2539wtRm263p8*(xU zc=>pJX=~eHw1t$)Dl3;TRurI9vWJ<^MtVw0#jq>cG{=VyQ?wq2lafhFTa;@pRv$vv z63@c0gh4`!A|fRzkcR(Cb@Wgv+&-Sm>UMAHADw1>@cUj;|9}7h0coCLK->%t85a%; zEVQM9DvNDW>?!tczhMl-1U}BPIPAQFK-iHHdc165AY1|}>Inlp1SQ0y2$xwx z{#uNhfUHVr+3RSEuG!***<>|jG+u-O7{)7qnue1bHy~1wLmZcqdy`P8BtP`P zZ&L_*bE+Bt3#Ohx87P4m8!}>NBy+E!2!e>uFwKo1hrUexxg^z11C$vtI)w8{BoG%8 zDw?!+QoKC3vj_()0+k>TU4Y>L1(bRyG?$?uh$fJq4b=%x3`1U`Q<^Rd+F=Om6LPR5 zQgvRCtG3k*!usD@??@n zQ%BMe3_zSGiv!MW(!(%C}^p=3HvsZB_>k+8$FPUMJd_#Ni3r4Z9{&5)x5|Q%Pm!)%lVy$Hxvo z92@Om+GL5Ju;H9ZRXhbx-yFKQlfW*PWewAEGO2#fxI>nl+8chHo zlqNNi>Adn8JB*~=QVwtgD#Kc3lu&{y_#bf$wr(;@WC_)fJj0ESL3%B(5Mi9+9ZP`D0WN67EyPMKtbLI0zR34 z)|wm)5Zgfjh4Q7xs)O2O&N*} zE2!yVw!Cb)Q?Tlsa}?`kF7t_uM-~(fvGTk-2%l$A*NYR7$~_$j4hf0?fe!B^JG_?` zx}t0znpxbKMw{%=jr1I}#0M)pi4FMf{Rn9{%|OUcbA=QFg!@EdB5ShW#}CSwckR7X_lhWAw8aD;jddz=~9FK_Lrfkf?sUrz!<5Nz-tW5Ac)( z!7%2aF0V!LMB)p$n%Avx`iENWGq*UkXoYVnxkw44Y zvKMAc9~vff9PKxx6M%w`?on9LD1u1pl8NKoX!Z?l9(h=pUlZjZ8ntU7O}BeJIFld0 ztV7cn2m~5Ss*4aOzWRl|U0~a@C9eDar%;-i!OI0cEgYem zrQO>{&kHIb+=6X;v1MH$4pOaARro?}Eaj@W!zyQ50fIEaV>I$e@S^sMwq*=>(QoxP ziFmX{n55h3sUGD$XLIYE5(W$bb*HX%3jyIo5t;R|0m-^QXQGmYOP2}PA~u>8W>bQx z&ZU7cT3|O?;m;{`PE`Uwk*1T|D)FHHBZv+|y^b|&!vSO(#wW}uE#W8%u3vp_#0Y)` zP57{rb>dV$^tRG{Au4e65FfIVO&!p2%jfOs%vQL^hqj58_{6IZ)z9+?*wnHHi2rB> zK>oz5MOw$#br0`=N7I{A_=T{S?sL@vWgbxzUY`S~EJZ*nc>_851YXn@O1V@fUw-%% zRS_>MgB4ev2Gk97d}k>#$fxqcnQPQk+C!{_h=%!K?I|_YZMLyoMiE9i*7#6+YcZ?N zqH8)fa^$fVYO1K1im4R+ z;Svi2FtHtUY$k*I-D@4PRq~WaFRji+ACLpML-!$kx(<)X!SYQ@LN2gUlN!!dAh;R= z!Eg@vsO%KE2@c^7Uq+Ns%qTbLY$g%%i-ZEBKrl0GjzkJy`-%h$|NN(-sJ^e#kp_U$ zMWm2Hacmw54cM9@u%t5UJ@^sZ%PIRw?qdzrQ)W|BVET?8Vg~Tmo2_EpBvYAzjb+4m zLCHA*n1lG1KSm{Bv>0@Tg-|johDhUR7z{utYKbU}CqL&_2Ul-JLQJ{>qP1@V^o036 z$@=NFtoJR51!tfD00CMT=H3`2xa6ik;gu77J3sR-`qB!C4dh~-&y z)h}^w_ny+BvYw^u62T=!iVCe~x_Tt2gkaN`xsAs8=-fpdO4jl~sS8hA4NZ4my?B?= zrt1!@)&QYkDJCbLXPMoutU@FNa*kdWvU(ugp{j|dcp92jyBJ!=f@3J;6Y-Q#sb{vR z>P&B^D25vZ(ZB8CqA<~NpQ>vGuy1N^W5*8UizzST;(X%k?25C8I>Jvl);= zk$Lc_AVa21>l0fIrcHl^(pBA)=P4&7-uV$1`ZQ;vC_`^RASUD`D<1AMe-0^j@J(l9 zrm1+KzN~nv2Y?iycPLK5-e`a}{Psy;PZ|_^Ya@jAm=ib)6zuzB2(sshOu$33gD1aC z%+}HMrkkwPuqN^EMMhOMYa)WH=6FU933 z@lD{T%;k!hSoH9B*YNaMJ|0;jcfw%7<2x*j;ZFxpCoOY#t!3l)%jE_SV*bL4+7?F1 zsI{~DdUk*C&4)NEtnm?3u1WZroZ8xU?&?2d0V9YKQUuX45KGKMvl~K@@hK<$nZVGN zlygubEz>hU|MNFTw!Q{GPml`51v}E#H0tj8NL3WVqQc?PUK+A=9J9`Oh&hc-H@+V( zN*0)n%z~CiUZJwk4jLuHgQqnQo(65y4y7so*|=P^vVcz*b?I)P>V-mx2>E3+;=ts5 z=)Qc)Wq3>jlqs7Y1KI=*=pdbQJswL`DWssJYbj=ReNx*zj|x~Z*aJuG#WL@8G_Acd zi-9l{WUD(r(&yHsF8Sier@9kj*1rhi=eYS~(k5)JpMbr+Dy0(iHNZ+8rzuZLxkXny4OIziVzyGkC8)Y6 z%!rA#V@RXJw!5tENp&V?szF(vUO+nu$sN4+|Ns4BFY+&N?+m&qGmjro4sjRr!P^lB zE~jI+h(!IOPME1~?sV$WPaJ`&0veoBiR_;3_sJn}-Y%TzzD|pZXNRTLce|VAGK}F7JOi)dt(=u9ZbLFTDNUt;ieN{htmuLr z1fRdr4FP~!`Ncm>^U%WXqW zxDvIMLF*p0brcbuY@y(w=4=rML3cPs6MHyz%9p2}GtN;37nxx=Jn%c#kp)DhbDZB$ z9yiho@q7mYNR#vCQ15D72j`O(AMHLYY;bA$;|agaRPXk*yot)Wf|!pgv$1l-b(UO1 zSxb{mK35}=1BVlWdT>t*oLe&MIWc8#sQoFKa#x@=boCDNtf10utr*LB6DX<$(m4q> zQze;nLV~lWPl!3#@C*Ol97UoBo;@v#MWZRBj8?=tR0HDRX~OJRSEG>xCppUMhXI<> zJ+=Y)2PhkvAEDrxs9>i6pUgfMM!r_iLHJ$Dt*}4lmUB}54w*z`!5IiWK2Mjqel!A- zqN(NF?2%+_bi_$)T4;$xzGo6J{F4>%o-P_4c(4Z~EFQq{kTrNYW!L3d<2?e&=&$=! z83ty74uAM%*PFG&QC)op-4JnJr_VK1Bba~j;_oZlS&Iz2xRB)+E=hu`kVSF}9dbT= z-vvkBd!@b0{VAfte9z*VRWFgCLSlQOkMS2#28^?`UL;*(86D@QMI?*%+M ztP^VO6T8me7C8S8DPZ&j?YZD!V>1i%*uHwasGPp_oJD#ifoflHaXV2B0kl?8eiMxZ z5A?O>0ntd$vMrrLmFB%p7-q4<7)0{isn#$Ip>` zlbBmtgylAsus0dgowL;(yNe$`;E6_u*wyFdHj5|}Jc2EKQOF*wU_{5iMg0E*5YxGy zJKXlp$I~GP`F}8&!Sb~Jo7nLS`F9R4GX7YynD>o4w0Va2FMyv|`B-ss4^{Fk+bB6S zaR%p70=dHF%lVT+7G!-q+fZ&sk6?4G>b?cfFRkh`BQxqC(MOF7Q2eIS;s~Jf6Xkpj z{zjq4vB^|M_i_>Z8U_ALK}@^P%1>369WhJ8uIi-4%FDqf4-k`W!aj(pewLar_6uZ> zoUgpd@8rMDD3md5ap9GWGFsl>*o)_}YdkFyJk%y?A9!_3EU+*b@a{z~JmD|x`F9!w z2k+zVk&*Xx0Hr=u3=d@sIInPWP{`>bNAp1{F5cxF<81DY3Ghb$%e z{hjVhj!b?Iv|&Xe#GyWX1wF$}1nO9;lJhG}ve2EDN(g0RM_)iFeVj^-d(j>gnM&T_ z!uv(F#IM(tWr6Sd0RcvSD626yM+mgz>tsMTu!}lLf+#bMFpmd3A^SX;!WX}>F3!kO zv2#W%kGF^}5Hsh({3*12>5BmubBzOL_?{gV55mImy7#w#SD#-~+A)U|+PTj*f_Yek z0Wd1lEq~QL--1Uda6n4Q8ZEz6&?cHu0oQbNdA0Q-Uri*}I4N%-LvZrBXOc#}momP` zi+k;BA0OS9HEvTb$_kv-sP*@qy`>(k#0M8V13b->7tiR=b`t2hKeL|>nf416IoCwe z38r#m!&%jvVT&!GCm3cSM$uZ2*^Fc}5lA-FK%&J>V92C2 zI?LTE4U<%cxB}6J7~>N(!dn=H5TY#?;T+ph5R&P?ZO!d_dq=pbueQpiD!Z7`GF$x< z&WMImAf{>RvgjMmLXU6EbZGxRib+YXgZ1s1?aV}M1;dzAP79M;yksGU(vj>S!VRNE zJ0MVY{*BQ_l8sNql(d(a8vCM#rFTT2xIT7O5`qlX)UKi?yIDM3 z(vO3|gU4(|Lgv=z>hIK|uT8lc%&VZfcrTT-cuX1|l(livlq|K2$gx}Y)DB1zV(p8Q zG5PpqDoIu|)e4P{b*Q~4v|se;zS*D~?5;~zFPF`+00001ahf1dlq3Wj1Pn$vK;ev$ zfJmKXNa!)qq|!CVRHqeYxXg1(oSiwu=!%;?S8k>>PgS8Ad(q9tek$)`^qr3Y<{HWe zPgx$3_BKPBu}8HVPE?JhZu;1qXq4QUx39%@ucX(!n$@2*u?-YF#V&Tr5`qdg`ZZS} zv+M8E@jyauaM@~#l0pO$4?uy_tX4t}5~(C_b)_v>rFb-p!SI$&B)F;swYOL!a2i9< zk@CV|M+XxPV35Tb>#MCx^uGfB-@t zX-{Sq5c`lw+*cOcT4%2f6__C9Wj%6^KbBaV&TsdsZq* z5F-jq5I|T%1Y3kQK>HQ+l2d{cYfoNO2!RL0APV&e2!o-55`mL;2@>`|J zT{N!Lg&8AtP;aa(Xf7d4+%khA=OB^%&EYg?JF7^BUmyNlZ}fJ~b%v0zc`jc>XonyI zSS{xOXcg$gKZEYX3I}$H$=s^za(yr27k#HZzAk9LD7-RY^n!;CJ5I=HgI3yTBUDT+ zDZYZRRDU3~8&9@dQVG1!BiG2+92Jenizmj?aOM3j_j@vB-=mAV_+ev?J=k)#6sb!i z$5~4$PPjssrs$_rWg&m0=^Q0PIXf&5$cF(-tiuM$XK*Uk)xZIMWQjp zG$IZ)Df9{?863r^U+f>s#)Oa|jA;GJT%OVC}|K(5C{n> zBnDw3kP~1JNI{Vx1%^uk|1vCoL&ohCY_`frTb^+PX~3-b9995uD_p$Gx3^$~R17H? zW)^$Mi6=NDr37sO8$d*`YRv$pLeN3f1Og!&>Y*m!t_MK_q39wgP%#an4oh~K|4K<` zFyf&?UtmD%NjjNt`gE6Q#T7F%d}f9z5v-*ui$E9v12Y5C1V&)tsH%iBFaZfufiej& zlElo$HB&=012pAs%DxlQj*JR+M^b#bDf*jUg~|KWh#TZ`7HLoi0NtwHFB~|CntRuY z;l?1eQ8(fcaOEnfk$N^a2-^sQ6C_W;2G1L#QI=1IgU7j(P$k7LzA1Y9@AcZ>%)lKF zEDM2qBI6PCG_`P9| zz~=u7b?XEjPyu!@rCilaz%Bx1tWBuHr47fg?mi!!2;@N+4dyV)wk>3~6fZ4W+tPHK z_)f~4A{--|LO}w_0FGj4<{S83J6cb@PlvujejnQFY#26iI0gVaSYN0AK>(I1Wyrk(9uqG6AHO2K2bdB9vMc(~TG_4xYxmPxN2yD;ZUrzQKDx zQ-gvX{2*Aq!XMu^N#-I6PW^6^9+_8w03ZPP1O*`_`9TKBxInYP1A-Bn2@L^_mk1Ot zCwM~Q1;rC2x5m{(jUA)WJ1Eofu7D|Ia)CpCrB#~oPwa_Ly(AOfn&g>QoH~L03-WA1$5#7I-Db%6cJnyNNxSQ zpnzcm&Bek#WsX>pWR-0ReWs>2EfHLoh7Lk*FaZiL-PplKnXqqaV`P7bXOiWC2-!4W z+L)(|rLxB2)k0wf%dyC8YfG_>H`6=46lQXl$0RLohUk%_NUznjngakLm=FMn014<6 z3RDBERZ!j$;aYP;$pED?%7dE2Ug!igxq~nb!ZN}Kn+VZC1kD74i;GdP986YIS^rMg zX=L^BZJq<3AqS05xC6>M$U%Z3=q0mMNuM3JoeUQ%8v=qhfMFM52EqeqA&@}7ive0N zCvP_7xx|wS-@DN%%=)>&lEXh_`R(H6A8b$HSlxZhd|0eBfp=>%I)5p|hnbMA@mHCs z2C57Y1qfEu5F}AG%6K?3K}xprZh{_$oY8M4R4#2Mz!kFfu(rYti#Xf=W`_J}5HFSq znu_2w1NVq0iRPX{!6LADL{LKDgy95@gf9{u!$W_WqK~s$MDfM8`f!r?K=6VrA<+3? zjtmey1Udo%18{7HTjSlAMzlmD78sih`(dz(AcU)DfZ%OdK?}c)*c77C#)^HQwR4mv zklL7#kQg9waDXgo?7yz^Hs7KoVy_O*K%_(M)tCF7shTMnDKdfp02CkqI$n56NLfR; z$`Gx#At-<^B~+nyltD^K6tK1F>tZIIIY!+;IpsHS(@~*>k7uV>-EuHAZ+;^H=1T~1 z1u#jQ!4}~jU@(K>0sWyMP7{T}1ZJ}*WAffHB98?Tc+|~6V37C;f)NC11bKnNAD6r! z5FjIa@KF^Uv=h=T7?$L6;R?;02wA!aY4l_H1aP`^+#W`dx5CycX2oX+K>`J$P_P0U zP>7H%ZkPZ70doX&2pOcsEQD12NJV9s5WmC`Y6`f3$pn75YzY=a z&w1&kf?3{b$|ml}Lj(Z6)l(ikL00_=6Oh->P?O+ucYRJs#gR_UaS!afZ+4wb+zutScO4lah!uJ7n=uEbwha35LS4B zou}7V&2NEBwaUOFBM?IeF7JH*o!5Cdjv`zb?74`}f%Z4g^`SJm24C{P?>tIc%2I-9 z_~T*k#WMM1Ia50!7OXPDF9#(w&&NSHYoE&r;U(Tzxnu^Ikvr7AI`=JoBWiqgw^iNX zHxm?-IrmSn{m9zE&rzg8L|DrDNM#pK7tx)4s2f7(()(M%Fjt_lVBEU0*#fj~ai4WO z5$X9K*_1(U4jy51gy&XW5%{@Um@>oGSW>x$lGxH_8n{AWs{P*$(>8^YR_LjjD4jez z^UQdRh_|0eZ~M^ir)g0mV*h7j;4rvyoEF25S2MOPmpT;}4D5SV{`_$(veKcvIKpf3Xf1^lJla$} zD+ED&RKaVWME(UI%ghh{Sf{4!XfpOR;l3|9^U*$7Kn(E|N!rw1{)sXxJ)F5B7ls+IZQHph!}n_b!nZ zx|0VhuAT4ZlrQgb0Y^F53P4l5pR|1u{I(sQ*6jYX7`HDD$_8hWf6p;Xh$O+#T1ZPv z(4BN=DH7`2nJ0Ywf*;B)XA#BA7+p8aG=sV8{IS;7b?iV#N3W|SVl47*oCGckLB4;Wa& zLUuz!h9q1Klg@^s(0FQ?HiAb?@f%aLgkB(;+>Jl?%9GwOkfMFeWHf=X3}rJioS~!4 zD5bGNjA}qyA`>H=!EqH`@dXf32`rHnmYc0N^2albHB;V2ZO<8_k}RwLkAERP@Px$H zG6zOwj3=V}=%Rln6|wTQG@1Js#mN@OG$kWrEtB4hYDCV2vxLQXDR(=e({lXRvW$tr z#0Q_>_%AZolwCeAjapn$9y`lYPF*_eH7Ts=!AFJPl|_PyTh?ESN!GK(uZ5s@Xh&f|iR!IcU zn_tMt&4tu0r5qinoaIR|8Ip`FIy;Wwb=Azs+=5<3H|XX1g;8T-&Jj)dwqDj%KO)yL zd}syw-xdZ#$1Y-ysC|}$jW^_=l|15g{uVY6W2cm&=Vyl4jy+2hYU}XtK6BvvA#3dU z<8e7N_R*9UBQiP#f`BV?0J#>Ze;6#MB`SuMYyRnZ$QQ$qNK+i(>D=@TWhEcq#I{q5 zL{PF%_Z4`u-nDLLw{d9d5~@D4mWb(0t(^2nPGvPHpi7pL>RPacW(l;2r2$W!-=FTf z&=ymklCbY%xgaB`^NCDl;^^dYhRMq!Ko%sF7H3i6><<;dxX=9c12cl2ND7yf&Q|3| zFj2~~0zWK*csbmf7a9W4&JNp`W>LoWEKa;f^~*~YQBHHJHYbv5b>Q6eNLt0>+)6Yw zNsAA-w3MbI8Xj{}QdirPl9pNx$D&-(DQ;>vgpgKyn|(PFA_Hfw1aTP|7LqgfveQbX zIIoGH(;tBo&zar$x#IF=AcR_-#bjVJO+2btQrIA({hj|zM1epugP31s<;^+GGNg$z zUuw?`iz*_42P*8jN>8(dppxkM{hTGfQ-0$n`ApRkW>NKkAs6K*)R zU_hgFS}gVwV-^{U66_eIM%4Y>4WcBY?eFIDVC0%0_D~~YeO7)y-i3_yWHOgR%_6d^(t#P)3`6#E~P@e|5x)W66H ztdvYUO}$H9K@=GvHMv{-daxSQgvSQK?0bXG>sL{^1Y2GiF}+36csIA6a>o*@o-O+< z;#pZdP#%F#)q+8tIa3Y;+^d=OMIJRaLYAWuKQW;pEPF)G9qFfiE<>un5cAFs|y?( zx8Ac!PPy_CYl}0S zWMW86_%9?4?q3`!5VOH>p(M%9ab>kbnVD@9?p%qrLo=5*HYB!4NTmXXkZ}|R6o+)hn3Lr# zFE4#FYg$&7j8gL;u}4%+i(WJWX0m{&mDB(`@>T=gD=yzw3|PhCR)@dAg!X~hQM8yjRSye5&^jP4sm!&kqp#W)xGBT++eU&(jiwSz& z!7h_ot%S;}-(Wegfo#I^MHo{^MH9^JEiH>1)Zk*xnPQ4PYR!nnzT4pfCNkh| z3-qpuO}8dCQ+K}Pt!tlJUt0900B&pnq1Y4D0yVX2I=jH`;>GD-wxBJ6RREk$!2q9$ zPvYFm@oudtn{1>nnMg&idb4S{1sq&lNZyF7xb7|RD&%c~ww88pH9W1(wT)M9G(1o4 zo-}aSelm#^*&wq@ixD(s+Aq|@;Q_MbWrMYb$(Ipkpj=25nXwSGt7|EUjHKncvOUQ% zhF@vtk4>bkwO&gWAbe9-=fQe{#fTdwpp0NM#x1r5NPRe5@YI*b9QX-159ZCf3eFdUs7W?ysc$!a^p;A%-a0q)35(`^u z<4Q?e10iCFL7&N5jk@mGAUE`Px;#t}EXw-q0{v%zd$9Q_j#f5yTSNNf^9s3x0zk3! zvvH%uHcYYD!2!r?qJ84ybwITr$eo9wM`}@;ctbF& zxvsubHxp){hik*6x#0hoBT`jJ`EsRX?e?g@$-u-~JYMm?jo?VsSlH_PH0*NZY;Be& zsn(MKoW7aRJpl)L-rC>aNjNQS?Kg;sNT?7znAmD79r*ERAPhxCANrp=Nfd96-K~}) zsrogt)Rf6>3nDOK0>?MY!ieEY1RgX<#1MkqphMB zjr8&}>^7W>Ac$@O!US9tMIh&By8E>IZ@fk)S^}ewq^*EXLn(Uyxgv{u+hYQ@DSY_3 z1)`qVV+*51Bo>Xx=74`~nB5k)mzA}o07(1FCa{Ad5;%p~H)twiK?2wF6`F=5QAHc~ z(-H>}D6MF^x8Y2uPi)|}bfob)a0XEo+o=XvlJvB=j^4jvPSG|puN)uuJ&Yd(U=Toj z&5f4#EDkPH6ri#;2y8^S%#%^Av!yDW{)kM=qd{WAWaht819-QkBvi$M0#YK8EEf`0 zKHD}mIG8N0ER0HX;Q^;JOnAcIzwg%Ew4|dZ)MQ8^h}b;?1n~x~3W-55eAD4FVyjG%cb_?}rz29!N{P=A#E}`AF1Hu5dw*?~0FWnnF=}x# zZk*E9sSKFzP@82SUr81R+mCF$Rt!tp+5jc}k4>9BX$bSN3hP(13^E4OqH>aoylfrUL{!x>d*em?3>wo}$lz*itduZ$#eeV^>t0 z^rbH)uWGi45IBYz7m!B9(YIo5%N%iUpt4#nQ-jI=dMYN~bFP>d#NO{YWK9jLHn}#y zf0G{5rP$l&Gl{V9Tw)R=v9|j6G-%lol#f%Tl^o?gyxl$k00DG>@CJYkEDM$ZXaFz( z000a?14~iJ3|+7BV?qEh0}=oL2OLJG$Yi1lg~kJ6gJfVP0U-jw1V{(Me~wUdM35l> z001li00962009tyU;qFB@Bn)N3;+QD5dZ|k0{{WA0RRBV0KzaZ00Dp|fDM2M01N;R zSO6dZfB*mkzyW{&000I6X#fy_00001d6nQ`2nZYmAOIi;TywfHNvSh8Frof1?Y8Uo z<0J{Zk~w@#Zee00>d8l@x6R@|L7jkYpH)1IvAxr)l!?ihC#+k0v{@?s3J#i|o9u7KBOpcHPLIl`WLrf(DC1DFzFaWlif&@no{kqH5Ou^+y zDJ}T~?+LLFh4aF2D$gZ90PljNGph~pTSck0VjI6KAeccxFR;)RYzc%A6S=Zj95u56 z36UC!v0SVx8kE5^Fpj|-CsG(fHpK4uV3BLG;~4>dSJlUbOVn?gS<4kDOqfQtYC z00DXf0RX^YFaZb#00IC20000002lxa00004LBJz0OvC^H000000000000UK~Ccyvz z00000002zN6jpt}0000zc$TtLswBT~DOMKK!s!saYcWEjU>GXQYe&;rZ;8c^$>>id z{j&tgCVvCx&a=pI7ABySDI8T{E13G`6dQIAOT6Bwb?hJ%jvyKN9Xwl~HQZ2W|^CU*YsawAk~a^;hy-&QdZO|K4M%S0MIY1=FL8D5Ba? zj^;iY5KO5eS7Atmc^Pjj8UPs+AE}Cq&sm^|OyUF-LXI$lF-Irl5t}Js^XxnX9vvQn z2TovFEy)WKWr9s<*A!8V8piM>CVLA#CZhrQt{MD5l70<=I3q2!EtALz^?XzMmi^9H z7N)^1!w1RD^1ymnloL=?4{U*9;u1UT^U{!v>V0&^ixDY5+~oYf2t}eFQZIxfk4Zx} z4jy1ZutXS;ASOQU9biQS{zxw3l5tRw$cAzP!H%FVlzsFe60PCnv}m$Z$p28<~a&2?xQrkeOu*u};p@ z+7r1J8YV0};D*42faBA8@CY1~KzXj2WNK#)q@A)uPG*&FEWAddZj7a09tAro#+4ieyH7hblu zmCR!WK~xXwlF`#x52`BFD~SBqcK-^V!88#eb72lJK{GK_3Jc&7iIMJ(qKApH1;Q`F z36cm;K?8||0Y=?_MO83)1u&-MbKz8cMIAJYW5>QOO3590g=pTlA2cQ&XDIa+JhCzF zKnfisUY2bb^Ch43By@OPhE8+D(U1sToI}t+H-qAamgaMU94ZSB2@@p^&ZDHP#n8}D z&xz(oeZmAfCQ&_37FeJ~v1T<5NwwXW@011j=?mmKp_E}`WIA%}Qt&^YH)NBB5D7)|-vJP7=JPFn@#KC4nqzfOFRL8=HFAowjB>o|YDhl+@=tW9XJE7p~3G;0>bP{9L3GB5xh z5nuvt%_0wCK@cWl)ioyUbLjnuZmBxdrGd2;mdiyeoLhq?0ht2;^POX87yvC`hnV`A z;FU4Wy822pvsf{$@IX3$iu4MLO%@emy0irwlJ4{X*c~O>4}#GaUGi@xnRq!_m1VZ5 zMHfLruN>yJ{j3yS6lVv`O*|m%_eBofd3*Oli1B46`JYFw zFc5|S5^H6ST}8q#!Y$8)3K9rBCt5V`77=uE?xv9YgAv4|=+PGU;cF3$1|o&Xz#A6@ zgjnhb99|v~fM<24E;cUOb5$jeLD4NHRB{gWE!#vu7S4rKgHvd~VY1Q}UW(`-U&01C zwO;TTA{8rYCaUf0w81ofCc~n09k;50{{R4K0|3GqAQXv z(XgX5B62y_f*y%n068cjTWZvfA=Ml+e_{NPQOr)v$x%7KvXyVJcqIzsVYAn9oiS)R6>@yQ17Hta>GVW za$EzRpSEB{7q3?5otue)MsiXzl~qPn9yLV~?^8w)`n(-Va*~{S+b0eXFe)`wrE>Ja zCNzH>o2N-JN?Q)8YEceTc3GVPg@y(Rm_(7AT6Ff}|a zQd=OcMn^IwyLSV={r;iemf0QytKh zx48{@WwOiINp~YAkX!$?@5M{s3$HfxfZ~)L3|qUYmqYm^zsxz6RD9^ZRNr0eV$=oK zLx}+4 zcWYHIR^U8{RUzEAK_ERK`#xAy~(RZkS+(^&2ePRl=eka7M{|LUWfR+i2l!lrJ{@(upIz?b*p{s6c@%!G~Qy?(t4 z#42Gu{*r5)K5t^i`t*{pKG|RI(CI{4LIDSu&MNTtKOBZXfEE zA9Aaap!{%hYTi5`L+D56$$`O6#cvu0hZqEmaNX2UxJQ8j3wlu^lc!aYiIq!U`nrgn&hZcFzyC?OTo1S`l#+qIZAv8WB z7jnDy!F)UhU@wP+N``T)qfOI?C{{#ixVWyX`9w3cM zrju#LAnIYOlGTyO{XRKI0JL!)hP`%{4JZ~<75|*D%8i+D0h`#82|a3wx?TEh3{0+h z&(!X{K|8*-1~;m@JT{Wql*43D8ld=fVQQ_ygwI&8*5P6BU!uuAV_JPJYn0Ga@qTQu zsa7^zYqb0GTR(6=%^3fIXE;ey43TrxL;XwqvcI~@$Yk4^uqO3*ikIiFX3=j>^^0j{ zr-*zf#&aN7#AjqqsQ#0>Z_X5eYwnQfTnYH%iD%Mr-7D{5EdFff3d_-WS2!~nLcqTf zV2I^R|2~`n8W2Llv0p09&h0-+AZ)NA znadBK0?ys6RE%_L#7U?9ri&>j^0w)8v`EHLZt72jdw!qi+kK68Snx427Bo8Fqu zhrt7u=^ViJ4{v>wg;BFoZ#d&JRrW?^rx;vl4_(&$yfUjQ?4=6>KL6#0S1eezsP(l# zMwG_vT4XdX9P)?#zCXN6EC#pooHa&;K>KGHcJaV6&$4i%OwtMwtWePOJWyq#426p4 z9UpgySAHb~LLLCc97&-O75{ZNQNv)it!>lKHa9WBHEC3@LHo%xAxDM?)Jvaq_L|-* z=#+Ougcy^o>b@iZKLx;Bf^BkjK%XmIov{|KO#p2*Og3t6d&Euopq(-6s*E#J!b-%p zS;K!b8!Z?KBBaMWRUF|k&9ryfuKweDJfJKdfPfW0Kxv~{;lcJhixe;D+I`5{-MWf` zms)FH1ml5fx&`q#2qx=sVy$mBW-bGC1pZwf%N(QY_NN~r7(q>*)j*(olpVZ#&Qfv#wd;! zT9om9lI#ydGf5%V%^qC4m;F#k)p9n8nMcK8x#Vn))iun~)2jWa{=9B^q!57B%Ew?*M_qL{bVn#Gte3K*7@!32In0|uc1i*gvR z7T(`9Hh7QIYo6Ic!=>zn6+^%#rWQmGr?iR&IR89L3*1=g4QIqsEZNldqX4eQ%?DV5 zGB6|&x^v@t;R=ib%0@9z5CdPrc# zuI9~0{yUj;SSt$w25QyYf9vF(H;f1tl5!bxMThxINZpJFP$MEtO83Z0{Ngnaca`l= zs~vLPHq5NeZeq$N&BqLGH3a3_0ImJ2C1=f2r3N!eEFz>T0a-TH+DU^+Rdv(onBkN$ zbgok(CaD=%VY#yU7d&&rzx)JBTSBVmu+4POd6vULIEr(oHj0(lGbpn@c4@h& zRnhvvHlvcw>ac!Of6iZ8rw`1(qdRIE)Er<*42JQ3L4t-F!l9S7Ad)EDspwMI$g1sE z&PpGyGuH_lNW2~AreAT9h9oX%3uL0#=Y6pMSndO5e~VPDs|;4Dsy-xIOwKGmH-%NVg%-3>FuA3usg^Y9 z!Y{5^!aD*u^aImJ8nWw>j!u$YHyQ#y#m-E3RCt*6CDUaPf^uUx(| zcdU<#y*{d{(Q#1SHqc!JLovqOLaXA*jqghs>#}(JS6P{nu<`1%M=;+9D{V3a zHOqzEfRORVsTMWD%fAt34DbzRdYE0jIIc$pk6BQ#R(}1ZDhg9E`=1kZ9VN)~58N?A z)r*OYRB+x)EpEonH-wuPU-KzNt!y1cYghk_#W?P7I*&)^^Y8`R0J3xgrwYBV#R}#M zf?AD7waBDucw*?7jddqdWo5T) zC`B7L_F!!mDJ3k@g5;1qy;=9n2n2^Zd0GL!dHj5(Y5Fy!4-{=f)xzVQJxg@dLtL1F z^m$zLw$)AW3IE#!;RM^IT+K|cl+GrZ&f)@x!ZVuQqQ!v@CVUL#*Mfa$%93ahck2xE zEW`4F1eDzlB_GA6g#*vMSdU_!6AD84iyG&7T_t`=)SEVqyi7+M5@M>mfMuG&A+} zSt2}UVjepbORI#sRVt`sgH9a|MR*WQjCe&r0ViyRWr`M#L{h zr$x9!B?yV)Rxt6K(W3)VHcM`?t5{^{^pAxtsthuJO$=hK26jhPzqWb`^ydL>bzxoVvycDa5( z@#oLtTQ&n2JWQChy_P+yOm0{Q4T0%6Me^y0=k|_!cwE0yS$bOkB+fD)d8YM;7y7Q( z#hhlTr7#F0jYNZhA^d#7oY7u8hxj~4jvSvcu)uWQ2%A)d!!x@5>}*ns%tPo(O$FG; zv=rh8l+vF#s1i;9=4Z$_W(1La@Sqr3*}2Jjo8^}?4(GU7ZYvN87(NVV8I@35xmZ60 zRKUE9F@6wF+{H}d%b+=4_sx=mtVQK1>|rJAe8(ttnw1?uRHV%>?#fbaS!k0Inf=G~ zEvloh;Bb9^Go73PJxjrc{CjDOZ^$OSvUFCf;7sF1Us|XB0>eFyFGpNv5n^h&C%S z2e$=G;uL(bOk*ONtkXe^C#H{ynf@15>`6cfYcX8@Ss=$Ddi!9Wbvu!X5xyolDa%OlV_!!nwiux(?9B)))gVYH1`!!Nm!ioN z0Ov`;{nlo+{9X>B2W)+&=f7?QAx!+JQ6w_*{!bXd@3n%GnIPVWAQOX*9olYDob~>7 z1B&*8{RIt5$j;>J1AHJ96sGupaylPZf9N-ol>og={&VuN!9u}OKq0_#1X59~p~Bz? z4odvLb|`2AbM{*)IEzgwPpp0@(oYne|4l)O|8MtyD}s-b;{P`MA2|SMlaF-7|JMl} zlx@P!jRS=Oq8Elr$V`>80g-RCE~`znZpcOju|cXVZ5=j5Y`_ozM~mE|6wDYh4gIfH zyMvOo&6)eN4o_v*vzJs_6&3MUGHl>td(E8L0sO?u!Qfc|dHEd~F-3xIi0$uztQt4w z&n8k>A)%>J)D6!?jvFp5=i#YZYTds0gh_`M6_$o+!SMVFX>-WsCGfmZ>)Qf)H14c< zcKcyDBjSb(Xqt`4QS>dUT4HXuVO0|>=iZRTtPEUqCn&kXqY42!X)4DP`P^%i#73Jf z5uV|`($NUjK7Urv(&4c4b=gW~ODYwg48~9HNov|=n`dhw2_@fXx&IoNgb`zxvb z|40Ljvjmj&-e4orO}AdC_j+Z7m#!>yP0>uRp6bSY6By@BpJ*%fT$UTy+B-CU*sKr3 zJRBkz#8{@|zy*SWbv|qu3=iywl7bHWPon34UorGY?(PFQY|)Pu_EB?w>>uWb`&edE zCdErV5ca_f1Pu)(F0(@*4h1t0^=PZX9`#gBoms$>&m6E$Sy?b&9JRVsDCzk@e%!!> z|3ouVP#M|Rms8^Bm?R~6^8+usByMpZS=(T6(Ajx_L&?L;toyE97xVYOv0|IsjLnN@4oBB6x8;F_lf8WIDg$xYg1s+A7$)- zE&@t!TP6W$MFvq)f_zVHYXX*>8#wn&Od9R^nq^uZ)}jdN4kA3Pis zfQ=w_1=`FDrg6!@8soy|x1h|y!6w!?C)YZ%g{*uEsI$09&M?kEXhMeW>4p(+;O8Uz~QBi;fObb~9#+h_M|QP8fhIv`Vd z#0vj?%BEUp$~gjqw2Nds&Aw0w;YB?in_*mOyM2N=bE@s$k<)}1vZr+K7gmK#nKe8T zMg*Y-n$pt|UkP}YuH>AHT4GW+4ebvwK3r1%$W2x3{nkQn^SY{oT{8~6x+HHpo4X{c zG%e$AV0L4VOM-%{gn8gB2@FQY5LcZnGhqGeB(+i4g2)1l$qd9dHQ-cGwf#9i_D9Wk z9=j&aEm2RMM=jLLp$uT~`hgNH@z1+p%g{Bu+fyWH*pqpJp*ieB#hCjY3JsK+Z-bap z@uijhR4czLL>kmlCZ?!!iNV1BTK9;|aS^gy+$kZPYfpsySF9i6#Uqn^>ZhrY;Bi@Gj8-2#2R25WHuR`0NABK^N~Abfn+-MuJ$olUdi`G+ymRP15!|*4-~=oF(nM z*iq?+6bG9R*tio!I49HFQcOyGs4x)^qJ8KL$wT3O8X4K`atC8jG>@M5iv2!EIrQfxinDfSU!;#AF)l%YfW`^ z&z$+->1d+pXr~R?can~(GkTdp0&>&N>iNdRb!wLh5bCMT&GXdN`&ZdV;sB~5BxoRT;rhPpHTj)@63?J|tYMj3OBGT7$LQa{S#*8!V`;DK#Udy@ zF;+dPkd3k%E6pZu`hkJujPn@(d56wB=BDy8Jwu{_rhrMj0#~z|Oi!YX9H>Fzl5{Jt zCZcxHQ~i!0V&M)_o~T%gn128r&b#xkR(8=@sLU^(_PUNQEe5qRZdEP9cEse@FuH2a z17Omg4)?S$keK%#;$#qc<3XoOw%c%iLZTDlZF=j0izP+MSO1fx->-%hOZ9LsGVb%Y z@0!KQ15F>udZRDk$69RJqkw0|Al(%ZfK!MJd9QDwITrMtyag?pRnX-w>{-Y%)E#mm z$5?&hp2V#9e7e^+m6Yt>V~6X-AC2^|P_{RQ(l)%E5i^PpJU-GN4}HO>=Z3E8a*fRokrDAR%J;{z#WxqArMto9^i``bN{g zxV9}mb28)NfYBs-3bvK7-qQAd2WIkxKJu+Ei-tHU8;)w@b=lZHZ3>%Yo`>V4F=L(e zIfJff`z`+jD5_QFz74>O(YbZGyKkyIF`}FFcq0|&G@gN_g zlGl6R{JrRC31V`XlbUili{71&O2fo?O)+rZ1eQDd2K%?KCJ#Iihxs@7G%@mR7l_kp znHe!;d2r@l)__p6DCOD5pz8g8B#iwho1U+%%S;-BM&_8!=rF$K*WFuC1al@v-iYI1vY2jnracwk`mmvRl-S}#v&kkwSUB(hXJNq8cT8Ruk#4-`W&@B+UH zn|ct`EU{_1>7eWd7A6tJR2<~ycdmOqPUdfjQm7K20+Zs($CfhqdAL5Z!DXIsJQ5xgLHR>qNxMul3`~M z&C)@XaKK~*ELi#as%5J0(~)i7%mOB)ma<^l!xt(-?9T&1i$_z!#QSr|f}L3iBeZUl zXD^Zi>k>m1bx9*r0%}irTwUac#^{FzB>A^K!ffkpNux&hByR}Z+Cmd`OL?3((AMp1 zS>S1weqY|(#=_ByAKxe6!#4xv@ILV$TqpUyMj$V;pvCu#pxrcOr}N0n1$?#<$~WZp z@kocQ)6i>^a|$_P_S`m=-^%?bAjiVR3h3(8wbU7$Hm+G>ayQe0cOZM6XrTCB%cByD z&#Vjm$zMgezsu?&i`NGOTsdQg0bOQOCF>TeAwKWSYXZ80C&MQJTIS9M6!YAn zR2+;}#$c|W$epfrN^5)(5|dofX#G3SRcmf_v>lyLF_yv z=x*&h*tmFqZK|sN&L$ObIsErec24552o9zKIaNW<7`3=B1D4UWgyLl#_jip(jU$tc z6>7b$pH4kq&3vC)^IhdpaV0_WL*vZ$dpCqRBQc5oE7o6erjbY2G^TH#yg!1=##H6o zwOP!(wxQ8>45VqkY56fw(PiJ+7+kB%V^Y`lZZ*gUPpBb_XoUW}>B{!4k}y(rTf4lL z?=i#+!g1{&dP>RNAHk=zmSqeI5>Cj--e5PVVd#hSk`;RT31S{)5l+`2PB!H%2)$cjq_oPbtmlpsPv;h^QIf5 zqlGQoM7}5$U))G*PF8uPR~9+xZ|Q|DHi$j)W(RN^Ewr5YaqUnzql;?SU0mhWm*dzM z9l0p69(rsDI9ZI$?3EQs@yqz*Pv24ZEf|gQL|X)uTiU+pl`4q^;OwI1abqP!Ek5Vh z3E}S`?KJJ>5QgdE343}%XTaPJjY+UuhJgknN;)&$-V8p;d)uoCk8WG_`3cDXt*ksQ zl~UDSV9olJhsU0O2OO1_3iPI&HiBqPn)Z;)|dQ^OfLVpGNdo% z&|v>LE8b;BcP?qK+&h0+drnnm?kVn1g3~1P38qK+oRTS%!_UQ*aF#Ub0ikx|iAv*1_(s^1C?$ z{#0EO%2%{aHWmXmu_5)&+r#nzns3{=68H5aNlv0-?YB67y_|Qn$4Jh zg0uz(3+KiYXyQP%4i6Ooy$hqx<6&p}_0}}sW9>RTY4r8Mc={4k1|HRLP!`$AneqXW zYmCWrd8}#L-7~9z60l#bWcU8VH;l^ND^e6^S7C=zQRH$B&PO_xZr6{8FWP{b<(Io| zWoN+Wk4nt@)6PKJC;}~mh89>PRb9@lt1g-IwUcx`6cIWY&dzpJZWAC|!xpm}O~xN0 z1vvJwLoSHhP_<~a=#}upqF;MKqSj3I7_<$aYRr%nFF zhh3;u)QNj3#sxNK+*%#FqSq=5YliTPV2e0L3)nT70XKiSh0*<6nzy)@APe z@QLH4d8zxOXlUp*Nk2R|yTABegNisO49JGZWj@~L+u_MP6@qelkV655S97K=@efl( zqj6}rMlG@@yQKzWN^?X?LVbW|%PB%RVxh#bEp%gblj*;xfe-?NfE2Jv*dcHx{g^U# z!&$0f;y`?-LUAZl3jh?{MXw`3gMeLTuOG<-*JBzw5E%>+WG7x$e(j9h{UNY=GL>Fx zPd-B&a2La;y&zRqm6t(Zs=H&W5xktOvQmA^%gS57t`2k%UZ=fnD)4u0B$yfJ0FSyB zQv-uTV@qUo)u=Y;ZSv@p#B*hLi(QQ;wY!?Nie&ZaS4X4xaBPZ-+i02>yIT|gimkb_ z1tFVe_rOuyM*Rp``1Zp93IQHzC!NsY*G~yC>JZoRRQq?h6ryqio~V&b2=?N;8~7w)vICDZM^;m+ESVb+=@1??s1l(FWdX1WR3GiOwKyNSDs@$0cbb=B z;U>!vSV))&1A5G^Bo>D8HU1CGOVv`Cu$jBEhgj|Gjg z-gTsdg@2x}e__ma|LNjo`2Avx+fkkGDycINsa-DMz)oLY<4CL=kwSnzhN9q0p)iBb zQ>(m`t}k$O;dG=bght@$i(*T2NZ?y+(5@3zTj&qlRh0{-DR?eZ6QV3$C*G8g);0fC zoJRY`N|W@{CVGi)W5BmALzvs^{YPXaosb@+NWYYX+ey6iE>aSE40*L;`>$e@#3d~% zpfZXQS_2?BMX}4T^w^>v$Dvr9LEM35qXaP! zzMyvc7al(P)4zU)Q`83MGCQejL*$@fYkH$a0-P#s6qnlE801uiICOD{oh`YOb(kFG zVuN3CKkw**lw^T*rDZbFw!*Q167YzoaO4+xL?b()yzE<7|T*SE^Jas&4P;$d3gcB7qA32+L?zrgJoSy zFuFL&#HZq)ZZDne9sV>U{3>Yur5*#KgFm(5Mi}Z+W<}$fb(yXJzWXS7I?SAqpG4YO=`^J@#E_%+YhPbtkKs48GI9 zCvU5SsEfX}dm{D_*%uVhq}qCe4GOl<1tSXo|`+yL81)QE&+gz32qF# z$$|9cQO7bS4to<{CgLJ6UBC>MrQIrHM#7(lX8Q-q9O=m6Xt`2vfWG-xKJeGv35TFU z6`A{N0V5m_@sY}I%T9i8w8gdi1u5(`T;|*(otf(r2YO)>7#zp;D^Gs7&xVFHLi6=a z0yw=26O|yj9GWm%^{ndJ(@u-1!wNV!!VPVG0lF_I0wYE0>D~x2c8qTLIiTd+?gTFy z2S#|^z3swaot5YjVKmKKt(1Y5aH@(4c#`(OXSwH$P2=kHI+x?Tji>$R-7wY`yW7ax`*jGAxnJMh%C7 zgQK93MQ{R>u#E*yRgxMTxXHl|pi-2%Y0{cnRsxDvz@nOoJI|DYB3iO#$svdeZqpJ(BO48*fCE7i zqbMUG`$%%>8f7Gk67m*wwGfh)0fuw$VyGn98cb>6zqmrcLPLgX=@h9`%g3;u9)hkbw4U)L zS|5)yIlLx#<6hLTc| zAVyqvAR^-W+CS@h1{qdR|Fz`Tt$I`MmE|dm-jSCElVM$M)BCy^*qgkuV6yWt4vXAF zukYqmHUyHdmRz;uu;Jepxgh!3rzJnfI??)e41&FzG#Y~^R-Pl71F$TI|Gx9eM2^kP zbD8Iu5QQGsXeS2>qlP9S4!Ati;&$;d1mbh*sdOy+%9}bBMCu}?unY&+I2jFr7$S$O z2x{+ZoUU_M+iSxBAwBhk$Y30_1%fgh=p1CCreN~G5zkOvSCaE+5mn#WHzl8d!@1JUK(-Hm+GWd2#+^bOXJxK&+woE+>^R0!~ zf#o3*^8_(-CG?p0Z_M>3;Pb1(=KYZH$E)%~;{{b)fZ?nI&h?H&vl)HK&&KBp>%6)oZ zMV-%xChKoaImvXcn_->GfUn8~38h-lD4%P(e~yK9~i6W=HCq)G)SreQ?|=+t@( zys==32N&{rVD{L942ZJ&p9lXVD^w|s{Gb*{4Tvx%O#|u~sfsceVd&ZK z7#6XjdSI<%G^?VxSpGO1sl>K-zM7JYr`+^l0V}ltHafit)Vmq{ea;4){Tc-1&#q-* zv-B?Y6{%*FpXS35OPlIr!hrQZ5LJJ7}Dn|g9j;&G1D@B-tlJSr{SzYy~jJy4}EmZ(l}3B1Z3d_Acx$CCv{=sK`nJ9iF8sz1qM>#MSpBApQy;7?uOD33@tI~sb*kpcXX&@c^nAUSKJVz4D^1s zHSm7Jx~wG#kOdjgaKaH)RJ+I2JTOj?D;B5CNHjm+wGvccJ9ZVKCI)HrV=2J5&3fZr zupD+Fp8ip*pwv7kG4e#xGMM^qp~6Xl(_HkK2IpwCfSj{3L4SRAiPvid4xkoOLx((--ZZ89TSAs*SuS2XC@s?es>R6&LFEy0*6<9?L9 zz%B}}PY7Nl`}J>nD~5}=`P7qL-S&_KV zDd}DzqlCX!Fg}M!-Tj*kv8gI^I4hxqd#UWl|l=x=yvYsrs?=62w zZrP9@`e?*j@;ju;S6zK1(E}Ce7L_nkFpo1onKy zfu<6>=+py3JCz{0jz4fc%|lmQ6h~CD+j4Llk3->ohnJ=_QTX z={^Z{L`bYNsh#de)c`9}3ek+2N4!sm`09=DfEz1;^n|T~)<0wg*)#NSwsC}K6O4A_ zDo|z1?7i}f=x}(ZanE1D2u<-Zg>v}!BY}hyzlKhxAHL^HxGMngXJ-qNeRF@YoAb*( zpV5qnuW&s`!K(`riHIJwV;a25$tmoN6X*mxsd_&s+gsoi<3^<#1Q-zRp7%dL$|0 zvw69i)Me1Ah8izgGW@_Y>s7JDY_CQW;f`YBg!Mt(@E2>MI2WEIM)!3w!Ae>0I1O z!S(i%?P|`5e3khz$vj@hjPU8{2_0+La_(wc6jeH2>U=pi50CY?8Zwx~QXP?^hl>y5Mi>3#TtRJvsUJvvO_B^^xdGQ!Tn5FM49fV>>1FwIY{DP0 zO%VBiC468!o|U_g!&mV}NMH6d1}!|Dn+}YPz2ZiPdGQ%10??}K8HMWlc(_7%}os{K~S06T3 znj;1Y$d)#mY@K5duadR z-}Z|A*GXuDm=TZHy6n0*Hq?ycRTREv+rnlxD%i0VX+Hujl3tAy|E@OPYy#z&p8tC+ z2OK312y(2WR*hT1KL|8O(dR>?bVuQAvEn~?8pcFoKTb42AMZ2K)x^C=JHg;rm6mj} zPF5r)#mR!lYmy9?d(LLaI}-qQ6N><4ZE=zfUv<QrPQoX!n4%ir1WCbH4DBrEEnT9ZT|eqdZ)f)1t%s*n6!6&ls`3ue-^kQ9QQq#WOv!zUI zLy(2&Ei4Q}%GtYuQ6oP1v2l=vAYPrDj>5*eRK7xfd7e#3M5uMNI;RCAKCPEbp0AovTxE{lmv{NikLI zYr=MNj`$1?(Y6WHJ7{nD@LaH?eO(YTDRuiH4RvzNlm5fsJ$_xz!?;=DzMs|weXg0g zq&eeo`JPxQm=PasTh`hT-1H*v0IvqMsxO|fGWmh2Z2ui9P$82$kBa$~4*b;dbmfq^ zvAw4ghT$Y)q&{9P`-H-ZxSC4Q^9P$@TaxsB%WAxGja|LipIavb^9z`)9=%}x#btIA ze|<{+4g@GwU9`+c0-#C`kgC_~BaAp0ds?dMj`}D7rSvu? z6MqZqb;8Rj^oYcD()R92kleVDjfnK=_x?h;HvTbhN(vn;>Bd6Bgh9tbQ#GTf|D5;T zWh$1^H`NrHiC(>0sybXN!n&?hU*5dr)ADWgY}+N&NIBm*z9bS_8j-I68$q_59giLZ zE0bf6(c#S>)B+TlwyOY1Iu0JeQ!Qv0TSO!K>$>^ZiRmQld~wc<&Uuh+b6P_@DG=ou zRBJD(?*xiM@La&rT2Kbnk5Yn=oI+WU(0ZQoQ|#hk#zkforCQfTpo*!SrZ$I1o?;H# ze>C+V)k>5;#vHgI!o8!ADDydNWlWZEAO?JwAHQIhLWUv{?m zm9mInTV9GM=#`sz6-$+xw%A6+y*O)06D92U8dJdfumMYHztca%I^jw!$tIBQj=_TI z3;u<^&8+O9jl|(1D2l!*0HvWqK>T8SgydQs?oBja$cGe}uEf-14Js8AH@f%dP=vsE z1z9rP9$go5oC>>C1Fxqtb)^V$%US5_+J|Y9pH>IsS{v`zQiYK5&;G*gQ-M zsMyGX!2dS?2TKVB_0#~}^527xLV`OI<3rF7`h7Q5F(okApKr}282Px=g9t}=e;01- z1^=!+Es5rFO9DVfMnc~U2wA1kB}53;_Osb9c1W&zv|uZdI%0!|B*93TxpDu&jYOb? zAxzf{LQ_q2#3L(Di@qM};uA5#lu99ztKg5NFr!O|`C!MRmVJOYV9UXb|LkZg7Du5l znecbjcYwW0&>zUx`_W#2D){GvNZ)fIIoe)5f&Nys`vBR7;@FgGcS}f+Nbx(kPO~)% zd40Kvb(@i)Lzzp;Yw262bD6k=xe~ZUT{`_hz@Ix_;)S<5PvM-h=3|8|h9ss91QCvn z8yNgk5dljfSUpPkF}X!K-Urdt9b33gwqe31cDTO01wqxXV`Gb3!-uJ z_ag46R2&oI?}0C#_4@i-sMxl-Up;7U8!g#B(X}syfGBJdwv(WH2lKYk>=DRUA zMq4)$w)#dIIGfZMaHT&X3V-_JzwyOcV)S610`)7^=L<9b@AR*#{h1UWuuP36{OUjm zvgV2^n`C`d^trglU6_PUJvWDg>Sj5m{hO}jyO!Ag#gBEEFv;4!*Y;bKBDcd%7Ofy8 zUbx#Lvb{EE<< z{Mojm9#0>^%C$2Q=-9oA0WvjR%zGbF>s||!u=Jv-YH3TFmeUZDwL2N%@)9U{G$?UG zy?A)J;bf@fUNneIXBR&1cPFS+x${dL6q2(uvn`BN@UWnr!CxPI4-195NL<*+1*8(% zEBZlJqF}uk>;-;pEAcD{YE1K=?YLZ{BhJ4aeAmJ_TC}yR%ZF<6^lUTRAFJ;60~9-S z$&`ZKhM8T#Bz~jR0zL%E>`260$kh)H0!s1Y=Sg-_R8~)&GjYvq8th2W;hq zL`A4V?)2LhanWVW%6?T<;Ls$e5Ex+%YAU}dOoj|%atKr(`tLp)#pakFD6Q!bGoIiysnS3 zJ)j==x$-T&oisBo*-btB_yjw}#Z>&yi~HC%CAbMo8@wd{g6?=I!^At1hc6CcI#W%e zBMw~&g7YbYJmBj{^ZW}B2$E3SlYu&)zE4~wXligO>~ME=k+LFCXnXS_QdAI90knE5A1?)ock z)A__UUB9H;GsgCiW{O-V5iduRGT32tJpR$cvRiug*9eQlIWT=-9QLgXnx5aQ2O73&q@KPAClxVwPGMrP9jmm(T zR8DKQB}Gygp@nDl_A2&OP+70TH{*L%xw0ikm7F6ldf+t9^x!x&Xgr6W5r&h^)dMV( zP^5Sq6A08?oEVhjcpx8qy^0`rerk)nB7Z%qf^2Ip-!7rZTxzwhOu)_SKUp|vL^W8! zU}pBF8My1<{=L!=JLd&ZWZ&bN$GXq_TIY@WkFBFg+-<-=s63sAdDG9!6E6*< zldniUOfj@U%s6~-FQOuRJ4K-JBBMyp)ImJ>0vrh^WM(#Q8@&<=Z7HcuP8dhWSSs|) zO>a2=E>*tpQv!<1F9j23R*4angHLT&M(sZLRW4wUMkVw82T{>wAnmoOC!9Gwg-lcq z^IIoLbSsr4MGU(k-aw%p0{y1Y0Ba6Str3O5I`J8%b$M5huk`HVRS`x(Z}9GV9e>&? zXS!eMYrt%U{ODv2j|flc(If&TMkS>@bxpV?#mw$$> zv`#4;IK>I1UNcdUOeGqug7z>pNKshowvf7?|up@TUFPJmOE`7LR(@~Ee1??1hxG?rW0(^15i@v zlZG}QxDT!IDq2vK1sb>sHZv-ixEmA28%}3JIoy5IH-QMmY)O ze26%2=rODcs{hqUAn^?GhId48j{s*Rn1*}02zyvq6>%{n095gJB`IRaNa+dhSyvkR zds0YClewUHHU@6Q(enI1tRT5*5oDke)GiPn#mY`9>PK5JIS_jKD@W&*Cnx{_0h1S? zKvF^}O3NXLDJ3$P2n06KFqO+!8pUfAkXc;|iTz(85G9ktX1Q+S4QO2Nhqh~k{!(jE zh;ULZ=0}VrfTBpCB2GxW;==wjAkehw7t?%9BfVmFv=e5kH5CVo=|_SfpaQds!1zP_SL&MaaEeO`1+Ny#Uw(=62-Ol4 z_EL!&p9v?;TCiQ5&{VBqxPn)qXq2U|L=Z+@cGjN4wzp8GscD(2X3$-rw%51C6O?2Z zww=qFw=j|6TX954o7KeIC^q~Y4ol7?rTeizgt>SBf$&l(ADQrDXEIeuXq^(WaJX)~ zips?MrNbQ`9$c~TD|K_L$G*tXcfb7gYUjd`YOxVwIP)zuV(`5_=#WBTpj2|wPXCA{ zN(4V8SZf7fu`eio<-1~DuA+^tOcc*wHL8ncvMN0*@uI?|9BL=IsK`8i78?O#jH4_R zC!E5Mh@&Nf<9BqMlh-nx5k!v{hZzR%izLhNTc&2cpG73l+(|s!%oO7wn=X`J4l@RK zpxFsla*Yx$Hi|c<-U~upB+RGXN4~BvNQyn;a;dAGlvIjY)f$xJkki52lfI?0buwrT zO=r){Q>HHRzR(IT0T+k8b5nJBN9bBixPU(q5MlKRVn8|4G6am#2Q=Nr7IR(8f7J+2 zn}2arVuyYSF*)NSEb}ayB(~D0V!<-~NS>F4`F>8sMd+Lh4~v zlbUQH)=(+5?ld(iWJKXbGGL!iS>-iWk?W*KgKILJ9RWORDJND3{n!l{#fF4Io0&Qx zWQw-djk+wtQ9LmSGB|A1iv`C{7+8uNI7yq%NgER#nAUK<8WhHssx2irkV{fiy4Fdw zf}Guxy2C*sW-QD!hw9(Ai`BrRUU*Z*5JFW6rP8v^%Th`Pa>^-K2FMUrQUwBzA-H6o zS!I@UdqY9_a&p}XD7u6it;eT*8zeaA8#MPuI-T|0MC^H<=cR|e%137s9_uu6*|kYd zX+)WYO5zeouPDZfUk8NB278Ushc5Fy=}~ockVQh2lz5WT2Q%`q1X57Hl04&#ske%m zdnD&A89VHPSnQzZNo#7DK4>WxZml0^syzD_50*0|nTTBa6Qcw?pt^*7S^Pm=`Xl`Z zTrPze+shoSoTw!!92Z$&gF1F)0G5 z<>EO74m&%op_A;G6f+Es%n0*P=#Ls`B)%X7F#<i%*n)X+<(hST+dOFCAa^puKR9$3>f0MZrx?kgLt%{YDSq zve2=Y!7KLvoX$V9kOa<(g$FDh3;!=ziY4#JzIu6Bd5b$23o*u7cmK=xxnn1Z`;R#D zPuxs$5PGNo#goRGDk_gLX|e|t-|cKysehS`?a8}5w98>^w3JKTL3zhvizk7cu`?9l zXD%rwOL-RA{K=iODX+`TZf*6sWjMzKHs*LO6>mgARIo-m`jnPyqTv;=m=sO0qK?Q( zJj`1QB(ImPy|JQdBEwD&J`y$((RjncFys<5k&oYX6Ys96DFrGPrh0HZv!G9C@XD3NPt4fV1wh4mIevApA)s3= zLMnO$>0}lU1L4Q0QZs_FXed}nVhl+TbU+MhQiCaGf!`wCR7T~eO9Eb<$k_0_X8J8# z5utX4ttv7&tnj~;5+|cz=GBT*MVVkN6$mhXhLo%ilSm zM8=;{S?nLC)6IvUiEvAw&{y5>rRr-;6UTA zbWt8Hx5Tv?2(d!@$Ul-$u@7oLmBpoB~hb@vO#G<1LfDIq}69^~dKByE9JpsUY9PR3ts>Y#KRP_q4#w<8S zVMrU~i(D5nBd5}}3l{j66SD}dUQ;eUIp~=~ex2`mA)B(p%D%=x)><7hdF+vq;l8d* z_6$ACwLtKm#O&7LmlIjz`Y#$|=H-FGjwc+yjM|bq=WV^lT!@V*97?TxI%&351^q6V zN6n%|pudlnzPtI)f!Qw)`WLF|!yh)klU-3_;jE#ex@>Z@yQPe^0m_QloVx@g6f~2E z!#Nhg(@i8DXGqIs>+qCep*PlxgKVOTM0lH)h%{PC0k1`;oMuIGdzRrKum3#w)(U3I z7FE(y6??YVo#MBUUqZq|F|)g3SwSjPvgy~llts?LC?ffbFUufQQAOg~crPS-(7vZT zH|68dF9(_fIHmcbxmK`BT=dwOyawlof3Pp%OckMPNkW{Xpg^KQfoE+EU|mjY z&yzFLgc`K3JSl1f%xKsVfv2Wob`Rvn#tn52|MSLF7Bj>_(SEbbqWPi-<%Ioh?HgRt zjgXjfeT1XKrAieiWtntwI%wKB1PMy%QzE;dAHIfEp22QoO$^X?e9W~Ah?8MZC}ORg z65S#qGGgObFwEOTnONpl2R5WpVEJ+`Tf1edBgt$GcbA>Mpyk6ajOJr5e(eG-UqIpQ zb1WzSQA1DL^*KJTMHe*=FD`#T>=bhTq2wQ9C`*j-c@q$2r)&ObqD;(xIC`7FxyDEq zYv?rzC-?U9$I{qv}T{EQ2|<&3kXdLfNdpF#I!vm-UQ6ZbqceFT zATqy%Is3~7HuJ4{tz1x(!MBdYc3e4I3NUhVZG+1l6{QJb^$f8)o5q180BpMxN+8_3 zfM;J9Se19>bqOAS8Fzw@VrA^-QS9jt>u&Uq&KW%K1jJ`|`*$K=hHTa%(b((|&e$hF zBmJ(`@L9z#+HK_46rHpa!F5>+JS^9e`+vu9%d9DD(yM-cXLTiG1k6{2uEl_;_C$dh zUkuHjTEx|pBJQQ~W17-Y07d9$e;NpB6?oz!u zeEe(KP;AOx{Xj+a<-yB1^!pOSQP?FHrc@Do58SWdI9BQmc<^yzUn$vU(%YGt1Ph!? zviW60r*Pm=c6F7|spzAl)RY@~U^so|Y)t_?`0U zKbW#OS1X0lv;!l($EXbR`zkJ5KT7!a*-Hq1+nz?CnH|938;xVo_LvX++@w&>RQ7ft z`zX)HuB|VJaLegm0WtEwxz~PcX-=M(hbt6s7IA-W%4tVcKF@FG7Bje*uP6g^>U6E5 zf_`LG%hm~&6Pg6K%lT33n}Viu#HdJu7sf|t%2y%@=IEo3Bvt#xoi6v1k_wL&E``4q zJ?mP*PAruaMJZmGrhHNN{}S`FsguLKg1BPu0dLH#S)$npD#G{}@rBb63GBNn2g!UT zyjkvZI>AQT>1AJ3fHTgp569-9MieU`5T^oF=ol@I6+x-vUL_hZfx@!IyI`oTSz#am z00EheprI`y1T`57I;b#{VJS$bL2^0${E8B4tqOWbG?I4cxo5qwVF#g3VW(|Yc~mi0@5W4L*U;E$c}VC+ChJZRL>MDP|1KM zn7K`fX`(3JxB4g;2%JiU&;z=61y{T#38;TEQHcH z6G+~^fw0SYrx6q-G~?R{81*p7SS4epXI7v{#3>WL#S|W1jW-tyVEjSDM(ii8Lbbx2 z6`+h(ai|_bh1=74a@Q6BZ2j-9Nd%Lc+~P%`m?mXsY4Wlh^;XflSXm()l}NxfD3f8W zAz(bwM9~Edwa;?u?G9E2=# z6AHMgeg;abRQfmONl`P>oKO)YLV??fr^PK|f?Co>b1q(8sG77&6Q|sL=R}nDK})xv zUP+Xq{z*CAHt=Y{8;5{^MuoXPS`CBCQD<6ZAjBJ#k>Z#v;_Ui5n`R(5sR|2s8L>G^ zm)_IIHm)gWoFm^GQeC8r^%|-wFc{!c+~r44wYNl<(OMPJ(sF3K^y--*_unRUs__MF zAq&Bj_%aRUEUG`Y)9j>sND!!j0HYXU3TifTE|HjbeWQy-f^n)_F_mmlhoKNE#X@Tn zjTV>8d(S6dkvh5%NAv_UIPyR}K7-wfrj{AQ@Zo^+f)muZ_S zkzVx(^mg8f>*ucb3*F2oO8Tbxo_?-zD{j(mB)xw~o5dniZv*@rg61p4Cg zU$?&ll5n;7_J)MhJieI#m;!#jwMdFe|NK^VH!S4>#;L@sE zOE|mBtG_&3a^Icq-_h1PFP0K6?$63zT&O^%Z4Q@`PwV$5bNozx1z6qaJx!FJRyj$x z=U0vYoxAV{0A=2L{9TN;LgUpaV=79KN&H{K#`2MHdMp=kmvQSkPBXnyvgZ=Eq;}Em zyfAO7XyeOQK6FCEG{t;3{#MgK+yJ)iyDM`B*Sa-s6A9KTs2m z0T4j6Eh{!Z>ob}(a$$PUicQd6_dMwZXSg9$0*8k}kkJ^7LJlzoESy63o~BIfAcTWN zQuuHzaBAEn?_YLNfY$L5VWCW$F&J2i93+#da#*9KjVKKC1Y?jT@w$}+oJ$Hy<$*{y zKOX!(Ts1p2I+qTL_W@cI5uo76kNE0Za%TS8Z>L2b|4U=T)KRg}A(7d)ylZcKB9pR6{6-61vX{1Gp?8p&ra1U$ly_8#i{Vfl#rarz#-~fFQTeJ1su)?*tk4_ z&Uj+-7Jd#8=Y;(Fct98sIrzb(bA+w2886nOt#5vkPc0+Y(Q2bX9W3BwpXLInLz3uQ z0YH1DW~8$e;mq-6+)9m`*Y3zL}X4ZP)JO@J@^NuDcU)(sZQ<_w&4&?buO`U zBJvt~7sw#{0X}vVvJ^mP!T_bMvvL`*S#`)qfm~B`W@x;V6x&7hflj%0)b#)L<-5QF z=P-Ckwm-VH5U4f-8Efn19^{%zr5^wwT*5c1QGhX0h}|qk3-hV!ku58!7aD`Tf|CG2 zVX?8yO<_~3wNHfGqk~bV!iv1Z5Rxa5b{8Pa%#fwJG=7S~1jT4NGLg9X!V%fCLYi@O zzXCG^m{*QMV_UA%E&K@wyh=_!4 z7gFwPJ4RYWWA_4%14-xiP#QQK!7`m{EyG6Bqr9j6+9J zBc+g=OLCTbiF)X$gcKlz074b2lS>ewDJ3$H2q=@1BPxg40CHtAz^z&tHz*R@T0Z)# zJ)qFF_hUDcifvMCQbi2j_JeGZS^73bT{Wmpw)Ji+m5W%~c_fNNI69Td#2})UDzQZ} zxSZ&aMGMIhKH_>Ed@IQ(u}Wnj2xO9RO%W{Xm1JnqzS6)dO7ki~>wO|AWRrap2_&%y zD1jhLLbsAZGGbd6HvmP&2r8wq7AT;Il{0NoZ!|*@>}~rXONIefK*W|brKWAS7DFX@qQzcmwgDjpEkYKoK}8g$fI=PRF6)pXN}7p_ zDk39Lhd^LtoGL7ZI5(P&*u)f|A`v8(btLX@pTS^{i-AQ;WP2veSCPot2%N=_8KEVE zbvdF(9C*@K!x{8eu@S<*jUov=Jr`zy*XpdPWtBIQPuy4mUd`6$WwBIOOS~tGm)^eC zAq*eW%y+Sf_U)u~>=^!GIle>AC^^P2U8o-7(#iob>Zfp-+5R1CD*X}2(N%tzuD8O< z!?O9=fBjhaQ~%2IsHt@;Bt)a1BEN}?A(3Q=`Ah#7SmLN%J^W=)$yye&BbSvL^AV#3 zoGak#5YwF#ZFJcAfv+kKGTxL-J+&o&xQiA%pFjUiJUoOTQ_`0nKg}~3sJOH$+#YG3 ziFyXD>hio(;^l$-Hb+at$lOq#tTbM_)RAw6p)Kw&^5L?nKa%Xe3?f^`I=miq18zWZWaFoF!o2!&b+f;s~I(3OKYW*|!c<%95TMoc&aE#7kJF zMz1*ZCtHf5vA>AuHA<+lX83t)*AZ?J%ZCRQVft`nX2D5(RIXU5 zx$PhPmXjpk01JyN5ISL=(D*Gk~v*_hDM6y4Iq2zJH~qQ zDSPswk_qi!4p)kFtg6~1eF`E<kooYWu-O z>1QNIrF32n08=^-;HPw-Z^<}$DI6c^WF*0@B5JSmo&4}Q^Zl~r%NrjO@evk6FP{sd zgY3Ge|1O`#|L&*s%K29epgui8Q$9-n1}=Hna+d}(Ty2=iA+gD8B9Zb>@CYKBO(~0T zcYLP6KeQn-h`fb*crGRr8-nWsi~(C-Jihj^d075opyrl+X@x!uyr{6{>; zDO@V`I^KzTrocU8%kks6o@Ey{44Vg#dz6t^SGO8-%q`r!I#+m7zgBDiGm{WsQA>pI zb!JE(`F8Q!enH83G<=EIDulK(Sc9WYYw!zPh^DnC5l4;pSdPM%j z9|(4QPcQG6Ov+iV)Z2dpyYlEdjPNtHBXr(+0ts%gVr) zV64`l4HqwC+P(gK%!{8kn^SU-Cg*3z$VwO6c|F%PWvs_Z1~R-yz${b-=HdG|c_N z=}1!csreoH9nOH$(amz)iy z1;eI&-l6dMB4wO@Go;|@yU7*5xd}d02-Z*~9pHja#KIKvo+DW68WaM}oof z^8^@i2v||1HgG|h$XI%3G6IJPj4CHIL?lr~7f7Qs(%n=e{j~2nRCqv>ErgTpJq8!Escq`DR-c)KXtMvxKb4YsDbwJYCZNAF;$6{b zl>}J@MMUe{x6>;$=Y=f}zL@Z*1N_V`AiVDduTAFR`OnK5WG=zK^=_TT)vW5vsR59deV&q3=fHEwIWx}ztWXnN27JuODDs>CPvi55f%%Ln`9 ziF}^MIT=euv&`|N$fp=*1}Mr=d$@xXLXIIzG9YMs$r8bpmrf9ShD{~ak!kvtme87d zmC(e}^s~F3na?Q}^190(B<%4Neb>`fX9QR-9d1lUawc7+RVA>8NaAGjY?u)vR4XZO z=##GnltK#BiCv;8t&?`?86(>z?8u7V%pjA;krWgvqL8scg+c%JUSiN&m6wY{l4*$T z;|g8<4rM3F*w>!2>3ATyCaazrXD=(A>|0XV+DY&>RY35T_bgO&bc5T?bFO@N!=P4` zcUeD|6f1P0#f&-kxDY8R`0(5}42s9luw5M^ca$X^lo?p(kq2dFa{PQ6m9HyNO@eCj zK&Elbv=Aeu*SK@pTY@}tywZFdR=k|gUZ%&7`;!Lie+h47^pnB7$_`Ks3xu}VcQe}% z@nxF3h#&!w;zrAVen`{t3@C$$N+!|#7Q|dIA*8Szb4&G9J{`&@(IX$LawyD*^#Ac27d;^I%{WKKt=zY8aPgczYjE zgjt|hAow|AzFJgr1v9(WzLXQ^6O~Ytw6kf19ULcu?iXaadQ-UJ2{?C=m zp=eKRftMC8c(b2Pxdcy-i_JMedBz>zE0n($`&g)6asJQaqQg3+&EqY0IbthTJF4vX zdGV@xQvEb38=ER)sg{;&D&2oUqjMJub!eUi5SnhsxL0`1G7x74xOv63KU(EY&xHqq zi&MGEq(RC3b!OCqg2pVfgY1&M5klGvxJw|xKB)nyAJ zgG!mxWtqN7)}xdi(F3Y?#Ip*-m`8Tkqp@9=QnV`cTU<#W*%W^T@q0+a%_yE3*7?MB zu+|F8<@f;>87{XJ10hq}%Zc;0m5PJ;w}t2MY4nS|=7Ve}M#*=$bXdlZ2@@dEXR;#{ za?ClvKd^#CiMM{HaZQv$CqP=wLM&t{EmLJQS^5#pI+0C(Y@S6lMXRJnlb1)SD?ole zKFFy*HksHN#plusKF$|}RI){fl;X!YDo)@(apd2?m=V&+&51IeXf50|_hWvj$(;mpwj=gJ20?{#-oR z(93?AgT+71t*cU$D_4Ae> zGt{m0RmCfX764kDH^y3=eF(~fXxk@WBE(;^}wQ&<-g-Y`IXG$=NW8wDFB zm&X)90}zCV3eiQ85Q+&BE~C{R!@230004@p&&pU z1_Toa5KaKcz;rR`Ixv9{2@sbYFAzZpkO*nOCSj}Co(>Wc$U#mWQwXVJC?XsqFed<5 zFoH@s2;PCET9_b1iH1j*K~+N%UR1my+n0eWDG?<@NK(95s9S2V^j+?U8!7-ICit{g zVwoN>$chb47*(Ju5-Y19XXCvPOC8g6sRR(BdcrtBB8ntC2sMiU*~GPx z?wLKQL7_ZjV_ELFVzP@;9`UzQtGU%WBgxM-z)sX!Yr!ogP75f6oEtx{hQ`vHK}@Hh-8AQvE6t)Rk~edtaOJL}OJEZ~M^)qnFC$H? z@On+@7O319U#Vo_%7&EPUTNx2N$)C$*CBX<=$yVTmiPbw0ipyT5JMOM0KfnQ00000 z00093000;O001690YMo6Mn(((00000AOHXW0!BAoqW}f~00Ke)00UlR_tGLl)Vqq~YMGS%T-6(Yd}wrxeudOp$eBLg0QAd?zGCQ`$(zh}Y8gDrSK#<0Kv010#+ z!eIG-h@LP;I$}5*P_IYtZ|rsQeb&jB%`&Q*X`EX4 z0Olduc%~;jxjM_m|Ljg5$JPn$w~JsUWQ&vW&T44-Cmt9ZiT4b_S(MLae}r{Y&PIeZ6drgKf%Sj_`>8wt@nTEx}`a zd3Vk;11k$%ch{clbPru zZAG>!NClLWOpTnQV2Ut;!2p~gF5TOS6f8?2=Tol0oioNHzcfC+3j6`-();$1vndK`$h; zWpUQ!I^~iLP0XCZ4XD8hJ#F~bNu5F{YBfs`K7~mxfU+(Tpnm!S1V&=)o_=|2w8d?f zoQfC+g%|9c7g5EFAO?Y5V$P}dDzpWeWqabqOCMn@JUUk8*29Q`v3*L+hz6!(Fs+qI zCWKf{q!<%G3nT;5p%(Z?29_i20$|=id`Tx>QugjXwq>1Zww`bhEa(%QH`&45Y!wxo?7nf zQ!h}nhY#t|QchlYO6dRP&^ise{$g;5@7l_Ffz4K)sd~48!aZhNY;=>%R7M#tHOdtu zGu(u>=QTsAid|4W89qZ< zj4HF`5psIW8}q0AWCA41`auLc9T-&`Nu}$Ms8GF?>fFB2|tZ8ek?`oFhxdDM*i0;38I%-Y$MyKbrcml!t*skj=3e^AK=ofO%=>IWV z)o~4Y!e(%AU{IBKPL-*bEjHKCiyQT^(_4va0D4p_ zNeZJ-Hl?q@`? z00E;D_!&e!Z6-o#va@1O6DfqC5JDuhbHvJ|aI&0rk_iB$q8x*-*S;6#Tm@^pxK95XfYRleaqfKm=hHkI$sS z+gu<523|TQ5D53H+)G7&sv^D@RVi&}lg!mjG zJAdYINoduQsIduDN;1nBtd6EEk6Wdp@ZI;J5OCo~Hog#n-vwzUR6<0g5-d)B`uJ25 zS~sek8##Npg{eSfke_0bDI|y}f(j_dnIm`)5Lyb)R}f@^(?-|A049sUzbfDcLBb%N zc^E+8sSe9Ri^@DZ`A2WuYK%gPD591L5JY5(ErA|Qf~TS(Q`4P`ltdm81>o8=m2(IH zu#v-r*tn|Wdz$it1EGtHsc?U`w|EO<(;;H(frX4B|M2;2S$J}{NPZC3* zKR$BZwfAsx!BIqg6X(krNgxm4zp3|<7+et0am9mbzqO5KRhExlB@a1N4EUTnnLgWf z8d{#;mR9GUS2Y!2WyP6)Znu&-w*u=Fy}2XFpOCPn=Ae(ghqg;IHM{O{Nf*>Ftya}7 z1%QWPll1H6g#sibuBhGFVx<~}sytq1?GohiMzpa~&7AlvilUM z0G$&Kw=^>48rrBXX{#(%K9&O+7RIO&<4gw5`*DaYQ4pgc#|800%6csq8;b^2ajj4V zGW13L(ZNSKud!Ke0U83jni8MA?sHaHw_1b*%#QB|1mhg1R!Yg5zGcpW{FDZ@tp_Um zci~>76|em{x6-UdqI0d&EdbQiKvnJn6HAr~oroN>T?n?=-%2&AW2yo-sm38ApFFmO zCb6VFLwu)Psn&|0FJaiEjb`vqVB;?ATWsAMB;Y7+AS-&o`H=4gzFp;Hq;dGiji zczHSoV`S%m$iR53vq1oxBw$a=2Wq;YStNR+iq|eyEt;qgD1sjnV?-kHGoN8SY864i zPk6N#pszIelq43k3xSnOKNJ-#P49IgezXc_h>`Mbk?Uz=-uh(uYIZo2o)6k5t^6T( zD}hSYsPTGpLtLX>j@!E4RU&7%EHOW_r)TuAmXvIk*5rVdYD7_)AEsooMn{%EP> z%ML=uA)KmmOZMd~wflw2RP!K#ex3vaXISbWOL=(~auG}sVeWaBA*PDkDFB}z+hF37 zd|gKLAVP6tn%S(&Q_GeZF78*f9gh3J}yMfG^z?l$JJ$%Q(2$P+s zf<$C_8vv2!WK%U{k#iVeaFCi zt`02f{=LewgYW}5tF-gH`IH`|zOGj8Jl!SWEI|;5E9LwKh#zhDEF}4z>_Bk;!GdZC z&^plbeF9}leTK0`ut0)1^wah(tRHo+-Yr_i{QRlVHsDe$YOzPmsb7VC1r;K} z`Fp+R!;GnKC?W9YCoYP#%KmZ2s}?4mSZwP$rg{Z>ZRhjUh8i-b$kehw`5zo=z;ElQ*LLGfl* zPdNBh|BYincf!c~y17j9y+QO{N_E#W>Z!>AT z$3@w64MI))E-1}B8|IYGYR2%cEDs|7d3kI{ud9M8Cz z-yZqkXEsZ6H0Ok6t7s6G5kXCz$`X%Oo{zwi1{o<~PUkn~fi(G=#SkZ%`kbJe|MEaA zSZCb;!j0G3};z+wwq*T9IDVCBiGFU5_0mUbQ3~Z{%tC3Sk5wpH_Y4O#TKRtS9w}xa;j*%|I@}u z6bgcG&Sl5)VDY!p4C$p&Z8KOBt5ncn%m7#DZ zUlZfQrZeQAx0!YLB)EGKq8H%A{$ai(1gYEvXx$zO-%X2xw?9zh(rHO9$hoox-2=g~ zO2O1gh5TwY?}A78H0iDFSzgtV*7^e^^aQ3&^(bx!KkoS7F(9Lg_>VEqQNz}RpHPLO5OQ(#1} ziloj=E!r*%=YSKGso0AbF61y)MNO!qUXnhNnWs;psq@bfkpCY#C@)}-%Yh45Q(SV8 z&1Qm0`#X?)!T%pcH6+M0x!m1oxJ%f!!DSKYqoab!JW}!7;L`iLNd9L4`8U1l2LskTo*R=}G>G%S+4O! zo&L@U^yF@EMihtuKH??Xu6BAvh#V8@KgeR}#hmPyvA)Z@d6~2s(fO02tigNMZp3m?JQnbL{5Vs(LA1Q=2qzQ8hQl3w_Voy@bzi;xGdf(Oad-dPWzhH_W zK#U;Kgd{))hzuCmDJ%Gz%Xb<4F)PL1;r8zO#QY?8uV`27ZRl-Xa>?Yg&+$h zMEDyB1UnLcmWsmNC!=f|qd@P6ruIQCS}IlaPIPR6;bXWUT+s9!e-aK}Va%`U2Czt| z5^@895mtmUl7w45^p`+@cDngLi6pbFXLdS}lxY%a8%x3+g+w>M!2wWe;P$bnslUP{ zViH~j_&QtKy3&p#Rw|30ePV=MRozcp05ahyq^+p8T#pg2fq1_=o~JS@}8kQ{2ZMEet~ASe_O%|UJL5QIu)l{V{$GgcBv z@?8iHkrg#v{O*hn>Rc@Z(*>VM?*o+SId)`kwmB@SCNHciu%M!3r{6cBvVy<3tD|`|Uov5-$M2#l-&xs!%il1eQav$%q?&8amD`9XFgm)L(@J9DsPCDZvWw zXyvUzUhL=WpNZe81GJl6ssIK_KhR*uX3=RbDNz}Y6i$w_%42L18ZIfQAOXg+&TC9X z!JWRXL7|_e(A%>0Br4Du7m&ROd_U9QK<^DoP6b>bKEXmwpn)5$AN`H%;YgL(V+tl5 zIB0StaM=ux0$8e?6^(`Z>I4;doHH)s)Uw<~6GancoLx2Q&e=^imsYLuoRy@>QG+h1x5>qGJhi8}vy$EV`0B*gKH14>CA-yeXHR+% zKmRFZj7Tv=AgLH&LHBLYK}gs&HCAop6bnPbbiyF}3j_x)L_J{>#FM}@Wixf0!yut; z4Ohf~3{?yOKPNcHGvR}8Zy~6VO-Okt>~%3&Q99CmC;dV;`$b~xkc;#GCe9g?z|Kd9`C)Zb7ixA zeR8V%m%dw>MTu4SJZ|` z+86qzA8I$wzV!WH`4;L~4W*)_-)lOpVvv-Z!sLpLCjhJ2O_Hw2=(O-S$;H$@FB7Dc zNeN$@9`NzaC+{#I7P&ZsXi`zVS#BeBB7WuWRmH1I^ub6Vr%vDI64#qJOLd6nNceyWMn{5k28{nhl#%F7F5$< z0J%U$zX(X;5})amDh)Ep!3ehS;*8H0DQUc6O2o=5dXWyOnlvq3(!zoaTw$tcH04#n zDFOjR6;+ow(Jet!SI?fTkfHTK^b*Qyhh39C14|&Y<-|1-iIP8feSL1n|ppMCY91n2Ec+eW@n3% zd2>KfGg8ntBDMP~ms+#Fe3Z2>kZL_M^ECI+t1eOPsId~(V^C4z#mk80UT7_DfIcRn zc&7{)*F#u0bgpR7LB3jH3y-pb{GZZl{!?hD`k1g&cIsdRamL#s3woII-&T?XcuMv} z!a#s88XF!SXp)K!Q<_FxVnf>FG+0`0r7bNnB_s|^$5t!_2}4NzieEAFfE z7d9_r!Rc%5nD9&O(4?J-2@4q{mv#~l2{N+)auyVoVdiPf<)MXv0LW-)xJ)X{#&sl1 z2j$Vyd004mV7b}Yl#?P3zm)Zv>z9DAwDDkaY8fg#WPfL1Aw#EzPZSex-Zls{V_g4> zeTra>lAh$RY-ikH!5?jjjAM&7$K|At6_14=k(AsrJNgs<>5EO}_wnbN1Lehvjz9%E zWuq0T?0`!%FEyBGN<&bfTFT5++Y1B*O6a>3%mz=UNr-ckQnh~TAY&BS%u)Cn6Cds{z>B9ki;gX?C&1b3<= zUp(?e%9hHl#bTzQM?K1CDo9};IUb-;G~3 zNpwNQ$*4hywAoAj=0yGKXX^YE-3b3rjm|Qc98sr<_R}k#1j;rD)QcYiFyrKA*N5eZ zf%hZiwX9rFPr_7kV*dvVpqepH=@}Cv!{Yk|pCUU1^3b>}RXjS>^!^f57Ygf{ty9AF ziBk=<&uHtPi2)?_Kf*1Hv}&(fx1KL5En|6Gr~>L~NDN%sR%)Y*yFkF^(IIfhN?Im3 zsY~UtoD*t(Q{0rgj(E9W39pwvTqaMBfI{R)$`;2-?F+XbJY4=I+vSQn6T`?LMZ?b- zRNGBIsVb11!|-{2gZ`eK;q(M#SV@^`5V?W#S_)dQpipx1xG@0b!*yKQ2!ut9;$7*s z&vUZ6(^NKwbZPEh=^H&pKP}THy;MhM^6AzxQc`Aohs73a(qBFvdGsiS{CKR9d;f`$ zvd}s8VYBo3BWQ=vJdFVtG79vc>l6r?{e(+vxikjQMs#&yG724o zY>Nqx_wW!TAC?mO8RdHU*OaRLj9IYB4C6*A+vT#C|_H&*_{VAPBSF#p?+-KJhuoifh&j{mR3AqL+SXRwi0l<9!fN(`2a!ugYEHe(j0_V^^J?+T15+6ya# zmsBd;e?V}B*2oTe0+xDM$srS(uc4vMbTf^Z>VaV?FTU3nc_q5q{?rPUe+Okcbe#9; zFb9w?NuBOy76aMM3R7l6Mr|;w3L6m5)B6)k~l=d>`Rop^{3TxRFYGgo;ujKDkqLd5Y z5gB!?R9y9Kn?bxp8y1ol4-ex$Z*+EJo`Hnh=Ug?hQ7w4ik$cJ>Z`!gfLG*!9*|Zgq z6Gp%aR}C%L;sKd-Crz5($*p+WL3Kk)$rZf-+llMk0DwE{7Y`e~qDnlD2 z8eX){#~q$4%^6f^&(vBVWsBa_7aO{JswsrBdmX28moPluqmieHo2cpX!qM~vB*7^w zA$2r{rJsP9K3kW{bA~91ECCEc%2IPsAzpl=uhE5L7o!9+T8#uy`_UyXbnhKx3$-m~ z2sDnt1_D9$0j(TqOwIj2hh{YygM^1@Q(8v_?e>&h2D*mZKXD1CX8fkcNE4zm%`0hG zsG5i-#JqDamznJF)XHSHVF@TT3bI+=Be zvLu?AR66~m2g>BHAm&U1`~(000590006I#xabdD8v9T00000 z04M+e000000KotO0|sFT00000000930006s4*^hAf(#k}00aqu002>>0U1mH3IGS3 zwfXrMi%R`CQXBybU0-XTCw(Ccy}~UwsIn%qXLIZFX~fcvQ$BCW_adVx;$mfmImxMg zvONb06D~zLW6ku!3;>a%_RFD|!=*np%E*SIgo&j>>ah$4umth<@RYJs0%H1w+xGh_5amvALb=w|ITFlWQkv}Q<2WAENB$G*2PJRr(=^z z(83&Rkt3~45V>CjO~z4Gb3|Jw;@sm&-Q^Q^r~u3TAD!w6ixr~czX)DX%SZgn4kwbe zR!gxbyXd5&qs2}l>7vtGv80$=>c5TA?h$B|d-xw^GSpOJ*65(46s?&7QXUy9(?`>k zAFwYe^l0?4G6UBx%dZ33SycnIZ{8?TSrJ>FC+A7diw5}c)SR$iHV0u>d+fGlpd9_- z#tXWtc*hunsFBF35};*Nv~Su|b4s!t9KM#mpD=~}DNCKlT0ddWhPj0cIT-(tuV7_^FN!?gx~g1)%k0RlEPtU% z@Tob%KUx&R+TLOM5tNkX$;fz!agjSSDz0?Rtpo(s0n%Oo-$B~k;vB}*cxnMuR3X|z zb1KY^zt244Wbqb3u(0wGko{zo>%x7(7f?fP0udMkKp<#6 z0isjTqoThkzQcf3>6@dZ+B4Jmb43s6t_aTKI0WVv9HIFoi z=I5dE9`>i}MW07hz13miqisK)6s{qazqbeu;TBy1!ctEJqF)BOYF{k7M9)_>L?kk3 z@n%0Q=@e;IB4$^A)d!|}JZ;U_#G(==q*8^(u)ZLfqk9O@CZbZ5XxL&V3<0S|AV9`S z*pLjUm71#ewTR~`%tO)H9R*H`W{4&=v$K#`V^ihQOLK?=;xdzaKdvm!Y(9_{x?zOIMKFR zUw~{52xeR0{G+se%z^LFDNE4Q2vo~%)#@T#F+%GYnEnPk`d^;Ltunu^YIxT$!B-k{%vX~x;=^|TS@a>4i0BZM(wxnLfZwzbw(HS($?o zi3-;36A&VOEEaMnP;PoOy$3A_JWxMHr5xcKX0|NB0<>HpFhDNx{HwB!rOJdlSnzRM z0?J~`nGmdRR2=bWxo%0L=h5WAt;NxIv89=*FhT+?K;H20688WM2O-@{bShdy-9pN* zO}enSG=8Stl*>Nu-+3sqt7&G5o=$+ma-y9Ff_1B0NF^#Xq>TFH>p7g%@lo5G{%G)B;|`y zLveDyGQy+g=^S z2YA^X35ac^Mg^1VxbzRkHPH%^?*@k(8gZnq9Npe^MDR5N4AvBzw6wn77=o?)^0yv~ zX>?mt3lb%WvWP?#A@t0f(y8$9(YGTnY({yJ=qddR9Y{)e`{~OI6Gza=kdT0L3DLI6BXf&+TnJy}ols)DER$X8VJg+Q8xoPG8teoyCWs7^wr-(|98ofh>J!F6$e#sUs$p z->ZIPQw{W!GQpSD({Y+LiE)NInH6Od%&nagfjaC(z!y8fu_9Fo?JsH?12wLNCQa#kPW#&7)=69U?9+b*q8{u z8zzQGhTjQ$ShAH(@CGirjFto0FctFF2=}puZ~_M~xK+8ONT^ic+i!IZjiPT_$B}5X zwC#ru8mM$ueHVXQM5NE(OiN#)l^qJ8FzjXSQ@U$gkJ)ZQZIS6*#N;NTAbb~F7e^VD zMHLM01X!mTNdWA;aYyB)@Q!;&6vS*EiaHxQTS8HEala-jo!tpKi+qft#mM@i&X*;# zX=yLFEsWzAVCk+gNg?G0`e$66g$`xhdZHkoGM)UR34|kt3gQ6}7T#!h%41;r0LP4I zh%|g)1qy0_0005A6TCtcLn^&bQ+-d=+)$zbQD=37KuXt~MjGU)I<*yQRCx_ZTEvNY zAZJma?p7dXPHOO|BW8pwKC2LLLsIz~I3v3R#IPomsMG6=S{YWNu?gP(+4Qc-Tv| z=c~zZ=Y!ds?rRo;Z7Z5*gVx#YkI; zTojJK7K!+{c8XsSIJuT7vg&ou|M6yMoN#frMGO?UsHA_#a=xBjE#SFdhj6b-Sn?-c zn`f~r^dgg&h$31^xrcsus5B5fQv@GX8zdPANym$-iSJZbC)c+A#m-*Fl-bhuZ2Je- zzk#z1Q^7Y@3RJJZ1jvl{6s3e!NrGZsab|5>LNEDw9Tc>!2a5kM2=KjAhr%x2RQ^hy zoe}ueT3x?m>!XSAl{M^9axMl4;Vo;=*+XJV2<0ZaXIZrr75U`|slyKZR+W!=^1uU8 zG&ar?&Bz+pWK>3z*2l~@On3v&`>3-JCci3wntc5i!MHJgv5>iRUA^b|krZ%K=Q|wr zUR#pyJ1O9H&gZ}vTNp(P!eD9)oIzaBC0>ubC`hGeP8qQQeZ zN)1g$rVTn`#X38xLAWqcdWDx?>+ zf;#tX9E%FtUn>{82CJVSS}cNm<2bS4h_xeH`t5G<&fTlan`+7@jp-6fdsav9rrop6Ncn?rw*hB31T$Yb&YH@Xt)@8RMoBf@%lU z9nG5*+n0H<7QB_wSPRaAnb@>4_Xa0;eMdaU!kvN;XF4`43cMT%@MMW!4 z(K}xN;P=ggZ6nR>Yd^t#YhEwZaZ27?vlGME*XAg8K7L>J)Olh#YfPT}RL;j1D|nG% zNfGz4ioqpKijm5Q`2UOB^YYa`M{5SP#hlAHZ`HVRf;3%vl|`66Ydr-{+c|RFwYb4#d3;g%B^LOLIpgW{C8R;aCBQnuvTWH;R3n%6P*P2Hgx53q^w8y zz-%&-K>IS%zFHH_=%62h39J%CTFGAQkScUo`5ykHMXw2>;pzNYMa)arr--?QGtCoz zE?!!;E>lagF3KtWVhOD9OScVA$!f=C@RfK!dN>m^S>X-4DF1pmEv~gxpa$h1~~+Tjm`ui zMj)e!9(m4pB@CyHOSN!OA(%)=NNSnv97u?Sm{DeMDL}1a)`w9 zmNUfCJ=iwf$d)+c@YRjKDm{E1oW6BXDO%rIP*tA8PsIztcrS{Z6mU)1&t{TRG05IrxenI-$f#}qCSLf&8<1=lfo?Jqml9myjZxD z&nag$`UY2Ju@Xo#rng6K9$B&~x1-bQt z>*oFp6Ss5R_IxIejMLya!!a0yGlw#k{LC6M6J_SxJsJ)!Ee78n1!VQa%%dVTwe41; zhY-dzcyl1-IotsI1sFjh5{e;cr%470hK49n$zibY^I1jNQ0bd>9{)SNX~=^+f^#o) zi5AqoNi27H6v3;G3d`k*Na@Ky#n8ME25-ax?kB^?9Rds8)9sqAftlWTF9(oyc;oQ zFKE&F>6|FyjTnM0H<)1%@R(}JBQ)p;x7bmbyfO} zn#>SpctoZ78EN^W|I-^>Gmg-f4AP(GrPY^!?m2N5;6!lHk`fKhjy&Ci(MHHO$ckiH zPaZ`NUD9POZxw&AWN+wY;N>1HEA$Q&^?a&_rdU;*H!YyJNmXdvNX&i;Yr>RQtiLBG zrv#I;oO!s{b`qUy20*i1#=S{u!S%%qo6=2j?gi zFj@p<3wJ4mh2&>51&KgjvbTv$&Vi{C+=rdXHcof!WGq~i*pxO5h=Am!h=LE`?qU8& z6O6o=`>gMnD;zx}kH8L|oRZaLuPU#A>_e&Mb@6y`l6Rk}r94d4a?f8NvnEBg_s)>B zJ-2@`v=m_x6vdLu5zbXdIeC9jjYhzy%POS1nWQLZC`z&hwia0VRJ^QJbI~C}hkB&l z=Sh0oEWpMMDwAV^YDAfD%@gUXgquzPeCk?$c@!N@WXCE9r&RXY%b8c6(b^K*6)%(v zazV%1k(axQp6oOp;hR}i^2}i^a7o<{W9|uh;?rjalz8l|vWy$y?1wpGp3h1wb1#u+ z7jBZ*772&*or(XoV7{>~o4k&wR7LvwZgkd_N34@*i#!z$(+8d8Q0h;vRtfX#mrnov zzY6oPMLcmjuE>Y1%;V@wQ6)L^3RTQ+uA z9y!Xu)&=$x(@Yg3@3P;b!F1@tpq0=g%1wke;pQ}(UCysDrWO)960|-gqd|p(x1O`5 z{uMFfHPK4Q775NBD@6XNVVXV1g+LW5A!ZQ;BXz`uPBRn7hruZm+Kofdc5vA4pz)F8 zNtED#(t|^bejLJ_UG$c~fyRttLxf~%9%cy#rw&ZR2Us7kTvuM7RIo$}?7g5;E9b6r z56$;kL0paJxNm=_Fx^+hrHF|G@hVB-W1@R8DM%J+a;$ow#K#;T$d@So6F+0M)s)gj zh2LvZ%;g?H+>M1JJ<|Y;p$HJJI&UCPw*;nIn8 zV5g3};=$&NMw(G;s|wi&yyz4GFj4X;Ev2ck%TD3`g$r3qT7RprT035+$H1hW-vnM- z%I!Cv;Re$Nu{{(Cnq?#AwWmhR*~Bx2hshUV9b1rp+^V7kX`Dz~Bg2IvJS51|-eJ*5 z5p1-dED)i?tjb3~f)rT3*b^U^Bbu-(nOuXGF3JST1mDF}vY%;g71w5jt+^HytV*4O zK67TV2cJjIQXoySc1fQ#kX0_N)Lle@r!ujY1r`?G-XnADt$ynW$kzKQbfo91Xah?( zC{MKhvGx5>ZJ}b19?I8ZUZRDly=g9n_Pw+^%tx5yQ&;S!0a6C~B2`P%yJ?oGoapdn z8dXoSO6*4Ip{tr6Q;8x25cNJ~gK*hMze zKW4mxn#oD(_hd)0IY489Ac>y39@CR79g36BO9BoY%SwAqsX(((v5wd9h!B#CdZ;r~ z5;TJv;Y_=%oa@h}p~$;A!&VD(Qf&sN$6p63Wj2SRQSZp6n_$wHS;Q2KsZ-6wk10?n zpK>Idr8L?IvwnSwi7l0}ERK!yvHeM>+rm67qqhor?`Jfcbt-r!^T<_a!xoc)Gnz-( zh>`wDDO%RI-+ix14ifI%Z6iXM_i-=788C@#fJMXP*DO#;_aO5pK;gDt= zWP!3y?;dUXG6m(7s26=?a;fVb z>i_@%0l9~vqK!5ZZBYszm?79(T;`OvG!vgJNy@>LY{o_)7`G9Uf(PD8Pq!JfI`CPB znN=0MI7uaS*vl_nn~q57p-!T(Z&U`_2D{B$Phn7++=f#Lz+*PG(v+hT3EEY@W9NEg zAwhi<)a0)C=aw*oDxmA&XDm@blz0X^ag}g_RP{6X)bO6Nq?#mLMk?G8hh)|~kzUB*R>AaEJgfhG2{U03tUc4nP0_(>$Y2SRx^UK*j(t zC`gLI0dWUuwiaB;EsR)%3*2ze%6%%J=3zgu z-L(U7fVYlZu-;n}CN>Q5CJpQal4N!%${1;~?k;9lB*Ih$)v8LZckTpVj020Dit`qTha9d) zfsQeTM04r5iecPMsADpkIw9G0#7w#CrY7=6V)AgvOhj&@Q$o)OW&12n&V%kk$^456 zv~;@wb0=2M0s<*2Z5YIiAfrbt`;KkUz_av8VN4|$k%~-wXfsm2($+Rd4;Q*ETx#2v zdE``uHsT3^T6Dl{KpAq7-ykD$x^C|9Y_{x2jf%BhEUl#5+N9 zQV_=7{~dN>F1AN;?+wd8-0>a_lza$+n1&G!H1Wi6WGO~GHYRQy$g~=HB#h;Zc9-nA z0=YC=uF0{&MSLPcY|Qe)9~aPTTy_N%O}Mlkuy$tO6$$Fv0C`~9bZS^HOGODO@tD}4 zSwW#7Uy?>f0fzu$0(uR_Nm9)=5LAg)lLMLhvGA?N6slrtuasu1x*VWwF;x4-b!}vh zm#WeMWVD`mfEp&to8&C+K#Nd)?1ZSc2ot2Bq*|L%Ufwq1+XdC=X$K63!b(J4#PD(s ztg_;>QR(@OmX%Vtrj?=5S)de1TS`KVlonn$l!9A=mZG?7iT!OrttX8D3?hU4Lb?zl z1MsbjP3SIY(Mf9|(303qHd|gvrWw+`VidZR_yt7dbZXIEUy4e5ndvWLT*JiiZd&|M zP-rM>+*Xl)Om!@_?k1H6im;(K2$uFF2GVq}WN$+$QJ|v?T$rv_LzF583KmZY(BxPS z*f?4@5(KQcB9z`H2ahU&Z&^5WIR{xyiFX6ToZzXzFDRUo&tWJnU`{kGUcB=K{WdFA zw9{pdo2^bJ6!t;m87^LcWMYw~eVS7m0s##AGh{%G(V;faIY>NV7YUiK0Y5Znk28@d z)<~MvsBto8TTs~%XGM?fy)`zW3SfbvU(nNJDfLMXs{LY_tjE@S!=Eh|gkQ=XVnEe4r< z0&M;32rQ0BANmAWk!ofbDr zA2GGho>mKvhYcKuLI^^_goHsv#gE_w6a)qU2D}&}3Iq=dssaEcP8n31xX?o?Yr9Ge zJ6lz6C^AOq4nOX2JT!I|555D)QHYTPQg&1SkZ?Jc(1;D9SyplouNy&-U2(ypr0&2W zSvM zU}DjagCXIcr0t%LoX*g&{1xFPmpO=tNg%XwewUyLt}nS65-#vW(=!gp2~Z1x01_Dz zYH`?8T7pRioERaV7vjEI_K?ue$Ddw+wVpE{Seg*ApD4&Gjg%9R)F%DT#6rqUUe-kY zNpeCa53X~FU6bJDSYjoXh89SfjJ+}47Umm87Qr^kl<#%&kr5&BLflB_@+y5ynCOPX zp!-!CV&jXj^fapv+R5Ezu-pLAYKRz3`pA|x{ereZiq^^)fEj38faR2*apKer%9Rx$ z*zKnRindwVl({zGb~4Xsp^(60{U)%2^b8pwflws<0wEF>zm47?WknH14V1=b(|cQ> zfp~_D5CKGEj1USWaf{_*Zm8Z%T+^}twG+2fu3UjE4v3z`ljH64rZCdhv zoc&2AP5##t&6U)C5CGXwB7!q;1nL~2F4uw{kBc~s7QD20_Dr`P@lVTWE2p94xBvhF zyDQNIfMq2m_iHrn?@;FYM0h|tfEPv?Xif5={n%tZ&f7o1n?|}BU`CP`ca}+M4F_p zF*>z?jeWO$FD3S=<6=&^0#E9k>S;2>DFULvI2!Ut)dYzp8_9}|D-gkpAW~r20NX4> zpn`=U3W&{$N!0|21R|22icm=+DnrguFC^78l#>#OAUrAS5P%^X-C~Zi5F$xLNZWNGUI=O)b?J{IHbZ7Fk+Uh#ftnH9E{0?)Qf@+2gQyCS5` znd(U1|2tyYY^>zUhKlFhUcdEuR(0!7+w7$|z;^vl`Anngi*p%~X9^_PaZ2Um^+z`W zdz-0zB30cU=`QjsEk}Hm==ps5kf|9y*{k#&vR&JDoT5o23LyBCA5A`w8TZ6N&;BwY zUrR(-397A}UMSL7C|WbZ_Q72q7q#Tum{$ALljE)CQ7rD0ga0nFm2myf&=9rH@>{p` zR(xy)or05mWkmLaXTn!Sc+{QFpOk+ir^q-G2)=VKp3`Fd5-umnw-U4btzECoJQ_=% zu5hwJ6Jy47!Cq9lQE8@6ROsD)TWZG>pAoDr8wGL@gE4t+5P~Rzw{71PPMIC+V+Yyv zSI9VWTqQP|8`$SDRfy$`ilpJG1f=oP-ZR%Nu^qGx8)rT{lOEmF%cLgekpU#Szmk$ix(Ay}@-@ z5T+8&LrN_&l!@;Sl6`t_PK*FLE?c1i--zV3LhGK`7T4|}lp=k!b!Z57n*qVThAc7) zScI7o$yfc`Y+Q?XICv{buqP%ySNe9NP-F=J0$lK$#2dsH9%^}KXTURZa# zJH*hcko;!K{g{Y9WqDC%`p4mY3u8iqE?yNsJV`*H^sz+b=Y-q@fw!iaO-ML_D4$;T z&wd6c5Rr2h?x12>u6ik$rHL3%zq{`?N8}II0n+}+8oY&=QuN4{=Tj0AW?a}JQ~b|p z+mi3DV<;qXL3Z{r$gB!I#e%`@mAeli!LU)qHs%yL;Yf&xlRYU!Ya>xUQGWP9sH{WX zTv;PNr!je*h(%}-6p0)N&LE^qUAA9rh)__H=3;9BGelh{p7-U(JOL4q}S2s8xLRGT}Hc{;78F7;!nL$;hx|K4h^MzSrXz|@_IZ3_zenZFS@=CgJl}Gt+ zBaEOc*i`+=>+pOjJ+?(rK~w7(bO^Zq5cJNNV9K`*FL`b&Z6D2D1F2TM&1I@+_yg*> zeFI9!VCbN-W=2RsenlpH_G(`+m}8&t?0zjX(%eSUvgD6E0Xods%a$IANz3&}$g$E; zPg$28cmba+d}tax@-1l)ip@4537PB#VSMT=n1?!37M2JtvT7-LXu&Y2g-o7W^1_sN z0UidUCJJtYt*M$j2#PHSk`BQ&@kI2jDKq0)_6UU5Gn;C9!(@T1!NlG=9P#1GXemV6 zhkN#wT6rUztmgvkwa1}TG|BC{71@XOVLR* zcWC>3T+vM7bc*KLyyIVQM}f;&%jJn2&lNo?%9F$k;3m*}NEdGz{u%1IMx8#OApQ2S%`te z52uk@WLOc{4P!3NixwrtRXc(qaAnd+vYFu|S~xF^jH>+3BFwzE5N&b}c5Hyv%=?rX zP)yPexIZ;}pFP-03xr2ZtcI+C!4n)F{oM{$>sbrRWod4befN4DmCdCWR|ea2Ol65e z3^+w|#Z66Msn%z=K1uhO57?h}ecAA`qj(8t@#Y>9!vqVFaAnoW^|`GuewUYw!M@X! z+f}Kd!);oWnJV>3;X}Aw!FACCydr~WlGM02KvUj8psbUJ4oj5+uYV3|aVK!hu=cG} zpm>d9GNg#S0-4F_>yMyBQ2VTW?{LzdnA*i0`5JP)8E@dGJhKbcgzH{MIEb!AWo@jh z<0zW$R7waHDTy*?+tn1ZH0ATTQJL5Wb%iQSp~Op?U7X@bu~BN*X>-e)ws+&@j3W4( zWsk#cVvHeTv#IiB^Zg{{?ohm~GTu|uO9IdH47gU$%k7RjXLkvM#@gn&wXRVgtbke~ z1QD(r_c6rLB}0dy48$2Kqquji5=S4U{ z#Bgj8RvamsPk%$F5Ye#6iFbVhV-hq`$78Mfg_eZ$sP)XCiv3rLOLCL=-WbIyXtf>t zCVgLBJEzN#OK|R2Vn+odDOJqy)D5X4DJR$I$StMF*!)%5`-2wY^ZOtuMg7EOwmpnG*$^Phxp4N#!jh%yoH1X+|OWljy$cooSGOuLvK18|k zay)HH*X+BRZqvyKI>F zNm`H0K20boe6n;KOGTw@LWqYPG#PZH`DLtIEET)Y7LI$(^B)){6+3KbErYY*Ih3}e zca?IvxS|kZ3Mi+iWJrV*Q6kL7Jf*b@I$+#}D2%9e#?U7#%0bPR?aecGx=+OSx9;2d zaQi}tetW#4`<|{r%DD@VY?cc4a*;aVmePmEx%uI1O_AV%b&RzGT;s}%#Nre+k#lH0 z<+_`*5QpThdR;}>KE(CKf2eMt?^Tvz64h9y)iN(Yt!fb&liV1L4-Ncm9X<^@zsH!c zRf{K%2~qT1JoJ!Ly;?<&5C;BK=Qa7hV*C@>`7fH*O8D{}B9IH#sjvdY%TbI?K! z5f&V|rh57K~HYwD`TL1IVl|WtbsF~_x@<3dK$z`>N%wFK?^3ij(ZfU1RckqY#7A(^lZ;pT&V^obUhu0l|f#;@mt44F(blL@+`yT^^Dq4jt6Jmoi<1KJ>y4&*Tszc5oL% z2GdHUDi0zvRPEu2s=7^$?g_yzqTv}xLWJMQ?Yq_nYiZXO-iPTko z6lA8gir2K0GDGM;D`;-;@JOKn?UKKU2oc1NZY8OSCUv^PHyV}(wiqRte?VL&}$`tY2^>MXS2~OJr|29OUIT}Le{DMa+Qy4N>7PA~b7deMvcHgOdHr4RF000C401(+Svhbz=0{{d3X-pMi0g5N& zknsVBprnM?!AJTSv}(5=imtPMFcUhkIm&DrP9U;UlW4YtkH%Mt=4Oz(x1gc#2_yYs zsk|3LWJOAa^WDtO$Z2A_!p(=8B5V9{YgHPbP=HQEjEDb(KQ? zjuh8%C5V~XCDsBK5>0mXvuCt2Y*G|WVq6fAGvjcO=I9HNt(hvt{NF3@Q_JF`;g7pQ zdRGB(!X!qlb8`T!;oG-+YAAWd-4wiVKz6D~`QqzLo>DH|vS?Tgqr&{JLyGPW4mU4iBX! zaSl>jx^U}>Z*l{9R@}dW!fsNI zho8y@StGMxq{M=etwHnXz1zUBa3Tsv!M@2J3%e?_FZ}PtbB&_yFB&aX&lu;Fp{ung z70n`;2kAhhW41n_IsNM`Yg77J;nC%s=4`(^bWsI!%wl@Oo~S#hkwKB&xLe*{!fm(ZtQL z^i?{iwX8&@gz&*#`%*9a&zO;)C(pvq@wrmA=3o1v4XtLKppSqXdpudXK%+AaYe_%l zRe8+%f^lsY$?L(qOs6!D)rB&j%3%QB5nNv(lw&t6H*9Ew_*_79SJ16}%jk%o|0YBuMp{%+w>QPe=(wDW2@v?aFZQ0* z*ealE=NU!ZOWG;%m0gg}5NLVJkdb~*Lv&d&W!t}8M}@jY>=svw%2}Jrj^1SxMd5S@ zb$zye&XGE1dRLO{0NaOB(TT^14KKySf65JO@0)Jh?!fD+cr7WjW-qDm@(TyM5vm~@ zdNwTseP-?kT}}!0lAQZtp!?Uh{(r>K^f?bY#JSMmI56+Ek$nCtfh^?z4CZcQcK*y; z&pJ8dabQBIxHzd>Qni%(CtWux3F-Nj+3c1?@MI?qsQZ5QDgNA7gym3{0Q4N?{&$+i zhWX|1+5c2qH2iz>uH=+TRx-qX{rdd7{^GpXDUVC{&oRWgf30!O(W6#L4r^LtGzZz0(kmW&45$Ox+T3U=-z|)UwNV{b-Jj zyS(6ZGlR_RuR?+?sT;v0v%fNm$_*@G}AkE19I^z(^CbjVaiqEGz>=;79X3l3w~8!_ih z8kcRq8CRX2J^>vB+xxSo%%{Ay7_OEHCueP`?4U+ExRc>QNCi|*U{C!QutynLu`(~m z^B!H@?@Ws|?>iKFSj*4gfk5ulnN05StIt{KlSu&b6^+eJhN0005QE6|BIDiA|k=&2+{bF)#4rmLV3R zapNxlC{njOr`VD;1(Y?O@U3%Nqm_>+`nJ4cQVL&qcvBOz#Icq;BoQFWF$$nVq-V<> zB)peCLZXlw%T!5Ai@_V9Bz(W3g(#j`;pt@dWUSQID-0k*uj-`OvUrFhl2nqzUn9m~ zX^99DXUZ)+;+=*h0sNt^+QRyxQMBfSuPD?aSkj^)N@UWhEQlqt{$_;#SepV`b-7nu zCM64@c0Q6y!X>7aD%Px$4*K#d774+1j55qGi6X1*s|4JYTUvfBeEF$llZ>l#KSxBp zskvEp#)>v1XGLI#r>MU|h|UP0D16fc6dA!Yf{Q*@qp@;a8-UjYM-0xgh&K-ec?6YP zWn)IAnc8)s*1_8`YA=Pw3JNok1twq7;d{?7>P zcJ5?OXUp&)w>a#DK6?PMFjZ&mr6;Yyp&h_@9+|{Ue_$;Ocuhdn<}1g7aONENe3MN7 z{#-nf7*bfsN5Ete>5IojZg4Rne1hwU?62IX)pu}RoI*St0uK;n{$_bZ?<_{kByLeF zk#L?fO-h&Bes~u0(#70HEeLX%xDhAqY@Dj}aZiC-cBgO8q6%Be-vA&k7N(=VGd+vC z3%G#zv4-Jlu%73~MSEx-Lt|c7(tVe~OP<6Peh+7R_^7flZx@`-pkWt*vX{K!>sMc{ za;HsG(I4EOF9^;_T4q4uU>wvTW1ce5i@*uFOZaV^QBbCMXBEl~_tS8<%=gCriT-Q$ z49~|sGK%@AYA+y*?n7n8gZw%hV8rhtg5mOnrU)_-&9obn^L~8shIr~ZZz%*Xo8y}H zIJRt_){&4{_s>JY+Fx9vCT&&mZ2C_4l~H^y#O1}FLcj2rP2UU_6T+OiI^3`03^@cF z6t|M{nP`ZWT6=0q;c$B4ADTX;1X@2tKJg;u;p`IBLnyZeUHG=bSzC;&n0kJIb8{{7eCor%%uowugpDVo^SpPJsNgsTGjrG zofYIB0TJ>GVp{NksOc_`(WArCTsMmRPRIN(TrZrghDXPq zE#+-x^rr3^eZ&_$_Ik8(60cu7MU-EOMPSeh3ZG~D+!)i}qqrq@IO?Z8h(5i#xZt3C zb?ycsAxDae$wmJFf}*L~6gh9NEBAmmM9wDtE&h80GS4+SC6L)?(Pw><;*oOsl>FW1 zo-!~dc92Ee(GhbycxIP(EzwqJ8a{I^PL(Wu+3t zym-r*6&(_}f8tW&XXU|@D6FhS%lcvVu}9(Lw|oGIqAfX;5I| z_}C(1z0m2Sqo(U(0jU^F(a9>9^t7Yjp0%`>2IbGke>_xpXZ(5#AcNM@ezwtbz0OHJ zXd=w!gm@e#7gZI>dk!BmVye$HvwO1p%xfVXl@`F@V<(qTu3WLv^05dXB&7pl=SAZD zSgfByf-kvt<>-3YyViy7c_K;g|BND1){MH-V)SJHg~K<4@#aXI+TwxS55%W$t`yhQ zEZ|)E8iD2;ksuvTQhD^ktgVQWGb#qG^4qkp+@lLQVh!V@z1N3wkWJ(h z`81y9tL9zI8ck)FG_5Ggc+8lp2A)bY`OqTIy!$8W9OrTiy*yE3b!K!~pEJ`uB*m+r zP*OkIID&t~636SQ{IT=%;Qm=Pn85x%g(A1!gAb+8nQya$@(8+@<{6w3eo&P+K;VtH zpqjTNZI5@G*Cr=!JX{Xh^N*N#E6yb&q;!8!@U~*iWr{B1GAjj^iTVBB;4l1m=ADU* zsZ`};QS(Aixw7J)x`Z0JoLo2g^O7m81~&AMCbbwjKi(N|d7TAT=8UMe2RWxZ#rIVG zM19@jPR;&Yr+a}b6T|;`@<7Xz>f4v%O*LcXi-3YYH_s@;;297~#D(grYS`14S7b4$ z?;OkCW;J8S?k!^nNAdvso*F$nV3y|u%vcZSp7Q0l52>E8Rk}&=5U-JU1DOQandKe; zrNrPHo14muo9uDP6e=o7j?3BVXm3UY{MjKR9M1i_W#V5BGimzr#q7*g;^&Q4-W|Yb z1}`^@o_0MgBrjYtMttEs{5*`aYZfDMFN>318$!fESD;sHi~iH8abOy=p~kLU?UJ;+ zan1{(n)4=6rBqGnV^2Ll9o}eygI^s3viD1vWj-o}4E$xla-AvIDTVpsE%qSkHB$E! z(vvF0#z6>KGw!Hla^<<(#md}1$WtN=qR9qNNibd|r*TTF1tmV5J2)h`ozGrDr6iTM zD=%oHTOolm%=mA(@O481u2J~; ze|T_r*F3>8+!YA2`Lw$@_3{}w_wnPp*Y%0PULxFw{))$+Hw9U9;OB{=3@iR2Bdj6V)`sYQ!!8?I zIP^He5trk;6|4*1r%(w}s0{Tkq~l&T#zD-omN`qwNqRAk1O~sjr?yW`g+fx8 zYn<`?a;gOtaii^pBD9XYM&CdvsW2tG4zbYje@Ayzi$j0 zg%x5)8K~%l_QtC}sU&4*t4`tUoEHdoajKC7L_j;7F+_GN=7JV$j36f=Tk9;1r$mhk z&cJgo&K+coJsQF+D-)3Tt56`2WdvDzXAAVAc?utuQ#}J@I0=?p=lTv~mGEcWgzlKP zwYoIIztTlYl9N_=DPrkSDT7nn@tlUJh7||I=vD=w$~=pwCvW+1UAzjfU;qFC$}4r; zc!I}YggRnOH5ig9Zf@mQMSr-xjuE6d5b9b3*oHj7g{>S?zMTaX7P5eg ziKisc?~-lY!lA%P3#6bTmu2S8k}dkvRE>fHAx0>UMvsp{h)eH+Xc5?&ag%MMqH~lL zC)WsXO*cY44TM`Pn3^_S8-OVgg{D7q5>}`3Zq+IiAn4hdQcE>=B<;6n$)&`EVe|nd zzRbWU>L9PEK;hgP>X~9qjpvI(pLM8HW8%X^#gJ>dG)UEVe$xUJq9wNYsZmYYaqTjT zU}gn^LxNnpqf@&L$?c(fUgv+HKh!ikdP*0;LOD52u-Sdcm=9TipbX-o% zmh&qz8S@D;8x0bV3knt<5G}VR}4mKwB;Dl2*_d z;{>FM<5f)Ps8Tj-#zkFqWFoa9Q7v!2SadQ{1)V3@yO&X}+{B_V)0>eukxGisaCe>Iw_*r7&a5u(o=tn&Z$7Y zCpq9RG<+Zj-ECf@kU-oyHG-EY*oqv4oRW5ASD?1HP7Jiu&*IUPk}t|ma|VNSu<0>! zT`KY)ysr_I!X>{>REk)dzTMQ$X`8ZlGIGN;zZ5f|tcl3hY1$-n3cEf$s_00Sa>qy{ z9U3A%*-6@|#i2?R>Xc&eK>-p;RW*$DT&o*%+RAe|@hPDgutL$P^GPARdfjRr+tHMr-Ml`k3lAd2t1W z^Z%<+m)cH?KBRjdZ=gbSf+9&!zy~#>4=t8^tKI49gUTLoQ(9w)s%WKx)RZ;U_ z#KicRnWDGpzOBB#txKD3pJ?ZjQDJLzqZ^MLR%ytVTdHq80}K`JcKH_|U^bkBBkUsd>2p1YK(G9mEeM}OxGzdTjv#Ep!quui&vw}~0 zHECGwU`Pak5r8DvZiFus6^bH907^`)K%oRKh=9pOlpON-0|e$;Fc6*mo59}N?xZBqwCTe!uk42IN8dwN5sqVfV%1;FSF&CC&D zbfG9l;@S&;;&GM~{Hs`|-YChh=XNC=aq|PNNGvnQD;8jpmES{%Km#%`03Z&GGAb47 zh9Ijd4dO5uHL`?DyUYTxB#*8y2##7?;;qxlr}hP?Yu?k6`Mkx1f5vF6>OQ`rtxcaL zJq@6-K8O(5$hetKB1i-sCjV+Oqf5f+)puUICJC(z5-pBe{8YuVzx5&2zf9M73OH7* zzS)Kxhh(lyNd_=F@8d>rdb9KnG%XAyl|t9ETqXYQP2}W?Idh(9kF8Sl!VLW>iEVqH zY|2rOiIskXf_BlU{C<hSzB{T5=1i4lanlo zKwOh5RFVZbwowfL%NdJN5nz#5TBOkuEcL>O5d=9%f=UF+Vy!TBwHsLJ;-mBHDu#$muc|pDgy{Vm@ zh(v}aFt^9}Uz#vSgLx*u*jOhD|B0CyFUc3LPBI{^`GQR0%Z^TikNL@JTeLQBdPuf> z+_!AEdS0|Cns!q{(o#~fRT>Y6m4aC5k)R9nT+rF;&KgUo@K`i|E7~+j(L|4AY4m0& zX8;g`5NL%GEgr>bl%`OjOjvz}7(tkW(cxt12OA84sEkp!#p|j;NgGIrj0pwE2tNzC zYtOgJ2GTrC$j@IrOrb)PPiV|&%zFh<5z_++i6CNW!=9gbc`|v$(DyY>a z=Of0}mCq~%+mxkIoEqHAP%k9XD{h+}dEz5Z(JCDH^mAWQRMTxN=W12vEcfkqg}zAOem@2_$f% zWNF-l2n9AQIT>vnWF$zDw?UH#Ap|i{lTdgGb>OER6j;kkOVZah)eUw}HgIxWOxf7_ zCBfwPX+q?lb5jX@@d=E~*zsfF=a^Du{4Q9@qVdTdqh0bJRMsdm+_O`zob)R?p1}!d zeAkN0vnE9k#%{XmY7+8Dc)-CXNI{pN+IMFnsR;6 zlGAYAcf13J4I4lv(oObjV6&0(pG1WUY_Q|sC>RSfa(y3x@jO37dK)Fz-h0^qoV1PY zzL?(7M`!-!SuO`tX_vywOtL&K;o)7vBEAZ7hp>R>68WI|BFtj}u7mN2%Y3(g~ zEJrrqa5djxk?oBgfo~-Nqe0zp^NLf0ns80`De-X;5;SW>v78@d&R0-)Er=6%qhGYy zZFm>(wQ41Ug_rP(pRBMkppz_fV}FR==C!(|N2Y3Mz&fC9)uwi1iUV{~StBV2qQ!d# zj5SxN7)$@>tdkY01pq}=7F)nb7kXh7K7UD=IW&CS)HwNK(~?V>5F@vdW1Y*74t(H zUqgb}DH-6Jk>Oi|`I1-=k|YHL0%4&LMv_o%tH3?v0}TosTgfx1pj~9J zG&$1eO?rdq})_E_=t?m&b^_~B<7TvEqvx8%Ldoc zB9>Ed+{`?nO{%}52X1owpeeU>`}J{g*QQq@lFQ1AK|YzYgQG*;3m{Mc{?k)W%a`y6 zz~$%#^*Sl+5LOOvjB4n^c}1CU524MM34dqq;R4O&BTNC;quXqLqXRY$8IeIUcTUJX zAEydZbvPa02_kL?5@EuaF|#w30j;0|^Egzhx_4#%{PB37YLu~4;dPxo4v&R#3(@Wu zickY%12EE`Htd!^Y6T`t;E5CFnL&8+R+0qO?8%rqY#jh-nT>t5R}fDSxen4CoT%!rgLlCn;T+PRrDp7uckn?w_t*hxJ5<9 zmQMPd=G401L*IXoR!BmJba_?wH4;gH!6ZiA!`n_2JFwPIBwfOWgk%~V zISu2Zn>NT5y6A6i{&Cia4NRN3k+gvD1u}!D$VcQ5JRT$Hp9Jn|zm3232lgx!`vn+c zS3=w7OcMle9H_hMu)iS{{l~bmCx1-H;l+@O0M+7?w)XiPWJ|$U65Yu_oQVfP8_f&j zxITsJ)1YV#nX{{VHEhgo5|!aO)#&WRT| zrqVVnoc9S1oRxE!p+Zf|3}q!kQu3lZV2dc*0K9Hen)5ldS|r1sgBI>frIu5ggVLkP zB(sYSoYHl3BCYsRaas(KfijYbVX1OV%WMKuqU{QXieg|7 zA>1}VpiSdObr(LNyXXwtL{$Ml_*Z%q6FD*Ii}2({bJ)0N+x7jqY+N$b3*VLZSLt^U zP5yX_*ERPsWY^rFuwM*>qvtm-p8IQE_9Fxa83sW^NRa_qt5V{@YT@0vEDjjrbQo%P zEPL_W+AJwAw#~Jl_9GbjGQwANIZZOmSq z&B5HyOC0~f-JILNUqNOOO&>_iAj*57>#6@iU6O^gJ$k|U6 zemmK8cs6^>d2vxW8;x|zf_SlWKp2czsCAm&i1PyXa*HmM+^HA0HaLsHU90&?Zt>gmJ4*%@zt1wPU; z!-+~InY&gnNX&QJ#;2HM8bqrz78;WCFGuvZG+o zFqF9cnb|BQ0oK+u6+g?8u2f9cCXU%0K&{+eImo9k2C|$jq)6gg!Nd4puQD_kHAmHyK06(zc z&Iq98Jm@fe9oD|tu^p^4rfBH*3PsXI29e=Y4Y|H+`g2V72Lu9-4vj>N+$Cc>)~2hCpC9s^4l7=!o*oDi%L(`_?w!dkOf2N1acN__8BvJyPZ%Snd||% zuL3&V4!L(I4tjuclvOj!!xOV0S>!agbQ0f$Yuc}=aE zy^u%-_Rtivt{gi$WA}zeM8U~^$ z)oDwgYZ7^jj(-yx3BsSY3Onj@Jm4LjGS1K!Eq!EQPp0S<0?dvJgs%nDTs%6pNjRvP z?|HptvF|L*o|f$bZr6T3oTy4x0WzwdQ|)hG4lJ8J#V3AcF;KK; z3KH;cN}T9c?rw~ zEjq0Ru}rtptuVPz0um6;Va8LON;Rq;3z0C8Z-9W=sPYX$%>W~WK}d`t6|6i20-W6^ z@)1Zzz@p43$#7PeF6!FKFg}>+%*qO-%F2V1H)UMTOnM;l3X7iMuZp+gpBLnF(9g5O zX+JWI?eStLl!UEQDqGmlK6irs-2!pbs(rETN$P6^6t3b1@1NNgg?UZGP0#$`@O?9{ zRt{RAD6;>W1k@-VU*x{Az`lUtf;u3vBMJpQ{u=FC%!ccjIY9n+C9bIk4+mI26LZ8Y zC^T#$-$Tr$)zk3ivSQkF)(ngA9Svrj@O_b+~_EI*n>1Y$F&11tzie@?CcW1XH@{?uPEtJ?&b{7LSRD*Y_IYQOsdu=72 zk=;X(8dLYj83a+;cL0i@D%8)z)WBpNL- ze#R6LF=y5w%RF4UG1R}_Si>$0*A8*(1Vo9r5k;E#qWjJZ;>6d>-Y!>rAy=%u!vE)E z9FEV0_ed;&SLpf%LG(4*4IQKKho^iMlFwnb-bEeu^j)1n1At(~28-LSk--z{kZiM3 z%6VTwo%%2|r>c9&Fi@uZy*XHOkCOjvKPZ;Fm(^#36K-ty{ik`W&Slc&r)18(S|UCQ zt2xG_L19C>e8;n~xe3XgCcaY@&i6%5-kje?hYp-uYj+faLmZ<&qC$NSO5S4(WhWAR1^ja3jkzj#>WMu9Y|}ErHyh)QuM*i7()Jx zl&&W6YH~~w^qDUzR?f`?C1uR-YgIimHijiqp*~Gu$?JG&%u77|KiErAgQyafmXT@} z7||J|#GfH65S6l!1v{e+k%U0hEyjVLWu#>G;n4bu3Z2Ou*}u(-1OZ-pFp{-HTP480 z4CE0WLq`EClb2GwS(}0Z0JU`zEz<~OBB+-Ru(?A66*;XSfJqb(fkdc%ZQGKXRWL$i zAx>3fxF=LYMA1r4f=wIKmwU50{_8b5M?8!ORb)d&JK`$TRQgfN>CnuYJd**u2Nke^J>eBo|X78cxK} z5JCgk1d$*T#*R4mJw5FhGT!0@a+eBu0)`V$Zd;+gh1`Q#0!`>}AQ37_iP0>Vb5_fx za9&b7xwp3zBW9*Zn(?Z!oZ%j9vMxXX00Ghn062g^FaQ7$00;mE000000000W0000G zQZPnD6dHg4000aCKm#BE1OQd2l1u@x0000$zz_gx8^ zSM?yf#wtda9YTQlN5;W4P}}wt@}g{`mif?AKkdQ64Sb3-5^kw0hiID)-l{qOOUq*k z9=`!8XS~k{oz-GVd_RJ%3;<~D97pK}pxJ^>>`~c4CYzVKXxpov*^FaXogPp+c4BUX z72qOQ9k6~Y3L!rm=U^!9V>y(hJ0?}zp37vZ0pbB3hk?b&Aq5;oM?2aPt10P?dQ{gD zMk$FLVta@VXKIO;#jVj{w2CkYL0|=AG<-X|OD8*)d zYy_vI6&OHCw4JTNT57S7nRQ#g+i>k{qJJsW{smRi#VaSKFs7iS|NN~>&A%Z?F-2y| zaXXy`weE*@=5mxkovPu4_eXF%Cc;c7WGqA>1JBO-E0p9tkjliTq(+d&(^LP_uRbN4 z@5_CRltN<;m{VIgBmfK`nZ~iT%>d#V>>@Zi4?Q|P^6GL~St@(3@b)gn)cl%w*Ax`s zlA?jPcf}RmY*1P!2BOkvb=!gu2i+Bt?BRZz8*;$~wB;nd=uET*ImyUmg&eyKnbJB5 z;o>n3@((w8M_J&a5&f83pSK#a4!=Cd8(k>8c0C1;A^oFePyMCYvhU~<$2JwXROAkL zr4sjUWyc`QNh?^K5Shh+07hCh6oO$sF0!Psd7xNG4hyh%lrMtDW%aNEg;KC^p-J36 zpu2@BNKnJJ8p@PN!yOxQPZdRg#)fet&M}A!6KH)axFA>|I9xmy7sIGrw-<~HxTESP zn8Yj;Z?<4SCL26xOOJ?~54T3_Jli^Slz`6!#0dlqJCtw~l*dAuVGI|14_z~aO@Pe= z5*^^PLu0`GmyH{vZ7O7Y7+MY=(hgI6d{o>lF_CnFfac4%@d0oAJDjA@yLci@SOdoBk+Mg~`9XG*hbfI<(a=zlu`oCwIWpE; z&y@wQ!f0(0Hc3;IP?4f-8y&y|3~dRL!O-6&Szh}xNnB^TtKy&`9Y;d!8$BBz#h zk)HU@8Wl|Y0GI#)0x+F`RDz~J^gt{OjhI~tVt`qudWxA~tU`cPrsGGeU~!(@bxR@Y zrowA#vaToHDW%B#)Su5i@a3tD14{wK$BULbeG55S0R!B%An1 zL>KWxWBlgWYMml^4M4W}+=cH@#s5_xAOl4Kg_5=>(34JyI*o#;wR$9`PME@j=|K-; zLq)U?pf!1mGb>2`7V}ZGdum{K(43B+MgN)0u=-!e3S;5NRtF| zpF=4U+?R64Tts+~JDh{!MYp?fU#{`v?Mb4ZG6 z550PymobLgo~F(~xIwMs6Bson;E;RS(cSYtiJz&nS%vFhfMVp%>rKMHPPC$T?Y~&Y ziX?Gl_=$3o1g-?#LQt9;JFHMdn%YjVxtTt%K%7o?AAHyb$6t^SF9j2@I}*xeCN2f) zPNEJBo+-xDSfs2g1P-!V+4|1c&~l+3A+}H$zQjByCJ0sv1(yg6ulGbx`puI!ey1e$ zWO?zhKw+X=7ndH9%Y~s4no&Ddq|AOmr;#G(y! zN-~H&XQir)d~@Pvde-d}T03aQ$-EW2c`yhI(|X^_#Af0wUt*`+-JNw3OVV&|>7IVX z#I$F+=&cnu9xav*4aLAvhfO?vH)uX5WUrN&04!o@P(cX5J+A-&PY?hg8*u>|K!~WK zrjKjMl_TnRY5UCRrE(0ifyBj$5*rsLC*s~GbCR7}<&AGfw32qD02y19w>5XLjUq5J zLxf7x>A)B=J8w6o6G#$b&v{|0+No(>drZp8Bq+CuZlzDnPe+jM9(Zd&r0LTZCG=pR0YXf188>dG zLv8{jQWGi3wmge7TF{Eav(R3nLxjjJ;7_UDg=fIzvE*69Ln~B6tt*3KW(cl{_v%=C z1#lIl+eQR#pHJ#Zw{jh{6cZsB00De$CzWy$j#@Zkx=6Rpv7!??Z_XC?2_QKVX)(e4 zvI>xfCeLuB9rlTnf`2I!;^#-Kwo@Y5Y~^Hzebkl;7w6KJOp6nKay2sA3I5VJv|UO? z5ehAXrr6!fq^fx2Ge0PWM<&{`j)4FG0n-y`)ews$Qo>5Y2=$dLv*Jrpa!Bg{0uU;( zOD#1T$doN6nuuZqvXCk%qLaGXY@jx@MKYig5_(*sC6$#B1UK9rM$64S)5!*~z`Jop z30MLtkRrU=dLju#rP5PW)PcL^goQ~XKGyqGAOT4NIFr3_c#(++Qe0{DAc2NLh-9KG zG=gqhwA);_X+VlZD^DzTCc&F&`Pm$3 z%Jo!MZBO08P~T%_goL z>j%Rg&Y0R6beGI0xt-*l7FxPxh|7ohFRW}H9EWB6=Kk~rsU;G20#~q55bC{=$dMfx z+%)#Qw33vSmV}-u2_RRvPytq%7)&J%(@zFi3i#3~!HlC2aEM+KC$<_iP|+esUB;-f zAU%(6ya=eV2@p|J?`N_v0%7q!5|%A^SWZigJ`Gmpymo}>fFZo-)8xT6dkkppMby%sWcYlBL)tIPI;x;&nW5=`yEmob;IR3A>47cGUGx+*MVBexiCDP?@2Fz%zWtNmi`N9yS^d@y z$_IV0c5}nIPLjVR#ZL-mZMD^@S0lI!Jigq$nEPYUn9r6oV$F+vXcL)5C{~Dd+IWEU zQJf;i)tx|Yi@eI;+pH36`Zy6}8b+-Faq; zdn_M21#$G>_?4i0IDya{odq%e;tu?9QcQN0H1#&dD1KJpR9vNRumY)T67nd}3By3u zou9IHLJ@%qMw;D09DtkZF-X%VeTJ}XC_3qnC^w?s98-&Ma2~|3=ggiUSGIgo_W*lp zSBokVcPjbi&VlfGV^z5G&xhl&HJHVVPZ?Q$dK5wOizmTOiqPguN>)H=5i7=Y+^Ghv zbCRwV+!nvX%qKKdqW{IV?5)4#i>Dq`PUIS%G#Du$^nb76r~Khb`)4FP*J8%j%tXDv zL7C_qLn!g#RGhUT4|rt|qD6+$y)qk&<0a8!z=OG-f_#9308q`~s@RPgxMytbcaV3? ziOyOb7Lwz37!_=^+nfs)DH4J)eh~0vz(ZaDjXBQ2Ib8=oZKrflH*)7L5-q2 zn3sTYol_4AqqBOq_;>SQkOe1lEh+LgaKNT+DTrFDFuc>kYpJIkWispYXb;s z0Thil*gqYJ4$r((J2bYUeQj#MvU6=MA|vQB9u-OjtfG|aJ(4M>eppqYn}{+qCP_*< z9>MUjmwdf)D={nQqVqra0c{HfB3TW4K-+Q(i)OsLhbHgormUxR?!Sa^M4eA*YQW$i z*Hhg~rM|mS>vx4FApU`st2)V+#HGBmUGx^$LK(<+W@2k@krsiuEs|V1neAB{J!x23 zVZdtNB;o}J@gMCsJQg6UllE3Q+kP{AL>UxI48N;`)ledS z(pgTTd^sDBChl5z(^2ABMr)PHv-^vNP{<^d%NZ`qSBmsRL`{#)jm_34L%@QDhJ;2G zDd53y$#txLWz;dNWcQtbFO||cZK%?WMuP7tV}}JPIZT$gNM3XQcYK<`Xk)3My(8XG zVjx11k9|e5X9E^U>Ideb|Mv&eQ_sK6P(wI86Ye;@;sj9Q7HWF`5?&O@yJ*{kd9Qimrkrlu#NXT2u!MD&1C}r5F&Y z*O65&NrIFUTHEmlHVFE(O^6~htg{bqJ=)3Qq%X~LgrC~Ho8aYut7t9i0}eATrtQOw z>oS;nK=(2|HZRjCjZA>yw^0Nqi#slIlVz%C5we-8&nZjR;Wv<1QkxOXST<$&CZxD{ zE=@@QG9H*IIcuuxiePA@Dp4|n8Tv44u%i5myDMa1FQE?X|9&!Gu4-sfIB5=@oN+8V zBiOVc6#heMQ@5ZyW{XGpkrA$H(Y^}ETEMNzby(nc!3sR32(){Wo*d3Xz_5;%Na%AF zUr%(=tU%q*Sj4JLNMR)cA#hPUaZTprui;QYPNS4k3A(M(>9`l=7yxStmBf~R-{ql+#4z> zqyRne91|=$zcbY5SBviL#NO3P37dEtn>a@!E~0_H|jPe8TT;mCGI6bWMOKFF$D%b&!vGtK~B5&$QZspw0Kq+fH2 zUL3!&yM!@@G}Y1k9-#d+<&Ddp@`_$1waseY6e69INGc|MBEw|@wOY%LUq0L-$x7!r zN^=sSyq1{m^%R&!6v*EWvf8oIM{>iW!!Y5@hzpujv6QNM>{?sPA!Fte2tvb~xA$6n zusgs*oH;<5=Q&ti8nv;~%6%2VI<@Dt>pjv>Qs7EforVY38(5_*P$2;vk5M#jSUt0rVpe;udJO&^tpxW(QuTZMf8soecEdKYDl-ptol_^&oVma*~$Q6WhN*Xvm#83 z?+YMyY~_^rcbd0KYuvh~Y5GeLkmfrOMFV7tra%o$^4jvmret$jb19;wp<0!rDIWQ< zU!2{jcv_kF5&}Po=AcsOKmhReW5?#5(fOAdPgXHQwM>m9&-6J?DTag)!a_vII5qCm zGCh#D5{Dep@hS4xl)U#&q(a=Ug~DH#2Xa0gwY(AS3*sk z+N5U2r??AJ&rcfGHDDT+Gb7*1Yn^&8duPq6m7Ce!Grm=eC|2LG1>}ItHG-xu`eiz2 zQd73P3YoQ~@>O5}uWRp1-2QHhb5oU}U64Ezo+F1bSk@7OH9ehD*0!`D8Z2_;pOq!Y z1?>J<)dVX*`MfAR!}1fJaSz;q%TAo1yVCC0k?}Cn4l+G z*0rs!0`+ZXpa;r!C(lcNQnXw-nN6$9z(vby$SpPceA(0qsszXJWywu@%=wdMTKThe zT%=#295{87F)7h@WmH@XvNWVNs8A4f|x;@)pSep%9=$$R_5=Fs(T`DLR53O=nMQ+EB zP3g~CCp$O+nfMz&SGIgo;qEj*qWC#$T|}oN46@EF(=L%!)ht?sYnhj9>MFv_Fw+ha z5g8bL*Mwu;pGo1!Dt9GGgn>gc8{Mml_tv#fUvn8kghIoI9&-($$U98V>86mitiUS1 zQ$Gj7k!l+*y6r9ru@EWSg25=Ccc|r~##Um^i*)3=-&rL7TOyIcq(?cR)vYA1ajG6j z@$Wa9XBwBOTZ>iMDYI6ygXzyDtGkaJkFwQN1kT}Vc+UVW$o6GW$ugT-)CZF4y@M@6 z%~N4Ovi;6#wPBL*pFzr+ib`??Gi4EMy?9LYDeb4KOm_0lh_WS`K16_2%EEM57h2mI z_R&!>b0?Gd4_jyhPP>7$DPfU1oHB<>qx@;*L`pwQiv8kyDk|xbaiY!!)2kRF} z=r+!k)R*QKKq~!7;KiPRSpqLre!R4J!tlIs}HSTq|+L=wVM~EeRna!zbWffpHl;l$h3fLcX;umswVwsRC zpsNPGX-u{2Q)aG5Sk#*pSV{)#)nOmD$}Kn5zOvZFBr+ldk|l*IYz>iW4hYY;Sulfg zk^le!*{on-#0mrl2o6F#QKJzxnujHCI8rK+U61aykiOorZETmyu{~++2tw5IvkR=s}DLB2&V9Xb2-XRTHW-;|g!3!YAhd&s}vV zLPJ{!EZ~9$ue%!Ls;*Jy`Zpj6bxgIl%$l2O8d5A*rEE&0XVzIqc&#)i78C4N5R`#7 zEpYxJc?CxMUe}gHiWOb-<{3oCrWDcr;{Qq8^3 zuCHk4f>>g6ArbDnjf0NZ5a^62B5uMG-!Ov8W+9{RaUG_Co-UkG8c2dIKBP@^Xo^&# zPLtDM`EhG_itHoVGtQZUzQkp(1uk}SiW{VtD4|Gd2|{5AJ00000Aea~;Fh&3X0ssI2003YB000L}%&-uc000000000bZ7=`< zfC2TQM4P|5mW%%Ju#-7~BJOsHoO$D_hiR(P4lEQGUAF;*w*_h8uzSKQhxvp+(B&VHIw zMHY)XT!a5B)e^h&F_I?<3kH=f2oyaY6+%N_cL^?uf=5n8w-y`W!jChU4K?&hMpr_A zn%&S#hchFd83c(GSqCg2=*JkdL%RE-WoKK}RtRAni=+s{lU!9)=FZG{UjG~n5Lg5L zO(A1Pi8N}+wnin;lOhUR5;0^ZeBP`3$h$F5hY6#g+*LN#$iN>J33Loo>Y>Geoe^-d zMY(-2NKc2K z#0u61`Mz=DYeU%!k@b7UGAWoe6=x8}@r9dat2Lr}#9V{LkU0n2_T=3_e{?hkNGBC( zbfV9bm8F|W@{cDW*nI}GBJV20Ho#qx4A2N?grJWAAH;t2L1S;RVozbvN*aiw8;9U=jQa9Jfr_VJdvB{3VH)FE-(Asc#SqP#)rdmFK7Ui z$L+ZQZ;Sb4ok;l2KbOL?c;cRR%U^Qg6kj~d2P9lxy?q@2RjhL?wKj*VXNojf-XzD` zrDOLbA>+iQ8oAZi^az$m?`%Y~n1|GUjp($=qRLia79E zGVWBFA90^He#;vYc#%hzRzeaa>y^V`sm<98Rve^nQ`W?Pl_-=05t$l-1^^ZCm;oUG z48emgbV!65e8N@41q*j96edAVr5aSAV`0neP!>`{Ii%>cfr1)rPKlYc!m9(}`nCQY z!Rh#sXw_Dd*T8@`E)oL>qX;$zu!>-WXS7%$H|iue4*sBFxLA%~ZLPHujZ41y{jBVh zo1PCv7y zpa4J^7{GH#B#|P3>oV#GgAk|y9U__nZH!>6MHUwg`jqv3Xre#KKVXfpM36*KEEFzb zX+wfFsxJC+S;o7mf)YwXr)(PxgQs_0r+u)57Z@TZ*%g#imR4W|J-&1{nEJZF#18q# zQzd2hlgfbMF00PvvG9cdf11XoOyOj+Y;;_B^M?ktTAG!GU=8K5;3cCbu}98nCT01RRQ z2mwAdZGy}I2!a`aK?zjiNMHd43X0Y^@N#jb-2B4Ib7(?Djy$jsLFt515H=?QwL5Zg z%OEe7N~av=2rQ0jzHp}jk)fyJG=TV|{b1|fEA=W`N3 z3s~9A?XAeqyChGeFKG8Rd#mTey$7wln`*TfyJ#l7*mK6Af}s5C&&t~8#9d9~Rm?ag z{?zJ_I%K8aZq}*yQ~q8yeU+I&V@J7WeU72*l(XwXiuXtWF7L+x$;LB$s9WQrN&lGn-rfHJrLQkxM7 zq#jo@7D0jt4NXr10TkrI00>_0Ah5vgaFB=q4`6_O8_az^Az7EJuhmDFzLMz2W`+O& z0oxP!9FWokQz%G6mMEeDB@{vWi}+E6cLTCEOn@mF@$e7 zaCdf6R*yGptkaW?O;b@OS`A#8wThO6M!D`S+JuX=fQGROCvzq@lG6zwaPBtB_Sf~0`kc&k&kyc8Dv3R-0U^^~>M@KNXy%vv2O2&DvDuY?#fEbH ztZ-+9sZ}T9T@~@v$wvLzCu$f$dW_E&-rFfbUdEtZ0d&GqZy!o%XpBBMWfD4)lHf#9 z!^4FQvRh<=(+LSDn~4)eQetGvAA+_rCJF+`9pcF(kwg(~th9jPtxk%>>Lh6|7gFiY zlQWcDY~=+qWil_El1nf}f;w|p0mhq`2ufsVrq*#I$wV5#-thI65-z!yAg|(=v<|iU zt0)E1oH^;(i9+mT5!lgiTclE-zs*%7dC@bq5vU4*Yg-x{=cYI{yV8lBhD14Hr(B5? z7spI|`-)}mpQ1Cu(_POD!_67UT!Kqio=nH~P*ztYvhJFjN+)#QnG>0wWz6}LIHBmN z>LcRg&Eg>G?O>S+5xDZW@LcZWCB-7dxbzwlI z{(H%gDqKoG&&^wr`6_X;WQvopU|bx@Iq?r89XV)ZcZMXoHm9^hE? zu}9)iu+d}Z8JwP90{@h%DZ$hJBiFwWeH7Rtu`b!fX@9J~QyhnfyhIUNZi_^w<^0zb z4`+e-rsYlEWsR8+yt(ra@MAotDhF<}GWqbq(%ryBltqGgM=~yQDW@?+=q`mt_MRW{ zJq8LQNBLsZh7&mv!*i}-Wa#ttQcPCm5j z&X!#yF}gI zlw&L$(f`SV;IVF>}hYV2A;l|0}c9G6^K&{bBTc%IE zamDs#O92dF#Ev-~$jLyG`=X4^5pI_05}J)n{BMsXb|J!uL5(ykxU_ILcXudRYMsZh z!W4#uNtyO+yfYb`T!@Ka&#Hic3ai*9oCG#c%K;bJD0iG*Zpaff0xjRpQ1j$g&xonP zkN9-q{O}8=*K#x5hQ-gF@(ke5WMgxOaAM9pNvIQWV*BxSgpRGo z5#3(<%a;QjT8><_%e9Sam^^jy;Gg(h!S_+#7|hr0;mL-X=jsYpt5j&1WVT(L=O;P= z_4_K=ZZ${4S1Cnwi7nWmkr5L$6x<3eb83-b4nC84Bmj(A>_vmiYeTst`16huva>&v zS!1NfI;L-htj?FB#h0ReKMiXucRfaFk4_v_Nq>vc;aYb?W5?BqUdvkiD%mU!UFJaq zqdroPmL>Qus%|UFP&TaQGbR+1yv0FJZ)*=q$?tS^HVPc8kwEO=aVZ;~4TgE$35vcS zLaocr)(YcoNeT7+8#HqEMp`_!BX6&i3dNUXM}m~de!`AvX#41;neKfl#2L}dEJ7%* zFz`e?5%~37OJFW3XMv-MkYqGbu=eZ_$A&Osg&Ib9D@ia*e4jxuaU*4_Z9w+hVwA0~ z1TNsJx!oye1!3J2u325@r;89K`iQ+9Y@~Fih4IdFooZCi-$lb}oic;FK^AF@ZDlfvFwY{l8th6}! zaU7Fi)5;zwvbA+Z`TlCN5x_wkSudX6KVtKuw18}*~g_O z!is)eV`!jOsvOP*IOI;Y^zr9PpIgMEiypOSON;zq$;aMODk1&|TEZm**&icraa-8l7}=lnPR zJIvw4eri>N&VH@Y#(`Gl%;tCSnG{?W{k`46#V?DCIYjh(&?;n)d=cfos^nX+q%R=} zS$`Ulnh!?;OfT^U=?eGp>kfwOe#(JetoHZ`-RQz?fHBJsGI zHcx=|cs~3ROwA{32p>-|@Tr-?Q*&92${HF*vQn98YubEIPWe!i2-#Rvwh;=T*1~N4 zm~X9_DrU1WkOLJ&nbz-KvqKQRX%_rV8$KpiW>C&GM{6bS%_)6*IHs{65|(C zn+SECH@HYfq#D`ZAy8ns5f9xmgpw!Sv{|`h5*Y;}m_r^JjCh2RnV8tdG^E&ZOMs{A zPRTaSW8k|DXM>*7+gkuHkadxSnAi{{SF}dR9!SnWCO-$36c!7hejPgOM2|Oyc==&O z6EzyNr2%z-3@THL;0=4&AbF+yR7*S@yu!f^F3w*wAQm1r_>f zME*D<27Ep6Q+GQDoA#<<2oh+RdPmeKV3tWojoh(^ssV$6wsAl-f`52lG(MuqG z6uWL2drrNJTV2}fr?b!~dp&(`#o)TK&~_sh=QB{F2?0`hX-ZOEEy|sY3>O|`XFa~SI8Ov*l14{^I<3F%vBY;kTWXvvfs!C!$&Ewrb4?F z7Lwm!MyZ*FoEv3fxq*pLS+U?|cuI@XrpXJkcu=8Dg%XKaNV7L!6i7f}qZ$+_b$yQ} z<0+XZaFFQHEj`HBna!fpQIm2~L1K&~kS8!|74E4qEs|X%UFocNQ#@xQdBsal&L?K6 z2Fg?mviS{#C7%kr-Lk_;0ikwwKOl8M3u&C!HO&!2LlAiu_?Zt4UZF#m26)n+#Jd)t zNP;8hF6-2JoSJK`YgxjM?5YLW5Li_4+S|vKQkaC-w5>+aSh|)XmCx{ZkrM&;ryWcl zUzgTTqSy@L5S@JguIq^947+3^wK?ZE`;o5f_4d_SeD`5FNJk(zf|tnWDqXRBYe2k2 z(jux$QcwoJ7pepn#!mw-S1?;*_jy=Z3NRfPSSi+?Exl4q6t_;zWHpq=(+Fm;7L@}WzLgw)E!&)~dU!P6rv91Ze>?8P$u4ZC+ZH(c^$0%lx3jPCEyL`m&os==V zRTLNgXIk(p*C$)V8Z-4|*bur3(3zedK(pUl`OS%%%##ZZxQNL3adNVdHj?jEErX&o zd^wYmu&xjq3ec9EiDii1)u#%xAr;vJBzHHNmeg>YEtD3eP_kTz5ywE*`{y&grI_YH za0J}vtfhgoShN=s*DDs~HF`yuP-GeP9#ivbMY-c6Wjq0RcHT~R*>svo)5w)R6=F*EmqdgWc8?pI98S}({ zY*S|UvTT?4N}4H$qSMxEKRO_ToE^xwh{)~+Njw0!sESws00H5z-~gx`7$PVPEr1=E zA+sV*q8%ud^OnjLOPd}E+fh1nb8{}7@Q7e#hL$VecT{9`^`l8~F`|Gq@ii2d(!}D# zmfLMKac4!k)XgNM`-tT!zsSvGlFHfzYy}BgQtgeQr-2A?q7-nlK!hLtO1p?6aA}-4 zy3?Fdv!zWG;7q}U*aQm_($2|6v=u8Wf$rzWv9Dy7oj(xul=N<*t8$S}_o$&q4nj4I zY!Cp*DPj$jC2G>WvhkWYN7@?^f%6Ej{)?O-D1AhVVx&Y#BI)zLs8gvxv|V8|$jFeD z7$F1gni69-7!!blCcxT(TU8xBbm(5rXhBl27Lcbfc7l6@x~UK&A1DNlRaz8ns(a97 zzrMwNNDq=iaO4zHqof5zkp3Oa$O+O8N!B-f~+DM2R{q)z@(*t*uW& z9A%&Y00H6v0000nfPg~*01N;C0000603ZMW0000nDG(q)7&LPL00000MqmH{009fX zQHNrnkN|)H1poj5n6zk$Y;jxcB4Po7kU)A2!z~vYC~>Bq+@u?GYC&N{wm+k2<4z@c zbGOn-VBYGoqDnB|&LmV4D^<@_V99pEPApkZHrCu?jT|^|os2&~)wPFXzGZ|=RIuGn zFp4ZijS@I_%mgY!lMqR0t4(sC(eb0gVNY=c{)qy~$jmAk^tQ#5H%%&p3QR4~w{3MS zcZQ|XKqfaK^l;&EdC{}byV_Qt4HNW9CGIXe#Em*_H^nGeO}wlDaY;cdCIiE9tTqCr zX$n0?3ZMh901AKsW(SEm3Q7efC4AgUZXr86I5lF9#5%pLcGNLLEg?nJHjp z^!554H5O^pmqTa1D_nS}hC3oFui~t*abWncvdI|AlnEet-UPU@J5n~&Kp+;E=kx$$ zQ*2{)&SC`wc<$qV25pbuDJLA2no zEN%|j6@5RRQjR|5B|Mc+>u(7nWhddX&1p*AM7#fM`&2)Wtf(3vf;F9vwN`m!xt_HSI)qw-&W5G}>_6QMLEB zgQ-$mHhRZNH&&Q@%+$<*5C8!H000)jNPuminsw$D!+X#izo0fup#k3)z>ZZ$^L(no zsv53fMhevCR$sm8{Z0^w5DGP+phMu41C7Re znwrO9%lxYW8`1uxw4G(Kf-Y1nhGNu#+H|>bJ*`tIs(pNpty!nhw#b8uL6a z>ubY^K%k0NW~yQUl5zm=jV2%g#K2__N?WKyLacr)38RvowaOcuxo9CRLh+A>Hr)F4 z(#(%f7j0a7@B~{jOiY^|KdU8sX3@e+`QqgNT3C(Q0You$LXtqtyq0p1dj2DciJD7~ zKnf46V0^TetViQ*m6r79c&2mTpN)D9$G>LOm5+*FiWx^DMPWN8h|OCxiAn5dMvvpB zo<8%7Lxe*_DOD0uaa82Y1R!9D#a@lbkl9~_SAGyEcvfVG(M7zzNz~SB6evyrB48#1 z1c(yH0*Q`|i7}8`q?qgh+5zwhl!{&;4E<(OZLoy)LmM%NP6&v;Sf^WG?3r9%1r$X# zG)cCC50m7#4hWA>UTrC0_bZ4@aZ9&TYRG9&lrKsq7o_3M>gxB$bukIaC=oDC4cYaa zZCpTtKUq@6Pz9*0OTEY}Ak(#%)p6**7Bp3gjoR7Fk|`C{1e%(j1cfovTN(5ijVK4m z4y}a1H;UCEtY?B!rJGUU9ATW^U@1jZ7j9&zo<# zqQt#>tXSg6eJ|q0no_>nKeQ$7e{)_Dc!kD*OM?EjZo~+^Plo{M9{kgXY}l~X8P7r=lIsj7CL$!7ssAFQo!9&7SabSSpLu6Aj(ka8Z zD%}|sPMD1!1?viiP7A)(*)7#Y78Mq%ut~MNMXl~5iYqXZJ=QPU0i0c}VzF>N{;c`L zq6u;3BA)hmq7l)@`w{R+yDLQ@NcXuQCVWm+B;L=}^&*Q%ovdvE54MPqUo|2z{VHvj1)oI+HB~GK>%%`2=Olu2ypVrrCKyfdbLtz(h9$q)v$jgXoq1i}%;n zCN>YE=w}ImX{Z(zC`Y^KCf;YcwGWKEdR&bd`>CKoa2v3)bgvGtqT-foexw&bVC(HT z-lj>e%a)KKsWY-VHd0GoO_0UaRGW2+h^NX}!iRY(rV@@5D#e2|1`LZrB|rfg01yB| zTItB6a6kZrNv|46gNGq(-8AqyqQHn02*$u5DBUSuySKiO431||t(UqyYB<{zgXl#@ zk|}n(U=sZkrVJLN^RrZtW`hJKMQh2knaz_fUi{tX zlA3pGVFk^Vj_rM@9F*1lnRtY<_fXq{1Z|}NNfLVWR%(S#u?+)f^HuVE6j9&^;>PiN%8qxdT!4)BeX@Vrp5&&EaH0ZzNFb@xGt0c#x#*!O! zj4w%xQ;0&=h_-*Rx-25baD2qM!WHvdEy!jM+n3&R>1~u zDYZU=yZYJ)ymUq^<*Mb`uv$Hgp9ZCUrN2|Hrp{pt%ne2kTv5Zks%FUw;{Pr0IemLB zeAXxRqgGn&gcP{tD@T$jR%7ehQHy?~j{pri+UwTG1%KS)lJ2KS{`YvudJ395%py@TM6i~USNY(t zs;5}qDgG=e2vW`C0E@{81LgKqo9wVeHi6=2|7EF~pw5(#;^5uBTW7)r3wTUun^y0? zENRZC1(y5WE8Nl4_b*iM9_3VbP|3*s#a>}k`xMY+CXfLG06e3j<;E%vp;XwS4){1O zHN+6qOv`X28n>0kf8Ik;uGp@` z)#a=a?Y&3vfnBJd^;AYi8E8%gDvC58#M7H-aNsOX`p2uy1Kf+O%EU8IZLNn16RdGM zR*)jks8*yV!m7ho$tTGU!6I?6H4$Qn0G5<5zM>s$m&@~3T2&K$+X&jvPBzJN#!JS-?k;k>65L?0R`qls!qdNfK2LI^9U$M}NQf7AuVeg{v@0fDkK}D#&Mb@fVU#YF5{ueUs7m@9hk@v>mkpW`JbEa@@ z+N$_0$Kn5Z9bo!Kl6MyM`ix-fETUDGfj)-U}fNVOmTt8A_Uwry$zz@=&3 zN`zKt+XFci%|H#C%Gv;k+cOl9amrWeBmeTon}s-JVqZU*uHJ(1A0sv*L|H|)n@sRm_`~d4 zyYs+09h5MKqQG@Gh}344zf9K9QSeOE6=gGi^HTtKg_C??9@>i4EilGMg%v+c%E+yi zX=t-EEu7{SOC#G2Fd>t*AbcS8=a_ORbzxiHN$T-`{%yIVY-%%Y22{45{t6Qx0%Rv7 zR_o#BnyYvw1;{)jWh(oZk(8e$@4jY7t&|N5U=~+sutF(~mI^E=*@Y)U;z6d9ualxC zK}abQz^uc`lv8Ovn@{z&6iqO$(`daXf&Wo%m!k9An}RZ#YdgiXKT?arV5DGEK!O$5 zE)ZM~-4~?W+Kugj$(M5tP%E{e5dGzu7^~o?2!x@+RK(78EiKB*3lRx+Jv}(a^k3Vmm5Z1>RW?sEp(QsU~hgqAKyc-y73oUoFy7 z)LX0w$gx$zqU?a9{XE&|5lq?6R1hdv6{7#rwe8nQ$VDs=;ZL$6nIp(d-&35N>Z8|8 zib``z6lnpI!$m#uDQKVZ>!pA09X6f1+LXfyc9H8!%CC4U!zl2u1si1~Qw!c;l1IDL zd+6wUSg>5m1I3oY5kzSrwlhrCz0oo12L}Uj?>t-Jc0AU`h8Rs{j^F-tz)+3 zHUL7V7DjH2*I)>lZPg=#qKylnz|LfNF;Q=5Gf10)W}XjXAzSO`sexf=?L7?W&Urg1Q$$V)tgrxPXVPilK9#9l6P z4BQ`qa<#jYVxhM>$@LAn#zDw-1;Ui()>m_A?K^t*#ryae_z{6jTORYZ?+oKk#I~r7 zE+jM8zUo17BJHFPI=>tUB`3t?opP3aGKEOV>i&=X%?Q(n0evuAnIE;E!53&_q-TkKaLivl=`f?1gKL87xxvN5g#$Utb>|UG-b1|SXNz-~S{jtp#JCDWAtn?g zt$i;I4J|;;Id0f_Sz!5QX#j1T?&%U*Ahl|;c;<3dZidQN^%(;ea~bAgU?}%3vQp6n zh~#!AA|!+1Q*N1=$0#Ma&phnrRS|fWSONT})s1~qwZEs4t(4G(;Pk!>?szfs2%3+g zT`7>~MtE`@8hYwi(*HI*M=azkuZ%r(*z+@{pDP^2R=~jzO=S;R#Kk3n-lCd^2(kIq zl;xSZpLsb#W<*0b-Hs_22~6=4{Tv4lxF&1eCA!d8oTI2mx$5-gVS<#8Cno&DJ5QIy z^$Pfd$60thv%{Yb_*48E*=?>{S%8*WK?+$hSnMqA9ECf?Vxfw9&AS0xglaU>L%tHMu+u5uCDg^KL1?lwy$jk)tS+9pI5ixwRGJ-ec2GG>n@oycO|dvyG!v#p z7x^2T5ps~Jz{Mm}FygI+n3lL@Sri4Ul4S!G9;!-OQbz{7+MYC zLdFS7$Vh9d^VJBr&^@|pk>SI*3z)KVu`yX<9fs8~7T#Gu$pH4@?7MPCNI zI)p#Fs7a3Vb&;2L>hmZJ^qJ9&@$$S8BF?STW-11|PK$jFBJu9O>4Fp_UA;hQpb!bq zmQrK#a>%(Z{zn(*H^Ahiv`x|Gp&3ec%15uasB>98FtcnHwRKNQ3UWmnP$o*b5t*$+ z1Nac(ks$q`Zb6h(}9Xk;>koD9>&sIli*C0ME3HeV=2 zgsu~ii-8E*+}j74>P-^nu$%IynV~68g~9m=pA*oGix8!xXCOxIHS8f2 z1O{Q6s>O z^N}-o`6kUuK^$S$GcZjZfUFCTE|S^>%O5ozFl%}TpeI(C6v_sHoMiH}!l&zDeI^Mp9a`?uiEpj(L51h-8`g*NHSIG5!|CY>{?R;15`UOLL@E5%?3rdDoc zG_1$p*mj50xbY(IUYof_(s{zN!@=?l=HA@S_H5fsC>ATK0|m^T8TfDm|ah$JK_m}uFM%N;dfoCXU;P*hlb+woRPGc(ka8)^`;a;Zsg=Z;0V z&J;MhPgIr?gj9*OMZiKshLMFfXA%oeH|nH9HoygDscC9;C?sb>yuafg(CBr+-8EBUh9w9m2V4 z9?gp{B%=yX)72-rzEI4HMr))nySC6LHNkny%!1D6y6>d6nmJA$lBZcbj&fHCUP~Yy zPfVfRJjZ#?dke=BR#k66tX(LUHG^^vydO81TLs3lLJcPa-i^}-8Z(d z%fd`luQr)uVvsd&FnWK(qL#Mo0Gth{u0e&j6SlUpu51`Cib_jxZ38(kKX-}kU~hW7 z&i-V+eVWpm*RV+uRtjlFi^8{K_@bF)h%3s>b;?)D4VcSXX3=BrG(oUUvqB;hd}>$zbI4FM?aUTQm)7Upw6X%Jg6i{@YP6jn?y(5d)5Lg5cMs zO2{ZE^9VrEC~M9k9A<=&r*H@r(x*}pPQ%cXN|LU*Z{ehxa0SH<%X^S5=XQ$pq^*}K z3rwL$>20tAlsn|CU`mo!8G^f1+Q)`3rroit4 z@Q?^_(-Fg6AjlbP^zOx}+59E5<;Z&%RNDpGa?}ec9)4bKjRn^M?#d4Bs&4>0k($$r zpXdNwiwu)K-zmWYpfDwAMiM8uAaH6V*2#s8k|Z_F7#GE9AlfcV?yL_xyxJ|x!|vN( z-N@y5lY^Feg;;fW-AIU$lSb#6Zu1GecOPP{I%JtyA?JaR7-L>_sq(?s6Bp(#2#*Ehm z6-Hs+1v-QD-3x9i-Na24q$8M9*J`RL8L|?qvZk=-*1!{B*~n{ z(+gJURh%U-Av7rwN_o5sn!(KEc&3i5Aeo;gTKB=D3#>lr%Y^|tkOgS8s+oDdGDw>NUJ%Ip%sME6&He^8&dG5A% zvJI~4WhvPC?kr%6jUNWKSxiOyJ})8 z{H&hg;8I}s$O|?NIQ=M|C2Iy#^D5k_v^OwD&iRL1>J^sM1?MfWxbOyyWeyn_QK%Ou zXSV>}2jsAAFGwQeEEghL%J;qf+D-flaOzv~d`o<`e|1;`Qsu>?)uDCrze8ZbioFEb z*23O>0}e|4NtW#i2A>FnK|vRTRs|Ll*PmoBe`PX2xit3S1uD*-@a&;h|GZ;juCU}% zoUVt%jzxp-OMa#-?6m z8W#*+4}GyJP-y#eG;^MU=cnh~s%gT{z;{a#{W^q$W^(5~{>Gut(F{ z#`Y*A!i-3y76i-+F4x&-kGYHK!WiKe=eFhsCD7aAe0H`7kr76Yh56uPI$8Jnr* z#{!{$X1&RhxR$5Gl|JSe#EEL2r1~yZvKo5kV!J%28u^U~6G$kwv7HjRW5ljjled{vP;ifCgdVyFI<0v2)>u*E3b)eZTWltjhv zxR{h=msRDWq2AX}7fh892kt{usU9}s`aW?n=M>LFYU38AX5t&nOF$y#_9G2A^-pY5JD2&6xG3yPzC@14TJyy z4fM+^fk-g`00D3SIE+cQFi2^_&`GXe$)HoafUP>6Bp#VaG$Q4cp4Fnw6+zV6*COye z+KvB=Z~O~NjmV-PDz1|o>5mfL<$`jAWb-3vBMtBRZh6=zc97+S%aeH7$dTwYmH{|b z9jVAFjD{d81+-zjL_gxU)Z`g8py{Go<^q%qY#HzjHz-HSd;~bTWFu@V2Of|e z;GG$)YXye15m1S)-caYdv3;J!gTM&;EJEZJqW z`6JIEy-*&eGaqv(t>?4OqniUQQZ2`+Z^fJWxVFfx;R_<5bkJkSm~cd$w&{17M&A1^ zg~+BN%r3sa@DhK zlBr|B9o*|DrQ9u7o1Jc7B@a(bBfSfja6h+@Coo6_vb5;Jfe-rARN?EKI^Q%O!Xhn- zA@HY*B3!?T%Oj+?t>*xm(iYJm-h|do6#4WSb$)%VPJmoq6mvW&a#gAV_a_mG5;8(# zcOr@+02knv5pHcVhzhre+s~ktY&Zm^9qXsaMTCgdI?xoeY9N=-R18FmIz(yRZa0eC zC=Q6+7PX(&!XYYrCzhu~HDb`EjDRt#20~oU3tpb>U+9+U9`Pg?Xx~=F**)(K^y$^mkx?5dSP6%ok>A;k;x%IhT641{w5saSN!GXN zz5^7Kkr`tqM<|(7Dv^$Q^TRUhluxF6nXJbT0%Y7@a|6x{;1#EHupJYwMwB`M?L z#_EA%T=q6p{Mp$}$sX?Jw z@neD$O|4ut?*g~Rr{gvxBH}OHf2VmD)TR!o;gD0GASAKmn}glLAOm2Pr96ko3CkTC zEnw=#M1z^`3mac!g}Ylh5p6G%_D+%DuGxehTo@>FVZi%vJ@1Lj{7fqvUD&b3ky%&` zy(5NDt{g6jxo?XhyGl!wY%x|t_5*wtnk*Rr146*MX2*0%*qkEj8!r&-z4o&A50-(I z224jW7YX1?TuLsdYI+Nv&arhuLb4xJV@#`toixg}3B$;`@j_|Hmt02RO<(y?AVBJx z4mDsnC_-Ro-Pwa?;yjY@WkRu`1^s-Lu0BVTiFQ)LX6Y_m?eVenWMO!{uUt@7Ox^p? zxTD6>)z2upDb52iWO0T!4hV}Bc0{mvD;t|PElb9ggeO>Fe1&_aI_G#e<^h3u4>}PB zWguVds5}(DWdyoO-+aw#f16ACYno!T(5!I>xgYPUOMnx z4c#40f%=cy~;}SI;PU!DNI*tulic>=vQ2V0C3L-sH%>{VzE5${#Zk6 z+qu|KO|gZhcQ$vc(0W-?p{(H=SqqL6gUGbG_U=JH$TQA@_D3o*!bRcPb-GjZx`mQ= zBom7v?XVwqSq>l*Pj$%E1|%j)q7)5>B~AqZBmFna|68aYBZPdu>N)bPW=mX`KLo(} zhYHp&@TJcj;SBL%Gf4iE4)C!}`ba#76btfb7D=2M4-PnJ#O~N5Mg9lJ?GL(`QGN&aLSO(e>$P9#H7G=Fi+e(p{LP4-e3K}_V^~#=UI)pftF)UJmQ{1Qp z0ub$QDv#1Tuxz9+`lVw5#5nvWCa)}~Ywlz|>nkW}oDp70c zj@*=3CA3Qt*Ah7*q%j1LrH4%WDIAm%Ary#VtT_#)(1I4tMTjMaEC%Z#9MGmTSqO;? zq{OmBDo|N0lVhptSQYd_X42Xf*>28-2XtG$&voPJj$y|KqqIR0fsro*9y-Alx&Wa- zUcb4mv7-ozGAB9R*U$_vjxRXRosnS!4(PwCv#z${P$20`z$mvMjs&+g#ki4?`@E6z z+AS1noQh1r7MS`<0%iCluYHV>$N0Z2<3DK_W8Ql{iy3+}0yw3cZw^VgL+tt&lSW+C zM=SAh*dh-f-e9Q5v%=Xe)9svu^#C;V=)Vwqnf(4F@sS8AeEi!sN5abw`5W)rT|Pc^ zS1Mz&qc~X`<%n=mElJ}+6mpeJZoIQ|tQH_e(4_2)(-u0E+ZC73Hdt@ivAF>qj3xNX zRN-|^{RABuIDCzQo5NEe=TD=2T_&sT zmi0W*t0mNvP`&iAKNP-v@#EnL5k-&k#NrH7Zk7jU(kE@m&LUX3U}Eo+z{?c_!Q6fs zLAD}2Lyd?E5f_!SbCGn`M*e{fWTz;-Gn-LceWtpj>5xcKLdZ~m@t4m@mzxn7A+*OR zI-Qx$`Qt+}kkFyFR)Rc!9@`(ys&;+>e~8fu@GQ_!Pinnv5j9f z{4&n?_XE~LQNMCr@EqhlO~0KT^p&ZkQyUS5GQ2t|3n^Q@h4DTu2cB<2QWs#XuS+Ln zcX1)}{1r9vD>~Uqi-&41ifb;L!A!1Pxgz5{c!SuX)WtSZEmg2m z&HN!+itRs4zlfmxu`G}(c$2x|zI@zS3{pU`4hRaDCB>kpi;*!L)bn7W-0&HLVB=5N zl!RR+yj#G`$U1Qh6Jz=olos{zXilhq)%vWcakcGO4&! zrnU6rJ+`v>u4He2uV=gg1LuSn;%t5VvHRP6+Vj z#a|F}iDD5SJn&h;y#1H%W57A5<{sQ+7a~HCMq3a4HM5}@TCZ1Lff0U^ufIi2{g$hl zN|W~%DO!l`=UNsCX>-Mk1p3pUxEsvCK4_md`&m6`4DME4DW(3`Joqo?aj->PHn{m#n!Y!>Hjh>)>Mg8A@&;N`@MQ7$Q;$T!{&UaG$) ziYen#SU(Oh4OI2H`(7C&XSwAZ$Q-%4vg%jCZp@B72=lf_F3X6IXrlY6{0f*eD4{NA zH7ImNdY+0rNOf0K5hfNqZs==mv0}FLGvdanmL?k4`$~D61XeQXk+FIc{7BNtQ3LEw%-i$=DP|O^oQ>{L#V!=E ze5F#=78I55Hrm>Fn#CMm;O7{BGi@d$Ud0me z;)2-sCY~TCKSpb;j^|EMM!PiIk9xO=lG2quB?EJbcg`S%9#oP@u4xX@5`jif`#$ME$ z4|f;xB~{FpD8iUqRwHOqtzxpP@}tUigY0E>?C@pt`~Zp#e9GNqzxd0`LMt&kR$!8n zclZ#KaBZD$i&q2`JACH>R_F#2-_xn+&p?T#;NHOgXNdVIwBfuOD+IxVLub?C4WOST z^zkipR?WF!ErS;ep+Rdcj*xkm(R}CnWsMVR_f18I(BwC!-qdMHb1J*|&d)rbQ&g;B zuXQ=(Y}eLkk6RHJ>oj$5?(vr}DS3G1HeL#(x1p-$wa6tEi1LkE}h z`#7fk^{U)QJ<~!(DK7_-qFaX?8T>fcW@@IeeJ|ckW-h)(+z^Vyc_yr^@+@hV6@a=h z-NlO+Jqp1yBzj>dTV}zMGWA_$PtbkAJQdDdtXhroThISmIQB{A+ZQ!8%ZK8Tea3-| zt&TsrJb7MPH_6P4%Sf@Au^HM^XO`}0vM{E3qv&(=YCt$1&gEtD&s9n!inM3-FrSvO z%}d9~i^;7j6Zv8@{t`g3JB#^rj|eJLGg*JdtLPU26!7Jd>q^vH$zbpOJ~W_R$w_2v zp?*ag1;qb8p|>-QNaTz8-MRj%DvntB^5nz?1Nj$~g0G*-M-@`P&Ckyj761SN@rI$I zdFh}2ntq~0`vDtL+^v;RPA1CTq~AGb8r&yprYmMr zCa#ppo?eA!iriVq8KTZwBe}Z{(|Hx^_~9dtWR>L+x+I5lqLAxDrOa(>h$POEK8Dw2 zN29Xi{5UbAmgsCYdS5Wq0!0_ZgJIQVL=wW~Y8aan7@tqvX6yN}NT_MNg?z6#!#D{7 zxr9o(m(>m1f=E3y^d&l*Ot82ZkY5N=E;gu)LRs6F4d(FMO?N0shN%m^!N|8Z5J9B; zt6HWi8@~M7j$5;Gyx0@SJ$19hO?FQrYYO8zcGWp@Na3ig`%$i1$FLnC!bYuEB4C6r zW*=2(PK@f(osw{mA~=G%5i~>zUq489A`E5b-d7*3DcS^>E=17F;C#q6{ zWsqhsd|MeAr8B=;tF)KTJ=mpEh)hSkuk5PD{jER$WM1c#b&s)J^dBTl^~eVX%Lzx! zB;Om+nq=xW!Ord0i){NOS5B} zBkmJM!JR}~QhS-=s|P>=$t6d;*eC0?U27Nt@d{hQUuAFiE3!sn)qQv+t?Y-r5u)M7vc-+sb%d**=bMh4jW@8l6*&P>TvikqDXjl3R zh|DzyVp683_fGm&)bGV)))R}fi2cC<_Y&uR%b@=T^SA%r4zseza=n?`sd0W1rKPf{ z`wio%>se6J>wXw>4rrp%Hy1jfKTGrS{#h zfEQSiWY%9vDkSvoevtLeT#p`0Cc6y8(sP^c{dqh#WX=!eNJ#vs{0d0*w~^!rk;FBX1yoi zOCWQ=+1tHz`DR|;+n=<+ZXRAKZxWh?Y^Mrhe5Tj`&VlG$$-WKl{RJ&iwfptBm(fd+ z<}qoUj%97YgR;9jaeltzHr$t`jkE(LC}6yNqnA!!Ss2mtFl6n!t+`nSxfey5t7|(8 z+-nxB$H%6wYry#bFZ%Yx)ZPT+)Hf33xgh5W8X_Xa6w;RCf`y1!oNMOm$3C6Q6tM5M z<14eRQ(Zpf-ebfHe6T3HDW@sQ1Nu@j<-&u+JonkLZNI>@hu-!{LQ|9`6P0phO^a}( zv-py!?Bx6ZA^Ku1*}`3e(Y8($;NIljcS{~GPn0ytN)d7AgJ*+2!EVPZSpm zI;LL|5d;I)I4V?>g*T*E!?NFNufaL2-g=?%rRlhjDY{}c28L4S z_mxX`k$vhlZ)eXhnAb=py9u=`cjdiTxro;-k?exu;a5{*9c>jD{8JYv$6xn)s8-{ImW-Xue8~ur-efg=$eE8%O2kqU6taAe>OypJ)0?OA$B${Vs6);l3oR6xJdwD^_yi zx2wIsRMfoGlJC~65XBdbIUv=gyNDUr%Y2Fgg2&u*CCil>`~sbDasWyQiy_t{+BcZ5 z=1z@@LWc+Oa_$Y)Y*n7PPbh=a(OQJB+|ubnf&(TFimyGzy#6HBh-H)$kay3X)$L=7 zxe%-})BM(D|8bRHaw#CS*coH`0_DIEMFSh|2R1%J>^>3FAT+UCG^CNbMU{vQhj%>- zpQ=>ckLYXR)VS$e=&J-4HOu~(n<-T!+F9Z0PfN+`MEnXY^t9T_B&G2`8oaT(SM&=y zZVM*>ZD(h;3^`@4PJF^(uz0NEbqg$6=tX0<=yE0b^@yVOemo52Dq3RIr^Byj7dqK5 zXt+*%@!)G1_2hXoz~*MqDCz!u$x-v*quHQE;>Gy6X+qiw_E=zpzHz@~`4z3dlJ`4v zW3C9OY|E!!@=t7$`QRl&bH))Kg^M9_yqdXLPtIvyq7Me)R#=gz!|6qOZ8N_UMLD66 zFYh=!Odpfn&&t_7com6cUP{iQxs#)+e*fd@D710)!IqwI{|)P&hF(IJaif{yr^co4 zo(k)V^`a;z#uJ1JN%kjx0CZB;XyNHzg53<@eK8kL z;PQy4b;>I7cjTv0w`->7uBH;5yBRZN-%&ZJ& zLJ6=dcFG8%qm#;fj$iJPP`?JqxF_Uvlyvx*``pFOi2NuttQluGsV+-~)jI=mVy4J< z{bV$oe)>_ll1fPU`jr=dIP9LU1)%g@ktgIWj}*1$qvdV0z|(gAVKKP0sLL5g2Gra> z!9wTOt>25?m5p;S%fi}a*0CZx6Sp|ODKX{;Wpg-kx+d~6pTaeNNyG{@wnEeSE?i5?B;)PLV`Ssj*_m=PPVkiFm{x{#=6J z^TAGhVp$iaSk;F3$R+JVyMb~|K>4}QF3r3tE*Zf;XdGQzTd88NmLtW>0_PTRj^vs! zx4VKC34GC&PGt~z-VcR)`IX?>C(-jPJz&_D&F{&4L~hOTmoU6TMAkJo!l&s@hl zZ!)!7Rxt6X?_^j<)wSd<9nnFt9LkyaA^3g2tZaZO@Zj?(&zrI2R)z9s=BF8(oIw}1 z9o69I7fA3*EYf1rlK;yd(*|3rEBwDa);X^ke}9&~f%Ov94zg-bU~(M%u|`?J{uEst z?Fjs2vbqMrtHI|^;ijukiC{Cpd(XJ_i;O_^5qf()+BzQcffZznN-u1aBz`^{x%OWQ zlPd-mr8>5v^oKcnB>%ZHN}=T{VCq!N?zMtC%sr2uGv$dxB24>A#-+ohDw4S>EF-CJ zoEIRTDc^x5?I~@K_0u@N>tb073ESfdZC{@`FZUyZV>&~&%;Th-!N~gFCK^9Igp0O6K5L<{XVee2WTCFQsyZs91h4X5_ z)jJZFhKjVa1r#UcwXS$z!+!ZCAC&G;Wx+mWVxB}^1fG0hZYZ`-ypAr%$p^6FThr6o zx)35JUM1#N`Jk*mShfBC51$chFIopx<_*dUT3VL?y(p)@wO-1X*+x#RNOtl?`RS5K zQG%_Dfadq87eD+@iBi8gm#4FMOJ5L2wFnO0Q9UDSP$P7Tfm_m5H#Rp(2Tj9Y9W`*| zek}CyHI#O*D+UTO@>XXC;kH^a$?BwrQJ*a_ zV(cZA`SQp5m-vwm=wi-uMUz+0&+ zs>DVIE z{ZPn>Y`oQ6>{-&=ly+NE6sz-mSo|`%U)*UZJ|dg&-@&t_{n>xYN!j5CvZBcvT=A;5 z0MzGy>pJ=uZ!7LnBp9u4_&nMO6=%CHqKi*WNuy1$5aT9+)@XQtpCexo6*(thw~?3f zHKEBOO&>?_hkj*OEPCnH&X^~r{tgb{z!(Bt)-pysT`UspT#YzKJVA5MRx;8>fr`J) zsQFl3M+Y{{mq^0K7m{G*gbXWdlKU;;AmpWzaF+>qx;*Wu8&lnGv;mAl0w`eD$uhrl5 z(3l}77_r*~pkusl54kVJ`rwaC7Uo4NSW!Pw*H46W;8i&}g{dC66_~kV=x&Lq*&lfX zyIMgMIPj;2DH9OiLPikHN^gCZGIg!CY^mZpbb^`V4Vlko%NY)2Cq(q!Kw^WoiqlFP{6*tlKp7KLHZ?CeVwK6$DVBD7UFu5` ziv^!oF5TXWJ$J31`93P&xml|7%jghY7sQSYp12Z8E>4|GnNF=@!OtCZ+!hLV>**(C46ag2$X5Z62a3}%;!*%J zXC;c3XWLxzR2!DxywugQ6la)J$YcEL5MxIRZ8RTp zxywIGg0X44uZHjdBVA)>0jPilMGyl27-)T8RVTM?;OC@Dk2YuX!o`mVaMSNAkq|F% zc#a4AN~Iw)1j#XWOT7b@lA;&)Z^|Q5=W6VRvxey98*{???BgTOqTs=6YDMAoUgDP17m-(TgCCV$ccnK1=1?8^VYYB zur+6hGWepRs4}xh$@E>oUOPB(zx~nLyq3v3qQr#A*z;?*#xn zBWE!yt2D9cbig$+C1A9Fb<>=ap~d>vz9%awB{&31-itFeEP1q5E>k{TZv&8S__5iE zHK%AdWj0SBe29{nlbtd1+r%4<6nyj4E{(b_&7Ps*N68K?=>3YKr6Z;BrT`QNbt(Cy z>E7msyjMINQpg&f3P3Up64lyY!+};fPXs$Q6iRWiVU=*lFei?skw0F3Kj@x5}bgDQA@0WCXdFbtK}5w48+I*R{nf$- zFk|OLK@e!4Ch&ob7>xvo!iMr86pxFmYg7h0wN6_96vcwAsdAzh)9r_6Lbj9 z+OsCK>Mdlcc}BD1A}SVmh)Yvp<1@KjbxIiZ6kJQ1e5MZ!4Kf|^QSygGuT8255 z%Lc(1Y*(@7UiKXx57s~lk(ucGQNdQ^1*veBK9vGgDmyj|EDp;DeQFnd`qHQPQ$ID5 zCsqapwSweHRs~BXO&oFep9TTqXdMb84E$Ep5!1!`c$Q|c^<(MsE{5UA@REH>)gNUl zC-U8A^Y^-;Fy$rUwZQFV;8U+JLt+Y2FL#6G1-$J{8GM+WNo#3;DYj@F{FzbeQvU}m z2+9l7hM9Gwx%KEcpO2n8EgAb5L>7CwMH_kT{ZO$MRiEo;X{ftTh1ZpHO?8t`^Vde_ z)0K`=%#4N&J#GJs{J)+&U5-R}$i$QF3ba_fkxTJ%Hd>Hw6$Y*om~0+J7-023cnw~7 zc|n%NUM|=o!U=sB5P6Hna@gMDuT>|+Kz}Zg;#s9B7k9I1ocD{&|0CzqCWE47SA09? zyq*wY%@;mKQ!6@cYDI(9yA-~!-;H7&!>!ET&{fZE!n}%1eB7k9N|p1Z^%+s;Qe}7d z@}v@J?fKDIw%5mADZOA7N7Cvg#E1Qr`R@p$wwp7|@(MP}iYlHrukk56+f}K1?dy($V z-e1VvBsZ8eKu9#B0Sb*>zqj<=)P7QF!+^|I2D3t zDlA;q^IJia|%GPC$@q;{Bv&Tod{wrTCAR(}&sNSi%B zzobUuyyvC+gPNl8rg*nB5_x3*y$cf%c#oTwF7r_%?teJ(m1e!@Ud~Q*FYgQ>r%#!D zaTCfFS{@`mEBMn8CU|8i(KIdRnkUcGMNU-knIFb&2-foT_X7i#Ft}Vi!APTUZX(|k#ginidCFg_S^YmX{9?P{mItGeDSN6krCndm9pxX zr1yD;vUgYSwRE)PrVU+M+ul&LL{@0#2P=t+EZ!JoYOvKz_<9=$~rPt6sq zesil11)d|%absRC^nl0X=S}2m>p&>@=62@GG{QQ_yn50xr?~5FFJR!qor4Y)m(2fz zr}Ni+!3Dgb;j!*FVwa4Oeq>5XV(DE=zzcq%6pz>}o{?vP|HvY}>CG;6$R-H5uQ3uxBGBd0 z_Es*%!aJKtgnhTg63IRSWRFtHaU-bg@>xd?ipP%|)D_u85n1U!mZW>}+f!I9abv&< z$zuwQPfL>8h`M0+>qm?D@g8?k_JQRZb+K^vMDO{~h{678&Ey2MwqO$S-S(z-1 zvQaxeXQOhpx6Sxw!Lr5vc&zd0wEiHR0$j0jGyRP>+n_`$&MtfwSxfPE7FnRs{S z&Jy?!#(1Efy%Yn&SZQ41cLC9DAfgr{J3bdFUD0BBWhy?_+2ltlY(&s;76oD=iSG+n z1@rTIR>)7dvT7H@O>+yRq)enml6O2Vu~LgD=&X3LR#>nC+&xAxL)Y!GMdZFCPoFnp z0mq)6KA#U-p!auk!S-D;7Fx2&9-zs7TmSgfiFur{p=0L`=7h`h){;f=7w$D~Sn=EbjmB^Kv^9vw0|rr#be^2<=Z+wv5wMjK#q^l{Z39ZLCi zS!W4Kd77}R^WFop$%=}UD$2*o%69|4TbX$ga^y_{68YzqH%v0Vn8^dBSV2&0E?lk8 zmYW_Cem;1)(Pjl^L?_~+w6Wtl1A!1|R|y*wNFwF-cL|%lU+_$cn3$DFq&pwiCP>Q; zWfxw=j(i86r5s@WeY;|V>Fxot>Kwx>0OMOU#C`w(0Rg38;7lME4IUg$^iriJ2)UHD z$TqBEn`j$zO7SIHOa93j?p8tu)<#j94Y~(NGwLUr6bNA^k&JHFhqmWkEQUf{FM^$d zA%yU++XD21+*9{zYJ!a}oPLE;`%sP+F|W5Mr72>Rv`9CRq%26ysGTQ-Afe3^7DEdE zg$jp|?+VP=y>7HpJlRa-Y}t<`X$-1SlRpTB8p`ugQjw!mrx7v*)2D&#khYDkhS~gDlZ9%UdHnCQb>8e?-C*nJvp3 z?Br^jQ+6AykBP&sRcn&;v4(tk3G6+NzyDroY=tV}gK7IvvO=WCSP)?d>kWXZ+K+0+} z)k-Bl8fF}nWki=FLw5*QH50d%zs!mhk4@nm&l|pna2eYyTun`$GU|>Kpb`>j5qR(2 zy1Y!OSPH2Us%J3#j{4`43PsJr6-iRZ6Dad(5|nx=N)2SsDV_%=gStAc=rpw8$Ab`r zDtcp)-1`pREoQi!B+ zmt34Xt2Slw#&Dc=smcAfH62on-rsNvXCD7HE)H z^ZgnYG;2f;a`?A3a|8k$l;l`B9BbCwL}(q89q3)K$B3!|-dY8Dq~#y|iWNFKCJ^yE zSS<_mAGlGu4|(L!l0r+D6BR{_py_#Jyt9LCXxw<_O$)}BqB)jx#bZolsyCFWCI}f$ zylZw*U74Q6A109U%AMxs-^@(-EtBADP=P`xDW=#etb537CfMYpnlI{ltVX`odK&1u z8EzsfA1`d#-dDQDV~-+nyP{e|K|!kyQ>hBr8+6}t>$TrZR8{3rVkwnX3Lfr*;D0V>%-|>{z|CjCRnGmntLtK z)|CKRKJv(eg#Hgi?y^NX^x8Wm{c4k{(a|55LFf>slK5=Ae)4cwm`Nl~pK4V3l%#G; zFi;#3ODv=m87Z)%=(D%)=mBV$q`p^M*9p9@bCcXmo=o4sxJ7}gg%)y18ZS6dq>k|0 z7pY3Kd7H9^Cs0YsNn`p*Iegv%l^O?C(A9LMTDSCywN48_c zCGEXkGDZ0^!5RbRLwB8DZ2WPL(Z|_rkU(@WK?8zUCT|B3+GZaj{hy1|V#Jr7RP=6t zl>to#bo!tP{P(mJTCVYw>q~nmxnd}$b`*;96*MoqJgvkM=~g>m0`ZSSXR(oJK*AzK zy!)t$9*_lxWxB6<0TU~1H=vWMkkZfDQplpXJqrpDieArd)4Xc8Mfoip8IGvl;72$$SCx0gp9gV<`STBsb*VhotbN!bywTlCiGG){`c8lu!j_Rr?m*Y zW%%fTbX2&VA^E=bhm!;SAA-p|`-o9s&Kqn;VvM!XT);abN4X`l7eq_=F3*&jM*C|( z6F5$OC%uSI?&pJ6ypa#b_f-J>N@Lztpr>u+*0Su|Afn0&LXDsnfLq*Xn{2$aU>jre z2iT3WcE)_SGNdM+6EVq76(eQ%Ad^II-kozGKH7hoGKb1#pVw~8a?sh<&i@u32qABC=eJL8t{640l%Q=_k zE08nX8U%%5Y9^9p4E-}^S|O&A>T|dKxhi!CaIz5sBNa}$qDY01`^j3d0!*5t zI?T29Kolz@R;bpN#e+%eB8Gumg_zi@vNyu3P2`eS*hwWDLe0mNO`!xa1rQ@KQgUF~ zzUuK}s2ZrAm4SN=QWVyLPzYEne;dm7<=w4rsn#1)LWCu%c8f!A5K-ip6`{h0>D*Q+ zxA7&3A41iKS*^&NqEWFZ+j+4O{nl(mh$w=aWy&Y0py;LVSsih`Sl<+ocg(wL@g!tM zeuB9!S4!PYQDw5=*p%Mn)=O{vM&%@uWh8p=QIH6TPAUC}LnzXSAW0xlWVI5UnF8Ka z*%&1T#w(gW+fXRGo+$n8tx;o9JL;7oyCO#`K|*!h^_FE4NhFFOq8v9;g2vuN_>brNhc^Yq~5?`kZ48`lbI`m(Z*trF^@$m-5_$?sF5@`LpPBr zOH(phYf^Celv(^U(~L^VA(5HHr!DEr{DT$z1C9eA1u;2i%VJ;VSgize(`6!b6%BJ( zy4uVi%GS_!z<)|Sjv<;wcYDe#sic9!5s{E7HgvgZ#?>yRV-}-ItkmivK8agPSb#JD z?9zyS;1q%?Mji-17;Vh?BZL&+eVn=voUy@B<~csmU8D*ZWhk0U#FAEtw11GYQjDo{ zbYJ;}eaMN!Z-6e6^;DBpGyOhC&5q@l##fG@mGmI6@Ff0VIk2 z#60wvva_0daEpP7VblR+OFOD1{P)B#l7eKV>&NS#^EPXdbGU~EE^R4$Ab5BYhRI~- zpCdB(m#8~!0UP8;}Oh+TpFt*wQK0K$EE^B*@OOFNMykxl0MzzqGp@c;W_%}MMV~OheR!++B z_AuZ6JB8{(y_gs-_JP-Egy8S00TbCv1;)=yO$QNMxb|2b#&*&`8cN+)^C|JLYjIS1 zWZ-7Jk=cl+rdB8CrwMp5aEsv$uCE5ET*GAoieS;U5TQ&IKS^}oW_$dj#2i-~k0>+w z;t4X%`1b5w<#>yV5V_gNz!sdFt%Yo*t)M?9`|p&bRG#rb5qmjm6$0~tx3%!*ddc!$ zC@cjD0w9+k9Ri~|UCM08;NZZ(RF%R}mvkw&3cB)%aCNb(2h*ZO+3OrHW#XOL#PyZgRv#-7r=!B4eCxyKE?yZde&EY9-&Vehi@6y_^gL4V z0hrc#WHnSs1Wzl>E#)^$05 z!eDS)zc*I4OV|>k-LR9=4nDwpla?n$8^_#tNh1n5%W3B=wZ1`OqDv!>2~&bdk0Ww$agM&*TERoQOb?pl_@%LH?_fm$`tko@sZV+F_#XXD&Z@s>TBnF0j0p(ZE)s#V=+EJR@PTnKc!w@076liM47&G+ z2e*3=g=dxvk>Et@o#pXkL|!C1&WrWT9_7mrC>L_Y<%t$9Sc72gsa-E&Lirg7MFB$6 zl}c`Rjt9?R>3A=For8f-<|_mkWhaqa(Q{;XT>4pVp3}NL6#iJqN5nxF6XJCT=3&|A zZ2iG=?w$Ox@bk)N0M4*?d$}<%wW%c|x z@@HA>+m8U_=>OW9dwI1za~d^Wzdmzvw5si0KBn?W`FBfJ#lgeyvQbmyW{a0HVysku zcbEGZVRj8_2ag_tmFCgoi6fe>6hncG(7i*QLkw-n7EKG{6_KEc=UsK4y= z9x0Wnh!cB*K-6hp5B&r1?TRJDukWOx@|jiqv@d~QJqrzCxI}j;$_qb9dNTH&=0rt? zT}Ynhd0j}C?C47|LG#2HB~Y@&u>?f}?vUlo;10;U1xjF??Dt@wNG@vVK9xLt&%uzn;bZiYrdXxSk#sGyU)2Vl4He4~x57neffI zVjSkYJpaa0>jcM?sHy0P%ZgpRH<{Qf7Y*ra3RT|^Xn#zZs2V|UP5Y0QdD&bnVnNiU zXP@#-rjr+gfLMcl=CDM*bIoWMX=B~=AeF<2Eu3eLXW9Ca+`aj2V5}bj^Rw=lCce

3MTE zvd7O#3Q=t}HYA8Zp4r?Sv)uLHK68w$WmNZ-g8t;ioxgQ~Qmfn*=VHg7wl_XKGcq&G z-}|KBAs!XtsbOQs+@T2*7Y{Cc=K7KaC(m@uvGa2suByw=Y^-f(77eFRIt7x-rCDI= z1T}GoVU_%xgCjwA+#LEAM|zL1j@T~0 z^XNA0%V|KA$R?)H%A)b}X-R{NnlCf?vx+0mIJP{`^J9pAcmnw7tG*rnTgeql$7S+V zNcj^=(R9NiC_EY4yzwg})eaSw6X02t7&|%=)F2A#2NCzi`8@OAIO=U z{m|bKQA<7^R8y-}Id^>+qI^^*o0~j3d2^1=G+T`pp9B}~Gc+WTsCQSp?g)d(Y`H%c z4#UXHpO9gLbH}{-k+TH|+~UCC=CrMJQS<-+0ST#~z%+;sFQ}I?T$+ab8nxky>HJE)0j5fpzU&i0003B1OP#VArL?z2m}HE04YWQ00IG! z003hE012Vsq{$#~ErS`Eg8;xVUOx8yH;!901ta#Dd5VueGFKb7Uin&Xf7zktu0`>qEd8Ob36lkHNXxzGFKj!V)%6c_&3L6Cqjm-yUHI<2? z2)A!uF!?`;gf9^Xi%E$BkUnB}=$M-&_sc~M5p9BKXAs}YO8fU>)$;z?{;>p&o|U6U zi_xVos|j=Tj$0#6oYIP#HgbwBje-lQk z;=q`f@4{Hp8>P8Alq_=oAVqatu%7@)At|Z|{OTUy;*g~k$n+QkjCf{frhgYT$RUv| zu&M;*IUXj$$@c@NsMGaH<u--oD%n0sv`CWCFxd025CuJj zPv6XWg!B1UGV*D=7y+T}lSwzAMpjf=Z~+<-2GCs!IY6HMv9Mzy^s0a`V1&^m@>PQj zS<-<)SnwcF3#ElIV-k)yy+ZkDd8&GncxjYsWX3-<10>}&yq3>+(x5sYm`>3J(;V?*_{kyJ`vYs9Qh zz$PxUNaGW12hV6k9$f89P>di~1=>)I7D`;;Qjm8vP$klchtF@O zu2LNN6lwZZ=5@e8)Sl(YibO+~zdOu|(DY0Hy@^#a(Tey=sYKPom+>?=1S?-Ojhg`Ar}@hWd}tVCTK+f(yldb+0i>8UyA^z`ZH0SRO7OIVSh*kaL`25H$cm~^%H z8K|hq;e?`iPN`D1mw}Aun@OxAe;qSQahE=`FEmF_&TjGfFKnj31~Ted5!95GTXO?= zaWH?JG@bciY+J-3>o8#{OrNtUT>*YS?ZzTZhm% zLf7-p*S2Zo_mFRvQML9354}e{ug=KdC4oFz{vk)Tj|wlI_8LYp9hFp*k@NkG-_7$j z3ZUm4;e-M+UeN(>vn@D;ovxIu!}>x(O)(eAbotxfE=$tw4#?jN3KIw@^lEm%xub5@ z$6xL|KE2DzDym)V*$c$PS&Qa%Nn_ik(+BxxNfD{(_=Z^=60JgS*t>;tLkbSco~N9C zrn5%4JBDgx>1dim`L@<*P*BUe()su~kmKu82?<Xm zvOwt;g|yh43kyaE#?y=Q``BsW(R1PWQpNPacRb);|NBe3>{eZ|*vLjC2@x~ZS*Sd# zhJiy9a*y910vze+o%3gGFR^AxHt$b^E1ZXudwa&&CFB93u5z;Df*G1Bd%VBZv(ZC$ zx;jS6O)FhuBtjK7$wC1WN-wj{Z%`FndZf)}8=z}cEDVP0)I`*66EyAniv(X9`9Xf; zTn;a|6DyA~9zP~<-1x1To7M)ei#|Bn&6XWeQagyG(y8Yc`5eBdVc7karNYg&9DGd> z5=9dst%NsY`@Z9GZzTL=TygzKTb`Ubj>AsA`p0R4+aF7-b5fSWQxVB z>5@xJcAVmpij|NoSU1bmo}v&cDYcDvLJ_IU6+}-;|D|`qF>7Vgz@+xKY}!ifSCBLk zNV_Sny9VN>9i5Dh;#0c%$`L@LNg2FUb)=qH(kJy5y8w##Dq^rHZF zm{`+nZU@s8{S30f(+f$NxmBKblwcTJ>*z*qs7d5`%_T?A%>>aZl$9Nc}r`qIGTGX7FjA%$L(+1faRpGv$Dw94Y&MqstDHP-tEN2HU z7MA!6?7vlFHU#qCb|)V6AEPV^`jT(bDI}7!bq$WR{jz%J09Ix#RU+4}XQJg&wYp!N znO*OXb*;)uWEweQJF-VWu^p&kWPF!Zalc^5(w*pxeT3}sZnHU#L9mM0GOKJk*9J{L z8Iv+xc@Sr;11X`uU!JN@B8Ntn!u=u@`XGRvq1|S#oC-3Po13$(lC~yLW~A$E_Hup7 zWJlfh8jO<*`al+sQ<{}~Jh7g4WpA4w|CTNOaIG~JG^`b%;CMi3e8>>=RrPpbLH}*I z4j4pCX}W+Gny(KT${wk+oqc;iM{1awN+55TPD)hG9z1{3mkODpXZ7I$QPWh4M~l`{ zN3(^hgg0J+%Kfpd(~tTSqZRBXc8k6mGkjl<*fGIk+#a2E5_zfkegZpIejGxq)=CAT z)`E!=B#t3kY z#9f@rvU_kJ_#$0rJ;HPP{A@wFtZhI&&#~XU@vMNe{=Ba?%!uej-|P@`_fge~mFXn)6$z(7-%fRS6Q_3vp>h)Hm@ZerM9T6-ofcu$1$AuDbdV^pUF1yY|H(?Y-;$?QRX)8wA#? z%)kG-TQ^lsXHV_87hiN4@aMyc&W!1BV41=nsohxr4WY}(pRmF48Kc;o(V8su_NCy_ zu1KJ)tdm?hNsK~XHS$!CG)bil^vVn4447$b{ZPf+mi8@OM4`H5YVGuoT%C1*t;O^b`|-e^_I?cY8q_q5Dvktk zVTvfAFbu$}q*onZ1n>Jgh$W+O_m$b4NA27X^Rx#K6Lxg8PR)e_4N*Qr_RH3VWg=8M zK3jU+7SNNSwFiy!RCkNA$dbWbMiu(I9)+&Uy{5qHjXS%dD({CG7;_kVO1+G zXJ5$Q2r+)10q##o67M-Im~YeP!Kubx@z-NT0uCqU$7hvgb2@7)5WkO@)8S@j8jw(Z zDu*KHrZ&nITWai-8UxrGyazrX`BrJTDa15m;m}a>IVA)jyTDP2qHDm9&}0#`37;{wKtCYtilSnL#0EOPjHJ1G&lKl9s3yo^DHsU!I6Y0(n*z{uQm}Y1P?DWw}q$%onow z*e`*l#KY}_IC%P(7)(bbt`vD*Hrx=O9YM_Kjv4_pCKd$asU-exoKBg9D9P-EJYV-T!0Z#e{@7)t4wU`)z;R)A& zS%I*-zvWC@<8L0i*;H~MG)|m;bm61PPzkL#7g`59I&^@XHg&u>55ZVIyEM1lPL^C% zxtysGJS9IOd~%u(9HS*TwC5?pg`qqF#wK~w-=S0?SK$UekZ-xaY7-f!unp|6lsv>~ z8gTIikN&tE8bY96pYD!4A)L&JGusz26>u)}Pr(riphFpMFDoiiP)& zFvZUZ9(?yh?T(*`hrX1aIHGN`)lf1D4 zd&C&3QGH6;J_$uxLaIaI<8j9-s0van>MLEnE{|}cQ{m4~Yo;Y5aUHH7rr}ba_xlHJ zPtTQX7sdO<9J_=!n=Xnuf3qcEqJ^0F`w^wq67H=avcQk_*$E48<&h1B`c-%fz7;5dcjlcL|(CyCc7TqHLp6S_UJlAl1bh8wE-7XdC*+xblqIm)?Oa2rM-^&Iw?v8Re?YtQbXnr z&f6~)jaHr^yjSX-St1*L(i&zQyNo$8Y6~da1r05?yoii;038+#c`U;Ok@s_wi=k03 zxx~}RS7dVE?klud(53m#y;Y5@*FGX&r=Ml>ll1i8H7;|=Q@3KI?e~%f#+15kiB10% z{X7VKd2do+T8N~5H&IMKzQFRWvxQkD@^_-FgTI1SPgmN!Gs^@}hQ_-sbmJCJ<~>?$ zuvIa{)qzCrS}P?WaJ^@4gjg%gIq%Oe8SblWq|r<1lYHZaG>kjC9gCyz@Qai5qf~?e zzHY0^d%wzNSHk;kaeHP>-uMqf;Z5zXDKzt>q}T6iNG_jWs##OTEij%;n*wRff#N`_ zNbzzbNmRu53~1L}>f~>33der|K5z4C6eP+7Brm?}4CBh3@hJBkId}|A-7=0O+4_Zf zr;Y8@hD~G@z=f>LW3_gv>_0NfoHW!O{Ne!yf$Zact=Z1bu{KqlT~8OhEqLD7wpyo2 zLOb1`kl~DX?;ET~jbQpx|IS5~Ty}SUFWC2R-;R2NU6y|8-cqgMBiN9Es)Z&V&$98( zrRPUdE+={ikHl9WMdrT7eI(xAZ}Mi8w&tY3{mRhr*tAe>56dC8-9apOLz}X0Yc&jH`+`2kr=0t#IA{_}+ z;7eZA)`t|=iHNwXxwmuk!#UVZhI8VEGYt%lHoM6oT%j4MY6W_dlxD)NPtlSzCBzpm zFYl1iG5%<(STGF93#+2n1Z@BHz1)rAL9^}gnnYw*GweXxY<{!~cd;S@og4|#Wnl{w zsi=NqEe7S2lUT_;7G*&RB{1~npNdoN6$~WT&QP~BW4`B2XQO_aiop5umYqymXKT!6 zxuZJp=9DW{`i?j|ygek{@`MvdB9{%f*_7qj&2-Z<@zHZPXXWpjIM;gMSMPpRo14j< z4|ek3{=P-8Lk zueHQFOE}}5r;MM4bwWqsIq#T~&6R*7MDT;3-tA<}QU*T5z8ex1d#Y_tt3duO6=#*X z076CD@qIc{0MFK_%40GH_iw=0E4hV_s)#)SX^f+|FB~)RrT3}jfesU0bZ--cSEEyB z&3bri{`*^lpS~gGvOr;i11h4x7{SqmqP~mV>+qnSk1Rb)1ZANLKkHkVh*5!N>}ypO zouRA?bFJW%!;WwlBh@zSnSXD6CET8ChK3$%`>s_RdhCjA&-^U@0H-8^Lh}(UMg`Ml z9NhAa%*kZ$O*IsoG2>M{7H7VSi<6~#H+&*l*zcSbxMKHvD@@F?%0MWN1@=yqQl9=y zJ6OT$CKVK$Az%(&jBwY%BLwjk?fA#E$twjZA`oU1%G}38h_e@kzjG0KPIWH=O`mebFa01NbmgV24vjo_wB7l+-%%L zqzf#&dCPnaF!GwQgq0Ic9Yv}P$31A;M5^@t7JmFZKK(boX9@lTw>xld^HoRdH0_2- zlYlT9DNyj6oto@<|Gt{l=-1lQ@8;$InizCAG=3l-`aY3={rFSLKcret*q}5M&w~+H zSx9jbaj&`bS8xy)_|YUcH^B-=V1Vo}XkKr@W8h@!B>k;EGDY0;JNZ5@dC8rx<9oO% zIc@6<@j|<%h&g0V&-@gfgQdPLK^KA5TZ>sy(#?Eo7EmeT_;kAOW=`1gqfVX=oSlgv z7tk9ncOu0`Cw(UOI@B{dqK`1&O#IF^M2S9YRz>sVU7Zb< z-qyK5hkkVzUl={4-Xx`{bl#ORkOS{F+D8_+%92SG3tEIjUzj97k*hwXyi*RII6FjJ zh0+b0ikY)Jn>#^a=h`qGkY8~r%?Fx5LQl~a*pi2t^y3g`W3)Q+#|1FCuwv=93+~6u zccWGdF{9-|fCF-QAPhE*?^!c^HS~E+pRT9LJ#7EIwcrFfko`B&X<-ywL(IZ0Id~wX zUN*2ECAR}&a5pudB3b0CTh{+>PzenKb*Kq$PkWo%tlRdKP>g3DgOa$Q&>8cmnYag; zw8ryk{jV-oXAfDaA!jaCGUN9kTQ4FVpXm>+od)hc<9(UX zUontUsUl@34am{OjtQulSV-bywZyC)+3Dhq>I-jr@_)cNhJ>D)^xgCpcQ|7@jDr25P%r*$@H;uaj( zi&uBD5E3U3^Dl)OQVdndHx=Ze_Hj$8&TEEOEYC-mJRvVaEXNLLC^!%Hn5#vsmEiDp*G!mY4 zEe8g6{@K!kYwhj4G9mH_44i_A4=l$(L?=}d$~Ab1u~P*_7+MlFqRG6KOViP`qZ`6d ziOmb)mE)-b`o!6NZi?8#v^F7XYH(A>+sLUA=T(9U2jEpHAr++B3wS7cr{F22G64D+ zB9skFaGgs@(WGR;&`EXFi?xBQtR(Krbjo!21o{B2jjWi#35EzTL=G$$0$~Y70>S7I zF=@&Vn=)oGSkkJ&-@kCio* z<4QLsvUq_z=>5#6#t~qqa6bHl1mSplb(SqSQhI2UWPp5hA5k|=qA>_+-8JODvQVQ@ zY4q@6Fs>95PhwYH#FHA8Ag7B_BYiPQLucWk>KWk&UR za7HX;ZvV(qruej6{d;siLX*veRl>LAF)<0u6@w;>0{k0?;s97S%TIySCK*?9B0SIYOyd)9F-{bq z51ZnO-)09nX7gNI*UEwF()*Zlk%x=-F#Fs*uI&`|hV*mharAw$*p9SQbh8>DI;el% z+ugZTF?%bN$+)>^Pk8-CMlM=K?YVphgT3ciE2^?Ar!J8Y^WTU~l^h6q4lG#{w+0h7 z_3%z+9qk!*%|=rEW8+XhFn4T?i=4Gf8y7((oPt}<2pD@*g1)q)8LOhi$LD6}X@hKi z^UgZEL!;U5x)V}QKEwa4L|&fVxr-~49A|svWp#u&CO=wbRBzqXeILwHSM6nDRW{uF z;M9D~lO5BzOJc1+i8(I3*N61!i{aysBlZhBj@ayM5wParEi3QAS2n^_R6A`B*!1;@ zKMLVTvG4aMO$GN3@DM2Ww`3z_gf^Cs2z!Z{JcOm2V(l~+AKMoh7+9DMMEs<-I4QPU zy7k*2ig@9_6h0nl6-8TSvx4gsm^A~JnUh^L>=iZb8_5|@2v)VH(Z|GY_1gXHn_~?{ zo^VSPh-8Ho2Swe`#FyJxy<(v%7DeC;;#12fJx{|e9lo|+i3ol4vumf`8ox9Dzk9m7 z6EbTLeIUIp`pvyTRA%DnX?`sFJp-AhrX&uoSF#>$d3J_>oRucKaV%9Md8lhf&Z7o5 z|B77MKsxm73Z`oy+l^x3j^C1-d(FH%geCfI)55+e5vs&PYh}N7sZ3*;(4FZXuc*YK z3Qc_@Pq@XHgfxxw5ql<7UO4eh;(RF|DXHWpwojc5`}YjfzmIP;ZF-E%4Vx(tQ8^oU zD!5iC)nPn}IN10D6PlCpC0PZM_p-&Fd{~o$|EOB$e;`*sSRE3_+pNDBJkvn$TV>6c z$qcvK*Z@suRL1Bzss!)1*VdiQw=f;g!PUc&Lj%GuqtHo}mfYb7JO0#yMmjf`lO)dC zN1&m#yWO3kZZD?!AeNpLl^x>WBd0d7fuHZ=?RSXz1Qo*EowBk!X(#eQX)%sD=JHxI_~%f8%qIk8s%?ZDhDuP@$2vOOya6UFVKNLBW{K^w zHVGDHTU@Sg?=G@RjM>gr)fQgGU+rdns`H$~owa|>WGVsLtW!|WZ$?xq#6IoE)vG-h zi1o5=0uPJ$&h~EwDBDDwp}VU_-m@LqEjX}%gyzlOTIIh$t_!}*SzJELJqhdzcL%K?QkAV^ zcy>(CX#T$x_a1(--*FWCZZ0%z>QZ&YZKv=QypJG6=$DiyD)nxuBs$risn-k0y-$%qT$lq39=)hR~Zwxfs>KW6D3ezSw>V zsX+S7SX+z%*I4KagTCKt)-)~nc45}`2d#VmasMnA#p$Lcn^wM8*6uqt?IS@M6YqCZ zC9+!&$nk#o?2Zlt{VF~CV#&n994WQL#&Cmauj{Je#`ilS&djrio#XMr=0reqjtLS< z997o_qnFG#*N=_V)qwiUH;1WIaIoSpUbKQjvt{h&+i^_0r0(E=_+r)#k6YZfljhZ%lO~iRb^@^IkgynF zR*u6$atA3?xub3rPA5DW1_ovvM<9_m33|wr{8}rrW^Nk*cEsvMv<29&Mut`21BPwW zYLnLRZBXL1%Y-x8mK-x~a-k!0hb6V85Xf**q#*5mE%AZq>au5T*_?Qh!5kY6F{(cn zk^GKNhx@iPDj@hK&96s=Qn7O$Eb_#eq`^I$> zg?UfVz_3RVi3vT6S86F@aYTnmrV;Je21`d#ZY7Q#A#J_TkJ$JhUQunxlc~<}jiYWa z$q{@uo!4@o<}{e!K{hfIjJh|Js_F)0TB~aAZ4oLVjHwo7w!&sJ;J;<1pZMOeA{KC8 zjlA%%#;fKH>@x5TgRS3OUEOry5!77pn!khNffH1OoF9Hs$<~c&Au=ge7bS0VyJXA> z@hO$5RVlp=CK)nb3=|=xoCZw}@VfWswNO~n0PsRyIZEtprGR`i_Wx5!`#;>Dc*BSQ zl-FxC5-b4v0aK!?%zrl}3JGgt-wb7!Hy{%A%-rFWApIVUPyF`lQx7$rPhVTVHp9=o zb`x2YumGm0C<i)gEK~hpLx#M~8~buavRw;?AV%Bhlz%Tz#LgkLlUnR*?s@>vJA6 z5Cpc6a~Sf)>H0Lkz~fVi&kQa?%)rV7q&_GXx(9|kOma(tUpl1?C#iYN$`*c9MhNL4 zutj>sYCj_=^ksH^L5!*@qmaqI;R>u+W{2m76q5f`X~Zm~G|(FId`DN{(~~|gXz;YE zSc>Pingmw2iW$&))k+rcctlUKX6iMRKggWLUzT#1I&T#w(Cf6$v0@HuvMzlLx4 z!*bzoT$`1De!*kaB2nqgxH;KC;!Q#66DP=2pE9djZWWpEQ?Qh!!8UQQkq;vuSP@Zp z_m|&R;M4u*;43}ysrtwdEDTaXV#{}df|M3=wSonJukKm5?C4mLNaAP74Q6;m-Pj4| zIZ1hmWw-k?oGf*p%3t+q`iyMKChqzkc{4@f2%!N2%KNlI#0i}tS}Cp~O3F24`{@ex zIv0hRd<-dEPXZC|puxCWl-4^EGY7w#fuWpRrcx_DL?0J=Jr3jjcRYC8^1f?hsncMy z5N^P2xMb6tu<=YSVB*CS9EItB+2jXw?su`fyVR&eP*VGik4xj*`Z)h+U-cPz0~KWt zxU{5~C;WVE9bsIE0iKJ7>TfhGmf1U5TmgctBpQ$A^>F*yadl^R-O*pl>D!_l<~7lU zGmJG&*vtaG9b{?2EHyz=yqP^t<%Pl|VA}8~C(5YM-tS`*U~$pP*b=jNuUj3~b2~~? z8t?+k`A#jPyEIhltKqMIqdP(RH1%(F=FBfsCGimiwcl4*7%i?V^^GRu^dAm&FW%{Ri zh4{5J&O!C_hy{n5YS!Cyy;PbK99%SD5pdvrZ>;fm({{z0D4K$JRm>!IZtY2r5cqAJ z(Vw!s_tKKow#Sx5q zlLKkqBJwX3_sZG=4yy-(_DbQxzoduNj4Ls@>D3V(JHrP8BuBr?P5F9BWSc==vp)HhA5|- za_E12T^U9az-iqea44QAcO2v*=8G&U{9a6`q+7ZQ@)ddd;`?!N?M6GxA(6vCoT??$j`uicbz+ z!p5x?pGgm-*K}rokoCDJ6Kja3<2gOldmxUv4@$=BadJ{^Z1&k;Ij`-<9hGXw-!bN) zBF(ak`OKKk-rtcDS`g*dN+q9jU!*{vZC2wMk`L-IhpN7L6kk{N^C;p4E_ZHLW$lDh zXjp-Q-2(Y{{eP#Tj%H+@PVLIF&i8wFvuV+*VF~7LXwWbSswfz-ny*h;{o&x^-tjK} z*P^=RP2svu$2e^nhyJD(B%Tu<{)qh8QH;IET(n9+@ijZ%SJs&?tb#c!a^vDd)m=HU zgzuV>`su+%aeFuy8Jb3WRXdT_k2KZ4fd!BSe~Xwbx&c4SY9{{Q1HaoUYgp@tgsB9( z@fP347gAYi?l~?R5IbMV7-Tky`q3CLV65bdD=AR;&2u)s$Z>KMAgJpU_ z>!$ql^}TMN>c~mZ(9!$WWWq03FXI;jMm}Cn_b9tkKQqU>ihh8l#ftlyGxd}Sh z#HV3;ikX6-JZYiaN)w)o5~d4!F_;TR=@*&()IyMc+mD@&E}1lc;H?e=#yhaP6J3D%sZOj?g0YZ#UvJgw{S?sf7%{dFO=`vDglFA%^i z?Ue*B7F!bH7mut5$kyb5!k z<&?xHW;imdC4v1Q8kD+;yRY>s@C~W`p>{uI&gQ1SPUR^7_bI);M1VrwTOtcq97cRq z?geYg&NGthOXM%HY9lNQo!}E#&EEOoog8VPIKPA)xv{(%+%;fbwIGV5Nj)*8N~~i&5IeB30r;_|lqogV z(eE;L=suzB?rNuz9Dvz}$i0*K9c3Hv(L$tc+qw^YEZ^U=QoXyNcI#x9t ziykULwd%?bj3Gx#ow$;Vfz;h5;+PzWVEs*Ower>)pJ4uY`x1+2}q@}{CzwcH)k zx(fX*GouTmzq9b_kIM&zaecHH$0)k+i=jZt#Mg`$#unC3FK#59a&zTn#c#8gzn=vU zq54%$R`%@t@qHWbCG38anbbmfx2Uf3GeFK`byYE&4O#e@Drjij^JTyroJ(-$Z+hAH zXqer{TdDXW&X8^l4O0E~+s;zO)RR1I{?K1>73l8LO^DuHK!8?jNV5{;LfUXnA_ZyD+P4dG2-7ppnW@|F;aiGsHhm( zI9nJlfH2-eLF!NH^|)MFj20|P>=eI<$&7gcl!{irDKt{%q7-uFlJ!hfB{26F5h?f2 zc60tJZ7cto>)9cmn*OACB)L3ld}m>e37Pr60@BYq4!L(F~f{ei$eGy#>4hpS}+HOR?j0pB4OGwuOni}!TsIOXI4*$AeNPB zf?V03L{qWFzTgFP3VcAgGT$vBD_VF*Dz>V<+FOlgfM%Yp*Iz?|H*0OJOJDVJ4 zXVU`zyxz_Fo>D3!9TjB4ul&qdO{pHs60M~QM8f!QX7^fX0S^&q@Xr$nfd5X=YmKi9 zm#dwvlNFbftCfQt52v%cox{u0%LV{XML}8NmA(T3(DHf!URD9J05lX7R1{=1R8&-S zbTkYs5H=PjCKf3HAufoLjGBs)jDmuOfs>hrj-8%@f<+L_&dtNm&ri)PEH1<=#>vOe z``<$l(9zMcFtJFmu}OGoDQJ2Bx64Z}03Qw64A~5bKnFm?M*!j@ybJ=UUjs7a*WUiu z;s2++l42ksqoAUpV_?2EXvKToDgXo`A_0++k&s?n2ff}0AmJku(DF#55NcbY(m_GI zp{XTk^fHZoZy>W541CreVdxk{#3ZC-j7-cdU{?OO0)j%qBC>Mw3W`d~DmuD)`UZwZ z#x}Ng_709t&YoW0J|BGj{KF$6qoQMCVIGPAOCa`Q^d%Hb82Rn?!Gnp;}izO;9I z?H?E%8Xg%P8=sqB__6qNX?bOHYkOyRZ~x%%=<@3N=JwCs-}{IEa3KJI|2M4vh3x-> z3;z`tA`%i13H3i*2#6p4V*|lQLZ;NC1(1`009##AWeSSuKFWi%sMto$; z)!Zk?_VJLfr)(n?tUAd=?QkJ z{;No`kl9$;N^OZ`%BkDU7u0R8=H_Nm{I!s1MQxZD ziwKLH)t+_d+*tr4&e98W4hi$B?tBA2LrgrYA(YkMF2LNHLJV^!G~1vEglhkA70}Ln z+vT|weo^jTVs1500_3ioCyY~Qf3fgOf_;JSh!E^{h&HhoRGOA>y%-;I_P64)0H=j8 z$%$`zF$MG4e|DAh4h9wyKh)EZXvsMl9Ob9jhKo*2f9x;b4NYq0D5+|q5#G-epzuPe z02T>>%0lxD*fL_|46hGW=z!^Cl{*NNO!DH2w&aRX)e-F>L3hBP@?Y)yFvP-0*yH}O za?!wL1pzNAXff3w4-DeV+XlN`TL#;=YX#Ja;?&0=|G7Mrq09y_FR?U9!rb!DEO5FBvpjP!Xz;Or;1b=CkUZ&5*cS} za}*BzfQ%r=GT>q!;8{1qIw8CdzMX=q0&s+%CUwpg*pjgz2t8*91u%$(zy0n| z9>56d^oImFg#`KQ_>EOQSf{)I9-a;jQ4(y#=I&q^xGwaf8)4gG98)+0xG|qwYR+Ij#p#AydH0&DPM4 zW95@t&tr z82FlQPFM~U5Vv7$A)#Su7}|H&zT;!%mL!!_9XC=~if`p)5YqUQr-Gsyb$_KTDuPoK zU1w5|vl~UNo8#ym96bFIF4&F0KND#)Ny~71sLnu`timfbsW&J_onIl(+{FjmDeljJ zrmhtBelW#?E+#!WmG4$7@C=I|uF1TiRI11%-75Y@W9xOO6qE?08xg~JC7AzHmaHN} zUoHt(Zn4x6xINa`;7*-3{ZqcWN?&c5s~fhSv+`5vdtHpm_<=8dB%_ z?TF!rN*EQ^=v$f8?ttwiXB&d;P;C-{grt^XY`hUlPp!=R2Le{Jq=bO|I=WH8%_u;5 zgq*HTXmTBm&bOpi8^HCE6XN4CeI6hpOSbP}E>__zV7`1<#Ja{aeVRX{4a?U10kYZU zTs68w)k^nWYQVc9F}Q=-=pyv1FOt#5yYZfZWyiZVbMd}DB&zuo}+-W{^~y|1R|^!K(pDT>a@cBy+# zOpLkr%!?JhrlI3P*Q9%yT(c7eRbZ)?^0*TSOzC= zGr-3`zrY2Ha(gRX^u#=sOn?kfHEY-HqK;z?l708B+&utK!aiKiuqB6K!>6>LiHqz? zc>C3o+mkDzE@pQlYNe#@C)bH05TG(#7n{y!{fZsAs&T@ILQ0ZoW$8V9&_S&A=~;g( zGF&s?C5gINK-^JIo3G*X*;9$*%3WOz?R*G%M3^o#280FpC<2k%pwQ(K6w=OfJI^K& zW~$g`xJKK#Udit{j&sENzC?kMYQr1_GDZ7BAVdns81y{UIT`syVO`i_vmS+{Qs5z6 z={nsdneeLPG(hPr<=$H+RDrUUF4}{EBI&W6XCwIfHO?h?j+Sn4ZXZgal1z$m3BP{l zmF}c1H`7Qr@R7-54I08c3#f7fc~V$5btdf%e+T6hkB&QW7briHgVQSZRJq8JnK?wA zwVGLo|1%n2Qe$YsZCNf|?Wjx|GyxJp-v*tlz4s&C%TcKw_RNds zUBJgn2BH*!Y=p{rk@-X08T{uBtnaj*d6W#jDzd0r$%Up+HExi{RI%*Szhn7Und|D` zd(M@tj}**lxoF7uZvVWf;NQTquW2TAK&%0+}oLc!adP?^L6gvZIV*K4f$&!BPwH!x32c=COLI zG!$JmSw~6aQZ=+74u#~^B(3QjmVbZ&sk$5=X23z7Qs}*KkPR>na0>%|Q4yVcn6nYv zr^*22?AMVV9ypE!7J+&Bq%cPolbrnXr2MI;QqUJt6SO0#H&s(`>qz%2=Rz?@j5QW) z?USo3csx(@)aD$DRagL1PMY*^CU=%K-G@u5kfZDj! z`s~$fEPWU!G$s}&g3}VBEq$y$ty3^N#Rmaai96+rJ->R=d&&bTk)(zEE|w{EeuQ+@ zHGhbGhS!5v1>((iE5-E)D5Q8XOyR5r(7jM7G_ozv^cpgd?8l+)gB*&$9y}qEWY#$T zGm8A);_hHxR9WQ&Fm4^-Qu8c`2f~vBr}R{j=hD`t{iZ1$=f-mm`G_qDB!MB(B|XkJ zK0v&Y<`8V$e0q!Jxy1|A%M-^USqMIqLSLG* zw9dXL2iCU&D64w+lZrB^=TZm@78)o-phHLnmJa*`$`$*qY*<>*u}P&SYFO2XcAn_- ztDjKaqqv?c+zVd-up-RNZBYB0mUYs9{u5EthmcukyEPr3YDtyP&5ylBsBk4tLZtnR5}d;rOX2Mv6{pB11!z*M zm3?CGh=sp-MSOfFD2BdqD-YFF?+F&3s@)j^Rzf{e z9qL#lZuVlrSS6wWwi$? ze@m~GOu)R#hHg85j@VXwOpI4qf=**mONoas3|wTOI5bUA3VJ`!5NqmzEF_>PHn;Oeyjki^ z7;pVN9LJDlRQOz<#B0P@rUQf)L!B*jypp?9!q~v0dDWIsT@m<%>#PsB`U~)?Xu`Sz z%fYyDN4k_Ft@135yS*~$<@K+%3ePmL^?)u1(BnyZLM9L}FO?&PG##-XcE&AikKmb? zLCZ0=ynACEU%+Zef*=duTCj_cPLo&r9H9ANm;Oq*+k1TTwZg~d4(Ed2U zIcH%1yvrRZaGo=Ut@nWmxBRB4C;+YR&=IB*->D4`C5IFA$HnNSpTD9{W|5_dMW z-Tv}gjfIh)5J^MIOdYA*T=MMoi2K|{N?%=#P$GI=w9th3&!rXC77}=dSvF=1v{!{6X5AY$6@1If z#XEKuI&k{uY=Mi}SZm0YeyD&i+dA&bscD+PI+lblts3-FQWQEDWuYp&EN>pmLW?r# zhDGPE!zcOM&E3^`JG3?={4JV5kNc|?0L`~~o{T(S_rsp+gRENMFTXDfL> zPKx`=1FVRcO|qB7a|;6`n>+DL`$HeAaYW}4P@JGePKxF%hXqPw3&2-Sl4$9igDN47_?r)ay6!<G_20eFpP<$VF==$ z%8gg0Mchv4fMCi`%ZVnf3Ns0IB5{PYgW(b_J$1sHZm>V)cC3oxHL3^dIpIf+lH=+1 zD&`rVX{c^`#`E*c2I$wTP>~;lz;IFP0+Jh$0|o+JXzB?K#JV`m4>3J`B|engU6VSK z`Kp>{SW$%(l|;-2E*g`35BX4OvkC`O=%}IHkMuZ;CkkEOR{W_z3=6mg!LF58^5^*x zSnj*PDq;Q@u_lxc^AS1cN+@C~z2U#R^n5E48`AK^ku6YZwkdQp#pQVjLR+Os0PgBM z!;AC`4?0E(A>k?DZyG!W)>SeswN(N3rR2qN0bpxD_4XI5F`-ZR3H-XP{qFE{%hbS{ttpbNkcq&Lqe7DYbOqIKI~zJr?bd$Nb>!rYJ#?V z!wPhYWte4j7{y6I6f;!;VLwkwXbSA^OcB->XJI7;@%O3Lr;p1|q$B+Kg_5O@IaGgE zm+KcPd=yovESIR%06$HNJ{?jn?H{UQq`Om)uHD*uLr;0=Jn&2Ix0lzD+#J?+m(=x{ z@UOYDYj?gc>FToW1+#YW*SR-WmjR!Df&aX!14{L)`Vc#5J5rISc5du6TuzSCmT$7KR}WQP+tAlN`?<55vjl^KdD`?KlHpU9LZ5a9 zyF0>=%8ykX`)*)}Apww$o7Y~3s9n#4U~^Qt@Iy7EF@E3(e>-Z?P2q*eJc54`Ht7ji zXi9`kLtKMZ%J*>E8J)D80^+HQkQT6)@Hhg(vLw?eD=FPzIUa+h@FW|%v5-!S%~?vM zUzATHW|wIpB(->;IAL=t)^TG!Iq@XDW=MLMU6do*fI3D%R2ft)0IHVodNB-(Iv^Yi zC=nInBvb~cp)3M>##xc>B}M01ilr9UF^doJeGq$%IP3SNa7G^w&i^lt&OMOn{r}^i z87AdYt(w|g;;?mNS+!vd$7Sv|y2z1m*qoBNn8EsN4lO_f$u zo*WsiIF;mF!g3!dtwSotKwG00D3hp=)LM*a{Y?W?jfCOl@`Jepnl)KUEcDTvA$K#} zNO5w&T-HvTERlm&0ucciWAgh_R!Hv1tDJ%A^>@ z3W9%a|G3)&HvupXoLiU_XI%O~c^!x74syx?Wi!ulpj=YPNy6;Vc%`NZ1A|Mm=-m|d$s zkz!IgZn@k$%w|NKy27D0=0`ddKIgy46~s!%I6QyQm&&UbXr_Ja`)7SfogG!DWdU^7 zr*+MQ+I8!^pcaHup+%E`qpv*PE_+oQn*8YV3m|ri@JAQerPhGqV{}~#2_;l-3U<*?C z3fv8qR3o~h&ZX)#b;lQVuu`UmD(Uu%Njg@;25Wb{g4W?Wxo1RiC~^(|XyBy_Wet)+`qXJBJ<% zDP)S&sVuMmJko<5NfD((UoeKQyq@y?>D1e*Yyg0{Zt!+Ldn+teYm1_^4j~0D>Wu}l zuwDT)r}S}NVp|X_+I6Z`@>Zr)@CaLrjEJ>(m=rlDw`0rh z^Wwoi7GAP~hInf}VX)oJw()u@9!W1F0)wBD+X9;-s)`Jz_z=8GQEGyhwmYza6Mn~W zpSX{u)*1f+n~yL7KgMe|b{O{{Q^c7gts)PPmUEEcTM=nnUR|jr(%;ssV1UtwLBM~2 zek$TKoh69l+t2uN4Q!MHWvhHUO-D-}hdC@tpeO6cjE-f~oln#u*Rp{i!z8RHo-i-U zad6q}Zsga;=!QQQ(rJ+V=uxh6wEX_8WU5;VAZEy~8*G^lniU$Pu~G;cZKO5Ruld9R zaO=~wHZ2oQ?>FilaHgH^9>^`8EVa3bVGJsAU*A%ct(svcVBV?Vjk0@m@cA)cowE%q zLlL*-@4N3qtZ}0J2RI-M#PCnSvSx1s@%^xH#sIGws%7tOug>*#RST%bN%JmI5eI&1XZKwcm2XE{wNFf{<|7I22+<=vJI=BEAOz;`O> z@>WpEGO2H*H72Xq1K5=*N+PY)HcBt}pPpF`jT=@A^!S6ssR$O9^k|e(1r$>kh*H(vD9xxj?MVdaa#`W*uD>(~ImE#k?=lr?WD~HJ_$R%{NS+wgo z@**3G-6I9KT^6TnGImOrFI3chzI^G7CQFl!u9=c=56(c zr%sK83>!t9;&4kgb|+I4*BFlUFyoNa^ujQ=)xo#s$)!{Z8{T(9qf zSdH!Txgduy`4MwwyS?kXM5&XNy9U1xZa7q}%$2*nl=t%$b{5@tqR1f(a8$!dRvrm2 zAwKBrJa*CZ_{gfRY}4rLF$=7&gK13 zdLNzU+sopyT@I9Ei<3pGL6v9P|4=a&C#=^y;m7bCN)OKS%((>YW7+ALn>cI!?b(dY zYY|0l(;^`I?x=^jqoA5N1I;92eR;zAl7Q{(4P@30fzD15|{6Wv^o$)^Esvan9u(+y60;fPs zc7aXL&kdw~%_#5{(Seaj3OfkHSWyEb`i?Pug-Y^Z4;JgyywfHKHbr99EVfzW!LOy% zMk8sr#>=g--E~feSYcI>3ejd~#2|NN-|^M7nT2Va&$JK8W$%-Z{_JqcDdY#m+ywi_X(gr znQD(y%1h5xu$pR#yd}ELeVR}Fc;g0c$kyt)3|d>uLUc|Y`n9-^6H=Qrm3J|_AZBcN zlZhtw%!pu8{53k(ihXw4{PtT}UBF!oa`Oe;bN>xP?@qa{Y}A-pQ*y1q0TTz*D=)ij*cPd~asovw=Q0Y|P0FMqendISTLN4#fATrpL zZ2LA(Bh;M$7&0c*+?x9~nI%TWD=I}3(LIz{&i7Yu@2uwkfi$e=d;tZ&3!r9twlul`Im4<;>B&-wuPs=o8Bll%buN^Q7~iF$yWZ}?bIc%>(#7J5fH zCwa>z-z7G-hq3k{ZSmJ#Vkrb`;qA)o9&FI$h4-J`ZVTe}Y%{m4!udQMOO>R zp4vOS{a2@d5AdVAz{!y@dL1XZZ-aaK3;xN(Kjr6#(%OBahps<-I4j_vKW8bVI|x)R zVQ*ZwBCnV|u&J}KT9kB3IyBW$zfOF0oR_Ykl{Yb9rfdAzCtyjsD0R8jV7Fx$_Yho> z+lgo#(7SlYhag8SNybd^A|Pcs_#Jw(a9tU*&U48qbbxVgIGchR; zy|G+x@Iiygra7_bYkb0pKeB>>Ow_nQKm@r z(P2@fYZUmr^gfZ^${08$t~0lMTj8@xRpqhEWt-6y2_lh-qVc$J9f{Pk&?kY2vD;Mb zI%gp%wh} zwCMD`8tF{H6T_8WZ-P~C7gk6In!opC(+IjefeH?Q53A-J{Qw#qXjC~tM-*$a=@}B! zC%G2{`u1dg`1)?$8n+~)@YteRxnr$FDTpmHXm=?$Q{jG&OmZOovqSmV5+kW?;H((_ z%m!XDP1%gI|#~5^STYZl`U8u;i@BxnGaI+}j-%hDKa&oh(`Z8X3Gi z&UNcC$Iti^vunN8Y#6|M-2fo7hw$n)bG2`Oikg%MFH^yhhL;z`&YJdL%nD5V9}SKd z<(rmFkBsw>3{U*Tod25e2?kkKX9K_7TBW6^cyf{Lrz2~&$zdk8V~l!22DRmmiMTSn zL>wT$Wnm_+X+Z+v(t(Nb(nnd@^rzKupj(OngNtZ0C7DwP*v-q) z%Y1AuNm*yNUQOx_OGiCWY<4@Gs}b27=J#ZOXi<|ZZ~E|V4+}}x$-D1zbM&tcv7V*W zFg}G9OCRtGpA@B-FJ3$E$PDRyajA39UYgX(yLUS`zUlrj?=|~2B92Q}-ps~CJf+*? zPl+~a$MsV{HFh~PWg=GehldSuTgm6xF2A!vqmnn9pdyEw> zR9BsDN40waDAzraIx48ttuG(C;kVBwO(>n1lBx?y?47n zjKb$7a|3*4PFSSvB!Zg}f16Kx3 zF^q4~A`$d)Sj5kgwcSd-gP;dXlhxU(yVYUt3T5FvA zEgM7k(#rGJ7Ntn1y%J~;J2dnjeN>Yp2*TpK!D$vOSH7Jj`aVTETnadBoJYeKdSJUBCbY!550NQ{bmc$p9!Cp z#rrL%T-DPJv?+{tTtkT&X9H=84wQA?3ssW^Z%|+;Fj=bhw|N}zKiauHZgH=BN|EESftxb3DVbDL}C=fyBwOF*-lsqdHER|k$Vt}7V(p(2ea$H%xukSZ>s zNmbRV5Q`?nI2(~hq{*0nLAo3i4Br_qMUgHM<2bjZ=;Z@}PuZYwq$&RcZlGt_kpOaD zVtx_k9smUgY$YE!;a(W*b*!1|2r{i+IUQ+fIa2 zy2ve6YWk28IbQl0*8&3_l-@$Bf46pQX&O@jC@a8g!A%bdlM|kVEsnQ6b-RClZNhm?g3gyA-sAPjcbJ zB)cNx;H=q!l69HgVL)I+e;Mcn-@>J9@r_5)J8|oI0d0F(>k4bd&1e$|c0|ecGu0!a zRhGE3gR_3C*6pWOD5QsP7?ou+LX&5_nFC4eWAXl*gGVfljpu90<^yi0j11U(Ou4Ix zjc`(Yv90#6*)BS1alB-pDF)=KE}F{|}&COW3qh5&@IKCAL*1o9PTm+xM(bI?X_GeWkce&`-ba}VqYYIna4!83?1CH}d&X3Ld#aZ=d-$oNYZvXY7#T}+V zku|Ro7jyK3vigkkK{q26_ehgXGiEGnq#sN?JACPraQCGH8tDC|*%w7z>%vIqh%e`b`m|TA|yY z{#nwJ6Q7W=C~Xgv+5|i<2T&hSOn#bU&nENlsUqFEZjBU0cO6TWn9p|;+sxPFwUxNW zdFhbnK~o|o`vYS1WPN?JA#IwpN_MhDT%-DeGc1V~Ruq_TYSvDc+oEdPwzDd_IEmh7 z<&H>=2m=~BT=wJ6e513b)agPEQkxX69$EzwdnYlH1K-&3Aw z;BA|U5>?B{>xMUe%6etKWtyD#)88qYOFwy}owXUR;{R4znwCY0u(ET@`~_e zeba(Sr$f^Qf7^1=eu!taD1uEe$9a##V*dl;e`{d_;o#)r*F|2C#46d5E_mcmoc!r1 z|1ctag0c~$B7e;jjLijf;e(g@58q`hvwwSogV@$tClaa>5bZSE?g)&b@;ftF7|1M4 zobsHBkMwq!^ZZvKe%FmlKrBkMS#yd~e5Y)K>CAg?BOvZp{C=%OuYY|XIKMKs0XR_{ z)gz4PmyVXtXze&|JaL2}-}2R=Pb)yvjJZ7HnM^VoFL=0Y*x$3VJX!vrioQnw6t<@? zZC(}~*aZt$2tqB^tQKlU(rWF64;kd?fii>DuGA@+)a9N(VusR^Ux$!2`*U}r+boLH zBwHozMks^5xodFc%^&^r_x^;p#F-oU7&zVZbO;I&uz^@Q160jDkap4}A8^*3g+9iu z?S!+Gw|oF9XA##Z(=Cc~5~7tKX^w7cfR~^HPSAd1n*nz( zA8>7aI7>44fX0CumZ}7$g??1_|QvtXu0hvlgnSrdq8XE|Xz#kwF=fz0s z9dD+>xFkz4-6;p6K`H5#pL!$@13yMJcd7rk{k#{&=}**&gYQn71-$ zJMo)@Ah-BLPwoc8S0e2P4cYrMLj>j4vncGn7ZX7N#-#jUQq~vNSvZYNvfw{MVsd5H zJS#!(j33md0g6IfBKZ+SG{ng4NIYaw^d$qX7=!~#vVRwY7XSsv`Xq3GN`4?PBuLE* zrO=_=0%<#)k;~%)Dij)MQG&5pvD#PW?&(mJc~vhV3v_+FAvX61{wjk2rVhd1f^)s% ziwt4#=D;v_S=bTgF1r?_K4H9MO>nnM1W3Xvb-5*v6`a|Ny743(go?ka3j?ADOY`uU z`5&0(4EPwjF%K7K!^irvY0&VKyj(vM1_mxHSBT)-$fEr zg*yuq{!lYh;pHCysF_b9=-W>PK)L-bCqzj7058~FEw)WNs_5L(CrsM+*it}PGWIxE z6qB))!=;&(tV96eiwN$)q>HeP8D5UL}0{v~7h?ZOIPrSi-f!f%zH z=32Dd>zB$1ZTnu%R6MEO)2gu?xD>0JoS@v^wEAljHrPqD7gi1Lb5IHd3)jA46G{|o z?r)4)|5S&>!U+AqR+-e|A61#+de;R6$rr$(R zDy}!Y*Z_7crlx$Y{w-kivU&S83nML(p_3{~VGM8ZET<#J2wxfHGRm`R~;LymsYFEEG1V^bQjc}Y}pE_h` zg8kMnGW~mfvDf81;e7bsJ~rh??&P(WLz@7=kijnrZx7h+l9t)+L-L+1MQ`?KMP+}* zbd3M~YeD^7=Xg2tdj?TwBQ$6qm8$`FJq&OR)&6J8S!&=WKo~HzWB25zXn`Ux^sm%* z-#GZcXv-YFa#-gnwt2Z%mJYmpJ@O)V``K3j&$38XeK}1@c9<(r`+bOE-cv_iiaB- z5kD*kb92J7fe6hbrQ!-H0lz}mJ5nPyA(GnAxIC1a;}eufL!oC#hA>=HRm_4IFM)QC z!W6v6&?)ji0wXHPz_Pm80{(NvknUX4qL%Wv|K90X@Vjr?SHjYxh$q)Ow-bIT*hfIJ zpX2J9lFAo;nF}Bv+{WAL@7#B=pVTv4a&EK6?>U1;2tVX#K+Ac zKYBsSN1<_wDrJ-QX+#UM`0%-bA|4mRaWo4HsD}tOn@QHYpOonT)-=hh4xpd2A7yzm zXJ^P2@d*xb4cI~g>H|_?`1oJnWePBqO*c&LpL6tmFWY^46BY zAJzYlWm2lWNEjLj7R~THpf+`wk2-+ONq^gT$FIy_MVT&I2@mdByBu;Zh#+m5TBf?T z*#^Jn)1tT~m&Z%%tXJV>;75E}4#Ww@OF!t?Hf#s-;~t?A``dRLz(lIYxO9X_M=f9~ zR3OLR1YQqfjd9aw3{%i&M8v${6%OP>$TMD+b+#t$NtkAq`#dNxhln3mD#G@{^EB9j6c zNpFM8pCT3OysMz<-I&vbHOqbJS$$e=Pj4psTlJ-{b71)GfXKbiPL|1d-24!K>z<^H z8oxZDw`kR~GONw*dts<}F*&b$Yh}9SXa03a@=Jq`i4Y38%U*tftY7%vdqgFyS7;q5 zdGJ+d>n;9Z7p%_BQP^N*bw(CG7aFiN%%g1^;?F^yiW) z%6jbiBM*CH{tn%Jtu{fR+Ee!B?!C8<_tpIpce}%$%=`8|q+mT}ewm_Uo-$c>#_%$1 zRDj6qtBa`bGo7@xe|g$?VP|KRFa5pucW?8QJtQ~lV$Y3Nth%1wbS{}FczX(n@WeyB zz*zn6Zu$EFeLFnZHrXEix*2C3Ud#(Ska$>p`+R2*p4jI8#~S;<&14LBFFsaN8?_z6 zj<5CXAZG1(rs?Kem3xBR1@Fje2xY_%P^zrLck7KCT!&HZq*~ zg3D6!FVc@o;%Kkq=U1ye=Akz9Zoh>(xr_HjkMC~JehW@&*?){8Nyk{q9_=|+qUL|N z@@#h}t>@`+q`uO`y$f?2`x*A~<@MWXa?-uFF9+uruS>xzA)IHJ%5ksG;K_{!bB<}t zA#X)?G55C*&IV5pccT7?{WUx}=nz?(;{8j$ce5umG?}KGn0pqIE#F6nA?o&L3}@== z1_Ei<)*00GaeB&(E(8iQ_y@&l9v@p6p+j5Cvl(Ge4>#?trJasC?P(|e%USY@oafu_ zRV&gzD7xj8TFb8C{jnGGviS7#d-PnGoDE5sn5BBHjdGjwi?PI=(b^9M`p+jm2b_dY zDqEH8y)m2x(dzTtii^7f-&0nVI+AaE!3qi0TA{m{!I8L)L3kwl~W&N9XH+5yDE>@p$xn#l96+2CWtVMiAyMflGZ~rLHC~GA$ z`40@qF$47h(X`Ykeal->UnQw8(po>DA#Y}U93uG%TOPl6Rrlcl@$1)ha8}Wv4M9x& z0H~@!g`Y6COv!6UlPr+4wI-I zHyZ@HiSeWW>@qcxsN;gFHEO^?eP-F7?i@xS?(+OcI;ZeUmxr0p$xKtt0}rfmZ=Z96 zMes12PE}V(0rSQ2yuz@6cU^hz5Lf3$=|_TUv@8IVtSDM7iw|TvD&}WM2D0#=*`hK#lW+4tzU$ zGRahvzfU`PiZm5q$@MT-@{b;UT(A>i-aEyPHddsA@tX|=OUhTmo4+ZiTxId@r|@P4 z0IbepN+Z=&78M0o_&5Y>L{Xn{mnA<_>OVt#H4-@-Fm0YA^QPDl*j7;w^l2g{S?=X( zgM-8@%FU++N}a}f-@%{R4sb{7vkdFk2=U`(fHoysKz-0V%35Fi6IXw^>LPv3$xm#* zi*%TcHP;gix?%C|#XZ4_QX&n2;uAcOhGZ3Pn}i6=6%4AdD8TH!{7$wQWz)cH~}Fo3@5M3|$3 z3dxKwHqZPm82-2E6TXOd8m3j6_R`opGG{Gm-HYgC*mB2nZo6p6i+S&E$5VQ7Ig=xJ zm6;LEww%I zzWtZH;b5xfs#X4ltys*CMCVIehHvZMY-r^E@_XX&Sxe$JC?-I|>#w|^blWKKB_CzRXsSAQ!Ik`)--}lTC2g}wi|v%}`ps<_DwtDTuBh8JX{GOJ;uNZfEj|!= z+2@+FI;`rE=6!5IUUism0V~6_M0Px{#^lk7VR|lYzGoA~UsA~sz#{N_0dcvf5t{qcl{oC`A-2!B9>g{zcDw}k_kke-Z^sY6TNA_ox zA(d04O&eOGd2&CirN$dQ6Fg3z!jt0N4OYtN*P}W8xiZ2A&n@L|y{&KDVD;VJ=+2n` zjA^~r=v*?Nm^@9{ee|^yJtp90U)%Yk);+oz@NtOZoq)5G`|ev;2q9oArX3@RX7j*c z=_WHI*VOr8FPleiCrd2ZG`$Y=qTvyxUD%jyQe%Xg^a{<}KBu&mA8-2nuWW~+}Y*=`^m1tEUu zY_m`c^mj9RBTZL{lt}(@Q~`jA&>f{W5;WCmQzQ^$5X2&*1 z`!&+m&IQS06_x}Qo+{m*H{3%p%6U>459n#&Wi9{vRTPs7DHBl}EeqRu&01U7#M-w% zYO&thxROSRC12MD2f7+L^WsEGVxnH1d#R^TimvT3IEdSQ0>t{it87IdMe`!r}nL!6kl>?=wnl%9=RULGMdK=xY>knAlgTr`CitJBnlh~wXYncvO-KK9y zm>2&q=M3)Dh)f+QN*IW=so0J|8B&C# zEelecmAdij`-h439-Ck`d57u}q+G@U0KyP@F|RYMUrp$D(ssL8nDpBpwU^V>{{c}( z=yH=>GYslF>ho?porCwvQenc9p~ee$(FBYjP51B5i@Ua%XNA5lMfu0Q?YNP~ZK|}~ zIm~Fdbo)n=1N+`rT-~JOU(x-188>Gq>uvF9-G!P{G3x`o-QGrGIuO^4e>X!FIFB=I zpKmjK1Dn*n<_NjI{${V->LNEi#jGyYN@1Jq?)@n<{u0Vf8GeeqIDTb#tALJu*KjcZ zBdC{O-@-*#)LCIMG^HXBY-EovsXb2~`%W#`hn$q?%uF5L?BD;_uMb__?OIJ=6;^~P z8UULOyUEufzvmu*3HI)OA8CJqv0$M{8*aOr0~s@iO7mbYr~P!FpPRHV%ABEQ*WLNC zO&^4b9)!DfIyR~O*Gzz^aD+qTtnUz*#F{tcd#vtmBAEZ!23#ju`ue~6y)R~`p8JEFUO4})T?)UJKUG%xqU&5QrhB=R z_MSXKlJh?3?E6-uKUk}%>IJw z+dV_(iE7;L4yUATq^Bk;wW2i)e=Cec=k&38VpfnI=+g8P;7!D2O3RfdF-n~aR%qTT z@}cK6s4TD(N>PoL=KAR>ofO9rxMfVPX|KSrT&*`fO^J4j<)LcUnvQU?6j9Q418b1^ z?`W>YvP(}m>H9Y)yRF@5Kft|Y-S;0bAmS`c`ROg1G8Cn0fk?`3LFyz=$CJS~Hqzzf zDfk(>h4GQQ2y)N@=;f2NPll9rD+EUHhe6sIEgj<8PDC4-3))6&cNhA^_Vq~v*+)$W ztF$BPD+Mr|NDG8}ZsEkzT?Bm9*aEyvH^4FYBKVTH6=7~D0VnDdzRlX}U#|f^;k6GUP|A>fO=L!Mzt1Gaa>g^ZG&z)6$qPhHE{~s7tJkc z{-M@$ob^@nJOQaj1ZYsTk~9^cp{ldCJ6XR5TP#Q2`3Cwi3~w4Bl`ID(_qk9>t1G(l zDuVr0X@LrX9Y$pQH7U^aR0&iVXj;MmzoliX->Jdv3B0rB2DtsKBkj4PJVm*m?tg%h zHIGOi951mUsL8AmhDO?+qn~C^o>KdauSdXVp5$pn--8oT1AMS}DJ*G(het*8gIiR^ zp0M~Zz>l&Zh6^THo6_+z;s?{mm-aN`{_Oy_BS264z))D9O^qXnHo`H_fp^Ax%}Aiz#x}8^G$^bG^@UShWR0}B%=rcMawN?N{+37 zn)jdB#!8C6QEJY`h<^VoStyF@4^3;tx2Rxsp>z{28TYgz?CPfdq#s}C>c?rx6+!Xm zq7ZAw>z*d=i+)@OSl-|qevg>HHf^FpT@SW%Rn`SH9U0wyriyi|Ynv~fvnlBLHKaIZ zd&-`*<0UbX%ha{~fwc$YgU-j(yv;mqimjHU5cudL}uTe zK}vd+cNt7d4A}=H55vp48~l$KO~e)YxVt}F(>T%)Ww*g$ZsmG}wPK?0;e9V(PK=$( zy5<;!e#EWVY-lS&XF2u8(&T7{nxFa{UW#|p)HqIF*!rvL6s;3VXoZ`Khe`)n@D~B!5)a&ld|>&X{QwY6B6hCXSPKAvLbTM zm+i;kyTeVhYh)k^$vPPp4jQ)~>|K@o@HDln7MK#nW4z_I$e57Zo44mEaj0zft$^)&2VX9k zQyPct{@69ScFT%r8YMqoTwKv!Gn#mI_3Jv^vzMaFowBV(Hwh+n+qZB0r~Qp(xBzIE zHs1a2SXOrS=!(14vF_~gT`?2O3z7-;Um=5oRZ5`&cJ18j4eTf-;69c91q!xIm-bBO!-095uS`1h3FJ$od&iz2G}c0hv-?2DvD18?8U`I#a)3D1wdg#(&oAga<-^;KsV-EI?5Q&obO z{(qI{etI{m#>DJP-jYHEFa{(o369jgU$c}Axcq#SL-2@Vu@zqK(0lYk8_EL?k~K>d z>h~;t_q>6!GdW?H!DU4fWAsu>pp0!4rq}wjq}f5yxDn)MzE6s~ai5p28CQR#N8)BlAB~QsgXPxfS&0@W`ckLZWmk?54F0&>&TvU=bIZqZLL(MXq9J@o zGoSSE-p|`e0nFKMP$N+myVax*G~+xelxX0{YsaMVI;Iu5=cn1h9g_lB{N6b~-LJ`> zMCL;EqO?WYqpQ>Mfv6rdEomHQ>;7U(VtDl^(j;2FWM8mB9*Dx6ZmuC1-~8wzW?|;l>bWE zjY9u(Gz#^}b5#dQXPdvyY_SxTL=P zgR-d#$fkAU7==;`1oC7G5XbXfac-2r_z_-8Z#M==hT3}?oh)fIEopHvrDK>{*l)e0 zb`4(IilQ5hw%JlitJHE-vpNal6kD{GO>(>s-|Xt^r#-DGU%@MJePnmYyVHmJ5+1cN zOSeEbD0Q!`VKa-2aQC6odyncH!Lp=h`h(xo3{TZ=*ncc(lT(OsBbMvhQky=IM*iz2 z_2Gqyj!*H0*7Y~v{`oLrc|T)ferxS9-}R=Nbg|keaoaPSIvWH|=|59s0HA2lI$JPS z0%-^K#w%$G-EG0gi@ROP#{$Mg^HYa+kDQMz(DuH<=s@zjD7Uv(qDc<|V9ZOuku7nZ z-g<-Ab|yt7>29uijgniMLkSz)K1XKkukjzgqvUSec;bpx>QpFVFp%Pnw7SOV8ORH$ zJ~e1sb@v|u=;c`nCH%AjWz!DTE=FOU$1v`=%}30^M4}O{#qSFZ;S`j);s7F2jVLBt z8(r&hqkTi^i(e39W?_*LGIsOPOe=Ks_va3})9xnTEnunaS+HtbM`F{`xv8+5?pll` z{VoB>Fmcp_BwLzt-5}$^>yOd{v>ygf;VluJ~R6xnG_|M zX{sI%umULzZ$pyYu_B=U*{)A)40f54GBHOoTwy9GDInygsZK;1?8?S8Nx_1iPB)ke zR!D8!JC-RNZsRowV~Py2(u*xs#X^wj0+7M?ic-|`)iEbS!gZCz+S6Hl-cm5jK_AG! zRfTyFpJbQJr@KKwnwF;L~3dmkhiyGT=QD0*AsL&{n(85H)9BnMg|Q>s4OfR*%? zz~I-4fo@G5Fpal=ZQ4w4QGU5*oS&k? zQ6~9}{}CS^$msjHQ6^z@GTd~T#OmU^^|{o$WfLX1NS9QfS-Dacu1T0bsI zGTQU&`96Ly+b^1(21cla5n6j9#tYZz3?iC)$L7VT(`aNCr3Xs-MDIU~yFAW9$&M*v zd5PMTbhV!jqO}c;swGrIW$|un66uEaqosGIz2w}$lNeV1SkEdD!Y~ym44Y|)ho+ED zaT0PXcBC_>4$-ZoBETusEbu&J8c@Qv(=J0_AV{Kdd_%pAxyU{2Dz+%YsUjBSQcFe zZl-F(7CWtcNe=FKf6m6KKZ`tO8hC6!d+X+aK%1@nL=W*d{wdarfu4{ocr6pF4X|47OTJ-;*HNkF1Qh>_`t z>E&s+)dmy2USSTQ0A*c!r^qE$y1bP$UP@GB$zXZvX=8U- zKz5G4!-5!!41x>~umjExa7!Ro$Lp6vpZx;?7OtV_NjkmfJx_6e()7=HkabH@pHC^ol#C#ef`n~pBv9N+aLf z)HOY`wZv_22#h|o$hg)XpzEk#(jK(43)6{V2b%{mrbhW`O3*ZW<}-Ks@D5->i+|(5 z)rtNr$5`G`*eQCh-DTFl1qWG&JclQvEu%l@wgpdKX{-VFC=55S-MjmA%b-MQ3LerB z__b>L-+*IETLJ>N(2#p|%`dCxCg%6-yZtiYpc1F!+#rf7aQ@I1T1;}%PuGH!KdIk2 z2q|p8ri$0dalU!4tEC3vYi}SSMILywuiFW+gvmPDE@e@UerM$cOK`)#5YntHEQ3)& zC7o56DFhCbAId!;q3Io-{3Nr?j;jJ}pXb!1Lu|XI#gWsBQU< z_-z=7iL<278=UVzzW^4~gXK_@h4dtQusw>O87)l%wWubga%`U!XD#`G)flC?-7Cz^ z$SG9?Rx@CaXtEc={?T$Yiq;4_!PM(M)`N()sg-IbbJt!{;?4>ic0uMPLynwKi=rY( zi*+eu<)ho9%Ce_W6Oj&#OUIiFQY7sPLLL-n5QVZg^+5eNUhd^_mA6Fkd0vW z=X(9?2@9t}u4Ghg<_+Tp##tt#xvz0EbvQl{<_^waB6wCW7emA(t9_noHUGe1N6R0) zuCslS2bMyp!v4oh9_qB&>5W>!5AaB8i+NuVL+%Z`6&N37oHFI9n=x66S~8KUdwR4W z0iQA?6T7k|d6qmspa?C;32CiufVK)cC&E~oNb#Qu(pm_h^EY=SSe8(dFGzl;;6#fS ztISp4ea@>ahTXhv)q%AY^`K{WVp9a#o^<``HTsxhp zUp$>b>)`U%sxbse`Ffyet6}q%915sDA~M=`{(_cZLGUFC3tl5zB5q~io1YnvxEQfp=2`IdpdgzFO!~4mv8;0qj?}kUK{#dBk z8YSVqVT4LKjzz4^X`iJ9bzofdZpjj3{Ut^agMj`{4_rK z@zALv#FteyymaleZ+4cve3A0G;_XpI-N?Z~uM_{QF8>U2?E`-Pg2fFEca_EDQ)??# zFoewK<)d?GnCYwQ{TFle<^6hAK<2eG%(*b1-YgG&M(g~ICF+YPg3ZurtCkZ?((VkLtzWTkyF(~M9Iv-p z{@eFvow%@eh*K7Il=Gm52YmO8Y%}DVQxZD~6y6&5)bO@a7qQ-=&NiJvHcg}S{o8z~eW00nw zWw6({3m~eX?#)nvf=h-fkJTgzL&2toZ#MZ~&fp$@wByL(q3fjSJ(qYNeG7`au7Ett zx6ow0mDb)iU#~x)m4&#?W`utzJ|NkBO601HxE8M;#ZrkdZ~)*;a^;p8t7m=eNApA> zO@P4*nSG`skTo@AkYw2|5729=t7lxskI(6DTsj{u{;3z3W4RI6`KwcXscd!G3_#@d1e%HBssSX$&N`^M z6+8~mfXoYxSz}G~(&axh=;x_hGQy0im?G{D{HV+bB;&cKhg+{b7|i9vcqUcEZ^0aO*`%|%rDsR76D1aCdU3nEGdU z30kwJ@II!C%7ES-z`AucI+C=cUq~8mstZ#b^s4~PB3)R%-T9Cwh__fYT31Od*hcO0 zChH_Ru8HK@ie0;=f?XT+nUI z6M@g9p_jlkiLPt!a9MR)q~crP05=NM4IcUq*OssXTD@^YvtPRPX0!onnz=~DTS0>9 zcN=)Z#8{@k;c?u@M`4`utlzVyd{8JUN&?3T&^kHXNfDoa9yHTaCA26|lw6pT&&ylv zmgj1G33Iq77XUfTLv%0T6G)7K5buMS3B@sJ%JIqST-#Q>a*-SS^IMsVZDhyKmDbK`8{@Z};V zOS8Sgd3k^hxx>-pMeDCC*4?-J$8Grj=vqhhTCDXY*2rbT+jw=_VTeX`9prM~F1tlq z&zs%bZ>zmlNZod+^vaE2*4-1=Ee(RN^s2o&HZ#G`=$1O={%t95dUD*5v^I_y^jpdX zX+4Wd-SXyRre&K+q;wAypdllZM6AXp_fnYViS#|C9kj$hvmnP@aWbH4FEm- z3o0J0V{;wEQWfX$R)}=+cUUUSGestYy*pz<7$j!UW`E$Kvo3)m*lj;thKm(Kzi{=iVL5hxEpobJaNjPia@(r!thxpnl!oV!X}eLq87j2|yGdYuK_cCycX%HBJ7YA7o`t8aa}E z*)!AmZ4`UXP*VSrce-{u@fQN5E$ysce+zN?=!V3TTRmCJ>pjKln}%23Z}m3|Cwn*B zO(=E)Flu|2P7da+%i0xU_f>QQjU!(W8}qR|M=w>%jf~BuP=|zhCPvd=X-NiF^Ab3` zs-kpfu%{|EuHpL5HS~|{@f4|kGCI6|n*2b-4g6nt)V!7Aeb*hyS!lfvCs)Bv^_Rw> z78xF(v6Qed-lI;L40@|h2C-_*6XdmEjsI%6byagtx=b$#)Bb_2n(LC|cmUU9&^gv& zHD)8|rQjDp0M5UC>~=&Ds9PjP`}((APkQS!hl`iqeRBrg8yp$_#(NB@5}k2|F61$G z-J7DW@AR*npWOjlv^gnrsGlOg#LGS}Vu$qY_;lw~K+;JBK|wpAp-U|1v6|P&3WnEf zy~DD^jEfg;xdzadeW5LNQ)LydoaP#W2du+j$xFGb8C1E*I6XPRuPvc3ZI~Y|T)Qf8 zd^AfKwJD?L0Uk8R0tQOizmZO$0NPQ3t6#(>vigO2tNG%J67GTjgH%P86~zWl)LO-D z!$M-!5c~tD3qB)Ku>Uplg;L!T)_@aM6JA!Z6;|xDWbU$zC2eEfsKUQ znScddv>*gV4glLzH$QgZOb2}B$8vtgkxMe3nsWr~Wy^dv5dgXfY!s#*>;3}}B2RJc z2RM}kP`6=!nzO^>DqtOOv*Dqzz2L|YtU$IN8v3!OIBN)2*s|+N$jYp*>a=aBr`deA zP=WiWX*@f~e#OmmPs(&RTDQ7#j7)ul4*ze@w3wugSQc#SaeCfen6z8}dDvgk#4W*3 zDE>|u3hy}4`DoQI-fx3LckS5n;CaLKSFjt3!S<@onBl7PYh&l;E06SwSEexQig;nk zUnyezr^(#`Z1zYP};JBi~1(gpr2qr7r% zOD?s)pBi>eyl1!t4SwJGzYZm8n-C~V&#+VV#Ov#;ylAc=*RacdFzc0;Sf=t+AF3pe z{dRvAGk3p2_%35kxyrvirSoGby`1g^^qI+>TQOepE${>9>k?#2;Iffe{vzMKE zP4TL&6$~Jp?lb(tgoK6AJ{gp(z>cSY;?0v;xm61k|FUy!?wd9xEq+kMZ@7s&6570` zVkLEp-+{}U+y$3>qhRgh$v3a%Y;=p&;K=LS`?s!SBai82m>f`FwUY9k|MGa^8Ty^B zL^(Y{n(C&7X^;|U@h5q@1r1)M_)Ki1;Y^bf8Gm8Qa}-`?Zar!Mc5M zeaNKBdwFel-rBdV$$ybu@GRCic9F2^9(o7~9`t7)-98Ri-LAa1!*M^XXnM6|g<68n)&%l~?$@Jl7^ zFJ{oRs_1qf|10SAj`HbR@>HO4S=239HRf8P)%HuVaPHMjCCKFft@``=ORJOs0hH=O zn5ZO9+C{~xXQ;nW7pA7?sr`SDO=xb~ly;L)Nb3eIeezpU|2Bw99X6KIGKE|H7JjCX& z$N2lL{{290U)}>>Pc^3I4>v;=|FUgpb^!n6l=lsohixc1parD_kuBONk6ojb1^8K_+8>0H2&@0iUljTqP;Ek)_wXnaESP*>Tl zm%WVn_DH?yeMiUMlc{G3#CHu9bxWTPI1CnfYUKKfnL&=u9I+MNZk9inNTt3ftic!P1pk0iy4iu~|v9o*Q*RR}te0Q&wA> z2SJ{*%7{Z~8xS*dATpkzJ_NZgvmE;xmdFenBl>K!8U@6>Ib@@kU{rya475An`O~xj zmJ&jek{~0VF~JV){I=>iXtC~sZA6rLPF(9N0#z}hfzyLeayYIYGLfwA9^rA%B$S@V znWlp9ItF%TRj629QZ)nv$8VT6Ky?Vq^m-^JeImK%S9h|y;@gE)pK zZN6e;Aw^L+SH`)J)!l743MtNyGry`hZo*Bj0K4lt%?0H4TY4J15!!Nm3)aa{=!>vs zt9h_7t>5zySd*&q$sQjF}7&vwtK%9dPnADKm=(namrWl4Q@`TaE(?j<@yE zoz$NHgKBXT4Q;cqrD1%zYxxBKY(3^H$Rb6V$wxi!mN-=i&v;8yI4fwxms@?LO&sQrmgu5;mmU#*OSx{wU z_hoVUZRQsLQF_}JSB`aud8nfQuv_}AyW!RSqWi8S)Od(tXJJBb?D%2-r{alQ!vn#{ za~(EAI^9jJXQFSK%}C#kSCK(B?d#$W{C9&$@r~?jL)gXkoytc#q5EbaKKlhD3e}mR zqJ1z!sY`>O--_I?zu{lBIq}_9?PSCnZ-(1ToJ<7fjIW&Y%sY^=M$Moa4ziz+TmmaB z$gDcq;co~woK~PH<{bWC4hH^7f`E14W5kT>C)+x)O=2~aCUYqDroLs79FS0_TN6lR z2npJNxe8F7WfPTSepCUJ)`9gL301zDlQkpc_BnWhcF%_Xl6Ngh&XrB$3%f3^GkHla zd&e2rR%CH}oa`85?G}QD^$BlTz!5X$+?H5``*q`$<8RY&=UE?2v&D z#IHkKIb`=syK<{h;ZgMXSOqp>B;IgJn7?-fl)p|@c72>rZP)tyA)5}NnG3y1tU}sp!8!BCCEgN4^Q&|6 zcEC&1H`gU?_hLXJCnq~RhScc*4F0(SesP-Ii)@fLI|=tdUC1Ma=nPd_mtG-kAgsfH z)oXZFj9Tb@Q9tQ#h_ur1vDf^qZdlD%#0*ve=wY%19d=Q}WuShNtW7_^OIOhHyTM|P zcn;HLr9daQV%^WUr@FO-n6+Tg(Sn&4+#Qgr9*RR=)fg7?z+gk2iGg{5E&Lw^FvWR- zXP7!#7Nch~ZrXbm@+t)ox^%4%tlyT%*z+5Gy>#(jGkaA@(@3u)YISV|nb1Smg8#PaXn_S)4Rxx~V+*QZkjfZd%uEI6=pBpf zPG@5@Cy_k8v!Tn$q3=dVUI4tgBJbkbyc!7nJRr!_E(sg|r|tF&@0&TN3d8pQvy4w} zq2D6Qoo`fGwZ|(@T)t>icl^W2=RdXv-q!yxO^!Uahl4q{y6RCmvq++(qx0G7?W zN=-Gx`eHPTM`QiKHGXFhYj)d(wphC-OOhoil4$X2fYfmcEoC40cd=?OV)@>2QIEen ztrwQ*5%!Hs|Ez##cla++Mlpc4>1J5gI|G8lmU^FW?-Pk{^)`>TY$OO;-=i!KH5&>I zTrATGfY;GixHeV#gc7yM(4AJmB9~TUK9E~LMU>ss33&XqF+YD)1M}zjXzY@Eo2-5Z zORe#lX>ZL(Pz*w8r~O%9Lcgl!0mIKuZk>qrZjykE-PQJ{DGGRe>chxl2B(n#e}aUy zx)+i<>F78i31mWi&$v@dzq9eLKHu|)e$-C}y>mA?1LhFVnnyljAq8$(SA+!xU!nH{ zm!SC?#_)B``dr0H81KpFQnT|HfUc|?UT+-)g87E@X&OxQo#8GPfT^2ks!0pr-#P_t z)xl#S_U<;ihKan7Cnb6At03xk1_Myy+`IKYF^CMG%_t?9brw(XJ$f4!!ZNyH?UR7j zGdEF)nkZh9r3GE?iaELUTi9OnhgFZVb@IU-AJ(pz1mQah$x7o?XHA&ktDmUyAZ@qm z{jpg1GY)dE;I5B)&<*92m)m!+weFiN~o}+nS@f!!w zLq2+|DfrQBayB@0LBBPOaT|{$t%T+l-wDk+?wHp}j~;a|OU#ZJ>s-q};{OkV4d&N8 z$ZahfhHao?FKr94NXWT|xsghW@=c1rbBxIgn^;F~-YC3vaQ5?!{}qiTZg;+a6Hh#O z^V}(yt(j;S^mm_tojy&^9-!659t|zKEJP+({hdl1{bMFBUJ3vK=UjtB#X6eaYGB<#)My8~&mlfZ zOR01spv$#SR2obamLVSjM(_@g1sY6o8?b@X6*2X)MP{Jk2+O}sFS%>0BN4%-wsP$4 zm})jHcCOVR(8u2F0c4W8Y#9M5DUGy^pf%34SMVF%!v_!_K&p-vqYCCJJvOCjEWcA;n7y{35p72w+!6!kQ-jxU>3m13K*Kl|`&y z8FEEG(hg}F>Nn$D>xfHYnasE{F5x*+S2$M7* z3g=pOD+lBDwy{vh8bU=D5w*A07;iEJ8nv>@f8G>X&qNgUu}^X`g|q3150*;H0whA) zLc3G^>d9Zs7W&@Fuy_C4g2^!(UK<1XVFy1n4YFqk7)?V#ewv%s~B?&A580)rb%>z=NHB9t&85GU4V% za(J(z8eqH97OS8SZY>0~6oD|cFuW#y3Op6i=lnNGpO*ha1zGIDq8Z$UPZE9kJTP{I z_B#Nwekh=NszY>`&Dmp0Yn34Kr7x6kgh<% zAFBl5-9ByV-3v^!-Yd(sF?z0 z6L_2|;}i8`=N$7ia(m;~3n8we9`I|cGk&Au#?Bkp6+ShNOY(UJ`dIm|(kAE+`Rv`pZpgHrL@a51O?61wn`DTRE&9_KIPAFn`*J=Pi2w$I;o1gV&!(ESr8euPd=&2m-uWr*%GGQxr>OzwWOoFJ<)lb<`G zbZy{{WnV&TRRFg8|HUpl)wHbsd_TZJ*GU<3@&olZu9*Gusj#In_Uq2L58qS?P2qe0 z&3$fMHg;G)@1$;OfA7Bi`_F$`JEXY1HNw9i@ikgn;yO?rW9oL?FPf)(!&aaC(f+OY z&2aJfx4wux*(O8S4eu`_6NSg`tP$~|H1g2jIK!xC%4o&3E1~*rf%Iz;2b>NdLvZj134n{yJ z$f0kviOL;Z#>ADvY`}kx+FWhTaCyct#B`xmkOo;Yxg>Sc7rY+8p2!7=Re7&JFmp&vDpEcJ|81AL&p{&s-Il;p2O zHr8+tfvgz~_NtL#tPyU({)-Sod1878g80PER}~a;-bNA?Eh1RSjdsjZ;YiM|wkbf4 zmZ(xH^u&!A>$lB|Rdg5vfL41MQ0>*xyq>OVyQN}{Fj5TYpzLm>7=R?+!2l}Oz$P2_ zM+<%xJ$h7l#fBMyt}azUdR3r89n~ zf2cn!0=6oun9xiZvpX^%RL?!*g$(#Lzr*7v+MjrLkqz5|&E%0;nb zusc41FMQu}2-?Bx&hHJsUSJMoMBf}-aU$_<3&w15-v?*m{z&4zNad1Rlk`Nq?5r>F zX4PhL#9tr1%*hYIDDjq|(FOj4zg54fdWJ`vG+^>x-Z+MLn!VnEn`vI_&Hdl_a&fJb zaEw7b~}4Mj_2s<9Mj%_-4VkfJ4D`bS3V@r<_;Qds{gz(3ZX?R(HnB24B++*d(cf0J`I+HJoG@R}qi1z6lg z#&N0XIOv7`0`1d&p=&3R!484@9jIOW`3!UiAG%eLQKy9_$iaH@s}4C727}E@K-=J_ z%!ER6LbB${1>ZvSjud{-4Ci`l{V1DY&25Ve*8sm`-4Gt!2(ti963LOgo2mZnQ@ zvkmo40%yFn!`FD-_NN6`t(tM>*k`LB#_ocO9Yi$Vik3~@5bTS};$e#;><4gh6qw<3 zKp`;#66prE6arGDL2@E>V?yDpJ44)CZlbU(hq7jCtjpHRS@Y8r4Nts&>n0J}bu{N; zOp~RF`I|^`tllw<2jl76sh6T%F$FCDbep==Wg80a<-c_gpNWKwq7ijr(%kqBoEjGX z@M{0ckdoJ1W&)d9F)154jC<$WSGm(KkoBdTZO*36p;akBOH&#j7&|J;^l@5CLp^n23#k{Xi8)Nr zQ5xgk;0&p~ILnVEN&jB;IFF*DmX(opt5wp74Y0O*^STZA*7R zs*JS!N1;r<`g%L~@l-vU(2ic1HC|zZHQ%7(f z!trWWuNAI|x9l|$gPv1Zc3Q~Y5Zx-hi6-?(xyThHJW(yc1!i3d%})mSf}De(DI!?K z7l_rIuwDf6G%iCm%2{Ehfap`)18#FNND^0v0b3}(x{)JEMQU(@jIcY1Fz~5IJ{F{m zeeF?NI{cECiI)@UnmWk#dEN>xzSUrz@%al0?=mr-rMD>n33?z1%60;OuLRAa0LU=h ziaKr^AA;|2vNp3@`W^eQ%HlqQH-HYYzv~Y<^-8Y0{aJtTAjR=A-`Dx}DPcYRgJVjn zu)6Bw%Vw1S8=sdo4`=%t&aNT^BYW(^M`G1SjvQ&PUbUzGQn=_^%I-t8-+Lx^#XTd} zVxtYIi1^BzOiui~F!pFk+5Cmod&R|-bq`>7Tp@ztcd17 zgemH1A?zBUrktt6b#u-Pt{XI*%?kZBAa+jbRJXZbnCcI%{Y9urUo21=(KUSfJAx!m z0f;W#$Sm^W+b-N*cpY5sh^PjJCwSj^$=o6a(S4-Y96`jYhXAZmOS%BOqznY2+O{w2 zk9N6@81OP5(Li~UN1LA%0u{`o5WSzHnrDUF6UU+jv9_QN_>L~?^m7DMIbcJfwoQt$ zM$IGLuzpdr$Q6jTv+g30$>mKBaZ!+|FvJKADpD`yj{XzCAucrfPKS;pe%*LT*i8%j;=<{b#@`C~%=0(}hs4awQ=m+*&qaWvc=a$;ie(d;Jil z&x_E!WRSR?pWqdoT&(m27r}|Dy#}_`wo_~xD=Uj@n4tls`>+;-#QL;g#d`)qvPg%t z!F+&qO<)Bo8x8Z|OUVviY8wR6LT<>L6+*D)v3y=wFrZN;&TIWiN>!c_yBoaliP#J< zu!t_q@df>ygt$5Fgiu;8YmxfGGt6~6)^21ZfEKGy@@-pqrQ#nt-3<$EuW-_2q zFh4(%XT-pMX8=I_yi6P5cSb|{>qm0bGGPQ&WD>Qx(JxDFQpg)4GQ8@3)A!?JT{2P> zBdc7}R_%d_;#3^^VIru`E}Qm8%)G_Az^13jqz)Gn5JYnmRKym~3?Vqkcf|z1%Hji7 z_5<9{)S`_=JYApntv4wnEIUO*kSD^MBsTa-s^+*om?ZCt+>v6{>PGI^l<{-!4Au2< z-N8643i*T*+{#_LWPz4i&LttsfE;%;&u$4fa+RwX3xpf4>63+hc`2aW%cP88)-rwR z3n|jY(LXrS{5CDMA``RFJzx^F*_s*Dg=?6mxl9M-16pT_gnmGlEYpfHO58^mB8%jD z%>poxQu$_NQD}>+F*xr!O$PKfZfp3Cg=gG7X?f&t%A?12%4J5u!=5IM$14V{_SuYVdX@tO4TBeX znK$>#@s1Ns;}f+B8($bNdpu(9#;>bBs(AbH=ILY88~9sNbx8H?JA0pg^KfZ(&5f@^ zhqge+3hh0=?XLSSuibF_C?@5^f1S*IpUU9pN2S8CHCv$d?(dSQ1{+^)dAt+7s*)TX ztleXvzVesyF@4%^(l6n%*H7O zOWakneZ_x)5;Fr_97%@6$|kgmud^*41#DGLp}I$_;xXqWJHO3RZO#e_=&%bo(-hQn zK(7!3$yzqCXUWQV6hcE5XQ+Uqkgv{LQX0Q=I>7g&Rw&bBHFa!u07)ocd!7J1|ED_4J7>GUN4#lXW@5}DjezN>8@52Wk!LX`h>0yF4M9vf#Nnd-K z&|F(tL7o5gBD*i>Z8K+bsb3>!{X)T@IhG40Br=|5XH5o8&q)%oMh7l9X8R?iOKs*z z)(yzVIa&P*Bxpv%<(qt6gEW0-)5ogeE3*d$7|#!**9t{r$oC(P#pHSiMn@%Rg)ZsU zM>CA%_tSrgLT?^Aw5#LKDgCT2!;1f+a~nKq=wzGPTQ1DLYrU`QTn&(E6GiCJVk6== zU3s>sn-0Su#8+`8EgpE8UMAL0RlwrcrcUG;4}6;q;JfwlK(2)wNC7k`k|UEGz|W*h414-N%4L#6S(7dHJ5Hia z((W?@y3J2YjHe!ZcfwlsZ*B-i>9&fh>+YJ7=M`|PF4RPMK*-Kb+xtY|n;-3O`DgFJ z4Qb1`7qh8N2fhU#Dq!siz3_Ke$KJ8NTl?Ewkl)`0nZDRPHmAtW7q?!&A$AQbYu8mq z`MU;5J;(Y=zR*yD5_gjb*A~c03$)n>1jWSQ2#CraL)w%Vl|C&*_ma@v>^Z4utlG{= z#IGnNnd@wTPMcw72Uit7pw`Cp3CvxGIjB9Jv{i+Z;BC-|TjO%(dvfE2?Uy&bEfEYq9AWnx-0Y_P%WxrR>L`HX?JI*IAH z@ZdO>V}24RVYMS^aWgVkR(5uGk8Vv?6M8&V3P|i?%u;r25~F$`O-`6@aeERGb~Q-l#V_@f@D-a(xQs7&p8xb`A_=y{Kures8exVflTRF=y}UzpZ@(0*p64%CgT( z94kDbzj`#uBqO2_I>NXsZmj?bqB{^S+`}kM=*2O z?zt^4uly)EN4vd^`|jPV-%|ar*=B@%Pb=e}G}oBEYr%vFrUfhNa5ZYv-3Hzo=nGZ>I*GWf7E{SBa%RBdD0Kx#V*Ui$QNifrIaY-Y2yi$@qNGqdslab}=f z%9r94{Gp66*uLMjO;yKZmpDG9S}52YputK*)XSRsV_MJb3?;8I9UtRgCIvR-k&kf? z9myLJo?kZPyY}Z-=72b-=tQHVS;z%bF*7U3(}cNJ1P(&kfjiDvu-)@8&8=p(5xY^b zvE7(XFM$+jCK%gSrH4(<;Z(B3BsW#@l7S<9Mng01J-Zjuwt5Mw^4EMurhjoMaeHfQJgmU4X0eXdWYu?*+`m+1WnnmY>HTQeorFX37$%naO|9zzSN>^awIE{Q1%6C_#elFvTAjJ%Y zzQNQ`50HbyDIEOTUcqrYZqiueddJtTc`NOUlH*C5MgW*2T&FL`uVDOLGj4K6!FWmA zk^;K(dB6IQ6vHz8v??n{KV*4%=cjl#0*h z%I!9osZ12+NwB9lRG?63n~jRvsA(S4q(~BgiLJ4DnpD;K9W|U(>Mta00wt3WvA8; zzwlXl8vwI3t+w&=6f)YZI;=*88hBx^Fl`x{w~M;oYi9$vdGBo~TAeCp zhHoqIN~mL!T4=jk*GK$VZ8hk0@7Q6m=W@x^q6i2=)#=`IU;VaH$IBA7`98nxn5vt< zvFw$Z=nnDTzE2OyXVWXDAPdUI#KV8zD0yy)63tnLh8E`$-8#tn(dm7jW5o5r-`vCP zzNSaU;L9grmujtD9-jmcr4;<>Y0qWD|4y1@ZAxObBMNkqoLRauYIqQeZ^ua8spiWH1 zSz{nmNdtkb&G8seZfo?7&qJJ`07c?!Kn^D@@w2JTWSHUX>B>62LQx`v^GKEZa5~7E z@r)aYIE^bWDB{szei0{dHv5tPfihnPO~Yrnr%J2s{}>dy4XGxIW-0)zz@}E(h=9J) zQYHiS_}HXiHuY(}G5TGu!SCT#{e}rWe9s z(~fXV;laO^)tqHqz~o-sgYv1I*)o{XFe=EL8h7lw|Zs?{V#iy{v)c ziX){Wb1W3o2zpoc5<~v>>P_ju&K|JPt!MtI8w_?bR3mY62rd?+%0Rs7RjVPu+j-Td zNeUkIEyhfDP5MQY8S~83Wq4v$QxuEbmuKqiLQviYQ@E{8VgBGMafI<) ziDr2p&_&JTI1N6i(IQYJTdYLW#=O+8<9Dva(Lxw@rt{Kjea!+bj*D6nAWTS~m#|f+ z5f%kei4?0PX=PAj#_8~=iQHB$%#Z+R#rDf=zW%}PZo{7#?hlVTC zxB29YXcQY7n$?o6tYr=%; z`PL!VhCjJAhcoT+YDdVAz?D4c&h9NXgFcbx@t-TNrjBgM|4sk=I;VIJk?4F$jjh#q znqz2clPjTDqO~tF`n?Uy-1il`u7)rARo+S+-pzaeV|jYD5A!9el|>B*T@!82>bpA! zmDLl8>-{<)-m(Jx&704j-~L@61NFskynE~7z6Y)#NJXrI<`f1S ze0vHfBMP=P$PW<4w%VV+>ud2Q$W_Dwn=V+bwAwoOjtuNC4~S+0z6eQR)f5E>mbF(H zOD)OqBs~mUWPexra$wd_pE>d?pY(-GlAuil;%p!sVfEf!wJcu*{F;5)@98jNu6&a@ev14WDa}%{ zN!H&h7kb*p>Z~R>=2G12Hvy%61)P<0QZMz@DbkN{sF4l+vpfN`bJAbG1MvnxI!up) zu>No!A^{L785!R~{1iYNGb%FD`Wr#QUiW>Urk>xuM{e5%?oIo7oy5nrqB#ChN)U1C z^|6|}4fogzfVTom1y292>;H5{(^DLj;>4& zz#WQO)J*OMlojVzuCMR>jp#XK5_8T{a7Df{lGAwdM@q?-E7#(0|D)6s^-D{OW6;c9 zf?D3gy|d~b)Sbf*FL}{z^$+_oca5LV%S$>My}tc)YZN~A#DO|wJ$+zI6oV9qn_^}= zJ;J7cl-RSySh>S(hl$7AiS~h-e&LC^*)$&P8))dUl(?cYz1@-n^%1{PtG&*8JtqU6|R^dmPVgS>yLS z$>;`*V|{Y|`agdKv=XY8Jw8wxarTcWjh1redy2`5$*>I7((~ScJ*aAY*!xvl`B`E# zlg&GFO;?pU8{}Xo*1dNvNeB7dl*KBeuK1l_GeVy%w`U-fTJu_(Iz$x|7$fov4b{FM3+lmwKtBJptxBb&jRWiXw{hT0LXYL8#iuTXa7gQ7Zp2IIuxP@*in8?rK)R-Z#(p?{mq<0 zsn$e>X~a*>ZeI!MuV(ooutpr=AbVN){=rN#$ymrZE_D6?Sg`x=$F-rvJWZuj(3LyOC1LWsY$Pei@l0;~P{ z#eY^~m|~+F_58C8n?sf@)s??qFQeRf=ND16{;$~C4K{;Rv+L<6%qU4px5lF3tJNZ9|k72^aK_2)RRn#$yT_b@^yG$~2MP zQxE5bxo@T0PvZ)fro{||$5mT@Dd((kEOfk*$1nEm){Eo1wb%lr0<;Z3MQLcBxFYfh zOuRk2}Q1Vb5Qy=iphO7SrbVEmNmy$J3FpEaZ1I$^h*M+;ds9rR{x{3 z;Qm`y-fBzf#((Z|?gnjL1+UFrm2%b&9)K76U7K>Z9_9s&pq^kDI4ghdU5DD zKE|dtt;25VN31J#%GXt_hDs{mV%l1qfNV8wrr#m2cKdx6B(5s;8B(XESjnK9yp1l{}sxRC|nre6~Kr;lZo7ooI zXG)}Pe3VmfAO95{Oc8&kZs(*QC6Fq_y|?m?>B39^4;|v`*J!8BA|Z&ClL2$m+%v6t zhQ?!!dbx?NB(KJ|(1JNe=@}{#dRSE3!6yBOlIP^0uCom|l@oT6@N?Bczy5dg*7C#N zj-8yoy~j)*>i=;sAt^IH_Et{((Cdy&`}DJ8Uq~QW&b*9!ablaCmCIBfHQ z7YBLa{hMxY+9N?#Cb>o^B%FEa$H_jfg=3acVsHe^tMrm>aG$_5L#)nmq<1xLK2g05 zX++!Nx_io~YnX7oykxaAT9iLUdA9XM4KMuK-K2QIO6R|U2IQ%CuP3|jSUH)1aIw%Mv_e77Lb<=0O^ zF|&CjXzs?+-*D-scx~ufQ?& zopdKI^>xI-XE^9W-D<|bL}4AY?Q3{!zW6E;t6GXclv1*~+LVp79qUxO-ZPcgy-evz z!#Q=H-X~&CESD`?)A2)zvY9h1vDQT-_b)xh|MlSGSAe5)Rc7na5dDfg9X@p^K1?t& zMs!B=rQD3XuEO5O&S?$zzqxYPvl=dJP&!`kxba7&PtuCjf9|S(GrJl#ln(B%O?GsYjOe(6&w!~$n=S+YaUf8mgMI9o6JYOe3D_CcA z8@&sHtUYKN-hzrPRzD2>PaWd&|0p{5c&7J1j(=xZ$*o!)w7JLDm8{w@hOiC8&_$9E zn@VOvlN!42%v`3@VpiK+lCBh$S{IitZX=Z>nXDyAZe7&x_c?#&@#xWIe7~R1`~7-7 zpRQ4<(nkBk2c;-c^gkB{yQar|4>KKwO_1F|DYCXPeNtUE|Rjg;6(1%L86mCPT_I(LJ2#ZGYsW4@J{=_N|Bn7iy>kIU|Cys4o@qkgAV~*`n|@yN0UivH$^w~}BgcU% z?kW`n5r(qy(g`31$p~^DW_zU!@jqM#BU_%qM#S}sm<1)BTC9383k>|RDy;&KzeUi! zJQhWPD;II%>&szde&AdQo32Qe=n7k=r0!V7LwPe{RGclm^`FQ!^KP)1F^tkr8Oo2> zUPwCj*No_p-X4Ii!Yf(;i#P(@(VO5kR)cgH=eN=*SRp5-tF1*&KSE&S4qN4M%$sm8 z&~2+*s@2kGVozgUP5I&sq8=wAGnw#zz&Z498^ej z#=Y%`ZNRB^9Pt0$dNSx^gY2@1?s}N!HT`fcpu61(vNUZ8_n%bAB~>6N^0N!@4hU^) zSUpM;V@HkuAiRUdre_=N3h~&ze)#2Ixk8agsyA>>XdIo zXDjTcK+5bV- zf{SM>l!aXV$$&O&JGO?jkevQhwItNwdu%~YpIl5@2OA4@{nk!0v5dR2ap8j{bJZ39 zx~@I@mM3?Pb9#^ST2cIXvDY)*WRE2VpLO@9-iYX5eQ)I*A3UnJuH{6ct; z2o(?`Yy2Tlyr`0mQ=OWbCnLJro$0e}Ccw>ZM(bGwcDSg5Haja;7JsBDcIbQyJ@D2F zl8ahI0>5cOP}|tpX1}*n%OYVv0pfI@`idd>pTkSy8XIdDlm6Xjr#W{mO<(W&0r~TU zhjC$+0%?B2yjKZTk&c?pX4@jxp0nA2heU0+lP|}&=?#u8@u*L%ySer`+~J|ybiV4k ziF$ofnr8<87vOH$9vCWpC>0b}8>b>uT+@*E4!Cytd;AFY289hSyo5zX>;>i^(zFEe zn;x6@(RZ(qGz)$}yw@UGWpcb~iKR&g@`M~?PxQfz3yPqlQ~&L7OX7Jh(_rKdY^$wr zfh0n%X!-}HV>%cW%p+nTTRn_co|+7=!4R+e;D_@3Ltsaa4hhr~_kpa@5`@`L8xh~PdO1b=R%DnvvA^Z%wGOgUv zd8P@pI1Gu76u<7P@LsMVyA7G-8`*P7cU=I;)s(2@R*LZ^D|ZLAr4mMd+J3lLlJSjM zzf1s(NDhW`%9(QUId{3f!3HZfdApVn7ynk|_0Q^8$i~Vsp+aWb&L-)yJ2*})1Zh== z7MNYCa(oT~c{s2Z?f#42zOmvma%;2zx{{?$|J<7`HA^4Be+C1h-q-`@4{Mc1%8hu^c~ zhI6;!2VoiKj8jm*`*K-ahpjMZ!Rcj!!>9e)Qnh2d{o*e6YW)xDb9z-VSsnbW;=zZl zpUA8pQP-^~U;hnE$Fr~GWD`!$yeHA+bf-R9OclNjhhnw4)PM)YV6d+nXzK%3v#VKT zt++=Kn1DxSVq|b{7r8wi{N;$)qwK)(0BA8d?wk0!4hi|cLr+|#?g|lO`A)PBWIr9n zlUN9Ok&P=>x8TO!;AK{i3r0JrJMMLROpj7AS}y_Y^3hpMkc0I0w4|$92M}##e?#j{ zB_2)*f}{PlGd@BzidQS67Ju1BoITCQ)#za~{MDSm_-6X2NlTq$O~9=XUaAn|VNkZk`Jy$!JQd+Tz(IAZ0abvDg@ zp~(gvPu)%*e)K10?x{ZE^jYSrev3!9c%446|GH9))88%N^Z9WSChE4meDA={wj&?U zecN8;F<5gBWi{a}2}3zOW|$cw!{mfpQK?4pH?&CMQScrpTzg9YFb{Ur zIcil!BeeqS{BN~C{)qhTzv}bwBIIOSN^0+h5D%MGLw2ZRiPMV;Pjk}i-QTKB$NKy!_&aI zDgGgEZGteaD&+khFwBI)jUe;dbCQ%MauYzHkGI(aXRPTA*jkhS+nvvSYES=+fxWAr zt3(j1>McR6$MBbk23nQ_Kdnn3wO~pSF_f?TMl%ZcH&^ji!9)mLZ4Ll3Ityy)D&*oq z2nlt~W`0tP(p23dM?oW?i9VF1Tr4u2f=~e9pVeJP1)W(QwUhXjNLy&&Pf;nftg(2CrhCn;PN&*B8Y)y#*_5iN}DT z#}H7+0F@jylsD4|&f~x7*XC224OXKAK`cDT=|^zRXKa58unWWFjR)oWPEBhY?Yhc1 z&<@%C&iTJWuQkuJta?9Hsr2CmTW>HiH%MryA}77KJ8}=I;LMF#{!@1qHnJ@yZv;TT#p)E@ONBle zIU&`tag`74177Y+@{Us!rO1B)1K#5Y)Fhia_|l>fwlDEINsln@i}q-;qhT(Q*05VZ z-u*wFY!kLa+YBOVD*Da}dZNKNxb{Q^vSCK*Hnr8G9qZss7ddyEDDmY5@9W%eVT}@t zI*o_bxY#M8=0`g_paqERs%D3~n;koQVl*_<7Tneahm?6>yjRp+l2U1+dc{`)l;ZoJ z$|!Nicv&R2KbpI2s$#NjW8+#Csne(i zAV=paO+Yk63dkX-KZk2ibk|^AL$+T<&f7Ju2`1AX^9t@vhP|F{Vf*{bZHl6ud!kdD zp^@@)ZqY4`o7>s^obc7B*4O54P|+uCR~2l(@GzCgY`>Ly)@W~7;=-+mK685A)NgLS zh-z$3*n<&oKRJ|}eKQ{x6Y#|;GD8Y?K(3IW@9Ejw=JTmmDQ;=OZ4;4)ckb$;4)*wwT8BZ{{CDMPIimxEK|x?yHsF-7%PA zn|67mxGMv%2_3)nQ@dbn(^*#K?>94-*0n1^J^;^`eVK$|fEEdIsm|5f$E01FY)K=k9t1X&*iA<6y5|W^Phw=z**1YsFppjfj z;UBa2a{bo5seOuwYzxq z*RwKvF~}QgH<{uZ)A2GK7dEEx+2X1+*FjgBNKJpSePBBi{84IT^8FqNT%OszLSpM2 z!+h$Am8rBRBnu3Y3n;?wM(1n^aE=*qfF@-~_NDHUU-C=!#Xz4 z)6iq2w8=ZCWCquOYo_!B3&q%Tppa-^FM*5bWN?5f$@V5M5Z~`f9VIhHTWTDTSv==V zED@+wM?qq{!vwI5UY_&mycaJz)4SEW$Zy3No3GrA-eU@$W^-&_;^FT-wUVX!1bAJGB41bx;a4Kw_thZ8@D&IxVUI%j-L3yt$4R!7X)g$ z+za0R#JBT+ZRch9SjlOV(JikE!VcBmK4hh>s;mxH!(D|zor?_5HLb>&AZ0-8y}0j8 zepZvcH5Ums!*=QN){fp{#9=IcnEnUfwj8qiAc}Neoa4XuFEU>4VDVNQU}7p+SXP4o zbU&br1^VtrBfI>Ra!U|3D`NZQQDe;9W|-+uA4;#*+55-Rjbo5XLk`FXlrpnoGrIcn zYD`CN!ZJ{L&MdNXTv0b*gp5*N)o2e6Wo6+GXsE;%ts+B^HX>ETD6?o_l#x@jhW(09 z&k*Ur^}@z|Lq22E439>o%3uN~-$cgPLuCC(F~B~^$FoErvC}=OJU;%Iy&@i;PTapk(46m#tTht$cm`MT}cL(j#_~ z-?ShfVZWbxKQ*3ZIx}7UyxN~zbH|q9(|@447s$RSv5x&=z5yrp93T>EW?iyWqNn#f z?rJ9+>58HmRZ}wea6={a%`0G?!c@Ay7?H`as`atnHD02YZ z(TvzFr@c0Y=V-RY_+2@ zLT<3db>=i6OKh{Wb*JuX(-B~eY}|^Vj9`9A@R;8Za5WJH_X?+_LS?a@li$=F(*T7U z$u}IMG;@OHfu@bgx#7P>_dzo*+W@PX0>Io7dVJs6_W;X~?5;<`X!04K4;P)#n?EXw zlvw$pa}G?{HG4r(;a zFz+du)dv45J?HE}u;wkAiJy|3Rw2Yw=O>iKhU3Z{^0J0eWws&+)-&}~Dz5D>>8kI9 z-UJW znC!!Va4d1ry#umQe-EBl0c~7F%gG@<8TXiy%fEtuElx4oX!cdT5u75|eej-|r!(wqygUQ1-JNFgNN~nLnHMmcROREloJdcWR(Vn9e64}1rfw775UUU%E z#dTJ~K=<1Zv;!q1UnESCQT8Q8!g6jE3r990Q`{md_?+M-Rvx3<2;~?060d5Em z)?-#+szR7PMDgOhGNJ+g+OGc_76&i%q^irE!(LMcXQrkuiRo1l<_RzM)P8ti71SKj zVS$yGTbT^P0$cWn7aVh}dacs_iz`+s^YtILesxhs2@)b$0oKI^?>fRGCIj%(ZFaPD z2|{HpL`_L8|1hR;P*fIJC^2xQjh|pG!kquanYWxnXdERRlpy=Peu;=6BGBQbA=#>t z3eSV!LDY_Q{K?x%h1@~M!yD0;udZ`gl`5BAya{82%wz4n5w2d?;E=$9QLZ&f`USL3 zfTw6*AvZ&t)raiUJM<}y_8rdT9okl;nH}6A-+}=`o00G>a zJf?(0H%~8z0(=6GP}ye3PB!7}d~wH+x7NAzQdTH8tQhM#dIjOpS2YX}8l73u@dR)C z{i{fyFwMQLv4+!C($7hKvfgfmZT7Con4F;grbS;FSqs%4H@os=(+fA8ldriDlcKSj z>|SOwjUIKpxFQ*h9rSKLqyEm}6{hWw4KC7I9imOo<+&Y%yY`Bxxw8Sg+3y=M%h^0s zqHfWoL}kOXX`rp+^ltkJ*5rNZmnh4l8miYTFD=5)ULHO5Z;3eBxo7VSVEZXAQJEJN zE;t1y{AUC&8J;PlprPh$$S^KzqKt~d2~Ad9b1(_Tm4Oe5=c#Y_D4(Cxv{otP4};B% z#q+wY*@3HH-i5bqK@KK82=RKU|Au$q&@Bg-(7Q8LuJP9{lfJl(s`|vU^!kT;GxR!& zm}jnhy=Lanf9>ItGBJysygfBJzyv?5TPrx}@xFjGBexM_8_D6<4W+2i?0;r|MW1~Z zhc?iU&HO2Em0SVj4ZOtTJ@F=Kw3n}v+c6gWTh^YV=P5;a6Y%Y_g30~%o5L3|qu;pd`2%K6 z%3zPa%VZNIE<3ILs|)(W$4+7*iWT&xfbYST0I^;a4{;!TVGRDo%V$xcJf1 zUwUhnTB(sS#L;l{qOn(Bm&BoTtLJ|>_jXOUCHxk4hhd9*mf)W9607$Pe$MgC3*o-N zU6eHGqXL+g)56agT`#VzbQ0S_fnET2y1sMUr(M!r&fLJ+gH0axCte&nVL$R`#nG5l zsi{fLf*+=aF?kEGBFyW&OiX2tZbe*n#|LWYzJ4sJg9B~gi<20?L_RThD^vlWlbI*e z68u5cNqUuLU}ZR5mf*l56EU9yHU3dX$l5e1QbF_e`l&pgIMuJNlp|Kbw1eO`pW1(y zrs12h^N~3wqivQbM~VnPU0#sW2DxrP)R-b_Ht<7WOeYPcBY{Ll=yGjs)n(84!&BwD zcml2g?E>6$=0(LOQr97Y5%Rcw0%5H0jG$;9b5^cWf+;`?9{j0uN)X-_7ZtaB^ny{W zg@qW?78_&=+L5G7mR5v&b!&iOL^l)5?y&hTv;8H&I#IY^vGu4)@Qj|Xy~te;ihSIN zgtt&59Xmey!|^D<7`j`cLealvMCSwUMT53JSaATKP$m{TFU=m%nK?mDqds7gXoEoZ z=QF3$njCWxSJ4Rr;<5d#5uMEnAn>^|kU-vO^Oa8g9QoL1?nWQQ>|oG`-vwd21J8a$ zXZ#9fs2CW_2S1)_5nBIuXuaS-fW?YM@ZWf#MnneM%RkH>nAA|_u81r z)bnH%cohjt;@4XNo#a6z#O24hhlfQ=b6OHeGD98k4vN@)H%;9yx^*Lw^UU|L{suzz z1nWIveB1Sl-wPDhPDJC)G0 z@vf78e^~*$3f=F9Y8SU~Xm83_etbYpCk!5tIgEO*z5S8$a8$I$I=Wxg$DarQX5=hh z)^Y4XDbKkRGIXA<2=T^%(3eYB58b>$J}ZIO*;{sN=E=0ya?%>@6Z}P9UR6f4vRpeR zdsN9aYA!;B1YTizJN!dHDJ>G#F`3-QQt1=PiGdTf((>`}=%}7xq>!VmECU zZFp)MZ&!WtlutB^*EKJJ;L{3;GWuPvnB)Yd;2Jr+yYqtc)7B(-^8$EZ=4~O8M>nsU z((GTl+4EAtnvqqkEh(xcFBa@cCwmior+|?#%XB&F7No+BTb4fbz?-)1_0zd?{rjmE zcAdga=h%v#90B z#gv}^YE#p2Fu|w89LK#^FSpd9!H_AV9W^G>MrbWgdIbYCsm6vfrSb^)i zdeNq(j{F*qXpFZD(LX~yd?eUx@@cKDT(Gq&p%ecnQ7p?&(}M+m-2}fykvK)P1X2j z@&N=cHU`<}!Zol&i-DF8AUC~TQ0$-GhFQMIvKmx0SKlaH@658B%Di2^ZjDTCKgy7q z^o}cuN0~*GQAs8$K*5-j-lmc)HB=`uOK_1tIR;Xo|AQ_Gze&0Ck-M&g1&jM>G{-`2 z34*7ZHps;k)y3DJr1)B@K__hEp*JJBb7Du@)2TKq5V}n4h;(oPnswYGqK2cd7lqP` ztR47+K_!#R;dg#_zP2lf$m!IJBmf3wn~5C90Soa-KVJ^G_Z_-lFEvr)O8*DR&HtXZ zT*GAb3H!V9L7Nx-mWEx&8Ys(VR%8LoV@r*R=?FiWrOej>=7Ty^5afgDARWAThP(Rh z>!+#mp=LHeUR3tQXhD|k?(J2TUvA_!QZ{!a^kh`o+q{TMAKmsW!0}?v%C*#rmDHb} zzDuesTUATM-^lG`n;P7@^NAs^hqwxE#>=OxxBtF3bLsn&7<@A^V2j7rJlEbv5wk7P z`%!?}{8*sw4ZVWiid$#*8{}`1$U6VoeLHeP$y#~H8RG{Igr}O#v*R}C&jc&Od-0aj zRZ;W>v)A19&S(XFIF4O@vSqrmd4%;Uht$S6Kbz?s`t1F3de-p)C&5rn_FYnC%%;2b z6?vSK@imx4EDW@ir@`+1BL9pHxQTopgz%vxDLQXi|OS0I%#k-y|4LKkL<~-x$xU ziL4i}CSapQzPufy)rPEpG*l?t)jw1^jVwuXKZeu?EXsBrfS~SyQf0_`nTB*iFSt9$ z|Ea{BAai_ozxG5qqiwm?Qee-xSp3BPqxv>AQi}UJ6&0ifqasYDb!!+fJ}ap8-RD%z z!%H_ez}$+Sw3Z)O(5eaLA1kUKt zs6u8k;|6?xdth|t3Pe3@d+&|g*M=RD$|r@%G|r@7{u+wY&)l+h>8~Io^PVtUeIroI zN@=pkg?RpBqs#$5nARacHJIOo;>7X%0RW{7V5#l0DBRL2hP1OQN^hPi2;iZANVIZ3 zGY!y39_61%Y=z4$r;w%B3|2b|c2bjwoSuU=yd>})d~e$J4>nZXs4>DNBf^arww71W-V%h7n#k~ zXZd<4g_g4&N=TzL5x zGujDLP;`3QWC!6Cfh-@k@(iEV1Z^C#!4L7xOG0jt-inC~6^@&j=^IG(?`}m7IMHDq zwm}4Zg>3)I%Z&NSNsu(i?#AuH??ZT-kV$ja4)5E?vhEnU93Bf?nb#Q3aVtO{yGM78 zirDva>X<|dv} zBxg0PMO@W7SC|nD=wA7N_v-Wh?0{$)FZDCDpTrE%&f|ba1VQ7Cm5q~hu`>NX%%4)5 zl1}X?jT*m9>kon<~g=w5J3D5 z9}u*N=C=gIuT6^ismsV)B^6N!}w8xx7n zyAGn(!bu_huN_&xN z%kP|b zg&Ll=F>#v>=L`$}_HbDxU7a~?4(N7bWovn?;e7eKmIMak2o;NPRZd?r24wQj$bJ@W zT6#N?xmEYJe+YGgHtuW9wQ>Dz2KyB!v%$4hpn{W->)~Rf@OYvow2Vrg?-Ify?H#5c zdskvc3P&DQ>Vv0kr5bsBt!dlpjTb5mIh`;+Z+p-H3aH3rVvLK@)TrPo9395~q32f0 zkm??VU==VQqQ+>l-0}Uh^G*18S3re>B1@F!MIZ{$Fm#EQj{g;Q@nAFI(oGdYU=$wh zWO{sPetG6s8Ya;~zR})o`jYK@RnAZPfoXX&kvKt3*MwS6pDA1ZP0M(JkRNwuyDnve z^J&(@5c;;V)nTWvwbZZQC0lm$u3Py{VPT9TT95o(p&VVO^x>{x8@s zMAkwE%fXJ92l=B8$U98XjNxhEX0Ah5q6}+KSa|t+{_YCUG!fYR*dX}zEMFxLt50W- z1$3C#rpn%d#wQS#>ffBV6Y>`1yZ&Fncdr4|I*JZc^Hi=?A6H;onDY|9&Zt(~7sZ6HEpBlNdNNDroTrwAnFW zJt1r#1}vkCBErDl$Ygdv-KXqkfP)h*gzZPtLB{c-kijC1R_WN$G}g6GuLoaQR5QN6 z-FLQfYRNm%g-hFi_R{x8v?9lT^$-#4_HBZ%$MZ|_ICTdSz6I8`FEh2iH0>J1MT8T^ zd>lC70s5+Dxrrnm`2-`qN_FD-mwd+~wG<{g<($;9_|WnN{v)QTUBDSi9oP zD(6l(KAAFao`_A7RDgwAwiAN`UKnP7$Bz7o; zTHM9j$|+nF2b`4AAUtW`cfLiw_A0V_jKX&$JBjP1z(o`zGS;hq*ru)2-v>?j75Hnn zGjR2|Zt)X3EF&I(4_IV8^2;x!37a&^bD%NCNjc_Ii(j)Tckdf4d!WbA=>YF6Xs&-s zKHlVDd@Ca)*l8rJYuSR zcox@K#Wi#U>pVn_OI`>lnSfao2jsPcU{`7{c6qsnJL0;=sif!Y`!zJDzN$dyFYO*J z!J((0?*6CsunUOzBusI3OjW5@U(QC~y)7=j#Mcr_bHX=mI$Y9K(9Wc^IhDlK%*!YL zPyxxK>*Y^cRgu$fCA-#LYL`pf$&qzZ+~#DLg9~f-d}>*5=(np_f4*yXDwj}`llX66 zW&h)kV~QbB+JYsSPlxJKs{B2^Unn@M?eI6OSh@-Z7|yRw<-l_KPOXM5`^Vx{YGjB$wMxZjlvw&+v^%4^eFkh2d{)l+p zvu-^D4JtWil%yD*6wzwGB(W*{v~n#KFl?BVvtCd7u>K;s0E1;1>uPk zq|6Fl1l%u6q<#EE9KK~|xWn5!6LiDl1*go1&YSeJ+txS-7w}vT$Y1~(e`1vKUg#fl zN=1+X9NKjc8zeUp_K6@z1Y1?BlP@G=Mvkm$|6@_hEpFZb?@ zzH0sR0M&x}Sp8ns!8H#<&yLj1(FPfXSCrdMKAgJhat7T^y3(YIc~+%HVz=&F88Kz_ zgSz)oBICV~zt)x0b3I+?FWPB`-F6-rPOflXk;NwGYWAJ`;F_y02z~$f?6#zzS}+$`#~2>ZHG^*<%v1n?{-FT()*uxD0ss$6L*SXqV7FHZdiTw;`C>2Hk?;UcChE6_IHb)w1V2sp{S z1H?)-GU|Zz_7YEHAw@`KDTPP?aB8!(=7X<(lffQJVj8h1RfDWtOD%Au{D>J4%+ccu z068c;um?%dVR7zkKa4{$5pg&5cAAu&Ng)R@2l za>a+z&P+qUSz&KqBQ3VvmYu8@wLbR^jVjod_y%DtP1+4%Y~m= zJeXUyocp!t{PmVmzi}U0x&lPtjj>FSvlcWaaMRFD8@08tuczfe2xQ`RI_|~BVpi}z z+>i6ITp{Jc*#VQ+*)E}rR`5TtMnet)me9pZfon$apAzUMKd$G$8Qn7U`{GT@UHL{= zmq-`3j>izMfe$qvijy%$cHPRlgy&fODJP4*m;r8_k^z;z=)l#Y(J z(P48bxbaWwz|uwmQ@8@xP#h^ zl5Z&pSo2!(DKdaryI#?E)zTJ2P+z`ZIsKknG%i}||kUdhe9 zM)}U7O6M*`NuO6yxdMKE9^ zu_}X}g5yT^n7h!U0P!+G+Ya1}QHi*F@jP9OhSE+1{i#VIXr;giW0Zl?JB3F^ac$q`_P4w!Zf)B*1m zmpQ_(RVvWF_5n^m0VI+*5txTjEjE% zez*O3cx!Re#cQjrnFl`E8Q!QYI&>v@W#`QfR7Ti_FT|kcTetV5-gdA$bzD!yle%S9 z1SCZH#h&OYVvD+)fFt{PVf&{v*SnkR_AUK0_Az?H_xq~eJO6_gB`TyJI8n z=`ek}ow8@Yll8gdVW&_95xoVM9C}k)hk%u>VN1(IynN4m_DV;b;O&mC^IMLE#rBQn zJ9WNt9+-dUK%Xt?{WxpKL!GVs5ngGK-9g)#jc3xzV$aU|eN8qsx6;RDUsyaN*7M^Q zSH13uqgtc%Jf}^(lMa+mY-Q~|m!#V_6PeKdRazC*3pHUi$9A)G-(@Tr6nxl$L^oi= zJGTX-RcHUaXeM1dnZ?7cmbtEAh zMoBGlRCMvt4jjB>f-=Snx`#>v?ot&1$4^YjL0@nkdyE`?)*h8o{#E{Tlp<^eCovX( zb~NBK(-#Wn>uH-zjpRJ02m9;Tqeg_+h*g~6l3Of=Okv2;GO!~L9aqS{f(1}`q;4NTVPDvrU$28W9%;Q z&!T?MO7A=V42`-5iNGe#EMK49TTC;8*HK!ihK|bOg(;s6bQ-ZO?{SX|=U^a*$Pc-j zQh76*({rx1<0DyDw9CBCKA7x{v*J$X^_Cc+*_2y=b(Xfb`#5X5a@H(~=;Q@^J&PMS zQR7lU^(yJsQd~Uu3OShGQA27P4R|^@D<^!yzLw~!;JDyvunLSYbCyE@9 z)5VMqT=Uvs51EE?hl?_>0z%O)zPg9gX*n%L#Q-U0Y^U!798}b+s&l!;tZBnpW0x_& z#Bfa{YFZ`gVF{$xH?J&CB_{@i>juW`UeZ6X<=hP)Q+mS6w~oxD&Y#&N>GBgbzUIRO z``g-~1;~t}zI%P1B<>I7WNuo1uY5T^4&oadtUDOi%s%5T-}Bilvvv{YR_X5CW}ogt zx4K;1^7+~^o!$R>S$3FyPI$8T&~J`Di@M7G^_A;|rpfc<+c&Ok{n=Q#cj3Oo#n0_i z1H$U>B0lP#TYkAff7rM4124s~G{9vefj^W?wdo4Wz>?KCMzm9|twwTSyx`M(`r0AbN6!$VD$kUoFQHG*4wMbr^+2`{7rn zHvlw7vHFLK%o!~zpLB_5nxuf|-&Hak9C+KFm^Ws?GBHp z?MBp~`}MLlEX64K!l_|ES91KJhxLkL4Tv~Vzq&NMGmia#0<2JU;IV|`ER8V|%{8%I?(*Mv$wX6#4R*7 zYoOtO(4rrQhdyOq?D~!zZVKJEe#fRA7j=%W&rRx@+W9|d2kvKnU;IAO)Rol0f419& z)x5^zA@e%={-qs7TlYP363a%8ULlX0J`>E$+)t>|qfC!npIgsFw^t`-zxznu$tK@} zO<(-}uI_E+wW}j3akE$6Q@d5&mu*fh48Fx3Hr%SDzF6Oo_5hBgXZes_L!y!nFTYtQ z8h)ny`{P!Z89Qe@+}yyAO;n7oqGV}8?|JW@$vAU{urXleqDs8Yz}0kXCE4xGs@5mB zv~KTbO;`WhiEeLj4wb~neWY1*y#hn&btJu0*XMeoZW-8G-TRSyIk1M4D$l8C*ZcaD zv*r8_?L{9rJb~0|+$YHw`Ti<0c3QVskKL@xWEXPs5##zE`#*B?el$hc2tgM93NkulG%fL3fcGYR3@9G=X^kl3ikC9c`hxo2>0*$5n>X;YFdpT$gCJ+ zA}ly^gBA&)4XdG)WP6muI;aShAIOQ+K+CQfeV4bhnyenGaWPk^kXMU!R!M4;9ZBAf zFdfN9L}FYG!R^(U7~sM+ieUM*BzQd>RuQqFH0y3ge_}`|x44HPH}n{rezUZ16C_=xvsoIVy6!r8`s1)riBI?NI-S7+Ks{s zj0}VtT03pUsxj9odB3B$NdKVv!d#X7FsKl1a0$+*30OZY`(YQgP-d%Mj4;)gm3PZCJ825Xzz%@Qjyc zaDoK^7SBpsg6WRVsTK6aKSZ?tPA!pthH`@E1Sa?rxEv#GTn%3e$Z5DDs8NHRKXmpp z#yIC{jSFfTu**6f**-pOfa`5w~Svv5GP^K+oZ`oevOg3| zQ;ZIrBOO!K*(*yhY5+xW8BS?hLl_bkbbpt(!J$ZIN3-^8r0M6ec3rk2s+D8jD@mp ztn(q}y3{$j)yg}9+`=y`5Id3?<5V4Jh1QM`S7BD~vNf9^$;znTRWyJZMY3jIh0GdWmv-EJ?ZQY&p7a6*n-4C!MdIzp3A6WNZucblxI*|76#l0iL{$dA_1&3qs&54c z>jT)8;IN=Z9-%r-0%qupM9(>xG@tTxoEJG4{E}fp2W29V=~jRSwQ?3rYpf6vW)WR; zp`~onf&uU(9woV|>mZjOphYqsFgUI0E8)Zj!P?j1C0SV=xDw&OS4~eJqdhX0G+*@+=ndDi6lij8F@4vio zAo+H;>9awQI1E0QTJA9(C( zLzJOoUhmEBnjLj+wOVVcQE{>m@x=>>lEpmEBBu`IxlN@6nZmw+CNcbTX_J$A*~VUx zFN?0KameCn`}i6D`P6EDZalCLq4Kv8GfX}bzG68gJu$o_8xsN&lEs&=SSS0<3B8vQ z)UW)$Q19xsDR;^i2SbSKR*eTmK??0$My7D+E-NE$OnvyGM}a)PuIUwd-Y zyytg>BYIBZPMQ5-|1MiF|FXQHp?l9q{m+5Rt8CyuyH7uGeqepM-LQ%Nt|%<+ z*x3~@1o3li{mE^)8%1vg-DESb*6(*CPb(se*B4mt!`pwC%=>#$#tU5IQFb?Ysr|Jn z*(bcjXLyZCoLrx{XVJ$ULftEq@>yK_4g4k zH4uo-2g*+$efL-i{&#E|O=d6IQmK)1T|YV`{ ze(#_T$IIa>$7IzHqVXnwn1y|{nXrqWHm`(bknR?DN_C{dzs0kB2WtbAp@ksTU|$CBV`#L*e<3Y8q1Uo6KA+ zk{x_Da%f%-{NACFJPmPA5Q*@gXvVi4sEk{tcqwz0qerWx`tKA#`%L#d?$`q==_`$Y zN~NRo*imRAuU$66Wl(0xuxT&VIZx1g@sVy+@#R`!XjLGUiaZ3HLz9u zLPt-r_}TK#x&J{A%3qqVq)3xRl`wZ?z~8AA86uN|d;u3{uxaCpu;+xQ2{mtwkFiba z_Uv1@YV=$4?VkD(nueECMzhW9*w%)u!v{C-z3*=Wbc+wt&h;LC{(eou`oTBr8-<-l93)^vCcC&E72eje;M%}@NgXtd0;@gj3s595`3 z_4l%n2PKzp(+n4N*#+oh+iM!$e!1)Rv#}G>26@7PFQpeQYyGO;qT7I2sQ6Xk;d|2Y zvFFdu4Us-_#G1QDA1yz5@2ASA=azhB+Q)Rm$y>|z&(4(&@1V><*f^2?*h+xxILw@=h_$^ zr)o}66<5|pd$9xOwp-p?dHnRP-{`U82Zja0NR~}Srsj#pgC}QA4%}OVoy1?8?$$js ze+?c~{IDt^XsrY1{EFcN`UqTn{iivkZO!{HgjJ@p@nzR9MdF)ICv&6e1 z?3VXrZ7{`$Dg0X69f<9tgxJx$;eZT-6HcOI+rg(1Z2c`4+5pDI&tExZ3b4L7u?yuJ zoOt2$P|2hmh$ja#wWfg}0w?+iqV@D)sT}3`!B;Xh!kz_>Y z{?TTq;RE=*q2XNJ5vFF}-2<08$NO@C^23vWey=?|Dto1O(BC`lz`uR~X{L^e&YHKY?7r|Wi_F?tr?2%x)}VDoGv6RD$~0405Ip$oEzSP} zQ+aMGK(gusq|KKP+%^a-`p_MB|7cD3X!5+t7%vDQtMpzn_jQHeIYPd=5Ai*%#%!&2 zUpw`+*4l_+lk;Znxaz#|h{YOJ*KP+&JGsfKq%6=!;&M8+!`Toz?m;W1YMg6AK0baV zEGW|yL_LKT&b;HU` z%&}2g^I(>Dgy0zbGz@hWJt10&t%KDw1;#yhi6Qsl}m9X?30hQH~c*@V9cc zmgV6DJV#0j$TmyrtWU%_fnqE)uVBTGWKd<+b@~%bv-61$=&Toc$c&%&3|}61*!4=i zP^?$CWgk}ECJi}0D;33j7F!S0Zt!&NtJD6>7!CSpHpeO~^^3F4YZ4xs{iSHC7#wz; z9x1FtDQMHdP;J;3^)}LYljSK{)uwcB?$8-haI}TW&ZIi;!YIpt;`JAeGd|tbTmL2t zfA?-|_wL4NpSD9`ZpD&sp|`xu@5orx;eBn0I`}nQ`B!bn9&-m@8TP?KoArBQ_N++Z zMNqhQVRFxr@?h=jL^mF8e|?wsBcG$~_{u5nbuq?Sd!*q;<44EzV4qbVE?qbOtUr`x zVVbgu60982e{n3oX`5}}0c`b(ZJ4%ILt4@t7jx&avx1_Jw4hze#}l?_3|&^eLS3Q8 zu4x$is5Zr_K3oLg%y$aBs+BrgqCU%6@ms@88hDQ=?6d#fxvAf>X=j2RL!8U(-gH0^qmODRfe! zc6$*Ps^I3oQq2pW1O)}-9d)_#^91KtFNYDp=xEge(7^jFt9zpdS}6Befw->X~i> zEG<+uObgq04$!d;CHMP3UF{%M8oeI1nJBsX4&~%ikklH_Jn%q~q~2cs%AUA34fgYG z^T&c7)Tg7NWoI^6a2qb?c3NwAP23PRJbZQR@d}z5KBgO1Bf8gc;m?ZM6=$ z{<|7+cf)@pl*MK2z?7a1A$`v1sQu$4i|3ZlPn&Z*4weU~Ly+ph4ey@bTiat6e)W)Q zf=sWLef4rr)>V5ok=1ndfc)Y|@v~Rg^1b#=B$}wBJ-2l*JE)X2{R+qOxEBL1q3@4{gzni*)i7D3A*<1QOMZ?# zY5nHF8w#nY(o4p)6|P3N zeD}DV_l!IIr&IsV`RFq{G+HKvmbRGnOc=hh$3n7cS(1rGBhPxzMMWQ?`RG=iMz$m= zj+JWEmG~`SPl^9@km=^tQP0@4J^tCO2j3E(8br3}i-Q(wPaajbs0%F+AZNX{^|~Wr zT9RMsckELqonG-j?%1nH{KrkxXrha;w(n3*asuo+_N5>;$smmXBPXHeU?A6r)4ePT z#G(9rtz@O{R%zvk16-4|N}8V#o+(21vcMP97rK`Y0#(xlzpn6p$09l^trAMT5YGDcdr4T{bZ!h_$R+DOI}0!AS;6X(M@T{z`BiG~g^8MELbt1>lE z2~bka7D_xnW%ytsOoMl=$io10AJ|>IvijcKv0|UZbxI_ltdM$ z<}IbgU1}=x*yOQHGO+)ao4lUL{Lxo5P^@%0-czY^=NSX2jL|1OcayzV3T1!4|FTJN z_iZsgj7FMtu(we%Gb<2R6KcoobjNi|=ijVG;AG9g1p#%x2fIExt@;o_6o=+?8MOZ? zU7+mFVkFnzm&mtqvYILnwA;P?nDJw(D>_ZMAQpw)Ele27^VQO_?>T8V>=B1w@1YLK z4X$ABIPy6!tIfAaTENrz-m>9 z*rXX9Rp@J7YU|N`yun~Jco=Shthn?C7~skg+1YJQDUTS`g&E%w0=`_G;D;7w*}N_5 zF1oIC8m=a@4B9R7<;z*;awe%T14(G&O$k}edDa(2l3-yQ{Dv2R2FFKPdb$=y^QwL@ zo>HaL&4v$TuFT99PkGQ@VT~y!UN!nnGlQ3;+1>7Do#luq_P1%zP_(bz3eFn<9;#p} z;lU6J_Ys{cUc&*BR0!YsH=DJTB9x$PVDm5JBBMqGHmMwr9Ytfjr-4+YVN))0CT`y% zvPbvPFmvd`3f?#*h z@^|FqRKUw_+g!cu&Mov0hpxTKdVfye%pCf5!twkDl)4F@)s{( z$!waaW$wz^x)5@hX#RL^*SqTjg$Cn)^lUfp-@M_|cxfU%Xy`@cq0G)|jNj6BwKu!C zOm(B&eSUMnN_2jRy;tBjRbfHQq0jNQ|2P$n_*rI@e{p;n*oBSe>+%v1DD;2e0RX#< zNFHfaLkK@j#m)E*ljH!2VH*B&8%kV>@zgI5z?Cbvv~92(md^4*iKb*NqyWhT(?S)Q zX&tUKfk9c-PIG65Y0pQ%U*(1#NCjrUt%ZciX_hPTi3#_?(S-{3=$ry%-&GwvVuioZ z5M{9<@2i7?`~;cZYS4y??IidjTf!j=>rHRJM=r$wqn!3bHp&|PJr(t&2)v7{T<#Z* z?+ZD}SPm*pc{+7YSg4*tk-}^$fbD?fO(G&^=BF||FsK$w?cz-xZ&Oo(IPb@@-tIr; zN7+WSWb8;Hb*&G1GMRt@f8teaL_`faoz=|rx%Z{JYU^-|`rFR8gZCFZL49tihkp%m zDOc^qU2>>8(VDNl?oQu&%iA|O>gthAKd$&sh(n3xi&yR+3^*izKoXquczb~IC)&+y zBQ5OM?XyM)ej3DHV`Q!CPnP|%t>-1NB@cIdUA!kh9MfgftjfD7Utbgc@j}m#1bfb? zs;jj9+IRYs6I7n}ndtn;Q|&D$Sod88iq8A{g>k#tKwo|}?!W3WM*6M$Lp^sHy>^-25q=`C`UBex8 zct-91Rf}a0hFZS1CG$32yeYkWMi5-g?pQrgE?{)<%xrT~>?61<@zLo1 zlgL287d2SoKR1qEuJepBf8DvChp+J8I1wFH;23%D2=ZN;Jr-r>kQ+L#nOn~U!#&OH zJiHJ)$2xMn{wY{O3fnfu5!Y{gC9*qEGSm#A4P3}!`BFBgBo;rB$-={pgL0fxDrY+h z=#&KXPL)a!nU%4eA~SO=MlR%TL#sazj6gujHS&|$(jTm*+=N>N45_RT z7*ScnPraM&+5)#W=^sJVl*5}k1XTltHB&?hmKjF(?m{4$bAF@9`eEs}MIo%6s-?_M zpe6#BN^f%p8uJcWWhrY`o&#axpz3K-DM*BDtt`5`w>@uZ0gw#K>Y$A>cdHD4a`+n% z&DCG(<50nch8M8I=ysVR81nN(q5lUa$}eb{Wc7BKxDJXN{PgvEcu7|%=T^>s-qSKzInje~B~o5muBjOk zlv(Qdt!~xR{NJ|0h5L*WbQmXVwD@DC8Zts`)TYA|Z%rfOJh_ZH&N_SR2&h$D=l}JP zd?xs{Dt;JnH8#H)gvoieE7_$B@vyI)`PaR)jQ>GoMyZ#T08o`?C5$fSFK``ccKR4Q z)vjWmuh(Uz<4Vy3-?Rs{`&)7^Be25@mUH|diE-cV?7liPh&tLI)%c6qfX=fZ=_H<3N6p5DTNVVrN8fkwHtP zl5s+;Wnm`iRk^`JMc&h>E*r^#E-SnQf&EesvCxbRn<_dHCb^CTHkwkjFJz9Z+??9x z$YTT%-7Jnh3b$pCu5e3qDcPHMtYO>U=DudE)sF2dcQ~*~DoP1eRqfn&vHiVbuz0%Z z%%%$6n}XK;ws(GPk5@BOU;V*kfjsf_%0p>g!_D)PaYku+VRO=JXShnjFYZopmIv(5 zM{4OW)Oe+pshzqhQM&YDvtH(~4nP5Umbv*>+263XK#qX&4PKAYuS8b_Kdk>g{&mP! zr`h}xDSw)mFqu{x7?y?Kr*PZD6dtX)u^i~>v|5&aZvRKqB&~`(vBR=74%4&rvci3u z9rzvSJ;(dpRsstjUecgcyzCwJQD{7k>@bkGtS5r90BS%VGbUkLTMViUfNf+Tn%PD0I1@y??m~m1cTwgVsiJq-G!)H!h6^8QNZ7 z>z=@}I8|JO0d{1*sZB}yH`=An=w4vwG!YT!;J4J54xB+$+B;k&fMU)7NCVs&o6?OI z;1}nsAR-(KC1Fcu2TOc`nhHrD;c(&EifMPVl~veJ0L_He^fAs-@m=|!6>FQi#%P{S zT(0uBHjB^VXP(GDc>m!8yUIg?@`!7yu0=gr?Ou0!7GwzT(fr0x|6gSS(SE4STm&Rk z?(2~)@whg9WPJcUxtEm$P&{b0i4u1+Bi81=o9+-6+-_}s0)14YO!^~AD}}-~$P5X< z5WPf|_4*aXDm(5MyDr0gQoo{i_S$os+n1iTD}AN=Xj|`jxcYA9lAgXEaSKJg-PRy; z&d)DR*sThrlWTm&lPcwd>|P(Ziw_v&35)~aHK}4ywCu}yBr;o#jkydKNlO8kmKECW za3gBTpUM)BolYo3A=oT_6I44(=U!_-;q_6up#-RWTmw2X8|Z3*pJ1~hOwZx8)d9d) z#)pAAE=+ASx+k#;2f&&p^T16Di3u*YfdKkGZUW-V=~8{+tilU{v*I)@x)j^iAv`m-fo`D#GnSG0-{7FZ^L zl0Rr)_AM7%b~KUh+xf@VH*EivH1eo}?o{X+cMRJOK0KhG=nA*k+F+J{XL^|C%{9Wt z$E!MwRIdPt0Y5*7ZuHwG@k+40GzsR4~yGOC}Xv<|~xcrn=U9czx6v;9~v?ZOtsj*BMj=TO-ib_~=-% zuATMBr2;}+Bmpfvkhcn?X;a4|FYrjHTC!0oLz>+|sKK?XRjJ5JxhrtmzbLsrf$nh4 z8^{=|!a)v5@i|d)$pJPH{E=v*{tPHO*~bDwLh}}DY&{gyvphp#?`~{Te^d@4LDxZ2 z-W{}6t(bNdiVU)SePuzI4`dI+>ryDR1UkXTeWqs z&(D{2%x(_=pT3^(4RSk`F*UfJ|6cw>Dr|rySI9o#-=Oj=ckg&~OG`0Nyne z$e_z+0ZcNb?B)1{N|>wS6;H(+`xMz+gYRhDc-qxP+yF1ZLmOCn4+eOo+**a0VQm`(^?jl* zwy<$jdRlHq=Rs0w{CIuS_$a>BRG7nM`)IZ)V-J*F zkm!kRtdjBU9Hq+#!+MT4fzNOli~QHvEV&!E_i+IqkA*TE1K;I)0zQdC3|K81FgeRV zkOx|9DHCNggFM2dnBF%hHUeXW zxhsDOaM6koN_oJfnh!X^+tOssW~;NkJSjGBfnJqUEW?iC@Rj2!0t@2+*vo2*trgj2 zew9V91C$c9Oa}_#H<8VMxb4W|VGnJ*XxhskFK2B-%1nfm0QD)B3pm{Q0Ow08e$vKz zu&_=^DN!{&u)j=X{Z%yG2G`VTbT-5xI5sHsaRIM>)}CN0eDpCwv90z?$`SEcj9 zm6EtUPmra*Yc%)4oe%IGfVb_NAFZ{D#;Jemg#GeHzuG^%QDjV8>QNqsvl6O8XuW#c09@Gvs3%8HAwP{3>qxGL z_vh4MxAbkD|EzAsTs=v3>cI@MO_(x(rDn(nig%cq$m%xw&kFF!lWsjchoMdAfDpmD zEYAifXoLXV=O*0l#8@TwW2SX3W>tU^3M$uIv+`CN&z7|pD)Ef0r~JSQ!zwXW9H+_v z4N*fkqhB?@qV%VH<$Rj&27kW_ChC3xfPj{TI{gH+Fp!u3OmBle{0B)j61wsDr2v@N z4WwDn&8j;73?D#a9FGD-4eCYk*twj8)*~$OIG8VA*pagnQBS0=C~H+GJlx?U{A^NqFexhkf-X{q37cN{PO~=_T^$WAZvu z>Qn=9ig*3UeF+7@@X~6w>fE&KWLAi7b=cg1@Il|7=LtO*c8JYtrUTcUilBE)g4tBF zuQx;OZ1MY}`cHz~P>o##@z<-0Ynx3}X{4}ab!NIZB=Vho4;2m+?*vJHkKy(H{E)(r zR@gE>Uze>9f{5=k1*KOR$;g(V@6r^}pZc6faS;Z<-@T3YLz;q{1fhhvU|4}aIe^v) zP~QvK`=?XO-7=BI2!Mn`@->vr+lQ03&L;ss7tbe(gVuD^iKG6eGU%Ql@oA@B68jOX znJ!BJu-h{7EECAH(>3C$Z{#dheZ2ASSgnC9f8y49zBX4aB|e=MFJr^~Ohs65NI`!? zMi$+Ptu%uhOXYn(L9926p)S#wV7=JwGi)_g{_CEfFA(tES>%@?_|VWgvRFE7@N z%}O%U1S8ItQ1A|f1fsvCcy1sMvH{$iILL?63toL-?+V_KR6rYdH#gG+UW=Nsn@PT* zM!WVH2G}{S^c&d3y>Tc1<&BRxlgbApX(JOsmTZ!BlOO`SiLk3dom;JTrbl~$|AN$s zul@?P2xt}vk$0pq$+`|}0?@)4Kr-aOQ+2#>sm%#QFHkgZp3j^&&kg2>qSk+!b#HN6 z>ETExZhag3t@5NJ_o#x@-wVPCAAM%KHsS>)B_D}I{31c&8Fsw>#ByWl7p+w=#M_CY z>+fBytHb_ajZ0%;=qih5Ctz6vj~fxh3BdWSPJdqBY|~l}|5+cADXBA%U!#Ke+In-s zO)^6}wnIXORO!>6uH7C~o$`-VKo^C|0?Wu@N0$P>_qIC%afjn(0^qm?0f>Uy7;^=e zGTM{C&>&)^GEgJJ3;G&`kiCs%OdZJP9R)g=Up4mheBe-Sc6z9)WoI<~Lt1jb5o8GC zApbZAF?`Auv?R5G9+tVgG(CWk=)k(r9gCujL#hWzI3+%; z6VXiIvYB|{_UBps?Rz}0R7xpdZqo_}XnBJLB+M!S{lq|`r{mVr zW@DA9W5G`r;t+MPTgSPYiK)Od)?gz3f{iNV1?Z3??6Px1PjZBYHyGnV8o2|fm5)Bk z9Vnt2fO5~2G~F-{8AG6cB%&MwwE+|vZyca<1M|tHWTR5y+*qM?gE@m6aF#YPA(`P;KRe;mD(xg8b zh%B9=0G%ivSSiv3m!}p)s+niHY=OyIw5C{>pBeBl?NEQ0M9=68Cf~d(s%9pbRrkTpfo-|AuZt8{%&-#DDrBrf-keKkQ=n zcI4WIF_hNHZ@n|@nfS!)I^USso06MFI-K9<9Q+#7Q&#-@L2dp@qIc8Tn=f(-s9v!N z9o(8J|4mBxpVQwXg>OF|+zgLC1aI5-Z0PM7)KWpa|2h-<&K4%`4YzzL1~7gl-8$bX3{vp=|2iEq7kU{c?C&KNdwv}l!_VBn9>)! z6tjuw1W;-=Q?GcgZ5xKiCrX%sGv00314Rvxamoy^eLF`M0%+Z&%`g!lTsbE++=v?5 z>5)Y||8jw|t``LV(fgg!n;Yu3Qe-0%&UmT(?a)#2pKNBbfq%EbM$GW}Y1{|3p|q68 zX{5g!i6Ly0(nZp6?u!8X01t;Bl+uI~j{oUq=X<1%j`k5<;>HW5XVV@&KU%oa9sBkv zKWOLdeC;-;x9fJXKCISs7!H|?@C*$1)s$!|ETe0z3-@d;8^h8+Jo~fz`mD+6v#>$R zz~R#BBHKpWj|@jXt4CAEjYo6@>2kmWK?cD7{~}!v^kKaucWC`uutl!t4kY)*3K37%(WUToBt>$UlO9VSa9=E?DI#+a6m z`q%bvG&x{Rb=HZy(kK@ZcEEuFQw<2FPA;Vgnm4?($o2qdMVQTa&<$`(fY9l5qHzR8 zhN3ddP8p0{;LI~!JFC()T){b8vdKaxE;JtTKj<3YHgDOGYEilHBTm%XBH0SwCIcK< zWd;zpi~<;)D~WHMB$%r#042K={b3hd*A_WeC#Y?szHxw347|>Y5q(tj3w+(=tp@ap zrM^Tjd8S{v>b%ULN)z_$lyx7zoc;>L@+>&>?H!}@i&a4+Ilzd(^Ib>fcVee!NUf&b zOk}<%(hvc@lmG<)^|MC>tzhYE;Wc&M6T5xU)^MI%rzITxv{fBQrMMP=dD=TR4x)Xp z>P!PA)xys-X{pfW8;A(;wsM69!0sTC`@ruuDZKl#U5%sZ--Br2w6k2T%?j-bsIJY8 zy7#<6DiVCi9<|F&CR&!#L^v`TXUyZ2zB_!Cn7Z zH;|6R?sv2BsYbY4)UAVI|1m;!Tsb%ueA#Gi)OXs*wT=F+BsMpgIm`PmStJ>c^YBU! zXi2I3+#;8jc&V0!p3AXd6=h+veX%fI(+gCG{sX1%<_6IJphDuwPLXmMP%>M`$6Zyv zxCA8B&Od`vC>(}i1X?Zyg7_?ZM`^@DCjg+TnFYs;h@9ts^m)l#&aYDXM>@`FFWrGC zukLJZvr>5hT-6T4f9jWGTmi8LlRDai0M`aacrw8MW^pMiNxTRgkJ?Rt-P<|iMK66^ z!VFC@sLU1Fv}vkHuz+o#L$)O*p-ve3NI9Ngzm-FP{sGVSP_aQme?!rsZVHw%=3c+U z=9lm3lu{kN@b}(IPRX^z1I{Nq5*x3Cta|)8Nq=lt^w)e^r!LjR`NNO;=<;oo^NG2OF{BN~pKVKH}54BnhTvEopcy6ZE z=5yB;zW-KS$&;KG)V-I-pG=X2JW465}+6V=Akx)hMl$RqV zexY1t>Ce%UNdqjyFcJs{{d7>jW1VMNj>a$_Ww>(oNM=W?foSVPZnhJRxa>E&|K*~- zNKrUx6JgR=nH!JBnTFb@C)Ggm>)5ElvQC3VVargV!Y4`#j&jGbm-~lvN4^6HMW9zI z&Kf(KCT|YVc)$u7Wg7>jL`~Z0N2mh}0*()OEef1jW;?pk@(=e>o0p1chPAZh%ZdnMV)k((H6qbKi+fI_M=(J2pm*i5gF(ybsG5O%D+oK5+0rt@Q{RHvGqd!m8k9*$wO4E!I4IqZ{_wv}Bc1 zo8I2(8}iepC7Zp!2goeuL=o!)%NSiv{RMBmJKhJUbnQ1?F$BFRtU;+8_ra?yRsMMj z*>dl(ZE*N&w%?xCVL7!kA7q)O3)yR@pMIiSBd3#seR&B@8 zOjoEZR1w+KRzQsM!*$!lKf!E$@x&>v{y*38q`E~7BtL54_B8>_@z^_QLDbE%o~Q-` zoCxO(r3s&CW;KaL7^S(sI&xDtO?o|aaJSFqhfx;bF=2={*Ia<-*-Uu5zCIPN7X;-` z`=-6%Z%A9HuF8ELuRc+s>DtW*7WMyo%Pq5UR44A51LemlrX(&mJ6P%Jr9{{i#iAf1 zZllP5MM|r%GPaA1PmoU|5vo_u|JX5bneE4ikue^QO0hGn{IjKW!1uX`U+6NB z{h~I4pS5~$L83qM^LQ{y+Y>iMInvn%A?nPLGfzauFV+6zpi6%R{}C7)vahAK*%|n$ z7E&d^VqGn?4{$Xp3w3C%jG53HrhJwVCYNtPh|J-J@RI3^?a44T)#_&6vf$E ze^ohq_80X@zm(-GCpi_=7z9Hb^KEVJrWrIgHEB&nRg@V0LbSeGHE8;!-1&- zn6E+tBhZ6Dy{zRDN)0&Sm{*N0mJ@2q_mkHDnTyFKS57`_YSF8fnT>BZc*T$Ta^%YEhwmR5eo0p6RHb&F;9e%@CL)y75R*U2Tc#D^!H2T+K}L(0Z*KP~M41#*Ew< zn0>0EKZ7{;QtP$mF7wo;O(uy>Atlo5=L_D*ppZZVoWd7+^o&WxnYxnkU~P4xWXtO$ z(M*@Jd}^@xl;nBtK;bp}v~m-hZN%Msp zD}f9+M9F1@SDa@O?HFTRKy&~dQ_oO0-P2THA^kj`j8uy`0sgiz{FQOvO-b_>Ws}Nc zL{Czcc1{B<6+u7)0_AdkAz2lHjTzuzMlw(PS4lHT!2VZ`VDzPRnd2=r{7y4bxtFjs zeve%m_M|kz#w^O^6z*snb`J2IP=vsgcspfoO;OA8CoPCo9LzN~U~ea%QwM{zZX zW|~ZV^my)Xj+dPN3+VcUljXRt`A^odFbbW10`V zbiQv=U6oIp@)auWXSUO4NQK_7W`#=>h|p0^lV0FvpqbIVp6_{~P#|%N-P<7$L7*Tk zEu8Z9f@7QhR+>5e2_R`SLlnpPu={cv%b^UKzdl@f;v(?3L#3}P;kh@l$%03IT4qyT zQMbj|i_Vdp6Sg)m`f!SXJ^O>AImUSnI-Ps#%qN&>N?G8O#6OVb;oy#_q(a5t1h@`s zg?Bpvy%~5%nKX93_n*lwD?&|TtiH}y@R15on{P8HS21bH0H9`XHpR60J0Lrks!*wm z2a|MR+%Shz!IHpT2VddpcDp}bSM%e{FL(4ImCpLkI?Jygh*zE9gIAhwsN^Cn^bU1e ztmu9*{w>M}H(vViJnu;Li(O-HUS-*8mYx?SUwMU4x}EDnes$R*_BWLT$>u=ra+{Ku zv9O#S^3*<_NSe5DZ~K4o!ZWw~8Nr>%!{fT0wSCiO5udGdML}CW4Igf8^IR66x5^r6 z`Dyhg^WLfp{ljersXM;k?>qkD$}i(3-pzxSJw%GZ#VC3KY_#uN3|`K=^ssz~MP_OL zr;;iJKdFj~sPgICMQ<4^H1Ifl@|@V9+R%RZ)Gzm47tFuq#v$41$+bQOxnx_?juohf z&9=^L)4ieP#;P>dZH=2PQLMUEUPD6z*NMzEOB153^){ms5v;=NLB7Tr=$3D7B)2=W z^OZMbBSM*hfpCpbEls{AkJd%Fg=xb)3*Zlnr zwRvoV3EjK&=}VYZ234E>N{RCz1$n|2ibw1vpF2&O2W({YRYEQCY*n+9!o$wRFz!ow zk9~lrPhX}=+{QW^3xd})D{`$IjH6+l0yAlhw0I=|Ky{}}KUXepDsFr4?^j>iC`X>0 zD{$=XySxPWc%6Wj2m)?{*}QFUt7is^nPYq$GW(qf7eRa7gCVw5E*OZOjRK5ij;Vip zo(32m^fM6i9gIS1?wbmZ zw>M6{a*j_cZSasyg!{V%=M_JQBE)ga(nU^b2Cy6McH;&9p|}18b7Osxb24({2trz| zIv(|5Z+F#cMV{tY6?Zm`#Ay`1Y~iJ!F1qvbldX0NKubq~d-t*P9mu)}LooI7$Vja^ z+}R?WS}5NZ&6r@>fi1*HrYDx4?-Mzm-y_wPgj0vl%Nnq{uNS6+m2|;~BceCk%atU- zEeIMmGL+3m7s?a0%%|GG*d$jd6eBN!R-fRG4&BpOBkb6NiOjPtCi6XZkVy6j5XYH~ z<=cK!odBuHC(}oz%Us;wqm8HoZT1$w5$@*_-z@-%EG=HviAP4oV?14%vHI|y9{5d8 zb{!DRmri6-TD3bQ1RKjB1}h;fLcaB-#q#;Fq92q$$eethP-)5dsK9w{BriQ6{V&0E z=ob|Ml-BLcMlvFLNaE0Nnimj%&6l?4h8?JZQaS~HeUnS9 zWT;IO=rrlmZYI9g&c;1!LNo+*#8#4oL8tp#G}tZAAJ(1mcwdUPOCBw4wo!Ti^ujVSIg|*|rU!Ft1hax40YK%5l;d^_i?TUA}qje z+E3hUHc>JSdT+cGzj?rKRUZOXAJGOh0@<=x;kT^6uxktFBqfhQ(bop_74Je)t}C&l zT&1-gO#_MZa5Sj18I9yJD2O<}DnLp}KrqxybL%z+y;A&j8xfbW`H>ul;U32V>S_zT z5SFj-+*)63!NUXD&a!(&>*t?din2nnBYu8@{ENjy`2xnqr z&F0jXj!O9p#uWYN%>0pSySkw#E^wZxb28Qdi81OJ`?mvYu&u@^M-=5rTeDIUPpG-> zaI-b8G;p{fCDCAWP3_toV>%h^x0G-)-oq?dAk{^y?E01bz1uU77~O-f`jSbHUG9=$ZKoN#if|0nau8RL1S8Ox@9F@D zL2Bz`4nLrEwcb~`YVvZF?rZ(~7UDkq<3~(GoEp1D)V9mr#|K{`@;@+l{>{`aMrRQxKm)K z5}#^RB{X*Eo#6C~**J@;y0Al5QMVTG29@$st(`m+v$UmOIX!6kNEH%T3Id=m6nH(Z zY(^M8jA}z$fU{=F8yT`?sAueM(XrJ&tO5=y$8GRZQq_N=)NhDoE&C_q^f%u!m*t1# z_^rb`X&KO;*6xnQO>f`YP?M5tHa;q6J+rQ(q^w*8F6LD>!z~dDm1|M^6J+tG`p2JnF5a0JkYY*-X%-A}5b@Ba$9r$?L-LXOrwa#le*!U$r5>r~X{;0OV zG+nQVQEpro&V6q+AJOY({53tm-*29owUwKbncuea)JMi2WCmK`^gS-%cvNZqNozC1 zgehrW?*bBny}D!b3E?)#cZ_6nTq|0v=gLdPKpckgtig98u}U$f(!#=i*_4NhxiXKq z@ouPJedGKX)2U2a49OZc9{MSr^#w}m-?1|a(mP~*OISM3hhB8A)YzPG^K~|jOAx&7BW|%wUXtEGtEUS7_n? zec}x#Szoh_9z^SD8K-m^_qLX+bZxXWj8Dj@dE)#Mx+t1=rkJEh{FG|fLvxuxqsa52 z@30MLIO@E?04 zRI2V2#|7X%I*`8Sdl2>EtcZ=_I)T1mQv{D1;r{;2FjO|5YNyh=Pyl$G4M04u9rFSc z?uU?lpKSft{@0Bwk9GzDqlM9+XE#1#z6WRMfLr~nH)tiNwQYGuW2ZZcjJ zUMqH3XB=RJKniM1xKW(6+U4)ra*_25Bg|KZ!5Q*q6d$++8jvM_oqncAoBZGx22Xj&tz#{4(`1WQG4? z-YwOZZD3@^!7XZ4nWEc0-MrQFE%tLfz204b7Haf}#@gqNyO)^Fs_1kcPNq~?wP}lf z`8QOptMuX!HpZ$3`b9}m5b+CwtyQx^xEcWud@}Tr(ljhboAH~PZ4r^^hZ7>dBxHE{ zQT;E-WaMIlfzS+o4#)S+8xl^LmE{!CRXtZql+B%n%hx`bD5 z#L1|&SJk$4dktHtybGf87Zty4h6xHa3z0su1aEjE1{#LEuoZGzVUXK?Ftpikl zma{*Ca(w!TPBriL{^bfC$mSma6+Zq#rP;hd5Q8lFftx78%dzb?%HISESNvFJUsc>c z5WyciGesOt`kUM}2V3EpuC>auKoKv89}#e!itLKdtm;`Ox@0ryw7q=L>3M zXVsQ(H98j3l9rl8RU>xc;O&d#o67TbyIwg*@wclZW0dKkR#w|mt6zVOd!os45820m zxx%0eGM3$K2JDf=E;B1ukWoS+!S>bQAOGg;((`=!Ybo=o3@4N&_&t5KT5H|3HK#$% zhtD3kH%V_g6L?IVzeVdISKhb(4s0#^a(w%#!%VTh#mBgv|ASK2@aL}_iBknfoL#@J z!l;q0*K`#mMc3HA>SK{4a4&i_G1O zIZh#aUiR&=>(CD`u5dbYzIB|5_O}?!WJi4U-AK^UOVKq^#f)&##?dh~*g0{W-;YWw zGi&7oMN^%Cx8sokT9KKZE#>2LnO=BH8Io;}IF?dru8tcka!$dPn?7lP0x&v=%x*N5 zM(U813t^JVSbas8je>=94p3T(KC19-{rMJHPO;I23Izxq{<#;Q2F9;GQQ#VgsG1_v z_;aNBDiG}>;=~G4E;$U=cfAf#c7#DhVf+AZmN8M}vPERhkziwZuAQPq87pFq{Cb_f z6UPJ1&~}s>m$frBt0CR*y=`V;COJxcuW-^>o~HE#aDs)=r@dR3C@~Xlb~=Z8+kr~0 zJys$z(@eySWWVZX`Q)YH7u(jFX_K=Owa}w9-nJ9kHsjyGq@!ZiOGS&=omva?nkS$U zH9$KaUOZo}Yyr^=hbg9h{Z%e*q`^F`uC*@BTdo0Dg_Qn|m8`M_dD3i(XfRIc%>>IX zqgT!FK4g6qt9)gF1CN~SG%s9}nG;ITf>)9Eejuu|Ff-nq*fz-84;|Ygn#fb<^q(&I zP6;r_09>SvtnzP&jtM9R#?l2#sea6YKxEeCq#!=+T5pvQi)^6@9#Vni1_^dPKLa_A zJ#XniaU7Z5XWfh}?i4D?*#T+#C@O~diOQ_ksX}rq&O+J`q@#2WHwpWQ90Jo)o@0gA z=Qz(}Kf(P`)r+DQi;+uSh?SXBEFN?^^+h&je3ilU_BnA~=IX1CrEg>WT6=x%x3#|GrQA#Xx6ZdUMFXhL0XwnD`TKUNR;Yu9 z$Mvg6S<5f(9qthV0F10=zA}HL_*7?WrF@{IEH0kl*avf65J?!Z9bgn#idIWb9qqqy zDlK?(8X->G_U*-x5Ja_t*p)9L9e5apG;azsq4^DZb&lm*rJMiTH!Sc!7ILi5=)y8K#L!-dn6ZPcE&09{V~ z6QhmcC08m+M_TgN-gLfh-WGcd_a^3_HdQ;P{$yxh6 zV;B^l9jn;r%hCH5kXnY?FrS#&%1U_V)b#eykZ22MM(`I5j&SdQh}{DoRU2IO4uX1( zLpNa^h6BY+k)LNzd8vP*2G4OasG3I%zz)6A!JmL{+ro==E&H3ql7f7517^kkGmC)1 zyUB$9?u%#`r&O%AqZ9~?B-kZEDYBq5)OuW9-7;oxQ+5T#$PMlU4e z7OM2jj#lQ2f%7mdQ)0p$b)5hHgqYXQo*UYqk=UC03$?i(^rtzP~DmhamJ8mHWx z(*B+mJrBzE4P*!M7boL9aI$1m4y^uy6*l6V6AejPj_Y=xyYOup_R!_? zIeSIhPrqDd#|tPPhYb{@>`=OF+?R&};>?17p=e{)IU{W~F|y^|t$V!TnbX_Oft28} zzUTCf7qO>?Mr!|Mn8v$%_y0b)RdA#8yZ*w$)m=tM>psy!Qz$AP*4N1$Zwt~oul!fs zG%t9OU}uD6267&WcAhS51oKV72f>fN`@w9#M!@cN)bJ~3@;GWoROmrBY97tlwXS2QA73iSQu`~i_V_&pyFNL6IBzyCOSHs zA9TY$QN1#^n+HiuLmf-&v$#j)B0JRl7&|&;EDtcHdz1iekogm+;(%}x(g){0`5=Ic z7FiG!noa>kak)UG-&szq`o#+a@f#Z%)7Ne_4rCBS;zPYWH|=bswz?+W^H^^uAY)Xt zC~Hs+#-)XTz9j5EaUR;}lnUmG`R`ah%hSe+u8SaZvuLRa1VDSvf7h9x+}A--rLm*B zuD=1eXdco9Ytw8#ryrE(@s&)%oHt1_zz%>7VY&4bm_wJj{51ejc+TY@$ffFln`UA|w@%@I{m@X7r zb1T>6L9c6PIUGrQEuEc57AptXiG*WC2rSgBVlZ)OkiDqNM3ugsoJ}Wq8%@108bErVb zKl)8{)c%@BBGq1PEK7s0o9#R8_8O5g1tzsY=|F@Dp9(Ms@qf*8E9Hb#;V8XlDe$f} z7S?bCmygW;n#n$J_4MG|^c~KekHf)_;tJ!DvOCn>lxqjQooUy0{!zMlZSCBiOUa~7 zMi-(A+KXv?oq@V_8nRo2SS=2MaUhrn6C6Ff*o8E;7Te`-ir7!ap1eI@XD~x%2#d^*Gvo;X?~8b7-Nq(`?uw z@M{a0jX31dTH7cgJ%vEpE(m7?U;RId&OM&#_W$FXVUkldH8rOQ)5&4g=6ooJVHi5d z-R)FNC#)RirXd}6ub~mGnP~@SohXVTF}m+LY?36ok+mdYh}7?QegEyz!Fp_;UDx~l zdOe^2FdF{Wms)_S4F2t&5!hnQioPh(N2vUGl(XnmbW(q&jdtu{+!iB_Oj7YpBei<- zU(Rs$V(osnLxa+nPr?{)4#zs&7RW=;ag%)ysZ3&@ua%E{B9R?<&vd)A24-O(n{mRWq-2+ zIlnAK4uKpHXWD`-H~ih=k?^tBUZ|B(-%5ffk?aR<&=-XhrM33g&i_R_U{0+`ppP+HVwV-do0cAEY^SE#I6Mwa3oubeTV3=${1M;PK$3&tU9JuZKvUG= zgLw)J!~lInsK%e9g@!{wOaVJVa~7B*G1ME4`$E6|b+9OI_1a;%@pc1aqMTvQA3jo-PrWg`vdXcY~GznuRaiQf|o!1BpP}peW&H5HjWW@ z*UXhcvO%ZJ_;rco!N&GLtGSR*4L)0841dgj^sTX~7u%GIU?9PPXsm*^ z$Wws>1vHIfPzj}>m*Qd}sGCk%^qb9qZ}uEmc2^#CVCJzH@(M`j_X5$%0$mc*BnZ4o z7EvG|KQJF}0ioG=b0f!y8sGRPoO-g$RkU7*-aB@pw%MH@L`JdLN@uZk%s|0U5XGJN zU}MpXI+gjqGOSm6uYT+V+_2V2zZCE0#mxZ1q5oXgWwYSE{cHdGf#?@I3~!i!XP{GN zT~y3*9TvE+vHI7zs&q0QxWjpj=k+mVi{p8K{R|zO^Xv;`#VU6a3-0L&fLQ!7=~`Ht zLKwv%iNGq;Nuhy1;R0sPgY-?l%0~I332*rfVU?p8R#pW#O$z`OBa1K}<4z3ml>i6H zSTF;$Sk!GUAer_8#8)j0Zcov-x~b#15pXiEw?_o-a%b}gd}gff<;{{i%;q5*j9v!8GRIr zi27jm&L6~AE=?c47ag=`3wJieM)QcPDww#Kx7Za#-J>WUcx)?WF=y4!Ba}dGIKwVU z$kB#jTF`>uz$$2^A-ku_@<(^eSV3S1ABj(FxEmR8qHfn_OM+u>FXDRC5$b zlf)Xo0S;Qc4dR7EXt)k?w9f=Vq6OOQtzhxpJQi~8tZ)9Uuv_-9CA->{%S<)cRCCuXQ(7j-=2s3p-D9v1jf>PCdGJBo>lBT3=At#@mY&t9h*s z)HGkh=SKA6&m1g2t+9c1G`B#MMeZ9gzUDxqJi(fL=d1FM1QvEO@>kgtC4 zoC;>$NSPZ#V;vNe!L@P`X7B`d#y1kyYhH>^!Sq~ZLCfRskK5-1RJ{}{=mqwdfbIJy z6MS(UULKy?nJ`p9=b?N~3HqHuy{-&V0(Xpau`{H^%l$-%La#&5OK%tqH1R8;>v)gR z-~{$$!e#vch-ZzLbS8K%3YAn^WpD>+%V&M4d8X@hH#g!}tbu}^&vfZQU$gxo^@N)y z5DYj4rT(Ev$m$duUTcP%@hOeVLs0^Ioa)nK<=xy!(8|FogiJAHLA)Q=`RL?R>;mn`7IKJ|{OkqB^F3 z_M9*%Jdyg2y(Lnl?_D)DnVs3;(-`)`lxk)JRn%NRT3;)@7x&jAJtz#dTwyCxydoKzk59D3S==QRU+a6UO0YkCneGTT4D~R9 zL>b~A={99#ms6tNTggZr&`2$Bl#GV1q!H27HGb!PKK@0h%icNlpcSH4 z@fztLsd+5~2`nzY8_5J5P?q4vshjAs!6Ju6E_=>P3kpoH4gr@!@pwq`KtK44Y=K3t zw~U8H0F>QeF{IO$=9U826JQrH#n|z@_Iu_u8`3&ZB`(>9l!M7ZlDM$+$1R^pf!>l(N^*4@&h3JgMcJ@mhs@= z%_sw4v?y>V^3Xzy%rpHuZGq$ni-?wS$gUuJ3y=U_9;sq`IE;0E1@lTj)`Vs)-iwEv zbCjn7vcDuz8@%EbOhMCxQBZ1csLM;HU~hxL8#nEqBBugybqA+s5Tb1RW-&ACvYri6 zyRbvB%>@cRj|K6s#RVlR5Vv;?E!NRq+T;Gaf(tRWF4HtJOc{7`*7J0+n`&$Lx{@`+!;{o>}jFHqS^?>gXc$PB5w5)@AT!%Sreg_dE7W98u2@ z&hGyT<-ORK?0eJV+$-k69l2%7F$Rj!terJ`2yn#IlW@52+rad4(pmM9p|I>m`YVE8 z!2b3GB(jp|{($O=+Ti^$SJJTeY=P34#&XTSs0o49{d0WNDSCJYW<#eZLhYp9qH_*f z(Xl^MyG#F(w}KBFF3FV?zv|iP*7@&9S6&{XtMzQ(|gnN*gNBJbH6e zSpu)b?%;L)F=*Ho{V&b8@+a(5_Sqcx7s+0g_WoPmmsAs6vWP|=iAR=Do!x_f?Tq|! zE^H!S^3XrDKQ5EHSZnY7#IgeCIK2wHDacL|WIS^<_#$#nQe?)1Bi818;f#V#eXtfQ%9mv7lori_ zUUj1w-%j3m$fF&uJU}N+(^OQmY^9)B7W7DJ(&Cw?h5mVMB0KnsJq&Zl)esL|o+>gZ zXuXz&!`zK9E|$AS*ct53l6U zGC-Y;s*wm>N}v{_(X+Lo30-6GsBj}r@0h_)TZ ze}Bw<&6N9$GKRQny#)9^M0KG(1(EyjY#4Hq>|)S3ADHqQASpZ>fsN)z`Gg z>2;D_9j}``un;xh$p2?9JA}+?`O9;}Fb!9QU91i2yR}=djX%XSX9qQ2)hggI*peg^ zksd>H(Q=V{j2*%NOv6|@iOQeI9L$?!Id@?)5Um!g{WBig5iDhx&<_=!#A8SQ#@wEO z5RqSRv@;5L**~OkM|rydVh>1RT38-jKX$1Drd6!O7{UblD*y6BPTis}A zVfT40@&T-1i{7kPZ0{4G>x1^#dRTNhHS)1Su-I~l;_^R}$eaRLrb|0`xk?2(X+#Cz z7&4MDA|*ggMoUV8zF6(7eVN#(6FtyrvXPJ`O~@8we}dVf+A>!eW_SY;#R64dW$*&C zU8cPt@nf9ZwOvRDlTQKVWvchTXEZo$(KhJQRwvVL)e%n(j%k~|NqhMGu($Zgf%5Yv zX4PT%Xeh%YEtvn!?3*h`5yNtC>#=r`?Yp0YDQE`%d2n4&&+}#^1TG_5$|D}Jq; zYT~qb+kMae%i$g=)4{vHZvFI~mu5X&`6bTh&WpUv8=d733d{0Mb6!7PU{PqRH|(Ns zG5UMg9n(o4tXc@&^P&CTNtoaa@TY7%S3G;>;yzg2H}$bd;kPmJ!_L6(hivZsX`vaM zi@$piDZ|MLfsHZuL5}_ZAhE>>&SaC1t#x{6X=;aXO%eb59kXvsF|}dI0p+_(1t&**eG+;nh*v~47N6C+ zoErX+I_Ef{_iJnfl4{dz2vsZY^5LJ2U5M{L0PKq!RH&v0fWN!n{kt@8T4kGkr0J$d z9(6rxE@XGqFm96dToqdxeq|ma0>-`}S;a8<6O0t0wt30L_M`<-+hpIldl9n)3&^ZDn;rDR z?);y<4MvDL?_owl-<%hY4{K6l4iU*+W^4;6|95bd8C#XGu3W`YPR%^D7ZQVMd0x+X zuDD`&H4cvVT?2LUWZ(;xd(Zd`{tYR`yZ7Su8KZ7$dbDR}4ziTch^=K#30W`j{Sk%B zRYex5qPWIu!e&F+!JFrdG8u35&S`@&N^Pu{0at5^-T&}0GWb^6U#-X1Lrx$5a@1`8 zwPyoWHck9ceDu}(%wMGEi;-ic2O#0Ws354b`uV|PP=Wy3EYyiSu7%g&47-j%vRuV+z&UayNica`n zqM^Yg&oh$5xZr>=vX{iWxexNYzN9iSIL1WR#r#AG$-dMbpYhpIZ03T+K)4`M#hsk< zvISp?fr=UL#Th(^CMDV}$z3jwWqUUAhVvGuePJU(S3HfR7P2Q4NZ8~&r4N^3G40t0 zV)hf*-@#3-ZPQ*_@Ds7UvXKBK+0-=H82!s$z}u|`Apuqu2&5>)gdQ@mv!;#_C&6mz zV|%Sd*Nmuki;fb`xo`)1h5>*kd98`)#`1VI$4Zx3DM)aLfOeii$@U;~?y}Sjngp=N*e|4Q`iHF5j?XO% zy1~^O5@XaKzL7rD?VMwOUX|7UN%YCheUrlkqI{ZQq@r|ZAV4X)pGpB*5u5@TLqVv& ze+Cc7TsBL+OIPrkz#9!BA<~G}qs1D)obwyARdvs71>gJ=?>#0xR;T21ufr6$!LS3Y zu+wXDcpcgsaS`;r*>qXUwn}UI&pp57g zZp&hVSr>8%GZx=^Q)Q<{hBa{12*Ajm#8ow@C;qbQe{Yrv$MP{7$u2W2)xAz77MKF^ zD0K@kvH>?EkABf809G_yBEm;FACL;XUA7;U#lD41470&xm9kiokexlqbd1C6KXYnG zl6(rW62TqbXela`*f%{aDAz{354$!JZ$pq>-42KGBQ{t5JW+^x)U|d?J`|kzj4@I7 zX(K)!u6z6~=JrZ1;ziMahrKh}{(H9on}UxGc8;}li^=!9A`7f!Z};)^zn}a^>sQr| z#J`!D+h=|@E!V^#$)7djEKc7co%*f3_Qm3B=Ya!rTF|P)_w~SdwTez_Udr)=zi|S?cnh-cDpba16rV{sCl&0ojvYw^jsv0$L9@B$0o+h2oip(8CK3LBj4*O$x z<#qck?Dd=5GqrChXfmPFrOBz)WAB??q0Pb;(O>P0cj!r1w%> zdnu_2R4a;f|Kz8%rSfnDG@p6+?sbNmE+XMmqinc-_xR3_25)xX*yNV!=@9(Ej;Lak zG{tBpBL8bE|38S9m8HX0*x4R5q^@54;#wsc@PsQ&7pUl?(SNM=Q6%$rzw0^mHBhF1 zFXa@eb*V#1f8YYpN#oPDTHFVHc&t!1W%T=^865M{F5efjA%E6inbWY@AHE=f4`wox zeqR8dlfDBQ;B*L-YC7YNz;bgb$LRd)k`9<28(?|hwT>@ptr(;-)p5`H^6dP;48+)_ z)lTXT*@HppI5*%3B4NVHoD@y1dVGhp{%{ROK?%Uw z#+;}8F_QZl5SEZrnRE%jO-xIun+sy*`KS!wQL*&cjmaOTf7hmf&4=4}50V{fLhkzc z65b|(wF^3QQ9cU7wodh9_ES{o4Bi`vW|`#}jSTPUe40DwcS-E>jQ2poC}3~k;V?{8 zqbfs~r}fPiuO|1x&U*eAObsjz_0?~mYUP1GxS};;oLiV^MHUl2SnfAO8x-`>EALKc z`gTI9Z&prnt_tI-wON(c>k-2Jy|tmFA|!mYGO9td5DN!A`~1uz^U7J@2`=B(AHB=U_Igx)%(( zTc`14PFCJu@AyXDNZ=8pop%*)tE5gyr<`-lGth8As=34P!@~SlrA;Qez(m<%Crw}n zkNQ-!^OVvL`R@AoPtPc)zE0(Yw!WsZZ+?$s+>y(S1lHfr)!GoR%rAvHgTgu{0TkO) zfC-t&6gBM7Yh9H8U(cuK*xhkATWn#Gkef!ft_hm zZ*XOMUJ!%Gq3TUa6DcegFWi@eFK8QU&Om>+Y5)6jC2&F(n=c4{2WJ(pKV<%Z*I>PV z=8(ZaWL`Vi7}8l_pFmWf0bh=n{#G{7gg1tUrA_5rbb0M+s@M)@EBDtvo1b^@ov;4* zZp*d&u70J5b&F?~_&>KrWv&EXP_de%o$?-=65O)gw4rw*@DkG(X0DtO{36gBbTZt2 zW_!P7|GvNzm|?*odSZ|oPmvguprNxa>Yo2*+!ij*5FE*VT=y4Ru`?V+!R=`mRk8=k zVw|e~E!Lc^?q&fp;D9osFk?<1f^DJwS&L!+4Db>{S@szi4QA$G%`e(X`(tY7@h&0Z z2|pwX-Q=%nNAk!a{G9%!CqWYG_RrQn`J;C}ju0<^wgv-ayr^l!><2{R z***irXc?H)b%JxWA^t>t$uAQ4CJ*0%NZ{1hUrlHxPHv$2l6`2Pi6iRmwrk9MY%H#K2WhR3)2_P2q#3DL>Pil=1f4#B#ZG*yQk;y%ShWv|H*?UIQ$%9qO zk9`E<-4C%t>IVV_ij48`O^&$&yIqiA`qq=La-!@h(w{D_8{Qe2-=j2}5*<~dW+T8C zzawetR76(1?LqEP7$+R){hDMAhvQ#+ndm01Lqs8+p1;xTlhvh`!7OFjtbE&L7a?5% zV-jE8+}!GxI++=K`S_EoOxANMMCFjuxKo4G7$t4MCU3S@IZXnZ--}=4AOuG*-W=bY zWjo`B1h>O>p?#2}ibYQ%d^*?|561dN)hI>fI@yY3KYqhoO!0<`QzdNFRu5(MbE%V( z`x{H2y+w#eSNJ_((=73jTx(=p?7%j9$p$1NZPV#*p zQ^lTrDF<@wE;Em$hQkSsOw}XK71T7INmkm23?tAqQY61mf^&uAQ&R`q5W z^{uvY&j!FF2K|^~nULg#l`{zVw-y=4Jbuf6GqE=v{DDBb00aWP|D&*>l!h*151hC zny<(Qp|K-YNbv=`%Y#qmP4AAF{`w$MVvkBPKx^_H>v|HCt=(nKpBy)91@{ z%BEr7g~MSgN`)^w*JlCAAJ5UnIkd0IwYN6FM6>i|@#To&J6(VPNyPDioUI4f8){3l zm;euBfcPrXufX-B2tJdjC3A9uf#PGIWDz_D)Sx#*2>GkWaLIg|7%F9M<@ZH|pWcTySJMcS*goXDWv@{s%oCA`0y+j34TW z$JWXToAl&I-o^?nre#g?5gR%BxrgqlRw2IToX3ANaPi653Lk;Nz1k zfEeASmwx9pSgC7~2XmuVgFGpa6AI42R-%@zuWR=NU@|L8JTYI~H?4u9ia#dF=`J%f z%dXGL;XArNOJbR4C*42aXvX1JXK88ILN09HLL9m^VwydrGpWv?GA@$I@SSKZkB7w%%T9$)@L@*5oV$wbVq z>PFg8^(!kc)Jxb=s6>k>be=1)IAs(@zYL2=6;bNun*XE}cACKj#{AV&j5I}=wW>v@ z^H$p~5rt@Zd4CZq!0|IkGxVagRKWRw%m$vF@yr|)F$Qxt6YdO1Oei9`7XjV1;r0$> zudcK$Rr!`=ef1@qvt@y+QMx_Hu-^9xHrU$eGZhN{l75}n>ryw%8(&j>8KT-h#;ZR* zy_=|t3@9SfZBzkEcmpA$IVc52i^gEJLkV#BG~P>8YXn-_r>M|gOw<4oI-ki3%LA8~ z=13-L5d*_}gWkp{bCkY3)|WaKVATs&rN}8pizb|Vn!6=po542cYPw~ zvksmhGZnhN2m3E49?*YY_@vzAXbm?nxz1}JQ~lG!Be|gxm??Q!c*q#i+Dj(L=&RDl zY%pC04KU=l=8KryYXAxpHX+!fHXYFFjOrH~3iM>z9T=z>dtusdx>rUBJ5{Xpr8xuh zFFht%QdIVpv@MgZA<>CiBhhirdr0kr0Q+*PScfh{a2fSATI)b#5IsT86DJBqss%HerB2gY+WVZGLL&(EH84AlA98G*b!ltZ1Q!t4IgW6L zixo}fux=&ljx%#T>7=Ve>9L1rW<3(gH15_zR`jh!N_U=MsBDGUj4VRrH1?VX*vn{p zVE%*xXpi+EuuiqYR*8*}KwzP20{}+pp(91bFEk;qUWX+iZ z)m3+vFX}>v-sekpp;4QRwC9AJM#CF+xBKQk(jay6<@-CG!rLC?-fEycb`CAK{1&P0 zA6IV{!}-Cl+(Ex$szEz95=E=``eFDF(-BVTqseW1C?Usv(6fKsRQu33`lELy=zikVZz~*;IXhNuJKAuQuWCqbIid9~=+;@sxh$ zHxF7!4 z!tqPdVZY)E-xOaj%uY5Wh&N<|_bQy*l zzn^^{r%&n}ce9osYy3hy#eREjTh1XNMib=p|NJ>QLY99h6NYF zVE;c~<=z%!2L(ue^Tm)ou_BZti92thqva@Xon)PgPeC+Oh&l;Ai~`OO@3E%!Ro{M( zRQ_t8(j?R?6)83!%xphJHSph-#t<^u5>=5*ymxME8Jyzc)%7)YiMJv_COjEs+B2*r zbaJ+T*f&7g(_w$>0=NqnWOB}DIS1yRz-+5ToFrvCPY^U27D&4r{N<$zG9%rR*xjWk zKJ+bCM{%2n3uVr1wC;`)AL&Jmc?vc|S9+U-kCRH>3B8DyDc$3LtDSe0A2QRvH{o3x z7w%k9UQNa7!Z9-+_dv?%9Qzw|FH~}+Q~x%@+ct4L9YDgb__V&r;E;87=0{}J!>FXB zF$z)1EuVEh?03PAa72^<-e3erfZqIx34Kyx+E@@7_*jJyQq#))L)ZmrgIUTL$lwW3 zNg#guV%kRx**i{h?eq^l-+&E(w4`_ZL6hJ8xmHUozl9ZrNuqq4-*UB?=F=f&g@Q8= z#(CzMaz9g|`#FFhrCBoLVqAONob{px$l zsx(z30VXQR1VS79Vzh$anI-{7m_C@xa7H~Sj`Ixw$bn~eqy7SpuQY+US_=Tapl0(~ z{y&W;vWeGd6zE|G9%}!!eHi7et9Tj%cqvW;(EV#$-$*tq8Q61=tsB|DI(Q)L%|E!C z#tWM(Bln$9Ti*D0PA_DsX1Z}Hu_68BN+NE;;f+uC6_-xW(Bjcgh%Kf+2fmLKi^Qy4 z<+av1|0_M?i|=-q+32Ds8vdx;p8OQ9! z*?UJ7Nd8+1lRNFvHX&b z48hBn6jJ}@MO3QVOW)a$SAtVbvPjf#<--MrolGgm;+InaWHC}p+oZvPEOxW8pCiD( zZ>OTV=T`@g8U;6v-=Qz8$uB55$Jx4e0g125=agChpdMS_RpOOSQsxef48xs_YS3Rj zm8pKo@&str3;9a?vS1y@bn)JE7PFo!Vq>T*`v;Mu3dL}KeeTu&LQOEiVMdl`{2UX! zIWMXD+1-3cy8tWFKsXC^gI`^}>A)fnmMRx;^4s;_U)Yrd^{&J}0T;mdbaPhyRI> zYB$o0$o(_)ss@!l?+4rE<$D>8o#`MQ{{yrCJjA}Raq7X-i~F|!`?^uze(KJV4RO;N z#cN;ecdQg%U-6b16#nrkCi0!AAvQGJgMXpytJ=V`C(@UmOZ(5{FQ_h7ZG3;DMSS!_ zKI_bl`Nf)xhc2MqHR6uLD{Eu-)}0-T|vmjPxKqo zfG$Ax6eVfJtz(DJ+r=>bcAvA|8hG8x(m7na#p~O#V!)Kn?)21cyn>p5EtJRHjD^AH z_^rKWOr0`DJlf}Cs}Q_ej)Iyr8|p5l`Tp#0oAwQND!2el=t;mj#iY4yWKMgY&rsBB z;B7x*fYJh#s#6Jt;BJRN7M6VU{|c$>t2SI6bfL zR0enMx8KV(qEwlmGYY5#Kdgas$$W+HJ1|WHzbZbzoBl9(jBo!cEHq4VrYl zd`Uf*UQ$~*q}*gUuc>iBvl&K!M9Ez=<*vPf zK7Ep3lmO%BzeqqYm8D`H3OSJ&+imXnKn(7Fa~(!oxKqq0kp8y~dJa%Yv8sw;i7HL0 ztyjWm?jHyQ8}L8?hEKNu*^eB9=D?5JX%Jsv_k;NXyL^UY1@u4a;ci)jErtkADc;gG zQlcXoI)UZFvc>QLqP7qnt8ms-wlL>APlrkXdKW3 zf_e@m1|>++_0%%q*8tv4OiogrS$ zn)NM}ww|?CN@C5-<_%ZP_!Dy-K{WTpmpcP`c>!d!P{}(Esi^;hjGM zh@PHicLuZR>;w>~Qts|B `olQG0jPr0%0xs-8FYJtXFC6h|Z+VzRnj+qdl=~_H zb_wuNncV`b57dJ93q;OU;G+PC?1>fwML(xhQXKcu^_$B}+$i4F!5` z1^qEoC)#QKYnJFObsm6~S**9qJEBcj5ViBYN$UBmHFk&zQe$MJ<v-Ldj<*WoHxD)^}r1@w7zk8^q51^KA6WpJ=lt$;OBq%#OP)Ns_1xNE|H?4sHy!# z+2q}Z>jtNbdB&t*85cEJ(~)#!7R3zyNz_H^Ia=0Sj@|d&(LMxM9&;{jb?bHN*95;= zKcg+61!CH#1*ldHF2+tRavb)XXWXrwso%UepzSF)LB;bzQq77}_}GNeMgEWuD!VTz zF8N8mM?xd4$I`~*n~IvdJ&{p=K(jZ<^988D$1oH+@fJNcD*99mBv3>F$OLl_9)}-U zbT5?9@)^QwKm_S*we|rIoB*pHI2f5y0s$P0!cqp%p>1gfq$IY&l+rh1P|%5C0ERhY zLBbSj8f}6l<1d<)NLDIoW#SE+Aq-9z3Ibmi==xL@I z>sJ1&in64lUTn>jF(V;c!u1G?4qArT4Mw5kOfJO1k&e#>gR}`d2}>7G4%tmT`Z!q6 zcp3c%7{GK=`lWJj4(aA@W4+ly23f4HnkJ)#`>8zgD{wis`rS^w@a#gXd2ZYjzJJ0= zYtD`pS|LtvZ1C$$c}qQ%{sqnR@UH3+9_ZZ3A8HIw8w^=< zzpCFTNU+7C=DhLV`iIOXf-fVQ0N^(WN=fFGtx5m_Hia7rfB=DmOa~%O88zpLD0X}r zNOReXxSIXHCOJfVu&5RZVtDQnCSAhvRS$;%s3{)Ugf2{XI7G65+C4{qj^@;Ow>Yb4 zlx4Rp5P<>5k1H#|*q6+K!SfNOHa2*{(Tky1d;&hUFV>=Wq)w7{*q7v*@lH<2kNr_VUfz$5{A^{- zY1!$Fba;D+ym@jb`_z4*E2`0f_QwA1u`PqSWS?wypGv@0bvuA2XF8msZl+7gy`g|2 z3wz`um)0IA69f$wZ+vBKc^@*-aQ=qf&~Z;Y->paVtS1DKLl3XtiPsbT!+PugjQLUW zsA8xeasOO~$H$isPtnUFK2vBPV|EpPzWZ=*);iU}>4Cs4@h5kc+!bWGZi3MRbjbwt z?M+-Z)xmSw6z;qNGKZ?W9j+1A5m!^wDIL3s4f|66&iiZDOVB?TbWaPffpV zAh~9$ZsXRB=p;u2-fPnQ(!`5UVzNtE^skSQaB_z?awQ{dAfOuC1KPLa6(`=5yw(k7 zCn3gp<$+)?RP-4grV7pO264+2gZj$`Bd7$gsPqaTjiJ~irgCAmJM^%3sk)S0V2wJS z8;&kvXcG!HhGZJnY8=dlV%OsK2R*@X^C*kuGHgUw4;uQXLlm4vw6Z)BkS=!bQ}jj4QC+c;lW?XxWb&Q|9uKQDNB$l@GYO|0P-1s(`eb?MXad4EdSMv`%U z^i+{Uz(35l7+T6y1%RWQ6&U;wzy~h!XB1qxl8Zp79*;xOgQ*fW!y1fPFl*r#F`Xa^ ziE2?p0PIFDApx%m30;+(Dtd9k0^6xdf>4vWAXVk>uo?g!&N^iFgxp&?jn9}3B_zza zKtQop6qWCmTa-XvzTO;UcPuQXJ_oJB{)7JO-V7>!dAiytrIF=k%%P(555aStgBsRcbK( zj)2Hy4t$?*y2Wd;YLh5iiZC+5eNI~q0@NDPkVCj+rb?&3b*gCOHzEqo^nP3VlDgsP z;c&B25sGWK5HDsA?L+Pfvsun*52s<&)Tv%J4n+XXs$_X>_RV+4Gb4kqMlg z2I8x?;J(Saf0bsW9Zn1_xHfqmzaL`IaNSNv1}m$TWBOml<_K~*Da|c znFqG#l4X40!17lMqa=qnY9|pF9LYYuZp7ubyNpIS;KSyrnAh5a^Cl3krv+U-adnPM zWHcD2 zSZ(YGMGQXjD_M6w^c`z;T&^24lr-0<6}MSV<(;qfw6~B=UFJoV3OuE?u^;b2S&!}~ zT7L5nbWsL-L!LQZGWQLA8Tf-pnPzZEqP_GF`z8K@dL2A;{bq=@P&t3pAuK8xImJKy zkTWIiqkU?g$f1t-#?J%huk}}SG;amd07bYREyip4a zyouvEu>0b*2dVpa8Cs7S4&IA_Fne~YuDkKqZ_=l{c+vGk~CkC7d86_lDlI#CqQE4oD;`ps%O*1BD z9Ap&IKSQv;VpoY1bf!-(sDn%Lq>txl=dgUGXvxov`l#U>HU4J;Aa?X60q>j|u=i*} z!XC!o%MJaIa}D-h($sh-qFX+5eDhoNR*2WcLglRvUXXcCjc$omPO7;Dnot!t+kv~~(yHS2IQ`AFON+w)t`GB^vKV$_ zOk!)zd=?hhReoQK@!{cyx0=LX`B{qXPj~P4LDo$AR7dS-M_uV9SgQVw?(j+4Sun+S zW1|-Q^mHpL4sv6tF5{0Tawhd${2gQs7%y1En+HE=FI0wqOThV!1yn-6>%#!eC&+vx*E=a@z5+>PYSL+xemCew#^4{!hjcsjUR z7`B^z>#PLs$c+`cV=&FSWyXJv)XI zJJT(cN$90`2zgIps@Q`pt@Y;EE%GhXKoLzNi9g%Mt<+!PcRAzTx3G0m`7^&UNnB7- zp(Q?ss}}nsQGuOUzVe4u(WgKg)Fx4_qd%hM2lpV1@!^oUu89TaU$VVbNVpDV znwu*ChiUYG#PJ;)JIoTKb3&yhF1i=n#t&omv88hiN}th(w?b0zBwOkY$z%*%HPJ&9 ztG^r3vcDj_h~a+2-OX#&&?31g2NLvV>FQ;`@<7iV%(DM|VPrB2LDjOOsU9+~Jz$n6 zijHE1!1QwkM$>~Ooxme(0GZ14W+dm>+0Pp%E=*6#KHRm4E%REY8r*+SlUDo8$928r!0q<|1P+KQ* z^)qG8xW`D5++VRsakKOo)Il-R;q$*{dbokbhTv+C=FGt+t9~_T*Nn;4zip(-q>c@Fh4iWVgf6#3XP^ z@I>LNcpiR^WhxW$|?pcXp~ zQnc=ydM&)(+Rjts$N$FF z?EiJ=Y|reA>DgmbMr0Z%q8c@sU!SN8b{GabPfTsdN~yUOw$bj5v2{x-f0h=+0pM11 zU=xLM3MK%{O@LaKd#Q+8EIzAjryid&4fwb-K84@6@f##ut3cBJQSR51D!gfnZ$}Ya zL5@o@l_!NlRr#)soAUDmWiMRiKBcWeIvd3H4neWKP6Lqtx@5J+(^59THS+9xYkR_Cd^E8fTQN?^UgZNAMeGL`fXJ71u-!l zFx#o>RDYS-lYs9^*1ZixO#3!%^us>(3_Y#B%gh|t)&b;t#6FM->%8~Qb3Tib9gH;^ zTR8G{$9kmRKNq&&8M3>xq3+G<>OiwXp?kty-{#WRJEfuBw+`Rh!Q9rQ-+_O*|BnYA zI^nR{fDwGYjjWQtCGcKQHiML@I{@WPP#cJ1ar1v~O|$c9kI3=4dTNR3mW-LpHq7A1 z8(K`o=+QOibco@$p}Fqys=uZ5d{&ghf@bSq4O=tg+2GFz5)!&Y9JKD{f7@|r__cOp z)#Y0b%$sDtgKlh2g13ae(M8uNdv>yTkX`(!VPY7 z-LFq-U2Qo~*|Dvu)6b~O+@U{Qf6)*hkb)St^@_fH5m&J-n@B`i=~uXTtm{c5&XfL7 zXD8dZzznm||?eKO`#Tkk0$>_l>JK@U_X=fzj_vV8 zj9FnP`=E>b&whLH?!ihiU`WLin1e0|lzV}9PaoYbFjli3kpjxEmo;;=NFEfvX|>Nz z!a=J*>>KtM2@W(^Y5Vp;Wy3{!othS=>Scd_wom2)MR^a&^F-W1i=P9HdU6*~Au$;& zh8mRqu2Ma)X_)C)ac;}BFNE`mg3#pa6fX?~E_IrJY+ujd_knU=-7pr|el19M8B1tQ? z@)&-nC>&*y|Ci4PCMBYYHGkE_GM;hR>ry4$cdSiSnGvQakl z2!t&Y7@>N4WQ`R|GFryVS_ZG>=;H@BKjSt<^liaw^^=+h-?3r)D+h<%aEQZ z*>67^nAs&{r2ncuG2W-;Umo}R!jPV;X zU3AV;vM3;Z&V4AhVwbD=CnNA5B6xzn!5v)ect7%@_{Z)qs+N5DTezM~*P_})Go%L*RT$)gC6kEx#j_4s5m&K`uGe>Qdv>dC= zTaG?zoHsQctDKO#4{1>ii{@3aR!Tv zRKa8*=qWYw94kyrllXvC0xW#C9eXiU|5|;!{!vH*IB+LON`X<4H^{_nwC?M( z`F;DO{z#qKZ6fB6k>#a2j<%NhyPMO z!&}DK-J6Iv<~UpjwtC$)FHtDPIEo%MGH@$=Tj6WC!Ih`ZU;jCO|L;ulHhk**gRXM( z2$N!qcP7gDflD11w9hoN!v{lVUKF@zwqXkDIz!e{1qKB%|4-4`$1}bDe|$3xF{-K2 zCZcS*VXT^)F)3s2H{BdLj;NSZGLx7T>2_&oDy^B7%}}~K6qTZ~(K&N7jwDGYvxFlX zk^23v@4xk^hZdjDb-mxO*YnwF;wDQvP2A$jUZ4YPKyqyYD9(bQvsVJ4HciEc;DZ7( zG(iCdX#N#re*-q>Vt#kkC2Ra2&a3JP^Uj=mG3BS6Bv^AfY%`BuX2@)k)(NJA zyA;c1uO3*g*lo2c_}kBgr_$yln`w9`- zX6K%zQ6XNwt^v(=-kDrm%RYEoM#RH_{_&M#TP-v4VNyoP+41~N+j`IFWp&X@HJm!^ zU_B{o=aF?W#0Ac6sKZi2FCnYt4~tFRxqgh9-zdvHPC1M$rOQqa{jxN>WX46?5=ZY~ zU#d`Tpu^s@e1J)3p7Xr#mP<+UK-6Y&uHrputCOOIJy|x5WB1K8ltxdRp3`x;W?wwI zI@q3Fa(3Lx#&us!hk5U7Fhs&x;75hOpQ$)0Q04)L3+#q|0w{*J+VcyS`u;8_bhZK{ zkFuB(`W>WiV~Wq_&;E)uik_jZH;uccAiBVSbCqe+Baitm9a-L+2Lv5UP1DM6O1IXy zdDni$_lYGK1NcI?US7Ka@u*eh3u@t3NIYL31BjC&%%Z@a_-|sFA)vWYtYQSSmHv@G zc3u+a7rePygm1-+p+0-D^1E`}4f%I`(D4!Sefpn1emum zFqk{{DTr%MO#+7OuOKz}J-_RtVPT;;Az8PGh04EG*kmgpT~mC+O(Yio4>j2yt<#Ao z$fp-s6kRzdtOkD$gCpw1I%y8ftcgX2XcRukkDo)o05+g;t0w4CL8mfVj|cIhB_PE! z1?@M0%rIChL3gKQ>IrU@n0Ob{W_r0jlXzU>7@Um{*mjDoRC9N1MGs#tL5wjPKxgtl zQ7W-QZ;tS(n=lZY&E?IcT!sc@&2 z=S;KMCYK6O4x=Tx*VJR~cR4uic&QE1diADJ=iwzi3%uyD30`M!G5vy}i${7DPv3iw zg^&zyK>88`11^3hHrqFv*)9=`nEZ29jrg(KH0xjg3FvM6WV6NK?4%s}?3w;Lhvh4G zbm;4<3QT@uE2E%Zdp^id)K|^q_Wo5PT}6)bgDIkylj!@9NilQEE z+J3yKL+xk1r9Uh1ko}p%dT;Wslai{=yH295cZ?x$$Krh?+oFmO{IN}xtV&P1sQY!a zJi8gD&l{{hG?@Ot-sa!!g@(~KJ|@9TuECx}$cKp*avR`7!vtKxt{U-|E>j`J@Zo&} zV|#}@!?S04#w=&r2h7LMzds`Mq{r-xO${+djD-GH@))3XZp8(*p}XH( zEkq_XdKztGm{UFYp*^oRVi)L)9`F;7He4gb+_>scMoYqLG@)(np-zYNW`y>L_LhP!siCo}Y-k@P&xxHk6~>E9GxoaPMq)=FDg!c#2i?vto?#IC*95Xc)ey za^$GC=5)m4d{%G6*a7Ujn2egNKkE+mQ}6x#cJngpO+_*fPWy}SID0QO=l)v;$~~6( z+p*m?$u1d_*i)TWyZNCYqN#CeLue!3OOQGEPL%{RcB}9ehp2!gI5whYK{{xzNeZFp zz;tVuaEbocM5{l;j&aj28%Mc^{}?yzN` z=k6Tyq}2QqY4!F3H6iX{Jan#s#27GD*Q`rr<*Otxt9C^880y8V?@F7V{WIf%ul}ZeKrQ%letBxtuPGVinD>-@0IUo6h7WPHesQR^B13+p_Nx!993j^cikpt z^DSPT9@<>dji$dfU=Ef$Ovpb|KEMvU*qo?a4k3Mso({1+q`>FH36lfeM$IY-R&0k7 z{D&LN(*bNvzoD0zVhq;@>YV4%7J*g1Z>D>5EQZj_n<~mmX!ln!8pojG*ppQ9$1R>c zQq;oq&c4Ho3rf91>c;^52jEv;qh*55(?Q>-!ypUYE0vOowndOU`ofwBU=~r?^st(B zE`-tyu{0doUwl*)(S1|2PvQ9A=(U^8;~}k+Kpt__o;J#}QhyTz&5KXIsZNZ60zMT) zmD}QM)wDRK*vy5Z7Aq~Do!EBc{kX3ReXtOu&f#^KDpxF!1?+(%c36$_>YN+IGGcCv zO;1@32D~hEnjoR{o@A@=Y(W#~=jDP^lyxZMfgv*#)v@LV)q@oP^lTQb&7z|+fYz5s zM8cleqLr`?y;8E7mFfSuT*T3$^KfqMbr|G-pe3OjCA9Xse9bjsojt;h4_5^hknuZQ zRz5e6ipR>m8>DJeV#PP})tACKmtPu9MGD;>0B@@d`o+iko=3h}weeKwuLfuxf6i{IVH^J49qkhGuG6B{5*elMP4C5cthUA{15R5gn(kT zlyMbT_E7~=D3gZqks|9 z*3nGPCTA)(c}H_kaoxzTtrl^aaC;%+%hPsciYNcj1ytdoHnru313#S<&eH1#iYX6V zt54=H?8@&a^d8vp+HR|9UeC_GSd+uN7g6toUxqb#(E-uWoW|Q*jAZ;)%Y$0 zZF%TrWBi)S+2@c~XG7*1VrzPz_&>j#vF1#9zL9)zN!tQ{6_{u4f0WTg9KOy)tmM3_ z5BcJIC(wBJ`o73X+l~F@juNZI${}HK(~;v!m3L1Tt&F;9#WLP=9Oyto@(56WPi5r* z6AZf`C=9#j;wrOu@FPhd3w-PTjC^`_I?(v)g@w_Qjqy7*)S-Au`BSrM>YTLh!TIST z0MSU_S&-XQeQlXtJ~&sd=eFqo?cLp0gPpMKT%JES`j^G8?=FiwlHNZ;9v!`*$B206 zuQ6_F>e#nu&UA^3+G4cLw=^irOE+Q-FcT!+@z5$HAO}5>w=CPDH7^U9%Pj z8#pS8Z(gkOcg?JTh0({~OCW?F2wYiOz98~LsKMs9ARTrcQ^f>jKIDH)aPdSdf$NAv zZ>>lW*5+KR<}f;>ssIn2lpE^S;$ls_dCieWrF;sM^^>=QLn0@F`ifNWDP-iRculKb z8K6TCDAAqJGC#1qbyrLDXLx*g%&n4^MYjOoFN_Zhosbp?^17sAxWpu|LNI&{WbzyB zMsv>{4|hKls};fITFEb`t2rq@o>|j7>5Qyj1S7wqRssyr?3cEp78z0@PKy$#iG=HI zH@V2{M36v&9Fs!Akk8_gN5_M=MR20r0``puzUR=3LNJUyFjxbDhGqp`CW^M{Bul* zl@=%!G9~I7T1zlEA7x<6RX0>?l2x|x!dv%FA&jFz01JilJoiV`Ci~5M-=v-?K)yRL zlrPBI*>IEQJ>^(c9cHzpXgu7YlVHJuWnBnwv*BnlcP%=ze{|AAR;Jr6y*Dg0xCij2Lq$J%$u7EYmIx|M4 zTS`qXQ`nlG#NNMG-8r1;Ok17fLoH_#OW*bCUtqmNoZ{U8xD7?}bZ$<7t|A^LN%}qh zO|0A0Z{$w}(j@WZh5hGcZdXW7-+r(9LjcgaH~FXUH%nr-SWltm&((wrS&sLjYT7-A z=;vx+E3MSZlEI!y3Uc5m=xEw%g8t1BJEE6%)G;)@hTqS}6&(L3)s>kWQd_t5Iu`){ zGuPLr{+WK5@M`_`G0St&=zrJM;hbNDhpcs&#a!$^!99vH{Mx+i@S!Di>pxu$cf-&{k$cc8OQiypC}Z>5?)+JQWi1ib zN6()U@o};L2U+1`;>Inz0^ZOA%!yrg*&x@LewoqNK{&0tM}+{Upr`;0QcZvF3r3@b z#ey#1@wa)w1|r=8?Pxiv>O911I3L=3wW6*rtKllasln?i0SfibL&l>=?`|xbF=;qp z)zm6u6eP7GSk2>f=9L-1#DJWL*8=qYMBv+d$yWl;N5eWKYn_4m?=cm&_rl_s=)VkL z>LD-T24KcIP#|;|MaS1vmVXKa^L9?zRoq%t2T~A zoV&C8B>o~gm9^_g!pEj|19}s2B9AXVov5*n{darOoi6|${5P>L<>MuyreoE^V9EX% zJcrZr=pUmvRH{)8)81{xi9K_h&1z-&yB`!8MkZ|Dd8PQ%xqm#~`bTbcAN_0c(~=eB zztuH_Nl&ZNg_!_K5))K-To~t*oib8T%N2fHqSSd%6KpnySQ89HgeyD)TkoVjO&m56 z>Dn2i{}pDj=m$wlzP{(K;@?ZT_*u<$Le@tYsy`BfHVwJ3ih3^^?T^Tx>~NI)w(1HH zo6s)JKKk0-pKhNxmZ&EiJ!)%%-$`>%xPBE|I;%5rqxnBvF%-Mo_tWh$!s};O556L< zT8RnqdcgysDoSBUS}Dk^d}6~2 z8!$8SqpJ8vdc|Jp6|OUUL##S4+>g{dX|l%3s^b&&U8{ly(NA!fnjHBQ z)I&#|yN9H)X|o~-*c^X;(4Q|*0>zIJ{=Fk7n(6N@0i+%X)h$o}+|^V=TpOwbKn8)d zCu>v;c}x_A8{p`=TSLwcWl8WVLLSB~Xh&1ZNS2azl#q;h5?7M<)*USNxvB2j^3|no z$B2X`W;c=`iHEdx2oE4ZLb%TMZ-tDg5aX(KgZD=on1P%gX~&=z8>z?kdsrM34{*O?CA& zk3xZVFb}+Y^_2IrCNyMB)yK1qLv^>0h9inHOMaYuT&}Va%!VTQ(qmovc`zZfJI6SI$&FKdR3hsLDjE>!Rd#7q3m8b)|W> zbi(Sd|6Xw1@O<#pZ9KhaNJ$P_Dl_t0`1j|J2Fuc=22JpSq|Tit<;s#}x7T?Hx*Vzv znJqi74sAC^&nT-m|NYP+>@)3OdFr1R8{ch5AFDq3+7JtWe$v`=VLI~4g*fzR$%$fB zQG4bjmKYCi$vfok6@OV6Bfr68v;zloFIung!L@nC-MNT^YI<1VFIWBp6FEMP(j1<$ zI&|V6y@xiRGsPcrUIp3L??tG2gXL_cWH;@?hf zptr9=(-%8MHS{O-yMKSSjD$U#({}ivRdaIE@RR$)_j~+*l`BZ^Q_vSlXETDyRV@+>HiJRKAyOO_T~t6Ts4W_+1y^(8x1UG$UF4wty_q}zGiq?|A| z>8}>#K|s1x3a?9KjQaU=>vC2Stu(u9zl#6f1nu{2o{I2GdTSJ&0+qq(d$&9}b`2zS z0(@x@nn#b~o!*Z3e>Z1D);dAZOC#5wu}bl62{4wqDePU|cQ~RsisXoMEL7kgSdq|4 z&vWO~tGkM;wbfF)2Q5h#mLr$)z&O>r_VqfFfulcqKb!tnpbQVF4=3jIE^|L%0W{Ay z`D7`w7Z{-eJ`^rWEq(g;_e0|gqHgoXm{ip0m9y?Q(o?f~5_$yzUi{EoIpk+H^;I5e zn^8_ibHk-&z5)BY+FLW?-%5htesh_J{PFUVN7Emfl7mYhBA^&Xh0GV*>X3la%e`Xt z_?Vi2lt;haohjM7_nrL0zU5oomgSeVKbSncg4FKbG|G>S;Ox5a*mVD{;+5y)SCtr& zZaZTdllE9fe!Av(m*p4u#o^C$Xp5vJRXH@XHTQ>>bIyL-Zhypmg7(--m}ymh?|b*l z$tK9m;GI6kHS0@5bvb5ohszmyRp+Y;N={OZVRuhD^)_^Ue()sm_b$%S*ra>_jciOL z?>1!?61`|c)BMiu1&OPCQI&V&tqii#D-8DAr>`PPFE`BlIC)+6X9W}nuAjJs>7duK zO;CtPn#ZW{{_<0#q{Mv(pe~e#+ePx+j&(P4(Rj-dp)OGbb1;EOkJ_)3JS;5rh~r7w zG{aP=2yo#4iZ_n}@$F)<6oOjA53_W{IJp&u-30W}DSsTagBqi4!m(3!taT(n7W0*H zmy4IrcfzRr;Axu8trBuaOsy@{JU3jdjE%Y635TPt(YM1YoBP9PbeX;dnX57@0$7YC^4sl!*qSv~f^N z%kexJ6~V0?)QUiIh3&zqkhu`B1sd^@_>nRZo8v+mwie!@%WncD%(0q9U|kDvO{pm4%2|tu(pvn@9IwEfD9> z+U_{C4=PVMI91-0XYjU3Kzg&eKq52OSv zI;n%pqLN)}9b<9N*5`AtQ1`UPv3h>(tlmwkzH>i+d1MJ6n|x?#r_#cFL&IkLwr2}H zhw3$8qm6U&4u>l%_FmOr=3#QjxFcGnEVF+0uzLHMckM{$8c)dO_9a9A$?FL5k5zkj zb=8Sit~mDS<|cEmoUq56%LoDGTfKwr9H*I&QG zKHrQhcQDyAvDfQ1Y-~qR{Lzhqmf_f~rs!`@Dyoe3^+a51QnEarRI_DSX0y%`hDFE2 zE$@7dPTi3ZbV+>^ywv?{B63lVHA#LffnihA=wB|Rlhlwt41?tBx$58n87nt3dGgrt zO1XDkaBKPy&wsaMt;M0^2mT&f#*(iCJK5p2yVGI|=JsNeYN5e7=xNQ~^(=dGksHri zkdsC4OO#z*lT#qOMKTvzO4-mD&)(lwWdo=N({P4ciW95(^tVg8L7}jSY~m{e(JOU- zg+-8q=WOY9S<==^g$RUqG4y6U4(pqIj`JKbEmub`(vXKL*E||JQg{rx$7r%<@%4{B zckLZbT;h8;VC07mq`3X|_=_QeO%FD0Klh#>!t_P-3SL>Rt^9*<*}J&!(mv6fxIoq6 zt_l77Uz46)gXVmqOm9+tz*9cNE<_a=g6omF>Sz zFE(r{+hl0m4%e$%Isc^l+2^K7#^#h|ey767>%ITvU47R)MUM%F4t?8^kW6BT@2+dv zkRtciF=|IwJZMD>FHY~IJFn|}Ry6qJch||FpiEnQ`R#&X4DQXYC_R@mWi(>zi1j_f z!7Xa#6UTrH8w`!BS4QYbfAkGkxIVSaPd>}ZgfKr6N~d?(B1;#-lLl`jUb_~w{MxD~ zmb$r{UkyS>4)Sz0j9T6iH@RyOcWAUyaj44zFLW34;~(r5GFaSs@8bIA7L>Z6z2riR z;Ca+jdjtCvq6+!;ksY+1rAS*5b^3wkc2aBp>7~53=E~rG+@YsW=QkOe!hpBIj$+a>wWfxV9IX8`^V_ZY+mHuf_DF|@s^#gPxp^-$am*$`N%_S0@O=#-l-+T zYbPiUv$xsar3RA{)0JTl-Tp?ayx-k^jNf~4enmg2sJzgSCCE~;@wdbgpWqNQYnOID z<|UJmg!pup-pSF!ZU|_Wo@r80T=rZz``duZf!E@cn>)~x@Am#)RBX68#wi)^&+O*A zYZWku6NGXv0Ks1g4U1_sAm}6;i!>8~ZC@Z_!rIlP&c0x1vkP*Io9Hd-)LS0t>y?sN z0S(d-2DJ&W-jXv!HJ_n=fgJL=vXua#Y0LX)G-#%r5C_JK{+{&vui?mAR-hj=ONnR@ zD=gQnxXf|QqLaPQ1?+g!Y5%?OIxh=muu&$>SXywThInbP?92{fXa=E)_np;yV=z~F zHD_6ILNBioX_O(hFXAUN1`g)f$5N=#-8Yow$yn4EKofr|*l&aTFfa1$2fTk0u2jP! z%LQmek~`Up+vw!06{+oEd`Pabyh=I?PGKMf?!M4z2P!k+nPOnj0hqL*Kmi|zoV7!1<*5vIwt@by->Xc6=R|1mDg=t+ab5NOb83PzbFLf|@gNc4 zZ8Zz7SvDli%fhS(A)o_Ke#orgad96nx#ZRVOoXzUeR8CTk`8L3Rsz7DOMrJT=oE!e zS_uu*DD+1Xz^1=1LgoRMN06dcaoZFnmf~Ft*rVydO*>qefKI!`gZjnaR5*Lhbx@DE z1JEeAQhAb~R&ydPK>W?I69~`F7?v1wk^#J90dT;lf(@s+j5GdB4o^ZTyTO4-2z#Rc zbtHP4e9PkW9x&_K-(&vg=$5R1qj%YMr`;%xn)}-MAQI-hju`QKS6(_ybFPi4 zY%8vuTD-ktaClTUm}nP!!DasZc;rX+Ww`@TMY6|MY)IPraPULjKP9HG(CL;}zg<;f ze)K4xZbda!nw%QYX$jp>De(|uk)AnKAR!g`4*fz7Ea+^m>~NfIiS=yirT#x0%rwCyyuwix>_0-kU1|F(OfIQ_5;Rei#a*krz4X7I#{n@eCbgvHaI~F-yAvk z*T~ZE|NdONanr`+@~1@BKSwmQTfKL(N@`BAkIq&sjhfhpf`KjGKiBnI$zx_w_s@sL zB>gJQIi}~gFZBiq9FdM8nzP#mAee^KLeKp^Rk{CaLMX{;CfHR}WW*0t7dq zR5p0V?=9aPLo9b}Bv^M|*4-J!*M2jn3io!}zuvD#_r`kZq=stLcuNqcvB~P)6Mj5s z)y;(ZP{U+ZFpmJ8{iY(b;v(F)b8qJFjMs+bKA5|-`|RgAJFR+okKj z8<`I_!7aT!_l)!;8Fu=3WD)ZhtIhUW{PnWB!E$W@g4~1}S-NxN#y{bZ7X1GGj_^uJ z=aRSB({5|>g}Rd6mv@9JS3+4uA>V!-Lg)gF3I<`AER!oBSf{U2)}~!p8P+rO1V6c_ zLm?;DERj8GXuLYyzkJz?|5V5u_xCghyz3^~3x{iVK7O{z2N(qO zHzjj25u&a_mR5bZk8|&!>Z3<_1Xf@$oYi@-ASqEwC$B|XQw^~aKwT_dP|md2nUcnP+K~t=X=U6;-O9B3~i%f$@VBNDpg!-@A17#yP>FqRT6 zboTsIq0PgtV+}R37cmjzh)Dsn(Q;ClJliqc1-tYYp90u%r9It&UvUtSaL!oB#^p&oNoQ7~RNaHT>2jSI z*ybkj?F?eMmkw3#?mj_=isL^L(vaQV$R-~f+(5ccjOJ2Qp<=ybs@`ja!2z0jPz=#7 z=vu7Y7fk%y*-F!N(CQ5$8+@BxWX1m56~Z3P;%W#B!;mXUI%gZ%K^Pa z5^l*cLd%`Uqum75W6=2XIv2xdh zNX<`ZoAC4Dp=MjBLDUi&D0a86S%+{({)cbXOa<#lOoV;KPRQ9lS0MHVO^$UGr?d0b z!M}=MvVU)#GAM&C|q4;5iu`Sl2%-5IekKI!5!_j%@rqZpSb8@2}-m-DU}^LMxt1nxWwF&Fp!n6 zPFVh~Pdat`l)3kn)DP$Bg&_$y2fqAC^*Yos@~1oU!d7r*{Oxh7VQRT8=kccF53}Kx z{I6DR>gk)d@y1q~Z3V(YVdH-|scnK6|K=)u(PtctPdSvD(L&ohWML3WZdSPddA2w| zAJJ1&x$@FWk%M(deTw|E`Z?pYu8lAdUnSk2lMpe9)k@OCi6@Ys!h9NS+k%=O9-dj$r<8!C&@wlaT)8|_DJP3%HbW4+zW5_kgv)vts zEB`hot*op(l-SCB_h@Oika$yc)Jm4k+}nY7r#yXV13&vH>;dVca$P|1ckseM^g z*F)R8#xf^fMVnE~xta~BD8cfk>ZN!0n5uc5yAC~=Y#`cW7&c!=atpB+WW($NdZ6hk zAnrW;>>z(j@@@K)C$UGX_jAb=IVUJbWaWp_ru@IM0!!tNoSTN-8h;tdAPkN8KZuL| z0)76{uLCW%P805$p5D{XqpyCkFNlQ$^bxusRGLS-?Gn7aSuEpB8VpO(mRJJUN+#ddZa$zc{r*6-QBMOr5XD$eam`f#>rOzjzB(<5rEb^lig-} zz*r5csNjdzR?;2@2026-7G+Kav$<@B`CWHV`DfgO&Q%l%i>Fw8w@8@hL9U>yGcJEP z_u>?vROQwgQI?!&5z))V`?JWe)dci05okK=sRi@^l_uy(KFEZodMdjaAEtvrbD$O! z6GZwy8ClA-u|$yp(cU(kVz0c+eb%X$;;!}Tq8y^(+OwaA>vfSw4ssyr%>Kg7j=^2; zkq{No@4R$jG|lAsT8Z=(HrjSyv`LDW`Ty)%<1PBi)l?t=3A?$_li94%N;e%_-c2yg z^g6NGYKbr@^jN$XeN`D7lAMi24&=ON(<>npKr}O`E$8b8xWH{YvvLDaLN_X#*<0AU zH&5ZTg;M7(qayPVCibtO<-f9fbn*SelxoF$Xr03xVwj-JU=nDd{D&%$bd^qV6 zBb& zZBZSYZS6rAHTK{&4#aG0|20BsHQ7@qb(+x;Vp$zZA#t<{QVLi36GsK?h^9$5&IZ_C zVXfjF=|u4sKMQtuBJ|zFeD?z(o|D+l3bpwOD4vO<+;cn%klw!t?WqU<7-h<9HV`(0 z+IE0}Cb0QSCens&eFQUhA5rcT75eeb<&q_VZwUfG9Rqm+FH`3lBDQIP?vF2eFY(N0 zkqtA%;t4*eBs)jpJE(5sX+TYwMh?Rtat5iGmsjLPNpx= zuZb%3{h_DKPt;eCUKl(CfXkxqN>d@E9Ypfpo?h|cR1)c&$f{-=r)emz9FH4HF$1fO z6`u481fGA-?sw5C?yj^Rs7idQA zYwr0muh^9&3|4uqMGOUW)NCDHpW{klD{kjEkYw@mM(V0+IPdK^*{1gS&#IO^`YIG` zTEfA6GZ^9Ziyh)I)h$oX{Ec{it7^>dY*(k*-}%BT$P0B1t-vmzwD^!z*TYfg>BPBL z&I2OiHm5yJ?j4^)_T>R$cdo^@oJkg)E zgpvFQ<82eWcHEo1xSXf0D0w5&>$5^W|Ko4!sy~bJtuy!Oq)f95i+>3O$1K^NIquaq z4Yw^S-xrdqV^n|?w42aY5psQVVCgLf*jot@E4OXlg1S5OVDl3Cc@+mT=5+O?wHv6y zik1sk=^w2U68elfVElaC2jCx$-6|BTy^FhhYcltp^^B_)nn6%EJ=AsZoUo{!?Jg@F z8(j#8OZ;;m6noNXsiFPW*Onc#>ABovXfVHEN^eucio*6>Ksg!;?mv7E zZBLBdRTTPZV%zp_`)}djx7jA>)$aO8+}KuCv;7g>ZM#2)df!{OG5SD%5tk?QJJi?><{pggIKjn+Q7F&{;@VmhZ-2?PDX*K{`ErEASmOq#S%qTEGHYVx>s-SQ;K7=T*7tfV@ zvAbkgi^eK*Sb^*+4+%k-f7*eBk>MwL&gD_r02I||L=JHVhrzUwi2n(XiU+f30vnb; ziR4Lx0^fxo;uJ0sCDKa?i}GOh-_Rjn(6yp%YW^{}@a6T+EZ}2k1A0MGJ2SRF~}tTsZ^k$n>sl|N-&aV(c%l&UL7$99K3PD=4IF~oNlu#-k5N0RHH z2B9pn`LDEuq7d{9KipkSFv=M3Efe${Pangv6cG2n1|qk|j!KZH4}{p|V@TLVx4lLILxaAK4EE2OoPS8!{1{fMx5rO8{hT_0w)XShMWpSED zVdo{p<)n)bU3LfMOOXMp{Ukjgk*E>S5CFYC6;?5P?GfM<(h?qEaGqKPcCG>{!?{b^ zaU}5EfuzWvGhW2t+*;7nJU+yeCTzHs9}YW5xK&7-25#krg>JWwI^se%i3tv!;U`T} z;AqZaPiYN=n5KY$b;H030!vsrM&3jQYZYw=l|G4+@?!}CAzRtiqZQFmFWy{xj>9g{ zEV7iH-nG`TSkiY1N?WP%RasTQ3aFv)D!@`d6bw}41=1Q5WAra%9xpEpCL;8;jHpQ9 z+auW7rna%|E3q8Ytnjm7eH7xL>LN-^t?5Z!r5~ne1i(Mo**K9}Vuh)MNH)Na$S&uO zQ7{TyQ#AMoW<-1>5}FI)UTIZuq>+&r&H-tt!W4Wkd_Q=!YZ{v0bSC~<1NYWO>+4T9 zOJTA>VtEmFm?sU6U|!7SGECG`TjiY2TU(k*sy^*fg^sUt`@30FM9-5MD=_{UB9qh| z^^?^T#t?z&uIoRf7#uYR0!AXy8}_4~&Q=(;t2CM@#j>KuQum5^7|DRPFP>y?HRhq> zo2J_HEZ(qTyBDvZRgS%dubS2mmcIT+dN~mB;k5O>ZH<5K{rZ0pT)SI;NoV2hZ-z;m z)?4i_bX(vs4wXggZg=nTYEHVuziH%$vi`jP zp8rmoJV2Y!N2e%-e*Y0CIH{9A>KzajC9+#zS+%L=mIuUkuHILm%MjbtB*t;s0jE}9 zf@yA#+kTx+Bx4q4NDsNUNps}x8ZxI(&AE!(CRmm!HCk<@=|EO|Og!{BDtLb?Fw9@IE9pbMu2)W>JfCu}dh9W&7ar)t0>u zBXQCI5?r-=@y_gU>0dC7@@DIX$Q9LnrqD&F9XSaOCs4ORnhv2|=W1spBO`AD4opE3 zug}D<{wHpWeBaZ|Ch4VyVcroMTRGD!hFE7urklCK9g-|oY641Sk#Fx zHR`DGIEA|oPz;w~62}w8@jO0i384LnH3~rC&TOivR}sE0(Bi*Mky~@T{=i3RTO=>{GtY2!MD z-DZ0WZU|P@ds@v&H=gL|Eitf@X0hqswRiM@T7)amDV$H#mbK^TF;?CUTfXjA{&1kC!^Cw^N&g9M0&ZD6UFJjYK@LLN|5~?AXn|z zpcA)hINJh{q7*D@$R)edL5%^Lc8`eM-a^RglBpnm=+7)Vt7ykr;)2pT)Er<`KL`8a zb;H1pr{W}MK^2hI?bjp_mckQFiv=I&!9uW^t<8yf##3^M<$!b%psj|om*L4aT5Rjw z|Af{cp?B78ESo{9a>avOT<$5RaL3jfs}35&GxB_RR(d&z*u*zlwTTScV1tFU)Qk>f zV{riHP1mP4%=6%`4(Z^JCEwJ<|b9LAVb9Rv+l_Rk*yCT48XnS-saBj!Lr0i3Ovr zFlp59w>64Q*)Oc4FK4X2w6e!=K3-XXO@*Ldsm5n6UySUvs4?riV37i3jj*JjXf36sl8LDI8C--QLfL3^43p1d}6SvTHuhfSJFj zOkucD=yJVW=oiZ8KtTkM2m?*aCQ5ScG2~z=jtK@dQ~Y4{DSYT6!%db50TSGW&P-&f z0_@CXtO8l#(Q<8tZTa{PxX{cGGQ!O7tQV_6gK$cjW2zH%>BQsxmHQN6Ox5*$I)pgX zZL!ELPJqEBTfHlak5-`)Ua+H?t>W@8;N?#b+2k=pNrEJfPxyP%l=LyX6H-DJ$M<8S zGXYYZE|D?Y-2&LL;kNAv#vA{XtZwslpvMx|dh`AcH!lIF&^o>%vu*gwnG`VayjoK8 z-TEZ3nFSV_Bc&1o__$CFKEJBX9RxFhdASsQew>9)0xFrdBSYF*v6Y+vSThm+z~tJE z1P9MOu(yN+Ju_>qc?uawy?mT8V~dQNk0IFk#!H~fUNs6nlX4KYAml{P0OW4( zwRQQ{kgU}bx0?0npNW?CHlp|%A5M~1vC(CD1E@CPgWigU3kB-uxSWqk40lO#Z4Rq9 z2ijZOw)#zu=W?yYcA*oNDW}G`Vy6_2hm_DPnoS626Jgyt|-+*?cQEKdTd5AFqS4DBp7kQQPRz32pjgt_9SD~z{O76#A?BfUd$Qt&nVB|-|aif_29?iDs)r6 zjxUf|oi1|Bnf1%?T(`iFngHh8GFh%kn3_T*XG$hG$Dq4WL-gkr*E>fA?gN3XEdj5S z4(=cdi~Gr|9t7oc4tqJfe~7dr&#EOj6(<9QBFLIVu+DBKC(5%Z04A7zUt=e3&zPVb zg3T+T>^NQ(aM75ulw}1}2-yG*uUiX3=SjiSl-}HYomfv;j4)sQ>j~L2LRlhbQrN*= zVAHkLMi6%jz)>=GMRf_amzl24(HLC#(9NOY|d`=8|G9&CMP7{A6VWA8lV_*dq@i*x4-3GZ* zB$HeG6)J!QfLoJR+~IQx;_P$DiqsA;5-eYUMRyZu#S2{pNjOL&13ZNZjo&roSCVy^ zqxk@>^0~f3PdEU;w?*ISxue&)wN0SN2*+fKHB{EGtneHv>1S2ogg}`F9t6+7mk;KG z0`+>x38b|PGa$QO5^G+AwqbY|i+*1~%j{^tzMkGM-!ye-Ku5L;`acU~) zXCm48=Hi%Y-Q}y5`pxK~pnR=Z(m{nB*tp)Dy07)na^M5g1cd;mQuK&gVt4L2j#L%) zO|1Ks_Il$cU(^TA5h`>c92Om4)Y0fpRp}3L{`l15CQZgd*)@=*Z3LUlj$~Yxd6ePm zGhkahE(<}&BO$bSE-NVL?V3tIU)4Q7Y9^Z9owY#AQ>=q917-fWP#k2q@Z3@4*XgMc z@XInr{-5{!zho(^np8FG6OjLW0>RhV5bnPy{bPU^?6sdukp!4{n50zX6$KSg6XDar zM-3RP8Cbu7&5ATQJY@YdxVy+C=LBXKydd5Qw~?p!n5If<7LEG*}sNhZ)v`q#w{=Q;K{x?^woH#{>KRy|C42+|Xd=AAJ*y_2wt5Ey=dP48L(W)ts z<)F=Lu=+D0m`299G{RP*IfELe%~${zr$=?1@`0WEd%|)X2}_nIZ!icZXLT&q`I{ zF3qMWOY-a+w@ynIy0b$d;KU#XYi^}=;j$}iR^Zz~p~sL3#8&`N{7nb}$mn$g6D0d! zjukhvT%eP9Ym0MytfPnGz1X?FKR~G%ZV$$yY%reaKn~7}e$elmgdOR718b)K}m{RNxa2Fj}{Dz z3?_m?;Eh@p_HZE}8ke!%gacsoG1ew-&#n~33A1J> z4%40CVfzA7nYn;Jzo4A+;)LB(1$F1sEXt8-pj{ihzzMrKS|~r(Oh_Y?CaS7{gdHr4 zc!QTq%v(F6wgrMr>y}d9+Zu@NP=vqXiQ;hlJG8Z@pqr5rmO@J0wlbaJn$7M`#kMtD z0bs^HO3bao)l^S9*=`{mpk~F^zz6?)eu0*f;f`E}=SOr4g|!fLb|Py0?KmZxO=EKs zw-w@xTC7wyT5wDN^C_#2I{hq8sJ8eH>V&BO=4493V51H`kT_b4}2xJz*nEK zLMKc26>)JHK;<{I6@w$mspL)m@Vboz@FUW=-pIYhR#k)X1e`LmiMh|4{H&P(662>o z=yw^-!Q@Ek{V6{zyt9*(2>mb}B7;+-XMoP4i2+BZ)FNtG^WBgkfCXytL__D5OY^?` zuSXD&AkxmrIiaxj$eS`w=iYymqb#=;{WsY7C=#jZT#rc4FXHEgf!BubR*qhARt|f zbcZy8(y@dz>@Euk2uLca5~9>DB_$;x(w*MpcmH?p+?nsY&M*$k?8|b_d7t-*U%*r# zTT!L9j{c>mD<#SP$dgjStPA5{C^A(b1rx=fSVgEc-TaRTh}YsO`pHL#l)uaGZAJ-nT$d^ynSJvV&PkU7bbQ|89F2UXNcA#v@Ly_m#+S}HjxV!#ksu= zSnRglz+RF00cL`-6=qdYd+rfUMGab|;7$z=%Ayd|p22T1SY#0gtfJVihavDM!IYa>s~Nan*nJ7mzJ7 zhv=zf$A~8KVnm6B3f^ogJP+@k1>;d72%y}ZRIawbI`VD$D+vJecz7UUALT=+^E=e! z98>6mlEyA30VPc*WOGo#Pou{$QqC|B)rXhtU%?qsm?%K#>!UiN-A4~R*W0>Uo<2Ie z0#PLv-pF2s6I4G1i0zolYJ3dvyB%XzVa+#$H!+Lgq*68Wxts1DBl!x)y=gl|4PpE@ zKz9PL$z4hR3%cAKkpm3Vtx2FAwueB;vwz9f1S&LHjE(VyNx)v2tBbCxAaUVghp`hXu^ZjYBW7TI^woz&8fc_{;&EYi4(Rwt?*;ON5ef=%fd2 z>!hw14VdWY_OR>9`EToJam_*VNPDC$Y-I+Sp!=FW83qAM+1vRlqHZQz21JS%XmWr% zI_hw4I<7Nz3w*Tr^rHb*v-bngMUqnduX`Gd!%$*=wiG|ZmoOYw?HxFgGPrG$kubQY@>MPsV8T!U2xkpkmf51&ENJ(dF=x+_cK8-d z%m^H>8GL$*Xh22C0xjp*sl52riItLGaNaJ=7qp(C5hVdAO@;cpuKAVp80+ll6Q2Xg zBBsy*y{$><7p?MTCrd+^5y`pmQhK5oz6*CqK4F{a@n9VvsNnD2Nd(D2ZH>jZRac^D ztI$ADep4K3mivz(r5J+THuQXh-0DH%vXbfp+U&t2`~Z?VPUNSBy3ucvZGAp89e@&P z>p4Rz*J^(%Bmx75lE=Wr5&0F>uLq21a7zmTkG9XIEWC1>^ zcaBC;&_lnmK=ArbwEpFK6sd8@Fe5MAK0As^aSJqz@3=H31Fpeq!vh3>^VP>Fn*#g9 zlkyFLxNx_i1UQoCnq_bjRR^~W@#=xxePgzuaJ9~L0fUMH>c%WpPZ)B|45UZ_@iDL$ z&-#i6iJw&9WrMaCi(<2MNEB5iwa?TAq3TyRLrFFuAJ1W<)niz7m*3UpZ$1Vy8f6hJxaz$|4ri{q%r{Z%V7d z!&$n?kG#Z;0g|GLhOyAFL)bhX8tek-ZDF@np*^w`)6mW>d5oV5DIw4n3P1uQI>kP5 zE3+*v!0Tek84f5)93v4wj}Q%)6M(Wd(2iW-SEnruGucUVv%zG100sxe3xI^A`1yDr z6IVAF)V>Nf^%V%if_SsKt;TicP`LDo1bm);DxWKdIYGy$%TQBej!^|ns*&AE1#MQc z>Cs~PK=^Ja|JE^bm9Pk~vuXvGycCsXyms9bm{+?KxN(F8`sxHaXVG-jEC%w?yfE|$ zk`T}{2YI{hs1-ad>9QU{oKtP?I7{XW-KJqMYtI3Lvt^8+>c-PvFQ^^n*(aI%us z7=fs<1_x8V$;3)l7a&KRf2VCbw)X_d1qOytq#(cZuD$w&WKot}X~rAJv?dKt0TRh?S{z;s4e<$hHM=Im}3(CPh*HbQaA zE@2#Z`uIX^|hV4D>xgSz}naBf}dQU`7cN2WC902hd$0BC8NtSP;NdNoF5OcQh@Ai!p1;ActkH%&5%r<3SNknD9y{ z`Ef;*u|x#?`b9fH)paZM2k)wm06lS)QzVyHs61d{7Mt4SIiOf2Afq_Y$%~5#1w{Nu zU_DD`NO2srOSAzX)DlsbJbN57S%a`5We1IIP6ddQ*#}By#d{Kz0^sxzbul1wu8mt`$&U^zfH11t9lSUS10b!1!@oZ~cS% zq$-L0bj}^Xg{MHSio3xPdWMoE%md(UC_G4pb|^5`0I0HoNJW8AAHe86_5g7=GtCV| zwV^i+WX~OmRtNe7fN8j`$!u(DNFO~85RuaQ6H8eN%|h_fhJd#b)7>R^^y@)WshUKo z_FQ87|0S$&lRj{d;#LjdebkQp&5!eT;$#Wi2@{X^TTc{hJAVkLsK6n`u#l#`Y$cl~L zRF*SK4wuIg;>eCRi*YMpwa_S1L&-#{`ceWjy|E)5z)9>7Ms79@9bkjs&Hx=EIb(cv zG^Ut9nsLXFsgz6!aaggDXzV?)cucN-ygij4qV%aSGz=TEqY*cNHatdip>;v47nmLP zmmIW(m@8_7QNC0_gI8`W%4~2o(d7u`$-fDEr8y$59gE%4kPQWbQiZqyw`VVOC3qVE z+DxT?Spv?qUPS9LYRdo=%edsHYsq?s02G5(F+kR#Fpa#oeyuBaX_5%E!a@rp zno^Phl?WQwHWF;QQqz8fwLqy00Qc)`&|PKyaz|w)OLj|tL~@unxDS{8XQ63imQJx^ z<*0(O_-7Qfkjg@G1_QX&*)sbUFW$fqeC^=f^Bonk?bv+PVg4l-XhLk(BJlXH)`~5$ zCaU=jLW{Ou8RN))ts*iCb&Cd6hFshF{(_>-f~eEB0ZVy@0NLv*5Us(rEAS-ZY^%i> zS;KMiy&;=-5P+1QUX%dRSeymLO6gh(^ia)=rgG6$$W_)v5D}&*6)wt+Ib8$N4=;5< zI`U{LJ)jCF5=TYhP=L}0lcxHRGsxsN1jz*UD-J1NB{k`Hl|4oF?y1D2x^7@%^>Ne6 z)>B;pUA-{sZJp6tQ8#{osR56VP7DRq$ZUNKd$v?!*^d2E;f3qD%J=a|<$-?2zbV_# z&-uoH2;SA|Y#JI2LZ=g{>&kM?X5EcGYXe#%troJ^0>OQprK;GethvRs($Oy0DhEi~ zP$Ho#cj&k+?Nlle*kNoOF!3r+B9PXp2yNh<#ifNEMRE>9I8S~eW5h2ok9^@)Pv{diNU8(?Es5Mr)1l*$?&X#o-dGy+}k zlniA7sk``W638z`*}_#}$*dt=T-)y)bEhinbfcev^-`qVV~6s4qAx<`vX1@ngeE8hKf~hR>7CV znk(se`D&7e)(9CSUT*S{;f{gzMyKGRpm`r(i=3IxSCj(tbLKlF`4WDZ^g?zAT?8NS zj4sHWqQI>GOf_SNaUq4Iu-m2%hgwcZx17E`jf~=v&R@`Pq#|&R6I{cTNi9qUK*k^n z+1J2Cymu7Er#_XA0|*udkN9bYJ_dmu5>-gHbtwV7jXkNZGHbpp$}WL%#7_^XVu14Y zm9b^7H!>lhFIhD%WVkSrI1uy(~=7!5Vh1`J5rM}tDKTBZaXKpEF@pb8-Y=1M@>Vv;ciq#Gvy0X$zG>m4=@gcd4j4S*H_V4Zsa zA>39)bzW8BVXVx0e7{aF6p<=Gu09ZobD2*($jvN4Ww_XM3EGGG%@*WK>VqZ>3MUen zDqo!;3F-iulGRig3|&E>#^_gQUy>@2v~9#imR|~H_U2A@0FMsk%Hr`xr|`vQ80=&U zgk71nmlEDWVC{T~KF5HDwG5Ov^!U~vjRyN8mEd_4imr%!8(kH?7pB1UwSG^FJw=Rp z9)RMaF}bXciITmHGNnW=sr-2Pt}@$LR{O$^v!wvQ*g|O@YpMKFL=#4&3xY90kF8e< z_Ka*kE=J=~>yN(E_49>My>n9$P~1}NF5+Yb>`Nt8`mXs`x3nc^3$=_UjB$Xum5Q}w zz88462*96hpaeHc+|=h-!;EEsqG8Vfx)OR?5p+5317bouq&DH`O?QI$fgN^QN}Y@Y z@G6Q4c*Sc%kjhrZMxn6P7C((BFYcwKs|mz3N<5g|BDhp-Z8cq7^{bZ!mEk{1MGqT4 z5+QSj1i|D1Z)y!0O7U%#c*>@Oo{FVa=&}kY2~PNyyGCnppxy9OT&sOjTXnNC3gx(IW&epsqNEyB-s~>AHQ48+%e}*RKJg-~oe{ z^W_4{f&5tZ+5oQ>a&e5rD?SEwMC%Rnu>LEbW^0@h53eB zsC!ZE2nDPFAoNI`uLPgJ#8mC1!lL}NUibr9HB*H+Ox|>SHZKma4c`D4ZSLqqwE>84 zX3DU9tAlO8v-5PA6F?WBiHeWEfL-!ci;oik1k75NHYE&47EI;Y1llFusO3`!PS${J zOgga^QNHR}V4r+9D+Ux{A2uc)HYT&JGe*0Zh%d~D=(YkHzO?{G8*2pN=gR}4^uyr(5VU_4j^*X}PsJ)KR*bhmDFZk*I%6@}B|p&TA)fZasIJVY(MVB= z1q>*~jjWDQ70C`vTZ@Hq52N1fOfNMmw`nq=pHAL1XCnEwE%lGsO@hBKk9}9;Fn&H>UwJW z;`GTEi}yjV{EYY2o^VPihLDqo7 zWl%+08JbGhmdjUMyA%YNj3~_jHrsfeK*jE5C_a^wRmNBmB`~vI@UvFIejK7B-q@>tN|s5QLEKy*K?R$8`#^K-3o>G0iXLugc5WjXw$kMrcL zkK+!;^sG-<{1s8C*=Q&LS_Se$qlk&!YkySF5|9&eP)Y&=Wylr<9<740fOv_8e|X4x zG-V&-Ixvm(8(0Q1`5OUrF%kGs9D@L+i(izA1WFxO3SmTU_%Z=odVL%U*uS8-e0)A# z*mj=)G;T}`Ia-E9lmTiE5g}D_`!F~Hg-4kXtr=2^bpv4Yb zU&F#yaWj+1C1=KUG+jY^dW)%r7?)-S9M_%R_006+VR@kSdIXrWA5#)=lI2?fI^1j} zDIjp6Nj{NmsoiXDGhZk_j?US7DzIy#=k9YbflZQ0<$yzqEOk9LQC$a+O#|ShfMbz3Oa|gA6o#SA+0s_S0ODD{ky~0XjB$Xb zXFmxFS;5&9#|m&EF#Z6rq-e90H5I0%zn&Mnt&>jyJt<2LGMS40scfODt4Rfb*tQBy zM)=tSaC{ZsrU1I~#15FAUTN;5zadJfpc}7-a&L6VK zy#Z(f2Nlq2Id~|xN|b1#lgiJU5As{9;y5x9t#h**nsC|kC?$~P<){7ej_S5PP)z7#9bWmNOcv|}yW4tRfO8|@v?%z`Z$!x2F zE-{YBr~$@dG0MDQS?v=j7Mq3=Bu@tJ3}Le0FsDOF8EUP#S%~WI4`V$%d@zU*L<|Cf zI6;?QGv~n+AP`y>1Y!bS33e9^^74J|=j!C-?IeT>aJgUk@fXe)-D9ikld#6!YMK}i`Hmwo>;l@*=|BIT z`Tt$W{oHjVaPMu0%*cnuXWesOQ|Ih+*-Km&Y$B{X3;g9LWfgZZ;XdD;7v4RcyxCoT z7uo*T3eNsES4cjHW7&N8gXqSQz@L-q9lb#9w;xyF5R=1)@Py-J9-0fO)S2LvIf zirqh{LKC3Mf$eei9U7Vk$8aye9kYwAarF(E!29sf_}fXnh-zfh=Tmy0gr@8B(9l+4 zO1@XY-_I^C?$OTfu(sG8z7QHZ_DPF~Jc!?VJmefHvqE*zB2>My^@7Mpv95A%1Lidw zi%htBmdcj?L*D5Wx;@e<#zg+HGa<~mH1gMvjiK{Svrcfyv{ToWlCpEXRR30Mxy*~1 zimN|bjR$OqX(HX#Lvt{@j!Glf-3OH z+T;oS&BGUqju%JYn1s)RR;fwm>BC$T{>mp5UK6hCcGs7bw8Nu=q)#ugIGg(=?;Jmo zSi!C=ijrboztU#5k=qP1mQq>u&rmO?4b)1+s}V+6!^MebPoh56h@J~L>fgF3;&S56 zT2HK6*p%{M0p!|H+f;5I%iu{_srZp!1UdUgHJVr8x1#n^T(UN?)`3fRCt-?9p|o(=gth?UD7@y z3<4{PqzFEG6A-J!KUA$M)=(q(bkFIuq-<+@3KbgIc3OAG;?YS84vC!_s99E zR}5BU+;cQ*S-CYT{^q^0SAsvV8BX|y%mxNTg@mhe&jp?;6k?(@XbvBp+2a`Oo86ab zc~I-v85%n^Q^TVt-IkH=DMo!qBYcu$CEK)XU8^2$rzndJ@&{dUqyt*Rm$>y(aCB+*?A5js~0DF3+i6iL-TH2u&3pnb`fey-o3x zGc}MHj{!-x=RYvv$^@DSR27$GJn`zl=LBGX}{wLQK^bG2*KVh3oLjewFgj3U{KAXMb;*XHI}iuTDT#SaI=# zYr0QtD_Yk3Km2D6KVS`kq!0H$nx-CTG39*y^udF&5_P5K z-65c9BU`Zdbg`);g`NreW7^zSNrLxvEqSr$B+JvGS}%kLdA>U*wYiv6?UaE#kL}tE zuN3+w_p)1U(GoJ83(ZO^DO(df`g`v7Gl|l6Lzef7DF+G&g-r5TBpPxiSa;%IyaI0J za98FX$3$;&*agb=jrl}WAE^V2q*UY+QtaUr#SEZk!Yu{ce6GGbos$);F#48{=W|(N zoB}t=RCCRPasQk<0{Ul?Ip$&Zcb`5MbR_uHT)w3#O^Qw7rTHiaB0d<=1uMbQe z)byFHj$hX7)?n)EV|PzU$oY6NP`$5`^_4hDJn^gePlI^G5xXC7=AgE(zvO>ck*&2O zv{mH025USSs74q1+5g=Q*t>r=?aa@lc5iOhBKe^itpX%bv{#5Z{Jmr%=;`JBL zDuIE|1l@@w9#EOHQ8RavB7P|g{Jn|!BA!S3G-98 zS}%JK@*H<1>KRx2Q$Et_l`msl7b+-N7$Q#me^kEMv)|PY$JwGd$Gp7DkVvpbabnS!nb&SAZ3{fB8H_?( z$4y<$9MTo8S2-{GHqeuJwa02I(LS$4IEyA8h=BF9pIGStUmwT%U((=&7<8hcooqGz zd4(yRUf*msKj7rN^|C^bXi&I3)3b@I&&beuK#G0yK&avLSfjDd-HOg2ZBf(i!}tUH zR+Olc)9CchJuI_kt5g&2bA#vH8@d);u$`?3LaxnCnvXTq%GELornGZV33N}TGpFjb z%8y;OpU->5{~S1e?mz!LI>}4mH{afA)mcnONsdg$q`BUHW2cNnqSJW_!TM(ezfmLo zw``L>u@GBfEj>$-1z2zfa@ef6CH0`BQjQkHhQ z_|%A##9ZHoV|m|po6sE_#e;j4zAyWYz-cX>&caaCrLepF1n#ufGj+ z^j(ed*3wAmWG!!O4zm8pzDJ(xDdufP;@Qtp+wf&Cp~)o(H7tJY7w6WBpA@8>^x86p zj(!0q_~!G)`e5gR+>Fo5CV6kYdf^yP10FK?*e*ptsN45_-;-b40{6}?4iFa~gJ0

OF&0>O(aI5II6=K?*v!_4aGJ2mq z54aR@vI`-6SI)3kc+q<7eYtTrY$WZgPj2{|6Q+Iju7zJllGhHAx96e3-*pWcefqCo zp*P}BMs8b6^qDL-NOQcZ@bMF_a^LH8$ZxLsI>T*DeeOgT)6K|P186> zxxijXc%yt7`@_EvyR$pL$=Vi5@}nJcd9(6(;e)h9-QkMbppIYk9 z{s?)|M*}RPEG*0jPRT{=r*grY*OUPPAi}Ke+c;XznbN5uulv4>7>N6(S_{mqOMUgq zBX#6Beq1$ZCeS!&AQ>K6{{GpsX+mj#A{O=J)HfvK!ZFN6Nzdi08-xp5KD9D`zA1|g zf4Jd1xP0MZ^pe-H4t*?p#VMR&`>-hdG;YW0uV<83-Q~@Jqr#ss#6kM$PoBTQZyWwt z6;|e~pAiKg(Db;c^)Z#WJ-c%eLvECGKX!^-P&C=yc$6 zm2ZZ|efFt3!|aTo9o3m^IDg*GN~4f&a?*th`jYCZ%Zqcmh)eHWsj%u($EEC5jNK~k zuvGyg8x~rNlN^uTzfX>yDF3UpK|RbyOi_Y z7GaYobC$a#8GjbHUKNp8GW@ibdnoa2s);+4r~R#4SA-F+4vk6$kFFxs6=qUNj)XV; z^>=(?)sovok7oDlVvm-j7vbUbMXe*uKSGO@MW<})Mk}&PBHLu1y9d2LIdXsV?)~=r zy&tE4M3rx^y2CH?y&~qioPX3s(@)K9zn@;%-KqXDKVtKK(mkxW+v)j>!%VNo?;*GI zFJPWOrGEVRL0p?N9Qbz9tIj#;8d#z{&Pfgb4wrKa#Zedl;9fC zoac4uaoZ@b> z;I_LVe7O7e%=zG2IVm9iARcx5X5;O_i18w-`M5+z61(r!z+E_chnR=6Iy zIJ_w^Sd|TX(GYV703kV+g{H3!2&G z?v%+G1tL7DE9cuAH_NS-5h9cAMm#x%O?e7?h7oAw&)q{hWr39(cNPy%yuZFIu?_{B z-n8dupLxsa+3K}YL|UUG+f$N?$GAQ`NIQeZ7|tDR28mS1S7-d9-pZqPo$ZD4>biXV zkyavgF-^FRSKJU@F#ad8ZWc=WZj`XTKD_RJDJRo6c&z0tskIc^Ieuc~8W$%Zz@!eK`{l#)5S7yXg~mi%xqyw(bgAx~UzQhLOJ?>tek$4qJUPFZlz< zjr7)Ri=K>|TH7sS6EgyOa{pYb(n4MhJ(1C=@@|L7RNReNbL(7v?jF&X^4D8$Hty#M7sIM6k20uf zXbw77`|ko)sE?patu)L!u0mz6<0@!AWQ}#kv2h>sm+_HMB#_dFvo;+2KLFZDhNF3YiF$ZV;^&LA6R}?U3_%()}zwAk2HfeQRH0xxqr0ksig|8su zW^6X`*6s2O{ckI|8+QVTG5$3SZZ}{Vos2I*Klp&dEP9?~&6Hv~MGr4p}B(kHSuEGEePY010C zt>x79x^XKf%}%OnGeeF--|ZGBaGJFXAaDpb?}!zKf030``YlU&8-z7R-t1! z(Ruu_#3HpKIBsRhd^km4%t&qc&1$uXrqybk`UvZz0BA(hZ*JP;P&CBQSNFbc`_LI~ zAI(dwCsB*e8>E{N!BR$Xsv~C;mA&S7)+cAGW8Du{9|km%_zUnaP~N-t0at)pnoDN2Qa0~E_2{o;dCS;(cCDP%M>KfLQp`HZojg@TW}Ut@ zhb{dFY7{v-5y`K(z8wxId2c@8v}@jKg-hr>Dv>yE_&ry%SM?J@d?I}BkUrDoo|q}k zWI0OT?4wHi_Kb*kmtUfy#W-ibfAwAA4CA5nY9c3u!%02U_kx$b-(PdRAZm>cx4j$zCryq3Rxd~I@8ila+&)+oim7Dm)}Wyay1UAY1y-nCkk(#vlDZm zXKiM7&!GLCZpwQS=8O8F#976}6c_m(UazMYFY@u%ATK!u`C4t3E8?>xWSGR?Y=K*$ zK1#xa;DdKy^@LuYQ$WN0yXs9ptzo^pDe8T7&l#W`2@>E3i)}vJias)YCf~>XPs_IO<8>2TQB|JZb${TDq2w z>@jUM2NDBrX!cl9+%C^CN0}Chq7HHVdyPaa!VXw&*^pmnwq<5N@PP5CDy zknBoAkr)Dp??^mIqwo$7Y90fkqTOGm)dAC{1F6&qi%F zndjKJ#V)qhs3Ks?4K zOY-fX>4(1`f~i@C|NT0s$49<33ohCkqw@M{hs?K~Gc}Vkc2Rbz)$+{BQf~uw2-)U? zHe6e6etF2B670|%RO;{9(<)SH>Ak5qU5=ZdZEm0RJ0%mp%~?zBPR^LeSep)UKf0nd zeLh|B*ehTTM&z9KhR*J*_JDKDQtqF>GQZLuWg87vF5E@jUCUV<%P@3+Wo$riTE;r* zg?}Yfhs$uj5A<+8Ddc_8$s+mngeao`YB<&hm#yA~x1X2Y@f>q=7EU*)FCV)yhUK+3mStrWD?SJ7Y7$!NPUiKIx6fIU z%UbG6lgmCowIoU5hUSbtP%|T0(Al(BqoN6gk7dP)&9pr94UOv!6pyT*{N(x<=YgC? zjO;o^%ge$9-tWJ^q3!|vVZ6P$MhRU1V3McRqzCv?BmDpS?x?F#lF1{5AGMXGez%F z>I~|>nN)8uF~6utuTjI+#%a

$%=7tBTv@_7^Q9B2m=c)KU9f7SqSJ&TZ!NbhmNLYS-^YstM2Cb9;JiNtj61@Tj+m@~*W8E&69>Xj4=0rjw2P zE+%Gav(zI=Xh7Won;c^F>a8FBqI z`P#06W%48odYh_hX*8jkch=wRv|+ivOEMfi%dX}P`sKUtDn}CMf-U;I8d!pKc}hfu zW`J%iK$1>7(*=Jnhz}n$|BqX3DB|tI#SX z6LggsRx(|-IF~AcjZ&D7<`wsIAFT45#aK>Pd?C57)?G4m%SAZF zOYX-s-^-r-U}TO&8u3$Jw#byC%&W|ULlvAe-@d4P0tBt;w*r1mogb8beG*%RkQPcs zUVb1NO*Z&E?NYZp)H9d!pO7+HO!KK>){o{u)7sGNTe(Z_X@+IuD;D0HJtx$6jGT&1 zo?;80CU0;9*t29n-&ZpFVK=3KQ)cxI$!m8NiL%pPLjUjFMpxb}N+#ONf3)9xo@-yM zfyBKgx1g{cG@~4Q({fEA6YuWaKxRXNA`j7MbN}-{_U((m-_|4F5ub_u6tinduoJl> zVkD7Vi(AMyfM>$UO)lG_%XCQLz_ZM);oISqkN00UuPx&^!cJVNMX$^5QzmhI`vd%k z6z|_X{1nkmQm`l;%5@+tQ~|M&%5EAGfgQwA>G4Q%dF2uARSUTV_?2cj{+DQC{;-lN z=|i5^c)jK|msxEkq$qZIJv7BumM2ZkP3WnjMAG9=FB?1=V`=Hf{>SF4FM(*FwdzZf zE>6k5tt;CrqY5dzLm8-qzUqBnkqL*G4k2;6=sGCD5 zj!afLcA6iW0!QRmX|%^e2*Upxl<2>vxxIzuT4HEm3FQ5>kL#a|Khqi(6b0U_jgIU$ z^LAD!xQ{R+;g-xxmiH(BG{tOs;VjTMk^cX!6tdny{G>Fpr?5gelIfw!$URuRaW9;ve3?oz@btb~Yw2>=<-za#&jBR*G3F zAcBc{7Qep04)94QCoAHQT0XG{Td=epb@W%2kbNu$_D>72e@>~KC@LEqDa@PF*uXnK z#n!nI|04v%s}tPQ96!ah(mpz?D_U9xhUir}n^H2bTE80UQT0}39bUmZLYOp9+wxR9!#>**fq54=x3Db%>Ugf`IJw2mJ-_kHR;0l zYI68}OuV>h-z9BYwHN9Dd7D9AbnOeNULditHC@La=K1QeEr*2bR8N;(AWrz09%xQ) z$F$lWy!^##+(jtxD<^bF2ToSKmI`@cc_XV~=$?P@^QDC2Hrwb@8{%-&g_)^)%6`y< z%T7D2!t_kl)ad!uZ@~{_bUE85{=!_E%KEVHat|M8L(w(%f5xaODrBku{`b9Iwrt#M zPjytpF9d)7fTB>jzU6I;nSDRyL>9B&RMz*yQ!tZX$MJuEFXznH)N&vp6i=i-+VNLg zh=grN?2%R7)R)_4THYU;vHq9zmBNeyCNq{Z5{(jfJiYf4-f_S2R|)$+yJlZO$o{&4 zYP&c`u*>7*|c5SZkcFbN4{8D5mA7f3rEPmw74YomjzxrtIJs?An8tOkY|!!ABz^p3y%% z=57BN@}GRCVqa<>Y5L@+@hcOY*XY<2P_7$!R!dP6C({ja9*qff4KO|^{H2N$(V;|4 zxEDvt>-OW*=Z^`MAgYH$f(AK51S!vdscg{x&Z%^IPP6yRNclzXllnV0-}(w_n4dR@ zJvo29=;_eblHG+3G!Qwg8oB~QPaB^yr6PN zKYs@I_`?rTV=V52t7vz9c3dx-pKF4_);8+&p}ka(T1xKvv7a?`F6ng~6n$A~HgIPt zhxGn-655?;`PuEQI$t)-u}G5$b`hCTvVatW5PnjK!2dkk};wE)3gdl zj*2R#!THYcnjtAzsNdUrcUgb_ramX4Rh<3BTX< z`+lTSNmcJl0^QX1WM=RR;^z+=xadVH?6{u>uP?IAw47qc2=uV0C3k1>0PIUFCD#TSO?J&2`w)X}n%kvgzyE9h4}@YAE>x#&PGZo#3zS8WNQ#<4Hi z%ySm;hF}AyJ?pBX(}ADa(_$H(GCyl=jTD?-DPze&2gTAXHZ0WZVD3K%b|fmQ=T->y zf>!tb`=mQj?N=9rl>6c1)@qyaE)U9A9>ZjMyF@0+QBKcK0}{F&2b|Z&HN_-mlmp<; zlkjw@-&2~GQIaWg2>War?cf~COr@OXxOz!7IeD0j6{ZUInLy}2sJNLjz@NGM9r!6~ zmG9teB)AR#U35QuCWS7s_3RjKvAhNyNJc0Ijv4GfxP0wOn|V0;7c>x$-chg|l}ehw zJ+Y5?E%P-;?>dDh_3udT-o4AMIU1&4HajIrCsK1`RP?#{N%(Qy5s}}dzV%&7-#aN3 ze*bJ;_bC!SyUtRXI54~zbTOLrOXTw->+>UzgRriGu|1W7cro0!?ngY5q|)mbSInku z+}P*~zM`-v>hF(CF~V$Tbu{nesP>zJvfZxjHU#f$lAX7``0MuSd`a+&Q4iniXYu$F z0!liM-q^hhxc>#^ru+PyyEnk+kk;yMPv!t558<0DJ5WFC5{Hi#5J(M-npU83PhJ?;DJNbFgvu4Wv zJhxKa{`=QN5{yoQa)M0L=O4cFv?pzgHkE~yD(CLo%e9y(4g^F|0gxQ>8tboZBKy(g z{rRcRk0k17UvR|MsOr7ZU9V^15aRZ~uFI7DLp0MI_p#aPZ6+Utv7N06!9x9wZ+zEG z0AaYnHYu{pF%~!)k)iY=!SiEv@ycbi+=3hS+pneJU4MqVTexpsEK}qGKg7 zU1NKm5AP-v0nWl@?9-KwR(xakVWC`2#`;Rfoz}AlRjD@Z$2LFw(fx7)YL*OtHFjS= z`_(p1wS73bpfl8boc%@27QoO(Q;2 zY6432?=*eu?v1~rg{PU_;95TAUQ0>XW>VfXDla=Ty%*wr!TpT*Wofv{(|~U$6wfLR znh899JXWjo+Ejz557#~5SqqJ4{%F#bnJ)ixi)O#k=!5YbSg&}@uC>&(zav#(5M?TdSnHrsj-$2>6X`AC? zIiVZ}PcDnr1nZ|d(_T5%KZWWe#S27pW&6LnO>opRXHwcyf4E(mWCpa>r{h`!?)?SXxz=v5~)Qdzp<#_0xV3!nh-Sa51oFbuJ?_+uJdtU<4XD;`i zecvfrP$cQh6bY}f2;9jNT9mr@Ch<33p#Cx4S)-!o$Bf1M$BiFv48tm;b8~jiBnkQ` zbOTR>`8}2Y9N??^7$jU#f&;cJfBkZusl79vSa5%*SX=u*kI-G>p3xy0ei%}_Wwi=H zSzmJfRbDTlP^ioCXwUD#JN=!SlEIz81moUsbH_Jd8!x&=1NYO;hTS{AF>F(DO%tUB zYEj!{OlS`3X$11=RBwc~Ere6EdM)eU``Ad9HEf@~V|^rjePu`Fzc3F=p{uA+t}W7Y zX&m4|d3we)CQz%VK556QeSE0=RqXmg`dBq2VqP^x%f(QTZa(i^)oDgU{DE@*Ba(LB z$c3H%i?MeM?kxJYMPu8xZQHhO+jf3Q$F}XHJGO0iY^!4@H~(|)d+)$0YoO#h~}w&0DM;;GMqWuQm)5 zxNm*-aiCMT8MKZAr!*YD(Jc)zE(}*@*IF;qfWKNY1Q`wLZsG1vc6K!L8)L~I=uF$T z=>-fu8A(O4dWn5|>gxiP@TYNsbP8+%MW~SG5!035E|GyVt&Fedyd*}Zx1Dcby>4ul z&+KP@thy4TFIWsDgGs}&HpdzMYb{wz5Dnb=VFwS#MjV7h*}l%RVfA<1Iwt+Gfp@jSOWc>bZBrmeK|92O0RM*2=z&m%7^ji`T+>=tohK>I zQqi~yt*)fu99#xTeR`qORDsk-2Z~=-ogTe^=U_oT(uiZ^j=M7!5ot;%Ehy{PIBb7f zARBkK69_#vM(mQ=w_7W0DvRv>{HIr9w`?I21hh`Penn^I*atFw_s|{ZIrUf{4vlbd z!5pf$1mr1;t#N#@+49Y{)WaiLSed7Pwg->HRM|ONZWDi5nr55FGTua={FF7>^X^}H zvo?gQM^@_%bNf8%w2ZOhN_e~fhJR{gF-Dtn_!`i!OkY{VX@bs1Yu{6RdT)GKXTgmo z8=l?UyP9>d>RR+-z}RO~37M=lvPzl{l$2+^B`>ts)RVahzqW>ezNkHcSHZ zh++2LBYAj?nxH(}w6>PrYV=7cB1Cfz+l02Kt+9Az>Voyo_8#GSkh-+s#T zWZ(_euytZSZ7JF=kmUrm$1ptQYk6B^2rO2l38)S=6fFcFJMn9s)Fh1T9sv8`c_oiX z&fuKPFe{no+UV}xo90eh^tzpe<7D3Ne#I;6`^DGv{^zfqC+F^(8W5&W z(En%ky~>=z{{bBcXxIM#UVUf%PxZYTV)%McYhOOyE+;f$GY8dZ zmMCNVQUC!hGp;#NOf<*Jd^PaBXT!kX9${3z zv$tEpp=?!iI$&$t{wd$F{`=+SI(_(Y`L=0&r?%y)r@i}Y9Dci5=&|+b-_gq) zTRCk)gW$G-V2(n3Jw@`tTj5%59Osp3V?^&}YsA($STBKqVqAQLh5HG^x;^EY8&CG7 zM)oJWw3j;;X>oV&PEB@)zTj2X=dUoltgCad13>{hg81B~EuWaSt@D3JXSeC@oxWhm z`5YV5XA!7A{>{3*KHuIu1RD7*1<%i9hPAwF*XdFp4vhj$qdzRhp!*bTb6O`yX57Hi zjs~6HFHUVC;|>A(R|WAdogK2OY(P)1Gt+v@*Ebvr?KaK&f{8_~tBV)o*{hzo8K7*N z%Z2T|-2vHMRmn@A!{cB1^7mI`pS$1nafnx~y@VW|-`#7RModhPhW4HB{@v>wy(X5r zPC?X7Mb?7NSD0O=pZJ~}zsweZghM-z10I|B)vtbLn`e2%#>J6*lA@)x^Va8C>(ho{ z*7QjP>O;cz6fE9n$JW5IlLW~{uxK#2-xyWw40@Q~Yu{d9XtBBE9$uynrL&%%AvHt>hT%d^R z9z~l$u7;xl;ku(H5&{$D=qNgb<{eB)-z;~=kHE0Sj`3#GTjnh)yg-WtwWIRX6}#66 z`qVdaR&NjReOI2}a2>W93RUR1@W!q?I{WlI`A2x8I0<8oFIp7{>GL3@>*=0oGC=^R zj96&+R!rNMtc`S|xnN0KC5C)apcCkFVAj+Du-@KBsjHhTfgWEt6^w;o=*)*29cE=t z)E~)L?wD+wc`}F?j`2E8fi z!m=uY6^bnOyZh`g%Y*|mV4F5n*k%ijm8)29xo z<|P>vvgtxl!3OasVWO%0STZEQOw>50xzog%Wx5T!}J`&<=16pH+) zLUbBJH4d3@8F{M8W4be6w3Z&6ZRBST&-Qrlq1&N_nePp`3X2 zix^2B<<`|qDg0;=arN;Ak+MQ@K>?OkAUS!xE8~O`--FqAh0>NWe^UHKY-gqq6cc6S z!23#>Wb)!B{nSPET&B$UC@IbJ#xa%>*h;L!;NMZXtfWyQtbj^$Ww9z`xlHCohU~vg z?4U{zoeI%@IoOGbl3BMoEn?RTaWt_MG04Z`s=1PoMm7>Q0CL!|ifvQN;U!NR_~^rL zkt!8@;z;Jqs=ZV#JJS*L2@Ia7YT%5h{VZeC)Zq|e8rx;nItVUH%_{ydeNs$|DYl0P zKJ_V0at=BdI_*ul7i8JgwB=;tLk?8Q17?}%7q@h-2!&7_F|l@E%kKzFtNsHHH2 zV%)CdL}&NW?GvD>@Y&SX?vSh>l(834vXs{n`mHu=1t3+78JmTa0^sbjJ_T<#|>amy-lTQ+N&-rOvw3_Shw~@~#cOmE{DcJDaB5s)pRkSQUA$ zvJNPn+7h~3`Zn-Rc!-{|7b#S#S5}pDN-XD_X)8c--l|vcVN(Cxmv+lAu3@Mx2{pCa zVAUc87s+_Io`}-<_ZTbTewK9p$NtQRmW!Sqv7_m#(f7-@*{$fw_ zV0|nx2Oqb|!Ry4z3Pj5wQ4;KnVFdaV7n~cNJQN7jUQu7}vhdRxXlU2FEf{0UUSCbA zIjO-VKcMsKKsHX@x^%&9kU8iBy}b&_tC1_SR3J@m4eKojs8h z-aG9>Hx#Z>(0QecCPgL8+hp#mX8%xmMNZA?L>pJ=G18yui7@)BCn@1>nM6#JG!<3aQ)5$xeGGKnDMJ~aOYhW;hX8jU3k)YEDdVhPBEm}xd z=1~0nabX33| zkv&^o5LRPoin23tihN3ODx6GeF}2okgB|cukfuqyQp3-pSR7@wiDq5K+x$H|Cu?E+ z?}(>69WFauXNo0Ng;v6RKOjaJWXTdDpq?9B+rq9ScYf*@$Ucmz;;ipD(WdbEw5nMa zn4DG()?f`f$e$@$YKhVyC&h}_PX-ox9KDDH)l!S~hE!-)wu^~)FGzUM-BLDD@nPfBr_*%%6oDPA-#OSOnL>M7K>Cl5_mO_ zc9GKfq7>q}it@S(k^cTBbv1m|)BU@#LQ=@X^<8OmvV2@oc^j`O)OU!g4f^Qbqcv z0BP~4n%QH9Wi<-A)v_AwvU_t!=S0Tef0PPcE6cf+6PMLi7_rGyr`ZiP;3oTCeK57A zQkt@i!5ON%%IS_jQIu$+o2Xq+hbK@#F^l}P#U}Yy6zx{$rQA=MYe|+6E-ZU4-6;`oOn}AxS zB1&4!g4&!W4c;i3+~6CKd&BxOwnX192Af9yL^EXiyI}rys{)$Fv9J`mYHI8R0{IGF zyFh{xd>@JVuYZztzoMP}1T8*q#0nXWSIU!SIKyXVhJ}<$mSR}9Xpe8AYlZ3PApWw4 zgT`!}hpg8C&zSsaVKF}WMyR7LBU^7Z&3LlI2LfffLhV^p24?bwkQQaXW+#o3Ah`Yb zQB`HgwR1vIW*PwIZ-=Xw`%8B*9to0djC~CX?*H^yE_Kat#i-e6w2Y zvf{ed-iMhsfeg_$0~bVp2{*)E%FQ1LiJkT%SVW3KB1SW^- zEvifQSGwa<@_&g01+#-<4R;iQDDPnXGb}Oi(O6{{Zg_)4xf9Ev4vW^YdPbA@BAYVt zNxxy{l7uI=igRaxGYqhp^%Bj$c$U{qP8a|6&T!G3^ z45k}?R}H)O8QOw)S3g5=uw{=ZN9 z_$k??uGu&RStIj}A2JN-5c`SR%?om}*@Z@Rxn=2TaI}FI_ zL`rYzGw;Fui2pGGgGUgW5b7guerSw#KU!{| zQ^$mU!NRd{CU|ZR`ra%jmVoxAOx`~k(2Gy?+F6xaKNn~v*yzz@%MvZ*j$Npc@a#)XU~jUC zPGEngR){vO@AFq5ri(-pIQCF?J|LvZR(5Z!f>E|c!Ydh3gV0F^&Labe`URKbbXWvn zcBafyJ*hkr%OqpdB*`5Y!|M@T%&K784mR`f4n2Y38D|7=;<@l>^V?*>+D0a&3>BE?LL8sV)mT`Ve;Bf+1xysdGU^D6yeH@EB<2k+>uTTFrZju90&f4oOC}{hp4pE z!yCn)S-Cl)2{x1Iq65ubS0fsYMIu?UiWr-m_hBJ7NG~qoV4rA1mXMBpq8ep(BODw0 z#gaf=IPOCD5uB-YIX>j5i8nyq3yj~k^ETKf) zhDNGKocE>+mQs5P49!qcAwfN|iM>@GygaIy@jo(g>1qgspD8Z(#l` zN8Yiz1AS5P2DvRFIYrZ)A=&ByaI%Rmf8tVw9bPh(oA3T+U<=ow2}PM2afy1&1L=~T z9jUy+QwnjiU~sQ5_N}9ioD!8SVJ7_-eN9Gs$WtH$n?}(bn zDu`NcJ|19d*5!pe_?&QI z29|{^XJ2@RgF-Sqpq<4$^Hw7zWtNMHh4C*)MZ>rl9 zg^rMy?cG{DLCLzp2!Nb^efD^78pJ$($9O>l{_I#I%mxi;>I1D12mZP}_|0v{`OfIJ ztlwy_An%3V{8Alv1q^`Ms?Afl>YRRB>T{L-!c-=;0J%Bx|yYC%}o0fYk$h z+Z0i);-%BqdMAnhN3(h3Tj>ft;IiM|?nSU~6^(#!mlVHz8b@HlY3Ew;C! zy84bGK+&K7)<;X&WzqlLuF03~;?*2{fp~MHCrB_2#fP)iPUOi1^)d58028pA?Artt^)XY}dbr}@=^h|9Db#qe>|^j7`Zq?50~+uB|K zKC-zV-quYP+sE1H4R$EKGcAaFZqnTO_DuPrF>&qOsa>xyy|qk8xMSG-eii@S0EoS* z|97`3`|ci}(aSgB{~$#AuTm>Mh=s3-WEMfdU|m#haW6ERAIzm$^Xe0!%xULR&Uc@{ zG%(Xz*>ArjB8;P!BR=9OU?TwX{c>7)PZj^O`5Kj2$KMaDC?Z2+upH4Ra^o$!Bn$u~ z$V7pR$o{M%r@FgmgcwZ3TC$tCMPNb`8=>wS$$jN@Qyh`87^i#1KlI?a8GB89e7S$^ zh!}kO=y2&_wCCbN9hEex&#mH{Cl^Vkj0XP``?%)n~)C$bXm_~2zksN1H#v5 zt`BEuvQ9CZrOT&vIVvB&A!&hFjCI>{;z|~F5oX|Z3j0A^sO$lLVzpbpAbZrPw&zEHXa2%FF!}- zx3A0ZZGVsp#TSd!{4=)9egrX>doNE%?KyPEPpjN?`42s#y@t2V4_EgWIP$sWmiAGY zV~S8kM)~slVZMBde=J6PmmURw^#i zaK~l0Pd>1O456?D*>f6bf^{37b)%g18=bsgH@&qU@!zl6@6Ur5(mP*1BA{1wK{t4* z|JWNDdpttd)@q*=t7~oRDhehG3f|pbT*AZA^3tDn!bsTCeizt8^o?2t#`T3JbAUwK z;2>>Y-0fKS-hYGqkEvqDZ@Z8rFd!gQ>v~49eke3Ev9D7OoGj8|*m0 zr^iu)-;kB^%Bi#j{@5-QlWj6lEV{S74xE&(GcoAqBx>pt=z&RqK>qK?bk^TZ?VGX? zC$f!bw0XL^jF6zHpxPOX>h!XIWof%HG17Q&$#nQYcDiw50E25rj8RFADwn}mt!(rr z-X?ogf{tE>v`9)ip96qN*yM~IV|C?f+SQHW=Q zkSCU)zaJt}{EzHTHUR=(If4nBu~KC-9<_5;tlBvS%^%POc7&e({{G(h%^y%i`&e}D z9d6zV9QRgR|1N_zP4l0RoOp7=UJ$;W6;FnJy7L&i7~-gdHxEi8@)0eQqm_dw69yH1 zU&i0|?_4l;p%4Ex5(Kz*WXOx~1-q!Hc=EGBxHaBx>PqQU?ihs40t*oOya0o*%~@bZ zNmVaEw0kJ83}6{+4><=i_GtQm66sMHM<=b7>y(iI#Cqn!m8eAMN>AtTsX1n)hw72k_U2{l~k%F+66_PRP>o=Ke{8tZ96&|W;?nnhlb`LvL0w#0+v&Q_sRMh?<5L$%`Rkq6s|nC!xBD}$>aDWTu?XC;8T4h z;7gF%Bp`0kIRqZ%`Y&gpqLnH=Wuv9oCvt^!Y*~gH9C46z9YxkzgL8Sagrmjhr-nqv z!9K5X3{f#2Z0`M1kTUhi7Dl12u1Begh}hdjw(wj|!m*4Cd-j^+n!x{jLR;TJt7vW> zqC3k!1W?GxLvSV%pYSnCs(VDMrd~P^V=m68G-@r;=7}hVjQYbXbDEE2Dq(M4{a$9c z+M%V1YocoV9P?M9*StQ6K209X5!l=D?g-S(&j(I)pDhH=16 zHW*k2{=y7bE2oOR;n2W~_K>UlrlGT?TiNP;H|B9}umc4pSVr?V8EvGF%NI-0(y^$T+;CPpKiFA$f0QOQeUW5gP^o0Lbmvat;&GpUN zyQx{qVB6yD>PkOQ*HO%OaHmKDJ-O2+Sc_uLD{O7bpA-b7+@txO0G_;-+$B8js5=l) z&wSql&GiNP08xe3?GS>6?e02=udDG8%ZRFir&1 zm6A#rq?L9UjGjxu$^poFoz>qy81ZGXE=a>Y!$NkDMLK_T_AoaC!{bs**hXL-H^j0LXixG&ejs#peY@YJG0_WDQ zoG_wbZEiDWo(K^9uB_@ia7f;}#DY^e7+KJ;-ZYEeXN8;J5rTU{o*RA5;mJ`y7z@B- z@^q^}sRAeyRYHnYkEyT02;}GXC$K|MFv(KTy++ z|1bkpeMV3VT&;{?SOB2}(WuC1><_804VkaKH#j0e%TR>^VFJ02uil(tZ$b`$lB z9}5>cXJZ3x`M*7Y3w}K?MX%{+94Tkzz`xkq_6?ZjC=?wY+xHi9#Oa0^9FP)=8@KK z!C?uY*?k0UT&#VK4bu|{=D`Dcj1Uf^N@kxFTnah6l4#MoO<-6s~BG?y~yN2H6HJU?JdG@wBhUJpFjMx%3+W$;UkRbc_M;i`d14mZ5Zbm|BufIGdk&m~4r=O*~;7 zlxG`MaYtCrBDi;KaTHDRU!a&xhWaQ^4B6rAxZc$VO?kyUAxj13X!u!r#lptHGc?R7Jxb>|)r>=Rp?qO_!X}5IWv*)$=?NE9GsR*0qtQ-{uB(WOA;dTH9-LKTjDVg#RPWJbvZ5~_cA7VqDG(-+YB zr1DwYs7Sx&EPZSYR(NvWW27zC~t0@jdje2vzkIdbFXOY+Mi)3ap zonAtLHk;;ndc?S{2e0Bw{3=t=p&f4D*7EDH!LGCHF4ET8EK6ona3nCEqJ&cvjEj=w zfCw2|$N+9?luij8$v<-w-VV0l0CGqgeu%oWHk(6wSM(8wnwxF;8=>V zit0hlqL)enM+*a4b zxBkkuVd7XJ_O0T>=sFeH6d8tb{s9hgUQ6pZGaOak>aucoRq_#4<($P~`ATeY-?jB< z9vj{3imW63g%`~P`O;&oJd@O9RPecgo%1ctr5%BXen5Jp)S=2Q-v+lz12D@Jw~1T! zDxuVWoFkg6d#r;1!PnI4fd+jN6>2!v0LNWDH5gYf2b#T6JEa}i8Zk4Q-s@J%` z+)KjQt=QBCh$_PZmMke4CKa@e{k-KcyZOsSHIU8bTf^oG7YQSPg_YU@Gz-8UaB89k zLJd(xvegdb?nH=wX9CL&k=INjD=;K*yHS zHeDTIG-=rHd^0_wE5Wpf+aBI)0*|AU`}Gr&;!@LO%%YKzIo$A(`k!V|R@lAF%V+Z6 z`4Peuwc&(pQQ0EJ?)E6}=!{H+sqj)dW69gL?1~O~N1r0n#rVYi-4%(KIe#3%Q2@ zV5B&J{D-LUj!f-()(zP80rAJ3V~>E)hi|C5MIxpvQkS##8%Q|p#}_-yi|c5?TFVfk z0vNFC#xAbGxUI2!8w4|SPUkv;cPxFXK?uk6>9{j#{%Q$30=CEBTTvO=ff;%r+10?F zg(zAWO7Ts*;rZ-IRMuLFw$2?H(vR|?ZVR{5tq6l5u=OL3Gasp)jnI>Cgq9&TS#FIZ-K5Dadn9S%*?8Uv(=}wE0#7%IR$F5yI%Te3Ojkx? zlD-iXv4aFs^A5)E8@TJegKo{S>v{w-u#vb)@?*}GFqOeH4+=z8V+h;D3Kells^El5 zqRMA3Vc9Y}Gf@~a?Q>W_tMg3Q3JafdAyHt-5d8CA(Uy8LzG(svMvdid#iR<7T$k3Q zFSZJ=Ok!Zs?%|E+35KgLnec`ZZes_WYX_wWy>XCgx#14r)R=wr%0`m%z;~_sEysJP zwy1zovTyi@E(Faz^TJSB7D{n>)S-_ZdZ*>r3GwtLkV=RCbPTSTm*m_1z(Iiatntc} zWSul=<%;b!`k3{%jW2CoWkkRN>OA~VgVUyR_*>_~Fg!H3gij0h@3cmA>VG{)uJcAL zvB?;KLiu)~pNEe%gDRDojHl}Hva{JvR#B|t#Z3ns`dAS^me)A{(I0K;M7GTC6je+a zOGL!qz|rVBPZX25jXC`37P!2L7u(ioxI%uG57C#_Up2U)+&>^XX=QoWPc^|M5%@w% z@kCVlt5BET23a2AThI!*#?#ylxM-wohd2#ZNPX(ita}}MI{%BLWoITf!8cso@31OS z*U-Kb+HZi1XVcI!qS3_UuGuChku2Iq6TFnsJz}6~27a>XTovX&#AO`pK|~8^CR#BY zZlM3An~aXIBFYyvRp8#%EC!CVVw~1s>itimbo^bi+mM9g;b=U{6WTXF+*OTAnd0lK z`?XnT2#IL70_sRz!(TI=Z4a{4TPC-E@0VuW3lBR|-)J1_ zn-DcpJYYB9%Ioq#d`b4ZBJNp6&1X{noD-ecw=(r#WZIKKNB2lN=;gHDYx<+7=jktgGsLad%*0P-S@&nX6{}c?tnc?+uehhp`l^}0slO+CF zQpqHe+=Gg_)8j`lrG}&_KaKW`C|)h7out8`a{yVNR58zY@H^sxbhHAJ*)-~A9hRDHC?VM@5AvAz4cY%DguInOKCVlryWlGX#(CS@f zLJ_q?&}Xn(^ycEVWch@!d#}_(TW7NyZtFYPX9_lGzzR=qv=D$=aM5dk2?r&of7VbU ziX&gR=Bs3i-q|yQ`LwAlU)hczLu77Dc#E(5GQcs^RVb$6iXY^$8^0MU5e6|DP0a%rhTF(pb$>0yadN&TtWojUM3z|2Q(1A77E7866qBfm>O-{ADl;p~(ljpp(Ff_m zw`6J1Y(4;3sjK3apV`E@DcAQ8`+PlFEcx=UQ~aiBN>z7inb~%*-szYV5m=%bPo{eL zB=cTRyF#8-$XFGwq9*`}-8M47#Mi8F3JcMx3(wIy8^}t1U@m*SGtr6tXB9$zdO_D^ z3}72)fx>`vxyzCefCp{7RG$c`qS@}?CDxBN&OLxOYl6f&jOAmSS5~GsCJuEcbM3)_ zW~~{dGr7RBP6!`i?7@4#-MipaLt4Af&2nV@a98SksBJ#&6k@=XEx#mf`v-R0p5YI| zo>wTY7UJ-sQ{mt*v%;BN?S@`NPgGh{=z|$6xr8~8P##^v?iYTVw+|BuCzp_-vGi;{ z-@z!Q58HI}Lj~7u^}MF#B-!g{&o{7}USIXKrAmtm+LOA4JuxSOxs%nSBm_-R`nt4x zrNNX8^Up1Zx+Pkofm*=v5x0~UML}-aawaTPz}cKUG?d2x%-;>qdT?q!AQLbA&aes$ z;LfhwPMYB7E%c{93MavC`QBZ;9D1daRfc=-<#M~icwM7kNe4#i?yP_JyX=(2x-kG;Jt>rEf#sdHMQv**JrU% zz&P(%YAbz9$IKPOe_09JpFeAqwwI9_o0K0z^*PlTOc7QlmDEf?+7&MAo5*)@&f@hk zy#q`Xzk*bry;zh~BJ@fa(SPWN6u>ifXcxj{0c;Zor5NC}OAfEKjLqG$=#=)>C!hG5 zv~^*sc)rI$OmWetBrex7D55xPkmz+Qh~K5PtzkVEX1QTx`3!iq2!gA1$~Xp z$UsZ-ISIbRTq#z8Q|MyHx%rOWzwLNLPzD|&tTNABF=Ku;AeLO<@E2r+iRDdG6*A>3 z1XESlMYVKVqe#Zkcp;Z}`?{>PutDaePSb9gpP_W+jySbriRW}%ui0rIkK5{kGPoKOU zt^bl1rj}X+=RDx6fzal!+FwNpq$Sh!0!-a{u}P4iKc^5jc2s_6bsTx--i;~bPkzR_ z%aHz0OI>GF3p-U(oE2Kdwj5~I$;6kClelr#NEV`Jn;JziWpen+5~3~S$`p0UD7~6X zSx*z?tRkMxIs&)qV+_A_STtX-4(9*%gjv|!(Ra)S&dhu>{-jj?hpY<;A$jK?Bp@Kh z(*JAL<-Z8NF7>S)Hzv?O4GO-4cUxPOru>ofK8VI$-h$X>BNv}o#g#D(sglUg=*7Q% zXLG|#%*I{lESXuLc9jmD(s(_uH@RKCPSOo;Rx&-3)!cOsNw@q=Pj!+;he@XECEf%D z^AJJwtFx&L#k3PCNk0WD9}N}1KgtcSF_!MQAbcxx_8N}D1Vkw zCF3cki#NyNeALt_V5qxA*Q~DnGRNAM*4L13s?d~P$hoEL7-RI2aJZnFepJ&>h${`v!>nj~{55KhUGMR~nDygZS}yr-j|U4$!&1Gv%id`i=((WP7G)c2(m#m+EVtNqyg#abQC>-r6y7dyaxq z{woW0W^#vYJY(Z)6&=muPX3K<|(|EH0K z-+*LYJ|)&|9>##tKybyhjSRl9V?{od?KX-bT`3PS0f}1o2KWaW*ls1XN>1&=)}^a~ zbv2KKU%ZuAmkrnp>+ld@d-cgGVXra-DrCx3#FjzZxOz5UhUH+cIHHj&Xsvuj`l$1d|Z+??``Ttgr&?CSl3 zjgdw

2bdJ&3+8i+7v9f>Dt%om3Bq4EB6vnBSax^jioF2!_4)V3vi}L6Qf9y0i{h z?zPMRrX^}3G0&9DXzzzTHH7}SDN>k`G`BwT+{JIJ0CT7+5>q(b+}%|=HApL%W-dSK zQy83O7lyRE2U~9@NZ20`W&C?mSJUh)q$4GXrK!^P{6mJL`C3KTou&uQPNBGWE(tl> zuw(qINUP@(g~UkEX4AZQum9X`G-F3A*FPA$L2mM4=kZ?-%T=^G7+&hB=^_rV)4FfJLCx<R3HdpnbY_W)J2raH% zg@^)op_Xv}5tT}p@SeqM@398LCC$d+s>1~P@a_r$gOYQi&+m446GHo2eQQGj$D;B3 zLw?kpK-YFy3sx+(eS&XPq}T{yEw);#k&i|{GHH_Fpm-C5B#?ycue);W%sOc&xy1L* z_(-x=*k1w;of%>KWP05=@%FjMdTtYuSE&>*{cfb)&1I3MWBREpmt0`*uMHvAQ^IuH z^u9}SARbe$PL#sMbv>qq7=3PkyXd!zUl7lOu+6&DEc#PLHMAQff-T}Cg@v_j8kZhL zEmCAA?U$4A3~=?h=(t#bW=6@W6nha%!_+a;amuK+E!U$8-65pmS;KNNGrmQ#@p=c(_8P}J+N1?A=pq2? zvi^v((6tGTe(5AVdF8icuU(1T&qmaLJ9weAJBfMHP+yHskq*sp@)&D=`5giVw3PB? z=b!#W;8i%sx4=nR-9lp^gn0AAlX6xw3f3815s7pj-E+~}+(GFmN5Zb`wO#8buCx}f zO2bdh1qn*;UvLAx2xqH6Zh~=v4ZHUk4F-hAR%W(26tNww)+D8HdJZTNr(xw1r6k%B z?HEACI$=zKSng_V!+E`}tr__VxI=7nBQ3MO+wt(TlIQivU`CTs#vgleeJV{Bb3ts< zLAonS*u@uAL!%024eD&P*!W%J^q4||?jAk${k9x2Ldh{bF|+yM;>?z#Y^>F|#s8JQ z#(g%V&`eX8UDBaP@6aqR^U`?*z<@X;3IE;TXY?GlExCry!Epew0!q-=yJ+Fw9wo!! zkx|mJEP^o3;mQDc>J^Mz6}B zDPcaqSjNMUbOiov;QVMj$$C6kBAc{jMj?OLwS|2@o>@pV8#ool9Dg2$n1I3okDG;s zZ|(;i-T50e)OTy~Hi>#5&uzc5V!OPgsQa+o>tbu5q&yO9{O|N+^Kp+{nsQ7Jj;3{3 z*-&*w6)FeuKV!_tg%A5&#H2`B#=2I5q2`9BuBe*Pu#$?`wk9d7iwd8JZsOJQ4qD`v zJIb|dWa4r8$hm7VtgN_Vu@^CVvUX@>o?IyT4a#`+N@Gh10%cK@oP@%SWMd<6r^Xbx ze6s&KULBwN1JZ-IJww${NLc(zj)cuU75wgG$>x);NaOW41CR-iDL4;0gaUkjvd?qE zhD>w1JdH_)K}_6BNz5gdjXE+*ONBa_|b(z@*4^|oFCe|uGji1&;UA7 zt1V*1H3XX@=P)|DBFf{vFMgnHwtoc(;-P^(pKq)_sMc98sm!Ovz`Bqlw(d*3ETzdD z*A14uMhI3xLNkf07-S1*>nd~{?X*mYvwh&k)Ca_<*dgXpibbUW_xE2; z?e6%2SQt0ef^3j2DE^awB~C%;rvUgF%iS~>H`%!G0Q6H1J{GSfuEEBvV|ahS}NQcw@snc2+22rUowurG!eHfWjDgV6S7O%+^shfM>9@K(!+3n znY%OLF)VFl&xxHG)MsfFWiYvFi@m(fVSS?=V}o?!-}?jFaG+$$bWDN`a`NQeO_FuU z`%t@;He`Kb3ZgFyB~kwlD>;9CCQ`p)h5+glK0_xgyhl{(jF*2-tP)-P1W|EM?__f5 z!rDQ2cB%4Ru^2?iEc9e6&9aL2E8mwaRNL5{^U6W7!5td&O;NR9i=%`}5dHGoz7hQ8MK_EROK%baj@`BvlesF%XO3nrt3v9C>I*{)o2wSk>{<@%5|Kp z(93=9S%YrmWHmQ^#1jCs93oZWjV~Sunz`QbX0s4O|2i`$FXYctp zb`?iKG}vJjRN{Xdf)@;uYVIl_4DHlIO5{KGC`^ag>Om;)Fja6&z}AmPK>aIO%$KEZ zuMIj`JG{tm^NdDquDTfUOrsHBR|ZSRJFN`i+_Tja`I^y66j12#k6+^2#+e zGZk?&hno8bzt-}86XDx>NCYpkFeaK$=w=L4#qojjMRpPW(UPsJ;|+1& zU1g|J@)l{w;(Yt_@2c*;B1U=NaHfR zDs+&^5cMlCr0W$<0;^WoHx}_K2|I=;o#`InS75DWff#?s6UpCIzZf>IKngY0OKdnS zE2NgWtVPAEC|Gy{(UEgzvb2VEsySUu!6HFCg4P_0Z;4PcwC7v!z zH490FXIa#Ym{I0FA#S4;9bN=iitsppEzx1QA#oZMKMCFWk~84KO{@u#F4>0|(8j>* zafE1)H+2y`@TalkcD-TJgKdNnB_J>!J~U)^=;3;=40&U89>SL!3E&uyo~&}GFIb|Q zBP}%=NVhKyy5vtc;3NJwS#}@5=9vtFZ^cqu4*3edb;4m|=m=RDF0|U!Do?09cIDLA z>e&iP7j6024AZ|e7!g@}PuyP)><9J{MEoLM%Qa5rKvRb~NBPtYIWsX+FX7|Q+Lm*s z6C2trKgDIIuqK4p^YEVd46f|eR(W8~Z&1Jye@-TQF9u=6UFCMgx>;BYbIINJ{KDah z%{usXs@;cZzZd5!>9KjfSuMF)RevxmE!*~vgeU+WJcpqnJjPhBSZo*w z9gr0tQ>DNd@t~&nr+hxX2IuqObvDrFgKDCFSvPI@f6?_#VWKQcmyO-VZriqP+qP|U zw{6?DZQI?uZQJ(rIsZTNGWR~zQ{|VH6`3n4Dsx3FP_tGg*@Bk#ZkpkJi|^#Dg|oa? z6VzC&h`Y?Co2Eb5s>=+LzoiTA&8;$yoc_q%PlQ^iB?>wrjTm;%EDe2qW@=lM7f#BU z!|c~=-B}JbW<3l3&04rSe}63TvhVf}Px(k(=EW!?-0##Cs!7S0(v_jRzFs2QWZaxW z75-%3P7zkdItPdwH#+pY6H7C_v!B zT-3aUPkzOprbSo7TsnQuXY*MtDY?iQ941xcMwF|kp%uPOA`68L1lOonY$iovDF3dT zUP3vwoa990ZHNvqx#dY2#^)@)F7Z&#{7S$*Yblxg(7$R=IQ?@JoqBV;XP9tUW6KOZ z=nVi^x{XRY3*r;yD6;`oneJ`-kj5 z1?s^Yt-0>Yu7{41tOcDs}K@*R56a6uR7q@ znQSO)%doPw*d;HcX+M$nj3CQ}npHd{vPMO0jes9y5JjVWo>)*b zMWbS#S`Y$6ycKvh^;+yJhF>4KG&s-|bT#v?OT1I86J90o0>7SeNX0TB6u}u?dQ&FP zitAE5lRL(g)XGC3y-eHJ@M}usAv1Y(7}$U9eF+dDz(COS&h97L1xcOtN82aKoU~_a zq)NC#h=NcTyg}TWeQa;Cw(2pV68i>%s*0Uai?4BKbjJoBj(46iR#~YR^S<%td|;GJ5@uRNpv1+w^w&G3KOcS$S62KL@9KfBUiIyVbk_V-cN=` zL`~OU3LKe9H)I+46D`e-Vpq8z1Ra2E@M(i);@lak4`f@>=Ym0HlA24akG4pf5qd$F z{vn*79|g%mwu`#sbitbu7~y)&j$YJbCB*868(T9clR9vAtBDQjUnj=>V^MM_4Kl$> zwkdPiFf#Ni%{p#BseVpJE1`SzDP-Bev4s4-Tt=wSqiJ)2R* z!8J&#c?gVC8Mti~gx?0lUR0}qv*eP;01t!0%?3yLlA~=zfmW&;#$D(R;mVSZQgKJ= zoBB~U!&(_92GwCM+&K%qgl&#eTt;WU3s)9U?9vWuh*gtEpfIn_gXRV$<*0NGn}(O5 zr{Q3A@jS^F&?l{xj-Vb+!6DY>FtfK7=JM&lvu zQ1O5e)I-=Oa-j%OY(`Z@SbnHBgtegv2fcB4SH%%YR!x;*A&HlbOqEnPgA#9QcXtEy zEw+q!NDeHFL0WuuTUvbPY^ZoM>I3kBCMfhmBrohM$4vC7tt8`{fF)sTwbTRrl`y7b zJXJ-4Uq1z_A=q-y79Z9Q!5M zzTsf}+`a*0FchFBjw|T`awoOD4|(Ch$Ag%w)!9e}V+`~t)oaF@4OjYNLSi;_sShyZ zHXFSwat;?Uhs5Il;o>B!fif+k=_icv??k(5lamwJn8R{Cx-z*&yDSP-NTbC!9D#H=cwv+jN!rD~3)$;xAI} zLjJ`qC%^P^nm|MolYWft)fxh|WT$>oO175TChzC!gN$T5j#b?j7GK8Gp)Y=l3C}fx z6-6L5M*>(T2?vEvYixsuLvL)HuvXeiQ4r#|isS&{Kc=Fdh|?kIZT|-g5C<4lBZw!` znBAB{bqz$knS#}P;(YF~J4~NZe3Z$o`lvy5Givig045-j#G8QO^mBnSWV1}9Pf>VR zTyU7&^Yw{(Td)N`0N60)3Qc;bGjhdi(c-@1qwO#35XjJu=0CV0Q}$ssGj}kM6EK-- z3X40`IBBu;L8C?!`9bP54B4C&n=}@tPMR5Q7^{CP6u=_&$*;pW z%lJXOH5<8{{{a(rfR^tg8)z3{Lc*^O)^l-$#H9=(vMFLP+-!%V7gn)t6Q(-FAQZdw zN|?=-K40DXSWr6M zZiS`7hN?=qN_-B~WdS=kB>ExbJ1ZyqMkll?PiB*%z9o#wWj#MoDCQNB0AUQPf1Uc0 zURdOq3UJ6@ji{Z!79XPC4!2u+`C&>{RlBbkRI_?{pzCI}Vgdi-g)yk&=vRey*fbE~ zu`)vS|7mtvnp)Eb1cPEx8wDD{w4xGl$)r}yQAioi1M1E@pTgIJKx1z}TDSy< zFH8Pj0ImOrJ>FSaDt~Y@PW0F4lscI;osT*}X3+}pI^D9pR*O#m9+dQKF9BpYXq%hK z+6szj4RF1-)lM|u68O`%;Do65!j49PIIabc)}`D(s|C;2q1=B(Gj^GspYEu^kD{~% zce#@5Fr{YicnKTZfVM#E01njH2_S^`VDT~W%MC*qwZMBK@}bDTy>pT*dKf41K%FX+KC@q%Z2W&Uo0Ov?3qG6%}@X_^@xMn(O_q+Y=;ShCS&M3*A z++sgf7gj_Eb2-1hGf0M5LuU9~k-Ixo#d2oW<}NQwXhcGJ4JRD?YI!XQQ&0k0#u{ zy{9~8lgee}FE9+7!h_HBlp!1oh{a%QBo~;z`A&Us;XrbvtHYFGUHKgAOc!bW^?hko z_Q_K>itZ9tjh4QRrr^m@&5_lXj;M9tYm5O9Xxon(&&_7{a!ZKc8J)(Og|D}_x3OK< z3*|PDj4`hekc@dkwpvM^c58y!(Y!SQ7E)e^tOPZ~ysW~>a<(s+nxz(<6f*80uuqy} zL2`m`cHCH)-^WkCa(aqu)Z>$D*jvZQIR(a9aIs217^hbMu+USxvZN*82mOp+}?OdR*WNQcAX`1t%_ySf>v+aMrqDqZcPoyh-X8Lq3YOxhU))8=JTd9i9>JQLLf^PY2wexn5S zy~|0Y*a}X!vxvFVH?Vg2`2plu9=0dDNW1!MvQHc)sr0)m%Dw6O{u}T=onGS#sRvGj z002DwoM8VKIblY+e=B6EX*(9MAbDL&eFF~&ZZG-LgKF((4U%-Eow_h&Siej0H8%kY z5ogAHz2S(f=_M4NPImut`s3_$&8><`J`p3UY|afwLso&fp3&MYe3psaxJCSgyIsvA z)J(iqNmC!cNK}^-R?A!M{bl|-`qH(6IIp2sDr|7Q-mK0RJ^EZYJ{ZVcI83WKTv0g` zdyO?`7msYApvXc5D^de1 z85b&4=Pu}na^B8r8$1XhZzmdj4?hF%k>QnS7o(R+N2HV>akNZvyjeois>Rr9K~Vb$ zM*dIvf;$xYEkw@1UJv!EoO=0wA%)Z{)&i6>@)RM|c=EauH~<33-rtnlzmundB?zx0 zX`1GwUJHw>L`O{m3o<C1$u|xCSoq&=BDjd~o9A3t~=Ani^#;@c3qjf6`hoEe;P3 z=Oiu>E}!A=l>Nq_t%l_|f~%PhLL3=y7tr3gf~#e76Jq5Pj`4da^4GL$!pYJSLmj@y za%q?ul&k`+M8wMB%Th0(1>NP!kGlzKQK4v3WwuIL#S>S)kcRXVBaV;9%_*J!BwRkC ztwrW33HD*h3SRFH=u_+yQM|aLB$;x^>pH1yZ|f-YF_iI`Afe%(!=Ad%{WJPF=>si5 zrs(H43fIhJlg@2oX@i+AegC}`=GVDH$HsYVZI!Os-M@=?;rI&e?<>BG5RJ-A17yEcMo{`!_ z%WY50!-n55HQ|JGC6b<|=!PxC9-#cO2mTg)dwe#jp22C?VmjE@$2#4djd}(_q`hb< zVpww$fq#p|hXl(|RWDkj2;G~*xs6@IMJmb{kaZ4;8h@VQ>Si)I2_8Pwb16RVsAK`I zFhmvSqzVmrM~12T7RV`$RCw2ih*jGEm3it>rlJ%AgZTBJRrlx_$ueB}Tc-nVaNoxN zj1%G^3WXZ;bmv!*jxC#|IL$SHN&hzLck}DE2T*o^s<^f-OTmr{_;^~|U zcHD9y6}`xmv!MzOg*yo&`1FW}m?eKJmpCSHR3`c#ZyRu0bFUgx6LIJn+5P4ZmohJQ1IEv}yg`G)nJwp&-LvoB`<}Dbg7{ zSx_mo3P}!PP4ktPhn2cyvNYpw|MZwRPpGRST!Di~bw?Z-77xnC+LUEAe-Kxs>(Y)z zFD*OsXCtTr>YC}yTKhBqy?GXN7Hwq#ZyXYi%Fttoc{pjtXXjQL14}|h)JV}!tO^rq zau`v=gO_e5)MbGE9jF{%_19%@zxbeCA8A^P7TmO+)xqn~Lvl!(V2;Kyw}k;{uWBJozi&Jl(3-orKl~-mN7u;tAA+gBf6# zU>|AO+Id3e0^u9BH!v95Ulq)*>nusbuE|JvuB%+iN7=_VStf=yYXMzpt3^D{VVZ58 z6-#5!)>&F4LT~!fky#40R9FT_8D0Y1)os1?wI+VzK8xQkWh@kUy?|a$n03 z{wsxv>7Q@Fh1yS*L>44(+}dxx8|&ZI&JEP)aZsA}!GQdjOq;)RjVYE0!hpne=k>q6 zj$`AEi^Pu$F>8TN10>^)y3>hU;flxfOS+pn=C+>*kbbvB0{o@Z18ViAhe zn@oaA-K20^^RG>Lzn$#WCQfyk7s zG1H~O=M_rwQ`=Alogh*~fT(y(R;>`;c2C>_IggaWKPRzYp8$B*vfPmCX}$&&%Nlo5{h>R zKM2-SstBZ`y4Rsp@V<1BTm`~%3QP~K8Gt2tk#}I&nQnR!Z5_H1tT12INYx; zv{Br>QPAQoS%sgIoSQDjj@JJ~h6J0*o%7AHM6{{F2r3z!Dv6`yw5nKK@jX@A5(=ey zFglA2HB3f1(y#owl$({KDo6C6j&)j-1BZXu)wH6H0`Ra%1Kd+1K_`g9sz1nXlKb{( z4_pGwb+$Ie zD=;Y(M`t=K+l)LY+1YIdosih0#rX&u4>7YT{5~?@d~?uZy_q`guGr#Q(1-|0(SJ=F zv8Rgm8PVA%C-g!Hu-YfEU}z5Ip{d!cA8+Hr)f);+VbWG=FYzSMsTp+TR!K-!FTl_+ zk`>9q;Zb!Z04us`m+gM4Feh_o;4na>6KiM0Jkh%HP2$ZUcX3#?|%y3NGZ^ z4esWJ^&%s|vlj&WT2;6s5}<&dcrP928{Ov7vuGhQ0g3piD$Jn0j)TauqRw?(_7PwL)rwGe~Vd5jDN= z+>WYHqVvV?iGW+#euIDARy}R&0dh&;==+({1cc4G>iL0*W4qI#adD1x=k>M3p1{D! zT)j@r={?dG`1QelP%d29{zo6FpuI`M3~2Sempu02J{&-<4--%j^h zi7|`#(&w;jndR=!a?7SY+cnK052;FBdzsmE^|a%L3j5o4dAeB>OsjL^Bc0cWT%!-Z1!g~1<-_?)W#>-L^79fk@#JXyR}5&P&=R}EYh zJ@Uny)Ar{hzf1C^t{hK3_aft~cBH@QS8yAw)s=?2ul%%gAS}+f&S&0soID#QaslZ* zOQfFfuljGVMFMQTpMo(?a@60nn7^)+LiXGhO*(WN6d^4KWVa*sUW_viPE8H=v9>S) zh`rlr!$te?w%`S7FEF{5|I)e|o2FbPlyvGKzxLE?d!@RXa+@;UY}l(pf2weanm^f< z*7>hzL_!Q$#|d(LTwpQQ+v-&x1bum%Xa&pI?m?Rf#u|SAAtcE(ptQ~@Z)dwp!kP}d zwPTOLchch`0gcGxY##+KP=fvN&I)l=hXt2%-(fwb|I}yanl>bG|7fL&jUV^h=B=8D zyzjN`Gc+OFho!|F?5j4|dJI-HR&SC`^chnz)C{m`#Vbo#&!~61+OaZ>Q92G3f*c9q za^mc(H^d5}M%RV&cV7;oTQNu8scG5jZ9DZLmSUHm3=O8CswgcEFOOL~h+k2dBJT47 z3ccia0SHwy@Dkv@jvkRyt zX;KC7Moib)=6-uY`E*JcqGMEEMK; z%~w~FBTrH#K}wY~6R-r7pDSa*1Z4+43?B_NfZg3;A;Ojr*Hpp7m);&@qU*K*XE5AS zMxa99iNx#}4Fp1j1Q8nGP`0DS8?rPMh=UlyN}q=29e{2RJ{aseG8KU3=U_)$~@-j@}XLNN+g0740+i;|-8nXB$>|{Z46uEv!jUL5_IhUE|0O)*E&dp&l z1M{~O+y`IR;Yi*^aEj29hl?ca{JaWhiX|K$dub`+Z><`wNh~Y<0ClDfJp_MTi3Z7B zW}OjJOh@ExI#LaPO<{_Q#CF9Qv#C=~g_f}` zGw`Oli^!QfnAK4u7^NJB7Gar`+lw_Vm+puKqvJE4X7wqD#3@G`N~xB^G$OSZQs%Gn zxe6NOq5!F`)uQkP4AmrvO0_5 zd~1>z2bD!M5GU&>d=*N|4^52wgP>3)q9JD>Pa!CNu%J-Y>(P&3X$BGo8LUH3qs^U{ zxS&vSWWjItDqR!})S2w-^#MVlNJynQQ_~|y{M){+*UALXSZ4sb5T*<5L|y$Pjch3tjHzmd5A;*=#YY6%EaEth7M6b z;V_sv`Bdh=q0G$6Ozppc6TZIOT`-T{N;V**4l<=h9ZSWIj3v7-=V@EBR?bctFZj+AD6|h=p5*?i`E}ZH@GczqKf!tB#A`?c?Wn^ozxRAbb5VIKmaB#|1&PVkK2Q6{s<=m?SHuPB70Sp(_)=3#Ji$w~HzxR`ZDsAzO3rIjP_H`1I3 zfFm)k$6JWyLDcM?+A3@h9vV`qx0QQ)eZ4)&nUSj4uo`aO`dzd3Kl8+?j3~9c{?790 zMK{=RYpWj-G0r<8qHhieI)Yf;Sqls^GBHyt-TSj54y!a^tK9w+7SV70X(j!%1u@l0|AW-zWp6#(td&SIg>LD!DZWj8Jwxm}e+C z$8aq|oaWekOQt8T50tYl8pj=*uhx*wz87%#NS*X$3Yy=IhRA;rvuA&|OX1cl{#h%c zy$1y0F<#eh&M|~}yFM=2_tIeSr!P>;ym>RZn$(iGIn1#?wiOuXf3 zLibc9+mHP7_9)8%hU>Of!ZB^-7R7S|YmQpP6Z&$km@{_(>Ac}5t0`UvJ3Ys#Z0Zrk zv0`1g6o1yMc&(ImyMC5S@n}9pzKH*9rGRVNj0dj^6>Qn+B=}~-T!tR=opK9DA4ld;#Zx6GGaGsyU3(6GxLpA;xL6}6amJL+qt*h?-JKvN|ave+j+AAm~>jzmOU4prk zMsJP+Kf$6G;`iv3-j#V|_tr>R?46F8@$zn9?1%sWaYa=Vw{7Vh=a~-ntsKLCc54gS z3HRoU^lCRx#S51Y*|YTRlbMc;?ta_1OLVu5*1>`Y(N!FSQ$q(22?xj;wHdLk(5;jh zY=xeLn$$aHDk}(!d3OQj`2hwKw+(HQ88?A#JCu%$*qS5T?;k?Z|1aAh7BL=R`?Dbp zDgNJMZMJ`6?Y~;mj_Yg)UABu~U`eo^n36<~`sSBX>IB5~7N!);X`9@X4A_<%)X#}0L5%+S`K1Xyj)BeFu5Io{+;i)_xjuKU6nH(XKvduHo>1d?i(sG9s42g zUp+qBpLXllS+p7Z`zE^B6YpOscN^cgQ`_Gz&t>Jj**Oz;^8tbTuif8&+A@y<`rO~O za9EBr&XjQE@01opra*j_a6yk1wQX>Oi+*U@ze5uG^cy&ziUQp?g+(488rPG}o4nW) zMCIV>jRL4g63Oub)qz zkIfoa>#c4>NWW^=mloSR+Bf(%_$bbv-C0s$@J^>T_hGs58lKPYPP@P1rXuDldEFdI zp&xRzUr((*w>WuKbCw>jZgo2hAuJ6uze>voIxbCgzob~U3?G8|%(b>u7ex`|xDen8 zz_KTk&{A5Quj~G-bzaa;SbT49?jOE(^LB)Z42W}GInL28mUM1-xpn6Ty_j&2_^n&~ zzP$0dt}So}cC_Y+$jK>8Bx+9+8Bhn}IGRCa*rhI>e>(hA23uYvCLYgVKupMwTNqhJ zN{}t1X&jjd{qaXxgu#3n7&4-JrzGC~z2q^K41M-VnY;QCL<5rh=3W_n`Hex5;U>X& z@?)Cl5;Tmi;^0IkUei#WQFiiWUMWFQP^#6*akaCpqC%Ft(t0xP-dr%7AYBlbK1*+v zKDj@695>W%J0=g>WDWi1+E!$Lb#uoRp2-EIWC=l{7_p9})Zj``7}&xI zy<+65UcIq=-GlhtMiEBe87Pg2ACu0G*Bpz zIN4>GeoS+9nDah`j`GYgWSOkI6!EXU(4Co(lK_%}?I0CVb!Fkud$b!XlAgz(;vvp+=gjl*^I zP3*(c3DiWS7B9NXpEMn@3W5eH@pV9Ijv9Vs_QNj56!G^l*f7hNLv7?oCQuO4v8rh% zB?Cgwo%*)1-AP^INUQ5l{)7vaPX6&oQ&#hC7Rj-h*I8<1`u5w5OMNdZ$PIcZjF5(= z%9WgT4g-5AKV6vgU$RI^k`K1jSH%XgS<_mVKtT{Y1kBMJQ44>Eu)*0)s0O z_iLByQOTN2HhFStvx9yg7Li0)4d+c{!nOjpXq zwPGY#25U7`*^6hB&JdesZNmF1P(jir2EQ^ElI|#3Rjr?ELk)~3gsfT)-c;lQ)5fD{ zfYmU18KThLDSxhWfMl?rG(Jt>MHq};<7k$$N2!N}G1K*0mg(k9 z%c12bie^l3EZ)Z|*Pce=P}hh^{nr_^#SKV>wMDYb%7hJZlgO#Er3Y~~?As`{ ztwh`A2Icjth}Tb}L?@^*DCNkkBHO?#Pt(Y?VbNra=c3>ase*)w#HA;qL^;qCUsXs| zEb7!QrSz>>X*(7Vn|E!po|ZN0tyxo&G^uQQ|} zU@zArQZ}hox)#?iUy`iHn7)*uUYqR^Ia*3OK~cAuRr2T6+LIZ`DPX4BF)U-R!9wx5WsE~06_#c~%d%I*6kzLyCtbxSQ^`NCd$Gb0G?d!tq=eW;%C3S<;cB@1 zCgESmttM~KD zNGL%c+KkjCD>zZRz&%H!u{Zzg$c8GL&Hxj@ zYJF;>&{G#0Sh3CRUTKuFX8WZnN(aVUb%olG?^293Y>UcKP}67~d(Y|`?|Ix%8EGPp zQE4Jj!yIp3lkGz1NCI78jx-?;brf>U2vD*@cX*F@j&&D%K0voamGPPCeITTK}Fp)&{1A@*qTa z!Pfs6A|a@sgw5yI(hAIQqK*&c`?wPKFeJm1bIT&sT)w5Q&-3QLXtgP>Ri&m{EChtr zZ0+Lu&7@9d*AmXwD86JgNRVAEJOej)W8ysi{eC0v7czM(MQ( zZ#~W~kZZ%^YoN1~elKF8$i-R%{+4LV*EfcgfNoTn{mW;GJO1OE<(w!5>P{vv;73EYL7dK|7YyBX%(iuL+VgWQu6(7Md5&X&DyJ`PbRt zGnyB_{i!F_t50FaQv1=lGGaKE7&Tf;iY;rRGd~Wm=(j!bduWlEba=1>W%$4AC@u8_ zCgfgKpg8uBYdf8-&Mr@EN|7IHkZr_&^9QjDI9ZFm?i7ZUQw=kX1lRIbtQt0Rtw93% z`@`(Fqi5cZpPZZ_G~PNkpl0h8q|w&^MCOsW=}6L9^lBv9|2SAuMi61bhDw!4=4dG3 z;v{R4%f^lP;VP6$u^;i6Jg3cZvGx^tlNV`Djs;u%1A^*lII~db~9vj+eX?j*QGBd1t9OI4T$J&>%MW3lB=D0CWp_!(KNy$vceUJu> zgkG=2x{E;xYLsVYC_PFj#`HGp>L1r0F=UMbi7Dy2pmq4=eL#7siT93x3FB_CX%(a} zYs(N0G9)79Pc}PF7MnJ&a?vya>mMV1KC2^0=$b{o)WqFgoVJ0#m^z02V}Hb-3drJW zOjAthmXk~xbW7Cw{1(O>%0M{ry;^@^%-QKR}irMXIVBIWE71fNH?v z-Utjbzw|)T_|2=2&dg|P&Fdd`!<=7`;7=o@EpPmqF??b`^eAf0 zF~+8GBj3IvsDHTSNn=2V|5ypehu)%i(x@5jIcLBoM}}8ddygpeYG=jN81dOmizy^y z=LVUB&aJKyikz9~%Dos*LX1qS{dkK~k+{{<_WxQE;pT~uG|6U67*A$%K4h<%)2u_w zLfN4n2O3DaT5rSVagG7mLZ_uqliFiz)bJ#(P}_N4it&r#2f{s*KM*cdPv>qkS&A~v zTTc&K1*^kgj6#9TU@G3NKrKDhk3&>Ah0vMpy~EC0Mh%mS#8|Ela-+gpFX9l{fep)WW?=BU}sFmsiv}j*;mrt2E{Q6R8U)o+`@hF z82M%c!w5=D5w)apt#s|ehq@I()E!#vyeXu1POY*4X23f^AgK?~b;bU0CvfbDRE$>k)SOjv9YmK-7U` zLr^gVi6iFhWYimUO@k05tUu#H3gZx;B~{4A0*FD7z?;6|WRHG>i*{3SWn?Ve6ZiZ= zOxIob8!Z1R1Xzvqu8gw>J_Wvft<<;pn+cJk?=zBJn+#kmLgXH7gX%%j&eka#L=s1D z8mzF^kAp0aXq~o?1_&D_iK}<^cORga*xoDf^wS@6wze$OK7=1NuuXx_K4!i|@aMx7 zm{(#asHOnL8g^@6FPIxN2oz-XT1uGqxiF(rSSE0p01y*>I|KvRU^^}N>;-Mzo+xCA z6M<^oJG%7!&1L}D`w)**{pn!44b}98Awu1GNMa|>QCf99z*#}d9-|-xkNS(0omwB6 zk|*!6pL>nb@qR2kI=J3n4ix8~S1)s4+FdZxKdB|Ju+!xuEz`B_aNPtuH_Xa zUXSh#o7h2D8jjaR=qC}hM)sVj*CS}j+>is9uMS0o zu71pvHvZ`va>AC}onf(_zt+MNUhDN~+r#yhp;&{7yR2M(srzbE8aZRV%%nJhnkx+^ zkCY?t4@>b0zhoL4n#`T3FY1(mAd|~v49BLdH33Oi*&IKVXOtQI?tB{u>Snf6?6zV( zo`CUE$4BfL4sbmz-r}LH*e|MndauXH1hKnce|^{&F#>#6b9j&j9s3wLvU@wu|ET3e z85y~||C9sZy=;!@DDnJ2^!fU5aMN9ir%R3uA>>K6`xYb`{}FJ#ygIbwjr+}&Meg^$ z=V;Hm`~dbeOA>pvSQYS!R~>rF;WVbW{Q70(o7QeKskGMRHS#G=R~*GGBum@9{}oBM zjS-QNIrqGQJJ}Mvo@dx_-NO5Os(a<@Z5f09=1wc?=04(=y>!b6vU=7T$02{*? zhjDfb%zf1SKJUX^aey$}^ZgEDJ!@CmeNw% zUo#QW?6bRl=bW@A^v`gMy~Lku!0fBC{$lBma6Tc7E=pQjQmdVv&h5*u-WDaZbI}~{ zzG+m49GAz}I~1K8kT>JDb*CQ!k#gOZ;>mt7zJcF5eV~88O{eH(j3#c>&R7xrb*VJ;_@0 zBl~Vzx~TDMtWNk8)P?F81>Gr?-4)*LUR(AFQYzbMxmuU6VyOFiY3$R~0kQ%fXd~R@eV`Ag+wr6_wH=98p za!>5qdfzqf={Y`-zlmw{8RtF2#qHT}^pOC5E*bm`t9qo+b|dWdO)2trxV&z|&B}>p zcrGF2;{Wa(`G$_UDWIKhLN(wV@qD3Vk12@su{#Uuqk}kE2xI--ulaTB%fn{CJG0UA zb^onG%bkCC+LOk4axWVttCPrk`dcCgF1TC{D)%vC>t!xw9nK6&gdYu5{*?M^jH|os z^~|gG265)Ap+fI~_^D=V=7X%eE$e;tqB_W@qs;x$9BtX_kp*qh#~tU$^^fP7Y$t6U z2;fV6-#~{%SR~-{B3R-P?h;x?*{NPh@ZBz_DV;dhTgjR?g#o7wkD1b3)r%P=<&3C{p&2$ zUNIgLOqBVyJR&Axhukw|URY)9w7oaov;9LwU}rgLe4Z`gUWKZYXnB6^&_H2s@zQ+2 z`!)bO^m`i`0+i@596Y2X`?ZD^xSd4VO()e%F{bsS>?s}L7$#YexL&>->jpFrLkGXS9+atQBZ@Rj)-f_5O$-oX&z1WE`_sue^q zVQ>84Lj&*{4g)55w*8<#fJbBs=4!`P7RXnUE8^XzuFbZ8Bg$>|t43`46IWmOu*KZ^ z#!Keg;$NfK)Y-3kg!3FNSq`H&u`$7h2;|62#ggv{r3W4Ql?-tqjjRt%6V9qJ~6(Hoy^;MBLXpI%*$wlNAfL?Mq^QWC*TnqMRMZ2qT|h5?t7Q>kUX(uF!v9lZxsY&WCm zZ!+0$hNKZ$^qW?64BO(4c))HLptY?wr<^N2;ip(^1+xb_k;n*X6{HV5;dh33t>JZj zGR!*(0UT+b$Monsuz6vwko9m@0C}MjE2r{Y#Nom6YcscJwS$mg1%p!`tew^oU4J!ju5jt?w#5reKDm=2Ef)Xxe}b|#&1zb?QxqPy_sJLC_N+in_%#6M!#$)dSh zh`UE;^?U;92x99$hRh>yVs@X%6}PTe1Yx=2RgdAkPayCYkM`IPHAG*Zukq2wb3UOj zuj%ee*nBNu`r8r6ET#QXihcA&LLt)BX`wGN=U^ z6F~z~kt6v7up_#-eU!cqp^JIxOgrLe2w<)Lx(1etUklWM!&rk^Z&iFDPSrwlHk>o) zFrrgeXH+}Da)L>f6grV}cvUoT?3vJhALfCY7CwDjuCHuLaZ;<8kVdb3vw~2^g+a^UBg>qKg<(Fzb7%zqw(Bsv`JtkaVIX6-lM8tdD$anwg6 zT^AHwaMi0t(CV9AVtHAkSEoBRo-bvHSAR6*qYiHolP z1-{#}R^V;+O=!c-{AQc_N*=&(!gw-Q`+RUZ5>~A6dF($%FK2)>)ly%Jb6RI!I=y7_ zis=D}KrNfkPSfWGy9$DVq@Qv?R3BeRPAo$MtGcVa-p1VMh|vHm?N-pU#r% zZ$M0He|@fFAWxh-bHu%!l?kmLYuYQ+r+4^2KD@HdT0bweDMIgIO&Oro# zhcLU%l-U6TpT{DRY^}bLurjPA*uhM)SKS&GMfgz38&tbq*7>K$D}mPfljh%E<7MGV zB)@Vy^@x{^j(sw=27)b$AT-eR4bb}~a{y30n3w0b)kbF0RcnL?%%S-35$9L#mkd@{ zk)lqXfWT({iN(l0YT!ni$4VbNXO_t)`~?in+hOH;F;(7ys9ah>@=6M=q+vEaA-gUu zj%I`d%c5N*`7&*^!@%7nJj)9-yK{rsbySXI&$zbhEk|-ZS!8h}(rHUD*CBTGS}6!3 z;bdI*XPlVMh|K3w=Nq?Vy<2z@Ot+AiBEL6KgXXw2rJRvCxe|Q%xg8a&&_3P#VZ+G668H*XnnQ83qg;t6 z%WS>DEkE4q*coUZ=Lv+ipVBq+AZY;B?W=m{jy`BmKzK#a&Sc#wZz>gEgynVyXx9;G zVxC!^`om`?K-Z*82m*!&vi$y#E!+(verO zqTe(Z@RdvqP6~Fl3jjl$6wh>FU_t86W4wb9Q;@&%hye6qkUH`O#WnsIt2*>PG|g8yAC%(d5RHL)lNae9_QbswDrQ=6}a+) z)H9S>F^h{C;2+Ixd1E+^0xr%-Qp7X+1j5#4AD6fFSNFGr-d8Rt5yp9evUvR8^J(|& z;3FZcmq2fp6bAN)jVuE0I?!29j27nhZ2Nx#gOqY3LF#`IOa%<}m|i6}wSVznQg7A^ z=sBbGjwzSso4)-y%fw={h0Rn%S^8)jpKXab;7C?9e-uWwO5iHV)Tn8NCLF#zk*5G7 z@X8-7_m80T!(qNJWwG?U=ARftTmse49{3Q9sE)rCeXnQSQM8p&U;SGHF!_M{;lp>E z@+7k&lh>xzQX|DJ_E%;qXwoVED5A}d6WkMpRvC>5y43{OFJOGlx?(s9WHO35Ip@k; z7AwZ%`nieyy^VfcbQ3#iW_@k`G~3w>#K2OSz(?~lJudKh@RjX8K4_r)@UxC8j>NyQ zHuvbuhx3+^qzYD{nuxsimBJ=(1s6Y-m-Ew)G3Pn+H&6R0dYMk%RNSDP{{I0~K&!v4 zWG>-hIrm?4`0ZHgYX(uEb^FufC(h4F{29szyjzsF1MLS|%P0L3iRXfu(!35DoU6s7 zvv0KBo%<4>47Eqm9we8}&HwsOK<8#fDXZ48fa2j*T8f4ac zDTwmzKhjM@52_Tj9xMOYb36#_T(}|tLlHl^D`{0qt+ld!r_Md_*ng!Pq;`&2}*&cv6i;(5Z$uGusc=&2VkhS2K-wb4z-G;(X z>yB!LM@#*J&GEr-7_X=A1dS4;f3iFxAt>8j!1xLNYyR zRy2PX+HsXy@;kgeOu3?jdsMhz6}`v~L)M8KUO=8lKVp&Y`#r1%nXH8byT;;tM8_67 zdFO;2plDYw3WcndAa1d-3+t-LsoWHQ_LV-e-VN0Fh1}c2T8yY$Baf=AxA0EcoZ4W| z%rW($-&j8W(t`<6Y@vzu3bN9^jZM4U@85oN<81l*$;R)tBgwIM1~X4|^$YmT^wnf~ zWU;koomEOVuyXPZ6tiZ!;lW$AR)ONtL_>Wc&#D0s>k9zQrxje)UU4R?L1`n+QlPmA zRfA_`600HV3U1ambW)Fp`LbYSGki1mE%|E3!DNC_6JXC6u)u@nS-WHi|-29;16 z#hYxwRiZi=Ix`Oq4I?Cn-uf9hupgmC>;&F(^pS+)*}J143l(N~5n4;m=RU^9AT(yw zZlMm6TFxGTv4>&&nK_x}UX-I*Xa6 zMm3KKLUIld)0u^GLUI!hYc8xE-m@D-4yX%h)j`GMsTB&U$hMXk@Lf4@Rh*i7MRPx; z%YvJk(So#+%VEJHZ27~{6RHA?(Kb8b2EAxtoPso!M^6zp$_i1?M;^?ox!-5zK1c8U zbhV9hLVVI}7Fu?8Np`#5QP|0nN1ul!t<`cS03vg%!-)ts;VUq~Gdu#Ts$n(oHmy*r zHVNN#kQ;?}*Hd-taC~>bckA7!Y&r@$8H_2>1;<`Bd#mt6iVn*4w|<4yPzP5WiKDqF7y+Pse%WM{sH?dNqvq|5D_Qkl+QYm3a^y zVfIVKJ#+u-GQSdW68)>cFaCQ>Oa!F`;~<~Es=T#jz*~p=9qJJBumi}Q4S+t%hb+^2<7jUkcsp5s zz$|9?=wG!c4eSfGeipyyD1yXrBbqOUq)>ez1~;-XpEC>B=&nJOMH`0+9z>rgTT3vj zdR5cTPS2IDQrw#T=~7xWdRwC=0M$gSkw1;*rjU(*L>F#4S8U!+aRJ70+sH6zIfz)n zC~Z-cJ;1B_7IU(gXOjGOA9Q#QwOVLR7^Kzdxy^rpCgvy+B1c8JAfF-axYyryKi<9) z9L9w);F5B7SKzHHPw4LMT1zBw$#l2HLqvbBa~gilE3=E&<<3X%=|(9}BXf=BdUr3! z4(?vy@D%++O%BMe*_6_5;d>0e4yw;D5ddK$@@V)qmHC9XJ?Db=up^g0g#-{@Dc1rm z@&pb4$+?eeEKv&NJagvLqhFs`e5slH#vglVK36SIU>gM#YeoFl_8PeT16{~tT={cw z|C`t{|DA!YZyo;Zz7@vvDwAShb$97?QM-Y&3ykgK|TWp@Jq3 z8N1G?a#h~+9zS|xS#xD{xvGIC4HueXA_EzQ7@1~9pQxNtMYHvAQ zz8MFlt0B`Qi+8I0E2>*ZGKI+P={bcJWeO#0MO^-6WxdM%HQuY#iB?Y3j{L`u9zW8F zO>&`?PZ-^v-;_f6n@T{{ZKX>>%H$CDh(R;alTYDh+BGkrml}AbA|E5mNu=%v(J0KB z2g0bM|LZ^fcha8!`cMDkNtbd|o?Ppk+)g%INmAKPrYKKPp%ymr{1)9*wDc@02_3%`N5nsey~n9!UA-rb%2*CHl6;p|wNAFj=}dy1A(ZB@_sT4(6)R#Il^wANQh z+)mQ9&FWdHU@#vK)cG;oy9uTdR15<8PLDpYFrCcZJKTfvkHH{pxI#AbjH+>Adx=C_ zXc-Y4ONq~NWTP=RA1PZgU7+U|{6=`fa~3fao6Jk5$iO8p6COys#VzN6^fZ%^hFBBB z6_k|;oAd*F8flYg5){xoI0#|`($|2K#5DT~zuN$>Yts<7vou(9Xww4(Duuy^vFlTi zf{-{e69CDAlSd{I4ux@n;U=u&CcTAf0rwU&>UcsjD25Ts@V0unH-N8=OVE}5sWik!Js`S+{ zE=v%#e8{dQ@XCc+*^ISggk}CYSLpM>ss%0F{d?Nz0qb{6Qh%ZI4E4ENT*eWXqAtpt!VqH7LtF7Y*bk%K z5-aFwg%C+;qpOFPDipGTi=a!P+Yc{&tk8Us*;D;pAz)-BA>tHf1Zo+=snifYq(Gh{ zLyTH_zTP{5ec)^)LOe|8{!d^ndvJm%*&<9oZRaXNi-vkZym3 zx>DX{mb%!EK2Zi6(X>;Z~-;-H~W=5UF?SQ>Nf6ODsIB*Ed&FqqCV zWDue+#L%a5Ub3*6nmu7gv##TPf+&0!jJcfI*@?bzmX2U9q028kxCnb&8i1~>`no4q zr>D-~`HusgO;dD{c8~>i5w}0K_M!(n6wa*#;d7b#Lb{8{6j~W!_8UhnvZ)dFIL!O73$uAVhVHZnr4kw zsk&u+k@l5R@KE)lA)kRjVgiJy5vOMW{Adjr1&sw!ruRag9{aruPX49tF&FTbD$^tHs0XovcovEQO2m(9f>u;XeOXmxh zx=xw^gViT{;4A_Z!g{<13*!rDX5yho2=!!o?;d@0%pi6d z6-!)|jzr3{HgB1`I`hc9FD$p%E$PuVsfekpK zA3y3qTe)np3W}y9mkXh!mbDgsta{lfM%_Tc6YN&JL{7GdrZXZUS38Zd2@P+b0 zKN!UeDp8Df7s#^&&C@WaaK1ed$sLGsD=b1lj*rBM5*TS#MdZGl!#Mi(z`pP?J@*@g z8%5S}=FwQ3?a_${9MzHp6@nw`bc0Sx>jK%Npsp64x85S-S=Z}=vwm?{9gnIgCB*54 zQ<>yT17_a}&MKPFcHyzBSeGb~NNu*V^oy?0>GLw5qqG(3QN&&@((T|Kq9L-FHN_jm zMsT0Qv3>-HDQR8Cv_(qO`qj^nk861c)3l2HZh0#nt#m2w%7?#UPU9CZ@(;DD%V}8Z zpBWk&ANG%nAClDjhA_r~2heKow1KLg-Vq7bs5*9p8uz6AZgiD-L4*NnTd*l^&}i$1 zTJ`;I9m=DeJiWyhW|E(+&@t=7$7+se$K>PQVI-`)Gy8S?jtSA|Q)4i~21mKR^76E2 zX-<*3zumxp3(p8l2K$`#U*WMZd?yC@4ON@7pbxG0kNuHqpeOzO- zwtR7Fd-1e>qt1HH#PiXU#z>zi3jUqiy(Rx=0~r$NGKowk8lMw*ev4@m?mp`P;k+^X zLIjpk!ytH+Qt9hW7oef0vHs@@*92Ll62nBNSwK}_A9e^&!&t(&t02A&M!OH>d6*ke-sKN&?mubqxZltG z2)!7{;d>kEq~h%#{qh`#*mvWg#0pOM8Y|s?jasemvoCQ)RcWwT$H9$gb6f7Hzk1zY zRrg#gpTISWU8&Z!BH&hLeRk9=)j$j3lM?#wX{l8x9Xu%14IVgVmr2HTRTE01sfZFI zl!{J`ONu=wNvyE8H1!QX*{gNM0G%+sYl_Yb$fO}D=`CosAwr#K$RL`UD0CP2KXr&v z-^d%(@q6QReC#ND zU}S~VLxYiR`tDd{@LFf?eiwX~F+j6qdl%U&;>2+Z<|{_?NV_0&FID=9{0xkjK3=aW zc{BfhtyQe7lL~1!42d*?$6{|Xq+IFD(skik-wSLHLaR1yruV(MYH8=Z?^8b?#~A$v zO~Hx)DXW_=SR52)Y6UIr$UQ+jNgtCp5IpdcmZ7(!t2n%F6MHI7lHKN}^k5Y=H0CXa zInBv$g52pVp;R zAomJ_#yHLI>jyJZMRQq44;5Y8iTGXBGuzXQjC znq*9G;GZs-0<(zx97+sQ2-we4=mmwLm7N?`3MxXpzWoDpzk?g5ki!lLby!~U6O3gU z;{XGz#>GM}`5XQl+c*3-FD$>|5DaR+u|dFbR{srQvkV(w#|9gJ+cN~% zy^x~p^6%<9`n~71Sds6SZ;^jj-$Gczk=wxkq4xD0fqf1n95J2)1!hWpuPaGJrXr&Z z8OFRDxx=1TUHz-S&3^fu_3MdRsV1t&7&`(3U~;`l~cRYm>!FNR%v~K|W=p)oPM9T%$xz z9jJum;ka0Mm@@6N9XYNYNG7#Tot7k1Fl!pieET(jZg@-OI+8TG6l-)7u8?0amO%no z*6>aHXhg|!54^}ZyBYc6*Z+e)i4a6-j+Qet-Gh42UI+eX=DLsMbN~`eqzgsP30l1j zy$ruwj3<`gA`b;Fq-ctX3$X*a69!*sa7O4%@(7X#Vu<7zr9PPJ^Zxu7)JGB z+y8?86(F-4iXxI*rinM_fBEVD1EJ1HgNLh3xh2*3qXt*5(AXrum`;PX> zzltdv1*J_>g0@5m<14Feh;SV4Yi7LA- zuTh*$$@I)+4P!n@+lN1)t&f+~PNwEt#tu5k8G4wAYD7@fyiao?YU{Znope4bX1l44 zv4|1<510+zrCZGClC5z0<)fKXS%A!No_@{v4?bX>riN%GZ)*@sC`3nLiifh$Pd=KV z0VtcDs@hKBQcnVk92f;1R6MEKY7aN>_V&hXiOTbV>aY zJ8I!oL$f)Q4JppTfmbt^j@e}7f|MKNlH)|)tBGo^lad4FE51B)TRnK|vClGOS z3M&yIu)|gDg;}M*`_m8fb54&$Qxqa$G;VO4s_7|q9S1vOm~zd2yl5^0QnOd1j8 z_lnwx(p!zU&|9fTiLp@6IpM__yzz+95}VD3V@p7G8^0*ucnIyn?lgRg&6xaCNk(}D zrUKW}F;F|Xd+gCB3Y`6{kx*6`Td#Kez*K9T7Y|JJzTqonrpg)D=GoQ*EjJyA(*c8d z$5kebDUhR-xGW+2hPBU-y~d@+R(=rm3A{%sl%^ULU}f>|cF=OaMFcpcZ7B||MHJ+l zLMIx#3!Mb!HMw!A#6#abWywixq9VywMy6fBa0Of)zM35ePqMY-@XdiEst!rxC}qSI z`_Yr?H1wk{X5pEp9=;OO!RSFB{s~l{LYs%EU)ZbGn7#u1vI-3Itr-6R%v(TqXyjN0 zg=;AT?t>|X=*D+#O4Zie8pJY&(sl4$RIb@uoJ=}!Cd>A#%1zInx7J3(+ z*MpdGar{Y8&lxn!kScD=jKS%&{K>ebMHbkB1dvAJ5)8SEg1R!t>^pe`HzpjB#+38H(lJa18CXo0_1L1SoH`+wj3F2_r4~-sE{;UZ)C`2O zipil5b9{^&5y6>5%-+h>*GpD&f1z|!)MnxYJkddfE|-yQD(_hHR9*Xad2yt33iW{1 zOR{O(w7r_4(sV@YZqoDbOh0OUi(-^Co2i}B2pjliNbxB|t2cF~cC_Q5DGgE|ww;_- zM}RL%3JLfuPB$0f)wo<`V)s z!$biQtsgWfxwD``wuvy}}#p_rjGTi&>n#c*vVu35A71`0@ zd{1r*b$UyP;(N!Tt%q%@mHlp9n|8dqr-&s*z9?2Q+V5Faif4Ne?(2Jui*=HPm5?0v z$;TqA%QcJZP?b-~w>EaK-+QfFK*~A!2c(CKyB^5#LJ|9&nljmeb76Hi+vaOvg;RZDJ+=_ugrVxYqm>E zojQ`#xhOnk?%*Z=R1y$A`LX!Pw}MOiaeXWbHsL8MI^+H1Hk)Cj{Vf_dlqBH>0ylOz zTkSREzKf8!Q`!pV%f)l&uD#mm>aK?<#-epc7RLCTAcVLQBbr@1D z0dplih{itVW24rhrR3GSS!!d!?Czu77_6RZu4@~GYpYQ1wq>^WeVTd_S!=m>?H9U} ziHdrX7P$@4=^;m|5Io^>>LmOUU}+SQS|H>q9Z#p8y6F-Do2o$={7q%4wh43pIm#C? z&s^?QjMs!iQ4Hl&^Ei2iRrX^ER_y8jKPkIi5*QhoA z%n*rY8uoF2+fy%7oYAD;ser*qK$k+J_!5q*V}P&LFK=*dPH?8fL)|k-K!} zB@3Oc%9RWeKbFssm}cp#f|ZHzFh!4fChOS^6cW@Fuv}DsjNWrB(-kcx5#K}i4r&vM z&Kz;n>L+6n$WyoL2ZYR$)Q2SJoyytTQ$pezjDdfq9!->Aq4`)xKLN&gP&CvSeZ4uPtdcxE-4rV zH##p^C+IR+#n~-Fvx_*PV^V%7(8~~`H4!QrJadq}9*uGo+u+RgB{QrTs><}fpdIks zKlH8x@+x|j^78)iq3E}#jh$lMs#;xp!Km1VhlufS6C5`0!;U{tb;5d#vG5#kssy3{ zz!cw#REet*GT`{ui?g{pH_)!-Tu%8Fq%xm2ShFXR+9L95n$^u!%LC`0(Gd)ir@E3* zF55s~SX;|>b!LG&a)Qgw%7_^(s0s?FRpJyp6{xMAc?KDor$>$9%X&na6vFqbJV0DTa4b$q7xX z70L{GQ_vrr=L^PYzLIGDMcia54l);YJs1D=Ndfs;Co9q4Xag-ndiK0c! zIpdCN6yu?R)%ae}a}8w<90OVupic-T!h|b_MKcYumUkgQJS?;#u{h ze)$rBOCJg8D7TflKO71Es6V2ifK}Sa+~eNy3w(b3qKH9uw@zosD1@<%f}{Xqyjvt` z7q~(a1L{0a;RYIEm|bAcL)h4{Ss_5XrNo!j%lSeHj2uU46x8Y)MBe;4VaO_DE6jkDVzF-kv|1tUZdCmY6C|6 zvGk`vl#k%>qYZ4-Um!CgL3%{pF!gPo!o9$`10iILGg^*c8g95X@+sWY1EC}VfFfUS z!^T?&vXg^4Rk|-SsJ4bPbzO@XW1T980je;=YQa{^H?ISpVQ!8w50fczEsOgS);Z-f z6{0j87<8~Ew`yrIJ0~cnsCTmI`!ew*t!!!EFyic~tBUTsJs{{Cm6bO@i#6m?m+?xf z`U}>|nfhAuzTSOj7Uu~E)>QTRbJPr)KQ~~{mGb%Mg}k{o?*LtW&CB}E)UYxcEY$n@ zz8>T9*#SbTNSc9CDHo=lRF~y%7Hz57)AAGB)8-b;ciZ}P>vai|>dLZjxQ0`HVq2L* zW$sFTQhmC;@ zE*Uzd+ewcfcOA@kFDoynCLZ~T4SD>eo*KxOpV*$}Z!)ih{KWQjUoLDz?mn%v2#~e{ z3p#}F#rYdSZMvT0Nlh#HWq)hyh`&$W<}u3yHPCulI;v7(4XthK>0i9N=1sRBr93R+ zPqP0$tP-D>`e#Q6$+N^bO<&5%+sZS*` zxasiNa5wnTs2?mfb45-g`2Y)!I>TL6&qt&NR-@$&SoU;H-{Z`s*)X+jk;!Q(S>?WH z4NW5TiB|jUs%5|U);rWy`<0XWkJd)GO2G8Z5-Muna43HxMY8-G7+dNc@_G4tjtY`a z<=?yfD-EuGw73%Jh&$c+$HY5?_1P&^i;#gy)eJHnn%D|hPY<+zs=x*8XMAstTa!?# zeThprlF?3GMxEfmri;(nD(279O{RXYXgCj7B%~5Z~z@OPYaHOjOB`u>(r+C8nZfR_0>o0VdoQIUCat-HR9 zAo||LNlddxDSKCUfJeJFMf3%}i|#fwaYg1S(S;Cd9G!iqs+?BYOb9pDY2)bLocSg< z^o~MyB%TDqRaEo<)EtSOYhk8Ko2;=mL%q?&DH4Yc2Ab|Y!KZP}$tsW1Y_$3XHxOfFMwk9Vanp-)INYh@*@(1J#OfH_*a z=HS4Y8)@sz8Krc0xD8V_M~J3>6`+YqE$e6&3Ug1^3s3gy6fsIv;|}2lgzF2Y9*Xm+ zsGd0;(OfZ!;nb$0U6$8mFze#&xv%|U6RBet70yZc*}H|YPaZmQLmRz?k#58ss*5;9 zF4eV914b99XeHmB7@7l|mm9t#cTEd1=CCEibD@R`e5`{)T{foIQ5~7S%SED&O}KJ~e3OZ~@2mmc9d!OC-J3g$N=xQu6LA3t1Xo0L+jdnQ!3GjQGehw%>uy{AVPQ4IzSL{u^ZtAQIWyitv1ln6PcMtPFpLHdEL6w-2A5{#+3Y?f$9E1TpA zc99edjg~xH4ZDeXo=-fFBd>ZH3VVCD*RT-1hW69Nq81XG4LS{P(Nj}*)HE(KA zwOQ+kusD>m9~I5YQ}0wMJ5kH4gF`9Z!slJ}f-GkRXO)EIKhViDK_eOm z=OXDtq}M%uH1;u$XUteMdcV>V;IATTPX;X*EHTyFg{Yx0-zHzC^6S=lnF4Ka*a~p{ zL*(=#GtWr>TN6B)bhGw$iN@@AWgE?#?2u5+0pk&Odk$DDS?RH8XBic- z(Nf~Wy}pYkoW+h&Q(C>+d`C&eLL>(>d3$55bun%8gX#t}ybdVeSoJexj#Bu;6FBD3 z18C-bVFTl-A0dik#Z+$+_N9hr_o!XXu|R@%Q#}OjRD;%x>LisgXy-^TR9j`OqRBT) zEwC|)?7I*N$JNY`?^1?eB@Uejce~wR0grMM-S2x)4ZZ7EEh`s+|Xflx;+w` zOKvW6S%a_kudZPKQr(beW~Q%iRQbL`{>i)1()u;sK(ON)CE>k&0&d4Os4ydRv_?_A zJg4OqcgA7X_hZ&Myxtq7JnKT)LIL8W zUfxCVC=WZ?&FI`qLJA(kJlnuNWZUJ%W~IIQ<{K{$((0dq;LX zg2Xpem^O7J`$B(2=u8YZExEKlhT>zaxmA((1iaYNXF^H5Zw?31H0!^ib z%6}dBRIth>x{%(FhS#6S;Y|O|Tb#=*3J=x8$tU&z4LT-Ya|pu3*d%gQvk~(s#R}o) zz@MxcdR;+6%M9fA9O*t8udhUl3JdN{U8g0k^*;6Uv9RksKgp+XzonKLSS#<c7ad)Fp1Rw4sS%QZHdAW`*`>9H@X!}yg7s8moHx& z_91M9bZFCxDG34wSw(EFk&9UpS}de;mz! zt!!vR=b^-0n*wLCbm5Ks*Lw>Zwv}A_d+r0T-y7^9j4Gz`*-7Vt*N3n7TGDVIKYHNx5Fm&Fzg~j! z9zWVJueTHYnbBs>nRxyPrcm0V=3!rznB*@HMcLE%YA(rbde z*5#SXgE)H-XQvhvfdh|9g0O^48hE_~r1N&&L&056Gf6YSdRYKJCbSu!EM+Mjr&ngW&jgB{+)H zG4xcM7Db1h9Whhr*^e*!KQ3tsJy>*b3VOG>Q=2OgS6vs@P{;@S1w zg9kDAAO@F?TfB=NQWnTH+bC=0A!UIF##)LsZd?pADph=snfMIeOUWfE5fv8G3T`9UsZs9 zml+!m2H%6h_bnKFM$=bTFogE3`DB7lZWISYNTiu4ACfU$cT7wnz;i%CAR>?V-S!7=*fd11WeIGWR@A|37 zd5C(F`M&+fO>tAUL{f25Ds)#R62-mu+H0@9e!q1dPi}yjX<9*AQC1eWv=tPr>hNXF zD5t<@o>OC)SVo=H?j2INVcpl1DsE=5C8dO|EN-daxs?&Cui#dOTPz4DZDTFRBlwMZ z6t+22g7jJgQ|wfLep+4SgxK5nb8(tQuZ$tCOFDJ4)vF-k&cmkCO&(f*VX z?YDp4d;1(K(Lnq;l~9s7M3ydF3&@rOAegRk5MEl8!WUmIs`tg4L4ok^C}C&Gaz2W| z5CKysFEPJ$Z`-Nsb2<9X-!2j_K7sM_KqE!s~BbZhW!8pTpI=aB? zuweWTJK+IW0O~jr)}gIW2jlq=gNQB42Q_f0_=)K&Ajy+Y7U%>(3rTE0M$%-y z+_BCZHtJA7mkP4@fyJyPC2et|7aqX5W*gWN@%5%R6l;=T3R8eK#AlRN&@e^EWl0Ha zf`MfYF9D@W&|gpyPeqqRnShj$VRy z^bS`k( zAZ6DJ=1I6ADnelpcq9?qoDIG7BR=45Fa7}JruiVlWGwZ;0bsSZwDqC>^X0&ZVq*z; znHs$Y7DvIJFkQNY2?0$-D3J0}!6I~bHDMPi$gc~10CK&pjUCIvX^g`0*@c4Kn!s`q zd9zVq4qYQh!M_(WqvcX^FT6(EH>pld08~F7LxY{DY$4-EgsBhKA*vxdD2|0WNk*bC zU<;#lheCiYjMlBi67IX3*+x3-*QhYumS${WwC;@P@**8T0K!2Pv3=4w%B^XA(X4+f zO8}LlC;j^dpkgjl`x4*aZFHW8v9{OGTQJ)CJhr`lw%1S9{aPIfTc6*yB@vC5L=^3P zWw17X2LZ&ZDSTmlEw+?su;`j%&I19(kOsz(23+hiu*AeK(>~Ginaivh2B1VhkxqT} z17*7Ed=;!CLyP1rG?!t^EAx+c%}{r^cYlhe9~mtCLH8tlu46->fq9Xhv+Z?iDs=V! zF6Ows5)qkhVJ2?*W}^s|=%EE%Q?#h;$=BAJ{bMBggqd&(he_M(b5mHj2F=i$*lA>- zFZF*mysh_T+3tCq1d|zD!7_B|{Vn|4e7eLuX^PX~v@~1ZqI7XDS(spE_!7t25rm$= ziCw9jv!8n}^~wxGt^Br%1xVlPtwD1U`~rxl@D+!%03g@MaL(svFMVs6wHg4~R=sVj z-cEG?7$bYMfUrf*$|)3X8L@?2UIiVs^(p~7X6@xoUP_#xuZoqqV0AP~6{Be#NV&Ae z4H4?RC+;+kCjoedozM4938` zPO4i);=&&a906G;gU?OkZG@}D++bP-*qTN=h|N`XHre7d)28*e*%)79HpbmA$<^^n zZn-B5m+tnSWZj~yKNZRJzlG+WRXq(#7tq@NNB5=JGUk>~E54Cl&Lu+7CEwC*?5KHc zB>=FY?$ldDb!(`8ZbS7h+4$QFSox~gmhs!}+Mm|U%lz^|FE?kbx;2Sj*>Sx-A2Zt% z4Km^+{`)+dq9Pm^e*hOLl&2Bo1YZ8(9H0$@aR`4tz*VM0SyrAa(FNbLe}dwUG>fJ+ z)QP52tn#u~?Od>xjD|*W@71^8bcn7ni^n&Un`_jlKFizr8G2=Yr>DT$bV4@ zC0bi_=?TELo&ao>`rtaA0zqTorP+KK0k-iXxCGoqkR#NPvN9 zd_}h=@ofm^p>T@C1Dpm+VDTwO`#BkckLlSjg(OE?q2aiU6jjH%}!M_dE|PU6w{W)P< zRGm)&1+erWDpm-u0R_dZ)kw-{Yw`x-24H4j77miXaq(n#y{1o${}zHP-~YB{tG9Ij ze?Q9pw2T3MKhFN-yDr=c;H+ zl6rv$E#9%%MY9p)u_XemXY~W{ynok8x-IDaP3T}JB0=5mJ`>5AnCc1mTO1VvT z7hZb@>HYZxano|xy~jo2+@!@=l*0wO^CqSwUbdf<#O@8f+YzZDbBshZme;1tg1<&d zGz_3`3jj%d=)VFpL2dtU$4X4-|H<4{?hxflMgaE-HH(v$A~uGio1J=xpu z;eYakRy+pEMnk!Ts$aNn*42x$-B;@=f$9wydR`1Ni0Hfs((=*P!ejLr_&ZSHy%%%f zPKMaP6YNHmWpG@8WJMJA_w$s1is(NzCPw%vTq)oNJ3=4>12Ur&PP#Bbh$54??}%wY zf=iD#J69QJAVLhK9qM`)SvGt6@Zr_fRX3c&SC@5xf!*D4idB*1U|(`;5Mc=-`|59V zZ>nfgpup!12zn0PqG_kjS&oy=i!Xl+=TWB>ffcCQA_&CB6~j3q8zV6IejiQ6dXFCn zw>`X&QG(-A=o)5dkF%FZ92x9_V1o}Q$L~+A;Z&#x`9}H-;bkJ6M2UbO3uh=?w($sI z5p+5T#$Jf1Rsy%{U>qb7dSyt#1H5?T%WLp!`gf<{m4@oa#rzPT7@YH6v#iC{^9t8X z=AZeJ0zcWqbUiJ^C|l0Ju<-oBgAdkLzI+Y}sfD$S(QyeOHLxvXD=Ah9CvlbJ6B12} zvNxE5wGr*eGl(0bN@TubqZ3F`{F(vRSa^Ygjb=#Cme z=Zi}gD?S5X{zY6y%g~}|Wevl9Y+T9c_F-Rn7++&5y*%Dld|meikApN2dXagG76cXAe1>ihctwbEGZSg z86*BjwnpR{(P;E7NIr@O=v4!sAPzBS*AVI~A_9SU^H^ROV??a8#)A%SQnXxW>Mxd* zwk}sb3$E%OuC+66CRJ&q3w*={&+wMIC;oDxE}lH-W3DS_h;MUZM`b;-?q+xrD!<1o1lcl?&`7dQQF^v4{ur`j*D^0t2-)Sm4vb7zUR zwPMCQODb~R$Hv=QF%5)1w^q#8XT`WLlnvQ3-#tD$kQtn+b>|d`ngeFm!*o1DGBy3- zaQMU0T*>Ni3xS>^BX@1zk14DW$y3@jE6t?baX$+acswWC5I#!~g+Yf+V3_EpLtSq{ zkMMNL;^J@l(;)AQiEL9CUy?XpIf1cO%+F1~7hSqbmtgU(tZcZ)$?aUaS4*te!phzv z#2F^@5h?-FpgiK*OtNf!#?9d)Og$SV_{T+37*$A(j>5b*yfe zXW{hI&DbhFV$_aFH4yXBP-@U;A<}RjY)D8isJ4#cv|7sCLfee0zPAlurV>G>-(YW{ z;w{ocv18i`f%hW0VG7mc#!>F5jTw}&7BhcPClh=^5vux~%JeXQ7l|iCp*5duh|M;j zLA{!y>^?e!w!{>kVIT>om35|!KzTs%6=^3@V_>}oNSqtR(vyaX=YUg&GA^kaJP7sNW^vfoU1c;so(l1a4(9TQEQ-&X93iRd(peE<%0}-d6c0 zy#Txxq5^sxYoL+PhipE+mgcugYtduKSv>W2n1iC}zyd2+FS7oOEp$a4C(Pg^+e0?k zgkfV*JqdO4GUBESihuq_QYOhhCJp>iL4;nA&`r7hMlo z1|83II#fCzT`Cn;!j^p^F*er`#JAC_dZ+3yU)WBAarw{lW$wM#}mLG%-9r=?cDeaqDDlB%- z2t6EjoKI5HN|4HZJ7CQ7NceW}6w}psEOBgd;a!mHZUwghPC&80S)bIKh3Ts*Wog4D zH00n=nZn0*6J|=DFyZzT`;Buy%}myw5C>q1NcgJGB4qa&vdAn@E|$k}KF&lY-4qgl zXHE@iyjVGv$fD#d{X~iZ$yfnia}JLm6Ys{sSqw8WPOP3l+O)X;#<%}GnCbFkk@Tuv zc|1D_Qeq$&m9aeo>BNd55l_lp-r)hwj*%=gm2vKL4rd@T7o%Cm*vHxmjo<%c>zYO9 z2oh)X@F%@eI6tHLM93IvP;1X8phK8PnEpv*$l-{oF6`=K1(hNy_mR3O@)?;@gnH+f zF>}cUGfjf&{2bTm9AG%0F@_QThsx_^`_!}@YN?x_bPanh~{ZIB)TdE6aC@w+6tU*_;zff0!o1lQk&AV|B zBxeB(ddMv*ywMaFC1YbIFLMAW9~fM$iz(P@IrrO?*`|AgRhkw9+jQ?QC>_reIB-R* zt^VOf)gCG~g>-QwjN zyq*slA#`pjY@F72RC~XK*_^xi;UkmIN4m=Bzk`BMc$7Gevi#THGsO?GtdH(KOW9~# zO>@h`4LEL(Co_ezXlO#`;j|?-*vQF-CMcXa^r*P}QKIMuETNrJjqj#^u!$JOf__X_ zk=aa?piiLqO8iVAxMmT2B!T)sQ9#xov98l%d;kFE@=70_qGp|s(>&=mV3<f0k(x~WbA{U$p80$ z_TC&n_d2hC+_QAp4O3~WFpJqlSj<>ypx64L=t|p zPE@xJvCVE#tpG&nXP*N4q40`Vw4dK*x4^iN(KF`Qd|}xwB7Sdje&4Hmy=v}H@6m>He+;K=gHD^zi~p?~L^3F{r0;1@`1qx+No#+ zn>K)%HU~JdwW78~&1jjjwW8RA`YW}f{B1eFlJ@KU+y~oMme<#A8?~SdyN&WjljHp_ zQx|S6HLb~@iF^CD=V0XogiT~vewpWBn~1oXM8w~^P1v}XXOnn>Tk~#f-fhi08Mp9% z3=j+i(EJ!7GI({zbJV&A8w-(r_vq0bLuB_LiPEjVHC(;m9)v}~vKPQ53knf~U_L1$ zD`=UFF9tV^E0}_3Ze`Qqg&(_{}n&vix~~vNhuFu;2E3^mb+!T+vS&mE-|h93cIQfhm?+1}LyJbTi=F5+Dt&Y0=bM zrgVif5PlM&t-(la#9*H7#pmZ}AMxVk=a(+i~&zJ6Ba{* zRxDvfjo+Ni6fsIQ46?urE`tb_qo~)#Vn8hXkqxbp0VyUc=32xh_|gIuUh`>7pAkoN ztCbr5(_X7u#myTM*Fo~cwqMsG@?ik7v`vgf?TKpBIL31eO=~X~Dijmhrc7K0=uYdH*f1Y^6 z-JP;Q3nSl} zj1U%PBG;~W*wZbK`iB?5gGxpEgVOU0+O%r^6PyFC#KXg2ADzu0RPQ8IAArT836VWu zyNro+MPQRcuQ`+`g#ps=#j66aVg?Ku*nWrmdxwwh7jLMn`Y;v9&H`uV3T?v)W(T-Vc65gyVExX++sj#8 z&RGqh;^svyiLG$Hk$Va44bpG5-z|&2*B1cU|VCrV`!M0g@`}Bx9Y_BzQd4c4riDvb3#fM zTD_vuKX<*4aA-G~5#*O^3u;;0ZY5$P{ht<)loVW85%Z|TlSKrf#%)PpNNu2GmKiHB z0&xUV0pz3lF2E68!uM%B6R8EBbn_6giB!V_gl%}J<76ZbE5A_^1LqDn^)mZraq(qN zFDM77m&A!pMrYseyu?5I_=f?C71nohJ*ExrNl=|HZ_6NUg#6FaMaDN6rJ3?BlCrJKb8=C zs&VQi69JDP1ghBgJ3ZmBTV;p+XJ+_?c^#N9?#sL~w9)<`XO%{P9LE2J7I$oc)uLF7%}JstQkgk_f=DG&4bNfJ3 zRbLNlNRKCuORoNFEABO-DFK>&&a6{#7~|u44+fRv%Uss{XviyxstOe6DU*ZwBQ!%9 zqZ<>LGh%kG=&zZp&PB#N4e`X_hCndoy!eev7B@>ax}%RaxueI@g@KF*_=a(><~zr% z25;xR_v^p^%VY18$quzH7)QYFkFX`ljkkjgY%c}ubGTFe8Z`4_HhDaiy|-ck-)aqm zuC#N(0m$4CN#a)#^Tlsw&~SB12YG4$x625^RCQ|wOQH9SOx39B$Xov$_)$09kzCbgd zA093~iAZDbyW)r93OfnU!HU<>RDMSysP?Vm3i~8)#FfikD`a73PH6WTY9Z(k^gf)v zg0li$bj{#JG4?V}&sASSN#lDYzOx&l?z#xO_DcNqX6*kIUdHERblpam1G6a2*6YuPi(7L>uffFkYDVr| z{Q+r=0XosKIfUbctWUc2$mX8pn-C2!@B1WA^7z25J?S{+M1 z4^wK#ngi8DJ$*mZrDy?pgx@8D(cuVBe(ygg6XquJ=v5D5yKxm8t&qh=ptmzdAXz1L$ zzJ(`NUml>vpjCk9(FJi5PtlWj5{xrZj2@L+cQ(B`Rexb=iRe%}2EH%5XI=+r?H-o3 zv^MtBdv9rF^iQC88UHEqQqu$w+q>wpM*Xm9suW2Q!dWVHfVB;dJD-CrQy~m zgP+c3-MehN7a<;uP%}E7vcV|=$mg;%YRZamlt_!*3)cBK`l7s?r{e=R??gDk2rqn7_MJ{VpiH z|EQ(8?mudLst0Y+b-x_Xt4r42QEPJjvKjAJ_)O8KK7bA(V14+Jo$rP#fR)PB zP(-R2L^t$isn}rXl-&hzGvG7S9ZSdGRdAC&l?%|GQ$(22zHoxu9U6zY4upOYoD*zE zCbhs49U`saGDuL5%K0&Lmc|IYA>$<#ZQt?vAb$X8JC0ASDr#{>QF+0ON^h4%)c6vH zz?=v;Xxb8|X(W`FW8B5?0Z=)>4`p>iQAgm0jyrQErg(}FgYA!9H@TAxB} zN)qT@yn(Tes2`s&aD{nllT;6{nYZ5c>0ZOH|M*{Jdt%Ljmd2X_<45hZ#KqjoAj!0* zD!I9QpuP$kJcrUZN&-cN1x{5##GAI(?sKc(nYY&@=+eCoXJ~06cA9pK8PZ6{nqzBk z85g8de)vX5Ky3vjbLoPhC^NcjiA^rd>mc`vBAQ>)6u@Z?Xh+2e5kvU#8Ar?wp~IuS zzAH+&7z;9#bFHnZa8L(1!bld*Cu$GYmZQ_1tC0BzU+h*;kVe~PTDM|8OS+lBA{O-@d~ zz}_dVpf$u4FBV2_vX;gFk(hi#v_usbry+QY%W(t?c*WW7sg()mzfHqAbRc>sH?anI zV`km$K9t(4`Ns%ShM9t=_#$`0t(kch=fnu677tAM{Fjx)wMEWW0KiV!f&5vmW8hW* zOd{A>TLG|X0RV0d)9uYuX1uKiu(A+qMHAa<0N97MuVc6Nu`GzTx~_bJtb`Q)O<^Sy z`#MAblIq#;jz~zf{?U_uAC897Xtj(PHxGDkyB^>T z=OYyAq}6E`E3-qzXve1~Ctm-%$43Vbgcq1zQKqv9#>tDhH?i_t6KPgnv;XGg^u+5O zJU)EXGy}THIT<8-y#}>*_b9pwzXe3n4K$iNX3tVBTS_f>F@7*zx-b`^oY`r>e%t}=S7avFMi`VWQ|k8 zKWYCo{MUHOJg`!=8&Y#-Gg!WeB7T{7pL>rPHIect}I zz8ay-nbBZ@0X?Kj6Hl2aMlDy}84F0xUMCHq)9REzkqm|l!t8#t9ss}BJ`qkKn}bhT z62e^$Gz3eG^LAa_dXNSQ2&zX8t83X;2PYt!%wl9eAjq!OL2*kPm>eXbG04ocv={H6 z{REP|XG(%8QUribrVw)$QFvqur3uN(#y0tkg++o32GZD`yvTYmK=39L12JvJ{s_gz zB296n^P-Y!0fK~QMneF9bE=4kfFq^=?*T_dSsISd@h8!93rpn9W@=2O*@WB$Gg*=8 z&{gk&aU~Q5p+bW)%sfG2VyeLHu3%!5dES;$i{2@Y1aiu|1wx~iznYt-&^3!XRe6#3k#NcCU`Bf}olC{R31 zEEj{Lr1z9*HFy*qwlb#qDr$mO;Kt?IC*)P+jn+%^w4vq&;s&(t74+v>JibZePr^E$Yje-Esipe4=xmAtHo zag?7EaG{m(uM*7k`B;2%7>v&l`JN&;CwLmw@tOKNnD$H5#1|U009cK3HCSM#VR(*k zq&&w3-Nj0Eo5NtKI=S;Yt~}oX?^WxCZU*!yK^;&CSFoFf;LN+j0XBg!beBkHpNZUa zh_;1N2c_DTFBb6j_L6|ZK)V`hToM)Mtp(mVb_l0h!}tYeGhCttAM-eBy}yFRO9Ry! z#8=ljl>Wxgh$)S%H$#UJQ0s*ibfp$m(4ZkQOtnl!Cr!qD=TMJLKTYbW#wHekJ+Lf- zjH$}ZBQ5P6edDzj1M?qZOSHfomyv#Iy}E)>ZJ^9Vs{pFt^BFIKf6-mnw3ov?8 zCNyhPN%rVWfbEb7V~7eR@{^^~3iQz{f`bY*jFbe%DGUOqZr}1L+X@S3Lc{$R77i@M zHV#2S^lOu-4H;UYXV}S`x70YV9uRtu;2Qk<6$S5~V@8XCOygz(01se|;aeX@s3U|V zUXX>ioAo~c17lAIi(n9lu4!Rfp_gcne6JzUQ(4zhz84mgKvy5{7Q#S&8X{J!vpLv` zdy1MIg2(7S6#cy?As{`OMz#{dL`Nj9)9J?6*n6m12~iJ3D8|wF2C*t^FC7*tsX0#y zH_OOSn-8NeQ-D#<_kmUNCrWSA+ybzz?;K!Ty(7nmhb)r)IP$K&o&)kyw6d=FmShLM zCY-78DOO--tdL^960!4Sc0)cfo&0nBRp@Uk%s?_g9aPu6e6l#Lw?G4hyYODn3Cv-( zykFXKO*S6j!s%FLd)%7W)&Yq^@2vw;1@M344oLqXclhfw*YJ7Eo1<=hjffB>m*I}@ zeF45kxAb)72Gp_)iteALZGe_|+EQzaH|z^UFWrdSyva7I1mrqMaf+`d6`0`nW`?hU z0Cew&s5z+xjfB`LLltr?w1R=Z3qJKIi&BT4jtOP{Jt9>ZVWdQ=+M2CfCf&iPT19R2 zJGaxlUxxhH=;1!zeP*1X#pC@NSU$9af{A&cRn|ocfD4J(l8}1%S_#ZL347Q3^Ef<9 zqi{TKKVeybhIOi(3-#9XXOVi%#!|X2m~>Ls;@T>h|6n`NZO(-9} zwI}Z$OKbw&*d>0hwE^zIzWoL%@slVC&X9AHm;DxwnERJNu-2^!M8Kj7CAw)hqkA^W z(`TQSGX2`vsO@Qan$7^r_WjO``CwAp|1F;uUqkR);_Y5smBKAoI0CiRlY6^XINQ*- z;7Lh>uCNg+X;4+lN$+saf$g^GS-gp}a*TI{Nz~_)=Vm7gHw#)$m@l*{u)@4n+9C%K z3Wg-3Y;FpHe~g~(0GdpOfPN-oA*wCL(K+gl5Dike&Jrq^Xv87s^ro&JsC0vrLY}*RoOAe;{y7tWNQ|ci!(u*`K_};uE==e5#yjfA6t}$hHD% zM3N4l@9jN)pngGnlQDGBW8GP@RUG|a9*VXn#EBbv7<`Pudl-G<8XFy``k3oPMP78Y zoRZuvR(cPc&!aj8=|$Td`ielh`4qtCB5_xu#fkbBq%@-}hvoOoXeQ6V7a~9&v4g=L z;HS|;#>yr@1*0z2>3aW#nZev)^+NK8Zbk%$=S750ZUhz;Bu1mRKKs0(FkB3nzdevw zAUEUcA_6q1$$_(ZfvIvPDOoV9DiZ>rKT3K;b_wq=bIkUE?s1;?| zGS-%{$V|$=XzL#T6|mq0%a#-6Jx^6`mrYOcJ>DYgAp_=`vzAdNl8al@T(_`f(4Jz%JbfIr zbG(4)+;|7nf9#W8$|}i#z7rqO>D^Q2kJfWCU$l96Xf=DVzv>_1o4&Gi?JxEpJ?u%X z)_m%gM6WbHH+Mmno^z3q26G~oTjXNVpCBe%nn+~;x&umd0a;B1BMCrGy@%aAa$sjw z@YxZa-{155SG%O4`1>pV{hj%%`1&0x4}XlWh|a!?N>6Ri=g>$B5#CWAib_VQik9?| zA~CAfM}cBKN@6r7!Tu{RL4c(TRSu8~tXgFpDhVV*PLK+WwS<44!~4Lh>{L~@izHv8 z#F->t!R~T43wKN#2I(_V?<~@kcfDs3>dr2raj@&XoTmyS6fTfm?={fk#|Tc&(dwjf zZnjRfh7tM}#n+OaaypgcXhFF87;YB#-o^>qsZ};gvhVk%#&m|@I8Ym#{5C;jPZ3{q zl$+ICoqw#8(*@ryGP|ztgs?~L4UWwfYUUxhwLC`C9ascBJ#$tq3sj)MJNenU_a*cG z48~A2%XX}^*46jN&s`rbg>Lm1RxnvOO>n!>a?e1e8EcZHSxy@bA{7^&=pYs1h?(5J zVpoP-!sP&Nkhw~9KpKbB%P5JbP|eWT!q9MI29PzTCZ#PCR@RRE<4-UjaV~FI7ma%) z7_VU9-)hd+ZvZD!;6!jU%up|R7WZ&xvR9MdGhfB?Vm(NG>{dLMegux7Ui6blVG~* zRWjg~M7OJJ_bmONqUlH8wCq48;Mt$6)>b&I<|lej%OXn7twxf4#hH2Lpi^l&E;2Pg zl}h?qX=8hr>`=oyOy>(}UYjfm)!N356n z7+RA2?o-eWE*v$v_223y;4lAtW`XihH8xebEEJM>{Zdc9kuEFY3l>ra;E*Gfk2-R? zcoo+Zm<|%udZByuq5)#X9i^qK6q2mA#bqQw>EJ9shtJxa5X#Q;=vv%}%DL>gK-$_t zi~Ke}X2_ua-0^HjxIxGd$L4C;xAI}B*x0WL?5A{5*qUxb1f!p>G)~i-LibG;jl#hV z-3J5&AYN|)>X+r|#-Stp4f6ac%pZ-3F@sqSVFeQyM)!sGpbP`y%YcWd6`=&7_7MDA zJY}c(dP?*w?UPh5lF`}sJ1<}EBi2l-9A{g}QVQm5G?^ z_AM>OX`a?v4>2J=!iSechE7F}uu?vwOY@9gA9TYxK{Z2!j>&f(TR#(tUC zYLTvj-`dSel|7zS0&0mqZLH_d+Z^s-{QXX!qD`x`I$e7s8*po~b}1KW^|Q7C9p)4k zJ#1(XHbVnK??rgqb>4x%Y?7U0!NC+Hx}+gEtCP*8tT z8(#AuLChoZ4srKO|FZCV6jrLxZ(w-9n`Ez=@;vt*nMggdJ?Itr8j&|G{ocMq))(p< zQ1m3{p2ye7ab+RXz1=fVFaU?>oQnx=Tz%t6X^Nsx$ru6zBD6u^@d41VIiu zQs6Ds#XgGw`2)iI4E=NJ3jUScn3WEdgr-`R$ISz>Qc4e zT0yerIcIGt>7L=2*%&2n7J~u_k!;8|N6|>6$2cnaydLm+Cob>3xi-+1i4ItmUdv2K zxQ`J8KwfRJFfb1RU_7*0LuDy_&S=vFf3ipdD8EBg6i$#La2X`bCX~aLZRmsYk82zyE$YhW{5p<+Um7 zGv)RqM#UF`Tj8E5`+?v@>B(3CT~uYp{CqDJVa<4JljNQ--B(K88Vu*&m`2?K!tAvZ z6wVRel(icueT^6x}>W0Ykfqv@qvvvgap;!Je!vlWTc#1W&^S65t);M#9>FXBrG zcvca5Z6*1*eYU2x0K>uXw!k=HdmD7rVm&sJi8LGt(uoDgi2^L)0be-UR&`a=tnI%? zN9Z@mrId&WHy1epZN}0 zL8&M(X3c#Tj*tMyjlfix7-O4^xiKhnz(m%Nc|cVj#;_rW$TS+xA(do3d`?VTN4~{c zl2!z4(zUAB+=twGBRK_1z0q6np%s*-db4xW=5D@`Hby>noaNS+`#I%OJtD3qsp^g8 zW|c~TVPt`9@4kZUvW1nT6YO`kkKl`a|B~LhJAa5xmNp z+*3zuxkJ-u3}e`;Kt<7euiI~YweHDv`XoV_uxr!6$7=T;RjoHyebzp(uT5`~rzL(} zd)98^zz;?75Xc&3NQQp*&>NLTt;K{DBXIv z?GJ%$iR5$ZhTBjk^xJ7TpTtwZJq!Y2A;Ib|(Vn8TmXE_t7r0+%die0Ed)S7VE%#%{ z{wcV!;>hodmCcNmlCJ#g(#ux;A}#+?stzAW^0MFixl92FHNWp8eU*y84DINm#KZSxw15Zfh=Y50_47niJG=3GMJ_)NF5lL3JGr&m^w7iQAOA$|QMZq0nFQT^A z1UAyNvzk4P+f*_8177uT{s}Pqda6A#)FmTJmWIjUh5A7ug zYypwNA#!6S<+I@;gs z?W2!`ICy)9PI^8UW3p^&7!s8mU~hz#67xKdlL^wD2ve~zDVtpyxOskv5t~RZ;xKS9 ze_NLT_ZzsO2&@K3-<^&SBq1>+5wSpX8z8@3?D&BoApWHekdRFs8m)$>l-oAnJM~Kt zpARY)d*ERszx_rMoSO)OE9h7TTOQ&`AczCYM1*4&K2pqm zLH^j~?u~&K{wZ*I>1y4{RZ6E}R{Lbu8)?~%RO`)dvgyM?87Jj0Bv&+@Bey}E9VL$Q zz=*x%%>UdC9V?hYo>UtUjK@JwFw{C?X+$yTK?~Z2*XUp0ehTng**MB0H z#`!A@+|4e5Jrs`W%%OfPv%j0~W05g?_qI3s@uw^aVSc+iB(}AME-|jzrncwCRf*Py ztfD{O#GZ;6?@i(77P!bQGG!}^a5@(N{Om-Ad^L8}K&qG0CuDt40o5NM^O@?*7~!fM zP}m}(gNh@Knx=ZM$cRtrTp5pp3YM-8u+Q%G=RpWisVLp`)L%rK3j7%b!faSUA1#ol zkj`*Ud=dHFaGnHH`Nt7Z_tA+lQO{nWNjbW&;8&CRbeKhvbJ|+Wtv+S<22fjb4rB-a z8XF9YO91ADylSwXbJ(WW*Y!S3$6<>66D0m6S4cz@*@VnX9PU~<&ft{U3^^%Cie@u} zNyuhAB5MV|tM-?!KV4s9pULi`8zBWD`{t=KgCMU8$CFSJ!2nq+&Z%rtl4i(Y@xJ$j zk4AT<6nUW%6RyKLyhS8)j>p|&mB<# z`)sUSjCN}Yl4};Z;$vSlo7|Ras%fLEF+wf1pmtI_u2Zn^|%3v`2Qoio#}h3)AyYEszS7YK)OqP5@n<>4wMT{rdGeKoRn z@SgTYc2D@=wyLZ8>cUzLlU?b(t?+~qZ8qn%Akkc%nQIN>qdzkIXegNigpRDuiA2v` zw6?!p$RY4Liv<{b=yew1e*Qmu=eiq5a^?B&4fH!C1gwX$Me5c!w|5FqQ&M-s-Rho} zJjTvqu}D@W$+C)7<+?~>fAZIPhZ(>atY2WU^8$W=eTaUN{ryiwWJXp-k}76aN%l72 zi%3>wWSls0uK#n+FD9$sxEovr9%AzJeld^x=2*YlzUE7w-L7739ZVF5kO$-_v?>cg|jVy>=Gw-3Pvs8t=ha z!}c6!<#7h>w1scmIT$ne=uVaWjajI4jN;ftU+I`Q197#m-F`)z-Icr*<(9(L-u~ff zKL64t-cJ%tee;zDKmF-H%3TD`*u`07-`7XaHx|A59@5mx^3lju!3EqFsmxVnxP;Bd zmU3Sw_2CCUfNxSykSbNvOb7P8;}1XJFtaBM+MU5E7w*T9yeR2i-oBO2K6_TY2H{xH z8;R63qux&hc6;)><44b5SmyZxK=jB@AOdU%;PSO{i07nL)v}-%o)aG+nS{P8Sb039 z$0aE$RBe=LDjnxq9^Ritg~a=+zh}GchDWE)`t4IE!NS=?3*G0M?^M>*uFi7?PuVc3 zjj2yoq_xp|rX;eDPFQ!+;d-$UUNquEWyAxh^`zjC=d*=k)1WL}lNxFtkBTGv`kWc2 zq%451Qq6qg|9J`;vo?bYP$sa3DegQcKVE?dIOSi4uj8xAFPE=soFp)8`L@Oq46(`? z>TP@rK-b2sI&7t0c6g5L7=nlxFWvW5S1eeBF(L3+shu#s(?67t8LA#MquS~V>I>A6m?Hh8OKZKow#lv^pzgJ|o%m$p>w zE?)oY%xk9=l~Qg^w03%O%Td@~76siD5tb(H&Q+mTLOUW>Y-@nf>9qzA-$Jl-zt{U1 zNMG6}fvY8>x>=)f4P%xU)OHA*)l9+f!VHxBm-ee;`+_+NU)U%}hg!5t zQXM(`PR4fT>(zL)C$@I6H(6#o*iH+B0zO!+S3hC{rWftonX)}bq4robInT*O7gWut z!qH)oW9H%(ojIp7{%g*yM)dE^)sEMe%$sSJ@v=#`zG)V1zrh$CdHlDN;$%5CR9v~C z#u_)@&!DM7Z~m|}2RnDX@y;FTa?Aj3jNlP~>`Xmkm8)-$zV{X1h#7rnJDP!(qvUaK zn{qd_c}qH;5a#HdB0-xEjG*A0@*%geLAJj6ZKr31vhjj%2m6UGV@>L&@6`<}EE@Fh zZdIh;uhz1m$z8iJHQw5|!T?om@_0H_Wr`J;$X?w6Z3eWgJ;~P>`4l{J^7*~i#T&k(pKv=!Q(l0)S4j=OnA36|aJT+B8vo%Xb>_1LUF%xt-#2}B zWWMR3m&N#$U~umTJvj1SQebf6fJt8JCbHA_SjTjp7Zv8s{fOXj`gknyIb_x3&yd4nDcU^xFDqEhO^!j9L(!5OQdr zUq+`DRR$BhQn4OMj@9{sTAX^Mx(sC(%gQT^lZEEm&;)6q>>M8<^9ELjY#nJ4pC_YakWYhM zv<5U~LTnfO_XGU*L$M^sPVToyP8+-hQ#F?BCW+F_y_4OwEVU&|o#x}o8hJ%w`E-LF zn>PYK_m@xJfN0e>Ov0U#ythU+h&IdbTg;knNBo?R=!tu<6LLNy*=Z}3SFLyC8pUUJ&E&wQ6fBk7a=?j094;*$OMy! z=n7RV=d&a23Aw$bz4gdfd zHir(45W+AY`=I+C z;Tra6jl8^oj?GB;n)fjGx%NK!iHbwCTm_MFp)AbHF>x(V8-1cY6E_~Vd2kSVn&CPN zStId^y}=a|^fg!evh1fn{o4;e{psIznJs^m!zX9!*;?5r4#drT0~S#%#67R{ZH}y< z5_Lk}Jd!oA58VOE&pA~TZ2t&Mqn>c%m+$#_bKr8T92>R;@w->}V@pSs)!-SDaPq#t zjOWGLJY6tWENPl`Au~8z zUM^R~MKE=x|9sDkI6v1D6+Zl6PsP=yTSCXU$>mY@t@9P7f#5cgpqOKMT#Ok5eP%HJ z&>GJb$sRm8{_g2hCco&+ZX-n-46+0AJd98`;S_r2!)Gu~U&L`!Q~D>);G?G5(lZ&d zr`(!1q$IKIV>{3cQFrw9duAiFeb`bL3_ET-$w^dX+&&yqx!xD~AK)v?99fWuM=K&w z3j<-~yw<%1(lx>vZey%Ynso4SlYX5Z*do$iK!-RYARqc9G#TH#UZIG$X)~^L~BHC25o`ES&D8sV&`((ro+%*Yf3@ zDsply&V*Q8PKy8nCFl+RjtIj~@amn04Oj&ig|mQMNvELRwC7sNVtZHK?(_T{sZ7c~ zjfx1I-xmtd!jd`h#pxLYVNe3n{PK=jURbab>ThWNdMPi~r_@K*1x-Oo7aC0!r990!`~c9Qy@3B%6A&U6oRu!NimlqFxE5ZRas@|&Ig1Zhygf- z%|EEp5W#Y{%Y z17>6V^*@f?mLK3$4ED$ZPQ$w*OFtJ;mQof6 zY(ad(FSw;jY;j*NZ)e2v?+}bvsz2lJgvLwg2Nq7K%A^%54DX)GmyM_OR3#{&9It`< z0fnADrpfEGnLn0MK~rGfiw}A*O2a66Erjzbv{s3t?PVbB<`;PI?&^^nH?y0dON-@e zK$bTrTza{(d~G0)*f*}oojEbu~L^h#*CZpF*&)lv4@(fwDodD;^zoEJ_L=!o z(fXESrBZRt5M2E|cZ`S@{n)3dom0{>GUNipEK14p2__G@-eu0PQuu#V6hzXb>Bkpy zbe>YgXiN98fFjTbnH9AfAM!=ZE1>SihBV4YbgM8wo)kAK5rt2gf_L0~c+%zBtvfmF zEyqkyBLK@NLsI1H1t}d94ye`P*c2`AV_GhL!fn&?VFZGpA1C7(I689DKvI^V9xp+N ztY|tBoIG`+Fl0gbQDN>V@mJb|{8f}N@y*#F5vNmPC7ej3iIMPAw)~f*GY`w0NwD4l z8{jh1w}NwkF8=tYh2VWMWFy*OCe2otb8Iu#nv;+5Kar$?4p#C z=gm&kGDD5NYj6hdwO(ZdSS->xKP+%j{Nt_rx9}pi35KV2Te_WSkc~TA_V;6EtU=Nu zdt$RM+@Yv)&TOg@A_ALp@Z}v+4-!mOTn#mBQ1ug8#ij6VI!oAKtsVh91g<=#zLpPH zkHSivj1FzlVBNJwTY4mbW@~VA%`%7{*GQkO-GqipiVd=zoi8P-7YqO~FnKecwey|B zGq-B^;wCQcR+(8vQ1Tz$Tjra9X2V~wpCrs8YsP#VCboU-QW|nn?K>qRN)oINe%ko< zUoz!GF7Or_hY~BtogGT5SI5qe;;FpJfN^&^PzebUD`X#B5TTA`MUoOnkXRry&hea% z-$)j$e0E|FG)y&G*g3U2v|ZR3w^<{a%UWEE1Kt_ueRN$wa~G=Z=A5@8O8rh*FOkgH zJ?q6G9xf<=6$Uqb-;K{=Evf{vaZQ^6(sl3%{jls4jxaZu$QS! z0%c2Ca3}d{crM2XUt&!dq*xq&Mf9CN3mDLvI_z;vq{Fwr+#*UeTnM>`I^J z{p++{cem})kI;o!oKU);W0npWV;~1lty)HTGaGw7*}A{t^L)ZsZG|$Mr&PO8+blJB zaXCL98;sOa4L-pjR%m*6mT2F{RNy8qi)x**~p;a8duD?2$S(25{WwcZCrHXcF89-2Z<%c7+h+bxJyf zylUg_cPF^_-FxKV^ua!QaeSOT`1sck9w@}LkDcM6SN+kNE8h5qUbVkZKl}KhT}tmc z`xspamnAx&{Y@O{;Mwtu}6%3>Sx0%sFs+&!)8ylmq1rp-HS)!Vd7-8Kz1>*lFRB ztX4%#r)es=n&C``F#FtGko)RN3uNFoNLg%2E81&@sH|FmkXH!5EA`0#^7 z)yj=`o)*E`?}%&qERT0w4-(4Ra#E2TD29{fdC7IwPNfT45;k zgrb!p`JwUXcJ?NF=ngaFHS7VOecI&_u~6CpYB6QF?_il1U?IzjsJij4q!WJMcu0fx z*_+EyHdR_c&OMa5E03sV<2P=ObZ4ixAN)6f^pu0=8JSNTP>#_CsH?G3r&U_GwQ^Y+ z%XQvZ%aVH`S0NAgvVa47mSV{q#*WsC@C@c-&uNc?aPvLK2}rf~8CMg8U2H$qfjslA zyc0(Jj^3gKL^Y1y?DZY38g=^K#a8PhUV^6SnSI|T4&2?qPF|9J$2mTg3aaovBueG0 z*WCPOAlxPTd=*&f^8<+iN2yq6u{;-KQmSo4z?dK~5v{hEXE)*ea9?%8B9yZzH<1pG z8l^lDb|fOGN@|FIS^yY1v$o<5^e`rC^44`CM~gyi6)ZbgOfscqoY@XmOUTitOxeM@ zLJjQe_^ydGYgq0Tb8EvfCX|;iHO*Q|25BICwLK#ND zuu?yvDukf=$MR#r?2@Ch*RphdQ(DEDGQgF~JB6Cxc>OmYB-X=BM>^xQ3+asXrOv?^E zF|JO@FrplNDse^vuH_DC9Wp#Ofgx(|clFSNV%*H4QzZ<*s;Dw;+Y)%tCjTdUv){-3 zvdCVg+2qxOc|-;wMf8y~BEl{s9)%3dS< z30_DzWgcBl8m=mDbAKGr z{~ia^KSH}+Id_!NrBp9{M@~D!doZ_GBaftuHDhYHc3#$@jF~#iY^+vOgl2ELcBzq{ zDMxl|l;*HjI96Voa~Od#~)f@ zYbCyq)TAdi*}35_VK;Yfs+XU#ChCf}!Rh7jVqPh}s?A%13F_iw@qV9?x_d0q>RnUy zH|t}FwvXou>Md!tKBgXNqxrHm$r^uj)jZyN8>UF8hc>qazQwzq2dlaidTi+4mdf35 zj)#tj?PYC3Pha0lwo^B&+UJ0te)DcPAv=bwYa+^;#<2)O1B3~wE^WAib=%BisM7W3 z7o_q`qo%{RoNOP@x!fDh^QW*$xkobFAAwSH`26Ho=xxrLkA9j@~Blj z7t7X!kFA_-92bhDGA81$DL+-&561ligWro;S3H|UyAxAcJ8+k)Q}T{l(SwP_eCge5&dYA(g=Ib3UJg=5u~?!D z39L=TQ24d1BennBW}(BmRjt4`Naa;fXOioaS)Qz@oN);Sfnmb;xltNYw8kza6L(L5+ ztk4b@oftI9X?p&mt_9n~Oz*4Wqk@ZK#MWXR2E8J-`a0;xQ7iQ*xx8FINpM$1L&Jolqhr{|r6mc$;h;9MB?=$vhQTMz~2=C=C7 zWGX0iE9fyR{PFdc2UGM^*}aAcPEN4nCY`?L_NmUK>OwfmB{fTMOx2=DW}{5}xqR{# zEmmebL7^p$pGNUIsNBHc4#5?Asp>XKY7f>tt5W{Gt`L-)opPPLZ;Pq<;g^G<`RBZ+ zw+8-$eS=>a)DL3=N0v!ZY5iBT>l@jZV`~_Kt20Z%et64A zl$&GS{<6+Be@U0K9PiaWN}BeY#)8|eeE>?_V+OS4Tg?%Nw?%aiz5S_NU$#ArQ_*;4 zN-iRiq&Nrtdj|ES&r>(SX%UO$8CaZ3@q9MMa&*~)-h%#lXNZB4wp35oOEqG^QdL$8x z@{eWc{){{X1-53Lus0)v)@0vWFP zslL1C7)N3-8Vgpg5KXm@#XMSvE9vbh)l>W_Xh8?{+>r5rBhVVb3Uf_@D-~Y&Wie}Q zYR!E2zlycNT9$R#>!yvm=%tYg2nwgz>AaK^!`Q1+okN%!hkC2a#;Lw(lIq8nOiy6p zH<&p^J}IgYCNZWWUG<^3aZ$j=q6+RR}Ds;S-dg%orw345N%jyuYx2MtS8Clqg zF!YGxs9aJ}YzYIKWK5_(pn1R!7OtK_!sY_1WtOGtie7Y_DZ7Pj;>;1<&XXysqd&d` z{9`wW%+;>G4Djgya0)mgBx%v&n9%F0Zp#Pd z!jy968QW-yfhfDqrZbRjE>%GxM@G_u%Z+7C#fN)a0)2J;Z|-tgJ)ggAi_U4QBEp31sYej_?~n&-xr zn?j30%-xN@e_=Uw`i7|U_}BcVh$;foITIFL0$pUlnTt0S6j-;*H=?Z-32!>AIAca2 znj`yi%9$aI+;xli+Ik+DSL1(PyE7`2l^|3^yx5yv_}8yR`ZeMDdrFz>0Z;}I@C!m| z?-dRh#=KJ#&2Usylvkj*P$tskdZW(Bxb#gq|j zEl4V(JhhBB)9UD@EDc1q0yVvSvCNk9{y>;(1x`m6&5*?xTn+vS2a5m64d)R9*LWGz zI&(C2(+j+^^&yX~^%qN#9O|6Co%ci>64!P$gt$#joWM6kJE05~TO#|a^;OXjc@+-% z8x7gX(Z{2GKaIkSm{lYBrj$7vSexrx>M(LfrW=(8_9?!uCv- zwqRu<%vXDAcM{qx#4I-$qwNSfFoSq4XBL>=PY6ymC#zhmhuLU|5icy4AVilwlQg+xO@_-OR%>miw`Q8`ad7EOJ+i6Z5X<4p^GS9mPa<4wBE&iC!7 zJY1s&ic}Px!c{mEx`$_4eVsf;#7alb`@P)G@Za2X7s=Q{i4{W+okTtFY6p08cUF`R z#E+7_WF?kjvQ=y$PbacFgTDg}s}xWb*%AxmdEy!w^w?FjmWe6rOBH(wE*hijLc_wy z7vzQO_*)Z`sKpt9azhIqv_KKRnG8Q>zu2{4fz3FA%PF8?igAZ3@{skdcLa^%ANtLBVW@D zVNGnb=urjUm0{II;cL&G-xTLn@!NUiZ}Lp$mzs1VzfHVB)A;!#h^8If1IpPynAd?F z(v|G%slQrP#nIuO&Qq*#hPotb-h3`LiZH9GkjK*3L^3Y6enmWL@ zmD$eS*uQACAazSNqFxCdqSkzD^V7yhvRnlP$~6|+W3vnilFDg&7f||s%`loyC`AiR zX05>^%BKydiY`=b64TEs<~$RkdFTXR!|ornSL5TNtWhA*)ql;SN{(Bt#+%H3sMwmI zQ1e3w$730N9yZ9dxfQmL8kI^%)WTM>;+68AXas1f>^&#Bz zmyex&sVLsD^+z;0)gN!}gQQw|k;Y*6) zCRMsI8!d}sT~yf2GNphK&)@IE*N#%zr@HZ0$|)BN_he02-_s1$9=0P^(pN}nU19!O z8P7$b#f46EhVEi@=cThTYOcTc%!mB88+nTbcemP?0Si69tfpsO?9F$3s?my0qHqJe zyOK1a+j?K%aEiVbS^+Fb^(U3@bo20>4j?*O-YeRzgHfZG-zP7=-bq6-jS9#^STvjS z9b)r4%o)p7v&c)BR(np`J20+T>MK|A{b!knfD3=5;obB8QW6|(m%jjoPY+i*`EOy|didB%aPkqw zW~YlFjyp@hYSi^ln|vg3>urFndq`i-#FG~fIS3nER&zYPawiohj%;|`l2ZV*T&k3` zd1#t*Gs%%2oU_T!&-3laNF5uKnkai}iBUpc*N@12;WY2f&(%pP=3L?_6@1e0a%k2v z#(jI8w1Fz9uBm*MKZin@luHC>yK*-hrHXRS!T81|zlU&oKA8Hzaf`2)$BRri?>jTP(NLPW+dR73+5E8^bR1LvC^C@5Zc!Yp|VmalVhm)qnD@3$|jHdM0EZ(arP zy&?A|QPQj%%7n&or>21eszu9{Psq)Zon#4Au% z>CxW1a7nD!h9cvs_ar;`ENR%J8f;6Q7{mVf1I|WI4cdPl17ox>dWQu<)v-Z}m-4<^ zNHe=Bg}17WQT5>WhVyF~A8Jptfx2Y})h ze*e*AU&b15$C0)`d-*4Vt9p5c7b^b zG{322#`%pp#(CA2vBGcx-&KGvBTmVlDq+H=xAG#%HrC^Sfvr3GbhTwh@@!?resLE) z)`U|=$e5pMe88qN;`)d$M~o||=fSB3f4mA|Aut!w2EIP}r!B~f5j+C*=gEPr*wCPm#yop{sFP)(fP%>EXFnbpH5uxv)4)|@Pkb}xK%O|fk zLxO#vS+Xe0;219(cE_;x2+hZ1_Y!Otv?=bjQ0Rvzi;{UmCBzX6`$GJaXQ5~W9VpWJ z=E;^0Ho)6cwaMk>e@DS~t+3Mr(4L~CB~TJ`(GTRbADnXY0;mw#1~3@)dv1NBmUq;T z3-W6`d0$_Jp88yq;l?+M*+4XP)2!c16HBM}=Arj~wAxu)U&myE+7vj-&AFY4=IUc` z-&kcQhZ@Af;{w>O)yey)DI%fqh<0zr)Gtama`vzX8+f{9n%W6Nthj!c3S0h%`Jlfv&Ii~v_^IxS zVRn~(&TS0|@o=yhcJ}s3>d_V4J9z|4h0#qWq_stTyB+58awF$-U2o!lSc9pVjw#t* zUDexgVff|;^sXV>99f#d;I8`&o{c(A+@CeHy-Q4OP&^qKY)RTzDLFmtZoX?90#!xV zYGbdrTv%h#Xd2Byq87}anRh0})}&8grar@Aafs$Rxt!I>KTkZrNu76bB0}d)b07wo zrE9L&8f~S##AD`K`ey2DgY1jb=)s;4YFBj7NFV*8HOf*e;O-koWmbZl(+sY&1nmO< zBrf2kyW41S62t;Sond1Q=Rf0mW^HhyhxeD*g_U`xT1Ly2PU+TRel^$Y|V4w}RZ=`9)%vvDu8-@QzFpg}GfuKANNr5?(KY^GLB| z!@dk9jDElod{NRCF$M3~(cdZhE0od7E)L?eJx#JlYj>}WH~VBr*i6?7k1cm>;?cKr zF^=xTnaN|+rv~QUzK6Vxq1ycewHiTH1+C!7;6`AaZ}P~lQ-`gcW(2K~NvSn#XQKbm z5|em4U8~{dAj#G2fdSg*TSFf9Qr`r3pH_C&q6MigcaZX?o;LPO8YdDyHnxs`Tha42y)H*?o}mprI0|Q1(v~~qEh&pEl%S-B)~Np2cSU;%$Z^q;>Q`WT;%YM+9MAklNKbOf{&Frk>KbW*3W0X4^u>0`PpAyfoIY zh_A+ELk57Z{YJ{CW5N~DL*Bv^g2v|kOdwR5t(z$t{3zNNc#qOWk2Sc@oB#Pa zPH31GWX;&`9C%gZ85gr^jkY219jvHljSXFs5H-Wlf-ud(5bu4!ldz)=+FV{+xer=Uo1PMTIcZGljdVpy-U_uvDmc z>9MZ9)$!29-J4J=2``T06At1tKStT@;j)9NoUIu`^{$gfAkg6wpiTgJM+*_(75C2a z8=hpN8|8sfuod-dK`!v$WDf&zGlmEeLztWUC15wJH$1kYEgTKG6?e(>a@5uX)6MRR zW6*N~1yG|+`pg)j!|3t=1`kRD@0DN`BV6YK_|(70mB&^nFYA4IjN6?u>-*IM>d z*{3mp_o0hwzq@khG6k#6P#IBUX&qGMNhlh)l*Jj$kO*t6>YG~qaa`RlT#@!Jc@Hsc znyRW3;_KNzTPb+U_N2C2qTij%CM~`!>lsdd@;-7E$O_>4K1Xo%I^RS-Z_~i?wSDq= zx$#PN>s#V08)xf#*#iex80sb?&J$J*^i9XFmtaToJ@8w$vcXy^?XiEIIyJ15ho05w z6j#$(z8eG$qq!fN=--Q735q#=HbSsdrs8@_A#rUoRW=vf0iG_gmTvp9n6pS>MexMz zo;!n6J2}4K4opmGB=Ir{EJA4ZO4R+!PGp5p&+xb;H2$}}8$7i)7i$r+3XNqNzXojP z7X;TAoKGue`FVaV?X-#;Lk{}vV(J4ttGBe;Wi)miUOKIbC9eA{iZt{@Hh|EqX2IW# zoe_Zq=talS!Pf_oTUIxkCySEVIMS9Jco9E)jC$+XEkxai{5O|22}GgLD2CrI1oCz| zj)~YGf}-Fx?tPv_!QU7SdPSsAiLIuSU{Rdi1qdPP!dtvvYAkBE>98`3)IWfgh2hyA z`>!ySS#-6d`r+XR=nu#kP~(r&q;9n*t(^jVdp~>vkUg&MeO@5RYQZ5y&>uZ3QfN9X z6DUvyfzADRveIZR`K2Yd_#9n=DUxFZ&c~*hjyuGe`Lr->iAzRdN9+^i$F3 z%rekx&n^u_^|XW{5kB5QI)JAxN-7t_S2e&R03uZChH&y~WF+Bb4u%J=jv|FJbn1jH zdd=B$00#{%F)$kxCM6s>U>~M3q~eocn8(sP8F0tGhuo;bnpm+G!<=|U*Hd0|Ge(WU zBn(DhNSvY5S}u$!vIaFXmIt@4N$jZ9(EmlZtW`0y#g{;1;<`G#}85I8#CMamGbq*!)CIKmC;s|jRm_e`^NVWsTWx6f&+f~i5724&wU(bZ8f z1vATQFyD_pmL&w`bKaDsXd4=w7{i~`*H^Cqq7L}$s5SDb`0g#5RCnM^kK4M8Ce^2< zCWiwLd50}7@(Vdr=|J_`wm>CG7pbIFjf*)q7J&m!!FY>LO5@p$3*#H|V(B7Cd`%G; zfx7ZlWJm4q?f}b1q_W%Mq$NdiiBD!%*1qV^FrEm&nwhe9UxFtZ(k6;C8dTpeUWSOZ zr*)K^;;B8J)^AC)5i@v4)^iFQ_I(RQdsrZuO;;FvfJ?vSh-qY*PNJR@Ni}5!8b$kt z>fom^vKM8E$fey~eGzL_g1!Im#nFvXNh$(*x{p{PXhxdyNXaE0N`lNkJ^`hvEZ0wfuWM1E90JPc!UrlUEqE|M&Kr%QNQECxI2X?D zZWLkyCP+SZ`Cd^uu_t*%0jS`(3VOF|1YR4X{gL`EvF+g=_{`20^=kQcfg`3CVX={U zcX{@9c5!x`*PN6^3py!<80*5$3DR-Mk5SM+DEe*8TdpI~o@oU=^z=RC@zNVfSBN_q z+WyS5Vg8a;;0iN|Nqor$Jk?}8dO^xjYA0!RsSE2;P5^d(ZG34LeR7||R}hlI-OLu; zfkn2%({L4enVSWopWo(cwS{g*#z8nRHX-QpZ7VZt`vC}2Z#(Jwh#c(nv;}6chPg-_VU#?{iRLBptg|#jw zPxBqkmaB&}^Ye3O4o`=swK6bkDM{Kf)OiNq@(j8XA5$5Bb|x=p*Pju;Sfzd^7JLN~ zIr-oZDddXc$);|yb74CHl`XFgmih~ea&~f^DIlE={#&+!?G+y0&%b$bgvc6(N0~Qo z6@@;P@)^;tXClF_{!Fs^xp-_gJ78~GO+{pco0|Zv5Yr8mayzQ~u)!#8%~Kl+Uy)TX=QDIS%e zg&=t?Gpc~ALVA)88GWUQNf7d}h>~YakSr*fu8vJN!MhdzL~snW**pleJ((exp@^$}Ro8*~?h# zKCYM=9$(V|LDPL&aam(4vGVkuwNGqC-`L}+*=+UY)%gFhLR+mp0?UmW>x zX7(&`P)~W{nLUg&csJb4YB_YrL!k7n*(9=mT0wJCFG*YcYD?1mUSKc`Y}@sDk~ZRN z-SJZW>E&gdraE?vpe&e2dP(NE>Db{`4aAXR>>xPePsYAnoMrV{PXKQ|z?!cl_|Uf& zB>C5bK`}PjNt||#=f!Gaw@nK|3qFj=H9~-wV+!kdox<}AS48t$1|?MG{$M`3{1(?I zQ0>Zx?|r?MGhJ>^f$d*8Xv|qC-JPWyu1%enI_vut@0Mj)=Cj9wXo31UQzLKkIi<&;*J2hh8n5GKJSZ2DpV)1J1u)Rm zXYY@F9!J$doAxz#J}A6R;$#s~$_&FJjUA(;U4nTHtm%K+WBOIY!r7XEO;deV&udK^ zNU=j=R<5CgJc4v-ma5mD+)m3i$-$_#NM?5Y?qPr4d>si^{8;q=dA^G-PAk{q|3>w!%~BgOmJvNq2^n^>z7J z{vr-jc6$m1G6k4K#BeC4rEER2oxx(#1u1y(rR1{?1e96-_F;SoTY}I=ZI^RTaz0JW zNE)lJm+(OMBOmFduCI8O4h9N$ZE3D{p!OGq;`ly zK8>c<^`31!r(^8g`9J~8$B^)AC-xca-CJ1sV_R6m!KWvWbc+LU=JMmx)il0sxK?o= zIok2Y6Uk)KZHM+bGjmE>i|?WeU8h2+tu-LLD|j2;58A!fq+ec@+eP~Z)AMq4W1GZ^ ztJ!s)7|;Pn_xqL1Q@qc@K+bHZ*7xc)?yB}n?FWVQKXCD{X=6QBfA z4KZM{iVR|bELQf!JLy*kJ#gWMnk7|1FQhKd(C58kl~g83`ug#tQ4LsrB{bBJu}Ae2JYalTzg?ntu{!$%8OQ+x;o+Z-8gP z=iH#^6Kq0AKx-XE)~Y?YH+j(N>fKphkpZtfwMEn-!U5i#BsYj&$`zEZBZ7k^Tw6Kp zt}|^7t-7058a5Qz$24jz1Nk`7Cnw|Bu@5AuUAD(}fA)vBUGViWyZn&me~v#GwGI=9 zjwA@RY0k`(aBg+ya~cs_{y8AE)OSc`P0n*}k4KT2K*^JLbX!WfGM)nDNL(cXd6!OP#+2@=;dA$#+=dbZyY_aW@Ty_S{w z&VektCWUMOmbC5~%mX6wvlu;boR?SOAC18{;5X+KgTW`}cl29)b>YH{-_@Bkp>2@u zY4`o1`Ei8f^cG70mUod_;)*J3ti!^qdjmO+opidm!fK25P1CR(^k_0DR+Lz42PzQq zeKmlDKK}XR5JvVoD>2)57nWIo4}L?4<5FI_8))widHX20`?a|XO2LN*7!6Fl$u|$o zg4p@hLxe)E@Dv#-c?s}){rms}$Vmc&AOnB_K>R-A0|57U_>Y4F0I*>Go&@}T<7P$c zYU^O>Xl88eOvJ=nUWaudZssth?bX;hkAtD>cW=YhVf7r=W&cD{Y7HA zt%aHk3}~(`q1g0!gBa2-n;D#*50M9R0E%CxIovJdwuRhFGrY`idn=veakNJ7JMA>Q zCF1d2rA?5BI{`@yA95?X;(cHIRZX)_4j;R{_?#rN!f4Awx^MZM)>FH~IvSRy#?OL1 zD>J;NZwKWAkkipE1Xv60e$KB<<5_8;ex$lB3g|aU<$}D?f+(uc7>SIQ)mDgqIr0nBH5X2jr9Rgj z!>!xqH|5ZT+sRM~lA?$NcHa^p2m=8zF{D8KQ(WnTf_5@2u`uGstvxkhu$v&2XuvFG zGkSrrp2@Zy)TSN@MBlNY;%k?4FSN@r)N0xnz*7f}p7LB~gl+O(^`$Q}{a3dKm&E+M z>;%9D8%WC13RSwN(K%quaL$}D7m$@WBt&XXTMai}unjrGazNI;EutW61%$aRMinQ8 zV?u4qx1B>w828Z)K7F-|$nEU&zH=n4Tu&A9X(F8Dsf6f~S-_h5=E3Z$_0u+N@fQb6 zF+8h{%2XON{)DLA4O7Y4E=2{wjD;0h<+*N7)KFp}50931+oX9Zun9a{98Ky!&Y#KK zF2?vxp~OmOt4#zuGBzrQ@JTAVbCf@H^_Edj)n$v9YXL_Pg~b>y&Kls`1JBB-M6`6z zc3WAvWbm5ddI6`iXFYBqaO+m+%Cyhqlnb+W&BYQ+9i^!Km1|p~<*4|Uq+To8Uil~@ zDzOb8j~U6+d~mk7b0?gHZUQ-{ws;ab^-iDmj99yL+lxvY^4u+h*;tNKlV8R*=A`J* zGG#YjQT`W(5iE$;2m^hfNZRGbY^S&RP=+&Y6zD46w6|VhUxDK)f;u(2ufww7L=GPT z$W9YT?gqcduR$i+=1VBWgM6NScdxZz5$r~2gbYJ`hxgNorv^&TVJ$s+~ z93}#4RqMrR@j6^IVbA>Df#r41Rmj8Dp=N`zE2~&gah}~5he|;&;X$CeAXH@S8R!U} zX`c&soN4^7^mxMOp7GIaBkg)sin^`*Sx0q)ttL)afAn7cY(oUf;0oj zQ&cnlLWZTCdy4_!c-H2x;RV=2jPrjj|AOa&)mzLgG1eE9lMXxLGb)-=C}QN-_S+K) z9mPzIBVx~=k&(q`cVTi_E?}%_k!)3-D_dZk;)+fwMW{+WBYLHtkyR()RiD796dGZ8 z?#d}2QAgSCUcFIzq!C!Hol}dQ5>2uan}>*3^escS8G^u_qQ?Z(c|T#G;Vd)vacjmb zpW!?vs@y00tH?C8*0`0K`i36&bYCAh2i65re@3VlgBNf^mvvbBJr4V3hr_5;;Cx0X;d zwicagKbhJ50kHW|dhbu-Vb<@Qc;F4<2~)=m)k)hIfSl@oCqAeh9H*CL&`?R4=&6A#_l&7`V=J%&U&Qh}ji|1VX1Z2xTl zsXb}GK$D0r>1ALvrbIy&uT(o?gP3G zzB?@E#yN-b;r7PN)s>O{B7?+vJ~%U~$HqI~x)ZTz?mynt2 z?(Y45c(^{=H0QK3T*NtFI9W->Yrfh8rQo@K?wDZBe>8Dg-R}BvvXXro;db+#I(}+i zp!WH*i087Q=xLKn(;~;35)zWddN75avE7Yub-TwTV93h51il!5b1`Bi4x7iZ6P`l3 zesCZYM|uABtc=*zlfD_X)9t>Q4>M|CsQBRI`w+L)l{;7ArP8WCy;|rKQa9f(-Dyn?Y<{5*{U=e69aNor=CgFoL&Y5=D_w zTfklWszY|$kwjpD4&Rb;j2ZL+GjQv?DFDKZo&{rGzzb_6=&OaM%0slJWR2WH^r@(k zB)%|X-038xpgc;%c5s1jNCBSUoTupFKT+GpwMsx?;C?*0?1Qo(J1tW$8sdkh5=F8x z3CVFj1#<4wV!6ZBpl!2_#g$SM#tlNH+i#Pu*`;HJ1Zg4oL~SzUkTGtZC8rE8`~6&knrn?%-|AA z4Vu)vq2cS>%%gE(6dVaKne$s?(hQ3cC5gu7ksm8#uzEqTkPRcf@;?hcaeEE?EAHY* zcT6dV3QU5x^OK~w#9#^4DKuqDe_#8_G^Dwdh~*=lS1-(Ul9nUOK!D)ETADXq(}PxZ zwB7idA@J3kpIe>NY(`Zp&ZoH0JCi`>%|;vPTX6KEnbw|&hL7npWwZ$+;Tsr$Rm#XY z!;bMmp``wP{!PkHB}GIKzP2@Sfm?OM`K$UjQ-bAgy(0`T8MA1O?2jZkO38dafzA)) zs#w$%i4(Li3RykBzbVsjTzs(_L({XVj19%ke@{1 z7`y_BU7sJKH35ElCeDxB0M`t1$qp|<-n;aby98o&nIuC_ zQelS#a}1eticv;lhAXw80tRGdi9rn!b;db{WV5T~XH|*xL1^gf|Lk?Xk|ReD4fVDj~nqLMjoQznPA`dBLX_kThvBmLl+|UL@J;z#8+VXC9yFW& zgS)1SOf!fe*hWUG#p*<;l=~uN0aL<^!>!8>Yfp~BdP2q(ZDY3h;8 z;{!%E&bb0j7D>!6yMNGd(nyu{@F@X>b=Dvq2SXwYK5uIJ^;a+>h;ooA1PR$$MjC!k zPro*xC)qATzG6TO9twU(uX&_LDPprCx~+W1h1{bcIe)NMG3l=Vyvoa{4Rj6fT?i<>bM82yTl|FCY4;sHbi#RD~c}xV8KgHKX(pRL64{EWh3*82rBB@L24_`4D z2G2ZDitM|Q9*N_7e@xy*-hep#TEQF028e_r?SFGAs^06&W&-Jtw%>Jgb4b;{muUQr z800|HxoT;N089Zh`s?s?LC4!51O!vRXp{>{VhW6e zUZhnJFBh_gdw1R?`h#hw08)mG%5gC(5w6Cwtpph89%Ht_h}6@5omL5A^UHwq#F~t3 zp;yWDU)Kj67YkwT?@R*7`R+N1{{67zj$iQQ=t|`kPS3u{QO$EOW^$`R~Cq)U=P|(Or-vo4v(OjV;EE=^Kt|PI0sLt#@MKIQ2yrAe zfuwQ7KjoJvQi;ob7V#$7yWE=V56`!1ir7_`dQgr9jS37YDjt|2CiQ41#qBN=$)ghT z!ekVJ^2I`mmtLTT1njvgQ0cO5$imSV9ksN=e>#8K^{#KU$QI=y=IJPf&C`<$IMlTw zG(6NeR`;nLO!4#4L?8zfg+q)aUSWJWvd@tPhZ70c;Z1X4$e&fhF zFz;MSEj<2Y@Wt3+x>^V!ia|!x;k`1&;cFxY8ggGp?*a#d;*@hFyJ0eRAq_OljK^uW zEpSb+FmX*#aEu@{B-J}4ba?6ML!lTXOZ<{6n^OHpE&d1_no$MW!mLURol|B0VZMGs zQpIKSb>xC0E?WQ%x9m5xA&s!LoQIa1@5`O-)^WJb$RoC?`%ajC)g5YLrU6X$By&mM4y?&q$2yPa?@T=eXuJOgIDWi}DSwsCpE5)x!9Wwfn~}%I zlkEpzn8OPqkN;U&+k`q7My_BYlNJwe{VGgO)g)9wF9=&XIsRTzZWCZn3UI~w-=0~I zNn*z%AzMyKv5x==>rENQ9XG&_3{1g1Ix7!Gmq}fD81()(f=v^%4KcqZlS7=ocoeLf=S@WP zn6tm?#SMWjFGo|tlrHI^gi4Ezr+bh(9yrqeDUO-t92K>|+%4n}iLLj0gZ1Y*lYW9r zb?XwBqj`kAkIw*mHH+ITq|$q>T3Dzd+Yfc}#gp~-kf#1``ptQ=K_|(@GGIvFMUm|d zJxCckkb)7_JCKaYDw4t?KSxW)QpProMSb#vV?U9dyw1HX>HI~>vR2()QN0{1^aMAM zFinJgs2d1;Nh2daAGJHD{>0~s_{?xFUUMqSE7V`SOV=26`R5D-`F9Hlv_ziMx?%z2RE9Qu*4y` zP)i*Ht&pAcEhePs6+K4%h)Y#k3MFsC9gs-T*uNF*jZny9t`-p05?owBsFmR_!=BQk z`Y`=AXAC}jlKh{4@@x{=KPK{rHYQdv+#TUWC47ZBQ>pe$8Pn~4%2GA}bc(sW+0217 zg$sHnWAYRdVxd%$rUlozq_(BI5?1%gyJ~iO>{}C%{{mlH-6kBPZpYkwKY?f&#y5SaXuLr!!boz=y{in~yuWID{C71*u&hg6E~h2rYtSyI z#j-W3(UlvgBkY4a$BD?0E9^H;3sL`HOuYqAThI4Cj1%15LxAA!8r&Uj5o4X{9Dou&= zu;rhTnsE?Gw`qBAg5Q>Ue-aP$#8L+F9!9&d#EcOIRTjYq`uSNA|F;&?r>~1w;!#Pv zu;`!sZcS0uM&X8orec8^tA}*L)Z7`%{ffImS5(s!)5|1Hh&Rq-lZ+4aJW>Z zstgSN?J@kJN#w?N+jqjHe>>f(r!KHL*AVoe8?o0a)fAat81d;Wgk|qkn(aAv5tEmP z(lV*BbmFo`airz0yi2>456$?!o;RaVRK;Yd$6?M7hn;%v=Ey;eT)61LLI!4k?-A>Z zRLL_$njdTaBN^}PXEW_W7eM1KdzG(?G)agNTzS}zVl&6;gpAe*S4((Q=%0}pGoy0b zPL)2V%Q?u}H49@nD)FP$2N4#`iW%baJK!VM&8UaM-_*lkV#6E?$Aca8QY$xzB zuH`KQtA{vmj{ZB!Q6hYSGls_u3I<|>Z`2LP5`>J5yJAf^hj&`(JjZ7o{EDN>qt0ki z&gc6=R=Dmb>K#$BxcFN=Y|B)1R+6r^U-cLeag6BV`oXh1%0?mFLWOvADI8piQ05L6 zo0i{_;^rT9kf(bh*^xDVdho{f1R8HmluHRsT7lq7+ z+NV`@Y>W|DCYuQ@vijZqZsXGWW;sKlr;}td6FB|XgDq3?Cj3J~l0rKXqAsa*MmqE+3r$l~haI(qXBnY2A_Z8Z7R zuV`z=ZTH-Q{Es7vE03VGOIw#qX068NMKDi!Q-DuevFcbRC`DGkq$Gwx=7BdgWpa$K zay$DnCJ9s;`a+_Ej#|>f7M+rEQ35V3PfALL$<}VgluMPyXpE8wN|n{GDT%R_c@Rxa z&A}6RFS1Pb-aOm(_@z1Mlhm#mH9a$(Ghwrf*8l>t_c~wJIMM z6cfJ059n8kk-)9qDt#qI^|SuHbE5&4|DqO#mBt>cQTg62;uVYi)y(vJJ7L>n$?*wE z*sgA_w!f$)5`}o~`|tPIcheO#2~g6&Ae{iM);TI36s|I=bAeP(t~%KvWiiubD8 z`=363Y&qj?Z~9=l?p>QduRIs(O#Xee@#4dM?y|+Sqn$)!R8gVf4fy%9@m z{m0Ug{T~Z0<9~n%{x^Vq_ded@N!F}^tc(eGt0 zkMjI|)M9sER$ReuiN@2#=b*x88~L`WMzK?ahc`Q>&_a6A>iLCmd-c}(^U02#(wot6 z)b!(sheszqp@gDHU;LIy)_lOnzbs0kd`~~;R!U2x(}mg?GEm`7_Q6*z}lw%*|-V`A$w+!sN$<#;LSRw&E#SPlC@2f6G-A4|K**XHjU3^qi~ z%!v#x8e~1Tb?oj-29l%vlcdNtjR?}-65yuTe)mT+TZeBo8Q{W-{(S~Z);^hhfM7l7 z_#{Dg-%o(d3e1oShm{z>@%6T1{L9^yjlb`!$FZOYXpR#Uyc9k>}HTgly zLwg*<28g@kA8ECV|IAa)ZNbkw)Qp+A^lH7|Z+J3BVbWOi`CyK~_w zs+xX69Rc4{CPU!}_>Q@#BZw`CB#e!-qco(RCU<}_XigQSOhU}`2f_7#+Pe@WPgJ+X zeYBLKW$I4+wHYSfRNC?PZFGO7$SOPWd5hTS#j(-H`yeg-4&&_GFtZBqzu63<)U&!DZBEpC!&> z3$k9&?D8b{yVhQq-GOR0CBK^yTD$|f%c|puSRXfT-kL`+8ux6Ta@IcWXuhrn)U>5P zQgitf44DrOl_48^$&6~(yWU1O5n8P@*5*+=Eq&<}<{?)Rk}%h9J}ddyf;8Y8X42&V zRkjpU@lAH1zLoI%Ea6Cz4S#}Ut2_(K^Ud+j-68+>^j*tU;)f$}vZZr2I@v!~qj6jx4ZzE?kDuuuPTV7iv;YI)4}A`-a0(WYWQJrj6bKXF^9G`a0^ z_P3{$`}+JCut0gY^)hX!LdGe}dcx|KwQi>OF_Ikafi{FcHFE?^z(+?j7gm^|aFXqphgkN)GN3T2Q zcuI5eK0Bxx*K9i#VcMZy8VBDNV1%FJddjbx{hqw@>*(Hy9Wm|o>u@${yLoV5&l8Ky z_j)P|5cwUqcV!>_@Mo`%@-uiVcVzMX&^Pw4FRI_a@8vtLwN%_qoyVWv62!U+#t(rX z*5;`HZi=ukUTrn6kDbpegk$||`h9zF5lO3}L^EMf=V1{X92t9`V=`ZKg}-L~x5Ye2 z(vxQ>#SJcCNZ%66h`d-rp7i8Q`6T2~>#F|o8pRM??0+RKOx@Nz<;0s=vsC>6GOYP| zO|ou(7kL}MVw-*&mPaf?Z+(S9VSc}2!gji&*l6o5@7yTzC1W{ylQ2V$@OjS2#Izwh z)bn-XOsz(H`}K-2Z-6y==BY(Emz^r`>DSGlMASK-- zgp0j+yuJSOVq#UVFUa)juMf@lci*xb6N@`?aJ?V0^RphWI@X^c@Kncpjy*)Xk}d$1 zMyl(JYaeN5y0uZ!1=GfxFF6{9a4PF&1#2`%_kj3<^Lncf@3(%7QLJlS>E)`PqU1Gy zrpSF&`z`oOXARKBvGA?w2Aprn)}0aa=g#ww2lsg6pTV;Y@Q6i|o|@bPsW|^Ccmx;M z*gd>RYjW`d>m>rHRgrM@3th26i0voLciXqEAWeJ&mO=!&KbDb6N=Id)u!8-fs6@~1 zH1kx`U-?XDV-X%2Rbc#vR|NjD@S$(Le0|%w{QrHIQ2%{+Ycw##r$*K-)-W*tI>FnK zH{T^^Yb$$mb~`IqyZ4^&`Pe>Mxhg1h!~S!1LVwbD8~1wfqj9nFz9eVB-oIDKzO8oGvN5b2br{+8;XKL5R_Zc zhTH$0L40GNuhNDIF@hzGNgCoNB`{ZqAd}O$J%q!;l6%9FVQ+whoFr$fm>>u#$Z*`k zs4Fl5>T%iBGI$nvzGNCQgfw(X`k6U!el9Fvd3@^%zEKAtD%2a2WcF1o0HcOXk0%ST zAmz&pSQSdB;A8O?NTQM1t5DdYmRwZplj>zy!`Z^CA&E=FS6KChtVCls z{3Srq5R{-W5Dg0Xz>KXqh+j#(sCkXf9%DX|RgMyb?!qIni>i+|=-T?;M|D6I#pAby zEp(M~3>$*L+-d9Z1>LTTZZz5MxBYD)uSO@5dSD_76QftP&f?O-tT@9b1$pBHK=#}m z9DuqgiW;P$_EwQp_Kz!9g|9M=?I#|vY!lfm93fP5t%)RaQw^4bu^je0tBaL$5tlT& z9xlQ;5V$Ybmg~}{{s(yofHiKj?#ZhzX#FlQYAn;RT=g_(z6baTVQ@_)wqO%ggGk4{ ziwmgj9wldg^|+WcJmUyFKja1Hd5yq zYaEy)E?H?qChg-7$eYZJysa}d5{X$t za7^sBteF9l**HXz*s;Y=Hbwk_NI-bS1!;#)zE;gnH@pv0AHa*@b0+c+Y8@Iyetw>v zD4d2okj~J=AbJV=MBDTY?=L^CJG^-%{F~h|iXeE>)(}5gEF8n1Rfgh^Wnb`TXo9Vx z@>2L>!;GYL{Leq1aBwLw+*fRpG5mV?BuZG>p?oN(<7l8tX`~%is|0{3FL8?`De-v# z5Fzgeiw0n0N@suR5Q~HlO~s6?F=?2GrMmg31Wu>kO}mEll^_9~ROCSUR336B6z|`0 z?I>4*)t#vnn!!6r!wFpTxKd|A+EqV>Q$zLIV)?D7jq{TvVxd)#mYuD3Kn8$OlL*?6 z!hUF(n!#EjuTZ5gqxqtr`#DJJpc$>@s8kXn5>G)QSguM(Be9zhCE5SPTHYKK>pV~e z(4*sK+Z&QYAerJO_bezy5WFX-&wn+e=Sg`+82DCrU&vClE`X;HUqnqaaIK{;#47G= zsk}xSO(zF)8>ILy6?gv&9UFZqg7UiCL3&+cd(C%@#((Ztzi&wn|zIxl1fBF zZJcGXS1Ad?qgv&}gaNsu)l)TiJQ zvGIBOeLKeYzAphK^C78}@2*`cX)SGzm_v%4mNwNvfTwDzVUVz%8>oxeFf%iOFyAFZ~kslYvl1Vd6`4ie%OW`C(p`!bUz{)JqoC3m(SvhNbw_t z1|EfNM4eD6anGlOdZDJQ)E(Pbr}UZ4D5Ir+a!yWnGWNO;Z6)-4Xp3@*?u+(%nfEOCvq|jYGmI1htWmR`$!-!5|X!r$X<_WS_i)Q>uD5AklkHZD3wL z^kxpGxuU6udn9o@y3A6T6(CzRt#{5TxT?D?(Zx(tCK+x%56IRX(SnEMby%Rs=~J}t z56oc`QAR-ekby-Fh2H1$X`m$OXOtxgdjPp8@XvkY!Skam^tGi(FVPIiqQ7v3T@NN4 zENsNMcR3>TF<3&0RmLV^I!8koR+q<_!{-U?^t<8PBBe*J9(3?FGa`ul*Ku#erYcWR>m$EN zwO5F##P;y<@fSVBe?+32Jv=A4`@G#$hTNL33AWFZl*0wS;%bpJe=3ciOk@E=;@WN; z{97W+M-&g}>S9-%`;M1#)zi>icsfBU3!}!Zu*U?_F0dL+Py7=@UI7bz*h5e6hM%`Z zV8aG|6lM2dg>64eHE4cyAvDVdv$Fh0slxpdPqW6{%W*6;u-lD+r!3V-r`4kp?G+Og(q35Dh9yt{3KQ19nJS?BVnScPNEkGyt;+SAJ zjPCGxKl6AmGt*r}rix6q$wopS%1Lsk{MfAEin@u7F>?fQ6juHl(vlDQa9kB7P92|e z-Bvi@&vpyfsk&{-OybxcSKMEEv@`ws6(^~4rjmhkO9YWIM4z)dL=wVI%jG7s&uCPX z5yjQIa4@QfbwR+Hl1#afh`=o-W0LKLQPXEu0zG6Jtg|v}8lOxJiV_V)mDL1HMmam3 z7Nsgo7_-s?(MN0aG^XQ3F{~oh5&*mmtUe>><=h&F46bUD83*M5U3?6jQpTSgENyc8 z?&u<$)GHdgh$pEGES?8_QL(y=i{vxAX1kV=A<%l#sq7*jeH)Iq%+9>zt2V#Nm^j^7 zloO1!QSNBU5S<9!=XDhms|d%zW72r3*se7(oNWo2@Dkv%oT%wsF**in22kuqmG)D! z4WPGCXWF62XF8PQx{UQD1sV93zULz^S8|Q*sED8CM43}$KX&0YBd;HT zSPRb^X2m;XB&~5=PX}!lz67Yc6?ADrODJujIryR}6udD4ZNoEeC*G~NiFFt=C zeBJxVYQx6^{W~hS(QcjPe*3F$?1He_K%!?mGm$9EF-Y7DmX=(E7F`m#8b@&3y9Jd0ab0U4bb&1>3h8{_z-J%*RK!o|&`13DyZ z`T+(?`=5I<&ia@iNaS)@Blg}p?)Po$KJl!s(EG)hg4x(7F^?rLu zi%7dU(6sW&2Cd~uXa>1n#(6UKPX5zh=(30;D9;{Uen-MvxG#RPwLyeBIMk06;b)rjp zW(HN*>}@0`%ee!K4_MegTFwu3xX-ki8t>Ocu?Q<{Bh9~kOKrG`&p|s$l-_JZi8p1A zs4@O|ppwIn!Y4q^Ih@CW-GfIuawl-!q&b(~AQb65W%+M<&Gxh{;EtJ?EJfY44gS3nWKdV^juCHMel0rfaVN5}CGo##_mCL)VzwkG&seDjNo zcN{I&a0rr`;#3|JsFBJO3}v+9Rk9s(BGuz`^|3pO=z37lM-D3AdD8KM^snlt93xDA z>BsH0Tj=g6-)F_7#FW*Id?);@rfqJm6iVLU-CaR4Ml_pOwGIvGC?y>K8_a4w1|$&aRtT&w>YlQ?yjVRbJ| zt8vz<5=jKQNUcXv;Evsz!HzhcVK*o12KZ_$G#Wkp8%C+eN)|(kRn($6j{?7&JgTxT zlNi+*saU0Mqxpx-U*kjdB-j&!*6tWN+?-!^@&_xx1LcdDb4DX^jbLCIJ#HGz7s-#s zm%OJWT+ttecFVquGbS}x&hZcslv0g6Dl|7&^)%^(cxU`GU0De*-{ZHxZm$WT)Eevf#1L+n`@R!+$tN^m zE=$F6sSHsLKH|_0U}`jS1pAdn-gjpz#(EgY8h0?Cp zwX=$ti^AZ)!GB}@V0Muxn@;WjY`cjMx+Fiyili}Gl}O!iT2tCT)4}+ zzzVq{)R%qnBMdOd9Ntt8} z5yb_n8r_HE2jF|HNTV0ZMNsnWt`g+NY}-2ESjpk%fEf{KF&H<%9Fa&qiA@uzkf9UT z5(`!8vRyTIS8MEnFwzQ+h|I_|_;0wW2IswU^_EB*54d{*N}feliHcmsqk6#Bw2pX| zGt6oWdKYGViG6%NfDkFc9q0gmbhtxSv+s}mT@Wr&I8R8tNFcm9F~CxuM{plqga%MF z5P>cy6D}Y7I21u{q~|siNBm3gQ@t9#^r+yZaEOLX8e{_23B`M4X^z+(NE=A(I=fAy zJw(iiWJQIpErYQss~JfKumrMDk6JJf@{%!xP~bpPpdr-dgd#NPC>RNZ??z#4$Qci? z^*p*dyWM0c=W2s?F@i^*C7mr1f?lH_K(_U@*r_n=l$2ZZm3$#qcYsu;Q@c|pBoZWp z?@qll`O}T*fWau#hB=f=q#-kVvTz9;BsK6Y-c&|9{Bt5U0IQW(+8t#!)3Oi>h>Zo{ z6t9xs_3w;Y$xhJVY%lH&?KDS01~+yAG=T9dO$cX;re72xIvx&GO zE0~ytBJ=nC)b(MHc_!4ahR@Xgi zEyC4%F0{T{U>|ki%2D3t!8CK+kvh=N{gw-=KA;rBtPubgG#^uIkzt;L{V}C zdl*e%VET0;ll*6nNfbB)$bB>=GQE0YSBigw3JzaHU@OWb@sMw-s-dLc;er_ml>mHl zM>xf7R!d`swaIfxU@(sfZ{qwRo}2y$f`S6R!ajNdu1(yTwGv1>a9D=AZzsa#s8(mji~*xE?j(HIWQk(Bp7ObwQ` z#MUYLj;|4Uo&HjkY<1^^|0z-3IjTVWlelG&_GpKEykDAjgI%wI5F>J}Wa72kwoJta z#0^y3mWr1zhc86PhZnS?vcC0g>z&aDDK@jLX^bSTcr{F1%fbYNftwa)!!*Sl<+wbE zdF3{vOs!e_9obv9UwvdMDl5r5poID;t|}wCfe{D?NiX)iV}sA zJE8D-Z{d(iJM^K5iA?b~0S|;3vJS|SB7|ErFfh=2k0p?Y*UNyX(sQ6UQwa4(ihxyu zvlzWl&m2rAg7h#?vxI@8}O=oU4CNZV`(D*{$ZzoE&xQR)y26-UpUE8;k z(;jgVSGV|xHXv*mT1O2*XP@GceElTx1wL#@ZWWe@aaC!Fk>`C@Z3ImOB;MU@4zuGl zpGg>GL8)DlBu=Gtu=&odWWR(ghPj_$aV!|*7Grk~hbv-?%CV{n;_E%57G-m)+ANqd z`|^It>Hjuh`*Mii+z5zhcywN=Q){t7h9oX+3cG zNdKN%I&xkv-*{OovTd}$TR+*o!IZ8W8@_Do{VFEO%cu1KpeKLFPgMy` zbgUOmL_2lF;P{R25%0eKMd8^GmPEXkpAc+r52O9udoM7Ke0@yEJK-;h)yD8w*C-~c z2;j~4mOYk=@$a1E_Z};>$yUIQu^2yNkcx|o;t~X)x$+IJeze&2=@$*T73kubA4ofm4&>Yk>8JJWCcD!^a+zXf% zKY#Vj^NHl>HcZn{bQC#0#F5*H-C)DgUgd6`Y_-K~%q$wh#@F$kr0Cgx$8kyJ5`3lrW_ zjJFU?OCt0wi%`&f{)#!ogzMhm>=@$tnVHY}2*FIO)w|kKWFUOeDE{mahrd#6wj-E7 zCgl)^%ec92U@U`blQ~MS<1Ih-BLwDjBI|XU%^wrf0A(k^~!OF>7 z599Y{XePbym|>GPaoX7J`%@#@ZZhq6DT6ngA?80C=GZPZ^TOt-E{U0i6iH!r)|oye zXsRpU4zCH>EC}X23a25O`e?fD%q#{$-GQqSVx&q*%q`5aR$LNM4Xl&!Qpy6M8K9LI zxJSab;JT+}2TH@T1fn9(^m^YZpHpk@==U{`*m8OP#^Wp$Y_ffcH^kW_2fD;G^+ z_15s5X4?Jsp4Q?e3c;)R(>4wR;~V-aeInK6B19_RiSFXx-3&8{^9*TrVfXO^Ptc*E z`(F%}POxLUv@G4%-wni5k46j_WyRp|SZ^|j_GFS&v~Bv<#FGVR7mbhd5PU?GV2Rl= z)Tb$=KS2C#D9v2j82FoP9Z~YA>XXYc%+(&OP?WE2%#6O4uB z54{!TJ|q5?mQL)~TL#{h<%+gwTm|mjgGM&P)}{j?62wyit9u!#c&oKz3J*(d~{SJSrMov_FON!KV{#2^+&mQkrETnJ5hLjzr&x zg_D-d5|CicIS&!mt2>Ko>LMXje8rI)lXq?L`+33FTdvDQ>kdz$U6-K|;D1H9YsC^05rj0nW`jD@KFLIBeHf*C zVf%U7dmw;PNF9#tDZ)%Y>KMban{E+FE>rw^m=y&s-isRvaFOk^Xw@UC2-MM(pB%lc zs&z*c`lD``t~q66_z-(eKd(0d%S&#uF7dRjCTX-f~eKJaQvO3FU{V1rNxn2%huUzsc9Qi_>p-{Wn-aU zTAG;TXaGhl-Jtvk2f_rORzV$&jq8mnusbkk@YljS)Xf-|#4_B9z}5;|PQQR*r}5+7 z^X5c2!tpKwiRKjBNg1CvcQJ&wBIvxe@5}IS;=~TzqB)$xM=v5Xs|7NDwVqeK9E3v& z;>98)A+gH!b2I!b*Ta2rw+z_DDQ9)Nkk65!%ZbYl?gjwzcyke!2eRw5CQp?<$XoGd zd^O?Y?i$<+<1Dawaua6YkqLcV)u$9(-XG+wKA69yW(}$Geay7UB9oUUaj{^U<%>-; zYx?EjEkLL=z*?0aj(t^Qo}eO04J~TLg?6t8{4qmf7ffq4T)#x4q>9og>Zc~hkKT?v zK6&&9YZ*^6C-hV(T9EGsI18J3G0 zYJ`J^2UsPbz2NewgLQtjjwz}_+Ql>^^CcPsEw+W?EWqF|YP!V<;dHc@;%Q{&BeGw} zm!@(S)N#t`LY9Ft=>*9HqwV8@e4L6^YyT*hq0U7agUl;(f}8n3j2#ntT~Nn2FndUt^ht^n=UG$ya_&9*>2&zshqQcFPXXZYzh~d>jCRH!a8!G78w1Nz-oCBMj+>X>yea zU@O0hm`5evkUy`oEJGpt&4o!xXFi5OKF0~CirD5~^NUA#VJ9B@^b*x*m~>;Hqx0%X zqzXT*(R33iB#s#Y;9o;bL>vjSwQpJWs7;qbw{B$y;l(sjx$sKzJTjJ%7fa6I)JxDH z9fS0HKq0({PZW7^Y5EB@UEiXy?l1SQDLdJ1qMxgwT&YTg=$ZtuR$=iPe%WdThSclX ztB(VvlR}xlX?CXYUqPP$q7RP*#6*h9<=68akRc|`NF0oNnTU`K1AeV8Q0%0}P;Nac zNj&gVeSHq2)I`EuWoi1SDT)g95{#xVnYEuJe}apz6IVvaO&V6r8~nvqT%obalQ#?) zbc}=e3Z;DU!fdvlBfr6ac20i_T$iGtkZ-e8gWT)BcJbtdW02#MC1)j1QXJB{vQ{l~ zT9O~)QP1(kyZtfd=(PQaoQ<&CKd2gs#i?=VWtLsaKjAdF8*TpANvzYA4_ZBX#k|p(t{aPiap?+er$C^D zgNH>d2-M|Z#d6Dfkmcm`R>nkupFOf5+#z-){Ly-w(-_ds`DaJeiSQS;)(}vOR&Y<+ zLUy)Q39%RrnN&~xr{z!1K`B{KiMw$>d@;b>1|NtsAfJUEiXE!`q$8g)a5p1SS@}*C zcH@tfH<)18IWP!2ad#LQY0pEaf`(JNc%s$_B{8#_o)a2Qed%pOqUk5yEQhagLpS>k zdy)~`zaNu0R6PO^GZG;f1Ve5{JDY>6%ot?Xrb6MYAdDq_zhdV)I=OI#f`N(~kISVh z%wSN*BSRA7_{Rbze>_J1??Vq#V9Gl`13FR^l2Z7LB(e#B;G{-F8bEd?T)1-E#f@Kn zV+S;Pf{9XSiU zS`5t@=E=8Yj_W!=#SaKbx`!PSa}S*&ZHmFBtte6=l)5$I+8~A1$KWZmG_P$>H1{2% znHpxS6^z)S)gnhChbx{*@YR;*wH~;xz2Ww1E&Ia>INHaK{r%h@41+{ZCbOb>OXxRd zuGVCOy=*nLAt6vd?#`!^MW|lSIE{yj(;q#r$f<{#BXwy918L=hUWYL2R6Xr}JZ`S} zkTu!EpUW}>tBNj_`zQt(|?z1QZ9!|`yYbC6Mhh~*aNRS}de~NCBQ(BL= zD)V)21_u1z(|AwQLkh=ANOrV^;@qATb%L5v_A>Kj#+{jtKB9)WG_4sSNt2rY?M>(o zS|AhrdX^~>` z4L$nB(=9gFU{gx*fZUW{#wl%S+J4*!S3O@VJorcYb{#ROWKU(sRq%1#yOuuvCX-Q8 zqap#?SVdB#H%v|zco3FC;pq%$!7I`%AG@U^aOBzHRM-@Uba|t7w2S6P!K*kCIlI+2 zl@z4Do^4@HQo%NebyCLnNAEemy}$mt<^S4(G1C!<^{)@Wm6?#<|JP!7V0J)W!%2|#V;ZA*|Q z_|`&BU}a3W2PNmRprySq7FFIOgn}brrN5~7iL=RMDG6=H-@b1s;!g6W4c0<(g_d@uZSEclU8zph}^`mnpno0%x`FZv85YR;D{bjOS{l z&dOO0Qod;{GMKC)6I#y|@34*IKTc77{AjPfi{n5*KISQV#V@f=@0eBVULVp(de$p3 ze|u_^8gOPCIAd0pJ=Cl5!yEbG?GNszL^g*-gjzCW?ZOvT$TNh$$b9i zGfS6Hfy8h$&f8Z(?YSc%u}uIUp=y@mt0$)0*#p8thm;YUz1g&AfANMf>&=+gc831; z_LTxl<6GkaA17eDwvXZ^(+L1DHP`cBYI3_TRqiHEE39*5b z8i+WZi<^t08u_8@_-|K6l11Gr{0JsFB|aEr6~z#`#=$(?SEeI!oyG~m2bHrfaU|}Q zXtjKl>8LVTcAg^XHs0LpC z@YWj`kj1sgg70@J@Nr%*pxU$?!-nB3D@X|Yn_o@f@T}B0K##xO#EA2juM8MZjj6rD z(>odJTTGIya;bX%5iND?(#wSbycBbXEhxhK;0lm9Vd;5QiJ%Ab2&bYx4{{Ep*(j8& zH!I81MfGFF0W`T-xM9Vc+5m~_NPkcZtjbo6va#_$^+0HNOcWDS$`zM%Ow^5MF8le`>AMF^9 zhK^k@C^q#MTd|@@J(Y!^UXZDk2cy5_D*zC^5;^E3@ zfBv(Lp?B`VVS})|Q-3-Pv=ITFt(M92^>)a(-RENDoR;5;0i!61DORXp}WJPE9*z}YVhuuDN*`jV={d1zatbl}L+ijGjW z$U$@K6frz`8{>4aYe_7&Afh8Ht6g3-;aWO}v&x1P!NYo1y-o>xKRj!mj zc#FMc*{2T0)vWkM(^Uv28mW+_dbFPP;jTw}*i1_>K2Xv2rx>{#2)-*@NS~f}vvf^_0bq zDpv;0e{{wz)wFw&>daBMwdwjtUj7P&!0Sc&-TAXKa+BoBKM?0m1W$B{4f3G6pI7lk zrwbBq3`M2(TYNm%ya$MMP;o4^+ZmLktph2KU?Z z7cIoQsMl1;j{hZrUZ!vMV{^2ze?3fx4_rh`D6FZIC^z5EB#wDoB54EKX?||+N+WnD zLK*W6qPbd-T?>b4ljajl;*4RHXK)o9DK;yx|8%`S5HjUAY3R5iP5CmKRq$&Pp zA@19La#6LSMAlLY3-#CPCPU0RDY6cBa9|E}FClgUT_Ki?t#|{FF90XLiyIR@TA&R? zGC``y<9}P+KM+_!Y-l)0I!N43}wyI{mjGba2CU=AxSBaJA4sKJhg`{Eh$5mzGS1(6qT39 zon8b2ZLqI5+=RC5kBEG^E~|-^TUPdFO>mQFP5nDTv>2`6Ur<#uBfyB$nC=YhJp*>+ zv)uF9!}@pL)L!VUA4zk}EQ){vuF=c_KV*$8M1471J{_~A+W(<9vW_cB_gX{Af?CmE zB;I+@q+&TI(PhKW7)~62#xtTEvnD=fvmTE#gooUaSIXc@)RCyk4P)GI{T**ap;uJSp$LW;Mx^h}b=Lcg?Ltk$V$=e;&fV-a z5)*BGWZwsYBeKon&0#n2&AAo^+{t4C(1Xp8(RA`1)`$JYv2zF3m3Kx)VfFab3N6!`2GwYk;D1f1c;e>fhzF6a>A~XmCld_la=8gQu z$_0Z71BZcNhlawe83+@iFPMg6q$j#a7FmsVrV>-_Xw+2@W=AqqaKI=*3+ACF4(C&q zMX8(-TQx<4fy@|H_#WSYs|Y^@L32Oo#hbcHmCQEb5Ph1T@yauonks#3+uDsbLz1Eu zH1Nzp8p$rg-ma}5Rja`7``zJiG}wB3d%IQmZA+=S;ICMtuEo|Qx-nR}>IM-TL>nI0 z5bsa_us~L1?{ANOHH?MT_xAQcj*r-JTSoVtlImv8y|Q7L3+{EZcih4@=e~KNqxG5(d$ak9BhFd5ri94*m~|+VzRWYOZ)&1LDJS+BYLEk`b+eD<4xK-tWusb zkdsw>FCGh#?>4EG~*zpYOknlNYZGtMCipzOhuvT31h+cP7qA{sqs-Bxru%ojuA6&esiF#wNP}#?gw1){h)XttPT?^* zwD^4-9Uo)F@bAkeVHA29NoR}Rvy5RniIEGW1kxkUb~Du;(q5|O7p@zXoT_x;uv3p| z3oBoGX4TDm)(QtFrCK)v{ej85E}urm{ac>uHn%<7Q6qypqNRv1?e`O8lT*}XZH;~- z?NbC8z-J|CmtZSJmc?M}F+vE!9#wi#`Ey-2??%h(N{R%^;lFw{iiHj{4Gc|artCPu z)4t5^4?8HJHVdfNN)YOW*ZT>}8;)e))F80&;IPMFL*S^8BxR)#;Ir|Y)%{RoM!myg z)ZzLgTnNZL7mbpVjRziu zSOb+Cdk+_tQx1=hvokjfr>dIjm%XBHN;`h-dpb-zK`*<6Uz#!Io8a$05n2e*>tTvo zwPPF#L0UF3j9u(vvHXWKT13*W8-GTm*oJ~(C9y1q!65<_+8-kc#Q$vqobVN ztQVUB!jEJo1lcr``J*2tVi-75`>D;p$c@OI z+4|>k9fo~D$HyJK_QtiJKA;57%juW}(GuED>00PDm{!Gd+hvHA?v@suK0VsNJ5I>YPD&E`U`1~cbHm=VbxEWTOMX58CS^09%i z!A_W;U+l-2it&6_N{F9T##IdmVvI7G7aS4$!@_801JO0{AevHi;4Q4dru%xBkV%`XaFLA5T0M~vB=iNr8HOVrvXh36 z0qBjwb4COwd2P&c$*!^SjUGDAcjwr*0Ih3fuJ2us64tQ{Yy7&{4c(@W?X;Z#bmwL- zn|=;cijhVwfYHXMO@L_~?x|Y!w5?k}+Zi^PakV1PL3JtNvzF97wsJk&^|Bx99JF7G zzB2*U1Qcy9SUI9EgJE4j^vbM_JfF^n)NcRKoEm4JS8$!?oqhlRID7ACxZdb*bY=|3 zXoJyvAENhebVeJ4s7Z82L>DC_MhQmmH4H|Lh#n;cQAUd{NF-X+G=hi}*Z23{_1?Sg zU-#a9*0at!>pW-H^EvxG`+3&v{n^{!s>j0MiC<#w@PXU-M^i-lhCnMkT!Sw|CoZ|f z&O4RzYZtv-dAsto{g<6()m=jGz{V`NiVfU);xL)VSg^Cb3MoGmnUj?k$df_2I9{)O z$Qm5->EzprtYPxV>?TjAdFnItR7xKukG#|mm-qNP++<&B{PZf=Ia#l&TCtNeRj$Qd zUIi9heyZ0Q{*BO{BBwrLhK2i)lHXf!9mA^(HtW@shCS|b#Jw8av16X{{FVF?CPY^F zf!Ch|eEseDLh&CL--MIWuLi0)X)GsP((j6?EW8@-#K+3^C}Gkhc6v{^)cfNHaT|Jr zIeE3H)X_qk$DrYL`;I#43jzC*>@6nmMRbo!r;t%WxU)97yK13#Q3C%E3s+rTk9y=9 zX^7&)d_t&DXDK*R=4TGilwxU-)-h(Ixyxu z7`>@6@%5v3Rjc`~Q0NDXvQK$0R5-^1`$Q!xGQOs8D=un7qG6*baHb5o|;5>vSu*D3?#tFh~u3@X+ROJJ(5)2h+-4U>*4z!3R zj)}7x`85`;_5mWS2}lYV0O9tUDJ_`iQmBVpN&U}DcE!M1@BUqHqUqlx;}=xjgm02Z zJAW^Ho&6*EQ$k6>J?5%+C!w10V38Cmlulh%_Nzh`%-xOyp^-Qd6Tja~9ba>1C4ykd zsQ7hV|FO4A9r^f=d93@0~vg^yVpfY!x1GIlndoirz~->(=@=2?EZC{iivslH|)m*TbfIL|lVa5=l2zc7Y%JeidxyMYc3m04|Fx3@{Etzjj)BTCj-c5gfGY|Z*iJ?Ae+XbL zSKa!rx+|nzQPHlR_)o~i0ZKksX9A!KV)P>m0Hy)lvrl;pVk>GhL>{i&B(kM?i_qm> zrxM|eMcH7$vpWr3KW5GglQ{1cnUpo8N9Px@5qowvLyyFl9j$;;HvUk}4~yh65|9jH9W*gdzUVUe)EAJsr? z9MzlOW|*|tH9UoNZ{`)FWZFx?Nr23*ZsQF}CC+9NrCA3 zc|&GQT_o?i@aM)6QVBUFk4kYx#n~uHbe6*zW>y5Qc~n-F6C3A|Mq#jH$neBCcm%)+ z4l^foW`Dr#7}_vUejF0$mifmL8L-#9KyJV+2(9NNUg9EecRQHe-uY^ z{ijgb3sU<0o#Hd)hm@Rvmw7q=KHjbby5Bjw<6qNU)-ZlkWSdM;dy}DYdRG*q_t?#L zh#9Z)n@hM(!0@^q6{0ZI7dF*1lgu zu0u0ZZ8nzJJJ5MB1u*=CvuYvWOejH!t~{rU5A6@9~t7Hj4+(VgWHMWDkL#KMcccP-&Iu=k>A=F7FDV ztpTzw?PFjvAd#l>Mw;)hm&lwC$P&q<`m-sn^va0^VTF3|c)t7+S$egySe|#X^)Mvb zzm1WTm;)B#iTkN@)5OvuPjd5D-R%zz)M`)Yw_hejj!;Z>gVAlLa!gNKgNij{znqHO zzY_>J`-8BYw}Rw7)Tx$B8Oo{fMc)77p55S1KWx`Q_1%%V@{SOf7}fcwbbgven#pZbC3aVj?ca@LaBClm|qnkV0ivX z?9cUc4K+vc<~ii8GJd0-D5@WF=P~daS8Cd)DDhJK zjqz{GOckPG@<0LV=%LlRAnP5dKx?5|&3Rpu=uNerRW6Rgr^JP)XV^%!Yn^F)4-K76 zS_2eOF+TcS%kj(+8x-$o-TvW}lTng<8f6*k#~$r?)rn_+e&=I3m808WB4%#NFBf)h zQxB)4z99_%;n#+ROXNUrXx6$*<=jFjW2Qn4qvU1D)0gB7DVEdHAnn7`wgcyk(ZMFQ zS+2BapC+t772YsQEGRNu>~VkDKi2LRAT#ax`1!G^6P_*%64mg|TB|AhuvXxN(g1n= zSuQfVad@SM9rX=Ai4r%1TS1Tb9*Fl^5meoHatzLPhb#sCfqt$T&&A zrJN*}@D12(p1*+e&bn5>PglWhmRRdV9nBUJ9;A#6NXp4|A48QNzuOQ7eG}RDz8zaP z*EPP)Od^2_%5i567*#0vi~Ixs8FwWNHgdK*ydEFtIT2rBrVboQ z!98+Sh@Wjf|H^(o)YPacn1Z|E!Ay<_3QabKb?*q92z4sis$p`c`0;H3m*>mh6jb68 zY0_wx`4N+~vL5zAzufe@mI~Y5Q|XIpe>!(Jy4Fzpm>M3ucUW0g`Dwq~N)nKjX6Ee& zxbS#nDK<(rx$j(djeMYc1>loSjwqFU6hHQ9EI8VC=V&T*UB+Jb0UuPDj(vJ5K>l|C z>o2g-sKxc{>lW7K3+^%CC8v)jT%;N$L*ewF-5ur?Io_(tb0?;pvUUpko z5E+9is8koec3F?nIh!Bq=QnAFR=<^4uw5MPCbP_ zwOl9ihE4`w&gygP9bn4k5J8X7%9?;##E)IP1MSf5LpVLe~Vp$PE(gPxOcp<;c*w@}c`g>W_Sr z7GV+k@0O5%{YIeP^888CZwsK}*F|K-va-e%5A<}EN2L+n!eYG-R zxGDKJxx(Ut8DD1eq=V@?#_y~mGM_B`Dp`^Uy{*P-y?E~XKJ4>qBToQM`KW_!JBlZn zVBz^>Utrq4g^$NE%9wt$6p=`$FX!b3=VHsL7(8*XTz#uHWHvu1^;Kt5t3DSP{-$o& zJ3r)8d2^F3KvMD@KCk_$WU^NxMOCHoPcxz`Dk8yb9Egb;mFe^_Nh#DEU-9CXUq6?T zb~%ODSWsNQtC$-(EEH3l;$l#=)AG&^3q>Glbdx{VH@q{>2(4FM zTq`cijLA&`n54i%ihG`a!nULbdE1sBS9zM9s9K$VZwJ`w(nVQB6wXMdb+<^yuEC!j zX+_7qsOaiH)w%m%pow@@lynD0w)~jUcD=X)KLa`odAF4_dQYtUH_^J*+#_b^#*2my z&agLbT`WbM86U=Y5DGk33H4g1*V z%5}^)8nJ8$8-QgnFu*?LMWtHok@YA?K*??|U+?TUcEy{xcfU3@_qJ+xXzcT$VLb)f zh=9^>hOX26qNoLPbZ_g`GON!uy&d;872|;xZ9j!zG1LeTIFI7Jzs(}O!93>dmSZM5 z^;NIrF8|V>Ro)2QyHBRkWDRE!708)fZy$7?TK&eLM(@st)#m-V!JC`Uc>U<{P!PICfo<=d7~YikO+OkOBW2r0ozqC~F&%oNOi{ zq#vm3Dx@OxpD2V|h3xanQ<#+9>(#{FKm(-#*$i3HCYmlsj02lOIo9}Vzfm%6P*rn# zWGDL0`Vdnv>#v>ZI$7|Q?>C-(#^`p@y~VjbiX;qex(fO8>q6KT6PCtVx1&K*Wuira z@AQV=VZEvp@<>9!Tz@*yb}KQ%G1nOY+Jh(T)V7}&XdJIcKHEj`1tM7kwaL`Sd6Uc-`Odx0bQT3*#gRF z1|4R}xYPw+4m-v%j|sj6TWiLJWsu%2|O-n z7Xg;r&iJ*%3}>!UTz}gCK_F2RAMt*vR0C=$EZF~%>Bcvn6_Rg^ynNx{bQ^8Oj(1-% z2eSUYX`ePE$xgt)Bhi=0#i-fSLnZX)_foJ?mtb+fx7gjtkPH13XmPy>LR@&2UUEsV~aGf-9p2!rc|JIGl>H=w{fQykP>yzD#^( zU6A@kn^?djqfi0Qr(#Ynq2gDI-`Hz;oHRIG=ku&-#vg}O<<=+;=J|@%%;#|@CL1|e z_~(M>rAw}_k1UvxT%T6oCUmC-tG*J}Axj?{%sOUoAkUj|Z7kV} zImhE9MabK_+rm2R1sZ?Cph=lKHD6Kv5`%EI7hct{OS!+uD#=BcG#WWupPz|bzb>~i zx6az$|D;TSbo&u<-7NDjtyfB0C9Ghe!m!p#&H7qb^L&?8uKUl7{PKkhL< z16VpUu_IZNA<|Nbv;sT^IddpkgKTRhGATyYiloV34<=iRza>Vhn}o{Y><|ACxwE+9 zHSP9(FIsaXvQ}D^X^?rz#yU+>z46ZVj%)sMmy%DPw7Hb!>?SGdp6G1g)(d*5q!%dT+j%l`V;Xph|4wUg_GQ7?e4%$V zGs?xm-|t?g`gG5y1jPLfVxi9+34Z7&r~s)H)W2^;GbsRxOXArkx@B{X26mNiYCcR319-DQ{ zYzy{W9B7(n0mnJm-S z$9kBd@d!4pvT@l5r5tzd63B7<6b1dQ20S-Fma#oUWM+ZxW^BJWi~XAI1on7bm6aU- z0a7U#E$5-dxSNR^(tlV3{&lzs)#I<~i0fbHQqQ~Z2)L>AKx^Bgw0c2GovTXxY0c4SJ?+N*Hz|0J2&2yt5tKU%6qECy%pC| z2{SHf?VP_h2>l|Sm?}fG4iy7Q=7-5jR)PEq|WszPrF^VePYxwvE8o z!h_4BYmAwcZeB)ik8`x@?qyt?4cB z)p@strY+tZyV2h&EZ|Dih&WEL4yfbzBTtMgp`#04zhD{Ibf3*AOjH0#kR)p&LnejE zI6_w9>|VdVtfoKD2jRAL$4a*^sPM6y4(3U6ELk!CxB!pR+-1FPsc;sDcghxW+)14fK40w!k_9s9G5iZ%N?GPjls*H_vWJjoY4=xJJb*gc);=0|`O*-A)7fe#_ZpB@)OjJLie?NWp) z7#qIa|B9WdN?Hvb`#fwteY>E$dcsN4Gu^b|`BI#7qq7C*=#q9i*t{b}_bgANs_)AJ zXL_~@nh%nheb8RiTN}WB*;=@z9s%r#2OAA%#iYgm1?eiuh=2a;b1dDeluKI0Xhp}IkawD+6 z`u%}+?=F(^)-m#yu60`St8scfnj&ga9Jp+M{m;LEfS=#VYv(lT^mi9JBq8*zEOPnB zf^I))^s>)0Nx~xN)v6qoeQkvb>LaV$dGhS^#^xU+#Uxt#DCzDcehioeo4C&{$dgJn z?utYETR}@dt%13fpHlZ|FWOApf^Q;0Z1;qyC5?Xnef8I+^)Ib2K+Lon|McwgK0)Gu z6#%Sh7jsst`#bKrz?)^pQWWd&xn_h|c$I#{=wFoh%bfBL`#v62k5(z9LdBfwkh2HB&(g*-3CIN?vb3RuN)v5 z_)`@k3+tpDABZ`i0CbzKV6IOsU% za!s)_{PS6)n|Y$UCC3l8!VfOyasJCoyvfpR;%-#0YN%V?SwfbtoiIQhiGY?DTalGC zvFo~}s9cnCyt*D@{qK{e89T3W9So=c0ULv=rhK9&^i$3`^}#gKWW?}Zh!K}R?p@OF zD78W+lE&cctE|q@#J*1ZQaDz&dK~DU!hxs~SLv#*k>UULR%o=5iv0SKs%SVhv3D1|eo_j#XRsdJyP@yjK}hWlZR{Gz84_06d9`I-iADFT(N9JP`ph*$c%Q!-O4 z=u^VVaE70vfwQc^h#jIc_L5O z^xp?N;I05@L>`_k3A-wps8A(Wc&`v3<&&Z5h-mczrFT&L3s}<>ey^~w+0n#6lgE2X zHO=R5(zR*wU}b)c<2LtIw#bW{M%_2SmG0G7bK?to&!c!7S;$nhsKajdt&#%@*%)-y374^3|*-}6JkS14rb$=k}D^x3-|ZqP%@ z5b{Mc*ZR)c1nyVEu(1Q9ACb&}h~mDTm>J2K=(j$`#X4udQIpLr{FJrX*M+Kby+O@< z)wO|qq0|8<7UbVl7!g%?1vttkG-Y7pL*mMik#HmVVZZ*7jA08-iiGZ`!?O7p{B2S5qd+O1l-ALnvk!>15G(mqN#q z4a=<=if@x=S-E)#oPQsA2c!HC+Z&lxcK_oy9HV4?;NyOvzn;m%U|~JXLYP zCk-rhpS-GOO4jI4Fi+ExX0;8fj7=X9^~jDsU2K=m_S~YA6+i> zI9Fk1@z=a2780tTU~i2M-GlLrwWTPKe%PIY`gJB<)l^`z=>lJ|qO3!?`ZSQE(JHay zw|^|>Pq3TBpOPg9bZt@vr|f~h^b-DxOjHQKiV3RhftW z>s03gjah|fU<-P(_daaU@diQ0bk)f9PLAFGrf9R77izpz^6Md(GiYbN5DmGj?C+C4 zcXrzDIO7+b`iYNv>yfSoUYfiDg*`SY%i^6dP?UhqcA<{63m?2H{6(7P4S2^KQxRS! zWA2pdRMhC27rWK7M&cLyK=j_rGG!v4aL>( zH2(XA5B4A$0XMSRn0P>oGfms<@K5=lbmf(B49d{?Ws`<$m6PHJH@z{Z@Wd#@ zIH$5fr$2aJ&ORg|kOCJV(ItNdjksTLU<`|h~v zWm(N`nCO;5f*dOqQha!j{b1uwOhie_;TjhM1(vni{(I!)FS)m`UnKP=NKBp{lZlaL zB0WBRW?zeaZ=UzO^`B-N|8$QLGoRqX6c#@nwm0J8fA)MZ_v;HYiTJJtZjIj2+;40T zsiDwGJ0=$%Ln!`zYs#Xgs)L6|5nWaUJ$i-N+1_zeIcl0^uk&8D=cb9g#*(v1-ojo} zH3x8cj60HUF`~zMQuqyXFqzzNS%kMGo&Kqp$m+r2j)4>3E?uD~SMMNBa=FM+Yh z3VdImF8)9gtEbQ-uh$!M9o!0ac~f9?H0^e6w5+c?@D(k!%y&LwqIt1QFN$@{-AeMt zT$EH5g;d*%ho4zLUUprlPyTsK62#$H4fF?p9X)VU{hbu|Bb!M)EC(Xuh|`_k-HNaQ zPEMXj!}j=bU}(q+sNwlPzq@EF6Vs>PeG}}9b-yV;eqi*Ad4GtwQ@kPmAolmM-fzB; zuR`005;pj&0LwkD5Hr2nvs)fdC8ID>Y7jR;qo}#GZjWDj1er$XIr4mA=1I2iwXoK< zU_bQ$-{-1D1yf2z7GW+L(P8|*CYll@s%8J7w|7Iz;t#k^Ax@leFDA3JBm6^i>s)Iz z^O0FpzZm=MEBFT|{cI_V*zKbk zYykG6j$=k!Ms|K&YM##%h5Y2Q%__IbZw~j?Y%C;w_6kha<a4n5!V(}av*SwA zHUzToCO$$q+^TV@M0c^)yIhrDg6cV%`c!@}-+NoeJ5T5`x%wEWK@47o|WgcD3CN5L1-# zO3hjgQlnX3I%X=?as|D6KO3{XCbgEF#6C?8;Nd?8KpG8q4>^P;g5a@F`W;56G|b=8 zns;s+6U4Zc@}4|o(&UWnNsilPZ{u|md)jdeCb(>2LMO$%bjEA&Vyo;$VdyAMG=uDdh%(th#{?Q;|$=i z*rG?0ytocUItKde00p{=5FA9tqO0sb^sRz%IWaRZIy0iU*lUj`Na)46C67)lna-LhNh-R+A;@DTjIffU-hst=oA=kr zgxA20zwe5-996}_OL)2d1xOtPYi@kV51GpI!odslK7aYGf2^33d4rKVv=J34~*nhKit-dYpt_kA2pjDahTR1 z9+ie zvr42ipSfCmbvvoVHQokfR}g;(Q1@;?{=Pn({$}5})sPsi3OmJBaSxeB-l-d&%U=n{ ze^hrM-7K)O0wpXpJ@xx~Eq?lvE`xg0vsN?d~ zfQ*#O%k5sr`LI7OT!hux%qq^xy>ylXCRhGURt=Jg5gvHM+FJcPDEMq&u1la7fPEH~w`8`H6X5;GC%X{}FexS)TnFh9CdkzDmPp z_hp+#m2}sOMi#LN?jsIN5YSY_cOT zeLguiZF=y{0}(Yb_^tDr@zF`Vw=*et?LEKUvsu?#QVv@Rl z40AJ#Li%W%rPkq&;&DQa#V>F08xGlpR;#pBM)-J`;FsTjlQ!8!b4r}7+0EIsuFuNo zKPumw46tsh8G|^!D;Cb{#Hnu<6bYz)t%CXB|D+74m^AR;#|)5prdM!=KB!fAd@tk8 zIPmUZ?!VY)<)+E}(hOh7idWzC!5Q~@*(tLYpj*E4+Qu|=r0E;0-`S5kfwpMDSYDf! zn@E`Lz3Ow{c5rWeteN-Xe4N^6zyLr{haDjIB0H9*yB{c6kYOKt7XSe|*o|xSb!JZs z^E$PCUuw9}%t#HaY!_fv3Z6XcNhWu7>St@Va*@ADe<=4hKLg=2qy{x^2@x-;f4n3r z+5@5Qd02v>xK^wZ4+lze>{!@1g7ZH~^-!|${`>dRryUsTESLmPeFDMN#Gz+X7FpLB z=eRovLJj&KLdk#Lx}|@%^FwW*?Ou4IkV6*HP&;VnhOiun@##i{U_Q>>x*njj)b@3o zrX0xd=?)Ez8(@)-YArZ}ZEfPHC+$JcZBZ5gOh4+`eHDEyMb`J|t>#$D9wcPZk;aYO zjTFt`GYn{{&zw@vk&qe%<2)UPL?cEm;=t<^%U3~XYycSmJ0N!*0)VP)_SphGA5kE` z1AwIfy;xu@lo~{}Dr1thv)Oj^>ux2dvKZ^~Xx;lxB}o^{oL8q1$^;?5#sJP4fgpgE z2AeK_3RIPq%)$M-MQ_n&gN!dmeYz5#>R92ScVN>b;3U=s)^f~}ZzlPdPaw=i+Xu_? zGBMJ%7G@@-1J4&0#08}E*JlqTs48M;=f3`~RicZ=KUf$)PF%TD5j9ltrKDq7KSL|- zrrn#k`2I7#mFx+pXKmj^#-5i~z$#Ma7&(>Op3syU`Mp{0v~5InmvbJ6W;2=}DLzOt zXq(wfbvt0S$OzZ+uou`Ov){KF%iR^(<`*nzbgbY^>J>uIOc-RKu1#xW{v3oUbDM8Q zz?BfQ^9(8#Pfj0W+}r+TPQcj`QVpKovH9%#qT@MCIcg?3r-Cfv;u^(Wo0e05zDT>^ zmDavBA8$OgHd)_(VaUAmI!{}_v&4M=o7BFe>;?gh11=}WVkx~vo!8w_9UIZA?lF~pW<`ttOX`?!L9Z(Vc*oWI2+N+aA8drML(OsL51t(2toPpa$jq9!9r&yqU6 zJ?h0ovFOV4qj}B_sR_3G^U`5XJt;zOOgzR9{kl1o4)t6b%4b!TdeS+==oW2h7hc=2 z+3<}r8mjTNoif&MKZ+<@0n=8&q}L_wSy8?lLR6D^k+)uas4b9C9_{aY>zM9Dl39m} znW!EEBC92BGeKF(NF>y;&c*EgYc;SmIt=pc(nfk*jGyXqlT)XWiXZ12mZEzI<(7dT z8Wac@Q#Z@zU&ri{LMaQr^T?W-`!I;<9fM@cStSEspgs3LI19IDs0(MMw+m`%ecFlp z~DGbu%Geg8-dO0{Kp5d1$I7_VF+?YvtDYoUz zm#9cw;(L~8!)E36we=*n)EotN%`c-WcG!;l&UqHbG-_|?4WR5@lO51N|I0~`oCJX2J>5<*s0xdu(kgYUpUkvUNkW@b6 zd}`L=U#!cUf6pkMs0&9R`{HeJ1%q0%;5)rS#Wj8sEe?jqPv8Syl0$r*iara9X`hEC z1Ok%cLih;)f-hCRq%Pt5;6yz}zcl5>9Xj%S%cjBhwRCk?NKW5!n^O5Zhg0Fkvp(HK zIuUb-$yjEh>Vo5!u8AkqC&y=|8-{^{OsIvtkh>1^!*vWIvSS zN}zwa^TDAEmgn=}%=b@5WIXBt0}l~H0Ju^X`THoL#k#a3yJSN~u!#I?+lb6KG0K6w zx)A{ml15TDV#%PrE707IV6QoWC=`Lmow}F;b&`tgs=#w=IN0p_xf0W@srgsF^S>#W+QSOk}z)jK+Uz$AtRDQ`J$a5W$yjE6B33A1vdn zjU+&2dngNxHn@LC<#?h=|${ZO9;EwXde4dGv2Y7*gt()V!r?~^GZ?kW|2jjCG9RIOAt_=-ejKC zrKKaE7Vq9RNxsgKa?7byNAv0J1arS)j-Xq!qecDaIcjYb=M@(1a#-#733bfCCXV3}T z1vIYHegT1ZpE+fOPufjV52%RF{j?cWh6qj+1S_s{l8pGd5(4F_3YJ@xfjx?>a+km{ z!+JQ9_DkgGlFG%>VbJJ!^l&5*S`*My<&e1RI-v+I7w^ONWyFjew3@)?}KiED<+8iM_GA z0?qWFwic~c^#p2e@U;(4Ck)_`lWB>3chO4dTAJ}I6|*+#-E-FCkTU>$c$-n6s+ygh zU+|2b-AQUC3@O?B7@DkLZzgf?=G)k<3E&%zwlae1N1Llu_y6gcrJ>WGC0__+Ij7^@ zx&DiXzCcrx-uYf;|F64f>Bn$}ui9Fk-yXwknJv}>-D14n7QEhzO87nKd*pR{sz5XL zSU^oog%@#8E6Ak{M>+n$p5V~`M9dN6A7FR{n2e?7K$=PXqkb-NlI4Z%SJiM3d;Oi_ zpTG(-a|tb7rem99mXC9t6>rtmb#-4odjSxd&-2fF%Rc08UmbEHnI~bW*i>oJp4!+p z-7M*nh2mQ?C$T4%0iR1is;cmK1kC{pMJR0O+R`3|55fKX6S zQjkL^DJiL_AW#}OEe$m_4Lc(fJ)E0^mxr5!i;GW4N|aAPLXe9Kp)4jLBdegGz$>b% zsUoK#C9fd&-;V&V{xP7TreUL{Ws~FQ;+OmXESLR&tFi#Cz#}rC006`QBx3+x4gq+t zLix$BM*H7@|4#ve$iUPg z%9Ts3plhOj`$Ekn;Dv7SNm}hF#};q05}R0s!){| zN&qmJ8XItBMgamH(WU7k*p*7N~@al{M3oL9B`e86v2uViB8#@S@FFsM&lyi2&Y7<2mt4A37lbpf|~tDd9jf z@;6aXGwXT+xPKJojF}HHro=GeEi4_yVuLLeI_P`|;3~Wrgh+>tnrHo_qHy636^p`H zv)v_X%Bjsa&;kIv7jq@p^_?<$I3NrTrEf<3B!F_cb_$)7sL#AXp40j*lo zz~+WW49l<-b|I>=5{B98pt1)2NbG2dznIQ2;EEf^L8;)DMV&UAi9!ZhOab`nT-?$; ztgiT^m^j2RTP+Z8#_%DJ3zKWC>&@K|Q9~4`BDn3~&D?9)wekQ579IZ8f=jW?f>fSEN?vU9O?9eEuD z52k%2Z5`RLh^zrX1+$sOHHSw^N(v(gpn|jzQ)4prYIuiN5iNTSWv3KkRoyC(74DW{ zfKa`d156=QtKmfiN_T~#okE2x1NsK=<{qX^PSpt0{K6)U!4P<8DyWd=uvVPO?w*UJ zsaELTNt*$AmpF>aBB_m$)o`vEex(bm_(Rj)w4=Eqsvj87h7}?KJO=len>7QE5qFm! zom&}$cbC#ISJ%TLVhd=X0sO!A!Uu?`8HUH21zC`RauvK40Cn(U;s_QA??+s{R`xYH z#9mB;(WK_STADT6tI(sla#};R^|=fLNQXrHX24y~W@V^C2r>q1%=GMG&B;mtfyDh2 zqIHJYngIapUc+~YQmN)1CS%EEt2s1X%A&2KM?rStD1fx(s#}#Owfqa+weeR|2Z%y& z%^H)}RHfaU0d2vp@QwfrtgOYpaU=l@j<=vupL5H~KmgCDL}cem*y1hLN&xa-OpVxx z!vM83s6Q?HFhCuY3-_;?0*I*W8~HlVF2yq99aU<{f{YE+;chs4l&mRU7D;7d@y-wd z?6B^xifws6i+7YqQsJGWW=qWGVcpeQdBqCu3N#q3doG~mXwZ{v9&E?v! z5?I~&SOSI1tmW04*$#(?ZDZ)V6}neLR*POgZ6#6)mRP?Ph|^S?0mT_nJTf~xg;#%w z}n;N?sMIi{_LlnJ^A%Z}OR?%9B#|Q3Y^=G2Ur68I|rf+LNut0>Mrr7v{eOoH_j4yi>g@8DK-V-od0f(3_x4l8RKzA98idT059F| zt{Il0$(_rEudCFM;1K`SyRwEc^%rw&-g8$L$qE^VmqXN&gXEF>@yLB0E^CBk-#61a zoUw`!nolFNhU*_Zw7QZ+AfH0ip4L#r@_xYUSP*5t7;5^|5WqZnpzDuJPKmN>J|pz- zcw9-K01hyqqR>6eR>KuW1VJ4kC&Vck*ldZsxyDSaJYLz_WLRFc&XsW|E8B|onlY!s zXI9=jftin^AjWRKNBKfg}ssu)HjoA`FVGJNnMG@wY zUE%4e>NlN|@|E~K_f??@+|kJvvTs3)q=z542+oy3h-5w0o$T-qfYsHPWbE!UtPZzk zemLi@a3FtWdJx0v->WH#sPJgS=nG*!7W{t-UzjyuujTit!t2q@8o(h}?smX5e8Y?@ zMr=_Jq*`-;sO|*toz!q~s3?RF5L|-QFmzW-(k>p1P}nd(5Yr*Jw_kmN&~QgRxRsHw zqZtx0S|iCu1jSEDI|ewaf{KRsjRUdr+2#R`U~pDUL(L1s+VVW-@}dyHB5K~T#0eZH zYc5h0+eP_AL}xFuwvhW=>tqQX$;E4BruQ=|a(^{_eZlDw{k5JLBS+-yxH0W?)Ll^Y z@7a=O{p5&WiJ*1&U2=042AA31A~uFBYzV4fJxnUZY>GD>psmo?s4@4IKn2_>qcteG zi?#P4%*Wdx=N?w|n{kxW>e8wx!<*!y=M(j>uC4)v;WOAlB01cJH%i{nhs|nORJAG= zigJ`S)3q{y13YG@q{PHx-3sB45Ib3Mc(oZ+M(v}A@E27u08}P z+tu87VIVAv7c=1dV)~~Zpa4aT(2~)GOi9U_n9lr0gWOB3Obz9c022JDB%o6og)|n! z#+8c!IyfA~Xi!)M;=H*6KXI$Fmi3K~!t0Dvq?ka-P)6BrYZJcEDdj+gA+f;s3|4v9 za*{Ij=JH$CeC2Ma{+_s)*Cj*j^Q~GwML}D51<5`~p@lN6o@EC5DkV2eTG;)~B{jmT z?$j}g>0Myj1b^U8nc2$-LnP$C@7ox#A!lXGD?Nj_EmEH1EAT3Zyp1g08W!#e)jBfU#C}Se+VXb( zZ<$Y6sB_~jD5_}cs-Y1V3phTllT(eb`e5w(9J`EfglfIfTp2BY0kAF}-OvCe_Qy!d zD{M^hzjsudH53D2f>!ZzV#)FbB1TK;qg+rIxH~si%h#OvQ#%o$&WB;qtY5dvMkZ{} z;!NXW>OrwITWMAu<+bJ0ul$iDfJZoS^oa~-7e0IwL7k#eb!ClBz#XMYKIG4~e>AVh`Lk(uwC4iL$3Ri$NN#3^;armvDp zjpVRQi3`8Nh=S}%Et8opQ)X21MrnM!rAX1ilZBAwd0nJ%pQ3EUL$7^L(p(S_;&}2HTEzFTm!n|Gxt0Rto3~Gx}=&q|aL>c-y~krbc%x)qFVf1qYYtAcIjh}?_)P(a2=ecQvxMqw&(ipq2=*AL0YRw*(~}z z`F~?|kl4Lr`jM=$z^(I!^_Fi|;woGy%LVIKk$*q^X+##O+u&9!G3UE?R2_bhcpnL* zyskiHJMY#Y*)D8wnKh=Mz|pyKsxMX`?0WgaL+uJjXAYk!Db0OA_fKMf&D9PM6euRY zZ?SIxP_979#9)`T^4u3@$dK?37Bp6wX$H-|ERvN)DOv(*J;3TB4v{1NqFdo)H{}1>5khLZ`bLO0^nR90E=Xv(t-Yfv6kAV=CP%B7mKQ9`x5=fyA zi32U=#f|xQ%IkmtTM$hU3W%e4F2@08+CkWZigO|Oy_4-#3CP0L??-oA3eK*MAh8XJ}59P)L7I1_^TPz z!S*ta0XJP_{VM(zK$CXQCgk}|n#HrGba^VKpy9Ll)&STA(oX;UiWcSZKywI8IJn;Y>Z$kMkhB!YBk#Q7Lc)i2+Fz>KbLkoh&7*5RpYr4LJ0Qf zTZRgnvH$E;LJF?UshjM=_$Q&Br~DKnX{+~ll#wPt>LCA=OEJ+( z|6`R{hO)DI6(MtzFUU<%b+cQTfkbVo0N zC+mI=+&28)%#X~c>9{~h@a}(HsvGIKR+Z3a9ZJEW zZRC#6VLZjIg!$3oTiwZZ7ggLM31OWQ)-Sxgw2aCYM!kY$v`gT+XMCIw_2oMyDB2v? z5Z_K-ca%H}WP$#mA_z(I+=P-B?DH#kg1a3$!54@7YRp>@RAKdr)WS`3DR9GiUbavQ zaImZ-16iDrA8=ud7^8>IT<^e%7L%@5NW$3ojxfQ35=}m?Bdgu_ff%Cie|wzN0gPQt!Pgi6 zMmzcvPwiE$7{m5d6+B#^@=pvm6T2`}w}3yKdE(M~4B4zM$+--Yfg?<(BHfIF8T}en zb6B%;e4Hd}`GQ0#p;14qn@DbDWQU{fUAgxzw8N<+QI}k5+D1`n#4+ck*brPO%tb#3 zPA>J5unKUW=?q5|h`323b9!n82hrdiD>%XWG~N_*uw6$Rw->SvCkRI3oi;Sovs3Iz z8kOOg54Jdo+=%2|g0m(-m3`AwpE}HlR4SSYTLOwkQH@#*IhSTp+fZxhfR3CaN9oyO zQ)mJ&&Kc<)6Zfg{8$>x1$5@BJL4(?Pg*tO&+H=;mvR?_U!f%^hw48PUPQiOUX7NIItVH;(H|%fE+1@BD%O?drMf9DaprrPe)9@HguN~=RnfFFcEzY= zutoHT?PY`D{2wLs3#sIT<;0OJ$~7SxO)c}dh=+{sE^cHS-uh7Mf|h{f&(eCbwqlNU6(WNawQK@ z9cz6D@GY>MzE!2(l+h*fb?Q&BQn$!y@Yxpm64LD+=W`VGd>4J@m=NHQ#82V@{b*Lu z!J^zIUmZ^_|A$#HRCldDluQ|eFtFQ~vhgNgjrlt+SpKHHB$0O(VL$GDQqD|v1&Kiq zg?%wmT0ul|cHCEHFgN$nVYX+@E#m{9s-*py+5%l`0+fV1_I?()cpTpXn&MAEZTBuq z4&=%K*3{VU;c~#2T-uzePzvAETR?&Dc{`RhMu#a_%LU$_>&}TD0fxi=UiaOY3W5X& zYYs33o}*F=7UxzO%+C_^%Z-!NuAD(ywcHz=N9Cq%?W~_pFwAT=o`xhC`}D9K7gJt# zY6$~foK!T7wy^wOj@?)URu9<5;yVh(vb*R~=bvPO_LL!DKpT5m;fM)fy&1EVhc*P$ zrPVF8ewkHRXS%8T-r>7!81Q;6Ss9cp0Pz1l3ghE@E3#i1^oc42?Y2B*){v z1s#kxNmD8g4=y>z*&kx4wyba*Okfv;o zEd4}!Bx#k_IDg=nt6V9O#wa7q`1kQACHs-_f&VC>cf=wFN_m)Y+dFfXv|C^6cl4oZyx zdYV{`cvV*rsjKEJ=DxC54;DA-wx2bpxi=?2^d1IoCI)WAfKWHD*hYnorBc`g<5I2T z=goZX+aYF$lP#-VoTZj{S-bFYUbY>H#%2b+!awhDX5Z|$!0vuBPzrV-bF<5~Eb(YJ zq^*bHOYKHe(W)zs66PG5MY|PUzN}r+xCL00pv)%^J^;hIwB3p0K@AVSSQwQ}#<&=exfrq?pE@%mRqU?kRB65cajyH8iTbPvlrIxZNlXbofA)fhy zo{iFBWaRNqpF)GP@8QqVD?G$-&#$nA=oB-5Jq&x8`m>PqrAliR=+CzkI8T=1XSf!m z1=6+xmxv06JWP7$zp{>#+AGl2VlE{(EzY5VER!UWQ7dlhpp7TO5_UD2`$gq2+!zE) z04O?(er41zaI~i^YZSLZI<8Gck|y?6I_odaCt#%=$s;6d<&o@$+C=jqN$Yc;Y|ClUz|1R zPdP>6VqwAwoUla8nGx{Q9;LiJ^p)1lZq$vBFZ^iPc{f2-;dpf=?%=_b#DycAUID2$ z`Hg)(j%+BjhQUr>WOPVKn-hb zxCUowXSm=8qb$tlbY`J_vk!SMbz>JDBxNa3v|TB@Y@2HUGTVrK=$&ankz8Avm6>+s zt(K~<1_6>4KsI55G9^O9l)=j|Dv{YFoV49szsPF#cvki!Z^CJma6;Axldc9a+24Eg zUcDSL%5qzhFFsIOcgOE3RmsfJfwG_Rt@sjrU`-WCR7{p>e%!YFITszb$8mDbcHm!X zbGG(5j%fBK8%J*Rs`RR(2Fp;btf~v}Pgnf7X=G{F{il@tl1^37BTuocdj#`rn@`cR zU?iV~L);TCJd|HnFP<`cssrv@p5a8ID9Ho$2*xhpa8kKFnUtWG+=ii?#~DL|9(9 zOA`L=Bsb6mAhH3G?8=+0mnFiZjqBwlg!N(|$01`6nihyZ`=(3{o2T9-5;+oRe?VM9on3mHlUp`uhrpR)gb)qzRfYtB z3emt)R^nJ#kby&g@(ns(X| z%*RY5Ew?CL#$7|Ag2_s`RntXelWzeN*nV+7YtP4tVSDI5)>aL^Jz;5QJ*tb=cBh?A z&Y7*YU-Y8pTgZg!jwh1`tMt>yW9~TwE-ef}rOoxnUY_dlH8;Ax_vrh>+9d6PUUBKV z%w~ySXv|^q0H(@&U-3@o5gB*bU)Jge>A7`z=l?A)ZK>CpCTEIaWAE!E_j6jP=;thA zhfu{BX-C`A=GJQCjqEOpwfZ#EM~{M>-pFi4_&vr+2bd?M{Q#I#FTeYlaYhDs6=na^ z)#FEgL9|fqnES$LRa}Y=OEZyH!lGZ!Q9R=BV{1LW9YIv`}p_ zeYq=;sz1{YX~#?}vds3#B+rgUABHuJss~ET;oaCk6dR>uF5c!Rab50HSMKDp)Yj+x zp09NC4tc}KB@a`!Nj$*CH{SvhUv*C;NzKwi40Ks+O3n#yE-(^iQoPqtMlf>u+%7AT zn^Q{e77&IE%er&AD{)CU0rY>5yP)tzBHY-c08#{+q8++^ue!i9 z`K4Kr6vgq&as+9_*v%ohM02RFLGzaLm?s)w5HW|g9)`wkDUPD>5VF4AXu52*@mP*c zIgeKYjpsg;dL#IgArYRih-5p2k)9ChRL zBMM}B6D~W)YVi2SusKa6U02?EsDB7g{$aKJVoX_C7J;G(pXYRUIPGMW*3a!6b%<EXO$isoXLs(y5#_%y3=`Wu_Qk9&vM-y6o|#Tqk_JxpWzGqjerNs?Oore!aAIE)hdwjab_|IqE+~92#`HUd}=!_AiDYQ-wri!Ord0 zKDIDg{M#@|{31jOAogx2lqKEDLoPAV9!9ZTezm2^J2r+|&9ISJW%0;yJ7{qJIm%rD z58kAvvdq2Sut2`$b!25h87Lv+Onp_`H1#WCgl-bX5r`^177ok>vf>eFd>cWLjQ)~n zVg$Gtq41ZAW+g4h{DzFBaZv>sck+AdOrSv5&JVP8@f3jrTG!ekEM{3p4-JQ)W`_-n z(|O4h~ zL_x-%hjxIpEv2KZDQroVka>8@P%||SuB8bxmu96hA&{{O8&$6Gf|WARTG^O$p>2g` zmntQ1q$#=Fipv>f**x{_^O?Propt3l{7VC3N<;-wj%m?FuNYZH2lMC^TCOWL`|xG@AH z>0Xnnl^-x$c~cF<$XoWGueGU{YqErUuW?8z7NeSw1aOlUx5-f0sai z7#~Y*LKuYD14Synk}3$4q%A4|0Se+psYM~aqfI|ne6ghY(P@xVZ2Jl60R})Tbt*JF zB=N^A4;315ibwQJW|6T#UOp33^UsaPxB#cX=&N#|Wbv|6h|fWZ5|Rfzc-|_QZf86y zEsW22?g1KtEFj}N7$w7uE5<77qThgkh%kNQP9=)uMD|ThE>KgU-8x!-WCQ_}$8;)$ zLr^2&PKCtn|JWYHGYZ)Y3cGutuN1a+P8h;6OebiEn5HfZdjS`BV#j!A`O2BJb z8jvh+!aAke%2Vp1K277E_pA4McUtk;GO~h|HDPL?0xKIcCrPguMtVtsIcAP}k3s=K z-yCPE5@Ii9O?-+tIIPlHW?_|vwBB&IYrT|q#pPaD*gqqVE0d<^6c~51MTk}wg8#DF zWW&i0k8G;cxs%pQP=mL7H{@WH^4~pQ1>& z3iHi=fsEGgOK-zCjjZ&&5j)A+Wtip9wBO%`amZuWCki4@c`_YK2sPVm_;cA3iZlD% z^{>Ix+VJlvkit15PwnNHb>L|D@erKo-xHad%>frv3T+~miaR2s+x@WjiB`}@WEdaP zLtG@&=Eb zX;yyGx8mHFzkO8mq`of%&jqWM5>{gty1OfK3~C&iZSj6M8~s?Y^US$#+E55{5!?r0E9*q|KxO4JW<_AV>iBv&LY# zqe-#+%HV!xP@C?Ph$?Ouw_sv%c5U`@hy+Z1Zz=T^tInogLl&6yR{ z)Ih3h{=0MOUC7H6RpV2PB~9?*7)z5L?N=NgK6bz2$@`(z$o^)qrsP}{Uu0~|q`$&` zl@A%}@M=K*%4z6fq~4XJWa7hq4rH!ZrK(`!9Wf%rn{0ofPH~R*R{+bP-0Tw&8ve8`M@5V+**Ew^6YGw|DQP4p=X50a#tog~|8z zdV_8|E{jk`SaUi4!NVXq!qdCN2{(^UH?I>k{COrT^q~AtS!w? zisg(Vthr0gBrU>rhV$T^HgYkD*+kp|6x7MLq0ui-rHV8aUowH(+=e%Eo_w`STV}@2 zk)C$qxd*Gq-%cKccRT2w^~-w8;vFjj)b}j9bEyNgLJq-_JIHjt8h3U5D0Dvb+6D4k z^jY$B>NdjW0>N0W&ZH?-zH8J)&F+l)btV-Vh>RrEsY}QmA__Lbis%;eBlu=Pf=^vmXQr8L%!fC_MS6Lrv&{DPipeeSne6-3fvUEr@X0xkO%D$ zY7OezJm_Oj01N)RY(qcByt)Ph67WldZnPU+IX{?H1vpOpw;kYrv<^V|fEN0%r{6iB;3_T=O*;=$6CzC_ z;{2{ETxoSZj5lGzS}YjS>0G)%lSsRyA4EvhiVyZEO5Tp64n-m{if8pR`>;pXo7Q$~ zafvQ6LBp#<;MjB?GV%g9owv2N0$2ffRs{*;A<%Q%S)Z zCV`2fzF>%YO55>Y6PV`wE+ZaJBvai_y^%5<+!a#&cX$ivj`?eBj`MV}OJBxHRarRo zY+*d-vdlh#W1LFU%h7}e(|E;;u(}o`$PUBhTbf=-lFo!_zZflJgA34W43e~Y zvix_U(H?=uBYCJm<8b8-AgPrDbyWe?OdU7(1$8`OsCG|swq8Gwj`39{88WGd;dh05inN~84VAUm8yj;$`h zrl0u?=V}Wz+0-YoH4w!U_{!zJ31eiA8BV{yV>-p8J`h30apmq+Fk(fH;zEu}Md5Li6trsN*P}ssnpZ)yg>wMQv49tdWiDlSsEFoT) zq4dLDkX2_2PiXW~>PyklZEY#QpYYVaa=CrIPQb&}OXJnC-`H-YVGki!?39@=%~E(8 z*~bVybj>HJfRHq6GN?-0g5cvU>=fFZJsJi1p7~OAnuH67AjWob-NQ1krIKW_nE<^M z*21;RONSEz;lLb8FjpYLCeYaCp06``3CJ$%1Ai#XgHBNz4-%t#F)1o{DR09WsEPhV z30;D7fdgDrAzp3hMiMlf=n?`bN%)RpP3+Blsi-m*Szsj%n9(8zpe2pepp;>n0{xl* zS9{*MRQHckL$ehAZe7vgE6=qjN}Rf%d>elz8i=5uJuMepz58$wZ(bJenoj|@1o__% zJqsEl=C}4Vn8|4{8O8Ha5^*QjPU?bbrO64!_`2)D~y#Z*YLtGp=_VYHS|2jm!0-cUK&t)wN1TMh@)p#r^i z!ikkC^3&cK*+YLYbxR#Kq!Kpar$w9%S}M*_S7iCw8>WVL;HQRs zOVpKoFp|1fLJg(qz++|!sLK(DRMLrb?U z)N@KJlElFYeJ^t0g?5=v*rhNMzy?IiX;ZHsz=YSq4eL`A1BaA^*@HhPmSF~5A{)+G zg5J)>U3HDZ7xF6DJSk$9IeLc$U4bPs>G?AIN$Q{VY7_f zDQ21#2O9eEN@}6)uu~hnCtb3<#u;0d!*+yI9jLNN^wfz`S|%E)-a|;_=X(AgbIo3E zZT&lbX7nT^o%!v&$`}e`!e(= z1lrG<5Hz=+VIU?uyLe~~D>2V82BevmNEnB(9f8{hzy!iU$6Cr2>iJ!%?pT0!^&Pyn zP^MamC6$OnQ*;^-lRSo4V98{XD|zlPgnv2xs}g(NSfnvBOr&uCUgP$dmc1ga_MOut6_%g&jphwp=U;0H8%BgF{tWh|~HUb(XdUiS970Xd_RLaz|;Dw*uBF%16j;sZ4|F;G;p? ze+Yssbp>yo#xc{X=B>h!0GkuOAQl_5nSC{rgmL-UTYw+$WR(;S3wT&J9I=VmRT;Ah z1{1IVlq(Ff_rOzlddfjrlYe{5g07bo&dm51`wn|N*TZc@fc@C;YG^%_YI@$vplTE0>edziQD4Jfe%0v$ zo%+I$Bu+*i1mxsML(%GHLGZh5^?z_J<)#*~PMmMa!5WIUt%MS>5@_6QtFI9%!sg2; z>UpL5pPCuSL5gKMD_2vAIl>VO{B?luT=o`yG z`$E?hfS5kQ7FKxB*qqfxO`%rFUnk~!eZS%4%A|}cL$r9gcW6%`Svpf(vJqKHm8!E! zo$Cdh`wJ)``wWC%H!kJVt+IyRh7`fK016MhCu%QKp!UxgVLuy!g!9G>zcz9#UwpYP z1m1R+rBTVRAGO-z^I&zp**1?gcya%$=TDDfn9;@iK8M+=zX|EBxWC001NR>lon6|< zd3XvYZa;e3BzLBqLD{s@1tT3AkA`lkt?CTW>Q9nmUYt$G1$@di2s_sBPYx;mO!?S| zO(?X@fUV_Ca}}SZK?*ooQRw&|$GG}qX{MXSv(|IAg@U4e^P-jnH(LBy5lpsWaU5Og z)9fE?Dl^Rt>La*MY};=EEY0jE3;;fkM~)S7c(nhi&p%5TvC-8h+w|_5UCWWp;TnDc z3E6W#r4W*e%{Lim>|fHNpYB7Ja%e`|NPovo_+31HyAq>+&Q5Ka2#@c%qdj<@8SxLX zx+9dKch?Tad<%GHmnO?L6!x66+2dwv{RqQLnv9N)R$^O9WAkl4EBn_8mc!c4CfS@^ z%N2eILg+Gk9ea>1t&=Eerm7V(M8fI` zV*p9(*(ue%{|`-ql%U-!=zX`E-&M8ac^<&gEj95Z!1P8djIkkkjDjLzsnYcVf8O=z z1)SKU@I=a01(lQAdD9hYFOql<5++bu^QEjDp%N*T-JqY z7lD8@#7vAT!`nKazBv)Fm(*ZqPRhTw+Ul&{0&1P;?~d;Og@exeb$QRE-l@)&61~Rf z(Z3k`qB<@0Ql$w)WPJ-r)>bLN>NU<~l1`qK5?LtU0@9h>-Fva^r~OQ-bJt*I&i)%s zCf8@T0Kp_Y3^=o8K)~A(bc1~99+>IgT;f>jM4%iUA2WGc?tABV&f}~dFoCMrEMk|V zH63xl_!&`vyA5Ymm{Gqnv5lXjrDvV;q_H3o{hJF4{x7T zdENpz_x~DeB4r+Atkt*vxe{`r-P8oZV9B3D7>NqDtk8m5yrDh9*FyQ6euu^A5kBQU zU;K@XZV9;^R|JELv1w-P5U1iIRNkhx6&OR9sB2n`*1Y3e^lh^kog9aCZ^B1cv@0O+ z(oqnX5dLb*2%`}+n1KG=nFS32tm0b#6r*j-_l<6Vr+9fWKAQ_M2##{zHUJqzX|X58 zXgdn8;4N?wAf`%cSQEg$f$#L64ms3b+XY<6^nNbU3S3CSLW=JRl@Fxwyi7Aj5|&(! zOZwtFMV?-{Y~2FhgNzZVD%Cm6+bWPL+3UPbyDg_;lmI@GB<^r z@5A{2hJ86b^Kf$aahDeLd*-2|^A$*jKS&M$eg*!2#iRo9-w3|qql*3)QbqLtv{CBp;WZohG(aM0CYs8g&bKpFpLNaV4@=e5d3$WX^sE_ z6ut!WSuBRK|yW>C!Qo+6wI{Hh{7MqK|zPIwP+6~i`4qRe~Scv zHjqkBjt?B?wW+1|IYkTV%w#rMM0}SFfJ`c9jMXOrpnygAfc?8059qmo;9uzamke-$ zlTQrLsJqa@aFPM9ONkU$e4Uv%DxhmR&_K8>MewO-fu1JFQX1HKu#*LN7s&5o8BgBA zQlzH$jsL?*x{vX*v79{GnIkj%&vM$2ZF72tDFrJ6d&m5xwFkvDVlAclF=GOY0xf45 zuqML;2?;x@F*4#u;D$=Y2)<8qQcYxPBKR)jrD^wim1?|b1$3h-sE`zee0_KSrs(SE zaKE5b-4y2bJY0ZZdlk-A&l62%){NzDt2DIXnV#kg(+UuK7IK<#6J0Ek23 z%zbtBYjuOET0X}~yN9NW@Zw%9w2GF;@K0Iin}1cZ@0jUpAv$cLRj9}6VG2$I4u=OB z!WE{1a1Bi3kCvp6c;}0#3MtLBC%MZcj))4exLZS0!F1g(rz9C}uh{aY+ISH~w(n6z zgr+|xQ}thvehb~_*1U`KGU0L0{(?aazHl;rPX8Gq2gaJYr!n@A4>;5*wn>N}@s}_V zKQ=OYFo9+mxiL{pW6!AkRQPhxV4Fx09 zOy!~lYJx|VF&A@`8zGzY38v}KU&J@gd3To#dEO0-b-AwrQQP>suO~uaAxuH9i|%Ad z^I1|9>{SHbpA$R^^qF|h?|`UaiG3veb@|;JqO!}3$Dfj=-cp0Av5Vc|*)GL-iAI)e98+$P;C z`k#H>sR5Qz_qQzib?6E|zk`t47-Rs$SF(N@AvJLq8V-(ajuL4DG`FHafn5YveM;Pa z?D002O6~!#V`-MkVnD8zgTqgKsD5p3c!u!I8<{d!=$6K)oT}**X*2s3;e!X&v0vHv zLPb`~eq=XO$D(fTz3c3ld7z?qeEdK<_3rELVLK{)^U2WK@L#ZK|46XlxJg`G4Y+Z1 zi0w{K+^?SSpIQgdf1wWFlHBPLS;+LeJ%;QOG2?eg!bBsUnnpMsgf5*{hx0yA9&_34 zRQ^YT(|sS-P&Uj^$;A@!(6PefBQI%rUMO$18QH*8FlccJ#-l56XWWoSG8Ss~bPdF$ zGJpx$embQpY9$=@F`J$_I}Cnbd;#_+% z*y~d-s-bxA_qp%wtVU`$nTrxqn8dbSSj?v_a9!+!Lq;NOP%A!yXFo+vt1v?SrBzsdB?R|PygxtBX&-zvZfKZyG}JAh+ec4kWMZ+?+9NiAC^U5x zg041iNR4JDktV+c5QvHQikyPCQ#Ce92HQW&R;#CpsnTw6dXtV$eF+hP>BzK)Ec{gA z4xln%t9icmc=uUhE%*49$aCVL*d>C+i^-FSDblcKWY+iiDg2|aK&517uTNC@LW(Ny zeQ1`Z(qw8=36JvZq|!~xE|F(;ycU07s6-42rT?lMKBJQ;az4Tr^>JK8Vf|ZvL8lA? z`&C0GztD`Cg7y_{?MKq@t3ud7>?ytWftX9E2|>6-ulkb{q=+)sB;Ia+U)wnGSmUtF zjBaF#*)07ZZa}ia^HqdXv(KGW+({n15EZ2D6Lub4!JjHKW)$&=TfnT0IwT zkf$^|w|EHZi%3K5`M=tRY|w~^4oi-FyJaq0iqKtiOzzVQF5|iPJcGyR2|Tzo`+0@C zRjv6iy1D^wI+~i!blk<89>~9M5M$K75Q!FHj; zpR^+8zrP&CXJm@*BH#fKCx6;)c5i5KB`LD)ddEsro~nt6K7*QKUDu|PU^!LEV2HKQ ze%kTgl*uG)1QngfEmMfrWf2^762CnD_RONQEWu-}ef#d5rHSbV&w&0!aq2u_?(d8v z%*jg0`BFhzk`oR{_&kj%j>sA6qdmVUkevJMO4-o!Pk!g}FdaVI6d_cT^kR*3y0=e= zcXk?pFiE4Z9YbWqchvyhkj{YO`7j{E`GWtP#Vgu^Csn+gxjwH+OwWYN(NznJ|TX< z!3%vA;`7%RvhM`{hOk&6;jN((GqI)SPgk(!ANn%gO_FPXl`6zs(s(6VvO3a#Y|3gr z2kNa13~y}_s3e-u-(anjc~ts0At+D$rp9vaD;ud$xEu|vH#7dLS5NQmP1TzZZ~N<0 z|Gn)>BK`K+7j7FknZ%y%_|~1__8b=AJVrKLLhr%hYFxLeyXuapf%v^I4e^$vk^{&~ zvA~iI$1z&$_%NTx;baDq&!uCFKYiH>1=&))m;BJju@+lR6|up7t5mf<)>?IS zp34KYwCUv_`-?a;<=8T z#+8xT+tqxt!#&!cjz)GORg@?Ne(09POMhubY-_1)@S8swp@oTQvBXha3PkZkeWZhM z!4RI;v-u4aZ!MWk-)m~Bf}k3UmCp4OPpo^aDL4>oW5K5?&q+lVpCeB$S-8a_EVTXe zmVoJ$X4Fhvm2dmBl_}@m3)T5PJrxORv9V~*Rg@qPaSGnUaU8WZn6B~;D6p<4@44SW zQ_}>pDr zKY5)?VW`%Hl$g2OMT~dyj(J%WH(jB88slI(s^PgX>q3Y)_`KKD^n5=xsiQoFl99eN zrE;l#b5umKXDt6ieBJb7TO&CsOAF&;C62}fOWc5HO~wOt7bJ%3@e*KtD@jUphfOWam$FdL}i^+%IUQ4zs9&N?1 zd5#bzWrS2~(VGAk0#DoiwwU}Al`B#3gH?Ri6?8hVxk%G&oPM5%GsyTzRo<#f%u0k- zDi!h`S~ap~?OpnEe};d#zCHa;nE2Vl#p~vvA;TkzzVp>rPj(+=iZ9R%i58b_WcJSP zV3jG2v?qp^#6k`~Uo8ysg%>$|{WR(PDOG1duI?H)lV>Q(G(Kpn4CQ*5Lp-K%uKwk$ z=Xu%JC%(oI=MSMS=kJ9%w;59WmLRtp8`RPtah!bpW5TT3VJ1iED(hSj)$BokhRb<_ zP}bM?48C!4-Gs*8Y2~~>=@U|L7BTaTLXq^*7hT$kEIBIS8AC4NbV*siC=R6C8VtBuQdr#GCrV3IWS)Q4n%%tba^kOHs4_*EYxJ&# zp)2}Tp3>hKQT0N30Lq?8p~xrr<><%Qgl~%9kl)w}EG07O_M!|@9!JQ}=r$Zf-DSnF z&yCLl?~|wHbjr{FWpMlL!T)OzAFLzFkXT+hIoFKaaA#rfc&OAI?4$A`dgYmkN)g?s zKeP~I@F?&0!WPd0pq5Mej+BX>wVFA=MnX=1;)#ktp0Sl(j%ywdN+os%9B|j{IYDiq zxWRjkf-S&%8?(0`>p0Kai#AEaMaYY>{w)`(T7oSsW1h5O13v2%(pJwZf z>?s{}@j9d^(u^2bWBuWLSi78~&aIVl_W@x6=XXBX4D(u-`E9tn(7=^%uZ z_zw6xc*RH=&73#;OK%{51AGh?eH-2tRZ?HH{gtHT-thDH zqLuwA)Shx9(ZL6IKr8zb`ZK46O+GvLV;mYQ6Dw*t+@c3Q?YPIC%;NKAOWDO)_sy{f zl}d57#rLxz%Y1SJ;WHy5J@AJS!?OCv903cD7UvAC-@1HIO2C}Zy*e!Kd&go|Y@6-6 zgbG_|G#F^_)gC@|E2uOeQ97KW<^EMpp0pp+TmQ;}GD62trr8);HJ~2K{am&UpYK_# zas1b&L@V(0 zs?E9A^shCC4ZJl)-WWUep0@K)R|727Q{|J0mI1TCJ=E)e$LmN@^s14w+-Q*d+1rZB z>d$3@U)o{<$BaV@)DHf21T$CfHx8ZN&mEcgNq@4m>DSRnSyW}Bij2?etIxJb#5@LT zN?ynro)J1GN8InTe8HJREfSkoo7yu&HpKose8|Pj;|cn>r-DnM{a5VZMqv%H%$C*+ zrVN}yZaL_DR7S^Ee3?e_RSbnU+(=n`dNag6l}W~}a_ya$Pg)Joyf8leIlU>p4J=SK zd!EeeeVs))n&nP@$V6U#^IDg;zt@7O#g0#Ht++S>xLqdwS?vk(BI~mR`q!h?b>W12 z@O`a;3MC;3JkYZ3TJ9OHJeL{v`co-9(CU!)&0Pe=8W z7L+?lX?P9GHYaVFWG`@XH6p>nWUJ6p zn)mMNPg}*L*h;ba)Fal?BLzsviP^3Cd=IN|Vt?VMF#3Sf`iQ6Ppb9q%5mJ?xo8I>^ ziDGGYIFly78Ymg`z&4k;j8+qRH8b&EeWqsg!i_~3*T4s>J}nEsu4<)e^I|!bL#e5U zT-cNE4iVU8Rm$3zR-;JcYFP1irC>sxK8ri;0W@0HpV>7@Nz%tw#)vq@wwM8Q`qa~u z4v!;f;f>p&Z!c_|LQ_aXAm*J7*N+h)3*BE4Aq)geP_o@6QZP9%bh6PF|3hEhX;8MN>K)eo^sg-1t<}Iz5v`zEU-T#~j^+$Y6?40K6h}i_|1aV|P{X z;-oEh#Wb1u-I>|RAp)&%R!xb=3>a3=0ZQ11D1OuUVeGhn)Jpgn z=gEXDKZAN@PgQODPevm7pfI1`8zoeQA4Rg{sYDk{&N+jeEFFi412j$-Nwsr+fBhW? zg)`XzxGJxN*Zib^8`8hMOG6`U-E1^?w5qB)Zkk?#QY(rRMvY({s7wJR*HhMs(RKO;7ydy_gj&_W2^FA?FoCXJXYPbQ^t`>oZia4{LZ zI%V)y{rfa~hSNZN16jy>YcrfUb%=&g?dx^$zho81>_-y>zZ41=n`ojoGt?UHr$0-W zBv$Yg3JMWOO7cG}%9i|i5%nN2UV&7n-RhdP5lL>qZWtCEaH?!uziK3)++8^j~ zruktdbEz36ZzkhbBO-090lI5C4)j=gbD%F@cWSip3C;dv4my4JOlG-gCO42&jI8=< zBJWf2hTdJ``){;6b2U>;Osp^(w%YtlQ~U{5nPFQmCXq;y$%Iom)X-;p@BT$IGW`k0 zff*5<-`t+7b_LF|Z#HPh=|}4I9u4I1M`RE=Mu+WGUNC<<*bk>9wwoKS=9d?*13rM* zim-x$>#sP9AupV*3g9QCl)IOj&p&JcHg9F`QU~nlsUf+D zY@eQa*0dPWo0&TX&ox3m5RdUh9@)@%+%0_ZYj>e`)VhzX0=Fcdz;tvQZ5l=s){DU6 z`i8I+?j`53Yio&2@iECvVKzW#1}ey%!r!E*nzmp-l;8fM?#x7bX}Klg6CPsA_XP79 zURFh#k@%!HQXiKKVPcHox3jk?kPr`l(23&bam`#2g&Xg~(>?>a*U>2N?ku4z9x!j# zSW2iq=hJ&1!eb1oESz~Kt$7{v%2_i{Y0@Kl-%=dDdX+368wbsHb$g*x=trSNH849$ z3x2e9K5rV)GE!UN74~CvR6;9bKIn~iVAtoMGz&c&oKhN=w1EDPlI}%C#M3bb)_)Yv z{U{F8#vv8IQR*ijwf+x9XBib$*TwM(V1@yPp&N!Cx*K$cZiW;Pl$7S7rBsIQ25E;z zx?7~Bq+3K72AlI%ZaTNi4PeamH$=Ks;sjVoMW=g=X{ce?mvSV5h^jIGu&?=M$17c zB;`vBQe%Z5tdS+rj%2_2Q3*X+dNr2#>;4<Vl(kzQDM7A&!>%ck40X9HwnfTOmrn+ETK@LfS;D zesRgBV%x)bmnnr9wTW{WQ)Jm>C65yBz`u~cur|LBmJnD z8*Jpbpe??Rp5P&eYnI+-B?JERS`3k7-}ic1zh(i~=ZIGXO%>OQ<|pU5ie*CL`IWHw zfq+-WX5V!-STB;XiiCZwL3}92lR(P>)hn4A{x>gV(&ZQbeX1dN-OJ2J!7;Lr62ehc zQRe;;pu%aX6)>M!zk-ypxrsmgw&u&@rB$GiFX+E5a1j&eqn0AnP09bI;_bD;%4wf` zIL)(%4~|8&%R9eJbuVvcm%}tn`%z2~-Y=;H4YnERpI8LoM zWzU$Ie=ULT)9mPTS*{eWaYiZxGJechJeGz3N%t&&O!;2!Ew7e*?nmsOEdn|zTLb8s zy{6A54fRT7_Vt%}yN4{DtT`l)Lgv?*vuke*&-Xs+$8ZS$@IuUKI{euqdG)V#uX0)U zRdmk}(t!GL5WfR;49Ll-5!O7lZsgbI0Z)UHr$X-zOv8hNS>|MQ<*2se~Jb z4^+yxzc$&QYm1bJ9IPrjza#r3FGLZbI`I{9WKA6J1 ztWd!`V^xSBv!U?$f!1p}fbX$Z3dj%rfMwEX*@XI%YL>q)_4;0+f5g|PEfKXR@q-?);5$sn2_jLrRanq?GQASBl37k7)h7D%)w6yRbZGn2%OlhNnTR)zm1TasT}bqrI4*!x zhMSKmO}q|o)%aSN!ShAwkY7mHE5g=PMw}ki(d*TYVpEiSLXKYfVOz`iLE+b^*V*@K zqZLo?^A!+&E8M=1@DkJTbNEIqX_{91`j->Ceq{Dr`~RqR8*1^H$@98bfhc3F>$Znm zmx1>&)VdhqcW3yjMgUwG7Y`k$Fi~YLXW2+md^+x zi4TL_sZYs$eyv{;k$(!(e9tN$8AFh$PxxQ%(<+&5)l{z0k*RUd)_qU~nS#*%?`heq z?vnZgJS;T#}oPYaC&u{j}(kAd{7*L(jCrM4{Ibt{5fdqUv-px7@ldQ-K}`v zXVUNIa5;GGBtweusB_xgGSud|00jcT-0zfIvKS9~ybU~O41D&7&lS7874;sNw^xiW z-Hcvp9`LgXm|dD^d(C48EHw$LSSNR~z0}~W~`dAEW!l6>sxj)V4Q1*8ew-OQGB@V8D zVQdW+pYjg={?W(!*2&N^{RMjg<{g0rq+~S8=d9z~rTU{t63joLd&L}B#_lKjlyr3+ zkK=X>dh~UZo!(1U*CYi{xtdX%%cmD{wEyt&aY(Lk>A1(`_l#!p5eec1=0oQ@v3gRo zO#=;Aptx_*F}Z|v`72ixW7e}?_=Yssx)i~GGTu!_@y>chldvX`wc{zWZ<)4;%pk?+ z;^jQi2em*Cy-Mwp+Oz@A+D^LAsfmp8FY0V1tnt=&%+B0U$TVhGLusJtmMycE$M!VW z=03}~wJ}q6|7?213iXF|EOsuW?H+msB5pu@*s$h5TpVW7UbCL154Q<3oDt33jridkN%h8&D)xS*0f%yX{CDp6} zEM1!=Q}EkwNr~ud)&rQj)>1Q-@B?Gz^#2Gxj~4r#49Rz}5AUq{1*x`O9Q?L+!G>P` z$T!xS;)LQmNCpL7E5H?JbG#a1Po!?|)MiQ|Uu1D!{2wbkZ0@ZzALFKNi8682A-ZpG-nu`&7g*M&`P?tJa>yc7Q$(J*FHiWhenKR9kl==V@ZE#HLjmR^C}cBN4f@j8ngK;8xbfOYq; zyX5sp`Sh1|78VweM;~X%u;0Af{l_(bk~;!J5xlK5IT!3Ycx-dX1~s!7f{-0pNQY=N zyorrRtZ5M)+mi%Gu;QxozdYpiBlXfwuM=Qb8t-7)d+8KlK+g3uoP6m6dmtRIQj1$) zUnqJ6uDzAx?r5fU?(Fe;8s%O+MdbkaGWh)V;LBqyXOCXJLvc^F-hN0{I>3pTB5Llt zlEAgUEI9oD|JqBLWna+b1Jy!v@R#fnL2$ zY!en6jSM$(aFFOBkf5daQmHc62Hk0jd~lB(B(Ono*s8UzMJY2Q*yGip=+s!r5P2qx zoMD=7X;l@m(Rf|d*_kkP1$&8Db0M<4M-_@5B8^7&Aq?Z!5NWYd&`h};D{}$|QS@-E zXkz1Ry7-Sy1P(-BA{NW8pF1WhD;6o5L59o#Y+%9xqN(-+af&f1h#{Mjn-W>Wa1?D4 zHD)w6s)QdoG=LbUZec=>J7{)wXI5G+cj0)7bZ;S#Gv)#o=K6u&dexCgBe8zxIW>Cd zTuHpk`ucKPgB^W1vpc0U@od^MTog@!42w=QETwnnE(L*PabSu>R16}VUxUSp0x)H( zib_FLr zqlkj@Z>t^->PGXEMYs@9$3_Z&vmUz|)!O{yL)Saz*h%O&A8!yTm{Twj$GSKs z1})6rct`DkWY3vVb!uKGl0`#Dhgm)vbq&pgMTwPJnrGX_C`$N(R(`vRy|#r?4@KWJ zfe@E)Mti3m!DoYrsU2ciq>Hr3v>{?zHj=$mHd%r5wsx1)FxLY)mMLV7NrXl8d+kE) z2dkdKss09mh~bR%IAsYM^2HfD&)VNK0ItC(N}KHyXTQKb)J07e&R#twqC5)tMg z)<2E}X#%FGQ_jN3Mgc^kAi)1;@X&XQJ{lwnL<434L?{4#80nogor~I*S(tyqR@N7u zpz*BJggt*4v+DU){E5pNT5ToY4@9RJL#RKv9l__!0d@HK?A+;$!dVMOv?ob0fE zRx&d;GKg<^#8I01;uCh~t}+Vo`FD6&+xgF8I4O^Ji#k=C+N~vn)O0A{t7n!5UsV-A zG!t~q$Jh3ERHoZU_WN!4!t@5+f5CF8_^)d3L%ZMBywc*uzDn_rKHP+UHFXPI!CVc5 ztPc`*HP>dVzq6L{ShO+tGF0L59~Zr-?~pOAb*~p(TDKdXP!Vz|MQB9IyG`lN@+zHu z-t;5ckC#~DiPqQ|F)cku@K&Wm9)Zl0-RI79$m@(hMmjMIrP1k1Y$ZemorPK89IwC$ zt)5TPQKpPKkJDwklj0cB_uMMb^$tq^>vR8zf41zosUF14#JZxJP$lk)QRNzV7CG9^bxp*0>nkuIOp>Ro%JlIWXpb!*93>BQ%+{?z3TWIM%AdBZnmwEoTs zZuagYL<&%0`RfY9gcYwUh=n zec{DlbvEJ5h?<}SVqAMKOPQ@E%n)gHnyWQ*PC-D&@iMJJ*6%vLaK?;+Oq*4a?|y7b zIQO-jRwMke<9|h`#!7rE7E)24LB#Wx_R*ZWft+g1K0eb`Z9 zI1;nCkaJ$mzl_H2Yg?pRokMEUTUlEYym-GK>+}dtKS?RJ)A$WgSg^4AnZT5oXlv=; z{GByfci?b~Z)Ai&=0YwyyTgDynn~4D7rMgH#Mxa4hR)sVTiyS2g@Ba;D=3t;jsTzsd59K`T)aHhL z$!VhILRmdz{f=oSS9G`|DKd}A_S?}r$X+?1_Ka4&5fM;r(FoRf;b|!S5Gf*7Og-_T z+F6^IG7*s&fgQCn)H`Pf;e1g`trBa?!Ok_VMT$z)Af(PF+YlW}L{O9>>=GYteUQvx zcYFG#J}+CL`#@Jj5#x0?mLjY*Mg>3$K^Ud+&>Dz8#zu=%1;duO_*7BVxWb?{g z?y2|A^Gz>s0BCQklAMiXXN3@v>W0`$5Cj9l>2gV8Dk>--(Va+> zOn?dA(qJ%C)o^=Ig?)RGBmoF09Vq6<_Bu-SJ0raiC_zf9F)hNlO$o17K|laADOQR@5JkMx)pz5hy|clKqT}jFD#ff_KQ4>j|UBYEY>mG8KPePPI;Z zwygSuzmk*Yfw`u-k?8i~fWv8mq}!wpfM|DCHC1q^WR%kJ)H9BNhk@t`^HQkut*w#G zh9HWSTzL>@i`tl3hxKQD<~RD7T@>V8QcIim%!k12P>1m+5+nwQ@uX=C4Vt{`71dD|Gll77Uo8b2jhBxztMTMIyc+|p#S=B*g; z0|YGs=0|ehlOjy(-2YTByOAW+jII_7Wb;`S!F@$v~2pe2;zp(9qaQWe*7g;8?KcW z9!5BRhuv{L4U5}A8}|SEH1fuTLS}sBwMJ98tL;NG!Yn{7>35QY>8zRSAaz{ctADq} zyEWqH4XMBX*m^n{udpPKp9rKMkh$aT`-|n)^R#tj9F}Cy%BKzZ+2*IMxq>L_PaNM< zQmF_Bj6P2R2NBGA{c%FGDU4C|#f&9DOvWE-8QY?w^#;3A`s;W?5^K5%Y>OO)J}#v4 z6M`Fd_d@Dh(>Fv$RiC~EZGy2b$9HR=&4t_sK8w(%Kv^e)zoy~X=^X&R4XsuWDA$>xD8+&xI7`!Hqc-VylhJy`bmfjRe}lh0ME>)$Nf zJH%WMv914pPkx(geV|OaWOaFl*Ft*!SD&LD7$6Y@jI5NcE-LR$G-c68RmpMBJd+$YEG%1fP8

W_zL$;WA6-7#X<@i5d`Tla?c)b-XS1s~hSKf;%lCq$xcNe?<)pQZsG*G? zk0JG%P1Kb=$t!XKDlb$E9^noVxksMm_^p>JX#$aIm^lW()F3H`L2atLNkMlyHuuz5 zp6WFI-k$4Gn)qDn8n>`a-&7OfPtPX$F$N&BI83^&0Syt<4zesY@dsZz+6_3>jkOph zYdu*bjfi}*??pAps7|TfVFOYUP1|#PgcNVm;7g;r9K(!DsO6U3M8`O)I=JNbomZ}x zjt2)j*yq!VM~RMwsY!6mw+E9lt)*L$SIbZ20W)wJIzAL6vH+UEJ`^nQvmTX zekfwZB2V+{B7MV<)lBAZ-VXbxw5EfY#>_xLd0K`z%_pG#^rmD0g{k=#ITUVAz%jm^ zrod4_3UKP;BBKLF{r*v9%1uSW#lWlkBo(RYH3CE6;I>oRQuP~iO_Um`PpHFN6bA0V zkSv-2bpUgAQp1P>2+VTum-l(=nlEt6xYGo#6NYF?KpZ1q@a$Zd3s{bIXqo>Ww|S^B zLAaHhAjp$CgPd&*n}*LL-5^H*&aK*xe&9I($n}|;e&7jc77zwtwoyz3cS(NOt0O@H z0+RTJfx1LQ00L1MpdYdWKw=dbFg)~1oD`bi`a)W=!l6Jhs`29N5`ruq#53XoieeN=D9_@;4xrVu&B@tD=!^j!Zm_l552yQ zd5qY7nxTh0AmT3vYnxx}1i%G2B(@(Lf(yR4t8dr?GoRc%n>64Vd>B{Bn!^cQ*O@ z&1X;)+;TGHb8i`{CHB4}O0ktu`p>8(6b?Mf+h^nY&HBlN;(Uv;ztUU1Hk5W z`mGF^7hn1udQgM|6>?I)UWL98S}j^2HY8np=|xI2z0yw6W!{Jk6v+8W;v`_&H-~DZUQsvA;`;pMy)p?}PIgdM^L;kd zT2g3sxx6;Fg_(U8NkEB7MBs`kqRYKesqS>s(rL!I#G}*)6rJEb;ulw?o$Oqe+62HhsLD z4PI!>J;GR+|Bcl?<-Z(VpKm1t(ZjR4iTp(=Ts8*R{YFn8eMk{Q>oNydi_ChT1yw|K zXoPm{x(K6A03p-_kZT9PgZ*C0r9=SPZ5nX<=4F!z(+NB92KRv!Pz!+f+mO-&GhavQ zh0Bn<*Sq9d$x%q7NXwpk!l;hvZ)*-Ck>L0^hh&Zf_pSCvilQVM5$Fhwc6V`0zW#gc zNF+Vs#m|kkuiwy{07npTCX6r9lla`kV?e14CRoWn)ER&DOrc4c0(V5x%sA>HSX$|=n=L@(CW29j| z0Qg;ZQdP0)&=qVJmgyi{s&TzmE(%QRhcE+5`-xToW?_=y;KWJ<6b+`>w;5=rAsz#u zk>aAj)qbE2pbD4^AngYOh!pW)dSLbzVD&By;0`0~M=PU{ZH{3Mvs>pvU{=-NA6dmb zQe89!{DI${`B|QNFy#%^2t8p~wPhdwi7Ohn>&oWZlwjV(i)uSlaRWliL#5R4FNMGy zMp`95Z(drtt^!OJIec!zUp(ffXR0zCCgY<7YX_+6^81xAjt;=5GeqHY08zziOrAe9 z4^Se-=&*OXO4nRd^%v0ns`^dKyAa_zasj$XURCZYE5Rf4aLGhQoWzB4s*EOSIL(_#_|yc1BNxmuug*}; zm<9sJ#LI?lqZD?81W#JI%dlvQ2)ES4Vo27`W{$*4~w%1f-7&gMgmejtK1&FL^4s;J0TChM$c0;&PF?MF;09f?Dk@Nwe~SUT~vGeNxa4(M-HC-o$ImBw$#1r%D;J)Mk8biOni?{)q-vRJP`4 zRnu9d&A&{P4=gH|$lEHvA3G>XC9X#3YYv|T4lz?q!=KKLy-Qj?Nw<$~UeNHPj{ns! zZ$bg_NMJnm`gW8pn`1$zS>`N21b7}%Pk4RoJ#!pGa4#vsI#2OKFdHi9fV=H)-?v+HWxQ|WzdzTp(1FLKD|LSb`h4MnYiC03SoZD! zz^vE{jaRORHT;_?IxYXvksDw?ymZIBH;z@6fhw(&&0vv7*dGIVY7*Yoa|7^$=9kQ` zYOIzUIu5lXhxO4I3qsfdC23)6=-cK&X?_0W{zD8OlHO8@afL#Y;|5vzq$pc7D{ju_ z<7UGWb)kVC399N(^B*T)_3^+8lVZLCN6Ax{+**svg{}%)sz+O;E>-lO4D3-}(e*2wR!c{)6~~jeZ<8 zfa%;;V*#T}n&*YZeWqAsaAYfsa$0mej+3Lk>%Tm)=kixDdfXH{b9jc(7zF{B*iiHn zYOWz21Qxvwh>jGUrWPCZA-@%4FWz`BkPk|qqM#9i(nx_-!;Y+^1Qp&~t;ktTXm-n< zaRf>px9L6L$3|hfBqKPX(ME95%*@p2inMczAsD4?F4RTKsmE}3O%jKSE8-4%bQD*LVvGTd>{RsF!5hrNPyF8qSX}Xt3 z)v#b!0sJH0aK<(svz;hb97*g0BOgR7pnra($Wq94iB_evZKOx0MnS!z5L&6{oT+k} ztG>Ud5YBvrk+zzd(zAoMq&_g_K$FkzjTOr>pRf>iGUy<3ibLE>Omf|!ort|xNW3d^ z`tuG@JsJ_{-DE}HDTjw?=*eft-23nO;4DR5>~7+uk7b0u{UEX!8aYpOqV4}Zvtr$6 zd>2t#qU9ifQI?w}ER}z$6b~E7sUwR3V9av>oRBC9uPkO$@i0J*=N-6}m=F!X-6hLc zF2tfBp19{(U2kBo_^I59MY$nO=rfq5dOv^?h`+m85C!1+=>djVQBtUn+4ON5!pF|2 zt>2g1S!jt(3bfvyI62V!j;1jJy9qFpL_SOaJQZFA&7l_{3HDE+n zfXw-;K9~A=#;pOYgGZsvdlK^Gwfh40Ab;JtOGU@Hj{eJM+U}8+0s>Z%#*{|lyX+=3HY}@e zzmL67`rdsJDkeoNFYRR*`5oN^U8Y*D+7{4I-zKba$JM_0i8oqi)K z_3A9#82aT(BX266BBhGNlf=O(OTcGK%^P^$b7?qTmR&xFYVLQemo#sAqbhGA&8s>Z zAY;^RK1cHRNDgED&f-|0+!_8oY{XLfC7t!B(~X6P0c3@#yLqP%9LL4k3H z)H1b>3v8hxqnW&GqWFZU6=FXjBtL;0fxq>_Go+X_pBp(FWHz+9JepEqm}VeHs~l(; z@qRJ78}&7nn$8G`O5K~t(|ys$0eC-mAR@jMw-g+PFC_$Szvb1rjIzyV=r11t1HiN% z8e;vWVI@F}Z+V@^n3~N@dxq2(?J52;LPzGF6mJ^Y$Fla(bH5;LWjp%uWuL;RUkOTW zEmjV2H!s&wAoy(H)*plmeV0$c-IZ;dYh7X9D^9M!CB9tocP%vz;<0jCqa z-54{?_07ZG?|jn&-3@6C6dPT96*^XwOZDCxisf|(SytfBn6POQhNQ%%r9N_r585Ii z<+f!MW%hOibfx1J?7G&qoFmucd*XOSBe4n(Q-t-C4BF1hvQ5$pLdea!E_?+GDRGAi zerWcBXh@g(;jGOis9_}SyH=*53V5+>gi!0^tskAmECgbtD@1#$Y^rNZ5?S}^scHc} z$b^_q&gU1!u=v*GP!G0o$F^-Gj#8@D|{LTC8^ zIto)!E}90S5}hZTY<2sh?v$ELK|{~Zn)i8wSrFk&^z2RZu#bhvZ+S=Ujun+2VatUX zVkPcs^CY2IqERmiu>>t*pR$AuEnx~SFhOaX!#*m02#cE)CSaaGY!AUHARA|{h`1^y zzRJSnqzGW#!vr|S+GcG4i$nW|Bb?DdWf;BTt7a%G0y{#ANR1+8Ya~YF)U;An zQO2xdWsGS@5s{2!AQC-En!peJQrSBeXwe_tK#u;#@2#AM^-1{~@;7|0EJWjF65;>= zDLsM$_As32&ZqrSKyng)(>zS~(R#yydBx5)&M*`~;`<5aHPj#{y26b$iEteyajY@r5Oe8xwbm}U- zt-^)RayfVE$*@O`PF^t$=O1&Y<%R&|f~Y9(3bHoy*s1ScQmz%0-eC0X$dvT z9K3*=U1DVdZDt?rLE-SH*|2ASI^c}^@N2Ilvcr^4-GmZ=n6L~3pMR4Y<$(d`(^KSMG#WFfP zWzNtV-u<^hJ@IOSm4eP?L0b}u$#lwUf24I-wx}KL&rq{wQYNT6%};Eo9QM8BQMUoO zrQEb$ty2ve-Hw%KM?dfaU^v7=6I$J#MWxdtiT^^kD`Hgz_FdjkXQ8x~2n`fR^csl) zpi^hSr~+}7`@Ec*?YD@l&xXq2@s0Qiffozp<{!1MG!x^QR4|}#GhzTBp7|Xq8qJ~y ze8oVab?#?R#b?Q-t#zJ2KFKv<$>xYFI0?P(0+_p?q8s;!bG#`YfY#o$X0T)imS|Zd(6`%wo zJbERJgg%j2)q8@*@t(eKSGV^g%lL>t0ce#f{#;3Soo3eoWvvH{i*S*$28y4awl13q z4_``PZbTD|fLW>460QPh{k~FDeLUA13vXE*r5DXLF;(NA1U_5#cUbd*_2Z8;FT;)> z5-oQF_{-BzvdwoUru)JhYu^r@V0rM&!dy|7NlzGmHCyK@c|#8x=(#&{?TG#Hz#eXx zwz$pPQuGg(p`On4KCDQr;x9h(w|JW;2Kk($iHz7AbC2)blO_XLYX(VxXO=ccmEMEZ zzo`9+W?!!xkiasC=?OTb~K-VIoi z{yccDu08+|E6X<}(_g#YALBP%FLL(wxMo%h-fPl|bJ#-%i_l0ZWk0iIYRevQdjGI< zJ$mS;ny`R8&Bhi-ki<;d86~%i0B*L-!2hhT)rb~^7Y58 zC;+X4DJDSi?0O~usiNcX`4KqN*5Lm04=w;cxBBXRm8wo^tvwdyM=6g@fWHNksYR)= z{w%cRg60ubvaNL4FK=uN>0&=ne$FHK^hly`&eixco>vbv+8dSQRqxpM=7UDfJn4k2 zU~uslQQ->z?A#nqacbzZaG4Qg4r4SaYIvUpdT3#F#Icqm4;4DM)>a+*AA|EnM+|!O|vCewYh5#=&5fw ztk%`iQR?_!!Fe(w))^Ko>F!9(B-qiHrriVy?jO%tjaR>mV6vUc^^rJedH9m03E5-u zMs38J@}v34-r5|baer99UnH2A7#U6=7|j(c89NjObEueJB-Bz;Jo|x~n%_b~5uCL2 zcD%^)uHb=S<8T+0NhlEm`*U-1Nk4HT!0=11*imhF%5IO%q#mzs~(f-*Zk%inS=+$ei{cK1(}3Q%`ov(DsU$4etakX8x$D z@nLqQVBuQOwnM4jMe2(d2sYup^80dXEcwk+r;rlHt?21(`B7Q(#nW%dsY9K&)^TWM ztTr~Qwkphs3}NmykBzFAcBt02k~LO!1d+igsbvG)qA}L5$XF5%2Ijm%>EO#n;%X&Z z!r9F=BV>Xh#6{GXJgjYHt{!dOCHeQ#vT3%nr4TW5xpwLP9$(&nu`wLBMTyq|-o+=Y zyGqm=(@Fo(ISNM6K_y{Owr`%!8C~gGJyb2jm(+u4o?JO;WV~?O7SJm4o1|4!@HdQC z7}_R^es;T<9Y&Gr^`o=NE5a5$E=I$Oz|nl=A%PO{IHgXDaq9egcEV^>U6R?HVwc@u zW~>@ynBr-(*~+4wyxj0bZ@ZX>2USZN;p6b8ub}OSvgehx>06_jQ3SH~t(GV#RPu z1_EYLbc6(HOptQ2SAelZ?Io-Zl#;JtQWnIZ4}lU0!6`YTF{HgXz*K9QKw067Z*Tr3 z7A_8Bh2ufhxuTkIDByrW-$u5-v=|;&h1D3d;baE(qXB4wJI8N-SBSw801Hx3EMQnP zOzh4~T70M5hJc|;xTS2OE4)9Rbl~!-^2Q)scRyM3-kaAA`xccf#F*Q!XAdW~*sp~3 zC1hIjOl6iU2UlF#MEIA>h8}VWPGCd>1L9!3VPFX|(#rSbG)MBApYU2r1%V}-iOTD-2OoCBtu2=Ik1`1;B|My zqkR(=!Vi?k9CyjPo6UbE1ZxBmbK$Pi@vj{n=pt|o0kFMTI%D9h6L0h+331mkd2=L( zgBnQ{v>30(FYCLPZauqINkY{1#5EjmXfcMIZc3m3)xhHT+`EQQ+3iT<(assO`~0yW z26Bz{voSkbb@z;uc;v*v;=BJaZ>jo3m*9Bh4WhK#_*;x z1B7(Hft~<65vVU8*Q>-vfr%=$utpt{-b@0t!Q>Bu5o$4U)K6 zPe|On>e3bDzjAK=gQSS5+OiOCQ={0ndqyO9ruA68Cv`DhE%>E0a-y`;#5Q1Y+gd1T z(pee3_faF2g6=uM|KRKO)rnO4A^`+Thu(CC;RR5n5sU~FAZmXYMpUb7A9a769tIB? zFvfTKKs1cq!l>EjQ7i@;g>u=Z;bHt>evmBw_F`RtZMSHEe_9M0@r_-oK)3O0lJLaM z%h)jQwD(=r+TDFKQz4q+>o7l0G&MKc!I7T|=7V=5$oL{g7ob-@_MG~JUkrQuBk`p5 zWY|`9!0&M^W&)b#&8OCtDy##qMTvgNg;0$McaU~RvXLjoY*_vWGWu)+k4Z)UOypQJ zf)?HN=A=!CF65Q|jGky_mz0QAX09Dtpb%Ruz;fy;Qe!Ib;InSlnvDua(dl%aA0NJ5 zSqbA*eD?4LldO8D{~Qxl*|AH+a2M_zBEhM#g2evoh$(={SE%C>TK|atJ|F(_X7;0adi?Z zL^3Xq8;TK%*$5);tJY5b4$Q&Qi54s8-!WE~({0ysk|-%~-X1u1TLMzA1B%=N^Lim~ zhbI{P;*)Gs6>c91TEagbLNvDm)jjBUpT21ze)RmV@SqyoXD{y*4BWq~n!1JNis`8f zAWl=1yl&Xp-GQGDM$+8>?9Ka&eV#4<#Fi{gK!C0V#`Z%TNSQInG-6gXUB3CEN4>lUo zkLx2epD#Gf5A!lGx3Rg~0nkr`2H1d+cmB`@z)5?z6%he7j20t;oeGHEi6dKf&esP( z0F1i;F#zdZ-mHn{yc>rD+%cQTx|YRdA;}pM*)qW-{_sK_+6>!07EV}STPoU% zMJ=40S&c{Q;@%>+#h|c$Bh;D0kCrVT#`u-1E(%oMhT&!scM-AD&!hzqDa(4J2GtT$ zABldQF+?f17-mZ;H+7z+a+9m-IWk8k1M51B)Je$M9_KR z8hI~Gr@_J;9M!_)Yz#k~5uQsu{7J%HCIGr|coRO{AWu+T_@`oKHPRz74a5D2RbtqN zhsIy#>@XjbDotAAor#|@eOvL%!8KICuiH>;cQxJKx2V#Dx&GyjdT7K3qJg+(rn7?I z!mpR*s)}DxC{pkS1L?^-Krb?DZI%Y+zkYE%x4AM-cWw~Cmzh?&!Og#;vC}+!|7;Tx zmN+Cm^}SJ5V~VaJ%9BZxgNnlZGG8rQq^wztxqGeBXT9XM9NXF)wszfgQrO+ zgWht&mnXvFk6V_nn$>e+eS<)kv20NmyPEq^)TWie4U!z^Gp_hAg*1wvy=nP$d+HV2 zW{e-=q|TS>^mW%nP+Vh2u~WSdGN--E!Xh@EPl8Z()39b2w-6%4t zAn6%w8CP9oQ=bKMf!5cDdo&V-N3^nGRXHXXX)=eulY^_*tRHeXyZ<}z!4rQysLnc3 zOCIeXp3w;D0z0=qS|*P|nOmP^Ou@3&bP;zr0s#VG>Kjg^ZMXT~Ti5brbC=y>%4YVH zJhOYCeTK&7A->kG=uWF00>OO-0xF!{ui9)UDa`x=(<*VcGSH3OotD@N~8$57Fi0ge^ett7o!Zfnc5zI6AvsLOHm`(FYPoQQz!M!6> zJM79@e)ZC8Fi}r$LcEzV+nIdlK?Q?DcW+(c2zUUBK} z2N-0i*8?Rw_OYEw`c%(%8Zq~fpSf0*_mw`7RGm~vS(2{{LF_Ik;|j|s_-^fBxAIv+ ziUW%+pa%`R^^f0<^}QcA?nMcJ@=zTAA(U4fKQR>=xO6-smPKi=vc)<7%zFOkF=frm z%b3)sxus^8_mEUR65-`n3R7nUDgyD+-sm4@+%|^aX1NL~Ye>>?BYxkx5}bSlN2T{* zMmz9$;=ydeI2J3i+zl$h5Oj{(1F{ImA6XxNzRrYWrRqI-#%Xip>j-~O7z>~AJc)mJ zpl)-pyH>EQW$fZmkDhk~*KKs;Y6NAP2Op=u^R;?#8~{$y)vBsHUsBGsjkF+CGjH_K zZ=q#srpK>U!N2}cQ%i&^TZ_Qwl;N6zq9jQYd%JS=Zn*UX$l_zF;fP})GQ&^UHo~P)VKlEQpYP^*Xy$Lk80)5pKmwD!`hV85^!X0zsy?#ncwRQk3o$zttb{DP) zli_9)RFQsfaYL}?z5aXc ze%jrcYv#)&bLMx>ea?OEp2%5QYkFm@LE__7I=^e)ja{b4zxtD}YIV$C9rWv0FoV31 ztX}x7)R;0*sL}7wKd=CC?0RJ8x&0`?*1i*N4_@wQfuw z6_oF7F~Uo@Z{ABjP@g}fPw4d)HSvTyKgDiL`!4J=$*KaM{^+DOvX`1L%#O(W{s9O=J;3PX$vcr*7^5rS2=~2Mb<^9McV$2YyrFS*u;K zPBGCtGE)D9+f!F;cj3>L8B6Xz3H1+gcDe;g(x z&i^fy@mH>oua3ES_nKGYni-Qj({XnnUjIrN7rK-0-H?rUc(9(Cq2ECponm&?yoH^p z6+TL}X+3v8e5f5(pgwdr+K5V8CFptNGX)7o74dL&j79C7t@4X7LGcTs{%z_cb_>VS zk$?Dl!CTpFH=LEs3y1EH=4VOw2-fer+d$>&l`+zKfezEflww>?hUNLjjajw}H%xSS z*(a2batfjTyO6C#IAu0vZ%as-I$PPJFTGyO4rRKq#eX7a{Z!I?sNaukj-2{WzfBmv zl3uv8AHz}{MkDP!&2gjZ6EYC>GCSj&{quaI+|K)1(mD<8qS`Ybv`8G=*UqjN1GV3==iD^dy|e6Zq?~uvor!_I zVrbK(^BNzk-q`Im?#&A+Dw3)5?mg9fc85SWyPIbU4xML$m;gotJ9it+d`H)2OZOER z)*$A>|Dn4w!DFt;dGJz*cr)h>hw}K{ZI+PP9r-<$plYJQk6;~&ojn$HWJA@kc8~kL zvlT)|-_vUsQJISZdd1bt-#f3bjoICQOR$frNL3D-`WqFGE$PRJT^o`__ytrRJ3X=S z&-Yi(XQI-4B{9i!7Yk(%NV|6k%b4(~8QKl(YI4jrUKf1GEUp?`+AS_m^0b%lIvyJA zs|{eXUyziF_@1z$>jl(jn=yYUF}L<$QAZB)CUiSx?PY+d2z0;1J~8Pbi@25ce1sau z4f}E5yP7?sONhWeZ?%4Q)_z~Yoq{#FLH`5!8+KB!SRVmNzgPh5-(g5fI;GbGY0p;u z)>cDt1nt!P`&C}uAKkL3x80(t;vv3N*7rPR6a$*xvs(OZ!Ey(GO6p)9bh_y&IeU5BG6oHQIw zfs&|NbA@oj{E(E!zP>u;7{kySi&(-KYNeBR-f#!(;lBzfZx?BIIMr8mPIJSWojg|~ z?RYh$uRm_O$i`c#MLJ(dCv3j^YA+Yr6c)p}ZdT?hJG-^McqdR?MiDjMo+x^logDLN za^|+X|F);HlrXJ;4TWv-xNH9W6yqzA@1|4m43qeb+G<$fzf}WlKH#oHNTbk{$(5A& z2QPbGF0emW(vIGLh^Rh2iCuTCs6I81Z2nq6le$@(GOuB&Zz8U^!Jz7h9W`=R@<-()kU z`|nW|T>GMh&HDFYr|ncd`orRu&=||^aGL?LNWacbgjl6rpS%FU^K1;Ocb!41HHRj? zyjK3A{kKeSAg96N2#k{OscC(}YeEk*?Yyune^9R9F}>`A2xr>(;tu=n%lsKf;%dXZ z23A6m)rVVrg#OMA8utL_&>ON|};`>zf@i)Rwhz}&5{mATvMx|dlrkzgueDXFd;OjG_JC(Z;+o#pf zEB02;KGc^C@A7i!m&t}5SNuJ3eC%XVHp}>WA}Rv$L4OG%KR2vU{y&)EHjs4Gr(Rzv8z*HyaqG>n~n~hR{R{-V5qF=?=72 zT8D>71RDEzg+?a7Jn4=B{{#qvK4$)Y{NoS;|Kx&P#z$7D?thz8`Vz zCttR}!4y1dukMO(J9{M(2aZt50Z7Lj{einPb4w-0*7u-+)A*$J zmcNfc#r=WtY19=~QZv{013LHtct>4*rGrKjW7^&sU9AtlaR?>M#<#H2G zRePKMA3~WfM!xgv0|EN@7mpsi&P%3>XN}q5&`-HmBQ!!#5tF4}2PNFe3NTmXR(+Uu zUFF^~ot_$dNc^pQo4}34Y(|>Wg`Suu=ahL`>MQK2$8_4Bb+(s#%afZ<&y@`kUVl!O z4aQU770OO#qU|5%re?pJ^?{bo zZfCK z-oJg9RH-wSchz3k`p?y39=!1&?0I|lgMvsvZMQeyl}y*d@Re+qkd5?)cGIicLLNxw zSD)|IX70C?T;1l(nP8y$8VG^!@wj7V5}(R}r971xlx|UXrxrz6{1SS>P9Y{IX9#3K z9RF60qQ9)*H}|DJC*%VWDk6i&*@LOb`BwARsBL?#;}+Xt+bn@$VY%9Jkw8x8qQ&jgCLCueOAy!h$1xA1E?0cIj6a@R@?WJ0CK)Z4 z57&HgeSr{#64L;DgVMeHD{h3fpH?$F2^*A`8_U*`XvN*|vFP=;o1d;z6jyxKU~j}$$t9E@B;+f!JTq{+ zWBHt?Nfk9)+0DaCjAgXUzuah%tGedq7bb63 z%me8naqd^%>zG^jd|c~zFqG)$209*&waGJVzZF-WN~WW9F7VflOIy1+cV-A{97&jk zjXli@MtMJ=j3#;>ccy5&%^>(KI zajN<`ZYR~S7F3q(t@GINq@q-{{;W?*(sz6EelB;|l|OB;fa?l;rbENOrS;ERIimi2Zmi3#L5e6cWf^wuGE@H9rq6YI7MaK%rsqVe~GC*Ns3lU z=Sw!+K46!ux{>`CxA(k;G$8jrd%*J#zX$63?kt3b&p9shUbwk)oy{#@$qppP>#{a| zu2guAo%OA%N0w@OYK9MT-8|^wE8le1EO)*E4b~e)`6DoAGu}v{2ito`me-B%pq`Iw zln8FI1%224#CUYs{e|s?T>WWwhEd;YmYmiuPN+=6p2|*|zCP!c(97grO#?3b6GQ`DeD~z` zK`-uS5LsFrg)bk^bnlUcANnV(w))uD6kBEPoCu6_@Rp#^x2)Sn_YYihuKTL zpP}sytJN;VERK4L^y)uu?7%|kbUyujp4Pj4{6+>UbHkm5^%3+{jgGy4q*Zo8(lYnY zgn|R{ur6I%OF93;rS(8-MVHPW9?-^buMT-_*~wmSM_%pa{9R|^K$KU-nPh>>hCREn zNv7>DRljSY1^T%WmB7Sgr$x(AZhw*_h=d`=ZyHMK6KPCx|s`sv+J zqjAk$E-x?j7O1%L>iV0rw2F^MJ4>|c_oFIuy+A)Lw3;At?u^^|hAzTvwUyr%6%gnR zF z)6hFGK6ghO8KpQJzBS*)#Z^uUnA+D2ea^_T`fYTvJj|E@t6=ShB%PHAQ^zQ)CQyt3 zxYa9p$LH?1lcSfq&%sMZ?V>j7%YTZJudepJwM=$zuA|0@C;b6wzW^w(o85i|SY6so z+BVUB@<+u=6rg#V)GW=h)qq~){$u6-tUjvsW%A%v)|b1kj5DT^&P$)FUs0u^rSH$F zd;i$~>g(mD!>1hcdrnA>@OxK8#|3YH`a*lLwYMNw)a>9!A0aXo%D0n~)HbY`Ac1}U z;F_s&IjQsaI}W;Z76ItTIJTAafgBXFI>+n@yqTRYb>^f@OY> z7Q(N|Q?=AU()rXy?}n{9d@Kp&X=c9ntbezD*0igW7W%?Bnzg~z9q-f5__^Wxe&6Sc znudVznKhlZHxZJN*HawydPn?IPgCwWL|iP4VYjaub7nZTM>>r=ujtRl^y+jXMs}5x zA1}CDK+9r!R)*d1>lZSQz|T#ZeCHKt25skzil|!xt1K_?dpzTIMKSM+_AqOn(n{9` znLcz+Xnwg-<2)3IQtN!t52?t>DZI*3nT>u5cDu%SmR^xt`6ZI6+netCU2y3t?lx;K zgO$v^>mbtp1rZMefhh9$0?&ahRlOS%l6tKEPCg$A?Op zyDt*!=<#t_$yjEZDEQ2T_m{n*FnmKCO4wO*(}Lyuk4z^*5}v5AqV2)#cXsW}Zg*UW zv+8FkM|Th^jlgR05XuPMjvI@7^6}jGT7gA0<-4!YYix%%MGM^$?(0aEShK0mUlY%H z9+xhsW3M#HG`r<_0KWF*QLjTg;WFS8Z#<>ju^vZLnece9_ih5JS4h9^i&`d zQj4C!xfaNv@Lk*VsGRHiUyFwCz;-J{AgR+=_R3y&NMD(^4dkM!9=b$0h8AibXC$ z0mbSZw9mTb%^y-Ev_^{=mv<>LD--~hHU9lUy-ry-X?t0}VN(q8PP;3Y4$46{=nPqf z9ltXqhsCeNB`B+Dx{SyD+MJO~XZRdR(VT2>X)pKesaO}Y1Rs3@iRRSAZH$3sHfqAb zRZwXd-e$l$P8rluEzw1%mEELz{2DAs{BB3&sMI3o(*b{Si?`VaYSp9Mq+ikE})9vD5ng@q4*BfXpRgMWefdv-ci z0}7JT%VyXP(y5eRuJqdgW#caoCJj?eie&gJs%f9jW1og3P1SMs*Tk(1z6i{kmy{~* z6V&;ju&W=5GX)vH078|UExYbYF{Obj7FV0b~=JhJ%5{@I2@K^-sm$(OlqH+pM&FAt&TE3X?~y85@I`qF9|kI~vv z#tbodOx0qUx+no6bEX!PV`Y;lcjlOupE8POlnMY5d4nOVJJg51{$Q(xh$%PMO=U6Ww@14FEN{>9dQALeG&NlI zl?K`^#4yp^VU$pCdV1!}%DZ6#k6?day0qWYN&of^zFoeV+J-*=s}lBSV*C-K zvW&&`tGp8XtA?*44?fKFX+o~Rw3Z#@%WXFIhZf2*uZKRpk4cSWkRysDIzS?=;?U&` z{KEENDL{t3h+KhS$}FoJ3lnss?e&NI9Q+K-33=!Qa5reV6)QyZLGizv1c95Gub|8; zv$Mi>WZ)`*V3IXpVvh?Qv>^#1W-9ozzX45Xg^4!N9Ko}QHZCVSB_#f5cHEiWbw2aO zu^hvu#_-IvQ&jiKzfM+li$~vLBW9y+(6@BE7mF6#9~|Z7zvt`jPEw;mMzKi63v-; zBmsv6%XzDV*Ex`=eo32T+B(jAVneZN{99GP&sT3l&&8#VeLnJQ2;U^B7smUwR=)Tq zc`APBqDBP$%IA56ym2M#F$C@qOYynN>d{+OidVvdicTd-!@Lee?T&7_Tb5=wfD4Xa z)hBbbegZ@3mVJ`AvP?7hh#HiU8J;mAZao2)$s25iMs`ejaP=t7Pv>S5`|2bb-aJ_5 znDP_H2xU`PeQcxHg3@VuuWF;WVU2>=0vPC8DN1D+xSIDkX-wWsSuLefy50$8|KkD~ zy2T&@DE-Pcwew;_$@U;q!3=hu48G2BjqySC-Bw=fI}`nBFN|8QD}3okTj+E8=zgeA zj?2)L{3J&x*f^5DzA~mly9_E*rZ9dQH}oK0tm0p+cxa!oh8e|j zOq`bn*IeaT>@^rH^G~PLO^VPY#lPW=hv4q)LF)VaZ$(*l?BzheNKEa$wKZ%-aEBV| zit>0F0lD`ikUQ;Dm%F;TfSkm<&=KX7S3mNDe^zJJSo$)=Tk*>(a|gM&rxU`y#J7xk zA49nQ5eV-N#5!tb?*Az8eO))%^u5u^v1jGk)h>}3Eyn^$DiAF19x~6XgoB;3Anbf#s8l!04?*AxYn)S;HG(Zt=BmUa z{Kr@&Xq1%JVBLwCP$j+CyP(Fy=g@X7saSDn8*4^&8#|*K^~v zmnXPTK^Gqp07e)4_27_rM<)x4p|GK_7$e&3i(;>r7>nEc&V_ek8t=ly>C|dhmb(Vh zt_glizA9A)GuHklki$yyzN>^)goLv5Q3)YYxQ8q3w>#ReXK&x!4`cbsqz&d5ff*_+ zuyZkfyes~rv$i87t@HiofzY|LKM-?0QFh88u>!9!QcbAC={FO@S`*9l_6>~qOTU?f z!Yf*ZNpnp<(^ywkbulo*n;eSc^mM+Wnzs7%l8#qtIr${#l1K+G{NdsUqO%{MefOr{ zRF?Q_& z=aKZUj4kJlbO9y`+9$Ghhi@+>yOgW|S?&OyA0uM}P5WVY*_#D>b-b&5iuvCSTY3SGuG92uJJQ(6`A1 zr@P+wk|%T^)}KgH;ae7&njTGO>clbcAEoPQ6b64tL>E$EW5xSH9Kd zWz4|ola=ysE<64^^!Ow3T6if=rdH~?zog?_%q8<~9)H*02jtdXL0g|u&~_v>WO4m? zZ>Y~`&lIld0?OkxA-9<4W&X@wyrC#H;@;awJQ3{?{$~(#-G{?w;d!>Xa$OOQbKBcl zrN@C!%CE`=J~7!M6M)XC2)2r@nFXo2E>a6v%2Gzy8vs!he(vNy4hA}dR&Hl}d_EWb zC@t+9KOdVvxe+d(56~QEU0c$A#Jy*chWW)JN7DDn1k)n#Q~*McQrQDLq$s4;8|*T4 zwdeoug?a<1e53v$0D%842-)c;)ceLmcQ>^24fI225BHnWUcT-g|K|TK16Yu{2D)T_ zARu6od;f=S89!r^d!F(oxcIaO(SxZHm)0n*aaGSD+{Ffww;3GfJzNB#ff@vjTON&~C| z9)W;@018$hh!yy+7r_6YuRr-~|NG$o^8iwSD5{)ud)KcLodkLF8gGN@#>`*LAa_CJu$=$^MzNbXTu&aB_)=iiyJ{ z;5QX+DJm&zY3u0f=^G#|EUm2X*x1^+y1C!?@I-qB1O^3%gocI3J&jLDOnQdN%*xJr zo|~7Cds#{-D<@V|R@FB&HZ`}jwzYrg>Fw(uAPo*pPEF6u&dq;XSXo_L|F*HYwY_t6 zd~$mB;f8b&zMNS&U}rxz zLAe+j$nA`hx^7w_dDJ1hi~j`ORblvw$kBh${x`D!cfex*e8 zD?kG<)sJrN)0bV!tdrxMD=CA9o9Wr3Kyh&hfN&7e1OD{TZ$!)_8_R~NtrdG$b<0-IK$%rC^gu%jWV7yg5;%E93p;{Nd?89 zOEg6qWrmiGfOuqdWD|gpy@#A-99}L01FBO4poLgwBzlNX2Vjtb@c}Ml5WYI9wMvi# zoy^2?auAjt{H zDs38mn@4f2MueSQ`~sc^91Qu$bfO-V_L&dD_eTa6S1BY z3Sd>=08@(r#Ss-wjsx?;I3vmoe}9-u)Ti4@WfZtIG=n&BH^-YVo8V6a!Dva#$02Jj zMWeZNzoS7^&|o5KoPO8CQE}iW3Y;zz8uFd*bY%`=Po0s`2UTxemGMOr({Oq5oQzrH zQ^F`^KNP6V6D&j>&83Wro1cDo+#F#MLt4#CWNL-aninpkGKwQ6)AGzfp{EdwW^=^V zUz7K7^h__aWp3tIba36qW6=>4#Q_M`<;t@WmAEq^i>!J58jkYDNg0FYMmkIQxUMJ1 zstN|kyN%D`*gY`WolIx!S4J)0<>eE^$fI*3b z517nm!0D2dAWv_Y*6=dvz9dubiAFQrK`t zPQT3r)~P|%1%*eWXsw6PV7Lsg4nX&wt4p!68;Z4+%kyEY#ZolSnlA~`y`@J{M#)sP z1Ecl_u0~%AriKL+cUVfyD{2%O6k=R>i^EFWMnsi3b`2+^xrQQqVeD^1D&^z5EAnqQ zd$PiK?&H4RDx>+F;3-D#b7n<2;RwU&8&z3S?+c55n&TXU;?JW{ESFjAI3wJ)0G#4! zHNSKdRQ2E9n*{p zHu#0&VI8nDNl0fdJt|c-KgEMM;jWOzfTd`b=rA>OE9V-<;`l@p*nWnm0>22i-zYfm zOyxK)r$|>nEUz4cABL98EQA0NiE;V?-Mp~;G5Arx8jOKvQ5NSz%W+yJgdX7y8<7!G zqAn&Lm0!_f{n{ih9E8`xYOa+DiA&-@9=rNI{78V8%;-YMmt7K>)Tg=3PZ-Q7AF&E& zOs2a9?W5vi8mCQYR4rI8kBU#1L!u(45xCH`^v8{WRUoM8=9}fX*<5(XV>pn8+Zfpi zL@L%w3DMffnQFH-NlGV|6*S<(L;q$TC65u$lO{6^1a;eDZr!j%~@Pe z3MQ+TIzPpY|3fsTk|SDIMzh?51OB%Z-mBY#CczIs=Po5UO!q04gWg1Wmcmi2-sJAb zb{v`OK_w3?f_SF6=+j|LFdFD@b42fNA~t(jhca5;Sp8)*FV4l#oE8ZD%Kk^-;T5cC3+lIo<>Eu<6ll!!$a@>i6BDS0LV{ge9Jy1I(+HVr%Uh0*|ZG;bj`46?Yd zdb+P?@&xIK2N@xBS2E_Bbh|dUO-H9<(L8Q$W+3tc9Kxg{#;tjv&*2d>0ubO(gr}(6 zV;*Zst4xf$!U5x->_bYq2ZV6WLoKS9@Mb0iUfXRivN*fsjY$}|OutKRoh!zlNS$}3 zmWMCEh=NRsgjT{F|Jci8IvF?fo#%e z>i+@nQa;py7p0ntb;4IJ`T)`aBb02$CW^#}U*jNsDsFC@o>&5(B)^LvbQ2T@ngA?Ol__Qcvsv6GdRpYF5uTKMFhF9to}HN{ z&lGasrxZe<09qhuW0~zjmB=hqZM&m#4F|~e>_^j3;AqugraT+zK<;<}75&ws(Ex+F z3OwcKVm&*pSmhI(iFs#*Q0w{>OG)d9D$Am!KZ;;^f;S*&*jQ%=nChQZL{pc|;8==_x zb!4wpjwzOnHR(Rh*haBUO-8f6dxAh0QjdA1N9!UWu0o2x#wp@r;nKQO+hUMmKqzOp595&<*OCI4E;A^@j+X@}0-0}^^(a@Q83Nd!c5Pf%J z#VHgK?F*4%=%%C7%_hmi0Ll=qc<6tYh>I~xB%gG zVi-<Vff! z8y}}IH*6s<4t9)L$gqkwM|o4QAmNRWX!I8#(SmLxnm@zbfIpAeq^Pj;vXE(IAHmMj zXqupExzfXc5lNBR@}l~9eLMq^4F0AB0qyHo6Wma1t>u6KV`r?6G&-shKuw*yl&1+6 zDieodJH}-gdq*sRn)OH6c|lBr_!M00%IhS1jWkgY&Q&^ZfB-g({Xeu=m_pGcci!W($3iXWn}D zm&<2@&7-bVMb8cpj8G)9X5gF`hUDj(q`&*3lXO)Q^t`+u7Mmgij;6|FQt=NVK-l(V zR#pZE7BPd{h$|V}M((7I91}%+5J9%WuTO&$GRLu_o-IJyMbPyKVW+$1 zg@cLbKg#R(!Amjp(bVL!(EE=YUuBAWvqYhz3A`)WM<&kgrSZ=k2o_o2T$qiHjBc}L z#G=7q%pCyFlxYo=PtF9*Kke^ny~aTV&5u(?bXE{ATrjR;zZbF7lS~2n9LMsQ$IFi! z6aCoJkeQ{W!hR^(X)-sZ3-L0FumA>RXgQ^@_T5a7(cJ7*WzhjxLwi5*2mYwkWQ>J< z(_DR}zBMRRj!w#pn?`x4DZ(?}eH%p&G{XR(v~V(jN-OoEc%u!Stw(~GQv2vXK{YU3;}U-vw2r|WCoga zX~C|?%;90GZWgv$3}zIE(SGTkUQUmbzC>8`2OwyezKgH>E#dB!Y?dc<#`8Rn;j`X6*o5?2BR-WWihCWh z3wfpJ1rtxEQi|ebx%D7CfQ3m-8I{orS}J)~Pot)TWva zATyLPEd--hcWH1aJSESE5$<<@V8a%##*oV6Mt8srvgc^P26q<6x~1#768wBrtxt#{ z1>>Y%Kq^mlvo37w4QSdFrgt9oOf5-$ued%*)4Wwr}b=~6v1 z9^J!c&tsV;y`oWN}BV66QM`b!wWM>m2CvWaoIiU}6SgWVL= z&_L+&l<>3c1bdu+s}Obipccp=rO+bW59h16k>0z`Hd{<2&#MC?@?ajTO!>vqtQImd z&Zbi|uX+kWH*vZE25h6`dVmq#KDVU%<9%cbvq_TxfUZ`8{UR4M8^h+ekQHp54=Ko9 zD(=ea1BfYZ>p}uAJ;zkJz#Mog(w-+lh-V{Z-AvYCPv;gMzB0aneVNBd$wa%61tRY1 zce&MVBUIuk*ts=eySjU92Hnel1K)H)XbgogogR%cg&t@wSYlFm3F75~ z-q^U35~iNU!e5rI0(GBfi%q@**3CeRZXS~_UG$)qJ;H9&?)r~h5flnxXO*U|+eRSj zLT)igv>xDG5ng#7Tx=}r+cQ3O51K{Z6>;*NQT(}NwTSBy%vc+Pcge=Zh7x#qg3BL? z0kGL_>1d$%W)mRhc&$e85LgB+bcq&n(i~AU7=Xx-#5!e774ft{&IK>|Y;TLBrHt-n zj0=Z8e6|Z%H<_LGf}>1=TOt$!g=7da+l8}in`uY3ECj^uqW<(`jQ_F#z7NdUH6Xd@ zc}2zv3F7pH1Y_u1Cyd6LAV7~WM`k2eoAN3u%FEh*%934u8pHKkcD5*;+OJPY+y^nx z1Xoz1A>nC582k|3b{+sXR4ItO*Z1e9ATS#5$YUNM0qIjJQ}r~fDGcMXp!Ky*1`QTZ zCjhDBu9_#s+kR4rK&5NcZsCckJ89GloI3v9q^M7pjRiOsjtC=_mwpGFn7I4U;Hft; z+(JYo&ERUT;#w1c&cD$ghEZ6biV^mkjE1D7Oew@H6=fmGIYo4-k5W!_^%V(9V71>C zJs!p4K=q#lM`KEeQv|BesR^L_5AZfJtv!7FJ&d%@l_ikCRr2NAJK5tOKk(r8*nrQS z@}U-&mAB5uw9MagY=VA`%YJM4t|MxCgaR0FjCzWxg-=KKid?=#*#)I&*?bzwB9c6wabOyU7 zV%cTjk0@7df#CLps~@bOh(x&{r)m&0+oxr)@3!f8rqF2VHw6?#B2x4 z*ZA@>FS#quSTYvf*;#q9#x9bcZuTv#OtQl*h?tI0+tFzE*O2fu^0{>5oBjs~!snz1 za#lQj#ZMh`B|(u0VAM-+Zu3h+TDcaw#9%&I^eOU8@`VYe*HOBpUkT!CoZ3eSPrb`# zV2|N|vtQ_!^R;ah*5CkDJL4=p-#2mjJo*JOMCAmI9SO$rt6jg}W%nA!D(!jxwZz93 zTF`Wl0B&$Bpi7!rXv(@(`LfwbgFE8Duu(J`Ul>RX;>1%*lJ#Z)HnLa&Nt}&l#pC(l@(F?7GPNcYCOmNQ?T{Tt&q!#k1XshOhId1B?+OxN+65=`^cNsjg&eP7XwZR?Q z$5iyA#k;K5c$lanRJQEwa})MH-4+vK*lCrLP2soO4AKB}UvD%=XC()vyvWp9WC|}l ztNv4rWB(ZTTn!Zl~p{F;(akTkg-mqEg>Bb1G2th{5RJF27WJJ&XNRjO~ItJgWA?|P-cY7 zixwZ|8hG^kRDjy!!0uhsl*?A34D-^5s)59oq2F&UfIsbEx9DIrIq!2g&r4zm-2@B| zcaxC#7*a-lM0$^lTC0UI1LNF?w5*DW-mlN7o<7Rvsx-wDc7rcEFS zOAqEYwM_Up_3UVXVfq(wRvZ57L(i8_D_eb3EZowbIL<))Bm3nqrYP($=Lt$g|LLy- zIDmX{AuF=lG+eX0{LQ9h*8zfQO{r|H2?~8tCcZun3S;~`azofD%FDQ8*%jAWvaRtM zS5YS^meH8MZlVy*FooRX<}UHPRxJGDTx_TzwRxBvoIIfy;P|QxZM~qD*WAq5qLQEY zE$V?cLGo8q#;GE9=^cJv2$eR^(9=J!iC?FaOc&yZYUgQstezX{K>SeSf(MW$-}j; zie4$;<<%`gLneBJG6YM8Ufp^ePPgV@=z)DetCxc#2EzTOFm;^gf1Es6@Z5~ZwoJ{FqM;wDNcr!<2i*Uv!hMEp8~3BoQ;JZ-4xg! zuuGxP1Xtj-lP*@%T0iY(nZJg(b{fu*RhnGu*dlaSy8P|}P8J&mFL|HX31uBnBJ)=M z6ihbbmY$zk%h1n#Bk-p1O^w-7>(8H$iE$bFfTE5mx7~s8uyqvEQ&uDDk{y+)H1I+m z^`xKaaxEM%M`GtZue85vA7>6*--scH44{O-MnUELIcY}0<(2N~9%NH@Fu&<6=AQig zguZsitH>{~o{W9No*0~`LuVxf#=%KooXq7tF&1itFa$@1qht;+DyT|u4TWI0MXMPi zJ>2pskhE0IX#o7*Qcy z*$mTe;dEBsLA$&9R0B1l!5PKb2$4VfPK3WK7>YwNE)5~I$} znzrDRscn4>-|qp`0K~i3ow&@uVtl@&7EkXT6&@j2|I8}!dTFn9!c)7ZmdypkKUPK? z2#-@H)xWJmyxqu%)qPhTey4hiOWRI5i@i!(SSYgE#87D`z&<4I>cYc^C75x=gzF=I zLhkjZ0H)Z^E6pk1Nm*CZaqdr>Zb2tgfk&q58^zKY=q68=9>*|=T~|r8?FnRTmEN>rY5NwInHb&t;^`wwpmz$OEMMqM+Dhcm>FUX<9hBLPPdVkT9VIm_wKvP z`*If-@9DN}Q4fcfSr%EbH0Q5F`kHTul+}#XS!RwJ4|OYo#@CuufNg}~sO#yu<~mpp z;R`SIt$p11h}qQl_?h_5E~kEN2IQ$&rvtBq9Yr&dsQC)rFmM0bIX}2Ch;MDFRjY~P6Qsjrt#H;NEQphP4%GQ(FxN$|1uf$_;$+J68pCw&^~ zxWc%F4AUBw*D%1Bj*S=`wXYs0WO0p59{HdeJ?H>3yl_%xQ4w#HtRd~Cu(*kxkxM0z zC1DvEDl^*FU*>vz*=AG;ANAVU<mv8B3+V=KRUWFPz?Uo6#0z*fw#~$Dq%7B91rqgM5fkTWw3J8 z9=5OZS5zd5Q69s#x@~~Nw=|0zp=xYh{sTeoVgAn*esq`9=4oCGVNHyKa&lKbTQyBQ zoH1Q;=%r=={t#?pUU3k;&6PU8k`o$5d{noOVmrHprD*bmlt-VKGHE&A{Mg>#;x6z$ zjIl!>=*P6gQT1a}O#N))r*mVHPIXj-akztcDe1gud4`HT%iB`9nnr-oMq&c<1Y@IH(c&%cWB{K(G|@`F%PywIo|lyX5xs-1J57JbTi|ODC2H zu7~!lHLgz{Ros2HUyilhvJ+iwI~Y+xwcKjgnW-AAH(;Y5csyfhIu-bp*_NXw=V46? zAHxgr!7cfNI}Z==t?ikL#MC8q&O1#io`PvlS3BdhET^50J#6pM_A6{w{HR%JA-*@7 zM$)|jpRr4uf_S|+m_Zb8I$Yg;CB{E`xJJL>Y#S2X1HygorZ-zsAEtl4W38b2Yc(hO z$U(=YrQ%iD9>U9zkh`BbDD_I7^!a1uM8o!N8E*=u*LT`l z5P%^5R7Dmh`Mz63aHr@vxD^l9fBWXiTZ6ZutHtjFLE~rTVa^=IzSA_39$2&WH-*6-ULUCeyDnWg^T#gWaU^ zTj2SrUzpqK{|O8znyxa+SiKrq8_-!Lvk?aHEY}CkvF=fZTxVh4G^+$;U>Rju56)kf zb)CM97Ips|OQnykhf&9zSfVK2%l)-v@cZ-W$B)X#haM7wG53NN4ezmA4 z#(0#8rW`=6GA@e@-8UvHCg{`k;62-zV3PtZxf`PUL8~}#7xjizRsTvma%|Qh31q~j!uq=4t<@-v(b7l@m9${Kx4J3O_7`V zUeBdYNKkvo^hgQqc8aApk^cs}0HpB8wlU4{^yve&`(J7fR^$fKzvx5b`qaM~H`g0C zA630DUktZ8+0wfg?g~)%c~N8Mqy?%du zuiy3i^Y`EPkJr_8b*b&L=bq2UQ=)eU3K%^%N0#8=e$m2Z%4N6O*oL-9e+COkLuF(Ifeo#Tj*ROXCJ5*91tvxUdGzf zAZxT@Qwr2nR^VFHYi8xpVTo4ed<}#A{HU6AF3ryO>FRP-Q=c+g36x-{-be4d_9Ev! zhM-YM#nZ-|&u~_7 z2yKq@a!iQP-~v&=cU1Nz-B=OZI~aU%1Zdx68g?98D;$m`w(9Jw83RJU?n*IYU@b+AWy*79Q?-sCo)_kBph#hZQ zsVYl^JtpRz;wvzIXUQe%T^H{@b}BnDG~l{}XO)lE(XCD6w!Xcg@I2Xjk3jccdGT0C ze*U1MYtQ;C~J*a7^^F`rm((iwO?F!3TOPBpEck%3hnmOVL zl+-Q#~mGg?oUdVbtgRjs=qT|ee}Z0o79z~^wq zA6fn8dWkc`d;)vgaCy$WG1ULKcFNT=>+5jbWJHhC<+IG%6|JKcJ|%j>{Q)_hw+q|W z;JX%+e`qo;LNkMWg9m&!>08xru^1C%+ZOxg;GKhfXy`m(wq*Fx=0UxozP81eA+Z|I zGxqts3)erZP&J?z5S`dIEA0M^(=YC2B*`q^s#IQ_s5Jd9rz`_b306RT(Hq5L}i%alzw zOceK=f6;kBZ|pSZ>0HeRhm26_>;2VVqAD$-hIk`^U4CJPtMf!$Zwyyy)U!tz(*4WF zxHtz9d`*bcvl}of#fSf8EO=9#4VN+3qrMM7$Mqg6N#GF(GXX5e%_HrOegXz!ypDO8 z2|@&Myi{^em+pWR(Xx5DD*t<0RIg{dk~;MtP|uci&=IE>ovhuR1v^1#kL-^kNCz%K z%ZgSOJ~1uhRf^tY5eqp*a>s8WmZx%@`{6(4%crUb3iFcbhzGa9u9?ipaMoQBlJ{ZG z?Qq9AFgVT3n3&yJsC>MFoP8|+?|2g3xZk*Z0PG=V)~K{^^Wfa}C4Q2ovaCcUj0Ccg zAZB5#b)hAj@VrUZKeR>V!7#kTZa+JKSO*HubtXa+)JK>s@0@xA7q90IqEoe~%|{SZ zX;uu@OAfv0Th8E6E4Bj(z7%9I+Lj&gw#cmavuk!Mb8^zPyowpw8G$&^@ zJ!)zOZX9sIpI7~HF@9~IVEz$OVuLDp6T1KNA?Q|`8e%5yR`!d<;86J01gTOtwAypE z0-V}%tVPu4EhUma@`BfLqwdYk34Qx|^A`1as>B6kCu3Y8Z~sBRe?V8uL+VB+bT(lA zk(pA0n<@7zglBj}fUut2k44pG+G(xLxgQ)z&Nq(#uyy&w-E;iX z-jIxgv*AkXn(wuT&wsJs4clOm+FLW}t zvee6oOpb~NW~CDe;a|pY0!y~oId*`*XW3xJdL$@nQ}ZS|^E*}E4e?~%Nzx${=@Tp~ z)HC;q76yOLM4W$cw!={WMo+JqOBtifE*f>ysv9KR&q{pMX`baXBdVRYB&=`lOj~zd&Z#5(1D(c%W#?$6S?5w7XUwN zAsZ$D5~^oN?GE$51hOn0jTw-(d~Z;|Fg+xS6lHGMK@6}jT_DtEwpF1IkQu2D^cqn$?S|G zpDbSc$|%^;zqmj~*lP!C%6}lq5OBSaGp9MwHV zQGigxibAZuO%$<`B%4g$W0dMFc+mNws(Vd4pM7_E9~wJ~I17BqjdA6q&-=EayPb9Q zi&!NMIrBns=(%5|2 z?0wUpg@VNE1?{I&Gvm*%%KX6A?TFxsx9ARCzj0Ua-DIRI$KF2hz(J~;>zktWJ@#c= z2c|}jP|v}D%FxXIYjub>MF4M_zetmR`)O+Y_IK9^#Z*>Gi$%-zPd-K;;|{QtK${VaClT2BfY`)gy*i92ln}8ynPT8T^39#&$5enc)0uYxvB4a zDTgjTV?mj2D2(S*>ejJV()AC`Aj{#bitFb9#QpLh~ zxyma8{|vnMZF!z(KtBJw))?Kk4bd?I9>M?<~^>h3hKLvd61J7 zMT%*dEh>1Xnk20dv*=@ZVod_`iwDKm@{(jW9v@D-6<=7UY@(z)#nLNuvpx$Bmm=8S zOKe*TV5PiG>qC?$PaBW4rw#@caAH7oOABEmFQemdJ)$Z<^L-WYyjVJ#5ggHZRU;VG zB~AI)WWpf*zwf>o5r0jDzc(6|EqRO@D;EN=RJ^^Ir(ekq!(#u`0F}~eBzJciPjMb6 zml?2|PY?}V-6Hds*SVoL`CSz4Z}*9d(HZB;i;kE{qs_ZhSFBUQ-^&HHn3 zWOwTVHP3Z!Ss-1~YjZ!M*Ur4wWG#*#Y~7@gcIsDjWjhbHRoopWiHZEzvoYs_|C}|XIhkDuSKgi+F-E`$@K0;kbhKu4QsKM z204zyC5r?P3{bLI)@aI9m@IR{#H?rkoJx{7OhvX;D1L0rftj^b>dV`kRnvfv${!wLTh)~ zJ@S(#w5TxdNa5h227ciEPg5YE>mH42Ph~SBi>jmAv^vl^G`UV0Lxj1wDCIL&HcOgQ zBY?VLzoSV&o;>{B0$#Zb&h~sZ$Bx@sUhB4cWRztZ_AMA{Xc*x zjSNaK=Yr=W|3q+?-=_D|I81ADRGO{i$hBq6r}vCf-&`V)%Ush&jX0*Uw;K}DTnP*omQ~_m$=K3$;<$2ovF$51oabZ4Q4#LkL5R27&4ULQRwUT|=>p`bxbI{Zo z0V@vE8eMS9c}kEUlZoiviPwroUic4GS#;UQRR$k_9Mg*-V==4%6VW^wRzL6EsX_t@ zP^=t~yM;wBexd2_D|@AdXoJgLc;wM0%3OjqiM$^a?V?%OY}Ngi>K&X4r2mqX=gC!B zwkK;ROrF57@UO8#lW$cTnKiH%NU2@^IjD_go-lUq=ki*p@fCS35JA#wHx~=?&z_H= zNVzUg4j8?V{dhc9RBWoGpd#0)!cdvk8l8?^%#fDh;fK=(<8ae{Ia?NqCV`knmADPRb`awrrYG8u< zgM?@pwPbs8N=5A8qvRMe>>6K2k03O>J)8G6L7=6~l|{65KqA|6liaZ;IjHe~CA=KE zkb4F@RcSxTPU5LDfs@c2zBoS(3;re>>X?V$gsDx7i-L7yyy?7n_>Ine;?(nU&y`~E zy}Fr;B-|UkN(5eTv>!9gCRf4%_E}qa0kHTRX`q%TA*GIni|_dl5?)i7{xfv7EO-O>U9biLrte{k?unSVK9rKo zc2o=MjT>N->1LvI4YOV(0dccn90HT|9w&$!X`N;#2TE!!b=_C=EAn+rK#i_*1glr$ zuhyE{l>``YnQOjTN*2aD?}ka?89Mr<_Xo%_D7!2;1cB|I8|D5w+z^sZK5hHi^c!C3 z_cXNDLM^EbKkw~A$uuBF$sBaZw$vTxh>fIUh^h#u(p^qAfNkEg@UXj^k-ZqAc}G>0 z#15HMOQNUhoL?j#?Y;(4c189JV^bLtq>MUbx*sA|{3E`bKXD4CxTDlBEsOt}ueZ zo(K}VkAO7Xp5-sZNDrbxn$FN=hk2#I`JCm-x<;F(HrY!hP^HkfwdknqDnXxzo*TLg z@_-GTORG!6imE3-=m(qq3^C{!m_ts|1`7E=oX8T<3wnZ=F_Ur#3{XF_#HN9gl8T+A z9W3a=n-O2Uh!cYYmXTpns7j|~2NWfWW{GetD^`l|fIszo#*3?bjHxZZJXR|W1#JQN zH-Bo{%X~1b2q;%7F9D+zum5l$8q%S=g1OS&m4r7XHKSfj&#;63+_Y0A7HXM;lqbzD z)$0#V;M3$Gv`Ck^VjWh@x(6JWDrf&%jcDC7aR9cNJI$#IhZx`a@b5t)cnUs-ETL}dI>tZeust+>rl_!ek zSl}3}_;egbPV4Tn))Y@C788=*MRc2nXL_cx1K~@#wU{*ufYV=5V#&&aV`21imG?t^ zWlPPoen8c3PjCdF`5!(*!GnmGKj}?Db7?W+)SORY6!aHDx`~!(2b~~WhI*6AUoRRo zyepB^0^6tRIFVt{IhZ{qLBAo=R~@hLLVixDF#ay=7h#^8?bDkV2H+0Jbvb-=?&-0o zA1r(@TnqepNP&(ipUSPZ3CxEo3@bPG%a&Zwys&`RIk-TA8JD@cgRX(k(MUa# zS+XR{I8QDq`DH&-1<9A0!&YLT9a1c9H?+!Yxqh+0!D1(%l-g?v(;-AA5Arj;=?SN* zZk$MIN%^4JRd?+g3q%bSeyxZ!I>Qic5_pR;W(KSq@UmFLs~+|ssv4FppC_XxXJYW3 zp>WaWXof0TmW1=@>GuO}i9$ps>9n~tChoF3R3OLWRmzFAiu&7&67du4xoMK za+XE*+Q%&C?g^djg9@dw+83IN3B81dVbG4U7sj#^qo$=PWQyf%T3nuoD_-R=L{shw zA*PU~k&|{6X($T^{sEUyVg~1oi&Id7#R8VWAkAh629z{q{p=M%=oq1-#mC zC$bZ3FD^ek%Sr73Kr@+HMJ|V<-|&re@{$h|h=+V5+pE2~Zsiz&7wwFT!b3UiV2#w& zUc#A0baV_@J}RvWw0fj6a9Cjk8n5($G4mdE6V+aYl(NAx>8s~|RBeFF_c1;t_DX5p z{!JxUlsvacPV&7{?Ky2@h%@kWfiF>ScXtpN0*aN5;kSX68c2`+ioD%H$429_Fttel z`-zcKZ7&WrW^GJw74*YH?G?3tik@=WvU57`ee`>&^QFH-|sMfp48LjO`9{M zSQ_%Q4^0flk{+&~LQUnVYAq5yWVx!CW{i^C^!r6;s9ut`_n(oe^x*}32G*EUAfTY{ zO>jl&cx4Z}s4wJ55pOU+-DsL!oK_4jI|ZFoq8$7wPKWWPtrx1D5D+uOdl#((&z3kA ziDvzzVbZ6nI2!q*Mf%vP>W_9H_A*p}kCa>V;waEpNtOt~qG-npJ4rB(%p2gT3Zc4X zMH73vg}@ibqJkMUk7@ilkV$iLLOBk0ihisLpfOw%`x&rBDVyas_kkTzUa0vaMx=tm zUabzB#AmZCxDrcJ*7>1Fvj} zn2y{+)ZlceXl^VI(%7Ev6jLFZ`Udv5sCCk_3=D!g6 zabG-JO{0cbdOfTBr4HbmhbtkV#RBCn7e3hB2Kwp5EH(W>06(L^Op|x08JWuoQ`^y8 zc?~O^%GA@r3eZn33vGO~rZE+%=l>|J!UgXk*P3Oym0EB)Y5~JXwh(JbyGIE_bWYAS zTJUO3ue^3qdy*=praMC)&alx!6qNt*1@sdHMCx#@O-vzPv0I?KAtel_%o#}NfC7nA zWvU=!Akn($LZ}BC2b#{<$y9mo)HY>cYpD3KE=F43*g|d^rSGL%s zcAY_9X!?NxzO@^Gl+%)rgSB^Fo`=wIvwf8X{9SHRo^CEP7mMq#H2vcQ5=vBW`Df{E z)q|6ZU4EBaT&7i&O^p_Kladbiq!8^SE+A(p(TkSx{EL#8o`wUhue%xvB75I0;D4U9 zvI=%oQpkSzO>h+%f)Kk5TpxulOQxV-e?&Rds7~~5PviqjT+VbvOm|K4u}YKbF1R5O z-B5qKD=8?6LN*Xu>i%&|rson7vUndRQ+qE&u46|8N=KG6Ed-2o*?8yhQ<%@4mEkDm zFW#>EgAJEGS7(NMME+beR`0@Nl+h8q1eHT=a>}537$Q(So% zH;z$@S8xY!!K?1o>d_LoB=&nR^PLBSM=P8&I}>WM=wRj0{vC$_=Clmc$y$cm3CTWH(J8*BIB!wDVDz6;yBHtFNPrEfY#ef-V~{2(_mcnaC%O$DKCZ_9BLTM1`>6T z<^OUfI(|mk)`?ki{f6|AF5?VowD2-ii!b*NPC&wXS?NtS9ewfs>76~DpYA<9l0$(JScngmtLr0bUoD)XH-j)79RIub7Wxs03Ku+T$lzM!~nb3GAe|obp3f>A~VK9pIY*b{y#}{|9XI z0AEIG!;$-pvLY%Wc=+12dxtF%HfPt_uR=Q+adYri_ zYIJnB#Al1lZs!70QcA|T!zy=<+sOwP9^!@He@JaQh%$(>{&Qsger#rey>j@rX`P2| zk&j!-Biy+0(7$!FDc4Dk-5wh@$~15H(!Cs%Xu4{1P%-Mn)(tlPnIn#YO*8c?<}Km# z+~AM2rSAt(?Kte4K1qf8o2#o{(u()@E)F19Z2nV<+TVF% zYv1b0pFf**H~!F1yI>b~&uGiXj>g7|KJ5J`gvzI$?Y@WTcY1Tg`3v3ss#+*?-V2UW zc;~ASzcmsZ6F-TV_MC%q&&riZht^;sZwy15uixoudY7PiH69hFYL;-Mufp8G?{HCx zU|YM^f~S|bK$tBDnog7Go?Sx%zCAtKhe(m18L*A=tj|O{PsTV;i~PKg30ddXXe_${ z0ItD?1+-Qb&U+2FXekn;JCh`y%lrb8IWbs`vr@^H7YL+iL6`E%pOwhr1?J*hzMwNq zEla9UT2k+sXG@3d{7nmp=NE*HaRba!WQ<@#m%#=q@skW-_Ll0Izanh?9M=5_#p3-y zz=It~y5&MM89-OT$_*Zrs^mD!i6M8ufl+VzfAgSSEkfe{HYrZb*!g<^8kg%Q2VZ=& z9K_P;fG;*sVEq`X8`Ba@vH|}0gT|}wX6RAj|J6UK)-oNgNl5m(`}HVi-zK%T_$kGa zv5@etok))f$A7?Zu3!2SKe*$jJLylgd4VgQnTtCI?kea%3QjufbIamyZNueVRukid zqh-h5nw|?zPO(#U9T~gfIO@j~8H=04_fRLLBI4fpM#7VRD-01XiOuTo*p)t>o|;sB zm;!6Wfh)(FxKj>sfP;64&Yd@{WpGywBv4gFZ=7< z`##tdLo4kT?9G=i#J-IVE$}mqd&Z)A=I1G6!6W;k=gNw~6a*X?JR#>FGn6Nm_{>vi z8$fd_X%}vi7OcjlwDcmzzIc!up$gtF3m8#vTa2>1V!U#YW_d9Ls6%xp$_fz7tW2e* z1|`6+MiC=X)@2P!-Y;|gP>+eOP|~{Z<61Kn<~g$zWM`6?>jFAgH1r!X>IW#%NiSPL zQGI5m60rdCF-TC8P|I!zX7ua+rbqhFiR2_&@I(p3`65GN=HS!LAF%x8NCv6RGAu2mQW*|7r?utt#zcuDR8M=nb(aH<~%S-}SW z=h^b$>yfO$%)y`K2RIiI2RG*330CSE2hiA)Nq8>aN zNFjk2`f?jT(d3j{1SThHZ=KmsNA&;hGGI;BY_CYkyyMT@mzx;3sjm<>8m%7lWXJ8l zq~otgJ!5VC#&&FLb9w{M@9dkGM%{OR=dp6@&X%xcJEQQD<2~+&nkSQgpIv)YRQ&WU z@<}~o=pPW!5O`blZO>|Yii*4HoW!ws_pi&=9@6TU;_Rq0CXZ&-U2eX=ssP(Ovbt*X z-^mkyFKeY)>912S2=t5%-oVFeEBy-7;8rG&fk2`*A~k_icAgH?^m? zJyM68S1LE>3Qe111KxB%6Q@(hC5L{P|8^{ExY@QT{W}PrTz_%kPLl7gs81%i;6iVE zNiL>D@YD=hk;l!yz;z`untE!Q@zG?N?Z6}$X~6>>>bbRM*6vn`!VdgXskA6($I>vU z9tkkB9?B~mP@pfRAU~j#!az^qSgl@|;~OMGvL^8%M)fg74%K?+*2J;GG45fQpEO26 zzHO?gAn8=qv|gB^@=RISqyjBw)eWIH&yw_$k)yExy(WfOYK5a$a~MAb^WdT&J1`O* zs>i%#=PMbM!{r-wdKP{;f`R3qtaWiqced<| zf9N;knk~0qZ)|vuT)yhl@Fw65+0prf1MJuO{_DdUpSN~h(S6@-`q`29Lv;9Xy6RKr&|i2>kC#e-9Z7p_Fbpyo@?iq)L+}eT$Q)`aL%-FH19UW^XIn2p&FGc_kI4qy@3CKJ|wHI#i^> zNJ?S4n-fpc+5X2sZ4qy-fI=4*dfnrdH8f;mmIa-bjKR#*krPJ34`E}yfHm0Qbb$d! z_@}0Ef(|(%==0 zoU)dn0|^JN2;PuiyN?19Uzn(|uqu-|KV(G%5?S%UK+X?&chrVB>fe-w!xOJ>MFcmnG|I{CL${tR9j(>zwk;h{ijqFv?6Bao z@8N+XpX!fp3yg4f=puU@S>ViC+SPsj=arqMj15n04!K1|WLdhr{XV#sKmTWeY&mSL)7)c)o&WoC-q)+A_OQG_ z=S1ZcMptPsUk47MYyKz^tQj4+6A8m)DaiE?O0v4GcKf@rT8{@9eyUqm)MR|G)-vXW7@VItFv5Dxtlhwzm#$i;uL8bw6*p>@9i-*S zK7&$5qxsaIRL}IE6eCbcB6p(X;jP|51!;p~(0kbBM;a{Y1yOsM8l1!YSl9sRKE-XNn~w2fHffYm@B^ zONR|NDLD68S@YJ9h;MxGiynV5d>Q!5b$XEBv5WfP{&4Kk`i7wDIT`l>e!O`^0`zU8 z-(LS0SL{BVZ}@FKyhA_nqQ`Nq7vhcPInU(3{JFmJrk#0D{zUkrLq$#&*Oyx>=}qjR z2?yhLN8i)dD!1PBti4)ve0id_6&$MAsP8-df)?jrU530Qmxla+t%0jS^VdIAm7OW_ zG}{EL`(EK)U3AI3~8QG;kchlS&=1c&Sl|+T9v}Z1{YqWBvt%9ml#k6*q zRFMLj5Fi7Da?#~N6Wy;UfRhaI9H1mjm5_{5abHN7p#Y1WXOn=$lS#)uEqRY8OAdSm z`{*5P&Lfihe(|ObI|%ADJ$`11dMxjrJw!N~u!`^Du8px5PhYI&8lT``Z z$;x&%KvDuzYKAWchg*zRHsDY3fPZ3pYv4Qei%M2R`6Rw;BuW*o;XNa1Vl`UMNPhgL zEkbJn_f41wjHfwI3Z-8GJOvlVZ~TJC00p|U(0#y`8>gD&Q`*yk;YZsmRQ|5`b6*6R2%#n1=MUSWeQpWb`7m#dr&Ue^-Vx0kFh?fomf z!|-D?7Z3Lqdn)ID|IvR>7*^aZ^QJJ!+qLP(wN{>+Uo~o&Y;ZN`rkz>3Gg6-6 zUrzkb3RmV`7H$1!A!g*%%5qh^8r$+ZI_H%MPzhU?S%=RoUXwpU<&0>3M0e~9^6bIP zg>wTJsJEXkco0!c9mJ>~N>y_khiFT|RtSPlRq77NlCZuU@1Vk#9e(augaD0@*wPAf zYj-b}AraQTN9VPgepFwn0d5XHVF(}FG9ns2NnPr& z71f~FFD(B7`wZgOALAX4S4(Q8op+`I?>upiGp}Nc7B*FVIo2JQ7-?p?(J*29Zlvmf z!t0!!SB5ql*k|!#6%QRwTRL{BkhwiVrd`VLVg{~jdZpK_LVVm$uydm*?Mw_u2HHFs zDRX%6*dZM+wXW4}fHg)=)_1U7*Oa*#>iUvX2X-pM!S*X|pPXuL6u#ek@Je0cTYm51 zDa`)mG4eJ(V)|!p%?<7$QK8DLfpyG*q}Ut&{wD+TR6JL16>G3s&@TSfmp*rB?U^{M zkhZUIJw`T0Y~E(=rAIvreQ7R!z)+41et3N0ul2#z`>Bt<$<#I-Y7>mN*6H|e{PS~BVlyVU zVtw@k^!%HowAg8GDD)NLZ+hYIIc>;qR<;lK;K~%79#fV^dCr*U!?ywXeRX(Pv zsGly#i!-&U;QY%lTbwbUleTi{LRj{6DN8}Ic z^sD>CO-CQ>x)*<={vQA^GexJgT{QIlPa8rX-_soWFf{+}AE2yrA*-)?cth?Nw65y> zq2Uh!zj?!KbK6|D*=`&Gf6hQ;zG8YtlR2RdC-P5edXetNZ;QdbF+KO60WHydsWt?N zA(Fd2{j=BcXNsvgB$D0Cq_3uaa3BF$A!KD1)^0PJx|S_Jkt2eif@iVQ@-i>ODGBhB z_8R_I_%iKV||6pM2gsM_7ArBdFq>iY+%&%db3!kaw^z#=7_C z^Tbkn3o)!OlaUrim&4;~+V*GJbAeLLVBK#-1bAFlL$%Wipa15>(8(no6ySLE)?$8c4uSfII74=qAuN}WDGYra|GR!l! z$}~97yemFEFaL=!c?RlKN@a}x_?|q}w>g~eaJeG)`LE&d*m%p!f%)zx_{w>&Ehp&x zw?$>LXDw>&(pzgT-Spax?=qDzNSnO^z)!H^8ploo`bx_h%3f_1m?ev2&5C&9X-yNg zQvzKv*R^%E2BDu&RY?AT64e@w9CbFTDfzaiEU){*R7KpBAef!eTqPYcNZSQ&x_u)y z26#_QYj9I`iqFZUi=V%f57Z?H;qo>%J=vFQpmWf3mWDU z!&T3|r*48iw$Z^=gIBUm?q5RLx4C8C9L-qXn`dHwhiAd>ahe-y*|GcQp%dC$M+d*y zXO$b9SzKH(DFiF=Z3Uwq+>?9WpEsbhm1=kqNBUaUhF!!BD`O1NLDx=sLZ;8)ijC>o ziPE8sQ{suEo#?H^kv|>GnqT>SrZBLcs@qwAE=4bQ zBt|^uPb9=G`@IoO_zP~VhO8J@P{M?!&s-?we$jWQdF*P{7#eCE&D(Y~`Z@b|4#ZHU zO0Xnr`B2qQG^-SFsz&1$$#QGWw&B$I1sar6(=%13b7y7cy1FIi>nl0OZ*wtbtW2nSNMY#b<%7eACtor4$zZVTc9L{>H zc2>(Mupl%aY|De>+(~ow+}(OkUEiv9x)av+#k|xVyMt4CWq!}u*MH{KmACf-_aqN0 zU+^IMxzakd1Rs!JJm~BfL2ljZ+qGj;lmEcL_~jY}~YU44_|HUcH&@ONdpjf_o|@ZrD9eX#VI?8)q8$ zV5g@p?bz+Q(7mq;ULFgvuHM#==dK$3WpAU2?ZKOQ;}5sWQCV_0!x--AYr(#I_nmK0 zJfhAx85(Uly-lg|=E)q@e}G>@z`p%y4>R5M_Oq;MgXe$U`q7uH`1{TRQA|?ZW4K*A2jk>DfkAMoj{tpaU=x%;|~;z$42u-#x62 z4`q`FA1LcESfk)g+j!-QayLUe%WIq1!KIb+w6f@g*6W3LWw$hb?2E0~(jEOu4=awX z2}nm&iMjq!lul6o(X;kAOl*#RAj?Ig&JFP6j-U$6;G-R z#?>G)D{VGo*sewqkn6pB%k%dLrr98N`{%lexGJ#MW!gTj%IcB)b1*kYVuOa-Xlda- zA*E!crF`fV!p_{7z32OUM8sRuHO4H9p4Pc<)rj~GzmR_1WbE3jL>V)gy$grR+ht%K zPp3bR_T;1tHGOZIS*h)pWuoWLp#Ezre$u(WbLNKVe&q= z^VaNup8^il!kz&`pohHao7^4X-2o<3R$`NYBO4k9o`jO7*do6j~OO{ZrO1=#oAUr#GstXP&H(ss6 zfAg?h%71P5>qKLg_$JXpW24Vds(#PpV@*Hij~daHnd40wz>8~sZhAkl=0o=n1mE9Q zBEmapS^qsgH-?*)+}b$x=CzskVl37oio;$$sdCz5-|o9ZgEw+y#40*}Cv6Rcr`+SM zi?-E|Ee^t`Pdrdsk!IiLr}k3P{l%XT6>RybHTbTmN!p;Z;6yUvu5@qB>nb~~%TAY= zrQOYy2lP#b`Cr!yH;FJo8FkOCpW{OIJdPq%{lEK_Z(Yd zeq0p=A}8HNNZ9Q~+Dtw*J-KA{GX3!Q^CH#^61 zuGVL9tOWsOU&5|wcuQfw#~VBmL3yfOqj^eqU;Rm`nJ&zjU%+=zM|`haqWJU<0I6xk zp>Glr)6McW@M{Krk9QCo(7Esins%NxLm4a94#*5D;E^o3L26>^P$8HjD#d05CDEhG zs!A00(<01A3%^#v{Q=I(EC({mgL4n1H}hSc6fBvf8(yu;e7SlzuO=!XlpgtuSvSF( zGrKzaU?=Y0hJvD(qt~+KQW%v(#kow^)u;u^GZ+1$ixSK(f9gPxFimZ};glBtdlaFo z(b)x3M%v+LM;*;~89>QkeX|vZxMzvTlMe_XD%MnjC7Qm1t1bzd&C@K2qN;OCGu+)# zoYV}LH_SNQL2uOgbJ<-mQBwFhfJAh+Fy6JxK?c-`pbovxJEUrD=y{*RRaOWJPeTeA zANk6ig8i!ofxAniM(FAgog9X(ev(2_4myW~&I-hd|i6_C#SXt75Vp=qlE=8{wC$m-S_K!A>Nv*m_C zZ0QJb{p^*MidL;&o7*ry_cN^_5`t5QH{SoA^G`|Cf>$|_Qq+1<%n}S<#lz3BkPs=A z<%bFpQ%ST~5WU@`SF=lh@WirE5ghA@0|p=9K{91D1z8iuS79v+Fkg~R#9H%CCfQA0 z%01$jiNOSLT^B}k(lO^IA(Urolmz}MzBs^eo*OnZTbv_f?o6SawU8Gst_VId_YYK* za-BVSgGI<0u?=duic`pywaG+rEa?4aT!zxk=iCb!2LdSs6zArXiol7RmOrY;>FS4S z&IPlJav0h8^QQKDf_Nb*(|@kFEBB_0S>@w7k?nI0;+#aj1BI)y3rHT2(#UCe;+3pm%j2TXpCs;_ zuy{*&36nH zt-(HK>HTm8SW@cwur4CX&FiQl!Er^FGYRT24pBrbb%CUNuhFSR2BJ$R^xD;6_)!G8 zk|@gkrM(E>qhL;EMx@0i%?P(?O^BcD-ayLjshdsJa9vsTj{>^wrd<~ zLSm)8@RpFRVCnylN;!#ncb_Z`LqCni>6qtvnINkYHW=u9lJwxcgP(8xDM3KyU z&O6VD*9JL^_cgWiWIfL+eLo@R2-7>tYa;JEQ(?oURQIzM`B_4f_#Z;}lbEhrqqMKq zWOx=w;c#YJUPD6~8!vsV#LWq#-hnP2KUQ({hIBO33=Sc6xZSO_oslRE$Q<(v)U;FL za%w4Rx98wuG%eqg9b~kH9jJ+dziEIXHt7zygY!~F{7sCKf?uK^+FKSvhKft?@;2rv zci1aXP$N}Pd{2#(q!=|x1NPLo4BVgvOR?0V++bBG;cYa&?JE44&m38?TxbXgB=;2# z7j@#QjI{m}=P6JcL{cmzx@U(Bt7?Vs5{e1p$!xRKfHzzb{158W0c?hUqO;${5P|{O z^e%W&MzvZ4J)Vl!+pIV5w)xb5(qJ~%2YHdom8yHrU?CXG|K`DT?SW^SSvI^9?Gl2! zz%v(mvg85X!+WrvjTC-BHE!e3#U(hLFgT|uJwt%maauf^r-BMY`pFC6G(;#yFwjs+ zvXsJB>jsIKsm&M`N5SP`3iHszsr*b8RH|>4g}L9|=N<0*Fc9Bb^kvO3k&WUGv(i=; z+uQd+*cS4X(HQs8L*LY}F>kqVc)z^uj5ytajV6j@McO%$G+$PFinpOm#(o=Mxs6cc zQcIKt+pVDdY?QskZm!W#D$-)Rk6BS^*C=T4k>YUkloS9cd??lD^c$`M+C^r!yI?;ZK7d_|0`dB0T=(%O7nB1uB{|a76I{yA%c(YPAbYof zYaFkU;PrJ*n@&!0fvLH5-aX4&CLTb&>u%Jw=L{z_wHD5VbAbUJta2%CAQU95TpJsg zL~`NMIW+;Zx=KnE;0w>0+2^AwNKu4(*z4u-+*qJqck}XujvE-{Qpd&t?qQ)!yqXQ= z>~4M5)o(ElcLn8)-;iAEjBcRz&<)t&nHM<$>{wm5!o#<8bsa%YibXE`B$PmKSsIt( zXXntKW+=_LJ_IvKOMk>-|HL+Rx18W3J4_d!YE7f2nDf@VFTPK5GH*gprq}VLGC$#K z_5%v6c}NE-oWXZZ4#Cl0)!BX!mlLfT-{DqQo<)g4(`>X$~e{rQBwHGE|BW5W+%G5;3pw0vtdL zm$thd3Mi{%Wl`ncIM_gEK&oM^;z^8htx9>EL@oy%p0fUn6R_YK2Li+KAQV{S66j1W z2gvphQT4Sd$~2M2x;iN`o=XYkCdV-*DVOnAx=%fllBsHvDxzQ)9h!6X&Qm{U*+xnP zR8729!-6SD!O zb<*~&B~(3^Znm_Iz{T)`v+WrcU&3yAuFvWMmB+c&G64Jxp{5?O+dXnI*U^`92TD*FQg*GHbCpJh@+h5%rv{NQvv(;eij9BLlc2?Q76I*Vas0*f&NpTj+PM5zYh zrrzKm3OU;w*E6rl6vO=2XVSq1wrA_iRci#}oWS(huvvgYDJKCW4!WgpM!%dA8%lPv zN=hoXaxg~aEH#dGGkKYS>~-g9rq^P!dyo#)LysXF9-HrLgT6*-8^X9dTPBm+hhSDB zSz(dxj>v@9_6JnT0}fn31ukR(i?uahQGDjkr^*mldu<>$dR2dLJWT%R?0->xal_U$ zq}LIvs+yR^k#Bs~b5+i4U15J`>DLn+w`mmce)&N+i+3m#mi>XG${~U(X@?W$$_7u= zvn&(q!ZTu>F;W(La_iIAG4*o7zFew%9QzCK&Iz~qI?KNvQ03h$7T_a{asbbLL%2O~ zW#VeNi82i`gl2M}$`lFTC>>-m*+z~_w{f$~C5$%w7F*kE!tD&0!e;v)xk1vw z<(t*vhD<1`GaxGf`4_WU9yVO7f};Tw>Qa2uC7Oc_G;d}USj&7wj!a6-ko zU)5{M1f^fg)`2hI;g}mv&?^>kueMZ$NhLVkG@l=Z!$_&=fY757yJD`J<({(JGqzhX*Y@jTy`j+hZnT7I1 z4&B1HfXmjTv9u0Qkm4gsZ^bQKw&emt$X~DBCQ&(z098TL@-Q0bp<*OvX>N(ryWC}h zClanT^wnb(U)^%RgV@q>gw0AU$VL^^1*`wElrwl9j) z+iDu#tJ1D>kns!d3mhyR*)EZTzAa%nqD9ByG?9>;x_>y@f#m z_2pq_d1tlD-rl7}FH@!n^?*qouDBDpER|l#cTS2g&*1rY9LUU}Gw9zG zlLm)69#on9kQ|#LXgpi2#KG@DITNM*EXIWOr2Da3#$W31`)-FACsHnnO7Ga4mKW4q z|JvIqOeVcdWX#@V%*+)}JtxmG10)WTUnEc0NrNodG*^dq;6dys>TG$UW@x#C~joQlJ#iR9^`TRQ03Gi8)fQ-}5fw*TQuS~Lg{g-60)nXf zzSejIDWOr$PkXNB;$hLCXnK+mn^nj_%Jsi-hkWo%8Zy>Jm8ZysynZGt7Q+q5{ z-q;+PKzScBI+zu)cP(&}?LTo!AH;>(4m(#)cu`lJc1e^|_b+AreNO2OtSmu-J<0a9 zqqRp)NE}JkJj@0IvP(q85!gD+)2t-?ATF)6SApX=?ki5)Z`!@IS4ZOFo^+V2ughkN zGUw$w+K15|;F*)AZn_7q8}G4wkM6<Q_P8-~D z2Wt&i%+B1EIGKodO5PY!*sXKD>&zjx@=q7U* zyKq%na25#*IoGT3Yt2TqL)R*C^5B$>gSBN=c_@qXEUN2Er?b@ftSCk#Y$J##ktY$$ z#z8(%s&~ou0mApfILf_l?RAASoQ{}iS{}QHBjZzWX<4c{t}AR#I*rp>$W|aRPF2Cy z2oR>Tu=T*-GIGV75|K|6zPX52regDmq#ko%Zf74I={&QJC@xjtb zh|6!s_EhsT@wuY{hn(H)T|Ha@IH)fM^byn+4XRlilQFAV>*Gvnf`IvM0GK$;02%>7j!r*jn z3*CnT{)OcG>&8SY7>3TxA#1CapU6L}*)I?%olMGbgqC4AI7Do)Zh*E7A|r{RI>q>s z@3Yq;zm<1UfxvJZ(aX8roDd*@u^t}u7f`eoGKDi{c(`~;xQ14yvZlcoP#+ABr zXi%KnKOB30R7y{PrM*=?!8jSUi1zk-G*!$}uE-LT-t?|4kFiT5Z{waLxYAQDDel;% z%jOzh#GWU94fSrqttZ56<)#c|${10LIB(%%s+icut_xR*&+%{-g*QVetK4rz?L9&W zUEJsM^Up@AL(n$jTVsmHCFCCR3yJ-}&d8O`tdz`|bU{tWaiAgrqW-?Dfki!qp;-0sHeJ#=CNAy98|K_^nAO2pac(zwoqI0+$e4X6i_NEb;8_(dDn}3jiwWjRhYD zFw>JDxPD!O;{P@-+Oj4U>J6068unpWg+4(IOcUt|%;ZuyPEF8C1XoZC?$hHng1J3V z4iM!t=G~A7AXYY`kDTQ~0obD?Ohj&U5fyNl2Z;e8R9FuiM7*{SIQ7!J=KEv@1fW?0 zVD~_veH`2dAfNz~b3>JzuC8D;9|@uOk7Roy5im*vTwY!*1Kl{Wm$7(fc*;m41pS`f z=dYvZb<;*LN#>CTtAf(rNW;KkK&BZW_CYd%o-)z-%wI1`+2MGJPnh?B8E>bG#w;tO zCUWOCn{makNM1zQf$X5=>`R*Vx}3B28v*!yNf{N*SbS!(!IgI>aj>C`lrVex6Q zQ!O-N?`gb)hfHa+hug(Pma74Hw>JZ-;Z|3RB4~Ox-STRVW7i|daMeXmCHT#J2?W=` z3UQ&G3*N3|m3hb^`8OTk_-X7&pOqo!_B9BretA(;5_EwX)pQHLJ$w&u7E;_@>b|>B zOVlt%1`(NTXvkXhb0fj$-q*H>HJSRe&vLmLEPUk^M1k6A(<(cAN)KMYN#9-4IzUqq zx_dWcf17jIVP9YR;MiLG$C@wsL*gt00*YuGZ1>c?adx{ifAyJ~VGL32UQ`AAIo$^# zE?!_-<#Ns4cc8G@wvLvlMmMdp-SUm3c>&Q=P(gXU4z9A;6D(X@Ly6wVY>xtBRjyY; zv5lkt!udeTV2QMUBrtJEyi{^|tpdOIirmC7Es1=Dl%*}c08!^)I6$>McDy zmrQ40bs=cIiS1gD=ro2V)+n5Ye_<4&n3+!7fs`K6VLR^g;vYl$OEZk=K(j7bv5-W0 z*Y!-e0D(X{ICd>Y)&7X$Y`Ye}%#}y188nABO`du8_rSA z${8?^mA$JK{v{Zj#_B8D#V{uSLEeRGyc#=`@Sfjy_*&kf0@0}3_*KG6)en81~7p3Hz;0~`Fr9wY@g*gvDg;kdnW?EtB1TFTdn-!^OQQQfZb>DG?h8sqe zAYmzt`~c>s6z-~eipBtkOn|U&OUf3`AY^DAEK7(XuZ=~Pk7l=nQo94fW~tFPg% zqS!yezp*(FtJ52UIR*v>jcYvRb9L`pb^5`ob-$k8I`&P% zI(jhs5X#N1Fquz5^rZZmh~i?VQ^}u&1HUSOD`rBle9)((8778beqQFc9#=A{Dilt_ zBbLZJ4?@7BfLN$Q&j7Aqc$j_)&xiym-yKiU7bCh1LRtjPN&e6UnX#ro)( z!xv&!FBv-X{OEaqT9`r~NtBUwV`>Z6Y@@iLlX^T5Otk9G^z5J1y(d?U)Op^%)Pc0@ zRL^Umjy?(A7>?`J-7pL`H#c39x~{yxz$;V+Z5@9hBYoPT>+_qu9}z!i-pKsAbmfCT z3`_*vKyQw`UrJ}Kf*E)!Ab=MIz+eraVpv1={*RhcXz zn#&L11TN8XW5J9Lp3_Q#Im2zyp#nYr0D=nUNLfgvE}%I8=+U?UUK%Z-4CFn>0+bbL zK>+{>pemz5WxzOq2V_!jn}7Uv!M1_P3odZREdY?J_+WtBhff3O13q%JpFYlt;j94k z?*4C(W57G zG4Z;;>$?i)9PX_?gNt}`74y$fVrviX2RH}#gVUiTwOKV8_qDq*STO{HLdP7ux|Kw5 zBq+(vyx@W8&W+$>{|uS@gK;ATrMjdw_cPLNltt}yPFc8mM9Owt+Wvvf=$FAA=g)ES$RA`9!H^V(Tx?}P6yWgto=-2Ax>-9Fq+d3tSe z)#Y8YbML(_Fy;Q2A7xhA*>3hQY!*AJ#CgwPvcQb-^1|!cHG;gXBa#nKvuvmzqbJL6xT{8>|MId1p>Dg%>( z8!Ie-gbU1y{S|c9uSwxeP0f3ro}Tu~8j$GRSk9zxCIU)G5h+zNhu?o&YZ5D zhbCM{$&F9c>M}4sxjD5GS@gA23U2AP&MZvZ+OAt>k@{xBh%&75Ta5^wnSSwGsg&E4 ze+m?fkNHUZG=49#th4Z{Buq3i>YZFcBJypatAlN3(Th!l*adgqE`0JF>^|WDo&ks9 zkkC6Y0jN9}Vihg#2Uj?Mn6N+6dvZz&W6jL4$4KZdry>=-z47MlA#clrt^{IN zYDmI{JeKX%K2NT{P+JWC5JKuQA{MgBH3&A6)sNntS`Qxmn6O67Vqpsykr^Iai*3$h z(uG+DJyvWI0v zh8Z+p7*NZ?bhK&5m`c#BQ^DWPEAX#=Td=&y=hn`rJB%5Rfu~F8qmyNb8&NuC19l=N z?YK~u(-~ZfhWGHp6(lz1y-qIxc;C9JdEk}D(IYLLo+uCd0`Hn&{^9=m5@xIDyheXG z*X`+in99A#_^sKVA4>OMPq*D4T$Pj=$=C5la)1sQOjF`?Ze{TczM72Sy#%t>8$4yG zXX=CG@#}b)f|(K>R$D5o8A&5Ey@1;s6X<_4M9B zqcfy`j+|DR_D=4QrSH_5U|A#BE9YBf>P_A6jvJ}0^@c}yIZfatG<~(OlCDp0>G=Cv z&L-|l=q|Q!bDhEk9E#u`{3|D*DHs5ngaIxH9^UDsK~p%w1PaCjNjehnzcK}*3;=+D z1i(GkhX!)~oY}Jh5o&xS{(aRf9UsmgWRY4F#rb7-3Q|g zaXC>SXb{eg|1M_Z<2OU6)LS8FH^vn@97?n&i_^G!qXhu*AZP=Nla2bHe4NeyR|Eib z{^t<)p@o1*s(=*$Hb?{0k{8ZYXSTSEH#e(yfU2#geDr6c#0qWd6v3JH1>EzR^m!%l z0=Aj`Jy^kiQ2a@FgrpF&#vIhG{12DZHzWmsmAS*C#@LaUSfoxS*jpgp5Pzy8tpE-H4y60l#ZOFFw%r}wQ0eH;YoAQRQA zZlluu@7VEAS$C$G zK@Yrq8}y)O0Lf1A-MKosWTiC1$J5AGrA9sZuErI|`r%DL*Q0d(PcbYe6iwp@a@F%O z+ycQNih}ol64^<#mUSnrzt|-v-XwDxuZPWk0(w_B=*tJiVV;jXN*j||m{z2~pFR$w z8!p=}bq(9v+PY<|AO;jt%w(Xz1c4(5UF%evnwrY&XAK67={zavqtN3Z+M+VzJly0f z)RV66`N+(;B`wF=zJ6A}r?)_jl`R8oYPnA-*of3=c=vi87mSpMvhT z@O?VZ+-W=d{KZv+@s`9mPZu$$mdS zj9+JG6uZT>6!NtEoZg12|C&|zmHeT>M72?#c|t+T0qCDINkc6d6Zw#xFM-<~mmZX3 zQ_#TpU;!~#Jo8FdiPdChA;n~<@+ycw;s9eRX2$n=_ji3QnRg#8p^ULU z^1csN&cFOk*U?d?(c2<-O!xo2N_yY9Rqb8$^l)Em@A{#AZ(pkbT?8~!&P+og3_K0J z*Gb2-PD&Ra<93U+Mn8+Sb=-Y_TJt$JMfD$A0xL}iJV5hXctBz0}RU0RWwj@N_bw9REN@|RSb72A?-YIrme zj-xh`j-S;ieK(fF>mtN!zhjW-fD*je)yU>BbO`Fvp1+h0j_V&A3yl1AFI3v2b=+yc zh)nwMC!&YRIvJ|rePEbBobINi4;7n&Uh{9|vp5-a;kc&M(nF+Onu;B;+IHB}=df1~ zk3;Y40lMHl-5OD{Z<6O}*Nb}j<3ehwS?MN;lOLM(XOIhvLl&E(fp+RC?@RG3j9Yy+_zSiMLu^v$@R-O)+f09c#ZXigN>U#f-&rV z-hSRyx=2142y`>xC}8qDe)5s>4VZ64hMf*^vWJ_Km5;(+1tTmh7F{wGIixMT8rf~CavWIH~N3nEA5&Y zjZR-d`a=g0nJL_s{-_o3fOv{$=4L-SU*ph&1(-LhfRyC!d8^5N7=ukomY6`Es)2_L z@Uw@NSl}+GAv{t+3Cip9*x)A!EXxa&H}p(r+A1@?mEjX%qO&&d_7vZ2luk`r6FqVf z!dy~LK8nYyh+G^?>D{=^+|!pDI9|>o@AbZ{o;yzB*MbWUz2$lyQG26ar>{mvZ69#-kNb^k)jIYn>3P+zg-PA0|!0ikIp_njnN_<2_A zi1VpkMD`S%{pT?Fi*dWun0?J%9b)R-=3$i2Ttoh0R~s8GYhmPZab(fwRMmxF^{gN6 zjcmP6wcVp~3e>A`fENyoJ0k?rrEKM(D=2cU<4D(eAUy|;s3mS?RCeg;eB>num90Kd zDuJpf*?;;qXs zfl%}cM|<#n753(Ve9cSOlp*T?X&EYidPW8GQfv?39vGRtrksK3Um=1peejP5;J}9u zHna}>i9W`>YDkl!+HGt8FwGMU?Ku29-L9~LM}zqI;s|~b)wX#nJyAFyz_I?p+C(a; zl4u$?6&4MAlm^5Nf)fNJ2p<7+=V8zuUnn5G{t*u22Jj#q&{73Rk6RH*QhFCA_HMH8 zavho@;QnU;|37$vzpsQz5o?UypAg_yZpV;QEA`q>+(^u;oP>OLSf;>7Mt4b zQUe7@m70T6u1V3UL1~X8$tU>M;|W=RQ2ToGEx&igA~rsGa`jH~Fb|4VjA4)14Z5ru zW}B-9)Hw8&p_1RFht|??*<0pa_~l|jNM1mE7Tc4n(>3%)%$I?^M~V!uWX_vO;+vEo*%yA;%wCK>ADVA zvj(L`KEd06d{Dt*G+wqk3GJ8uM8w)&R0bX6xM=Ikep!{XJY5~eEF?n3_ zEbGn17wXcZ1b5V}AIJ5ohH&3X96BN+t)qMK1Jf=94-Lf1@tWYOopv6V^zRTT@T}xd zy-k0yCH7z(qqaC-+70K75r->bbPK?ga$2A~v`?3j*@SJ+ z;NkH|bkS)om_yQ%K;3qeSSR_v9|488PWJK{^5-#bHZlkS*zT+GyZ6pe#P2$fyS?I$|-8@S&L$+Hi*Ck@>< z=?lwLgb@(}aGvBXJN{MBd*V6mfI7Pxo*VH83lVx5Rw?qZJmcHMvVJV)fHRiRmZ5vO z!+gWNYE%iM#~tiIWkT<%jh!q8Y_?wd*Q9cS%Yk zq@nuothSp+&Yg7kZK9l6JEp)MKm0klbOqS+-jA&@zG##Xu>w?__+sB_ZB<;VP}Dfl z%AOYp`q5JKY+CMIvB%Vz1l8b(0Q;_He!EZ%;?l9~#pmKQo<11PSktttA^(wHd-w~x znRKAmtUrSXW|BU=os+p<~^(5UwdycUf*7SpwRIJw?^Om9(&*rHDp zqxR*Dq}dB_C0O#{RdqihQ0EjLpJ5$>F-mF08kCzQOz7u>Ayx+r`jGi^cx43sER6;T z{64og2X0sN%*XDVZQ7EZ^Q|mX-ZvqZzyH0J(@^7a>sK6LYh0K))BFi7X5e0`4=khYI zyV(nJ`#QT?beOI;QQ3Tq(@mL7&;F-nXO4ua!o!biD)22gR*U|b&aDXR`1R@TttYB^ zrYWQ+LLCFV{NQoOgQ70V0b{ZCIMlXpS^8XGn@XxXKEWBvIAeefgs|*SDw#W#z?K>E zx5&QOa-O3$2Qa6DRTVDl&TtXcrtGG?9AhPmc~jv+3jUv{(V~@|UOD;YGS)XI`5Q-F z_6I@khDK_VkuG?-{1W0o|Y7r}I6`aoJGh2-BIapFZ@;|m6L!?COK@(zlH4o$+a zgp5^b=xw`hn{HAo9Rd}Cd4?9xDPyQKQ7)9S|5{1A;-;h~%(5roE&4 zifH5;XnlaL5-gYxMqIVpkG1+PfVJt~goz1KL?n}{eqsqth<>g!a;L0#ujeF*;Ugbwr_6YuM5(@8FGflN z0|5A@gw7_SGTLi;dU`fCu2n|!U(M3e3HN4`Dg#Tai>E5KyY4&Qxah6WbzR=&L%7-3 zkoaMjYshd{lgwNT+#B+p+a<5Q_&*MWb0MdopPJ3)>kBPvJsrmQC!;NUr__UY_5Oo~eLy?Opn)QR&F z9XKo5^|P|M7vipenzA_RD#q(xpQOR(0PMzNsLZ6vP{5K0j0fZZ2FGXv0I(b=022WL zTy_mHG%0Nm9r(L&MqU6O0I=SJeQ;=B83cMlh=zfrHdymDdzVA0a$Gu1DzxHfCGU~9 zoD}ErSP>y^aHs$r4=AQcpeUmT|(p8Lnn$!tqc>p$Bi##mXM)zk7P7UUM#XCEdX zzwUKSOzm9td7dWT-)zIclylFdTbXy%2A)3o`q&bkX`N&rX*;Hr)$9gVI5Fm>KVmrr zuixOJr_7B0af67R=BEKl$(<7|Zua@JA_@xE1a_>}%IPO%7gwq0NAj=rC+(Tm`Nh9e zft)Glo92Rx+}9}tY=h6Mi((E$XZ%(&R~0Q2$oQUK>a%1b@g$d-dtFsQL7~C^QK#g~ zE&1h&U#A`|{NcI>3K*n zcFrFYRrH_FTvf@)g&s@d>9&f_pyox>{rLve1`sJnkg~95*rl`4HgN}PcMVd=#aj(Z zCnBEZKJMV9>rP9;(vHHl#89T(tYsZW+g&Iuz2}bT!@W!yn1OA|nB8>+-rnDE5#id& zx*-DcoY0erkib9(a_!5m>s}s(r$hct)0%O%xDNCRZ3U7(QDlLr7P_su zoSJ~g*vCEGQ2*^#SUW=@_|@dULbSgN>>Ct;cX5n5mWzJp9|RhBR8D`oOxC10A9~gF zA-(Q^L%-;EM`S=^&~V_XV=cP8NfW_(MaeRj=gzQBv{=7MF_OS}7Y%eElCv+f$6rmK z%)VVQU`+O(%eM%d+eB0&Z`XKZymn-=c^hk|@}v5<-aY6V-R`?lpC%OWLA4dNH{ZjD#8V4EF4p;if)4ynFcloqVD$ zDNkWNN{%uO0!<9#o`u3CgKWV5ApE@JGf@XH1dvV#rH-S;fSd5sdEy`%oG0m=PC5ad ztRswR5kCpW(E4fMK3+@+T;1&DO?idWH_Kf*6zztekrl-^x?4Qczk(v)=hVb(DuDmx z>(*MX+i0f}=hAw~5i;*K;bB?RHkDG2DOIg9VLC2_y z4}beFLQHzkX%vOe!4CAB)K~Q27U7p)-hboV#tADzF;VdnAn1%MZ`4Yq!mos>K98Cx zc6UBY3SRf@_*3KH>e^(Vgyu2%#waYlas~cy=^Da0u~?N|RM`%i&=|#Ns#v~>vOg|+ zk=Zh@gDRF%&Z1-GA3WAYqb@6R!D=o_vU2b}N*?v$T%SGm;c<$+3?3nurI08~X*0AP=ljvrcn{ijArbP&=2xd9+s+Ac6KIQ%>j%q0~Z zPspg2Psm(VARwJ3{b79sV1NsH>|#qb9a{~e>v!6p#{|d7%Lznm1TRW(w|5GS=N>r{ zFLYO{{vf1xGv8oWOwrHgd}b$d+`EF2o%Oco$lxAo0$tr2xwazktrOhB6N4R26%)Sj zRlH;9oYuFB%Ml)Lye-EG;Hl+Xo!14L#}?3!3N9aP5^hTncw^ZmQmZwT2}O#-kl%5O0eIu>9vH@}_tJQdph^$4Od(QU%1N$_pu-4) zJ@rKvL*==aIo?CGpH0^iq@s{GLW*(WpcU$5brdUvpZK)h-s`oMyKR%+%@v;EoJ+ip z;nu;wHVxq!k4!{e>94^t;{r+Rj2hG$qSsLKGJ;D|0?F;vI4S_EhW!vt5tg zUyB~N61FAz_0DYiBEqd zT==VKw)BM%qtw?UE7CImNVNZ|Up$ZU)Q%07x+t$6_+!B7pWAy49@fr|KhDmaeD|u> z=!ofL`}dvtz1)GxJn;h#?bB-Q&PE?PA_DQ0d{V0AYqHAda0RIYxtjPbXzlFjMhgsd z9OA|l8?L)}!cKYCPX(<~5_MV(s4u`cfB)%ADX}nuK6> zkmy`^f8Cr!>8YL^bFBfvYsw%{D473*DLM(Aq2Q#J{_!E)<`Ybr0G&lq6?mQPIne>U zrJas(b-)>`XcCj}`q_JU%>Xb?9{K`vxM>Th_D1khHE%O8clzjW2oeP3fIP}dSw!Kt zsgUT#0q&od?`y;u({q9l>xdcHH0&dnxCQ<6q$tQX3336r4cB0+LmD%oHp*%z_iusL z7w(WHxx_qT?Q=v7xfJJlEjDWp$k{UZ6);Uk%sgwVP)J>amrGxE?Aq6}&I=hajYg zF^Iu~P+@=Y3i#|YZJAl{bU>#?p>;s}3*<>u!n@lx>rPJ&d)^53^$V?*>#!ZQ{X9>) zH_=?9apx!b=O4@SI~{iWpYGaa5Cn1IFT;#GKNNOSRs>&CdlB;Hn@OOlRQTM~+uM=w zUq9jMtKqtT!uz==4lg#xhhLBi+?qm96^mP+X%C)ap$mr4yS53zFj?2_fjsZx74erJ z3GHulhK&!->SkmNjfla-RQ$Q~0>+cth&}I8?D$9We{7j}`GESaU#W`uh(y;6@Ga9G z(uJWu{NFG~>9SjbsUI#CoaBcs?U=~$J_;?T3q@Uka&yV^t>d=6CHvuiiE)rATk-SS z_z!t)xjKTF4o2Q`U^q8q;dJV6o{_{Ku!o={Qf(950u*^khk%jSB?A+suDqALJl$pF z#v-*wN1GgS_7+UW_c(-_zo|~Mvl%WYN~d- zKe{*ba=ov}*@Lfrh;oDgju=qil0Q7lcU(sSrBw+)mfBSKP_t>N+tk>W@gntRvd}@x zh9BF893IUlh)da)aLg~royTp=UO_78ZCA1{1lyoZJ)MWdZUGHWT`iM6-l;a=8%lUP z1{BkhJ9*bkkryN90rG5(au93oCSmNvAKWZ_}prQv4bW{*7$9zJYSX@_qZ;%Em%jpOKr3B*1b#j#iUypMdxwUe{0N%MaSO=5GZuy8;LeoTNf&j1}{y_ zL+@X7-0ze;CYpITCF$Osvmc#<%ei<+{)Ri6Y$LD# z8X=90*lAxcE)3A*@f1==s- zS#XceSs5qi{cl2RaK<~!DGKYf!VJNNAStWKdxacGJG zuVHF!gv8FQT;Yh9MTRCkH`vY1|Xw#V%f()m6T*@5?vW#za3;?955 z6;4lkrQ>DHy7C9_TIy-R;UFq9TbQ&DPrg*uSf6ZX>1~eZ*ZNys>vVESEuYTsdZbr& z%VG-YvR(}N{S;}vKd5+9=cW=w0kExAl1}>Md9*_>%TJx{e)lP+4RLPU4Rpf&xT!oo ztGFqz=G5;tAH#j0M~9bMsIDbN!>`9heZ3Bz-h#v=CI@JVO-DXX+(+|2-(ndVrjDg3&{RMcF-g%(FErxN#sw zYp8+Bknbm|@3>}$j;O0B6CL=*bTnB&#z?V8@XY|0@-aEyT$>m@z;4eY>7rU2?|!N!-65M5)mP9okW( zR(uY;@_AbS_Hq7O*_Mh|e}+14@cUK=%8cP>^cB3B7QKU*mGuC{mY@s;2i?^bQMI!< z>QJn;PMKNwOFT^Fp_0!sXZAySKSY!-c)$|_${Ho}iUM)A34Jy)+ZUQxahlN{ak??k*h*U+B=W{b0BGCB$uSIjc;P_VD}a%elnp z^h#Q;vmiPPdRFsPg^R2v^yNjAQH#^8CQ~hydX#B7s{ls;I?nZvUA+3eSw&MIG4vHd zxEK@!;1yWq=NSUqTs(`h@rnG3Gh7D>PLAAMyL#f^`wJCfN2^E{Myex(?`N&xBK#7u zF7YoNNj8?MHr>;h*_Ru2knV+t19364$RhZ(_kHB!F5~udpS)ZM*?jdC4Ed-GeB+^j z@t2uH@Q{qcPei$fKa`uu9quFcBFVSklddR(KacN@^ZVgFiyVpe!y#sr!(f{xAK zaw5?k{GsWY=D91-p}QYXh((L~9=>s>-tfwvBjy?S;d+iuAsnNBKxZhL=$Ml*Bn}UA zd<45V-ts*o-ll9g5i@J6Ag4h6kzSak=-21FbeAq;{9r^kC6hJuRp`QPP(ub8O4miF zLxtYsG|H`g0;MKHvLc>b!jniNIR)=aOwPrP#4Hz{-ftXMF5~S=B5{4=Z;&2*=#V{P zU@%d(cT>scvw~?O3-C#2^G9W7n+nC1jQvMyY(VbYlI^OUpqIH1l%(feiJ+krg z!a#$v$G6Y*)$`#`e1|+LOrF$_zJ9xCHs_S2292vQ>TyG}Wsz>KcgY9DlN~Z|l4qeN zlQMZV_1TPvzivA0PIPVYC4YUX_00OT%R$5&IhaFt?xe8?-t*AiwFs6jZYF8&H#1x37c+k>Z3sJqD3C=BKd(?4n}l;R8s@NiKeC zk%seZ(SgZ3w93Bql+1X>EC3DfBlajbV2I!BU|O*0429Z}x>XZUT4)GhwS zBeAt|zny%^-Sb2CTCJ86G*HdOM`m#$G~4|AOx{oE*XK&Gzg`OOKd!&i-qv_g1VbfA zMZT&c4J&~HpAD=;LXe8OY5CmPR4uZjl^glmZA8Cy$gXhWZRFZitK!@B=Ps~ zGO*Mr&O!NKUc+#-(*Y_?K-(V}y$Z>^dSKJ{&0w)3V)lrbvj+&hmZxiLeZ^YcvzIEJ ze_(EZ{jONFFyhtYh0iZ<4REChOR9W!y&fQ9@%Y(j{*L%imc{r?;E^Sz?9*+M9vp8T z6jaoYLy2KCT--u}nfWrR_a(fhergHFn)V}eB27M>Ii8(RF~TjT%%}2V!{Jh0Ozm)H zIpwI#*O#vWdN-^lH&RrA_c-Z3R4zy5Kqjx?y;r9rtk>MP=klSxc+dRc3wfCy5OG*e zu%JqG-${|Z@}WFsaWCb=#GhHp3zc%7l9!4eJNIeEzk4XDxTi;eUbT@kM1THwZa$k% zTSdp9#02a;l&ux*ov**>YP1NENADUGnjWi?J}eToplB%MjRAN#MkEl8=exGvq_FQF z>d}XCYh&Jpp^yCxfz91f5%ov^{+K4py&UKp<}w#M(OOC~`>$0P4YcacEv*JSedaFF zE|vhAYd+W>^;?%RH#ajl5>647^W@7m_o$G$b~puYrK@|Pd^NvKaZ2F*2tegnrtyF^ zDF5P&h@woM+F7le+UtVyD&F_yU^8&ml3MmcMgd|2Rn`Z9${@`rWdN$MEiq4~q#qOx zfsf&e?I?!*FEbrW;6OwqUIvbaagdXP094>7UVs_^=;v_m;7=>l0mtYB>p%sZ#Nd1$ zfk7a_ZH~L8%k)A8s~9iS$YXAg;B#JK`xwALi1`pLnzo?ftf(A7-?yb53nUklc!?c_ z{$(GHq->)MKQ(SVu-rg?+G|esK2dw|DEC8LLBU8)ZuwP#s@{|Q|A({pj%q6C-bNF8 zuc3!tLvPZg*AQw#M?|U+M7mVzJ@k$=DIs(b1O)^E=_tJj(t8s`iYOp_dEei6zq{7` z>)v}#PS(mfCzJim>@%}xXZC&;sxBKGF7f8@UNrj#Mmu#IiRte`O8|Nl#6mYQp8BXD-N8%PTn`{bS5_$@SlA9MQm!wALe(qQz zsp#Ob(5GE|VcI0~_0DiKxKpNppv5@~r`MK;h*_|R;QizJFOzIat`w9qnlPNFHkRdA zmObrPMtN43_|lJTpyOM2pJtAp;f1GN<3#M>T{>l47PrU;_h<4gomVRgm^@9V+9wy) zHI=%Mjv8>ARmb{zepgkT+=ovJI=4xb6y7k4B)!}dK@fo74?xD;S*e@GZrC|v@ZYWj zME@DzB9BCd#R=?BpZ0Vayvaid4&bBY5*2_6@j{<#0LI3RpF)let#aoLk*G9@nnA_X z50;ba8B7F^}}x($h!r>t-euNdGiVx{7I}4o!s-oU+(R2VT_7bRH{H9NJxvFqe;PnT=-A9 z>gSc`QO^>kTht8kdpai7o*+T*_Z~_S5Gf0j2ty)dQbj&Xa!casCo$1pzoRrvu}4Ij ztu=d;2!wOlas}=a^MJ-i1BhKCBDYfQqA@J`-Lx{>T zvPL+k<;{aeE%={4nxY%+=g3IlqLJd1^wyuv^mzHMO)M}jeJqlumI?CoFJFYqVAQj5 zsR2T#+K8n>W8ao8Ga?QXI)um2Pi`Dhr< zh4lmw*nUG^9VjrfRNnL4~$r{hj&U&>s@Vh`p2 z_iqL#;}tf}Ye`YKNx(Qx-ziRY;s;qTzIftx|C!U7q-2Wm$NF&N!dl(vPt*!?J>~G( z#~B_re;zfInyOPflt=Dni}*Is;8CiEt$1{4RN5uOwqJ-x?dO*g*EVpf)>tl}lARL9 zt=gL%lI9+f5#6To&8Skns}BdUAmq;n{fiES`vIX_o>ht>EEz!nUHEK za6Rv^X@8!1|JbiriBVkT5rw8C19giC0pFDOg$5pPH`iX!lyTJ!4zC7B@RK?{)%1Vy zI>to3pg+Q;7KMQB=(p2nkm)Y6J`q;4dLL`)xvo%YL{f^tKD^VYgzf>QLz7&D6+DYT3M3k(^C8}X=zcSdW&an zmua+`8K(EsU`LXU-}3b|(#A6MH^sgHNrv-F!QTrz(0AaC%_hv>(#G_M$&rT6@3gph z?NAMZ^{{}*YN5*7QH!wl4dXYIma;|UCaMrQvk~DJiWY|WY`lw>yMzkvom|gKy6t5i z_T)(wDzWZW_>7LKn;vT%uBdiG@rBpbH^b0JxJQzzR2<1`1L%Orc-Xj^n4=+F}#<8WTj^b3RNH0)WE*p}2)FL+aR?FR(gMsLd=)TM=+RhGTCr7FCI}9JF z`fY9sX|}%;MkPS-Haky^E3iVpvPA?Jq#xxKtLi9hs+lSYdj3w{ph$p6HHt_)g9{u9 zNdK<>O`1aZ`Ii%}g4JT;O6}_aD3!=m%(RfkUpkTgAigQuWySux2jvsPfn7Sl zO2^S<4l334Xp8Rjw7r8Ssm%w^63d#n*Fl34XXMmoL;X=qq7Z__Y4&eQ2ip^sE0=^l z(m=+(I)8&gIFgoGT|IJkT!#7ib6m?mR7N_COL)5Woq@ky>lqEz_$2Vsd#=9nk@Y@B z=mOlIp1{l7ocs_Dy~GoL-i!azs<2)S_Hh!9NoXL{tDeNJ2!+SSC#W&y!czT`>6V}GgZr%e3?u&7GpC z#4S7$di<3b0E)+Z{gvp;wUK*d&DFoFTY;(a=gQ=^XSEnDP*un}0tan95RP|-!7J4i zALgI}YS%LkhLC3P^^nj-LKpkfxc-!@)Cj_jafMjIs~?QkyDks@H+aF}{|aFMaQrt4 z3;^JM&FmAUmX$6{9fM;C(CxvYseq3#S#vV01#$S*GGP<25KWc8Z>3P2B6{y{{dzRk zSX-TACcI};$7BC4dpChQbBY|=8gY_V?PDT9@AQ|YQ_^E!AVN1CM8_Tb!!?o*7oGCz z*+FVl1Q%eJ|0S4}-z5Q=e56|V`m+2(-zk1XM8lR=!qI!bCXrzxvQS72R2*sv)lLJkS)ejRKt<4y&3VY_P9w7^sE`-VDEaAW>n4h$+nh278+lIB0IMlEJT5_HW3<$=Q{Bv2 zZc)f$xC|a1ue?wlt(&!Rc#34oWork7O-KY{`f;Oz9+XL^acoo%sc$lAo&@UD{{!*; z{DXU^bN0OA$c*H%m+rCMxv*2Ii7mP00&U`T##APXba$klAsr*JBw-0oF&4o0K6v{J z)@v-i$hbtJAq9g)UX83>X| zPN^@=&M2qVBW%R)y47?gI#`NXq)GCx?aJ@ppVjYZM6^blwW$5nI?dIx$?%^uYVftr zkeIsi@V#I)mVk0P{_2S`GY_DAbg3d3#Lo-7FU2i;@tM$|J1hc!+p*svleb#0y<%Ru zQim}y8|(f@N_3FD@8=Rj$%$4PUyrd}xU3l(w_eLdl?)WLkJwQFs4GSh44XeE|FZGQJy#l% zpcu)j2Jy#OKZGt$(s-CyP4%sRjPF-l4A$5dL*OT8K@kJ@zwpcm88WN!1m?$ay6(Q? zOB5^Okwbrw54J_6-rrwG`Tj?*HToakSfU*;NOP+QHvbI3zIHvjgzZx_B6{*^a=bkc zW9)&0`IOzu!9B>RN0Q7zuJfNK!NUKZkRVsGOaFA!d-e`yKBzZ7lV^)^u)?uBnhD;b zwC&JNmmOg(RC_8-d;EJFxce=K^hg)4za>v5)=RoGGWK1@&*bXtx%-AQ(q|FonZwF^ zH)y#CP3JyF5TO9Wad+>e+nEv9W24?B=1(}Kkk>S0)wv# zTRR7&4s3tGmT@ow_|H{T4OsbSek`mCGw4{3KabWKqO<7q967dp&6U3L`)gG@t5kxN zv6~t{-*8{UMkNkyzl2O}7Cg2kouqe^{h5~S(s`%pU_id$#}rR5JRO7^ufaAxGro59 z@T3v156leFbh?R+U;aQFD5xl#mDg5WUWImL7(C==t8}MRO}rScMGq~Fy(QbwMDjn4R;NO%g;!*s(cf)5_vxk-*A{)zx&9U;ne(Zn?br9UI27F&;>V|&Gp?Rrk@;ND+`OW}%*bn|D^@``Ds_fTrvypPp84;_T`h!2tvdH8I z@V05)-Br7A?`Z#O{8mzlEzmU85v-8yc%6eWYl7C4)`;)M0p*w33FcW1)pw0yj3VZn zFaHG9AUWSnI^a5Mq9&!+lz5k4qXF)3-N)ho6pG=MM<1S+?FER2mt7NvE<00L9 z%sZ^|q?~?N!od2TF0@dR)H>rzc0e;vMH%>}A-{qm^5*ozP@~0M)|1ukhc)OakfQ9( z@%fJJl^(A?{u|(N6qHWm!;K?4`Aa|kzWn^U$hY(2ZFQF!cOn?@ue#^raoucglC_fS zr&y!twc=b+hWIyf_3Ta%qsV928OCY!Z*LSjXalX@0q9CUcQ~1|-aobfkbj^3oLeS1 zMfr@24)Z3KUWe>k2mY7O*jQNOb*~ zoKElYp76I@x0(2vh~l1BO?LUcv;X}A1gaH4sdq+ zOQqMt7TGUEoH?9+jz!AUV79GD>r@abGk36*N1Qo4JHI{N^>7s(f3d3LwW+g8V0DlR zauyC>pn1U+3 zyVxlMFKt`R!02LMq`oI9u?ZM+>e@WG5qyu_5E>n%I#;U z@tj7Mf0!8jLW_r^S=BW0gKmUL&(--Dbw29lj3plN$H}13|I5%Q>pJk0FsQS}{ zu4z}BXU5(%>Q6{HS*gxNr3o+Ib~V1dRF_Q3yBBuwG-=rG0C=<=iNyDuI zG2tyCt#?`9+^H!JP%{)3RVFPxI)v<-;c_P>5dHu@C%-yAG>LN8!<<32jb^PkZbLoE-xqM7d z`|^!bc0O?kg@@}(OKuT@6rS>2BcnthbNF}Fqs*XwjUdQ_Yyr*$!snT8*0mF#YomJh z)d5LPS|QxN0v)@eToegY`xmCU+ex^i%J@|;>F+T*CHDXUCflcBwpIUx5cqghAvlj} zF*y$)FZ=U0%6h)$Rd(?rF7VW-J}u4sQg@qm!`I7I61H)pCnMcL8w|iOm!t&43m>Wa zzVuGPFWjC7n)R5Ox8G7i>F;mU_LcvX4G@xhN>xbg>d?YTmf{R5y?=b=luD`L=RvHusHm zv)0tGqCO7MsBJ@3zgCcVf>wyGb2x2i>(}Hu5Vsw_45_AHXar|Q-_1<==rI|uqAClq$eBj^O*S=6HS;8@uClb3#3<-n8@NqTlmtEswfL)MvlJ4xb-}T?FSb&|PrU*{EUSd~E4_ z1ZZKCNl((>iI(2PNT{9-PA9ZDysZErn!%u06Wxl(g})OTKo*@uam_2gWLj@(@T}YS z1Gy4+w1%sZrVOH;W$#}QRrsjS;Q7!{7Bv($Osy2qBxwIYlc4^N=5b znh!BYZQom#wxb9j(;u&lPS6oRF3YHhozLyllM$N6Q*;GpLROc;mx=Kd_&~!bd=xQW zlqJW7k1{H;LT{$=kJ4sP!;~XOnGxWJc0EO5Z~u=NmqI+s7nO!4YnuQ&s-8KErwYGB z%*-1R(HG1?{g0vTrrsk*1lIE*Y^kkwp3kzzLIIC^-@FOAei2h9#)cp&7WT0s_r?de zMq3Ve^fJAgQdL}MGnTRZ&t5fog7V=Vbv9z>h1io5;p6C~xBZ0=j~DX`ve^SK##2>H zQ=BkzDeLo5x=G(cMnLJgLZx}*`6d~$c<7L(KQj`KTC%h9n{msig^fP%^Q~M0fI^5IClct#p&!G)1GuCrC{N z@u&EkioNCg^y4Rf>CsfC4Yrr2)y~k{C{-rkFF@N04h=cc_k|QdygLHNH223U4oJ;6 zdo(!E51ak-dn*O-e~-i*LPn4lw~Itq8ImNWU+B&dpURe|^LVnMujW&(2C~Y6*JjS% zG1my*ubWU;yjH6auxdI`T^?y;n0DcE4|DgpHlF^VbS1d(EB%8B-mR5ZiCO>#=cI+J z@^%sa*ko3EuZDg`p@Y|ypoNR~*)}io>mt$lWy3;DE6ydac}-D*X3xA3y!dN&5KgVN znOOY|PE4;_1Vo&rC+CEtA~UN%Ni6*SPu065&@a7&!aBORL~Xjj*LL(!wqarpS7-mv zSG@t$gLU7s2|7@t1)+f2+M?e}H1?_Cqcq{9^#kk24>)Z0#tu4+HB<$ks=m^jGBe95 z@egCfCl=bH5u@u+C#<3H#u+Ht{o4{=?$Ww!5*;mI=JUNDj64dLYTz>@#Lu4ljrd5o zsqA9P|N8iQC*$6BU@SJ#yc6vTYBJ#3y?{D|Q=Yyd^mignbmD`BQd8@pI9UsbL1ADt z_39lX#QAqhKku`>k%D*6rJNtkGB^MG#fM}mcx;a-%2{5I3TPbo_>S4Qp+0$zib`{v z`=ne-3e?m9-xfWqwcn&tEN@tYh@yJ~p|VD9i2Xuz;<{^;?ayB_HCZn|2m(DY}2D86J zzN{@}pj*4p>)l3*bLPv(@~&7d9IW`5>EmqYP!RxUbRP0c2jjfaumP9u@W`u;(hYdq zSk!TUqa}Ev^;29>?K2Ap&qq1b@NhB5Zk#Rrd-WEgwzK-siD%f=spyL0eGOc31iG(w}A-TCBMZDR3C_fbNN*H40nds^&x$Y%!$Y8~a}1zcB#q z{u3cL4%ik5ckAC|tLdmUhn|fHjW#SsgsPg>t_<2l3BGq@=UqW%m3VZi&DK(wmTQm5 zxt?T`be~YYfxLif?H?%+e}YM_DRNpAJB84`sk^OR@}~G)G(w`=@!@gCXq|9) z5AvwlC6A(19kKDA`3e8o6zk1-6ZiGR?+vrXhqoCF3|9jzh`NK8$E{TrmM<(tR7~2c zb3U}u5Lz;9N1E##yOeha3W({w?(Ly_joK7qzGN<6+K;HME%zn`CgCY!e0?5K0UgFz zj>@1kt~3@YUx|Y^w-JwDkLY3PiQi262RkT?ZPLAF@INvdkg(|x8T{tpbLK(KV%A>~ z)NApeci|zS-47wuW?LgbYK>EvW7OXctPqiT{Ol*E8pG5yph%-A;ynE1%Y;22hQES- zQj8>)sliQ8JDlaqupwShJohWu$Kn$X-PDB2=54&}JLw4RD;6swYNe{6^f?%dwcy`P)U?Lm zAC=aJd|J-Hrb;jUl6#~PEOebEiS+v9uWL`_G8aqdl%%j(6}{(liQ4!}yS903dyt>c z`fXh2CXWke%a~)>%*u@`&s!u>SgZ!o)wRj_8pq-NbdZ|kwE}v#$%VJyYFEUS*XQv~ z?)Dop_1SCum!B2Eoo2%Rm(B%8*B$-K#NcvT2}$mfBPF~?K8^yWr_eT7_E9oDG>8!&7<$@<_<4| zr1hHn1HlAwD$8-HEr}-&81+s(=M?3}zMRb>R2t@hh`k>e7UyEeMW!LGX(^o`T zte-_zM(f#|ld*#&N#UyZpc}Z4&KCeSv_R2?b1|PD>xk6fYUyj9C-r*N*Y_EpFp%i5 z@>(4=XQ{U#R#;7Dl}7ZMsOTr-rPzHVFlzXRM`GnXHiP`gRL;{0$4bKau<9kIjoOC9 zxhJp7TSgOhmNyN3Tx||{JU%&AKd@vUoB^*FuOT3n=cOWbW;0!tOOC`rjjMY49>&vG%#lttJ0SNc`6 zJmEG;4`A(2Jr{EW0v^slg^~_$1I&HaG-0)M%bfaMy?ar<)|;Nyg29>UO6G6AYPSF# z{!xCu8P2(XY6j_(8bp)eTkuG1fnN@tZ^kf)FXLFHiM7t{z}`QraTUaQV{Elr9{Kgu zS8-F^SNKSjbkc_5EhYGCLVB+psBB6`&#dg(Xa3Lp1I8q!*!ssvS5(00ROy(F$vwm8 zK$S9=`cIuSp?;O`vT*~g_Fe5{yvU2!sd zt}|d!OJI7i-EH(lI9vQ<6G~pc^zm^h_;%-%e2+ZUc4MH;ou4+b=hKz2MkAnsCJ4;#*@81{A9x25e=w%m($n0O^IPTC3dqDoJXkXK~`oD#lYvJ=C( z#oyZND%(IE&lqGc?$#0xaP@op4bv#_Yd507OWgS*bBD!8&N`A2H}LT(VT6*nJ8=C!k~e1iPr*s#A{Q!+ z<(W^(k6M_scu_w8a7#L? zhb;mqdi>3tlSEZ?sP8M@TfW9;cRzh2l-yb5p1=Pe$?l(rlF|3v8IX43hM#y5MkxNz zPve{uRT|#!MR)>Mf$Nn22glZEjJGxCRNE|3Da+@HQybE^HhVy9^@N5cSk|TQVnB)o z41oj}JUkp{r~#LZ3TG^>9A;A0yP1T|KemJ+7@L1z{*3>-wCmJ`9NK$JRV6(g2E@wQd4@f6DZa2Z z__|hDaT}{KGcpi^DkOmyM|Siu2l+-oR4&Prs9e8)%+juN$ARxhI6n5s*49?tS7@g&`FXWS zRd7t0M#UGbKVE0)+u`M~;9^W-Qgl^TR(BkXNEQfMpvR(?mR8&e#!9w8=v}or5TEDz z2&YY`JV9vv4N72eRQk^aEj^n*ehIJ(1fRgBR(9>-GtEQBp36i;)J4d~M$~?K6DBnn zrY$v9xooV5i%0U`KtljFj`^qMYu~RA0D%7-Ane&dcd_TrPDpz(MGZhl`JohfRhB48>jt;8Ek#a7w5V(8BErxx7J=kr`z~-0Drebcm@_9w`T(C}I+N z21X`kUOs*Sh@kWX8Cf}b1r1FtZ5^mC%*52p+``hz+R@4Rsf#Pp&DZaRe?VYRaCA&; zTzoIF!NbGFBm568AWi`Gz@^5+ z=ae9zQG*lOd((1BMiPP4Gs>EJiMgc^r*sZJQzY~}(i^tIUoamyMC%xx!m{O6-R$c|6EB+PEMN4ABbMscRiY%idK!z_?}H$lI=8ovIQbD zgm_WH#EH<~Lzvac(THg6A1^?qyOD9B)j$Kr3J{SD3I^mj*XzjXQTv9nDY@umR&N1x zL(oD8x_TWE%#@9wb#JxaBLl$@W86EF2@P%7<-wt#;+s&@4BBKlIvr87Ha!dl+ozExpXf5Blzm#tJ|b>VP76sF(q)nB zmsL4rO5~c_avq;r0EZGoTv-|4Dn%H8K%s9LMuaF2BqbrLE+L4HiBbB}9fbg5^6QC3 zDYW#7IC7YbHlM)iwaMkdbvRN57~EAwKwq{Jxir|@oH`oEl(W^McqD_;p&EPdqZ%5w;6JJXf|7OFT>+h?ZD-XTZH$IE-EnF#-B$ ziEin3q@P0xw`HyMsb>n(_!Xz)F!T&6u>vo{FArpK=L>YfFG`7l7jnNVDaRF9k5G8&@?|y})YF z18{UkZ=JwWs?L*5+riqm7nSB5$tKJ6G0hw*iZ2_h%Bmv=EOmYK0J4r5{|-|vXPqnL zZSQ9Jr&7v5KMtl_?2A39wD?z9nVb9U&JE24dr)2d#Yw)s<3r%oxH`qB>#+xZ-G29g zm%;48lW}mLDA~bZlXJ**`S03{e*as8jF-Ic0m>79;TA8Ce*XP&54bvo>j<QqeO;Lhxo)pVd0quWgwZMe*`aE*#T(7rW!OE2r# z$ae7~O5ClZ+i|!GH*$!3Iw#JcEpmc;KD`E9a|@|mPnBoO#@0c=S*dzmaG2?j848vv zf^^!FK=hWLf(aw&`#g9bU~;>is}gA~8ZlZ^*?Ak?1f#A%E!;4(ACW_|;Zp zrGbG^i4H-5!`mLU>uHB5Nv}XRh07y-Tx{4Pnp@fg_^+m3Y7CGbTC;*oa4QKt933WJ zCj1&GbY!+*+%Qo__bAB$X%BqaFRyWJs(Nnj=wsTE8lDmwddLLV`5M2YQZ*lQlTvCS z&=VcGaBZHA5c&SxotRML$cp0}6%2LsQahNOJ0UJmaW1?ILJ6`TGbv&DZm&M3tw6S~ z;cfqU88f#hkP6ADG48nQ(JbO=$}E{J#0v=| zY!zc`0l?=|y$1+a(+T7%q`kivW-81^{5aRu&43! za^~fxob>b`Ozs#q*H2F>1*CGgnlapOedgu-lTRvw{y2lDI@0rUVCE#B4>0u$OU>9n zXugV7a!#I5NbHa&cjF$6{ga!>B3d5YxT7y>xysVGXE08#4rZey$n&-qX5gb7dl+^Y z&vB+OO)!AdF0%>wtRGNq_753ySsEZ5w=%p@bHvZV##|F$LwDYXc*`J_wIAv_9_Tq< z7cVrs9XwmRp3J6Y5aEvgz zO3vPE@vxNXq)9~;j zdjbZxGWiWtkoJCfCC3P1bn0#uzUqYK(oafQoaI-~)Y>4EL%}QpK77#fl&LOE;~%U zKV*g&s|=e982T~kA`{)KTHrv6EO)E;2UaX6?b|oH9R-GNN(<sF3D$dj-E z09Ca&pqRQGd1CE4yko?cO$^-XlAx)fkgSsa_>sA>CAytL=_7OSDEQbu4g?f~8Q+A+E^FqIzQhpn6;Z9=~Ig>8eI*5f}Y(2lu|%IHioyA-yz}>I$KuEq%Ho^ z&#%x!UEoQajaVk-?4s%IN#Ms>#Et<=l3Hh7wzAc9%-xWJx=(%R&Qo8&A9&d@Kk*pUH` zsX=<6N-TnIg!n>wS|>PRB>J2T-mUZp!}%5YYUHBywT1!zd?d;cB2|Fo@!Ksh)Uh$4 z`qz)3Ex8!$e{o>IKV2N_z42BaG*7a%TG-7^2$~t<*iFLk^BtI2wN6(U#ag0ce~70nmXF)5~zm`*~3{)@ASY@teqLPlbyxS)MwgrqUh!JnnM0~ayE&N$Xt%U zQi!azxG$B_BzmvWI>qqk(<-mkegu=iwv$N*87lG7>)@~uR66K(1rlR7bH0qA&d?{o zjXpLyf@i3@gZ*o%b|3dmrpA@u43(5)FmfxyM~0hkrzYm}q7)Dzk<)qAoB3n|(3D&L zZkUHGmRnI1TMTr7Wa*R1x28%g(c(mVd2+~<;U>@GzUu-uJsCSpc3!*u*zHL{)>pQc zvUAm#RUNo$INWd<;)97yU_$mGG44-bGQrFMe{v@7R@rA17ljGOx)J{t!PBf&t$e?r z&`Y#9_vDPO{Vcr5L=OR2CfDro-zz z{}1cPPabRCLtT8P^r`3x9 zc|)a-CT|nFSEN7t_O8!98a?enJziwQq}zD&h7O3QyNaX*+xH#}JS6gddFskP{pz(f zQtm*N#z{8VpdZYJd_{Pq{nO1(aihaTqs2vjv#=(?mVQJvtJM`&f#||orY^@A}zTZoTJVLIg?7*gV9)_PvTDgXK7(Ix7!U>l85R!Z8 zUaoI#3V8#M)z-Jcp^!wrFbgmWL8Ls0>1!9%jYfFSg^R(W0Vtn#wppN@;!HE6eK#&V zVC$?B+wB;pnnlU3yG_6U`Sh|@HI7mG!l&vPdxhx&GEe!c2~;}-zNBM*zwvDsbi%$E z3ms8Afvj$pYx76H;%GyE!6lTMdeq>0t3& zEhsWsV#3W;ZHc>qad?c+D{vo)ohFqL-yUeVG+I*xqdcE97*m!PW@!P83T)C~vLup9 z&m{W=(S8*Uzc=%6l0znOUp6gFyW0gyA7k?HjB%B{6yV*g$iFJFq8liHofk5Igrw{k zg*4KxVMIePlGn@{Z7)D;lIbLtsTF4!CMlSWqx2x>M`Ik?0{h{z$RBQe4lO@$lSmS_ zK7c&Q4IZdd<=QTyg&7?`lvTWV5cT#7!jW~fpzeFYgqU2@UScZbv^DDXmd&Oixi z4YvI%q+jhO5ecklBc-zR@yC@8d<#5bz)Jfxf;`Zu&1Mpi>yw-kVFrp%7-{;{plbrh|n$h|D9D$lVD>)Ps!DsPZ z{lmK3=i&wKpCq+tDqszD!t<&|w_KD~#(6*=iSeTH#bf~46{stS)y6wr_Hs!EmInw9+R&>JNz?t5-%2*L9LA;w9-<3 z;g3d{fA7nHOG^Hm$=FAhf-R%R#3P1EAfG(tJV&$FFKVG0hC5fF>E4m75vtSqCSK<68sJd1Rr8i6U3P$CF*HgO=Yl|252wU}2Cfbe>Q<|OsHvY_H zM_*v}Qu?Zb)x{Ut{bnO&)EK2hOw7qQF{k8i=MbOO3L#DCu zscy+plmtM9d`Du!q z$T%p-m+X}N&;SZ+mB>!b?pL?UzFjL82oLr@={GfC&N@3qmQlFN;*liOJn8U->Op$J zQ=h8Ux@X}h5DIdB?n-e6dGrt%-isxdB`&}+H=q@baebj$klh00GF~|frokYMaLCQ4 zV4Gb>md?cDuwvP`T>+KoJ5ysoU{w^$k*)#uuL>Atbrto8jG69MoxV`y;qv+{U@H#P z1U1?5h_A%fE7rMUBnS>`Axlr`tl7+%%-S8eirfyKamXTkW?EDcVw%k9bqK{a>@{<~ zSD>OPMGUpDM#gOLY{qai`Init3pC#0oWgrA9r*Q}u{U-oj)pq-zeELY?YjZIhi~1S zx!JAbBnV8mTA}jSGu|bX8|p=1wu(vsH27)ynOud^zGA2V4xepM8AYIyn>Jup)6Og* zRC^8b`vC_BN?lSym8_>c&%QiA@mxE!Cf{3CRG~pvV_XR$gMBb5e4`)%BzXA16P+#H zowxh5KT>DA+N8MN?P z)_aW5;#-IR;mVh6WBtg?WJIQXs)%sZJjzzQsNT^|>7Vku<7GYg)s};OCWBc!O_NPu z_>om{+~sgF*B<@$mlV5xm)uy@Wl1QfwUOEw0zICPqRAKqe0G%=HZPP(UM9Fh&IQ6osdo zp_idA5zK5P(h-M-^SQ47#@NU5?XjBY$N#WKCjWLbxGT>V#~N6iLtWzU2^CGQyyw$1 zR@15JF%|Sqq2)kowjGxnGLno z&?1KrGL2dqrH`iWU%P_>FX_|?5^!K(T6msNU)pI^9G(-iI<}jcjJw=NR=)clXIN>p zp}!oG>K23VJ&ay~83x09k4$6u2~Y~~0z1&tWVk9}usXyWMGnx`58zrB9rCoaP`}NF>|Lz~eix8w zU!}pNEB33dkS?{6z{XqxUKp$Q6SbdLwajse7`M{Uj!~u}zx3)=6=qfmUpCwi1%Nku z18jJOhGV-0`tMQbjt{FEBO^)!-mKbMPv<^}UeW)T10Bnsi_f|bG6w3+r)CGB0mLQ) zdcA++x8SMSLUhWrah7oeJBYKMZNuf-Kj`^bPN3Z@cejP71rzi_+s#rGLsRL^G0 zA1xyw5_)MHDwWWYZ+P}Krq6pW(8}dS%Fbv>wIf7Lwefj0qNy`$Aq zRySi+`P)M)&0@+X^uG6BM5-${H|vct&LvvW7fQJc37Oo-(Q+6t7P_R1x+vt&Vk1LGXz6wDb;9@*g}9zN$f9bQab&|^mV`{ z0!#!yZ6TOSPj5IK(-umD*^S?L_KeZ5FT_-Ti^os-VoErfQ? z8W11X{&Mi~ktc55LtvlxmG57Rw;n{1rq8iM53KjJIEFbOUPMzv+2?Qll1%OdxAMB# ziu%9$iZq9sObhB#|DK8VHwl#>?VZgnC8VTw;Lv={qsL!_M&D^V=JMgT6D~8?D0e@1 zy+SG|bbS)X#c`T2C{Icq9JW6&9JzR4_^A5$xc}TEMQ%Je`L`VA`=R+2LfRXuS3QD2 zdmC;_1LcN1D}%&RU&=@q{t9)?Z|>m9VdV-pDm%8Vr3jg0efnAH5wxQzNA2ABc!JS; z^!0dl&g6XZ=~rf02=^ciDt_ptQ-;Z~*&)V~LIZVLv2O+N`OIubP(FdTVGmaUL?_zN;96=%a?UYnKK`ki3^s!O&@MtQ~q zBa@7uP}NXZR*CO<-_u>HcJu+s*kR_=W^sW!B$A$-4(m1=un)kRgKkd;FVTO8+#Gqg zrlS%lk7%3$!4HBX#`tJKYzxREAe=P3p)P0|G_2-;x0|V-+Ai0se zCd&C#M;30zh`*dk!7t4O+A6zddJqm}Oys<(Ex^A?(6Mta7-V)Q!D$s)iy2|bNCBg3 z&am`61^ng0l`IQ?og2S05~L%eW4eI*TuIA#WWD4W(?lx!CwVgfR=VO!<&<|s1m;n(q0Dq zc>a)@Eanm*zhG1;+cj@xp3S*H{|4z)DCf_(lTmZk-Fc9Tjt)8H#SnW)5R}OW*GF+!{_SrIQfnNyjuqF^ z-9o-D3h#9NZC`A=wwjb!)tuW+srH+%axU;_z4UFS)JR=D z&6fOKV}8-!N}A-XsOjSpU-L4O#t(Vbjq7(UkLUOjR@Fr?nH3xCekDviqp$Hv6c5}b41hWMP9av0yp1ATmKNuM}|JR>Y=Q2X|c#J)!| z9+itB?`*^X&JA=0*-|Gr!=q1nCJ2ssFCp3zQK9v%h#$|hoQOA8slz0(ZWY?|!7 zLk3%3+;hrwvktHw(9?l8287kGPSkPcFYI{|{L(OuXm9Lk zsU{;sIe8Xmwd&#V5AglS=O9);v^c8792^kE9rQ{!B5q)W(^FdthCXN%`|- z4&_CdONVDD(fZZI!)*89G4jlJhAoRIn|r_JA2`Wqx3R)A3);JV2? zuXtHD-+aO<(UvV=RXd@;3Utuio(%r&<8IghZ*9-3mgQG|*7@h$+2WF9DMPYA7iugGQ^+d_q6C)luy;|`)xKw>ehr9=r zJko;xooIm*BR~VGI&%?r63$*(0ORu(+$57mz{l zfesZeteKe_U_ks7;p1LGbdTjXI#;(SDC9uP{0ADq%XoxyqJ6L_o10~*thg5p-K$vM zUVjzJDqeAqgt%SH44bP%1?s8SQtOXKGnW*lMMI(!a+#CoQn%3D)pAVr1~?&YYN%X= zbR_AgBjXYH75YP3BWAfTZd969V`7{&L;ViC8M6^fg(7T~T0Afy(RiPyr0ueh8;#*< zX_Cw1I3vGhPKeVm4!ow*F@Ta@qb1{}!a{uK7EI?XNK&%;QK+MZ;#3O~l5ac+U{%~C z00fP6KQq9~ECU-#)Z)?0N>Bf^8obzNNGN)|JfAq}(<%6EG3TN@?AwyLLXx6+&9fJ{ z^WtVB0xQ1$$+jnZ3=igA1;%CcV!IiAynR5Bhcr5klBAt-EyYF9&y%x$ya zzhnJPN^cL1xvp~TY=`?D+;eXknEo`BFDM3Axu5K|wFF4mk7tsnckW!#ZPR!%_=XBVH>(d-Yxf*i(qI`*^Rq(-R{~@?~SN1r}?De~>Wu$Y)+6Q9wKZm}u z1m<3qxfwPQ8ru|$z4}b@7le;Gz$qi3?@$}oM1B~Gl^Mn;S4YgFbg1$~?}?u380s@P zx@$A*+Apedtme_{xmX~IGb0QpS3y#$B*-&l zH*iAl$-E0~kks{^-^Afqu_I$#G2H=gg}LnswR* zY7^-=>#5tSGE=emWdgu8TuN#DBGvvOfSfUeCTtm75wd=ZtjF)VVJvNTF9% zl@W)?_4RnH6YMZo*WX_it1y=uBn~sylW!u!7Eqw7dj&v!@(5qW@L83;SCwckTs#w@ z!Y8nok8osC+MmRsRRC?p?!)1xqh~7jaAE$Qh0<~lNdZO-BJCBMpxTFAOlBw@r}%dR zPWE{&be0Nrt7D{xq-xz%uf{&(w_eELFism%9WO8NJJJeRuhsA({f&TOQfV?h%w|Eu zMn?vujZGY!*$QC@gB@R$N1tnmU)QdSZ9N$bo9EWb$%-?j17FpA<7bUK(m(cy7Z-;V zj9}qva%=(=L*mqzhBa469_|7P2nJgchGowMGNIXF-w?10jTiAx%d}t;Ixc`3pnf{; zChg1?GGEjH5d=DNC{{DgM@*o;Kyn2vc$=sU42Z^Nm6gIsIKLY?yf*>JRYatv&mq0# zj>BdVr*^@IU~%;VUk+?+|lvXmHr{wFcU&q^ITa<31d4va9l;5%A^kEh=F-r-VM68hMxkV&g%eM8bzm5$RnNc zkJqsj`SlZZefv~OAS!!p5-HZy6&I!(sAIMlifD6v+b`*C+ za}?Q`$+2Jc)B^oT)cw|zS zV=LW9$BZYWof5=TnVnq)zuaQ6-NfIjDX;1G%-V;QNY2c;KF1`Y)U#^{qNE*JXZ7H$ zvnrM^zK(A8dI)c9d_S>d1Szk#Et+7`d()u2DY6>~Pktu+BO}&`reDx)c3j$yBur36 z>Wj+7Qp^R?tjG~({;;=mffkt1l9EzGxNal4KqODWB-@Z%Jp!3nu+ES`1yBpNRitcI z6!NXc20%>5iQa}Zs0{HCbC=a{$4qknNt?vuNSjE%nj;RvhSvFwau;*|15p3*&{CwB zh+9v(pd1JVHGC!+5^4dCm@Z_JXpKAKM#c37^dM-98GNr zq*4c!HQXYi)>^Wrv8}_5L4VDoL)Z@boU_8r`jFzL(Aqwv#a4-+_4J_~G$zXkCof6m z@R!R3rDbKWYp!q*52P8Kr(I0X6F(Cc9XYG#?xXoY93P7y1d-q%q692;eFz7zOq>eN z3H$JQFC%vWWi?&_%barw2@;@sqO~PITYIEJLJ12wQ+=Z6qqBhplHQszd6;N7arGnn zqQ5T`XzE$fF@fM(=7`h_!2oQvTfKoHb(WzUd5^WLdG3H`7fH*7DgUCMd5#~?5V=&c$7S0<*FVs!^BrK(d{LxgC(YTA;Uyfa! zgZFq;N=fKsS9{q6^1 z);wD_Hz)zu1eir5-TEiRsl}T3#Qlu%A&p%JD)&+m3~_3RP=|-4fS^?qEfU$=*-RfB z|8x?RFZGK_A<^fpZh0WJ^AgO$D0X|4H-Ph!TKNJP4Y!f%} zx;!5be<_&5_{av}fnQ?Y_X6_C8D$C`PQV9kYJ1q3zeZFy$%Xx9#(7=-Kp9iPt64hl z5!4%52E-=rAQLWP6u-LaW(>-w3oRk=S>U9|z}1AyU&$T4jl*(9ihxQFqAQAU03ID; z-*BimTPJc-6c$|)bEL-tsletDL!zbh7m7#O+lVIdsVh!&jO6EHGn-)m%oSP^;YVN! zB_J^KGoz-!Wp9q56*Z<~B4B=va1n(e1_}IhPoOlP!6fxGkEe$&1%3rgwaZe6)=5mY zYwWvtWAYxM#6cHwwH?RLe}tQ3vQz=7W_b5<#R-W>|F+-H>?7ZvU0JT-Z18@RpeY=p z&^J|!j_2H=)>N|^f9`@sb4Z@Dc07{MQ^^XNCrOPSC{7>FlWex=Muggx#OP=`_t+Aj zqgILvXZ^p=y+HFD<(?9#(0S1q;}e5^(Q>kHWhn<#C$O=ZJn)rd?{^Ex!=@{q9y zK$C@ot;c-nOr38R7q^^YO@#uR6JGh>ZDLExC1b&dy=l@`6R$W1)|A`qf>_PvT|RnP z8)-=xlf@ajt#G<+JiJ5_AmsYd317Ib6cIUW%y9b&9cP3F(5?oDLK2u%Y++*4YmN&vP>+DZL7sh3V?t`K@!kDVwB)j1@_hiPmGum=>#V# z3E6}1!lG+31#oL_7p5tZgyGH#wF$QIINxE1N8eA~f^XIyN~v<6{-`R}#D9RBO|XOt zA*cYiQJCD+s2Ty#v(Xa(&L#NEZeU;3JdLK!iiT+_#2NMzBh>K?+)lxNpw~zO2$oQ9 z!eEG#n+Jpybe1yBLr15*;;tSR^nyx$H!mpShPSc_ju z${((EELnuZhc|B$k91jx=)_qfjXm!y?l~_ zYHi~xT2@3w+NRK~EJLB?l$d*_hTNzj9!hzfE=dS$EFO`TV?v({2VjewUjwGp7hZvG z3?c?nEr4XA3TC_pX_(qOkKxr>zatgum@fZEq|nOgI#wF}w6ye*tZUQ?!cir<4ih*f z%}4BErHZ*>gK6SvK*hBGo;^VcW{jio3L4t-l!)~Jt|@KF#M86i*UQ^z;tWz`1+_W1 z4+Q{O{ymB74zRJ$B>SN?F@_e)dfRxJ6#b7?|I+^rl#$Z0^8IUmH3q^_@5G2HwyYX* z-Udv(oyPMTy{Y5j!0}C#!@WAM2GZ(wKmZ~$9Y(S({Sc_~3r6iX<>6b+=yi()N+fOs zqMUG&l97Gxw84M~m%B4kz@Y#+Od-zD#0G;20FXYpr1G;sDj}W3Sg;kgc;;^#;5^(E zAutJm_zs$A^7zFW@pGEsOK37ymGw3Xr-6S4iQY0^kddOe69kzRnTY&?qqgn^%v~Nsc8wmIB+7( zcB+}0;}%*-T`Wu#UqWYM9Z9DDCWZ#6W41@GoX2VBXH1sq-g&G=AKOa_K9n5^i&{m9 z-Xpg_;ZtgRgr)i!3ChZ%{FV$%tSYbSKz@3}Hdes6iW>0^W(&5uCFC&UFZW?B0SBa6 z^j-`F8*K6>Ku3$YMBW6C(lX%+>3}o|@w%M_%0FC)Q~v>Z$a9XyyGCb?RzSBQfP(&t zKnQy-tqR4)!-cF7HLz_3gx#`$tR&i92~7PxL(dn9Z;K)uht8V8xuZ$JOI6WqMK(U} zX#CothmhlG&I6pM70($Vcc!m`0p-3xA@Q(##rn(9YzqiI8-N0KF9&2I&Up>$8byJy z;_g75twJnv3beoq1 zop3tLGtdV3Sh6i;6hy8ju37^$;^EE;gHj{FOM9tKAKJDQrtx)fk;=XRRSvOUe6%}I z`Dix7MQ2UQh_wkIoyc@m5r|@qGkl`whzm2=q9X-z6hf-&r||+oDYHe?CC-_VTj1zt zMERL_n|kg*1!fPUwW1zNTN z_#shM(WDM-%f1zWK-7t$a$8kQ(rSR70Cy(44icb6!6#QU>-P&wovQE`LTWn6Mgiah zH;MW5XICt&s~ZGOu>nw@sw?Rcim46jby9(1kQANM^Fl^v$p>c`ZWQR z>kzzZrcH%#6gWb-_+E1z8AJ^ikliG3--bb3^xQY6dI4;Vv$k-GpU`&%%)Gz5h5*vP zaYzABVjj*-DM1ROvcuvmEOKHq9pg{naI7rO9^_Yn_3Z}etTypRGyxRac_L@^RS#5X zo+9kqOeAp|rDD|(0!VT0Vxy`85|}Cy1&R)~F)-C%D1cAPqL4V6&n?``$E{gYLln-; zjLpTG0q05&fG7xDp$T#xpn@6#0Cu1^I2%c!3Gje8-MzXUkFw1~;6%qoXZfp*FY>vK zg&c@P>quu!wI-`bO|r9sXc~jCKphGI8BhW{%pSL9LjZ};Z5)o-G7bYx&jrk2^SVIu zidn|EBE)(=zTe8)_`^72DFBK;(2opm&3d5h<_G|>o@XFY{4UJ)^bQ7#jDe;Q8lH`|4C0-2;^}7f|suL1quo(bSR4 zjIO5XRk;@w0M6fSOFuo#_cb{;>!QEo47=Gn050?fP{utY;C~^J|A>{D5M%}%$VY$y ziA_WZaC9)L3ZcS@djq`mfZ@m)K+Z4qG!1D&jnMeQt@npdN$u)`F{T2M& z-!s77&Fw{i*#CUUh=zE3twwqV@VvvW-#F75I z;#7+P(tP>nX%xQU*N+yme>y+nEgf-KPL1-sv{6bYc{%>Z9Cudy%1B!Miu3i=`QydQ zwd<4X$(!dK52K@(Pdq;UJwLrw?(ux{y#$(j_^@%XzJ0U#|&Lt7qlJYvgI|3P$5U>kFK4~6;HQufd_6cBN3aThgX1OHMC z3sT@Ps{H2rCyp7op%|ge8a%~U{Yd~TNTfv=m4<*Jog`rv5)i@jaOe;Tb$c$Jn>k(o znJ!&UXalLabzNVJsf5Bi?picdB2ds-SY9wTy~TXv28*aD(j$y&LWG*HIk%m@Vf*m+yWeZCggWUNmp0ur(*=9f;Xg~e;dAK5kleJY z@$Q7u`Kph~nfc*ReDzNicncALyPLC`?f#YGui)pHyl~MsFYen7BGq!9b}LZNN>=64 zpb!Fq8Zd~PtmCBgN?pu>Mj(t(%RtZtN|)oIUSwF>4EKAzT-{J^^*aZxTC{HOVjb{huPArzmd{}j z$;~I?0%gjnFEAfL4rlJw+clo<8@@T^|2^2`ahsFJZ*kVlUkh{e+sG!QDxpub&tQAp+$? zeD_7X;qKzEHqC1Vn^>oOhf^#bindZ0pC&zdwduPRDB)5$9ov&ivy)x>)JuF` zVoWxP$ls6|jyV!(=~sK3xWdb=Z*i zG~10@1j=G@;^q!n3_;rg@$(1zs2|hSwky~_h^_SjE$R{t2|wvU%^Y z>k}l6ON31wRsd&Qu=mVJ&~LaEpD!C5evroXAPe0pr_!Bqa;OtNYB%7^Nm~4@NCcA7 zuLJm~Bktznw4LDQT;Xv-KIbKXH;vUJs-S$Ha62xZraqN5X5ArUhXLEnwogMYXJY*w z)136x3{AVD!^Fd+h<}+E7_O6dh*i=H?7`DiMb^f+$9Rb@2P7qG1G%~@7VO@WDde27c%SZoDX%EulVgRr# z*ZWHC;s%%l9j@%;s8+}U`Meh+g-5p{zmwaTM5BD+IQ35;j4=(YcOO<1T#^h)KKE69 z(Zt$-yzln7RuiEO(QpbaX!lsN{<_#urFbipmPBaYX7eCBfoV}j{b>#QL!D#F)BDe= zYWO)?BfoVf;?LOo+x(>KRbo!2zlZKO>1@H>I6-^R(?ThrIgG$~t2S_HheX>92(Lz? z8mUnV4B8I{ntXZr_q&|N_ZRz>itYv2U%3e3$tZw?DJZOMpiHgpt~S>$4fry}>MriO zyb@|9uq^!hT)a(xS51hbPTXm7NY&MH-3edi3u&l(QoXRqpJ-@tvB%A^kS_2~=$enC zbCir?(&uaz^pD43|1I@|w=dM4^Q*`Rz1~-jI=+A7?`_cTM7mt{T2rS}*bAw&cn#P1;(K57%>rT?FnVF) zbXv4;?~5dceKE3N7QOXT7Vfyuvp8(dVyNl@=^z0MRSMh~00JF9seds@J(N575{$nT zS0`S?7;Tddbl34-GS{*Y8gF-U26*i1k|6>A6*dqCfK*+Sr|sD2|L?LVfFF+ahEe1y zBCiNC2Uetj5E=sdS^#UIU zf=1<*>q6l&VL85Ok4h6s+2>nS<$ZL(yRJu<*70FCKphjY!2RZbc(=TpQEQvsUuzAVG!c>| zlaVDCDIT_6P^WqFukiM0v|#bcto0oaw2~CKp`@p;PTCQ!KS8(fb^ijnO#0^5v%~dH zbKmfq7~FNeAMW(NQem#LWod?v_U)>Fpx1%C%*P=c*`lv5_BPAp^he>H1re|E^<4$W zE#+j&VJGg&v%^?G>(tfG=hIAXr_)biJ|}{@r23KDd+>$sF3*si&-Lf-2^RAo+Phz% z&fgAT5d$CP=e8-)SHzwctGt=5W;ucvziUGmt z;PEH4N6h-_13%Av)A)##LOd|EUgFH-A?#YhZ$DWTP?3W01FEkh|GgJkue?_iC+Oy1 z&G*pY9NN6@pW^BiGGN3XO4>lIPeDJ6LM7n0rULaakg|Q$6Pj|Xld*PP_IUMXx_%;Z z#J~&+@QbC=)A@wDGlm@Jz^h}kpPWr^p218@w*|d$+5KYjGiE$jQdo7+e5Ia1)1BPA zM6HPX0C1pO)=%&iSXH8+SBk2{9hpVgj5Gf!)}Lg-;<{g0jHrxVlj zU(g1*A2elWHS$J#JcG_ne6Dxlbrh92-o&Wy6siWIXkydExO$s6T3aeUj+XxQTKFkan zAD9CJ^w5?h1zXj`xJ5WINWHMkG{6%IK|-?W)o0#Yg!_A6x=|lRvMa3WS@mq$wX9)(g)A`e4vCn+Y6FwdTO89a65Zydh9up^)K#6`d8f(nxNQ)}b! z@mTbqluIhi(j)hdOqe*e>RfETZ~|@ef8+eLNRPMODW-AE30cv__c3ht9#$=uf#*XU zi%bX@Z>;GU59COK39xtp7&423X{KZuZ5Fm8vnGtU*jhM{0{b?Al(Zgdtn*b2s&HV|Q>ayRVFH-r z=xGu{Fpog0Xi})Hc;V*_59L&3v)^th9tY1BwkAb1epz<3z1je?W+YmAo<>_r70RSl zdgBI)Cb!{{v?4BEdUI5OzW*%nw_WlyWN|2nO#h--GJz|hCpdqCEI)sTumPtAL`9SU$Cgr72C@7#B7ZW1kuN&)=wg5?)PEtXO+ZBwu$XxLkVP zCRG3O?n0s3&j@Wqv+8{L^IR?q7t;5nyoH;-I&dDBJmw5EN%a!x|9Gcpt?TSWm$}TI z&%!KHD3_ZsVT((K-K)}2A4%l{TUvToW(g72e9sV4#ah+m+0fX_nkJ z|3|21X}N`=QHwA`M7MV#uG}WNW)mFXM%CA!}>^ zX5nB6hs?7gr0ud3Ac+XwD5 zw=TT05Ej9H(Bu<}jLuVa*=p407Nudx9Jc-qyJ5(<9y*2bZO4IdTk*KbM+vX($NSxh z{okebHfvARc+O_=c)4vILxj>Zcl4x|V)-&_(&?2#NGE7RzN0FE&sk3M^3$k1FYv1V zcUD=M)mf%;wKoOIIO?%?5)iS)P9706Hy;^z9*gIr0gfj_ESpZio!-7 z>M)_|Mc#?te4Na5gfN?lBOKpTrSjhI7eEv?g!jm$-sA8zC$!c!NSGgto{MEu@!%sv z?kncagmeGL%Q@4AL7C6uSJ@g`uh!TB!~g6TIW%ZqITc~n$US7m5}*97`d{8SHLVB-gel zfLFg4LPKKdwO@a*O?KTR$FcIG6ZsXttsi#XZGYeQ30QG230xgbq;aA4o=Zve?*Eub zyB{;6d09R2h9thKx3zPh0n}2W#9|({R$#d`bQ60G^}y}HzgE;x)LmqwuLVhn+HV{HWqWMJ|#(F|D?UVWZX4Zp2hKx zb3Kc*d>k&vY?U4&ljJbUd3s87qeoy0q1bJ{xO5kg_7dKrwPi^GWfaVU^7&ub!-wr( zog1Q@B%Afi3hFi96fiBwtV{o-S(8Z>RB#I48- zbWK%j3dlIV`g8h;KQrzmn)Zqz)BUDY%3@({D_aP>dZu6?%Xv!bWG23$s^K>et^9H| zSA6V1h1H-eUx-E|PL6)5&Ohoim3myk9lkSGmF!t8f|*I;4O;bm^}A4ZPcNRH-EQe) zEAPvVCUM?R(kDBPur9^AHeNAnoD*eXo)IdUEvFFe?M_f5V?3nEo!TQS%B>_R%KSND zey4M>Y)O8bdty&LcOdze+6@L{^UIp2_fejTBPKVWs%?DJ_5bm(EpF1`fwI))o79wC zWKs%wleDO$qP<_1#XNfkj@VOD8U=g$$8MtLb>=RE_%gfd?ue4KOT!*dIe6>OQ=DkZ# za&JXr>yuwIe@Zk48NObK-mHqhR+Sw#_VnnzsT40NfHBK`T!1eBSx#*}#F&r#l7{CF zW>igcYT${hbT!Scutjyt5v^L6-uv{7^X%hi3foc8cI|&Ur%X=_hgE(){TA*@M%Qh} zrqBZeYO{6G(PagbQurQAG$7?HToau?6tJKv73PX;j?5ShRU`8qx^6O+aA$5&T9?0I z4J>)$qC(tw{;I#}`;8*mD36KPzlJI(Y`>x~Uh5e-w_rQ}UmfKUHR9IJ)nA0zC7dVU5qPx0Bj- z5;csATDb}-oS0s2+k`c<+l3ShjnifXz?dI}Nl^LpJ(}vlRW;@4|DBOSl=mm@X)l&eOF>$ng#3}K| zctVzD%4lf@;-v#Bz-c7~;AR7_&$J9+J&OfYlYadatIH5fGgHEe>BS7rx%I=z9*GiV zO#;Xk>{uOZ9sxQNWdN&jWB~0@JV!%)eBr0WFUMm8<4>o|`Wy_WPqn!er4R5z$$%AD z2&DyY3XO0!p*RhNxW+9Y4vli6R{dKZ8}s6xLXN3dP(xw&@h9I(;L5QDd3TEyn+{g(SEIo98rk}ux8PC3M=A)q7sxnb9Xj?XVd%ofcTFDMlDy7My(gG93Oc*{;~WFFJcTme>$@TooI z?W$?T`o0=b+^2Q8-uD6o1wZVXIu`0Yp2hE)Bw7vZTipy1!DS?tw)^zmMwi2^FT}9S zd-;6-^`6@E;MTEPihU3C#+v}nI+%+MVL;X8hL6!{+?>MOZ?O&48#GE*2X6|71FSFM zBLC>^$|T~$#babTHq`?oGUG9=UQt4%l$iVK67$P@+kNDTxBVB*K0!dlU3t*Wz3&)GSx z@TOWz0TmTw0lJ3zJi4#Hcj+946!FNV`OJL&B-LSW;^B>ZiBh7nt^x^jaSK^*avq3! zx@F>F!>osh#TRh$`g^JVox9(4>Gr$Q2Q~BI@hPLpop1cUUGR*^s7E>c{hM@Q-}^<} zm4lMT?@uO5zA26AqIYJ0##as{-ba(4M4S_$$v1U5^$qZi`~8eJdgxt_$$C2fO$TvS zcyV7i1~6p~YiuykZdywF0Uo*s;z2OUzEk&srUnG;5;T!Ev}R9M>QAPqGfuhK+h?+* zl|k(&RT>^WnW@8DGUv0NC0uS&h{l7-!xXaQhNVp4O z7MZkcmA?wOE9>L-#uZKNrTX`n3e#xWerXn8zW9|oGn~IKMbs?gvT-D-%%-*7=RhFc z$a^o)>Y+)utDSd}a1q`1H?_!?#GvfgjX!4LIsNH? zaJKxi(LTbdPTpOy5^U6-cP_`7!_;QtpYIfhc3&}dQXUUk)o#0g8~xzE67zaN>xNY} zJXZvm%JyoAmeG@WWNDhZqjZia6-SLOlS2{inO z0fC(aO~~U?BW4+xdlUs=UjyP;3F{}NJ2spZ2kS1e3{3***R}<&3V$m2aX(ZC3|#@? z6PCHT+;a5JwE4yt8=PKkTjgl{`jqJ5*AFp^QyU7k6M^UIdtG1Hq*iVPF4a>-x2?9awDu=;FO8eaxdMHXd< zfl+$d%(qxK8bhkq@I1nwD{qi+WrQYvYtQeoNUhiG%!D?jDP)!wR}2*S_taxuvKRd^ zA?;`xKE}6B13J%pDN`TQjuFb<&3G&3AI&|Z5M8rFGVpl$JIylXNE<$jSfAa%60vK# zZ22h<@bY}lbx!2Fpeai0=chcy+xFpe^eT`YE+R=4IXz#5)2BcGV)uepHc{ED)p2rI zTh>tjGyS~!+ix}v>4TvveC3I8ALqTAoB(~t{e%#*A4KP*%b+Z24O5)ZzyUKQ5 zKF+$rKOpKghn#GcdIrxa0_=PL38Pzzq1Mc2KSWk5p1WT7e9{za9`KWBfH1X|Jt|6W zww3=oaNzZLhV?5l3A#=B&seWh;(@54;K zf=-n>qkA?<4}01MjaIi=p`AE^a_T1+-NT3WtJ#z#6cy1wG}ld?Jub|d&ay5%@Q z+>@pBoiET~l1_QS1NKRY@k9DA8xB#Gx=Yuxg=wq~)GJanTb})yj@DU>>nUoDJ~bM- zp!x1s_jmg(3SMajZRo6QHhkgKJ*~s?eGGD8C~K|_k_~B~)(QF%noYC)PqDjE5VNlM zy72tzeTuu2gJ|Q4w<8|HS=X0^1!aA`ZyKe(Ps*`+ddi!mzSUZkQLFRjx!&*w@EjVJ zZAiYV=jZ)o@@*!NrZCdQ>PfZm$En1$qEJJ5w)4Xmz!pAdBaKBRDi_Bt=<8abqwOrv zs{|Y^t)}Y;3+jtelCumHQ7U@p&(zA}#KKsA9DzhV$6sT&>$48RXHT9$AU%) z)8rwl;6!(zl2?<`7*jJ=WN6)F^5$limkZD~*%b66N@>$kWvZ%WQpzStRYm~DGF_D1 z4zCr7mN8&;H*{5@8k#1lkY>og9i^Dy?*u}O8I;LYitQk1k4gOehGg9d3#y$co{AIv z_fe|6Q^FJqtsO!l!ZcH();3Ns^-sMbeg{cquiGGRz!TP}q;?)6sx(M?fsLWX)N+)N z_*Dd_bq*0De7JvFgA$IuCr+Lf;{@>+cjoRB$Nj*yr7Y$+#*j4E)Ap5=oNX^aoIEYA zGMSZJN_!*UDT$oCIxCKb76|9^7blmvN2G~mO--q$kyVw3-)hoWe@tG#tCIGznT-{i zHt{ti`!VM_u?urSU3S?TGzB z8j5T2HdiG9sNy?zz8%+VafoF`5Q+^y)=Ce;B!3=kEx58iwg!b9lgK* z+iQPm>hY%5Gj6&zn4Im`rW~kLiOy7&go+6XP##vf z;WHmPUw!Y^NUhb^P`6L@eIxq*A-{-0@G+Ns=MYU=MY1ZF>3I@7){{9B>5?!*Lc>GK zK4ap`QzHEH-Ye%axU=Z)-Z`vS`F~LYhvkn>gGa70es5PCdK)Pd#d_|xdpzxwdsQ&^ z8*CERd;dK=p9ay-C0+-$e?7i>!V&cQ+q~cFsIY;rOKUPO&&re^Jy#z$?h(74n*7na z&cOhTLzBR7GhSW)g}uEq)K_XQUl<7#K!J@8TUV-U1^Nyz{j7Y-(vNy?FWoMGpZ=UU zyqmQFj#`l~1-Dwx`#2mOEBygQ(c2-YtIy0?4f!FgMCEW*E@20!yA?L(lU+i>WAT5x&HZ;_n`Y5G+2eO2U1*8g*@dT zqMN=G_ICn#j+}LGHmg>99{8A~wQttT=5ppy zmDzMvzf*B$dVhe|XomWnWt=s5!Y+BE>wS~iWt>l83>r!CchkvxemfU-`@+T*yzitNULiFRult5I7anAY zo}Ag~qydX+-&?6xpxp+o!te{t^^!r|gv62$oA(pXzJ7>U_Ff#B#AJk%udKMl#guOu zroKOGe%CYP^ZR$$OBF|z*z(m7)<3pX;SWj;m%e&)et6DK!=>m$DQ4X8h+0ITIIyay z*ZH`>ukEdiNbrk93IYQPJN5z_*~&BPgBSFfT@RSz@r{Ts>?N7TD*hM|xwlP_^9PeH ztN7mk`7UQVh}WZhmaIRWZKl@cN#i5do8oz^Hr*;cGQLE|)|!$q&B@)w_ob_Mk1~E= z`}Bla+N*-hlp6O2r!&IFcQH)Vs^8xWOC@PcUTm^*a|vEGl?y$sfANcCQr{D){A!vP z%Z;C;@|xkE2)76xrh1o7>^`%G4FQp=5S2sxV~zUT?Sr*g^aBUpHpI%qak8Ynv61LP zG=YNvB-#8O2EQ?w>{fm(C4M0j)L+|GG1f*K^Y%g{pvv8>0-nM#OSyK zYc7BUS5>iMcJBE6@#4!3o(sJu?u6r-dbQ7LsZL@;vZhJ1J12*!fv*_uHF4qwqsn+c zDc%y-unJ)!p%^Vmf@LPegw*89)bL5?G-WpRhC9c-1jn4`fsqhKDha+wG?-UL1>0zOD%le0@ljQA~AqUVeL-I5l;)7(OY!zd)j6-nUlcdLCxaVl<-CBB0FZkJmIaX>u4*BrWBs$Y)!kin!EbLK-i$go1~PE z?I#xPqUoJ_^nNolxFRk3xFRAe({=DgizYJM_a+u+%u%4l(NGc!zMZe#h8+10wA-#1Zw@)j7ABA1chR!b$2=k>rOTu3ny8}RF`!cu zWgXmKYT!7^r$3`=#+7S6pSZem?RF+}yaA;rvIDd!7%n>KUyetn~CSatvYoBQ?jx3}2<6Uov%g&1OI>$G$Uq2yVAB^DA> z#vGK2KX^dST4>^#%#KtbnVh0nJ%7g?HKkkMf_KWy9Q0E!_)ppXA2VpJHPBI{&8??~g78S=vynl4@9i9> zmri}1Wmg#Vo`kG$B|WRq3sC;u%wE6-RBa*o`uC&SOCs&|8G~}AakJf#w?#7fD#!!L zg%@U;XM)D6LS1fV&-gPPLw@03<1bZKtXsV~lx6tRS9TEOD-5U{uC_4P4f};hUhCPk zF56_b3{FK)z{C#8c~ttGiQAffdQ9}rHod>)q`_AC-E>PgAJt!THGyeRSj+LgK9A@0 z?~e!hsq&Po-=p8W8920XvEV6wv-VD*s#zmc^5#TYoC~{{59FY5#U~#X?yu=gZ4^Q8 z^Y%qZ5&Sst&s#PeUJaJd42|1=Zl<$-l=-kNy7U^D|2@MssBQ&`2$y1*#Ih}T2R+}I zFDRW4ny@%{PtSTge)jkM^}}!^&FHH>c9s{WT}>n#3E6w>c%XD`M$52ki1iIU5$Gnl z5#tM8+0yjqlfCV=2o^4tZ@W}GSy3dssYsuKZeeJ3PCOVkZ!K3FLp!eZ0bNJ7f>?Jm zg-KGMYw_-?*D^rl9bcy#HNz+5n2c`+_Dsl7M%bQ(a){yTA%hzP@W66R)D*Hkv9&Nz zNX)mnfcOUeaE*;du8HH82vjsAR9+d@9MaXJI7rD76bnZ8;29&4;-t6cQ~cPB!9^#w zERga@+!!{mS9!tO-ABGU|-c1uL(o(!) zyheBKDb|-w+<}+Ck|;bH!^>S?f;i2wE=t%qK6w5y3G4VlndKGFVvoYU5#KH-pFcikc%G0?{@W$UQ7FL|XJ3RgvdklX8SaNaBajPaav`BVT_ ztlMW*$*E_LYMkAjllS_Ex#G6(s-r>TP}!>FV|w+Q;8l`J`->3+Swh28MnmVHau1@{-SMrlgsQCUUeDM`G_}7% zJ1=p3&fJ1EK(JrM6Q^K=$pF?k+KVEVa)4zIeI$P{nS$bU?-}$t28rzGlmn9Qex{FzL z{#z_1XZgE)GI?4X{M98WI;27PSvamD z^^=JhJ+CGbNvd0us;a$mb!YqbfDDSsamOQ~3-G;txUw#uVh9+_Jxw;1?QjpKHt%Zu z)AsM)IsWx;A|tJ~TTI`@F3PF!`LACOUBo&DB}18-Q(EtoZ_HTc<2uPzFCJRu2J{vr ze)sIOGo(E}Zxh%TMbp8#4g38%`m_G*^oOf4cI2~PcrMi}TJp4O7yO@2@n=E{<`}lZq z8e7`kHH+Cy{1hl1&~5S8r|#qLUXM>kU#BZs6)X<29u(U~e*XQ}%Fz)Wfn3;MG+LJx zpd?P)D7nYeF&LL&4f-nTxZjo|*TtW1pa0^ycSiSz&bzj6r_1r)B3A2AkNKSs>_sd$c&KHX#5Uixl*GRy7IPt>`;jP0dEKA)kzk9 zZJG$l=j_RvwCzm;Dbxpw2?kvALSPDE9`@J25eBsrzrUqQoumE1c*6?Lwl^Aw_|z+E ziv{smkPJP#HPaR4(PM`nSVo0;#MSwWP|4s0@HLdNB*@;NsMei@X}5i&F4qf+yvD5J zTpWCv-+OlGDb72+MDyS90=O135xLyX(@8Y#2pCB-cz9dl`Du@1I!AtuIalLD;ap>5 zYxj2pXgvx(*lkzR7#(ed(O3oYZ3xrLWxDmQ@w($n=WhxIOL?;qO84-M8JZ_v{7R%c z`gcD5hvQ9d!$;efkT2-cVd@{7UU)n-a0t;0D<$1OZ>tNooi>Opp~+k6f3Xp*%u-Ce z_m(6Ld+4go^4+S-^RU7|Q;v>a^W5%oaf$B74`@$W7mttVfd4lK5BEDZ2Yd?v;6Ih@ zN#p-;@HpDKIllIKEyC?<>!zae8Tg;14IBXQGY|lNlHNR3w9iizFHiUX6pa5%M*WX` z@zfdkKXUz(9P}CQfAr1dg8whM=YMpfp2q3@A34bUzrzCH{oh`rYyMNK50&)wi5%Q$_+u`_HUU7%;$pr%GCgK;Z(= z0YJ)N*m@;c2M4U9gEub&j>jbkm0-s}#{%Yo04M-u!jnD#zvn->D40cp1;E2V{?AG; zAB;R0@X#;_f%0nga1cQKX=oV03c#`>m?*th71J}r61m0zLL{IF6|?3>OcE|)p3+<7 z3<>fn6LD~fMz09ks5=UiWg}rWH+Q5(O>G0bb~t5W#TY?SwjPc;>tP8z(Fs&psA-4ANin^+crsdiUfDD3xGWkjm zsO9~p6S5c<;nmFWV)I$y%7B8SWygv0j$*}w#9Xr6hnL%|+H>>YdH4@@SJ(A5ko@Qw zNzr42Dtu5(#k_;QOx9il&%#{gilLm;7M(wbcoJ;8o{jQ<^7otzZGk15a>E7>SK=D_PQ=NM$Fd z+4bkUEKrM+Vd59m0d@{`b0CQ&)^{2N7liX(zp$cGL1~d5qmvhF4jtKLwamXJR=BONCKH5 z)d7@CIxN`ME&6CDfv`;XE$s+GLyXI(KjcM;E`iXdiuk7c+c9IYmp=Vl%=s#JYR?nr{XLd)k|x6TJ5}%!C)j&RO<*{U;nVa8>uF9 zdhlRknI6heeS`W4b#UYLFsfm-O9eNeGI!YKUht5x5s`)xgMv9BVQ`3MOg;@NudvY3 zRidxJC4fuGKSq@|fYS-nlj%Kpjt|GHIvi90TN8Mlh*2Pi55a_uAc{6_^=UU5`qd+z zzjaTMC-t+XIwE%+Quo}nK1)n8E>OW5q#t57m+*qCFet$y)cvtEV6Q{N&0$CK_i|ye zGX)`vfr%B@%8Ty{pBRNsgV>YdIs?5ObQ=PRWsTVdiZZe$?8aMoc#(7xQaizjbhtkb zK93@4uxv!hMF1x^tK3f+roK>FcwedoF)XlO6hpir(7MRRUUhqu5mC6vcr-{UZ%rH% z-o)m7LeZx{lnk|bXBNWQA4=``FLp?VCW_a7Yy35+kBiF7??Kr)6E_7J72KE4@cmYS zd}+^N-;SCF-8Mm$lP!;D%sQY6khwpcpqk7l?P8Ath6GtfmcgL1YCKPPhevYp)DjES zx$6c!As@XrIpPWb001Z}>Z#R14V@4;%Ahdt(E$7&%GJ=a|MdOu@*j)^NdIs7|7ktr zANpc6@K(BA3j-O?xDN4wQau@ANmjHrhFr0i1%tY-5|0WbcWFTbXh9g9^J>!> zah~Sn3@60vdRNAWAo*?q z>%)DvNsw2EGu0HE{$Ui?e*n*F`Y6~wu|^|E2BS)6I#!CzW-JU4R(I@D^>Qhp0B|wA zoj@Qm&c;L~&@}ro6)C%pb#0Avi3!iVP!{>6j#Rxh%a|OD*%1nX{rCYwC1ea0m#qtl z|Js~ABce*S_rxf<@Ji0l7!Zt$PljzJ$>EV|UlWUdmSDl5rZk6Oc5v=(g`ZH*FPDlj z;&~Z+O+E2NhSi7M7Jrsf&!PBH&6~>1G0CiE+r2yWPw!|-K2F_M@y>n?H?r^rj+~c@ zygll4Ga|__KqShp3iC6+vWlRP=w93BIj_n-Tot{-6#3u)UTnFtTjMc#Q3hML`92kVM?X0{odo0akI%|P z>`AcmdAIl9Gn!aE!l6~MV4yP}s1)$Km9L!t6CNelU6xj7A|`pAn(4K6@P&KbMI_;- zR@bJYfwQ2kYsYpGG%L?vM<=E1!bUz4YR3b9vQf}Uw_aW1%C5Cnh58Q&kuvFQmY9Jh zMNyF?7>GpXkVFWhFIUrtJgcIXVmnTHf`})R&kENZX-v+ER`K&dYzk`aed||8W0|D#CZ83HdJZGB4`k5M` zAdec=P)Oj#)X&o8f!_V`vkb=K4Yp?=V4Y5eU&F}As+kkVf7a||D*VNVu5A8>5vZifX3R4={bi>%fqBMar>Z7efv8njZz@L!`P=fSF=dnroDHfKE{Tl8J+ZqJz|3*TYBgc@@ni&FS6LUKJwt;g1-TAhs>d+ z8c;pK-Zd#t9%Bm~b9>@-8N%$CsoBR4Y#{St%!U8A6v`Nu6?1sTwbx{_UXT(uY?5!9`5R8h=KVv?zo zw96!0iahk1Y%2IAeay?rAN))&uW4)+C>A?o;Rhp{CD)kzg@ct6j^%ZA|F8~jt6Bul zBRKN;!NwmnvV-HKEh8Cp)cgW;c#wz^SpJsvw9bJs-}N>9%g25bY8P^E*JPwr}Ip z4tJDlk5GU%F_d6w2LgZg2?{Bp%+O;Sq&E`JUhcfl`b8I4SavNw;5KBBDc19D$r@uA z-6=?BDy>J5hn@2w{%;BOA;%bdiUwy7WW>2OT}pLPt=!0vd0D7r2z|zTw9-YHp)hb{`P!S+bs=t zO4plzig7@*whnO!ph+PdDq@;V_~gB9 zdaC|zkoCzSnbP>CN)(-mRb~NAA)=yR!uLBtV!=!Mg{v9l4=1KtqsqH+uKS5PzF;_3 zM`EEb^vJHsXG`{ip8rLGyBu?|yHz|l?w>^oMhz=cAYQKhF3laiYWr|%2HrrBBj3w<_s2&KEBj^sUn*YqJ%U%7c8)U7)^{%KhprCMKij;9o#Il}RmI zRQ>d>gCcrnb(QL3O!<*rtJ-8IUu84|4~J1QzklT47y~}F>~^c8pLgUn`3_NLz0bDN z^~HWwv>JzHmqVm|rR1F~V;HPX6>G$pPdY3t1Dn?sMr#gYK;wv3)eksKK`1+6GCAM6 zgV7t%po&Pj5=saqbs82tk-18VNr?va?Yy3fF%y``s`hq-%(D&vz^yonbt7+^7M-%= z(PP7~p_n!%OED}zQOfK7o%E1bjEP_iLIkQ;QR(+^y0RqQkN0D*M2vK?`4_}9m%mFF zcwGL)1l zZ%6yrclTyjzDqJnsK}?BGMY+hK9BAKK{J3dh%?!Q#a{MxQ zpJw&7bYeZKqu39fOUWLz{p(rlDhCJ&c}9B+nYumeTYc+cbC$79QFJb6??%bvRQRFZ zLk&En6-d<6C5b2SI);SBI2O9zS4a{`mYVU}W+6PJS1PcDI^RT?pVoAQCWYoy zJ6u~Osh+ZYu;XXri|+=^+&+T{lu^e7Zi0SZxwEg7BH1cMsO(eBSTnbv?wc8Sm6L(Y zGn_g;mQMWn*w7N05(l-$-@a;Otd(!o`M$GH5A0lb(A@URWntteQcbkeC&~LaLbY(JQ>*S4Pg?a?`&s#x zX%0AJBQw86x(QUL9b|vdn0+_YcjybS3WRseBHG&N%|}(2-AngOr~LUc0KB|wy|z09 za-6dj+2!bCiGL2s{)&QnRH1}3TzJ&5d(qnzk`HLzyYAW(1 zC&7__Nucbf=19*W8cI~`j6{EQU$G!MWFOInRhE`YAGzj_pRs68Y_PCu@l4Z#Jn0!! zRIWEBS1iK;Sd^)oUvfXA=+wl=ooeGM zB^K3|amG>BghVxYfKtvG`veL7s3{>#DaRCP9#Krq>HgAwJ|hf~H38^kEofK(B%(}> zmw+CS4SA3Dey=9ZE2Z7jXksdRbm_FARW$J|_XLuI^JI~2j^mYwrbv7Ye&i(`(1WP+ zw`-!)d!qs-F}>aX{RmYc)%c3iIiURTy8rLLA976V$q*B*Qt0jTb)nZO2JW*8`x542c@}RrCxU+7@cp(EvY3;$N#DKc-Ti&@cb1$md>&l} zEl9LBsQUTO)-gVC@#Zbual@QhfRIlvN!|Zh0S~ooM$#jedByyg*IcIGM@q;mO~~OE zYy6mB&)|n_R+)z!>=CMvdASca(;6$SvtPfoqEk=2cfiHbo^O83r_+xeUr(A+Z-=A4 zDR;&h%5%QUyO4M@)bHu;wFiIe(lX5}d9S`pFgjp)(rGS+gq9pB6y1nC``nzO{C8Vw z4jVH@3$rSYWOUU>YE#^3XQGgynpMM0aXG!}ltjB6lj{IJcbYwQI_6mR4+W&SzPicWf>Q%WAwD$QeLHLk^@vnTT; zyJ&7L_&w&)cM`4$%Reu7=?1sM{;0fFAEA@jDt0yzb#jr@G`G;5GmhpOu^&CD9cAU6g?0j(8HkVP#w#xEVgHHplA49bfLQj{v;Om zG*{&g&q9sA(UBZW3&!H@qn~Dy(^3DWQ<`*wcts)O8;bfBkGzRVe_-z07+FYaF??GX zVgN_xJ?2diOJkIhM7nT`4Y872KkwTVRT!*svZZ7eMCE1}n3=KevOIYfwx@*WAjdz$ zfZD{S&tau7NR2@Kz^DmJXtkJS zL1qjB-Oiq(56n7`ehp-qKETpB#GZbBG;W6b1?D~?$?Qrj^Pe29k>8$6 zWkVY71b^(lGSxy|6=twFJq$(B48S8L_+lP{6dZXOrA#zlCTFB+0sBGBeB?CNY5&&qzJ;!W)H{iU?+!V)H(&Q%az|DarO(g#wxe$d zdVQs;5z9?#L!TgTVul|77Ik+vwy1ZnZmmD_o5#uk+xfCHI=oc$OX!&(s7Cypni9WP@t>KM_71PB#`Fb_eGyT#@7G z{tn&cAG=?_6xft$V!(R}n7KL62ruO33(ul&ZyWZbz+dJv7{M+g?!n9~j{a8pqqN7w z@H^i>2qKo0SKOfD$5}y4G&D)sG3jM7o3I?Tk{@A{?zX`v1)EWqaRVAS*(1LKOtzxk zrIVSrZn;f8h9~K;GnfWH5LVO%DA4uQ?sQGug$G1>ej|S~MH)q2cUNhB>oKVD-NeR9 zep(zqmCX1~!@EnRo$m@v9PF!qe4|j{Y+Jw756or3ol`7azkp_Zxl|pPZWb0vsH0PE z#CjmC-A%3}_^40eEs;DRUL)p~<~f!voV7^@?W20`jfU&F ztXfeO7-J0mNjLCP%ISwQ^^ZUt6V!M2^7wLTADo#;u*W_;QL=5*#(K4OYkbK3qf@V)}5>!X~$}5)ZRg}rF z+6!TQ_ROJ+YOrZWDK=;*y|PZZsN&7>?&H#HCpx5P(oPKG@pW?Bhc?dUU0XJM zy68OXBPp7E*>LeE1V{ycFEm!_! zv$7>${tP%Yb3)m+!x>hrK89n?98&f#VOJF!dSR3!(lE1 z*juoZC9Mnw$fWH%>rH8t$DphUO{zaqWK}aBAUYkp#?kx>x_hbOzB zqmXN{#>EKFioV;!Zo<7})(pqOfTr$}Jb#e#SbIzX(}$GxPL`=}hsW9;BI zUhN=VgwPmrnyMpNM?m_?ukpAHRjYL8Ymumw|!D3QG;4$1Dg)BA>F z=8O~lVWK|9L*@R&LH`1+PalDC-Z*}r!L*b65rg6x8h$3$C#0s5?% zPZaU9@RuoT_m~c)QI4s$He$SQnaHe74l6UYj)3B7b5hD5>4Dbl&aLAz999LY8J6!g>Oh z9-*OJTVaXSiGN7K^ObMMSSg5gr!|A7K7VCpU50n)r^aS_(HLF~9`>bNXd3?#wL$CO zc;Ss-C5?(?LDMZV9ajn2+l`u|Y@Cl8=hC2ra63hCJhPH8T|{V!iAiY7h46&)s#--g z)>X5Bg<+-TgGwnvjqqiwf zj?UG;RJ=4_VsX4&1%_McyVVaH*Z3kLN86F~w{69c(ZAwTm1%3WY_}3{@9@;T#>gqY zt%G=fc!C~-tHF7RBe9Ow;U2^-JIAm5f?}sVP@G|Y8T!F4X7;19|6g`viZ;_80e*^G z3YWb^s$VCh2zm)KR*~$Cq0HkXpc{aCOc9~fQ?VmB%%*9!FRFDdjL? zzn9XKNRIt%cY?Q)&ghA2&LcK17912+iMjMkxmGWt=GkjBFSzZTZ336mRYz9Hi5NLO zmHu*3?H(eX{5C+C7@!~vf(W=-y_h?jI2uwsvNj$!3Q2I$maNKetv0m<_;{r3?o6FQ z8quWij7UyYSlyVJEh(Zc2Lp;d@Ar2iCd%1t_nakxT=xa(ygziWn7cjmioil zzpS$7_GlN^{8_$3TKdIT<$0bVeGBvx#li`HHGBzCa7E3_#BPCn#X5~?nBB4?@5N{u zI-a#TrYPylL9!MPzLWr~p;Z;r*c>crzeXB?o^(^CXVbo~WSWw9cL*Jux>HQK@&m~x zH(5L27HO+vDtdeN3ZiPB#Yl@xuNRO%yJ=z4x`QX89yB_5U0hAh_VH2gxcC-;MZ#r& zGG^6;UMS`sw`9le%SUsa?T94q#Z3~s%$~&Z!fkWb7$x+ASu|m64rLp;0e~#6A{#YL zeX*VecazLvmk52Mh@x?1xJIZ)di)U1%*$OVxk!wJB7vT z7+(Tg=G|u~oWgI&fNuL?Gln(L=Ujg!z_8TE^J+_uJE7FDts<)K6YN?(2_{G-Zcen4&07* zpArqPS04U2*!o@l8ILz!l||~V5f&~sQgj(J!D$2BTb&PI+T+NqhhNTbE;S{^*XD0- zV{XnlswlznRCPkklSe7W{5+8U%8|9&*(>d5Yv}SOWKnF5Ce^~yte0bItlRSUwbgd4 z7opp{KBl5FHf#`puwfHUo@MF?yt71xAzcqA1hbP|$#F^Di-_0xTU@Zct@!=&?=wFqCBB_Bro;(Dej#UXJfX=}N+ZL# z5MBB!zxsw}qDo79apyG7YQRkmYkN=S!g@iensIyAp*cI2Ct?**#}>eVnwPu+wE}M} zAx%u8CQ@G8Cul9&pXxMtLGYN+K|(i0V1(*%HkW5)5`a@LaI>?@OAtZj+B;3qNYrL}?T=A_q zGEc77>d=*AWnR$9sLvu!{{7Qo0k0)hLS%4uvqPxTd}FH2^iohR3cM)0JivTSpFr~v zxqC^{tFx4q*A(8z86h}g9kNkCb`$~=+guKTNAzFU1WlgOz_OX&zCaT`619in9B1}e z^H#kniC?;yRsK0yqq#E8&)>Iy-z*PZyl}G`Xd;-8qx;e4b0<~N1`?j_d$t^?j@LEb zNk>Jm_SZjUNhY)%jm=ev9qiOuR6%(p_~s*Dx&OOpEAF zG+G>+lLN^;`GVLX)A2dF_McA(4FcBEZLq7$C!5bSpoL~*+wm-j=u>*h@GL3i;bPT~ zj4QfKXF4+X{D~Ku1aSwM`yu(4G^E65urGgYtyC3oXxX&;#YAr=V>s^|LPW|^_Lpkw zsiBGw4aws{8WFkKrPo!O{BcJWI{$ce=dM@>{)KmiGJ!>+d{E={G->v6FLK<~6#=v1 zLG2-o)5`{ci*>u30-~ypr?Z^$g(h~u~bspNB88W2YbSoC1#Q< zE?5|Xu@j;3X*E#IXG}Ut+&f^G^N1?~3A$co*Ml1dcNUP^!heyn z@D7syc){cWZc5=66}h*Cs!6H*5TH5$qPysHI;KHH)$7`IUA~((ywUeyiTd+U=Z+)Z zbJ)NYRpN1*Z7!j8n@upnrK1Ji+KwE2ZY0I*h(<_^pXke`$tp9aZ-5MV!yP5eGBkZO zX8J+2C?=OV*QF=Pkq8*U<>I-1nk@Ek8FMAC{5bUWyo9xc2Nyvhm$}#J6=i+L&=%vh z+1&87{1IVEDr2$w{r)SFnjRwZ41^n%Dw;Ap+1-!rRyh<)rnPN-uxHl81S<#&^Wf;U ztml*UWPeJfSKb6q%Pgnrjhrvdb`KZZjm`)pz)Bn>7|)jdT{}iAX_9}xNCBP{$q~D~ z`^=+zt$Qhi?^|cCh?~&dKo;~}3r`6gKFuVWn_z(}TCpP}ELO3c{|pUJYEZkMST|zP zHeG(}WrO4wP7d2GL?YANc&`f6`bNno@Fs6ta3ay00fB_bK8e1>?I~F2oDRiEEN6_8 z$FvGCrHw0-OH`KBo$<4sP?V!ckogu53Ei@Exeq}q36Xj{{G)G8m<}@R*C>}4p~67G zNMCh$DX(;RjBIfg{0*cs$9Jpty{@4B*v60mr@=XI`v00oU7m4ALmk z{vHyHz;r@9c~n%%llc-!$cjlRgV;#S08%N(P(b=ggTfhMAv_beOBev16dpWf2JE0` zopy7MWgD`j_IzMRK1f1+^fMz2MW&`eV3;)|M6Hd12~Xb3T@f)ziPJbh0Zvq+)L}#j z3CTw$YyT}0RmW7E1>l+hBx7Vk8MGC_i8Jc=qag*V!Z_3g^#SW^MV0*hAxSq3Vc^SH z@E2=2o=ok!2p2{|>k=w5ZjciJK97tX06$n(EGBTPxUhb@hzMgOHYi3j2DYD=H9;IFN+<&sX`#j1R%O5v zO1FoEg*Eq*C<-fwSdsn+_lk6cB6;9lI#yD{SO0d445Lmt4uS7-x9%ggXOv)`QJD@w!%P-O z1p-~3DWo~T0Bz~KNO6mUIh1L3uoV|L)-muUKhqgE4{s=W5twZzIa&HoZc=kF<+JIe zj6sTD!@nhph5?4gpJjPa+&a4 zJ|Gez3~9`M8Hg4qFs~#X5mD09XI5fY|J(M>6KHY5gV2iNC7k}_jX_qDX!orh<|Kk) zv^CcedfA;|d<+-)gB6vQ(Tm6l^8syaf}qw>7k#zbMICmW4hO9Q^^G<*vUTC@f6wRq z6Nt_n*p0nTUO6&W{{03NC6;yhV%>QYWmo;%Yeo?rW2%eX;<+dbT581`mE&2-ay8L4 z&;||>DWJ?avrCGxJNq=5McVkAO0sGuI{|bjSAktikG-L)qUcj7Gwmm*hheO_Nis9r zEBS=G5O0Kg+_%GI+&fC#&%tqe+?Psn9^IDCCdNz!(mS^J9io*cA)!PHK6m!yET~K? z2OAYm;lynOr zB%+;InSYcgY_ps^*9;{UY~k$KQ9Xi_?gBj=FVKM{EWBEj)T_-AmB$j6%IRf4h^jj? z77Z!2@@0>FWrFC171#G-=An8W8Q%yvGIrR~qsgH{&d&?S%9%;`xbS1dd931vI1xLv z&O6&^^MMG@ClE+zY>*})q@oPv#{tD}P$Ue4w37*NA)tI_EJh++YY14IBL3aU*Y+<$ zCxCTRP#75x3IFq3p}2$EPYk2Ehge z>pM!tlJhqGB`rqR3zEj=(3TtI!F>Uz6P8a~rEA{8-+!U;3u_mpuwU{fj5i~(Y1+Ir6I01)jHbOBz?)s zV6Xx*5ZJ?^YQ;cD0|LPr{S>_Yvg#3VZa>hQT5VsMRqIc@@EqLe?4V3vQM?|&20#>r zgF@K>hXK$_^u-9AL*^b{gdXC!f>R(OdceG{PL(;|@#fa$fY^K&)ytp*AssR*0M0_~ z*&Xm@`Nj(|c-?&UL`C&$f~`_dZv!em=m%v4t1f2`q0^b*;k6J}&b%1{w!mmyJb<&z zOdLZxd1-wbJ?aC883c1R;q)1alr2UYw~ReXbqrv69v(`?0bXnoWiUjZAw&8LWm=0h zs$@)*#f0)L08EWQFNYl<=1`Q%==bV%uqQA>=j-`DkcQ6Z%%L)k0@Z)xcPg{JYDMe+ zZ>Zx_KMETKe7XRjtp5g<%cH2SR)E?0Z`tk zX|6wJ^kQ33hxM^pM}%n}T+O^MAFDMmQ>`piTXZj6?)~G;(u4KGD(xq$!IH*j-jlUy1aa+|Ogu~HHM7q$Jl|t`JSthi(JT|T#!5?g&R&P}HSxLNk4acLn ztx)#dUserbK;udF3ixXc#CWJRipsNafXxEL>d-bC0s;!qll z00xVBdF+}p{<1m2jnUuGJmR9!c55maTq~ODP4;F-JVHIlPEp4lJl|Q4sX8xa{-U#(slG$U zm6xh{|D240)tf#EV)sMedVwr~alrZUxp+!qNbL@qdG}-Hn=sR`kh{4p4DaN%=F|D0x*r4(=9nZ{i<# zNA{oU;jc~U$$!`c0?lE2I%_iI7}}n=B8ZH``{K~pk?LqDsTgKx!@1WhgOTRsp~h5G z(Sdv4a?37K|IZRP@7BNLZWdXIn}(GjdaPnA)7(NBiP&D*;hd2F!f`)8~w{wlnvDZ;=iRYR+0J*XR-91508(FYiB^ z<(ekstXK6g4kvDuS3+*6NXXC&w9g4~0EoIbRI#$M+bgwGnruOJUvS-OT|dvcdaL7w z5K<9g73T(5Iq;>)2xNxR^E%2-C@KUvuZ?;ROQs=~?PrFSN}8;{Xh?Ro(<~TCZ2t@jYKbl9 z@NoC~_DzW`*fc6KC(EEMBc|0SDTB=RE~lNjVB`Tu$bOj&-o!wQ8g5H5K6YJ&afAvo z(Mn}V;i6Lug}Q3(=>iws|*?ce59(X67MNW_#$Hxl2V$HcsT(Xmt&?mM?^7Yt~DG51f1)taJ{O+J}s zZ#rzsjWep54<#O~g#;`HLKYy??3RUA9X?b|F)!(#RW!@?@4wvG7A1;tk@@k_Idq^rOv)ZjiqjMQ_#k)Ax}X;O%n_FU_Lw(jm`}uNNk8bx`FEzgg64oFfyy!_E$xM|J!& zEp6*xD7e5gdQ0Sm@T)sO&+xh~Go4C2jII-+smHv<3Q01b{^|un6iSpvwY*~^N&hXq zeLF5x3(i?^R&M&7ZiZ%{i`s+NS1=QVO(x%0;o80ygVZ`tA!mh(MeP0Fw2uT*!<&+l6+KVH|CRyIw#G z1`az$fXyp7wd+S^A22zuqKk)#*=t*DFCQx14&jo7lRo`6KGFbd?7_v#pYEA&WevOA zi1mZZ0Ev7eaC{7@15;)?G=?aYccCR3FbK$Go^{BNwJT*^z=v(^DB?UB@Jow`&~D41 zweb;45?fHh-g&uCgJ7*Y=m(|fy8PEyw(jc>o}x&*>=tNN509E+Q&htzZ{$q4%wBW3 zy@64UeC2BWmvA9|@bVxex1u6?;?)xOlGc`uP6SwaLOo=-31diBA!InT4y(mkq0^0d zh)AG{bR()m%&x)j8rzx{+ewDQfMwW?6s8T+Ha7O8;-_f5H**va_?<}K;O*Hr2^>_^ zQNL}C(aR-v9Ab_Gx4|)qjFt6keB$Ie-w5d7MOXzgVSwJi3Vb# zQsKu^8Q_*WBOh6Hpqrt_MUZGoOhTV z1g|N{r`o*EwqmmHgC-USgRa5$5e2vY85S4eM?(Z93Wpv!7@{LPjJkbsr&E|ch{-H( z#lwUFjD>ms!HB!Tc1r4-(%^#?z!&1#*G!a8KAUC#BI6MYH2Wdg3LT#~f+!6^h!5{! zgU1U2mHt`K7=-W{vlIW{wvU2gm>eSr#uO4Fe9$NnE%D;B8vp_wHa@G(n*t|TELH-E ziO`5@Y>K3TMDw{BrFy7?d~lY_ep?L`g|48co#+2@{_L{`2)Gj@>@LZgm!@EOi#m&8QsKu#UxM zQ48HRG8wQwFwP!W=cjrV$Hw$)!Bbd#j>!*o!Q&2JP z2U-?Y1eOC)SrS-7*Er6v8j6FRw1WWCjciOx9Qrd={!2Ylb$?kvln_L`(-8nacXZAurL#pFAll43csc zJDnx_=L3&^DcK`g&U2^fF}R(5g$?2-R>Y_N;$`cW>jGz{wG@H0?mj-wlsC^qn6PbE6D?r-QV}3AI|TA!ZxIKtu267Vx2D<48YYbB4V_R0$Drl z4;z$wO+h(TcWFf}DpUd??P@R>pzC{;tPLBmGRF%i<5Ty^J$M)xB)aBHTVflMg3fRb zMddhRaI^Opf=-~+x2Yi88G`DS35dfish}Tq$&{RlQpI*B$04fi(#uig6ePrk2Yi^r zb6Jo~lGjH9$O8oWW3gE3W1yr&#mgx$FiBw4AR&Vi>oNEtq2|R*??qxl5V)la&djL# zYaC;gmgdoDBJl?qxW$I)t6-oJs4>j<(vjFP(U;d-S5d~uTHspb&70p`c_$85Rn+coBqP_y$(ocf{mZRLPgwo&42WMp|XlRea}L>ths+QllL( zV%v#&x>aQK`@ERt1|hM2O%cgy8y8xlk`}$}@1d?IbSd~n8ak?OWOKxnQ_vqUA}F{m zZ^)Xa#dYtv(SYf%sn~VH*eK(r8jx_=^`oY+UhC&E?INc62k4KmWbR1zpL^`(1Di}+ z_0TVof8@5!NmDiarof09)eeY3KAr2MOpF3A5Ry*iPX(V#-vN9w0fuqEK!;r%4`z>i zQ0Sr3=KRW1Oq&6l$Jw-^cCqC9(ok%078oP3$70_a*S)H0VlvfS16HK1FhVihi4NDK zIK$2(JTQm3C}@7pBEYzc12gp#YneYo>9qcE4yzgh>Uk77HoCW;cI%v!73DV>nC!%W zq2phZ4p#6b!==asdcPN2TZ4BlPfpb^4i@_)S$+QnU_fu0{h;9&xklY1pAAq;#ciGJ^UyUw#pU1$kanJg;bFxfpeo zMid?VlQ_8g(ETxPDt8seJCmoZK+C9x|J9rzbcGbgY zuvJl2b}I2bpx0h(U3z6H2`%WmzW}G(E{bD&Z7tulg2#eher$IRZuSztCWn`rz$0ID zIG65I?_V(+2nbAN`iUkt^F+=UV>0i!3YmsX;cB;p8WLq}N4$&|*k5 z3xxplRD0E_oa}cNoVv|z#OWtESQt2&D23ztlO8F?_oKW#6;)JG^Byg}8cBtbi(C}B z%=zo#$MkmGuGIU_;1}UU`s{?>5z_Y*nI2~umhWvq5ip=jKmS?!F%Xl2ArfPVm8phx>yA-Cvv?U3yi#*Ff)P1l`H>cKOsnp*Hi(; zkd)kQOs?2yFyMIK3~H06vLw$!uAD0tG($I&Rj zR?sWIR#V2A@Eme#eXoNuST}z?UU{dRwhzqdAB0NEdB zJGN}tlsrWlO15NP=11C2naqvFH09|A)IKSUYQSyOCr{lNi?fX))Cd&LqAh^(8M zAwR)wClQJ%RG-1zi$o&?Q!6hBC5+1zrIxC~9fXBsiB2epmVA_t_Z(!hO*fEnf%moX zkGcx86kr3&QWK%DI7}tre!!eE(hR(GYl;tbs#TaK(Z9z5*K?i1u6g?1{u(AzL5&wfafe_%b zK32tBw{BpdbhRcET%{c?DERIxN_|oPEvhMza3AIXp`{a5Zg~-z{ z!po;X0O4w=N&#c31rtIKSn@k`M2m_Y-TI;sL0d#;Diz(;2xU8wtlA_{*%|#8u|wQ0 zs($C2#-SMRDq%-bE_QB(OzXl+2gPH-7xWvEKkc=0(?u$9xOQ9Lo*#%yN|j@xX9LUX zR{uOeiv3i%Dkx$UWs{Ax$Uf=}^PnmufiJH>dv>h`RUrYX*X&Wvs_|HXIgqqhFLHd= zQqck5DVVdMp%8Co)hp%$JL}p@QYf%!52(VQzc>U$tMrZAP`wOb)ZG3S*UM`O$_^Jm5o>i%E*chx78 z71fILn=xDYuzT4L6lo&m`eDS~;-V!FfmYVimRBJ#h!@B-P9qq)PAotHuc)-CmZ>1DLYX<)dIY4EiihflA2>?WjUT zXxOnNbP)|tUhQYu@H*V7TkPMj)2;Hty79%PP?2RBSE*cw(y6+JnP9NJCc#&RIeSVM1b95oM4-!n;R9y7nl%<^_u-Sw=3X z#c0Cco}S2mxmn^RzygBdKFXv6&jLl}$cXL)kSHZ6TOpwN0~q)i`Sr_(iqG$UrV=1C zA!TNU+@MDZSJHn;t;OJmK=2>Oz+R-$lS=N+9+|4c*SBk5jx+ob7Ps(FI;U@P|18Jv z`IV~^lPLdaA`L$YIC(TC*^kX;id@R&Fghr8s8OVt+iJI^1p3!?h2)lQ8&_E5>`C?` z=X|BPk&uo7mpFyLQGN3Kl)*>QPFn)X3vrd(#-fJOZm!(Ztm1yEj~7(j`QAPa`8#j@;751y?2{K0TD@T=$Sq1BP6^1l6Rw7>npG&K*bC@Iv#*3iRwSc{W@wd#4^ayV&ATmbp7O4YTpO+aT7p=D5MZhWS-3$xh~eo zcm9mMech0|%4f?`>Lv4Z1>-{Ks7k^mzCOEftf|QioR((mjz-< z3;@z?IlR=zuaC~woiK${_pVOB&WGOt@`0rfVc%EWb1AR^ZkCdWq+2W86(`gRo=ill zhlr63xxCswUWhF?(xdgV8FngRSLS9D!WfbPFpI-32+nBs4%Ee&mXN?|M`Smc!u7f4 zf3XK<+x}=fKdHFo;b^U7qC^i6G&xe2kDrY+L9gAg^i;a6qhlRNV0X@PiH`d zxHa`j_Wy!alKyfOj%P@ut0GU*mro@zReUavLB5Kw z&l-0yAvi$jM{Z1Ft}NPx{DT;$m1T0AN;oF;Mcq~thrWd2iLr)c)fdn_#T(#Eu^yW3-U`|nh8 zB@7OG4ngbbSTV3#uf9w=2Ie;~#&MO#g|tWeet!v@Qgz&3mkH@6)1N^hNqHv~>Twyk z$mC_G!JZ1gBB0u0gx!&d4X-U2y-qr&YJCXxk>UCbWj1wJ!%IT)! z5th;}h(O8P#nh8@5-H{2*9mTZPg${R#lbUuZudMN8SUdSqTFJS?#SuD94nT21!%kN zGhNceIvV-(itmM&BUvi+D)d3Eae_WP?wOQo?j2it5~-vg%<18%*g14S1>Ls3uaERr zFS{qrcJVNZFV%(ytk!7^(80Q+)FN?hAd*LPs~9q%i<8)SdcJX=ki%4mZk5|QpF_(G z`M(b#aqva^0$-N#yY*+x*|V$i6oa$UUD9>Mf{BqzF=Cv1Qx zHF@Q5{CFe5d5>~Yz!HXJTCfhEpowE&!M0avAIA#8Qt=4p%sV>+ znpr-*?beO`rNy?oFIjlPnLUhi-V>n!q{>`0B>PlmX)|~#P6nBSX{@d@PJ7^`=91bi zD+Qh$kSr6AWtMH8?vU*aopkz#SnhE#u%CvPeazgryvl*#!o=#Vv+7;;H{M8g7Ma>$ zU(?{urhlJVtf%26%K&0G%fDM?Qj(Nl8i0-EVM5c~HY?%@@IPg~)R(_hU!3#LHU>)>Uqgy@)G>d(Yrtemy(t=J2!KZdd&>0|+reBI%Bg-kCHI^= zq^(I$k;vm#^@ER<$h;2pL`h{IN8idq#3=t0O73+N$+w3SI~{dN%tl=mo}S9stw!)N zX;DPk+SrAaPnMrRgY7vlCL}&CvGvAtW>NXBM;YqTvxpsIg@Eqx8N1%}3US zmZ$L0(MX75p!mREh!I!j^1vSR4W(DbW<>{^>c|?E*G6lON;4wLX){;J9~LFwZZ5|T zlC~5xWQ)1Hl*%ko@Q0^5ilb&}l3%p~d&Te}=n8HuF0t+BO0&OxLv;OLf$Dm$=q5H> zn8r@VN2M$ph)71F22uHoi$!nPVKpaD#UD|HvVYXXo)Mp^n~9a(b5>I!am<%jOP}o* zvr;Q5tO|#se!7RIxSCO5<~62^&2`a_kR*+e7oHhJ{3f@sU}ThomODcYJ=27|I8LlD z+74z_7hTa|5)EyX_6y?s5)4#(pNlldaK#V4mIfdpcG9SdTP2q7Bmd%~T=z6Z3=K!W zp_o*lN^`?|>vr2m3g4wfhigSshZ%C8>Vl_l8_L)ihU?Ar%W`Zq+98T*6xQm`jURXF zWd(ECkNrLRx^Fffw;TO5ebvR&r)L^lz-A^M3WH{&r{v#5_gCmjMo;TklY!{C>(>RR z68CCpkLG_c!9b0JhbgDE0g_B0!*E0b?6IV-HAfjy!gpY;O^{o$o++gQ83s>3?7{rwN0uDG z@Zn)dk%q&lo=qkGN?&ZYD1K*+AK0mKjr*e?!8G<{2~K*pyh(<99@KlB4Ku+}jIOBIkk&>lig`|cMA4B>$?+ngf*=YpfJ36_Zn&z-4==Ou*33Ur%XK`i*a*1K@Z`&4FTI7$2^4^Waj-enic1)ptF8q zdGiZhD^`A`e2BzK_k&D>GA_Vz8f;$hUz^~sS+D(?zbaU*119BtKH4->1NR6sUVLY= zgk$ZT!mJ85-{Ob6!BbFBD4ar=wgoIGK^I!t@6aoK6Wuup%&2>zapem zRD#G#@vEofsezZe|O3V5%XTb(~vX2vEAb3`tERp82`t(lh06T~kuZ;gZiVe+EdX z?@(aNN7^W1s()C9?U7*<2V;3IJn)6ork{+%6M$U+`xv$#}#fiU=fG_tueZ)_` zvy_Z`C<$}-5wKG$`b`FJ^2G2gIHr??sS28{!K}XU*lN8ZedL(or|_JAvmKqAhNJJQ zLed3Ivt&1e(g6+I*7hUmux*jtSHA%dXu_~&DQ?TV?^0Us!+&(yNLIc^VoA|rLbt2i zz@_kxIXw!AIdvp^ug7p~{feZScOCYa9Ys6(2GdUdWtv84K0X~a7 zgM#uUe(g>2{#h~i7R7eZr5R9Qig=l z$-A=v=CDgU!~Ehr>tFOB>%^GAZiw(qXj)Od962AJ{yK=>So{06I?Lu~|GzHKy_56v zw3HJNgy}`>{HAM2+^hwwed z9C@F(mA&wQ3$58Z2$FJ>siVj~i=ipcLcm=I!5pe0l-tIa>i}GICVH?c##<*W{rMz(0BnTwaJsDLrQhaVALm$igRWg$O-! z{7C&Q_6n)N2lO3ZfL_#-5M+A{RU4v~j|Y3e$l1FqyT1>4KWe+gfo%2{X0fYL&fBj) zk%DgrqY~+{iUmpXu|k-#!>hDx1EJ7zV#w5wDz(*M!4C^laHIi@)4yVB>h@;A`T;-PueAmN0=ggsHK*iS*zUDJS(+tKcY!Mj7toG0+m@-D4%M1FyB> zb+TxdYv=Ew^~O{Op5$#BQ_>B{TRmuke7X^AKBT?e5u&DLp~kmOw{)Q3$e!YkCqqO^ z!vums#l#ajgkrm73UM>R#1ue^dH}07&9-yJ26ljTZwuk4ix23zj}fjWT{BHz>I|%S z;FaJoPc&EC7-8$~Htdd#X5$I_Rblj8OQL~=XE1q0_q;ka&TO~t##9d}M3KG?)=!}- zZGBdq4_0_YQE7T^L~a{qnr~>*oq?okn1%a_IyH-KdcsZq1&9?Qq%@5iYWr_PJ&zbR z-e?JN?H7ZyiV5&>`85`^HfnShO5)GJD5#N@By$Kymk?K^|$ zruVJ*lvjqoWOkrnqnLE2PcP+IW)$#^^CVQp=3Xo{7OvYNgF5)q_W*UmQwEV-|aoS0`kHz1t+iJgc@tCxc-tmi33Cyxgb{sb-eLzr@oLMHfWJG zq^H5hJ1g5_%`=eeXoy*IA+9NgUSQOc_%AZD;9M+IrMm{bq7R5CkxuN%Oe_1yn>o0M zrjj(CA984AL++NM+5vjD0K^}HNLI0wLs=eIvR=ls;q0bY0KQ{=Q@!WcxNrOzm&nNE z2L{QKi=;4~k*#P-89e~~(LyJtb?&LJ_yy}(Boz!$C7TtE)0*e>Wyf*&xcf#$ZO%rv zQDxNm(^~zYR&}9lWZ*6%Xo^rD$7mQqWy(Zu&{8m#5Gu`l=bLic2yX+yfR!@_Yp{Ob zeC3%~h_#Mk)6P`hA-wHc)EdarHGT+s$V#C01y<1_VbJ+;QU*tq zO`_MstCt_}rLH*42nWnEeKbOi88AV9m;#S7#tK4uMBvM^e42|RdfD^^GgJAEaWZ0& zXO&CI3wzO$WKq+sc=3NT{3KI`SC_weLgGX??2y0gy3^F9ZHr9-1#|tv#IJaoF304F zrNTs;u#OF0 zzhuENn;$rJDxQ`H=fH`UYZ4YLAuFqamrsAi2-Sio2_X?i8k5VQN$Rv|BR=H)s}UEW z*jK|!!8U}U#hywS5CS`29Kx(6EvZ=Q``@XckYQU#XDw^9x;%k>aug*Ly zanHwBbe_7&uqbv{qG-Yw>g(VJ^RK|~*btMbJ71P7WKVQ$9RB^S0Y{^>7;gVM!ZfQY zZ$(g>^VjD-$s3;kGlURY(WNe3#)}8!8C4q2Vz@aij*DoQ(5);Dy&mS*uF_GwrUbn7 zl^7qByFsfl-ahO-(r#-0F?~pkZy|qPLQ?fWf3?zf2aNs0zN#-OZzpE;-88Dj{0J&& z6MJHY|M4Qm5}S%ZI-du1tjjehfS75OE1fuCdCCii`j##;SOZKE#BQu+@k9<^by6)S zi^d^*HJ3a?S3g>qPzmkU4tWzn3XWgF2^5nDWm#=D27g0tI~GL#w~xAdZ2arb<2$3L zR|a_jfi~D(cAw7eBcXwTUtIR|9s&r8P}9c|9XS>ecDof$C*MQKz`KPNOA-5L&WAy* zdw_#z0pTQz#~YPwfuD)?`To>=h(Lu}_VK(EI8ZJyJyN94^u==o(5_6@=;u)0)ZZ(F+N*5PcV`|2^T%5ugx zEoZu?w2|WpCl`9-?xUy3$8YD)y~9VSTc-w} zPp%5ah&o7_$}y8mH##d^Arba-k0u$I7nHwG=ueD1Orz+89OHU<3aESFJ=g*1PM~=+ zlL`bGV$=Yo$thjSyPF_NVTT}eAcliHXs-EhSY`4!>yD+6+qJSxNW-yTXfxt=?xEEc zNR6Z`a$?H>2cSo{#Qt3#H^a=xqUdZMOj)cTfU8Z?Zd54xBlK7gXj!Ct1)EqPO>AT` zNdc0*60j2Mz#I76?b@PQv=9yuCuK=b1Eycassvdko<@ElkkU-hE8AF&*IBpkQZ1-U zI7^acm%53e)=Xg=Wf$hC@TVWCKBS(b+QBxb9&NBJIsEO@fAn95k~t>+MD>eBtb$gd z{Y4eSWCum2RDFy&3zj}6rlM+szlrF7jBf_#E>tQ$7uzr`Y~E@qXCR)`VjTN#C|FD#Vye#p z@_PKvHRhkyWL@NfZCcLcwa!=TN)we*K@9PTg{HdKEIuL>H1wixsjGFy-4~IeSU`}A zOv|OOPMwk5aVXAU;%)+RPn{GYr|sGN30FKKd9X~&NhP?vhOy4L$KCO|0J7RWF`^rp zw57)LbLcri5m$@cR7i`B`%>U%57&3e*eI;TL#`0mKTrws+G(XgeeLXr^HuX!Xi9C} zLpEEZOF!-A8uPyo=RqBSN%obiaIQU>)*pjZVbZ9Qrb~j|#dga;K3OE~ZqR*=P|PqM za`-$;DO&?yM>ug=6s&i6UYXl`aStZ3#IT@Ph!G8j=X`PMJUw1d9l(Ddjc)ik9VZdLxwIP!v==8NDduxl)Il}Pu9?^x z;KhtgY6@e+B)(wQ+21oEi_eGrryti^1^hB!JzI1g)Kj>7y)n4Kr`yCECybJuQo~dl zDgo*#@_3<>zAB%p!RLMI2Q@&Vw4|c*NWX^_Eur`Q9P;Dio*8d`S(Z>d zce3R&5C~LHPCqdbWpQG!rza|un4yBr!wZBzRlfLo;YLAct9ol;yc+(WN8M1Ln0bW<{D(ds00H-3*#Hy}7K#+Nrk{zJzMtIj{~-?kq>uM@cC&Z4wX*VX zXZf#&i`mD~Ays!XIY$~JP(|yX*oedqD07b%Ajhl#r2F(~nFTUzaO0@WO%cfJR!#D+ z%rbMR>mIFiLO8Zx{qERITH!JkU6=kY>T}#B#y@%9wGze1ACJ)IoM$LHBK% zW8A54c^dZn^Kdjqrk&9J`pKI?WQ|dHy1HYBzft<Yv+4q{sI(Nnf@RTodNORjY-YJhBMBusfNe4FB1; z=}6g}wD~;=9_WVk*X{`7O@?2Q+KtHvE*JZvpH6b==*h8n!e~5?(x^% z7DXDLN^(uO;16~LM6vrU61>K{h>J0+HdQL^!hI*tR<4c&)7&DVx~AG+(*(s$Th05$RV(U z9{C|%v29axAeP-u7W);0AQThv5tBXkE<}sBVCvne21<~P!^`#P`JqcU^fN%1rq0p` zhO)r>$2B|)9WXz_<%D5OC^DpCL3ApwTsHp}ou+jmR(NB35DK25=ysK%tf!xV9YHx)xXmaFxQmz+sIGvbY@GVDMavk2CRJj}wZL3HEG2y-8% zXB?UEw^%3awC+-4MF5}SQSwydGzFa+_h+@`WF-~gm6SF`5W$D*>PJ|EU7fp zj~J8(8Y;vle5-}HA?f+HtIG^2>y32XGi?y1=B42+!S@Ai`WUCQY1gSg$dZ%_1q+mp z@KI5l;*x_7!R(GFULy|PI70HyB=q7MLqroNZQS`F7nL`drk7zt>$?u?<+f*D*c5ID zKI$G9a!NDqe8oFV&uzI+VJAx4{3mXlxbkJKp9M8zj%5ic4h+$af#f~Q2W56sUfp^U zLx2g}CJMHEgKJX{0Ykr5rcB5tWLy4wcgw-~fVCn##Dp*;VABLM=rmg)l*TT1X6*j- z_<4Tq;?G1Q6F=UVQjvq_KG8ARH_!4FUreF~tgqL*H!J%m8baLhl6+29~+1CO0K zaqrD|3Iim-%%CEPSPiBZLw9@nbT73W40-nN)yD^jct-<+5s^m?4|3Rnmedpk%M3bx zQzR93t8+K5Fv;8w$dV7EH2GCdB(@u^!es^`V{}Tf*3yI-x9zoUX{=q}3XD6?9feOy zpH`;$4WBE$T~`(r$%udnVSI<3GzoUoa}&Rt=eSJJB#tZUOR=nPCe+_0ex@JOj9y%K z9L=z~ex-Ll^>kig-v}_?pE>G+|DL|S*KgOcej{m-}2x!Sz zBo-d$lgoJ$QdEDmcg~O&Cc26j5=rl6bT!-7=Tq-n>>r9V~zd`K7u?vHc zaCN;j=uo=HnwY#O9=moV^C+`JGF6tZbpa6&>YEvEhfxy4iG-lYhC45|&AZy+=e)~Q z`}3KcS}k345?;6;1Kv3qq&FOlhBEoxG) zJIIHJ5{Y5r^?nVR*(b7!-j0EPTN~zDlu23JgEaa*$eDoEB%NIJ$%!S5B&8SUg`2VW z*HnVYq37$J%+1r#c{_zn*5(xsc~!ERvZliBDmmxXC+HFGjBU5 z8+VrfKH>P!taM>y;QV`(AdqGLL-e`^6>#?zlM=oWlX-^^muCHc#HWYd4+= z=TqD9&+c0p+fD>%#Z4u}6V4l9TB{w{lk(3l-t9(y%A^`K0$gsU%w4ZG~3B?n4HxiSej%1BE}3PJKa{@@+b5LFs(KX_QoE*Z^tsNdT$BwO}%kfW!mI! z8`bTfi>K}%cb$tH%*b?Jp6cV)EKK87dF0Lg`yNosxw$--9VDpFDXC6&_v~I_^5C`*Zo|OIn$JlFo;|)>MvFvsf!_HZ9>#i9I+Kx5|J9 z-H{0^Qs-4UZPz)5WX{Un#Y49ipl1y}?YUkE1Mat+oKD=KQpSTeptjz~ts-e5FqH1C47yV*nUUKWkBHz{oBUvKg61iwf=3YUvr7+K`KJF(5FWj<+6bD(zj1^f2?*<=|L92*T9YlS&l z?L2cv&so=5Q4_$~@{69EDZ^*%4$S2^wnlpb%re($jYghUemOE1CE zUfd)8-PypGyTq4h5A%Tl7sUWFYSXrI{L?5n~1*IpK{}+ z@SL^TU3|*-1p$3gE8d-3$%t*?MSILEr0zF}6h7JdQ#Eh}nxl{r(!yJEInqH1CH4uQ z;ZoIW7-=EwSF2(q0%Z0d17lnNLSn8oB1e+oJ%ZCtZ3>^xN#WnwcmiErW+*y0Q zg3*mp5qip+c_302EUo71-V#J#o$U8)P(N!CA)M!<83A5flbrs14iPuRa%>;RUxkV& z1b|C$SU!P{q?z%IY@^MniY0aWw>&M+w+DtPWVNrXTZmdgt{ThG&LpWBkr|R`JP_+4 z`mX=NlXLe>u4{I;s!XnJl8&CJNbYB)SNpX-TK)g@MsZUKN$7~q)%}#4ZD(aNpMI1* zHdOB*aAs@{*-i1mP1V!a=Fvo0nIMqUp1*{Gl^xiKzrS^I;eZ|aAQD7L6|6JLt36sO z0i-6qC~4WWHC9?-BQZq)fF7Qt@8N_PTNK-t-;$W_4D6sDi-(O?2uN@A{rTVX42+0v zj~u`6MI8Ei4V`<#5y1!Tvc^4div|@QqhUZ0&D%n;ln?bGAOvaCj;b($*0QDi{an z1{UF{kr0%jLZ0m*#O{v%pdbaT4vww710>0?0!mLI%WI5S>y0fmcRN~1p0Q9MP`^Z6 z=dMRXg{JhI{)01}f4QCM^1myKf6aoL;tFVcVPE`C8TH!5K%_b|DlFVMq59QdII-b4 zt8g<^oaq6h4!ldPC|ibh=I<0U6PKxD?fPldG1l2#xM!~cxLa=NwO_I%a4!(HoHWLi`d_d2?d!Ew{Ln$QUo1( zCWC81+IuTRcn#K9MQk~&&R#X6IbxaBb}7lUp8j#AOrr2_lDX(K^wW>+Kiy#Tb=DgX z4-B&fcie6eOQ~S#Y&SdR`L}0FS%SXlRcn-A^%B{_y{j0DQCLAttDZwxn-b0TisJXI z1cMei9!u{lX3y$uu7$^tTl{C(jq1N_gG83~C<_XixY9433iuUZ%q#9oBQk(2L{`ZA zi)RX$BqeCJ_oZ+m<J(|0>#8 z`mO8Zw}FlSP}cu*4D(FXR5KcigH*L_`U8iCQVZ*}Oclm9^%`&3aDcvpfajUEvYfKI zy?v=)?}mFZ{aWJ|9v>z(sibl@XCz&+v@Zze(Bi`LYevAN9um%S#zr0o_Vl`H9<5~e z_nQ5fgEnQKU&zCBo#X(hNK}PrUOi5PN(96(7FzDxBn4gZgz}kEJA(--lgh1u?7bZG ze*}qeL*4mc%(#tKGVi)h?82Q}-`pb_wXhc8Fs!|cVVhbBtv`^zBbb2j3fWhJHSC2u zr^%@=48w<^w#qi`)?Qoo3!(6lc(AT1XNZgRplIz1N}LO!BD76V#w6hH@YK}6^Ot>; zZpKA#mdmM$gP*B?hY!C9tFRaGs$|fqpQ6P@7V$>7sd$}f%a(OG$PZ2@oYilvv=Ew@ zh3&5m^gkK-@2+WBxL_KJMe(x<&E*>_GM5RoWV8SK>ls!aw_c(7(kc(mIeatDsgs?w zm9UCN<1>K-fld_VUdyFUnZgcSVee1A_#aAk4du=`S!GmXAA6amVf=&lW#UOG*S7$+ zM|!|M`jzT1d}~u^>^R!wOECUtLxh7U4?J;apt~#A#5mNP^KEQD^5Cxhx?MQw%VQT( z;$0!f;%59OHR&FO{zRiclfVKu4beX(gUFN+=D;OWDFAi&lHNc-WeoWUL1=GSL#=yG zPHf}-$NbYw1~{Fnh)#m>yWMhzQe%|)?pC|5RQac_8kpUT1!m{6NIUb-$~t*;`@_E5 zv6vxJ$)S`b6D>$;d8|}Q+CXMRhOk0R$Dk{oodV9R-Z263QPPM0PG$Rl_XVaaPI(Pkw9jMTBEFT5Akp&ddb@{2=dVhkc`eaFE63(Vf$ z#jd$Hdd8TBFJ2hCDC$Qbsxyn&+ov;MEF!LM?%c5s&_c7izuLjG#5JSnv!XzW>ST!( zsSO_o4T_6dP_U~!1zwM}U}Q<@(mUuOAS-p+e*EV$JYilx)RY!iuJOfFQ}T7JAKsIM zWp71vtEHWbd&oKPv4k6B5^OM39oCLKs4Kpn{l!A(gPOiH*GsNV^(PYNo+V=+^<23u zkE(YdXBOo);FQ+p*-=>qLvd*_DqvHAj^Srq4G|3y@MoMC>IrkQc1aH9_7dkE;-X>^ z9ik-QbhLdY<2oJep`cv)73Y*&a6JO-A+Y^Oij@Oe-avB4b$hKMF`Z@lr zNou=6-<|u#8Z~CG8CzoP002{J^-92cr8Q1l-_Th4zOikBieV+((mC{x)@^u z4Aw1ogBq>%X~%AB<}pI}CS*IyaQvPzB=^T4@X4Z1=Q}ltd9IVoKVReXck)XhH}M2k~} z@2!V+Tf1TN_!q~2Ek*J?h@SN#t=y>gAG|*Q&FH#1@V%0})VquevZ{R3}MO;{O79zfrQ;B$Wyp4D{8@{rF@-`X4dP{}Xr8S{IG+F+f1b zZvSuG`Tt!F<@rzCIUQ(}K*iH|_zLw(7UrjWA*`rV+N-s>3|*=|skm!AR4>%EMkirZ zdbQ%2rm3Uev3Ym?1VivvmO1@+F$f*IjN?lgB8ZYK#xAn+@xD2AxBIkx+ATs#>IC-o z<_X>2yLoOF3HaLnGRBhAH{%Rr*f)4R);hvrRT#L|r8&AsjI`$wxT zku6!|rys;bV=DQN30-H;&yS4)h9yahSHAvYFLNf3bv9O)ho7aiQ;+wXo9Dks6Ikk4 zZ(KjR``##GcTkK;|7^}h{L+4@Yy`qB7JkYsL5CBvK5n-Q6C#n-i~ zJ-ihC4=lP!9vr#<)6gTV@Z|C3V%RfX29em-nUBv#OlM8&T!M3B9y*UVPaD~e$fX!$ z%jRzL>%B`8=xTG%M^-27^rPihppd}_X>K2J-^!2o#lA~)fo44YzxiXor{)qikGIhe zE(k8a!2??^#(v-Mu+IxOG;Q{mfyf!In_rs){d=q9=RW*DJYH^HntXI(|CC8+hO@kT zylq@O=Jy%ynms!OBPTc?Pu)l%SIj4j*#Pi9NV+e8fCZ>c=l!QDP639U8F1Igr#EzW zi2fywLiH!0i+L@%naz^u*@~#CmsZ*Vs!vBLR!qMLV8I>ytBSTPrUY?GH!;|Rn+=_T z{X4DFZY3+*BCR+xKSM~NXlDPPCvBKz0PS^^A}Ayq(8Ngu`;4m%KDBkyaSFy%L++$IX-X(*qm~*bwG|c3 zr}+0S!A9KI_x?Wgx+w#fhQ)~`q*Y!6C5I!s5^RYrdnWo5COMr(qPdm%w}{L3XCLsQ6OamH)hGR3kN}n(B-H8ge^@Vf&+seYvD?vEjIW} zb*bJ~c(GL<{&0y@sLSLsbU~`dxIgd8hU~@aVfY2k-8=ofQ;#; zjI$u~#$X(GFR(DEb1qv(>Qv^9AMKH%^5g3@W2)V>7Ja4o0zbepb=*Z)VPXEhhBmQT zUEOqz<1jbD!aj)lRs<#$(O3{U36 zj%!cDiUz5N4P{HYH%EDWD&#q)=AFA-@mJ$a@;aoB^E#wSynTr*u4p)vgr3>Vsy3bw zT;65k2(mMiSC?NH&)e>vZA?yV;DE+$sxY_#qpF3TGt68GF6kH1u2i>}Nxj+jm~(s7 ztYRHx4A>V%D3wml%P(2>B8(EscREyd!B3Q`7QXc}^paJ^7RIXRxSlP$j1&|Kxx5sB zKZQ$Gs?+lD`J{NAQ|YZLtyO~w9=;S3LaW;;O%+XSU46eRtZ2gST8eySXSnM`j36+o zZ^&9YfMC8b?{5-FoLd2lk)+Cdqm`<2HUq8HvVWqe7Rx(j*IO-EGXE`|B0KcZKAww~ zRTn#Rk~tVWkEDr!U^6Ruu~4Xx*O^SNn9G(z`$kaqr8MJqHSC{0uGC9$SOeWR_Aw7X z57GQ#kFb0g&oDBB##0L+fj4%=<)yTWy~TUjfBGviKj94mPpNQN-lSKq``>kn_z^5M zo)@Tse@!q>-tW$x_EpcY_#Lt^Y07%O~bN{yFwnu4BcS0o?|b5 zc8(Ymu{*FBeg&%bWPTk%SaE%G$n z80xKCDY99n3AST0I^Trvc^T|pU??5qkNzo-F~DmA6NgHguV_`MoNs^8&zxQ$Wf+b! zt`e<~&0yqqRyGZ8mf8~FqH0c_`QJ_{K(na!bf$%edBRk}tjA%%F<21$l}@8-)`jyJ zhExSJI2v|r)qCy1FjNggrMbQ4NhTxxKXkoiSe!wVHk#m0(BSUw!3hq75AN>n4#9@t zFu1$BI|=UY5ZpCEL(ntHzPo$mJAW9i=jpEQ>9V_fs;WV3aU+oGfo$O;COhgL>X2U` z%-&UCkK_XxI@Em3SL$|gYEEwtq}tufk{k-zWz#z(sqcV!g=eF;k6zj%MO(6wL$8>% zW@_(sG+IsWALG~Fep${hJ+ zc>BtfG3$tKvE}^m3;(!$QaG@28p0>q*WS}S{`m#XP8&yuKEe7dQW6a-XqQH7$=12)eP|iE=UBoSbmZ3HDktbyuj*NCEy3= zs~OT??)q_)&Al;P*Bwx#D>XnG#dGRygaapVPf`OTQM^iH#ErIaDQ$WDTn` z^+jsj#WsuK&q_r^n-E84%xH`kn9$IuSx)1aU+Bu^2Q#EM&T(K@CyijYm?Y@Sg*Die z|1Uq;vDTv;n7h01uAcP6-P_)WnQRGE-zZuDq}+*@t<(5~E1M>wxooNBa#!e+Jf)5u z)vVK;*R0Z=*BDlbh$Vh+SC)EEj_FnR(hNEd@2aO!L@F2qQmD}{@%C~vyfasmIg*8W zbU7#ZI#nx<_cIcH{kjD3b>Uej)w}WO=*Rwgc32RJ`N&`*X}h>RMY@fjJhkWg87JiY zeU9V`NRx77=&OABb9=$mdv3U*=vJm{rC;)`PQ!@u93DiLOz+qmqGY#nxQ+}Kl2K0c z)N}yB3@!W040l9;W;#i0xH99wlq(HQsaxgLZ?EMqUmLA5zfoxEaxjceLiCq?gj^Z7 zw_*>Z@}U@E!Dm@Crryj1cskh7f^jgg^f?3TOO})XjL-1L;yOm){Fx-A<{bl^w(Nq= z$*Mm;ZL4KB)o9Fn{MVu@y1*no-DhKp0-`^@9x5v0rz@{g?laBQ(VrqF+bE`sRuJak zgv=+p`l|uPb+x4xZ5H?!VpfCO@{ywFYa(am^QnXfOPjeG3<=c%{M}9IlM(WYW7#82 z&-UoXZJb=I*dV6Ka1m)WJH%u*!G;{-4E&PQEHUoVHii6Bl4o^$MRY%!$~1PW6e{FLJ84i(4gRMe1e>{3wl2nbJgVuVdquFtcd9@4XXwXnno9?PPT4&aofNQ+wFW|}r zAjkzGd|5lHDc?_anV<}PrjWy@QIxSBZMCsu6dm1fEI~>J&?}+>NSB0!a!CRyIGzD1 zIq;QCX#|r?Os*^Dr3(t&-9hs@+H(B_$R$}VOi@7jaSTR@Ho67%m9EeK+Ob2?zNCtY!E#1##DK5@nah>Sy^a4;G{Y*pWr9kkJE;8+#rnc- z#A>=n$vkCe^zNh)BDHEUl|hQ98M*u_aaL-M76=XuZPCFUjJ+>wy{$B7REtNJik+b` zaEOgK=!~5SCFb9%w;ZnDO2%Jw4=pi1!{XqQ-`%yk|r4;yW!D!=dk2Y))gxKrOCUk)p$h|5yOFZvp zB=67QI%et!xj^P$7Q*72h+X|XM;>il*7 zYfrZ&M@JfE1C3SIKPQ@S7&NQA@r@Wt*@lY_sTEIEeAWm;Ykb$|S43ou)ikF{j4d`R znkFW^AztCg4rwu=@qf8!FvW9`fK_U0LND*#Dpb#u-pF3UXsKE<*FKkFtT0XxLm7O^U&~e{3FA> zEj_d3JmFKionPE$tn!9)w+hPzq-+GP36VQ6(fX%bD-Hu!Tc~I3+}Y?OnqL;ZR7$GX z%6vU&2Q-&|978yo4>;tyyl(il-hh1>FX!D4`dGt=%GobfY;Lil#i%{3HHesX#AW3U z%c)3sU}T)t0!ZQ0Pot#N;f3qkwTz4=~{$X5dLCp z{u-@*<>D2yRmM;}K6~mSF;pRQx;R)p(fxeX)-6$Aw2U0=K%0GcJ)jQv7kR>HH%`b} z9vQ?t;0=WA%-ragvVIz??%u0W!@ZBR7v_lQ;!K&%d^vZTN`nhUQh@g8;r|VP05(Qz zHaP7Z`>uv$syg1l)rOK3~vl1c$kAjDlNAqr7MBvr% z;|c7Rn4n?+O)3-uUe6a{|G{SpCePmV9*RU`c553^=oWMY?%x|4xiL0Vlm7aGpF@n2 znSDfY&A_Gzw6Vod5?x$L+1u-5B23vqO)|pcJ8Pwx}=gU zDda*n=>Nihi08T3^CqjbY+kOYA^Z=CDd4;@Eskedp>Pr09qHQN;;$T^6^?7wxeX*X zMOOqkSx#WXw$T$KDwM|yR!$H%gV$U;Y{CG3`f<;z^->3)73T%CaXp^h{da!WCZU`G zQn)AftCLgGyWFeIPRz9P`N8I>5cV;1D(X^?%ca!+7^P{W%*QI}3KJR!k8+rHfX&S# zr8GCp`!q2)CS+5RZG4Oai-`gns-pk#Ep(KlTfe|jYIu~xT~PmzByX}5*xZr62XnJK zbgd}Igr^*PX!N+q{!`%%Ps*pNG7q#ay^ebp-zS?GmoqcBx#}ma`Mx!Rxs z3~4fprP-h{6~z^7Ui(~$B45nL)6C>rh8jzYS5$WAw|p`l<6^5?sYc=XI>R~b@0~Q- zFkSc&s<`evELSu2pRj~WYr|}YUXxa@)kT`j7&;U|L?ypJ&ke8B9k%G+Lb;?^IOH`_ zOY71^IYaE~){6Z`t0sv!T(o={BLcI?>sE8X?)TW=J%X26R6_VX`RS-Bz1mEnLSF-r z!gX18kYXReP_50FgaO%f(=FwfA=)=HMHb84?!EumAPS`Q z{5;RYXYMMa$6rdOuudD*U|{B49n%?|qX&z*7s(J@W{+@cG*F&f6I2hPqn|h!y2~)-62EMu_e92g39ptIp+Sxb;i`$Bct71aR7@ zs||DjrsDFKT^DjrU0RmzWV3R%(KfX_Gd+%xiYW-Xymd|o{@pD@{d3l;eo`pnQH^B- zDrQQLfc)K(Jb)R;Xr!bEQU#>8L&g6>c_!Gwbnj_~W-;oV;5pG0V#DLM+jCR521R0P zWPz2_5j1c~fZtINF5zZbydyY6@kGY;!JJ|k@8WoO8 z2y{Qrkw2d6v3%pe2mal;n02~|x8(E8ZwBi&dXNtK&?S%wKkJW6(X zKrH1*VUeyJ$57l@Vfam7@+A)BB;5mX2}*e|x#>VM+PUr%>;FP9*=qO+V--x+{|jQ8 zq(4Sy8&kY(bX5p$My8d26CBKLDLAz@;QWlE>*8fDtX%9$c<= z1Jv-o(*#<;7l7OKU^|Rx;)BA!lX%59@S+=Zyq0>A=>`=2L9})rE>o)vsYJnENu)~^ zT5_Xc?k9Md_#CwJofa>pfwzD2bVrF@zC{oewawlb%=3n@Bz;P0l-Z(>=A#Nahr4zBaXh>N@ z=(u)Q=%D$x&aLgtRE{H$O(A3dZZ!ufMzzN*iNcv?_o@foN(85qS>lM|2?d;{^A7Il zPxy2LEmGyeur$R?Enk=~=}bK|VYXh{DU6XbO>YNT6vpj#9jgGjGM`TJfO~$A@hT%` z!l=;WDE)KQPTq-n5mmIvF=M<3$sQWoJZ@`+Xo>qUzG zz@{ckQXv+tR6fZwPr_;f%rCfwXg)<+)15R!!`F6n~gf zNexgNVA2z;;eVDWF#NT2|; zxx$Kn=eV&C8B2h{3XuG-cDB&o8)+Y{n zRkz;<)n4%OY~ujEkE!@{PUR}NslY>*(FQaYPUUT2fgVe-U9dCvKKS~iN6!WAQoa+& zBcV~w5LH8h)C-`K_$r$(aMLgm&4y6+8N?u$&b>$JSH$G;GuUg``WwTZ?lp&Y?0Vtt zbOBqlYC=|TUB48e(&Y>CO5<-+wVker0m5btx6I7Ca9>rmOf@O1X(Oan_7M8Cqm@h( z+r55Xhv*qzxLSyqst9@LZ($cmi@KIyX7q+K|J(!xhn?U@i)M4CairvMFO8K8gwUJA zG|peMB}gG~c>c!xVfCg-d8dylg}sLegnkJwKW-5*uF6C50`l5i6GZJkTg# zns|l+(kz-eON#B_j_&%{lixIDQ%?P{c1s3r}a2s{+>Hp}Mh@Mc@A_|#qm z?NZ%fj6s0%5pxh-%`3In=9J?&DfPsBJE65aNQWgvoO%3Lp)4b=0SMl~)rd^9uL=&f z9f+&%62%&9t5K%xTXFDL0AhhBOi3`L2L<&QHE`_5>tq8O z1*b9@L`EoznG~taNBtv`(wi0b7XkRGY;=@B^*82CZF7~27)8*WcnDE*-mnKF=AT{6tE%iam8%y47Gaozbli5fj zkJJ61xB>+iFX#8RpG5&n z2X+K}rVKCBK(%j73({)F8cJlw*Zp)0n|aSnF#0+*q!6o9uEGGd3^?SVcTW0r2L22*kC-RP^PP<@eg3W^u$g*~3h!!YzZiG(bc{1uTR1e2!HTN-9vz;sGW( zNa@yrK1x+~)n_X&3BO1DU?xzT10;t?IPWP@yM(NF`2BN9C@Kb{h7m)4igDXSefY>k zP>|9=ZyRhr5KqWl!uB^6_Pv<{!3GNUR`dDd=Q>)|rZ%B5{>Qb%bihK+!?CfFuh`KT zs`D=47ypZ^ERZHDInR$1L%-XaS|Ps3;WN2CprNk|Q`CCl)ar81`HZtKcIMpXF3H7G zxArXV^G;oxkWSEjGp%N|vu{b@ek$v%$iPwTW6Iyp<-o@^xm)xr_N<)y2WWnk*8xk* z|9Y~M-gA%nBJSr~T-z=2_JI`R#1_(_&URHGCu}PD3g8!C;P~fngM$3O4e|!s9p7;H zmrrdElynSa^efvjz(aPXYd{j=XAv|ql(zAh)Ex7~M zpUfBuY)guHzI^jUgW*)mL<7mx2#Ik^irJEMnI;Vy%sn+4%!}lR2?xrKa+Y}u55n0P zEN`9@e~R>xbDjd)1WtR4R*Y^e@_(-sBGP#p*T3d4Pc`rrS(%S2@6FL5lctLEr_IFO`Wd8=4ej4-`K3qxl4x4awC3!L zvHJGuUpr!uH;?siZmhp=#xq*HeP0{a^(!vSpLV(*j^ax9%zt~WlA?z!U;KH#^YZa& z)1Dk++&_bnT=L`O4R}U3a&ia>%q8^wr1@G2d$DJDkd(Pv3 z?oBVh{2U%fZf71A&QN06^x>|o&2Ued^R{jv+58s3_pNpyTPP=P^0_Bs zR8Fg6<_>bOtY=-I`3oo1_c2RU0$%et6FPxWRquUw0%PK=kUtlH7f><$_pQ*tuQ52y z;n#rH*c+<=_Yf`HN;gz#P^*sGY7#O(qz&%s5Hq1SO>6Xn_ynRY) z!UR%h)9z)52c3Q)e+IGwPU+_zkIRwdK|CBBPo{^Z5@fBYB})*a*Nw-(8WDB;r?jV~ zUjrg-L#l@u%s(DtY}2MFmvP0I0VFwOAp|)D(PcZA^i6Y|S|WqH=`!H)2 zK}QVZl2rQg=g#{H{t`N(Z@BOYXJex{W_L@6x`I7@qxN`2%9gBtfq-|s#rC^-#zcN_ zmtrMZ{{jOA@I_~aml2y5xaRh@qXA7-w?q79vC4ndET7i*7EnYxNbwNLo8 zrt~RSXXnS}!W%R96gaq@<9#pSE#M^Hic-3;Atr!# zTQvjirlRi93%gjmozp$Iw0CW8ZT6g#Ze47Wv>uIj?m=Q_raLcAu8`qU#!nuey973J z!nQX8vkc#QaBSn@&0d;9<44|F{Jmdt4=!(BXGn59wn#2Rx3_-BDLpBnKYV+*32#k} z>r8}^r!w(wI~Ng-w%mQ3uI(I#1pf4IAzfKEi-_dR>Z9kf8j?lL1{qKZb68hcNS_%N z*xdZACeVoyE;XyL_+9Z$Y!S3K>$!xw2Y&dGP@cK*=MBl7khQ1P2DZW?F89_g?lLbh ztRkkTwQ(}MEJJ8&o@Cvy!bY&{mQ*@^XhD%c9DU%pLb5c4+8@3b#>wtge+~m2Btc79 z6w=IDJ`2jbB3kY>6L$skDCmYrN$=0UQYjlXjv>K}QMD9Oen-_=X zCZ7#ouHF6$oS4N1+%qZoek~DGDW=YTpSJe3I9SuVirG%4Dpqc}TFCmXZ5XB1|A&aF z!W!UgEe+I-DCv`3~a7bE|z z^pvU}x=X#`Zf+My`hmh|5Ue5kh4P^LFLQY$-~K? z2UH1C6V+$1!z5dWN9%Lz#!nsY!(`zwJFY_Fq)T_Uc&p9`&2ejauKvD`ITk7h-e@P~ z8NRf7tYTnS%&5`%=Kc8V&E-{`^uR8QLk^lsbj60xO4LR!tFNasU8;uG$vPsp!+KP5 zR?Z+t$(~RQh&iM_^CVozWkkub^kT>52Pxd!%f&A*KX3m{5eL@J(q54OYxv>*8`3vQ z14bXSfwY*Ge6PbPqum%8&s$rROHh>hJpQSZrXGqoJk5||6UIq^7Igjk2mRX%w`Y&y zaG)cP&#bYO;D!y`Jy|t|Mi^T4>&>_e_XyWe7Rf4tU&KWY-v_sQ}NF|m8d zuUC^!do7t1vp+AhaMp!l$gVG%4^{obT9WZkaT7_-AI-rC;LTZ3#!+D!)|!va<`t(p zzQWJNLV>n{&R(0%-%&h!4y3Aejo~3Yi2u}5ijVTWo`KTWc{j}At80ZH+H&EW5>!d& zl<4=b?<)B}mdJIy*MY~NVAy~ECrXHXMt(p39a>Moi%spQ$VIN_dTHv*&b^<{!0YyW zfbWxOGv8LtTfNTf^LVY>i{I0HiXuYmbf;l%Y@8!&Xa9j8BWT+(4Gyi-aPls)_D!d& z^U2*SoG|F>n`f<3?ryQW4R$8o7@|kn@szo$vu}Ka0~t#;HH%^i3gUR`i(?Yb0ASC~ zW;Q&7+nt-CYf#2XaytLVWsZnZ;N72&93h@W*NdO2d&Bb@(Vg`!{5HR;7nio;^$g%d zy7Ncj*8Au4gp4Yok1AIVh@YDTO#3!TNIapvNdP5|?j2Huee2Vmfm=Cs8!jY*lvn-l zPdjH#Al5B&(sHlUgoAMYNKWZ#+HHua+k>xX4kzRrADfLS38kmO_{$a!gbI^ zDdkk*;3{*ZH1(smr?>CmDp$q*&1>#T23+rvbSQ;Kobm7ZSGS&Lge;;wX9-k_xKg2J zyutJSNzSw{eP>gVl%ADlNdqz8UanrM6GB*2l#7Gb0ps%yPwU#* zRE6dSE#a*fjUQ_FudY9oj*}{VL$wOY!pum$_>|WH`U z3V+*<$9xNdTiQGO<5f2_^vfsU6Wvi-;PKDV4`riyS;pVo;G!P%=YK-+d%=BNE1Z2t zx&RAB>>*5)M9H)^)W#o7`$#-LMdcS$&r7TXN2pgDriUGjCI^aokA}64{8WjxGKA&* z+tx3~k&LI`a%Qk*kKo$@w(rb*=X*s&IO_B2p?OinYMiED1C%cCb2|BU)G2){TZ8K7 zw1sG1-uPCUb&?8mITDgUw$t3*NgkgH!c% zO~QDiS82vkS8(X*OXt=7B4ltzGC*=L{n4iJ;7{ttr(4q5(^(MXXHn6`;SX+qe5&qq ze}A0&BeKFw-7PBO%Edf1q5Qk`g)-K``Dxg3wx3lVBmDm- z-}C+rHyzN@jmwn64yavt`{H%1YU;paw7fayDPU7*mDn`R6m8$}o$UMB#`9wUCp5HI z)*?-XnsxJboNEtXE1zrn>uVOx8W#Onng!R4h;=aTv)`( z5&1y!;@78*X%Pk1CNCzXP&ER)2A7iD3Wi)fDf}E6f+XmSL=;1`CYcaOUSpxkAuJ+A zO%e^rKBFc9&bb5`BzuL6=EFNcu08uJ3tWXs1uGkjbe~$v%Szb7<%g_KfE{=AtS>W9 zgpKZusmYq9wmj$5AY##kK!W-3Vuu=1w{s|h{m6xetTQLh{VtmvMcto-&=gwUQ4t7jD3mo9d^_5|!u=bzRo5d=t0r+}=NV z&!H_}8EH}*ZfcTgeO7UuZ>6&^ijX5L=>76;6Cy4PGZvMb!l>)GD8je1)Z{XriKQ2< zOXA>{X520kHvKwEQ;8$uN|B1q(7P}iX^IffzXvkMXh)DY^l}Coz(kp%3XT&Ae2^~h zuCsbV5cgtX%vhq-=1$zMvyCP9`#`k$8)(Gj0GGoZ_STJEm!N6{dM?A+%Yd2&nN+12 z|6#jMw$hR*Mkqgfu$NieZxWT{M@c}>IZ#)I^_&kj;F=JkDw%-hNvuXJ+?SP5-rweE zq}zZOKjk@rPtnjtX^FAX{h;!@d3+61gYj9o4?j}G$PeSIQ`4T7~k{d zFcRxk&Pau|Ff^&=`=g)!Isfqs|D@+$dp}oc_c1dgP%7-XwOk)z03T4Ag46(vZw|J@ zHmf8PfL%o%kh;{)_r!{^&Zl~W&$dwG+-UAl|Cv$3#Fld<$w(dbIZT70Nh3c7$zI*6 zRP2dlAqt-6E)WM@YLOKx$Svx#s0LDlMtn@L9gbNk*%N^%awiKE*ZC)bi>s++dB2i~ ztjukP%t(QbF>lI6#gk&BYBj5Bu}rw@efc${GR}1mq=t`Q!@`^9Pq@kqP`zH9xOzCe zO3?lJeu;^uaL*C6LMHoJu*c>1kh#FvrC7+UpV246cvRdg(F@_|a0LlBzmuwBc?oiE z0@D_`^7^wo)mFQr0pXClb9Lxdjt^%9CY@NL2l^`Z1l_M+0s_C=Q!b*l+2(nC_va+b zarr!K-|pi)SaF-u#^Y_V%j9?Ag#4awI#zwN+S*0BCeW6g z`+A*YZ6VT2Mrge8>0FoG&Awlq#DjbBjORRTVMH?(r3KzcPVkS|s^dpJ975QS$lzPk zbAvzM;!XUHxXyjs{qD{xUe>Bu&j=biL-;kTGId7!yTB>hm+qlkRL!=<1cdk83$~wo zTqWOnQW}VJ{up31uKtMe(XaN6HBGO7NG~YunhL_L_mBnwXBP0it?^ZFVlF(~W0 zqclU@IR~}%fW^g*lZ#Hf68Yo%2I3MQ&ejvwgd9%pQ{o?HzYC=qIWk8XapzsZ?)@T} z-She<0|BFSEa7jFveEBwo)GfC?s6yve`NBH2G}guh?cg+EXI_ zOC(Nl*J<;-l>lZs1dWk`FJ!7-NV}o>q$pfOhE2R7ESH8_qIDu4KI*6$<|KWyp(gjM z+vAH3W}><#OzhEPfp$R)X)tO11btBw#nf1x>h(t2C76YLsWq&-v!?r_;{eBn5i6X9 zLSILuu!!N}HR}V6a8#4OhK6KxpmW(qB8SB%^RK&>DM8n`uC<{vs#JHC+`VZi+6iSx zL}6E!%0%orkZrTAt4Z^A1{SxkUp|* z^2LMHx2vI|K#7Q5`{^EZk- zJ|JK=QDdo{NzWlGQ67<{ef5j@Q0VaR#Z#3)^6rdPG~>-<`YkYvfH~I6S%5I641uL> z)~<1EJ&F7$+s{|n|C7V3H~Dr(!}#u<`}Vtc_z;))f2cOY&h^*hRr%|?67r=SJV~7g zDjyr0eli(1xt1$fa)BR}=V&x7DJZD)Ijj#(vC34%EGIu{*!UJO4SPBGi8CS6=UC&< zuWcyaws$PT95*jpJ>LWkU)qIoJi=f4-LD*+{F^sKAe*$OY4qi{XZySPjl0E@u2m8H z9Q3D){=2w~lSfC=*P}PDw+pA|y<786A;aFj*ITET1HXXoZ|!_S0joWBia*h6*M$Q9 zxbgPbO+6f4-Ata`wQUHNOR!FV>hCr3xoKFvsBI2=GL4PtFIDOsw)ggWer(vtZBE#` z_jZ-~qh#n&OIv?`oo0Gz?)toUcBT{;o~oJl(B`|D9Y|NWtjQYpdlGW=)Ar{f+9!~8 zC{wz=`V}KRa8-x|y|lmdMj)+o7B=Qgurqz*`&{^MK)7M7<_F)Wn?qP{rkqbogYg7k zuJz~-Qo>*671bTuy#t;r7$2R4+Is%{dbNf}E!(MyT~|V1zS({K*?$!spwjYY+WO+* z^7;e`D*k2f|3m0y-Qk;LNPhX7J8#$XW1IKpt9-gp|9iO4<<=r3Xo2xThY_5e5q76g z1#n91N}09OM+ZB9L_C#_SkadoJqNwmh!txNN&|^{7S}h9SS|P2{66)g#~CUe^+&yj zq*#RiO|b~PYoIigz_RP9{I=D!s&aMNf;S=6Dig^6mS=$K)!Z7HzW&`z&0qZ#CBjcP3Qj$vgcSCmes7RF`EtrtmJIDi*Ug_&yJitT)k!jM#(9{v2>!bQbeLIUncUyg{kwn5Sj@LDal zEFa1#kq`2Z(20prw5)fsJKD5v6(S-i;UT|21qOHp-i#E5(Zr~ws*I*!0HtJb$SV=F zrDcf8Q7QX%OQYvI`;xBUzcf@+rS!CSC9Na5xvY5l_qWRO}*Kpe~Z- zH-F6siWjbzpUP3W;fPn_=?p6qiz}eKY=j6(&b&}aviL*-_X`^1=?|E=mXxb;3GibS zgi`-sL;ga+9;xKwUoup;=D2ebA|~ftmmFGpY5I^ty~bo(7M;%k(qM0j&F2RZpkLqS zT?zZPS$RTn90&wS>Ct|T=Mbwv(3TwG7du6;#*^iJ4|+ZaOv71_<(XOidXJI`my7l@ zIOwxhOBCyWXhG47XuLKpeHb!#F69>^h{1j^9p@v=aPdL=(#xrf41 zo=?9nCa!4x|D17*RAjF{7mD&RaobDXJ0U*e3D8fv?G82j2H4g#qatpXxTx|3-8kqJ zYSh-~d=5|rp3dM5Kj;+CMsUOxdVnT}j7X`4>o*uIs3(vZh)=E_T18<-Ozs}aML>Tk zr6N~>M{5P}GU}kFS8H2{CSp=R4#g=UwoJ^!Pv`Ef+pa5V6}Gpw;iF(Zf;v=whmUxI5)=Lz2EC6-r^R<)hFL7D4!Mdf;71W{D+O(UAvz&OG3wT-c z&c)(Tihm+vkP?-vNpp{iwbCiWgJo_~td|Nvv>8vJ;6hQT2evLrE6N<&%Bz?d#<-iE zSPMpreGzL!a=cTEhIZ6BoCSo_a987cx{FP%KiS?&;C1Fi1Yb=q=?Mc1QjckEmv>h2Ys(DA| z5|vVxnLhralDb%w?b3!1*-ZyKW8WqsTl`xlv#U%oxvW2fR9?wvMv#=lGAXWTz!{T< zy|zh@FwcY;oTeaTc}W`#%L81{LjMZp_`S- ziRzbmXxQ7!#-fVL!djo~LZYVY4E?S z%I!=USx~CQ6l66XxdS6GSWhSY7;j(z2{KbG@hfWm7foy!0dWOI!|gVF{k}^%7~8}_ z<-`)a78LsP)^W%J$JWWSeH5FN17rejBmUJr;Y3BQwix$w`KR}UIi7QT% zufzPBD#}nzT@G=0rG}vLW^VU(<-g=1OZq|=dr?kGt>T)_EQuinNdl~rrjkR_w@nvk zV3s{qW#2zZP1st?=+G-$159V!T0FNX%j8;kOVA#Jj^_QEgfl zn-9u2V}1(XZxawl+a82!OWmv0#GSAqJ%mU*wQQq03SUJHo(*yDGGEbu5j>GFBy_1A z$gB75j6idmWdQezY4=i7{;mkO;8VtLWB_HIy{}Ab{%4#)k?Rj-si1|NkO)BV)bP{a_K;NK}TYtC6Fg3(Cvr-ZMya^IeyR|`N4VD5(JMVoDP|9qczxPwpBcv+IzYxl{NZZ4U_3{>jER{Yg-X=yN%TOi zJcJeJ_2}de3gW*U)*$DYKl>8VY20Nhn47@>TiFUN_I=q5V;g&gRd9I6athTSZWIM4 zZ-TU1QpxW^ck`l+rG^+JuFO&yixra`;c7ZywK9_tEH>JtBe$Y(>qo86rn1+zy!yb; zNI||xWrY@o-?vBXM8#>l7P5;A3R_VWt$Bgzkr*&m8ljzJPdJH!#h?%)c|Fc?Vna%x zy$moIl#rCQ_nOcR2!4&en&h&<$QfWq6fK~Z^f`b`prPxg76mVUJ=bF8z1kkEJY!IjMhN1_q!&_mawP z+I|0Pfic*~q_;@JQS09z|Fri+?B5_PQF{N;Uty#>U$h_}cV+nvd~?B=A92=h6M?hT zDSJd3Cv`;4Rg*si+$x z^r(7DRR_FKYBG|@*1zz7Q{$q5roIm^4`YJu7rHD=Ght>UJMOx%Bk^6@kD11q z{tngv8LX|t=t8@O*fbScLx5?t!I-I-RY>XNL~ee<=>bjrs#uy!4Kv+alcQk7gPSeg4O`RM{lmI54wwVRQ3C=M( zQWep(+ek-=@hl9{qe|PTvO{S$xk%cIB~G}2X7A0=%6X{hKljT36?N3xh(#!0^K*zj ze(g}LaBHzuDpZ=om2wf4D-Ozp=Ulm1dl6-a3QAVbVUXmu3howdS zgx8Ut94HH`iUY(TdrV|ASmlng$iBdq#J^C0(bamSOt3Jj(Wqi^+`I6wVkahAbCxOd zSmMfQPAB+@5dO8nNMpG@J%1ID1lQQ8NUinMo?gd4HHk85p+h)f0g0gXbdbW5r(=WF zXI4of$|^7F?Zr2361OQ?-A-8o^XbD|npC`euQ18*bfS^n01m)gLM+a}d^4UctF-AD z25FW8otQ^9uO-)ZSq2<_p&3R^T9UaN%`F*zN=mT8g^E}DcZOb?`xrdN-jb!^CB!O4 zBUDq>z|S7{`_C9)sP&!`YMSVumUl#16zwqopKhZ;fU^1?egcQFKHPacEd#6_Gn%rp zWQ%T2b=CiGF{{rwJ-PVC$rBV8boBf1HNlH>k==vAE8{*+j4+voI7(r|DsEVb%aH?^ zH{P1+ftZv{hmEWxk+z5viJy^O4+vQ;E5oc3!p72&rn9i(nO`&FnU|{TQjXpXv4Eqj zcC?@>0m3EVnN}y@xpq*nvoDgoSC_w`V29l5BQZk~)mfU+1_dHoINBRI@O zIoqd4oq1wP?jN(Zw|cgY`V0&LI}d6S@Z0id1bHZvu{g!O=UOU=OTwQKD^0&}aAjKC zvt?RSYHhxAmzxcjkn14khbxP6{lbA0trguIt2J>#P(PsdB%{JUNmx%se`;wOY&FoK z9P2cIX?k&BCC|5u5e4kX@bqkJ2VfFeO!QTo(ln!M@fFR1&EA#cxln43H#A5=YoL|4 zP>t3af4$U$x)H0;{Zu5Dd3an($*{)GO~Qr(?`Qsr_jA+~R*H7jTtkr*1mpyFXcppyi0POu0wxl((Aq!JS(uK_Q9#AjKo!IKdQv7ep4aq>Y!nrl@UqvN2T+z|h zttKGQ1)KIGCKAB)y2g^8W&;D`gmOS$B8!Q%UBit2bRgLr-!Mu2|BvxryX8!QfTQ{1DfbWk_e6*v84xLmJAclwB}E(4SGkB) z5uq<9r1|EFIW|aT7IU;cMFpFg(;|WU373#d++jyS7JG|xMmz@9Ft+I6utf|i!v6sy ztTH`MXOPwm2w;3$RB-w{4pkI=WR83u*0-1hYlCy$0v?#EaY3kKG#J(at)y=*aLoiMOkOfWcQ+_Mb(XVl_a zdrYt~?g_h2#Gz)-32GM87K-yCr0s2~u(_Bj^FV^IsN-vqI1^-xE$3jver2F25;HVx zY2tmWz?s#8p>^m{k!M6a_nbxgAOo|UjT-wtecA}S24wFt{1@R|sd0~OKN-D!NT*SK z$iw=~1k)frA_uA)NU%v|SCbVR*ZCiF9BuMATO=+ z_}Sj+e>etzmr29cGEC;0k41Bk1zrt=HNbuJ*h~1ehUm&)NMRqaKoX;7HyIbnTdo@^ zp;n}A%vVrGR|(n2N)zFzbasT$Q<0#toi$teIe*hwEl~Y%OEKTJr@}kMG3j}4bY_=M zff~}CKNnvV!>9`5ThVDUf#ruu*FHtQ2!dd|=m&I{tNo!SQ4OklUZ>-* zG0dyfd5S{qygd$428-V2RtSM>97-?umJ>6^A^w3Sb4TjMp}*S#@LFRUY_CvKud0ya zjR^;=vHl=U0=n&7SS3*fSI_Zm_s9N(Q}t-F&vo6j9g34wW_Ggu+R9z-xRotT^x~At zy9s6ZgMErCl9+|CTU^S=bp)){p0?~rLtnziu6EX_C4D>o?qXzsvym9TPkcaK2>fG? z*@G3#axQjw03TM^(V(W(E>A%#-?m@_It;#A;+R{LDB093%}gih=oRlU%H~Qc(`oOJ zXiXl|v#!<EF2r z9ssuDmTAsV{mF|sugdg$Q~nZ|+)|`5Iv+sxlu(@f*@M#UzqSU{wxm_iYlol~M%i1f z4|9rE);4{a)@-RPp^^zf#*+n(<9HeB)m&+)X^g#Vg>J^M>2NQO_Wx`C>HILCL#r10M)Ml234Qbd{k*Lui;m=d`4~Iz@09zr(w4qo5=12QssicG_ zuZdhS1=*m9Ikl8Ew15Z*mHAC|y*6}mTHWVYpihDm2O>XVAc4J=>bGA2xX5#n%;h*m z2SBgO()uaIbn%cR5KX(7TugCI2X=^&{bDt>#M~L((O}o{7XsJRaYPg(CmqXPrnE%d zSgcj?4GI+Zd99!`!ZN21_poOfmmQPr>E&q0M2Y0+F~un*UX$e_W%)NfCkV2HNVRLx zdu7t$6Z)1iCQ||u4SB?hvlMpq{y{cY#Efd=jlI}9iU4~~P!+gdAX;A#&^InXS-j=L zs=tnO`2%6ar;DnnCamID2U=R_5wkk%EdZ009g&$y?nBd#KpEyZ8)<-3K3B?$CGd zefHh!yz73s=fhcx74l?~$v=Nhp2;r}_aLj^+osc2a;S}G;2~gp^cHv496!$Q{Pkrpo%g6vn$2dY;8fq(ZdVF9@I|X-u@1qUqBtD zd`8*e-J`ftBPQAGF&8bsJv~2tDLXH)t(~&J%`xP{ zKaSg!2T=_tB{#o6hN=8M*i4&_%c_A**v*s{`=*#7iraUM|2l4>|Ncc96$?#N)X zb9NLrB115b9}#Tm0nrMwGos0s3}ydFq_?t(VE;yRI8)Ft;?%ndMG1YDz={~A=alS9 zvi1C1&R;lmv2iWtPEi8#hv~ybPRUsx+89}qrm{*Sr+SE3RFb;5*eZF}XWEF?cY1I2 zA@BFvQZN$8&Y+9Ncex{t{W%~7hctPS_grD3&vwO5l58y#x%`qJ7J{zuvE`R+`n4c$ zK@-VOl=Hjd;kCw`(nU)(Q?{4jIJ4Cs3(WM5)d#h+wtBg)&Nz^AE`=6;+rDXc?lIsC z~|C^u2-q&RS$`^5tFc9M&dzcUF5p?@Oc>L0q5jg`VVyuoI%R zjU~Pg5%c%oktDfF)|kl_-44}TwrP%%pIPOkR^15CCOf)G98CL%=)j@^ezUz-su ze=H_AF4iPhY(YVke43!cxvkmZJ?;o6{r4{WRh(SnC9+=kF`bt3VjaYXbUrpndu}u- zU%yC}tw$&iIAPF^k13j)-X$Q&z>S>?>KCx#cI;p9yi?-;T2sdi6FN%OnAjy_^H;XNwHw)l_e2#WQ@NC=A2 z`%~m?)PIDi_pd-Q7a_3-X&XdRj2PeJ4k0_86Dn)~7G<$&l3B!B;Hpn_R_c5F08&NY zaGVRJ$?$r1{Kub#7KVZ%kj{v6`=^-Y;8v7H@EzT#VSLaPrb!u|B?gnaeIoO2K%~GTMN7uZ>dHpd$Q~F6B0Scy%k$h?2gh^``1+Py~VYQ&T~P$u`3 z^zmDWXGG|jl2HwU4q`Y5!U6~PClbXqh0Ns3Y2i#&wZR!(o01I;s5_G4db+{~SzPmNJyr6b2({RDZuLXHj26RH#+uy;D@o)EQ=8 zHnW#y2m>#Nld%1Pj4eSa#`mQ|Q-cAkO>)JlR%glc=UI?Z*lcC%S4qqAbQmT&X)~C$ zX`**V-Rmg{ChFX2r$oj`h^}fW25$w~k}%?YZ#sMrz1JK@Z2?7H+Q0fJ^&dIP(0iv7 z7R7$aiOG?`4Utvh6AGD?4b!ox{F zXfi~}3;!4#NgDBPH*GS9u2aPLo}YCFBX@7;(x%EN>6Hl}qgH^IGaGS|=xMb;lryR# z%GVXo_$8+=zpM+pU)g@}CNDFts!;fO`#SS}%(Sw=^y8fx_3ZbbchklK4~xKa?H2ca z36CS1wQ;G0D5I;69pKNeE$*z@;Q9d;{Tg@HI&-&Lw>tG3dh|tMS=fV%$v1Oz83dn! z*F~u}^@Tx!b$l1#j%&b+*i!8iiFRkgb2fj@Os)F`Q-#7qNu?OLer`%&|FNRdlNvEH zGiC=;NnPOi_{U-fi16-O?H+dJjx>>Mcxa8TX@Rd34^cf#$g&%S(M{>u#Tj#C!Jl5l%c z>uaZi6lNY^c~knC8^lZ4&V4S;HI5NNXU;9X7sb;HP^tFtW44y%(koeAN%NhrRJ+!i zuU*uS5FUQ7fb;_SuUNnbIzN()ea=}OTKGEv>!Oj`p!$jPGtgmhMz+?_yntdyWvk0h z)U6fuMfWq=$c+p~@o<*gMu~|g5kI-6a9<(SbF#eHd6EtD1h#3M!sSq~&ixZJZ{M!~u z{%?IZ%D?q1h#<(5*bAvwR13E8-%p@Q{$f&K5&l+i?7y^_%5WloMUZ52|3#3Lj{ilx zXm*eNMW~#!0ga4tSJFBx8u#q%SKXZ}pDz=)HrhORPmvx<=SB~%KsN5KOR+4hiB)VUD+N4Sy4+*yG=a%5Eu!bHv8Vr^&R$$Nb6-M^0>D4HT^|Y569E^%5xoG zMk10R$=mGb^A7T+2?By-f z_GyOP0}sF4o`N3x=J_Go<5y2dbu_S##1bs+i4Th1% zQ52S!88ZHAn0q6a%o+?Yo${7XXjdsJcC`OS(zUW${5=$T^mPMKAz3;FPRk+FTm22D z=`1v68;W!VTRK7FSX=r0KcW1=-|BQY7J9xa=X84m1l>}<*~q0H#xOd|zs(nZSOi$< zYs+xt0ZjB$$1H7J+Z}W8&&;?b0*xAmmf2-#n7^;=o6Hp0F7Yn7hfy7V7p-8IHjZT= zFGABKt}0-V3;0IjOhgAG z{RIcDB{V48R{Q~jJ^BdkKqP1HkWPEF@TZeEb3zXJS@32{d!!V}#|WI0EWz=9hnb?U z5&NTr><{4u-}C%dkH{}l*|}zEJ&31iQ5AH>d5jxK&Axfh)EkX$%d?2N{Ye`e++qJV~BHil)mPu>2f;$la^RB$=Q3fZg12 zMwt4vwXrj>H5SEsrNDb*zT?_sy|l9RmZ_gVeZv03GD5gp?=mh%RdZ}kQ-**e?qec8 zI}>|UtFeW_BVhIM=*;%gd9|&mio>R{nS)brfFc?NWU@Fb2|jP$b8k{ltPLev zP_X_$u%C1iF41A6#>b_yHO0EPEV;$5Qxit_DVf3aqN>jpmmzsvFL($geOY|VamOHq zOB12ig%o!(tnJE`!Gf4Uizrqp8k6`+d{8>4=>^kDFoDm;|G4ar1J29v;~Q zB(b7~wVuj*U?2zEh4pi~ueDpqAMD43QelDL$6B?o=!=Oa3>Ak|q%Hw4asH$W6v1OJ zmG&IOW?WY|dTE`#ce>3Ri>h?(+kb+aK5>}qEaLVn?%uBPT8Ju|ETN4?Em@6lvQ3Pk+CD`3%;gP!}UrBM#4wquzH%G03DMdRg0yqxN@ zjzYLGVCQyg!=1lPgYgbJqIWK z;KGki&;dr1mQW+KXf2OrHR3d|Ow(jdeRl1TN`$}{S6=rydXz*C^q`EMK3^VQtsQ(&xs46C8au8jQFjiX(AZDo_;qDh$B|MV7TRWU#~0t|Oh*jN?TIj^d{<}1+i zQYGjVfX}!%`Hr#U_n@@?8F~W|)5Um&O-x~sk^wZ!7FA3xeWO8OXk_2{CkyoMEe22Z z%|_@ZNtWHe*O3*@0k#3M=xYo=uL2e?-pQWoZ7?Vi73~UH z|JY#o2=xKOj0Ej~coG$rj%WcjhVIG;;g6q}u$%>_zDAe!V7vcv5#lJ?tvS2fjak|= zSjv)9;Hlv$5~)<et6A5D!uaM5-rc`%uKjzLN6aq(O;MhVH|{U=ZZ2$`mpk3>0C$br z>|QPHZO%NF+60ZVL5VAc!vc=hi7$6RuNP~=PQu8}c8?X14Cdg*4hXn22Rr~jA0C1> zj!s-2t~btF+`1Vukq7obA6|Gpn_b=bP8y;#bM^{Lhrr;+Lzh;sW&qbRVbHei?W4;} z6%8`-T80w?MdFa{O&wqMv$gh3rFGiUWzVnUjK+brj`rt+jkCv4TF(^$kgOLVSxbvo zV7XCS3uypUDLe7x#~7!~D4NwmZe z**cy{pV;T2zKoHmEZ}jBcfaH@HhH0&hymqt&anm4e$0}Sz@OaP0T_y5T;Y#Mv zHU;Y%+YhrOZRDUeO26yq;K2)to#q3a-My{8t&_{^C7`K?^S!{s0B{a+csgO|0@&To zen{YH=d67J)alNb?LQR6^LTa!0s)+nh~m#|oP`|DUogkr4#gR59^7tjT8ACg+*Ll$ zIRT-kI@6ztc&3kRz-mpLru3f>OkoR}yTQiN{v^LQC)6V;jC>LgEN?!;Q z(_;u>kmNgX6y}ltgmTZZ#aTvAm-@$(=edOrt)aeJr~}= zN(rIUo-zs_iQj;axW)wQqyiB!9;bx0Zt_QYwurFhJ2F0>zz6rV+wP37s)l?%#FJ>O z|DA4xgADJVURAfPM~v@(Fq=6y;fSV)^S@_2BG-b(p=MJsHR<_*M`;E-YV~E>q{t9% zg;NP^g>r8)h50qc@iy2Oavea~UI7R)l*l(QoN$ko$h|L!#f zx=dWJk@WR`ugSOHAx_hIfw$lkdQ^5=7WC`SSG@=7sFB@jMUJ;ebkzhR=ILWE{wFDwG&=CPj1SD?y4;a8>oCW6; zK<;2r?jn(Ng}(PPB2vW9kXijpRm|=DS-D?aQ)-xrW4ldALW!ERMlOX8tW>7a(8}g& zQo2O03%nIY))jjW`tzr-m;)Et6MYJV#pUh3x_k83r;$qf$k@9 zV<5W&aHS79>~3krxmtOJ~@TM4n3vz!HNi8(}IitVq#WDx6E-CtD z*+=jvxh?U#Pbm=!<%P*2`k!&kS;@LTrC>$SO}XdT)lo&PbtCi~3f9#G*O_oAzfW|b z?5^S=k6`UN6RZoQi5XS{WWG@Fha% zc@Y}rtEfl6>JlMhOI&mvsf$*kC9%8;!&~ftALSpuiC01sr71#$k_JaYzLCm=wp7o8 z`dS0)h@t*Jwbm#_{3s^c=t7R%s;rzmyl>LVQYYU>@og-=)Sfb|7Huw5)vSJjni@{H z!jTf%&`7j2TxrPG)%690|JY*7j`5-~3miJ_WV2E|boCjK-@pD6a`g)XhlCGcj;7{m z|AD5(bS=W7nr#k72}cE;aX}y8>9F3%j00uPXH=5U)-6_Vg&l3h{&|6X#%xn{=s3~3 zxD2*hqFc|4rhi+>pv$0hXc$s})4j>89+k{5XTUopiYaBxZ)7_hdZKmf`I*P1!jvyq z@gs(L$vg6g#b3-vziP%oB2`Tz5YnRtEy|+eNTd2fY4ek#R&Q6`%q)OsTTseDjpA~*K)27`lKKb4};($|9L-3zQi#EO!RAlJUj4ySukse90-dn#MVpANg7YEp9|}gphUX#$@E=$;}^@KV5V;o$d84N z>zS1p$&N;4gf;w>-?f&r(Dmof^euW+tdk*fAyG;5I;uW~`%MaSG~{tX)i<64i_Gae zK{n(!zw}6eUF&LC@mDpH(e;N|4>6(I4QJD85@+Br5*J)Y5JVYwBf!xy+x!@24&30n z)x&=(|3udhiPos^z$(I^+7gQsm59)>O@{a!l7UK?0zCUIYdn-odt4uAOP}~T$Ny3! zeeDWW?c{o~JI~R7R8N(Eipx719}*RiT*5vPb1G~HHSm^ZwYLva*L-jqWnJ(KO;dDL zLa;6Q@ge!iayAKfjIX$NlU@DoEX2(fN+0Nk6CJQ?W7k1EGoL3Lvwdl_yDV8GaOEI1 zzHo!rvTP9$V~JhHC+W!Yof<0SK^FaxNS#XHOfu7n<)~7f+(gbwnnHN1FJ>i9yyo9n@aj~qVlX7P zgs97g>k|VOv99X!#*3I7K&tXBWxq`dO!5ndvghXBMSqn_it@#+MV(V^opU6!Q|n0{ z-QHZkW?#y-<{Jepsrb?{-hgSlS2cI#=qB=G5pzOZ14C77{%|b((StZN5!9Q~Kf=)0 zj95#IA|CYY`_k-1Gk=4_2Z*4&1{gYwtlHz|RSbrI$5Z5sLMd|oH6=-i!3RNi{*r{r zZG#wSoc_--v-e@c7JNpF!R8W3A6f05Z8-AV&f-YWG5S21_H5Hgx@;Z2tY>yq(j2Bc%yy{uVd>j7nKCum?g2rztz$GT75uYIuVEK3 zv%}XKG2URA0d2jMg$B3~k83SrbNCc700sFoDcRYW~24O;@nQ1J_xwGs$H z^Z{Bi`=j2zfs);j8E()dj^LIY#2d0lYHLmk?;K8zC1%o$OT445w^DOUXzN8UMj*vd zutmSGv>lhot^eN92#HN>Qj*FwP7Bi$t|

<&yoHw}8H$qwU|B%LbCy=(WeX(=XI~ zW0{had=z{Z9*LC!G_u39+NuuhX{xAXrTK~=Q*q>f{sao(-Rh&)9tG}#W)qPe1|coQ}4qDGs|qW3~n7# z`UdqboBl&wbD~p|CU$=rDrF=_dOXY`p=&`hHyLUnGMj8gt+@lbNsZefZkP`SA3ZkO z&25SI(1QGmiotC1YZ<&H7Fs~VTVW1F+rd^2i~}m`9mbJE)tL+6h^E{gm3ARb6nISq zffVrcL)b%~X=3|cc}->8Y)~{sSnj~5qZ-S^^m|QH+lRW<(7Nm|_x)ek$^kBe@j~Kf z{#b|--FX3v#RqoeYT@7J!b7xv;;8IYZ>uuyZm1GiO)qxg^xM=1yOa;?)^Q^$c6gi` z!ecFqxNQo%x-wIIt{UWsRMH&Fq>p`2xkF<;BF0jN~&^DIJUc_Pb1s&2`HU)z~8m_LOmdZt_F<+U(Czg zQ+{N%kUF}Us#0Kb`ABaw+B|W{;ux{?D0f|F0mVZY191Y zO0yWcJ>`t+jClIkZ&K{4@%%xYg~|k6Kn~#+mG&>%*E7Om5fo%kQ~CuCTO^(-$GYTw zwZDgtnbnviBYDgST|ue`@5Cl0WMdmzBz~1In{#BucigU%uQ6fwLd^8i8e*nm=f*gn zC#!kv`%iexzXy47TjyIgngyQMQE8%OBToCe^MxxhBiciom%qaxNtN!}Cd-m2|1b4N zl9!^#;}_6uw3qO8!D_7gDa4Hzg%qpK{d}!uWkRRQG2ux|T97zTWa~Ihf7DH5G`UQm zrY+j*gOOTgfPfz)UHL8$3AbiAXbrKpMyOU1ayNVRL?F{o6I@1YiFRBRAgVkzLgmO2 z4WHQ@*=XdVOPRnIBvLNp{b0@sSExy91(JT7)L#m&StOfZC24XBeqID~YgvC^{DFdx z0!&9axVV$FSRl(5LV*tKkk=?3^0t%F4$0|{s2`VfG=n&KDo5=^CvG&x*;G}0vo*=T z3kmEV-1+HwX6|6CA^uza2n9fCJnGQn zhV4+(g`#NiibGc4&s+nka2&-h*C1*m!+>33#jHLd-2QLbmR;M1_a{HTpBnxG&2TLX zD7f5!hw)k=_c;vfKj|wI~ zG25?%7x{IL4`U2$Ej%rZcEs(x2RRz&pg0ZJ&*0=-NHwvFVudokk(3Wt~GBhhr5DHKgR{b={Z!xL5h}Rxpeyl<%{rPVU>tV z;lmn9Q_vF-=2=COO5Dn{LA&$tVw7EDI-(Tfwy{+wm6e0+JML4+J9ZzC>&N*)TU@2* zWz))uod-03@Q!H6y4%Fb`og5gO*2G@zh)I*8k)N9jw1 ztUreH+sr-WK=D*gjpG3$SO3&7(LaIFmc*$KORHjhamo82n9%2XKJYjuFTWui+m@%D zRm?H|g!(SJseM?i4;0%5&qN2GUE5@dZ^Gmc@odBZ^s3dSbjYmDWtrfA>1|F2ZX?hh z`H$|Ej=kY_1J-K95=6{REBa5iZbZadaEXzt_He9RKMz`MvT?pxA&cizaa$qR)qPQY z;P9DMk7if+HUMhe+PbC}=Z7(pOpT`)dM;o`n-vx_Bsv%S;o>hM*w6m9Xa2J~y+E8I zB&zuKlhqNVw#vm;rO9jzckt*4oy2UD8;!PJ_kt0OH_2FRbf-d zkGXbT`MXfCh@3}MG5gXNlgplz$Z1w&yk*g(<|0=q@ap`2{nJRfxRx9#hb{X(6PoJ? zYxI}7Xz~^vjt_`4PVoC*Nq5^=$RRJ1hzm_}Bok5wRje^fJ&cUoto~V&JDuuDxNY9v z;%KW7d&Lk1R<~l!mqB3^`cHLH_kX&wiQsq}rkVYB%HCf#5t!2)tr-}TXQqCSgsQ9b zLG{Nx*;DrVkR`ByBB8*E+F38=iy$#PgtOpd((%*bGeYecv~0^n zU~DL4<~+o?v9kW5bzK}crpHNa0gd-OB%hwD`4a^&e&Aj||Eq*>9PKAcD8wzzq$G#3 z-kB~wEvs;8F>1bvYPqa@bjUoKe8QDxDll|kbsfG(CeEnW`zC#UG{Z z3=vt84S=iCP5`8$wx%KRp^PBoar?@yWVpAKf+ziXvY+tl|e%onTJVcxBT4oMeN zNX8T*N}ACJdVEe+eBSafNJnLm(9nY%Zu#!$X|@d324`H{F`Sou;0bld9An3+Lx=P} zJ44bXKk8QIGJ+Jxtti|eOlFDOUoo_8zMooWYLU2khB!YB_afy#i~*G2q$-vDqJ1r= z1vr#avSA)Q-Jfb=>e?VKliThyEA5g zMfFAqJmDIBQ(YzAeT!Au2m}F&@OL^K3S?-@2;8^S_KaQti zK|GBwWn42PFI4FBy&2JiUFVw<8redLyHj1Y-_#;#i{honUgeo+sSLUF>OZ^a5qWS> zFaz)hwla_7f|z4{>2j0%>~vY@zA&W-CTAL65fOw(LYj#1Ot7cS;_2ZLR-H#xmaE`% z;6jd|#h0d*m&x8j(#hUp4pZ!wt@yr4;a8(DJTAz4i|wMp{0PVbQIvn|zaOIc!1bvJ zEN2TckxSm$dxP<4fKlq3sS(yI3u9QEkm=`q#&XeQaC`7|NmdOe92}d7#Iz}BZSaG7 z2-9IdQrP5-VM+xS&w$bPS9gaUQy5})cc<8v-9{#q$Qp zFIU*ahIL8>8_$r@HV)EYWB(HlUIZ&WW+eB7BdfX|qFr2~+|*>w;A*M2%%3)X(<%TQ zVuA>cq+dP)c>?piGCeK6kY9du|ITkYST#{A8?S3vdOHbWn#t`iH(4stJ#>h_aUp*& z5Llovb~p-6+5{26{8J0Qv!586k--LOOV56H#MF;zEDnkv!LSkdZ`)AV>GCAQgS#}C zuF3;6W$yHx3pOdAgKZn=M>nC|`Q`^!bD+=5b&x~jsrWHQh`#iHqAGn*_DMibV+bZ; zU}xz-9x()fwgohCzmD8yuRG24e!mgaWm0ue(x+r9=eK`1XeeS8rpV;?G`uG|wi4%LJ*R~sB+j8V%P@M&>Y51aD_f)U{a}KVtnK%L@0tAlcbR-Ee>Ek- z1~vcUjOmtvEudK!;tfehQe9CF3h0^c^Sb&DfcBbA>afOnPk+JDR+c1MDICljUUrA% zKYogUjJTfbYLOR8K0(wWK+v5LbN<0@AayFFJL}ubC+YP|d#5JnINL02O8_Ayh9~mj zBz=aA8=yfGN*-VG8oN|fopvQRnd}(w3B11_%pQ`b2upKNvOyP>2M!M7U(k7$##3vbgRoucY%v2Haye_DXvJb21E_>x*Y@i8MYphWeD zf1s`wg5o5jhS+P0@CSP^IGRg%A>#DH8Mb_&O@&b{YB(4=7mU?Qi_xEaqrZJp+L9y4 zQ#lEet{m?h)HHGlKkjB_94+W{xG|isu#m#dUK9z(v+MbR=?wW_^5uk}PbiNAlKm)7 z6YCH}zB{L$oZzyHpLgQcmh(37+vjK8j-e*rVOmWGYiVN1SZq=2>bsG9)BKSL*b-{* zi*@(+hM8l-kg5E7wYv7i5FtHgAos5v18-BYWsg{8tVLDtne8aB31(y=gR#ihR9T;A z;jSn0oWzG;osHt_4tdo^&Y;pS+7lz|;gNd&!`)|##`BVXbFX%24x19IbMt-OD|wFo zBtz%MUs9C9aUJnQh6xUr4Gzc(2gKv-fydywBlqT9>nCc-HU9W1(BxB~jo|&fbB1yq_5fCsHu~RDy3J0=;7F8E|Mt zB-+Tt(7gH~RRBv$wmRrJeChY0>t*yw^M}++N%ndyDfaqz^8&gobTph{lsdG^jE+WF zM}j{Y!wr8(oFrFKk&m`NZ+uvSZF25SuY3>GcuMEQ$e{=i@XLhRG%hSLvKdnaQElFA<$Z__Ed z9ms8K^?sZ=aMnVto7$bw8!e2I1FREO8Q`B*=H3C>=Ac%&8J9LtQ=Jw7k<21X(xx>~ z$!6NT?sHh+5BMyZ+`5g!r7zn|2vMvFABVBS!vG`v2%D#^JHI!GSyk{%HRx#_vzn17 zJnU4$3H@3s)#XXgcUfDT7_B&G7qCp=5CcVU;Qg`*q_(7C#<95lVT4H{h6A#ZSP?-T zX1r5BUdRljqO)P8YN-qqo#jwza2}}rO!5aK3>Cxkd1&}M>v~GE-xDmKmT$d4ownFCJ+oGs+l~!riw)i)|nE9qAdS29FUvV5cQwE)gk7? zd6s3zk>d)@JlVPi7pZH3k+c0w&RBN)ThhSw4CqWp|Ii28%){O99ijjI**5 zvG>WHNEpg(B8WB4dvKBFH4;N$sGM+{IUedCe-oTwTS!;S33O|s}5 z=;5s*>2#|NmV2Oyz{GR zzc7FQ%AWrs{^zlYFqJg7HF|&Fsfy`H5=6$rCXA3!iiO}nBt3$Vyx|A`WD|C zsX^*uT&9dPiceEr$J9sh{np$!c9ifNA9HvM+E0Hpn_T_$(~IO<{DfF)CM6HFyqB_O zPK!ZC@*3A1ob*Ge*-L#ksQy+kTOt&%QJODU-aQSHBY%BhgIh^6<|sC3p%R+nE7EQZ zE6Mw|KT8B)NqSA)7-!0pC&~q1^Y$4DRv(r74;_hR3e^23Ms;!^DX3ea(MYHfCi}I- zMXiM@0jqSWk1*K^QHaAY1d=ww%CDq+Si$jsE!i_YD4_Bxv%(}dc|g?g%$y zA3mu6-O`&)*7}sr)^WGU8BhZh<#&r%2ecqbe(Scx3<1IK7nW7A{VSSE*u4{S|c5;jGlF=pZFrvXUHqtojc2HgW$h z-cZy2!`*etNr=FW7+=$Cof37HSJ^`HyS#`ioI9*)PKo4ePK^J9v9ZphIt@Oieda3z z*rE-MFIl;1CCUMBg&L7^CE)$7BFncu;r)cZ0FHQZA&+A~GwXl)61%p4Q57+T0kE)` zTEA)w@cRE(lId1H1H)%VyMMka>%XXM0d{GsU+$}HQ@j5~!vBY5m;I2AEPs8{c*`LF zr`S~yYn|Iy&Phk4>LWzsy33&C-?KzOH@vOetUs~;MY6QyCBzII)m3;^Hk~*XHHc|i zkZrNS1V9YenOaF(Mzg7BQx5*_txvFff z?bIsY%xCF!KmW8hKG0)&W3x!8MX%LpZM}v(Fd&Tg@F_B1$V#a z#L#V-aJiG8Fmike=z4SI@0E*u=S7&&!PhCa%@A~YlKGI>xN=^H@jl4Fe>ZAw<=ph; zB2^OHs}-tgfFSTPKD)062mz|dOp z8xuLmnn5hUq15}IolpmpzuoZWkGUA4p zhR@>9414x$nQ+|P3eeyaT(&l!65P)0WaDrsVA9~Pt}%66pO~JMwUMoY1i{BG>esmK zzu$vi@e zH@?cBvMl(2AEvT16fjxvI}ib~YsC{4w5L|5iO%({&(N93O@*g#_O;K*ydVBZ)pj#n z;drIPFkFZtmf4-X9dx@lOOvT>`!2lI`tv^V6|N9^pnayuG(9TuT34Jg9flBEc%_UL z^vbNGg zPcPI6+13Ick2t$3=WA9tJuFa{ZoFvT@ssDCQNio;{CX!|%bo4~mM>i+_t~`^+v{@W z2S`@yPMX~MWvC)^)pjtu8q})0{@~l>n4fFr5&>_B;-Y3O#AcN8w9o^%R@cc&d{!Qf2kV53g~o_-c4|HK)DGp%~hmAD%?_4S(=l;l``wn#4KXaH-{w%!+D zzzNSlG=usAvyL=!>NoC&exdX-n9~kT+=Ka_+`_Wd47jU*+8HFnq!S%uWZUB* z@4r>_Pim4u%h~i(hVbel6&Q^-=4zq+q%}Ua0m%Whkj?#m)OkW;=!WYNl_CP#Su~To zGEyY!cPlXkVq|2K!>PWyr}-(u=qsN>42Re`+}6#sh!9IY14$9B%~G~p3xS`Rq^ItU za7M744V$D$TD>(JPwaxuR3eXIcX#*&(I#;t^-vcuSE)oIovs3db*?h2`B`B9U{6m7 zOJrl=JPFktA)}=Qv2piE;YiEghmk(J{IPgcD-@s7(z)Su^{1Sby!JjqK1GiqjmGzm zNs?G+;cG>OkI`KBfSM3K5ObFzck>B*WPw%U*v|&EaTY|kuk%Tl;*OvLxH-sU`MNDK za5WqNRcz$Z=^OYoRYGk8>RR8Z53#a!S3WWV>!^0cNJKf!c7OGkPhYUI#KqRpJ&_bt zrJvlR>byJ(m0D6h_DBVBB8k0BVO8gw z(hYp*=o8Z^6{RU$T8ac!rW%?@!xxu_#}=>oPOLtc@cQ7@TWD5&+c?c8A;+LGMkC9D4roxgds>UGd3$aTS05CGGW$cGrolj zZIe=NO@wUQziM%FS&N#%BjLZpgcqk*Gxyd2syjkuj*-7dUQ2&~A3?q9xJ#1Ks_okr zD0_|wl8u&#>;)L}eBR9{7{lx7{+SnDG0BJlRI#k5X6%{bN!AB#qf6$5zEr8%unCF@ zpIb;#GN|#`rRbQ6%zVdjSxGUidK)}REFO!n5t~2R{tM2}yyZ(SF{7*Pr3`cU*1=|! zRd25W3(Z0dk`FBIK8%>y4}!?1IxWX>5wgS~0}+llLN$lZiyf)7$>Yl+spHi#+a(52-^R{C zlviU|fih;l#pv##mO2X8Y+6_=shxMhX{Z`Ix&9}QH^48GxQariSLY&rakN-1$f*62 zy0A2igaW7G{-xLncb_jq-)%bpp1RwQDDA!c;9F&s)>cIKgpy;A@>Q`M4=9Py1Jd!G z5>-JX=CmulJv?vvepGR_dGPbT_}H%Ny+k?TCG@!7oR?*N%j3sult%B*G|Bh?nj{B-i?Xv;O(R?Wr;v-TBguE0 zKQ$P|CVR2`oYbMQ!anU(;ee#SZ;dJK&M{1SURBZ?_Wfv0tuSB zo&zL5LfQ;+8V;MOOn%0)+Sd>p)92d$K_SZzF%@>?Xn;=3> zOO5*ds^k3E_R+zWtCs`#>EQ;s)f#!J5g62SK0LGc1i5+Qw#}>Am4|;luzSnX4Q$`+ z(pvJ|p!Ez+>;#@#D|;5p<_4A$C+a z{s3eMI!hs}`V^IO*ZO>RaAEpz5sath6yjxd0-~-tI6MOm^lat6jKBEAgI^vcZ(anv z+Cn)Iq~!3B*OUiVt{XY{o8ES2G%~C;$l|v-7IGDEj+`HzH^R4=f3F_6ymm@cPnI3h ztU5q|?`82zP=5;dO;}Yx+~`qzXZOZ{cmrjaJT2F zJ*0p0hT-<#aRltIhjfp4EZJ>~#Oyqzj0#NLGB%huXp&y^4=WW%d?0!&c1WNq*?u{n z@TIoI?i+LS5N-UlcIN=fiS4DBfj1wrS*?;He%cwFfbC@y>DlvmCm&zNQ_Di9mD4!k zSeR4do^k5l!%ENf9Wdy!^QG<{2)})+WW#4ux6ZZp6Mll#?&Scg zqU*ce&E0ni9WHA}XFbmdde+Y^ocqj%I$VLCwIC_JjxY>r=3`$0%_VA z+U}Rny6}ian`76hQG{csp-ZjS6hL#=Y2262rO`R%(^KQhOegKsr|XRe&?O98V9WEK z)y>t`)4lDb@*fZi-8w4e4CL;r6$XPWxAkTEIB9vIrn9QMrsoT1N~froW)DvHXB*GU ziX=^X@=JS{tHzZ%$J(c>J8wMlQ>(M}=iwvW8v{Y=tEUr`zCN$K*ez8xV8+g0dPW)X6W_cb-qrIYNx)U`i74zX8=E`6nP`+r#b z%BZ-SX59dR1b6q~?(XjH?lQPraCd?SXK;6y5InfMyK9i(cgXu4x$AuQ{JLxPTCit! zSMQRps@_xmH146iJ^dj3%Fi6*9dXQEoHlI7x0wxD3=)fPq zY>8ieh~4Gu%;M>Hb;5DMaGq9gD!+01q*^FU9Wo1}MOC0AS^jODXl5u`qp#o9Xv70d zse+kQyaKMKff-d7y^9_t0IEVuR_L(OgW7$72hd>#M^B;ea2}y!VYZL$PLqSo=+QVgr zGS|+qLR~xA0vQKlx(6GuXra7Ex8nC(H0I{LF@fcOyqra$Wi}lGS`|fhm zf!5CemX1i-N>aV=TdtZF;+pim>O`qVgOiN{3bL5v>O?e2Fs6GydvR?dgaTXfQlQd} zy&4I`^vYP1u%QeFg&IQ<)NBr6Di^fd+M+cZjmE0=QnksX6?Mg&jS}faNPRNYLgj}i z703euzdeKpN~{o(3042jjK$40l8rB)Ged6GFn6FH0hYu+x{rA(*h1)OjbC-7!^vB7 zC1_ZD=Rh4lj9ro+d&!Ukzf^i8O3~^gl-7|t7N>xF$i)K% zJB$g?%Z7{_W68MO;K5X1IV7#{rLIq~q^-h>ShYo@Q5$;zt34?l4lo&8w5LZPL|D)uCFTXWVlCFYGnRN- zOlQM{2~mJq^mJPF6HVpFSYSZ~8hV^#?<9c(Yx5_`R6vV~k`8Ft1W+Zjz< z8#nl3T++r^(g#;KGO>aWUn|1#ioTxZwL~xXC)@!i{iDG1>uve_`$BZc)kpKy2;@4- zuwhkM)1bh~28Qs|NA`_moKCT%k0p^GHSy(C30VgubIiKqyBN03M5&!6lgT1@*hm8W z$=elwa(0EHBGhXSCgAaa;9-?L_|*kbr$2!kCz9d4r8IaHq;S$2L6z2}^a0c31%*uj znwkIYeiUU!dX)5B%g`Ru)WAhi{8eQZN1xnNTKy~#Thukd_m3W{y2HHMdsBTY>9v9z z6|%S!%YsYVapY-k(PU&rlWU2b6gbRN`~^vHDIo!h58&^6aa38*egSRRxQ)tzAZew} zdWd@gmUWO=2VW)?1IY=)49Mg#4=aKShT}!M(t(0$a4In@d)iXECG+v5U9rFG2LQ%z&60O8;yG|*DgJ*9c51Zu%0njle%}yAgnI5NVqN1H61>CX}2>D6lEGXPD zOQ85!g@V5@%d(BnUP;^jV;#p5V82_KV1k0|{HD&Q5~L_@M#AT5ETo=Gv0-jT80R=u zL>{$d5)1~95+0S1c$EcEIaCT4tF-zY1#Bs^th7OP!9%E*8wmH$B-oQLm{_a?zuu{t@I|L|~|4i=HSzj&*+wQW{$NO7}M z>QJbW^rlmzLVU%FZI&tNCVP8y@`)qs=TsU}qv^6#!%n&T{Lt@qqb%+q6O-S#?&RuP zqjX|c-Jx+?!RYwUVoyjhg{`tWQLVB(-Pf_(lNjJWPm=W>68ZDBy`%h6E}Vmln@4!g z^7s=GrKktavakq;q*PW@^R@gy9_3g|i+psG-n~N`t{Y-}`Xfu*ux6-7(y4LQb5*e@ zK67})OD>S%nEtH9?r8$y)(<+hl`#^%>lo_-D-WXG<1j<{&xz|R=!eG~Qj|+>ej=l3 z=oiZ0zUMsWE_<{Q0&F4yzSu=L7RMgGl_XNW_#&krOr(WQBwu7RaYKPt_)EC_K)Jt0 zgja?Q^O3a>r=n&c4F_dX8zgD@R5S-~yf_`%SsP)ne3g8%L@1IX5X?1K!XFhG=w}2Q z7+2vgIOUN6qrX1pn1eqy$7wS5*G$aTRK!ApR70wzlm>F?D6yKX)A_9O2S1e7SZarU z(qL;BVkeZdde+`Jo%_WI%T@VENufW#^li59YLLs;qDze)kd?f(iew%0)Bt8&+j3){ zE5F&k=t_W%MM~uvH7raA$3;=Po)E}X;fqMY4>F*G-qc9k=~B*$8gm8&#&eUcKyxZN zm(faimy+EZLCW3b)OmiIPdOg3(d-;wje7otBj|p zj^@SWg9=)>Qan^yb{RDAt%(N7qvp6lpsAoK^(_UHG8P?gE|N_QMbX_EGg>9h;~)_}EJX1gTA+f&~H@kf(+f z-Ax#K#-<#vLpBMjm^YD1!8eh@rxGVDB_R{yxd|IOvHYN`Oq{Qz>{WGmCHlt`528A#X`w@&vH(?xiEQRkV<+NhBa&k!mz7e*1V7B|PDfz*MH z!ugJGlVtOc07O6nSi6eCw_0}Gh)ac)A%8%gR>LbT=5#Eu zcuDw`%|S;9%QcgsMia_X;!0_8d7&iI(du;xsvm?))>P@_{ppU#mznD$9Jd4-W08HR3^KB6lk_=G`m_wRcD4 zE?W36H(nT9a)=3Rs=Oo{ZO)#&Z4$o6?y<$3>M*t3vRhWgDT8zpVAO@)MPbMJ>xW!& z@@$W&Px;v*cfrWAoC$a|(lcuKc=Iy)gOKXw@u#%X6D#Y!^U#$;;_~OA&PR}N%Q&Ys zVK}F`1@7TbDV?Ij%DU$yfakP$Ew4n5pJU~-HD#UW6Std=m)7$zv3Z-Tv(Rz2Cl>fp z-7KxeJBh~o(hP)-Of5Mb*0*y(Uig-eW3@lB9(LRmt6fX$ZPzxmF62}3km|JvRiR{u z&0#oK0?e42w>C&?*aKXn=?>fK=&naI9)ik0JNxOybLHLx4vS$9AJ{+r!NvzL!=uKT zl#U&~+c2~KJRBrT{&J7g(Ief9CGD?MYyS^$mwd< zsVX-CNQB2ui&z%2M{P~^&06xGkYBhuXoEk`Jp5MV(83`KOc&6c$h*Bu&?@dRl5v(+ z$8fF{rCW61q^&^Rs`;s=?=3-8ruV%LowPZ0_0bU|R!)^%1!(r0gpKA2l~YPkXq9Q<_va3*Xd-whzOnb0!9 zN}vCxgT_A+@v0v^sj&7j?KQb>06mWKB4i@#x$2;V$u_2TX5_Lf(3Egx7A>ZWMs};x4;*j8<|DI-DL9Pz=1faLq2}sDZfdZG5)J7D@WD zv*HfdO%?D1F}G%|%ZRP^+gvcm#hR#lM~dvViC3pq_Pa-0EyaeOH$9HTNeuiD=O0bs+{15*>WEb@F})7*DX353dZ^XeguI#W?)n7$%LIcLV+qpmRpHu zV44V&k&0%f$D=ly*gQ4Xhu>N+f<9{m!R!xy&Vf(c%ce_ODfk1TLM>aXtR_^RP}`fT zH59CdoTW?81a@~DQoA&-flL^XtW_~wD;k{+L~S%0-h}0gh|>g}V<~C%4x}%YHmXz7 z!Y=D;G{~r_h|7=W0_R0?ytsTg(--D#Wo(Y&327)2unZ}nHq-kSTlx=M+9XB>Pk?`KC|sVMy2y* zo9>77R&#dBeN&#T$N*Go>?l{G3z`Zm<)RYx6}fhO9c)T$!fejMP19DqQ=g2)`;>|W z{66_{8y2*HtM1P^r2PAy^fdrJ@!3fCY&-cqMKIL`1xRuSl_EoMjR&?&hwuMn7OY)I zafZT>fT>MHIBXu=#pD?n@#J>XX=un>Y3WuyEg4YUm(0zrWv!6=uTbploe!>ALIn9} zf?mL?1c%)v<`{uFjC2$nh+QzO4a)Mx!69P`jcjq`IY&W>2xx(24EeOVCx9h$2GH*^ zik~fxP>VT-piN_~uzFtxUe%iSX(R)UI{!}f1e3wZRXoT~X9@bEwku>WqD=V~_kf;X zp~NgMH*@OD!44wBO7H8G*v9D!agoYU?oj1;_>_HM#vwB+uw!qrxf#9HULD`paFAA@ zW=4_j8|EVPZeGhjwl0Ol?33cEb0a&O@My*j47H{Nr{FZa2(}AAB-s7`crDI zjWj5w9R0u!KI^y&if$@C{}J6d&zB9d9cZ$3^TfzAt|HotI+>PfL=?@kdiQ=^N-ry0 z{_3yWmP<^K>b}HJq?Sm~uIlGpXCz&et^vZ~TAX;4YD=K(;ETX^^q^>RBLAUD^wZL< zrws3pInSdj70A!Y&49D~ny#Y7vu!!{i&XKhp>RN(TOV{nAZc@KJf!b%q3P`c0d4tH zu-0>J`IZ6Hjx`}^Y8OGq048l3%OV;G)f<%NSnXfVV_2Ir!vrH{71vFMeIMp06AbZ^_FPjOW|H;h&uj(9+A-s+~u5{Rig?9pi)PT#i(cgrDF zr%6}eag=L9*^#fJ%iS!}idtUGF=9LJ9w^fo^(QGgTI3wn%34|2hB%^*ZRL)_CsaPd zRu;Zqy9qtq7Udeuy@ZyI_O*S0q+Sv_Ic5UCCJvLP{9=Yw^6DjG*eSCnv#aa5Bi2nq zgFS7dBHy7^Dt^0Jq9KJ8@(@ev__Vt4u-6QG>j=I&?O9Cad2X02@j0ao$0&_RF0y1y zBZc%8w7{|->zj1IwRwNiz!WQ8d1^@-C_rf|OuCx*M{NRy zc$&7#ydkedj?Jp_mUy{}L9n4XLWH8%+$O%9PDXQ;XMY4uSAv0d((%l^mmhzzo zMh==r4vU762xqy%NS2!_UzK)*fK&wv^mGa~{reuttyLm5Y zM~vwyLy?9Ff)%lX88xjUVu&5-X?rnzZ3xzy@ShHVFdML~UW8E$UmLg>1(RZs%&obV4i zu_eyZc7VN@WzY}Cq-}+Slg?XM6^mCpY z3_SP327b|Yc|)Utxtr<>A)AYYvdeYY2OY?xbBJC`Dn@C7TVf1!#Wk_B2}pp7OzB&v zxy!#|)mO^3ouT@KIb+VZFQ+1 zs6r^zxe|X!pBL9d$h;+A%YI4#KdTv7;xz+BJ;nOj? ze8`b(W-V3nCRsBa;>;evrrW=C_l@LNLi@pt5nLS&xm7-JIpsn95nM>X8+}xcY0}>l zA*dH7s255mwECrZ>?JlL`Y0>S{=0h$q#wmvrNAWnD30;At$03_C6Yca5`*5iGHvMn z;?Natw&!^wJPyNU$H=38$C*ycUWTLl$tlf%`fFeC+!JB9kLmhia>(0^3@|zQitv%p z6VPD&A6=%X(GoL*0Q}6Kk;&+mJLz)yiJf^=w(ux^WxZi}G8^^Y?f$JajM?VLZ%+^F{jMT8y=N1_Fa2nO&%F$eHq zf)Ju1nZmY(K85^kL50Qo>2{rM#or)qcD)&SZ__<_R+)OUn~!xv-JM2ce-y{kuuZ2- z+K|>}fDvN`Q8bMPV~jm0*?dqVLri5dMV~Z#pS7ROKSl1S*uS0KC?0cMe7|k7^qWq$ zSn|{MUnY(;i$XmzfH~To9pTDcEG+BS=e(6R?jnsSO$9h=&Cb&7hxYo9CzCPVCd~SZ zOr&`|u}*=FsLElE2KtmglKS?Ox*YuU3kSVYYViDQgR;FBed9C>PzBO>5}5ko>wU7W z(*(U+xtp9dB|Og>i`Ao`I@Gmq812x%EJzav65((pBAsie-4={ibOX?+adiwMa=tAs zW5P{quV3*J+d{!kYo{!RH9^VPkxh~hS`vHGeW+K@2h3*V78qrHws+E0oL)w$&MoM^ z410&{54r^>1D(+@UDwB-#Hy(+1@o)Zk)!+|gNPrAIh~5AfOv|*v~tyI1A*iZ3&RATf{|!^U2B}qxsK_amv8ra_*`lZuz|08w*!sI z1Q}#YK#kythhjhyHZ3JUD}mzgV3EHDsR4N&21BLX7YEf7h|GN^GA4~d2+G~9-#Q;^E(`S3Yk0zo?Vovpj#gL zpKB02dr)CWfoqQ@@z`d!*8P}?J9qi#yS1h^}ilR8#`KUx`I5g za^xiAQ1hcQjyAIQ5j8>mB(<|8(#%vJO9?;_PCw8H++CDosej41WE3c*AdyH*R05V5 zcxO;SNJZ(lw{D-#;#$^I;7eygakW@o_bX40U+%dKQZ)PvC}~8ENp!|HZOo>t-GBz2 zEcWHGR{NTo2uY<;?$rM#jO-9wMEe~b93(W5Zh#3;xU(hkNkJfy*-B-DJ^_#s4_cB@ z!OtgUi-w%|qa3HzbK!A~1@pY62Z3J$}jP%u5eHoib%8_D>xjciH#Ao(MEwk z)u-KhA>9T+WcSQZ3bS#y3!;a>E|{P$DA*S@tYYl%?d-_#bk$2tzRWj_A z8txT`_C~|#GPU-nL4VMDkM~Y8PcpS9ntpN}xX*@7xd8tGL;K*sK^)QQ1tRZxqPAA3 ztwyM=CaA4uuo+*K0D63_n|iJ5m2LjMa1Pz`;Tt3w0rX>rq9 zB#N&!IVfWNUya>x`Momzu`-C{->?c|{x7$nadbXOT=I4K-bdVXm>;0c$kpC|R|C8VUADjZZsEV-nI8NdFgkCfw=sNq@L=Mvrb~u`!qg_7^d~KwouRK`!eNsNKuXEOKsJ>qoQHe#ChgE?){DT;$|d_H{*t2 z281P#KgB}`!iZl$?u=&uLB``xwa+mBy%eJv*$>u7Ngf)l%!lsep`0lY*1>wWWdHKV^-GghrKoUVW z5i;=Q#jM_MmH*9Hna_rRBP=Fon23Gu#4au`@52d0*qYUo$0E`6pnySB*ExbfrJwKW zO(;?|zwKQPyHCKxxw}DjJWRPLBL9j#zc1&Yg|FRF28%EFZ_~z>4%=Gj+#FiW-zzXO znlHO{j$apYbeBeBD%+RNsFNl580@TV`p9XwhV-tbVw~poeefOWJ)Ba#11DNHro)U} z`PXi3!<0k?N-&#Uhm-ffe^C4>hn$t(Tm$DSzT^rX%uX0jThDTgBHX@fE+N58P0Uys z*0qSquDC3a{E|xcCD@nGCkpqi6v`*e9ejOTptNp-xSB`w20F?^ z*uH8(;k*RuDn~VOupL4%1kjaIBS}a$iIJ+>^C}kki2dU!vMBu;TdYNhD}jFo77Hjb zZP7tx3w4J4aJ;JM%j)lP(udf8(ELZCjP}nR3RJqP?exS*JhhgzH}+P_`f&9~z=F!y zH)<{44(x1#!gO9k7fCN%m0?od-uk2!N`nB4@6xD8lQC_(njzIYdH2P;Eh6q9oPuvP zq4ZN}&5UAt9T{H;@nk5bb&b4P7-VCnbC(p9#-wtrl7RB5U<t(%h8G8+P%&8+VP*LPB z?U7UBY*V&Hom!rgNmloc^~!@_PKAljkxQQc8k>3OFjOc+>icEP*hy!4#6uUSOUT7_ zI3Ln9H^w=2z#ajBj&zXJ;CV3}9Mc`G?AYEed}JB5RCtZsyVveg2DyxH+t;pY^i{Ix zSm4u{@*i6u;bLB1@(sL{#67NX8G6!9rLIiz`Nc6Av7^-2)>r~npTKp$%B86wZH4Ke zo)L-Am^eon@Pe`+Tqc0A9*@}a8jipZo&bAXoT{EvYq1J-j2=wx5BF7LZ^0{@^ zbAu*z&UC4}(g8Oz`yoX#JPGv41}m1qL!yTyH$LDQ;p)px<8fvo8!sE_&FC#IzI(+_ zBw`5ru0QFMH=q(su-7#NBLcrX(rrn8ajAU0&7h~~;wwN!Pn8tS&z9M3jwF$nV?w;? zs&p!q=YaDD+iQCJ86mUF5xv_Ik$b(5!Qgev1NlPUGmpWpe^VgRMJ+4)d$P4=_ja^B zIOgT|hCMZ4)b-VS^^`&X>*ktY=Z|O4wF?37pOHCDh;Y9*78DrXELtBLe9p58*}HsN zP6N7ZE(n_l1vcMa1l}I^jt<7wk@iC!@4XjapTPu5PN4;U*qk>TWb;3l9=>VWg36;2 zpT>R{_gWZAZ72qHdrNiyBphiz$!LCbgWL$j*u2jc5bhi^w|BASZ?_G+Osq0_t1UY_ zeyscfY=`W|g3R!v+}O82vkk}2ATloq|AV-PbI#OJyNu+_E;K4t+kQLt9LxuUtR8Ng zLDW>JGgv%r`1pBSu8qO_%h=qWtq3ODsjk17f6hKV8|xQ5yFdr5_=;3Y^zaJ1O+}>e zNwyKxkY2Ac=y{ddTHADi9!51?hV?~C^GOoTUZufTkq7oDJsCDgTKx>eE9tC1acANN zMsr6W{J*IDUiVqxdKLmOE4U)qP(5~1;d?(s`wlW3zq;S-8)lR*jVPfB@Umn`Fonp! zWhU=_DUFMGc~#(muzf*Kd|SIX5DUFJ#_sDo{5{^X!8E3yE*(^ef=}Ph>Ki10;yn}i z#i7SuZ-~`H0N#p@GQ$91-p)(CqK5=)v^WPm$A7V!LFdx~u;yvOz?Z2HS~YL{u*v37 zpc)Zs5XRiGsq^yFBvjb9mddY{o99a#RYv#4l&y0C8z+AnG4J9@*J1SAa&4#AYV}#V z;O9U0)!DGmQHj6NV~k7t9oGUL2pBp2G?--A)4j~EB+(s7h)Y5h*)`c`E*ZJ)PFrt* zmrAyX!E{j&OZAd!Ze!gdKQGpD%61^IEU%d9`=sd@D0bGkQSH0zyS)158wW8fS7-Ow z?B8m9$8$BzoArk$b|dSxt)KdQC-vp=p=O0Y=VgLn;=a8&b@1%vvBs10=}BR2>HOj9 z{w;Ytz3EHllBw(MMZZg?sn4x_a6R6tjm#|IZ5n$}Dm83%@Lsl(Qxd_<4% z)z1BhI*CCS_?=2Wui{iw?d#vr@?3ozzrM75eZ+?tTDn^xN!~^L`ZD;YT3}R52v#8KegsV?QG{i4Ct@%6*XM&duR;?B46jW^Is_+!V*&(j_XgSQ z6JZNcKS1^xhX#0__w;jg761`^ebVkvZndt4d*g1(h*p<2M zUT{Mbmg64QdwwKYH&G(@qwCr+?1bw@4FfGs`etYUat~6&wMOf1=Prk{N5sUlQ=-zB zvlx4G$L-DQ4;XJfoB0o`SjLZyYZ`B1zXxxBL!flnc(;zWRu8$)Sv-t^YNH|E8WFSJ z=HKqa?lBR<^nIkrAn6ww?lW!~s-5bgPy{M-x+)02wy-YPlDF9Y{{5QD!Yx%m1uBZh z^+_<2HV%|ajovJ0Jft88K=~l_nBI>)oxK+_|5m)XZ|5r;e>+$@c{{PcnN<-DpUGhH z_DtJ;qI#|4?1g3&d+NW{;-ee4!joW&TGEOU`DqRXRVjLqYQYv8pK&szz>2_9$@0)2_5VF)1 zcc8SAf{a(|?vt^{G~rKTjcG7AA{QdzYuZ`~|F4D?GKZngs=OcM_cqUbuhFkJ1sr1C zHW-Qd?w@J}2ukSB_5GHgLu02F_CpLvN^)UWS)K~J4DQC>F#m0Ve2dDvkK?=yh5(6kG<9gO_o=3BQwe0geL1E|>E7at5h zZSZ$I8M*nnw^k{v+yc4J2rjzL=* ziq{-{JWKT5D0Dr`#s_cF{jzhurl$V3>r|5+6tSPYQ1BYOeRY|jqaC+hF3HZm%g|G@ z)sJhRNyg>6KsceByse0gPzb+zUzft1&=fOLyd;O(>KQHdN zX5HL``NQple9USYx9z=j>m114nTZizJl%IT+c$lU2E#r-@A&G~VPGEBWj4bEda}2B z-}}Aom#6dV(#PwC-@Z>dPcsNmL8WgMWjoaww?_AF+@3kq@fzr$>1bKr6#f85C2?hUTJK7c}qDPqe9Y>qjw>8&^S zLB3W3aqkzk7vC-Q(BENz`5Z(bitZ(@meGgV{adHX*tTNX=000E7u-K{wzBQ)OtW&) zR_WhItqc8Iq*0%(sLXdnqiwV|e)Yi(nsPeVwFJyTFsnjL?$oMcP|q*iu5cV2kKpg4 zhMrv46)mOFF+T(07{C4uH{OM=A^kXjUXRz*>i;~r@^C445!Y<*g&Q-3&5~YPOJ0Sp zLarhSSR${d-KD{c9F>bU6Fe4@rlGdM2!|;x%B^i&noHuB4hg6RcjRA>8@$w|8FgVr z3>jjxVszJL1bn88_7;<-R+(;3x>-oNF_HGlNq8k8d!ZwO4ElHh2Q>sANDR^;+=qfdtny4en^fvt7_7`}#;KSqNI9A>Na?~6!V@(v;FOrUNN{0+ClB!5 zlO1{#p&6tmL#Ha8C4JU(j;1iNjul)6klMmBkfu0%PTNKV7I}z#SClT26p?h5w$X^b zk;_NP#zR6Lvf@qG4pD0v#%9fa0-EthDAELNn~J(o!T}7=6s@M=x|({oX8T7C!{hP5 zZ7nZ}N)M5=kl-T{Z=CoJWO23!-BuCN^`O7m;EW9j2bsTSX5Epf4wYQVLM{uI!u4WV z&hRD3Nh3EW_D{!uU zR=sA5ykKaPQ+$Gi32X-wJi^OUuT%^X;bLojxRQO4DM8%>dPvvSuVtz^@DwK6S9$Id zw?Y9etfwmkqS&@mtb{^rhmLw}^7xZ}wjK9MF*tP5(z`ef8`s1$lpE$@VL$a6)xNroO*a4IvpWt4&Sh4#M z7Qj_oQZo5RDUL<78q4`JBShj(D9E_-aagUusF`7%Z~(}psresmSOd3hzi`$XUTzJ# zwMiuMO|TZN3(^UOSPzx6JGd?Nd)mADn$IXNLRN!2QW5?k0* zVEWu#9{aoT)Lt3(qU3TD0^;Cz^GtSIw^?Dntc9DP7$9xX?8+OMcYjP1U25T zBWE7h8FK>-AD5n6R1plbJ>ABYq_!1*m`_fRtMY5AM6PoZ7Sn<`oQ~ygxVN=j4^1i< zRb<5zXMJ)qTUCz^>v&!?Qge|B>o=``O`lCF6FO;(d;DY8hnI9j+%hGEA~`wHqR`T{ zcX3BA7m~-+VnNYqau`L`)(dAog<9zt6#EA^D8rjjan@zPfMyRHRc|Cy3f!4{vTQBy zdYta&xXQG2V%?8s$S;%9B8jG`%v7H6_MV@g(lfvG!e@HwHW~WqlC6Z|b_~QPbqVXKDKDiZb$OF3*lfc4!ct{QbH}IwOdAgQj_I} zK(3Xzg9`DviKTaeoo3DzTS9>OQ3-GKh>Ls=FHlF@y+Hs@h&s)g(&!b9OJG?pW! z1tH%~LE}4=AWO2D-H(YuUG=|m;`M!%#6drgDQa`lxh?6j9yuy2{N_>^y~>2-ghKey zwU6;uDs(QYy{GLPR0)Ba2W2sub7Vl!w39@k3%NwT8@Sn(9u%*QV9z5#S_+D-U@by9&t(Io-9=>E6U&X zRw0~D%C*|^l?$j@gSyWS=Op5k!AT=`?QWy2Tq-pk3-2ko0Njs0l~ONLXOsy^e%6$n zc3q)|$>HTd{aPf>#>Z)5WQPVT^Sen8u5zuOWrtG1WVm_N4P=c?Q6Ot<2U+7ve=bgw z9;>XEzqzbbwT_`G?WGEiFedg6cwa90j|-7E*0- z)_ZcyRaTr{l;oY*OE7AjNwDa&!6hh#m9f;0MI+$Jb+kWN1Zn7`3$xb)r9lqMc8IFa zCQmr2g`2vsm0r~niD7jRN3B``R?$eu>5(y`MB(0shkXgdyqTXvWbbe?@}!thNLT6$WQg#!M@@=Y!>6mzCZW499$w$t%K(`jyz8N(5q7VKIXPwh*}0;QbWX(7X49JKiy?KztEUCRjwW{J6=Jz>6K|nxpwvY z2eh($4_zKG7fZzKf{BEfLFir_3;%!zmYT#H(4?Cg${Z zb9M7I5WHC$zwbwqDU+{fO|X5=*JK$1c}m#2V=S=!W3q6?tnml{7g>sCR*T|H?k0f) zPNOyuCJYowut{TrcQpwCDK`k{avaZ#-Gro5LivFq?(C6yw`J&M4wS_xuuLhcZE1M+ zcEfTJWX#i)p5!|DIP63^Kp4b5muY25ZdZlWl3yrU3B`46zYt-LUXwozZ)er?1ZHw; z`?q>+(PT>ab(Kxj=~JQ~_~pxL6ZNf!-)&Z#L2hSvRY!)%bXn_Owp=r> zB$d~#N=OJ#;pT6=IR<&8F9e;Wb5s10Wb+jCL98W0g!11Tb9)+hZ;bevN8&(R^FCrL16ue&`EVDkxA+ED%&+ zXm(GIR!OGND%FmM;9HNC<1T@{fr(QLm%!GO#TwtihlID*R?zy6c}O<~djsNhaw6|E zTu`CAUMyE5vm%R0vkK4{px;vvu%7#Cy=hr?18I(t3UpJ$su0U~2Si=v8ScvZ)NlPV zh+Q#*9#&x|9eCvaz){JRwkv3TdoVi6yk9jxa@-Z8IZFc((WBJ8T91i3TGNjE<+k43 zf{kU3RvfjN7CuhklWL23VmnP^&2ny!l@VOP(y;L@g2wxBqS zWM?ekm4Ho6C0zAJJC&`+5R0zS30{N(15L+j4qQbuT1`bolr5k36;Ts4#MXGM#AB4L zXgwX|^B}m`wEUrAHWvX0N=|PQv%5(rg?YM-1mse3*PzUlnoUYN;Wwqv8wpA=K(DbX z1;+eFJ$;vM{+|@YF=?KdX;|EIVAjlJcHBx&7J7Xwn6m^I?V(Amu$&(DcS3EU=g{Kh zGMULV4GaQZV(qplbo8#hIR8S!vMH_6w5g3E{Lmsy{66g|WM8_Ey^Dri_uyn6+a#&H z5e{oXr(2Y?L4o}z8rIRJw%H`;$~l`SmJ9q~B9oo&)HjZ^R@Kk!TOGY>e?kc73}%*d z-}9dx^+IwfYkV(ZhU<-sCT0y7VD?qI&h0`8MYC!KE(|DwCO(MrQFVoJ5dY9ou!@vs zo`~C4F>)$H`cS53^jEAiiMXjZsuC>^kxh#O7TJ>d1(ZxBUdh@(hi#ZSRV$AQEwLy#R@vB4+Dnqrf+`g! zhnx0dxMxf&^M>=2)pd z!@Hi0EPc%=CO0`pGmK#AlF7;l)6KNZeYU%IuM#qVQgfQ~am-w|N*ZoVA{}ddks_@D zY-fR-nW$LeBtXU2+{@dFqKGrAYEYHjQHsv`D9)KDuCeU{S>W{JNDmGSV^Cs~h=UHY z$u3!?`Z&;;sHm~hiTrAux;Z+e#v_h#8Q^9fhbkZzte~qrT z30j|3&C5fm$Uw`e_zb&D?Yq-D9DxvZQu4+B`9i5v9^u9dl|-`dFV(t9!0$h+NIb`WtcW{>*?7c_-O-V>Lew0ywfNak#S!DF9xF6SE%!5>R04X~ zKu@j^6_|lY7U_i`KMkiIX6||_awTe3Sric;F5Rgaw@eAd+OESG8RrbN)-}ub6W$F!bR~t)63C3UC_qnoEy#wyr!@9M0n{{7z1Di%+GQbGk>9+|iT;P^@gZ z6c}G^q@*-c%2t*|O;#TK>UtyKL;Ag1m0iX>S$uA|eRw(7p^v%RXDVez8Z^y~YkD&TuVv=VG}_S9+#1Db2&>ue0eNs&spQjY&YS;o^ov%_aZb zBqT(Gq8vh?Kvgs(tu%dp9GrO=Y%#V zD(XU4F>+4Bs01+XMnNH}sOtt0^OQz08=TdgW1oIoG0Gm3Ij3L`%%)RU1?OUL%qxE6 zPAbN5j*OylMbOkRaa10xMJYn`&=C&mlg(e@gbH_5h$tkJmSIuW%qDh21`=^{kRgRT zH%J5t%0_*ZjzE$`6$_wLiWJ%ZxUGBa8jCD#i4+cq7o(o3G%I zG!BH=U~Da`-7yh-X%3En;(^lp7rEoX-#j?&hU?ZYA$<6QMxA>RN1;D&W3667I1l^( z+SwM`%zq^FRbsy#?qGystDd%4Z@&=|U}G39*ApK?ypcJsv!N#lewqCf;FY62T|9u; zfmzuLdW4@}v$%IlBR(CUnM*aLdk9)XJFZ%72Y7j^9~YAolyIm*61?n}SrXoAm-MNi zBF=tIMNyE`S7cz9et)WU{3H($8=cP-SD$@<5~lA?U>)0=sxPdC{s{2Aulu2U={iiu zFT{yoX(;gcp|ovA-RIfButq)?d3h5y{lKT+?+Q~=qrDf*&*Z51tqP%9;*l}0a1%HA z`QX)MDeK5O1>QK)7E<~KPWxfP^H2@F=2WL3sx%c$Sm>= zvMGsrm3&xmkWf9eVb@FYfYWUWY9zrpXx_A=yMBAh$Uv8i^vJ|xu264 zQbMxXtTxl4F=(i{@Z;=n?+aNC9SmKmBX^)}C#Wb=?3N8GO0b-Df4p$5k@8}D5PjQ$ z*832}xKY`tBM(GPR){T+!QC7pm;KsJ4V zuCEM>D`?V9LV(}|cXxM}5Zv7+xVyUsw_t<2I}9+m1b26LmjEHS-$}mR{d0GJ9Ui)> zPEU1L*V|ovss@A3y8(@_P(()ZNIwe~5eUQJ%i>`fkFz*o;~B!!N5jGip^X)|7b-1A zjc;5#mx-0~WYA_31VG-K1Hu=|i=ectu+zuMlU*-oU1D)ciz8inI*~rFnP^soZd)wF zdJD~Q5sEj!jPyD(nLLQ{jF%^zPToj6P$}%pN+g*CJiSm&ICUq9IA-ad$d6KwAunz% zNu6U~KL5I}BS=_YjdPPw>W7*gxAw6+$RhZ263J_2cVpql%aFd$w;zII0&2Vr*i{1W z?Yi9yj8qK_w;IUO$q+rYKEMfvTt*{LHr_tg_;1*D*lxWU4FSsAG88_m>-Vdadxs$J zDkkLIYT}&TvnmoQ+&eAVFD$M@5{9B&T$ImluXaX=mY!R-n28&gnX@s3 zMh%Fy8#o!FE8~&2GVZQ?J}b)3cEE8wFQq;tkZ9CWDl+^E|7R+>+Myv zqmTf!R6Nh82oBAvmM0V=_s?NGt`?H(5iY%We(i;f0;`v8Cx6rkI}J}Z&fenWzXUA1 zeew20b9U7u250zDAPxiF>~-o4`S>$D$XI6t9De{?oB`J4mk)-~<*fA0sTuLLA7GZr zTryT}&b_-zPH#-7PkkT$>>J*-YU_hg<{w(_>VJekV#i=FnK-`O^J3Z5%0$|{aeS7U~J-(0`>s{bbFee@=DWIT)cCfIJ1 zQ<$g14VP7~lGvq{cdlj+&y!0`*H=3-XpsM6JQyU5H?Zigw)au4Iy)M!{s16+@oMes zH{dtFZg?lQDv#3p;IML`Xg;efjIStpJ+U*GNp!jVY*JAb1aSV3ldE%-^v-1U-|2d5X@<{Z6P z;)r;#i|a;j;7DQYUD%B!LTE}Bx0aMUhK^d(g<7orrrK)N>tSbQEc4rI)Z^Qvy;n@k zHayS7e9CkCH~)^*XfDLxj=o;H#2B9aZT3(;?612ISA;*erIYRiegzR&(V5s+hC6^h+^{`+hdT4*LL)Phpt3n1eA z=WG-)7#b(ESI$EJ_a#H@&qfK*YDxp>dc9eRNq#?p*Q29h>zW?Gna;!0cS&ALr7x9S z7Mrg*|9hG2rG&1#LBefyn6YQ;0hPNCh!-ICYihowql@q!nSFacum%ZrzH zb3DO$46VRQNy%Ap*~<862X7{2f^prq9MZSrtJ{admNRbJU$>{bDJh3JTxYMi3_^D9 zt5@#b*TqenYd@b{EMiY%`Hx zlH60RZ6|7wd+dqn%l8rtR6GGL#nY5^&-wFL^Cyp2AOE^$#(|(?2d4t!mleO4mSw+3 zp8@>PCIo?{_RNX14OHnP`L>|udw=^*O8sECh0VUnYT%iLBR@S%)HLFm;^Bo!GN}?U z$;&m5N18~qA4(WAR=dlHFB*(Pi?xdrC7uY~hnc=r0yGkW>!UGqq>58<8+74l0xxB2 z5VD~WPNn$L%4t+ho;KOXoGlW4KwNkA(o=25a)*|S_8Xye*`YygmBIw(R<)#YD zXGZ{9#Z!jk``Y(H-34zR{23D)*KZzA#huEfDtVzjhT^?4K&ssk7R<|XPUiNB-{})k zOx3UvDtKQ>3oysIXEyl?J64H*FDv+$Hb-eEq?2SGNPtvS29m)liD}(x?~62iw#JUi zW0V|LVw6}H@jv(sUxcIhVAxeeE7Q#wm_YJpsf82*;!(d1oP}OlEkE*?8YovPnAhdx7^Rt?4pe{=c6LNAn7XWSMhDOiMPHovs0zAm zw(_hZ(#LwoDB+9j$!TB2*~@nLM1Wiu3uX zDIr8Eme>I;*SRO&D<$P|bxEw97*C1bu1$*aUHjfV^M3X2+{g&cQ@Ri*L4`(RMlno2 zO-k)~emYEJ=J$yqVy+B(H?NVs9?2lY0f3Z~*?b;2qauc3UN;Qi<0k+MZNHqIzzYo0 ziW@9rBdLf3es|`j>jsb>WdXNM=Fij3g}7+dpyR|^Jl(KT!@51_H21(mC5?ECkv-|K z>nRmToR@!YEO6wOC`RU~KK)St92iQ@45tBOQbnFo`>6CVULRArM0oncJU|Fd-2ldl z{&H@#pFX``Wm8f)DG1CroSdo9$Dm3*Ew&`pnX6V9pXFBdRRt4hC2mCNJn9Qzm|{T| zoQtrX+$rjD@iE^rty70DWg}TfYVZ?AU*3D)^1?uWHZ*}F+YMboWG76YNU2U*u0he5 zQ}*G&^F|3v-pC3zMvspc(<0J?Ew`&g^-B`;a(0JKqorPUMQmlNu5bICCVWT!h4G`5 z0?U-Ck}0pYFVmt8Ab)ILGI0cnls^q~&l^DZG3=q@nlNm@<{*xwa&8;PhftBZ3F}#Z4-T%V#b*R06vb*WnOC)ovqv9-9@ut%IQx)oerV6X;8j`WwD z4>qAq_Yk%4iT^|O5grp|8$-!dgen-*GSD@PMCnfj`-da}aKg(A^ly~_&=EPWxJc5z z$xVw+7GxtvpfAT7R~b#{8`(oF1UEp&zQTeSsz{qV5?J{)W%P=sQy_{eI{@Avru@t0 zpUe;C3_~Z*EdsL$&PXOBb!U$~`n{ihs*!S3AmgO%Tli5&nOM1h%!NnWL=bW_swwbN zJ%oZDZ5ac0lb(Kbn2ut#7JeVwRc1W#GXW{Q{Y|A>YH4A`-|lJ<(!ML1;PIy*NjF$I zaXVSNF*mBytZF5Dak-&77!@Byse(oX1ic2uz=Z%^u8qFt(P+qPk|mK^d3>9p-d% z4dPf(bw9Om)9Z%vEiI!M(5qnz*!9|m$h1787$PN%trM)9BLiEnli9Ysr~$A$NQVF9pgvd{M`J= z=3t%7S9N&GAaS2y5N3pW#EE{fOu31h8Xf#w-MjJftv0*d@%As@XvaSJD)0yY985Aa ztjjeSu>$J5Q-e=13FV*HVTvSpk+JFWd0KELhmy998koEx6Y`KQ$v39-h59&!Ss zQSlW%LbI=MXcZYMO_UdXG@Q#%IcWLDnErd&KVA3UYI^Sjcd=H#72LST)|MXQWeN($ z34oE6r6d_AT~(HYu_{?f$g%AS)+)kae;!RdY5@%yeE}`HRYex#M+K#7wG9;mb2!yT zDG2BOloB43c)sX69RgckzIbZH?_(e53^VLO00-%zS+i*hD1D+s>4SNwu4=KBn5cO1 znO!MH_e`Eal;vGg)iBJ#KqM2QT_p{`sM6zRSJFuQ;AX9s8Ka+>=Fxx_I3WE54v!e!++-@H9lQyc{rR5wc1f4FyjEtNT1^}1?y!>Gq<$# zpLIzPGrsQt1}@A~w}BXsO`z5)>Y%KTP=+yv2!SE=WRThOy^>GnodRKTjovb;a6&`F z)xHVN9zw{;QVEW?h7QDvqQG?0q*R$QdWQ0sJdmpP7Qcv%>CMsRm51LZ>SW%lW0_#8 zkU7BbrzkQYe1wPQ2VovX3ISCy)U*{eh$*|j5_~!dRdT!0iA*TSN(xhnkBk1rzu&{4 ziRrk(%#SpTcUsvy7l@$mrW_H3-8Ta2dLo}AtB(g|o&PZSocT#*jS8XU7hbxm8z*Dc zFQdwt>0{UtkikBZGA1LyjaN>~jq^liS)B#+Yld`VjjcaX_pSXa?R}4hC&=dtkbctI`+q!LJ#fZi}WRhwISf(3#hW~U8 zVsXx4e=TlIk=opuQk8R324ZnO2RUu~axG>IR|o8cQQn znPb(KmTCUy$+Ft8`fXE;TGFl!5Oc}U`n|q-TBRoN?C3rPu4sEG1DphZ5cn0n zJr6(yRx*yg%TgIXvirH`~ntYxxc)6zH ztw67zu8r;5HG;kw!Jg*(kY|H>4{6|5jFZttnwBMSJm9at zjYvwxCF`T(v4bQAv&O?nl}dZ`)GrtcK%&cR#Z6W1LK>&tN|&IWtZDPf3F4-C2q?ps zfK(gzo|G=LnEo(f*z*CTtO?)znXG;PJw4)^{bw?$%DQ^a8|zGu%?47pzsqh0T;azx z+V?)-Ixm@wc0N#e(w(d63CfrLC(sEkFCBf7<1UvaqlHH<`v%I1bfu5rOO?ou z@8ST%KLblwd8Z-o?(-+es{As7|I1}cxC|avE^~e|;P0{l_L4cs%-%8MTg--2bzdG} z*I_}ME^U^PE*%lUE#in?93k}X@{tCViG+@yn2OYWvBY}Wz!VMgd5_H9FNMdP!*3^* zq=<~lcWl3x!s!!&iPmOH)9z03{$mygbrqi)kV22r-5|akNFd^(Mi(e34GoHHB_fcf zu`u=EwUWkb5{(04obI)qW`C@XCr5S96PsNNz!w$89&K!%qrtJkf|3zaIRD8ss?sQ8 zRJ)7a9(4bEl+s09>vznOg)CRsS3UD)^^dapFz%*Zrj8m$TJo5Bh&F_E$5y}ip88oe zSwGQVTWiWwFsrQKx>_2!EcFNWIHm;X;(AyTG`R$N>RXJ^>!XFppZPQ8%C< z*v~}E(Vkip!0h6s8h?{6h)*U|RLtV{;Zv0-!14_#2h+vydoP)x`|Htqk_Uopo@Dw& zbahY87;!%hOGRM0$C!rx>?lEmTa}Y64zPm95lq9i5lOoR87V-c1T=?fzA+S8TPauyf7EBFRh%TY;@Utn*XN)b*z4Q_r``zO?#} zvRwwWEI4Cb1pO4zRUtbHbvpfOKO2?_4&pglvdOqttnixNDTO2SI&D^1IUN23F8EfL zH{IXj@zJQ-7c?m8LN8Q>6lli@bDjejIe03dE2%2(3RMv}S#4k5;}7X==eMr4aw@K4 zVpV$*gqL~Zxm6v|5`4R&Ni!eJPCx6pk_QolwW#FhQ(u1egriBF%FXOjRmt56iMfxI z0bRfq_*P3W{=!C4iL9(2GKazR`G8$9!C~~{dv4Of9!=4x$9)6T?z3j9%)A0VN^_OU z%+eSs)9J_-t=5KP10ad!u&#t^sfjklyERIW2y-WqU33Lm$ z5E{WRpZ~X|3JY>S5%D@g3f z6_}Gknm6l;sy0I+NiJ=472IsXz@9(XZvv9&7x+XQ5(zL+FU*Bt&;}Jo&nk=OxC+dM z?h-u;^@OTJ1pm7)0j6JT*>E~PQy{_gGjL0?OYd=tR-0Q(*tQNE5sYQb`9^Vn(#br77<9F^Hg#P2l zrvAt8y!zGa4I*79JB}VACleogWHBV(aRmf`OGgoI)7VDmrlu+s$)1UfhjXlMOsu{^YcErU`39EF16|Ge? zC}yXW6Ab%JUP+KNT09RIf%akth6*TCEeT>2J|v&v+NjA4PsJ#HWrPRIC&b;$-VIAF zF~w6G@qSLTDj>Bzmf!pL4FAvbtXFO?&4zsCEoC6#_7^2tf~^?-IGQKbYPcJK@{e5O z=QCKDe*{W3b?}Wl%g2(gpA@*g7YeAN1YF`&wF^B{q|K944L3h=cxZ{d8B_AApnufy*TK3tC*8!qb<}*ETlxj=N&nBZQSuq~ERgc2_u{`%d?I$#RxpVbB(0SXQx5H=gsq-0lel ztNrZVnV*7W9~xfh{MU&T#xL8Q-T`;s`@O!d5xB4RVlSW6E^{6Z*izCK&zA{)Rr^%q z$J>Omy57>Q?=x6ExhlMJWq%smCc)B^YP(4w%=vX|qu7@>7n5N-&U^6S_%*cAd3_r_ za>>*>z0`bmTQ?e-G$qZ8EoW`MSu)5o@CtK_`fmNOjR}g*kEzqs^!(`lE z+8txDN3gNRb^+R<$9bP2(K)Wz=ZuUNa}Po;|8PP34jS}ptOcK5jT<8$&0Q0=D-+~# zhlw0dHW7b=el{PK{Gj6#tOK|WRYQUafdCtqYTm1lp_Mf!gMw+>5lf#AEddk1#r#Mw zvl*s2-S3G9?Rm4-8EaoLIxOLElPlR7^G<=T#gx2=uY2c!g3ssfG^P@`k~s-Z7J20h2u8h;>KqkMYeQrAD%a zo5Bv-*V~23>WC&T;xa5VJtW-PJ9+CXZhuQU3y^xwt_o#j9zTDhqO$p;yEeS8JJ`n9 zOt2|PmLhDYIN5gNUf8AJy>7-LhRfr&jNsLvuy1eDa(W=Yvcr$9|%ZKtroPOhYg}d$`)Yzu$ z{43|<_H9lHB$y+v-X=+ymroJ@*0>@3X1?sRLbO3hlwp4dC364dcGc|Lx@ph7v#76k zOPo>gQI5jMlgD0oW7o*&{r&GXn?~lRryQ|A@QG=nxQI4C*l0E-aJOqjqHqBQQzn4i zAA{ez`VDbQpaB_JDTu0FEF7Ke)d6wEpDScUkhfNd3s`0Y@6tX4y0#7oDT*w6I!%61 zu{7K6cu{SBBsAFuslEnI|B$-TBd$JbjP8u?Hs5wy$RjElWGd*l>5-u2E+SB#3`7=B+^U069ORQ-YJnk9^#_i+ zZux`{v~uvWe64`pg#5!0BKMe+dk2o@j zw%tjW!g^n=Il{|kS8`>6UJn<70Q%ls9HRV0v?yegLFtRvvSoxen`?f=_#;-A`+#g!9RX`;W%zq486_b!Qd#DirpS>?4KQs?!1nx8%1^ zn(@iktixaXmin-P9rjw`IQjRekEw>FnHdbnne`zx#ow#7J{^?*pzTw(>4o91;E|(# zGWHuW(s4w^VJIe#&Dio=^|RvIF{v^Wp`e9J+ZQ zy*!N?&YtJEuZ};i3EaM3uD0oUFZsTqyw2A@ErLzQDPurdh}O)tyqiW^K@sZ}FyxZ4 z9oFHZR9L;EYtp<+oxR#Y$sP>E3r6*`!(VlRs_J1i25>&J8Z3J^xiA;hUVsHnW%JO`^w=U6|S8!L!!44lkaYQ~%0j zV!x-X?3~9=kfo#bPisGa8*WHIz(MFn{QO}-#p-EYsCw>dGitT_qWAqR#dhcF;UKjF zX|3d%%xDV*7QkXgJViz;_cXYET?0c?Jqd-nD1D?FH6`##+e+ z{Alk_$Nz&TeVxbKDPS!BS>)C5iMqH#>9{_C(BT!@C#P|6_Ce6Wsgcr-{#U~w<1cbV zH~+eC#6;6uEskwpC8|Bnf;@ItxzBbB9!pX)U+7-nUgbAuHm{3vTcI1N69>&+_DwY2 z*?T?RY@7Z>-%A2u^_6c8?xqmQr&w&kov{I=C3qR= z3^kCpF6N*l#rs*+Wj#m|Es{1S^$|}3g`_Vy`0F`uc-d_j`*EGX%Ysi(P^8^i8$e`O z2&=d=9QwHFjrxC&{(1|ylbx`>dpH01e@B1W|3!a&bz|{)!TV1io`~UZYMQZ^+|*C% z)U3TpXjMmS)+{-Sz0ZZX_UM)u&dODErR~}d7cby|-6XhbbhE2aa;rjoB7Z&xnZ!NZ z+}dwu=YU?9h+^7aM%zwz#?Nl%Z}$z~n!O*c&mVI-L4M6`9emkb%&{3IFQd2XH#w`j zH=7%fLQt2tr?0=CF0b6YTff3F54tbrD3&ZfWn}F39-dtt+?&0%`gSuD--R8H!@UXk zwDNWkHD*W}Uq8FBH~-996R>wYTSR_9=*EVH$mXF$>E}|f4ld* z^V*xqCT_*JYv+A_-MIysv>21%2fR(bE?cUgOTuyA2x;qdt1o_`!vu)A$fZ z_v(4)uta=EtZ1*a7HwO)Akdb!o?CclA5H8hq|?2;n!`0&YJ6Gm$pC-yuH4yFplPjB z;QUAP{=xBf6z1dk*Cjt6cR}WJe};3I>nPeMVfWSQ!L19;!O5p; z$Tf^hVK?S)E;y}^`cE%c%qSTpXNqde=pVMQXk5?2US8elay?y=)=SxJq4KsIpB%6D zkL%ZjUpCiwkFVNJmoto9_;G(!Ka}|Y>Reb|FPWsCWAR|`MM2SzDS4@bEt^JpqUOMU z`{}iz%#e@3wKup@n_tCh8*LI^* z@K>jv;mH@;!9^r_v3|h@G=IovkN5;!YDmL+k!z?4NW+lP^Gn#ym4mW_;=Wn9Ky$EbPXyK9KSqmU-JQJK9N*B1i!1(gh`Sk$9gU z29$3$CO8jPZaYeO`KWYgFbGkIl6rG0q<>2;RbqfOq^jZuNIxN_3lCoj18C5paR6EC zENwRhL1P=bigv7?52&e#=Rj10WS4Ul(V|c~q$(UVWorazziP}Gt->xj+Oy2)9k*8t zY21q`AesWPU0FUYqi%U-Ns7szbG}q`nGiKdVJDNSH~?w1cw`%?s|&{Z6h0?`d|>-RQj2TfunEbB#DZCY(_;Q zRV+kRj=I)dRulE6hS}09qlRu2Z&MmUBMl2$6E_MZUIz=wqRY$kcDCHwrGHW#Pw553$j96tspdg8w}Va}R7Xq!p# zy%UVsS3|}%ZW3KC>kC4Xd~@cJRxp?LYZelfm8l>^dT3Xq!wWMdl(96|4+A10J$B{Q znY?4Pp!{GN8PVtM%OfYo$X_dC7@=r;*{_5Zo>YJ-N}=2_ArdbK$=FoCGHoQe0;r1# z=Jw(T+QbF@$j|PSHy`MkVQK**R3w7?k`^3L$Kql*kq6xd;umVN)Z4%&?$bOJr{W|2 zPoV{}1?0>|vKcWBk{Q9%@wmHk2u~(T6h%qUvwhZ>#txtO-S=xQKXw39GpTkB)}u9? zk;3Icd5&5O8HvnyH^t+%VFfkav#Tyiv^sQth92&QNh(-TcgQ1B%~&-SEdMgz+_uj^T;vMezYu-b4EvMe|k z@%jrn$Gs9}?mIT>%lzxNC|b4y-C_tAGMFk=Mu6X4Bm~* zfL9$%E^xj)f3?R=GC&`ZOj=$K7cDeN=@F!NIdNmzppigR@*Xq1LZIqldxH z#z7Ri18ae#yt&#|rE^OAxkDmuvaFxD7OZWxtxFx1xaw)xFL-$@)yO^+%!as7@9!ScEM)f~Sv1S1snWH&Y^;`XnZ{%SDDVS9XmOmC zt(~SJ%S;5cI&$RK3C{AWjs^@$!FV%)hPdXA0g>g>!o4PYwUuCAH-ni)1ip`j=qX$x zqfCV=QVgX|N_$<%H;^&mf_(%+sFzI%KLz|Gl;SeWOEAM24hKwemX0F-`a)Mkfdv^9 zCxfv31(n2l9m!l~$e?8EE(9cM+(mx@2SDvhIf*n;zJteLBn(E~b4$c4uiuubTfi&l zoa3RPPjK4oV6*KYpoDL}q?q`C^NaX_h-bgdRYrm#H7+?q`oHCl%)!_y${D zL^fvkmYS|p#~|6~&ldO6lGdQ(2uvyk<>{&fsgk&UK=SJ-jyiK}cXbmokKwDf4w4R4 z6E1jJZa6aOW*p`->14XsADswfNUUPGdcMl>1KV2;dRA7a@7+>g{t=61X1{sww zs_V)BY)ATPvX${;!DLfMqffB)D&L8CAWzm{l5ab-$bvdS1eS8#Z!edAnKlB8my^fx z3JuR=4P40SeS_CcK(|4^mza7#3-+U-YWL#?6-g`Iwq#wYqBt$%{ak~&N`kpouIjcp zD^f>aB+)eA={TpQjsVN6jiCT>FL`%E87}Vd$1b&D30Q?=UWO7QF{-SjFKmc2D+{_( z|CuH&Ceb?uO;0up_-)L%nh2^aKoo~>Yll~dSA{AvMj}Z;Jv#DQhfx52mHO|+dZ7Op zFyC)};A7tCRzU=73tqbe1vl&Pwc!ML%K4(hf}A}gtzej|nvNrmMC8V%%P!< z27eW@g^uNJP309$-UYwM85K#4kZZX}1^0f(+4f?9nv8TMWLjeQ5k>-Jm3OQN{W|{6 z2RB}n866CgPZ&qlDsO+4GrrK+u%4mVEy_tjG}wjXhj9Q{hTNbL#-9 z_Mvj)Ci}C5Nf7xNOU?OA?WvUV^|AAaLZylpLz$Bjj(-olPHOfK5Pz+ep<{G(5Lls5 zS6ZJMD8JK3_Vdh11Q(;W2Ztfj1d`LblIBx_1(RSH#Kt0YEGlHpAvNRloVBsddcF@N zaUqX-v99;JG)D&84Bf+?-S(R067?G_Kr^?30op~0{pobD+gnL_NkL3}Ga6|#z>bQb zndZ;|Lv2aFL5Yxavf?iYgxVA@9S(&SawQ3OV1zOZGz7?cA5vheX6e7EJt60^JqM##AZk^XJ8A8SYf_4jEz>RPXwg?7 zYw4Imv`yY=Y|aMePw;S6j<=A$?3%Xw)kCKnqK0K%PJq=ijpas)!yjj*$s@D#hzD!x zD}^8I;3$&#`NjL(ylWQQDiH;CIMlzJp)WcXJL|qVe?_V&u}_8`Ry?~wTvy7M55n5) zVzP^RsO3!#RX1j=J+1taFzv;(%;RpwI1zW`pyqh-zS zyOXCyu-nb?H)P6vrFC?7YNdjhlLBOB?kK{iR%M`E@D-#oq;~FEvRmU2fT0F+s*UR=NnucpVfmO@@6-vM;X{4fsRl zm%FY-mC{Ebaj4{1tcX@pw5!ufF(BTcA6ZVo2>Gknkp3FI!h9wE+I2jnp{d~VY$~O1 zAo2W`fPzW1IDVUuR~?qP*n~hY--+lzc7Vz$pmWRs(|EfV_Xl*WY9+f?RySUlJk9B? zd`DYSMs7XLN6Zxi|ZDyUv>fbVWz&z!Y#$M-XGDSJcL4p=DVzi!4gQBHFhCW#2oi$6CQC5ZZJi#SHMvhDN_d7`juR|1T?i>$ zm@S-HF;=nc)oLnq`?D@xRZ9^ovyKqfK-CcAOk1{}zmhOKGM!(TEZ^%XOWgn&VX6il zEpL9jP2{Y(8QH@}r0^D2X$9Cw5)l`KKv~~j24+E@Z>{-&*fd$v%S;tV^uVk4hQk8M z3r*)=|DiD*eLIP~c2->!rZF0>`LPMbMEM(raVmorUGAUAEDUGf?(4;wE`D^8dn4;T z(@Y9VT!Im9>l zIyl5B*^_$#<_v=^9LA2yXYAtp7Sliai_h2>(%cH!v9K35Vg{N-C$(mEJ}mHU9Sl%N z8_s)=6CC%bH!4)J8C(*m@G{65LIFk#=Off%89-pirQmGk%i;BPDYr;vJ271}80Ro+ zjDe4^*e;XNYAlKHzW`enhHeRVTq%S+MTa##Bcu*iO8!nejepE~x|2@t8~6T=`r7va zQgj_`7_6r{cMxw5P#Uc?XwRs(C!WlnO7#*9RdP*$rOLY($Zd&>I({TK1n`=%6e;_V)_n7b5!NZ3& z%}S-1)6JBkvXqJeTKbCEXP$2L{l(x$(n&%2U2=+unl_Tvp??ylIeu1~pIL1CxyKPP zKtQ0p1p)BJ>Wu)ex@%rfp4%tJ#ZnwB-cUD^%aE+b%K$&l6jBw`(>Htk1Mp8nI2%M2 zC8HY=*MS?XL8YP-q3}B`P3}a3l6LlAwcKi=gPh7Ze^T)4Fiax?;K7UEEFKz!hejtJ zPNHZfix!|T;U5^daYJP_0f_)_Iq+I!?d@E;HumjnHdS`Te-M&v)x~S;+zLig;R3R? zd==rLiq*Kd^4n;8!N$;ug|gLn@mbkTnj1xyzO&)knS~Gkb!iKNs39XHxRY~1bAqIv8m?kKBC#B3Pl)tn2LkqjxV|Ydz-_VwdroB=lh*_o+?I^P+ z$6P4(;6^cOHV*uUOHEYrSti|uh}Mi`>>U3ro4ie!T?QQq*zqW!cn~lmy899~Ba~fJ zobQd0YAxXc;3yJG%k9@A)Dfbh>xY?{XQiDa?h6XWuLt4=G&s~r9Xi_(Eu3!o=g}>B4kwRfPa0Z6O15K;idTXA)rsZyu+1RgOLGL>o|oIfo%-gkR95WD!edm zp2~C<%=!I^8D->{3{LB3@m+JDKv-u02)2pvqEKNg~x4q3URk0Qfye>*oSaGOe*AOHTr0M$p zf@SL3naB)Oomf|;`XHs7s{h7)I#PojMZvr`jIGW6P3;U5HXy<<>((TPLU#A?7X98d z@}CRJ|KPw5jZQ+Orb_K~T}RyXUzMy*u>`L}*DMt!{$zwt9{&X~QL{<$2J^Wj zd+|7Pu%)+|e=(t@+2nsAgfv06oK8C>RqaG|n4ejC=(?%!wFV{vnL;xdXm zEp1Lx9^ZFzJ>DzWYv@Dv+W!`{e#;k%rKCXwDKmUmH~1Ee?e-{m0$yoFD4Mjdu{sWo zRHm8Z6v=umU~=Jxi!#ryak- zQQgiF$kBY!ZqV|uptMRm;zyq}2D9!49W3q-)7E+I=9UTQR99I7 zvJzA>Eogm({ees&ix@D}w1_!%&imr;OFZrkvU+kg4N+}s+qYcqW~6J@i^XIgbES}p zwxDDYX4^Srwh~7vJR+oj8So4@ykGG_OGEaO3r@y_vC0!hUI>9+bkbh?Moe-_eh@u&Z<`^fzG}n*YV)J_g-=rm<=r96 zQmeV?Op!eO6_akPk)Df4WOpg$V+3Jwk*zcvZ*va!`*67n%bWM+*Wvroj)r1L)Xqk0 z?r`pdW7DRu*Sv5(PD!eUmYFi7m&5Y}^t_G()S7Ai><0Zx&F)6ORPv8ytV^~NDjH`< z=q+)gxGS2i*Q6d({38R8ILdkP(2T=&m92&hLcGx>382)-@H!yY<& zcBAL=qUN+?7T2S)2j0a9N?r@>cvD7(5jpHbS4T-;YfTk>F76}7?W3p?&175JAU&Vi zaIh%S#M`zUjZ`bN#QdsLH}~axN*ZQxbI8t_HIS$0*oFo~K+XKpuNlf-Xp-2yF1JI~ zwTv}#U~|p3_Zs7R%sFx+C@h_hFbL2%(%NU^;Tn`t>#l{A>P_Wma2c+(p*=4KBxL3LMks_1Q>@WIdq#}O zQLHHHwR(kSFalD?H3tZDqF#%Om}@im>`X4jMYaQKk`@v38$*Uf`bB9drm9`gFn@+b zV~%>hQwD}?OtcVq>K$>gp<=EqN4P>QNp`L|*#YE`AKL;Id66Xe+Z5cP4rn; zeuqX7&cs1vujPS{ifuM7#JHAU zx)zh&SETjEf2m=Q!Vget zn!-s5nIkajD8l2reWIRgc{peIwX2CjZVCC?_VqjcKJXsKq z=+~~LNLHR*pQ2NRN`RJ*Pw&)6Y-*h6`0lk|^3~E2UmxE_uhej2zSpwuk6?$Cy(e+g zMeHey!Ts)#2eU1TutP|1gG9`x{H0kg=yx2c>b=aC%-f4q}Qj3^PN4oGhKf zg6B2OA}MBpByM8lbOG`&H+FGDp>jMo8fd|V@(X~(147l3vLgrSkuDuR@>LU5 z^A9J(Gg<6V_`{KIModHr1TQmO!P#UAoGm}<%Abr!pY3E1Y({*5oG$()mnK)2N9kW$ z&$}*|tWnGsuK`TYerdt)%+cKGo=?-i8(cXzwHhaCrz!~0E|-&nZKVxoQXIA{4;-Mj z)DZf^)C#t8X(qppD0onPC5;Z7v=l6s&M<=pv?AaW zI)(A?!v6dXRa_*UL5C-{?a&Pb1;+;Hh*tF**Fraf2*51vaJ1x5(yd}37Ih2MK zm6?XSN2ujcWbT;dP}C0wacmZyoyy#?u1+P1y5_CKGkHM52n@mf<#Yr2BIh310?Q%l z&JQ$Er#3jF-ax10jqG|jk0a?D*YFR=9H#Rr0?Pr=ie6Y1fz-O>J*h5Bl!|~+4J?6U zZ5?U>%i4D8?U>hW3i4mgft2mds&z$A`RA0HE0CinNDpcmnr9lwoQnDZS@mWRCY|F^ zh|Xl9_I0JbgEvGhxv{3tj@;|^RQf)+>)^&>SLq`F+zPrgRPbbj_!+}7;%XuIV!kIw zW#eHE4jB_q^L;FU8xZ)o0di>zA`yxlOKqyu&~`9|jPJ2F0|LmU zD*QlkGNE+tI6l!W8(Q-b+^o<%W8|r+qOiG|LXNw;4n8`7_Zp~|Dwq6D6}-m-i!5IeD$JPp)5}sQaCI_=X37p4 zOdamhhwh5H|L!ohVZi=(51U_QEz3Z&jL71*pD7Y23GaInTt5l!f~|DeO`8g+Il?=p zNOY=2n!g1()WU3|BfSoh#FS0t-)r^xyf)$(#jkA~#jE8HQ9R2zA0hfydPTXGmKj zGuGcWB>?jFUsCdI#7N%1QvOOk2v+r)|JFP@Z1k_~{}4kd%0Pf#z+Y-Zyu%a_>1vJI ziklcJ+60rA(JjUO|EPP*;JBJ)OVqY3$zsW3W@biLCw92isPq|k+R)@dk1|J!c9-7TC?${GCW7_4ynPh(@c*$JR+ zz>YQirzdo!S&2D49qs*)_G$i08R4cU4Leav@!srX3r-FTx7F9skqeUnGjs?b141+2O+e;`?8@V(xZf!d1554_rA+e=UI) zZUvI)Pltc}GJgCs<7X9M(x2eJgL$6`2r~}S@gL`r!Thm=)&GBjhOu?x0m1#mX;Tqe zAwekibMhDQzA-FS2(*)Xqp&CSlrM|y)d+O|RvGeT)f0){0nC9>VdWoa|Nm`0kQhZk zV%+5Xx5QxoLk#f$Gh!G!q)(CG&rf9QMocO&Zq;7pFtv~SCi>)FL;z8iH_imX{QMu< zRClc>BMtd7=A@_23jcqdLI0uk|8)%i-vn3wsz-iR5#YU2Cnk^TNXz3m(n{jdZHT1UaYOfB+ z&bqP=Xn%QlKOVc02zfR5Sa`R8uv^2C9`n(S4UqkKYW=}=uI<&N9KBj}ZicC@)~|v6 z0M3LAv*f{kuF_UCcdz^Y)cRuJ{p@(NZDs-4D^)hN+E-LzcD2y=J_c28BaP6l5_}F^ z`xU;u)!A=Ao9p{#6sU7@Mtd{!HrfstR?(wAh<|B0?)hp>@*oA9ogc)G13%-)`dB#f zE-!Uarm2QZRa!1&@4UHH^FwPy-%clOSURmOZS9vDmi1~2>*e;0(Y9It_K){?dng<# z?2TQ7!3fQM*EIV_#54Yz%5fg@Bm^ZMIg4T>b-Nq|^ zjnIZ4pLOLK#jIr`2|i`2n- zSv{|8{|xgn(h$Aj6P7jl9u#f9HV2OF5c)WX<~4GM*I5i6oxV(Ujl(Sxp<`F7TpY}O zl6$HqdwRvPZRyHL$abjSp7#W+m%yB!zk9eGRdpqi_-5p*BaZcO1Xg(^k@;p6MVDsM zSKLdhbe|0BMQ-aZ@Dt}%-o#rCuUj0e#>Da;8J&aWobo?yLE&Da5OiI>3j7kZChWC# z0f~9Hith$*u9By(;k#**g8wy!uCuNDZ8qna!{C6YY*&{@jXVmt4 z(-8dl%Am$RJUcyO!Px-u}RE^mW=BBCrg|Dt`_f8UQj-wwIUrs8=qVts7WK)AMC z|B)ruliR)R6)X=sK{)F>w0?bOc0-D?%IX5+sQNV><|kb~E2<0Q9`VLma5+rxw<-aF ztP3j}usMK0ML0%qkQ)@!q@=udw#Ayw7eY&SPv)g(_xzuujps>gyqCrg!erf;>zy^x zaX*?PgF>6=n=(?eIc!+4m*aa$}IfSkEV;BwQHg2Pmnqp2wb%)C@0&BT70QOD(e0 z3>!x^ay+aaz3|zr7OOrISl}{fK_;g#>kN#z{`Wx;?V<$qX@RBb_#l0IdMx216*pmN z$zEMvIHOEDzs;j3;u=W*ZOxcyIn;H#^NJ&Cl;k|U2wPEBtZ+FrsKZi>o^1z>R@J~B z8)=j^RJZ7?T(~r6<0twX2~~w)7cx`3P{F|KD@3R9fse^bQe(lusG@;^rkaVEAQ3hW z)0HE`5M*c*YG2a6PiAGYBtDV`dNATDGhV z0Xo`EaBZ|xmtJJ!JY(zE+b$fII^3DuAY;&H$Ok2kOfoZDH#FqNH{~<%!rPKUa2u}q zJ$M!YO#0Y`2)EN|tQ3Q4gzARZ%&|76bBsD0RGb&s*Uc?OdO^PdYhXh%6fRK)Pc49S*ALf6v}!?*)@5x5r}GO_wCh;7v1K7Y~=^X znfAj9OOEV%8=QUXTOYr}kJj}cXR#bzXFKDondm~9lFpCreIIM>TxZ!I9>XgYF-&Qf zBoc)ApGJr&j?DV4GmvL~9CQv^3QN$=k{$*#eqPU|R?gR?o9si+h?ASrvDA6LJDfYc zH+rac@14;hX|6_q>J3ZMvHsz`;cdYPZNi~`(y=|oDT$A%u@6@?(RGhYS7(`JZ@nUO#>(%?ldTgLa}mVQt8K*?ripZKnl9HYKYLD_nT9$DyZ$=UV~XPzl>}xz zM?7wZ_2gB^+^doN0w^pX*tW@;^>a@nEg$YwQ}9w_h~wTtmO6wf(NubJnF;hsvP|3D#p7j*YF4~L;SrsAQroY-_uaX7 zOyMJmSPS*~i&ZthV@&y?B^=c!o-g69w- z7gcRCtHC_DbWhfGG>n%HH}Y3myPAy0Mn=7%L8q{;dqcFr6Jusw?k&$vwDmEa+~+tf zMd!NlvxyS;R zdOutro4CI6fx?Jxo0yo|KXFlbvuFR<|FwDausgxS;&9k|VDl%K$^DS zb#8|6B;`fBe%Xa=4e-WX+sUPTy_`7R9g<|qYniF%9U|Ib?ZTm3&E&q+xjuv&qLsmA zJ;>gyws#qw@M~r;kdE(N*zkZENKS!i9{8$!YnUQPt_5etniedP-3INvYvR$0R{vE0 z_Hy6@61TfBcTc#^aBa+nDQ#_CPwvgYL%xkTIMy%hg>E>I%PAxUvg7ZI}a&_u0-x5WJr$d9sj1HbqvE1`xAIVBw-)gMcoH*CN{K)>_ZxE3qiV?x4`1EOF^1t37 z!tfs(L|WqZUq0RZ*&vegxv?zaIcaepN-T9$a!WdYX5IO|24AJbQmU*#U2LK8>b_nTkOHfv|ja81ivhxf)E?rS_&PT9DCkGq%O zMc3yO*YztuDjHwbpSSN{o?Tv|qd(rQaXT;Iym7k9e-&YxE@9&Wx-z7z=3ZWQca!hN zPF$M2wJxvrT)kb?GOwok4qtXp^*Y?-1GO6;)}>8cK5AFa01ZLMxsg$CH#Y~inU}bm z+KX-R%66*ODx^!^ueGi}Y8#V>SWdK+gLyW!z1`Nj+W7~HCY4RF5lXz5xp3}>-foUzPc9mAZPQ5~;@wT3ANj7Y#tGu;4a-yD` z?h;C1b2yU2S_Zrx>g6Ie${VAtTXW%>GFM-sakE&qd^j!+s=d6LGmYjrPGOEhXWur{ z?|$V!Jfs6pMEv!;+V%O+xJfuT_h;9`OY$a;%Ie*e;xY>Cv~NP|{hZeaDS2_Wq|rmH zv=yHERlS#Xhm}nD+x-V1OIim9KOoD(q+-OurF1tXp2V;yQg6!p_Y*DSBGEsj-uwZ3+P6F45DE~ zE1C)yPVduw2G|EYRzvkIbGVzFj6cXs`@E0x#(Kkz<=ILB7-8mtiiDZBA^HNyy3ZCpEE789yq{cU zEPFT>GN?)jk5wRHuKCD*FJz!VQiL6{GL;?jqA=5a(a6U1F=PgqB!uz{8R;Rk69zw` zD@OqyYO00YR5lwYemWG)F?hTM3r0}!8d;vSBbVdXQeCJuHgyuJVPQZ-F%I<{O9-G? zeOa~+CVp6iFH@J1`RnRYEnzoB4q-Y-Z@wF2zsAAUoNQD zcw42S%KHi6PnO@?A9Qo)Wfxa6BYYx`TBaaApsWn+e8ee`-v#t#D)Hb1$94J zMmqyY!Oc+lLdeqyYt1IafkegaJ}Zzi;a^6I7qV-!evwxpj>Qt=7>Xbb(x|^wG3DYk zAq_T%bQrM_!0Q5RqFQ=1Nvvid6FHGs>*)x_k*L%;=7r1~&ZXwfk;+Z(8sxGIP_*y0 z=i?~0n>xt&$C*k)*I0_zj(2{d2qVR$Pb0(J&mvh8{5sjeuuz~AqXFH%+-u^3YAucJT`^YR_Ko_7RHe?7(Gr?F8 z1pF0O0E!O-#bbctdq8mmD|5*>3GxBX*s{9#Zfl`t<|!tU94E5886iyB3*NQy-jFZ) z8uKb?cAu+eizzCrSn`M}5{%msD>w`wOwS$jA^7q!LaaWIl4mZ?1Q9N#Y|$E^>?hHW zsF^7;!&@-hdNzER75#@8%d&3&$WXau%cdq z%+|14+NY3^S$?7^=0Z|Y!&HmY9;N1YtD2Z8)^LdEMxKiNCOw)bL^Wz4*VF0|SMMgH zVkT?Ds;o26YECHLnC17LRB`Ea3Fb6JHMh*aIJ9;uUmGRraR7z_J!Vk*LR8Y1ZfTcGTlOVX9dNlB_}tvNT8 z(2o!aEvwL%^x1p+JaFn?+H5q?w_B+Ajr?Vm6S6Q8UFvkAu6%x4N_}hd;L3c8;qNyF zc#i#|=>^bF_9(9SB7cwt>LS9Dy5*Dz2FkCh_%CGhHj}*O>m^TkIV1rhGk6Qd_`RfU zy@K18O`v4XcmQ``BQtd+x{lFjaRr(yN{CYEVT~ILme1f+)%Z&fKNTt;2$Y9*e>kJC ztE_CBZK!o2L}rjh3khl3py!VQ?~=C?a-}*0kYBA{7Ul z7c3c(q!UtSB;2tt3ddAMljAijbLd5~%$xrk?KU|E88JMNspN?!D?Cj5*t2J zMU!I}yt9ZTycg^OyYC>B-@sH%@?QQY_#sK2ERs1@!RJ472}MqR-Z$d}P_r`Dnf{3s z4Fxm=6ipOr>`_(;Nvc9V=4+D*VA>*2*^BnO!M)QkV~Ii$sG?n2G?3fK6KqNJ2=UUE&c|k&tVQ z{7SZw%uN`?dO|VxGvrNMRncf?rJ)MJFFjd~Rg?<+O1aN!Np}h5gpI8zR=h2s?8XhC zpX<~U5I_$psnmWMsqXhQ&#nx|O`;busla)~UwnO%rp0;1VClv^)Mz_u;@gJ>=IMyy zaL=zv)R9!_j|LPcv$fdezjZYQtPI71$aNllx2xvDbsxvF5ynS8(szF<7q8_uGXrsv zPAjIzSSlo6VtTEhsjOiEjepIZ^9tbc3oq>8jA=vhjD%cV>3>}YOXSpA%K(l#Ul3cr ze>GP`^i>89uIU)@U*#vSKwwR4VX0D_Je-WqIE!E&QE-<2D|v8(#EKv&_G~;Lol_Wa!GTteVPdqLDhM zLSm@IudI=}!+A8umqDiKs9bcbn+D<4x^zD58l<^GF)!G222eTBv#Qy`%R(z%{a;pl#<~_ zAT0vJeUmlkn+UkeISqo3w*H-jf*nD^%KOAjf#=lzUO6DCl@GMyd7k^8F+wzvw1N)a9~V@JO)t_C4ae@hN~h`8G2OX1tg8& zy2}5Y#xk$x|A!1@x~y^rep->{`u|K+4C1sPBR4~}u#JMxoc6J=eIo}l2?u;_DE~~F z=7D~-Lu4iyUMME9`%436l99q{cA|$B&E#3eM5FFcoV1d{zkRy9-BQM|sQ9WD7e9^t zuv%N|9eqt@DWu`6@zwk7I4D#-y0|qp)M^@M2w5QzSCxh9kPtPJoz6*05b8`D6ZL1# z9Pur+m^ja>TB$hS0tS7-A^X%riQOv)^{`fs#0`ZIn)m76!Jiq*r& znzh5oR0eX$;lRm6gBRK%oQlwbcyvT*J}NG~cz+YYfx2o6Awv@b>Lvv5t6ksMD;iKH-juyTiDlatX6j6V@B=3Qp~OqaIhH| zrCF8J;7k|-?}5%#s7GtaC?{)fj!ksj%l*j*I-~2*JOh@%2@m(;CuL*5Gn>1{L~}|B zL#8T2Tx^F|S#|I%Y>ojv63!UMt@R#59%>YQwLP(si{h$qMS!wjQ%pzT%@Hm4ufbBS zG}M;Fwk4DV!RC0}!&DHkt%er+>jXHdvF$O6p!k=uEU`OtHruU$lSNxVGk%=W?@@>j zk02Bq`pB@{j%qsA$OGkrpEG_&F!s)^v!)luDP{FLkR+9}X-3qCfG{}$KibK4jsh4K z!J~mlCc9TP1waUzf&x7mzYn3QXT%L< zyF9yt#rP)&s`-JALhKs=eWPtyZ|Dx2>&@w$8xsGWEm7?4WMcvV4GN zDIbWEt2(g@=_d@22^uP@r%aKoo>Ekx|DqA^J5#4-MSF^u1$8o9$u&%9cRrBrMUQ@{3e;L8gjTFNbJH-X@1?8 zMg)SK=kp7tR9vCbSEVfUv`nf6smh`ELHfo=p4c@}MFjeY!04apKxQDqQ#;4}lWP%E z&R9E#l%|fApnoWb0Mu)u*ZrGz`^jEE&#l6WkV8VuK7^W{5kN{?JyoM^ETCL`*qkz) zRDj^NLv$Kll-Cah6hE(&o`^(d7?ScvEaWZ`a|fUa?mlF;E)LOZwUWsD1wi@P=lmxLn5GPK8OYXy*5k}6aqGf zL{Lj{Vt{$vkDuoY+IFOggxE}t9votF2Jg%FuZ*<=kMKZ4T(u6HL6^G5)Q%v2oR>+* z12`IinQ8G2#G!$eLnV({Yagc$d1Po;W?w` z`s)p`1&uvN6y+&6l@ksL6fQNa-0s@JCpvT(@HFX#(xf!p6YB~9wH`b|%Zfrp&->PTCS++@!k zi+M0)O?UuPJ)(C?wFt6rs`<~O%EhC(f5SEk3TKrAz|)qm@{+l#-3#`~7KNiy(iQrf zifnvTnNmUaK_yjF`4$Jr5V9kU7W<~HkfcH*zY^>K%RCi7?`O5GW~9=3qb5CDh0^ZI zaPtG(Kt0~T+{7>>*2AFwRNi{D z?-B7mF-%WY9hkdo8C1+B7}6Rn3r)JzSaKtX*RZ;fQYf33+L&v@eOr2%Ko81K?0A9u zb=yy=HIWo@tQ@gYfJ0Y+7BXd6jIaIAqdVE}zC{)+hO=##^fi@0f*{Mm51=j8!BJ1S492SI-gg4v$FiSSMA#*tv zyCM`K3We6!vQ$p?Am+Ln7Qgu*8qxcyX_r1-()b_*UQ0KVk@N0g5`_ksn-#Mk$8)+cxrwV4v2(^fl z_~o!wd@7%>mA)^XRn4hpGET0ipPU+`PcAb@bu7qb2+fU0_5J!ZfL3W=Q| z!mJOyXP~7IHfYvJHyRW+yYBcm+QS1B5(*S3V$*#N&4HZ6z)Jn;QRJ7o`{h@zQ&~k^ zFxuqr4w0zn98k1BkD$#*XV8DOWnlU1Wk!D;GNFQ|3Y~KZ64Ma$_Se%A@u$Yiv;TO0^@9t?Bs2PXv_=^d1YLPXF?3qsEJzYsgzLWd9^wCalYWx5}8ZeFvr!5 z4!my62gubm(seu(?@6_%0v82oG5wg>L~!$LP)(f zvwX(o3kjZ@?$vxnkzgKy%Sgdy7&~a`fPDh)fOxt|gwKPjN4<7*gUsOc0kYq|w@?ZD zWAh@S@A#?=wuJRiLTL?bB~so8?>%|&dS+_LMmq9{IVuPPI&X1aRevz{;_;(~bGj^u zMMO*qZGe?BSK@Pnzhoe_od2+~f;1RxQY5ttWNZwn1bL~jHn8zi0^wxkBACb=pzLu;6&d)=lpA!kI^yvVvhUJX>7(+yvjo={H=*vz)Y zxx2ykyza^t7f4;D4PmoaL|l4hP9~q^CskGg)Ea*?Y6~_YD{zo=Wz1iYD-Bc~<_ewD zal2!a&=(FD+g2C8xvzJ!0snEMbQi4@!(mysZt~>>5cz*mS zc-|4tdeZi2X2aaxA6WLmKs8ZbtdBLJzD6~nf&Ol}ix_@`uF+qvUJ^ZL5C!;#WIhOE zV*wv8el(62GMie3vnrm<<{N)J&&5dQEf!zZrCR@aAGTk?sE43Va*VZ{>ZzsWoP4TO z{6$m8E@_I7eJ0Qfi}l=3n-EInIQNvMhi(6Bu8hu9vls`L_etpRmjDadYTZ!<8oG@y zprh2IyP9KUBL?^(jl72^wer*JUqEN6!|wbYs3ibqvWp)8=yXYtg=PHJ@Cz2B(oq`; zX|D`OBnz$1LkV~^WB4Xy=?bAof1@pxF+b@@mP|eyOfh`BU$8-(MB==l_-nwSB1bNW+`M0WGp1{G2ZHhe`{GH zF5#CBxSd8}?Zte)F3>n1+{pn!vPcQd+v_loald9aZJ25a%~2YgSFWkhxM0;?pQD2& zXow{EN#9Igc1-*^=NH9RD_>Po;c;OEalymc&(Zw=?<74qjyz|s(Bp;bt5efixo$g5 zv|%SY0R7S;|9CVNNCWJVn~pM65YVzZe_Lccb*Om3hof>LqUV!l)nk5=ofcajj%UW4 zEnN*SW{cQD+3Sr&0b2to8Zp}hdsF&#TJ(MJz~0$7`W_`-SN{h6gz#Pql)|T<_4^%< zEabAhE_=V20Ca6%DPwPG;Wxe{x|2oQXnhZ;gT6Ia>l+82Zq8UYH}Kq3y_ju`=1^~x z;@49*zC%V*_7c)bf`dn8VT&;fUu7ZwK%|c_qQpp%T3D!mx2-9Eh4Av?Yl$O z$9UPCTz~(KcI*rA75Q_*-?y&wI^OJOGN(gx#$9c$TG-J#55Yyjs{_SdKH`3*+$-MC zxVm)L)3TnLm&(Bt+8?KC*xb~MtJLq2`$MnpU7qgCPjNaAI(Iy*ZM)Al>MozC5qwTw zPM@pS&)(+?vldtH%+8Z%ziXT{^K>hsRl9MXC#RpAdCGoxtiLw!ymda;Yf%avWhLKj z->9Q|+%$Wy<|0i#{J5UbdwaFvJe5g4fnMuvz|uJHAa4v<_)4CoH`dNNP-%67J}On5 zaT3r1RYdq3P zc2ywCo!Zl=Hp}9H42Durp0x|%DMHc+lWmeQTl968^aekSXm1Q3OqriMc!2%4zv|p~ znbN&@cJrcWVUp1;2+w7DFNQw0RN^6s4G3oHI2mKK=(;_Z{xV_uGlg?LV2O&NK&Hme zhq_1d941lOJzaWuTE!uMuKLgD^Lk{Nt}Mci&$l8j*ax7@>;+s{Q*>a*uo{*S{V8Cx zgjTT9cA6^T64ciP;@qkJ?rt)uqiY(7(YQSAUdxw@MH9QU;8c@s3X%Jn_qWojy0`%6 z7vQQ0;98LWXBpzIC8J+2oK+qjlSuUFi%WeDAk@Ln5Zm2z2al~%lhAhtZK63jHX-Ix`I+0q4P?D7_b?ly_${2@J4HmI2*tAL%K1T5)A|!!-e$W_P9jc7%yvbxVk(DFL!E75dgL4T6q*>-lQ~DDz1?}C$?j>| zRyX3B-6hywXwc)71?1aIfj}&|Ty3~Ovgn#XcvPkoQEOS7D--}iD=xOUI_#uVrA}bl zb-=OSrhx$-eV71-nfUFA)ErrH5&HzC{m*pI;36qg4T6Qf-WOAqg&n03Jd9Q>8Hvps zQ|D=vZkUYb^+(AOMbChKr|%O-jpNC4$Bu5^AGNOS8eKmsql((zwr}37PZzeYp_0Pp z^t#q7;T}YYn_sebPkEFnTs?SOgVkJPCrtsc&wf7F3jG}bMwD`G`M=KaPe$? zoMiKKb$F=bGU?_Z)UBJ{9Ov>VPkFm*@c=foalA(7d2S}IuU$CGowH?h@FZBQ{C++W zhBYQx&doYR)RsJV`{nmNbeD5VCf!<-}k-Y?B5KPiZ;AzavcMdtWv>*(qY<@q}x zg!fCKpQ&FZ>T>I3ObEHy<;YU&Q8;g-Vr}$seV{Rqcg~i|P^BUTSSlzV-==fehxR$n z1MMa*tKM)y(TZC2rw7ljN6!w|HA2-DVyGP{PqeXj{$Frw1~IpS0kkLBrctn)?0{PB zTBIbAI}$LJQD@lko)TCAx+uVXa!ltXmI()R8Q~gh&W3XoV76P$=V4vHbK~vJ^QCpe z3WrtW433yeXz#KD4g}d9Dm!z=$YRyyS+V0TM~5Y4L|Oewrf6aFMJ8oSnYM)3P*~+U z17%al>#26*yvx&D4OkjS4O4LNxvXJU9V4JJtAKoO3N{YI)`gQGPas?M`KZRqS&OK+ zA4NZz{}a;$IUL82hUdwnzEjw2^+4m>3L9{-2}(u|rCRvs-1xdX(9C*`u7Xzw;R?F} z`P2T0PW=NsuP$nqDq!7QrwO9ny9wUoihM@;u1qUf>^rtJ zhFiQ023BSGBau{Tr7m(mC5C47Tjx`|*Xw(TnPDc2?+&wxvALoi<^*XZcbOjc&LK>1 z;bBvsx$}y(6YIyd@Yvufu>3nmMK<95&fT+a)2i#kr1eDCNN}@IUAU)~k#<=}Zzpm? z;uvC()iK+u_c9n}LhnW8)wS`nSf<0HzE!?^rm{(=+mB2g?!GI3=~l}g@4W2y4Qp1J z5lHeydt?$V-$hFB>mPbG!aV0)xit{$H{5ZC>JeIM-lilbljwoOu-Pl^YvIOwb!et#o^y|Be=g0*L}9=-F(>M`Yz)1>nVS==XCd~tL<0OVL=1my-Yf55~R2JF3X>(vKHz@f*c+=#e6C z(ky6q$Nry!Crmi_q_{cHb&f;(oZZyC`MW-S)br@!a44KXv9XGTOu1*ol+Fo`XBy5} zpU$mPN=s}*c3Hg-(ohHwUn8vTuAts>Tf+{`(RLqyMeU;Tk-3D!ybV1m2-Yb0Btv%9 zdS5a<*Hr3MV*dK5_i=0ZUdphgv*7LhWOKQP3tZEuxl{eY!Bei{jq_xQIQde$(oxYU z-aZYU<(c8^#qsJY(AHe<(NW&HZR)&4NaOp{K$|HM!Qs{uozMTCf&UGI3?{eiZRH>u zmnGZzrSG|f4eK7)6HbBf3~Kxi)PE2G;a0f}cUY_+}30{ij082+RRnS_RH;+2s6=kW`S`HgY2CRE{c zv`q2uRQ|cQtW11w6^sK2jO6q$35J+X1d2=z3T@kV44JhJbN$YHFXJKz@WaMB^`}gwq#OZO*RXf6_ zqF3p@O4_ zdRW_W^>%t7s!N|(eA+!;S09qs7jV;e&D@tZbx?5uRaGo6Lw$2jAN%jmm%xhSDOx(2 zlc#TUZq7^A7gZl?8I>RR$2uSTyG?!94|BgJ4m?1iUgqBJe%(AddfD5%y|%ilWpiU` zv$|`#a%1T%n!LKc+S$AP04&N7%#2+a+qiSKxT;w{{F?23O)=QLdTsYyO9&onN}hP9 zio{}VyF=gS@m%lBT3Q)1h-yi`yMAc;g^L46TSa&6+P0eYfh1g2rHylVp8U4m{N66m z(S@3SN4SdO{q;bnF?y))_{!t`lRax~j$Y;^-~ym~JSURdCo@DD((z>b=EsH7b~l%B zTSTS8-wdp)UXSdkQRy6QU7PjrtLYbOHaE8w{^y3(1=|}B?>E`;4+A=!X=J_UuBLQr z($j~sxnF%v&&{6CQ|Dg(_xutcyEZOQ`?ejcucE2v)9+2ZB}P2BuwC)K_hLp)h)W5e zf}mL}z@whmU0s*nvd`z9PT%gdcyc+{}i1antN@#cX##J!(|2!`T4q9 z!1nrbVJt}#fx7yg#>*?-ICvn~%+{SXgW&D>m9$~>6P1~`krtW6>>%%Qw~Ud&%CCOe zR5W7A2t4&XB(ln42(ME4aX)!U5;4SP3dtNs?Q&5O@{0tBS3^W+KKd|n8q!kvoS(Hy zBz>u|{Y=f~$+@P%n9Bvd_M>;MZ^ygWSLcxHSQSogT5~yar;=ByGvc6R(@4I27B)xEdwcetGI-fzuw0gsN0}(83Ib-fwi8P zDv6osuqz;9lnFq==oBWGMU&@df(9KeRAuKtVIEKoRprB8EXvA~Kg)v-Q}CXAGW$}H zC`ykR7tg*gy#HzkXN=q3C3^-g?z2dV7p1&kiDs%~cxkk#>VC%%FbZGFZ;H(C_>CEV zo`FbnxP%#ut!pu5O`$@Fd~Ff(KS3m@Um^6lV&8~t21!8CVZ4y_Y-j$Bd<IR}GqpP%Hxu3H}rorlH zWsmQgxojYk9Iau9RY4LY%OJ@z6fmLrQDOM>PLR&p=tp*5j<6;4M3YrY(=G?MlfCoH z*IFlip2&%M8)zT_$`(ux9ai{f1e#J36x1-YapvDuY8VF5)zOEMMy)eBg6Gk`V_G9K zWrcbjpNQaREj-zC#l`VrtP)VIm0 z3>yX4@Z8TQikZ6T>cjK;`6;rUNommtwuFhOQg$GQT36VMxkv&T_)-#Rk*p$bn3el; zHgqud=Z;i>TyYHhx;LX}VPk(o3DVB3j@gJ=h3LnG95(g_y&p`G674t?C^$yp!m)N!NzMf8Bviy z543yuHISCMDeyzt(8+4$ zv-;?cO5~Ow39=kxD-2F8x{(7rR2qQ;dxh#Nzl{Sz2||yyGJ5>*6^e)jekP8=m!dI1 zsNgFG%Odhu_~kVS@*HbOi0=&8^(a^F<>YGuVu-PWr(H~)u{Sft1@xsTgDlM$ewRtL zjs==Shu&BqBPCXSsQYoGW`MH!3w@(Tugw%BW|AGC(g^hdlA6epzgS7OJ_(6jgHTFZ zC8nnV(FS>gX4r2HL|!s(SL}~>P#Wanz3A#0rj5Xh?L{N;Yp(y`y|wLmmrtbKuajbc z-m)+LBUqDseGCbL=eCvU%qR_rO@wWbGFYo+=_EdLQ2!v1DtGyK%|#z0&C7Q@*50Ok zCY|fgLIhW`JW@N)ii2zdlpuw-V`Pd3RR8o(7I9vZ9p-`XWL8D~>f)WVb5j37F2C}@ z6nd(Fz6)IeZ3wx~DwHVzv@)^@GVDa;+FIsKaoExdYVN-MmSxg@BnCb84}7&E3`S!_ z<*7zFBmwH6LKb4V##8F0M@aTj*Kua>(4xviblH3q$7I;wd%sJll7BP61FDiL9|$0j zA|9F?RMp?D@EeTvXI`0T0u>ay+`7Aj7!D*qyfW*FG20{-I2f*g&JDwlxA|8(q9{(8 z6a|=QAP=Q|l&?T30M5}F5>*)t7q|l`f+TyDzAfO-2gsJ?n4Xh=YT$rddDl90Xhs%t zVLQh?p>aH{vPCXCEs&lYClN29XJk-{D1G(oMHe<$IZx~v-aJLR?{4+9L8V>?7RYk5Sml>U_UpU%2j-MFRj|^l7 z==gBefkO%ZKQ@Lz9#NCq{nTwSx;R3W#0!h3IF9qf{~vU{V}N8!6D`_3J#E{zZFAaY zwQY0Swr$%srfu7{jhX4WHRn6$zW3w3U%NIkGInOqy8;v`*rsMS(UAr}e>{oLKsg{r??~i_;n_ zmMwcSOs1O=ZHK0EBUdOYIdZ9zhJW>7QgiN1o`@lK^aU>TFNL@p2$H{{jqkl$ze<=) z@Va4teVwDlsPtl1);4pHp56zj!!&RL(AXqEoS57Gf%DT<7Bp@z!e{;TaI##_kTw$l zmGZ)VD)(RA1%SG1DD(43tO3WRM_C&=;o^Hs~132_(0^`_q!(msnq249x=wrIo`7 z&Elm~@aY_VXhLlSlS`@M7egKf=Q9_DZ=#Av;<@_%Vn+AzxIQ-iabbT4ut3foBHp*e z6axG%?vmEQmTI&Eu2LG5p&lyDng#N(xxYShZ>N3~81`!aEmpXA#QxvbY?Awi2Zkj8$zM#&A`n*YoqjvCxL zjM;z@M+<(YE{Fue+F3sT{JZiuH>QWFHHWO zMx$>o?K#bDh>>guJ3KRn1w`49%*`faJTWjp$Y3R`17iE-Uk;|G$c&Eo$z|@ir2pZ@ zo-k5jHmOJl$@^7fwyyi~hcz9k22TvL%GB8He&n+2UWw(&RmDIDReU=55i{Qa-=eRtC~d4^-z-C56@*5k6`1fE=^tc8ja@Z(Z4G=q5OvqICbQ8RerQL?6-cBcJL?>nMkJd5>$__V6VAORgJKV zM$XFAi$?4=nh+tjqIf^S*@-5eyQ!5=*W1=%3Egi6(H@mJ%=c7dSG2isvby&WdfXVs z!;P00%cj_e9)l(o+&VeZ#P}=|R~_fw3(FIsomYg!>?bUz8!Tw32?tZXBok{cS9G6d z{pvTG3!yWXE_ZO_EOF{AwpM||k<7o2I%~1AHjqu?t#iIv)8U-X(a1iVH{AXqjNaFi zxyu%iU%stypj{w3iX75N`V6q5UC?1Vg$%}G-9fLN|0G=S+|TqADAd&5&n(SAE?-KI z$OcZ=K28(Q0J|J(1_usnMr-tOh&3vV@ioE=<^a3lBhs8Lf`7$~hBojwp2w zi_aadMYw-C#Ke?L&R;kM?{5snC9nf)g=;e> zPt^U3I&k848`*21jDQyHAL?WUN)+AT$$GG*yuzjI=u{)2LcCUqNmD;V>9DoiMb(ww zw24p=gs+OC?ye~_%|hdpjm_T5u`aQi4l+EogV}Mr{?pquR?E$V9NhO7#+k$z`!rWN zq$G?kqtb6Vej<@;gu;t z?(iyL=Q}~8A{i&lBd2tljdU$WcX*SkMogR#5ORBo=Jrd?*YPq$6juBaaAKVqK_?xP zan@o)htI-VWt>rGNwFwlOtF~S&>fE*MWDYI8=tZJPNVD@O@ z$FCB63!} zANj&gxK;T0Ee#sKt`DR2j0>E@b=!e4+KY4`&~i+?=~qk!dD5IHVZz zGpA0}n<>)_{&l2P`OrHAkW(>@1KS!spOl-U-j``iGnc<|x58xXy(b81!T5VgK+({(N%K4vCWGr~$zO0Md7NcLCOai3 z(r0kj8I5fenoybkFG7G{p`oH6jJav`E`P)aZfhaHC~MeT+$Lv*i3QiAJ04QFUM#c* zCl5sR=}1_E@yh(CT%~`*Uqw}Q7clLW=tn%f1L(M>AzaVNIdEs?!PP`5YK?!R(aExj zWELR7Li;yj{wfN=WZqsJbKUz;p}7wC0&56MeUzGRs&Bo*eL?|?vZXO2vZeIKZ2K0@n7aaEMxGxF2C7=crTFO@3IUoQL~BVi;j%H1z~hVBa1DHHfolGdP-TtxPtF~pTc(f z0nT1Hh>_D0<1|8nQ;M#(zK!b*wpM#?hPcAWC_Q9E_6_FQg>2R|SRE9i2JOTG{VreD zUpNdT2mvMPa!>r-PYM$IllOI6Q-NWeSHMBkz70{h3Jzmwkxm`$f_h3x;gR7d($kcI zu;KIpUqSuQ0gM-IbYF43jwcrkW{6*PU|pYy6fi&^${bz}8G>;pTj?$y!lsj~*2<F=Iq`+KSHULU}8+L6DxT(An3DpBCP*B4sd%zF_G|cLW$eZZM$&Y9%n6$@<6g*53-~m=Rr!e&77%^_t1{b`n5o~(N zqndORsCjSA8<%y_>%YL2Pzej>iSTU>D#U78GbN2y;5RMeL4xcdE$@2{{2|}L-~fpSCVH(h^-CS$Si!KhGU5zOq#d-U z9D6$9I-`;D4L_%sA!=bs6%Y$(lFr4waWa}Z*uW&&zX@sd=mmLhnh1p0Zw#j7IdH}6 zfka0aFs@!$#`+#9;x=9g$;dvL=a%mU0b6N}!AXmjn$9akJ9T5@o9l24TuaMzGpN$i zbT~K4Hk;Z~*aBU34&rw>Q?7}tC8iLt04t1DSb+4@va%sQz^p#M#LO{wPTA%!!%yKZ6cy>a>$K5eWEH+gE^!|>G}KZnqz%zYs?R5im3G6L-g|>yOun@{hkZ*UXE`=Zc3zsj zkhL=3$bAUyXQHQb$4lzZOQG-bdP_pX(`jn|Inal0*7}vG{sepWv1VC|uDr_DG1tL1 zVm{g2)WFBLU-xdl2esAOJVM5jC@TfjjVo|pr18o~wg*=t-9h z2$u*=wdfceM(`4FmPMrL7|6u?d_q)}n#t#hqU|lA=|v!-FqBw=z{%Nx>x^8D8jl=( zr2r^E+6vD^Gd|S?y6oe)C+smm|fi=e;5kI z3oP)JPwJ&7F*K@-rZVi4*)t6oIrM8(N;QFBzw&9194Ids<<})Uf$mFkcflGFJqN6i zypJcFCWr^6v#2zVum@$L3f#RLBa z^&wgX%@~lmpt|5kTx#Z6l3zj-JdX*Wp*wbt|KE^22FIgB!AdoF>(8p*3r=0+9`#*A z`RFwA7){_|BrmnLs{K8l$2JH9E z`cyxKo)rGzWbDisqBAOD0O4h6jF|Fm%-W<9e= zpO1~Cd*!9vHxXk6uZyZ!M=!QN&n;yX3+cWGDn35f;}xWO0yuC#H7;kiY#r`1Wab0Nd0*{2h z&Mg&u$f!054kmeguE{^b-eTqTy&^t|d&w48^$PvM84I6U(#{B7M0NE2kSz}s+At0l zaeO9$mkz+t{@3D86%*)q6Hlq!gtTz z2cTjetWLn8u$`EHL9&Orv1XhXJY#CM_Yu#8{fKZMd!g3{D(hbP@>kiFD9xsy-ws-; zLY{Y)y}csd!I(Avyhs8y;h5_EAU{F8HyZn&8sH6O{Jv>MbOPwNpjUro4td>uY{(30 z9K<;PeK|;5{HNX;YAiB_WfQNiylS7}_GJ@5-<$Hn;K$HltLS>{(VWSi|NP;E1Z@#d12GGwE{ zGi0A0WX^p6OyKN%cNo8fjU(@j#mXaDq-^YHf$+k_qIM$pU@e^-nI zP<+=|Mu&MD^7R3*NB(VDGjrVS>|Q&LQzsuizYi+k-{&4&_5{G%ub&sLK0H3WczHK< zz~3!V5~!7sef0J51^ys%aU~DmmW@vP`fL##>Cc88PJVQ6UAevCvMc)$y4f>&;l97$ z$$fTg=W&caE|5qLk+S*q+QoKVf4XN}ST=2DbGp$)oT-)#B8!WIuGpUrT6OW-*W3Nb ztJ@SrIMrXxbH_D=y1$q_c{3%2@qYI3*d#@NiKctIX#d{Z=bJuFIK)4n$#6exqZdgD z&iBhubBfSGAs{E9ku9@s$T;6O^4{Uo|N2rga=aToPThlgW4${j1$s9)Z;^6BRA$*m zZ&-OR=*IaY-GdDLLP`8Gpsezgo+6n^j+e~(zz0_^LZj(Bs)EwgrUe6RH@Fdlo-Fc7 zP}nG?^ZiZu-Nu(=2Il=>4fXZ~u{yeZkqEE|NgN%^LXEqUwC^EuaZJ-jEa{7s2F4nt z?IbrZuTTBji~I5i7$mn7FdAq0$H><1Mch5nEZu>aax>>K2??}G=h?lTSbF`CR;N!r zOKa#$XxbV3=-q|(2=?LR1Duv8Pa(;YBxnJ>3|Jj31cN?>c03(HEt(+&ip!AQ0nE*z z?oI=z#u|4w)=zoqQF|$w?I<#jAm0fJANEMQ$`xe6ytOUl387&oTL;iT5*0kaZ@cmq zf36PFBDOyu^#sP1Po49^7-phRNDx9G)bZt`6CBj|d!J2TCa_UGi+0Q1FM;ua-m9cX z5_}nA|4tfox`pV0WD)CUL_Tz#hK0+ZI|u?Y8%6yl6a@Aep*v_>jJ15gaqh#}jv@Ez zZ|-7+_)D(Vy?g?+VLtX3w3mZVTGD{`Ktbo3p#sZ9^z%vqP|2 z_82yJKRL~q^?ZL%8yfw1U%zP^%Sj39{g$_Qxw~TI>KNydivgMVZhx7!`ln~jd;Mnf z_u|RV-!&kg)<55xeR@a#9Lxf%uL;=4CNiZ)hyDKk^WB#ZY1QxhHlN+D-i;sCP~P#& zlLrqW=TFAdx*vsVSp`<{D^vzQkNzO44HjJSUWOKkc-O5hO`i)X@iP%c)ZJ&Y$umZl z2@3$zI(4OHUU#UPGKmR!)L7rw_@!ptg)_fcUJ=M6!dTw+#+&)Gxp9`k*T=G*)i{6m ztDw%=jw>ws1LjjJ^4LI*@lpiIQ_7s2o(dZ*DYN0o&bCQ-$lw0M1~#RJ&5iflBH!Fi z)41r@rQEIXY@5h%A#a!n%j)oas(db2jD~at#}nC3bhWlw1?_0$%h79u%TL0YOFujT z<1@`Zu_zfY!%{k<`#p0pL_dp2Z|hiv0^T;bVSlLqGB{n$bk zWSyzkQEYe$W-`&+4dL4J-$vz5+;+9?^y9)#xA%G3wnl$l2i*K(vMi#PAiMS_qn?Hd4KoNxhYUPn^jiT_h&;7|D{Xt4}UH@ zzrWFx1aCI3PyDJSY=bhPYoTLKbjrq0u;t8cI$+Q-);sQf=SC*FgI3i23!-Kt9P%U7%gZ%JcPcW)*>tZc?C0~{dpkxhA#GXGl-tY& zZ|T|N@~pi>c-8agdF3|g(FlUT3v#XRPBs%o&1+m1ZO5T}slAJPF@4x`+O%Iy9Mn$* zjjn0d>oq^D9r&`gw#9W97wzaW($0YM_TM6>`197MgS5KLzcvk-JBv1z1qo+P2PZ>- zsp)$cl6&v|sECd{{s&4CzU$e$dX66fmA@N*Lvjf2!IpjF;vomcYS zhC&ne5TcjhKlt>7B#+;7HU1fYl}WOhGIqZR%)U$dP#by^jPmpQ@Gy25J1+hKuNZY` z_WNhVEX^DX--4jPvvk%rQffHkMB-Ct~~a@wA<4`-=7Y@jlDWQH%I?`?h1JG;{Dk-lP z>Eq(~zW1|H5RWr2cmC#f*x=E^w#tv}MBnY71jl!8FyK~Bg_c=mZHwBP|J2O9yoWKd z_gnAIkA8nVfp)QfRXvhMZsWSjbE~wCntnXYvO67o-hRFwMO5Hb6#DJvx&b>_)) zT^R?!6wk%?yMtiW^U*=p%BVkjJy&Ds^I%!G7qj*oHht~bnC^?8SRZANh!-gVEhf?o z(Zsfe=CXSV#ztH7BDmgh=;gai)16TcJ3-#P}Tk|;LUmOmlSW?09BoMR>$Ok#`r|^ln^?@msbHp zgFnv=XU~FLpW@=Uz>=C2qQ`l~t#c@BAv$?vrX*SviE1QTl!-J6OMr#jf=6BaZ@?PH z_ZZP!044wyy>Yn9B{zK!E}VqSS84$r#PKv;>cjq}ltKXaE7j(mI1NopxgY_zXKIB- zO5{pKIZNUA+Il6a>XN4msXc#pO~Etf??5_!omX$j*_Pruk!BL(1jz}pMp?2du||0^ zHIj;$uku1cBv+0eK5kjJADj%*Z+Eu3{=g=2Hz1A-OgIP`u$sxYTfm-F=2_5ds>j@K z08w8Ks>GD7r2@*&F1fKgJSCp;nTh$$Fp9L!L?kuiA&kOqKUfmzP{(N!s!^p&EJ*hUieCK_!SZ6caWo0yD>l;tSc?4f0Vb~0mqBZJf4T4^(&GF9&s!P=Qo|GkNseGOis%J;vfr2bYntGw6GFpG1MCCg}2y( zR2+6VipCVBAwu~&tk(mcYWDEe09PebS@zX}mGXU)%qf!O6y{3Ud~rxSf_PTbNacup ztsdk&2{;<3pj-v3C%7yy8u;?F@1xoP>{2-e+dS7>X(s)xhR9lHp%i+?a$w1@B0aA3 zvZ8>?-LYj@=|>}dKX=HpXyyz5&m2aLZ^&wUgRU}=7Ai6M3!0I@uPlM3=;AYPW7eZv zFlaLUX$lZp66OJ^lyaInCQaLy#FmZRiONGRqEYatT89LbB2-szIQ|#&4w1dr*?M<9Cpu z(`gRm^O~y6b6)Kn> z>SZn$ymHKN(E!H_X?i012<0wBo4F+k!B5=rj0}drjesig#xOK+BP0pQAB4Ap2II?m z&EF;0X;cHM^fY2jB(pvZPpuijh(Qts5#^a8qJas;e zfgq6>z$247Q<5MyRGb<-|KDJrqprZtSEjTQSx7djSr4QJv{VCXTFf-DfAE=~)Aaus zV8DUbLeo9ensjM(Y@DNe^fpw{H=v>6**Z9h`xD*q4bUK8gt8C_Ke;p;mUF zEqqY}WFwXTXAIwypWMh4PREhI+hpdwvQb=_26V$Ip3{AQXaE@C^YChZ>z^mc!hROt@X)FUaFa zNs4>{{DblmBph+ayVyz&YY)Tug%tu)P0m6kkXiz15@^gt)*+wn4T+d- z99DAa6NWa1E%b!*1dV4`C5$Dj!|-MrUDtI;h^uFy*7kN{TqgB}Ky;2N$82`AG$}G* zK{dEs0+9c(g2gS<5dBEDbc1b^2CooVQ_QJ@C=3yQZv}S2scJ0&&py(9!o#i(Jz@o$ zv@!mm4`Uww-KbWyDe05A2P9~c9}Q;xo_98pzVi6jcE7iZ4CN!_fedX{uu^87y9UNE zjH#CV$476x-BGNB&8JGoCLokV|iZS8puigjn;lDY5rYldF^M;D% zd)=QYm4Uxwzh z+>fv+V01HsslL#UHI~PiczL~ZRmO@9@I3m2fHz%I`Mv|_ zNf=wm+W&i$#D0$7U4tf?&zHoKsk{~zpZfb>h{O9Xfs%MC)Z3oiji-1l)C$x=?4h#` z4uS_VZj^p=A_G@(j6h)t6FYsu(8d_JJ{{8(9ggBuOYIj4AJkPGG<8r+ zt3&#z7R8XSs@RHzRZ{vp9zRx4TLL1U%AyM07wh7X2mE9 zI8DfcZT0a}1h9#)plrvSi85dpaf4Vt>cAM`rEO<^KPN1knfl^~qTV@7=oru!t<88G zU!Z<0rspxQuB5a5>>qaOu!o&DiQIO$LDMxj0Ns8W(44Z8IaW&(5hOazb7&Itk3_#>fFK#Zk! z@G`VEA446cRppMRujW9Zc7t1=fK8s`=xlG;IOv-|Gh)2~{M>+-;45gVKk?$%0;1UZ z2ty298g;dWsbR8j$GiVy>x_sR=)^`HaOBcf*oAFo?xqU#V8q*Ozr(O`=5uN6$pK6X zCO}NHnwuNr#dYgS`|JNN$|QvUnhz`?^)rh>?c9$K8{^K2>|dX!I7K!Vc%*j{Dgj;R znlLLYd4CtdWAAHRj|TtkictwegTfYBr)p&_8(t&|i27<1lpmELrp-pA;^L0dk!akW zCjkZz+eQ3*;3ivP6?-G5+F;kh)<`fjTWw=%g1p=P!xf>tk({Jl^Rh)Pxx6GqPRLfC zXwJG|pQ_k_$5d*{yWDU;UB-F)9|RYcA%!lZhJ4u0EbaJ95^Nk>62b%gF}~ryFJ4kV zxSs~}0Qbvrb^_&alQ|7j(1wT$*d}rNI?>{HYkL-ih`~)r!7}w+6j)6XV_mEh)!2M{x_mpFNcC z6KIZj*+;n8Imhk!KU$G7Ar{>d?d90>@)>pM1CzX~a8^k8$AN&l@}9!Jq7%2VOv*oA z=FS@;pTpcni(cJAW$YkEk+q9~t|yFQQbMH7lQFBHt{w_y5VQb@S5wDG*2Z0r?;cZs0?zcQ3JYsY>@0lwO3ek@2%rqBAr?eIDrd9#G}UP)JWzU&$`fLZeMKw?sIB zt;wFk1ZZoSrG|o_ykOi%?I0~0^voOGQpZUqQJMl)vXd=kt(DDW*(pV3G+^^2tE1^E zL*kRipACF;wT!2q%XRq|ifyJ)_FwkdRcP)*f)8S^Pl2V8qp`ffEP)^ZPr;?mmdGSz ziUlw?s4TAEkn}v1O7xEAEo*8~E>I-Vyv&APSvtRSq@J1|Cnn^&)e@xPLZQcQWR3-`K-4ERvES zE*w}#2wzICs--ebY;4kT^P-=puW=;vQmM-msvxpNo4a7bgu#Vz zj@@wKl$Ewe9hnrmsUGb9@I@S=lr8;CATGsFjOP&bq?i`$Lj1MO%XsDZl26k#3hq_` zdp$fi_vQIaUo-7sI5xoxb$LDq3S6jD#th8advozeX2kM30JW6O&B&;QAT{i%(P*WF zwx}QL7?Kt!f;?Ft7n?bfj{}glU|Pxa>%@bmf(VAFlve=q7rBzNY5TNNONp5PJH^T3 z7zv~l-m?E$j&E&l&t6N)1hj-j0#Z5XT!N!pDe%b1=-kaXnp z*37Ey_R}04{g%Jl(;FJMLYg-`vqz}*{O)LBj+UM6X6QtHU zmX8Bu?>cTXrRHo}14@TUZGj5H5FzcyBqE+#Y(S?QAEyQc!!#0vCB-csNML9I8zVuo zFq(>p2F}ceqdtN8s1&*G{p)qXozWU?!lIBJOf~aC1keItdw2(1r!5NIyP%Dq68%y> zs;{kst%&7qMT%N6LUe(p?5HZ8{Gx?3p?n0aS?T2^g_8*^cSX^CY-l=-EVPA9&V*9}y(x)EG0(Q#o1%W;fFJ~e*|9?tyN1uDjU%A5FMUCDb3)TtY3 z7gJl7J}FJ;Rpc2^VQfX&G`mJgjnkGnywfBxBD>6={)OTT2w!S?x;#7N#|BC5OvQH! zfBft#`l8t4ew{ByNeLd z`kA_aspvTdxE|Fkx8Ez9Z0TB{L#B6_1p1o;J~&aYZ9S4OopcI>SRRRTLejC4%%c|@ zHRY^7wjvw#Yeq>6$ieMNt&QzLsH3K>!LJT?!5@XD-0-3tBn&U|$)mL5xuXhUQ`@Hy z7^@ip7$o8Dp`am6{R`?Onf>dHHl{+3kW6!cuMP0Y6Bw8$w-OZF*;#J0yD2b_cLaiD zz<5uVW>Zr02p9xKN-bN5k5wh9E>evYJJtOYWS3-0P$Wu6FlqOU##*u*dkhBk+1bTT zYN5#hxPUx(M0u*9LhLM^It&NRIi1T4qMSu7oO>yfBrJK61wos^RKXPo?|S$-5fKVo z6}DnSm9(5K)kwLeaGdvjlSEyDyp+{Z%C-nu6{P;QB^EGM z92w@YQj}>tE5#||%gdIA9jHn;suM-+G&{S+iG1s1GW2T7psdXan33MyEIrKx{f%S^ zwCybpmMyiWs71BP4tenugX&f$E>D!+AAnW2MCqj&&r0!y&hMGEAmy|}Y8s2vwx*D2 zbT8?|Jl3h90q%FeCj5mg*Ui>T1NP0z85uBihg-!dC}44py&gWofW#XHKsj-vV*Rz5#G;^`(YH^KV@Y~+@BtE z7`gA|2VfN=Px}zAmk|GIogm9ZKHBdTUHD2KSVUIazG&$xcG^ChE>g`@A5Y!d2FkN3 zoUamul_P;QUtvnDgpxxoU8qt-!qXyInzV2r%cD&xnqzdh$GwMeO5dRGzt0vndKqMd z224&DQDicO=#q8NB8}!+Y2=7iNgisD5XZAlm|`xOW*)VQ^ww9LpeD zy9z?W@&t5opRu>%2<2-8Vf6qNtulS9yL6|PFv%CHlMsKhnn$vZagh(g4SC|&k_ciD zsF2^4WVi_qnJN+5#?cy6Zw?NO!p)Fr|Iv>8jw+2*ZOY%huw!Nhg#-vUzpjQ`2NXtQ z((l)ma{wqQ6C$H2Rzw*r2C;RqjNBcnDpiY^@niGpm`aD@v7L z>-KbJQfJcd{hrN;m6s+5JMwCJ9Y_qPnWo|J^rSpSbqq3R6JGYx5GzuF(zf&ML>-Gh zX)SekAn=VOB1Dg=YVjde9A#{!-J{)M4?h;YND*S~? z%l(xr^S%}C=u1bAbc?)yfc68>@>pX7SK*mws6jv79cz;;W%FX?KV1o~ zTN{vO0c$gY&#==R=tLFc?~3?5zwC+s<19(k1ONNaQJ!uhwpq`ZAc;W-NSIu)bE< zwpxZt0!Ac4c(@wZ@Ms0Fa5Ie2Z9{t%768^p zy5;%#V# zo~N4bHSrJi@PjHHq%zoOOa*l;2$9|w@C*QZvp(FrxEk{CEmFWkGY*k1tm%Sf3(`=3 zwPB?O)}0n+`@OnI?@d{65d)m!IK06#iztH8_E)=@60R+5!?7BsaSPQUTOB12yGZOt zcrhgF%RNjaB6ZjjQORfIO}n9)7K9p&ZAERa492$R#9#GgxmT+} z=BTrR53eKB`h=-;W!dhmbY;JH-kG2_KKj@jRyb#pbiwXsn8N(wtFAjojKeuZKI=lK zl!?=%5OC~sm6eS7`!;hlk1U|fS``aD#Iz<{+DR!Wl2U*c&KZIe>CNI@G)iCctil}hXj;I)b|B;S=+ zHejki-CWsC+^FXfe(^@>CS`xSYAoScTQ0BHg0?r%5Gm;wEgCTE4~nS|*>3g^MCA6U z^FNqH`{BN5<*!Shye@u;>Nfi1I3F63;F5le@MfwxS7k`t^PAe)aV{$$@X-pbXcdao zQ|l%6E*?XXOhM43K*$~dKUWpvbR+xSRpXQ#KTCI{LC?pyt%&?g$bC_^? z&m;!v88wx0hb)!M>bvZ&S%}vo=1dZ6*)=#wvq(uc%Q)6uY^PQzW>xCk*^?ox>9DSb zy&x~ojrrux5@8nE={1!KFC$ldyxQz}e_~1>_eAqP;4wqQfz=?_Z$R+2idPP19bA7q zKM_@<>v@v&f5svmpS-%9aHM7l2I z^6GYQ{oxJG^~nIaFvB%31~<>`oW2enk?0RoS;+&|h#@@J&H$8i}vD zLjrBArQ9Dtk7MX5g#oyj?2aC7jS>54Yp~A{_@QX4;ml(iRfe7(F{j=Z(9oG~q6=Q;eGM~P&!x|V*AL^< zk7X*6&Re4>GEg2G@+wEm(E%OzGF@h(U5Z|_E>L5kBSQuGvz21L*(kYaKgBK(OIHu` z1lB;Xis1}N8`BUqSQC1ER;!K*|79WhDKJ^Mz~)rl8yv*F^kAJp5Es|M9zJr>l2%O8 z{bjKwUsybj7W&-<11|V7GI;g~Xhuh;9|DX~l<3dj*MDp~LviL6!>@*U%P}#+Nt#Z^ zB7ag{4fHd`>58Rb9CLc6s-yY9EJJ5i*EA`nh`+N~)1s^fURXDQCO8ziQ;NMzwlELc zxP2YwF+|YK6qG{@+!Wr^2r^1*9dOv-VEHPxsy%R{ivaWWQiL?HMUo=Dao&HAPGK3_ zW~hh|nxdhZa2b9hm>7LFd`~G$1YCC#6)l{toa#@*K)58l4Jph21IEzOl}wNpeXNKnfO6TwGMf(0EQR@t~* z8iSx;Ga3!{)U}PbtccypY9Ir~vyFr;5a7B?hmDGHbrUo^OwNk6oO#ZNNPXh7<SEDM_nJN0 z@EM)a4)HUel6rq?+WST3dc57FWYpenDP%aJ*oC04X~35#I#=c8IChPjZDM&)!wmz+ zu)CoL*OUML_$5axGZE4gDqPVEzr3tBn6IiYdtou_Z7Ox7^=nF5 zcr_GB>3VR&MJZp~e5oA;1V5N+03D zx>r@#?ykD4dhdI!0_^vMyKL$!y1vTzlV-*^0^Zy5cTEmYNm?HGs*^(zlX{J(2J&-^>%bp>FazlOP1-dfM;I#Yb_ zh&7+){8s{>L&N0y{POw358J6rrb8da7pOtpnI)=oRmW4 zX>|=k&Ic^kT43OvL&r9r8{~V<7rFePbA^w8Z(D!#?e*&Ip&pSOK>a!PyLc!$zwU$r z(&`6Vj9osz_GtN3w&JzPX*skhEh3jYb>_$~FYP@z_trSip4RTfK?X!Res|&ctb4xe zR1JyS?6Qv4YcB6sj}2|%ZLAH)4XcS+pGI81FKw-<`-M+)q^CA;>{HYecq((OcTh0u z6OR8w5VA*Qm+{u&6Y!rt!_gnimyfn9*eJ=OiPyka6!~Za6F6PhSGrx{jEe)9YZu3n2FHvI$7m3BzNo$db24fm zHq2+c#az-VKGbUX+jTu9m*ucrr2(G%UN7@_s=16)&^-cWzbjsY^ui!JZ$zz8-Yi1| z5-sVk$CW<7=@Z7%^LorA%)qptOsGG;i&Gb!E!$hw`CU;UI3sO+#HBC~l=1lv2qPcc zxkI%>sxcm;7nTsXNOqR$30%(E*^{<)a%T5|ok|GLxBrR%OW-@OOY|O{&DE;@i12&+ zyNZ@rp(Ww0O4;RFq(H}9PkF0C~;E`D3cgUhUn7dNEA4wl*>pGb z^xeQ=<+F)5JB})DvBuUH;ls9AaO1RNc^N78kz0dvNqz)3+qGo*a1wE1jGaRjUY4VY zxQy7t*-|1tGvmZYy>cEq9$`+RB+z*D_>C@=nFzm7N)FP`Zua;wPdHMpB+!%Xw095F z`R$NJLAoUG=&%YqHqT#V+2YS7J&v+DQM3z=gm2c+W^@LyJ2fgxa7=I}!ri*_)iqFK z&Q`-^qdDPZ*)eWrC)vHHLk&@rW)I$`kqVyN8Qi4;7kv^B)7b&66gYL?ZKu-8bp71V zq$6a48Z_6&1uz-LBk=p640V`SE%@z1*|0uY<#qLG+XWQx8V9?><*MfEw zH=cP$3)0_!(9q0}qH}a<@1mr&77Xr|RBO=Nhsf!1IGkPPtb)58BrC+Va(k_UryK-N zV^(r$X#u7P9&scd3fo!tTzOVu-Q0sjdBR*JLSFt;-+mKh2S9LH-O^OaeG_Gzy-rn! z))As3Cy+<0#)G1g>OLc| zYqpF1HUE5I|K|Am>gweE7J;|x&BMcQ7uy10A3fIq$n$KLuRFl7zH7WQBcF919`D@6}k1HEWYsAEPQ1ixjCTJKN-p+uK5M1KH&I$0vxYyBHTi zm+}T89)zsvl&Y+#>c=vkhcS_;jyUxR(;ZkLaaqk&Nm}+^yQnWwxqf#PRj!Y&I%~Ye zSTB>Q@Yaa{zp1N9%29#xk`}g5-yRIQW+lScDRKnN}ch2Hv zQH9?O8ksfoTeY;8vF8`pKlfLBTRx9Z9&yhy2wLnYUruk=Q%hRj0WnLmf^a4mDQ$i{ z&b#QDDMxUZf_kp+3Ayq~%S&Boe^(Vh1ek3WVV7)xmCP{;|KTNW)o z-miSjV3S#nmGbNWov;TlCOQH+*dX*XM~wB%S1dlkFr?!A%;b@BcK&vXMiqy1hAtw| z8GjKQ5TW!C{w86wdk|(w4oxyl)NCK~ES~331G`@ei}DDktl?&OXWpS8#Lh`)HwvRg zc77xjf29;_R(Nlb(6GXsQbzP>skr9iV*KHHm=wXd*%3Y82KRlEkj-OaVJ~~C$X-#o z9Hc0LfK+y?7Bz;gi!&t&-3H_65rs0%JYBx~Fhko`cN)HrRjMG)DH0w!5%$SALQ|H> zN_-#+L!ugC(4B%R?|!G3jNJtX!255gzF)kkfo+0;q%`?RxY=p-V5t5$#Fb^LneG^# z^mui?kL5q982ES|{!E}n_ayS@YIq$-!2UdJ*)#Ry)BmGWPos*N2!B2_bEuvrJ>w&6 z_Id$v`R9Clggel!F{l{ULzf*6BD#GAc_>8g$n=i9IQNIKuSMw8@CfBmKsT+TkIzh* zBp2;bWx8CNe3(@&w(=3nuZiImtGrgMh3_}qc_#nP9eEgHup7bTwKPp=-$EC~UUo3j$r&Bbf>n7ZMS1!N(ykeUh`dVn0$dy59K&YpbH@K%$b=V5n+sDvLe%9 zUXsgvm^bgOx6>VskSF%HZ zxbAMJcG8Xx?^=xZqI4;zl{r=;oP&=5C;@5NM#QDO1lUMoq4swMg}@2ctYKTK8x=$cmg)u5Lcer4^t$A zm@UwQ(J)u*eUERpa*eQ3#&~?Q_4k^FMi@DkvjPt1CrGJB^(G2?GwK;$pq!2@+wr%p zFlpz+?Bo)9aJ-b^*C4e;q~! zeSf>Zis1L->*Dp>D)sXfr^9F)_QBxV=+A{}gXMkh*Ic8+p%cli7`Wj!^}k)Tv-|VM zvca#t{BcEWxQX`%M(c}BWL7>iTS2q>O9p<^)sn2UbB+G3$?M}Jvi5UHg_%3TCeV@m z>t094wJ}dCZOESg+UdGaUPa_Cz$cRSefQeUr}IyUYYrd<!73!fON{>mv|9AyUFZ zvVcmg<=yMU+d~9xtohnyhu=;JsMy>wvQOk=Y4641CcqN}ox^A7X9ZGNSdQBvKf=SY z`%i>nd>iUGWu6~K%;(S$x-H1JT`S0&Fj1y|xYl;)fri>$K&f1AH{O8LVSoL>OkAJy300pgh4U zu=BPYXoQd6vD(E5`Omt~5Qop_Z@#=k)_3@8%;_J{44^%9IB|aAt;raGHPzny+v1h96@ZYh|4MH>6ll3`?IrI8mLj*w6s0q0#EZlGB;0M; zxw2#n@_5_+{aUdK6j~B^yqJk_>jj!55IIHgQ3wkQe#P;C_i#=50q@0}Swg4p7vgw8 zMfk`h0V#wBs`!3%hUZc&%J>m7MC4ym;BZ7DtTentHMuc#gla4CNd}q=jbuqw`s;L@ z67UP&CU^^A1qppzta4IMAn-)EMF`Oa%%^p0fn-rm^E2M`JT3tEG*6GpF1-IR5UyAv!8geD!Ih)7# zdnc5U-|Q6%*}4<`DM>DI(0F7&e~agBeeSKFjxXk{?^(F5@atk;0)l!szm^Q#+I}8i zzvT2(`?dCTb7ir=9!`!M^!RjsSOL6VhC=~fFI#@Rc%K|TTL7<@8GzS|t{-2{Hi50J zoP178&9C{6fpyndNDSGQUk;e8iH0;al#~j#=#Jah{&^ZGrjF$B59J7%noHI!_^0IwH5!tSNv&D);K2kiw+%NM=Sfm25LU#aJ@#%JL7ez4SwXP2P^ zgh{17rbg`Xa#@0Ce>`3tZuj>)xjNqtFP`6?uRTAi(>A8W=B+&LZg;F2Hho^aLxN{J zI0<-sII|FI#3TkixH^eCo<2`p#H+(_R=kz@dn}vwb~kk#xCyt30dc)C7ssHesv=}D zDJZ+H@!f<~qcjH#g$Lo1m*QcK)sw;aIWZp<8B81G(A~>ba=+=)NyszAi5G$J ziw^RPi8(CmB!OJyS(&hPw; zLXZ{#dMh+~mZR>5H+2zYCS+wKqg)9K@rB`J^wNL8h_+~%wPv?fOy}<0d2t6)9Q-a5EM;w6aIZo2>(HK`=J(}b05eqLshNi+^ z#9z~GE~?YyGY$}UXl_R;++2f^n;>QVGmh-vyLy!(nF7)dkR-<>ltdF;$jUSgUvnuE z8nu)*Xl`}Os4pIH`}dXRSMra;yoBb2yFfBB^IkrDaax0Ni&H{0REF|tFsh6c@gp-d z79u2`i^L(oq1%j!`p+V;oI7{geqyvS{GYOSTLl1BBHIT+vjHCrIV{HS83#`ycoNu& zflKV@1;=8|8YsU`dZznX1t$}_hK8RcX1cCQUhmZsy$!y$6aW*o_3BXpKY?Qt1=vJg z5!Jt&U`$he9*d{Y;T8nQ>RMwC`z-izT@n7O+02iSNh>&gKkoPD6KSRZ0ofRVhEz zei}|-;pgp`VW2rCgVNAT(9|2wnp<-XH;L*rt22*Sxf&GXz@m83M;1SpqG@M52UCNV z5ssB2h>J56B$_W33fdA}fUK#H0k~f2-Z5gp=S4p=!*UI=shY?;e?7^yr35ihq|Gis z%OnMg3CJO6rN~~YKJGliqGco8DdNw1M#b2Iwx4AOJ^bE-d|(uV11$DFmraE~q$e zDoYTW3E9%HkZ3bkr@qgsfmHJZ^mZqnH)?*FBPFu zH{$d=X|R?0FgIhxa6F$Z94!@*OfmFESDB&T-bB+}g)p46bnc{{>?DXFoLc7_K%;10 zsi%@834R8ZTwn&BMlEQr{6-LL5LQR?U7!eD6ND4gR(VQ6Ra@279+7!bBW}e?GbtaD zcS7Ms1%(c%O>oK`O{7s;%mo!d`J|VCQIW*J1ED|p&JN)B))Cb$1Ii|9_gelm2m1NT zZ<++grk$uw{ERGfl^$DFAzQ{C%d?LLR+Wp2+KRl*zHJfvlueU+jKQqZLBX)zL^EM) zXC7x)ex3>ybH7CAvQ~OQ7kkoo19805qq-;f%4zSoedHWBF zi8q0TWruzMCeTTxBnYkf7yWHrKQE7D`kVi5>^=wAr6%r|08CRwLG3a~qLLl9M0euc z$_2Tg5l1yF)@6$kzIqtezv}rC%iASTs z!@E*MB|oTM@JDhG(tJMp@5$B*FAo9qW-VEz>0;6Ksku(?{G9u8Y90sV7S{OxA;qz$1(q#!?c|Zu6Pm#WWr|5S3 zRo|eR2vG)3x)bZA|9Oh$o;5@0cJavK#t^8bd)id!pwdO)!)6;s@HqQnV_2$nBdc(F z!=+pptaYU(iVm2UhB4GI_)AzSD0dCE)RNK)V-hNkLM4BakLvF#ja2@D*Vm&XVkqt; z@f#gQzwbxwRh~EA5Wv0&VazEs9^wE=JLO6wAu>WIKWTA0SF;Q565R zT#e~+UBP}b!AXSw2c@8S(tajVcQ)!lu(nMJgRtiHVIPa_VhgbX>)?D`Qi&b&x_cwo z8;oH#tp38gk%ADQrh&})!>bP0ew6y*-XCHkKTBy|hM!BrCX`od{9U-n5aoSun^K`H zt;_hWJDz|1!-dM%kB`Tikh1^bRo}^UG&lQN!RiDoSuHWC#4vtXPi|%E*z<|`%lf#O z0|YL8nlQKn6kkDnq#IQ1R&0#Sr5tKk#tBjQuPQ=mBN4U2AW5u%O>Fj$MnG(4IRzs@ z!x|IC1c3-8NR(1g?VMhHOjk~}*~|T#N&v+UT+##Z{D3t>y4K3uGs}hozUoBghenS0 zR~~YS&u^!gG3)c^r;FM>4Wx=z+<$8HWqh(bZ4SW766tGpY(7#2$$;d)`B0b)Sc|gy z|EUGJX6CLWEj7*3IYG&EniKYJ()x(9EV-O{y;G`~SI(g{Vq1ym9>aC78@^Sm_h};Tu5) zo4D=&%FhD;K3V;!+;EMkCT015fk`}K7xG3zvbOs;nj)UiQo-!7F~j($6zso#OEvM; zZ*_dlSpdCu9`J2VNr^&M=oG`VDWI(e{P-q?2!e+A*py5DkqeuQAY^2hzGSE=?pGU03 zz)=L{mj+u-*0(inj>EvpR36$J^(<<^D(MesXJDqK-d8mU(`Ys^)97ZB@%5GrrMDC3B%QYhFhMDFMQi2;W9+I? z?4^Ndx}iH8lE^vln*WVLUjs9ly?Zb3eBSxOuiH&=s|GmS?KWRj3=6>Q06z(> z90j{m*w`xGWv#M7AzE-%p%O5_j`aDvNmm$RwJ7h*Tic_pm6KsMg3s!z*Uq?vnHQ@^ z2I|voBpa*fF`4SKG0;R$gpeeUvj56!vdjy3?pGta(f? zz)eppF-*hslAOC(IThmTUy=ULgfGm9v3=0`&kSJTxn0|3zqlM;)(}_~6g) z%E&g_^DeGTv+IJ;6A$P`l9sO#QpUXaN#?@84M}#|oczLIHmwv7WE62p8^pBZ_gxg6 zA+xo0bif`bFp|r2hYdB&Vh7W@38YnA9?{STItio`0?dW&d9*v@Vrz#{Og5j*W%+gq zA{i1KIj5l>R1@r}od_N@0`hTRKHiY%f-AXlQr?mtyo%;aH4X+JANxS=v{2eNrUEo2 z0Fw`}zhX~x1p~3o7elDOpf7m{7e^ILT}nkyeTUe^rkW_ruj!Kwul)Qqm*Ty(9JO*Z zv+_eV;T@M-BGOjj6i79%()ML2A84o~2&72Kq48O+0*dC=nKi1vMg>i?MNaz?ISi9i zwoJ1H&fNb1+JX|dnj_?G38=YW881#w((cb*LlkGw3OW@FMWsT(d?A=iPZtSIv$Bdo z+BwLQPKvIXPAUN_Xo|CojPaqrA*&hBBTvi)(?T>=xG%3mu}D-h9)Jq6+*)V`aqErZ zJM}XEz89;_0r6sEsQ7qm0;}!X&O(eJfsTQ)_C5d#>yu9K+!ovwj@K-x z8oAkhdF^4WRxb}|%{Iw$;5B;L^;8rEtl`$QX9a-vFtfUyz8v3{oBx;Pg12@fIm==#N;=PVSTHt^+#a>a>QvRW#K6ky3ls$Er&Y>Jm9o{UD+lyB1XiDX)z3RDZm-OFrD5Kzu-h;;dg$DXc-fl zIt=BHqIG4CmF6Pr

Ktsk)@o$ZgyZ8eXV)+fC?A4r@8-kb8PY+%$R-3u88tN)a)* zwGWCgtEGSwXyN~T*%afCo{enL*&cS_qbSm$tlua1Ojc5+$!;~)bXzDBe%~rp9(d8s zH;eRL7?r#pKtigaa2jJG6g+29D(o&*Ue5$UVC$^@dBS?NGfN-RbIEyM?L0e#r4>(& z8$$)YT*Nft;`)R9G7vCDR}zrJQcjmyVV1H=@jwu;VoOVY# zELeW>9g=(dM!PQ=P zY;jBv+K<%XJKfsR;BtPE&F|hHC)Uvw*Phm8-e=m*Mprv{V z?$k*ys}^@rLnq}&7L%kclkAh9gC4>@{xUY?;Y~{8H;g;D9ibZ&y_45)oj%19F6ugR3wEc*W><*krcgZ^u2d>oiAs7`vS z#XqEJYRRjdQIm1OxnZOO6VVSA7}29-q@U6>H)0K?6JE(}i>ac|0@Yv%+938{kRCk0 zbvG30e$pWYDV9J7ROQZZE*OJJIDg@NcP>^Uc0tSmb9M|e9pOO|x2E6u)}%1!i~j{q zk{54yW8K#3ZpK%3o8r%22kRGU{D&;TA9d-_!O%V{(>S*`Tu^eWH$0_?6Pkin zbF0XVd~2O$&z`rrdTvoUT*bbYDsZ0@JPd~xQV8G2=;F~b+ngs-mjM#rJ z14qH9DRY7ygNeAKz55YCjwd(plw?*b2Zqo!ENB^5Lg;nKBN}EEv(PVxMEz4z-s}mR z+y00jF~GPM6Bpbk6Y5m=YKjO8##HY8&L5Lk+EI?lACBIMasV28BXpi?-XNaSLUBfd z5C(HpfsLNl9)XlWo5|{!aXo;~zdV46+a~~?URstXa-Bn}B#xhx`6R=`Qq;K;qM+NN zHIZXx7TA3|JHGUGia|5)TuqU*vd-(pLZA0mKC%HW|A1_HiOC#&Aa^c%4K-_B-#|*f}q;arFJ+pt=;hCeIBTa$ey=5?i4h&OpJm@ zA&A9NPYA;-8)2N@NU8F*?WS3>Xg(P7Rzqko$U&n&c=YS4r*ffl zN~8PDy<^qJJ4fROb(%G$$K-zLv)4mYG);VZo^(0+u3rW%4y*Yre{3Nd?VJcN`pX`X z28T>{So|5ea*f8Fw?TnmM-a#3@Wwz`fSt0%@%KV*x3P4_bw66$-KZw&&lA%iytev| zzoS4I&~QyaBMO_S2*w~!fLBn?(r3`6InfXk^}3;5z@-C^hnpmlp1X2{iG9SvF|M>y zC}0W!qk@xk1evInVw#YzJDlnSq4QB$@i;e07uNEpjw}1ZXij7|bsT{LUP=m_BHB0J zUoxW7e9YdZ#3yLo4%`oX$;M`oCrp3#uBrYTD_#M8 zzrRfM?ZY3Dqs1j3dokEIN2O%}_eIdB{U`}C0y@t?txL35m_@A@+KDNsxlLbxyi z-!LA2{|14DgTw}_F&w~ws3B<#>8rpRlGiq-G=~9!gvkRfS7eqf_cAhs9?ptR7wV2X ziP`Q$g4A^xV?uyGV93?ldoeN`4c9sLA8<5$WBOfaXb2B`i}D1rV&=m8${Zk_)u^=n z1MxwuvJX^lC-PcV$yRwKPv<@7Qnhr@RvQfzW z`{;~m_L+4`cTkacksGjCIikw(9rooRmsC(2Et4LaM>we2F4U~H)=U9eL!Sdj1#Su_ z#O-&8qMIRyor2;v_+()_VBa3F`4JGjbtBfx@4h&zy%H}T7(sPg+}>)za9KdR`w$x6Xj@p0O)WLE_ll=;q=sKA$s{HP1ncQF zMe<}~t_|7;YXQ8xjki!yQ?|0ch(a7r&Oq2QEBsl?72$7PtpB^A;^XC9n(AnM%8cDn z7Gfa7EHh*#4Eyn9K?!3!)}Bck^hXKyo28^?Ur~w&E2<`VIww=Dg}x!MwWVf;ER0xa zeHo}m?1X;QPi;$uN4Md6g+Fsg2}1r-Q$gZ@94aBQz<_=t0O%*ONM$CHB**Y`c_QU3 zzOMv>@uUTwX%m9U!J?97H1QsCqpbuKP72XSp$v7a5p>YqQX*>J^BT zaDy2B}GdvQWIj)a{z@ z+rhZ1VXTUhm!E|bt&aOc@7lc^Ko9+Al7pgwO?m-H0u*6XFI8;?4@i%x^8%aqx!ol zTcXL74houAr-?LXkr<>z$DgEt|2ePSNL5b$8iL6wa`1}{DzM2dG zs_Y5J3K1T<*mTL(IHpmLK-Bg+uA8vIlYgbewL9c0@0sT*j6v`<#ewh|k$O%`D0GKE zy+q02X~Z;uWHd3!GK=03PY!ZB%eey03HA)1_}me=6BC9Powmq^D_7oh=Ho)Du`=kZ z!gc{$;GI3^u`iZV%YMkH9qiEd9D&x`>$6V5Xzc$k1GQ+xK&|6C@f;<5xl1ByvoGay z#aU8{<@*q@)FK@86uv)xVycQ2%FcUnPD@%65ByZ{;nMG|N5{z{WGtN~Lr@(yqFS0Z z@?imiTPzWec6KNu#4DG7%(C!V_!D}vmrbgv>v*5{(mF|Y?<0O2C!bh!S0--_KSAi1 zLOYuCvb&(*gFh+k^V6cVJLVvd&xJ)|J3nrkbT-sVHirY@a@881VU)QkJkPZafA(3& z$c+U)CCi|tpv%DY+Xh1m`}74FPb5qS{<)G5zL|nYUQK~cdCer;;_@uR;;?$i$*Fnj z$vmm>y$hW7i8LPQ{q-_;0>Cy-==2wVukGiUoA#AB-Q3GrZE_7DE7x}2$ntRFwu+bX zHXvNWR*Y+5HwTl7p7^T*<`p8KP`*s<*W2e)b3zvQ-47bQuM^8Ni1c=V{bL#8!mwK{ z<-4X19iNKcaI2{HPvK`}i#c{>^b^nHysupDtA_3$Tx+52Ztmv)_D*hqul?Z9XXx(1 zy%y?34*2i-s1>M1VYv)3>rg%Ize8ocGFhuGBExn6vCka+XKzX(Pib>*M$&K^_F%^RRnmE-$;m`D>Dt@K zmqDXSPDvuh4s$#pE3JDv7r;(!Tj;mv=GR;M50~55aW!fo@B4OM-?ef$Jzo6ovv?RQ+898T^7kkA zt~8#;lXC`8v*$B|Dh2=v|LN`x)CXphHCOo$N;qVvLymhugA*csdp8HX?vP*axOf@m z-nTh2rx2D%;|%aQx;cxuQ_=6sk*}d@S$r^KZ9&y2_@o~F`0x4y0 zMp26Tvhc%M^lcy!>i(Hpd$FVCE>15OOxlRbBdmbTKR~`i zRmXKokm8P@-3rPWZz?w^`Xk#tX!$fe!uWtX(mjPGtl(Fao9hJ~Q>%w?z54kZv5b zLmPjJHVL*-@J9NCwJX_G$d@6DN*idKyY#as!1{Ve+Dq4o=w4v z@Mq~PVHjR>8&h#1YKSs8zoRLlZzvMw>y%~ULk_wq;7KGB4>0t;J4z3i9TY&i9Jfja z-cdwf%#jEitq8ixpcv1SDJ~Kgr4fODH&P;MJ(CnPafk#N^HM@GVlaSW>rj?CM5JBQ zWo;8e+$EDt;1QQRsy6>MRQ0K{<8XHjJe;vXW_y3COG{)OUAgGHv~eP@HjbmI{HV8H z*|w+`g%N&I5{VMW9c%G2fK&pRz~sg9XGaxwxhUN8mlSIs6?&%DHj8P)5m!G|`e3kp z%SkQhBy4-&)`<-EuzDN8f_MvDl%w7EH_`)yvX`OMMuLUVdh72k-PD>9YMDslebzYW zBf;s#>x^_FqWQ?bZGaoA4ZnA~^LnrIp6fC-NT{3!=svczZ^FD=gg%dmmAnDSjLSQZ zlk*<888;i?_{R-eDkEqIaTq*wBGFOA#vns2SH$X!=05 zpcQ$OQ^%^hvFkD1!kyi-wJK95tm@~Dv*smHesvi8%Slt>LG0Z!F)v{hg}nFw%F``+HUd7D1`ow+1O*PTwLxd zs9g^cu$bN|h0!Q&PCQCCHnR&H|EFa>NXGmN<`^=t(jlvpGhZ;@)04F zht?(c=z#I_*o`K_i(s*8Joy` z|CZWvK7TQOx`$Zy^4slH5w8VUiT&Zz%;DlSvY}g8K?G7>W>V?VGD0~jC7ed*3HlEv zMPF=a!CiG(P~(ghebG8dSA+hyBk`!4`<*+**XPBHX_b8Za)-|c~CUmYu(=)WuS$Fu@O5WJQKr`NO zrY_<5g(gZiziLv-+fb&!V)i?RR7p|F{-`=*8qc1nd^pDBQBZetJ->p(l3zLO3k}w~%{{z? z0Fs-b4DV*C!R|V+;L!v7Yvd(RT(H7pP=KH@f!*n`=wlyciVrUUHCHp9D2S%(&_)8tX4yH<>WhaTl^>tS@6pMD42ydEwdf0n+dNy(qrT(PZzzWl5x(hbh-8NMTw9Uf+Wfyc-C z=n#4o(v99G`Ze#T5i45JXP4G75B5=>A%BIKn8K+tk!OGap4O)J7>D`fgTQK;2ida? z981vD9w<~9Jb!;|9Jr*dk9j(LBL5c5f0bG7Tyl7aJF(YhYotDc_hwqtAEGyCjdfYIF8-rUaFj)lR^*j`ey6Zk8DIy4Y)Com8aAms_zKsv#Iz9^?( zAF%(E{`udu1sD*J|Nlt`bi)4Eo<%tD|D=2WYZCz|r|-XM8$flwK4b%%cA#<}(sjYS zZm!XzaO$!O67nkYK*+y)9l*@N%z*^J5D^d%zBYTHeo!N8A_<8Ba8ZG;3jwD>1%6_F zVEYphe=;;N@v)P90(^<3WJ^A^34UZ6`FuLyIL5nYdX2a!Vmxg_IdUU-G zx_>UlEZuCDeV%@vJKk1*z5>ci2M7>hfPmBZ(uvamf>a+M7?A)%bPXWHV*x^v93YhD zziiB10K%dlAncgGbZ=&W@JR%SK+`Whb`>Dvl>j2`?n^JT1c(YSfM^2x(#PolVxkft z78JhpzdHbNzyJ`Z|H^*`0VH3nUV%V>iU8+9;JpC?VICmR-oJF>TYw-n0|=VtFP#em zAh>M-LU8>{mmdKLMHGNg+xi3o6Z-k@wgCs_{&^F@BSeBApmLxkyW_fwZ%`u{h5qUQF$ZGHk91tly9j3yDg>skV_!%o;H<4aoIA#FG?z=$=;l zc&K)H+n;#XB1*Kl{uyjiwCo0X@sW~UI5KjJF>m9o!0My@2%#lNTPzLVEIm;O*|>}; zDo^q$#_F}V02VN@s7iaa+8By>DfAzY(}}HPtCsc6M=n~3-+)?C$HxSkF_(5 zj-6+xy>j-fGF5Cm5AOxgnn9qc#`58M6@i9;fSCSu4kVzEe|!D*kRxN$Vgb-E4LN`a zAW0~!jjUC^baQin*3KlravBGOqYqiY0NPyczCmqZzcaX4K)ejWyncQ+~ zg?JV7omzV1q45TLEDat#Q-P!>i&v6zVEq&2p>-4zyaZoFS6Uz$xiZBj;alOc3sQq`zbc!dGcRD=OO+4%@i8~<0AkT0T zPZtp1lO84Cf|Pzgwi&{#kr})1MS8#h1G`UL0Am${FSxFb=)cW!s}eQu!9h>~tEIkN z@CXdm7-j|{<1+G*Igt=0%yW5+>XroY7Iz-iUQMbB~){qt*Pe!LA@tncf~Q zq>F?lVF?M2lPzPM&&A&+L1}m07orzLG?7k<=jn`IG_)6S;-xdQiFO}cW$aKGO@Pie zxTv30$9pV#4IQ17z?Ur2mWts#zkv}lpgj^D&7{k&kf5PVLrMU6kxjZ;W( z{ZbB$EW2Z{+03;G23SMp_7_)bst~4d!nF_u#_OE?oFr>U3XTbxWl@B_at#!1AZfoc z#IYZe&d;5h(Dj=cmJVqz$!wo85v!q?62=`)d~6YXL&G;<)i-doh-xr|h&G87J0zhk z$omQ_`mPK*Y9q8OY zn@JdcayMZ~e3f!+-6hMtmE9~sS4+&uS?@%2nMO(lA?e##Rdss`Ree?mRY%+{L2X7` z^*9bzwnCLtniw~fzYai8(&zXlMS%1Nq&Y=AbV+YFnA54p^1c|+_&euxrDqL&m^Ljw zVrD0LKCv|`e~J9#nv_-O5)tGaMi0fnHPb9jqcp_a(dAzbihEFYN;-o)L)fhBKYw)D zR9<=1^dfAY@UwqBevG}4Fel$W6wmtNf(JajMvXQn%J#7XOG6OLA~(%ABnR|KlFzVc zk{rboAflZC-PB23-)!H^yvgED^cH1(fA*mah@VpFd>$wbMS>qJo40wgXs#h)rfBn@nHDybc zkv}}%)czs98#U}#}HB5bkkwkus z-`lrHCte1NM<2Oye%uFn1__i?uDBNb$#Muu1JijeY6}w^PI{ufMOb+WN%&v%lVcvC z5gfZt42orA4EpwV@jQ3VT70M7;)|iXk!bq(?BY!Y9`>7?gdcS@7CsS5SuIwE;XLc^ zp_m0Ix=ybPCMuD}p$ed-yW)xq6!bW_uKIrqHfJC3L?I2D`^2N)SI>5TwH3K85c<{~ zCiiXhh{yURUrU`XC+pI@@hcEOK83rcGivc}jy`@KFsa?FPSBNUpsoeSaO^oG9a-Nh ziekFVUNf{|U+WNpm67=nkW29Ib@QIp=Hb3)e#^6wj4nKEiVTbz8wf!|og+(AVT5Lm zRiL0nT;gGw$AzN_<*eU&Bypu32i?Fcwqz9s+K&v|}sTu7+ zBdyi$u|%BhT~7stU{nL=#D#zw31vTV)UUEJ!zJNrWq^-|;gb=^#Ux zNxVY>DpHC^##=?!bH|x!vuTl~l`K|+h-?4^Ab4kVVch?B7n$S0S1v<`=W9 zl|4(w8(dCamq5%m3x}N+{0N=jy>?W+V4vupvh^cr5eDqVY&F)!!zx98E?7A~YPW<> zv0ul?F0#3nI-fJq*v5do(+43pTfY0J71_!3)#9$`^dXrb67 zjy0WSk!iE3TnCBkvUB5D8vZ0XA}Z!yBvV!wmINsj8=701W#m3wuXmB)Fm+aE;JmIB zpk1{cfsd9$>s&-#9L|!~b-k3XFLf%4gqvYuIQIv_oxo8lb?*gbTq>U=RoyppHe!Em z^D;lr7vf63RN($rv~P*?RxEKUNz!lFSdZ8y4XqwmrdJ74lT^F`NGmI$P(G5hFI4!Z zRh2Jih(995?KDQT!ZOha9-HXTJAg8EAR~*nOf%Zwc8L^l|-zu zP`$|x+_CXjTf_C_vUcXnJEcGalxlE;`B-1O-cQet`$ z6%O!>9O~PFgV2=c%ffy@IAtn-fU1MR>>9|b+jF=$9XS*qtsJcV9uK7IEHk30KcbvG zRcYMtRsYFJFbt{r9so_o9Y1Dt+XNeP%`4}HeMxyi-6u>r-F4*-fXBt5W5{>PpPvpv z&Izz6A3SoUPIsp(mKD#KMXsx0M`0m;A6d zo`p*<0)_i+tqQa{gI_q}UIm;JuT#Z#ekpzc)*R{to>5QQctlLQTM?j@bN9D^CneL& zE9(L9?T9)`#Eap1q+N)%*tYj5mkwT685UorE21u`He62&wV#W_cI%~ao?+sWD#0|U zhBKA%Qg4P>e!tT^xoABpkJWSKGwced2Ql=RnLfg76HvyfM&WkYQ$_j+&ifn>Tl$IUgARx4GXcJ%<1G#)7g0q#c z+hy}UdZnt1tn{7I`q|jBiRno#NL`W0t11W!wDgKeydQ$$bHr;jV6@Z2xzMF>TXgZQ zvL>}5Ar@SxGnvQBK1qUB2FtU7yRNb(L@dM)l?&U=I%gf%;$%A(XI-Dn!81<0pzlH( z25@W60l+6D;mqV!n?$CDyt|J<@WE0~Whw&Dx&G+)%zYDPcsV4#DnAxI+Iu@N9pA8g z!5=xi66a>g?ZRe!$f#b70Q@kN5AR|Qwe-j)*C#dQ+4K2RUeCe! zTLg0ONG#_-p)cb*5a5D(vgPntDT^pNWXar52XLI=a^Q!qEb-a!wH&$Zr;HH-kwtCT zdg(17(fES0kJ=$6+Q{x(fUd}{4#^V!OXiZ ziX4lH)>So`$pr(YQs&@3!*2gYCq za8o$K1uA8nOX@_YgCTw^g8%~J3>nZWC*JU(F7oBy)( zHF;9unJsw2z7(o>J;NkN>da+xwwNhOC65<#Wy0=ds_3!{q+QMa!=>MxyT8QQ{kE5 zGq$jMKg9$KLNctN39~Xu>L@Knb__|Ei18~s`D+B_Yy4Lgh@*B=ej3zvr!iP0jHV$& zEDUS!Sv}1$_`_TH6SZ3Xmu$`|q-Qg^{)jYC6{EgPxWDGsxrXElj&qSOB}vR zeRoH}Ju4aAhAN()kZB$lE>QkcdnVh;%i)x~Z3C+E^1zwVzlw?Tx>ph59vwizXqTE3 zUgi9;_r5#)z`)+){6&>cN zgHHDus-r4db)fT#Q`p_ z2W-B(BzMKOh`d3Qwx15x3j+|SqE$2FXBHqiCZf|wj}=ZmPD_fTx`#RsX2^j2?Xih# zkF2%)7rJ?r6r0VsD(B`9YxV##`)dbhLe@)8cWf3A4~UX~5gifC5jN-C0<*GUQ&Q0) ze9Ev~0sMM+*B2}LybV0cIH*qBfRoaJBFW&<%Ms0xIyHVGzt-R&Y`SYn>uySeE(y_^ zXzfQ?6q#O>(UgaM^=8Twj&SN^oK^=0p~d_O8(4PNG=C~&kmUh72uX3)89CKwnWyCA z!6lk!gtuMHyh>ZERX&S$R%u?2%)nO_N$EDhVs0)i@;?CaM+I*ZvA#V#_-(?sGI#vQgfLBSq6bjmV?>Tl63e&L-h zQP{)CQhpsEKf`~v4f${n{)TXF5Nf5LQhHK?^iOm;DyH=TxFFD~stWm(z zdknV~(4(fyN>rJ2L2D*0@XiOx-(@yN|y2zpzY{$r|y_=*c_own^A{FUDzOx2#P}G znW|LXLkfu|z~Z@Eq~+WC^SFSdcOu1w?Cg~v%fl}{%%4`i%Z3N%J z*`100LjUFpcJ~2pY)xZf`-&Flff_4jR72uY;P6b$x_CxZ&Y2W&uq7!k1v7^w&y)Mk z8D|-OhwzJAaKSlZW`$hvS!6~>V1*^YAu3%I!^kQEt$5X2Qk!TN0?$R7&5>6WUpDw4 z`QN@2o?Up{CF}!&Y*uBi2liAK30H1d4~YcQ+f~C6I5_hRTZ&vd!`QRxY@idvf9L*93vD}J&ofuOj{>Or# zg*`V#fSGO@-xkm+l##u~R*(5h;#P5DgVeT0kq}krFn9M~q_}0tr(2Ic*YUFz2Lz|* z8Tk3|7`22@awYECI6Gl9U&fp}N|I_@1ilq+17gBIAz$E?JUj6{T*?80B}A}_PSZI) z^V@Hd5{1EYmFILTflEB1e91Rn|1yUZ&*#D(0003AhC)K@6bu^}1`+~hKo6`DBpP=d^SD{nI%hTPei4!QZUfDB%xoDlLZV*NB0=vl=sXs%#v}rD^CWPZ zCD?XFlz>X|&S*|Gi)woVk)TUXwd;bV7x|Q)XUcE|tTX zI|6Ct(;c1fZu&oj1qEP|WEIKEEkEfxRT1{YX0F0-P4piC(}gw@CqBIulXYHjQYqF> z>i~j56?qAkUtgTGuRt^5)o#v-fJt}bSYMjTOS^(PpL zbm=rCixyee2NYGb7_s$`g~8Elm3wc?;p+%Wn29$0xU|4vUAT@GRM+z|5(qazKZ%AZqi8M_#FwB*@PG#mEac6( zsXp&e;OG%r7PWKAW+aOkn>_|%_L^9fvf?#g40{i*;q;9tZKWK;Vv9-hYuYV%~pXy`%kkdAXT{*WI(>G)2Xc!I>6s+UOI$`RFbp zi&JM%jvPz4J}i<UOch&4aS5^`m-qN}e&%yUs`KHT2qNG|ITi@LTy z(fVBBVA-ss(cOVe+<$+U69|D4W;~ecp883brAf6D(_61ngJI!2dt`&bdxg$;L#4+M zNcz-}i{8FPE4{6O>&_BcO>@%o7rohKf0;_A`|7?!#}*vWfEhdua(U|n;@g4jmev*#%ORyx#&thBYQSao6hSvqZmXonkUnu2s$z)WR{V-vbM>0$|0N45?JQ-F>xhv(j zBx!u+S}|tI6w!4d=HY+5lb3K75`$MopW=&cNdpyR1S>+MB4DMHY(inNwYbg$0GDN3z7pi6WP^ z2U3FVs=9Z}xo{&1v)ER}8I5{b<#9%bBr)?EImbxvc;HLr5n0PCAg4zb4~k2m$WnP7 z7O7eMDbzAIUAKHvox+ny;4LRC;C{Qwk$E`louUKOb31djOaTO`lvDQqUr6fNB$nAa z>$tI!fhPx+UmZO7L^cF(-+IRcM?`M(B}$qk!SO zF!T#Ko^pi>_G;(p0@`2XAUz+dqr;GWJH~$>U}afcq`<}M0E$jXoGh2BYVpTI?1{}P zDWFf>jS}$6XpPF1c&$1WINOaP+Cs;j79DV;(@7LEHjA?B1d=|G$(+JT^m)nwZAMNn zLjOX>M%9zYzh8%I($0Pi#rz)u(bI(P|H+cl{>Al&Dz8c!7*rtthdqZ#)KNzkmlae; z_qO?}niy9dnaUg?lT)vmsbc%nIb#hyUXFfx15ZU8$nUp%+(<9SzE=}~8!dv6(GeW- zf?%8VVk05ooXFL>b4e1oM6RA`cW`UN+}Sl%FNTLTmrt3SVZn{_vu6+9VB58pCLlGJ zBvKTXYSaIP6BsbDtt$AhxJ9WAZcV+$kx|(T`y}5FCr|#W!C;P*O^>6N$Jb1v(I{Ok z2lIb4e{l+QRJQu0gp2Bw_SfL|#wxLdTP3$(uiarmxo9ej#Ki48a*7;c>a+MrsiV)u z8p*_esj;ML#1++yUD~;2@!+RzkPM)zP^b|+o(dh&YLWJC!eFXqnQXBPA~|h@6_s-& zc3EKKOh}ApFDL*S#2P%*y7{^Tnx70U@)+8m8Gi7i)DEdP%bkM;bP0 z9ziQOY9*0IRt<;1lI+*t4WGu}obN6K@#mq?q5)$7009dt&`>4M7FkG%3FgYk6Uj&t zl5AKuC6q#KR>ZxPe{qIxK&9mIudH>;J!Qutvv?C!q}MCyu^#|=6vC}j3Iriw@D$jn zs>ZvQY}6zR0a|WdP?nV=6t#^ud$P(5otiYn!~3##%Mj`*E0@Y7_!i|*5M-5e0APm% zybD_8bK3H2imq@A*|?F*NI-Z13w4V3R%j1+YVV2F{M1#Y4XoxrN!aS$w^KZqJLO44 zrOvebSxaXvD3?@gf*T;5x&xV#pw(2eIB|raS2-?)Q!Kn*7TrM3(N_|Urm8j!#XM1< z@rD@$Og5`aquY+)9+hQ}7g%sJER zr4B&Lwf_pG*ZzbH%vL&}cRJ3}2oPfvye zSu)ah`H0Wn5k3SLf}crKS=c8QgVCg}M@i<1l2$C;;7ZCb56z*;SVmof$ba}i4g;)J zPZ^&Z1e0sHt$}4n%NGOarHM*htUIA0^~u(H0RsS?)Y*n0)Sl#N8l3Y1`7n%Ncf2Ea1RK42z-b0aADEI61zok zq(O(^E?I<+<^$mr9_dzm7hr&=+KZknSb|&PjWXs>N&s|RAv7d;-wW)@ut6(ge37x9 zX!_Pq9+AuOKB^2K;5wWd%<}{r9+*F876U+rzFHi*IyLH;v2atG1;r90z`sXB%L8&9 zl)ds1miIKm;O03)nN>t|NVLF~xJzY@)L0eHF$ZiCaw^E?X_r;=GcuIH!GQQB{QOIz zE+^ufd18HIXePl6a-Ue@8wR!@&n_1LI&KSm8SW0?P&^)9ocC~o_Hcj9H0Vp@$vZ-D zMcam=sYP($?8~QqN!|z^D@kn4qh2vfw6sCO+_Q))4sX>J83Bs8dN)56hF6QK@QLqZ zsc`vXgstXYi8fjU93q4BC|!0)s$Cz%VF>9!=D`$!7yr*63|T%RtxT`PiF8uJ!OybK zV<;>WQnX%?&O+a?PnE%yj!FBl)-dN>s7kZ?cTMHzfYxEdq^hMPEbtEGWJ!Vo+cxSj zjK2D+EkEU9mP?DpPmJr-qc$&w&c8<#NqNtST&I5oj|Dne-oqvub+CF~>w<9gQQ#0G zhvL4Wl8z1_k$*AX*LgW0;ZOU>n7K+>6i?>_d_S|um&#^=1>q&=M3_44lUaNvo0Ygr zk=T=KwKSeuslINJ1;^LWIplHJGFcutN?d(BWzV>|v2P5N?Wru9cz=n+vCl3DyygP* zesFeg!zJMT8Qi9E{$l#eJpSb~AxXVVUL4zo__&5A=@$y&QdZsv>R6>&#Tt7Bf+R{% zSzXMvLAA~LI5hCdV9I5JWY|(o1(vjOJ_e@XL~Xzx-kE>f@AsD&;}-AM6}Q&(6xv0$hc|N$J(% zP7d@F9e}53G6=jHvdcal0$1|mfgV0lHHovj6$9l-SOv`lv1-fu)7-h@z@za7br!_Q z!a#4=E+Qx867P^*lzv>*vD#2a1Xy%bTmszr@BeAOW+9N$V``p6tuQUo}%;D=<2UUQTVFM4nA3Qpq6yY4q)-G zYnFHG?H)-R&j_=ln@laQo(YI9tzT$djCS>&C9CiZN*qK|@HWsG=Q zThS*0f{k>=NpaN0&y{=mlID!L#7dR}E=6FX-dw1Tne!3Kk!LDnAn)#FoffwVZ4CZ) zO!+>U*0VgmXTd4LU+L~F9?^A9O-e=V$roD|m58=wPD#?+${H|s5~!KUnSQ`r(LEJS zxEGb{Egb^v0IfokdVzwUM-@|k!{N$~48J;A<(t9p;IgnfaUn1)%EiwXGq=W5E0J(M zi4ZQsaE|FL|40*To|@>Sz}nEg6(2!g6{Sq*xMv4pvJIb24?!*$%2ob};Ovj;#74`3BKWjQs?%{>ani6v;AH4>E%;eoLh9D;1m&A*d!>W-pj^!zzlL z&)}cO8CWrMv@GKZMM0fqSyPwg*uN_((<9!hp{vZhI~K$mW?OI8N?24!&X%>$# z?(l7cD-btqxDZGf2z-x%QiwG=wR2Vtdi)pk6oA~>;SttL zV@HdSb*FlZ4zNd@BILU3aI}+6!jcAH9VMg1bH5VRC-%}=E)9!huwa9^anfHMUN5v| z1j>SHGEzeKN<7D;OBwfco{BscQ6@?V-L=?US8Pa=UU!O?GD(BU$VhB1~0^RR}4dh z(Qh*<4T7DV!DzHgz8s}^;dIl(g9TD&H|hfEkHAzEmnyCNs2u&cPSy%fa5p$VI&2WVL7{X{K6+O5WG`wlx({R>Ydi81SVaYSelCP+TW9smc zadc~iii2F4R++~6oGy~Z1mS7%^s$6m-dFJ4rLN~CL7#7F6^J=gk&?(-^-0f?oEo$( z&#^kwT37D$8*oW-JNg0Cu$MoQ+*E+D)C?u3aFiVQa|=DWv?(OKm-%=^=jM|$G=0E} z75$=%EV4-wDUscJYmdc6tx{PqA_-+8r_PQGMVue76dv;pBCM+;E2a~6XQy*`Y463R z$%yn;bW9Hj6eTpv53-kouwg8^CUjI?Fg7BdoK{ZI0>U(1sikn4VH^P&rsug!w7(Kr z-vm0u`0!d%Z*0%S4+oN*BK?RAE>k)})S}WUkrY_74|2satu1B1kCLC9TaqzI3X24^nODf9$14yux{O z6HQG%k%&l{Vbx&xcepIh++~7DT9vcs!VhQgnZ&lOCD}I9C@pWER(oSdMWuOHq8co$ z7c#gP5-Ku(BsePg2ldb^1iMOIEU>HHy;*##T+>7rJL?`mOsji1KE3Su)`=c#$!oLv z76|4i$WKfZ^te6D46Wf;4)yI&<0k_a3V)AbE`fC8v4ncTy=P|a`f~70$se;}tU8fg!M0K5LDm&2u3a6~Ea_)) zRK%&`knN3km96-WUQptOS~B2Js?7Zc)9^6KUdsGt66eXTyyZ~2psk+`@#mVygS`&5 z%*__kci@?0z{jRtG%NpAc?y~?57oEmCWQ6dm|UB4THqp^E^UNmdU5bgtgK_J4%c43 zcfTcOCCjRE#3%{)(diO-)mHPCzavQ>|Nr^1tKf@rToG{K+#^06%sq_o4v&cz9H6PO z%XUy9+|_@aA(IWS2k1P4NCJNkwkQ{cqW%cf9vyRNFJMpmv7^Qewcq~vy z^W_rHTIU~{Ui-m;O7$XvV1iIOnwKkjMMytM7X`l-6_ua)giiL!WOCQCsH)l9D31uj z2ZOSc9}J|K>Sf~0=E|Zi_A@JG#9AY?>)ex7ICFSA28AvQ^Tla+x14cnSESE1WK7F+gpLstkeydKGh&%ZQ&{}wo`)&K?CK(W#6Q%LD^U>Q+2$fPDfBX zE0AROD2EBTC(;Ry*n^X92)&hCJSXp*^NAOMJX_g6IT3SoSjuD;&oAduOYR0!lpd{6 zI`ZJ~m8n+^*l@`of|r5|0@EVQilIARd@X{Tr9pz3&`k<@zg>n^7r>u)EF|Eh>*oU& z4+?NbrL4bmgNQ2?%dL^cc}x5N009w+0s`z31P=ftJje*ph~)xKsSV%*Btay)6&7+& z5t}IqIeUZA(C%K0Jvo|-h|L7)Mw=!tal4|H7HYas0D)q6jpc1vJhBF!7pw9Ow(CrM z93Nbfh;NrlF+pr&f$tM(KIX)(=$rDTy4pFW(!S;h)IgbJFN-+qS+Gy7lm}*3Ca6sD ziBsf*%R*)@QO4=yc|b(Am*D-)jYQS`BGVh+DdTK(V^NN***8J$=c|4bx);F^l_amY zVs!UBqf$akL|&OUvAUp}ZX00M$A?*!b+VF{DwT(=51#VZw3opU2Z8KSg1xnX-i-+m zY%5T3VNTz>WPx(EsR?=zXRg9sRikmp^E@Nj3uVeS*o81Y1bSXcfr(UI68>dIXN+Rp ziGmRCg|1z{&D;biYMn1riEx^QHgLrb`4X+ZpAosQ5Mtq{L@_eWm3*EGra)4ul&1+a zo-3J$UTYFPyaOjYD5(?E?8jYb%f1x^P9td)nnuWp0Gg8}(!Phu0ZchDL})*t0003J z0~pQ&1CRho4|MYyY1(l}AwUwC^gPUvn#T=kNxuok{V3i|3zI;bYt&HDQVF~&4SA4Eh(ePk zp;}B7k`OxL!D1SM5-DmqJiXeQz>D#d8Vq`)%`J>e{z4wtNouV^V}#_`S8llqipf#C zT$60e#L76jT&Y${Y|#kE0wYOv>O$Ea;wP}AE|zrD7hKbSwzX&JTGhcBFODh7spY+7 zdwsX}dEK+!ycd5{C!04@Bx-V7XOm?vMaU~Or>D}FCY7herq6a3RtcIec2@+8HtQ-e zT=#}6Fo*_{;M53Vs45gtBBQYnB{86vxoNRUXpL4Yc=#jW|15<5Q-Wq^B7mTH-z+FC zm{|*4#e>fki#+6Uo|`CuL(^3ij(9~5lSPG;of8lGFVLWRQ94%x!Hb9@n!X$PzAbYv zf);y`95`Ls2oW*0WRjFUX^{()%1J~6tVxrmaV`%A%b@h8o2okodS*(0EkXbcxU=Sx z(SPMI?Lvs?(~ERm9S}B!l{sRI%ilJ<(cFup$S&JQdBUo2pv4LurCL&)(Ke5bx~J_C zv`FJ@g6-v$`^$tKqLGvC=yEBkxm%T(((ItF`^H6aF06>Xtus8Ej4=Ec&N9h4IVpl8 zc8xJX-z9(S9+^b#V38ZL3A&M z->?%Ul6KTxS5N_(_Qe`iKEMpr3l*90i*(8L>p$7N;lzh z`B|J1=xY)(nX{jH@D@GZbR!yA-J2_}zb7VlUGl`MQE!;vF5afVgs((VYKWLudRR35 z6xp4cWrt7bQwB;MLoNxj*mF+43ym8r^ah55IwB&|Z$;H(Yi69H|0K$eD#`hrkRT0W zDpr0?PcJ-aKsrl+x{ohb=>{a3P|iY13C6~#kt50|%wL?T=bXUq2qO7OrvmVn)rPZO z1l~S(g~73xV5~*N0tRXmaF#(Mr*^(>%d+l@7Vyj`{Hy?G4Us_EZ?;5jEbgaIm;Zh1 z-$@+BoNu+CY!+{{L{zExC5m^xL4}WDa+5B5WF=<}ouP}1pdFHzT1)gbdy$jrukKU` z@Pa7e0yzl{u2(J?hO|WqEH!|(A{$0R@eT=iVKm;G7Rfz2waU4W_zghUh~5#{tfw9j@-gG6l zr55|Y9^05Ibvk!r+K$AAr(nDFQ`unH3nRv;ySCv3(s@2c(F!ij99KXvF5WY!=cNh~ zT4fs!etz^b3EEsmExfTY=mHgLGt_x4qb}XYaa#suVE>gN1AV2pmUqf38D5gsW=IRhk1hD@F*CuiJfq!%8$EyeVt>MhC&tG-TK%S9>ufBrbjS($fc zbHpsp>1$}5A35(=@~7pT1EW9v*JjyL55dq`keEAw<-gRbA77M#^1onRi@m7Gm+jX*Sd4(YIOPg?g%mZ1A zTasCygz!?UrjWAjW8#&v3)sjGxQw)?HkW)ZLYw_-%hG8@GAn0%0Kjm?6Z85kl;2Tc z&bL|HqgXKR@?hR;i(4TJ6VA6B7(=ISDy3ZZR%2m$t@&lLP|?R|K+#SPLDF$|Y@^Rf zQlgezE9xPlvWunLEcKwgmk7n2I-}R#pGWwq-a$9^lNf`Ef|9RkF2`Adkhm-yvHthN z$obUTL(S(q*Oq9%oUc?#(u%ZlctKdWO=T|zgnJL7jVD^bw`pE8EAkM5yG7t^UPTZE z?@$LwDoNvbLEr_xMtlB%*56Bb(y{?r<;s!3Qx`uS7CoHUUuOUz;JYw;P?6(CUMxZI z>_sHZDJl1HBU&P|aV4U;s&PT8Tiud!LH(+kNG`hld1IOew6zyYc`cHZ^&5m&2F>C` zDIXzL$%_TW7IX1Y;#}V5k+0gY@}TCi#HqX`E#+1A_QAPX&&Z3BWyXv60003K3xtN1 zrL3_?i1oDsRH zRpCi}05nA)Vz!B(n4Q(*lpUazCQ9)xU1=`m4iK*tR&oMOT8`;yxYrsF?Gt-xRlT)VhUX$u6rH3h1GsNI20)KalPO%PNlEP^pbb5*{=S9|}A8ImNL#X(YD z4*b-xOsnR59L>y;*n|Ls<#bpSrzH}asr}z6*~bVuZ|okM^#vZqTJ zK&ztzIt|E+4o*}{vOSu`s;_KevcxMIDN*2}*-E->c<@30e)Tl?V0pBcKl{uFltz9=#oa3^85-Ql#i{#NnlME9c|`##96m3qqd)i zdC7H~T-nn@_zxii+grn5tBYSO0!7nRHPbBlh@!=@^1k z^PU{O4)o6ibLmW=tUT(=#RtM}{~;(O)a6i|5qxB3oFmm7SCeg9>m9^NT&JL#yeSn# ze)2IC!-(O?%3MW2emOQhXoR{27wQR_UaS;Dhc!*iBGve0@Jo~EHOrPkNUA#=T6_}U zh}iH^f;+OM0~b4KPlC5uwg(LU0(aoXTT7K$Dh#aMH5@d`Ok7j=HUa3g zhn5$jE~dNICAfg&%*wj@x!1Lwz-r!xvOELeN2G;r3S;Lg-8moqQ)D7uuu@%Z?PmrG zC3sY@aDq>}9lt4%T2{C?zbqVF;=d*4b3(uHd_+{LFMPX*ju;(0h6-h-%VsP&E~==z zl%7bY2(!hHvl9iOEgczlxj{_m`~{S_1QcPy?t2uvPK66h3@+S?Ig2Oc2qj+kq?RMeu=MNhPz%5D)o9QJb7nUkh< zFy*c`;pvhoZuy_Yc7LeRx{pCWV81R)BEc%Q9$3W&4bO}(N6lL?B7&l;P$78H4pL{%;R+rbW!P z=><)%6dTVU1aF@0G*~rCM?zy$1A3XZ_l8`TibWw#4CZ2tvo!SRFO^{cxMW@yJqYK4 zb3d=OkTy`kuvA2K!jVn09Ym+qQhdMa)jIrvdRMT7Lx)M0fa3146l?>=q<^ z`Jp=U38g4C`*MQ(x=k7jGw^X2nWy%43BI@w;UKQ(bz^QQpb{K)(#5#2c73Y`cv_39x7Di zoTbNL9UyF;iP1{?1$ZevZQGMc9embp#qk#F?6FH0t=~J`&QjKFa|VSicNi&{5?pR@ zcYZ2+PfC{j`{YsG@aj-lF8-?fBFH`w-+u%=8J&Sken$|wD77r`rz2Ub1%Rh*M{;XI zAhccCcnZ_{SbfADBo2B-*c(%?8SGz|UJgDyjhnBxT4Ni>PN5_4r`OOqiutdsN z!4wVhM&eDBw)T{r&Uns&V5%@gO1ilwWs%vDAu` zui_~W+ro5UO4nL47M(mri8uL4<&K_@EE_2{#p~8`mlr$NF99Qo(9n85$k$IrNpV2i zw@v7sAr`Ioly=KrDX@IOD3&XtuU!->-mlq9F9(e$dL(c@cVv$D>C=_>LY^DrihsqS z4zfQshPFIqi*bZYMYIt8P;^%X9W9&`g+21Mk)CHLI&{e&7JOPu%GK4jW#@6hG&tz; z4KQq}iTW1c=gLpP>nM85nrx-aVa&WpsJ)nulXxe^otyOQQ<2v)B=;x7Ptph-8*EYB z92|_J*|*>=RB=#0qs=2OSS96Uhrlmksit3+4hh+vz=9TAbTE7vDOY-% z^a7tz67MDl8kcLq&?`9j7WbU(Ue1es9+~lDR-0aqQ%=Z2Xp~rXPEe#t~yqu*A^F7RppeC#h;5i zD7lNP>`o-rtyV#8%@iTSs60WpCWKQg3<)pGJ;#B}E1AW~e+UqDer0G1>k$LxhPr596LR&( zF9cW@Y*XO)X|z*3Fjk`GqQw)8WyVI-Dq%G{o=X78EZMpnCo_}>VUpDxJ?AWx&#vk91-;Nmq0{s%vw~Yz1QtT-6C4tde6glG1LbH~DIQQ|DJv8(Skf$iws+tK&5evx z(APSM+oC)pnUXG`xg+?gcvm{I|JX~#DpKUM$9hD^HEi139RtC>8}ECRRb2eG!QASZ zEmBNJi-Vm9QYs$!rQnaxj;wFdzuMS2qSqK443B3^MXY1{=~fRc zWfQPg+*Nf-KRACp3R_`O5yi3KK|I7vDTN9}$?)#)TVls6XC+9Xad^K2m9>J4a9|cd za7qS~r=q(q61l@F-W`f~sQ;4Cd8`sM+*2zb?mlG`7ekB4CAL3>_;7fLwH;L{0&qey zqw|9xaEgtUo(~Je?al_>2ju`-ne<;ib7lS|zNDq=NU?0)Jd{En)%mgXRsr(Mb?xLtO){ z2`ty@m^0+M@iq;$x6S$SP8!piU*SJjC+1btCYDf?{;;`s9?9Wkiw;Q7x}P=+d?Dq} z43JR;SSmQVrg$c+E#5UF?0153VO8u&i1FSC`3LQJlvG>eD?vzNit`1RZ{uw?CsS>a(3Tc<%u=JLq zRLR^K%r(WVh zfB*mi8GwRgydDM-6aXaQV2ZV001Hyo{G@Dhj#pnx0?_Q7 z;_6t_5sN%*Uz0>FI6AnX^cOX$6|QBP zM&vw^fcI4Sgm?8Pg(^1JeOH#@C&vi#fVHKu!kP2OKHzx1vm3_}Bs%YY)IY_DJ^BUBfv> z`nrHF9GclL0i6bz#A5; zz+Cv==ujO1tw2)010&%INdYoNE=d*1y~Z52#s$IOXvD7`It;7_*Qc)A(9zU&O(mt3 zaDMiN3W=*WHgzYm4AgnI1?Rl|A4;hqErz4RwT6@Rcb9}_GmIeV2v13~Vd#EqI*TGi zqs%ygcHN)n9FA8|36tx4^Q7Ue|V=+ z*@{0s)(>8*v(}up+r#e&6C&`ZIPpMDoMb>;)>Wp<*}ID04IZN9=Ba}++h$K^kRy=W zz7E+yh*@-_Us(Wk>!Mn8;QEy00tM|%1G#tQFVNI7srL|XAQ(`O|I#czKHg+R6nX4| zrzr7} z!#x)7{8-ZWAZyMhLkcGW>m}%EYs5S_VPo(8>ka_OPv#fW>@{N#BX=o<*A3x z_KichcWcs8fQfv!QDvel&3!cPA$2PG^fPsJnJUv-puy%2D!oM=ma#UVIJBe6v(f4J zL&ikyZ-6tF$ePg~%(ic}1#XrBdGf<|~{ zmQ<)~?%1>#$-Z(2gxcFSe*zU)!r%_;4N2h&-LIO!2YIb_2&vkds=e0SfkEtj4+wflYc7rBS6CN)&Vym z{U2k_v@O80pBSi=gYv{hP^D9(-^vHPRk;YiARRvDmy6u{0fo7?=_Z zQ16pj#cEe4J(SB}UTngQvuNv`8uE+l@QS6R5?^kk(5{D6$05 zR#{O>LO#hkR8kQINCYXjI$1R@S?zbxE@qo$R#Nk`nbcZMPLrkGH6~ottPZjg;$%*E zB6vGiOE4dcBMl~XzH#59;@Ag{?(%laOe>chnKG_J2Y ziFEB$-1)FXHP81rI6Gd84=$VRY4!&>@Q8|sMDjKNmDk4jzSUi9XUhW4+<4iVN+r7Q z$vJ3culWYs-uO&?@V7iu*$#EKEKE@W_{vIjP9nj@C)pUHX9l=u5~z`v-N}8V$_n-j z#8$*)eU??Nu6T7Tfn*|;4$AS-;gv~P(|7K#^VK3(KZqJIQz%Prb0d>@p z_%B`SBzmiZoxW#YWloQcxn!}-MD~l+cc6hUS=T4CD~wrRY?kE?#lwp|=}!AesUMu# zYSstOuw66MdJ?LAMaguJ4dRRYabAe)kr#o$iIpqc&+k`FVgs^U!T%TeTymk9@Rrf06AZXR4fNyYXu`cqE2*sz?1 zeLo@T@m(GgQy7tJ0QjSeKY|>h)k2&J!NPoeUZiT8Wc$9GP#G+*nI1+d5qcc|NyF4F z{P1-(NyUis{Z5_NG^E-g=1G8OWNUa^1C?9uzOJCu*pf+KGYp`7qYK$dScnV7N5i;| zaorCsVagWkqh&A2q_4$3De-Ix@VfFU7hYfcZf;%Ml} zN;a4!gGKg;bK&(VbMn1cf>Q0lDM)VMUd8+IFG#7|;)haHCD@un&j=#KC1b>Ihg0Z{ zv@}IQa)Q}}xt-9I$BdfmpWwGIblzf zv>P7!v%yCo*4Fj5QsPm~vG7;s`qD3jWDct(8~z6}|J9n4`IFcZ58wAOS(S45Y!Efj z>n&?rigtqoFA?+n7secnBg47a%Rd)`$L}E2dAlZ^)y#8x42;oJ%;a_M@~T^0&9Hlg zHV?`E9Hk;`dKWHgNSLUwoWB}l=?5D>Hq=)@CoBu5nHHjPL9(EXsJR1b>DqJVa`$y& znqu#MJ&UJh%G|zh%Yz=!Fr{+~VIl=P{{hAR!Cv#mo$;zrm{6CYc$Wm18&ANsy3TM| zEtz(_r71X$RxUu9IxSjB?6kXuPd92F((Zp0D{{4LM#Kk2G&FA}oGF1{6rg^YF-YtZ zcDhLXBDhYW23{@@p97Wk=Z0OJc=4oltH?9LnKv|xC9)oMs(P}HbC;Ka(lT4r*{^{K zObbwOqDj+k4lW?2Xj}$-s^x#~u8A-vb|Ag(gr*9sa0YmGo}XiBLVqxl(CW=e9iNEN zMNAXiJ4qTqUP50i7=2qpvXm&iHw_{z8&(U#Ma-q#CAJi2s)#CALhAB(zBW=JS#L^N&KmXv_AFGF`W&9R z6Na*(l~TB|hf5D0c}!8me*nm8hQpX`_L`XI5QP|05K<4JXu zW}i|2hCoA`4Z?2f&j<09KQ0*C1$$1SO5vUnLE}F&jP%_FK>13Z;T5RhiQYoYyl_gM zrKzs^AC>?~KY^vwdx|_Hh~dhqd=`=G$vW?E5|Kht^hqxp*cNhP)0Av}iZblIlL3m2eC0Ppv)F-h&@7q(Ab(8)K;?H#-)#bx7PNJw%(IMJVHs=H; z44kZ4bt5ftLD5i79hHHNRtjQxDbI|2JK0{_lEt`BwfsR-r+XxMe<$gjyto&VV6tj1 zt>z<6SA{B8fb_d7jrLOD^_2-08lMIrc)`UCOHZ`P4np0brye~BZ^ zC8feJnREHxI zTuVFN!{}BClW?U}(=5euL;)b?<*h+=+uG=o(zt&woX&j&^Ar#4cpUm3y6`>qHex9+=b9F(lsBm%ns0Z~ zLk}|LZVni7-?4srk`XvMAC$OW3I7>`AOp=7w&pAv+t81R%gd^w&6^aeV$I4g1FFRh zz6}N}Yw&HshkjObgy2;{uy#j=9W1SFsxL=M$2pXL;R2HQ7$g&fzbndAEuRUYW)8Es zwo{V8fp z$&)`5gt7QlU@kj67z&T3#>+f;?mk#0CC!5!wFBBf+L$&8uU|{sI41Unn$KB*@?H!j zJ|g58JGPXhYBCUtJhzZ{E+`&h(PpHo1P&8VGNuSRD>OvQuyJD#^;3^$OGm?PX!?rG zmifFTCQm*`?pJt~1zu$b;qZMc#;GE-_FQUel6KJPDP`qgfXdS|tdSlZ*Ln(8rU|j< zx)t;lrNmS8eBhiJKU`ICj*PBB`l++RI@H`a)22w^kHIc^vePK=cO*r^#tXOQs9v1; zN0na|N!RXKF!nVkVDjQBQ-huZAnLTY`4_~G$JRU%ImboDZ^h+eB`%3?IUSx4MSmVW zbyR3>i#%M_{Hzd^}M1CC-KT7!e}q6#{Dz##s5)Z$frW)pz z(%bn4S7k4sb#qLu)B~yW46a{b*LgpF$nD1)>)vpE9W1%BWTL@^f{{hQl7df#xi_it zBitO&ZG6ZSTZ7WFg7YsCaQwQwrR{P372HM_>?IoTl3mLNnI5aXkE@o;PbyrN*xxEP zmcjYUuvDj_yv*g4P43dywh6JD@%*W*<75;I(IUetL(v7776E(06&ILvlc0x*<-@OY z<=7_F&$BdKWQ9^w&3#m!zz^zYM3K>5!6ihHGE5qp=Cs&y!z*|pbaTnPY0#W8+ufH% zSUGR0a_~)-Pp6?Sm+sCAX9~+1hy7vR#-0H#$L<Td_zd1>7+mJ)pe4n$QIGp1VlVB|lU7L{a^u?B~a2?M7{ z3KZ~pV2F#bS2pxZ*&nymu|(yIvWV9cFVml8$1CR04H-G}ZePg4W+9+()X<%Q4^H_D zm#;XYF9A8#D;Qw8>MnG)`RUtD-IPENsWwTUNpH!^qFg-(jvjnVEK`-3Ulm;Bd$vUWcxZ%m2EhiPLn_(rYvM4#CV?a1Up^aOO z1g^N92jNuUsX# zhdtK|BF1>b`G`+i#F)sI$dNR~rR`i~BV4G^1QUR`(?M=ewjVGVD+E7YU{aXgX#Bcp zokZ-?RnyjV#4(`x>`R(e>LT5B}=D7NVqE8z-sf2Nf*<>ZYM{nMhC}T5EI_iM0 zq%Yo?Q!+0Idy?_TktK$w*Gd~W7DdK6)f78@>r-Nz<|7) z5CD)O3qw~J`k{X%G!O^7|-BT_J_>@2fDu)iiY)|<6Z-`or6s7R zc(h>KsIH$P72o>B)SaKwVwXQ_A=1{u%euZ=49n;iHl$O?T~J+jS7iYq(|N@rKicqcyiMH=~_}5-&uJ}H2++bkI?T*No z60^No3bNdR5!3fv#R6+3@cTARqUG9Z$FnCQ5>>=Pq{UPhfe@mC2HdYH#DZ!AET=8* zu>r0PyOicOhk+U8bxnX!$QxQ7WAqEMvz2r{c!avogj0*T=}S={Li3C`F%iNdW*BO^>kc!BOSG+)+613WFY8+pO~j^3F0hj3Yhznn58_Sbz-e zxkOvGqQNXZbW$bx%?A&*MHSuvcc>&NqPIu@K)@yzDwn}u%6?%c3_fGL0m9E)^)h)L zmFEzYU}g7DQYR@U`U&6`jWZOmn^=)UTpo&fKBjhZxrHxPn)Sj|eye_w!T7uf0>c_8 z3IWz*h@Sr;lVl}mW{+HnurhbK8xFSML%;9C0d@eRgCTqXA#nm!t|XB*@mn^yX`-fc zq~2B$VafEFn#y?*K9ulwBn0)}h^8n^{A~pK%ia*;#eo;8`~ENaILn3W?ln{w$M|UF zrEpyB|5WR7N$zJc5#))wWsbkJ4{<3zwJYDlrh@Pf%8-9uOUdp54KQ?@BGWG*Ul08{ zWG&aP_rMxpb3jq#!N~vzK%|wJlSt+UP}hN0e@d|ecmcqX><~&MWoJ&M==$XRI=uSK z*|O4SYh(_qSOJelm6DP6c=`AnYDh`BEmCKH4JXfpy3+Zn+PZh2gW!&!g5-0;4AuqL8zkXe(xEEK*fe8!naHT2~o!aJ9LT#+`_+ z!W?z43o-8JiStaA5ma(%EP{CDUfGzEj_|2Ca{(+&v%Iu3SpsKK*!e7?2+IU@WW!&1 z;aVaT9AWv2J#}g`lbCE3r4Dd2%g|wIL`uM9zbth4iIQSPvnzQe=od_Zg>w6*paFnI zwy}jXjC}5#qHI#;fwO%J9=Tin#4mt3OO(Dj1*b`WNR^hckcPbCRjWlY%$lo8Ox5>& zt64E=OQ55LIOwIRR0S;hKhwS-X@C{tvdB#28#Q|?Ze=B}!6T%=aQmj3)C0%~KN(@0 zs%rph0^vS1dQFAWP!jJ-+290Hv`T6RyFMC+u0;sBIbfvhVQEy=_dQum6$I0H3wh_C z1JO5QzWrxPvnEv;>9c%DbbRz{*f#M126j`u&{^{Z>F^~-5k&}En)+^LUaSCwzz+ag zJJ3!n=D9?d2_%39WI_lQlPtFC->n2vKpm%HVk8C(7@Bx4&#Kszy@1L#A?|L7l$R_MS zie>`Pcd|gJv90)EnL`Q`Ow6MC5{p!V?O^ytFrG9!l0h58C=$$DwB(O5FZZn}t$eNU z1V4n`+xjJH&9NooM_B7iSS& z`rY<`X-(Pks}f=5+#t5V0003a2a8E(vW4V`if-d)W~osPJx!1y7J|cnlEDZn{*!g{ zg0D=y`^|7wgo$B7mKyg7?=!?2v0w;b>jW!``+>Om0zg!dc%a$r$Z_?JB5`(#PCWviG{e%A6#iK%Hn0zhbf z*WnV;DG4j_FR?yKSAl4N0CKSx0rM{Df(Qg1u3Nyfs?C{|dbkmUXsRnxrH+Dv3a~pp zRP{!z3n+rQDh&aE$G#XA1eFE|B3ElO?k2iCjc8t6T(Q^5ZzPz&-oY!JMZdXe$wneH zju~}X5J7`;Adl{px|>-B<_}U&0yiNp5y0vBTB};wdhkSeYjmtP!BWN5Iwe&X%!0bf zpEdRg`DJiHYPCNuO4asYHjJ_etQW4aLZX{@|JS`0##E}tRJo`!mhmN zEF7?wcZR27PO(*so&vDSO8Y<86;x@*;)EnDj!r-z)PA5hmD)8?jJ~gU2_=Qq$$H zo)I}xZQKzKTG^i#6Qxbgf%i7y(|mPd;1KE_n;9?CTFBonCni90) zlKq`y`fMYgDfgxSQs9^~xH;2PBL;x7f(D!@G^zGhGcqkZ)?Jo?7Q2!<$pTuI--Ak` z^V^++VmunAeODRxp}Su+=btW;35gNt<;gW*!RvF<_#gI4$+85X>bqLYW&55U311!63b%e7O( z!Tg?+9DY9lb_n<}r29NPE?{K$0neW<3?MuaD_#ewz7bfIxT4MVMa0<|L99CZI2-rE zreka;IoZ_c`Y@eO;8BG+s~Exu{zP<%4C7 zrDYGtNa=XQ4nS^+7Wp6{?k|hr;45%}72aax%!lknXI)>&bNH#AnIpXm-;tPQaA1UW zRdC<&(Oqe}?H4cn6@sa*&yx%k)UyNfOj2=GS=qAfa*H_f8BhK)%>A9cUWBaYwIj3Y z5owu!jWwUkAzFczf(d+@2~dNMFpxsWyDK!?7{Odxl~ss2|S57eHT1cWDeVhF!OEUT-$=D z2&8gSgqLIsuf<^FvcwcYtTpL8l@zlmQ8-c^foYnbPIpCzWc&K7hJ`IPPEL^V?EVM6 z^Xbue$%wr!ioTUtY3@}f%U*lP5Fk)bCRO|ZwI|~$t(bRZ2VvKxxHV1io|M-sIRUC3 zd=sLxUjrF)kBhBB=}PdMbA22db!w=6K)1bEg4&WhaA0eE6 zcgr5*HfTiP*;YWsBk)4e;q=G$OzTXbw<)tMMzzeYQ}^-rc`RtWSUjiV$rw)oX)F;| znN+@*r7a>*kJk|+sIGHt7}3d>qIM=ciR2WqN(+66;?|Xl%Efu`2h1av+bA)T=y&v8 z!N$0v2~POK=_ck{Z&_{^Yr?FK}IZlfoB#CKC#Xo1+{whSR<3UfY2JHjJ{rb zi;>peYZ^)qL6WaqWLE1J(!XuBnsD|-XO@va1u)LXj&(&qSUFqVDiVf_S4AQytKgI+ zB2D=ynV$UU8I+`+UEsZ)H%B^P?T-0qS`(AUFv`UQuAcpA-ldci@(QnDk3<}horRmB z-C!wHxT*P3sy;%gl{Zw6#3D(1mSFxfm#gzr$+Q2}`p&`ZCEN`aH{&|Fe>GhT`0#n@ zo-9NY6uuJ42E`Y|9eGQ|RpsgAT4oD{MbMs2lL~H@4LEw{MIH(3Lbc>p07=PeD=ipbGI;Elsg81%ozI;U>XR2X*|2n+ zs~BpPf}tTtDmx;uXqU~GWr4uyNGlGp(`z45VfcvVb}BEBWybU+XxCyezCOge1a`og zVa&Al)CT9wKDsaUckpI`iR+qDxQSRAQ|H;EOmVFriC*y3JIfUUWLU*TnsJYhV>5-+ zeXZk6O_}WHYq|7+zQ&m3_k-)p=h;w6_%^;1%&rkdc4toXv+zqPz6LnUUZCAXjxiNV z1eSjcudqe@lY~YE(*z2Wg7^k_ur=9irLB8eEXO5R@OfrSgnJrpSRXr)aBLA3p)ps% zUaa_qVyy?bcr3a4bD@0cmb?xur{ho{P&BF92obHVV5E)-AfUuj7I^;#P-({S3bV z(FIL(4;)Xoc(lZLx#B*At;>*dZDkaZj2rToNn9mv8rvL8(24-lp@Cqv+j8Z_aZ%IU zPCVq)iK!Rg3?83)AK^6&D)0pbj<2KGl^n4K*PU;nSh3^#icn9l*OXk#?={ilX7B$@ z=T9lpPQ0b@K0HB^;n7|mpK1V=**2*W^n+}lIyET07msYa1kQzkJC|+qWN4zsywl5v zE2{Vd1tsSEjp&lx)>nhX)Azjt;8Rl(_^R+03*GVwUFm7ct%)bEj^_0-!yVq+bab6f zwh4R9k>e~@4avQ!r{o*K^r@0#3QMW_D2R*`ogOGH46T_!+2PB^o|$#Ly6Ki6oFghP z%p{;0uPe_NGo$)JDCt{0%9aZQl)fK)j!d&XE$z!@*DqsDV2cGRqGzOZ^yPv?UiOhA zguZh)?7Vmec!Ms}vJtMD-U;qW*D@(REon%$%zA2<6zZZrnP?G6SrT-ZyR|mim6&=c zzAgsdRLVS6+uq=mueo`UWn~LOA@i)alp1g2nOFzTzAV~XzAiXD!&17kF4_cjHtejG;^=iaGlER= zn2d{;BNnO+3bBRg`;oySTboDekQa|K=iEBV!4n=><|F^`{D*U%H9Y96V!#xzS`p_- zVbF?`K+;a(Hpn$m*rQ6r)hs2J8LViqZBJ=QHGJTJ>&UD|kw24_WUwR<)I1L-7Dq*T z$(3o=UEf1tNW{JhMM$%)8CHLT^mYd#46um|3^IZ%W1%V*jJqavbfBj`$c_6en3oN; z&bhL@D&YH+sn;&Zv*mu~azu`ciYynWPQV&(WVLOnbY2ZH_A3a>s#)P7NqaWb)=}9l z_SA9Lti>d za=~^2k3bdUbe$4>V%iMD-Kp+U9pVo>sW9m{jVM z2Q~=o8RaRK2*u&-U&V1lMX0-s*YDOH5v`D0jQcu~+4T*utl&*u`A( zn($z@pMn{;llF8hrN!hWdyzjUf;`E(!4kc#>>s(w7-lA^-pZDTx6gtSSr#1_mN1AV>)C3nR~Vva(QXJkVYWY4G>A zz$(J*=`E3=QY_<5l&(jUu7RnZL6xf_>d=~4Nj5GN3yQ8VpsDE)zc^&ZQAnjASiUOy z-U}-oykk#-y$}#Wi5rtSPsvG1pl4;Et^`RzToW_$%>P0ukl=-l*Z7#YZqm^hZt<~7 zl~Y8*w4Ggu$S9M_uJKtrvr*wsHZqWJ_izdv81R|VgDlAOObDSf%4>~`;W(0}>2ua_ z>cd|oJBUgMp);jKS8HN>r>~4Y{TWqDq+D zAUVK90vAYccl3R1eK zgi=*~83dZkCwELES+MM+HWTY&GuEd-FS2)ng$Z&G(xF(;{^Vcf4bYl?+ zAb#@q9^!0TA{Ld$7-x*alQE*o>T|E1%i?Ybm1@Ieu_F)_HBPypr{d^}Rhbmoc`C{{ zm?PfW4G~mFkk99fB>F_9JC*gs^sk0$#Q@FHVEck*j|tH*iLf^X`{(ZXwtzR>n&~LM3McxV;{!lA3 zm;e9Pz<_Fs6hXp?WGP!Wrr5g+T4&wJva?P1l_7OmIpRH<1W#1eyVk(O2W`a>Ru+>J zvPr-u5^8EpsMtl5%<>xUk7%H;OyH(OPrKOI4MlaElc-?%tz1g=M-r&!8L5SuN7B9G zEpQ2ZG5FZPTC2BoyWer zR%D6xPnOYsXeQz+F}JG7;Cq+2=GG56)y%-Z1aPDBAjj!jP0m4Bp2(9T$~}`Hb)6^~ z^x;>Inpx2*F<35xP+&>s4kDt-3b<%7m2MR$(8n-3xA9bklL^#pRqMy81oZNfbw2|~0>RI}Ex$dZ_*F3pm>gnO}MWX&=MKsFfYV_IT z{Gx*}2*w=j@;&4{cZr%K&iXX><_2Cp=59?*F`s7G?Mvpj*%62Cs zax;RZFtOBd_?#x50Bh1gooDmMhz{uEVEGhz65222Bmiv9>a~|OQRL^(>P1tR23nGd zq`B`<_+8(#nwir%JOOcy1|x}L?4X!=bg@f;Rjik#SgfTbIe8UwmkCd`ista2^Kd5n z)V$^*_WtTlcuJGX`OeIjBAXkqyY`Pr*EeXyCQ?=UQQ0)qW75uC#ri1L-}Yn+ZIv`Nj1 z6)t5L?Ab6&3IpQD0ny>*_DL@4k@T5d2@4*V(PR^}@Q0NQIpXK}eC%HF|5QOg9IKtb zMXgNWeX9jd64{?P00001D^3RdnXY|s#`<$4!CA|jAXXAgtKU!P?DaC=*qS;-GV*a}tg-+?Ps&D7XDG!yrj$b{Vtk@yf|Ua+%#>9AZk?dXeM$H{ z#}-!Ww6YT=n}pZo_fpug41p;!S#rcDOn|3~(_|CW0_H+kfHJE4W~Uas;aVe14aqqe zmKZo`l1qSSn2J^ybSa3Sl;&vL#Tn^$nKQ~DLK{Nd%P1t7{P4(hvIMNSgiU3Y6#Rxn zKrITDbDYIp=gGz=K-%vqD<&%xB`A~Pu|-U>k-^K9g^qdWEJHEnh5*2)E5yawb22HO z`bsJ&u1tAggi&kQiHnu-TSuh375f%4vH?3SlK4h@AYQ=##vsk!p9`SO&CCun*nP5I5u5qR#WqO!5* zO8hGveS(Sft%wiA;RxXAumf%m3fL3-GO$3yB4q>Nw$GY=aq|39L8$PA>x&Wc#gs|Q z&h(~miH=?VSRn!lZQfi3^!lO%ddym?KkYBnKLgC};DF%N-w{C}IuxUs+X`_NvhMhn zO|+?~;JR(j(|dszjTe{C`LD#1_*O`$dS%Z(c!E*E1DoYbk`hjyblG{~vaLUcL2u0^B6vrsOJ1T#WcqigQ{c2W62n0MH8d-A2fJI*`5r4(5m6C~) z=~BL1c(Io)p5~!q4uhgcKC(30NQ+w|#RTg;d7VDQUQiS>sGy3sg4LCpoTW@_-rCAX zfPNjnAhBM_`vg~~epVt%yeZI50XcO7&Q2(k7i8L0;K}H&Rn+<@3!2!^nxhx4zbThL zkgH@Ma?13@OQlxA93()N`Mh-_mbx6ql48hKCey?k~iyh>PH}%oFhzKxpO4%EOkWsq+zpb|8~Gv7Zkz z{tQqSoUq#mPZyenP`(&067C{Ao}br?adL;zX&4sU298L8q1NJ%v|vM^!6{G0TBmVK zwmC|-nXDJ?1IUXq%ucXa8eugQ5olVGjEKDN$TXtmfn~#^ZAq?+gmST7BIn>lI7-{3 z%tuso!4%3`xE@%``vuC8L5dAKo+`lKq*qiCc3N<0kFxPu8r(6j(C$<|$kqq`G>$}e zT*~3hrEp-DBN0d0EFGQ@AZlnZ$uz1Db5p{Rm>ETMZ^3SA5QVBvht9Ou=fGz&jV3HE z9Z2jJJYK{D_ym)ZWl{VK)ZI_R2ESl~sa_GEh&q*J77JR&9=Lb6@qOb$%w8T}!T0mZ z-cKk}O-sN)S(_r-BiWX28KS2zpQy@GDaj#;I92e>aqdO9yN zf+L?tUMzU~wds4}{FsuBirk?-sf-p!5K@msAnl}>Tgs+TNvs=0`6ij+zA^bMKdF(w zCBn&fi-E)3tQQq+8Q~P4N9PGyt1U&r?Lf0c&Vnv_X~DOn!Sy*&S!jSbO97q;a?hHD zi$4d>55?zpbdtV#aUEM#OATztO#k;b)}|Gc7eVg77#D_hh}of5@t8?iyPm;t$fVSx z7BJ*kR|XaPbzQ--dG)Bnxp)^_mTkB&B+Er8NV(O%rDPP~-k1U=ZRcqE8b6(+k7)Aj zw)haAl-`#=rgp&o#t}NfCk}Dk`@1?)^N)tkhN;o@`|wRkL9TF8t@#QcG<^bFADn$L z%a5E_xE}nTOh#W05!MMFr2i>SGl0vb=y}~C(Mux=Zz1K`eA0dmT~hUi$M>t8A~Ami zvWqh4m4J4?fOp&w6=KgU4084iM)*C5yAGLHDcdnRgk$`R)zw{`0S%Ezl_p|d1o>ZC zJl{q1=JZ5-ed?xMMcL@UBoTMQPfa97YvaMmbo<;6ykl%ZvG6T>&(cGA04O0phm@Jc zfD>C0>-`3)Ko^x35@Ya*<(ROxdy>Ybi^FiMSw*s29zU}0O+VbmH^QGZ>u)JaSDxxB zuI~-LKgJvK%H!1`9QT+{VlUu0`~b00zP)6epyePi0_Zfj3;Y|2)Y_q{ndXpE}8Nd_3;x5z(ImZZqyPRclREr-KelntM4k@R-TVMEQTkRDS9jT%7|=5Yptso)a` ztYmFzQYZhtm8YUz79W%B(3PJ!{(#Sx1b!q@&=UmQxG1SqR2DgWG%2E=Bte|nGgDW) zJQH<+X|PEoJQ{$4B$xB4rgX%7c|{1kMh$a;KGh$`-OZR{PN_ zs*oHACYz8)ed?{g*9?kf21RWG+!k=r+XNTtsjYky-95g9KU5ij(*^Pco}y+Q`Nr9~s~mo-%?d zbMInRJS7J|KO1*{9IZA8xQrv_TH=bU!wEs`T@QpsmI=yGQ-f1|Dbwud@IK!!G1xvB&#APFRp*M0fPJ-c$l3cP0K@>nZbgI{uL#soH-Fk z4vQ*|%$~r2S*eX4HXOt5J3%Q-M>sl!ISn+2E76zPZT{|3Y z;;q5R`^z3As;&~cb;$EgY$><8Z!TmIP34jXso09Giv|?BbpNOa@LNN#_a#r2$Mh!4 zR2^qMK>1(E;Ltp>9QXGeyE_xCpz8u$4KKr_zABO^Ey2OF!A&wngS+K{o>Sl9aJYF{ z_H31s3=yn|q*Y9FpUq$XHl*pj=VC4jJTfl@IUJmUq006tQ!2^e*DNN*TL%RmP}Z%% zgEuY5AJ|}JD>FHYWiyW+n0SL^E1*q?@Rjq8IotUD9=zx#fAYtUAoB@lgKNuF1;Uo0 zFvmq=z|RO^!?LMsYy!l9Xn-(d2k5LHj=84C+PtwSL_-4ZIdZD9@Ezng1}V4ESn*le zJt+%J?si?KaChQI^0&m*ATxMphe$HwdGp{pEIDK0TM}HuWNVi_8g|I2n#l?z8h6p)<^8WI zK~i3A%SSK3Y#+tep(?m=cr2n$*p=hYUrm@43@d1nd)^EjSSk>v(f4lDwU}x62aaX$ z^WWyx59x68|28IE9Tc~*&^b#EeF){05+2RCeFOP&Ww#eraQ1dOo*PPfMTmL8TEGAR z0Wpe!gG?9(1ql!~tfT4@S^%bWB($3zw~f5yULYSK$t$1&OnTuor3j=nscS(CC9iL> zLZlRY+Hj1s6d7XcAJ1rH99_z&xsjx>_?(0{d8`a^V@@lS5W8J{oV%#U;E)RRiH~wA z8zq7ylr+aIpe>Re<)!DzM|)1a@<_qlG zTNAt%l@=p(`c+U*i(uO(jb@89RL4BWX%8FX<(?>$V)eE7f+@d1C7q(ITykd+P~XL8 z#go!&?f{8Wl-j8}(|;kpQhtYIKWi{ebkL19DCw$GOSgt19J$Q$R%5XWe#WQDNE{~F zq`Q0owekx&k&!B#X)D-@5Ry&*7@RO(k=$hL%gYuSk`fSrT0%-ien-r*r8gG$##B#u zh$qsTQ6$l;ZZJm^;b<@V3S~qbv+vfXIY|qmrZRkvJ#XYwMqQj3WgDpL;W98$O-qnd zbSH^ZBY?5F;J{KtMi{CTX^FL=v?3N^01B!O=An zTJ1Z8j80d!T2svFQ|zKEJy)m69vcmx63qsRqEE;N2xT;_+&0XAk;OHr1 z&a&9}ET3_q3dAs3-BOrUFAjox(C%q0%ktD5Ml8Cq`(^<7f4ZF+K_G9yA4gf@{4wJl z7O&0=?Uhc(fdF;7DO7Y!@|c&wXK3-qfY6L`DYT{~tc|9ETUnegB4u*_&x7|Nv2vOJMDA-twTB-KDyY`ht0m29yWBCl=AUDu&@dj+K_4&}_{-dLhnIn&kq{}!q_cOyW zh&I|LL}9#bB*+^jT;cU3x&|jtMn54uqd?LSNWh+^Aru?roPn5$2_T)6ck~#^-~>NT@`BVEvc*F9 zy-A`+i#u*Y!FE-Pq9V^17CHuOHd-2yT5!POb*0kQ=K!5RV!vdS#z=@*%c^*$${9sj zW}->LhVh{pI*tX%))rbcTjPlw^160jXRs_uDBPgS(kB8fGDB#y9e&A5j1f5i0AIn;rk70N7i4@q+nfOc83eksaGwuV3EG@# z9epJXSU>G~dy6gp3~&qy%Uh)ofabUV;ue!4W@Cvu5-Gygk08l=^MVY$H^ipXHapd(9Pt;@JCb_Q%v;BcM-g=a%x6N*=D|6US_;u>#+x&7O@GG-Ii;u zx(+>mF?5K7OrOD$k31MFKnfP&SVRdDR14>nRUTxD(7pAEbmgOF$LhPHDB?dyc`So+ z!3v~$CSf$IdC+#fMCab^WC<7pZlZS8mjdHt1i6hGUL^g!bcbaD2Hg8wAOr3U)V>fu zRS;NTq^jG!7yZkn>VrNm=rpDJDf%U(@y;O}27r*KDGl|+D470{G1oqC9c3kWjo zOYtm66xRD87i7xnH^HF@;=?BX11#bd3#ji6B+uL58;=RHYz?q;2L4~|Us(wj2)z^| zZBoh?l(8jEzcwby4F=SLN>#T;Ev54KnP6c9X1aA0(E|fZCUFi?>aE&&MY<JDJLafPm@UPf({t z&D-A(449m^*&=eGs;aB0127NWV1k6OUdBveaWS;SAxkOhOsm6#I1z04fhB+_KV(r2 zMZpjL9e`D_lzv>qF=bd4+gT`!4zP4&oZwC0R84PF6gJd=#L&?e?PA(E|LaQJh3=b2 zT~E+p+hU&r1kevm65wo13@xEEe>Pj+(J4teK#knwSnKl1a*OeBVcI!_?5pF^2}F$| zbtj&zlQKGZQQKWTYO#Pi#YyJXV4S4Y$8iyR5_EwgOQhIy{?BRNsl=e@5&ai-mY^wF zD^ydb<6z)m4x(8oo<4?Xi>eO*Pw)e|*X_qnBq+oa-s)7%;%s5jJ{% zM!|B6kpL0mgo-rIN>n*pFXOASHrY^Ql4K#?aBFfQXV~jBG;NT{UX7k4wIe%F_}zg1 zw^19|%tj4}muOXiJM@fvqCF3>0tf4YVb!>?G9FWvfIuI~L_&t$iDcy-mRl;_$fYV6 zN2Ss)4iy-$5q7D|op+vz7mr|%%hfMA1q1?~eTY;eMM$ieI{A+g5%23go5Cc7AAEh# z#Q-AMi_=03Rd2X}6?(o~o>rdpqcok?&xZUhC+0*m#pLot;i+hK#2`^UiI7PWO2H+(;XxsaAOs)_Btt+Df{@F1ktq;K3_uGK zq|s#*LvXt3BFe>-Qz;QO@`waFR+`z&`K+CVB+!=boh31rOZgJ0D2Ae`D=DS4OnMQJ z$q=D~-pkGaBFLEy%j=4h7cA|&c37n5v#sS$VP)$%$yU`It#F7H z1_Xg=@^Mi@S{4Zj);-(=M?uCEh9u1bWC*Lh34V3@k-QGdpji13QR=OspA8ora{qie zpEg3vQ?+Eo^%!_LI?18%N=B?Zx8ewe&i91=Jn=Kbo>qjL}gsy<;QYY%N$>y zOQ+h|dh`%FX-mN2)kwnz3ta2A>xfYN>F+yRGFQ(O!5lOQueVDYq^}gED4o*0Ud2c} zC4Ay%aND6V6j)kwhL0fMI>vBXQ)i;)1s+lwx7m#|UWi0ul z3^#tf7R4?Ku_M+F9eYRHV&=h&|X%iu$Z3r_7;A z7FPVQL1~l;h3NTvsP+=o?4AiF%bgKzA`FaMbivCnnWqaPOj1vLeJSKg;Sr^g0P{@0 z`=(o{t`))0mxR)i1Y*pTx0ar`ab{p^AyUGTkzuWXEzP|M{4yzMmzHL|!!wo3_w9F~ zY!X1cr4Cbk<0H?Xa9_wD5Vlv*UR=6~A{tUXAPqBOEL+UM2dZL4SX9oUs^t|r3hF6U zObbdP#U;D1i!FQ~Bo_O4!pn-bUn_mFgtk=mvP+(Bg5`T7j-P>)wsucWzpShSw0x~T z<;LFwiU_#W;OwBf$s-*ygJrHK@(uS|kJ4T5^*SaJAEACn?)DY(8w=T~bh0UFk8ywMrD<77a6?qDn`?NcFwoy{2Cy zh;R*j`Ac}%#g2A_T1Ps^3DU+NOx8sQsLG>N;!VyhrR7VuOu-Ny$4V80pj;Uh?tM+1 zxtl6dhir9B4NAYVfir@#u14AvzDs$@2kn%cu&{JgSp~%dz))!{Z8=KJU$d3KMKtas zp#y?pYRQSZ&JL7(_HkR5DbZY4#Isob9y}Pfccq9ei9B`inZ!jN54_lduO*hDK{a3H zX%&bwusOIwNwrr9pn>24Lib;7WxgJVoUqET53LJwa_&9`6zGq zDvRW+nxI{j9Q@Fw5<$Ea7Uh~E)r%luT$yMtmLIx-eTjKaXN59OJe>8l0RFc?xPyqO zk)?2Y$|&NBDf7;AZDCxo6QptXmL%M$p7BT+WQtDNi$so$hb$=&HF}uO^k;#Qbn9Z^ zHNLTv-fdU}5!@D#5=_Nq#!2Lv8gWc~gC&BkjxYT9Lb=#7QyekNjOFF4#VS4ca};>2{sOd z&tB~oJrse5(`;+N2M148*Ro4F&{%068N+5A}pD^{GH~H*n+Y9UvsjYQx5qIG!k<+r<@I-J#y@I+? zN2GzU@g%^NSTew+%3sr6m3Mz=t`r>iO-e76e?oGiqOE~)CxO29;Dls%E)^G`K^YVs6o>woC9D2rmYGxbTr;M?KNI}+*SHM9C;BvV^;$AsNrSC&ULmd& z&C%+g2l#k-yt`9}2S{?NM9vL0VD&5>wW_dO?gSVr(>q<4O9#$}N>SrkB22Fu_yM%@ z@=gmQkF;DCwEWCPNnQm+xGHlBa;RT`Tc3#gWivNMa6W;9?_jlg$(yjh`Xr7+Q()(a zr#zDfi&10>RZTLw8FA{kAwoih3ND6Fb5>nfif|UoS1}uWe%lqr7 zpzC}Yc$t%To?~+LanzaDOo>O_9h9nf@n8Q2^c1BZ;aTd-;B%D6jFRfp(oN5s$B{2# zvDg?gTsfdsldogqLnt41--6=mIWcH{A2vl(D~b$)$S0@HrDqlfSDZ-toG{psShOq! zE@ezp%P+17%|WQ0IYqUCX7n#@SCP@!<4(9n`d86IOkZbIpo%_t&4{|)yWs-H6qC0I zs2caGc%Ivf&})5p$hYvup4uHb9SZ~+!&b$BLX_m+!dZPVYwDPT(prt5OAHV&2}=05 zRP`iKSv;BXrw$aWGObg}WcEQVe#&R6a9T?~i>0nsLGej8Os5i80O>A{@dDkr0)kc3 zr?*Fi7bd>hHdfmud2I%vSxF`ns8j7fmwO6jD}<}|TW2JGB)E=MWdU$%P^7R@tDhoK zTW2dB+^e?YXB|%)TaP79JpysYD1?WQN<-qNa5il5YS{EmoK{1!mWqRWIM$#Ej!B$B z$$_vUlteNn8l+wqqQ@X&k@=;*F+nkD1wCZ8c`ON$5hY>fYL9P7%+D6xX1Y8H9S$Ed z$M~=`zB8PPYl%s|T(1JqOx)Z1K>Nl{JKIGc#ukRFf&!6xmyyl6;Cxu1sY^8jaqQN__s_R{+ zrY_H#tcy{Xm|3My1pPdE5o{1~h%*#qIb(NoS#;8$Mcx5s@AglB+O~sp zmg?#$^4wC2(Y2Rx37RH@Y!x)%w7YiLS8lOmlt%1*)D z>6b-d-~qw8DgD8cWb?!flVtg?@r9Ez+){qGSAzzZns7=5uf|&bnJ70)lJJ?_r5@V= zv|J4&O`YhtCNf-HvSAb6XrF4Xt2L`ZvSolys&?o<*FB|#MD(SFGE=cDnbS+1lrvFy zW%FDuD{B2Gv4Ui926)%(LCC@<`NZha>6BP$JHf4rzVZ&0@4IYJ^qKck;VC=Onb`>- zrn!)mZD7?Tu9E!H;G^E6d~qm|%aMts<%|POzE72_ho)MvcOi74bu@ev7M2v;umkI4&Jjb*msP=R=L;rGlHPDY1|=FHAc%yR zbw|U$R&`vk*TeRdldQWFrL8SZ7fIw6y0*n=QY+z;E^u-{qlLCX$M_Y83iiBZ;Vjk=NC9^YNtf9#>pW)1w2FT?t>;Xxu z2V_{}bXXgt@S@R8$b7L^T`UyIV!GLvPjWDUPDuI=o63s@&O)Y5msv_Kz|&!=7Teqx zHHA8%OIsowk=G7bKAad5L~FFE2Yn#129|A3iDdnxA{2Wy5v^pICA*6?*GL@^6eIosq(#jJ6+9#cN{Wn~GSAE! zZ8Gp8ao)lZasuH`*&e3S zNLN`oBKZWMbNHwpEOA=~(|=wbg)9)F&9qcmm6R*RFANP*gDr6MTXCj*MuYPDvpsty z+fgO(@68`mCD-QTfUp@k4U}YCGf9tntuCvxrurj_a;bWr_1*j%P2kqcQhkqny(WFA zvc-=mRXb)ckW8EtN7dQj*@C#Lh383cp95sK3_Lxnt1axOmpkD3Q_bH6%%i#8wg~ZD zUA9uHI6XIg>I98`nH9)99UL-|5HefRIf!#98^KvXnG%bcCUD84{b{VuUX#iujE`)B zA!WzilqLjAT3v00m4wK9_P6k{1NMQZTarBwAN{GoxXdXZH^<7C!Uf9#JM-svG*!7l z{jzv@JfkZg|ETk?E%$l$-0imf8VjiP!@I5tnI0y(A~tR>ok+N*@+h<6NT7TY;GWCJ zE?X3lMLxDnxIt=!yU-TQ%v%j{0++{k)mW5S4A_= z_MFU#R>lM-LwxbC(Y{F2a%oLC`UqGx#(<`Ho9ktAGLuqphOrSyr&>c#YLl8=S{Um8 z=L8cDD>p(4fh)peK4z?e{LN^E-g=MaLT*8Uho#>|>}umt;!>g{zOVAH9`P0Mmw7nK zmcNAsu&ihqqeKfTiYJh#kosXu0ET4rYR0tqOPaEwa(`vTdZJ0{MSmc3@WHM|j%%Y8 zu{j|)lXfghzNq$95bQxutf>xkA9-VJc*rdvj#pw{l}`u+i6I)tnV+SCE+7_Iu-)(# zdNX2lw3zMA<{=3cfa10D)XB_nw#=}B7P1ptc_~q~j7yVga12cViw?6o9U+u-sv<3$ z3;SA8ZwPI|Nq({Cjp(7Nsu@aVzc2s*0Xh^ZoU?(-AOVN~1^@s60000$89)F40003H zr62_)0F=QP00000!2kdN00ir55*8toK)?V1V1NJsfGUELLrRV;0005w`O~6!DOrY7 z@2?z@B7}0EuMFLG!5X%*6r?lBbUrtm+3- zX@3)!;t3Kp_UNx36N)KyBB8%P1EoC(p#YuM5+QmV6 zS!6)eCT1^jA~4*NT$Uu9@w&p8N!LS`Ua1t6xtObwHK}Siq@uPWKowC6qxD3mNaUTj zRK-gM(sX!i+_Kxb4C3DR80^r-TbV$sKOXTCp(L=1Pa@8qmYm2dEE9<&gxRj2s3leM2XZ6{C&`{%)rQdsMIp-Cm`T#W8*r_tFg0>kg+Y6$ zXE8>T*s2YC(B-m&e%P{_slc(=k_)v4M4>38&VS&q(_Op&=rH<|h`V(5Who|g2fZtB zYue?h6lD!X#f^D5-}N>w!A01F23@uJTM!vj`b04U_4Ih8&E8TdRTCmbqn}b#92cJ? zQH$oszSWNXUX5EX^vK-gi@x+?`haqvxpUi*PBfUIZH=a{Y8;HQGRvcaozY^p@i+V) zg!5qFXroc5KS&#kn&_S=Qa8ARlQSh~CbUGxlF=&6DhMhB9CE`t(6!%$Vv%Q$QqjX= zmp1(bX+$Y_`OiF#2qD2&Bd6X5N$9Uk_7XpwyPD{d=KGqS7&zW-|LMq(?hzPK=FO$$ zSs5oxLdH^x53mvCE=`p9KpjVs7^C8TIMI9ojHqQGZZs*+DPc_7 zU6JJ~K2b$x(k<`jG-=TTk+75W+paJIo}Kgw%JP=2;x^f=td<|5y5EGDbO}NV9iB0D z0QA0^cR_v=S=>Mn#N+D=&%-#4e0r3Al{ej-a+5;PSh5-to3qV;Ijz&gI|-ks(D|wq z(0Oojn=HjrnFkPX12{D5OtLQ_%h~+xNY{4jq-?m`hpv#VHRVCmCwN1nrLxy&c$zMy zI~3v|SsN+ztKuS7k%$5?+pP1bkP7%khbV_dmv zU@<~sA23p_hAdaf3yTq`+N9JE`67u3%lklVsWPD2Loc1^FWQ|dv&9y3yiI13M3nkm zgaY!AlLnqTs1(!x49P44!s3$MKpu>f$ktcfY{6duNQ363(lJg&LLfN_=#dnUvajgC zrY}UKnHBFSr-Kv$bWw$-Wu|^HQF;({1v%p~qVBi7e_*}j*%U+7GxRVfL^xpii`23X zP%?QScUS`tlFC#xE)$UVY%oQDgM{RB5hvMcGe@6@kGd?CQ&51yc>Hid1|yr%NG@a6 zpb}n`n6YQJa?nt=$ideW)5x17d$o3ofa!M`-l-Z#W5mhBsrN&)03jEaG!Xcr#Aomq zvCl`3y_R(c(y6ODEN1d!_;_YE1F#%hO;RcGD86A-G-&`X4*bea(1ixj3l#u_h2_`j z*4`|Uv2S@1ff$p-A{+)*j0IQtA3+2#pwk|YUN0h+#+u$T=WFiQy(w6rWt__SR#ZYP{AINkp+Y1WS&6)0TKWJ0cR-Lo(e3O zG}1*$veDw=XNi<7_(_=jOsU1`q&dqg#XLnV&mdO?UcZ7l* z#nqn0n6-=n`iwNZO@BofbTjAmT9^Xxf&D^7fj5F9zBRi16mjO zt@AvXW3aVe@{X?al3|KOY22IkQ{_LWS9joz(f;NUW<6p^0K^0;BCp$V=Y?|7qAA`(I7fK6H&fY=SZ&J4Bn-sJB~}*TR5Y(n3X%vs-e-w9RHXjGQQSUR zc=|H;pz1~pA`4=@7VcEHHhj{pe9V*KOL)MXo5?BDxY0^lBAsZSw2k9LB+VJj_FVTx z5B~`8M>q`W8kinb-C%`~c;>>1N~g*B_^4itOFKSFL(k<)Ogo8`c4|anQ1~RIk7|gl ziEL=d&rU{q+RqBN?OM5rtP zF?r5QA@>0BO^Dbc0gM4c0CRTxkR3QfHY%!1Gk-Otc@Y_ClHES8`YtLqeHVugW7tVq zCZgMdXbXl|K+w#Y2DiZg0003y7obHXN35|MN{X>+P1Jc>)NCO#9{z*DrO`7&~glnL!c`t<(`^ zCwCSGE>!xCxRW`Wte)e#;-FNbI0B}1LurZI8EWseoK&3&7 znSBm+k^-W%kpk`JwH$2haywhn~1%v)*`u;!n5JiTUVJ_lHcm#dvb(fuTx?`^Z;hZ9Us% zXYqauC8sNrgB^ov*)EtG6}%s4za;NO^-_H|&QKM3!jw92R~o5(`~0~bq>tc_x!M@= z9qH=zc_2H14(K<6Ykn-kke6rK{oD(eIT9>6ouR)2R61tpT}462Dr*INAXDi*ati$e zA<1A|^hq)mvTQtyn&|v>bi&hOObQBEKP@8%>jfs(%ll?%X|M*mdEokfh7EmIloagy zhbg48i<%|VRzj2o4nn0&CiJD*4|%bVGn9PyNpBwcPwvj1R<#t0N%9Jh8$}%`yYs0h z1=aK&p`@h-y`fjx6;FshbdyVriddfoYKP`Sq`6-rt=E&>J+2*ew%X#CJ7l$>`b8w& zlB=EO!}qaB{&KK3bX-v8vL(fVqE!;!Wl!TySAb&MMD2Tw(^m-h?{9I+(2_cgo}`ty zdgMzhyAd0HL9<*Ht17n+J=Lu-cqWnbxANMprma{98{9@C`?oOi2?bJ|J`9+x%ow*+}Jv)a)+z*7+%>9!Dyo@Qn z%f0 zcb2N{llc9a$c3GfW*s#xA@%TVshuUFTcgWjL(F`(UR>t--#!RbT1$Qwo@vS?9z#!C zxI2{x!7*sIi$~VLn0D^;d=!ibCT2f{ZXZr~;O``?FI2#LBvfZYSV~}-CyNFhp7k$4 z)lQ>2DPyl-EqqllAME`Wx3QC^U^>Pl$XqLD-ob7wP;r5bQP+2Fw0kS4(>al;VK>i2ITlg+ST6Of(PY3#Q*UMbPk~@|rkKFIt zo*e%mBw0>oQgj|5!2@)`Or+{LdKL!f0%VI0WG!k;k2uAChP&Y2xteB{tt_!dn9^s( zfq8gSNyr-gazzr@g0ec4T$4(iHef=T>&{}b?w2dYw^4GEkfJ2gfpdZLpX9T)cS(9w zG|Y*EhNGo6fsZrVH0jMG{Iq&wdHAZN^)!Oa$yDHG%`Iq_fPlEb-KA8Ys`mR}J|*eV zS4qnR%+wka3n;P8-Im$qv_*9BC~`h0=Y=LT7DaSa_;=!372k6QYdKgxMQSw5=u9tw zI7u#&->3)Gm2v{xnq1v%J_JpUKp@S2OrBsFsxG6;3B4>qNS7)yx6yf)*^%jcg{H~5q65L|*yQB^ zPRPoH^DTK7cQTiX$5=HUc%<~-gp>3294J zjHo-s?uiB56AhF_6LgP4&?XSGGBPcgQmRST>(3vQ38x{6&ZotofrRRLvd57ZGNXaC z{7LGQ-8o8l6SZ_pb!$kMvg$_RD%hF$Q=8}z zs-ANFmQqZYl~tpIP?!!B+pOhqa3n%J1Y+fn1`?k~0I|z`_f1E)mq~+*CrsM-Hg0bx zJEFD$7&&l;pZq+rgUa=s9TX7}JyUDRFIRd^HIz|tV}ea!#Zvej9!2mai1}m<^EySZ z!KZfRnS@t!{02?V{e$_H>6O!2Hk`_g-U_6PNbo=>qG#F#d@iS%H%12@vZHGz@*|KTs=al;8yz~qTGg_Mv9xjnflWYhpGG(Omcq>W< z%%nW5NGPIXQT)nin@}SlU|IW_JRFlo<{u7cH+ShvL>bfv9x zVy*+y`2kY8wyj(#K}B$ZQwsxZwhC}(KF=*ikMeRlb3UeM@Hi#bc1hSCvqhGr7E~=^ zArrY^1gu=FUKIykrdht4U6L$2+OYIkI>@P>xg-v!Vp?5HnJn*Z#lf)yQmYVAXgv`X za|ce5Q(W66v0i!FgT;Vg2boiDYnfW&(WX8nAUy06x$vvvl&;ui9(gvMRkB#MzUJE< zE2h&{3Qfc6H%n8`14Fh$)aIK-29&i*)hietEziKKc~ygTxuUlmjt=-#*Uoo(H!hEd zQJ&u|1#Ox3*xjhBn`Ot^%cAFHa>p~Vt<-WBRphB97ZwXq<%%>8C(4waGttqUI^`qN zul$M#bLHUruqDz8o;|L5VkuK)N+KQ4+AN@aEd;N1!r*GObiv=d2K^}QP?rWeTYtH^ zX)!K%vu0L9tJUGs{lzR2lpLVQ-p)I7?*u)0M~Yc+XCG7>*+A7m?}nKb68a0k*;1(Q zqU#^G5Rz0D4ymzQEV-A@%o8iQW*g#rNB4ocEL!M1>=hR!J@(s*3-C!g$M*sq{8xB2 zo}3ksF+OQj?UX%z9CMt+DM| z*NvDu&(v|tKyVW#NJ~prQVW^#t&FtEw4kJwgQ+%YFyuMG&?>nW3%fdDV9p1xUXM$P zpjL1W0YK}HU+!2o$~ZQZ8)#b+El+qYN7;6hE@}HYbKJ05){8SH%hU`NP#@Zx>r10@ z*Cnjos&i`AazSUexEDC0(NvAtRzP1*MXAknHdAj64OQ@vJSSkVan318mx7ur&uWEtHK=*HK-}4N zGxC?E3Py8<8dXd?pu*9_H5_p?du>!gnZhBcvOFqCmPw8{OCm9yBj|X~^LEf>;5P{1 zs*eEGgh$v*0kZ`e*AAP)y?$i_*`3?>z-=8F8FdXU+BYyg2Ujj+aHTYVGc08#+ldx7 zPnkNMfPX_~E>6kJ>6e9KzzEjO77-Su33KxxDaw7B!Cy4O)itFmu+>UzkpgD8B?|@2 zP}RdYw*r^FO`H@vaHR&Mj1Ptnf!2eLoELY8%Y65$X+uFgWO%uecUgO&zEDb)bri7} zIwH7~$w~bd)DN=*5?h?7We(9e7Nn-kthROL^$ zdClmd>Mg;KQ?Q=y{+a8S4IXBlqIU#p)ZZB%=);aNgkp?KG?S4j5%X#G@+csAY}p4K zQe-^z)|3?o4k%{j%1$R$bzH@b0l=bO(o*DM0vU)1~U^ zJe?O*yGohf5`plMmCZ%P3t>DeoaQu4f|^C8EY7eXuMv!M9vU)-A|J6ZrfH>`ExJSO zbq}!!K?o#@L>z5QYg)ou>rP+9Z$9z+#%le9I`EJX12T&ybeO0OO`k& z11#l2RVMmQBL;TOExM69)RLe}5btm!TqfqXILPNl+I%=C%NfIc^Q8iSMEYfr52)gW z;f5N8tdVQ!mGat5mCMEn$l3!QKJBhgCO!#+S#VW+Fu!gjzuPfc)7J#dxAf~$pOOJl z{+LJ*9L*PH7$&3jJE3cbeQ#M@k^1pbN-dU~PM8&Mi@~$oi&KJoUQ|r3B1xitaDy$o z>##K|IQJCVZH~%#M_jeOlyLU}d-CNAuJ)81h~TTKP%*=n{FO3^#WJizdCd4{*q_3p z;F)<#wH}?rC^4~Q*Rm{G5&$_tqOkXKpwkAKMNEnvAwgou89Itv-03OdrJCOOPi_6^z=6Dc-M>~%_& zWhG9IKz%yL>c!MYDD+0kI@+bA-v8ImPP&8;k^b?U4Qg|M?E>KE6ur*237 zmXKf4-gM|c5B6VIgGhV`R7upEW~6#8I}2fi%#Uh$n>xA`aBPFoMT6Am4b%jARE7WVL!lFZ7Fw~ctm zqJp!OWV2TKElUQ^L$W2of??0K(Lvko-+#zD(RrOS&JQSR**&KDL2$Lsha?V8zhl8l zY_!%$F=ssZAom@DTM7s&>8fYXJx@S_)NE@P5%1K?gNIjFxg=BB6Reo__vuRZqIr{)EW<>@RF7d3g2lx&#bvblNf!GC zMA``oP%BWRh^mTwGdJIr+O}O%*V;_Txiim1Vu|J-f?!Qguv|_-cV$fF?;l0Xt|>>) z3a|w)X(H2-C?!G4z%u1$5q2qOEAyA%q~M4tz}qJ|TN3A!WjxsCnYYO?GlSDrz6Cx6 zgyi$^V2*9Kvi#m71jvlpUj`rZ`~{d|iB+{m^TFrhc3AALmFCkaG#xg@7E9U?7^u;RnBvA~tLQ^oFT z5|yd9bk9I-YnmbE$n?iIGqy=A6FACA&PGWb2v;-i5*hgIgE&dH;eaqSgE+QKQryT$ zV}%Z35rmZCO+qw-a#Gk_uJ6IP0hG*$JI*Z0#tdwT8-QAur?p&L zOfNMw?nc6y5uTK&mh_EgJ4>Y8Y;)>F+v^b-kg@M-0s+SolQu@{FtLm%w$Mf`-LNhk zdXJn6h|36qM4`inqX&%4=yJrxn}Ky))bkdA>Bzw4!p+TbX z^V^${+;X09#(qU*dtg!&ncPDXV@shM3n|imQqFZL%+g7+%E8TH=5BkDVZ)tOg~Xm^ ze(64`ryd^*gJ&o)Qe2bAYGOr$abNT~zyJUNL59KOtOyPf1q=>UGvNq&Fby&%@G*6w zW$#cnhx7K6i*tpN*4WZaoCX-st1rUV5tM)>7DttfPh_nuIEZwlZ+m%Nh|?ge5h${u z(Ul}WN-9oB$!Yz;)Wm8?iSS>O4K5Ll|8&|Azl>;g2cVz)8zWs(5YyE)rD zjat5vk_0P9Bs{4oMu8xv$WZ+(-XVI5Aj87*w6%U&D0Rb6hIYq{1)Td)Rsj9no|Aog zh6HNVn{8>7jK$Dq5qXACLASEf;X%bD_q^YBjYNX4?=UO5Dpi>UFA!{o#C<|Q4@?HzE>$` zz!nMQK8dIan+0h`jXZ-kl1Af(K=esgEEXMfHXOo75^g5x%0t3UYA8wVn09=1EWnhE zY6HX%26ioPXd2e4a2P`nSh@X!Lx~abBv-{*Iduxe`CMYDJ4QyK2`4(D-LrrI00BY> z7$8Lg96(Y42mn9;00000AOQ#f00001AdLvr(3KPz002M$05A*?0001l+RDKLg8%>k z0R{j70uYCM1{eSU1NM+;o#KPkxC`xziwgKAqr8*?uW~oAFsC=sz?p-8RlPsr36ThX zJ}1Dbh=@b6sS|SEI-dTvBomRNW%PY%HMzx%g*I!Y)i1V7HbO-LNNz!xw{zK8wyczx zq$gi7fm*Y`qZQ;;eH6-)B^u8R0)*QQ8p@JzFM6x{%xd?|jkCG5u+GAJfNRSvv0<=H z6XIZ4nswo+!QyPaoOjA3dEm)oG)}K<)7NUBiB<-~T#>73EU8qJQqvSXSWMwYvOcmp zT8}nroOe7CQu_lG&%`HrvfsxJ%7H!8oiwRyYwhvmWNweqZc5Aw%HVaP=0R(vlJ%Z# zXb~x7+&43I0+F;_3uDe%e6ns&BIw=@n%sF80#?Y#q~Nf*9=$_W zx?}=wid6TuR3!8)io;2l$pF4G6Sb-Q`nMml^dsomHMk?|k<8)HnFN+xu)Xk+c$>bLRyIZRMySoCe+L)md6 zC5uHhI^uYA>k()}^h8WCv>a3}R(9XfW>8Utm9Y|c zgS6znM|HdDM3T?B98V9#OOq$r^Bs|Ip8Xm*TriX`g&_vigu6`M4vTB7Jmg0 zfs_rE&zkw+Zp1?1+xFRGYrOIL4F>i+t8X5m(|f_3%yH+bCo)z!Yz(-1OTU*5=2|LG zD48eB0MB?WOL3G@2{kNgLN$)Xr%`Mk$g2+<)9BIlY5O90Y()f-M-yn^-U40UV8xtD zz$Ty?Lo7N|CNOhi2S!$kq6T5u#5Z5PcHQ` z9>v)_=D{!q1dOuX|UZm=uOS5@aj7}#6yi(l!XhQn=?89|5*@YPdZyutc z*hncKmDV=OSla$Qvw~xYc2DbLKa74qet?4^AFFO&`ziPxlnGbc`=;EpV6G>zj>SsFwV&CHY<9@63& zk$jc~vT8{&esaU(F^WB~NU-6kQb&)Fa}9B4EWwKuPmX)o%8fhBq_q``0G+Ib^XRd@ zGCpLYTUMdbI4oe-F*|y>|1T!ni8u`GN=tn0Lf{^qMI(hXXPV>AX(5>#P7VB8e?(I} zWdV%gor`5+fi%)?hrGxv<&%JMKz5e7L{i9FsGcW+XFXZ~sXTjvlOMGIg7@GNdPoz3 z&&oJAC$P{k2bk(g$iaC=S5qu8Fl>s(wl$Z`8!9S-5?&ji>LYU2CFhw(ilOqQSD)`kfwb~6O#Mkb4fuwYcTOBRmFQEEc zJM{Fscf0;kgbJm&Hr6Shl?FWv3yT68IC2O$^Tl?G@Q8O@5<@PIYlhpJO6>eIi(ps^ z@a2T;rRv!3-%8koOv1$&=ZuSqhwY@$F_IxcqJu<_2)z~tph2=!>ODO(I&q&hlph(E zbBub%Oywo@%hu(5mlSx_DuY??z|lf$uQG*aSUTvoa;CCV^J5TNET8HLjf=EO4k9K> zh>w;;sIf5f>(s!luf^DeuzG}joPUcsnRf$iw=rIlDR`Jz=H)b`n!uC--50PE@nc(( zk3}sOtv!%^j8WBtoXDqYP<0qOspbKLl$gq%IFU;hx7dhklOvLk4{|J=lj%B(nS&7m zqfm2L-OU~d84;Fw&4nnKxTB1?g+@SV=VC8+3Oi(IG^6q`Ypcnyj->N?6DC+qQ*Nr@ z#1sy>JC@Q7PXYfrWKi!;Q`oc?AYb5#^8z|!H8PGlWLp6|0+*iPp*_=uxqfE?3k;?^ zVcdsCpGU<2_gJr(>TThjzA7JYp%&&_q{Df& zR1hMVjJ1-jlIL_F3}Nt#Sq27}OA>Ys#k%UsNZbYuTUJohMK#Dd{lHOvZp*+(ys*3nxswFV5z9bV>*fNt9kbpXK zeOWN=9}QpP0R#wd5|o{mbS65thfIE4xyO)Ij&#TY$v^S*SwFAg=<;pgFF266+!S%-2E3=nb za?c4Ci;LBz-98AudjU4H&rcw*dXEmAqbXh@=r%{1FeNYIf@6f%E=m?I9W#wN9kNY< z1biUO_qYk$0qF*EPZY5F^nmxDIH;};AqHv>Risu15LqqU4t&hh=bgo_6m;e7C$Ge% z`s%(Zoj*}s-kH2$awNq-sVqGBVu+IGUjBTv zT!NybuvHG3_C?tf*n;L9iQ9td!i#PdHW{DFr>)yz{0lK^qM6+Urd^YN9`?SwLz%y8 zC|lXBxY5S zCm!(ReCEm}R7zhemt=L71cS1IKGHHo;1NES}n&C zK1t}TD$0gfMv7jn&e=A$+$*>NkxkfL+FO#B1Oc}e#+f}mC&Za_a7t_nPFATjz0 zDe{A{1kEyMK}W^XX!qHq zUx$5pSA0@4@MQE{E3x9NvW@LFjTtMs|j_4;LvhZycpfNK@@c4{}(({Bri{ z?{h3Bl=R*-^D9iZjHSv6LS7A17s`iyZ_zj6TCIh6p7sfw@T^ zDg;n%^Q}4sQ_iv}ZpzrEd|q>u6yR-uI>Ulab0f-)@@EH^$Ul!QyBLXjK~uQx4$vZkCB zo}A#J5HphP*6%46ISS*Xu|Z|<5Em;fV6O?s!*x4?NUl-#*FpF!&RLjh*>91-T6pI{ z^H!esLf5!UaIETN#Wy-2rro(cI(k$?hwWJkqtSZ{zP;p6Von_%u z*cW92YKsa)i(9C(o3By8;+u4c3aHIr4C^KNb~=@dGTqydJ52ioVa-Zv4n)qKOB(WB zYgCT1KU`HZ&CdQPw4Qog#92l_xe-g{q6Wla&^RONopJTA?K)Gx>O_1>wf-5W;M{rD zSX%tV33D!e$|%1i$K%El<;*Q@uxxkW_5}y4PnwHPfgmDO>!v|nGa7K4KQeQ9`%Vh;L^jH^{{*Q$-0u9XSvc*V`X)~>IxNIF#Qc3u#cGYMQ z9ebe%0^rz=kYdiDR#^~zVg=z<(m4{`SVVoyjXeV$_WY%s*)+)T+#5~`!kmKO7YS^N zFE|>Own(CYw#l*zk^j4AU|iJ7#2EDh$x6{{q@~os%`oycro6t6hEN=yh-P6XDHG!5jA0(JEB=kg{=1-&_RvR}fl+Awn`#y~P zRUqndx7pyGZBydNl2zuh1vi6m4HOQo`GP54D9Ewt)-aCgjtU9F^*4r|3}UZEl1D~b z`jX!)T%u%*6MD{=D@rzLwUsM!Q_8aO;`*TW>rqt9@+wb3KhoF}GX@YiN#JhZ8cjzp zFgd9)Fi#4;1)e?Se3$9hyI3XoutTp@>Ya3XfN+M4`Z}iG=ub4bUL}%0%@=}%uFWf8 zw=k8uuYP9$OKev~PMLhl7W9$PcyHZh@`lWHVX{(zEE3&=xTk}2eGsV>LCiZ*(6b~6 zMYB>Og0jTJt`#w5-Y9+ic828de;-Epgvc zHQ_Evs24jr5msIXHJb0$L8Z}!+FGSjcEKYPTNMGN^r3tP$!OeiW)ByEE6_C-z|wVqVc z`#T`H;VnEnDF;glzbxR+uNR*M$*?~@Bwtnvgr$63C4&d-FVhxi@NXrXV zZhjIhKF3CyhdI*2kv!2Nbd;k#$2#At6Sq^LVuA{w*^+LT6(y5b>PcGdK*CiQWz?8! zSwOJ-o?$F9gQV!~UhlVH<% zswL1aSdRxZSzASkk!=^JVsuF2%RXqCq>ii^*zgv7b&wWbMN4^0QnUlX2{GMo2Ds6c=T=+YL8FFGbp)a8V46q4i?o_7+3xf)xK6NC(hcxT7>4>2Y|7;Y9 zQs_oJ`GdFB;-$4puxMQv76rjFG+0pY#1vbCr{lpgqoj;BwLGLyP~hoOITG`gx7V<5 z(@NmpLa#w{f-t4DljH2Pc-8KZZeNb~-Kg=%7(G$IGx{X!JBGd}WV4owEbwfKi^T#F zR&X78$XUob|fu3kK9xKv1?5q~yKelKO&5m>K}Oh1CK?PUXJ zAo|W0MEh)opTdU4l6oY1CFeSU=ik=rarlK57uv(kX{hIG4F;NUQYwm>M3a=7o(myN z7`UXo9$jkFsR0Op+W4N^lkr6GeF}= z4sV8_*p;@NoGb^2tA4-6@__Ar@!aDK4yW_!JPNB5^J zIi+>@2V8YOFA!EbSam&1!5ZMq^_U#>PqiE^R&H5sE#4D%KIB+YI614{J#vBhBHXD` z!5H%_DUpTSrX8>~nG~E8;C5u20T?$WeG+WBX7<4X60h3o_)QvqATs2-$5hMcvD;9% zN-Tpz!4{JLN38OxY`JpB2S}-)gKJ*I4`&ig@%KD3fwo*Df@tf(aDC62r2=%Eyi28L z5NV>Mq_tP&o51@VGyv}|$m|elk=Alu20&XAjgwQGFnduaJ$_Y7C_9t%Rmr7i65=xT z0{PwC1!3-G9gGV3kSRXK5~UWz)6krt<+!W&b+cf%mIy=_1h_qsNA4R03VTcggJ{aQ z?^657J(KTPRQ0~I?_%Py1!1mvn|~CIHN2%F^yGF1r%rMMWX|HdYHV1v{aOfHl(W`+ z4c!$K&9xOA99dg;LE>;r!NEx6#B^E`yH&zad{~V8)#aX0VE^Ydj2Lw9zVJH)qw2~& zvy}9>NI?m3$vHV*G&797i6USN9DRcBaO1+;m-Of8&f4|W}kCJaAk*q)Y+OW z_p34WAM_EL&EVUwd*VkH9-#A~+`f21g7}w}i9OFl+aZ*>y#oi>RN3>gnGH&c3uLQ#mjQQZY)RjP5LTZfs*uAsF#M18d$eGP!LB`VL1BMCz1px5UFG(w{uiZVj8zB zvXa`9QBb6FARDu4q}W*@b(%%PafH1Z_^2Uuof`$awz{joG6cN#$; zX?o?>Jac1up&IcgTHc32R7~AXI7&ChEV?OtE>Nvqd1PF;9c1)>WpnVg2YvTORDL7cGs?TF&CzymOa)y5YR5seni*yBHe@wgT8yYun|=l1tsT2>vv6#U=1^V* z4SJIF;U3!Bi1&p&)2*pptH&nCJiujV0ZcSbk`Ts?2T*gnvg1vQdR`@lDNlCTL!4cL z3zEW_dv@!VPR8XGYB;Cn3C!tPWc5`%iEO}WDVhF+F^?o#}qGlE{r^LW?0!{YG&n=r1TycYT29ijwKfo8+ScIYBQ>SE!0?I>!TC zwsh^Z-8DNLGUUYBSDIpIDz>wc5>l~SR7{o}-lBIjrqXbMOSU%(I3$jw#9-Kr`4qFf zm2j@-yg9$Oa40dEN(V`P3J%l1GMc5G5o&UTW#TxoL70Q5fMZ-2zZx$}3+pXDgoTV#HCN3Wb zaYKg@Svl}Cw;tNDUB1>?;454ql9oBu4K%B6=6~G^$5otRIp^#v6Z><=R-eL&6c`+k zaZ_aRS+lLo=aZ4Fg_>Upg5Z>r8BN9}NMp{T6aj;gvX#{3Q|e?UDoYfZ@|+)z{0>R3 zW<`yc`)-?EtooS~WXZ~$IQBRf1n7k7Wcf{fLxe}p-J;~pX3PGFEbVni57gP|GT^%I z2++hsE6g)e44#&kNJvaXDoskjtQDrarmEXD4NDL9S7ousc}~*$=#iV zQh(qzMZ$RV;ZL|zhu|rnrbcDIJ&#F^6e6(|YHutdIKHK2tQFN(d6Ao=^jqi0Hj5zs zInj$Ecrli02NE_@E5*0cB4|z?i4?MO9q@BN4ZIm}h?l)6lsZnMd?Q8~ZfmCx+k#F)W|Mhk60IqNXucv!fNS-FNWIPuOQ0LY}v%d$GHqz}B zkZvi#I$E7+Y0>*5IBk)ZvW|j_o7CMP*6xzc)m3dBNvY+ny9@vw19Si| z*ob)1`DocnO0@j&sVOp#B%{?qBGw`ZL0O&LSQ)naG0VoJjQQgl3oD{#&xIK=OWK^? zy=bW~#Fs3YXtEO?yCZLErV*UVR3-RI@CGbBYoYWS zb-8&?ARWF5uYHCoMQ-&ja^;0>?%?0X6ld^kyNtOspqyCq zx*JH&Zw^TU18rN0BS6HP12VvIA|lotT(fXl!(tz}wY!!3w^sDUG%nS3A1LeOt#H-b4Ap_*>xl*^PBi*3Bh;1EfyxtSYa~a zx)r!+rF9(DFn12K!pz7x_OL@;QjmLDay}{iZ#rhN#731CSUr4omr_L&vl{Uc5o{w(a(PXYMDK8XoZfEl$&s%Qv=7)^x;f>$|rXIr%z>@8Cip zkwtox1VbuBGz8@HFpU`uO}}qonB?~T6fE7BoNV|}0gyHXV0UC@_(zo*09~7=g8%>k z0ZUFTMF&QxnzYe*kvU5zAcaU!6AgTc0+Zi+2uVywu#$ob6DO7eocWruWih?0d z^pO>gm!%BXnG$FxXS@@+k2FsQIdN9R5!mGo*z&07(QL+fmRyIFl{roQ0uUzBx^!aq z7I{)dlLZp`1__ITzSycD#I4C`?tW*z$eoEWBxa=Y1*CQo)2B~N!8}t)mf%nfp>hO6 zRW_a8XrW|!1?S2}np#+dLXsrtl$qx)5LiJ)6_%BR3m}_Wac$wR__~VU9m@*o!!xyj9N%BHWB1#J*tkZtMPF-Lh z7)$t-Oz55zisxAKm>^{|qA_~LwoSczD^~?9#jV~*^{qMU`9q|e2Lhk9SFEx`=A8H^ ziDutN#a@9Y(wE8-luZhY+hdc)NkX+hXlZmpQmo!E-4m(0G?JU5B}q zVsnLAM!0nrTE)+;#XHUpyw3X zxF?G;I8#of`X+l?>(orJi`%DO>(Y&XqKEN^Uv${yC)rjD7MfPp{Z&Z(8ax4{ypMdu zuv5~&L7u>~vCs2lLecvGE_Wz;N#Jfo%P`VMzUfQa%bDANb+<{}G~u{!zbio&6-((( zy3SB@c%OqQXNhsPl&O>$Dry%c?I!%}mYykXocmgJ zNVHWc{tU{2TQx~+{2Q6Buv~*$K82LB4qR!2y;82rSnXv@x;!fLIIwUmb&(!H)}F0Z z;U(@z1r_BhY_j%_`P=hvo=6%(=v;W^2R8J&>q{epBUin-;eVHhinU3>;K%(3+B+JR zUezgPaM4+&=h{&(kcg3Bm2*~Diotr$(R(7fBpyT(4v=#V#eq>~+*N6CNh8w99VF?h zMQv&5v+qh=WyFig0>Y+5w>)W{)Yn-gk%c1e-WuVmi@~}kSPm6Cf~sKO%AM)GtF2+v zbLB^Z3?d^i47Z5l4Mp&+ppPqiK1lnJK5;A?J{I8s$4W1Rv$`o*P8ntpnRyGM3cfIo z2K7j);bzH%aVA$%$r5|x$@?_*XX)RZEz72OB1UF^Xy)VM__N42M8aC)WlEHjHf>l` zcZ!~KiswSq@XtKPiSw;OZR;@a0|ZoR-A5N(}lD#JE8w=wz{mWLgTmCQKYAr^Pz2862Ker7n|j=CD&E(#0CV zHY|LRFQ&>{Kg;jO)nZpPsLOroZa@+Nm22p}vfBl<(nWT~!J!|+gxQ_JH;EofQmX|@ z!OFI_#FyX+1y$%xLTh_+OH!N2soPBCWpA0_|H%THO}x<|Q&gZ#pG{3meqRY#JUj*V zSr$;XC9*6^c^xTsUIgiax#>Si8PkI1wgs0@4uqi6fxZn%uyj%mK9(B?A}M5+B*eX4 zA?PxBE(?%VqLM642LSvVPCG&JIjrEiCElH${(ao)OIvQ`ewNr6$OZdK&<5v<3t-2U z9v;``q||;aN_zwY+|ICA0Z~@Ts(iCJg07jvJi^J_biV>EG`s+;rsKh6ur!WJuWBiD zkuuXyyC@fvPr25gSSFokvj)&tWvt{z6y*Ifeb??!S%P=noeb>`lK22C;NtI4N$v33}WZ0;!+X8AMK2DzF zrLHWk&8N<|ZNUtzbu&JyWP3|pLxE{{D(PTQ$#6}z&E$+Z1%i%k{wNxbh;@K-4cOFD6KB-ZwInNx>@g?}_%q*bI{rsc^p@Lkk= zhdF(?po(Q9+0$@AJ?=Z#G0pG;IiNS93xaOY#k7mN7!%rd}m9xoRoWlh2_kXaWXo{OtjrQyhm zSu(t}d_1$uEiD1?@dU44Lz^**Fb_}9r}s`v|gU`3@XBnK3=q2ZhoZJ#mge=}aj1Sq#_BK(Sq3bHO( zv4n8dFHmJfd)($b1g4CiK4x@x@my6EOm(pQU5C}VgG?D<8Rcr|!@e}>kEVdJ5LzVo zdmjiQjlEIx4;L`g)<3jF)k(>&e0rU)X0JsmgVMBV?oFmpCsn=EN$05tO^|+Bzmdv2xlmntyT{3` zDhyeNg-%Jnl9vtH+7qvvY9(JB8GK4KysmfwPx;_xdk7B7Iqb^UBA?V9JfNx}b1qr~ zLXlz0qmt#~9;F@pY#hp(M7){FW-CKC;mg4zw6(Un%EK0J&8l=I;yz1>e0htWG2vHI z-~37gf#^>{dIe8T20;zjE+inse+MN*|B3R8Hnacve}+g(Qs*Nf0C7I2SOx> z=>nUHpptRj#m?kM7dV!@;FGjDCCAB8OVyU~HJ1S2c{%Wj!kV3-ElI=ygqf8$g2983 z78#$<5MKgk99jwTxW3EgaCFdn^J!e^wrIXWp0d8CXrFi}rOfKCSQJI@SwXD*B&)8H z@z`K`G9{=9sEL%l*QC9x5HsNXK4s$Kw~}hM45UFQx+oHKaAS)#L&i9TgCJ>}vX#Xq z^+h31Y(d5J%ISms;CWWPJDpM`(ykhcSn#Q+&u!f-Pn_`1;NS@0h^v=Ad-5TU%25bfD=_a8fU-}I=(Q^n@~JpKQQm}zy#Cz%1~sF z1;~P;^b(+Dz5_}i;Ys+}Y2J?9dvYodME(wbzGYI}DU@iQpkq9GU`#AI!B!~Cr+-Yi zYMy{qf&joZj1e&56)9<6JY4?BukcM@AMqhnlcdiZ>Z-4CFh@xpLNoumzZCoNB9py- zK~?qjDI-Om&~;rAPe>>LObYy8sVamXhzbovX&J0}#04@SsJl)! zJPIs=)K97b>Yt@nUICGta+y)!{j%z(iBaidxl%_}xKA>Ybg(kwb_!Sj1}H5@hf}N) zkAp9BjIQM;Dy1GgZi~weYy||>7iC#YTC3Te!coVLB~0bP+AJSV?V?;1u<_b)@Nhc~ zA-68@ZV*XCMk$flmQ|_t5Oni-CbcCb*XPK%Xt_csgZGgpk^SPaMdb2#CLrTXb2|`c zRL@qwrY=b-Gz=tBBH<1c%$auaR`|3;^+nxtn{b2*P4I%D0hE!X#f0#cJvRyFl#Nta zDr+N_u|eD%36x<2uY-%94HmHmJ`7#W%x%)?e_@O$sFpiWGxz;RJ zBXNb2;Z>9moTK@c3+53KScAde3l=iTB|i`cMYTsqaa>JgVWM>DzX$%?ethR`L|QHq zL@Ca1-ui#wt?{&g?r zar5QN;LFHUDmis!*~6N2(>^G#j~6K^EF3G_JPE`T9=*bfSy&cDgUWPDAk*uw(I>$9 zAQd}b6*yYylV75iVy!3}L5ov9?#{VkNj0a>B=gM7^$Q%l?ZKcQ62thF8H+Hb?5dmpN8+;5lnqDnjtT1* z>`&jB+{&E^OPc-r6Ihz4tFY0_r;QU05fL~I5->Y#X^&u$+}J;~_)D2VTLydduAGo# zsn?y#WKs-6U9byL6+Qy){RCve_z5{!gZTD~OvshyQIJ)7rL0`|Frp6p^k}00$UpJ% z(9_Yp8=sDHWAqzyjF7j2qOM7}LNl#3s^`@*c800{76}k!;;={6>e(`~q_+Z~*6S2P z+A{MAc%Zd3zmPRA=%VQ&I3?zEvyYT@1D?j7o@HzEZfzv=UKFbD%1~RpxNkw7o3_Ta z!7rB4eO^{F;f7uMIpctqdn67>@xg2qi-hAa0003|j6!0p1P%oz9#RMaYEamT3$b=Bt?T>dhFuHIe69R?DSFDZlacq|jC> ziK%w=CsiiZ2%~~b_7quD{7=IXX+hp$3busRn5~aRFY7YD$hJONgW^0xpckoDnVxW{ zM8xU%#7s2)K)ECqXt!{xV3wH}ObLFlX~-3yjKut30FbO=v8#lS>8#)t6f|D4Bn|}5 zkFON`6>cgIMF6Tf`m{3Xa?*_?s{0v3kS(+~8^Ku&g=)_BvT3WKZ&cSpkTlB+Fa_r^ zO=__PrPhMc>w`gzhV@t2kd$60mf_!~HiiLGj&m5mva7ygeb~&1seOrGSxR38cqIw! zb1qppLJmqdj@_vQ+)|)kxm3igKUXm3F4(z=n5g^Wc1rBx6T9PuK1@%?2Dd8&o5zX`2XNI@;dDyE=xT0oiYYxd!r&z5 zEjY!Ea^#)K4+4$~ePkPVwo&14146_m;_fzYTX8wU86L0&(rrz#Bl?rFa$4ml_GL8n z^Oj9McQH!3B>A}?Fn)TYUPOY_6eLiZE8yBb=pAZE8r|%FsfH}5qiuV4qJk~B&)NI6 z>L}6qYJ4P36el9>$*ddZii3#QO?e^DXKNJjMZVmMSA)wa6k0ZHo;@yGWiDvVaoeh9 z$zL*WhPGiBPVTm+z2p};PLB&F2q}^V$FxlzOjPpFtexkJyn^D3UdxjGOL-9U3^RCN zvo4k#`Ik9zWODND{zmhb3c~jNt6{gE_1Z->*{4b?A8gsNFJBMBGa=d zBG!NlY68&e$5wi>L_k(F|9+{P#h!>Sx=_FlkwU z6;4~rj?Q*ARC)4VRm5BA)6tmliNkl5hk*PPFTd+MXD`Kgo2a9UAwQFt|N9unGOI=? zWCuJTVx4L#L8v=}&)J$zS_y;eC^jO#A`)Eo(>Fb$izb!9iSZkfTL<{a;1lcQ@t3j~ zyH`v23b}2!MO|Mr)?{pYT(h907JQU%l~RF6$Oo4c6j>jQQeNJ1%{19eJS(oHQo;|r zMNgJiZE~U3Tkvl1JT*abdgDpz7^gXui;V*ixJR?pIJlj3VZH2 zo0pfW6u;B$`%^Q{^DLUr{72{GAIkL}mo=NW7QBSos;#(11DuGb2y=HyR>{$h+A!i2 z%KC7%8_k83&IH}k!=|@tMPC8c>nz5eUF!am-g@*?5+`W|)15i!a1gbW(N)S|cEQs& z6t>Od%BE5LgOL?qx%2S-Uuoq4i8l9IY46046ofU5%f4!65fj1zB7<@cwSC+%wuLgjX{%d$*mOGtSt%`TKQHz$XmX=aalzO_`&mf^N zVIT&2*@R8)NQQ_cvyRE=F3PF=$@JPM+`9uVd3#GY)v@HrVA6v)eVa*O|&(V&#_`V=FU zf%ZwMiH4=v?LF9v*bZ(2!~rzs>Jz6MuQlwhB-S_6&UvU|H? zM7Gmt-`;S*v0gQhr(?`Raaal3KDXeyYAgd$t5e@qU^8q-F_km@s1D& zl^&;OCIuQ*oph@hvO~S&&lPWk(1KjX{e?wiq3p89|ypzFC!uXStzYSeWU;jhRb^z!^}gGCifj`nsYLRg|832Ns)s7jNj~M_0;|zf>>S=o z5fa~8;2Ltzt9oxH`yKS8{bo1AV$$1pf@sM~v(nmnUSkrBOae%!B*2V_*JUNTwJ0y? zt5W;GVIq+ABfAOQ5b#R^Iu~ALfJT<@N8-dh!%tGA%C&A94fVhb$8h%V3Ok!p-@(A@ zq}n^I3&icq1W2>}_&qfgT>De)1ZI#{;U{WfX$L^Es4YIxxRwA-s!NB`Ub@8r!<0E^ zd^!V_&Ys#>Q5^bNVU7(Og^_>&00C1T2Uro-LnsJkQ(BGPQlq_OkraeLJo*~1$xJJQ zA=0q!z=RMKuFX=C3m!a~gb7H}-r*!>pgrmnbO#k^egqojG_{0TQKHEnLa=83R%Ijz znhfSOjdN=LShh(KXEO9k5 zVg1J9O>wY;0F0m7;!1y4h%bGLP?ZBVIs&C?Wm?369s+8jKq+H&H5jpH*7B`_`6@1Q z@J<^{@Tk5Cy#labgi&kCuz&0FV#E>iBC(iqvGCd@w&t4|ci@}<_xfDVb{ zCa_6zR3!p3BiF!E$g0Dn&pmcruP2;ehmYo00AQ@E1&C>K;PRoYEo91q`x=w*Q+|x> zOCsh-tGqb-kDocDfdxwk#IJlVI$Jp_7fN)cVuYlwmi&)E6=2k^e3v+rzp*0r=%p6e zGb({Ap6E?yU}8|zTv0l8xnKnN6kMf+U#AIUj?T3L#$CV-uR>hIds2oF4M=XFOVTR_ z34#Qjsm{|9BEiRl&?P0RPc)7kywinv`Zp9&dIgU{t^bdK8N^=;hwP}l+$WOtZzwJd z7t_JTCRK>@_Sm=9aIs><8QDcd`aEon#Vo{4WzZuqRdOQW;uC|wyr71X>~+*_k(GgDcQi&23c>Rwq(h1P z<;!tN+i_1pG=tH6)9Nw$RvxapRxibmo(I{%81RC^Ac4VXdPtUfYxpoyE|ubPQYbXo zLBz@_(QCFvQwF>>r)po$C$H;u9I@NWDP}7vw}m}>G8zfZ7C%=vuyh+!77jZyx*x}a zzVKJ~IKLY);M7Z|;R2TOta%A?oZ3|gjcbbrTxp{5K>t2M%E1idiU(ls-*}#Ws{k#~ zj=}Khp6Zc2GAep9iCG~P>!4YQIRD;>StzbQsoQ@&EWM7|Me*;|jG;at0t`5)OPqJuouF~k*C z3l|5PM}bpr8uJlI7lmixN%@p!^+JPEeulHcBjC65=jBj`$dM&U&QyM#f>w>N^MzY4 z`(=dOf$K;oa_NpAFSoN;KV@#sa&HYM1V(Gg&)p^S%XYnrv0B+Ld_e+< zwqh+YS3c_Evy$O)BV61fuhjF;LR_Wzbl|2QWxx99xpdyWux*}kd;N#9J2-jS>dyL1 zmL8&&fLbR{V7tSNGL@q=`n1i8^ zZ308vV5Ny#@2ahqwXuLnb_Jy+idWoGE~edYkQm|X2SwHGK;K&MQcNr#(ehk!djzcO zNRd>}AcbTe7$(FJC{uzm_=`?FZ=hL}?MUz!R!!0%+*u}8>Od>0w3nV%9bT|(w~9vv zrum5;n9w#N!P<`|dQoui2L`;RJ{f6+}O>S&fu9TYv}t!bOEwxu3r{=eRie?lnwN#1Ogj|HXFIf~=9?*r}#aHqyDu z_6P|g4CeVbpzS*2k_8(;=FU1~((4%DuWMDZ)xdX6C#NVggS`ad5mTn&MlVY1&ESdr z1ji-)J_+eJZ@m8kZ;3wR2M{$SsP5M1R1NeCVJxP<%7plg%{U#( z7OZSl5SXPa`6H&OSWst;b_y1*mR+%Rajp=q7OmUo%EZACIoN`86&^VQg!&q=M;-waNkk)us`&G# z$J;3MZrQ=9OoFh|srLa6bgXka3GDT*Qa%)yPN!B9fzQOM3_0N%>0#Jb=4DxH(xQ?s z%%NApbc-~LeK|oiEZ=O@k**DuXKxAjtLv6moReKLDb4O17s7!`dKVn7wV%rN2t1r6 zH5K=!SsK>*K0&$R2nwJdg6X3)eOX}xi&-67$f8Rv&ZJLg{=-R8cn%{CHoyv`eWX_b z26^+=P^JbC2H9Z~Yo|4iOQ6uYC_C5j9RvG1fpns2ENQg58Reqss}?j%Ddj3mNx`g z@hhJ{=Y&sy@^bJ~{UYI8!o1vie*Q&7;+o#DQh6>Udh?V_y+=u~muYrJRZ-Lm$`Vsr zyC%Lt94cLcSeqIK9T7kA=NlAq`C9GiS4`9%H>XvCZnOxI9r$gK03O-o$-cl*l0WaOAD>z&TB!0v-m!%6JWIn}r3Qmd)~s0xdBTtxWrgFymy9WE)X6-%JcF>)Iq_0@fzaFo^>bq0=GhF(G`Y9ima~6#W@ssimMhW zw1x4k$*0Ez)@4NFg{(IPna_>U(k?*)AP9L39(yawdt*cOz)NQ5=ZLrfS>Jxnn<9x5D;jl z%Y*!^v{^zZIYvP@B<;Rf7}Gxj=B?wfc&ZEoAydKhqMO@6o-C?a$;t)ROu{6Uz0t!X zthVCLYJPxRO*mCn?hM-%4wl<+IT75=r67^}E6x-v1d0J;JbmOAhuPLB_S3!X55iy*FktVpgHug&mRw)cW%Cz|=1 zMLZxSIT@y%vEWvMbpH{5oj43Xo@JhRHP1MMEdo_S+>vTKECN_Kx<$aVOEan!X#rD6 z;HiQpbV%&Ow3y3nsiWvAQ=_;@41_3evum>}eBn#+kK_Pu6E<@huW zE$5er_nuxNJV#Xf`N$GnuO4U?GK-l@J1~@t;)RX+*e%04bZPw-9$fJ)A0_qKq>Hr! zy7T!L%hDa7KVQZ3b9!Yw>=4r0ODXQ*4gQ;o(eJFlAF%IdIi0>C$6X}RJfSDar8o<2T2qFy>p zXVXWS!LJ2n;D>u5OP6VymD6s~EpJOx$Ao`urOjI0I?k`|8S8n!2lWIl4!^IL`HsQU z=8eXUI6j)xO>RZBerEH0T}LVnGw}*krAu<;!yS5M)5E^jGE>8g2nps36_mMnA}Kzj zot$AXRF~8q$0fqBd(6SS3zp5+Gowe*U6h$`RpJxi8>1*4#(1|{9F zUKT1!l9Ur;g49wmbc>pDrd6<0g0eiuu%&@|#<`OZM*=en^BzKGzrJR3{cHFS3h(?T?;3 zZEzDT87;|m&Xl`+66b>IL>P|Svg)vMoEuAQyrwXfP_!-BWy|_`e1FU;E=jr4OD?RN zF+s`2UzaX~*Io2fr`Y&;(ti-1{i~q>WQzq^jAWJMLI{Zhfx`UnC3kFnY5im&1 zK0ItlUIlrCKt%v*xC_bl6nJ2&uGLY3Ma9IhA~Mw=xN|M4YsnaX}vAtCDd}(w0ZSnh->ZkX($9(g1^vTxnqvaI7(7LkfyGh=%UF_ zl!F@R;+C9^XgIMdp(k1~HJ4!n6mj$$0kX4PK*?J?*D$__52TVO zsu?&;LdSW)00046B#;VZC`_UN5CK3yFaZDn004jr001BW00L8Rnqa}8u!w-cfM5Us z003YR002-?x2=`hAVnMiNEj%X17L%ji>+$NVB$?RFOUj48(aV$)zy7408B>!05#wM z(2{7)&TrIW>7>u4iz(f=k~Rw1lT?B=fEtp~Ka~YGHVz7HC%6i3NJ#r+)@|g+^xrB* zq9|u{=Fp$fE#W4KO&2(*4X+TJz-?F7AixmF6gfBTZ$PWV`L>I5jG{QOp`#&^C`lzd z5(GTU(r6NYaTXEudK$7wzc#TcwTL9qD_!1?Cb=xqtVq(k)Pr`*y55B|M=WtRy@-H# z)k?H7a@3eS8$)nlh+A?FI7XPjjJm-uClhjrk1h6!_PQ>&YNfXNC%pW{%R%*4U6KMj z$t|7QsTZ4UyHv&5@wPFeF&NQDBhe=h5z~A$c;#%iKgB^uVDePyOM%9&c*zZzcdAy+ zT|D_El`3kuuYg7zGLFc$8+E{Bu0Q}p0GC$N)1HJVv&4!adEToeB)ce)x#3W7y@F`l zdIQL{1*R#i4SqLrX_egdz(EpGRO0JJS|TA4F?u{)PDq3MXzaWFf4bf%(O|Q{-w=v{ z>=6tQS%6c~U;;3#Y783?zyU)*7&1(R4`eXS_ zq@W4Z&<8=)h{gySXOa(`(GO?V6=b^eq|snj3R1RqQqOjYq_!lJ=6V9*R4EKWFB|O2 zm6VOaprx&tV*n7unjXZf>xtIrPb9JGElO>+#gbJ=ZX`5lvUZ%Z>r0!XDvSdDXy}P1 z>30(jHV9g~`LOCV2P=&t?A>obfkCK1A#b4T1$3}Q#k$pcOlYS#lIJy)RZ<DM{{P*ez;YG1*20(1}w%keW9z|QmvMkQBy zhA|PR3Uf!mM2l!oW%N$>O!o4t5~-(B<8u6l%7me4r6y#`_9V5sJ*}evU$oK-%6CIo z+@Qj2Qchu~SHvn0d+Eu-n7J7XB?&DP-YmgeX!$R#!X?SOna8CNlbr}H%B*VJd$_Gg z;wzDq;utUhGcW)TFH(BJeuo8Nu+*q~Uh-h~K^Lm#%0V)eRz1qDhrViBJO|b6QRuWV zfn?e>UXsg%k}W)8r80pel_1s-K9mtq=mFTQA3<=1;Q^c>P$(g|`D)lc_YyVDxm#5v znRT%Uy!bBXkbo}wV?t&O-3G#AQ*q9gcZguQ^A7QHc z`_P%opyyN$QzQ|=}M0Tz)P$^6{7 z(|#C@1JSmndp=(-QT&U*s1tw`f(F_XO&@PI`yoCL$3BWSpwfImM50R+%6|27zRuGQ z2zu{cq|`vs355h++5JvjTD}@t<>tw~yQrv0ejuRj+>nGel=Ik^3YCCR05G6VOi>VS z=%cbJ0GYZA5(OLZA4Z9qvVXopB&6xCo%h!p97)*;kOTk#0s%tbuah<=4<_V|k~bO; zU)wD^?ON!c=-d)1O5z#wdIp(g8>;|zwqiqWDKgMeUAtYYO=!5^+H1`=wdA!jfY5Dn zRGZSWT@M=t9z)^nkRt{FFvJIORM$OhwJ9s_A-ygi-maqIS{w{>Oo9O*AuMpzic4_@ zx*LvPQEvEV{kkf6#3042e^0C)9(U2O+fphFK{=?mG&Yo*NGP=*L8lNu9QbsiZI_mX zisfU>c2*cCuvkZ&w?8?Czb(%1T5KS*hW!W%d1|^~DBC42*#(3cmg+YJ+S*0D!uKijE^DV7mrZk zHASr}qAI!OUouIXp7>csQsX6D=8H5*#Js^`Qplf$XdpWY^4~~Ux}XeW00J+q zu$P)Qme>L~^wg)GnnfeI4YJC>Z~81GUwhqk@)urj1+#~yb za6puTN%(E^$(ER^SB>d;LG?J2yrNmR>wHpr)r0rAmA|ZSXsH%;Bss7)JK;pkUtr;J z4u=w#lQ^^|dMusXOAzt$71g!r$$j05u@_%M9yTpE1Qda~~yg!Y#xQX$;p8A>QJKXYjN%MGc;vB0QglgH2PzDMa6lL?g*5=6N3RWnM!B?w;hFNivypvQKvQ&RXw!-jFy0JlEfhyj{^|>>b4`{FKK8ry&ndWzjVbrp>XV zn&U|hEN-8^TCsyk4_DOH@~MPIr4n~K))>*ohT$R*8R;b9Fd3{KDO=sgY|dv4VIiic z6svrP+FkMnW~(|rOhsx@z#TbAv~-@1;3bWeG+*(Vn{&Fqpxm8vZWd*{6LZ zDT}HV`ucYRiHgu7yY>%%Jk~zA+aZ_a~=I877a z$s%qNziUFC7I|nUu(1{_*<*i8QDw#;=Y7=#;Y^#pAtBv8I}#7_m5w;4Vja7c96sj# zOq9!Gs;2SCKCVcZs&*@98o?ct2~$Rf@_25^#E_~`f=4kB$}z9r8*YaZo0kom#Jyis zQ&Q$1hhV%OLujjW9~An;P+t za~4Vi*>N&OeHhJBE8I3R>i1(H#SF=1$yL?L%r6=`G}p;)mtK)83jcL}F*RMb$*BDO z70Ec)LHe<%fiupm+p_q!Grw`E6oN>nn)QJJR#ABriHj*+j@6bGQ%Pg8W%Rd8${jw= zFpzm*+^VFF*fa7;SsnyOjnW}1;7TG;Y(8h9Pb+f#Z@n|L0 zFyx7Wn|qd8GWvx4SYdPMKt2WQME*{-k>A~=oYHwkpXGB~kZIY(?+=uE)8D!ed%({%1rAblL?QNi zp%mjfS68TAHrnT(8CPoAR@rGq1pNUl_KGLYP7BnO^)ZZt%FliE3LUTo+jippcvr2l zqLP^7KRW9RTe_e7pGmGc3CH8x%kzPgVvF|9oJc-<3R-R?VQu~Ocv=&RK3eMFQe)y! zXtoGW!08hF3E*tgiSqPxAJV%m)-X)Q`R^+lY~%D8ZN_US7XdCO>;)QYT6 zvNW~x$*@0{4Jy5vmctjG7tF{4%fop~__9m(B?UT3l|pYc7f`^6A> zZuz0bjn|n^703Oe#8br!i}=JsJ3+lG-$Saf*CD5yyT)hxi_D;=NBHj1dyiRKr>A)FXzjMItG8d24=QX>Bpju7$s-z5jdcay&qq zzTzrY9`~i9J$#H)N2_A z$0MBh=Z61kQ<9e^UwXV$2z{qJF4RwoZ^Ig>f++R?&Okvbed-n#K)^v(C&( zn4{>Q`q36^ivH*758Camjt+C(JY&o-7!PR1Z&Mac>nqkLie z>%zdBx}O-UONP^eszoVxlP7r$9j!e6msIYLJ1hhgUSYy{nH~V_$?#iaEgYzSu?6G#NH}lD}yDUcNn|;~Ff7ou8 zT!_*Ks>5Hr{a3~QMKi$07ToRJkyfjEHb!h{jo)BJB5rG3p>DxmAEulVb_r#&^s}-L z%Q;I?fQGuzsW0}GAPix_3`jskgf%Rh+}hUM{(4PS`ZIeD`3yWV{i5C?<7Qb{^3{GZ zdSe{FAu0zd|5XNWkf47Cs&-Wy%TxMDFl8AiQJ&v^V@6bgh#>O{;WP>Dic6wr7GL#G zKVd}X&7M52oL9Vlk;}=&UDC4OloOaIRwd2k%EZpyift?SI{kK85-I@QQW0SKlzz$x zVQhMeTi5JIfA-hMFLP=s!=#Jnpbc@xjr&F$_luP*EU=`jlALC^hp|-(S4Z&i0Ef-*6S?Q7B5N<>nh2>^N8Ncp86% z5!WiYU5r=MUBTMjHI36m+GpNwFhY9E%Uq24z2_Jkf)~ZIUA!LRXy2@m^V-vZBs}C^2_Ld3g4|vT@7X8QPFX-OKJyN}mc|^kWemUvBarF4o?m>2U zYOi$a(|KXEr$=gd%D+oZjS0Yi>;w~KhXej5w}Sz#dv0RDRw@_iB&Tu8>C5R$tkiVL zZgK5`rZW<;jb4LV4GNR{YO=YW9cc<)i-;D7BSd_2#HoKW~+r4IcNLvbi{7Ss6 z(JW)tYEi*z?3C*k%hs&wK!{HQ$BN1$^v1U6H?|g&+0KLQjZ_c?ZPEt%JElq;oW8+d z7s}xaj11a?HB1!y*Zy>L`$=p>=d&ue4cv}N#gHcJ}0qV3>Qwn zp`R#0e^v==54$v9ne(=tn@%TV7?0MHer8cpvGZqc*OX8kYRHs;p=S7!_mb9fD}VB>&gNU6;B@OYHCI3 zl2M!w3!0;!xLn`6eX=}LBZ6%zZPVOid2a`ZP_^I>W;n2ZlSDCcGV1JBJb$I93XGD>W40P7Qfc2TNTE0lOoKBn3Q;BEmKCbwH%kvDV~f1 zRmKt0SY0xDNxt)Q7`8@-NM!c$N*U=LymBrWYQPV3YYa_Dszr$Ch zF4x>%QxC{1%0%MUi)VUzYt<)CzAOp~Ni2;_+?{%_ zi}O`s$9i1XS9iC-*vw3FIyT(Rgz^zvnoL84T3JHZzriK>ezwDJ~uy93j1f{K@Cp zVk~I?vT$!cW_~Pj+fI^X$^Ip4i|?j8Bw+waQ>7?FB_OSJglO*miN@MiJ3_AdM50lAS= zGwynrr;Ps#XM8W7*Gk{-rc5!B$Gg<)%-7LKKyZ=)SLg4WgIs{?5Pf1^M}jbc&cB>`5k? z*ANNG06)k2HX1Kj&Dj%PVuvVnv`&gSq82kyF>R@Uo5ThfB(^>+QLr6Zp? z-Xv`&*Wn#W8erJNNUE(6M+44b4GyJHUY*sVM4U7!%k#rekR!nfb3Kyhj^*4-(pCHi z%<>jm6`jG|GgGzi9KF@p-b|fL?#rti{s>zVoBD@R?i(msi6#I`WY~k}CFA34)2CXI zcuLux#ni;wcXlntPog}n7c-Gx2Nx&VEJTEBL_{iVa)EtXMGm+%v`W2cP#)MOWYC$e zSjLgjZ;qFPK%}0Be0SV>#0-{RP&YlQ*xbY>dC2@}&fj|#yT_XKW3`#tpms6wf^d`N zwG(fa0Hh@k%JeqCSzmQtUeu6Y&4;h4l?Xc;U4hP_BE-6(mef#&`XVx!Zl(T>vi^=T z*3ML4O2kv4b$*oRJk&uq7XwTpyCU$9_{GALf0l@N>B1R` zw@Q4&rPiKGLk5%t`{Et#!Jj3jx^6~34>s)DkU`ydzYWM`AJOxP)N{DKY=(o$rgcax z!zxJbv9Y`vEOxOX$7oXgL9~!<|3di=SVxTOL&rWkd4OQc8LHP}dU6>q!mgNk1PtU8cQaM>%$ zSFES$>|5SJPC_nC{%#dMj;;|26>q~s9Ki8VFgyht!l_a=2!&MGr(X(oILB8ZQdMyc zZZcP%WQONCSK|N6c@|M!{~pqMW{;So9H>5` zt$4Qda5-IWfH~)k%p^NFdsIAQ(Td`}RFD<(|}D)wV}zOg?EQW>0ZN zSZ}2+ZknJ;z5z2+K&nVOr<-dXKK4}URokAQ+NC_+1KE(%w#N@703e!A{}2KE9_wG zHA#*Uc08|vlZHjDx3TzH2^!YEEPHnn?0B6vJj`?h?)urW>q6&dOuPDz_BVOT0h0B_ z8w*10<=c#x0-SV}90W7;_IB2qtm=4-{iC*eDx0O3VosvJf#G z^FN}>dJH3`#k%Us-!g_b;AE20~6(z=EjqFP0DqwslJ+}^%7(hVoBjXl2{AcyvH9faL>{pq_7Y_};ZjV92-k(3kPp!g3cY9AU z5>#crG3;uDLUuD)&`9xucu{Tg5uq+_llGt0I=n)ZsCqHc+)U@END}cwW3v@#w`Uwg4#@bXajtZay z42c(>@V0_hXxT=IqKsqkq0F){j#nHW34?M5TcfiOHYJ!*gglh1yoQ8gcB`OXgu;`b z!^eI&-r5SD(OtWzwXWDWS3w-Ka zk_6p9^-wb4zcRSzLr*R=yNn<@JW2-Q?uAVbbpcr+XEMh0R3phJx-L5>h+K$?=ABm7 zn5*4}nEp{?rYdbjSQwM#BJ|ElE21yb*qPYT*uBZ9+_tQTZWgFnI&4+aPe#&Sqx=_V zwP5s=ZY#&K9w#(CIR%PK|KxzvILIBwmM5_oQMUkWw#L1(t-n#m*cx(hGW;U78bTXS zh+b_aMWLlddh7<8cks@JvumtT=Ha;+WB3Y-0vyvXxZ6v4JO=ui2K-}Nhx+Jp>t|H< z%rqywJd+KRd3JVf3-A;YsI|dx<9?6GR1{u zW$!b+SDk#Jk7s~VGD*iu6N-K-i5M#l+6L05UnZqEWRC7zM9BeVvVK6MXKPx3zy zhiSypxLBL>;D}WZh5ZrmEZCFV?Y552Bpo(P^TEesZ&6aSQX3HUQ78n`eX?n$^y%hg znf<`$D8{zIE){+2OCVe`Sin;%=`H})wI zOMy(Zn2NR-KAypbczYPGImuD%|H6?}?{`>6d(c;mTr)VrpCgfPzvZ7kI1J7>=j7HuxDT$Bcud?I zj*@6Al`%gp^jjY5%4*tAIrzU=<5T9B`;bN9&?2LIue|RkIw#B#PL0KZXI;`Y^NwJD46B` z~IJ|KG=OZ^|DHYr1Wo@~?$}xR$-P%_YAO!+wb) zF%d~M{v#ZQp>WJr(^OCrNbnmH<2qk{X3bqJ?{)slR;laaBQfo#0a`v`53Un;J1V=o zKmTe*dU@hl`-vkgm-wWS^lz@Y)wtJxD+pap7Y?j1HY+Qbw@{ho48Gv-&*L|#^2nVM z&^+ZzJ(;>6h#p5t&`C3L-Rr_Xu!9^4k6oxNrM?Z&OoS^|_*1hA&d9}ns4>rzq=HC? zKK&2?4AFMZ0U)q0FQJ=GD;H1%ltKkrr9dZ;A)WhiEF-Qj#yJ}@S3r@F&g+$}HQV;* z#ER9+M^+)BNhYK&?xz2)5Uj26M`_4_h4H!6+eYix_recV5F-xET(L|-4Pm{V-~7H7 zUfQ-YNT_A+_n}C-q4&P+DK7;ChTQ0h;+h$g-Yx#??bJ^UufrtyHm;W$C!hY0(1b9T z3STW!%U?cLS$H0`B<;QNELSm z*fHPZL*6TXL1Lt00$I4Fnk!{(@(ZtjIL-0lDMW^@Lh2XiDJL1cZlGbihgfLVuSPR zWv7_ZWh73*e+ZwLX-+X5inR^<&qO+UYBh;WMqhCW1bFjqe@41o$|y;t&4Fks_!8VT zik*hQDJiQ`Bo9ib(uxiK=Ief)-dgUugN6e)SwsElN$F|8T{-H84rMZ4^`@OhF+U?uZ8!( zDQ}lBCcGO+aZQw#&2UjLpqB z@QsTK;@I8-1aNsTSzCNT^Q8v%Mb|Pv9BGJnIZRF5+IwF9^C%@2=4&)b_w~8u&~`Z^ zdmTcIH*t7N$3OR5B4_IgSN;+zYoz3WXBNlCQUy6-K&3P+mj$ju2@+{`T*lC#KTUB% z|J8V7^gV6(c||#&c0i@q48rTY>mYKSNC$xHFXEs46(2G}ZRq5bsL(a`G}r+8vkcos z`=?ekUk8ctqb(QhjJ^+m#s3+0cjL_aGtFy8X z@hOx$>g0XhO*eL}M{Vj#eRXB8a5y}tE(FKGu>O1*H5qUS?b`0wLCHD0tG zfaMcgm5p0o20{yz_KcF=i6QR*S!ze9i2EKD4WhF^hOH=v3GotT8k8x1INr1WmsNiqmGWe-Pc87WgN9^Z-o zz65Rd_2}K*SI5_(5G>*=I7^@;Qm1`h9o$#4$q6yov z`joxK<0q#a?E3sN(&Fr=xsr;b4?z2938mr(JdGwTFbUwP%ixV`_Qf+tukE&u*fKsn zYO`r@;S!iB7tcy^TKp4I{}bXmeRy(8>88Xe%1DSL=;$Sul*3p+`qMePdf97V!nphs z4Tp1?W-tpXbb-bdx~*_ZJI2q-uyZQpK>M7fAz%N>fM?a)@ z2UPZLA^$t|SpXXufF1zo0|2m#pO&~%p#XLdNo7PATa0=bnhcZ|wG)4y$OrL)L=JrE zWKE*MSL8|ldhM-*Bm&9-p|p3+0uxj+kXLnuPrls zYq!~QxlkW+px$O5+Op(;qyk}&qsbq_m;)ds@bBsUO<}TRs!dpk1>!(Ky?-whjHbnYr_qD)f@5 z3ARBd&31exo@Tk~W75~3y! zNBS(s4)o)Npy0|>hg$xu>b62yvSt2xQ`E?Wa=n_>e4wMxxWOAqeO0R1NU)xUiB@rA zZdVG2anf*I`|A`mLYCrknfV%Zwl&c;`w@XjW_Yy-4+5#`(5$RWn*CYh0hS!erj$mk zmkFuhbemYs>P#J$lI}o~d4V%fI@v(h-7KNhM;PTk4jDv*m)^5C-QVWx2K)3fGg=DO5&b7@OYYnK-w z9j(Z%oFqNjPMzc4>fP~8O-=aleyOI@>o~W}ajsM$(MJh=ZYff#0Rc$sO>wokozqe= zShi>*Fsi|cFhmHFOLHpk$)h>qOj)NhD`70=pui@}?Kg*S`6_e4i+&{F6kKUez*sgJ zcUzbq%6@NTb=a*{rXEivNch34`K(S4CKRO7$3d7*s%%xoCT9fDMNnY^jH+do?No`u zO%eQn7LqzF-6%*I`aq^`H7GPgPadgcNmV5SNk)pLNDAsd1D8%EF^P*n;4+3O zm`caeXmpkwjC722P}DxCwUG&yZ_@Dnixt|z>104~PRrjD>b$MsUI#GIE=`wm^g9~A zgO$Fu0n&A$$ne!KdxL z$yu?x?QbTd*BgT6)e-I1n=*^xtTDGBPV+bYlj3>vTnP(*o75h(p9~4=U0zP)M8!Gs zz(}W5a}uhUSzK6|F0hV8y{*ZBZ+tY~7%#zia>E509*FH{Uy?H?Igv!=K?o@Hr?nq&H- z3^(5Vo|!;vj`VP$OH-MTRRetCZz(UiB_tED!)MPj#Yz!x!@AVu<11=^u=X&_VJfdQ_glXyN41`* zDHG2*HJF5!AQspPD7_&$KxSG83=~{9jg0QW6ZbhV0bGaTJUO*^SjhU}No1pitIXh( z(Y)*2tSY)Oyxd)AnpAGgZ!NW9LV9ZUR=na{ouvA4TDVa-KGBF>KMw5%%Gl-6?Q|%D;Rkom%t4L_yAuma9-bE&!YWm9KBagT?QHZNM{!n z(v|mXyeG`_aJ5T#OCecn9ic=nCN0O?)zJoiE||a3Xka9O{GN}nYT-)aKBbDFo-X_i z-Am^Xz`+P3HyxejxWG4Zt1D!gtijMt;ewS#Eu<6uXdLQ%7t-r}nO;6_J5A{~?GxuI z$lqkIe_CsVjzi0}nuDAn&G(R_2rkQT5tn=>G;{AQa|VLXNx8JY424dg_fMnkrPrnO zDtDrPYg>^YX6x8Xxo8(@H?I`yX43HcNO93@y@u%}xIE?Xj%<3fd)~3$@>AY& zi;V8-qqa)Zz7kwTndaqef%G%7$1R-C<-l}*4pOdkop3f>?Zc{o5bKRcGvto0`Q+ph z=qKiaoSe*9`dXY`3ej(~FH=ef24cW*_z5^7!sojDkUaOwT&XLwVyEO@);Cx+O|p^n zUhv(C5oHVS@NLU=8|Mb)sC`i_pa zrg0ZpFnPn_BJG&%Ir#-J2j6lSb1)+Zx^!;kCbaZR6q}{=BaiS1aAKgC^&+h8sUGnC!f@~aa4u6%mY=0=sKeH}!eRfDp)G3|Ab# zE;i%Ov6qP&(p|9jQ?-tM+R!YfcZ=|dn|D3HOyYt2rEUqo72}yek6z{C?gwKX*|&Nx zdB5_;7qlOi`6E0v-#aHJ<>4Pe4!L zp#^K$fPDhzH8eD&oRx8dXP&GP3D;pO+kM<|(0d-9{+xkw0*i9KEco$t+TYY-$7~)8 zo)b4omeq(1OPtE_@E*LD8FA&wz@SbJ3J^68jp$rcb4yk~zcD@eZH1vI<}rzDW`pdv zU!(&}@?s4hm2ngDy>EZbl%{=+w~_YT@mCQY z1%?}zCTWO?Ln@ODylH6yCK*{`JuFysM6bj_WiwS#vgq^el{a;Gxhe@x`oUw}aIM(kC0krpMejoJq92vXiz^$;5=Ht)eU5GH zDTxo(`&k_`OCrQd-_{GGw5?u$q`5!46m5BEhN6;n{q=(vLsy#0uno%?Fu_rNIP&>m zbZY!eyYuN5t>JVKlLxn-N9yhUYi-w8eypSPn?w28S-`GtrIP+XaTDL)RY<6{4%-G) z@Ha&Df3N>N#p4FMu>D!pgyW1NuQd(>DMd>C^BOdj8Ff`P+{W+yH}=oI7?L6bJb3dd zYmJY;E*b7H%VC*ey2uROYM}`wCvY{#j)-=8IVn+SF@-nCbN-&9S6Ekl_!sr`>>pKQ z+ol>cAOmg+Q&=*Tr=>+H>O&pZVLI6j@i+diiXi4ZB{Wnrmhh`Rh}CPQ?H9LPet9X4 zTMC1X@)7Dsfz`P(IXe6G8ym}rj2L-BGfiAhU7M=%%8*+U1{`i(1bZlW2)sPV2E=7# z`oIsW@LAmVvo?6JkL#^cgdw~YbN;8ybSf9W7nL2crKzA|MU zc7!x+PbaNpy}Za&jzTJ;iP-As7^*3yX3AsOJe{FI3@n)^^<M@#~L%%#;vGry@>^pxYfHczc4apv&1k=~w;Sx8lEwTlK3wa!)aMiWi*i17B0X zPIHr!gvk~%9~}cOAf*NB(O|W-Q|sZwo3YIKR+=s@Es7ogw8k@jVKB6n=~GbmwP=SCf)`M&h9Kx zRE|m4AR{ts7W!OQ-wDfR<|`!-vp~y?`>fKWwej`or};jU{DExs2Z&TVfS~_vHQ?bz zN351{kuG_0ERu!xU(=hCo+sFO%Qhf^HZ{G#=}e1T*^o5ze$-6I7MZA&E4tTd`^iaA zBE-gL>+35;E@M1-f4+vwMZmC3m&=D5P#HareyW`=H&^oZcR=fDaR_IKfhMSU2sn-~UVz)ogRJ4-6Lmv_ z>tw|yCB2|8oAs@AYY+@#iNA~a_O@+EJ*e5quqk>G$8Q~ox(941lbrewPQdMhOPJ+bAp!3Oj}IskL* zBGCljlvLQ1ha}1EZ|^!ESjReF@O9vh^)6IEERZHH*t(hFq%+X_pF{sR`){fCO3}9X z3GX|)iXklpHP^6T+!kVr@?6yd?UrG6$8%Q*g0;r9m2SEhTqw)a-#jfs0MW9Xgg@$RlD98dA{`7#?{88uscE z=5U`^W+-aBzNPq@Nj1#}1^%G8p!I=rtA1K-K~i?Y)mJMWH|Nrg4T0|CqGI_*?b2^d zXFC_?8ae73HZneHlU1^OFOL>G58vj9JNtm8hQ;>FNa#J&=gTB#xn~0FQgv&^sVAR& zXiR?9Tpv3mg;CD9A0>LGY_>N&co{669SZZ1SlaHCPCjLH<&nGGB!c1Ea?f%yY;c)U z_peTC{eBtL2!D@RWML~swIXtaIp0x8tCuXbwhY(!9(Wji7$tpz?3>Ph^3ol_sw3mF z?2qO8;jf{|g{6d^qvZMb3*SK_r#mA%`-J?R)CyVWc$-ik{Y@UA;o1J(#Vgti>x6AB zz8FJ6wqfKN%K|{q;j#HHqK^DjMZZ0^&IOxQfVR5; zzFQ2DLrrRzQQkkK(7LxP@f$+5WR;o;GB|S?mLr(sV55+q_5FDp1ZnT}0Jh7DK_t%H zGlN15yQeGOLXWZhsm}-KsNj-o^l4eE;>Qw6c62shz1zm$6LDs~v9Q(G+PIZ0dm5YW ze`}c&C_;SV-o%yZwA>yJ3v;lwxrNI=w+$gNVB)`ATo+iFR_7s;`_1~S)K@;N*UX;N zF}~%};|RL&qRV?-#ecqFE$6CmGzb(CXc%-LTzO%x$&=hv1e|t4ov5v%l z`AX`|%OCYoAPEi1|xV=c3QOgrMh7)0x`_a$ab%TWejNw410SU-KtkO3HpRmJ8# z0MHsBhuNXtb07{YaoV2uy0BSS*tFvml#o7*Na8rYZTbgU(V~mXr>n6-pgpg|akY_lyJ**A7o@z2R6i zGeF{U(z5iQfEi`j7)yXya@nYXVSz8Pg0DOFmjIp1?Pcw*5z&$D)l4HLUEZz-{AI}b zS8}cPZ6-P)b!%`U!+N-pqrAuL5(JSML09qwwu=}rtN}()JdySoNZ{J+(q#Zy3ZYb? z)KEMbAhC>Wc{LN11SoAPem_gCrqDF|Z}~=vAd*gp%GCyMQ2Mj3z345jMKEXJ_J*PM zboOh}Jz_`-h{+n4Eynd(@#R1JoR4GW<5drF#+gZn z$dt5zR)*-}LP7DQ<(h`pK-oH(F_#H= zvJ8Hinv^kM=n`1F&SDJt?&xV;_s$$Hqw&<=vGndDFsfA&2f7Bn_JFp<;7O_&QyKGr4 zNNgfJps3|=*vu=*mI18B#?i!tU8@$U9lUW~kZZzECUl~^4InzLzWhGx2qp=9>%z#& zkgY_1gt<4pE|)r|&c(fSzmNhbPs=ucnVUI;H88quU$#I1BNDC{GSRV3UW>(>!7#Ek zsL~W#*aU{j`;0fL*mm3BE^3RU5&A!n?Qe#o{?$;{DKE0R?YgFJS12&xJARcHDOx4P z4RV{$;gS(knXTe5GvL8o)MmSzH47XFc0sy&M3ePxxrNqY+Hf|tu81(HeR^2%*1ejy z^U@?`oKKl4ZWy0+s!pjUQsI<2LDh(`X{W%>m!xs#yP8eTrn;qCx=x zd`rla(gYSdc8v*_cEN_h7HeWf4iPvylC=iigArWwSZ`#l2c{Jt8W)3t+%LMcK5 z4k>tKo6tT1RAf?9@FOtMT(D<>IOyJhlk?(yucw6%ofe;xf+v-PS%eiJ{Y#`j<{lb5 zzEm)Vk|ipaD+#SGn8E$&_*j5`z_TN~V~hluct#N*U>1Ywi4d}hr9PxKB8TPpS`@W1nN43fu+!!@Wz#S%&t3c>n)2MT8WJ6_Jz{8x`~LS5no}mk@-rP484yH)20T&7D>F+U$x*{C zQPvk`)`{fqtNQ9EC#fo!4;Rhnat934s zG|GWgrZD!ue%NK;<%_3e6q+*$-*$P5A{r;0?SI$uf7j~24H`|OFv68{AT$OI`ScL< zgroofzzHKL3fu2i&7n`Yho>7`jHFZGEvG;ayO^aM+lb^V94!1WfMyQn_=NK4*Q2>6 zO_BmMXlC(P?uK`7J-NEBG9J8yD!V@6GwzfW4GV6LzcZ1km)(A~rpLQOl`d9Pes+zW z2D+AS^0Yl^SgwMQfhjjj10wSg26J9ODYY`)Fa29V9*Ef4S_5phqRF- zKr66qS%9r8Z6}+n_aV!grqMhD^l=;gmb~;0!d9{vz7q;2)2`)<;u@a8MLsO-Bi5I3 zvh&Jx9Dq|}hHi0ryGp?`b>*MyG~ZbXXOU_Ds9B7YSnntKVrHIjt<&$V2;s4GHnL^_ zdySSZe1T)nQHcEHeJku1L)B?d?yKAP7&@6*QeU8};+P%&%pE7JO4SbKUHT6#ukH!N z?*&b6A5o9#X_!{qVbWDVJ7iLS5-hhJJY#P;@l}q z#%hm*HgT>B(IZY*%PawlUy0*?tf^8if3(D>7HqzqAbSrGg=o~xxeHE{PBEJ&|A>Lw zCFxGtk?Go8E$_bxeM;D4ZR6nJ1iI&TZktW0;8`?HnSI{S?cIK+6j|(UeZE4G@PT|r z(2tZbkw5z=n?t?nFo`4uMUScDyX+aGB9Vr8Blz&J$Xu zcu``HnAS5_LXGpxKPhB6iC~32YsyI>!zd(>4Ung&S@ms*?1GFNWzMPs+^Xu+0MZdGd~SpGB@+QSss#oZ_XLxtE5Pf{}HvLF@* zu!BTa3NFt}8|TcDxvJsQ5F_*XxcU=%Ej8F)oD~BA|g*= zQY73!FqhOi>XPhB5I;tO(1tti+ZWO#7A#*)H7jMWLLCTE2~9TMGNd{5eO9w0;q?_N zyEV=wP#J(NLP5Q@HLvZ~$jW{;on>V~z;oTyHa(kfxAt0W>6gvFeElSyyuN9%;zU

o9=i&Z4lB%A&YSr7cI@iBq?Tn0wOk@V)+uz>*-hrpX
zAI{m*7{ucsk`Le^KxL3)Fy^DI3D6tVeM5**xA74cUfr6`g=Pun907H8qXuf-RseM!
zH(Bau%7MgTLQS+-6)6@6#4N9T$RX}h*d(5c!mY6kmJ#c{P?x(tdG*x?GatQv|MPdA
z|M1mkA1_SK-@dvs)b-NZ><2GDc<1@ex1QU0`}xiHUcUR|`wP!5jy^d>e!z#(!-pbh
zw@=cKzb7krEyS^q9|c#|p{C%>DsM7LZf$(-~wntYC}%Kzq|$I37@oVIceT{
z8ZIWb&~^;%A!{r5t(67c2(Gj@XovSK8BoiDT_XRSY!rJ
z@+{fSk~bORI)h&a9@Dm~42Ycd3T3&@5jO?uI!~ZAlnqFHiL#z2E$3lLW9M1&EQL3r
z-eS`U3rfp64qA+vP$s!$>j?~yjO4i1XsCc6^tc7(SEC+*CvDVE0?=Cl`isUdp^PoV
ziJz%9ZK;7}=+l+vr;W+Bj6^NlmU8QpS+|~?Lx1yl>KE@m`1#xSK6`ELlb04gd2#M1
zFU|k#m8IXjbLZD@uDvwa-n2cYP!X#ga$`X6h<06$ao&t~-HcFfg{!xt?LATU8(#U6
z&R$UI^AdGlAT9`08*S_0$aa=!CT(YMYcpXzgQFgD2$YX*4LuE2JU}Th2~Imipl1L=
zfF(dwV+e{f2vJ*FKz}jI6Rkud2;_qRh(6P11~dX+5xEf>%^_gS;L3pE3%K2^+*E!V2qyaghM|w!$u8-murj;2LxUFmkgIP%vIKwnXbO
z3(|C(`TIr>Yddaf$1E2Jct`94VQa^%9T@!ZI4~HT9;n;`l>nQ$3I1x!)(Z^YLE)EK
z@*+z%!+8+;bp4ipJhAm@_y$gfK8@O%g3VA+JBBkL^yw3DmY^1@E%gw9WD839tA{hg
z8Uhu!T5D(>AQ>~&oTs(2TGPCW-w%SB*sb8uLm+NBGhIp+mN~(s7
zyN4=u;w5$r0=%{WK^GA>PsMW-+yE`oS#Y?cob@PzD~_-#GZ_+Q0c@abCI`+7sfA#9vdgVvKDoNsya^zqk^*ZzEJ>}S*Cub(;j
zPRpr}JKKNKedWE2Eic!WzEYg=V*2iTyW(Fc%y{SQsShu;ywhC&LP7d;v}e#MtnNv9
zwlw#Zlhr@2Dts>U;M(rwHySEGzIbLf*55CY6JB*G&cC@W`c7)}Jp5fEGv(2yeU1rW
zwkA$00x-CrC3+cbOy#E?(uBs$xWxG|$3nDk(rfSMDA)|BJS5VC5kL1h>_T3Mk9u+5QeutIfwq{
z@zkd;FMRs){7+w7{_>*-KYwHS&h2xTat>8R_$qbfv|qg#>%1QCx*q4a9;4ri(r-no
z*ZktmfOt`7Iwb0xNCxAqKsK{@6N8_kYz>6<6os84Z6^uqNzBq(qv@7hX(WD
zgQK~j_Sf)4^|l(?hX9O}7g;IDE7&l&CPLTu$_V}%Vi;}cMcj6o#5yUc<6xbn4dRLs
zs6bdR6IQguQQ;B+ST#ey(@xS@W2}b_{u=P~8U$&BxC%koI$;~!as{_u!7ZJ}p^Uwr
zz#Fy?2J8#Rg!jD+q(`mj0CK=EO53|gT05Xj+Rl^MIoyh}3Q1c#ZtEayXK@RV_yR?A
zP*^LJF;lRuDVQ|TV21zLf2@W7YBYqvXsSZv4Yt;VZZ)z1LTb#RH5MbRp*1!LQw?US
zvV~OJLaS_{)p%$vX|AWuCwXhDO13-Lb50Ia7^2O|wt2XA`1vB$^Raq+tfN9_N_4h5
z(taUx$7a{5&tIMR?dK1F{*FQ4cQ#SHedp)z-uvZ8kN)ZX2Oqq+_~fklkAH0RpTAL+
zSsm}HPjELRc^i^F^>JE#j9ecj)`W58ZmQUh+K^E*GMJWT%Tuj+swH2;@)RsvvSkPc
zYkAudV1s~V$z+zyWXW`v1TKqkdxQtT*p9G4%36WA=>mS3MYu)8g_W!&jkO$RY=;>P
z0)PZ4%HW7hp33COqYMs4o2&7qeh08QU8D+KO13~F4aJbiB20=jGD{kqlF8)h43PS30coJ4GguqY?xe)S{hcR^9?ahS
z_?6WUU%B(qD|g;`cKN}~;Og-0<$>-er^pZZIELCGfwk!W5h9o*1)xPbYYJAEx6}u-
zkpaCZTk2`laT|*MsZq)?uokm)QUpj_AA{e<&9`l#eS`)0vFvkg1UzGka09MCHq#B#
z)}spZi7^WaQ9T?5+xM&dxKp0i`5A#)aH)4wTpi4XRt+}j=hIDPMrkCnYqSN7xLtcSak7b4uF
zE^#5s4Sc=7J8?12KjGI_;=)(s!e_%=lU{Aor_V)rro8%yE=+|vr^8)iPI=5Oj_DA>
zu)+<=+)Ti^6zyFI=#vg%NTP>iW=LX(M0QwU0MBDGi>7A~=>eAL;|SQGU!?jKW-4Hx
z@M?V$a~
zJ3n5%y>Owfc~?RH^ME8|w{Zf>AHCnwErQV3rZiFe99Q-+jIVaQ209u}G
z;;CkyZsN$3G}b_34HSNYz#0hK3Bq<9w>Dtb2Al1K)pp!!Ic_o4nM02oGpE2uuM2_G
z6a}2Gr!1i-O(CaDMyILKgo|2qjV9SPs|l>P-DbT)k=I!2DnnhRscSURN#Q6loxl(>
zfsR4`5!S0lKmqW1-56_RjP0@Bq|i{^E)tF9?IE$-1cbGRw4qVCBnAbD+awy}+fCX2
z8fXwOg&8TZDD-ajh3}gjB8p%*bhSX8USaQG^
zG8pLsm8CE_8keoGAc82-iL&M>Y?cTPY9ua^MiMdsGHO0bnh)Bx9>hXm%^^G_jWDHC
zwoC>GMjpgMQMQ!PTnvcKVu@^y$dwp?B_Q^YH6)1bqofsH%HgRrKsZa}i8QRq=BWZz
z%;wolmdb$I01n(mtle+fnkzEpZtVzZJAhiV(fTZogd-dwEb!JD3~`7sS4a6;_HN6T
z7$^gD4b~zRPG?a=`T?j1z*82aABQEN7sh4tYNf4uSOo134!cIU$v?>sq0e!vHq
zE@&>wmO`^3qJCW9ZjiFak=mkoGD}n_nyTU~{8LkSyKT#5JQOZOofz0{=q=nbC3DM~
zxX4mVim>Q)PDS{}BYk6j2O#!3W*O1sIk$b$p^Tcg&S>(>wbidTH@;L=dVfd4f8)3)Ojc7~%*GDIC|ttD(Vn6(;(rP_v~
z%4V*ynrkekYD?%bODJ%+))Z0)r*8<<7UA4QvznbmS@K&^XQ#!~WHYzo*0Z?v0)<}}
zm~KV9CGwXj;xZr>uteA{VwTGo5DvRRqgMV~G=2*WI>LKts)xdXk^g@|x4hXQGZ<$zJ{r|?0F7^H~-3Ww;YvA+iDhcIG@#s`8&qlrFvI|}ckh<-X4
zI2@s$g3a(g*oK54dTFAE#=B^|n3nGk$wZ3u>r0qwD}Hn$o2Ps@o>`?ag4l6{e6%Q)s0*w9*<<
zVKG-A?i%Q|nai<%k5ZedlC+dzrfT?!vCuMGNCk#w5OrdtRQs^wYN%fA-GmFWy79e0Xx!{Kr2|#Hq)^1+d#P
z7g^%KjU*|oNW+VDG{=*nw!m6sS4RclE|Dcuz}hU8$yBIx@LCaA3%~#~L!br98iCa9
z$rA7Y_QqiuJf5#{St1D#g=MCInplxsaww51Q>1cKHdkd}GeGhYBTeZj4dQ4zM1&qf
zV}uZKfv-nULb3$~8b@RWHfON#IoT|p1l*#2S;7i&n6Ll~fum`FVJ!3rX5Jt2qruFHugQl%%HWT18o1=i)>2Ng6ROHl7Y)ffAbf6|C66lK(rf4i*=8nfjRED{-
zB^r*I!_zrn*bJFY6Ywq>9GR}L20KJqApp$qSA+4Vqgn`Rh&}>P4=%xyp(0{nI9(uN_jI0sDht$R
z(3c$i<^jft$L2KFV!+r8ftse-pbeX{WJ|7QD|F#S9;(R4f(n-e_yV7h>E;hRgOKQo
z2+l!a-g4O*GVXWIMfip|x(Bn|#!Q0@KFkn<6h12PlXh*|tq<_j4fB?6>()WcG)ZD}
z9JS_mJ<2-#dVTrZwM9!Vbu0@WieuT_=&bfEiDL;Y+{#?a1`
z(U`CyyVQl5Z-qSFZF**q##SReuO8a55^y~}u;+h1TK{%_^!@fzzgrpma-!$QW%--?
zcT6Wl4u!dTefDmTy;EdvslseR#L~97#qDv6sj-hU4}5sK=Ixr2_ZyG@er4`|y!OKX
zcfBOBp;`eLvJ~)>5VQt|%)dg?Ymwr3d_lL#t*Ba|zuB&>d`Q#T}S3c@E
z^IY!XcdPO~tjT}4Ghs2xGv(I?C1O6t`}Xn5cTd&6US0HN$44mKbG;A-I^c#G*@C@!MxT>T;BKA+ReY=-VB3Gr@5sLb(>HUXM^NdH8mnX_AOGnQoOJ
znA1F2hi3Z5j?;K8h1F2DO59S3TdN3bH7qe}C4|jdfmthT)+(E|#)xW*x!N3BZ4Rjk
z-BPvnM>VL<_{=G*3Do{9fn8+iD+1T8DwjFBgTgOS2t1boQ6RV!ag(J76md`%2PAG-
z6#F=~hoyU13TY^5=`j!s`~zg74ibb(1j0cIV2Qyg2*@0!uwfbkAEt?6IO%C}j3LJv
z5(*PEImJ+u3@S|0)FeEmX;?GO(!r-_4LoIN*k+6-#u;LgrJw*u7-NW0Iv8*$e2Bu)
zdojc?O+pMoFw_u3_5-0AvX{o8W`I5?Lk_U?5YG+^+=wiW%SsQ=^$J`U$K2rPn;Z>J
z3|fB?{FsI%eu<-QsdAswaZM4MNLvR-8(H$^T1!YJe3_vkRhH072y;le#Z(6LwVKOp
zmcK?h2CTJ~TFpj;0(~otJEfGuk}#JOrcx}lf(WS~LrzFovx8~#@NFKh*+sW_m^MFu
zHbOcdtF^}}?Q!;|Xh)4-KAGfRXfONChf7b+n*aF6_cJUKg?196KqvAwGDpThZIAL+
zln;fJE67DIO9DRw23QTCVkkJ|xIx^4v7t^}9tZ(8X3G=_;HZ&LWHFMA5G_yyQ-2wV
z@6&)$8AmO#M%%2hL~L9J9($2p%V2=STowm(q%v8&)UBOJj6Jh0rP!e#G>7Jid|gb``J;#X>#I&A#ikS1
zj)S{S#6}#om=2q^9yW*O^4yu!Z71U6^Az!rW$VGvr;k`eGDs_8Ght1`EZIDhEA#t8
zx18RV)Ky+|lp%`jO6%@zb@9>pcKHZp%VOyahD<|#9FobC1)2zd)L{xSI8z{?&XLC0
z@>D)Y;Xr2#oKmq%DX>c!A_aUk8lvG_1+tPEA`PrH^0NT90BizKja(Tu%cItUBRu>f
z6i_@vB0-Kpg^@ASKw`@g)RJ#b<1A@LuGUd5^avYrgx!)Mgd!Vu5JfJs7%=Q-ivnC>
z7@y}C(wy85nM&Zv?GE`sr02;g@&i8VP^uIffD0Ga6Q&R}1PHim3TY*);rD;TDhIp!nutKGOjKQZVe9{uSC~==PpZc`9Va4y5
z)x{}Q8i49MVH;7n=k}()UYL0=FY`fR&U2;tFI1P_Pd_;8bqw=#A8r}2hD^)sWK?)(|&(zdE2Xx2(_1dY!N4
zX8oq;#^)EBUd-A1dcnchijF+aO?$1W9<2Apio&}`53cOrJ)aae5$+vuDg%D!NK9bT
zr%vkZ2uLTI4#+kt)8n9QcMdl_;ULryNEVoql
zmcpWeOf-%HObM1837k5M+gdRTPz=xuBtB^~owS+jQR>zfKr;B`DPtCEB$lSF!9Iv5
z=g{9gp6W?*U5i#P`h|8U)27j_8r`OHXGHo0M;vGIdz+TFm9<(2CG4l_6WIL$`vf)mcK%%3_PaHR0Aa5^tyBZ=lW*
z_&LIMjc0F3LbojTD^i~<^oU$HtYPRbh8_^uK9=s|Xrz)9*dzh!2}lDC9iRYp2zv%u
zfwBNsgu`))7^lf`nwX$aOg$keHN#L-3^~n0P%|tw&CydF1p%yumu6UcmSa%aD4-?F
zJSlMW9M7&u;w;C)Q`i^n&eCv%X`Y#ay*OCX6D$>sNsgXm;VC`NP@@br#!{%ZOOu0$
z$J8)KkMPW>$PM!lEG!3kc2HnPC1G4e^NNgW@_;JdmicQeeTgP7G1L`~zQ~X*gzYRt
zToAdlGB{nk(%wjB2xfDDY
zhX4S>8X$3KIbkj#Ld(d|O4@Xcvz%0jRwvu$6Pf|T9VP{}099p6osQN6doSf@mN@iG5;7HsM-Mgc-`%`@Tal*j3)ylM
zx1?D^4_QJ$rZZ`*NE5G>7EWB~7&+V8w0CDAz?igV2^0kU;qaZn-<1K*YBWRxr{PP0
zdP%0l6ngX`uU6=k3Y~JkL(JA#qfUbXeba%jJOu#G5KuxmY>XP8IqWcx9}%d-9DWeK
zJ%F@C9Tmwm4g&xmphA%cGiD=9Xm~Mev|ezbY3$ZCHY8mzXDhZmJD%?%^F4H-pDqpq
z1`F9$R^$`R^vgtj9$y#YVl^Q2X)umixPs?xe&%*tcsb
zIbnHQ%7cuw&76$&oQ!Al(l>S_jyq*=SC>#wTa$e$saG!=}1V&NqL2q2-;1>bGi&UnxkR
ziSo?HhrM2zcQikNC^FeClz2xxqIPX$~W5z8{==_XJny?E4B0ZpT6Jf5qdr}r-1APLT
z&0|y(hg4xPG4js7l-V%nh|Knb>}-q1HYrS_M4u9O43$F
zSj%v0Ibkcst)-Z)1hJjG;e=8fK|+fg2Op5s+ZbsET4Vv8wE}%>XtIhSD`~un!b@=*0x)JN
zHNt?gr3AN>0C$1GxCxe}gsFrGDaN;!Q>H4~bVA0Ooy=J;*XHF~eQaA8*B&9ZM}q{b
z!IS0(cw|YobOG!ZB}rvUsH-(gp)%!QOY;9NwT9^el@WSzl&cK(#$h0}#!4F+rOH?{
zSOif6Er>3`FvjTy1E7m%fcXKQLF_0CJOwGtWInH*o`b`)}KuE^I$
z22RJvWWax)!`{4OdqYCP@woVtDXHfUr`;?m?##(LN)bm$4A|VXZ_kCCoJ+a+XZP=`
z@Vaw&8m#wtLUfs1KVaFKEznhA-eRYgr?A;Po=)4+8K_L4R`H{>75?xv+EyO!JGCPv
z-!5fKOpe3?hC%u>cqF*M*KC>1*Mvfc1VWqxbs&)jEzXjeOodICnIi&dE}1S-=@N}_
z3nb?8Lm=935U@d-fFDNHCS=10Y11LvXp!cT3a7EAG#2#=r=#X*YmREmbKnK2
zIhrZ-vjzVD1oSpqo@udcX}5%2L9^+A!durxJ#XI
z>95sReY>*oYF_4?L!NMHGZDUpxX5X*bK0dZgnREF-1&Ugp~pLtoPMPk6J02&6uZ3yP9^C#xWBotfzV_w#;IGH~f7#vn!O5EC
z)VPf!`+t1q#72JB!l8ZlOA0>USpEP0>%YRExlvv;92FQ#h#pUh9gp+_+a`VXNxL+q
z3)2o^O6R9EZc5{)fRPG2qjEC}Hz{*7GCL=M%#cWC1ZG-frX^-drl%BUN@XWxdJ+xc
zb&NZ}Ea_e_SGzDA?(BBT*Ce(}<@=oSkVhL-`5}cHb4pWQ4Zt}Q<=r^A^To21malcB#`5-f@pUEOFzSG^R>}h#mAWPfv>MI8Px-W642d
zhQtA$>Sxg$`y&FnK@O;JA0U>qjfXoo_NI=xwQdUQ;ixXwnBs}S`=BbI34J`(1?z#t
z9M#Q{oiuiyu%5%M7b*M((8{iMDZ+WuhMGNa>sicdII#_I8%!kz13qmv1y7;BeLU4_
z=UOzbK_qKgtcJm=X{?IE%7D0}trYwT$I8&P+gc3QYnwG#D6(2gES53=unie-EkmB<
z=sFTRhFNND=3^GqF*C~5K10|Zx1WRe_@Cc>w^UNpK@puSeN*7Baj;|tHEGnYPCM-r
zsx%~V0}?+Z^W(BGt19!FG9~h(95Vv?$Rc-yL(j{(5I
zUF5h7i9icWhMN6eSQkYW@M$nOXtW5ZL8b~WZHP53RQ8@_RV1Z}mjW96G
zED9{d!uN-QK)8kASP){s@Vv;+3b2NmgUv)9Vov5Kf!qQ&3xBU7PRqi$#EpRd8lpce
zax+eCTvK`lu3LbL7~3NYBTj9?>lzEV$D@6HK1a7xzv)oVP}phGb_xY{lE&(3td1sX
zNWiVN7&8}H&E*7ENs|=}Sx(_4gsl*_6vBGUT#Q>_X#^_3#w9qcG#4WVn+l1oMPx_?
zZLSxvGdkJkVbA&nWWzooc+&g;k8}~sl8J1U&Qxf??O&UVpBSx?mK>DY|80#0l?^bb
zb67BdwV6hIPgx-D|5gU~1(&5PnLM7W092^@l(@E|hf92pJWa^Ai@7S7r-=Yvh-`@s
zW(ym6zZjZ2gGQrzP(w6j%~QFiUCG5RB~KMsZ`^$S(X)?NS9@zJdXJS4Hk~}5om&+i
zmO)wp?U@`|?sat*<}~l!S?Y2&BqcQO*>yfEeeiTc@3HEOM~^n7ZmSFruk?FQr6e|{
zCY{-qd?7RKV#cAio!e^s-jtsq&ZG6wD=XU$
z9H^oXPl`B1n6o7K9#FsUA<|mlR!?k?ZP}Yr7aPb|cu?C6km&z76<%$S*u3b1lTL7^~MJgRaq74jFX*`H85EnZH`pepY$G~8~Gl+7K
z!G~yoZm=yHG5CnlF`UMP9%Vq>O?j#<9~kT+o}3~-;Nu2?aEn@uN!tKn?ZGT4H)^5@aN1Nd3MTfHB(pDn9FCN^svMu(8CfzX7KSxx4Oy(vfcEu&%O$fh#c-Q9s
zZEGoUYf)j~9$o+K|1%K!^c07$dej$_A=qM*r*;|xxrDhyHoEKWG*GeEXPOO+mrm|gU$cs=EnlAA=*u
zcvhl46YwXC?1UoBxU_Ly=wq>7mgr%L+blL9QzJUt&*Kw1cPG|!KhC=mW``QUf=js@
z<(+j%<4_y0OA`_^%wR*Lbx!3UM0r*`>J$)NX2Gia1gaN&mmzw9tQ?7Yi(w@M7%)Si
z*{50jCXL;quzntBjVL}KFaX`lxVcZ`mty_Xe#fXo9@51wfx1Frmuc)G7%*uy!gij(
zFA(@e5(hKB%#jy4x*4~gFoy(Bp}&1Rb&MlwSON^GjIxzewh9s}Cvi~QV$51(vlQE4
zX)VIAA{z$8Ei{{oEaoy)ORl7tf+Qw3l)g_MSdR#`2laJ&WNOytfn_>Cw(5EtIy
z(YdzEEY+=uV;<)i0E3~sIR+|pvtGx9E|00=puoX*Jt+$_nmD71)1olLb90g~D{>Po
zH41`j^v)W+u+#)aPSHS9dWym!W>A@gfu$EYW|3#nl4F(yenpa2
zMQNGmmjz)(6xS4aO%c~bepTR?d3J%Lmj!NB;8wtNQ6n?ICW}h~w=8n2lCUg7h`}SQ
zKw09zhMz=`y9St{0D-8?vcTYAyEJeY0K6da%d!L*MnVjX7x{USTa<+bNt~6SDyOcv
z^ktVer>j%CJf$nMc5OqbGZos*fZlSNsAS0smM9{ug_s4A7{M6AT8KlK
z3oug=9%=yCTtb?Q2#AnUYHJN|X>u}cK0bKT`~VMd+;jo;$R7DV57}^B#M&Tk!F|yN
zob?bBOyNPBf$yUAyrH(=^Yz~&NMbY*6)f>WyHMs;%L96u-(C@Ll>7BO9Y8|o$xM-5
zDzr<$-3*RQXYg#1F7eurr^GhyNvR34
zd2(6$RD4{u&s!jg4GFOw`*wEhO0DrYi)FDu6pCf3!md}jofQr(k7M&hp>=0!U1WGR
zO&16PY*6CR&+Oh-8Rp3rn3Fq`DkA+A5rM_4mu{96fJ|RHwEyhx9mgWVD#LsgeqUu+
zSZ#c4$I+wxb#W#3OEa7E|;f3@hhVO#a`zTV?1$zE&ymz
zjYJo75OG;}nk{pvtU@q33Impmnw^muGr78uDKh|I;4Ty(jsk-L>V_E~=5PQovS9`-
z4F*%d;9wFpp!W#Smql}m9pQ}t6{fbPvs*L8zuSWMANROr3+=*8-Gt>fW$mHRZ3b=<
zmM+2qS10&4hs(t>{QJ|y5NYcNJmZ#rYsesF8F%n^6T=@RM~_h0b<>uc9I+7VyO$if
z=#UmPVbLYcIYe}0Q-?gj61{+7r#kO*toWUelVcyH#LWksYmuJ2k)BD~Hfr87g_*~#
zrdd^bF8#pg*Uo=EGxBn7`h)EWZxp8A*_kvQ8Mt?7-}26sL7#mtC2nSA2PqeFY%
zswsW9zVfZo+}F|%yneRnovG0;7N`E@pMDO1)c^f&|Mq70t>@~hmyaAA3inO<91Bi)
zMFEkZ=6DDi3lB1^tW=`Q}Bz_XE)dDxhF{2C(UNnq4)KFI%3iK3YiGf$gd1hQ-
zK_|w+reH6TpO!dKVG!b3nVFZEd68L?*ad}~P`N?iqC?)?zkPjgYOh_m4y={AmBjGH
zDEEj&PrBsw
zU6_V_d2(82rZsL<0i3f_DhHbl!7egzm+0frZ2}H|)o+QA1FL89AONScI
zE$Q!GGoLD>u`-${Md-!K2&@DNleHMoi`xLbg*LcwTXM~zxu#IS?QGhq31aAx%2IC=>PTIcb8T9D*Oyy$CTd%0yi7*Ot|gC
zia4r>Q+8$1<6L$-=It^tW&$%Z||47=uqTM6jC{3KKLAWgsguT85Zo
zXyESj_qd&=3F9dN+?@xDW$8JV28&%X{x@I=^j#Hzpu7>n5`+O=#8)7$3~c6ssSv9Y
zzb*@a-c?yxk+^k5*ihwl<@=DObpCPqPQRmNPLm|
za^Jfz2g_NWodX*N1D1pZMO=^pz;L<gtG3Xmwh=&y6Ateyx4|mo3-zodo
zFxDX74JvOCx2UO^!_z@w1^lRhc$^^+nGgnRgN~amk$}~FoiEV&e1}l%kxRX5p2Fsc
zRJK55ur}BxOQfXV~uB7LV)!ESd{`n(k`SC!XO
z;?%1G?z-r(nt-Rq@2d@uI35$%5F6JJ9R*AUqpgjII2H&%)CByM0LAEtrsTwvF)T@iH)+R<)MtLhDTm>$<&?T3+WJFn+{_8SN<8n1FM`N>9CQC(m=2Rx`@P-CE3siynlQu=y@a*f8afm3yjYOC7!l~Vg^t_hS+_Q?i>O(S#uqvI
zuG{`7I&9PHT=D2jetkLMnDf~O9qM#){KnCPQ-1fP%q;`0J^Hd+T@1J$ryqE~?et4E
zCHFE9-8-;*{ot;(^!*PCGau)r-`%@?`S8B)zWNgWoIii@)43@B2w@&4Et8aGn#F*%
z^8&pfF!KV?k)2k+wmHD(D9?^^oDu90#|*GEYQlv8Yh(#j=BZ(c8If2h_cO#GO9O+A
zV1_w%RNzscn!t_;%sA+*aZG^sB=A_~;a%pzckTSDou8Ab8Ht+J*eMMqC*PKtZiVU9
zxgnP{;*th+Zdl_cT+(8UXDP-r<5!_tGpvA>!UrG#sIyLa&ZVH1WRXI{e*v)^G0YKj
z;m-Bc=sPJIRiAV)mfOnmsp_SmH;?*RNp
z4Bo?&T^w<77NM{~fB+R>7KnVCImc?wvzp6DqKc-9%B4zrxVtfz2m3xQwK5isAc@r&_OT~pRnX-$z}F9ccuxg@Nr@)GDWDo87`w5*7r
zwjjGeTnHd8`0kP{zy`3{ES!RVT=(n);tNI?Ee-71P~V>3K-57$!wX-R;hd^
zm*)Tg(76heD>FG@U;>Gd%-TSILDvdgN~zagi8^uJ#Xh~zEf?7NJWw|ZODC}cO(=3H
zz?*!9Ye-8KT6k7uuB^ku9>zm0rj3s6g9}?M>T~>!Jc>
zPOWLrjvEyv9fuFp$3+#|)htfBoLew=>C%b#xZ0@jrk&dw6H|^y$DT?_>8`H4mY>&@
zy5nTx?i;1Y##_%_+MiYz9$D`5w4@|9CdAf7g`Z4{zm}idUtQH06WhEk`BL_gwmo|;
zWu)IMDZG-Ib~-WcnBUX7J*nEMr-z2*3rvB)7K$umF*;-XH3
zU^g(7A)a&$2UVCw5p-fS`U|y1TMja&Ab<@I{^3r-zdpKbp}n|yn6!;iwh0K*I*gn9
zaq}RBK@5=AK?n*ZF!$5eafk9wL+!iG4KoQ5i_zY-NcWgP-L{6@GH)4Si7AO0qVZm<
zsmHW+05ea>{8G4oUX!M9%cyDV@l5crV*-a@EHjfJ
zrV2Z!af>>?qVXGcVciZ?W(F0iOQUZ)xqgp0?3RWMBrk+JXZ?1R=j@aweAwHN&QN~8-cd0K@}LXV*4
zWvYk9rkwI}gsWeqZjzR6%GSfcpGNgDusb`Vi4#73*rnWJi5sB2B0c8S2kp{T%6bca
zUzO{Y=y8v}5a9zmLbE6`#CZy3V+Bv4zkNIf&@BYwqNNoswYfGEKo`m-Bo4SO#jygb
zrHsJqd9Fp%Zbn2jDN;R6){)q83U6eoa{_l!;Lfx3d6w!4c>eY4-@-xf9*r>1AUi;U~4mKKnDGV@&bp}BR4hHASX7I
z7dBXRs+&-Gl!Zq==R>b!B}iyRUQ^{okq5p4W!F`4U6a>(KA$>OEb(
zYu7e)6|J|!1~Nc*SwZN9SWzWF@(LWpSP#%$0MLr46?zfatcpSLT>wZc@`5JMD$}jR;)3R8
z2}CdoG{6I$EfHBFo(Ta33BU~d;&}>Fq4h-qN?HvaWj<>hJw7LHB`ucL`jSG9zCQr6JKQY@|Rdf09p^lx~PsYWa
zij8YY*>)lAaA!vP)%5hsnVIJgA8OmPyLr!^_Jap6rycItzw6?mJr@t`YKRKdxb0OA
zwNh6~1umb!j+#Pp;6I%qvn-|(nX3(Vl{ln^#E6a~yU*-QZrqmAx@%|0q5VUrPEK@O
zIG(hvBH%xs5Z$zQTifBitp|6XOp2-W*$XwU*dYRab0iALTA=e#S%EJQehc`G;HQCd
z5V~N)e+{$-4A>wsnpR9f06rq(N8mS=h;->mW>!#zgQ-}DIQ#%(1pvd5k8rq=kQI7}
z`A@LkwJ_&`Q=Z_60b6LFHFTJ=jl*>#5e7+pvSylN*Uj3m*-?YPZOj=UKIa!#N
z`6-#76p@l52mx$pa)6=w(aZ#-F*yO%LlIpRag)Ta6A;*S!gdX}UBl4L(Ty-cTqi6y
zNes3@0o$V~4ahEr>PF*2nSPW5#Q?ttd2mxS9o4WvkBaP=gqo&7vS(y&LE#q^c2Q&2
z?Ci1z{!LHX#W9yM;zr^-0D7$oLoz#T=U=VJ`KYaaDIt8)Db9Q3S+_Ll5Qb$qI7m4$
z%o5`QJuL&{$x)e_^UBNN_N6d=O6TDh0r9;}TYFeEP-;}7hFE+QsvQzPZI>q<@`x_<
z3Dl^@F9aN8nsA%K!EOPoLvE!{nYLK7#mO-Dqh15
zY0Rt5MEd%5Mtr$qi3Lsj5-
z1#UaVvFBu|Ly_Ah@w_Bnl7ve@U!K11)PtS7_e%-}?aB>??2)*IDBp5)pkHL6;xH-+
z;Ba$xWyP(pd!0a(HJ3gw3sXEjE3nfXJ!Qx)ieQEmtTCFJgU|)6E})?1Kz1o&md0jj
z0sy?gl8Y?0XwY|_qfr+x@R$QO)36r`qvd(dC?onBWyE0AL`=^cBwhgNL>mB@xjBwq
z1RhJmJkJ4i(Ni9l^rFPU#whEGWgvpB*$X_kq5z@A`wsoF$N9jeBXw3JSh)s>6$OLY
zGOWAWJ$
zsv{!1;&T80?mw(DFpA4fMv@>o<;*6
zK*$PpJ|9e1=ZhR7M1d~kX*{qtSL1W-VzEcBiwi%V7?~q;M_4T1rJO%{pgtiwTjtN~
z*nU3!NJnN`%fa2pQ<6^a+C6rrx$pS#rUUznJ+4zbws%!jc9&H)CZ$xm-8aih$6H#*
z8k?`=7d9ksYuvtjy{~WX%9W0^Bc+;Jz;P#HXSAAGSrKX>biMf`Q-cw%EvSUZJ&tK#9UOIH3DJ7{cGV*3oac53;%g)rZ
zsoPqTlg{nk-CuX2x9<4W{JaZ?4mKquo{o<0IJoC>cG}h4^c$H++rYxZyeDJB8`04|mYOkwQ6Z04>-L^H&{7g-lyJb&mzQh))eACX9nU3@Q4JR6RZ>#bObG{lTaq8mTZu8uy=&W_9i9|2i9R{kS0ex&6DA
z1D-+3){B`ycE=EXiD??2g=-f_j!@Wb^VaKI{-GZa9iglvxMe=fwZ0>6F~U6|vx7F%
zFm4^EFxY<1r7k6g-${vH^gDWN=0TpGa42Z*VjLSKu$Obw-l;9VlN8m@Vwbo6L!Zoy
z+oeef%!FLB%g^skeKY6qYe)CbxHXW@VTA{c9t3F?n9Y>fw<_}At1o}0AY(Bm{H>eU
z;luyG|MP!-F){RbSK>X7z9BG6#sH03j+sJ9tf;?sh#?1QqMyN07-KktGyQduwwuNc
z@PW102wNv+yMkFSq^}Nl30yB4Drgj^;hYgz6-iGb~f$qQ`oM#YC+>2c$vFm91
zBdnVyZqwv#v?PG&pv8k6>LEs*#2jj!9uv7~MVM8EIgOv!nPrXM(3o|n@F+R#?XvVc
zdlUOqwqIg~6=qxqlg4@}b01?H;Lr%7afKaMSy0}kfW8^$TlCteba_nSM^$b}rf)O0
zevzDT@C$BvP8Y{GYLul$d1?p^Gy-eK#_YnRQyvuQL5>{asS%kSQrLbOO-nf}GoZr5
zDv$bfNy`n67}UiPmptZ{r#%|{F1jYfL`GGk|Y3+A9$Siyv}
z*t>n6^NMsyS9&9SJyHG(E~QoG8fCUg5zaZ)MpZn*wS8rdR17YDD+775hCEF#~{
zK;nhvYjmN`BKOsp9GQe|U|HngOFarGFPfbSwq%JCms%U`2fM9~bk)WCYNFj0VUCJ`
z^LTuCsaMP3h-`@|^MTa*3Y}`hwuEy>_7*vmbPCI2$a1%%)S(}Xh!|>U?5(M9-FM)4
zYSQtf_{MFiXAd7}+q1JFDl%V^+YcWBNVo3YU*Yo?YI?QT-*Gstx3=y^NkwO7-laoF
zFC0qiE-dUVE`sf=-JXVs=#K5Xn`0B}T%LNb=a}17?RM6O1x`jqo{oubh>WNY4{L~y
zKDX~+%eL(ek>Mw!quY1wx|yBbRgm9bRncEvekJW-Q*wMmY~L_<@tgklOTj|$}>_V>05|DM5lz+e@wkV$HS~cKQ7LF@yPx$mA`?7
zUgwFCDBsfV)NkH;13vjLpL;wakTX2K%;Re!wJM>}l5mxq6xcCi2+0Vb7j@jC`G3Ih
zZUb=%+fBlH9l(iME@7q%R#S(?bj}j`lNIFruzk!Q&?9Jz=-!quOS9G2F*Ccp~meok)2Z5S(TaB
z0Kn|LL<|uj6Lx++HZUIL?f0l%BGoU^V=6mgXTf(Dyy~<=7*iNvFj(&pB04#t@(W>(
zm2k(BSDV)Oafum|z@Y`u=uw3Q=njkIv|X6i;U#w3Ax!}?dAgsa26(zxVCJI(FJ~QC
zi}jCk$f41=Z3d-4_o>`em~%koy5P6-C?ig(iz5b9e#9vcXac$$y~cOTbdSOg+NFMn
z-0M(+r_kR%o+<+CwVFY2%PHa*PuB`eHA|s191=glF|`a?$B<_=sng@QVAsy6Qme$b
ziQENQxS~o|B>u9%T;#~Ve2IGR7YgzgV$1xMyXP0$rwGm!OmS8SWC^*puC8?3#gr$1OuKA
zS}zCIYm^xGfXq3@1kXu*R9r~KCu7V9aly$fLf#0?1b#8baYi|33T?O%7
zv@7dA$Gs^3oiN{&rogv4X;-IQ`eL|uDLSl^#8;D|pFOl=J|?V7=C5!RxNoOGUlEv2
znZNCI%xp`T+nqX^6w?)OU34htbm@}UKD&F{d6)ep&ooM0lPWYS!f}Z$XR$H{D`SaD
zo+{(WA_~hVtOXQS!jh#NRl@z<#*_c!54bwR#rmjmR|7z42C$a583im8aBDOmXB&|t
zA+lx(2*9~AnXl4-+dP%dl_^*QuNLTBiCZdh0V+t?tk5IZCWklfO{j|tR7ZKMqCLl=
zy(MlXTS9;-acSiNXL-1@GRgx{;#G4sp)}0bU0r$h=;4a!z~$WZYsGo(M-J9ShgEp&
zrB1a-k%~2~!tJS#ias6{cQP)q&lIBP?UMdClv1
zJ2Pz~HlmNR4KVniF_Gj5O^mbTBu9?1*a(Y_OZ2!v52O4nYC@m~3G1v&y_XU*qYHz$
z3Er^}3kAI%V+llDfnM~vHxm=@@7%c(7c=QpfEH6uY1}CdY5bT^dziNC-u`Wq;jYOY
z$-!~D?_ImR8gM=e=nviUipWof9NJ<5^qQZ9)qK`!IcKx9
zV`hjB4BZPZcu%=&BzDu7m#~i_5PhE*FdCQ(wUaS{nH1S6|
z{O8X;h68;t)Ia8R^sC~y(+*1cY
zfM?O;T=Kc*0jM7Pe84rLEA!#r)#Uhv#ORIf33D;w11|lxE}?rQi_A5dyQWDu?P`Cd
zep?mDl@XE?G=;V(GVc879C;ZKV6DT!^?H1Rw4nhV6;Yo1n3snS-A8U
zI)!|l%~R-n9d-H^JGlCIe`SOt-^rJU>lNYl@_=3*W-s^aWgey2DVDlru(~q0UZ4rE
z7ofVp&I2JzeD<<{t2#Q+d|-D&YGP%Ww=OXX*qkr(CA!?UcgM|=f|lJon|JNJl$kkj
z;>1k*g@ucq`AurCmLe4lKX0Z*N;_%IWy{<{dk)Q6mxES^2w<13SF&o
z>NOrmo!?dOu~+F*u|OBnSd~LL6&rCTKKew2uiB+o+LeZ=u(sW)t$Vf&HXL8PcKvd0
zM&q^wfbq?e?ACods>6Nf_U}HG6kG1IpG=Oa@Y*vdYmPvad$nUx-eTaclP>}8+JU=Z
zx@>{Y7TLKXI}blcJ}@{KfME?x7XS=${Cz5x&H-)#z`-2pZ17-}%~YObN~3|l0vaL=
z0RRRGesYTZfR9NQA7`*p$~H(^`Uy)vZtcTu5WOhj*=(#a4+A(kYL+7>7;J#F^e}j@
z!uK#_KVhAcn0W=&;3q)HXj?yN?jub7glU9Cjncz}0Aj~ZImJnrG$4|Wjh%dM-hHi(7=xYjj5}_fj5GJtU&^D{-EM|c?hgpMnXNN+&
z5$AE#Mt#m|I&ZV0yU*d^!RQV*0N`FUNj~@`0iO-b)tLK_hOc5upyow-S)rFTdPbr8
zc)XLb^}5xWgz)9}KG-(EaP^89HcG0J;hB+p{YguB5#fLaz2wpN`M4+Z*dQt|u
z!|_pYibHS;ONgTROA*?j!rvwa7X#AqzKIhZB82l<>y~PnD4sqJ2&-xq-
z0q3ko>lJ7K^KF(~O9+3kBW~QO+~%m8P|Z@fX`f>;CTzr^b}@gqruft`o++iUG77I@
zsd|oS;JMQxcUF^|WWJF{EzB(cKF
zmV-UAv*4+qzu!Z5jwR+8Vu2=?7-|_n%TOyUy~@&SEVIrrYaFx6F)JL6WY;iV1Y^_?
zZ45CoVgY;?iLcS1&7*W;h$)_(go41$E8+ytjtktBC`<|5q{vN3`~)mTBMBY~C?Otg
z47*Ho>@3eM2m(-ZO_c$$cXZ`})BecodK~aP8|Hfy04j#Ph)S$ky?9u_c
z591;q#zrpr-D7rjNEN5t`etI(kX;^hs8bRCB>*ruZcO+EmbfI4*Cp<{D&2JI1L3~m
zsK70cy#p=>(SbKl)~#e5Sv+$1Mns@R;()>Doobsdos`)+o<1S5Cl&sL#8spAXR@55
zDhvrO_yHT7(>WmS6TbdCaS?!nc1r;ufwhM6qFkzMgkb{ETjUZ-{AzimtH>ke=~Q_@
zDf3808e6EL*5-vxPWst>JDRp9ZT58a*VR<}-L+xfGKXH_^>*fD
zHzlQ3$gT?qGSBVZe>^(8HsCwv^VWs=8=|AzckjM@`0$zN*m{@exW{{T+qUcZ+1+JD
z=eO^?nU&R7Rn`)p1m){TkG3SGo{5S*6B&InBJ5;%pfNhCb;tJR#H5zE#Ln#Os~MT?
zsoSd@?#AfYTbY>v=Cxb5RrsPE$%kQ(|meO2VngK&d1a
z^ZbP!J5NW16%f`!3dfmreUz^@+7H-nO-VQ&8L0L+DjjOIQ|~G-UA}$u
zW=U2R7*rSvcEo0gLc0LC&5(mPhGKJcHWz9!L*kpaW2#;{=Wh)4j2pPV8;
z;G-7=l(c~Rj!@VLi5cj%4&c^N3ZI~fNiYO~o00eth5*p^;-+rf))AiA40kQqC6HR6
zDeOCdn+FNY2yL6-i7^HnCM{#&TW~-M>$jma=3yF}lGp`Znzu_6GSfqtdvMgFJWLVr
zzyEx4)UsC_RhTi4GNiD*xVeWkcjKlm+_V}O@#3M~GhWAYHD&N=|DS*R?{DTFxTAAR
zEH=YnP;VFm7yQ0Y7c{pAg2HbTwp&KF)D_GEntQ<-dfpP+4#EoN3g`{p+8TnQCDhQ|
zAXCjIR4@T?L(iE_5N)AbP?)y1nT#cfvc=SHF?U$4?KWeACxgLfZI(70DxAl$4x0_O
zIcqVu+YAE+&&Dj*2mmnFP2;^Z2A^;Md=vl-b%mh3f}RP~fvi++95F7&~7&XeOnXn`6N=`o2Jmzfcf
zhBpGnj~J6)4NJ_Z!ht{!iF7}j%F5a&QY&%(l?V^8ppU_Ofar=aqKm^i55K~Q!oju6UJX6gOCwQh=7EenYC~qx|
zHOazxO>I}Dvx?BjQYT65tjrH3M!#KGF%}nfMHVj#>{SPvS@8e<@Bca+>A%KNJ-WD*
z5Or@y!e&y`tk*HBNi!~eGu*fCc1?=>D9?gvm!UcqZt`zjS)l!bkTIm0Nq6f
zv2&KjL25x{fuO+#IF%#wrfl&2>I4u0cdmL5U_yyyWAei)Q=H;8&cm=R;kVUB`b(4<-{HO`CVs-W1^rH3vZuzDXT3j{^IztRE=+ARQ>?>XQl$FqL#tFe(kj*EIJI{evyXVa-K
zE7BsGnnT)9RoLLZ$FZo0^Qa|&10Jtx3KDTuT7pB#(!46o$9nBRu}0nQTS3_uJ$>PMRR@#?-{tZOP}hZ9AKi(i|5DYI{5~sxcwHArLs>^`7u~Px}1F9L_RD
zt#&wDlans*-+L-NqSoy_=J6f(2Tp}WoQa4$6B%*R?>+8upNR-R6&Bv$4{MEzZi$L%
zijF;-l-#jn$N62m&TdO?2>5CpdP{ulg0
z_2d-!0Ux(*=2@5ecw6kW!Vg$YV{qMIaFF0}8o+7mB`n>z`8EzhY#pJoaR!H#K-r)W
z51=rk_G-#HM4AUlGsrINiyWG=_QS=UvcU4+gGPgtz}q&$-76k_O6DhIb{K@rX6mt-
zMmTaM%subchB;!uXe=E99x(WAiP_9O0w48%{mXZoyOQpDl@*a%;D~8}4NHz9-=*Oy
zH^2}OeKg)pU^j8gHDtOLAnrNS*4EH1Eg@T4wnCuR4F@0qaAzp0ipyY*yH&
zdCSwyTb^m&@}uTw{t?B~!T5)kXMWVS^_jDwTh4}VZ421~2W&NNua5lKVrqr3nvf9N
z%;x~Z#!3jofK344PQrGbv~>Z-(7oUYa8M9XH1#7~kPZ5R0nbPj=nQ64lM(qYimBE_}kJ
z_6sQcdRXFy1s13`VOP+-^;n`?{JYo8ry2zIl*lzo{3($=$~D%4MGtKswR<62|yl2nx73i}H<`WsX@4IxF&5MAikGSfoh^
z1Gk8>2)8T=>w{(33|JeCWrl_|0AO%m<50+bjT|cm#25K4nq`!p{2skf6C8#54w_V%
z9>8t=B;HTpupC5p88Q;^gkTap{FcnPz$^e7QFfTPq@g@1K<|pgZ)nn*EUb$B3db(9
zEG&bu%5f_^w=N2svUE>X?rLgqi13CaEd!E8aZ^RT#rIwMBcJQpF!#fN>yBHWmpDN0
ziYDK2+c(|%BGg?(b^%E2(l$KyRfh`tJMU2DoeG-q%Ar1pi+naUeq2}P{qDOvk~X&|
z+~1%2E7!bwyUe!o
z%*}A$?4dm~2X>#+)#EhYAX05kX=Hcm^_a+$;5Q=Epl~M?rbhhXu6n@~Wut8wM;*Gr
z+F<7{>b^yS3v2Q;1`1ic4KDY&5|%Auuo8sWaAK-ZV@uHGo-I)60);Mi2}Mr6Kxc~`
zLb*q+@M?uR=&uL>E^*04c6e2+4A?8f9OXWHnODzO`5cihacRfnBU^T-H115Si;Xyy
zlrYwK@@igYrO#gOR!Z&Sv2gFT+}zHLjHcv7U^DW?9m$n0cgOxi{Z%zh$w}u@Q?4C4
z)V_E3xjnl&cJJ!gmf92>(-<9ndGDU~)Kp;Sr9FEu?%LI!nsRa9o=XSzp5MK*H8G(j
zKK{yqeM{$>Zs+Hm41`@sO+A;8&=ehgVfRj0e`)XT*2Kid=$JFnG3Sz!nq#9uXItW8
zn&V2CB~lcx+-PyxYyObJ?YZE9W@T^bZq3M!v|V+
z?zotCu)8R`EB|Qw-qceGk>_@&o=J?ZcIzc7m&X!Wq$QIwLu50y0+Ftd3A7#D(RN^G
zLqbHEL(CP3+8AHUzLW}&S_WUBPc3zeB@V7wqYI(ZqmTs}1JH#Z0+xur27rSN(S-(m
zfy5|uHVbB_4`64XEu`1H6?i#;@@{N{
zG=SFBi--0RrXk8YN~0Kppsd5B4UBdaNv(B~!KOHToUx6v*eFlHRenll;UGgmWy}nI
z3^F~4dV(>)Z6ClGSkB@jEH=bI8I2VlLe^^obsnMdG0-&$^bWR1Nm#C8<}23F3zm?xW&ka4
z^y#LpPXlgIAgls(w>)`j1n4iyu>u3$@=VjyKRWY||8VNR{g-y!G8!8(l@dQ17uoCc
zbUF1dUAai%uTM=|oSj~WBqqjH&BpW`%IcsQ#&3q9I
zm_YYF@1ks==6x)VuEStHPY9zbJ%iD`#81(*nAO$^!P
zbB)DE^#KUA_N;oFb!_Bz!em)0iO2}oX5>{Fb1N=NXbMIMBjp&ZmzXnpb3u0JX#&E4E&*N(C^Z<2$^hV1npy$G(xAM=
zDgrRjmso}fCRiE1yM(fx5yI!eq>UVA1HDx6UPI$JK4LKqm_ujm>dS@cpLL)8V&d8t
zGdI7O>-xo9*JmS_KO4O8{>9@D(zegL^jl9qGsr;Ai%X^EdRMg)PLuE@fQjAp-D
zhl0qjN~m8MaJwP!cSPZi1i{~x#XBOu#v>RnKY=l~AqpEJzb^836bWJt+*jbhl{YkH
z)2Ti1JMa0NkHS6o0eZ^~E^*WZl&PiP!g?BgZc6oni
z(({M*EW}5Sc=YLT?_{LEOBb&z+%=Kw^||gGIe0HKZ7eyyFTy{wBMIoco__eUL%HOT
zF4?6HnQ!IM-65|>c;^rATg}O6Rirw?dd{O?2yE
z6#^n#!ZJl$wgd(YDs0UbY?+(|mQ`N4)WPKlHsEfajOWV)Al3jal`rB25MZ}D11s}o
z8m{~0UZpBbuL#&n98!VI6iQ5y#+SO~st9LwgbScs>DSBMYOyZn2uzt%YlsOul^9iG
z7mrxCWD@2wr&Jr|E!D+*o+?s>Gl_}y5&lw*KN05cJbK_}QEr9HS+1+iDG7Zwl@|`~
zt<>d8m-BQ|(z(5R>chg%Zr|3GopE{Jp62-2dat|2<*4_2TayxQW@UnjR_gXsk&$Pj
zqfhw)HHuuubETqCrQ1)2g}21THAaNjyIse<-V1wnwO-<}CExDSJ-nM7g$cbaOOAA_dCLfQBD7DKu
zv@M6TmsqGW#X1L?TkaO&M=92UxNMn6sPKx#PPPEGKv3{o0Cb-)
z*Z^=LRE8i71{=W^*qL0F&e!?6SbvFEJu2Wq?gl%9Q684|!<~eGeM~UeD1!~swjKiP
z*3^TU`f(HR6*V1mP+vFq5~00#2#|P~v`*2)6orkE)%Z-zj}S+%h%R_
z{mRO3US9s{<(1z&xA=>V$xp^_y?LSWZcZ9VZS_-60jA
z;aN)xyPM>@7w^6o>sj%uQ|K-W%#_BAiNI0R$PBxT$;=#ldnz};6ClccjIEcp%{t{J
zzdos<`}+=wWIqS*YlW89eb+fi>xM{>L%!b+LBOO5Z`G6igh5q*O)M=4BEwGIuds?7RabzP;w@BOtUGDVQ
zn*^raE?@EJgK-gKi7_|4j@y3sHJ5f(lP(I(hs%qw|Epa$ZYaWt+p!uKu^bn0C7&%jbThyluD5X(=
z(LyYsHQ=~UVwomZXcC1{4sv(#d-Q@dFLU$?N3Ze>#EKEC#w5&3l7Q}8z%Yxd^!Dk>
zpH5!?`uXYaK7H`#&mR8%gFAot@Xnt;y7%W#?*HNAdk}y67Wf1}nyJ5^L2>`yMN_SOxLl)L0ejU&&!%I-$Hf4Sj
z%CJ)8;OQFBTH=;@c8Nuz4$TkHsF3fHtbnrCb@Mq*2sCs
z>s)i&S3Hh2ziZX+T=LqN1J1>ObHVRIcf69BwUoGr2X@UTMbE^A_c-KEk-e!3T@Gb3
zA?EJU!_Su#zEEBIu&Qu!?~c)=*oTGrv%9w4G}@orRiQ%_&&phj$h5oV7aNZ~uB+_d
zme{0lbqsdStxq4?)3q%jc+&g;k35wG^a6AZ@wGu2F5eXawJOq)C4mrI(W@esD`G(0
zLWElqHFZja0bt}?xuC+Z0qm$!#dfC5%@?Xv4v!ZoY`Isfjq)6e@l=G_3++NSPh_!p
z4o5&#dDMnzZ#pRc-N|Qmq|}B5s+{(-J5rjH<7(XY
z0+u`)y0uuAMjKCEJbb8B5<0WfJJS!HOG&t}YkPln`AFl5(=pLN#|wLQo=J>76Bh+s
zJQE!WfNYG8Jil{WS9;p*qesp}MmC0rx5dStj*Pr`aNl&x$#*yBe)E$z{`kAkzx(}9
zzx%__{``lZ|Kayv{PL66-+Qq7+}!9)YvYxDdylC~rN|xkIGUouTH>Nx;$zPy#GOrw
zZ-a=7IUOE2;rBGhMmEPpoQVu;ijAoE*vmM&l){TiynwW2*+OgFN=s5yoku?v;cefR
zbpF7;lZo+VPQ6rDujFP;wl|;MpL)6QXz!W2j-zSqhYy@Pw7V|aT?7rSr7!4^6gkYEUK-x4Rtu>iD20Cw=eV36HB
zqca#toToFH5>f1xt7AL`E-_c36TU68>v{P0n$87gRolR=>TEsGj6faN0@=%z>i@D@5RlqrXNF@
z%;PjR!Qex*1-yBLvBAC&NR+{78QU-of$l-xM_F%^7Kkp~bel9!Iiy*SHmdTQxf$>w
z|MJD>cRcc%2v<~M%4iZd_CohB?}thQW$h*`w{Xi1o4M0!x?~P*H;1&Ewl;6w(qwQq
z2;G*g&w$;cPF%DM?XZ|TOr{Gse#7H<+)(-JJ5%4j^WgWNJpau{&;IU%$G?03@i*^1
z`ue?xzkToFSMS{a^6h&NU%h+(w;w$E?T63(?&BAJ_s+v#uZ+D^U)jlX%}+nw{LIrJ
z#K7`kD>Ou_#nfU%vn8a(vK0W_VGX@xGhfB6HwZLWc3%*^sOy)2ipwavl@2}0QA;wt
zrZMyAF2clR3ct$JwFICQQmK>f9CSDTSTU_+caKYRWDy2OKK_
z$GFVQI;HhU_n5@=z|X|tV+sS68?fF{g`KoZBQiUzu(O~#QQp-k&#=PX0^Cy8>x8*i
zAUET~S0X&ODXbFPfnrB>ljh-;7)1w#OIA;5RnIBK1zS2=1!U?A2wdX1%#5VOn@>h3jg
z&OXW8nqkOE0>2j<_SN&#-@LQ_+qYJ}d3W{O_t*dQ;hn#H`rt30J@~_in-G8e`0k%R
zeelOm9{k~>yMO%X?zbP@f%xX5yWjon#XCoL-?mx$Nqn4VrbTW+73KwY*_ht>zEiz#
zR~|aG=e+huF7>Wm*;FL}@P-5!Mo7M=D@MprMpXfk+Z5qdfG(OW8gv=WGR-k70yoDo
z%dke3*L5Qq8%+c)EK0&%zw1Fv*mFtI&&EdpcNd^e<9FSO^sR)s`b2id>sXBNu0#aZ
zW206RqbDM~-Lf#^bzb4=PKmuNu@?olKP>P-5r&bT{T~6EodR^_z{#{o*j={v3
z@omXn5rIoCtwWQ}s(hO&v?|;&Tj0sxrE)2N^d=K)`31X`dhEc1dPA@|LP4M2hw5?BjQVTmM6ql214r)cHNfBLWSP;isa)Pew(YNls|qmV7EK
zaNOfQ;rBH~N1cY3BEl|gOKDF|JQE$&6cv7c&n{qgt=D@!>*xy;1Hb^=`eCryIlltqC!0De>()
zl1~KO6*7A|+E=OZd4&0Rq_-(Kt~n*Kd1vyeq(k-jUF}JGpUtLS3Zi
zSeX4pjHh)^;)#SnG4N6%3PikEp(>m_a5pHvB|1}T=b&8XQ9L75tyl;M_}?k(d&eK?<$_rrUT(4-Oo)
zpyp-TIzXZIfLP!wAk&ak&|G7s5kr)1oF`{w7En3}5=@wfAxO(GdI`lSjk=9t38;pr
z-|uA|;jmEw@24$&q^X}a4>MMf?{NlSaLRY$0_$;Mb78Ilh5h-X2k;@^I8}ScuftUo
zoO_%`1DQaSjlnZmABAp()J>RgVy0_W(`BpqJdn@)q<=RE-M_{e!*^Rlx3+9~=B(M&
zAL)O5vhvFpR(}8S^WS{@+*j{D`0cy*pWyc02M}MrbMH5A-Tm^-yI;O__c!m{0|tKu
z41V(tJcU=k{`k3X0n*PdK3h|KP2^j*Y&r9f|JV|`6^XCS3{H&1*K7(7Ndg8NUBAeE
zuMxH`0>4e-y%cI99%KN$C|PWjqsLLkE4?7mn+|qbB6>MuEj9Z7&iHA&FsZV@&M`D{
zmjWuITNUvT#DGYReBZe{t{~#hxs*YUnD=VWZi|`LMff$xcyb&~DoOS*wh@hAjrPxb
z?PCfD`wnaTwBNoO<6n;rEJwN*0?rw?HVQwe$V@0a*zj$Z=vVl0k3JXSnG1KXCPX~k
zlQQLZ-lYESsF0^l2~@Mho>hfLk*TNgGXmY|(l6STGoZY(fHc>sciPn+zx$Tg*&zz&
z82YL#OzhbOJAeC=PcKr~kW0U}E9u#N+m~X)CVh^@aL@ge=(QOCj024$T6AfXvH-HU
ztjP*
z@89ix?@kY(_s^d{{AY;I9{=f6SU&p8XOI8<$pZ**;@^L;`R)66{`AY2KkaVaj0sH8
z=q83}{&WG&5xpX?fYLRQUl)W8fnVb})ZNQ6>mt7i$dsk~y7H{Y{+!Qo-=S=3(z1Xk
z3)|n-nP
z^9)9Zz0q*&PwVqzsYxTLN&ht1^}_M$R*}2tkh>#1=N$^fSxsnD`4*KsCDKiru#lVf
zo3XCb(hnyb!M5cL!IC3kxe}HG{)+Nmt1;Q({1fvng|dKokgMk;GJc
z?5#Ueujl35DlNF2o_6ujq4CqFo42JLe)=B@XuO!Cia4rRKTn_s>E^)KK1-ETksr;lHKJk(X^w4aHJ=*i1!j*6_7#1fXNQssJw
ze%!8>vQ(AKpYYflypEQbu#V)|rkL;=hgQO~l@fnpcWPfrc5_Pf^{fMfl?C--?kc;|
z7!z?dn-F22+)7y$*o)Fl)}x++gtN-#>Z{7Rt2amu0
z@bPcoL!kZg-FsiX|M0619)jJ%%CA3o^bN#^k0FBPuit-U02nd&*Kch8`mMXL<2SEu
z{B){&{@|`_65nC9putGrw?DU8Q2I2`x7i%h20CsrU9?&{ZPx1;&=-8&)(`H^5W@^P
z%uwj|?JNW6otLOJm0ESOi+*__DQqq=e9EJYYwUozQCn$$AVv*RJlP48x!dXg+&8`1!_V8nzF+@)kD~N8GJ})CfxFbOCC|Vex4kV
zm~o#v=~ZXE8tUuy>A>AvxTQ~^m*T@#6T+b~G^`5!3ODT0=3@ivDKWuQ=x-ljy=*;$
zpAzU+MQD}z7Kw%BMZ4OeOBYn>id}7HsRrBz<-yp9$<+AaxbVvY^K8di*!hF0i7Om^
zOXf#?_W2n9e3XAPDHRqO<#I>?&{~yPyW-7m;U(C!+-wyt6xmscy@QR%%%0)rH!2luVfxr
zPl@Z+rCXZNDbRf$d%w?d%dPZAcoz2UxSMgHH^SR4b7Q+xKkvKt;q}YoyLa_PN30$_
z+!q@S48Gt{F1huyy40j_O)A@>@n>ZAq{v*04GW$$KfohPu;z$1)M9K97r88wTElA<
z0*T`ROnohsPXHk;{3%bSTa}PQ7fHF9%)H?=D%gw%sHgBfU@Q@SljlL?!4T3
zkG)bAsvSxZOBV8UsVY@zYC}ZW*}Xe&loeh{Khzu>(Gc*|d7Q`Gt{SiFWOPJRLd;2@
zr-J7y1pextoz2k^MKoT@(S2ow?>$=k?JwW`!`Gku{>u;l{JT&8`FB70^EYS-ru*IR
zKMOwn6N*oOyRc0#zWwrpuVJs>{p9OkfB5?9)UEuihRBGyb1n02&E2_KXOrX4g!xW7
z9p#cxXV*`=T;&v5gj-8_>Uh9jt%;|?{C9gg`)Z0S9ZE}lRAZFC)~VDulrsrYof!vv
z%1W+hWuD);y<_LLxiwl!{EPN6+W!E9nPjn~&E=x`4RVV5LsJNJs4ol^&_a
zuU2^__~vs(8&rUh^#XK}>>}$e2N-*x0tD#gL6?JB&{YAg%qs(NOMu5t0gXors<0CQ
z7+?&M@8ENEHdFae$Z+n#OuZ;w8MOmLK%pNE%!M*?Q-}dPv>y)%DlBXeWNkOLwHKk<
z+;8k
zTW_+~=i6K16Mi^7xg6$LbBME~ZJMx6P^gy|Wl)or9unQ(@D^^qj+vgMRsnanqTXCX
zaDxCw=soky(`TOf5lXOn=IN9F^}memP5p4X`xmdS{QAB7zkFl!ox9`DPTzVodHwA>
zW50R#{x=^z{^sLnQOmOt@YKMtL1-u#82%avZAdWk;CJu;>b13>uMFQS&pR7xYWdNR
z+CsNBn?jnA?*^Nl5qga=#3AS4bK1;TFxw5%+D%z|Xj>nHp&`GBzT_B70!o$?dIOF0
zCHr-LW^c-a;>_1eGS`zM21I;JWk795cnSjb5DWB_NKZ*L)P%+aVp67tdAyIdp~1~8
z*~gLNc5%uf0h`BVW>OP|czTGV#w0Ya)`-9ii41HoJ)p2R
zNox;BOgN-Dzhm0#7?k)f0_$a|DUW?KC1%{C-K75Rwc7CDt%v7YO-zi^3S=8*XLtcpR
z%m>`_UdO1+j{st2ep==ib!pwLqhwu?MFWbSOxy_QMK>Kn1BW0@_^jPKDHGy5>nKhnS7uYp;
zYIHfTa;P$~&M_N2yUDW~#*829929uieicnT$#2RcKzCCSS0!}s!d01HSA=yH-FjgW
zsxJ!4sa{g0Rb55%foRgAU0L$jSN*OjkY=xASY*eX%A2`I-p)C?o*cWJ5_4})%3NIJ
zc$BwOWG+E%E;iy(&e0c&a^`n$@A7$i!~GlS`+Fk&jhOYa+kU4k|NZM7FSQ&W+mkxE
zf6vtZ-5n04%`TjGEA0*m(A%tXDD)rhe!Zym_{3SOXs3d8bA
zpfyIor9V%y0e3;dN^}Me0t~43$R&0TWn;+{tS_^(u(CiU0SVP%_J+7XZJ51SA+yM>
zC*u6q^3vM&Z7a8nd8D~%N7AMA!&iu?|=F)zejd!G&O(rmv29Z!XLi+=&PT<^^^A=fBNpD
zPv3w1?(3Vs_{l4O`uY=C|GQtm|Mjol|Mu&jJRa>mzhg(Os+~MvjB7At*9xkoDZpkcv9I#;Cg
zNQ>=U5t<_<*aVH__{k~q13tzn+bC%bCQPB6Das6iva68Gh5%oYzoKj@GeG(_y3LUZ
zs60wp$BmZc5z;zLT1Jq|A_gPhr2x8U8?ajg#%3^P;4az{-OJB54(vqlh2C+D#>Y`N
zCpKb0*AQ!zwAI7lH)!l+5#V`pS1Q9w%dgDCT_lF3%z35
zdeOY4BlMZJ5G1(3T@=s!2#DJRnrpN+qwz&g|L8ns?T-n(bm=sJ^OtYk`Q;lMzj}RR
zz5n9Cx%xLYMt=F$=2!1O`0Bm;NPpjh!jt&sgU8=~{MX!|-i@`EcZ#!p=%m4~t(HXrR(fk-o-Yw`J!3p7;m5VyE5mxWaTu-pe~Ys&G)t8TIK4
zabfGp(ZN&bZy!&c;EB^B-7EulQM5=LK=%ZVU-8&)M+a^NJU6}0OAhr`m}h2t;!U69
zio|zHTyO@f#gc+6JUQr8rUTBIaQCoN>E@|HaD0^?Q}{_$TySWM4s}Z87F7ulvLJCr
zFRwA0$e4EO4p79H4|3k<;x&49aR{WaMq_eNYJ;GKGMH}AeOFPYmC@Av?{XY`ind&0
zgNH&IJslEqFD~%A_ZENu-ujVfYIo!FQ<{-$Bt}go$E+UM`SywGm#WGJqN6)q_UT~o`Jzwo`NCz8qftc!xA7`?qExG2J99lYD94&X)L?
z8i#tq?>ZIX%OlWjCyE6MNLI$vB^*`f(a)tMTt9f=%7Fs|WhJ9^m95+2&+bULd|*do
zq#v}hLKABpdId{2hI?P09{lxBUi;lwAAIwh_rCqj2Y^ygTjaQ3e*%R+LVW!(tpDS0
zKmPg`Z@v6r=Ka?gzer;i1+&
z1UpzLgA-Q;lw%Q&GMALE(8b`>Miz9i6&m8nDe?n8fT_Xxr;vJ5mVRI@fD^SUKe1TY
z0C0<@wE`hF*1%>XXo!&&mV=10rhW=teN{b!%TC;Xs1e^p?nG4lj%MLUwHJ-iQD
zwdFQyY7V_-+j_;i^`d2KhiU8C(BR13EvRi7FdSlV*T{2*!m0oEUpp9LKL600Bb~o|
zbMxnKtbg(9%4aVuEOxc@pRNAj(bQ`j!{gUZZ;oDkb*=BMdt;xzy!i7sH$Hi3VRQ8I
zg}Ur34f(z2ss=9{yEA&}<7a1n_2%Yp-+u%i3~c`LoqOMW`1sSg-i_QNS2+5_|Mh>N
z5yNQCXHyG=!Qd7%YJ5Ix2|aH$UA9@SqPrnkx{&w=Q?5{_FQ9jr#m6{&P9&FPYEhvE
zc&v-ZdsVhq;d&*mSD^ZMa)1v`vOx_?^m4fKeq#89%J#vR%o0PWZJD0Y#c72P&f+;H
zfa#Lx#>}{B(jiUgQa??s#fClJm9Xg2#?ZXb_>3;h+NDvJ9-#0Z%G!mS`vht#V1KwX
z;lZ{zkmG)Vn)chDJCOS9?xZPQ?xFGP_}{(d%u{Wu0Nh1mie$D?pul=>_*~aLj>}H%
z6iotgM^j?EBfQrfT94n|<+EQ_(7esRdgFE2`MK(n0he-3q^
z2-dsmbKZ~eE$H&3zyN(W-TInS-muFH0*h{XPvdh&b`|Q8HAWK!>5Gh(#+SZtTSg7Y
z-@7ja;wue^MQdP*RvO|9`nv|fkZUXjFh+a9HYhWTn%x?*8E}1hf9TtH)_?!u=3jpD
z@L#@o{=1((`{&Ode)q-WZ{J^gZQ`sdFc|M}xbfBNXb?>~9?`*+sfZmAl^%(F5(Mq}s>!DzxPYKfx(x*H-3?z_VM
z|A_m~=(?^eK^OI(`^LE46)XZcY3CeIj))||AO_`ND@%;XIR_$=AVCm0=L`^Frh+Bg
za(2l{mTWncqa5T^<*M$!-S_tGe)aBnbFK~0)z`y6i*?2vd#t_BKKmSihxqn4*Ia7>
zUlmgDC6S!7`kJA=VQ8-#8UWZyM56)gDr}*BlXOl4cd_6Zz^uu44fQ6e0N+yNI|1|c
zSn#!I@T#G1+4`rlqHko!wnEmLZQM>oKAoR)BN@4tjBLe1vxa*8VD>vFp8m`eM~5u=
zvdmo3#355137A8nz-ThI{_x>fU--o8u|or4`;Awg`9jf|d%Js5v1=!u|6FC^V0OI8P_AS~I)b|MrMV9egf6C+fxgTMl6l7LF+uE!
zUFhCBvTMNiJQ#U=#^%r3d;v5p?zG9CF?oPQNmM%v3>_b!M_eX
zGkf1NJ{)L-=|K3~Q
z|JLi@{o1SV|J|z}eEs!zK7Z}YpWXi1_rLVppMT@GAAS=~``s_T{ksp}{r#`r`@z>f
z{n}{X`6Kz|x>_g-#Ufi9v72)f<)(I;@|3Fb^w~3)pL`4?xL9Hf1s3o>dg_HM&p*|C
zAotv%+{@2BIdb-uu7@71Nkq!ScE|Apb(zsK0$XG%B>}xW>aWd-cRz8Y=h=sg!g_5^
z^!%d-8}s5-DSuVcs?Q1mZcm$7X;l`{D&uBxNG%Gf0O0btSr*aZ&IVOD(`q;nJ@;^K
zZGNmcp_iqMs%(E%b^wGJbJ1~w2r;T~VFVx@Z8(%!7&Fg+`0nPP&qnUwm+;;Lr;Y-+
zVtA3kAhjghJi$A?zdkY+2xzyHTZS#b5?DJWcmcOlJIApI3!maW;IFHOFe`y5Ba#8J
zpud>JhSNyO8XEX=5`@0MU}_e-dzl%D#)+dCddqwgJ8Y1r^n}Ho3WOvC4EnG#-3(ZTFdURB2-?FtMPCCx<`}l
z)|~nF)$yObbLW@ecu-JPqi?t}5y`wA%me{{!s5H|=u=PNe1Oz?rjfkp?VvW_<&Q-g`M`ZU(2g5*8F;N#WNt
ze#;PFibxn!JqnH^Qn^{2SCULB2|U(C(BD|nCaxz!i#RD5i&rC0jS2L)#4h;t
zTl-S4AI`gbFn2REx*7{^BqG~6@f-X8Vrc^Q_0~vigT|jTmyKnr{Pv8FOo#{88JUZo0Usc5oOrFcgT@9BYysjc^
zoi&skqXn$qQ4z7PK@ip=cL|SyuVBNNe^wPZ6D@gn!KIr-e}UgX-mm0MDxO@Vl7Xv5@LEyTpxx4vfvfViWxC_KB2nY^q&sxac
zvo;59I8xvjPMgeWgMmgx!mLP{r7^&*NKRl+X$(NO&=OB;Oi55Jic?OE)sMdR
z`w!py=?7nW|DD&r|L$AA{^{5L@ay+~`2Oeq{yT5~?E7E%-nZWR(Rbed)sNr#!!Ok4(}ngw|H+Nc_Di35
zsyRQeXtNB<%9AQ5CmqGJ};#t2${zlt#1?
z0Bu+;j~M{t+U!tGRN0q%=R}PNH!hFEKQh&QKc}Z6vdR%
zgkGMqieozHFZKk-K!Rmx*B^*C986W_M$vsk3eb1wD{>znW2|S4_2P(L-b<>T(Qzj@
z@K@}hT_BaovjAfPW>i~1vH*b%=N!^si_==+3A|^DcY``(;u;W31R5GsqL+XcDGS`4
zM&+ddv@^TV1ysXv_zW9S`_+TFi(z|Mlm7X`58)HudEuE`$>0rJUV+bpEC=c%ci}US
zF`i+@GeCPTgGzec-N09ZUgU1Zo_lF$6knph&42UPm*5Xk`N?l>jQ!#pum9rfuYLdR
ztMA;NegD(zKY8cQ&%gfahhKl~r|;bT{+F(Q@Wt&Pe)Z;$zjpimw>Q^@TQ|qs-v8X%
zhwr}j>-XOL$=}`n@N2JP)zx=*GS9z$_pOiKed`Y&eD3?#W^SK(e#mc}`}oJPr`dz!
zeRl(AsqDZ>Hr(ea&n3p&&;1F#ILD*{1mzbMVO0?}ReoFJ?qr7Fc=W-Wj~%`C=;2!r
z?Z28ATMp|0-Bn9kHU$hasCNOERp94zRN-lrn^rjBF@Sl&l9p^`J094M`xiiz!Kzgr
z@eIZc=PNu&_7plUH>vWAer-KyYzEZrsJ#^pEb8(q5H}}&J1=oFFMcg2x)e5N1KOSA
z``>!<=&eIJixGQN`O9-SH>g6Jh5ftd45<~Y*HUnJiLG4>S)-u2saS8&z7()V6Vb`6
z#9%aZQCBW%;*UT3X?XFi;(`HPo(vkxiQq~y1hJ8f+|J9~hz8ffforkw)qn-RrmL2=
z?bo&pWm6+-0;2LFZZ|~^tD12@5sPDr2yTJCsJuvDY~PevKI;RGNw
ziy3Ad=DR~>*b+!{*U2nb&U9BGl$#8_?Kl4L>80O(?fM_yzY7orreYcM-+$)+`0?Ao
z-S54<_UW}tpIYdCZMJ=Tyz$GoM}PO-*WsLh{NAVj`GdFq@w=b;<9FZu#}D58Z$JCu
zSLzDK9{Bj0E^V0#;jX-`h`4kTI4jmzA#^d-jC_^Aac==uu_POhkcPwKoj~Q?IT`7D
z8v*QubVHLNwpH;eTv=DIgV9>r&47uk{07ZCiSVsNWFu(bNQCDtZOV{e&CkBQKWjc{
z&IF8`hw?u4*wL|oJ{ht5O=ZZh4F`=YetjTdPG&~8KJn;JriNZUbz<~62K=cPVdU-4FTNmo2L_3#1bOLHF{#Aq>2lGO2^
zh>NLa!dlXm3rEfd1Ps3btVQS&*@ZX_s5YrnCJpE<3QC23;S9L1#g#>r;-CZ`d>ZS3
zs8@8~X^RJAt4vs@b@pZ6b4C~1kL_
zPutN0qi0?!Gt?4E=sAA)t=aw`yz|DdfAqDFe*BH!fB5b%fBbh}d3)=Fci+Th@^8NL
z55Ioz_rH4gA3l2j5779j&V_0z9^^y~M&
z{lz<1FSIn~WdiK0O>OA$Kuhs>Pny_6P30ydwKlX{I`X70?
zB^fV53HFu-w2nuQ-ni5;U39uO9xV-8WpJ;Mo7MOHQxgRzM_zuuAv<0cP>XG;z!J_F
z+!>8Kt#g%et1&MMURxB9i-Sr<%mfS
z0QB}#?mo)XyE~0Wiz}_!1t1uyv}yac}0KlsA;))T
zGhKiG#r1#w!JB{h&TGGa|J8r^;PwCXy|;e<-rYa`@U7o`Y3usK`NQcCIGy~fa9Of;
zAwc&!s_ITBENQoq2G(n;n})h=8#hAMwXnS%@n4Jh=XGg25qcv(Yc*_5ndC?qFth!Y;C<
z>bM{7OHONa5&X6TVrf7s2}q@3r7WVtwlpkP#I%OIU_)LQB)B||04`6Muyq13jJ0o>
z{tHhW=y*7x!i*bHdQ3BE;%^weS(FVR^X1dOLaKm%VzUPyA$JI5iMld&xl3`-O)
zEU5C(9v8f0B8BoNB7LW2dPc@hUtrSL#z)~3{&;!j)u^$pVvW@T51$hYupK)G>m6a-
zgS6`k8-_yz!-*b8l~tzr8i~g=>?a+Zy}3
zJ9EJ7-+k~|pf8p>6YKredv5`}fBS`-Z`Ksm{ncO9{fGY@xO=~v
zrahNfUq9;`+)X%7;OS)GxBWnV_+~FSVEm+}fMGmI^QX^<@jJUtQMZYXNJ+)YcSf4RIx0({S3zb+le~
zQ*gG-ra)sy1y5fUm~DZ%F3{Hm>K4FNWNwHIP!`(GE^Kc@$lP6p-)SR*F)0nY?DP{8
zd&V*=M|^kY>yY{Bzx}J*$M*gD&dh)QE}-|dKYs8UNbv8!edizEe+}sS5AWUm-Fvq_
z`o@iqzH#gK-@f~Y_h0+{2d{(p{_*`czEFGm#@@^YO_~+i1%+RN&ky$yvPc$I!XIiI
ztFp2YLK8oI{LojQf8yqYdne!qFlc|_
zg(qfWfqqRI3z|0{Idtc#Ut0
zN^H4Mq6(Od6TXa6Rj3WXP-}|TEeD@ze`tBcp^T8iK
z`tI+4@y(BZ`p&O@^3Lx*{N`^#c>%z`c=sRv@Pi+J_lt}5C5@TUGmN)Hq>Ff8Ax~A9
zTF3spi^mR^s$vmO*9NUi4;^mFO_pe4P1xVIH>)E*8$KR<$Rd&JIJB?x@V=((cwHiL
z{@9^`Pd?s~n<|e4N+N-}>{#o;?AC)>RWY+JGt_b*t0^}I=mop2id&Unv>_RZ8(1j?EsudBnCgpG37i-Q>v>Z$}?vKF>i$h9j)Tl^U6$xOlS{N29a{R3i
z3&
ztZSSD$Mpc`oVhY!J1cnSd1`^DaMBDCvxK;0XfKvS0E>T(3Ow
z?v2Txe(m;;zjWiLU%CC^*IxVR+gPqlT=vtydGD=XzxU>^-+Sw$??AlyoA12&+wTCC
zKkb}=N#<{VidZtn@4xezpT4=ied^iEw%(ey=UjR^j^%Yqt9FZ=35i|p6hSZJy~28j
zcxprh^fFU`UNXn^oQ%_4ud4i2UASg(cXC6oKD>V=Co&r`m!sBFP+c%_&d6m`Ua^#A
z6Uhqx3W~B4(61%KTd@ERBC?f@kiHSnR}6VhM&iObJH89QSWQ?7sM|>!7vT>Xpv3@t
z*y1GH3bz)})`I4erB6%zI7^T7>}=4yb#(vx#V>v3>4&d|{SzWPrHY%$$YQ{lRQ~dm
z8VxGnqKjR&-li*c0$VR}ou+!;(wY^aT^C1Ek+mcH$FpJ`ntVBEO=l;DBY^?Gw*J&(
z@Zx{^`OkVJ=CaI%Xx&PNw?TO=Wz|$(ON4F&j5P%dgEw&2
zDsEMvAvOdC0=bL9IMxgLdrbrYQ`dzZ?%sqW0)1ViZ%7O@Zip-d9K>`qo`C1Tk?W#k
z!#nlQ+X!G3UkAN_{B7`WiCuxaC!go~q0|SXP5<<@t^f4hH~#poyZ;C_{Ovn`_~z~3
ze*MND-o5?L@4xopote8Qo?Z;wm`@P7DT%D(DDw-l0M@$q9m^KvY
zPSAfVXx|Llw<7k@mee}Z75?3fA?_CVls4r@$@U)Sil&w^nP6$w$;f*
zU?vrr%S+z*yh}lIIxo3=Fz<5I-)(8_nl!pM`|c|*O&>qhq6^&-oxTLj1rQc<*1Q+=X`MP_Fi3@{2CjBSV@}H6Q?j=}WzOnsfytG^%K^-i
zx5VblLrNK_u;@K2Q>6x9q;V(c^a6z)I`w?_qYoBpY>`Z#V%;zM(oQk1lT_MS*3}sG
zS6K3C-cw^MjX|^4(9Y1_lRj6Gz%)bxRkl&(xB8!cq%l3@{its`|mM6
z_k(Y}{pw_Y?bw#T+UO#dCoGPv#hsB;EF{KxZ4;FROs?))>mvQb+KSmB2=pK
zMKW6*GA}=N`10`st;uky!Z##Borm+PB37{}6>7p+i8+7#&|G=JmFJ!~cQ_Zsx6t5E
z%T$5RRmF^^z0sz9F}zc;_##U{^g`HTkuB6^2U-utOCxegSgJ}GH7N_Wv5>s@WGVO=910byl!4GfZVogA9+IEQ$K)6i?NKiD_r
zfR^(jtqGW?3Co=xVo>2pl4{05z&MVG1a|u3c%%u|Lz2?e1m
z6G)QzQ*iM2?|$m@6)suolv9q(avdfptHw_Bg}S(*iC7wWwjoFt{&BFd27*$~z^Y6K}VQp^~w`>PFa})g_SNDMMOG1a2P8eB=1OTl-UUwlZr-bLL;1a{Obhrre|o
zH4@XP@Lh(|VJM9f+bFXG5r1#cY*mFGzcv&L!tP)+Fq@kijRr3oN{=f3>YLwy*IzsN
za-Yf%!!1TUIHZW1@z6rRm^0O@WVVNmkaaa^g57Tz^0uj5Rm4@1T@{%%2!Jk++}#k^
z4H4+eYyoZwcR_r&i2H8yGz4Jy8h9|z+>-gbfHV=|3Ji7(csID4B7aNdF!}71Vv*rV
z+nCBG+$Ga@VDcH40Twn?5pDt&ByJ;O-`SUWH$QvUP}X9>rD$M18JY9z!z?w%Qj>ELI!_u~c=CzOoaW@&>2-p0?>z7JbT~z+wTnV7E>b1$YQjX~h=UY$3pyK)1jGg%yfy4jRP)
zp*SEG+Wc9AKCSxB=u|~Ssf?=SVW|XOYcgjv8t4m1F7^v2MEA=~8bG%$C){>4r{!R(
zP-RcDu2<;vXa4p-oM1c^5r17)v?V{)vNv9)aRt1mK=Q#kb%{W0ZmdXQPf{7Lc+*aJ
z_SA;WwtbnWc;89NRml0y_%cp=(@#?wr)ke=jw%qjGEFUz#QNOi8*^8_^Of6w|LwPa
z{N7tX`{3;lzyF1wfB*A8{my59{N87N{QhTu`0l5_|IIgl@ZM)$pC1}{<++x;teR-3
zE)i|ppIhZO3OHYDcDy|&(GWIEB&L9Mmq=87!e15AOBA-oQfmEbl_?d=OtH*@nwQ9Y
zUBqtAjujbl*F#5_YAfd|&h|Whq%kLc`N@a+o_eI?aDGL|>UikbOij&NTl2)(m)i1^
z1*QN1t_UjCalK`4xHUgk7FJ4wQUz=SVqH}h>}?(J=2_Lmar34*dZ|h7)UuQ0P_IPo^jqi&bp@HG~S0J
zh)6j!5PA-T7zh7g2QX5WTywX_*8`3_D`PFy6u31RJxqeaUS!_)=EDzu{+TDHG=7NA
zm;fFtEHHSO^M1Cv3_j$4``J(a?uDneEOA{#s{!rCPr_oVe2npq((WOG-YY&Aimy8j
zi>+Mg4sM;yGsZm(yKuIRc6UZg`kqSxee=vG-`g1Z-TQC-{2QaK|M2T?eE7B3fAPgz-`}48Y-i2OjlfArR;hTt<<>WD7QfrdxzxsbjV_fH$r
ztRY{I2e(7^rmbz7>Z&5FDg0GcfLNFKH6Sj@HUoVLZt1H$y(Q29
zfZl6hy09xSw}H3<0}Xs?m%9+RCH@W>ceDdGQgwyismnK2GOr}u831ds$ctZ>gmuzi
zyC@1X0=t0gNQ={0P0me9Jci7{FMUG7#UpW-6uH3(h+Z-^IiMF_?il_VRSa!TW78pr|2IIk=pm`x^^hWH95v#*eTQvUai=X^TbL~ieHi&Oe
zJkS-jK!V$X`nkaUD=u{=&2YqbH|-4Wi^M$*+G=9z7;$T(=@R;);F2ROu=xyW6k1H7
z%@+B&Vm}Yug$8Dx;fT!@Lcp^oQ)tjT^-mQT~JVu7kK
zrOF^M)mJQ2Lcl}E1N^8Yr>C1i3Kicu&-p0&WRnRKc#HOs+`6KytA*&b1{{gpZ4sytjU?LI#oOQuDmi
zB@8jfWQ@`2SoW-dgyEtHz@#zwThIBvvwaml=QqZOU*8wI=~vfyYM%1~dZ%%9LQFf4
z(ykH8HSBW@cwK$o^d8TiE_YfR7F(qe@!ivy{y*14
zM(zq=_B2YT#LY-Npm$Mb*A(`KC0w(`X@wc{%QHEl>ql~K9!M@i+u#=i%I&?;n_0mn
z1FM>ySkQ4YjRjrA?6HEYE&`ahA{KCWO2oA#rZs*gq+iR#I;k-JD=&|Ki|wn(7MgX1D}uZyq+#IoqSJbOprZ;RX=iM=DTw*}@d!R;LxKCDdPhIRxqVg)75*UB%f=5xuD01i+xJa6_;n^9v$3E8)Kf+zL(MY~yfG
z#81ocOBX?$TTR_bkVTr99swoUa`zyS1OFR!JomP@6&_6e8J)^aeY3H8
zA}4Vr79323u0-r^TWhzJ^C7b{fL*+myl?XGzNzB}I%9T6*yziS0(U#Y_fI$+=3Ig2s
zEZDQ|D=_HNuvlQSCj>VTw@BwI!+Kp-r1?Nj!@kVZDszf=7mB{qg6|~fg>A9M7s||O
z&U1$MlmI(*;S`&3l1V$wyU&Wg0>OKh&Unf7x5X0O6t!DYVRC}2Cajkm;%UZR#8X8;
zU!Mzv7&Npc?k`|5QCuuCXK2@1%3Z|z&T`%YkuDS&5am;h`>a3}0L#H#!$4fVMBz#l
zzCfhlYG)V^;2cPQmT{GcY^lVT$wHMb*IG)AC6}sVfk2<(JZD9^CSsk-jW;;eAY5SgeYv+g+e~?hzMuF-MIFXJ9tqnbc1a=pvg*3i=*p!E|8@
z?SIwqPVIK|IzhU7>3M~j!y;$jgy@|BKL(0u{J2by$n=m*|JUFD4nFEvi%#4OY8w)>
zj1yyl`0k*0jCPMuZb0u4(AVec^SLfMoxbigtai>wYfLBf&49S)!SEE;LPOvvpp5j^
zJrC6W@Bg7OZO;Wuoj#twaq<(}MK9i{IC-b`>>I6RuQn8I6}+(W$wx=`W;W5D%D?@q
z+6VpyfZ9R(THG#(RuAwM(CcmUcmco=tyouu&~2yOowVmX32D40%EkhIsl4?RCCF
zfByJbt<1C;a+j@v?=~oWyPXM~i3;VBy>}6fK9`e5$4&1c#>xQzW
ziYo%W%u{PTjpEDG%d}^W^KEj}CQDuAsH?0GxC;OVl-}gIn>;iCtK3ZyU`&JZZgajZ
z)(deB&g6XCoOhG)Y|x$!*fL&dz!e}ip$!2S
zOHDDpF~&R2c*i*37)y<^^e~H4uMIMAe@aaX)Cl7l=WwDEIAMmzWX_VnEb%0BE;1Vu
zOGZgysn;D@1gv6zGeImIfpB~mDGRpc=>5)v<1~GIrmREc193k+L?Bsdxk(4gXESGz&JlME)Wx5H^|tc=xpA#fG1Iq{gpSm~w4AP#^QRAI$AKnqLP0
z{WD`%o_uKV$zzR~VQ~8T%y326EYP?L@ZE@B7SgI>*17yd_mS-CgjE(&;1^gPmYQ+`
z?fJ24&{H68TtBxj)|3~jP8!t-y*wmW1Aw19cKMSJwjNAW#C7;3*JfIP-m0Wom9PqJ
zu`VZa{)xjEpFPreC|Mj*%40gvw<2j(rtBh|Z&GbKmUHfreXYmycD^F_@!?EUg(+e(
zoOhgz@da}Qf?}l=5ZB2_6VQ^=b{eD)7+wM@j4{rVd^JLM$8qnWcc&rx$beuxj{Unh
z%E*}m3(p^iEnrxor(|kU^3CZy#H7fKiS&p_Z9M)EeANH>-~QXDkLQ0TH?|>j^DKxj
zqIZh%Ofc>-#yyGv_6+$v175e2c|Pw+>%`=9S}Q;|{Q(ESgu#F6`gH<%?80tfz%cd`
z@A=!hzy0glzx}Hk615-yD`?mL&0jU{c>sV-)H%J`ozdp=wo^U_v=|T7+qd^Y~3{F*n=%pvImzSB7*(C*KY1^-X*?<0tgKs_g;CyCeDs0V#
zjA>Jz(Is5t&yZ#{VOGU?GZrme0dUo?Evn*@DlX%ERj9nMosrpjL%5a<+|G&KNQD**
zX;PqPWNssDUQdOG$<}_i7r!lb0nVnKWh0%j2B@V1?Mia*cX5QA`
zIG+FN;oPh7z*^7%TF($$n^ykfSh$a2j!~By6s|=Rn>C?H;V)QvyCFA7Y^^{8dI7+f
z{Kh$1Xpy;IzcHDJ^ji9OEIb^rx@GQ%Z{eu2FJ0)kAW(B5>k3dx6Ba`z+L)=XhwSU|
zFfN#HsaGv+Nfs7)b_Glq+*f25SuY?EVxG!aK`wgNS>F~F-?{5C1|0_{e`66;0EN;vijju6v@XGtcU`0fqGnI2?^zSk51XJIAX(%YJN
z(^TL#WmA{0!A%UUtbRzYeDO^eVOxqZ6y_6N`yAD<8M54@cO}=
zVN)56RW)K2KWLY*R+XCFWpqQInga?z@{
z8AyEvB6g-0+kV~*bs_T<}{lD3_inV6p3CS?#mf})szbM
zJ$|%Uroe~@ribVP>
z>ptyEKjGbT(wkl^&@EY^+K`S~%(_oe>8E_@#k{WykQvZRM5d7Q0%GAJK-Mx-Y)l4f
zf_jyu_B?p7H8WlcMym)#GFzxH)nTJHY*hKxN?Wc9o3)8xT|Cg79c#*t6{>uB#6I`n
z{@zE94t(;d%b$3vWq)>AKr1n&wgXu`j~?nizP~16H)n@C4`$Y-0+nI4GNjbTO%U9=
z6kJNj{_==YlQ0`|g3Wp1`b--dO?xACS+?W2*pyj#Sy~Y3GCu!r$ufCQiweJGNLz-ytVvUTZ6suj`n83a9{{-;wU&eWM$B6D
zD>E9uY%8mNb=i~`$@Gv|w@hMQ6P8eRReaXM+U9AAnO3+ZOJ4D-i{lS5
zjg?k1Gs=0kvqN8c=GdJBsilB2#(T$jYTi`tP9MmugjoR)Dd>H;U{znZIc1eF3XO6^G-&
z(O9Tkm9F@WLBBo{k2n{ah=&Gr;fh3G=6n;Hv=X#$X2!P?LHJm!mI4f0)ujzxSy6>$
z34DxJu9?p4PXi3bFKT3qw55#z|?gr<6e;6KOI@~
zr93?QWltk_N%Gl`zFUC(xI8E?AQrRAeuOU3++Fng0ljRgpMxl}
zXaI0AC^7_`Yy*8gXEe`QovMm!6=A7Zr;81yK=GayTxVs^NiH3rTcr7lGzxYh3N(13
zP-cr|1`nDGQDzC1L8T_FR_I&-<9fyYw=cRrevS5|m0i;r{qp*43I9YsrpO
znPL&+D&*XSg7>BLzpe`#7Y^l|Wn3?&{naU7T9qzVY69qTm93VkVr|$zUwWqVP~J;>
z{;JXt%Qdcma~Fv|@YezY-BZ4dvy7)T8EK6AOTnr|@M#ZR{4|{oR4!NfDpRSn)Vf%x
z@9~E^_GQ<=zwhDP_QQGg$*2b-t>|iZesV!86hb2oiOPflz^+ai)tP2h(x^(}c%-V7
z|H9)3JC5hoWCzRPgoIg{#1ypS!8>1(`}i1V!D78rJT=C7hgtU^lQ9COi&QFc?V;F(vtCBr$^f?>2}5lK@C#Wb8zv
zYY#TyG}46(&;=4Zb_Q%qK=r?8q=9H;UfPkv}ykFi-`Bx(bPTH*FTvU$W
zE?}Lr1hfY6omYh^ksjxLuO7_&@+XgO#r<%EbTZ;-X(tiw4C=+2EM454)=GeX_YvNA
z=lK3Fz3}AQj~rQx*q~(N90hjvEEUc`@(aNed)Q!7Hrj7n8Eo9{rTf#
zgu6nsE&+P$!E_}CaNA|7;JXbndrlKBSQ=J7Yf@j(8j1$affgIeQhxSe$nKW;Zh^jC
zUIG{ThadfLK;sAC2e8#~RT!7KLDmN!1$=i=7p?`&HA|Thm{mpGP~}yLUlHJ@j9%ub
zHJ;tznKckc+OQP;ncU2Y4f
zv&LGjZCTjH!e*>Q+t%dkhI-9Z0lgcByr#+Prn(Nk8_>5x=AtIes^YD@#GM0KcMfN-
zWQN8}aV;ynm;uTF8H09Btv9dpNA~P}+3oIYZT|SUAng|U5bmRVkn7`9fE`^PY
zVFMZv=Yz)ika<320fxKCO1*7<<(w_ISaPdhJr_XwHv8}2kjhtV?q!R8*`iMp*#+pH
zGAT!M0lKh@J-e8E<_bvnZGnYBpt~cxPP@>?Bs1)m_&ESA;I=%-mj*~1I1L!K=<)zp
z1}7U-f#y3cdrnDiklkXFDYZG^agk1!8q68VbBfP6&1akyJ!eGsNiOXK^S~J)qfqgl
z6)y=XN00VCdbl*86zM!zW^GUhYLY#q{p~DrrTqMvXV7Dq)<5%lK
zW`)8x#RBblnZ=4wEVC6lUnF=-B)ZCyTT;PVl7Fr;Bsg-G_f|)(3cp?~^JSJ?;n!-z
z*0~hi2dHO6wmKEAP6iutV#BANzw+!8&3TD3{P1k4#n)#CYEyP)NUe%!0N_G{Ew*^z
zXy=j4OONeq-50J13e^B$zfciXEK(`{MRwoUR;OZnWST6`N-A^2tEBOIy(s(OL04P)jnsEaPH=SOqQ7
zV=_G=Q5%mu=zQ#VYRaw}{2H7iP&n9^^WIB7j{|@i_b}rgqOkHA#~tBxSMEz**98yu
z0e5-Q+TD9vU3<>C_TUI$M}kQ;)}JDcaCgU&KMqG40LHrv1{((bCDscn4D`)t^JR2V
zI78$`9JcGZ%zFDd?;!6Z0s
ziyDR7DUk-;E@;A5*t#0AW>tP##y7<|G_ar=2NcbaS)CVw-qhW*KVQ^JL0>eyl@b3>o9l?2@U8a^!1_g0(Xh~
zx{NCOxr^>gU`)1%+ieMBOJcX64fG|`
zO>Zk8yZolY!&eQsd(+mh8p^sMT@UCtL)JPdZ`fM4)MZ=U44YdKdovN-%8HH~(xAi)
zDct7X#C#&q2RA*IG8#4~;-T?qaA|+m?WZ1^%1&Oiw27Sf(&4({N>kXUTeso-D
zpASGo?(nPKA+5u&bcFPdpxO~oaePrgZ2cJ*Lu-(Ewo-tJCk;yL7mloXLWC(MZv)mlRXQ{
zE4yI}?Lv(zP<`Nb#TI*7bQP(-LIu3gjTn|ZsKTljRJcf`DuWV|Sn+ipKUkj=g_BD)
zrbzUjrZb9oZvpQuHN^8r_E!hBS3G~)vMe!VoJhrNWTP6~0_yOC+k0_k!A%Xy`h>c``n>K%l>Fx(ku_j4SAvN
zNB3TM>OlA7`_CQD1nySGwd#}!u3Qq9OJnN!Cl8IBe7gVnM=MiyNmPUF&R669F^_LpD%GJNtM
z-MqeOiCY@G!g-bi?*iB}=sU^SO)xmeMWYw447aB@lrc++_hn6SQ;46KHAxRrs=LvqgC7>_eq-pS9rdmwvOm#0N>(KNPm
zQlEYN=+|F(;#w*)!NH9YvtY<8A!Awbg>f|_F?)x{d
zk7_*J(e$yNc}v+0S#z2Qw=mbDHt7G2hpt*ojp)17m6juV!z5cgg5rf=}x8w$6=
zdS-olW+`AN05}88brJyV%b22Ez+fls43q`a9i=h`QF-?ac~N{v;3*_D&>GX!KwnVj
zc^X;nC^c*ssf-oOnY%YxYLoS?g9i)LHcp3$+(p?XOFL|dWDv8A0qDg^trdPt5wB^|
zwk~aH(xxV_sKOE$aM-*Z3(l*;R>ax}8Vfp3`8{V!Ljrwcf96^;aQ#5`h$#&oo|p;f?L_V>=OBV=Ye0cGcOS>~zG!kUn(T`P{gTO$_3%-4A;^kD7zDk*VC>~B
z+8H>s>$rj4oU;vWwj==1WlNk4v&8^?0mF{9-cb;^2C{!IuGWQ+tMl4eFkm?6t*%E?0fO4{^uTR-=8d2nL?Q^
z^Q&cXe`RK{zExtU!R|LhHsM?krZcN%Zz&B=e
zAIs@`>R?q|D-Vg)akVC{He^}thZ953JlK6SSrwCO6WY0hu?vsyzxc#~rv1^1h|-c5
zZp;plLDh2aGsos@&vZSqzYdN7eUoNQ%0dH<>ouAF#{G%5^?D~c%n1_}_5f~&fxAdYv{evdJehF_O&Clx7udPu!35QKDKZlll642JfNDZw
z#5Qc<9Rb*wwI_8I`C}1Tg(pYa@L4
z|M}nk>$@#g@1OeQo7s^S+O@=ai2?hjuyTdGHLxE(Fzp!yU84zuX;(k(>Z3C*QyIO!
zbcjnnSC2R2yf>p8*Bs2~bmOAGPIS1^b^~@ZI^YN#2XzL4_PH+7?p}fe5?&zg5J!!W
z0%jaIB+wJ2TbB$U!r@XR!;Dij&%@`WGhR*FZ|zTPMXhO59#Vu6RUFr)DHCH7LKi1g
ze#Q{*?u)&#KelEF8-{SzmX|bsUgZ`|aU-N{g^g8P1rMH7*jZCpiyAkx!z%#|-&dgE
zP3JIO%;R`1T#b>P);RbDZtsn~d-l1vj^{7?^-17G*t)$hb3R~9Tk2MJ>_$#}D;}JZ
z`4NepiD+Ls@$|dJuUyNHO)LBe+>^=ttR~LDWes`G{)@Wuv09l0;zHDsY;%LmIR#d2
zns`nV>qMqm=Gs-U1=uVy?TXN?N^LTC!IX!?_E;ov$xzw_rdwosB*qzA_WirJF0r1=
ztY<`G;k~CJRN-pKTnlJ(3O~tF3o?(Dx|+P93c#Bs#=A^=v9_6`Rv6C`ilcj#_O1iH
zKvn7VRitk^h%5$;u}(Vx{u6WwcQN6-OI$QyXn-QG;ubClCJg}2fLNr`u&KmLdFUDFUgGj|Ph5QJSo7X!MNlp_xnh$qw#ABw
zR+BKRV_IEipe`#^<`*kNQe8r?OX|Sgs*qG36l)WD%id7?!B|7eY|ON03ZET*;UPFu
zmojP+S`9!nra+@EWz}c-D`Q$kLhpJcujh&U_M=%fNwYaO)Nv?Pm*p?=3*`}Y?BwGY
z9@$&s7aaE`VPSwG$MvRz$qP>&-ua5$$A`m064;Lm!U~NM)-}v#jAH5-^l=BbPJl;_
zFfItJYKHSse}TBT0K*8A;Q$q!m>dWAk-lNhjbIkw<(LWvADs}KHF`;<74{tCb>JK_
z!!wYWq@xAz7(7dgu*L-+Y@Oog3CTAuc}FB~zv%t&%U^&W;kWO0~lvq#^S7ui{1?2
zF$u6_h>VLqS1;x6r978>uyyy*o-2%Jfbk5&?}zh&JC5=+Y{$t2RS+bx%;5}EA~!E`
ziBWhZ5N
zT4Clj9+xU2v8)SAvalkHo2IgE$jd6O3^=Xw3qf@ytZzom>&XC6X;K8ch1at4IP(V1
z>I^)Fo0uWqyPgc*J&?7P2+r%$7z>={XJi3B_L#_w%j~Q!&Vfd2!XQu2$AjN0dF7px
zpS-y*h1SdZrWAfc;m72^JdtFRCW7(;cOmL!wo&H5cUx7VPGo_>K;LEnvq(2XTj85T
z=A6v+n95+tx@f7;?$X4;fH`RE-2&Ccx!=Cn4Hy0W_de(s>3+f2&v|iT3Ymi&9Qchp
z{oae3u%rl!61Oa}Dt*hc)+vaM_c868v+Hg
zyD72jB7@5&N?^UhbzQz=>DNu=sxEIC%C@O&S?ao>t^tEhZOOouoUg*Yj>N#XZ6g_2
zO$KIz>a<^5N(5IkBZG$A58nVo8V~5RiO@_kJRG(rlA+~;*>n4ogYm$Xur(0%_XdqF
zQ@I#2`od3jv_7(rGJQ09`+dF9H~#Yop_~g>WoyM_6k^0IMzc5xvi86rlG-
z1C*CNVX~)87S|dwnVrcr9QTDSaMvQ--GS~7eTxG-^d*#a0__%a&H)Z27(Lht@@z3+
z+oFqXy4a!t!w@ATz<>)iZ;|dRf~|^Ci0H*_xy2PK-V@B86Z8YHTNRRPfkr{GM5Ru%
z>4l=FRAUNMUrj`7PWjJp?o*(!8rO3;yEzdkRk*gj$!fn+z_?m-;YQkryAk`h$_EUDAENY-LgN~eQa<0fvl>iSsnM+Cd0*s03KYQ^f%{4
z;n~&$neB&j8nQ!`5fyy2E@@T3CkaTk39~6DSRIzDf>KRbsY@6w`y-u4Qk@6m^$EQ^
zAT(wB&*euu4kfw|r@D`1b{)-ZI~Z%qg)12KDWf*2*Js***!F{o#+*Q9Os&nd+72ap
zp3Lt$p3|5c0+0(Z>;s$zr)}nKoJ1dp&hVx
zkWIt#W+r1dA&i-1$5t`zOrYzerZM0kNk`vfGm0j%7PHX1iD)wV2-@hlJ6*hZeD?&{
z{Z|Yo*mjm!Aca?C&=KifmH^chv@zEWB$lXgg&LK-3kS0Q>mPm(KgiEN{pLhSpSQ$Y
zQR|u|ugM7DS?qF#pN{-2_^~nY?g3Nia2w$orZYf=ce;ehG7SBc>k6Gg0*??yCdX-n
zGyoe|JIs2ASnmiD*Eh;z8TL3&P4M)jz>u;goF!vgWM^@r3}Ig6mt|qgR9}txUrh#A
zOnEk9&+gBf%8t#zZdQ0ctWRkCv@XtQ;uJ_Kj%gNVHJ%hk@e72wYqq?IGd8meDhJjJ
zu^BYBLe`=puBZTDc@5Ab;}j0?0f4w5*{cEVW_Dyd9$2we96GFWOO~{RGe3(niZDcD
z+0@O0Id2?4aCd+9O28mXIPkNIFr)C}@CQ8R|ID%ctyplJWiET&8+n;uJ^lRWKJmzn
zywtP;kmjc3zg*#5Co>HS)2Nc1v%lPMu|SB@~yyKi92toUAhbs
z+zKR?*j`h;0?<{2PKoQ&HIhP)^+S55V9z+RWd1&&%|sZ|cEg;!bc8s}XDU&K0R7m;1;!3C6(1oDpf
z!WNDrl~Ie+!FrvZ;8h>GGEv_26$~UdHW0cQfZhdPIs~A1nm~7&K$mROC%x&!XfeiV
zOg^Ld68Zvz$MD&7cxuMynuaabYGuq~-BvnYnYgc$d4_(5CEwYbTnL*>F`P2&
z68t~0q>bEIpUn4TNwYL)DT97(A`x6Wn7wu|cQEX~WNCx&4c;3E*}W9dA%MQ;Z56B+
zWcPePhenrQ>k5GKB6Puh&-oRcz&Sv08&qHm?%NT9T@+vEOLHF{&l|K8FPbR6pud=Q
zHpy&O_d0z|3hShh!4$FHd&)~v&A{CNN-glUEWneFUL@{L!WsK|0ln}na2NF#VGIp8
zZc@c2Rb)`b1_ksjBQHFwcnV}!k%F>Yr20w>sz3n}`-)ZHDK7ma^T25)twi*e%DyU_
z?*JgB%tFaiD7h>AVol5_(b)pgizQkbbz1hE<}wN;kYINqlm3e5fm6Ocg=~5emr=l^
z7Ye@mL=flS@O->fqR!IkV8g)R5{W7id=&~?sq^JJSIE0hdH0lC@?3e*@C#4ZgjCRC
z9BnL9MG{pc)5RJK6o*EMDRn=5sN=!CK;j~mDN^Y&lP}e|0?|`!aOWR6*s?cStZ`+w
zT%QT@n$>kAuQ?}D;g^baw#*jmQZ^tKI9iu7;a5@N7wV&WTW+X1#}7tZ5fpolWsf{}
zv@)uc1h{Ij+brwylLtp%e6%X6wd{-aK6R)uFHn;Nd)C2yoAcl;5{-GGx-7dkWkIy=
zi*|zbX8UV0t=cRb1Q*O0(0l2bV;7z{*tj=boiJ*W20T>-U?yt=?|en>}
zdnY@*ZAk#&CEhpBd1m4E0;|2yu<_0SZwL^>@I#HzZcInxcuUU^1mhk87&ERxCIbS8
zT4BAk8;&D%In>-?_-z1mIckijNN?^=@f0{EW|d`bLE)BV5HK>qgUoIPwOjegFP?n*
zt0gaAJDfKe(5{HSL75rV_z6vz)c7e~m@!0fO=m8V84`eA;4UC@Rz+|^kX4BU2po?q
za}zidB)b~YZfA#I%ZXf%So3745>6*6vvY7}KwS-+Yhh#AudIdib@&5o$?z69W|u6e
zFa~!s3O8@7D-mle6~37hTd~v$#^>||!%YB)`Y
zrCXEQB(_atdUbgWC~K;h4SCqsFG}>}q1^x9|M!2w)xX$zZb0<)_|irNYRQ)2A7d*K
zSoW*qoDWQHE1)e1^f>KW64@OdS)}t}(6^
z6kIZn$SJm>vAPOPm((^dlaqJ3i?QrW+eNQyo=TtdrOi@%W+<#up6~%s_l$ef#<3H3
zXME8PXi3AVy#gM?2@~F(jP#TjfsMKh^d&=;mdMB@;=6z9w8pY+CIbQtc$EeH^9#bGGJB0Fs=
zOE{2RUx->g65WgS%u>H4&1FWG_NGST0rcuTH;UFfW+Qb2<$M
z{DMX~J-#Px`ZUlNJADDPh}g3hg}4oHWTq-iI|GIt1{VjovY>FUq?z!QH2h3yfF%J9
zLSH`(QG(VB-1QY3zH&cX8RS8E3w3V^yoKQ-?o0Gn^A@Y#V#QM=dkQ4iDei%qh}xDH
z2MiZTZeZJ4(S1h9I4ih-zC}Q205+dq7t`DG<0U!`T3l`MQ`1J)L3zVfKtdN6kR;oP>p;fj!06_FdWtoHn9
z=izuwOsfj3lP4eR|K#C@Y#TJUJR(&kjVqrx+(eFeCd&<199MSO~QbuYEyR2
zzXy83`H1=9m?9u07Bla-U;?Y-TdvMe{5McF+EgVFbCF?67i3#@bvb$GC<=qW>C10DdT=Qj95!X}hmn9bW=Ug)IHn5|x-g~lQyMp|@v}fv9SfM9<@~0B
zc}PBPPU9AIa9?O+XDxQz0#kAFNE{#pjcJ+1>Mf033@WQ(eJ!9ZY0|vJ&tnxdh$)tL
z!EXi{+d1Jkj^}N}EF`Xga3$qeIKX#O<_3N4g`n}p=O6#fqldR*0W$9)yJ#uXia0L9
z2?E4~#Edmk@!}{jH3q^JXuq3coMQ)k(uCTrhp1CUWxRN02
z!wyu;9+S*7+U-sv8d&S#cEgvk>P~6Bv5Plt%(Dl%i@9i|H82}q3+_wAH*L}9B%BewV7fruIVydg
zPG4f&;JeF=2TPzCH~d^{B7(e52HE3QB`Tui-#JvENwbYA#{gPkr0nJ76l{-zj1Gat@q79&H%RpbiFeaaYzJBcVZG(oR
zzacEPa=tY8;qju$KBrU9Xx?XmyQI?>(0hVd?@q#bXNqRWbg@C&PLRT8z-^F&ZOLw3
z6%rQ>m@C1uXS&o+mjxIIM676
z65UsyVy|tMRUQ;8gHl~YtBxquQMD$n*T(d=
z{n4I>a=MSC>NCyqkl2{(?>d@w@sYi7ThMhl>(Zn9uRL|Q?O?nzB7p~=+aI~~a9-EZ
z%=RNmh|WWawtbPtY`Zq80dxVqaFN=SS(8N8b{)^{`{WT2V$3jS+MvZ{QMoc{48Qzz
z-!l(2?vGR@w92?%lk)F;MegHc6nL}CRAeD$Vo_(YHW)Lp={um^?c#M{IZl(_Q)tsT
z6Tm1L&*QxIp6P<-4g+*KfG!p=Zb;RL+A1-eii(N#e?QyC7ip8$Q4c
zj!|ajMS4M`AQnYxNun2ddRgMPL+0BL9sHo=mmYWLJ~HuRZtZb}BML
z!*7xXwOzE-^`NzEDsWe^mKk{M;r*}e&)N*z6CyiHCeng)W)ye}d0K{>18pM`oDbRK
zfxleg+~O>pps4zH8zi<_0RsjGGmR1h&;ffuBrp{V_UYnz-gln$%s!a^|NP6pz}tMjwP}F!US=|Ssq|5va(+92VW97(
zDKD%1x+$&c(yA(KYT`CdS*+aD)eVVX7nm)HTj!}|GS9{;rkB&#K_Z>PD^h{wU=-&71})$(q}`)gsn{Y)lp0CSGj(T
z>r?nXLtfdRT0f9A7_tV#)>Kw>Bp$jFFoq*muU|WFsTXYRQa}g#b{cY*B?Ef90k>Gy
zEO*#ITjMIJQF(#B7K3v}0)uz^dLec?eUZBay`aK`xMe{ixIt(jYhkxM#FYiuGMg#2fWb_8
zfT@68BrXP^7wHSACIBur0mdAhP!78w!Me8;+*fv&8*~+Dv^d-34L>hU{+0
zG&>H)N_FZK^*1FtHTcR?m!E&EJ~vV*dkRGt0J79zi)8OvF6|7v=M0xtAh=2Z-XO1{
z=PUL)t8uM9Y1F2So=08Y+aUBn`wdsH)Q!6GW~U#n0&4R$@~IINTwwBf$i{7ywvMrV_)wGn*jhO^I_ro4Va*YE8s=k
zqrhDUy}JPjC%Ix^uzO1MOiN_84dTR39hQS$h!F^2jNluV=x@zVIX~u?M+VRH-o?D+
z=Hb0VhB%uD+X`+LhvqP_z=lRTpIqQubIGa
zZPQlP4RJfH-$>Xu;`Vkxxf)Qf9Z21L>gdfEo>+bC&}3e;-xRM%%#g^A%lwos&Y04)
zAx-H{dYPXw1c2@g_UU4f3^O;QvC}FGc1r?Xc1Fj8=({983~-%*k6|k}Gs9~E9l5It
zi;6I>2;jItU$_pi7SqT`T*UK6(AbJtiI~oYi@ftZp==iDP65qfv<&7N|kq=lpK}{DFPF_1M?T
z0)4UA3QZTd%QY#SW4-kx=M2OJ>vguxKxK((lesQcXjixvfojJTv~*tMyI`01T~N5o
zn$WATmqeJsVs7dI^BM%0Ea{1V`nb3vEp
zG+`}dtOoQM6=wrq3~I{}bIcG26n0SMhjnq-kcJI;%+@C3{+U#0By7#+#8>xcO(epX
zEcJ3g8;J)l+S-+%(PQJhLRF0i)M3O^iVz-z&MaW}{UfJ;rP+@kShiz+jG
z#k!|Rb3+sxZfKWkK8Ol~skGQKldcR)RZ#_zEPF~+?2O+^PL*g>u}T4D0m)TL5{<#
zklgS_q(>Q#j3cM9Yk7nLknhw;@8Fhqk8%iLXyD*rl3N}p1zAp&79JNolURgBK@bLe
z;Y>I}9ND{)9i5N)?>uziYHn;w
zre8mr_vPmwd*fLCtNGctv!d|l3;t-Y8RBN#zI|-(mkM8c>$xY^bK>)<(0op0`9S8%
zzSu(28r9h`FjQL_k(oh}o-)K~Q=B%0SxcHR#Yv5Gh)Z(I!ki%@Zb4h&J^&0ACr{>P
zb$;ID0k=~sGo|c=^Awp~8B@?WdxpZJ6QlA9E0(h6S64u6z-wh@T%zH!q%N9VP~*pW
zAH3Jy{M4QO$*Xbyk}1IzkiH@_0oab&w;s%U^RXjKVS8NW<}GbGWG;n_afKU!A3^2U
z!sceozi7zd$72G$o(yi~MB#)PU7V2Eo$t_}J+QAA&|4?d^)ij_3jmhs7L9LGS@c~@
zJEQm_eM!REiB^dN^frl9vqX36LXR$W$ZVTPbu0W(&=?LH{g&FRi5Fz{JWpNV+&!%O
zTTAose*f}6{>SFik6z(C{qS|w#tXaP!On;ykX=IDdmij)E@HRpxTG|kmG2~QQ;S3vlhAGTQlTzn2M}nu(
zp|R6g8nzTwx7j6=PDSYR>zDodMN0(+cUuZTx64wxES#u$Y;Us7l)3^c$Sw{jBDKxf
z(d(2q<766`bKU_kX*iv}&X?vsJbt0}URRC}WtOcZbid0vjoKYmZN>m`Ft5C`SId*Iq^tVXKC{)rhc^g*BOa^FLq9B98
zgMoR~A*opMwB$rCKXt6*U}Qz*KNM0l+a(2Jqqw%lZE
zLNc6FX0jC)UttU7IMt<4VsfP>TOE>tyP&xsxD^4AU;z%+#Equha8+2Ti)zg&yD@>Y
zWWcK+u#7pP!Y*L4DJRg97dn?81>E*MmfxBeDzn+@n9{N@)O9qo`*3E@Lwm10eQ4xYIq->NBhNkDbtqLGmOy+Pl14qiILm53m^gntukAphF*^XD#Supi
zeN$FLcAzOQ+?*GwPx|WC)c8zcu!yIf;bBFoewt$F55)&0BB*qwqbN;l8xP{YzzK;Hm
ziN0acI|K}teB%l;se*vg&>oh&1j$sN;Je6s@o%_5^~&sJnYk>{eQ-`t9go|iVRIy4
z3|s0DFf6QYEanMWpaTx&Z6ugTqEr<2(xF03h014)Soq*dZQ<@9vQ)E4&2^m}*1s&{s
z0@P7vhDCZYYJc&W$G-6N!?*J@=Y#sRr7VR_FnECX&Ufg~9v=g#g#g^vDWJcI-X;w*
z&xmAFX4Q!KXVUvCG7Tbdmun%`+bjZr**1x7mFQLp#FuW9=pIezlDW%JHI<}PaD
zpsn_Z^aaj?!MeYH`=;~8pKhog;=Kc`XPEa4GOjt5osnsrD3$Tfi}a=?Uk@3RjAxdo
zmIY>0=C2#lRfSt*yvu-If!*Zj1*Pd^nNd5xE~3P^IPE*
zS6-awd7MZvxbF<@A|sSsvp8TWW0CbPu%3C=vr1NHn&Z3x-A#oDgP(=toOhD;tef(+
zps@uJwl)F=7XHcXYq^OL-Z#K|M>TFStj`6NA(a`2yE9w40{_68fRknz@_0ZWv=sQ=
z4g~eN+{Ab?IN&!114duKIBzN!Oyvq`L!;A>F2O+y(F+0Y+d=wwyKEIq7odyuCFq5~
z1}N_?aoYlFJ6bR1oH6YTa(o{rl05nU<}RtRau&}wsZ(T4g_9Pwv!((`L__R2u^()h
z0tqhmV=a{f-6GIdklG-(gI-5@gIr~ZufQxcRccd!TPNTM383%pkpS|z)K8TIhHZ>;
z%U4FC)bx}X7-a^yue($Qh4q#jR3(7fW-4u_+yY>O(Yir-ixgLx;jJ(MsDMvbx#}qg
zBAQ^XG>{m)xy(TEEj3u+XpLVi#nP>eDvJlrEzxLj)^mB$OUL&+l&y(r=kkK}39Zba
zOAWfrV9E>*&|7A(aB?~5FQC_8%WS?X1TUJ+iGnWk4JorGWn6q@@947+
z)n^8~j^++NbF4no0&{K14t5;L9eMHb$&*jDMv5Cp7rUBR$7+8&Xzt
zP7sI-0B*>#>p+FG{B8SVt$QPwg-+V%_9r@z6Yn1h3QwQ%aW&0^bCMQOEkcB5YCk8QH32*7zhCEIAQIS#!admG$w(O
zproV>YDOltQ3@_*;0WuVh^t|tvV%+j+`BO!879mE{Z%RV-6Wi
zch*qRdcy`BnN;~D0Ienr33!jPlnUKBx^LD}1{u#F{GHc?`M*335hk25=L~R_G3VTX
znP=Pu1{2wJO0JkDK(a!5f8iX7ZUEm!3`0;Y5_L{Q?zW1)PK5{Yg+{l+_QBtMP3)H0
z3jkwHysU5+1OTw>BIo%`N2~MpKfHTuP+|sH*OWw0OY{s*Ax4km5|}=4!F64_YD&|b
zcT*Qv;b-Q(D-yFNv+FVoRGXvRS8;j@enVhaSZay(EHa)2z%a_O2YBoxeu2Alq@)>S
z7kw9?3-_%!O9pZju#Ffm|Y@MZ4<4t@K54-Deel5m}j
zG1>+93R5(MXPR+OGp;E*1K_$M(3=|0Q@t*6;O(b}bp{3w8@?ixWx8B+u;VFVYv3x1E?S
zPN_lY3k{TDl7)8u)$YRsJ9o)ERxj(mmkkQgi@T)9*C8=>{n{L^uduuOitZ$(VHd#+
z0CvQ;h*U2FcS+hAD7)jkRUzJS)(Ssc835}A7(1Xv$E^x5)j_rjY}ijDYyEU(fPsUs
zi$`_=j0}dY<*P8gWxBi4^3}j;map9Kmg?>j&0VayN;DTDnFLU|RP&UoKwqW;V5xcw
zBo{<69I;qnFc7rL;;Nu+_=;qAiRvrUnIhRsilu#6evH$1cuNhcOb7AxmdL<+3N*S{
z!#XeEZgoI{EugnVXDV#2Dkzj%Y>CN~SPV4kVp?lf08AG=yD}tJ1_Xd;RY;TDQBRSJz}+GE
zGeWY*08xjvu!YkgfS@3(1GKA;0$`^@8=yOiLtSw+4v?4-dWX~K%>Ze5iY1^W2b~iJ
zQE(BWBRrUE#xN9l4V)%;
zhOHMz@p9N8yCBEj35lAPkwXByaa=A5=XV^Ju%LQU!h?We^kWeT4QzJWumy6%c1)%w
zh(m)+gHSp+1j6CCAg6)2C2RgGfL>>45FUXyf-RX|3TK$YfIt2kzhH>#0d3imalEob
z0XX5}j{72RNwpNx+7L-r8Bf5cNEI|-ctU0;Bp@sD7yvwm%MlU=t9Ty(?Vb0+w`0d8
zW&~Ih^WWN=*vbse`&HN_J-FHLPuZmRsI&aZ1cFnC48nZcJhACP!m
zWLLm1Io~3SnchW|PHKhs0gM+B!x?k5YuXt~gxO=Pr5bQ#*SF`A54ei~0EXxR27>{6
z(=Oo_po;+Rr_u*0xO>GM5!~dC<1FM@a6bx{g}X%#cV~HeQDhe-Zc$|Bcxq8%<|TSX
z`|8n1z5kXUp?J4Yp$%Kcup7FNtN$nlNmLBc?QL
zt0R7GG-OW30^&Y*^ZYs(No*-kQ-Brq5O?C>~v|K@Oh(PW-C=;sXTMT>>@i_mZw
zOcK%e4EPm;c}b^V(kVdo%LenOb8MXU`3zQIk+d^TEeQZ-a8gMp2#L%63_>@+VZu4Y
zREB`ZY*iR+7>+a51hmLt;IzYCg5>`Nz~I5Q59w=Dl{Q^zf$T!~s{K@Tfb9C|>L9!X
zph#7iRBc!Q*q56$psqS7mg+tLe}#=ls{CBJMVIPc6lDXn*j1#sK|Ncu164L(ro+qG
zy0F@k6K>rbuL;TJ2Asy!1jR}}M~c5ZrG~f6LJU_2g!+gIiV0eIE_BZyZ_M;JrEHLC*d6-hv5ODGMX=i#09=zaL7E#D-rBm+BNk^A_-Brt}fu=p2%R8+a)2-+~6jsYmW2Ve^RT%-}%1#>0!S%6YF
zNVM3Y?4N?rmmqoP3W!pGH-M7^Bm;mk0Ir0!a3lkdFln%b_7DfJbzX>9hI5d43su}}-A?7+G$tk@dIaVx$N
z0h84bqkw0mEC#OP0MAMkAaDXi69B0&_$;>Z2(p||6TykJBZGgyeF3pf;GakAvPBif
zXK^~^DH5p2WKhtw3K|VEif=bgE`{jT`8iVrkp-RId0*ftkXXjN@q`So5*7`4!4zk7
z4n7YMcc)(&i>NWDy=Y4Fnm8@<;}Q$9J{?f5=EZLAPi|+1Clzjp^}waZ0KgKwJ3pat
z<03OayN7`_aeFajz`G1_^inMN_9q^Beo|as>w5CQ*Q12p}7Ac4&H
zYT_jTum}M50Dv#D?q1%r`RtRwegE6e2l`-hZ6c__7Zmz1@(
z%X5-%L8Rt6&$_~`$n+wrFuf`<%YtuR2iF
z3MVi1k>z-CA>Llvb(zIUyo&>20ntC#gc^w91;#@o;Ou0Sw8XbfP+)S8|?d9*ehU;8u|o`U9KcN0?QZUhl^@LkipsUXKTs
zEM)+mGQ=hLc}3r>CHKP3FAx`Nski|JV^HJ4dIvyu{rYTXcr5DgH5G^}eyz_^doA^n
ztqp|COSamji#>1!zlP`q7?ZI>V7*;rVInYHpf8Ro0@m&dE(s*DGqR{Fs6mj9UL@{4
z@dXS!^u3?xeMY06!=b$_0Qd!iei6uOv5p6yw)rzQ56XLjj5vCklt90r(a&qty_4Yx
z5E>WTH*pG%f&f?KXG?Hc5sv)@2BZ5rvWpVT5cC3ZF|mxw>o7RP0(}X0S->YD=nixt
z90o%;$MGCE)6Z1dbTtWR0B(W4RR~>QIfUWZu%|@xlxf}ygR0P}V%b%qxM8;hv{eIj
z_Td)VimQNoph!$F(>x_4iH+w2J}t&60V}thY&KnLQk6lzGe6vx>j$*MkupqTvz0bi
z6BKGfQdI!9VqI7UP6L%80JPO%5dv5X+^vtRu&o7u#hkO+08~x@xz+jv;<+)Y!7dzx
z-C8)FWwsxRUw(Z5mB;fNQU;hYP_`juHKy$5>>wy_+dgnyKbBJ^4KUsMq+Xx0I}T^f
z7d+edSU$Klpt=zpH)+)-%$_5;1CJlBifMq}?t`h?xBeJ#vckPM0uP>IGy3Q>h<+v=w!OXwu25+}Ypif4rVHW=
zNARwFm$E?IAr2>h9%5Y1)!-nyFOtASEo03h)n|w?~oXcIUW2M-g*E@4A0_I
z!x)I|VNh7)E_U?pFc^89aW5kcT8u9tay&+Qf6=5tmvJg-oWRmK2qcCh_b##%AjcdM
z8V4^4K8P`#!;(TYk}NJUPR#2ueGB3X1P;f|^6(!uzT`DCr0wAM6$^2taEJvxWfh#{*Rl4{56bZC;lqC3riyrU3LE;^7azXDMcX>fr;QI=XK=85(1J;~YJu3d0gJ40iy2
z?fSmd&Hb6vhBW8b))S$XkblNdM^s@oJ9_8%{+;j8pFKVX+^ths05EVD(W|mmGF2zx
z6jyZ!TFgS%D_DdDyH4*fW}#&)xoY0gUsC)mg8t%gqZVwymNZ1FQ)Vw2ScKIju|2AA
zUScn*{GeYSwA2fN4^z;rtA}%6WL=k-jQRYWpMK`8YcD=?nRZ=a0eJA`z!kWz`1Zg*
z`Le;U8N#B9gq!BQ%PI%7o8`Of@;%#&dzf
z1t$AAYDmD|iy>0pHZEem0`os)@W6mC4Q>%OZFwUg-%bQ3MXI0LGjH-MA$1t*4{5kB
zTMB3cf_GXM;A=4`QiBq6S@MmV!eZ0{)^>~DOA6huizK%!U)IEtpg9(?hQro)G%yhh
zTnT6wbn${AT`=SerrK>P=S}&dtpaYl5W4CGKk3{xarjW1DYX;jbta6&z>!4+!!|;<
zGk}FxPIoUf&O7>RgZ?UQ4yOr*0lm=J`PTf~Kc3gYdUxVw;<&FE)F}(sECQ6Ca>8+6
zc*>+-#!0VmB+~O_3XYd74(Gtq(ST3c>}fxH23K6ba_Ax)bcFL*RXDyI;0Sa{=Pr0E
z_$~<)U&QUdf-WFANY{i|2s}=pOHOdkp=*LnO@OZPQ@F*Ts%>x8PWT`yZEv;TTNCir
zh1e$WNJ8t2`SJ4yVlCNbLqe$w3$;PEJ}fkou}Qs;=Jp&-p3AmsLp(qoKnnn_v_PXV
zRbCb3s)HOfV7EHJfj5^La8JNBCG^&m*%a4+xK)0kHY7O#+^q${jmQwS5!rFvdf;wM
z#Q?Gbad!jT34pHNl+qjGT4O?Q$~0QCt)^_VKBa@{Hm3aT`{I3%=AS>5YQ|n$e^a&%
z0EPhWw&g`HJ+iO!Pyz(H9<(^Fw`BS+9M8S-OGd%u{Ty7lq&;rdtU6)k-Wy3zdE2+2epQnP1atNcD^F_@v*~N0$PWi4jN$>
zd>2^ja2JjY(di?&j37>(F-&sNP7g7JgKg(kj_<-#@Rx1p2%wh?Si}dG`#%qa
zoaQ*OBh3)IMbsV#ftZ@cC2WcE@}6N3WrVb65Ka@lfWUFGh#`;?af@=fBfDcFJtkoa
zdR)a)=TRBa3(q39ajih702{lUrwDx^;O*eZvaM`IEwEu|1LjeJ!G?EUMUaeHYb?Sd
zoweAfJEidRh75rWhK~*W2Fem7J23%NCTZ$%GRY-Qv!(KLhO`>7=4^G4^WyL!TLoGJ
zfCoi-V_)*kCm#IVV-K!JtO0NOkU$LxbiY8)#{<{$vu^FnT8;R};L55vXR3>S6B>g&
zweubNvj;ApP^+*tGE*zl5H%8A4Gjr`a`YE)i$z$w=p`!50EsaXjl+D23QJ_{uSmCG
z@|kHNMOZlYSH=pga}o{c?Eo7VecdwKt4kokn2VO!K27WaC+4Y3z&6fv8Eles_c9s1
zjH{1xU!v1{sPtjD5d$*u9{3u;_Xcjt;QI>qWeZ@0RK_IlTUPl^Q@$QFHiP;Y>zalm
z8b2#gD+;#={{WnKR-|Uhl9r1y4{h~_F*vw6h5sQJ={@7vHz2~#c$sw%E9`(%{wFgRMXFb(dqiKK
z%nw`2ARv?TbifxPY)`~&u-jfs=?Bxb)ho6-5YYPrdatd5-CneTyGoZKoi~&Vq@1b~
zZgdQ(+XNCLVzF)+=_@(hg$D4r+phwNaq0|0UnluYa?x0L1ptO!GQlJ^0Ljj?u-*CA
z{M$cXw73@x24&aJzGBfQ3<}r@@_Ke>wS1ga1KU{Pj782TZ6GwrE-Ej)kW7X}zi84g
zLBK_H`Xs5q!sQmoL{~**GL7;eDSme9nSr$==ZtCRFbB#@(2HqjV!cS*nh@u3cL%^^
z3kPe%Y;Bmq2r;!mh#mAIef<R+j9d=39Zu4)`o<7AZQeT3Va1}^R+?1El^g3
zBS2Yr3ZIQiwNa8!hW4)J)h(!bVL&gM
zZhg{h&5L#&NVQ}Kn=-*=4e(%)+UBfa_ra`759eQeXm2x|3D-|(RY9@yKw{vj2jMB8
zY;!7b{$Q#tD^wp+TT_9?m{}8mn-8raZq~=KU9R&Lh5)D4M~!krC^w}_TdBH_U&4D2
z%pntM0_3jHX_tL_`hc2r`eok(z0@8wU1|>i7`%3ragBp?5;F#}IM1X@OI8c
z-~;0c@EOR1Who-?mV0Q>!3n$AI_%3z>gR#ILcC2+`0hYi&=d}<{NfZXO3B>`x
z6Y%#C&%tF9oK9kg%_zz{4I;$YTMR(O{#qbCY{6fr6aj0MMaE$;#26WRJH%74y}3Vi
z_h9yf!d;;Y`3iH{n>MNmH;*59>#5_fAKN!;Nu%(Q
z6uw`e`a#1iW!6%sHEB%dM(4Rd%RwFSGwK7v9)0Glc4ay4u#)4-;V$lZ-
z2IxA01CVwT(M_ZTx(*197^WK~3iP)Lwg_M>em*Cn1Us`mw}_aC?pFB@830VRi}VEr
zlg}3v?xMm2fG^5ikI3|h)J4H}iSt}!GcE#vS$8k%a!7oU&giAn``C=j@MU7*djS9Z
zzFAyJ(FjYHWp*^zSsbzZ~WUQ51c$`=f=$CP?3xyMofx;<#RV7D>|
zZl@`ckULDN%@6^%&LokDUWdMzbH>3%9V7)!o+bHbl6k&IT%>Ohp$q8U?G<)X(-=G7
znt%HT`0L9Scf!wswgOoJxLTK~OcU@~Zoy3e
znr=;yuL<$BpvYmNChSmFtdEKfF<`I=kOuT3iK8NN8h{;_8xnFuQmKn${43Tv$z-4%
z>?(j>2ehz-Xin)(N$_2*A*D3}jI#_ND+z!uDOXNG8yweePWf9>{)U8E3$M*Gk--V0
zDPgqc1Un8SFCNS7I+#3{7Y09W%?j2>&GY%0ow>2*xYdyxY0V7QNA%jD+7Qtjqei7I
zRrzJut+YiaN_4K$F9DLv45365$_#PmD{>zn06daX-UHCZ0!(Tr;2>-Px;wiBw;%?6
zyKDwdLqNN42itgrlwvtGS%j>hwoV(+h?cy^Iqn?9BP0-_4snsD*d7G0<#1(wr%DFU
zi~X`B$&Ap&T(oO|1L6|slGHQ;m~(@BpxP3FhFgJM*gJV_g!dql+bNkw7?Tn$94PDr
z?2_ZC#rPDdlpg0uu{0@@CfxM^hNl6Cz$8+)ObnQEDx`p^xU!*yxo8OBF}kwobIPM&
z7n9O(j>BLXqu<`1_ob5ztQegUg86zsUo)z9m1eg38oHplIH&fv`OC4l<7d;sp
z`?Eg#!V_0BqqC|wCSdv1u*8A>&IFB(tmw2U4-52=0Jj(7ob{I%4XlvpDw(O0sY=NQ
zQ3dpss2T<73mAsBlZdWWP<*iv8jGAcv|*7*uru^Xrs^eMgG2#<9R@e!j8`akcgb9r%(jCHi!?~^d7152myD=}TXuiuu=!$%T)pqt(B0pPPq^bpX9^PT5tU~nsy-pRVV
z;BG)>hHbgSmkuAV7l$l+$+$PysL4%Q!UgZ1A(@^Is@VlWcOrIunOANekkHQZJjESg!BxGIG#ZH;K641tzfnL81zsVk50`y)o
zl?!0B2C^2m=S}s3rFI*nkcw~@J9o+WT}(Bj;NnEhD7fIPV7KJR&OBDceVw+0XX3Rx
zix+hxeRqiq=q0Fz*!kA{+docQxKz+;=)p+eT@^;|!q(Y!j*wjpYy)mF
z0M#r;5Iz6~Cc48M@D(WQfOaRsNZk6E&=42u6JmW_sw1GSPXJ$)Iv{aeYDg%JNnk2~
z7T^kPttqMRf)=5RK^VLn$Xz%G0_fX}tkvsNT762#2_{i(5xvB2;fT?gWi@BnV7lFh
zv#vaL@LW!)F>W*_%%-H>7&n2+mmb>Nk{zn?%YBdRKYuW@Hl)@B7g
zi`ix%D}@Y(KS2=a!N^*~Ed-L1@Di@jN9`eMi|BPgdylfPi~PfbSW1o05-mn}?*LNUG!X&;TBf;1OI;2@Dk)5K|-_O)yLn(Lh1bJ0yC@
zSSGBO1}7dvM#8g%yRiKexxt!|HCjvE%Iu^NjVQ@Alrn6}mBMDW&u?6pK_L_}em(xgdM9N<8rn3b&9?IZcG
zAKAa?Hvq}-r+z?YM+|8*H?fuqqnIiDwDlMNW`3+fW-3IgT=Z4Q6aW}-3$k0MFx7xz
z(FeFCS!l`$FkpwiV8B3J5MMIm6|||wdx7Znq5hI+CI*Z}SQ3TFXORSEp()T`rw*%I
z;V}ix`_4;jzad}IF$;Z3VtN&}NA&f81at077%m8~;Y;YgV8cX(v60b3?}6xL()#cl
z=I*7^d#SWb@ZDwILx5WvzH{zNw5!LL-p~7b!E33sbKX7YeCZG^l&i^?R_EQ*=u4~h
zK2YP`Q%|MU)9F>-Jw@sNvCRAND$mDT7GU?i-Nw6G=!`Zxy$deo%jgHX
zYkZ$Tbz`4#+65XuCsvSk!;J!w_zoJd?YbaRmlURxbGNasPWYi@rblJZE9_uEn@xo;
zXkrUbb>qaGa<8R8bZLBt!uI*qp^(wYdvVOJr2<(yb+HRm$_li}z#+BMKB7$Cu<-}fXL<9o_tamcUDo&fi?*_TWTQ_UtcAaLy?QhP-K
zgI~}A%s^-yhJ@2`phM%zzC{6?(wT6Vslv=N>My`=H>He@>xi$zU2Gt3QFbxm9AWDs
zn05yAI?C(BJq(iuw(CL|&_KHl?0~rr0xTK1?tmOF1zwBq3yu1y08tmgZGBW~h{=sH
zxhXC;#zAU@It;NP0Rf;Tk;G_BB6LA^QF$?7cPE-sDi|&DHD%N%)Ec;2Qfp2btJSGM8ERz{_gx_O+cv)
zsO{O|^ZS#avn|O$4>?$_^Hr7vrdw@GWhz@`ij{y^l3^|d#41dw%9ko!iNcoP)(O5u
z=8OOG0;vCXj~)V4#2yAx4Yt5hLgMs3_-lisB*1-l1Q#0U!QjUv;GpwbcnKT__&K`l
zuoItklFy`Y8Yk=U?E!U$^Bv-%Nt0Z(16OFHRg)87cNd?Im*X4ZC}C7#LVbiTHZCLk
z|Nrfs*>5CScHa9B@HF?#jD3%c$c0<6sz_E1W=56`*_I4L&|=uV*3RO-CNsGg*W%9F
ztGlO{QF}BaX#h#K3`nvJ%YtP2L3)ra$WOL4uM%v(_<8(&=SH&1YP8`8bol03yNu&SQMu0!UNO=6f+TEgAJ+UoF54>*>|N98(?V;4vUWl!-Q
z5Za&gCja^$e)CtZ4xBie0GNz_=o8zY_NL$IuY6c7o(1+vV1LkG`lzq;ED0Za_Nil>
zdDgef@h9EseM|e`LgjaV{-?h;Jn%H~AmABDzVF(fe{=XxCg1qL
zp*aD|E7|6$0A|;kg%9?15?9jBv!Q}+=6azSK{5i#Lc{M$B3df2C@H^U;T4Q8mtK%L
zpVf*B;((cjmR$5oU;@K%z}T+^##ZERhR%j>-lH>yA-1*vW>-5(!u_JRrE;@w9vFsT
zH^E?Nhx;6y@t&O%9s|aFMOCkyu*LMsa@mg6xovfAS-DNCYs1W~8o6a7*D!L6M(3i@
zwV-#*>g^%~oilppwB9kLcTQoib?Z+1aot1-TU`4{hM}B6OZz?A}SdCC}K3{i8~8H}O_|bH5TjzSzAUyNjL%
z={hJ-Z6M%KHj{
zgXUof$^y3=RSJh2<=~#gXvC@Qp5hkCjhKfBvTw~-zY(-ByFD&&OLyA@Fgto-aJ#AZ
z%f|Z^^IDZQ_q{Tq3&GmHof@DoRW{$RShxlf9`ls+{(`|e0^G=Pz!l?W)x0Z%jyTmu
z)l|zC&Gfkny3k9|Re5F-5l(cL&RBYRmE{%9XRQ4jQY2>3
zR=$2=^Y0Ed2K$zW`c{W}YduBq6}Vj*tj_lpCsVi9S6t|cXG#HLFnFTq5ww&b7C{k+
zweE(ByY^iuwC@IJ{PCc7502Jo2YoY|ns}{m-vw)hpqbf){T2AVtbJ2b)9Nl^?UC7a
zen?JJ;AopFpT?m|Un{#TmRF$rLNu@J)&(Z%G~|OaOVQ
zfce1CdLDz;i1jC-B&elBm-0Ck2AFylQV%%l*Z+tM@j7tcGAv4e61#A~Ph;<)FWwh-
zh4z`NKZ@)RtMT)4_$YRcVb&A>vw@!P4qo`Izxv3>1-R1rpj3Pqc!!Sp+yCSr{Kt2H
z@p}Wk&m!+Ea83gEFtGPS3|y%U`!LdBx-O*4qa7X33r))UJXoU
zp#$rlZ>{@G{BDQVLE>#kV6eFp+PkrXmJOIo-#U!lUEkbs3p<>nBfsP3RItlEXYF8z
zu~XQw^E-A926TtS?bx(BH_Xlzvwhj@fPY;yyFk-&CacXvItyl-81(=$G~h@1sM86
z*w(~{%ZKCNuSUn+$wp{5JZ+=s?v{e>)W_e11BbecD{(Sg$)FFH-)x_~PXE9kYyB6~b?
zV0p1;5Qu=`KEV#I5v~BCHyG9!T2A(0<(Oc1o3sn9Y!MSkDu3QXMvqeEy
z%Ch!wS2ID4=MarTcSyh{E>^i`?&)+7b&{CYne3!<1yiAYVJZ%B7oD+6O~X&q>~?^-
z6mCI_%@VBxTTJjdhUIpA8~}Xc=8t5o6dUF30iTEm0=kOjr*0lVRq1O`_FTa2saud?
zDY*kXckJe+o4E^n2H1P~6P826VrmSygoDo1v5yw6Xona$#HnL2JJ28!H_*=_gSF5R
z@M)k0Iwi18k?}OPKPvf8BUV(Y#4?MhrMgPGdpY#>L13K$z%ok)K>LH?{!gpXLs!S`
z4}j{({-me)Nl${a;O_IH2cvxA
zqoViu<^Jzn=mCRwwXQ=)|NLU_$K54(;xpeqhWB;!XFbWkxcdKrUiSD#)+D@dsL#ag
z{hb!>vX@u7d*OYjeT|@%gfr1gBwGuSS&LcotS~G|X&HlrmO!tCkRcgqFjys`^#)~d
z3TT-HdbOE|MzD&&)7OF3*ps4Y1L%Se-tdiePrv6I+mU^k`aAT*-PN#fxZ09iSaP*{u&1Gg-)JLp
z4y(nZ?jjCrc77vvwh|v_IS)x-9^h0pSq(WPdcEjvB=EHs_Is6Rt?1xyg~klMU^Z?P
zQw#JWUPEI!;Czs(Y${7WGylxmt8$>quRvVf0tXE4ZpxZPBrEPJ`S)-QfLaQG)vZdj
zRl%MjXnDw%?Mk#=jS-^}arUkG>bG0)xU8#U6%_(0k8*BSUFdq1K$Ve22$(d!QFYKF
z^GaH3KIf4N2lC$TwxC;8lf#Otu*+QTS4^;U371Ul!Cmm1gk}*IE4gl0Of>>n=6^OP
zdMu9d?YCzDS4CMSgr%;k--5)a(yBtFX)n<00Kkj=+>8DubelHUs$~L$rClCHvkUY}
zo*Ar#wXF?!^-F#O5Cuxb=>ob-gAnkRi7{|H2-XI5oEjDYzvOqp+NI%SX&8PtUTnHy
z;VW4SzYD?mD(Eh8<|$z?icrxd?Gp#PP@)7ru_d%QiI@I^z_AOrxQN3&>zOg
zE*?TQOH8p{u-D95(*cVljmJ~x$iyDE(6CDVsUWrqa$cbF%)CVvMT3QWji77iZ?SK8
z?Eei6V=s?|@Nwq`npRkT09al?7iL#=Bnxo~W3(^;aYcl&!>(ThxE?x^J*};$d*x=Q-uJ#W^qW8RtzZ9%
ztKY6B4@2i+;vIO#j+x88Ltoh5m<-MF(3psfsmKI($9-KTpTXT}U(d45QteFcip>RX
z1-j=cXzUe+vmr^ezX2_>6hE^93u-X)Y%B)4D#e1p8%3Zc8I=SW!}h`WZh~9B3Fxl+
zG{LZmt8luJy_2|Gk-aX?cq_Da;D$p$*WM1@o!H-Hd9b_XTU)+y&(k*n_Drbz3A!7_(kAKOWvHD2X{A1{%X-#j_rG;U^Vga2ZYT9J6B5nS~*-v{Z+*9zNxob
z@>Tb(3Se`$Sn$ksd1-=$p!Z6?V3Z~8q->RZr2yb+w4IR{
zL9|ni$>3LsUM@^z-w?Q}?py3tS1#wu5Dbg21&qCn(`2oEM}$Bv9jI0@LO_IzyS-i|
zXvtc91fX8U1C48C6CRq4Bs3aL&O_O4kM+0{JskBb!;P%zZe4j?l@^AC#B32{W+GqN
zq5H!4Dh4lJa2GGAy-U_+ox!+3k=ULW`Y!Z4^ZgDUxG>;|+}eP=6VcApUD-+90!yqesEnP2hOZqCETiy)4OTaC&&{An7?K~9FD%CGj
zwM%$rW%X)L?P4_H6^u1twuwnHJtP+PCyp`duAZ
z?cj8H%poh2DwI{;RB$M8r86daL1+b93)Cby31&gvj^46sw#gt4AtD)mfg-^$(()WezjRtaYjFBA6Px5-+?`{tDy-9cG8TDV&p
zT$tDVk&_3)5AEEclT#NHsKhYLF8wqN>w%NoN8scD*GC-et0~Yvl5s%~9I3-%{+V65
zC$za5?mG1H(2=K6@U?KgK4JjaI0}qI9|6~LAZ`OwO%r_@T4)iPg2CcnRmCz5E_L45
zi&GNY54qZbedZYtJ@c_|Kan{%2x-qeam{1b{A{562j3igS`1DcVBUQYIvh}ndn5a4
z>V4XqepHE%T;plA`0>T+v2VfbK7gx^oDn#YP8drO)@lg!nt-k(qTz;_mtOXD
z?ALv3gXUOAJ4n1+^tOO%)=L{}p0?>5`$caX3=Y9*&S!a#LyGYz-ol4-t`Dp3GXXyD
zLFR&I&br39YmB-2n4^!m8Uh@O^eNAr^voIGn)GZ)yj$2x^~hO@U{bA`
z4+fi!&{~V#waA98uj4~uYD2T;Yw-8m<>K>iUYfUaXup^G0PRv_E#UVmI_s&o=xa-%
zxt@6NwaY~p=mjquiQ6bTQiROmxv;scMwTinCX?Br8*aQPxq@O@p$J}w)=B>2Vc$M|zx*UY886m}9-}-5v*)7u;>4
zm-HoKy8&|Z-Ln3ERXT&qCR5hfmyPQcE{h~3(9Rgw8MG(5IiJRh4qd5-QYBGRv#q}blnk2R}01J}AS_m$gMj6*!aOOoIE_KmuT=wgi{l!b9uS!0jC!ALX
z<7EOBmKOjfae>~(aI{2$ogiotPFKusCS`w@uTXHe%HW;@SmBluD%Tm5mxd}(O#v9*
z7xcYIzgx#1=Rdb_e4{Ya+47i#DJ;1_8REIT{)am_{aR!Qj!rg1}T^
zEk()#z@a@!%DNMQGZEO6K7;^=RQ45lh1-tV0s3wdsO%iw(>u1cwoMHnB##lJ1*dj(
z;Ikb*7=VO?i_{Jzjf%%;XIZG#v2EZoNn8s=iCbRT3ZX?+MFH~w_U`!u6>CN6Mm#}2
zh}R1;Gl&wv7W;SAp;%i2J3FN=!)t-vftLVv4LE(|
z-3O5c`^yQ4#JRHFH^|z^KI2Fs)=!;y#52Im`IZ%QVO~8_SvlZum&1?BAy2W?%Y5J&
z&tvb?O7Vlle@y?%0Yb-t_1(+8-@VlPF!mlqE&vSr!Use6lt+Q{z;%ut>p|>(KG^rk
zh4QgyJc`{9EAhwO$&t@tsK5PlKmB_@`;XY~>*KO7eN%knE}Sm78yL_;h?x0j#Nh5^
zpaa7*ktMN=GRpdW*$phYXiol26CBxD9TvwRz32m0kOqS@PLtgFf~24&7tM<3I)vEQ
zBo{5|Xu4qnxB(Oe`bx;|VNi2bhAQC{4#C~Ez*rY8``QXf7FioIaR)%l!ArgcY_EkD
z+^4jgu%4?N;DpC=DlWVe%=-o)I!%GKna03i0GJFmMj=PP>uPr$4bZ)-(CeGi_@}`$
zM{RA&)n@RX;hFOu-X~!0@f!i9u)_4g%b^Y7m7?Zpj3ayAE8rJjOP!UXJ?9k~v9+3d
zOR)``i$BFi$*)JIkl0-XeG`v1H}!$uWwE(}+i-;@STHPBSOBa_tHiT5wLzP!&>PUv
zR@f7ac44icm*bRt1jKF1s;>P?xQ`3U!EVWifL^NP-!BFC%Q*Gw(0emAuBXQPoDDG#FGOf^fk*?K!QSnAAb
zEQ-CqC9c^ZTvx@L*nfLp)h(ehsQ8-oGqd)Z$a43-pY
zF9FGte7+p54#g`tQD0!V>YxC@gCvStBV>gv=`vfRuwXAD-EXNi}F%5|YE(L2Z_
zGwd&jyTGLplKH*}(1p!i8}3;eNM|eFbjh75`O}H&%C)k@GG6N=3&b4@MG+Ir;$O2g
zGEH#k2xv)Jfv!CnIFo@r6*$v@BYST;^rr%EDsZt^-;h_iZPV1k(Xw=z+|@g`^o}h+
zSKKfSv3O#IVF(Tw{+JRsyeBcv(liVCK;kW24*feB|cD1b4A3R|XlMunvm@jvsQ)jRJ=(vlJ`$09dti_ycl4iVfut
z+yacOa1_cwo5>}8!C-I{0b`#FB7vX^qG)gWW1W^)d@y*dpv%%K$w-SKHqRo?Jct&2
z)}dW^mij-qI`COf0^`f|hB=rpvS
zSBu}ja`}Vqbl<@bfS<%V3hd*+KEb`Qdm1_?U~>|FaIbs8Wpl*DnvY+M6qBbyal
zs!?4KW{^H_!M%9$VxTR0aM;Xv&->=AZwh_&Nl%{;gFEhlxJ2xjX9#Q6o&onnGEa^3
zVq?nFr{IiTea6vevG?>jF9R^RP6mtVUydENcm`04vkQT?lDf;OGZ$zCZQ|e%f4y2{
z1GFoN*NALz7i3*Z+@;h5TyY5c0=-N)%gXjLY?s+)nqXEq2cWEy>Zt{5fnJ4SxZ5Uf
z{q0h)SBZB^5m>uJ1@O4obH0w$18a9n!G7u=l>EbTa0uw8{$7GZ#@V;#tKV*>=FP;o
zo;24i68rm33IN0YO4^yoWNmZS+-6GoI?Jrg_himz+z8^noq)Tn
zx}wxfSS5I0`~9jT$!#vc07Bo86_8+mN4m{Xjy^IcW!%v;3$L;oE7)9>XI7SXUeeJJ
z(EI1V|GQu<0)<zxacHd)|0X-xmPBk}h8%Yblj*ZrWcuT^`cu
zHilSN)ffb!%fN8`Qd%EKVRNB{o@ln>&v%CiCQ}DCcQSD%31`P1Ad)*Fwn%d*jY%@)a>--I3?*+
zZYG~`7A-8Q;$1Ad7SdCAGT4ldAjp~AK8G$LEx46xEUAtrv^B!c)&U@f2CL
zV-iA-woUs-h<&{iC^TzY`2V!>5LUI@Po`&Xw*nXV2XR&=0
z8pk0?f99KyBll_SaTNs4yFkIYepF4KB*Bqu?A!P(9hUdgf$C?MdQL%B*M$8&2`nJ?
zQ7JfyoPF0gz>kNY1W3jOzJ;@3^GRqQIQsLR(r^C5pZt9A!sF;mXMln0HSdPzNMInq
z|0-i4Eib)qs82@5M4(Ru8i+d`())744M|7Kq6;=t&~U&q{{|1GD4JjOW4=22bCKk`-4Hy6)+X%RXT=MjWhs^!=(^G2Hlkq
z80J_eMPIqm;&b>wd=|v{Ko)#BR4~$nZJi0sDZFHO22AZZBn%$&ObEn1r!RsL4~GUk
zF)o+@eSKrvH$dM>Pn-6%S)cZI4wx7E&hZccww8>rA#Kn!otpOr`~qr?xo(o;C4R+Uqe9m0D-JDb&&eUX>gGEM`>{U3ekHj(QYK#
z^+bpLy^$K%QWF9@nR%vpW&ZhXnY8&G##}n^dRf(55wr+Iio53fWrKr=l&^)s<)RA$
zTIof`Apopm?#nMZY$>9~6To0V{cg82-pk(Ki5_#JM+bn#?4C;%NoDzGLGSM@43MK>
z=fXwnFaPXMh~9qZkG}UQe#e?zHrLPIpg;Wnr{^|T?csD61{~Z7exn74Km1RB`qw}F
zZ_7i$%9Ze69pA%UACCM}*jxmE{Hwo2;tt24>|gx*e*@$D*FXI4;PL8kx_Tx3t>bN8
zJo?u1m8{cuX*gXTE7Z>{C`R-t*
z?9G&Y?BRFE6Ry|~vn#BnYmoVsdqpKHXt2p+t6CqwN?O?tTo%W%=S$sqaF7On_IUu
z2t-6<+Xh{)m}7FCzL{*M-R#5@XroDP<*LD8Ah`>BAY4xI7BG+06gw{I?#y}fl;ny*
zado8t5>O;}K}`S>kXFUj?4QOHba-XHTkH|xFvqy8OXl(APqItscJ5l#p6uCz*ya=q
zdmPUR?&csk+C7<#U!|S#kOOuM=aq|vSUIH#O8V+&w5qhQXvC>=i6I7GEuk`v?*Z=3
zdVIwhH~WC8z&P-6Ry%}y4$V_pjUN~$$id@?EAyX$njSD|pG5XiU>*4;FbU8;OTs6`
zKxLKB-7UBae8SN_Er-u5@iA@$n2W<=rqwygC6{@~MjQJa
zf-EjvI%|CkT%6C)3l|HQkKfdq^er%$B7lt%$khN{1b3Snh4%%6J$)RG+1DrK_GyJu4+?@WG3*jlT~J?n+6}3kEarz+*Hj=x$V^)f5#BwQ#f{aJvgfn|k*XZ$I(C
z*F(75#6K>Dr={RH^^b}!mAD5IpfUT_eD&LnIDa!K+)DLZiFpI|H`Q;HjBAn*ey`-f
z`@WsnZPli;lDiEz+FJ^(olw8
z;1(i!|KRtQhcoo90KG#g_A5gPw9GEvbmc1iZpL5)@V?7e%1hXjzT~m;z69`4Nu`?M
zdh3@<3;pq2Z!`zX3+`6DsgeWH@22*6VvohvC|OJBGLc5tOXJIyz!t&yvRjwExr8pc
zJDIW825aGHGqa1B0RfCg1zm~&{xP6;wa~U)Xl>+M8im&7LfdK{YF*8@tZN`{yV`HU
z_0r&G4)~tdwpM6aE3~d@ZR-FtZ7v{6Hw+%%6I9Lxi`XgMB-*>Vpft7_7
z08?nEH)TZN5Y53`HwaSZ~{SFsk*1$q&j6E{=y?1|Xl$0V*wJJXLs
zhrS7`dI&1x6CnV#=zUO*9>tzu-ULKH>PbKBru{u}xjF*cL0si)vmme!eDg4}o_80Y
zl*0qsbbOqHTb`uh<1~C;Ej~(u1IK)Jq5AnxUdg^gU)bJw-_74}3wHv2#0OyXJHB?;
z*Wh~LeeXE=QBPynuN-pR5i`$BJ3}MkKpTwH?y`^ALU
zuT?_s%OS1=p4ZRItN_}SUA*fljIR%~t6VP!3(@9AyAaTu`nzztlz*SGw^elZOa2kQ
zH*mT|cOUMy=p85CN$MRI-Lup`;S&AMNo=3Q)@jjxP;|~B`>got{?!9|Zxlh_{H;{G
zRnl*l4Pf|2iSsZ^ewY(fy;XAFD#81@Z>2Vu7fiTp(c39(tHbqrg_Ie3nSyp_eus_wWOeB3XUF5Kgpp-eb#ip
zH7gyxaIwnxD%U$d0KQtFFNEJqp%;2`<7d@xitXu*p9gp8o8?}_fNplKxqWc^7wVVX
zKl+u=)FBYNJj7Dxr9mc~|M=HFU%gU<(EeZk;P+OBi_m$(8QaGrZ?6)u>C%-1B7g~9
z_WL$i|19(szl#7uP`gyDUrrmB%Z*DVnBCfi;?l*^VqbBt3hriRcQSRyiuNdbb4`lS
zWwoaAyGmJN`6aO{*LS8MK$q4w18wur#o??^%>^%X4&dxpdWG9eu4OLYvQTKF@~w;c
zmO3%qvRr5ZmDk~eb=cxgF}T!*)&X<8thFs^txpu+nHWSn!A{{6A`VtP64+dftg8^DeS+kS4^Ux%rfnnerR(ngh
z3++M8$P0$O2p76CDwIbfm}FeYWu
z0%v^Su%nk`71860A*M+c37!es`(9zs&EF@03-GTeTx^E81!YNJxLzUddA#oz_HmZU
zXRZ(UBzA$`Bl>9&+Bk`vC#CRl5*+z-y+AJjd=@#t?ZeoEFHzG3+uR4fH~u0h~Wd{1Z;2;XF=pfq&@P4~yZ$Bs})*J;&I#wCp?dh3$>^
zeeGtT-}H@}zJA-+Mgr|_pyU6d5l_48X=8|`>PoWEI*0s5?Du5~niW_w*A-`)WC=7p
zF6c`Ez>z*56U^Z56wr%UxXS`*CZd^(#`SZI=|SNL$!S1Qagi}yGJK)JvlwNWrh{{L
zV2`^pFe7e6XfbMZnY!?poF=nL_l&ai*?6p!gUxY%E(*W{EMZB(U9fY)(^=^)J>R2D
zEbEH6cUtSp^
zjJZrS%kfoRAH}!G>|68IZ#UzvTXFt&v2Z&s+$m~zV1HBncFDY5wr-V-n*UUT31)n(nb@`ka|Qx?UluJ*P$)WwpwruOe=3
z0H&6j?>FaVOfYlK;*}+!vRkrK)WU$fc*$eu?qwgAcV#$QqW29}hC?B40tPQ$WWCkO
zaEuo01AQ
zc&g-1rS4?nj1{fBF^Fr8a~_N)YneRbcwCiLh7c$bx~x@Z{S+m!DyO2gC2MJF1+*TM
z%m_k{65=ZRi#Yp=yuxj?^K0W>Uz_au+H|gEx~pZX>uYoQuhj}Ii?G540JVKX@7Odt
zU|xaJl>%_vwpeJJ&$Z0wTS05=C1|Y`TI&U37}go$T(-b-p+%6~4u4GP?dxDLlhPzE
zQ`y2}2rV$yq8rhdDu{=R|EOu70R$>V<=S?K5
z7Tf~9((K|nM*Drc3+@&i1yJ#D02?hrQ&mWnp_dEchyY{7U0!30n)HPZWZ60h0m1AQ
zjzZ%!wg6NBSmwPi0J_H^DVv#H=AU_pE3rRjx2ts=!qLJIGp7yX`y_In#_r=7Xf*d-
z+`^pmY2+Z-cX2xa3|nl{76(i?V^6pS_Jhb#JU;fU1J^vpzl0!k>Yo+a<4f-1vd95<
zAD6<@&^>gmeaC!Uioe}oJqg|Wj&bN&hc4{2^cZHEVi=5{_3jmiXFX?1vd-^OBXLC_Sb;G-D$so03@C}ufURFND9Dc
z!S%puhGe3V^j!#TFbRwVdKG<@2x*8I=DoDSktv>7dWa*kmPNu5y)`bAN8x&#j}7>W
zpk5SYdJuh@zlAaCYB2Ysc})LJNr7kV-2+
z7kdyoL$9QrLErTfC)R-3T}$1~lCRLa#eyj=w{TF34olHNDTLX*pZNQdQa&pBhq1F4
z8YeKgz-{cFMD}TD;hU;T0U!G2Q_eijna!VY#SboiDZ!VHQTtopZbY3o;~dc|x|3*k
zO2$ap6d8A5g3DY4kaf#apZrb<#@7-1YhnLR*?p&Cy;Cu+RZY-W2L4LTb1w%V!TS=r
zY;mtbbBBq^5U+@+3mxhR5!7%g80IhPp
zD($>FTwImhvLKdwDXPkF%R`lUCUI4Dm86<+I9z6`nNw<{jlpDPxV$=40e2UqsEU3U
zW;b=9$;2KnO1Ey7VHT$=-Bn}!U%;90IZR09mNQA|a%OgwSY4HM@xGi`25x6ze9sR9
zcixAbIZ^f%d4=0Z=ieFY{Muw^%Vg)96CDWNoXNd8UjSK2-xa+B#&;bkEx_8+69cq!
zIS5|46`DnmYpLbH<8~k!zL_M>Bapa20nBxPTx(g@T7cdSvvW=FP+&&OssW4KzNWXX
z@vM*-K_*g}zFBYG0x9jz9gF^(7aOhjnqAIWa$7Rn*bC9sU74TWwmP>gzCDQlmPX(i
zHrFC?WrAK=!=@=ZT@tq$i|YlIL0sV|k*sj5;zKEhQt^3?nyeMj-k0^Fnb5m`0XUc>OZZ<
z&&0)ozR;l$a$650Pj&jj{z4BTSCJSl`M~1^-x=)v&R`$h^PvaJYvO4D@LB48e6joE
zf$jsa*0&!d!GUXmz8`j%9u^UQd4=;^PT^fwf6vq3bG2)pek(BV1jcPo2XgNE=19N_
ztPy%&U5HD+%RxtKr6YP@rl6Gro{qGsNSlfD88N=t%cLCeyB4`C9#?vQ6>%wX#>Pyj
z&EjmV&XUl$W-icx2ijFhMA6KDlSRw!dQ#V
z#qXj`1bn5SwPl*UaNE&9)?2Oy32_nYw><5Zr{8o7*WJQ3H~+qqzh(o;z_WqB5}=De
z4!gDZn$Hmw6A^H0Pch&`C37+US+V$6l0VU`cwhb`fw@?8;e8ilr;#wXyb#-UV%WzI
zT+g6OfwIg(OA8!}V^Y9y@nae1aYrgvJR@g~J
zowtfP=yp;VDd~XjNLe2#5xsXR<{jcwfz!!qrqmcAnISS;BS9wO;JQXKvlR#X_QLpr
zz96^3$s=KT#qV-n=pH@|ti9Fk-0WtR7C|e$yr3^7u2-aH$TIJAn|FI`XtdiJ@8Md%
z%_Rj%Uqw(z5X*eB$~-d#EtCaQRd+9h7HXgw@B+C8y5!Y4peU>l61uBbqUGTbL1Pfc
zm$~KTA$ng3abq}M0*~Q+uV&nZ}j{I;`xN>a^ITE$9cymzWMQH5JE
zwIXJivA3rK{6C^PbXEOS=68W!h?Eu3&UrQ{E5yyT5O_-2SL79L6~d>TM7pjTpGyFmTwqjCO+;Z@>y$
zU7G-TW~oIIZvexbTekyv2F{6Uy=7G=+V7#=?&Mi9-ynKMWgV8931>R&W`{JP%S1Gj
z-rFYY(c~6-Zk|$>*CBvas+q=D@Qj#v28P{iX&i8O-y>i5KxhFi3F>LQ9dSUL3lj4z
z*eoSfU@!oxKvlmXO_7l-p=!EPimTZhGDD>GD721zcxdfDz#Lj2D66hQ8;Y2-dGM;~1%KdyxL?E(z(lS+K#+lL;maZmA&
zD#rx-2*BX%JM@L^jeqWH&|4l*V8&fi&n1U!
zid?S`ZV!=OY*SFA-ktt;xs&eWzo462E)w%p#V*
z570ZGIJLyZUkr^v>|)~0$4oc_uCTnYw!&a%xlGW~>;k}L_WlyX9MMa^yGjPT*sp=R
zbh^R4)Zb41Eua^;WpA#(SMpf54C1E25u9$~9T%PB2(nM{0*J32-u`6%mnWR~)P$b;
z*0TV6^QmV%_lyrb^CRE-wr{CD^s)D)Z*YI>+l`<@)G4kv5BiRjw2@T1lWL&v-HLIy
zVvbZTE_z>eWU@)lZ>7fjLclPHONjOWqU_Th?R7_coDms!1d+kaKa`s^5
z>C~NwO`Ea5JbWGc6urI!V|=Vn)`sMx;?=z_kgfO+n`XZI!CzAVLE
z1ld>Q6>gJEGDEFO(_P?hOO`!m-k8~A1W;Z0I-hTYl;4FvRu?z4_Id$8Z9`*|yDhUY
z$8s4NthLQ)Z3_@{)J#*?3N*_2lt#X7DbI&POL|*f!>N`UJa@hYUKzncp=HVJXc)Nn
z%|-3ay50f323H27__ZCD*!PS-uV1601J
zODz~2w)9Mc#~T9RZO+2M@+$xpvGgCe%gQute<^hgUgmdr4Ni4(?N=6L<;6yGtyRGC
zD9}}v7AT7g@IVAg04;p*t}Ixm4wXP(l~U&NId=XiF!8V1S?sd#*a3{;gLO$P)1*TC
z0IiG5xMDic3!4FW@44EpTiByxhCh~itALqjg>4*40Fd(`fbIbdE*!0A-?#M#Memm`
z_dLQsu#Wb@h4Rzh1Rn>!K8VAU&;yh($
z07*qoM6N<$f>28X1PTBE0000003iUD&BZ}VegFVUegFUy0001ZY%gtPWNBe9X>DO=
zWj8KxZfA*5PDc$28VUda01ZhbJK~#8Nt-W`!ZCQHI_uZUx
zeD~d#bLj9oPEYq_jb@}71q1@B?81}_xlFliic|v1MK$FrY+M+OjWD*$P=EnZ2!z6D
zG$YN7G^2@~<9q$OUw-%9oYT44zu&jcdEFBBf8OVwyZ2sug>QZNTWjrg>Q?T*c@P|R
zd_H;{92|t7s5AYbJSVN(fAp~UKHra~o92BjjhZN1S1p_Mn#JQI#p^EYsnhqAJ!!jP$?~$;1&VQxtQsIaB%#*Ni?fpUZI?LwSdTet)&;MUXt*+9xb(VBW
zO5*C>M~-ZiKdba>F&ob_Ux6q`IeS|w|L9@8?G%hDIY0V1K!To
z?rV=d*XlHn$SC)XY!oQ3!9j
zLIm?$2bbc5RxGiylF5
zNjUnjw;g*sTUoxquphfSyL@+|vbhnBjg26S0yg=OFm=(;&;U$cdS4i-^y5QDEoT_3
z+AnI)^G6T+QiYU%1xMxhFmK|(2i1qxYg!Fo*(Z+DDhJPfR0ZSV^KzJIIdN(}+We3a
zL_n>Ynq+4x|H^aIM1qebZIR*HQ7X>=wQ3$7)r2~T!Nas~-g2(BlZ53jADP72M|NHt
zoU{|yq;+)lMq^ty1cpG3tz?D~Vmme#CP{0J_MTDh|Nl64V{3g4f>ZzgUaYPxM^j5<
ztSv48%TBBdulR5Ju?>{`u
z^M?{1mh(tldakDBHEEWpU26hrM;$;H7<>jJtWCU~C2QPOh%GQx;Q3e5%~cMGrbeVV
zS5#hw&r=;5WxraccGT+74y*dDs@6_<=Dh%w3!e*5TWd=!Ev>}b>S}a$^<@4%o{t>A
zK;unjimk1^*xg2=cekVdU?+BVwxhXwAiBC>l-jYsN&Xft3gXLQE5aypcK9}AoAve0
zTzl|*cLNH`XhoZp!~E8>6Z;!WvAMbuJ1~i$Z>+7w<_h1+TI}!cMPpM_G&R>nYkOO?
zwzYBH3}Y7W~{Zf5ytL{4)QcMsXeM@EAdp0#0yyZqqy`iU(uA(rO@P|>bDNz_mVz+lo9ga
zdD2PTbDJQN9gRTv=-tC6|1cxuiL(vXv__^0fS0w}JOnJyA8MD9-`3>zQdU5=wzgsu
z;_Pm1b6+3bz1?Y(TR`^y-Y$gOi|y^bXoaZlq^-=&K#1lTJUm9{$kW=DK<-N1t@T)6
z-$Yff#oEF`Y;(U0(hoM*BOrPm1l|RPdf|cT()p{Z>C)E%+pe~UIt!cy(S=cE5_}Nq
z5f}S=duTTMhC6Lun5Ur$(*RMM+uEZ6!q$_vN#Crp3Fg_y?`Q@7_O4Ets+l^#0e;E$
z)(%WxA6>mY(cRON%w5mDO!`sAs2wIH)U=z}wEavh=j>0y&#hX)e0;Mmud8|fC?nOa
zPofbll!@h>PMv8Y%Zq(Dwn}UsmoyNv2eS!ON#m;8a80iyKv}*HqGD6mHz3#sglLHF
z&W_k2&3tXB&0SRK+VX02b$7)+=}Rl?aroq^sDP-|g&9;nPFqVutS?kzZw+Vepb`x`
zt7!cS^=u;TFcky}zx$9K2^221jUdQ$+Hnc1c356sj#iK^G55$X)Jo|N<<{0#idt9G
zwE0!Fw?+$^pbpqm`siCd&Y}lwlHSrTWn~zBn%!M+$Md?zdbCF~ZA0MHfH3%0dDh(C
z8XW_@(FraRMl{U!?oMj7u09x}w-=wIn5se-X&_$zh?M`)qe`SSb<%~T8o>(;rj$B8
z^!w^Irep*&$?ab0L#Nw%jrH`ukD}n1_j%}oEV*|zl
zd6jiE!s-Uj+zR#Xr+L`i+=M|eH)tN2tpV8fWK`hwtklYUjYyw%dy6(38k@KW7R-hW
z)6(3QL~es%4b4q4G&sN+A|ch9k@l{R=z&-=Ndt~zM^7(=Z=jyWlxh*9MzFmd2)qMM
zB#zoc(`Pv~%r@qQ0#T2q7#JB!tsy__8|jO6c6UbK;2?0cC(&fK8WC%U_Ya9(JwOu2mrT
zdMx6#S7=Aou3yn4M?=hpgykUZyb+Dwdkt2F)U7OHOAtN^P8j1(H08e(X8Fnap>qo=CjwzU5jM=V2-&w;3WR)s0nk+=9xL$x=;IPo6nc%LfveyeLMX6d9!PUy}rfBBgryWDp^C
zKI>^pMA<{NKtAUtnM*jyCuX$ua9YBY&Na^}v?ufJAsCxRFiIP6HiCzy*4F49>WxF=
zV=*|~AAQ3E$vDkugC-fMp$V47q1@gl+R(hA{b;fUUqk0}m%7%ev%3$iFftMyFu)qo
z$u^AHfs;B6qqOLl3U>+>2Qa0R$oXL(Ig%M_&+S)UiaUC?G4*ybO1+#)0Y6HWoz}j7
zI0$56&T=*Rw{h$i7v^IfTi%T1wRR}&+erF4or77Zrh@9;SYC>KI#@3-054Gc+ZDb#
zgzK?@R+zpw8MklTi&Y3;hZ$(5jYg>6tYpJ55?R1A_67Jx94#mzFP1d&B-nH_Atx__
z1{?(m2jqR|x!70ANLU%Y0p_SlPIiz#@6-OnH1^fBw5>eX8?a2)MIGsUl2^EP&5QJ=
z#1RGU@LaRAO+6bji0!mAN8ivujE;}S*!bZX#rbX5!E9?nh%ikMe;-cR*ueB5U^=iZ
zm?kwwWwB_5u92QNbmAC3O*j72GK{zr14Dyo3bY3Tn0=L5@SS-ug+0eM!@NXP(MgD=B+Er2wt@DNOF1+(9=akbF9{?u
ztX>IJQwWR1kua9>n*)N?I#LQUk+YXx=eayD`okkpmUVeAg7O}y@;~q;^7zUW9$8kn
zA!LSwBF>KSmkufSwqw6ibHFHDFi0cLXeW;0@sr2m$jPHdO4RPqm;pid)@p#yWyn!*q0bkPrIs4^()ma3=
znglbDnMXX7Qwl=&kp2aTzk<5f-s{|LL)ZgUx}s=2y|%I(JD7$<031rd&i!_*!Nv1a
zGcj@hK}=0d#0K_W=I8l<3q0pCTFp1N>429F#<3nOrqO+xKa{FY(zsG&td>6`uW5dPXY1J2?**>}I?
zxd`$hVHU)mpPow(+%O7=qe7z%^hjH_0b^_%uj}b++aUfv-n{DS!M%yN_5Q6`Sy+v2
zhiR$2i!e-;FH&n$xGC8nKpfT>pmyw#E==U&T!=WO94cF{GL|s-g=pd+;jlm1o_WjvltK!nELPjMj)aAF
zYNn2aqJb@wngu5nrl^3+)vXQGd|QlQLM}XVA	nK{(lo)7cdD_+ggc+S(-y-iQix
z=>WId!^Ne==p5>gGnX%-Q5w+ROVQTbff+gyE%+<7_B=}O%8^6N36wXSyj~@2nVFiT
z;sY9JO^-D>kPaKKZ^8`Qn|QXnc=vqkRZ}agu`n|e@4tOLrtZ(CnP{b>tvEwyxoj|z
zXqcKvMy^TRgTo7OfJJ)Rv?O4an0~kyu43y70nDyCmWqBPMlEkm{h8lzP_?Yzk|9&I
zF5$^Km1fSir}>c~vK`wtA7ASE%eKgn
zb;>k4-#}mLhFH7vuPu^LAT0`5SH5%(%
z@!g%6QXN(EfzMKct5ROTPP{8vIBF%6u-BZTjNdbp0#bGCd~Tr+E6uuc
zK?w;GB%da{1*Rm1X?}QEycXM~z8VtAV@R1k10Ty~Ve=>P3)2a|wxno6l0OO~^_r)A
z(H5MGvuc0Ph=h}=UHG@Wx*6Nl)!5z?m!7yB=N`X^vpEVgV6HI}b(jeww54SP7iY7%
zp&6R3#b)fpX|&2H&gmjFR%?zQKNjtTw?(4@XJz{8!P4SlGJq1_3IW%!K?13#zlmC}
zEG@-O#qoI%i<9Gc`n@}MxYM$AA_>5?quEg;PE{%$M80^)y6rgU
zL>`CfA|i=F8J{aPdCytctfUYMmXdf%I0e1Wd_J>NT-zQIW*$j28`Vx*Cs!i70Y_|`
z+GSYl(&3b$c45@?u1Vj*_NrAhg`Ta;L+z20Z2MWBdQzH8sHyia{0B0%ZBnlqOd=!<
zl;M==j!9(yYtL!J=lW6(KKWdjB=)x95bdr*@D0N7@zY~*@$pM>?&7(q?`)@C7@`T^
z0ch5j9AsO~_Vx2rej}$(#L;snW0`PY+Ke4PigVf(b#MLNf5@J-VRzP-mqCj3-cQxC
zxx5Gi;2#Jx8enE}HYPr}8y}znHerTt2;T_6dgeMvI0vljNrHdZO9xlTn;XQTnWCttMoM`1K8*62KcZx
znW4!j0=RZ?qH`>Ro0NJRlM%9y;t5>(T$mId8J)wn(j`-QVr$i5}Jza6>
znalCmGfze*4rYB5Atw=r4(0~Y+9H~pDiPYi)NIDl^QYqY`SYW#&R;5#@6c)zXSOBznnV)2u&n
zUaiA%0wi2QQ;$R6mQe%vv^F4Seydd)MY;!|B=Ysf?Qg|U7-AU9*7s7rXN5i?-Mq;UwE=Cd8>G#hBBsLMdVM-k$4p@%#-zy$8tN?2Rthq
zmDqp|m!7^HAN#~J(T8tPj}~cyDP*vXjjfo)`HyY!QWtB``_!X2qNfQz-~6qAec-5{
zBZIrEm;|MWOncj#F>&i&Tz&2BxOekzv;kCads`B#Mm!+Pb58bD5vmFoSUYRSvx5Ma
zh&Pe@B)6F)3LVV4I3%x~l^9;9#E{#Vxt;K73j#Pu1p84&?^_8{O377)p+%dTa>y-7
z&E&B^+o<*=auo)2SGnY$K9GnnOl(Qbc#(cb@S5nm8bku@(ii6>vQ6Mta)mzoL0Ppz
zVKkpZc#xZh6`eh7>B8(fs9^4`3A1y)@zg9WVph
zX?u_MFyFv?>XEbY_;XLhAtQ#i&J07H2dS)AV2Fj(l+BH_r%C_8FaMthYx8rlU)hQl
zkh~AF@7=l+Z@>Ch%-p_@$!LfcoRL<(J`=;Wg&4ce9s-yIN&A=`lbCc=2)(9r=4n!b
zRIh|I*%^_eZW`enbKOEIOF{s;6XbyoQzR4Lvk)i
zlZlKz=mPa6?dbz~xS^TMBQtrJ$GTf-yNz!v>Ek^;(Meht^`VdnPnG}3*-WRZoBMj>
zf*_;_09JnYj7d8}YM$56mJnq-KDbiqn}LP3G4$NI*?oeq@jXXHM;vtRsGW!oiJKGKIJiO%hPL
zB!gixZASr0&B0ggk_&LE<(p`;MVR=mFRsS-fBy%uFgG8AL%qoe0F%N|_qRU({K1W@
zA4D&b)C4q14BFa*!_xNKxD`V%8%kj0csNuIl<7QA;?r>psK5n4b+-@mNL<;*+C{F@
zuy#<{-$l)~;m|nv)QMC$V<}^}ib&$9`gB^m@lO^&cK<+stdi%@(Xp6%?`EtMD-WJL
z9=Be3Da{XhC3&=2P1f8Hy&YW;*R>C8IVCJ3?g98I;_BOPyhBv5jS1_iV5W}8Z9W@e)WI97!Z7zWRuj&;K5F=FyrwCUKA^;S?{46Z3(~T^Lm%k|7h%0Gz%CA9|L|WSOK%_Jup@O0$Aw=}VNl
z_VI11T1I$b1m`1kEDb%E*4E?6Pdpu;`N_{lYd2cq^w!pk{T-dr4AmNd+{GXk_G?Qj
zbY-x9FK<%%?WLh#8ZH`za>vg<-tx}17%)%Bn&q1%ipK*$s;3!6VJEC!IH6H)skHzuBBhj+H
z9^;f-Cw@M1>S*+!QC3lnEv-!;MmE5_VTO7xUx<}EcXI6BnL7{$(ZP)!&09n8;zGmuVrwgYmfVHAm?P&DC7G|-;Iy3L%8fFz`S$F0H4
zwWPLGQ^)`wGQGCjMLI3OxI^UT#Gc`~nl`lqc_o1W=D150=XotHyyk3vnaQtXF7*no
z+KKG?H=4Q!Hy^~y-+v|gd+Fz2Iep|nyO#?%^^Q0Smz8TJUdi?>SIcc4a&65#m{}E-
z#MVC5A?tKfq6>&zti-F@o0H&8obhlWnre6mr_Ld42Tm@2`h{4So{h=3uckSohFs6r
z)!ZJVr%%Mt*jOwtuEbM+?XSnowRdA{WieLo-j7%Q?Z1uH`Pt~f-VctB#OCTo%udZ^
zr#q2&=PexZlyP?$zAKIsV)iKrV
zA`xT5L$QduRrL=H_Q%A7nHWOlE&!h4e1~N84`k(&q|GW6%|NSqcvbscs@&J2XNr$YbzA5@T+wt=2W9ahP
z82sE9uxwzrX~Og@!=PpG4JoCs3W_+C&{UJAps%|pCg&Gon|9Qws&>upHX5Q9rm7jFgj4Qn
z5Rasj+>v=oWT!^=Pl8Kbmk>4~hzgzgd~T7tzkFomVB4@p`(lzRq^1R|owJSWGw44Q
zy90+Oqj=a5UmDgk&PfmWwT=4vT(1C^x6|+pp0&I=a`tpQ^6`(w*Z%o0qx<_}e{L?i
zsN?XF@fbONJR1670DOV#KX^I1M+V~V2e)GbCrm`NHn&Cxs{ZIRPsD?Fug38U=VI)c
zkHs(yaQFK4SVV%C-+4P$<`!cGMnlcS^6X6P!SOp>HxmUk5KHeX@x;zKq2>^*gHj5^
zmW1qpNh?vIkIhJ#2z2776)o3@ns4kt)q{^+wAqmhXJhHXWG>|wC%%KBW@&4wiyJp!
z6!6i8iq}N8(YE6?Ti{woaLRcTvs5ES=0RO=5aU}{hS~Jl5zDFNrIh3ya4x!K1Vdfd
zV>TOYkw2p{>e_}GH48c5#dXmTmZ7KwBg#tRb8jBCQquk}j13;Bs#Q^j9&&(%9S108
zz=}#u#`W4s@2$Y8SdRvbSR;U2W~8k%2I=(b@-mLtZXCUE9s)MSott;kLpOGnZAZt)
zqPwjny1Lq9eR?i7I=kZVQ%}ZQ|K?XRlpGiviM92$IRC{jqP_>>`qzFt+K(NJE%aII
z=~Hp%YhOddtVPS+~YNWAp%XJed*L8q>{Z!kJW4#oRl`47>CXWZ7)7wtp=
z?|%1tapt*aVh=>ly#IcNnucB@FMK*y?%#>Ux892TcW%VU*x_6oYv8XHbLEiwNu1oN
zI}c(Wrqy(8?!utZLai&x9ZL4S2?vP!2>T`%7E*I(WCpzyMx|W5yYN?n8a1TG<|F-z
zBT5;?n6hduS7^IxiY(bqMlgSAd>93ws)73{VAa~iBJE0jF%vdMnXJqjYNKZZJ-xBJ
zu@oJ6?>S~q9fyd+>s@)&kG-Vsy~<{+&Mw5*kt5OFR3D4C?#Ag~_ywG>?U?@k-;Fuc
zXUF(>ocq)Zag><6t0$w
zQD!?tN^}fuvj?%!pXoem##F~0c-1?=a^|VWV(Nn%(bkIkUtfjTXcU-Hl(cvC#^Ur0
zQof}%O*_9woyP1g;WILlA$HIRI<5;#YcV`L5KEW<2kgY|CS}C@7Bq7CnKO?@Lawlu
z29kFN0vOE|AED|vN@@OfF%gD=@Pm)
z8WLAElLH_2h{JR}Pc=e$R+poYO*DAo?3q}Zn8Ge@<|}HhxM@bZ8zA`H)Ks)kuG0Y-
zLa^RvpCS}%i#Pw(uSUa>u^1U0jdeWj#i_~o)Gz*Gym#&Wn7(x*>LK{r{Ra?gJ31l!
z8A81WcP8WK{_fw7w|?(iarBAD;_7dFJtpw_myyhE5L_WLIC5+}Rk^;(sYfs4>}|!F
zFMJ`|V93drz8}lCZo#Myh&9F*c`khBGx6HDzfYvl9Q|X%ap$EU#VEwN`8wuhbtNh=
z&EsGG>DX3_tu4g;sl{}3r{8@yx`u{g1D|JSYbVWRdv90lZ)`<-e`oCC>+B%qhO0|D
zju636RPj>+9T@VBDMwlx!PDLbjwm?Zql&
zbc7Yo)CA-)+NhZZo!=Y=;83iKwt&W|DY)aTFx36Uv7rM2a&|6bPqWdE9J7o_Dcg;jwDcEW{G0K6zx2Px?7hj5-}m;nzAo)H#L(kcV(O(=QaZN?@76FGO=zgLrP-L9m`;h&
z3^-z1Axzppa}DABuc%s;7}o(3l5PWQ55dLKD$)pUe21Z9{Ae6N;3b&#)BnwX6)*ks
ze-X{#$5-hTCbdTsq1ZMK;g&uMen?LbrUEBd0$qIJ>3Hwu*K%RV^wdn^Q;F9k_Yd?$
z1!0n~3uu}BdTIuzV>rEwL{aNb|L<-^KTN%e2_#!ezJ7#D;#K*Z(o9a{>)eR`THXVr
z)9B_=kK~ZPDuQQw^jQ+u{iTsXXkBn+K!xv`PEHSY$YDN`DQeNey-GvoAao
zH^28I;F?d3tI5^RYC*`haax_j*uWh5p5!R~UxJy+wDS(3?3M&d=e(t(8DFJ>;2y*V
zG*J7BbwpN_j<|D71@=!rJ+<=ahkr~^lD<~nM)u|7IL)&_(adf~a)nV5+w
z7@(=L5u=Zsk5iY<$L{7%+`IQ6>c{H_-OoK2z4hDid;jF0#sH4u
z?KfV>)F8tWI6F28(Aoe$+
zA9J*hCh0Z!|5=#QMfgv=g$fA!QYi(1x?QzOWLHf8q0S@5aqoxOF=o
zd+PDHJuw-LNPBlrCw|XzI$FNbeA;zk#hsc0jrsZW~GN936>AiIiUX%2z>p
z6OQI`lECS0y?^s@O6`;;ghSlb!!$j8eX%q>4->fRc_-J696me}_wP={2HMp;a*;#V
zYVA$xFwE6lXkwBf&>FSK!l41rTWSdC?wSm>L)~8)9mHRd3)BQW$k8{n8kstey$>fS|q`bUOh^z6x~LlZQdJQHj0U5!;j!PR^BaYWaUppH0%
zmJ#?9U-)v2J^Cmi9TCXAyYbb3^3UST=ROy=UVA-YdDG^wO!a_m5#4YAJ|#%2IxzL0NYDO{RIbwb__Kf;x)V>tpy|x;9-ln_JOXre*H#v
zdK8uW%ujzQe)aGEFVWE1hC19wQ#7TW+y{}v#}CJAZ@(Xnn3qnRE0?|X_OwS6(q36z
zkAtPv93SXF+WHTT#39VY-q3JdAcDC2+K=Mh@BAPd`v+nXf5WNsv!DG`Y~H*T?Rf9K
zFjEJSgYyEff8$%xM+mfrX~-8iWH>tQTSMR=k^!!R2iH+dtTj=C1qghWNAifqTV>o}H
zTWG&zcqg;ShSs1S`ng1#hW>__`Ux_X<3l;^|5sszbPDNs7X>;%Qj5grp`2OP2N(`*
zp{ARn8?F=Jd&Jlmx3=_enH>#x2}c)Sy*&K!;Dn|FyO`eW?$
z@tD7TFP7(*(zD+(vOo}A&lf0vF|x6W8!Pdxgk{$y;>!OeRUvC+(VZYdV8U5op7Zlh_Mq7(R<;Ou5#
zHYRU@sqBM}q~R9=l}IV0b15@LO#(w|LZr`^Th$I8#`I}dwVmWujhol7)V-A8b!&@N
z?C~zowz%7cfz&5zR|TL4yFYy7P|QtEr^Hq^w;`$$?pgu7dHSJ*ySCxjl}lxA1V-AV
zANpp(;7hzthkM_EBYYT>h=Gf1KYSy05L!nXWr*R?p?oWRbqifwT>V%7s?3u>P?u^c{USspXcLt#30WJ7%XcfPAIIvQr1AX<4S^D`v^d1;yuLU|
z*2peFZJ5A8T32jqLiEgCh_avr+cy|jCv$ymBgYAhVxV|3W;5*^Ie9!L@7#-uk}r(l
zdXtOcTv)RktCW)o+Pc~Z6Sosa@u*f=M+3BB1{?4voe1+~m~}L@OU-gNlloR+h|TRv
zJWt3yiB_5-D%qspF1A^4%mtxsfiax?nq66nZD5lz>;B>Kahym8S?VBuQBU#|X3q5U^C0hC+><-SMTr{)_Ref9HRQk?zj8cl~Bc(vWKgFa?grc=8TUas5aDf2j1sI7;sClTo{ttpbYR7sV~~X
zqk2N}MXSZC3?m~zNQY$V3~l(+32mf})~32x0l|xKi$leo&PiYbMu?v76A|@}jmFyS
zT)qN0aNSABScjIjs4w^p`({@7KeF#t&)zQ>l99%JrVD{cO&6)
zhF2@rg^)DC98(ihX$D8|t!9ac)?f%i*vN=z)mRi(JPHbVK|uff*f0DP6;fb1K(P+j&>>)>A>p*pWE(!VB^BfAPCUXI}mYS^V8;!CB<
zdcIGH)Ec@;^pt-HCIhQ2WClB4j
zZ^d9wZ*F+gj?m6b&4J66=b2-@x2F@!D4*pR2c
z{N-4{nVY!rL87V=WVB%xRGaIlwpH?Uz`gF4GWghq*qok?<%#L+kVDJuXO9!UMTU{B
zL=p8mY7p(|Kl}4>`@27k>+iiEz0OO(`400QxpFxtZr*&kFwf2sF+Wm&;gcVStaWjd
zj_r4M$74V9rI`52Z^jnBhO2#){2Xja;=&9ts_IobtIbrxrg-l}kREux6Op`)wj(`>
z&t0yw;9iX=v1I}YFC*kVh{|=DT>EXs);G{zz06=eXuiYGT!~k|{llokS;b{Z|3IhB
zVc!;~u7PQAbdacKBi1)JfdJ-!z}?*)8LqD`6G72`N~JUB)VFV$*#UQCal`el#8BF6A-
z2aO^it_%YG(T?Bo$e;cbu|#Ni`^|S^jgF`id+`&-v1Prz{qf#ce=F8p$%M98zCRI9
z{?t#UY
z`cZo19n{m_PT%U9ax;uAi0<}8s`kOd;Fz;7psb_$l0nJujIC4RGLd^C80|QK)`CfS
z{Q0Njo!|QdG{8<&^ml;671}ORJ$C9y%udYZgwiUwYC@AZ`nj>P9<9B-arEMaSbuOo
zZsR}r4uqQ2IiI@!bPo6oojMcG{LD|q^{@O!w5+YfJaIgVpRiU)ZtC-M#S&CRVGG3+1giw?}RX5;St2XXWiA??h3
zY!Ep(*wsJK7qd9_70UaHT;2Z#Be+;1*Vxf1rASZGg{2NG$+ueo>I|P99T^#liOEUq
z7S1BMeUs*?pZV$d>c9Nu^fUB~J6c*m&H<7SC&P6j(49dRaG1s}o{ihDzX7v3^0${0
zJ|1l&hw*+}ANx#v@WwlF7iJneb0+F<-HdJsQ^6VA&{GF4{Q;#9
zUQH7LxJWypE#={p^xoa4plSnBb9qQanL8yAVrJUfV6w_yY+-UibMy@lW`r}NpwRY(3ukof;_CGq
zIQWfmn9%ax-HGgL8AWzp0%rK%jvqRZ3H
zU_^T<{apL@Qkn*tz#|y}a?=0u-r|RO<%N2j%Cz$-FlalFE=+z`hoB-I$d+c}
zc8ETOV>pBmbh--r)_v;Qi)Pe*FW&y#>|)w+@nBiubD)U`IJK9)#3+KdwgywV4S|r5
z=18hLt=)StYr{B?-M}Mj?#JZxeAaXEvGZ|{_7;f1G%>wHLor9BU|4(T=pn-Xd4vQX
zWNR;upFSQ9Kik{;qFm?te+N`to~7fqu7`^x`3jkY6dA1`&;1S@KQQFc$ue)O5A
zV{3gQjy?TIj1P9j-oi2w!cGo$VNi-{rSqCqiI&pOS$KVoJmDrSNhzZJ&~_4?eCY(j
zIN3Qes-=Y2beW4HRR+;vbcvoG2=!4%i8vr2*P4;kGCt%))wC1Q1JfFZOyl&Pee^;s
zPtN5$gZ_&PRV8*Z9u0I8H8?M0_?P_hNT!o4l$R#)QFKlNh>?0%Y%WrY4I%-0V7%&psZqv1<^T`$V%
zEl9O*{J4ZkXHJAX{`^xhiG!w8lm_Z!4g0qWp+uzbL+VT|uex=Mn!}MUS0O+M>Jg9H
z@0?IU%Je~2+zpj}9XmSCa}Z7kA52W9_j(9_VhjI5!s%g8EiFawp`p0_!HwvI$(-j$
z0n%Y=mRRB)q>1?CZtC3uzVrv=4)O_;4MOfb+6eDlznJ6qIhIg;Kt88+y>*Z$qXh2K
zbnq-k`=l=S$zWs@M;4HA^5CR~@R{QRetOVm4y4__GZB3Qy*bQV8bP~=69^+SAHm7n
zoL?0+>DjyBrI-BT-4RIls;oJ;E{|)$B+p^v6}}5sF6A~x^9a`gG&y7Tw`$8-b-Mx41gXqOHpSy4l({OC;AYVxXX^tiWVG=ZX{Gyoo`8o*wd-zn4tn)qH*q9>gzZb@`fqZP(d0`)hXs1d0$l*`T6Ahw+Ef)0_U
zx~=owHY8{lFIh)YNpYg2f=cctd>Wzbj-z!nuz?fljGb>POQbD*1qf^OAhL=EOFfWC
zPl@7?(7Amb_vtKB9=S`&v@?*KcGX}M1Ew5xvJy!@=QE*0G63K)Vs!mgQ81fj}xo*O52dbcZo#*({bdHi_tYY
z97E&dIC69fPHG5OLMDHpG=HF7uy?*_m0QiGdhDd?Y@&aVOgGElwOgk}J1TBM`tu3liX=
z3e0GM77Z;_J-Paa`+Nh~w~j!#9NF2>lKGuC*A|PBT@gTs9Pk(#8NuOO%I#W|PbZ~1
z+KSgJhLuds1#A?J#MvDXW&@kG3Zj(g4W7%C!<1`+@Eag4qXb6-u_?Cg%&3l{FUlDG
zh(%FZV}?}mz$1gFRKo;kKJ$D$`o&L0AHK~&Cjf##eZNjC>Dm{ygeymvk=*;=eJQ^3
zOaCNV@rQC-UGs3r^oDHej}!pPw9s!=xFX_074#$bz|Qj)(CUKI2T1bx*^{xpxE90x
z?a{Eam4dW{!{`gMu1XSS`_e^txV*du>@YZe(qVM73s+9n-eEWj0hbq+GaOyn+K7|q
zj>p8U$ymZnyQ$~7N6y8)tMA7Y(SsYFclULnh3ayL8|Ppg$^78X-8g*mL_Bu!V$}Vk
zqoZOf38|#}4uYiF+{Y%QxNWdY)K{0^e4wLT+=2N2r`sF~2J4g%}x`@-zL
zPB#^*4Og-03PcA{#?m4_Qh#quJ(xk`VrtM1`U)=hck;-s_ncb4e}5|bX~SnupNO09
z-;S-iy%;+(7Jcm5tM!igB}?TgpxR~_m~jqPsosqMeq*ZpE{SSe@I8Ha1v
zT*;FvNJ+4O(E-r}(o{pT+^JgkUI#?v_>N<~Fv>GKrwl1cBF0iRW|5J+cOz@(E+mC*
zyMm{;n-CP>OJ}t7yT0*yp--vt5Y$-4ZK&qXx(axO6D&hAKf=ZWz+d-;4^{nqz!Fpbj<6=fm&R6dSYOpKd!%hJ!g75Iy%tq
zZ5c|QzHkaZ23mZ%r}M?!_!8*1K&Ef&ssVgMCu8%yG836$pvdQ=R9i;8YpeS@yP^dR
z;S#pZie7(l%pA~=@LE-Oy!F~!3Acy%NMzWOb#N(8D4qU-HD;~e@XW=tM1Cp7GqZE4O{pbH#%)k9s>{kr)V1#S{=1T@B(LotVN_&*d
zm(c*}5*J#h$-D5yPsXD^|5Ig71QS;Q(K$~b6HsqTx!h~@5}C9#6?}!i@7Q?kudc`H
z-Km_wp|vcR`LeB2JnN!Cab&-&(Cg-Agn;WVB7u=dAB}Y+S;^f&g4L=rjUHNiOH*uY
zY+7yFc2{CKDyltq+`)k*-=lQdoG%SKSmfHv&c5y(d%6D3^>`GGGdnp8o)6+4!gQ1{
zy#q6S^^L31f?z%I!c(~{@amgy$DtEPFNA
zbqmR*ClN^Shi_2N7bl$&4o^%JFPl{DZULu
z^(S1g(%sQXcz8Zu{@yF8Rfa|eqN}|t?tI{@|2y%>lfEB%i*WHlJo@-!F?Vk&K6w8|
z&h0#f=BQV-8-uC^B#gU<=nJ@ojGa#Iu1b#E!>I}UjiVfXMxChyJGhs~sz&7?4?5(k
zW3__bvrHypwlFmkDMtYLItpg}%2oOrAfPT6jYgau8;(t4T{XoH(8&ZEa`9fu12N|$
z1Z{ZXbuy&zlY9~cbfWrFw0U^UVdN>KJbo-LXu08?v<;*EFW```RdtP|pmo;prQ*_Q1Y
z0=sHSLC^v*9tq*R;Wtc(SJ(!$|
zzLEa;%ujq8?X#Zd;ppk(G15O6fAIBh#mMO+@%-~2i`g4@>c9yie87bEQ|rDrGz=+%NJdFY-h}
zB9OLpuGB)#H=M-@TA_nZy_BFy9|dh-ey-AK%&%RiLJ(S|Q69o`{P`zi7~epx;Y%j(
zU4Jjmo;wpSzw$b!0j+`A(|4HwQNQvlzZ#QMQ{=fGz4_x?{$QAE3)N_Kv3`3Z?!Wgz
z)RRB`1XJmY9~oX}QC{*%vT}kXeD)dD?+PrmtI>fAv{*
z<(T^5Zsu+4Xv-h|@a5b7qla?ikI5T%O4Q)&qA_Of?4e2$5{@J)65`yvYE(5Yk_`t{
zV={>ZG@nu-!L|3QWC_yeizEQ2RER94I2nU7E}Qb+;b)mjlVsZ>&Tj7?G(=xVYgCp{
zr_Pd*N0X4l)tLj+z?H+vxttDoguw@%B%lm+`cuzD@5y77sEhm9Of`T`(zWX!;wI@
z9N==VnKHCIh*eC%9$Ii10=P`iiVdfE9BWIf38ze(KeJGA@r
z2u?Q}9f(&ObNG2>X(hJ>c;cxmF$uvJmX_n>sgt=$s*Hw2$N3AV;|IU@-RK`b6a&3I
zQSX3^OYn??Q{7iPC2{3si6j_~=!p#98Pp7jgj@qa2lVDO10Ie;X$3j`BZp$>*wJV^dMpkA+WC8QYqkY=nHL^PJ8HV+eO6?X
zvq-7-qx|Lp@N(R{cQ4MIKbwPHAA9y0B(6O!T|Sp9eOxba>C*Xl;rZucd0`bh+mg0c
zg4(9$!Ft3+wn5t&YWn3~Gm++mHfx9J>1&BI%HkEYlK
zmyXjYAo^5l$^N14s3VW>J0y{*Cs%~gJzvmue}#4OU3l^maOme1#&f|C@qN7f(#vt?
z%K2QS^a>hq6w~m;Gf%|wEZp*(STW8$&pSBd(F49>Yo7lgku`_rLwUSiLuynyK``gI;j$efm??Z+^(4
z*(^iN`?1m0n@jBuA09-qwsT&^2u73Z;vPGp_DcrmW_`mqvs?o*m?Mk!H#aO%^H4^(
zHrLl<_Q6baceh7pcTc`TKa6Q;@9E6p>^C6z7-rd2g3{55E5Gn7)0#
z*mTO}DS+vc<{8DN@5Eu9F-j7xoI|NK{8GZ~kBRyFnRW2O
zAv9kFbN9nP_(7a|;&L3pANuy!em|c1>?dQOr#oJM3CCF{Oq*RfDBi1}+lT~ErHODy
z9E}8&9-m3pwg$-sKyaym=r_m|=Fx_yefA4NQWHQaiLUe0Olaic?jnvmv{P5E`k|Bg
zqDB?@xxT>q&1_v>6^a+863JvOzs2B@Im^kcWZJ<2o5UeBZ|)>QeThs{lCdyHXHUc<
zkDiN*m(IZu=kr;Oxvfes=FQ*!X1-eP`;j@$06Y(gUTyY6dF5kSZtZ(M2A?jsZvd$d
zH+N(5Tp#KHp3Jhgj)_1sjGs7?@HrIR)6-?858E+PQk(S+bmx-6YIAw+!wk43-|N5k
z!yGPe!-@RZk9{%@V7isXgZsZa!!ItNFKVkpW_5MLT5hG(pgODw8oOx
zYui(b9VJYsi*Mh_6EQ^Ou{yN?vlbu1^g=#Ldr#Y{?h-K+m1(L}uwOEjOW{sFdj+*w
zynT^b7?ZX@nhfGtO1=auqtizjUeoCFo%>VqYk%h-rm8g>@esrh836_X4x@eq89XY@
zLdiYQ=qx%CdiJNj6svO!*yNp9$K>TE8Pt;lcbr|zxU{eW0UBcL@Mz3U&&dZ>92d=6
zO!GnR#FFWJ)#?sQj|{>b!p*%KaoEp8$HroMayl2Pc6E2eP+xDn_M=zh^p#7|*VY*?
zfA>c?u!GU?lRcd;+8Ha)IG6^raXKSm6gka;r-C1uzjQrrM=eAjD6iRN%
zCv$K6yHb_SIQi6Lsj>9_WrXYlCL#xts%7kRY6GDo!8f*l@K1j^X5PP*8%`94wXf#2
zgoH9Oa0XJ-;J_Ns$!pkc%`RxQz^kvm9gWUQL-4Z~Pv=muZ73Ml(M0qh15$A=MH?fu
zOMig~!2YM-L7l!J;~<-@>sK5;dMJ0QS>GU3hj9nc2JTfcH8B~Lz3n)I*^{YvsK)_B
z#b^@0p$i6h?D0qAjUT>Vn|(xO0f+-YiC|htCP<_gASIj}nA(GL4hK`twE-eTEum>}
z96@GMb0iyp1M9bpL~>X(J6od|7r+*eefraJ@8%7Nqn|+Z0Wr=zaV1Uy=-i!~+K8;L
z=6s64)Eo(uC@E6z6-m@;1F|8+1pc`jccZet7N=kar`MCQfhAWsb8j7L1Ir1XKy4wB
z?|k(eaqZhb%)y#6lUjtK)L+^veOCay7dN)AQ29(;9K@-QJrU!lPsZZZw4xtVIH-o%
zInR+$i*p&QS~E$$G3N6_Cl2SY&#U5X&&bA|SUl8F{*HEcHxY>@+=(l3Prn3Y6My60
z$f?YEOnUAmcIW7P|^iFuQzM2GiUC!mPcM{$o#8%3wIM+I^(V05z=B44@Seuy3
z1+^L^>oL}rVEPeTn58W^E??B=nO~Ww#C1reFKp|1<5*K2*svf7UMrtvEH#LA1dL`ZxMi3V)8aCL_4u$H^ojhRv;L
z8y}6~uFl*=PVF{Gxa!;BJ3HEb@K_Ztzv56;p1Z3+pRVrCd1wmtr3Vl12l4L@Csr%h|yPl~Q>!
zgZAEq5)d7mX+y^UIk(TX605B)J_6iNg#w;Tf?5>!Ik?0*nIw^G8JLE10_|*rznw3+8cNEbc@_@p@avquE2ie>T`xh0`8)AOqr#~Nax9-M`
zx8KXzP20-f{QSqq#}Ibaqui_{LmIEC&`#yOPzjR{K5~el+DAl-8U2YW6_N=o<5>dL
zn8xEFQ&jV0D#ax3(7-^eNrq;F?8y<+Yh2`Y#@@E+T
zT_wG=o7s~YQ?kjY)Hz;~?=YH=e-7RVlIsPNnJj056`>Z?FEW8YYoLSe^0YD*!(&W^
z^_b?cde5;#as0_A;-znXFSqWKSPGcVo6F41w}3WC&1u2v;ZFejKI7ofKrAdQWtuaO
z{uZ~tobLuC{-TbHXAp^M?+VWKd(e8>ct
z5Bnz33!J4c8Jw%UFNZaWmr~B0`T(g3=%;0KtpV^`GPMCnG@tGHGe`@w%kkdbiD<|4
z4E6P7MB+P;ZaC)rLyl!okD+(^A;949w=<8cgp!Nc_%44~gN6+OyL&q1|W0XIpaJUd}@L90C-nFZpCN7l$MxNMODx$^2F6UH#{c
z`Gv8N-oq=^ug@)?Qp#D4<-nTYD9ze_#X-M7O_0u^%_Sb>ZJzPG0Vmd12OE4dntNv#
z6)1N-*>e^WrcmqHh7p%_ice=nok&_;TuCC!G#)NSsYN!nVPEgvxkqI6Nc45~#Kb*(
z2S+6x^eWxYS;|XKUx`_qU+LvW8M$vW0N;l}&p-J{boF#c-9I=wl9=!{Y=<#Rr);V&
z-?-U_dzunN?f-V^I1Q0*
zG8uvTJxn&SXgU}`%9;(>oGb7}UZBeg4@TNqzZy
zKg3sPMWb!z?CO?NzH$uk`AraFEI0o78VTa-1b;Mc#Qr
z+oQ*i#pvOoxcbstsb!pS(rhekuF*t&3?ClO0j~*&@A}N4k>T)nJXg23qvPm0*&hvMjMC2MX1WYIC>ILOIeUAuo5TD1kc5eFJj~yw<1g6sb3rE
zy@;1sIV4MY5w3Po-5Y(#|CZ5dYzKIaMFY|#BMAe=vdw~7Rksieti&{h8obT44^N)c
z6lJU20H4TJQanr-J_)b1>JMlJtlxgQ;MQKJPe8g&`AjDEdoa)w$G`l?;v2vDmHdU5
z1N;MreqEa8Jc1^6SCdN9EnP6p#j`PkBbibO2rZ~<`&B}}UD^a5G8<-Vs&YeAkfJ{`
zGCUX)cOKB?#(4VEACD#KSwZ`VSB1+#BzIbI*n0fP;rww|S6caAtHL;QpK$Z1`nq4t
zwrSKOk&c9!Cc#9Ak%M~$X=8l9RBTh1KUA_up6&ge=pwAFbB7oELi8(wql4D(v4*DZa#cP~lH`U4~W3P_i24>6?&7wM`gb5{xVJm%
zE4w*OEuluoM{`pQ86xq=p$1t+%5UAdA5VYw6S;Y(=IbO5-?g`{M{|2i3>+E6#5cxo
zf8}fO#1}ss{fCBQc6vUA&_%=U>o{?9BKC0u4jnq2V;8Q5&iRpFI(7&RDS1?)5DFkO
zJbZW*8>mkp8Oyqa!YCdxjfbjBsgjE&TusW%m0G|&)NAMR=j~`cM>1*KuZ$(@xfsTF
zj1FW9L6gv_arn3|!Zzsd9TE-WEE
z^Co2Fzl>bk6rLjGIa)}c&7sDy+l2{WKoY@mGHG*1OMLuK{#?BF{U64=@4gougnkX+
zDPe~Ja)g$$`NJpFh_Bb#_fuw#kpuYc_tQ>;EWB=W<
zz40Og@-S|FGeU-R&9mLOX?B=vhka{dQ6aqQ5w!47W>Lx|x*bZi
zgDr{fXr<+?N4fNDJ}p~n2-|}Ir4_3y<%FU58^uJ)!zH~)RL0!^BV*oq_gd`Jnd2vq
zq<8IWVCE?`ssU((BjKoigdzI_oDx>5K4civGEt3S3Xd~yfm4Pm14T$M1hw4Yk&pEpZPO`l{etGs
zwip=b&4DC0<8-GLHK1nPx104xdi%O##jyigwXK;M%mHMK`jqtp42uxv7CN`
z!EF=je7&tH=E23xy$6_z@(!oJq7MMcC~C-By=o%5kPRveS)X_TD~`$Sj-XT3?H!%@>$EpNxEar5
zCT8#5&z*8T#Dh%fuiI@SKxhQQ#{^WcRF&Fl!WL|m9pDcnz!W0aPJHCB%tNC2<@3-#
zuolYdQ+VXh?o*Fj?dMm|EQ+E}xF&$*KI+8tZbcrTw#vAD57c@LXd_efBN2C-rDbz0bVV?_!ntmDL=D
zbRfyjXGjYNZCAFVbEr4=(KhZRFIKWWm_^ARB684CTv=Gj_b#MYzK5#Drk$(!Eua7L
zPsaUQceAf4n84%D9i@Nv55|WMikI#>0_-g+X9Js)4?&`;nD(-;7smhTOmdsZ6&N~^
zh$WA?#H3eBk!NGyn(v{ODMT?$Rl3SZ;4U6hs%<*%QC2%a5b73aGAU#r)v^T*ma|=7
z7}3cR*_w){f9%t7BUT74ur{k`CbXaWWS&M*i-S!_g(=n_)KlBxjW6m@X
zBkmJA`d0P!mb>JZ>FUm|&RE(l1A=Z~ZkT#_{7~GxKPB0s;Y&STX&R(AZKR|EX(6J3
zLU<1!+i*<_Bm$|FB3Uj6i0HIAMWG>Qni?D7TF+X4!)J+T$|@=5mk?HBUJq4Y?Wls4
z?a6q(P{ibcB=&48DWAF|Tc7PsB3^1U0eJ&#SU_zF5tMIJEJ%!l;~TFoK$POQjm
z9!kG`*H?1wp__^+M~MSIs(1HNmhr98xp}rWpZjZw=?SQC2GQ6cCMGaz`UvDt6_v3(fD{d(^OvxZ
zVyEOvJX#4(0Xe;7D8Q!5(?KM&9k!E7L2j)FC5_J`4$_=w7?oZ?@I|Z{CSroT}No6S;83NJ9q7^^P!8!bsa0
z-2j_Djb}#@bq6LvVdm^YGO%5C5NhPa
z;b?2?h_$t~XmY#5tx85Cwku=Urhb+*A*{%_R3>Fv&O0)@zZ8S_;*@`=M}ZcayXeQ7Pn
z3|wnDIWZl_E}o7lnA&CS<3|p~>Z;okp~28*B713JDb7D}IcedKr?_M8t@m%niN`MD
z_w46>3ZlC19~>Fxwh**PXE~JSBsLxNhcMizN`k2NB(myQr2E{?Y7?!8+Z=k9sIF|L
z6!{7h=x-$PxR()%Y2fR<`7*B>hPvcP{vP@V)pq=5)KdMJKM`tY_$W>3k03cpM{cNr
z)mGCbEEJG;WFWT+_JtQ}2sg+aJ31BWZb-tW}dQKrEpE|NO@Kif8FNd+dqr0R1{b&F;^Tx@;
zIdl@s-(Rqi-F-JGbB5Sa+JkuRGoOsLh53AMq02q8eb-VfQU3<8e)da09#?<#YAh`-
zmPx1L7YJLiaUNdVNeSq+EtL)_)c|ESYRt5nWP8mwi2$*@mv9dceGi@$^U<%j}|B$k+2>?S^-DE|e!8c*4G;w!iEC)k
zY1_#k+>q$@M0;=V(r8eBMl5+>=24tL%KmdMZQ79iHy1>Kab#GXwldmhYG%oDo(rR>
zN$PSQz#UaeD4x0UTGcMjr2`4M(O9d$xs9Wm0>N|7ZpGu0I5*d{E}!4Hc@y*J4~Z=0
zc1A9Mb!;Mi4eGja<5rwQGpx-oMBU#z;xEA#X|oe{nwHaso91kw&vgdnR@J;m>6UBu
zQU6q$F)0YL6S6>tOU2G)x2(&%8i#wH^zL8uC=wbERjEYIBvarJ-79D_Hub^BQ8I3
z$q=*H^OPVEnY)sR08)&hGmN7Z#{;CT;D~O!=Kq|C;$wO1$vqpbla2|XN9h7*(nY4J
zIw{sG60J7jlwEc#}A!r*v=@y4pNJ9^`jhAD??|
zm?uMfIE-vxQ}Td8<|&Lxk4R6J;8`yHf|1-@v^M@>^*N+Y-lDOTA8L^(wB_0krPJYH
z8CN{|EzAT=NN8$8J_=58p1Bit&c2sW7^WrjDINA*oehFwesv`dofwb&)i>(3-z!8A
zw&l2j`#rcSTwz)v4E3j*7iX97d#2+2BNt;9$J2iAZ|%ZND?|-F?fDXHB9XrwH{h`G
zRCgSS7|;AqCLmuT%zN^vwser(uFag<%#y#@JbO@+(n73);8J_3&%=%-d|pNA*fw5%aru8-i8z6<$Xw^%~cqW*dVSbB|i71&&9P@
z-%dx^{Q6M#d2x9e5LErNF1IE^fyfX}fOYng3U-L+UKa+@u_>BEd+BJT*LF0CUF}d&
zr{tx>DQ!N>HmJ|)_!LA^mPCmrUTj-$xi-X0wLGUrkeh=>JhvY6>kUhQLNq?4SwKyr
z=@C*#=8Wk*{0*amaPm=)h*OI67lgsIgoAtgtZ66~j?o
zI1(BKN@n3sQ>wOESaunj>L1O>Gx3m;O@CJi2i-|k2h{c*A#|Y6h`=3JJk0Ox=K^Vu
zJo#wsRkjI(HB&GG;ozfBKOQ&V#YZ5F^ws|bnB`l){mtCHRjsBQpNoyfKendf^F3`Z
z);QW8rUZ*4D@|Vh
zRMV0nIE%AvKe1g9s}$!@EnJckrK%*OYS`6JqMJ*SsDa0-*P1$(7&V8?k2N+ol^tV+
zF@NWQGD2pUR>Om4t}tz3ylj?wGmVc#wYJo3=BJzx`%E}|dBxS(K1*|vb@)`r(-;eQ
z6UW7u$aRFaS^Ws7tZV(wx;psdlyR4XNGmJp5L$i~ttwo?uAu&lYMUn1HEHHK%O?O^Lgx=5ChbF6`OWb7Ojq>SqZEU!S=U)6#i
z8NfQlPin!uEJQ1eEaB^79#7q8wUt?xO(r5y0(vcO#KQ&>Uz}3P+b8lT+%T{v?BvBW
zQ2`!**kk1Qk$m$xnT+-v*}U=Q)z|=sCovNmpf=S0%{mUfXUyQyRI?+_tX|P*k?*)+aL>
z8s=NdNmSvceoRKXj`kzVa{z;?*f#YY93AzUu%|kun04n4F!qW3!s6k5I^1R=N&KZ2
zv#(Z7n(IMJ-wHFx1lH@dnnl~~JVo}8kKX^e^Jntay4Qd7N;Km?I0+{04v!zk@otH?
ze)w9Pc>Hpj9)QcWBda*8J!mHBmBP!p2`BvBx30$JCmxG?H}A!%^QV&88$RFN_M#ov
zX|jMTeM*N^`5=ijO@W6*@@s|3u_khDmpqrRBq~Hv`Xrp!na}e1tRNsgWgd!f>rhfe
ziqEvUX$P}B$W207zYSQ+hlkpLB>G>{vvn>gnn!^jc+JG|P*szy^npLyMDuu<&o*ns
zDa=Wv)7T6Xh%2=l<;`cmAe!3C;bJOE7^#vLY18KdV?wnqMazWRr_@h-NNE4aKstxD
zCF~yga|SS@Q|y*>*VW-eBe`_lUv$$?QxvXU`yfVPj0)O9#+Cv7&FWnu6q(B(C-pb9
z))rRt2SE?eG7b0){b(4lTm^=6u3Y9Ua-66r?=sRc5ex(pN=da7c8;v6_R_X-Hf&3^
zSLJr=lxvd!e3i=d=1Et&lKJFpu5)09dnHYT)Hd)`v$$YZ2}<2$U0J);*q)ABc~?^y
zY)4|{b>`C4?PNW|QZ$X)g4(E4$tm~Fkb-Q|5+9TkZq1$yB2Kn2PiZze>~m4)<|*Z6
zn$&EhS%LS(8{k%0?I+j5E#hRvgoBU&o12`ef`uOzSXIbUlWz#9eyg(Hy!~i2QA*@slTVmeQAHj-5IN1p9I0{r8jUuD@|L
zdi-VH^k@Od4r`A@iigr=7m}Op9A`Uj9}}SvO~R#Spp3RnXD&Tv3YJb*8OuC==~z0H
zA`>7zvVQWU)RJF@kXWiKDlX6YlVH^X`A?LlmY|+&FCTIiXxpGY&6V)fG=N>*MAJwJ
z$3-&Q5hm`-i>bm<&c&mUp$e0$ml9Drt(>}8WjY`tP*VWUMiVNE$PiJRmPAQAa+xPB8OG|6|Gfr6b6CK>Y
zbtl&F2aFb6J0ae#UB4O6|HNmK!Q3CarKK?)M@JnW!C$y`^?KC(kB0~I2hg%H0Fxlu
zI1Tfc_E1KU>+GCo)8+P$9@)Xt$0Ve6cx~tN0narz=~zk}>Xb4fy&RlnIMVj&K#O%%
z>oZRwga|9h6>-*+njo{4|5>fi_{c7$T}pFSLSzPekP=M2!m9nO4Sk!({1Q}RsSRWp
z8Q*yenNL%u#uTQM?rfPO@l=@9s4BICFxh<`+lKWTeYg{A77`wiT<~4p@YI1T>OVju
zyU~_2p+%b&N4*0^aLCwshJk@0;D}h7U!VdQ3C3`5%g=t{Gx7HKUyjA~br^{Dn)YM3
zx4-Q1jQ`^{K+9X3@%-mL8Snn+^{98bw@4B3N<$JFpwjD?Ik=X1cGwPzWHU&BkA5Xi
zv0xAiVAJ80U`aGOE0VbO5Yd*gu5=`6M;KhVVI757)GNYx{vi{Tc9fz*_)?cz!Io{w
zJTh`UuvyOV4EpVY6T6x1!X3oE>&|
ze`epP66S21Hp=Lyw5D!8`GetJSKnu_Z^DsdIb;+z{U#TTlzU)6+NFnZN4BYQLuD`Zzo`N_5d0H*egI
z;qfu|Vuk=fU}JJtAqvFcY=?c8$f_c{@Oa6WM5;=q6&UOL)Dk*VV7jPnz9LMOYMN3}
ztI0Yot0qc9W&Tp1*>eX~%KG|U!YSeNG3`lA>!m(7uP`m!q1OB@X|5%NhX|0s!lj*;
zS!G3%vo9X`W9cG+Ldhf+mY6=a4_=V8v0ZkeSBU-)lTxP-@?{{dQp?bQud*4Ft>@xe
zO;5p@@H!+fbLCGYk>)P>_a|qgl}JGIrPFxk{AtR_(6*9Iq$xg6Sm~U`>#w~LPk!S0
zn4h0Vb9T(BE$m7b2o2&33}h`ae}2H>Rg;=icW6qdKz#a=!V=0su->VWgBUj-1Rg
zgYEK3)KS(pF;u0#q*7K}7!&4D;2zhs>mB?nIQ#lxB)Loa4`a
zac!t6S+ibXunvi?&Pn)4cSt?eKY2a-qbIhJn!!3Cqzout{m1~~!9Lae0{dcKhkP9t
zHr<&)AJ~rf(^GS~SA*|D`hzKI0!uo~ECW^6E3vq`T6TS(c#yP^POF%Ri;rH4d3RRD
z$;@eT+V8`c@b{_`Z?xemr+Ot#1WOz_*J({xD(z62>QF>UTVFgCFb7`jtep~Rs_KF;
zh$i$R#(os)q*O{!4^2#we9@`Ym2|z~n%St;>0vaWY0*RQkPLv8hjl4!ne!vaPO0Tc
zW(9;icrM{`WKbz3pKoHBSM{ygkSS#P5+P8N1hEWXf0iiyCepJmnNUC)fR$5fKfWT>
z`~}7m@mPNf4=EZNm+Og_ET8q$H?B8uo<
z3X#mnP+u%hO~r%hDa;p#x=W+CSB13LUgdHf6+{qF6%apB74#D~M~GE%}`7HY`F
zg`j2hPxV!hoM(HHNGKKkpNW!TfPv+^x|Z>y2d;?3P>G}R(gnZ
zn~-smsc6*BXg_@-dW9p2!6A%U0r@@4K-m&!kJL2PYnevd>)z4XKKUi9zC!jl;f1IW
z&MGyH=5<_OTl`VtrN$uphj5Sx3@(KAkQv-a^g}M>F*tCGz2Xm)@ruMPdHqw(TaWqN
zv88AzV5IG?whsE@Ku|;6fQW9TYrhH{4zcgY5)$21-xTZ1YjODSXht+{CfW}Jyz|N%
zaq8@u95oduzP0s@Z~Q@=J$IgHV=wx9dvQ7|;u=N(<}?ccpM*@{56U790U|}j=c*y{
zr^Dul-cUNfUf1UsbK(AEAUYzzGJ(WRnq^&*mXB=}{85&4?!{-(9BLfD)+pv}>_ctg
zkq#A~T7CJp6W2nd?<4WmJ(d$5nazg?7+?uD#
zwwZ2A;w^Cld}L4mr~EP=b&$h!VNT7PxGXr#@df_W7y!a$>4WPFjvpD%XX4D?+Z62?
z^>Fr=<7JA}xMWJaQvT54Ly0%H6V~b7z_;+%dfNzXufFqMboIIZfCvb!uudBTN5-f_
z{{?}t9?9+k4J#IO?`z(_13rdKGKYN;}UT0ZzXPc!y8QJ|9MU;6YhAo?xsuUXJyazBUjp-;-
zUIOVj`W1;Xk5Z|m**|}!W)CB+xzs07qp3E{=fW8^mg?3r;!VcLUI3RPc?wQyraX#-
zC!T>re2BLc6x(XWM-Wj+zsu1ZY#aD!F7eicPh-V1b94Fnn$EDqE1DQ%h
zR6!!i`utx-J)KShOVDb09j`=+1uaV*wyPO1ywgv~(a4l$>X0zh;~arK+W@H^PHH7{
zQB7%v+pdgokoEdG=9!SigsGm~Ov?6i^Z`_I0bedz-k@EZJYx
zxNUpaK%c~Y;t9sQ{K!RAdRe1r{l3m-S+a2CzbeBAj&VzT?^}P6E1jK@lwH?WR^r0r
zmj$pe%%`ibyxC#7Pe7F>ZFBJfNFamHYxzvFQ*yia0xgh<&}wFxLy1T&V?jH>Maf_7
z5P&BkK!j7->Clnx(6$U9QEP{YF3dq1^@-Y)T*{R>3)#zOY7P-zBu$M4I9vfe-&0%nV7sa3s9fetMkY;jne}i@
z>C7ry*yr4$0GyiF_R0z)>-4RqN{KA=FX*4Y3F)C}PvPTwSZ9*_zUtoI){53}34qMB
z7i*i9xct;(G36eQ;4HN`ADMd>#;bRG8P~vV(PK@7>km!Si#Ae7iR8Y-{&oz6lGmYC
z0iw>F%7n3s#L;~bCqoIH+$<5Cjmsp;ww?L-+OCphQU6J>
z@>9m8O!_3W?@#F2zJ!qxQ&l2CmiIcf03R7H`%L~z=B^7;Cn
z2)3+4xXBpc%C(R(mgVi6ZNMAsBGAQk)@X+7sx%otw{d7%2duuEBaI3yHe4mDxoSu%ck&)bO-`Dc*-MJql
zs_i+umWmB%|s2v%UE1Atj8;*N8$L_t7
zC%4;-{xCcU5j1JfpsTbd^$VYvmJc`eWm4<
z)m-P8OYy*!FTzko3WL87**)5uLahLb@9S6J&vqN0=xBa1W9fqL#JgRg9`2QrBGvSh
zyCO+?(@A&{$Jz3^m92R}qWS!Im_GsKEN|p9J0{|7i?c^AE8{XHTTE~*%Xmn<1V9*U
z8+D`P`dEjS+UXqd(6*Tp?rK@@Gq35@wlX~9xsG18N5djIrPU|EYn{o1q>D*aw0*KK
zrJBS>l@ZizNM&j_ago)eKOxf9PT4l;*5RfX3A``>zXTMfTma-XZDtevFT1XJUBxK>
zQcysVZFz5dmJv38oJ3r6nM`RI>0Cvw!2p&Xe1!F-m0ai|Lw3S=t?jL46|+01`4L!&
z>p902I7^)3tjWm&K~7uY+B~>8q(cZY=3*4Ctz(<#?vGp{X`Ay7g(Z)UoT(tQoepMD0x+KxR(68`pXY+Yp@28Vw-R0c`+K_Qb_q#<6
zxm7P;kNl5x+P3UsIm07~on!FTLl})5M7W5Oc@4=dpY4*SX-OwAiCZEbiI`21piTFz
zDSg@1-=az_%SYHXuZOVxj>Syj7f3UQmBp*OtUAglT*nR{&S(CpN5ivStuJaD
zQ$UwMlu)tgy?LqEYX@iSUPd07
zZhq@3&SJ^WmrI}fgC4e%l1v_b5XWO(z?M8cNB
zK%Xd(1hM9XhsOy!Wv$Dz+QI&(G*%l=c&v|#?VlPT%?=;a&E?X!#0wSrs=D=AJc&no
zVKrc|`Ar5OE$tTfO0Oh0ob*UUla{Gmr~MNQ+b~};gZAE34jT7E
zZxzD?UTsnyi8KhL0O>#$zxnVihjWvWj1npmA@Byo(|o91{DJFDkW|7zp(s+RpW+Xk
zQ!LwbwU39JWk?DMVtH-3`E%cA;1RJ2KW*nC6V#_RT-9GpixMe(#hI&V0sg9eEO;nk
zobAA9_LH{ElzswQN4QkYY66{6XH2Os8BT5Cz_*8*MWJ#ET$m-CjBDG@$s}AroPM2n
zq+Yf1;6PujudgSLWysxa;V=x}gAvNQ3I$%+Ca34(@c4Lcvwtnn
zx`m2;?Yl4n>Jh``D_C-@bk{rr8H_9Zvphox#VFfyw1fttP8A*a<9XxY^
z$1aU&HjG?0c~+tP2Iqa++koh59(NDjr4D_K+*yq(oFua@2gEcDGO-9ZzcKVSOi(jL
z$p9XdlVCNtM3x?OF;}Q>>V!v9LndSMEc?jeGef$XG^Y@7VV@;h+VQ*>bDT-@-tbbh
zBdk5WJw*dp);f8P@ya$NuJAcCYJFMmZ
zE_iKh+*WIkn>ZBxzEb}K;yZ&4=BY_WB!pF^YIjt%Kfq(mgbrY2doro2{`X!R5)?I6
zU%S$3KXLKna_>3!oaFZI*mur>OVx^D<>DLUI(%TFZimN}`~F?!rLLni9ctQ%fv?<;
zT)B7aSAX0dYni{OQaX@eP&vG=+`ZOg?)!@Ec~8}i82JFZjgURn@G2kuTGAIt-FJR~
zQ0%Kwa$2iB=enGB+&Lfpg={@-2X}2NgIc$|>xzNxg`AceDf%g5qFYC|zUjb(_5uWd
zH_aNIm(82qk>X_?Wz)KePmAUNj?#oId-jgayL^lvwZo1p7l36S&BLEEj4hjj;c(xw
z`?*N=*Wq3|ZM|}d>kPC9#5ZkMi-!;VNjo8QM{~&dM(H_no@KjoKUGz*iFOt7Du_IS
zHpJWPNaj^RnC^n4+6H0#+1$o)&H!@_bib}oSmXFBwELDxp+uu^nCN}cG%e#N_JBJ~
ze2ca%^%JT>gh;mWwnc?Jl7*R9?8?}SHdR=X7!`O|eKw8zw))f4b}`Xl+MbDkaKeM;
zfYBSlo|H3)?Vb*gyig-&8s^j{vjm=x+e8;&K6LF^wH+`_a}&?){?MRK9hZVV_k7UP
zv`XGt;MBeymFviy_YWMXlCNw0O=g0$Kqw0Un+R=znPle`8A-eZ?Gl1Winn+>F+=ia
z#i3u?m1BFRhWs=&Xr|^syLsNO!9GD^pix?K&Gsg20Ij!x@I=*l!$P~DX>eDgA&ln7
zMuMtn4tO~*^W
z0^_q(V8gSPSl0quCDqhiF{iE=fqoH-H#od*b)i=7d~o)UOS4#9;kV2p48v$n1x9ks
zEVNi0D!uMdL58zrajy%TO7J&q3gIk^&wI<4Pv85V8R6uL8{zmrYDdWi2T6$|uKDO=Wi~EwZfA*5PDc$28VUda01Zh35t*z;w=9;k9nsX=p@V^5k4d#@b
z)|JhP9?cHyeVl-le2=C?7*DDR<8ey1Dh%#_roLSwdFJG!OG?I|l
zyZucRyq|^*)A7w5;%0;OY>TH`M32xYQ##3ZU3n*uyj5pA;9SuEl
z&7JX?)3J`vuityPdF0&G+=9RP+W6djo%d*a_toyf9+`g4>%Trab-KN4$x^v!EbAyi
zHD?yI=M@i>!X`1;1b+!S(NNXSp$*D-%~X7ch%q4NzBJQ+rL(b9#<|&CxXr+-pUpp!^fZuX@y}1ais?E${W>)zzvh0J8|aa+jnkmAKU03
zI=i-ZY;5N1citUu@SPr;e)Y=56RmycCMOp|EfaN(z4oeCPMlqhb={kpUvCOt>>unF
z$YzC#IgYp`D?heEr%*>?A)r!2rA^r^WoERJ_8*yClgMl$AFXG#~da^
zb9Uw2*!0zzRb45jktXo-B$@(91qv6Hs9IFI3IwJCiJPfwsD@*f+@2}Bvs1A!_l_EvWn$k
za|4;H&neVr7HHCPbXobGLS>XKQm5xB)3TLmISw3Iol#&dL7X2RTZlyMSkh-VZ`~T7
zN${7TAd3=U;NCsDR7-%IY4Hphc=Z(6uwFQBlAR2>c6?QH<;G4iy%t*(1Q03(y(-4C
zL)WhpH!+DG3VyD_u;H~fP>|obH@kA=e*$wNA*lYFe+7OvI^8$
zdFI^W9%ET8hFFiI4r#25-hetiSCO72NzRCglq~|ODz`wAlIfXd?>6v`NvzAlw;j888SVJoa>j
zp-sZr^worUjH|uveOf8FVbbeYuDx{Tk}x~J0*ZE`2*%uEO?s{qiErTu%^CUn)NDg)
zmM%F9Vw}S{zwd2rVl{$WpQr{3R&DA$X|przW}^i1=sb
zMjR+ekj6OP)DR#N{WxNXM33OfL7*;hq!^XiL1(wp*oUhv^?3MNLuFJ<0id=?H~|)|
zLna7uY2b!Q(@xJ=O}#p=Xx8q~7M9$Zon5bObfby-Ls|NiY)28)2f;KG>1Ano>O&dI
z18IizywlN6z@;{)K%9~;PR>xIWIK_h1b+#tC!*_#^$HcSI}?qX|I*wV6U|W0OY=%J)yL2iU}VGGVT&yn#lVsj-6_Car~A
z8yLK$V9%N_peQIYL*U?Sd1hf{R&g&|;zttP2y7!98^+OUOVNh(T;;x0OCd~{nl3z)
zDo#!lC8zTarAkw>ciGz`4;AeqU|cw?3yXg=-7{@dfRjyFVk?7r*lOwFQUBv#K8s)X
z{h#OK?6M1TIW^xPEl4y{o^xs>fDkhN0wX
zIrXLJveeverl5x<{^*(Kzy0#Fk3N2{Rip@DNPtn*!E|j(mS}&P@IWeHv|Xj;Kbb5%
zkP`paztBd5bJ1n)GpKx2N*xvj#!8SxiI8c-V#$bHn7HQcSMPlD#rxN;U!1M0Zl&PC
z@7}={OqzA|czii5*T+Px9;xzd-*{OGG{h2kVR&b5>9A0>
z8fp9X+pph$_xH0?qjS^aAr!f`1O)_Cu|GASQi)SCga-km8N7YT^W`;(?@o}HL7%F$
zJeVGL-3A3xlylh)voO;j>C
z&$RTJW@9w&=TWzWb*?ef!9JMU7KzT6T
zSPU2JPZ1?&@D8SPpE$_+&A!Ca+UsRD)ab6DVlq_y^*=WpD+y0jWGS<6xQAXiXdf{x-C
z!$L(Z1oPz=pMCT7XJ38x@uzRU=_*D9v1HZ$G}VE0{{B>Hayn3)>?aQK52W-7|Hj)e
zAutv+-ULNeAW@4|<=~79igrUVJ-fjCoWB2am`Dke=x#W{kEc{Y5e^)w0)w}s2o3_R
z0vp#JNiScz`TP5K=7N#KkrpS7b+$R?DZzlz(@x<;No*ei%h{h&QBWGj(<<_c?YSl3
z=Qd{+NWtiNGNledXe2WMquc|jiEm7h0S42SLQM$d<0C5-2y~}d;ecU0cv65soinKS
zF8T|#s7;+5emxB5gkho_{+6f43MqAwDHUk)tfRgHO$65@jfY!S+q<7Rb^6@WO0>Kt
z#FMGC|ddF_p7pMLu0jgZFVK;XuzYTFq6x+0`CJ>Qg)
z1%ULE==D@qgeR3ANCV&jp%m;-=I%cPh7Rj@`xE>nNL38eLJ&F#QVT&EAc(L?aeKH2
zoVS-C>_w<164Q+!)S?L05OhT`vZ5GWQGyE5c~vm96^b=Ov1M?)9Sl<>0W`oU_+ZkT
zPd)YE;)Q5M&8wGh-rPC*;OG&rTH9Z4Z{dlao?TdVdFxONYayaju4$mKFUERg$(i!x
zOv%A?2Zm_KD>f9Ai1(+eQvb&GD2rg=7Y9dqL7@%;)0aS>o*UQZ=dbtlxllw~5u&^Z
z37WkaRSrQr-~=ZcZz)1pfp|bMCK%QP#~F8z@rK;x@{I>it;M=ux^ngE#`@!{H+r1z
zG79r(caJ8wP+JV~b40q#JU?HeNXyoy=P7av1P78u`%)w+8N352y#2|tv~1q~L%b&r
zCiqK`ya=i)hAT_pno`h^>Qbbp7@>!t4JA-399d7KIx&Pg0?k&6vXmf9g%D#Y!dQwj
zLePLY(9AF_K+yn;^9qC;+%W0h=`$BLH`ltmUp#g8(aAF>$0zQtuirg$X24dt+~Aew
z6h7WMp~@*xq~%m#2*AJeP?*mj-jJncRKc;FeTP`T+XtMZI&55Z|44QsLs5iK79&(8
zD0v}V1v!nO47f4{Mjo{J^Rk17YFUGm(E-~H99p>>)RZg-s0(qb$F4%x0(lkAEyHgaK2@{@sBD
ze+dGdB^Z_FL!|lfBS2JHgan8xil9JV0n>opxKtFyIaZg%$C(;932_twb6C*%u@7#T
z^wme7{{Fe=|Mck>x6Yh<>GHKVpL%e9ZGFgDH&gH1^oFL&9epa}t>H;+UeT?gaeaQ#
zu-2^1%D2PN!sK*2949@Lrby1D|Kk%0{t_g~g^BW^l02v+zXb5N3n%pY{Fp4i6o{+>
zFjtIJ6atPBAix3`1CanM?y`eP^eeWN{i!dnIImh{xj{IO7Tmt6Dg(%}zo-&w2++?iWG
zJvjQ_@iJ9}P3)90A_CI!pmV*>
z8e)^fG-@LW@n~$YUC8Pc?>cOEcaDGZ(yL$o{_WeRPY<`WO*V!fU%R>z>zWEgUVZkd
zfK<2B(&-jRUOalLO>6w@*%!Zl;UyP|em>THHq?65>286dnsbU0oc&0*``b2at$ixq
z(I&@sW7Va0eY7
zSnUoD--#g&naaCWI$(`143FO)n^|iJ9I0#EuvI5G`;okOSdfl;ey(rbZEd0v!fbNC
zmN9LUKALEMYin|?)-+{N9B*>m84ka@voNG*cB#oAwL&aWl1wYde_j64u%D^j!78F~7Qd`)%%@QhR$xpEMU
z15=q@pelk$GV&@>oxEtl0xMub_!VT1U_V5DEmd2V5-O~Pvy(P!+MOI_hpEsY*33fwK}MEk&z?!j^_
zWv;Gq-0lMYpP`_5H5d^lr}b%!ULtMWQqhQ`4x1{Bxux=yEOlm{GBq1;2^1s1NpSWftu~b39&DW~S3H^@
zbm9XKZB{`A5-m%~5FbicrsvAiaub~WNKt{Xl`pJ9A|I~|x-i8TTAMog3@?W0N0VBJ
zv@x-0L?T@_nJ)SQoeWk4Pi>*H=FGZgHu=$HpNERM(B9lYCQMgb=A0GaZb=)LB9{{Mz18E?*F=Q1852S$Dmv<;t
zv_BO@-wDosq*?+h$i~*7(QOjJv|T%CQM59+J$y+glitT?-WY88;fMbOm%V=J?4(S(
zW-aSx@jwVRC>Qi8xo6q~twM1v2_I8Rq7n(XEa^<&mJ6UPoujSoe?|Ne(o3Za!ui!pgo2Hi_0f>?Ic
zY5*~NSjckVb_0gf-9s10ru$75W;pKV#7r}VS(6Ky)0(?jqVK-_c4zDGKu>3ty=<_f
ztqD!8hhPAUy438&=2kG++4~O(K)Ai{Zz3;1Abxcc(1*PZO;l_RB0oT+G$08PBH>J^
ze(#DO0B`^K@XmSAd+EllX|*bVrFxLK5R)3^b1Ps)HCRFomRP>~=Ow-M@IhE*+zGUG
z7);j(M9tS
zhq5?N{7u*es1k(^^JvFg8cs#Mm)reeGNTcN9}uwr{onq$cf}7soZ4B~>;3TORx*A{
zsrDf8Z5(E&l)veBhq%0mP*j0Jg13`GX3J)K_kgEPSy)^NK>_BRIVJ5xW&;HKPk)F{
zT7328C!c=u!H4g^(}*T{5CkBL`iwjWiUcArfFf_-ArLSmzUoJ^BM}c4M=H?R1~O%;
zOz+3joTZ2k_D|0EV_7M+U+WpfVy{eia7ez~TFh#+CYA>(U^VJ%8bHSf+n)
z?!tSQFR%K;9td`jujrr)zWMyiZ@&KW>n}e3;**cm4L_2`gOSyNp;(zcs?;g6v%>2?&c98EOB(KAjDxH9SS-Fx>=pFg*}czb1Yx~0RAkw2u+)t6$bvP)_U5tg)E
zOIlueW})Uls%C#$O%W6X*W%qN0O5gD`V;$r>RGLc-{_|Vf+lrwsk#{Y$LH_sib{Zx
zlo!M7MTnYGR6P>whGPIXO$1^aljp@zYM|JvQcMjD)2G#kIczH&Z-L7OxB%=nO9DodFu4(D|54*
ze1+mrwx7;z7bsmYTpflePfpk77D}E>v6mo#AXXx<-Fy|`kMp;2AfQAL4T8N>J-r49
zq!NeR2zksUkh8P%)i88L2|6)FQCW(qMUla=Q>HQ%LyZt*8HoI$SP);wg#<}3Aqe1Z
zNq3GN?Q=K1`QZNc@Yuss=bk#eeQ{{gD^-lzs)Is_E-SwtO|}(5K(MFG$ep!TyD?ib9086xpsfCwSGCAT`BEeF@qMMO$D9OEJ`e#92#G
zwi09o5?cmA>Wks#-DwjbAto5s2mzrqF3xCT(rhdcJ-@tq@7Rf{w)S%~3zrYCjW>oi
z+S*%W%DLJGMP{z_P-avh4e`amy8%w5Fh0S2i2V;wYVry@lo~^Jk(b0waP}kZ&P*WV
zGZO_cWicv&C
zdI%PT&mf>qMEl0X5BLMBZ)TwYNekor0U+aneGwAG{JSrK
zvjR)}^xz1Z5^%f=@NUeH1bhSL;`kNs#r%8G{>N{;^W7&O-@APE&1at38k>CX{H60#
z^J^`wXSzpPCCUamH^LVC>3nlBbktNXcrsbIKUtEJ!TO(1vhZ!;m0v{;H7
zD}sy_Kqd>}qj`|gB1B()$uN$3(rDi?mtV41ohYxKS7}$|+C`OaNv2s4E4s+6J~De*
zZJ5^?j+EK%`BJrmBf(zMI7e`;A#k^=@4?d2ONTceZytHLuy|{H3V4qXCa0cR
zUbztM0CxCDbL)`Syk6rTHJ6W;*~U%Q?Uv|9Q~1vK?6F|W&GE^n7gz4hEZm)%y)`;<
zJkolqt^HDW?@mqqm_l>R?p%@ULRp1vStXG;#6=zXC9T;7T?LS#QurtWIf=v1QmG3<
zL4v2hOWhn&jE?SPlZGU$VJSaE!gUL%+m5n};fA9PHIsUEpM=%Hr}jxWULtJEV{_x6
z6J_#wyD7-T^orkApXJ7^gy>t8Jl9K7FoSd!*hKqTpuDiX$%Tl3m{`VZJs$l3*`sxzhD;
za^^%N`qlFc>23EXH|Fc=>a0r
zi$e`a`7KQR`C$E-V11B*oh(x$YVBJaQyboj_fM~n
zTXe4+9*l}f=i1y?y8?HI+CDkG^zzEU)&8dc_2Bdy>!U9$4;~9Tx@61%6B`v!x@0^r
zneb?`cfQK7RHM5)99ylm_$j!4rNmDq%-Re$`&zDa1jmfB1bazuK6>h3KmYQ}4?leW
z@#A-1dTn!Tax&6#bYh}kXM6hann$G`D62fba(F4&T+0==X)Q)H@&4A4)wbB{S1(W3
zcq+-%sM_%C_6c1H)QZFy@*zQ)x{=HVzKj|8vjpl+@6dyZ<g)x$>KgYlNr&2<+$eQR|U0VX=kMF&`jMrz5FMcN@FKbmS=t<&}>X*U~V9m_9(f>gRY2x
zGHF!@nZ$MpeafN?Gl^F^niK3Lef8l7|NiZFt6lwrwVs`k@nbV{i(S3F=JGS+Q{x{0
z$?l=8t^q$&c)n+(8cU8!RAq3CwFqV@fRq(N)!Bt^0!5csTm^jDtio~xPL-CU$jBM6
z*k)?oqRi}wM84+sRUvVfBE->1biw1bO<6i3y^s6~RCVIrcA2kUZiKt#Ve^@7(v+G-UwAl*npjL3cwW&|V88^wAn79xJ
zG;*7merLG#Tw862jPmOGFwhUJLh7>9e5tExC+uz@!Opk&Us@VpcG%{t%nA0AoHXV;
z51)JL+Vz3Prhr_%9&10-JACKN>1rl_JJ?Z)A=OdX-3Fr_hVe7Fl`xDpGhdXFVT^BD
zDpF_VKb&6((|K3=2F-b;4Mc`KC0mn`tIjB}7r_;&+47XEDNCg+Ek~V^+p8-xz);{L
zWrc7>Wo`8CNeLN~4HPSGh3huLWqg_ftL_lqmGU_R?
zIwI;wQ|)BAe$iyKJ1
zWZ6ZM%p7S-wj?D}Q&@D^*SuKoGvz|c^B~<4l|Cg~eJI14S!hVlEz2mVfuQth`PL%T
zsqTRevAPn11yIUUGo`5+bvTMVJxg{d!(3RZ$u1~|pdvc6I4wt;TVl+Il$D?@y9=wo
zMgcmekqjR*OFL!EA-(uibEB7m9yUwgKe=+ap}bW@4ziKA2L0E&n@9ALb1jV>LfV8@
zHl~)x*epMh*ve#vNz@KDx0y@_ohXUcLZWprIo*7IJBK+S6)oC~i`DuKx2>6p-}Y6#
zyfpD>vS+?Z|9Ew%iG>XdN%zNl{4DaYMKV&RZWRef%XI4=XP@>j`mwvb>WinI?Xp%@
zV#r~orcZ0`)t8wIA*#$g2NJK!%vGl4DARLIxy8?2yWxgm0c83^S;piXQ)(_a8dBrU
znpI>-$1#~9(%a1yhp)Z
zuPxuMuLSZns!@f=j3Acm!w{ncdKgD)CXr(lMg&jpptHfTpC@W2#QV(zN&rh}!c&^b
z%qX4X!{LH-e3(V_Qn5oi*@~;WQ!aKBF&+xxT3>qu1zSgg?gU(37P(s^Yhu%v-Fq8{
zlDrI_xd>iCVGP@=PIe4##$xNSHsF7|X-s)Wwy^{D+zElGMxuPk)zOSV9#NHfh(qv^eZ0AYC~4gw^Du
zk;ly%U=W%)q$8e6KMnu+JMRKe0DM6L)rTcUiL?j-*G{9y$dntGmNEpG4ZWsUNqr|%Q37FoC*7YChb*(oFH%?j1A?rva4<{Fyn2y|^>i7X>$w$?pc?W~1k
z?U{v^wET+9qF%NnMqzi*_^lL90}Rs$$8~9p<5kWOmD!A=1u+yy5yFQgf@|zKCGlCS
z18J&*shZSmB^cmond0O$;i33;HSQA!w!K_YFrvTVg+oh&n)
zYxTHE@a?9C5T9d5l+;tGTLF)kK^Zg|0$g@t>mHz_ckbN3fBZy5p{XX)#_i7deuli_
zwQ#$i$~n{49cFX4qwV&rqO#Q7_+~l2+=rnAP{c5f{!d?i^W8UJfBn_xUwr<_7oUIn
z;Ro-1_~CoYb5nkWg}(Wqk~Pk>2!ey)Gapq#d7y2PSJ6v2Zc
zHXzVVC~O;rx=~yCr!PO;otWFB^_kcYfBx==AHLmM9ee+sSHJr7oy7T3xeQz%!4m>#
ze2~Zhzl0A*sKdbO(8#GWy$egM#Sv@qBqyF!gC+Pmyu&_sNI-KD37x9H=*Q(qbANTs
z;XpK|GHvz@-B{ar{?tWjVTrW_Q3b(f&nQftG#)_kyYIgF
z=IgJz+M8X~
z{6sP^_tO@A9S-fp;9OX=4N)54@SS*~mq~Zx$u0t=YImgrP|_RM?|7xk6Z10>qwUeg
zcB4XO!D0c3mfX^6B<{iSlkQ?fWo~I@ZgD4-GcHo~b0k3m{kuQ>@t^+mhd=(|+dq8w
z^|#-C_SwfDyzK)b#I-UglQ4;8X2^hT<&2oCMqlK7*t5KxAu_KVyn1)?AXzvkrUGkQ|`vYlhbv4
z@yYRpHjzBS6CDk=3@h~Yh498=WDrT}VDP&c{CTbI#f3L?
z=>F*Q&p!VA;}1T2>-8X>?uMZ1N)YAQMZj1}5D_M!Cr-FPXIDsQCD;w}3F#
z!LjvlOalTtAeQ!sxSziE+}?-(FHnre?qTx-7@!ugJ}huKF`zZzh+Z;zvBp)6!B?WN
zprJ^;H9b+9Xzg`~HXRdLwY_
zqP+MbBG8YZxeDN}0%$jtJ1*63tN@GUesYsjTU^>7{urC=1AdpAS{?zzn=Drl}6Ni4e&iGR@z>r!9
z)CflzpfCdjzSZpi;No#Vlk7ynq5>Ycz(b%`Ls5-5vKLK^F*%(aUax@rhfm-Cseb&s
z^yeRbXlC*!)w)I$F2>{s@H96({*!n~)LJxlz1Ho(VC+a#1&Uxtk$`ttg(X*@i4Alv
zIC_}zuLhLVtTVoH>+X@Rfr(ILHPGBtW(}F`ik!j+bIVW9FOOR*u8qa>Cpu|-PcagB
zIsIJOw9?SU7EQ|a?oyPi2c
zg5%0yz+{&-(pZgDQVW-TdSaro1PP$5hM=5Kv=2{?5E->7M3heZ;eY)fdw2N-Iho?-
z_%c6jN@oIW*TOJ$Fl;T15TG*a(6}lntP+W+0@&e578tsTBeo%MP7=)u$CM+9a_~6x-PR%S|UpYKpUe+#F+Y6v!rr_Cg=Y0r#
z1VawM@gXD`D9s>>*h--L5rhzi;z8hR3SeOjwGoN~4yOJ|v7?_>Zh#tnd7k;xp)w_@bG*1g3|e4KUD9
z6HaF}fov`=vcsTJ9&e|&zXl#(h^j0>dvFvViPDH6wy`)3C~T)#7Nk(UI9xpj7ooE~
zSVEA>XcvfwWa~+WWnLNyR|c9E)T-+o)T0DO|_)v8V+Py((-^;WJ=C9rDbdOrvn2G+;zjj%wDmw
z9#1(J?Uo)$GvpKjGtJ$9s0xnZ?K?PHUcvgGPXHUudor2%Kc8UzCccyxq;V2F{aw)Ia=@?-
zDB1x>H{qyG2%?cdt|*4qK#`4jY7?2}fT61)=o%<)ccl$o1H(I!cn1(SIMxEiSYQ|{
z0=4LFG(#{IXmSmi72nv3z{eN1;5ZA4m{=qPlytbW@BG-r2ajKV>$zvIY#u#4KCsl^
z_w1$1i
zg(6gx?rudcLfDEBpp$47alEiV10=+@V)tY<6bH`N;|O6U&r770!%+aiGN3x3SVJ7p
z_`cvWSbQfqK(LC)FhDWoSc(-*0_PL#B|Uxi{M{4B*T=?Rx^sJ?F?eQb^2+M!2Y2r;
zG{=q%kG*;KX`nz?LM?4_!%RbPq`IcE6mcTd)<9$GGV&B@x&7+0!_~DQ;L~R2os9K>
z_#~dWmYILHZQPPmEIybf2g4cok11Io5IoZ0m!xEf4`v7wi{1y*y5&X?*hs*5-XCa2_;WDMnw4)|Vg+#qfTk9mtU#fdw8FXx3tQ
zO?OUouKe#BlgWUE~8_{xf5z*pDjmw2%>Vi-1ZYYMS3kvl`B>^rM
zz+{FX%1U9NnM>dRTvHK5R|xg8xmEl+$r@17Q|GT7?H+jf+O4N=UcYpU|$
z_TZ;rYfVLOJfo~aY&w)P5bSWl_)&$BJuz8Hx+P<3rk}B8Zh8g{^riVgQSR=9-aVr%f-4GPpzW=b7ROtB#k>S=fX0_~HN{910&B;S
z^~G=tPzWVRBNU}CMd~3K9RvkH1PCUUS>qR%Aa(Kc7#;X*e5ZPR0ayz`gQkZ8G;unB
zH599d;u8zkfRg_7`PWyDo_OKXwIk!>4^N+c^}$mgKKs%q&%bhU^T_7t*zwWvV|{~T
z&f521eB58*{CiJLo_X8>uWXT1QM)eO__5
zTQLL(>sYfW7}9`-%My4AD{yoA-EW|L{A}fmB6m7H}#PJpEk)
z*oh0FlEOHGdzco-*Paur&hjECkdDOOeeg1Y2+#nD4rqVb7$0xoW#S05L3~61?t*k;
z*%zEooCJM<+V1hMyZnJZ0S?2D{RE~7_L6R$yY#PL|Ka+%3+FaAZy!IsJu`o9W9!u1
z!YdCSo!#8{`tA2Vd+m+a??2U5U3aW!c+}B&tfSYCrM$6obW~@)*fSVp3g%r6mQpw{
zaLr-`7_(Jye1t8k20En(GN3KfWfd49Xb?O1$_?s_JYZYGEWws9!1&D*zSPi-E(Ix-C;^xWLkfT?mP)EbniPc+9Yg|J#Ixf(&(4n`sz
zkqH8?gkzXb?gL?Et3cKvl=tdQqU1D1cA+dSOPZXiO3C(fMVxAeDJANdZ*0o2VhqE0W}w05ME7Z~?#+oR6zi0NJiK0OzH}
z@hu&3J+P~40XnL3IH2GyEkF>8Re=ji<9i7K
z{qK=G@&9~Enkt5m<`s_@K*#f;Be|u$IVEFg!UT@~a$C>cKzQ41osnzS^yXQqazP+l
z7OA>O%q6ukfWS;@^pi5holwi7uB;D3i55VDS%uMzL}Ep8EW0R{Thf_Z+?ik8Q&7@V
z3>$(Xh9QVaC~_K4m?e`J*qjxqVoj@BHE5UZwh^QD&F3HOG4%`TA<;X@v^FAjLdKm^
z3tt-Tn9~c!q|Eo0Mvm87N0rQO0rg&Q^r?Z?r$*YgT$W}U)=xy8kGNWx_+^_e$|Hvu
zlzF=`KtY6P*a(Lapb^i6{b4GxnM!Y_QAbp=5R))(*Up(0ug;IWe`0ysC>+!BTNv0a
zm+{eX+nhzYTA_c~-@0Zuj!3y%HO39QDMs6K!T}}q<(3@giJ$R?XZVt9_5PDK$8!S{
zrz+|$g`(4D>w}4@Tf<{-9Xt7WZR5t+e((iQyAN9w=B*cnUvt&`MR~iCD#DJVLq?CoJ
z*nTPVwWZ-N&aS>N(|x3|vQ0>tGAWiTb$%)_!X|Wx$#Ygyh)!vu5svwsBRc7*M$|;d
zo(MXYYm7Jhf;W4ckNT=-&B`tzHB7;UsdzsT(at09)R$jv^K}d9EeyU&U*pBEw94uYz|fT)SRZ*(qaoiP?i%(PWt_CS;Ep
z)te19(?;d6O5mknqAYT+h_m4^o@}ZCk`9D)k3WFpi_2>ln%i&0`mPTSZPquPjc=CwqpEw{|y4R7d*x<`|y)_u=RsyT
zq%o~zQ2y6s@}#Ssec+G0Iz0Bqxhpp(XU|X1-rqcSW8=uBmBSz2eROMM`{dm6=dZtY
z_r$60O4q63i5rV+b6q{RkDu6xbsg#Iy}5ntxszvJI)3`v>c&X0xl?JFtM#q;LZf!a
zth=FGZ$268xH>R=zN7ou`K7mxo#+?IM`h~m3db0Y8_diPr{~2bG`Fa;pkxU0tMg`$
zhFg!;RdsNwegd+MO`9{TXDzDtwwBgh)^-uyPeUzMnVuT!X%{mWs*UYZTAP@BbEx&v
zY|k?@eYZ!W7dnH-0<~9$o9~RZU5a_$-C1~gvh%6&*6(g_1=!eA%{9lv_Nb5;V&hx*
zlomdDwbrsx@AA{Ary{jGP1UVJ@~BCA*lmxn$XyctuvRgsmMm5p=j?w~L`g4Sy7ugu
z^UvJ8{pj4q)vo>%!;{~=_ueaa?tc9Hw~vfYogSHb_Uesyo_^-7Ten9Yo@2ekH&q&r90!H2DS{c{*!vsXEpqM7(D=ixBOQ8chu*x^+}Ula*a}7+BwRHq@It%$TCaDb
z-h47r{l)#w`=ia@UEBKh+Q$F!@YugSzWUEETpqWIhK<5j0b|T8Yox&Dt8|~9*%&fN
z2DJPL7rzs9E<21slSVl7Q=!I~fa#}W!wg!d_^$~KNtagFzkdIdYe$doEG_`zKpnsT
z+ZW$l-P)dSZoRyGxK*Lu?C*K7vHkYlyU$*_Ud<6aK7Q_*^_{`mhJZ*O5X)~au8vx3
zE)I^=V8{biP74APmaDG}4wn<@E<72y<(&${YDaH1n!Z#YtRu0mjZHtdvRMX4Z#D+6
zPfXsPm_Fk4oN5ei+p0To)GjQkB_FcK)Gw%mM+=hC;|9esUwyZXv+lOF@+lo+1{iD2
zeA*Fj#dEWLE49Y;2IG#u{CL=PzTF#S;hPxnWNM!|C3sb_Gj+
zbzFz3r~x_iW?!qHg7#A}*ZacH&h!MBn3tD^f${Y-aLrum`^V;&oZ10BbJWbe7;C&Y
z5`J@IeCH`9iGm-J{c|n``e3wp{M=j2KzNCeE3t
z^YtSWTi(i6A*D@3eK6j3e=N4%U>($n$IIl$0?sg>>SqyyEF93ba}}mW@?J0lDCyPv
z4|`kB~!Lci|Dzz3SOE8g2#8dOVx
zPM9iFO<6TVI_Z+bbfYJ7qN%P=#qL${4mVi6VDR!N7h+A1SBDPQTfnUzO?HC&cSxD{
zMx)1@-Qa>wIp=KD*R9|;(f?`~lTJ;~U*9}ZBa{Fw*(#UM2LpGGZuMKL<{b4F6tR}h
zuO%=W$P9Hxfi5#&lbNs0Do|zQRl>0q5VQk}SElD0vJ17D`TDE^U3PIf1ffaKQD)?T
zYvQ|his9@2h&nSL#M+vSJVO!0hQf9zwNI}f*=*_h_|Ai6w{Or^1^lYRO~H$U!+T8q
zf*Og~UYR_?qK}ybCqgybzA6W%aJ)>>NXD+XOv_IFc$w%}q~c$nzXV2cuaW`WmqsFd
z+NK;gOWTCxlR@{b{ubcPOqf;675c-Dve|O&Vx_rXDeRH)TDZhfvmnGlU+?w5xj8vq
zsXEc@o~_V#$oXCx(L=`!>lGd{V%R8HZLpn)G(`B6*EeSe^pbk=Uk6aq*_r9v7cSm9
zeRgYjv{|h?-8*O`Q4hCt+aUM>Q^mO5wHazL7D5EcY4Hr))Er$#zA`ljU}wvNXo^ZE
zEESU$yMsb=KrvP*dc%32}(^B=qq}
zy_*1CtTqPO@F<`3!u;TjO$$^fkVGFD-^`@0+O0tnF3O@sne-5u6lJoaOh&&<>L+4%
z+||ttd@GN3D(rl1b!4H+IAv3J$S6K4dcLM?%%bX23P#J+<2F@?g7tWLV#20ha+SxV
ztP!)iL%FwD2q>jt@_|+2WH!ljlaqyll~p!&{X|LR4jR(fIUz`?Xp5U=-_f
zihxX+N};x5n7IH_iNcxkN<2hbh{3DG5*lz+H;UL>;dpUl+ggIuWE27%WvN;6w0Lzi
z&;c3~993yK+WgW@f5=DY^v5^0K`q6w#d?2_#&mP>@E%jYpzX%0i?Jr4;BJq^e6)C-
zJU@*b=Hja1kOm62O-g@mvHN7i(XFEQsaPvc!;Y_V(j;A~&`%kZGX`A?gVrYzb#OT$
zGC544__2ghxx8N_TCkdr);kxh+La2^f?dyc=;hr?X(JWSsoX169_#9RZsYjXg{6>I
zKh)?oV@MV_R+*m1OU;xfXP6;KO@2uOo^Hq~2J)y)&Nigw7*cZdsX6+TY-?5_P?Y-Y
z;%X#u#O5q3gqsUsiqvdbTBf}OAw84g@y=Kv_ZxxV%D;{ED
zr^{7ao@(Iz_~@vo=ek>@v_Ye|SwP?RyN(2%K{maa&mPb#hD?8DIB9cm@cEq+r-o+h
z#ZqN{u?>c<#uEpPWt~DrRBHf=uPm>`m{SA{ix@pC4dWVB2b&WnQCsOOKb{i6Q(7tUVtR=d#*sh+P_~lk13Xc$K+??<_KC$)
zMtPJ+9yLfk1a!Yb_UyvQrS71Yj_lJ3uJ%RSmE58
zr9P%I+K@ym9Bs#w+r{c(lQqPbYP0htIl0FC5^Z{(HZ50|nfKyu0
zJxh_EL;vlQ(zI;W69=yKjarHjzs!FBk+z%4S6pTXw&ZNgJ8V+aU=Usk-9yA*?dtGR
zarOAp039C_(&w$(!!>0+B7Ub(;Kz`B@jQ8A8=2M3<+YG#Q33_@TZq)eR?-lb5Krr;
zv%+|a7ftZv$Q~39c-L)wX1kEpF5?~#dgrU{0XEr9!j4;vi!M8GdbR`3CKkR`DsE&_
zgWSKS>?So(xPF1``sAVk1`n}Cm4&cI7O&lC(&ra<>hw(<{^g;OIdkPdee;bqw^*N?
zr9YGfaMT^ltjH;O=^xCjIvgW_i}
zKRLJc^vr+*UF1TSOj)#RE?b0#`?r7or$#g(OrZI&q%euz%@zXD8|3l38O#x>w2v$3
z;WT&&w!xJ1E>=&hHdYBw@PLTxy
zuSCR`XxD4pmW+bVje(Y!n7$0eP{Dob#PK#JKSZQ8VM##(HGl#VN9|-X
z1_h!`yKTFw@@lkY-ENza$+~%*HY&BB!yOY#fT9G_;KvZb@Nc2gyZOQ+wH5Q_#wm+p
zyiDyTA?t|nL4#u1Fw*z78LgT}#3*yIp(y0UWDIjO9k(q%S;C6Bu$e4q7VO
zmD-?KDo)9+hGWZ$AT4}Jn8>WoDYc~K*|Um#a6$`-(Z`W?kT|P`@-UuSTZD8&FkU#e
zmn~{0G8^IeIvCcFnv;-9AfBe2qN9OkbxO7p`YhA+v{+N{C%i*>I6NHNIYX*Yc
z%4BTS*K9VF&)Ri!F0&JZbYgJb3RRHDtwh7;YO5k5u7^(dv3@eHPYq2U?e4c>@Ma`>
zBhqqWX#Cdbv?jYiot3N3&evqe3-(s+f>@qbP?=R6#8LoW{@twh2$ot6K@Xa2efqLC
zI;#nRcbB4FMF`OG!Erz;0hIA}Fin|}3+(l735#^$!4zO*>@YNM{~>WohBQ5scOY4q
zoGD8F)qMcnDoHI4=OI&T@u-M^T1!Aavobbll=mnBg47CVeuy3~v)aKEcu}}U6gEVl
zv@CGpa$Ksg$6i-Cj5
z-Jc>jm?}AxzQ@!rXx472#ba8fu(&IoEoWlEs6;Sm($`=K4m_%sM6AM~>&QP@
zSGc~q(O2nMZ|~9P7Mltoik!kez4`qIPuC!cE)4P2`}ct`TGR6@a!P=RH4_2sTTS5*K^l$&`yRSZbwC8^eD+y<_xSCtjaDjSSS$pdP=vr}Kwz7&gb0-sppl2Qs)ed@7nWF0q&RRy
zCvcktVlR^(m9oPER)7~D1PMx-Y48N4>RywjU7_P;7Y?hl`T{^{sY@5|3W^Zwg!-n@44m6x91IlOwTcc1}=
z^T6@7#YiBUJNDVal
zOjXrVo#SFpo3S`=s7&v`;+$ys#diOYP8?woKYs1iP`sWg&Wj}n@WcTDuZu<;4ZxDl4-X%2@7E*nXQ$>jdj_sAt_5{vA`qoy7IrDL
zAHVuK7@_u@lKK+lkU-u_;k1#N1NNG4zy0>R@4ox+z2CP-L$AN~(%Dl-@87u=YYo5j
z?4#G7d!_-7Z=-Sp7_y@f4nR~N%1|9lH>Bs*qKMqz9b`XwkoV*v5G;zGOy(R&22k?$
zr;3u}yV3TT`UMS_naAy>5v#cpjjli;E6~uekg-^;Z=}FC>g_-tyLh6+Ci?~yz7d5P
zlZmG^+`p*BzoFyXb02^F`*`oq-~agjNJZs{RMbkQw9`0ESaKthSP#QCkx3^5jV(Nu
zkA|(q;~ZGz(Qw$uX8|OPrFo$k4-8We#m16qFGZ7@?ISWJ`_uRblR3XT&>`2Tv-0ckG~iV7
z_oZ^5I3zgut2jCdI2Vz4XT1Mtu)Y#m*ev6`aD252URaOE#zgFmhN>8c*C$do;i%mL
zQH(~J)=G|gs}p+hXY{8(eDeMG|GM|$FZ9lwVfnt&B0(mFVt5w(22
z#@0k50@VzD$QnFQCg=)akelk8#iC)$UUDIzr0a7l&zv}ZYGLWYvD3ZI>I+j7V9;3#
zAiAsq51D>^V5Bmqs64Zvp$O5#5DampF)H`-w|@VJc*UVVfcD+DUjP;P+|&2#omHQH
z@&Qnk@4x$&J-@UTit&P9b+?#PqA3ogbDum|fyBmZm>x{yA4t*U7BYT!5Fl8I!UB!S
z+xM&XI>2Sx;H6;!vl0zG5%D;&C_AFm2F*L)+1eu$4Odip@bL=8z{>gYmsFxU}|X1up%SA>uK%jb1_%I2G5_{7NoaDbVuKzB5{_$rZSnOhQ
zf!oxCiDxCc;TR8=7^E{@SnQctYmZh7zOD+5J06XeqfpaTRY1e6d;eMsDCv_o-&z|O
z7zzf?OfQale6K3W*Z<+O&zn%B`Vw?q0ep}n?O_Rfz{q
zk+_S;`Qgt$*MonTfY3$-GBA)kIl?vu&x6F*LeT(9ABpP50;|n!7D}rzxJn$p9Eq*L
zQ!6nf7m49z2`YZFK`yD^UH{JA+b>+Wd}V#T)oiygcxEQ&=F;J6G=8+Kyn#Ti$cI#B
zmw-s75sLG}aBXDPs94oa;Z~^(s%*c
zDhRR~f^s9Vz>)4?3mUO_FA~#l)+FxmUr?0BZf9}9u`!-jhXWSUfy6Zu$R0dty{>M=
zpmLzGPCRM3p`jdwwxb9YXrc{)tHP2Kb>R|}v@tmR)aEf4Pt;lEy0d|MQ<;d*=CexxNVq9SR?zFe4Op9gsu>)(OYDU>G-wP=~>H$(3#b#R5Ub
zGmv&00M3RaMCBR_8ed7Ih6I1D^_=wVxeJ3X_vM9!_3^Pc@7%q%z4Pk*2Xh_Wts3pQ
z&aR4LfB62y?LX?cc&
znWpqy)joh=sx7D3gQGTa1Y>$D|H)(^kCH>_E+ihH$@s_LaSx=h4kinpOlAJ|Nkbt7
z#EW}O{et4Vxa064^)Qqkiqu1Zxd~q93*uvn1$cz>`$4{WS5ICR~65x+r7hI-n@HhadoS?v&&Mx?Qd})@#fs(YdxbEx`)6A>Pry-&4yA;Rc@*2
zV3s*K+mxJbPRj#Ono@JM2jWFOteJ)2UGS-Hg|-ewh$9G$$?pydQZqs<9_zPHPE^ZZwFaN1
zptKr+uBTA#C5ZB3cpZkc3k{~S1YTW=0=myxil{^5fE5O40{B|kJTHN|n^TCXC`N$>
zI!+|97EJ)n1_!`ltq5#@FSNjLpjBchiJYWFQrypRJks0WW~(|mIkOaL?y}lHd;PV?
zH*bx$M4f!)&iKr@Cpc77zt!GbizNf*qEglC_Z~cV`rM3M?}gx8g@~%05-$vENy~{Z
zekJEr=0O0*eG>JIrE03C;aKl57`C#5>0m_n$~3@F6h4vcK;Y<4J|WM@<^kvNcL#X~
zlKHb*r*%QYnFTs
z6%crNF${2PFGlR93}R}an0N{+k?z5geMGtw4rCBjiv$P)O-f9p##NT09WZ{cfF9#6(Y1`uu;5b;}dg1ihfBE*C*B;)#fBMwvxtSNP
zTw3kzy|B6Q@btMJt@&*G0N}E`6ke8JqDar`R_lW@`K+aCSgw!Kd0s3PDCQO_H%wv;
zEA>kkozBqP8Km#DbOK`H8C3Yh5_7X^^NKt`6TVY5G0^306
zn_*Zp1hZRuG@c-rXf_NP9D$1b8yvT$rf!}({^tFsZml1_y1ujAGZM2_t@aF@pPZd-
zZd(qwx!C+#fq2+aXD)>v@mLV=~$>^^V<4D%W)O$!AQ3NynHMku_;B-`}Y2YBqVQdk2uzOr0{
zB3|a|N)cedbxPHC7&@LP98c23c$fkM6azG4
zqDpEaH7=1{xcicrsO6fVB){2wXMOYT$Z+vD~Ug|Mw3?p^ja;2Vud2DB?ub?X@{V!5V#HWi{pZ6
zD*k_50sn*w{EZGjn=wVXd>bxy-iSGjMWjs!d}!KfAQ(4X#C6
zDoK<y#X5(0|vF?Q07!!{k@54$-ZRKlgSMTq9P@0%2w4Zl*v*uJS4jG
zK$_%G7Whlrr7FNT>v#KU|M-L=Gl%iSesHDWi9+fny;;Do{dm2jM=3=;?&8w#|OogQYqYjx0$SHsifD7QO
z#ZoGum~uGUMW9q5Fcvrpz-NYHO%RM}H$yXlAV6)R+O6Mx=uIV&0hEaW9)~jiE&`V*
z+?$}J#}6L9^~^Jmu3Wvky?uUl?T;UP0AlT(_WlOGHpt<1fv_Mf<2~wLF#y}8rsR^X`o0o
z1PNe`r@R(}0gf~w35l#WRXqJQjwTRHfad9rzCL4_pC>SvmKuvn?I>&+1YvHlN)U}KP8rY%C1{`ojl0+Z&oq9AzvjEflU+eeh~Zw6=I(Qu;>oV?y<}HFNvk8{
z&s@5C_uRQtL!(EB#{TugPhPro^@HbLINZ^DZDr&5=)|qV8&huockg`&Jfs^_b7R#m
z3k(^NsqRcKbf~nISh5R8u7ZPKGM>&HlPIgu_+f)hdLT8#5{OeWfb}Scps2swXDx(w
zh~(uEWSc~}QQyQ*jxS!9Ls8nyd|+gF2UCD2w8zvhsGPu%=0g+Nt-HCIdl{PGr3$Fa
zc+zlODu0yCDk8%IOf4K+jVA;IycVgvTc;i?FTXK5*lW^u8Fkedd?S
zJ8!>u?fPOgc5Y$0*HO37)^%xN`4Mn&8UiiGidkR7n8*Lp&hc6jeZ46#Z)Tql~S%PZ8R=WBBd!aVVk+o#FQFDrtAxCMBQ
z)ApKvoe5YNpgILlCXX6zAT-=#>KBx#rVLO6N7?SfsX*s1IHKYumI1Q6WtBlw7Q)nt
zVO|;^=|(t!18GGQ3{bQV3~Dq1n0rIKRy77VfVxt&VfRT^wG5t<&ILwH2Lh+~Q@1cW
z2v%Q;k89q&=S9U64gZ28a9shWKf&>Zdry7x?uVC-?A$$j{>HI0%U!*f#^&y=?>v3s
z;@PRW#aOq4#+h$xfBM2@k3e#DdU@1R;a8crLd`LaVa*>l6~>?Eve@YJ(7E!ooY@K&
zIHS!gj0zQCI8R%uE77=GG_g%253z;P)J#hWtd2+libLL`$HPdt;q##L1{ge
zb$4+kz!G#SG!;O_GfvGyAvug$I)3yDE~?
zs!&)koXNj=A}W-y_Z_m7z}de(Zx+v1&4-GM;%V23bXG956~%uARFYo;>i-I`PX}*S_H&)FA+O&9ta>1M(|mn84^$?l3KwL#PacXcWZ_3Vi&Kt{udng
z&g}6Aa6CD)_{l4;e)Hj{@4orww;z4>(JOB*b@g3eTst*0_u$ltfF?Q#
z@r=UYF3Fk49dAHM}Y(9a%w
z_)`++#-D>HE7(n=&fmikNT{>`A}P#Y42QtW_?bfJZW23ERtNzg#w)%T6f271?96Nc
zYXZ|mdNt4hK&8gTtr%bjU`_b;aj*Fo$fBfvTkAMI6<7c1!!^fZg>(^gDICJjO((0WvXLbe$7rXo4e(=~7n
z&bb30ox9;A(`rz75dT#nNnx%q$PsIEimfH^(F%t$BgdFq3_S2@TXlpjlpIKFVsIrX
znNgMm_~A`7jyfyfhQ!Bf%{-aRd*T2%R)YAU5c*%(Yf(N_R0tClKt;KwvV1VK;qk=v
z!cu-_AwUx#7)Q1c0=%MDo#J?R)ByDFuEtap$FYvr&)-v{zzQK$dr$&%1XX~Sd#UVT
zj3+7q{D|gW`%x;vy8u2Qk^ok4H-P3Ie*njS|IZ>=7pLlfj
z+M~>?NkF)^ZnY#I;*
zb!q%*W(oR#>jC`#hyGt2|6lrl5G73&LMQV}CqOHLj}^iPav_5S&=Ck~o9=%c3qtv}*?ys>;jpgkOqFX*shigrw(Qm0Rjwnp>eDXIs@^gsRo-sx
zx)trb-QIQD-FUS*`eov8O+2sdAB3Y_-%
zy2SExUVj&pJ0nxBsg0XD^SwZHM^`q-6?K#%=V+WrPGL(9V~^9l_G}05sn&1VnCZGQl^QdX)3vp6)X6}~Xq
zIxMA4YSz^Nw9cwK6;Mmyx(Uuox
zhtIWmHtMajcKIjgR$t#3{pjr4-I3VoK*N>JwsS51?MCO>h;P-z#
zwcqNF{PV-hX9JF573Y}89;6^f)clo7Jvbh3tUB#?g17pm^j;C=La6rT$(}YAeoQTB
zrlP^!R?79={J-uWO;FPF;ppk|s&Ni~kuN!GsTyYqZ#Kv7L_44A9yk?=zI5Cky-hmXS1lX(0TfjC7ZF0z=*eBPpfx2%YZ=92FJeEYyJX-Xj&5+{PhH8>M@|{e_ZVUt7P`Km2%YAJCcz${9
zx%rig9lbBDu3zo$@7I_v_Y6%|ICdh@0gZ97#&xlyf32?Ze5`B5+3;w7>5U5)&UN)Z
znp?ck+PUaze0FW~?)c2z*`;STw@*i6%dYzS6SJ55ht75MfO`%CooA_@E_WUYMkgy>
z9u{}RRynLT1w`U@k>W~6-{CqRkmgg-_GjmpFZK-InV5Nf=lIp3(L3`C&m3OAJG*$T
ze|WvF@ml}TwZ4H9{?M(?zHMhiA6K%VG|meZ(|oBvuOyI`+mxOg$|`EfDh4f@13K~2
z4Xrux!a_im_7+0=i=pu%IHmDNBafrdQ#c@GA^b#Cn2HOKaA68%P%4hl2q7x=*|E-9
zvvRgf7NR1;H1xXLy3t^6=3*DBb@NraGm-j@TI-e0z?@wN#PN1t$L+zEb+`G8YwK_C
zOh$#IGZ9aSjecoq;O>0Ss20eXq*KONZ!k3ra96qlOAh0pPCQp(I1#QHP>X)QG52t^
z<9bhc+go|A)$?$?^RU~x=rGP!>(*SBJ{3E}#I$gU18M8|yX
z2w?`TkxC5EC_VyyNF$%Ns@CglM?BT*wbi{cUbmPNVvze3;t{=asnXIZrAK+BNrU`C
z*t2XmPUz%a0{R|sf1#waf#zq%rxz+}236V}x93Eo|4!H7PJ{pM92DA%ZDG=^Ci!mKL6~_
z=?1C##Y)~$w$HD~$#
z;g0zV{bZTKLxctxn7gB~4hf@)h8;1=8_B3{1$RIzXrd##24x=LA
z$pJdmPbc~5_*NnAe7n0>#hSE8`!t-n3T2Oi72%*~?XoTzdBtf4axWR+Pzo10*emawZ71fziP9wV%t}9B3L_LrJt+R9`!qB?CN17@8&>gwbrs)TfW)g
zI39G|8ERQ^*_NFaFgCiRteB8`q@nV-zqW~j>5&O1Oxh+29*83l%AH0RQ0=oeFq}LQ
zHg49YUaz&a3;&wrnxLf3aO<;M$8O9n^q1LRyLA29%H{`;AHV+SY0zJ4>wM|e)IVCk$T@Vr!Q7OY&+_=
zYHAnsmN}_rgv1W#luVIX;oRatMqYDHadT!tTf8t+QCn^yFzb5={dcI7%MFt75ej}%
zFF)DndSzuNw#>}#29??rh`e+C@9_ArqVp3K;
zsU*b491YY4Sm-_-r-g@U;gS3_bi0_|t)$LXOWGx*FdG+P6M`d5Kk3;yWgf>2_i9!H6
zvP&XvB2&hVx*#1N<^OeWRDzP;did0b&pv(15f?WZqae)`;nvvZ3b7W=~!r`P*>pFMkSt-E)jDLn28Xkgf0cjK75
zsgg{tU~&Cwy-#g8(LdHCQmjYYTU3VllSJ^8L3@=bGdo&o8}>IH>Fi$)G@qZEZP!>k
zbhe|-9YBtkJWaK9X0t-Ag(K&^fnL4EL87`C?66v2MPW9Jq(Q#qY!s?e7*FL_m@a$ad
z&5iNLD}4*q%5jrmwnjNyE?TYAv`cUyK4QTkpRJUGufEzHxDfN+AB)}_iyjYFpA0$r
zRIGk2Yuc{pk}>@Z%#>AoGUB?{8-8lM>-s>;RD}k31snA?;8ARQofBo+Fq_uGV;%L?
z4rzt$B06X%S{iTnw=PwgC(D!*CXJ8$*Cm+*CH?CcU)()$`m=Z5{^J*4y?+0x$2V`E
zTU@z3wQ^!|VWM~N@%@L(gG0ccK7aPYv5DzNJ12W>HE%z9_`&`AeuegEp?XJffnpgn=cPdG;oCFG|KUb$$4+E
zMXKLuYf}}KgvGL2Hg|h)*ss+3c@j-QNvF|N$Kp-aHA=E_rYqfNyNAqhgpbatf}ngP
z#>JW0qf^s%3|?CRRTh*6n8J$#BTG%eCV{9$uKMo9ms?eaCKj(vqS%VWKD>JCSWEkw
zHx%MYTE&XXgCj3*ZQmFkdoVeBwXNq^Q)tp;IqeOc^9IkURTKReU&?$PO+
z15HoQv@f~Tn~kQ~D#e&tJZ_Opm&<3$70WK&fPp=r0eXwD=`qb!%BQT7K^=3%AY7}{
zFFO@W4*A)rTYZt^KKo9S_4UI;FD`Um?QNVa7o2Q$w2AQ{4yu`t?b9h7fi#ttKeQMsQQPxDqTxbgbo!ze!
zFI1b(H2a#lPB7V)y{~Yh7B``F~QHb#3fxgyfM}kxwN=;ZDs4#E4NNh
z%)fs3sV`oA^WA5jzkBS&)s@3%re+*6`K#A&o*kPWbJj=8?DI{{_YQCOTB@eqjemUO
zZKqsyZe%g0GWVNIH5k&c)#>NSYN;Fp9NSY?aX8ef&Mh(*!<(7BDkOHIqNY_O>r|U#
za!oacV8}0V;7Hp1B1&K@RRX^}HtrLMj0L5(
z5~QUBT1TYlatlYxtL2&b5x$~Jp^b3G6J~oYk?Lphbw#C9jygM?xfpJ_F+IQ96y6NA
z_&DOLW3w@ZZavVl6O4wqVn366Z)Wb!^z25k`S#G*W~2Xfq;;pE@q#}zF8b9XLjMJQ
zbaZJ@!}gQlogyYMg7f9t_qG>-7#;OHJEhzP5~N=%YUWdd9HNhbp0H`WRMeSh{d4pE
z^j}_x
zx9v)&e^A2@GBA^6a&T-FkXr>L;3?Jlf+RP-ja2Y--u+$_knc$-k>j{_!
zB4(~qztvdjCBp(tw4Z^z(B{6;*K{gUb9*H6>_X2|ld%s@EUq?`b*tG^cEx@@f&HFCOY^cw2y}FQS#2U`dWp*nCLmXuzaL{1q=O`zSMTbZn=U8?iVRJ&_w`~j=u*6gyACzg0Ysluq|eN+MG?YGey3dRKoOd#
zY<^0*IwMz^m9NVxv=<{yxh2|+JY8nKDm7c5RiH}CG3FF0(sLA9dCHGqX
zJ=m!-ggDYxgKgASz18TCO4W^Y_F`r2R#Wg?XU~~f*O6N99zy>e`uN0hzna%TM7eM%
zADIH;j6NlA+gskJWY1Tbn)$>rv-D!S_q{W#w+6!t)rJ6r*sl?-xU7CA*3ZIptJq6U
z)A^X^dSCF`KzPh5>XcJ1cDmQ=O=D(WOia2r)&ZP9;F;a*ZGOBovg$J5>Td=i$o-KR
z=p6OcfN%js;@gciARL~zn^v7RAi<-0(Q#kRhP(V)SLkA!Z@aPTt&QoW8pDpSYOz{>
zGUOW6@}oRr3!m5~CiSV=3)T8=H3wMgou-;cQ{6AGj*Xbbqh(4D71=<+ct}V$9`2_T
zfIMC62|t?bdAvLd;_-GFeLyFC|HSI5+j^>{wt-sGA|khn8TTf7UOhZ>zCEz$v;=uX
z9}_iMuAQ>$ZVa?VMZbuwcZNnEoH)JKJ-F7~abt1)-m%kjv5r`o{cumuMr-T&!67$?
z+a!}O`u&|+T`f~^dS>2^rQBUu3yPE@WtBdj)KrR4WEa|CXnP6LUW6F8RKx`$yGWZ=
z03=D9nQzK3-E0iVQ?pIE#Xvyg_2n}2bXoaTB}jc{fjli<*F&FQB1%qgVsiD_1?IeB
zS!Qm#N^dQO$quFK((^RwxyrO$O=hk#J;z)KRj1`BQnRHgneno9nfZ#;JZVbSsJXlX
zfsXLS6)2oEr=XE9ZsLh6(f9^DO`cce#8L*0wi+_a#pL(cs@}VC+W;p#vwoxv#5C5b
z0kd`88(MIC?~P7Hgwkppc`La0*xUaWjTsd82D^YuG-*~pJ=yo#%EV@aEx$j}=@(d9bpD_gUdI(_e*JM2K_F4h@3l*~{s#b47Q$a
ztveH~dob4a%v8q<^WE)YV!xIRg6cIJGJs4OkKUH6gFbCRl~6{sp@P;
zk14z8*2GjDjvQg|29$Y{tA2m4*3cnWE!KHrB3U&O_vW>04HUMQKyPD<
z8n85TA$-E&u0|0wSw))60%b<7DkWE)RVYu+0^$goDm_=460eme&&aMP(fxFuEH%5V
z0H(^wm!{=-Y21E|u}z{@WfsT^3Kco|hC-+`J-3!jQ)d^<)q4jF)@m%dTdw!hxh-Pl
z(`%bSu?$G>pU5BUF`}^+mtI#^NFCdPs#08@FtC_A%zIU^34oVJC_-ul7Ht@
zXR*2Cxsw+!&#xTq99)WaT$x+GF}>KLG4`13EmG}lum!}_A(42Z&U0aER+>``gt*6E
z-E6lmjrO#bnVLnixpK$dnZ;I#q6&rE85o+ZZP<>rKY!w6m&y=ki^fdlleVfJg|>ww
z3R5`k9Lbze7Yj*5m*lp`V8Ak}^h(l1a1dw9m0vuIU!hw`(g$Rg!+Ga9A$y6!3e+
z;^p%47@OV7WKHVy-2xF1z95M-Bv&@!$jt;=E1uRuq;@iSV=`4Uks4#N#?*>gqbABE
zPUvLQ24#qX9n*-X&GOlD?b(+4`y*}7&GcRA3=HW-z|H8EbA5Ew&4CsNrsUD|0Puht
zskjr7dIz@jN>B5+O*3Lvjal@K4D3s*ll5d|4W=0A%Nv7j%XQ^Z5x1U%Zy=LK%?2-x
z>?Y#6mC|n2FIHv78@wGAj&4ImvsC-|`1yxx#}(9=GvAz^6EAj{oUS^U7B7T$AYGT7rHLoJXC#WE
znbPugDLLBYEFiD;BA6;AYreY
zr)Npxdn+>n9KPsaswQ567MS~dQA&C}nIX-}--&gd?HitRH_Fm->ajFqJ~TiVw24)~
z83-_VU<~Xb^xvUZ4^M&U(oaL*8;beJ_(n2n!DR%_;&XHT>-Dx?73Xk+_5MWX?~kt@
z4LK&P3Sg=0Nw5G53nJ_Hb{4MpMu1KQvO8jw*5i@2C}aa34RmdgPHN>b{ZvA`fD@sU
zXNa=vO`So6f#y_&7gq9
z_hy#;Qf+6MeZXKb6+&d`SxaueF~8K1SFFr0ys|i_DJa@#XwszTm*tiivr9naAv=^&
zjlfkw(H2BIh0XV2rtVmE(gavs5ZYuTMWCQfK4~QnO?^g?kA7cc@)PS#w+6gpyu0_xZV=qY-Djgw-abbSl|nHr3g-z_s4y
zdLqt^C%B22t)|*~63Ig%HPMLmMB=@X9v21~U{EKmsxXTdO?Z+IaEL(kNrX`@W4YQoZ#Q3T4c_XD
z%~}neB2E((@4_NIBw{TA{KJN^5UYaTjg)S~s!aZx^F*rYkt;yoIy3-d{R
zzD1YdM7!U-db>++p7S&v
zpPCtO3IN-u%PFXaqYe4R!=QX+?IS
zJ*%KBEneLed?Zm^QVVqC!E~TF<24U=Fia1#7AWVClc81
zxS3AP09;8@GepU0pf63!6s2W|(=$cs@wd!HrJ_Trppz)xX)1*A_oskAO_ZDo+)Wpb
zssP@?uRoRGzn~j^5kCVRU=n)O@_I53n51eH9N4CakmI3Iyfo^v%Nb;G+yqi18P_Ia
zIBmyH^v%QdDEooL!5U$ALkVmAa~Tj~~9+6&^Cmz{y%7vW|dm5wI7X_76@SS#?*rNk~7N
z>|>KV)sjuWyF(=!x0?n{x<89C@9+CO@7>d#
zq|nSLW@ct4+p-KY$+l#XWs=Oy%*pQLkq0!%2TpV>*eDv%y
zSLYX2o14dLJTaRiqSh(X(qG)%Ql+Hol2YwCs2cDDMjMzj@ef&urf)Yk;?rE
za){jrk=5sRe^!F5XRL@zQXWc{A5H=O)bS~07?L9gBR!C4$wZeE8Op>ob$qfm=|5eZ
z_iwanGP#OGtt3$@NyPQKntrpcnnLoih+P`N&B2zignYFp@a#l)H5FS!h5hs(mtIRH
zo^K7FYxAzu6h1f7Ia#Pb6RBOUC~Ok4rtHRFfARU3@4ee4Q35Lf9|8)23d8`BjWkY#
z!3vY903VRIXtT|l%q>(}zeL(6mUIh*u!TLxD&5^YZof!4t;Sxv%?
z7g`!vq<)M1m8J1*e`Tjm+M$&+%lH94yMju%Hqg~?H??b&K|a?*qgK%`J#aLskO-2~5a<
zi0n+tDoM_%&m~r8VO`1DJ{+wo3saMW@nT3}0zJy$w^6xmG+va>>t+kPxFUGR*P+SP
z`M3~;Q=F3HOwO*zL|0~EKu`-3GKx}=C8+?%y)|MXzua5QrZ5*HJrt)(O>2}YKo>#$
zG;vAA*%**O$SEOe?*{HfWqfiqlLIkYvj3oLe_Uxk9%8yOAsGa+6iWeuLEs_dgcSMl
z4E;TA(5$`~YrNXi`tzMdFq_phd;^CV5mRQ$Eny)iEaV*tdS6|h8!fO^kqI?aiibo7
zTT_A0EyJev8l)jE<>lFd+kI`DRmD4X$Z9H}Qs6><01*a|1^P*peu=D;$6K^n=PbGl
z{;CO`d|WG=Hfz^Ptfzuii!Q^Czv}+#%v+aFzH#>G{q^~G&TL*DXgeDXO<2{-HvOW_
z*ui1-iiAMwRo#b%5=;=e|)GYb_MAe~WLsF*l
zz<;__%im}o8ZN37_83)uE~`_k@iN)948oo1-YJ*GO~BPNXai_R;mk^Dhuz9wB8+Ty%G&}h}pN+mfyN}w^JhZ5=mYH8Cg4?Ob3AskZ3IoR=-R*
zV>R?j_)`W|uaLJ@;uw|-mR!cSFKzze-@pFTpZ@os_7>Cm;~)P0-~MTLNjJEOY~dLq
z|H1a({^iZn$Hq0vQ+3soI?bF#KdDuZD3ya!*{sR5TId9&4B#n{0|1Wj9tc39$zZh$
zxdS@+ov1fsMcj$+XQz>y4H5?T)@CrMAUn8Yy#Y
zv-6x3N}JJ9E0AnP+b4?M>%NeOD{7W$OHo9xSlLzLwq@kJ^XSF1lQT#nn4G=0pg7=I
z6qjC~Pbg2z2@q(_G;WkBfN@4JdbU#4R)~bU&V247jJ~S7e}V@oBmP3A(4_AXo#D
zdr*REI`mi4YdbiO!=_*q`eOQhxCwmZC
zpZ8FbWPhA;_kxk?P}1WW`g_{hmL|Zi68wQkbg3gc>9Ta`WsB9$3!RNFOzOKw7G7VT
z8g&{6EgC2N*4U@UtfRm*2a9#&tJWH?&RXg
zK;+l|_zO7Z4}bXgfBxs+Jx247fBdK4e0P1KZ_KD#u$TsA@^xo%k5CAK9@5GdI&)B}
z25H>YW?F>K?-0s*l*(2S7yONvMye$fJ!E3PL3_P7>Sf}d8Hzrd>-DlI?RrI*QG2pA
zG+*QP@pu(vTDL`as;jNP&=S?CYFW%qgU&DDd6@Jn+Mj>*zt^5PIyk!C-QVRbi&_g;
zLd^qZm8+3feGclz%<@umTPcetj!)8O=Co-H=G5%c9IP!f&z72{OGvY&=j_xs3>LZm
z^`HK!JR=W;5F#lghy{sYN78GuaSdovh{))dsM=V9C|lSkQPpF}Ei_)8Q2E=hzW(N$
zufP4}H^2PlFTVNZ*IywEJb(H1S6}?%^UuHh?2|7(`S|k>KltF?x88gG<)uKR7DMzC
zXf?Um1{|d%Ew_y$f!GZZAGn9~6e!%o5xN1qPFzYA1`;@CpUz%IWP(6SpE^{Ir^xmL
zb^u)b_e91k4<`zqIsgM*LTXg1HYKJ@4#WYwvIB9(lnn9TEOh*zwXp*I*%oi3Sg_;w
zh6ISage0Gw&
zV=IpvqA}}mq*^Qq+%6E=#N;;M31b>{6OG!=;Vun$Cm-B?-#UuOyc*0|GhZb
ze&@=@=3;+uwBgd})qnlnrz4$__ustt@4x@*Pk;E`*jUdSZ@uydKoa!xUw*$)S3RNA
zov5zr6^n-C%4Qm~k;G`Gvf!@+j?n9I+l{Z!dCBjN7Ii}G8jv$b`Pxa63iAIf~
zioq+)$9veKn9)`xlD>QGmOd?Orq+9QXspFxyM6R{uhSh?=&PifI;i
z-y-dozxvfTUw!%cJ3oKpvrj($?9-25eDvU>58q#&n|}4hhnuTQn`_HAuU=^O*IwJ%
zswUE^^RTt~#OfRzMC~w{9Uw3uf}0K`>Gs8GfXID_Od@M@9!zv)6x)nfU<%@42y&wI`NgI$tF2_rqt@j=D0Cg
zGsPA!4YyoT1Se_Ya(Wc%S{$VoORmEq0y(7C^~&U6ICjcQw@OMoc-&LI$`9^b0+M#o
z`vJtgws-U2@83E1r$7E9aQVkS{qrCH^iRM1#Rsz!-M{OcJNKOApq>k~;^8O#}zp_vB89JxH{$0KWB0*=5XB(FXqb<$$%)2SEBT)kS=
zxu(#Zt6;Xo0Upjn;lvc$A*;QLOmmZ|$lCN|dL@Mc-A$rZ(^#cA(sR?JK0f1kOJKgb
zq?&;{-}#rH#6HoW)OFjPXM2bHipnXhdVyq~x6%n2;yuo}Zle
zD%1@E=^IB+o{IJcgwi`B6MaTIoC4B2$8M%ro}TZ?#(`O`$;L*=oETfu#uRlh#4(m2
zgeBWkbAI>LFMj>qKSKNVJA}xuzWmhfDm-~~_4xMM+i$(r+Yx>Lowv5vmQEerg8i?&
zc>kR@Ual-I>~0Cae)mpkMxLL@3=)|@WFv(WWeH1DvWk+j%!iV-`{MybkV%BdLrFTY
z-tnnk3af_64=VJtrIpJ4@!(D%Uz8m{>WOI+QpHan6dgRQh))$geOR))R5{Y0J|qQR
z_an=y`DlOnMdcsUicnY=7JnudD#E6D`Q*7Or<;s-;ZVax_QL#}N-7bl9zZ4bn=~;E
zKP;m3Tjdc6?NWPSvD`jl)qMNq7elUM;Ln2rT_o3HDP97-7Duhc5|HXcELw<6Xrhy&
zJo38#FF)=5&l;RkQA(I+d)KAYGsidLb
zzqI{md!kJvDI<^}Qp2{2$}A^Rs;G1~iBUym!_7vCA|Mc!k^lTt^}Y7QpsT!EAUr=l
z{@eFHx_|7KB%1m@cItmiL5ruJDYi(ihAZzr&%;uBsoH+*w0*k-?&3C{4
z$8RAtUpjwkbg1{!58pp=Wc&5kUi|sbU%!9v_S>(&^4{BTeE7jTAAR^P^bg*D=i~R^
zdGD>)uP-b_`O=CkYH^Zu_dO1v++|nTF3$q
zCW3309*kEXPPV4!>XXui2M+U}K2S-d`&a_t67CZ3JFGaI3}}Ma1|5|ml?ndS)e`?k
z`}xV^C3vLf2h6^UfGs29+(cZz-53;ex-8o9GP73*+L`Uf=UnY;{_QKb7Ap#dtvXkJ
zdXs?OXFxs&sv{r)8bI`52>_*^Om7#8V;s(c)q2uXF{+XE2w6P}*1!MLuYTmB)BpBw
zzdLnoVWh9|%g^8Y+bdNAwpZ6TC-m~u_3q;}rCVjitxV>qS{ovgLu6Wj%s|#RhIAH3
z>Xgb?N=m#GLM;K)EaHYltUiOPPp^f(RPCyy;M^2)C6!u&Czcb4&2mKpWT1NWw%7lCEi2-k*n8vP`t9?@WQfF*ue9}r`|Ms&lj}MH*%=Qur
zv(aRA(Ks9arbS<%fiH1GMktmpRC*?h%U`^Fbu-!t9vNJ4Q4+F?QZ|gx8MHi7ytO(FCk_8304I6+P)wyS%EN+K%68XS
z^D%hhpY9j!KLk-*@bm%j+Twlxo!qeqo!f6S2Za1CliG>NDkq|9nUu-OqLVFNHz~`{
zqjwqP7rR>ARI;0bE6hvw(1;N}&qKoQ_{uJHcYOKYdtFLZ6|&|zzJWxq%EtkkH7H^y
zUlgXmmfb`pwDTF~I`-<6|41PJaAbRWb8+OqKK_q?{Qd8K->)-AsO)~3{BqDgtWdUd
zSPfW0n8J$jB|xN~1VoYsRqB{X(5F>&DM$H{CyeYNe}p
zvv26y(ppGsbhCIXjg4kho;e@A*3_y_&8omseQcpUHMfZiPoikZR`k-@3-@=9m#5{q
z)AP$xaw^jEDl_t%shkduxQi#9RGVNMAu{{<@~Rx%<+aUke+9butKa%ukPf_UVTZ%D?^``X^t0^6{4+yRDEdzgj7^y`E!5S#s^E61QfddJSAmU|KcJ4
z^4ovumZ=A%s&2j{%HlRtnY|+UZb<~>IUwmHcp5ypg)M9oNJ1=b6Hm~kR@YJ~)nv+8
zv7-c!cH!_{2E%lDNxM!}$EJI^oT>8iY9_P8U?{|5hMmq)r!%V6mJo2)hx%*TfAw3L
zW~=ku)clk`a${+|zqtB8IE65yw^Xuy^;e&M`PHXifA!gyyH|gJ#jig7=!19PzP+*>
zB(VYnW@RoGLO)pS>U>;PE&K+a7hU^rHX37ix^zV-^*8IQO{`jZ6mu}9O
zY#m(TULV%zqXIFAq8EqwYtQbJ@nDD{8oO7e>yWFW5_uh!T8<-Dk!YoOaxIHlNuf6I
z`Q;=q*9_PLH=S5)6@vjphNMzAnH&^}A~IP-CUs)at*XEJM$b%J`|Tsg2J7mtZErO@
zT*Ds!N^9ryJ13t#b^4u0k6t)^;ge_X^_5l5wZty1?ey84oid#+F|EUB?loH1Dv)Zh
zLpqBWMfReIJ~XK=58q1Rg|PH)o~)B6Yb3K;nf!Vb$(@A>5a=#E_3IBm`}*szfBDVV
z-+lW_=%9|@efx{=zWw^w-+lAlFTecun=e2V_xhJ#eDdkX?|<_CJHwtDcP_Rj4_l8$
zsv$yR065m<5g=={98LlL5C`*pHy%nXO3RV&kH6G2(r0#niIMI*WK7Diq-9I?$3qec
z4qCeZ5a^}yK*H{YMo1jNR`0K-F@;a==l;V}eI~p3se|Cb_a^A?YUbSRLLAACCY0hS
zMHoUM4q4LAfg=?lH5f=P0=W>2Zd6JO@^g-a{1dK%PL;w#rnqtF0Ef|M*8l!Dzo|kK
zfJNw4C_+^}p^YnQq;on&@@5uiRA&f*;pMZMSmX}#-WQJk-z4%6|NBpVkz&T`I9B5s
zH<;i(0HO%*fiRt2j{{#t^57_-*1%#bS5!+N_v?(4j-oz;p&W-V!{RGQ)EYXg1V^Z2
z@myF!n@SrLO3I1U3Mv~qy!3S(Q7MsLPG(lpSTziGzr_I=_T#_(eS6~ddw1V{_Sx5N
zTwiW)p9qFcWZG+|&$k+E7CdDt-1Nn3Z*C8bt@aOn_~I*8o~X`T5H;Bh@oD;`%z74o
zy14vUwBuiX`@2!S&67s}Pg9R3*X0od7+Q=e8j|S-BFx>@FPq?t3-9Gx1ayhr%SLz4}}RS
zqmRu;J{#P3NV4l@7OPYW{tJ3nkKfOLY!
zvZC>Z928Q_1q&<^>}XuSqo~VlwWIUx`KU&jxCosOezRF7KGo>m40`6=MMoMuqjoc#
z!HvOth?KHCv>Syh%Oiyt{5mW-Lg#i#fJkgmyD=jxJDI>gFGCLc^m0|~jruJ=RG*V&!(d8jbQhUw#h~0YVj(Kqo|n@o6Ljhompa-9EaqmZxB^eEp;B(`
z96dWZ>&6hvQTR#>sg_80qX?B4d_^t>Y)uUc4@SF1h5&
z``x#{@h}Bm3ax=i-R%&XDZMf^OnVKM9Afa0iZK{cJ(1o(W`)>1&_y4OS&733Se%ml
zoHBHtpUbIZvfn>-vQ?=m#t@6J#1aCd7{@3fFw01sQX&%&L`nc)NYxD9o<_E+jRmN`
zy3n)SKk(YcYuD!2oNPhZReb%(k-6sR$1lIU4(SA$8>A~@0
zDl4GVjXFzANf`}HepF+atMdH*yYG%hyE=H%+H6d1KEa!dug}K8xQWQDN0EC3@*sic
z$5VqOW_2DRLS}byBq0JlNTfHBnDx0tFgorW9J~wR-ttUz6OGrx6xN~1UL36sL#fKe
z*Wsu&Xi`NE4!nyiIoon5#dr|%#e*P<+Fc@HV2MvP9Zn8VIgX4x_5K9q!9@8!=!^w_ZtR_B%|MUS5gClzKApalsKc1n#
zr?ne(+bv-$28~D~ngB9ch(p_P`7w(gOrb|4Fy`f&^KwteqPtfpk>Xb{D9S@OaG3Q>
z#*i6Vr>YuHs>C3raw^cswpA#v#!;$pl!`oD3rh(8#!qFm^Tbhsppi>oE-&bHS^xCM
z|NVW~{;}bE_qad)?iar;C9xw6p$|vtma3ZA+zyeyW*m7>(_>*=sqRLJYQyOl?tX7Cdz>0;z_{
zEyj^c2viq=UVtL@SPIL@>`EGf>F#s+b9>^8mtMVcWM{zd?{m6W!fn^*7O!n>j(Qqq
zgH0uD&a3zD+}zska#viNo1d+zUk!%4U1hyRB^^fF$yl$OOy3AZj+?yi
zEHPv!?hI6~SdD~xG&#nRMCkkmJRNqnG6eM)3dmtedVWD-rX5(^A7?(8XxMiMSTr0=
zuqLKge%UO&PI!&FCWy(huX}4j?#yn(|
zVmq2-K@rSZsEd6Aw!Hiz48?}R6rj+4F29mQ^pFT4E^_%jDwDx$U%FfHrZg8)tbYOeOL^P|yD;pvbOo
zzx-ybE)-<&Lv%Lef-M|jkjjFL5Z?CHD14aC0bh@daTGV2P>Z8@(B#TIL==1^`hdpZ
zXR)h^q)wH}g+iBL@gb3{1V<{yQ9%)%SPDesLNp?TBhGRdSJAmn92rvT8lI?x$_&WW
zZYI}>N6O7W-+N9!v?tCluY~Q+Z{Gg-&7((0>H`zLaMIBq_RCZ*xD>i
zBaT*;mRFsH4&WJJy;~^U0EQf;@gRZ^iB#LARn1HxWJT=)xsO0ENzV-s>62P(w@?`%
zFj|;`s$5Jhn&i$zS7l>CAnkE!#(fFKgGq>+-k)dyA`c~il>tmaS>ct7sr08BV}gI!
zCkGIByAt^T`Y=+p_~}D?L?Yi6Kb&Mu&zAgje~U~lc=~|!V4OBCrPtt4987@NEqL-!
ztIB|woBjVC909mSjme58f-YLn1h{F;!#c?f3kq3t+=d}pQ3M!+a5^C6KoMMcvMmo|
z&&l8NH8e{lgBD{s7UN?fno&(4mE>Vckuq37B%vgS=thyMaAe3Vy;OP~i4tNk{8V}q
zo7Ko*1!?eBWDV-gOVu@}TVp<+ph=}_ci6j%i%yM=o}Ze!yS}y6**#TPUqz)gvG{&6
ztwktl<4gLK+J1$0RBwUounvb@VDgffmGFnqWDkJ`2?Ho}6_yOzTt|Yp0Uc7?S}MH^
zWE(@QfTR%KGdQXXi)4gIRVWM$AShE@ct{qJI#Hm1#RPgGj_Slws@Z}ApFZ;fIM+>Wb(%5*2@>Kymay6QfK$wlPBMK{^19&y?*cPxtA_p8mRXTGz8C2
zPEY&8wNh=9%4o)5yUWVfJGyEW%CS0stHIhO*SAZQvjru+N$)`g`{
z9fJMVtUO)(f4au@-)P1>93Z&6dOH^4_3pauI4g!=&c_0vutjQzAsxHk5VB@v+rWuq
zaRGtg?)X?a9#cUe73Ac)vABK%Qq8cMKrKTN%JPU6XbKQnmPanlg-&pzAi2a<<>SG6
z2dE5)q#g{IaeRQn^b)AcC6$#ZTn&!cDirr=bp2|54f5#@wTZ)Pq;nfc^g2AHL!xLG
z%RvQ$3{E|j0l@jF>`Dx|3QK`(b$5%@HmX1)b=|?lVka73jM**ohM~H42Y};Vhdo6Ih>v#`5+2vuf~^Bf3CeYD`d_U=@x`mJ4>kBd
zed(p0!O?~G&fCY2pPZaMH^2PpE3dtE=hk?nakaB&xvQs9VQi4<9d!QDfsvuos^yl>
zkW@b7EP>2s+~OS6+d8G{m_&6l)Z8M|-X5O%=EINv?Vta7P_7%2>%irdr{q=xWQm!@
zyIdB;r4_}cyOOd>QgUi@3C{Qo$Dvf%2?!P?W+C4m-!19|1M`7o^Fd%S5fl*yj<{6h
z!|@DMQF3N!W?odJD9OP%k}}l$H4fr$U
zVoT}VT_SOvj$&5UKXzy11T?|&tmZ~*d8XwFOoo9-YZZB!5XkD
zK#`z3i3}hQdJ%!{;Ys%p-0QFhZtkJ^c;dcqPaGW`zr3=tGca;@X|vN&y3yU=Raw2*
z7JKF9tuqS?7Z&Fm%gWcAqf6mPx2yEZ{NgV@c>mG0>z7tGUb%7WnYFF4%KA=I!SS{(
z51W6!XLzKzvRSG=(HI?bmQT6dQyIrJ&v@(dNSET1xW}s@a@$R&I=(QQx
zvXopz2=^!1K=bw|f+Ftyo&n+SKoat~%l<@bTxw}1DnMd+b}LJQ{uL7__qUE5>+Dw?
zN&*vYPDs}tP6iNF`{RK~P(ff$nV140SiV0l!jtHe(>XtVsu+bU%0bHxBH1By(US)_
z$Rha%WxJ+F@Z6x9p?Qf3Q9+@tMc|Co!+vhUW3f(`@Nxwrj)#?hxU{^NV^zI^uFrK#D8
zVDP!)#{yd8C$GNp{)0z%j-I@EWM{IkcV}UKCffS!@ng}t>MuY3aH1u8Y~hzc?wgG&wuQ5H^un?#x_J!HUd$Kl0NMc3BR_nVuV!
zs9MEJQ&!&Pu}LK)d`1WNXUNZDMy!QO$P{vuQkm}hoa?f`U^r%dRgjDsR1WjC$9g7nkI1JLLJ(PrC^bh-xc>S{j
zihXfKnfU-82qdI{Wf-#f>9_`tP@kA)O3q~enqnLh6}KH+Vmt#ZdL&r>&(lyW@g%QvRzoLn}n2guc9EALcjXxV;34%mXCMkV2hEC
zDb2?LF~!+P)y2JEZBqlbI-x;?b$oV1qssb78&oBYXlaNd*M8J=rSy^97m{U
zaFNxyvhzH2W`|Z6k;?7a=sugXn!zgs+JG=L$pHf_1sS7A_T8dyKlC4f+ml1Uv63Zp
zGx)oVf;2+BrrB|Sh2!m`$ImP+{`#{|W?Nfdy?y7-sWVee(IW$+4^LnG@WBh$SJu|M
z`qpASN7{O~y9T;SE7$r4rlakH{?N-;u3cJOJTpEvSXOmnWcv2f`f^(=WU=`q+Nm0^
zpDPaQ^o1;zEhW=S$x{|>%XXgdkg1K^EJxg3k
zVqJ*#TJvyK6t416Vvp7F>c+M)IUU4oz*4YYwdMAk`*Plkx&%ENBd1$qDLsTv9sn3n(S
zAov*7p(OCvlAj$A|Mb6e-O)*A0&sifmG%aJodr#Vo4dtTV2f%s8IN?fS+QtMRu)TM>Y5^KxFKtMNTWfx*_jvVy+uf2{G
zSKO+rv+aiCn5h7yv4X)z_=Cg)j=?^zC%V_+m_0Os
z!o4lhac~!{l*+SX|7v~5hvzQdI(~d-Wc>d2@mnWP?Tk(Ui^qm0zI^%hyQj~7^wNv-
ztgR#7HOb12D@n6aB39#$PlJRONvqDhb@Dh?+Y
z+f<1;@2KO
z^U|4%500Js{DqfJj*Nft=;h%$|J|b}7b4N&s`{|OxZE7wigt$O%BA{--lF1>ipnD`
z(fdb^-5iTzk!nC=9w{nS$ETHHNg!Zt3T;Rv
zSEr-{C0#OYZ$S}cRH_3BfSM&C1Lj=~L>`FmHQ5_PQcYaSi_5F+Qnm1@{fYw#kPn<_
zYBMBfm0*YvZ6}M%LFc6V;zkQxL7|lYv!}t|xbpGHSH7P*;LJk9E2oZ2Rvb#GBGASQ
zO2FBGpz7mN;4W7dTJW>~jAk{0#%=a?*^>lt=HWsi$dLGfs5VT6Q&U}K0!LwxNL3iY%
z%kkubT%>NjEguhH0WpsuLwG_8u-ftodu3Sn_}ja8Zwve(PcIK&#Ss-?kgB>6!NIWs
zc}Vp}48?*bTTr{F`VY03Z78H#D;)56;=XTBymaU8>o@N_bK>-JfB#$0+`V)19QeeLqb#&Avj&7((8PfpK9
zqn9=}kBm*sHAOoLO3sZ=FEvIAIh+nh(Lhn@z4_%jj$q7H=HUvD_4JLERMyjZU|l!r
z1EZ#b8XU!NCka&n8X_<&ekh{cW-m)Np%qiUTwBg>kZT}C8XGBZMAkrRWmbr(1bFqcn+H^v@+dxO8~L~|b8g}hq;
zVuZi%g%h4XexLZ{ew!kG)Fc`bX=%4%JiTl1iu|7QZ=*o>pS8u)d-18Af@ulU}
zt4ph&z5eDeKKl6g|M=~1fARH^si~jeerC!azBoI7b#>#}?IWi~MtiC%R=T^cuWl?v
z+ixtc&9}CV`5LCft$k%RGc7Gk9nqux{b0VrO06Xi(_^)t9~f-6*^kCzD~%DD^oZ8n
zYj^sDk}4W|J=iSTf2c!e87V63&>HQK`^TroGzR{@!{hGiZgYVlHQkwyRmCMbvE-QA
z9AXPK@yLfOio;3TgjD(dI2V@SWpcHNDP0;vugXx4CPFR<#{*jvPPaNCRhN)%NJy7I
z8K*grSWn{!o;p+l8B8V`_!d2N5Ol?!nOj3;)lfKLjqy>N#^6D|k4P!VXEp{pywU&%
zf(Rs(7`!D1Z_Py;GIOkXXmd`!B^PVW!`Sj+i-)lZjzx-^-227n$nQ!&
zdGEdFE?>U9zVYbHrMIu$`S8V8K78TDK~KZ^;i>b}^ULjBgYMduw$7N{b)tVH<|z5{
zxfkzl9e-ix%&V84`Nhlc47zJJ`uje4@L)UIJ62LrOl2JJ?5m_PEqUlxy?LU<-D$Fp
zmRDb#nG+w1p9wV$TAZiCt(ugqe!FYc8}hM*WjL~5D2Yim{dz0(UZbrTMJ&gX8^v?Ng%_r>vkcEFUH)uT0Ye)?2Bi>paUL5j;heTe%HPuVkar3aA0@XazLT?JPgUAwJd
zEnX-TZK1{8-L1I07I$|o?(Xgyf`tGHR@~jaIKdr)_42*<56rAt>#RBZ+0T|(*M9+0
zBK9>b&EFbyqs+3o)P_DK61M{;mkOdVz2w5+vp__E^-GDIWWK%gfVg01*`MtGI@3B6f
z=O{T+g6K!(p0Te{dO_4Wmm=>zV1;fPnPRg39!UDtstLt@IPG%$^rh#m<0oM}hpykq
zMcE!p;DVQr1MvnvS3qQ@H9jAB`qu#e=kC6EL$BRf-DY!LqYXyqf
z6&t#P$?OxzA|<3LZ|KTJqG^<0D0qWj`D5O)p+eCz=xTr1`uCTJsRY8;NK3}%JHlkP
zH^o76xV`p90QJgHdK~92BqXLmydd|eI}+FAioP#xWE41`-ndx1C(zx3LaTb!2DN=~
zk-CKV(fd(8`EtioaG(+^GF&jF$HQ6d6rYR$qy5wkQ&DoWn59a0x9?pB^V*Xdj67JU
z)cKc4QwH6e$B!9*{hZtYu13y^uSLJKs`FzD2TYECeIpSuDrv)d^|qk>VqG7Lb5ERpnOgX2FS^0!jOoN(`2L^fhKKL{sEc7c{IoRnMp)z`7=$nAd)k$HV&cI6
z_&4@3-afDM{O|D1)sgN(d`?E38$ZbDdUR(MRIX@;8FQ`fT^0H%UfA2k-D{eNwEC8w
zeW1q9mLu!9(|fMEUC%t@7D{68&D&!4K`Y|bCAMNlfbq~3!%Mnl7?#8F3+L;|j9@nf~$
zRNnA8il*&U107M1{yiWwvkXqOU{Ik1TwW{GSuMo;^O#jm%nP1O3siX*t!?@F^`@C3
zRtkRhStO&)2u5&?IIdH-Ajc)wMOiZXbCvKg9S>VY-#!1cCPij>*bqP+67vRG*VF1P
z{g<=C_qyC@uVun=xMZK*U+UJ@f+Lm~H{#%`P+QX77YEL
z$1DtA4x?)gA^)D*j}`*%;F?tU=~P)o9?gor*H6VB2A-aey|1Tz1Ycu5-5WWNFW~lJ
z{FbV=?V&p~I-XGv$`3w2QWO+q5on%Tzx%rbFEz3WhftflcQ{^Or*PHbTJsQ`5HeIk
zSXvhil@@=@5pPaWw4xZE
zjocV@*QaW2NKYL3#SHR0Uu;(&cT$uem%EX{($miu*`$Uvud03T_I|4SA;F7R)-bKx
zFmLdFvk$sY>BCk3Q$xp0~fhp_TEASjm*pZrA(bsY2>pFbCRc
z`w5M(OR($3-8k&
z%+8ndVw(X4|Ce>-vyS^qDTnr(zE?BC)zbbt)bDOZQE(|Q<7JyE;AZQ_hRUTabAHA2U{@<^C@tGW5CsjJv&@07y7}p=X$U>#GgEkQ*0C>9-j`XJ3<149#z#vf
zi`_2N&hSL3g2~e)^oT!r&Ts0Z%6va6MR1qr3`opw{`4GVl&r&fYmZ5C;1j>*!~F)@
z>KDTlv&nq$8-H~*7_CVNg^Zs7VL)#&{=Fm6@_r^BjPvjx9KGlQI8?{TlN##5Uj@s;
zG(ykt)(L~oiy^+VKex@D_j}PE>yOtb9)jL*aIwo3lVR&ccPXG*A-4nMv@?}Tch+&<
zeTC0xu(s;Ge+r6cG%z?O@H~1rDU1r^8zIVHg>)`Y&uFVntLk~X7{9cSEO7DpAjtyw
zqCSqx$K~Z_u2nc(yY!*vJz%ukl??ik&6A`Ji|I)#lNRDipk0>CnWoV&@RhNtPc4O&
zT(gpcqx#Vt5d@JG(=*(mKz*EagtWf2L|w50k70IJQy%_Lrm!qkP7f_k4fwHeMl8o?@j`S0sj;qg({vg-tbXVkag|
z-0z^U&<695?a55qjIN9s41A$AF6!WkFx?u>N7C2{dK=qhVrdg^dv+ocg>n0zgAwKh
zIx3*-r0L?H*w-;ljmMTc3iKT196WqkSu>e=D~V~ZL+4C#=1OwvLT>6pYV6@i589qd
z_~nHde6fpv)Kbv>U35OVY8fnshSx7|Eb~{rW=WI;#96!8fW=Z%{^4`Vw;@&d#Sx5C`PI97Ag7EWJ_F@QFMYlP{hfL+p@-_JxbZ4m#1Gub7
z9Y*baboG;Y4HBGTzz_Y>E7E@M?op8`WxuJ6M;s;yHYzTwkngtJVG$*k1cc0tmWE~A
zJ4N%4QgGJ8#>njxWH*3c;z_G?qxbA
z(GM{lY<~3}<=j|{C-tLU#Anv^1QqtO)SNp_xvU)=Brl@q=^=}L?f|gpv#0rsxcQ3~
zk~KRHM_TZa!Vqj|FuSy2fuhQSFo^4^&?K(NB(x?v6>Q^u)c6x@=Mfv3LM2OAUV51O
zZs9^^!YckuG&kU9kzNz7-sQdFF$u5!Q9x7cnM%QhoL`T(*W5{5o+^5wYTzIrKo_&j
z+#n~bV{!T6c58U7DGt;%c%rqR)aPFhvFp+2uwwS8^OW_zO6zlKYTIk+aVsk@{XKdt
zg3}`nV}SA4!FU*?3G6Dhfi#&@jjM6jZMU4_QeAiQm*r=eGl4~;NRgb
ziTtBjANj(*$8Ad|ix1NW^PuOBW#LDgiw9AFeMNv;tOs~w{X77#!pV-muJq~LCf0qg
zHrOc!Ni+E>b{tyylyR*(g1ksCp_L3M(bd>ei3!q6kQn^-`0sArzCvrjnAsPVhDXzw
z51{MN&0Ct*Eq90WrNA;e;0sDNcSS0P3(Z?zsBTv#-K@aER}3~Kc|B*G@MYoe?sTCz
z7=0`OQ|*QQaO0bDsWOd`Ys`M~PAK$tX()AUISIe~(J=EYz|HLMO=_3T+RFr^?K(+>
z0yq6aYq1IEGpx=7+_0lpe3!dB^#SyvR^Z)TLo_M9yj$%~1CZ@{|GHDFCXH=Ll={H(
zVFKMfCbA>QXMve_*E<(grP|dBr9x6M`d+2mS+wz`Pq&$PiWaj_D-+L>s_DnBT_FFg2
zzO~_ptMN;hzEiVYSWEGaGw`2`ype_p^shsf5<%@e;)I5`qK{a99=BU1hkL8XUr~#N
zwTmIHIO6s>p-UtCi<_|%O^tcO97At6zeiuGJ0jVmg~zaUZttxn7~F)R{?$`;HbK8i
zob73E{BS$D2#>3|svqa_h|~K@44IsAadF(yQ#_j+&$FqoIT>C~eYX!zTg)11*Wa?I
zoR&nqRM(v{b1>>N(pM(ZxvGn;T*|dn@nLLY5d?DZ;7r;gZpw|lm3u4o`x8?A_3`*<
z&N{K0gT{-Jpgl7tUq&>E$o9a85*k{&D9P+!EEe3y5|yUfm0D^vc;G{?VE-;tt$KoV
z;=$U}e>L-cCi1X3RL<>cZLp59T}jbGlsuI{AKz(^>dj|mMxJ3R2M9^|;Yj|O1Kicd
zyqg+^#RfGyCJp^-Dkc#kX1&FlE}Q$!M_)xjO?a)sQO~x@&&KS&bwpRlklN8gxfUDgU+j>M1R`^tDRj16yaY?w_0fo*A96Ty;_|1s6C4n+_71C
z4jQ^cG7%(Xq})c%2tma*Oc1d)!q(}%4rM)BE8Hvnc!X^ThyC1zm`}hYC&UBoM+-ZI
zKIzhc#Y3;Li>pMWtiR
zB~@;qv(h%r<{0n`Hov&@syKFBD4rXm^AlSsEb~zX-BDRI9lhVrUWvaKyF&^)bG_EH
zItj6G7MzBv>(m>2+&cH|(;cO|ru{^!iWkl|I_JAO$41$uS$bn8E2E(*qronKNyhq}
zDlKs(HFF_5_;g6*Zr2$3>LS?k8U>F_;m7-wWVPQ(;BUC}BR^0-E+vU{TC&n>%f(w9
zNHudJG4_*BWT)oW#2eaO%4OjSsLcP?sZ%rc^yvQk=VD~KhX7dpWR0l8rt9aShX;x6CixM
zkI`Tmm>@@5L}-CoBoHmd2&Ot0PrEhOUfjUD=CX=XW%fUGQqk^8nmwr|K4^S+_Km)?
zP39Uc9!+1Cw96tWFHH-|qh@ADT{@A$bL7`Xd7{~uLEq166XY#SRLpcg#MA4~CMkp)
zZ#y}_Z3{Q2w1lpKhe-yd75byrpIM=weZM^#_i8GRew~gU7&~ECX{+!AM3&0S%+Yp05#r-`T%A46O^jr#9|t@KtCsH8
zjxy;x#F13ithj2%)4Iu04g}BF@RX8;l}jr3_V0`~rR1dT9Gm}G7>y{~Zz?lyw%8Hf
z7~=++Sb05r9R%{T|40$D9Hqt(k|=zan4lzjY@jiSk9(&8CMk2SW)^u5|pC|8!$W~JO&*VAY97OKQj62jb5aj
zjJEZi-x>t1ke4H99^yQV7UlPi&w8}1dGz&oPOGiZWICR7)G59G1u!11IaIrHkN#4O
zB;VkUNJY7yhc?H_TwhLP!>6{o9avS7!eyBj%pRxHD1uR`-xbX7Ts1feNbcVWLPDaT
z#gXF!Hb1T~H6rwnW&O&fr!Q(K|3VdCI_3IEfhksEo1>r-3)x2d%6Ad
ziZ$z=CXe^lW^2{04-b=zW1ID0Xc*mEFoS5Hwb?VQsU}u9Ih~1jYHnr_?pqT8ntH?q9M`TiPhhz2D@DYa4wBAHEICd~S=~!HF54O1GsPOwn;g;dw&(hh
z!UOl?sR-ns{q|8HrYoo~6M@>Qk%!SkncRzCOb80Dr%5)SgY+MUlAEArw`{R<)erqb
z`ZZc%yQj4G@%oH@+*SJC;%N>?Ln8Z4H}S9TB6K$CF+KN;t}kp>@7P5D}dG(<`fHzX%kkpX<6y^A%tKsCOmHi`sXe=qNCZ_WF4
zrE9rli<;3!?XxU8HYN>xey-_yJu4wRYRtNeT-q1Y!VcZ=Qt;e{y<+*z*D6J(2$(*Ki?8k}}YX3Af>$2;y7wouUizv9YPDbgW?!a^mMiH40?t`!aVrmj+zB
z)|JYZu6*D+Y3x5`a>zL$S^LnmL1IWqeW#agsB`-e&n__$E0=Tp)$3mu>etoQ06*Wo
z&|H)4(9h+(NR)uKW=eddD7rZJ+x+Yt18Sfj?4WXrb^{3OyGouh8E-HPxZnAEo=|)*
z+PJTBcCKP_)xgDW?8Z6NI1tQG5XYvTHxzZq*8Y5!2k|TfVdmXN1BeO=sIpe@h5>0Z
zbc*4+WygI3gxykfHd3)=3_cf5HWyLDxC&#jC3{VOIC%gRA0pS}X_o9@UT-Ku9I!_0
zzp>)a<)exlOFDWc46%Ij3VKKvx_M^Or3;5@nJ!f_+M6b1f7xLq2xuL?8Qj)w$BcQ5O^8d^3BL^#sW_t{`FUDL
z)0f$y*I3cB7AX=4jWz;-_rEB1d4FG<&&wf~k(v51Q+{kie?|&6P
z>02mI=j3}R^NS65I9*udxWO+oH*9mX@-x~QT^zO9uU*$!!LW{9DBCBxE(^zJ+R$2R
zYiQg9^Dx#{cY4Ez!H~X4Vbk{F*7CN?a^Q-}QWrcF_hx!_S?1$mZkO6JwMlBK9v1fv{E^pCxmX$o*
z4GazZ0}NiUkoaWoTLa|QXv{r+YV*xWydDvL;=`zqi~g*P!es0qm>s`+gaZ1s<^Gc!
z)`*5)lWIrRoA>)>1^Gm<5Oxf;a#F)&9yh(toxvh8Bh+
zaY%_>sV^CyO>ik3YV@q@4|AO+NMr5HTQzXH*S@1UANL3
zcH43lRv7c+L5Vq8d7ua>t5x~OSXp~y>I)SJ3F`uO^y{E_^dBMT#4+#U;JTHWcwtgl
z26z_Rm+XJpZO2sfxXy9crH1Vf{jyy4m>eOb
z1|8leCO-3Dd8hbV@N8jjX`O!Cx1x$?axL(k$pcUM=U|-j0C*R&ZtioeM5%r%So2ZJ
z&$my~MGDaGYvcVQ-gsndVVGZR38*ZUw{ZPLL&AFnektrDJR6&ebje*?80dGvj5B}{
zX}K@7xg7UKmd%rv+5;M`fd#IkM%fK`G14gl>;oPnd59W5HF_Unat8uVK$|}$y9K4BbR99an+f&eXGm-4mh;^AV
z)23rut)w%oq+YIOu+ntgq(FGT0!S5{*;uDEliJPk;M%7m?zaeAZuTu5Gj>nc;MTOa
z#{ER4|G*f0?j2xSB+jQ??Z-TKH9{wKq?NHD6u?6M%irt8GF`!`zWpWjW)nwVJ(&U;
zP11pZeg&_uaba+)rN;oM1vW2)udig?4;*D18tSinNLxE}@aLX!f-XIe-yXP6
za+oG7;9B#!K2egb4fINiUl#{P)%{+jw6OD96GXBa*uMa2i7;;O!r!7?vryc54z|#BDIong6~{_y>Cu!3v@CW_}oV@fLiz^)}fRTy_2*d*8y(db1n}
zI?Lnt@b}zWACKI9+3c&Y*Q{OBi+2mSJ8i{ZSoo^fdbm-}s+&zcsaTZaJ~ZLW4j
zRsIFTtvoEC>Dg2B^J2=!u}XOE&&C-eeRR&e>K?f$YfXxTrv0;n%fpc5kBm6$-rjh=b&gVV2?t8J7ap?p$WNb=_R(G-(Uh
zB7)aSg2+3V$@l2%>76%i=0;Y#S)@?1Q$6dbG2T2
znysQt6PWV2hraaH`C<_?JmA;1OQfz5a`y`OTT=I$QJo3l(2$Vi#7jJs26FH06av*c
zJb>$(w@&fzMM{aBhWyxIp-qde*O=tYd#rTgzed6QdY}+iOPt#;Ua0mnnQ0I5hOna%
z98F#^Dk4CB{sEM0+Pen)`sA&Btj8Emh5`)rO6&2Zs!)qLf9*^6DV=r5zvDdtkh^M&n=*+|9xFX+xim+x-E
zu*2hcln%c(j3JZ?nd(fhjdg7azBE$X=5%oh$z0NK*;F{2lq-OpK8%~zIYCPOfbB=S
zR~EI5^m1;!Rlu^q=_*nB-QixnQ9a*)$3?z}&B!_mA%L%Pw`dur*ks_epj(hMx@}T?=v6)Q
zn2K|D5S}VavtOTVY8tXC$^J4wS9q2|#@X|2|B&K%jXejhpUd_jq$#VpdBDSW+yd!4
zesSJHbNIwf%h_1dDk(~i%>{o}%-S*LD;{>WSiD<{or_mce0eynZ;q2&Cw0)i)S7RL
zyK5Ri29l!;3wUcM$lkCz7DO1};WY#yHh(t0(>+q%FMg@~G*cRP-Z-*KYl5a@>SAvr
zE)#C*+A-=29ePhwnJyARBYxxRoG!^~xb=m#GJS0v?*mmYWmt=xP%^3MOxRdJDpQBs
z{%L6H&HjWTDJHuj*xmnS_^8|>O~~`+=5?ERF@{gN#^bj)lWySkZ?h-8)*xW-8ur2P
z9Bx82F)_yE=Ki`Hiv0|w4BE7gW4Cp~nB|CR5lHpDaLldMD72$-RKF;Zz};)>tWWp}
z#F3Gr1NezXDgviL6->E;9#D@Gnb&$MH%vYNEzef2qiw^yW(XCSVC*w-*9{Efo?NV4
zQ@I~4|K-VMV4?+PE2Ox!cV0V6uhsycaeK+NGz6+Wp5|J7PwQ?)wK4hZCX2oaXzw}7
z`{U}Ru2oiJaY>0P%XEj9b9gAYzUWLg4?etDBP51kMFKTvt8vrqT4)*Pkd4{nxEKbq
zb08+pF|3F$A&rhIk}ks=&+W^TF~)R`&put`SDYD^!>5s4Khp+3Ll=y2AK;XV3hZmu_xf4b@Z@
z4(JFD=poI%5+id>Q|}}?r5lxgS$$GHT!f!}%_pK$GK`q}=WFs5o4U!wRPFC%znj^$
z7d-{tSm$>KEd;a!ZkxH>{X2Lr4~-|dH0L*XIGsUE_gl6Dr5F>~`5<+XOeflT8;19k
z3h9Z6evtlI6Rhe5JpCgK{nP8$NBetwU+8ES=nv`LEIy7EU5KJzW29m^&tI`Hh3wtM
zGhS<(mS`IQob5biplaQ}
zKrjD)kwL-Fe|{_)*R$8SYoW>sZ=1;EhO?udq#sgJD|GZvps`?91F*l&&>cyWGDqpqVt6R9Iw
zcE_v#SxrHh8oc>affg{Lqm~fND1}X&30H3Cp`VGtO))Ukd4%^7S-kd4a^2X57sbkK
z@4ifVzvdR#qfZZyDUASZ_{>Zt(UVsSoAqEMP##V%d!zH0%VirnqHK;1)tAB8+dPSI
zn|kC4X;~4~MXbyz#dImJO019_93p3IKk*PNKjo$OiwPq3Qn250Qfk!oX+^Uq&>uw3)?=?0P
zg|Sea=~l=*&MZa?E*_)pGzCSca3B6s^x8&#F?4vf;322ak#mUt=0|{feH}?qg~`T?$!**`>}L
z5iBC%VX*cQ%B)+j^Ufh^U86!ujQdfp!@JJ9-I(UXY0GQg-fCdljj6swB=?xP7%4YWwC
zYXi%3vu!bq
z!Y(1RY-{)2SY8-KS6$$=Y8r+zWmeL*W(4E)P#iB6SmC@S|B
z;e2m9Bn2UHS%$JA5(p_IhD&V03|~nzTbEYQhL$4qIZjxEWGGo{H*+
z@POL20)r0}!Bz&@(>h{dBF??7o#o;5cF{G`xz9wqw%N^^04qz=2DL0FtDbx=Xr)EX
zj+8wb%3d8Q3b(B^A0&^UsqEpDE`H+yh4@yg%s6c2prrG&E#ev#t*;UKxPbow=K}Zp
zbqq3Mfj)NnNNM@mU$K*o374ILW^_u+5RmELp96xr_!p3
zJ}D?D?EC1WC2W%n%I=L3Og3&*5;9aiAK%lfHRw>&o~*=H;2D!5tU`(zCS$w*f-)0u
zqgstgDhLI;UB8q9&ICQLhjbk}9e4X%Cj{FdZclSQ6Z!fZ4}U}PyZ*hrY%8AS3Iurn
z+8q6J4=Ef!q^SB3cox+8qfJ#+(}IDThi2x
zpF|=K$zR5YR9yK^JHO_JD)o_Mf8i~og=rSXOS?TBuj0p@&L%C1G*x7E!PH=sGQ+_-
zcH*T(&MkxpTZ~f5wE$nXN!O~%_8ud?`NbxUBacmKw$B{tKH(0EbB-(3Lmj4c#HrN$G@1XcB(P8yddW!9)8aEfqxQ{{##YGpTNP~g5Ub=XAVvPm
zK1z0|#@HaSw@GH{@tvOFD*Gmac3~+<`8kQL?tAu)S*|rKXvN*3aaSh&pRtr*F$$Z`
zH|WHxblt|-
z{{K<_Y<3A%6*WC=o@u;Bj=jkbKCJ7Zm@fpXyM)WuwmHLw;V_;-6bqA+wa*-{)&<%S
z734&xU(PS46X)J0N0n1Ud`G%moN0vACn$Byrx5$&1HBW>wl>G
z9tO3Ry_2mfs%La{)ty$p;U8)N%_b%i%@B+cEIp)LE5s@j@aY<4VEf(?eS`@WyWmaYazMBk?11)sF
z)qWM6$I_!^XhR&*j;M?`2dyi~Y`gQ2k2cML8y2`@DOvVtp{Fqt>slmG4y+|B>JGM5
zZllfk&%=-Cf02~_23r5jP>sDowSSx&|2yQU{vKxmfI~)_8G1B_`fNK|AaQE8wY-yq
zN5j`$>P`(GGdB1wf5&2lE~g_9i^j-Ji?0_0=Tl#OLxjJx`H0pndjg*6%fi{5mO^d6
zqcU-*iPbwpA4?%Bmx=w3F(ex5-#*@?V*}yBgYR5F=>YwD$wJZII)C_S8jm#G+3vlw
z>ADct*`oY2i+SKQR4ORX#V)W?#U(pw;SVKyBn;j5DP_jBy&NL-FFoH@;9{>Q
z{FS0(`I3Uulk8$gqPn@)r$jfnE`@1mdpE1Uy8QB#xMy@2(;Rs6UtuXn(KmebypNL{I{W+H7nx>n?dSV5c
zpFJ)jmSYJs9TWXr98s2nhWaDIa!X6yjUZDaQ;M0=j6k(v*INxLoP)R&FtAh}2;YtEp
z-3EsWb11sk1lTqeF^;Bpx@@hQ`Z8Iyy#*oQE4$wMoz@^HQNu=!+8$T*7isr3z)pu;Mh|WvIIANyszGdP85P{eF
zHe^yuK+Wnzw-DQF-bh(aoLas$f)ho|vbs%Pk#e|e;cBDG$rt9~9z97pN)(sDU~_om
z%xozhDXJP!?ek;C520)nuWo1cuCM|4-n95{F+qZAt3+X9P5Knw@5Yj#l*9eMRJlk@
z(OmU2NZ0tE^NXQO_u8}Fkp(^am&CZdh-qexQy#oH2DLdm1YO;mIC~%I(JkMb
zOR%;_PX?$BMZS7BqI_+xY)8&UMS~_vNvuRyg*CcCDU`sA!i(F-yM~7X@a_9VRt|?f
z6KA<8)CqTI0Pgk0P6qm&ZQ}QN`to2ZABMBby#rIcfh90@
z7^04w6E9-(S+)(WTdxu(Q|3L_@9njeYht088x9^-oril&e;|EG2wB3Ab2N0oUxMi6GsOBD&
zOt%0P)xD|NA86&Yk$pSHh~6nhXHZGMToqbzlEuVfc!mPh#23gp$aE+CrX|Ej?BfLW
z03yAEdKHgNzG^^BL~Uy@RN!SjjgUs69LB0pGQeY#Dkd9Y-5!?
zd$YDCD$wr&0~rZb@rqMaW!A~lSX#-`vRCKO9oMzZ9aj3vjm=Bu7HA2(i%b)RfK)n4
z@aP+<62a@Xj9k}`3~#~@
zm!803e`NvLQo6<-7W=On?0EYdHJN4&(w(|@wrTl8Uzn>_c4CxUeIdj5tCj=c(|$&h
zTCp);Vc|HK!?VH?6On6=nLp={XGzNi$miN?_(^@*_xMRFdQFz2N!2cIVc}uH8t7v7
zAkkbp@h6`F^d=fz?)bMd-qt70D&k`I-I$R&3};JC4BgLEL3z6}1Kw^2lwQJap
z&D^+ZU==5sU3ouPLmfBOX}RRs09Yc?d#DoG&VDQ&SeO<=QeUM*5wr4sELcONIqlK0
z%m>`>&U$Q6!5q72w(^oByS52a83}9N5nr4sPG?lZd*n`u$k3c9nFmR8pxKryOqV8N
z=%ge|gn@uJ{*2y*%d7{J#17RY4K`Jk73Ktw)`}x^bj1VTIY@L8!{gq{ef^)LG_tvN
zU61ICAR9Z6G7&!)$n|+}YUX?Ll{^sBy(vws5KwHg`)+eBR6^doj70vx&4+Ppv{^e!
z!2>b8ea_RaS-KMA$L#lPtJwS9lb$8MX0kO4^RxZ#3Z$S1erAHw>eqOQ6fx
zA%a)m{(P^Ti!)`2iRscrBfSsCaAKx|2=iFWELU}$?AzriVR6-lHzFp+S+|a#5bTAL
zF{#3nLqb&Gfu1%xdAy8ZX8aj?)mOUco0g3V8zBdhn@$riPrH6;v-uvKDr-AhR}|N5
z2?qeA?2rd>{N;N4*hA!iSit0UuYiA7!aG&*Xh#HznJjYdpH@E
z#D>4PPFz@${PnEiV>UD=W=CDm__}nRE_Tnipl2v0L1I^7iAUB+{-xn3WiIrU_=yWz
zyHHp7T*1ikxYBp*61(2VI*=)BmoMWiKnP2VPSd-^4mNI@i$wYMc`2l*^y7z#qM3|4lk!&Tc0
zw$_lmS|wM>_Zb&bMpHfuJK%yI8LYqAws-K8m+Buy=UCmm{#{NvhFY(a>dAY`CZ3Ny
zCh=9)aIsWwNgnHVRr
zIwP#9wwqs>M?x+aWq7}vCsXsIs!4MyWS6_nmU5h)r`;zJz8H@Yj6QZ`4SRX|bz1r__
zK>rN;5CI}j1|ch|!aHjn2~*sCqp?=NGC>k6dw4QgyldfyF=I1(ILD4xtld?gP!8)dZaB%!{p{67_+Fyg@M67gK_s1BaixUM+=b6fa<&k43lRrgxA*!^tn+@6A
z)qalLlMuJQ`UL=w@d^rZcrI|aPZG0Ro^?&zsh0SJCZNJN7niGV4zb2|$-Q+dD_SXv
zZv(6Ghgan1fsQlQ+^a|Qg3F)m5^c<70qjmgU-JbGWef24Ov*<9yt_I~p(kYZMKbyU
zBAZi92aT-_1D2Vzl^KqyURK8u>yB=wtb?DMQB!YB6|#Sl%xEW?G0ccafpRQ^NR@}#
z{oW;syo-b0tKH)a_k1`EF%^@M6v#!^kR(bsh@x}~xNKw~dTlTErarzfZsuT{2pRZn
zUMSCVK;r?X6r}j3KCU@Cw59q)e4%Frj%Qd!;S3C@Epk!hZ0>YER!fKc{olfp(&KYE%Kqh>Ld8%XvKMz|Q@e;l*E-E^^F)5)QniWU(8r3}B!0AlGs$DYS)Z1(2&DiYyKMLFU=bzJ+e3
zy*zfHMn~-v;!%pqP?t1Mg8fscp6bWx
zgTih1cj|L$?4CREigtRZ7>a3M=8vMz&?MgT4~O0ggJM=nRd2pD8sIU|8+%xm(&b%p
zmKFqxePv)bw8a$oPmD#R|2)B9D~aZgulaNc2S_1F;=dmo;6si_i^WXyLW5-J${vy6
zS!h*x!wxb5sHpyo8)>mbG?i7KD^JH9a0`a2Qqbz4dyTgGqEU=w?RnoDh3P4i7?!Bl
zHh-YE#PT=tptBCj`FJacU_cQh4(MnZ#W#tqmfkiM;L885L)9?PNg`i5F8l=F_h3WM@p#BvC(yzeKpH%xt92y@%1(u-6<
z40xV`kyddrZPu(VWo`XQX*gIvWu#}dJz{AX0C`lyG&4t`PCY8*k0*B=<@{lk9*_O+$D{$b~38MU`!Lwn?T^llLio#m^#(
z-$oq~B=HdXX$N)sJul2E;3UF;uV|(brG=%?Xw~u{P1C~T
zQVkd%Vz)tNW9$Hl67Bx+tp#-D?dq>~+aa@DI`&&?gjeZ4PWo)QRL!VZN6R+d1?!~{
zZxagd!jEDxl(;H{@~mJ%&SH788>c~|WHHg@BY>*Cu>u7}xdc)N!#_E|ohj%{t7K19
z%0!Lgu-P&Wq0Ns{zjMiveztDA_R1xbj^k8@_2K_{f3O$3IsHe%lk~E5$-|!X{RM^V
zI5hRS4V^VXHfI0EcB+Eu1(zR~Tyb!@G!@d$98o{`YAATml0&!QON47`t0IGZz{5EN
zY-AEa*JNHyMQ1I_9~nJ_o=rc&Nblg`ww9H1#KFyJ^X#%a$MqQ2wa|H3*z{xPx?8hI=
zA&q0g-%SCC1aNusQdU8*v|aUPB;I@G4lPO}u#bQ?FJeparjh#a*ptY6M(!$T^M9JelE&04BvDK;1Wu20|O
zCgYW?!C;zWV&0du(xIZ>a!PZ5KKOJ~a~^8>ey5CX4)F%A6}vr3VF
zcK@GVb9dj|I+!(XapPNdskU*XSk`6GNOh4wch;ZP@r63Hq>K~L1F|Y^n{`n0R@Moq
z8BXXKNviJ*vJ7d9TpBasd$uw3WYYf3T`5VxC`I*ha(E6IM=_RE-Tr3Th;>xttjwnw
zsa=9()|1MmP#PX1y;bU!*!OpJ0L
z%eIgFz&Hl}Ie`|P?b`CIm0cu9h6MT34?hyhZ&P^>9
z6wr!G&3MPo2kEUc8T!e)etQ`|E+VJV&rh)$5&yiqNy5{@n^utW^R9sc)&A^%o)kMs
zQ9)qj`|y?G&l^N1mWj-H`KJPet_#zb<$4b~gk{RY@l}Wp4ij9%i$IxMNZg+z8xupl
zIgK~Z!+iUlH4xE^?g~;
zjEO}M981{xV;<})Ek{efa#|v@4+ClMtTRo3P%Oug-Zy%h5uvr^MPy?UG)v77x=n|4
zrx*hoHc@f+BdxC8Bmqmh*~JDJ?tjWi8D~TKQZ&;fb$5t`;tfXr1zC`?aB4wvwmCl4nUP^%bUci$20V!n}?crYoPT~EZ8KXMEHyV8{#j1$R@oI
z^&JhC`&hVBO;txi6<2#B&rWsExlLXUu7a4=z$Vl)(7(92bAP<^-bg#>=-Jk~0Eb*l
zB6x@d4+-7CAk|ZeEh1i!LmxBiArV|HDIU}7V|+o7LTjXRphF@UVQ`!1+(rtciN*>M
zsV#JNBbnYvV*-ecbXKQGIwV)a{s@Hu`@n#9B&y|CXT`S!-K`AXZUQ@2|0
zTKATGeqm?1rnpll3-D=8Qf8wBa*y%`4sE-ke#mC2V^AB#oL-X}dcWnbzBBf+PaBB<
z0RQw!L_t*B_udN?6y921d4A*QuU>g)$XQuHqzCjyRa!
zs=}1)0uV*uFEPWBkPhUT<5GY*Yh1GBaFX$0JV>MQARw3wdyx8-2NMjtmG<@f6LkCI
zjc{Z>dH{{?uR9n)Z8~$
zC#H&Z%~HmINqTdj`OZjmtD&;TESo6SR^ZV+Iu*P~r=q_1PpzM7@ivLsem=RDN?5Ng
z9d&4YOp1@nsHf0sNyImnX3jTF30hRzm|ske_-+C(CBhw
z({NR-E(_Hl(LhM;DR7={@6sk`F8iCN>qG0|W(afE%p9*kR!*Q>QnL#(^V^(-N4q*k
z3yUFpvnFR*Ai}2RnG(|*I6_l=+G1r*t4uR!u$5+^3e$3cu!4jP+o4ozT&g85WsfTJ
z!DQ><6l4#K4<&&j8V)2F4<}pVlB|c5EQb=!NKXa|jRzBf%iRGSmgGpuvL|PC$n-&;
z)Pcee6}u~lbYn`U3iR)AB5aYtNsyvXe6uhZ9S&L`M#~+hSJ%tRTrr
zS(OCFweI1ZA&RQz9j!y5hs47Uv#z2=id=}EE3xkO5+c%qB!-{J@RJ~vLx^WLkZA!btpTtrcTE>r#_h&A
zmwnKvI_9exF=_ma-A`Yrq#7#8%O;*{Yq&WW`|#9yOe?BmlbV&nMm}T2VIFoEu5>p=
zRXl)l+-aRDFQ{YDyNtR%tFeNNKN|FPX#et8zfWvMyDkk+-dbFpDD(7`R1{;WwM?ER
zAKPlS8#D5}Ou=kr-L$(JJZZbu64RJ$={Zxb3V0PohvVR-b!MX>KeHrdAjSO>Gp)&)
zEm9=9m1kohB3I_%ic@kR`Li8Pg>F5R0%J>DDzYao4L~#9BuJwMM#>M0w4mH
zmP08(uo=7vq@D*7;7HI&2;ZxBvpK({9s%`E(&(S07O)FD85~9YLv*4B|{3Pbb&Yh;D59uvG(Qe4)%fX4iBp_&3@kizSxrn$qR6!a=QiK&J^Y
zI6xtw106s_5X93ONz5iHt4kmWk|Os~B6gU==vGU%>)kbEbiY|0RSKqE_RZSr
zN)m3NqSVKxc-fR%E@7bG7Y};r%*d_CCzz5ms%h*?Ba_$qMy=^N+V~W}5p+>;D87oy*nlj>9YL4tcBH-xA##EEps)NaU6ZGTTfLXRu
zQ`n=ER1h%}#g2Zn-a{jmVo~Q~Egd>l4UO8sVK%V29xA<_M(fqf!vb0@6Fq2`Kb&qq
z9jSSBzW2q2{!yDE%p=_!ib0fIuP9h_SvoZGAdTiHGra_wk3>V%3ltGg1t<|2BLG{B
zc8*|FrD>tlnyB=CiM)-;j;@`fzSuG4Fl|Wdvs6UEkM8MlT(94)rSbc!`!g_p~`(A7Lt
zV1GPu-?t}1Qf)x2?y(fMTZ=mFrA;bBvsULKQp#|&;vAei7Z0YSMXu>DDzy=bP7>Lg
zmFJhKI*W?B%$Dn;<86B5oUfrtD33~16SiVFW52^$oRL?UoCWX!g?n-c0}ww5%J##l
z#fcdOiD>~mttJOsmxu4+Nt=kw9-a)w5ef??r4~)DN0ZCb^Fb*=5%(gs{=jbHcra17
zFMe+fP?{1_>+p0xOC)&uFzB}%M*|CwEQEY0Ub63??7-oR9o;Zi9ZJv~PJ|>9=#(Ce
zgOt&poi9I-0BC~1gHi&)fS}@FlJsDrJrf;Z2rICESp(v~Y_lbfr3z=8Ocda8t0~l4
z8odTmG_IhAN(+hjl@we=EUag+JTz*HjQ7R4)w`o@J3jYVfvy~vRZB(r=s2(}$9z?z
zHqE$0H(z9K;!w7O^>F4}v;c((dv-;U*(a8cD3k+YVH=&X
zT~a!2Gz~~)fFta0W3on+s#Yd_(Qa+$uqL$neu=DGAZ}xF2W9d`GPRAyY@slNSW1Y*
zfG7_jLf#3)`$^ORl{zZqjv6&xGC?DY+^?0bR)LqNzPdEkXOP_0rgrroY8+FyRM^~CW=
zEFx46mi9TLmFdi3D-(&Bb^*SV3A$=bS(g2D!g+>n!J
z#}gb_oIW)}mz)ukYhC&HfBpUMpV>L;!BI;yQOE@vh`eBgfkIHYLn#Fimk%UWq@yac
zuoW43?)2Q6Y+O|)x;h63vk+wqgJgDqKyPCSU|f%-HUMN;nkN@mnwnh##t76A5=ZE}
z(g>brPbuxmnME0SK8B#rTBuFU7%nbFK95OE0XdZIJ1pIg6g8J0h37WVo$xP4;DkX$~dR?ZuZBXU_6k2@#_TSIGMFgy8tV6=nB>*DhveFSF%jwj0I
z2Ph0sM^Ie&E5N;pA;htz6daX=%PEilHU+;*k#WY||t!UwsGYBDAwVH^wB>;$SV
zcShQj!Y;im$Y+Pd!Wt&&T7Oqi#0v}gKx7q-;$cyn6oT;*%kgGkC6&-&(Cp3I5ABH~
zf#zy5%aD|Lq_y3Fr?%;g4RY05IC^Dtrn|K4R8Oy+NE)cEUiA5mnK>RduaeFZ9z0Z%
zgSMn)*|PJ>@T9dGU#Hpj?sNCQ`|_({quooOyHax@3q&%)-2@SONosC+T7Dym9l+7s
zXo6mztcAqxV2J`~aw~-sA~G6qlzJ4wm6Gkw!jxv9>TuLLEVY#`fQQuP5~{Ot5VAoa
zAzuUp_aZfPa6+Jw2FNm#v+ISDX`fe|l&pT>AU*H#4E^W^`BM#rR!yc=ktkjk
zZM@igy4CyA{Lt}mMHMNxih}jAsb%=QG90Q&#yipIAGMnzLbi{IeQ9y9&m=k%sqaz?
zdv%h@LPHfH*Uvi%>D&mDw`W#h+sxvFg9(!v5fTGH>=lbZ^ZLZ%HU_IlDC*_&
zn&~to9CNvYYW1YeJZm#|3wYCNRXdw`x4XTK#cJnpJGh)~9mk!sI?saSV{S7J4dEU
zDk38JY*}Te-qa5N7!7jX5S3G$o(qW}B7wWs1o0?`Q|$+nJvsQgJR(S7O)lPtp?WbS
z2+$Cw16WFoA@F0#5hA0TBkExChUGd4&>#a*Mt+Ak*hxl
zi+e;u$Ofe>gtRX;ql(V-OTov)E8`N>kToI|db6wqXVR|JRE`!{0z9^dO06Q3ymWFk2~|nR88Az0DVUYY!ue9mN=4y<
z)AG;1{q2?cML!wwDA0Gwpogf82!jlVyn}gk3Wwv8(*KxON!DjCl2{(!g#}w*8
zvAl~bXe876#mYUq6C%(cSONFoW+Du(pGNPNNg{08m_;36Q7^Xn18m&Oa|3lWoQH-z
z+1xN)X7dY}qYkTwMrq)%YG@R{fPJ>T5kPd4@r^QGvr-%q3#Q7P{Z@M&n+-(Pvi|C~
zSF^rQEmzoPv4kZmBZ~0;a}P#qf+yQ2mRh<`b`N%23+^o}jug85e3>mDQ^DrR;!-pT
zsa0f#B`wRBknj
zSe%B)?Vh>T?u*myi$el8axo~;2s;zg0|H4w7OEJ@{NkmD;~`8#)+jj?Cw}^XBO}+G
zmZ>-#uR5FnDWmidQuj)FAkLA6QXNK;NZBE9Jc*M1ajL_}Me-8N-~BzE(=83XCPkM{
zT87VQ*T_pS`H3JcoO8|@1W6EyAP5j7z?>79bIv(SRHkyyIoOgcXIZx8AUWG|>YnbI4(_`O
zpfvqTbYWSds)>Emh2
zHxDm7dGqRD|N8sC{`F5k{q-+_U+kyA|Ni>dfB)B~AG~z+?#j}TQn@eJwQ93MPG7Vb
z*S)#3#p7f3y}C;+8c5gnrOAg(ss=H=4Y{hr
z<7K35FDoo#v%!|ZKeJJ;EM!7asD-@jp;MYPirv1-!|jbem8{p4mQSU(=yWAqZo5Ih
z@oPP6FN{?A4)qOA6csO5*SA`;r)uk`%WEsd+KIdpBNpFcwa(Plr6-{e_}X&N#C$sI
zU{kvjOIfa}aTBRFG|neh%==H>7GNphHk{GPIpC4OEQiO#0Jy9oLVe9|VT)Qh;!-rR
zU#@Fm37c2~0JM?HYo_r=WZH2}dY4$)A&~XU^gbpJs!6C3D~a?d)%>D@|I1({w=2UpAKmTT%+ygC}IT_6}w)Ap;RLmK&lDSgG3xtwL3&D3tM
zaQ*(X*M9oz@BZpX@XtR1fq(wXU;Z5){)CL51BtY!4}bJsn2!+H(SJdvsy*Xafn
z%IS1tr%*JY00Yjgr?VRvJYW$iA3-v;ngP9HIp48XnA@$F)Qjjo3Fqc$&!9>5{`y>B
zhO&yw8qCZrrm+g>v;sP1u`us&OLL`2JYY39>ty9ZHdvN^OJ=KH3yKH@<^P1mAKw1p
zVE^d8uD%_<7B5d!qfj?x7<=uGvEtJCqS76W9rN{#HF9k}jbn;Q$xK9L#wVx8Bv?|g
zy(Vj`CbiFG{q57IbLG`V7>YXv<%&*rK#mTL13C1>V+#`T-C|7>TiC{xv~y)cs`PG&
z1~jq+N3ExEEAZ568rMT+4q0;s?XDSbNuyNR$QQM8#Za|W;%R^&cxuo^h@xbCJ5O4H
zqn6^RS&@m)S@h!=mL43Q9vTgmVj2{SK@nh$fkMzl;7=VIj&KR&g@ntt2HVkipGxN-
zkQLj)kgxL%4g(@#H#sP1P`EZCP8}XC4+;ejzHx+pcB>L_r(Cw)41`Rv5rebt4fOlkoIpHIRR)2NeKmdE$*
zzH$0=zb+NjsFKR4Ak!)-NYT>3=GW4gLuz%8OwcXicZ)bZ65&{?X5Os3vV8(r`wIZK
zfgIrY@3Z3_3sapZkF0+F$=g5u1W;}?*yT^q|M^e%j~m~Pd@(W^Cyo#{rJPrKKkIxhYxS>*xjQ}^-;MsRPLB64Qk3>iMo!?DaTX2
zDMU{q4r)hpSZvx>NYl@8378X-PU=$MR0A*mUTN4_oi-=Wj3x~H5un15>FM4r{
z9Yg3bnl16kn&5C{P^cm(OdB4nM*Ow^gkeOiHSrgFmnuHrOCdrcE}${mwCXZ0tt(yT
zp--4q9|IVh|6!hlDGnP)q5|Vj87_#cGj@=X31sGURTpl{6|O
z=n4um0Ae+bSxI4lF1Bz4y;3QNVy{9nnXaESr>$2Nef07LV9+mq&*ksWfBoyf9@{r_
z>GaOGU%fccRkLfylz-b#fBMtEgIM}^M&$F`M{iAK8Ao*TojJ~(PS^7yOghno7(mQo(D0$noqQkz@T@^VK+3BTRdYwXa
zzQ6lqcT2C?RKQ?Y3WYaUruQ}06mgh7m7-QASuQCq=CJZ4wV`py?aAYb7wZ};Wm;1_%7Gzz*!;}s#LSo^NM}W4*0Jfi
z+XoIqRR`JG5uFV7BEVv43K7gQlpWK0laIn_=gIn|`WB8Dcq&9wwl}qY_sJ(;eD?V_
zUw!q>SD$_Lk3N3<;fEhS`uN>H{}=KDh!7xtNcb}~B9M@jgTuhAb+l}9Dy0jW%C2@4W5w@o7}V={}V)J8df%xWlSQihDFlUc@lM-SXOu)l!|mW5qL
zqBruyU}l^7B7m};FX|LYdu6h2nQ+dM(XS9+AMJSh-hDrLf7kx<@BjAQzU?D7F6{mK
z$s4cSKD~Wz0O<e`Rr|ch~l*?b~OceEKo6<4=G6;e!XweAblF(8^=Y7!5uqt%bt_
z7W?JOPLaG#ByZ+Rps#1~eLO+GPPO2$4QA+vjA>muU4vK*|B4biy^70SE6<;BnwqrI
z?G?pke0Hl|Sw%AM<>GxDg^J+;;TU-duQ3)l9nH)rQI
zW!e_28uqqzo2ks!OzW=Z&fQ(T&E_moXrw+qDKiP}#8aFYk`qNR#V6Ymv6ci>5rr{n
zbHGcq%G8diL`cnn<(r)7WGEABNX!NrNWBsY!8ShVzZQ6{CNfIMoIA%(fAiHBPrv!<
z={H}0gTVOtS6_Yh^;chf`T1v`fARzo$PYjG_=ES}fAGe;H?9}pD8)E(DV7Wn1D60I
z*y>s;7c@9CI4UzV23gYqTOC;a4vVrxA|L7UklFnPt703nvIv!*IRT~cFXaG;$Z|L2
zK!U=;SO70V4V34sIj^IIX6c(A^x+n`)4D{fXPUYea~
z*QxT!#C!_5gv*1YU&>`wi$%pOW|K-(Bj6WONiR+GKiE0ltru5uDU}>z4IfD|9gr^7
znp!3gSS&|^)-6}n(3p)(W{*VTV=!9zoF%*YQhVbMPu|(k!M|@my>k2P@%_^mPOdD^
z^h^#lfARSBecLCF?qB%nk6--d-@bkC;j1%qBY*nyA7NLJ$0Oq-Lu%!iUIzg`Vnn0w
z6v*nREU4WBE*=au^uXeb&9tY;Gh#~X)F><1>|z?NoW(4rGKwh7)16)UWNN)a<)%rdU(8A
zpD|uiQNa_}$+Yz{bvZ|qlqGDt$b~h|P7lxuZ*y+LM+6FOipk
z&5OeTi&x
zenlOENF$8($eMPzA|y((B}BeCq)DnahR3BxCqkx%oNkIv3>=`J-&RYV4Kf}W6gL?U
z66mEc@+ee5u-j+^+gQM)d+4-$8m)jvn)BMrSkz8~{8UHfxz4(S)un4i?oo5vWM1~~
zfBdnA$tWYy%1F#oBD0*#04rTVrglmd4Rl72MBK<^bqNJ0o66@(UBKLb#^S!U(fN`3
zzy9@`pZ@&APk;IDr$2wacgMv2m(TwB-=6Nzf|!#GijOK
zQdujH+bt2da)k|ab`5eJ2ER+Ht7C#rGays_>tPCZ)i$Ljp@&PW>h$RaY~Dy&o-(3`43%rN9?0;38`ov&&5
z>Z`B6{r0lf?wssdI_hcAy
z$>cmL1O5^o8q-Um7cdy`?r+wrAsW?cH-(%}BiBhp4|XjcX|B0A(cwVH7LYKV8gadd
zIc3lM^ub#v1_s*YiV7;LjKnA*&`OE4MxF?{luHIC7xJ>KPbQy8)9om6f;;(7K!oiP26!hDZm}`1IZP+K~%<
zBz-bj6C1hw5v+6ror9bNr?SC0Awgl5k!j5$(WK1+Il4nF-&Nur&oZ{Ek(+QdNYn*X
zMx$H}EEY0>$p46ZDiawnY2BHrvtHLku5C0Yv+p18k^I(ygV_{Tr`55&x^c*n+h=#b
zd-P;JQ_$rus8;HCRJR`L9A2q!HKK^)1y%a6m^=!7Fw2>ikW$9r-9K~w%=mOQ{E8TA
zaWWB%vo{e}Lu7#k2Jbwm)OU+ih-+cGoci%pJ`pwg)UxN;I
zbu{nYz2nozA6AwYJ$m@|$B!Q7=GaaiJ9zr|;d^&)w>LG+4G+C`?P@NHR72)e5SbMu
z76h;eY1*4i0BJ;0vp+$nZVf|9MyMmhHo~G@}(0_P%f4NXl&gJHju+==)<$-1|1vP0;@6?L(@rmtfA-qT(
zkL%+Kt7uRxGAk(T2A&vjY+&=Msni~+q+25D5{vp2(npt1_bSKhMM>N`Ask}?5sAmeQsoW|G
zr-B4TGNEi};!A2c>^eSoUqx{>mvNxBbbn1*37uU?rx!AaJ}}gljDw9n;16^W-jiTo
zymU?>lM6V4SQawaoRApl-G^A^4bkqt=4Qe
zjXzmj-DAsZvAT*hsVlzbgN?28m38|YT2{-e#rKEF`H5_#
z3#tgrE{Ud-uV`b4t4OqZ3TL>a^69tV{`TANzx^I`@mnYm@7}&X*wa#7=6V0!xBEKV
zUc39!NAJI5&?xS|e6yjp{Nda8FPuC!+}V2O=s`ppv6M;@3v>|_u}`kABGBQ7+9Ki+
zU3`WkG6;=^Or3`&+EZ|D2EWT_&BIf5AyG;|FeuDRW@tGpmuyXV`U2
zMjegZCgj#LNPSB7zkU0~f0myAw!to-dO!X2r@#E=kKmzy`sojEz46kGYo`w%Slz#O
zabu@v?aoXSYfvEiy?hpS4z$
z-Z>EYyQ&LEU76eK^Y{6R>SU5iq0~!fmGOknq0Fa3;^xA`ev8dZ`-f{I
z4)^yT9U3~;KYC$ouG8uoEva@hc(0wkw9?XbYH?+txO}p%X{NTh-Ql)Um`*Gi9E>R{
zu~ltYD@8s#Q^yh(W2uEH#QY?Dc2rV9B5pvg16>@Dr;h3}d&HVCWx9{S9XDlv^XS8G
zzWerv@4ox~dqDBqufF*7@cQn--uB7Sfr;_K?JM&mgFSn8EO)gvzWd_`|^AfJ(7}DTHFNktHZhA-Lku86g|q1^R$S8bhO9D8fLRrB)!*
z1V<`1hXk(chOs&XlrOZH&MhD@B%6Yy+d>tgkwBz$ODN=JMQ|i2C}^h==70HG_mtZO
zIF<{z5B4nHm>$W-V%-!96o@$l0t}o)T&0LTU!3#s*zTo*tkWG;B}{AumoS-=zN5&w
zUR8XgxATjK51}S2A<&C(R47Zz$t>ubh0-!2rJl)X<8u})#*@`W6IsfQANgOmKfUwz
z%Xe;`92stf2MC(}hSZsV$MR2q{q57Qce!1&W@8H*@k!Mratm8nPvccn*i{IT>1?y;#(tlwTk2o3fjiy*Y&xN--VZqE?i$ImP~k?mQ~4D?QDpQa32nZZfS-p;##`
zZa1WQXi&hgidZ~QN)XPCAN{Po(2$mXY98b5wln*$fiIsdwod~&46#R0Yc#Jzb#Sxj{j7lm+Q!4R{Muu=o
zXX+5hs^QIzA=MD*B|`ZRKYahg_uqd9{~;`X^Y!OXs>%yLdjH`^@4q`gJNf9*J9l5c
z`R4t*58rzI(fjXw{LycxlGukP#YC?!%s5sUG_A`BRf
zd||6VxR&Dthr8WjolMtuh#A)=d;L^x{M`R#`{~0+uTBoNcC}Uggq(xiGCbc2*gm2Y{Av1fZAsjDI*E{qBwHPwu~R
zdgsnYyUWTH9vB>JF*{~`ElYJxIRxgcw{pF8WJgPHHj7)%ms;Y{O$x0YjjIqzPqg&F
z^L;E4s9;etz5+)D3Y(BCahUU_?0SZvhROw>(I?jq$uv#6Ot33I{`lh$KYsVy-~Ir`
z<(sd+_~xt6zWD6%lgA%^^5o;kk3W3))@!{T&0~YTk3R%M^XStjAAbDN2TvY<@Z`hy
zpFDWo9G_gr6d>npFqB4?$eWBWKoKorv0z^U-UWL7mQY|ZJtWEy9J!F4??jOr#7gzH
za7|dG3cNEEj$1>=vRtyw!OCr6;H)(vQ57t)E+i6Cvus-^6pP|bLGmqO(#=82;PAi!
z`uQ!FjPuax#T-@vla)s$eQreZ|QfW_1H7&WP(A9?o696
zpMW1Wr_beD4%QZZ|K%66x$X{`qE)1X9NoYZf@!E`u&SxFHXeUWuU@dG4XP!*D#5j-
z@t@5iv_D=txBt<@SN>XM5ZnY2N*xLv?rvD*e!st$pqmf`XO^a0}%#A6x9{@62+fCu65d
zD~=40kLMMc(fIQdGmd0jt2(ueD;%_Dwq=Q+{(JAd@#!ZYefH_cpMUnrXP-WK^5F-cz4MkW5$%XeflN_H=L3;#9BDx^!4!;q
zAR%pAcmT(MeKCf`q=m(d+nhrtyE-&VvNc#48X*e_RfU8jD!3&y4az~TNWLXl85AMk
z914|XRsveSB}5t=2C6CD7Gg!={x?`0%*yOY)452*6P+#HnR+`qzF8xylyKiUvZGBe
zu9I@|$=LIQZB065A)Dc*pu7}xF`ZJ&=L}>ZH(`QT=uoLUl&WGp1uOzY14jrNSx4ve
zNMyBiQY(+yCl?;CE&b$;m;E6A*D%5!|Nh7C26}3~{p#_?)c>;W=^bt2i3U}=Rfm08
zqwW%k1{F#WmpUe|p2hcH_06lK(EBx-Hko+Em{S8J*VY*{S^T@IPB@l&6*7j|_IT$*1!JT!82
zeiqcRucWd%)3&R3sKcFmU~r&BtKQqyp^k{QCZetJC`TgJl|s-3M>Z-oH9RpqzX(k#
zfXP^tD<;Jin_Nd`HBdMUMtiSN*(XwUa3$R$bpxH#Vafjf`yZhF_Q&rbe*ED(h#wFe
z^YwS%e);s9&%gZQlXu>H?d>=29Xq&ha%}L^Pd@hJ_~f%EAAj=r!%yFM&5?+Kss((K
zI}z)MN^0Urd`uyvYyc7XgMfMwhz!(=j(DtUD^mHThR4*))j**N60yG)ghUJ}TfAvo
zDO(`f5-QmetPP7Y#w3np<;b=KBc3`qToDXb<`?H^Ckc~BCFav8ZYr)xD>*aJ;ilrd
zGSoFP=5m26mw@q7iCNghd>XMz#9ePL|L*QZ7Zx?|%64N>MPy{Lt&Gknr6ClSlNmr{
z5sq9=1qVavmdINK{1L6XM&C1=9HO2d|ttS%4+w
zr{IdPlwu5JKxrsIksOhU*6=vs5A1WmxFBhIYgp>Ga90v8CxvK@O40^Lrbi-IE+VTr
z$T^iTNgn+c5bm@_+{Omq;Ea;Zt(M&*sE{^g?FAMW4kwHUe`CMYGHXq1ysd#>Tl&pBNkI!z&s
z>LHW6jj4H5ii=3vUtc?wm(!D(R>Ea>q@~@SpIh!qLm~U`
zzvb?Q`-e_ExOBBhrJby9=*;z=oSM_bC6Ih+nAYqp}=
zi6uFbuwypoj^avqev431m_%^LpmU=V^P-Z960j8*3e=8+Qf-e&HIr`b;>lW=0uP$}
zAk8`xsV%fMeCN2mKgx@wMyOAU$|%P+1Kt0D8M
zwgOlnbzz|EP%k2yw=Gl(xi~0X78D`b9Ha}4)FP81^5Ag(zijGGGf6jxNVkLp4$#kU
zIe2WhHQkGxTtQrOy-Ip^s&7|)(V;G1E|X+JCFKx_*#vSfiRz)#3K`6N5^|Y-f0}y4
zlsaNcgI8#i%PS}xFPc&+xf$X4-gc8E{ngQ
zwPd-5)%toWGw|u@Y6_!OC~IH|8@VE=6hW|&%8luN$W{T-dV`n$)f>znet=a#llc*_rT4;-jzsgo$dkPllN$UQu{
z$l7eL&R9p~m8Fo&Q;3xqN*#d#6he+(G}=ehX-j5D7hmp05sFesm-p=d>YJ~A_!{JJ
zgT(-jkfwh`GBwnWpML(u6G+xyeE#I~&z^ko>Ekax`S|gN?|=60+l5qCD^KP{ks3L|
zQY^WO#3;s6pfE6p#%6%>L3R#`&_N-Hd^ihX5ghd1x|YzlVzc`#mSPUyLu2K`Je3NH
z2rRaxrIqk_ZZa7(a?0&4<#D<)kQ2y%+g^C@)=PKJoSAKF?<_7pJ~v;MX*oQ%e0FAW
zzO3^6frBoYrY6m7W$|9UeC@>GgcnbPOkFLMwy5>HtLwge|IwwnC19}RQ>7Jf85IFTeWk>9^m1`_1>?0g;F(0*;WWfBW4x
z-#z^bsz$&OK>YFx=s$rR{n_IWKlqwZC
zA~=RfH*K>dqD3!m1raqRqTIy4KXdOSo(6pd
zhT1^p4#`v7`Enma(9V~Fr!K|OyvYPtJZ7=A`-{)MeCod{;@hWRgChFlE2Mw=<@Zm&
z2(ai6aL^xr{OH~H@7}g0W9yl`G90ZKO)5eWkgIiY6n6s78Xj-h5{7&%(7(RuUt$c;
zib~W6MYzc92fNp$FK*L?M4IA~RolWEj72MD`Y!{;ll%yR9MXyjv^KF4SnQIi+r^3jt*%ulu4B>%
z^oj-!?b}Zt{ht=bKcCuhyj!K1$S{rQQzz0)l~fjTc9%$lHv{y@+B<~_I^7{vb;>oB
zEN-_pbs{Tk$?I_wNJR{`hsN}&G>s}P6d^Nt-W)u+LLe?;@$+b0FBk?2t3AzB%9psv
z%tDT!!;sOW{)g+j7n<7aOm1gE!JU(*FRULtwR893k%>2to!Zgf(_*l#_m4DZE!r=37pMLT5t53iE>a%Y?|Kyu5
zKK=5OPd?}%L_Qg~0U}Z?
zTB8yi{yY1q!ef?8E3%T%>fms7P56&W+8?2-4|ahl$SS26tzq~NMjL!mWL*RK$c<=nMCfJ!(a^R
zbUjK%yNGvvaqMTWFa8(J|1y68dsC~o)pG?t4j-Jd|8rivPN}Mv&aWUb0%b!90els^
z3_L!8TEXOaiIh@0+lj)~i=`tryHBZwr0gORt7Y9bEi`TVm_zW)64uRi}2GV<47e)1(4=TAR|0`apa
zj~_q&=%bI`d-(G060y{aA(fL@1z1YENCo-|>R5`SX8S*U4dfw9Imr5=e@!PS(ij?*
z9hcl8(-adJ1zdp%gM;Kdos(w>k5O(5&4^6|X#~v!2Q3G642qP4ci9x25fu;hB4lby
z0$Lv)BiOXHkj}|Y`TILn{+A7y1N{RQEqF5YpomriDVNFiu(%#3Cy&9j5inU8EU@Un
z;oT(4$@a!F4&}+Ig9Ao=rw*$2{_BShIa4rsSVBII;K5M5a4@N?dOEj;$*rNYS_HyA
zm3qpQIc>=tOqKrIZ@=+hp8fxOLrnRr=U>`g-qa!#PGp#uvYlXADk;o*7QcZd@>hyr
zT#y`Hgs0c>M1$#>?Mh8Cm6lH+&N*}4c%p|wLoQ9CvzLp@og`Wzlb=UnISI5HnFb+`
z!h(Q-gFpj~^e}j(d}%)OAMTMnRp-0Beb@e>q3u0ACl{99zIFZl`o6Wn!5h2R%`}cv
zq$pISdIgF%uU&uV%Jp5%?H5KTdebbW96=ArI9GIbY30?k=d&Xc3X%!Vs3b>3LMfW;
zib}2ltBXRGzI(;07Pbfq$9fX0jV`FdGwccIq0)+v-hc1YCyzgQ{PB~=A3^`w*J%EZ9>
zHVgs+X^%~ICF4AJnm#r`77`9GBHpyk7@IU~vLjb+2ZgCZBR~TELKq?03YB6g@RuH)
zq>G4yni4FFWJ{1SE-CMq*Nd5GqLo0l;7REz=t6-g6N3j9ZA6k4Pq5+$b|QJ)>z*xk
zeRlrvT%o&=LGIM6+&EMvn_0r7Hp->d0_4*Lg=Bg$m6eAjd!Z(Ve2pW6WoZ{Hn|Pu|
zu3*lV-6{~a3q{RbYF{=8!T$*sfBN&E{_y8Qjp|=EdpsRgICWIRMU9X
zbZ+3}cqxGnB?MH8UIH1SgvRXAr%l-GH%G?`>5P0T-AN=PSBH=RJC2jYa#MN!@dk?^
zjYS+$9*xteNz12mVX*NFJZmr17_A>%y>)(hWo=}5q`B$R{`HId_7|iYzJ2@c3oC2;
zhR5eSyZ6<%tu}Xb$`BjR1QhMU4;
z&5`jXU`1)1)Q~96ws4JqSy8zyO!i_>s{huYsvzWM5|E>1TSDaEpu=MPM8YI;MYk+C
z3~+>0o*MCsKObExQJAp!BR$=7Wrb-eNe&vVJIiV%5G;5?iCAJK5bN}c93s|~9G^=j
z9&D=V%QW;E)A!X>xd}ukmN=b*tZ{e6hN8cK<@3M!*h
zDsSZSn?%ATo8_$wC;yKKV`pJSqd?lo6V@@gwG2)<2@E@TI@4Z^qgK+mWn@+fi2(tF
zR;j9r%^S(I6jSJBOjZ?->&BxCsN{B?uAI;BNK5NX%giCsoFt~3%FU$!i(C&w3?K$F
zH4H!$K^yVtL~*!)xsezL5l%jTFX
zuY@0PXmBi-!7CEWR8dh`i6~1{c9;EqOBVyV?w
z+Njb{Lt?Ib%i8$TDgv{SA%ya=hQ_TRP|NUSS4@&ADozs~Wr$5`R_iUXN%puT4~pPT
z#8nd+WjJaBLr}xul~Y-s6ugfus-kjgsoWAA%@Q65m7;ztvWOE9Md*>c=|#pHwuYyI
zvkr-NCE@@+U<b#<4aY@RXL&AXrczv^tNy*#8#wU)Py3}m5H|m
z1Eb|6orOb_f7iyxfB~bsJEUWDw{#;R-6-AN-Q6|1yH%u-4rv9XLAs>l-Sd0@h21;f
zQ`hx5udRx`RaR+#8DPwfj1y>z9k1`~C=l*XxLg#i#J1s|sN
zCDzya4&sU0&y9PVE_dF%ey_Lc9(kwwHh9ZtVOU8dNugRJws2ROG8GyFKSm>Ysj*P~
zL{+%aBtbP)f=dDZGynQ=J+C6bY32&bv@Tt-j}zTZml`!*moAUGQU~jkqGVjK7`yS<
zQD@
ze)(JLly6|@z@6>c;aNytM9RT*+`dXq6dE;ZJ9l^xt5_@(ObFB=`TGsRT8=dT~Sq#3T2mTFesL^_wQh#=?@ZqKg5e9fnbCni|}Ngpn79E8aXOpq)z90mk&iA
z5~e-)IPm-q&|exp!H1-KU4Erf{8MEUN^ALhV6k{Ec2nNM9%5-TtJDM;ha&g)+N1nW
znKL<7g&T0nOHy7CzhXlg0>=9YeNSi6IIY~>&5BErSD30ge$c^ep+PZlIzsj?w$cLKZi20HtsrfjGT9x0fGr+oR#8l;9x@M0A*k?I$UFR2A0Ks7>`_7_
zxf3Q^jtsp4Xa{r3#6|2F-e_=xWh$wP%uk-k^dx#8=UqjT%KVW!i~h^vWg4ISIU4Ll
zt1|Mcs{4~g-9UzjkjSR{^B@XVrz*l)Nq6DhBhTvbANUPjYg52ah!IATR)d!^?4>uy
zG~1;L`8eQO{Tka;`3YkCzGi)D4(nMr6gGGvrt#ipV>xG>6hjmqWWUM7&CARDv5yxDG3*1rPWH>#MYeqeb{w6$wv
zSni7DG~~Ps8^Y+ZQK<|yE<-A(
zi)}JD8m{qlC?#dvRVn&4>rd7ajL+R%)xVa{++L&2pdeQ|<=uiJ*NpQwM-Pma%#~<8
zobv7pTyJYnkZAcstBy#yR5L9>3Y};^0Eg>vduyv$*b+%bX=Y2~X-rK#+$B
z%6PjXL!(J;?aoCcT6J1Z#c8)=kzQNl*O$DcjihjUhyIX~-WXu75iIpIZkeY(Q-+_CWVB*SANn{-$9T2bn^vfGIxa0u
zBlDXXp|iwEd=WCFVKnyG&HJ-@7V>3+A`HSp-Ko5Abut
z5{aOMba*rD=2^SJ674=adAhz|6${4$W{^o~b7GpE);WaTZLT48r2k@CkuKJrnHD{Q
z&)kIp*dJe+eW{Hs!HF9ufnq^Qp+~1bM@LFfq(b%ExlFNoEi<$lKPF$mJxp73g2$CA=77d^=H+;s(
zJuPV>mwC^gP%yJET&2utxANIS@k!AmN@Qz5Cul%6G2yUXqFvN?xcO|q2j
zX*^N%Zl*w-lh@DE+45WG_5LMp+V@Pq%ITtf!-vxyj!XlgQ^x0d(Wqm*j~ofVOJ?fQ
zkBt9xzy1(^{{2v%;Yy~-s#BKCJi8l;5HC!y*st5xLPu`MlnkE!62(E8e!M@4A>p8&
zcebOriGCo9{job$tefJw<&9hC#uZqPtaAH!E}uf4VYvqKA?}_jU?b~Z_j<41#l%Ch
z=8m11nJ2{vZQ=Nrv}Y>cN0uHl`mc3#%7yBICWoXSJO7Gr=!g5^{9f-W!yml-oM
zx>nw@p*J>1HyrmgoM4F2E
zzPcXPDqcm}v>WpMTb7aj+&Ot%-R)9(QguqtXd~`9hLWv$O7y1saLh7?VYKUmzi5-_lu)
zPP@wPJzS9C@lP8g+C&5BDPO^&JfyotWW{9J#LK1(CvVN01E){Q*WMD2&f}P*H&4H`
zz>QF7`ArxO^`gCr?gN65Kp}*6ilD3BK|P&GK!}^}7YTL|oVsINaOxZ$0lbsB0qiHu
za4W0sVdHJpuV5=_!poDExM-vDqu%N(VMEaxBVaa01M;)|Az)s|F;qT~&|q989SbigSl5ctG&+(nsasIwR}`Eli{SH@!l)#N3>azFlPcj
z|8NC$YB1K6wJ1fGF$gZTWm4Je
zF>qW&)mEsIc_#40n(K^8P7o}nH-m|5%&v|FOEe+4O<{nu7Y}ChVyf7&Nie9EPm}PTy??`F*a2CcA8Ehb0Sa#vlD
zU1(+^V`c13orB%WbEd7$XyfbM_OAwbt$BV7a-W;WW3>(cr<>dM^)Try&-16l+tUIz
za@~$|CfsTjBB|QNFO{8seg;tq{X&9#yw+aJEwbd0DQ|0?JmuC#oQKrT6nAd#U01wn
zpfrmD!~Xlqu9DPsE_sOuWW-u>v9C@jI1SJ#>EImz@d4^H->|Kpg`^2ylV~-W+8TpRtBITph8YZ=N(aX9nlfl
z(w$J29@ThgF^jR*NNCmxfOsT3srZt`o7(vZiU7$X!y@7ggd@hVD;GCsz9YgSFD`R=
zd7(%O2!tS7#`#8C0Z0JXuZ#xgOT_w+^RzyS`YqFwqCK}DzmJE1LUtpwa
zrQIxG#q(Yi^P)sLvfj$&^RtP&x~kdD@y}R=1m$T%#Y{lm7d1u>IvQlDb3)lK
zNKuSjqh?GQ=;t92l6RPL2v3HJHVxiAVli|@GAsu%hE#zF735Td^YE-7=Wqmcd}?{9
zxLvF3GnEt|Wz~`Zjkzp00sgM8$Jy6s@2Hse0Fyj$Z(whE#^mEErO(x`u(aRH>?f-|
zPSz!QHY@AGJjTZDJ{-f6DIFwOxFQLVTf7_Q_
zX=?&D3foURTE$9|h&E^EM-P3|
z5u{CnS#EDHyq#zFlZkdZqTAT0N1*aUEr3L5V*lKz7p=??$zaJk<3Lk?xIY^#-7rD=
z3!@d#<5GHvEE5zQbt`~DKc{{(-_y*+8QhG1>f;PX>vyq>wpB`oFtYN}y#LOt9pb-1
zKTedl#;C*3bTgVjFGXW&_dm%Ts02ABktS4YOeSrTsD&6rG^BL^S$)qFIACxhE-KGw
zuIb6Y{N2y~EpgmcIMG&7Qu@JGdZz`24k>d}{=Kvch~to2!b9GZE+s#?P7C?fU*)n@
zihV$<|A#kcnN+eu%NsmOvJKPZM+T>Ha}FvEI1!Wb8?;|TQLx&3?kd-+F&Dn|px($aLN
zN8!hf%eewS;YiRE%fz1^Pm6jliHL#QTtnH^1!;?U-OLWcOFWq5#cw2YomFeuWjIae
zAa(wCUm97>WrALTUoEMcJLZ7Wx#M2}Z9R>ca^IciLV@^qa7f8ka&%Pu!>CC}5@yMi
zN&gr&TL!mV2ey+{G!&9k>bEXo2Aa%GTX7$3s;E&a#sLxn@~+;hcPK@;S!?Vc3@lP>
zvi$`@Z@u07+7G2lpagBjm)}era$S5vm^T^&=gWRdl^+h#W+m(6%(ZN)e{#;g=QmKy
z5t(b`uY{T8RT{01{^sP*fbWhC)SI+I36V-3{AlzsM(+p;=U-(=
zz{V!%^QDZF7V*^VdXljYUAk#2#*++@iSm+1IMaL(r$v*~mk1|t2R$K*q
zoFl8?JH&%KE*bvxY@%7E79*7(J6;_d8zLM*o*v}K?ER{*8(i9_R>24i1peWSb7BbWgbucD=nRV*4p6?{?y9#wcl10BC=6rR!uM}
z+~4I)f8m!UDa)#%i<*uOS%(2rCAqIYMS7io2cG}>%vugkSX(Ir$~hg3xml=3Uqy^i
z!}h&bQs&7|E0I5tKoSNz-iA6dz-SsOTX4d^AQl6(mT~eNTl7TFAv(-TgM7vT--PqU
z@`BYEB5C<_3dV5c#PE_Pj&)%55>^ocj-I^rM;xv6ezOdz7#=$R(fxEMjL;LbmZtvh(kgqgMdU5TCSPkX$_@$WAtqCVRU
z$wqpb?2*WCyM}1hq4c8){Rbrq-Aw9on%|NYP_!`#M(Ch5;p2>b>U}BqT_r$~?qr#W
z3ln=uR)%?af}sQkiO-Ru#o+KLKn~$&F~)>hyrFlZENa(Hn`tY?oQy;`@)o?h>2gpT
zGkHPp&luR7rPRj}qp~?=;O4q$79aujiNHsS1l{^sczalj@}q60Q>R3
z_nA}O@bQP5m{FC(#^Rb$^;B1P;Ni;9jjhq(URc!9yAfYzmb*KQc>K)#f}A||8j&8a
zyXEuVx6P%~3d8gAm*ay9LJTjolYi}5&ax_?o#wM*@OOKL&L-jYmXC%mW!*b}OEI@>
z$j-@cT!z~5R5c*|dBIGo)INQsberQ^j2n7r+4!@vcFt(X)WNn%@-QO`BU<8n9tbOj
zCFC7O22$aBDC2;7+$b7mh7a^>Z@=Z@4~EJ}neqsk%BT=Tlqd-H0=E7dMhwE11_HI$
zQ`>NPe0FO@UgxT2)34;{wkm;(>Ey=6-vdK=Ff+NL$y%mdi4vbf*Z?++ln6%1dLGPq
zdTS{!-)yaBMW!XNp-toF)I&{Ku$q{bFyn5flV7tYLm#^G*>$EZKQW{@R!ZesbO5q4pff5f$lrWRPLxuX&K}hIp
zfH;E*^#3YINXtG87oO1k3?4qQk>UG{7Ra9Rr74;=#1h?tk+L7^EwHWFedc2f!h#P2
zKsi?goM(Qah9M5~d!8DcllWer3?m(IoRX4UT3N9z^Cl8}h$qbW=D&L}$Zz~`cKIWU
z!KTCOCh+m~tDjt@&Tl_T!=S(a^7xY`*?39n$O&{~q`U&nz7nflrsg=34HpJ~nj`s=
zuw-mE-5jEE&lU7AU*x$<$nnwbQKm)_4Zmgtwz+^tBP6iO59wgrB8~|tIhWDnJpeI~
z8NsI-3bKr@*pcQ*3hdO7yR0QuJ=ZTkAy1R5d=R^~Zymo=9b%;ahS7!$v^5c72|74i
zqMLw^sxE^1@Lt1%jS?i5vaI)dyYvb0O2Fv4_UL1ST9Ul@23Q6O{{z
zX)|Sy@A*6+yl5naFcf~}cCj^132!i>Dc
zUz(j??I6P3s$XQG{=--@@@2cj^}!^rwD%5X>_B~TlD%FwnZvV>MdZ>5jckuoOP=kL
z?Y!C`Do1c?FA-g!OP(M*;wxG?Pa+=FpKJ7DV&*G?PHO^kPy49g!YaasMwhJ53pZhkE=FNQJ508b5+~fAxF}p^9z514`wIVG(=Q^ZSJN0pjhj2cbq9~X83c~+$_4YV`ODzb9?G{yg!9vGBKCqQ#G}GY+$2gXYCrt
zEPGYx&P|pzmT!mzwux1><+rq?FJT)yq;Xyo?9MPJUNE~}eK2*$_`t_=X{F*X=nB#=
zW2SAz(BX9-_rTZoq&3kAEtQPb|CfoT-^#|N;LP}S@zWGgwq0hUY<5xMLyL;!uZu$w
zA>pYv#HXCOnE6%5T`kYNhSp
z1NeE;_Lq#SP8~5OYs{}xI_g@px~rMV@l^=&Yov0AHvFS=ePkCl^goM{UfdwwaAam6
z2?RIvv?eu+TtRZlWWYX&et^tQf`VyzT4h|m6Xoi|bo2Ts+x`T!s)=@@+#Od>l(l6X*^uTh
z5%xp^9$K4Z65t4FF0^z2LzScxs}SS-Rt7ij$iD{(|9>Nl1aDor-q=5dQw71
zO2M0(g1g^F-Cupb*pT>F>SX=ta(%fSMtyg8D%2Ttm$LVPMd{)yWU!~h{#~ZKg-dz<
zyA9nx?v|!ae{7kyQ6n8z+0p*~9L=T`qo-7}&$M%k(bkeu%o8JTb71OiQ_7kvvOZh3
zo)$!12G`cCl!Pe%?k6!xVtA2gcVb)=aqtX1b>RO^f=}Wm6-y82AdAh6sHqDvCdbPp
zAt*;ipDF$+i9DqdQ&EMmx1XGENw&+>hpow1McW7N!`E2NO(t61$I|jwq|QLk943i6
znj=PhYtipuBHDycEdSpKEVk^^Wrf2p2WT}`VX+H#kzl@Xo54O!CzFF8wr&9wA+c5eRvX0NIvNcd?vu?UZBky
zkR)&k78f@TiAP(Jq*NaY2E*E1KuOT#ID=cuC~S-o_;fgT%1TR7?Z`dT&rPZ7oCT57X#y3
z2!kcP1@<*I9)`~;ye!A-HtZ>;<1AtUEdbSZ
zYS9Bvl9BBrZtB$(J!gr-y3hWm{!}KTfV30Gb(%I4pl!tW>vOJXc;U;_9Z_cek|9(yLa>V83h39$h4T@K5GftGYS{pqm$(9R`
z+a>XN2yqU*ORPy-m;!Rk-G#J@LeOWRn7@v
zYCcNVPP&9O5UCzL7LYBmLB%^L-8Tvo=A5(fjnIDzrB&uqXbM9RQIzizV`bo`M#O1j
z64P(t6)2k2yG;-Ea@iWaQjz>?#-)#93pMNzBuZ`H)inUj{?FQLAn^u8x&jCv7PE&(
zQH9SwaSLorZIPdzd(0|Crl%{jQjCwg?@5?#Wav
zJMm~lP(c?rhOAQwm4l8U&czDd-mYnyc^RQ&16VDv=|_icbD2oeG+En0uuDhC)Sbz#
zb-!lI^TACY6TGoRA$m@w9!fgEIf!uPUCI^qYYUzHsuY#$|4Jv0lfzR#@6)4(jqlw{
zx4+-1y`06(cw!`+*d807o}S!Kgn5^AN}5MjUl;Ivl!tVn
zOJVqJU#SyKSKHCa-l4-vElbBse|^xW9Ct&L|68-3J!9ayZ4G@y(>4>A%rIZ=zmCJQ
z$(5n_CIJND@4odlfurUeHcj&-=09n+>&CL%4(}%>SOoPn(>_+Nk?6cj*0)GYz;(HJgA#n8)#6vG7-`@-+Z}fA#j?lLIS`w<2*#fo7BP54f~d~}>a0Y&u@t0<
zpOpuI(Vk@G=^Px};CiAqUPO~VfRd6k6o!pM#lS<$-!y6({RakU>Ch~tY|o4)2fcg)
z`fxgjxt9a#MwQtU_kR$!aN^(0M3iSjB0TR!xxDQlLP&Cxp?#^;57yKy7j&qR2qlMQ
zoUIDTAFQ+emyp6|!DTqrIy8v#5#H>vA(EzK-pC6MmrDfdeZ
z5krQ7)Cto)c?7IXl-jC7NpP;*EH*}XnU9jepZ7`D0Zf@Qbmqg3yU*rkgzHAh5btP7
zTtLim;dsX?>Z`ZrG7K-Fs~F;6Lg}%bFqq3)05XdmoX*_IFXefiV}TDILZ2AFQ6nM+
z2*qaSh9i=-R@1f}zn8oMw(Pg`|
zDdSZqvy4%5Q=@$3v?R^-_B5SMjc*@dv5&!Eu*=&saC|`a~p@XOV&4|^r
zBSP?$JI$B?^fy$o&}a!`IJI2qJ%9nSrHqg(HCafeY{~C2T_{38~)eY7=*=?J@nN#eh^P+dSv
zJFilIkOecyd#WuwoRNvWZeA@md>cr~eYDu&o*%}4z!{F%Yu~|by~tbtX!Mn*S3To1
z=XMMqnald}Mv3xq^TBSbPX^AznUKk6!z)rhOv@oUU1YkBsv#g`FeQ8nIq6uQcjI^S
zlf0alQ{)&9F)V;nv0)UPMW*Gvf$g6#ydI!tGqx>-3%=vTx4FfrA;SS(6+OnCZU?P+
zj@h}NdalL+yW2Z<>CNifNcIq-+9wPQeZ`xft9*DE4~$2AyN|MCnN)9gxlv!acDK+-
zy={gwv3A?0mel3fHs`J0NX1B0IH4D_mE~CIWAZ)Gwq+))9x>U0?zm>(9`cr80KgjAnUOc?gMe<(?
zFfEcaqt&J92~F_+R&CcdPG(;SHFc9Y69x|>O?Psv{~8}s_fX_^U&^LO%d9tM#HSxv
z1v1PFb$qPE;aGIU%n0G)rpV*{Hq6Ldx{^T^k>)8wlNPAO6``H^|5m?=suKdc5ORst
z_@7#R0CLE?vd_V}mv7EVyB4TQX$fq)xAo^FWIlUq5&VsYemCPRCSv~gBg1i(x;pOz
z&^wdJ{jSDe{#{nXv|J`@K`&F>go(pUw+mUa`A$d#BH&jdc{a>F!p7iC%Xe
z`t~pE%b$%-6$9qSVyZn$>$6#^xvfM!TG)E;bGg`}g}_CF!G>rbN==Z{ng}4J+``MW
z$&Vq@1OdPfkT>ie8KGub`F#qyc8+Z-wrn^6Jf8+dB1_4jGR4O6N)Va~r{Bf;yMzaX
zTBu6>%X6q0N>>aa!kUa%B5N12S2+BR#$EOiDROfld3>ehHNMWD26wk9m!tC?E|@W&
zPvt!Yr;M5YoPZXXMC5CctR_H`>cpuz3^0LqJwpjf2BTpOn5vQSQiA2)L?93LNTze)
zrTWpM+p56}!Jh{hgk#|E9slcUF*gFAu942ac^vOQ-JOa0KTL0B?7?4Oa}db$co&A}1oYPSEwI|TDy#8r=PD{%pAq;=3c0vnqHA=iA|Q5zfrA-2`;3vIsj#az4=4Q(y&89N!w^1WN=*@v+x;P*Z@
zvNT4IT=zLqW{D*4$tOf3-fubt^eul&HUNwOTWmh+u?FjnV()4ai?WyJ3HMI1##_{YcbQs(&
zZfdn?=HvMi+}{>*AYs%`hnHrfocj6!2V^j%4XyS2!JSqM!`NL>UTglZgtf1f~38ufDix@QYqSRb@5?7yi
zBFI!xl1xSjtr-{&HWiG8S~Zc8@*Sm1{h48-mvn+6^~tT@v);S*kV3RF;E**QL1Cc^
zATQJ~CnPwU8nNN`y#W}$r${QiyEi8aZo3VLCxx(p2ZH*jf`}l@G5|RVP6;zpEF!1>
zV)InGwAHAm9j3
z=p-V{&ntv+^i51j$K<^ZMGTxb^@I?$hLy6I-hSI*IC0jG^km>eC;z-J^s5|staiu)
zT`oJU$mP+)^270*Hln(pS~64W@K>r56WUNH0SEQyQxcb=CUFhZ6KbtSR(U5MnM1Vh
zkJ(aHB4OIdz^m;i!;`??;@5-$y(Gm`$^S9qEdO|^Vp~>0bpy%5#@t0RG7;k$w4@QzX
zf2`+@V?q61G50I-HMM2y=arl;2RQ|0?R3jbM;jSQ4y)3XK(oN_l(bGKQ}>z*vy$((
zn=70v^hM+9G#a~Ht9v-B-xCw({AVmbxg@YVw2vr643z|6qVQD9%i@ihP_>;lK3hFW{dg+Y8j#j~9AWOteC9eE8e~
zf4MGOrhbpquS!=lI1jACBbi8B{55oB^|^SLC9qn@nn4`&W%BTPnic5
zvDG-vFbM6@CRj);N88GtV}G3@u)>OVTo}QATt)W=l6k}k^x1{+1tlHQ$07unig6N4
zToV@{L;J{(>9o^Af};dsE)hJ8E>{3hVoiQkueZA&n_B~+i6k;yhMUA@7)P0L*P4j{
ztse}Glq4`$PF}?>3}!ZD0NaJqVa!PFpeZnUGT)nMa+v@*fM-LIIqD?VX2>nc
z7sOs>Oj^lu&`(mO1WL>a3M-n0U8;3FGD8BFbOtozDe*Ao5OK-QM_$nAFnq;Ho}1FP
ziIYlF{7k%3eQj+@n%;zL%mOX@k{X1cKohtWz@KE(EM
z4_ePk1_8)%R*(%xFmgEJCaNi+1UiKjW;|#g9uL$ZMhQcskasyjIcKH&DDiGvrE^H(3%Epwj6#
z(Q!v2-{`sEA!Y3Shy&MvK1OdItNjQ;LxsZw?FvHu36e$0*l@$-sRn33J`Kc5QTY_v
z{sbXhj4W52ePl4$Xe&+X=YCpql;Hm_g1FPJZFH85yFH%9kYM8yBBoijzsvG!vpQgZ`o+O+!9z_gj_gg~capX+47j
zD*d&x_-wA|EzY~|D91I80feS>y-ycG}JPuo+y-YV}TigWsq`;cIt
zG0X+f-*+z<5wZ?6c;Rk>=j)?EkN~8Fy#K5i4M>L*z*05?xI40vVngc?;)7+y6T=r|
zlo`O|lJei9c?K+fArz}{JeV%W$m4JYVPg`M>N4We@&#B}vceJg*&)G?{U%aNs+5q%_y)!EEA&XbBRWm
zNoS#0ufg(`5kG^hK$EoIa0rYv+96Hv`Uv|lh%29e2sEJ(m&$wM;QF|T|CxCL#5IxH
zQg7~AB4Z8AM!Ucn-I!3_QL=)70%1{bG)0(DB=A-_Kn^;qXc@Bf|54QwSKDa#<#l)v
z)7bCfjI`4+2nNjiuvF(ZAzU**d8b+sa6O*T2{UqiKkwUvk4l_kB_k^eJQ$hEgV8_y
zw|5ga`Wq=ki0Z3@_J+o!2M3qE&b|j7olJ*lREc4#POklKzuSM@GAwp)_~PqjP?R){P+21fJ*(;BaafWMyp_{PMPf>niu8?oWHC)#sz}uVl4h&t{8PzsgI4g
zqv5^37Am;QhKFhgXe0^ymn8JI=bAkF4JQAzm1{sbhZ!m(e&kwc?Mj+a0N1hbE7x!|
z2Ooy-JYoCdZoRB{-FG`Yv+vA9xU+pQXf#zSBqU?%{vmXsnI7>Ab)lCgFw&qr3z$1T
zvw~=#(IFI7|IQ=h;Yf%8q3jHlu-BA(v@B?Y!5jK36a#)Y=pmAsAU5gz*2v
z*XQ4zFaX+R8ut^XsP99@zss16!VRxRV{tw~q_M8Jq2aPVJyOKk?0ea)Y83#N)1Ye-!Q@yjYOv(gjr
zGbfi9DG$$!n3#^6yA|oKJWHoS2OhP5`8c`w;`ny7)hHB;t_y!t*RBA^s7L(ZK~DdK
z?UDif^p)L+lEOk|q)TBzR;`(ffk_n9z39mlW&&SFA#iS?gJko7k#9c2|dg-uuLPh4F=pbntKFQ&w9UQlMvHBOc6ME
zx7jN>XR*UywQ~t++>7%${Lj<_Y(Vr?p<(YUVMo-E$wn~+8^8$%K=|N~y*S56*^zuL
zgK7F0!nJo}!7|uza^3`tj3+w>uBC|x9%yKVX5m=ZotS1=63m?5ubiAaSsUnB#YhR^
z0IPpt$cdfL`Vb3=vQg|qqc|~6zPW4`
zwi5=vEqeXP>g4dc>ves6z8ucboi_A7->CJPHVOQDm4U?Zrzha*WDj0W2Nc!oe_EgS
z6~kEE+4*f~K`J0luHwQ~cCc`Opq5*WHR$aq0mEr->@sJ)REz(X{IfE5MY(CzT7+>!
zli>V9R$k}Fd4W8GtF0JR4@J?k&3@K{?7)B!Ed9qnwUI1dE4rd
z*<}=^=qL4g5-cSy%qvn_%H#g3A#5mFa%M!hv!cXHBoQ6aw7HWkq2x=k%n`l6fE^#Z
z=@-b7G@N1pdfeM-2R*XF6Senwon<3KNe86}k`wJmn47*WfpcdK&NG;qu22@~if>30dlz>;JIMhFb
zsgwX!CbM%gwGJ;OQwUab}7EpSe~f+$>*OUv|@eI_r~dpU22;YVW?EB(VOHrn`~pn&-59MpA1ib
z*#0S&##S`Grn_wTZdnJ}lI^ICIi)V1B|P6QUdd(WaM(TYD+4+dj;v8-lGq}R8YcMR
z`cWRt6qz~)hp(({POp?tLg1j%|9PPFN})|ID#`U#yw`Oz`Z4;D3{CQJn-8lO2-d!|38-eA5UMh&irqd!o>aWUSRXDr$!SPM(Xvc5|iv(!2X)N^mRf&l&j@4P_uAcBCw|+J62>x%fAw%`uc=VTDn!~4XrVm?7q=R(Vpcm+2Ph^$Fm5F5**aF74tJ=~c&-
zsTkTM>u!YJjcw|m861(8BMf2Kf2Z2IP}1Kgd>0ngBF4+5z->fN`lY3TN+8TjR};&j
zl%$*ui}R9gZgZTtYI}ND+A1s~Tf8?Ds3neB@++Dc0+l5i5p_x;sC-D$gJ|Vw
znXl{@>d9a6J@U~B(rl34<=v=G?}sQ+{#`6sCab%@lPi46m))fkzIx;YY4YoZ1HJ)6
zlpkZlgME@W0G?P3yJjlQmG
zee`(R&3Sq^eMUxNP#;-^fSI8`Nie-n*!c9TMmE+pgafWYb1D^ye91LNQ52MYBs~Oh|C1Zt+uhWt$YdRxf6hVoAoQ%+8by7eb`G>_X
z$?_IpAvT)KJ8|QM2sx#|)^`2!owrBX59)fJVB?!SwhNeTzzIY)KZup^-)Do1mcXI$
zNOn#ei@p+NAy{-dJTQE`gJZvh``jL*uu3-aeZx^j1g!99MrXhyn2N+H7&%`g{A#Xf
z2p-c6ZMa;FYdAT6iLNYo_H(NGuXNam3=gXgsS^Paps7Pc_mY54V+m#Ka{ya*#9;Ot{FZc#h$%B^SofD#GOpfwXA`85`B^Rn57^in0tQj9v4!VAvCSreW)hWxrO-I}JYr$z6
z2~Wq4E6t8w6GCSmCQ!*0%>g`op&cwkNmw(|*BvLQkYym4_aXn~-o$DYIf(=66<_~2
zO(3P&kiiHyWL^Q)WOUFxdeT(+vMKK@&i9t}NvAb@Pg!ht@6xc5SX$d23|gH~92xIK
zNU{_>DhI3@m|&zOA~@{y8B9um+$=p-
zI|`tv_x_rj1i+80HdZl@PL$4vz1K+cW{r*r3#FNBYLccz(o
z-~0BnFJ8HEo-(#p*f
zCw~0+@qBmp{j=v@Idx{SyZ`F?;laYntK0X?)ii#6_l*NxgKr%@eqmy^*Oh<&;L)9}
zU7aTD)z#&P*Dib6qA6Fwpf#u0l+~G$RnC=EN#(5?Lpe)iPa$L_;dAkHpInneAdfh5
za|yI86s}AlE@SiOT%OFBr1^s45;iX*CIQ^8DJH3!Bdiz7HNlY?aY;E?V!zD}7}d!%
zYvpx;yCZ`g0UsC1aHd7-c*LjEe?vOv0&Qkc0>!u&7T0RtPI~O^{we-gHS|alkcW
z{oVx;LZ~JoYr9w?=x55RA@k;Pc
z*n<82M5b-zXe1E$QlJ3>HX5C#L-1b77^Fb^{@_}h5C
zHPFKo0|D?E{Ye~p82?Ys0e=1Q;~&5J`qGJ$=MEfx^`*NHUU~J$@4kKQ*6lCfd;jx?
z4-c)ZoZh+n!OhzbUV7=Tzx&tod-h#CeE9Og12;~dJh8HRao_&eFI=2$@BHBQovVBH
zFVwZ38JV5-RLqsu*Jv}(OwLrvH2v9mvz4_c#-?|5b?xr%D3&VkudbI16oc8hH|MwK
z(s`hQx7K#Frx{CW{H6SoZoSckp*Ab^t-7?-sJLo@tSc>38x^~&rk?*lelzRzq{hTG
zskF;QW%8||6ZTwde9Bao3;I@_LB1_Sw0T=0m8lDjp3E)mOEX&%P!&vpHY_@DHw)S3
z5Eq%|!jaUQLsEkxMZenYNX7xLV8BZlygWQr`s=OYUvJfgM~Q#=HDj7&DB8f6kTi(|
zbplqEfYBu5)PN>L0#=>qw>1d_EkdWCq`-O&@)Q&li;#8;L`p59lzwUS0}2lTtia61
z0I3BLu)xy*WC8L5Aa0bKAd`q$L8`{*n-DJj;it_X{u&gX0%Mp5s-ABR4F2}v-$EI9
z2uMLO0JOn40N?XLrhok$^77w;2>fM&p@FS9nwh|WO&QpKs24Z>|IhZ%_W$qpPZs~#
z{-4tR$>KlT|5MsOS^Q`FXZvUSXZ!p1Pi6dP`)B)S`)B+6_QGTmb|MKonSvWn#*QSS
zr%;6PMC@=}%18ocG!Z+Ngda=9jwWEBA4$Xx#3uL0B#$Iu`{U5PiMVkJ>wv*DE0FBg
z8m<+Vo^<4%%`3cKS$Dg(>3T)oF?-(e9M2w$W1l_uq^D$AZ(K?>POJ3O3hlI1wIJ85
z88Qz#^A5T_%W0;?)XXVe`VLF>o^1Dav;9P2*>Y;;yef50ojR%1PO9|_X{H&qVcnj)
zlwli|sTcIdSxwrS#lFL0ACYV4(=7Ylg;RRtTDJRiW!WzXGd$~sw4
zve)iBn3H$RWL}PSrCz{xrjIEDKXo*j0ib?87K(!~J
znxYdLB4V3klUibv+G3MB6Hp!TDIJOEw)hl?Rv5>lI^t5=W0Rrph)eEDKn0>Z5e>b6
zXH;hr8lKXbgy~F389?C%F@zxuX$V7x!5|tB{Ro~sh9gd3i4%Cz7@jyzB9D_P;}q&7
zjUMRd*qj9}ZE2-Hzq567#9eG*8-vry5wtSc
zZA@-EliSK7g76E+*T2}T}Evd5f^h)
zulLuUYAU|eQQNN<@API}?P_{utZ&MaI%U=G@Yqf^Ae)8^vQ9a-OUY}MQkR_i9yPO$
zgKglF>pA2GF13M6^YNH9ELxvdxtL?C<5GMAhEG79vT2Xk7ws!`4rRz2_>>k2174v=
zCFoa+Iu)Ew6?@XA9LyB=8zocO>4QdXla$-3mGNDP~0
zBUZ)k%G|Y*oCT+O%4Teqi~2KCJ9Ub|3|*I24$-ZXH%hq8GC{qN(=6ePWol<^`VKk2
zNx*Lw@|%S0CLzzq=QIhq4Ll}yTh|YGuQjx&t+ZH9T@1
zk6gJ^<;hilY>j2
zt}nbXH?XJJd9tB=F~>BVt{6y@o@uLGbQ(Gp%w`d#L(YO2G0JD{`bDR4CM)&cSl7+I
z=JTypFAsN&rYpJ>+8$FG8huSZ;R1Rna$13yM
zM6@Oz`9MkTZm)ebRX(hfHgl<65>B_2+b&`aX=Lr9zyJDzziWsx24V(H9816q#H0J;
z(E~~N{$%_liFrV4oZ*OX6jfX=D!=3{xm{fk>TuMVf33#1X3HLxtJ~@(-=Gv(|sSXa|+O9tC&TGsyjqC-XH$IGg_g|g$NRTt`;FSU2B
z6&9^m*4`YOczJ5(aINpo$i%^l+FeDZ=h`~YwsyQUGJdYPV}EJonU>BY_03lXM{iBc
zoNn*B*xi4ox&2gQ>&33V^Ig4n7niS$O&stw-I$nOZ*0CbGk14k`E+OBy@i$6cJ01C
zGk3D1`&3)!VPDh!nz|h&6sA9M+MRW7QdgtX-GiTMJG1IBsImQK;N2#ZAnBoL?<@Ip?uLvjWJ1$
zQHf1aiS4l|t+C0iamk2uf@1o0(=Vfl&ca|rVdGJO=uSdI^rc`CxkM8NQFzeGAq-&{
zLmVSeAVvw45gZ9(oJ5^e$k+tH|Q6PY4gUk1&eXfYFx6JR;r&NNpp
z=b7sG#8xS*NyMsRP@2X3!BjN}L@k@vBw#l28BKh88_2OUvqJ`2!0grVI~0sT18*oz
zFlkZF+I16V)!}N-ndb5nzS3@;xIbO_{_cfuPVIer`|y`1SAM*@|M8*O-(ETJ$-%jM
z6K(J97=3H8|6)hkz7p%J(;ctPcb)4l+h5~e%D3*T@a`yb&ACi4KHN~Wqu4&m1b
z-dGtu(pb_YXZ5Aad(-4Ag^murq(#Z^)hQZ9ob3hf=^XoHwx!RY>efp~%(^Li=5oGc
z%#ya^aU5$Xzt~Z?!(%;Ao_CmhR6D_5u
z+bY+qy}bs>h($ADH_SRSC$iGo)xv=cRkNJiAYwL%8FfNxw^r0DW!G~^oig5fv3n#<
zv6y4L*5iY8GN@D5v1pAvRvn98%cfT`h|MBalaN!(rnX7>t9e;FJXuF;3om!ozckYR
z!OrPD#aY+;8{U}hztmYXXpn%&g7$$L4(TNgTvD@;3bF|LxTnx@y|-y^QO@ICbEg_g
z_7ppg)OdGzEF&4x(G0~(u6e?w?ND&%vePFmT1Y}S2bxa#O5Rx-ozG62hM5xQtlcnf
zRBxd6pR^aIDC{-4=8PlvT1olM%IZ7yjVIlny+-RH(7SZ&x+(jDw|sZHbuG=jid1$P
zr;97rY&p{z<_oPIS9<%e^$#7Xs_#|n?$0fLbm-W30Cu@AitLhI_)La=E
z18usqyn17C;o8j1`v(u*UtWE6$J(nqcioy>d~?U{m**BQjE%p%x_Y{&|Hj13`N5I9
zD?6^v&Yc+LHrf+a>t?%;4#HI0x8#8mKI(se+j$Iv{etCBB;>g&=kd4B2U!qTP5=__MX*T$zVkBna!7``$%
zva7uEV4d$!W!16j`c=30R8#w_Q*&3l2X6HZooj5p+1a~d$zC$rX7w2-s~b<&H?QRt
z%vtPD`zA-Ak
z84Axt5I#(69I7n=)AC#~5z$1!7_-v$
zQt$(4;sA;`h#?MPiNhe21oAkQHUSkS^mN7)lQqp|&u}@jJl+gnFfW!YDHO{p<&sLV
ztbw9ZwU`RhpSox?E@fse8q=3e8LJl4lEu8i&VOg?SMt9RFb4;gdOD{B4&D-?Tnd%{pXjm(57cpl{x`}jEtBARjV>;Jdxvw~9
zE#G#^R|fB>i)}R>V*0FE*(s$#Z8DdY)~gb>h!|`6Sq)sulr?q6mbyLP+AOBEN*SF>
zZljPspKYA78sLot^9L&O?~QjKsK~oD*z)1d*)NamyfNH)yuSGUbpO%%;!8cX>$R?(
zrCBQl=D|$aT&{7Y*3kFzVa*m
z&83~l-CW#phn)V
zlyvKqO;TaARNO3;RP)$Asi0ZGZxGYFQ$+_Vy+awQCJDP)%59bNTNT1a38z8C?odnM
zx2gq|m-6cP%z7cSNye_?P-k;2dnlTGEnyK(ATzt6`fbZa>6a^_g3@>m@d?78o)%}$zi8>sy!?S&<^e%FX<3E_C
z-F|y%`S#r6rQz|H<`(WQufDXr^2*xIYZFsfhR3dtPo3-Tf3Uji^3eFL>BYPAD<`^p
zkF10$e57kUOSbPrq|8NV?$ePev)+~DY)l^yrjcD=TH
z@9TTl-`;=Vt=;?X&MqBm?wHPYPiN&Gt#7$GJbAHyWWBBl3d6Hq{fFyY*J~Ru4v$`)
zoH^XocA~L;DX;MLpS&ezuVobMUFIXV0C!t$ZEj-%bZH|7`5j*Q=3S$p@u
zVc6}~^!%GU_S}FSW*1+cUAQ?hvszSou(n}eMa}u{ft#b#uPm%w=o>uWJMik<^3~pf
zJw+uuJw*qKDh?G@%%)k#v}scY<34x6v4XO7hkH?z4$;fxkMZRdF-ct{#*|Ren24*5
zNv@Ag^2H>9ZZ^jxw!|bi$D}mHroc>d9I816RC2?fxA@f)ao>olV!M(sFb>q4;KzGY
za1i}aT4Hg7SnLo6Ka2&rB#aPAqh#^~l?K*(8Y)UAYm&*F=5Xft{CSaZK_Xs|OIP*U
zm9*3)L+S$b>4wD&!v;J5ovl+yo6pqE88!RzZ67U-9VvByQ(m&`I;D&{2CiGq?N#!2
zy-y>)H{Jtpywkqo10~r$
zHU{)@+^B+?L4)j2mG^R2!-=}$E1h-ku1-B%o_KG0@~x%OS7!Rw3bPK>dM2}ULuqoT
zLB=xG0|sdgo6rZ9piWjrCv<|=2pH8YQiFg7`ZZ!vj@gtA5^}qSJLNEdHVtMfD>sU0%v8^ydDKD|lCfld7xvKl_A
zRn9ryP(GNhETN*hwc=N2hSmzRyS2i;RN1`Ke6GEI)swTUIPYkE<+c8fYrXBqYAcS`
zmhUOf>re>b*XT9KhceW?I%$iTJ)oCQSqvbZwQTZ9U-_NU&X-0yJ5|Cm8h*^AAI?xW
ziJ84x@obi%PbXS*nsygCpPt-zxY~QMqju7wK2()=%2(Q@;??m;)f{}gf&;c43_hf{
z6AdM&o61+*=G{dOsQNch`%l^nr)uiY`&w@G3|?&QI^EEGYiRU*XYa+n!E2)v;8L$n
zOkJOxd3AC1#_;6Tfw9+Ccivgqes6Why~WkbLt|G)C(jLy-dW!M`r58L3rn}B=I+id
zpBotd;K+#|Zryou;_RuO0nnWTO|3_oTTga$?yjhs&&lu7qz#yC%^Lk=mIG$mb%ri&
z+MLrnWOK|`R4mojU6`2cw`Cvi?t{K7&Df&UF6I@k6;&RnZah@mbgH!r;>zGySGwuK
z(CE>wzWog?yUVI!a&JxjrJ>OwtK)#Ld9}2n$7mjRxMtj*j@0x~o6{#zH%T?^YD1gG
z&>+_i+MLb0j0&-0Z++9Qs=6_Ud#11$p0&N8^hiU?f%?Yv`o?`V4Hx=`&-V`9U)+9o
zZt42i%rws#F{)29sPC9`9{
zyXdf|^kiYhj6y#yP&6gsYr%RaU>agjjj^cKc&slfu`V*cHYx$}>9Hwb)th5cO`w~x
zAd!elLV#Q%3!VOlZSm-i1YCPOrUxVvjq684If?H_;rz>&ppy6z0&&d0ObIFp0V+Am
zVuMglL(k#N3Iuav@v=g>tX3_lRU7R5ceYj@y@^fraVX%VhEm1HYCLy`+YXnzpqt>(8J}$S8&0KV3_3PANqT6M>
zg=`~4zgE_*6kO`4J6c;XlqT!fiw{fTgAgP78;VuN0^
zDFwX-#cYmg)?us@Qcks34V%=>a?a6)isk&AJ!J)Z%f0it=F{yJw6(YXsyf97suj@|
z^Q>(u{=wR!Mk!-Yg}XadGLeE`MajpY}+
ze9QS(aQb6b{jf>btPuLdydJ%>Lm?VBrFE)h^?WFY1@OcwHnmaAYL>E^B}^X_j~4Z#
z-P6~=L^qWms`5bfdak8rUuoW`QQah@H}I*D&!8;bKCT6E|ynCt}KRI@0e;o)}<b84=|N}yY(Z(aCHu_-N8dep?#7P2_t*A~+H>1gX@`An`|6snjnB?|N|p-C
zkG1z)7@1fuuU@UHJ<>C9d3?H4pD|*#@2_s0%`aIltv=G$b7N-l!T!T*^^H?SC9m$@
zcYa`O%%1z|>aKGm<7Wp)R!b_H6uMTm!HFSN@+8elJ@ma9maYu*theam(Ade&-tz;a
z^Mz%1msTI{KX|mG`*>IH{^k}?$!kzY@7#57&)$P5K4cUnFK-^h}L)%
zNM~CDt|JlK9*-1~P)>FwAqKoR8PkUXt;F_YFnwsu00s+nB?x8UWDfZ5VG?7H5Vh*kI?svo&#Pms{%B^0P3bbZ9w_7I%OS`A65Yz<9#%2YlRzR!bk$a4?4ufE4Sx$?J
zSHUG$^XVO0@%AFeR8CqYk60(7HOg7@`IcH9rGkk+P+NR=dZ?03u9wh=m&1n`%8u-FW7HdbLyIn1)VB<>Y=%sw?sn)7GAsvkW-twXqk83*1
zxa_v=E%gi;Q_r+DcI%X#8hNu!*s2isr)d^)9dl0Gp7Q(?&DGUhhEE88YgUtxThF8P
zXoQf-z)D~1Z8}_CaJs3&588j)UbrASF#g)6f
zWh<_NIg4{C*E^N{|K;s3oSVt-d|!P2gx|03-A!iZ0W&j+nVHeDBufU_7Bhn-+me}?
z>G4B;n3-XoVN5cRNixYyGRfK9ES$4vH~D>J&+e^zs#06`)-UHy4`t|N^
zNyZa)*Y)21HH+i(Q)f@R0-Ig7IiqRIV~|*<+q)lZZ2$JX_b(1jEcAFT3{HM@`to$Q`=?j#ZU>Uv!PGCFz4dbc;;-L&
z_uCIXd}r?zc-*bo`Kyz&_qX?c@$}{8sfBre?EZ-}FRtJC@Xq~{>EVD#wi{30oLhLf
zv^myk8S1iq|IufE_xV?6$EMA6?%v4wFW-8nx3lNs+|r}d`(HeJ@o?|tMlhC=YJEcG
z!xN_;?VWzOwfEt2F{*jDIH?21b7iH9B|;d
zIXwDwesRy~yBO|$JT<%H^vA~ltV|!iZHMMR{rdbp!w$!bsbRFjn-RnZd
zForaOA;&7}qQy16rL}?F(r`{`G^Zq9P!TRD3+9(b3d+I-Aei8lV4d0Xm0*+yQh6A|
zE7BEJnTqO6dG%0v&0sn7R1H;CkJi*e0WN`+;F42F)D-G}{m%Vgqk-}5bQv#s?F(x0
zuz==4*G(&h7roXCuAYw(mohUOtnZMI0G4j6nub;2br4DsV16b
zgJNNv&Ggerek#$8$NDKGKZWS05aKLqf~5@PL#GH18KvmpWAg652w$;??}%q*iDr)SmQrgG*iv
z+ac7?=*62>9Xt_`bfQI&6p%*%ta8?ng1u!oe7rHeWoaE%aqgr8kk)Ue!Z%WpQy$B^
zOB3T7VVp-yiDDkX;y!F#Z&#o`6Z}$z|
zUf%rR!u9od-*~@g7
zwVlG+>h1s4^Ov99y5keb2HShSegDItRMm;2q&vGWE-uff`W~J0CoT;RKV4Yfvbnb{
zPEhjQKr=(%@8Vmq(&#MCdwp^DaD)SwpEk%<@DgBM%*W$o^+WenuQ*GW0Z-H
zu<%I%CBnfkbSNja;yy@=WV8)a6XOuJ?M4T#=8V5*yhY%rHicOjz>1qx=cUvSt5`ug
zvX@T^G0^=&>WGRzAYosOyT`O5;7){#Tes==d{!?RJE>KExVDgy3fu%tNMKDRoh7d#nHY*`HBYTg;2>79kl&rU9UwmtRk
zQu>Uq{c6H?e<*m?-+6n$2YNfIqMr1$EO!exY^p&e#2|tL2Xxb~nbl*>>~ZSC)`
zjK7%fTk254@ng@`3Gf|~v8Gx?V2*tPO23ev5>O*_+;od#LM_|(IR}L7({5Xm%LtHh
z5jyDrnuL>1>$Q0BjK=~&eptpGl(4t0Z4ZWGyLRKYwRN#gv28Vg)kay^jD!Ur;t!kJ
zUudsg=^ePyH~3(D`r-84sc8IkAacDg^LTpx?&SRS@!3x=U;ovMSO5C`_h&aZzk27r
zkFMXjJTZHHYHmBxcXxC9!+UpMUAz9#t-C*e@4f%_^RI93o&M^@tA}ULKfQ3}t?M`6
zeemGH#q%HByzzMN)H~O1+&+E!!pQVkkK-Rc{rv36)YILwS7(+lOf7!>@h9JY{q@bQ
zQ+IdH{L?qTd3o*T*~x|Hmv8*~%P&8^_c+zwy%gzv@5=S}uHFdiTForpb|iIXbn3ku
zw;ybuytS})XL)_p>d@fHx3^C`I(PZ^pMQOFdfvd~zr1p7KArjH`ybre+`ck3yA_U2
zo9%WQ=VIURmBERGQhRk~@y6QbmoMJh85uh_HFIisEYsTda(nmo%$%3Si;3imZr|M#
zr$2c1^5>s?`gH%|t%cQ{fuVseYj1n^pvBQm=PcU15uvi1Dfovke{p?nJ7efxwD|7K
zt@?P9C5!WHqOV`0U-tzkx-2d#bJglvv^u`NaqITv^s~j~QA6jW`4t~WXrnMaOm18v
z4{?Oo(xW$q$DdBm?*+pjo!kF#|LooI$;-Wcw@1hC&(3|Ya{}!0$?U?xC9L@q-rz}Z
z@M0h`DOIht821c4LoCsv#&9E&x|2w6cUmvmeS58)OEUG2w(W$bZIZ?vCo)3CRf&rF
zWO?0iJ!-588!xVe=nXoVHOl;K`c4#PjWV9S2wssa%HBs@~*aO`dH*X7RiTc3=>cjQUO#Slj1=&`p}JWDmF$z
z^|OgF8sE|=tI7Ebwcj4*)ixX;*mjHH2UFp<@4=yN=YeeH3!IVL|
z=jrf}8t0A8P>;rvR}#)gV!|<^
zV%{DI4#_z~a&Cx;oi@mpyIbZuWW#Dkf=^1zm~%!&f=2>uL8cy%Gxj_NFQqC#Z?a;m
zJfsFFHxa7dfvFS#SS&R6;Kft2G-U~Zi3am6mtO(9k>QB
z2{qm>(0Dbkdf!{j}G-)}uS^>zUHZ{8Tg?DxxgRdy6A;23ao;zvD2R
z@pVC3-?p{(3CLGsE}-N}XUk?!ds@T=a|9ZOsDu%jXw75v2aitiSj+9YF%{UQ_LKGL8Qp(zA@Q~M&s_Y;&HMlQ<*)8+>^$B%
z^~IeBtI_29*KYl{ufG1`op*op@lSsB@n^sP;^&{g_3GU__fF5wpBkBj39c-xyu5b(
z+s}S-dS-TiYVO0k_nuw2w3HeE`&;ZExUjnV)0eM)_p{Ic_{(4Y{V#uY?d0iiKK;pm
z`|6j#yPrOKF&9q0b^gZB?mxdWv5?fXe|Y2W<5TB%1|}}A?SAs))vwC
z+?dAY^JdqVH*Sxc?GcG)qSN7#
zs!nDGFOQB+wzqepFzpEJnjEPR7v`7Mj&$1}ZJp>d_1sumUkb-3
z?QRE)Ki<|e)@eOIIe%hu4&JMPM!yw|rdkZowoaVs8(jBC(%LpNg|T4wY)r<^&wYO3`gphP(&X&rk*Sk?gLmgvMzyfvnrv8dfWsfv8>iY$7Y8yQ
z?43Fhh>mO9?+i~ppIdq`I=SQWUW_NtMYD1HdNO_1?%V0M@7P?|68-z0(B(kvvOm_(
z5}tKXD>4JMN&NaYNyVPZ-98~!8Zk|Ci(Ze_wjI?78$x`{v>G^eXg
zz`{pC`Y267*#Fr$sHBh*=HQbeTEC2$QF2zyx``J4rcHZyBz!aNNy}+ND)#lX_jIUp
z$D_LxH@}$gyA-pY^0e)_+5j2zM(Km$Fg*PB*6zC-1HZVr@;^Si@$H?h+iB3t$>h+Cp7Y>lOx-<
z?&nj(V`?$P=NYX69KV-CKe#C!2dtcImQSgrV{+l0{$z+ob7S#NG$uqP$5}Kt1Ry>CDL>Dj4;&C$uXA3pfEfB5@fz5gMInG1&T)h0rod>D*
zo@<-iyVLVOdGhSa%G%o(E-!?_{T*#*N5@W%jh`AFe|7eJqNOdNYrng(^YPVN!(G;=
z>$_v!_92sb&gENj2d2$Vw?MKMjLw+tS0*Pvx_IGCIvs7%?9WfV|M>3K^w`_iuFQG^
zi>{y%O=?9GW<9~Z{$X`JMp9P4=8JWZ>FL&vOiP=GDHznXheUEP$AnCEb95pskQkBJ
z$IEL;eXD^;xiPa4mZ~~1#A`$2V}?#yNx7dVYHmdF%d5|1Mw2?@Y9Jhi?5uCw4aMdi
z?o$IpF>UKxC--+Ey=Dq?GnTrsys_*KFWCZazWke)@BHG~Tk&SYd?fbq?K^Re9#r)9
z#N64`;D$G_?)0x%-GeGUWcD~q+}?<4L!j?Z&fLn3-b#-=9G$wF7`Qbsav~UcXZOSh
zr%ppcztKPVd~){j@Z`ln>}F!%QYd~Q6r0nvE$P}LBwB_iT4~m=w;0yd`e}|h)`$sI
zH6#$&p8R5SUa_yVdWyo_lQo}|YZ8?W-kf4zPH{MUg0d_MUYWfPUIse(!?yF+Y`fjY
z6Xv!E84cRFYSip>8=`dF^wZSHt$
zdd!Jw@R1M^1_t8ZzrMV8K4^ELYXXF(v+mA|AK+g=*1KB6RD7IG
z`ts!J^T~nJo~})E>j_uKT90-}!A=Uu0}?vekdNFLW}qQay7BccT%(VI8dD2gKU^RA;`ID4&ad1YaKD^OJsOWZnT$>7
zI48V@U7zuU&$#8*?RX5ko{k|kYgEITHVQZGnoIGXU6(d3Bd=T3(7)qs8P_l~Qu36R
zyJ7-Z3uXX>&9djyv8OY!J}K_yeDB9w
zBXPuwf<|jw|^0^`-AZ@
zm0(E5fyBLNRL9xG4SV~obhwvG?B$TQEbS1(2ZWqn4h=-|O4PUBW%LsMi__(=efHwz
z+c$4sTwc9<^6cMz@%7K%e(#s>fBdWWKl%12KO2iAE-kMA=7Wz<&n*1(<=Y>=c_&6VYDK7ZWeh=`PsJ^PjVr7q`;)xDD%{?+>*
zy}W+&or^bCJduQ4b!}q$+U&xa;V}nKbaQU?#i?_nU3L?JF{teTUlWy9?I!xyBMB!*
zm@&4kg+iy2DP29Xx7GM?V+(-QiN$N05X0tfJptc>!S=Pbn`zuu1fjJND=aAGmsE5!
zIJ@Dbt`5Bw=v}h=+$6S#%o}Jmtwj?T(!=uds-&v<=J@2r^pFWhmX=nArAmDhdQhz&
zZ!sF{5&HV3w9fd!xr@u;$cGm$&)M9n@_JQy^|sq@Zo+ofp=2dh+ws)n)y-}^WfXX1
zb>E$w8|$<@**)`g=X6qU8guwwoV^qfsRy;4)18hBy(3E&?~9F-KfnF(`o!GnNGics
zjHwOt#-6Fx&Xb|oTWi}lh9^$=qaHHTi6QE$YQtRNqv^RPi_4q7z_!zOwLf!fbnM~u
z?4y~57b|Pvo3}>BXN(=2J@)hd=$KryqU%^SbYAp@o}@>{MT&K8+a;^#oXM6%5kr;r
zi8@5Eyte09fhDIX)rdLUV%!wUr-%$+ewpW3VKApSQc(WGw)59)_xge#EsQ-Gj30j4
zZh%8MZ8s%Zq!BUu^R4C84m}+6eMEGU#{fZaLGGqvd_+`|OOG;%9%2&&$z5mLpqx1<
zW38B)?`1;o%%#7-wtKbL-X|o^wn~x$iUU(`$J9p{BtHe`C*$0B6!ZruSXi2u(ln;w
z1NFvQ_;&_FZ_TC8g?b*1#lJeU{PQ!*x6|I$9>w)O$CZ?Awv9jC%317`WaN}l4SUO}
ze>{~q9q2saG29&vzP&JfI~{i5YGWKc;5EX=UX0j3Sf30tQ3*ai%tGyl&Ch51ul0F`
z6m-bN3mwvP;jX1l`LLWh+003B&|qyNO6H`FJ7*M)w{WKPylEY8tw*tGRh{u0M^uzy
zB{?G}rsc$m7Uq_%d90Z+sb%fC^;_1K+k@^;_lBO$2Nz9(4U6*U=N8^u?*Gk|)nA;O
ze=;8V?bV%EO9Q{UzWy(t-hMFV|J9|He|diC*Oyj)vNQJ9T;i>T-s=O72jhXqbMXgL
z;j6vYZM$~XAPUeC{bK5Lt7t^U7*bM)l;qVO>6%#%@5cGC`Qd2f{%~N^s(Cfv|MmXz
zlc~h5wD-N0;SbivZf61+87;&>O=?B+ZAurR#)>Ih=~A5yb^}kxHNyEe)uyd=w3!b?
zduMUv-X+IczW&X&6B5IUcCC^%;mFFix<{+
zuAMqNnMyypeC_U;{rB(Qe{%lf%L|v29bHk4e!$on)965vb_YjpZfrR?lKuYCfBMPi
z!#$Q$>4DE~TzmiWrHk|PKYjS{^QX_x&dq=M?D?lRZf}Qs=RN+Pzj(Hj8L~^2uddwq
z>gC(FH@0WozM(FQoiDn(xE^aZ?8XL$+sxou57u`9ksn>XwbPqc)F8z*P4Aw+vXRO>
zIdyKy7kNCrY$4NZG=`1FN~*O}4u?Z3cD1zp^6mF}b&!`y?e!3u@vFYTorQS^hoi2p
zRaaEY%PacS%^esVBd_qz`sVqmnf^A@<&lX_6uzaRMqOTIp-{qN$!KTio!PmJt}Xk&
zXXVwC9UUGvUsY1ujUW!FTTN&}n8EF=L)y?pOB2>ykG3>moM@t=tjfj{TwmR|I5ppj
z#I;n{NlL3a2(+j|qo`@z3-=BwbaMvF<$RfwTvW??4llJ^r^(
z?SF9g;M^tJ=5?3>au09%9Ta5m
z0gh5IK?1^uZ*=3EhGl%+E!@s+EX2u|0XjhCk3lnS-
zgyk3upOG*e=-MQYnqZTCMC6)Df68r6@F-Ujo_AM9Kiru5Yaeiu}ms}sD
zLr%mxaMcc6jU8L-C80)?f=R7-zFl@U&~>xleJ$k}Z(+Z)oB_LhFdBS!IrGWZ*yV)f
zzuh_c%kwLTE5-&+68mF0Jr
zQkP<;U8m;ry~$0h@_eZ4tlxCPY4j4SGZMm%LzCbk<6OjuiaM!f#yAZzPE&|gALloP
zxD6q0V@ixY8|=89@je`noR66A3o@fA91k9`4V!N#cC!
zppthsY?*D7&$mh8DB>d2`zdHUwk|+JrGzvWzG1D~a3)}z)XSbuXI9Ovd)}Vg>BwoH
zdEIOrQ%h{<+9;c_*wK8-+XHX=e$cvQGp_gOH?q}wGZjd1hygO%OF(+?h!~Ufa47Y|
zruG-wYwtgKyuZBi_}qnGy!-w)pMLg_zyJNe{{0{C?qB%HvzMPdeg4g7pPiUn`2CkZ
zzr4Qv>f-gg+o%8Vv#-AV__Oz(zV-Cxou7aB@vlGq>?bc?o}XX-;KrTby#LWh_aA=y
z>1V(B?6bEnU)}5-m^QmFjZ9yjU;6CH(
z+3lR@u%*>)DTT(xwAt~(|!E?3t#oa{|*`GNqx=BnCtuYa_?OHx@IQEPP=g0!qgRRx=cq#H#rVMzDq
zma_jLP*m22!pD@_hpU?lPTz2AyQZ#b!RDFiab%~jtW{N1DN4%q)eUX6O)0+ASXr;i
zFO?iGiis3axuzXW8f$4EYc^PLZTEmKE&pCHK8ZMrQbfjqNku&{Av1
zg1+s%KfG&q-AWBSADOu1^npb#OPeRz!mVb*rn)svq}vP2(rBXh|M~yR{=aBmOnomM
zKi?vYQZX?qc3hT4B!F_uq<=D!x{(Zgusro(C>fy>yae>YEgeWZs@9Eb43M$CoUAD%
zID{FUc*Ue%>()FNj(mP%{`+gE-&q*>Y-{GU*R;DV=D#Rj|+@9#PZQEy`yzi9g)g+YfbIh?qXy
z82-cEy+;$FyMvxrV#^
z7vo)*dwXtXoSQb)DWCD}#q?@V^C@5Fqp|2avjg`t!7B;-`^&?>*k8UBw}jY@s}|Ke
z3z^F?+pPibyNl@;GriY(?PF@@^Qpx9%Y)A*8mw2_998?gW
z%tXJww0wU&0I&Map#SlB{A$v@WKs+%=^?4J(7lv8AGN-hj}OwYV`{-nt9Yri`BKb%
zCE?x=T2{MTp3e-dn{{K&{9R`|99{f0bevD=m$HIPT#QG)7u&z!%yv~qKE=dG*PudZ$W^@pF5ElN^9Hp6MY>B
ztOZ9;DOv}0rgk(%Q;X`t(_+%*R~vghM23UL)zu=`oPo5uHN+9>s~b-Q;z7PdR#?_r
zTB9wic2k*V0=XMUIvtKVi4;vq)qtYKN~Af7bT5g~2b^LF40TN>BXJ9nA}c776_!d0
zi&ez{wR&w$LrS4a2*fuAM=m7#x{)|lRgJv5=GoTP=|r!cLZ9!pbYbu=2KULzdN-NT
zg2I1#Ma#TCl@QWu^YVe`d#h4P|OO-ZFZzeHYKE-5Uf
z=j8D#t5g-WZ554f9HX_oF2NHUY8xGRO7^cpaFn!66=3uIY~HHF{cvioy#Z-L;
zC9}hhre4_O|K#vcsF?q*^a!j4I;aL3uU>uO(USDp`B`^7XTz7}i(
zc3rT)C>x)VF-O(Bq<|cxqx@9FxQ0Kj5hVo-H?iqvfAHo&@K)OQ@#f^$XV*`9x`vg!
zIG2zT5r);YsaDQ(D}PGQU$-=`ThzBRo=4;1HM8Q$WaRNg_|xt2_gB+TCZnHjP5{3i
z3`fuSy7mLzSK^LaeZGwz-AbossY4Z@HO?C)>)q;2v*tqBd?)Q+?ojwh^)^&FaO%^|
zsa`JLj;*v~s&?##Avx1Sth=6c{bGM*KWI)%7*=GJ15*>Cp{^#}HwOHxW^EsjWNRvS
zV`?7`C9lN;K`Ius$V)`J2?!VXHL(dCD#0Vq8svT|h#_&cTl?YK{p*V>U!0!#WOwXxpJmOWJRNA8YZEP*
zWQ!*0wnx8WQEk|DTP`C&@ZNCXXM0m%xFFYW&G-M~lZ)>xrB}L@898;wsh`kteAL=7
zt8v$*ACQtZZQ5;z{-cf2Uz}fhd$Iq?Wc*^xw&&@XXc1gbd7;`YGM`H9(amw(*t-Yz1Nr5t}Ly*cjM;yxy5LA&+k6{
zo6PZ_%ItnGer|JjA{xvS%IgRPx*4u8_^
zowU1WfXgEj%kGGaz@F4~Je-(19f>$;j1ClG%M*)>oA-k8m{6fAscEf7>S~ZajyToa
z3JUhC+Yc`dj>}6cwAFQCw!lT8u5_5=3_+00iZS?#++r`8G27ayEGSDW^=VDpOqX4d
zSF#^Vbu?uE%wt5|BF`&Q6_s@%FkMJ&ClYHXQR5tuCbzVupd7d+%PEoPmP&GqtpwV+
z-T^m@$2*qGKXP1fG_Sh}(^699B{F*jGB=GCmdLM+Pk6cx4*>Y{Q@MRkzFpK0w-=9kzAWIKV9k*Os)g|fVo=F;ls(i&A!MRQ4|vaqbVs4^u`
zq=d?AL!)7l#DXJPFhp5liM*t|6N7g$SzQE@qN;W`k$kwe;o%CyB1IdTWFfPAa8xsz
zoD?ahwC!^`Q%ctIbam_D{My-YGA>f=MH1&@ebf4`%l)Hs9cE*7eS1A(&m9=k8t%=^
zeRk>cz4@h6k;KJB-;IIcyCW0#Cubf`OiyZC=X8eizTi@8`$?}~{rT?lx3|vEx2XoDtOcXeg{?pM;Ra-!
zLyL3C9#UhNi3u|y)z$(H`$Sa8*OwE{dqa`WcIMw*n#f2wUNRD*^n9CqNWmP}@Z6;O
zK{@kc)P6o}18O`POPunWwrz%=?9Tt;?*12N=FdmF_dJFrlRPb>*>ROle2tq}7o;OV
zd{QF(!?ECLztK&qj&U$aJ}Jc~56RdbLW76U=p&-SG-8l~hb}NHKtWBlh|?0PmsB^c
z6E3vLf;7aYMSme=9aV9IROGI`9pe9{MK>s=Uy52F^KO`1o=qjT?5*P(;j~s7V-nX)
zt&43fNgjRA(GBm+xKeOFWFHW*vj&YvrufWRy*kVwdx)43r8Gz-+c8KV3FpKkV{CGQ
zM}fn`h>F|GBLZP3HNtU~U_i|DkeVV4Tt>uL?ojSJ^z%mXgob}_Fzlx^*f5nYVqJiN
z>J{LhPW8gu6=h?WyP9|1o$EHknzi+6pZ{9Q_h2OYcs%y$_QXkVJNWftrxg5pT+5hi
z=dbq2)~%{tck7j22c+_6({X_2)ujDa#tpU5Aqg`P0Xo7*X#^m`v2ER~J?ZH@8|?XD
zb?nYya6i<2Z#W1+J}qYinCJi#6XlaLDqe_9Oo>_RW&<43;LU+3J*}6W54jfF)ML#8
zKNU3~VTKu4KLumQ)b)#4LvntQhP&ApITv*Pu&Mop_S&~U``MT8zIS`?)ZWzWZ$JIX
zJ6CVs+}i#0!QUt3&$b@l4o*KX}h%zXUl>E+$M
zt@*{dkdZbVWRLU)o9M6~M7DEY+qOwyd8Nwy
za(RB4BEPJ)yk1vYD?45+%PE58$f28Cd{~Oy64B9oU?u-(9*|CWG>>;QN047+L}A9-
zI&5_2&H06Q&YsgWAolw+Uas)c!0?Gkf_EerIM`l?7**@xDWHrsjUgs4!WP)jL{mLR
zTUx6ruW2r?RuxxtHlanig|gx@2aRc`F-#bIYdyl)fR>e1b|46vDnx*=DJsD0cc3GVi
zx)F(qN|Zpx$20TiW64{Y(c6Qgrvl+C$^QEz&FRdDwM7MO8J#@ewN*ScFkrC~KTEV>!JB>T%|ZqvA$A7|s?
ziRKJacv4uCI0pw5PV$K!Vgsxvi0!DFd&b{=E$MkY-uryIA9{dOHwOa4&0IeN72)EO
zA}Vy_d{SD%gz6L0d=#Xc+!SD9LoAYqf_9ORJ{sCjM>`4iaO?pST0d1kzr8x~Xrh1D-E}77e6ct-q~h;+d;D~alh_E)+b3bqwkf9!l6P0f?!!UO
zZyD8yV44Vr7-kbjnuUFm|KfD{Yv*Sc&(AGw4-B85oPW4;>e<-~*Ee@woWGRmvYsEG
z8nQdCEw80*&dtp5``50IJ6#XfH{wc_MnTUzhoBr5_KNgd=oJkHx1S%tvG-2~-
z8?ehJ&#b{R-P+Y!)7XW?DT~XM#g#rP2YAt3Tmei}=a;E-OH|-l1!daeN@Y%wDyLXe
zSQezPfP+x#f-(@j&YGr-SP2jNMT!Bjva=33*<#d})yR(*0yGU^i>j99qVo3Irnc(F
zQI*zIiyV?PyRj4ipDYWzEGtzd6?P2KP*w|bIWVLoUm`h{FFRJG$SIZ{E67fH9PnD8
zfOW_#fyJs|E*NsWK%O02nEkh4U}$c!FsG28TO`aa5+5(p*CW)Gb#^?pU#RG5#02Ra
z2=Dvxe!!NjpcE`sQBc}aTBQUW=avD}b!FA?s$0uyyaZZz9a2|bW5E!lc|~3Zd#2mE
z9g1B|kDN~o4C&fUSW1{L?QFvK3glbf&_HY3t?7lZM78J*-d@>U@kR%v+LTzWu56g@
zwqMDNn~BVrM77-G7?Nv-6)hLyeebO84C#z>-4-W_2FIQ;wQketdAhKCB|Y?LcJcbq
z_?ckrPI`1yt@~ly`D?a*9s>+9Bjxr9*me}cgC}@Mu`yp-B*Wbp}q
z+ef=&&t{@mQ`YHL_Vd};FU~DJ9*aGjO5V-*ezHCF`N@Tw>EJ&+x(bo-TEYXUy44@P
z8h7^zC_{4A!;#o}Ps^x^vtiZ(l>kx^Ci;Z44WhIYSDoPE`-GGvH~R}TQ6_do$%5f-
ze1ngO>=V$}y0m^WGRh#vm?SH*+JUJ~OX#bn=7m=2)re!eTi46P1t|!CAi&W>sCVP*
zprHRs+&v(oMHm>s^r(s#=ip;3?A!B0|8)Nn90p+2mALC%zznOgZEHR0F}<8k@45^Q
zeEBJF`x$>1v$~w`p%>{0}D+zq@_*XQx+&
z)x7ym)tbe4B^g@jHb$9bHv#1$V4MWB1CO#{nz|9S9x}#5!2}ru=nlwO=OXr(^Fxm&
zQk(X+b73cdEFqx6@EDhrmb23e*7>OI`TRhfhux2KFPl|+K2w-WNJ*Jd9yz1r#)Z^7
z!--9M`{iEWmZM|ZpjhhGy|pwt(;=TTDPw$+gV^AqAP1Ga3o-Ya#W3H|ydQS_u&Mop
z_S(gbty6RJm*$p!`_}s>hbCTLy!_s|%iw((z3KA!tVh~BWOKcJ>FPTduTFXc%dx~S
zpFUsp`MU|ki~Z@-iQb(=Y%kq+vaioC5-)h%mnO$D2K~5R@5E3R%&uf>`Dz36(C|)vq%i`*)M}YOtXI2d0Uz>ELJaYI!@oFh~fm8&4k=9jhPmr35tH8-FmRCZ@&y$+nQsIob~
z6y!0hV^xi&I#g#Z0wCC4+t^Xv0I-JVk^>EoXG@Y(AkN8`%PeOzF{+l>LRhB=jO!p<@C@#}qZF>XKMWpTd!simn+Y>V{Hn!i|+52JJ`D->isv$(hM;L@rrEs}jcgF1u(MXBx
zt-RPMgVf8VOzXtwLOr+oJy+uP_m&19k43kv`Vj>u#wI$kwSbry2YV@MTWC|bi1lE6
zK_+g=q#0InAw(~Av<%64UJ`QG+3{?uf7{+VV-&AjwNtI4ZI|)G-I=tUdT%83>E6tP
z$=I#YP`{M){>IRMfB)v6fBw$NK#!YPJ8giZRz0BsT_QSg)gcxd!lnyf^K3HtU?>8b
zX+u|n#)7HcNP2s@L>~!xt1tX;IG*AY*Sj^lcH>%)X02OuHQ@%i+p-$Z_`2tf(vwcZ
zMwjN4qjRBEnP8Cyg!Bc20&KCDLmE>EmW=8hOWTA}IIa+F^|WpG7#CYrb1kx^R^^mR
zG}|mW$Fw^^RAh+>n7a^yJ^?fwbZ7a)2sJ=_Gzs=$)iS@gp7nW
zp%(hdr~x74dao}dVZe%=_IECK$=A%vjGQ!Q6pb}=rgZ!f6{BBFn$mKiR=eaMtq)&I
z+IJkS89C#V?V0!2##16nH==T(L%Y^va1k4Pw59O|
z?vM2KiMcbzmKc{2<1zdUe27iJGir5Q7#SThnQT0+S0tL~=$dFZIfbHAsez2n
z=o8BpL!n1{
zoL35^Ev`}(mIG6O7a)DjMHRY|sulq2K|#NlNIy`{QXmw>VPLMlyry5QXsxP;rvUf@
zvmAJGj3?67)Q9<^Eno2Q+@iXu0>n_63kkYdQCP}7nz!Kzh6PeJz`C^BjKB>^)v)lx
z#kOS?uTFZr7zo}|hg2Ld1gll#mq>tpNAnM%DLj$~v7P^B&Wy3siXlP_hlSXX1Vv7X
zEVop6q`*m_jcX0!BEtM)aY1o6
z0%t)ITMDb1iz?wQ73G%-bBg4J>Av)`)iu>>YN@CjP_>*4MITPh&30PmyKHkk_HnIoTHmo3jC{0r`mNP1JCV_e
zz?!jyE2;G1rt?>AxBH^K9BPV33sJFt68cIs@M3c4`NZIpvHtTx+lYc4q9Zpg+J!dh
zwMG|WMW^fOzcNoVHU}PskIXtB0LggLmR5vhN%v-@esZOG^`U}2a#~ytO?NSF2#G^
zS?b$$Xm6z4PsdXmW_^H(4ze&FQvGtL>RiAAvbNEq-?ewd*~A@Nn+M{-?~?{u{#ndD(Hci&^}=h5eN
zswuUkk4+nw2?KaE^epO{``GjWE@MV5pHV9YxXcWn32^k|P+-LvfqE3Rs)ReZ{8n$(IHI<*rz`B;nO{%Go8
z;S87sun5iw9E7~QYHposl~3rT9tsL7#KKRt%0{)~_qXR(EUiCmYJZ`!kVRVTL#@);X~7QspU`
z*2@qYs!>h~XR6bxu4?2QD~QY09uAL}li!KLcAzl&hNekV*G#wBOr&_39BoC7kIZ!A
zscDG{xC!_JkxcL!URWZtZd@Fkt@wF(*S}?svyDx6A!Q0$c|@&Hmp)hL51vCF$|Z0
zNFFNyGKvon30=|AJkgOn=m+8(D(Zx9=16i2rTN7Y2;IlBr#>x6ys^4LmRBs#D{U#O
z6&x+#A1@5?Bs~}sfUKo1!vRYYT`I61`$;tg8t%03e;1fw+ZJij?cfP
zpHjChS?o><>&D>Nrqe%XvVMB$>U(GRr%XLRY&(C=_H?2@L`5%mXf`bdAczCq2z(rr
zaH9--kcx(M8DZeSbf$H(a{=r5ko8VFxMkH@kfrkm<)e|_Cu6xJ!mz1&Gp@#gs+^*fR8kahhOYN$S9^;5y)XSmoSWTNf?UT*2)eghH+YXp>HrDhp
zX)!Wsh{v5(tNPijQIRmsVGjxTv(2i04r^Z1yxGwnr&6M1QiMzh;ILj4Hi*MdDWwx~
z@t8y!r!hTPVuZ@@VhBkFdw|0k;IOBZ@_CIa&0_;blT6yQQZ^{y08fX696t^TJoRCb
zPDJgnh!cjKi$@I01W7J!K*(}pA&=L)@U>7;7UqPbZMjo@z0beUuH11Lw`_)OTgNGn
zWvR1eN-w(B=X`f%;9R70zFo9tR$oatACD&&+MB&(G^FPDR%gO&k{MkK+15>IvcqCY
zO)EWyr7m5BL%ciOdpckpYZ3QJ7&d%OM#)MDNkJBR(_vWbQlAZ5&x9<)%{&*SVNx$i
z2^cN{%8o}yI8-kccQGCu*UJ5L9H4gF*|pr=y6rUG8HxiU!7H7_riISdjDIYT^ZGHt(LCPk#~^7cz?hEY0xmT*wW4FWvb-XG
zZk~lgJ=dGEVDKRd%M3}gq%y`9`l+l3V^h66$=O)%qTBQP=g)`q1`mlIq_HP7`c12I
zLTl)g$S3v2%dyl{i!qROSoWgRwczoXFnD-4p)q){ln{}bpmME^*aS;BDr<2P7z?hz
zub#iUx3JnP(?obuO;v-qpv*yLYkgAEU6Oi+Bz?W9V;gFN>_87M;ubHSGrp+Mje;p
zu5%&lg^2CFl`$v~HwUiDMXd2r>%&a63y<^=@P0DcOT^tt$41ngJ_&igQ!%XOkE$eY
z0>+L*XXN4sqiHV{{pJ3~m;39zB8r=WuwZNbbW}z~53uUTwd|CT2uVE7r8uySPJBa%
zfxbQHe>v9=JO6}+KdfNx2YSZT+{qUH!9&)RRtS|6kYFIt5E#8}GeFNNcjswO*TKJE
z@iw~kD{UPRPWg65)`5J0=x|2-pd^
zbV?!1@Hi{2IvBEQ&;k1*B+?+Cn`F>{p@UpOg2D`8$-Pv@0E;~?5l<;)FypY0AE%O|
zWMV&?2~V_c)J-WQQ4*n_#fa00pr26+J^-vCVWQWe-7ik;zdCcV
zhb#7~w3laBe*5kxPtIO=apuC5-Rl!5Qku3?{UgiqzGPe1i|y0P?qIK4x06U-nVFxq
zy4D~f#L1{{>I_eND#g(f3QV>kAOI1;YlSm6tImVjCZWL~@$EvBQ29?%V)q{lUE9z9m
z6`VJY%L~dB1!byYNZf+9x+W0tL9x<}C2NW+d{njtOV-sQ_In5H6!xw^7UoGbRrLX$
z*vk=Lo?m`-<$7FW_+i`mYc?>ii(%WCnlqypE}N7ydhtqUv!C2Fo&BD2%hSoew3GpG
z9M=eJm?|&1ai&%BXe=>jlx5^}=y@<2TkFwI>!s&{_DfOkXIm?A4&8#Rw_|J1hAp>-
z<8eO2hHi3TP&O`(*{nj0CO$n
zxYp;oHst&H`Q@h*v5R5roq-?#;{H(Nv+dbUi|(Ym9oBhJ#t1V|9%9|FlARV)2Sv2g
z_O?a6Y^_7x$03Z$SToI{DV69-(7C8nrg@A6ot$LQr(`lvMK>Dh!J>N^j8Ty&L8T?A
z)Fhog$mfF_M#vzZOY)&`J|rf9#Km#cehMp&
zCq;3D0Xj2;!3ELSD1kJS&>a(t1~|+p3E$76Ewm_3**lh66(bVXDO>w$n|eVj
z?`051B^)5*ia~wG*?A>mKkYHi=%foqWky2Vv}mF%G(i81uQMa1FSIL8`?^Ndyab;J
zho~o$eM1VKi_qvHHDzS%9eaCHK(pfzUJ5qEBF}f|W(>_IhISAddQer9dih+N7Faf}mwV}`01MYEqNgORArf1945+P#(6AYB0$rD$2hZBfiQMFD#l~1Svr5%)c!(y
z?TZ(0&4lCErWO}%{^>5~&H0tx)X@3S87o&Z=MLXrKk?ekvibGhM~}94HdCqX;lUS|&TS+U!zRf$F?)D(rH_1
zw>r=iQv;??Bwy*Y4De(?!0uY4v81Lsr?{)CDTt?AYLH$O(b0fuE3MY%mv)rbHs=&+
zju#mVDxf+_s*OdJ#-b`+Ua6t5qAiQa3TIn@ROQ+R+5`l
zQJ|_Mzc|7by2%V5mDSmRROV*6$uBOyv%G4dGUbKkHUbR{SCC)AgX2M7X>(DPsUBmf
zYHY1)l;)N6N!6Y3=Fm9WTEw;C@g#=z@1F!l*a_!vtjdo$kH#SIdHW-h|hMv?2
z?q$M@ZHm+0uA3>}rKkh+aK~m?Gc_+875i?}mZ@c2%9(4H^wRKsOv*)%eNrYI7I0Dw
zN`gink%$MloDs2TR4SQkY3XBgBVesU3N1#VC27nsf!xPn5AuZY(2Ir;
zO^lOiP%#oU2nm{S;E8m0FOeEX<3~7xJ_-XWh9eCzxzl2K7(?)*un`g^NoOV~)JeJY
z;54OlOw60t$k*F-!(#49Th|#!&!j>$+bla}>)JBums;fudfAYa8D^kIl9FnlyBBW_MQ>)pBO1ZBvtz^FekNp}
zYu9)v*dUVxwm6}cUQPK!Y%E0YFq`P5Vr~!iItZvig=E`djd3|KF55#UxJfu*ah%We
zQt@ys9FX!MdP7CI0OJ4RPdi?FerEs4{`vd6C(n;eo=FY`#YzuH-(Oh;b38dP_|fI-`$Lnf
zp2$Fp!AfV_Sv+-hy}F`SQBozyDWJc8R8UYvJ9>we7e-adiBu)ZBCIcw^(zmKy@Tf
zc{ERTEKhMXSMg>Jj8YxRm%p9^1wE>x1xi@4Bl$2~bF8rWc%k}Op)R-7R9@d%S_?hx
zB{eO%r9IUMeNm;MytcKpTA5P}YimUkz~fvbMtdDP$&pMd^l_Fr#+6QJI~B!Ms`9#y
zMx5k$adY-6O>vfk2l5Cn5JL1}@m|jn!J6b1XBF}&0I@&>#LPzTJScH)Aq?TXd5rhw
zalz3X3mV^>y|1W1Rag#M3e<*fOIfwxcs}pV9Bp|`pF};;-hF>@Wz1?b;E2ka#(BF3
zkjH@(pH~ce3&?J(Z0c&jstYUOp&6OIt#V9l&{x)jpTc?$$eMRO;U`mzKWsaH&E_Q|
zh85fijp%aRP=2c|Jd|Vb`Z5)P5Ob&);Q-
zeU;o8=Mw`ARQ4-BTh|u+;anOz8NaK7lOcq39fscU2K_+*Y&5vSpr92U$En
z5|d_eda1MlHYda7_R{J7Y<7%FiBd?@3Pm4_8N%a-g@PrWX01&-BIOQ<=xbe?yXo+l
zins4K-|7pzzcjXGZawcaZ*{jO*d#BhaoMB>VNVIkX(@f)sO%Fmoj62E3i$+Psy>
ztVYvI{^YIc<#k`|O#kqUy)z$Qy}lVwnwji?TshQc5|>p;%BysZ2oHm;D29w&)=j3p
z+}_y^MpR`L796n)g>8dm*MJR@IWyXhQ{G5~FWGYY7dv_&EO*zVw8fRJrM1>3!mzA4
zdtb}Z0&^qAhQ!N{7fO%hYfEahWi{EIJikm+Sgt9pbdso698p?SDle;+mQ=c^tdv+j
z)!J^s;+;6Mp|skKCK^kA5WV)2>Xw{h(7@(nh3W&eWqXbns*V*vS982TeIyr3bu?Rw
zBRK#^B@8)Qa9Hv;a}{r7>j0F;m2Uzl;bD&K$H%2VItHbDGY?Ao;~Xg2>$%d`bCgH(
zb@`=TRSkyXN?l<^jK+o79w0G5R{{6(oMLHiNqa-~_aB{P=73Bc0Ovv}+`aulW2=aK^%O{_Yq(e_{Urmv$~}hG@KQ)()#U
z&u25B7*0ZMQa}c6bYL3Xc!ZCNP6{cH#(SsrqDwLRVyAMsOMSxAac?MkCSW=3H$R?A
z-5l_p4Ro(|>-<#UDflC@tEnW!Kzw>)J|-Z!DGfWWj)!B(k2Yq0dSVfxcTz~-u(j?u
zj1wAhN=Q#jnFl}dLb78Ttf+b$s>y-IIM7%(7Vkh|oM@CAm;HZ|FpZEA^JaC;{Q~Z&
zLfS9j%;}oP78A#VpV}S-H2$TpKpTLt3l`w?H10tgYatu$7;>i&lF-c)0
zNYprHn!f-0q3D$%3Rs*(yHh3TiVwk&R4aW&Xhkj!i=Z&2oxfpFzDvgKxek+4VWftnk_jcAg$I03?NchToq@F
zlYDt=MMIxJ)?VG%TvBDMZ4wMIUwoqGKSW#Lr+F}$O%j3Rz
z97Nbm-t6NQ+oW9u1T^NWn(v#4s5jAYelzyc5}I
zN7UQU4S>sOy=t^Y-i@p~;kHh-Du8;Y0zGfdXYLGz*Q~l7Py2?;_;Pg|K06OBdv4K1
zM?Kk`{^b1Dg@pHP#C3mcU|204R*RA%dXR;+;p&&VwBuUowzGSxwb_P4hS=l{hpAsK
zG-DBQK4+=BBgCdzu!!gLQ&YwkHyJx1698L*k}eYZhfVD-wAbz~uD;mV^|FNlp0piD
zPG}7uoIDqmsLl_MKV9FMGW0~a(g;uLpfGx+io0Wzqb;qnlFB}nE~V63$xK;Ejk=;i
zR$eVBD)%wC8+H#^j6A=%9f7~pH$2CRFzWImZ$LX6
zvE3C7fI>q-dCT$QmSaV_oRa1v1yJfY^Pzxo(62dG)C>rNn0XY2WFKl^IOJmR#{;w-
z(i38G7IWZJ2a>3IGhg{eUKX84^EAh@GiDc(jny!)0Hy(+Dv#s?5CNS~K*NI>vlAR(
zH;YB+0m90EbR3LQ1`{92*A-WS5yNo;;%ZW<`Rew)enb0sr$t+Xc~?4A
ztET2&5yeTaZ*MHNVY9#V6`-L9mE28R+q>)2|NQda$2%)~9&0a;8ln^YBvM)=wIZ-~
zB;JL?yYQ$%8F#g-)kDO3$RrnmU_&9}9QtI7(ttZ6ZG(Wpsss4*HbOd<{m
zM1x#$hAVP6VZwL{_#m(k3fKoj+z6}}f%P?E0}a?d5;IPqjSFP`bWQ|I9$@iEb(B?|8cOlNtGhxG(NXIC3d@}USmAT^rcLE}9rysHTv#1neyv;>0|
zrBfCR%^o~5#bYPA%n`W=4i8B#b-}0_Q;Rn&?RN(g?=DU5xq3FOZ4-Lsq)r{8lD$NN
zlYny(adte?jz`$gO;${!hk{E8*hvv5E$78}^eC4$u2nsq90@Qgl%PaTBe&5Qk~TqMamy
z4Ucw{@dHu;1nNzD*AJW8Uudrdq#$vM7CdpMKXYPm`1Zoujwg0H*w?RVn|B4L%z=72dKs_3CG!b7P4z$G|o7Nanw>R4gcLxHL}MXI6-
zWl809d(X#vXRnS;Fx%K#H|_-`EN{_RoDkB%I|@sN+aBj9?+pnHhO
zLsn+9Hi+br<2;z_crFz881!UE$?}V`7rqac&{|WkF0FtmVRrsem@6N=UYb{`Dy$Uc
z6oNwf>FjO=F9_HR4&dmiJk
zisd0S^owZ|I@z;N0=lFvU)_tdotPY#MgMqjl*(&lz|@*
zldnW=r@b8zx?jx?ZkhEDh7upI&kV^p`+n=ipkq!W9TGCnxy?{>8p*hfJENA2O88z3
z!i_}5sgOOHjwXby5#a)NBhmmgJ_OE>zySxL2bc)ZIizF=O$;>Q{Eb-XhEW8-ldloA
zq-xGEn0^Fekj3gHkq7APAvQmYMI2>>182mqId^n|7P8WAu%RMs4UgBXGr))^q!
zhz7j{rf0)G6p9eQl44{=lEF&S8E2i&5t(GZwRuV-OL7^*GGW#h890!~3AHrJBAp95
zFUGt!Ttl2soinOpY6A?)008i
zN@0{siSy|J2Ejo)HEU3b^}
zYtu0v#YJxP(NOc9ExTSzh)YdL`6F6Y4;B#>GW;yOlZ+kHX?rEyeudD-pjz?hVU6mC
zP3TBvHd4<`%x3s*aw%$e{tMW^ArPbQvNa@#nysyh|Grk@uX2-G{o7Vr^^>k}7jqO=m&5y}Zs@(cr2^xNDIS49QkeZ?9^AqjwlXf^yfROr^EiCpuPa
z%q!D^gua;%3_W~a@Xh};#B8Si&u|T7{2^jzPfh+`&^&O=?yANVTi8>NGM3he-pu74
z%aavXsw?XgBE_CBd_J0NuSdXf1GttfydkNI13upjX;<|@h~_W7H3CetY~yM5@Eq&x>3+Y+6h=Mh3F#U{WO{x
ziSBMfm{BMz2JOTlV{BrAM;zDicARb3`nL^1$$l*$gp6CAZSi^HGP3P?z9S5(4_LT9_0uMw-Q5DyAD*?Ia>H3f_=P&@W}3
z4p`q^nS6g^=3?A4ZBR`c)IJ)~3I`q%-iFQIXyqbe9e8w-w$Wyz9Zz!-=r$bHge1(HY+=4ErP2ksq99is5lDL_%4c)SHXNmwBWbU0l;;$h
z>rj&_eV8ls^Z9lhdC}syFf?qY($A&`m;C;aQh7F$IhjaZADbL8bPO9iZ_h0}Tw5D#
zYqK$!lRZ62b+ZwPYJ=lgb4wc-&y`%Vl{PRDr1i~<+?cg>V
z4W#UYYbjaw9i(P3IOrZ0L||~btkwal-pEt_I7jt*E&x#vEPEr@kXvHNEAA<;u~gQz
z=a;%`QQkVVyBe7!vNCjj7)hMqN~ihqK^iZDCVT5KP<}X`BXEwIrWl?UKoMN9(bu8V
zOkppH^n*QTpR!lGl$*-^fuO
z@KFZY{CHuU&TT8J4U<@YBEwLN5at$H@Dv-4Y^cco{r{w{t+Ng(1v$+x0oMaP1iEGG
z;HGzNMGY`cd_2D!fq@AGZ{~#js
z-~ATW_M|wr1hS*l#nsgs@QR~U+?o>>-SE!O3nnWCw=C1
zYg>Q;$G=81x*n<}vUl4Qf*T%2=EID9cvkVy3OfoaT8|Z*3afk#xG09|s6zM~aPBHZuo3I3Y6LwD
zHNrtMd$@MhAweE(mG$=OMssCdcSUVyX;mA%@T$hH^16JXL+n{tfEOtVB@1i@B^
zay7xxo)|z9<2ZVt0q3Y{>MpJUN_G|3beGk(7ghiSp$;$ONMApG0LSBp@|YdDI}La+uZ7*(P^(|zYik>xjUXG$t{rN
z6e#nH!LL1dDsYYWW{%+CyV$%pkF$P!1P)OaB>v#;$Sn0>IKVM`E)qC+BnM~+iJJ?=
z%!ct?ZuX*0-nP@DDX(Ju?HlaZk3zl%j8gu;KLV1nUq7y^YETqa@Q!4^yeP~m5ablF
z-#B)->HJk&MlLm@Fz`amNSpz_;{pG_q{
z+ns$ellfqC?%nOV>jQx(7iYm#?)iFN&W|p1>cVV_oq)FCP*bg%OVRL#*)*i!Js9cR
zuo&Z9Vw8hl?$P|>(pE;vOo?gNlfI>PwTI9!)grzWajtc>Z1l7a%efA8-K<{K$7d}V
zbRR!_2FYtidY#DCq%_B7_}QcMi;IjK*4)S7$+X(A!4t@Lv8|QR3k|U
zXkASeZZaYzW;~rvFLh}bP1*g+k=U@_Leb?BF1C+8Psk}V>hPWjB5k|40D-N
zM%_ujd)MO_*Q!HoMu^RHl8Id?q>X^LV6ok3N_w_0u^MT3xVlCV6=6Ot&ONoJbA(GU-pL|EUquueJf7?RHr4#lg8y*8(qLJskQNC
z4_CL7+SX1I`QhTyqQ%~VKrZ#hPK}R*n$-(lPgE>zt!-#7ud?7tRwAXfzNrm?9yPSJ
zHzNCZVu+Ad6#i@|mK4jNf^6>DXnfP*nK7D%n)Mse#J~LGKmN-f|8ddmh>#eNI!)zu
z+ME&%P!CWDdHLXi$>D_*0Ae;fLu5Wyq&rsBQCQhiTGv@n>8e4wYti0%Y)?t8wYM!
zvQ{>@>#^p_#1LQi?UrvdAzMp()lJoVV_vbyX!O32zE
zum_iGva$NjTtHz~8-H}{FkEL(KElAG`7la#tU!6JKyj?VSXQekt~4|v{36j#C}biK
z_o8tRjUhdj4;m;unv=cf5t8-m$CNom!XF>c0`W+WG`A>wsT%5NF6ZDJVwQkMaufxn
z-3aW1so4Q#GyQK~Ke(2iqlP0^_UcUz&{mOO%sV)1$@uXbUK-O)WzhbQAE}EgHf?U<
zv3%y=zM-qARTgH0HY`n3RxQgbQ5OF1_=hYjx*@`%*|Dh3`kL;h`p)`VHwkybYr8$v
z8{<)yx^y3H&nF6YvQNzOQgEBLu09DD)WeEt
zIv)#oDTHnWs3;=FW_j=g3#4*Hy$#iHCSW@kwl0~J8&=)bgr}pn#DS^XbDE~Lk{AoW
z(W3_}Mj5yvF?&oQx;QilYxpmJ{Nr>-j~9{z1PgTbhMNF3d(X|GCqg+JP<}Mti^M{K
zUipxiUNUWzEATfWqi9?LPY$CX$r3V5S}z$pD;MrtyGOa4K^9|-$Da@g#s%C3xny20
zoo`kQ^O;i;E=+UA+?IU`)wUT0f|Nu3t)=Ov;!iFiRK1B`-NLU&dy=_OENSYiT4P9EGF6wKc1
zLky$f*iQ{Kf?JRyz(IH+@G1~EsK9{*2QY*X?jUYs$tgO=hrxL<*nT$aqSra2mZrJ%
z`4;(|R5;0@_VJk`a>0Ozy4Ov0@X~#81IOOGS{jR%fOe^`x
z>5VfXmje&O5jHFWKDZuaqnAuf@VRa(;nP!FXCj`HLHn}VIG~VNaOiGyQzx?C$D#x|
zln|Rbs#Wbr1CXO*0!~IH3vpNu648psnz3k@7`jkny5=pH^>9o3OYOC^N_)9~@cPi$
zpw1XqH^+6_4idQoo4pfQTG_DOn|`)?cA&MpSE`>d*i-7xn+rQnPF*~kndm?R@=)5U
z`j+yVAWw8E*|+L&MfjqtgCkedLnngaTVoT-it1ju%1&WScXT^xOe=|MsB6-d*P2lT
z2Z`QNS}8q9f;Jp+MAf3qEnaZ@V4VPqNtV!B)nu)1ir{GG@`kqja${bZ{@{!uKnJj>
z%PDCutTg16!SIg4DqCffsi@js*>u1}6rd0)h$Q*I4Ut6X0cZ5qVLY{HTUA2{MF=AB
zw%SH>ReeucZ4gDURX2GWFxINZFqR6W>ng1Q8U|4$U}&fjvmkBmBeD7@oHU(3!Vzb$
zCn5=!iUvn5%H4>A^=vPw=q#?b*C0EKsvx`@^2_ykrP`cgeO?*x5xVN*MTa*4Nq>AC
z0yQWk!0|uti#!~d)k&D(NM3VMMfTTrODeliSQmo{6ob5+y;^;E8u1t)FPo`3KYFvX
zwn<-E$9nw;=p^@zV^CAAZ5|Sh^W!7@13m)I_(yZ-fBQQ9Z{Oq|InF(j#VGs7N5C$D
zk|33KG$AFF@($+ZzImMU#xc&D$3Yc2KRymR3DdBDd{h8H&oAX4$>Ty8hYbE^?%}5M
zS8cGLJewUl8?t|M<@EP=EM*dAnUS5r+lvfe>NoC`ZYTAjSv=R4&!
z-5QMaNjM;t-Axd_Km%C`9=E-&CdOsnO!wUx8tiUrw4k#m9L?w^8y4xK;%(UaD3>_b
zp&V-wj%oP&A?voiZCJ^7Vrw_et*{TrSlEeXfuG!z66E>dY?ak36cm7
zm1MAeXq*cHZioX+fKq`&fl>i0frfrGE=6aKiNpacW=bLfB^>2)rzN6Ekzh^RJSP`T
zNjRsvTbDGVekOidBU{s{Mg@!u4%5D+W3SUNo&AzB;e^j{vEQ*8Fg-uB`n%6wefRkX
z|NMt<{`7DE_~(E7mp}jefB*Bp{qvvy{a^n4KmQ53|MQ>!@P}W2@o#_p?e|}N_?wSj
z++3Pi%l_fLVY|~XB^FHx_zP0;2#Yz$VJ#@+r#jkaM8bKgHdn-bTzJ{SRMk7*FY?vf)i|B2W=BdA-e;
z;d4eMf;$82uGp5c(
z!E~eQtXPzXL=H0Ob{y7;CtT@GW@Pe(j!r8M3qA-YXvQKfIFyZm8BmD#{O+VgFx94g
zxHvJ_)9#`X%mnnXM(H5qIuUhlD%nG$_siv1`ugTgCL4hO6In=yCv&M{;C21s!!w&7~DEDtqGMSRVUFZ^9^;hJ7@L
z{brVckgwUJ(UI&moa4DL7Q!;~Z{Os-0Y+H>aOA$8!+Rr-_eO5^hlO&B
zB{_u2;v!Kv6O!h)e4+7cUgakvhVlX`jG(_^ACUjS0)2K#1q!NVam;{&5
z%O_6jB!2>nYcTaQAYje9Nj^Xp`SadG`a|TW0-9m-)Z{<3GZ>JzQ9r
zR%#Md7F71z%IIuN21ASzX&{V;@flJx^gHU2y;SRNHfTjA`WzC
z$%4Hr`3$`r!1*785KzPU2K5tN-
zaG4@3d>69Jj4cbWny#fo@F`o74Gs)?p}jN0VrS%X8wO)WBCTk2_H)ERKt_Q8dg-)5
zwYmp`c2US14vUkF??yKo>nrR;Os|+bqEU{tsHWTXX{Dr3Ch10Fde9gP4mYmXPa2FS
zByyysd0hWr{GHKjBktg}^%K{ZHa@#{>&f=^lGlHAY;rps&luXz4-W5VhE61tC;R#>
z40cN$LRMPMD=1^-6u4Nt!4|!t3Dtoi3QHVrDw2Ds>?lKMtf*5JmdOiC
z#rZ|rs@e!!V5miO<0;SAHri1bWod<^ph#0*r7S9y=H&ZG^cUwYz}kFp|DhX6u+^d<
z7lQ)=_zrCmk}_b?06Laa3O%jIi(!I}g37ksvYygfu)Gi&ut&;^vKq`Rp=yCRuENY>8kXU&^G3Up}0E-+THJljhm2q8F%HPN_eT2X+Vn9l%TFUirVg{1CtPl0H9!z$Mxh)8
zv>DgXT36&_U^eX?t3Af9rn*U8^L%?NSYbvc9BGzJ8dS3#x{kVP8y?fyP;)lq`r^#m
zg^2B)rJ-#{>j_u;T2IS`h~x2C|9;SMJ000|wht>fDL&nWX|f~h-IyjH7CEJFf%yDC
z{^_44^!g~78mH1+2&4yvb~mA*zzt`W&CUh{^h3-9I7SGReg+$oX@S%U|M^dV;QtOl{PUmw
zZzu%F{R!asr~m%^$*q;e(U0DL{JZZy|KmUW=HLGf==m>y{`3F*^Pm6yaLWIs{pTY7
z^w0nB!L^H*(tYQH{%es?l0g|{P^N^uRgHYxpn(X#s%ZgX?5EOV`0N#-m1a#JC422V
zj?aGSu#ZafH=)94e1^e=JqR56@SNj;LLQ!7#SRPjb81;1n>?u!u6MW2>J`&1k^mJs
zsS#ZWI?i~k6V1|I9(_Q}?rJQ9L(!~Jd_HcylyIDIb=(?=teDy^MMHCjRx1)|ZbUk;
z#2yqn!eyThcm@@cTbbm|Owx>Mau5hE3Z(~)Yi~e6UcNch|Mu$KL~HY^6~qwJFPBcV
z>e?IYqkL{sB1%ccW4e}@fCoJR7Q;iMOd0>H-)BrTw=R04!|k?Hy@SinfQu{QmsEDs
zSxdg)+5SN*l^JC54Nb_&?w%o|F(i@B+8q~0#l(oD*f}wyR
zdYiC*1TKOhg;B&lGBb>!fGQ5NB%THw1mrQk90GMejps!W?A1+SG$}@)2e6bFlRw?j
zb7f-Y<+<}8-nskDdmsGfqmO_2;fKHe^pkHt{p1(#yz}JrsYhFzcjx9-t+otb3W2&8
zOHIHA0msY+EHKgEh=(3nrmd>cQeJN^tAmvR6q?IwUA0JKZi%I$9&$R!rm3XHSXkMd
zz5g*+^7?T(NZH>U0X`mL@jpO$RPtl!9#cT{K9D3#y17-OI}dI
zf_(k@Q9i`#qghqt962t^$rI(|16#AR11_`QvB{II#U)VJ0to85&RYQ)%E1E+TG1r;M;E8#a@lNf^^fdd2i0n-CY$O-mi2-}^WUp7?J&mX!3foVmry2Aasj!!Vi{eq^Le7Fha-ySkLd=;_O13+VFGe%l
zJ%(kA{?)my|M}0q&x+v>7|Y5YsN%u<0SyKLCI9u$fBvU0K6|;dGJNjD^my7kHy)cF
ziB1m3<|q5NH>O^_ynn#Q!}gy%JY3ihy$1~d`){AzyLWA3Xr)uTpq5Qb`J+5WhCvLv$GGov%;{ALHtmGHXR1X#BolWvRE?>{mt&p?oA7jc;K@|Ko7k9^
zaApijGqS>tt+itst!QL`L5+*JNvQx5^iogzOnXbeOaO7)hQ&cHwiCzzN07&EOrw*G
zi3!;uEJMkCVYhg+AYBaTxOy8VY
z9@KR%IK5+LYr5Nfd3IsO8@ji$HQ8yM>9ztHcOp?$RZUnRQCBtCX{_^o1Ct%5HY7eS
zZ60s$iL12RiPZU#2?vckrfv5zx$R9TReAM=^vFBAr@PQZ2Zm&*s8%(6Bq4$%M$sg9
z9SROyDI#NxBOc>Oz!u{;Y7|3`W9fkg5I_X%=A{)?}E_KUAR
z|K`ijzy17YzxeQjm*@7^-QF;so)u3d(N^1(BC|jb!41I^hnRvGmJ&h}p?po*tZl17
zLb&cOtLrSO$tLS#*>7ztj^t%;1%D$~_WD7%e*O5NMM7mSWFI8%>^aAS-`Z&}uQL=?
zDUTP4A!S3Jg_NB=ftbDD``~0^_L4O3NVdy;{TSq8&KpM$gZ5$f2TC6D?#&$f-@FbJ
z?*>A1rtTnv-BH~jIhN1-KYyI1$6@E?aonvzQXkB-W7
ziVioOziKl#qB`qpx*Ds^hvr
z6!XwAo7t~G^u&dhZuWy2w?*zA2jJxz5Gw-W-|q)vW58fBb#oKuh>nnK46O}F581b`muN~DtndI(SZ7o
zdlm5qx|ID!9dx}2w677JAkg4Aondf>+1!3AHHbncNVqr|H^`j0qt_IH2y?!oWn7bouBy7bn|hfki||HnW6Lw0e0%98T%
z$v(JyXW8BrpDDNzP_zO|*7!-TRS5gCcZPbR}h
zU~X!%qtT|inx3Y58w%0OV-CuhHwObBY))>w+fRlpQ2}+fQyt1kVPvGp}=%O!tV}AMhiM^;=
zlh9~EB;Pr8?(y!)jbz_aDBMaUrCJSFCZ-~CwWy@3hs@ZEB%3Sh<%Jax01aie*?$5k
zuF#Za{~MsWsN#qJZ^0KY0JfsZ*04FOa2O
zq^M`}LvXjCbHJ^)@+937)sWg)&*C+MH)rx)Nz_hazMm$Z6l9|d9v#+VEQKrj@OfW8wLX-FcA`uW{P}^}hYNv)E
zfk-kDag)dcE)8J-&1mq^rihqky=j%xQ>WA@{@e4#32CiLy(N`q4v%%yIeAeD2(OVb
zhVU3e81R&6<_?bm9M{QI=ID4+)W4zyW+*Rvm8Eb~m7^z9<--|14y#Ei>opr8-=dN1
zXb9|R@Lijqe0A+4P_jSA&}r1xDP(ZnJ6OzsfL|pP*30D`27Q%4(4bHT1;U_!-yj!v
zn{**Q9>A~$iKJDjXpjgR<=j>^Z?eSLB*)gf%T|@ASCPT06dJZsg+WT{qr1{lPmIZ@hWw
z%H@;$_bnbcxMO6r_r#eK=y=3|2|oUK=k=?bgMsOSoQW*m`m!QWk;j{A;hZ~!++LXk
z%=L)c0C)XfiMkmRwBl&wHQWGziKJ|VOov#p!Rnka=fQU}V#t~+vw&gD@2oY)C$DaJYfxAQY(Yf170pZQC@apXrL$C?B^pB9TdY)TidMFf=vc)uC$d67w0r;Bwc1*i%wG|
z5)I_%x9GG!9=B2`0*v(nn0~2lkxtRs^QY41805R>cDei=fdIqnKhS$;YR`9bNVH;oCEmhaDxJ`U<
zBQYc%3PG%ONi?loX&r-WPo}oy6kU1Y#5a$=`s(4MCtp7L{>kI-zj^%ln=hX{`SQu*
zN8fz)=-bB+zxncuuOB@?(EJMV5#WflB#`m`{V(p{dvO2m{d=F?yZ71MySMJ#{p8lC
zAAIt`&08PbymRx$d*?4sRXC~`SdfOnTLT83#KI!_hwF$-w8A~KH{)?y^&Apt?8907vQC6w6|7vmKsq=NezYWLQVV^_Vm
zNiMj#b@TPj8;xu{hwSXFLbW6vGQ(~RaD*4m24^D}2HMXSs5
z$MTKaL(Yw!^2fJ;T>scRIM6HzX-uJD)qKSH8Y#^k_q9lh^wB>o5M}$3GGB?dktSO2&V;
zJu3l-{psq(!!x5zo7ePw_|A)e`{TWD9=&(}*7Y+-cf9lZi(lNk`S-tm`RKvByEads
zJ+kBdw=VtZcc1_5&yWA~`>+1+!5Apq|68VRLIac$-wzCKYxnCH*GtI(zxnO5bdGX_HhkkeRvJ?`xJxdkp%OrA3`u
zb*oBMBal?{B-H{*gH%z)6IAg<0iF<|QUJnG3^DHyG$>VW4&G(Xp7;5iHJbjsd?;B6
z1V9x|S<5|K)RP2fKb@MF
zl2MXQ_ll$g4(F9U`=+aE7HS%5RJtR>~L0g5W98VI}n@j_F2+9!u;WX{q5IZfAjU@ub+Gc@#OJWkH32KvPpWM0i$!DK@bnNhfQ^yX^teWtjT>?sF;SOTT}=Z;Df6Y!-O04_m}JyV
zhZs-@Gz9kL{yaQ}1SN9Zpcy0LN@9|HG|UEf1zZy1O7r7V^Apqak~2!EEMsg^l}zd3
z2@BAgi0L5fNJ$75m~4PHM#XBwBK2XBnLx?NSm35^Sva9Ckp@J#1k)XrV1$5Y0hC0I
zq;Xkfqg3snvOq|dr%*jCo(~slmquup!J)vg|0`Nx8kB{F$tZ6U{ErM*SY-{h@WS(5E#rqqepV|k`tgW}A_c{r1ocJJy|
zDSMDwRCFt~Jt}=8PXchPVe=qu6J=e>}b8v-?q_Nd}_G!_Uo5Otwsv9|MZXF{q)lh|M$mrAzrSj-f9JNjEeor5
zEzX@evH!1s0U`V&ved+3pRxDx-MiD3l>-K2uUIjrHw~#Zy;9jKvw1cz2Q2pblG2%+
z0&?UvF&l*(ZvPD+nF%ry0|!x89*7oV1`5zCEh6!BLH^qElF?jqr$*7EN3yX+F74DP
zM{>-Qg}I}-nKeSZR>Z9qa)W$ftw>QTQicSwTCu!ZC=K#NkcLDks)Uk|SO#gOK;q*H
z1AH+ASZT<6If5FA5}t+Yq&GWfe^+OBw!SY<2Z$Uh$~@fL+?AybN%=lLdsB^fq0(L@
z##h?@*|_QcqLK~Obrp1MrNwn+W_>`UTH_79y|`z%)K-u|^GM_tvEu03`AeG@Tg`bk
z4*%XumtWp@U|n-Zoz6UFadj0|6tIP3t|}`_D*QHewOt|+pb49>J5R7Cqv^^#j;22D2
zw_xHSxv>if$dk@w7p*oIELz=b^Ge%!()Go*trfmWQ+~hPu&K-Rkxvn
zLb$}e9FCt0T;{gvjPTp=aRmXM$iZOPY1AqKze%H*^E$iChLPg@F0*lCFaSCc3Y~0v
zcb0KJ;Hg(iCoLs=nwu6wRStT_NKtlQmflHA4dB!OFJmBEQzPVf8Pqvj+4i7kG}pM<
zXCKIfpRT-3DFhb}rvX-aGC#kO5BEF)nrsF!QCPzU%_t-@ZDK`>P*#r%z()^i4Lu4a
zkg*Gm`BM(5(a^miCD>2AjnC~A@h|kZU)i|w@4rI>3V#OT{}m>Z&C}%ex1WCc6H$%$
zx1av;7r-J>0?+;pcKhk4zx?B;KmPc)?_Yc6%+^h-cWjaWr&TqMZl*^CPel@_+ry%R6?CnDbU==T4c-o64;hySuhj
zSf)(Ine5#8qOu8t8OS)QHFkjWWdjo>4Impi;x?hOi7SOn9XWEGBdo)PAgfzNvU;wt
zn#--_^MW|LPRMIl$+uPcx^>DubwT*T*Hjemto3j3J8Q(kYN4c7q-v0=tA*l99(S^|
zq)np>aCvQd!%$%%NX4K?N;1(8DugdW%`XCY2pI{KKmaQPd9n)3GfP2y1HZUEw@_76tJc+N4W%@!0u$}%?q65iG*s?b>#v!z
zx!a6cyX!lGGL4;_|AjW#Ew$?B`{eEj0Y<8$lF
zc)|&%Z%b2GgWS+>&Tlc8hRZCKa1SwL4VBv#>s$6Tcf2;c@baoP4?p}E&R|z(FSuav
zp)DNIu*x*9%juWtU2*B|_zX`1#TB0ph;+uL`;)1`bY_ss4$-g>gHuiCG_d(~bZ#RH
z4MeE}yGrALC<6&uNyS`T(I+pz@*S#0{Px?gzx(dnZ@&HRDH-80knz!@FFttpo%-rP
zUw7-ws?oWbsgK^f@%imr@85j8xxQv@W)(dA?Bfsa-1=zK`n8ol=f!iUjvd+Wc35_7
z-T3~^x88i?)jd16?b^C|)7+XJ3v*)wJ?GCHf8*GRPGfF0l^desV4^E2V6pK!wh+#(
zn!y84-7VFE(FR-XNu>J72AQZtz+XPuF#WTwCWGW7>fRU;R~nmK7?n^Kp9bQwBr!cJ
znbKBb-O$yyYk0K9lvNm?Vk9dBqtVP1s7^3E7A$sgLfTYGMPXdB2@xsbbi&%
zgJVuM=44^5dVNohdD>pK#$&UyD1CXEdpqjpD=Pv*W>CU)uqkd1!^>k&Sxb6zOmzzJ
z<=IsuB?S%^ty0Ks(W$*S9^mo)7-wHo!yD^X*9fpp0sG3btTqjAFjuuPP!7s*gTJg(
zC)`?PJKPpJGtm0_n(;%e)gN6!ga2OMy{kovh7S|Ja5j%YTv6VHQP;1Kg3g-B%^p(AN3^nTDHrtVA0MC@QvT~UU>XDv?eC~J4;eoJ
zH~;#F-+%qatLJuaU$=MX!j7%8t5^1|T|ES`b>sB(WbZd$fBEzP|D)~qUw*Z%xoxJX
zWHv9aS1uh;%7OBIGRdG4q@r+0rS1}mT5;j(tb#t7rbDQJA7B&k5f=j%Tln&NOa#%0
z2GN3)R@AciH7tHD&Koir2TjJ+WhJc&aLw#CrKCr%Y7p~6d{(nUP%Xe~1b|LnqeQaS
zS$?3i=Gyv+cNSN#sxWV^wT+bM`|?%rM-K>j0Rb>k+^Eu3OXPmA+k6q+G6_CPAOMjB
zIw1pyM3f{R!b^lTGHDwcL8uLgxED9BefnvCVSDcQ?Ao1u{l`~MU)r>JN8jMIzosj<
zbX#Nltfy*yb;JJt(Meb3NSWQm5l+|xheoGQ&Mq|O74I1w>nJEM#e{7|mQT;W{KnoR
zXV)z*wDz3cwC&R3jzi;9Zyh>PDOOYqT#DsH3!=wDILr
znFUjZ{P{e~lsbD{o7pLn4#~AWQeA*2edE}v9{`Kre)Ije-~RCJci#XK5gp+llzoiA
zc<=1-BSD{Ybf9zJ&dv29Uq^HOYgaFS{Nc^1u_2$!_U5%KpMCuP?T_ETeEv+8*STl=
zmXF?h8vt5dVD9Z|*}i3A9)5xS-QBH?t490B2fANAf99h%uD!f{dnKD!!{pU4c)-Md
zg`robg8fL>C`O!CV(d
zCsrg=YPgbBB^71Kl$_XVccfBM>^_P?519EdiH$kdRBl
zs&J7l{a-QH&b;4$a(EO3f(zrgIjknFxJf7I$yFWfY1&#J=*=~34EpL6@GRTMvYjb0dPVD|{-^L4*UDr2FH^|xj*-9^#
z(xw&k7^Qx88bl>Vh3LvMz&U_moGmWxl56_Zrg~fqK>`s{h&ql4(pp?p2M7?zI;4tP
zHr@cgf1S2pDV;JKhBeAH1=-U%rcr}@O@VHcGy9cY>;Li7vo1CN1smwRpO9Mo%TGW3
z;UE9_!~J_7?A^2F>#rX@eHsZ;5R!lW5#q-`|Kq2>{OOP1U4QfHci)0&MKbY!yb;g5
zclDJH&@?J#k3!NVm#oUloYLtA#F8$d2*@}GiXKfc4n{k#N2-Bq8#qXk5ts-m%5XqG
zN}G7H>Accac||>H?O1l!X0K-;6STQ&)>1rKnA0fX_Zc+{E=!A2Mog5cJJ#LSC=)d)
z6_s2rI0i4y={B2c72>Up!Tmi=+Zz2tMOi>MFPB#-K!Op-=*9VMdJ|*@^NS|RES;H|
zL9qyIHP8?wB=E74F9SqE#?KRbaoAr7B=rl$#Hanm?YZ8s!08?0;ddwxzSE{KdWdUpamD%HBg$q52c+HlEtJI8j~iQtH+<
zb@bRhRi?bt>o%XB-{O&LEo|P#hV~7iMi-sqV{+^HvKF!0kboITg0Gy)R?>8wB+1Dqz=Kw*zdb0%bXlRzi3z@LI~ZsSTI9gyqS7g|>u^9EJM
z9;v#OD;ZIn`Xrh`rJGBllO1m`tbH=AAR`2jrVR|2gwOu`_m8K`|OkVfuSFN`0htH-@f(gE1O%}D%pIv
zK1jg`Y7r<8X_r(B4{I6RW?Tenw-FP9r?$nVl|?533P}@9>cnTVk)$M)02WJ$rkH}L
zgjGe>YFzB4V(ThAmJ|w_pbQiuplw-%X2}Y$)kO)ZV5@11L(x?DD8@f
z3L0y&#Ja}jDNm(BIRq42ScCxKNwn>t0o3HB^Q&(4
zD#^Nlw+5x`6e|3&&pFGTWJ@94OG&$~hiZijSGpp%<)j#0ho^mV{-12sSRZZRAs>?@S
z=<)cjY}qzYRPMqATdNz&lQY~j%t6Ddc;ej+t<7q^i-}ip#n<*7g13MB#OY3vx`Byi
z0}H0mD-&sfBzk2kvmOwc&H}**X1R$iS}3wDT0PU|q6vNOpiDQR&6+gkbW2su$bcJ1
zG^Qz2UI$m&EzvX>b8ftH^*dnV*Wdi`-S@D4_rte8{O+6YzyId@??57Co~@b>+?x9;D*b^Fs#KKtnXyEorCF+bNRQ+v`F
ztwIHARstam_Bn+PqPP*4)MLUBmF-WZ1u1M0#T95&b($qMr6?kv91;T@d`3wKC`5`f
zET$|r*_M>yp|T+=8F&pQGB1lNO{R3|%(+nsrWH}37SX^y)H?^|K^PXqC2y;$YnEvX
z;!{xjGBNH20P1D&aw8L(WEu~XYt3Mok(Gv*ph`)iotmh81ed)c#;`o9Je{5$6;JwW
zV>nmqLtR-mDZxOV*}?W
zhus)8z-QDe1wIb7B0b)VrBz884m`ElAh|R*@%rX90RgMitX}Y2ecbd`qqthk@-QqfQL;;xw
zAc9afk(Jvfmh~!>ZF~VZ%?_cUQ!MC~2`A0k)p^G0Y~6@fGM=f};3~MeXXD@g_$?e3
zi1lAbM%dt3fBW{yoeQV;?pmDQG(Y*5KYa^2@#&NQ6Wgn&&JGk6jhNJ{3o?(?1r7u~
z3#EB`0`@a)^}Bt}DYJ2twR|Qow?`)HmP-4Ts!oZlTaG3u13otMWGw>pE!ARtqDwr#
zTdD3+DC=-ek4m}TZe3SVw!vZDR~H(}F%B1)2l7k{URxE;@UdxiBEf(;b2L9^OQrM9
zkzI=of&Jah@9bK1av0SzF;EZuK}aHL(rDU^Mn8`StVCCc5U_~XE0t?Kp5db6t#vhn
z1-Yk3hx_w#8&t}ArD|g^)SZ=GE0cGa%++$G3+FxkoWHO=clFq@4_|tz-|d}i?-=%1
z4!OK;g?iV(@b>Z=!4-kt^avH7y!jT$#P7cQ;df~J{)ZpFgZMpU
zKsJ5@4*Ln&JWce@x&PId559c#`NJ>nJ^bP>*?aN9=l4Fpdwc!dOsLYmV{zf?OXt^4
zPtLDdb?f8z?%%uh`Tg4uKEFfkkM_KO@6P>uw?Dsq>+?IGfug+k-aD`C+}UHwZWXJV
z`SNywqMC-+GWi`sB?KBl$l%q`xgjdYn?iRaWS~hTiJ8F3zK#DK79mIp3CaW99gVxhNzal?2rIIIc
z&@nfQYmSK3E?J=ui$LREfP+gS9Tcois4PV@*Amr>ARd=T>Xt=nmq+NrBDKrH!CC8;
zg~Oq&R0haK-SPy#r#HvkVbXiK9QZwKsPcDa>iY9d{dxLUz0A$d
z@L*IgPHQvB_IK8uo9sQ%QS_0Y
zI^V9AP@7sB;&ZFGxR1s3v*=ASe!T>1Q*j5f6eB;cD%T(o4V%pEGG#q3Y~rKl7u28C)t66APj;?d)pzTow}{r5|L5;Oyb>jkAAU6vs2NcjOC%g1HFpJv`;-P>F}l%u~sKRai)
zcInmQ#d&Tv#fLLI9D1ux5ft-Ait{1%ceGAf%lmS2dd%kD?3^H>B|SJ$QUD6k1wuYM
zbJ}ic)F^@y!9uX|{Oai{k#HbCugh$5V9aWzY}{IgKIkuR&n+}}x`nEaoYE6hv#oi>
zE4_hLq2S{1z_G;*myaAgux|eR<{bfD_Ede_%}ZCxl^VA~>y#@$IC1Kw&6|TpKZsUfQoZPIq#7dsHC^;Q6IZ3IO3`S{uYEe{Do7&i>GZiPMZK|x<)7)N?lHRS$
z{OpZ4;q6aM&G^%pjVyjWgX>MA*yGcji4->)6P@8pq5v`bC7KRg(#4Z?a-~zc>>;@x
zGQ$c3)eZU_GLom)S9NII`)9$fb{4U#-
zm(D$Wa0jsX#e=&#26-}>m`2k&ob>+~=p{#;905U@trILs|DbFigx
zd(hvml6L82J3_v5(<|WwzWC(RPPL{%EN&2qfsA0N2~W*~G{nTKSzO3N25faL1PgEE
z@Y)5UPO+#7$HokrA+;RvF_UMWE6&{)@*e4F{KLJEfH(wqkZMH#{!ect#XkPz`t-`K
zwX1t4hg-gUc#O#8@GpI8TsSJZk-P(epm1c9FOx7op_ey08
z#ijiUB@nZP%O6&o#!b03EH2sWn;a5T!{RlfwZMd}Ldj%S*0|ZcGCy~|qHJYRZoLp|
zR|p|(QH#4x`c8vxI6vna=n=bRWm(~3$hV`R3QRzYPI7FhV^2%%YFpXS!QOq{tqvB=
z&*%7f95BvgwQ_%6-Ws=iwbS|Gp+hxtxs%QAGMhWiX1`F_q|>!$W)2k>2c=TT2W8?$
zojM@qPgIoN*ttl4)?eD5yZ7FEpIv_wEjhiov!~24;;Ec(?X)X3cAatS)bv~DFMj;$
zYahONao5P?h3&g{j!txxT23#_A6_-Jv%l}$++0AZbW0>{dAa)shkA>O3zO5!lPNwL
zhZyXUVN0gjQt7UAraPSlKRFMJ=jRHYbaowI`pW);@b<@M=0Y^QGKJ<%%m5m?6Cfz=
zL`ooyZjVa|P?&WLZW9|#d^D)gkL$7qe558pu`L=qVYDE$7ruL(Xrh9LR)bsxbfBVgr
z%q)9SMjgh7i=&ps3s4wv=d9<5fQ;T$hA)i?tn_EFD>K;MWE$KCN+J_T8bSaEAy3kf
z)Qs@(87uSA(uRqa*o-Q!G$$r0Cn`QKJT5ytR<|U~nno{(OEHBr(%!Si^JPdvY!^Qcv3fWj`@y@2&Gvod3
znQ9lCW@k_w45|;uTr5VLN%ro(jjKJytvYE?h&dQ(equSm8VNpT$zA0wYc|Rks$64b
zc{dL4eE-O<29=;mBi>l!>oBO?3|atVb!wC$E<1>0K@L{U#aFuBZ~}L3+~`oL>qVjv
zhYK7eAV{K+2LUCh!I~p%5{R3H;ufJ~NNXC>7{`pJ5rbiy%QdXkuFlC`oturu1XAerX
zT|(Ko-qWjz(1OT
z04pbSS!3$V0imjsC#z%fT@=ptk;(6$dr_ygPue*m@k7_dmH
z$Zx-W{LR;20vsW}e)8z?R}Vl!e)0M3^Jh;?PmS)`xd>|UlaJoLfA2HWM*|tZdieQQ
zU)=xl!M(>{+<$cc{ug)e-uvv+2cLd)dh@1o3LRucC6(n(r=!{^9Ch`oV}YQMO&D@(
zS%M(=YZh8Hp&}-wC@e0Y;2`Sey&{@yZy`~L_((Kcqvy@Ml^PWds3;>H(v{BLn`Bvqr<8(MW0|z>&xU+E8C^qApSoMms8A6BaG}x978B
z6NU?mJs55Piwy)^fgCi^nK2?ODz=I%_Of_+u}R>sfr+RUd&R$EPH&KSojIm`1DzEN
ziVF?+6M&%xnc(GOPK@d2!Owv1V5B?Q>65mCVp0?S7UE+ASJb1_Rnak0JT~&gZ6bNU+Bl#wjv6x?
zc~FA42>EMD@)zB<*QdtU`yDSI-ibaKq83T6|JAoYe*cF}ZT%Bj`IE-1abj}DZi&1{
zqUaP#yTx*H#p-5U*eBNl2U`USxKEHHg2*6;mc!Qt-w)hHdR6*Pxw=cG>oa6FOO*{G
zS)Va;)@q$DD_dnLuaim^gP~5nv05aq6morhwx5p$1iUVD=16g|gT=BlnUz9erBEu>?td5q#vW{~5pgZu^;bYqdhW&ce
z_TB-nRMBqEnRGhWHP(K3=G4ZHj$xmFT}S8Pxph-5Esc34Md?_68Z(c^bnr#hBIQD$
z=942Q21~8=8vT`-bw@h-f@oPw<-99UCsuapvtHV~72f`%Yp;heVJ(winaZr8aH>*S
zl_`u+Dx-@vxdp5#~|f9K~Tq~fqtxrPeVN!NjFXKF^|xRWD137kTubG?Mi2Oshr{@YHkXx
zoQ97USgUz*!!j_-h=7m+9MOD>5vZ9ZKRVGv=NOlPWd^MWL6koWAY){_j%=P@7Oq~h
z!niE5PAEs6B_m@^pexa2x8d655kZN(Gb^`RqF7b#uw*b`Pk0G=>HMmjhl@>EORjC4
zYtgHnY^IyTu`}tFLjJ7Fc6ny`
z1LL}Iz8mNJg(3%_kjw4NG&$KUFBflCtD05HIj8+_d&}9O?gP!Coz>nwb(O11^0o(k
zivjoUp#eC7H&36c;c}ZrvKqFqktYo?c~x{A(jWt`qO$>rfJM?)cSu#8QWfbR>xrSn
z;3#_(#9I3T!P=6dHAVS*TWjvVcHtj?{|h1Hp7yQ&Uw0$U?!$N9uQg`xsSNG%1lAUm
zY%Hq)8g8v{qBZ`-aD~fy6zT>pnp2||e*E3}P#
zakE(7uF|&3RdoV!5a-p4#UUQA5=YZ$25`O);{^qhPLsJtCf(QGx}mBHnCQa5HS^%s
zhyry>L_HSCZr(mFZ?vQYP*|%}&U!o(Rx9ukbfSmH3rVG5v4MafCl7RXw(9lZvfUi4
zN+g(Z+QEVxAM7VS>Mw53<)txKR@QDF9O(-LuO2*lX~&+OV^fQRqnCE?U7Q%dd;N_8
zZ&h89<@Ba)Bi`Ulb=}^qZ+Mv`sD6FE`Bugr_C^;i2l+}n8g$bz*@EvIk=T^=9^-q6-GuRSp7}93-N_9<4
zVI!SiN8!{{ISn+tfy!xS@VanmH%~UEG>)q?HxyMI3f50&6%MJ4JrdPQQy$pr5xIU$
zZdjXHG@vw&C^H8Hni`I%&+WVS$;XeMz<*zV56~mJGXfcjKs0<7Bp;tj$Zwx~Pw){r
z>&IV!c>MCK2M-_Jhxig<5seyr^bj@Id?hHd>>TZSm=4(Md=ru87V7o8ydex`{X9s2SJ#C%U61j!W
zs9;jdX{i+~nhnD&Y`mP!EvB~RvITjXfXY*_atuQ`nY~8c=H@0if!puA)1lM^SvY+2
zz(i6r1{vHSlN)05D`}{<5tLC4XhtI7Z%w3F4U5yv7lDhc#qe4Vr-{$&kc&t2O|NcQ
z{ryAKYv<=F7ynn?$W#0A9~X8VZP#ZFD7Ec;ai2^%s8kOsG#z}|m?0Z%a;HeqPRz0c
z(XTduWF~YXYO1QkMb&J64GN^M0gJ8hEJx5HlC??|pc#Ahrm@_D;jCQHj9ofiUzWK|
zqw{mPLB7bt=DOHiA6MYUKo9c$JfV-vCkMK;=}q0{Y@lJSTrp8@sgcP*5>^UDl_H5x
zAoB189v(t85tjx_d)qS~nt$G8{7H*cr=lsR(
zx%Xds`P=*VkL}oTcGs?nrp8x}9RBKq_s?$MUMdhDpP9e7b?4^3;WHbz^?E9+^NPnS
zYgX4ct?BGIG{3NYYI?A$CZ8j?v}xPkk;z_*{pN{N$2Kp1{MwtJT)BRHYR$?rXR}Ck
zu&MLZ&{&Jgu-fW4);qAPu4%g5He+$Db9i1qatzMkwL>rTpqXiewG>VrjRW4fmddH4
zyU2kE>j3I}z{*BEyV
zjop6d-LD=!e)Q&QYH3s=IpYp;)61hEQ%tNFgMdgxK{y0jG^RK@u`DU0Ua1`_s0a$x
zbyBsH#s-y_9Yzdy36C{HCM-4+kQ$lbVGGRBiQs%m?+hr^uZU3oc8PY$ik!%Jdj{(7
zofQ#}rlgIGH-^V*mPP8qV)UpPIxH(Xwls~RTOO`mx*|6=F*7_mB#=31Yz-k5Q6KW~
z82!?JMcee**|9-OUO7fBrqKX@Ru;$2;X9dlNUDUN!J*zBpHOIF0~xtij0b5s3$Nht
zEiA5$$#rsgm11cHleMuny98ja0z
zX@^!B;&Ymnk`RvriV{xXkH7n!pNR$NSP&h)F^YS)3ojd&gMYnsCvto5|&iTQP)4fgWedRB1S^KBoeFF#opKc=gRX22Yw{PC=
zDz*)0W({c!?E*=cL^@&0?2^d)6`C%YvQw&T;fXp#GN55K69+hU%Qf&lkP7i>2Y4b6
z(LyW@1~HLcFp*o>tu-`=q-_dyoj_D45>@m0J`U!`xqasBZln3i?A+G+dawupzMgF0
zAm7X3dqMm2gf2GTqBYdYlx~dcU}7E)FTfXv#B#qt;^B#_WvUi~*~#I1ctST9Lg3|#
z$QURnZq({q3??*1sUZ{YuW+1BQx^GYe`$MeOYhL(*>$JZZQMODG99ex^ZUme8|QlZ
zT5axE4;|k)Fn;yO(R){~4LE&!h9_U#ylwr!;I@gW?c*yC&a68=x8dN_>Y1AQP3>Jl
zW0qZ}+BP({&^L7B!lnMI(8<|#0|jM8@u_WEQ-jv<;_RB<($WUKVYs+-oyXr}$l4sJ
zg){iupa0S>)vV4hZx<+PXm}lsTSMj4Q1LntUvzE*o!fy+TG_%jOw`Gh&YBA+^f_zu
z$_EujFxNv$!-(3{&XczCq=PC`r&!%1(M%b0JB2D|8gtrLbL0F=j~_gG@bJrr577)`
zPaXsHz%Qft_M6AweGBpsO2~MGY8$_P`0bO2Uw`!gO~CWjgU63PM^%asKmQWq3&=cp
zggWa06K~zU_0fY*K791i2WwlK^Hb8C84R$`K^i-NAc$4dxo9l}ju5ce1};M&tEORr
zG^ct3gnGyaXv!mm3qT@-;2%cK={0bv6FBt?lYt#{EMT99FJ*8V3o)r;SEmi^+
zb<3l)WWx)jgyVi1#OP^tc%&jMT=JVGph=sgpq}^zamj{=Xpo}hrSq$905~fHt6`dKU
zSABhPlM`cu7lRT9ljX)(UJlDeqtpm_em1*PqdDBxvZK1n$EG*Q#a((0XvshQ;SYcL
z;~#r6v+MYxYK|a41>?-CW}$I`fW-#Bw2?2Xq+`GWZ~!4X2kdh#iwC-?0S8hb+1SVx
zwD5%u98Lol?@`J+M7%B`x7Q%Mb@e>@c>fDZ#{W1aG^}R6YpPkJZ<9${(dCIEw1@K|pMRH>8Y{EMe%`XjHQHaSU$w;X5g6!3k5
zkFMp58pSd|WQfOKYqQPTYz;DbyH;Ndg{G`dQ#NoAz~^M)L6LO9U)7@3SAj4DOB7HRPXu++Wz9JH5E|lgn2cOD(VL+jrya>EC^JdvRpEslxu+$x}x*ZkcLmIlgY=
zuEFuPf|5y3V94&Ct!ut}@ygk`jRR%QmYm|3ckR1&?Bt%|iESg3?_9Wi`QWiPPMy1P
z@yf2*4V{77ZNn1>`$zlC1$G8D?e-t)A8yhb#!4-ls%myMwydde-#m2|PU7Z^=fN;`
zNi?-|ZZ(AyBBCmt6#~Ri5G5Pv{AQ*QWMd~+-Yrs(>vG0*xqVV?GbUVoN2D5%syq3z24Y$VFPm@SOHVBBc=Y-GM~|LPFZTE=fFKy{FX16b!Y7ZP%0m?J
z@XOD?e)Qn$ho3+G;{I1Z$CnT8e{t{b!~6F>C+ze6Tc6y1>#fbby(M&plR}5vW{`?k
z(YZd*xo8OlUKJG$;)e5Y=gS*e{8lc4V^s#TjwSFBv)H;)>8OnbQ26s|FnP-n93ct-
zh(AxmLz2-Fp9(+7adSa6CUny|#)w$qe|tVRA-P$l9WN?t*BW!8;!L3FRzw<>M&!mM
zELPVAg%ZQ^2yofCF^ND%vMUehN8NI?)PZhAv}PGUE^^Ah8F1!7PN{e>m9Ds@Me*}-8sS(t;tCdSF&P8J7#Y2ehHOsv~v
z7|P3>bCm6V=rFsv32T{Lpi4D^5WM|p(Tm-j*nMyc&&0(mr`5F!2C28
zqyZXaa37r;VDf!5PLPRLQQ6frPOCs(&k=S?73(dwl{tC)f+2{B%&dv5teL`s9X{_w
zmg!(kU}t0HN3S3_{;$PGbT&W!NX%vXx8MJGcy7;7skdEY?A2(evU8{N3Y+<&$*kNS
zg&Ndij{-Hh5S?34dxd@#(^O#;6VfX#9mzF
z#Q~kdT7|Ab4Ory6I6?p-q<}&)4;dd{8UlBP38o#ssR}pj2Ia))7r7G`y0{|pqyN(O
z-1T!8_Ae}4*uU?>uHEyUJ^t*>&HcSDrK%w>e|!JXkiYWG;?_H_Uwi+>a|g#)P6mQ|
zCZK3+Puw3@;5r7?pv9IhLnq&tO6Aq!k%L|Uf~dWPh^I^>1S3IA
z#LAMW_@c53MlKjE$O(%0
zvkvQf+c%#Z?^{`x@1kcosA(>Gx`#=1GbmmrtxhZ$wcFqv?tk=A5ZoD!S;^)F*gP)-
z^UyILAd-#+z+Yp+dY%L&fJW0UmX4XsJql$L55y*W
zuDEE?RlYyy7|AoddGatE|9>So{zT41_Qfan2c30|3R9;-->)-lvf1HNz=r|{4e5YJ
z-yu()Qfe
z!I3lb8%8TbyGN%!I(^~F&RtL5d-sjgC*OVP;@RDM=K2R-J9Fmvu3e}1?p@j0(dF}P
z7#NuA?5;BBHWrla8JpTVIQHnqdyhZ8HP_I-*wTG*=kBuy54`izONZAkjQfHMHI38$
zK#fM1osg6rgVvJo&(3d2-^vRuD_uhH?wIfGH0)c!st1O*rPoaVr4uQ=VtKlX&q|NG)>zjG95RE&c
z%bv+80UuqN!LDZu{b|fvCO=5!1TxsRxHL3BIk8R_YIO;VB|CEeXE^4Pt$M04e3KNqA;d0%X8tXGJAshR5lbM{1XcgMu&
zK`nBFm;eIhS$GwT6JmpHReIvgIlW5tu-*h%oGU3G&&(!UpAiZ%
zaUG~dVnQ}ZK_`YF*!*fX%Agh)7QcxvtHp)YTtR@vffV=%Cc2V^2jIR15M**Z3|61X
zIFg$)mY-WMm9%L!tE`sslCpq+->g-8d3+m#4N4zGqLU5O1NH&(BrcA`iAmkK%*BBe
zLINqcX_Ac3qFHAqQCKNbK&D!zsaF{qH70lpCO;fvHp=~f`9UB=RDJ~C+6f@4MOWSvUc;dw^jcsk&xgN1(Pgl>T+Bz$p?xeA-
zDU=W{s=@_6I;UM@YSWwEc>y)We0Aq;k4W9b5Y$t-zPOCK47`mawa2AZ#HP9uGLVo=
zV^yXy>!_S2I=71}oi^l-DUBVt1jsm>Q#@a2nb2o9FnRqlZ3A1_C)4*!bY0+aP`wQ#ukY^<@ccwJk^*3r?I_Ut*fZrxl_dGRpY~gXAes0qz-7ap*7(%Ih&XQs%b7xV
zr!q>Tlgr}Ma#qCH5-HY%bn|l528{;!ff8IEX8w@7E
zq7~y1e`mKO0*hmOj7p?)zQ_$H&Bhk6;n}3>*TkTL>~AU~+(rBbhmsOiqtlU(LkH
zM(P%U6bJ&^YS@r9T~O346mPIOW{OJcdHi0LszbLRE{A!LcgbAwHyh=9SB2x~78P^#h)2Y_ADwLHtXH7-LTAQU!
zEnVldY_0M($|W^ok&D6fV%#c$V71fHqSIYoy=HfFdy_^V5J`PPR9j+W;ZBZ#s6!M&
z3b=G)fJ>Q&D6IYsc$FOW59GvOh~$)}(F7q;itb`NYB80~lZ
zHg)v@&R#uqbld2}k#+MQUViC=moDv_UAuc~djIsAD`!p}*t(_9?%CPZH(X)g*wngj
zXk>GH*T$C4lQZkKboV*L^88dPVA00FTsVJ2Q``2={vGWDGl80iSFfF3H-E5y;9ysG
zP#~@s$wzaFUY(imFlG)Hm0q5m+fmU|AE={1mL7BMH*D@K*;rTutYq
zE;wvq3odQNr41}WkisFCnTBUUB!Xsa#3f{Bw^os|fs4Eq9119GOUke(W>nEQaPrkO
zyo!Q>j|MW9MkkiWB;-dTERx=tRE|JHGKGgw2tWiAT@;m2MaMnqOf;cRR9s$Ud|pI+
zPDEUJLV96LQg&EOCfSRd7#|IRx_qPVjZv9^wiPjkrBQ|@;dxOBK002z736
z!9FjGR6ie%re6#Pr5U4H9tF1A7!e1ldRb&)GQ}7Xiv~?E4+o8jmdA=u)}Uc9QScJ|
zvM4|PPo{7BFWGENwqGa+DkQDhMyC*W@No;q$xY2Dq%f^ao|PrEu=!;Sb}5}&#$s4G
zEC{zqSSgp6vFQ2K^ihX(TYJ-%mbz{24OWce;xTGeViyLQ5w&SL**FSR^Y}DeOmYPU
zx`RfuQ|Xl)ekI1cau}`jdvxtw6~^_@SYA3wMh@sil8>Z*tm8>S9MF$M2?GzZc=fml
zF3UcJZp@T3sLKRmw#(JcLg`diejjj0ESW6GT~(4dY*crt#jh@|{oyX?)1OxigycVZ
zJ3{8atR4G*PhT`iE&TJR?|y%3%kGxU{APu&O`__Msrq!LA$@kg#x!Eg>euSw{K+Qf
zQBz*GLf3!;8P)A#RV_G|;~YaPCk{F2Ow=$`Dn4b=^+-2Q5X`qIwb
za6;eSzrWt$+vchq0j@FmO-x=56{`VrO2xW(vLUIq4HLDph3%LK1mmDg*C*9&F0rr4
zF76U4z)g>8GSMJHr5>(JxOG?2*sVNN^Ejx`_lQ&g+&Tugj>&Cc^TBbCt23uf`NK+6
zErVCj5>&%`G5G*HpdsM0N2aT!U{zEOgfEQ=g$*2Wr$hrlB=b-XHW?@hBt`4BGWm5J
z5rDE+u5aRq>);`i4@|elq?Sh~6@|wZhDAfS@WFVc}DpAjtI%@dRHl@B>Z`Lmj2kD2pCH|ZO4Z$xX%M5u?h07uhL_>-x0?9zs
zmJ$hRq-x2E?C69ZV~zt9XgWJLDhVvJ4%B6MY*{)ZD>5N7A}%L386N7EMidaEm2@j2
z)GNYOOT)m7gM-#SA6A^0F;!;Ej{aASo9@Za9kG_?rzhoSq-?0KtJ4_*GF1s3v>~^g
z!763YbJNpGn6$N({wo{jUz(peJlr#8FSB6GA{wI%%sIh|w2cz%Ht
z5s-~T*yt=fvS}Our5EQziJOf#%9YJ3`Hao7)@f^!%Yt0)WKq$dh~=@mva$h=9V%@t
zPfRco$jAi_f;a*)LWY!+@DM=Yqq72Zb_2i>K^movYzv2c5N8BaI`}aToebdmKPh@D7Yg?u2
zUX^h`Wf;|GjTp=$CiBX?f>yC)K&M@>*uWJ5>xm&i=<)^#_GNjWMuSKS5cD%yy?RrZMh|?1Z?clj^)fIYi{oWu+iPoE)oM2j^W#DX6L)j?
z0fE@V;X`b!s@~VpeW-U}!fG2REVi*QCx=(T#O!caOg`Z`@sZ>b}wGuN84Hx3Sb{o#iPr)J(gcKYEPZ=YMYX=N}pTi;NjR^_XeGyQ$@
z-F*$_f^wdCp}Bq3<=xfZ-JsB{_XpPpYdW&?_jL8I57mv8Sx3vP2YZIjt)4$MF*9j#
z)X9`{p33!A_1*cU8){o7Y@Y6%!hKV#;GF*Y=RbECvq5|{V4?w;u2-mRpy8ksgXzp#
zDyNplsm@?^@?;P-G`ty?^orHJV%3x}7h=B1I+dB%C)Y2OIu6yetS@s8tIex23qesr
z`KZne=DJ&=g6I@0+jwZ~XNbxHy1`$!0T)WQ4R}
zd3fQ9h(fYenrL-FhB`d9Br35qGO08w$(c;^z+0p-E9u-OiMrRAbF{g8K$lgTl!odJ
ziOF>UiVzgGJN*EQ$xG)~-3n>x
z0lBEopa!#CNX;mqq&s+gpH%X~=uo4{&}cSoXl*K_(~4=V!VG2+m07}I7g87_7H5+w
zznG4fFnMJxemRp@&IFR;Rt9Eg;a;wwg2t>
zy%VJcArU@SkUN}{72G@)MKPaZs|=JBgAj*r0xEV?pqFAc#FfarTFB%uWIkRnRf
zA{8kNV!Udc-y)Vb2_$tKeyd0^V#sd91*^NBN&jS*F`p2KX`To%SmWIrtDxtDfuIW+gx}@qRzPL@S
z=#;4&xWY!RxJ4+3asXmA8?8MDg0VxYYL}?HawR};%K-?&ngt&Z=itq(`>8!E5yt5;NZCdq_t`0EHE++0`0SYB<
z@W_Z_sFsj4!jQKy`5^bI#HuE(8Hm=KTLO%mw0c1I*;zb59%^a9gia2CPh2h6HKDs38P~DA_XI|aCZ??Mr!u+Ne#wV}s+jn@?%#N|i-`~AcpI_|2#LZfhmoMlqC@G_`
z9T@*;|In=4SEtfX*j%foz{(+YCaNnGslX9~JOmBc%9VBsRW)=j
z90X`sL+A7>bhQjTl)-L>KWZX{oLH=iSm&T3Cbc*mO)pj&nOGW;P#hjx93E2=5nCD&
zUmO-!Nc7^)L+kEGLZ&=68H~0iAw7r*Yq%00ja!jSpUf*?Z}%5RC%LIun?esJ8qKV;
zJi-_jX$pUeLI~g^GSS3DWB@NHMl&F@sskVwYoBcTvH{#>Vya_0?K!0hL-rr=zEs>@pT!%H)IS|hZ
zEi9ge#VJ2t3rBNXr
z&Ci{!u=Zw}w)OYH`P_N$y#R()VmMLf$n&$fHUd?9LU|0=@TgT=5B?ek<0It%i2VuCIP=eBJ4D18+Gcf
zJsscQ`rxM@9{==L(5+}IZ&3X}
zkbx7y1sVbwK`i^3II2&8p8(PIy^@YM@T4sw1w5?7MfF@!17EzVuyoj*({D6)Y4stl
zpo+t-6^J1-kd@P>(K~1?JDs(ms%D+9$_+OXiNe9+B7R{a2WoObm5IPdU>{js2q{=&
zNUd}Z6rw6czGST2;S)&h7$5R>4j*;+Cwl%ncp~r_bvlz@s)Q7jqk~kDEP-F3fVX)1
zHT}Z&+?y}Hc;(>XbDOr!w|4bAeH|A2hvzR{+O_w?vlm`JboBa(QxD&H`=#A`wsiNc
z41^A@oO$)g(ai(HpIo{6`L#FJHMFd%tUkDU`r3&mVZ<-HVqtH@5`E(i{5^o!_wa?9|%bZC$IK-v0d3lVj7{TYDC2
zTBg0VuWjCaZPShiAE6~;K6~wT)RCJjY2!-J6pb_-d~`E|*F?kXsT{D_RcVZR1{Y|!
zN}n^XG&R$CeSAfqKsg}RAVdNI1u{4SD9S#O5=c5A(@vW5$4vPRTuD7g2&@Es=cizv
zGzMG*gF5qo)-=)~BH*i>L*5twBp8)Iw7
z(MeU9aI-Ho?+Uc5Os#SQ^2p&aIZ+7+e}q~D%bZ23MWSvIrNn}NfGrSoWB?f<0E-Sf
zR+NwmGBZ0ePWOBmc?8q)Xz-c29fPnjaR-|l5X&qKcCAX|7l@rq%t2?`
zC{!N@s}l={vNNlB+$NcGkU!YHbZ4t&a@C2bpLp=AmN1L`dBf6oi}v
zEeR#;AjYp`;{g^2{9};AuMOd^aRWilu~x?s03Ta~iaxbz++5hDFoakFh#->>pBfZ#
zkRt$@3|J)V6Udqbvf;i_q-a2DQC=^UG)m-kLP@ni?4q+;)%p&dX{@ls&*24tVhr5P
zz&%W!hb?dc_{d=KAO$7@yzFccj8FLpDOvb4E)hB*^DGZx2W`j`*Qj((zId>#qQPLc
zVq7~{NK(><3v6s&UqM;3KBqUg)XSB6{;8W@KRA5nop)YXzj6J*;5WBFySQ)P%BJS&
zhNkIY-RU(8tAceQbJpVE;I$)1wvCR}ms(bLb$|ZuyZ3LtJJ;E>(Asr=aogsJu@`nM
z9^1F;qw8Z#qGl$znd@a%ruvzgDn!Z<(Bs5
zmctj}W$~(c(z3*iAYW1=QH~Z@toPS$3f9j!eIJ}UL!RPm+jg$bFXN=UaxCHYer!3=gComZ8{3Z&A(eRuI>AS#ir6sv%Vz{fUR+$UDg
zW*7H}G+jak=+IGZCg{g8LoO)9MqCmgDi*;eSJSz}+AOfoq>2Q44gz*um(wX!G-E=r
z;iy3-0}G@w&`O8#>6WM@YjiT424o0Th*ohyZ7JbkpJSk;Br*Z~GIG;lQH9|#Wzk8X
z69I^}#EkNo6iaMcx7y^Pb85tjqNH>$N7S2H@aEc0{iZyC8rWpR(g-s#3NSk&4oO91
zd&!7FY7uW@NHwqR4A3;WDqbaL1zc@dGUP5QX4&@A983O?kr7YA-912T_7XlUm
zh&I3_l~JBSu_Husdvc3V%@hl>QYga(`3-VeNXVP9S*k_+dYQz{Vz`;~4vpsAHq=7+
z@f&Y|>Ity9@MU_Lcoi=6(Lp@oZVCs2U?K`A1ZNGH03ZSuYx%-zE|5`zYTOvqMu8B7
zSer!ADVKLEA(d_Qcqel5K}hZhR1Fz3XNt-;*xhR^wuz#WgYBJ{##hc*Z1rMEx8BgE
zQZ-7YH3C7MNLe
zy;@_JN>>j*L#3uytp}+H9=ThgZ5JyBb(yfwL{@&E+5m-h9ATGS3x+xb-#-MK?`LqU
zaZ!jP0_c;~tN|vV5cOLMf~e$*0gC{~I=-}CAOm#v8?u4IlZ7Q958IR))VrG_1djq*
z+f8G;Xqb=9_kb5>A{2r!bh3m_CUV3!3_;MvLg6HUNCt_&XL(4$Dcdn2L`bO67p6yDg+M!8F=XC|1&rJ&Wjgj+B(NV)gx~I@u}GXhjXE=
z_0ra@2WMv9K7I23^*6Q+j~rSze|F#g*`eVV_Z~R4ZRe)pvDXeBnX0K<+uHv2*>mR)
z9XfaP!1c2yTkRFo?d|v8cx%__suME{mlt>Sxjj3_Mqb*wWk*-nxW&?LGEZ6^Uap`x
zmC~p&H!6)Kap`5TY0eZ{QFKynWLzySYUE4Z>5Lj&)TJ?v<`!K)g9gbwzH@Kflvm5Z
zDya-_D%F=v^(RpRiL^ihHIPX6#HPFA(j74=m8nc`A{F)Qp>ZmcX`wV`D<%;Q
zVvkKlD-*<~LZ&jE>4-~%yepAn1*kFty;riUZH+@cqX{!2xP92#w40(P=_8gyF`?B1sLHK
zpe0cSWhC$}EH6IE&EZM^{rPS6%>%iGXc)}$X!Y~ql>+Ies)q73rfw;klQB0Yak8``
zCniY)uZ@nkP#M}~;pC9&^RTKp|OE+pdw4a9TS?7$RqHP>?6?$8iAzb
ze*_by6%5pf3ATE;ykcu}i;Kf?Z~*;40>8N6rmYNSIfYUIY7ytm+HGKFchuGFYiZuw
z+_cu|7%ePtGw41RYh!ymoY?Qb`>s=O8Z_ti=*@5^BT-10=%=Zl!S~X5L_i7Z6HZn{
zqVA9wx0=Im5=h2Oxd6vX8mm*T7|va-5V8lWD$*UJ3j
zR++MzD*#Y-s&%z|)J#06H>2Uq0%^Y?vt6O?(VAMN>K=`0z>wV}QXo}`3930lKpvQ7
zQV)V!{JGHyJ`qxjWC{Ta5fJI6Vel$|BfK06y$rUGiJ^|%7_U(x8!(&aozDKu%$HYA
z^_jE1Z0Z!kWt_OoS|MgA~##)W{DhxNQ7r?Og__Dj_s5gHx;f3iJye)IOv-+1$@
z_uv2c+UqYJJNEvouU#bAGU
zp*t}>NMUsemGyKqLz*v{=1HOk(wGpw6uLi^Q5qf(G(>fXpa;X_%cGN!We$%n4g(-Q
zi?~7ph`>kK0o159CaIny@T7ouPAra2gnK|0gWDpIgQ3okjGrpC?Wu3;F=UsT}+2ORzie@$t|X`fRd#Q
zPATj|WsTXK0hywZ0Z3Nlq
zqO#n`P;)&L9$?W$VgGEdxn3&IoxvsBY5*%hMo>%vKnbLD%tvRT5lwWkuG|2X)c`I^
ztN}bQf_90bkt-h7WrF|&gA9BmyWKSK#SH>Ui$oDXv#9Y}gz^r#7Vt;F
zj!WV!#1YqUWtA*JB})irPJo{0qw|88D8Ljz1`3Ihkx+;_Ex}9R(}B4TaYap1RgfbD
zY1yvSPZX5;Io#30;&!b*fN{M{EWqK}C>fx^ZB&Yf$@H>VeOWmTDyBV^~kZ!V-x$%yHJ&1*dGd>-mz_Np!>+ey8GAOoNMj6_43t^UV8b|hD`%j=a|EPZej8I
z;giSLZkVd9p7I9`38}g1^kNEk*jKxfs2az?Kqw^gPsjZU)0r?)F~ZVD@e
z2|N^5S$t}PNYSk^&6L}#1@ivvqPI3~n{oQ@+(5G;|M2+9T3@i4E3E@VO=0_zDc<-D
zLNlfT8U4w0FF{E+Q3$C$I>i#60G=1*9stglOs}EhjVvJm4qyi6UTao~u7o63J*
zN+Pl-G0hMjtyvMFUXI53L1>q(D2hu8@gHMl2DHVU_BVI(q3n&0V9HNYH*7@no{B%YM
z4YT2Vzf>MnDFZUuXoamHgHp<17E)-16h=7mwr(}uJAiV8vsiAR8!
zQZowE(kx7tmBpz5uT4jlj}{u+0{0IFW@SKz1sd7O#N0Gytw0Qx5JZrV$+`F8M{tHO
z?LX+DV;&~YN#i
zSHtt-eN3mZiW(1viH5OBgCDu*~{
z9PmdF5b_9)WPlZ^i*%Bk}FISez<>D8S=)XPUOx
zSHHV;aVRgpPAadHD;;c(jm>evJq9(ippG?U)gj48l7`R7h#mqKxsqox5CDfDNMyh`
zlhh-@_kWCM`y(qYkV8sdX}`2RH`mm*zPWv@D)jQc{qLPQcVP9}BWvbAK67EAv7^uK
zIlE=sU}g2j!O=f_{`r-oM|aGwxpDEO9n&)}?%sWPey+BlV8k8R(AX7F8rRjeZffov
zw|SZj*`Q|M-1ownEj!*lfBERTjj!(9zq5CEV|{C1x$TXEhepaPHdtNTt7_I(xYyZy
zTLLvl+Ilv)DuI$K^UKy--6N*l4ux*Ku&mRV-DAujE2wCY>8HxwM|#IL)i!^8?G5tO
zuN^+RBT%!`7wQ(t+c5s1NY#T&T3Lc72EUob_aWE4OJOQMDYZXyRfJ=8m
z2Do5A6#x#(0d}y19VixwcC*K&S)!5veC6Q@_E=<`5h$Y)El~+&QK+pMo+4XXkY*%S
zxq<*;SQ3#y1d@~J+3p+^{s<7#^h$i-Z^IP|af`2ubB{mNvq>bgj_3!
z*`8-yUte|q!kI~zy@-}k&SqNJ>@p@+L}h~ZEM?-QsAYy<&fu0YFbml-LuFe)&eM5h
zSZKTo8rMPxfyp1pFP`@Xwufq_ib{9aHa5$YZW_zW;OrO}BF}To?sjHit_+Tw%JDLA
zHw|-ASZH`PljEW?+*G2Wh6a=bVlq8cCYVz%1@-T#=gTS?Xy(TnFwtCLJy!%o^HG?!
z9KmR24rs|B3kQ7%h8l=gkBfkhtzrf65kw-m;|`U!UMQ*I2_XXyhfHQ5W4B7vCR28+
zbZ7`O6D+wLj#kCsH1Z`i7_U{TMBQk3LMW+b^ZV4MYV2u43Y;N``=*x-P5_DKX>8u{HB8=E03(6dvf#rBeV0n2FBh$
zcIMLVeLZg9!PRTlbauUW`SQE3UVZ1aSMR?6?z+*z8!w%|fAhwNufBF|*Z#HD^&=Io
zZLOW_Dr?qyD>qa%01ex1uIZNciJFFeD_5`W=$>!sTHn_DwshUj=5gWJgBgM)5n32G@=RXQ8YbvsXv#$ppwRG?AVDGU&a
z0LQ8nhAkq=9+?bM5fL*w*%qB_jRgE9l>__2;vfTsE+A}tI*3Q0VQEBsNq8Lalx%|r
z{6R|65Xe{(nE=QG0y^L&2^nPn$9lF1IBQR)bgB%;y9Zk}#wJ~6e@VH6E2!5P8q~&+
zP>~xE2R5WUA-yO%DK8?9WFi0&jgp3kM3YN?OcGgjm=%+7VsyM#snISC&kT!J{rl3K
zsQ9%NF1RQS%OX@umK&mCbYYRzQe{vmQ~mq0!r0`ZgcN`#S_Kdxk7&^bGrl|uY&GCg
zw=BZ2B;2?x0`#MciK~CRT=m;!y5)$T5a6}pjg?|nuO66s2tdK^_PDw4IfpKP(GFj`YYua*iEF5-&(Ezg1!r|m+(2MBo
zLMk&aomPVSgd;41%La>01Ug_T0|Usy!!lqcU>AbIw$Qlch>u(%I28=sN@Eu$r4=Qm
zxfoc3Oc~@0YsHdkfvC@%)nm$Rlq)`Z9o?jV_susoBC(r^IcQ8bjSXaUWH9XM3@3#N
zcH5D`1Y$zKLkK{mhk`lbQe>c7NI(+7O|st)>Ka+aLfj#O<706AOimC1lml?=QKEW7
zKZRMvz^Vw%=wq;fjJ13b$i^x#t)O9vRUpC{dKV_DIs_n+q7VEp
zoE4l;C8|s$t4E)G1v|(6m8E_DIM~FnwfWSl~Gb0kfS(9XhLVJ9=JBeCJ!Q3gd
ziug28g`RZgY_Y9HsC1>!ohfuz8WYsn8mDg{uXv!i!on4;Ywf(axbw*5tR^B>`+PV^
z#hi$E@YuYlL{zs(F60ss4N&vr!YZC52N)U=
z=caRz`tIm!Q5zJ$Sqc_g`TSBlo#n;2hA=cgBkBveJQ8&aUyg=X10}Uf!@wPr0Xt}y
zgz1)r7sRK)v)U!$hUHPPkAr~$8o)t=#dgv#OA57H|4*j;{4d!+Dq1FHjK>BreFCapuSoeKrNfAR!Q_>C9OcIpk?I#ZKW34+nf01po868C`iq_A96ASM%t
z2}T>R=t44+4H>`|5?=(c5Y&F|BS|PtP9=*ER0=XsSLz^xTyB9|kBe(DVUtJ!L?c^-
zA%%d4fH|OH6X1iwCcy`XCE&=060%wO=W=cpTLdx?HK`Nzr0xtvLju-F6_PrUgd?QR
zbT~bvB5Sy^7OBol=XGnd8${}Au56~<(W=lj%QPKoL!(4l%@f>?|v7^NOpKhGCoU^+U%#dg+y07q2#C6>e&=kPsD
z9PUN%rFR>%++Z=Xawfh0?d@IN*+m0+Wmo1lPuP8fB^A4S2j9PPmHbpM&CD%U)lOy=
zbqQ2Ma$~PZ(~OC#DeOijzl|gA7N}a-;y@C;0WGe8d*Ufzx&e!>_%wHXT16B%=;Rt2
zr-8w3VT5fvAw6T)F+WQXiac67^4$v)TXY2vh_7ho#woC?!b6qS*t>eCg@%f
zZC)M)QZYL`HY+j?b<-g-U|=Cr6rXBF&C_V1ebkLH9AqG9z(`9PH8V2Kh*nsQ);u3x
zmP+f&%$@UBtq;|xmaagOa7C0QgKmz91>IMikOpuBH@5|tYKt}EJD-25`5T?Wa74?k3IEYgCE#V^Inw7&R8lX9l5?bf{Vba!C
z1%ChCcW~OTpFZPeVRcePokRhbt`CeV1BcYl;(?qbTqo`TQJKzmQ8*ADaH&jzhmI5_
z?1nI!ftqvxTYw>wN*)RxVvE6g2k0C>jqRs%8in$1l>s&8z)L{x(K&5$ErD0SAG=;4
zui;7naHRi*6pmAkOG6w9VT2)2IY~WW90a_nn~IYuoRx#fz`3E*V+oK#q=O*kRbgT;
z9d~4~2%RXX#Q4=*k)Op4;=&q{Y&gHTUaAb>f`RP(HjTjnOave@a8Tdi|C|hg9gZMU
zHK;SKRFISW3Q&RoFSejCg9R?w2C#!58l9oAoWLJybOum@#3R@TP$SVs!jVkLAPXS{
zTvo|-L4_U)pP6eCh5tEVXYxw>rR}+EhmU=5`rO$~o3HHMyLDjT_|&SYKybFX_1w-~
zci(#J#^uYeoH%i5|G`gQdG+%TKX~WLD@V8PJi2AugLiH&PL8h`?7n&B;#611nFITG
z&Ck8{;@Qt$ySj0B@Z{o_`|rGUdgqP}V`B$5Z~ooA`x8wq7Y-ggv3+~1-Sx_zgWGzC
z*VHt&2d#rEJ0iGx|
zBPfz)B_vg;)MHMkS1hSfYw8Wgtt}nfTRL7`HFL0k=-mSc2dovB*R7xT2R8?**Hw7B
zl*Wmil76+RSD|YYDEf#2FxA9RmPTA$kBJ7^{&SQx_zpSUJ2gyUQ<-7A2-zQt2g0l>CJBoVXM)*CByS@!y^Yx{c?THi(sA
zzO?_g6l^ltdl99?8ZWvf;XpKS)}|Fv=Eyie6@(r%U|3XkbUd(9570z2lEpzDo^rBq
zJ00uLWtJyXfT3WVK}e35SgQpx)Ubn;V-#w@SrQH$1cQuLA6$xLqx$(3;M{?X>i@Ph
zA8rE)X}agb0GB|U8F=yi$^kfXGq?LLuTNg=ObSc6Rocv-yP-riGmT7Ep_XB(l}0nVXK6(6BN(
zhNgF9uq;$sVM0@QZvFRTrY3=b#h+!x4i@g*?!f)PrOR
zN(nmq7--Q=crQrdeF4^Blj{UZK%t*0s=_4Q+N^e^p-w34HJCfpdJu*ouBcV6L28u7
z2Gvp{l(uRN(-n?tvCKwe+UP7B+yg)rvUzq42*|Bq@~Y*!o}3cU=AZ!qi&h{VK#C&-
zcZ}2@P!DxQ1Y+_mgh7U9(eOSd|0y(ou2qDm$RHU9uZ0xk5m@YJC9bGv&+_Y91mUbA6K-_WZ^j@&qX=G_YyKYink7k2D;`Rv(O&tKTP
zY0JSan|H36UN_jgy0i1Oqo_vIjEaQxiew60cGkpn
zds4bLgPs!}ogE(SXY*YQd`nHkw#Mf5zTjwn>3UC9o669w&K%HYZShs_t!sUuwP#0F
z{aTA_tG{}q-QOY8H;Pq5=7J$pev?2koS8pl&L7DwnzMN>4o@AdZ(DEoE!e$1+RR#9
zGE-=67pnYJ%*Vt>ib^lf&3}FQ%8S#pD4{l8SXUuam;=G3V`R?JP~E
z0AfG@f7=i-L3Xd@@i!?2d(*AZuMJjC|GcR))>MO4L?Q+%g%RxDY
zc#_-P3F5*W7?;Wh@>L?LP;}I1-m&q9hS}z5y*(UgfhTl5tUI&XO`2LbsEj6
zrMxRIr!7l;X@2tlxg#g1`p2C`ZZXrwWt1~01<47832`lLmAF3s!<5oHtZC(YPXJa5@0tc-m_y|5i
zO5%(p+Os@~Jha=-h42tS35bN0tW|`kY#5|MpIB|jB^8*s0w{?gO-lZaerbE|=B1ZD
zdiB*eUOe~NTW{Zd#E=jLBJ^un#{Z$AF?{R;=Sk2M5OZP~au
zK5_TjTL)+6MgpN1H!nVZ>*n_1$@+rQHLV@T7dCF_AL{j2HQOAYzyJQB#l;&hzjXcL
zxkKyLUEQQ4Lf@KE^pqvw|DUL%9)KF
zo!ff*`^v0WckI5hd(VN<@w=za&V_0&FRb6y+CG$DwA$%?d*A+DgF~zRRkJovkJfZ$
zdhOYf$pA+HKB8NjnHwGN;|ivo?#!sTqWCmhDzjdsUhDA9`$O%AmXRjTQf>njp63ZfD+
zmqwaVXKXZ=1gJ=Jcnoj~b>#s$85UWR48K(_fH*HU$+#k_G=MhP%MGZ>B^pqh7o7;?EsjqGC_@IyHA}*Pk6^J?zgbqAoZ-dz
zus=ys&GRc%|Gw<$wexFk&rk>fyhE@vWCP$pOM1jgRJTZBWhGO9ccdzOrX1ZO1r+9{
z(Fs-}-;JK7qiV+j3KL$HmqyP{p@RD^q%sPqbO%pp#keIjhKt9u`+7R??Z>f28{p@_eb+o@{ozGV(6jsof
zU~XJ&+`(Y?mXv?;_B-UqdGqYKp1eW?M=HxfVY=xU=tmNWpt;;MmXktvQW!*w4eJ^B
zNVE~0Vw3C(u!NA30lPg5av#_k^6)CM1RjF=v!}683E+~3yXag8k#UpI{Q3Bh0oe$|
zgn*YoNrPAgIv36dfaqp&{FuN2CrM}7sZ3i2)6L+y8Mu?ib}=|ECJuK6D}`>Q!mWbk
zK@)L{oGk82o2O2tcVGe+F0?Rku)`LRY`{TC89dO2z(i!3!Jh%(zzze~h!ldDXznTg
z5ITtrVjM>V4?+4t`V5FgEwD4|H8o!Uwh@=jd$L@t
z))g28S6E46I%*~+rpW;y=0?P2t%wG-SQ4KKPBwc*jP~D`fyJJwaJTEt1qrF-5NUFh
zi;ITYQfZ(8L1j0n^&=(adGX1Oa!qz*oHc_1*aZij6PpN>%#KPhMSY>opNd{tKIg@E+u_05CmbRs-_S54B
z-rlu&b8T>#H
zRk}<250anj?F%n?SppA}??^}ZL-luX_oabyWP@gOqB=ez2oxe35_*utA7tP*57>GZ
zB-h9t$dYG!0uV|3K?>jlAlj&y9qzsiu7i$y8T=qF^$`&CG5I7GVdo%6(r?U%hkkIQ
zJc*aVsp5$Sa|->K5K!pDcrz8QjsDsIF6lDl4Ca);0fRz$tIq6X^Q?5#az(bTpq70I
z(3Qk`J~kEzLvF3o*sRO;3FP3H5&H;)mC=c*J?LDJldum+OOlM`3@%AM5`~b5fP5((
zC(Fr_|6`EQ{O<}aEb!n$D;vNHYEb}w0%Rlk7x|^_xj)^1@bZC!FKk$U`S77#Yi7DD
z9Q#Hlj?Ztnd;P6DZ@=^DwKwkFyz$AkYdcr2ytsYm^%ss`-GBJRmc?CDQzsVY$Agu_
zKJSLkt_zDh7TUT8?Y@f}w{7koI6S-V_}uz&f9T^==l8Cf0cU;f#L2^J=eCTDfA}&`
z_1z*e*
z(t!)M47#5ysFuh(w8pW5@;Oh{f;Y4P(l4iY!s@(p^31WZ@ix7wPAJnqACVWEYL18>
zEwaKsa1B|h%sQ#+Kv(~m+jn^7%&Qx>gU8H{j>}I>87eL_M8x#x7PhI41u=;w32CG+
z2F#TtQUV<5?)u&tYh|O}d11_iGs7EA?Q=G;qqp(n0
z4Gk-&vLP)=XBESJl*aZ61QkqXKqRe}sN5J2uB8B9>SA(j87w=6jXJeZv5E{9goBE~
zpVdx*au$5;b{ZQ3q$O(6reO}iO&Zgl&Vm5
zCX!V*io3?!U-usVl-MahsjWgSK?O45f
zuBY$(<{d9@+xzP7g9ld5UOjT`;k)nOIDg^ycW!ST9eeYIqo)?PT->|o&6CI1baot^
zo!#6&cE+Sohz-uX*M7q>MzJ!iJ>zP$I)(M^lzw(r_A
zvFhf@GuMwEd+XS-D?4`7X6L-Jd*65OeYB%{u-ja+*5CByh1Wkm`r?agHys&W?Gvfj
z)V6$f?qa1{yATM?IsHDaI3&_gH{H@-)YJmbSku9Fts@kdAr|5|fFQCZ-f6rJJKt
z{J5el8B`c^(3Cq{YPTk2WGzKADrQBX3PFhMh}Z#BZVgX@I%6-3$VOdrKz=5Ias)S>
z9Uf;6i_M8lfD~*m1Q=dG@H&UDQKkuU#ehfyT7e+Zn$F4$k26KY>B6IdjPvfwPGfdo
zc0q1zBG4@}GBzlbNTY#x1XjY43#lApybbIO
z+7mBA&D?k~l~Y2)O6ict3MoufK}m-~tQc;|67`Pe&KZ|KBvk_+-MFwpZFGXX!X*HU
zl8g)soo=BqE#P?Ayp>jGr9f5zOawCvzLh2LW1@kqBES&hR0a!R1jGb&28!N6$NVfl
zIBpLES>sB!2z)eBf~m+Fdujhs+vuU99c(EKkb9)pMtux2-_
z(0WMj5sHsP_Pl|V=n9H~X0)-nHcU{bHG{VWNCEyJCBHqAl_c+=kPP&YAfuBn4#-rH
zDQ6;u_>8I~?@-D@uK6kceg-1MvqOO78&x%0KsGY|*-HF-*RFg2
z!b=+mhK{V8fAz?bJ>x4kcl50aHLPxKd+*%ESN0vgv~BP0mtTMK-iMbC9DH&2p7Xo+
zUfh51t@9Vo9XN1oaq+dIFC3g%v$22Ri?`mo_ty1KUU}uim#)0L_u$&*PGI7L*RP-2
zxTVYG-8wvaa(+`^Aar!Y=Hv4lH+A;SHniM4b@qk1g>IY6AyrrFOhXpCN2%_yxpoeX
zpIEnXSN~XpCc6|IfmpSsx@pManeqoKxWa%g^Wv86@4ayBrM2^`DqKFExIu1ov&AJ8
z?CO@CYwMfeIeN??6i+!l8>;I%vT{$2PrbZ$J|L7X);0#wygupX$k;)P_2TSYS#m~s
zVtP4h&k^NECltga<;NvE8Jx0YijOB+Y;C(Ry{0ESzd@xfO{L^T$LB}I6~bwdiILw29ctQEdc!p=q!j%1ZNGulbp!J!njmxDlN#9c$i$m
zl}GEAhO7U5nS;WbE_b?_eC2PJYnDWSSvE(-0R(fR6V$(5F8}u>s0wmdRvT~o&5cr7Yr8B`q7ZWYfz{HT+SWGm(6w8=7g0Ec8CVeog8lPToH8a}LgkcEa0>;56+0l7TIguh2LO?noK*<-
z>`H;SES(B2+eTwLnV6Nz07C=e$N2$VP@YEhVmu_!C=7V$Vqn$`nwQN5Cks2HdQ3Xo
zp237m!p{)_#R&Ex{E-}V(z!mi(2~l467cN6K?umBr--}*QlKqR30RC~yWs}75(k6h
zW^pS(r2>^8L&I!zkc7-~8oiXlC{6>uW2G5Pzd-I_Bknh-GeI?@fkQ-#iUr68CiiC}
zT!tj!&yZpgydxk5OavZ*Hf%EH62L-qD+5tUl*17~hQsZRm`{@kCchL-vWePiP<13%
z0=q%Jl!4}&gL`2aKoc0p7M4Ov^yz_};f>I4LLe_`GFn@3N*b@1qwUHf-Utv)cb?!^4!zL|A9rf1$bbN1Ml#p9c{
zeEaDqXLjwpapC;C7tSBqu>SDE{E5Xa8%IX2pE~`?m8-8EKKkYhCsxOCz5Cxf^WyiPel}I#v}bDddlz2n_4?mCeeUeW#hIF>)m1fh#;jYHUY@FH
z+|)fV)7bjL>e9duFjra-M#(gmSZbdy|s6rOCrflr{)$pZ-Dd|p(KTuHGs5gDI|Ip6*=6+Mouqn5S#RKqZ
zmW5}>C6=Yp_BD3^Tk|90%j42oWm*r7Q<{)QbhwE@T@jZ>qJD@`aaIO4-HO){^DE{;#F70N-T8J9r591(+7(2tA*
zENYg78J0)3YK%d_|G&NSjA|px_I-bS>&>0+b|mK@lp{H3M39gK0ttyMa*ifvlT8jL
z8CF_DbVjSZwiB}y(d~e`auP*qO7h#O
z>$z<=gn=X!8JYp|qG;>_Hy__mb`>~#Rq%xfe>>3WMbOLe-ShbU4oI=lW6gHz`k`yn
z+P*uqK;Ej4oqy*7SVT;uFoVeq2_YUa8G%_?Fk&)736u;lwE_c5){n#8BMLG0{!g8YXH+4h4V`)WaplUnqqGa3p{THF&NM
zVj`A8=$RL&l_zKLWFQ;qOa+6ZvT;=L93vooVcQ_$P?-mF@_Q4Klk6Rp49L4#N(LK}
zRsdp-i$_HOdJau2gOlOlqGDTTI=Xg5#%4LX0U4u-moz}KlEQN+aP>~$*n`B&aBz!-
z{D#4c1C2)G!Y?Jj5d>fi9Z<+iv3AI2_=OUNkenjBLS~WZVZc;?dAn#
zESs0%=$h^939M95VVBrw4m_O;hNwsIh%j)Fk1me@>@dHeb<+TgGU88x{~(BWTh!cE
zVBsb;wz&53cCOGD)w6Bm?A_$RSpskXK@>o24t(f>L?RJJn0*At0hbB_i?|g^yitu4
z0V5y^!?v98c}6hxq4o>QM+f$`-(SD<`Db^}9hzG^x-j0}zOj6IZeZ}Ur(_iH1qX8W#9KQa%qxOC
zvD7ap!P=o-DnF2uFC|lzR*X2V~o9<1ZV{$qVqxsgo()j
zHH0&vB~1ttp30Omxly)`Vj818Ju}VMUr440Q`W0>4%1{Yl&rU6^gHI_&UJAy=y
zrh?>TN7Fgbl)$mgbN7j1@FHoT1bO9xkQ@)cq0H>b!lI5iRbzxwPNR3L6568U!bl7y
z-3F9kBq%}Rl86%V4oSif93+5+OKdB^W4BNY9Z7B~G@0t|VeGRsR(k
z&o7*~ec|GzV=wW9JUdKD&JN*#6-Y1EbUXIzL-FeeKYZ-ps-hL3oiQ;>O(klM9#b
zEG-X}Rrcf+HfQAQ&CFgqdi3_vsq1s|&1u?u7~*VL(qABauqlts6QWQDHY@l2jr
z*Ej(Z9}}w_2e&*&50Q>hkdaw{zDa~7ZC|J&iD}gkouDVW>>VQ8H^R!(AunUcbd
zErF+?r{Gx3^YrP7PdKx;>2$^3-iX*Hu?(bKoV5d_v?2pj$W?{<+%)a+$qq=M!px}xT~ndHndhfkna&=~@<^0i8=36!4|3nO%l-E|;M3Iv
zigTSk-G9H`cZUvOH&DyKZ<`hvP#EN=*N$J~t*Sy2Glbw5W}?W7rLja;?-Wlz(2_`3
zQdy8kOK2Q1l?`PmWZ86-fJ2G%aZsJGsx}G-y2EIjQjv!dDW$_#$ew^BRDyoQ$`J)%
zp8zEik{X8y*p!w;JxEtDtd$5#svXc!QEb~nKLKEoxJ1JXBh$m+hndMzFc=YZI+&bB
zlT)b?G@61=kL3V8DKavUlnS6!(&=HA6u=^+qXGTzHkqlP2
z6-7Z~#`Embo!p{eqjWCF!w3p=0n(xD7@Ly8ji7-fWQ0>_5p-rG@pwvrBjhx4DrC?$
zkRU6lY$bySy9%072I6-Uc3|+iw)_%oentXc*|N
zx9+{Xdh&~xpFFy8YWY}4_hMJig+tRL)wOjA
zsRwHs+S7B7)VEDnHdcp6x5THM8yIWJ%v~8hxX?H7*SBASy6mf|ooH?Q>h|563yY9J
z-#&Bp_PKMtmDMxNts~`C(~Yfw#d~XOKRkLoT3s{S-kC2~EcOo`YT9?WxxGCjf1s%1
z!I|^V*Dg1v=UkYceZF?Fzo78!(D2mWy{Ufuv7*v}ti1O4q(oQG#pbrogyd`w?=&aZ
zTo3OoSC33j?@T}c+Q^tlYkPlvlSn2n&pRN=)}<#dc`Pe0+0mugJ76xacqY4WC?UN@
z5DJL~B)MXJ(_lT5I0ky|R-`4ZMktB3cN!|L+#?LH6-UU;$qA4&nNq?`tz;Gyz#Ndp
zM@P>agx+qw5`IvwpZ{W4*Rk40DRC2?0Nu)BAThNF)G>sb3jg5YqzoV(h%)>pgDQap
zVA>#!fE+g8%MX&8uBiCQtbzoNT|5uc3P&GpJ-}-i=vixrSPEOHZ74A`OJt#0mcHAy
zA;pFSTy9E6PfO<5g0IC`UmHC+qCQmCri>M!x5VhlfW>B3
zaxxtfZ9i@OPz!Q^t`T5bVa1S|SwV{J_WSLTR*cc)OyIlUZe7UABdqB8E?yu}y|(ZE
zbu^=h4Cyc{(2NQoi?MS9qG>1zS`u2J6vHY76rzoo!V{4}A@al&HU=VsCXFMapp+a_
z5|I&2Zv^e&fXRqUOhCXQ^bLX0s5~(lUE$fJCm6yXwyi$U5W=u#)Fj;+Cxpy`62AFJ
zMlsNpYdMW0qp-ut>;zlqwwUD`Cxh`2)EJfoGz6rhRf}Ui_7-(Jdm4L94JuP
z+Go0Zj^`B|DJzX-v$9-W>Ov%Wp6+}6ybFE3YD0osBV|*CIo0Bz2AO0eGdb7GHP7Gs
z$lmHul4YE=bs;|>lEqDRb}I@9YKe@_aPer1jE(2ohEwQ}FeN!SWw^Nm5Tn@KXbu
?+_Il)WHN4viw6gZMpI+kgfAg!Kbt~ayz!LUrs~K*k
z669Tr4%4*TMj6XqW--BFHSi0Pfs4Q`jIYn71AtZB;w6>MD)UG#tvbQ
zpx3T}S9UwK_+%GG0IFWV*zF*HOrPMqCb25FlfEJT7yNEL@7DXBItWjB7--0==e&B}
zr{jHEfzwN{M}j^Urcib)XavBCszl!+*=6^f=v|Qfi$PukY)1kHMbd`&xqxRX
z=$=T+GyRfnqvqPFyP2^FT&)M-lCL)8+glPLd54TLcubknd*Mg>5tf_<`l17W9DZ~d
zd2$?ke29awhm`px-^cBb%rWkR;m7+CigIH#wo6o2FP?w*wk*k-jabr(nL1Hx
zK5EWIjQI$xqh(a}9rS|-{lGy_zF3PK52zv#M(~GS{%D2YZ*gbC(Czi;)fx@%?`(wc
zZmJ62*}x44*CYjg*kXF=9$fNa`1w)ftz+fwlL+*(^Ug`+z0>Ib;*ZryTzKDvGz%XL
zCD^_W3BvO%+L!rRFvr<27_7ObZ%S87>gt4HrmVh}(SrodjB%?+A@VQ3_-ieLk;_t6
z0f}ic7%D_{1vWiAZ1Q`QQ5CFaY{irX-Zvf5Ly~Vh>oU{VEz-=Rs
z-@6`dtLSFwRQ!4;xHF74^KN+4enS|vq+UaSe_g5gf$Dyp`oJn64XX-#0=GbNr^eL^
zu4csxOg738*C=r-HMvpZn9qYvSY_$K&-Qrd>6IF7H4AwoK$k4OuO
zIIp&0VJ;$}KOf>}SW9IxAx7m1;EW`H>`6_Y1p(qx#z*W(P#
zB#;@;T;s*FrYt?9{@8
zRw5*r;g3DQA(h=Au)&zR85B9U9+(7rfnhq%`e3IjaN2xb@RH_kRe7AtPTPX&j~&)!
zhgD;@EL%;Bb_+UMt7+L{T!L(7jmZQgFR4f-h~o3Fu}VMM1sJP5ei5U-cEj}b@D{XM
zmB+v>ePIS&we>hD%S_cv9{W88mB)fd?{^cP1-AiDMZZCXF}yMyv&8FUP6HC>VyUwfTsyo42i%
z9Xk#8ai6E^U7Nw%o0O>ag2Z76h<&slenb<)5jbN|`RP&o*>U3ONdo5h-d_0bZirDi
z@(8Ftir(7~-(e|T_z;R-f;Z9K#~he$Rd3bV%N7RCdGrHsYq$l7|A(6*sHn=-aGuqq1jEbg~I!e!D4e
zz-D03pLIWfbb+7v-dm5dK}$AdNd+uP*_2XKj@4y9v=+#c2Gy>q3{Jy|5}v_k%3h{L
zM3!g(kftax6Cqjk(5gQU^KiG;Fo)r(nG7zYG5`$Fq9t1l)(YS>n`O;|@q82njL%j>XQS}tdieHc1UerD&PVdq
zMi3YCCfh(Ap5flM{Ny0=>@WftKR=ATd8E8~9De&W3cZ7tf%%J;GdA-kwEeQ{
z^H2YPk6v2|C41FoD6a
z%fqG!PIs$*P{pmN$A~ka(>dg0_Y+
za;^nWv*3Xb27p^-AdqZsuOSkxt6aY&wQGL(W01I25o-lMc-$=V?Xn0Sx2r;};2pGr
zfHCp7%=N2cuLgUK_X;=yngX%-9DE=wGCDwVt>9@@1eNPht>CL<;l-WcG1=~Z
z!PTs@n6lzs8~q4gh3GesG~-nWr@*$O_|W~*93?ACE^gXp0`V6teG1Y=mT1O;R8Ixklza!V5JhO33Mi3167
zcQND7#GUc5B@!?N1s(0g=Ux!Ki=t;iaL)(0r69j7dgpofwBVVMytATvA{Soj;w_;DY7@D@uLrd(pUNwSrU$7~HQ!8j2B?Wl#~48UsmI!R8H3SFtwv@d8)
zt$L76>k^O2RkOKXRSeSCfo|q~)r2p~`632i&qIUIMupQyIf`JDGsY+2)7WZbcyww-
z95;}04*!%FH%rP@6({W-jWX&lSIOaSQu@<64k-mO!42ecLpfg$Qc4%4cLf0EqaL@v;yuRLYgMF?pPfLW7^X+Ymn
z#$3)?(B|U?INeIxTF*JyvL#wlT!>ScTJ_4HGB6BVys;AA=qbDF$&Iek%(+?x4+uSK
z1-ARqPT9ZOlm|6&wG|k&Lv^sRQ3a@Ga3SM#1?%F%7ePS)ov8MqfST-cdzvnFc@quXKeVtPKGsLa3Z8h
zN9fm;2rtHh^U=UOjz{IiSYRhJ}eRHy)FxqSAOSGSkXwdKJT3
z!?NB4gRSdL+o;Z9+^}pmfoDM4yk0l0)(mTP6OIq7#O8V$RGuj(X3O!pVss`Kp2~%1
zfM<-)0OmN&Xv{^|E%_
zCvnzhopm`tVy)mcfYyHJ0`Fc_WK$$$4a>Gf*sDkm!DphpEgLOBqR=$!IIL9G!(yDX
znHO!wdGHvhW}L={6O2_~OTaeG+bxS=s)Z$8+bnoHJ$2ZCShBV_)9cWxRAz}<4=%*X64%`R-1DrAd=Brg`Fh<=J8M&12lc5^tU+pB%>S?+}Jr
zT$)xov2!SVO?lM&3NZZWDE90$@%$|L^dx?bjl+QwkNBk#1OL5WIImlaJnYg?;$
z*>;MwMc{55Cj>X^;>B(oKkHW?|0EN#WC_NEVb&72k|8S$Wr7IJTqau=q(YYpTET-#
zmN>`;hA1(cYGD$RVT;+s^9$i6
z6D!4~k4O}qre()0Mh!88ZjGSDSV5f+W+~GujPX4Qz#uXGzt}-#)e2J^a%B`3US$);
zI7jV3|Df_q07Hd@D<21Xub(mi4^1Wz11=y01g=U$r%ot_NDs|{SG(fhlRhqyR*
z!{G6gqsW^lxRRqlGTOI}qwk!=-#(7Na~ys1Ao%Wa_(x|^^(y)wA3wNWoXWz~$pCZ1
zQD9h;XVb$FO%KO4)dVrPl0ZjOOKNHuD9sxpKQ
zgd>dt*DP_35}4|$=6%hw*sTStSue~ncv;E0A%M1+cBmMJS|DrAUB>x2cfIJPx#65!
zMRGQ7Q85f!*nmf}GmnJ^3(<2c%gG!K)i7TaQ0l`^e@{6vV>FO7%!TT$^AkX%bG
z)>Dfsc}=gR8&(aYx@n_j-Dp|>h=26WAtyT?SbHA)_=N4g|>nRX=
zF0ahwBeYj$DmYEClMq|eEYC#5DfMFd9v`ff$F*2~7O%#lAMFP2Zxf*j(i;S6mA>~j
z19#UYn$Fn>J=|6v>_qQuC>X|Kcze$Pj$YGxJ<4!~nrVYC{z
zO@r_3p$uxh(~fsB9@{l`d@L}GH@b+y1AbkA*U2LO-!)VTgr}z=HAP5-{W3;meMr!%amx_fBPhU%
zA&1yDJ^}x-?`-S
zWYCwK@jkg>*kUjkM;`B!jRvRL>@uuy^7#n_43mK5XJ_eW=UMgQ`FB4ajy(5Qy?2M6
zdu!Ys+Pb2DqRf33o4BsIO+SAv&FAuZS}aZm9&g1wBf;aOWs=v9S)LTeMR~Ijl8TnW0l8hsFtns0g@@*iDp|V
z%*%3;(NaL$l90@3p}1tiaWyhbnN$B{kpW{m6R_k>P+Ty_MRQy-$MDB}Q9+s&xumTi
z2*YZ0T2$lJFMTtaV>Y9#*8HMEU14UI6~WA+-1u3x2wXcA_h3|JUnUg-Q;ELn*T&ca
zPcsUQ{Mh_4IzX>ewayH~DvV)s9l0nF>tfus=i@4FsRfnU5u$G)K`<^R-8iTU{bJl%
zjN3ut0?v=wig8CVVJ{|Z<+!a9M{8-M?CW*@upc-Y29E~P$xuEYg-?fY!-37Zce_DZ
z*5{+pcS(P88z~JCqh9ygvW6Mw}xSguwjr7bfCL-nMlnbtKkS|V}Y&?$n%mO<49
z^(!=6*{fJT|BNElhZ~uCT95Zqh#MGA=qd?AIiWAcL1;Z3a4xE)Hm)lsOdxI_zk-d_
z+Df2X^|y-da?(;s+b#~vof-#PcPm`G=%sbTJ!NYcyE>{JuIG9+>0pbvyWWd->k^*!
zYtl+Z*ji2CDHu#syj32&?9@doe-NRrm5olo56?MVPN>~7VYkLwIN?_1TQz0%gyN7
zDEj=)8b0ukzyDP;@58_C5N{H}D*H0@0+5Ry2w1f)dYsEX$AXV2IPbB~i(VZl6%=e?
z*_l*)aK`FHtk0uoHdM!^Z)xt(m0M2DwAEYuHKN=m6Q}1yY+zx}s2@GG;_oXm&z!w&L
zX82A4^K51f&kJ19s+cY5Q8yLeZ8bL!m5a%qtJp^
z6FQXSCFp|G(S}8BJVe!o!y;Hd7m=27QC&T4T&+6yU@S(`?QP}GcKE?T^zk9(OOy9y
zRk~;*Sxu{E(P?teyWwa1v1doj1Rujar`|eCzj;o2ewI@8_GR|%i_DuB8TI1%cR%iq
zywJThA9#FsjfX#012(ru(nX&?Xi{CdOUiPPPW!@1UpyJe=d0oU6@le&ar>RX?uxk8
z@X=kd%-BppY;__ThBzTwRmEYE1#<#a=1mDIo2ACIX+g6JW@eXZ
z`vukB>+e8
ze@8BvmNP{h7zC#yP9PaP&P1K5h%Fm)=Hkvw%$|x^(=j^^;=
z41U>viDY&JP8w(0i%BOF<8<6n0*{mSauOYDIclmWOzSo8$uP9j=DIoaR@28au0t5y
zUyMLvN_%tYxjkCcnEH
zQ8TmJCC{KC)Uq~U80c-~J#9*0_N}f2HhbZ%USwF8w)@e8jr93Jd1sVVW6rA`r3D*W
z6?WIspfa?-o?q+4JM};z<;o=-fNQPbhapzM3D>(dND+70Q}|%jD3{atgTbR?zy&)?
zHWyeeXI(J9aJR(_KF5`g7&9?bHfGKNs|i~v<<3NKts7&qE)h1SBBoTt3<14`BrY#w
zCTc3C?0AY#1CoLEe8P$&u+I1p@EB|^q^zsG(Ahy5&Un-b6_OT~*kx8Hj8y=`9|Or~
z6>*MsI~M2Exmz`*OXacZj{~frhwQ&8`)>rfo8U27Wd2q4JQE2oXAnuEd
zD%Bj5)3q+!^t0%AorG0~idg40j0xCk`W3~osbUw))?Q>^8YQs?;d&cY@o^Kqu?j?B(%OKKbo0vter{WXaG3
zDy-yn9upX>25ea${@9iY*;BGLA>*mzpE<`o^fiwm!1#KO8NOMz#Uxu?vd1KAOrkJ#
zRAL8Z8_UBo#zkX{MXD*FeI2{jhq&c{Z#hIeA}`C}u2VyGt-V?>SS_(BxR;5?ZY_qq
zfN{`|ftt!=v&v%{BB(iBA(&t_U)oBPjpDXRIaxSJJZ8krL@8H`gih3+jX^l#$i>~+
zDER7u(9eUliT@w^!Y%{1?8ffIy&4^$x0Le0hP@y$2`|xGa8ANrO5omWFM`K$Yb6dO
z8~X(tZTHj3vG-3RKRS>6`08KAtMgG>kP0gd?y4%pm&yrR71PM*2*U*o#n3q|HvC
zQEGN+>Ec-R;Z8IlT2vn?VoQ<0FEF&{VA
zGLB;091ku-sfaEcHc#XuKJGF%tj-)`q1_*@#Ag@u`hA!cb@*U@G>D|AIi3_g#+?bbtt
zRU1te(-D|gmySpbzB*`m639w^7ib5X3s3x_kTqn|ProQ+
zJ#R5ASWSdvVAyHbF)CBeHo)w0QKA-z%P?%9)(uZ=;XEcaSS`T&@>bq&R)Ni`f|x`<
zz)UBA%7Pytpg#Tw16m^y_ucZihSQa~HHza`65>jPiB5
z*2BZ-tXXyKB2km|@
z?RBK1e(0bpZ`6J3Ro`A)+Uv^Xm7D&(73rWGzO!5U?JqvUPuW?kt24(rHBPJ8vI_d@
z>?sT-#dUE!4X_2sAEyKMOu&(nfoBIRqd@^}V2@05$ethrO$&U{Vd+#3hGZC4iX_t-
zBvve%jZ03NFX
zr`6bXz^7L@YnY?CSeXc8@bx?~%?B5g
z-h9lHkGXR(H(*>ykctU!G3mierPOr?2hnGQCV|8+cnrC(F^rc|IOu{cuEgy%v?&K%
zaw%%2%_ju{}0fz5x#V^+*=cDlXD1;XMtBvs4s(8}(
zUyj7byULqKalrW9)8sp+WRBlIOZ@0G{?SF^qs#bDuKrb)!whSyv0#Ll&*15&AcxK7yr!zUl(6DlcPDXA%^b@iOFS9R1g#u99C
zLSIW;N=c&{tOk13M3pQpBI-A#jeZ124!5$qYpG#7
z4En+)!>z)P!uVnY1VEx?#Kpjee$nK5)9yxrYZm#HiiB1@2PY6Iqn4Bct7?Il#fKE)
z)|Ha~;d$pbKfC*vKfd$TXYc?0uOEK<#Ycbt>yN)h=kpJszy0CuAHTVe(Lk%91Chw5o0cCp{gJ;
z<4TpwC(MbErcw0Z|FoF40l=gn71UH%fI1?PKPHPT%_Jksv}KbpCHlq)$^Nk*m7%__
zrA0jU--__J;?hJ$p;=_rAFB=+WL>T38H_cA;R3;USXvqum(c0w7dn~QZf>DlSn8ED
zP`|8ITL?B9y8Z<9)2e#)V)`B*7X$z0(0^x5U<{_XG&&D=Xq&S~yR5v=b(a*`s&NS;dX<&2Jc?xoQpvYgMC{7`0;3Y
zw}vAOYb2je_Jbmpc*rFSCcj7Bd)VZ2Y5_BtSLR>U*;%ro@V@ZGL}e#Tvk~&S4InGz
zVX0NDPsJ%c6tV`S!S6*crE3vx(NYo_D=MNsb=u&kmq2t_VZCm`pr2ItMYb4b)hZ$e
z!>rLbZ!j#HOiO0-vc;mYSkO|(Zr3|#I$7s&0;sU>7S7M2(|-JqP`nxvIjaC?&k=Ni
zVTrR6hAC=|w}8+jwT2fC0?F{l5@(V*bBL!}PPl6)!xT$o>qISykR=_l!bmtv+rDF)SR!UNAb5#!D%whZ=R>#
zx=5=R&%gU|e?z#x4)h9C8;&iMze~m7B#4q2)+AaS4^(f`V(aaOdnKt~E!em%`b;f0ya+oHa=4o}~ZKr7pLSJ+(OKy!!p=>=cOy<~60aT8AnS3BIgE1IPR7U%P!6YzP?Ud6X
zH#&Gqb{Rab0>(*uCGD&vos|UGOj|ULYVO0nd@`VoXD&A)S6fl$k0~XEv_@;6V3&{j
z;&#Jx*yXM^0uOd0PY+_xk7941#?=BKR0-r5wm9*@Me;}IG4S}Ox0C8s^glj+00tN1
z@W+eg)KWF0Z59m8qOqCRcZvpJSariM4Kb5t)Ud8Ksl)o$F8SGg+P>-C=cn~7t$iw`
zwD|5>s$G`Q3(!)lvip(RD0j|3Lbfl^VOBF}-rA$}&n
zlRs7k9tZg;86>9pV|7jNSjayX_TL1L^Rc-~VzH4~>X-GaHN&WG998w}Ro$qp8I_jN
z0>i`7!b=T`^Zmlyps>)*FLv^aE4c-<5bSlo#2oWKftdo`WvzNKeUFcan{Xb&gH8G2
z7SKx@>OI~KKc<~-!>k$(+hT85fiN1SsP%6A@qX&bUi!&?>d}7c_IB)O5ctiKG+f|mekEwFvE6x
zD6CC!X}w`etDn?p$Cou@TJ1P6Y}8K~bkl$_+cg=-ZC&RXSQ7mVDrL@18@};8=O2C$lK|vc7G!S5nHY945
zfHov9gvGfaKV3}e*P6b)o^U)AZf}Mk>_%aHA05TujGvsupPVM)bm4a&AIG1ZB;Gtv
zzk56X&Q%UDes-Dwv!5Nu;fz&aGm9K2W}g7$|3~YO?{2b;!i{Sr-&>b%uK~kU4-Q88
z#R@&?k~S6#VRU%89zGogR!ff6l6!9@u)8Adv;-hoW%JP>xZja?+kvfyxZ4T7`{Wcq
z;`!rCR$I!Ng?)_LQn*<~F&-j@5q%YMkZ6HhvdFN@iaimwB_j@!V#i;K#!q27Ar*4M
z4Z{Bju#DW7SIx6TFdZ;Fz!O=`uimLYq2A7Z!zJ6N=cIHj2VmpT|X?c3SgDNDimJ8
z_ywNRc*$KRmkb!YplZ@pPuUwO>uSYwz7e~ESHe5$;676pk_eQ=)m$yMrScT)e0KL&>DIUQlRpkFB)
z+a&|kt&k^XJcctispuWnz-AL#RVtX(?vV8
zrY**4@1}fAmrdw%P*hJyjvL{O(a9)U9BCEZ@XD1G+$so7H8h}1)KE;>U>|qal3T;r
zMlVMB&rIrMaK90*WI$g#+-E7{E@IRJTU-)L8Badx!p)+Xa_3`Ip9St20+Q2Vb1Ck8
zd@=as=a0Vn^v7TP=|^Au@khkn&wlddpFjFS)t`XmpM3qk;Ji~!J9Dh&3w}BT9v4#1eA0oA>WR_*lR0+ccp_}T38^T}MrY&Z
zL|6|(!=_hq?p(r3nO|XjIpau%F|0AGlgFwQVHS2d%*{l_xoBWs@{g-XR;zOaUvvWK
z`)+~9VgHR(aJm?sFU4lNMRopIJF05eD%!QOhG}_JT3jnHjVg_g
zD9!ha^9;}Pz5HA!H`B?^pfe~f^vlcL(&9>CzEfQ2mA?P|7VpCf?}k|cYJpZ5uZyZP
ze#{EdJ=qUG*;k(IL6OH0tLXIPF#d2iaepUqXD4>K6@7R{ss3Mo^+h%73yX%Z4AST%
zKUIR{{93KcjURosk3
z$F<92nx$K4mzQoWE!@;Dj#>1xx~0jb`7r?SKo7sYW_odM3@}!aY%wlbP0J3e)?wAS
z9eS_Rz-02e;EXLiFw6nHAgfLC1HCq)tY`y|r58N@XQ}15ae^dR*}JSkk&c8!dx*Cv
zf(1N|%4TMfov_6P-1t)7e8QEA(Bz+5Dny}*%Cwv&BB8H~QlTzANDQw`tqeTRgU5-$
zd@FC=Uhz{_*JkM6j&grD`e2XBVFI+!^CO6Y)$g8X-(!0BG{f?%71-jpFVfG>k}$+?
zpXc7W$i97^c?-J8yn8$M?iFoa^MCNTHHGUno&kSiocy~j7WM#)PckbuM7E>1KtJMGaqozi;fx5KFwPvdCR2NaLcKA&82mpeas_u=n<@xiCR`N`*>{P$n}{EMG|`25bv)>^kxN`+#wD;MFi
zA$MMJXT$DH#FL4*a}ie|=EfD3LmS0i+MAF0a#0Tu3*$>ZI0kueyqNH+wphh2==%>C
zryxHeIYmfjQERt~-j@t6qmyLK{Y!t`$QjxN<4V!gDVaKDQ@3JXDH%Ft!z(zl!t_y0GeATQw
zpRkwGu2xy>*2DFJ&?rh6r#H(&KIJH6T(uHc%6W?!SWIU=<<3MM1m+CD?8+w`*_fq~
z_y73$!B=4Lp8(?zzCioOAAj+O52$4%hW_@a51=o>-OoSz>a&jkV4R7kUw-xx^u?cl
z{FmRq_m@xJ{p%<1e)_AYn=7%X2%D={r3SHapGrq>e8yZvoDcY>
zf>h3WD&U`#yyF3GQt;f!#j^|qL7ZdLXw&HEmJ<1*C2UKR34H^^iXLkzf&XojqwovDE4&JmsH$g(E@V}
z$1MBFKnHmkO`2o{>cC?bj;8vQG)W93dtjp}N6h2UdYwAp8Liu)grm&pOMiQ((k
zw&=3VJIwP|!;D!!Z86LmbyI+`VR=lucw=$ywYljZPTl&?rMa6TXCDn(j~`t9=9mBd
z*{8q%{Ifs&;getg_s@QOc6!ik6nUS+tXl~34$))sJAq`K*G2Q$5X?F#tJ-3)HYnN&
zx4bPNphNu^M+my;LofRw$q|(7;eah9+u)C*0b3&EhzH3QN1>o4!Zs}cba7S3LuSAr
z9)`yNiJC>bi|bg
zo&jkE=!Gq&5?5^15b%tab=YnV>Ut-(lM-Aq%_YZV{Bfyx7Dip_&Ws^ui-UgJ>q&IY
z^UfL0Hpy8h{FX7^G0EA+?92aUoc@0m728kVzWn(vm9^6l;To$c72t?1ny
z>fGCj-``E#*$Us?4n3ya!}znq=<}n
zrF3Zs!)%`kbn?s`XO!h~%2ZC7vk};3Los2ZJ&dEqLd;ZRZuq4q-sne9_eyZarL>(D
zr}Ph6ffkjhq;8qka0Igv^UYH$v2Qekl^9)g*m8x}ltI%*=t3<*V>i0IG>Qi04l
zb+hDve>%X=1cccjH=T{)pUsR~#TrjVFO>uly*I&QnRa}d2>8bWzFPs`8_B>_E;`rD
z>AFRIzo=WS=!SrCahXjRFOJGU^3pYrOMvnGur!BOr815Tin9<7_6sn_(@?(vuM8^B
zwldSL%nUl}#q>Qs9`A)7?S>yyI9i<^jy^qzfW!}XLXURBc=}{7dW~eNs+fFwlzem$
zf3O$3zZ<)=lepN3{_dAl8uRJx&3x3B3_Bu>B_ZA<(PpmtfZs@n_2?v@fo4fXTSy=P
z2RNf5+kv7;5O&!Sl5CL7n?#%j)5(?zsrJ`lr!rfVRApWAy7V+nOD@^OvZl2#(^TXO
zNVZZzO}ll0igf_qaK`#syMD%Qn6c=l44Mg(Zpy41*UY`LH2WV@H~*hT&E(yyldr${
z?7MHj`sSOzef9MhOka||`U3j;>uY`U%~#)k`}J2}{^jcYFeG{0cCFyYn1kkkVQ}Ge
z1EMWJ+y!EtDuAy^EHN=R3{Q-6&{9XT2W1DfB)r`cq>4+bC}gd|SdmSM>zYb1UTQH1
z8~zzW>ilsmY*GSx5-}LVQ$s9dh=%m|*GEHDX`z_VuQk1UJ^#^wyS*8_yBm3QlAwev
zD(;bZd=z_xF&6G?>f|wAI!S=OFu{z?$#>4v?_Ffxzs$UQo_zlj<|Fr$`=t->7C*dO
zP%oZ;_v7J){BSdPe?54YV$>9!zQ0bZ;qR@(H>>`bbay>;cT>5u5xrbhP6yY!6sT)k
zPex&Y8OCd~;RBT^mA4z(?S{6yF?{}~fBr*Gu~0Fo7xSjHq(_}wg<>wsLyll@@4-M5
zowVXkhdk-9I~_*fl|mb)HW@+-JhMqneq3HNLEF(
zhImQ^2=U81-3z=6Jf83xZ+MNbyL7Ku7XBkCTR!>t{qMf}^4o8}`u4l8{{G!p
z-+cGQx8Hv8?bo0G;p30?2P^MAe)t_x87Tht+i(BQTD9}{Z@&8L<>7WA!dDY~A?8%5XJA=4>vdAe0U_7NGFGU9{aK<@5SWr%r
zIR=s$kLd&ux|()E6t9LkPTOlK8?|X$BV$|1+qYWW`I>TfJ9&E>WBvH;jVM*kTvu*y
zQ0>gyThaS_umQB4$=#hGZbxsQrryOck*?D8`k^)-xzmGIs9hF&jbN7vzg&>GUKG%RxQUQC8MVX}V^CZQNz0L-o39<}ERponPr4&q5%y|
zu;ibTxM|u5nVS(k6Cg4AIEXeR%!b7|v>>q}&I#@@@L2THo=eyA(Z&yg=MB;Oy6k%+
z%->80Crgo;W@fQpR^!#+@d6w$v%(81aa95+b`XEO3m(Tn>nHoPfc5zayj1$xN&4|&>i%BxYAc4D
z-QWK5XME1lTCSDlD`^3@n}A;nu7m{)gBNS!BsgKFnrVx?R6wL$`h1+ke+R@^B-nw`UTVnFLwcP*r_
zc8E%PLHHxaVV46C{<1V5q1L%1HnV*gW%rWko)=v6oNb1)j(d%7xU{ePO%q3J&F{YY
z^LJnW_1nKQ27mj-ci(>T*(bmJ^-q8F?Kgk@_M0!h`12o6N28CPKLe8g{@vffVfFW>
zKGdflyz{u8mFpR6O0pd4&$yLN3IXjgz@zo
zRSZ+4ItAD3sinO2l&_ZIsu`}9_Ej^mXZ}jgOUl3#`>H7~%yA9QE$OPJoRze*mU1>y
zj(XbB%~Pt~)n@E+D{%=DZ^o~#Yk(-%{uu3M?A})7!S3~q=*^S#+b5}aPJv+z8M8mS
zOuusyf3g>Neh~cNBKea$nV;VMSF7ZI(0MUc+$$TqB|X$B>w7iAFl_O)KxG_ZJYH>>
zR-5Lv#qxb}5H}UmwsOW!NKTjvX=|XpKcsgu_>v^Es*(mX)j0c>f
znDC3G7XV(X5~voqW>sw0+SfXi^1o=fA5dKdGk-dedkZVd-qSjeHRA$FMoLN$=wZ@b$ks#H%co#bZ`b?S%dLG
zJY+5T&ud
z8H4e)Znj_kW
zqncx9#dR|D!C1f(!x@9bw9@H}BGS)J6Xb@^Qtw}6ad&(7BK4!I+y}SwAKuM>bT9Ye
z-RzI=WIni;{mG-!&mLF)`*G#xk0_n~|KRatBlLJZ^khBsXe0b+OMxD5g&%AN?u>-1
zA?$LPki4O=jm4C^bQ6!AtOCP9=xmMR)#sz=*)VcC2p#tVM?Lv`6akWtSL1uDGzI?2
z?|zkIiKzL6>w0eWMMg34m?a*o9R_13QJG@bglcqXvYA!3f>$O;<4Bmo*U2E8MGnzl
z4PrT8v_?4*VoQ^W&9nz%gz9J-qr6`6X@lM+(K*jsXME;ypZS(cdov&LfBpIIzWwsk
zZ@>EdyKnyT-8Y|q`?o*8_uy_T7HvkOzk2W8@4ou$cVGVvm*Q7n{^jrAeElL?{g20s
z=il5u+pT70jFn++8EE0n{DnA&_Meio2)$%{uj$K^5<(emN~mPSa*882ob*;wK2_C}
zzn11|86KT_hHvIXv{fj}<2ZO+&d@s5YSv3@Rx_S*%2iDQ%s{fUo^}Dls+u`xx8NMr
zJO@4Lax->kCwXT(es71wc9n?X>HXcrqy6-wz0||q_`|&z-G~m;&yO*DOg-I?+}RKx
z?gZaEOMQ4d_Y+*Sx3l2!N4Nhs9(PNIPEpr|O8S1)(5vdY6$wOBggbHEE0Tw$O>_voRyA
zaI17(v6*&8S_!nv{&Ln12$gArVXAhSiNZ8n)IuDIkS-R`sH=o?aceo_t`+=^vQ*Cc
zOBsJY;h{?~YNt8lv@0FAL_>Pq5pWj>a*F}qVwhiA@5Uco_TGQK|LG@h|M|D?eEPfh
z{`l*+|HSmkFP^~!?~d}>s2u~Vw;t?#{Np>n{OBGCZCQF{tCRfwe?R`sNB2MZ*`vd?
z!bUs#8NKUGyb+)9=ikC)6W8B+b_7EpdglZDGVVtdoeOAVVM8RSQx_ap^SBhe=)e~D
znxR-whyR6Ifx~b?HP9F|1o_2O#Fz-{6={LYF+U^oGlFjtUKtD)SV=F@OML>ccbo@<
zedC;4r82=7Qe84S0g7PXP`F!B{zf`*tDc%`XDMI0UnB+(ON+xIn@)Z?Vaz-+XiX~5
zcZ)Nf!Zg}mX{KMA9aM0TO(Zh|4YBa`_rL!5x-JB(l1OzS4kB>IFG!q#FbIA7B=gou
z2LA>gAH?tPD7QC*w>K%B_4Zcm@j2u1pMJa64CSc&vK=M>IAOAayCKmc^G2EWZMDRL
zl=G5~xC<#h74e1zSY)%rTU1=BR2DglTHlJ+@6wuGlgDZFI4y1mI(TXp{1#cT37m!2
zM1jO^Dh*9?>)mz@NUY{m!y?-(Ggjlc!#Hl!-!d=XgjfFK?>_$K@8o@PHCkH7xJr^uLwwv2jPtIPt2W(xl>UW?&*|0q)@%2eA11390sGQ2n{GP`br8(8rG|A3rYt{891a$0haR`FB4aZU!I19B+gkZ7L6m#33Ac
zv_sP?k9MP1qu|vjp!(yhweZz?jD_)HD#+QoNm(p
z!ta0gE2?o3r{z6F;)I(_Mck3cosBq6Y|hb)GUe7~qOizhl(P|cM)71Lo=nt}jzD+gQ{_rLu9yDvX`aJYMWd*i=9eCsd2|K(4f
zK78});@hvk`UihsKGXx>e)shkpY5%+t4XPn=2%V^iIy!TfMl)^_kzLTDA-(1`^)Ur
z3VT`tu!-4RG377gy-6_GM+{DL^^8Dmnqb_>3Lr5%NO-PiB^;^cgj!yx=0RwG1>Py=
ztE4^kw6C7_*3-^L+R@5@%66E>X3o*cJGR;a{xqO3g{g6G*^J!ZNj%(7J=ja%{r~dz
zpFxrx=b9$SKWnyYz1`E>@`@H~wlh6Fy}L8E-PZS#ga!$%32G9eWLD~|%FI<$8ifcpS`iQtb99rr}OUpUmJinOeZ_yCp&5Rfskc*Q`?#%l$k*4l^Fm2kkAoT}>VQ7yFo|6%!(U9t+N+a6oxr7%E
z6`NqQ60UJsE3Gvpjpq-asQ3ZA^{q=2u(m&ccjv=*c76uEz5TPdwm*1d^UWJe%`s1c
zz8lNsiX!<-q?EYwF__GUVZ!K;?LjS`uW>C;4z;2;oHy-
zT=Mmc(_tTO_tk#aalv;g96SeqfMx-ZEDEPp2~Pby?o$l9RglkdEa*9*hR%W3FwMA^
z@%(BPjSt3SXHyaHO9p)bX2955x8G8`Zb{Q7?@#^QGcna?j=rTR3K-=%PzR&
z#uq}a17@f+9xhHwB^kA}SubnV%W34XQPHZEwrVA9I`|5UOaW@%Rm^bxWr=a=j
z0(GErRI$fZj~r+W`|7<;irfNAZfA|laULYLu~{`}D3SGCQ{$P&hSLp=ryCnjH#D5F
zSk5^dbr$RCdNx4WLiyMyt#veMrKPUAo((vrMJ8zZ#q#r~j+{S!@ci+^Co2xEEzSPn
z^E6)KYI7p)r(Uj*OsQk_WHM9xe5z%Wo_YnS+V`pu}f>SpMUb}&p!Fx
zuRnZW3kBYP=Z()k`{d52AK&@pQ~KYh`2VM$fBwmvuV0r%r{HT8ybXf4(dWWvA-)2-
zU@#X4Fso3VfX#NI67T@tHG-!m^c
zC%!bJUY@1g>C3Y^Dp%+AYm3_TMKD;tJ}*JHmh@Lwqpz$$=Bvx*>#NbXF2vv7OuVu2
z7xKp|JpeEzRP)MOzkii!rO&rE5Lky*8VoJ<3DfQFi5BNfhi|qMNcK;(d&k>-(_NwI
z&hSKAV64?U-670%2WPv4*=}LH&DWc<_2#^|{>Q)nh{b8i9a7(FnEK|qbT-8!#0GQ1
zI+IaGg>@FdE)$ypX2xcSoH2`9lY8b~87gFA!$$k+BoABDkPQef@R$~Aq{SJ1wrX$F
zQ8*cALy4=t#CGn8F+*#>-x^mZ(qH>G?&-q-~8;IKYaYF_g}sG
zi+5l7!<}Ehd3|Rhm!5BHo$TrO?9RuZfBxAQSZ1})$T#0vnjVgej@WMGnGh@5;C-VK
zxXboXuP|WT1nz>$F$Hdz7|aOG_R}F-oYVv*@b8yZIE=YcDoX6JB>`g%M!6}WHIZFb
ztw{|6%NvqPV@j=~RRpz~jCMY&pUdcHn
z27-(5%Kf2*0b#n+HQv%R)nSJ>!0qVDoPKpyy*eXbou-s7!1xxlpxj(kZY};v9#f1u
zTHPE4m1(|+JrYA530hPDB^QlbW#aYj^r_x7@whj8ZmipbYyIX|KTFD$X0X%{$~Awb
zPJPBlRm!QR4r4x|sV!xXYiQP;ib!WshP_8c-!YIFbpSZzsp@GBWMkHWj!<8l0Mo38
zaj%4#KBojvgHnR~XwY3vt4W8>x2C-Lq&u!RMdSvQMBh-2-&q~>oaDnWP$3+8PBt}^
zS{lmg&mKNr`6IO4w^sY!es$%;w>N>(pS`uiO49ppP*?E>Z)^a-uV0;;8O=`&rf*-K
z1*c!TI@^{Gv}c9Y`OXjC-hBU!&7Zxw1!oKlL#TZ4<`yjSSbx&zI3Dz##*6xJ8}gmP
zT}cX_2?tI=sPGX`tml}=^uS%3Ym?6(0#wKK23dfoKLLvz^d1F?d9d2+D5Xp;Td~hs
z1~$VYOG34!_GJ*-Qu`8k3{Epqq#8)JeJOVBtbfT-_oD1A-C9bS;qtV0G_6)-l=3X8
zG$)tjmExRI1mf-@wm7dI<|O87)^L>LnS;5cSt}5lBboo0zQV^Qcswj@g2xoV4AB~V
zW5MmQ5bz9_%*?S|pz@@=J*jR_Xj@bI)`Yq|Bu;b&W`{Gl$j$3JfQKy9hS)^*AzzK(
zQ|ob3=CIp&)O`Q1mq<=x18k2{~TE8O|?_aFVLC2a_hWeEUI}_?gV@PEF|)-%Aep5FX~72gV@Y{vONxQXV+**p8&bIBQV+NpYEcygMj48Hvd$6V5Tdy
zJ{FzpS3mifrgu#n&RDp?EaWj!Pile3Y_4Vo<2p7L2qZ3u4cG;qiOtM66N9ny3lbB6
zY4|dqCYrLcX-rfte(f~siTp98dhrBo3SYZU1?(rhP1VlEN?UD-_1qCxUB#<6H~#R4
zPhf6Y`N`*>ef&A4F95Eezj5pOt6Lk}lOu24z62V4^825^|HjSV|K@`~eD=E!KX~U?
zzx)Mdbm2_OxCWm;`@yv6dket?PGs?M)
zayDn2>r6C`wtA`M)FUhoN@R!!LbH8=#Q|YuC^+Bk8_(M(+nfu1ft4ZLqm&)oh$fYb
zQ|jeu$~U|=t6ZPOFIl?*f4rdG0*n{*TMK_G>yZ27W8iT!<8fhr<2XvH^U9aO+@3tq
zUf?kWt9k!%SLQsf^~uM-ORGm?;R+*I9+Qrx^s{>KnCz?6gU3^PZ6th3@>YqSD%f8z
z7$k;J-}A>HH1-Rwa=}%BL)dA``02ntp6PB4PmLsodeolwa8$vsv!*rUi^z4%S)P&w
z3X8!OML=$;?H}rmUfmvh|Bdwz-vU;N
z%Ao1{Z*6_>*7iHEuf279`Q2AnuU!~jnrI#Ej-iSA)~%ISuFMX0>2mN~OtZdnZH_;M
zv7Esen{RFX?CqV=zJwa8V@tyx2aiL6vr4E&37^v>%Cgo(%9B)r=hYCoWJ7}0AQ^jOvd?xv_LUf+@}!DeVP#q_Pf4X|xdh6{#aX#HBOS@fN5E!)
zc2@v%5!9?5fmm-bDg`z(-%OjR@E_Ax_+Xh_em1I@&Hn(6Q8L%AITm@~`qHF?U;o8v
z?c%g?aVBzMTv;8K76zo9rA}Pr7e9a3?>Z@XD6`s6I_Ghn@wv_mzIs524e2@UbD!1~
zOGL4B+`D;A$EuRTjEJJp^k1CQm9?UPS_^XZ+vL@nwDW?5R4!1dc-
ze`tpM;ikrpc;u7ce)#)ezn|8Gr0je9^&5BKsQ-rt<1rcKKYaf2`r<^`X9)+IfDVbKDT}LTHiHiGjK>Zr?&31Yf0v8g$VT@}V_(9%Y!#M4<(1
z4UxGwHhnDa^rcg0bzL{xI94f8!rz?O9Rq$r*EvqIoa->>hw)@
z`DxTsXJD$`2PDsRhavD7_x*vK`-691$M-nYm5AeRCR)flQmD2Ou7mw~Ii9I6Sr0X+
z6wq$agAFQ3Ot!cd75s)30bdhiGaNHqGQpSyv?+W|-wwVS5)WL{*MuhNIT_}G1+i%%
zCbk}w=sp{!39e5A{DG$Grn5&{)6%CO|B`a2KQ9bwV#(7C$bUff&XujTxuO1Fz5T`?
z?tJv#D>pC9OkcgQap(8HXJ@dpcDt0{ee1QjD#S#mDT2Wuu>&NIigqJxH7N>hjfSnU
zur(ptVj}iiW1zA~JjVGj&?M>)w#8&Sd~<=dx-G8R0Opk81dJ1^GpR%Nq)tdK2qb1o
zP-#t3*#H=)wZ^p8kkK15MqNrfpVMoa_49pc`*<7W;w=ry(0pHTqRlnY=A3GGE%pfO
zL-P8Fyf!MWkBApW<;^je1pI*YE7RIFXhyp_OS&?vLN^$UZ!P?(ti!M6BggZRYKZc-
zOzw{%V3-2b?eP=50swP1w*t(`Q#@+TgbIy%!o35RYmL`V_WD{AwTiD)4OFOsO4(PY
z2dm+X0b^KXnbr!d3^*$idL4XlL^@BMNuFw$;IOw^a8+rcGYP%HlxyNfeaf`*B@5Fr
zyBeY>E)>%m+H-+))Siq`&nsMJEqG93-`V-_-5q$}_g-In@3pnJZZ37Dg=W)rZDZus
z%QNrXUY!}qXQH08>At)%_Tk%b#w76ggSWTA@}IqXvAaVHxM(Oyzs#_hB@BXR7YS&X{~t~Jhq&tc(uLeB}eUxqPHYvoRWP<
z%y3y;DoscwDXAnW9)VC{_2QINoR*Gc#3SkO;jDC|MJsDoOQF0{l9h|NhlU$Q*{mFf
zTD2o2^{ZdsiB=LN5{EC0hPFmR+oOffW9E#di<2UaD40@c&!n<5rR_}WJJZJIl(9Cd
zt_(=aLzEZu=_kKW84ivOKN|b)vp&Z;uY;n{e7J4ETNfnQ)S}S_f2@WY*Q
zulIx83}9Yojh7`PvjIX3x>P^spou5X1IYk0jW2T2$Rf9$x}4#X9ZeM3riroG3QIOV
z(7EQQt>&1m=D4%rg!Nph7Pfy19#aQ!A&HtHnOyECloa#P^{rLK)pTup{j)p2{peTk
z?JQ4STAfa4VX*qnojY{qmmYgO{_M_2a})hq$Qklmp@6p$REA3yybVDX#72qFg^J%z
zCF>-HOXlXdKIo|nQH;6{e+r6Jqx98?0g5z$$FRsW-G8u_6Iu?|;ZLWti5jA8$^|u4
z17}QGLM($<^5c$=M&~I>I4M)^NVO@R=t?(^ce!VJy^H(e|%+DySWen
zi8+sNE=B-jVEDDQ1Sj#UYl$06=JiEj*u1$CyS0kacd^Rg$
zGw~QyhJh~lW0v7n4e9
z9JQq*ed#}Z{u}r&@R+0M^zU%$36IrZCL&=?1zbpgTTjaj7n^Uv=5erB{c
zu6Say)0FKb36v#s{6(-D7?$kZD-)i{8Phos%g-VVlQUKvZ*M?=-;$>(=Tpy(&m%Q)n(v)&(O1?BHUxd)OA)R?6b4=YQ4@Y0VSIad0kso~svuW#~b^M`L!;2M?pUcd0ptLxB>
zoypsmreC`@^Tv(2*RRjLb!+ME+skjk+U5suP{jM~S61Q9<>1+<
z2H$WR=nZ;Lh5V-k|H+VWIv6-5_^{_V=o?`3gn+>)rN9|kI3H0Oq~K{SObbi+9TjMi
z2ri0F%faJz^EgUfwqn1#0u>?os|z`lmD2$!pAzB;sZbNJ<*&^u*j_c7{7Ib
z@szql&R9cbYeIoJULPfYygV41>kIN_o#w}LO7J{z8y0E>Uyb0c@j1`?Ts1U)$$pN7
ztj`L*^Ej%68xs+CM7GO9qv)#-xog9|deLuzeFU_CWRH`E>UvzYaLJI
zj|tbgY&FiNvuys2bHrx8q!KM<2rAR+4wm|3mfG^h+VX~)$}2m|u(NDPG0MV&Lf6>*
z_&3wTeeJ2}<@M!HKKjLHpZt1rX~qOX{tp
zFlneEsk>AGNNz|NXgAY99TpCy>|gLe@}CWPkHZ#cqt?!h+my~^BDKBEj-htvXuD&o
z+p|0*Y)yz)W;Duwnboh)88;S<>r2MXl?c4=?WM>o%iwYJ)^e1y`T9IgQ?LgX`OOQd
zH#QQlteN2P8(RtfkH5IP%_tW*3p-+qB7qbp6(JRIs(((;gQx5r&n5cfydYB
zQ%TFTv=m?F0md44+S4KTDJ5_Yx7nY)cauWapMT02{Kp>z-d)iqJw8P{`JFdzW}{+M
zbP!yDSj8SwiOQV5C}R>kL`NNzM=d)TiQ$H6C+fsw1*JWqIw&;F{W0S)EHdZ|f6Ot=
zD=ctr2Z@@yC*y08vv09hc8?tI$POWX$YdT`}lO4Xb5p5kBQdS40
zl|gYC-|rx0b>W7yF{VPe`D~2IpfYY;o8!`M)Ec)Y`O=JfbweK7ciy@YSB@INO3h!P
z_^V_e{Bb3p{R4tI=4`%dZCtCxKUB$I4bvR*9u6uC}D+T+#V6hfkl_fBN{oisJ7d-uLv6zxQCkeR^ZD@7>on-hYF7g#lyKIgf8$
zn%Y?C9_@|wwJFUBFTTs>gfAQQbY#QVFO0o@eGy>B`MvFm;D-0Dur(Gtn<|~wDlu?Q
z3DpE)kv%7Zfio^grPE#kH_Sb8z)4eouypIwrqUR2RjcATDR>4hnWc1{jL0>#KBIW9
zuQRMmXLz462<@;IIhvruF8dL;jm$Afj0z82^Vl^23>dTSOyYZ@2dZ)
z=sXw^N+JR<3>bsHWht>N7AlSgk3<58qrt70+Z~!HY
zG8mkd4rRgzv*Mv<6a4x6uYdHrUyt>gQKdl*)xyJtz+(@76}15`iF%P8XHbTGbs;yXQ>O$i
zppF`{Mr5ZNvPl6;5CGc^@WNkuU3eCa9df(s2*A!dw{tg4&F0wvj9KPX9iIuy!<;ns
zleeY`vra=!>uGz#aeKotN8?dzZCS`)^V{FNcjwMWKr*Z?#2%k~atCDn?DE#;!o=|M
z^x(pH-%xv|D`PH<^{>rN-M)I6^0&V9fTRB8(~s}m`S_#X{W4)n0Z$_s9P&1XJY9Ho!;3#VXoH?f4ntG
zOEz7FGhQ@rEJbfF$8Ii1uPx9ZW4L74iyQOWjalW!g7)evFr0j4J$ZXIPL6p!`Pzl#
z>s#s9x00`4piv%wfyZ)hV6n@;)FUkR1Qz(b5UBTtARu`e=6FzC8I<9P7yH7j6qowM
z#a>{TLel{ALT{LM_Df6s@_bJiNX8*l=6aQ}Hu2T#+jy1LxskNyfKnQe1Kz+3qGUaz
zZ1fKI$|!k-Q<*ttQiO&KHNib|1~UUq(glhjYLo&-oQAh9AQ`35sQBw~4s|>i23FCU
z|14{a&ZikJgI1NUMyX`Y@!)GWw*K%L8oqZ3wagn+g){hz2Sv8=i9Y}AlN*;e^Kr!p
zJ0qeqDmz*Fq?3j%$pl@_V2)&z6o>|f*&zr%7}lBp1z>hbDj}Jq!te6Xv@>Zq!C*LG
zDs_rlCp9O|
zDgJUzI4XL|)xc5sV>n~UTLr-!tHBerEJWyJz*)xqF_5eVPpY9)VxT(YI~Mc+SJnBX
zJEk@IY?Y$-WJ}UBKc1Z%&$MOzQsA`Tc~qvvkn=PKTp>kO3lJEQEvDL}hU+1=&djN>
z|GcHP^vubFCywtgE%{+(*-t7;e|+ZTA(#E+xzj~e=;8Ax_IKpOOBK4#f4xRNnj|N;1bVeyORJ60IGL
z`|Wivg&l`AUy1H7F@vSiP)RIANQPqJk|>ZIIs!18LQy1ekiZNWhl}IEqL^^Fpx~ic
z@L*Kf4<*BgK;oQq7-c$iASvwQKjM5rdjJ5wn@L1LRHm=+u{Oe{gzXpBhG77MEDx!-FVEpRuix5Qnn-muhh!Kv8UzALflsiB
zH9pT-uZudB0h_RoGMGZXLUcOhw?KOi66c3$vyc_#b=JFF4Nhl++tKK8Ho6`4ZU-P;
z$6O|^(BOAB0Lgr;5e@v^ogT|Wb70YG4KCYRSJN3MEpd3fv93Z4G_dL4dA#~#fc7&U
zw7vuLapw=8-MRD0C%m7I?s7E8!ky1P$G*b(Jl2iPJD-30%U`}9kA?u?kk2N-76+`n
z3mI${16F)?e2{R!%03i{J|F?OKw>E9sRxh4lt*1B1?ofa$1ukN%yEN^J94OAml}1+
zV#pRaW575Q^{^@Mtmy~^17TAlGObFh1bIxGz$^#O(e$yt<0=h4KAwxzjduE`djkst
z!OaPEXU4cVODU;W=5gCn$xqB1SD-oE!c;is+eH?I>JBy?6a)l;z(vuRw4>Y7Nq6U%vb1?Tv-WuI5BS4MZhR
zLh-~zS5$Jv6psn-%fr-QGm{y1P$_aZ%z5nKc#bPhD51LW7ue%5Wo)SqC`r&|0A?gk
zM_`M&6)srhFA1ApHp+Mwr*ab+Wy1m8VR53
z%(_73u(t{p849{9(q=0nS3ek5WWm-G({-GWU!e(mcfv3I3CU|AgQ_u8L>n&}l<#<*7$-;L%eHzr;}>l;KXuf-
z=&|k>Jw=k|h!!X@g2hIt1d32utOpJo{zDKfa!e?R2}h!VBGZ4!^dE@Qo+I(#5%4$~
z0FMib3I}8U{jkeWI(#@I{u%m@heeQ>3siO!TdM@E
zx@b@6zSgwjbDS02wLHz3ol`5gP^t6phNE{uTjzFJT&{W#@a&)nHmoxc&YkogycwPg
z5pPteD|)xW2u+-}(R|m(dOK5}-TBp>&p!H?O_2Ey!_j+nRJb^dIf*~I^XW&Qe*Bx+
z$pJZN7X@e7?-T=$kRRN&N-x!Bc@s4kF_w(=?Dxf6yGk)Getur
z0;i4OnY4DkH*25j4bJul=LdwvAz^tKUv6+~oHF$;Pf||6r78K=g89mF{Ps$m+vVG<
ziC0#Wudb({SJslRuE8HCZmq;`Eyr>6`aw;H7|c{4G#oI|m&`Fr>;aqMmcw&=IEQcB+A&|b&fI$ygqPTw0f(kCqnh5Mg
zL$+wxVTN6C*_%>)1Y?HPsNygc)@RIkY>MD6J_79Tmn5dD1sIj-
zkHC-&E9_3`^e19}D^QjI(m*Z0{!sjn#>+kJ5*p`l0nEhX49Su)8Z%mbbEIJ?=bq_?
z@m1D_jpZQ?!k0MLEzI=_i-Y3QkixY%D6`aSX=zAa29?Lujd5*#Q~{nhCvcC_FVC2l
zXW*4_v%=j;yD;%5=L6y1H*XMnx$(_Ms&YnUPOk)au^$zts=NUn<0$20v)Mv`WSYi{
z&E$2eIeMxkewOzow8iVA;bW2Dv7A}gopVdxO3JMER)sy4;Bm-P33Ci2!yoftb--Ef
zca)jRxt6q(uQ@2Vt7BS2F6mH1rxQj)N8Se}33$5yXxMi=sy65%{>`5gT-AVa%5?O!
zEBTZ+5wUAxUC4J@6YIfdx9wO{Lj_=b{>+hcXAYk_ap3fcgAH|+XHFHJs6KG~=)STe
zKP*1<{lf>IfBD6y5AJ*Jz{}4tJ$3M0JbU8ki$}|UbgbgX
z$I5?n?)b}=^F@}LB3pg2t^SD9Qtq`M^*d-?lz@vCV;86k`DDzn!0&n-l|lbWF2P3=
z`Oo^MKkl-Ycpc>)dzsf>hR+Tv`<Kfl*-;M|^C>fF)=Zc6puO>Bd;N>{+Ml`_Ueba`CkJIcRH^t&^k7*eT&4$0
zHQ|UJIARD#B2eHkoH1nh4w-;)pePnR62%_>LBo3>;yVZ!qmD8fI0#OgV6*>VJaB+%
ze=>N0|CqkQ$NGr4F)D4q8IP-|&{+GC(E3PleK@=|0XJ+y491b2DIHDG?Pcntn4y=n
zp18Rhzp)y-z7oB$9KF660fqtNTXZN%{&@8-)PKA^=-=-5y*3m1#f9egm($lr)e8gS
z8rffRz{{MzfNrm}+^;SV0ME)opR&*|&G&^D`o)DlBJm;tn1`&vW`LPWwjY*DT^!JV
z_ZwPRVyrKX<_;OY2yrE?J7Jd@q+Q?&OCg3_P*QP1QQ2n7)~LdIUdd$whp?Cc9$Y5t
za;C{NXmC-4=F@-*@ZOcx09n5zmd|V>HivAu6hnJqY!aoCaqvrcQ73Blbx0zC>lw5trO?*%OmI05;LOKwm;H2QZId}0`bis2^}CYt5L1rpOA
z=YLSfbo0uWc?{uCmqtamrvYyW70m{JoFQ3S%%-lCt3Tr!Y4*@;roEwge4&Ff=({i=
z&Gm)m@I4ODI1UK=cPls)oaylc$(y(r;T|;;+nI`OO_-bGk+osm$8>0O{7?2DbK-L2
ziwaU%!f5|*NlCZm6@>0k;%ckN2gA2>-yDLx!jI%LoOsxrds(g;JfV(2(J*tMz_?=bmrZR|@
z2X-F~dX5ELRRLF}5!XUSUfvivHtT82+ppWkjx#0w?id
z(coYomL{^s2bTmu8m7G13oGm>;gM>_JukgW=BP5g;#uclKZ
z+f&As8S~0)^zv+UXC}Hm6~(WAeOw2Rr@Mvaaq3X~!|E?swM60`P2=1&b_LB>`U30-!QmY4LlQS9V)`?nY4A
zO%d!yw+raSX-y&j7o&_I)Om0i;z)*b<%gJsr3(O2j0`-8j7;F-QxGd)}g{gVpB#Tj7qDoUlhBJn_
zvBVS#rABBc4KL(}*vu8R%qZ8e8GBBNK3eu$3LF=G)j?NfR6N}rIX~I$zc6WBoG~bx
zw-~v+7`e7&f~>dKDE_<$<6H2@D~X#ciR(-8>r1igzXT20+vOGEs}
z^XGoto{L`@RdxnLn|*ax?
z%ZorS-O$5xy)eY$BJSgT49{#ozqyl!9PX;n3!8ily&a6Qdj+r#5
ztdTWLYHpeiT6OWx)R^jssboW0=W8LT%aCk~Nwzqk2!{$ME#u3w!r|+Y#vn9jD&9cBt7_?lWg2Jx85
zl8;!rv!2NwX=&J)>zC*IL{hJW7S&v@INKYZ?Fr9Q>q?yJ3efDQ-2%S5wJ~F3(%hPk
zZ%jni#&l?PR0ErLr7sUFOM~h{|Nogk29ncCSyrn+B@ZgYA4jUPdPPPn&!}a@V*)d<
zO%^$49LwrQxj2|xq9?#(C?7rDY@Yrdo5vrvSofDHzB1Kcr3b4eZ-wZs2>U8R9*FX}
zcw!gChZ@5@gV1bLPpRKo>2p*-fK!OllF#H4&V*qBuE46Ghq{(ircD=XV589_kLyjT
zsFOn0nib|4mAGLO1Lp+KDZl%ay$K|)aM_Pr8Y=2)%j;_^&YUT(ttmf!vZ(s#{_|%`
zE6ZQ3D0}hv(Sy}h2dXLv%%w+u05Ai?$0}baJ@Wms;_p|K{NPymkB@@N6+b>*{nELU
z`|Hjgu03}sk+*;EfZTg8STA9dSlSqs0rn$~}1OI!qfC%|J?
zISx;(iswwFR`i{~=amDe@Yw_Iqo})^O7Yh~1BH)n^4N?Lk%k-h!^
zcxoF2t)L
zU>IPAct!K>*L@J`(0*)c-hGPuWt6(-fZ;u;d-fY(^PhpoYr~W*P5yXHxiG41j!~}+
zb|PEd@R$|(w5Uz~|voS|}S5=f4qF^g91Yu8qBwdEo@7ffvy$<{!bR_)ezBF30TySO%a{C;>sjKYN$yLG%~vk%Shw{>UPOW#+UhE
zP`T0X#UaoRr~{HgT!5BPhx(Vfi?Xokw*+tMa^Sq=r)F>f(ywmNir0UE$JJ5w`nd7x
zY~t2b^y;X#)gRjI_1zp-KUm59d_Di#TUc+RbDpmJ2E))E)*j*Y{c$}Bk
z!jGc0;l*df2gFX4?86e6!C(Nm5S=y(e+L5dt~2K10N#yMvkL7*S%_N0CBqzN^`=(S
z(GszCChTMFp_yJ8Jf7`?Bxt5PJlz$dna11v6Kw%}N9$uzXl*nC;alTjZR}qeHdaTl
z(^wnTS4Xg^F2P3kiwi_|iT{fJ=;Lefz92EoF}RBgFq{U4byO&S;X5Cm(o$R6
za31I_f-JQqP4#6Sd$rSAWosx8`OXHtG|VX!I2#hq`aCDx&ZAyuVdiST`bLKgyoVKkkr^tDh0B;HE{+J4y%i6a@XTts
zWFv5xlNbV+RnLBi*Y`F#q&c=VY`XVro_*jktTX>HeT5I+0RwG}DI4SP#04JjA$fZW
zFxCO%3*#EZ2Oexr7&}wu)>L$JDtckkTp7{k2gHw9+;4ic*^sSLxG^Nu5ow6WwX(kv
zxRnA8QUEXp`CyUlam{5aK#NTlaGF&K68|7A>`+6%EkH{ynIV(L@A_N~UT1^PZS{JZ
z1Rtj$;L0gWv0@R=`Z5&#lw%d7JT6hYxv&4G}BeR{{@3OS4Lhu<+r-(Fd;t==5
z^eo~rL4EJFc)3?$FF_?#KzOjwe+(X@4B>AQ0-GBcgBumms)W%rp)fv0J{1at!U0Fv
zYCJH?TDSq+#U@-b4w;Ho3Dt!I=R>}8VgET%I4{$Xdg?#cLNy7key}Y#+Aa*_os(UD
zg7LVrJ*8fn)vqrmZZ5&^0=Lnt3(+g{=G6uB8c4ioUR#JjEOs3Ok0B0YZi`=8&%Cmp
zdvznv%Is?wa{R~h=YG7hka=|>b89+&bws~D8hLX*`^r?}@}RQQ7vAX!-5Al{U&+0{
zp1(a8+kr8HV;)kM2EbjyF!|$NqAv$9v{&c*iOK`&@}RaxH+1t&nh)y_uim_rk9e7U
zD07ACIAr^Dw>fy4x3
z?vG)Py=j9BNG7qyiYui7y}NA})Y)}XEbO0B?J2b>t=Up44^~^jvr9o|FL|+-zmq&D*
zGuID4&D&o1TIribh5w5F=!4?bEoL>mFD!COE`=usk7+(dwJM_#i8I-Wo&}V
z1m>)conSML!cqgwCwSC4A32#bPHrsr;L@+$+*JLgday$F6OV)LlCZBl=qUq|;gSL1
zfU^uRM(KwfrBdKn$OlkS)Eb})d8@;|lW@QgT(T56>u#!K6X723Y6V*Jiy*iW+%
zXjXV)zw5ZyaZH!$lcpo=KLbJw-cwF{m9?RaPtqj#&RgoSdCXFOw4tsF7WvHSqMGw1
z4RsX_b(O&L>63@goGPlS1eg!j0Nck8A3ypskX&=7sNvj^#u~t~+TK{H>q<{;8ZSdS3{?j&`GDI
z$W&{xi6(q}NjL!pgT$zVzThs$u&W71nP&fRH65~B57{gS;fZMvEv>lU+3>Qj>7d)X
z-_eAf`
zDvAsKcppCsyR3R%mR&EZo|pKK=_`C}j3@=M;eBw!Ja$bmp5id3U^TbJJJTjN$`{6s
zwPAI6NLm~emxpEWczHzKS){qTe*e2)O%0_rk=!0&6An<%F?cL`>qSZ@hWCYUrmQa9
zV&b@YX^vbhkkH*x)fJHeW4j7_y6Z$CxYdv!KQOD{X$p9n{9cQXSzAs@94#Od>
z1s*r1ovd@01&a4z2@#kBWUL{{-$Wv-y^CIfpw7-LkRHOGeIE1}aLKqn$`B4w7d!7ZmVdQF`j2UjOzb4leyCm!)k>5*O})h|>6$NOOT%8Z
z5QKBiQzjSXbDh(}XYw)2K)YwES6CWRR`G34s`wr+O+_xx#4gR^OVs)3wafDn;_g!X
z`U2q@bzTC)@W(tlOOI{rb(8n7`Qsj|s`BaJ!t3cu-Prs6j~P)B%c;
zgk;!dSAt9DqUbKnF~L=F#Z>rOIO)Q0BSJDtigi<_73fIDmzYYY5ut%wJOzB^J7pLC
zrJ$h}p&2U~l5q~aFZ00#H!Q=Z<6jedAtq*jnF-e1gk;!U@L2IA6qMwHd4=uaJ8?lz
z0{b-|6DsV};WHX28C;o|KlY^!h`Z!M%z(%9QKmI_1{F&F!ui}TI|^CWEWbKy*jggC
zu7tBM?HR~Y)MonRsUC5nD>T_HPWMQ&Xh@-5HKflEX>$YG
zG>&$QW9|N_?$G>zGEdzQ)ZUu!Q&@$XT>Mw`M;~9y!2T)~NvVuiQgS&eyq;ymWphW6
zfMoEP`{O-}3?4H)ALZ*(K)hf1_1jyx`sMA3ta&!%&?+Mfmsa6+jP{%m{HV$<*
z2lFYP;5q4Ps$?l$wWdm=GQ5uCAuml}>9$qTU?j(hrp78uePv@^1xlFU`kJ!3^QG2?
zDwNpMP+M-dR%6prUtV*z$l6c=p>DHO+N_msN43v!+}2PEIV?2539l9Oo)QCRVag*)
zBe&*Z|LKtLgx^^u1x~`~tD!TpaB5FzYM`VDp8tg4ISK$r8XKef`Y0c3
zPY#&jR=qH$z*lh?^ZaU%cndt9Ha9719o-y{Y>XLeWBSrC8mH2DmoU`ozqm1hYyRy0
zxAO4-?gED7P(mP6qZFcmtw{dZ3W;E(--3!3w!sv}G*<+7F8rI1`6FnUNBoB50+n^i
zErsoZA1)bQ*&1Xci-HhLGnfh%G9vET;sPeA%NAsXqXn~R^bv`l#$wuxyVk-v0UNRT
z3tHQRfL##mA+Vh7q08=~nnL27=mlC6fcfhN12&;>K1Hf|OM(lpLcPv-1E|v;ycr9N
zR9i&qNUoDY^^huA@#_mlxw#
zmJ(N&0N~`cMHu1~baN%WSGm2G<+`{Q!Umi7IozLBz
zPTiVGzcQD7Z6Oa`pNQR`@$O3g_H6R{
zRD5g1Tpupt+8NB
zRLB|Rl0jvzOvIBlJQ<$W1d9wZX@C=tV7n6_AHkR^u$$m6h)6UA4jGbxOrjaSrYk}UB=1pn7-O`uV{Wz16nEf4qVa1tN
z!DDQClBzwa+E{5#D%ONz$rw#tnZS4#{_?SffylyuKG(0#_Q^AB_O$8lFfcsTBTx6L
z&}_dxgRc)|uQJ^YLQ7M<(qxZBA?`kHzF!A`=X#~tK5?#(A|kUrWR#iyWV{-nP0HmE
zNW3QwW(
zMF}ti!$5K_*`$f5d@M%IOOQCCoI?o$c^xp#RRAr=EvSr&$5!F8;_1iyG;)__)xaJY
z&6w6`D)r4NPixMv%XNlQr%81HBrLKaH$*jC*nckIJ^|C5h`2Pd!H}&U#|b6W5b~Y(
zxlcRo)lHU)aInT{Kh{uNQeRu_upPx7dsCIib+VzZwC3F5hPq;pS1I8$LGLlvkz7eh
zUd}3)t;}I9_PHu``Ml2hk{y;Jv`Bamn@z}767n5oy~xym%;)`p1P|Oft-VNTT)RAW
zS&7ZG=5gabny}hiqWNHg3p@scW4i;6&ESy;oN@4o0dp)Ar1=l4-b0%2FocTYKA^b1
zkm@?9IH^Lk_8g);?t@(X$Mh9Gz~c*J#`>7HPO)ep8FhV)>@tnG2ah*lh^Hc4pfW@m
z*V8f53>3dGX)X=nW+zSeDib}*wTsKR?A6PgG0hi|-MZ{iM5h!2_8LNzS4?4HkVy{N
zAyu@o*#v2Zkf`c5M7th_32*}By5iD6WznfhPD!+fLpDZ1l-7X10oVhoIr$jv$gLI>
zv=`vF+v5vx;!J)%kh#lm#!kSS)pt*@hk}k!$O)GmqL*;+Ysw)9j5tA^&d1Z~xlrLf
z;0kymF23uGIe;PlG5PzE1nM=H1d9^3sgg~Tp(b6jXkw$O+M*iT9~M%$K1yr36MDhm
zJnKJB=#FH>6;+$qGDM_^#In7_My3WWbY2UeQ-Y^r>iOnaeQ(Y_((an=6IMo~P59$!
zV|zAoc_DFSA%1xdNH(v`6OXSf#;-0XuQU3hyoSn3`sQl-)@tVFYUb8j7WHdOsY~@POJ}TYlFt}KxAnsI@6=U4Ra&|
z&v400g9ebiI24^9h+f&8#Y_M0x4-VmDXqysOTyn859H(ie9WJV`tpp*d6UJlO?TGx
zLNJIO8L2HLCdf*Xn@kawAkfImoTw+xMoGc-a@vuFC4U$|y*ragu
zE^djP-l*(}h}h$eO2D%xD!EOHRMVvxut8Zmhk^VH+(KV$0@8{PSHPKEan(m9-Y1<&
z0d1f(q3$*>3ND$fFjv74qoVofGiuc3yen5qab#e}S;`xW-qU1W39Tt(*t;`<{(Nw_
zO`7V_W_q>RK5epF=9=h|P)_wIoWzqo3g0=}8XRGo?8YH&sz>GL%=D1Z(wgg$=2_~GG#)PDJm&k^lo6$Iu{;(o+bfw}E-0fN%R+iJ
zsGNx$PaD-~<2Xn1*np`8%Vl2)2XoS>33-6D5=I?ZXKwb)`UZleN<4J?*p|1&Q}^
zwP1)rUulA)*rAn9)i#!aad^f5Bw>(+%y?Tq0jgqS!A#M$R3iNmi^Agm%UB<
z0*-?Uk+>`x!gq)7tHKO|%7kHvgPC_5gU74{m$pwZc`sc{I+%@l@=0Gd=FTU)*|@to<7un>PDkZ)Jvrxiw=mluo*M`*kIM9wP3p8H*Nm|}V_uq1TwX|CT_88ib$yX|d~G##
zV=cp!y|$deIrwrnCiDxFkxjyIbaN)QHJjL;OD0{`;2B_UerK)g&7~GN=GW&Fzuap6^;Yhq&CKsEWItSvzddLC
zY&G@k?UrBdw0&@){nlK1Yc#Ss8eJVSm-_Vu-1ocSsMMu?V|mbA8HulsCO0Ot8#5iB
zv#B&!<_6o+!PZo$B_TA&2+3TzD3^~bYYOm)86%J~{3PAajU!_fi7FHU_QR+0=y3wH
z(}>ea#gkIKQLzwwCMr|O46amwbX0N@Zdv%+l)!b6l@pgLtWKucB;V|gsdNHA^re&O
z{5>8gG+zt=R{c@DwCXiMaaM`zD7jY#Zg~VA?-O-jQl|(uJ_tVP?nk5d&nwjOU@2fR
z*^y8j3CWg}?MWI>MRR)r#xczrSFJhI*_QCO#hn8!!SQZoybHLMC%e?iE^WHUfKVB3
z3HN1ueOX_BE->608tah8JLQRPuvr0#Q3BG_-3o{CbT>+Qx<{Pu3C%)X!gQN&rro#F
z8@f6Br$*&{jSQ1miW1y~_eBLH&Zw2#A9F8-{XlY3u7E!Vl_LV~=4C0libt?f5{&ig
zX5$n}VsqqpE_xytJC!w0{rXow!^?~hM!{p*Un+Ua!rqFIw@L|}5Zo0oc?`oPu*f_%
z%N?Q5SPiCcQ);+A
z;6B-s4rCLasAd&BC*h1?kx>H4u-zcN8m?t~s^N^4@VSWAkc!%6;SBf39$UH7Qs%Uj
zx|_;fP2~%kL{Mjj>aR7Mp`<;-pEZbd1BC)EVAVg
zPq%h39y?gP8s^w(Iq0x5()&a@3pMz^M-D5=6Wp`9rj?RRlHj`Gq>0@|U|Vq25Z
z^-*J?U!CdG-+Sv8E`IsqdN5EA;|N@Zg{B}IiM!{I4auc}reTLBIW^g#%C;Dq;SoCg^bSrLiW#6@Cup@RJY
zFefF)B(Ms&(o=$XmXo{TFBr^-iwZrF;eYo!jJ0376dlFRkWCix9@q=*+2SwGX;LLS
zKCdR>^V-ntFepQZIuSEbFGw6!Y)QkJO8~~+=9I5BE2LvC{NTG=#KEozP1_W<$kgRr
zs|0IQn$(&^s}I2|iw#kwKB3k2wRk6cLQ~zsOkZ$mNLn3Lz~i0S*v@Pm<;A%;1lB@V
z7U707TvwOU*u){$839onYiBmWT3W2JH67oYAs91Jh5vZ|+>eVRk)2@!Fy0x7e0Xu-
z#&mjfK-(J7p^GEt)rrLQspO5B%#E4cjhXx_3$1Uiw7<2|{MKUj^_j$*3+Y#8QULJH
z+4SX6^U|<(bIN>sCH2dT9lyBP_2x>;rHR<)hX
zuKQw|7b@_WIF0u}ugKD>@jg)pYq1F=``uzAgye*1
z#Fs?VoW&GtYtlE=rjB(GdZ)UX%>{`&wUHKixLNAY2D=j8-i$EPCXctP;~nZ)yUaD(
zp^SAX6F3<#2ERKcV0gLkzK4_|evY2u_WuEi7ioDKZzo*piDx+XEQMuI1knD4oaVqmt
z@Kgp|6&%uR04@x4DcB5u3^2nYhy0WR#?QAmfLO(#HH{i_Re^%wAD=i{3YLJ`i>+y!EtE;S@gmmyolzy53Q{dfE$y{=o
z;63VdRfqyw36w_-?s9PkW6vIp_rlby!g9DQ+!OD2H=(}IW!>j(I^b*CFM5kr@R;`v
zqvaGVh2l&xp#(^d2JuB7As+ilhM$H!aj_m^N~;E9wcQ*p(3eqpzY0Qw%C46c>OUqP
zqYjCV7x<6qD|}p>PF$Rd1HdrHAThwaITdG;98#xyrB`pPz1^`&Fp
zgy~I0eNn@$N>)R)M>LNvyKypuB01e4j4b@9=zuwvM5ingkHKb^q3s|#f{UU9C9iNg
za!ld`3ZXOl@=by(bGm3ZU_W~nN+v=qQI=nd^rh=CU;f3bP|0|VL*)BKXGHO!1cqtI
zHMty=WR6WX*GF7)L@A?(Trv$QR%w(fyfUTvs5T{3ud$Vdv@jc;9HJa-s)TtO7h8Wf
zSQim#)!wAu(2;hHb_8d7!}9~u;;^zjqO6Z=n^TdU*(g{G;$B%wURzFHUnK?u$(z#=
ze0QMl_Dp@M8ZjE)BlE)O=|ydU4d;9FDxX(fi6u*XmGg5)5e9Hx@?t
zJK0>G?9NE->2O;r*qTHsq6Ckd<3#0rJPa7;;-PFTNR?PP8x7~oa6T$#BOwS>&P0MK
zLx4p_2`Y1>!CAr_XBgxdjLAbMRM==guP_A?3UDr9Cxa-cT!=6;!|emGQ;HAQ0UbHf
z_mB)8gUZ|!6FxOR;TcyT27|=##~i@$$7m7a2MK3fXciEaHR^b#h5|bWPv;o^vgpdp
z*262u*vKnv@*!BXUxvT8rz7sRl+c|Gb*B9N`OsLqGSViFcf$B8!!6=SE1;{6v@65y
z%21n(a-@yw!|l>Yhdk0QjkS@+JLHK@@K~GdRHr+{iFR?kExgjJ+?tI1d^PpE3ptdp
zPa7Be!>e7vr5lX4J3Al>fbWzIZrf267S6y}H`SN0
zr6bC0mSSstkt&{#s4&pgc&&(B>uJI#LQ{ZdGLZr&L*D9`R*zB_&*u_O-lOa$j}9Kg
z92bMc4r>uSF?|p=PxY61j1p?9r*)h-iAjwIX-+N{qjp*MyRG|OjW4H7+mfyYrY!Nle$zDLI6s6fuRV2jy&AP_2iI1?u^7r47;j!|L{$1wS0
z=Sz_2_$mJ}eT9#$srWYTwo|d~srU|vI~9XVCc8XIK8eJ_*Z;^FbCEv=&i6PCi#!zv
zlGi89UZSiinQOWOVJx4&%31R{Wq;?P8xSDPvkAb~CxY6id@YS5vEXbO>t3YY9i
z#r)Y+D4hr*w39;-1+Vh3C=7%`ondoZl&Eq;`i1~g(K8g0z(OvP^C5fom43WCb
z@kh`__+y#_Sr@IE*q}>|iHI|9IAXL`gd-jGCJk2{4H4O@Nfwz8h+>1eAtltPhU#F8
zfn-x^j42Jx3CB=-c(^?{(ILza$g5)pAi6!1xHy-DF3m#;XnO{&C4FPUU=BEr_R|g;
zRlF@V1L($f2)aaEaQ6a!3A@htAL%c~)cC@Z4TU8?4D>-ZeOLArb{W_q(c4H$5O5d^U@pa}pOs9pQzzISmyqv)ScSX=!1tgr=hs8&hgyWpS#A6F@Z4}bD>lIL&~
z490hamJ`kUL1F56s0=~{wwO=CW%>_Ce1{?wqdpw*9-_%TAeKQ*7)Hs(cr1U(C36z*
zi6Qw#{$u(IA6Ms^FHWU)0OKi+Shym(DHEGnjCzZ~n3I^pcxM`$yL;$lGEz7nn|l@+
zNLU)t=ZDmdxinWzdz+BMij6~@tFDz1p^rfh2J^tFWpRwZOJ6{o4W0a{ri
z00U;a>MDb%cADOuIpvM-lZ&iiUfY+ZG+0-caTNDLzMG{6L>%#;_qJpr@>vy-fF@}
ziyDDsJY?#wSi}=IJ?WSiN}6s;sHSmWe8LA>g%`9oBwUu}3{jXrhJa)?K_)3GH+HuO
zqkYQspguRO<8Qt;9-%)z>ci?PrRHfHqtp$&JriTW3^cYP+!F)Ie?*M9_yH8^v+1q5
z6oGjPY=)(VMaJe|C|>>iW8eJ2lizGO`jckq+*sN+)8g73(YHrIUu}ED*aV4(BCx+(
z!zKiGyEAI;jG3S^@O*JBdU-N&Z902>ruphrmKZ#re|@Fn&DE|~7Md@Q$1aV>Zp`Ix
z&NW}2NM0O^?TkdIe;SR*iP+oA`FGb^-df7NHkWyOwf&b@$KKrP|LxD;!CU&|lix2*
z_V(qq?!4AT(mS(yXI|~dlG@X1b3$xMNUd?HEg`kU#OAn|k4yO|d1VM-X1+O;i-thx
zj1kPhK${`vm<28{m@42jDFDP$2Q3R1bI(fo(uy~0_~r((OC$Nkk>=6Pcs3%mCFH>t
zvk&hiDW()q(}OZe(^(T)@vnwTm}W4z;IpaQnAa%=PNIJ0gudH2K%KZwbZ4`Axxr&x
zjqp$NZu(-9Cjk+j9Z-x-C`NOK(aOp;Gt?9l?JZH?KrFn}fONwFd&Rr0*+BtvpWE0|^|A2~iTNUOx-
z(UEnjfilTk8upgU!qIfJP6-|p++}P?H2gdGOx43ZKuR5
zXHy9(nFQ`%Cp~t&!_!LeG_EWLPEbx3^S+}0Bn&zZIU0*m@w=-$j&g9JC|I4%q5hrS4!;!=a{zgA}H2DnbcS48U2wcRm+BBX`EQ6azCZi{{8dxBZ~Q
zy3Yx7+_cYY+b=lSxTau5G+ddGC=H%e=z}00b5V>saM&OW7i4-4MZHC+fX9Sn=8_9>
zY2JCvgVOGOBDnjdVNSB^MM!eKz$#z;_~R>c%~#+R=CYS(GZ&|m7eQhIbK=rW62c}B
zOW|u`Eg316Rt-x{n^d2QQp6ip3{RO&?#v{&r&C)~$<;A)c@&Dy59-r>>N{`Vz-ztt
z?i=}}7}GtuM0mI-J=~p2urX1%9q_(nO?DcJ%alEUGy#>(jRg#AG9i}ZO$B8s1&lJc
z4LlK2ye94)v9M_bBDxReScBLV2+ZWFU8>|(WY}ny{6$f2mnsAKBxbLHYNx{LyI>|}
z^OLz9=VT=}kNs39(feV-tLTyop8_RbSKobgRCL)D(L52&9Z~VooFLN|GsD&*wXEIG>?aV}7?HPYx
zTd+Il>CJmbJA>mL!dSa^yu&x$6NFJ-A4A)ykRL$bAQ(K$#KX>0)Hh7%(s<6?I@+>@1ia!PMb>uWZ9^O5eH!K8QRw4SWqmC@Q$N^4SXO-OA?r8S|nB~`FF
zX9nS?_aL2(1c}WibI;VlOl(G-D$GC^wCkr+8ud))bZ=KOG}RO9%La406WD8w`iEN8
ziLU5KyV({Cr78D{&iu0fCcrauOk#UbiE7kyOm*;^@V|FHcCw^vK6DB;nkN4u7=y%7
z5$4z%6{!NnB??p1v|=>+soPaS8{L9#cxgM+e7kdPjIC>w9+fC^hzte
zDzwlMo^KQ8TLKGh!No3drANkBe__a2=~W2K|0n)fph%_}ID-3ijEzq<0!MWJ5zb&U
zSQZJEMqsVjR1yX@nM;nr8H<%sl;H{!M?+;v?vEwxDNT??hRTu(P45LN1IAgM#w9n$
zPyg(LH}JwYuB_-n1-!EC=SI1NT(Yw?uGRP*r9MXq>M+Nk8ZSAIoz^3c#v*&eVXwW+
zRBE*FS(syx68;#@7v-PU2Gwx)4s
z$BjF6VJf*k5nmdP%=PPAiv#=>R~JVN(aHx=#Au!%>e)iupCy&-5(_PNR+?y-M}(;E
z2iORQ%yep^DB$L}-R;RVL_unZzW?C5moQ
z^q@j){sPi2mL>-JQnELD5Aej4#Z8#!Fvgjz&lnZ{(r6{{ccMymU2y`&CK-Bv(hMYH
zf@yeT5g%ZjjRv!^U^3#3>zww6HDgqcxzy-g99e
z&CI0)>rAP>IpOHedqz5g6TRZ}fIQnT&JQRs$19^I{_+-w)n(M>y&GGcscxHPddvPMWGl5EaV>Gcgh!f1~Gr3!{`P*~Nbg7Z(m5J2F
z(F7rXG5Wv8fuBlEpdtWH**i2jf8S$2%Ls{W{?i0
z4N^)Eg327y8C}R4{_dalbx|{Tvp(rU6dLw7
zrcqZk5qEbd?PoR`VCI_;bv83ATo8F~Z&E7MaRLpvVlZZG=6T?>5LR0<*qf6E@*u7_
z+#-#%DWk2@NK0rm9~jB{hSJ`N7Gb4Jx;>S=Jsp2-F8S_4<`*mZU##SQww!r;A$56F
z+Zd4Hap$_F#eRLMPn+)wO}7PR+J%MA@N$nd*AbfU41>YTy~=981}##Dv9!=F;v8tM
zGc@1zCwZ*FAqge8gX6|cb3yp{(3gTUjt0wsWFtf?0zq)YQ5L&4aWZc41?x-{hi~R3
zqcvq~r&Ml{3$ul=G0GIU&YGuY#|tyf&P}BCP=)NL*}MGC;()Uh5CV_AFut~8ubl)F
z3;|atGjU5>&J*+;1A4(il%S)>R;Gr|Fk4Kxg`8G6&Qgb^82kfzsX`PdkUJWQk+hTX
zn0jy_8d6otrySvl?-hpdTrgV-ogU~_
zmC(tytV;}3d!1!!_>8sg5Gd|*RkAlz1l(F`_c8Py;F(#d>>?R3-jDLj6@D5!^MJeQ
zP((f{xbf*;c3Jm(Z3keB{f>iS_hHqCKRcR76>+hWF}O4iu@#O1T^^m@s{qNo$Ety()pqa$wh0N83
z?2X0Tjm7-6`RtXsG<0n)cXcjHoL&T>GgoF(S7tMC)dfqy-0pDxL^)
zoP<^4Ss-BsGYKgf4P}zyL^P0y2Ekg6Ko+>(E6K~MB0(B^P~sdV3=;bk(F19+PZm9r
zNdA~OEqioOTy~p!z)=0Fz%i$)Z$Ap@=jzsoL*_XAT-Pr<80@kppStH
z{q;eAgBWNC`|CpfIx$cm_SeV(TI5(2YGMHHKoP%6Q%l_2o$(E|3X|Qyur@oS%#Wx`
zBgV>T1h#l{9Dnv*&=v&Co7|X$yTyLqU`p(5eo685i74L>ZBCOd-kweF%w@J`v#VpV
z`2lUJ`%lfZ@D)D33kE-NAIj$+yXQNP-U~hZ@ZHZoa?kTm-1ohwu=DGcFFmc;s#=x0
z{+MO1U055?HisfxqcI}rsJS+*tqvON!?Be?b9KOgfZi2U2BT|3vDKm2`dD&fJVgR}
zr?T7Q>BVjh+8Rx5ji$H9@KeuUnuMQD0mjhQc>2oUwAP)0dp3LWW>3!S
z&gvB9&Zr=CXBv>!T0v-(3AK$uI%fjUa&rt7LNy>wCF_J{`C?+mpk%Rpl!=;m;TBVD
zkI5Ygwb>M5uPOA+a=bxhMqlQ7VUZ({KY`yW#lR_942&lytp~mcR)f=oYI;_Zg5>0h
zlZqcmPDpG-H5;InkX$^CD+nGe5Y4@
zbu#|$LjGsVt?w`7-=537F`v4LTSTw4*b!Xlq?M}Yx}>=tZKhk9>5wK`f}=U_M6)p0
zAuso7%RLHQ@5X?BVZd1L(^h+x^#Of#Km&$n+lASVATZ1|+Yz4Y6#1{{k3PN@@gHFp
zs+i^Vz!pfxrEbeuMBxlz)S}{#~qEuJi?4Cz(c!jWQch?pm4SN!+npPgIbq*R_(XhxS^03V_SnwU(XkVMUStodlB
zEw(1a0gxCauPZL{#JeQk12d6$H#*Jy@$SGU#Z5iR{KxbaKDMW`(9TSHhi)I%@Vdbp}}~@&pm0iHMMd
zK)6^apH@?`FxU+20oC9%oHQyiLr9o7s-Z52$g_gb1ZE(adtwTV7edo0HMm$7xW=YL
zeZ6c96%%v4EiSh2Y248L=%{R)(VTR8;UEUx(z%l&?HkI
zvsDf?8H!s9+M+t%s=qK-7cDqpfq>z#x1KG+*g!L=2z4Pam@P*i5v}Qnt34xhH;4LL
zLqqN1k&f_GkBqOzmQ(1Q|noyl10i=bQ?FqiwywV}lJWd7oG%ldF~vCo|DP$pZ&xej%GFupbzUmr|u
z3}sgaQ}eyig}&JGU~+XRbz!`DW2}9BtZlX@G10D$wTR;_q4{p*!g%tPjox3pGW*H<
zYoC9x`N=!$A6}n+V{`EGT0R7Tq3DZ%id_O($NNO+&Zw%NdF63}`Fu!R0n#wKKfN60eqf
zRbYFzEi|5W&$I^MYiHU+qgmfno47t4Umr5571gifoD~4LU)!dH`S@y>kOjwZb$9
zXF9-Ok!z+SJl!6i?Ud)b{^b1CU@)H_aTm!&fU6#$tS(3m6lnrM8h3o!?=RwWL@+Ry
z>VE7g29IH>ag>?k3O@Tpf|9PQk}_FjKC+n{Gw`fer)dz>@sxfHNbYWS{PO4T;(fgH
z){U5YLKP}xUwOz~>UR_;jXFJiD&(njTZ@2a7fM?Rtfv}21uDa9ay+|Ph8HS?Y73#4
zc*%(fFjIV(x@-Z&nKgeO88Vvuk|^~vC~q!pT(9B0kkm0?xqS*xvxXaC!L0P
z4nBAWiFBWe_U#>UD?w&PqIsP))-70b;>g>Ldn$
zxd2^{y%^j@T?w6FR6by9+(#K(ENRQtbkN-diwqvWY>G#R+uf=MxGlq15a;RB!Quq|
z!r_uwkQR#I2?3nDhW{W0FoVYs8+p7tx`_ZxwwNQCSJW>JWFira$scnhGb+C*I>{vi
z*eFHEi?GZ5$Mh9Gwx%-M)0v$aLh{Ag)WtapO7F0!CfpUwE;bo=!RGAs#T+krh1K)d
z7n`pwWVj+kfId*4#c!TM1ip;2FpZQicSN`)NQ;Q6$frv5;dhv6LC>z
zGkfr!W4r`2&E&=5n89Pfn1C(f>5eG9H$e;Ab&Z4M5$2FGyI=}~9<)wv;kVOX0V(w9a|
z{9)I|UeB<)R-SoW_rR4
z{qlv0*p-$==G(K-&+0c>&qWrpM7I%^y+-q`dIT+S7Nk1HrQ(PWC3Zp
zH7d5pWdOT1CWEytF^P~IliFfzCj)S+NhEHLhy-I6^rqBqP#N_|CM+H?
zjbPTq9yS(>2g9+G4b$RTW+^q0R{SX$@})#?M)EeRzD_gH9rcbiOLLw2`cUHPOw0AT
zmWz|Q&C%@YKyqh1b7eApX*9Mq7+LGlR=Sl1K(Sq#ZX>t4*sZSgMOOQx>jSa%fyh#q
zJliVFwECCO$ZHQ?8PH!DOT0drdTla!eJr*;Yy!Z%&9u^Itda>os<3r@F(AlmEzhDF$Gl;H7f$Df=p6L2+Qh(TrMkGaRyg(C_laj3+gNu73K
z>^;oPaS>xM<$OiRAJbECLPVga@1}i~!%x%5s4$J8V$+FGUow=`D%1MWv~e_R9?wKh
zLOm_6U;ct_f^WWl)ew)${&F=?74iUn6uySM_F}tTOEmAn1GQ@q1>8EGsm3Xnx@3*
zomuL71d@rbEW?X;Bx93&^J4DCQuB?a{EelSn@i24Wxm;beZJ-TLi3e{{KeVK_Dl+}
z-M&Okfh9dKW=IlW9joXE;xQm+$NyC+lxDydj*EKD#2qa2S06R}V_CT5}{@Ya&mQ*o&!AAw!Yrizq5eOt+9gD3`Cf3HywJ~FLR9_!A)+Zt`$Ashw>O#h!
zos*cO7bUcXFJ&gl^Wm3<)VW@Hwnv`rRTc(y{1WiRU7Sl_o=btgSLR5UW-^qDKbhQ`
z{0rq*e-|Wv97rZl{JqES|L$Y=KL6Og&pmeEbC2B*3_t(a11PET__v;W^nqs{zW3>e
z?tbQ>yPx{@Hy?lS>rZ{_o8N!@!Jj_$?bAg+jChX^W*uYAZVI1*$^+U`uQJ~)&-JKt
z49UdcPIbCnn(2_~R^BB~b;@A#Os78G4oK^BJ(2l7c;fhcZ)|BGx!9jTeY(>aYmvrU
z*md&Zom9e(z?!<6j?M;c@@la19)Rz{Aa>{IXa$~&X!bIoxbPvkq;g;Fn
z%y@fjxY_8>$h|2pr9Y!hw8iJUGi!tS?eUIVO9QX355K!J{^8ZR53eo${QAO&S7v^8
zY3jX;<8N$@-&!5Iy3oBd)3G_(wmg)b?@!P7rRRGy)7{C5&ctY|Ig~dBbNWb&Io28(
zZPkZcw2>BVtW}%nFebYqbN$i9f%xihdSf(uajN6=vk6s)9^v#LS
z-kG@b_QdaB8~g3ekzZdOe(yrh>x(UyN26Q)+D5Ok)}yTV=?mT3e3v@kg;Gbk*bRb4
zR{Bh60e`m+b-Fb?kr#%N?ry`}^dnCRyn!GxhzBZZM88SAyrPWSxwNu*Y
zH8uxhJ7ej!emq^B?^I^mq?vYd%<#V8dO@^@d@vY1(;-eX5~Ggh*JNvGFy-k>x&|}e
z!q4cBJ-(&}4ygfJk53B}>jFs3Jn`<-iJZO=x4$THNcJ7V`MOZ5`mxC^GV{;^&4;|p
zW>QkFOvzO|u?XVBl(Twu);OMF(`vH7^(i1Zr62FeHgPKd`d1(Jw}+$Rv5>3SYlAI5
z4EyM%88nZ0tcN_-!|=+Klgy}0E_pX14X+&ZR;8m>I9j05QbT~merw&KhT8q{NF(qJ
zA_BJ!=l0oHFEY4js|O|zunM0QixRK6xV`37-mB0B8Ck8ACQV?*^$R@y62JM$5P#y{
z)A2%VJTY7{2^eNQ%KIIb0*PrX6JO7mR#AM})3iSmIn$G~CZsC%r=}JU8aipU3Qe4Z
zRK_#plM?(fAK=943qwpD#;EANgET$$ZZem~)`TdeQnR5=d=JDKj0z7{s~+I_CE4);
zq&QzxT`xhf$UJHdFqL|2B5wNY~e25U6FG0wpZ9w&DgN-uti#6)E(
zDLReKYYUlMEAYqJ8;jYSOSzlNfN}oDV*VC5y$CipGXtH!wn(Px@?7TPY<6op#lot%
zf5jJvqtm_GM3=I&GVNtw0z-`l^xY(Rh^J&_T^OLb~+$?|`CuCDHuk)}u-d>W922rBXKw@u<7%UY=VL{v<
zv#GwAKL(qbQ6>c}qQ9P{yg6Dk{_f_`U~71|Jv`niPW4K&1Ip~6GCyoA3`Z75BFkgu
z(ulD<7FiuLA;6W!e~(AjpfQv3tHHd-UV|^dg5N_xySB)
z4pe^Pe&{=o1I+h6`{=ze%HZ*{kK6|&Kl8}F&pdq3Q{TSp$#32L*!_1s1K<4k{m(vp
z*E8Sx@85sq8^u3+oeo*
zDwFNj=Db8q0e+hraB^X-LZw<#C%VDwkx_knAwP(GyBu3hz!+B#MB@d+K!HfdKJ(3NLqyuAFVKf^Y%Y~;}wW;>V
zbVqciGd9~DpXrXx_E0(96`kseOn2$iEC4XusZO;?W6iFtOGS`2qrJcw4pKw2Nn8iQGNv_+Y0lV{qMwLFS$~^q
zX;-Zv;&Q(^-6{gc8$+?nlexih4503jm``QQd5oPf)2i>V26+2X$2kR;%r6pw$=*Ga8D*B?MWQ4x
zASA(Zu=(&O2y9NO$3S8TNKP9kP)VrAE^g9lJa}B$nQKkeCyldVU%B5^?6V#5T8q4(
za?=qvNK7&6Lw*
zNix2>(B(WPzTyzj%X~2EP-E=@)bSEt2j!O$R^icE?l+6A~Q(Y)Tl=(Z;K{Y<34z=&PmL<`;RKT&Y}Bd@jaZ!9LzjYO$>Iv$f?Zyabb)T
zPAE|M&k(O(9E>gv#g<2)=;~-BJ|p5Y-2pZZsnBlg&R5xXalIE%d>znOf!r!
z*qi{ESvPa;#zOwaLNk@1@^Z_~<<^^vE!aaPJoIuac3xd6Wm#O5vXB@8%G67a@6F^PL(F6=ioU=ISY35w)vjUX`Dn%6tp
zq60lyY$l^&Ko=(ftKcpwIKQhc0Vj<;EIA7%JH#&HPr?>!zO)&J+m1&laST|+3A~IO
z{uD?b2~cSYrsj#L?g$*POkzQ75=Sp*Fb{+CNI2gl`U*CDuD*`=s+TH8b#6_?T(aHb?V$sp;_d9(wk{|N5PW|Nc9`^P~5C_tE=EkKOm3
z$HC_No_*vVkoeh0;FTYQo_qBEXCJv2zWJ#~?tSXvyPy8{Jx_k?p2zRM=h6G`dg`Hj
zpL_V;=fC~U??3eQgU>&7{NN8x9{!R4eEE2*ve;`b^%@I38Zb;2xl@^L7pFSHI+%;}
zXCpmvwbPV3qv4*oG>}#%J3!x-wXvR!@!sX3_PPH2Xj{BLYjmg8wwTxw5n2qPCE{<7
z1zRJbmPoigDtE@!?u62xhI>xX)BAI4qwSmHo!jGGn`0dtV;yUwoogfAOM_i={hhOY
z9kacyb3H9HUHQ50mc_odrT#X&nZ>~t`0}-pw$+iAmC@#ZIOMMdo{=v)$%oM`XNB8*fo3TeR`KG@chHTA(mA
z*(Oc5gZC<$4pVq~hX!Gj_O#1WZSqvBJeCWgoNN_4jHaAa+m~=pv{8rsWSiKZ^0w+t
zol$p-=2Yybou`WnKchePARcr20=;`Q1!#d=#RDW$WpB+N;<5J-JCn}gJcg^*0!0c;
zGh1u`3^v6wnrM>+x*3TpVqwbuMajjY*)VezF$qXMk&T=JjFVb57bo;cugJTW@mOCT
zG{RMqw@h#x@!5-fjw4=skt`h5!pB`!%6@X&_;Q5gm_2ryr3)ZrSyUvD(#4h#wgbR`
zaU*e&3!BuN%f=~LYY*5PjtH)!0C_TE$t7*NbcR6NNT3b+s>DDwu4btNZmHLq7~gnE
zlg{whWiZ~)IZZFx2%OW!0eGhc@2xN+CcP6Ito#u>%bl;481sHQT%tO}TEAQp~
zGI2SQQ39x(zI$Nib?k>fR^f(s&9UZw8JnEP9LBgNDt`_hkG2NK+d?zl>hfTGc`&g&
zlw2N;LSQolB*S2RIhxJy@|UKQmziVcfon?Xn$KLOG;A6lb!9epbvA!}0nV5L+N`sg
z#k5yiZ>+T5T4}q!)Pg-Xms+kbw9tekv$+eC$<;B~Wpi%Ooai$~d-RJJW`6a{pLI3M
z*;pVQr9qPkAXfF8idUChYy{Dlqt-N{$xwVIO_A?6b-zKuVH%pO%kGFqfoM<`ScOXl
zssUy$Y%kX#34UTycIWGEtybPi`d;N_O(m>9pXrb
zG})_7^=UH$#>^mTZYZ)e7F`*Ot&GRkCn;}>$Dh%x!54I4BDFefF7&Ijz2aOiEkCz7
zpb~w@qJS>`)R$-TySW0%OS6S<5G3Y<&UYr`+mwb~Xoqc0p(FwDOi6rAo7kNC3&pFO
z{bxD?XXaAgO9Sy6lkNR6fAzlSzWd16pZ@mOpLyhNKo?e+^0`1?R`NYhLl52aEIH-}
zo_y%uC%=97;}72T#DjM|djHoSyZ;+cJowEg9{k1=4}9aX`@a6f1K)h++joBl`qo_~
zKYHp+(GR?5i*jPaNIpESQtIMj@aGSZ@swdrGR
z#%QZL)~b!S>f^22SgStT5*cldjhQw9%E&`m)jf
zY_vCHqTU*jS`D$q5c7JtHL7%_jQ(6~rnhBoplyDzV`aQ=ZE|2~v}a|scc#B}yfZu2
zo*8OR^`v5*akDd~b;i`Ln9^>9+q6)-9!8~A54GqaDm5Xm_?f^|e@+SH99tWP5zP)trGx?}(4JM8;ao$@bWEM{Kq$G1r-x
z?@G>h#%J4OGi_05y49HG%@h!~RT*oRhjP+DMjXn9hx6i4E)1bEj4~I-3FB-yGD`e;
z0pOV~oynN$&`0tj*HBh~`jXzBxVzJIpu|(Kf3#T|Z;?myVo$=Kl`OLD#Mz=BKk#4w
z^Z)!;|NOfT-@pI6&%W@?lZBtrAA5Wa3}&E(2|mP@`T>B8L1K;8&7~+Tt0)?(+xMw|hL=z|@%%q8;DxzVUIV1`(4D&K3lqIFAq+A`Bk24*M
zD@Qqu!REAnBBjAGQyhD&Py67#*ZA9g=gq5^F7%k{DZyRrcLK~serGZ89QIXs>|h>&
z8JGm29RMvET(ZUFn=OYS-eucZ13!9D^dB>obJ)XJPJ^3Sz1Zt0#R*N6@XRC0|3G{v
zF2XAydLy}E!tmZsej0llly}DWxEc?;EJgPEgG>jU4S0tKlSWOzS?sYL^f?ZDnhpeA
zhsSyXrdXv5<#Fj~LaAh9#wyZESxPBQ$)to_7MDt6BL22TX6SG|hqBjj6r$uWRGP0WV1LW?d7Q(v*m`-s`Qlt|XEwdTlY}SY
zAjh@Ew(XhLv34zQI5QDX!tlfmZ;A~fij#W|w5HV7q@FOsn&dT9zoB{~8t@Fm>Suzl
zh2MpRg}`YqsNB<$8Xat7PMUg%xlx9_#>uSznA5#5(@0BJ9~*ARIoQiRh%0P!Y
z+@X$jYcu_kg&}icC<-m2oiv_Yok%QCL|4YmrBP#UP?_nICOUq>z!E|+qO+Z)M%gO^_{H&-u@=ozeeeg5eDlfs
z{@XL(`o^;lgTC;@_kqpeF`V%ao__S1haY(E(TARSrdYM^=BUV#xsd%IMZd$^+cvS)p45ZF+9>1rb(Ea}A{}YHJ*l)t!&wc!S!|0)&045g1#ZKwnuxMR1%{<|Q|clct@UOieOa?7
zWAtUIf^r}q?axIAGLinY-kVfImMY*DOtKRCUhqN=I}^P
z1$~!#GP9kDNkErMbG#)o(Q4w*5M%97MjFb<*c{F(tWKK)X^})(Y~j9is6QtT;LKcj
zFcSn#$AHpiiJ01|g3Y}NUr!vw_4X#b-7!zAW=Dyg{V8EE6Y5U}`w~KbGSnLv`VyhO
zL^!XwVt%Wq=J@&YL!~c#_r>QP{mIjheE-o${?otzkN@hQ{d1Jxef-fMJ@a_sXY|J&
zUjtluM4AccEmAzd^O1-^Ba9Uf9VGyJ`O3IogsE|Y<}X%!MT-9j1U9RIBH4FHg}r7+
z%>YyurAl#BVB?tie!!R@T~7X3tc<`t)1nkrN$qGtt>OzcW{eYA9Xg)Uj$waH#?k7I
zjP>T#mDg_X#H3?tpfqEiof?*gx_yERR6ZPV6#;DSrh_i)VLl^=!%7oUGDA%LxRglc
zD7RaR;*t77(754%gZgVJP|Vyaag@V#kE4Xu#=}nX(6q_-*l6MoF7m|IhJ8(q`vB6`7g)gCaxHJ|njt1d|3xYZ3+=U{*u=k+m-p@-`ImE{@aW@QspxiF+F%{wf
z28s8wv>;kHf}HWolKn+UabojjZkJ{DEPe&3@N4?&9>?}Sd-Cw}b(KFB8cJFWOJCMA
z*c=$l`G;GCnI3IvC`Qrj;V8winbyWq8x!e`@znYl88Vosi?dl6+>3L0pcFv8gvxC8
z(p=^W<>KzLmeRXg;m>#-73j)r;RNz+Gr3FC*^5&ds?6js&*oTPX66bsow_=exH^-(
zI+MCOm%X*pervUBZ8SaAt@ma8-RZzki`JV{*=lz}jFS~qW`-E7g=uCYiwq;nnYz2_
z(`Bk~VUrV@v6({F49wKc{AEJpOiI|Mz%`v_;3D8LO-|z4n|wu!Eh5>q~@Pz73KGPP;sTkpQnt~b3-Ljq2@k`WsOaqa3
z;De_CV;XeM`;rOUJUUHQn4ZY2FeQJjjmOr;6Dy;!rD3kaBv9*D8(qDh%hfh5B?QcH&(B02G
za?jI`+(R+yNA7#((QiHV(6^p`^jpt9{@`QZzURq@;guhF{6UIcKk?AL4?pnDhwlI8
zBlmyv;d{US*u7tW{63)lt|#xm>xuixH$Qss-#vc+*PnUto8Noro*zAO|BoKM?}aBH
z-2dFe6)!&5crg0s|q=f16i#vqxPny{)~(dg0{s_PU}y~q!jD7PAdaRc_1YZ
zrRBktIGC0OP$s3pl+>RL_ospb$>3lzJd~DD4y3{Z=^(J$mkRYJg>HhbhjG`}Zn)ZY
zXK%van+S9mF6;!S;f&#%N3w+Np17~gaOV|AMzm)nhvBXF)txwfWPkCGzPs;x&%OM;
z=U@EpcYgfbGe3Fm>7P9Jx#Hi2`VRv
z&DC+`SW*S2PsZe9s!*nfDx-3>E>@`_oOx0gjtR~Z!BysEvxuZ)mQ36V3W|YhcwZO8
zGi}x<2|
zR$8ww!dSOon8?rcCq}!Xy{&p@UQe5WgyCaTU-^Tnm-W<@?lY|
zq@-*30y!q1_z>=5Z8mLh-k|Gm>h^JLP85dF+i|>2U~-qozhf~I^C-*4I415u(>-knQgRSW?2S1=*xIa`Bva4v$KrHgk<`5;ChM8
z$sMMP)ICgLXZkx&-~__(Zu}#`d~j@KG)`Fs!!h{sx#8ICpgG+SMJIdB(T+bgvhyo^
z{QJN9cYpJ5|MuVi?Z5wbfBiTA;jjMYZ~x`L{HuTZPyW+i{p%N=dPK3GO$l{z*YS3-
zW+d%d=rut^&-v=-9=i9TZ~nI@zjgOh58eCtx9)oE!EZkK?R%g4_5)8mc>h!1e(q`zVGiJ0fvF+d%ynZeW)7P9R)c2oy`1!{l{NXc?LO*);iU0av{?~u;Pyflk`k(&q|KI=ozZ8B(f9&x!4L5O^
z+Py%u4`3#jjFPdLEk0jZogOC;wrNZ%j1=z3o_&V@u8k;T(?S-SbJ#!cNedlBI3+FI#J0a5o(gePxoj
zWO_v0UP({%`x8@1w^lb
z#EWexuPwG-TWY%kR5R0DaLn^0xNV{`xikurZ?X!HlS3=R=JHSkt%0S%$nuZ@a-eZ=
zVLY=n-Mlr^x;@*zFqB*xO>fS$UYYNBb7$njWajo}|Lx7ewTbM)SY~=KKG7W+>x|3|
zr2F$qb3(``gPEv5uF+gz5y@kUo|xn{Wv?N5b;+koUPE+8M5iG-^{@k_DY?{;QwloZ
zfYq>D3PLU^=#-%l)n(d4lZ5D^gM_9%o*uRv;ii~kkLk{+=17^ImQ=7KBX(uQwq&3q
zEp+EYgB{95Uu0$=IyV?w!iSp5QYZqvq`zv0+B&mn@sQu8Wr?RiTmmf|@CC|zju*nz
zOtdf;d0*C4Ds%>?!SAi9%=RQTacK6g=>(0EnuxQ3%dyolw6yTYj4uzx76;9_J_Fw}
zty9ZH%h1xShw=#PH!b{n{>+d6@NfU>-~HQv`yc-1Z~pyX|INSqtH1u+fBV;e^RNEu
zZ~o2S{_Vg1n}739|EGWdFaO0o|NDPAefUMwT@!Vmin@>I!nMQM@ZvzaCn26I+yC_a
zUw`zj|Nhv$6p?=9p1Zzv*ViAs=Nk{){f!6j{pPnHyyx5Z-}NnQ-u3tQ-~IIm@B8Kh
z_k11oNAA1p(fjUt`0lSibobXEzULdLfBWvg|Mp#f|L{Fuf8xP=AHVPJNACW{!*~7N
zx4-e<{_cPOU;pm^_}?DB@0(9OeE+@w{r~e{|I>f`@ly}I@Z2Nt)=xa}&48^YWUr~I
z*xz{cK(h=NDD@@fb^}-v2eZ;(mTWZC2c7}dc>@BE`_nqCb6+;nlPRb#7v+_15E^DW
zsdlAQ7WdW$^X70%e55r#*lhM^4Onp0hgzc8HjdM8+$fXIAz#Nfh}uB6(DJxN?d
z>q?>`_odaol+v4&deTZCl))jnI}N)m_CZN{=luQmQ7PdgbjN~FPlD7N=M^|$h|F^WyVQ{ou(bzx()O&p-C)_nvs-JC8o{-6tOV-V={K|K#J}d*;dKpML!N&pi2q
zXCMFG(~my$_(RV={?K!ef9nTNgT#;j__@bXdHh@V{`J55fBe(`>;L8d`L};v_!<4N
z$Jh8>Tk*i@(oC5^GN&&KTp!{v<~|sL%~gDd!|wfI*FMEtILe>GSk804D5kA?3Fo*7
zGugCL1>pVE>&)ZZ2Ake%SG2;TK|`k~xhx`-B;{jS?Ih5}mRN>Ah6u(i;fo^JsAnR_
zGm#U(Gtd8uD@UVYxb34U`8bpitE1tgX1FRU9&L`*w8ZP;>IvCj7WUvhRE%^BP*01~
zYdh>?Jkn!otqY^ETh@)({
zHnmGY;&`|?1|GAeFgbd;IFbp{%pZf(hW|h$a1f>L+s~%{prbr4&Bf8ntuWuidCbAg
z&kWmN;ADmPIS|7w@pvz-noS8(@WlK~PUXU{>8pDj`N1nXJYTt85
z_dN$HSG@Ri_XNEGVF`lXdry!c0RjXFLvQ6RMen`$
zMwYUaNRg6SE!V9!=ZxE#*}Y@-#*G^>FLU>r=e>Vcfo#q0iFxXdc~Qn6sjRH5tO8WT
zmw%e7WjL*$o^SjC7K2e|`3^
z|K-{L`Io!@&p&+gFMs>|U;fMUfBmP||MbU4|NXzc{qO(#yMOrc$sb?c`P=Vz|LWTZ
zfBpW!KmN4;-~Mv{U;ekR|M8Dc{_gt+|L_-2|MQ0jfAiggzxnX^r`J2Lo~$1}Tzt8^
z^5Wsr%f~A(9xc6iy!`Uf@;8rH-#%HzxAfiq>iehgoh#Hp0GZkT;c)c>KG(~QpT363
zD;yw-wS=R8{28d!V@;_^&al7KLMGDB3{Omr7Ly#>86U~rbwTL+eD!-We|{PI0Ws2O
z*&MEZ_iW|;9`$&ZCkx*^ntStj@tcS9&&f-8Ciibm0>FE>r}l17AKaOR_HIo-yEFTI
zXa3;sy!-C?l>@^U)|ln(>BVNUeZ3hBZy%PA4+~)S@bWq7>3zb3<>kfm^$JK850qx&q#6^N=`d!QlqpoiKwPHXQuPa
zQs4QN!3(P+7uUxw-&-1dusZg5a~4E=urUKnKHQjpv<^-$JldRjyah-D%nQ3)WDI!!
z=E~vimFGLFFLqX5-b1|l^4`kf-R1q;3x_+)&+je2xW9667f6Qro`D{1PCeY1e6%t3
zaDDR8I?xEvjz8Q4aVPJuO#;>TRwnMRPV6j?-CZ8Nw=!~nW#j?)x;93weHzAvJz5pvJ!J~o+&R|pO#vZl$;Y6pBWdQlaQ31m0L)DXmZcPnYr-!XTIAyhMGyV3N0WvFlj(VgQnTbuk3UG16J_lb;JtmBFZlh%|
zXqz9j1I$ZfWG*qG7a3h9TAyv&oTJ~e+_+92_|>>M+qga7yahtfHf*oxZnyZGOCdW~7!p
z?{lDLX2=OGk2kJNl672k>tSQQd3Ck{<{lyq3t*VMd~~-g8RFCXnJ
z19xdQ)4Pr#jjE7;3}(8(F>$AQDrbl%Mt%jn@-daM7joZCzg(~zGHc2+?PZyEAeoZ0
zJi}R@SzD1+YsdtQ8!B@fOnD7e1$D+e7dESMTdND&YYMNn;v;vgOq6;!6ee17Z-}uW{+kgEHN^V1c{2GMb{^@Y@`~9^KXbO;ybP#Uk
z{Zm@2Z+BPTK3RFUxBm9&+UuvQub)6GZ}(STKUsSHWD(Bq-P7eayNh2xnt%Cl?wiL8
zFYnJhzdu9Xe@=VBy)lnS*;XhxcY*JjAi{
zUq4!S^?30WS^&FquO838dOY`fcmBC$(5iyxjXemJDol^rg_
zl72W``f#uapZX)2yhfHS{ekLE_`?e_S^6i!QSxYI#1vDB{iWCb;@kTp<#9>*qo-iv
zK;+Ztg?=DTclpEq(hmnqD}JKw*WBOE>D+V?Jncu@xjSkX7A2C-;^fKSeJ*A)ic{jcT5D#n
zw=8ybEOnjU9=*1^I{pfvx-~y=v8604StkqC$z(B+psZR4HmeoUgwry_U^AE9k^X#6sGmq39-0xWO#;*-Llaby$y#N&
zzliB|g5miU*V{uUmt`izfh$=F31TM8kITu7i_VLSDu|CNNsXz@Pu1rn`+oI1RiNZ_
zjj^k}uJ24^c~)Y*v1IUa$MCf?)BTqQF1OANTwR~+*_!FwnCe@f=-r&^hi=ag-B}pk
zp6TX=qku87zhuyN_||Oi#`v|x{__izmIp5lUu^2_
zaP^(8>*;XypR4a`w_j?sTxqel*(&NyrA|YkO`mHn%G75j79_>xCB)^##pWi0yD{1E
zu|*ka1*u7e>B$9YP)bf(a%M_mHk6b=eNiB8N^xdpMqF%GLTqkwTy|1iZfa6?a(qro
zd=6?$O~_7)%}mhcr^6g4XQw7*rNSsDXC}pGCdOqZ#HQ$?RDl5ra=H69`cvUIG;3)X
zgSGAi2t8y4i6;guNYJCpC^^w%LX0$Joe7EIfRR8ZvC9O>)#H5@Iv(q*A~gW#6tgL>
zTr)RB#+4}#O%RTAAx8a#&D6SQY|__*Vhba7Viqaa2rIcdO{RUVg0JIs6wb+;rs!vk
z0Lfc(Aawo4Yy-45LuQ9jo!eCZ_FT)>eCy^M(Z+1c=4|`gR135|-HLd1q6sk|4K0p0
zE=>a7jf+&gG*Q1Y1)Mjol0j?0l^}L?rfD7CeFna~6*&}l$yrESfwU6H`<^#un<)Cy
z%?Ml%nhp)LC#F9Rpi6j69576W52Ye|N+G_|@Ug*MGKWf}JJOs65+X~=O^R11`O^WUJzjaM6BWF4+PblfAtNaF9qP6ly3aZ8=A*A|LPm0
zN#ZX6<5xGJKYqRahnHJFz1W0)e7^O=;U@F}^^>V*s~-;5-|wxyB`{w38ptFhUV5{;
z^!5ozy!6c@IKrjZyUU1QJzRuH0@@{@`sT^XE0lS%^!4L~SG$XE_Q)nGdHHDm)$Rf^
zu?xa3l7niWETbI&$i3TJdh4DJz4-3w0_-ofa*VuAgL+mdd9Wq@L@h$)!xgwyn#W{X
z7I~r;nazHLRd`%CWsz{N0H(P6$HUd14p+h2pPrLt;-sq?bskWknuv5)z=gkiviN2f
zEd%l>v{w&jUp|<7^}W7GyUM}f7N?=vVd!Y8Zmq9!-#x!_5HQ$028-=Y(98AZ@YyiK
zzP{c*KAv7IUj~Q4gk44qNHe^>Jv}_UN$`Q6hKJ^Oc?i8uiM>2h6tZ*9>Z#6ibKU1>
zu6Hc-w%nS&a)>6^ou!*o17~ceyjX2aM3^=*LLC{VQATK#pfc>TTq8%0OrszP;5jlh
z$n&c&r6Q3=p$zhqGQB(mOrIbj55!H2jS(<>SYD?Xr%o_Ve5nWtij7hdBaW(6k&s#z
z!S*rE
zKBv#Wq|!;ACkeTwG9;Etp=t_BQACU)BTvr~;y!_rsI;?YGny#(mR=!H)E5xN$*9HHnh<{@-VE-h`fES&A@
zmL8A>7d5P!Q=L*LI;E`XIYY{-Dw@XBqfF?g$pz$?^@^2294A{*5z|OYuIa?I3OT7U
zxh1sH5!1g`%!Y*z$cIu3ijjaD!ypt~hzK#WqZIl@6c3CP
zk&O_`hR>Oh4w#YUc^gQmfpgi3=|T;e#ihx{%}7U#$wvxWquyk
zNL7=tY9^vrRnd%fEoybnF12ya7Rvs1*%k4jZe8a1^A9c&r*Q*+EGUCv?I(Ut9rlzq
z;2jFvEgREE2BfhJI-o=lF7$1y2`yxGJc6CGT7j6)wk
zqInHcGA9x8XABXvO(;Fl?7A)0ql?!5^*x)XUs`o7
z%k5K3HYFFVP0p7~D3||M=r`4{REg&46wNlI9kauByfo67dAQaPmemr$JM1;r$QV++N#ioM=S2kHh-&#L;m
z_uhX$KI7|JdwW5^_sFuruMRBX=K(JOT%*~4j;j6Hf{g6dXPaVN@VjS?@BT)wv-_=Y
zdWoa|D0o3*YAF-Wvne=hyH9c>mjgg8vLyx$Ax(!A$#~IQH(1O}AI$iz#}k
z2Pl9qFmO-T#|2}1*VFV3)82pV@OKmIk>8_xg5l%W{&&V|9Qy7}P4A|j-#_c`?WUGj
zaI4$gnr^>P*O3i3@XK9ZtpX9x0(jN_vD@ul3cPFHmIrl54quo
z+QnJ=qS8NgU;KFP9g?d;6tUSs$G5L(6#=@Hd;qJDDCm7(AB@cp7Xu5EUeL2{C%Ri%
zK5$y_yMA__erBGxY%E=FX12FCUpsKoKLa<(!%8n~L7-5Y)_6-5JUnriD;
z)#f#Baj){dB$*P&oyph!1er)qF8^mb$-+NEvq`IArgCXDGY!(xMU
zp7d$sg1qK2YokMptBc4xnTON*9`E%DP6x@Wr+OdWKOIbCyQ+zsPMrq7Gl7iFHnr78
zPwtk%ABpR1Yp(2QY2fv&YA9!;7l)|^i;N2@$K*wf+mV#X#ABBzk2ph!1IC^^v
zetyb${{^02Vxtl+P7rD2?pWJ}YLcmm2z&au0F|i*heEE=gtmbXo4k(&ei!Bq9UEmnj8bgMBFn}{~ed`xNqoy?3Cx_3Ld4Bln|e%5P{LVo#lJ|_%_?9p9>rw
z&Telvjv>}l8gZ~_=%i7<7*3BSVM3&5W@Mw~<)kJg3u8CES|}M6OF1spwRD|=*Y05C
zu{X25J5iopaesYr-<=s;+F9v)UCP`As3Kr|;&ahnd~Xg3871|Z2S$4+mbQFhEr+C<
z%UO%h>b>c;0?3W#3ECRAF9MjNi}~_(x4m5ApEk~O>Bgpm6-y8*ACdq9T16Mle%zz;
zXR*vH%f%Ii4lgY8B;i8U3(z9**FD0C;zVSs=uks$2RnTzw(^*05nlo4su*>PuQ+TMbTnu`
zVO*VXrPC5{3^FGh;C*+0~@_37YWel$GA@C9pe_l8y29D!icuZl}->E3ePNA
zmioGxCF;%SF0yC@KdzYWr4m%SphX-#;tgfY=W^}Imi3#m=!9|YNZ3*l(47q5^uJ=2
zeoiEnJGv)Wiae^Y4f?eGI3E1sUmP>pG%j;0Tx4BeX81G5w!G}vF@8oN)rMBKoNT&eaYOx@&|d}vX9`}%!v`lx$Aym-RiyM1DV
z?98t0T-WuAd|4lUH%-5WH$ZFiseixdKMy@V+rd*HCAnu*BZa~d>bt
zK(wy$BumjeEWFM}_!8I+6uQ-Xy?I}Q?`30Qm38xCnu@k0ualm9@@T&$iOjuD-)vNc
zQHQyq!`)2r^|iU%yX~J(YXEI)F~`|O^Y!pFxS3t7_pFz-mEqaM@d?jt{}v7g-StW-
z8|aaY>68B68{Bzoc%x;RGEcmDdK#dES}Ues
z2YKs-mi-x;i~_Xu^7P8PyE}D2N-l^|`AeL(QCgc981O^n;4hAYhLEpRk+P3SLqB^5(1&4STrF7|0g>>qR`8SPUXvNELX8T*(A}tgdp
zB?t@@&@XJ`Y?zEDIVU<9C?xB1FH)_UgNF}qUphKMAR8Nt)P$ie7iU~UMhR8F6bkALNqB~+1XQPK@i+tv9LQk+_>zQq%pgCPq^3bp#PoI9XD8&$IftIH
zdB(+bsrwZHbSC6gRjFqcKjj2v
z@%4l9_CYXoL&|Ihf|=EzYc-wo%8j=Ju`{AB%&DH%0fIcp!m~Ftj4*7%!LwhJef2s
z(Q#TFi{_3CBAj)=ZVCEJ?GfwDWEi!xO7!wIQG2*#haYfg~JF5vVJO~bTOpv#a2^bMIKA$E(
z4*}?i=_Oe0$6Gl(Je|6IoQjPK`b;XT46Zb{o$WT2^*&o(E;N;VRSYUSC~#fZEhy^K
zj@KofaE?2E(IlnReFo#DWRs1_#)|B2PNRmZ!Z}D4G>#aN*om)=3BkRNd1ZhWRrEIX
zs14kbau3(LtA(?_HS4uKT#Iq7p#qoSmqOrfrg=N*?yg=Ze|ti{wV3sG^*%lZfSz8)
zp}5bo%BbyL;@8~!#QGtJ2a%Op-@q2eg5%%p>p|5Exx0x$^p$ec2{60Ld&J{`2MUVkI6hY4?zvlEqcDf9Fe6caf6MeMevoj+@3HlORnXE+{PjooCDNJvw!1eytT@*
zvJw#Z9rKV{LU=#pT60d_ET+`q)AhR7-+c`XMtwfk;nDSY*W0%xFNJIlf6fcwzr)LK}T
zTRSJWv{P+jPuak#-1WM&GL`SB?#L_Y+EH88vI?}g233{f0Qq3&pt`VroNP>Zf{#0>
zKg(wA_`H5i1ccHVZs0fV1^HwkEU@HC?6OWq!jHZNr~Ovgp?omy30xolUER1KtJO=t>11&2FnYK+f6s-c
zCeBgQ%%M}ts9@)#XC;&lOs)|G&Xp+)2|T(Yn$dgcDQiMgY?F9pfYLJJSRu;e(&1-$mRTd
z_i*H(&P|8?qh2L{rc9+03{wMGBS;4i3%VDA11DamQe{-gaxpe$Ucw|>lL`(RCjR{;
z5~$DDz?TP1k0oLVu*f-bESN&3n+(cq_!YBgUbKouK{7=&ma~O3g-x?&-lDKs
zlJ&tzp^1%?kdusq435-AVZ&WVx>^>yDh4R-ux0*UQ%5_Qj*^T{06C|4nbcg|7fBQ5
zqTJZVSu>gr^D0i1bYhr7#Xz&Ms5u
zt`0tK_nNxZ*t7y@SO~<|SBD|xF1>
zGEeY2!gY#(21;oU7SrfwB^g*m09Z}L$Fxxo8IxmlBEyO?3ML6}Eo`5ge-bWts8p!G
zUbV+}#&X-04NKgv>i-^|QU(fjsH
zZnNY<8exMJ7VWzfBC@Px0A)?*k3*dB55ECF{O1i){xn{YjBPT4jM4{T^z&)5o~>b)
zBF8p0Ft-GL-j~j>m^i$>kRF5(OJb^wE3%xmURrH;}Nh6P(
zL`NPd#ox3tt(6hF?Tq#|Mi+xqkH>}O;oEZP`c7=gJ~Z;`=1eC{Y9NV|0o0l`?Rcm*
zs>g54S}DZUCz=P%G4VKXmHE(}841+YFsGuTXt(l*zjVPgs$fUF)T=#OL`K!8NCm$r
z9t^TuXn04ZWZW#1%8Pzk#<^{q76((BuPXNrEd;jhc56Sl*>{dO|G@u$nGF0ZciggUhY$^P+#ew?Fat`HLx6_qw-xzUgD$56m1i<&>1Uo#5HZ0d>B%mbRve
z{y`6GMGG?vt&M%oz3p1?tk~W;U}EE<%DPICp))FKYV4@39I&W%0;o#4>z!^^QQ3rjVL4GC8a7}{=d6mpx*>V3BC-U+kD4
zI@rJZu3bFb-5W1T$Q_2;i#Ul?|8dVJz(CK=4s9{*T#B>S0fl33baitwYyT1$tI4~Y
z14a)p4Oo@Ar>97ty%vWBsBP5K#as3o>Ek$hu#m{)A{@d*J)Mc0hK54E
z|Ku(A;eq#_bn);=&F{sm!1n+nghsa}JThEA_X&Y%Z9c(~fnE}?c9CMg<6T;{+>bw-
zjY_m8R+VCpeGwT+KW*6&b8#|g^eF}cE*h}!xW67K7%bW#vjqxui`=_amNrgx>|hB>
zyi8eiTmrB~8m#uPa+n)0yf#?`vPSdET-`RtTkRc@Sr`oV5YVCYy~@wJIhcOO5j0GVV_D8eqHqb5It5Z=J5q0+Fa`nzEMz>$
zd(@pk@sFTiJUbJKAR5kp@nHh)(i}!%gv;Db5jO#324qe}+zpV_yLRAZ0_uIz7A&aI
z*!?uD_|RCY0!w@7FzFYKkx!Z;p8i&o>Q(L)CD@qPMEAl`!RUwlO%z4(+T8Ot8Tfb=
zmGV?Dj44tZe1$!AmYsP1XcpnPLA~^MoBLOZ%hM+@ZZKzZ$i!`KUf+GB7{$oaVemM&l%NUc7W`3V;{NM6i><(kC$fgY
zZBa)w?U7NRRTTdU$`ukG5j4_&58NjXYe2keBuL^UL=EC&$MqrHbUzP&X>Lhe?o!Ye
zFU~Sj23C#(ehbA-)lWNmPcm{x{thrl1)+b={#nhEtb$sU0i{emaL(c#)y!0qfmCiy
zJ<)vbSpLwC;$78M*keLXTvOM!qH<71>y-ZMg4R>QEr&=3d4DJh0(CV)R91oEsDkz<
zT?)HWN)zY9RIH+eMuhBH6@o`t{`Pu;xA|Wx&gd
z7@kcO-!_JK1J9?M^}*fiYP_bRtgRH@^+brW&LLIH?xj^>?|EnCkC#^6YpWj5`Y%uB
zhcy#!@9Ae{a=YcU%j#%f8$K=XhURKp%d@k|{olw_PE12i4dmI)$yt6nePV*twqoyF$*i1hvazfVu5o`|DUMhz4IpN<(YrD^0>^h`cH
zJpgv<#!T7KLa{h(z(i6RJ|H-Bk@LCOVfe&2QzuOtIC^M{Q3FqaM?M`eq5k6tOqkKg
zdJVF<5QvZmC=UnGOP!SuwXq}nQe|RvIX66u-nBCumR0O}W;PYIG?EeYlhSS~7}_bJ
z2T#iGwj%QS$uRM7N+Q9PM1uhHcl`jhX{+PAzAwjqACCkD@@4TNVxbm9fvkvx`c0~I
z$c^hnaDODxFoB^a1SD0``~Ior`JhoC&2wblK@4w*do*juPP8N>G*GETEB=n7N*p&g
zM#@mFh=&6C9VUN%K7M~MAlQEx3<3%Q{^8}3{q(^8{BD-_{WAOWRW;l9#OuLCM8eKb
z@^Ll$qhyTXPpc#>4E7G{d*3w+T>PUz<&rE|6QL|dT?F8pqlil?M$BK35U@A~qFUrq
zNl~L&wA^1$P1vFciiZqbvm!dK!U&Z@#iERhm5f-mY*xamtfFgWlYQIO%faaEWoqqZ
zY3@{Q=Th%fa5<=b+7TgjErc6Wbh_!eiABG>Im=$t0qHQmzmJ4A8AlC)@E+ko)F4ll
z0`d_xmkt4)8VVK>Bv>+llsl$J0-Fp%kP7uJ_#L#}HlGJ&>n9zxmvlfR1C)uQoLQd%
z#LPG?J_m-ig65lM*qV|lEYn#R=iREcw69<9(Tq-)k?FQA75rq(=V1cs&Mk!N<;>2p
zJw@R0`LM+hqtyr(2~&#aawN!-=m3$EABpIQKQtR7YAK&;NQhXA!?;Z?OO}?frW4H@
z%$s_`$QHLQT_#{v2}4CP=~p3UuRIHjI1P7DC1f=cJv>|Z5ck9!Z847@{F7RLE-QbN
zdSm>Po-@jEBSY}0-cOP#tTQrBm+assEF?ZB&fD0La;Wn}zwnxAUzBi0phO&4V^l8aKp*fs9EFtZFE)K&C-KxM`CL;QrG?eCHgil?NiI-DEl@!(
zR!KHhKCPD~(l}YPws6;V(yVIc+Er0h(@i#ELRC&a=A0}{9hv(PeJF+e6%BtoV{=<$t*;M;^9DHH4L!mA-rVT+=Ag-I
zlA*5H&)w{P?`PsM>~i*|hS#q?z{t&R=4M;N`(FS1er4;h=6!TCO3s${dPlRnfyvRz
z#o5c^>|}w$+05nY=j14-Wqz}2=uhg08{6oOo!pK(re@ylwl3a=I)-}AHSRSJ&(^l<
zb#_rvFH*ZrT^*PSp*Qn1oKn(a_>?I57d7TeO<6aMw0%-hqPuoi!Hxpp;bn6QN2L^Y
zg|LiE#I|N6$g~kc=ZdN+Bbs_uB+jyDR>hnpO}+Aw3ie~o$W~^hcUsArcU8+j%SmCs
zPj$J+vzC?d8D?mo(?270+qpd_|Fv?l3qphbqzFO`C|YU~tlVJa?S_@cn&UtJ@ZIdD|J
zCXEjUZi~a}<^JLOjC#2w5fE3$r-y-wlw7W&hI*P;Q+3X@yW-b-Z7F4AW@R&bK2rNK
z!e*tCN>@3q*uk>kW@Kya+g|nQZ6#}{?JTU`t&K;Yc0L$XDEQS<5HOEe&?%mwN_Oi0
zQO_+WGHIfKXpmViFXOHru6*G0FnI@HkxZkFi&h8+FG7SS%Ap7+I69`%Ac-0qqcU!^
z{D2|ppfGGeJvgW@?INk7Y)mq_8FhY*TcT{CQtYKcgy8eOeoHJUh>Ey>H(*Yx&n$jX
zrzBQk5*gp$Pw)57s~KjAzgMs#A!s6#qJvDcARuYQAgQoX5)E>+IwCw;wVeMlIX(R#
z+S$oLA!>QctJbITbYj8$^~3nzi1F=)`02)7O34p2^R^k9C%v@xH3sJ{r+sb9tMq0`
zXeV6Pa&lT07AkI7<`B{GPeA~8A3!gQI1a(S)UY<=75!FyIC&^AnnQ5Ffq%GvJ%NM1
zvAuD+Upl@R5(y*}EJPC2cTmZILBPI%??1XY^1Dq*-xWZGKZpWzak$KenZ3-8
z_1(^=%)(%C5x%AjI$mXH{62%&=}M{4A{s{=CEr
zd8nlsw&3yeXMR!5M)Ole$fFjT&dflCqh%J;uteWYLu6L@6)ZjwNX|Usa~~8jL)%`2
zD5BCj@VuOd_H>IM{JuJ};ujv!wO3Gk~^AH3-7~G+#p|hoz*;hn%>HcK3X)?|~
z4~MQmbl{=tBzqFWg8rBZ{zK^Z!bH9DL@4i&344(4h7}|bV`%s5+9Q;`vuculsf^^N
zXO7z^Pc6&yPLJQTQNT7yIxQ&*x9V5ck+A<>7-~(lTuELNk+{R_9p83#`!GbV-XNYmPY~(^NtG}r%gjZe`RD1
z@n_jIXIQoBa$R+}l%PlWjd)H^L^=PMeYT!_tdw^C-uHP8Bm!nPCyoA~iQU*uZSCfE
z^{~Ak!R_BCbwSJB%gII!vA*hC*_s)>oaeNJZ9;Qp
zHC;XiZBh?ODQ#Olek%>7b=9#v>)Kp*Y&pM27hNiDw>-{3UoYD{qsr7qu6PQU?p-ve&gcIPua`(O
z*9NO?d3II*oZSGcXOVtkqld-S#^mc;ST(JpkzT0Md7G=pQQw^bL%*;&^%QyxDm9kQ
zh}#r*qK0plxMR&07NA4JW~*b5a)#>Qp$#^72~FjMVU3qG`C{MzXd*|CHNp~sxX4jH
zu{w#J0?=>2CjRF6$q&FGW9xW99N#s2a~*Yg^wH?SOY=f$w?b(*qDD?iV`}Wr!o}Ol
z#J5^WUL!M(lVR$z1H==Cq;WXCB69UC`w@TwalrisPw%JK84r77*gsX
zUTw%wYM7W9(EjgaMvBeF$-^dkAyUOPB^h;)&CS;%vpi~{!8*}lCd_5okOf}el^L%urtUKFNuNJ|&bYC1kr4jwWv*WFTZD;eO^&6CgC
zY8XAeyt6KjKb;(`^}IV=t8N~>uMgUjF}OFk{8}siX+vjH
zn(449`RbZR)5+F`Cxc0@YcmGX9z%V(9}r07D-$F<{0%7VN9c
zMhXC#S&O4ba|+oHFevybAh1=}$6y==lJK9S=O;mRxEBhjzMJ#6e=~ixc`6&U8yjjJ
zyX7jNXIU}AIj<#=%DQXXw8}mkpyy?rSVCZm(H%Z%pkuo6nlef}tHCM*ONj%8Nm5bl
zApD884T
z&yM=$|gEa~#yJt*4e>ISXP5fgZ4HKVWR~S$U`A{sO?6O6cufqyQ
zlFf_8W`VJIR+37Nr~vu#Fh*8c*r$6jNO6OAJST&1Nr)+O9Eb7c@S*Mux6S2K?SNs(
zkoe`-(Q#RNqHtg|5$l>7qrFI+H^aTcn1X0TFA20WOz|3@=*)vsO!*37LzlRA)bQ^#8aaO=0Q
zFE^X-Ha99Ek&mnOYewdA!eZR2*X@j+4n9}U+%EU-F8AUpH=nnu$HBvc@~QgmdK7Id
zr&B`(dsj69F^|NgLGBR~w;&LR$r$AX9i{l6WK*>ZC+a5;Q6B-Bl!C%y{)tnF^j-nq
z!N`R|%c24bzD>E|XY@znp`dD0Ar}=){@fI_v`mzwR3sxd)J>Y>&;_6f|Dj_Bln42+
zngs*Oum;!kCpsw)otA=eTgz%jwiV@N4QlL485!1-lg!G{iwV`Tl4T292jv#_>1o+^
zIp!s0t!-^98&{RKWtBGehDl+=w35FT77bZhmeSL%#+nO|T_9`n}
z5m?zHD_~YVLr0C6R+SSrr3;;zlKl&&bQKL}H7cG}9o;Loj%yP-4AriNmKCukI94Ef
z2|>a}HR~otWatD)y}bI)w~ZfBB8yB@3kA)PzSu{%w%36n9zYMCRo
zE$}+F9BOtJQ6pU7$FG|iEnTVj2>RvU*mXS0mD@Epu0E`!`
zhH&~lr*@W53-KoLoTF$2od{t91Y76GoGy4&ao$!tq?}hhJTMy>x-^DEL=4CMO|H)n5H!e_MI-BT4jLa!-hUg5p{qe4ED)hSWy-iNU5^=k
z5-#%giSP-@@grCpJPC~$5eUlrK91-z(i|}pdVOxyc3NjAr=xLZrFUhghik2OWu=AD
zdsV)W_x0u0i&s``sH-92>LH;j>#6OUS<669NzT(iL0{C^-Cj&UE?af-;W^ZOR(SMr
zkX<>kFx*a&dJBm*q*MY?$B>Ni6q0XeqR~)M4WeILNyC5*y@=#uh?h0}6ftjsb#cY!
z6tWFNlBP)&NgHaY*3z(ITFI!Us^TAxD%;esVrf~QMHp7HU@Nc>71lCnQB__+=e9;=
zy$tr|IJaa`QO%gbWupRDHEzquSxJ?HW)w7ZLBLTytgfX5db2TgSH#}EprE5*RoATb
z%(~*()q*s$qX3IhG}x#aHm(t*g9_WCTDGkp*5y)IAK*-*B|hpXT`4(y>qx@nd7+
zUEt@dQkWnnK!qqGRw$3NLOP5$GGuUbFZ>trygnSdCxssi1~l;uu&2>SVkZ$r69z%2
z6pNB!GL1Iug&{ybN%u#4CEtjbhMOBR8Kg#*9{g*V)W1B5ErzJC
zrIG--IVMJGy`@G2kwL+aoHOmuXx7v-K1c$&Y_*5j(KUSy=ao1#0-0{UgY+Ee;RIa!ex`v
z5EXT>l#~$FRPfYn7uL?mTXZRXwv^g#Ney*+ZgDxOY=Uh$&9a;)x#rm2@o6nu*VKv6
zR?N=T(9zs5Z^*8wxwc==vN_>wnpadTP8vsM-2jnE7DYqE!$2W|y*rd>@5RYe+5uwY
z3^@Qu$ivqoF?IqT&aYFSLjH*Q1|t0l
z@CAH;@Nkze&*P^-HAvIT&+F4H1!)qnRB)GhczRP$76|?9S9@FtWsdkD(52P
z^1A~X7xLpHjt^qFvOb^95`Er5Vu?Q~eTJLPK0CVae={y#dN#Qf`l~Lz*aFHY`(Iz_c{)Q1QqQGd
zA(IXmWIy)#p=3P&jICSVyJ-h_eT1VC-$yIJB>h==I%V+PP`
zI|IHnHPY6LWiL4`+Zt!NS6oF+(8#3N7C?~?9A)a2@ZwHTjaj~k$N5#jdCTM~kn56F-pd1w;
z9u9T0NC8Q*l(2ubtp{1f6pGw|GBz-(6{dH7TD!?ZvC!%1E|Bf|dOeQE<
zP*kuaXUdqE8dX#jf;gy{NT`@F(zH(-)~Cx$+c72>RaMn%*s`jv(WI2aS{$uSrNm}Z
zsk=5+pp2?wKeL`VYN=$PGNlEK?lo7HHez*EP7qYG_54-TwOLWiikdDBv~)sLK%G%n
zR>`nqI#NwG32KzrQ1Fy6u(VLfEFh86i&xN0E}<7CCL7J4WlT0zIcu6e_GnrD_+^0Y
zO#Z^)W}=*2p|!0rx)v8aw-=m;XWTZo+}CG)>U{IdoZFkcE6ZCxGY%!wnrbTY@uf;2
zQ7Q!j6L)uW{qcML@pr$Tupns~buyKTxVpHxyLzxR9wK4dWC~S?CZ*ah-?r<&fng7(
zv>ZO;M�lVLTE9$TGyNy7iz@Wb#;8zfmbY<1{xMx*MyE434-`5}J&LGU&ts!c|FU
z%lJM^VnftSv78tzZIgz5&r&%v2M*fSDo-{HNm8Y^y)J$zyk<=B!BYSLLyYB7J{y_(
zq%kzRHZL}#));B9C@;ReDD_~{#XXrkxeV;lr-DxtQ7nJ|K_ojjW7g!OiG%l=HW)aE
zHw#mDH)a_(J1-2G$8qSNJkWmTcuG?z66;v}a}ZMr3>rT;dg&{48WeCSkN`mefBrrC
zJ5pf+Fb
z0uWzi3PeR2H$b_uQ^r^tLk)Wm_!hOT5*6*UqM7)`eLAj;4pP0ick?U
z{SjSAJ!wB(-l#B^Zl?94qz9s001o4WW^pQ{a1Z4&+%xD~=pr0UDlwb`d?+?zF{&p%
z)p$K|^Zq`rzDx|&NMjblk%HdJ!|?_DN8r7JKj$oG;v7amvH%gvKu#VoMo?ahz^(JS
zmGgL=tC^Y)!Z77APw+~M1EQSNVRb6)xUJaPqht#{q8Hl26l@ZyJBjC}_=oXG9Q2sk
zrF8Ixocol%|FoG07*rs~%aGY$c2`7Q3rJkTyGUrMPEV5*(L=o*>8QZVfHn4`CCIid
z-_NRuIq9V5q*|=YfhatNjlAK_cb$j&fC7~D7!3-tN?G763i{R40)Dei+#Vn<+Q9A-
z=%t8K_#$i(`=uJTg=#{Goo+$*#e+sjel#Eb^D|6y=w@FXY?kzN@I-$*eL?Y>`in*nWiBe|~%g1ubxZq^46o
z5_oU(0j^GpqES@dz~lRL;pC{0BtU^G_`~^>zludgLfKT(;Iy50GHwcFL77t*+@q!eR^bnEyt|UlE7jS`e|7m>JiBRCOGI@g-T<0cXV|0aPm=mbMjkt
zbn(~K(^fSK1rHCSA{rR@?A`OsjP#_W+{}dd`1lOL#PrzYG|kxL)TAsm)fg4c6cyDJ
zSlMLcBgE2UeTG_k9_WQoNyuFe=|^GrLt?k1Pi;kGyLMh3{lqf*sY){HK7tZxeNEjQ
zdIn6%$O96FCj^J7d>?yTAr3B@e6b+>`^^^>#6||EQlv9#a)WY-M^S>b#CiXoh>ug2}IV}g;O-+}A
zn|CcuNj~V{bZs!&=D&tx)oEwhXJy`}v-GywX|LPrNby@+Z`Au=MgnyVa2j@9UR{$4
znlagkF!f+iN#Gqq1rd=nCgmyxi>6AmBG_%!Qst6ELjzTbBIJYU1dC;hG+ISGHS0xr
z{Tzcwu{J0Ub#g+&TFrlpne+jZcY2!%$$BR0D|ulW7a)Z}s3065-2~X#tXa-SO%qpT
z{cCo3dzX~yCn}M8A2dKlSR5?ovqlSXnd3dO<79@*(SE~@aWaq+Rh4%nzbQlLcJAbX
z5XLiI=ezX3p}=6Q9@21eBJMB>W?@n%j*vkE7HHDUVFG8eXxfZxGC%H7
zwftit8Dwd&ky~Iqp0`qM;*H`vGLRB
z4sZMx{vdcu@NlTrsE#4rXuoaH0PcWN<42F6*0_OW@iz8u05$UwuK@^sLD=~T@8fIq
zx3}QW|2gpQ?Ji>UzhD0606y-|=)bprfE%LHruv-akpRD!govzgt)PCOyc9493IG@Y
z#P1##em>L|AZgB
zgS(4cr(w62B}LF&(2Soy=2$(F8eM#43-SFLZOpYFO;6iaFwg9){}
z+HArzujZ%^)E%SD!)UJ@=UX#|nEyEw7fA5nvNxI0GPgH5WCa}a#sj*ZD;81Gu%h5(|rs&84mDH%c;idA@K&oZcVi142CFB``0pPu!2hkIqx*c0MSuVR7*GHJ
z#Q&qCZg!4VPUa>i&QA1tjwaSl^#5Hj{zp;i{#ukKveLIyjIxh_V8^rv*)dvI0NLyGE+(&=0OWkk;Tp`
zyZX7YybTt?C|+)KMpI-1H$ENO&KZDBW}1^zPsbt_Y)Ee;3jT<8QU+BWl{LXQIwEcYJ{(j
zh~umg=K469?W`o6{p6C>8;gXI@*irB?E06sa(cp-z*{K@$`NIQIzd27IdnbU+>Jh$
zPTapRuI7P=IkL&jzZ^)Y!GjiRo!&EAAI5!?ftGeO?+<8#1YO)xSxgU;U2C5nNO3XW
z6TCTz)&_aU_fyzKB`W!=r#PFE-I$ZrH>tacw|30$B6UR0{|FD{gw0oBjf){_kYZg
zx|UNB8;b9(^grMsAw5^a`1Y<=w*%|OapynlWb0SQG6Rh=u;D;6HH-gthywt}_hkMg
ztqJ4gJf5E|lAlZO@RByX@IMk6o-2zHE3KMiHHswHmVTUWHWBNsMkW?RBQ+(}Qe{V>CpU-kFX+1Sj9w^)f}$lo=Cpk~Rd$
zEV3dYm3ST-WcQ7LYta?O_Zsc96
zRd}b#zR*O9rB|h#9QT1a^c7@-Y$?O>W&G0UVkq>XS40Zopk8al2{0=f?B@IGhk!w1
z%Y7OBNA+in&G7@_9@1K8KQAaadj#D!M}zNt$|n2X`S{SLIsM{a`tvNJH}Q`FUPic|
zv+vKc8S+4qTnCtOaT-YgNBXF-!TE@FW4QjqyMIeIUD*dC)~rLnUO2BCq7Mz{tY(90
z-0h?JJ)tBe0xHGNpt>V+V!E!Q=Lo+yvL;8#E#{^@I6A=c5rw(5kStxzTNh-gJ53Sf
ziq8%xFLF2d8+0ehW;?gReVVyKZJ8&-U~do(I@ia|F{>AM*}SC=5CZoD&JC|I<6EE{
zZN%FIh+rc5{kQsiLrp>q?yT6Bf&#Bos-b$#ek+BBA~>=*HaSDtAf)%IY&@vaW9N*%
zI-x!7t}TwU*y6|jc?B3j;!|w0G28fh5g1Nb0t)7SWWWeOF#N_r2Hg9k(T{5-7hN=@
zF3Q{wgAjW<2K?4XRgWAms+VM_%x`d1pIvWu;er`S_S!Jp`o$^HB2rp*i
z=*|~m7|>qlsx`2OtqFL1>K=<362@3_8lzFnJCvFq_Bo5=fCs=a4LH?^iolXsToAnS
z@YU$f)07s2m18}upX*NAU*d2FDn78FF_0r+VVNl9q2En0gk!8l^o*a#9UT?45yyo?
z*^~(e`|wA(zxW!F-5(J~2CQv&bg#0adXN5>oRVxX6-?ieox
zZsDYITMZrG7Z1j=hO`dtb%yYaXk6^Zo&f{uGRIUB#YNRre@Y6K9xxZp4WfdvCwN-q
z8Sv8COh+Bm+Kl-8!^<62*@0hWdAnFS!VBC;57q^|fILewKFJ%|t``zd_w1ggmJCAF
z%``u1(ugc?cBWACwSroEEX-p`;tD?}p^+XB;bCtQA)d5ST(ck>oTNla1`^z=@+`p@
z@7NzvlToX4TI5nO4d8za(UMH07;CnuO{&ej1}!hKg3B?Toir-q-`Hh9}ThqaJ=
zgoylaV4bbtJu-KWoi2Zc@MF^+*;4ZoD~u=fQ+Ktq#wT2=*D|hvY{ASf=Cm->u-U*Y
z$r|==4--^@ZiBJKcoe?2)x;^xLuMm#>I$jg4I?r2N5WAR1#NRWoq_+!7!=Jc3(szo
z%#nL5{3LN56jslzWa_ZJY}>Ytx1aaJjr-x=j;M&Lj_8Q4s*@-4{PUM5pQPQ>6m&MwA8E&r<+it7#R_+U6%2vUu+$KIE0a2?uu
zb@R%47lSps88=(6=UKlGT=8)p!1kaNpeg2|m0%GgUyK>Q7JGYga@r~rF=+2JhLZI2
z>4UU=xIdrLz5~tT-dLevz!4L@^JSxmug*NLWrEU=u;qfl#D;mIG=TXVBXY|$`n;K_
zVx289WAPgq6{Lc7U7;Wd;)EI8N4hm|NkyR(!I5YLzP+(a-(cvT;RB*Ho_|Zp@!*#M
zIS_~$)T8ECB71d5Ner;K5&++r88XRvOz*}G^tNk?Y42!J!FNZWcx#*cSEn)GEZm&y
zbb09_&VlL?MC;bMfF4YiA+MEAYc22mVdn_9{1hfD>0>(7C~1H>*{Y6SZQEtldDChZfEwuah3I?KksAqT3Fn
z3Q=2oL+3}{MeygfKYgljKUsW7xHo+O2HVBPkQ>1B2I;-+^FUE7fb7Rx;^7eS;sc|(
ztL-Bmpll}cM$L#u2y1IyAQo8-d?A)g6^qD-t8{7T-nMDRD65mfq_>DTNUwmaun96ve=^^-^D-Z1$KGa?x4}8Jo0T4^4GZdY-P4`|
z)-6d~Q57~(sT8!bt`G}{uV~7a?+BUA`}^#vAJkMB^ZQTdgOGfYuI%j8bs_w3tEt=U-mk|rQ|Nl=Gpb9v&s
zKZIVt;IdWag8ZqzG4Mgm8Bm}RD#vQz5m?~M~qkstmk
zBSG?{2-bq?MyZKmsj+RG4G$3tB5nyub?4*SVd5h>mdGxZkw!VU%-7YxOrnm(o4sPk
zkpPM(0o9lkF3B)_SdBHF2VkWr+Bf7Xk3FcliW1bM;-PivY79I!D7~c>H5_|i)%5w#
zB&#X$1#~3t-Dav<_AzAURkNiswq*Iw57cCdIXx!Ebz{k1?AJn_IAAs?_gll5Nb)6L
ztwuvB2^Ls)3yz>`
zWZ;HUP{W#ZEc-}FWhy|b_?(2vykAZAab%Fl^DXB?$SQm{N}|L9k1Hd0;1?F>at{P8g_!j|60!m#`SVJ
z9-axMlLA_aPh7M!t@;#f4qXWIPaIOON*2nhQT5^>tSw$<(K1QU49pVRuuP)Sm3RcH
z8kSF_p0P}!oix2^)GPrjs}Mn!2VHX1!+n(zZa~tqQ5>KVM+*p%>izAkq_vD^p2VfA
z)xl%0PXGJBbwOl5ShZ^LF7r+kk1hYIiE6q=B}`w-D3(OReO86*Je~CT%EMK>G%M96
zNaZh~Y`m+uPao-Cc#%WbcfllL3F%2fNO>TbYM*=E%;?iP*~-5zb7Vo!zv{
z!Mo+%_r9sC>vfzN|9qI##lyl*sK?96>EOuBoH--VnufA+6sDf>{FA
z1i9(5*|*m&&k5K73NCHur@C3K=6u0t=BoBz{jib;MLAw~1Gy{-lUWL_R4}qOsAqqGl^KmQ17Z`N~yy
zheu?y9Ggv0s8!3ARyUJcdS&GbD|^)haltKn97BxVWMWsI8iS=nf
zr%3~;WnHKnvma{p{YCJ}PKq{nz4QH4ll4uDv+!Jn&u(X-LOYdRn<;NxI3KQ;9vn=D
zR7ZG>@eg!gQgeY8vjfd2j|t&C^(@q;;6m53{bU3GJLttLv-irY%`ugD5YOebTd
zmnns1n$IawZKt9ui&aFWhh~w$oAy%#pPf6>V9MrjHyco>i!7zG{o|xAG1cVPC}KVX
z>H>)O(cpN4z9W?ONRD#(NYB#fiT9Gyo1>MT;9tsXtP`uHSe|O=cdP?swMbs|kO4Pb{AYV5UZ=
zd9#*n+}$6Hve@~1A^j$s_!#APUW9FxE%duNi@@nzy?gps;Vz
zD0sjTp^r<61b-^fyIz65d9WIHL#>pPxMeDZYZ7bpS`aE@ErzE-fiqii;03gg2UV{G
z0UN)GcJ35!+o;}fRKWj^hRhiTB|7;-L=Pwkca@0KO|RI1VCy(D3#p*aa#1O&HP)cp
zm|fP8sWO>78H%W8Raz8Lj5L?kF|J-Ktk`x$mwGq+w|dond?Ktyk0ysFC;QYTuId;T
z)@rx;d3q4X-}9eE1%z9cr#Ga{!#jh`0-H06a%ep-OW`-IIr@7N*)W*mzJ39T_En9W
z<+PnT(Ug-oKGqu#tybF$8(H5JDY4nr8E4hDL$X;dG6W91=`vcqXf=oZs^mQdFY@da
zYmutkEK$02$P~Y$exJMYVY
zkz8-br&8^+<)T+COr%o~%H^B*Lh)M?DGf6s3z}n{*O1c?>G|UZsV{sLdLxFz?2NXO
zcn4;(ci~SoKIzZIhJ#QmO)~C32K8v!mFr3d87u5vJZdfH&%jWgN4lTBIfi*+E#h=r
z(1HvC_BsqZM$4BZqvkImTSjAj#$1%fisP<(xdjSzV^(Y`C8fb{=Jg$h3TVIN$eAVe
z{+!-Nkx~pc;om;|rHJ;>VA?R_bW$QuJ+te`_|8~EvSjut)
zw-*rCrv=*R1NT)Ai$H|A&z0Pc*-@QtzvTuF^B&KYSi@yE7^Jk
zT8d4t{9Q)flF>neqM|S2egBZxJ~`<6^;fqZ195iz#j?a}vB8J>3_r!00b7$(_j+#J
ztw`LuW3Vq|ge&_Nx
{O92$)6XQs#g0Kbz)dc*nJUvyCM#u)kV@Sz%{J>>4>l%eM
zJyOTu8Jd^yy}mTg%oz%&Oh&x`m(9z*;pwU5=jhzzfcO0!1%XC4m6{|Lx4_)LI0g@{
zX2xROXCPFjUUIDEFy8Tet-bmP9#;q2@_%-+BhnS+NIuGwZIO&jq6F_C_PcN39NH{O
zPS4}V-qIPjQHcT2y)Hv0*h`Xbfps
zP)l|Mz(MFn%>PZy+Q}-C_m&b0l%w~YHmp>z!D#Sxv(^~p&ccW_4nxLS_U@$D{*xGr
zCNQPeWARj2=^Z7iY*W+ksc9r>^lGN2!h=RH_9AI;uIEIIAalNK!LjDapGVbn7_I&y
z2Jpy&Tg_1u47_eg+VPR*jMB4I8tHM>C|e3+9k055Kx0GZzw6G>=#GjzP?gL`_5q#W
zVi`wY?m-2)+H-t+&096QdXt~2!8#8MRpzMS|A=;~Bz6OZD|FA4uSYR~r-lH^^c8yY
zF~-5M5EUr@=y|?n@>4s%{ezE_Hp5mkhmSDv3Vs#u2y#suJxVGh5n>W$t)Nbomfl*=
zb9gDmrJl#0ObeX-@H
z_pzI^BH#No?BvkPgTXQ)%#~lH0Bwqb9!=$)$T8SP6dKx{tjt7c|FTNK|5G9A1@sq^
zcov*_Pj#5i0hc3!inz%T&&!yd%fnS~VzFYN6zK=5(KEer!>PPfV
zaWrCrOthky7WFV6!cYAeTGEETV)-|DDjqh5H6FIkPa}cf?StPZ;GPV+{C^u+*ie^M
zs6+<^z=r!5H9NApep$YqmyDmwv@>r-syVWMhWfJ1TZveLb1OMFh!V`;Ni)6fLEcb{
z3d5|OUhMeZb-VQ>{i5RYy0tz++
ztrbKx40und4~d3?k+Gx4CEtJhj>5uaS|prDff0CSjy%BNDysWZ)-RdA(;7uiWUMwiX7
z9z%P%xMc*wHei$etU5qRkL0MC&&O06VD4U4rSbF+F&9XJx|p-VRGo6n9~rVAWRu=r
z{8I&EU_ei4j|H#E3aOHa$GpcrcbXb87#D}D{<62h(DU(rMX>#~{KD^vhd1OhWE&Ch
zDM+*t72C(iWEH_YhcuQS{8Q)+j2O-kHLfj-7Av*s8!*Ld;S$+2>`>w=QoH#h$Nzm=
z#{Z_@k@NnK|0jncA4W7eA(%KJwXynaH1Os%VYedb?qDQoM9$b&x29%0nWiy^R6v2|
zH`kLuuVDTuTj5h;5M5`xZ@u5+-quR52gM;%*Hd@ej^E3Y&;a&R#Q`u}C}`4)JVPJW
z!6qXky=_~m4r4yaJ(1ul8;n-Dl0QhR1o$FSlCWI#<&M4nO3=u$)Qq+c7UyT1dbsXt
zNGzhvwU9UvDkeE2G5etWC~wBEa3=*$z*tP2kcbi$ZLb!J8&Y)ClRv(NHlSJ@R;Uro
zXN&FFyx04Dteb;%Z5_B!0w->8*VLjt#T4T>-H^pY(D|Lk<3Q}PZ+x9K^P~nauYbOk
zI&hOsD7f_dSD9t$>}f?#7=XmW-(Fpm1;9&{+TcJ2k(j1dRNLNNd@EH9m{K
zFwUtCK{EO-l9#qvn5cZBjMNAtCU0GpipdO9YYaJXTWy(~etdrCfa0o>`TuNdCzj!9
zf#qs7AFIj~PhaM7RG9|idI+drs`h#1UN;(BJ>GjhTw#H7L2IeHY6`5M!5@LEaA(&L
zj@_nwxOgde(unVt-}esM8?xP=W>t`<-p2c|Vy<-G)(qM{9o;a1sbTcl{atn5`H
zq^qG*dC5I-+}l1^h@o2%<~^^^a6>^I>I#9>qXw=#rIL9@+(Lc%b9hNS+W-nmrw@0e
zw^>*R4PvSpQ{|LOLyu*T
z?j%uEzJa$r&`>u1kWlV!~|XhKn}2<;R3z4HkTS8IUxK|x(OkroWB;fM
zf2#Y+=+T?}g-Z${WQ8t7-%h0wVl_3MG;}(`0(}$Tz7oHmPwp
zh_g4Dm|AQMy}6%8SC{LdwKu7=S0i-gCtiw3q_O`F+AjvVYimxKBi7vNB{P%&q&abM
ze}*a*I9=1m2GnQDeW-s!uV4Bj(wYepQhWYSTA}|mHs%YD=GS(ws_IYdPI7y7
z+8u&;UH0%})6Y!QOedrk{{0hlHK69-ir9yod2(bF2y#W8H`Rv+v8ED$Xx0WaFgV)Z7B1DMhY5G=3cTZIWBeV
z%IB7!ab+=|d}(z0x^(7%BfexicWML$))McCFtmId(cO;|Tg`*iHOlW&<%>YWMZ%LmeA+Eu|FSF`{hlBGH>$dJ!llAfBdOeq(|cqUf-%d{@lm10gYE*kepU8-(KPDDda
zoIyl-fd9xDl$|K>_u4Gy)@Q<9q;$n*{lH5_$}#PoYTL2FX~20df=vW2m|;>5r@8%5
zFe9E9I>*Q8)MQ(<MWZxWjJc-n)m~%MQc&65nI}GZ{-O6h`95H-t@V|ENd?M(*
zUxll6nOz8nx$u2Lqv)RW`37*KM&rxn>h2Dc
zNSCRmoFG8mL9MpMasb(F-Z>@WP%H&Ds(^(tB8QjRT!p
za*(RMjun^QC?U>tLU+XbR-NP(c|(V`xyH&nSCjfl-&x!*GRsZJcltTF^9>hdX+5(H
z$)fP&%rZ;2_F*DkRz4G2G8WHz39J;}l^O(mf*EM#8wl#cMM_OkEG^k@s@z>@AkQ?@
z7`wL2o5aOhx5WH?wd4K!G~LYeIHSj+!zeeeg<*2_gLmSx+RAsBlm8&FKK*Q?^yF(|
zqTZ=2$xP0aK4+R?Dl9p(;Hr~Ar}ugeE(?F_^K}>yx{#$c_&)Y;93r9moPvKl;9!R&
z8NqWQ5O6`vvS?QedL`eAN2@}^?uV=&7$XQc*?jQLGVxS~eF5gsE&}vR8CqOmbE7d6Nmd92eg$ys8}3Ka|5EQ5h<9Z#k<
zCy@}XEEf;gsL*Nzw=o;vvF0o-v$%fP%veky88Z@R$;x$?ufbb;eC6$umt31eir3y0
zx+CTQ{q_5=iC*_%fkaMWooca1q~WrJ5~c>m?|~bI{THKXkwC7N%Mqx7Ji@j%+S|}UyaX%KTWyE4ECbUBgNYn&G4d|#@etF*w|Nr
zwOSn`5wxkrC4o)4D$Fiy8v=TS-~3b+{TdPlOO24nekYN_9;)c+V(Q3h6iPAGMyB_s|6+*LUU_6
zd;pTXu;HxBm=Ra5*g+DypI35cy~8p;UJ@ZOY*i_LET1
z+@jUFqzXZ-RG>lzKdGDNKii>9K~A0!eGxQSb5I2=?@G-<-E!;>9e`qV_!!|_V-ZI>
z$$T^mm})_A0tj|$k#S$gWc3TirW{lqZJi@r)itFfO_A
z*?S)Sp+XqnWVPs#iaE%L=BM
z@{>qS09^|`OudF+4qN>3Sm6sX6E1ITKbwnruX;S
z0|UPs5z?ZuAw)iq4k%%~6B1h?>@3?5c~?w&Rp*0)2@!Ri7X`4Le>TAnOlHAq|J2SU
z6*(_^w*dVr70Q*OGlzGEGN$r{~-QC$>PVmXnM8z6Y9*00NC!oZI~S{&92wD
zoS%7U@dNo-HENqc;Jn&2UVzl##2oBVHmnP^so%|Y)=kgbdFM^n^Yunuh<1bHdTMNX
zA`&Q{M&QBFl;K>LYN~fOo3vy~oKzH.i)Ypg))DTsNNskun!VIUqrib#pO@qK{2
z@jD^-eg>^a#1m|bmwKiq^-95|m(B$B9Z?^m`4cvZ@KFr}Rl+l+G20|6h7}&(P2`Cz
z(Wrht2R(OPFgFFLUk%FpIUKz4c?sQMKoDCzEhU8zg=T64MxrqG;Pn1dJbOR#+7GV~
z>l%T;A+u}6KU)-@k_@Nfx*$`lLI$C{9prm|?RMMtK1xZmV~_@%Txk(>eOyV4XiaN+
zh>2h%JF*_ZX=>mhl@v!#m9u=0CF|)gUj~UD;xFCA%Ub8*dML8De;stz^|&9rI&sK;
zFClCno7ol@ZXq&pI29#dfxBj>4%$;H3L^c`y@8}8GjP?RMiwh@dCM~L3No^aCIlY`?ocwcR<2`8)8(u7
z^R7rsHJMs2=}l;JG}|UZnG|R7LXw|82zvcqa@4So7OQr;9)P&!HU79g8+n3Dj!N89AYMj%Ag6UVuF?}5`XWtWiF8o96Ho5NZyy|@HU$hka
zWu1dX+913A1p}rP|G0wk$sX9xvO&{K0IXyd<-My|F)=MNGLGMOg8*$~Gl@NIRzFMm
zVgv{>#&BiE_x>wx`{$V9`>jrg53s*FV#*!f$zA(HEUNWl;>Uu&g6gU$coIJ
zTuH$XKCj^~nP%cCYKV3mn7YHuo8E`>4>!H9=ctvP*J)USu9uuMRjzZTzRZDA5U5iS
zcU;`EP$0NXdpK?VMDTsbS*29a&Ag6
z-mz-A1M`Qy2hyW(?j?+<4gZAx;(y(}ire=38tkmg;bWpSn|c)}+82IIkxIWk=%-D|
zh6{yYjlik3FkU(WunTxDn9n%LO~bKpo^e+X(YAT^A^x{pOhdgX!R#j73olfmw{xaAn0~I2aw>f(?q6b`j5u;C{(1
z14rrgE#^*~>mXKC1<`$M^#w^4mMu1hnT_c@c-`)FJ{M}I{Yl=qlQhqa3{~eI;kd&O
z>tc=P0$Y|nUzSa)S!M8IjiWYDhUJqQ+ARwj2wrJQBxXd2jmQl7zSs!
zTr9jD4)$88r?oT9Pdxr0aDIG*+hDBuk=K=&rdWE6B+AP@2qc(GMR`aJB|58;5|f_!
zJPM+xH}a}fr`7y%@CT`@=Mc~zLQ+{$)QqM=-IX+{NTaA)tCK;FI@3H4F0UiYx3pYw
z1~}%4g|{_XT)Y7M{x$)I$tEL#5oZdR%*#ddSe&-gMbM|jq+?UbZ|lWiqFKA4&Re!~
zq}Mc7m3l7WgoUHPq>#U}cHEbZF_?>9eX#p?bORCt{Jsybqs#RPSHgpGGO;L#ZDXA_
zLjA5(9Rh+@|Ez~W8I!`>{46{Jvx*ha?y;xU6%W?TW<-q?{R9s0BfI$ON5p&ian(YJ
z8}yZf>Gds3(Tj3$)a9z%fP%GF6lb<4x7##$oo-OcImnQ*u1QlNIDf$qg5WWkhYF%w
z{{xkpt8~BnU_v)v?!+osLbNU(6r)O}fBU#XUC;4Eg(y@wvIg59)s_Ye6e+%JRG2kf
zx*5zDV3^&UJVg%#8cT&w
z*rMgN>+t*B;nO~5My%<&I>`U#Qp>n9ZL9d2mFD2vkeYH`Fn3a7V_H=x-PMBYsOq<6
zfq-(xVY&tJ49F@DZ~Uyp@I=muM;8hVHygDha7>5CT;f(~$YG6Q*ks~+Mva5=T}KuG
zB8ddsn3J(Q!w=5Y9oZ}QW8T9^Ryuc-{BJI`SD#g@>Tt~P3@~tR#x5vQR}P{*z!K#l
z7n5U(uGdy&#}1VpVduBe()dfD)1>$Ns@Ijt{o`y1wiR|}yEdoWeFo61%GTDEnt!9r
zBeTNQu_X?Fj6oX1l6Iw9GPUl_!_sK;W4c>8DU&RYXN2=a|rX&85Oz
z{NH7z)+{V7BvG*_6S+w=JyK>MD-5E!-6>zgIrEKf>98;FvE8<{3*&B@?Sj3lHYFc9
zr~=z!0&|k~{LJfy1M+-~acMTuA*R&|2yR+b5Yxz0Qz9ENq*_tz>F%8=1OI^y;en)>
zsBh`N&+%j-Mr_u3eOJ<#{u217Nx4xLcN)*A7a@Cln%!i@4mGwZg~WV*mkU$&p-gD
zVSlcEd#LbJVYE$C7PP|f4^RU20kQ&nQoGGUCOETxVbPLc+mK<~x@c=^-Vq?9V#~FINvDrdY;~1veI8w}=uW*?f(SptDMfWaD2ojB*K3r}GLLendx)zSA
zK1zPrKEyC3j+v1eQX^b_mD)J>w>c9&crqrobIG-!cB$s5k_}hQ17u!6IfEXE_W2*#
z&R9`@RGBbGEvcQ}OqYG9=gHdfTA81RVQ9tdj5+g}C!I=F$*O0IW^BDQj7wEQ#R_t>
zW3fiu0gRTEid2Fn=fIb5W@Vq5Wr=!L#FUGaQVlLZ8;p-fO;UuyJ_T`>T;;xOCSbRG
z2?x`n7|FvW@bPwbXEC-uWSR|-tlzLAaMeO672a3(Pu0XQgz*&0lRv!q2cqt8gUtk%
z38z(NbmgoKP@dLY)Uu`>myBA7+KSom?Xh+l`qT+yp@y64f7KL25Z7vlZ+4}&J2k#e
zvc#~wOfT$Jtw`+&l5i|csf{CL233+(Eg9#?a9m_~@&@INE2ETiE*9rMXo4e&Hz~kR
zxjDfqh1im;*c`X{7B7YN=BB*4yrl_w#eMI-_@X?e`JViIBJ}=f0hcM;yDy~1{2cYg
zhPCqFVW3~hQ&*clqzZ0n&17hq;As72bvpK4Tcb+f05|G1rxhhTgObrB4Mg@WfF;FC
z5N=?~>>1LsuW)owp{uGhWld=+O`U5Q50#x-G@4wXJCWXMS#@2QlwE<-$iAO)ifNzb
z#c}7;12AA?mKQ1}S#z?@GFvSbJI#-pTumP`gUTz+8;#S>bPp`g;LLov?N}eXVre1c2x4$G;CWu84?ZgnkDS&PMhw%YO#wyVPp0_;
z?$N0RA)be0HF_@)qG6_7uQHe)prBg5^_Jt7s|nvC
z77~%@4k!<(goDAsk#Cxg83+{ki0i#??Y!RKe5uY-4PO-a#9go5_vM!1|LP)uX?ni=R_au1kY~khmg(9=^x67p
zXh1_7(;Ul&bUDJLbXe<(5sR=Vjqv>rc6HAX+5$>fUcb&X{s9zEkC4t^Y9{i1N
zr`H7N&!Zgw*uUnShQ=B9bu#fz0TlF{z-DA6*_G;$^kjmsStc+hHh_$UsL?UmBnh)e
z6`Z#l1i-U)t%`uvZ%6%8WJ1A$LwT+S{F|aWe8*PlP8ATSk2Qwb)mmp*tsCh^HoxZN
z>0mBQG`fjvQi`ob-{v59O2+n5Yb9{HAFoPF|5awn__UhfI#2CJlxVzM(lYLyHCf~t
zSDBnWT>=_l_TCudh^0T+&TLQWoMZ(4NKy4#$DSP8Ku(w|ujLY+nDi|D8vju#h(_eSBC+1z#W`STtZUmpOF
z=(}o~yWA1fC)>x9dJUF8r6*RM^8gNQwS31_h6EeRny?CXnOhQ>Td~!-mOv88YRfKs;{t%|pUPwiA=By~I
zYn9kqu;PUj)^0mC$as|!=Ho*F
z3C0xS+yoL4mP9uuJ0usJH8sXJnCu@*Zs*9T>nj1l`Z{9c%1@#I3w*UVfkN4@lljIa
z9{+9sD({n=ErX~7QcS_!!u@GVb`kZ)Zb9Gg-NSxcRgKXXr>eM8$qA~g5;y<*IMJdh
z#8R%YU{Dx9*(#hM&r%lnIGR(5sXqO-8@4FEikU_%}#l*(ewX7XqV
z_*2hZcq_7fwExP{0%**z@4AuP&A)FEAC92r8GeYYfpU<2If
zePEX5G0M|Z+-NLKOMj#1@`~7B`O_SX71?irtAV_s;*`)~abPyPK*NFmhKv6qgeZ*3
zM)|2qE>j_36nOM25^L(0cwPAfumBV3UQKulY&tH@52;wgpnRB%)^FjoNQod|`mfsB
zLBKLz&TwHi9m1{$M2*it&XZMndArAE9c;|&&0{leMKK6KaERJXX9!u!A9UD4i88%A
zHhj2$<3u)5pnr^+88e`xB&o14LB7HAXQ|GKdINDRO+=eX?Ua`oQLI%ojLdU5r&3s`
z*MY`o=Px<7-FwuP(WR(QS8=kTMvi*o7cmmS3bE7jh&9~=j^jo_68f&-hMa!<+@5~C&X3k;tJ@a?h^lpF?vh_Qswa~kZ7@*E|9-q
zKmq_PW?6m;T$7zjLs;IX>cq3ErVpKXqJoNj#<
z1?KcDZYkbft%5!=9x5scF?q#dn*9Gx81j@DCMAhox~i!Yk(#1o0+rOhKW2OkAO9G9
zQ>Up>uv8f7;V6!-{b%7-ALfxk%G4~Kplxgm2I;_QH+|a|C<>0!4AA0{!YlnF)KxKL
zXiy}`W`U?!Qemtr*sEhgZEU&P+E6uf5p;iN@%yzbUUpp2xm97Tx4$6O7%0;6{(VR5
zmCpxKkHp6z0W`!Vgka?(fsS55#^ft5TRUn3O)nSf|BGa?3Wd?uo#~R&_^h}Lyj5mI
zzOC41V;H8P&jBr@tHN4NPk8#hcLtsDQP@k!%^EPy|83sg2Nc4?U
zn^E^+T6ry|3d@=w`jZDQall9P>9=SQH)@3+xX#m}(3na7rZ&R6NV`*&PX^byh-^7K
z#BMXV5y#FjF1Ny8Zjra|%bM&+jIe%BL$SWQ_OF^3>HuT{vUTUnm8&MYWHBIo5+n6>047Y_ut6sNw}|FL
z+w$*Hwpevs0N|tV6oIRY)Y>Mp2VJWuN?8j(l2Sp;SP*WuXfmu?onfh>ghVtBC-AyZgUq>KP-S2KS6@aGLdSXb~h_hkrPCyGH(d
z-9yi@*{W(o&oUh3{x51%68d;30SwzhM^8F*q?~wkL_Ym)g81jTh&sYUK-4VPB0|I~
z+gUo6J8}73A-We&`9Tfn?C=LAA!*kkVA!5j8dX|nS-CS4Y0y`WiXFbC6XPKp7SqdO
zc&8cwxYgRS5WOxsfttkYfQC1p3Yb0m68kjGE^(sOiqu(4!YMs^mcr4MgP!u>t*TI^L)8I663`@{&k4%%AOwwwX(`t^_pjbmheJ(j*XKlyk&c{Th_KikIY|RU?S6dZA&3RPGq`e4vDc
zV!{j@4BkYMABgR99hzTv7t5NoLcwD54wqEf(YFbr;$N6WfT+#DLa?FW$L4n;_I+1A
z9(bF_dQBHsEox>!7XY5GeFqM#Pz_#Z?LMV5YNM#ee4mBGg$)#4TdAxGMaCS@50;Ew
zzD{mk@VW5Q1_1lW(BCLabUe5WL)!Li7`=)5goAlQcL=CqToHTsw4OILCTa50bOR
z=-&d{=cC%CMYT+XYyd=i$2nQ5rQJ}UI-iT-5x3s2G=iS*9lq~vy|3M?pKrCB`9#7!
zdaPCm5r}GUNlfZBJ^-&;J4)KAg1nmPLw;ot1VAPHPmM4gV6GJJp%3^J*omh`uGb>(
z-V$e|?llxDC}~p7?Tp%`Ki13#c*tT&OZ)@*MXL23VucsbM~cVDmCwXc&l4Q_Z3B#N
zirq)jZz~k~jfBQjOD?Ihd=?G!!2E#V==s0nQ!@lWm>e1R#15k%Frz%DHm$X==@u^g
zf`D8+I6K-fwKXGfIgx#zRlnYk#+#*7!0@W{?qEw)o>U)X83pr7;Ntv2fcjInnnA8Y
zE*C9UjEna7R?c^cEBLScE&Cw}{oQA8@51c-ZofBfdcJb(dfYFjR&+fdp46^;zRo{x
zd|$fVdg0WoCsPi5MHgwDG|BHJV8g-8{p)~Q1VE*M^b_{{sm7A1faTqD{l5UgMkb&+
zo;0--6L{8=>i)d7K>RJV&@|HKx(UyaaDa7hvTH3(zNRf2DjgW|EHdKV>heqP%e?qa
zm-C(aix-2A$H70E9pCQ(gq@%3ozJ7rKHwU^^vziQ1gN{PO?Ee?n%F(?Uj^|F7pJHn
zKx`tw-sL+l+YxRKkadz5}WyU@Y>KABkLrmCTinr(*
zxI!Q%iZ%Hw7o#IgASwQJBE<2r^VRS5{(QOpoaOO-ml1UT00`sL8jjqze{z2I*PDG8
zYOjHkewds2(F)T@GUP=xDZfe*b1Sea+2A%9fncJfzC%22U}|0v@H8UuxpO-_n(qg$
zrkA2#XocUrGi?761(9FnUM&XxG8||sQE(UxWVQPCC7G**)MC>dfRtW@fg-2NXd}Ym
zKvgXDocox6Sn2t>gS_c|S>CYgsZNOPdEI2olKnpC$n!XUf3x#FINoy8^*EVIYgFI`
z0+tYU4rzj86)@lZ1A_cig*1n1Q1-hQjlD3QIQbJ68^%F}s>1g8>8Xk92yX^F#9`$R
zDpK$_(5K(;XnPFhL_EY0^DLnzVdfqdlBc5ytAHfaLfO2VZT*b4nOg5Y#<(@bTvga=VVQ!E
zz+R@M7}1xQapXKha3`$?nsh=rF&?7VsT_H1aJDprCiVZ?bvW
z{l15^8xuY6o>MyQ0I2mw-KNip7D4aJmEySKpUgx9x;Ef0AtDL&ykP!*8^(YaAk#|Y
z>|0SFsNa8iU+I?+3vmEmwxW2krmHq*0X;C#`%gTytT9NE?Utae2QBcv66Gb(ThK4C
zA~_jAR>AkQJ^>Ub^qH5-RX=Ei`K>?8ZQJYN?PceEc#EUwZq94xYj?{|1MZ;elc`;Y
zbdxH3l^%W0lF9c77Z^kubWm`}UVsdo3HR?QJm;t`E=;?HpBUFK{^MNUn>>b3A?h9o
zvScYqc~N$ncHaZaYzRB~UAWOrJ|<%DEG=W_*+lN{h~=z`=7U?DRufnm9KC63LV%#aIz50TK5VvDC@anWyhvnDqIwGL>2CrRKXSTFco=
zz*w}a0p50S$rmWk0O0begql?!AX25I9JWf%f<`%O%O?$`jP1m7x0v>J*;FOxX9@xG
z5DQK)e>qF*{qV_L!jz5}n7kXY2_OZ(70xLoYp8}`nCc}r{ySTA;UW;jXKg@PgQ&6+
zl`si;Govm=L?IXLhJa&__Y6wfD?veo1fzT#WiXi7CK7C)7~2Y!4;_4ruZIq9I<$Y|
z;RBn70ENR(jttX^!O`KZ6QesO#|RLDamw`|oS^lj5FxmMTSJJ5R4UxAll7`#nVHjqRwYkdF~NKB11_c-2Mpw!s!v(
z-IFfA7{R2)Iccy7%r-I5V6+SL)=7&4UWFK9b4eT?8Le8Uh3jJAAQ~l0kw{Pq1w^gQ
zx{+<_dM)+Q1?SSN@$&i5`BVN&m(tfRrZ1gOpFW*MKyms^;nXQwF7dCHBeTV&L1tx;
zTj->wnBZJ1w$#h;2?l1`2}r*g230^$%`&1*FBDwO+L%1zLn{Xe8%zdeEXi77L10JH
zQ7vBbOFU`+P{~uuSn!e(RUjhGxqt(J1CRm;T2)#<-KzLtq+lkvU5b(Eb_zTJN0tAE
zYsyh&EvaCVayF$*`^GZ<@u+7M1Jtb9V^Z%nsXl#zB;6^V+>W6PKnTVuZv!wfI`ZVm
z;m0RNw+tWNGBUJv=5@al3M_@02296l^
zyDUS%f!lI8U>}Nk1rUV0{I~pKDHhemqAHgIJ%AgC7$~eL(nIKMhT_t2Smtny27+RK
zL9W{?vAG0rC(RDT4pNh2lFK6^u(@chF2wE;xqK3jj}nUb0#cwMo{%S#vV4y6Zqxw<
zRzK*N2OZtYy!q@2FQ9PqDm=%`&8O41o-RFoy?X9K{^a@6FQps#d|8>vO}C=6Ty7rF
z17w*pPGlCRvalTxyv6&Nt%?UVK88TF-wXjIT!Yk!xT6KmC_9;gt(v!T%t1A@-mH3?
zRe!5SkG9|>Hn_PDSOge|M#TrGq*D*IYQd>y0yu!{K#Rre(GD90GWc(}rj*pw63S{q
z0b>EbA>|#-L_|)*evftNjn`f>YiaHDr>?^`iVolkfF8I+4rA~kxP_yK4nJ{tXv^@(
zHeSZYcaDwoiBGoDQo@OCXbS~9@FyZ6ps1aIG(-`xpF>y>uU1)<jON9Ie*)48QVc5x~L
za4b&Il6T%TfE7RwXuzL<;ox@$06p9a*w~;Q?KL8l0IeD6)PuMc2p=4P(a-sw^k51@
z96>2?z*fBdR&=VBXfc$p1Inh@67EP5riai#ON6wW6QO77h?k0TbgRTSiBp0vSw>
z;RCd!7{aeA#zheaBcMSrxeY-CJ*bfJkDm5AEr)}ii9}Em^$Ag@f)b#CUoXRd%P$tt
zK(U}J6|}{orbx@NHKh{KL%B>ffRfLv;X};LrXyj1Ko|%L!VyU@BKHSG827Ls{;)h8
zQ+s`aU_=~=N+VHGGO0);W$~0eo{*GE>S94zt7uvceY<6x>RA?M>@$7csiV$|r@WWX
z2A{q{Xn5{c{@I)P=bkCwyj8n)jX8IzeDd6V(Qst0x;UL*p3N@|GKufGW_QhTBmM^cvAFl--E*8xJ4n}C4vJ1y$ZHdo)=D_Yz_ouKE@Gu
zaOxkQBs8E6L69k!pd?ZhRZ4crMDR>^+l_~u<{^+!$TJoT2ogbIIwXXzkdMg`^cF!^
z$@|Vz01dp9OL{K$Q-c_If!hy2RI92=MF;XI6lg(yG6m+BB(tg*ZTl2u@*1c=8WSgT
z>O_iY00e`NW%ANoPJ(z9WWcgI_>6;&q1#k0%$SZY*iIdFpFichbT)MDV(jMCy-QP=MW>8i{!FM&>)O+D1#M7+Sw
zgHQMDy|#W~*1kAvJ-XyxS+Jcv;y$tBg1d0;r1#>P!1W8kXP-_y`*ixnXUi|#rkp!>
z?l3oQuothfzqIk?^QGO)O!bR{esQW-Y&Fu;Q~9ZGrqhbEl^|0J4mzn?(Ki4HdYL|#
zi)p$`YvS>em)ULx>YQpNagiI)v@)FMgC3{;dWE(K;Ci*}@3s?cEdot<0H$`TS&#DB
zoa)sOzXlH1S;|8mY1Wes=F^y>mQw)@;D%CMT+1k9zL8v1n2(CGQDMk+C>b1&`zd!1
z7{Z|5=`bIZ2_HAA_vlo+DHD`vyG*i^5+F@JB@k?p$#$UzP^97=aw&YqEmAlfGD;Yy
z5breU4(e2Ut;QjkwQpah;3%4L16
zX09-%THRctT32Swbw*!r7=VLD%S4HUy0&)9(&^dIZsKLf+H9L?`Et+J?b>E%z5TwE
zmO@QA=4M>8b0l-~&f_cIW6RFd$AhPi_)i`2ojT?_cMMPnf*Y=03g3DxWR;(N~FO=8%zv>ix5uh
zv1Xl;{M4(sn1y+E=rUM@Ph)%UjuiCFs>^5o-z=)`1J5|!%5V3HJS%1i&*$)J075fYtA{D)Q
zm&0_xtlMMJ??v<&@lQm26Y-!BXg~vez;EdW6i^pannX}kN@;&-qt53`rK$!caKvCn
zgZ64LG~>*)>_v!1{()%Ag{mnP1GNK_ztv-+kW!N&wu=*|F_Ae@G+`uakds~
z)KXA6Wp}DX(T1>03gD}hqP0q#HXW2BU0kokW;?|Jm)!}4_7_3-JQQFrKoY6Y1g<0k
zV?YMKvmh223%ZAb?hzPxK*5j5%{it~Zr5q|Ld{m=A-(E=UV8xJUZ>tCns~yf-;aw1
z?E$BK+-V)Mn-9CJhXbxLr+L5EHVhEJMaV{^fI`$SOhw62NJS*jeLO@9E#X7tQW|i>
zFKyNNd@0v7)w+(Y!$z3+4I7Pyg%Hr-Hf%I)-L|{ac5#Wd+-w^{c_7L_4C^S>?2)+M
z>6KX=VkwP%V$H^
zFC}i@$lkn`e*O;g!ky|1cPh7@VQ)OsIdi3c`qF*T&}TDK%}l4BtQEpcIbJKppcqa)
ziF!R#ty1DH+7rQMfe%QHNtVh{zCnnoCAl13@ztFn)fjCHp_eh*A5+D+CzazS+4
z2vbc`qZ+GM?=N-BpcJTO7(Wd}EomGer5fqd&`chg451^P<
z*K+!LUe~TzncXY-LT66KZ(J*%KN-JzK6mj<=F+*`{7hhJG2QP)ckEj4_3Quazy8saTONM=
z@pTV9{Lq6BKlsSHhu5xsc-{Jk*KT-t-MU9NY*@E`!@5nIHf-K}Pl~$Fmu4l{VImMT
znia~)R7yK4SvT#Rq2pFu@raRDzSEi|b0zO#O8#oeU#1;3B;2u8w0VY4W(dh=T;Y(;
z>6Ar+hD_3iw;zc#@^dFzA?ytCyR1riUpSyg^wDW1^BK3rDCA?yPdD8C
zyWjls@BPMxhyE<=mOQoLPY&*UWXBVKv1i*u0f)E{*Y;{|K%r5vcFK-g#?UL-TRBrR
zs~^;C<)k7T5vRE=b%~%P8KRwckZeo|9Hb+1v}1lzCaM4?Dk)7hqb;Y@jl7;M>${8@
z2$*X)7F(``mTR`Yo?Xv2&jGdOL-!To^rkSp#
z-zH4V^=%6S$KtI0=#m$5WYN30=$)tCcJ8HRKdnnx08qHbqGx3}cw{NCxa7ZhHg)EB
z?82$!h103?r&322BCT#X99B)uBo*q>uYC1Crm~Jq-U%o?^yt^0)X{$N>gt{unsqE?D8CY};|jl+F&5ND{OWv)Pgv)GxYBJJ
zdR_DUz%kP^Ee@P$EKEBWX6?%h?xi{B!i;@s#<|2nVR6YfH}9UArCgK<9Tyja;0D@(
z3I14#o;Vu0cqxDCbmsi|(y8OA3#XHdv%cO;us4&K5N)$LRW7%hX+|G@^npj#KCof)
zqieYxm>brwIXeQvMGBaYD&h;-~hk^107eYMGrs#DHlDovx+IfJ7Os^8@u<1QM7oW5lRx?H%fJ6yzyCY`#;%{lizn9qC)7Ki_^MXAHy6`3
ztFA%A+bmdsgJ#hJ4q!97R$kZ0Y7r2|Y2&3R5fFsE<6Lk^p&)9%b2#FghQ6n3PPkk>NmdRp1cYnlbkRN2%o8RzQuIo3Acbj-5$`L=VeML9-)^~TFuQQl(I
zjf%2alYjEbPoKYYtlKb5wN11Ww`Cl3jMH5+fI)BcN%!~{5!lEC5SY8SoKOTGfO8NBh_^D&jb0?EWR^mriQZsXrk?}pFqkA_$
z@z9Rl8y|TTHsTT5c)4larpGpJd~Cyp&FeQmcFz$*pD%4LrE4|k0VZhIWpQ;|)#_qp
z5IDElfyV?cl9YT*C5SN%0o9WLD@89q?xFrf)JXcK^A26G7ulp8il<}#l9UdWHenXr
zd?V;n2fQlW0XGC<;vs#5+Yk&ywrdE%
zgl7_en2SmZaT#r*O2}x}Wm?tA)2_?us)av5aE7tXHSB%HJWb%ZFBB*ZFKD2l@6@$0
z4S)MLANJe&LDw+onkgl1m-5lhO<5M8;DL1xGHvTkSz$Gn=iL0W#cEXr94yXxfPhxV
zGBvPI&$tHj{<(SDLAAUbSy}WycZ)r9GIjMr`3%uR_SA{g@=9838r7M`ckbCVDc-$q
zJqLx2kHA*|D{Ojf{p0tZQTX|Sey?#f0QEn6>jKDtpG?9_w4r$3YM_l8CZn9AjFtu1
z{xCJS8pTPPScK#)%0imP070Tz@cIpZvH+i-z{eAWTG0O!E(QR2f)
zIRFb1^=t4?Is65hOr&1o()q}R`_f^}mW}^q?BM3DoBylNAtGK}iK1FAs
zWz}p(*~)9X-1aGeU{Ep7)U2G?<{Nex4j2nq3ceG+SelHoUXd|n3GKbCDC=cKx2fqg
z)GVWhrD!(P&APS?tk6-MrbPf^%CtLGm%8vxNYY{O3m=l=+><}fPnQI
zQ65{r>G93*6*fP%dG#xPp%l3z3V9Cro4@)2aDWB`ibtCV1YXwi9yky@MEHwnLm1fm
zBAf{~$fKNhW84EM>7)ge02%-SKoam7OPoa@GAMX*83$|!Kmec+wQxJN@iE*Jcg8=(
ztw0jR9GCYl8`W*u_@{?=uiduk&tpDWDWM(Iz2Jau(GCQ3i?(W9HO<&S2C;yM--Qh|
z0}#Bv9Y)%K>oOnY_gr(!QfSu=8hFcXp^Y(kiw9853p9+QP6j3-o}px5tP~YPswp|R
z0n#htKN@;vcqGPVQ48Ta@r$KZSHVC)_i!3o%7;9>n{R8QPDf&eRIVx~;g
zM0zc7r_yno7tr8!16JU#LwG&$=XyfmOIGr3L>Y9Z2)E#!7Cq<4RRjlQ@GgZ6Zm1k&
z04sn7>PS%Mbt%ZD;Pz$1ri6WJ{$HRbG*klkE4UZc&Kq}lRX9g>IF{<%zX
zz~fUPhUCJBbsIO|bFA^_3nGXvw}2oQGv^aljDBDOXyAuF>HgEBESZ7_?}A0hOk`;z
zHvGzb(uSJfGKCt31K>auTF8@K04AXR&o*Mil=waB0^*1gorepa2>CT&5z3g&kr4hh
z>Jrd{_=VeSxkfzl)c);XPlc7h!ED{zFFOWRN3UdU7mT$eI9#6z$-o3W2LKS@c^H11
zem^vA)$N0t(Y70gw6a|$%^{2KfJsB=$3pSAZqXbtDE64u2dvtIF7shraTpG`P5Zgk
zY!kUS?X_j{YDlZ3Cj@Z0$om!3G-I8q+fehJ_{Gw!!31ak2-t;YUD;$+jV9Eu2Ozj)
z<$Ba0fM(NF%uDhGdA_R6<>aNZAz!78%)zK6l2Rn|+HBbv&uWrcT_U4Q=QWwUhHW`p
zZ5M5~EgKpwm<-q49Br+fpZDH;x_aqcZgDZPxDY$Kk~(%Yvu)d2g?i+{2meGM+6%XF
z^Wz&Id*Z$ZA|JQVx@2xIHZ+|K>A?^fozM!P08H==yagx_b8v^;HmlSi;T%bRI~2bc
zn_vNm#w9CIARfLoE7zMm6omH>qf!
zwL!JVsy}Ga?$yb+>$$zTMlSa--UUwp4Sw5j$O#!i4Py~;kHAu-LKAQ#s|gt*3pS$y
zAle08GpG4g8}hlG*UhS`UQ;v?N-&hDyv~xZz_Pkd$HXO-)A7q&G8uW9vBcAga9k3J
zOTsAy)E`c$15srtu1sWf$&5alRpra3OhJoJ0u!j~EoZ)LU|RMr?8TISZZ5F6;Jq4ur30;Ong^#tlr?GF|s`M!^bJV3JUSzMj&?
zKYc0y5P%E-0?r~FH0$=-42P|{gBBg-8V3SUL*=~iOQ`uhwfsx7_MpQsY*JGuexL;2
z0{{`Q52u16+AI~G%*QD!18@K|K>dIM+y#)tFCDo2`I0Y+D6^?Y=5)NuX`(BsQX_FBDbH_jfADN^z88yX%x*#0JH0{a9eNYqMaDGNSq^soI
zyj4Q%3S{8xt*NB+v#nsCPDrLS9nGw%SF*q~z!vZ;5CH-h2%rJM*CTd-jbN%uJ}X15rUoFWt`Qmh;uk;572q(cVkw0uFzFAA
z17UeEA`e6~{s?W8qV4xle)~OTWeCO;@r(`
zczMxx=49g3$@Jo42y9Vn*fqLQnR0ksxVy#%AHTnWsKZk$2l{NZRio_*+*4;4^Z`t8
zn_DQlg9!j8pudn;8FDLPK`l4~ji6f*@<1uNuvZ&!sjT`5msR30i9%jg4zVTYH&nRL
zF&xrHL&l(wJOds9zz~@RZm%s+l?dxAoUe-ijz4Tv=nLTMt?5==JP0806X7K=X&n%d
zjwpZt2tMSoQF$R(upE=Yg`~$&_csugB5k-XmZd-d)r_j&
zwEz=rP0bJ{=nuo;$zVjt?U;}RqheoJ!k?hXol`Dz2P7Z^mtW=y5G;H_MKG!aLqwA5
zbj}>jDbocF0KuPMj=Bvr^gJ`Op@pU3@#D!;$CAfZ;_bGJZ9Bs;AfI4Rj_ax5IcaqxkL*PXc0C73eF}h&@Pw*
zQp}K~5>}WAw@VuGDU;xpgtb~AmjZtUd{E7qhM-3Q9Dp0@6+gIvYz-Gp;GXz;Yv3P1
z_?$hRqOq0J$Nb`$Uj%_^xO8qlU>~&`;r9Uta02#Ik_{U7lz)RK0F`97n$A<_4_2pC
z4S1=MQQ{7O06d{l(8e2L4msuYK*Ov$06>5qc%Oq-#Mp;G51Fv25R;Um(rQ8qC_wm5
z{9>VG3`H5`XDKNvWd%)1z;B?e4Dx(NeCkvqUr@v3gA9BTK_Du1`9)5j!0r*)+(M^U
zPT4uU5|>}<3CaNrr%ysqh^T3+byOKisS_!6GOJ1D)Y-B=SJES($P_h9)7D2!G3^5%
zoH>z(Oiu?J9XH$bB(i3+T{JwlWB=a!29u6PRK%fmT5;)-bARf@dB0yX4
z2LT08H{Rmn2q&D3LYfF56*WSmP&sP9OYX5tybdXBLDZ+_nE*BH2u}t)2m)?72!_8Q
z5CBvmh()_u3&EdQWd$yGlVeb`Az0{^Oi8~8u40mopdmC&wd3&lxp3fsO?MbL(8~DD
zGrM$hD4urUt0W);%EZ7yVUJQmyCu2y-qmz1a(I!19*!^wA7nd}`^*|x3W`V(hQ#QA
z3Q;a9Ehgy%UN)nFk%GP8JMoJJu0WYP#DmYrz(WCkLyb~Xt6zELdXX`K4BP>MJ0S9g
z1h54h4knGZaVwo{Fz)b3EY1nLN96QMT|OmX;RPCEWG_Guv8*mtG{(}ZWKK)xew6g^
zA}fpqW@0c+X&9E4!Z)tgPoB)oOb7dY-|T#JdOAKK*ez3zt$xKXlvd53Pg9QQe;F00UO6G6K%
zd?rLEpF_bs0ss^q2S7kRI
zZ9oA0#0;0Kh2PK!J$bFeFbx*%A=m<5kt*3vjhsJ6PfIQ@OL}N{b8eddo9CpZdzz
z{30&a~2hiX!3*b3|X~-hbBLpXG4J;0i3ET%Y08vWQlTCcR
zHS?^eoi{GFeA$pJA5(HTkYpp`gkMlh8ocHqw|T^A9I<#0BF?;tM3
z6}d2_CjD1SF)!iw-mhlv;h<0`$kS=sgc(gpqY0TWBzCxo3HaS}CYwNK8dGWybH^VI
zYYd}m{b7@B!se3LJwkFIC_jtB7gB}d+E5&TP{cB-bitS@8%tGFv7~FZ91U7NX`Y&f
znILXBbs~N7On!Me-syTyo+=zYmdRxAo5>b9pyVudIs~It3#6m^Ox(afcY>K9&k-&?
zR7Ihqy^?i8_i!T$80$%ME^gtW0Nv-)&S#%F`_c=SUwrPu)906L`msb%osMdO0}w;l
zrzT|hH6Q>00zLsu2GB!o?#TpUh1-e`j|6syDSE*x_jZFoI|feVGf>VxeurlDzG-vkKmq$Y)6CuyBiyk2n-^g!*^6ItjYu27aI
zA)rI)TJYyOO2k3-0@y-a3WwBV9inHE?uiu0DJ0Ivq?Po2H_!nDpV^37iF^e>p#(=E
zuZSk;n1(<^;t$CjUZK?mWlK%q1Jk%#KMW`+wL>!1KDm0oQg?u(hjF_b#K4`36`&jp
zbQn@x8BVCeQB^XlPZ#xY8=1PLS~Uy?fqLCAHSL<2@d66VN21T)>0G~BJ_*<1bnf(-
zLN0sXsHaQ0n?lVB?RDul!?fp>@z+c49Q2*Af(B?CBw|Z=j!b|plS7Ar3*}Yww4kAw
zwpB~MZ@zT>{rBH|_nkN1efzubz4M)S-g@=!o8O$9$~nzr4%3*=A%-=flrEp9a)O$H
z1KvwOjnI+E0GKP03xdz!-Aax-jcS&0wF`!FLYoWAixEX3CWFBaI>-(7nhygCHXY#r
zI^)%*6z?P*ODNe2?SSJ{u95E3NDt0Wl})NKt?ZymL|L2gE=Yp=7#&vx1ZWipWa2%C
z4{TD1_vqyZfGUI`l)*{9%cPC|
z&E&+_t}TTVv>DPH7P@=_cmP}$Hwl-$YZN$;sSe1L2gI^nBKb~{WSc_0Pir`Aw+roV
zF+PcC0%(ANfTak>mC2-r9!h34xq_A+MNj)1J$r}5HZ$v8SO~5xg^#bqZd@ooeW`ry
zQu)l8%;|g2um5}*wBxiTlFQ1&Jx27>#u}Dd~zop-X+{2
zrGw1&0ucBlKChJTr))i(kBJb&pgu^V*$0VNCuuEoXZ(qb6?
zTC5UDWt&?)UWcXIBd5AWW6_j_-?{>|@x``Pb(_r>qM_RaU-{m$LDU%mUzEAPGY
ziq9rY22~-KBo=5k71N~#gf
zm!jfAL>h6AK^YW6>FKT3iLz~JV|fX9J!V!KAV|HHRl{^;Fr{qQ|H%I^E`
zedmWCeebV-_>SM9P)PSlgu7^8{imRzzY_1k6%`%#w|WdB+)1rsAN&TVdDv$k4Y?=a
zvC`5Q-#F08cj6Zd_y9CeEXV+YD(5g3i;7~AKF>WxkoZD?f)D|M)hR-l2hTvIB`64`
z`^SYlM#di>8r_&osDApB_kZ@24}SiSAO5eO|1cUixO@sYk3QN8L97r>=_sRHR+G%D
zYc(@lxAvwS?Y4Pp$~oP4E-fLB2p%~SIe9F8^J?YRt>)E><@5L7Q#;jwLlB@-u?lXe
zA8P0~qg|GgV>GLQIz2^jFhwV7w&ZD+$WlOP5JP`C_s1W;^}+k^y!Y-K-}}z<&tAXq
z&2QYe@$~6eUw-bjZ@&mu_~5it`93Bly@ph${yh2_mBgZ%;
zZaTWa&>40&PaT^rCp_xAuipCBbCaQixQ?PBrL+4~!a
zW{f*BE5RjKK+s5sg>idi!>h|*DR%-T<{@qQgsZOkX_fBA#=KK|&v58r$1
z^7$h#KY#7gxuZ8PpZV@9&mCWxe(Uv@-+$-Z&pv%T9a5&lnt)4`i5n42!Y;6tK#6l3
zK@V^_VRu+=T9RLAnN3*Xi@-<0*Q1^G#e}k%HB{nKK6O{ZLy@slcMws7RtnFK9w!3|
zQURrGl26icj>54mlf#=QhBp26$KUz*?zca9`^7iEb@lZZFWr6Z_V@3;3LEh^KYU9l
z*d_)V@Odsl6Vbz`S==CUP=b6Pmnd|PPDzf4LAA%M+2ghxrioDZcse92#P4e$zzT>U
z3KT>jo}}b{unwt=VrC&1ih=3{unwHhC@@&Y4Ax1+4wTDHJ1mwR1S^bNdOSCL{?MCYl{U9+b~v(
z%EdWPtD!%(5<0>i+2rBN0hZ#*y~jm;zA$-LtK#ROFw;);=~TTSd<8D2
zj-yeb$I^{59j3^cj1XrjDBTXEQ;+_)9}*PafB$>$z5R;Qs($Itm2bUx^X)gj`Q~fi
zxck<(-hK1sm6=*8sV}9>xrDKtbATA2eh>qk29N=K1wN}NYA_A|L;?Q`P{2ieJwSoB
z**CJ2r~Z3w4Wklns!pt`Mz)!<$|qT7PoD(iS3f{Z6JfmAv)G_^x(Sp-+T^U
z!uRifyIl=`@8zpUXKNq6|6M@gqr2bIX@QYHxsc5TJ&Fr*$cGkVP=sk5Tdg53FP*_n3VBM0GT`%6gygbu<{nh8+ee0F?-u?EwZ@pYAxQj_sK4}WNrEo9cfd*W%
zSU{7C7{CxP2jngwp3HmUT7nyZ07S63Qd^ylN>FlkHl@r3CwYmxC-8>Dc*vmG3t|8t
zz}1%vDbpwTKs>f};_&0+hc*KTBm365&4Q2L`PTbyedD=nM?ZS&h4)^6@%taV{=<*o
zgk^$DA)MIGqd_cyMcDfp4)B&#Og;x{*a$9;*lW=pg4+mpA;PVZNz!Ak`(|+i2NZJj
zXaQ28htSGmQJG0Ar{}W%2qKx_rzQQ^POm+d#pw^Egj8v*e<*Ff>eD{z3?mO@j
z0EKei_2FADeDcW;fAPoUX+$B2Br)RQH^3Z#9$+Kj
zE+D?>HzTcTm@QM1C42^TC1(RZKpVAu;DDTsqZ#
z@2%(FfAfXAZ@lo~yWjrs?svZZ&8yfe7{Pv
zlYi{UQ3B10Cj#PJTv18i_h}=bz#9eB6hRazom)CB`NoS^0uiAnK&hF$^jtw~b_(>i
z3H|Env2?1kN;|I942J{o89)5_KmOpmuUwy<%KyWUKKkeX`QM#BmD{iM0tyj$jxzEb
zlj?LvmCwO#)Hj=Erm8)0Bz)#X9dKmXVb@yC5|0W9y^{saU%25bG>J8HCDgk
z7fPQE&v(->5OduWpQx+LKtuGv5n6{-fsCRDV-&h?)#$)U*oa2O2Qk=^~>WyC7;QwoOR$num$wYs^rN=DNi6?
z^6>&&pzHYW{Btc_$Jbla%IlgLbtNh($0VhQC>@;im=EC%hmP_zt0X)QwxJeJY!Qxb
zfoY&aj}LAh-nZfK-bW7Zeh8u#@4R_w_N6fv-t_eDOVTN4@^)t
zKh9}@+ep@d0|cxCA_%Mgu){dwwT*<_0{$seE=s2qaeer&6qp8>1JsmB6%Oyj#szVsrWDUoU1g3l1Q>UY6PR1^t&73}&
zJbog1{8;w*>CBlk>Fby8n}=ngo9wfpPA$l1+X-X`pA69B2R_
z{s|R5s0J~VXz3L6-9fxiK(Oj&%bs?PQk3&n1AYU(9;Nc**NhY+A`nBuI}zaW_<1cO
z+(aU!>w?IITcv_+lcTFy9Y+p7PPzLIZalDO?Y^B49oqZ#Lwg?{Ik<7?z{auRE#o6k
zNf0}%8VKNEH}5e33WCY)fQW?i6#xZ(ZUX~~v+{EpF>XEN*>k9o&`H532>
z)Ib0l#WHFT15IBAqvBvh<_(J7J`o~Ar&nrqiV;Lu90)1L0SFii1QbTQ!0wVdy$Y*S
z1_Zc#D!W^TmoA^oOYQ>YaSBDar;RC~O^5&0Yn$e$or}}<^QS`RPX?}>&s@F`zjP*j
z@>KfNsoe3?`D3RucW&M{>Fdf=X1+~n+W>-IJq!?l4`3b8nC-;5#E#U)TNtmDc(Lrp
z_@>yB4(~?8iI@UdY1N|hgBnweRC2yXnOh;9b+oE}d<+68z{$wO3_L5qQSH_Y+j@EfnaXw|Lea|8}#goCZb
z3S7q5vEe6yhT%hx9XzmcXg}0Xm>4~@d1UBuF0J2FT*5Xw7M#n=1T#UHpnQ&kT_U)U
zBs(OcoiYi~KrR0?inQJ9xo6-4Be4(43ZbxT3L%7VTO9u;?`+E&Np(cENMh$*F`
zk@+iv^)wE+^)Fg%X`90t2Bc2sFltm))P*k2sC{k%q
zg1%6sC6m>v{MfSV=%W4N+2G}K;VT!S7cVETUddj*R5*J!f9iDp?77m_i}!UK7yH?T
zerltPXq4-f{&{PduLdpO~z=arQ5liW`ZWOQ@|fr;})n$^%$Gr^VufI^!#Nb$jBOaUA;
z(&RZNyyJ1-WY9k3FdhiGMeyqRhf8wtHuClbJ0z3aCq|#-^7XB918*!iOguI^w3_A<
zGX80zS8xMxAVeGihf%mkC;$j3%_qQ`jheJG1O)9*kBe$+)Z(Pk>xmrAbmhyUDxL7@P|AcLzgy~ikgB}Qg
z;(-aE0pQ?k-jU?Jgf6I?_Zu1^KE*3PL&48nG%7AoMJ;b-igqX%&H-=$SU`Golzphf
z(Bdev1qClm4`Rq>mFCA`5fDKT4V3&4&T3GOPcQ_&-Wn#Qs&NT_^FaZiknoPdUjr1*
zoE(^Su;OGOKnzOpR;8E@4x!T`Cg49(-o~+!Cnv|Yj|@FIH1gD;!%qzlZyO#0M7EEP
zZ6hd9YG67fo_7=|2{e2K!FIR^fP$2B8|Ad*X$NrNvrh(H6H%Wq6_RGc(qvEqZpg>(
zyNan;RDl>uC3PXM;c&1jg@QVlB`yiU?}1&2xRr!nEyYF<=;?yb`e3smmfB48l0pLKJXO8(Ext3%v2n1o6
zc}S<`?=k^ycAIiM^T>cX04q?t8SmF)jUt@@z~nt7-2SI-JqBe%dMxGos}^Vp3;;3J
zN}}#_nP69ag+f#gG*sg9Y+xc2m`H^tf{tM)EnC`i;q1Idwu4)vKo6c}!tG!M%I`X{
zb$sk8XnK5%f`yUcr$$D%LxxAT@r|M3tv~~x+7n^qB%m{~6|sX*upQnad`78ck3_N?
zl%QABnT0kZIgAim$C0qn=K!N}=2D?DVj>*y(9(iTC
zC@Ys_y@r0OYoJs4S6mlP`>&i2J$)&5>ssp0jRK%>{d(o*_1cB2wKL#`v-f2MIO@wY
z`IVVGG!2GWnE@*hB`|pxaKO6@JTg8__!}RzDcdh6@tJONy2B+5Z(`_EQcu*t0mz`7
zv1g)Y_=AWHiT|sxDU|9LYQ~6%raMf8$x%x1E*qO}r*H*c0%~9dB+=oaP~%el(gZ|A
zm~aml;u5%x5%-u)zyHGz-cm`oSoH_^8EQa5A=n8h2%y*T)r7yJhaVq@X&^Lg9VHxW
zHKCO{0TfBeZmL=%z_oQ9CdA0TdkvR&N71bj*8J{VDY15#K7
z%K99X`a_aXSQ?2+VsQ!VLLx4SMuaVvPR(ANaSghL*(uA)oc-hx*OjxuD;I)*!tLvs
zXK&`7y9G2zyCo~%QL0r*}{?e;^K66
zekuhm&UNF1R%)gLzX4Q1R)cdM69B|KSOJz|DmT|p;=?mtumZ`T9i8b>T4;Jo4ZSua
zQ>{3LK9r3bYNmydId{7nu9y8i#HB4R7cff*K$~2}lE0Eed=covvEXn3^1#!3W26=2uZ48vd7<#VcBPLWE<(@9wj%0_q@6!=1dP(l_Ai^6dj
z0!5U=N;;)TBxD)%Lq?g&z#G-DthUiKv>JL!wo}Jk=TG@AobcSb9KU@v
zcIRgL`DY5x->N=yt9;`|{mRwaxhu63_n(89?dRqPg~dSum{^#~FHIL$W=ePoRn7J?
zpYsp{z{hNt68jEXtJ%L1L_pBy{04jy<2wRB0GZMM6xdh|f5Jx)^^B&PmZu|vTuekZ!Z(@>j0atZV}S_(DnZr0vt}2f
z{2SL!I*j`@@@+B^Jx+$P=btWMe2jMBPNwqHd#rOEw@^$L6faNwY*uU3sf0EAEN
zjJjGugPt^S3BXn9G-Z3|);x+MaY-N|1OngGx3e!kTY2gE=IuMpOP8ys&X;~g
z0`P7t*=Z&Q-82R$)J$36x$NIy1t0@54|j5qo`uiY%>W<30cvQy-=y$?e}n)(0K!=f
zIyMeWfR91({Wd&_6kGug3Mr_WbX<#cnsG||mG@BWz(jxsKKnO>&jSs?x5C$3Q^~4J
zX?ZRxO!>zURR+!bQi1Vga6IH0ahmsg?ew?_;XXnMxp2cHyPxSwP|Hwfgxh%&#yIon~rwQ0TQ&4UWCr
zbx?hFVY&dd&Ga&JQ#mjMEW*MdKikiebkcl|_}N|>e#TrcvjBTBm79SP>7{@tf=fF&
z=unby+yv&IDf*yncmQlAR4E47G9`k?6&?ZIMjQmd)=2$rcnl1Hl4{n`;8=ly&y|uD
zlhPs#L|P6?02I>U$*5=4XFCvZ4EY^HPSZiKf?B#=r`ju?d{Qdjq2Mxm3j}m<2%rFx
zAekT#a8Q6hL0RB|2B~B>aG;RylhcWVlrS9Pv>fJAv=9jV&f!Ez6b}d@-f=)76O|U?
z>SA1#PXMF$U*`I`MDW#$fnh8>ACT@DEyL<7tg+rO0ua?Y?We|D`HBj4iJQ2p)%4M%
z5FZ8tmp4zv=85@8+cl>lYosQ7W`ekYBa_u6S_
zo#7HXHCZ|epk56D5Kuo;2{-Ft2=E8Dim8^POwZMqT8oa?U0Lz8??&3f(gp}E+mrJ2450GpBO^8V`5^fM9iNgMi=E0nu&&G
zF{ls1I%w4U5R$m9LqXSgz&Q%m3A#ri$$$`!0(T~W6d-`l2uk=BS>S;Knl0qAAk-O4
zi7}L67g!^VMXhdzj@hOW(rB3)tf9dgp>noPBvGzuIh7mgtfAF1qYd5T-FDm3?^-&P
zp2spZur19w0Rk9>W6SUs-KUQRP91ljIY}pl+_)IKekFSQMhdRJ>C#u>}{o0|B;b6#EpC9dvM%YOhgyfF3NWcYC>q2Z$Tp)`Osg
zfNLb|9fzL?foY)W>9`7!B%k|}@5C<_G7UT>R87^Ypw%(MJbl-P$yEeQ#HRa+C1hCIdJ7?!y^9!D1%f6FGJ&@DKgC{A+
zr~A}V&)E~ctLGzEFGQZXo_PLt?%7+}7w?qGS9p$j?uGXCXIkejGso`#;F-_q-Rl(j
zqX0Use795RwlnQ!rq=;U6#AVEpwMjr6X5(5&-{Z<^36BCiN+_N{Jh^?z1VKX8uc)0
zxB^_AfFshX$LYie8uW1}n>z#`-l~)O0RrwQ0MI}ZG|*ykCDm@E@qHTgG*jkMcvAlN
zs0h}fl#pgP=Me~iy$CoCfF2M{q$s=`avJtIEr(pz!&=2QgL;=$e@H2VzIP}&?*S%5
zqdp*)?UstS0~z!LLcCKh+5z43M}yd4Viem!EhhCYuVaXJ4&W*R1dv=*mWj!dVcHQ@
zh^taz89~$&0m?Ca!d_?1}=@`oCi2qT=t(>_MbWyI=nCZAP?m#GKa2wSz~>msCzafO
zEHO_Eg*c^wg_nTv;a5PRQq=8W#^Aii;@1Srs?R_4A;t$dKDgGyk1E_TJ=n;LH`8^KwT|I+Q3{55lVipTk1FHm=HQK28xH)
zVJYAo@a_U$($O(o1LgzKgvWLW0#<-hE&9D4`>;Yzr$U$v814uWci2pHB)Lg<5CZd|
zQS8!b_PZ>HjhfvS{l0*EoKCHGjKU&N+!&r
zBm2Vb%Ja7?&py|D?oRvC_2#+D^^^Bs=1S*wKr!5iq{BkEqdVweh)SYdrb8U+wN#aR
zi`N-%Q0ldKgK&e99fP1j$9^zqN9#5EB<@hJa_7L*;u!aIy+SYPU)1T42>JlsmhMn5
z$GU84x}9B^Dh(RhE}I^-bMpiG&THT$K-o|^+(yKZy!t@~XrsnknW!+}I)o7n%>fF2
z*BHV}=vb@TZP4ttnGQ*XTcqM`X5)}rv0JCy=dzCJwfijkgD@X1+lU=xU_KD>3*jH|
z=LC`ZgQBo!3^&AWQxP$skd4dXEz(;dE>(C`&YKCo6Tet02oo3`&_FwuSX-w<8(W(k
z4M5ZF4#A=W-FG3LdfQ!V*qNrIQn!}tj$F~|@hdD2p_!(wWp=mB?vXh?5~ok(^2^)-
zSs+APVnT6MJgZHY42`yHX~B2=NZ|DGz=boxr!U2CUQOS+p1yT0^V~CKK;h1_ja#>x
z*KYOCz*jhZ-|48CcD~0ZYK0JnY_%Az6rnsCqxE_QJVCt8rmJ9VHp^gSbH~VlGk5`u
z5G)8KNsM)98VZJ*D
zP?~vQ5oQ8}fv-nU;MEUS2)Pb@9tx}Nn8;(>NB*6A)MkXH59?IBjN1JYxCNr^f{7<5
z#-E%Rdt!X_anz&38z;t|93OjpY~-=gk;jzM9cuYbt#TJEi`Pc0+9U2UL<*UZI2jaz
z9-wcE6ygfRlV}4CpaPi9>~8Efe9~z&npo
zD{vY(1HpgGUzcB(Uqj*7<=5rc<(JEvKlr`h{PLInE$Tn|(r^FifBf>7fA6>G%$P6z
zTQvUo4}bTMzx3Px`44{gPrm%y7WG6vZq7#aTQ>da-v7n+-(>;En}V4
zbzA0k+uZ9}TP;(sZSFJ;Xm{Jzej8WJv$Nj0Y4_|DopdqXwJgrKjx7hKS|+@lo3bBS
z@Ij6)`d1eH^NZdi%f7`W-_o+5mu1Ao%fXeE;L?JZ&On*>9$gL|I~qB9G=Ahr^ypIf
z*mCIf@z|-Oku%3**De-rTq$2ZmpOkjap_F@+Jzk2Xk0#Dk$E
zw;Qb0Jn@7s5Yni16My<=U;gTY|M{tHkH}O*!^7ME=#PKL7cf2W;GaM6z+XJ@;MczP
zz*oQi(1Q;?^tFfAef`mOk36#W;YZg#yl&ki>(@WJZo?ywu77y#`ma+KeY{-v=-LgB
zuHUeBX&`->R|
zpT;N}&{hjxN}rvyr70VtqlOO`gKRlm&U$Nw08ka>@%qjM?A7h#!}5$
zx-14yV8903Wk)4NXH3!HFId^Uxt2Awa^^wV*(rk^jLocx&FEVNW4}s?0?P?iHX=?&
zD3LHNV&O;u662P#;3Z$vF(ce@M4t%-9-j*T7Oi{XID(Hu${B4jMWh2FU<-P-s72i>
z8yf{8g?7cI^;#ger;@w5i%2MD6cYe~5#lTBDz!9|MtL$gX-1!`o{Mb{;x+(ct!kmm5y>3|~py3W?@m2Dkbj+Mf
z+Oi32I&J}X@KVTv9h~I?<>1GFM+0LRjVyQa6F4HBpyQe_jPYSGNFr+Sxm8}LGUV5I
z9MWjWz@HAq9{|J?2mTf};nQ^ECOo;&zsowaX&c%Y{Iznh%$*7Z?x>W!wTd5K5}Z|E
zJuWQB)}o*%{A=8t!LMT?tp*)V4FM^{BWABlS+9oM4LZ-
zfABm1=0E(wZ|r*V;jl;g_y7H`cRl$PFv7lV4;|e3$nK}Uw)2U<*!I|;5A9tq7wn7&
z6xp~spVYxDcdM?cy0@A(K-fI_0`LoJS(s>Zt7x6Bx!ZY5lc>P}7U-4DsF{?i7?Ty^
zvQ$tM^>G`hL(*7~(ul@G;siZ`5c6~ZzaSG)fHFRF96%X(34u33tEIy-{$o5Z5J5yG
z<&+Xq%W9aMj!v>GoB9<~ziJ+^)?UrrXDm~7%QR!@Gq^(MSK$iYnq}>?Ehk>iwyB=$
zxad%;o@c(}Ug&yeS`N^}Y}XBrnCss6*t`3cMpf0WYnzOUR?pJ$MwH15>;UOE4Ih8_
zTEAt4fD2~2X4KuDd8Th&7&zt!_SwFTPDq<}F3-B*FMtl_rfq|PWoFhkJ8fH8a4*lh
zmgZfH^UlRt$MU>~PSyh*EO_VUTyqPa=@|!PZk~?H;p=63*9ZRs&c!?(qC{tCfgR}J
zq~#!G4OkAIJOU?z(uv%V7~PoId-O#3@sPorg@pAQcP
zfo9j8E4Utf`2X4P*n``4ZLm8e2J@K4F!AL-`c0Ef@E2eEldnJg^+(n|`0)A%9_3En
zS_=nZ{aOed1o9U)Ji2MqdXmj_Lf>XOaAm`$C)V-3_rG6w@1TP*P^F`qJ|ze`BdJ-T
z^W5k-KWfujU%X2RXmajM%$$x=wwgkkavOpm*iX-HfoFk>e7d_#+?@_E!=k2)GOV|;=m(g_RiGE|CmbReuf#yL+e
za2Ar>fly$CYAJ}(3jv{kCdhZ7KcTZ7ig_20a3&+L>=RwNe1z*h+q2{_R#4=VUHl-q;&M)0?-Gak%3Rj08#*n(9|Zk
z_N9_mAvR%hdM2%I=5(C`cL)uaSiW754-HLGvyg+1O?N&`74m7|Q
z(+!Ayw&9p-IHp+}SYwWL%r>1fb!zjS_`hF33M7n{4!MEvP@(m_gRbGD4_-TUtbn&Z
z`rx}AR@bVl+N^4-W9+we{gwefLcdLXfx$oBF)mKqmu6fG0~?KhIv>xvj6qIh0XlFU
zS@f*HUzoPd4QzucD>weVM;84@7yJve#0X1so`pI0^0I#xG03zNG8j1L=RqHIz8cq{
zbF~&0KoAsbtgJ*=RzmPEj;w^volaeUnmK(sb@6QG!kOH~v-uM%!BaVHj4z+evMv9Cp~t`W_5XX%zAd}=Y>vc@fA*Cx=Zc|6*M0Tj^$$M0_Cfwo
zzJHO8Yd1c&Vg06cXl&TL9c#zf+v@>!e!vwsKFihFoY)y?r+iX!#HC|V;rsyU24$z
ze!Qz+D+ai@BUmqmQ1gSFBLboTjC?o(;ea+7H)Yf09l#yn?}op{C-IUlW+{lEkfcQP
zl+W0CM&RjyPy5gF0(lLbTY6nS(%KXkvI3s_IA$P$eCMt3&Mmx*deE5xFqh=jJ1{5RTGLrRF;Xz
z5`onNN@40To}<1=ehCAp0rh7Bj=*)A)ppQ{B4O8P$UO=!;8#I`5zyu%4!+IT@ESO8
zLKeeY0bwdAOovvbl$2Lfids_M$f{d;Exs6hhfYzydURDm4?&|}GLn={c*&nf0EYrK
z&lj@|J6w#J1|51wXJR%STp#{_DDW3R2i=CAKO3)8rXX9rV2
zmgbzZ1MA|v2N4InhUHl>1vRF7)~UW_X3Dm-=;aUGoS*Y7E%@f<{DXn3-L~|4a6lY$
zv!1DeeTEL<^UlrtX6Jpp69M<(DCB75#EImUOQjcXx6Yl6pE;d5dkP*z^2ACQ@x_Uw
z@l(e$D~qv}g;+YPNn}lSr`Ti>KmO#}uRieqNEO3-4?Mno*Lsz9eDf0zKm6$2Yh{~c5PSsqDSnT#R^;;WeCjLx
z|JnP`Xv>cCJQvl^dyh@aM-mn6V_(a%ERkYB>Wl`^IftFo$~otpbIy6Konz-5(A{XD
zyAcTzOaO=+NtzTTTg*YaXWVh$uWI)u;-si{E7DT9}4ULSEcBIUh8o)u?(9W7Bi#AlMadkbunsuePgx!!7@-7|Oi$0(C^XT&_
znc2Rj2p`g(ZC&cJ9CeruJM@P@1ccK_)33d@A)LaKA1C4>D8UFH+uqb=?spiEdaQIK
z6pb7ch=^wbbfC4w0~55@C9NwWtR-cQl)RBrv@)u0Uen2`dj;S?J5x5zRV^rIE9U8v
z5#?NsVxeK3uUi-DHq>cTRM-mm2vnN(-+>FwimF{BC^X8lZWD$=)~YHSWks{9gjfJI
z*fDrZdZArcwj0W+mVxvFOh-pM+0=B}+Fr*n*)jkPvt1Knev+U-8?DaS7iO#rv(}jz
zOQ)l6w{(sQpH)Su?HPwc;
z(K58V=E-UM^o+CDv(8O9re|Dp3xS0N-_i;hjpHl+lPiInPZnt}##8b0r((CCsvKYR
zzl_wHoxG7+?bkncc#3Ngl2GLo6a;YR}acn0|N0Om2N0k^l#g_0p4LF1j5F3
zn>MfCwE2;Zo7cfRJi3)$Tkv{x6N3MG_x|!brJ1M+$;|uzU;m2q!gIH-APt}wI0)7R
z0#ExjK%gBJhzK<1;ugdwhbIyINUj|aI2{KdN^EmLoW=KH06}Pn@eB@FU91^L0wSCO
z93@EXbkYJ|00&5W7zCgJ6hMiONG7DoR!}1Y0T94t!rEILP^3W(8$b~BsU21kh=VJD
z2&=fEVF;hsrG%SEu{|d7H5d-)Ytz4|Od}Dc0*$KjUk|T8kc=FR`<3Z{eA7e!X~&ko
z6%FqgKD_C`jtBN^`+{1!-)SCBg%!mlS%$f~w^y_`QigWU($1NiSz|S+gF5Ks%!o=1
zqCnQp=_X62T2h_~iK2eWe?AaE^A^~SR4CyEkh)L`LMFJU*heI*dno;4L76v)FU`W9g8XX32zTW&3Wa~JsR{RQKL!o!y65Kvt#J=EZs>WLV-O{(rTOPbzQq_Z%#Uz9c!m+MPsR=>Q3Tn
zj&9H1nR2$LQMy)+#TFKWb4#>oFC4_VGqD%$)X$%eo;nr3cCB#cWcc_}_{`b#%3^3{
z(%op<^Lb+?Z%kz^3e^#{ZeUz+VAt-A`}c3%u<46VuVU-tkF4JaG;G+sdCR6v8))A~
zCKevuvU$ta4Zi~y8Z5CBL0vX(jt8{-QF3ksP(g0+#6Sy5p69%RJmH5S$
z0ep(g$EQW4Zi4pr%O`1F{ZhtJ$+@#}3vK_FwC0hn8Am>0%f_r(wtX=80#rd?kkCld
zzF>3!Pj5DwNMa#H6o52H#eZuk@;TZSDwlC2V#Yk%OfHwE8x!~xWh|`sdsJ?R6kNb5
z#XRAlT%a2h;6*w~It8vFpR`x=s}$q^Gz5o25iNPTwGr@YR)0QlAr(?@dhq|+x%G2`
z!N-RWZ#lHfSUWsJ3i7G;}NN)dS{ZqqrV|x<=2Rzl?mO+no$f~2wC@pLgQ`AvGApgBK+UXdLC^-TQ
z%6(=H?MKF+#mB+C1;;y#w9geih3Os#GMLezO;R~N%$fr>!p9M-{s1IN&@~cv(Jp4`
z&_pI8Oou1ZzR`S0P>P633EBp=mQj++NGY2s<=O_h?X0?!*CM(FP|q+`CT9VE^#8Ce
z=BK^*xFf6tgMzvRE>vYu2eqoKR+G0H>SkTtsHy5rO|^zB)e#Qr>Uve#Y@x1exAo}Z
z(dYABcAHHdqR~KUKt4BHhI&I+sc8~vaWXlP%}UvtgW6I_+iX~?HAB9ltv5{Vmc3Ng
zXL71kR#7PFQW<5rW-iyw)taf+GF2MpctTn#>&g{e&023-TU|%3W-R12l`7jbrw7yF
z?oGP7C}%y>3;turV=F6>rIo<)Qs65ubkClOoIjmBdnS4HVt!!;CdE66Q>J~LuB+K`
zH(EZRVNAGx|Dnf3(xERs@K?L`ZW$Wg(P;WNZhmmf)*g%r!w@|A(Y^)<9%#qgwL~hWkpHxXHa{LE
z&oo{la0S%Yu0tF_cYSwvFjk{W1%xte>b?C9mq
zQzdJ!U=L@7x2vI$G4)f?(YQ-c5_NDkfOc43_8(vNUA~yUd?|P8
zWc2)n49fXA55Uozbe}wtSz3%OFCpR!OBuRVp&3U!{`k5h13Mmn;(@+_?dvx`ym8A$
z8f$oT-GY(18~cw8}Nop1Ww|11e~TmX3H;$&fxBF>*%mWJaEF
zK%jyYLJLoOoLFPgFyNpAb`053m_t*A-&J7;5Z2SwXu*MpW<{}hs;9G$xMeG
z$bfLbVKl%2UBd(s{uTHu_UIK6B~hi=0q@S51BNyAtmGhSitwERLl6H;QMrn{d(mA
zg9;}e1}u!K12_yN5TKFnQL=4_wDJRb#UZo$h(SrqmV+$pnEmW;9dzgpI}JyIj^T)V
zBu0<(kH>uzQO`)!I~?>pXt#7gL%pu8*Wm?}3=p)dUcIVrHgxs6F_n?IgF~^TIGt5O2t*RnSVo>HYGY|d
zDz6PDWU;g|nw0yaGIv1W4v9QraXhDwWpvS$rdY8@qN+edh9i?X+E5LE00J^aT{J1n
z
zCE+g?7eXgbq>dj;oIH^}bt;3(@s;@WTx?)u_tqyK{=%33>*)BwXu={9@7sUyiLH-s
z+5Fh1&5y!Zz)Re>UO)~*?L!?vDU?!ns0PS~UM-B0D+uHUQW^(DeQIC=3LkHA3eOoX
z5Rm_TtN|3@z5@xyH(x?jk-AAM%39uCD|%ob$~k8x4|PDJ3^Sl9r8kc!(vejR#p*aVbFVB|b9na%|Zau5Y{
zCnB4&!2(2rI;;tUx2MVN`q#@C$&b-jxZUKq_L01vK;zVSCrr*xU^q
zy!!Kj3kK;y$$&W+vtpYLIQ7C><`Oaeqkh`3?*p8
zc3)T#h{}U8g*PDa1VrJuBAU_$ld4qF7^TgVRGET4kx`?}6b!i%?d2X%EAnLnt_&iy
zdhP;yYOz=|)@$ZQopyI`_nfVsb8^Nzy%3yV2rMp=c6jn)=Jcu9rStifl@K(=g$ub8
zC*sGBMNb@0E-i+8J-^N{p*094@Jo@;i$G1QJ*tV^!Ki@sS
z_Sl{x1c(5+!KqP9
zQS#$NPy?Ap$;Ko)7a%x=D+2WACFUczI-tItjXog%kgKvUM;cL^so$XG{M?F@5K5!u&P!;34QbOCSIAaa<3)Tlm!Oy)U{J|A`E-R;kT176|Tj&=px?~oslgVD0~7A!#EYG4Z9
z5?^F{;W$V*sE(S|N3FU(jtQFqfarId`cQhzDEoZY{-9$Jj0n4E_w*D!$|uZ51i6r)
z9FssP5DwUI1JJ-p!DYf)x%w;K^DC2`$QMM_q6`$M!!|(s6JR0`ufP7nZ+`R3Tuz!yj>qE@v_@SRIWG-H#gPPUh!u`2
zLlK2PEb@gU-Vkl7>5C|wKC#m`;SNY#eyKYk_D5(VH3UBOh7|6A%u5GL0#PO3!9AJR
zh7z)PRt+Z-%czohU8!MNqXTS3rC~)qpQq(enoV1+ZtirQpu_B}e|E;VxENeq^dCDG
zxN$Xq;dJcWspO@LxuqrWB5?9VVtU#Gi7`Fxi)U1ajy&@1pWy%
z2DsIq4_qiGbxkCH%{__8lT1LgvnFt1uI2_B%25@Q54KuDosY;PUP0I^NCw4x5W&Tt
zk#vpWS}XGr-I{v$Ijnm&`}h*5n=D@}$m;ESOIBizP*hzOUV&u1A9IYz@Y
z7)e~v3wdHHglc4S)cce^gQlG&wjt%Zu)V4R31
z98v{s1*bO(_Uv2##V`HM)+g?N{sP+(9_dYrfbF2xD*4(~f45GKfckmZguEvgGb8hp
zAw4ibBLxr?Y@##{z+v1(@Z%AX46A+~9dFzMULZ4(^I!z75cViTZUwI9cSwN`uTAWC
z$O2Be-$el^#DY3_fp|!tikeWu5hNqfCiL({E@?vrLI7Ef0BceaV=O|mu)S`X$0c>x
zgigBzf+8L=6ym)Ixo}l4a0<|oY(sq1`DNLaS3l*K0vB{L+AE)rQ0U|b
zARqJ!8q~x$1R(e@hs)UKW_LgVIQkbkNBuU42znG8jEMWjQUO6OC@h4Biue2~WyMem#f%7CK%Wm$0PTSM&le=cf)uWy3~Nx7fgLsWcoi%IDvg>N
z^&+iYDuG5gcdnU*q|YkiStaCvKMWTzL1w{E3*jS~UH);WPk^+yxhH@Fn;R9O#VN45
zDEM2u2e1&i{5Y7lW_EZ^^9JPppu!ha;8S-%O53s~)SYF|_oPAftQ
zX)Hym0bBqeU|7HfXoqUkmMv+kEo-@9hN0+moZXIdX2!Fy5SU-|fevR+#;;!~ojMsm
zdp5H$ADW)^&n$&oQ=W3&-tGlTbfKufc#ZDN~o90UpZln^FJ
zU8n$l9iH~M2+lO~kLp0f;hK1{?rtY$yT$F2D=_H2x*=PcE@-
zig6KCR)0QlVWHuLSpX5pGL)^e6~|=B)Xu?3>t|~AW=5S3h>`yZ{(z%j#9aea1L%+l
z(KKG<5)#a&ryB$o?LmORs_nOG2OtxSY#@+2?cbV(y(;lRr4S%EK+8Ky4zT_0_akI%
zKN*FXwhp*k(py?6nk^cQP)ZK69f;6KAK_}aGD-#8;8r2o!*vAy5dU)=792omL5c69
zlkW!?fGrlZ4!PaX=Q7hY3XgR#*gYs|KY!2xYJy=x;t9f8aDO2W#ns`23V$mcm%*?kvsw@#nN?>BI#y9ZI20j<1BCx?VefDsk>i`plU$=rA)K=yV}2+_k2&
z)$=UOC#3S7(WF_S9ubTC9F9+2kLA-|*|-t;fMjl!gY61EQVBZHpabolK{qd4Yfhj<`B56_K!w^VRq&iZU=RB|i
zxZtczl!hvh|2R18Re7xt2I
zE`p#dM~z5eWIG20FZp!rkXsq^YocBij^_v9$a={~^DNl?kz~XG)c|;L#({320|x{e
z@fNZA^MMO|Gyzb6G?*-z+gU?1qnU3wdPQR;sff78k|8O7^Z*fZjiCe-5HsC4l!DXL
zXHnAz!xrrk&;j=_!4uCRhDJ>qVl+amV4U-s5eX!sPf-?fh&`L;0u&;Lz
z0eIPT@IEw1i69?jI6@<)c0xnM4KBc0Oyt8*2l9MK1R~T^D*QyPEDVKl^;f*-*XjnU
zcS~O3XneJ+-RIU89jeK2Q(}!MwXZ3)uz4P@y^UgyVD`P
zaVV4V?%DUmj$QZtJZ1at*6{hHF&n4NnDL)JjUce~@Da2)dV_Y`=+;DW26JsC9=
zQg(bdE@AM+(oq6dK243l0fz$G@fJ7$Ch!)4e>*-x%j(YuE=(6~(?$Dy)!oS%@!vXJ
z!%WrM&gqk0VJawDiy&?KBuWKE=t85O(YapySHJoNygE8tr~ar_OJfRlLq8k@*9bfn
zdDkr$?m~X5(6LMQqgUtIE}38|K(rekfs6w{AV5Bo5TN?%-sT5E0d_ELW4l%XM@V7_
z_L0hftY8pPNe`_d0~$m|XuwB%*ygw7Rv;_rYcN0{I5JT3FR78yNQ6$l2Xuh_F(_$W
zd@s$v9tk>V%7foF7_<-Cwfn-3!Kib%5S7N=BdfpSJ-+~gd{%^@Ew|GGUO^+cK+b|G
zhze8#BSMaL=a*))@>rCh5RZ#PQL)oM;_{C=y<>rh#0fX&fj~gOEC{S{3QnQPMw{ap
ztrKefutGDS&<&~$!w998_TNb}7=H^tOARdfgsN$SXD9&fV)C
ze&lcXuXpdSW|_9+nxqY&{mqi6TMHt+Q7L6?$U{hgMv)nc3T+ThJ22J4{4OSw4>bCS
z3K#+Fk&Bs&DI0D5mbVqt=0eI+%QMGuch*Cdl5lmF6w~T!Hzvqjlrt_84l&@#5({X(
zPN~Z#vKmGq6Y@!$!#IxPU1p)%BJ|iq5w9{C)yb9e`X>M(5lnmS;qNTUE68SOo~mf@&Sl27bGAh%@z#NAk}QzHdWb$UC#S1Lr%
z!3gO%Sr0l`faE`@5UtV#*T?a|1lm`@fdgpFf)2o^0FXjNgBR>u?b9m{8r4TEx_*>Y
z(b8Bcv=5tYO>;ECg@9uu>{{D27r(|BrtmpDYkoc|!n%G8k0^qrila1|2fWSW1~F>Yy4x
zhjd<(DQL?TLp&`lmi4siDqCl>R$G1AVrIrUH|OC{038;W{TD7|FJDYwy^z0txpe$Q
z{M4!B@#C?RCle=6rB0v8o;aD8$@*4*zI%T0tv3*@il-n!ff9=|(c@V^F7lyskh))*r$-_Q{$4&%sTHrnez(K$xhmipqxY2-9-~nWSAZUTa
zz*_*NoLil&#Y_5z%t};fss$SvDSB}vzl(v75FWc209yU|z=dwk*v{w|>aN+Uqa0Ue
zLy}ZTnhVRbVcHBb>>ABQCFu|?kpL*bdk5@;IL&2T9o6?)hM*TLnuG8T{~HlF6j0K3
z_!IC8l$ql3-3Uri(SFW|H7+QH`w{X9B=bS3;DAi9UnM@I5FU^V_Uje>;?dm%1=x*o
z+Wj0?K&)PYc@P9$^X^_X{3D=5AwDP(>>C~0E(IyzMDVx38sQ%36ns4$+=S{d0(1Zu
z;Dg{PT;?I5!OtGhVh>*l00p)?Chc!hNvrcQSuQHegg81&jqp5#WMIb`V?;$@U|J(tRkw2(cWEhd>Ioe!yUX4WZ#l$PLheoP|dM9IS=M
zFLMW^o}k1ZhMQ3M!-_~;6N<^g2?cCLIcIti1Z$QC8s_KeIqn7agvHfMnV0T#ubfXkb**yoZ2Ho<%#{ndi)WJO&gL&&%*{^!
z_Ws#DzNT7{$!54y3nF?TLdD;%`e6j%2!IUe2);KD00Aq}s(8y8I}iXB0D(}5TZ>5>
zWCDVZF8~m=th<_l#qieiWHIQ@1)DF#a}S9}$~;H<9Hb~D?K#%lPj$1ezxvYq@4fNf
zJ8!)G)@$#*`^GzOzy8+S-+JfGZ@&G;E8xQWZ-4WhH@@-KtFOF^mhZg$oo_vN>1@xW
zJ?gfO`s|{BQ<4a(5h@I;cY?fFtlVI2|We*omt@A8{dXTx@zKi=jS^ZsekVr*QkPfI|5MK|I_R;=-v0LU|M1;6zW4sOK7RjO|Kr2ge)PS!e*B~N
zFP)uJi;n;qlChnVvE87ISU?~UjqRfAhz*GxpKc;bwI7_HxnAhNir}lKqlDT66gh&A3-bOdV(aKXFS{g*T$1rA%vjz
zh`qPkBetqd?b>^<+9S5wl-jGP)fTmBZAI->MQv)Uy~my3|9zkAFxz4$+
zw`U{|>sidEg^(yeVN6g8x>cOAY{5q@OzKfrR>yb@7nGT{csLMZ~u9Gv#~x8V_~alYXIHVX4(B#d}}4m{e>TY!-sau6Qzv^?ZDI=)JFZnC_Z~VCT21$Nu}qh0XC&nPc5|yQ
zeS3U}zZ?n?@!KEOU-92xL`6woTrGb*{V&7yms1KZDn9+QTjxc-TT#%}p?>9wc+Iz)
zg<&)QBf>9*I1U0Zmp+EKH|ZV$P+4kx`;+Zs7D75n4O?>%JAfMy8LkGv@Y^K(#a`OI
zWH>I5BlHL0yrwe-K_}~$?5~ny4_)_HK@{gdZ{Tm!R!zlw$wt5KjWBr2fkWpZ#X5%3
z?=jx8GKHUeSPxyLsj&6`T
z`pJ@F+0G!ATgX;PbLZ_zdri>QlG}e*$kTVX(5DFf&Zo!fm8av2f1&5M_|gFzN~o07
z@~5+sld$~tR7nvJOK(y_Q;`lV`PFAo40RmzM|4mCP<|Dw=tBxs8qV<&REEEz4C|Gp
zlsdLrod);vz~!WrwJtRuE56}{QUZIMOZP6|kl>@8APfCbU5gtPl%6(Yd%ds?`&aq*
zsmiw|dh(n_T9_V5E?xPYJJVKch|=PMPs@HF~ZlTxL>*
z-#t%se4TC^NEh#Nn<8tr@}kmPvzp+G?XTK)dFOHKmc)CP0%EJ9T_pho2sHru7Uxph
zCsN5Jv218GZrZbJVuE744U5V7{FgL?4HA?ABmG=E)aItLW5pc-fxb33*>j%sRw|xk{#yAZBm`
zUEbnpq#r9-05ja_{)A@@;ntK_WpIAH3|%m)_nIn
zY^VKp8}YB>27e{=Znt`1f2&L6@U5D$A)P$Pgxq^I(6U!&)s1frVBDP!S}<&lq2;td
zE4&Y3S(+&dEWA(p5h68Vu1hP#H?-P>8xApDOj!}lIfl?5Y58GQu-tzBFr}*5^53Wi
z(gp~idk3=xM&%KE0~nB)D8*w{6A>t;X3S&vb-h1oB!;#Fc(;lVnfLi4Yo?6D-EuG6
zj%8^P>B^d7O4cmWw;KLS1c#`22CDK5jqnC(@QWv%ikgUqjFg&;VsTQqUr|hNg_hCUx_@A
zrZQePBHgQ-RFMs;XdPA|K{eN<)~B7Lt4E~4@s8Yvy_)^~dH#FJLj4A@k2I14hxS5=
z(*jAm4tIa@ocy~51gy*qindHiNQ04}e$Sojp`9qNp_-0~){y5{=ZRA~`ZyY|xt3eB
zTLMmWNSB`)=DY>?r{lt*2^cczu|D(q%2@)i*BMJak%~Jr_sW4H@vckBgwY@5s{3U{
z8;)KHeyB!Oy^PEP|FyBkl<_oN(T%Ue_u
za7Od;^^sbnIBbry=;G1PKw
zbKPQUZhtM
zmd#?RSZGNx#)-xd9;IeE30lW^!0P~a0M@M87#p>(Z;C~&D_c3mvha0|~k88$ecdMhB#2a@V
zH-Dn^kMeTAM3q;k3Y+>nI`HE={#WUP|Mkv=MTg#ZFM4lzESzZ$e$j{pIu)rHxD$NB
zI0lNX64T9~-w_`GNa5tMda@w&q9THSbL>!q3pA3~ol7Ftlhlp5wh=YOo{;mRRb!b`{?jx{x8L;7;XQGW}q)Jf-P@g=u~|b=2xpb
zmmO=Lm12Yv6I}gw$JRAMPsdPT`(=plnB>Lg&+*6IC07n9>3q3iM5Q68zsQJ#*g
z@lMniA>^@mv1E``0uixT<9@g0Odl~qn*Nmz(}uMQM{%pWf<8yrdTP%^Z^?1N3l;RI
zq~YS-{@(J%yhAp{v%~uYCy(XXT{8Xm4;=9Y?*>3Goedq0Fdd`x;*E`PsKjBCA@m_f
zCWO)JKQjJ6nsbE0}oXkF1FjZ^~=|>px2MbLGga3O7qn>TDy7?iD{JVMOi}3
zvg}|S>*qRn1hdYzf+9VxJ|J>)^hh+aZbjC-Se3Ep+XZE7J{QGojU1d8FKb|u!9k~i
zw4HZrSpR~ryTvCUwBMfceODfDb8CXP65TqkNA+DhPp3wWxKHn=^{Z~K=S%}I7rOTa
zgYNdn(QtTSeNoNkd>sMKO@wE|vg*Kd*%^+PQ8V)`VSseO?KHvs>~Y`C5?oE7a^N6v
zX4)B$#tyUMwvBG9>}IQdL0+_+BZxd2{4r|6@69fA#Qb0RE+%+IvR);tnvwj1(&3F{
z<(3I6ItJT6GWtET1hMF}g1RgxDwdYS2a;JjAA!?absq#**`zothR=XUrk``JYORh~
zhZ=v~Oa33F-8G-OK27P+WaSjfK##ZM@S?)g&WQ+y0GVoE&RJFkb7P}iOG<3O`%$XZW*vwG*r
zp1{*NzT3l2=(o$^!l2{*!r*hB&d0}^r<<6k(_Gr%!wgF9H&?
zW2$1P!p4ECP`?8tE`opDTYC{lfE}mU5<^1a4Th)e)#56j22FvlQk60(1#IoLkwI$k5sJoPY;$LLl!_qq3%|6hhA_(eQ!@>auK!1mm6k!9vs#E80M6IW$}zAwX~PpH=?snbpl*X!~>!1y8I#fQg`4K$5}
z3u&pK^U2hX(N)=}ZY50o&y*r9k5iRLN^Yq8K->()$3xxyhx*HRWAy`ekd=UwQxx2U
zpAD6_K^r~ReQr|XR5mB5or9gde?QDzT+u{v)vX&?TY
zJ+2i#-O%dmiK*B0phP}AaHhr{
zw+JVLS(2aygh_=P6tUF&6vPbEDS{x-xd}91C^cr2Id?)c3
zrSGpxd{Nv46tgIlIsnLSZt<1m%-GET+D%iP*;tcUgRXDdO{ec#<+^xK_hA?vvrqsvSFSz7L~Q_EY8As!i6gsWypHXG_0XE_n-d_Kma%ySzoiKgmiuynfy{_KLzHT
z}Lui-Iw@IIF9*hHv^R#1f!-Y|&1?vA+WZm4Eog4fqWH
zUZp3N;_SVi5JL6-hyy;%-iLD4K$ZkGdVWO#y5mA>Qj03+i(#XkK9n|+~kG$!2K(i`702p4HE
z4Y`wIqv`_lC5lgwGTe2!I(|^El4+rxn@OP)>$(Wn3hpZsJK#@59ZOCAh7@9GqM*%+
zy`}+?>1q$9bw}p*H-2IY|C@(HR8ABR2gvdFWc~6IQUGpfGBN#DTt=j?4Az
zv!!-lR*dD<$N?Ui-}#z244C_|lVXnHrnLzS4S)IaZAPq#9C1t753^(?>Gh#Q1Vs^!
zfF{{52k+RDS&3uJ?tV2EK1>I8-tWeA-p>2NI`2`H{^_J$`mWqJHtaPv&&_2UdfW1^CwnJbr&y;v!fsq~ydXYb?3t)PKPCr|
zK2IbY@m3^Q41?%oq;dW8{?>MZ>!-({t9uZ%D=Nw~Z5jvya^=CmSzu(*doNk}nX@m7
z-HDM(yk_QGgn-jxEuUT~0M?ElWf`Jg6)nYCg3xVJ-CCxo2M=Q}h!LbU+)h#+|8(4o
zk75-)Bun}2x6^jeKn>p8Q3!MAU;iD}2tAD2cMICTL8&aD5e&rfWiBc)TGRh2->u{7
zm+%T9Fu{uHpuU<|qmzjgSA
z$3OQOfxq>*2D4c1;fAd%AH>YHXq)VB1*=hr5+QU(G{JChP>)5Xx%B{gQCBpf=C%rO
z>o`>jhK414LHpa!dZkzCO3KfATrRfb0iSl^qRU(I{(_Vn!Sn4Ze|zO=ES~n;3E}#K
zuvy5z#7vZ@yH$KVkAijy_*3gpHt=%{*ErnB@D6P=S{_4x$@HS
zzOtBQo^Vl40xb8u1sno~5E~E&EqcDm-Rmb*m4y?-0zg(iSFytk@*+#1T(3WW3y=l?
z(obX9)jH-4i4LO-jvKK*1gnG+s@`m<;7y`b!!T1#``c$Z7Odc$(+cuh@yPOV?~up%
zkyUKbf{2Xi2P2p4R2K}V|rz&M0Wb*s;u5C&Z?g_HuVn9&7+MuK2>(6
zhTerzGzK{Wg;KksUSjT-s+*hGEB*C#XWK;E<1FKOFHlA*aesCkZuly5SJW9P|6I*x
zL2%pU>Dl+$!hZ#3I*F^^?=Yz;G4Ru9<&jPZcd_F&Ofb4BOPMAJcmi-M0uc80=p&afdB@VJ`G8G%2_r
zpba_xp1gds^B}w&dNq5MdhZrWE&1o=xa7@`YMw9*MkZ9PPOj;^_n!ES9Z0OzDM7AR
zPET=0Uxt?oL)heLq)0MH3_T_8wuSRQ$zcAIsvpFhpW4GQWSTYokh+HM9pSV!y9`
zYd#T`XwsGldSaKsi4US8vd9)C`8s@qyqf{uNFTD847da0ucakV3LPO5HWQn62Sxya
z|GHYcTotJ_j|aZ=1!jDZM7a+>2hoNW{Io!)w%0PuU5j0u!Q!sHfe^J;lxC%n9z97h
zv4HTosRng6ZJZdA{B_CT+H5lHOzO;FNmR1)$i!-xDHz;p?Ov}`?(hhLlsuzDI`SH@
zG()N+h@)n?HcqWhUPvR`vwi3Wi>5ew!
zEcB`O>FVi9L;7hJ-{^b7EZg(NesH|p2LbF6p}JuPuK-4x087~&8x0FNo=8g^Rt)86
z1K9%AE~?6UavQoD&`c5W-W!7Msr{TbmxoHL<@$l(@}$=B0(UbB(v~1@6l3!KXY29S
z*&2kDXq%^WjX^!1p2!15VA`zQd@E3SW+y<(V{I1F6u7UL@t@l?$4!A`K`Y&B^jMHG
zKz^ZD2>?WWhFlY{3SR9#|9nNNJ#%^Us<+2i6f!;#qN%PW)(;v!?`2{lVN8Iq(kNd9
zHc=|L(h{h^|4F8AJ~1K|wH>S6V@kfvEZ64z=cbX=4fQMA{PY<3?_sqaB@maOrXAhB
z9Zzff(%09C!W|Fyhx_IHeD-+0QVv5Kw}x576t&2s)!sZtgnjIc$&l#j3okaCi2lL;
zk@*VjB`L{=SKiI+nvzg^+D*~WA5`IGH56}DqM>ld
zeY5Mf1nbuYwaH4TJ=&`z6boA9)6?<$#}Z?#BqbaKt
zoMDRgs!T7QJ=NlKsg9S7e>h-=1JC4%+L=Dg8m1jYGbM7au7roenh7!c>0*j$?cKAn
z%$auHdd`vMcJitxn`8aZma$;I7aws-3*yhxhU36R;35piB!#y8{DY^yC}dcr4&F7`
zO>^};SyUnxJH~kRJnn!dY@Y9DLBU5mdS`CFz~2_CDD68(=>k0#8-Y4(@g@OqP&3G8
zO0nUVNoM)Ky}nt8^f|jbDMgkZ04!aje8R|H2HzHIZlU<@t;`;!mIrz_Wh(4yh6++OKeuOZzI`*&7GkI9tHTif)_cM<*OPE_@Z#!5U^RT>0DCUVtD6NC
zvS*TL)=AjzBkKR?e7-LFg(A(Geynu7V7Ndev(>NF`_S{zi3eq4$*PPYUGONfXw5V@
z=o4X>;9rU3I$sy~eC#cNi{O?uB=B?zcqc%YY6dS522{4n3%yt
zFI+&**d(DrQF`7xA{odP@wY;yva~mwM0#X_Ujd?aY-$|Sa&Ko|&SVP@FRLUa;BF!c
zNc8GJVky{2Xe3$@(W$a0_5u&SeFdpRBfSZ(JYHDI>x*>_xr0yHu|a=kI453XmIjnl
zIKP+t97j6&8OsAl8nTC}Uiun)okQ)pm5J1U6;@VKVLyG6JzDDp7c-ZFe1B0b6)dxd
zkpy(vfke|JbKk-DA9)x)D-$-o%Tb4tq-alkoh3q|A%JfE8;kNAjHkt<1}_+rHX;^(
zC^pIQBOyDNhT~5n698`bn*U!~(T3fL$3*kKwFpW?I@$*p?}&$e$Pn_^iAwN-ukeNBFlR))=x;N7zB9+K@TO16l
z)~WZ6|KT$ctg>s$B>QckLh3^XDsQybKDoAR=Pr*KCpM}!h9*7MpCt`QXFR`)+O1z!
zyM8s)wLz3%P}aMY91FQGX47z=p`^k`ACL&cCc_CZ`N>t=&P+hEos~$Fsb~pNZSo)?
zQkCj5#D!su5ILf$MMd@lU=tum&3^s_Z8w;#J!)5oITs+mYT+@Ft|YXtwc{SoCLznC
z8fmtEh1#NdpTbF|7ilRt&qtM6=C$Xin?B4&M^yDnt@Tq?M#j6>(>)Du9F{?MwO`G%
z_kQveoSAe|N%>B_+4}bMKf_J<)*cyEE*1W7Pt)z=w^O9JzZw5Q$thSS}^N=@$Rf>|Am?;Ga5LK
z&Vr5=0R7F13f|0%6~XM~4uJPqN$oYBw{p#Rty3j>XTAtVl*3soj-+zIwB6P{&~ES$
zx_j8bHTd?%MJ__aog2PrctbV~P5vM?p+paQ_7N^rqCO}R{+{JFS&DC>IoRHO+x!WN
z&K{fE{hC3peIWWO0SY5NvJ6-5X6&U|HFqW>K}!QpnbTSZ1=Rqa+43Q=QwiuTh3%PW
zRu
zvRoMSwp;q2yVfNyjDc
z&4X(&(IweT{Ya!&STH!Iw77PLHVwVxtGzBo^01Z13$ZfR&Bh`FshUr^GZ%4fOEb@%
zs-nm@{-hsWhab+wJzRfVJMg%>cv)=srSFUBv9v#%_lD74<-R6f-M+rn+?UcC6AW0|
z_PE`c*SLOe@PUSa@_ov>r4(!k8q7{|7HEiCOYsdQc$m9M6
zC+tb+<|gR^+h4gcMMMhE#+TlULRLX=
z)Z!V#0p{}QWLUtYRs{9neD2KbbTHogLu&$pL_#KMV&FN5pB7tVBcEvp3UyO^tcy=55-I`zRH>iGTjmZ&M^UB|!BCFX|A@Vvg6$bjhiN
znpTg*u_k1nDZ;Zb=i-azk|xeE%$N|8Ak*ALd6l6-ae+Oo>ta5Wix&2I5n`xj(GeXi-AlQf^#2~;Bs
z-p5IN(m#wqRYLrLPlAeS7
z;bo8aZzCI0l^rku^sQ?bfotERphR6>w8%4!KI#*7#6w@FML*8=eV>kkjkOih!2G#B
zkC}0eo&a*5<6!%nrFdM2?EzuN*eRA5+YH=&)@2n9xZLvniRpy$
zNXJ1e42Ko_zGW=2$OAN#^>{)inXIZ$oO3}=Wc1^|X^zXYRjF_%tP0GN-$Ii+K5Z7F
zZ7&5oj0Zo8e#nDU*WuYCeOCEKVrVee_zTFWeq(Y?gr+l?FTy^OVp`B=nHDAAHsj;E
z($at^R@s{H@MWS?6p`BI^2q+8+a;Np*WT|eo$(ucr6v+~m*|0NKATo4>+SfKDh`bz
z=HWCCf)zW4`1c$|qyQAZg7pARrO;*2MU2q%R7UA>rd5PiCmedO^zDlDR2pq4C1cw&
z&iTD3TYj`-id{VtL>|}fol>%46CMr*3AziX^5ophgw07GK~()fpr#d9N8GqMHsf$r!P4cX7ltrGcC!b8!ui^g`52nPI_)^xbkkKwf
zt&(qlvoiMjOaSG{%6>Mj$!tm|{J0DYa|wUc@$jlSNPc-i92C5_jOePBsAiB3D#g
zr&v5E3`_)Uhx3C4Ck_;~;y&`esAo%gsm(dK_w1P@qiKqdIc-(dP?ClJP{%iO<2<1P
zgRdwmAUg4vUU8G-l@>x7iD0gikvHogP*zK@0O~~i_i}XVFn89@HJ!(F%%nrF!@bcD
zXfJ}w8h-33Og1P`@0CYT7s)R$q+Gt#8R{SEI~A-aTp}~+GGU3^tg)pY^a2CF@U+CP
z%6FCf4U6_11yAvAzP5qM4_h7M12*YO&stTbjAdHSotK0js*mtz9L&K9#pAaI;SH+py#mUwEYXVIrYbAL8h^R{H4nOUR_?h
zgkpkDi4_*O(rQ*QRa0Wk7i8Y6s2u$feL5?A5}|_K^b&Ot?C>6)Cfx>Yggix#vv{`;
ze3uIAeICcCR26tnSnY*-+KtWq`-gLqhj_{w(Im2rNX6pM7HNIsVx-Si%OZ<+zz}~+
zFntAD7O@#PRDl>AFN*{jq@?#-rC_fInGz+x4zE6Zzm^@@SQMxmzibylMg
z`_z``+0SpgeQ6k$YnvZ-e~SKVjPGFK@vkvGmkj3e*$%j$-+ycOMbS+AxhcNgpp5FKi9v9%&!~pJ&%Ek$rUyVds<1Hpm&`
zR4>o`sEt4qrcm~Tqg?|)E!GC_uqQCgUU)He5*T*#!OX>97S0g&{(_D
z=CN68xfjL<7(D3PSttOcKgoyLiK`wJ!%&_>S#AqtI#LapqpTn}B94$3acnSPfF7R&
z#?|648KFB!%*N>y7G8PpTc}6+a7B7@HPg|%(|<6vE=fL6?6u~IE}G8eLn3oA)Pd$8
zEF$0E^xUJK0HrVg9e}yNurj@xO^@>`CWB2UFh8-jbX~csVhlVqNj2|k{(c@ACl@;5
zDsoVdPxk!zXv36Ecj9
ziEt(=D!s3bYemHNLx$bZN8AeRg#q`z3Q+)-#WZagJe=PMa&IN)OcZQ%L&8kYs1{{Y
z@dTBk&txLt6(b-;y{yF|1ES)G)8xyF~>PMHtFUoZ>WaK00?Kj@yKuwIAdgyT~AZC(No
z>-Ag4!Y}9CHfvT`O*-}3Jj?t}hNgDoZv-+Oio*U=35{~b3Jq9kbH~Rue(3+@uV30(
z_xAiqWbxo{-A1i2B0z_@(6juKYm_y@sb+)3OaXZtSfTrMCt@~Wo@1y`nAnGlOlCvB
z$oUEugEiNh!ZS^vMVnjzrOa~$Kf>rvr~vIISD`NX`5)gXlG?vZ;)GegyVY?;2irN)
zg&&@Mupc9Q>9$(*iYcsX3josZVyiwdCs^Bl@5LSBfr_{T;C#1D@5Nx+6Y>0S9HYYL
zhea-_IK<4k8BWCZWFW<<8W8P}qa&Y=ljQFL=w7R^LpM1#O1l00VEVH2l`oi?Dl^Mj
zL2FXkmkzfo7>6SGk6KA`NeV76jFJ3@lD+IXx{3VVlQ?;+Ybt_ao_Z=x`l>X1-8+`1B;hu4sC{_x
z9
zNL>Bi=R_|kO!{ozVYj`eNW}3H4Wc#t{85bseKzN#k?t?21s|QoT@(SprKY4XTTsnM
z@Zd{n>tZU68UJgk?eE^d(CAG>96CMNu4gii1vH`yIw-!q;kvy4d{D1Z4x50COX>tX
z`rOPL&o25pYDm5czTN%tZtmwcH>rl%V1B2z*qf()9?ntXl)ZSJ`HcCVQ)gEPp?Y*V
zpdDYXao!8L=bWl#a9VS$zilVGdQ{}#;INq-*M8gflc>r*6CTWuaFUNi<~T;SZIg!A
z@#>yXrfLAw+4pm2EVu4husV=hBzPiRSE&}qM(U3ga>^x=K=L{slgkSKY(;MG>xI?v
z937UXc44S51E+jBh5CTQct{WqiROavhn>aLAF&#Lg&v=oP#{S!z82~^TH%D7m8Uc`
zI$rO?sNNEmd*{^oFf4qEqMX(IPRJSTX_k#+yqeV~t80?*^4d0W_gJ2tS1~IVys>Oi
zc<4^gOXvx``J{w)*`4C`+eNBM|0ulJoh+GqJi~(y;&O{AS7*!wB=%88XZ4-Z$sjtX
z5@hV{<0VE{l}hB%9FPJLouKpk+aI5-t+@oFB^S%yNGq=bC>Ku{T6|T!m6%Bqy&x3^9A`<_tYbd_3pYXu%NKqqM62a`v
zf{Y%>zl8lOB0c|fhIolVAa80Zop`8%3pz>-m>oz(2b|YbgE$SQ&9rg*Trmi^d5vf
zZaYk4=)oe4MGzJ@DVADMl2EqUF(J=OpTJxSGXWmKOH_Z94rQUkmHYa6A-fHn89lUV
z8N)wi3x3tR>CTQ;RZUMc?&aJxg)~`Z?SZg9_8X$9e8q<}y&G`0Q~%AA=L5ux<*<_!
zu8E{0Drg1P5p;Ml1Z?k$thX8uZ5IqlgmPT<Dv;`?Qd3`g{QutBM8ukXJ^9@jO;2xTxpmP58h0Cuq$7cKTBt>X8A?QDnz0z
zq0#gd{@sEg3mNlW>3T@KR_Ph*S@sjl$w~s<897GJ1ctKhuR5i2@wYx)e=3Pc#YVxj
zu3bQLteBU4E&~`G{`&1Ct42s@h0;!DC8lv-xOqJVCX|2*@BfF>Ke27tDp{GVZz9Pw
z2P0WdJv@4Z)9eD9|3(mLDTR&*L>A!{y?&_cvL6)K5u^z>UG+V64pNQg!W3JSPMr=u`RwDk
z*=`Z^r%48k-fT1BM0qZX`7l-->n5>R2o4;eN9|801f3F^jn)z9Z(4cEbF>75~!=QqzD7>bt;mW+||9~k=9qd^tPZTKv)!Tpes_Y}%6iT*vgz@}Kl9}kT
zmOxETnA4^VREft?wsPP{hLopcP--b-c3M=##$<&EEC#|$e|ADmP}d@ouU)EhDz6Rr
zrOWQ=ic)cU}I!iouI{Y+4my+>egmul%v~NBihX@{*OQV?Sa71wrg2IXFiGo
zNwTokzx|Tu54W^$xzE1O!>`XjUQzgRnuUJE<3>FH-x5X6k0jBoU3C6(+}X@sCu-jnCAJ)rsBT;TYIp?Sd?^M!*J|IJ5EHDnnRd
z0Q657u>h(fm<>vQrpCr$^JillWnoOg&IY@TX5l52M20K-E74y{iNt%mQ)wzk{U~DY
zIihPnLZaG0H%j;1q&8KhKYv5YPbyHDxtfLQw1f1xl(_cYzlA}a^0jDeVth^cjFJ~?
zs6>-|D-;@OpeZrg4U1GUdh%?#-22Yl8;i4R=U7O{y#<0KGj7CQoL^GPsYMq<*wjwO
z&DQVybS41mTjA?WnyrnCuZk;2iD#?_I~o;+G^?}?f0TBdrMA7&yNx)4p#lad6n7g@
zp&NAL_9MbH-q5-WedZR$LHVuSSk8EG1h~q?Rp#q64!%Ov2?a8{k_&skU-LYYh6XzsFJWa#9c2v%+>D*dP
zgJYY|;_qDwyTHHw4vVS-ExcAcLR%b=F{}8b3=BdD%X=4=_n%_VSc13J+r|n#O+^kF
z>)gA8A3j|DV4|f$mst~|e;jH2Jv^S-acXiBwRl77N?O?YE_AnbA>TLyMIVuRP~E7^
zO@!#HkQRPILRkJiNo`rPNQ!6t6Wl05o8ZNmofuYaO7r^uhtWiiBdLHybh;|qHgH#V
zA?cGGTv`Utn%F!Hn!P2FC=L&V*&Ak!t&{OaNgXo7&`IIZ#XyuVFUU3vZmJ3YzWddi
z*YYd%Kr0pcpegzQ&>y&P$^84X5(SfV9w?EGIJhw!3tNLjL_a7hk0?y_%PY{EkN3IG
z?x}h$<)TTNz;1O8m0v|Pm0jYxa<7g*5XxgvIs6*rKW^TH=S&)j{`u6umjMQ0304(S
znJKgXbnvI68&Zryg8D$Za&+7>7+kP%IOtofA6Cgxx30ScITb|g?%OXp8U4`T0;~1Z
zCt3LIYDz`li{YvZ5k~zqE!dxf3XMASs~2k04lyVg8^n6Kg(B>Ee%4L0{7`C61mdAg
zfWKwCX-vb?k&jrU6XDKwiQZmeoV`2hC{;4{t%pj8JFq-f;m(~`ojB6~s2a!=8y5U5yr`u6d89m*|+gOIBPvl75HYjg!0JiA}xz`0UW!0PDXpk=*_jH+Ti
z;a?PD=#6uYDTK8TvlOp>r|x-@J7~Pc>qtNQO8@4Mq3yB8x%1rDwYVgfGN2RkHopS`@A`pGxe^FnO8o4&4!G+EP8
zaT=*}FRIge!BO{LzVxn`ujj0igg@W$OxfxvN7$l9bTMhccN+i8fcr6>w>951?-$~q
zA=diE%TS!r&TEskR=euHsPg@0*XEi(6>|J}?I!osEfcOxVx!*e*|Oe7yF;#D7RS!T
z=65UCty!?CyUWn`5SSo;5SvV5>A2j^he@;uYB+d7hCuLiQrwzmXY;X72kB*MJ%(@F*5QG45_dPIFAc?j9X?A(cScxhZ^av*q4jwPu
zPV6t7$9VsgL`0~!l3Hl~iz(NP^Zgkm{wnP|f46#>H;*=PPl)p-cB*-%rm~DTnL=Um
zeT?dF#VqrUsKKD~r*9}DMkFf&8wWsifbG<$9+gg$`hJRkq87K};8%6hPP$SNF@fih
zYnf%CY4C)j$h!Hvbn_q+!H>L~g0wOS2E_AY00rpC0>Hf&mJFwde<(Q7)l5rf|H@~>
z&p0Yi3P#jXVj(E9
zQgMwZy5Zd*6qL40`>2={O?Yf7Kfg3R7Th=
z);$}@COQ%rkYLHovr7&f%SY{3`4mVcDW1YM;oLp)*EMEP$qVb_Y|7L{VXNkXxDP>>
z*?lj^w@d??07NGl+duzDzn(um8=sok$hSioG+a&ER06^jX?d2KlkI=K`>fcuhzVsC
z`^>rAluNF=Flt?&M5P=~ns1Bq6T~+=dfv8cijReazG#5gqy$>aDZ3)Pix#mk(vTP`
zNob{#q&MHTLmy^qLarZkM;&YPd>?M-I%Ufi6B_m-0qR8RIJyM)=|euB=HlqvT6BXO
z1-2Io@NrK6O?-Jbh62&|&JwE17p1&ms6HVfPx|whJV|$(Y57!496nW{=wVO>c8@HE
zIog2H8xVSoi=*BpBsH%rx9C?--`*r;2<~FI(tGmeX<10obM`ZpwGh7tIwZe$wx>Th
z7>~r5j|CtB#63qq1TYLo83swvS#jDGsJ=4x#&U^fU_Jzvm(ecBu+7swllZ8As1Nof
zo531wW6yYuFjAcrIGUA^qCj&+kqu?Bu6ATJ|`Nx#A~j6lso{F
zz76r&uMvXp>E;=Tj`W716*hNosv;B*wHkv8^`J`i!xd5$?+hMS5#JqSt%`Nvey_cK55mPha~hNqcO*|+?=$cY83
zvJrPhrE%;3vKelZokgmA`M~ijp{$L~Y_fjh{a(Nn^o>=Spfm8TJh>fKo&*GP
zyN4~)K=P!LlBvp*#mDnc^CWjW{C@Zz<~O8LAid}3mM69!kP&j7-a*k3p`*Xn+O-vW1mtll}S0y;}nWPJ0Z-o~416IL2;
z-bq#@`{173I+=a<3!w?6K3oOy->^vEnAKj5O9x(D=$n~l5Pm9Ds@mW+{lLN!JJTb5
zbMkb59MRkrMfynE*F8lFd^qG5NiJc{gl>Qu1Y_y*pn{S
zUe{`tkbsEGI@q3vbd8z*!ts+fPV;`H?enmT%nk58{Mv?{iI+)>Luv6sV+Ug=+*4aG
zAs!eNq?-O#l~{-WHx4>s!AimPp<3L82%@VPNx};X3*Z-Y6+ZOJ#urhGq5dHUJ%f=1
z`%G(nwiE_sA%l1wp=7f$mH3%Q83=h+Xe_!o@z-FAEt&3XAx4RxZ|hhlpw_5Xju;tk
z(q_iC$U}0J{&Kfl2?1;aEX&tOIZsf9VW!6WR&U*{nK=I_`7^xAvyh;4UiIB)V-o2_
z?0}CBr|AFLJU!SU5cYoETj;-|%6Ip1{D^#VKZLc{#s9O{1^K_e(ArgyxTGwJDVYrd4
z(9?L&QKv0x#HoOzVBjqVIADF&lc^1~)Ora|
z@w9iCDM<`CSX>FYIj_vNjj+X{o8_=EdaTf5*h&tB^W_f?=n>{#w
zCy@y{?p~CBJb9{`rQaf~17wN?+R{jhawqX1&yNH*J}oBGZ=Wc!rQE+-Pwm2?xpR`hG7dP1Lp5l@`VO5zuuH;VJ5Mr5413IVd^XDLi>{6
z`4=dAuIp!R5yt%@e9)`Bo`uu#kfiiE9}DdsD%-(boW
zLYl|Bg_gvM@9GsIor8Lfy0q%VDzxV0sowz^Gdq5!$8
zk3#iw)cXMG0S+idTt^hfF#sYT4pZgbkmgg3puz8U>F$$#v2Ct1nopFizyYg=;PRFc
zGuk6r3A^W&ib_GJHY&0T(bYph)xlj(^=RUFi?*u{Y<{KYHGED{-w5Se&RAE@zLS#2
zlo~Zyqm_BjZ=+Y9Q6^2XH4E8E5Latid{oeA5J2Q>Jq?+nbM=-%DOcOYswdncznT^`b9^;@#os;>NN5P|ThU#*-
zHlEk(!rq*S8tzI*Tycm%sGaBzF4?eu)JQO(;ZYxOMO@T8aL{xh8(f+jyAQv{znsv!0kkOnj?M7Ux$+U@zx6Y=z1{ODDX5Gp7TzPp7kE$KW(MF5`27)r`}?to%J)sjMQ*vzt5#*
zKPiyyk*g7a5MCrHcqt7DYtX!wf;tU3#U2Ix!;~A5(}6??2cxsad&Rb^)ml_Z(VtlM
zpR~sjU?J-DQsrWf{Mc`J07DW@FZCu(KW)U0KgEM&VIZ1)%19ejKiNGXP%#tiUm8Uv
zW%5wD?Etea+G=h#AhHGG6mABS
z*YgYC+02Y}dN6|JT7I+gpO$9VXg3v2W=w_02%5SLahE~$;&S;7WP}#NwuH><>%pX~
zd(AH)adj)Q6FmB7G&w4cg@pQur>lxdn`}U_Q%Y(l=DiGW+gFruj;}Z2cArRsqz@Aq
zX_=guKg9p~9R0Otqj`F|{m{m7B*Pd!YTBjle7)czvxeD2Hv)zJO=^v;t64j5j&Auf
zUvJcauxEGfDCW^WpTbj%>AoYG!3TBT1n!EwJc}0
zcq>~1$s^C$RWmXCdp0IUHd^cL0s@wF3u)wZyENuF#l@<9fvOhmmh2%pMqI*29ut|s
z#tQA(kcGWj(smSUrU{<`WK5@e#}8jbPPP=j7j)~ZE!<{x$wl{26u}}89O^M{KDoUa
z)XJUJ8Y-86fndRup@(~HXNo1dax+vH+JlZZ{F^Li%SB%ltva)E9RY~Z
zCfwYsld3J(n>MWrqdd%ibmC;m4O%>!va1Nh`oouA|NT4pTlcd!@U`>lQIt6F_3^*=
zum5iS*q>i+pH?p5HO9AojQ{^@y!dg=URHO8gv>{($;@`&b1I}qtJPziUizDr^lD9}u(d;*
z#o4lBcXo?zTWfXMSZ6@l@9ZjJUtYhuoufs^ni%U_hOT^K(HiyS477Q7g}JJePRxKD
z8y<&aUX^NV$CjJ8h}v}?57I|?Tc0y&C!1DxSx#=_lh!Me~F@Gj+=UbGrJ~BvV%navuC3gC-`5pM<-JWDL
zWz2kFHy+IsOEWUUm{LZ*7W`Oq{`<~?*76%Rc_94jY!hE^yj8+4k}?<^$`8Ez`9@`+
zeBg()w8ikzxH8|p%**O}?vqJZ}M{(M8+&jijjqX=9fye>e
zHte~R=`oN#)4qV}$7Lf!molW^>OGXJ^zE`Wv$!v*i}fJj;WK_PehTVGR(pAR*138n
z+>d%HlG3Af(cze5Z&W{R-%CzsP5j_iAT#jRXZLo~H$o0#%xTQH%G2C3WkPaQd5%VV
zkvV|Y91WTiK36;J7-Z$8FNJ{6jc1HM^)Z_m40;$Ud+j-C-~b>Cx4mq}
z%Zc{}tt0FOsD*9DWU8fOj91x7eY4H^+D<<)ZL@5oXnR6}Z;<<%689O%YD>&E
zI_W#Du5e;|{Y}K$jt-MN3SR=Xk(90+a3#L~B?|oAkwG5K9})5LTc|*?4bDbDU}fUs
zKJM3~V{#l+8O~C6d|Vg;8_TU3a1hu~V94po9O1n5qq?vt|7#9|L+e;J#ay-itiWb7
zP1$j4Rv7}FMduEHRwroS$;UJ4?*03wTD$rA-^Z%Pv9^4RE!o-PIg7TlA2GkASFZ3W
ze^PD|ov<4DahB~XdaXRu_09Fcv4h)%=$LpR>%
z@XuT_nY0<56Jea5z6S?KX9khz1p2w9(w5~!&jH=VZphO;=g$V~i!sY!e5I`>1}Wm{
zVP|pUZ~kIl=T=AK;rA)T3u?w=#zJJh-t=w<{*TAur(>3LsuMk31ZS7|nC%N4PP*!?I11XO4~IC!$m
ziQ^dPy;+95;!^Y&fq7D~0sq;Tc~&5x~bRB#O1N{O)`-p|Rb6&-GLO?K3QLY<2
z*J8Ic=o?*>>9&8Vv4)F&oERKk!9>zDB=u-9oF!{8%vO<_xbsz7k_I~|Fq{>Sa_nO4
zL*ldTO)9$BmZbWqpLfIuEv&bET!NIGK)S4ET0Fk{0OmHOb2p}>hCZ|xMl3x#$>lUv
z18ycmA@ex7&s|CXG>C1}6bynREaG21>j#6qa0(4BL1++Ak>8Se
zbf_r5HFxai&Ofewv-kU9;88^N?HTc>3pn88^;zvT@%S@J&;xOh2xq-8{v3U16&xt%
z`*heF&M44+QuxJCyzQxhXx!3bur_Yd{r*LyaWV?yih+Dh&Hv$EFp
z#k=fBFR2A*vQVNC-3Y*$Qx+LuX{2mJ&!T
zfC`VxEM^2Kq37YV1g?3$c;Ang4xQzMqkkA6R+XV9$@As<^vCgeW9+CSWyc}oDr4IE
z(1v_sq9H4*U7XRSZLiebRkHrV<>gMiLVHhgwXkNrXOX}CgggHssFdq)CTORw=Vm*j
z_ok1S()(y)79G1T2nEOpzg71~@{3)L4kItS_@j^lAwSyP{tZu&@i}h6(1r$z6P%HV
zb%MV61+vYg3*D>rDhmtHu2W;GBNJ3Pw$QMX{3sWbk6=CPg&MNGN2g52I5KNGR~$}L
z(W43Uq_MwjFEPm=_zW!z25*Bsq?zqi!!SpcOIWT%Qksj4W%Fpyk~%AzWZ!a2hjFVA
z`mtj4=p|iNw)5igggpx-NIADfb*YljkPa=m3i{O>$hS3p%xKJ2
zhE=jsZ`mOt4_^`NLD@yxuDX~1{%}~&Xr-f5mWWz`U)W#BFEzj{4ls~tQg{O7LoS~k
z{clHYyN0r*`~;S8@qc?k6CE%B`pap;%URI#UeJ^2%kFElJy@cgkz(1|e_Pyn{buE<
zEr^5d5x`2W)*^&6`UA8
z$ih&jnp@N6TAChpbk^D4*fYK7q)|XdtW0E7NSDAs8_J|9Ktllj0x=uW7KBAZ*RIhj
zQR!J+-)t3O@em{*gA7ZP<;3VY=n0hRD^9>F#RYa5w>8PNhI}3lWgTTswa&)2Ys7|F
zsUO*5R?D1vPI6BKyjgFI80SFH0DpRJaA8I;d71((~jroL99aFH7s5B(B7XSwF5
zv=~SorVRHAUex;xrnBY9Gl_Ht-nM=FwKAX$@3W@?;KBfJ#gTz{l(sM-Gs68|?9Ys4
zr%;4;b@}x_8iEK*+au+t02fXtIX`Cmuo^fs!
zXX@sU$Uv*qD`$0p?P%E*%}bxp3xx#wIeUi%@=O5&Jf(xa?2`zNv%l43W5G`3nMMn<85Ml{U5*|-fYY%
zbbc(Bj%Bws&9zB7YH3q_5-i0`(r+CfXf=LFeZ(y0nNTOVLyZCjN(}KQU4~+%UPC~{
zSn_^|b$j)Re&oSu;z(4%q!^gH{>sS-3Q7uKBUF&|5z%c59fDnOOoJ|;@(SC6br)}u
zHCj5*dP+n~PS2(gE4wu-0(|z-Nq7e^*F5tnmz!X=Rv`mOeKadCm-
z-$~t;SWxS`CB7TdM2yb-=X<%KkTU1a8o9&2LJ@FZdxX;l63^tqA$oc^6N_~JZnKm5
zFrT1Z<`>S%Nduem&n(wi@JJ#F`kMw37t?G{_8Fn{U&gVYQ9h!p;slG6$F;$a%gA|#
zpfJ~9Ty-?~Jbis#TS~`aVf{S;uWDy8=3*>%wY-kd#b`QToUq%Q-e<>ScXxF$dT%FX
zMCyYY-I|kMlar}Q^z;;1$oRttW^WI(_2LBa`@YWJX!=vMTikDkce=0t)c74=a{7~u
zO&_m*ieB~+QyKjI9=Re8u&a+BCRnbEbokNkj1W?A`Ho6)TNF0T#DGX%V
ziUF}rmnU%D>jMVoBBLk1Rulv*sl5GK8O533OgHc-83R?fcF5luC4F4)V#p6EhX@Tx
z36bMt+Tv2zF`upoIpO6S9#}t$Z!Z<>HclkEFzOq_xeJ>Y3%;Aj^0TR*4aS7uF$D*T
zWq56!T^C|GD$5=9g;*_yB@{fPlK5c1MT(y(bNtS_7={iREpw_2BjE~m2(zHv3DK-b
zdxoF@k`U$^P5dLJQ)Ox1;M)G9b9RDw&2yrk%HjiR!VS~ZMAR@n0a*a@ukrNHV;^3Q
z#sB4xC9-ehWy6)x+jzF1^)?sLsCqaI^nC5nM|-IFTlZbGhn}(gQMQaj+iq@E=Lv}x
zQ(0wcT-?`=+?2M~Lg@>_hiS920R--x
zjTkMgCBdzEb39zx2D17yRYE>aZC_6kWoL^Kam!9@(DWj*qj7_eVIb092Fnk8Z$mv>
zt&wqwa^g$NEDH}Z9kf_m1Bn?uj*Ni_N8`QmR7_SqGHavUmYFF7;=?Iu-<8OgK_RY9xw7{+0c$ZNa^>{|
zHlK7NqeP4iIUI^ZiUsavyIJ#PF>%Y0@KdHVFHt$V5j~`IJ#Fb=UJxtrKJ=mpOS6v_N&s1xKx~G{OIv-(
z$|QM6n3U637M_(v9P5N3-NzdA$ELearv;ZXxa~wCd%EH$6^QMxNYX<7nZfzrkQEIH
zVhVIp8lY%1f`_yakZ{`uA(6+VPx#}$$Pj2gM;L69tTo#1`c?~v-H7N+9WC|QZa_lF
z4oD0QbDu+CECA6!1dM)I8^dB3=ws!S{f&ugaetto1cY5+ONAZr6)hFD>D&(;avIS;
zKYS3sUY!X%oO#{nwjGy^;}G$4^67cFkLZ0IM{mQr2=sovLx$tkzQgBUoBd0ja5I-7
zTD1s*w9l1>jcQ99vnW$vJJPv4u9kJ;f2z;&e~hSX>`q(JUC35c#KcifS7w~R)n|XJ
zFkdCN$9ZAP1(B|b?6w51xc(5Py!kA}l&A*}`Q1RYhD1rd;tFnrBLJY@fT0gmAP~+h
zitP?Imn(8G*9ei;#P`+lRE76h|LiL8whMG;+dgXB9r6OCtD$MKs+*Gz!ZMpySrLTo
zaC5_rkpKWw3nnutWY{#hQj@~F;J+z*i=@c?3cffA&vnrzsEI-IE!5ETez_BxRix*8O3rr1Ww6LGWq5$RXU^0@v4kTxgS9OVBAN
z|I_pgJ{FF@Q}}`P>$sxrf%pB7hIg0>>`#EG6SYGQBV~BAN3RFH&u=3nvE9>#?Qrft
zDGYmOtv)tuOJ@?v_iDMyGgJw}8@rx4uXiqDfAi^*lTdeh3L7?y_ac$y?t&h6di`uS
zGbr`{_C4NW)85;Hl!u1d$oND%-3AYDQA~bzc`gjI{dJ;B|DXhuOhE;*<9G|VVTeCd
zQ57GsGj%!qh2V7IqQDqO>1ygR5|NB(Q_ry!cFhpwgZq}op-6GBeu;KRleqF%%Jad=
zzW3ytRgBi6rJu{Q{}x((qUr;aav`E;YQ0NQi6U+HG82Gl!N@OdlDARf^tT&r;b#$$
zYi=x@uwjB9YfiR6TtMuS5QS_zs?reXVbZcotJnQE?Z;L4Ga>Fh|XF{deZp$-G|4LtsAYr(o$!c9_=g8YNw1V%fE?y
z_^S*Fw(N1E35m?JmcFFJZYSTSBP~AHkVksCq!YUp24bx-5bZQ!UnA3Wn3$zY3`pk2
zL@j7=`hhf);&04zT1_5HPAFsW6BnM&r9cUz?%a8r@Xp2W?!Z>+)-s+Wt&->
znRxcma{@$W3k~Qo|KhM(K&(EX4nTJ359)vNeUIL#Xfj_RPeQO?7kK^KMjr$5`5*RA
zWLz8pB}PwQ4azehCa|VxUi&@t(L^HJn*MQqeB#m(k_?-kLt+H;Wr9kPu-OGpA9N`)iuM1D9NoE!|bP6g3YZvOT}xyH2?tFqsp4eDfI
znYPzNC+BGzR-MM6;o*{n7HT!Oaz*$WyjK~`G<~OwkCqv(4LgTino!t%rljnc%CFit
z+U^$xnF9Nr1drP=5gCuz;^C>FU<4Q-xcUzol};b;!>m;9xhYyv9_JOka)Q-B^Rp2X
zGZKM;zAf?Z{p5KTZ&T$EqAbw54MFCV69cW8n`7k-pnBHxoakjXz|~q9X4Y{Q
zyqHFx3(={m{~;41P`xe&iDMBk8G?DzlZ}02FDxv8t5*@
z_WDysXv$S(&PBAo!AnKYJ#J337MEgwr%b$jET@6jcO`H{s3(BTtYuLiRiY
z7f|Q7(lRumD)E_5)7Oke0kOpK=I6CRZ@nUhpJy9r|9bz$LQRxi8)5rX4h^<
ztREhL7g4r%z$4d=w;S|+xDcN(`d+aq+dSL;Gm#6+t6LEI6>kU
z=&>FbaUjxJpiMUb(>PqZ>Yb@Udsw`sp~ik?B=rZgUyBtqy?+>j(sm7gc)fh}#v$#m
zQ$@6GfHCmB@Q%Z~fLH$sQ+n?S|6J?1y;hu)$T!YJn}Az9w?M(OH3CYUqwZS5N^OK|
z`dZvhM_0n}3ITMrRdj^#okz2pT(?AO01@v8FVP2ng2X-^|Lu~Nc>%Ec)d4o+weg^d
zVef+LsAUXlSdM;bQ(-}QX6W1qgo7nEE{_n$-Rf)n
z9+ZXiGYSRy`Rj
zKG*wvy+Cb7vCfOxVn3{}8O+F(zW3;4{I!N{@kj)G&c5DzhjM&Uw6piSWpY%TU2fOD
zr20R6f2vnxNWBB!bHL-njEOu2CP`yY9
z62XcCkFtvLvsp2=8R8L?jupB=j&5%*I$IhUn(e)qijkvbE=6y@`!w{?>(c5l_$5Cl
z$_j&NY8Z>_PSf0TO_SY;fj6nZFY7H)<^=$&4|nL869TfsQG&1cxJF*6sUWcdnfo(^
zH$(#2^6L30zyDkqJdMov@?R9)T2}7_l@f?O$>l$6n7$(S8soV~W1m0oTAsYxZ}$xs
zKP?Y(oo+mW$*GA?W5EQK^^K`zPw}%TjMYrWEDj*Bft{3SB?3W39_Mn(n!VAIV)ZvL
zTbM7s@;A1A4oKu&B=UI~Pcji<%s0rTaHM)6uK}yvSwv_qiu1?(g~dpbUyUHfolukt
z+Gj^@dAMJzo-BTw7JfE~aLItfSqC{KjnI@wv?YP}qgfQ@r7qz&>d3B+0TJy}ySuzP
zZJ{rr;A)83f&ZqEX&V4J7W2sh!Fhn|XX~Ie8DeqsDG@n$NNUhW|Yvemh5FB+n1tgq?`kdYEJB|S0dTF9E
zfVeNJvbJG$e)?t-26{WJy*~TQ%guJ5R9#?JUf|Aq0Ke|yse~Ko|B(>r6BGH^jd9`nVDz|F$_j9^
z82fZ?^}JEJINmVZu(#9U6ZBzz=?f~w?{xwd1DQrzt|geB7f+Ta`MKZ5xu)37DDm%}
zL3mv9YB$|8r&Xl!VeU4E&t;?YwxPzb?aB}5f2&cWTXtrcw$aJ4kMK7V3ClQ<86O?U
zj0Q6J-jEzFM7o0Cpy?r{%D+W?P0b$-9%!?ZL{~%Nt8)3;=aU97Z@c0v69wrrxpbuG0g@M)f^(P}Nc}OPjTteM)IqP%QHmSdJ_#iz<
zV056~ZG@%=H48U#rY6jP+cf7@%A2C9aI7_v`IoMo$>n3{%)hqYsE4J%r=guq)2)Z2
zpOioTK!3hq!dp2dApQs6*S%;RyWWy%z2_b_SrXLu^i;g_UDj4369yZK%E0A|Oi4>k
z-I!VDl@vNl;kvPrp{#m=FJ;Mx5pZ^pKb8WJlZsSK5z{KdBHn1Zk0LtL7?5}h*U6OX
z&PqTo`@!1qVQ~j2gaffpUnOM%Q}Sf&dIt>5Abyc
ziwDZoeB!a*sG+-9J#M42&RNq*aXOmiL_plEEnR7%F0=WfwQy&kV#vtcY0Pqp5Wr)7ap$|j65Eqak)g#CoJg+41K)GNjBEOOb
zD=rH*%tp2WdHc5ebOIs!60HcB^7m>W&`8~vsBI(YVvNalLCmPnxc(JiDDq9x
z$9|XV*9J@pxNF2tJAfJMP6G>*QH
zYY}fvQ+jLC)>p=oyO@2rBpL=eJb*{6`fEr>p7Z_sc`h%($h0A&*=MjeFcDB#^RV(s;h_**m8
znYh|$cp;J!1{@PY^0zU`hfF-4>NxfP)StX#wdJ}O=3CY}y|fmbwMti)Ti1_&#}`V)
zej_`^bZSw&E+)fd8@GoK166CD6kHuE+<$%3omUpmvdYS)Qc{-f^^Ij-G6-r~D>Vz9
zAjg=-pXN6l$<~e0k2`Xk7aI7oBXrj1PgjBAV@$d&Wp+FmY1uZu%S$JMzFM_+sl`gR
zm(v`GheZFBCW6z_aEu1w^&buy^W|#N943=Sz1hM&N8&yrfxB=%pJKB{TdTpj|LX2t
zv}Z)2t1?F#)oT0i>&OHVx1-U!$dv$R$*%mNfx}3CC;!xQN#_Ww0{4k!wuGX_+a4E%
zX|=;YQ~_e9pqu>^
zzT9vk?fXqM#N*OtZv2)K+DYLdHb#8&0M5N_WCFbzwaSUF5<&`=i5O_<9wFKYAQG%B
z*hYlw_I0Wmqr06DSRFRxDr}_=G|9-trrEZ)68&*c6BViy{x91WiY{=qgNH~g7lj1V
zyV)_j9I$>p>lqK)ZbKh_*e^ek+hkBn49dao)=xo%=FLdyP&aK
z8!QyVF{I@SukIdcCRh*2ghR%9GXyBjIBb=b$awsvVAE(-4|37mu`XBZE(CGGmA4`K
zheg|%edW*Ay<#SD)em@>b(y2&a=>aFv{e$;MEeZVp&IU
z&Ggo#`93Th;_Ph7aU$P90T3->P*bI4f`%P83H9T%he0k!<%D%Bl`>{$-gIX&hr^9)^sR$~?QzBX{jt%d*h(^8v~slwj=VV2?o9DklqVcRJrw0T
zkuULWbM68GA&z5t9N&;5KEaF3q%^-DwSFOcjPw$@yfk&dq$OK++UWA!i
z|MiCG{iuIP`k$0O!Tp_{e^T(%VjWfo;i#+?D>6{cCDl9DvKs&pXO{^icIO%N!e
zNFISk(RcSLm;z363;N=7zNXXQ+Ig6qkU3%L|F(gt3oKP`OLvNRqFiU
zN78$W`wYAEZr)DgUADunQ=O;)cy|NAKE809)8k1)kDOe*2pY}l`dw+U-%5DyuC_W-
zoVv=fu*|y0>iakcVL?*3!Ji3+;_uo({$6``d^Nk~%K~B1ycKL1_kj_>Ob%3r;GlT_
z{`A@RtJKlmSwykCXEj#9i^f}#^^>!x8L^NX+36-PcYOL=V6puxDZ%XYNd=^U!u3si
z=r&`2erQkMCjhI?pljl}tx$yIG`uw8Ey)|DaC&!6jbU*ln$)7c;P!M4ZOtoLSunqb
z8WX7k*cFfk<)=sM97_%^Ht)2M45)Ig)c>vOxF
zw$&ewsyEDp0rYGRJd^&!(Y{lNX!~f{R)$7xGdr8Zx46nbrCo`cOY^3v=VH#LrX;&e%t5tUx#xl;4hA}F(!qil0D!*Qz4WmrLIvTjdRo9-bP;t^
zrA=PXdResiWcM|FWy5wos4({8%GT~XMDe^{nGRVXBMRd2Y8V|MZxJHyeFgBqDLpxh
z;kn9HUTcXwTUB
ziTvvI@*WprKzG4n)8!lqqI{e2aMt`!{7294x{)U;vXgZofA5LfntZAYKOWpfhR|ex
zWet^+@&erPX`QtpBrL~SFaUTAlcX)>K(uaot77PE-Q2;*iZCTnaGp&PR*>Tg+utXN
z6(S8rumQ$H8gNC%3JGxTQ9R7xA6!}ekSz7-CZ-z$t(k<}Kmc;D-%cQ$0gq|+sfsu*
zlLP3LkN;H^P?!SVT?td;$Woi%*NkVnyjAd1L+2`x3gi3El#+l$Xt4`VyeKgpVaXV+
zsa78=fZqUVnj4QzB#_x}?md1doBt=y=+?+z6CA&%`z6`Jh)8Tt$W&yaqdnee@Ls=m
z6c}zFH?H_zqdF9q8CqzfyK-zlinvIo!UpZjuW{tRIc-pqDz^K&{HL-<8A-yB)xOEv
ziIw&`lAcDvj)zHQKee=~!GODvRXZ-Lh%Zmasz1DlPis~?XIT=JYsjSb4YxkwT8f}&
zhdB@z?&&ux(&Q#)88#SB~i^Xuf4hYOwCmGGhhME(3xW!`UzWQoX8&E;PP}2tgu{cvp=T
zNZrCn#)Rh1_TG#lb_y`67tBd(-=8YK)JcuKG*2MYgkc4P)?CyDN5lE0YfB(9T;V-qP%p(_1`V0R2iw`{f$k0
zP)Byf+y;U4$31`}{Q}AOFI09je%|p2h+l!)2#V@`C1O#{axW)@$e1xwNC&`f`(Ay&
z(E_o8lnVr`ALU_q^)OS!`+Bm+%Ss6!b%vkSDHlL=J>l9Q6m_$~L~-Fz%Ht3eP>u-C4te6^hn8&kRY=vPuWII|#W)Jt`c0x_ibdwI3^&cCiI
zuw5yHjbI3hpe@xjPS3Tpe-=@+ve;66Y-0G+{}4WdcDXNu2pcMtbZkU%IB%
z#G{8o1{>MDjB!;#v^4>od7GqB_R+vX+C-}&J6ZodO-&fILPxo!s$dkq4MFba|W!AV?zC()F$CNcr>nF8Wu>NrBN{yW#dc_3sU!+>$`yWJK{TBVM|U;1$vax)2SI4Bi~uCwH=_D?*T
z@}UU62h=sEkl6yQ^A(z%_lX$D%Jz6D&(cQyB|?sUz^i`-OyMS~BM6K*=o^{uu-!+i
zL~R!+J&v*4mE}Np{RNhc=f!Mn?i!rr(qgLL>~sp6xnm4emqx3}1bMIW)uLp_%HEN5
z@W8C~zKjl8{7&77%RH}eS8)1E1sLx1OHOpsUr_w)OIjuG`=#Lw=_pidva`
z3-tq*|5IFS)+#-I%tDW8fG@8l|K8VI>86*(=B+#ho{1SZeax@@vherj_i@#P!OSefGy%v8oUCO5?umeEPp=AjSU
z@DeTwOqf4OrY#`o)XG%cYDqX-!|V&$gY{O2)M>nB4KaduHj@Wnz8p}yy1tu6OEh-X
zh9}{J#Gn#vKj^7e7r#+RtJ@SGOG&5Q#8@aBMJt(8DQdWVvX|1q
zG={-Kpy-;-?xc|7C;Xn#;;9JAYF_K|vcja%>`smHXw*GKkabh3IS{8J8omCF3g#Oi
zR5_k(#EdFC5vdtnsmU%(&umFrs;Sn6KbqhY{m*BfY`jvgD=rqIKHd_vW24nXS@H7d
z4@;G~d|6A6G@7Q;r?HBm?*e2#vQ|%I)MRzh;b{#o96KsthwM)b8)@iPWi`wia)>>71lntg5@Ln@bs3dI(oWbFSQ!d@>j7YR54!LOES07U~lBKC?KR{4;4c
zG&V4A;q4>n>p>TEYWrstw>dl%S@Y?R;ow-5wn$X`@lVjpn9^&xB<~vxhe2F?B>;M$QdK6$RxTGXZyHB&?F~yj$sQV>>=`^et
z4HYk~)AJc*M#c#K^R3JLL1#Di+M1HvFUg*br5kUg0t*SEv;fFp2fKA&j5)W*3leZnVMP)YjAeSY;7p6ww5h_3qAz`IbtLT
zN4?IW>OHTK6uhxtdoen!-hi|JT8os}voKQt2X|OAMp`yn^=(a5$^M_O^vT-N$;a}V
z_)*NyxETW@9@XqjYqYG4yE{XV%RgI51l9Hp^8V>q}`%k5+V
zU1)Tg7eD&Jo!pz5=w};7wqEh+O04YjI;w5XUh!1%`FaX@V#b255U)!!5b4gS;^Ac>
zMuF>*nXd(Nr`rT}>-l}Oq$unA8_ameryZr&_1bQZ-kYYN=if7S@z*mZft63|0l!9G
z9+(ffCxWa3Iqjs7jbN@YD<}Z-s8}WsDgfoRDx#mI&ZwucoM3(Ldaw_JCw0AJu%*#?
zwvBU1MW#^bpi20Lq=`6Y5*#)9NaVlpQ~E=UhLaRl@i?`pe+}W{044kO
zQYHS|e9Bc$J?C<*4@wj@+`I
zD26Gk1KSk7Erf{Zx**`*j8h;H;y?wqec~bb{cjQQC>d<63_WAc?0@SZu!f?k_hlWO
zN=GUoHQ6Mntemvo_&G@lKS-c1Sd+q+~81
zvEt&PlRy_wIh8Al&aMu;>I=R{bEEb=g4(~nSXEPyzS&|<`a707h;|!g!2fj)+iC5w
zIK$*+XU62=H~dFvUJ77T=ChoAmG^6I$t_Q;PuIMY?N^dYI{+9;k-X)pcPvL2mKHd|
z;e;4!YFM&Xe1A_7jaj~li3DQriY5?D#vsSM1$Bp&dlRzFyz=I3%c|03p^{)Aqxd^A
zo2xRgWu@}s7OVWk)8J;m5^Dn?_5af8JmqqwCYl>5Mj|b@a-c~%D`k4V9
zKHx#xDQ-a6hE*ls!#S#{lHn1OqBklrZ*h)d)BK@?FL9i`NI!w55sV7bM`&ozgWupY
zDNcPn(O#$G{5u`5DPDvW!h0}r)I0sgtFZ|v!YM+Ox{_^%(0M~w1D;ly)I8$?iV-~w
zqxdqNThpZ%!k0`)mOCXv;aiwCZZ_qH0hw=3pPE&g-4X()no@A
zeYo&)V-Wm_Efv%NGYj4p=zHKpARjLPUuZfvk=;qM9ucljlFrlLV>#24Jh#3;ddiEb
z#6t9==fd*Oi@y{rsCY;jLxGgR=wY{Xc;uLUz&hT`>Az$Fj0AMwix7PawUg77Gyz2>
z?}3?Npz4OJf`QU#V(4Enpo1MYm2u~^Sk+rfCCf~Sjp^J&(
zlEI7wA$rMwt$USYwOj2vE6wkDPRZ|j9^eiCUP+S+dIrfM^bSZ}({2+aF15GP-YcQp
z%+)gR87l?YqaaJO7KCFKQX?@wW7K@wUa^0Rmq(LvFX7J$`ktOPbO?v=}3lZ4_#ZQA;Vx0uwM_WEKhzP{ZPw
zmU4b);uCygEKKHF;u`jv<6FO(;St@FS?5tvhF&dfyhTg}xxz7Ng}C%+!-_^(7CG7e
zes=g#Fj^E>pftRuDNE(Y3D=#zrypylsLmjJHKk7vS>?3l7m&Q;Ik;UG>Y4>}l-n*)
zYy`7m7X(v9n)DgEk}{y+3~ni*4U}yCA4yjk)^y{wx3RI&HM+Y|5s(r_H;fKxX;A^`
z9Ni%)-K~-mf^>(pNJt|c(#^Z)|9;rDecX1P>-^5S&mCBY1_C|@HxeOJ(@^wOyCHOm
zf)U~X#m=PZ#|f)1rJo>p5W;AVg{py0gv#}?l^`PqRi8Q8Z$&UUP6B~3GlIvreFBPJ
zHWD?h^S=f%+fCaAJ*NQDYkrZYP2gY<)GYM>)|W%fw!;5gpeGdw%Gc8Tp%Jl4?!-#a&pJ^go(duos3~HDC-qNNn8UHEB8$!jd_55RSju-q#ZOc(7%2)f
zWlwHp3(muwWXYl`E$xYM=4zj1gw-P1PUmISleo5BNJ$#m?eb|W)Tnnt6Wfd@XDdpc
zT}5ynT@~57^l6-j_7c8AkOpZrIXC;C7+h>C@BaSBGXjaIu7_t+cs${gr{Zmy6FMoR
zf3%I(y=}iQeLR=Er+=)Jms}&*i%DHYS6jTK&t_=;Q^}8o&FBS0mRb3>Rxs$GqFozj
z8vCo|Je93iT$Z5%#!n#JE~|jXZmL2`l9ZNTeH;k<5Lov2&j8K*w`VrkUMXlwZUc>d
zA2&qN^XoxpkX2SIfCD*#j4o2^A3^R9Mi8a%Hz@yb&w1Iqev{~IXJ&J)JNik;MiW|%Qf--aCFU^wWe~SxXIs|5FPdVEKnUT2J-h(NUXvE
z`iB$(JEwAR!2WEuz@XfbNK~4z)Nze)P$`mL$ge7roP2tNt;xWAimYs8NASP;5*+vD
znng!fW??5NKAzg?(yD)k-#03)Cm;#}U9BbVjXM=KpW|=(@Dy;U?;ks*~m}
z&(xi-t;u}Eb1SY`LE25vY*)8^H=SkZ0GUd4C;AhN8o-uNFbz!~#UDRkSNE-cJ`HyO2AH7GcM^;^3U^=B_6S|TX8dc9j
zE7Nu>`zP7stO@9F$Hs2sXh(rG+0XRr*0Zwk)W=HvZ%!XA-8gjTi9#L5&51I;bjuWq
zt)R(>mw)JQx42Ls7iwT8q9UJ;>OELgP@{CWGU>|0)(J13LMq%X9re>w5R5>vF+g$(
zg4dfy)&!~n4IrX3jxGt^fiDrzZ%&kv)pS@#-y#{gLF$G*mDtxa_|MO3`RT@?CKY97
z^sbc{e5?ilrr)vBElS%0(O+&Rs`U>(3=vz%kP)L&O(vb#h^cps^2uMfuYRMo%%%T1I;C4@z3Ui71oEUbEP
z7|==G_|xxxs|o?Fiv7#EfcFxgd9jmjgZ=9aem81#9E0h&ek(n`=Pz$SRFBOQB8F+$
zj$Y2AXJjEzV>W(8RXyoESh#C0@E1d=L$RikwMw>Qi_#AaJv76nZbwU?a{hNPY(5-)
zV`=~a)j;ZxOB6>npQE4zUIT;|KxrE~;g
zf~Dm&D+Y#1MNa5tIdnELJ_+XIAWK>HJtd7m@>SG{Sc?~`ZltUh
zu~3l86AuKqGJvi4+B-<#w;+DAgzXi)!9`#sJBLEkoo5B2f0cBNMgxh>amCC9_5`Y;
zV0l;)EO6}(GlU=tCqG0yeX2_q!FJq?y8_b3OTc}OL-aeZVQ1(?eWT!JPS(Zf
zDCWoO+Y7nWRGI#cP@MB5h3B^FX{l)#I5-dYw`)_+122k7U#`B5yXN}V(Qzyk>P^U~
ze?FI;m}Yi;oBQLgOQn=xME}|V2klf;*vmF}~xSRavsRMo$cW=F=5z(S0U8vAn=Y-_&A{oD{6z
zd<5I4??dq=LIN~gkIzxODBNF|t^nBa`_6WJW#FT`Fte#MVnujq^8OkC;o=kWU1S4*
zw>uvXAJt(P{Nyn4P1zMx
zhe{TaCsy{M^EG}R(D`c(97h)2uDwyD8
zPEsJZgUX{wVyM7^R0*Pu(3&C-HLjTAsq&BsDbf6S`N#wvt`lW7!>aOxYcPn7Y=~5@
zwD=7%|8M_eJl?tRiV8i=ROO*?g7=Sqb0uQ?O@FY4Yt?fq}d5U4Y4{y340x=p*rEEV=RX+9>
zkFU9)!4xn}mVr{Y0vZE1%OU_#9z0`T5^Et;u@RgI@z*~Z!%4~05-Xd=<(iRs+(D<2
z8X7sc2ecgB0pKMW&+Nb_5P?Gk2_7Q+pSNc#(P}8B#0MY>(Z$>?1+{}lz@#x2oB`?G
z{{k6Ab+AZWIMgw!a?bzh&thermPbFU$k$(@3fRVR}eRfcPpaajt{0`lRTl0^9+
z)ta6o;A4QrW2Ho6n)tQpFP1vE
zf_MTwwl{oSU6f6};u|z*hrO{{m`Tib807nA6>b#PLF8Z4%sk5MYdGM?tS*GciAewm
zArpqme#$Kz?NydjYsiz5E;-F`GVYUFxrqOMzuh5>Ad2_{BudN;@8+)Y>A|o1eMrQZ
zg@!#hu+{_yfc!*!xr?+cA0|Sj!N~Evc;>chrYw}fxcu{Z13mK5vTl31AT_T6xa+`{
zlW|u#``%lH4t$m|dVF4x^vj^s
zlk`zN#4)3i=s-B{ESoU%vkJ!p<|-;C1QeVI-2!mC{+wSclkX+qLvv!vkGVD}#3*_9
zmC|Pf(WbRlJhdN#0fA>S9fKI)aacLWMi`x+0alfa!;9Dg3^k$?E-$R$v3Cfn4>Smc
zzg9xEH>p9_lD{2ANP@^O2sIHOMeS
zk;kbA`??Og#PwiM&Lh>e&^O;q`5KcJp#Z6|zrrrJsHsnMjIS(;3=;*SfyV`2B;H&v
z7!Y8m&ewaF3yM6lFJ;DIu!vA;wE7RLBh(=Vli3qko0=TZ?uBg*w304o;7$8vR>nnT
zE^7$nSYfsD$Ez;mn6THKnYPs!hS=9IggbYz3uH9-N+ofYkx&*tVPP>LB)u){LQ4O|
zQRxI_`b@9Vx?P95$9JrfBH+LOSf*(N{`yO1WFpKVwS2%%FU21y9txuU%eIk&5{JzY
z?qWmr!b0+q^4b+n%GpEI%t~J3!R=pvlDSsnUPm!%GeJ8m;}5W2hpjC%`~%
z$s#Z@R{zIcJ7=j97Atffjh()ydpl=qNH9u;)B1_66qu@E1%~im<lYffcoOW@@G>A;2)y}HH4n!p=N~}+(rAsB&BZX#WL^}nyENQ+!OS=W^-rbJfb=5^>>H2
zHUhr6x^`eEM$+Uf+F;FGLO;Z+e!K5QU*(qh&p?dukEzrhoCa<_&%p$Gte-m06H
zvWdS^=~?Rj^dP6o#{)&56svIMRvFIuugUv}G8i`eb31K5m_LH3#aXuUcQAfV0Rdv=
z^^BGsxDWphOE2?^n&+2j>&!EQYF1K#Z;^Q&xcFDSvt}K@P~%{f^oUpxN()icUD!*Z
z_7;6QE!Byw|DIapJalAB|6SJnB2b~6gL$SS1=QW?O%DQA0Jn;?gRHci_I~ZwmF9+Y
z6}sDMaPS4n!}_fPKMhcmg{~`WD6T{UfI7+u93}%38C*i9a0SZ`k^Ao=M|o>SA$p|=
zFGHOOo9>R`O!bEV08kLfhv4TxVFH3gU{skMAI*(v$F|ogO}MJ!i&N0IiR`WXKve)O
zIuxfDb^!Q+!p{L=XE(gInU@q<%_;p-fFZE#CE{zv>b2?n_T298cFp3Dvb%)@|8tU0
znRseyp
zavEL1xx7ysCynbH`j5ZW$D6I-Sp%~
z6Wq*LwOmjvnl#r)Y<{XS{n2&#zD77{Z~Csc9x}VDmktLu62odqRfQ7}Wl%9)PoT@R
zBGw9Oh|qC}nH+yzFt2l#N5)gE(rW;?LAt;l`XwjgT9BwJsxdNwt{Opo!hxY~_`6V+
zMaH|{eJWy%Q%-oaP-wlnAD?gl05Jzu_1#kyiB3!K=b9~j?6xBk{>g)>RhcV9B8r(7f9q!WemEAvj<{HcIEK8=k-XHQZoDOl&{!xl6i_
zZ(LxW4~Ke7T|)3czd5DOObCdrAV)`9zQ%9QeruE551ko8gz_g{vN+%jnhIP+VX`4Y
zlp(T6xJuNlsifOu=Yft?I!{>vrx#NpOrCY8H7-WRIL!5%&j6KyiFEV_iYP!cUaYxW
zGyw9$P0^P2R|a(A*&M{?mIK6|naxbL#UT#Ch2#NVte%jNivvT46}$tT1Cv1@pOkny`R0LubrA-?}u0l=!j|JrJkD?78de|bD6$76FaA{_4(g$2p>0VnmHpov-H?f4h$ret$$)7}O9Rrg<^0XTk2LJA~MDeR(`kB~B|u4K^T
zNh{l=&7N2u`FAwT|5V>?Y*u_k!obMzz_qtw`a%^R(>%T`q*mG@j@c8TY7iA|yU6~#
z9rPTrD!+TE}pvlJJUF#-!*}Kz>YAi$27E
z<$}n2{rs$EF5xAa34uMdK^4cf+Ro!<9|JfGcx51xfQ6+kB_+Ya+Xs*R43vZy{D*_B
zKd#Xd8gnMA)XEzga&rsA8OS0aaz;m=hAU3I60!cZ@?+AlSk)vmW$1*juLNZoW26wX
zv_(vkYjwhrKgAgE7_jAI-2*$>#$PG8{k6!pH+W4kP2qk1m#EGpWQqsBme{U*afMjK
z4-wh3nbv&I&-D`1D&l+ybSBO56~FIyeObLw`s`+<-av?f{KpX)PKs#VH|6hC{?0fN
zo=4Tp)OL!&Pcz(yC4S{w6A|KQPpKo&!q(0=vutrR>a>zMl1>Z_O@tY_@v0+Wv82G}
zUL9Nh&w}WR3V$pPuoL@ld|&Ud^r|Jb#7OYZ%Qrb^20Fc^ukv8$l;UTY`L}B|C8-(C
zgpLK(@sLei0S%-5XxveLWoe7wf+{sZ@Wpk!TGBg#)+hlC1-rU1nzw-16*p*(OCCnh
zA~fl2;BAqpK6sm9Y|vOX#)&n7I)TFKnO$5G@NLv+Fqr6zQrg|4Xv<5xg|@$G9?^58X48*h$#fP@w{>6T-to>F{GW*c9_
zpCoH--g0#)%k?LIa$N=#hFypwST=8gV}&@%L;eTTM*NuQ%J@Op8>d${2bhyEy|)B>
zy^13K&ZZym7AWxzzPq~tT|RAo`Sdx^7%cCalxr(7=5*G=W8T>*MXK-*9|06LzyMB!
zd;sQ-JrdTScJVjZj%gW~e(7S+m#)-o9cA5Ec$F{nlB29KynP=K;+oI7#P~4
zGXln#pE*C}3KBRD4}FRcGlR{#1D{|Ew^|w>%nm~_hdCHK1d5*FJE+N^KsgSv!J;IV
zurGrWj@7uGYABr6A%OL2PxuuB8G^EzU6GkQCog8yFC-p7gu*m>L8Mg1gyqFAqfNJN
zs4I-8T{xT)+nZ606tcmdcjy(Ka|S`bWt1CF7CwKrnw8&K!LjW~r^TVk7c
zjoXdvYFG38N!xapi?54>&esK-t%BH+!lg5c7-q?boyWQRgSOMx_6<*$U_m%j*|1^X
z`urNvdca-X7cirm4Aw)WJjF$zK7FZ?vjOJMP`8?Kj;kSi1xAZXO}u4D4RXj}4*=$C
zaEt)bRvc6ry4EX-c&GF+xAG_=lb^?_;&yeSqT8pqT#Q15)?uXN`@~s@Dax!#)GMlg
z<<3SuRU>RGRH_Ix>_SYf;YGj3w4nz!If=+U{Gc+4()gw>W*1SvQTg|e^)bhhdVkDZ
zQ}f_ovsH~e?I#nXN5|FxPG1c)zj79K)pbSkCzk;Esj7u6GpD8%tHQHoOL`V#y`uRt;;4;h(a=XT%*UZP527$7Rc>br!_dD8g2dthU~2iRA}4%
zwyh|(dUl-r!#Y#C-jH!Vh}Q914&5
zWpN>2{s-gpQ;w_N9Mq7^RMu~JSOPZizX;EYE-YQ9%5d9255*0gUd-u0M$>T{?h*}``@87``0-)*;Aad2FhmA}F-j^d4lwMANtgg@{H-00XZ
zxApYI1iX`It*0>)$yjKYY-oB?IgRi3AFhRdbbxSR&@Y5anDStAP=y7qe?A>g$(Q07
zUOF9SizX)qTTPr`h;%fHx2MM0D5?y=NxUME00q%u5gD1b1l|M%%v<
zlGl}&*bmpw2PvW>H5jWLoWJ@Wp0$~^`X7FyW?%L^Kg+Dj@milrn*B*H;%+`-O(uU|
z@yRS3_f4Ji%X!r-0SE#)B-#;#dKI^w$_VnDi5X#k)A7slvp!8H%ruyzq&%ovougHD
ze_(v{+ci-lmZKp!FHB-C_xJMt@nh}cg&G-e_GgRogX}lL8TKY@EZoKQy&+UojI@c;
z%<#1#Rf8f@G$~0xzq(
zgxXOjnsNVua3FVsaJt^YcIzDVmABW%p3~b7i4e&ykiOX>6yw+`zd;dfv@*y8@b*nS
zb%V#CI4E2iDef?*yhL`hS6IWSYUAp3G*oYw*5D2yoX1iD!Dhx|PIMU9W$mRT9%2$OiM<&t!PMvnt
zA;IQ1()$Qc7W~}t&CtjMW&q?paubWgPs;j}Y6u%m_y-i0{asQcqi!jn>xj*j)$Yg-w%l9lq=@j>3eOed
ztn~D172=BGX@_YI2WdsKE}B^HN^cJd-q8~tRFKoWA
z=DIVp$A090_p31cNYeXkbsb7C{{8Wx(C0|v`{UA|_@(csOJDZV@aYZTp{M@AYBn-t
zPq6ZKXtl;_JXdJ`Iz-fnhKCI@t0xPf#1;}LX6=Wn{yE?
zYDsrsMqA0Hzu(S4=oaF?2bh7|t!figF??3R_&Q>5C57FNzyx}=#9`JOqkZM<5;g>g
zJNww=n!1jXaT+JBb33~#=tDA)1MXTLI98)hJNAbXq&Ujb3I!rj!K+?TcuUev|g?Vk1QCs11R1`Jck+1M7iL^E*L+~SYe|{ij&pSZ1AXE_l0NA
z4k_t9)HHk?@cvvCz4h)BlswAJK1W~p*?5i!Xhq?Ye&1amRR68bt$iED^Nb?t|G=(6
z7DqcwBWWt^&eYO+*0_-F*WceM$f5eJTSuE?>Syov3MVe4sbd0QwPIcxhQs;lHsp=Z
zVh{sUwcsog-QK}C1N+!BY@&kmR^=v)2Z*TbD&-O{sh%|DpHd%-hd`sq0kIF9x3QI#
z1V=w^&;BXI)A^sQ0N+dcI$hp}UoQEatpwlZwgy}lHXa3>{ko4|YIX6?9ph`DhSHV*
zTbw)W=`MbQ{n_WDWEBa1ZCH|(VQxHqLW3s10l-cqO+VLRSWpJk=%3iPKS?6
zaB#r1!OIbvSd!)3Zpaq0b8R71o)BnkaClWZ)L^NaZp*_Vi?(TFLhxdcXc;pm1%Avc
zd>n~v);Mh4l$w9a!H`Fupx*b5vu`gI$ot`F!JK4c?SKZ2fQsIA@pTiqI&CUkd=2+Z
z(`r>=oG(t@FY!`NUJ~Y_ym`}X;3vQBa$S6SG9w<7{+
zK(`br14n{i8JPvERdGQ~MGPq`Z;(|C2fXMys~(B$5KG=eb1jLYqP+(%PfJMe4{6{Ni-wxi(vt$u6U)|=C`>5#_S1rWr?cPD+}t5zfl=B{l9XY
zMt^#KkV}T7i=YuEgus@({caWq7mGh^p4wL0YLJa(bLGGED)6-Y
z=6UB-@jqJQs$Xn+&6SRr=v#C1d#A+ezZi`$RU)3(35Gy%Q;
z*~&w9Kfw_QNxALHXe!DteI)HlQ!{14M_qhFcFLo*Ef4TbS5?z(infmyz@G#!(
zRWEbmHW&Xx@zYL7OB6BJ`vV6@lCr3wU1
zB}{uY%Qvy;kf9a&!HM5=_rVthYQ>=GQJv9KbBJ;l40th!Zm=E>^^Twt&Y(pB5T!Bwu^ropzmmZR_vB*#yP#U`5WBn!2QmR7Zo
z*=x=+IZo*kRA5*t|A+#$+~dzox>~n>bj|3I-^?54iSrcXVq}zIWZ+vlAohi002u-E
zflUZ{?$^Asf#|3=Ue$1&dXuNE##AF+yO&IPQ3XM;5XQ_ejB8=I6BUs`$N
zWKC5)Ls@&12~G}uEzL&O(-tv6PV5!TB=pfxzE`d)gtczOkzVk(JS7~{aK;?*^-yX+
zr^Pzz5AmFOq;HEsjT*}`SMocl25Su4
z6F35b{z^a#qmZgZapffSr$M5L$ezgxS^3PLdr@+)`TvtGj>i3%b8cYIZjLIEnE{jk
zNq9FRE~4g95^R9-$TM1hfQhbjrIR$jsERj}&~Ec8mg6qb!yz9_QO_F45=~JU4)}ib
z@F{mF7&etn0rIveAsx;Jw84>@X1~DzdFX(Tg&va&qxfECRDEB>}vQMm!aoXeYAP9sq50|RYms-ny}5@PX|xg6Um
z!HpOvQHW-X*Hmr+eN_+bO|`Are7kj)QuIAzLJBQ_P0tfJAl0!PvQ!1qSTU`+B5A5G
z!c2laoQ^E
z-+5%Z5r`YqrT)!xEK(-v@uc^MnZ*5eT|d3=#o13uKmQ{$|NHIJQhHfm(G+$i9;&O%{&Qc=2>j9*r|9
zBX=<28UE=N`Ya1Cxt92J4~d37;-X&Q6ukmZjus}Wbr;}uucgVIjPh@~hkA$0x08E!
z4n^TOGLeLX_Av&*PhL5Uvh!R8ojB=0IC`{=sB%;}3zg>Qo_*BZI<5CZ3$;{M-KKFNUhUFJl*#iOMadN2RI6yY}#>Pk4*2j5r&%
zD{oIV^PNY~R-|aNXBTO?7lzRT*qUAvOoeKTBtuLo6fB(W462z_aWOOE?Kf-o9qP}6
zUb+sG8T~Owx{>qO)mnP65E}#FR$Zekcq~QaRzai5lT2N}6H3F;2>{LSGns#RtGNMQ
zM?3e8fx%C5magvx!*eBXxAn&)A2v%p0?y}t1YD0M%~pL`Q=QvJBX5J-WWRx}w7elG
z*`{n6U~b>HZf`Tr<>G`x5V;do6GMvQ))b9^Rzya&_ql0d2{d2-h~Ey;NEiN*&91K5
zz^7H{yGiz#1b~F-6e}<|A?dO{+!gbw61cp5pf6$~8n9Tz&hsG$mGhtxNN3CCN71^PXSc-YtS
z%^TKVY-~9SoSI~PVe1Q)fmKDuub_eB0K(M}wv6e%DfqMb&B#0?$GE%dbz+;=q<&?I
zcQ=e?n(F(Y((QhXkHZkwI^g!H*q)JTn7sL`>Zct03kuZT?bo|k=fmILknh>5|NWW!
z)mZ$Mh@W`Cs%!KAKl+Ou80{TW@=kxeo*}gAQWcY!Qc{)TPbkd;ZRlj~#%(j~%8_q$
z8@v>l!{pE7?0`{Km>WCkonFXChS5106>gMU9gH&l5y6*|AyA@jLTE9)%ct`1`4pR;
zWO1rM-}diruA4oc-YM4Uve4tu@9r?Ok(&nCh(==`s?
zJADWaf1H0B!aMRm{%Kv=Cb_H20vamQ4|7@oOEn6RJYUg(uhla|sgNpSd>3KOB*SAG
zm&SD843}C#=8=^7u2fbF>MVL6Yk}1Juv#mk8uO<9Yp>}QA9&t7TAvj+5hFVu_d?6+
z;ri1_6)rlOQ3Ea(_B~46AVBECdy|(REcs+#xKg6(*_fWrcEn=jq3|O*06`CmFP--$=h2xFU>6f!Vp*DI6n?~ywA0})-+c&qa)Q>H
zh^}Df_xuuOd{nV!?FSO&7xie@hX#qKBrdjJ9(FR1B4puF6NmdtsB!v4?;xg9jcqLD
zxhxRnIDqeyqja!!h?)iky1AxgFg80N3bsijJg|ye5FtbpC5)ZiGR%?(^f!YY11k63
z+jktqsef)ahGxwq9)@Sf9&XaM9`7>6aBv_=)&n~!V!p@t$}WTg(Mq_4S1rSp_72Rt
zWR?}4%Fvnw)r#kaCj7-iHTNqOf*-y(mJz{u4&orYd4HacsJ4{YCkEMCE{cn-i^zH;
zM|Vi=FK8GGJ3Vc45q3V8-kcm~Rd
zb459Dl-TErQ#im@2-k?gGeL@n}l
z?5hn+t@Le5@|P7zDlk@-kkd}+
zj1P}`7%U}BK3z+TDHsW%$`rV`rs=+V(Ip$QxR3eEF$_fQmr#U`1|h}|dJKAU#zAh~
z0b~Y=YB7Ndz{BILATTJmA;e!oVR4WQFaHzRI1f*UiQni}RwXAyJ$HaQap9$<@dA2h
z?`3>8hn74ek$d3)NJ{F30-4e!`WB48pdg!h8}9#0@@#4;kp7b3-qYzyK_hqZZZ}?|
z?XG*O>fsptZ%a}_&iDG3J>dRi%4!mqzB5@m4abQvP|@Q_s<|p<%n-BE{2GxmWBLp`
zzfl8a5!b6vuoVVHxbD`};o|<2FM(dYarUIvZPYp;DQh^x_mi
zsyy;Iy0|vCH)s>}wchBNQ(KiS4bmrB6^VZ9r%rU+wZF9MB7`JHH98%8d^U|LW<%a)sPW8UR8Au!;3U#WdRAQtV&EuRC
z84-{6CECqmW`w|(0jImWrRbh>bM`N(|1wv+O#$n1P^>1;uQkVqTG(^1kNU+Jy@&t_
z*6*W5|Mi~-FNi!OeYe&Ll!V2-&K`nWjuxAIaW5E2!>q?kx-)bX@eYEkG>3j`y@}?r
zU`p7M4T-@}!YA)wH|$bIQAPNsa^WoUtkAeR5rTkSfpq{$P@51)AP{p0yBL`A&_YDKV4gm
zUvBn2==vD$u^eV~HA+tKa2*Y0kBh-TLsY~QdNm0~ikJm4A(^nEdv!aK8_?&)aY1}k
zgj2LmE8c_~;mIF{E+ZA>_?NeUH#$f4l-q1N{!n8r$vT2U-@jTCY%1X)ycBaBc>
z&D3F)6ECbuI@z)=P87Zzq#tM`6s?&vI*D~n6YG8A3~jInjT#oXA*E_0nV|5`e1U`N
z+QdLeriw#-oHQpI$y7c7v|?~Vys8X-VW9sA+!)7gTF>(LE9@`tCHMDk!_k2|qsxzn
z54rxA`(pu~59m6*-6a?s_g6xC-poq+-yALbF4@c3)jofPy^4pDJwX^i_?|+glBl||
zbd%kKri(w6=%l*Gsc%i!-{o66zIZzt_DyT1Lt^CTcXG13Zy7fBgN@ZICZ=aK8KArs
zDA5H8{`RjKC_!)BXO^+gHeXG?8n+oVJ2yLD8(*)bPhL+wG1f-0=TfTxu%F^jec>?b
z@x;U0=VejN!_Xq0YRk7He{xpXw)Ae54>-KjL#&*L&v;qO*bgJmEa15)s#ntPaOUeere@WZO`+gAChXQ+0UrC5>`
zsf^_%FDzLUVxV_pGo*r8dpfbgMqXP59W%!yJtRhRIWB66U^GAKrp|+le@^ZYdb0CV
z&xk-67Haq0MT>KZ(aZz;4NpSMJNZ0jnt6up07K#9D9yRsy)6$3zvG{_1j~N@kE0&%
zJ{#%!5iGTPKVDb|TaB#~yc56Q)=ksAx_dZylH+?;Id=4TGu1MTLuw_Qhhibe5@Kfg
zyv7lT8)!ucKnQqpl0SE2_!FAC0L6#Zub?I6VVDwgfixkmEvafPmM69?*{M2HHc6)6
zi%rbNMYbEygK!1`2LmAuCqLMpkgn3&y%tpZ%D~I8!e)mnt;a`1WX`0>uwm`X_nJq(
zFsG)72N5b?F3Ho-qF^imvrhxEkHpT(H!O|E$G<{@S%~hnL=XR^Z|~%ys$HdOhs_n_|DDmu$V=Sj{etm*lVxI=9@*?311^`cUy!l!H#Z5brm=#QBSJZRLljbR-<)z9sSbVv6lh*F
zR!GqRA>-0;21Kl^ftlj`B+=`h!q1zFs?*~f7`fSU{`oWv=lZ-^j1IH`Vgq@8XPEIKs@&`~Bv4lR>rI(^@5g+DK;1C5u1G
z3|q5A)uw9Obm2y;OhG#^LMgVAY%0%f-TK=~-Q~TSSm99&^#Sk}vO{G5=^@_tFrueK
zkqHq)Uq@u`mTL%Dg)nQ{VyHB@Sw+}Ex@1u?I1pWaxd0~OGyry6LV}PPuF4NaPiV%h
zHfb~$ws9b3jsI-rQwP@S(T{SF^G<*UIGA*V4`
zK(Ag(k>r-;b!?*moCbd;BK=uyG4zHExu?N9p~*jV)qKx7GjsiJHU>#JLT}^gm;G+8
zeiq&~qQTjV@T1n7Uwdil^sl@Rb}1WmeQwEL075+ioPQ)>6`l@;w>SB0sUcP;et6`*
zY|Vx_kVttga^p4ktVr{{Td^$qluxa@wl+45U7zUk#R;a-$qkE;Md~XWa8ug8B$$#t
ztr}ljhV1q1;ahRk)`wv~>BL^8U;1xFQ#R68u3#WjW{^&8aH(S5s3r)l=2)i>)ncew
zp;Pq?*N=}`{&AYRpqQC4p~vcoSF7HJH>udiEam;Vdvu#VTRIJIobWpP_a^>uvB}eyN_jP@@rn44)7?U`
zs6CHSS(kqG$D@70UZbAyGg9K*cb4(bFmmSIZk#&EGwR~W88A>7EX1&2>uBQ
z>Y6`+UcpT5LLvujSD#qzd=^hhUFUW54uT<%F(L2T6Jo{2m7yL8%S+h)yN~GyiHNCG
zo_cs<3h4^N4QYl%^LK@cZKA;oG^{{?C4`Ur=;*XvTnObiyIi9zhF&oGj)<13G
z#F!5vLi0qJ3e|1VK*nYw5Xq4u5Swb@{Osw3(38>YzJ)Nq=%r1_*mRTEW8%?3=kY2A
zBf?_2_7NZoE%3#j`j|5EZ>Fm}>H5WcX}08d#$R(KQ^Y(jLKW!o`E)*AUv@mHzOe+$
zq72OK0L+QoW3Fp&ioq_}15PaNB5&4D^7WhqRmOh{loK`gOht~OPGs~@L><5-km|7u
zhG=mNq{8BR_5f=(8aaS+JiT>#{8y-9=YATza4F&a=6s-Fl;N>=^z>-)`&Hi;oTFB>
z&GM@kCHf&Y#V#V(K9?vIli>Hhd|ZzS5TWf<#Z##0a3t4LUI*d7#VyO?Np
zB+<9!sRUNj1(vQrVr0;sH_KU%B*O4Kn0fY<4hM}rS$<~MF>SU{nfCRsZ5hU|6*gzR
zAqA;=jdfu*%Cm}Gdsto)3FcNJ_okKZ@k+fHNKHrEXqa7(
z6zd!l`8zN?+0w~^84nTnE*O!(_&WTBlDrU3m{1J`U$q5j`Yf4Ng?Oy5)c{0C*4^bp^)iiBBdK!CTVJxak0>
z)Mg*(OPH2bZBMqRJf)Iix+=QeH{I1&5_hd`E^uS1#c395o7cyKuoJKxbGjmwUwod%
z9n!sLvX3|TrSeUFB6W2&O(ERuX5~P}?BQ@OH{fxjQc_&3wY^4IAHW<(N9D73J{9oL
z{k+Gl?dC4?z5n(3i}r`hfZMk$HYYbJI(o249Y}zu8jozs$EGMLDN3~gElM~3%At+v
zl-hiwXYl9>o6N(YmZy6;c9{q?2N`3y%?~H15ZbMPAA(N{>r~*8;n^pkdzldw41nv!
z*$^qju~eBkEVfRzIybwck%;|t@-R?xmuIX@XLdB@xJ7g!1|h8O;I~z{CBwl6O-
z!!c=bJ&V?$2VsxpihJH{EF~#;Kl8yZN3ko(TPy{N?31k}DyN%xQq(zD$
zaAjw?7Q_O0TD!vAD23poD#{P#F@PCLh=X-BfMzS0ej1r~YvG-L>FX!()}qHHa@4rU
zOBojr45{EjpT22v-@@_UZTEGAO|<0_9NbTIv6lf3D@)*m~1()%{|rRUbadygE+mQ%`6!=}f|EqZz}{^G?E2YEBl$NRQZMd4tT5wp&D&3Y
zW-LabM*C})$UC7#HgtiwjFd8X83t?Nk%rNYu`DV-BX
zjj`E_G>LJD(HFHq*q?i%)e|&VI5XT`Yhpg!jjRi}kMRm9STw0wIgLA*e6RB^`G{1x
z5r=gF+?7V>@A@~s-RFW;YIP^~@oEnJ+Mi;7AMkJgVEO*^2QxGy;9>o=3XP-hwcq{C
zME7a4hl5=5%h_veSYs|W_Cp>>mZ6w%OAultGuo7=Xd^h6h|iy|Cs^~tV&hAyz56dg
zv7JvDwQA~ysi{A>!@IQCOJtxj{qcSAUpoW|;e=2Em*NBoZyt{`yT3gXJ+G?NI;9c}
zgiq0q4u!Xwb+p?-c6Hlyl{bJ;hhLgwEmRP3yb)K+59`&W{|0S5D@X(LKNb7iRgmU5
zO!X+}xfbQw#}&aA2QC~(vS9Y7O7*+0Iyn8Bs+ma^g8LYvJP8T)HOg!bTqTQ-XO*@a
z40Ou@H)l&z3iOjFr5a1TEEvsAmlv7(624nu-5dd@ea)9kZT|)p-oI?}xLy6RfFwcV
zz^B`c0=;`^z7-c6Z*ejuKVxo@gPdqZJY@QcDzu1~ynmUW2&bS=5rIL*(tTsxHUAl0
z;Yh%0{ATCI4DXvty($I|g5iMLQOKiGQHEU{f%Z?xa$oVh+$xlQ{R^pH=3xJSBwbZN
z6W-h2#(+^{z@%fOG>C|lu+iNhAgM@;l!VkqBi$`ST0~MrLb|0z0f|u(f^B%0$+X?GP`tb2Ss(Z5@_P=>CI>0Z0`;nnh!F+Axuo0?c4-*(h{r2AIR@0S~EI^^JS
zbDwQKo0q{x%q4R<&9Zr2wl!bYrvPdhW0uD1WQ-<;x)@oC7_
z<({iBV~}YgGI|j2gyP4q-$}~p{lzQLLI2rl{37VZyGm51$r4Z?Is*|N=WL@UN9MmZI2(Dc_=FVGXi-K?A}gAWu|
zhvbm#UqzD@lB73#mU(7qQ1
zo!M#JO`t);vntd^kr<7%d)jQIlnQZ5Y98mQMIRJ=^*g;N!+$+3w>w+ccPZul{Pyw%
zHWDJ|OM|>de!aAMee`?wY^mA#N3`4x?o|!$p!;lG&i`0WI&rW4^0-rmCf-llRShgo
zRSi_5F$xdZtpu7zG~{*-vi8+&uJxadPXGCBqcGT|(D0H!$i;-o4HU^rScU#VK
zS2T;~X`4~PcA;YvZ5tG!OBPHA*E@=GA_R0WZWBWQK5O693}r09FF>fEB3J$Gx$%~`
zc8=X53a&H6{FOb^+R+O-SN>IP5kspgT`}bNYEnnz-$?}JYakXoS!SUgd7b%4!KyjzE#jWKYDlz
zkIR`MdZ95xjO^@BQ{a71+Pk(K4botL%R@{xjJJ*`3s>{qd0;%3KVekKFzzGWxNi3I
ztJK+5_$&X#S2i&{T^K@DF1?~AcW9uR?@5}*hD_udi%)AC-++p~gWAMb4-N{31*^A?gqPx0(RI-}>DNIM?mA32Z`
zQf4}C!XoY+3vcFQ4vgdf3
zkQ{RPxt*wr6T09=(E2&Y=h1p9p7uU(BA|E#0YGx9AWP5^G&lp{l&yu}IKJ{Ok4jTm
z`WQk#cf{%5`I633R?7G6bp5Wcb%@Vxm1bEc{#4GTCR(>&&uu9ljZ~c+`A!
zv5H^NeLXr~e8SpdiZ@M;sXm=bvU|+eq2WrC;6_8{8?BDOSJMC7s`<;(teEaP38s`a
zo+8p~X?U|B?GwTn>m!oe-thAoi$^w*W4p?wO^?vN4AC?8W<%Dck76vvcVPd!Z`J%v
zM3R1cQ7cvOicC_g`+xbq@HL$de(3Kn&8^9!&etJ_|7yEz;8kF$t<#u%R?O_ZR=JT`
zJ37W)P^zM%&l`##RQdV?_R^H~d|EKFYggc_0)w{46V;fZ`h)QAk=?C2fMS-(kO>w)`cX;qSj5Q9%K3kKhlIZ`fuzwT73Ah>06B@l
z2m%nqF}-zOPwN5aCs_*a8fVa}q+hG?fM@^;Z~Rj%1ze#os@fFWdbu+N>=u*4lo`w_fv4
zQ`s=ECixo#$N?00`=0RlfH^TiJW7Ji+=`^7Md%8er|p
z?}4ldy9l~$p3MCf8bON}8Xnzc(hrtfe4=LR0Yi6?T;=_@g2T6^>R1u4jt@G+dXs7z
zO5rJA3jSav|>_zHfn<}#{H=Jv_0&WgfVV>{h(o4EYj^YaC=#J$DW-e;fs3tFKx2b-%8
zS?B$)x7vK)K6=fjvAorNwit3Y`8DE=qhFC;4Z~nu+V50&c+nFs@hf#SE+`x_VDlbx
zhvoAsHx?tZ^m{Kt+9m_jN>ItCS4DNp%+F1~xfJo^IV;*1A{kXk7wRn{NVV%Tc2-4B
z`gJLoG!HTms6(7W?lP63@qN;g{SBDVjE6I(-zml}4h3B7WGc=H{VC$%uMBMVAk*f3
zT3HCTFVk~in|Pvnf(VVkVjn=hH&ew2(+jy{OPf~#MqwKFvHEAhS2x@cup3*)fA{TH
zMS4XMu}qonx2u&;_m{4Iy==eu{ntxJ*e5f9iBq(EA-sGh{;l&5(vg^-2{Og
z#irQxvu^{9+})F?tBw#lw#43s{fX$^J+qG
zaLz@F@vUI7MLQm0Z{SyOH*2X5x^h=LTlv0A&E^8V@$V;Gzn%U2zl&`ecq0;u+
z;QYa=6K_O!)U&9^9T9>QT9elZF$bNE5D%Bbxn9Qq+3{vDzqOb+vNPn3>Ya9i0xwKV!=B2-~L7F<$r3jaLYya{LAyOpE@4|_bW77
zOVOj%^6d|&M!ur_6xE
zY8^GZh*12_>*?D0a3Z0OhJsp-nOKq{U*eZe>E#iS^ckU|jH(jy`%0a;LLYw3RF6sa
z)KYleDZhPhk79;ct|`dHsTsnHVD7Wx6bjv5905MXq~B?>L%U!LRqtU%n`|3y?{wmc
zZ*60a%MR>#`ybWomXPuK>%G@LS3e*9x*fLiZoCfKI}ItfbA2cx-0riElc}!y8vJ5?
zdv<-8E~DT4p2dc0qy$7oVkMPZVE`x@QB|bKzHUs`s4rtgHggvT`;dHbCJZuoo>X7mNj^%
zlH-V?^i=r|G=L7gPc=^F8bC-Yp>WT&5fT_Y{qpu=vEb{?dS=MY37+ISd2D?f8NHtw
z66$iEczbS%c-kOYY*O~kF?ql^%mvMh};{_F{4fv=)>`eDp{uSub^D}5lJ+ox;z{bSM1{7{j
z=|2h#7Aw{TzhY?q^MRd8T)xY{vA^;`hZ9G4*&YQPFQ*dk$@}kj)~ouC
zN5O8cW>xWnfYhB&U1f-iVKXnjXQAXkLNviB0zxxDlY`VR4duY&3DmjtKL{FqGZ%=syl1N74NcAy>g91WiXU>i=iv@{j5l$v73JdRP*tV^7_rC8Mss>@J
z)fNp6v*VBimH&f~M*Cv#)TeN1JD5L7=u8I{yhms3mLXl(_H}J;-&NV~3Jct1e;69z
z5us=rd2~)lT|)`HCyuA|_(Q65JKga^3(H3;zckJF)ValaJc_925n3u9mkTZqV?uo^
zDSF`&9;eDmi&!wUi!RN7^Q{hbWvp{NBvsqdC;A(-c0_1hrp_szQ}$e3_0g|&OBdE3
zPgKZ%Q>7~7-3-@cRz<*oGsm)$lqLyEnWRSvR;UAalc5D$o%#^(G<1D5n}}b@w`kCK$0I^J&<3dBFj{W!o6l3PXC2^8n3C4#7^W7`Sfl!OzR$sjtl>l@cTns9le+zGAG=LBs2w3}7k{X{i$(y33SF5k?&r_9^t9^BL
zdz0&^MV+7?rtgH%ViIqbRdB~Fl%lo|IbS-B86z=OG23qIu5~dDefk`ssPg;qn^
zXs1fc{p=luO2aNstL>A@5g(Fb%y5~{YvV=i=$5ghtY<5!ICk$4#fdB&9}jzoAW>QG
z%*wk1ACTdykMz?>*Wo*qdXP$zqoKUuxas_0WG&0dZBqJ??OVnv78!c!AX#t6f@iOK
zLk=Br-wt}RQwPZ$s2y~9Mn9I0<$bIEPz;E8)_)`(LZT;`Y;87DAZO;c`?}?Ss@#~M
zk+A!-*M?3|Latlc;XpBH6`q~VF5M!zms5}Q%I@j_{v@ks@gw!-*u*i{5Fmj{^xBT$
zpqD6G93R_jmnFQOu=w8T(Nnfb%-s@bdr;qU%qT}J*V
zR-^x%2}6YT3RpDRrO4Fh_?ykVKMe&pKURhgY6$}1=`lQ{(Cnz|4qdronUq*QkIwok)A1$GpggYKOJ_{=_&y=+in(h|>qWhFqI{n26JG
z$XRPnjhYIE_XDsfgl75jZf-jKDUD+8d*m1P^T*5S-5(zp#DPM-6!;!i4V3i1H%c`q
z@wgdr>2tB3t^qwd((ANkdBtA@#1lu<=5O+En|z76x+(wp+;V~>={GMtLPW&7bpM@w
z4exk@g+~%S3lGav$h4s`i{yhy85yr^bVBD`n<9BDQMApgH_5jE@IOH{mYId`{T|59^~e6L
z{K!t4v`diZm1T%2bqwD-524+5B{H_O!4J|oX*~DeXedACuVA|KqJ;O4IQjk6A7Pq{
zL1d!@nymCutE#eP2^W-mUd-~0k|EOm2d@9FD(IyhbV_wTmOj>9OJLCq!~dp2?eFCa
zzJ2thE%+efryTPWH(_sd*xJ`Y_)~ul5^>x>pv+e_<^G;4$r!>l3D39OF`3C6Z}Nyi
zu+)+9c}XdP(VBSE^xf{xU3?{QfOt9&{>;qY_!c-C>N;n$>#(W{3Rs}=yrIEX?CoI=9%
zyz8$RF=LR;JqYjdEwfNGKpH7>e0*iM_mS=7@4tz~{M#Ag-I`0)wt(R8?Pqrh0z$-Q
zE)Djq^j6Chud8cLpZme^rx!D#f#p)w?6TG7>pN>8XEq`r#%;B5c|aVA&U3Mq;sfa?rN8+i(CM@lF^363#V<9X=}T
z@Tjq}!0GzO0;rJ0zeU!z8f4S$QW=Z9>;3IGbK85|*te)S=H+Vp@7i;wDYR4u6y2>4
zO8cSrM3vm9p-3ecu=}qAYy&Joe@&L~X14$Qh8jrWVgca8BH%s`^&=b23t22m+}M=f
zaKKE6I9$W}%4IXgRaP0d``0U4C2}&>$#Oi+@TwN)2QMlMU5p;o)BGrry8KG`tMmEK
zl@D9T&YN9Zn=zb=Q~hBMI!eNCwckEsX!DbJb>sc}`__C6jgw?_QNI|X>wqR=wX!#z
z2B~=3HOu@z%(GT_k0_!?;jY9|!e}GsaOz;tlo@y)Xav9_4{c=!tH3F2Qi-nB_ADi7
zcWO3`g2anzS2l_}vQtOSxqe{@yK;5?75F(ueq>s5&L$P)Gw#ADR6cML2>raxXG{Pm
zo$kJ`Hhb5Wizeb{&X9FXE~z1hfo8L^B|P5MaeHGh6_jL$Y-JBL!^r~`s&Ex+%z-y|
ztoTbuM4_(X>Ea4yDl{Jfq4wEt2=kqr3@Icu{OFdRB}fwHpy_Nnl{iVqvC99I(G(_|
ze6DlWL%)ynFyrP?CXithX#ihil0!$Hha1vwy(T>-xsxB6
zz4K+aWm*{JS{S8$`2)8swpXM!Bi6o5Riu{PudK{o?Vq}vuz?IuEgN!F7t0&SmrehB
zp#;j@kp9|!{ropk1-CDe&tv7IzEw#kN
z5mXKyxX4VhV)E>~Xj_GT|2Mmoxq8Ce;|Pcy3$G5~eP8oRQrN9V`tX&Au%sA<@eP(a
zQ$C6o+lnJK5(^DpS}ZvI%l;5Zh?-EW+1$InK;8<35ik)EOC*rLU}0I55C?p9Wnh>W
zq+g7*QJUfED4+-N;o-R!)&`B`CwK*ZqB`i|nu!z}S0X}UjKbn1BHzi(8>oG*$kGyZ
zIh7u{hCZWg;U-_;C)IP$IR%k6+%I{C_!;cF@3)lSWw7a7&$Ak2w6t%|+A7L6=JI
zO-z?_sRa!s1a~10*)%#`GqYwWicB^2&|#u;j$}l0buokB9%(vLZD19-g}Z+VYjbQ~
z4-=vmz^ue^=x$0H57T{5O`Sbnfrw@ug8Pz
z3S2x?e6MOY);#t~yhyU5kIFdcMtR1pzvVw-Y4?VDBD@lM6#n)&yPYWA^f*%~Nd}d^
zW|muVZ2bSJPVw2Lz2~LF(eTt(NyYb@ik+{6QM7ezLLw?0Z62S-xZ}3U
zg{j`vsxU9FtLJt5p+1Ed_4N1oDKg67h$9JZ;EqC8H*A1d#3XoAam#
zrcyKy-ti2`i)0TQsY|^A^(g-^8*8x@uz~sA6e+VgjC!ZEjy=}GUvQ;xadC2n%=9jf
z8f>~rvO%=QAv$=z1(ijh
z-i-L9<_O>SxvlaU!`Zmi=g(`3kM2W9`
z0`4i-a2t=)A&EvjI;h5N>rh^7=t!Sg0%5JsT~#Ud`Zd1JZw>n5#D6ma84_Go$!PZ*
z%EHHf70NLZI@GTz@NiCFD1X)W?D7^LZs1eo3*$OVGUN@IQ4z7l0d#1)`ZZ#md-Gv*4(jX;L%$y_(VbANR=J`H?
z)1wB#_SvYefyVW}faq=Y7g9Vfb@+~;jxy20)Kd!X)^2^>$9&+tu;6~I@n^EV+ASXj
zBQ6>kGpSf7kyN~lYbfJ}q$wR)m#xKyHN*2~shnX+?60Qb7h2r>CsT;m-P)WJRq*FO_9OAFxX)Bn+m)O?>Zg17-*dz=%6BNH@(sxY
z^Z!iI1R$nuL_ub%%z%0<_X=ne`PBA>?uMtCnc(|3qEyPt`~uo{(h}bWdS9)HBRhPZ
z!Ejk%G(Lqr{GCRK8dP|uO(ECi`!ZGi5J(Htv4f?+QGr2~Xfj~KI1~~|z+8x4sFB`k
zY-o)La}R@9CJw_KJz!Fa
zQ!_Xa{-2r1nFj>`pXO5;YJ=064hCsn&HbZ7DN<|S+6jnG6#oNJX1w#(bn*6EW2OJG1=@?^Ui$?v*dnBl0-ubB)yewx6&@uknU*boBj
zIDXc!!#lIbR+JtPHvrJ}6MvH*893=?8W*{J!OY9_vYU^4nJaELL4^jyV0cd|02mv
zzr$@PNHr{sCYDV=S-c?VpHnYi7IA}faaPng9lV-#)od%t7hVDoE
zv3%h?IZKO2Po$d7(TT|a-$=7Kj>aeNsG4xbXImjSu=R@@7RUnPhg6PIERurbol*N4
zY@KBX_Z{YtifExCFuc4DK#-^@PAO|S=Job78gzVRI-+^M=>69NqIeL}x`qKPED=C`
ziYevy_yU~ncmy&B|>IMm?syDQG?)46ziVOf@`Aqd9sH?gK8Usv8rbGzf(PY8zd0=n_Pb52|ariUO
zasq0I2VXI8(}WM-x!y>a3tVcSniSHSr7hjPq|2XrmO~KxnkgT_|`|gGSYsXbd!V)6WxpimXPIzJY80XU-G&6
zY-KAPxv!JT?O9}xq^QP2@mz}ZpGDhi?uLQeSJ?m#G(73raKtUfwsd5Ff+Z3mjID1h
z77IT=-3Lp@k-hba(4cg5@ps{N!1prWOdV=8k^8*3`=>LUK%EGOCZb|&U}H8y<_dYC
zZ3+ho@8nECq{U|yB40127quB9IT(Sq)@YN!u1Lg2C+H(Q>GY3Fxzm>2pl+*U$`)?p
zKS&Bx!p0lhuur
zgu%>U?0@ZPMJb-kJc9!QuGW2j?W+PsLsd9%w^CG&hxixDFhwO&LV=DPLw21@bZJ8)
zae8*mY|+svM-5$Lq=!pDDNurXdG6wi~VObZR0FmI^9Z-v{
zsQ95K(^)SyD#nN&=W{$NKRJLGy}r8>woudmjF9D2K_onnKok#U1nwD_0fm^A{@41K
z(rRiHMwUe0)U3d1SMLs6s385r15!duISgQF4Aj*f;_M3}oyZlK$zx!yeg>PAnzM+K
zEK*ExcA`cYN2Nv(*?|aVcQAI{HxNih4~3A5-yISFlktK$!0iP>
zH+qsB@smSpP8{0ZB{5B0nGv%S#{91X)dP2Rei>Cd^~?12GW1Wz1v&Lebs$N>zil=PUR07_;<=1(C2`q_)+wW9
zP&hc=1(9`$V^T>m!wJB%P&Q=moXS+@&LXr`c7!AHTvhs+yy;qf(j(=|=JfF&D2A!3
zDpl4She*=cWxMq{^c$pBNumn1dm|3|K4<7WoOJ#OXLRB&cn`QtI)vI^b)!MMy}#Mi
zS3~6b(aM^>b}G0Rucu9NZ4=G#vi<=uIJ!ftM9_^g_VTAWkQPQh;B~eju)Fn9gED`mq2Nszu{*+RA=d43^llILi#B2
zKXz^wgVrs1?LJk32Tw1qE)EZ-=O+w%r|1~_O=1yUwW%VlEKF%#hvIdN$+pj6Yj9c~
zYKSO^A))e-wo3VV^3gzG7RXLcnwfU92w#~-+1&mh1Kwv8!OC7xk#o1uWlkRpCT4mrFRmQFpa6Zr{fE(^
zi1JSu)NofaTJ%u{bCLW%p-VmOa_1xx59RwsPWJfBDe)JB@_CeGhBt-Y?p%M_w9Zvp
zGvuN?C}kTLYA&b$l({WPlEuF;nrI?$2Z$pOG=3hyDkJ1DgA+-rJ6ToSJF~t9Zv)Xf
z;Owwg4-r2SiV}21`yw09I#J}V%=B~fzuKwnG5xslj1y?mJ@gUr!!ER*D2KaKN1-U5
zX%n2+Q9>ItEF$O^!10LG9UK|A4cpAksFAmkx~~FXdGV8zZA-U5qNX@e3IMUyB`g|O
z!qhiWbqJ^aIcHln9A
zi>PrRwdG@V7FIE`5AJ9hu2$?OB_CEKPZWv<$-SxSJtkiNiv3QP5w7q~&xl%kph(}0
zqfo2#&R`ldV`0`~yf!@0YSC@ec}F;_D$>60nd|iTDVpEi#6g#IEKwQwr&F*W`b8u^
zAy1x4)>q8?!UAtez;raZuX^6RemL|~*!ZQDOP9p=e`=7DTMV4kGgfk5W|7BtBXoCkzl)(LNq
z$c`ScxZ77HV{Ui8Be^g}s|R@Q4xP(3@oSxJJJgj3d$#iQX+sW$8|OgzkR_X-p*xni)SuE)q(!a%l9i;o6l2J$AYmPcwh5g#&_9W1N3
z!6c#kv{r6PcoF<)_$A)(Vq~cHeion8RR>@L@*)ukjeF|fCkS|pyNdM3lE&sX?wvJd
zzmsrjT+P?_p^o{Wo$gJZLYt#a$j5y(`$z(Njw~&t>-JvI
zmk`Ojfi5jg51Y<6gviU
z1_s?Bopi79uokC-p(U$%!)Znm?7o1)KDWT4-pCp=Ki`VGnyqj7?3NGh?{WQg$6`$N
zLaW~o)&6SG%3&UlB4VuTJz15almMvLdg86)pG%(TbpZqQi
zwuYwXN`}|#(OnUT+u4(Y_t$Ce9#)E2Im$N7WbJZg+Iteyy&10ma$PUgMAER6Q!po=
zYgtCne#kiujF9+shqd#FftYG@Uyh3?mrYyGMr4BeTXyZ{l^saP9SvX^FZkPIe>bIm
zmBfJJyj+4?mRXLu-!GmYsut`M{#QU>WMx|$3eqSv!JU2a`Hdjf2=;jvU=E8(E9K|R
zEsh>5u8p*BFeG++H*i7X2OJ9-|OOYXT~N@`8`k84gHN}4>{Ns
zT0FRY_z^?V42+}Jj~Sl*8^?K(gjm@g30IjaoIs~Wl++MN=`fujb27MhL3b#GpUaI;CK6^3m&TA9fGHp
zJZMN59%ZkkcP@`8DpuF%B5FGxfP7&|1UM)-6f%iM0R@o-rBY;0RN+cW4^s>#Em=>q
z8oaH|ihL54KR>RXx4nOy^{Pd%*%C@K^K-BEWYwA!U(O7+?3TL(c(4m(C9;`=S{H|zVgXUl8Q%7)S<}@VCV6JK8!S2_$Nui{~!1o9=mE;Ih
z+BuT8RPu`by1qZ
zlbW7?&`GF1W9`MQ9IR$rlW4Y#i3XYCqto^
zzYi}ra6CA^Ix-q};x#e^2h2hn+e=jwR&UcvyQV^L?K4YOGA
zJwS3%cNiTTU)5`|1ls&Zqw({-cu?ZBags!Wz;h2&>B!wt9144GEcF(8dO5s@F3qjn}eROxL{-o3M|u;dIBsUW8ewW`MvA`qa6R
zak!y^y4Se$WZ>E<4`U(o{JHn_e~6*`?**ANlsW25wTKEr+o@wUSMK4}razO^4f%je#nYnkpS7k_-Y<;nG*UDm
zJm*Cpl>YjR1H(^8o=}RkJcc&m(Pmjf(^wUea9)CiEZHTj&0E6f$ocQTlH)3ui^tUp
zf_5*hge+PtnqQZ^-qKi~ESbx`zkZ+2Syh)Vv4D>)Ym5Z)jntGL!vA7xomUII)F-
zL_R`op`sVX(`Znd0=uA~ijwjb8;%Ktc%$#}?IG^-Zv1N^&cDEdPyM#@B)kZ>cCVw~
zC-;d?Bw|?&0-0KL;VoXw*p5>(j8;-|_EPwtBghf7yW0qaJcUxWcF7EE*vdZd6d<#Z
zj3ZACrMJ^nS0cwM(iBK)OG3`??w4)G&PtFTPwo@xgujyBZ_#sN)5VK>Aejr1vr0EGeUU9j+
z@ik0Il{?xfirFy(r1nhsM4ho_67bH91o7&=2flG$T)_vUWweP^LHhxg0ABZ+xOBgFpA#;4Ky0Pjd|Y7H)UG
zANB-ack2LSXQb+5pu=%?*-~NAA5NpV({9-TpbN@n#0imO40s%%O9dIeW;f$~50*iO
zyMy=A!JVPyT-hnA?>GX@#rc&BzzP~~g&ZpqlF~rn^fx>O#BlP9yoLpFi9b0emiK?$
z)6zBHaA2W%*2jmlnTU~WUGg}_9r>)7$Y(BQ8JxJg#mWeOr|$`$W#`WAL%v!G5f+mz;;6^R0#dk}Fj(MzCA9_t4eH
zLwaOx&HFAnawnIaU34K~OcyB$KOIZYD6JcInaV?gap*sgzGyCHVk*oYP=>Iln2zVZ
zBZdeT6_YHv8K!IBiZv%N2(lLp&9v`N{&+9g>ph8tyBZ;A$dsREd_{9^JVJO+%@qx(
zh{ZkjlXFM*hH~sqEDHX^gUxBUxjxr@>fAo~*63rtR*!rhNwpl%B$o6GiY9|m`6c(p
zdqp!NggUh!r)r;Ft~sLUKNiM>tMo78r7@c4TWkoneopJWh#t=RppFr{Wt{#T$x$s
zc}qLHs$>UM)p+!7$W$9eIdCh9WO8ji|H1*ZaR|j+qDU)N))Mp80a!AjNUd_}LYYD*
z?G?$K59SVhoMUEX^KX2io%nH$rO*;lFoRJzL0QSeO@@P+%j=Kq1zt%i%vYh_YRpFo
z@Rc{NN<$kDHr{RWKK-hH2(>j6+Yidn@r~&SJ@eSDG8&(JkD*rVZq~v%q7zN0pppeu
zBD~v&Qqy+}u2zOcZqa0ZpcHn#?)68s5xH0<^$16KV<`icAnRx%5yg9V3SJ{)S)3*@
zlGITuunU4vHTVxClz=*Rkj(!@T6P5d(zFJVjVl40NvOVp1!mi8Kdy3i?EX}0+xjdo
z`_t!~<}H$=`G)7gea+$yv+a)7<_*lI5^OSSvMr3VLGvO1vi2so2GZ+mT{c!9k12mF
zNc3WMzx)q%{x}(`{0Sj_T>U`U(%GVUMmDH1a7Al+Mc;BhsrdkB%vNdsEXwrw3{IM{xQ!
zI@kXEi(o+9`zn)#k5OmxerLN(JSRRawv^^!ucI``NpWx5vhijH!l6m3xgq0dJJxx`
z(-w9l%YIs043qL@URVhk^>zWb>D#IntH^^s%s97j^{g
z58~WPf;bK+KeqwC%bCb99J0`Qt6N@ok8phazmNqWEKRc^nVoV`H8z}>&Qx<6Y@&xn
zmYEdA0GgB@554x0Yr>AM!@aG)#Nj1JrSA8}c-a|vSE$|DnKS)CMI9&vC>wDIR_P+i
ze#i?6S59scRLYf9=kQRMF5(gbP^P32Di+m-ix(J|O=-}l+F4`_PtuBHi^~=C$r-4V
z%xhPbI!Wy7Ci$BGdre{A*(&-XH@8l!VLG<{_qzX|$qyd>quy)SOI+|DY4~Urkre!6
zLF`f!tldWrUm1Ee?UMb|4X(yxA=Kv6=6Phk)ffLSz4F0KROREjN+Z4U4w(;mua_sH
zdS?&k?R;#dZ63+T(6}^Lkhk2Ht2Paoa$BZ8t
zQ@pooKJ=xIHT2&+>fIv$iSNLUU|WXZUanythC=afF(e$vH{xR2GD}|NRw|{8@p)i0
zIB^)|*@tOe*Fy_q?Mf}vL1;qHU`wdp2MhpH)&UGmeOYjx`O|oE$*kzzt=8Om
zoHQl}J55lzE~>yHn5Z_MO&U;ZpuQddA4^{u)>hYa9Rk566n8Cd#ft_h4y9;uXmN_W
zCwOrw?pC0<7m8Ed0u*<53dQ}){XXBn?Cb3FC)YkRYtO7%D+t907F(nh`t8RzEh(up
zle19jL0hN%auOvw30B)8|b$s)qIXx%#6bo`+euShN!T}0_N
zQazh;G$k2GfxC4EYjBwiV#Bvjt)pyjY!YTT~#
z%cI@3I9^2xT&`ir55CO
zBn0=Lw+{yhQ^lPYXY+BL^a4Lmj-V;Xtk?)wP)SRG)KQwGh75=B>sJq8r%DOFy_C`)
z1{DSrSlGEo!IR{e_2{9kjXP&0N68MYv>+23Q*n9?EeXCfZywIP2lJE68%Z~Jli%W`
zR~s%Orn3<8aIZ?`S*kC8Lqye2QU
z`DTh_h+Iv}^4oxxz?9N0G8=WqqoifRp};5^AfUg#PK_x;g%V0D9l{?ZO!dmL2ds(^
zOXMO(P~oL9RNNe=vL7YvXj)TX7$Nk@ub{}t1^RDv*c7~2g186~cV2RspuC(xxwL%g
z4{a#&dm9r}iCNn7@HrHlA?ynMpB(db^LgOi_QxL@m-)!;P}z*!!9>cm
z;j#CY3KzkI)7~igX5XP(XCQ0*Ec`R_HnA45OoZPr_Zjg&+$6niwohjC!FZJAVV3b9
zw7K1+D%YX>rk}wL14z{ZK(sHXe4Mtn-^9Ma=>}`0%QMg3-hw}kk@8B0V(-0?Oy225
z;r~7#i*R}t-BL9?*%C+@8gp@~z_?;gA3Vs5WG4fmNK0^yzhUW;KMRtU5LVJmlP+{#GyOeH
zf``o{{j=(N9{U%ioIVv4GGKAqZG}YOGeg|?B}%DDn{_2feWXb_L~F0`R};G6G&Zo?
z@~bsFgoppuH6SDkR3r|(Tci2}`7vz?4?%T9@Ls{_rYT6^4UYBD{tvA(qr?GNihdo2
zZK}MjHZdTBodV7;GXyI}`m75-K76U&_gswjHKlB8g2nqXZj<49hY90r;49KIDuHZz
z1=gXVlpF}JIGDPM6MZSWO@_&B0p6!>eZ72mXix``{##6A1`N9=!+*WoS-s5WP}RS&
zic|Lh-K*Ocyh5iUxTc745b;8m}Uc6u<}+{bL%2}L@#>HA*EJ@t>x&e$2TWVOttPY=>NA;HRzM!m@I!ak;r(_tjoDA&uPz!6etR1JfVp+o%a;Ql>kO#n(P#Dt@U
zPf;DfRq?%Mbv%}Nm+4g(+IUHi6mt_#vK&@6FHXW5tTSROYr)x4NQ6H#LKBs_Vhf7p
z%P1MUUYsrn1DGW0A)9+u=)o=_)mq->?5Lt4tzw>@(1Y
zvM#fP#y?Ub!O?I1;U-BKlWG?RSOw(XR1xZy>Vxk>K~8k^90QCqAr<7Q-^GG$*1)m9
z#h#$jm~QB}Xhu&uPadfjadWFjO;a7n=-in|m6{&;v{s*_%9puPzYt-VK70ke67)w$
zB6g}pczNq@^SMxvcsHp|k9>PHq{9Ai0AmNzBCIE*XyMo_I(FtvL4iz8kW2h2N~L*X
zFcJsUTPl|`b`?}>s(!+6=lPSf9YB^_gC4W)c`fq*MX!YdeCXE0bYJ!R_wt~}V_Wl?
zDGC%?0Hq9+td$g1-{e0B*wOq{*_Q*6OPN$ooqXKD`k^fj?>dY%BA6sXw@ZYf<nC)3S%h)N5(q=!CDvZUrrr$;TsR
z23;JTnc^x68M8(K#BF_2>cI-#OJ$Tf^iEm1fb=eHWMk=dN^@bB8vdl>4;W72rZ8O$
z$m8d8=5-(`?_jV>^Q$8Kj~@WE>	pwEYmICRNdYl&SuPCzBqw@yH#Y`WH&yDSOj|
z1C4urL6EXAFnPFs!z95dFDg}_#Tc(b@-kg?Ocg?Pe|)rorLuF6I=w=IAH|L{gu^!P
zI7@&edH8vRKWxa8D@q8ptfLhPP6H5VCBlJ-=mN*Qu*W>!78AEut=htIUL2t*d|%icTgahpE|3GOzovWuT
zDu9gHpky0CDy3v*Z;U(*%6wP2giiS-l5q%4j@a#YL8Zo!$2!0oKq4nEXq}9Z$MnPT
zLksn)S8FkNy_B!{g|EzW{_+mZ?|%a{~13JPJs!^AVVV7
z8XnfyGujQrrCFj?aA)Ol=*zVez}DPqx=wSpoN5*RY>?J~Xwu(srjb}xq7kp4r5Bi=C_a%*BW4DiRbGC6gvpQwXr}BQ$
zoh9^NW;1#9%9rJ~g|>i7@2C6QbXRTM(84ttR!Y*`OjN9Y@fg!T)fw)X>$`qGnwwcx
zu#+i-koaqU9y*sJ?4j_E$dU~hSA*#N{u%qxJUQYu7%9a}tT7h5UAh*raow?Z8hQyu!(v*pj9
zR<)~9<7XQ6!JN++!Z8l0UysDtY1E=$&vHGyAq|leSO%yL(#j@WR}^=>6*g;2wiR-6
zDbS0my*8j|o^?I6)xqF`qVwPuf5TqQPfQeY`ALe&a4Inv{^cY1>hg7P@4=Y@JrAMF
zb&HCqOjSqCuQmHq4B`9sChFYwHHXDQUHh4`rXNL_Zo^a}M8(DW9jf$R?>Lr=;y*OL
z=aO4>c!eQ^i9!(~tG!NJZ=Frl5DN28@;dhtjZBU>=;SqApt&
z!U!$^1)AeV0KiaOsX2f-FdA7!7RcMp4Z%u}
zj~k*RaC!4K4?quLC46=0Cyhf7!1+JfA4;?=gwq0>9ChQ51V-e^?yj$0tk4w1=)g}0
zp{uKu{AC`kOgY&?i&CL|a$~#w+t=ALD7p_o(huDNxiJiQ;Cd5
z;eu%u!5_C-TE(}ObVKC9z>kpPke_LJV1jO?byFsK^cJ5yT8;b!b5l}lh~(kP&5~!h
zVf#L9n@+|vr3)?qQ>T|J*oT5L1aY@4TB)2n)fj1}rLZW7QDU{vh=wMH|Dd4?&|_TW
z=anwR8??$@H9@F}|w!yb{$l+vV*l+xr7d;!9mz}L5B=luL`GX4C&Ce>w#X#sn&~$}P6660
z)O>|;6Y1&BF>wa{1LuE)#qD!5>c&*`O02%{CB>sQg@TwL5zU4>00zn&V%jg?zoFmE
zqLV-tYA5W0e%B?@1VEQQ+AeI{{g&l*n+-j5RZ{M-CVU7;9UOi`siw|Dix7r
z&+o?$kDA$p93f0ltZZdneRa$)mm8tUJsmr<+p^S#>qx|-D#`F5-07rH*6nT5zDrqh
z4d5=&%~XdzhB7lF??~_;m<*R?U6|`?a8GU_d~48vQ4lB(7Pb=aJtsu)m-hW0X!X^@
zZYE)O1L0eRPDRF-1)Ae6PFYI9l^mUbq3w2~xWP%)b
zF*Il*I(Z;N5ELl(;v8=VtOlYC)e^@tb^&kEg+Z4vRFq(J3Bfn3LkMmqDo9&EMh36#
z_n>r8Ngi@u*Pm`{LHdZFzV&bLW8oE64-UEZLJIijmvjX=uo|mD`vd1R+C`ysH_;ed
zh*^nVr*h#uBSA+2*nV=bIT(xlZKVJ>!EPRaFp5CWCr8OFO0;L_toTlMtVCZv)cLj!=99}Bj4m4Q<2Qavm21%~S*`r$
zI9=ZS%l;`IgW9fhV3EWn4uBb8)j2SW{NFHs#JyY|zA)D9<7*wA_?mn)Rl%xZIie$3
z7OTtui)yq8yEK-r9~fG)rP``Hyi{egqdQ?`>eI=#=DSBf|II~TWt8dgB_DnF3AXT+
zkw@Prl?p)>u|I5>H=@u}N5d>wfzJxdLeevuv_2G0Oqjib3QwJ;K>;rGRD7`)#N1LO
z2w$}l=1~Fy;&oG7#Mr!jb{7A{=;9u+;Ru!*6p9%cHQW1;jh31ne%+#j>!Wk+8+Uv`
zDS0gJ0q=By`}=`5U>}78=>aTRl4Kn|f*w15m;dhe$I1_M5fH{u5ed_=L%$$DJktWa
zF{XRuxN6&>q+V+BOG6SZ-RZmEo8m}l=ScRz@oM5=M#=2Fe}qQH+ovs
zE5I8*jHra-C{C_pFlf|4C6?KWxxQXAowXmAah{Q@@8mbBfnL{SSAE8VH?`OvYtn+b
zc@`9RJYOG>MBRnNY4+(M13pieDGS|F@NEzlo-G*7-T%!zK#R6%{#t+XT&-<7lD7^LgH~kb>{OnDHi+&hx9<(7`55UnC`ZKTwoN8VuT}5ck*dwW6z=;x8unLQC
z{B8HQ`M@*XT@)d%--f)=)nv3#nv$3%WP6iGRD0C&u`S(IigB3{-<~+Sjh@us!Y$-5
zw#|4D2ly9^Mat?0LPAs2i~bTnVr`T}XdQnXKb=^@iSVgPY9hIW*?$;nmSVM@5&hCH
zPAz)!2bZ`@7=TG_#~lH1M+oF_caDd~`^NwMgH6wfEG^5%f`tE%R$ApN)D!9q^)L0S
z)=peY!I;7P1N)jx6n(`O0kF#}7j)ZcCC=6`GLT|wt`wjTYMJDr`q8(;_Zt8Sd2eHU>4@(2BW`Ptc4ZXnoXKd5$nz&*}Mhi2bLYSczKG#jhn^
z7_wpCTZiuwZ%`?>OPEIpKJ(zdQ$xE%LU%H&$lkyN%BJN&H3r92NSK)G
z2mrr7TDE1QVgb+@>0HUQ;-Hn#WYZsXL)*v)AVx{VCC>4@Bw_C}n4IXvG2rR$&qttt
z7tj#u0og5-9GizlNv=i(6Bw#?5kl0}KTTWEa6a=3_pv}ev!H|$zmm{l509ToE{IFU
zW|_cO@NN5Tice!FMF_^d?PiM+&LeQtQpC@*7fM_fZXhpH!$M_Ss$kB%lC69^Ihn8H
zr&g?j%@9UnD87DOUbNl!GlT#MNJm7ecpq-v@!1d?T!Rsd492&X3a=^0(^)3+#ZmDPfO_1XkvKG8_ttf-kT^*5Pi-fGRo-idB(Y~Ty6
z;z&wL1}w|?5(%bHN7lDJLf6T;|
z2y}5(jRP${ZGtl}iZ{2lVXqhoxC=FTyic@ej^Avg3G?#B%py^R>wZ8MVK`hUJS6jR
zy&P@S&Ck5D;s~q%L(CFK#_uLlxLZ2yGHWlo$D4~G%$;u(fyUI0wQK=kja~{Z4Wy@#
z`TMn>b^wNvex|bQ$;q%QmH#164-Z3tXXEdl^)|6t;fFk9nb0ALhUC~#1!+6-Z*!v9zQqf_CB
zkA?+=bxp?|jk~|vPg{I@U2mAkK{xFN)>v?Q6adzZgAWElsm)niz!EokDBK`Uy5ajn
z=H$&VvSS{4FQ;3{u-y$Pj^#%99ilKNqv|HdmraJnsqoxf)H&*Og}Op{1Mkn
zM^RpRvM4?uM!F@-4wcWy3=3fAq6}Bey6=1(3k;fPln>YKJ6sLGrn3J7mg-ugXD-E={2BR
zlVARri_T!MCU2;(J|L9m2%DC>I!_){pkH@E#KAa-IqQ~DuI
zih#$R^aLb8IW7PF9aaGtOD@Ur(?5ZjpsWbnqUk>(d7L$w6NN@_wn>$?PqR62cDzDw
zmxYPDY?8_DuXoj<;<~^pWn&7L-%i1SJ$u6Pv2ri6bQr{GV{%rJ>ekCJeKg~rZ<%>u
z15{J^k#1Z?&k_gHhZF0EbWl}7tqHSSU9GXc1n1kux@1}7m%jbz#LexalR~$eO!W6K)=_+>qJBYILOVi(Os+U6FZlS;7Qkah7u^m@F+wDSIG;P_B
z`z!pa-nT3lLuh61B}b77p3h5WBp)08ZM|oExx}Lgye!;h&Q+lC`{;Y)e|HksTHQJQ
z^X0qS9*K!LCG^m%^6s+#U~bJ;9WRIi-Ihe8&zKqSi(C{Sp-5N=XUqqa
zb??S^9SbV+eQrFz7M%FEiMN;9C4vcc#jQCxFT69er)-kA?b!+A*E2GCDASne@gG(V
za7>S(kg6=yvN-dO=J_P>Wxso>^Y$X}elPHPz$@ovm-(fIZW=4Y^d(_-7}ohH^l~^p
z*4-|8@$&fo89jb2zR;aD#6yZ7iRTJ{=EA~5=$1hyc9u*}iY~#Cu9d&G5{dazm?BL8_3erIt|gUCrWK`mvFECx6D==SolnHVY~_+*SNxkFM@6n0
z8AUEedfS#s45owpgziG`HBny;OZHmV;Pn&O7u$o=c#^&M;V7Z}t{E`*x&cdMryNzF
z_0<48jt97fV|6)dE~ODa-oq#F~8=kzT+SxBpG@sB@jyZ#+RJ0U-d4(f|UW%qFCx
z8;-oQg4?k$5>j?D#+!-I6fVRsdn$x|pJdr4AaB4*pI3SFbffq4%0`a1*fx>TRh2i@
zwm*g#sSTPU9Y-x&X;v}#-F8~1+~CMPN=vBc--vtta!sBA(#RSrc>_mfQ{{}HCmhqw
zz8yv|MJ4j!df9;2dcE3(6agT-46izcPxtUiIu)c_-+Um&LAoM2JHtc$qY2<$FWt!U
zbsoo1`KWiv!R3>ZBCf2QvqQ8t{NwMe{yLZVOZP*wbb$@}@-HI7SJF)SXowKO1ZNRz
zqww+*f;f76iQk_l&Hs8|K)Cy;b|_Cn^n4pu)kQ}|pi>(Wb
zA!whFVvHk)>r`)@b<-nX=WA0&O?ep?IqtE29>yTV$G(B#&m<&ilBuVpgsMc&722>=
zAh)sh+}9ZfJbszPTWbyUq_&sU{LX{)?Gd5p9te?A6x;Ty3A~?vS&XNbyc-IX-ZepN
z4~jK%$0+$Ol8GZW@kR75Fp
z2)R$IAl#a-D!U+Q)R)(}7vHAcmhIo3@ML!p?APTu>yKL#RnzWBguaWD=(A}*{M|V6
zAP`yTbHdty&Np3MMkp^Z{8^WqCM(;=e)C^I->6y4AqqMAsUZLiA;{1pm(7zi|3?(F
zd3!mdTV)~<;t=$~7ZWH4u|g6DMLib{1i*;>C#hZ2-WR^)%kRTvfsUb!Wi=h^9d4kkcr`Xc?k-`umX-Et)1gFJB2!1j=5<1
zkOYLgJW0_H#VWnLkvfpH!#fv5rHn&iCq>)@t}a8XM~;*EN0!X4-prAoD&~9Tj0#EPr|N%=Cxi{>vVOW}ey@n=^yj_*0FbMzOeX(Ik;fVT`}&8v6f^V_pjV38{FbPRP^J%d0ozzyi&cwlAc
zwea<6VT2R^RJ08o$#f&>rk)lw=}D^si8>3Htnj~=xs%VGm3;nr^^BG+?>K_D7H=F#
zzw*$hYy3$A@o&IhSIoXjwlz%DRNwY#)r!?o;%WQCPk2G+qo1L7Z10Kr8SS^6d@v>0
znw4CGNrCqu{ic&mEH7{rdB(oV%B^xtCM!=S>r#OvK!G;B(2#_H*`I
zu`}R93n%RW5^IdCOvo$xr=j=HuEnqJM>-$pvV!mLqJ^=@aW6q|aM$x(=s7bzgdLJt
zIyb-0d}gH3?HYRu5I`v;h8aM1nFv!RiT`L=<0DS
z66&L!$~tinToW|-dnA~uU-=m_EuuM(+(Fl)mw&L{*z`B
zeQ8i;f}q)Mdr?HoS6!_Wb1BvXsbL~Jut-xEk5vjY^(ND;M4PW+8_5Y$Eg~R(7pd=!
zEe-@DMIzyp!qP;7Jdk35f}CM|`^o!S@&b{%C%e=8E$gzxE6!Py1(LY=a}bg7aPd_7
z4)$Zw^}%=i;C(6D@ShMA)~~NKt7XinSetQ|S->12%0|T)P&Z%nx@gZ(?$tGW*obYq^zK>-i;jgLVfQ-GZ4K&x}}~-q|mU2CBA%
zKK3Mwp*l-?e}zSjJWIC7FSERQd}TbX_Q}V+?~!fEBG?B&lh?k|TKo=;(c{^DK3F_|#Y
z<{&)BaOzczjsWi4*sjAIjv(4b1{v-Mlr^R
zT!q}nn)BZGL}N0*$t83&1l3c
z(FNsznn|oVScux~isqvRj1`)eINf|hjZ=FlW%;BelqXrDDO0@M^qdYwKIUPJymaOp
zL1VL;Xwl6-A+iHj9Bu1U;636fPCQ@c7QEs|D@Dsj&)VdE+3XB|o(p{Xd%9+1JEK{O
zHW65!Q<2P|kq(D0hU!yh4wA4M`1%Z*y*O(>R<>|RmEZw}wP({zEr{3ykLuw$ftSLtfjYlMCO;93aizQ~Px|B0KB+H+kF
zArss_|1KN-#Ul4grORXX^V_lAIXlS`-F8cXEa+s|Py0Pu{T=+7V>5aXroGQt#lVG1
zT&wNw+2~bjwaHskft=pySSF~2$3G(SCV18qTUIeCxq`|^!xKfcho3)as#T3zDmaK
zH~sLUSLurUWY+kf>i0j5c!a0>%l+*WnxHtp(_#@FUG+D54VnsT^x6
zoN@k8sNS5<35G&&q$reR8qndBl>Ag6CM83*(6S@ClKZPsjb9CLRxS_aV7VrC=7*R+>j%Q2wkbh`XCYhZ;Ss{2
zHroIsI13NM`cTO=y~Ni~W;c5Ln1dU@Hj=k*Bvt7l14x`f(|)hwOa@)aR?vW6d+&;n
zZY;!Vy`Ux4G*d@vHEGc$s;!y`nVI^Wsq`c6w;UvSd=daKoSu}Q`D7PM?gWDnk{RT;
zbBrH+{cXl+*g@83s`RZA)*A}7bwX-U)ozF@)HqnPZ5X5r;*UUOI#bYWD2QW{j~e-f
z;s=fGK+bvmB&`U;s3mj5nVLK(bp%#I-WGrF2l`GQs#s$}q3wUZDvYM^2GYng_@Hg8
zmL3#my!%m5pSMSx|DpM;H_jtJ)~e1yh5(924Fm--cN&wV!9B!RDBbjIL@B7O+E2(8
z2WD)4WeB$&*%XRRRiR~qFGY)5+u8Kk1?;q?k+%o8qYv67viVR8Bb^Kn@Ft`7+Vk~H
zKGK;B63(F%{BV*^AEwZFt6KXho?_O6gfq%jc+bEXmkUE^JBH}xq!D^1jQV$l*4XQj
z_TOpY{*pD}s*3-aI*0TR0piS@pcXHH;_8=KoLTE<9II^2zL|
zFi!uk|GdxBO8=4LoJnALz~3>G`H~vpijicLkcUw(v3dQ?vR!$QO?^r~U%w$_EIf-f
zb!*1L-
z*46VPsRSJN=Dc&h&uZ_w+&I4$nJ`$L9YEh@8QO+yjSq*=5}+mig>=PQx4>QL0+HO%
zh0xTuZGm&pF)@!-*(dh2+TLuOAk-XL?5m*V%0+CnyW9mF%1Yf5~1y0$BTfr#>4q^?kOW>I6>2u|AV`>E-gdP9n
z$QA-rcx)#%vKrFi2g1mpPk##V-&WEM3kM~Z{L~lJq_cvbA2zeoOG##zSb}zx$|9jMCE~j&E(?&7HcqmjAQ|BUvh16FIp>_ZTbSM*N#VfiuYK$GO*ZFk|u26^AGP{vDycd}U&(c9JzmB+t4w
z@9rQ615qV5)obc^K8D3wbR@D$7P6nU#>0nd3Q^PcZLtlz-iuQEPO_*ogpxaHm%{9b
zgHY-9%VlMi@n5IrTNC!r4H-w{PzkI9&thbw)C)#fNO}P{S*3b0O~s^ndF;%)qAh*Y
zLxu>yt9*vntygZ%=?6`9$ZoMActl3YlP6npNY-7^JWL>T$&+O;Bp#WH_f#|wAcQH*
zMhqcvB7WtRjn%?^Q6%&6bM`-N2VCem(wv1@sb#P8&ZTnXg04{$Ld31>Wgo;+Vlp#I
zJp|9$6eIqIs(OzKZRb1%zU`yzFgGQzru*ysvB?~vMjLp
z4-r~E)keHztobjnlY=fvSV+4C^j{;L0QEz@cww?W-~+kHgS*}Z5l-#n=4pa+MmIOm
zI3k<}YMdbJXIlF{^up<}tp8Y5>G}Ikde*oLY7M6$Z2a0VADj@3M7GQVW)_TzU0t}}D27pu))L5qe#I^xW?*%9RLw?QXRCrK2s3TU}
z7*-z9ly@p^0FJTqr)%sLKlwKvkvgoFeyq!RIc($e)HYoXDKriL$!tW;PdsPzteEO3
z*MOy91vKNwWa9^ek#K(~XrzylX}pucJ%+ms<2-Bz1-ggIu{f-qt#wlU3|xAN@5y3t
zl)&t~k$YSbvR3tMK&R4K;}LAs((3K-kz`VhFDb(x+}_kg-E0nRiyX8N#fjwDH-Nx;v@%;|
z3HVUdBbGS1kbA;{8S7#57iY5lAGG#)Br=tNjo>_NTYTDmLoMYl%m%C=+QCk+{p_bo
z{R-Xp9B%amZ&_%m_>-tu1+BmP#PGxOj3&mfl%G8Cm6XRJ8CNBgFl}zrmjiO&o+}{;mFnQ?Z(u2<4&Lb;o_&^g+l!+
z#lB0s$n;*HC!6g1-=ml1@RQwoj|;N!9gam1mI!`pp~PHq-X5k8PJ@1
z_?q);VP&5eK+pwJ)onbj7*s2=7&5L9;eBTyoPTjkPshXt#C;N
zZUg?bHA$(B)0nVAI*7nyNw4A^blH=pF3YNq;?DCOqfZ+W<|Iv^dbFu0(`v3t
zG}f2VD0DWCM^#?l;oI!jJZFS=iuf+t&Ur2ol^kD3^L?YbzZMdAv@aW?dOifB;qU&d
z{g$Gge??Kb-A<<=f?2Gh0agpRuRMaHW;{SiP(Pz6qOz>Ts4k0Eb6;&Ni=~2M~rSK=zwTvYc6`SGQDF
zG{(G;@>IbYo%%U|VIleR?IwSHee&VRka4yH2w(;uzRbA0Gj3U8b0dEnY4U1Jsxal0
z|DWmsYc9~2?EGwNVb=pD9_zJB08>^cC9a7ga-#vDtJ6kf|6vI^uQ77Th(lf3lgVM1
z*t^TyOPq7YjRE?A)kes!j@kE_KE{-=Fm4PhCnXU!@jKtGH-1g6G8Az-?=jv_DT|)fe@kj_tDZ4>ppDx6X1F`sq-+sD8ToL&Fqyj6@z9lE!*0
z;<{V?gbjx>^Twl8YoLp{S!H|JU4pj+e
zD5$q4e0+J
zC}Sy9-H;+ua~iB@{fSkTzg(F(I=xOnS8&$c)p5N|CW#i#k3zkIS4eO^yEW+R$h79m
zezoyyA#QDAI*M^^$S>%$cVOnd1k3XVp3N+x7X4oGpyMH6E9NE>Z#AB}jaAZ1rsFD#
zd!VW5kE~-0=j$a6N<3_G;Fs~nf4xjO>7#j|ka4%8GBt75!Yw0gZ6&jRqe;+tjGhIz
zBq=!|S+P|yFQkM)c15WAh8!%%z?PMiKfZt`BqK3Kiyz5G9k~{I_9^yeQ#SC|9jz{U
zWIi$w^mg8WGt_PeoPkU>CiONlK&t(ft+w^o0Uge09mjbEF88{Tb}{p^RGBDRW3AlN
zSw64ZUonQ&+N5rgE0)xmKLHM500wI;T9?q}Dr+jaX1ti5{l8YZ6B4=p5)Tm*Rxv&Q
zTRhM1)yr+vPyDwEJi5>;JX_fN-|D}Oe%E)B_kR7D|Nr;##s40@6i)1QJSUqx#Z*7t
z&viVqgZI~NhpV6Z!~C{JI+YG|1O77`1|=e%ItE`ZQ%
z1UvuPb>75q`(ypP;J9Jcv>Oq+`FlJ2Ox4-x_|S}d
zdLOKNBk6g(qZ;3f7I?P!{Fg@JjB-l%#vkusGI%2QZ7U)Q`%e>aXY!XgdGS_^%L;^s
zRAmT^faKfvZIi`MBAX4)@pep2{s~|<>Gz{2)b;zUF0<$zy|(*xXq|i#Q_yJ4BNUm!
z#EZ47KaQSo5hgde%(f&<;9K05pE5J-ZNyn#X33x2@I7%#fy}5q&yf&kEKzYh>DyGR
zp<(h@wz^MbOg>8$3Q74k0h$6+UZ#mbG{2*c?gVDa236?AvLiJbWW@MEiUWjxv?0CJ
zIVnLOG3(OED^c}^$Z6GS2Wd(g+Z5T-&Q*&GYIS&Mso2MOJGeU#hPHlEeyWC&9o%~j
z?DH1p_#zesekHc{x*s_{P0v;?{1PYr9CnVIQ==ENI^;?tGr
zwN9d5kXUP`-#^-?>#avLM_mb@=IhnW;+r+L&MTIO-QLlyhl6Hn^EK~w=osEATjz`A
z`I!6xb6jHenlj==FBeIW_nz}}do$a6>K$sy!S*}3oz?cyf42LlE6dqS3lv9XJ3C(0
zB%?dg?Z)Q9sr-5q@&xw^%T8y>Bqf&bS^tn|Esn^)KlXLLpb@+2`73@Cy!Q6;P%vgA
za@Fsu@v~^I?`b9)o-jfLHRBI|xZGqRuSIjc
zlVHMn@BAkD6QE2hf1ja)+PQJnmUWa)u?;Ke-zE#q=?|5tU*U@yMXc`*Z*z5mT#}8S
z&~2tZoiuQj8^)}cid6PdzSI6%I<`0alS-*X6(7r>NU4-=l3bOaGjUgd(JP&a@)btL
zBX#ANn8lQdz#&ugy`AOOx9MkB`g4haZ(Vt3Gu%)A<~nXi@?dLsG2DRZaqd_3}2uD7;JrK(J%%5<64
zLNhRrc9~_tr-?8AqI+Cp94w;Vi+eE?WOPL-EQ6;GpzQMNk?Y|CvI205i+;rCd5R+#
z`Calvv;g8RDWH-UDv(@3-YUNc1qo6^vfO3EE8GWw6{=$d1K+8{GU-j)SwaAx{FyVH
zK%igoy!2YGa{Zv=AY9q_s1&8y!C$uCG6L1%S}v_FItF70PCE$Ay|um?7?2nyFAIRs
zD3sV9%vLBY5p8Eeko^}XlPbg)M6Bl@+?VnkWEPV-g2U|Rov;tV-AL|pH5`
zz82XGFY1iI9mqr#DDEAm=N;2qab)oL;qV!XMLA78>-}jT56htF@A*r`@0_Kuvr`)9
z>Mr$X)kfy+GsFCspeh~i@TN;qVz^9+-2tA>hexTkCLXuZEBh#!fkPmt0ut^=gUcF-
ziOG2-mp5@(Q?fVOHP^)3w-pkP_KTK$q^fEyV1GJ7K((13DH<2T->+cZapZ*cT?a^|LsT*e5sr=sNMq*3`$81
zw*_!t-Ae6dGbant5UqKA3w%)AnQUJ^R5Ewqg4>FO_rf1}bjpSKSpAvoe$2G>nth*9
zWBEh!K3m-FY=<*E?nJ_OV~2s+G%`2PZ2B*ipUn|0waKvE!^PwJai?6q>F@n`ayheF
zPQcE3z7hAA`)5RSz3C${p%g;~Z`kQmH84S;{Ic3=!_ES;KpTq9MnMVz
zF2R6MfO^mF36O+kr3K^%Z5Q>lw^|5wyTPpin&0GP`(B?)w|f4qss(c$FTA}U6R)2*
z^b1|1!v;bjW)4u?Vm+x?uU@CuEUQK;7J@%vueE|Lg0j^X+4M*vV9qdnSPLv}=LQ?{
z1N5HSgWm!5jrk@m!h6k9O)gr&Y|CuOG*eGHKvmG}9hnoPah-Edthj>0rg6O-re%tS
zRpX7IkSnymsvz=@w;eKJM>EAW8^qE}8%?kY2WDcv`y!1&8_pMs-$%!Yjnsph#Dnvg
z-H^t>V8nIX&qUcT%34L^7q6sWPp0t?VG`*z`YMLBojPWq4ExR<48|Z0#gWAQEfi{F
zMJ%=BM%;~gm&K6V7%Vx30VL^1&kADsv0fQ5LNNDrFOJ2>E9nk@Co
zuS~L>25tDZbA8PSYpVlBp`N&QNULl1oB-tQqM@q+LXd7s(qwQ}72x|GEI?x%9<08_
zOIzVhWMXw-5nUg^Ky9gEObkP(CW9%vX(8`@Zp5Od^T58<&7bf`%+GW>xBsf4$a!(3
z(%Uk3!z6(R6ef4t>cD*%U~{DNe#zuz^KZb(T+Ty#b@tn~5v%l3Ih=HBCO!rL;N?^i%18QH5W_yczQav=4W%`X}o%oE%WOI00Bq{-%mwBgBik&QCQkM*1gevNtni|
z;cB@GsEzRvR)Qpa#G3sYiyw!;uN#JAjd8NI{u=h;A<+XsP*A)_AKl)ldKVZhhr()C
zVSz0`E8Va4o?^+{uG5@G;nZPFapi~-(8IzomQL=Slr^JFW?yf8m^}9MqfrypiPTQd
z=fXkaP14uyv-h>N%r}5E$QhF0TeQq$HPSs-kqlk@^qoRdtocBI(x82tU8E8EXAV;b
z$Z$^{^cz;3-MZ@b1s7Yo4l+KihMEaCDaAVijeJt_cRisx3xg0SAtU3z1jS5>$TGcI
znO1GhYD=aB4u#r<%JkO67WPaSZf_WY9{?W?=v$~Z2v-#~{RFQWZ>GAiXZ~r{u><7F
z1E65i7IH83)vB?GW3>8q>`*-ca(B=?+V$p;2q72>3x{(@`cR%&L*iFTM;}vOx>JzbguP};GgX(-%iKoTKd*mg`
zO1r(ZBfY)FU9*ukcry&O3nd!FD6@AMWM|P$x7v4rO0e9H-%(Hf%I0>~7BIY$xj|va
z^O6&4u{Tv`XED^$x~*^M!o?v%Onfp3gD>g|1(}BSy}lu@40{Ku!7L9HRpLTJ!aQPs
zrYH|6;;!&C4`K|MF?+v2iI_0&81CV-rt{e;&O&Gw_Kp@Bt1jeNH+8mn_b==MsQ$Qx6UXGP)
z&Gh+4`*6Jl+}>Cj?ftcoX;+)P1CP17Jyh~@fBR-XeCZ^Q(cABttXcO%`MYhO&Eek(
z1SQvOGgf0MLo(q_en$o-534tUzBe5-hM5xid`53RRdA<+iJLklxwK%w~s`2Ja=yP1Ks6SOj3SN9965
zMVr0TO3|AyE47{@vEl{*%mxHnJY5m>I9Y^!%EK%wLMFLBo^SCCKVy&Agyow}P!SeYGhMbPyJsgOQ&Zn2rxK$tWnFwFr-T;HZ*UHUPQ#Az*3WeUkd
z`0etUDn7i1SD+r%?C+ykWyOD4mad4etM#NKpLz{vz@so#$I@e-2fl`3^+gl(eFT8P
z+wt;9R=>ULxw?K&a8&I>k`gJ>y@|)o2~DX|Ua^jH3Z~=bF@$Q%{ml}}?P~!^zr`zFhS40vGFzIy9jz9=&6)^r2=^-M*fL{
zyHfI2%f4F0U#Hi_5hXBY@q6HqLZk}$A;kLaQ7EViSBozW0!YPeIQ!W5AXp(TmW6~)
ztG=T!@Czk_KCQz#<+9J1=k-!f
zQ!i>EQb8*fbwGhm%?xQ(jP0t4q+;wymX1IHkinp4o|CM@ng!`X-M-XtEH)eq4f}k<
z4p5kD!p7U?8g?k;NB|QEG8oH3$2F2R3HCxj609tAAfN}7bj`IrbFF^}ze265s#cVe
zq^VX_^in-pEjP4MT~n9U9pFMu({JDoXxoyeP3WLSW<%CA>N>e@Xg1AaB*KWa-8Rn+
ztnId;(bRTYxBgioHh0K8-+9p&2beQkk2Yu_HXIU87mxqqUo^`QrqalWQ*MiU?
z%YE#!-&l6vT=gytEX(uu)dlB`CC{C;z^zsPtrg$RW$(>Z*mdvPs&{pjOg_nydx^LK
zsfS<4A=cY=Lx-#^d6pJj%Zr}n6)*Au5X;LRK)@>bBz)^@!L`)@NMd=(yF{z^)6#md
z{kPUbYpcKoFO^^6ML2!zw^&;z&jhW#w=tH1!s{!6^|cVKEBS?mbgAO>1r_D0uhoi$B081k^pxV5!F1`^$?Xc&>0rc?%y@huoyKtKz{{I9
zZ~fLwuWUPU>fp&!hYlWk(Pq88vR?A|XLs)Y-uIvX_NL81gcmk#ePQ!fN@?^#$hI9@
z!3x{AL&&eNZTsdOJGbxv1k&xhw`|+JW&6&}zy%c8MIMEnJ9mK_$eplTj5UB8$f>Z8
z_&^LjkW*przFm9vK6Agq@~{j`&%Oi*bTvc{
zU<<&WjurhT->n)FHnPrcvlBY@*v8@{@pd
zAOH&(TGYScu^?-Tj{cZPVDfRb*)&}qsx7sC~9j8jlme+xTu
zE|3IvAuZ&bCFhNuy($UZEsSk}oeC3P3^yM#n9w~H22XF%f
z`qu#sU;foE|N7^@`i0Mb{fnRf=2rj;pWn0PyKc)QejGv9R3e~^`xWPoZQJp}*Y|Dv
z?U#0c>+pf+P9NTO^3}~Oz=b0RpFe!?`Iq*52e@$JwXGB94p?;OZHDuH`_*(m>LP}qmNir}dMRsc_)3qS-tOS@nI91Lr=K?QtZXk@jul&YLi6yvi%gnV=+6QTtj6T$1r@KhS6
zT983JNGJe>^br|M#eB558)w3(Ga|sKk12t3#)vTH07d}_A2nY3Wh}^ix
zI)v4S`ENQFTh4jeHk7Tf{qxY9js-}=F<-aO$u^{<)a}S2VrV%bD8q-3`Cy0?9MEbRG>?&Y3$x$ng$5CO`{&<|Pad6v4~`L1`N`w!t)pa6x^tW;6eYwCJU)sU1e
znXsTGX*zW>_PwT2q$EQTSO9xZK7+QY+cb1rh8{MN-?LJ{LEkptGY>mP4n7!kEntFG
znCE%t($E1i01!Z#>sptF$Z?_!;ey};4oYCKSebJz&Dr}ML$6~P^o$Gh=7o9N@}gs1
z&;!Y`XKl%~y5w43a4gN!Yx`Cf97vZI9ji+o$Qsf`8nakgaB~h51Hab`tN>#VeSX1-
zbVLCqAxwC&4B8-f#oAhM9c&>+E`SR+XsxZ#
z-J9Y2wCHu!R?@wGNRph3i}CrzSa%p4E=H@eSEIkQ|Insa
zkL=vF?}gv`y)S?JJKs3?(w2Q_SdMPh8!zNbE`{dQ#fg`5CEvv4@x2E&KmWoXytwK4
zO&_RqYzH^IxSeoe+qP}wU;qm2fb8C}eb;u#ww+?=VPgzp_nsX)
zcW(z1AcuSj%nBj}B0%=-+XGP8cVO4v1JB&Az+(^);KEbm3u9s+D?ZK?qY^>#3T#9q
zh`}%mnOU$S16Yv^|rsP-p_oSkeY85C?)Pd`uXPQlN>G!fq9Pgd+tH
zxS>|`R&wrQ%8`s101)YzDIU@x&BV>fi3PPGuQDFe`(3j>=S;+}0WQEihXYzz*=R@y
zZh(=7ZHDoKse`G84oeRm0$Ye)FUSCV0Fpos>>NyfA___%OYCziV__q52nGDGmj=H_
zi`3&(Aq{x7I8azqn*ah-V#9&3;y8OD>tY`Oj4q^Hpn(se5H8?c>_1@70gjD^b=fop
zYKUvb#SopKWUU;831=&g!q|l}Tt9NkMIWWYO#)oV=Ny@oHJ!8o4%m?ZP+(s|wd9j3
zqpEOK00p810S!Vw@u06tAQda1i9zP|H1DL!av-pv7vIL3;tf@Q=kqysCye2M)8F{ouQN1|U*Su?@{KQj{u^KX
zN5A`xUpakrXUL;WhIA3{WZXaV|NNi-`p2Jsz>b8McK^YNS2mqHwgY@{{N)#c2uBZ5
z+~O;HzY9tLD_lOaZ)V~(<>XjwM#wPH+JD
z0HCnkcCWTQBpnYn7dwOt5ax!3mTR%)S!(}7umXDvzyY0xt|hCwO*MN0`b~Ymt?Re-
z|Mx%t7{wmkFL&xXF5Io_P=M*-Z~o?g{vZDBpYm7(4>!zrO>Kd?a-hjuUo
z1u%BZ3w_IcpCT6LyOwzlU8Il&H&Vzb3Sq%b!w~aM*#5;u$Ks-WY0)ZJ!MU{HSQr96
zoJ(`I<$3$!oONm5HfDuYA?u6ob
zqU#3C{}PQ*tSoz%R>XmV2_Q>LfQgZUOcw9~Z~>Xj3JeW5*Ftx0MDN~;-n|(C0o=bG
zd-5pr_8WzdKak&fvvluv?7`jilZQ0)@Ze4w>6@>Y-g={Y?_OqQHGFfO4taPlH7al~
zbMJO)ZqB{9fOAEcm&3ijcQEvKhXJ`6@c0xLCtkfeb^OxRBWEtW{L*V%onF=AYHe}3
zYO!6@=r5nYbolIrS6_N%`?tRRm0f$jQ?7aER|=P|9)4ldAH4A5_cw2TaSO#Rys&N8
zCJ4C@c5DVQ>>xPUx^4TGojbQ}7b$Xf02f9=`i@=Oem3s#l+QEKmZWd$^9U(gE@oG3k6UDXn>5I699<38}N}&
z**I7-ldzV76vDwkY0MlC8-!tk@%h80KOT|@~mnxKFa#yguPj9^~{r@)br
zUxO57xEMr)AW*j+#|m7aScF{K2_hLGf*=6ghicwk5km~@Iml-noB|i1fDf>Xy$<6s
zh-#T!3)Ko4eq1ChJ)akdz@PvfHv#u28ZzP*0b-CTRVefUOaQ|VTwoUhg91lO0DS;k
z>6jS|Cl!4y{Dko10V336T|o)0T0|~|DPYq%fB)zD?b1D$M35cKrT-`7b~DqaS^A>hKm&0ubT&%bP$9
zhYvjW>b~!R5)SWw?!+sbuU$B#o;q&PoR9d>!`9|wx^l``Nt-|bzyiR*K=uynzWHWg
zDEZn&M!Pv-ZstH9oK2wZN7bDY!=yWbJnSsd_^!f!#{$;@3SsEM$!OquJOo_077sz8m0?rC>w*>NkeGiW=9`H7Vf#tM
zQnnLO-&Ld`_a$2H+Ib0xz*xY-l<>50Chr9w024bGk+rY@~s-^4eBG+bZfhMLncfG4*T4o(Mz$6Ho{O>4Xa$oq)`~WP#8o_LdD0
z5Jn%H70T&VjIB{9gNZ1l0?wdAhV>CofHOwJ6LtHXWSy&77i!jda!%M5g=z#*=hHlU%oqY)%Sqmok^MC#!iUA0?JU;jDl)4SWplw1)
z$WMRzzy905{8N-4bWGi*uG7%8>*{VxKi9VmI)Db#e9w$s0ENW?puw^{=NPt)!;AQ6HwqwKTXJFV>YRPCZ(W|V6Ka4t#8?Ak!OD_{hbo{z78d{_KXWG_XL-r9wCGxx
zchar}*Yd*X^`VRNuBAoy>WXh=*#|gST0-huT%?pKVUgc2O1r#Jkh8K9SY8G?gx6Oi
zw{FB}ZpC`^##-d&dg$)0$n6`Un>WJ`AEw`YqxjxCwI^?s?%q$|xs$weCvpE?>d}Mj
z;|KXSUN1hppS^!Ob?-*>-g@};JBc^$ryt!*-n)~!cPD-CPNrTrmn-^C*VF8{Ywu?&bX`SiHtmgdAJwN#UZ+-KH7rwn?$8%S%9L;20!I18i
zBU>CEMLOqs>DBF~!}gt#aaqRt@edLc(V`Er>Ogme8D9j2hV{|}%71lBBfUyTR
zjL;$HDhR`m%zWBb%nF#uyNMz4?lClQ<$qfUP^5ydly;UgF4(H9AO@ZsA?zy*Ee$BZ
z5F&;BV-G+2?y&UiUEtm`^mGyy*IUYZiYZqm=PPAANQ+r7S^caBCR~IKjznw*ia81$
zfUSkyWn5r%$fX?sf)vfCFi}*2-~*hOg`*T9bX3k$#7XnyazGEBD?wo{&mIdDgOtHZ
zVkn_n^a2-(S%L%R1Dpa1k2L@kxEKV8fV5WeLpX=_7JcPB&PbOH4&c*8LtrDF&#m-(
z)S0AxG+KfGm*4|Ps~+RX24sR8kdmJxP5~Uaw;V4CP~fOZ#szGW_ksqq@Kd3;-Tj@<
zXdc9uzwmkXD17b9zeLJczwnhW{>nGL{L3G{_cjWpLi&JX(r24k=;g5a!;jwCx8t`C
z?)u#`N4GwC{T6ZpZVhnZ)N5Og9enZCz2ARj&-afW{K4fj`&8GDTD9i`4p?G!KB3P<
z)y0&dnzPga0ae#1Tv2v+Dvnms)+$=-S(B78G{F!hN2h3S<*luPtyQu$i&i;nY!%JD
zs(mQghgEy8WNj8qkVZ~l&jJ**kXBwlFFV+U0NYuKQwTyKGMfobrbAO3GMS{eLQG`B
z^pd!2WExf<2A*3tW4bc+}TSbfLB(7sA82d|h+
z;khm5JJ6I00Lr50hM0M=N&^kPB?@RDhXD-#!h*ZkwLk^~d%y4Kbgc99ZqA3G%-FRs
zKktGtG$4hnqW<;JjhoSxweXFbvGw&Rxg1slH*o5k5hxtuaPLn1_1E(se%O5fefjYt
zfC5dteEnYP?#<|fyUDj77a!b?-(CydSr6a86~BKw`TG6rqkGvqH)4+;<{#e6-n^My
zTnr5czO~iF%^PW?tLusR&>lOBb#j-nQd=mo6Qjnm%*-?13}q
z4(>hh!Z&~W*Z$A{=yS(T?032~lQZY{9N4mX`}13NytsMWrmfpH@7TF{`}Qq6wsUC0
z4t6AnAqF4<$?ko-AT&>M@6J8@cS8p~a3*h3x|cQ~d-v@Xzqn`kSsIks-j7pZ(Fq73
zDDc<+)BnhW3xD}<{v|f=-R!|^qxb*M|JjeRxiR`M8h3b_3C1xEzygK_*mYJ=pi!cu
z8r7gw^6?Z2b`|83){W_uHl$z(NIGW9i+L6h<_rjGW>!EBE`v`E9Rhj)F;MIt_3wpU
z6l3{F+5WLHh5|u8Qf#td7o<|~Nk9+vm};vAG8|M2~zFF$wo_?A;gHg{VEP$06fLY{zhZ%5>!bUdhndurMf?FEAQPTWg+|j8
zAW&e8g;k!S7eT<%i!lX$oelE=((xwJc<6c}bbb8Zsi(^mI*{|=O4xnL?>GkuIL?Pa
z7@i9u?B-p3YT;ne!|D?XR8{O(7_{_#
z@)@Z6ZQXzT4}ba7pZ>1{noCLc{trLBjRHuA9W#vm;=qbB!!FH(nD0`oqF6h@G~Xuy
z7NFlhY?}lVSil7H$QjVs1eNSil*4?_GVB_LT_b_QqH}&=nH!jCpka>2DOSho&>0<&4`^7SX%zmYmEhvCe`Pf^
z9;Be)hSk8G8)2}*-P^HSx1u+0MAp_qj~-_K@YCLpKk2;rD0lZp_}2a#_>}J4dzL$;p)q;?bvtV#Vc2jU%h^6&%Ujj
zxBOu1_Dx%97-F=P0^tG>VJA&_fU;{3&5#5lJWUKB1LlUObD$uF?AyOj{NkSBXLY{9
zwjV|p3e2rY2^aqQ-~ZK5{+It$FQG?BB5VK{g7&tm!TYy*IQ&olyC2IXZynv%f*VpV
z`&w0saAcd!_8T>$eim319!j7&5n}Jg8HJAeQC`^oQpQn8*~{p5ryY=7!a}AoX#-F2
zfJG_eET-)!Q=nNA?jlSk(4^o&ZyTFbAnQc88)
z^1ua{(hN>SLmQBSh&p5-$Rx?W!mL6^VTJ?rt>Y0RbVxqy%w@>fv%$vcDy0#xu!R;@
zpR6?wkA)4%m?;%Er<2x9$_5T7;^IZDBE=^@H9Uc{laE2T5Jt|Jjjsj{;B&EX4$fPv
z_*vQb`aB-tLCyFIZpSnbAsW*A+zK8INhfSLFMt4WAm&6+TA`2&a-u-MG|8AH6wvxz
zv&o1NcM1P!{#76aD+pf{v*T!#3ZT%cLZTh%=fyUD<<~zC`RW%a{mQR>{_9`(r7h3>
zuGcnG%{sGD{r~cx|KorDPyg}w%Re}<Yx4bkIx?4apKj@Ctut0=Hola
z0U`ht&K=vSnmp#RT#5K*QV~@ysxHLT<)p5fHnd9izT_R&$&oOqx*K^*Ev2u69&+YJ
z&I~x{6m8vttpip-PL^^23drnLo#b^WSQ}|$GizuU402jkPRuk5S~6Oa4Ji7lN(}9_wkp{any-A?&&oabF5KF9aRu14wDyf!<~pbY1Z~E{@@V`GBqj
z?DF%*AU2?3RFZ`UFL1S}ie8xMyP6O$&jlqU{8yshi^<>w^jvH@ADb>FX3DAAT3P`(
z04PW)!i9E02T)*cfWl)FgbrDf4gf2ouBVjkoVHugV-wOV8X!=R(=Qo85-cDIQmSUa
z8E*bu%_3j|NMT>BJ3tTM24KWMw$78|!8(vFqhJV`d=liApfYxp5kJ3Y`vDVhFP{bx
zXjows!${GKE#q9r{4f6OBNY3iAKs=Ig$Av*#Dfk%3KT<`fAMD&&;Uy4wRF9fw%gRQ
z(%*0x%=bo1Em1&22RY_>ihLwESir81VZLhsKrD1^i+x^p$-X$WE)Fe7feQzN>Pee2TD4jfrV0Wm)U1wag(E)1;zi*C=@A6k1o8uD0OpumM?ilziuIF{y}D@z`p
z;IOjfo}aT1=j{EVt=plRX==s-MLrJa9CJeyrb!cP%f2=8Pk2_BybJ{M^KNiMuV-&G
zOf^Z<>)YD64+A@a!kiN|EG)X`7d>+e-nm8Z{E~k`$o!&rfkrO8IDBEj17cWR39PLI
zZmfoof*x+Hg>T)8-Mg2(bt81|cJ#w{YXA7t&WG<*9^8%Hy&b=IH+AoB`r*CQ8;|mj
zA7t*{irroh-?dggL)>D$~
zve_qMN%N_52X^gy{>14+7q1)xCFqRTH2Nzus`Ce5+Va}5-G^S;didC`$=OqT5B%WZ
zE4wyRkRv%2L?k1z0!@|Ny@TQvc5f%yL$VuiK(Y%$SRmkF-@(1R_Yo_w>^-n&@4h|a
z7xxT5oqD{Q_b>;b(T9;n+Nnh#Kl#aj0xJl^|1(fvyWXmWm=*r)PyVn`@dFV63XL+l
z_+F_<-F?)9^2`COFgma;M_NM{ANDxwk_+AjI~z8*flu+Y;8+5PB8bETh5#af13(Gc
zxCLn@W`f}aNo3+?j(&h-5|%7%YQhY=OS3LBj$GOX%US?Zh#YL9TbxN)OJagzCQbf;
zSOjL<43i)BYtu2Z$Ek=Zm!y)AGgwJkHVr1`6^HnW*+vw0`kavYQj|j
zykHJ^nu^8>zAWeCs-S~2(g~7)SLOF8*_VJT#~Hy-HNadsP%HT%l9+xe5C`ZWq8HQ7
zSV$jmD*+0Hv_mTTWMH58m$k(&Wc(wkkMe^Ju!0nA%W--$-Or6z`0}s+(wBby^I!b6
z|LfPj`1$94{~Ko2rEJ6$_0Gn8vzdq%l<-&o<6n--qS5Tv{{8>-SO2g7@;4Vw?mqg`
zi{OL*@;5*E!ykQ!P0jQPi|#_$JCliOGf{Oep)RNOa?UI$!NbE1y_y?2wUnU_8pv5X
zfP*~ET!4sa3l=EA1xUZ_=#}h{X4cfm80%?6EupT(m5r>XUonw2s+!O_meR^fLXnTo
zggZ?TpiO(q%m1
zwVd|b&U(zJkOu7MV80>!R!hbLC@%9E4p0y{Lc+K(K5xi%IU-V&84C*V;Vh_u$0_(&
zq&S?v1-?-_G@TAjF01BXlpG8VGYzr;NT*JQDb}cp?`1dWhT%(`Vv;4FqZL_99IwFRaanPdJ
z0vK071Au^0fK&d6xJBBF@@-iQbok4^_~$K2-EC@wXxnuaSYgni5r;v0G<#yuHg}se
z06_@S13=&`Mz8`*{z9MDV?det9=R5nB(RH|4Ky%eTj<-C=0xBEO?IH!5I0slkPTL_
zf=l{cL%(Ml^eyeKsoS>h$IvhG6C;$O5K*!$UoU7Hb)Z6A-!yw~s02=x>Ktrcz>kb^<
zIX7f((YLq~Bw|?f&CPih<~)l-&-}b+aWSy65?Ni1t*%Da*2t-_5f>S_xfZy!9=yFC
zdUz-C$p`WeKd8U=M)AqR?8CdM*Y9PYJjlQOxcv6x;v0{$H`ju9Z$uy5PCQ2b{oI4w
z=|}f+H*WwG94jlKTQ}nCYf+qKekr`L8lPK^4;GW@f<h333kfAPebJvP^j&8c|p$llFcp4+i=>&{&}ckEzd*e*7=?b^L<_ulQh
z_H5g;cl(~bJ0Sb^?cTe0H<)1GzP(Tm9Kau1h-v@+J=om0|CzHwqZ)yUtrb0zh)G0S
zkFKGF&SKGr)*l7_!@vJ4^b}#RKmF(pZ2sAw{1F?2zx+4<@~1!juVWw(=3%r31L_(3
z5@<$)7%adpHvD`D3m=GLJY53l@N{{ukY%io4~IS~2HPegA35f+3=|M!8SHNWLy&(0
z9rTQYVS;sV022mspd_Ql3=YYWRVLekY_
z{U3exi@)^Tx4)^GIUDvULaxb(XDSs^pE1QpqsCL2>1Q@UE#*eF_iwb9haf$VLU9hH
4SIZ|t8D<64
zM%N=Qn{}=*j9s1y@v7~Kg#QY$Lil<%3VN8#$F7&-(}06Yd|J+_ak~IjH13eo^h)|}
zQO6>5+Uyjxy|MwDkU@nwfDwUlVZ2F9FxKm~1=%`RGtWzw<)#yx<1*M>YKpN5G5WwV
z8kOj{zzWN4H_H6Ou!4v=peTe!Rb8(rrP8cinW+}9vqbZb4*ClV)J*<~pWsouEWG9&{Z67QMEv-PSjo
zx^COl?^%0YOPBl^7SO}|h#SPDiLQm0cU%&~2g@5PIYJQ=EFBb-u;5x*bT2Qsh65WE
z$e?Q;2_0-W>n-h~D9{>iR)`*umz%d)Ok
z(>5BW!N9e&6oB-4_HNe(W8CjM`vYfx=o-ws`t$C=yjNEwn14AJgbP+&0U
zB7rh+4u@_~!os|FZoxC0_x2b3!^Pm@a)?GKzzS=@Wm=Rv1a5$=uZ3?=bY$q>?f5%S
zil2Vi`1oDv{;e3~;oaop2bs4Y7v6oN_|B8Uqr1sFH=}oMMDN{7J)*Uu)62`KD!6td
z3Rzu^&dmjf!%(&EiY7FLvMUtPTC7)3p4l6W8qD@9%b@#5_TXyayKG?Nu8-*^?Oov^xmh;~2VzH)eyFd*4ckS7~
zXV3n|}m$dw^r_-|Vw(VB^h)KyWxxSa;4G(*r{QHpjcTFchS`3kvFlRmOR7F&yy#!6wr2
zv0RcjSw|+Hf^{l}PObPZ$VZ)&vq2c+99T7oRQ7`aIC4TJ^6=FP6pjZ)5}^;mrQt;%
znhIXT*i)6#2eCdN*HOFY94*y6vBQ5CI;-~?tUt1&gUFB
zoCVx~z2uqLSSf)8I`)D~1P74tUe;*{11OVq;2M}GfEw|L(c_#6`qbfoHWJiDL;7UQ
zL?j^wU%&()16&&r0X0-g0$ju>Nj~EiD@M?Ppo*e^IsQ-aZEp!sKn`(Uj{ZT|q=mLB
z00oM0WCOv`!N{)8P(Ja{Hj7drx8#zlWZvh+(t1hqtlm_yXIw`5GB{WhJ
zMvi7Q^vb4oL01DJ#HX?mGKy(hQIQus7)2!TLI^O@FxYJPVOg0NSdh;-YMMkaI7scdX2AD=12r%Oo!g<5<@PAjFX
zs*;+iCTD7?St+B0$XPWh*p*Q=a_V|kRm&|LPXN3n#%Qq#H8{)bqLsZzL7
z&R>x$!~~710<1u|P)0gaD^AOm*?L6*4roal9<6}M2QIK+bI>*kp8-ntDUkZ0S24W4CMSbPS!gzSA;vnz~j?+iYnYElsPf?Y1<%w!Ygo$aPJqJnE!Uy+V0u#)G$=4>Pkh8V(qq7u!4hF0egFnUeDFNJREp+#0^8Ve-
z%1RJl=k~3{jn!zo>6n{~%+JS)Ra>d*D3+`~|5Ul^^#&A2kMHmYG-k^+h3c$Ef6i#W
zqSakGcj4vZC-xmWwDk|Z`b#3S;Dw!gM1TT^
zDInb|q89eh0K~4{Q1IYt4JXVqSRoZQBt!a4)C4;XK|VG8PuXVZ
zfA%MTgaeryVCLD<^InukZ74I&WF0B;vB_qJ&xn*Wkptmkyq6E;O)h{;SScI@fmwn;
zVWb#!_r)f$0(B@7b$x$(lHYhils=|N;KGECmTE(7Z|~TaN~>k#4M2k`7Oi@2;c$?a8}HffD|&W
zqF7>*5rJ(#!vRwAc?iD+(||aOC?=M&Ms1}$`43PzBM2&th4t}>0dN3G#%Q)eGG@Up
z9D3m!_aeBwD7r${}$M3zi|NCc;Za;l^
z>&271FP++R>D2DS2cA2$>)XgbcYKFg3-fu^YoAC()Y-Tu7gv{4`g)Eip;vX!*ZoV4
zz@Xx4WzD?Ga<^#bv=2}a4ug8y04(6q2X-VhvnDyEuO+l{QYX{8iuz&A)+rhrS#2|~
zt0tAX@Ki1`m5oj(f-wJL1i^b1h(MGe{0c$W$Sc6M8J3mJYS=@Fz!LIYiTP<0dr<~9
z7?v2;8de-)H=F_oIE>gl3t?zL0c4^K6t?|1oUFBodqC#cqN9w^VfaZ<55%TF$yMP%
zq&EEt2%nLGfDhyg5NAJyVk}$$*9pNH1sGlD2^R@JP1?+aX+X^E1AedI*jycHZqY7PvoQ5a*?aK&_pqMy&Ri@RN_;G@YQ^10-5>n)lz)2l9(<<
zujc|+^1%r(M>RGrClx>kq}b#fU<7ahDKLVm0x$v8AVA3|n+2M;+03h(1x>T4g-BUt
zqoCNgkw`T=o&f=O{1n1;}ql@7~?{xP6}ku
zG@{c#Ku=vnJoKAJl;KbYU_lFp9|m4Xr>SqZ^gsbft8IX^JH|FmjsRYm2C&UtTeoZJ
zbj_WP849}o{l2Z$g3%>zfWX*Gk|vY6md{UBX~jvkT+_)lElhH~X{t92wVJwK*Q4JL
zLrztpXWzG@wt7Q{YTIp83%gEczSFhUo5p-;Hj|x%ITyHKZZu5Qs#oOW~E}
z$gSI{wYAvFQfPTGJU0vuhQVgj(`tG1C1bVW%$2O+xW*fpHCQg`%@;I=b4JVc3zv_4
z{|CRlb;tL%?fBkHuk1K?@$liJdk($4?Hv=?AWz$+pcFnXL4m&ZfzJ*H2Q3PlVN>2ZUQpvm}@t!Bff=tp%ef``C}UwbVDbPH1iUJ@V+s=T)A|r0
zzXrrWUI7#n;~fGNXsiK>2x1T~m=JYFf_l^t3sd=2)RawHD>?j+d~(582N~pO@+$rp
z_%Gn6LcRn63PR`~O~5B8p-jGnkO+66YC#DBuO^fH*_?*)=W{;W)nrgLb?LyKE#G{3
z&mSB;^xTy*doP^Wb?(>>$ca}rojJ1owSCV)&K})i(VUBTW}+07pw7j$#RN$;ZDn1I($1PTl)&Q8H5#uW6;jH#Qq_6oLs(LN|US|S_)h){{C*o!bH
z*#}iiw``QNnsP!>iYxN5*-V7iPYiDi{Ieq=8JdPZ_8hS7=MOxq(BM?
zEVMA;=fDSc!$~L*&KcWy=%@-d8;0L!2UU=<|G6UUJuLlc)P@5s+T&K;39g4T1%;5#
zr$CDGoDbnm2yo$PIKWp(g=fZJkiSC2b0zG)9CTfZ(094ywc*N7`yA&26m*GWA!0g)
z^FqjZKI}Rl^InYkE=IlQW4;Ti@Re-z8l;ezDkf==0<2JqPC}_AXCc+pY&khy&#P-0
zayB%Jx^_{|UIdD45GjX4j@=AARM9V+dS#k;IjEYE(z*`VRkI9*kAYGdsTF$%lxgi(
ze-5|)|NYabDVmZ3X-ihM>*|(F(kHn2v0y0d&M|H3%VAW
zotCcM)S^JYYaH}UD1*&zTi0o7A-%S)g}q%BsENO%i8QZVdG`lT&tRj1#Ld3F642nzFaX#vPG_2D^+8$q$?J6
zl5DLtZ6(QEmB1XX#l^_nFi`KU4oJ-obpR+HmE|)>bdn>O?yIL^N(Zd~Db0vo9SzabWBA
z?_arg`qI^t&%f~dXU@H{@8G82{H-tkU;fem>D;B4msWGvt{>UCbIYDRyLaysQyzc=
zViqNIq`PP;#ID`@_RvC1`#=+;c@x+*`prGF&yB@eyBg}$!Yo}W(j*(~lk%Qi%$yAB
zG7)1sY+wbZ0tQ2dwT5YVYStnI#)GYhFc{=-z$P1hHtHw?g@p}2r%&fFA}|d=fi;3W
zodc1J-ewhiKow#WC#r971B#&@DA?pvV;7&7^C^e-a)+4Q3BKyaw*U|EiI9RnKps3Q
z!A!t|6buKv2?cO~l;$JwT2ipPIVX=nq*D}JSrBVTK&XJ2FgZ5uOaL&_V-$d~AMb?@
zGWa`Xpdb^%dr8ucV#b+GSfc@LkOCDAyowZTb2z9A2eh~tFb7IjHztUVg{ws-Qm_lT
zAN=ZgSf7j<>3tkgBfb$0$MCGzqK|@4#f=3bAcyYKhNB2VcUVB1T*7?|*2-b263J)W
zG~^M~<+ILW!IRJZoH63hnG`4XZTsy*yMF)3q3=(e-*@rU&I>1YTs?OHa`EKuBL|;9
z{_=~LPw&yso=60h$>3}*I$KIn++s!e656o(Rre5-Ab}EG&8)cr8X#{0Sm9^OEz=tr
zvL-0l6iX{oPBpF(l)w>-7BSXfZWjzvMpKH<=E4-dM^grZQxWeqn8q*{6-_Z7!J`s1Zz4zYCIAQB5-k(iuWUd=
z#WXCNX^^67MkaAXjpkcIM+$%#{Q#fk2Ux(P2|TQT&9ML=r1BK#K`gJtprEYFN=a5o
zbydBtkt9{UNiUz2>gtA2SXf6YBWpn&TA+7;6!fl3L%VHmwk^$$MQWfPW38qx6sFVZ$$Va&%_y@uMX91M6t%g$
zIugB}1q~Fn8DvU^O5IeJjYuWg+-x~W+D^IcDA&#Tsv%v}tc4a918eKC)wSr&_2~WEk@wy#zWY}B{_PY%0dntd`u_dwlSf5B!}@Y)dEU3O
z61s6SvA7U!HXTdLvE`M-U>Fz<0}G3hcE?*RTH-OS+dXBpUbefZ9B8KF_Ult;_UwOg
z+ph0?=X<~L;^uE(ojPW7UH1kx7cRe)D>@qO=;?DW@7%R@53$0IojbSF+oASQB;#)J
z4hS%UP&nFgH$^!<`}a&PbaOBOV^BZ}bU+UJ>o5;cTIB$sAr;aijr%o7b5V1|qfAGP
zuo*lA0D}Qj0kh4PgKaYe3hRsxWREvo*03~Ok_(J;ptJ2^;d(d|2jYyCoU2iRQKyq4
z2N!??nJQ?n5ae@htgxW`_ySnyq6PHJPVZY+G|FYd&o+0Ud;=p@L3)iDpKWo{Bjr)2v0Jib8f2O*w`Gm~gh@3=O@X51sEP|AQd-@9;lY;FMn~1!_fqKH>DalwOxI
z=+k6VwsLW_fb{5R_tfWeukQZN(f!X|JAZKU;>#CL?74Vix8mxN$%`)m5sn^u{_45C
zX7#DCXEGb3cNyg4s&YzO&FFbKgh9=NMBR+6Of&;u{@
z)X1rMLT0<5<0+anCliE`*K!Uk3=>QYqaWb2{BVFmtvDl<6?I81Nou*Gl*LsB$krCghpsxz%R4O>vOqoi&(be*QYS=ZJi6=UC4SZmu`Xa>G=s8|1p7Ch1BQRi%t-4df~iK7c~an5*iu6I^Y(bR0QYOXfzMO0NYHk$T!%heK|hPh#&-}7~Q
zUXTRNl`ZOUx@z4fHyxd>8=ZcFhK{?_arSzyUJn4_>U5o*fd|~Muo_xe2`w%MKn!bZ
zksIr=8>^Aq>#_T{lW)CVeE;p*J8zcn+)3WMm$`E{{rbcFTTjZ5ALQ59ql=6F<>lb*
z^~CL)>0Z~!?~~tB_1{65QxvMKy4H)k)`P&bffab
zVf>GPjJ+xNI;fdy!hjWI{`w+iW(rJAK_s3Z5K^mYs#UctQyik0jG(C&l@(lPRn_gF
zU#>=exvB;n)jTdV2ovbkC{f)#QFO(Z#$%A<@vUo*hir;EC5Q6B*=
zB&UOksZe}69G{7&HPNIxmQsb2vx&SmTQ%ltrb5+{EgLf>L%wRxRZPje7HPI@h-H)!
z6w9b`B}2Akh-cKXv@)Jif-N90{4oDz$-?FzgptfBb9qg(<*YaCji!T@X445)Xm;Fk
z%UO}FD48qiixs+NNw(BwYqv*15ACkC)3fykj&9$Mv^Q`L=iT!Q-UV7=IKQq(0J=f;r^ZY{kzFW53`RR<=%W!yniRLwj2a8tgJ*Rh+!qVzLL0i
zCx3G-wJ;1Iy?rBnYb|;EX6DYF{PJ>QX*nH>t6zO>tI<4r_QKIauk6qou5RD)y~9WM
zOwFEq?a1EW`@JvkKe)*s)LprDY|sA9J9cm8A&DJ(cW&LYZO5LiG&6!i8u#qoyLbQo
z{kxz2JE>dMXeMGTCT-|ALL`a}9C;Mj&A@33cDfp39eZgEBJ1LS1_*~kGCkxIR_uD(
zoQ$mwo0jIrtEa{Vkp6$?uy8%&e7WF*6_m>`gri6ZW)419oCt+Sr0BAOfxa1dJdL
zM9w+J6f*GiLh6k`NN^9m=)sH%6XNw+$(R{cLC0A#VgYGf3BE|RNRWYB%C~~3OOO^Y
zg1)Z^|HR!!0lu*)!~ZXe>JXsdbI!y=`Xa4o#p4vT{01$2z3^3afH)O(Cu+#x+vT*e=;RWqYscoU8i)3UgIA
zWM1;HF9FcNN>8kd0O_MJ4MSL4Ib%Je1t`>#%2pn>#0o?JD>QSuYC=(<7d+Bf1F#_G
zzaH~WM7>wzVv`9#cnippzytXV1W3mK!Kv5_jJN`O4{Hh&I~G`0s2ie7nKJ9`wAfYaG@XYKlPR_z(H`jka;+M+&f(a<$RxQ6jp11s1K
zAf96m!%3I%lv97gV?N`v0uj!JT^FJr@+-uB6RF^J7O`H_bzlJ`7o({YB5HvG7fPua
z2=bvLlLhop$tWsm8jk=sNLgAgx{(!*gr`=I9xtOg9)@6HFT&H~4r5|qee?r-mY-UY
z=0mo`GzY1wq+tc{fuw26I-W(@s3AuoNs6YVY|APNUubF@8-o#IngdOCXtXqPUB&JM
z9&Vu5TZ^os+)
zqAV3>(&_7|%w#-06-rzUCMVLxnQU=3S5#!OGuiBH0&JI6XS3=|PMt1k(q(N?HWg|{
zSn*6jhs<2bm?{~PC4Drlj3pJRj5?Z}ji;4?*c2p`m7L4H-Xf)yZOg-YF8s+uYlW3^(G$xC688rFKp-fWSy$;aRx^gYAAuiJ4Chk^OI
z;QTPSv=m-i3epV81^>!oV0k&Px*EK-9(-^o_Q?nG`)`#W+=@QFpM3pZ>dAvFh~dti
z^y+GaqaSYGNG~r%`#taCVt92W4n(+rzl`+mo&2qvnH%frwUy+;eB#oTgU3(p)tawu
z+4-I8Q)ecwo_t}`@18mH(uw1TUVQQQRqAsN&txE^x^m_4uHBpV(vSqL#kBw6zP
ABfd(2x&8}+Rg&fXgg&hx&df5x%oJIx5qQgBZ13?Fxub&r&!WBZO!tBWQm$4~a
z1?)~B0uW9GhJ!p$e0XXtYDhjqt149pCI~@L8)c4IfnpJW1w6RGBMUI|>_~uQQ?wWZ
zOE^Fr07T#w6+=F?&!cn;M1X-$Cum3l$CmS+a^6)DXOsXm8%r}m^4Zad28y97R0zUw
z+NOg(Z9GDel{hc?68L)Xt#NO~paX6~Ek{?*158hY(Z*B}f-3&MBLxzrBS!oH(lIl|
zPh?%Wq>aN_fOL%t#g_mOaR}-h{p_ClfED&>t{u@{KXUQd_Oq{TG0Yy1c&5`4bs?cG
zCw1kNPRbfuMRP~2kF+3r7i8aD%>y#vS&mEzA}#@C%-x~|B6JhdX4X)RtEzEjEd@%@
z&q?nn&uz?307*$7%ROd0&rk^>knL4VOIYN9OszRM6&1t{~gjhs%
zf)x|vg7&mY4Z;}J#v(>WPH;ej-*!Iix*T*|jJRoj1o%L_@B+%^u#18m!41gdmsSKF
z=V@%heF?iF?hBBp`(n&{A?CXf@tli#&qJWZ{TEZAE6L#HZ1`$1a-HKJIRvtrn1PgI
zQ%I3BPO)oD5q8AfE}i$Z0R%|Fq~D%
zoXjb+C2h8-4aKLz@u_HXCYqW>pFWlXKT)H(1YHBrp;R-c0Ux-kk{+9!S&^-^hFxkp
z7#dIpd$T19l0bg7X_Gq+x$UTToSnXR(DU`Wo?eFrDOyd(pzm9l4=pZ)mli|w^W%?{`n0KDh7TrsrSy-S0j3TZdlR
zHZ^;0T5(Qmn6No#&z?W<>TBEg9o+od(F1!9?A&{B*UtUh_Z-}{_kdWjaX+oHu=m-o
zududI?aER1@IyGHF%82Xw^lOFv73RR0j$8DhOr=%_7?rk(kR3MDeOlkY6^RlG+GhV
zMZ78)5}-pNX&adz5wXZtr(O!+ET9wUur3hf0}j|>z}x_ZGnpq?#tZ@BbrjfoaSdds
zm;gj~83r469k#zLbnYvoD-7#JZ~$W|R%aSpecGFK0t=vn2C$2L2FOHh;}lZ-+4@Vg
zu#)JY({zTMKm>|&%-Hf-S}y_pd*q0v7wp*-t-Anwk2Dt6g8)3v*??E=_fYTwbf;~K
z#qUujBF0SI%-4V`=M=`f1}k3l(Tb2Ie_1RLIXWY~+uDq3V_^deJ15u)Appfr{tR0D
zk)VeOfbO1PAbcYVaS->7ZzhEPQ$;`iO?-#3iTjpMQrt!&tdECuxJ$@E0lxE8UXUOE
z7o?&OcM=tjes)iNK4(*(y>xuX$(Np2O}rek!AQ^0dP-tpW;t(em2Csb4H?#4^hO3D
z>_T7xD*z)P!i8Yt5eMKxBcuP>8VPyhux5jFi^h6JS4paKk(so3k0Kj>FaZxYaLS+n
z4)EH}`^C})j0-4?G~lEalvzhU3IGvcH5mm64q!(OqrSMAoCGwQU^kH8p2G!DjLE>H
zJ!a4xF=~!NpzBqKb&A8<*~13a(Ge@CPNIL$-UYql*q9O+6wKPwU
z4l)pMa73>-qMbRco<_AtbyUMqg9>l}=0H`@k74sEg#^Wj7#JFGY8Ac+h=+UdOAubc
z2`O}7K_YO8`5+yh$V9F}axwBl6lvwh5gD+63}|9xO2KXhh5(L8U=Cn~({Zo@bd-d$
zv8f&X0H5VYuBoJoLaHj|suD`AJS$g}V)TK82P3M;msAp@N_$5bAuENbnv$X|t6Fsx
z#XQQ&nxv5H5M`sKu1m2O|+p#;h6A$j^-+R0M;6ZME
zomOhPbu0PcLE-l8H018xEYe%I(hu&JZr#k>TukkOcapWVedGa@I-99|0f)0YKqu$JPtN=zz087%Y&Y
z%(wvQ#Zdv?WCcvaCJi-L#4tR}7<$#{I^$w^vx=j{WCx*-rbj{;6d))`X~A6-0}8Ov
zu+!RVbi|
zMGPpM&rtj$2mn&tm}&vR^@!mQFVLqT)?~~I7X_a#8q{+H1Fw+)O2A1`6*z_*3BtEg
z#WyW^C2$5ZQ+6`*f~)ZD_$>IovH&u^X%PG)kdGe#I}-5U1PI1LT9n7FLki{qwBeTG
z|HA()u8`|Qihug(XZO_Sb7x+C;lj}^A^Wv_R9lQ|D=9-YZIZHIoUVd
z7-)b12t*(P#VEA%G^s(vEz%~^wpczvP5~5jz=eL=+Q4fPF;KvN#HV{
z_u4KY<=_Jw1s}ko|18cxuR#C)2#hxjwoY+`4Yug(Q%4^(^&!Aw{pM|i_nMh&d
zQBpHA@)>9aTVNOIv#1u85D@6-bhL|TU}FG6U<6SDAA)n)XcXg|U4PDDIOj0Za0Xa`
z-68B+FsYA&ODHfxeaxyoZpYUr$HOs~348!zIO8^*MhbcWGz1+WiHne!_ez}N9NGOa
z0bEFjC~5(Skd0mg9E?Gsl$t3dr@;!f#0+Br(y^-mtkB9)=;9axI^s1GJQBeJ4M;ga
z0s63J;V=aV@*$%i;IsS`OVh>jOt~^k9)${pG}bDLYIzpW00kt`kYUJGbxFfiL77#R
zT&1yqT2+ZnsfuFCx}>buNH|uJM;|IRC6v0D6M2XDXl*;7D0f
zF3vz{NLsm~DV1h{3n)`ABPCWq3LT(OEUB_ZRko~47qsaDTVfG-2&-JsCbQ}|40d7`
z5>KO~0Y*BVM;BioO)9_&p3qgN_lnyOfB-to1R^BC=xh*rY%&O>h|UJ0D5*pmj49$7
z9nx4@ABt-NArw=xzabP?g<{HZTocb4BWYbUt&691shlBGG$*pgOx`Sb0+(mZmCU#d
zTvfhoE>g8~Zlvvjx4#hV%?IWdf{Tm6rKQmFa%g=$esewY&XdBY
zA2wcpkh*gxap!jG!M)t;ub1C=L&Dzm_1KLY@!PkP0EM-+7}7g;GRVJuD|2H#wXz&u
zSn$u!1^WH4&2jC8O}_&;2!yQ)^@Kuo1?l9>`Dw-ZiEAee=E+MFM`x7hqDkAalZW;m
z*gnFAgZuU!I*4@in|o%Tm0=l{z9&ZqjX116TU?+3+5U~#LkO%m>^+Qx=sQxklJ_Dd
z&Jah9!w*?O8Mfunv6oE_*9Lk>h;a%COb*hxUmFh+LnI>xbW&4MBl@Xqv|wXkig>h}
zZ5Uh1v4Rx&=(aL;V3TG);&dn@V(}n+-jU54M^g#{;Chgf*8$yPp&(_C0?z)ln*k{g
zI9a+ghfYff8#HQb)b~|R63;+$V==37W
zoRb%L9(y35po`CuiKT*@D<@-5LmSRa9M@pa#B7P6G3--&>{Cw5HHY=O&#j1t4Vi?s
zQt(jN=0*S}*aA6F=%$s4ibl6fjFsSDjC(@&O5D}D@YCQwg}wME(o4K>A9Ai}K!g7g
z-|A9^_M%u7oUyTDCJVTM|1T((OWXKOp}>gI&+e(u=Un>pg(xF}p_03qEOU}$ShaTY205j!
zBtQu>De;bmsF=|JL`a2a*o6Q|h;@-c2^^6CEMPu>FhfA$=?TmSWHoiC?ZWx*G@Szh
zkl}~1)Smz@5HSc=u(`Yk>%)!z2sCe3DTBn`2YWRv$WZ05+lUfe_@d
zJYASmrUXv^&MwHfHt0AO3Rl7>8lU2+6Cod`IHm`|D2@ONjA9hSq&jKUp0Q|7+jM8G
zIzZAHr-?ibxF_HzkM$gI0hAE1U+~+`do2Kki%>Y)G2*_&t2v1U7|z9gmlJ-PA`$go
zq=^#2tEnIXL^d*+jZPNgGo{1~k3o!G3*&KzT5?tvvmxp!0*Em*us)^-4qO;x1cZrU
z^aFgBpF(k}P@K#cu2*QGMv`i27G}Ew`wcjNX(wB*tb-54XhpX{FLa=p2pbb4AvEY9
zsq2y&^iY+Qv{~244V_fi)`Uj^B^es(b@C9%GL1EexCB$PX_95FzybwQP(rz^lxxO6
z|MMT=^8WNsf0)ir#*!29)I_c@oz6_9Gc$?IEIQ?(*d+Jb<7ovp6B%VHr%RBN0Jwl&
zyBgLynFS)Kfdb(;4k3R)IDx&oAZQ>m>-1i;xh6aTvi(2=K!7(i;|nW%VWmH!48_Mz
z1ywMn2`6-+xE6{(qS_E;Fscni)&2JJV@Wa
z6@PRu|L9&$NOqmd1eTV9H*Y5I-pSp%nZ0=<1zcEK3@^-whXem$=e
z_Z@iY0RQBk-DjbjLnj+#&=8{xF#NrG3_>#wYN56qYSn@bTHD`8X$9!u%EXK@zd92&
z=HeFE5}28>Uz(f~wGnWP>tS?YL&7~yoCrEuap9%N$IPgTre(%0*_b&V(1zTKm|w%o
zPU93MvHVe1SZD}Hf(1q^5!RFUTXeNy$We^xfrs9)SxDLPNh^8Ru@@#kBL)uA^ioQg
zUYKN9=uE;wB}H@|Bpov+!Uj|edkk(6&_Gimm=%zsd<=beANaCB5Q13^z&KaZuAVNSZ3^`pnkEh^PKyXiRL!cl>d>ug{5a5Cc
zI>En>|AWK|!tgT$U=x6dn+9Va4QkQ}nkmY+8uy`+b4%kv3gHc+$PaP4(Tx)D2Svs|
zML35>Kf9+spOdoIauSqasAY@|n19JL-wZ4^L-X_=2RB%uUmXoPuwS7qUh>2`g8~#@
zbx}%c8yVf8YF(()#D{iX-^gghyPak;VR}bHWCIJB3?O5Vf>$hw2v7heFetFXxPW|)
zNMKN)xe59+4g-YY`E1Uymvv-9XHien_yWTL@8!d>iOi>k3q!$PJ}(5<1112?Kmj7)jL75*)+y*j
zU1EVBoMvj)HWVF1k$T?S@hCrWmK7NtLt`gYlHxdO(>KTnku#W+hz$vX8Er=nPm?|cwA?3t$J*(!B1)4Lt!36AJc$y3#
zoWo?m3U;wmflH2lfY0(%E&&S^u=nI45F-w9S=o}bjjEcbP1ZMtBzQc63RGyog4_c&
zg-CynP{g9dfsM4u&IV!#&X+XcgIY}^COfDA2bBtW5lSTmbf$#=_TT>NlP4WX){{G-
zq%0O@a=Gbb>Uuge8;VYbVpHMxv_CxI3r+aLS0jm;NJ0^gBSqJLDioa!glEE0RWPgw
zMQ4y7ge{LLg2;(!0ui+*2r^Lm!axUIFsAYZr`&-_cVNmBoEE!OAO>#;3P~WU0wsV6
za4ZCRB&lcdM?n=c{^+zXG6~uU#*~m)8U;WY%5Xvz&*;)ceIlpL6b+FScBztiT`Z%H
zq!jV2T7*q#q2wxtV$EEr7-Okf2v`9+paCgxfr+6z43=x=a>Y=s7;9CNRI}7-W=S?n
zEqkNmY;|0{o~PIKz^->Y?v>@({2Xv0xV$2WK`i35ej|4CM)>Zn$j9%=AG}?C^Yzlh
zdzm}8Q}^%Zo;)e9uSb`cffRw&)rc60$e=1z2rd~6{Ee1FV3{&oG?%L0K+v#z-=-hD
z@SS}Jwt*WCy}a$x#IYIWg{j%ID%~ZQPxZ>-7p#t}I@6_BkL=lhXz%_*`wl#Nzrs?#
z2ugs#1~H(;=kaD(dNFe{(r-ljP1t+bcyC7zwxvK@@*{0je3gtdi*9tx42upMKMqGA
z1GC}nM~bT0y8s2k0~`>-1u<;FJ_)3_3={)-z&KG?6-GK`PlXLYhk$b?;#d1!Gw9UD
zg4%dU7xt+_UL`;QImnN&KRlpCF)#$@qa>76#2EI%rjp+RWpFI=VMnnU62{N#nMp(p
zI5zB6XJQtlKId%2uLTW+JSvFCHtlub0<;mICg4(HuivTkITUW|jNN$6X$25WQ)-=Y
z+h<+2X`A_)UVXt~ne@Ark$^4{G1345z6&rYY)Ho~#jLA9lOad%z07Cr#hkMu-uVPL
z04@L>XzGMmfFUD>HWD#IG^`H?wQk1@-~%ae#Os(1dX&is`Cym~V4-2=sZXDGbI%?E
zkYX1I_Cl~pZWzH;!r4GrKKWCaBvP=t{tP+*<&AvlWdy=v+;C`j4%
zbA@9W(*qO;_VVEj0T8YhDId!PI7Q}oFN9+rjkq4=38sX*{D-UL`7AD`k`5~bu!
zIZ3NC@iI-c;sUSjNbjbimsK(-FcvTwAfNdF^7Jlj4r>|9zUZFXY-~+j$XiDmiOd*Q(nz~w1RI7?gc@~5rZ2xGQ1Aw4XQG#YvlzzA+2PXos=e)!=HToNeZ(St^{tSOe%xq>R4QzWvp334aQ
z6vX04$*c-?E0IwG5kL%p17GNxH+a<_ne+s&y8_o-{;Tf5bq~iUhGu-h=|Ffo1iKzq
zus^^bArt@>K)fM#B&f*tM^xD4e5Vh!QDEc7s009liXmn1f}jTqYrtL<12lL;Q#?X}
zLx2ll1xPfdfdCqqA)wQ)lpOxW`a5rw9zV!Dx=RZ_LLNUZ-M$@PT=dS(xmQ=ickX27=K>4!q5d$?
z?fV7`;r@IGHMe@+M#tZ1NAg9l-Ki*+!z%6NX$3_s%&IP2ojNh2I#(v8EhKkA5DUQE$`Gq{dxq_t%m>#t(vbR`<>U@HRpjHVrK&k2Kg|`0d_V(#?cZZnE2aH2$U!5wb3VriGrPD
zn+MZ{J}V?0F~XSf{0o@0fE$)x4IuD2r-2m6411IjuPWqL1YNUZ1riVG(O34nXZ()o
zuv-;$DZ(CA%&!Z<J;@W%ShDwn-=s^Hq<1ihJ--kRSHZDUc!uo2V+EvM0g@S{GTY
zj+~B}p+Is;doF1!q#c#~$S2P!e;pRs;7rO2O5hhz@jIx}NlVbLayzHI?ir73MvPo&
zf#FS}TgPDRB6CrxBQz|@@3R7qTfFLX;Kyv6}#0x~AWtZN1yo?L_>Hqd$*O$v7
z&t<=pRy$xyaBeJ;2>XW=J!}#^^fPt?`q1aymWww18T7O5hI3CFW9=-A_iJo}*(x&x
zjLkEfWW5qODE~8G0vFKEqQD95%rVW>VeJM7AYU*6fPhed$$;U2cZtJsYO0pci*$Ta
z&ga6MgS}ic7ek6nR*;UaXO=F>fJ?oJ{m8BV*6XT0Wf0oz5t^+G^M$Z;tw-jN-2T?{(Uhn(l59&$Ob67yb;
zc`k~92{6P&GI%*fubH^Yl8uP*d%?H8ERDDx{Qxy$<8C3E%>Q!a%G8
z&A-2A`l*%_U46T7}jy06LV46vR*}O_xejmC9_jrmBkQgmQVNSmqFinNoR%
zeFo!{K%uInxtCR?Oi>OrheAxF&~oU545|?E5ar@bsW4qGD>B*XNceItr~LPS{cmwS
z|Ky*(6;EAD#V6Cr>3m+3$taU)MIIJ0tcZmK9MI@P&78`q6FF6}X2K?*0c-@N
z*06&WWU(p(HUSV7$y$~zm4*e-&>napt-hz;C2r{Ty`7G`-}CkdzJ-WZqHMz+i(G$
zfq%FVYxM$U*%3=>EcOYfPqp{pCc6vY+6++88m=lemnisAc}8cvdTHXs&Rs9Q@WQuF
zpLyk#BQNn!?%92AEY^5RB!?)%{Bw9CKtalR8^u7Q=&$A7*hELOEd@I=hyiJsXHUQw
zK-ftz#tT@Hk?{~Ajj+~02MC*)8Z3>lA2_fgrXjGsK@KV$69ZDzGghc?Dxwz12+`U;
zG{nFbk(}Oat^`BC+QBka#8ODGl<4EK$;>B7hX5~-qN~jw@>Il#>x5*YrcBh52rdLoT0my)dGsZeVp(Lgz=F*NFt)O599DoVp
z5q%r3T&BNPWm@c2~qStnTqx}H~G_`@;31?sng+5wF347gQC1$Zs;wiI+
z7DqCvXxw3JZed?FWRg!9l&6g9GkPWY_CWy1=Q2o{EqIfyzOdX!HPgq`Q;_4D=@aTn
z+SJU#w3Bs*U1z6)MsZX%{o2!R1^|RkG2#FS6z%ND&A|1eB;wB&^grac@8m+)h12oX>(w(sDPdb2BBqyDQ({@mW=D1CB)S)}h
z!xNs3cVSb|sO2nj{I>Hx>-m8FLck9FtO#_toD5v$6{C{@dKWfDMljTN`c%A)rwMt
z7AmTeN~)=7c%r6~X~F^n0R=*mlRyY^Myya)wi~nrLS52`SV*FT(I!oB(0~{kbuD=s
zsw(0VdU1ocTvC4W(M?>*fBSF$b#WmfW;dvlSw%9ZjHhQo32y%-PvDBfbJ6L&>blM$+UBBk^UlXGVF!0l^0J#Ui0WkTn{jmB@AAo?EK%l@B
za$J6-Q|k-Q6(9$O
z!W)`lfgX&h#AHidBCCgFOO|BL7)@zIaYZmO6UnJE6@4tHie(h(qBfP+6sx9c-3EHd
zmklBmL(OpvfCeA}cmmJ>*_c3KEX(Ff-9mFEIFKjm
zQ)ez;Ir{QTo4oGXZ04E2V|{g@+N;OVv+p>5nh}Qu?ga;zjuF{*S
z*&iTAE201nv5U$elRK155_K?vShs*?;e#8Zrb5D+Pgr4_*&6|Y0=ohxz_B9
zb>VPia{d?{xLVF98wQRk`y~;e01%NkraYh$07L~w5r&OKOfn=Fy1NYHjgGh&n8%4Y
zauewoIL5*#z-E{Xr_fm#6p#ti%Y~sc8I*JGY=T|}k&2qw*#MiGNm!FnQz~YL5(#L-
zeoerm^m`OO_pIA7<#kO*0vfk{((j%XfMS5DhSi6_inF1Gf>Ven3bOP_`J}v8?4m1#
zj$ODaU;!(D36w|5l)!ia9fHEisF6J}997B{;;Yg9#8JZbk8i15@==^4_KKTXNZIk#
zfC%(opoOpq5d;y6=m+2et^qd$lBcU3{p_Cld~UH7SZMl}8h*e5lK~W7VM)w{w9nN5
z4bG*8cV2R}^X690*vuLr{jzPb;hvWrouWxfX$mn_Hlj!dCW#UPlYoQ7#xzJsOf1;U
zBMwNTB5DD9!=8zM^)LPy*YPj^{GXzC>$99guh(Na@BG=I1M|Ttn~qok{buM65zolW
zDGKXIu6Wo^TD@Qc0ygBBdit1l<|ORBX6l4)7OX&4nJqL^!c&GE>2d80${*8A9~YE>
z1I4j3C)6{?g`7|kG#rPhrU42^p=cE+I0uJ|c@Qi(_0M$d;!T`r3=@JaM#4Y<8Dqzo
z5|||Tkg;FkXT+dB!SgIoEl5bG05s6u5HLZrH+k_#qv{AV7W-zP*mNhnR$7OO1=NNA
z4v+gV%!Qnn19qA~5go1UbcL67;`oNqt0h9$vZ3qQ;I&-vS}8g$oC*X7<0wc7=P)8P
zHr8?C-`_L+NF@cWxm2a4ohyauQgNnQM!#P{k%m0VAgO5LLs?lvPFW#h4@u$43p5)-
zq%i-a3lVUjricd|2rQu44a5qB2tW{&uZl?xC1ts!{;R+G*SL&7{^NHG1zMpfn^R|m
z2R@co1f$ml6U+bw!U;t*r3}WW1JOx;__{9)CZHJ&4i5=*m+zXJ5aF6Ta2+Dx;F{fY
z)#1GgUAPA(9iB;-Z^q%7c6g>Bb`NFR+}Erw6eEmq`KC$nP5XrBz#RZC(0Ig12`D`Q
zgKq1!$G%l@Krfcyl!ZQ25}T##^tKAKnKsWFOqm
zKYUQQc{91V5CUiP=K{^1r#BZwiYv($4W*K~)%G_!0jcGG_{N}A3+;R92fOxtfB(T3
zx9$Ay_Fdn5
z0}`PCI}hrx0qDoWkeB=*17uK5MTt83JN0yBEVcRSdc*yZ*zdfVzWo)Uj)$cAuw7HTt9;aXO0Pj%$_Ji
z}3NXn3mLQ*ryMAG?)o_
zwH~|NX6eLJI4zg7g}j=0*qA1pLK;jVOatuin+Bf33GB`xOhSBe<9k@>GmU=&QvyDG
z^I5zEpOZf}5CQKS4e0rT_@m%7`W{4_2Hy{TIkhleju-NmfM=mp*qjI&@rT3Tg=hHd
zg+X6(e`Kf@!Ux716$Ntu7W?zG8n*GXd+G7o){#&X6rha*oOG~5Q#IH6e)r}f-^Ky=
zM7eLQ*fUzN4(H6172Bp^&(=}zh5`Fn$y!SpDk(!IqE3dCnJ5Jk(h(Kl05m||7zHJ;
z@8OCBAOeIFM*0Ik{_s6M#E#9?u&dKgYarLUdf>OHDYD2oP#L4$O#O&3I;h~k&D+=E
zvbF&Z#0~T++(S1gK|_K19#LKZN81Q0kQ;{MUv5;cFsoOYG?;`pr7QqOBay^XgL;{P
z{JP)+#d4i|nO3$;uM{(CTy2#>wNj_VIRpwi<#LuDC*xJPc!L`-gY#kICBznV1ts`^
zE`loZfJ%a2pR@sV*}yI;n-L|
zaRZ8`39K*EHH9R2qXs^7Xe1#G=@ATHq1AEb}v0%+c@BRxm+FXdTI!YAJ0d)K~_|xdvthS`vv-Bpt${
zH3HB9Pho@&oj-d3Z~yscPcjir7;ec%8!?FFdMn2da44eaEiURV(BihXyL;Mcm7u8w
zBNzJd-7|v%NdyU49O?%OfE6s-)dUJE^5PsG;sOLw2Ecq=HbF=T&l+*P(Zyx
zD`0r(J6
z3IYX_2tPE{JhM5&h|sk8sU};18$b;Bx}26)`nrrO`zT34->u-V)lLg2q21Hh$_#-?
zvE-7nKOhFb*p({c=?uHtAhBYC7EOQ;1R_XML2yHNKGta2M7R)>*ODq;U^$S{L;Wd$
z0*JxDHV|R7Xu=3+;NRaXeKhI@#0Zs(N`?m5?CJRs5WwUAjs*k#dQLaMrcoU7I5KD&
zrlyS|AJND=P;aG5MZa!c@TZ>$g12qWC)28QR+GwWoxV12sLLObcmiF%kTjCeLjJJK
z7m+Lk3}_5QsS~q5Dh(wRfmp+f!+*nV3pIiYc2Bq6(`j>e_qn=y9i4s7ZktQW0w`eY
zwRiP7B`^dZC@?nV^vNAw0uGzIOE7_qxxpO(M&P}ao`A|5QhS4HPe3i+nsOGDn+WN=
zL5(-WRg+Y&AP|8RNt!6eAVLn2gn^XQQ|&_5lrCBmIdi7elPXX+A)XPjhr9^@k;)l!
zB}=|!O=b>qLrj=EvgL?0@gHaP4Y8g@>Md&kE-5DY-W
z#DsVK1}|+YvDvp}3+*Pgb!%k%_UMisu^ro^+jqqF?Ma_IGkEeyW#6vk-reba`*H^k
z6o?phq&ICOR#*>#8`g)11|5@=q0QSe>o+GhY>IB#lG?I4y>n;DRh|_twoFe*F0V6;Cvwvduo00m-&
z$suq;6kzaktqes(WC
zUgLF-ObN|mg^99leZLbxFj46pEm%hiW>CVqnvHjR!sK|lXE<-pg%k;&Bok2uQhat0?*e(B4RJT{aUf6y$V+
zyQkGga{Vx8jO?(P=g8H){&NK!%83*zEu#IreHOiTuT{PBBeY&=k`7&2vJ
zBCp9+;4%$~oHm)KP6_d}E)-Km64X^G5R(Pt3a772;DVAf3l49mFfapet%PqDxAJi3
zjqHPXR$=$b``l8f$JuSMcN%-!%=Rv;qZ@~q>~%@3&h8!uV4~aZmJv62i50*QeJ(%-
z$?n0V3<5y7dB^5$g0lCRnGReLILiD&R_VBU}}n!pgW8wK^N?k&}9)d72s8c*rD
ztbs!d3=N}`{*ehEFrqeKs}J-I4cbRVC+zVtFExjr@J>#-r#5)jt#@tM=;O^NF>-Tg
z2#4FZhmRaCzH@4DdVhY;?$o}08Q{Xvqy5{rC213ijp5B(V!L)`w{1;s*ccg|2#&1_
zO>IhS*_Ph2HNAOrdh@niweIQc{?|&)pGvz7W~oBe{@Z{3r%uVr#&7PGJ+^HuO$>#{
z2ScOvK!4FWSn-uIwnRwRUv$+=R6qb$04Q*t0tQCRK%Aj?Nfd7w>4&okjPwV_20~<4
zDGR_p1Fix-20mjDBkn=DvO(x&Vi2*1&`1^cwQybjp{j4F>V*a?9my)!n_
zR3tzxUR%4n7l=T8hd>EUP!O!pSRlY|5@G-?LDIg**$`~L?bfY;4+bv4-5NwBK&M=y
zQ!IgZH>lYqFU6rj1OO!!YPT6yHi9RT1Bv-
zqtW~^C{2ltCo*AKIwZxfVjyGePw6WOZ7rp(CA9+?iYN?Z4TCx3P|h@zGXfVFJ^AIVDuBZH=)0aLx-&<{|kQsc!^
zNn0#xOC?>oWGI%j{R6!}iipD2U6oWpOPfGe%=wZrozteWx$cds&3#?Qo;Fi&yT#UNwRKr--97g1UI#8Evk^2%Y;LLDjSEU))1}-}rjI;r?sC~&E|~^uJ@r}-pn=;rjgPy>CtT|{_||WPyz8bs8#efW
z2)lPDIV&L=H-&fXh`o1i{LGo*-Fwn|sRu)G`fz3U?(EjBvCW$!TQ)_(3Y#{^CfA1s
zN4>)Y)MaTN{y|H*9L-X+u!W!UeU64+5h+d_<#Pt{@?$PU;O(2!#}xK
z_t?3m3RYM*5{1@}#m5F{JtWX!sOqT|fD2UG#-)F7z;FOBBLdI?(7;iLN$SK9pBM_^
zYLkN@XtWj_u24lJ2!KKbB3i)d2F3*(;#mqjEIh@NBh?^YJ6Z?6P$LIH3|@RHfeRkc
z11N;HE~FGjV{Iq=5Z}Buy%!fc@H|`{3-b{EEzA=zAe`AW7&74IF_JA70`M(9r6FPz
z8-UStD9J4XH>^BZ`o9;V;Op8vjNdvR~)#s=w&1Hcq1wJtTEjYv<9jFIqkCP$hfabRi;Sk>{&csX;5pWv6syWYRHhy+5Jzm=cKB&4k
z_4{CKta*5wX;6ZQ9GLKb`o=-`mJ#rTYeLLafCT|K1_iJnAJ^ufml&s-EX70+kF@^o0ipm5~i2DeznfH7ce^Y^vVaz1e=S_x699Xyk#ugztpSOTRU
zj06hsf9wUB5?&s;9uNlZr@;a2W#PgXyex$W)G|1Ay0aJgf~9)p5)n(F)PqirnZKn8
z#5oO@4;#{gAqXb^7CC_NvM`CaU^2iVg96(aNy-&QHB~?870V$Q{1jcE$|osR(KvG<
zd4Z=ICs4J-a=jX#0m!mkL>lNHF3@q!3-DVOVub%$mgx%Szt4%4=T}a<_+FZDJSfmZ+zlM=EOw
zNYVjm#MuT_lDbk{lMgHUQ`*s@1;hY=;NRaXeKdi9jsN|SVFF^CSV06B1}fTGS!5-|
zVoNH16fhxZLzmAh3k3=x6bdSULIF&WR>h*ya@qRjmw&?h?%X>VNh*R-X*e$Thr5F@
z7_wMO6-&{&M-W3a3BN1xhvnXo)D!9s#?_*Mfl9;-WUc`2@0GNCF|32<1~fo6m$b*;
zW$EiQ_jX|Hu}ds{-~%aSbx5oZsl^UZ=rZ?qntGb*Fj`xU)^?+{1M`+Xh6YMl^nxwy
z6mP&~Ipn|+84861pTRG82c%TZ5TM+IH$>3|PXOG&xImc^u@-|?Qi!Gw1PVY0C@k7K
zffZtD6Gq?ygnu~U0`;9V93bnpOPMgT-k_BVF+Eb|YiU5N(TQnD|y|qDS
zsn(M%gCq=<{@(t2Z>?e(8+MKjIVQ(En>I%3{k_$SWuV?SIA9wYb~YM5j=83$D8R68
zy?fo1YvV@$rcHj4j|g*gfwK~O_N3l9J#y~s*!2Fwp?&$I)0LA)>&K7QM1QB)mM!tk
zn`0ZdCf03=4UY$g#(Yzo5|bO^BjcfBrO)o}2uAd6?TeJkwJxvO+NWHy{I~p*dv%X(
z8!MB;(W%iGM;9iCBampK0Iwf~S01fXXn`FAJVY(;Ev6i$j0^wov#XvMh)oSACI%wV
z)G)XqFh1a)7znN#icStjMSF$>S1l|=4yY>wAL8ZA4OH+b${l#7MvEXISAWr6FHs-?
zxG-F!O$!Ig9;!X8_(rOM@p^c)Mh%^C!6tU_1)G-x;#KO7&_R#R(+vH{zH9E(jXncWDae;CzZ<5Od&Cy<8X(4H&qu11^P&Kydc_
zufV^ET{V9dn8c^$$OH_$5mC-UJp|B!zc=>x^re;j!}xmp!?gB6AO*zV627|TmH8$7
zDu};udO7Vt_WwVwu)gNpG~n4-cVmPmD~{0u)i6#}dN&TbwvGBX54$I;y(0xnHL1@>
z)aigCAJG&Nx?)1dd;p^m*8&be32~n!8v!Li)c7wOk@3np+;qmgo%iot##_E~Y7g}u
z?rZh+t_|AT!3qEc*zTUS-oAE@CAfQ9oz}J7afohwjcagoY!-_M*wwLb!^qC>Z=-gZ
zNe5rcd;tFnn;bbjH%8&$SLooXmAEe_ywE8YYvqfnOhK_+D{z5MgBO?63>7Ehe9X(2
zHJ{~6K|q0K6oC)f$1_I2h8P`~2KYKg5QDfZi?~6YiI?z|Uw+j~xX}1VahQQp5-N(6
z7{L(25H^PvmWXUcBa}kn2PLiQ#J^M{TZ9o`8Y34Bi~pxS$~wltN3EB>i3KKzA-8FUFL)
zuq^58g!uRON*_%W;ABKIAA#}Z#010<1sEJl04p>j3XBc|VsS*BQxDv1v8*i?)y1Nw
zTsD+T#!}HZJ9`6f`oa6tnT#fz)1|W7ct#URDFbm?IHB-|rGSG#1cuxflyPeWmrvsK
zb-4pnF~D^LoMjN}8k9^4@a2%xi$isvQx5eyWLBF5Gyo3Jo7;4zR)e|CXlWO4&|$E&
z8!TktS#vMc;0AGio6)+~+}Cckb%7P|EJiMC5O2{aYjF7#P9H6=pz;O3O0WVgzocRX
z5^zDqt1dafz}1c{PDVfi8YmwDT!?~@vL?}vS{F}g<0(x#XGrD^se-Xkqn1taoH3R$
zq-i&)o?OKW0Ua<_>U~vF>X^yvD^<(zuycUAI`)AHhKC#z6W)jq;JgHbMK1WZ74+%(X4aij01#2_VIuQjBxqz^uPrUFaQ_&^Pa(?UjRe^#8Aog)e4Sk
z-j1c8f8oY0g4&gh6lOs@IKMDX61|>D{R8g$w
zOh+g~4%q8ICF!jHwqV`0e#S|4tq4Xrq?d_*<{g$+6y>)ybv#8-;YbdhCl9uDI0JLAI3T1YOC
z>(%~uPYh{fOEfY#PIyq(QoUlS4lW;#oL#l>-#8>ME^whaYGq4dut$d%=WAkQF*@+f
z%k%Vx%PCNV-r)k?f0odzIyi4riv=Ie-m01M-({BzVxaa-WzA4k2ROiFKNl#_NYGF&tIK6gsiZEH
zR5^++sD!kcw0hT0>Jjo_=2|?VjKySO5mfMnyS@I-Pz0194MgOTgeDZz2BYdwRO1aO
zAP@1u-zpXzUWwf!vAOwnUv6{Zj$hX6kceA4ngJrEyD=@-p>$KWCdmKaz5Z=_`X)ubz
zDv5msUsCU@_I{_KdcKxbm6!$Mte*wutHKFOBtxWW5yUs
zYQiaXl=j2aC-VAafl3w%mA+iLCsj5jOO&MGo{zbbxmc#%t9c1!sbbFMw8g4rVANUa
zw+;?FhK3!ZW3(^j*oaH8Lf`19ZG6JMZk-dLAkq-NjT?O%Hh3YX1dN~r9yvF0>`3LE
zGec*N_a8e{ICi*r>`3Y4vD);((zb1h9lO#yc4fA2Pwm>B-McprMA*N-D0ZL9Qmw=O
z{GR>ge97J=c{>m^^H1*8J$7xWax4L?00A0+0+dGpH;ll$gBW4}1qk%O^9&8+gAwk_
zG*I>qReiY8uN7SBs0o7ig?oU*fD7SUOn4Cn0CizX{b!$
zgu#lZUUKypot2yo#L!=KSM#tbe$KeSX$3|BQbw#GNcI&{y~Q+*;G0s$R!H@fGJQCK
zL-a6k4mXT~k&E|m5+N5OO7Oc>iHK#_)}a%Jw|(;A$vZbcxOM%5ySG1@d2o4l=F04Y
zD|0hf=N?>nc<<7KJD>1)=f;IApPapP;nWB396WP;`<`us@TPF^@qj)XHD{vcY}}Fv
zX_H}HDxyz@_4vjzF`xs*7~oTr5pyhP;8F>^yT>kf^+~vtQj}O~xb_0Vhb*LM=_d05
z3=jhZIN)Uq&By^p3Nwh69dOt%a2nnYlfVdCS1BAn{$30L_`nPbu<>%7hU+tn;Iujr
z0RTb4hR|?7{e7Ef@;gHPC0dKYu#!#og?(DQ9p1F@vwP|B+NJ@|mLcC%)iF`(V{ID=
z>=+Ae8TNu0MvInu##o3_dnGu4VnSC+>LD0{4Ak%ttc7PWVv-vC(aO4zJmK%gP3O^r
z8}McT1#0`#w>DsF^Y*kr0u)*s(FIz$M|&JNEUj=?@MKNL#y7!yHw-?2=VM%0cxr`3
zw+c7Y;^tfU-37tds-$m2O}`6~QRQ{n9vN?^h32qF(WkCug45nfzK@AwPkgopePg?tdP&E`|CEY
zXRHrqnzuXs8y1Y`SN8)aDN}%-!c275M=;5Ai
zE(#v>Ie`muz=5T&8(3iJBf-Ig2EYfP1P&^&L^z=lW&kv3jce5Ul`NfUjn=ptd;oNS
zjZtrD!6?EE9DC@n^mX()x;e(c(FLcM@)6C>PWX6kYR>>%;OGLxd_bTOi0By<{2^T+
ztPMx?k+>lo*D)^84pm8QBuRT#L7{{?oX{pSX0C9gz6%s%FsDi;*bpW~?SeU10!CO;
zIbFVF8UQg2^cBm7QrR#(;usvV4~b=y!^6(an`jHDp`pIPq2AGP+sIho_@rZU$~Cp#
zvw3rH)20BlWeXYL1Aqc|YTCXtx^+9*(9xrnGbgJ@r}M{YX=VAH)Ads)`#}=BsQxhr
zKG=UCf8aoY46+OR4-~-)d-vsb?#fK9OQ=*U8o#+$_Sn9u4EGNX-~Iw~
z>|-$E){{q$F|at&zy^gMMD4;ze_%+|E2YUoE9V^f6g;9c5w_IJ;p0cPT)lYa#+7q3_pdyj
zyZvzH=7R?}W@m5DKD;wGdv9*;4%ss|XYb#beQ;xL2IKX)+1vB8cV_NhyMO2M{W}*Q
z-2V9f&5v$eI{V(){l^YYZ5Ye=?eefknF#5lepSS$40+^!r^MaY>9$Fny`7Gp4x6Q;
z&)n{|Nkd-R?g6+E@#(lolLep6RKei^IAGzM8!ZqpvWMnpA&>#i2Ylen4AomuOGgH*
zCT4*cc(Eldk6dWtL=*zlSjf~+umP$Bzz2i~^$1u2ufo-MxdfgX5;HKET>u$)$42Nv
zEa`0g>|T1j#*{Et=ov5euCF<_kA}bs8wWh&rM`OFSV`#eQ586VV+jyI0f$TmxPwfG
zBfOnzx#lHCp%24%
z{KB>KN8(S2kq>#EKAwD;29v`5H%=CBB$_mcNse#`EZ~c%WlNQ^r5apZge8pXRTk|U
z2)KZc%83bsiZ-*rci8-f84>V3^C6&tw!`jeb@#S<`e=QGySIhI2_OSj$lV!qbwqs<
zYLyX`bA<|o-$RooD{1^xv`{6jE2lJI1s?M;s$T&^@bB-HKFIfr%mVWP!NEeEV^esR
z;s*<7@(J|{t$nE14bUJ)>fB5z3Az+sUeN#-Diy6LSy1Qmnuias0=GVN}lrU&BOek0E
zOQy}Sq^Nn!7!z6Gf;n9
z+J{7FVQj)XKH;65^ljP{8XdLO2h9V+)`@jav3SxyHRWEv-U~|DxY56PGoZoG!~j0n
zz7x0*12pW~m6$$MICZ@I@dp#9kCl%d%AP!0eD`$y^r`y617a_UL&am$CFsPF%CYI<
zG$s#~4<0NXoGu(XRM@#KzHMuge{!$xv3qO(`mw~+XnbNQig9u{x^9HFexR^H9Zott
zRu2tT{czPH_22_204z9F0ZPD#8Tjvo5(h#Jpaa{&wfky$SH0k)5`>()nstE~a?Hl_h|n9!-sd~=k7zZ5AQylAy$~3z4P$lt=So(gqeF+XCGXfeSq=${KK0VAKt$X
zhM2i?<>CFS(1Sad9^C%q?)CTHJ+*uH)&aj$p;s-#?US>o4gWX#9Nj^;BIr>>eCnuQ
zgE8XMq{7Bb)SQk|0R)(a10mUXZ#l~gAE=-K8~`88OaKEj00Iak5f2%`2g!&TPjN~D
z?wtKP#FPNK!gqyl174i{J17H!*yU2mKA9q
zaE?Ggd=b7NeSi#YNR87PKf9M6uW>A4vTWl_#O5K-RLwDxxAvzE<%G79G*mODyr@nn
z#YyD^u|h7YP6g!x6jZohEF_e+*w+wE=s}{X3WNPTMw=c+W$Q
zB6xdR!p=_M0t~lhwbMj>h$%;|hlis=JP1qxaTK8$PT)z#1gL0)_u~H{rVbQL&nK}&0RX)2C=kv=2WGvT8mw+DlV~}fyQ&%oii?_y1lLPqE
z!tv8bYBGeN4K*#E{BOY$z=2V-%A{RQ!2@uBdX-kW0*KJn{>IwXzv*myT`9$t@e&F-
za6H4H#McO|FjH$Oe08)h281t}gEts^#io}myLpY>yqX$eiJq8!hSjc~R?)19QWC%g
zUKxRrT5S0Mg;I<$Z#RfR{4jtH@TuwX6{~G+6w5tb^c40Mujx
z9(m?(a8PX6q^hkof;7E1#QD5wBR
zXd0oIA{5ajZgR{rvk;ADPJ*Ehk9xweIt|Jb?bebHd6dxYJ+EN
z!VXrLSmzp_bgUO83j_+A8Uco8Tw%w~__iICmB8Vi-O1?#nGep5et3TD{F%X1N6TkU
zRL`EQpE*%Kd?3%1aQtxj?eJ2uzW
zkEVDP!}_r#1ZV&*;Beh=d}@g56~+g`6N40T;E2LN#a%DEM+btK;YmgWyb9O>&X^dY
z?I=MHnCDF?;b0~Q0uh=a2k-&D4WNM7nA<_?Bt--QqL$btD%YUxxdm-tWWm&
zz#AE>a$!Z>(;2d_4U6``+c%c*Hg|7d1SRl>$N@)d*hPC6aRLIM;Igc8npgK4xNq?)
zEA86QDAWfHKromUnqdY!%k_FZ0u)H_k#yq@0U+Rv7pvuO=~Qn+8a&Gt15J_;X$Xz*
zG0uE)Wr83nLNUmNYQ@<_OERm`gcPkflE8dc-
z7E6_HLUQ$DrDmyGw_Imfr8BNHTGp7XYmAl_OK*FRt<&L@I9yWxco1-bg9?Hh2p0ec
zqIQ8J3LIT%>?Og=DWOKSV@w-K=%NW7SRtA)BvR&d)|^Zm;weKsP3uUbDRn%fi=_>T
zj6R(=W(uZa$yzR13#CST$1-(;wv?+Du)^Sw9ndf^Vy_MMl}h%}_dW1OhAMjvgiZ(4qXHLq-0{y}HNx@$5j^
zJ2n8PP9j7YiBF9t2pvX}8%C2;!=h?oFbal%;|CJ}4!C^+xPej?70*D~JuIptN9#dR
z2>G{MhNyC&vIe+{ky-?zTtgkAD^Pu6(LGS6@ToTS`UYW5l$!-HbHz>osL*U
zNkK0#0(aYDp@AXl*QG_28$Oa32(UM$Q7rrug$UHa3D?96VUuqY%Og`^OMlTie^%TGmvGYl|Y?P)_J!g9CCw
zc`2goPid-2O(m%*#Z^??9+PLo(rj3sizt%;NyOD2quWhNK>X#;|Ax28#SIbMhC189
z3K+e8EgsyY_O{SIMiy!**rTUq4qV1)*3h~~4jXXffVlxP5Df5v77(DoxLB)rOK7nk
zOrTgSCP^CEVsh2wWpT?+AqV0E_+904l@dO?aj(xl7^mSD+^AY*P{N_Ec3P!-w~aoT
zx$>tM_g~E4c>3_#^Vu6O=5IcqzxC{q(Bs=L9^d}_>D|ws-GA|f#xGvXeEFxx_ilYy
z&HLTGvVc>il>rx)Fn>TG1KjSb6iZd&eO1!MG{RQE0Yl4aj&24xlD3ye!O6
zut7u}wCa^w)k=+WMROzrQbQ{=Dyo{~>u{(;thWS1Q1b?eH?uH<&vdIyx)l}!M3o{O
zZ|EUhSmQ8LM=YCZrPI2KxBcWMkH7`4U4Rksc0*AST7W8#+h|q$*
zmZhu&|NdU-qfk)f^SJdVKHzl_EFc1Kp+O9kO`t^$7#sUIRCTqgzPfN&s~P&Ce#1ic
zfl?2wVo}RMg)hJQQzEO0rPcAYI+4-D(;D6)G89#ag%4Dz;EyQ1w4*fjPImgJXQF7C
zKv)3pYj?|fo!vIK#Nm};w0i&w(jJGj*MWJNp{Ijn>C&4!bjEhAv0YoV0_a`jsZ^;>G~+j{*Hyk~o+zCYxNzop
z^*BJ`NcF^#>Zzj`D@P9%4q;lj)nSXMx?y+TkVW{e@<{g6--}qnz{+qH7
z1ChxgAVOl@P-4SqS||m8Xi6YOl$n4-3$Qtsz_AAy5C{NFKo{gf$a-{qFg7_7AE#JF
zY;qWf1P!7zl5jzc^jg42y@Y#W7YwM9v*QyoSX6Sj@x@b~YMvG~RCAu3SfdE{32(|v
z7U5H203*215_ewWO_te6giK=6;CCp>8PB@0!j+5fJf6Gr*DPjAK$xu>HeL|_ikT)aQ6x(@7=xvT$sIgW9H7a+541(m=lSKN3*wJ
zKYDm;?tv&}czAto=9)-JV7xYS_wvl0Pu@MTqn3AtJc?AvkPaKNQDZu+k9ZVuzZ!NX
zVoC<}@t`gq(g)p?p#U~zBGy#MO#5#oZG=_@55Ncxn}h$%3Ihu}L2zb)5JA*2aO8jx
zA!Qd$pc^HP?8w;$2T*3G8saDdd_P3-gCcm2suS`_n^>+%ZMK03oCm>`8S?NFTm*k#
z<^u)`9OADJHGXz4Jzm>B7TP@In<(2x3q51S-jTeuo;FmHy0ZBHy$}TosPMnMFx2IQ
z7SGmGhW?};VT5?7*3vvoRfiq3g82XZ*V!T0E2@Hm>01G+?`VgB!~kBkecq)
zmuSHOlDEl83qQ@2z+?aeKD%i*LJM3&pjc(qwH@8R{@Lv1FP`3fGIQz4!z)i`uRfo@
z@qGT~i$}LU6@mdu`0UA@&!61E`03NTpFX_@R`~qcgD-^s?fJ~te|qxZ)(1xAYOQR!
zs(Xn>vQ#StH!M|1-j;PQR)84f%TywSz~YbqK!I>U1Qj6qc;aJYBsc$3s)7wVO|_ho
z6oeYfK?!^vz941JYJ6|2i7gb%D8L}vGnjQNdrfO?mbN}~Ymc$Tq9;}`Xjd4u
zL=Qd2HFj%TA5Jh)wW(N~veqT)9DxgA{a+E$gW
zrAxM?t?R8$=@O}Og+#GjqF5@lq+7nYQ~G9y+M~?Z|nSRdl&SZPRZ{&rN8f%
zy)IY0E|>jlcjvGAtgFTcJv%pNjvg95ePZg}cQzk7G&DYzNN4-}A#I<)1&%8)D7;Jz
z1P!!`k|a7VsGFd`tRO~HC{C*=8_k+T!DBpQN{EgNv6McWHKj75Cv--i%u;9}n>Uq8
z)&eziv{IYrdLLM!S~gFNc?Jh;^?J|1U~hfUJUU^Ym~xGc+XjIPQ=WB`u1x@i^}fkT
z=f;h`O`H5+g>~!PfCdpxNNn4h*t#XYb!%+3b|)wkv7J^%?Anz8G3?)+IDRPq
z$p;e`&W)TsQ8|0Odj8Ddh4Z8DoT?w2uADehJ9Vsf=0yGU@qSutd9ZN&aQWEL3jgF@
z-DBsb>bjxmSS>hO4Ga`LLuKDse`u^fJVGrO{Uf#Dgg^&MObin`KvN^B^`nXPV{xu;
zm>7y+Y--&|qy7=-fTy@7ai~fQ8HBu;8Lg9N5)GYVz=Z|ipehH33@(5W!3J)tKp4RQ
z(O+@_Yx)cBTFy0Gp?ZZu;h*5BFjgq9-&oN{0d}#v4}P(jqV*Awu&GND&MzeG5ued*
z)84%D{`~B10SdFM$B)1Y59Vg?&duI__~7Q9o1e@*xW0Y!xLGf=_i8ts7kMG{Tbm!(pV8lZzT)2hH&duBum5(n8vN*Bmr$`1oR)QVfG2i83vBWLAJjhdopc4OW5!Woj3V
zli~ZJewPTD-z=3DEXpxc{v@^J$AcKNNRM5cu!9fL{=eKM8>|T1j
zwsF7%P@t`$O4i}LsXt?=ru1L}umabnmD1Wml7a`Nn3DGlq@Y4VS&1vF33WB0D#cX!
zh%yzBL_8f)Pe;t#3Bd@v+Bm2Hyd`vScL(TBv>gt{)w9-aS!1`XWfWizzzA_TfkOz)
z3J?&%tXgKE<$~~)R#RdIDi8C3OZ~`Dd3=a2%Go-cl?4U;KGfnRc6f^uT6RH
z+WF5O-F))k^7Gm2&*!cK6rRmqdog$Y`Rui)53fF(yY_tkxxMzKgmW46Mko}B6;vy=AO^*9qh_^9yIQBArjwM0
zP*F+(;#>ws$cSgfnoREE0B*1>)I37GuF`I4aac+C3-W@9g=G;S2I{pyDG4|I01|#s
zf+Q7`Cj4D6(jiGMDx)k_L|KSY1p{D|e}Av^!N~<60t^ZvG{OlAIxMQoB`xtmSwj+J
zP!m0y`)g!_Bw(|_Z~!r3a8Mza)nrm?ZoV`y>=Tp#L};WQf>F6Q*zNX1(r{cY;tC2-
zf}8pwLbR-a%Lb|Ukw-2n67P)GT
zOu15~TFI=?Eq@!J&?Q^c(f#|ju7B<5{B1|)Z`wM4)7ts#Hh_Zc_iEizjrMJ`W##s5
zh0i~`@*jVF_T%?YzWaLq+pp&^e)rA%_t3YGe)#s$Pv1WN>krTV`qQ(S`{y^T&m|I8
z;6fl`@Y0Ty99L)-Icj`i-~#@c)O3MD3sD_aEi{4(kT#suh2m7S5uw&hhD6E~PZ2Ia
z>6|5%H5W^L`GO^vH)V6iT)~(v=yN5pvsA68+TUBR_w`pS{Z(tNY8|Ne4Gh>u$DG5X
zed803sVVpHa8JE%0vT{DVf}jWfqUad&z3ELjT_t(qrFq>+?zKCckfOzBJj9v8#P)0
zA7CEF_8qYuyI?1#_oq)x=dXM)`N_GFcaBxgo$5b#X7Js2hEAWVpE=Qg_T&K9E*zUK
zff$Y*E}uB^%2{FemiqdUQZ06(!
zzzGfrhh%465ubjrmUuLK`^EG5Cr{=cJ(_#`=phTN@NkAA3N!bvKAF32DS%cdlQ&ck}Xt
z+gI=2xCG7IzV`6mby2baR=7d+j}&{jHhUlEe6)YZSjeUH+ht&dWKauGNQd>Ahyf}j
zEQO@Cn6eg9)@pUhl*F?Z$Z!%NQ|
zUIk42@x{GAJO?Y>eevYZ^T*(Zd!Ijl0R8!kxfk;{!ybdPm$oM{YS(}aVO#YCMI
ziV00IL2Dm!QF$4NnbucQqK9Kd!N0#(`Y08Z#e#y147h5cT+$Q^G?t2urVAnmL0HhF
zfg05_k_~|snsyO*Az}|0X|-ftw_!b1zXKOyNo69ViKSGDjLsjHffynQbtt9^$F-p-
zyd!P>AhwGXT?&FS5mXSX9=tL~gAy9cAM9?W%>_d#`Y3Q=BehR3T03>7cCDdZqsK^b
z1!jc>Tv)}d&@ErqEnm_hS=83~`__)%t!@7;tEKJNZ5_}rdwW-J*pPTUckcUd9)A1f
z?6+S&`u^*uKYa7-hi@=KPrm>92@H(ill@re$xmND`Hyd&{m1vuAKX3v{<+;_V~Iqn
z2cRH2KsQ!EFfmZoLPYC}XaW&kXdwr&unVO&n$*QodW_MeKAtgAXd!D(WU0{`AT6sZ*8n?+%?iJ8=4F`Rs|>>0@P4!B9DVq;mLBfq!zZ?y+zC
z(8jS8*Ck+tCI_SIhM<_}x)>H4LHS3jw1Fgydch416g{<^bD-!Rqqa+lsgX2TfdUVs
z@d=762#gq`*uzVdK(&zLgSgie$p~^MiP3)YF{Ax>HZaof1C$JkM$VvzTEPK>0trPY
z>{6yzv{j&73GFFG%OVIhh&F^1g1`h2+!A?2Vc_n$UcyC4q7MXarm1=#UUr}y%*1Wu
zBiS2Q&p&_q;Q6!pXU`sqhysDaqxqS~^E2}g@6Fu1{_x(FE1$e`^2p8)&mAqLgYxzj
z<#hP!NAF(!==_aKA6)+E+{F*iCS#t#S~~3O@j8vCkMFy2<^4N1K00^i$n^egAH9F-
z=G6b5zu6#My_Ber+PpM_!7!ldokUYOIUNso-}o3p!$qh(2x@CnBdMKPDa%5o!|=*
zxBKj^S#a$*qy`Cu|wZ&zbvk#!6bxf#Rx&E>x5HYC=~{
z>gr;vKp|Z%rLH8EV1;r_0Z=G}WeHD5+|!w&4FV)_UsuH49(1h5c<(kXe>kvv46NYo
zrJhS3+GBc^&9tINzr5E-eyGRzw*`9u0*Ips9AMyjMov2D6Hq<4sxn8<4!?4XbYL_6?OUp5A(VpBz8*^x>7q4?cNx@55&gKN&0r
ztg1Dq4{n&h^Zv|@cjs=Me{k)r!`SYzO0psAlY1XNxpU$Ag`;7&wnyKtmaN>daroa}
zJoxnS-A|w12P^#H#mpDa?$6!-q+IaAi^HP>6lC3t<^o}-jqE`gfD+o$3P=*438tTr3zXkq4HggL=!J=E%XIkazp=~=r2|NN601aMStEg9y
z#6*z_coFQ##E^{u9ps|!Rf!SYS&D--)%^Q=r4L@kz@ShBHx!kn67BFL{C#8L10^QJ
zOd|(T)>bRjkdbDnB7yh-g@PcclU3#+Qor@WOnwWcHJ3N!3x-nB1i>g*EcJR{y}xh$RB&S4Q>z+lb;CHw
zV4ag%DNHygCY+)`!3$&EI_J)vkxiSuo45EjZ}x86;@`O~2t?Sl$%}Ez7C!_y*txUO
zlxh2RS~|r|aiW4}Nrh?1Ohl
zP9LiXT)^zztAyrditvbYPg68jj&69+WT)pI!2%g8F>C
z7yhG^vDXSNQE=enoWh9MSAr`XDTOf-rx*j}ENBC&mo~qSjSW!oBQRnictD{A4kv&W
zm>A$Gt9d(SfDvGYTEQ(EB+!b9V#=P5nDWWqLW-Ixm9viiqGzb$$6-2ZE~I)(8CyPS
z$tQb6BPJ@1tmQrHM>AuC=?~5ynR{^U#k1LGPv@bhjRb@!S(v;3Wd6bY!`qK$Z=O4Q
zsMjp7<)d5H4J1R3RK$Jd<9Duna_*B0XD}W;xYK7h8I&Doj_$qs$-CDsox64I!p*B6
zT)p_-nG**r26@#3gQEzem>h@>)j~BQ0|(v(qcCVK2F~QR8I7OaOOMxvioK0ij7dW!X($2?
z(uP_}*Pqf>;;R0XZXm56${2>ThM|nEKcT8Yadj=J0Vw2xl9ab2sEf5aQq3-*wcwwxBJhZehewb<%V?Ej=&)n{noN(GPsB^nmiI50hM)q-9L
zCU}cosZPFJBPGX)Tks|gG<>IUqD@wigACw?yA~uT{XH
zRT2v@A((?ff#HDS4LB5`g#~f;feIcSJ?*Z(_CC`Z{2>_KIJ6)Z8L#!&TU~uEu7w2=
z__IPGcPH02Mm${@Y3Hz@G#!zPme0~$6vUv&gsFBR8Km-sa`Nx7CpBjunoLkGD2miW
zi6RZe4Wfd9iySF2Ax@?h5LGRQ6Z-p&5NtpLh@q)ML08D@(^<`pn;+m^4j)+$R*0rm
z(UcOnz$+xhs0_x`-Vn$@;tn*rEkVAp3akJ_Y!@lA4+}+(%nH8>yRw!ki5~_^}Ds5zi#RLRcqI;)tWa=+C@7z
zCqI4h;Wytr{N}4i-+ndw-B)ve`0UoBhaZ3WrPW_VUNaK6`fK_~DIn
z4?YAjd~#uWY$$PH&)6S6z4g;~&wl#$#ZTXT26XtJfBk&^(WOMn<_jA90X>w>ySN>b
z*v3L1jOqiiMv)`M6)31c*$41JJZVfMP4T1&h#*=l=y|J%WX4FKP%xK@=1SQDEa>m=
z8>rhVVvi^x{4GqinqhRbZ+zT7Hf9?bFb@y+;Bauzf^p*p+FNq-=D@^+4cfL1HboJ(
z?+ESO9@?`rvKxG`Ex2W)XWM4qu5H1cJHj{zCjc723ec`yiS65?J9ou*Q5UB4p1s+9
z`*R2OrO%zNe{_E2ofD<=XKEk3J9OdP@Vlq_&m1cOAWj}DpFB}JI{nI70kRE`U$oat6c2zfIWA7%
zwGSixp|JsqD@+U~gyJ|PfFO(@$PnQNDv$&ju)qxvCPg-+IT;wP`3Ea-fllxQW?(Q<
z;7toDEAGPaVK73N6b1$G2g|-v3O>wzVE4KMdp5#(fBxdpv!~GGr_htRCyyUKel+uF
z{=wYrokz2`X6|2pc<=J#*&8#rFJAljo!eJGxOVZ}#Sc$kz4-3g6Z^G_c6Xm)`-V}c
zRl9%3hASVxd-dY^Th~6kdG*5Go1d&3t7Q^?AO&VbT;bA#JC|^^*#}o1KA?!g{LIza
z2bUi|ymDyQ#BeQ?3~AF5O)98L2Gr@WEPZ8IR1McI-QC^Y-3`()Al-sW!yqU~4h_=X
zB~sGTJwu9gOLt0lbN2Io=hwi`VPCAh)}1ojNntCWAPNFyT1dj@1tOHq5btjeV!o*Q
z+$}-K;3q89W$wfZ3RKc0Oe!}BcG7wR;vGa0*_(sAskY}GheChh_n6)^oa|^dGx6iH
zJ%_|YRpCDD)(BEVWxNgHA~c3Jxx#2iJW@OL{Xq6_uv3k?u%L#c5OG;2=A8jI1(Ue?hQzBNs{TgbZ@dmoC5_}7s
zn7!*Q#J%u7>9@SM{V`%qCKAup-(qXzijYruhLoS3k$BLAA2`XlT)tQJP{an2X#NB$
z5K{|6UGJx~50)%`HNUanxOI}G5XNw+dQH-B%pdK%U77b-3wXYJtjY6x-Pxk;^7(Yo
zlZZ_irUE>qOH$mfhuet2`>m0!i2N9wf!kA>=kp~yV1}Nw*U*fvc7q@83==}pI6ChB
z-R3`EqfP}rJ>AoGx7==o9aJqH!V-r5l?o{_qT&lbFt*8s+MowTvQW*2+qS7{(nd}H
z8e*Fjp(s+b<#JHf<7afXkgD4HIiNq5Fq)0=6)|P}K;sQzL7{0K9%qVHaZ=Z!TN!S~
ze9f)v@;zCtEn-%^|R33K&NFEzk!PQG&@DmpYzbZsiyFw30k4I5>RTEqDiO@68bR
zuk?IS+UYw#9I_SuPX~i)93&z5%^VTyE?`WCj|5F15|J^3iBCXoec>Zpu&Rxi{3w~d
zzY>v5-ZVCzxmb=Tvt0#onZc$tGLI}^qUt4M^R4*GsywoehXrq2c1U|%`e(2%h!1L0
zNkc=-DL&+Sqz2^HzK#D~(t<~T1s_B#h67K@NSX0|BU%3vAQHOQPsV+lHHkG$PSdav
zFLB)hZZ;<`_u}Qyx!^GbFK2=ePPST?JaB79r3;kD0K&M<|G2k(UKWAP?{4+Hf;PAF
zVuO65m-RFka&x-e;xhfWQR6g-*wy?Vt^jz90VeZ@ijPgp?bqik*|aO&&qE=Sr0^KH
zCzeQTBf$ib3Ou?+`>5$6T0~ni7Rxo?yg#6KGZ4=x`Tx}H1F2tc+pxswHzuH5aW&*I
zfeL;q$6fZS^;)w)(Qd~j_2JRv2&{w6f8p*~BT-q0f++@x!KOk5@eiMiQ>foV%|2ln
z*)vw_P6`1K1|pBp&4sb?y4*=O(K-iS3>{X1vW2rmSSbaWd@)mOG#K~v{|@UA6OF*M
zU%1dP3M|tXZU0Ay$MufSVs_N3lqk~=K6-)~a|+Ms2K-!z406ctAY>3sb~lwj^O-kZ
z9~6ISf&wniNX(y$ZsYEK=O29L+eYXR7cW}UZO|J8KgGK;A0xl{N1vYA2t@|9i&v9k8Shy1wI%G~C5m^VuaPr&1^-5UIBPCM!OioyOHf;+TchmNhKw60i!L>9~W
zI}Jj7ho|En#%Ml*hp@7nqbA5ytASA&-8VR-pLJ)sz6o-|{G7-YFOQ
zrP+ns7yRf7rIEWJi3GtRoL;Dj_9T(Xwd6*21(+w$ctt(97Iy_Ln`(R@d8nYyM
z@t^G?s{kr@)|{HmKr7F|u2GD_!vzTj1WXWI%W8cOw_(9D
z&uYV-x?f&^Hn@`~moCfIzmLd_RLoE|5y>g!D;`2Xf`g9ZOap{oc$yqrNH+{N^l>e6
zK!}xUls|^?6g6tNoy=rQdjGgUw#^=xD4B|a3u${(V$N+)ox+jkrLlIn|Ke{nf6Bb_
zx;S}GSsyT@vM1vAxVOa6dUk~RjZ^Anm)9fketM)hKJI8mT%X&AH_-1WyL%+?=4c=d
zd*}03W>Lf(uu?A6yh=Upl%sA2A)O0gJq0m+pueKm1~!L4#oVc
zSYpkVrupN0xt_@Uqwk}WG?meQP4)mQHDi%KBV#A!eCvGd0;^U)nO>U*B$&&K8?VBA42m?3AlPkVS?KgOAM=R-)
z-YvgwE1Mp~y4_r|gO&Q5-3Zl!u@8?H%4_dX02y{YXvNPZ4PHT)}Kz`^3K6TGBy
zYtJoa3<%Z}A&R>wd`OCjnBZCmu1SJm@fk$V#C$zP
zwxLcDRuPzc-iqQ&tigD3>SH)bY<5&O;4$JG^t_v
znJA+sVBi$)zNJIS89^y{=f~IP@itXNyYkIoxQA#>*X;s;wU4tm)Iu>*LV%^f(<|U)
z?&;|I9zX+etH+i*vC#H;nIbq^HypJW8XbMcONL3cE!w~rQ-gM^l3sVu9xCt{^Ss^h
z(h^T=~}0l$E!en@L%oC7VGW$hRqUsyh?|7wiAPN34jb0M&Qs{~O90TM=ky|FQ`OzbF5=bi1T
z561ejj`CB_Ih0U>RF_);b%%6YF7#%;*ri5eX>H&2*<#)l(!(2smdo7@{3blJ5Zr6^
z!B#q7w)JLvV+WXkWJG!6Ykneum+bhxjjV#Cz?+9J@b=j(J2@RY=>Y3y1+ZgmTn#HTn9p6l!x<>Bc#4F7$r|UvZwmFGu!}7tFm+^cr?$S
zI}+FGxgVKBg5x;I3{9_`M%rc*qA*C|Tw-s=D}h7W4v5==t<0Ysn*1XnjtfwcG!AkP
z`bPXDfCoV7>;k%<-@Tj0BMJC;U0KXQU|IXWC^9W|dpZSq-H{=_G|WE)F057TsluZ@
z$Y=%7C5>+v%9GW)o*oPkI-7!v0YA&kVfJ6*U)u_vAF{jGEd)LYel}Dsw+SZhagSM^
z&-_EF$p4uxm|TnQ=SF1kFt59JyAr5y>7+0ZqjT)Uvbk^jM8ucrqfzthszaUp%B~Cu
zp`XB;NKytgi!h|AK`-=xQx!y_6e*#y-b2yqQ>@vjSz^4%ZNiY)$(`D{I(v;-Q~%*+
zY?8J+>wcFvzWed;;MPi(fZ=hmc>3*DYZWDD;N8=hQDDH`Z1>t8T(41J-fQ#t$;k58
z*J%}_z?a>H@iiGl&Zn#1QrYLb`*_(v_~)znz{mT*mxGO`od+;gB(#D)R1T{lTSN{<
zI~mH*X01f(7)s)~kztIQI5UtOuK$NjN0*U>Epf7cdeL4zd2GMlM6t;C{hpzZSbomeZLOk7tzmF^i4kC3!?x
zuGw?;ocI?PY^uM+D=OlV6V)q;7QWwoZw9^`W4J9*!0|wcZ%%chdj@`wR!dE3zkI5<5+ft%%3tXQh=B)`fVrW$GK0&CI%oaLcqc+)zGWfP~tD_w&Md;
z3&w6z)~ZOc{VCXjXDMQ(IgRjQ5b9Ja7WPT#IU){IBw0v%QqgBB1g&*>Ure<{E{s=M
zTdopn#GQ#TZbbm~e+{0(^BB)ZH}_^zC!tx%2Y4e<+R+v7t22q5=gw@}wJx8H2iCpu
zd-P1WIZC>lynC=KxN>Wt8^lVZ4!_a+pLqd`S|H#DR?+V;E(*p~c
z6}aq=bT_$Ktrur9EgPF#3r@5h9@Yg%!~G-rLm9u)rlrGvv?d+zR0*FCIUzqqFE6wd
zXPk_(`cB~sx`B}+MsKe^&?#h*2o3ZMm=DlkQ$EuO*EsZ{`B)pOM*EY)p;E!Eha#Y&
zNA~`?E1ICsk#;K6tk77$mPfxvXpAS47Rm)B?~yU`32@3$DOlS>(Z#S?eP>T~ZL|0tz^bR1CY+kCR-)JS@g{K_ad3lPBYV5kFH8D7!{
zgrpxj1ecy`?OLNpB3j$!U+cflDikB6vKwzi%nXY)z)fyz{G-bt5W09Hv10=X*1i{M
zG)=O-;7;AvO5Mh8^h{L#GfYi6OfH8a^@2^hxCY0pY8r_9x$&twTW-S$0ViOx>%nT#
z@L5oqs;T-Z-COSU4yIxqJSdn>MjA;>F&X9*e-ij)^Fq+2@&wGo#jgj;FOsA>%MW*d
zyR@FYc=P_snEVyXy1$wfRyQ8e18pp9N$Sw91>9_pVFqCWLd4sHEwlPtnbq3rzfK39
zf0=xae|{8$*UpV)VG!z+X@H@`}?BVos`$&^5GQ*>hrC
zPCi!+wv81Lrh@V#*fNq;`9#sIl3Oz9Zp{6Z@j0#h}5zwq~S2+2jb_q@X{imH&y6}z)#Yd?3L
zSldVwPDPc5GYRuI;)k}D?%>Hq?qG~iOl7C^xxdwdQ^9DlUAh0L09j7h$5``r^+J=v
z2|OXyR5u5q=q>vGr%pmyKk>`abe*o}!>}?-Cd0dpY&&R}TesiUsMT)Q{qWP{>CtMN
zO!o(l+d-WgU|)QUz|}ljllHsb)Xlj89$MGqMm=r7OEc~3!(e{s%fo!&Yt8HZPUjR6!od*lhBu=_3@@Oac%3+W8|6
zmml8B)YKSqfdZ>a4F%`>z8m6S@MB>aM@0CtvQTA<-p|!|#Km4$o9zMAi=fPEy+gg-
zQrvpeaghHb0kAeIhig9G^xd39pRQ7i*Rp=G_Huq*y*ugD)s~Zk3zPQUgrL+S$OR?g
zOWL;Ie!Mvv`X+>g-%DSIxpU4Kb~}z82oBhO_6mn#04Ma->H=(f@QkP5VSNX%HN?jAZ7^jX6UCE>PbePCNZT3OTE8rt|O+UO7zZw)7g
z5c_VDt^vi)vFZ5MD2+ADkuno4K0%
z-AYs?NO|lOO^fp8bJ~UITE!bSHDyJccl({}Hr}4DKHR~cHLy@q`n|nlWA7LKZQ?D1
zcVM0I=WBOGz!|MgG)zt^<<7mw#p2tV$4@9+Ql!lHmPOg@Ey=Y1f*4tkp}P1tHOX4^
zKddh6G+;!)0Zf6t@1Pa>S51JpeiO-64?PdskGj6--afvODRA9OLv)YeTCz}Syqy5|
zB=H8nZx^Uhjd6w(0JAVNDs{+rnAe8cZ)phzQ=WYiIYg#CL#XMeuU`H?q_Os|BxoOo
zZ58;34-WL3Jp58YoZ}-EK`KUwxCL`HoAM95Ed`JF9}siHYW3w1|RLeaP;*uiMJsLG8*g3(`zCTfirI?=$;
z_Y*`$T)!Y_M7s9AofSLHz;bwEI;@L?5*B!1d>=hF%VaR0{jOPn^dCHrRCedn(MGBr
zZp~EIP^**qFFvo^UO70n6|D_4L|j
zV6h+sECeDYfnep2$R$Yb0-d2Q0wjN=(D9YJS*kuFBf_)FvOx$Sm;ei1lmDX!*(18NCYC*@g2WoUfw0F|<|u!)vWcRV6Tf~l{>})H
zZ05$6{V(M0>|c(IHEa;X-J_9+()227IAP%aN$oBB&#&9Fgf>QMF^lGgxxs?Z=`)Atk8d=bt3|RaERYD8zUS#4o_(?PM73u}
z`s`r-w`}Ox2zKJ3?n6Z|4VY1)V1V3}uT37EfqW7No}ytuBo}>RLJgDs`qY2QS@Ajp=
zy{VGd?|Co6>iK@7G@j>m4Mj4LNp$g7SjkHL5;V>c_~TQfX_pu&^GrHz7B>-PGjQ>cn2V
z=G3~Ztgki=)jRouZ{sFjr0b+5dzYH;a87iB$!?C~j+Q9bx@GHLtv{{3FtNQ`YFa;8
z;U5TFX=f*tUqoicrQwL;X2ygfuYU7+kb8Mr*l?n)k@W4j8XKaB+yJQPRar^ThrgVs
zHDK#KJ{1HqpyY%rZvzbmNDyCWD5{WQ7}k;aix-J$;$VHaV0a&>nDMzak{pB#iv3T8
zvL@Huo@f+2!Gsct9b+SmgpZ;OMnnQZj6y^=13++S;32sM6JBwZe?-Y-)syPOAL)V!
zu_0tQf>4O{`dmj+J$8!2ITJ_`E}|#}!6jpu{B|4k0;}Q-e0W;0ONq+xeK^|K8pKr!
z+w!mNDO&hv9fs<~Gq&6X2&`FY^JTm2mikVrY>i}PJdTs6Z`}g;Kyf&R1YXshxHggA
z+|4zefv-1%^|(B;L|OUBwC27-UWkC24VeQh=5ah3GR(VMbG*jCXmv)KbfejqgpsL7
zZ!7U$H7wTVURj6d9d}72)_0p`H8TEg8FB%4qdy5|*h;_qeffvnNnP!+W!7ipw47Pc
z#o(BMC5;*RyA1vd%}GwD7?J=44yiarnp}t^S>()ZYysdJSH~c#G(*Z%(P|_%`}fgTHm{1R+ths1e|O-+mD@57iOYBe
zjNhTl$)odP?r{)cr?`7N1R>6J-dMGp2F%YY09{)3VIdd{-)j#^sVf2&+Me>4j9xSz
z|5#<{4GNdrE5$3dZPoV-^dOt@aNBL1#~*aUOGpA1x&KaSk=`c3|4G(Yuqy=
zjt8_$O(?!lh{UGlNwqw@-+icWH5=b`lg;gZ-o$@HlqcPaY3MEGdpvf1xgBuQ7IJ-?R=33*Kj)0VO1>O=fyiZ80SY55CfxWSFJu
zA@zHQdsTaL@5(g&m%{B`j0WTne^-dF)qC1ZP$MTq_PvtH5h!qe{XyqCMt
zr=yTtR%OD++qmVfa~$o*hvC-oytTV6+LPzI=X%;e@0YFdeBeyxjU)(oA(Yzyw!n1O
z@za@zq{0m33lso)wkar3$Y8(#(J67VDgpsA1i-<%8LnzhTEZ>*bzaLc99UgZc+6F|
zuZB8gGN+3@+RQDjxX3t&-v)NS0U;Q0W6eAQZj{-dt){|r|8@&E^2*f)2h<+pM!Sx)
zI{&5+uM0
zziao1@P=@Ba&+NU|2_fCGoKg=@D-JM71S7Uvcu1w6BB=STZRf2R8^p=
z)BH`Xq~5X*1b5I-aD9Ea)OP%*e~D`VP(ON?@i(HT98s?EDXC-!rMV?<41>RsWC|9X
z%i|%cGIY6$wYrK43oB5XM=2+W!B9cQWpB=~49kpz_>p^
zH0XkTs?E91llZk2pFbY>;2Z}I!XW)fE9-OSeKJOiR%h))w(V2Z}-VJ_y2z&IB*^uiA@g*_^V!~92>~jj6
zFmyh;N#(Wrc)o^X7u~n4q3O_~A|b^N70^?QDDdaAZ0n+!w=hm^n$#*V*#BmRijvT2
zOE{{(iRss;RYi!)#Kdy4xrRS}Vq$ph8BB(KZ+{K@0oMy(3n%hX>>Eg15)*w9Rv~)|
ztGA9UIa3e;v!L02;=}n3ZE?B=7A3^tD-3B9&uNvHS|{lc#TYpx99G~;9&edw-EF3>2t+jB
zH&(oksp5Ps|Gd-PP<5ByIQ&xHz9VXSU=t%>Dn%@yc}mj?{xaYB&yIHGb${|17x?f#
zSyh>MdXBeqv-0--7qTEpO0)W6y*u}K=_QMx=_e6*Iel-YLt|N_@Ee$zd#6TB9IkVEKu{
zY|X^TG#dS^su7qjoE(FO%%N2Ph0BqiWfN)*a;`RJDl!>}Oq34_#mEK$|wb8XQvTt{g3)kw{dPC-=25vW(RaaXUxVL*wtu&MKk?$Xrrh{tMyRswrVlF2q>-|h?o
z#Uijvc9vVXInGkfQN$dZT13k?A07>H2RaK;4lCkoVhb^6?e@F0Te_
z^8Id4>#bgvp2zbnI(;ukSV>Dtakc$l?pN|(_hM!Se_{|u$uEMVJ
zAaS?h>mqS4c#-nQxNqwa+ops(pdIUh{;LyoM9YbOTFpFb0t|sPyu|
z50)@`a3Ky9JX9NMQoVs3KF>-V#WfG
zgI8OI?IN(v;mGwjW-f1{V0eU3>jlA{XYzh*caQ58FgM#x>kZC48qNSJqoM)TX4VzQ
zh;^uPe-n{&q+$HkN$ouq6%QDNI~^*ff3DY2xW3Zq;&}qQ4t%^Cx@5f^&mWWZ6?lCA
zvRbr2d5K%I)_FZyZrkqVmb=e85aQb6c-xk^In*o3(-nwt1-^ZV@T&3mK7EL|bqx^m
zJ^j;R9elsw6u;*tgb&}xcZ-)Sx@+g^_prUHa!SKq?2li=zdLJJH23~D*?Ad*
z*hk^=T6)$rm0bcuK6o%a{?raZiXseams9-b)IP7bx1GzK!*YA_r%qgXtauu~i~SeY%Uga+KhIZ!fk9x0^Z|!)5Qpy4n&)-;o}X0R
zYE!KoePN^OT)BfPiA?nioa@fogt68IJ4b0gr0FXp1yTNR8~&iNb5SfXv@~_n{6XOp
zx`7x^3Og6`vl|~E0?jKR|CDi#``w)0fI62TEd;wmHM<)U)=Y(tV`dCW1spt!}
ziTs`S#RC~K51wePcga_r=py|0>1BF_R?Y%yRWxBOO}Z(fKW~p2anH{-V!ajcqlOjv
zP3RcV2OTufR`sT~(jP+p$f@pNmP0VRAU*#|MaC1RBXke0rUrERS{z}!D72nt)D|R?
zGcHY&Y)o~3nbIu9!9h_$wpaiN2wS$l$5Q7rUhF48x8$6p$Dl9#Qq($a?^vHPf3hHa
zCl21o9-K)&Ujlq7k59e;Z~VBiM7rjGi?Ed%T{@P(a(nhN$eXwJaw|LjdbhRrdOk1v
z0{nEF|N2l$8~DO_b*U5hQ1kk)g0guHv){*$K6%Lve1EN-KNdS#aemkE0+GR+LQ%-F
z&iF=*7H_kt8uMWEQ1sKBdeVb
z4B^s4osab~Xn2afL5RpapQQvWq}&^>Htr`mX?1cXEr4ma|LleGKNxUHG)4JmSKSMA
z28=WTeW8h?Wvg}J(3zkUAOe;^v-utG@PnZKhj$3WJf_6&coEVqog7$wiA4zI>-_-tBMLPss@h@tprO#*w?rRzh|Eqdp0nMzZ#~
zzO>%T@8Rw~Ibxhf*85?9HCe@rc6^24Ybd2ozf9mbz>WAnhuB7V&0y5k&Szms{#lq9
zJk8B$^>sLbe}j)i4w?$O2Jdnp9eJN`pEM5dsgr|(>4}>nAwkM5uX*MOXf~>$4dxN>
zh>TrS)ysXPVSz+1Z$^vpeh|z=5<+zd$NjO6AZ}{~7jTtZj>9&(XhQt4v
z@AQtSxlL6ZW<$QRxlxeR0g<;e$%m%q=s{!;ZynKEpa}f>gnw)_l`HWM)lu7%<<(}E
z-k51GnehWTV8}-K6k6gj!$FulmmCr9VbdLp?+POoYTh-PDCVZip=hGlzBw$!w}zIb
z^3F}8;L)M~QNknfdZuD26as3tT9M`?e1e3wo!
z1tADWz?}m@Eg(4-3yx%-gq{
zTj23kzs`Fcm6qmVE1%Zy`FPqb!25h9KHvX#Yj5r4Yyr?pzZ6Z}uKC}r;N}P3PSbY1
z9^lHpJh{mR;Q|Nk)qMWzvn(*^2FG2U7xl)|pT0Cx_*r{7Jy1C&d|UlHYx`Ehf`WG=
z7^P($_hEk~OHH1arnlKL7W=$Je*z_Ut5O7PjS@TA3JM
z73-|a3`ZNY%DdOl)X6C8W8)?Hf{DY!AHq>835%M_)gG%|f~c4LeQ%X-PqE$BoU^HB
zsTWCQ8hCxy<#OaUtPi0urWpVBq6plQcrCkloxOOPKh)wm`FUg1d1JK8`HStW^q=rD
zpHbm37^-V|yWQLZ#%acswr{C_ALsL&Wb;r$Ye3IwT|EZ-c>FLM1=V0S8P*UuT0UkWVC)f9^NCYY
zk_yMPOwy9PgTTJ|)*k*$Utc*^H1L*ptVAk}EX82w%%PI95k6%raoLHnaLx;*bh2f4
z>PM6P)6PUREzS4ytFMehkloH76)8;EN2(!Kep?-t(ILK607Sd->u64BK%dMC_UlR0
z`Fn}pkuFO7IS%W6jiuDBTR!l>?w>AM0akcK#{X%3a?3ZKW+mX^?q=&gJDyzud_39f
zM3z6Y<|n}Vk!F>s?Ys;|GGC~2DGFrNT|NyR*O%S^aw!oIy6%qrZ!%2#DP4aN905MV
zPkl&49LDx&unEL>1R@{L-0&|O)^a0V%
zl+jT3gI2`fA}fE{^CrgGIQptnQ%GS!8yNP&P^Hz63iUz*Riu}#>vuG|A-oqSLuEeu
z{rxP&I+}hxm@QzN0p$#7we5d5?V|CJgyji2r~GbWusf5^M(9RNoEf`NiXI`k(vO@F
zh@%>DWDo%!z5@%B8fqI5SlZPk+;JUJQ?oOrVh6sKUJ74HGk`+|(n_04XQ!tfn=4Ny
zxts0FmXhSdB#r10R(cSKgnqq|m{cz$H?p?JyN`UMj=sK*9Ru#1iW7yyAfq?g%U*G*
z@d_d!kr4IB2r`l93cfSKH@ee$gUqFt6nNQ_pt`8eIFcW7@yM;ES_1#z&yRgG(otX%HwO>5WpA
zo40j1bqwsJKK*;s_QNA_B74QcOdq#SAacX9L^E4y!aVCEt+Qqgs5`g%ITKDa<$
zKiQ9E7m3N3>bg5};|SD|G^(2h8Yv3A>B^rrg0n90E0wK=SvYG+da#DE4tFGW^tO6<
zW(|9@Xto?RY&9Ycq{CB1E-4~DS6N&Qfujv@W$KpRE2Xg4MiNV{@aq_Hu#LZ&4QnAO
zfYfC`3OV`=mM@}j;?!TI=QMj3>aE?Q{#9
z+FR16PjCNPWQ{-Fh;2G8>r49Mt(U1@!N_kC`2%fW8EMN=i(?6=sWtCn_kuf#t1yS9!Ng=#HNr~o}#Zxf3Qrq}@Y7%cqV
zVIgwbcUr|FHa&fDPuPsabM3__W|5)uiNk1@8Nfo_n(6+NBVS~y)%2jHOU!CtZ5+<@n=sI
zDHtUX^bfNPh5@UUAlmTfhr^&lA=nBggBdiq>kE~~G1;d&NI1c-2q^MzvAFVb-A;&6CO!_oEBA0$uzLx~n^w**F-1^=5`lFCe0N_`Wd@`i@B#
zj>vFbOA5THNySgZ6P7&ae9x@Up|Bp1?A)tt#0%RYGZHhQvmHn>!i9w&;rX+
zWKdyf#)h(@AQsj3ug-yW@%%beN$$R7c5$4l-&SueatmWU%-$_MD
zAoV@qj7fn^wLEH`bC=s25^G&@w$Z%<#uy5boM{_n2>)0h5tK85J7HFbRUKHQ-}qklAlz
zLNKjy%)d0ykmyqRW%@HDD4tXLg-`n6Rl;crW#IlmV2O;=eTe!*5<*phHxEy>UcZ5d
zgovo~f3aCb6k*{p6W~?8lxd?)3@AJVj$-5xiXnxl4#zMvouzI*ww!?dx%A0G*T@$-
zN8s5MOk7Y<*j$NkA#4N%UsrxMrl^FrtT#4FR8?3=SF{?#mgX4(;9ThKd`FhB-z;0mt2hbJ
z4Jp4zAoY9}x8-*FUsWKq5ljZ@j{ske;tOiRISU0r3x|hV?*LgY0t5Nq%=pn*#Y+9<(-u?Q>Wc&-$A|aiOe1N<)G0nex8_yeRdsDNAC2-iJB&rkeBq6H=m=qOqFE8wBtHAw$kIb@D#zKH~}#b!LB=8VcHG
zY+N&-(P>Upe6BrUs>>zWtJi0K+k5Q{642YWy0Y|)>ZNjXf~I+jNi9yc&^lWe*nIl8
zaQ~`n{c3gMD(`pH!Bv#vfh}sX3U0qPtp>Fum8=hv?d};YCX%0sy{uMNLqaaH*3AmX
zagOI`HGjz$tw0Vw-2YLqG|pg6(&F{5v(BT`N}Q8wLAuR@quJJiqy-N2SB$E+#YF(o
z^KV;i8bMcn?z6WvmXCF~eVjEK7%{K^T{8MzLS_NEH=epH6{196Yc66#9*Kc6i4rHv
z8ApeoBN{7S;<{E?uNFO$*kd$4h=<7y$}^}M-oS&B;~+46b3X|n2VBlcDpHRa-r6MT$d#0@4#;z59?JNwd*eb0CN?Y3LW
za_gv971o!+mokeTOZC3uK|M
z3)SoX<7#RvT7$p?A%J3-*WmT7SvU)4o@umd(vv5^6K%?%rx1A6z}
z{G!S?r3&W8phywClD0AHlsh`AQW?T?<-;Hj;sWnKcv_Bc#Tmi$xq?5Y4mGvYNB{jY
z@tYk`54(Y|rDDxg*L^HYaq$1M4<7%W@Y&{vSBUXTt$(uJp2%zXP?rm(g_($TiQD*>
zwM4|a5MRHDTU6X*%%g>q#r9tAqxGwozfrxJ$tv}waUXQ3)M%usBtJ{}9~$o-MQzqO
z)FPzFdeSv}xlvTg6{Dkm3&mVcjQU*La%%0)YrFwISl_q^LTr6I_{T^ltK(^d>3@NL
zYiU8;wg<<_tyNo@)c?>Z=;HXDX|&|b2H$4O;}Ra^z73=PcVRXlm_0a^9R;_3H}tP}
zO$RGf`1V+N
z4s=YbY(nCZnRrl}PkbX82v*3VD7!Rv-gL=bQ8p;#;{PUEW31VIFOr
z_4iW9IwKL_aXdbR+v!c7dlB
zWWR(cz!|NVWn9SdrDT8-+o)XU#yax?`Hppc4O0}C0akpMok_;R1Rf+^4kGOMCLY#2@N-`nPGO7fT~r%EMhxrwHUOAd(|
zD(q`}w^);-!jkcyHx0F)I2>Tyw(KW`^!VncvwYMobbg}hQA9?{qon|SQPSn`*dTfi
zEz~xKlO_mtbCL_b7w152v>eRA5?oNAbqr){6n~5t1+{$qS}p_I(iU-28#N=Ur{^Z?YSE$qwqPFg$Jw*!8SA-K80Wk
zRo`Pr!Y@PjYkm58=Ruwu>6O5+D*kXU+g$bV;oncIrkZ<$M~cmmFZQD~^VRplbVWt6
z>qS*NR+(?WuwCEJO)p*bTcg_W7zOa^LJ%xC(S~1%Ggt&ddBran*lPeQboQ)?_#IC^
zX99}c8d`>+b6)Q!FbXt2sB7b661?GMgF+ISY_K?X1hNu&C%-Aj&ZMh3SD!blBiC^$
z)Ho6eBH-{TbT|{Ba7XerUL6`qYH{bSij)%f)lSXU51bYVCpQo&I3wbJ@d_rE!_sy0
z;-b@tNLh#!Abm@+$p^tNh=}u4O^Sb(zWL$$5U{cPYNiB)$BYtYeIcaILIDSj!-k{Z
zV1G8ja}RS?zC3AvJhM#a$&F%-BKWTMB{s|29R6#FUZgwhpfEL=rduH|$l_?q#%b!P_s@s@Zei`~`h{*+^|Blv_9?gJGWZXeS7;fxB
zf9x@IhiOk&i#GwiK;mb)ryc!
zA~7CXhaLh$Mm=AXf{=x*-nR1W>%4uHY}U!5VF&eaCTLZ$?k3%{sE@Z(S_c>OUxs
zUj?mC9-Kw>PWC<`u7@A^k6>&Ns_2!*+W`^;ekL7i4Qg2`*{?##K4R`dURU7Vv&5$>
z&yBNxEPB>JminYCHF=;TOH&?9z1d%W`EbJMLg&{|%n4i7|Xo
z&%g#!?SgeEem9#aLPf#wbrA;l8{@zCR#;?
zprdG5e!1x-mOXJV{KyBV3Nz-jjMv0^Q!-#fIq*u7ynct2_rZ)$>5~negs{SKcHaP@
z`|@NDvI5w8RC}sNi+~>rM-H{FL4n!-C2sLxjf8joEaw~$tCqv{8xqZMa6|1%i82<%
zO(6(9n~BbwlxU1VfX6aqE5gmku*0QAM`h0`j*mvCV|1&{<78V7ckJR%S$qe+l2d+_<0gK{b5KymJ7RO-cr@eCD
zHE%g>)Y$m(Az8%Vn2HPqAuV6cM|U~KsoGcaEE<8%;Tv_xNF`-rbe&ih<*54j
zOmR1a&QIfY%E08d)OoY*1PTIv7-bt385HkDR2XD}pfBLxAd`
zP|=Ls)`JrZ+gWaYr&STQH5((O+i5HgK4~BVmr56+KP8%)^oHVo$#KC3gb+P114mS5
zyixoU*@m*JJS_>wg>UgZ&du{P&*7mll38t!
zjmhnjCZbm0xJbo)it)7^9#EvI!Ol$ole##G*+vT~H)I}TrXX0Q*akT-)w5gcI{uRc
z5*4UL;XMzqUXPL?rt8@tiI%0#1V?4_q6-*Tr){+Rn^hS9G~j~SgLs7<)8+Xx_Q*)#
zFl@|^Ph75}XvT4d9W7s=_mPo*-zWKSi~T>A&ibLr_kH_I7(KdEVsuJLY@~Eahopcs
zDkZVe5`qGf%4k$11Qe7QUD7B>k5);Mu4nJh_xa)e6YlG}&ht2q*D-gi*u~|Wz%%E6
zL16ZmKu_*!hOY*LNhI`shQt5C^c?#}Dc|_uf8DT3W)7vcR@{HHY3bzs5i})|1QDi7
z#zJl*xnG->nf<;Yhq+Itb__`aF(#&TRq!IwcX2RA7)!KNbU)PhRb*#C&%@$O2IAHDH-BRK7Ohze>#kHUYIVsQ#-JL&G4%WZo#*
z_kBMXR(VRYj~g;i2#Em)(^Y>UBVvNf3fRrnw;6DTfUg|CR{~;V23d{OIix&#h~eD4
z776h#HpQ`(FX_y*S6OP+2>g=r;b#pBucS0y+SG#RjQ*I0s#klDF#H>6(7h+b^zioN
zvZGO}AsHtT(KmJVA9(y5n>ZG)=ajbmT2+K>6@YY3_NSb|k@ph$T=Nr`rQ_iUTUi^b
z9V#{zCM6YiO!*0va{HJ)CPF@N+yCEG-CFMIuX=$;0%?3koJNHTFO(ngME$k8J{_Nb
zQPSL%K$bx1Rs<%NBBorU^x58={FmC7Ng2PP=`s5%K5+klBg2h|B8|263;Zoj-dp)5<
z9Mo7`Ha+D8_`BZz^Zgh1yb~*kgdI*J=a(!$?mm3}j?xP%;1_G4C;HcQvnObVM`0o(
z)t2;ao5ol=d9IX+m!h*y{5R&=JNX}Z^##J~p9g!htaQQI0LGPy+lN%c#HJL;3E6}2-VU$8J4-bO-14B%0iBK*(GyVQN89HL&AxbUy;$q#{Ko>p4
z`ZQIzBRpu8v^IM3ORrOrKBR)%PWj%)<;Ks^^wG~hp<8crr1N%>j%bvsCpoJLd@6gj
zQT+E_?ZsXf>GvemW253A{dE81!EEol_CgN_*DhGA(6%!lJ>C<@AU|Z)iW_S&xZ=tW
z%Xymi%qMN3ckc_aEQPu=F77V2>K&vAnaOmUzVoo-(ChCq5e$wX3~Wzg=;tG!32>bN
zD5H7Bn=n6&Or^Cy-`6Vss2w+H)U=Gf5-8Ir50X>xyi2DVbfoyT>X=e^5^evW4#=OW
zObMk_Xh0f`*Xt8Cc)4ZJLu~IpWt(uwRx6c8L$N@5V*2xf5XN3;R+svr2#UO$I8&_1
zj>NlB0J{=K7G=Cc_HKXlATH|~JHcscA{ST5&obFv{0>GPBg8P>yP{~rt+Vi&z*Ks3
z9CP=bi{KNX_r#uAx(!z{5oMvR{VH1raa0sXOjsO{ZdlS?3JuI()@BXECLW`
zKR5sNQ!{|{>*wZ^ZGXQUnP~ds-N&4F*a%B-e*#(mbw;lGQ!w#Kh!MxL*NQBvp&|k2
z8t2^y+XJ+}T(oHf(#l6@gk7I=4n@;H=NRTxD9BgI%qIwfDw%hb>=i>`uEws;IGFD8
zi*cu$j_rT=`MASd|Lw)o)bGSYdDepU>4OaEgFcKtI*Vp{G{^rjB?~
zXd0Q`x#B^d&0N0glAR2}muuDse|1M>t%B0XxK8s+dg|Q-G~PH6*qsAO#QJE)&MaAF
zVXc5Y!}VB+Q<<6hn-|h_O)$f*)JQ?~t5V4UC-mbf7zjY&>P$fYlJnyf*l5th;-kF=
z^4sDQ5vnuAHh_oAw4IX)-J*9QY=U;SW6tX9QcadYJrex!&RyoSADyt&(M+^W82RqRoPTu{lY6`6$r!-|E?ly$C
ze4~**RVTOXBAZLs$A9nGYnqc)2YqRO{KT;(AWQaism=|n
z-QF-=%Qiw3J?&)dC@A9m!`KWS)ULdvgJe{Co}V-^Y(FEHCC>m-dK!8*}ZOTX?PaMKVZ&M^)-VZxO9PV7H}q#>EdC0qOEK5o<&1AKe1a0)KYu4rwJre>c@?2o=55
zQ6PB7!Z8`tLOnE%1#&xfXIhbtuY(bZ*TW`8mUeVvNO_1nAyARX&1tsoGH7aQreFEL#CntRI`n*B
zv8R~7&@wSPhKLzWk0eryBIB)oA%KQt;t-y(^VV=wzIdgisQ|h~EMvMnFt5+Z
z1J#XD&nUJp(a)4K?TdQ=Rp%{=?+j3SPa1FT%L%2IrvP@XXMNF#kN%wGe_oaoaIx;|
zA7klDES8w3omhl|tIIu&2)qdjtx*S>7{tT`HGY~!xT8M7L=yqvLJJKN)PDTihs8}-SBPYr@GR;J-M{h<5cn!a`K#qS6}edhijP;
z*y{Yety~s4qttxa5B1xN8}s$U^?nI{(-wUrq7h#|{bOJJqZ-H+^3M?l;weyJQ*BX|
zXdTtA@|OuZ*EpUUxO|q8YbG$c9A7Vh5XKBl3Xt*OjO7C}i^+(oHZ<;+D?Rr360!_m
zzXhZ2ZYq?0hCmThF{H75`}<$V`>_va^sS}lx&|+^(7yPUA5U_9%zlby`0u~{K+D_|
zC1wV{^<5H~uT4v+u26Q2ZS|C|3xx!M?h^d<3=(X}x$?iY&89#rz|!bjVn<*iMxByX
zz?8L@&=V*b%?-ZgjRuWSCmG^L%rix*SffYD$Sqq+Zodm+EAD-vQu(TWn#@oM`m}a!
z;|XnJ_>%v3d-2&v0WK<@@wDqO)fTC~GiwDC&@*?*0pGUfWDTL>go>IC6v3&E<3BC61{tLK!XE{^$i6Zu|duA?6{+UOS^-?*gEGR5(ahWdRB(-DRyj
zg$RL&b<>|2%k3a{_H?0NiWiTYYV=$=ZPZ3An7A#q`zN8sXfI$UUb*e`ve_}tEux%0
zn%)9PnM2joNlny8|JZpIk@e3Y6}0$AH1*O4Kk&-`38)_Ao2c*w=R|~!sd{SSVxTei
zr-eV7j8P)!Nz1rFu{jL@)B#yL!tY6fI~>u=Iz%8@D+3h|V$Q0vM9|dYmr9?VeDU`s
zJ^@czd+2jm^D@!Y^J84`BYZEb%O-Z+Oy5a+XwYfkkg*Kik#M*~^cnVR27_*YGmq){
zr+Xi*#7gEN1j-`;?2fwY<~PKmLu|u?>NGQD8Zs}Qj*hm_7XjK2@c9Ye=K;TSzbD=|
z<7G4F;$638X-odz=M_WnePSzADaVh0xfab~wgo@FNA#{U9b{899|-L3-von&pwP=E^{gl
zn(s^kh>PQRE;2uBA>452+DK|tF23^MbFuinhMzBGt&RIWzH>!oh}W~Mhdy(%AT0^Ok#AH6AdUBCXelEWcC9>B&maBeW$tDE*hy&ZCcU#WoF(s%rVsLavbVUg__eFm{j19!r9h%nSk2yA(f+Tl
z7t(zzdjk(^|Vjg29T2;HEt}IXF8=lf7a*?i<>~Hb3
z8_#?ZYj;s6IUM_R1U){tmF
zWY5ihVC(ec9im71VYd*Aj8iMj>@YA{FY!tU_pNAb>{QOyYY7#27q0;O)*w$iE|j8$
zOgswr)C5`v)4bOqcZEMFy7|i1jhvk?oKin3jg+7e!7}I{#cg#adK`cInSd!RSFIM(
zcGEHPnxA~LAB2313>HE_`A&Vj0HnO)1qqPPIYEbmDyvCfox29u^Z&><_bo{4t&6$zNxG)nlmSD{Ir;mL0+Tf)odVTqthplG2E+8Y)n-e`_sc}e2NT_a4_P*T#M7T6WS+2GsYKB;(d9`I)-
z-FGOyjXi(oj_lm=&OZAhqe@d>RLK41F_op~ACwc0!wlI-2vd|w0B_)V$mO?ZGjCn+
z8GXeSM!Y!Ey*GocPkAmV6Y;zVj1^`J?|S|1p!4l&oJ${>fRXt~!8;CRJ9!y<`LKq^
zYaaOh7oByq-_;X_QfGUAO|IR38&VSJv7P!^jX5^{eG@HJGwv!u&hJqJRI
z)Sxm8W&7(XkD*eC#8pTVJ9ZN;K#9)2RYm_DiTzCfvw&~=o(2bVb(lw7Z``Gp_3$O6
z8rWlFEZe-;;Y#9*-#0a_H{s7k1}5&{&+CH}7VOR6O1~hriDiHRsF5BY8h_Xz`Os6O
zg6aLSL{jhHxyR2h+8_^%;5lixm%a$d8aq3M_Ti;}bUvpd~PM>+TkDl4^(
z*dxyQ&>(oJ+8;fe_x_chdXk<(WrDY)#N$Q%>BTVM2PH9ml^0x0A4q|aI}cDaGLKF5
zPZC%OfD@SP?koBd)>;giF~xP;TKxXFh7ICFz|@9$#;CH~nI|=`2i-w{2dR3+Mqk$>
zA%ff`EKsa`8LZ$V&QCO?Xf0J&NG!5Xk2je+_0@dX&vh4_znaPf%ONLD@mGCz@WS@#l!qym1f4LoIT|V`ZTJNQh}>@jZslzor@lb{StGH&&e+F+{{0
zFfE^1YG0xir~K>o!eP!Xbi0ImGX$ryTQ}C*y%mwS;a9@?yHRgn_U4!BmB7VBr2`q&
zW7<5+B{Ys=U!Bcz%)u&INAIhNddpzvle!6M(H)VDv4?7GHpZkDXo>?m-L2xuxTgB&
zfdGn@Qw$C&luM+Q5S6Mf?YuA0>_<{oOpuPPGObNGAe<&DKGTUX#CeDNm?vj
zF#<17+|7dlq)MSLyQGB#4YKIIRKK*xH<(?DI{Ghf
zhD*aTKPwbF-e(EQ70ji^0>DvTilyONq~d2jB_>8u3%yvYjogz`BAHq#CkiXz7OuU$
z<~(|u@o;xzLJ$N65;w@GDSp66!QG@0W(|`v20j4OWjGBUQXGr&xux6F+FX8B)E{20&-SrMM2x*DWqehY1}7oJV(+Bb&Q!m3dOX
zVXg&v%iFw<2$SGI1?q@4ASO$Hs`!A!X3D<>&Bg`dNVkXZ3yeTw=cL&EEjk)UXDbOK
z<}sX>G_Oe>;t1G;6ouNNi4Zq952)CfL@e9{)DCUUPFB&D0X%FL32K8@c3_dj-mDjuJTxY}D-UtN%+cXV&bx_y
zDSP)NyNVo2eB0#}eQ8yv{6t?+2rWO?>K`x7HRPf+>tXSJ`?Y4E*kY
zS!(h3Qw?s7_!W9Qb{XRGYn}EYpRxLi>P3ms!PUZk-wB<~>8XkaHFUYNg4YVa@3QS7
z9=R_Vv@aRZkga@~xpb3xQJa5On-3Lh`Dxe|l@UhPYS12<9eKuocxkZFlfQjZWe)YBkoj
zAb-+ebei@v^+>Xy8!(Gi_2l9`K(<3_2sG&PZ^jI19S;IOk&7gr%A@(Y8OEWcW}RPm
zDR8oVo?MELTy|)KLgFV*P(^s2_W&Z)%#k&A#{EM3D`<4nBkMJyNNe0si&?27fXtr=
zhU@e)rmf;*yQ!fJU_EX??PIf*ffA
z>MfD~SqhY=5_w05Msch^F3r-|k!4w5M<&KZclFLMqmpGZAhABZ$ke~6AV!BJI<6^$36um&GdzDTsTd~=1^)=cDa??
z#{o!*c2YyXn=g0%*;HP6%+B4>XUNnXTHv@6
z?B^Qa8Qnt~Z`ruoy
zo0B{<1jNsiu-~(E1~0I6L`ryohuAALAf6)t#?sX5!oVxJi@ZgB1tepsNY||{tl55S
z&fkiPp=|Lj`NwZG6^pXf)VDX+0T9QMIYP58Uzrm9{sOWX6Y?7|=}%x-lr7j(reKX?
z&l6P$?(=T)np)^AG&f#O55<3q_|+D$%b?r-Xx5#z0xuv5qYoGbP$EglN#SXCc)^2@
z?^3wknzg&v_uq*!_@GgwZlBW$2t&qFRBELI&#QD<-eD`jJ%sH$Q8#W3&<~fzqOymE
z1Mk_vg2xiiGPY=iS0yz?-kq+hmecFq;8himp?ny0_g*#%h(PA{<(u94E3-?-j3XvucAG1hvZBo+H(LHT?!vs2
zA=1A0je}$N)Jq&RGiC_OfS{69230@cBarQm8o-9~W3O--a+kj&UBs3xL3=~-$^(OnG=k|CM^n-WlX
z`Y=2eFV53un@qIO4Jloxi-oB*Rb}#S8m-3@Go)JHrnjg;ENFUqG
zre;Aof{CP}bahGk6?-`TIm?PvAy+W#1skCUswj+R{
z?7PTaz1qe{?oM)K-qhyLg%&>j{5ted_Uhc{chB6v_rcBCevcgEc7o63{0`^*0t=e<
zxBv9fe=3ya_)yMKjXUV7srWJ1;13!DMlw<|?Xr#JY|4RPGwNNokIuQt<)1c1C0YYn
z#=yj^{=|uXJ^r|1|KB`L$P}(7fyHR%XivaxE|SOVe?qn2$2v4-EU_zZYjvo5hS4|i
z*(m3oRL5?{^tqKdls;Ca-V{*B0*vw;IrTHxji1%qb-I@ji7Eg9+Rs^-u)x3P%x1UU
z@$1YFS0osxH))A*D3xc6XEcM};V-&~n&5J%?AK=iIm|voQ#$}8_Xf_lm>t)1{#k6=Q#f6tb@L@PHznDTxVY2OC9a|MQVYk=N%uQRhuDDg2y4;M`%-?=|d~B))
zp#XmgPNcqC2!}rj64*3`2#YmKYY^5TPk|xw-J#iWGBnS*AksopXE#if+
z(u9xHp3`cnFR6mnm3POex5jRM+J{7#B|RLJG>`=*@Igik$5Z
z?@=BrSA5S;TfHyb@^2LQ45A(RPuZQ(9bS@x?roOCcBcA~+FtS#BN>+TW^{(jm}fv?
za$Qo1M4c>}$HQ^b8_3RXCTcKuXMb=eOyPOnlKyjykjDt9hhB@|J*+Ssj~>_S>RMW8
zzggIqK;osmn{J+-w6ik<9k4&$WSUejuM%Mb`YHD8%bf_rRC{J9XCk&U)Pr#IdPpgZ
z*D&k9b1iq0YPw7Eje>BVsRikUzNr>0
zw{yq_vxs>EiXbxmf@Y|SmfLz4n&V5+2?^LxN!vioj}WcU$*T6QWbx*2nT@2)qAn^I
zrAv}=Qrmez{x1e69m(9Ayvt~5HXy}YEUDYQQYjn}V&B5_^5WuM&2=qEv^jB6NR+9-
z;7?#f43ig^2Rd7k6V2t(zj-ktQdme&fn#8yE?ahEqi;Cl
zZE?JJopv+ecd*-jwW@p{$@7vql%kJ0)3?3**N)M1|1-zCY#cTp2N+F5qe-)kAcw7_
zpS3qIR6&E=hUu|`coS2O82fFW4i%1h$3iv1Pem(PuM=4j)DyD9L#PS0^iQ4{PiDha
z5Ky4vn#5>%)9oO#UPtIkhIbO2#^-Twz&s+qdo@i%efVei_`{CB3?Dn4ETt
zy`MI{87viL%(1U`i`pE4I3adxOBX@=#lNIM-W!CZRDzn)^#S#Crz%5k5oOK*zU5J%
zE`q@`zw+UeYU{GB?1#6z0{iB@#2dZH@`Zm8D^K=HHT?4)I@rPlxM<$EPF`*o9j(*O
z{c*3B6Ia^1e?h3VZ3*!Xz3#s}u=n>Pu1a^6lAlTK;$S1qx8^21R}^QB*!L=qPfR&g
z-EgE|IUg0OFsSala%k6S56=%hAPhM^$36M;_0zu?d0GSDmgrM~lOqSeLOH@&(;>iF
zQ`SLhJLIZrhZ#@ftDPnm#>sVsCih378Smk&rlK-}^JyN^WP9pL~L
zN0H^;%C*2TBEE+|Y_Jp!K%IXTmWf^^tu`TzsJr7Lp{$ygUwQ0mW@>1};MYuUeA*c>
zB)L2v&mrCWgz4DB_|FV)CQKM@AJB5Tez=YQ6iVRy+I4RZAMyCA;UUIqqJA-Xe7J<43Cmjg*RZB@e2O`t{Vz!bB^t4EcJ3r6nYo3-+Nqy@8>J)r70)?xA1^yH+~nnp9+J%w@U@3#kRA
zSY+|rHN>&Fsg70L)PLPSkC&o{Q8(b?)R;_P6~D6y{KRHvx$@8<{4M;|X0&NJqz-)K
z+DQoAr4fHPDS19#`IKjcCArxIOojR*tC-rQ_a)z=%l@&V==t1M#21l_8~oDE)0X=}
z4{Nvf)E>;1`Fj{19iEf!8##~R-GOvdrZz{+@ehf5%^kdo(x97%TnKBw-$`r$?%!pZ
zU$raBHAimcIOe_bUa7ox!@!o*R9R^q6ZK-ssGHcBuOdUX{~}K?lvf>bLtVGz^@yy1
zpSWU#T}t2IDzWVCwe~n(nCUL78_;v1`;L79dwj*c+?kn(*sq1@MoLh!)&@9$*sBK~
zboY1iCSt1dm~JSkl;YC(f28k<7jw0u94_~c|h+WtO#
z&2{gim(Wl8)aZWwnpT&B_V&uJpJn8{ZJ6rBp3lANeZ3)A5!&gJ|Jb^3;S))X%b-gk
zuez%M#9rDdjV@{Y2UP=$3xCx&ttn$EuC%Z+>Kdir842B#rUje*1Y?9fA#`CG@md?U
z{0qNvfq_U$071(vcVCz6114jh^AJZeC7kO=M{xP
z2Y{$E%NzOJDUISJfI(4dtab-+16f%Y*aO>~34qx|bSUpUHhkJDm6lDzxSWqKQb_B-
zzZi$;rIBYb5NpCbj-Z{Dy3Wu)yp*2bqSKv8-z@H$bpB-hfP?CyaB(uBn2!{6
zvbrX*-1Q3UneP#=wEVxkUHqMH#cq1%by?^e+0BM7C~G2;O?`CZ#d79QvJr|C^7mY0
zxm)}Q#0Z)|T2Ye^s&fl$|0rmnSgqfkCCDTgUWbco4l}5_}ruG+O_L=3v-4)r%426
z?q9yx+0h%_{j}F5e6nb}N1$Uae8$8qY+WZXL3HJbD8fNv8a-p`s@1roz6($1xVDc8
zPn)mOnp+p_lEl%vKibZWWiuD2`rHV--AGrPJT_0uhPiQ0N%t<1?E76U^E;Gnf{@B(wR`czln
z{aC=%KD#5*jsPv%AoA_?%gf;5RjI&
zNKQW%5Fmo7S=Y7Wp^WoW8HL1J#-kFA$)`TP(Q4zw6T@);I310J`~wsT9S5#x=E-C{
zO+rKPy>VN5ComDnzZWY!y4Q&Z2JZ7%VCrS^jHw#Cd4}m8z)OhGDTaLa2EGg`FkXgn
z8~ia{Rhx2kc_3;2QjN0dPzr9)!nhklLwG7iUIO^q*$t2KOpxlWYw9{p#w07ibJee8
zHGY96J}U19w5J^7boI?>fbmi(l}Xk`8edia-6AC?mH&3??mSYL7{R;yIwhpHq-~(d
zkALOOzq#HH(hcYecy2{Gfm(UoDfyamjGMXK;Ou%e>N1UEuEFP^Ex`9~MUzxT>GN%_
zSAc+a1}wIqIaZgS$j}W}1c35@f6DCiYGAou8S!i6w0yIbNar7@=*)j<>o!VCMWJfo
z%bK{)PJU`1G*jH7Pm*?P>-_!$IaQ^<%BlP*4$KTlTsW>5O(m8jJpRDDpqFcg$Ug<3
zqOsDs2H}Wb40s5dQX3%PPau~}bb4@MrHL3IJAaM;Q*@8ahw-T;B@m|%l0@b$kkjt2
zmaW>@V-hXmw=;_@TUb+aL037CK*8T-(^-FQS$g1`h;LrI-#mSPP04LGs+Y$(eGTZW
zBIZf4A-`1~ck!T0d1xh~{(AT2F2km@nnYFnQ!(k`h<&TRh~t5DTaYtW2fj>XQ)WU+
zw_J;os?^nPXg;+wbQM^0Q5^BWB$^K>&un|B=y8d+8v7Cx1SS
zcqY5hggZ9IaFnOY%0D>`A(c)P%x*9QYcqO_DJ0O!H{kr2{RMp}^QLftO&)(iANoYf
z@66gsTl8gqmmL11F@Bf`fjX41P|Wy;`ahfhl@ZoLQ)mQ|+D|@3$&^3S`hJkZ&+uJ?
z=iS|V?9T){NXK(tGWZ!zRvL3e(Xq6>5TG&5#A0+!VrT~4>EjAM-ZP#atREhnx0#;z
z68oVy`~6Mb^pBbvQRT?(nbNFmeOBT4KGyOI+gHBoN83ebw}&$x@3fMIhyB_7MRjLx
z@uWuiLgpuT_&-5P_Q({Dh$QyN;;P;fqk)X8f4?G$)(22TgqIE{hie+u--M@US63@|
zC(j$R$SAqb^%;?eVvSc~R~r$#3zUi67Y_t(oIamkM_do*e>)Ch=q51Q|F@+%!e-2G
zfnXnvemnxJH1(7EFQUO{P?~W;40IekM-JaQFQMobV{;B$&VlH9NQ89oVrcXM?xW-#
zyPVnBHI_EJ87?9TVnb>;mXBbCZ%ZGo{zNEPRjLOmDSkPUU(*e`sifl*y}orC-gPEhAErc_qqpjk4KPU2A7lkc|=
z{fMvc;UV4snF2zPPUe33(XSpMu{c(
ziM401@j$Sa%i=lEy@LTwzTe073?rcNe=8b)(=h(hk+|b
z`^XsmnnIVSx-Q)(=i%if$<4iaRr;W`3!esb$xz7B7ymiUp}#3jqPGku6JHmT#gesJ
zK>W@=-<4ca|3rM^~K@~-8%mid62eZJS
zT3V5E)i`~B40+{70X>Wk&0ezV2%BhPy3V1SltlA~koRWhlAYzqyM`fkisIfzB0z<(
z5e`lYI3QoOM4ne3djKWzL1@G+e=?ryQwD-*8Stk9!W%>|#;&evsU+^xIu0oSs9m~Fi-E+s4&36C;MtY=wx
zRfjWJ6Iv?Q_0+Xd}X(Fe@x$bIcmwk?qW?y;r<1>Y;1xR#Ii_
zE7~aZ#X-Hj&3jjN^C92&82ZVLcfauO4)9+N4tggt3?}OnelVu(APQAK0_c!LoDNS_
zeV?8zJymTzi45PoITZt7=%1@<8O0i^_86)5rm1$LNZb>w(VYhlNm#tZ)38kC(@Yfw
z5q8c@suQw{r)RB3%`sPl32A3?d(wU?bg@ZuoVs&+q&37DTsYGEs@3~zs5s@MebTKL
z+On@Q{w&B3CIF(pPi+K-e_#(COZCBUSWF@~Ke#z2N`Qe7Bp$B|Dyv=1Z;ccKkvXs-
z2`vq*P^TSxq{B+JX;>
zp|nU0>Y;SYBR!%$nXT5xhp_`;K#!I8j7myF
z)KPTuHdD(+lW(D#?|@gikt$V0NFs950v>>chdF5fp8uGl2~yQ}aS^lfK;7B7XRpk<1qbit(2+p=@h)9U;~PdU*#f;aDR}>szcfVa
z^2Pu_fFVgVl^8`@xVQ(}n_CgWrw^dhYJ+B{fOYxB4EC`xIWIb>daH2J!$(Sh@ft>8
zyeAJgsepte(s>LM6wbtE%7p=my2eQGYM5ANP5k+r>y@qr)M!$!XuDH`+5L4--3E$C
z-FQ196n-AnzY?W+vQ;wTxNmqc9r;=S}%)HUQF9!SBY
zQ<}_H9$vS>$r;IfIIvpV@7LJ+sCBb&AmeHvp(F=n0<4nLkZOum_qG*y{SVi}*
zmoYSnL=aOeHrk+R@?pX-ze`@(FjL`8`7DtF!N!q$2OD^v*;K&r;vZUwH;9K`fg&>`
z)KZ^X6ARIgo71*M#ueK{-Tg%|2%-i-4=!U>Fj!u?S18nFOu8{RizeWSOmU)SW=lVf
zP>(mYc^y`qk>Q=DM|IBkZgsQfhGK{D?|StM@lLJop3@tD_Y=*`46p5nvqB|dd?@;TLP#Gi#F
z63%U{=O-)f32!H_x(_O5sGFQr1H#f{jYETSRPOLTmcKLjnr*`hjtt
zz^~@iN$$p1;O0DH_sDSfyP@yX&!=G(O|53(SF$%7_K_D61TFmj-qEq9UrBc4n8Aml
z;KgShw~C*pawxC~DX#BV&9f(5VHua~bWl`bB)IMv*`tfkuP*S!uV8A%KS04JCSYC1
zx?w)UqS$(EX{LFO1phPpx&XTFRYrrlWQc||_j{Ew0Jg})-=aPfe}70}+(AE|K#kp%
z5>?e_2D9CWC#~ly{G|d5y`IK>&4?MjLl9^A)ay9|M#C0?CFX(C-4n1)$~T`%)m9%a
zS`RA>d9unA1tXP5)RejbBFnB?^PE}ou68&BgATZVSc+)6P-7TU}RX+U?sl*+AlsumNJ$$n0e#FL8tBC8sF9$0Se*un=Yp(|AFs
znRe<*UWG4Q$(}t`LIRvAaqL((Nq=M&fCL5*_7}kvVQi(Cm+dvsrJRM!O)y`F5k+Ye
zGsTDR))tnTl%zQtr%Pk|u19w}|Ky7dM@(lCvXpJ
z^N4e8(vp7C(tLvTqhMX!Eu}IXbkGp4@?<%HSS&Yn>8-oKunRl`7k3~`>ljV;jLiQG
zo^m~tcDUouD@w$U1ISj0ZZzf4vsmUq1mnFqs0uAkzTy1&E
z6~_4dZ)iHBF-RhCK&oAkI(NHZ6FyJZ@DJh}smj>fT@jBxbslYexlIszp7}hlF4lkK
zL+DYuO_-ZSz%Z8eBdhiYJ%U$jwbQ2_U+wm*Ej2#<90h$N`inXf*8!#!#Vx-`#6D77
z$dUR
zW7HAY>G+8Y2G1U2f;=9f_+t0`FRRALEh-)3VCG=lf|Z~RQPL+=*k$FO-W%ojS}ro4
z=@vrzqn%uvNxLDA{E!sbpppYuXG)*IlO%%3TDZ1fEUdcoPghxm4~E2|W2HFIWd3Uo
z%~`_FcoS)u==xPu*XT2t7(HNMNBpbMOHw;BDXcM&N+!g$VKF8ojO%6L2?UY~h11J)aDPbEq>sA#q85{es
zOWgTo(dtiiR)3VY;IH{e->9otf2YkXuagfjfffPdnTzF{2HKf9lAS0RXJiV9@wrM5
zju;SEVuVas+g$Dbg@@Y753=uVKBr1bNa*P*nOKbEXsZ2u|N38D)1g@VSKISi+pr^*
zlfMzW(5%p{p0D$Va`%<1_cucK@DHyCVpd8TFMsGh@Vb5Fq5QRuZPP*id|iU$pEK38
zsqK562e1&`$5r@I9K(C#JLmqQ^>qc^jcj`83u066f2R3E%pR>7kmugju5v&=b~VD<
zG*42JTnw*HL|LspP)9t@NkhZ6g+nLqxV^hRss`!}<1F&0tp&Yl|B
zd_%_*d8~o>7Vmlwgs6~YwCno=p1K9K*5V(tHk@UAwx=EvC6hw`iDT6QGc>R10>aTW
ziMZ-)FKph-Y+Yv1D`^5=a=1CQNnLQq@iPUZ3YM6XRf2YTM8+0>DJuUN@R{!~0oKz_
z*|E&h@pDu-ZrftO@{R@diM<
z(uXFftide$hw8szKJ*w%F*k=Xhw0HptGxEOK*I=wifupZZeTp7=%u~MaW>yBl{#GP
zo1K~Q>FYp7Bsn3}=`n_xVA9;XZ07+NICpGpcMb&L`xW-NX0Z@j2?T(PiJHH=+*pG=
zmbw^N1mIIlp@>S*o#|%dqB0TxNPQrtstT3~39e>S8t6F(${-5{_wV@QT;Svs-$<`o
zIl5P93A-0K5DUPkyDNWtQ!^@G!C|V4V01OqtYd4P(VA%R&wl3P8JURc5JGl*xoc}k
z1;?1NShHz5>Y^z~*K`vfad6wb9uOdwDeYuIgD5*F0wkkeMgi_0@mXOWC}Yj?%eFO1
zS=SyNIv+SvtM#jSpzEh-j^y(NK^3w8Mi9e{6R>RKbTyREtXk>mE{O4NZ-x2
z9Ip~Bp?FDkvjs6ain_Xgv)d6yLrG7XP`VYDpe~gphojWN`+8=1ETxPJkU(4`XG3Ykz73)J-wX7G8ab0PtbP_dSvn=<53Du)`)U_
z*T+t5Nhy#_Le=iXJ`~i9Ha=*Q$ufPVOIADS$=8MpG_e#OHW4W*rp+bId_DGX>+6S}
z?{7jQdM12+-5HMizRS}vU!K^RA-ZYf_X{<;e_6ECOiEUbJIENnWy2QekE4ppXgu#3roC1kT{h5ZxU#O>tof|REk
zgFscd05UlEXEX`HivT1kha{Ge#W;e!Wi=>By1AzOdX?%HJ2J+wB${`^NIc5u9ek)>
zJue54aO6;oh%VnFI`zA^l1>scs&=ZeoZ?VY7>AZEAZwn$DllR*$Vfjdi`cUQNz?PV
zkzfyXELakvP3G7j3_N|(WOe!gX2|#^U#}W76Iv4g4467V!3a>tfvChr`7q*QTxya&
zMse9fSO)6AW%9mk`4^92lK>8vJfKQ||QHYe<7c{>$X
zq)OQ8ljor^$6o?=N0zR4ZsG+__pgiG4i+co;o;v4e$Q5|B%$s!$OOAvM4H#MHX`S&
z?wf<@N;9jt@{1Qr*UYlrCbQRHzWnt`JLyw-sP$sC8*(}fc;4ok%cL?8n
z@LX@ih+v{8mqr(Nr28mqG
zcjKl8u%uNuX7c}(YjH!%*h$3%^qCSlTW6}mdzHFpd^_Qy>+4*eYUMcS=fZN6
zri-^k4bC*U&h?Ds_a3vLG881MDCY;`%dg>+K_{hMccA$e_sa)T13y#UlcXgV20JNb
zDdkR}?LjCKjuZytB%v!H$s1bPX#gdS4#l>W9lKHGEt61$h(XzR9%>9jS-&gYsdKV|
zfe=6SBo|{6Ag<+;g*75;b8!8qmim&nTKr3x=;PUVL-)FA``uY;;T6FMBeKNW4m7I9N*j)DRXKbv`-tnW0i|moKIR|)GU+|R`sIIeO
z`8ol2P<_{W#wc821gSxiAVYL;hM=&JSH4@gU7^ak-d2zaAQebhFDV(kMg{n_H+{BT
zn0vpoH?0!!ZaY$>^};yhs_oxzd;GesjTipc`?ZYhfXvH`i?ABTv^)Sbun#WoN=M2kw-zRSR4&eD3k(&|>e@`5vUf^aiv(>{1
zH|L$UsasdPydTm?Z||dRX=8#Nct|GqtcyJ<_D+a~1O-&B$$hkH>|Ka40bxjq1XuQP
z$3D;};voX$TVcevZ*$38-ltM&q=E10b@6#{?W?(JOt4tc6*4+7&!bt3Uy4CwjC;XG
zTy%sgATN2#psuZdB^t`}5(SdPfEn{_>5+1eu7zL@W3JDlBOh<#6Zoaz5y1>kJw`$`
zlqI59ZjStG#tS=fQFKb`H##F=09=}w|z&U01$axDj{D?D&T9cnkC$!@K
zk#tp2QT%Uz1D2(i?vz-%Q)21v6p%(rkd|iY2Bno+N
zy_<99VlL*)cb?~yvp|g{32f$(Sgy|q6f9#VEsKSwrB9yzQ0T*-qG6xm7rjh=Y067v
z3Yc6RnVk^p@vvflHrrtq520;wVoSo8Qd1;tw$m$DZAx^1?|whreOUgk(Y+%rFbe2n
zrUR5b%8k=)un4Be0w@ER;DN3jjZK&{Yx>93$Iv1;JPK-B1TL&ip@M$4`e?G~QIx5W
zUnHrg2B*L#&uq14wZc=MF}6apIXP?lNeu@LJV{{raA+b0qp%)sh{=Cc?
z#HEZHgR+Dwvdu}5lsvPH8t;3T=9
zlq56Be4HYlZaNgJyyR8h2Gj+u<1!9$6->Y}avn??pMlG=^eM!Aw=7SkBUOgrW_eQx
z^o~%+2rIZ7a&hH6`d)*6X~_K>W0I1q!(un)_8ltylw~C0c4Im)?Li~0bLTe22EvWQ
zXdIr-pIe;K)vSTfZcb-?EL&GB&3~7EK6aV=>otCB8@4{PGkZ2n$qdr-MXq#%_}f-{
zeR_kQ{fuCWA$qA;PF%9Nyfzb$9_3FNnHe4#RRDP*q;*Av3K&S)3m6?Er0ebjE$-Kw
zudd4jeT-$KstXECiHS7-{mbs|{s^yO3P^tO(q#!4++q}XSAxmw&bnJ&G7FK7SX#20
z@Thg152+TrvMou?{_@@8aNQye7&RVlp+t8V7pY{vx9%HG6G8wY2UJYzO{xT$q832b1J9^`U%z!;T?2
zr>)i66;PhBKI#{6aG5!rDvjOCsfN+@dw;4Ml-(HTE(@&B|7XOxK%eVq@8N*ItA{K3
zE7qhz)!@Hc#6P3Wh^q!snmk?XnXrOUWyi$^-orQQfgCjCcqA(Ptmz?~B~>9y&fRLL
zH5&YO7XroS24PGf)|i6K82s-Bl_y0{BE|(nbUpydmP7@X#08dgR4DJ4d;f*Vj5Vq0
ztbsldK%+0yVXxzAY_Th1)(|Z1+*De;aQ5c!pag{!&A-Es0;!`a)devQxX>vjQjsM!
zDtF=rn|MeY;xOp+^y=!e%waVxEm(kSv@MWK7>h6^
z`ETsWD9@%*?rwk{g05fm!##G7UV;#sp$fXEb{3NsqY>|T$hxFn{7B>^-9
ziuj6iR}CU&*{Auh7Pb|5N8tUqyVG92x?z?dIwdL@-&VFXf0(GQpJPqA`S4
zgQt(QlSsXKI>-21a*M(;Lcw!9Z(eTQR~M^*4Aq?wBD{{nq;9A{L-(d3>W{HL%f+j#
z;jrd6jvTcR_*UtAE9F9>npp#XaXEZ;&}kK>-&n)$_~@vn2jYcB0H$Qu;uN-3z?BOS
zCNEZy5~6W|6D(IgRCFetwHqJy6bZ@ly}q?75iEX$RYKbsl_{S8rb19@e^)AJuNh*U
z!@!rWiRk)hC&^2wvelPBUm*`aDNANDK$2ofj0}YvXW5R#D+*_oP#>2vh1=#GLn`hC
zy%gjYz#{ZU9J5VrBG`h8hSUfk2Y}JjRuXL|Et{X>-p}$x6rLR8*cE3e^B#-U%MgSG
z_IjnhwmB`GH(FlctFFcVv_i&=-;FlA-6BXl|25U=dsUC3&kPt=`leqq#I>T@=7_i6
zKeeWC$kR8VLgc~L$=iLot+Au6{ZsSzN1B0McBO=D653NtKa1rW4g*ikZG?+SGj)`+JEu(zkYwqU3ZrMTZ
zrVK)%L2><{+$+>dQkq{0Cm!z3$vJV?JvQli!T?(j3lFJ0-hX<39k6p9aB&@gp?Hf$
z+S^T)ZM@nkA{q*U+H!0nBmTUz9Y9_#A5=s_vpksNNcH6`#+ATG1R=h2YmP{|x0{rf
z6ps5|e9aTjQRh7$gQOEEZI`)+nn6FIuVK8oqsxiwY1%5h3(GXJg>
z3DJ$;BFE`a?&8|ScR|`i>~*l0a3DWn{9FHsN06&g?$Ut*c3yNW4##0x^8xgfyO#xsl3Aex1n+
z1xuEiOoIbQCbIUYzf1ETYu
zVE-;GE*!)8sG%+PmfKA1{t#1S!F~K4>sV-eNa>;@_XCqrV_FE3>jq=
zO6RsnSm=fc!|g=uRec@%Fj@10diUrp<)H<^<#R218R|20mtl2|Xr%8CH9A?Sa)Tb$
z(>dV0@t{EJwF2NH`OVuN8aU0XcS@(vu|%tpwp*pNBq{)Q6eLS9nU>yAN4YTZy@-&G
zxN09{#*pFif#tiI?PY|)7px$JQh3p4sv8udJK~jcBg)wnPVRT?3x>8;`OxIL#~g7A
zQy&A*29L5TND0JZCPf!m)siKq-%iWCA!E;)aQoN~;YX8|rKncSRADW_(&xe_ju+Px
zcqz?hkFjopjo0xtL&K}(;rJk;+qs#%S*pAf9M@x3awEL*S2(3Uxi4q;3YFOp(NE%G
z+XhL`2VD%wv|ML0GRc$-RAfpLhgzEH6^%(!##jxcUa>zCPt>h^CKZSwuM=(i=Vsc<
zjZ3rhq_899g#qw$wZf~nO+|No@ruNSt6S;$&l_Sd4!<;8a@+PaH@Dq^E|3(>)
z+T3Ge>3fD35~YRD2%ak4Zl?KEeL^4e|wJ*;5ZPRy|{XEQ#Is
znSD1DagArC(fvT=BzJ0371^jTlYkYoB2O<~aP!&cc{l$2Bv%eAgIFXTqJIi
z>s82@Jb)F-U*hhaIP%&rOZby&qr6nZll{xDC&t>~rNm0zpwwq9QGgf)_E@a<=rSlF
zp{T=^)wCOrZip)g|A+VK@VQ`UK;5ru%C+A09UM3SnGkv0G2zlgTbm26vuHCt&GkKe
z7P}-aq`qu54k<2pF&e5SGt)3@Q^8T?9C?=5`Az0_UR3w
zfvHwF5#85B@a;Kg48^F_tjN&$+#PIDEJbxgF)Iv%Bcf
z^;fCvcyD55!c$+pZDwMx7-JYr6Bqhc+|+bbS+{t>gJ#(?iBI0$%c$lCW|k#u*a=k?5%VJW%I@96vOe
znH(0Pp=88N+9*TL{f2a!0AkahO*QWjm#X;|GO9$ZXlRi~THr?kM}s)4%jdBKBZ=#c
z+MIThO#SKpqD+>I$Ln3m&78Aitnh#Q&QVEXM|`gc5#JR2ut)%;?fQh?FBtt1G9d+5+Jd~XE!8`ScpoOp?@%00{h
zh6GOolB4i;!7y?bs$`x7p{V;sMMhM^tEoLL6{W^D1m=bXGZmD1tpq1I5uD|8u!^RM#g5fwXBmZ_&zng)nOMMWy3zhl#E81
zhGz{ZsgaJU8xqEDVq)BvWS~g9C;%&4#q#?o(iiF=dv#~O#29JPoOtD|C`-jE&d2Wv
zRJIbc#LdhxW^F-IE<)W%0z(attV1sFNBt`1ipgES#e?U(s+Mv)edg_pj+(F4M~}BQ
znyNlNu~_HM9Z*9F7n^(^lZMvn*ZfjHzkW78?Zzuw@k7hBJHKE4+4vu9m%3JU
zjbxtB+n+q^Bp!|r$uz(jf`vzKd=*-7yDoaS`2_Mgmy9<3YLE9}
zK;v+@sh_w~1vaqgz4y1xC)7|@t{S7jN&jsdd-*uFaGCWAkOlBKBA0T<7=0cl!dm9b
zCTL-HExCs+m?RtM!_rGjZ)5&evSU>*QdlgF^k}vzy*=}q0iewT@9Hur3Ta!Gt4L>D
zN+=1)&hI7|z*15wCWs+iC;AHE3&CXuncKOG;aaUZCZsyi&nA3E$@X$-_T;3RoKVAv
zRsR;&Qy-WgeO^Cxttw@p7y#BQl$TgmE)8@nXd9+H{>z!1v;c`G15JFy6ufv`ez{b@
z?8@kttYbLkqo_`&v~^3(OOjEPbW7IA&j{
zmKDVa*NIdDwUr0;7=vSItrAEPU_|6w3d1^tC?I#L1O!lMUvm;(Bf&B5x6S7<09&Dt
zG!X+w%bC(rW*SozWIsZ!u=U{_U)%Fo8FDy4b1C@nvnmC(LD?cgO?*44BLR~X_(z~d
zzbwhemGlKQ(iIIsAwp_ETlq24<
z5@zgaWw_#vH0fc()s+(%d!C5K_TqdOX=9)7VIgYX^M
zfSx|dN_6-;lk`AHx(6N2diNKVB0G9i@p_vHhTpFf0SpwH3T-7PdUN^`qN`}
zYv&2!c4SNBqOqm?Zw%NnKl;3ptG!abvH)mbC4K$2FB5UA>hSuTCttwZ8|(4uYBJVZ
zKZ3%~OFqL5J@z1W)RKAA^V&BO^9X{Q;rtyn`@!`Y@L3toXB{EPiQo7s#?G`~eReLA
zYaTRubKg?gdo@cZK!|uAP0_`)(jh-fs=adea%F(wVbt?g9AiK<=3H?G#CDHh#v2!b
zFD2N>e!b!*+t{h$Jtp0c#py_*YbJTBaDZq5<&AdJ+ITjYr>Q9d&W9WEWBi
zuv%EG>0ahbwu2fzNL+riPH&~)?OOc6n>>WoYv{bFI}=4^`ga+k^Ogt(=AH$gc!cZ5>M)(-`l8-3*(i%
zYSDe(t%ZfwM%Ih}KzOx&4R4QNq7I~LP%qX}{sn@>NI3B;5T>-~(zgLvfe}cR@2<~q
zG->f7*Un465jku2cdDJJf^h^^@Kvwxvih=G>}LCp=blE`5mbJSQC};vMK$;v@LML4{0!Zjeu;+-25)FpUh9N
zu(vak`dvqLSCN8`LWF4Ia-g>h;zwR?#z+2hK0qqBfiQ2L&0i%D*FGZspORCTSzo#Y
zh#plG37|(W2{K0m>AjQ{sFjIZd>Ra~oNs&D6s0P7IGlZPby%wT*^H&&_5V4w(Kv4~
z3zP}@ak{#G#>Ld}3M>ZSUaz{@nfrPBktKc9>r)-hyE&JfW1ZN7GM0IlFUdu}v$SN_HR!Kj$>i%eF%{&g=^AD9}pBu?7|
zTqlpAeTMCGOm>IOWTzcPy|$-f5$(7`i%lxYWe5Y)L;;x7U=0dy-!-O(>pDH?d=O@B
z5R!vXw)1AgCScQEw+I=L>?>aTit0C`TC>$!sK_VVd{7iXnOd2=ZOiDDuD`pf_W-Kf
zqoC8hptDKxv7>bxzND=c`ZDE39;XDPz=)B~ASwaACLj!Qu`QY1rM`U38Fk17-zcOR
zq_7pF6eL5EA_!P@)_298T<}oMJ6JGu-%`bRyRz&8Ap5vFHGP%8FKuY5p{O5u^=qlr#_K*6d
zRZ8vBHjWMOeXqQMJMSsh3RTj#TcQ=W&(m@u4W9+d!tu_>Gr4H^9u?|W7;T-dU%76v
z)+ZS@DA4G=7onluQ6H>0UTove{pK{C5hrfEeQMv+@QP$rL%z+YhsY#}-`II}%+S2MZ5@IwMyrSHAiH0^6u>hoMdHEo`iRShUIquLWKKD$duXiE#xz(mIHK~%WK`}%0=Spn)#yA#-~?y{NciPeK>Pzx9kfBw8`CE(ko83(e>@UGrZsP
z-99My^D&l_<1c13)6@GsJe(RGeKXuW)>(MlNzC2=Qlql&6_AO@4!_`D{@)0b89%YD
z+cB@}Z#k-)sfhnHu+tNd)#_J8?qdw!9r4#9@fmjE@}LE$5zp0`E2a-Ht6?c=pbs4)
zw$6#Ajppm?^?5;&29wK}0d5qDKDM3FA{sb(QR|pMJ;`tzoX<+xVDQm)(?Zli$hsji
z_+nd`v^4zb!gGDJ5}VWp2kR`%vahpsZN}kO=Rox)dC28AO0i7|m5Cp*0QA}$77~||
z$7?>clFZRd@;?JfJMvw)Xvz4Yn#>%S*Tlygs+EdYf&JHFCU|ikK5aEd$;|8YfuhU5
zF%{IpRW^U9a&HP%uN$`
zk`3OHy(ZLj4UfrV1zL?@vSu!oM*`%ZGXde{w;}~wn1ohTRNE+llVIC$bed4F$JfTd
z;de|v{LAN0)S}Y7-_qE19GQ3RT6G+?q$u)lhPAp5dN4+siTv{9om{qCkP&YSf-9*vU~1B1EA~lKiR4b1RHiF*l3f+y(@nKK2^;LVg{{b+hsDw=J~&?|WsR
zAh-R;v!dB^bE}y#XFG>-n)FFu00xhgc^>0hF&n5c@y;?C<&hgi(lpA5G-7iyVdSG!;|sM5=5Bth7Zk-tblO*JLX-?LTJ4jx<+@G4ZT&
zG{csEYMs|DQrTW-GJQBJz3tz9@lHW4UkMYeBNCaYZD>)n=w1wSoOT9z0gwQ5#Goxr
z$t|hGu_vU|=t^YqbN^&@LydqCg*^uOJ!8%Ye?sqMo}E->$TDWUHk#?$xI-EXD{XQ;
z2D-6Ym_j`6nZ08bc!8hMlvxeT5QYRuTe&NKY|!6IEtR(JpaldDwG3kweo&jY+#bs;@);OL`jx6+vvz
zTD4d46sZaOJTVdfFiF|6*CqWr!`ZciBlx;Ny=uf!Y%hiTwPE?}ugj@tO@6pf*>?hx
zDzf|=%Y|PX?z;4WkAb1RjJC>Uj5LCSq1`>|nRI9GSv8(wfB$++=rRs#P_44q8&*$J
zc}k(JKQOP@h_$BJ?dj60L#|l0|2VZ`JFRhED8M3_k3`GdmF9bJa{lj}I+NcPA+B|u
zZH;&w=Hx-iTImuD>Eh4R#d*Kr*kV&pF)kJ*XXoPtUk{$#RR2CVS_A!&AOw=5l%ugQ}NhtsqGa{p0cU|+w?KbEiVJ0RwEH|
zlM3=h+4oz+H|fPSm7EoGbNhP++sCl?hez`l#QUAa7_#q0!1#xiU7POl-aw_j)c>cV
zR@^?(C3@o5zS?h@`|kJWeAI1|?IR2SN^r~GMb*Bb8+8kx;ACUc#!Vrl)m)pD
z9@?6rdV#VeHq=-n4YZ#IbbY{}AiuTQV5_Mq{9+uD6bQO3ecWKwfJs9#0E$YqO(-4~
z$YcE8!4*p1MPdZ%4C;~Ur4kjKPO((XLg`m96s#9{Cy-h*#dkdxVFw$^6o1!6QgL#?
zTvOmuA{ia)H$$;b^T&n7K~%(x|+TrK5(!zq?p-uK2mHj6S@YNvE-b=iVO
z9SvVjO+7-es3*$~RK<4&iVIPI{+!@!6o7m1SoP5?+w@mF>@S3lxWUTG?92diP~WQW
z0uqNAllziXI>4IA8pI90V}sZrSy-!!2mq?
zO1}Fw(_K3^ymd3muD54z^VcBVhZy5gnyJPk61QuU#`l}-*8~&U`lIzz@8gUSF>l80
zzZ9wdb(-^PU2Q_(iiqUuf7E(LHAzO|4Glr!gCy&PCG=;b7m5>qqJ-KXd^K&O74ant
zdNh++Q73;*vSP?tJ)@VCMS@PTs>jWAR&>Id$4fnO0ib?@R0P*(9zJ_g;ER!u0ev&^)sv8y~feGAGmqMFL&o>VB2_XMr?
zKetwT^;!*VUwFUGY8kcqnp6;fUsL1fdjaDb-$6Wfj|v&JzUU61n^-PJclLyP#$2f`
zuIBjoCgA6YTMK39pNelqPGR3Veu%vMd9$4sUQt#_@z!jD?)Udpv9r(bPx|o8`v4pZ
z77}tR&9W=a@}aijU9Q2W(^rm}Al!6D>Y!v46q1+Yhi`9P$xbab>x^l7UFQc6?_;EM%Z;(K^Dot8qX1Am>CsZGPyO*9_Jc-x*
zv0vy{$?e?k58_I8%_ovPMTI$fX*|VxZo_J#5N|JidCBJo3}59A=2t@DFCtK4MK(PX
zi9!kYpP6iqT3Qx=H5(S1b}VZv2wJ3Wp{);hP}ZE|iaM=@d(8$>j2YblAPWeOUj}{B
zFA#0a6*)~^V7IatU>?8HWU}3tE2IS>a?f&jKq)dAI@U9*i&9`eQkbHC-Untn@Sg9`
z$nsi<9>J=QI*VTGGMG9n(Cb6mHasvcEY+yeQR{yo@i2kQBU!Oh;ZEnpdS!@RM&da9
znWB)b?5=z!3NNsvZL|W8crSLZmeLn{L~GCI$GllC>sW8S5e_)yd~5jL6ttVKaG>hD
zMic;?0zIU7^8?x86a1WH#(2!92==qXd4bwq;l6DVV~)H#UC|@JSVC?)B9^aX
zf1lq5!VUqQ)gPh{L|m
zyfT+s=m?~$MHP3Km{@J_z4Lp|6StTjw`iH%@w4f@JHBtL|9%bkVr$dB`^Psgw&zyo
zcyaeAu5=|0{943(*08a+f|PBWn#j8=u)msoU!1J$XcivJ&*-4fuP{YQ8EJL5d-H7+)
z66DS81D7bKLbnlAr+iIMUB)VPDEt)=W@r7le2%D^e16CIMRYNxXtVLBMXxDO+SWI!
z2dt4ZZf!WqYdZ7*LZZ#EXV~aBu{mGqcMKp6pac(0Pt=k2S6PO$FBtPjBS0L7!V4c3=Nxi{Hi>%OG)bNsf;$!z7NT?SHITCtJKkz;==J%P`NIM-{}o|*)ue)n(6@%a
zXCg?JV+DXvhYTNf3E!4?(*8Af2kd427YR3rRaAV*0%U)PuJ7b5ECB+q0lcWJG1>hs
z7S`0RtjEd-aW*JbXm$V7tn=qx$+GpnUjhLwVOXn!)!`enoQdxG#-C5Do{HD;=jWPz
z85cDDQp58(Rc!owhrjRgr*m{iizkHXc|D)plAv6eOUOs33W^-@KYE`I(p6SAn&LlI
zT7GiQ|GsM(u%L{aUO0`PrN{8Xy2Dz&wKx1Q@SNadZ?M~H__L!Av+9`6W%-^Hh92VL
z16ASxP<&^}BO&KgKlzIR@0&A)({Y8<=kjR-bJ2sln}1*QZbkg7IOep`L}QaUz+X*{
z$rt2A$nea>Bs9(L&W-J9P)JMjGclQ_6G_$U2X$J4*r$mMnUd_YV>jmhe2{~j{IV-s
z)@;rneI^UU#Z<(-vPd;9qg0zf*v4ivPO~Vvfr;R^fEl8xUlPV*CQc&AVEh??+~;5*F|iwdba5
zUW|Qw;>Rrc
zO_a84@rxME);Zc<#kQ&v^6#o`gb3py{s!2mAd6Fraw_@0M)AoAVgsV|>o%wYs;uLt
zh(xfE5aqS_0t}?)wf?J*>La5Nw*r6hH2{vrI0+G>;>FwESdufdmDdW1tkrJ*QtZy0^>a(zEU_Toy%AETG)DW5=1ptGg(rRct
z&od8bU?i<5QvV2}#pe1Nv%G0dckUOKCX}4VZ)bt}lRS7j)m;9_+|JaW=3kBp9nfmN~OJ+z#bMZ9FL_eqa`OQbHHo?1YV;>FfZje55A@A)CWu;>V
z&n!)nthP?5mNBphcEN0m2&F?%N-$zvr$
z{wS+p4~%MNiwVYB<#d-#I%tnOuOKDaA}VihMg47RMMRI?Kk4%M&5}hoNrg
zooSeo{A0(0UJt7_4++9e{4E8XtWPQ+?BYW4(0zddW&{SG8aJRfMT_A^QU_wBO#myD
zBlbMoe;kJLT1y^(QZycJFDrxL<;%jf$x~ee+}BwEb|q!vFL(`SiPwrg>zFHT+;aMK
z$u9$Q_{!5~NgBMiSjPN(J6iaQv!V4e#XJ++njKaK`8*RlP5af~O+}U=oGUG-H2daLLgNPD{Y2$)@U&9rsVJWKaiIW#Ik@QV4k1POKF8?d4
z=Kb+s3ff7OH(?(hY$>8qk(~wl1KpDR55^8sE5>7@(O3NBj}*>U;_V
z6T+J<5Wq)FpMJjcoS)sxGids#4UA5+jrE*w?r>AWJr91j^3m1ln_?DobH}r%maTPl
z7!7b8G1CI$iyw?0c}y?f7Rxnb4v?UaDvr$0-$Je($1iRh&#oU0C#%&vTV7P=f7&JP
z!$~vKd-|cM%|`ybEA$}zdhmK9@ovcIcg^mkM--%>r8h!{E4A}QXu%59;pnODQQ_sL
zNiPOh3qRllcE!=H8_=F_x%UhL5<(Q3
zg4{})ev%*7F{(a~pbZX;Uaqu=6_~{jD_M``hB9MeFrByS43QkaI?bvHxv}9$TviWT9Wv2r
z9MF}|G}3E7i&CF!RvT-~wh9Y?6I+{)gFg+hmk_XOIbIYshiwd~it$?bEUfK{@A5Of
zQV2y}NMeGOt-yW!+hLNmIY@k$lxLC@b!KHIR#BZmF(P2$@S}1wwv6$+SJ7L-m6BgzcCUKl|K)1d>*|CHyipKIqCx-i1*973C9&{Lb
z8?p38ex7~9g8+n(pL`nd
zOOM83d~KI>L?0DN%K<6HB6$uCd1u7x!~9N4pZ3wzOV|Km)-3$HZ~=@dajC8n^|v_2_iLVQ4c&ta
zk)0=mxC(=o&7IG_ih332ki0CTBPGmJcEut@bTiWTQfQ;Srhh*%IIY&j5l%Mxtm~|S
zjtp`d>iA^;G}hF^{rAN=4%;yhBY2JkC7Q3FKval|B&DtSfLU{C*m{PjwVjgly3Hw_)b*rf%7W%@%1TwI&;a``@q}fNdpn
zW9QOA&`)dN4T!h+a&1|D9zu^~8krH#hae^|t}*~v4N@nN{-{%K&5X(kS+tf|cIEu3
zgJBfue*U48{EPcBGQWg>@I{9(fp5ratKjn~PMHH5?!e`ZP7
zLEm#moN(S&ul87!395?By2W(%GhGz0dvCQwE9uW7-@hrx!^Q^8yNGrj=y6
z+WjX{BkBx8@Pt;`M6ld!5q9$!9-HD^YrSTAJNC;Bi{`M1{zjBW1RcuuX$Q{FXI<&_
zBI)`7+Gp9hL$m~D@Gq$D(P>n+&69#&FwIWfj_AB={UAZA!n9T5n{in1md~DvI!8N*
zZrN}2FZ8jX4Qg3%^_c`(q4gK8}vHx78
z)bd}>ITx6%n#1y)zEpnz=Oq*qygbMui4Pjo6!n^N&qtX@WoxGU(`Uhav}~tkG+r+x
z%z7~NwG#3IB)ph0C&8{Zhhmbl`5UM(d)3D%V)G{!0t%MezXpG3in0sS&Ah|JOaC|l
zhGJCgabW5-2*0loZHjH@1Nio>zz%Xliauc-0>p6?*eWTt&T`D+*1FDMv6fC?$=51KmH&u%!`9Ry%1uq#)<5I<4Uz~%(
zcjMTAo}p)LenX^
z`Sij4)aIXCc6Sq=Zvx6z_&g$NyRMBxT8x4(r0)(U%$TCh4|9$`NE!2&{#1LY-CPZZ
zfggCL#G>0k2_-)#`w(;rq<73%LP@0%NX{Vfq)XaE`uf7=0!{
z`gq+ZS5>0pkLat?pSl+o8cEWAE-4P}nSV&F8w%|yfzIe%f7&&G&~t6OItaORSy
z#4Y(OZ4cI*X{Q2MJh#ccH*-iM9iL{I6|6EdFLiQcHpIIpYTyNO=XRl@F`f^g~>
zc*h#`TS-{>om*YRO+UVw|8ZLCLb}bxjmg8c{KJIJLk%Xj#zk~}^)|nEs1u-hMZS_X
zQ(}BN(
zl!K~Laj9-yvG-xA8H7(zk&54Oa)~detc$a!0!xCiUzRBkMNWQT)kO8W@}+%FfkrEd
zx_r%u!QPM<_}pGt)en={i|EG}=)=R+G=*K`HBTB!GmollJ!!1+m4<6vJD=JGan*CH
zX0tbzKjJR42Y}>?s-wL6(+Q+m=3Jm(&G^XXd
z&x8NNJ?V{2iB&=8(60tmx9j&+3BILhN>Qb;H(Jet(Hl3{%?aapG{LvIju~1Rdq>82
zU#);lf*NS%I7I3Jx2V`%w^g`K9nGvuT)8l96Pm>iYkvlzNOe(0f=W8`Cz2FL&?K&M$s_oj>m=sfg|57zpzsCfaq4uPh0gFgXUw
z^(=bLm-i~UbMmfW0@@i#7`^fi6a9vSPykH?VDKDnfMH#COK>XR2vbjUY`rCr;tbMc
zgRxM&svO{sihIS%nB`mKV8uJg_T8Q}P91y3aG5DgGMybp`S*-;XZH0I-h?Kh-$INVbw|HE<
zLyu}xiSPUNg9?6^eRx=Sgxt8~
zYeNP}y7C1Qx6<4{pNf2a`lvSwkJ>jhK?(wUtHi$BALq4&AH5g(in&oL3H!d`u85M~TAwc_Ftdu8h}bOQ(l
z)cs(r1rimYuwDTZz4}@j_kJv~dU)V!25!Y!%bm+c9E6<={yTV024d<8+=z=bgi-_h
zj!_jZaY_xK$o}z4m!qZd^~G=nyEqAf?ibd9a$Toj5&$04%2mKB3#-eY}>;m8koqYIPaXj$kBt4?)ZZ!S8xW_o+pTp+a
zlj~uo{YvN5vQ3P5*y%;@$CnGYx0RMhmu^QF`yb@8{sr3vo?O%%X%L!Xl-`dLBEH)p
zhC-pJ=~mwoMR9X375K4!41S`b%Tg7G6sYetB@)QXt^tw0-vfAGoB7W8Z~5qGsd%~x8u9%ZCe8O2kGlqeOUCR$eOrg+hV=FIA_ksUKbIUFCT7>
z9_}CX(rnmZx8H2;jp%cHn#WjvtTiwZSE*bZ*U{FSDmpb%mnQJ&C%zRE-}c%S^twLn
z@(?0WICd5lx9f72AjGHy$D%P`%FUC%?_ZQ)siMRB<0LBTFP1#Wx(;L-qttEMw38*P
zr}ui}3~PEYFiY$ejQzP_jN?rRW_C*5&(ZV-!vtlo8Gb2XP#BX{#nBRI#jSK-3<|3~
z#_in@o3>S{3E{;1J&PsfnhtC(r+Kk4IyV|1mX*Qan;H7(
zSkpTpQ=ieRPy?{uvPUKPDeHJm4}*e)%TunMgh-wx;B1XHkZQ(^pfoZ_D7wP=h4RyX
z3)}IC+CAx|TJ>}MRfK`1N^see-cX`0E$Nn#fN;Qog>IW0E_g1C#H0RBx
z$B~M+0I$E6nD*y;)H%JALV-p0@27#JFhd;(TK_B
z981m~v+wqNZ<;%1qEzv$$~c$X#Hj9By{XQ(x790x^K|c2=ayVbMa670zod4wFQU+h
zGN!tQdd|`9
z?T098rDBQ$V(|jH{KHhj%kMe6>yM_sD_v%)6*;FbO)-X8%bb(&%K-TS*tb)~S5>Ep
zxf_J=YDQ_C*x|!nJ*z1$sKPo92SmRgab$fRV0|O!G3PT`yaKsc#UfgXC0dEU82W55
z%v83997s2Sngjlgdt+n?`TE2h3MfYQ#{S(~;uw6vB>AElz+ieYk9=r#A%>sQ8yn{Q
zR#x_-Qno?yZc_oA1uzXfD>=Oha}BBFP1#8P6Z$_TpgWJr{iSR%AzG;+bB)@kophXP
z;93!?T0tw2!&;$PYn-OoB7M$0UZH*+dRuCoK<@JkQ?wQRi15#|oVJoek59sPr!w9j
zpXe!qxX?88@u)yB8Q1~KFO9@2W+MxL@8>vUR&NGBOx0|_RujJBhNP+TLB3Yav!-$f
zFZ^1}jJ%hYJFVHR@iWJNSYEy3Bcc-{F}wO55&N0m2iZ#br+V(;`Y-tDseQHqpg+v^
zY%xOV@L{!RK7N`Y_2G6Z+>#H6Wr=2z&YG#G*P1Yjf>}s_#9BT@Q?x!iI^y0rf?%^Z
zys+@Vbp5=Ko-j0Y8e!Z(A}3kUP5lUF-D}#H%M`UaJRCnBZ#!^OR=Z9d-)n$L`ZF%g
z)q}WseX<&4H;BZJRG_2w4{fxKvhZQPr9S4|=@rJ02&Uh7p>tkAZC=7U0&wD@>bL7A
z$0Tj&-2UM<&{yoF{r$DH(896qF62Vz?p^Uh9xPua*2R+zo1&lGcqE}EZ&m^KYK@f#
zz1mcXu{@A3T$VY~vG3DRQF8&Xc+1=Pw{%ArPRa=u}gjr1&N8wG5
z5rbHgyYCMcb#~K~ci~;;l?op^!JK^g_qyWe%UwI4EW)3PpLIL#Tefdy==zQeMi5Vk
zCed+U`?uW2h3+J21`x(+0zKP=MO0j2v=oN}20)86S_lro-=>#-?^%fWTqq=*jB=T~
zs8$Rr-(}1ZVa&9>;vc%jK6F7j~4%?w_kcLnh1ODZ%2Y04GH+RWbKO=GDi@nBJS+eBL}-;=**sP9|9&`S62SM%hzz9HX3{Yb)gHedxLhB&Y%bn9
z@$`F8y889V0|K;Kvx7pgNo+@uq$v4&!>u8To`Pw`RC`h^56H=OvpPwvzV=^hQ=
znRc=`b`qt>nce^h-1OkCd+?y|t*?k>gM-QA_Y;#%C@o#I;D
zwOE1T?rz13wYa+#ci#T~$xGh5$xZG#yPKSx%%1zr%s1bZEYvAFGu)Xsr;8Dlq5QdX
zL;HHaz}tFvUWglZ2yNO{OuFnopB_;x5Z;8xAhtxq+8~%>^7%rH{
zAF9$m?E_Z)je3JPW>&Al!8o&tqWlybe1fYMq9pcROL%H&Ut_t*o=zQaR&lj7n1UfrYhbDU1)`tjW
zFtrH}LS?&9Z-&%LMBiHjU=RdG{g+Hzk4c3JCcS4I+Z@8u;qfYXnZPIzxq#{~l!QU?
zkrZ)A*fG4vPJ>}9aS!5{s5e(Tud}%aprL#sY9B|8r^r?rc{kL>rZy~Mo;4nSp^DJF
zx7){Basz5&ehaj|5&8k7HCeC7pNnfiH@eb{=HihGG9CgMwHfSCKi41qUH2^tDqqNK
zhdtuQ1axk+@b)
znRl(seV@)f{)XgAW9naq>x54C|Q!)=Umh(IyDTiYvcdUjq4`T8)BgV
zQDur=fWlT3F!rcOEGk$5TxxGFLN0}V)HkG7eJe{1s)i`)+A1s7IQ~RHJ>nD}{!^V5
zLRe9|pyYurw*K2@Mb86?Flsiml*N7_3=^JE?b>t_?4)PMtY70$)ncNf4xMS;dR9}`
zyx!73@3s9Hf~qz%r|aqI>wJz1Zaua3f*}xdm#c@-jJfB@wZ-zu6fksyYa`!5H1}dU
zM?LCCbQk-3fv8jT6{JyXh4B<;SvYvzP_o+S0X}o+Kx8vDHtL^ZZW~TJh&?Lj_ZRsmC-8Sa}AAe0=-cq6}D3%B8
zb$@z^dg6p;>*QIrD!9LVsaWg9IJ0q>AN2M{-jOFk5otuj4}nNbf7D>RM_h{yB!s&J
z8EnqlKgZz3!k|$87W;%Z>>tGsou^1wfU<{F1f|pmG6LYq4Tx^PJD;BgI^&Q6ytX8x
zgt17#yZZ{?Kf}7IT~H+&T+NP&o#6r+8Cm#nAJ;1gQMz{>F6H%;@;pN_^&fd~*FM78(f6D{Y#F9d2Ex}@&
zhVBm~AFn~BFtGTK9aku?`^NA7Grg~eAJ`k+h?n|tV5C$Qu?tZ$221Fp=9FDlOv$=O
zdx}#cWG*pE30GSA>;M})4rhFY-=>^tp^FeKTk@4puZC7
zN8dkshMjBBZPOq`0JGA3y~=XIMSRo@qRM#3?T|v43T;Kts%WE6e=COz-)Xxbtr!ab
zqL`7udR~daL_s5*J(}+IBU%quv3{juHx^w5Y~;OZIOxP=*ZDD>WnKNXQMOLD7_#VbGA`yWvT^-sT?+q-xs+t;=3T`XBgl?fTY*s-uY%QbFU3h3Mkc
zg+<^WG)d~+Dd&000fyE~p9E>%3`va(7eA#2lR6`peu^^1R@j3<7Dt_g2ShzA?HF=;
z4_ZgM;5V?&ae&X>DGC9RSOXgb5Pjo(=yA{q1mEx}1;?@Xei1s#j(ev1TR}rYL8fX7
zjlpSRrCNwSzqg}@$PZ(#HWuGY;vg}V8rC5-XJIX
zokB;vdd(iaky2g>ITWWNIj%TUNH@1u6J>G5tkkRmjAz$O%@-I0r5Q!k#-yFTwMB%2
zlq(E_8ax?^CyVkbJd6p$n457ZGX(>*E+UY|kgNC#id3sI4IgvVD-xh9a;RxOUo5Lx
zYFJ)P08NzDY!qi(uFl#2%|U@e{|{lLtT4l+N#rFUS?Md=E>-APx`d(r!}mV5Tt_^!
zZl;T)5Gf1Onc7t{gZLnbui65fW9B!aU$(uAkOrbXvD4D^Ii>{`~(nqE}*ddT)
zs!1$89F%w9;?7{q;tVhKwiStIZL$27am!t&=}|ey!MnP&(cs`V-`R2EU3X!m?>6B5
z*!SW**m>92{S9H3KpQDc&!(z{0Ft-JZqIy*^RAto{-p9z%jzracN06|i
z2Ogy>Dzo_@$I8Ec?g`ZV0MW0K@E`{MpM7n8B{)JLcI)6|T`17X(DW$ztd2E@2^pkH
zp*tNT(FecVsMZ4}0X@%>9M~xdVGSp~^9pQURbQ1kSJ@9vKIdwnJNLJ^Z}J7@Tth)(
zwU$m2zS+bsL>K;~k=dt;NM5sz1@miLEFwrewhPyj41XVPR&v0f#I{*{KisnQubxeS
z*KgVSaAF`!@{9dm&pg(}aBy6}JIu$(J_E+I1swvA5bcB?mI
z64%mbx1`rpYQO$mWIL6{lvT{H-4brrA*P8HW&4Iv!&~9;!mU!fa;&wo?pmc`>mpZ!
znzdM2*S^Q*3_p1B`A@F9wcEs*WA10ZE`}Ug(;GSx(zMB17dXrHz%_+a)V?L}P(4+(
zU6jfI3J7%Y%mYBXV@AyM*SP
zxn19T@t8v-;rSkqY;Qen-EvdH7sn)ek5JvY1aYqeyNrYr|p{UcdUI^;%Wdy3|fru>m!Z7WK*?v3S}||tHvb0
z31tSFrJMMpUf@HB-!7pDq?|xO2yJ&@i=QG8&mi3QQDp&{JWPU+|Iwb$L}4M=PBvQO
z$pF247V`)I3|2gN7eKyUABG443PjleLxqNtL<4YpX10`%nWZSA2E*y%?jT^Uw=rc$FQOV0mbcioS;g;;)?!=|Kbh3
zzxRLH+8q?5R?)ip6AnPLnpOBk_pkqkJj^-8An?0kJPR-8I$_#r-hxb`=b_%^cQW@z
zJBK9kE{*8c$$C&ToD5Y6#=39AsvI-#JR4XqYtgf1c}DI{*sthL*A!iI3v-8%&lSSk
zBW4&%qvM2V3XqBi_xF%Z^+B??hH|+Z0DvVu8A)s
zpByI*Tle!v1;%TP4?#PzNdEI$R(yBm0!pn}(+6PMB
z!OGg%6#sgS^qXO%#VjF5ZVZUTuszgG!?}Ykq@+
zXf!V38?`tH0E~ZSfH5dkk7$1Zz=rQ7M+qbAgLVfUAHWSh8NQWb(se59g5|g1NC{r*b3P>IEwap?{We9-8d^ExErnN8`e&@U5
z5AI{aBtzOKxrNc+FmM#=B!a3bzQ@4Pm15jg)?wz0;LTf7X1iyWaY}Vz8o+M58o=@a
zSi~qlea5(vyq1znL$*sc>>!s6aWV%ks9
zklaf{LED8*uRz+FsTbPRA}9c$kj08LIXM}{hJPSPD7QOC#&Fx!J2Gkp!yZU1rq*V1
zz<#OU8N+e-+r^#E=Iw7AslR<)smybn9B$qq|I3ph++3#Wm%X+aZlo)@3p_XpL*Neq
zxj7h*s=mF{Gw~NH*m?4tlwToI`}np}s?yzWk+fjx9GWW_KZ+EF*E*P{|BpSL2%Jtd
zl}G(A1EJ2OG3M{F&;C=HwMU)8tIrX5db%x6)%*qazWI*r1&%)Xb4&_kh2lzuS3qo|
z*#4+`poG6Ts%O+m6y<2HHsSwa$jR|M??gsgiv?YiF80&nUO
zyI1JD{f+(Ke?ofb9x@88A2BV@ck8*9ev9Z>^lrrdY2Lkw
z?z+BhQ8~#dgq|mGh|osqxjNu?ryBxmCZ=0MqZleZ3z*v49&=JJ$oWkbjT4OBj$Q%u
z4w;NCg^#y$)=hAomP$JS=UQn-^`l0aVIB^WwHpMhXqo*r01z&exQKgOU)1ip?SB^W
zFBU%|DUcIFYq$LdlB@1R&EJJ$(yg1^p(KK-3_SxysJ12*DijwgV)
z3rG)lZeH9B2Huk8-LRu*VV;GV?~az&%VJP{FgGxcp@ZS=ok@Z38(kL(rWY(LyGiAC
zKs+YJ!Sqr;@b1;`0f$tXx4hveia$4v%P2Rz6ggQth>vPwlo{c5TmHO}7`i9
z;v%EwCUuJ`R@qWWbm~$RXP|ER-9Q`cYB3!)9A{mrIR=#Z(v*LfCHHCQ{v;0Hpfxuawdnr0#!*3>bdIM`~h-
znuL}~TrnZ24Ui?^h#}yt^i`50>s=LcsKyd6-!&DRIn+zpQ2Kd8iGFB(Y5t8y
z(FbC@bt&3V$ROtjB
zSTf|uo?HY^XQhl|^H}>z>ido70S)8f1>6XiX^<5n8eR)aSc$VxT$)|h~SJ41D
z4LTpnQaKOz-jYS405f%(kBim5{+BC^cv&h`&t2I9OxnoG-7qS#?MHHtTY8_a3`~Ur
z;yqQ=1^}$uz_BSVH8oE@4g~bf-bOaA{F7I%li0m&@^D`h;v-mZ@*e74jwL2M)Z!j>pIA9wKDq=hu
zvU=n8&hW3xMM>p&N8BREV=xB}p;v)JS~xJJ8VObzL0#bbY~>
zv3X;gJI_Kf2(fct!cDq7w0PU|N#6TB<
zlIyVe`&$>2>5
zYC5#!8#W2y@YslBfz$D(CEp62_g^(7yk3Dq{A8qGfCG|$VH0XmpEj352tgn|z}Ou?
zAM3MkI~6Nf=^k!v0
z;(c6+mPU%9Cu%3B5I+E$jB3OnxtTuq$*9{R78wkTQD|RtV?s
zWSR(5i0%qaLKQd)A$}YIh|>0^KV?hFjbqW+=s-E6ga3`F)6GL->ISzDVUh-lRQ=HC
z7#@_>@}rhT=2Fn$LO_@aYyu1N#q0-E;FR`1|4kS@V)?U^p;+1&*l*VV!W2B}KeK~>
zB
zp><|k2CY4a)jD?p)C+>1Y7&OIHR^<)P^A-qQiCWhl;}l{jB3C76fCB|KLikQ{EA=<
z>h{&rtFyYe(^?-txrK~{E|xY4q{>tcndIwoDc;E(5B!enr_*IqX3Z=|PA8Cnndj1h
znl)*XLn$LDhHJ!TgCeNGHZ(B^Hqohe4F;OmGfsJyn!s;`uALf9oT*#jUE=$OLBEe
zO)$~8Djx5A{%KpubDrAxm*d{ItcH1JH*#8gMu?TPGhZ0U;%&{g6aKJnCtAwdb${7|
z6r+VZ@Itl&*I7T<%@;N>7x?F@I#XH9WB8C$aApw?k3`D_vL(0ktIm`O;HMUsq*^wE#cGA|mc%K4X)!guF;L$#x$
zfx_(XIrVd*lwZzx2Wa9GUTy7fwRcTI=R|?H0Bn;u&0JpeD;;+c_ZqZ3WX?2{)%tHwoD+zsF8KuL;nKqY!{=RTk?-EiL=sIgGa}Iyp#sy(ejBE6kzmixZC%VK!WWI
z#s8#P#r_3jvIyaT=WP*t0#7Jq@pi<0nCKv_6NG{-o$q1bB-ndH?LK3Bs11i+!*5K|
z#y;cJ7be4+0jMFhp5h^q6wm(!gmzruK(H$X(bmCBN@rE3kkat2;cso2C^7r(whr~+
zWoXzFZlrCA0C}bu6I-4TpxNE`p7dVNHRFm=a_-du`RF=$nA2%8+)$hMTk~WU>O8bHh
zRa}5rTVfo&e2pg9Jm~#g+)lZK4W{l^awTL*!=21LVGS3d3?=Uy1SdXavKt
zetDAS7xu%C9VGoVbnQ%0Ok1yX@7VXuSh)Bm7KbE6+V3ycCf1ImhoKFiJ~9zw`)Xnh
zjbTVGKomCxO6gE@Wy#H^ExiklkXlL_o1$%S%X&4dv>)0mUF8(<+4Jez_rL9X--$jP
z#=uz2BRjEG$Q2$_g#dK98IUgDGLQz%=rUPi
z+uwZ|Fo_aXZ6Q*|WGWp6s+})z@n|o158p?s&`R+HziT%wnx8-A>@=Rg?q>8_`9FND
zFPFf1@P&b?mzZR?DT0xjB?@&Bp$O?DQ9hpW2Aw71KY!PaYf_j~q28z|EJ0w!bSkOU
zO=RVro0DQqsQ^aEc_r>fI9ncVxz=?j-4uD{PkOr&C_IF@5{N3GN*HjFyH*Y8yP+UA
zNYk0AVNwJ5yjehrOz_}flX-a9ean%FwFc~6#Xln?QguaSeQk7)Hb=$cs4qeU=y`sR
z5^erJ#SxGt5bEs?(Lyy|>B&i>w_bvY+8`yhxI@2yq=Z}jz|=y~j&g_ccXi+%}&;BQye*E!}vCLX)Y}DHo=<{~{yni=&`p_L{8vg&y
zWGsKopW=ZZ|NHd+`FgAIe`M=TUa6wHkhENS0OXRFR+0KCVG^pQ2n~Y`00H13a})sE
z9v2~JAOO$>0{{>}X1wiL&0S5sY#goJ{_g`jCyTd(eXi!JV=fzdKu_$MFZEJz3!*ug6l^?0_n8*xaUlR0dMt^zWIOwV_
zq~ZSsY{-n|Tk}o8wWjaERK8532(fxD(h*c@O=hytqUGOw`xslo64|P;C{s0?>2Tzo
z1dT%->IhOL>?4rZRbU%+R8Zw|Pig1$p9-as
zJD%Udm}()I>WfuC)vbLI?YP_PXDx9Ik{`2`eXbI<@OeAvWhyw;
z$&z(H@B0}7xoh9}N@gukpglE=J5EP~?phBu5vd6Sq@^!o%C=Jt4`9oN(F|9O74J*w
zCMj7;hAN9I+$A;>b1C&MbGOik#C|AgAHU;tuEyK_HSPfqFIau@uk6>vNET0XgbmQN
zMt@01Mzb%Mk>O4qrD?aE&8ng~;NKF^ltqxi0%jSJ}W
zEncgeQgJSAa$2W%RWef~(=%t4)j-(;9tD%~G<*4(Cc`to70Q(4nIFmwfRd04=lDnK
zUS{}Jgf?SC$BvqtC9w@$x)i#&2BIXs7WhImy$-I8lH)!fvnt(=;frBp{@JFGt#}?f
z#sr@0SnJ$42-u8@2gq}=t12yYYUN-4O0;?*0suZfpaK7xDdK;23%Mu&v)yF8i2=}n
z|88u^48%+wEX-|8S#2Cltt{BtSezZLqSaJnQ4k6L`w@z~oYZFk02l&!o`i>(H`KB1
zg&t%8<@Q-t0`PO1_!u&Pu@YAn2LS35kzP$(c1deFpNv$8{R5dy?90rKPd?$f#L5BY+eR+hvEam*Mn0-DqOk$G+vhWzdc
zN5K~|Ao*ZF)8W
z@d_}ld3o>sxSa@yyeJTQg-eMpUY7H
zLk;UBT#tQfnG>-VGzwi=V&8cE8=RfjtS2onoAwmU3
zSnhzWZ{}V;Ow2qy?#8yGKglMLiVE->Y#42J&>b<$gUxlp*y&aicX}a}-*5f~kL_8A
zOlf2Ja}R3|8qiOq?I?-x{ruaO%YR4FH7$5hI;s7B;e_gZ^X|;Xdp0$52YNfGNG#)#
zfo|Mf6iirfjCyO~SWa<47PvN$CF6oMxNJ`Sw>~m_!BWjUwJWvkprWR!MTQKr_AFml
z!yb1bHq=HLoYhpjm~6OGo^Ntk#fJ3^a>Da!L&FqtwZ7Khd|n#bE=iG9
zWvMy8H0mxD{G|T-->bV}vUJ2DB8Tzk;bIm|_sR+E5{{hoEGFY<=V3k#Wbm~}tC`ot
zr*g94)AyxkH&vtcHG|W;XSb66f!B)FCZd+5iyA@&Se_Fy#^@%*=
zRV2SA<>2mBCtUKdv~a%mqXj-T*9Hx?=uKHRt~yLMl${bzHk@0|b19DzE009~$SR>A
zjnt~;Bp!_}4kZQI=u^FtI(m=^+-ysZ(x8$F`tEu6k*)OntDZOhhGU3}qr3BC(Y5(A
z-QN7TP7<>fV|eC}B{fZdI%Zm~c7@EN>sRK8Dxb?X%iZgvEZOwc_*lP;p4XG9;oz~UGJ7VF)vUc3cA+@V0!)pABvW=xGl6JZZtKT}5QIwlKa1WXFJKO|Y-8*kWtuw*%
z^@7E8C4ak(%GaATrJI<;c6GQuFDpkO_7+#Bm#zE&KIy%^12(;~EvptUJO$bo17v9v
zN)*ZRGKB)qiki=f{FWWysHQ#xTVzZ-Kqb=K{*34N8M8?pkRMirntHm_CMB+{!H|
z?G{8R8fvA49lnzz6h(g_#-5&5ilf^ojgY5m$3r3yb{RmzeC8w^zbXDn#9`#FF@LU?
zmO)jsenBWesxinx6C^w#+CvQneUBU{x~y?A0zqpe`k
zFz(KQjVepoZ_R~{;u|LJ^hcB^_7`p=MGt1mX_8x8{=KMKKk9F*$;!R0Ojk<(DjPm{3Z$78ZfBS2=ZEV
zDF4gFqygrV)>u7n@l!?eg_|15)%V4#3IPHv4WefBB
zbgk;P-JOm8vMkvCu2hsOSN5e|hYJ@~8rUDqyH$YVTP^|RMCUAmdtLe^L}6qG7g}i?
z!gITvH&yJupMKxR%Wn^HYg%&AYne}?(gA$i_c20;YSPOawadfM0aak>q^skQ>W!)q
z+}@Opw-R|BJLozcfk=`V*BckbZe~ewZ1tL*-6Hm-b;A|#q_n`uDw>*&6ypLLJ2>n5
zZk+%}SfP?HWP&_C{!crL?eSs8uR9sT97M{N6l-E^#8L=P65^_Cd{|dXa9xMMo?~Yd
z8q8dInX<_&fQHQI{Ss2X%hU+0qS*173O%Vec$ixalXsCcP<@@IhGj4Q}hkPaJMk-
zyS$t64VZ7tzY)1iwYtw;zJW1?33zH=^0VAW4k&tW)8}iHW4Q8(88s18
zNF2`MiSU~vS>Nk&hZG4Xqi`Z3{e4hpv_riA(S{b6G~d!TTyTvD#692t6Mah&?Y!SZ
zidkn~`f5T+B$X3TL{PhYTJX=i%*twJp54vS^B_7aD{%{F3iWyVFom?86w8jH$6b3<
zq^-?sw|!;{#$kjrqNmdBa~{rI!JH*mgHGk4!lDH1l;!olUXcN-cBU_iL%ODJXgs$&
zg0G{0t4sYE4P?VycoD1aF$ulfh!Btm-8`@=)v`{YAleT#3%_P#<|?Ee6
z>qp}K?pB?8?nX{8t1peF(rm*qn~Be5Tdj0$TR=vI<7E_^?Rol|Q=x2gRZzHDa*@#=
zP+uxmjo;5|yf(eR1O#5R>(6LaLfdiUE{79-TGHhLkCI6oR;s0DhwHCL<_Fv!&2_((
z*KWS^ZO}3ze-%1K^MMvICTBYpEr^~r5d8CgHfntBV>MIoGWK*smM8F`UVCUiE0`DO
z%cx71aih?jq+c&+@vu{>E&4K?cDEieudaD3-#vk75y7g}ZdP+Ya6`6g(0f(m^t!GZ
zc&$QdJeh9WZYFH}L+eCH04NpBf}~hx2l*S)(Q<(Tw7`Wanv=jcU@EtK`bNO%l-Gv$
z+udc*$2spNRNNfNm2$pz(a7AjS$LR&ww9v0l9oq1ZN=Eo_U^J{Po3Kn&ju}0E^l%s
zij3teRBgetCzH_IRIR^!rB+#aS-$tqr^D$Wb6-SP5xfW>T0s@ws{}O__|V`$7qGZOU>r#OZ
z;mIUN*+y}yey)qPY35|xKA<>j;S_+)o@1Qgu-KkpM9``GeC%K*@SbrEZVJ~Ny6u3v
zM059Q{^-*bIMF@id<$GRLz|$Q@4fwn)v)_+hc)P~%02oliY
z+0%{cFQtN&S5M^+*j&J|F!%(9J13k
z+A0yb6y|X8JeLhK9T!{uA$|;mE0rtp31#1mA?(s0OB#R8TGXa+8D_(0b(#fSF#piY
zsD(IKD|0MtSr*$>(In>cxtxVCW;pgd#6Fl;8Jnd_wctn5SORQ%H}S4~Op1jL#|@^G
z{Dcx`e5ap;6XBp6kB97;(RgrEGYdbrD^5>s98BCdmreyNT4#F_tp($0f;CO55Vd*?
zunaw>%qN?bFfb#o_!rW|!(iDIhIyFFp>W+Ya$U#@vAckB2i~8@(*MGA5r8Ye?Fywv
z42!0y&IzE538iKRty77jAqmD(Nd)%T$SXF
z`{!B9nQAN0)JWAb@BV|zF87unC2kgdS!noUoBJyMaNfY{KzLY=zJ7+t-N_+U
zb5Ty=Xau=!*LUqxL`^OMes?~Et_f{|b}%$8)~v~uspLG#D2U&S@cWk_4W;ts^Y~!R
z`3BR-xzcUXVy600YH!-zxP)BqV-D4ExGe
ztS=sXJdXx-wAK4Pt!TI@=EQr>xO9}w1uJ>$dJu$aRt|oW)|SPQZ{9(iR7?u1tWy5d
zN<(PRmDjn)bV`2CoStEN#c$+d1Cl3N(b?KQ9IV{?$22QM+(!FPS>6gZ{O}m>A8rur
zb(sD-FFzF7?$OXUtVuk_>00CDDNsHS+c(BNvuHYR9c)J}KB=So+(a2*r8zt*NI&!h
zaiBlxL_I5-{>(7o<(Fjn(lV=&P#aIKalpfRLH~K!%2)Uzxjt`~t1ikILaIbxIZTu2
z?4n)Ubky`xUJ|USizcG~5Zt?U@WeJ=jokOzW0#
zxMET492-Ccx9dw1!N0VMMN5Oa%eTYzqPiI{!2Ja&+@J<5XYu*TfCKZsG-Xbc
z0TaQ8VVKSsL4L8qAhyz8v$CY0FL^gRezG!BCF5k|da3m8F7Lv*a`D`&V^F0WZWF*T
z#YL=%0SJ5hI@nhai~?=6%#!IPIOv>%s}Ni^;}6T`!+?!vxX(~uL2dy1Ry`7TCpx((
z67vX)?QZyBc3VBbrD8)`=q&e
ztUqoj(>Ak`s$HQv`-a}0SXryRZGh&xFLCk6Dg^)R7p0)R&qaO=ubnKtZ=^jfo?AM>
zAfSQVoNpt;pjM#K&`@cH!plu`orBLkI}y?sE}JP19m^Np?WNmSGl*FTS>Cvmtcy`q
z%!lopZC(LF*eD?Wu&?|oW`HlGO{!l-s+RbKXz+Q2P`x=&I^*@lr_qS{{a?qv?Lxr3
zar^tPawFfK`GR?+*jEk1YHimBoiVFHU=BuBCJU9c2m^bx>q;U|Y;)#_l{-b5bNhcQ
z-iA{ZU+6kxsy1HRT(Nt=jgxWX%RRjVg&FnE+ZSn}te$yv=BZRc*9$1qQ8l&1x9G`~
zuO2n!B;7$^n}vlB*8O;0wirxDeK?jlkn*Z)!|zhqeML3kL~HCOrQmhpw6?cjysHbq
z2&->cgFwDPldoCw_dGedtOtdghyUN!_NP(kkfZP_RTRACUovnNAf&HWqi)<{h${pSQ%s;uL?7t~d4bxQSdqdd{S&k6moV
zo+z;S6QW-CG(AT!y*8sk4WewC2KFCXp>AAX?{dj7sWu#Y94h~vKSSf=<0-VN`6Fbt
z23^08n2yq+KmQb)o9LoqiWX>&8b@TM!F7HLBpydla
zZ9&uOf=^j%F3*h}r)qcvkqV1V=<`%sm!+3IJI;B&uei!}@aZw<=xx{nr>*&Y-ynND
zY|m`a>xptk0yEj5*L?vGB2&R}=U7>Dyes;7g>AnYau=E+(UXeIU0H0rP$iU)O02Y6
zeE6v9s`N44`(ciVazw`Oes)##g)bz`V{Z(ah)A%cIksax`~?=XwlWly(P^Y6ErT(U
zt;uwV3CuzNaV+)dFCdhryusZNe?3;Ik(e83Zn1S{wD$3jw_xQ@TU}ipo9OZ=`%&xj
z+kKrAQ=Hx;(uJnX<`EBsk-DG(B5_z?7eH0H6?||-imS6k;Q=p8!?I+HqqbNkbDVkU
zJNN}IIPvsL7TsyVdS>Gl;_4~;`S{dto?8DnNchR%CF67X5mxeectw%jlbI_-s+zw1
z;6zyCvt{%hN>B#(1k+e^IJr!7c13~ZhqHVU?qL<1-alXVUk8`2IqIbR0S9v$Xh!Sn
z&yVwdeuAfl)(4JmTt}?GBz^wg42}%UW)tbS1-SimO7sO~3vA9mE9aNl6Ydn2@Gx&r
zcdz}nMJt5IPO6j1!Pjd%_tj+U<(TArGeR1Ji+Wk_DLTyt9S*UtyTBS~YFPw2($QaM
zj%;{+P}p958%(L2`PdizC=ah;jAhJe_^qa8ZI|>33>9K}gPi-MWPlUPkTK_DU5(t_
zLi|N>TaRLE>4a?JOXAzMzEf9yYtVjdK}UOCn*c8_?^z4z?Y`pj)^EBn-j}XBea!av|I}uEDDM}
zS595IYgLgzy8UtP7bIm32{In+G7H6o@%vTF*fRSILcp%3H%@?7b01~DL@s!eL?!qq
zF2r*-Ep))#8=s$L>1c*Jh24*H8u$Q+9zR4LnX!Fs!y)uX9);jv5vQx26jmNzMlS!b
zpTLAXWh#wt5+Zquqt{t#JUGk;lv(C=srS*%T>8jik@ex^8veasTXFsLR|RVWp4#{K
z7g_zck+$&JT0oEa4m|cqs(RmGB{MX&`nEHFlp>`U-L5XA2qvuAOq`Dx8tQScCa=KE
zvpMWww&BE~Z<*rndGyolemyAOYOrS0LKQ>(jp~&;GTwK#U2`Nb+0ceFr6<;sl0ti5
zyAgQsg_RL}xHJ4_(32}i^ZQtnk64*zpx&Ad7b*CQY>5aLU(VGMB1L^VI)iu*e$D;{
z>vo8P(b{^aj}O*ih3@=uusTpN7y&IuZjcu^GvB{tH%m9m)xu(nxY@LjUfSZ&ZnL>q
zdU%L;+68kczKDWD1@#;qvFqVgjpen3lccO7KJUIB5e??9(yI!y-?o!lw`l;$yf15L
zU}23WkolRMJ~vJ~lVrq{>QSb}4w-GsEnGgxP`;at5nZWFfv19di6O4c3P9gym&>H7F`9t3E0GpeqT>JnD94n(cJybNISts6tufqeP;LwE;DS
z7@~d}0lU2m-sR6OQGFf$g~ZxZC>YQ-`%hDZSUK`jy)zd!;!7wLUjiq@li&2(;Pjim
z%tL)D-`&oVScCiPN=@eW&?h`GGIFmtV=y2O2|Z*$pCF~P$~*5r3NZGC)h=bahSRVx
zXo22s@{mK+M+3HuFiqtHxKW6Ds%OaBowa4pII@}5Pk~u_dTvv8e*05aMF0562Fut>hS$-
zOC;iKWlZpxY3eURBo9Y~t1LS%w%-?V-BF)LX=xLg4cdfS1M9~a#_jp>RefGDYG-zl
zyoGyo3I7#)<`?Aon0X$oE!@fq&0D?oG*)KT=HAJrjlDz!s(G@AdK_B-f)(2IwRPkhbzUi18x(JJH8dF#rqO*n-fd`h|*)QmQyPsaUPV9N{LZ_MB`D7wn?Z!dK
zI!5y=*)mhj{(Q-s_~B}fvz%0z9=;g7XK=k49$&JehO)e7pkP|^wn9Ne~a`dW{XvY6!*vg~ILQh$D?&NAt7vt@R
zjw$2*^{MFlzk}!dhn|;`-k0swETO$$mPm`A(`xD|o3fb{V<@4*y)O1~tGJ!B4Ry2^
zhy?VK&C{X0IIg%tULnh0$`H9ZsUceKxe8}ZTjxi7l-J5O$A%G~$>5_?IkLUtTtoDH
zd<=Sg_%OYEMp6kX8j}l=nkJKfeEmjH>$D_`r7rrk?Io-HMr8bSjio9S`2PC$=1@d{
zGhite6gfj%Jnzpxf_<5tC-yhsIy@uauj4Q2EMFsHkaBRmlvd1z$@!_M&+cW<+Z);2
zRe9Hj{Gn~T1PY{l$wmrOMlpC=eW6UUk+zrKvaw1Rl?|DF9?(sf#N5|8&+8#ohu%C*uH1ua9iW
z!CS6}_>0IA2`mYw1udEaS>D+4*l`1TtqPi(G$o8bq^jZ}RCD-4FA;t#Z(2HpTzDsV
zW(TkcU^rf=eiI#$Jl1Wr6!|*1GR=M4U{G!94=4+s6A?b-j|1cP
zx#iw_ZmT-*L7I2jUhI%?$d!GctmMrGL7z8>aFTOB{P%TkPS#UJ#z8^Zm!g~I;z-7j
zkS=4J8hhi;w|ea}PqOdI^A2K2H6EjOb5-H~?fFw_98b0k#>#lMl@bKq9cL;*(76om
z0@&;8yNlg(gj}4@NTac8hQ#L6aKK#@hEHNp+qeCkYZebrCLJ7
zeAj#_ZDPKV=k1^6-j|w-9T4P5Q{qay1AQVjp4|=GxSrkSS8bdy`n;gF9Jr|oiB9KS
zu?_215@Oh0YU?TLzjSI_gJzmmWx_`6e2m1y)H%73QCL#j?d#K-!EP4mW!jA2>tWPk
zq{QPKVk4YJTM6;X7rlrH0iIU)BpKba8K&MYK$L=V1m+e^X;r)*-0mhNdN^7ox|N8f
z94U-TFK;39M?2t$ep(@RAODAu8%3g*hV4B&d#bcN6fqmv?ss&U*fQU)qb*LOODv-q
z{$8|(JcUs!#ilFz!g`FnPP+wM3m*r&hpmy^L9E$#14!R={r!B&pNRwh9i5{}_Z+sUU!@DX}
zEb)U2Z7k}u7uu1Rc^g)$FuDy>oK({M*-JK<_kKMxU3wn7-1BeBX|;xh5Bdmofr(o`
z$u3Uki&lb$TztRf1jxhByST2t<*$8ajU_ZK+sRpw!TpYVxYpVpveFrZ`lWBm0Um`sPXaFp@>t{p_p>eePe-z
zTeuPnjw)609DI~J-yTwg&_5mYX-Nju9w;<=s%1*V6ir)~rwex5)SCGJ1Li;(zl+N|
zS1(_`)fz6ThSTm)Z`Ab$%^qmuqz#xD)iFGJG_5-hAT7n0nlQ
z`=u{*M(YN6whoG4t5pm6d^Q;JWi#j{~SDfOhx#BnI>`y2ew
zgAdQI>}+rEEw67cEiN}5IK^{Nl8)m*VG_BOH0W5kGU%VMknm}{?KZqf=oMP1<4(cc
zxtCjp!$qsn#vei#puseKB|uk`djuyLP6fx3gn3>X_h;Z1k3)z5EWl-fUT8pZ;tz2v
zH266D;mL`k*Ka<5`_|J&ix#{J0yHMP|4Jee7TKc6Wcg~Cug3XuRAzA`xk?DHGMkd>
zF@?EnbQC?R2T-`d@+SqXh^Z4zaJ2Z_3gL|P_c>T3o3;)(`SPq)oYS^u&)oams
zjd}M9n8Ey3qcsOm*o`JS2>J`$0T?7*b5~MHdJRsGsPP;ctU|()WWiI0I|cDpiC&sC
z9r5ecASWMs;4~O@ES$Y@`{nlhIx3^-aHh}+;Nz4Psi4bwmCrzuvIwarbs?pTMTv>2
zTtek?+TBwSC=WmQ@Spw3pS6b@I|oW*X$>K6CpydP@_FG&}X)d+*^p
zY#o$?7P7(hZ`e&qg6FLL#vgv**yKYr3vuLut2b_c_A{@T?LKTF`iUSgiUNH{%W!q2
zpo@7!DyV!~64EN0L2KoDMi;V%kaBDF59PrVCmuX`vQpQ(OIxGig417Ww0fOR56$kj
zJEP&K(`pa;9bmTC?YC$k-s!X()TbSYy3ufqcKfb5m*M>S!Nr|cX9OIgKZ9|hd9cJF
zn2;f?w?QlSG`QF}cXfmTJi~fHfkEIn;H0*iuD3KnlMfG|*^@_){ipx2V~PCW3?$x{zL@Sti9
zhRa)X^Q)#au$rC0aIV`$g9me?LAL`bqrtRhwcBZRI*_^9bQ+x|`aDg!-MN=rTK&1j
zr7g_>{~wOm$0@RoSL&z+ku$Uqh*jb4i(0LQu5R<3OjG1F1|M-OtQR!4tF*><{HIg?
zDbBY1Q!Do!Iy8Cc4<=}E`UuUp;5dAE^3b89Fj#bP;^@EmSO1%?clwK4YrEHWcQ2XF
zP*fYDtO;;fWL|^!szOO}JYQ8+R#R%a!t+c{SBhLMt%}8BE?`I{naLNk;X*bj)sqsF
z7P*{UOTp5y4zUabLz22&zyPekux8E`r?m2e{FMX2xSz2CQT^kH&)PH_{ZZzyH&JRYT)@aaNoa@aEoVlU1IM*Ha^@X8Ha~>mm
z*fVJgq;C#7`dr_ji(P%#(MDZ$u1BxKw$y9!y_V8%D=mvA2zpJuILFHFs8QEgc*e`a>wHo=x7i
zmCRQaX!BBDRXAO)6|+fAD$7EFucuW$51OJdIjNpem~6cmm6(iJgHYpq2_z=Mm*Y&)
zUn>Uch4*`2zg<53$Rm%P`OsT$z4gq&@|R!Sxpn*Yl}i_I-&p_D^9SpzYoqxUNSDf>
zgNHTfw-!d-`9T+C)t$m~h8+_E9(9dw*BErvL0ff9VbIaq?&cK8Z`jpnXHrY4Mc^wrhn;h+yHMw1nd20VUMRpB;*r}X>1MuR*F4S%L4jRtRzBcs&=b7oydCu>L#4`oCRh
zUh0vZLQF&S0h0SzKLS)6Ayj^uVk+NrjID{@MVowk-$}EZeqCMHL`m
zNs=K*Vwd1gkRD)e!o|=#oes_4!s%Buph?xh#7z)?yals_ge|L~$i`qW0s#S$rEO8|
zwxTGt8iTJ5N25-gIQzI(a1)OoJ~TN#jvhX7^vL9~qsNX-9!sXmb6W=+``4E@56td@
zqC222VCS@2UzEz_Qa+ce){41oGM)&h(uraz6AAl?m?dM?a=cQCR`M~SmMmoa04`gD
zEJF&LlxneJ+F#0s#Cn1+hq+>iDfwvLrikPHLq@+{&YXGlPyWNd+a5Hxx3(``y7Kh(
zy-(iSTwC3kpI;ab=g>lT@eKU4P6sY@8?FgFP8&jP*cuK=WHnVV&GAMgiT2{Cf^Eo_
zCYze*n37{D4O1|6q2B_;`G&^yT3V;6wH>Y1kXp9TY3cwy`bXQo%fb2WB3r}$V6M}d
z6X6Zg*gR=z3#`7?Gp&ZC$Z!k6V`+V!)qv>WXxQ+M$+t3rUFc?)<-+qvargAlS}hfS
z)v(*}0HHzQ5W!c#b;oJdYW1emgiq{_%{I|X;C@2WFD@+N935p`E7H|4y#VgS{gaau
zCnk?RaD4KCM6|H6ck{{HFD`BFo6blz9T{%B2-j0&YV}H`k}Kq*(L^ehNT*^ccS~3@
z6@{>qsdy?C$s~gDh(8q%rP9Gv)Srrm@|hr0ik0#K7+|5CgaPI&VZIU)Dj~KML9>((?Z0t2eJ+fA-3SrG+&}_nmj%L2DhS*=n_$%?5-`;)Mfl
z*&y1cp=qkjFf~=h(-D9kK>&4NWm%LZ7FtNxz{l|%1zi@JmJaa)+_1j7%Grhp(K;sA
zww1Ok=9bMtfq#IE=a<$uR@XVvP;^^29hPU|+(MV)S6e_<(}5nQv=3z!PxIw?pGb
z20(A&Z^yN|52pC&Q5fLk(A9Ku;^fp5o{jyd4z54DwsqNRk5t3?*o!Zr2Nf%9sa(nB
z%kg9~5|0LgfnYEgjYneXBy+M1CMlvf
zs48b_f~BzlcgImX?(zkQxnWAZ&Rxsgf4i)%Y^VmPRdhG^%&_1gYrb$ET+}>pNF=uROhT@v7BZ
z-q_l&^D^xAt0AuB2b9@z2x1=B>Gu{qkKNt9-M!0K
zFYVpf-(6l>@Au~Luq>lRGw`-0gUPrXePByy9}z9h5g=f6`8vZwo_Hn|VwPlsiOGp$
zwHm*E<<<+&f4nodW;oq)jW1NWY@w3K6l3XJD4qs%Az*(n;1BvCUWnG`gFL6bzGXnAnTu(kZ_4L87Yukp{;61a7Lv{A4x3spmf9V^adv0xIhc;G{;#k;}sWa3KycLsXzwWl{O*?95||`a1B#w*otF8*ea~}
zojUza87-{y68x8jNSirqclQcZr~^F=v;t+YqtMl~Dh29Qr+G8*VG3#c9fXa8
zmE8F>mZqb|N0k~v3*jNWIuDrAwl7&Rfnf9u!`&=`AH_Gvy9UtkVyQN+6=VzwP0J7`
zCLZ{2fA*2Joh#e>H&=JA7_HHhx1TGrLaM-oQ(12$<%=dffv`6a^+F#Lh6Ao#y|dmK
zFU?3j;qgw>Obt!e+?kict8ey+>8Z26*|W2==X{>2kasE)n2LqY$HV8V89!eMa%7c*
zVm0`|{_)3eJ-vVZ*43*|-Fou&H@^Apc9({`TpXBV@<|ghB5>fYh32FxE8u{bA-PhG
zErK7qo6BhZg?nU6RoX=8F2~4~s--e|00(6VWJ8DJe`o`D@r?+JuIs#I%3x~Eh61yF
zr%u0926L;r)oeIj7!lMBRic%Itq!asI5Mp*!#!z}Elypd%hPx(Z8;@LLjeixX4|%G
zO|c-(8f{{wu{v56BdDTkL85>!?m!!KRS-J6&Y(k+;PD0As#Jv?f)$4a8=xPLYjxkD
zLy$1h>B-3xexHAF>*|xYU+OPyKlRMV(j_)mu19jEa5@`IWPIV+Y#=i05Bfsk8L!Xh
zE(w|SOw+vT?78Wgv(wWbnV$K`%ruE}YWgfKp_n>1J@v$tyV(&ZBy!JLnCE!dlZko?
zDGyhQuqAj<0kIlle`m7&x697XrHfaeym;jW=xe;C6`8Fb4Yz6_NDWAumb-A^Q8H{6
zj7yb(3(*3pWN3;NT1!-|0wER<42kAT46VQ@*YQdRiFv%(D;b&rd<{OU
zZ0Rxp-MV{;#%~wh>e!8rY1uHS&?_(^5Tv`f-CfKIVlB}u=$J+0y)3JB7CJ+^b>qq}
ze)jIq-+lLI@4WN#ciw&Hou9q??t6lu)!juq47zMhEY=v<%~~C>mT?c*5@6aJaO!JuRq$m{@jb7`do9gg3k&yK2v7H*i5mp-?+4Q^{+nvrSE_D
zwXgi`*MIWU_p%j%HcS>OnNporpA@UPQaw*%rfvaU2eU=m8gz%YQ_(hWkaXx=)41mt
zNV7AC%IHP|y^So0OPatWbiCX@#D6t
z%(t7b|M0b+z4h+rKL6KfMTG&*X~z~BojL&;tz&qF*5WB9FOr=GivTs&ZQB1tjTUTz`{bhVsV8nEZ3&yj-Xwnmj&jcbf{_w01
zhi}#!^my^F$LpVwx#Ew$`|WT1&0pTWcJPHye&Wl2`FW_PvuDpf@xu>$&2d^zJu3g%@@}nR9__ZIu
z_2qB=IF@5F?jF$$EmMGiYxxqaHPkyPZ2$~568*zna0CcKHiE8#wcnF->DB-?5`+uh
z4k!Z6nd;;R)3_07S_xh#4yXM3~vC(05|Kd#jCMWu2MH>x>oOW2OwxHzD*+~cecgd2LvCT
zfM-1U$N%L&Kl|K^pZmgJA3XV-Gb9|B>SDT54<>VgXv!Oo&jiC$z-}Pu@dv#Duh;MH
zy!S$5PhURR{lRy>^W4)nb~iQzRy=#|FV3C+C=g6qdg}c2G(h|~Uctfw-gDu=R6KM(
z8J)?+rgAul{)XM`!R!Gsib}iBfgVT~
zkAN2xNSD?URhd$S&C{xjdM;mq;`;HAUjM=OUi-oKe)xm$zy8dNpGjpav1~1sucY$T
zEU9Z+B$BUi(BAmldYx8+;UGOt>uLn3YlsLfr6D8nAl_(QY4pw|y5gI-P1${%QK
z4-D}6nd#}7nQ7?cndv8{rXQcCZQ3|LOBBolf;|I2D&&768a$s*1+obbEHPh#mmH9p
z=m+cSD_3sqUAuMZna@1)v5)_c|M5SZ&aesJU$ekFXte_|7jhoJImgSVDs`x9(%67z
z9@@B2&X=m0Y%!fJWOJotrku=GQiWO~Ur*(0iCi^Ptfz~vZm-auR%iwE7(6eiYxNE*
zHf&RO8fMeEYu59(OLw>djox%RP_J$P05=wkq}h!IT%57X3+Kok>N3C+iA%#I*ICfR
zOumHbg=48$G8a$f6IoQ4^iY{-Aml3XBFr96Nd(&hhcdlVAA4U%mPEPk;6If8QFeOJ?_Pzx)*_3h1#&D(8=+
zX2Y?Wa1_#=^#{mR@&;zzrN?-swS4Y|Y*(mLGbGWoGczA`k0)p$qT81XBvh_4hBV`0aA>;P&E$OBA*`XM$SW_B}aQXShH+C~XIBPp8|5^2CXzn_$;8F2U1C1+JKe
z12qoui?T}cV?Z51nz&Rho6437#p<}iB;Xp4{tD#;;Xy6qZ(&EM6W4eMm7we{N(8=v
zc=Ydft7#d{7HA<<^>1)|>=-R;I^xDQLWg)-4yY|2)Lp-LF3QZ1b;hm*N*
zJn0QaXM&`wVTU~swrAGs_d>KY9{5gEkTj4zGYj|W94+n}FTsY(1b2D%Y>46lO~<1%
z$*8B8gHP;}>a;XjsYaDbNaNxf^ZwOBzg;w~yK-T7dFRT;{`Hmh-H(6bRhZ;Pt8ZCN
z&<#jhF>H7g#9dWVR?ucJW@Sbw*Jy+eN1@EoYPkvpFUX_sgJ+fCP|@`YE9Fakj-rx)
zxJjZw-l|TElF61@P`f7WbZ@udjpO8=IBqoh&1U!d#S5bmEmwhzAxIEIHx7X0QU_X}
z1PbN`-y$Xfp6Kcf3J5@MUb*f{owP`$#^NG*@D%cchHhk;Y!gg4x+CK*NhrbuiL#vNq1CupR!S?
zu<3Lm6itR=v0yae4F>(;sGruS2E2Y+r3&&jI}1V2%+jhpI97!7kbgShpLO-~Og!QV
z1wE-4tvWBJy|sLZt&qPYl>K5YELEdYHTb^m`0pz>u3ymax+B6d1v8>m!-4?TE!1nMhRBeB1;`%ewo(zw9DxK{4+L;^962PO_5h4=l;$6xv4mtJ*-t8!yNVm7JU
zR#`riFOb2AMnd6OAQTMK2z3aM4urhmVSylA=Gg#^XwFh7vjB}>Mx(xH*q4k3l5tNy
z9Vq9*OfkfkqkykihKdd<^@Lcbm@#rKDc!wA`+eoigAaiyF0O4aZ|$vZY_F|uF05@g
z2lF)d4$(Gf0Wuz|qS-hhJFVL~t$j7|AV~4L)*8>weWfiEw2y%JDh&)8
zx@*Alnhkid4I5U?YFI|cX+XNICao34>zz9NPFY-7HJz>i$yzNKUnps~$Ra!$Nzuq@
zrlBaqUG)!ru4%L=3j|o;6;L`-$O4T`)~g)PQ@{gJ)M^|_x?ZR4LL#lmYyzohf*?Rc
zkPfKVXix?EoW{IZn0)9R&^iGo1Lxyf(MACft_g}702v?gc|+HqdST=0Gf&=ns?lFj
z?G985IyH2QCaa*xWvX}CL;48cV*}MLrlD{oIdr?6Hj;s^J|Oi2OAf!
zT)T1W#?7baS1y=MS~}eA4%~e}(4`&tE{5UIYCg-M5o4RCZWINA10@+p;=n7d=9E=v
zPFlfBYuDX)n@+Q-YeuIQiAZqU95=nR|#>$KySb{9zK6ObG_ANnQgiJDhv)S3pg
z;UhuD@QmRvz%Y%~K0ZR1g^{+cmaH@c9;Tr^w%O>!<62P!O+a~KlC1LhNJO)Pm5Wb5
z_u}H_f!&^0t(IY-66EmV6&ghnnPe(auN5lQ0?U>P`BbfxVXC=&DpJgaa+zQ;A1Rk&
z0B$mNPOQb@AW8KYR}RZem?CM^;woMt*BXfyhsq>1K8=sYb^5*K)I*OveCp(-gIg=B
zTgw+NUfjQW`P$RFJC{a_8>_1;%PX7x!F;FFX*S#4Zr5>~cDq9luhFsq8K()O1GWiy
z!ePa8q$i73SxwupEtqpz16&=;?sc1vWA%F-;1v|Q*X}fIy+iW{GHwpY!};lS?ei|5)1&;xPf<
zfGiLRXPs0rBPt3-_QAPnHbJq#;qephv?Ewy3tgOLh}NNtTLvxa9@mN@VT^~m0OiSv
z2Pg#a(Ffv*%)<7S>rXwmuzIo4UVsLJ^G@S36cY~mq%H_FDW}MsDAfwZM5Pi}q@u{i
zWiBN$F@Z@dTwLK2d_6Hfspb8e5ZBm*!a|lwg-J-YumHBjl5|PrTtcoT#&!C=<-rpV
zKJxIHM@~JmzIo7}Us_z>+T1<>n%CDa^cGed-F{~<-|x>+#0e@CR%Bs*)N0Z>&`nV`
z8cj`68(=`)9-d7b0BtnK*PTYA)v}un8(;0Uo1JE3&~LXIR;Ok4yUh-9Ef`~~)3*D)
zR_E>|vcFyWqqW`bz5Z~a(;Wd=q5{RxR%mwv1u3FoDM100VP6fS$?;Ot>3;UJpL_P%
z=g{Fea6KY=4O!M}Rd=5juY%iyTT$pmxY0FmVp7_LVhuL|SkXGzU?^vF0$p!F8Nf&Z
z)*y&b0ORm3D74g=g1j6#e#8xX;)?wEM07Eya2Z9+NnAn~3L2kOxU?pwR5qgvNs9TyWHc^YO8X@y
z?uHD>XnacJ(khqI*vz<2zqgz`e)8nW2Om87(5X{rY-dhXY^%F8x4wH}XYc0K>)quG
zM!VPQLdL^xZ`kej=jVpQ0WDv58qT2ChM;i_dR=%IfEeW1r_inKZp)o`rX4{R&Rug0
zS<-HB2TFk6j>FAZpmyjEH4xc!Bloo_|
zW`lE^`|Af!-nw?ZHCT08J$E&;1;!7>4Ra=lu=T8_)J1_&B}P|kOgU?6HCZkhQb~pU
zgq$owx_O-7(1onZL9RuG%PK66B%}-Ys$5=SQ#xN5*Xj3`hfY5Hz=;PRJbvQji3c8h
z;MCg2rDl8R47cW1clQpi?d@LbE?ltMb546;I-ORlKN^mDy+N`x
zY1>sBUOch{1L`(8I3z1lN;cI8dNwUE9%uDux?P1KqT4
zi*z_H0;a$vqz)Ma+2}4%<4_6Z3ZoKn11)xB$-t+rX0Ov8aGX#nGho-_TK)6->i_l2
zKg;-k@$%0C{$IS%>VPAZcVP1H{l{?bF2ALW6BCDz9lHMrMfN##w3Mw3mM+Y#@6D}V
zTwUE%?4Br5m~hZ8N#rGwm1UR;Ru<~I!l_bSlbK>Jp-b@T@&c2UxLmauV@nB@&%y@t
z)pRu<&c>%BfwQr|*+h6I6`n05{cQQ3UehCwJa+owQ;$4!`pl`v9yxR7`I{Gh`0CEi
z?uAPS7hk+}^V84mZmzE^Ev>@zjz%LG-Ql1+8g>^(ZFePov)^xZJN8`P8V$_3p*8GT
zgRWueY_Frv^$p5yL2;stQAZtiwQftE>#2jTJnHGaHtmNPG-XT}D6kYJ13sCdZEbE22c7k`Rr2ihJ43Da
z-GBdK2=&mRBje345a*#o6G!f!glK8c=H!WNy1cfzH@~qDXLNaGLu>STo<@TqU0LE}
zi6x$;@G87;rp)t&N&)=2B5_$&EW&r14>T?5g*u&FNJ54vXSx+B!Az-!Jl!tBF
zHahr1*X%a&&AVb5ysz|ni$-J6?JjJstxFWKl?JQF
zj2e!3yWQ0^1M=$+`jR9-Y_cMEyKVTQaKRlD!nQ3_cjKCH+1ASP0=#V7v=-+3t1AoO|Klp%2e3lG_uqd%-W)n~`1b8*
zjvP8dUK4GRI9@L^aElj6y8El^TY7USDewdgSr#RkW>E#9qA9$gNjmLrVnx2J2t{44
z@Sw_KR$wx@giqxws*n-cq*$Z*dM<9)b9W1?|-$ixpwW!wI}yBo_lh0d3l)v*3A=I=jVE(Ath%S4LiLqSTxwL
zxiE4%O>NkRIPq#YrUXgP55}S0OuRzI!=3`*F7)+&OB}YOen%d3m7c>7TWYT<4QRuJ
z+HMH%i=p(sBI{07uveBhx}5>s9ttLIIB;*s$!c|ES%rh_ZSdfG}sTcK=tX(reSa|dr(!dj>oP&EaD-$g%~cXiF(5Npt{j$X
zDXyHT7lZXus9uDC!@nD~>^J3+haYI?vUr|!nZT%I17til5wxm0e1W5pli09x~++Wjt-&DbsNL3HRup1
zfo76@PZ_qAUQ3!E>hl8&upV@^o&#Y^wArbNkJJy?-Gm|;?M8F%CqMp)VYM{V`OIg(
z0LW6jAyIP&JtU_IJ=_*0snu!%B>jG`##9wqq#fp#+3j`+%}roh)-*+@xNJ1MMZ1v=
zV|95MZr+HZ<+gZ^ZP>O!GBB2wmhlB$m+=L648VlNTwPfjSLwdPhk@YZ_uoH(H%AUl
z0KqgHF>(CZ@rPzS!KDkAx2`{X`O4FFcSX`2K{jdWgDfeuJdx))2$d7XN~x4lfm$Y8
zDP|zlN-zq9q6dUV#s%L6N0kQd|$4COqi6
zqQOl^TPUI*t@-8PG0Te9c4&oAvx#n@qPq--L)rsjS`@#f(d>77z&rGLzt@4H=6N0_
zd0eG&awpk9If3UTiQ~Cy
zDj8LH+Hjsu1O+aa&4g5`D03N0E-~eVAr%!aV+dKPo)O9vWI?JWxMB*{m#-v+N~%_h
zS2Lkf%3sUfQ^2%$?aU*Oo;p1+nbt*>bq5I1C`OQJ%fo9L>#3jQcV26hun%eLC+3b<9P*#qd&KTv?@
zUa#Bl_uFksr8TaSi{K*=@R7rZk4{b;n>=!YqP!eAo=ldOwy$hldTM#&lGPc(x}Y2ys_T2puK@_
zsB05)bxd)705z_IRY1m$O^mvAcdn`T70nuMY;3~x>PFKtn-a}ok2e#yO_Rc~Iu7OY
zg5HG;pb5d1Xy2h_K$s?luGAoMC}y6gxj@5&?QH?F?tB-GM?&8CD_sNJDXCMh*QwWQ
zKrsFq^6qyBt#$)WL%fc`D7uTC>N4!t&mTLnR>Ebj8*dyK(>?(
z0K`HiDc6&HIh=}nYK5>+gX09#>t)M6t{7m;p+fxqQ3roh9zFBeqo*HPpKsr~xVF7_
zaO3i&uf1~X!rJ=M(ptCEN7n{2py+zN7PZWs7i!p)i=f@Iny_Cwr4DLBCCWU`bxksL
z+0rFbgNzkbVtBR;!Q-v1a{x5N+;40Bwr*%l+tFx~i$$AJn+-ztojU!#GPejvWkFO)
z)xj?Uy=uErKj0?OKzQ2$mxeC~EeH`niqN_(%4udo@E}S!K%RA-)Fi`jstO$rL6gs-
zYqW0>oyMK<)R{VOS!ge9S;Mb%K&=<&fqUAL2@~By|GpEzoN^jXP|k$o6Yz^Bj)FfQ
zKXxLOE-mjpwSDF3g^fM4J&*qAu1}+^ThQ;2XsJknUbC5ashEpKgQ-*u=Y?!EpGzj9
zv)QDtTu7%A{sPVX$7_W+TZ*TnGkg_98m2b@7R{9+OeFvrbERl4@2lngwR^9weeBHX
zGbfJq6k&IJ1N!-?tCwE5d0}Z~Z8V(!)vta94F)>eX*+-gUh&p8L0c`;P#OdfvtF+X
zBBRKhWx{~*@GHNfnlyIed5S?Taqy3!!`qJBw4|oZyG}6iEZU6PxGPTO
z`%1SvYPEVbUXc}3(+yR37f;h#c^SP7PaYJN=&?=H!w^riN!#p*Pto3Dh)|`BWi*8h
zWl38l49%7#okd@eC>0yf3{y^%j4}{!GsE-zWsb_unKS84dJAVl29twa@lM;lg#D{$y7QL3k3XA
ziBvR`j3<)eWI7g!2I8?mI_^&=!qKoV9+}RkV$r}|Q%{{_A-3Y;Q?Fmi?>Dgvtr^(Iu6RJRSO
zVF?f?fZJ|>aKS<1n-=%JaMAB87d9`nyCcPD=z2ra43$hTC28sPdZ-M<0_PTb7Muzu
z8AcaxA#D^QuF#AWz?J3@AvyB0C|@8tMuQTZR9ITu#jp&8&{Ir{=8R36`Gx|Z$WMj=
zf`+~VH<}a}Y}U9+Za~)~$BrK(zv$>uI7kopywTqcw->;(Oq7HHuWm
z7Av((CKZh(Vu^Sx7D*)Hkx0Z{;1LT3XCq;MBlHT@9B-*2MBB6!$CBDj3K-p{Jb-sai+*2OTV0clrfNCRs3HZ+>Of|YN2l9C
zuY(qZx|S3f+Q!w-Dx?CaK`<;s`z?TPqOi2}l@ixLUL1_EyYCH*8X{*o_*ay`qF#fF
zhII$SgX&>wE^T)pzlOShl-cyq93
zG`hd|#V-UwE|u%qVmXsZCz9D{JQ9m1W3gxyk_-T{kr+<=zEIGMBNq0AL*8&;+UK2$
zgneQER6ODZlyiwdy_8{!04`K?h%ZOkqK_^38HhITtLFnB#G)U5R1uhiix)Syx366}
zc7&o57^Cbzh?p`H<
zks)EO4)35|V^obiKuzU|g&92jD0fRSxHoMq#@lg~es7tdTh`2;1hV2rz-)KOK>~20
zoZIa#gy%RETMb&-X*9sBU_ogsvkc8l`F8l{sOWs``09k@<$$ZHx?f~@xbwiJhQ&l-OHD+J-51Z
zS#OV=Rv#Uw&ce54vZZP&osTCI5n7BF4uyi0&?p=Thk_wWuIUMfNx-y+*gqTa&V~Zh
zVgGa_;)?}6(eO+%7Rsi4`Sffx3+5c;OHsA}VUuXtoR2Sr>-l@C=>OOM@$crF&DGVl
zt?j*+ZfzZ0++JU!BxkTXkS?CZcy3jN=MNO9;~=;Spz3ZK<`|Bpsd5r9SEU`se3f>v
zaZDW&twYj0Ih&H}bV6wpl%XHdJ%Cs6ZLsTxDRoa|d;itvuC1+799FmofCU5$Sm>tiG&?lFMutd5pNH0gAl<#A5HtN-g-b!3j3HVa
zcr!j>>M%UC!&G27U>fjtCr%_-Wx>*Uh?e5Nn3UWAIDTJB-uIQ!Xo;6VgW5naLh&ju-D>`d6*Nt}-RN|``81MI@?`WZJs08^O#02X~|Yvsk87xxdYUb%Gr
z)fb=Y&#h42qb|iSB9`g~m`3w7-Gt8oZh|L>rv~`}pJhrl$3u`+Nk31^lGIDbPpQlS>DRsXztXsyNM7LM%=S-VfL?-mTT`c9pGUr`N5GaS=uin88ncZna#
zlq?EF0dj;A2Cu@6En4bp(UvHRA`6>9L&~rduqI>>Ayo%3x_n
zGCM^^fpk;3QX*XlCo+*(+8ctI4M8t^NT`r71qGOOA?xu>;oRey_Tq##t5Nb}N-y9!
zi?@F769F84fOt9*d?Fq9WD=fgJ`A;7%X#aiKrQe2-Fy@UsVnu7R
zYK$b%wj0Wiihe)?A-awFLq9VdEvmK5-;gX~(UZp}A3QpFBA3Z6?cTih7hAb*kH=42}?{tdd7A7-6E^)&7Hm7ix*$KePe%b
z`-K-?f}Ml)wXGJh70MiHQkRD#$BA`LsIim{oc49qAXInHc%_P0h%;NNP%4IUHSflI
z0F?1M-UfnmVqO%#g$iWsj*3uP3f)b%W82Wx_uOBKqUcQ;;xH+&Kcq;ZwTSc4UILmH
zl4XDxPA&SQJCY0m6N2HTf!@LJax8cC@>LiIj+|0jMGIvM(T-ISDh$zbJQ%eE`Y#e{
zNg;zm<44g60O&d|4F+@VRv(&dTqVi^F);xUPo94G^y=o$?)7J{J@v8HXbqp087W<2
zVwqBewh_m?p%`TB@dtb`sy?4DKuM0>%qLSbvlOL;ww2DDo1UR`AhR=P-M|kx{|G+y
zOn-EChVr-vednX0nM`c9ob`iS3FVMb4T*Gw`SLy8q@{)3<<*_Nt53i3iRafgb`};_
zX^UT@4GIHaAKex>1_iCMB8W*1%9*yKaRgZixJHQy3gv2H9OeO{EmJ=9ak`DMbln}|
zq`+MP6E!3Ja&C$vis?ZIaBNxcPeAg%!n?83>7hfw8f>vc8!2=eTLECf`)r$_46Y0E
zj2=L)uR`O`E!+6-@BRE&zxd@Z-}?oQ*MIt^Ea~W)&_iT*$%(Qmb)m+K5TT1&)X9WG
zhU_6=h#$g6C&B%lW_vJPfPXQr(l}@f==1Ua$G`iJ+xt(hA3V9acfHYF{^Tp4&ez0D
zr5;S=ys?Bg9QOvIo?w(V5c>dMKcwq{W~P`P=cXxq2c@E)p84qX^hc+r&*C^g_4xD@
zrH+`v0U1Nsv*#ip)uHpLm@l93)r%Bq3)UA<7Rq4=dt9gAEmv=Ra%uBm@8|E!D=J77#jOOZLeB$UMM<=6
zBE5#*0C34Qg1&Y`@&LxVs{Hr&e)jWsalHHUcYgM>ci#QkJ3s%*SHHz^8VMB)i}bb|
zd!M$=(bi!GVpR-UWj)@^D5}MB-DPudukBuM1miWX(tVSYknRb*{Mny<Rc>a4JGpw1t1b1C+YS8zFv>V=cV2Mo^#O5Kkt+8@@Xgzw
zTHC#L>l0u4#PiR7?(=^=np=jQbDtd?1`}9;2yjq;hmXq&MHjf0T8)D7lqiVS&)Uei-~MH$00g@cTPV~0odaTqydhom3F13ENdbU^mX;_Ez0j~VDC#?P
z`h5kS40@ZOQdE0L!Za-xtU8!E5otGfFVwXLj;_#}Cl~>AqMgn4U%dOy&)#}-uG4(`
zwI3c_*t~i9%Fo{YB~-M#QJ8j!mr5)coT%vIed6F@Fhi7ziTF0cb!1pLg$J~_9xFE%rSNVXJCRs6B6m*Vk+J%O+f49n+r
z_lA4Mk$Ak`kN)uQzV)rIef8^q^QEtU@h{Ik@fROG`}h-2(BVq=@u{hg0?ISfq{c)3
zb7B8%JUpFE_><9TC~B@4;>wY7W=5*q6T!Ei`^@_O&8ts-{9`YD`di=rPH(UX)8=fYhS*JZ)A|6V)$`?VbK&DDH@Tnhs=R4p3yYK(tdp~&T#ZP_q(_eV)M{mCN
z#;?-FTBcaVku5UWf}3%qL>tLnYEAwX4H-%_cLU#)7Ox0m(>6XJRtt)%JD>%q4^$-o~-JwEUxQe`9ZL6+GgdcYa=R
zgU*0RLj&Uk@8wWS8-g^1U)tkTk)vvmPC8ynozI6?rMrMqX=YyDt
z)jIqlo}#qSHt;&&TPoMydHwazeCn02e)(&=+xyqAKKa^@UjOk=f1W6C>0&)gVy*+t
zV|9%`f#n841GRzo;zsv`TMXU{OsL%sEzNl2wb$N$`{yK1Hz^A+TBg)A
z8f1wRC}eObe2Pk{MvIro{cX29&^54Aw6R5`ag}kE?gMs@PS6&#$3HqX+`97er~hiO
zvLiJHDKx&s#d6h1BIircwtrtRI^z#{0wGE*?+JLlGc$0I0@JU*_Ji+!{VT7$@a)H)
zzP_`%@YTQh+s7Y&{49a^?74FvIe+dP5DfTI)CX|s*>eCfMdC?%GqD-I8WAcK$3v=x
z`Fk(f`NYeAwX$>R%CoN?Tz&4RufN$IEV>c3XkH!CMauyZMi3d+-AKuhiiV6~QwtR!
zxb)WRZ@m7Kw;klX6m
z&d=X|`)6;x{q7rYUEkds+RmG={p6jue^ISMoNxq4kQ6(H7`0TaKt)NMphCE!Xx7GA
z)Ho18+93@<+mv3S2SqZj5=Ch_N~`QnghJ7!{hKd->hr_pZP{vO%0i}Gk7w(lWY!l?
z!$F!3MQ11>Rd^PD5peAHx|{rGzW?2C|KM9+?^;^d(7*E6pa1HYzx?>)A9>>3+&gO8XFmVcTDL#nZ1r^tcSz#~@FLy$7MLOc3PJV00U*XhaWh;|qy*wnrRul8^}W}B^2QIp
z|C7J_*7v^qogV_hKlte{;yEUst7Qw-Odg!;j&z}-$I$`YT|jpNn?XxM(y}bM5xqZX
zELyWE4=HLj=Jw!PaL{#wl5koUMPuh!(H-ufP<}X|pFtY%EAPGY?z?Zl^X{8(If~KJ
z8gKsO^>S6nS15u9!%#jRw_;qGRJ24%#NaHs8_A)@@tqp&fNDcCLzB_3H`=!IYa2Xq
zWMXpiI3S!#6Kg
z<(Z9zJ+FQLhu{3$FK#X`ef`T{J9iGib(J$wEdUoR?4#gWz;4ht9q^rx_yFRwnZ#^0
z>xKI(R{UZqz!kmX?K8n0-WOD|#6
zB=qzGRJ0pp3A~B;bFuQ{*WUQi_kaAo@4ynj_Wkd_8BLYbxoVP*av~2gQ>Z11;NiN(
z(DUdkqyS-imGRO>oXhY~o6ZLzSk+pZJ0=VSL#d!==x*>2sN%7TrtM-z17;E*DGJC0Q>paN-+AZF*WY~OwV%HJlh=o%#Z9FMC6KiD0{I&v%>i(S6`{MWwu&HnPX;`Hm1mM+zk`Fbdw
z4a8G!KDo%OKjaNYXaZpz($eR_EBs&2?D?6QY2s7U=fS6DXQuE9>AJDB9w(YT13&mI
zjZ1r<2>Ks~4bEo*xtK?+h4@kc@RcYg@jXe_%GOg08y7EJe`)vNsri-7;ry!E=n#>1
zbMc``c!i=KOND|gF~mD^u&ES^rB*6cGlgOry0|XI)1`Q(l**J-`EnvxO&6-^d?l5u
z=kU!6{S^VCF0w56EtE5*t$734k
z%?u~gcX(P>fPO=RDl}zk!?zw+2{!lv=;!0d9tiqE2REPp!4JRJTiDWD{lEG0SMyaq
zQ7l8i!C2ZCiqD23Krm!XsXxK92*>AVXxN#OyHXUbne)FMJmazT
z^?T2|Nd;$8vDrjqhQbdQeS9$@Rs%Yp67L;IYqW4_dFRUd!P7TxJ-@!WyRyEenhpd^
z-mrN`#(1DL8WsQ_;j1vi6`pWh29$|QXNxemrF5>CPG=LD0)U&!SApGho=LbV3W;i!
z*+Q9xZUld!pu{|_vT&!FO(2+J_G_@KAIPFIQ3qYp+rkArU}`g2MkBo
zAz+wxP!n>QaNnnVAJ-$H7aXqR&o)LeHG{%{~zhOhrTB
z&*x*I^Tq5;IWx-^0&LmKm4iYpP|4nNMTgy4*}C-f&XuRG-+W~=F4P*
z;b;LOZrD=F?F9I08ih%NbS+bD+&hF8ilVnbvRnbT(AD6=85V_Qfn4E1!)=A{g}w+i
z3Ns8H&CnnQevZ$V;jLBDnH+I~Vg;53GKP0lA!iSyk1JOgQKY!SIESPui)V!)MhQPy
zP(i@}^rq7!(~h5YSL=Px+%6sOaesWE_|V$@0@EC3w~>jbxplAvsTjCsQD;*(vZT$d%Nx=W$?n`c5dk
zb6(H+c*v8CdGbkbH5W<8yiz?TGYO#_XG=kqd4G1Y-xRAcSlzt5b@}NVw?DD4d;wP|
zSE|+0?dI493y_3a5z1H?k!PW0}r#5GtUY&cgt6
z*%E`^fbI_>!}AIR?6PQD00#j#9kXFmV5Rq^4t`$|X~8Vi2_YC_!z<3mWQwdZ2f{|f
zGBDEUj)Y)=NET%5*04;JFkdMYE2uf?XINacg@T@Q)hgyw5ug?8c+#
zGx6zCCQ!|J`Kn*2hTLqKVXc->tM`npbmi*x-AmVZEG%Ig;NA
z`0^s`83gPaV4638``dtvWGWv_vShWPYH*F3rq!a5XcmQHBoi(H)U*-oZpbF@ofLZv8l7u&%N;C7e4>lXFm3_)mxHG`UWd%$wE1r%KIaU
zKqTf1j|a0NJ~&I{C%Fh7k6L;tAvYlzhIy7!Gy}(8lKPa_Gv%g#n2iLd(s5rRcD|PP
zv*lT}76HkUD-neWY4xab?;v=W_Ag$${>gynO9ecewhU?|r}19Z9MM&_KpU
zqlM=QxWMTkmx)*EoRqII#X4|IZcn}h`%2UruK+7-ZI--b0t(*d%Y3;G?24dQ9N_Ev
zNU}TsLor<7V_G^z(X#aqR?(7dE(`}7YXjXdMS(OmIqNk3Oe-!RVBi}@1ob2jo5s&+
z9v6ZHoi0~ub(b?k591YtkrpX{Q@N4B(dSBKhJ(3f-BB$8dc`J22@4H-T&|OOuF}|N
zw@quqVfe>Yq6Ey76in&FzxeQDuYT&2U;oT
zs)toJtTPdv!e%AJdk)-l2v(baIWD}k4;K4N-
z9l%$V4Oye0aJ-~b=xtW3auN-CxP%Mc9ICrO1DPB+GoiK)&O*GD>|EI$-=G03xHJ#|
zZU3UMvb5eyZ<2nd<4&D^Uukvc(a*Y_E-#su<;XNVqC+!7Co66YOS{p86yZB5)PX?G
zRgR@~Sh$Gat<`EIFn9d<*9Tv#k$+#U(SRj72gDCWRcB&;z|?H=pu@sc}@nn)L7$%H#4
z9PtMNGd^D+MB~zKrghM+fX90dvh)&^r#znXKHqfEI}No=zzs}C!~S^0n~p=k9_VM5
z)(#+m|+XF0HNaj272E`O2s5b{`HO^dTG)
z(;|B;Nrpxlsc8lXIt|nV&!|q$q5xMCeSbVMP^tp5Lb*l=fK|g43L@vmEP{6l6$%RE
zMv&H9O{?V?I7mxF%y(zeeP3z!7Ut*Xmj(^^&yIs`XG1pdlW74xav-FaFhFc~@=>6srR#WPS5OCZA7bi}6&}
z9|?!t7?$C1Fc1#sU{8A}>o|otjD&pg$V@8k%Orf+l)sjb
z)@U)MpRWcXSE(9M*@(o1*gmefqgQ~k
z4go{K5}j6Q{vV54-72|W9kA+$s1_s2Eaw#&?xj;$Q$|`R12mZt#JFX4i<^#
zK>X-Er3wRckH5mtjjKd%(lH?T*zqGrjvAtI>DqI*p8xpT_JP@5l*}d+%hhYw;ViI%
zoXzJl*^=w7MWeBp*YAly-Vs`QM}fqFVIPreAUGKGLbO35%mEy!L?D;)XOq5KK2pv5
zxpG{rMWtF$VxrK}axF?Zt0_I=Jq3K~p@%Q+UEJBeJioTRdvN{Al^gTR7kUe{D#31a
z@%UQpK0Fi9NIX+g*Wi;HrEQ1EWy)rP?oUHqI2j9)h!`gW4ZsAHo~oJxPitbJCmDv~
z!0Nhg=n53F8$ijXczAAn!w*)`CcN|J02&ekFrBt5P6M1vH$mAn({Kz*+CqzZXqlV@
z!X-g_lTXZpb1Bf_kQq%ygG0cBg6^T9Xd%0o9bGYSNJVq#*FKs<5c-~R9a$ITnJZ-4xg-}=fInxl2e>bPsT&A+m1iD)_+LEoM~d2B-P~K-+P`xB>C0Dc4wp8~
zX79^i{Tdu%NEC;=MwKSLDFuT;QKoUAkHZi`-gs&-cy72y0t6lq9t0jV8A6WS7%*qU
zFm>(D`ecwQz!wsAGwj)vB>8tTyT7k2FK>VuG#naYgMe8MJgWth0YxavI_|}a!njHX
z1*ua}Pe@my6aYXlIFAK23vr^)p^}h2)!Fq3Ab9jwbXIgtK%csWY>+`A#XyU*&>?6Q
z0N@K+#wqxTah2|yaPz0rapcIcBgbNq%;vR^efpCxb{Dse)<~nYt}|yVC`Q=(k!uV8^mrv>eo99PU%5i6fhm<*8CV2+Tb0{dZ*Al1{Km!2i`O9I{oRAX%GQ<32lI=o
z3kyrFW)JX%x`t?>qk+Xng9b9;5mNA3NZo9@OU8jwAb_Ur@Kz>aQ#LunfU1<54T^ZE
zYs#?OhNQu>@RpQ5W$d~WO8QQneqWgzEOmzSL<_7Y)G1!UumC>%dXu8wQI~?%fD;TY
zjXJrr!o;-U1>rgciFd~@Ay;s3d<}h~N*N|dV?*UY4^`dO(fBfyHZHc@V0!4R(Ekmf
zQEz})K;)?MxJqM^bqq45{lP~j|NZ~@?{_X{2*iCmEz2@
z37t=)=)?ic?yLfbZ!CKX~$?haY_S)X9gdjI+45wRB;3V{>hOliA994xEOL;8-UtCcX&47W_p`U1#GP(vd
zv8qUT^8H>1-J;!U^g3PJf?WlXrZ_inoZ9X7ojU!#vbD8mQ9URD6m&+nI|7==oIp1y
zH&(0NC7t1}MM2Mkn{BwJ0Th9z4qYNm#ux<9ojZaOCfY^AUKAy~UK2nkaffP!gnaELLLCfW&7dE-%zGLOm+NnzHG7*%jybgb54PFy0bO
z*|^LkDb6gD2Dg&xcnj%*ZQ=X(w80OZeDD;3_~BbmKR=k?SiZ2gwR7dhQ%_%5z0h8u
z)DG?5Tz@d?bb8RM%_bNT?bsyPHYol@tJQ+CZqODI0~`l>+cIfep9bTF>yC*|(6F6O
zi-HOdDd?=z@4=OXo;O>z)$jG7rD2Bgsjh#}qPvB~3#Qf9Orm@4q9U5d9P@**1%>
zN)f?x3Vua(w-G}*jjIF!Qyx6{NTjHb(jxeLmc4%C`5RAv;@Mj_oWaU)w4~cj(?X8}
z2vkj{z081eymu8hD@->DO^7lx5=_nwdtM$)T~`
zIN(;p)Hux$U*Ix(KMGt5-yOlDF
zD$@!qtHtwh%$oQP`UixK*Kw7|2A??o5Cwoga$?dAEsT>yJkti5x&GYdg)7a@g6XtO
z1F8mcrNAGe2vBO6vx<<_r8G3K%*7NwF0xS__^!u<3S^v9
zxHJt~)uMRSco3_M%BFN7t#DbXc2AP^;DZl8eDYzK;fEhQ)$Omg`wPxseP!d~!KG_E
z7q+{L>vp@}>W;cSh_(+LySjP=1q(5chJEPkUboeQ7N>A0KzIXY6>{&iDBhGCc8Y=r
z6OE#a?M@r6(fFVk!;n2t4M4Xj&i@@`{N6IZxV5~vHkw}pd8XBklGbpihj9>t(}?Q<
z*@8f%T@=(e-gpy#^~^KRK}&z{yWgWFV1oA4Q@3!DWyO`1byczOHGuW?*WajBIk0`$
zVDy_xjR#oKQ(YGTI>{`TS+EM);I7hwp??^Qc13%9^7um&N6Awf>*{Q(c>Sptt~~wH
zm;d^e_GsN|4WZR(e3b%5(=JF@d{JN|kugnC5i6y9Op~e-U(g|7F=L7uL(0iq!jQ5e
zABPmhTFjI(P|FZ%y%4Kp{ko8WP6nVgK4nmR@U+fl$94MM^3chLAAH~x#Eg?a|BENm
z8OCfa_E&b6*SD5eRu@*coZ(`tKWEzQ;b^hfAGTZVK_4*gj^-$F?P$<;8YaX>F##R3
z+wQbz#j;M=1!SSs9j7~%t}9xI97K9NsOze0iamxCbPc@RsnhQ(qlK-#-Mvm{2ucN3
z4|qXSK+LUn4}?ph_3NNN7WfzVAS~`1Z@ghy76knL?|&bEj_=^LR%c&-{q?7wy1li1
z5qt`=hw*;$$y<;#j;fos6v`ZZ1;h$g8FhzS1$u=R!H32VwA(!p3%5qD4L)*++@ur7
zPESreFi8le$l#GsVz6;>_2QFPu3vBU7pz7XGFD->^zpKNcxk+@iLk_`&d6f9QcN0J
zm9J%WrKE9bL&|eCDD9lY6F_B({hg#p(M(3=Qwp1Q{URvygeImmCadGqdn5Sdi3cBi
z;Nb^PoOtNuL#H1+HJaOOv<8yhpIhD8+dVkAe5E_TX|#r|{;1KSoHqpD{;=D{$)Mls
zLS6Q|Jr|mUU|!nhq-5vt9u)*zi2Vy3Z4+Uj+1pe34g%tXoY%t{w
zpP=;c4-xH}IF^cMHnuL$Z(qH9{pq>2J-ap3Xs4p3s5*Qx2@bmfn=Gm->_p8_Sxv5K
zGGjqjDZeS@bTJ1RYeH6JlbVo+W;Vov#^zND2%gvYjKXH5I-FowYcT4x#^pe#$94MM
z^5BV+Cyze}F@tSA_`pMd_@RFph*njr+nC!J%&%{5>2@?KN9)gp5vycr_HQt85!RXzeD%3AXIu6jw;_odz%t_(HC&7M>M^-hdVdc_xkB
z#+46plg#$~;?m|acwcL1InX10PSiTxA$X9clG>C-0x`@jNS0|e>I{(Q7R^l$59H8V
zOiQOVH#7r5giD}xbcEe1=QKJvfxMx>t2NG@P@<_MunTkrm;ji0p2J5By2ZFkZWyJB
z2Z7pSN8l-eML#$}(f%iK^7!MkE1Q?Luf6c<%P+SFD~;Ajx0;el!*7ba#8*{uQ&|It
z7wbT?B2;vxst9#WVKk{`Dn*5Zr1MbMVl`<gs!{
z=m(CUJo&&0i20$Dr^aG_?%8K$wK-VY=&kN@Y(@Enq_i*
z9*|*{u2BxL8gJr8rysp!|yWDvv(=2>dv(z(-F#`p83%oOoRnjbXgNA|*8gH8tauxH@h(7CyOW6&|?293EPr8^jO
z)Imp^>l-*3b~X2{GVCd%E)Kch=KBsmY)f-JZP-!fdOE&5=*swJzpYT}gO1v5$#|t8
zy=|%AmT}T{xR%Yg><@|`cdwF872rVhMvI(mHaZJsPHQ$tt4qrlx3*i(KvZl=ZQuh@
zHFOg$PG6^lRfYq3GTD5DRZNNrb=+OEK^@wUBs0Ep0%b72VF_x
zDZ`qn!wp|vT!bgyZaOq^rE74vSC-}$=P18d4?k(cmDV>mR|b82#X@CJOIi&?LDV!H
zxFLxD($d_{_WH$(8y9ysE^MrjXJFj5H1Iwk^Zr9ejvS_$Vc_rxh4?=LaE{OKAo=jb
zkwb)STp>IkId*2>DJ
z+URO_-(8DqiK0#z7G#P-heE-{DaxQOixOW^L<${G<784@kr`As6E6
zIbc{3$}E?wl`^_e)P<77J`>}atSS{Xz9_@v=JR|lUC0Ka!LzBjr;rQsKyo!H
zGFhRXW^3_!CCruMd@02Pv85=`%jBbMF~${R)odsqzvoK)4=AS|K6Cov)2AMK_{^!(
zkDNYp<`mxGIQ5}3k0k=9m<%27?Z(e!+#=&z>u6^~@{ZBr3
zW#_`)+RDb_;==sG++Z-6pI;og1^)c}++ZBd9tWi^7`2D}*7D*IucJY0WxhA+H-^2&
zpxc-mG=bGo&l>j4xq$_IF3j1Zz6q4}+RDmeOIK?{0JW#h4=o^e4%b`Ch%l*+`g*%5
z4Z7O=z?|=?!;Us0h~m1@?<#X$WxlJ<_i#~l!{aO6mH?o3n^Ltv!Q7U$MJKcA-w;E
zVGkI#Y}zzTvl(u@b`;yT@wd2%Ns$UQ+(e}~-91&sH@gDI5Bmd=7gkr6EK|kN@3k7X
zHa}Vb9@m$bHddCG7nkThrqykCdM!7ayJbSTXc`oaV;Lr#_`QoenxX;_edvrP1)W9(
zfLv&YhC@G%a_1Sj1sJ9z9ESklLlgJkf9QVt|JeP1FoEOHp(Ee=*0&}n09wk!a`@1R
zi3xo9$OM&RN5>ZU$b=+_#Uiu3zTchST-ZEV*}1lI;b3R?(&Ead-kg^k15s~EiU}Pl
z$qMi)NiyvlpiGFcx;!+W%-7ru5CSjM;n)*y#i}ONG`S{=Ri>PkX&?o*y26wbx?EPp
zVyzUb7GpABFqM+b=U{$I`FJwwt(W5xla+C>X@$p0TC632UcM5qm!fPr&XrI|+t_Q;1m
z^ynYzZ0aXJ{^1K3d(Z8yUfqWw*}HUQ@AkFJAA9QZ55N7=7e96J#{S0E=GMmg=IZMD
z;^Hz{-_iU6#M4?
zh+4;OU7@?)Q2;$2OgYV_UK$LQ8botqT`cQ3Ys(jg3`c7++xSaMD)3cS#J;M%sKzZ!cqmMoE=%Z&o^vLNC0m*dbkw?G(oo}u6?UyetzVVaS
z_O`dScMmRIzV!6<%P&2B^^G5X@{6CicH>}ceTAs?%F4>p67gp+=ehaC!C*8Gn@b5~
zn#=Q}#f1T&+wV7Vf{TNGi$3f$27RXo!VEkQ>{dgZA2wiehkbp}1}4p3N9%XTc?s0H
zz6l~d*SBCH>AVZ(Y*Owh;F+>XnZu4w!0u|m?LwEh^c=2t)J~J{cN7<>>U`H|H3Zye
z*e2TSnpuK9{=DDR+BV;70lIVm%wrP`NROY-KdN+w3#@FbjUg{Lo83j2C5xx(@tLr*|XBaS^K(&dt
zu4M*c)}caBC14nAc{u3dR+^&0KAXA$?9oyV4QMn(PQ0+X0qleMixk8K6@zf$H;sVg
zF+auKfN=OwON(FfA(JGeSM#uKbI0WxyNe
zHzL;Jd^IlB(|jq);cYd6i-K#G*;1rl46vn8Ee|_<&&U!VP(Y-~0-yfSV`u*8j~;vU
zt+(FFMtvJ|tv7%2+KsK@*T44F=bro6rAybIxq1DCr>?#J!x#Scvrq2r9IPy_!2&NW
ztot^~BlnySib8d-!l}*v
z+&U*(!{IWx$lGtf)poiPShQ-u4PIK_{M_gM(z3=2vM98XW4B=oZE`Z3f+zuET}r@V
z;zv-&yOfiPm4nCC`yB}N}JG$qt
z*>I>ON$L*=b+!(Z%!^XP>7bL-nr(`}uguMZ1;hQOt>u6*?uSDH7qv`Y;6UBorDP7O
z4OWV};R<|XS)^E(AWJ
z0ef*-o^2+@D@^G*)8qN=gkMT#&w`{
z&{PL)rHd0v=|~=|o0Zd;>*%(^0I_4gx8uMvo0i55JCxGVrOGbI-Hb#y@P|M(UU6mE
zvO2bcUne5a`JnmMdlkDis&Q7kyEGimZ?0~%+dZIwmo3Zb3nGzo)odt+yCTYj_3XlK
z!TbWHKs87-9u{ESbPJ3JpaOdAqK3Ax0E!gPP*(Am=$XJX>@OhK2J3CmngGBWUjv9-
zdkcS6!A1NF(+HH}3P32)W@D8$AyLF=GEeC0aAC(Q8DUgy8$i`u`=#={fIor3c9;BG
z_#50A6=3STX*ghEu)~IH-eHP6Z6K9ajq*GTr`-)qpuoNpaWK^1a&#PZpgEY^7@mruoNrK~KLbg8IvMXsDO#WKt<{-~S@YXCE)jL*pRj44&+I;B?w
zo#x>KGbzPQs>i_IR-!Px5|a|D>3Tj`&G{&hxoeKKj4^;lJ2fom+6USFdmGU)EWofph
z0-{aYAZN9jkgnNksGXL9>*S$O2zddRZ#Hz>qVzzmh7N2SDg)dC!;})v6dj8PziXJ3
zg0tCx8^)O$L+0Ax3Gj}FFT;z5p>A1f*C8_tYm6`BQ
z{X0!#oJSBGwqblwO!a#ePHm~iU}^Ef>gxK+5(VLrR8!U(cvS#jrz7i@=teyRfI(wn
zGh3|=Fard4y6~j|Lt2;vI03EzFpMqHW<%@s+N!1rA}w8npGq73!Nn<*F=dJcTLx?a
zR6!72Boj#nq;Li16u&}4u)5ALwA_ZLox-X^)Lp`tJLC^jKzPz4rmbr>yj_5HOtCc;
z?3~_$vqL*D4C6Q*;F;ru@oE)AGjUE$&`pt-fa-Cz!Sm4&{Ad#=EikXU{b4{93>n7u
z@S&q%%M(W)fE#@HFeQwpCDccc!uzE>542nDfe$_Up(oCH<`y>>H!p2oy}fh&nS&e8
zT)BRGu()aW=Cx*5HXW5x9)fJ>s%ApX7`g$~M+-nD4*IEHuWPDYC}vo;21sW!$x<;}
ztrSv;2vaX-)6r}u&eV&QVkQ>$S4vr~o@FYjVj;ydWwx4TtC?)tFY~2(Imy*hpJBCvrT+K
z)F??9%!|~t6-xeQNVXwbx~R)cw`mAWzTK2;lWmw>x21y+0me9JwAlf{CXx*Bk9tiIOeC6uEgx
z9H%MLUQMuSnl?h0#|KW6;sVe}wPC@pg*pK&#+x|_pLh!HjxftI;U?3b0|nRH`1>~8
z5+KO}p7AXjG}aVdq`RTnI&uv}2*`2#!b(Yiy9N-4!3Xy2NAkaIWG*VTKfwOVv{
zEEa0@TB%sdq>`C*s#MG*Q_)g6mrh0!@ldgp1%{)MKqeC_=2H1gG?NO|O1V-#nv8jC
z#Y8b5E@UE1C0)vev&lfE5UJ!Ng-obgOz_oQIUkeRv{a3WwJ6MNI_}9Q{MBqw09CFA
z#43;(<|;w1?B^>XrVwC?6ncOu25Wh*o0ttY*-ajj_p$kVrZ@h8LRrgCf9TOur{>{j
zn%bvs?Ch?stZ!`Y9$Y=xyL9{N)z7|s^`&bEFWk7eLVK*%mzP)P<`+hTxnKVBmy1hF
zu(@Li!JF!V1_P)tG2Jc<1-dP0o@E-cgpOr8?%rkF(%gAP+7YSKjzOMf>V_^`riw4(
z1iT9$;Y3vgU6a8T4NWjr!PG=sS8Nkz8R&(@VZps6zT(($E-7oP0l*uwsmZXVw#IdA
zux{ScVWNRy88EgD0al%8xy6AzH!Ye628=1W7|kcabW6Z+i_%YtE$f3KLf)$=MsIFm
zeP?^G*PjEqHd~#s5k@bEF*E?YUXL7OFm0n&0^0NOr>3bbH~
zp-{*hC;9;A6C4U3QDk}BYNA~r4tW2543q6WeB50nP0Qeq(ts8v7pDAZ?ru{U;SQgUVxOk;Kw`Q~#WV<66wy0Vno|H-ti1t%aNLX|#
zmgD(+zQ8bSI-SlH3fX)vo{Z)4=~OD2PA9XOR3zj}XXA-vED{QXR|Cc=f^;~Oj;B+x
zXvCk(MAGrubixa=4f~u-gfq!NBI?Vg0?C*sn~W6F(MmRyjLycwGqqA2mRW!gTn)L&
z*CKowE^&}8NB9aHV_c8%B>+3Zl>7u;e5XJ;$?>*c^3{uhS^>xZ%>3|~)2BXs`a^&A
zpZ=dKBWG>cySBZwzrTBNe}DhtrOQ|MuV31J_37Q0Z{N7Ew!5*hxw5i0np*&R|MqYH
z7Q%y^27^8bGq4J2HPA6^6BN!cRd6wP0+aM2?63umtfPkkpYZ#1ywV`Q2(km;i3b&=
zY>l!20OPuD%FmOtz4Mt7b;u^p;ylh8ijZAP3vWJ^TGW>~@vq09_y!R2)p(HXFKT!gB`kZh&ZM
z7B147_c0sSX-6ff1J8-j2%UC+etsTqIrPq*XXF-&y#we@90iPNfcg(V{I6kn0bLq`
zo;dCT_~glBC!TnGy5C>9aBy?u`m+a5J$L)|3zx1x(;lu{?Iq0`Dmq*j+LnoC@FMM6
zuCZK^Qkzh=v2317CX-5~Gx20H8jU8?sZb=CN+kk;Kq3_dq=TUlK$}cNQpsp68URY;
zv0x8xKex^e!$Io8xm_U*I}H%6yv~mD7|7SR4aJhd8YrFF|9`*edP4X
zhcE9e7(D;UTl+h^8>{P^2bZoMfJpCO{K}_pJa=<{$!x}LKx^Yx0GkQpjK
zpuF2AylAOqfi25z8*tU&Ft;pP*8%kY#xeuX?kLy)j2)g^SlQXyZZ+GSsIf4=c9SI!
zmbU7`bcvD-GfVrgVf7j`n2bk28yOs$818i2&`)5n4Vwaq@d8h?N6iN4G;r8#0`RbA
zO@L}#V0B^Q@CvZuA~XQbL4KeD=q7FoJA4FdEWsC1Ohs{(f@RSbB9+p}(xzStj|GR(
zWGGh?#jPY%1H&rWc6h&#CXiXHLjO?eQT!s_g3ROQ_z93LO{eeM6djZAbbxua)q+dh
zSzcap91H3gPQ$pucb<`3?mIH!ZVbok;lsx%2G0a&vm0#*z@9vI{DGsB$3Obf^SofJ
z?Oa{EbZht8v(G&H(!sUct+{opzo1wh)oh9yDTa#|_b9B7VpeK=woopYE2Ux~lPx4t
zS-hq)lxjGhj3*LqKGR6pAMhlTIFAGaKxQNs2WUgFSPUNp{GM10SPjIYp$O%|^h84b
zaKIal`a^-)XviOr_=3Lkv9Oomo$$vZo><76h|I!U&Zc~ss5hSm!H!k)A(&s5QW^(A
zu=z@uk~o#{>K7^mT0T#4=$V3-r&!iLw&3MpgmXR|;|KJQDvzG|qf9K=)a9FdD?1ke
z)urv-{hj^2t5>gn<8#m7y1en^wf)f?F0Xv~D_{NkH@@kPWRQ?xMjQuRjz&aj#G}`38J5OKupj
z$&zErjtTw@+Y9JYa$dYP3B7U)U?z9^e+I*#mhaM+Ny3dl#RiXw#?$Pq+^wkB;EZKcVhWIM4!6RZTbc
zl2WQNcb<`3DB;d{$)p>@;~32E9V0wRy!zPD<10s_yto*LWZlqG(Ogu$#*^7!FZnrclru40-|J5T(`ggo3kf0*KjAU4$8BE85xn#JQ1}lb*4TCV(3pmIovtZYhw{yt#Gj
z#@_1c=IYAk>py+{6Q6v!(;c=uJ%|d>g~^4gh7ksO(HGG_U
zr66Sxfolfy3vUHv2P&Tj1O=X936|(gwVI1&upl>=ave?$$JSY#vz1B}|G*`4(>LN0
zq1v6mzy*o|0}~CHLstka3>XWAAWL+>P>TYCSI}=$gEfY&W*kdsm@Hmf4YgqsfI+ie
zrY-hbG|Sa&2%Z0_H69l>HoDz`qC2dpH=HgnYo^u2ftKR{65(ya#dW(lEUg5W7={ii
zkGei34s^q(%b-LwybSe+2ZxqITM{O8yaijeK$u~Mp&#L_vYg~bAEfaoQNi;BZe7bv
zTku`B-IbGp}f}6s}3XB^fZPN~2dKkv3!@kD|heX#g%rb>^-jGG2`GM7HOS+uY+8`MWL--T`Kuv@vhGC4k>^P6i4IVx%
z7(RJgnwSK)XHGnH`s9NT%LLP>&;IZK+y4s;9~|9Y-oJKmEgb7Ir_z%p#%0wehjYvclFj*R?bcDdWym3m6%W}*FWIc{u*Gh@0CeGJyM4rJ
z8Ft!7-S#2i?Q#uyont;XZW*g=nQ)DU#z&(;N5t<+gk6cCg9JqJ$r*qx8rz1zPKTVP
zCFWgQ+;53bT9Tpr;bEM8vsS#Zx3asw2H9@z9&B$PT)B4jTc5kUx3i81o|#_w$xnXz
z(o3)6f7UHVTMoGl=<_jQwN3`^tTtqMZ4<+QYG!7xBC}dbbu@^TX~$$n3t4%cAZV8Rg0$oU
zWB{MbL25`6=n+trid7JTH6Bc`1@VFqz7tV`Le{myfcn@=G=qq9GJlFperYag%$2zD
zjH<(~KvWdCxyA|(
znFk6RYxyESFkdL=b0wf&74t8%N0iJ3hLIkFs_#tp5Bkg;&x0p*SErEEr^OS?LWhr>
zId$U9sRy6`tLF%TOFNfWFW=eTzm5%F-ac$huQnm!hD>Lh%@-3HSt5fU=?};K;aD&f
z@%aOuiNIhzao_m3!-Y0)G>Q%z
zj6ADVWuP|)W*4`?vLRA{FtrpcPQtpN6lA6qs2IM?2pOA;+=EfDD)Z{f)Wzni$!P&C
zDH2VXFh(5%SHUwOfCQdliDW`m6j>o%7(*8O5fKjg@OObU-grandt_4
zE!TAEo+WLtWMH$&H8Lw~qtQl16X`e)NCt#PCIe6u4LBq<8hk%8TBf!%dsE6ad^sGO
z)1~DZtePudk>`S55z;xCm>#YLu~=RBGlhiC8j87!Eccd9$@BpDKnK4YidKlkm29pQ
zGjqNyYMC1@U^Ag#J%?5+@WH{HXvlSE
z0Z9F!mVQtMEtwV3r%s76HtV-epM2!(naBR!U;L%d8`!^kYjN-T*3pgEUw?gj|5|5e
zquN_2)LSrcrO`=c@^Q5gif8D)x^T2!r^|y@Mj4x{
zi#u#Ki(NLG)i!L>?-&ObnARbHv{{D*me%31(TldROBT!U$mj)7Z5=gND;DU=qSP|A
z@#rO4Tw?U1$UXpvv?>1K^AGgN+b|r$kwgKa0XiSYc
z(!7*9YVd5H503%q;~ct|ZF6O6b8-IW!S>?v`riK0_V(_Tqbq;=#?Afp#jVZ#{;Vvz
z-s?|SYt2@x*KYQabCjxztg0g*#l;opPX-t
zCytLPVX2hNQO+Nhzkb|dNNUBf;%X)ZCkvj7xnf=|87S&PwImhPi05Wq7#J`QI+lX%Xl&jEzyOuZ2hx0&
zp9%d6hV$HKH5wBQl{b5{aArW`$9ZIK51cu9=A`u1I(Zs1Oge4S@~JbAJp9Nf|KoF0
z)5}ZSS2wQQec|paFWi1q4<
zvJYdM$K4|VwoKSV^U2H69*wOx80gM58c?rTl>%-yE2~7P
z(k3L6;^ZM!H7hH76h-3*-gM*$znDLP00u>=jFwSyxRP{6)>{P07!!Dyi{bFJqHB5)
zfep4{eI6p<&#HM+B85HAgHQA}*N}K{O1hBE60cer&GcN%&~y?gn_{Py+L{Tp{)d~J36
zN^fDK(MLtg*pX0D4<)nVL?#eTO$1}!$*?yNws|M)mij_=4
z=t@l{!ce
zIu&NELzshLN6x^;AY7`p$`!H^2a6>Eil9y^0t+R0lTYQ%afuuh%%O&6uMakfwqbx2k;S1b2{u6Tdyks{HN^!
zvnQ5F=o1f}f`m_+6Q!Lw^YH)Y|NZZ(mHO(=)wRRhhu2@a{n8tA>-(MgjiR}9UOZ#O
zl^i4-NMt5L32!Ls@&{d$A)99s7~9vDWT!b>BdCY3D*v2fj
z5l|}2GL4M_OLOtOOT#08_7ZS4ms;b@MF2S}X9TYQxSZbkk&#QXFxNk>jLGrP5Foz@
zhDU~;6G)H9A|ia1ZR|OR<)TYW^+mV+V!$&T8Xt)Ttcf51wxOakQM)SW9aZCyuq_jo
zWmB_pJA^#QpnKX{wYi&Dj}}+9_pZFKyMOu03vayn%B{nL%PVW!ygM~L3wkj&4Qcf2
zLL@vA3ZgkwU8XgqxS+30_mxAKna@&IPd5E6oG5jkfYw~w4>PQwjpL~_LOPOE1eQX)
zg3rNXLl7^344H@xa}Z4hqj8QyvE=cZaS>Ue_jqNZIPV_A+x#q4EUWIJ8%@_u5RnCB
zD9hj&3y_tSFtEg^{ESes)N*MY7=>)9s8=gSrHrC50bI(Ljr-x@VxDQ6J=*jvqA{SK;AcLiNYe?#Y;QBI5B!?A}S|xPQ#<
zvIqmaM(xf~n`6}G9JV?zyQ3D%h%6)z1A|_mJ2YY)9+6e^h6Ix)VnON9upk+%!l>q2
ziRT5SBLY-VIyCegFNcOcIW+X?p-bn7ht3ay)AM8RR-
zaAA38@9GPiN4Kxse(Tj&U%GsFG{3mYyK}Qkt#;p>sbmB|r*m256GSmNF!;Us%m^9|G`!7bb?gbaU*?-dwBywMn3nv6sRz`SL`l9xiT
zp=dHF>)w+%0Lf`N19YQeg+k_eq3fuu>&j=L6iOa)J(*O}vOJ8em@EB6%<5S-RIBt1
zk$Q3+P9BgmX0u!ZZ9>S^N}*EDL(7Bwxu>mE?PRirVyOmA0aU|~L98N(t99}R7|4{N
zD$=@9Z#20RG_zS}uOn~FzAoTWX6pu`+%4!g>-MGjmjm`(z}HIm7&JE_Ghak6eD7Od
z|NXB&`rU7S``cgthV+|{e*N2D|N6JT`Sovp{o!wa`}^Pj=0Cl7_a%t1KfM6uCdd;J
z#$<_9ZmHQ~EG83wljrfYD)u;)A@-#*GA$*TL~H|i#6i{sCs8sj>RQ${<>w^ggqpmn
z7YP9{b|ypIsq&-v#XN{osn%+>XJ%&2@bm}u3+BYbl7xX}<^NL;pFVx+FaGUcx}4t4
z!xt8}ud%=N;_GYsH~LH4_4fSt|Ne*TJBR*wCZc2~W2uQyd^{Mldi-`@V9Yaa@r;kT
zePa&Kh!p_40Pu*_cAP{pTd=&NW5crkj2i=8Am(o$boa
z&+P0REpH#~T)ne>^_7F0uYBg^yZacDTX%o*(|4w47HbWeV!BpuQ4o=TJUkKy6iO+k
zMH!KUDH7eK>flz^na$+DGsQ(xO7t^uHOVt6`dRF&ykrmRA}Hx}`pq{#|Ir7({`H5y
z`S62}KK$S}AAb0szVvtBPHV+bEE5PTvX*BwF)0}SCop4}&E@c;;GB2O1p^5L{1vG!
z6J2d`vecrX4$>4*0Ig*T5Ha92NetG2l>v$LCj-Mp9rTi#jY`qDpYg-hMqkU7iE$_t
zqzdu{vI5eLhAh!Ruxq!wkS*G{!n-9|z8i~)xToj~;8pISW)x&`Ni#Sa+?y$(Wf>Y1
z%p#u2E>$Be_qAcOQND+mC+z>yJM8%?H2w=$G$(_{;ZxW3JQx!Tax%
zs~>&v+aLYtX9c4wwNS#hS~95e$E#i!X8p&|Xoq#2T%XXBT&+kZF*z=;!Q&zSu>(9b7N
zo-tPrKlva3{U^)C#>)PU-RrO3y!+~FpL=^@<8o(iU9GhEOianiT99ddGMe@UqTWE%
z;R!l@{xSFDh{I!bdB>cN5n0gGK4Ni=*&G&pugxjwm1M#Aj-a1GvMf6d@jefXheQ>B
z>c*ALpZwsP-~Z0nzW2?qedlXm{_Z!veC1&M;`9Ih!o^QN|NL{$pTBV7{HI9p?WK$7
zWyN{nUNc?z^zbE43e?fnvI_3V^On))?UqZZXqSD&W4Cx6VEB^HHR5($2v1sK0nD&D
z4$*ImPT0~xcPeDlV&huEmW{d9`>NBrdh3nNt^KXbFYI1@@#xlP_iw&-^ZL!3H*bC8
zo8Ni$_0M*Dv(<*I>1M97RWXXvWeB}Q83nrLF#yi}^LKyovv+^_^Pj!{?z`{(
z{Aa)V`OiQ4>Cb<&cja~D^=u#&HJS%O;a37C>gLT9uHeOXaOzl!Y^z
z8ChS-Xv#1kK`bR3Op1iTf##%k8iNbHLSu+$K85(F=$il#2Ig)FH6kO-W?nAPRPF7z
z-u%r6?~{Ro;a|P~+Yf#@VY9t)=k|L){QId|<@;a#%KJb4>8&eQfBimT@z=}CYkUx_
z@=$nKyc?r*>OcVGI(SHAMiuYC2jm+n6Q>A!sLxlcd$+;h)A|NMmu#|bvR
z0B$dx=is6oJb&o|kpA?Dxso+T+9oh2U2xmRT-Fh%^}>XAbi!-%I)+2Ov6x>vPQ$uN
z#HnJ8qb>l9A5Mfu!S*17?rD4T&9CkrTv^<`x_|xd*5Tb(KKI2Nw_bkn_N@;;{Ag?U
zu-TcZHrj3cOs%cwiZYhP6j5eXmdqPZ0>desr@1a8yoZoRmC3@JW)zPRIsuhggB6j*
zvJ+u3y`*HhRQdJ$zx?ITfByF8zqmBN^6hVa`^$g(wf()L?|t_l?%sa+CqMrAyYKw+
z-JgB*?k|4(w}1D2Unn&hhKdvZa6AwZPL?H?qY5byP52`TUIJ;@IFc}(b`&<2s&5m+
zvf{S%J(N}%k`D*Dj!aR%MX1`iuDRVAp!anw!fJDw{;
zDweUql^TB&41-J&GG$rr7iz`#a&IKqSOmYCuU4AyumKaBle$5?T(4$jSt~9`O9NW^
zM?d&B7zV)5@2`LL{;z)V^B;cW>%aJiAN>3ue(=-pfA=50`JMOPdFSuH{oN1V|L|Au
z|N86S{I1j&m}{c)T+-&knUF0}I2=>Z%-pJ(R~o7+mdr(B=odmqIhT`4EMnrI9|*Lp
z=_OevI#XoNck*tf*5Ic}lU_F8>GsWP^lZ=aIRA;nSx<@k27x-6@px
z*~g!G`p=$!Zs_pJUCi*#mAf}z`s~5Amu41sz;L!KJUmH+POHI0b|Ri~`J;AU$T<-h
zb@?nF|A@mk;`Cg?3|obYN9;C>-7#vhjgDDItd3DrQHz!yyErPXM?)sYFJ==H@BQq@
z@BHuwfB(&|-#XX|I4^zab8npgkN^5hpZjdHpnd&|pa0HRzm`s>OaOoCx#vH5{=z4p
zKmX~A7e0OA!Y4s22kb9g_^Y8y&q2;Zmo5z9ibp;@X4YL>Etj0OA*b!4!+ODGM_Qlv
z%OGJ(Y{EY2xtI()WEzm9GaI*))Pz;~PRDFo@_xoV{Oy;%x4nA=hIfu$xc#}W{q+~W
zapn4*gM*{r{qFbc8@tW!e5u-McBX2Gz+ACnuCxV)p<aP
zl~%rp^_A|2wYrQA1{kPHfi60^QrD%Im2}AfuC-c2+SSbg2B2DMs$`lQ8ON)nwHi!r
zHV%VfE|4HoC_tcTTs}UYP?X8MeCLG^-xuQnh6gZ~{QU8c>iOLJKmO5Nr**Kk{@%Oq
zzW>V)c)wC@136Qnh%5q-FmE~|0ZzJhXwsL1j7lrO8&@n;4BtY_Vv^0aec;WrPNj0u
zq>5+32}jJvLc#z#qAa~eoBTBFfYg1~1;F@%a=BJ6NvD_NJTkWj%)v=#Po0!rmeMSI
z`jP+jU;Q6L7e}vLd3kZ~>duurFMZ~%t)sisOFNDJVzwkgd@`zrQd%Ic;D_D8q}>;B
z`NCGGf6NmYlSRdaiihpaOAhCVSYq((92v6?Bc!bsS(X@MELB;<(y(NazFEAOGv`yYM(JLu;(?%pb-!)w!18}rj&fBUWPeB-O%{QB2Zi8KU!{=%o9zwpV67ys(w
zh37~YK=Q>47cXACbWyx97#=O3y}#6
z=uL)3)tDs{wJH&d8WCE~rJP!PEE~R`{?c#0_0^5tD~szp+c#d`zwzp;ufO@y%Wr<+
zb8q~^kA8CNg%{iXxq7qLXm+JSi=t+B-{$~bJ*dY*mEqJN6IBx-O(3V#BEzDo%%J~<
ztZ4uLuXav`g^E+c!|}Lb6hCYuf=*G2cH@^SfAFQu!eD^!w|LISD
zZi?#nfBN&^zWABH@q|*oP?F>az@fw>Y#fUFL-9ZuS1cx(uRWI2L<*_pB5-8nHpCC-
z(kZh>3jt~lpoM_w
z@4x@v2mkP+cgQHPNcG(X{Jn*IxGo1cD#Fe&_YS`O4RJuiou1?bN51vSq<=ATCR%7
zPD?r!`PI*V`pysk{)gZD*4N+u;uk*q(pTR4>u-MP?Qj0wSHJ!BZzto4v9Y1&&wmo-
zeEvML8PJ};a9*771-$W)9Kgmy7jebUVX(2;K-V&I!7_3Q9u_%0_Gy>>yxj_hk<-Hy
zp5b_4R61$JU24oNZA&q`mXJ{pTEdY}yS2#u^wawM7rwQ%du@JwXY=MuYgcZ+@XF_J
z+Nz1!WkHnfBZK(-cZd
zC+r0iN?oqWW;w*3*)KmQt0jszg^kg$VNxh{?Bpm_}!OYJAC2g
zFZ}iAzw_Pi-Foq}Gb=ld+2vea{4flhRCAc&iAZ`Pl(3Hn9Fqb3u+=?ob@@hJ-XXhd
z#O5AFMGrbs+8xr3Ln^dJ%rrV`0lh;U5B9tqvkZGY4qa8QUOxKfSHJbmuYddPFZ|8x
zuf8@rGlOZqc=7zDAq?>OK@FBvN?#P#9UeYEG;{$5MoSM3eR3G|k}iF6Y)l%W;9;Dw
z-EzrgAF_=-cRaSqc_}z)jZRo&lMt^`T}LCrj<@|+-K
z0L%dl%=2TtcAm_Ni
z7@n89ZmIX??GH(2gA+Yf*~XC
z3$<#uT$GUj{88c^o=_-X7H5)(an91iTWYGwz%(~Dz;F>=Dm}3Z
zm=_tQuSkuQG!ds2+WL5BN-;j^b7{kMPd
zA0|A$H$L;(%eP+q%G+P~!4JNF^Ui0w^PA1-)qJ)4)o*-jZTldc%0*J@WK3~~qV@^D
z%OA42C+yzIQMXU1*ygl2T&4kb4UO7ItkO6v)zN0><`Ii^M7n1U5075L9S=***2w7S
z=*aLzv;T&4#*$Xwq4PtR1`xf7%jG5M;w7;9+{n-+X-R^0hn^SK9R|#w9vc4C=*V-U
z!|?E@$41TrV3O5>AHHC>op;)wciBEY?gq~n$K6Bmz*syu8VOiA(Be)#?$+WCNSI`#
zy;>Y>-%mfS>BYA+AZgX(-i?6HZB5)m3tCA|m~J)YEfF+*{sYg#g-RJmO;({s8GmO%B7M~fPmrQTD7EW
z>L7paX{$Ep3MF&x=DbW?GvHygG{^+H=3eR%%2kx7v>x-<;8JJ{7?=uQ3ca3_Sv$BG
z4o2*NUamANw1lXWQk|siXscQWK7
z>jLpXWdTot=fWPRlUAg{BB5l-v1|d>)y+Oz(p)4>42tye(DXr7CB!Sr8RV0Vx=GiA
z(Gj6YlG|vRqsKW_ESC9sgHGKX^H#kf9mRySUSt*(lVyYFXygi=+#oOg@-YeW9ppGUyJ3
zoczd%kkvUp>hz8{Jwr}-*d@b=P|?y#jFz?xTWup2EU~#8Gb^P5)UUp?jE`kvwp`K!V)dkpJ@l)m+=HRTh5z;
z-d?$V`}O6mE8CZEukPL0f9Y@cj$XKY?bhP*#uxwg%U^u^%e8i2Gs>+_zuD>+j4J4*
zj3N|GdXXOO?6WvDh%T#3!;-2)EyQ^2Q#_?5Fjwg;$`)fR^;@EK!B_@nmSbt}O$5zW
zUvvC+bdV+jQA#0c+@F|;BqqX$=hQ?vIT1{e#=~h6NaoDADW?ZjTtQLMe65O|<4?yS
zle9`wGQz{C0}2+!%aqN7*~~@7%1l6o9MF~87}E*YYXq(Po11nnZ+eZYtXR|`x&b`U
zDD0{gI1g4qBUzW#@Zi#aLseD0W3f_}8ikz5<_xYqlZA)n)})suH#ukskovHc#3amc
z1|CimACoCmOeh?c2x!JW-*{krBIFN5#|6o8e+Zo-1|$N2WzdK;yn)GhOi>86AXqC9
z?^IQ~OrwzDY8)>+s0;zxTa^8!x`|?vH=X
z_M6`=ZyYvfR`S(;uG0Na|M&l0s5N4$9!h1Tr*t3+58KDhZXPbrnALk69dM
z2M>r>g!CAMY#kcI6^{-LvokI6uyoHF8XaSQQJ_0=en>zowbsJ`nQcg*D_ymq*%7I-
zl9$rI@;S4+<#VWL-WuTCI&2PskWN~kblQeo_6yQU%W=``0>eW-*QH7CsM~%%5gY}p
zdJ+$8$wsVZrL@@KeA
zYIcze>Yb@#rP*jt*Bf07aJ?aOwZXuYNFG(LP}YsIqUBRrLa&Sw=fSg=s%f4&7*6M+
zX|i1nQ+iT^b|zKSwb>V1c-XYZ5d^k08pZtK7^;{w83CM9cO}Q+*hCPf%>v-bP}(0>
z{Nc=aB;yN7?FKIcVQFN7@Db9KOOXKSY*K-&q(hR7ZqJ&%pu~Ji2M^>l#ZDAnRp!Gm
ztFmyhITO95TGgo4?x#+x)}Gdl8nVSOt9jrb!iV&=lsTnyP%+0Qs;gLX0!p>k;H7k*
zu2xZ=nY3OhH^^S-3!Fp0gE}y?@}GOp4K9X9B3q-WBVAxP<)!r%fA7Is*@%I(_!^
z*|Vq43|+Fl`Q}?!ZoT}@yFdBe?|=87|MP#|+P~K9uNIrLdbOh##8R70)fq|#<;Fc8
z@cP3J?}WqacX%gl&WSOba|}6cv5nbn!_cnHJ}iyIwoxl!7HK^Sl+8M7{v8oWUo@+@
zNPt_qUJgqS>I-AisS7?H5>6fl=K%HM@ThddLVII+2lUIaS&1d|Yt~3hU9{6a>~s!$
zoFfzNOOx(PL9a|79htBsWg39dOw^MKT0*`Hk%`f`U+i%%?k%a4Mb#&GPTtS_((4<$
zvkQldt6MW`yW3Y@SUO{^
z!fpWCTD=MIOmz*6<)ukV6<0AomBzT5
zs+bgsB|?!{EJc1MLZJjaY4%jbU!(vt8A~!}R#4;SAWc(C!^7~op5Xz-Wu#JC0k^uM
z6cF`fCe{})bAeE?n&%<%GM+%w1Aaj}A4y~gA5sm$Q|41LOGL9%$f0zAuS~O6E}L!R
z`9IJ#@bGDK{+&lopB6cN`pnrg51;mVCtB6!3wK`ro3DT6Ti^WJd+)t>aP&fFe!bM5
z&sExbxpDLM-EVyB+X)#woSy{4fv_(SarpwC$)L?MZu5A@>@KU*BPv>YdWf7hhdPX!
zqaADjb!;G~O+Re57-Nrt>(KDng)!4L3vOk=15^y8%}&&^2fBm7Nzad=nFoWJ%o;2i
zlE*phw4a}lxi81Uep@VHONL|yJU#9xpr6fV;e6bUmd>S6
z)J~|lnD*&Wdp>nP{iSc-yqPoFJNq|RHuu-}uC44`y?Xn#t^Hg3mv63a?9D7lujxi-
zHeYPW8uE>IU~h-gAW24#-2
z$j!i1C}%K}!-dLd9vSukDWFabvo%;IM=lSh%M}2_#^(I>5DJjKuePQ36yyeatCd=_
zTIGAln^LvekqMd0P;04NCd80eh~%uAM{nzz!2tvfq`7CL4O$dD6LbbcI|mY47nv$i
z0DH`@Gx3%YPF8XmY-%bMk0(<}f>#FUk`id$gmgX!Y~U6j8%xM&5b4+|4ZjlU05DGq
zrX@yTeR-*>#bgqpPNvD69%eIA0n95rQ_XC4O6R3g8r5x%Rg|n&rIk1c&xcb=TISy)
zFv%31GPkY)AsYn=Mo{!|9+}$%CuI(;hfke6d-}vFjPdDHk3z-&=KuP??4$P2zxnz7
zTd#fN8*l&g$KQMXjlZ5=*r-h{6zbEs;%uSv&2N9_)mLAqR0YJ0rEv=rp}5l*f{k6{
zlXj11#O4}vd&Zn@I2qQpIRwT+zZNUxE1YarM~_Ov#6rnd>GdIl4Poa?sB2yV@PSnx
z9lc<;isT-Vk;9iPBQisP#UewRK(Eb$g#NT`?1Ixa;t&QNb=gOxgESJ_H5Tw%f|FLS
z`?*BOuEy6V_9Xe9BcwdW;m%bsK3{DdWp0UB!&2pm>jS=w3ElS3XzW+P$)}
zzBjeJwRv>=;OgDA{cBgR-JP9Vo0?l+SeDAIYNKCkc4TgcavdH9y;8Gf5^}jJ)2~!(
zZIso3c@WZO_YcY$Tp<-CY1K$7`B++yp$ge*AEu(x|rjl|~QRY1bOF{eHXErL0$LEf5G)$`u4l
z382f^!hM6erQQ)
zb`ljpPypUsDSjA@BU8!ek@Cdr2v0B~A(b-_d#P9v9Ct`vY{h@ArO%vx?BogI;gcsH
z;rPs{M^2x>9G`sdlNYWW9$ZFFzw`Is{oc3Ud;b@!8%NFQ)lz##D>ZYax>hLt@P|Ko
z>6KU0{NZ$F9PBV)fG^*_eRNU(0g_^BC
za?$KjC@@9=n$1p9`wB%_dmuLFB>r0DsGg>xZskRFF
z3a|mm1I>alHrrj0^L5kNig*U1cwMtvTc(~w@4&+ZAj6OzH3KR}Q1F&aK9;iI7F;WE{j>c7@3ExlP
z;2WUgL_&+Alg(B`o-YqEo|Zm5#B1(3lg?wXiROF*7xURz6n!MkS4lin3cVoH6%<6g
z{UHwn+OuaK1;dgcDL>Co8kpB1H$slPw5cExqTOBT^cN`2m+%Bul>UO(rcKfK+
z0w>#KHV?;`6+-5<#bO=ij1aH|f*l?V{fA&-U?6H46Ee0+`xGxP*=*)$Bq*0;x47-2
zUh%ybJ+4b$mu1rJ^tpy7y(50#XeeL}2P`qaH6e?kIWjSa60;zo)u>(iawHtNxI;Hp
zv<`+-uDl{$KJqEAeqVn0$;Y2<){2EvsBHf9$$
z=U2Acv&&rE=+2gr)71ur65?gwXv)$gGSLi>u1W7gscr?#hSYTdY~uQ$D~Ke$lF8oV+-6hB7E0H2980y`T`%2OZIqfmenX48~l*leasq;s)U9$KL2#N#sZhHvJWvIrpn
zJ!u;yu%;Nkkz$?S?wH8Rom#d9VH$g5)Zy6aqQmePQc`^ho
z!%J=+md?x4N?3PtQ0BqYb!i-yN<@-5X$EF^fNC`(kQUs^)FnEomU+b>;S}JMmSjjZ
zE#vrgxHL&l#-$n=xRS}_KiLI!^MwP5a+3V#1|U`f4VQ6mJP3j&@ABaELTSL&5U=2w
z=c34%WWICoB?=llXCyNkL@nMsp@bs|{t7p6oJZ#Nz{wN%;fH}SuK47sQ@CR3uyyj`
z$Id>Sh$eS;4%c^H`0ls9@r5_vdgn*qTG%+M&ny|u8LigI7GT}9G%-2p4}{#~lODIn>zi-@W0!N(Hsd9
z)S7S%Z%A8|G(}3KD5U|@l|;E^@<~Pd25}9A5?Pl*pOeI`A&sk=%m|aiWmc*UuECN?
z4VGD#3;XddW!*3evc5#6P^-eUGAnzlQES(6trhkI;%(H0gqw|;iR$|qKfJuOUM@AW
zImo>uGiJ49&t0%DRwTNS$SZOHU0rK*GOAv!H3W*sJwRl(Du8arzI;ZN#ZwyfwxC-2
zct~?GJj@RqxM=h7b(stQyS6u4W%X!1~E$N`?3oRrA`2m#zV51k8m
zh!8Ny=RD6BNFV2sxjk^^44^$D415w27WAGr`)r*#bv93oiKcGd`OL=Q3s>*H{^lF6
z-MoFXH@{WwEf#A1d|4DVFy_INS)cvv=lD7a9vM9xjq>v*{b7F~;&OXE-bvs1gpe^T
zX|?+%Cb7c~mrMr_h#gLc+wHJfEpCs)ZnrvJP878R-E9M?V}e-w7*s59by{TRN?6xp
zcR4Ix*O<=@Vl953B{*T9@LIxtr{6ag3rO8nWWt`7wZg4gY47!9qRwm#-1qisFFZUTdsUUG;3#C$b3iM?o}9tsnS}tWX3~h+
zHEY#Y6G+Q3@NU#)u`k{_&Y*kQ78h1$W)`cBUb)uQWEL$M`9LPXU}b4)s`4vL>ru;^
zb5}}`kzVLhiA4g#!kp+-vvHVgDH_!Q6%&jw1%}K4Qa0h(3B(9u2~>!xhJwLRC;)l`{?Nq4xXR;9!}e!Ru2l^
zW%GFfveld;ehgyvdJx{D9v1+=y8KD*O7I^ngC`B6tq4e-4%vewm9y3SnRRN4S8ynUR
zZ_sKs_y_NsGpDVWX{$87iBPB^p#`P?$hw1LIcPPjgO`IP8jmyRUbgM6{ey$6O|is{
zTB|>hC)}#699U^$mDMaTtl~kq&w|-mmEQ=|agt^ZQ0}E`m;9VcldRA+S?Fv~K~1nD
zkq;z(I3SbQ2XtlTcLV)Q&Y0alqT|memf(AK&ssW)nYJV^jfC^H@vn1h58Tr7c
zxD0=b&L@CI;!35~;;y(u{t9n#lYA|~m!HE)zQ@El!Ph{>izU{AOOiQ5?dek|&pvYY(K9Dc{l#DW`wO2Qx^n&Y+{V%F%{RXM
zOtqfWPVGT;kE
z0uz%HlYYP5=>XeqkKN~U2K=62VBG8ROiX&l$6b>X9%z;{F#)_SUXN|u>+qqIy<=|I
z$fVEaagGEg9N~Zm%Jq+1lhKKI$Q}=krekg;B8)0ykJ7G!f=&jvvZ9ifaOM?fAv2Ln
z`QY2EjBVhIM^A`;&SgA&3NVYD#v3QxdK^W4Kl6Az@#v#y=_ejP_v90QHovf!)M~5i
zI}7Xk3!8^aTbFkaZ(hIl!r|p>JKKkIbE|U;Tb=2ZW^Zn3X?b&FZE<0Ker|DoexY8M
z=7dhW2Z|_sIAqFP6+zkQL)4T!k>BRTtJ1wt+6=3eO1)I90b`^WXq3t(^U9nEZ-RFL
zkW)q}&6FKzhc6U55*n8|6XA!VQG<~T>56DnDl$->4}#BDvo5`_O0`O<)NVEU-Cnt5
zG(c}%R!e9#TO~v0dTt7wkE^5Gxa3Nq*{X72BDq|@uRb0N3rq8}%gxqQq1vi9dfX&1
z2CEzpp`=;3T+f&TYq@1g|DfY4zum03mg!J1Bm6o6gA8(#`SjGBj9xQjrKa
zP~E1BMqQhYXArF51Q!iaa{xUGeo(ohadNOO5dmi_%>-(mBudzHzhD^pC0FC|Of;G)
z7_}JaE!BBg1Naex;>is6sbumv5*{%&hnti?fqqUX(sYD-%7LdQ>Rn08P;FlFe7Rx1
zS>j0g59TM6IpRsDq27~cPr$~f9yxX5w2(OB3UoOFieq%9b72LsMYpFQOF27}<-
z9u7KPu8WC?Hyw8>abF?=sUm>Kp(uE=p-8RsM_nh)j`NZ7-f;~ct|?TK?wJ@NR{=N^0V$#YNr#lQad&GuroIp3RJ
zo?qQvSl?UPJlH+B^1|(xcK5HoaP7wQ>_T^8wKKJ_va&KayD&Ao*y_)6ve%z)wfmiJ
zzust*kk-wn41cZH8{KYSIveG|Mi=`@2`g6{!kIPp^>SH8%$FeNVl{6r%r|g)u&clj
zNomMiIV`2j@M3mKtkhs(bQEroYh+0i8KGK*;(Oh`n#tDqaIMm5H@a=enB!WjR_iqC
z{a%OfuZwJ`$zv}RJMB)bhGEu;3YORh!=Z5)m5gL3y(!h|lY51|`Pm{j%
zd;>R-NXqRT=aIRY7)DD!gcFu&@njZ&(~rrlTEfg{Pn~$=p^u$v)u+=beSPoR_Vt(c
zuDlda>J-L3>k<+5x};Y^&dq;&t)qW1bw_%B6=ld^^a6E
z77wf0L?|?=q~icGo(d|N2o^Y#iexxWg_F@qB{80k`(hzaD(Q=bU24joj(e5lL@Mq>
zGpAx6B{mrkI`xb%;2l;Ipw3rN5Wp@y<<`?~_?81L2^)KIiccDWGxkD878B2)wMw87r`C1GG`WP*VQ&_#7~0CEU2IXq`JFH_l;MXGSp{6+j=Zd!V(^YhI?#aIlf
zAgojxrah4Xl}KywSps8Hp#?d~5{D@5daZ3j9lAzT6SxfQF#wYqDbQ=qf0j;x^Kv>Z
z{WtiAL?T0&D3=>1&eeLe1No;?Dp`wZ=kFpbxB!yps|X()6LVEHmrN=|LZeVbpb=pu
zI#*=O!ar>f$nt2X9zJ>U^eGhe38+}AwWMZC(%F*_!NsQ^KJ#d;(yf(SD?3-WZ@j#7
z<@Wc!{`Q@_cc&J%8&gY_7UgfYOZn;&BMTK|8Wb!;Gz(c-O_Tde5%N;0crKsK<<)R_
z(#WeYb5=!O#K*@SMSgxd7!LY!*-0%6fW7%_D3=K+3Q+fFGhQ|6&FjHj#;0Lr5yL5$
z8gm(%M@zt>UQHPfOpN8z0RUObfirWWe0et&wd)t#xxvf+YWpvx(s3t*K=(7F#V@
za#6UoS`r2=*KoXWX{TQ8HtTHw-GIjPomL&7_Pfnqx7Kafn|0CK5>epWW~0@v33OY7
z+G+j-Ub@<>-w%eTX4d9rmlx-kH`jMM{RL@AZ%@I!lzy}!Wgf(Kds9eIpk=ly83+@z
z1EyB3HjBlYm{`34OQ+4nkOmD-rZ5&aF+c(ljr76`x9{9!omEgI_M{ebi5n_lN37Afy2aLabg3n12re$B)>+A%ON?|5;%E8JQJLCj3hgBmF
zokz{)o~)c^^9sonV`y5e!i_bVuW+Sur&8!=?QI@6$?$hl2mkU8VgNuFx%!YS}dtNE=t13wOhpXeH}Vo6`t`($oTw~94V
zKYVRaa7^UlM85;(;0~O!K)3$h?}B4hMJj`$i^CgD-4iHxZd8-%Z&Y{5iZb>gs2uFr
zbfi66;tDb5y7b8vT)1jLlPD_-)D)g451y}lj1BCXJ@)-3expx(javz6F^{4ssiAlu
zk|TZBkVfUDQWbPmwc^DWH?;dAjS8i#s?BV
zDBJlCZ!N0KlrhxD`=*c8}VkU+%s5#kqTNY82d%q(XY7WEM~E
zb)joj_)8%^7(d<&${252{tM#@h%(G!!%RRR=fdtti~-A^R3*8Il_9%1;zV4&29WxW
z|M|XzlNig0*%%o34xX{6;syMbM1Z1&9?Z7=1p^9185Pby-6>J@0i9;cZn#GhYaouBU{NQ_+UB;;fREtINmlxxT}s6A@tv&{01m(5LAL|Z+*
zteyUW$=xQQTz;B!PkVr%(xq%y@6s$YG%KvPKO*091)W
za+c^@h-cmAwGYxO$IT|Ds4mUfiRG4H_G4DEG$-Wp`uBI4YBTBc^!Uzc4GC$^f-SVa
zWNO#+Ys~g-)G$SgcBxE_6vX0qqyQ=*df*l5J-=dNYa8R1AtunS3zVZ
zrQJ9GvNgZ-a7b_CHHb=OeTMI+uLmB*8G%s(lR8bUc>!c$aqxYRm4_a1i-?N(g6trE
zQ2UJ+^(WvbvD{fLDNd*xf1WlUFVzoGX3Gm^?TW@FZVZnv5p~vHJPLMojz;M)Xu-}&
z{&G4)LHXNVzOsp2k^4UtIvP2_iVs0z-rLX-9Z&b$IqQ6Xcz$kJXya0z`BLkuNk_Zy
z&1rl#_eM*owXb8%l0`MRjD0+G`i+Bjs-jU6a&e=tdbgjN$iSPkiULC*e~iQvn4_+%
zR8X$M7-=I`#~2sDNOYcd8S5!gT8x%O^}%yGnU>=qDUyuSQJUTurNok#JUV@PQjXJR
zH@vE@98+aUQJpdobl~zH&s&z>R3!jRf}I~80g+NsW1GIPLHa!?eySR$W^y0Zr0kEh_ZT7a
zth28?qMgGFl*2S&=hM;Q@qDQZwv?lvdmV-TbH!(vg7?!myyBzyicpI~an^rGq&P3W
zL5&anN?;AF@*Pn0n>~N9>@Pz7`;Xm%0w8{-3q89P?tNiawH_2|F(GOmKKlK-_hm=C
zi8%XaTrzwAI}6lw7`i||i|eP)3mPm0J|XO?HXLs0ZE!`F&@RxdNBzn~qeU2d1~-c>
zQ!C-dfGL5qXB`l*a&Ok?OErgSWtQx}g!m7(uww=BDOkG=_YUPn-^?x-ftFlRq@CcU
z!;Nob`LApxj>n
zHjz74QPp(<)*cx9)hukk29BkA?LusX({zho4Vygx-GlzC4O;%W2F@n(%-`YDQdEx?
zmhfCDA;JSN)dgQFnxdOYdYq2nO9xpjgM
zd&X5P)*d#$1yHlZm4@DvU&cUZBAq6~53AD!ahD2{M!pHDr>iWrr?VZz%5ardeC8x(
zqgIklkdHhK=F*=~_~HC9pCIEhDOk{O9-UDx|K->gv$0`PUbgu_%~ttYmf+1k@|D^0E(w%O
z8@4+=L>Kz$HbLC;bQQu(7qVTike`)h6cL%`Jg}2+2iF(DJIal&0m9af7HUt==(y^f
zIXRqf;ey7qPB-f^kPmuplTCr35&$08p|3sW_tw5nA&kV5tSWZ;J)f5s_;Kfl>%}RmgSsq%yFX|&1l?_cF{nie`_1TK^f+9t|k
zMt>)BEFA||4@=3Qo!6uu@x0BDp4-Gy1Yz;`pGER_?X&dJ69w)Y&R#0IW~NUvzGj`m
zzOYk+UJ=;cIp$`Lj5*7zFxmoK8DvEWyg|P_rVRDi=547^jD)8T8cQ|D4(1H`&8n2K
zBAB`q*+9>eunG^t(IrrZ?yjfzqc9Jq-Mu($tIJsHbkR^ia_w)PKyu~zhR~lKgVd2G?k78I
zm{RwfXfr(H>cn^wu%bC0iC0hL_GG{Ko@sTlLY(o(e4L}vPpnv#ee%A%`AisI6-r#}
z=+hkLR8{zwQSz9)Lt;?@;hc*xP?aTjqn9-Q-C@Wr^+oH1Z;7G1TS%bv-*f8(u|UEo
z{7kj{A5gB0qgjyC-XZ_nkA?G8UPm1zHx+5Q18Lx>sIfSe;lYmQUU?@w@HDUvY)7@W
zl!YIkSrOTPihr8vi65S=hVnx;Pp;lqx&UXY0+H9q)V%x==9ubZ@*A7|lFWS@#a$4P
z>RR7}cHA^PkaQUQ(gOSVzjRiR-^|{(1D}-pgacYfd-}%N&2@63#_kF%??>g2wxbNn<+J&0
z9@_s4kfl8o@WTW0j)oKj2dqWa6HUDrT&%83pO{=UI7jChrgzPL^P;2N$WYw@_?iuN
zgQ5|&^=bz4rm*2h)&M!vYe)W9p3M%5vf|g+c_p^PiSnp4U*PdQirkTk$|5=BODViF
zCazNzvLcqKKCamZDVjF7+S07jm9Q}t*$h{~_m1@C+5_a*-=tvx&`K^G@qcGZk7xN!
zk}hG(&qJ%vU$*}5)%yQ`g|+_tV)K9B{=ZkWfAS@Kw+oOA=0EjcX#)?SvUH;3^$^LB
z$c&eH0q52X!V*ZQ0M@^s#Ux93K0
zq08p>p)Q{Tkeu|cmHe@cWk5mNNSZBnm23IoMOMarPP!gngL6$5KkiJKNQMg8wfBcQ
zcmtw6od@@O79r{N$Nd}U)!~vfe-=vM986I-18Vy|>-BIybLyhM1oeo0krCrB24?HG
z8vF;bFIExd8fy2RGaug|DJO{7U_0#?{t~9fVhfF*M>t5D
zDzOh~x4Z;;X-GaFSZjz)NKT6RoC3@89{=cQi2c3RnH0Oa2GNCGBKly@#?7}SCRGOW
zt)kh~E22ReFMTbLN(eA{ZRp;3RDSTz{Pe_s(l(?EaJ%;y3N>w817>F*-IXDaQd#2<
zQ0Uy_>YQ$uxX=o-ng%kldnn9t99M1LFE!Cw8-#k7!MG-`sqsKH5TJ3LSx#;xH&meX
z?;fz?@X_14)!@|cJD-lg`}`b)URm4TQbkt#3U~9-gL4-z?8C!JuXppJ3%s=TzQWhF
z$>abGc6~qVc%aI~RLQ>{vOfjwJ(
zTcv}HL%D2kWWX>3FTIXMZLi1gkej`ddtgbRHJkmM3M^f#BE=?4#cTV+ZG5TleUa-N
zAl?pS#EVp#VcQ!RH;dM!b4V6AA-xA1N2z1H^Bu5SpP+F7ICacPUfLw{MBr%84rDB}
zGExkzd2eP9fbkB=z0aQo14=$3%e806KKG(G+FI~gSAnC{ePyEuMnUQutAZ(%*I)ow
znGhAMqT&>OxP7hL%)GJ4v3r%P9unGVQA4q&4q`JiX6IdQ%iPIUqCuq3ZvL$^U)oqU
zH8L?fZnSyVzJrh45Jf4L$`Idtk@7Mx`1~L0N7NHm;;P8Sue2f~&()dy7w{76rwZ*~#=57O;-S|$znT7{;UvYbU#-$;NZeoRXo#Z+<_8=inCXHZ5zP6a
zw+Icfr`@6a(8Cc8v76Yf{pYolC~#59Oom(asWVqyb?ph=8`G`^zrPQsHEZK{Vg6U6
zx68MKmq;t-%nVX^G_$(edwtC@m7AA`+KLij*D53q0|HOctO-k7Zy-R|t_8G_+1c^X
zx{(ombSc68Qfj^q&pKH_QGJGP`Dkk#?$r^nQgZjL+{$gF*kGt
zhP^05xH*qj=AHe%R5Gk&91&a8YqdRO^qn
zT9{J_vTg3755eLZK9Xt_5#qDGWzJZyZY@Q!vy13cqTtuZGuyp2*$N=O+$>c^eWug7
zqnU~cmelY6^oFXj=)^8Q7?P*r#w1keg^PT=+C=D-{Y2c&;UL->*EluuLNtE`UGB14
z1|MFJC^P_N#7e8HkG<^{{*JX>Ieq0DTS3;Uv$KP0)~mJ7DAQ`QsvM1tW^GF;Ko(!C
zui3`N5meGunPXB-7~)9_5#BOU{$9Z9*PNs%Anh+cDJj#xsVOop!-Wfr-z|OVsvg1x
z{>~zlM_d0yf=Ng@)5V*prgo@IPwSfy6eD(f6`C(V=2`yXvzZyrsO8`nlUPVz$r=ho^N&J})8JTHy+Yu@Fp&uGOH>PPOrv<>yCR
zvU~BtT-$gg3F6C9S{AsV*Kv`Hv>5D?v+OubEB6)V6-EpGIQq!*NJW#SA<-fy)Ef_!
z`{*nxxkBoEN54YGkEeM>#4)nFF17*9ch&Q{@oX|e9qATba9W%E6{f~Vb;8PE0v66t
z&4Ak(P{9rd59Q4ss0Dp!I$dn$Os8{D6QZh_yfy@E#56l~Yi}QBA!3VB+i=^$Wn)tO
zu`Jj7;IV#huCj{CcTb;xO&do?8rJFtuHCBEt-18Arv(=Ei#}5R(qqf`Q~jCb?-MO!
zvnIA>t@W5`XH6OKBzI
zeh8*rRfN4Wq36V64nJ~~K9jZA$YZ!jhaP(zlAMQrnj}Me-aUMH-dv{
zA(AjjP-;Xx;vvZ}z%tPxW8F7rfB@uzdWy$amXWH8t<9R(H
zXuX#+vrn&A^iagsoF*puQM~F1j^;Pl?N>gwob?c(SPF+|u2dBkKG@AL-8BJGfqx3t)@ukJ_kH
zuRAp-ZSvyaEIRRrvs9;GRQ03%GO5zFyI>&QHY>78y-%-%R%=H@+>aI}$;!#9xcj^{
z$jr?%GBeLS1ji1FNjm_4b&K;;5%^PI6F&5ft4%6)ov>|8aZr{tT;tDbp>?=AeMWtP
zRxBMu8{7`13!J*{vzNS;jIf^>L57-AT?f0wFU8RuH1bk$P{SeK
zg-p33PBb*Rnb_C%`sqSHi6&J<7fREc76fmbeP4>sstgR8*3Jwh95gh3dRtYoE7Ped
z!%lwQWn8EWeV_LVie_mxvZsqqUj0QSfU!(I-jtUH?*JF8A}1YMjAr?oq6oP2)`0gA
zV^Cf&H6?WJRoCRJThX~W8*>~hzX(_Ji=&EI=iah1CX5n#!EJ482?4>MG86q59j;y@
zVHP5z^+KfeWxdvjZvvFwOnrClstCx?q&UWn#PgiaeqQKpg}r&e{hobZAm+8i)9#Xx
ztJ~9YndJR6IrkYSw{!K$n>QzB>rp{>ZWiWYcR_v@9gx=M4oKtg@BZe7hBCr;0p=jk
z`T4cCTl&6al%2ff9em%tOPq(}FITmRQO;3s_pl>LgJV>cLpM<3kP5|1Q%*3dHX0#6
zpb57-LJB)df7-3nglbJYv$C$u>|rwvIB8MA5miRO(3ihwSusTTjN9i
z^_FPM`L=km;WHuJS^mA-)%-)@2FSu*tUA3-ik!g(;$O*&;YE6$ei*{C#
z16EgSE-uT&Og4$mIO)a2Z5E8}$w(+j2~W^_5x>OWK>i!1@SI0&-t`bi34QrNCvyMH
zyeD-cK*W@U5xI=6MGGtktyIRxAT-1~Af83;|$Cv47v!*S)
zTk>W}$>E?>GQ(5oo3L3mke1XmSVtl6Kfz@k4T%Wz(1#I??zXU7D5$Re
zaTKH>`4>7%CzN{rEOYjC<9>84ci<^%d=2Rs>2q>x4?eju$p|}-KiasT!Q)(EO4T0byBR6a2k&HVl)%AY6@jYGYHuH<>2wd+z>Vg)e<-Ck+T`O^udnis*qr$8#lXb0pJV7DWl|@nO
z!kwQ0m5mkY>VSorUsPX;n%m;5mBxCZ-G-GdifUYf-7d)Uj6SHw*tNTFC;(YQ08i_A
z+SbgCkglk(o8;Pgd4<%hAME48!11}@o0H&z8E0?X-_o_;zGHHb@F6HUK_p-;2&{6>
zaqEkHVm0X}-U057lSbU=oXScw%5lcNUsv*kzhwt3gN!ldtUiv9d{upjrry#<(dQMy
z4z>g6x4U*_kC(RP`U)0#stIOCOnzpf#bGlmWtT2*_7L&vP|qOhCgw+%)_c&)&^ppP
zjbP3eq7j{;&2UoB*Ue_O)3{+Hy;$#mT^Mul4QWgm54CFz%aMi)QXC|xryHH2@Rg~H
z`NLDfZXR<*xg+=Y()PL@sx-!&(_e~XlfKW?$m_=Z541R)@-kO*#`t3?x0`96$-2d2
zYkNaTK)~OF!@WM(IC26vUw-Q~XvyXU^rC<1>cuM+dm!_3_Z26A?d2ZXFilCOfsX)A
zrU0jYGGMwepA%6F$nzzvW-T7J$9Ul97#fP|CK&fI`*0FEA(UNH5sFo6mLtdM
z*P1&xmpaFng6U%rPO12Qsq`TpVNR;I>VmpF>fOZ;g^6uKu0L#`8q)jB!1e_}{p+QeorY
zk)gGECh>t~mg?!<$kvcpFM7#a@&_D==#eq2Ef@AVn;M>^n
zPf+5V-{GHMPmQzg@SX~Ncw2;)mYA0}T=Ki~nSc0)$W5w&MznWg&ZQK@xHls{f&CT!
zZ}#|w_*T9T8X{~*pv>3HdAP!}AHI5?;XhtOn4gaw+s||+B`%;KjmIT+?yhV5$;W_U
z(c7)M^)ASggmH%BhETIFHyurf|IsLW^G}I~J@U?LU{n>>%9u)AmHXM{;PvXZZkLew
zT7G`Mn*epoX2cmrZIthO)6;EJy0@$i0hK*o(XvyMPoW`|8_uvF2v^D*Q5brOzgZEC
zEj{k=SQl(IyI%(QXlU5H!lH4_qFKsfK8(Dn-%~!J=+OSKS`9PdDZnpIU1n|YsQq%=Pnl5}
z;?afaj1w5~Jyz%ytlKwB(Wt8LM{pt^47ZUPq(~@FwSBi~1Lge2%bfDM_e&JMtUSF{
zXDm6`nC6WqP<4>8MnPsRS6{(SppQ0V)Q*&dV&dY)7M*EKh>B*4{e7nmk2{__dA}ri
z>{fPmb_j@v-$PQy(-GUv!{cYZz;J#~%onmFJe>ClN*n*4U#jPbRoQv^owfTP_8Wbo
zam)J{(JkS1xcj~Vx1J*eIr>9xMoWkty82|yH`PL`kKJgI4x7%Vko)=D+dY8&w8O;i
z7)!o2%GJ;-(thUKKb|cV*S#Ho)^lpzy_7{9;ctfBTNyq?O>wvg5v{GIaWcX4&OHwbJQDs*R+n8BZ32MOyuNZ{YBhQ#0F*|6JV
zoqYcjn1S@=8as8@!(Pxvu#20Y&OHC>ny83K`{PVJJ9o$LOW33Zq_Y{^+1b(B(A3f*
z*7bYN`OZ#L@rf&`WkEsFFK}(1BhMexv~LiZD26u2M^|ZRs8E-wf~PChe4N%?!Al&s
zqEpTul{$c^LAwGYh02N?=Y>s}XP3@F(`ZMj=7&XB-OJq4Y1iEqf(m!ENebhN09Pdy
zx2_5=j`CW#6v7#+FGnCdl^-?OWcllIH@H-z`NiZ~>71h1Yy9lhiL`t3zJs}IR|20W
ztXbv9r0mA0Lzr<*S4)c^pZL=j7M(784L@!3^0329>WsrJ%hP>u!L);#+W4+d(b{Qb
zAsRE@y({@Cr)-ylHTI_kuVmY_hU%D{g)!U5${)D;bNB|m{-0#OuoD4*E(35e8=pnq
zDnMFtuvWc;yBb&BrIFY6N^;)5EAE$sWJn%y!6y>m62qztfAfzvyCTj|wJfKe14>Tx
zKUZ#1sg=)Y(mtgCOyf|ifk;Q
zzj&fm3fvrL7Lx4`+gsB&6Hq_}ShL*6YamdUr^L&VaKNr0l)w^wkHC%7!}Mdj-}11GP{?l8j)g3f7f!
zc`-9C&{BdA_0yKNY}z5axBw8n198#bD@
zue+FqYqDKX@9&QsMlkf=;ct4)+{R(0Umx>Lc0P<&opoMKJm~I7K0W*SHD%oS3a$s8
zWn{dpTkZ6?0k0T@UR8C4JVmcn84!|_lk2B1?33#k4=gzUIT_)gR^vE_>e`nsBsmHN
zinW)1+cyuwy<2g!{PrMTUWgwP!FX^Ix$bLQs)N<%Vpz`w0t*4Ut3SeO3F((pjklFS
zwJ>($G9yD=
zvdUmqfbV&@;-2-KeYsi
zLr%&s>yaIc`gmp
zO`O8=`=8PRX<5_v1`AhXV=6@83SeBfpPgOlEFx_TTo~~q)sfr4PegLAOJnL42j9;{W%ZGW5J)b{K(F28ds5jZ9iHDWIq6hYtASJHN
zlA@x>kAiS^J}|~>CH_#gtAod_NnA05raO+O_F5F|D?6`>(%s>j%d+7hMX2dSS?*0W
zU^g!HKpH24;);{$b@P3_GNL&clwOtIs4u=zO%AZlZEghzmzCa71y*HYG-^7OX_cqV
zA$()!D)7*P)YK!P+UUFJZrjmDMgmgD^~SE>bZayCN`G)SSG9jx_gW(pa+f^m-g{8(
zoXfT_bP>#AS7EmVo1PqECRKE{H*|J_v$;oP2x|1}%$=xtCu>zZSIQTp*-Cm`7`=j5L4*aBosO-GdKWXD;buK-JH=*brwr!
z^5y2>Xv!L|PA83WQ7@cwjnmgCOL@F;7F=;|#>R3%OkH5HFVh!9>^ma#eYWR@kTb&`
z>HYW=dvyu_+g(=Skv4mqdw0iYjBeySc({eTn7Rg*>*RIxmD<33xiffwG~U3VxlUJ9
zWe@J$WH?3%b1q=G3W+c+d?WcSyr>GON`;~QC7AE{D%KyHRPDQ54**5eK4sd_hPQ4Y
z!PZNn)LvF%BlA0GJcd9#XH3;jCxwxdEk&y`C6?$}&~OyPd1=vC!@ptRUfNN=|X9g6yw)nc3BH2l`y&ZL%&JZ$6So*=Aq
zVhxEa5;iLQzHW_w`TvgoHMLD`IAnAqwoWI$(uI1v`|k}-r)AVyJa5`tJi<+yU-~wa
zk!Pf5%#*=09zq(gg1aQwj?{dNPk^ja?A3VRP5u=7c1R8sReggV!7x(PfbGhuAk|z{
zVG5UzL>vNRU}eGsfN`r4H`wMg$?q(7>Lt4x?2UPLVSi)+pHkN;-WUmn2AdWY3OX4b
zb6vI>!P;u9iqJOFMbs+fF-yk3ud}FR;Li$^ulQ`4@B}|DVfMD+QuiH(RJ^S^HyD*K
zb!K_voppz_JlHj2bYE4e;Eg>YiT~gVhXE^a(Vm=SMrC{s$B&q)@_8sMjSUu91e2eo
zDoIua8YRJvrW6tAIA)>RI1_1v8gJ13SacJO*nnR6FuZdB-XFZkfQ)7ohGN`j0`#?&
zZN`1pVIGj~(BZvuN#2NqRP!35uX$$4skJU!Z9KdQcC1YPxg&L?oR3fE#jEmEzF_7a
zs*&6g8zRCJ!GfZ%-SP&+gebqyL8VtuZ@eLm8+&;6aJyIJsV_#m|M&M-CVlp6AG7~2
zQ9rxyUH{NT9`D-_<+7T#+%quuba;JhyriZG{B%T}adu3*w!YY5epZvZ
z;x$m|tu26R${<38v7NI^_gG~+8!c8=yze!_!ua~t#h#Sl>u)hnZ=N^J{y$8)JBO8OW%e=;EHK%ZY$o1}&sNOOL0E&uEd&PxV5l&mSD?(al5
zTB!M_wkW71Z34PpUlgQh4Uhb0r+GDwKg;xZ>o2A2JuE~*U`X6k|7j}y`|6cvu|{4H
z8j1>Cby?m+|14b{JatL_=|r>*iyh>2v=a39s{tX`1|;x&IlczTwB5Wx+NtIR(|>J5
zr$HbC$`CG>uGv|!-}gY_H#}RkSOV@{^gv>V-aJ*CD9iLgY{&ZQ3?5@UKQROiYcj=#
z$*66rjgGO<)rlR%977TJJ5_&g2ih`#mJ(aV%e2bI()te>phj=bSOEPgaztAK=GeO{
z%+k8RrH{K5ipR}4O3CAedPqfKfG=11tBsNWYEyMY^M`42wscApHHMXR2Y&C_5PDg|
z)Rt_n)F
zye0^I+Hn;ioddUI;g=Mp#86H1&1?zNWV1Nppu~o9l_$wCrK+jhY%|T4mi+S)6#lsb
zOGya~6r=QDkg-N&u9@CJbCU)XLX@Eu%woWDGZ8a6njC|7zKj4JD?vtpnw$&HzmB_p
zUerhEtVY;2asHn_kfB=FiAnt{i-3y*OD8W|>%Zsc2M%HTX-5kZe-PvnUM_##{em1l
zT&9m9(?=twQ?s*t@b;9N&PEDwX$fYWfsZK{O0Cf7jmXbtTQY{ipprG#1pr11dB%{6
z4I2stck!^*^sbH}Ob^|Gj!So`f$FP}4m;WYH*atc%Ysk@kAZb%ZLSncG^3-xx
zMrJ%j+_?X?yd-*{l4EmGifSjc=f^O@m@jucV%Ika*BsM;hdEgwBSp!cy+JWrS0VOt
z)`v&4_#9Xx{Y8>RFoQip#nh!p|AQLWzo>UWo*+#%g6Jl
z?RXaSG_SQI#y*8)OhdJae^O_3Veo>TKL-Zt+f|KGnc}~*v$uyZwvbDz21}`Pb8{~o
zsd;~rp8uBat8YFre%_}w&EkkCi?1k6gpN;qm;Y18(5Nf16MFJVHnx|Y`K|WEG&fDt*7`b$t&6wWZ
zXC-n;$>^efoHv1h*zhKg6mQpSa!}>voFkcz&!n`2a1n)+Sa&vBT&zKKVpm4iC!y{7
z5r^S?rDy@hH#v>=v#5+)2CqhxK-ON+qQPM8gpwaos+l?}Z_7er!*$|+9*uYqH*+DD
zlg`<+6jt2`0u-L|l01e=rv8*KJm(DEt`>W-Y*N7=i-SJWx(}lLoa^u_35KugOez!1
z>-byd-}EYX`FgqBBAG~ogYdzL_37#96Ly8>TIb*sFN2NH`^)9Shj%FEUqbiCYj0c7nIb}iT}64MxG=E(7bOPRbTpZML|LmU-CM$ttGxSVX>^JcX^F8m
zeVO)K0(vJ~0vC?fR;}X;FzJU89kewxZAy+*+?m^z^2+ifbu%6g&hFB4%x(r(_{W4(
zTfR!2S&+)n5%tr$YR6K>;E*=Wm0>Nv<`_m%^0;!oePR`Ws@g;-Lo>3BZ5d?4nwBV&`2tI#6}u};{8>Dg#+1zDOcJ!{Cx!xJfQ+0p8}+ild&%QP>BA-
z!EauB$=Huwh-p&6pu)9VvSXMbsT?sRqjSl=XDpbaU^n*YA5Ohg4M6;m`JIm7)mcJJ
zkkGx@XY~rvx#so5KAL}Jkh$yIW}H63aDrKxCpom{i!C@riPRv{Cr6wrQ5t*Se&NVt
zh*v7p5c9n3`5JNI7|cU2aX-8?i_BwV|K024QyG~q0ZlecL|PzTPXlZ0%?o~9esH0x
zC&r@n@r>-~!fRxei?l(0((xNvdA@(jH~@f&1cZ9OqaujuO{q5=-uD@_?y+>RnmLR8
zgwE9*6~ZF+LE`i>A!ui7#0E-7=%2D>$u{vJv8m#_B$+28T3*g;MFsJTa8XLH5#^1B
z@?_aDRU4~3RjB>EUAzh&&m5JHTHw&2c;7{$caXd;x}(79@D~~$cQ)SAPn?Kvaf*`3wM4YG2oSm6S=Z9v*Vt&Qyst$zM{?qUC;ofI}6
zF5|e(mI9yPJ
z@aRD@Nm1e`?!>bu0*Wm5ZOva&KD
z?!C{Jxhdmp?&IgL{y?;Kr5)8(8r*anel2(p%ap|z^1@irH(f!7oYHXRW+TiMyD=Vs
z@QR%9LQl=Q>t;QOAb@=XQm4#OG~?z|DkRus*`f_j8QmQdFfuMNtjy9O&-hq7PlfTq
z0sPJ>3uX+r`AK9r%R=d*Gqr6JpjLntRJz3p4B_ctL=~g(>8>>mKe3hU-j_;LscHD^
zPWhJf{K`nLL`((5!)9QdX>;*HYxA2;?-$`eI3q^zOsC&+4VzKb`Q~Wd@pdLk_PpN*
ziNCIo<9cCtrKyiF%sdk1@Pug{whn}oJHZ(`#k`>;s}oA6tGYyCEzYlhiTfPlV;bJR
zB$VgK?4zI+3&9i&Jx5mfU*-#=@v;3
zysHxe>1<_LxkT0nJEnv8_6#H+&-=)>jk03s7nR$L5I%3WFi~7ba9J;RH)A{@G8C?Y
z02tdm`2m>{??0!S%t>25gg1o2Y2sC91Q(8F#&?J`xXb9Gko4*|d+8iX<6fb;pr<^c
zT)fSw)Bwt2zwd_(H9ZxKE9DNO8TVn^_l#hDZ49&S)l2bn06N%o{9W3S?Z6!LKH~eS
z;#C8efQ`WP)_5|9w|kvQk@&*N_{2Ep9QBiSO*SfZZ?{zA=i$Huj7_$2;lNH@Dw`!C
zM-MrGvfx|5E9RL#rSt?|{ECLx&_?4xLbizrrB5HkaKfdtab8LgYEG?Nc7Epa*55Td
zSN$Nr!UAYAOlBmUK9SNDNz4>e4Id`|t|>{Foh==a*
zgv9W(rOzsh0JR@<_~2HCzuD2G*%le9N!V&I3lsuvGoYl1Z``YFJQB!BZqVlLh>kWa
zc>5YL%S(v!kd`E`9d$E>gAj03rwn=c+_Lw0zZDJZ*gK)FGB98L7`$~3A7fup7+(S#
z`+cxDrP$Lq*VoG+odQ?SiM$u4U)NQ4FVAk-j*$QXpcf9*6za#DE-b+c)
zntJZfB$)TTg~>GI-HtvZe4L5-t-Sy|!VcEr-KuR9>z++@#pdy;LGApFoMX_;=e8w6
z=l8%6HqH1s5Ex4*~eKq9jc7hz)
zA82fEZEE_A=KtB=FJbcgUzZ+A5*{P#0*u^n4PZUQ=xb=DA~+ByJuP-jYr?_0kHtar
zgC~_Kc^vjYbzyOFvc)&@q@1swOW96-PL?0b&>acBC4bamD@@R3c-=jLpzQH_>$JPM
z9$7o6g2Ca@$+nSLCA$Xk##5cw8pgK6SXr&y&mv74LI>kFW$O{J!Ncd^W+3uL$0z}J
ziQ&SaWxL|%0NW6sqUo$rxRY@w$5>RBP9r)sV+yLvR8}cD8`DXoka9rT`zN4ka28Xo
zp&)zW#USQ4j6Sq%)uy$W{I}YxSSD%s{1(aasU|?CENpsy!y1yyhEy#a9Ft8n4~Vky
zJlVb|UO;C95>YJdit09Qp$m%k#(m#MuAk~H2%Hc!F)Pmwg4dPV(mJ|UC=qR0eWN-F
ze}&T6Q0PJ0Ux;0NQW;C?;G=m)f`gBms4#+N>3a7u3hJ^MF`3725BunI`MEoI`)%-9
z-^|H$+>%&{l884UQvGV$zJoR>5`d|g`p{0
z2gnQW>MAbS9XX;+{{-OngwKf=rrrCyAH^`{Tb8C^0lR0GHObFH
z7E{^P)IbiPmkb85K}1gw{RwT_n$|9VObRq0w!p$bIbC5ZmR%KyL?J-)d^w)H^84-)Fl~>#x(s79WQ*gb)
ztHNsg+u=)YIV!?DV66UYncv_PGlnF{h%Pf(pMP^Qz0z)r1?7jPAhlK;eShkl&p8U)
zuzWeSfGCPm2bbC>DYOGZiWXf#)gl!^GL}K!l$csF?4WM#eo%qkuToEW%JzOXPdv4A
z)m5Idw68z{77-+^1nqmI_Wb$oM<+EnsRLsgejy4tQLCXHtkP8$+if6T8>+|MZKB16hX<$1McYH;l*Xr
z<>@r9klxKZ7o-6MSY6(g6@=s3;#s`dmx(1cD#=iA8J5vyn5uG2CBeoq9}fS_S%qS6
z^oE^V;NLN52_Ne?fQyORzF6|jfT|ME%xOl^$MjM3~MJGnPZSBenSgV&teSm}R?e;?1>h1Q^)5*!C6+0I-
zOFAh_aKlYzgvr0NL`o!@&U;}l67i-f?^Nb+QTHSD9)iQNQ%=62>2m3w0q7!f)xC|H
zjle1%5dXb4fIW@(?2>hJ+(>6#5lbnPS}s>TB|=^#cYxWGAT&|3#7PX>$dSe_y|ujf
z`}1Di`2s5KB{fO$44VcSgN<%HdaV{;fP^;2ie(c%%m5d|XpfkJ*i`Wo7NRYa+e2lQ
zb3hibsA_v*!T0+&mz2Q%{6|}^d(Je&hP?Cl_BO2N3UtCDw-Al|yTC|MEFp5gTC)H|
zyl7p>Y1+bij>($SwZV@=@6I{WiyZDw_rG%V)!LB_4B{j|2Z$>yS>D9T4Gj(T)JhV0
zwyhB-o_(1-@&7L&0u2~bmSsV)fwPx)n
z!Xa@xq1Ei50BnO{w;zakYHC+XM2!)OP8Pb
z&B38XSKu{#E$S%aB{}&*MtZuP{eIZLzZ+rCS8l-7mCut=Ny>O2tG;7%3+ijx%~w`1
z|KDhqxaIiY3Q+cJf-6(oP4$N!OIg_O#X5PoK@8p0m>#-g+NZ?>T7oF!0!z+Ro-y&W
zh>ry*SayNd3_{oMo@S)oSnE(NSy~gvbie;GdDD=tG=z28rVX7};o;0ermZEIRk+IW
z`Ze^v3)NEqTuHoMYEqBkVZ?s}E&^?{%xq?Amc!QT6LxZzD^e7riAdujQz7zq{h`~0
z_l_i|>$+XKtTzud6<(8ZT!EeMeyr)0VB2zBG&aRG{U3t&gncxnl{opM$H)HBXrul+rX3x{9kfU04jsm
zgq}QtzXr;PbMK9>iq(mRD!1TE*~E^E;6!WylYC}8(yVN?7=CU
zlxcq{?tclTq;!5!jM2?ZC+zbdsX8GSIZxHeZ#S&DF}QQ9Htz(5?A@wxhxwje*32IR
zO2jkjZgJD(YYjuLuH29a&#w1_M4_)81*kNblO2h~D1WG8Mn?P}00BY%zCd6CTzba6
zUJuxHxSbv^=ymvf<8F`3YK41UfYar&kNeQlyffx;+ni2|%W3s`El%68$IZJIhuz|F
zJ6#UWk9j>d$Jh`OT2wUr?6G*=qm$mTh~F9uIb%UbWMV8CcADL-AX{fPiLQ2OVur05
zsdL5vJJg7@2B#xqX~c7IBo(wK1Ea~n2(UlSp+9iH)
z{i}OBmqGB~zkTbK8~fXvt8=sSi}R~*yzyB8+><5Cgm}@+SRI}y$1?d5{|Nm8X?R#v
zmf12Plz~qJs32DwCJRL^t3kfRcBlh22rVG02ZeEqha1r^|*4-xhTgpGFX2
z%w~Dr>2;ycUaw6s13w5+al&8%wOX&qT3rQ9Z^Nv$0=fcVP61awi)=C-Y#-Kmpj&YqQuEB-xm_L2YR|Mq_j583uE-(1)_x_bA`8#iBh;r6Qw>j#bL
zWuwtEsvYR}<_mW~FHc@o^++roPpi;xB9WM!^oJtx@rmI01e)37_IkYI9;eejF)`_M
z*%7`_uia+zxZDD2kIn6JyV#t_V;dL-y&kuf1Gm%aa@g$lQKx;>4SMZk9><7n^n%Z0
z;{u;&%mrOLEfYR`vMt~p^Lxf30aUar6>+LEjKPzRh@u9TDk?gHY_=*9Yc^ujBK8d8
z8CnioG7(EAY{^C)$)F7wALq~?y}`iGoO|}hp`FF*4~idkPSH-Xf)>H4kjdNuXcIOCwWG7fW2otGcPT
z5!gmvRCIwil_cj;-8^2yP)h}&4klo!myC)-E#U4l@$-%vWNIVit
zz`B7z$TuFC@CPP?euvB9_2E{>JwO-|b=cirw}T_63sQB1TD#5VbjX2i%wZ=%who(h
z*zFi`IYu4!Q2^|6j=1c@z}R6O_6Wi)?A?wbk8{}T9`m|}yv`v29GY}S1HMGa7Yj(0
zvLa)TL`x6Evl?@$aeFpyR|K@Sj0{Dxs6l~oDr8LsZHbUw3EgvF=qI0i>R}EDm*OML^cC#jv-pu)s$@+gtL-S(n?&z+-3x&0#Dv%kIhwh
zII`zVGMS{D#p7|F7Vl@X8W=S(Eba#+YkHc9Aw8FLJ()P4`cbfTj<9?>pSzp_d6|sv=C1X^o%|fYelwr}b
ztleF#qL;1Ibn7C}FN3HX1isMmtMQSV>Tf
zbR~l^oM>0B$rtjRM=NIqy7>&K&JZ7S85L74ot%ZbxeZ*Ro>x&PYF-{en)t{gP(eOt
zOs>w?>TN~U^MnbbVy;V=t5w^?5%W)1N=0$M5IceZ#x@ESc)nC3(4emCO=&}v<$^&n
zcSR^^w%P`6x%7vXSW@kL;?!yBYjwt4o?q&;WYp0a>G}M`R^@Ze)6}
zJ-Tt@#n+a$E;pywO0DU7dx~u3TVzz1R!A#aES3hqlc8uNmc;f3f)U@i--|3p7|Z5!
z*gbAH=(TwvUu3bv0pWTv!=M*!?6ldeBM`5{VR1UFb{m>`%w@l1w_Ft5I!2wg5uj_c
z4w+OuCVQKl2f$7nFdmt3TPM9Xzt`^fI>M8#cu-n~G7(ocF2jAzDX);w&TQPF37ApQ
zHmEoaEe8e6YSamUQ__-j&$ZCcKJ$s#xVviPZy&55ZmrMFFRyKEZfx%#9PNMW3pZ}x
z*xy>;n3-K%TUqDgdb8W@Ot;$|%2vl*v6e?Qa5yjtxMhO}IM2hD$Sj*wrQ&QQnH9|$
z=ro-Iy!=mr1E_3SSAHR+Np?1bF~#;taj9BVderBYdDUIUJ0E|v-^
za`adjOQoP#Nq86d!Ek5{GB%%+wjT(Sll=HHK0(?+Wo`}j>9oS7WG(s@Zs!J!LRHHW
z4T{igRxc6;A$%k>&w)&ZMP<-Jsh&z_lNptJ1{(211~6t-`9q)=iiVseTI9=#WJc!V
zlNxfKHlCmjmeCOSFKlkS6vsr@xLllWbQ~pqF
zA`~4DM*M+@$1^cL>Gw_e94@!d=M(0IVO<`)uFL7P+0n^1v^1jH4VIl27y+h&i;fqrgP?}vexmsSd;TB+XEj7q*(HOln?fB_N)
z*lZ0({T5rT1|f{%U2n7iDVYeyP=fVF9r+2c%F?Z}Nv;7f(-q@TYUL71#_N-}aI*B+
zH)&HCI4>EV&lkXC8n?|J+)C$X0V-G`)S}_dP8vGSJfq1{{e(d|qvil1FZrrML6+)=
z+hmpCqzYm)x&hycmnI_-&ob;mKrX*aTAmwR41lZ1jeJ?xyJg5ecF8t2B*3-}+by7a#Kr+=7nVk8kJ;^z
z@Q~MK@xjAB`?zZ?;2n+nts%c75%wm+j+oz`l-?S4CE`d&1*M=@iMY~XG`6$`CxiC*
z*jwfD-k%Zm$ZON(n<
z3HKtHAzsKp#8R_`>Z{kA)q1U1E=jliMuWmvs=_2$nUTrdkj;o*089zPaZ#!ODn(0*
zP9_UVf#=|)u&k0!q*A;^f{2r5f4x{d$wd?8>9Wbgq^cnkK{rj=EH=2LwW@lp47_vg+WjzauRC2R
z*7D_Mt|Y#Wz+QY^=EU2bpQM1D`ni@R>(s)X{@5upFSD&z^nw+~eoYKR>jx
zzPr40_2`Ayk8a#~@ukl!ZX7me*Q(tGqaw@xH@j15HJ4Ddl&WKW{o&YTDB|^peEyKz
z=l6{Vy*@we>vE5SV7tR*gKnKp2Vk|0+8tv+*GiB8#%3KA?pKg(AGKO9fm@WbSYPXi
z&3egZfr>$_yk#AI-Zu6;@V1PN2*UBkVvH}Dq&?(zS^%@xVVQJWgI-H`-0pFXO?pS7
zeoH#)N=1cumGCICnS)H!Ds|B@8C@s|8yvQf?xQExzxw!}U)$T8>NIceZ$rO(myfo#
z_pe;O`o`V;&)hxQ+t`|)TmHch{^1L6{S6vP`bf&GrS(RmjaV}4tz_nwl1$_vUG^z<
z9HZ3$5_`%YJ{WZ;ts@$-AE~A$04!1&IV|c9mkSz|L^1_T)AS}ykKVlHbAjZn>AS!&r(
zi}_5aNioa4Fqh^jkzOQ!RRBaROXbe
zpp|7ZSeY(^fLNoHgVJWRj&{(pIhfXLR)tjYuR^>a798?D5IDyin3V_uLJ&omfJNmG
zNvjg(mLN&cLP8VBr0W&OFjh)jvGmzUCCGd-jhA`$Qd6bqs$NW_i8QrXN{Pmjm|>8N
z-Y0MQIM4-$L`%+V0JKCrs^#+KLb=9`ptlhX#25Z97r@Wl6~TaC3X&n@;|wx4>4_yB
zIUYK7QaW;AhEJF+z-P{!KJg#^?O#|%99w(WW_B*`-+1wJpa1;9m0R6~jmFeUsoL8=
zy7s%@{T|%%OXBHFFqR5L6XTPCi9pcl86OXXJzl@ZJK^$poVZ@M$7Y9!opz_)<+h@d
z?c#DRCilv*1-RPHy~6?~t(GD1>9pd0FF7nDwy}#aF!tDDxi~iV9OwnZV`CR=$Z4Ap
zwNSKmNZ8xKe%R$0^*TnzokMQx`GCjb_c)@Hw%DXK5wt0BJK)3&Cu0IsC2TjFk-)9l
zk|aGkENQb^>o|x0=Yful?QY*ABMVSJyUX=a#sv
z+neE$n6=Jr{0#aT0E?(A!zG4MC{!y=R4N6INH3*IUMef%Bjh
zia*h8_0Z}#bE$GK*0g*nnb8tT<~W1Q?H~I>%cL9}us^|>)2E>2lNUa9DH@HeY+qYG
zys@=={qD;zuk2iD&a5@2mWwr^U%ADM9#^uFgyIjyCxcPnWY{|yLO;8_e(!j|>m5fk
zJKSFAmjwMf92{7zRw&mFVr}+ONdV7o6>}>%90riWuC_}MFGwC6gK~#pU=WLPwv9e-
z9lJO>a$#)rqGgQpqN{Bdsh0-i4(lbr>=p%n(PbaW701gS1c-8I(rC!NlIia9Rb_-%)rfZrkpoEfBWkG&gSgm%KpKX-JQd0hd17S
z?Z)MU&E=Ji+jn02#e45{y3^H~>3i$aEsi}3ihoHIM9L8StY!1kCT9kI(QE}uSPljd
zS(_CM$IYs#f%W2{#zhiiafNJ!e&b2Oq_o2);aot=K_r?0y1+OV2g9jI43o>ds_<|E
zsLM%+h@DB-X*Q%aC0or%XD&8Oxao)G)<{GZAYCkI(y&yKNdl@RX+vsOW!eClC*Zix
zmW)X{&ZB$Tnw_~~r3rBr@~B+tH7P38w7bn#$2_P&yyOy2q}A$xW@#cS6fgk=$fVz=L0
z-o3GP`)DGYQ1oCzjis`oaKbwo^i4+HzL0M`
zVs}s4J>#&g!|4IQHV546usIOX4x4RE7+6fO*j+0M**<2ok66XiiX@!gVG}J^uE^jx3LHfXJ^{=WOJM_K-k==ld8uKN
z=}S!gjPFwQgkV){Eh&NbHNhN9WuoY3MW9I0;bknTgyX`)V3m_-ITOR+SwuAlyv2Fm
zJ^rdBdJo8pEQi$xmUtkg2W`jzIEN}VtD^_B41iJ5MMH)qO3#gw(yVLMiUJ7(=~mr9
zLf6Xo(-W)NnWE^ID@`$+2AR{$m#V-9TL^FgLkTflDngRAnv4Me#-;%VhB>4(u2R+x
zkm=o}RmrTuk`{Hg9FUcnD+R_<_c=>WNnFW*iTsf)esSMc$@=*=qd&zwGpT7l?`A+^W
zXUxBjyVm&zAPtNW^T_gOEDb;NDIymq*&k<+xyi~5sOX1I$h38E?-{i7X_-UkU;WE}
zb>aNz*3PxXo$EW-UVihh-?(=3c7I{3(O=TbP0+izyq?M$5hWK+D1k^41MKwqCqpsU
zxE~}ty#ipX!{v1OtPZyg!gWdl!((G3pce>Rt=M1-x|w5(1pp6^SuUcYN#J=5&d-vez
z^3|JH_C9}m`{s>Xb91v?)1R7weVeUrtJ%YkNw?jilq4h{^vjb2z-E{yJWJakWmgIo
z0LJ&?xKv<_VNs)KV>3y0R7&crKwB)82EZf}uD}>@4&a&&M`9)k$D=Wk&EZHQ9_L;2
zf-8iI`r2e_fYKGFD2c4bZ*hT6Tny)1JC4jyuebK#eDcQ)&9GKK(b{!QA=ZbtS@sVEyZutq|vs7;IZ5){B&4JZH
zWf%<1gX5%`ikvYYP&yQjA7_xcJplQhJo(`1Q>V|Ke)#lB=@f1D;yC#q|HG#}uJO(N
z8;iTw)(&pI@y460+gCc%>&>ZUy&}_UL%eYUPdXcpr6)qMaerjoAN5XzJmUe2)9dz3
zIy_#RT>vcTb-1i{nu)tJp3+c2s`@7V(%>}+*vjk}k3P4>MCfDaF@zVY(4
zw_m-vv9Yzccle86yw_~^DTu9h4+D&M!k$s;q!Lo9F{EFg~TlncyED(2DRazS+@m5Lyb6Ulfg9ZNu`$Y}-KMxp>%7#IK}nFYxJ
z8bi15JkJH^4dXa?*UOkVwlzCnxy-ID`Iw?EUAHB-foK
zh~f`?1<
zI(F|9qc}*sd-m+xv-=>Z_{8y^Xe2hfx;4LbZTa-2>(?KfT|V0wTPW1WuiSX-wb$SD
zq6$wc-cZ~hii3C^!#-GFi*v+2;v29J*&HK%Bwl;J&E7i*s_lo_?Xy_=2Ee#thz30G
zKwlp~JJ8+JOV$PD0+W3(z4X0Q&b_@5$(=$fp9DC2dQSB8p6Ka04g(A=O}O&pF`&Jd
z>KZ4H4fY)$>^(XNocD>=EDHyCxa_@7>j~dbpL?j+I}8B#N4#8wA?gE$+29-}bgi*q
zKX4oK_X5&V=&mL7%Hrbu==j#DQ&Y3cr%s<=-#mNv!j)hB?8dp(<%Na0x8DBUm8;h)
zjds3RsgxV$FkKPQSj;}5U?xj|Tfo35aDZ|08_f(VK&{O7!jua7C5Gd$Em8z9qYWk%
z6N=$PC>jManWBjxtuIc-gWz7&+@V-73=9LSaY8!GKZB8YARO~Y2;gu??8PAV2y`?h
zBE>nIxY^Ln(U;KDY}w_i8k_>bF-j`*C)>2L8J$abrAftw3K`bs6F3hK5#l$
zOM%^U)l7zSfJ@~%5b{kHLCt2$6}U$*Z>Cu0gh9}+#u-?gE)TGY=rayWk+<1N961k;2}sMTA=LUlWX#Kusr@sux|1pT^wVaJHiI_w#6jSLQrSY1OF
z+fa|iK47!;f@TM8J$?N!z5|v%wqHR!gL*-}{e8Xt@VdRdy&&7J9=Kd+U|^VHxVxK}
zG|}4$a00#EfG)_n=Om5=Tu*lQp6Kg2-iKGaj^WSVu47KCPXfSf%1XhEg+ZQRS0a{Eu#rHdApjNPITH1SqQOWKLdhSF
z!4h*HhE#^Gj^a2JOZrXB6W%5RlZ~Tbb@mvik_iPQEc`GCIm#)DDxjQHIb<3Vnn+F?
z3=&{E;XD`^<^V8eKQJ&%PBydXt~N+$MK9!vjSL4-mW*5x;DLFqR_n+g(E?OP?S`xa
zk^#t8s|5st;vkiCIT&DAUB<|wmPw|{WyXay#kSaT8V6JXbt$|{VN(O++~H$^VN(RL
zHH!@pa52CYV2PL5vIw-sI4+VSmjFK4a=;836-P#iP9U%=01PzZf@oCM^#VjS{shP&
zlyHsNY6YS;fh|-wd^zEY^T>SE5%|4$G&sf^@%CnG6h9O7QKQk=&LFXIGJ|Nof@=OI
z{>GjIfBmEX=gFfdSJyTtm(Q+jU4Qt|C)c(vG^dxUV{=ND?av`e3rl)1CV2vq%NHK<
zha4WieIzjG^7h(Y7RS(_-PLb(^jV#~gSP&`!QMf--`@US;1>S35000Dxd(sZBw*Rs
z*NfB*SoR^E>;d=E)^_*wboF!-u06fS1ow7!cY%$8ZNbUiC;GaN_Tqx>r
z095y)E}%WO5A-+&d+fllt;=aW>9Cx1yE?(ZQBQ9wY>~o)a?~crY^jJvjoFm2MTx--
z4@kgv@UA^@F<-fQ;p*Dz+Uyea^0{;8FQ2=3{gtP$pW8Y$H@AihM#rW~^(Gg-D%Zgh
zIWg)LOi&aIOpOOmMj_4CPS*5s;lUtcB^l_2*8+NxL}L{J98FL>haySf8E2rJ0ap{H
zU|lk8l%Vy8qc|g=8}ac~uyGuSC3*!X`=dlP5&$2>OAy{s0GNs8Qj8J7CNP|mVAN2Y
zp+C9E0Wq95IB?p~lW8NBHB`owPpid3I-jTeE$1_Z+;{Q7`BF2HGGGyrL%9N5uu#5*
z&*eNJfGwBjqy@SUVL(tPnp_H-3+MuP5Y@Rn+kv1Sg!SdnNZ4O`U^YIJ#(_8FHb4rk
z15O6$!N@TCx~5f1m3%foKQ|9RLns*rTP5JD6AD|lkTckehG^Eaco2XhvW_TCs;Djn
z{pyOAnFbyG;9E;yA86Rhffs!P
zgLJ%uRL-PRV6?Xj2R*&OFtjwWha?bdHeZ2qySlrMQ#|)lMR#{2o#dIGqewt6AdLhb
z28?^Ujso67cy|u=pS1KJw+(bT20N_-oi5u+-%xkZ-52%@B!fUN<8nx3;65qbPcTRD
zXP+FgNbFv^YXGZq`jKnb*H+i(R?nQ;+&F*viLJAjo`2%urRCM-)zkm*5C1>_m+OUM
zwZtKlTvy(#^0T=j1Qnp0%aSfoC{-}9BKjm!a)N_2z=Z5K0+MNcNx5vPiX|k17KBXn
zipDAdR6)^T)F_yie}-Z}EF^Rw5+S^)oRj7m6SrnE-z%=ihl7Vv{j)y_UyG^)Urqdi
zp1@8Vz>tvTWHt>Dz`C*go3kCV8BRzn;+JLNfz#|;Vhn)q!oZn)Su;3vp@jr4K
zLRW}q03Jp_DMR-wsh>Xk^q>Ct^*{cX|KlJ2_^1E!r+@h4S6^SgbOk0BmjG`Z!AgOx
z#M!>3Mq{92LJ>EGM-~Y#-*lm{O)0fAW
zwieefT)FY|%*s}Ma;Z?CeDRf6FJ8Ifiz>mm?2RP7k;I5E3gUIRef^FR`>-3_+iP+3
z0lik|z@U9#(AqQ5-#5@ZU>ShB?H}Z^3E&s~W}LrbKOGw(wm~CoB{jH?BXtymV@5{ldy=PQBc^
zaOLW`vm2Xdo_glFU;gs7R(qmQsG0!Q(*>{!o*%3Z_OwG#bixTkykQ>)1E*BN81gI$
z7%MS2F45T&iY3DFSePmr$AqrQw8UNnLYlS~7MIi-igIQcfEtYX1YCWP%^_Ss68wzy61>zWj%;zXooR{`B=9
z&HYzjeEsxO&jG`5!caq|qltowlhDt^8^DZ|QaA=Hmf$ey2r68h(HLiktQjl=>
z9MM5(AX>|y#qjH(pj9
z@1DK8_fkmj+Vk)J?cYVBk;To+GaHxIwk}_Pf()_I{hAcfi^^Xzw1d0KVow>-qm@ur}Jpn$)h;v>V613
zjJNdl9q;c$EpVd02N>?QSxycyd`G|A*&Q4ijQR&7{=S&6R|;8^0c$b@Gu)pF_sih{
zIckNp)*>z?VmCAB+i%7C#MNt$uCJd%mAAZkaT5%D;qujs*VZ?--hTV{*RDNMZ;V0^
zR%>u*FGlAQ}h}*nyxat!bo1iYHJ&IqQKv
zE06(_hz$TBgLomN2?!26Vc<&~WHTBKaE^Nb7^zhJE@5Re`I>0XHRm3Ib!k3x1*l>U
zRDx#77XV-l6{0zzm)%7u@){U8Z#FpPvt`cU1<3z0bPnj6cvZASQo?V-o*hW(bgi8K
z$3K1j^;chi{pD8x?N?uXiS+fCU-Ib7umAMNf4Fn=&Z)J{Msplr4V1Eyl{mNpxdi5n
z#qjJhl58N)QS(BZSvI=JAkPrMBmkeMS&K=o{wR7{jkXy%32cWf)*o4RMG9
zR5W^(t1(reDJoS?kaHc05*42WfRAnn=%3Ei=K@BjX9{zIu!pIf`I
za{iGE*Pl9j>5+-Wjq2EfmLvMZlHrfZWZ-bz3HR#_+ueT4h^Nmv+;1O38nBXtf#Gff
z*xKC>4{Yh~CxGE>sg^}kb1w&1bpf>CUVs*G?dm$#+5KQw&riBK0nvxLdLATzyB;)I
zx2yYDXVlz*iJaCT`p^{
zcc|ZwG~5^V4v3Y3w?o^BLD7Rsgl1U8sT`2Q-vPi=Pd)wf<+ZbG=Wi@+oIiE(k?W5>
ze(vm*jrA?OIx#s7DG0wfSk7_wpK!cvf`;k9S8?2ni0YcpK_sjB0&GYo1=`ZtYpkgTZZe@SUz9o*iY>*YD3cl?*$Ea?1X-X6W+6T-@d>5
z4?mfnU7lS(zjpS<#cNNjpT99WcdAYRb6u7I=r>6N><-07{9y;%t~>)nBS<|qXCLU-
z>gegW^$yy4$i0JXu)@B#9{}#{?-jDS2eKLN7oY`ziCgez=ZT)qV<$Tw?CN~58-I5F
zxU>5|gI7;csE-Tt$Jz2MhFp
z2Zmwka3})qk$AztK6$;9Cp;%6Hjy_v!vpF^vK!XZ-%!x!O=nyXy
z0S4F)wH4Px0f1G7Qx^yf#@5*$gC#sL85l?gfH_kG_YR1t+HZdS%0GPh*`L1r;!oh+
z&+mMG=hhduZhmq5)|Yqge17ZpXSeTs`T3Wh-}w@+FD$O%8IdXz?Bhu!IJ5@p9`$KT
z%|PA2+9biKlr8K`rty)q5UN@ZbvBZc8j8ZqYSiAqyck&xlOm%ch*3?2ke0o-qO^;qnEkkA%e9|t-E
zz5SryULm1-`@z7#a9>w108Hg<>SO`GqunR|-qLqmN%}HsWN@(a*s&j^up~1K~_m(OsZ%(Dkw2?uQ2ZI{D=TCvAf#
zoR%Jk^`zU?;{k?;dWRf6A$Nbm@00^JXy#3<)>eJ^2w)9pFX>^yopy^p|
zI9>?~O+mqkGqy0jF6XtxiC$AGM`F=XGzyHFqnd%VU^w)Qg_&?F0oEO;1}IL6yx
zPYGMp;D-CxPT3vgi_pg5J!8RTK|B89Y>MR&Ea4=K+f4Xoobc{oXA
z4pecWPzB~dv%n#WwV0xi1)h;Wz=C4);s9m6q^cZ5X
zN+_sn;C@974i``|9X^bMxnhH=rZee6z1B92zm(97V#hE#4D7yZ=f1tWcmJz@`LFsq
z2hLo$F}ieSapU6U>yIsNTx!p(6_1}1d@lagzMkH@IIphmkhkU?rugx{!
z@($RC`fT=|L0g~2($kOR=pV53bBMDI(CzEzd?G+fz_^F)$vqUt-92oMiiU=M^Xl{O
zy!Gq1-+b-OS6_MawU=Lg>8G)v>%@r%kDqw(*sl;$rIQg#UAMGJb4tU
z>%@NRY?b_X9g(9wd+y@Jhv%0!z`(QXmp3jy{n#T9pF4kXVZrP}nl6+Z
z(9G~Ncs5|&Qn|(!nru-wa!6np>`jS<(g4BCAwH6VLJ(zhw1z#(0jhb_-Me)s_nZhi8}XCHm~A2kM~N&;!-jx!#jfXQk*6RLBNsT?Yx1d4U`$3ed`)H0k7P>0L`2&qsc
z4RGb4=p+Z;Kw4vux)_`cat3rImDrAgw_%aR8DtgS2p(ooOT0ZM!laP?t#C>e~&!-3dvDDDhI2V8#JaG>Ae9&~y89IigAy~kpM
z0q&szw)MdG4!{H3dfTBFHVd#9yN00vG=&^^6AAjh?3FznJ+(U1l6uO!iCNo1+v!RQ&
znT=lkoP>DXZt1iQ^f)a5aJSQXa>Uu^9Ukxu^^MrNg6_VU&yw(4lVXZL@ErE^gx%eG
z+^Iz@+d1^Dx8~H@%a;-=NztK}*+l`9CW!{mgaXh~NJjx+wo3t8p-9pfjIyPQ7>WCzNzU
zLIb*?s3#cn1f!7C-cZ69N_YeKGlByof0$iOK?uTar_Ba%4zWzgC~9!nfPu^icx;qr
z_$(D7FiC!cp$B8a0~hkyjGoKth5UDE#M06XyJ6^@WrSQp{y?Vys2NVaW4AeoA6Tu|
z>!?b=(q;pGF2hb>3Vg2L%SbvYNfQ(enQe9;5%$>Qj=_(3m!fNPGgDvP`4rG4dhgu+
z>dvk6>!+T&a`o+3UwP)?>p5Av`QG~KTsQf-(8a$qc)9?b^9x7h_QFymv3-%Xa+a$3Jm8Miw^CPp_U|J9G7kpT01+
zcD^;Wl5b4C_QsnFYo|RCITVveg7J|+-06!By8YH+U!P;B&py&?clBCrJ%jdci@mE4
zxE<^nBnNl(4RjCmcK71|dpKZh(9ys&M@`xLkAM2%?>~6&_rL$`8*l&m)!)4O^6Rg@
z^!hJfeB;$ue*N+<_a{+#Ydih`pL&Hp1(9V&mdTh_EfpnLRkc>Kp6t7#gfUu^uW5o
z0qaO~m|7ZjHqZizh58$;YkFXF4=V5h#1}+4Fsd8`#!sM>(<8~kJiVYeEgX=
z-}r5#Hu~E)fB(+!-+$!cC*OPb>_}!2bwt?$DaVOKZF_q
z2QeITge**T*p%xg2}@>Y3Ce2b>z@djKhr`Y0^
z&BFb%;}VVT{+xZ$Lv#Z&2U
zOpV7`t)(PJ0>x^0>n!>y`4HwKG+2(eDYXt*F!x$$9sC@H>5zdzDcJv40A?$+AeoG$rOh^HIAK)nkt9cM
zpg=_9sNKy5XR2J$h!qWm!eQ*g@vrXOfq1_8(MJ>Q@zK`U>#x1BwR!I6&%N;bx88aB
zsh_>~?nj?|eCOj&zxwFYKWc@R(;px4MWgyV_(e56yxs0)Rye
zR))T#Q~}|et@q!wMdvyC3cwa)U~mSoPBAc$Rw#hSfKUTShR6q`aRIm)0vZ(!U%+J&X@
zW;H8cSYQ6dlTTbfxB2>uFa7$JSC2k~{~kPg>?g;M!xBG43?Kgq7#R8)epo>FXcrmy
z1Y4(j9_s5k3KAaZ?}7&w0kp)tLTeYCuz#p0Fx(&ZSVG=jDdJ3V6o*ZYSd^$$3iX45
zQ;|U_eAi>4#}>|Cx%%kr;^wLISJp2*e*V#yo_+Mut+N+r7FO|UdwjlJYZJh=X0cqu
zGe)_Dgcfp|LR$0|KtjVN86Y{qz#42Ykb^oq25lAtip0<>4!1~#A{>1oW(bB+T)w=0
z=g!UBpT7UeCm($D?jPQ}bm97&umA3)U%dLHUMOK4#@%=n^|;M8yFac8My=@jRe+8XY-Xx%`mcNzLAP`ifR<`Qn@OL
znYzWiSc)NqJD~y)#yFkJ72$z34K)t#4tL6_O1LJm9s52Nk4C=!{LUAj(EtO$NT1)j
zdF!JO|L~h%Uq5^1SHE~Z5%Asl^rJhsZiAa|-TXWpRiaS>IG$8Nxp-=^coMaPKgcdO
zm|)>JcdXGK#^38i>iBumt_=7zx{k{f;5ufMdAZ;p(@!pr8AYtPW7I
z=t;7|`u4Kz%F^3sAqDqCN^=NDPhV$GU)S(Z|L@;?4FG=c?Kj_k?Uye<_w>UT&OCDY
z+?CVoKY#M^mwx)x8^3z>jn{sC^eFZ7(W6J9nene+;0Nh}k00+mc@k_48{FU5C3=-a
zA5!L3swc26~S=tzCfeh_lx_+~ak12ZuS4P))c1S22swqC~7(oRKRf#(ckP
z1|FL||JdU{omt*oK6hjF{G(T&_}SHqSJ$>KEiH5X!PfXpsoq9q3J;tUvs;TL(u>K!
zsCrTOb&V6&QYwewMH4BQB9xD?h=~L6aM(ti`k5U(9G=0Jl0p>ssumtu<*g(U8gaC&MCv0S75^pY_
z%VtQ$x$okEB_)@K4&(CooRCB%oMF>F4)VEjAzz`nO&8MX9BL1cEeKY`tjcS81{9a(
zz-HtptUAD(1;|w~r;j5d6+?!I;M6YKS9ZWA<#+$^?w5D&eEHeuUxH*o!nZ)ech0Py
zdi7_|KX&QzShex_r?A@+-fNu@Oswqlrseke-4JoK$o?odjfaQWcXulQ@Vb
z46tilN}EGCP-C!JD}`%Nq2!>V@gYe$9f%}D3_K{IhJsB%Z3Xl~Xe5&m7Zrx2Hbmv6
zXK}EdL1Kdk-pzRKVhG3Xj=g(!?)i8B``@dwv9x(<^U9--J@fqQzkh#bi4s~bG;ZCx
zov)4t6M7&iyF+mf;qb=o!y&7~JK*y5*j&IZQn$s{B~tI8og=aO$-_MZfNoz8ClEqH
zgM@o}db)c1dL6c&U;g~5Pd|9){Xe{o3h(uoUzlxIe)`BYM|bCo&p!Uft1l#-g_rB347ID)GkdK8?m3L))$T9-!>=%@>%hWi
zQsQffYUsjG;fCuDRyr)*cyfP+O}LgbAa~pnZiUA2x^bnfc&D0w{cX}_22c}3o^IxQ
zD+lH>(p8N+?v|(Wz4x}~4%pPxrY;wvR$LmJlY2HuMyH|L@P9`WMY}5PXY|Ug#&C&1b@*UFtd%K(;9Z##3
zjd5vZ3!a;g7yIP}emC3I7~)SaA!={9sazFb5CYA~#1%3-dID4*R3vl?@24hapq#Le
z*tK=1FTqVQJCQ6OHOiZwa
zS`8|f=KlS<^;~J&7r-0G@S;!TA$-x>J$i%)ePPiCnUk892;@<-PkW
z%{88_yD`7zh)0XjTyVS$6Eur=+|Kwki+K_7J(M&DJij>xcpmhriFG{^IT?PA?Hi-W
z0t}LEkf)-Gk9X3}P=*==-v&m<_wSj&yUQB!Mysz>z&oQc{UP)TG#%#lZO^`~BM~oh
z;@uVc=8vn%M2j7<<>{b5^FyNXXDFI`jsp7+icZfa`A34I&<+$$}QGtcCm*LUrX
zop1X;jL1YDQwZ|E7@$1#3_5n+jqz`KH7r=?1B@7pDhm?GLHA@4Kr!IvntSTmRNfFp
zd3*bE>vu~O&V=-=!oyYZA!M|lWX>x_0ZIW
z@)ZuU*tQrWue&q5efCDh+o-ILVLtf5Zf_vsd7EXG@3ps6MnXbzis%skt`GDcq^;jd
zwKU8l>V%G>?qvcXl%0g<5H=K4&*u|JR_LMI=5*a_IFx|PZ6P4zmG~C>B$edd;rG06
z#V_7^doOi-I;x?Jr^%*s&Nt{F=GrFi2+oxKW#h(-Q~B^(SAt;BNJS3X#M2q
zmWvu|@FT#0`186zQ72AE)3(Txl=pF^D2R}S0QdqE?id1kW6&c;IzB-6>0j9>ew`;C
zJh6YcDgLtW)2)ZFjR2)lPYk#azlV)yYShd)ylMxk$1%`aiCoROK9WcNfXn(&Ya1DPdC^
z<~nVFe0d^uIJU}3nb5)KlX)+Wp(l*Un&%fnVQPJF4m2SwJOgJ&SwU}rTOA(y|4^sI
zuaUKG{`x<+^BX-6a3{R(tk4I%#vBB^&c<{-E}XD;TwKjWkp0wsj)!TI@R9fZb-Sq(
z3i9pU-G&(M9`yl)*ljt|jq$xYIdhcYo@-HhFruoSH#tpUH9f%OUcKD2Wm9~9qNxhT
zKLda;27N`9Vs`|wP9ty@OZaHLmH;)e1#c^^>{F}-Mk1c>rYAcC^2WZ$l|!nZb79LE
zi&6njtzy~Rx`!T>219)zV*S!w5%@jWC0v7KWhh!9h;-R8sqpQXA91Oi?`U@X&E<$q1{k@)FF}f~f
zc+2_u_M$Mp>`Hf5Aa7wc+01~Y6>tVmi3TI+U$K0#u=Q&z_DVEG29e!H;LA|}xL<8I
z!fQq?jc6zkTPA~~W`z`&rJjY135dW&sFU6Y!@32ncv%4{V2fnw3n7nrs!VZ)^c%z#zgjN(*{6IYk1<9J-FipL2uwV)F6>
z*7^X1lfJ#&B!nc3^_#`63x`>(JP$~q$X
z#E-lmaZ@B^i@R$7ZU)WOz`M4XWCF=<55Wq2us6(6lfZfhK7m4u&-9{bAkFu`fn|0k
z>a{gxo`pXmS`fSiQS^A^T~$6|factvL?)a4uLmPwPw9=n8&8ki2?c_UeA+)=URDak
z?#Es8=r1=liU}m}N_YzkWPKLuCMR*$*9{G6HV}Q<$>BhtZmPY!Eh9N30f${;^dZA0
z)r{Lxzl%`M&>IrM<7mXE)gAS%pUnTIGVVQzSEDE=Dwwan%%$-I6TbwDdU$aNjiU$LuJcZiB=2@*
z!*kGQS!f9e9AA4K&K(4#5x;4OGOCfp3puC4L!`>h`->rVyQe0O5Agq&hp`cG-v_%1
zH(N|l+X}J~D
zQx+#T25-v;`eP7&yKfz5hQ!)70g3T>v2m+Op;hlQLUU3Y^x
z38MbnF9-=k(izHO<4GjYh92{~8xL5ZPt8diRMCPuWHu?iG}B3D@?aqj7>{hAHwk2Y
zr9Vwq&8S`iW1Jq}wt9EO*Jw>Ap?oY=PatlzNs<&?wu%&dO`Ya!ce{_%4SRZNn0j^b
zxP3Vt3=5mn;Uo9oP8uo@@Y{a6IzAGAJ5uA0u?qm#j&y994rUK$R%tch5JEtHk>!!t
zCOhz96iUc>(aAxyCWN}h)a&8+B+>7bW3LWSAAEyM*o?i;8u>SU{_bLI{M&=kC*Jzn
z3p(#|Fl^604mn}^TMd&y@4_FpeCsGFR>*1ZpL%g;O|~RvaUy--uu@gYb2$*>E>8Lx
zRG*wu>3`$>O{6R-Oc88~dZz;=0s^XzcnEd*%Mm4&2%<4NoSZi+v6N*I)Ky3Z4Dk1)
zrI9M(hJgC0L=Y`%*DaZrSwb{LU_UDV$8nv=y;R5}x|cMIlUHU?j^YXNl97a%G9!3G
zkrP*VNk5V^oG(czYXbYK*j6$~!z7K~zW^77cBN}(h@g92
zs3@oxgrVmn2p$_ns(W2GlX3fzsiS}mc6jdZ2PaANuXl*%iRPxb)mOEnrlPup&zxEI
zam`{{Ok)PFd&?A;g%dlb
zP5>SmXG9>9)0J-_DwvO_$t&O
zzi^He>JhUX(m7o#etabx;ag}7Ae16z65>*k&D+aGoJTF)q!A-8OF1ABm1(-xw|o@!9+#fqO!1}(hRHjZ@br4X|D1?w0+p5&cvZQT=PDS
z|6vAKD06+1m6oV6iv%jF&p5-h`oI>aK>;o`KIM(%uz{08=y1;$gD6n^>vH;ZvN$fX
z)Bt>mG?_R{1s&Ys_&AFt7cIs&k%+Z3)K)pTi`YIfZ6^u#yFi9|q$xJ|tkSX-YjU0C
zY}&z^ptxPeL=KFtsY|D#>WYd_9+*4VKpPR}Yv~JDb;VCb-v(Sli9>D|F7(yMECz(Q
zpzj&e)mQ(!&lvvXqtEy*)Or3re{J_T6?`&Tdb)afdOU&6_`OTU0k;DL#;o6sE87&+VsG@*9n_}1`&v1QY|7zDxZo%smMrzZ$XbE0H+ZV7v?d!NhsRYD^1{0Jo
z?<<1eCn#~67>RrQ^S8;H0`_4XcW`VegOC^GhBhWjq}5jy(ZxMDtJKaKDx5X8f6<5X
zsL5H*H1c;9Wg-*Nj1xD~$+d!U*Q7`V72wLn!Ofu~g{H|+{|;3TKbquwm=EaFHkUec
z&4C-%JQvk0DF;MhizZTtt{7nk60=M<&ujXC+SSJk<7RwTZFXI@a*w4raT*ldA#=g$
zrZ$4h6eL###4UrewiQy91aJ`(FHg5zE}U%SUSFt(>}D8aLu
z4YNDoq3;B?eJ(=3*@5+Y{*MIqKXy3Z2nX?$Y=In344lx&HaN%})>4mxi(`$HMXg*ASv;O_^;#iIlRdCglZVxSS_ekk-HpPT~3f%Uk|=
z3SA(PTm;Ad&mOi~PIy;(^OL}6S(*4<(O+9$0aHoBkx9r}9_Zntpkhn%TG>
zoi0p_O&NJTjJWEM<>cl&#;ffHE4e}-1~ttpfD)u*IWoK&#-ewu?`-Jd@`^AeIHV;8
zl209FBqgJ1B8}h#+TJDDTkJS4T86u
zq3*WnDfJnL061dXOaK^J{+&onQR@6baqJZdLP21VU^#gi`OolrhV%>gOU)uU)qbW7X=*_yI6=K3GTW)hs*n#7$RDa
z2ue-IKNw2qn>u1bVnsqtBqtGN`Evw)fW{=jN{TjKY!7qxzTw^FIO(_6a2QFOWwr()
z2<&zDx-wH{&9#JoCF@8(u`1eV>|22A>j>Ec^#I~H2S6KvZM|D|YM0Y>zwX?jE-MVe
z%orMXk2{vBaf7zY{+zC7G?o{u0>8RC_cGo(O?#D-vcWUqf;3{Bp3?28GC3(s6Uw#7
zsUzgTAjHqqpu26O_NqDCzht4&O}zlum%&1`mb0LVGb{4sNbR9Wj~B$*Hi9=V9|urt
zhBSrGa0gt+rqfl_`I&-H|7ZFr9Y7{7nm_(~tajDAyV{l3W_gwz9xoTCt(Lyg+WOi~
z)tJnYZrVxk@0!VOb>s2PAN{A^(8$K1pvIPvQ9;{*0&jZ-WZ@>)Lw(1I!TzTs64V&0
za(w=bDTB3^hnvMXtHtJ;N%rsYs&&jQd_qagOAQ8c0J6+?xD1hkoSMcF$2_~S(H<;f
zN4UHVG~D|kCMLAl@B1jW;X`>MT(`dD07BBicqJSN0^&gv!yI)R68#4lpyn+j4D=T)
zr@xWx=T{L54Lt(z*R}k7r)sg?_t8nZ-L?7>1jyLgX>gn@5#~@qYkm8iRLEzLC#0$
z(>!zlpZ$u3VV)1__zslp5(~gp00~HM%Rmz7n968GqdTnIxpr+bHwbH0oOo!-itz`?
ziC>c9zX>KOMU+$^qSbP2;_d#F;U}X}QA)NG0QOZ7YK-Z8d$-58R@IeSB
zi^Eyhuk=D{X1Em}AAeqRp0<)z#ZUJ92wMq!|Mpkx-|5%{w+=DR*yErUlTL@%*>=I}
z&VUosS%QMYVVp_7*q&>fpNWZ<4yb0^zrD(*8wGh{MWN8FD0kccxm6pbZgqVV`OpOv
zxnjW5tHA|jk=IU+^J(gHyFmh^L=(9lgsx1+a_0rsWJWOPRbQkd4#1mG7|8S;3vO)s
z_$Kzz3kMmsmyJ1yA}^9U-vRpaw`(H1=y%R65j9)HkD9Zv&Pr=(@fyphLgYq+b}cSy
zh`b#9KlystIc)##e|fsfVpi7YpZxuBGDgoj#K;c#a@<9
zay7Hr?MnRfYfuRESFDj(9O8Ehc4fAekAeTd<@XXWQ`Dw-cZU}9(sql(a^YL7OU
zOrT^*G_02}uj|#A4&*e63MC*kQ=3VOJ5n)9##8mhol#W*G<3w77YX9>5SyR6x7d}c
z3q%t$Whbg{_ISffVMP)+{a7RLc-FX=oC$4C5r<^|nI=}Sw$KRGxJ?46;w)t6(|p>b<&@8J_bP)uRLn?KDkC{Pp1#_V6?Cf&B*aRDkaU
z#FadvZX8Kh1GJ8W82OZpd7WE{wAK}6;|w+LUpXT=@?2H*%FUDbPTX*GDai}L`>YraUVhDSB2Ipl3
z7i!?GeXEvD5!;w0Q8WAkJPMBsOUfs6psi3h9_&V{5kzT6`T+S1(F>=-rFqrkr+
zgn=HyWdMVLpIJXUMbU@#2#sq?d$hinZ74y{+D8ooT~HTq2kL>9<|06xoqxKBzYb!3
zEw&=d0v%#kFiHaiVxG`F$Mo0-z)S|9S$qPHRU&v?6P58k&dS&v1ORu7Crvy_B)vrM
ztzPxuvD_H&=L+OIiav_qE7N@jMRz5nzQHN?f3Cdw*x&PC$TEV~d
zwXVm*-2`%<{e!rXGBdwHhQ{|cO=dYU-wJ7f-Kw4dn{G}s5*LhR5x@BDbASCG3o8gu
zua+!7GZmJHvbw2yRrx>h=%^l@Au2WdBm?XN8)I(PkfrEKk3xfvCpU};Eo<4NrKMT#
zZ+b!8*tGLpkcO4ig(ZaZPZaH)ohg2PLrM1OHI(}7S~rO>K<6>}HchENR+@{+vOgCO
zS7NjTxA1(6@;iu46qewQ5`1-KBri4END?J?Nat%)qx;}+T)vo(pU30r?9rGjNk)z6
z?dom`V{#XL6^7e2NEA;yONC>1M%&?!!IP${tn
zXAKAtUw)&WJ5#GZ5729Q-vIbboi&&S^L|F4+lT15yoFdWp{|3H;UJUWT8jU6f(NWB
zdj*dJ#X5`GrFCL=YkADV;@k!s2XRGkG0{pmpMJ!nt|R15`scLU!fdD`*&4`p*JxX*
zx!-#~0C&i5_@D|Bgjip=fH;PucsBt$UM76f8?0j(12=&mGJ6*!}+M6=^`6~iQ*E~;L)BgLU8a^@y_&Gf@arWKe74imnE
zKn|NXMP7Ju$Z`)vKDj=(C;!VpYaC<{kP>S}56``p%ZT=qXM+K@2$UC1edwL*2O7Dy
zn9FNt`gvjo(z58Ho}|6PO2Hb)B1+iqKOS;5+kH8E06BcQ0N#wU=-CUP
zY3b8=F~ZRY>6u#_>Phy4NQ^nq4d;(HztERDuh~-Y48;kl=KL!mB$TQnVlz@U0R3MiUCq({IBS0;CSjr`
zH{W2xK-BZ~CXHUr*z2M9w!GXbLl4Iww@8Z`hEXYNOJ~~~TTTfI(pL|%3DFo%)YJn5
zRykxvu$|!_TiQYhzn~JZDET3wx1q(B{
zVFNY=(X&cxYMN%D_Cd=}foM>G
zvckA2h-Tb5!%MiHmf4NEMuArDJKtxC&$+FmivDYLDVIkfI8i{ntO9%3nv66{_`|3PP_F+V1-28E{aG
z-u3q6xHKjHc9-*G{q6J`mNj*AvuvHt>ikWYPYP?Xxi0sn`IBK|09Bvf-*=-=?m
z@nZkZ>g-_H?RA1d%hSW+0R15SfnEygG}i%}(F7hz+LLvYIzr&Uv5zck-W)eV8V;nD
zPn_u^E|*~h(bq(9paw1ICx9ans)m9AeFv6+!&2li=KO4~YogY|2%Vn3QtQ_J=?E*r
zn?mp5ox)4xU4RAS@YE)G#fL3K6^1iWCT9K!(!HBmos9BXUMeao)YKA!LfbrB5NlxVSNZO4uM>4HWf
zVEk&|?Vil@@eJ`Z4ZlBqtm=B287aw|5`8^=3M2X3`J4j_-tTqXi|6Vsvox09YQCTN
zU@?P}CefHQ{ktfWJ)1Ci?BL0gEXJp+2Ij6N~{eAqsG3
z7Jl-|n{)1A7Q;2eV;y)vJBao$pK3fjSJB*VPlPWR5;sixXvD
zKMc%oI+SN`qdhjFS^3%ZsGbgu>-a@TOFarRxZiKpl&C1XWgCDQBypQ3J$}Hv63}zsERV=
z5KO%fBq?70POH}hzmgpiF-)_!hPi>jn;%>;sJLuzK*t1!Oat)dmq#c*x9UrS_>9m|
z;d+MT8Fh0^k0FD=EiBcaW`)8+tsAjhCV<_c4*A^A&i=v)=azOnL#VlNT7&dD%3p>R
z{6EwTN6B-Q=t*ky&1ouEK|FMrT#B)6_}WEFp)TNiW?GFG)M0I`@6sw+JHOeLtS{Rs
z*eG~fj%9hM2F!91@DbXh-E}nrWPu72IxOUfwPqN$XtL(&>&~1LIBKB|=~cI`n6zRM
z-*hK9Ret8aqgkOGPpZw$?GGb1GaF&f-L^O7M1bSvJ*K+Yfy!(LyzuLF^d!Hb;q_j6!SWjE8fQ-+CIllgY?xx*a?G83PUPSC*F
z>Cry6m5d{QhHxJd!*S4CO_2ZWkFYT~&o$P(ZVrIR4x!VEs<*s1)th9EIN|vRvsb
z{jiDaC2iF_LjzH6&c3YI+8(01MKb%^@ZgLege#g&S_=&b)H>?3t>2L(fLKT!GGj8k
zASO!?@;t$cz~rNKkifwY_!3<6pQfAe?V!LQ>Ea}ocT)JX*;q(l0E9Vb3-;kX`tTYN
z*cOJWzVG2oiR{M(V`)%SW29$P6rnxL+~dU1AG%v9ajk)z1b0Q86JLAUEQfvsIuse~
zFragPXL;j+fm@oC+*xv1(@@INRw~C17QfQxB%V-w(8854?CkF3|4pJkp`a`R?)tKnf4FGe9A!3#REiZ7ImbVFSEmKkRhKg!d!iQuxkhHj?
zPX0Ji_2`tq^8su|EsJu2s%c-T<41Ku{=TbS7>)f**Y`k&%~g*@oPVYd*EYOOvwKxr
zMof;UI7}A6162*9!ZzsoN^m3e2Nx=l8!Jn-c5la5*+`w-?jNnMZxcY8)olo%0^^37Hl*Be&0g{$#Oe
zE0G@w+|(*iSvz%pTDOX5Kluh63tX7RP#(XPsUwi|=pKZ=Tbb)yJ_oS+q?!0teqX8T
z?=+q{nWv_h$m$4n_{&MtSr?(j;>)!$YeOU;w(MzEo8WqXmTr`!(96;7K>z*6r_7YZ
zw)a@&*yQsm_;;_phl60ruB_0x$dx%~A0g8zy71W2^+bb0v;RhJkAFRW<=U{c&gy6-
z_gqZ*K0o{SypAU4yW`QpFxP{c3HHzNaWJR!s;cW{;Ur8Gbl$9P6DTM%PbjwsASpNX
za*5poe;g=OWr+Nil!zNCjVlizOzZGkmJ3yu9-S$r6S8TQX;ADfB1DHb8^Ba9Bt{N^
z%PqD-IuIO+{7Rrle6W&T4Nrwl(~NXVCAl9Y5nKc>T^BXex@QyxCPa2eiI67TuTbPv
z$e`w5p3@(OtFxrW_hm24`B6&=Hks5`3Ya;+Vr?E=PE9xE`L0x{$Ba)eH^jq>ny1O~
zff8kwD0~1eaK$%m64d?Z8`j|aUa3eI?=~-c64$iId4iu@#nc3eXUFOQ0K6{goM^XSRnAMmwMt!!I`?h|64m~AjIDQ&nP7r%;ATaW}{KF6HEgjP#
zn*SkAk*llR8&zC*xadom%oitr&l5m%{zoA&a*V*`%L{%64&iwST9Y976#bmFX`{18
zQk_%(N2JBzGL~ITwxQB1NPT>|`ynM>hvglT%{wMKqHA9(@~9`7fPcsy1WEoAL|wk9
z93leCg40u5?jB=`5shm$pnDIDm3Gk@vCRt;r~cl3X7T%?A~LzDDE)1#UwfzFgYOetvdI6uv*x{k4n
zn^{?;*)=b7UC>K0E&fC(!r}Bauy`;EjVA$;fw14Ri@31$NK1p38#_C!l+Ao%LGjZ}
z5sf3BUY&)aO&|w165(#VPKM4}P?z|ZQk6Y=Zn}D-OXE4u`+-h(T&i}kX+BrcNVxg#@c4G~+#KdfGAwRHxe)Nff=i8eUu0&_md!rn?(B^9R&vUX5t;
zy)^ZC6kqnc8HVQ(1h>n^3fmRR*n{CIOlEIpgW{lZXbJ?W%q?BHEO~sQXvR!~w#l>9
zy2$xoMWf%F0!1buWejC)tv<}RakWDGWMb7gJZ*j5xz>EipQeG)?!E?=Iz9Ej7!tp1
z$%Um`_V)kC7d)?Uvv=I=JSyvC?=n9QmZtyc1D~uE=a=E6Yk|^PawQPRN$#HV94Lz-
z!);iWPx?wZ7^
zhJ~eIW3^3$w}V5BS6s0DW@e}WCZb(ZmESIL)poXWK{#qrx-yuxy2-pQWGn2}4HCtu
zU5kx0W?a3N3yo=_`a}qq#FM6r0wszV;B)yPLU9f38b6hDUR6%_kOn9c>N5JEA&jB?
z?a-A?)KOW(z}b-d;zK|kgB*jez#tj2Z1l-uIW7eOV@go%K?PFX5!D_ZYYky_k9L)K
zxp)ZyV%n8w()1sflzl3FLP!3k{jc~|^e2r%Of5={VL9-6N}tdp
zG9*@uvrv{wQNvKqjWyhUp`0sS!wtZ5{NZ7eQ49}LrO_Or(aFIC3*;B7f-jT(-&q5r
z6NdtGVY%*IDbraN8^L(bvLy2sqIzd3(-=1`%YH>ddrl`bB$W{ec?@EN_$Rq4_TBR>
ziA!Cem&hL(O`TgPy1M(0_lGj(aK$^YdQNQ#>V3(U)f<09lE>d2?_yHYXOABIwgLpS>9KZrMZ>19A{>yK2|g%dw|4UjF3<3DO!EtL$CmLnv
zJ36z^-mo9WTRFL!it3Vn1K?tQ77X}R>+j%vHhxsCY*!AO+4Hha;X(Sk|E+uG)ZQmD7Zle(5f(@R|7c-?ym
zb|>b!q3EMsh7WH3!}P}Mzf18KFT3mC$15j}UAKem0gq#9
z;$N&B{uq356VfMNLU~7PXcj42r%tSbHQt=Dja5QzM4os`c(-g=Bbl>c=J_#CI>aMl
z!nASK9zO=bi}Yu3Ts45}J7;EAuE;cq5Hw?70@n5c+Q8}Z7`yL?)SR3h5d-F*)zBjc
z{9&Yx#h(10AP0)YPbWcoP5NpOK^XNQ-SoLTGUcS)OaAF4|1HszVuv&q;k)MY;6!ynzT&JFHLn91r#1n%*AEs7bF%={_F6I(mG6u)j2w
zC*=C&dVHX|8nzw8O5fb|tTN2_-~L2~(U->GgzV7>&p;DEqn5*7t1jgm4L4}eYgU4*
zpIbq8+;@0e5!FO`wEkQCb`h6M16cz1@)Q3Y8PdE$Y*=`VTSH?CNBBTo|3`z0EOT2L
z)27D4Qn)IpIc5ywX^jO9iM6;8rxU^`r;>Oy1zIf%5z17~B&WU4*F;4fl-g6dG9*H2
znGk#6(m3CJ?~`_PZ4X^|^Yx)algnqS_txo5)!H3`{DMNO-zBU1+FdTVWxm467Dz9A
z?GBL^3BYLqofD2C+)|tqA<_lnXnqT12~*_U(iYGHFM-BeLh0WBtO=>3ZB*kJkUfh94V9Ne<-Mh+peNFfsg{lRc@S7}aA$S?5B^_8)j^ox0Gc+hEgv
z2wiu(L)g<lm^F=W%J6M~-Pr%`(JJ8n?gzg1RH~d+LnAWlrdIt2S(eUU9?`&p
z!k1k}LJqJM@g00_pHcJDUzY^kQ}m@otM234RcOcSD_cZJwGQ7{p?jd*vKc7b=b0tM
zprMOkkg&5kATe}YG6Q$S#87v0!!gv2{(u)P(!)}j{a*W5>!#^hm?fFZoe*VCo`mCO
zVh1YZl$;3S^ZBxn8mo3F1j^1B2HcXQwR}&N`?FAvrMQP^L`f&N7WuGkzU5s)LMGA8
zS#t;?aEm%8r~LZQ-SO(mNYo=86|`qA{jiEZi&7Bqo&
zdJF=uLjuvv+Im2#(}ciG+ifp_pCO=0Em*Nab(V&HWKUBQ;yVC|3
z+(nyy-!$Y_lR2%rVueb+;?uR`zjIIauB+&8b|zb;G(Nx`>;9A5FTW%oHj=OsCeGbj
z4D6#l^s2Wef`C=)W{qf4+`DQqjgE;`KO)8GoCB)~biXQ`?_iGmql2-GnsIQ&IHt`T
zZuP&%mhzqwx(Of}G)Y2*^E%GA{WCg-{x&_xffIk#Y*aW>;1jBZey^+$B|1MiE}9{u
z6{`TW&6rAd1-qMi17Wzi;x^+r;h^LHpVIpf6QG@H@6+^LeZ4J-oJe!@KZb^ixm$WW
z*!Z2iTwSf6_O8yq*t)vht(GMG+ZBH^uQOoR0W7(+E~=v9#hE8^KnpM2gM6=I&C_to4Q&b??+rqid;UdG1CGQlYNerC>Kgp+x3RfWSokH{{3EA$pq7AlLyKXt1;K3OD{
zln930@Hk|WE@k)p(V4aXI2`1tL0v3{tz7r#f}0nUt6VPFvQ<(!#PU)wl;Ju>Ver#%
zkS-4bgnkF&2xv);PO+JZ9MERtpt-{Nt0}lkg;pCS^r<}yg*@^A^$10CATF#|k>N`p
zL+QK-4-1(#N^-uMdYLiSobu)G%Q~;ruRrBjF`732rzJ#mdcsUo^+_L3S9kyL^3&zU
zg9o+v6~yluY~r0x$D?yoFQ-q`YMrl(?1Kk<(Gx@^A}HX+`aifjjT05c=C*cr%+S8S
zntnx298eE*v{q3dX6+m=1iMKv7r))To9oc66`;jnOTuB_tak>&Ckgy**H~Y*9K9Pv
z7K5PLns6gBjh20OE@(q^8n%Rxd07r}Bs#5ILp1Q9U9H~P)laFD;TpH
zgIwUMdz<>-lkr>EqR!G-+2Z*4=w9z??^9N5+Qgs6xr0e#G0**%r~THtqk);DM;E)R
z#WUfle=lKrevqQSm!m6?@j)*w$nSkbWY4;a4zkIqEeaz5LbHqK;E&(bnj
zu+2{4g)BR!vIXui4=0MKXE4G8Ij~jqXFg(bV
z8e4wl&;6@L#gb`2V51w5n3O+z@5N-k0k}um
zwz8Si=b(*KJ&-TO@e
zTQ6?h_o>{eyY_rjLH)Mifj0PY3zUnX=_weQyzs=EF@qn`5IM{~esNg)+oN8iF4Nw(
z0kaZq{JicpbHPAYik1Ix0AI`Z#}@Dbxy*}#fGPudv8@BAR;jJ@kUI72g-=;%;@?+!
zU|%-4;8MTa-)xy%*yl3l0tX<-iHjxI#_$w(>0_g`Qaw@Vn_JyuT;0IbAM~{>$msn&
zTsjns@tYuyPvTBXQ08GTt!b|aDgo#KqNfe9rkd<6XHqRKd~xO!L%ERVnmsk*TC007
zjOFQ#hzu2fl=;bGjUTPj^68rcbzC&Bl@jYb?tkMt$AwYiMUA14$KMUqr%&(kaSSfW
z$|v%o%h-(kZf^dRvl)EZJ1QraeyoaR+dEDAIl5%I
zCs6b|-J)E?_Op0NsU^OxTK(``{PL0jui<^NrZz+TsSA^7yITl`j9-&(cRJEaiX@GE
zbYD)jlAC(W>Ru!-UemB?I~n;bjx^?!w~IoY;M@phVgs2cRi%c!&=H*X!h_+ITpO&%
z_l!aMw(WP%uY|^!^-)(ql)IgW&(qfOi`}Q!)7jBMm>#Dx&Q@JxuQE|!`))EL8|S_2
zDSi##kjsEx1Fr@fKhpx(YTOUD6d@Wl)SzZwARXz0WtL=!J6Lyb8N+~rOdNz%0&kum
zuAxowPkmLZE*qcO1$*|1&L&%x&z_Q
z&hG;kphgukBk4I5E_w*QYb%N_{Euko8Cr|f@5CrZYy@FhWf8btJR!|}37FmBSWa94
z7#lFXM@Z9vjyLWYBQc%EP?fWgX9M9EkXvfFb`jK_*@4N<7>q`LWHV3;Go#zOE#P6j
z@tKc>T4T85`64ZDdm_HPHT@-$T${lKA@YHu4%p(rso)r}E1xDKiZE;XH=g=1CzdQ3
zwBlK^-Bw4d#O3pqR?t%xs7Scwj1CVbS&>g-2u9?hPn9vN#j+KMx}J?>z=#iO1^(Ye
zJ-^N8&WyR!>MXj_ruD6Dk+<9l{zlXa{4P~Wn*aOjYe7fE{h*F(VDP!*M@rElY}3wnI)
zayUhf=wjdy+zl0Nur$`D2}^&N)Sn7bygDXMADB!m(NLWCF<~XP6vu*DK2IsOWuPu}
zY=@1NFVv2(kQzdX2H3o{2$x2@Cl{*4Abk7x^5Y*}N_CoD3eJ1f_c1vQ<&$hR1%`&=
zu18le^nP`NK7kzlK~Bo`pM8tE)m0%+tiK5ACyh;8+nS9i@*jWj%3YQhl7e+j>&9Ry
zAz6zCUp7?xlw8SG31JlSdkYP3dR*#M?m$c>mNE-~S}wht?03FX4fJLA{wRCaWbO`Hf}Av-lDDqkNNvD_(AY0&gspdc-US;g-&pC6Mfe&7xFLiaLX}
zuoHwV%@>l+Z8kwef%$jf%N=W31F>(R?h7!Q_$CH4&0gQz&nkwmf}{<90UsD;q2*C=
z6?mp#z*ln6{S@pedxMQ_!xH{`T#^K_*XjJB7P^r(QlEw9&ZZTDA}8xlA}C;GfYBHW
znIc5+CZ~+QdSvRvEr2Xh=bI1*NJ)H#9j4_-gz57YKa&IWAfuYuTC0OeA7NPQKBw!6
z;NQ_-G6REESXsp9ZKgovI9Qc;rW(gmhP!_YyvrH9ZNwZp+hqFv>X-sTDa-!>0LlEClQql2k~G??wlwEohlS6_Tu5
z2$3U*&)9YmuiL+{|t@#20~42-|1zb4S!=3;Aa=HcSeD#rKTHeQ>!
zM5o4RXzirYvU>5G)(H$VG{8AURP+IWoJ|z={UbTAx^AOEnWoim6NL^)MLm*z2vg99
zZtNki!9wcA!`v?^(!jJd$PLX%C|bVBEDHy6P<3P*c^S?pQW3B=;skzlm<3mqU5kfe
zW$;1tU$~qMl$Id5!N3Z+sDtqy7v$yio@S2ozzP!+DLvgCDLinCwU8-A7C|NqN3yo}
zFh2g=?%k@o=zpr}&Fm;odU#?Nk9fN}i<6sJG8ZlorIwO9ZckgbSvNz+FZ
zK&(n1Mo4dAt_F7&&xS%;QPdv=ye!b9sYIf3#W3!4f#d=E^q9h=6wO>`@Ub(v&D&=@
z{Lm8dXJNEt+Lm!j%H>%g+d0Y*KrlbX)`EHl9%kZ%=-3$jw5LfQ{li?GZ8FR}PyK%Y
zCPCT0>1-(ht1N*VIYbmM1vwoGHYgLtJt%+CslE;1j$M0q+{4l@#&3oSD$?Hv5k$b+W2g_F_kX0lw1)Q)Yb;Q{N07pYZAx}>tWK9O05XmwS8@Hz=
zrx>llU{`X~W)PW3-!waO&=riXi`OI_Mhc+)rXd=yf_|a5?|vlKkpl;g96ER(VSHqG
zI2MX!Cg<12rxr$MSEg4^FPu8Nys~-r?1k}(*)yBxCudg2rdDgMnPz)paejVrVSZwK
zVr*;-^joRaDh!L%Xg0=B@_=U`vs?t6iuqi{Fo0nS>3psPLCaugf}c?qfmkHKG7tNN
zI-8tBcLS~<@xmDr_7sf*u8bc*N>MN)3{_M8})2aGx!fsh@${YK7STZXS4Pab<0Fv)-IECkBgD
z15iPFs8(wA7MKi#%&}Hto^ZL+#6hLn#4+H3>WCK$s1%E4uxN%&N3F*pWpI^@pa7yX
z(xQ!!P|q+2ghFB4K`frcdAM1&Hi`U{;CSP*7}=sjDr=D9T%MZ%<|tRNafBVVL~J-^
z7`TmGJTBwANUFH)d?lMNp(03UN=Y$C3RuDQV0%uM3{)rIPmSy0>H3PMgKi-)p~c<+0|%`K_x@zV_NL
zpMCQ2@!8c%dp=Vg)$&yX1_{i7$IYo8X_+y^IEYQv_qihxpW8j+
zb~^_Kt-+8Ncpe(I1^he%p!&Qnuh$M|J2C$FU6TrvcqYeG~=J
zEV3}bfGAS4*+wQqB3G-`Vv$X$C~yTKu;E&PVLV`5Pf4ujfMGVtu)D+zM!`{pfUZFZ
z3tpx9$w7^qMHXsP1pWuX0<N(ADNB+SkvXm4Fi_Xm1W=b?5&HnM#Sch11@=70(UI4RZ>#=AIe
zh^wd-;&Cn_tnmyxhjB6qbGto1Y`ZBTD*DxdTL6`fSOV4IND_J>8cpKf@PQ#N;DFrc
zlr1UA{yBUC>&ppLZw{3HSq^p<#P81cuyhTgVUT-3jX(k2n(%Yb@x9
zhX6m9mK=fUHQ5zOi#e1iX*Qd5W|9^)W+jFJ>=*-X5aDqcU0w`kR@p!e5+>jwuyK%)
z-P<|zt+&Gmp`hAXHIRLpPye@UtOP=
zUusV;PEO5DO-*B8ADtW>pBfvV29s24oG^^?S8t4hZ=20lwOT{TBV6+p*raNu4vmdx
zk7tZRX~sH32~Nox`3F`|G+(1S$KyaL1ZeRm-l(%@g|z@UTu5cS#1>Z^LqeAUH5QsI
zD3AI)U&R0QTB+4&0KiB9XsuXm)oZm%6}qbeC0inTtL0j?3R-4ADyJfq@d`XJFw9pShhuV!P+hzPDrdeopJ({u2j#1QmA}xRpq9ee3Gd
z=H>PC*I)nDt4}=sbbD&G+M3Ii+j_oE63!QpbEJoK8WtEh)>+jX$y8KBo}}>8qmf83
z5b~v@h~MuHNBjVAJRXQdJeI+pcr*|Tdjei(EbNYjJOPg*5%vbXmT=G!4ZHkaOC;n9
z`5Ys|{qfjHz-x(xTqCZN0Z+foPM~2aYLmh?B|ZcSm4#+j<7RRIz&a62*3HVp440E|
z0ob5r7+pgeR@mhW0E4B$+u+_2LmI*-WTfHk9QxMVL5Sx=58QVM41DPDq5UV0_T&l^
zwfbype0FkSWoCJOc4c$z)alb_F3&HlUAc6g}27nfaxqh3V6BwxSFPJmR=XYeZqUNV6SY@0X{SY?kc2o^sD00uE5TR_x+7Su{U&o;Rnkk5gvW!<2BEf%V=
zL`qZ&D6&9i1~imN%6TpUp)yXbk>g@$=G-g>#KWg?vOXwRG%r(WWP%bsi~2}Sb1Zb4qsIgrb4+M94L?%D
zOWPSFHb`iWh2G88y>|=uyLWfT0lMN20QkV}UHh&5j&h;CapqcmYW2})U%2t`qnEE;
zo19;+jLqlk6PZdAwPBibS&L?DQ4|qX(>Q{bp|g_=>nX)ig&BtI_6(;|(L^E?i-qH{
zfW_V;r6S?5+cV-yCH+z?0OFNm9#E@qcrcap#3HU}$SK8#BSB{(IvfwXeC~cJ=8pP@
z~R%%5c>)MiPsqP
z4D>+;229xQ1$Y}M!64*(0WSerCgS5
z?1?QFt0~1uq|_X72)S$ERnjik_0K7c)ye^dz)Tt+r5HdFK&xx)ScygxT(Q}l8wir*
zoMARTgLrWRqNSRMg`oxh#mrt2mqU!1i6V_7k#!%a$85|Uy&s9_Daq(@7`TIcI4TJmtEPsvV8vGjdRz2_38@{(yhsrQgb?2ZD)#A)Ym9joY)P+m4*n>
zV6bFGGBRpPj_W$iLpUWvQp5v6PbQO!MFT)`6n_PVRXOPOI8%v`n)1n#ClYihNuLsT
zdq?_oWmu*=b;${j6dlr%?s&uz_7CdP2!(D8cpLH!_oxK01u#}(HVwx~7tX`kDr}d6
z>1DGsb#emM7eICEl83AdZ=3`JLonlwY}rBr;E7%V=ItE%*4yEOhYsx9fA}CUeB{s}
z5b+UEgr=7pqYI7kdC>3F;;H%Nt(E1?ix)0W&MZB4@oIZ&xivFi8JjNDTb1Tmx!N|e
z_A`bMWvBLqbLDc}3C4dQ4wjtL6LwrLaR{9Wv(C<;
zGCP5RT~J}8R&O?HxENmLp5%6rYSUoGfkRqA|u)kW~hnlq8TX+o*9I
zkHc0}shnjUej>uDh;bnnGC(6RjAM2o>#SJWD#1De8ao>o!?{pN;Tt8kN+WNpklfoD
zBsL+TVRv_J19+!6fRF};J9dJF0por6seX6#+{J6Hh0RBvdEx5SM=xJGH#xTqCtRqG
zSHT$NYP|-}md)i+bunCnkv2r!U?r2)WF?_$lB%UNU4nR40clN&g#8MD9QDdlSl2>M
zhecBYy5dn~H{hCAl2jI!c5kv8%Vm2c+1X#v{gG$_{OD-ks)KkOZpe^oq
z7%4Y^muCNvU4YhQq(HeM-c`b(f@XP40Bgx%0cpx<(UU|ln*dJZEo}4x3E%yMetKY}
z!-ozW1ct%D|N3A3zt`8#CY5}1d~SMaeQtSUV(!$^%GTP-#?s3A`pV|Q?9$lGVsm`9
z(wqRxR-0p$`e=cJI>x{_&1M@y8U}cDbhK8hw%dd*%4WOWDio-b+s(FEhNA$66c{en
z*p9?e7Jv>u0ceGghQJntlL6X`9MoUn5N28)fnM0t??Z6n3prXg12NX1TUK--vvSZ?59{Issp;!1}Tq3AZWwg#Thau5Y=`&9AR6
zZ%j|l;6{urzNwiN6D`5Cs-6XjK}`_MY^dY7G*Dt1Zr0%V@JgkLa*s2aJYNDg0$_Nf
z(7h>2{!-=Et=o%>OXM0c78v=73;|-RLp^BFiX6JLit-ohFLW;h`;TD2I+ja!1V&E+cqIg~l-da;D62Bj^2
z4rj2C;n|`DRBv|^KnURL%=|Go0C+C|ymLnf=@($`fTG^FclQA#A)^^*=dX_Z^Z)$!
zC&3K!tLGQCuC8rf{>^L9(vLMJmn+TLN`1UuYv+sAe5uM#@>~Y=OA<~Snx>=;)I$l>
z#0p!skdLWQ*srS4)zL&eq$u$bx69C@itKgTdvp~T_Nnrak@5hmx*UiGAb{OcY*>o9
z3>k!J2ga0yQ%Shw*ocu5gCC)Xm65P_P>ngV3Ux9VSZHJDWRH;?!8K{@;|!gnBuMFM
z%zPu6R!D0cuxXk?Ix(U|oZn$-l|%av9oh#K4GDet$blpGAHM(af&0eCW>ZR`H9pg5
zPtGo_jm@o0&aW;nZ*HDGJGXf1>iLV!iP`4lVx>Jz#cw&1pFd=6eKrC
z)X8aKzu8PJvS)ka@}ht)Knv@;chBM79gNE%0(2Z^gVv5cd-ojNdGB7kW!UNTZJobf
zn_ND3VTqME
z=r;|`l8VTwxT++Ehb@_OOjpBhw_TNey5iQrz)7zzgNi-Tpd+JtAe#X^L!wztOI{MG
zG)zvG+3du=U)c@VhdupD#F61ix1J<8RnTb?&KAmfD3daQIt-#FErXMjf_q~QU5IVe
z4yYy!06THljaY~FA2@X2@WK6X!1vvE@bKXShXCMz`)~gJ;^L-}tv1@z6SHfr>6P)h
zQwvL*tLtZ$mp4|IPR-9Pj?b*tCuT~GsZzaNuD9#$@nWf7Z?)-!8_jlm6jTfz22ktO
zMh#`T*&Z8(s0MNfZ*U_vkTWuswh_&0v=ivaK)9`
zG=2*gVM$6Fa1K21vTOw=nFAh`Gyn+(22gL^x}~aA_>iyMYuR_-eJ`8kP#LIbs9CNs
zEE~8iA!gEpX|XpuV<)F(pL_24E0?b&;_|1Teu}TdNdOoM8PF9l*6?R1e%humX3CD;*96#xcN&QyJbjl4SY)GI}
zchozW3_8=PKpNG-HoM}yOO85m0p5-?X^=em*=tDN46*IXqJIlFxN+$8|`#^r16v5ER5
zo1;sh-^M5qnlAwj_4epEt!1MH0GpN=2V-Ls9BWywjE|0iaY3i;R--|yj13RF2+$J2
z5VRGT);!=17R~3gtyUAF6BmKSYHW)F*vgGst&j(20_3J~EeQ@MjPYr}H=vHcOrWAx
zsIr5IbAWLTP%U_#9Ys}+g3dSUP}-tG!RMFqMUIi?*evMo?L4}hZESLNdU_e?U6@<0
z*T?j9sak6n=m;wC_@c=@hnf!Z5;y^LQTc$-pi4n$AlO>1r9r+X$(f)>h2sM`m>d8A
z-txKf?OV6;Yk*9%T^H|q@7?#o+kp3{H*boiOhCvS<$_lsZh!mM+et|VF#@rZle0Jp
zAq`gi^{-zC=0Wcu*mvH27gP_LjYTEY1weZ=8pmxIVtO!xA_)$MHpV?b#;1*JIFg8j
zQ}|veAgKIkL;_vY>KE8Hra(gz$wkp@*)YXFbLX4Q><8YzHR^;1ngC
z6b)Lt;fIHZy{;kO*^7@fr&iBgesW{$!gJ3)d1`&DHa1tOPZleq*<#fwl=Ljj6)Biq
zN~#P?%&1{$T~Rn-TvMgAA*WH-BqM4nmNig8h0K*H=02AB^YIQ)|b
zA8L*-#FIHAS22oXA-T|=U7K9koLe|`=Io`p>Dl#DE0Z&8^@-VXYdT+PRGQn((O{K&
zqh&%D#j#Nz9cz!*t97X8c5AFyEVtWZ>`y8d0A}!Ny;g2CYAtB%dIfN8)S95{Vm{Yy
z)c{vK_*T6I28KXK1xx+}U6FFxh77brHseDCddZ^D$u+>TNS}-gfL>q~`#LWr!i7#Q
z1FiUwjIIN*ID=0{y@3h@U*BlrzZ&WneB*W=-OW~M%uLTN&(AN+PR~@z^?VUBpapya
zb;WWmlPv)Z;9JlagfRe&$_{66o^6L}2Du0Kn@FjWn9UE;({%QJBOek83A*s+&0A*U
zy!mz6OaV9q@^w7}0OxWXDgyxHC7=jg4WQ!lA*7#q=BEqu%Qz1Wtf^q^_wi8)5v&8G
zl@x8%(BTmgMg#QAkO?se?i{Xxm^Z5%fD_!yj-mpbIq?@T0;*-VMU
zX`!96MVM&~LIOJczv)I2^n1{3i{80w-_BhJIv}ALYxcmty@!OlCOJb_|BJu=pH3d_
zt~V#=SI$naUR*tU{o!lZ9=UdPbaJWGp3B!K@|9+WGih=ehVabb+l*{l*E!@zEJMjw
ztxQ^zQwbR3Oj=1MVyc?Rz-360v>r=qQJ>oeNN1Ipcf^)a0~y7WRsEVo5~f0yNA%P%
z&KQ!)X#K|lm
z4F<-Ci=L-!%9BCuAdLX|S&(q@?jv&SKLGR|+z-}03=AJUNH8Bhc=*7<`^LuSd;2|^
zTv<{JBO#FRN^5p?YGHNr?8Uj|jYlq@Z;#J6rWV*7-5kqTo4|0bNg>^8Pe3JBYpqeR
zF+@(Y0US3Qptx!a7;QFdfJ(DjDitP2am-x2O2!YCuI5cv#dW(~LAgK%R%;}h5KfFbPi%UqiZ{N=4I6>*!wQKk~h*+^F
zjKMQpLRinf@y44Aiz@&Q=SWMOZwJD}9$$^UBBo)3bpcmk7`%#;$W8zfG!AkOi{KkF
z*IQw@ERcVS@v%5s3$;u(Q;fxAcmd=P7#PR+Apks-GniIkcmX|;0Ox0m1?Ubup(@@2
zTZ3=;^Y;JmMiNa~y9J&P?d~|-(Q%(ZFCa}ehOXYdbH8nH$nNl7y7E|KdTrtSwWZV7
zUwr;&XU<)$kI$CsW5wF2k%hdeX4tou2Y@-khfzpTcL2s*r%93HnM?|M@NgzAOUan7
zp*oD~N;Iv-(`hLb9LlF7SuHX&)DLM5xMtOWmI`FmU`_>|-D+aQP(x|OuS5MNd|Az-
zQxcD4Mq%Jh1=Z{(T2Q#QUJ8_X;o{ItV9x_`bjU5C6GX9JM(@
zlA13yr|Of-waMl2+0~iZ#dBx2re~Md*Vad8*J=}U#m0E1+$h%Dl}5Y3cpV_&QS2d}
zp`~ewp`1~EIn1NlXf#IKJPN2(Eya1a3J87<+LUIGNRlDd16q;9_=F
zvB#B7+}n9{H(S0u(HdPG8v_e3tt_v=27_q<<8+3-!KmHf4|TCB67mCJgX}~`0RZXD
zc6T?#3pfOr;dsd`qh7$fmP>V@3upw#;tt7gIrb+(vSN<}BxiGs?2%(k64lW2sg#z8
zgKXJ7iz-0TG8~U##MJQ=80)%6>BH<*v
z01L&Gl#WIi%eqwNm=n-7m>GHjH47)G
zPA%NG_Xq*J3uc&egFE)nA>;hsj)M;z`RkLNefUXpYp2_Dn~UeJUbyn`wX0XA=T~9j
za`hHTIL~>)S>#R@(jVw0{~`xb)fj1r2VId98AHL|&{KvXCE_7ni-Ca^DV)}$StB0y
zxuB&pMl9rY8A>px2eD75fMg%=oYR77IjAN8W&qm@^y;!ZtAI}3aIlKx<{7qHfki!P
zjH8+}pj?GYn`h!qSX^+g(A%zz>`p6gux>gTNGClxWduq)9dqh;KOgu2!3)sB2H$sZ
z-yRS$&K!cQ-UmiLGC47ykjsT~ThCPoheFUS?U~i-`IYNeuC1Ipx3;`IIyu{#T&}ZLNo
ze_c%jgf+5Omi;kVSoCrOe9QKp#weg7TBoZhb%0{2TubX5?@dhVP_`=EZy{d+hD{fW
zk1gc!dn*7&p+MM!LfHb$rEP%TEN6*mIj}gKEg3$Ym829d#@lgTRUja7ki|>52f$TM
z>39jCO)0u0DGXRE)=~johq#ikBve2t9#25Y>jvu18g2l%O-dSw7c$65XE`$wx;hCN
zkU?cxsWrgZx`v#u1IF7KBsNZFpaF(X-m!P@9%yN>@$TKEWv>fJtEvv<$F
zA?L8gVq4p~*q%Q%dFsOK+Jz^ceB#{Mv#qI>QhT;g1#dL6#Y&F-Z#mqGnK&pEx>-@u
z84dq3xKJ8aA*pMCF=O!p$r(MNNShKP~&yYFL+jX-H_<
zo7enGd{|3)avJq;8s~vh)dRPzCWf^H^l%_80jNF=(mFAu#9UIysl~jSlg|tMmeDu8WZ!?$)(oJ>csr=mGfJZv&-wJw(4Vx)zSGveX`h?ELO)L
zY9OTZ;G4#1wE{dgVS2&AK(c7iYJ!1Vpyf)n-EO1M0>XeX-EX4-h=E-J9{S-X1TRD{
zTy3e<2F}?KB@A;NCA-epJvtL?(zA?p;YCB
zBvco*779A>0}_UWMnTVH*iR0@2~U7Rhe8kB0^;VZ09*!~10L|eoYIlY=^CeSr42?D
z0)}A&h3n(|KD^hAu)`6Tg1W)gkjF5w04gUxK@sXGms1+Z&r(Eji{3J#iH(v7R>7*0aS9YIPhguUozn&AhnQ@@EBL-TkW4--6mkR~fX0RH@~vhqpUVL8g?t9YD-a0p3VRF;6Xca*
z26DJo1ET`B?4H6afH7Vsih*8^;w%?IVbroHd4w-70NTYW!6qkf=h5A4qch9t(&*U4
z()h&8`s(JX)s04TOiM$-H}XXQc(hz?WC~@76hIo{*;LV}I#Bd+v(;*yO}j;o)`A8W
z&AbdK4e+2eLSsYU0*&yNxNS&%fEl#H-f|+p09fJx$i%zg1I#ka;hB0Gpann2W9*Is
z!lRKSSU1UVu$&Pg24lj$a>S(=Q^j^Kcwo*$kX7IlWDBB}WK?%878nNEo0_uQdm9R)bkB
z2#D%3_r$8=$*BP)HVmxh^$3VMBZnZc^^`lSfwuwRVQ6LmI4y~k^pLSrZXAQ9h43E1
zW$Ba;0vl%p1N(ETZ###+^(IU&LsNo;#W5r_4k)3)$%hUc{^60onO|JZX5
zfCxyNJSurfX=oCm}tyGe~Td&?1?!-5ClC`gt#`?+*Ch12D!A(z|yb#KEqe
zyFkSU_8*2$^!q~n1I|+$m&WH#Ppn;B+`Mx3!li3hu8vJFL;jVjW5seSoh_k))ERq?
z7}j;pM+Nypu7H6xm;zPOIaEtll|))gWFSvcab1=285LA)DABBr^RbX`IIBw;BN+(|
zC1c*S5;4?(LG=qW?9V8^v;v?4#(p4Bi4JEK$m39&Ag2vBWM39gPX!BVm^xVoVv&Gw
zfHt55-fV>)(J7(*X`BSe@fP_z0GQkhxE|QQ_wc?$`}gh><2nutZwx914K?QfN#yCTHtY%dOef(W!;iwT-#?<}&5unjPmRwk%uGXcG+UE;2BM#HEm77B5;%ym+5~4p
zyVC3C%CM8dB
zB|>X+JQq;99U37AWozge(HjKDW*7i4u$Y^fBO!}rB9H*QL_Ecri7AzfpK&5L=MP5W
zDUdc8SXHyA@c?fSek_`bMdfUUEm#b!sp!~4c!QP!c(`x8cRPc`cF*>|-*4Y<-*5jN
zZr=m=`|bPfzvJzD0Dr%Izx{W-eGlO8x9_+Aj<@dt{QdU*_TTaLJ%GR8zTdvzzTdvz
zzTf`u*}muC@3-%_@3-%_@3-%_|9iH3e(-}`|HBVrK&9XohE6F%@>ym6QKG`?icf!f6&)cbbs*uQJX0mio7)zNwUL@`rLL=xT+
zZ>3zHoSd7OT&RuDmB(k1Miy62!%INIa^y1|7{KEXw+RFOk>{6pOVPvbB
z;;5Eu$?2+W6jN$i(K9KHYxSiVjLb-JK~7apDYBfBQ%Nq%rtl9*l2WOps-;v72ML_e
zxN-heN{XhWh@nV^Drs^&t)?;>J|(86LP{#AsR@JQLUAT4OCd=Ls%l6#B56G=OFm5w
zrqx(ljq7qqiU$+XKr-e@Mu)YeS4#y{IiSk{LkZ$IoeJs6pd9rlBi=}0I2ss^1cqcO
zkXFJ*DyT~VUGi&^PlbpMeb-GAR-J#hbze)z!OJn#Sxe)w1S{pfG*`=R7CF7Pi<|iU*6h$>c;s;F0DO&`NEacvv0q;
z{@$ynfA`Xrrykk5ad~rfadvTjVPD4W`1gNdTMHBVqyxZ-ENJE6*XF|_UI`7
z9UmKOBQ;x%(ROpR-548fOpLci+x2FnGCtO9HLGKz^~s4=vr!&x*T&kl(Pm}5U7Mb0
zO^h{hvfU_;HOsAfVWM4~8E@dA-Nu!bR;yI2W=ET)@zLtUXnAU^JULbxZRJ{xT&vDB
z(Jqa(bK|3hv34H&iLnwc8*3JD!TByVl|;;)O0ypZpY+YG?~q0s$*l*3$t_ea_Q9a^7QyjyE#=XweSuk)hMKM
zgJv%Pize2oDrQ9f&>iK-J(P&gE
zm12o2{b@SmNQ)@8^)^aXrPOTH$|a7hZsWnH^-R{_koL4zDCTM$eOW_6Efn%uhHcPL
z-7$tvwSZKu6_K(z-N+~!syJ23rj?n=_IRtF&lxDp^?He6;lBw9P-0BXGQN=!McTDu
zAye6&)tJGz;2Sb&of8<#WkXkM)nXx^#(^2oCz~;9)l#Eg-rQInN5SQar@4HNOPHWS
z#vV7157#w0lU7CO`9eOIPDzPsr8F}=IXg3j4?*>uHBiD^r9v^CPAiI1;FizlvyED5
ztW_CnRdMsze1EKEP@y|%8J9uo;F!l^&2~IW17>PtHXm!Vq
zT|0K*b9UmRkOY5=^MY}A;WBaN&)1tA4EF8VeUNjHckKRG|I5E7`-T&qA&;TwrluFh
zrx(X&Rx9nf>exJI;Vo`XES+x6o~lo-jLt1j&dsl`ZGeF1=U1xDF+E??^K~s-Q`5DS
zR!V6FMa#*WA*p&&(IgqvE0%AP6;)NuSRslmiGtJ66l$^u?G8)fbRuV}mswgpC
zW9)&92ChvgQdCRDH8}wePUE}^dJf3RfSL-X^_ZbX6gjBKF+)q~3NMa@e6gTMiU#C(
zP?I8AJ)z4%Lka7tm?ni&ac?Z-iUjOZY*>*zy6guZBY~J1C_Cv(Mn}Q{M>qgxbp*Uz
zcP1VIg?r?L*N{QXesH-Vc{GW$pg9vO>BE6WmUVIEis+CWbtS{jRCGv+;EXc~dJYdu
zAx|^_pfeG4B*U(F$e9Sc#Ko=@=s7Zy3OQ5wgb;Z8uIEdChwbn|
zt~GW4eGlBng&)nh`G@a6bOgkF|3L=sec%X4_pgtDfXTr>eBj9aU|*d4>-+!ufBfqQ
zMl0I2t(n!C)?z*X5bKkXV$NrUwiDz
z`A5#5f8x^2o%gQ1^3>{2Z>(K8y|li(u!^fez|%AH^9xf`6EicDlao{9;(YoHMlW57WRRb53
zN6En&J{iEZwE)$sZdX6
zDte}@=mka3XY!R|wW+3aAmD6~Yu{yaj7BO(%X2~5j96Hgq2NlDdcDbDsfw1#w>#u*Nv!+O06MjUN3cmRk*L>M(t-GSs#W;us~(-ZSJ$p!6{
zRHafVSMng>dZPl~$fUU}xCqE1gJ~cTTeVU?t+yIgupp;Om9w=vXH1wJj6IM5y2|A;
z_-gR3Ik5ugO%B#IMa-}$;ILFIwm9pVK~TY{;Asd2LzkfjI43!m1DWB1(N?QkDRVNA
z3c?1P)?_#*Ma4(9n@x}?gR>jy8bnI1TCY|_=xa{30!ddH&LG>Y73XFq@N>u7jVYmg
z!I4ESd(OB9_|oaAi7F>|Y8P0(yqMTS60WO4J=O2yFh@zL=HLn{5nOr-yMy9cCr?+tI(ckkNCKS8S|*P3q>
zEW2%a@kU;`Yd35+4zTa&*dt~`?LTzz{!lOm7h1?wq_{dgwJXi*WDW}4zR7fTD%3x>|5hT+JgI19;I{8&j
zh8bW}iDxuf2YIJr8I?1v6bWY66OXvDPe#3l5=pD!v>MUmh$=<2R9H*+Qjw8(a3mG;
zW;9Sc9Clch{BXDN@Q823;vVV?daco*Q;K@fBZ@R6#hp^b
z84o%lKD);?FyiWU*}EKr$A>H@-S%#`tH(dm7Z~aH5BCP#{Xy?w$UhkL4n+M!F~2kF
zw?_SznBNxl+T$?Xen;423%PA!k3BeI^*Z{8Z9T5Rldi!Nj{ak|-UnTllf(9IkG*fZ
z?EF)1hYugQ|Nb8yIr76p2M@ym(*%QLvA^%g1NR*vC6lB<#z!7F@&E|FFnf9&GoQmZ;s(O+_2X3yaH}r_XGi-Z-*
z9=@>o__gzwww7OccKx$=Z@l&5nWwL}z#J-xoNxHLO6J3lu!J39yJotl~+9~+;X
zoCf697NlyKp;=UTL_i~
z0XOTVcC#`$0U9pzxCN(Dsn-h4S^@TVLfBujZ>uoY%7cATS4@C$+xf|{B9CEw$3W6x
z)*KuyxVcSU%;1`tsY<=7=Q44;3(Sr4ZO~^kD@=3FWL7v`5Fv=obihbB0Q-`aM?uwk
zwWNSzVUfq`nTci^oNBT!m`}J>?7^uS8g8T-csC7;3=@ni$H2iPWAHB6*Cb#PHmog}
zn54d)V1JE9Nvo4tBEW_59KZhB^Bdahb)elK4DRToO-
zDiTg=I&2(Q838MzG?vR{__%yN$AAEgjE9@dFvuFMh5}>A`HKw(^Z{8SX_^N6R)mqQ
zS4PL04NyoKR#HbbiB~|v<71;BF<9k#xiACe2#PO)#hc*Zas}kXIf`|t&LWsE#{eJI
zs+d_^%w<5SX-!o?=O8T*9@qSI0XGbg(EAn(pljSb?kAhcHtUUAr2@Le
zhv1{eN5}G65;J}fJ_kfADrBWzE5mBTrh~{wLCbg(BMPNQTlJ~2)@Y+PKRq!$Ie{<2
z4;Iu5Jpd-nfVM%+bkrHR=f=|Fg7C6jF*29S;@?HN%qX0G
zrHXe#f8ct?TVOP^Og6)C+YmN5j~|HNBKR9wo`=`tdMC#Jr9iw#&}YZJ_reX+yn-n^
zI`#{X3zprna|cLw_Ydyf$qUHJI_k>9%qX&2k5@#87=)S{xHAhLL|QrbP8vTL|W&cstn#urQwg0K`Azpj1H&bZbJ=bbXeY)@Vg;Z3M8T<
zaXQ^VMg>)e4Vlrs)TB2N8j1!;qF_Ne=F@orBYmw0sIU8#^m4%(HFBN?!!g0@u9n(z-K0+zVXnhe^KLCbd8
z`KR1|2y1)zf&1Zl@4KH4_{fn5?tkEi_y6#RpxXP6AU$vdSKNmyj@)1uj?BJhd%wb!m3t)T#BYt+Qvh&Yjs{xALqSkDdOoj&gf^^#r*w!)}
z>SVh<32ttb=xf`>rf4E2@3zZR<25+iu_g()UIvF{!L_3;!NINkB#iH9zTG4%n+eB_
znlUko3-XnclFOxp70!dbnspdod@Ng=aX_wZ+rrXsjBd}G^}Ga(XcF-6>l7C;`5bu11_09c)X@h)b#Nxo1nMbpGBiI6WgEF
zdR4}Efn}>jm|7VImtS2sV1L^+XazWURF`U{M9T~BTP=c~)6ELJI1-qcd(gRQ-0?Y}
zUt3=n*r6eK%J^ssM7Sl;98S(laeaJ$AFB$X0>vq!CCCtl3`?PwFb;CXbdK}
zP$;2thnoP)!hphkV*7KjE3hn1f=yB5VZ$|e2^Tb*O|lD{PT`(YAYd_-pG!dC`aC?K
zSW%CLM3!sy8Yn84HCiyoqfN$|&Szj2bv*?Ft~bi1B8)6)4bBp*iO&J+kfn1u@Hcn}
zAIICOR^fRXjYc+;0kJ_!;M>5gge~GR8?8SW%TjI5-vbu#DZ!qt#i#pd^iAw
zuTzyId^wJBpBO~UyykO@PP;C5iN0MW_u3D74#4Hg_+
zPQyx0B0-eE={D1{6&|FqrngCFc*53p!M7H$=kEXb8-
z?iIbmG`l-@u<@BROl}5e@49yF`rB{44VS!=yh}%m{jQz+cHB$eg(1dyu<}lPEG_TO
zZQ~1$7x6$kI`-}AfIr@a`ZN{^Ct}GVmsgf^a|@@(r`E=2PPM03+B0io^BXfO=h*%{
zzcDp;YJPcRX?0_Hb$xnvsn(p%mfGpksGe`gnTl)_)pSu&v+%ws+(I_e^+E;8Namp;
zDQZH~l4%3w59g?-(uRuMlvB}EDyp;p1Fy-?n^r@*98AT%Ft}mA
z4M|OoFu;fw%xGa<4uC|}q)(GVQq&*zyS&5w!;bEN#}@TF<)~Xr`c%oMfMQcz%uzE}
zU6j1+S0?Wc%V5x`OOB5~3drDl{2AtgQmN>$6d6hc9f^<=#y1wQ#=xn8!FbRT^MPFL
zbkcqc_ELzE0ONjZ-2eaM?Z3ZdNv``|bpDYi%p5zI0mc)&hBEJJNt7r`q9}mCm~+~d
zukNbu>gw_)v$9N<_f_rPY46SPZae@IAV83WU7oL3{)%*Oj&pi*ApL*tbVe>Qp=3o4alg-6@N7t6x&As{N
zS01i?@%FXDh3WmxjorPim21npd%K6nhewCkZycW9zj<)~*6xEF2loJ*KxDsey1kAzg^kV
zZIzYw?JUl9K=N!KNH=@!TDyS|TbS<@=Kz1NI0xM==&Fw1UMnZxh-hvZ(=DyvOtor>b|c+sB7!Y=gLVLqsLi6b
z8{oE@>o?1@t=e?6G~F~iRRhZMb+o!r7Aph=41Ieo^UQ;NCamT9&uY*6{Hm5(o%US2
zJ!h8NDWhC!&J@ZWJy(^9rA6H>FU(<6H4b++wpLf?`}6f`zg(NnmpYkj1qOqs0*#eO
zK8PbJp8&8$Vgt<}I@n|jrP=E7X~rm2D^03jsl+BYB?;cqsgyEm8lLxBs6&N75tLNT
zTD@VGiU#T;Z)9^BHnzZ6wwLt|<(m=B
zDw&vce)G`r=+&xbxtwpcInHb}D@#i=t)_I-@{N2QHv#*A3*$_ZlF~HM!-gSIL31N@T-%#o+UPHB&aEG;?%h~BxVgN2ytJ{uDsJb)!{eKaE1R8}
z<#Kbj)SNdPvqrg-F&orUBPVmg6-<`pj3HG|IhoP8tQM%&h9R|9reDkFF<6tK~Ll}v0^?Yu~+Gco(iX80V6$y
z*fn#gXOJArq{GQrKu=8;vXNpw&eG5(wd8mxXrBt$pt9uW%Yo!*PM<2MFe_BDazVSM
zCb$=#L=?F^nbkS-cus@0;{|=v%uE$@$(gIt=8hX6HVIk1>8Mwa`_fUL7K6cl&By)m9!fIgl$97%765C}vBZ=o9(1RqOPHmL9pJ7Oa{=IVM9p#$
z9!*BPvG51MVCnKj?#hHy&p-3j3(r0Sbe|L4K8-Sd`n6YIWuNDsec}1%KlaSizxLd-
z&;RTHUg%VR`HP?b_;3E~Pakd_EHCVAu5PTaUR&PW-8w~y~0?tK2u{r~>sKlt-MKK+x=o;MncFPMY_G+eE
z>37YAx%xEib3Wa!n{zX@UROjdD22Gdb+!jzrQcWeu!2T-%$ADMlzFyWE@hy|y7iWI
zFiBH9)8hhE4{kd*-7SdN?dMqn;Q5}p&=>U1v{AZ7znMAf43=Va8(OECY0FaUcZ``{
zuHTWf&35v=y56qp-MWNRL3&EBk?(R1^=z+U^lF)YUE;a00QePL7^Tw?mo-<#^@C*E
z)n+x@sEANz3nqnCdEW0A?SH2`TPQWPT&38Uu67m^MkQ@j>g~COrS)sqHZjgNRu@6S
z;=)q1IbAHZA&8zSeCIpg{mys4tI`~nOQm|H42;XQYO9c!{K#2FU$ZDPj#R2L>t?mq
zpef7b3#^pORn_C$HO&(3n4(pYeb{0t<8oOhNSvJ&?<;K_O<%@H^Di0>9-ws5c~!J0
zGS@H~twvqIp!nLZ^O0F90BqgRfLWiaR))t}(B4roQ>|uIlKvOXrcBVH^2ya?z7}X&
zuasKK`^?eM(#UAEyj&J)n3trAMg10vu&m#m#&9i~`9{4=5uzFCcB_U~E#!0goKY$Q
z<~l3v(`retHZsbBI+9v6RmMPbgFwK^bwY8TyXoHa{Omk@y_w6VQ+aCox2cR0VaR_iX7+Y9B^T%p>|mFh;JmMb8CB@3oFpK~(D
ztC2162cr(DKm-76h<8IeIgr9Se=13Kiv^KRK*7YKh52#Fx{<<$S!HkL8W9mI}lo
zW05IOGUm%>rbO)KLn={y2>R;D33RZ}GY}XXMx-KVi$+K?-)bRKlITv#JZ@S*aGUgH
zl4Gg3Hys;A(WGNRc0dl=GVS@xV^EpwZ6Wwad5bIbbN5Ie|r7sonCi203$Pdj
zOP2lVF59O2ZHck!Hs`0iOTyj$-0ZZ3f^;RiY8u@3Tj*c_Ed9RSCPJBp4=~Tp!t7eF
zSD&74wA-a-)12D1u?aX8*G91vxhfK|WmSgv`_-LZ
zs5E++e9bUhmG(k1TaO#nk|cIV7Ol=nIP}^tfBDO^y{Vk{U&~}=iuyvi{=M)2;IIDr
zJ4U{o2Z*&+yVWnE#AwIVR6W^Tu`JU@*W0aLrP4rDKyIXPz0sCQN0cwx01Q
zxVQ9(&r*CbH7DYK|!C~$AV
zaHWFz!tLeO$t5i;ETNb&H)MXvUJt99A8xtdxqqUbGdjPKU&=bSg>Od$FU(IbEza)k
zZftF?-@I|Uxv@4sH;uwRs}1jYJ)(vfK~MoCl!cLkUJ29^9$V%7xyu>-AL1SE-37@a
zh=Hx9%M8exmVw#gUWT=gLgNb;&PxQA${;T}sMVxuk6%3hap08#LH8CF5L>tgo&*U&0vxdNzKZ*FBCH^@lHeL>!D+_wnpE+Y>tgvTUVti$d
zw2?{iR-(`I8AFR_wOAfyT+p)FcrKSH7BoYPC8ASWB9ckP#MNx3^Z8`fh$iBJSQyzl
zRm>;yMhumlNruA#UnDrHr-G$?QbMuxkeUEFWTYoU0mu00P$cM1Cnj>4h#GMeMB|nv
zF}=(+kxNe+DHYWWYvX}@aNZEJwBF-xKmMYGK9b#N2ex5
z*LuVwofxyagflUUPe&++k;1-YWGodOOGo8E#BM6&7XNdMjh=MWrG&3D6?Ueh9yX>U
z-gMZT2(p_i5q3r_WFo8z=6?xjFGa&(F{G0IzJU^A;)GX(I(Fb!6`RY;U&TnV;!FT-6^eh@F{k
zEzI`jXS(fXb-LH;w(CH5VZNv4b{2&}L5}pg)#-k1cBVPgZz6eTy47Y)IygnD0hr&VPCav@!%WXs76
zcRBw&SIbwZxMiV!w{*r@>AMw_B7FN;9-KtJ1reNWH;txr4`(}d=qt`@xwdA3^-f&^
zq*ZVhI@k*1;%sN`X!Tn@AO=@k)46g}GwapPLONSd88k$#MtgpCVZGm5_|`Z7f_-ME
z=gOs8soXGSmeS(l%9_dBM(@_WhkSbX{;Q>G3%H_yOQouj$;zxf*}U>4cclNgBz?eW
zwsNHjl`GXo6G2%jD?-ThK-9o)uh(pM$`v$eqg*YwyP%|wax-WJQ5#vrwM?jjngkfM
ziO^Tq(<&a>6ph&JKsY5!P*o{bW@h^A4ExvtB?o*coIyHORY))lhDE@yS}B4$*n>h9
zl~XXeHa(L?uUqT{^L!Dw<*P9{TdgMW=j*ugY&OeB3k$Ot0h+urSRo+WKu8tMb_=~;
zW@ijv3+?OyeUYb)Mia5Qytq`ag83R20+%E`wbGee>9jiCR!5Ssb4NtE%D^WTf}6)i
z;X1K05bjI!i(RyQ1r44pmnz`7Sd_3SY#N!5O=h@gE-kIJ`1$oFmNzztSS0yuuiJ(l
zC~=mYjmzWCEG{k_9_}qKi_gOf1i>PwHQ?#4*FaE4hTvo*@|P=Db?5)fOT}b~>V>Ji
zpsLk3tom^uyYz)Gd=Z)Z=ws&}l@Y@iKlytva|}>K;HnY5m#{C`qU)Ip=PsdrFJAcY
z1#vaYR4o@TJaPHblNV+7C7Fo{x?jHZ#HEXmzx49U!Kt|2F%gdC=2x~ic8}**CFXf)
z>v(Pd=El*TrR@_G@U`8Wd;7N!4{ofjZTIJ{RoaWC_Cm2ao3HkDvym$`4YOtxsQncK
zGsnou1Q%F{O8R0?QnR@IMHSnY7k_{#VW=#@&pE3nSVEvJ^zs(^vRzBXb9$+Eu7OMv5+s|w@pphGRX-O80%-FkECR#RG;odUK`J*WJc72E>kR;dZ3^|Vt+pE
zH^m)2p(BE$qX1Qp`K&Hp7;Gd*GjV4&=`m71wq&B?nV4UXc`|Vs_^Zdf;*PcsK_#ov
zN1C{!-RY>CPqoN9B|4gpj;6w%ltf**6I0Gu(4Gj}6{I~$q|g%I|GGL;yS=yc!|#9Z
zM?d)f*FJsl`8#U|>x+N>XJ6+eckkZY-8(uwJUKc%x^?~d{;gvGeEnegt6#qUw}184
zS3iI9@O0yNXKNR+d~JPcVe#6^>e3R=)AGXN%Iw^7w?EtIbYboEbdQ20M*GURj&5sV
zab{X|^v;Mo8r=3MtS>Lk!c^sdZp}@17G`=Y$mV{t->F05e!D(5-Rk#|Cbf2}s=D!H
zIvO6@>0W()w$<%c`Lxrnv>Pz2KHV1Yu|>gYiFh*mowAAt24H5ZS!y&2B{N+tr2DN}
zx50Lil9oyqDJ-R2D`t94S)p`W#crcGElAEGE771mWVCdw7U2E65zd_d49u{zQtw;EcjCK1ufGEg1HK)oZVp6-;m)OU*fSWal2oOQIaRe9d;SGL?r
zft&VxvD!~(D%pH}W@cq=ZFg>N86o`RAN}aZKl<_P^g^@QE0*edu9(8wFUf#lnymTd
zbp$P`ccy2j
z;f#qWtVlQlwG>(aTIqVrN)VP3ju1siT0&*yrp}-j6
z)t5<$xteOFEE5Lm?gle#9PkV5DzWvFUuS}$eyf`>$GJ672xEHO%v+@fp1Dj
zETGRBGVZ8SrIqH2#Zz4=p>?>JUazmBWebgFr`w;w7LnPIOwcGK=4@O5MnI!k>-E~o
z1uoOYHfsgGM^9#C
z?rgo?syFK8?X7F;Ys;G(tJo`Zv(vO6R;RU9dEWba1j#FIWSIMybo~O?bB_r@FPwjz
zkM7;O&rZMh$rm4e?Bb)3U9yg0qr_W1df`JKIuE43^{sC`_UO6ukDW(EpFeleQoWZh
zK6&xtG4riFFLp+^Rfw*vngLbBXT*L9M2~G*@TP$)>tN0jC5iG#SD6l#Hc_zF`ABzYU~gn
z)1y$?1A`%J8tE*9gFV0%?F)JZv{vD5%#{p_CQe7}dK6{MTepI@-Kqxf>+9L4pR>x-
zAAR;&m4$=y!t?*@uRZ^L0!P4pgrl5Cw{h7JB1sb@1Ul`1jFCD$z_8ekZM)bDPwbR}9{B(bYUHjsHrh&j5
zrrnY8zO&th1s>N{uiNPN8=X#NZVp?$jG+&Jv6R)o-#W`~x8Cno(Y5SD^MwGAuq=4o
zD)*Y@eha3SWK2%G*lrYBbqJT^Bt_G}Mnng9Tcvir)NLSq>x#P)THI+CYh@^f@I^6~
z+6^Qo#6?~eTD4-QS!&hgRFqEBY}HM+&{{$=crW;Di=X*ye31%-o(9+r){&&yUQ?LY
zsOad?*>;&S&(%W2YIe3G7650kpx9P}nj|hv@%SHav}}uhqtKH`E0vlma4^Svsh`O0Po$CPzH2GrP@O2LQuGsNZlzG7ccvkOMMBCXwuSR0B|wzPuKN&qlL6iY3aOKkPcdr>;^dH$H=6<
zS(H$bGjmN~*c!+L2qn2jr`GK?=I8oqLbj?|$RdTIU`KunS6N4kXEHfGQ_ytubfwX1
zapSol3R%5!?UR|79nuE?wYv@$3gP|Z-Wx2$$VnnEm
z4*VZFX&!m(+$H$>Pd;=3#0qF-#L>k^CB4QukgS~2Dh}&0IDPp;)?i;X4*1-o7cB?1
z#AH2&&b@T$(#3PY{G15ri{~G|1bQU|T3pcR;}@QLJ{F0%?CvpNu-Tql+d5g=JYL*9
znO!?r-n+4JdjHzdo#ox@yT^C;4{seG-CEz+?ayDU^_I)+MYBF*R(ct;nk%7wr2{yZ
zNB)*Gssk9s3wa9#WUdV2=8ju+3!4tUW{ngCE#y_^jY6hiB83z1)y!#SlRA*pl99ZT
zGP9bIiRE(asijiUso;1tGO1}%xLZKc8sS9D7mxV$R9GUjvaxhB7@YJ?27KvsB$pN8
zn**GBD3urw_(88H9SxcYVl7lMBGSK`QHidUJ6cPO!_;yvL=h=0>9K-^bRd@;Pe;6o
zkO!e`ZLvyTT+>#}Gr|{591sS}gsBpu1-1b;+|?1mi7^etMv=3KTI8?9WEruEbi|jA
z`nBY^CiyyiMr<6#tVbsF$hd|wj(R0N>s=ijacNOS-;gsAvL_=H=~3pRWEg$?LFiyL
z?&vB0lg{9$o_)@Wf`0C~7hZVoW6wSR#%pi<@P|M6i*Np!wev53@$=8#-2C!u`v>bQ
z`+Ix)yW4F1#y7rsaCm%paCGa&^_wRL4{sgcK3@OxuRi$pS6}5)%XZy3g
zHt+?#0M(iZQX;TsyR+X%nqyzrRwF36+#S&
zvDE7o#AUu-F&fn@J9k>Nv&BXg0K>3chdrzLUL6+ZC=wf`x>rG(^7KMJB&peNK~}TZ
zQhs3R@y*Y)N|bs@ZO)Up4n2aa#|G{
zt#XXirrZ4FGX}$5R#2LPEonNMRWA4gii^%efzE=K
zt?OCT;!L|Ub8U5lHd!)qtgRzTtJT)efBuWJz5lQO>%qe}N~K!HC?I^l|NS3)=evJX
zsx@=P3PsQ4W$IZKp9O1LNN2N}HE8S2X0wHGM4~ks!f6_QXbPk2O_Z%n2@V|*e82;y
zp3zi%e_5b{aKvhq#veIXFf?6b3#yg+R;!xTDzZ3>epO*d1rC?EXyw;c^N`BS#7J^P
z40uz%XnFA!EG;IZO?fG|GbB^d%BJ)O^DneUO)5`q9fim>U^KAjv@}k3Rs9kKzY{v~AJ+5CiU|Jf7fRnJ;AoI$BFPL1hx}
zYNd&!=KS*YwVKtD%v+!f)VVq7bXxsndG-4Ob?vVfwZ_K_>EjDB<*)OxAZ!3
z5)S0sB{pPwritOxY)tq2)6;#ZY>Mk0)<{n~w7q@fj)lhLz05y{{06(_`wfUEcAI8
zEYtn-xr)6~MZG0cV_Ky{rJJw
z@q_jK+sNPTgFA<(5B3gkFRt#ir&p_O3BM}T`?*RhSE*-?UmMC0U;`wW)k+GM5S%2?VY;6Z04`527|JQP8k?6e*lb`i+D)n}n&JjAXU~
zw0;C}Hi2CBTWr=OI(jS__DTr>UDZPz^2Vk-v5<#lLW(yLR6;o-1AFHTYuRGoAh%R23o15;P;TCqjGwz6O(&vTb
zRcZVhvvb|)nGUTa8#^r-aWvflv1YSY>~&~NDk3t#C%UsO7zW9-Fl?crYXY!FuG7j(
zK@(SDZ~^vIOGX{_C5lc=w$ldQSxeMbikVuOGn7FuZ|jv@yHP5eI)yEQ
z@Jf!OpmMF8saGj_qn2q@g<+Ns26!@Bx1Q-WGMz@IRX1o$TXkq71<_3Dwae|gDMUQ$
zU6yz#3x`m%-zlNs8|7T1loib?r2Gf0qUrmvwsjVtr4HwN<)c=^Xw&YqP8Hnd
zXC-*M3g9sdxG<5zDnuNEL;UJ3ER0;)Ov}9EdA*eXfOK%Jvydxw^&HZ6rqx+oShzMb
zGe6y%URhXKyS4$g8qHpzRL>RbnL@Qx>(*P-(rV?3fBo0r`ObH~TWz%Sr78f{Tj=Hri|yTfHb#zDwsvrCO1Zmie4a)7_+kK_JN{0Sh~w4zK|a3WpL&
z1R|+;Y_3*Ot+^sPBP;G-(8v}`1Va=Qil${im({PCF)}DNXb)hkXl=7tE>abxLzvH%
zf~*297-NxGxuE46xlXpQ&OXJWsiby=6SB_5sEaJq)Qa=E(aAPrCLYy^8rA|)Id!FVBV>KvaFD`-sGrS6`P=p-UYpSnie0*<u^rD{g!dEuGiD<#62LwK~iUCABBt>e>-Ucllh6>I(8EYE(Y(?#Q><2hB<$f}!G
z1<8CbJmwB?XT;o4<_kXu?kIOYri{s&cSIUC(8
zB8Eq
zq(2#(EMyag7S@u%semUq;Y}r`@>%w=5=n-lQ)B)y`&4i=qfHfZNb0bejhMNpl|nL;
zn8>Gt$_tGeo+?6REg%6<;jwton@fcyUq>b)V|Nr*V%Kb%Sa&v^7xJ
z@=pWkQN~_LX(_$MyhQ{%W0SU6&>0Ch&g#zl`I6LE
zDi;R@23tD#g%_TG9vpw<8PCYT`oi>LyWTOg_cmw0@#giLn~O&~+dJF4>l<6Udj~ta
z`-ca|H&2i6o}RpR>-zoU?QeeN!8iZ(-q${N=i$l58~1MPZEvrvtODTmHKg#`(&Dw*
znMDd(q}!R9?$7so68tqzp1_~Get31Av
z->%)L&h%T;J=RM!Wz9xK<(LJxCAbTH(Ztfy(Qb>I
zzUfrFQZ+>q6d|J7mw}t;j9jBp0FclN&^D^DSy+qau9XdJN0w@P9z0h|!r(?VS1sxF
ziU1hIigIlfnpMez(X1htbMUAs+FYwSR$zVRRnGaaW7HO*>1Zy
z)30$VcwaB)N(G&w6uc?-hZD*L=dCUL>a*JOKEEoRg`{51wC;a--K5;rf6B?ti|66TEEmoG>h6Vz%nKr$HEQ?5+_NvmxZGg<~MTjs|WD!P`dAYQ9=(W!91R6zlA
zAXmZ<;cVO&PQ~HY<*|;|2g8Lz3FVrnM&v8GEIY^uB6aaxrf6AMn>8c`m!hQ&xC^Mw
zVPwqD&u(t6TXsep^GBry5r08hy2E+2dFpG`@>%V9&+C!%qF*lnROuCd^wOi~U{u*!b*C_7vP!xzN8d$iT}
zktdn-GqnCbck;
zN=36->Ho)ci^U@8R1Es2Qjw%=Pe;OmiSbd2o{AxeY3X9|u;1@R5@+>PDjf}l#(iFU
zXmV6?bY$YWOcWl+BY}xA_r#bd5e*=Y4LxFJW94itmkJiOh!GEFViPjZNLMp4WTQDf
zl8#M81K@B1=)z+)gjX_Z>4Mk*s4fBTOgNhkh{qUY#>bGkg4omqZ!-y*<3R=!Cnxoo
zUyDLbXC^T!!-%yBiOGt2QV~xg~ZawbO
zW6n(6sYM)m)TzgKi?$xs5WZ7tJW|-9g0Sp~DO-GUBpR@V{KL_JBkcbma#c$5ji;Y^
z?pa9$4Thh6=9%YtJ^S4AAAS1DfBsK9E7O~c)7@fzf4=pn50CC_&L6BVgW#3*t)0E2
zogDytc;o2s!OdIuPxl|5?tbkHcfRx0S3h@u|MlAk_ii3Hg-tHk%H4Vr^;
zuY+=-`Kw5TO9T6!M-drO>~us2w-l0<0+tnc%z7IVH^ndAX_jiV)ukM`wL%thS)DzR
z!nIPiDL!psx#(#mQ(mi;vleKfFDtx79a`cQ$%~9eB3Dbr%{BR6*En-L~RS~Rr2*R`Zy1pQKjI&T0}id9;!NETnQIHDyqTKw3mn9ZtQEo$n_xw*5k$ayq0y1(C+7&P{W%2iXZ6d|rid_`Pw
zyj#CWiVO=zdFR^zyKZtxt?CDqCrdY56ewA#PIo$U^;&y#b8BIarg*+uZRX8tp(LRy
z26j%lSt>W6Dh(8TrAXQh_OSq*74I}3)f*kqS*x{F4<*gI_}k{in+B2a!uk_v!3oz~1uztI3h@DE)mx)U{7trWX$N!QHTAYUev*NrSylzIy~
zD`n~BZ9ujr>RCqGK-`kdrqE!8X0zKx0q0>Gr-HTUKTDE|x)jt(RxFMJlUx97R%cLH
zH8}*?jeU^gg84|sENhugcP5)FNh)Zgi0IE|vZ9}nzvT+2l99()A6TQsaz2ORL{B%+
z*qjHu0Rw^+k+ucsTjVE#!*;u)dLX%)nvp3`_{fk<+!gE!uA#^yf=Pm0GYoOdOGXh%
zdksExJ(Esr+{1oPUN
zBm*JRR(4x6EA`%DwKG?2_Hwm`fz4QkzEnH@er5(k
zM8+T$F{cE&+-M_TG`YDZHw$|bMXY1db12+IGL=eE&&uU|JRXijLYkI}MW>>X
zpq5UArX~XuzNz2@TL5!98HtC3exCN^=sT$=LwZsYNowg(DiMlDCL>b_)=*9l8_8f!3mfUFL}V-ybnD4rDJOX=^#q6=
z2fbRtUob+YT(qErRhe!f9UevR=A?61!m0GQHEDh9&uTx#tPb)k@9Aeo?Ln~m*Q}DHsQ&{+>&Y|>dhd&BUW;0cQWYF!ecTm(v(Y$
z02Z+etp(VUCkrXeX(ci%6?LVfu4LFrNkv?VkRuWLAY!tf`N&6~`{+~8Km82cm0ZyB
zdj5rHf9*H_`Tw@PP}^JR%v8*cUgc}A9ewt6Yj1sZXM1~jZDRuj?;RW*9PzqwdT{sj
z^ufu=AHH?)x8HjEi?1Gk?(Wgu)BWA;t!pdmiwmo(*VY%8mLaj4`bcJ65Xsx?fnL=C
zEN^M%_?N~N^eWauT*>6zYRb?EBQbA^AU|BZdC>!%-Q`RXkSb3^tPZ+Fx*L;OmE~e@g15P(9
z`C8GSR0?_}uXU=0RyoJpydJL=rGpvfH7f91tCx&UU8XjI%FwjiEb*3)+I1OcEa+`o
zl2^nolDFF|G|F;XFhAX~MkkkA5({m;Ewg{EDA``I4^ZbFnXth`Ot-55+h{h7R^u!_
z3vt}6Xss%zdWXU4!mM&ud*0_)I^W2bK`BagwcVOtS-!R~zc@EDUoF?Wy*b(|BZnj?
z7bQ@sZNjEHG;N?oYxP#atTbA^Os<&LY5zf(jH79Hx@81b0g+Hd1Ve&mvm+RgV3$1P
zu2dVfMzcRNBkpJsry!(T6=;FgoI;CqShiZ!H!voBv`Xm~fB{>2J#mLh%u&JAG$^R|
zdZMCfA>lI>T@6DL`3otFMQWy`e>4kuSlm)sm?`B_DVNQsQ(BP=s#Xk1b|C>^lC#=0
zd0seBy8P4&*79Baat)l~k4JGq4E9xmZxlBUmn0p)WGG
zQ3Hp-UT%&;uQ)cLri_P@2EWj#cQ_9P?n8eC%MuC=0As<_8_fdB+YovKQm$uiZXWb<
zI2WcR^%6H+I+&qqzglH`IV-+vemj8YUS&85@_J=u1-K&4Yt{O6f2Jm(YKZk33`XFt
zudnvHZSF8s7C%|5S(aHVs{LM%rh`_1n}=0(R(sy_dIZqI)N>L%rLs#(zDdbUsW2=~
z<_i~|Kq9LlOekPf@1=|9WB?K(7!qGNcb+0a(X1;HU%L2Vt9;_)pBxx)3=X=p`P%mW
z_2tdOxs8MQt>g8RdjNR-==T222Pd~5?i}7&THBjj*=|fP*ZNE4&MW}VSDV=i75z;9
z=JJwugFgv>n1Z}Db9osj#~&L*52K7fFb0k|@ny7mQbrkR=~yhmUkgJkor(vi#^Z@F
z!Z#Y5N~K~@cHHkp$x;&Wa4a^(4nCio?a5>$j53}W9rZdU#=X(VWIQ$%k55fa`Nw^3
zpT`;Sd!wNV;MkO5wiq-(S5nnv)iHBT>TIick$-v)&7R)4l$%u=B{LQ5UMtmHICZ-&TDZ3VN
z8*zV5G22jmzyMf)jf9PjB_mSeAOZb%*
z^Mcr9)Rl-h;~~4%`>TcmOHRsIz#j4s1x5!ZyaVGNPBr8n`jpRpWoq;TiOKrtv(G&x
zNjX$lmXg9xKl8$KPjxEV;o9_Uvp82ZKYg@JXz<(tV;V6;FbuBMOJZc#
zq#>*E@RiC)jd~3=Txqwe^;!|oB8cB9g*y7RUSvDc782KL1<;H9g}caKDl)sNx5^FM
zKm+B_$K?_RXtrA6aM@Bc4cW((AVdzYl;tF5-Z1kj-J6Nx$naf|yH-Ugo3%1{26)I~
zgtDx&Pa&5s=F{kGWNrzCkcy&2TXmS7u9nl4QmRr?yqDpoN#wGkGF)e$d>4saN26yb
z5=7Q8dnjhmYifwp*&dp)ta^fr{dSSJsApv^U@I7C+-|Fa2v(iSz+3WDvV^Z-TcXKS
zv4}3-Z{+~zt0BFV3U5tph_l-BKEE<%Cs*p$+jBE>%g|9o@WOJtJ>6(@3&naSU(vYh
zMgA&H1cTy5xnPRGEtn;BzQKCRpHHI{aAg}?cfQN)*iD#JY(haOE%bpUQ((w#W
zte0p|QO#Vcc!N0=8);)XEi33841!#)Sg$t4<0yT=Tw#`~Syw&85M2^jluF1Rj$#W9
zGP@}x%S-8d3=34d6etL``P4cUNAL{FAYi3sIkA;N43mJRWPMP6Z!QvAr_*}BKU*r+
zxC1JLt&~+M#`2&#SKy9e$M8!jiDa6e$(iTp7x>BC0rf+2^=hl#>_`t%t5>TwQ%UyJ
zqp_3(`NEofd1iWnqqrg5KdZFcO)eG0bh~{uKLt%f6?2?N8}p`IGWiD#x7wEfpu}xs
zAMUmqXWTxkJ@0uvqChJtvD7GGu!_c2{kt;hFS1xjY|Y&8?wH`m9=&`449h4c_GgC+
z7cX9ta^W)N@+H>K|L*Vp?$s+cyUkZDwzv0gtZW`FZXYl0oNk`p-@N%MI(YBK!^0b|
z-njGT%KG8#(r%--TI;P8Tk~dPCR=XhE3JH~UMMR6vrN5!O{5Ai&Pe2VfxnSNqGd2}
zpl~{s#y%30P@E0vXcVl*u>{#6I2D)*22-hYC=`rEg2{LorR(>N1|~*h(O@_<5eiNC
z{GN%xSX8}*yB@dQ@AHNu!ALY14Eh3rF`v)n_SgV(aB3nvIS~s>UXEyZRP_*##-;-4
z*iAB2mQ`u+@DU$oP$#VXLQONp7bOmK0Ps!iu$5KS7^c!8n-8=JSpU9
z%%>(3^u?yU6g@tHde)QUG0E!eGUC2`VqA?r@*;M#YQ}|hjN(g7IU^JBbui$$8uAav
z!>)A9ttY(fX~a>|V|pCWy7V}Vcjz$(OD!xV9dc`7mlhF6bSeyeS=v&Okz{B%6&gu}
zY^jhvIb};u4W!f-$r>HBrzBal1WTXQo%i!4sVbjRlOa9*{8KVe_?c&(d@?jVxg1*IE#YJY}UwVX&F!lO|wRtEu53x04=aIWp*zeHdo5hRg6~Vz+6_#=X6%A
za7~FlR2`^g69vp8#EMZX32v<|6*Fg*VlHFmG)j|eU{9I&D_SY#_&S!H0Weof;^JmK
zmr0_vs%44)s+Wa}y?VY;OxKHAOU<3osOq(Hx?a{g_3RunwB@b{UC}OfMBu
zjasJLGF3PjCChnG#wh7#Rj-%RqIzW*l8m{M;Baw(%a~?Vvc!lXi`gGSD=7@)yY=F9
z^MBao_W$gwSf495W@i`HYxU0h+7>luc4o0sY1NxE<$B*RYbhPM*QhmnmdCDCu9sEz
zD;P`x5@{`ikboIL7hoWMVH(71h~d|vAdZWrDm-8d`!w4Uwuj-ylA0;?tOrt7V^ZmCTFX(ADF7fB$W4$WS7t>|
zXL$m8-I;o=#cBENk`Tl&c(B`@o|rqTqZ)P2r6yD8HB1W=P2BB@DZovqV1MukV@IoQ
z<~p{EIL)g~em946qj)@dHs|MNB!aElY&9fFr`0T|`zihCYR~^^zGy2DTHMj_RpO%0
zUAQ2*CoLU(R)oQ4b2CWr^ZColiT#dNKL7ZoOHW+7gb02dLHs+v^E+3s4%%(rLb0=V
zbboF8#{9;~(%$Wzo3HKOe0BZk&d%xm!&|Rz?B7`0IP5QP*L$ng_EH%D*QN{QPNCc?
z6dO6rpJGjUo<#)nmnh^Vwhi`5@Rh0-n0uf%9*@FWsvQPrA`uHmCS&oiuBRiBNN8#@
z7M+SkLz9z}kw|PJ5F8!zjgR|6ljD(4AT%{DJ;4*Bk;vp^&_8a`cg!;x@BwDF0OnDz
z)8!l)_j{%$eZjyO%TRDE92^_>x%__D)Z|!X$~P4NwC>=9(}(o*k3@p*XwVaqE$)Ed
z9iH+fA``LD7(0xQ4h4Mn=+tO<(k;79xg!DRXz?pvB#pggX;=Np_B?N0Z_{Lu?2D
z!(&e>%7OM&L>$y<7#wwFVjg&`qOK(Hik%ZvBk`aO%^jb#Ba2y&2iY=A0nh312N9Dc
z`NSvw-EZzJ_g81y6)m;VseJCv{`H;Jz0I|a^|jS&Ydd>~
z0C;!z=y3n=>oc8>iRz*8cjdul~`)gEwyMf9B5a_1&$twe^LCMHDmiU0hsVSXi2w
zoo{#gJTE6Fr@#E=ulU|Ced$X)e1g?(2Q^Gv$2weXvC?iJWK{!LRpF?0W#=|Aq#KAC
z9x|RbH9L*C^&~;A#Fv&Nw=F!DfGk#23O$INuT~%~0JgNUw1G0E8_%*Dq8i$6Sj4p`&Zz|3!tAuQQpmFdOC(CBq;SiU0yV2h=X|DI5+}9-ImolqEf;_&h?SgirF;ghOyQ%fo{;Tkwp>8n=30$%O?=&%ashA_8b!9t
zu)TU!??@6WiG`LtS=Ml=3IZf*<`S&5R0NrXQ&ol8?50K^Wt8xhf(TZ<$Pyzaea{k)
zEe>spiULClvoQngDat908aC?X4=7)BuGnh#mRgzBwbQ|Fn=>n2!)zq=
zf&rqct!$y9W%5PImL;Y4Wn)j~~LSI&%0$%+^gLQ~0w!NrKVCs8>vG?}lEM2@Bj*WfO@
zXd2+>my|UP2~LYG0nA(>*NhE;x-Au}MY94XF+ynVxf>WIU`>Yi~ec8Qv*t@tgJN}9pzOnM5A$V&ST95V+-?J;4Uxz
z6ym5hOO^+MJIs$_iH*Z=#H{J{Xdl3;===Hkd1ceIxMrT$Mokh|*6WpGiQC1ATUgr2
zaWKT4V^2)@bULm65YiWZR(sy_dPK!AOII$U_WWZaf-hWnTvAucSYa9I3u0M{!#p4N0OJm?rIYOauI6Re1#uJG+dNvrGj7B3zf!8xK51v$GxMY?%?DEI|L@iydJy9V`pPv(npz?@Qr%iE{A<=)MdG>CnrWJfpGx!
zKnlO_xX%fIgR;+#kaChq~pS|_<
z&zye#;o{HnyzPzF+#%A7lU00%8KUd477G
zR;Sh$?$%`n*LH`c=v}3N5ys+%l0hJ?I$E|~qEss4i4wr(v)J=k>9iK$x!I^nOqQe=
zqHQ*dCi+qUj0Fw(0C2T}EUu`;J$afl?8#Ir0f1==A#kynuLx@~K1B^@Ws2)8r{X-~
zgDY|rG(GcOL+f{nOv+g<=FD6MVO<8O1>R=MCNescFQlzmN%*QlPNoi%goVjiKAWzU
zb6~ZY(~5Zw(ALXlK9hpJU>FgMRtDs(i^3K$ZB$EHmL){C^jH^Kb@-Z*lpq3EaU*B7
zSRtE4L${lJYBVYuMWw6cR^RkJG3`~9l7W@cuWmls#J*0+}DW$v6t9i7@S3Uw`4NoK%=M6qP}o0RL8
z2u9S>MvEJdMn9JoTdZ7CLvfo5GfLViSBe!tKywGlRE$rJ`X;gty{U%YHpICCt_pev
zb(o{MhocaHqre7)10ss7lHM7vKm;&jjsNNOra1xiis}hAEU1GA#R<+MV}ke;@=}L|
zE>tpVqyiheaB{#YIjhu!yVOi-BNbLM@GAy4TU{D!HE2hyfn*|Wjr`HId^&|)C@y6h
zYOWJ2fyNvomQT48RAeBnX9}j$UEB>o%QdIqt}Yrk7D*xc*)4;*7N@ktXIa$OGx=(*
z#gFF9@pv+o(x7Im-Q^Y~Qt4D$XE&~y8_318KZNEaaxwB3ssP$rRa_0&7Th;(NUPZ@
zn>>|G_-#dgaf7+N?11S2jH~5ZiTi*amMHFuq!_6+`4)rIszbOoOd_6D{&2j+wbp8#
z)t>jf9yx#RafxSEer7Ahm9>0F<4ULRqmQ1y@YuzR=N`WVu=(`-;}Z6KK?Wd6AMnK|
zE?uC=Fr?r5x4-3fc3Y>eRAvm{>kmt
z&4d2JdUJZUKD|TdHNvN=C;1N(Tlvn~KX#=a0(UREnFP)iXJ6
zcPtuDVR5CB(O4`nITek@SeKq#zkf0~6$nlte5XRuQQx?C%*TI0a2pusZkNqJ=AN7!8xM?*jk#g7(_#0I`Xe&bYNn1-0z(5*(SyWz(LgQxXb6Yk9nZDbHeZO``i97x#Lqv;W44F)2L
zF~F>aCFe#)h9pUrN~>>J6AXJZQ6w_Ot=!JGbjYqDcEgf&64oj&G-Q>5zq*KKR&3&n
zp0X#=!BZoNkUhbkAzM5&k_huwH1S#8c|TvzKK=aDAN}aFA9?Eer=EZIBTocINA@@7
zyEU_9==*DPZ{OZKTwmSY*+BtcTV3DXKiJ*l-TuMB(aG__(f+~jzkc-RU%dJG2S*Q%
zb{<|o-CEgLURYgPmKl)*z)ArxEH3?(N-O=%Z+>%rezDsXK}&uqa62CJitRE10EaD}dgT_=inIur$IY
zNuzT%11lhuq<4mn;fw+Xy{fmxkl`0j1w<=-w9G8NNkR?K#-)F>Aa#LbGR(!3GVQ=w8ZQ?KT0
zB{jZTl7z4n2CE!fGHgk8>xwVhlDv{?Ln65Vtwd8>1rn>J6zf<@wU~s;O|-Ji=#XpG
z^NkNGCaW{Ou&{V-VQz8b+S>NU78-7Pda+PKIn>e_vjB8!B7zHM6@68ywM(^DzEsVZ
z%6YQ@Hx+Mb?rRkxwB+uffK}=N6^j?D6p2P1VqMiknO7fbc6*(6uS-?4e7taung&zZ
z0gh%>h9~L_Xr%Ih9LSKBoW+7Y6d(NNJHRE_pgMB_Fc`#I$`4eq!jc0Ou6R+0i?q7R
zASkJ&41zKcL)eA2syJZ*l#Ct9OYE4ir=q1YR9p7sOT~w*=asLRiYmi@*~rfPG;sxp
zo1QNM%rX-aKLsAc?03m$WD2^LOC>YtU9(tCB-5BI$rO6az$VajohL;M*FsrSV~bO1
zjUNT=xDnL@dnD>m}Qdafv=*EQAo&yVD8isdLpl5R)}l1w(4(nH~R
zBpQ#!6a0Om(P&_DG87KQ<8c@}Hs%dZO$LG#Vesha7-f8XVtfLm`p5jE9Azu&`06hyOIx{W>K
zoCh5|>Kyet#>d+v^y1
z+Xly6BS_@Xq%$1!Oa)vpIEo;iaH5H0q0vyll?bC&AuEd3r6)X^=vt31h;{36NkS>P
zCqrIDt?1XVU3QB><#$xCnuySdd$UQm789APw%Ap1Xc4C#ai*qVuq`<`g6ajyN$3lV
zr8tsPj`#mOqY0LsJv(5`qBAJHT5LiMjcrMw9-hjunU2NfbQ@vu6
zUI2U{MA$;>RyxaFP@-jooh6B-qLHG3Lle{R@nGv2LsKz@=|mzf2B-9~Xh0N}Q}->b
zq6%`*w15!Mvsu}n!WW@5)fS0<;Kf-~H;wWifpIjY?RF^@;MnX
zbcimTMx8@nYs6I9)a#XOLya{OWJ;Komj@K^X_J^+K_lFIGSgAcP<&HbfrMt6(DaB%LlgxFlSZEL2n>{&rAG^+?J*^oY)8
zt6nM
zPXGmM4vEiDTe7e@UobIrC~%a^OD42LT#v_6ISeIyTjY*819
zNhI=@XOt(n)#|c^b$%LOT9podZnCr(P#LAmZRe(m;a-zoCu@=@UffUa7Zxrs6yCG-1=B5ozODzR3;FN
z#Nx?#B9%y_khy_iC=`xHqESTa#KZ(*mw%AOKK}%I7toH6`+Pn@tjps9m_EO6Otz0Y
z94_$eANP&=Ju(Q%1(Ka0+&6|`g~1B9qf*BGUfx1kirYQxbPloms1nd#k9~BMGCbxT
z8S{*IQO3>@;LdhVf=YJr*2`Om%Q@_Ejj*%FGc2Ea96qad%+M
z8So*I9e$t9=R-yhjgLX)k*RTeXu=*v5QjXv%!4#4VbUQ-G>AxbrNV9<62sbvc%db|
zM%1fC-7<4S%tgs2JyH@LLq%+<93A46R{1wzwsKG_5{vUWG?IqR(vj@qBwCd7+fx9T
z?^6B5R@Hf5Ur)>HDH$UC)KhsqeDm;HBcH+Yynnd;>e24@wdL)dm6er+?cKxu!;}5p
zgT0;Oqobqalas^Ujjw<1#^)a%|G{ggZ`|A8+g!i4va_(T$_p91vT_aFe(PJ`;w!%K
zjXwvsR#EwJ$gJ%-Oz>{aSo|fTEvjY4S
zbR`^vwuXjF2@D!IS`8V^!CPsER3oS$N;|0u^rR11PzpzB$!PK{8e@LyND0YB!_I|4$H+VHd2Lxjt;Jhz?BhDRiwF*PQ}88o~gME&8etn(ZTf+ADOLMu~nBOnoY^CDMPJT=`>41Xqmu2Yav-V
zsL{$riUee_y_TsA3Qz1Fu$<0yR*A6x6oJn{>L>7^2
z3V?G3$brVx~TBfaB3hMsi?|g
zv(j$BZjrWDbz&VLQSCUKswRLni?EF|TS3U2U*TC|m1X}z$x!a%a;d6=s*F_7
zwa-k#{umQ7}DW-&rt5jJSq%s@}=p%U%zU;2JtFk}9du4y{}`2R0hDa>Z;&LQolX&AqnFBh_3Wh5yH6lg?kb
zbm8KqOP3_=#)WgR_p+K}Uxxo)zWn&bi&l5i+SaJNMqWb?=QEw_jV`Ii6qNZ_F%LyK|*x
z->moY)lRNl&zEcYa+RBZ=iUP@>leTH#qRzt?TMZ-`Rk{(Ts)CZq_feu7MzO3V(CZ(
z(VIa1`X|G|NPIFJ86ERYOpFHth~3fg36Se^d&az@zVUI8i#KbWo{na3Ei@+shD3#}CZrm5l`
znJo0&G77GGOFY%$k%q*GW0hzVJ*_@vXO$|8lQcgl9ZZ#3M+7e{O;69)>Rmlo
zF{@pbl%ptPDa&;joJS466O9E?U<{3z>hF}fkw8niQbpncPEbVSP8Fhdi9ID_ctjIR
z%~T`QRZS~N&I(K<(*#IBi27#bl(2-Fs$W=mV)h|;EmcR2qjnh?gN;`FF7QL9$w;QM
z^jWeShf~um8(0!^MwdAMPYC?h?0LEhSw1OzC2|oVgPa
z`rHm#Po*_v9%>&{bIlZNBcXe>413j|OcH%#W~rZMb~-c;664nGcCEU@S
zt3B^|i4K;OSZb1B1o1@~@_X*`#fz6O@m3Odu!Aa>tk`LhzZWh+?(>&m^b?P(@~Kb0
z{Hfo2#qSHw&adtt-(B0gxpp85`1s!2yQlZ>+=6H1YuP-clNDoIyt#cP0%tD$j6@`k<>$xL^Pp?V#&Z%Bpiu_BM~?}8JGwJ
z0>Plt-Rr?1}!em%%vw*we^Ji=SM)8+=BP}b-10!*g>
z*yD0T+EK52bj%H0-GWTO%YW+Sb~zm*O7%KmEz%aaqHaB)*TvgGr+pB1@|GQ(j$x-`
zNT}?wIUR!l)#DsOAA8+4k8{{La@935;6puoY+iWmmOf*jXy~C)_u!~|c+@>I>K6Gs
z?i-$*u#NkMeBQxv&ropG9`re;CS2i3PblC@%9IR#J?>MfGo0|)kSQNPulSr%u1eZE
zSn6?CChE;Z;4vh&35lbQbjYrUof!$pa%d3;E6K@WM6edI8?aeowZu~mdR5=BBN22+
zWR{xJ-}*DXudipGdFF*@KlZU_p6@kFCkN{}EkWD;#_jE!d&^sEE6{g&d1ZI+XnS{W
zXLomVdv{-Yf{$(-Zh!rAci%YOzH_wp`>)^G*;-p(k!cuKR@P`SZ``=enSc4KU#(u-
zY_)rBHPe|&mm{GTJUI%$JUTRh(#OV&M~-zqVqJNjI?$S^21ODPh-x1K
zu#VX-Ip=w(X^Yf2IsnFs)rreiYl}3uf<|ztC*ss~D~0d70M4Y-NmvOrMgC&(3ow=7
z)kJYv>#0T;I+x^kd&YJp`5tH|hpnU;%2)Y7{&
z!=Mxlr#ZJ_fNBZMX1iIC;R*bdL_Dsg5;-*)sP(DU-;Am*7IjKVil)+r7*(WmF;go^
zo-FZ2tBhB5iZEC@gPZljKP1Bv4>Qo^qg=hrQJRE6L*iz>DcUy&iP63)3z#lBMn0(i
zVCv8E^4j{^R;k#iH)nEYJ8QPnnKEjjSZ<_r{^Sxi3y)#236+c0tXWBFIo_gK%T>u8
z0lcJJQw`cFSLz5a?xyPKG=!9ZMdq{z1uC*nd08z_EK5;l;;goY@QQ@xPifIb>A$)R
zAyNIQ8O@Mfla;Elv{b}^Y9K>
zILx0J8%^nYzAl~4!nv$bOeGB%oXg7$NEyk$fe|1-2>=5&EJNw+tw`(`RUOjvU0EX!
zdL$&^tlH>$O^uIHmM_?yiaB?%}+
z@}FeU<=hsm;bytSoveyLSDtX5X7#-S{#v!g74hvXTg_ep1FF^r+o>cbrA%zhMin*2
zAtlJ#YBjM`RG>%;q0g!KUCN^%-UX;E&aF}f1)ogo+*%e?27YL+_&>?fan2f;BqNT5
zufpJq7tdW%39!WftWsZn_?(1HKaMsQmo62F+Bc5`(ad>*~
z+U~8D{o5NS_fH?ZwR?K!&V#paK6vByz1P?FPUly48#C9c-KBDCuH5XG>zz`yWyKJF
z^=mTW>sP<}b?c9(I@oECvfPd^0FI}pA^fr;Fy0L
z;`%4X;Vk+U`8wtsM;m)QekE`%?dt}(Aa!g^Jj+ga>~J}qF1C0*$XORl0WL4ug7g&?
z>vY&0c2Tr27`_5vQM$r)1g=f-c*NrzfVD3B6{q8>$2IIm1Um*IzVdcSnnL8Z-xBIh|TC3gZH=1qqu1vomS%NU`#c;LI%OlD=R(P~jGbdd;
z)`~@9D9T4Hc}r`N#|oCD@ba>nMH!Q1iZhvZ&B&&6c};Ow{C5%~npyJbJdA6cKS!{V;aqFl=
zf^z_4b&$Xst&`dnNnJM^L#{FIbi5{eCSiEN-rEE-kJ$o4snIYvdtZ
z9RN#4r*hpWV2{8
z1|p=ku-cNqgF1ACtZHnCjAUv^g>6+UG8jgeAvQqnEbO2xgNr1@9>c9zEMQMk2_dLb
zej<29Hye4r&Mb@LI&Y$O4O1eyq{hnCYBJ^r?GAsrZ0QPAf97(noHwzsxPo#zlh-o>
zQC<2`Fw~^0Si%H3-Putx{zp^s*sP0Vw@|WhsHL*hSdNu|tSr(~1hi`N^;kT~Q5?<+
zOV)Wh_@ZQrT2uy>=_Fr={aUD2nn>1gJQYbKWn@BCMo)99NLcD}BB57nol>dERr8IC
zqt$w|C4Y__Kea3obCTP#!c}o*ZeBKDiYAcTMIA*bgSKnj1k9#tttGutjjjc3PSunw
zW+LVJ#prdOSj4mi_)?{YsnV3m5Sv&vToa|+n`yRsXSL@&FLbaHxGEFYnH0WwS;1K5
zAG`>Fl`3Wn%gdKPeCg8Tl*<=Cd|6_lFa7g>_Rs7#=hZ7C@mOY8rvAOYuzkF8aP#2K
z>xVaAyL0dLdk^2Zb@$bsqZ>;b2aV}#_5Nz9J7+d}#d_NU@ciQHFMc6|L$sNP
z+z81uX1_$TMI*^rJdF=JUJU
zqIAWjJmv$#PA4!O^^W?`wy@Ocw0pg<7QA{~E~njY7u*U?IS%@|p{fh+dL1s04e9K5
ziKqp=09e$mYlH&0+2XK6S@{Ub>w=e#D^A-Lw`0KL71>fSYKbeHovf{MDWhe?!o5v;r`+N@#)d^qph!h{`w!hdVFxO
zakPg_*;ra$pPO4*UcB~&Kl~!+{LXj2J3qhNZuL8qwuoREmLQ3&cu-KcB8aP1$>XCY
z^KM!0XiEgseknTFnyq$8qOQcr42)^-fUEfZB$KT)VKj3}Pe{6YjAGTjM-gc&`c^oW
z1GL}{MncUvSk+LtS!`!bIqmp}?eb|V1tbvzTH4@QNG3Ek09ep#Q4<8SpA7I{NZ{MImE_1Qb#=45LW`bWH*|5Sy7XFvtnqayiqP%c{J0deA41;
zwX9Xkl7vf*N-|WMEgd#1xaJ$RY_)1sREjP@+ik0OY3W7IwqzP8nX{qY%t_)7$<~>*
zD$o1<+Fak5pPjGQ+m&id&z4H{u9hp)Zdd9ZmNFYs0j-OjH%$w!BA?H4GgYdfvs0-8
zVDzmBGNoK)OgS}*`$Rz&*XlBzJ)go|K5aK8R-gS1uqU^ldR3(AQPV&&DiNv5d8mz2
zKP8Q`a9XHuaQCFrsybP;oURn9g?aJ5B4?q$g=!&lsf^r|49pspRWfi<@n9;Xp<;6-
zd<&MNI4O0R_!s2xk@eH~I%;4}B~`XMhM_M^6?F48mfyQnQ!GR
zM!C2xO%JnkxsrsSm+Kfn7Ku4$v)N?@Va@mQE!=-GOo{?&t2co^Wuwsr|C|Awv*fq%
zGx?1yxj($+X4V_6Zg1K;mLk3a<)zQ)GzIc?XSL@&uScLS3fS^9L)nWLFR2xYy0VH2
z*LwW?xhF21fAZ3W4?l7F$q!%t$mL5^bbV52AP3&1n-P+l9&l4#yP`&Uxg7fY~|Zl``VC4+Cb8=c?Cz#pfONk2;jgnqmw1
zo#SX?8Dwk^j1EnXT@CuKh65wvNk<|i(+|g|9Lca0nRq`WNj4;a3pNK`$tg(8KK5kT
zMv-8vurnEP!|(W{izT~>XjXZoMf-yDNf#v*bZa4RG9(#1tg7?AzMlWcM?U%S-`!a1
z&$MbFYkP6#_wOGcZf95f8XoQ^61uUk^oDkkZYqjtUeyrL9z;utg?l5TD`iO
zB~8?W>gWZ_jb_6v6(u56Dc@SXrT`<(IT&OCnB7g8XU!VjD_X?zEz9F7qZ?@;GD@fF
zv{?$A5KZ#r2@~~fTILuLwVO!Ag^Fn&1X+UWI517iG7ejlsYFtvZL<7woJT=d&PL%Q
z)B`0JL#om+iEk|$;}GS#_Kr=u@;XecAfy38YL1K5p0%>tPEj-E=bLGw@t;Qg~#%fU?nP+bnI5D^%_dhD!V63V9d^JVQ1Bwo}~g);W2qEcE%D~5+f3ex!UBM@i;YC{H7cWI}6T|DvsJazJW$}~>#R{mln9aJW=5^*Pc$5&$
z+;VJe>55kU3zjj#Q^KX@(Cd;4o8OFq-?Yfhsm^N8dtQ&6Q?oT7Z7-Zd_+GjsDJNAQ
zu(+coYv(xoAR5Xa;{3pc{@QMfFYu{gdJGV0a=F_4os$0^l$kJ!1;MW8=tQ@7S0}0PB&J
z(NX?!I039zip%S8xE&6caxjZW+KGyF4zu!)irwL`v4RjrD?5b2ikgtv1|Zpa#07C(
z!*<62SapM5`=G-&)Si41F5aauH$?T(Q_$FKlc0UIidr`qj!#WC`d!*&Hh%u#$~
z8v(}ZE1bh_Cm6o!bt$4Fqj~EdaHEo)!#=OWKk8%&iTy0yHlJ%GIBK8r*{8-vru_Ec
zxMOO<6Q1-&COwlrwv2=)>@lDlb|=KiEV(<t-L1`y
zjjj2GrS1KLo&BTT-NW6T!;{0~>o-nr9B=;FAKbosx^?|<_s+q=+O_rhxn;`jTlYBI
zuYUEb#l_WH6=^GZg3t;m4}q?PR5X=%U`bmi$&6UCrbgaZ04+@$kVO)+n+o^9#5Umx
zt(tU^si7Ju0i>N`*Oja4VT)kSTB&!=JX8fu&I{N?*0XgIZP}NlFkA
z@e1Z#{hVGaK7Svn$)J
zx%I}(wOW7KY)lvHU9;Ny%Wq41gjZjCBc7NV%VDBjCog5tt`22w}U%>4dlb9;6#6q(IfRVsXiKvpeDVN*9zc5$;
zYX`srRJR-G3U?_s8!}hW>u`Zv;jz;xpE?{vHi+v%3QL$3D5bC>GS`9Rz3P!@tO5JT
zRhMnZF>=*u6OXibo}sTpC=Op8jsd&<75ngu6aehBy==3+GBSLHV&^F3(>^<`UC!yY
zU2(exkK
z%J^XPv`A;G>b$S7-~8wQ;&^Lodu1hOsy`94EC>zHbwHvve|4~VU55T
zEut)as4otf*dbQEP~1
zaRbKVP?_dcoZ);RB$hl35?RC=x)^)I>Q2rYX=_k2OCyua8L3jiP{WHQRfwecFtcot
z>{@D0C%9Y8OVC!mQc#m0%Tl^~t9cQ}3eVM&NaThZUX1*ev{@CI-dGX3(5}Pm4=660
zTG#K**Xo^$>P<^$piHe)X&{DVcu+}TteSOcosFDCGJ{t5ig`yhlR6_=EUM6#rkvfR
zZ@5r0sckZBn5tM(19xTG!Dds2y#Yvzh>`(BCSWK@7cF*?*mpS@e_oNXs#IXhIZWY;
zEb7BTAWgmHBue;-s5R9b63Tf4hN-#&V9rJDkU?!Z>FY&Ma$#UbxKga1=~v|<#%K^2
z>k@oVO`tk}SoTCG11fe9Z?p1dgK*>^l95lP-xs16O0@7CE)JUnRmJ2xu|fINO8%Tw
zerZF;hZo3%wZG+SLH?>}th4xM85|68MH91fk@pwQKYBr4
zY`J{t0tE!0|LBt!2VcJOiQjo~%sV!}w6?Z;b8-7{Vee$`=4(3#x3Ay2^Y&-ozI*S@
zjf3k8n@6qrjmGS?#`H?9HCL>5i;eDIC;;EOeJ`Fik{O{d42~w#Fqoemn2J$?k%T`G
z9!CLBh9;&Ez5%a4;0sKRjR$3n(O6(?bYg7OH#$1%bh!Ym)8iHHy4+6JC>VCSycCDi
z!_qD8Xu+*ry#O(wJ)3inLV>b~p!Zjw?>*
zRhLt`el4%EuomGf1)(go9b$S7z?g04+G4j>&t2*yTd7ot^tbUA6w_v*p-aU&?S)w^0azYat36_g)lb96
z2Ndv3^9PP;*3^hb5y8^SYlz`bQI2KEDl|={G4>@{JWWqZH{xkMrVy(>(xEO)WL-Fl
z{7ocd=-Rjj2;%}*VW$Euz}A$g1*;;3*&dCtU8oF?qcLkG9gVR)0eK_Qn8jeFo26@*
zuTUpX#A19)GMNy<@{Ou_MHZ){a&p!)uvrwc_^&MnXRz^sFN%kTO8nE7gIZ!)Y0{BY
z(nG9du?S)_FL|mFPO!PC@@+{pbxtOhP?XJ<%uKypu(DOxD`;ONuf%G}1WGb02}ozG
z+*rJY$I2Hi@zvtNE*VzkdB0zc?tH5|ZtGn>GUX!`I)6
zCZ!u7$zMXxhm)CLG!;qclcD&;WQ3(JfZm<*2O{H>(NX`D*Ei{(2#t-0T;2(fZ_?un
zxV&l*u*6Zhoo=t&I|hSM!0N3BdCQ7J)+J2Z;TS>PI^KD~W9X}Td8If|qK*-}IFrTg
zjQq9R2PwQ&?qcXD0Jc`x?r;i~ZNsQu0kCakU}*RimK3lmpdI1uRoQ>!701Xch-2H(
zOZH)rzr#b82);Tzbj3PEcC!>V)R!V^n4?&_?1LWX2=Z5@{uow0%>z!5>=JQ2>K-2R
z42`)5$47^Ko&@s^Mhg4ADp&k
zQWF0&B3NRl&oXs{Z5kWVzQN%$9xDcaF#W+R3+>J2ez{Pb>-GNV^;>riHuraTS5`L`
zSJw9qPWJbYcXsxU4o^;wPH!BYe)iRq&pkMK_2$vu?lx+9Wo4r`v-pKC{t@T-!WX{S
z>Gst$DJ>qkW~19`_FBy@B7hc$b_Ycaerb}Vd6NFQI!&SK7#2~&mV$(;NLL$=98HfE
zVuIokyIz_6v_3Ra()TOwSRP2)E39vWCP})=l+P`#8#Eu%^(FnaC|aGShlWNeSJkbn
z8L<=$K6{JRA4}>HII8^BFgPx;%@!%sv4jX*N+gzmrctGL)u{ljY=N&F1(G9C;W5Qp
zVTW)82CJjQQ?0%l#LBwpW(8)sFxB^V)*Bs;z-&3cb;0Z}KI=qG)4;8`J(U_3YeV^^
zb;AI_7K3F}u@o8Xlr2b>Lt54}Kq<()PaKd!E6XH|dA*cRS4xsvt5V8Y43_kk(nAb`
zRgvMs7K4SpjjEN$gB2CMRb}G`GEsK&Ym3oEs%B|3#6;)NCyu)uli4IoP8L=H=(Qenxedst!=sJE~UtqD|w
zt$@8E8Kf!7yDO6>akxO&;x@2X*{?VY^_i;9(yH51?G<|Y77Qr9LfjhiUZyUVsq$q{
zG_C|TV0rNjU|gp7+snWt3{W9O+{
zE(m~SY|;gZg}!)Eh9oHfKYsDz<4-;H>?c0{@=Ko@nhHi&*S6MouP<%iSUJ4Ccl*_i
z{nOXqc;n%N*X})deQo<>@!DZ;exo(JR_`sF^=_`xctZtYedViP57T6%^RZMen#@L$
zMlhO=Br~B{S`9#oPXxoG{z-H&#WxWFz+>Z6zVRuSciiFeyT&H$o-yZ`AML9;eaBG7
z4$;0IA+87XI_+Q=3afRO8{`6D8~WCIfnmF2*zOo~LR{yt-9Dmx)HX0|gS7zI!E%5C
zgDsb`O^IE~$O!9$a8%^1p!X_39T~YgJaT2k26vUB9eKq*bj3c*+bbg@FRLZQePwv)
zWedaXW*7Q$o~y82{L-S52OPr#2xXWJfDyq!7fs9(QO;Mpq~lqFt64!PkGieQTxvv<
zXGrw1d&ut@33x{)eItQ!+oazf9(P2>?Xd}GeA1Pia#=GVB|`Ria3~oXPKJjeuF6I!
zDWg@sXwkk({*K6KB?;`39YC@SZHl-)n7IqrR%Yk>jas>Ow7&eMH%^atw{~_8W*1jh
z*0=T!Pj+?>g~3NhH*VZG+1vceAKdxegZ*2F8#~*3>({oHmKKjsPdUlo|NY-j&&UrQ{LfxmC?v&MZ}|
z02zzHnAI|-Llm&cKoCr8lQv{YYnVd*W+c8rf1t6V<0-YMW<9a7R4OVYRjdWN
zX)TgWMiR+LG8IduSyAd104Jd`Cy|2WO=yvLDjZ`^hzm-kix*^CJF^0Mtztn`tytpt
zU7>si;AkAs@+s$$9p3pU6$(eg5mdKavvmlUr(DsfWbsK`4Ax|vlhr-UY6>-+1shT%
zI7foS0kW1-Fcu^mqK~x_W{(=Vq~>T!%UluG6i+2&F7iaWepP>PuGNraShb2)ElCU)
zxNTHT<+Zi~vT__ku`18|{hD1^?M^Rb3zc%MP16s6kwG-aw8dy*T56hIX`{_5_(1>B
z90TBHt0TjWL~B+!M*M%}YaKop-vO++wI6fWi@KL#6XHFiK5i(gti
zqOwiGs@WN)s&0EJd;!NQ1uTVi4u`F0&{d%cKuASz3A3>gSt{i!(=MS(RmJA~Diaoe
zRZJ&cc9F=soWNLJw)EOU9j>3k{>ijhlK@D|7P19w1Bpiy8`SFkHFyNHq%N$bB5?@y
zik~2YHO)D*R4`G-=?sTcIF*b`GPnU18F`$_B5*NukmJdO4z{gKmZq9;2}G(f_7Vw&
zZZ4JTnjwS1_{nnp2F#W&XRa2*g{!yhBowG@B$)3kF|M={qj{n}7XVzw_@uZX0oxE3KV_J1bi^7Pd~;PVQ};+&?_N`R1E%
zyz%IbL=>ir%
z+9uq?6JU7EKIwM=4-<{akv|Gq#`4F+^)r7@Q5CBWfJaG%%R7e8Obc|
z)WL1Y#xjNQJ=4LG$x;R^eIRo-9PjTmD$Pc{@%y)rKX>=&aBpXAV|QV7eHQ>99K+v(
z!_&iq)7!W1-@ShHmCxM$(rYJoPd4H7wUy18{;cJNKD}|f+nc4->TMX@YIjvIR$Gm)
zudB?sbr_6_;6VkqJeD+nmd+>^(tcq_^K|hrE8Cw(RNSx>go1RA
zDrcbbWeI?llUW+3XiASDZ6)Sk2*+cokS4BRsAg?ccD+u!6G7u9Q<0QfCX(TJLU?RB
zkj4Kjdn!^QSksZHC3BPEh-7R9!3w~@7|EMD6Tb08I2yCIScL|~glmoX^ux7ihRIjwlmR7FT>jjylkGey(
ztHWT+&kO=#Z9^rB5dh0ra;;b_v}9gtNd?1Qmy8_!iKptVx+_No|L}
zlH&}103AW%zWZBF
zWA2$Ha9LVr6I*h*ax$3XjF-_`JU5)y>tNW62A>dvoLD{_5`a*Wdi?!&l$9dHccg#_`PZZhQJ#
zyT4rRF63*ya%+a~`^7JQS#I_xBB=J9*m6ogB0IH$TuGH
zj0Iru=tR)%3)n>OPI$cIF0aq-9ksjM4yVWNlGKp^*rxJjNXiWHGD|>|rH0`#MTQ2m
zWCz{~aS^_}SdNU?hlXuZhDHX5mBzL7uH_}R+{MCIwK6<(Md{svVW6vsD=uZ_UPj$o
ze&*ppL9BZF^3d>0LqjhO5534nc0(VJ48H_cg~7vD9KzaHh6Z0A8hnWz1muEh1hmkd
z!=bf9%1h3XmspW;O)BUbQ$Uh|IIaL-3FDG%T*%^~G53JqGcfKRn3O=RA(=vPd}L~3
zBs%E`jgLeE!;!#HG&uCm91JqpSJbT}?m*_+wWuu}9??`Ht%L|-wDO4Mnic>@>?+~q
z2azXhXJeyOtS`2^pL=lcU~7AGb7$q+&hpys-rNfAS|^o}OK(wYt?-r(%iVcE8b(Bv`78SK1~C%PPxwBpN=8
zzO-UAVQ2-AOryrS^qh(CrFjzRz-~O%qHc{WYE_xokcN-)DG3M7vV^#(UIdUVEf=&D
z9q}5ctwDySbV@9drZG~j3C}8z^gn1*DF8Ad3K$-TRAbbD4M21+Fa$UI~k
zaYl`3%3A4!i>651N-?8+&N7E_tyHjPPE_a>k94(YR87f5T`NiEORMs{->*h{zF47B
z_0pLl1rirZk`Jp`0jupwwVp+%s$nfKhKfX`DyzZf08i?RatLGoRcf_tKF{3(j}?r>
zb{qW)fT^5TZ!T7yME0qU_L5AIR2OBOFXUvNB2mW5mnwNExuFHKC^ljal`YVP!Ms$(
zMpDbEV7&@j;2?45$ha|dZ4Nc8LKXzeWle-2^eXByy=
ztBb!krR6}Tq<5BFZ8`q>d>5CN&C2j%O~R~@=Hgi9C|H$DA%8QeR0dl!oyo>h8oD{b
zW0I7PVM$ae)~)!cc{Fl4F$L1;Y$AaT$8V`4OqK0OwG%>fsSsLvml3SFqKq|ClOrLH
zISCgAnfWLh*Yc=X6#@-+QM!OLr+Ca4N!L$8Posm+ObY2fPyj|l%k}WrWC_$2{xdum
zm=4uiOTkr21XDPsCDYjuk5W>TP9^zuISH=D)~~gj?fzNqdC%*S3l}aw`q;&f{rdm@
z{Bs`@1uUsKEvMVhHrLoyiC~7i
z9w}}Qx)tb3AhN?I-MkX|d^YrF*fug^bK2|@<$Q)@;49s~!*CY>15_y^gCiqD!^4Ai
z$B^(935(d36;v$TWkvR}jmZ9Bcxd>_&=3Fy&%)-RLEwrMJ|i*ub!hnIL1FMKstCC`
z&)~pIinuSI?IwG^G&uMvI6cJ9YWqLJIV_i6Wbtf|KxoP<4x4Ch`^ca}x{U{{@NAZ9
zP}88-ebwg~@OuZxM~7Idb;&p_Nv9|5Q-0f&&mQtQBk*{9I2ss^O^Rz;I(lWUB!?RQ
zYiA?NM9`KD4aI|l5~8Jgj>RcGHJk{35Mz@T=H~NeeRFB`3$MSr2Z47EmXjWnsewE#>}I!3wgRE!m^
z9>sc#qGct4ajAqaO8{)GKwLPg9LN-baTp2;)ubEDvX=#Z@2pT1N8=(yV{x@En3V1D
zv~n6Di&GJ$aV^|VMPYLaTb6=R3$xi0QYFm((S-F@!C0`ZG_l%8xv~ZGF)%M7B*N@)
zA{vnpt#`jyU6NcdT3IkG9o2HR{Avj+qanlOmpCnnrcMcp5mplAozW#k%Zk-f4L%r_
zDUe|>D=bx75516QT_#8_7G&-wHJ`FxmUPoHUk*JE%u0tYSHeb>2Zleg
zxOu=5)&?}9uujQHkOV57Zz@TrtOBrAs4X&xCuHq=1jJBwpJA-+z$8GB<;`sUN?5>7$n}
ze&i!hKKsevd-)R|f6+fSvAnXrv3GrG`}+L$jg6CsYx}qEJ$&=d{nt-U@2qSc&#mtE
z7B^ZmE0y-VQEKfTUFXZb^7TK9W%7Zj9!}+^5(3~*T$>E10+EC-7)At7Ohv~gLZg8x
z&%~5#d}?IWZyy_XjZfM}eIuSx_n6=97U#3gIXdk0j<^uPNMV=F4r1L_86IKX>2y0C
zE}P9Eh!t0}_?czIk=-#2N0kC*ZFodP@UYD$1^QCJFzR+__$mbqTdrmbJhoQgsL*%h
zDgcJQB8!J)J8(T?>d-6iqL-CHwv32Y2GZ}MSFQ8uD}#t*z6I?IaZ%6U`Ra?7hE^M2
zMjWf12jojZGMZQdt*^RmLv9tlr5Jq0>l(0%3ZIs~VT#W)EJ4(g@bXh*o|gl@;n0LF
zJPvUksj$))7}U2J!z8=Zcs)~v|1+&wj|XOlLvXqF3k#6trNTbT-I+Gx3G
zzgW*njI%5;|5?&jzKdSfktT5{Jo!A3tnifba7u1-6@Hb_^fLfM)|AlKdMnVi7%Voj
z4)Y>O8TD&nOz_4>N*uEtD6%vAL#3IyXps?x(DYjZ|s-k%ErQ)Glv*Ndr
ziG(FY8OU)<&nR1|!4;9+GBd8kcD>`!mdsXsHANiJ5+5yr4qS%lXBEIq4d;5Ow_F43
z5_l#31}p_61yfu>z?o~zWV1XR?1+^G@3{aG&N78QqSN5aEZIfT*EFq3q7<8zXwJql
z)O0JQQq4UnHb6=c2(W{%1MOnX-}&RKQiZOv)OJm+s#(HQmtVwozKGu
z&oX1bqOi=HbXl@Pt8v3JvH!)#&z-yQFaM9<{N3OA#L$&NJ*Dp-oUU#i&2J)wZ*Lyn
z+dsZ{`|fLZ9=x%!f4aE2-(6hqENrx9S4yoJqulwy4}Zj$Ra*T(G#!k=U?ZH;r{d{A
zBpr-q#zRS8FzOG-MuTCef5H=(@&-a4|CD1i;P6d?;bHff-RpOHd=B>*Qg{RaJ3S)~
zugx_&?C_4*UCQljm(Eh@`?bU15j!Gxm~{XPgZaD9v&W$w=4%NvWoUq1teR)oMGT9(7iH(q#k7BOM+yDZI*(6fxYT=R!(vRvCDRa;9y^FfF$0ublQaU6qW$`VmOdS;6Dlum|YSUwO
zm9>L?SVHBqw-P(84g}R!)p=iEw8jOqeec%Y`_~b<$IENmD;xW}$G7(mk9YU>A3S*L
z^v3<`x9+`l|N0-ke(U(?`tI)5+S=OU(zYdnH#T?Y=9gQYey!E5)LWRLFu2)}>ClzV
zkQD9pTH9*GFo}i1YIr5Bp;g{(D`}gorc+6l0+zd$QH@Iy%ou45d5Q*yU=RS-ME+``
zhLf6jp)DOOKuwDLJuB8Yc*S4=aGaI}pvp%UR>MNmcsLFqSqeS{+wxH|d=_jK4@Kf^
ze}}<KBrr
z2t39DKtO|VVX#aIr&PP;phoaYkyst^MDveqQaQI+VGD{0JpzGgCZ&H<#Ia@;5XPuH
z;js#wMq;3kb<;%8@oA=*%T!DGaw%)gYFq)d6|+*#m&*ucRb(2(LakURn|b!JD$o1<
zLim!<0RR+v;WRBXe#%$q5R%6Y**q%d!-Sw*rr2?YW+89l2;4^ySZ5v^8a
zOfWl(1t1=5)?`{FrHtjPr4L2Wh33mCCo<3l$(pc~YsqovP0q_oK96Efx0?04cW%G+
z#+%>x`k#IKFaGkczx`J~{^5_l{?)I2{trI);NE@AWsZ}vv-t{tb19-h^D?|$a=ZwD
zd1~MmiW#c00%ZYVA^|uhBnp^eBk~dOW1UYC(>kg&SCXN?(NrwSuQc<;N(y8e`53eo
zM>p`ch^_*yA*Er)<9aq*MEP_1yu~Kr)*@=r!~kB`Wl{%hXp6yeNk)NBIhLoJ9g3wo
z*At6Vu|wME!
zzV>G^%?w1exR#HmjA$wojHf0diHS(cKN<4}0dT}U5p+*Xy2mFy<3R!NsNe0MuzN;F
zTwdp>f5bWJ@c0C}s-T7)u2H)~#`Y@Kif`HG7(o@=6pU4Iz+iaHcIA8?7_kphSV7AU
z4qxRc<$|{QcLB3-*J7$HH
zPAz25gzdS6J4=Z>(ZL2QYO>*6%%!PZTEc8=wttydc-X2s@9V2nY|PJWzV+H0#|QhH
zn>$OZ+t;>FcTaBb93F1&9_^ky*uU|{_TKSZ4{p49_txI-{^8N->e}{gm6r0m-~F4J
z+4;UqwBA$6YiO%P2iNMYMzdQg$z-K8n$?=P2Pw#ra;0hwJm87tfu!98y`mVDc9G^u
z!c4?jCl7o^b^4-%c~&L83`oXImeChyj#-uR!dka%I*fd|*6d}?YBrC4Z7XRdq0UsZTK()TO*zdvlm)lI)#}ku
zRvhe;{$aLQ8kE|oD(YDpROLV})$8@VWMRuG7mG^zpk};>rq<1bqrerbv0ULiGLDEX
zmJ{1DG;?ZP5id1lPS7jz_YA<;KH`d|R&#O+S7Ir0Rms^Mi>Dxej-0VDH?zI9{`OmM
zeE)lY_sd`W>{q}1`LBNYi(mfyto-6XVC(}(j3VbeSf6ZEJT{A^s_HWq_dA}D#@5{
zD=ooU?Rn4Zk#mnecJ8r9&p&ofBCu3|vlt=PPq4%3rr7N65r=2U;ewyT!deM_9~Ss9v=G#wI<6`dSOgl)-)UD9SL
z`eu_}5y3Leu=ic3H2PR+UwcNSu{2^b{ctuunoEoolKy;hlr2`(d0$_ZdT(*@;P&kY
zh~V}0oyC>yjoll&CwDduPB#y49pC%(%~!v8eDluRZ@zl>`mMu*ql3ef#pU&{eO-p0
zzy8MC^Ybg6?o6xQr->|;B~gAuF}PG~W-!vr^d}?&3ClyWH>$<
zid$f|&?|(t%Gt3}fUe@SXlU6k9|@$D1t3R>6I(>^S+}$$h%FfN>%^n3Qi~+jq;HaG
z%StmMO8_jPSQ0U=@;4zjc(D;RoK*>jq$q#13=}nxzgEOn#x!L}u{fxULSN8}BrBJ*
z)oQL((o3amwNelstHL_Psyy%aO9f#y4QzmN!y1MJfT=~M71pQhHY!X~hdTw;8!VId
zXY&|yO6680lO-mg;(-jJEtO@&k!j{BrIIP*tWxP$BIae}I&vKhs&2^eWkGy<+C{
z)WOc?5C8sefBDm&D%}1|6`=dGcj+tT=RfDbBJRNjv6Mv%<>Ykzs60=7Ql2A
z3l|&3$nhj5^_&1z#bJS7EtS(m>4M&Zk*`oRLypR1CGJ{rT8&)D6r{sQJlj}C+$$L$
z49sP`azeuCI438!l2}ZI695=~(_&y)azAHhXX|yD3c9x?crZ&R_l)|Kd0Q&A<3+&hh=lt?L`757&o(@yb~_pB*NG3_SuoY
zPLIPgHsbUQ+Fe6V4{wK^UeGJyS5Eh!%{egQ7_>QfE0N7=IFah_mB?qx@bIAWHY0xr
zkiR1ikUTOxGH5AagQR#)T%g*g|)IL!uMst@F0R!
zP&y`38E%&W`H|K1GCm@5;v>v8DoFye66WyE2#OB~c^5z$CzS2i&U
zkFBcnzP`$>+0E^H_aD5uvwL)Sd}m>GclY$(&dIHf{TtYP2Y25(y!F|ecON`>c<<)*
zyEjg6?Ck6>EUa3N=&kMj`S~RP+-gskD_Ew@MiT(@sB|k;TFj!%SfeuC&>AZ4(uPXn
zb=I-IPa36%ye
zMG2v955A#j^gMYwB)YX!q#RkpxdTN=G
z0HZar)~MC!P9uwPkQbM40)sms0)ur3+!Edv*^W>m%xjIc(pJ2Ty%>vX1@jgFW~{M}^ojLuo@dC%*S#~!^T
z-Mv7653=m5s1VmB8jnJ*cXg?0}=aZ!0DfK`U7_V#K@T6<{PIBxkpF5J{!e728@U7
zh+tH&XUOhW#WiGih{IVjSDh^-cG+eZ5j-M&!y_`{Na!m=iCCeiE?()xMgES64_P^%
z1*ia6h=>wZC+}zA7yytTl_s-;ol^CH1r@EtMES
z#c6?I+I$I+){Rsy4-x>d1qRhgthyq3iCz=;sRb12i7c48vKlBXF
zgmk^TLfArHI|L~_j{J~Fu@cp0t=!ZZ1(T{)n!ylcMAIS2@Kl;f}&dN`v{Frn6
z{4f6UyIb1_lKnA(vMid6I`|zCd|8yS>KH~Ef8-+{`Q6|B
z)bD-b6~8~Qwso*^bZ2hsc>Unc_VN9L>kl5j`TO@?eG8?svU5DWvfW+WXiP67WeU~)
zSu|FACKxxS5=IyXr!&EXHXcb%L^WS9J~|QhO-3aGYi!cxpQ6~j$f6aQF%`S1DlW$5rSR$1<3_a`h$Q;*}Q%uY7XwstDYHE1wv;`iY?{A0K?>uk#g;
z8pQu{O}9=x8J;X_rdG;Z{N6i=kVZUZEg3{pZz=s{^^&$(x0B6om;NA`jwib
zQ%C+<{cSuU7Hh4ig@&@A5-F&5697vBKN>-b<%?EMX-ODF;Spt>N1X@QlDSDRl94>m
zY!u{3Ahd{Jt0}QoET6Mg6nBNS;#gMPib%*+LOH0>zUa>Q*|;DprA8br8=jr*f8h(C
z|K9h$_p_h=?8iU+iB*2|gCGC!`#<{O4}SE6AN=G8-~b~hqefj5yx;B{g_S(zvh;Y-5}ebqfcCCOY45)Y`7HnT#Z$>z>jqy*Ad2kAFzL{TYYu?H!3J
zrbH?REAW#(9UhsakxH>$dW*#ata@aTw!B4mB7);_j9TdomMQflv$_aVIfD?LY9?M~
zZZ&4B#b(PCwlIv?wH{%$%!Z=?m3KvJKopP$>Up!8R>?;AUMg)WmEjJnj%2w8mRuD@
zqSNz*Mnk61pfRB(;nrbGQoZ>r{NKF&_m>>Umfwr=4|!|p5T5>w%+<)u(tR>Z(!J8m
zXv`sDySu#i-h1z>y?1EufbK@a0|W?wpalsMAPEu#2@>AWoij7iX!O3{hyrKc<2(B4
zlEq*mD?2l*Dl;-Z`@3Vu4%|V|w_b1JrZk(Kxcs8m0oD`)q_M;WZ`Gckyq@}%NL0Cv
zlO}P-B<9Q#vk1$S(G1A~inspikN))^{n?-VrhSh(7R?+ubYg7r(7?>v+}i2c14j=X
zJAM4rxijbAnOQkHI(?vLcm^W4+C7@8boY-<<1=pGxf_gU9bV{wq$iZ}MbnNz)Q(5p
zAF()nHmA?(^64!uy~U%qx(rq)Rj<*mHair0Gvu$vXjSQrC>B2`k$FvTg65?c4j`cJKL%
z-Ftqsd(X?ecE7x9*DJer?cB5bmA!jdz*^9BFMz!VWtZF{mXN}b+VZd5*pBr*IN@&u
zfJGsU@vZjYTeS;sc1Oo63MSjysa5XPDw)YrqueXU2b=UACY{QpRT??R!yY+M*lJSP
zEefj%D|;=5-EONg=+=iloLx8`;53DCpFSBdC4#0z$eQrmQUOakWMWuW&=mI>lL2iq
z2)V3_`Hdo1CG_zx!QlG9;^E_O96fq=Vd3ET)Z*Ce!MU{)H1ZY>uN=9!e)jUh;d7@?
zpFV#0@WF$J=H?dnPc2^l;3^Kh_~zSvgQGpYLzQ|rq%c6s&ft0%piAx+n4}&>juM89
zNT(qem|qZ$DOyr2fo(j}SWo8|Zi<5EQx+&-JiYWYi?P3vBur_xVt7`=*ht43|0Ifx
zf=+m;aXBW~2R;c_iCk37c;yqJ$ew^7#q0OUVMsU|+S5QVP%4)`zy2v&uWuhe`sUH&
z#}6Mpe)!F!2ai!6+OpkY9j=)Mo&O9Izz%gXx@30~y(Zh!4VB
zh#IEvC>7Za3;@?Tfe-*5!CM)zB`eR*{Q`p%=@Qy*h+wp|s5~geGD|E4OMyAF&~_(M
z_}(QkWpyWznaZ$T1_A+LG~@Wy5T>9b-r^+$YlcC(0?F7j5l<(@1cJo^=Nb_VWu!E~
z3_PPvFBX}NQaD06?X-Y*5$6%nTf{JyxUlp}=kxeD91rV9E-8YUsVWtL3{G>B-E=CK
zils~0{Q80A-+uGpx8FU6-u>b>_&%_xJBU{QBl6A6_0G99*7VxN+_C?;d~u!*{>CdGl6JcRy@08fWno
z;|)=N0?}}kK3=+xL`TMtEJP7b=`7uX2Dx0h53_
z_5r7HLf9MeB$X~oESZPw4g_HfvV)o50Z($SjGY--EmSX_bZkt)a>`X=A_5Bq+8Xu&
z{=|8RMSOd`UN4rIVKjtm$5|a|Fp0U>IQ?)w&lwVN-*M9$^&a3d9?Rykm3Zv;R?eq3
zZQ2I(0>DtiVuTVHyiH8#5BTobzGcU@En9bN-~J!|{eSq=KmJqb$ws4lZe?S9abs+8
zV}AYAOstCEX5w|{I*MuDUnA;d~
ziXz67y#40uCr_T4TUb22vA%!*?B_SW#DT|8z6ufC(=!MiT&{M4!B2EB
zV;A$qA_M|duNW2r$qV`03dO=YxhslbFvk(1MM!cQaG1$bZLk9vh=mkpXE3&i5sfgt
zrEM+?S_FEhgKli+0B=1|!MtUeU1{@&yBKz?f1Pcn%#udhEB~efRC7
z$B!NYx}-0-d+*NuJGbuLy?qZWcW>Xnd*{KO+oE6vTkhPyfA7)#dyntk{pQ~N@9*CK
z-JJ)2^}#1!=WG2oU)1IgS-pOnHvkw5BonmI#8}#&aM$SpcOjJ7N#qb(nbViG@JwdQ
zrDQOquxvwRQ-uapm=`|^Vlr5?q+FtDi-Z&LXgb3rf{ZEx2{=%ReraZwmU2xHBArM^
zVcTT0iF77`x7d@x(%2)JE&x1v+%P7KZZ;}_aW0#L4i*EJa&{XrofG0y2Z9ko3|uT`pG{sl+ZvW_*THMvY9T
zIiW9hKvRwt(RWTmL`>~f1E&F0iBDKCg4V4p&>W;2OXoOqEw$+R7Phgt-}x!qh89BdKUOl};2u=uD0+06r)d
zXSR)Kgw`OwM3`ypm{~RokZ1BJ#ag3Os~5`bR)~qnFBnO<3k~stGzPqJi?KbQtJG^<
zwC@>foxwUvx%B(z5B}9ZdV1^T&098Y-o_l!JGN|w2*!)E7|NKet(&(1!+-iG|Lsry
z>E8d6xTVXU)C(XQ%fSE*zVF?MTXlooZc
zD0D{?!>!I>cC4Z(I`-%^dm$O$Jb(P*oiFZvedFsdu7B~_r#G&B^7$vA@72#f`Vibj
zxpw6;id_HX!}mYF{N6{G-+$-L3x!;A=PQ5q%FaK3W#?b+-1W-NohUB@#VC9B?A{If
z?%la(57wU)$lrah?B2tTd-u}&Ex5ZAE4%l+BL3Q9vk0OlgBgP@5^|}SK68(%;}wl^
zmrlJ~rf=YU2T2gp&s=BW{)7-WGBx5`KtggRD9~>#KWo?fiu+$4{JHSXmpH
zT$otem|Z
zN8>um>DACuu)v}herdXeuH3ox;P$PD_wIgs_x=xe?*DN6{%^m$_3g;SQZQb$
zc_I!xcb=f#7qoi=0I=NyBn$fbLN+l<5QZ`#?V3L42{y7c3WkrvQJV~14^R}yHUpEkvu+rm#RUid4N
z9A462&A=x*F|x&Co{5u-#Y`$)F3}gw>{>aFA(oZr=YG{Y2jZz>84YWt$vTrMqJ=F1
zz?^*+Z91pcfwY3D2Sp2@LfV3wz#%FXsu?>zL{th+87u*+6t&%nciX9UY|EFBX5Uepj=wk)F=*a
z4n;G8aM~YA`2w)^GSO%@63N8l`DCg9BPX8DfxHAWXQ5!eXq-P3;;>^J4pW;OQ}{vI
zKmgBmCKk_z@f3?>>@l)D6G^6Xg-WB@T@o{Dgds
zU+i+&{4=wwa|e%&&L5gwItmRufAH9AZ(cre?#=ZR=f>v_GCdYkb4--FhU10KD>6Uj
z{IW9?cLfvPaMB%!JA-j3V0$oT_JmBXpuri`*}VX;&gRkEoEno=Ww5A?Hig~_2CIw~
zg`T~?47SpUh-kg3U1MnHY)8rtm7+td#EMdQo>eNXLZubSv6%Y`e{BbGm4I!#@J>S?
zV~Y&S;$Wl>;Ft+FcB_@U^y=NIuw8~+b?eI;Uta(C`X?WLeEHptm8FAo
zv+rIwbLG;-OBc_7@b<+I-+tqRx8J(@?xm03fA7lsm#)75-qrWszw+LDeLY>f!Ck6h
zdZc&m+_?*ico!%O`3q?bB=6h}`tII^x01noD3OWhee6yaZ};*o1G4r(IXxenDy(TfIq1B|cnbklt1hLi7?zX5H
zBW+WMTymm*Z6aVu295E6p40gIGzo0+8h~Npc~-_Df&&1vChAcHo$Vm8*Sb$uouBnJ
zFu8vAwM&POoSdFpoS0tPzkFzZ_2}a2@u|g)wWF^eKX>WPOCP><{_N`7;g!Y3lZRJF
zN5{Ss^E6D)E_e40H@gQa_3m7;#t>A%Sfmd`5oF~^5^VXA!Fe&aD_Ta#6j`WXGK`jl
zph<|SPvw&g-2Rw(1NJze!Wjvfe1r2b$Yv!d3fc}C`7A}SBr$LW^s?)hF6basuh$pw
z`-6Tzmte5l6PTWw`R>u9?;k$==Ha79P`0;jU3%;7V;e^gtsd%Zc7J&J%4gR;JOA3n
ze73ZD;LxX^e17Bl%`b0!ef;RD*Un!2>gL_Azq)t()&of4`}e=U_u#j8AO7y{!@qw2
z>KDFf-r|m0JrSEHWOIYQ5W!)GP`X%x!9?;C&^lWH260<%YKJ=r^^6s#Hz@Lc2u&g8So4#+Y-kN
zzv3*{!h%Uh!px${PN${B4R%sC6u~2$jl{BEe=HD6!YB$ybG`r=-0Egd$}aqJ6$MQRSc`&<
z_=qy(ZoMhJ2q7V??D=+W0TfMXM>-!fshUX5=96T|za`e!Nv&Ub1I461rB6*{L)T!wQ3?U1vmT)9U49za1=EF^`}^sZ%PM`57;*QmIyg!AiQL
zL1JtKcd?DBuv8)uhjL$sYHu6+fcHWKGt;C4A9Lu{37_-)i6d9v
z1CKAm?u$pGyLP_3bLVef+4&bJJ9mkG;@y9_d-q>pxpNl?{qmmOEPMAr1ivhLf`MUd
z`3*(zlebt(;Y*LSj1j}z_LmjyuYklt4KrJoNNT-Tt=Oa2vxmh2xY0PQBNr3Av4ar^d^a(VDQ=6bqOm93RZUtAtn08I$}Vv@+uDh!B;{OZ^OEWg9^2aYUmyn6WTdk2oaapwFx
zZ=88`#(5oJbCc9Fu+ddukQYKWcr}R6F0dd7FQ4qwt>E$u*3bM|M~y7
zFoUc+4j!@pM0LEfEvRE$Nu;rd;v0?
zIkvC`7e5mg^FZSRI6O&sBcjnrF`vEs?pwe6?(uhzAAkQ1>H7~E3@{5R{P2f|_fg(H
z|JwU+ygu69HQC?y_|{i9u3nuS9DM!sshgjD^6>8M$M^1i_vjlknEl9P@cyZJe~=oK
zN;C}Pj2!)u!FY?u6LdsXkxDlnPka3l+H)c{3MQ|_v*a|6jYLs-N;o_q#~ec_CpdTs
z&t`(+9yN*HW*m!i;=v@a#pgp|eFx}4EL}D!Q+PZb?_HEmq-L@67_?iFXpZ%*p`C~FT6ih5EADLV}JTSAi
zc=*i1`iY~bUpw{Mo9}#hZSKI)iJ8^j5spf#_Kam~y@_J;umAdQ@EOTM&F%|(!f{Uo
zCE*Oj?EZ*75H-02W>>)E^lL3Hz13~Ba&jcK(W)}qR2F-i-b7!t4#m{2HSW{sJ5+j^
z9*bj>AcfT&7A&Hp^$HE33lR(~tJ+oU7*?PtH42#$8X)FGgrX?hm5j_1Qyz)A831&v
zxnsDua{K0|X!Gvfx(No~{^I)0Yad;|a{1)?a(_Kr&4f>^E*@Q33c1V)zrCxJyLA5C
z>nBeneC~6{H$Hmjt&iV-{~B7sD<3s#jlFx@cJJQ3YZnS%Pu$V;NTbL;U=Vi?xGRP4
z9-tT7cZ)zRl;3o;@78G*0?9ku_U+lXmtouO?YlUYA;%)`REueslwy8EEOlz8%F?L`
zV2yH@QM(Teh7Q(i_i0tTtj2b`sm)_kxXb_!LGiwAE=z~ks&?{iTiB@8eQ}f@-sTyXN$l#uldglNboXNuy
z?W#7qi)-=OKHA?|pmk{&)B8{cz{rZ@;|#eWiQc=#HD+F{ojSJ7jeS
zD23fDPWq^$c6S79W@oU(Fb5VB&(bL^z0(rLY^0tHSi(B=Js9lw$Nhfkd1hmWD?kQ|
zG(%|e*s4+oL*lZzmw1H+L%}=I{(~-HFjw%xpFv&h`D1V|{+dc9vbj_)mns#qjXE<{
zaOSxp+CD~Ufx(6RFBFrNuXM&zg?y<|5}p;*9|$1SC|RjM2muWGqGi`F1Q{A-*c{kX
z?p#7u6pm%8R*}gWZ%NHu0b&cXiQ-jAUhGh2#%U;NMq`PKCp4~1e#uKm*FrJ@Te2p^
zaT#X;ZmGQG9K-BP$H_SdB3;lpuW&YS{>gX@=L1D(8^sgxSUeI8tt`y{_S>7JYc<
z_G8px)Z}k*1PiKVxzg$L$HU=tARy-oqq8I^VxBqrC=dmABTln`iJAGa3bx2TnxZAN&ACQJm#4!2Zn*c>@UbL7YZ5&T={yv$>~j#
zc^Eplvm*Mv0plhdj%CwD*h95yr|c32o7qi}`~72+wmkjJ*3COmc5HiQ`_>(sH$en%
z7dfK2WTf=d+y3ZZ|GWR|KmWT*0{A8?|{OR!`XE45Aopezge<
z_8L*lF0J0G27}GEcB84oU{dIe3XVtOQo*2TEp)I5(PB?9wsff3Ps|=-$zYkFLtvP)
zSfLTY(2903B?Dd5bX+Ssl}27mtbjnBUP?BmZr
zxpM8wdmmrEJU2eB@7Pn%Ctg2w{N(zb*(-eY!;i0Cz52lw
zG#p?qz0iz~eg(o;L`pMcdiQQ@A&fy*5v3)1g7@rsGK83eltc&cD|`383RR{RJ|M!oPsR&Yf?;OX^45%agQqL
zRVTc^M84?0iM2Q1zIx>7>8bhEk^Kup`{!p?kIx-BJqyu${_@7j3un*2@y2WC4;?D>X1!ghrQ{N3a0aLazYB(s6_*O8TNj
ze=vt6fzwH}n5ldworj$(eNB)P;W%?~Kn;uDDL$XXuxJ$Mh!z8o2%ZoVU#MTD}LkfF5p0SZp5dw|!@X>=u5AQ#IaPQImyN~YNy7%?X
z+i$=5?!w&C#n<2Z^poqKe*D>mv#-B?{*Bq``KwnxfdamL``+EV5WxWO>BBePGL@*|%Z^H^Dg`cs|iLe;yA!SX3qoo00a0M^mmI@d|5v1V^
zdY}U3u8_iXKQkGH^h-mv0nUkZCZ5eDb4=5bu9TrS%Ro)32>n+Ch5_J0{uj!VRqq^5
zWARAa2^^C
zABr;w=Rc?Ymn)f6Acr-dk_1EzA$p>kuRlZ+`jthaYqn3V2Q~oI3OEy$9did-&ahZy1pE
z7%2bi!Qly~C&+ptoI{kJA}k9OB!EMx9xyxd!4PaX(a{S*982Q~@&?27MJGgzH1>xD
zEQ70Q-a&Li_2zuRgg1}~MzYaF5ipJ=3(*AAfJEaNu`@>o#?$!#bA819p+qd2i^n(*
zBW_tl2yw7HnJMEFJ%Ol5dzXwQ7=eKHp;qIFBiu^i9z)~6xVc8N8|!h%?l{bJY++*(
z$1P*8eyLKS*BUjP30MjhY(Z(&o}av)+WhoZPLae6SsbLab<2(|92vZ0>((9Hw(Quk
z6?oqEZ~xE#@W=o4&pX;xFsWA8U!7V$JUDl70S)4TAc%@J2GOP{I>SID=8UFA6Ff9YM1vVswTy7N)3#6xN#T
zbU_>KDzg&`n0Yx2SQ7D@s8>QP9^Y8{=Kk#mcfY>-^_O3Nas4X@jZZ!j
z41V|6!6lznH#ge*=9v?V<6}{mBN^~qx_I`Z_ujtt;rpL`eC5+?pIrOolM}~|Yt`Ca
zJE4FDgLl8YbGM+ca7XWj_TAkIjbNESR`pfAu{Dszf;3JXEvA05$<
zI3gyi)!&14#$iR-9}Ei}O(8vFVmJhK@DnvGW+w!M#9$7G{LPmhHpI*Ch^~$yP-}~^|$DiG}
zeiMe@#S3qK{L!a3KEL_(S9hfX#`4acM|T;P_5H2;zx(pe4;v?6cLtJ1XVB;fSlys+
z$m|MPU17UR>R^UI+dY0c5=oXH*YPD?95l>S91#Mm0~rh*7R%+R0`V5|3oB3yhFYC73MUc}
zrW|*~K0>DQC?t|8uoOy}eT{;_`0aVdXK_BINF*i=lq7RURG^e`i4yS?aLXz9VSJQI
z!WW&v4lr(Ts0@?F<-$@(VOb#B*zqhbZyJ|WE}<)Ntju4A!^OQwMPqoIz@I%X*K4Ow
z1H(T&26U;0fnh9v`1afHA3y%~5ySMqxp(L5>z{sp<;tzkKKt^ck3YTq!HugQ-~8m$
zJJ-LsfAiKiVDNoZ-)|m0{OyW%Kq;Ox@!OS@sIjwS|*&|dtedgqJ
zy$h`hg8(4FE7+Oy!QhfID!yESX#}gNReOH&dP>A&ZNqZgmS?tYc@_oQS0v10f(|I-
zt(&*}=l}GdcJFG}>&^8>eeLk6>D8kn3x}4EoLyRf_0`wkzVO!jH*PF9f7dT7d1H}27B1-3|SmLjm4pJaJB}G
z#m@N(Eq0CBuGE>-2BybS=}ihPxw{t(7P45S(kqxS%h&-htJQ594Pe~HNNJ5i&540I
zE3k%Rg4-c^)v9*MV}W5wVopA&Y?p6=X`NPKGAbh>_t`Ti9zVGK@b1_5zW(CQ7uRoH
z|MbSStDjx{;Dfg=o;$H|?&QXM7hgMm@W4n{=c$eLtC!ySl_uxF9PgT!Td5(OSaj=bulLB;H*j!kCHy>kS-H3WP-Y+Pn+`n
z5)7^nF2D2cXRlwlG{3YlHoZ7HvoN)GZ2Hit{Ra*&96o*E*y~45UU>73bBB+eT|Th!
z>fzO;#ijQ@dA&V_0qhPXV
z&`N0ggc=qTgL5QF0Z@QpD*-ISI`A-aP9))uj>ZyUks6vJSOjFrW<{)vKrQjiOFsSm
zx|fp!0$0)l#-z~Hl&xtJT;71!8(f@Ud3gVuhxeg_S)haO-F|rM=G`loKe=%3t=C?A
zHGbozA=sR~F-@5hq&b{wHx_&oX9k6&~W>>_5
z;tbndQL8Hg27|<4u+158xJg{QCm>_BWVn`7xT8gU775+Lun5ueFfKYGCt?y9<~S?y
z1L=E5!Ea~VDm;Fn5Ogrz(a|uca|bX$Vl=TJ3IQv^dL?dw0U!q}z)6Pgz5=$R6=O#!
z`%1Y#qq#V*0VOXA&|9xnvY8ZgaHX8DR(_$eN&O=eQGCNBLSug{MU`XzDx9QPg4BjehW?A;
z(&2&>L_W)0j^WAB+_2k#TWpbjZCoqiNT4+-I)7P%O6F}5!PqOC#C}9Bjbj-1JuM`N``knF(v#*6m`>hV5H8
zWuZ)uwUvK>K;HDLKmM_AnvJiZ=8SQ(&O*GegEo5H}5@|
zUpp~6v)Vg0-x%0m?H$Wh`;w)eci#H|pRuxb1Pu0sGv0907fv{RQF|a_3q}lXpUD$2
zIDA@*$6)vAZ61x;sWIAhW|!9J;Pec76QL_S(jDygHKLHmYMnx>7ilR~?HcVqwT?xl
zYf}QlI_Abws}velyPB?MPPwmc>rfH8?aUg@=x7E=E80YiH0NwkaZbZ_gF$K3cf=#U
zYggWXbobWXuWo+*#f_WSuR#zWUS5p)93hXjR?PM`Dg({x?D**WZ@%^E)lWYA==z73
zuJrfx>vUS9QK!)=cJ2NR3NgI*WyoBP4<>Z?poq?3h+w&d*ky(+IRdy%gkNDhgfEH$
z3>GVUMS?Abk`pvZ0Ar~U4AyYIrrm1IUY&NYUb9=Td_}L^Y1ZyF>h>CRdvxkuM%^B(
zai7!NW;eGxtqS%En>#`-b>xD>GfCuv}Gv{xPWD58Ev#HWaOl?jeeVs_|cNH69U
z)?z&!G-d+EWIzw0EUV7X`l|NM9XtQwx!2#GTizI(S{|I3pE`JW_Rz7(r9%f!TwHtg
zJxJlBM~`eAJ9FyH*)zuvFU-xIdi6CNc>Ttgz5OGdJ&cP+$>b}Aa-+tvNzF=?4925^
zr5u|CD>%zU?VN!X51U+~$mS9SPn4i9BRHh(907?V@sJqTFC2pmx#YaR!k>l~1ZFig
zF=Mir;tor9AnXmrAR>J*>iwJt2@g3LM)}(!F{mu_M0&hIk2`<@+`RYhhmY=mcmM9=
z`*$AELG#s}+c$52b>r)=Xdiwp-O*Ryzw-V&m#EJ+bN<&`elI{lP{ESr`+o7%P#G1m;Dh+$@(GwQ3V^jzl8(bGcmU
zZ1$9jHDPuzOu8%vx=4!z1?xOXxdLMa7EFT4wwMkY7{=90C9~mBoT26^0bSym!;4cX
zT#o`fQ#b)b24@y=Z;;FEa>o{&Sxl|LoEW0BAi=>uoarkTiN)P848?SV_}r@>USYQ`
zxXbe0_uu~TEu`?{hmRlLe|-O*%!+mY)-4WHzkm1P{d*7ZJ$QKU;p0c&-oABzacR}=
z@|$g5tHW=11$@D{s8K=i5*0>RY&6$|kxJh(ewiOt$QP#dCdMy$1F=w)(;}hTpom^%
z5*jP0UDyI8%IsIdz>TL0pf3&-BZE1R0U!r@@h9kPb{hrb{y>bG$I4Y0PN04w(NfZh
zbRM4q?d$Y~P^G;hP8;7x+}Rp*FpQ~mnzJ%sBknaUd$bbbTj8qXelWljUk3HJT4~m6
zUAUF7AOY`st+T*EeX{|t4EiQp8DXucQ2g3fD8WdXP@1D^v&|dsfn4@{?Xaa!SQGFrJKr9eV`y*(rQqDk(VOhSg!QnOI4!Qg~o6F#E>+LQb6tK~%
zHQBIK3STrytRsorv<8%RrmNJqYax7F*`b-2gF2YdpPTOv^8p2`!@X+A9Z@qo<`WN?Z-M#zO*MPAYD}3$7C!c=)
z$+hdBT>JE+kFQ+*;Ntn$Yn3|m^*+A#fTm)|FVG8(%Mrj&bgk^=WvDX>)(KaZ-Fx=z
z!I6Np(7V5BYx_+{`)@kh{<5Qk=#?2X+uB}HF*g>cYT)2tMVnf&SEB@F_o)?}F-ZhP
z@573^W2Z^iX4dV40@kT^>eYLU`h5KBs996mZO^4ZE57IR@eeP*ic|
zp;W~^%1lt34e3%oRW_*4g^UTWDj85Gf|^vskO&(<<%s*2=npP;P0p>KKlSSCbIV7^
z=hg-%7sr;?r`L{-EgTwKJpSsXFIJAcwz__3;UF;l>dgMx+1aJ>{qs2RZ~o@L_YF;S
z^$t}VJ;h2hTc~2$=!fuT8BmT3-t##
zx<=yZa<0Isw+KHD6)nS_D;8@|NYF_zGC)D;WClS&N8#*6Q_a5?3LG*N2Qi9tz@V{a
zh?Y>RkjbL0X9%=pFxu`?ktaceo=j#0ZZlBEsHQwE3>x-{CPCaHcPqe@p$j@)$Y$s`
zWzTz>GaG{BAhGCmPBF>>k}l4mC-$&Jph1CTP>_KRP}OphE>u64%Z+c+-`BsgwDQ5_
z559Tu_=m^eKYl>|K6>yC%H#XrJiN=0g$MT^i7nqgxcB(dyC33d(i`k1tJ`e%nQR`5
zgZU8M9+;R!tlKM0PhUv5ixO@>9n^p;L_TVcFAxDQp>aW0w;v47MmT$tv=vg32)=(F
zG{rugh5;6^=mWxY7fUiJM*xtV`7OcGv{EP(*_r?1hA8tq6a+k
zhI}wbGI^+Nn37P^zEC18OvYlV3Xaxlb=XE|4Pr4|x@;y>sIrr|A{qydXQJF|HBwXV*W!_SyA&55HMCbZTsFwQFRiIkdml
zKUU}*$ke*4U4!_H-~RS@&OkJT>l;f3M1Qcu&n{tD<#_VZE@-Syox`QIIW!i#%4AiW
zZA=!eHITt#&V~-1xlLp0U@?lR8VFz(W}{RqID3-5oiJ8+XcS6~nj?n6V6}n+h?%HT
z@|YOzQ0{ACm>%gisA0xuiOG~8n#E-PGJ31Spi^tr9Tu}b;Pc00sc?{vAefXMx5w-8
zqVoEDUaQrjP`2-7NEK&8+Q<1AM0QDLfu^o)jVxkDX#90=o7gBu9LaG~;SB@^NAD@_(azu)b3J3StU$LsKV9WJla<;!GC6O*$?kDh+@^!fAW-g^73
z4=!AM|H7LetRFcuFfv9YD
zTNF;@P{~)SEahKn{@_~I5OY=L%lRVYDKvVuTInhl>R2h2>RB<1Eq)98afRo(Ag0#A
zMrP+=77kW9*di#DzNKoZT!A1>lfgh~5m$keEXNaQaDdNBxlt@s(YT|nj{?gOziiuO
z)D?$ZM>x>|L%^^ZR|>4n!hB4K@GB08Vw5$Cba&%(a1NOZa
z6fDPI17SeA6iMVf(8poU^gsu=2%KgDOU{JB;nZUGUrtAurq2e~wpcFWj$=z5cNrHA
zR}2>xZ&S%kl38eAGUgkN1}ZA9Elj1(&YtrBCQp{|H?sp6^cB$Ev6UUe+jnf+v32wI
zZCjqfU;p^O{^@W2Y?sYwnwuJX^~`IF>n9EzJ9X`&_b}e;?o)T{(k_v$pe
zbn2ZZ{a&lF&1P!HipkJsHnck|3ZFyiwRQOH9RY{NWm9WB}z)|iPJlR6wIfF_%&(jnojEYHe|~gf
zb#Cp%)XLG(rQ=hF&d;r%K63oTJkw^KS~_rObYgmFZ1SB;@8Q_D-oDh+H(YD>qCf|O
z!BPjKl*)CqdQt~ti6VW`VueX7C85D!tVk-u08b>P52}DBKp5jK21_<$1sjtEpj*q-EN=D>vwoqoZf)T
z6L7g%pq0@=da%Xqw>dl(P}bqGxx99#*Xr;9x@I(acAw4RcfiJV_^l{pDhqH6`pPsN
zHg^D9L^rS>0Cr%bGX&g177Kk0SsZb=qYe)kECww3BJ3yj#azCG=+%Si(DDJ|clm-c
zzJ}=(0ztHc$v}t~1Z^Uun=C*=BF;H~P|#B2Ep>{(hHyJGo(PQ>ig2rvCESSpvP=^V
z-IvGRV(%z3AXJKlS`|nx;Jj!TtCdo{@(ayf*f%s2OOR}Uakx!3rxg}lCE<4FBPid#e+
z0N%p%sW&=B-#>HWqJ?SIo}av)5*@x{|NI~S
z%gZnCu^27Ob2D$h`Of^>@dJm?+_?VX)%V}Ld*}AuySKmp{`-?>-kg|Q>l~bJ4oo!$
zCi9KHbh(}^*Uw$#Y&IWXyY7o-ebJ0Rnu2NL_Q&u@n_L02H(>I3wRXF~<<>jgdYfBo
zcIr%ay~Wv~wnTe@!l+eCRwZV_$Jc&=h-2TeGwwHln
z&X3f_#8{v&i~y{wJ9euT`+#03V2xt8MhOMnCPxPAHT$4(#pr>RmQNyWOm?
zo0V2WhgByh_E&fvs*qa|^Q)qMb;zv=x->zDBIHy=T-vDH821|EJ{>3<^QjU6RWitd
z!kGxbY{-NyOknBN#XXu|CMK&{AL!~^SU+}d`M}Zf>6PJ`mEqZynFH(ND~HCHkIt>1
zTRHyb%Es~KgB#0h#||GoJ~1&pHZik!U=7DUdi=O|Xsp)R3n`p0)}VA7O=#lIQmt94
z)PnL{A)bmd{~~N*
z#&A;pitrG*0t}-m5uwpA^I3d>7(HDguZ6VzMUxbB`=~5`WH6O6Q)u~J0Ie_JaC==|
zpU3NWLzh4nJKYW{TCWxA*6Fc1oOZj@>2y0C9)}Yo=0>a2Yq5Lnz%9WnS8yJ7`by_B
z!*qZ#A-{Pm92!Lc7>&44
zCsYzKhK}PBQDbo+Dq5~YoH7C{kPB$r&`#064ESW}l+LEJ=_ENMFibEL+PO@=0H(<4
zl5*ujzEsFT2$vy6=!?#mMY8A$Q)PjLztH&LM)!CsQ%_|p`C=6ehA=7>>trw^s?g?g
zKnoh?W@k5}pap}`lmohWivr<`IwnPM8b3?SW1Zt*Q}*U!|4c3mVH;;4IgZPNt~iPi
zrH6nFmYu|C+|l||9CPwo>R?bgm!s<&pNRdXL4*B)3S4ceh9!e>M^HdqY=>@>Z&7f+
z0?eoy0;o_AVgI2*!oou_+ngq|-D-1LY;L{DZZJEr)ER9is|$vp+2$6-Wi;8$RtI;s
zLI;z<7683T~9WDa`*
zv^4cZ&>u`>JZS!KJQz&}!s#%c!~ost{9PiBGMUPwLVEoXd=R)E=ETD>JkdB%SdJEJsP;b`*=1dcBEz
zLsKRiFL5d@#z@1)%IAOo_+T+(66EhQ+qXWmZ5z0|1In0TSz;q(@s>?n{@?%R-|gMg
z0Yy18F@EWtON(pA77v~L^!n9nSKoj5@ZM*iUHk64?=HS|d2ad0z{q^pz;v^Jf2C_U
zU+c-#n$3Y>e9Uiu`#XOu6Nm%DX;&m=5610*7@m1E?ykpA1&rcw869rf84Lz1bQZP2
zhN9A2WpGxT&d?@uX0=ld>y%n;2lXyT3DXzNxM&uonoBXYFb6C_D04;!kQgFYIGMT1
zsr#9-L&R!{p-QTK?HzlS3TR^X4a*4)0l#(yXY%KahaDg-gs-4xM;j50x9wu~Lx^U<
z-5)Xh50+%G=-K7e!UQ((%q_cdo_5G+Y$SlmT26~3g0uGR#ew@29eYLDBT{qlgeqkl
zw7n>R@g9SApF!JZ)OBE~Q{(MkgL|K|_)Qg7usvIG}?RW{DUwQ8P*^Y~%#~K7GPx%!Dk^%ChSGtgqq0
z$$IDhrGqDr9eZtNc71I2;Lz04%<{(6fusAEjx24wzH;)?fn#S696GUZ;OODwr-w)P
zgTZ~n<6p_F(MOIq`-aMmZiYseYSm^}wb@;+byjL!LfuyIRG{I*x}>k
z2p!A@6iYH#%+?^r3ddn3$Ha3E$%{6NPp_21;Ur5W>5Ig@9IKP?hETZvMDMZM@|YZ8au5{qTh
zX`nq@$S2c`wdQQUi5%yxkPJ>H!!df2fmQA%TnH$*j1s`uj)DseB!kux!}LWbQsHnk
z7>eMpSeNc-Ne&QQWR+o@o!cMu1tX|$K(7;KpA80|+wSxl%r=9?E(<`*x$o?B$$-09
zv4gvIuLJdm^7qGK=mEDk1VDkp;F(KNt}pCBCX98ryKI&F93PIr
zSi=5kuP+h^Byc^jCwq>ILkx&dKBBXGm(Ey2SwFb-})M2y?xSKKwE}9P9TxnF{
zZr1A!+zVXTSQM9@Zjwg5yH@@EbNGX@!t?yhGuxltwoL+f%jQj+wrtw;{Id|j96J23
z{_qd??rqnpH8Z25m*0Ko@bNPTj-C1V`lmOpfA-+vo!hr=egFOM-uv+5r2|KY#};}9
zXX?EZ<*wmettVaSP86H(i%I1cR@VK|yf2z_g;O>>$)Tvt2cz3(b^8oxfs#~vk>@heK@PPKZsTD?n)qS^)S3IMl@(x%t!HS0K0lFbC@?lWk1SqyDXtJ33C
z`&}xZqr+w0=QQp0+m%6=D(F%~eVT;dm=0P~K~oCQjT$piQ#yimVMT==0;sH%O
zpv{C$sgN<@H^sdsS#^Ha*W|=(w%9kee|3HRg*e;G<%A*&P29A^R&@}RMI20E{*fFqSI=g!M#5)<4NPH6^hx#Z{|4iE~E%7Vczw_m!Z
zoi4xK<%igHxEXuJ$SF2_vO_m$@%XLY)}SK>SP72Oz3h(I*asYGCCp*Y9QONSH_BhA
zWI=1&6Z!(ZSZM(`5c5FLi!Y2Neq$hvmXXe9>7}Qn5UDv@9zW0*&0;jk&dWH*+fd21
z#v{oo<*A4Pi4q6la2|qu9tdFvFiNRZ;M+_Zh^>_&eIa}S-9oiesz6e59z&LDrHC!E
z^8DPdTIWzIS5M`trAlWygYQ>G)hgtfmNK7b{Q*$%!({_qZ*9Efi
zhLML_ho!Lguyon%PP4^fvN-Jku!HUvhs*Eq1n7nlZ&7b$d>^VMR!}ohdqZL*5^6{=
z5Jm9^A}9cG2#=3H7LVuS@oX>{!xrJsXV(vQ#v$P_s!%J52M7w#ih;uPQE}Q(1|MKa
zH?@Ft8c!$-9nN@obJ!@7Z=?g9Z#0^X8Z0du=uG32&a=0nQmxkNQM3shW}Qh=BGZVhR5-x{?jt+$#fYX>?fJ>;
zsi&Xb%$TgrTeooDr0rXno#UBpn|JKkg2G7~wr<(4o3#~io)_`CJPuMUmRcMr=s8-~*5?qs2nEH(zlrtnGk?%(&v
zQ{HI87frg+3`OG304#B@-5azx{W`1D00ukVdb?9?vf-`HYF8MHDziyt0)tIIb_OfO
z*d(P|r_plqVCLUYtCV8?U=X(*%vC9rfUsJFw+z3c{~3~3Fqa`$Sm7K>t-xvgl^$ux
zUlc%;j%fO#6>UQ7?iCp#v4mh{+*Ug?V@Udn6dz1F-9{bEo$0#keI-3Zv%0`;JwOrMqsHr_NwTJ-mU6*MWuKJ
z=oOO{?$c}cYE`>U`gV~RYoAHK$Ee>6?ph2`!}~yAs}V@vW76$*SlWUfRmjs3^NSE@
zVpWw0D3g9w!l#LQ)Cr#!3K)WzpbhAgK|Mz(1=N{{9)cJp#thQxup5HdBCF2N`kI|v
zDpUq~2ImhSJv%*nXkuo4c>nU)?CQ*cqth!J(+7@?t(;sud}d|!`0T>Q#_`t{7S;xb
zr-mnHd-_KnfAcNQu&}ZQ9b9ep=1cW_vD#?%R;%n1{&74K+DFhAtsYt~(K5127%MPl
zv7X8lQrQBUL@Xh8<0(#42;zdo5g5)Q*b*f!vh%|*hkXquNep8>7)=IYQ%At&q)%j{
zMIm~n2~6o!&Oepc}S(BQ|doFt)nFHj)@`
z!y=8HAKRTMZYHX9dKeK66M;o!S`Z9o_?15#LxV-5glV+N1GMHc6pIB{3GE#e$&*xz
zq%Yb%TV*!vC|c-oeRauA0nN%T-aG*=
zzQEs>FX9T&V+~Jzp&}?%Nv>ZDw>YmumhCg{wdn5Q0tTfn>EFusZZ=ql5FA0b#wn8Y(Sc#pn
z5xO%bh6v-YSO+G-T8rRul)?l&>MG|U&Zcu^&=+44&u=nQjHe2y+pKAz_7@;Qezfq
zTwxfB(8sA1%z`xT1>IMB@;FO$qa{4D$+n2DxD|0nDx1^OF~JFz0DN*}8e#
zGxSA2vvupUbWm^FzGKVw?a;+rx9-^fti$RCsyge<&p!R^+_^WF4jn)D&b#*>+`fPB
z>+iq+{>z(R{rCUzw4Cc%YoWS2?(_0)GqfG@hY_y5sEHkG|QtM@iR-0Peq1AI%
zf3;3b4-5s&;lj|q`;_g>%fZfIMTZ)N6A6RUjE+{fg0Mu0);?K))iyAdLx+KCYFXiJ
zCSloCjGrxrFahCD^f3ysO%j8?LIJnZWzcWTOd7km6meCYcweYtF8L>{ywZYn2lTE0
za0ixTHn*U(?^d?&RiF^P%!j2?aAdGTv0JI!ty1k$DtBqr0C1aG&zzJdZHH0YZZWo-
zIcdLwb0rzuZKig+xx;2`b6J&cyT+p1XEW?|nD+V{%81XH454tKk<1944g~E>5o;
z*}t?gxqM`H?ex;dt7}KkEFL_5aO3pa>XCt=$&vjFVDOpOUdI_ezwu?QtFHQY~Mq!oV$-se`2&MnRJ#T1mE>&}PiKkSS2_CNm&0j*TU>v~(hyM?gkUQy()T27tsvF;I5czki&oNAheI!HpI}Qn9UV)
zdgBtqps!p?7=yKhF_m%5?v6S=F^3yeh6u(XF{dv|5zNoxIA9K-l;fe935yN@KZisU
z!!S_D-3YkL!Iz9pWri%kmLqnOtyE3GFzE{lV<{vW$G74oUC?=^!78CZ;8x1{Qjw}x
za98Hy;9N;hx`A`GD%QDMwe}0?;A&@IuGC0z-X!pqstEEI@IxCdm|Bv(-8m>+j_j?~
z8_jGkFGMYquL+N38EB+(f)W<<6#}2^sZD3GKf8pV^!1_$vceJ(?#&o5noFl~>MExt
z&fuyNnM8HI$WO%8!gVUuVHu!+`nUyYP6Cz#iBlP9J^-7pT6}m|c%ErQioh=6w}9Ei
zC90y#3~pdG}m)9q)qWaVV1iFDqeR>&1ux8*ukSX+d1
z$SWQM{1uN3>y%Po(qoKZ_h7;<1H}EeI(b1K;u6C5EH4
zykQ=3V&H1E-e}ZowJKdVxneHM&WLik)&Om5)dF2O_|UZMP@w%-DAa0on31j8^OM(8
zoTiX71aI56WqYe^-LYdE=*w}#Sb1jqv(G>KqOx7LcegT?$i4mcyKlbv_QAuakDa;j
z_}hn{e|`-N{_3l*{_cPM-Q|xz+rO~dGdx}InW%J*7HWgpT5q}n2G`1+z4)-d`(OVn
znJeP=;HTm-4n&i(y>R)%Mw<)8?C_fGZk^e#HQ5YS=Ic=FZ5pFPZLk5oVpNj813Flw
zt89ZB))`uZlr&nURwv!j?NGzaki}>$xzeH1h;hSe`lCfGmYC09WQ}HLFvla&Da~<8
zfH4XKr`tN(+PG2ptFeVM|Fbh#`kzsRi<>TJ(aVd!^7K&5*t4zW!Dgqg^gk1>9Xk~Y
zAbBT5ut2p?%s7xSVIoEhP{*gV?@`Gq87RSbsg!#-RWPSW+J|+OYPVR~r`16Cwwv@F
zCOs!8gz&W(_t{My4wJ%VR(h;zH|T3s_#JAGMd`JvgKllutM$9I9;?P}R=O=6KAXa8
zZ4Wv%QLicDF$SI5kXw)Sgx`|zSyFyW)TfUJ^nh+L=|D+?+yP@M_)GYr*Vfh>&4E;=
zYjXO~%Ie9{$%WDBmA>)$@rBi?<--$;8xzaNmXEx4=*0QOwc|4@M;2F)kBrZaPR66
zFwCqqg3V7tRInn~1&QS_Ty_b|!m&(ZAQL^+%v}`{2{hQLZ1?zWZXX^fU|3B08+Q8H
z*9+|ne2Q5aVh&H-=@F@~M3A%aJQLM|**HI%S`G!~J|3JCJ3|1$6o`n79Q;c1OUeSx
zfrb*g1O=@sEE3ovVWtlgS}l%NlD%=HuMCYA42Bezu|*&XUC?QO7|SGZEd9@-)j~@~
z=X1SA^p;EDESc)FQZZ93q#+b5)n7;lclHd|JNwevQnkhmg{UW}
zIVCY6rd$Cna1o?`rObQ|omgk(5yWMeVWSf(;2)MCxkzW&VlY4s?S!|2jv^)qWM$fo
zG!t|%m^_P1igv${tKcpD{KD}7ZCxk<3ppT
z2Zcdn@LtT+L07=!F&N4luopuo1BWnzHHw
zy#dA;f?@J43L))hY7T7lah5H7L^K#pi0A=UCx8||1nk70Jl+uddPRy#DTVPf@hk8X
zU~q8E8-H~w7)%Pu%ejxj@k}_H4TTtXAi6?e+wqyjlbgyG!op3BUj)fZ06}U8lW`oI
zV1i5l8N1O*E~ZxsN1>Y;hk*wThu|mRci|hB$_?CQhDq0I&3dz#FQLw|WN=6Fxm>pyP{Hl^-;ECjako?cKD%Wz==&^VvdH6Y+eDtMZCe53?OUGSyz}L~
z8jacM@}E6>{=*MHI(X>h!6UEUzJL417oYy{!*@5n{Nk_w=C42d@~eddhkAzO+=WBA
zdOsMPEOjOdjd-?v=*m1?buky-RPw=0!OwMLD%oW2n2Y9)iERZ2Be
zMvLi%vBEiq#hixpL4(7P!yKQa;TR>ll!;yupY>$iu!0@OB3@dtw;deik{)TI7Yv3V
z#-Ff*%<>^8Bqp`75Z%UPHg^!H-Yue?p=kH9*SSrGPqSmVjls_hxx!yNI)K}~8qUwZ
zOQqPUWL^%=&7cN-IXA;TF+6FnLEENP@6l-X8ujgFV~54iW+Q<2KV5s3@!dgz)3K4T5YRQF7
zsem2@08RxBnV>Nj`XzMmfu-fyxusOL+0{FD-eXriS(}Hv1>$=T~r&|M9nfTkjsIcMjxBl*09{-ZEOr
zN)siWE6em9C>cOESInY?uXj@Q=8ADYaR)Wj&@F&=(AqM{+oqn(tkLqr6CBvQ1d
zNo9^WlyT8XF{df#Is}$Nkz^>uhhG+oNaz60r7bZ`Bnyu;?DNJ89yM#rkm!EyZva1+HL|VmxVLXpG
zgu_TUMN-`9kJzBOMN$z0Shx`V0e0!hOuQ(ve~vJYF{Kf`ng9dE3P=4i{7QsFCz&&u
z@j)W+O3uvR8j^&UXtS6LTIgU%Tc}^gJc~jGS1V;GO-MYUgDHZ6XX%S3k^n0~)V?c)
zQu!CkRavU_6w1JArCRMOmO$Km2EZ#oANAlZj5bsi7;R|%i^8)a*-Wo#G!D3eslYHq
z6mWv;BTonRrc|FeF1h72VnW37Q{ee
zA_{ONgP8*kqy$81L5kWd1a!>h3xeX<$P$DB7sf@vX>m@U5WXmYUN}xqawwDx1nG{3
z>4tg*G>UJ_^jKgp3LZNA3UC_7hQi4(r(hzp#V^Wwy%B7I`3uAZBPnQERLFR;5Krbq
zVO;7$h?6W4sMyZVBOiO9W3eo|jpMix90!4)fUkrtsayfqhu@!JmF!N!A>cQTtyG$w
zojuJ)XQSHaYIfywKrF+s6EJtOWf`DXh3!>ia2Dh|Ec#OEf1`srK6r;H&urcD?A9$<
zKC^v0sJtBr<}8K+#sBJG{gK_~>e#267@d0W(&e>{6LSYoe0crid-uM)`Q?rK4<9{x
z^!VO`N6V{62FK?*hbF7Nqxr^Qy3&&_b*2i9bfFea6+ZvsOMK+)!g3U5OEm3`X1w7P
zS_gLk=629%cU#;(lfw-R>!^e6W`|p2w5UxM4T{mi#L=QZSfw*!*$RhN>)O;>Cg@OW
zL1?8?t5O5KAgoZooHhvsTfkZXSS26|D1xuh!IZ@cXk{UD70Nc@l%_J~Q4+vH&MK69
z1#u;4Wsnz&@JqKa3@Wn=xuczm7E2Mj#lB>jV^TPuU*RkZ%)h~jkEnxN5?Kgq?neK!
zk^_*SdUvao!0>LhQq0n?YSXCO)v7j~w!@%nXXLYPpF!7V(CyZ1cbg4ucC*4^ZFky~
zE}P12rw9gy11?R_r3<@tQJ*dukF$VRt}w9J^bp-!p5N^=QfU>=^vULpPcI-8t)q%d*iK3IM3COKB+eP%C(+c
z5zk9+z0UdkQAC$8`+y-+atsDy)C`)iLa~ODFVOcwB=~&bAbY#Qb44Nobg0cY2BBgy3#Wc7qA-w#;qG
zV7Vmro*)_P+yTpAT*gMV5@kRu3okKv46NdT0yteQ*D;n5waoS`XpQruSp;k2Za*yj
zq{|0!4DQC9o*4EN0b=-2j#0+a;|=?Tw;ZBJhHc~1{XvGbph-fbiPlgS*{nZl4O76c
zba*C{nQW#tb01j3LSMARE+sGrAZ20ZfEdYqj@p-Tz0h=wc`g9A((_y?v(NNNC>G}o
z#zyI#mYu`-@fAvJc}qoh$L4dKj3|a*R;V&gwoc`Q
z3&8<5oFy|?s&Ga^U@#Pkgd>rNj}u%+!>FtD3`cx^hVEl$5w8#o_#?qUBow4^28^Ld#L9I**AE38
z410m`2&}hgBpk=77?$M&P2<$2!kz2w+3Bx{4o
zWU`1AxqmWQzIk%Q%E*HW%Yu{jHuOY{xT;pAW|4
zwu{hQgTeasWuctO|=3K!dHx{#V0LEJ(g}3e40tU+^NDMeX`<${v^~ztol1paZ
zzIgG}nb#H$9e?$Wi(h^9+2!{yJ$n4`tD9f_@Vmb{e)_`5)N<$0RK0(q+B=r5bZ0A_
znQ}8#swMN~WVZOXf6Iy1`-euNsaz
z`s&P9t;wu6TOfh~V3pRS(wUU(57sI;w?DIXFj)r}3_?R6bLIwemyua2jS~7;qZP_n
zs9_*k$raf*OuZ|DvnYib(xt>wQkn7>^i|&44Ze%r0Se5{p4k*cm*Q-f3v%
zy|SBG_@Y}Go>dI6VxKNx%&uYqW)?XXnNeWS$MiX)V58{z-K|vZ1%q{9u$m0kX*oZV
zN#AbJN=J0N$Mjo(AEy8Rq1x9{Z6glsSbHHArFMFDjrZLg6ecg%LG^f
zO)98Qg$=-PDrCq-%=xe-7qMi*Cah;c-)C-rbGHnz>tOfWhXJ@vLPM$C3Ns#
z{`r4BcJxSJ-&i)^)jv41a^UF1mkP_Om
zbhZd}i?_vcBgJ8yjcmS@FITXdMUx6OBUA|Vgot6G!VoNJ<>c-&TiN3%%HqfbbQ}W=?t7tSB(g
z31HF9h9U?}Fv|dDH`d8uDrOY!O;r(R{!VB$aW%l>WC|F5GDB6lTy@!~WC
zxjZf_%pWveg&fBh74vzRLSU+#pC1Jn7I9c*02mufMY#nHT(MrGEEX&LtE@af_p4Uz
zYBqXcrNLYSFCo$K&rokyZ=*6Y(Cq6ecX!w7^>PAO;DBI=re5p@yG=}%moHVs=%WnN
zkK>}D`T@+$G%502qV2}Xi-jrx46LHy(m_YzK-4{4SkyP^m6b*$s+_2AWHZiCtx|h|
zxKPsg2-q{IsM7So?GUn<6&OqK8?{uLP&gZ4Oh?;nkXKki~kl&1kplELMeK_POFAi25x~`
zwFW$REUnjUKCToD?*uU)wZ1?*HZhozXqf#KBD!JslWh#q8Y#tVOe
zj25gFTclX#f+z(zp<>x(tJOji%K$EDX!Z>&0rfVKwu^2J{Qxc
zBN_lW8#3gvC2Yu`U?plskyYnsef`US_UqB1!TH(cT((}W^e!wPnx0!6oty!K2PWsH
z4s7gSK0LX&zIx=$!rJl4#kIMWLyIdLi%W-w$7aT-mU{*!2ZpDIMrZ%#Z~g{nn^`ze
ztaftp22NtwRjM|@;B>B>VcI1|t^&YRz@<7KD3BPBE0$0ng-SgmI*hSfp-{!c98cvE
zoIsQ@sL50o>+BNdAd?(gN;GYP$}p%Iv=wHo7RNG1;#oY;^pAxT{wTwjWbqNb5^2m9
zB#YF(Kk^uqm88UW!Qc=ishin6TKmgG2xHL{LNkUH~
zI3;a{DWK_sPC<47vrLJFjm$HIKT%EOfL?0fe3spw#X`0W909drMncHkCpwt!Xo+Fq
zO#oOfxlgT%eJF)x<@vc^s7PIXBl&VOTd38Wy~Sd6pm$)fr)Q+6duDuSxW8+Bbg-+l
z0d}I!0F$uuXzDSP7ZjwonNe8GbO@}{tBmSYtu;~WQmyG}A@&=YY#|mW5#y{~MbtoS
z7igiCgC+JaR~q>OFif0-cJkz?hq-(npOj!cbQT5>O-8|8U>IiulF48(#)%2NLvh@-
zNCd=X5H*O)>HT92KL(h?5e_59f%qm*bZsOQhBS`(MJ_E+4IAb1NA8lW0>k*ic-tys
z)RRAeqhnD*mpeT96PFyM#0UebSQNoI_GrLJlPVd!j6`9_l+zhz(ZSBR4$)-F%df~F
zXFPGJ&%zxQk0v>TWIUFMM^ou!K1oPt0cLzCzN&;hZh>@kV+FTWRBy^+Gzj+1Y4xHfvp7&3e5i(pAE`Vt{le^S>LL
zv}yC^t#V}WR;uCcTQ+S)*(zr8Cx*9d--@@t+WbfV>JK^gwnIDC*LUIE`C}(9&K)}a
z;nl0xuV4B2ldCsAzxL?SgAcD>n^{;L7@ckO(H&jv9Lm=EGUe_}xieL)Cv%lpIybkt
zgb)7an{RMM@biN4v{U4H_lBYthtJL##e+7FUuW~^EDo#Fqqo?!CKCXxHJS|;8&t1K
zZ&Vx1N~1}kqiY)LY9JY!7|K_zRqG8{mpYgXhB($}+2spnw#2as2a&X9#I>nK?g1W)BpBVL76gE0DY$idPg$k?V@5
z`Vqi;MJ7%5^$PjhrdG9URC_flj{W6QwMVaE4lJVUPomXBF8c$=`~q62Pu5;*yP;m^!(bw;`;j9@zK$liK)ebk*VJP
zv7xc)x#cx^!hzw*N|iGy)zD~Gn&n1!wp5GZVS~`Bp!uuHE`LWjwKH0ofWd0Uie?K~-l9l~lHvNHdc_I7&xWEQJOl8%^XQaTW$k
zM>D}#)*lAOG7@G10GK&062S;ZXrL7k&;@-doxNbKpI&H!mU9!e5@~rwSeAq+4-pgk
zVmB8wuD~!|)-B&P!HnVwFvp}flz`ZEV4q+dNG5KDt`(9OIH%_s>KwuyO-wM9@ClW`
zmKV)mB*jn~A6ioS+tDV1!NTU?67WEa$dIc9C+*2{>i8Cbp}g=P-JjqydwkJsvC|i?
z0(p_i=a>l#+(oH^EF~05;s1XOE(_e^EdeYPuq>r|?f0ew{D1aUu6H+j26E*_B8#um
zNqdetglo{`UG+}1#nno^R_jV8@(@C`dUv_psMng%#JEami}8c;vrFX~=!=R3zQX)~
z_%9YJFk&Eo3;7CkaJACJH3TDLV(c#}A*vkC5EFAPfF*#m7z$MZgQ3hs$Q!3MggmFJ
z&I86pFgPu40bMmu!oIL%NoIjwe4-pY#?eX
z!C(~182T4CIuxSk8FwETLrsv-#Zs`7Z&7XVg{5`}S>+aqYPk;>hGS8YuoTf1%+~=T
zVmlr#c@nXXFJBTL0YX#7ij?CS`B@b7;#9&q$%MoB3Ajobi0>#z4+EtM_V0?(4cHBa
z4!)HjG5b?!2?-KI{&JS$I37$+dYw)eu(L2SsFHD;@ZA`CCWbKKv~oNltbug8$efpP
z)N_VF*Xq?qquyu$!|W37?CkDrc6E1mw`$K%UQcnZ{;go`4rZy`vSah6ZJRgA?qTX+
zAbH!??K`&a*uH7oGg~)zw6*Wq*_I54&zw4W>h!twljk>1zV^wr58rs>jW56W;=T9Y
zzx&|f{L1ywIq1m6S_h!mn0C1vE$rP&zRJ&|`{qSLY_T$HoqiCekkitm-
zI1oh}5wW?0jOz3U%npyy<}}+~7N=WlvOobFtab=uwZYN>$*VJH3?>aQtktR@5_Ni&
z)}U1B6iTf|tJmu2k)~T2%J}bhP%G6P%xDQgtWdYOtKtA-C|v>?+n`5Pq$!qSrL`2E
zYN}zdTqOEv6LDCS!Gth@O*tzL6h%0b0bnfE%Ds$p?%1d7*r!$l(z}&P241O^`?Nr>
zx=pPC{`acY?HYBvR)exntKF;7>=lzSF!=@;4CoqlZ6^IblX0Kb)NVC)Fz=O_87QHE
z9cGoss`gk_UaQJyR|cG_u*VQ|8^T^)(4`946#;uk)T?H~XFrf^NQJ~;q_8#{WywS}
z`ItT*Gv#Au5IP?>e$50*yQZk^y1+Dg{kF3lXC~B=2jP$H|Cet_D?OZt)5(2IkLF8K0Yxsw{W0m
zaJ+YTvUgV^A}ls}!)Y-X&5IH|SlgG)v_Mgh;vG
znP)!zIxJ)~f6VJ!l=(fVSD*l>1X!&
zVa3ONOwpC#My9{#fxgg_!^PZifiR=EX&;2q+OlEt`q-0)MiY%1WCWTXG*yi57Ca7z
z(H27qF|vlPEHrtL!lL}BgV~qKcAqcld1gOn5u||};YcI`hhF78vtJbpFm^y(b_Tab
zB|+nI>Qw>YT)kXCsXpN`ma+iAPu7{B1B8~9=jVQnL1Q!q>h-=%u9_<~a;OQp{J>ye
ze{bi|U|(-&q8wkyxfwZk9@oW}_#U<=pK+q^4tOvGd)(hjK&&h
zh8RUtUO^26bh9N~(x{*gYoM53DH`J_YdZNw5H;!{X~D!#ococZRK=7^I2MOs1yW2%
zNt}T*Mo1}4l`I0(C0ucA24oU95%fi2W{Fq=luaf$x-2ZTaxee}hXsRYSuueC0DW^w
zL_t&uXY3%N^IGBYcmz-%Bx^x0xx`xl@5gllSm;g&cZpv1?1mDNNLuvfVo#=x#BR7U
zD6Eq|CdrBr_B=$4`o(ndkKU82|qM;7w0&M*(-YZGDzK!Sp{rgST77eE!=uGm|AW
z@s7>g@rOVDzy9w%ue9k^>e>C1ubz5saqZaD`l)N5UU~iE#m{ei{^1Aj-G6ZF)w8co
zP95kSn(OSJuJ();n}g|6XS&o(u__cEZ&sh22ncPo^;
zA%C$^1anEH%fZ2-OPKnY>J~+{Po)O1>6fN!nxR$g)VPW^t+HL!0q(Y;U}tPpDd>DA
zdiizQwdxM7x?QK~&?FuyKi`8
ze0pGH^3<90IOliY|4^uP7HgfAW>2Zk?3HvigRl6f(JkD1oV=k}VweTc3+M_k*DF;vnVcC>hIVQ7Qg*+LZzW@j)OvNYr`15okga|jb1KdCTu474M=
z;slH%j0lxo!dRD64vX9!awH`)U|@@2Fm!4{bmG!SEqB0CVz;m@(xA`wxZ%{{!f@
z*5!6tur4dl&;6R4U51s`=Frvc9-A8O9_eci_jL^o_TyKh
zlE|8q%a$djfJW4xq8LvMGJ!OxW+*WA07#&fy~qU+6jD!8jiJ9d6FyYbH%3%3-c3YD
z7mAe>Gexv)paN`4ksU&a?E-L~%aQab(9K{k?f}k}&F1qt#>$B<1DJzx@R-rju>?*9
z=%O}5Fh(L#h~s!1jDbcL^EyB;()MDXF?N>3#WxW~8^tKzO8+_jigig}U>LLx)5>IZ
zjmEN}5Sa~&Bpita0}+OF1##MJJdp!srHdPYB-W?TeZF;wYjG7BCjv!zfhEvq_*1&b~f9EGb*
zKXW3R;o$Egwo9&~!pnOBFeegOpFe`{3Hun2Cp}f{6ptm7d0gZmE>}DWgyA3BOd>F%
zReOH&dTP_JwussLw{gZK(D&)>lEGVA%6R+M&0Du^V%f1}+yC*>OWF?QU;Nq2xM|0Z
zoLpajb@tHdS1-Kz^_SO9pMLH23vXTi;L2BDem1qVK0LA9IWSr49jbJ5lyH`LE4z}#
zM!Hl_peisxzc4sBB)`PS$OufhK!~}-yy2L|>G1`_fk4FT3D_KNv)$?N1`Jk*$!51Y
z9TuC_Y%xRZ>hu-^`-v@TgF&g&X$*R`PQ!RC72fGIdK5jQv6Pg;Ah8<%Kq5mHgUDI{
zo1>DHKrXZ`XFP0Is;PR}aZDF8!>I*^+m#H(YFDGs|4iJ<0@X|HD}*xL+AY^Kqpb48;9Ue36{sgMm?AhyG-M`<_d0N}kw{T{PX1X~%D7QNb}
zQ5!W7z6z0ogYwsDRoX2IyH&x7f$d7pgJe_sooZk>?A1qo#)wBBbSYzgbt0rmh8YD7
z0LOixtd_Z;1DZ@wmkk+mbV}EUzsttpdX%Bh%yi=X(do28JdFN2dCQCl?QH;Ix1DcYoJAI0^=r8z|kiu3ngf
zU~m~?rQ9eMA$h@IK(~_<{)^sX*?@9z2vd2~uwA;W(LiK#C5UD`@X1UbxP_q&E(_hv
zybYq^<5(uN9ay5pk?Sy)vCjEkz+*A_5}y2UI2EEApo2~p0p?cRW{acjHcmk|W1Y07
zP^LoVKJ2=K$RKgW&U7ya!fBFNY@yiYbSViR4rgC4j)mc$^7*1rArK!ZXlwAr@STPD
zpfm{uAqYSPJgpTpI%omW29d;JDqvgzijq*A?RY!`!GwmK5z%Of5*+IbTU+FN7L)jJ
z*iA_Y-CQxB6F%os74&7)6|`@@QETB=0#yWC0lhh~{Cm)%fWEalRj(*O_}~9kR-T{x
zH8HtRYYsGfMpAj$aJ71~uU_vQ85kVsZqAGiPEYiY4fl)<_xJR4!61R^1#T=DPJhnV8FrJ1EFzYQSq=Y6k9INX}dD0Idbw%)GM46)dqXY
zcrL8TRv!4wWCV9b)(C){LFpnZ2*{0{aR|?Z%5V1Rw8r6qkz*$>F0CJ*T|05@`n7ZCUw`M)TNf{$
zzjycZqbH9~%pB+%nyU4WRr*E?or9TbZ>HRnDs-lDb*SM89#K(yYPH6<-!ik{*|X;&
zBJq7Rnev4~E}z#Q4EjT1yPNZ}IowP)YOpxWc9+TKusZBIqX8mOXEd9wPQ4k**rYL-
zbOxgiJk~<*YK;b?QEvc@m1cA)wXx2_Np{(8V$tmKCK4y
z?ErUKu%cA}z#6p@LfxQM0>gx^vCXL8XVe43dri>0W|h^XwXvuzhV~y5U;({OtIF-v
z_*`0_QybtIBn{+m$fFIo)e)~Q>eEKNY7PZvSe8y^eoh9UYdJ|nG6b2c%LF+|u$Z2K
zN|#e4iNGs}-At4jq%#qHCSpnj&8d(z9X4YNVH~u|s`InHUV7=JKX~b%{rb5Vj5_V{
zV<(1&CyJHcf#Io{*_GkZ>5<6=Na2y`#j&}S(V6A_3#$tUHuldhE*@AvxPJ8D+Oe^T
z`N^4;@%_tPeG^0D^L@kndxj<_XBXwkr)HO$J;SA1SEbQita1iA5mC`qt~T>ee9_fv
zCvu&+=AEq+$UQsEGR(rh4
zTq!p|*?g`7Zs9;lUo5fC%9&)ct%Mjl{39nI1{p0CqpKQ}rH3O*XEhisF$|#$%0^Ia
zPzO+jf-#71tN_e%gfS$wbaB%l6a5rV3J%Ny+v0=ha}EZRfdG4j1$Wb&FF}OagL(L|
z!4Lz%@MT~+;2WYs0)F__SjVpb;XqT7rh^6|eliNwFm^~%7K7^qr}QF7T?-708UAxX
zOb~PxPp;UXe9dOd91X>R#pxu3uZZ)&ees85_%h3AwUw`wxci%j6;>3sVz4!j5H^01bb$W4iX#YyJ
zf2`CqTI`9DPO=32!p{W
z4yVWE_IrIHyUSy;+MO>m-NJgi2(pGa247pzTTJgE
z0<1XRxP@WByPZj=MQpQ-aF%_&Dm4(^rqw8PT1fH^yFW%Kvsd7F
za5gAovGJD}AN<^N&%gBIAN;|KfAB~D;$M!9jxDdO70O-ZTJO}<(&)%^FOtpY
z*xd5iEYo+)F0D;teR3Ad#g+BNm9^2asoA*$L!&c&gZqca=X!@G8a)F&17m;nSAUK3
zA3Jfn*2$C|oYqiGE{0O?>MaUqGH^=_i{#Q$*NSXMU1-7z`7-tw?IZI}qd6;;>S#K#
zf>sg@1eVx=!;T9Tpcj12h(AG^K%hW&V4ozjy|O3TB9r$+P^Ne9x8
z=fM)s0#_@3CUReOH&dWwh@6Zmf-
zZnqN2+n(97Wt$u~ylopJrA3q$HtyK5?V0VHx4Ep2s6TEu+Xwnaj~qQWw|I2^z^O~`
zUp;p6+#7Gc`P#V)H^2Po+_^KO(~G?$GqwKlV&_mn1W2bU-AOXIo+{LmS&j@5#&HqW
za!-H%fB*0Q9bf3sp~ERg9K=2T04y7*1YaoP@OYhGUoaeWIPDgz)#dit>~6cmOOLcc
zV}cmAIgKWpPHzH`wMIQKtkkHq2A#=lGMS7zy-uN40>Cti8vG+>GajENAtZxbMHP)@+0N`+O)kTMxk
z(KQ{^r^9wg+f>LX5@td8nv*~>Rzgs^Islk)SRr#JXw8IdnXoM#u`oU>Y)OYr$?z{R
zfAC8$y@1z?&p-ddv(G9O?Hh+SMn)#Gx$5BH;-g%
zSYaawWsCyJBDsr(QYw;aty9t$TOgVtT(Tkv3yo&A)|8DY9%(Gm)JhDaiNxc|hJaO_
z!}eh?qtQg0hzC`!kciAA1>r~xqiMk7iiQ-%HQ0;>0tL@AcEcfLvlzC4B0$LCk%;i!
zk-^ju4D197LEK=BZf9T>Bu2X<^#KkPQMK5Uc_nGZ3;#2|C&e@)YiI%Bhu~L0PT>oq
zJ%wG&JW8Uo5WfPy4!=mcE75SH`HrGRV-|Zx3;`kdT{s*+84q}dlilWXxg45&(6tQ#;5
zg@Kq%<|E-4-jb1#1d1;hfr*(&6@p=Urz4EXVz;Zb6v0%y4MJ_BRwuJz;kAa9P+-S7
zf$il4nvs;4Z%VqpQP@wM%7-I(K!E2Gp3qb#AHeraaS4{gG8Rt(Bs(82@g!E_@mwZf
zg$NG8;>52Ivq6GTc%X>?2%eW5M0ONLYK&br_=dP~xSQ#8A%i_(wkGp1k);uUBH95)
zv!fBf^93WUReOH&dTKlKQ$hi6+e`p&+p-zN-3}5nf7TYRw8Syz72XCmgVTTbPyevH
z-eWh}L;mRU%He~DPLIzW-Z=T%<;#~39zJvQ)pKuNeD&+E-kF6Io?L16qv0DbcaIdC
zgPC%7y41`R>5hgJPGkycc4lz=C4Wq&aP}+(FWxsnl(zUQM6=Os#@h~MJC+8M-e?4Z0dLS)
zEB2&M8Z6gn)F_b7I=z~a)L^!b4s1?`NN=`Mt?2+nRqA%Ei=)BXcD0(BLPU0IX0tMA
zl_+}PR>N_l6js?G}y0ibCiz|hd$^sgxp%;aMnb9y0AwZbm>BF;MS7l@LxTrWC)s*0b2?j4MWHp
z(-95@#-E^iGoWk;J8RQn9h9!fykUYMmXTSI!aSV4!scX%anU@MllcSE0QN7TgMa_fE$?>_F>E-_6$&smr!HL=ZO9#gn7ANPH
zr{@pM%pcr8wXn3jwzPEc@W!#xk;%p7^^u9$zTwHy{qy}J6FtKd)$TzQIom&82M(?^
zy87y!eMJbcS{I<(-7`?(Ov4bz%!E^KbYcZi<=a|AhSC%(b#OXcpu-T28d^piD;hgM
zmo*t+#u@VETBZP7lUvB7e~^G$w42Pmg>|-KkTuM@K;I)9Tw2_DJl+tLvY;(XCG$Wv
z8#Q6|#}ZURXd3WtU(6r8+8+0#MiU6>X#juR3P0;E|r?22H#BrrjuL?~}
zDU8E^F$M#`lM^#NJ%f$TzH+TQTd3zt%|f{$WDxU<0L9W)!xiSWT__ef1--nRqK}@MIG>}P1iMONSSD1V&qGu>P$~^h3uxgB
zU`sj)i>ee8(OdX3sH?ypDk^)9#TX}`6cr4=QPeAHL{`oxQ4aVfs4zG%#^mbpSTcvo
z2_&)C
zI*KFE@idF2FqKcrKd9j}d9kOol?iWLt5ThLIT&k3M>Lp>Y^H<{5|@iEYZUQBv!l9Idw%kIYWubw+qQ1s{50UYV=HhgJkLNf
zXApjR>(js5x`|O*EjG*L)Bk8wds|1)A8}Y*utbj@J2SJqF*37p>g-#`&b@y8?D_XD
zUAl7l-S;kCKpWUMvQX_AFL#YV4d-jEaZ1^8BaMqFa`Un;gfo6XE*Z~I+MwurJGt|G->rftN^eMwASmG<`Np0
zfy$7x9U4u$TGOsK$f3vpaErB2y~MCyWiX%sy5uy9L9d1srr3qj)k6U*tR}V1tg&0P
zHnSSI1$1pDrOT#uJM!DZJuts1vo>#=Kn4scf!aI1oDb&@G^fZeUPZ9{3}qGZ9lhX2~)a
zhXu5T@XbZ7_-iI&$i*y~h!vVxR-K>q_0qG?{rdSAUV83%mS>*-5O|6U!PmPXEk4(<@kI#+GuZ_;E?4LWZu)H?6aA0!(-0b4Pxuvz)rM1bKrPZ|~
zBO{ajLlXm|bG?I;UHzlgu7PUTV6oQq#g{knS)X11yxG%N>+H!Es-vYBI0K|osZ>R)hc*#STLHRR
zc(Ejp!D%cdk|hrDxZ+QE5CoMuIkD(SCU?`Y!3A6s8O~aYmY2+nQb41n0JG)Tr>KZb
zk%fE}JzI2o~4u`?P?oD(b9h)+k;lSC<^2tOx1;LgTGcTbD1z;qt
zaa)VU8uu;LD&>YuewojbzH*QfHE_0&Nf%KkWe_{+C;p0-78_A}QS#YxQaEW?!63Wi
zY20O0Ip8y!E20)jFatBFnb3K_r>w&uA65hlg>@*Hgfrl5I4!CWjzuNMQ7EuKe(WfL
zw8av*Lcy8&(Kwv*5^{1(Y0lz2KmdPZu9V2;!C!9>l`NA0KG@q$Hv^9a9fjKoJQj}?
zO`L?t?Ufm%uuY&n|5q|8a&=2
z^fBYMu=3Iizt*S>8ihXWkM5tGJ9OmL!O7LJrK5*WpFgmE^3wb7U%2qcZFsdK2%=ucOgsd6)2uBXueLH_2^2Ejz8s|xlNekcd`0^EYWPM6E>uo_HwW3bvFj!i(Uniw|N
zoy0SM+M!VB4SF!xYBO3a2CPUD8;u4%RI(8TvbP;euIo9v*kI7&lvoExrH}<>b&Tx-
zl@$WFt+x=zkiRNbo6e{*nKfpU#%j@76#M
z*J%WR?H0Aiq4T-)ez(EzGJ?U7yg`pX;MRq`#*jzHxs3egRLGtPn4y3ng%gmi5nUpv
zN`}lE}3r=Etqe)|}2a;bRw54gx#X
zMy*jTm-G2d8W_i>BE&}qYN}8!!8XCO9gD(_$jNk*l@jPg?Tcka
zn9~aau_*W;KlX=K24xFXSf4lpc0hr#BQIcr!QS|7C0s`Fwdo>aK8*|~T*2q!LgD-}
zCId!~G!$^Za4agn_!Pc{-GD9NE6|JmaU;?UW2!=q<42)jI|Mz9r${`FzvJ8D`qNz$
zW9PB>(AFFtt=jXG*HfS`n7Ro%cynuru;>W}ZaHzV7@qXZ=BKw3!@t_Jd6S&*f5)bO
zwD~{&`~TS9rrNtl5ey_Y4!^p5=v3#({POYF51zO%zk1~I=t-9vnNlNLs%1-+bOAb8Vz?lkDy0%0@^m5<%jUEA1srXLiXj5-
z0-+#Yu~;k|4!c|~tUF!KK*(pYLH-)e7OU6m0f{YE3%F~x0>dn7jT*ApYPZTNxAZ-+%x0Ctrg1wo
zUZ>XM(D>b;uO18zxbzX9DHbrrL&j)88}Vtv9(6nb=xSnq4L}IZ3gyZ;sW68RrNGF5
zF77uZ$Xbe8;d3@+#f-nAn8ebOWP~$^3quxT3%iX&+BjX%JQhWGvl*NPHJk~X(?Ls`
z4s9z0F%wFMevz?B&p!L&3(ujv^y2fse(}X$KmX!C{q;ZbdcvLEW9~pYmZ^+Q&U5VV
z@Z|8sLf_c@$jpI}nU%3QsNt2xmG!y#m9@1aD+f204jvvFo>*Ksu(Y(=J1{mpG0TqO
z;Ynb)vv0WC>?zl~yLyKXu5siNUgyr8=cHt{E;O?BMi->5oX@q{*^PB~WQCh9w=hUIP&~g8TnBOGpCojpT*fDg9q?CbXn7NV?$^rlT2EL1(9n2i_dv6Iu--Y4D>m|_da=@k
zio%tYtc8BXRf1$prVHRipMG^
zNIx(>0_qutE=Y{ai@$P!P?)2Eq3!@nT)j|)UF3Ke0aVmtd>>){GFBX<4}>^Z1U@?c
zWDKEr92k2gy9V&vaYd)-xoZ_Qf^_|tj(=~Nn#yRc=MJ`P{-T0ZQ^)hwMzf;
zZ}wFu0J6LS=
z7HfUEN_VPQPnT;bnQ~1G7v{)?Qi&O7P<_yTr19*E(f(M*Vv%Grp5iMR4En?2U?Ks9
z9QOL$!EnGMmR7q-2cc;-d3-LH#{nvvt!9VIX|Y*R)LM+6No@d1EgG{K7$%P?b9D@0
zHXAz3hIW&FpT*o^F}3S7d-a+&t6AxCsGW9z7Lpf)ZnrVQnf_;w)8KKLu-#=>d7a9D
zM-}qxf<8mkXO0IzM-_z~EWi&-FrC9qQwY@sij
z!C6sjHYT)kNDo@K>dw#kdhyxke*N6@zkcC)LE`6s{p%N>fBw0D`)~hquGmxQ9Cihg
z#aj2o^uo~C{=u=C;mM_ei3MPIcxHKQW@&cu;NsHi%*?{Z;o~c-8!HD6jg9SJURj-(
zoE;dP7#^EpCd(mUc%;!cT&^Jiqky_V@M<
zG&{SRO_CT|1O=LyLutxPd(^0Rw>m59XjSXdZHQ(S7{V55P2(vAQvr48V>%T}73uU7
zsRW^cD%irzj1bBq016Mh^!GCLWszHivf=#1a*|`9F`a?sPSZXwJlkwWnVJXfHO+af
zV1ITbbDsQ+YD&@f0N(BuTvqmrnBMg-a
znlO%0mHXFmLNU@;4hRNffoGITS*{dYVz*js*2>Z;T_<$q$lzjA3}M20tM>fNugS@&
zk)hH4-og2~8gcqn;uY;Y;PoB)=e;iFt
zGY*1;)>Q`L5_g9~;7WDTN!cPgmT`#DH0&)ZUEHrynK|89H$=Au_{URmR1)e#24E(8
z@}*j>fzJ?j9;7gFB27KIItlP@xg3~N8Z9u+19*^C^!hRq9uWzLe|`zW8GJ&LMCJdK6kS6h}RTfR+)_3}r|%M-8Xkho}XjAbCOPWR7s9
zniNT%6Im!@0+Kl_nG(zE595bta|~||g;GrJ5l3Y%#bUWYfK%~RP0p?y
zIx#YRaBS)H@z>s8T04IF?Aa?<-n($&%;^&+#wHeeh9?_+BlWKFVq=hVIaIrnXo)H<
zHH_bzEfhs4AF5q8n?vn@mgj6;Fq{G4cpOGMsu~uFa3m0l_>-AfI2Lev9Fa&Q6beM6
zeuvYfH)!n+v)AVg1UxR6!)md(-EN1&X|>yQ2A$Dl#5_)HC>UEjDPORu%HjT@!@wf~=moexuMtz2eR}*rp
zf-Y6mXN>#JP_#+r#Go@d1rUnUg0wWydNX*8(a!8b0=j0$(D0
zrc$X35?6$}B_pA;(acG|G#~XM@sAbT9kd|gK(srYhObayswTl>Ml}<nyf
zBTcwhh;6#5na866B=bV%E6}@ualO6eBkmXL1Mo}c;E-#2t{Wo@u;boIbS
zclSVN_h7B7KaXD{7z|+q9OB+pm?N6b5-cUy#B{=x!oWi`&Ut@v3#uZOG%hv7ABC?7
z=7JQKgu|9PBNCXq0~EnY03>__b^wN9bzuu&2Cm?S$^b3^GA3qUNThP8x15|x*h#2|
zC=89xG5&_hJ!Du`p@iy@g>V#XW__THOQBxjRH#A;U{_Q~DoggHCZUod5j4)(VyP-(
zq(Q7aM-o$%7ee51f+L+|loo_F`%U8Pfrfn$2uAQrfmkU_fhhbU7=i#W3b+Lc3pJUb
zpN7MYgddoI$IhawI2j0VNHMUAuY^D0BQrS=U2KMuq19H^c;wS
zb^cQJ#4|P5k%ll%#Ujy=pmH)C4*2}8Xe4Oja0W*A#>@VZuzSL
z;D{-M!-01G73YNTg+wN^L1hSKXlTmlusI#U(vpeTT6O2=e7*F-O9Hw;FC_3Ey!65!
z;H@C>OGce-YX3?kS&gNe{X+}Gql>+R`$r}h`^RQSrk6*jA%#~a<_<0%*qEJLo}QUM
zxO({D+L6(*>4o`~qw5>vBjW?Z%y|DyB}>R6Y;apuUjU$L`x^|jP|Yy`T})$3(*78
zinb4GAX6??fbnV-FoE#JQ_7AjG80+d?~C8
z`3s`AB(lul@ryCI-t1joTpb^o8XMW)+dI_R-B)RJr8wCoOfn`w1wLza#@Ivh;u>Iu
zN-M!Em7qeS*@G>(`!uaMOH!#;XAnM^2l5GjMnN8!FQ6Jgo3v(C0yWW^%YvHI(>sWL
zB*{>46nljWCE1mLQvoeFx>{vDtX8YIo-o<);*Bdq7p75BW#kv`y95tTf-?(sn9x4Ogedt0^VCokw=!c|0LZQuO#)*aiQ+XC)x
z*|CYvXOXm$1Bkb7rdHmu=~vsZvTf7$Z8CIg^VX-I-W2c$i}{MxWQST`KXP_qDWn*}uQqJ67o)Ep-m(>wVcuce>EbF`0fX
z10${oDU27VtmbSgXoB(#2|lp|CHJ2#11hkIU-yxqxb~&tbD0^#--i>x_ncp@7?NH|TU7PKU|wa|Hq}zuyk}
z`T$^?F5tBUeAsRZ`mJue!EVt8yf$p~yNw=))?rooz4)scoVMH5UbjBrHMyN4s@Z0+
z=v5xK(dRRHy=JFf=XU6DDxXJhGVU|zcKJQpc-RsT8WK>PA*@(KUPF}QdQI_wAsIGj
zVs?Q&&XmBJ_Jbs))TyGQmy8sCW07hjV913`dHSNMcXOO>0ZXi#GB{P(3b?XYm~#W$
zumoip3(XaVWiiYuXke5U#BPZ2=274`p^GAWk+~uwwygNvR^9nIU(Y@F{BuJ1q5#7$
zz3}T_zwpwFFMz=>{PTbEFQTFJ^z2$BQBLK$28L$`ho}07Cx<3x2PbC7W|oE~=SHR$
zCg+wHm)EAI=a*O3mJc32uzGlScw%K?Wn=Zwz`*F>*mU3U)WGO;cmHVrAawBb)b#AY
zz|ipUXm9^uPybMN?-1I`W@m3_SAS3M5ZXk@kw#}%XJ=P;cQ4vC2x4g8&Mxc&`cmh1
zb#*nGjWRTHvx(*qZ7p_&6oy=s9<6c-L;;(dXa=E&V5j3D2joC*DTP5CoQbaKR_`nx
z=``BYa;1ir4i5tLN;VHYjZeo3p_tK#pn*W^AOoD*>@w0j+T=JY^uUuzqnA8f(sRA>yqdM@4KjrD~(6yBmy6r;>O~0Z5rEquH!>
zbvApz+U`y;STIryAFARCpdEx%t#ozPxld;|0E`ntF_%jmq(sVAprK3YBnMOTK#oVk
z1%c+k&q*;4Qz9XL44_-bY3u9;u5*$ad_L@&3d%3!i)MGm(D>Z!@<8A4v12FEEO++y
ziLq*xvOp}<4=M~Oi=|x0GS0r+46Z0JjCzGFXu&1((2nCR?l{)j%Z}TEmcHJJh8}Fd
zM%-U)l&FwxItnx>;4MHd(?@Vz39CV|49jYEP-QjhHyB_fSqJI9E#y*f_Y473FDxp
zgSmo=iv4jaYzJQfJinjAitqygyg1C1P#n|*y-^5RtZ=|_f%)Fqa-iyDK;T?1l}RU(
ziF7)Z$tLp!+$5Mx!AuU~I3A4zQmJq<8O&v1FGXw)i`{7pg?y=WBpmU0y$-L(5e^0X
zJ~!6&dWFkvipG4Am^To>TcydU4Fz1$pgS7!M1m-8uM1Mu7Q>dHGZwN(0#=tz<8hdx
zL3=o04*Ja=m(J@pK+%T%mZ0C{_ZmY1teAZs1J>P6ozt%IdkvA0703ErX0O8-_L?FA
zqt~Ufnc4$xT~er9LM~=bMd>S!`}N6?2^f}sYSt#~e+fjz`ra>dL@>7bF0Zb9gD
z#0nBWkG|=Q`H`vFQLZe^Ev`<_EbpIQ!pic&jiIsW)#cUyPkZn6
zY)Nw8`SCvi+TFh0w|iy)DWnI5f^UkDc7qCWcSWuUJH)tl*PG){`Kseh9ecg^-M4-B
z^cWZto@6j~V+jJ(6F@vI!6(c`F(%+%ghfS
zKVMzh9<1;8*LDYM`<>O|vm
zr0&MXS3FK~b>p%wp(IO@+66&prL15vj#hMex4X0tenvLb&ZMN9POvgT_Zg3sGQsmgK)N|=~G=K2s-f`R=o}8Rv
zv~6u~Z)|N=c{e&kUqSEHRvV2g*M%NZqtk5lsOzCAfJCjqS`r2uKd35w({&ZGS~hPQ
z+lj`7-=MluZ6$tMvSIsy(uBc@Oa!hxS6&rpVO+Jo87^9}a6zbm0D;hGM{bUHS0`HmzT0c`-8RXmq^@gjmvfhNccX^Xbj
ze40)nAGmHgn*p(w=_}>&sL9FA0BJ-sYLHik@4|&N*%y+u2r?9=&if^Ibl&B3o-^iA
zt=8i9xHS1I*vh8&Am)f^+2t8(@Em?Aj>73M(939B5vOz1ws=M5=#pJq;WcjX*Tf@j
zG+TjMQ?adhk7c8R>e1Wt8_VxW-JZLA?z2f(;IVVY;S6rg{xPV`M|r2sP#$9!HI0&*
ziqAvks~68}hX2c#uKW+5{~s}e1Fy2Qm|I=ldGPcb!|l8MowJX=^OsLP{PWYZXFvKc
zfAj5c|M@q+^^K#`yMwL6W`C#I+ivtW%B_CX?1YUNyCJMLBQ>8iF&y|BCX|2;Y7o)a
zGXtWUg*StrjyHf8f^96RJeD$9tYXe}3XV(4yIvucp1m{qUM9PsAav&F{-TaiBn*!%aA75oCOh)z$
zYae}FP-c@Rxwk|m`$lso$oD{g_9iru5gSlw^;HrBU~Hug@o5ASUpoUZO3Z5`a(JA80_`eb|S_`$>H
zXAhp-efV^1`{2phqv!V@4~H9TyQjUi-QLDtV|l&NU#-ObTHLG0{bqMamD=tM8|^;A
zjG8p=40`=#{5i48Etv8M9NsW)B||_jOr$w&3#tqZQz*3VkkXQ?n7>5%oH>Z{jH%5PH!gMD&;XP2
z$oIQF?1~cRLFmIy6Gc@8zTH-1Aj-C}Qo5ZOJ(#$u;j{+Ks)VTLS~UW}6gud{{W$J*
zIH^$w#Z+CD5*dt>S$bON)y-?Z2NKufLlU&5hh=P~(cANqmz~3>y_NmlgR|4qhgfXS
zpMS)~`^%f^YrD|MjcB6_qwlz%ewZ!u*pt_M=^eSp2Y=CM^4g=1>4f$p@Kp2Do
zNg9`PIT2+{G6)RWXtn!(fKV=jE?@(4l*dSy0wUWDg+()p8JQ^!&1syX)RXGY#1CYC
zXqjJd1sTU%fw1HE{q-BdI@!r}vt-TS{e%{E2`_5wuD0LzzYNWYQ<98;NuVBUU
z@+$F%)Qmzk8}k5B%%ivGHx|WYB}om#=PzB2sGZ
zU635UJa!RKfA%w<`QQH6f79!&+Qn#YD!sRJa(e&yVCQu0^y$-&zy0XNH%}kF_)mZR
zSKs^duYc>$zJ7RmZ)NkStx5hjYn_#9dr)e2OLbLiXo#41v)vvJ`*rTT>{sQ1=Y_y3
zSERJ7@J(J3$F_^E%daRk43CRNESW+Wx%qr5mtQgrE<){WZfSmDI-6beom}V@?LsD(
zT`c5NRxxYanQV4`YVw^zcFwa?BuG3t`S#SEn|2}XT64ZL?OHR%!tG*y3I_Z3qG!#A
z_IzM36tZ^~=fCDy)4n@r6>eF1FnrSnY{gm6p11Rp`6V>&ZE%%@DBIavxy5&&uMwai
z4Vin(PTdToSz-3A`PnxY7rs`^swp>AxboCUycQ&gC3zEvFdOP_bQ@9z)}(JTxSH}v
z*k(IK=?bE9GHV0SYK#uhJLTjiUEr#7IZG$%TqAAIm|vj_XL
zT%1>^6Jr
z-PP@l{nI3^@1Cr0pKk7)92}k<9o~EL==sBkkB&|stgr1pyZ7+^@mYVkwY<64TixQU
z)?mHeUxU8&Ru2Hjz2#;+h~eVV9`S{=2{I{+icgX?PiU?+_=>$mjVC@HQ_Y)
z#QcccbrKY2-R)q}0917}V%^d>8{AL{@g)VU$HjMVbUHjq9y{RCFqX#MtwvuqRHmHO
z*fhH5Mzhjtb7wr&aP;=P`C0ns8}Rdf>>#QxZ_jTmnm37LCTX~I{?kbsBz9r#h07N&jl#@Bi?R8`b{g?WI&IcY5#PgU26l96nqG?+6x-NH>r
z&fY0k4ZzU)mX8hw-npqI4F~;pF?}mAV`Y@=Nww@+w?a#_uL!h<5%
z)=_8*L`f!~+E7{1Sho@+2Yd@7aFgIH5|kdJRDdY1VG11#v57P14Y;
zL~*^+s+F77QrtxHR(o-^->DBeXx~<>c3%L>7dK0@nFL-X<_L&wYRs$z;jC-jPScE#
zMXEJ4TZ5T_*v#RN8XmnpFL_zrINaJkUSHqc+T1(XJ6c;==hbTSdh}K+_1H{ok+`7E
zfLYDBp>{!j^iB{}{c_bsim7Kg&sK!y=c9sF`~9au)PRAS-3(q-g3~5uinjyfL}O_y
zzg*US5hTFJNDfub8sXOPASsI93Q!sRP-})5NE)@n%;oTlU;KhE!Wvo_+-eM#7cV|w
z=kw?9vki&a8AW0VOl4h)>NY6RtW63zhFhQr{-Jb@O`xlAs~{OQTrfkILtkzN!J5ew
z6VGinBk!@<7KvGdZOYH*ibio-d|x^3i#8;N!6?^E!O_~pc2QtLVgzx5K)!Dxh%+Wu
zD{HzK@j$pPhbSSJa}aJwQc}5GcZ_p8l`4=ptKR68%#7gNzwfHY0e2O67<}quMo}Ef
zAdP)7+l)f0zX!fJ&!2B?VfSbp8-4=Kf)Dcf`h3l#oaATaPYQ&`?Y?<;{$Cb!u;weg
zaDLqQqLVoa$CIfH$1YvFba6uI(#RuC&M`h-m>4@ZZsr@leDVC)*rh9%$0oq=h0k93
z!~gw{zx0Ja{lcGoHJ5en-FyGugAbRt?+&)_J^A2!CyzfmID7h+fAPb={{FYV`SC|5
z_Z|(__gcfvR)4$J*{HTxtIa{9+2d92Qt`DrH6#LmWYjv;4RBb4c*sw}%YiKhllgvt
zR^zUk&@F_rW%JwRsH70eMJwz21bartmHD4@b1K)zgj+0Ag7IV3@x<5I{
zXh=Mr%gzOUD)dvXJ)d5@HF@VP%St)UqHE9kF3`ObxU)`S1~u#zXG3Q$ux100jOtx{
z&(6iY-h9g_+2j_w%!eU7y=1%qWi}@~uGO
z&?=MsC~p&HrLgCO(CR~sOwZh)C9-o~ZVas&WE>8kXThJX)Ps_Utt=Z;^h|a2XrzwFN1=`iCqqE4qa$M90D6VOGLse8A=tvx@qG?T8PnK)NdVweAEC=Y0aP;1mX
zoC|~h@gM*37r!8h#5+5?$Y1QM4?p~fj~{&S5#l)UOPjB&<&#f70V-H{NnBE)V4>*&
z^N;`bC!-wyYP!@^rOF}@NBkF
zEZVHO*66^me&zV3RIZrU@YD*E=6j)ijR;n!WcFyjCNt<8J0Ua}PMhJNIf@}-=8RIO
zuS`0RWWx~UnMa|zBw;8lEuo&N|K)_@PXXfwxnGK^mgVvV3wfJ8WXAZA{ZR}Y%P$m)
z>T;w$hmBFovF6@r^CJqna@VW>0>3yvke*l|PlK;e$KM{4HFimTkQD#?ssA}q#tDW2
z@Wl(PMOik;cH#V$^XC=4g&@9oZsev;$ZaC4ul!$s^wqC?@!c79Ju)2yz?4+mSv
z{oT9w-~aQ|haa6hc>lu>KKj9TzxCmZCsc(i8>cNz^}ki`Zq%B?W<1b{`TQ00XWGU{
zY*pk!5rbKk%4O4w0a>ijaL>oW3V9=Z-{&c!k~!|0#^4~d!^pAhtYu|=j729O1eR;(
zGE1{oKIPb%Ff4>Y)+#I%vWp%^{ethMbJ>~c$+zv|JQxn#lw&Q-OusWd`Igbgvq<5{
zo%3z<@q%5Lb&8V6j=aqfbjB&p2<5<
zJbdsxj5>L%-0ZA&hntOf*zRw|!@Wv-t-E&6-#A>~Ia%92*xftr4cCuO9~_x5V6eKfvD@3&>TYbehTENiN+>ttMyKEGY7h_9aJ#!wt#_(0qSNgUmRT9P
zDN-77OhOrhVPM?v4@hmKY252}_%K8|CyE)RH|!5O?HIMGhE??{uEcR`0Ej!Vs?DL1
z~e5-i2s4mkm)(T-rV*W-RV>R}L}5gS0AdR_i<4Jm~V
zADt+y8fP-NNcgJQTokYw{ZWqJntB$gxx1mRM_h>f95rral)4xV(haI>+zu8Bhmfi;
zl@c_hhWO158>lxCvgrOU<#44iaI2M&Lwp^MCP7$nv(`0wSE*C)cEx5&`;^2gkV`Zh
zVmt!9)y5{E`ZV!e3W@oxVK4vxE~Vzm+V;KGjiW(-V|(l1`0(zqzq+%1fC1L+t+d*G
zNK?gp(oiiJOSMKVuGbV&S1u*N>S~On9xEw$r&Dis%C#04W)EOa;?k(+Rjq6MvZ`rI
zZo(2Y996$*YHw4HW%;&7;F2qwsuBf>NTp<<4lyUcXcMc^s8t0y7xGT4*+ogC%n|?t
z+8_S#FZf2RA?wE{|NiH&&~c!cD*SC>CCZGAU``{ol;bGhj<3mC
zSSlFMJS%iyVyU1B`Ejw$d9eI6JmFB|XO$xphfy~JwX*Tg4Vr(ksDJRM35ZJRCQMCI
z5{h*hPLBX=0<{cx4Rn<*T|g5XB%5iME}pyml`nqn%U}A_FMjdOT){g%dwO#J{r={0
zf8+S>gU#`Pm>p8x|K}Ejcj)B1;Z%vPJfE
z;s7^8c4(Xs4`7=H>CwCMGMB64SFVmvOaS65*RC1#0^kI_uU~)T8dSaliC@2d?e*8M
zz5cn^K4%r(gQEw2sgue@_4abyTP@XkseI&B`Wd&`9PW14_WK(L=-r*e`}2!SzZRi>wBFQ;Jw-EZ#4UB)mE=UEeV5r%aX;NVYL}oz)Gvr
z=_*PK;)=CUuQ%v+`)qf+1C$DB&|m3xU@$=JuPm>c{;_=Sn^5ZhaJY={mAARw24&C%
z4EMWoUrYG5TD-}~N=OEG69mHJ9!gOZBTsvzZfk;5zlZFmG_@&{0Ax?$+EfbCzHBJ$
zwF^jAqr7y)7>GwL6rax<#Q|z_N51H4bFJCgSY1Ed+&buX2FFMDwl{ZISJroT4&r#&9c-3s
z9RS>H^;m;X-j+tAh0#{6x5H{9EUQ5mNXXV|s?&KX1Zf%r3uf~q8ft=w(HMp|h_`mV
z9s>Zl3l5R9o$inXijafZJn)JfU(*^=*9(m^zb&XC>ZI7|a51
zQ0M#m2Ye|s>$9itv+>b~Uq}DJMVN{%guz@IT>bQ?Kl`u$^&i4WR)yL`#pcii4|{xZ
zPW;;+{TMj;fyVLpyTALt*~11Wa>HQk$>V42!PH$_+hpT=-~E0zgF2FG{N$IP{Qb{<
z4$lAKAEe9w#q!HvegbYWHPE<}#&t7LGw*P3*<3MGMEe#aVPR
zMv&MHg4R@MTU2u#lpsjvo0dX#^eQFiCeD8zm&yNIoix99{+xs_>h@Eat2ivy7u85S
zerastJo-4@Tb7OsOT-SLE^Eme)(%}zjgCZzxr+}W!-)7{^7}!
z!TQl~=ibr7j~;#a?W23oo;-c=lOO%{w?2OQ!TaxTY#()3c3b_;hMdwX<;Jku8i3)b
z-U{o@uv+JFl{LIyXnHNm_3UHkkpjm2oz(*0FGX;;U|abx
zusydJ_%>QOmrE6L85D52#7mhEynG=CgR{urz)eS9CZCyJoV!`_bI9eu%LGntX>M|E
z>OJ2f0~iK-b6^kXqDO&W`L*dn5#z1xg!Qal&HJq{zc&}PR(l(Vz0D)m>pQ3Gn};VS4^hMW
zC->Lax1Kz@_w^5+t*vY=ukQC&w>zubt>r!SpzExZo84-wiyChAhV{7D>MYkZ5}~4F
zTJ7Fo07}t{Ah{2Q`@Q8j2Ee^`i=-}1U={h=ONc$tNEN-F0;>75?DvPjn+?-hsa>fc
zBHPQuA(9x*4!VdZbZrIdbXpC?J&B-5!+417?)2MDq%sN_Riuu#NJ$P+6m|f&g#Ltg
zV4X_?N-9ohN1m!?N2ozGLwbrd0IS0}bot0%4F^r^mHf{LS?N@b4GEZ$trE>~vmQ4p
zon|#|B3>nV0W888qRX9)qD|Df(b+0oH_t~(OE4_TCde13DX^u6b5ciNry2%M5ZERU
z4@WxKkRIcp3doIE*MKLAfa58fPRTs6PCFjGJui6)YJKXc;o9En`rgXw=F!pd@!`?o
z-tNKf&Y-v4AFLyV9XEow?RXGr00(sEA`ESX$`{<*OKh?qi4FVwz6Sc>opZw$}8Z)G%5vIVfZ3W1j7R6~#6;f*`bQJCn)q7#)%>G^Z&1gy@%;MTMX8+Y_5Y5c59
z*DtAO@W^+q4U-aaEa^o{8She%0aH|!{$_W>CXJ@yN)%_wt+E-6?6l8
z+R9G`4tthL?n1?#gR-bzr*PBC-T>GYKONW$o{e;dwdxTR7H7%`Yj?r8rtjGK8_4Cz
zo-Nt)rtx?dscNu22|FE9?uG{@?a2^@YR`FU0G6j(u~#VO!nAzUMFcU2Cau(s+``+7
z(_hWZy_KDNCpGhScJ@Yg_NJYhaxzmTPR~s{S?E3=IeZ1B$XN=l#h|zt7M4oZQc#$8
z3bV!RR1xL9a3jBTD?5Kusjf!L6H1*&ITmmB|MMw?5c7>aHJjR`=U0d!6-z!PepO=KgSP
z`|$Ye@aXj3{Ue^O+b+fmz(^}hVuWZ(PE4A)&*oYC=&F)YMO{}1;
zE|8}l1j8tjcHAeK04y`qbbn|Z(cLcS<%4lPcRT9d1gL=r!Wqu8(eDoi{ee)YUQ8NB
z8Tt)-@o<1*hVAm-f?@Vc2)5Ot45W~i0#6572ou3rLN&Q5Im}haOEQHi4vU;5@LPh!
zCIk#w+^B&!DO!=zIN+#@*^nw0nAIe#t%jnPCC3{OSE3Wv3b$$`9<{|9Z!;pBZAs_E
z*PX0MrsEKJmvlCQSjD30jZGjWov3F@OYX;%ETN3D?{(W47MzP##?A%<6R?GF_`sVS@?rFEPe6V+Tu(P+dh7{iI3d3uN*T4)M-83DF
zP{Z{G2GRfwlT627&80(y1`&BX+Ho)O8>7`Q?`phnEuorhq|kIHQ^b?$n~U7!aq^~7
z`v+kuZ#&2{4#8UTfPC8xvqi^p6#PX|wYp~21i<9c6gakP+Jk?gb_x?dz&Z@0pa1;l
ze7hGfK4`UK(~9{|apqt$P~=u;sl&P=9=DPR?mZ@fYs1<*A)
zRO8U%QkFGks_(L`Va2LE;sz#B1@M$L;I@V|fycRA4gqczT{A?9%OyxyDoA1gT(9xR
z`&$h}F&NH7I|6PGT$#`?kqwGB%On|{L=FOH*?FJ2lU
zoU<-poEW=smG!^-KmPcgw{Ly*&39&I7LSh3?mm2fxN}rr*-
zwd6Z#-%SU8*0xjWrOEWdtU
zy9Kr2`qrdoJ<3m6nLDsHDWvQso@9jew7MPV(8@}VV!oylAGM^mwdfZ(Wj=!OMq7Id
zA7ed*boPof4mJc0x$(kwKvlVx?>dsZ{nTj=IRPyg)tjcSsUTFI-lE8Zz
zBwx9VOjc`gBA2gU<>*!8rvAKbg}d9Q`F!aMU%I`pgcymVT3l-M+)C%Y>D-+qyFS?N
zZyonH4pz4g);D)gPVPNEyZ7M!!;Rh3_4Vy%4cON=O
z-zvBYT#?A!>vdoiFavcc$V#aU8CvzkT`V0;g^l7QOWdgS<3?Mp!supbT542*v8hh@
z#>%RwD-N+X&AN)8;+8m+thoeeG_lPU=wGX=t(v6JFQvqEP$}@Kheszc
ztk+*b(Sp}{qZ^eQE@I1!oJAF%aFI0(7I9mhQngX#s~dgHPBa{^0C_O%C2y4JoEZUC4u`)zd^Jh?X9V{fx*Xx?jNGR7Z
ztT-m}xmIh!{#>r$d2(E5O^h@~RM8Bu9EI|q%Vq59XfB6|poZR1<6|q74E|ACK5tW?
z@0YX@RS~b8q0-Ehf?$#-i3m=RnJ<86P4y3SbNM2;OpF^{L|1WAsVw({Wy2q9t)?g~
z*DhHFjqODqc+XqgZg(4IC~x&<&J{D+d?q7FZAJ}~e}Zp{IfcQ*!@(?Vv@}_`o`4f#
zBJdr#Jje(ZDO7gdN({DVLE!*}1g^`$R-b@I;a+Q$CTgJ-J;
z_xkI{YX=W@AH3MQ_iX>}vqz7g{_qFiefsp-y$6q1HV?bYn=K5<-f|`GS6W~=uGHG4
zYC_@$&j*{%#79S3lUR+$2GZ-|g%P6Ia(D~)>0KQ`4?EB|4|*dWos&ldOB@H5=jFms
zV9w`Ku9Guu#uf_Lv$H0pBR>^+8I*A$v#>OukT_coGwk$=DUH{$a3k`TLT^zy-KD?*
za&r}T5$J|S=0@&3>$0~LIg2GPfn1Zg$Ge-cdIvXszzW)9C4v3<9hHPz|K#)bwl3pps1&
zBa^duhjkJ!tp?-VBzgSYjGLL%6ih{B2)HXOgW^mE=w`P;McBRe{JH8YggY`T*wcXcblCJ+iw)?a-+Q*l-lo2
zE;{8-y}#aB+ik7v#B2Ng&7{cVz$+CL-pTi_2iybG?qZ67GGuV_mJF;h{~_RwR&K2%Ijj5MY|@=@{IYX3GRt8gQoM_QaTdV5~-vbu3lu6OILL9IDhS>Ib(
z+gV-RI6XNzIXc+fSU)^C9t>8n$(rq+>sJ)#9uLEE-Q%D9?ob(F$~q29HBH-4s$$HQ
zYprCEOBg`?4uefYvPL5Z9#r=luZ-u^jIo*=$8#K)pHH07Xoxkcdo&`D0~^RY5<*Rb
zTWP-Dpj4_S&A=LY(bkX}xg0tqYMNnFjVo1SN<%mj*`iQUMf_Y*RPoG+Xz+em&Yg=mP#%=(9d=WncNZ_*w?@>kB3^lNXqj4r{E(Ep_j>dyM
z>U|pq70dBSuEvHGeOV)3b2%rQRmUW-7e!UL%gt~Dg?tgo%iO(XRAtMOHHt&w?i5hC
zyHmKkYvJzh?(XjH4n^Va?(XjHg}r@lci+=r-}CP2pYMB&!GOKi{u7ZiBV*2tjGQ3w
z*Rw@d$d)+rEwVCp1j?lBXYMAGMQaR4>%|y1ZV``_FIQsT=7PXOC&jno+SdpJ)G|qP
z&~Mj?%-@1e+{DUYFq;*eM1q|&rL~LPD7o6IC249{y)A?b9C6;n;t#Wz`kVnVnj^^E
zSEQkf15Zsq&A!x)8SELP3U1TX(G+Ixt)1G${0e}n<&_vJUKj>>u7jt
ziowUr&h~np>U`+A11y@{S{s~~l^1Lfnh%>IRe(*zM~jK*^pJ|EdMpGySc7b08M7PA
z3VNaaQH}dIz62%n;HK`N_Go4Qp1cBYsqpoB@nPeweybL19%!Wg7XorHU>jx5gk+1=
zCqQ>8Md5U%r2xW5A}?49^M3KE
z^-Q!X>3#CIp3j|btsTAE+S)pg=l%1`&P>O~dqU$vRojrsP>9QdldDw?*LqY)+eD8F
ziFTP|a*u5hhpD5AuU*v&XrEHnF=n|um|auDxQZ(L`>)5cZ;pMD;V#Nn)69HBzWrjd2i9FGo
zoaXB-fCC|AacInoI1APY*A1X6#5N9n&#|xH1KH~_$2Jb2O6C`4(DjwL@XYbR{l$Z^
zt@-49he%+hQNW>5_r=r^cwwLq1qw*dl1PTB%I{$P4UO1uvCt<{J2!v_a>
zMQRWE40m)rlq81rXAXYD)NiZss>XtwCN=
z!^#iVgfWcRLpR4?fSWjBt30-6|4|JbrTnro^#i0kY#)sWEiEXs1I&@m+zO$I?~&zz4G%kpQk&zlLC
zt?XYLrzZhNXC5UT6Mc`rcYcq|RW%&pbU)vZyiRGq9k_Hld|viVeE)gd`6XGqhP95Z
ztF~he`&NH>-7e$;?0}`|Bs1XB^+n*YEFj65
zF)kT+h`uF6%sc)4xv~NEHYmr2xEz@812V7Hl-COKvG77Gj{66U5ebraF5M0!KS#Yg
z&rLi%%*<{k@5i~KnRIT^M=$jUWb=FvAf1JNU}CLqtNSlA_lySMz1($j;jlY6TPp}U
zsNInt*0YVqR(k!k>G?Uo>adL)nDEVm$Bv~9d)bY1n8@L%p-nrI!C7nZrc=K~9!=Y$%|tFKLM88V2P)O(hYZmsANWwHs?ZmsVflenkU#PM=fM<>U3vUP6M0rl!a1E177B%M$A&
zC)L_U%?sx>aZf<^sXzx>w8BBq
zlb>9tEyPHfx{Tt!=KVBte44aDsQL7UZZ^`XNj;cuzrWAd<8D8g)A$)Jz}k(q6qm|p
zFr*>n;_7Eel$r_DA+xMA@7WBW?yRzR4UN*FgJAQvi1zcTo;aev()%w*v)7k0|C
zTPW88bZ;huu@pnUSzCud7-_C|QcX1bv65MRxc`r11nxFTt7VJo5!iha7L8oXo6GD!
zv{p8^`kdQ*YMp93>N*^)Fi;Ll4nuS}R$Y
za*u)aA$NXd(PZpYk6@8tgJMPi=B5?2nK0WR#c|TYf)VnYvvU0UEG}j+pE0jCyKSDI
zPb^(ZBOPFulw~-H!EDS(XC{WH0r8Ao7G)A07s3u-^uj&2Oja1@i-k*>*ML@}%-XBE
zBcH@b>R-&fO|1q~73D~(3HL^fuf;S>0!5cZ2_*_sc9s&4+?}1DH3!b)&xy3kKN!H~
zMT{0vO2I46?^~*1T;F4JS)wMlj)DLQaVPCYYFVhzqTln_PM;$yG7r5{_HJy8aE^SA
zro@uw)_yLVt?*0N1p1dd+W`%#k7V3MmO|OrG_cwRbv3G7Y?HRuWD1sAH;?v*M)!vD
zMc_F{tCdnK>-eJpJwImrKPXRbfasom=4&M;xAVzr%T%xYa#ZZ^*{MIBlY@MKve%Nq`$_55DNNc5Ch1Y#S7VNACsZnM|Lx
zh3C^gXQL&((cj`iCQ$3_#%e~s3813>z_73wsbl(mj3MbaATk?A;kaYniHkaxcc5`{
zKC48_qI_$g1h#Lz=+bZkxJ9AYYD%Lta3wwmey2L+7P!0((=7rKgKtziO3wL6KvZ7K
z$fbIJJZS^`C5PoFu_sypO04MYT<8YJRJv>{X`9G%IYJ$ivU7i|
zu-zpbl``*2JXvOx5of_@$S{mRzeDr*Oqe+&=M{H72hqebg}gZaj|#hnw)JyDmzV$z
zd7?8ubW(4oZS7E$BwERH}yEIz2!
ziWieWP`?vjIIX8)7@tfMgnd
zbt{4hSQsNV)aIa_bA+YRLIFr>trtzk6?*PEkY~1
z1oxF>BE3Cvl$y5a&aLGDE`x>JVAebr$~lTVyd&sFdX^pdA8E?X2KN6XxQfq(Ybkk>>W&kaP11q;U6$Ixk}>cPcnHT$iQKlfo!H
z@Xe8=UXV`k)^f3Bcq%w{LHc!BIW1_QMZ7H*zC-``P=cT5mdROx{xFFX94q@{8}feVKd26zn~2YVV6JvomkGzlWhp&`Nf5Z+wPP9b_VRq`_O
zWD*QdzWUA@iGHf?u}YYZSBH{TBq&J1F0Y)xO5DU$!wzGt)HXcmH!ZXB66tqsixD;=?C0kcWU8D62a}kO&HaA`t$qe%M<>0K*{yJd`%N0mxak4NzJ-A
z8r8$5abwe>`c~AEv*bn6-Lf!>%~$ISyeoX%oDCmGTTd4wBL|ef%HqfyT4cMk(j<&!-UOe*AyPX
z!oe1>{8N$jGk7k%?r~ah$%K-k!NTS(d2!y+
z`P5;4Mqjp6x?XeAFXwm3>$6dD$HYFp^kQMQ=T3xduV*=jaY{yHBo1NWW`08XF@@z}
z-&toJ_OXoNOi^wESr@WwOC}`Z)3Jx3{Yg=egoym5U9_Qrl1c0k-9Xq2_ZP9H0|{`tKloHg$6eEoO=7X
znHagfpYQJ{hF=`pdRUam$8cpOi8vr8YZg)31Z57Q-7B}L+BlzHXctv~`5N0BzVk2^
zmXn~wnxF-O#`+w3GI$1rJngwH;j!wKNDIQOz@13HasqEr1-Y=&tYy5?IX
zF!wQcDi{s{dJ|F-&akeu2;h{Bnl)dFJ#rbPPE%S7KaE?o!D{51Wr{A%lX3pwIQH_q
z-wy@$rQ7CeoTLJ5`r=(-LDf;GODv^|6@Iur)MJt*Mn4UO<#WA^)AT>CiU-HQ8vyLs
zf3+`Yal`ITb(#%_E!iPQB+(?b$g|FvEvOr8qEriKfg!Ah)Jds#{l0{#6c$F={b&UU@FOlPBUCM*>n|q>3Wf><0R#nj
zMhKK$yAEUp0t7Tb4Fp6Cc;aeF=VD`T;b3ZH`*=BCD;l8P5r4!vm&W!hS2eI&0(Jfr4}8wUOM6ZwRNJJRXjrlsejBCh98z`
zk^ZV9t)+8iQTZD5XI#{%80w@rkOXs!lCVhUmREKMnP1(HgLZRN!+j*!7WGaqhj%ne
z>kYx;#HufuXhw_*8f)IU^P$M**1g5x2bYyNS`KHlPW+m*UtNKjv!^hWuGR>~Kr?!*
zvXQ(pM8ABw{HpnM`iWz+XhE@UK-7wz_&&yEdP037Q4VR6cm{GlS!pL@!c7L)#Rue|!CVU!&p;_=AS&(MH8y2D&{UB{}5JqT{
zR5ewG)%{&5yG1GcqU6>sEtCFDhbRK+0M;X9cx65hGMzJ}I5blWHr&7E5C`&_4ihu@
z{)G4LZI9A%*b91^o}{Rz<~{xm7=?JKGrXG@zMX7zAXN?gZh$hFAf=4%gFdh!f?ra!
zqR5_c2S@G9yoQ6kQ}pS0#)%u@s))0URy!pA;-|vQNG269UE(dbKv-G5FwypvSCJ_<
z2*{RdfE3USiWF?PUj73tN|me^OA|zowT@OL45OLU2$G&X>sS7aUvy_f^F`A1NMym{
zvPGS_FQwyf{Ur=#Jy0lhq4Xqn{uFSS#l?K#X706o1M4?2$@EE~rXU6Fu3%NZos}qx
zWCT4*vdB8WPyF4J^vn_Ir9dbj2y;JvQ2AGB^3_vqDC>GZ*>A{o!$Cx%Qo)IQXfz_*
z9uC5n8w?3amDIYk2HmigJAq1RwHbn7W$RMZLp!8J}@0HE=s;gx;!hmR?
zA|o3DZ>zmLfyT)s6%aGY=e=SseYODBsF0O)iVr9B>bUrxS
zl~Z|O&3J$9>#AOAsQ5K@#<+!No-^Tnb8$X#*7bR@;L$bK_K~t0a=NVjAX>I&`8e$~
zu^TgZ2%lz7Y)@Au?gn`a`vWch8tW_$VE{4J5J;OkIBXOm&g(6CQ
zqMGN;{`~XtllS+|M{R*_Y1Bb}fT3?>N_WZ=TDnW~2K{IzBGsuS_1V%P+-~E)DxJbiLNB5*T$g;dFHQ
z4{nOw?e~^&$A&4l4>mDpACJu+w~wwX8+z!4ZGx4c8(-^x_)jiY{ywT1?V}xb=#Agh
zB-4-$C%C$(*KuWV@zW0zM;oIF>0bThVPs8I0k*5mrXL@1tj7Hfm%hWjX
z0<%0yzTi*7z#{enRJjlZK0FEF#zLAZ2BPBwSS5OD348R!{q{_OHvXTha7Z4c{t9yw
z&?uWJ(vzx-@i=&ubWnQ;euc$l6AT*c6yOp&;h{Bs;;RFGT}8CoB`
z6vQKl5!zA=%wL(wG&pZsehy`^)EQ{>;1uj&Q`F7AN>I9(k3(`JeBPUdJk=VEcY1Ey4apo7UJ!N9
zILh3y^ah7N6O3BHKya2_E8HHr7J`m5F@Z12<;(2bk6a!ja@Y_f+HZ|K3zfnQqPlei
zRdC|838*9z1wia}#4S=*t!n)g7{*{l_i}B~*P^5u;G+z=tUDZHD_w+1vaG@!5Xq(L
z8RQVlShK%Y${E7=B@|hH(~tiEnisP~MLm&|Betl;_kqq#hodxR0s=45K+U8iXIGZ9
zElUIga?=7RDlA8&J{|tuf%T09X#v}_Z5Wm5vVKk*H;|K?*&q~q%6~`G4_mDGF6u)
zXqry_@{BoeKVA^Loac^O>FR)5PD8G=RysfnzQS5TSi$dZLC(66x2zPRuZR~e9pn}&
zS3tG^HAxVoiCS(ZUs{|iCp{#<@^VMK@Meo-@r@&y#?vCiS&$kquGpZAbyr3?eQKs4JxsI3rs=l>uID=|K02bDJ7&U?4;7e$0zlP
zs;P`!!k34Z&r7-AmXD8hI>@J$t`fuibCmtJe~2W>$^(>s%QFXsX6)%?7CQH*QacvMPq
z(|W#@%Y5v-T*dg6R)x)lJy_{y?m;caUTR>p6JLKff3C^Uv1I-Q(Aq*;4rN1Ltva{%
z$I$33JPcBb^hcS?xA(!&`xg(Z+ZTM&EZ)mcr7V>O2Vqal(uw<+7bSFW)MoYAP{@Mh
z-*|&5eiAk+V@Gg|E5Jc^FwlGGsDl@Bm`%!k>H&#w=G*3&IuPaiqIIQ}{b2LNMyP}q
zONH=JDKIOj@&P3?|wys^cC%qgDekDKF+O9O}1mq$;!
zCqp0ErzYi_x*MwnXIbsc6b)OsDiBm53wgw
zm4)EI;0-$YTH54Oi?s^O6;aiC^g
z$oW*}^_2qJn*jd|3_rb|ve8N-)-<=Xn8UEAEg+tylfS$|;e
zIgRx+i18Bf-c~rOHW93&~T-jUBpT^%xO8z#Re=XU@A62G{^hT~WpQkGy;x8Pfq2km&Q5=WVzW~2!RSv!w
z9CzOcTgN|%KF|}cp
zb-c7y2QC0^FPY$`8hxN`m8JYr^rjkqpp6st>Qt`1LR@rv1^)+AMNsqL+BcZ+Q6aa!
z`AWT;OL&$pHKCBG^a$!*mQrwZq4Rjo+0N0@0b$6pR{7f2Ty{f#yW!s5SpE*p0`vmB
zLcv^!M+gp0{s$(x%4*@dR``KaPSlDszz4y)R{vhw1y~v+$#0Dmd-7zekp#~!rWjJV
zlDC34tT^!o-R1H|dP2=7XJxX{A_Bgy8Rx=NFY%;j?P$S{4iv4xL8
zx!n+rEyGAj2#x(6^jU&RLXcGYP)7AGm8Mv;A8J)iXbz%z=%=VR-@p!DQB~|iSGV5@
z&a%_fsD@Ya-@Zh%NaYkg$N1W{OrG7ga-)`X)U*K-pAyZ#)q0Z}F=Pz?xk=eq#USJ>~YM8&HVvPUHZO>JtWpNn(pkh91
zFVi?@=jh~enWcPG2Yd*D*+fIx=Q1~|$rmI$TQ2o$&;tDA$lyi0>>sX7Q+LLLLj^_#
z^%hV_S!k8Rkkp_RnIf8B9`|n7CV|KF<5eX0sG*!eAmSeFqq117|{b`DS4e*LQi5saXZ7jOdX3VR4I@hGpMwj$a=>{
zeR_hRt=28nq6S#+;3f^W5S&lGZL%^!z58{1^kZb$k~)W5`|R@Tt%ceHF7%1wvGPfe
zxaHt@_Dwcq@k=a4->cHS%iLOPvq>@H5qwR>&S4o9g*IPXXhyzDX3Kj2%+1xNfP2R*
z)tH~9Y_@vKaQfNNRQQV)`;W}IL)>Mkt$?+gnoSmY*6;7)G))*m@pha74=q#hB}7YN|N
z%NuxN0}f2NEF#W+-nUtkyTBz#Io=tafbsoTc1uTnH~hac|4(xJKSsYeLT=Qxp2E*k
z(jG|9g1gvYWm!hdT1Su#4z+du^X+N+XV-wV)<4WI{jbq~addS9RmKS`p!tH+>=5++
z_QvdWD^eA6ifyl)^=+YhRl^%#{=t8kPx7DUzY1sHIAJ>fG5X%RD
zpG>0mA@+!@zKRbGTi3=F8-8TWXAyZ0^1fdHF#qTazIR5~Uz#6+&U*R*06h>ukNUS-
z6!V_}urh8+rjH(W@Jg&*aGy(Dl`wF6Rtv}sl9v7}0kJhsl~X=@!P;8FjcBbIa>|CK
z`p4Tl&lJX*9pY8$GUP0M0vZ%CPG*Tr-`VNSDLR;m;3TY{Tpv6Z`ozJ&8x~~381fTO
zJvn7R_V3KSECovsT(~jBxY0s5Gv=0`Wr{P)jVE#o%1#BdI&h}&%mcG#Vv?!>Y8Uz~
zZ(Yu&nl?8)%M+oAvYB!WZlkH%^hY4W!mEYw4G|0t)f{JOBNOpM9+{`!!b74VU82+?{V)!u#Oeswk^-qMUoet)X*H!K8X&Q9|}&
z<<1|SKND58TsZH)0Ast9VG#2XUveB}d)(Z;b+^m&nq8r_>cZ6!|DAO~$W-5Dg?<%+@Fv30mRs3f_43E;yx`KgbL-vf
z9?BW->mxVaC24jP(Z)CV&JYjJ+k0)-?8XV)
z&Iumxf}m3pg_Gxd{erO5vdPrR+?2;g;@-H<27GJ9UDgqAyND1&h_D2aX;S}2d8;>x
zJg#6wAy|MgvV?9#|BiEl85E5IG1d=p#-2sf$m#|g@psHP8*A&%XzPm|b5%gq*t<3C
z<<)2mL&H%KKBOj6fT7CK5uu+%WK3uqASO
zq!Z)K+)(gKNqT5Pj%}VGB&ZSK#~|cYWkK{(S$zzJW1#a0j4!Xnd7aDP^BBu3Ef>C>
zskIkjfno0_z>%Ku2xJOW$nch^gpgQ#x*Fn~qnEN;kYdtrGY*R2D8M^gV5_$E{QfHt
zC~;el-@ZsKqu?H+7OByr<36L3sF}u+3ItrV!6n`jLq_uFy63UeJKQi-eJo40G6FYS
zZCN3&#R;JFzKrwH?fU9X?-zoeik%C5eA@;BCO*{6>xPG@B@QS{@HoE-W{_k|EmE=z
zJb4g;KejdO7w2eN2@IG*Vk!y3o!tN#?;a?wWOTr;!9|Qp5Dp(inJ_5BGqxg27WqQ@
zy9gKamz-((Y(FWFL#6Q!7!pDKek@rmX0D$6x&TFTA__I}HF40mS$tn|U^=ck`F5cA
zc6fjbH`p8){O}MG%#aO`eyT6Zr#uCD2SoDEenq>xLpcBkJf;KJQIw3r8~%u+H`4A@
zrFam-Cmt2j%sj9Qy1IZQ_UrEic^JgvJN17NmeOUX+W5nyg%HK1FYt!f?k6Gy`1}es~)RayPn|3!S1t*0SV4fK3xJaw!ZH
zJ!)PCs8Nsrm3*NPR|%@N0Tdk9mWtdYF0ND9A)(o3jj`mS+@0HdPXVFNm0aSJg4lS|
z{bI}G;=@4rtfKs*Mv;qM4lKN9&=ofw(tkx6UKkEc1rM8IyD8@e_*K)v7YW%?L$v4H
zz-kyg`Uv4Od1Z*fFh4B%_KZOuDEiPccxU@C@tKm2R(IILknWr*qkn>v$1^IH{m
zy#qNUsxH&wGB7xcQ|@=f2v9HjQ);#2;_b3BYQu8W%5?*NG`AB+I`gAwd;;x2
z=bXmq181#rNu#$QPWcPwWZ^akVT-_CFkjFZ!F+8tyG_#?CMAVushdiLz?jBP{65_R
zM&*&r&DAwVLFmdHt*@Xwy|;GncB?qtqFJG*4I&832!3Ke1Mf}NY5}pf*;|xx0rgth
zy%j>R(QQLS6P
zuh!z*q9xn+D1S8ys!P)Z|Ev6m?
z_V{m`VSc^xh*`3px-;YzoY~
zmS!9jj#N;?jVz*$Sq#TF6DgY$sFcXLjTGMEUIu?hf~
zrHvr{oRaav|9%nAJJEj-1I0y2AsZJ1J-{vZG8pcxz0_EoAWEV0{XwOyW^)E(6zL*7
z%?ag&p|dbID|@n>QAW3IQJZGg3y=Z-YktRDg~I;_Z6pCW=s$zhUz0UJU{Cfoanc@Er
z2gD1TjR6>9kfose9}JQ7KNuqZpA50NZBSXO`456D@?Qk`YHw)_r*u^ew@Q4uJBsSO
z_^9Njo2rqgTyj|1DO?Fu(&7cQZZ(KVIg3%!=1}Qdqc?g?+IblFo-?L)-J5aueYcW_
zN$&Xu#QaTi+l!BL`jPGn(~5(knGZRA|K%kgWp)N|6+=DDeL~k6^;cW$o1LZ;_`d=G
z#?CmwFaR1Ae>(&IT&CM&|C>I7ZxJtyE%6V1W!6FxJ0(NRW+l2)vJi$6Cp
zG;^V(@88_;Q{rX=)i5x`IQHn8Q|I3HihAfW<9;{Yo`@Kt`^%~D-#zhfg(8lB2Fw3{
zIzkQS?B&0v#J_a}`#&A=FEfJtZxpkw-SX=Hp_rYVUHnrrnnZh?I~#M||69dO>JPpvx<9xQUmKk)Dm%>*DBeMtSKX2O*<04hVo^UnJHFLAIi%gHhTm<=}&|6CLPx_*c0
zPaw=Ik6EwLBer84^FndoqtDo3vsnq?m}P+Q5QlJnhe2&gX5A4aC|mt_tu92ji@ev%
zwT<1ot!wK`!_yvLTr}Jw6uOtG-Sg~cv>ml@Ow!%5?!wKgqb5E1$-L>OixXh*rQ
zONE(stWa4OhGk?YU&~o^2nrC5bpf56L8G0MdDPO#VbN>~TT{@kZ%mnY^td21ct+DE
z8g=!m%RVlO^G1E9E>a|wu2(7+{Uv1+x25?~2&f52Krks9VbO?tZarOW*m&G>QjRfw
zTE`MTSB#`x1NdD&r*$BCX2+^kDsVMO46wBuXyD5ILj1)j?`5y!ASZmZx*pRvugs-~
z0quhVt}opPmZNTql;&|HtO*yihd{LIIy&)VZ^n*xpMem?q|q0CrB}P_MZJI+$~}->
zDO?ZoZP)1xU+FUu6?2vl_&FT8n
z!zz|4o=HSW*f%t5i)wj}XY*@lFx~|G?3-ZC+l(m7J7BQ?b!80vx;(@OcvB4ecQE*K
z8uTZ~$^!Vyz?GP12&GH_Jl)&|!eC3P}%w27mWq|{7dYNRy^AKv%WJe}@khUVbh)c`%
z$Q1o)<-)5LRV$0rm@-~4s9Z$|QE_U)5>11&(%|mXXIdxMae1VW9LJS<*hJ03mCk?0_h`)$MvLbXhN0kTJSfAXoW&MhA80!Ba*lmT(z%7065WJCHhG~9750{Xk_j61v;;|5;3bnEK|dpjB9HL2RY5uvs*0tVYRqQy;f3~p3?
zP-4=(yM`GQ_K6c@J{bhLJmcPtq_pciJ^!*?%{mm?{Jq-gZ;}sl_Q^b{qke>ye8#NB5v8CG^
zznnS7DqG^kO58(#7rhS@5hgfi)#tlZ`Whe&akT_HV?nlW7vF;)E4TVVIGS8;Ipdst
z@#=gmbocJ#262I9!OSo&&m~NQWr}%p9LpB&$3CERIXy4CLhF-ICC(tu;RotkBHq+C
z?e-H&w#JBcgg|iT-QLaGK>vwZpJDf|lK&NVfV1)3(^Yks;5e*zAyM4PSBaKU(vZiTUZA3B0n
z-L&D-ssalE+#mEs>~0X5SU{2z{q{=~BbqXnrIuZd;#I
z%fV;X5FQbuj6(ZE$YjHuPCoMeELh#WrwGU=e@OjKBQZXvArw8xEgY#-jS^Pgc_n?c!Z!^$p-u=uMW%
zBDTw@ty-*QtLf0>9eq$5E259c<#q3V{LT)=8o|(#uU7M0G4q=Zg3$P^p6pnhO9CP1
z@wW4*boaTv^1-{{4^`-{FezxwkxK`>Say(rh~Lx0}ffa5a~y@M(8M)W{Zcz8fsXoOg0SKUaiQ(YUUnFtN#7v@oA(
zlZV8-0nX-g*u=(zks)Y$HmLyERM7
zW(07P)x;P#Wo-pU@M70Dh6E8Kaggxi`o7QNyDxiZ50IvI9o-YdY}6B5UcO?(7FfNM
z$H{=MW+D1W+clQnw6h$g6TUmf{T^oh+_|6{@TrI0!f_B}9rbP$%u6DEky4RfUD@xX
zFf%l&RG<>|{X}i=OJ`jB-TYl{pLp^>`mwzDzM3Bu7#8>Q0+nW9sR#Biu1$vn+(@3F
zqD=ke>dz>k%<_a~O%OP1MF%9)EJEx7X(mxNFEcmIHdoPGG8`;(Fiykjki7;|BD#%H
zG<_I6&WQL8bvhc+e%VpXG3p;V+xs+f65+xsXD=;Qxa=-pASW~Es6IXsZK1(MlAuaQ
z;(zGx_v!7m1;J~RbCfIllsw<#6k)a?Bcl~lU+fP1uP;;`>3(5rK8o2Bes=aUTj{5|b7K}Y+6*&N
znRQ%UtSu}!CiHjU=l&EU5$;?P{T|B=7YIx7+xhe09OU7r9;2=urC+}2v?-_C>)|O?
z|M)WRiI`!lNtKwiyrI
z2H$TiFz3IYV$!r)R-IclzQ8Y0OrgXcb|bUbCo56!2e6DPK^-=&2-zaoPyVF%<)-*X
z>DFC9#Kzx;OxO)izliX)`5THE;p!V$*3L{^=d$ug?)T36kKb)I
zZ#&KVmHMtUf8ZTfT4~Eq3!2s5O{q4nEvMw-+B`SNO1+?DY8~>0p%}L4>&qFKZ34q~0{lSt^;`4#@vetv
zr+prA`HlSy`;Xya>B^)RZv*h;e}r?n;#v(UF`8!qKXgs2(L7qGUqCOkvo!^#)$;>|
zxDyZY-|K{>P0T~zrPLcjpFitvBu0PE^lyH%Q~h%Fu243Ox87Llq%^|jfmohK*hWkiP18!-HeX2YG9P^<);erSR(wb++^r4T<(KUk
z(JxKHbY=7_U0_<6>wMm7Lu5@U%_?bGvVa5A0B{{=0vE+C_m6a{n2}{o=#~zPUb@TQ
zq`ZHbP=jdoPJaU4R04E}f4d>T_@@?qt}1Oa4~WS`H~8Q1n^`skttIm|(Wbv$n^fT8H#q?Q!eoqJtXDwICPo5S);E257o@#%&9>4KaMW1oGHqAt%4kM!msmNqy
zML9ovDd}LN?j@*74r(A+CLzd}((Yvc011M#C+4V9yYP7aalIKWkgFX~@b)-^NP
z^P~U`a*fA*-oc==o)~;;o>er!607s!l7kOOGX`{0kpH
zt<|?mt`~{qg*Jp(thQQgXZ=~)Ost{_k?E!IoHKj4PA>Wjnf9ih%7G8PwysLPv{qCP
zajI-gB~0#R>iwUrk)3@=o}Z@2XV30pzvCToKip3cxWdb8Z=Habi@WlGn9-v&-1z2{
zgup?^y2X+s1gPl7WM0>nQ|?7suhpQSwK>Qgpz^r)RgH@reTwwmjKRbq*c1lvBdm%!?(PKAg_s-Zd->RvOS&OEj}S~4pmxSziajw+B4LyHmv
z4M-9yr^jBo=*ZHF>EbE+9~Aiqa{H1b+?=VVG{rK7_|&J(v+_}lk`g<}_~g#t!a^JO
zDFpOp8JR&J+L|epV|AHOOuI63mK>JBGJ2CTrG^KlmUX{geP!N!b6GjCr{MUJ)K1CQ
zf~PtSOOp1Z+yiw~3i>i;S>P6ta`mwoW|ciNAL|&lQK?##5Ht+>8QJdyi*OOV*#5R
zZX)Df)mD+#ybbHyLU1G5*7dB{8*B?B6Omq@$V3PgNudTqzjgAGatqkjS9S|oPeyr~
zm67I^94^FiO7&zyn2XoyN};(ft8cD-EO~8S%shDA;=o~AHA@H``{hL{`EUW?gTn$J
z4_>+2v)Qb${P*xU8nbs2;?`j6IMY`Tf{4B!yvO8TF3)L^EA2;8liGZw2txPCm^~0^
z9JHQAgv|Pda_vc9B&fN;lrb29zYCv`)Y|dL30avbYSO==`xOW|qQB-nubWii<9Ci`
z;l0jYb~-|lU9{0vdED#)%`*75`^b=SP_Mae;p+D@Ft1OUn@Riu{}r=VrNc6glZ(1`
z$HVgm#uuN%i+7h3K`@0X3oj4K-^V&>Blv$A!m71uo&N}7ihrBJ{i!XUtB?GlEp`C3
zMNCeBwy0piW=4dgrO+L+FIQp`P&|l?6Gr@xaw4L#3H?G-*i>ezebVrG+l+&blDm`Q
zYKSgA99m&?k{fz#UtPwd{Na53r7anm0>3(?{h#q5^~dN^%vtT;P9J!b<~Kx&_C^q<
z!l~4hRm%8K43&ZD>1vdS%MJ0Z#poHW1mX2K8bIP9eGD@QRzeA)tdI@d5%<(XFEuu3
zlW#t2_Kmx+of3=l1m`GCL6la>?euy6%~&SUMzUlkc4%hg|mp(~7(
z{YZ;FkUp8sCDhwKVQGHhoQrnmHU56af~Gb879!1huKmM4`A#|5!EvIZSlj;+GV(W4
zPT;}VIq}KwBWO&UQ%i35SC_05#v!8SWwmL46(qOcmGRDRV|w53YC&$P?`fN|lcK-7
zCil$OY1iNn=9wp>nRw-^>!NGy`{b`7W+iOo_lerFZwjObqHF_BqQBp?S;lt~J66t4
zNgeah;wmO0ly39n#YFRRdV+=Q1!g~&R`fhm$0x{bSG@x9t{v%7On}?RaHvI$PyauJ
zyjMn+{s
z-Vw1eU&>CZ>Aik&Pp#u{BRk>nZcYwhmIV?-mECxLzp3xll1dg4a->AxMkd%T7|80=p1tnr{wcUF%0Uod1*K}>g`$Ka#^nqkiqX^G(h5hPi1%eZP)ql
zrp*){h%LEqE<8s0A4C|_zs`IP)FvG=>Hk5s_0=8ILR=HsW1W9%$0LzO@}-us)Y^fV
z2vNiqM^~P(bqV%pZ~LU(!AJf4p#puIn0k&M^KTdd!l)tx0$T=h
zWr8%usu2#d0FF4O3TcMllY8@IOnDI^x{BsXn4@`Nw3J!7oSAYhfcSlJnW!l|d^5yv
z_n?9Vr3r(ac99WO{cUPs>_6qZekFpIH4NsR->75OL%f=byio&_-V(Fl;Qnz>b_m*W
zu;v%XTt9HH>e>SI5BB@OptfD8%u`083o`k~Xmd)mqTErfQdxSUVxp4H
zu>Muk(#!ZltveKuT-uKv8}YLLj#}FuG+$WoX3o^{HY)t&gIa~QvL(`z-=Z|$^K+cu
zF?lo(x(7n(2SKx*BdCVeL5hI%mQylRt(dp%iaclU9;Vm5?8Pc-%`sH;N};+vwu5dd
z9xwNAfyjpfqUSGy3rec3Ai#|WW)_^C5eD1{?X5Ea*K-F)adhm&FLap9msla7GrAfq
zpSR^`mBT%}ZJVcg=NanFpVkgcLZiX0Cm85~NR_S3EptC94|C3_gS^BY-bS4Q+zKfv
zPEV98HDCYex?=wMA~0Us8Z;2iJT>Q9^~lBk`aV_p?;J_F2Im*`{ZpO#pMd&I|2l=;
zP|=nhphxj$yWykub~Vm>Mg*g?7zm_`_$_Hpr#ZMp)14jYd!>vI6cA!maA&POKksOB
zHF^STqJG-#Cz72R2kH~)u4h!!6fX40-NDysfXk_$B<2WAkO|x%@O5AG1W|711c9ub
zCrS<`l)|pMVHd;bFO`@3L(j}KVO@${V=e86po|Di*QSMYyY{Hw2dtEBnc#OCuS>jX
z=#Cf9b1%kOBpXL{6TOWXDmOtf)6Gia2?Jg
zn(FfMlJ90%J-<`G>>d!Cye(WjGx_gwdzZp|W+N=!KX+XBy3q;j%aiGmctb|?k@pM4
zqpMXKf)_(dPLSC}A40G|TboB)m$LitEE`)t$5!9l;-Aln^nS(+inK@pZhM1_6NQ%<
z8v#CKHYeEagz?(SxoCX>zdfq%PqTgJvqJrMv$-?>bdCNkUmCt4N&inxkLh2AigUI9
z{RFK6i_KaH%e%-Aemr01H<)w{2`iF#oYKX+x2i(G(9eK1zp8-{TQBo=tzT2L&Kx?Z
z?)TtXsy~?$hIo+t(SA~9Gv1y(j;?}+d+li4ZkXvE;BsTcZuPXkLvp}B$Nx@xK-8Gc
ziKhm63s<0HByWq2290Kd-iN}iJ5#V|Z`-Gs@u_7ix@?DK)M&(zCML2WwEtT7jO6-S
zZ&9aC^1J$(1bTcufW|B&Nvrw_7wwQLXg1|>-!4ZOqF{$-!B=}~k}KoS74OZ&$)0$$
zQ&tPUx4jk9UIx@RW8^$wa>%8#@>`cc*`t7@O05>RO+~N*bdcxtQd)hgp9T6?CaSKJ
zoTE$1!kr?tU@~YYx{sUF{hC-*|01Q|JU7|>p&m&fQ3TpgtKYMyP@0p6w;U~)X~o3}
zTF`OuZVyhaotLK-Y+0>`+^PlnpD@n)j|aVpT)6pyPvPtOk~UAW8#Tn9lV;BTG*VcZ
z3p)C&5KO9nb}U`UrLZMDNlf6nDj3WCaMb4(yRYJp$LomBFGbAX)KHpB73Xe9R8(bA
z#jxi?8NOD;z!;XKYfWChkf&Iad#SjwMU_*tl6*Z6`S`qCh_$oxp*_xfqimIPVn4&5
z>!p3vsBNyrIfD`COJBa@M>B}By$0%YtG+g4KYd=SZ&>8T;-+Y8Klh8{YQN31zJ5!B
z|1Kx&?@8JkzvV>s|HxVYvLS4IbJoE3+3a_01>qhx()^iF2(2{3cWYPn}TL(v3Aj5Pd
zYC2S6BiN9rkY&|Cwz2f#Tq#m2U7SjhxU!q{uo4a8c;>-
zA-3kJ@Gd)%NU-OMoWq2x2B!!L?vLTx;c(e7qS!KTSB!=xj4Sd-aS1KZF4*`OPdLIz
z(Bg7pDrz2=iZkpfR*d2X4N9UHrNH=1%*ow_qIYm^SCaE;Iq*&*-wedBar^v&?TVN;
zCANLd*yjtu5w^g7jLeF$MJx?OzS2u%0=Kn2D{-yW-
zACn$3_g|CF!T6YJghN@t2fLlGbzqx2)Vk(;G91nh#*Fh`AF)aznu;%wO@#b*&7}UYyoFqG30vt``6y114=?UF3ML@t=
zO$GlVRiqrs;#|JCt-wlLv9D+u%b+>Zf5bDb|2rwYbi222OZoYvuVHFru->&?LkEC)
z47Wd1WRU|wDq2zniWG3A^;G2|Wl)B^bq4#HJFQxxzQMfg^N*^Li2bXx-z2T^JTx_=&jkTQxLbIg^V^6*B;L`%1hp@j}pd7V4
zmDE+WXNtjIhZcrp1Y|;DR5)KQxw)5NB+Y5qlVN;D3Xx5TzQos*O^!!
zsO!#S_@)_h6|Ao8yy0*+bcVT%Z4z1HkV1|D=6$z{dY%I%N8n&b^STYa2k1GQ6F7&K1`a8)0)PE3Df>!h3G)
z_`4{Didj%{jqzdqszOs~uOUw02d?<;{l;MIw_I%a#dHPSgeVb0eC;^|Jg!V_gp}~K
zdbfyk6J^Y3lAeH&0E^Cup{o<6Ltu!8$5>7t6-qf5MBLosmbY+?;$Y&X>^GDgJjc=K
zR*tMe-(v*%&#&ZFEig)!x!W8Yi6`3rYqg{=+jm(dGI-~@%q=~z$+RVpg7QRaj3k0F
z+i!Cc^F9muQfNHAo+}qD?GMFA&y~oq*{->@fMg1y$Cf4iaf14faf7cUL%$t^9anWy|tfB%6e*{dGc3_x7JGY&K9p2Bn30*k?R?uX6(NChHn0t_bIpNyQPI#9}tRT`l}MMudeOfuKz(W_De16BT(==8Q|
z#nff2v5dp0#*!I8q}^Kxlio1QynQew;z0+@3`f6NlQ~{&&mHP_U~nZ>e&FAS6WN)>
z8T}fb^HWF4RmSd`LQZ(iH&0)zICH-c93tL$yb^ZH@&e(v`Q^PVY;15Ku
zO+KI9f>8ge4?I+v(Q5l}M~5BOaDqPDxmj4k5_f(;e+=f)%>XKmMiJ|Yr|`wPFFwf-
z8HK&`u1e9th$)4=NF=NFTyl!0eq?%LRuqX!ME6trS`BuIh=nV2u@bAPT5eR1mgl{z
z%K?|l_-+L_mBq0lCK2u2%GEuzWn!W;^%?ep>g%DPBrS?*J;-n?G$7a!m}D+>#MoV;CY(_wvuXL7uLqqP@s^>l>F#bcU&SnL)KAG{d*
zkwItC5cuT!4cWh4<7nJ^Pe|Vqe(>Vk!uw6}zxrwZCnoowv)Xg*^_X?B1aDovFaMdr
zzL7MNEjkt&c&BUzxqVhGn<+;$k>s#F5$Tc&B^ze?+BbNvKJIg$fp>mi3E%M?sRY9E
zNad=8iAR-=SymDqRE(&oD0al7P`=s%xsHc|9=Hqf#Q{
zq#;El()#VQjW_k9-?m?Od_HQ@^LL$ANfK@RS=sxBwM?Z>_FESwTN|-rE-BRS=$@wH
zn1~UvC(f=J30zv7P@NeCYMWN^uSOZu-nlWiJlT652Z*YXVhFBVw`7H`<1_GsKIhYk
z%wHBMr1Cw7B)gi2p|o$HR*AWO(RikftrZr>63wyR!>*;{o0^LYcZn;Zx0)_N=4~zA
zTf@J1f7D)zC7%8ox#Y48u}*)xv`X*1s-g-}%nA&xxYXLB(-cFznJZd85nIrmr4O^M
z%jT2v@@#*WgBbPneIrN?Ft05v$Dtra40%PC5lc-H1~s5}eYVnIcrBp&5t`>b6FmKFdTG
z-Z5^4=H^q*EQhgpd@Jxr_I0w2Z$?^F{;;QD|8j7g-v!&1_)N%jV;Ot0j`?j_=IH`n
z`}6*=_g(d%@VAdM1LIXYGjRtdF;y4DJ97zvGlj91&Vd(;WWK}!_HVNK!1g((B2Tg3
z%G5%t)-IgAobu@lyuEvOs_xq!iigE&x(3P+ZV=ZaM`{f
z4++jE>=_{k;B0aL=KqRy1NC
z+RjShs~?|HZf^FU=)(?T(5U!WTwV!R*A3A)Ix6A7vSZE7ap0*Z)@8~C3{sgqb#d@N
zBna@j6J*PY1%1=xpkC0Ey_7apX!7}w-1^g$pa9cZ068)Srvqp3Ns|TnRY>q*k*f%q
z!^{y9B?$04N%5s_2Ywp5bit;7({d#Hr8zxI(dsb#rL~dfPcerknq~
zj|!(!#g8p%w;UEpU(%lLg{g}$#>Mj`sFl#Qo3}qJ1@y0N$Nz>l#VRrz=c&!eTYu#G
zcLP5BK}G^4$a2Tgb#qKG;l-9R4xMBp*0)Ori;k2*X>7~OKVI<|6T!ONW5_}NIMENy6N)3DO@Rf7bdajyb+*%aDFJTmNA6$cBgPfNeDU5@O=hPotNB
zlG5M+LF{`NJXxOG-wee-B~KVSR7jklzz40y+jm!7hT`NxJ<1Owbg7-}vl?O_eCSp+
zNg^e3lDn*36Z=Uhej>o+&+pvhf$+MzAWNZXlGB^luYAm=3hou&r-~l!=1cNZd`c7R
zZmDu|nZ}shq{?EXK-@5caM?$S39{Vu#0J;RaeVNU^%{bdsffT9O}x*AsFWmL6DbG;
z>is8_0qY5YKJhHalGB_v|Iysl*YnjATQM50}pKg4kiPkgl|$L);XY1Xiai
zPN&v^=G)+}*~nSy&@!cVPXkp1X_QTRr!_U-}HBcZ9}4MUA-
zq4$mBB1)`CgcOdp$ftt)r-3%uBZrk!wVY^JmKh<3nJb%3f*~j_Dygmqhi*gx{7c}EBylyUAfLNHSYkk$kG#aJ7p#jaK?c{Y7f(An((Kv6a4N)
zERW2gMQt}`pJEj2k&_rysm-kh2V$lQ#3tlM)Hem1-Ip5ftVXVQ=d6IA~U$tCGg;{+kHtGtItkHZGB2t
zDWWHGNkojYMDZ%m22imHmcfV}+TYd*RDp8w0uB3VwGlv+K2iIGnG&MQwz-%sPU6}pa
zSBx;DBSKBT#W?Bqq49F#g|G6Z`>V#FyjqFHW8F({>ndV(u8?rCS60G-k1sFn$j@Jp@yE|km__
zDd4folpuon>e&#vFlsPIv&5z%IwZkyfs5Zd8W&1QkZ2}IvHGinz)F$A6O=Eg^igmZze;EgnUe%61BZxCnDfd)
z^%Y`fHbAs7CS&V*BHQuEDm|Gq)7d<7y9}C-%94dvanGgK6~uh=wc9^ET8sSCU+*fr*OrN;2pd#=1DDX_V~
zl*88Y54$fl3wD(thI)S+_=c<5O?vKk#WUtg8|pidHF-#H+7VOFxCD+WrpjOKHqN4m
z&Q^IVv(s3nuPe(3ijHn->K>y6hh{2qI)7#tGOXpHyA?u+eyC7bTR9pXe~hawO)-#L
z!+<{o|C&iy3}-k!i?D#zKIEvdgX$hX17tyMz96kNu3@*9T9kvu%A(4eA7RD@CgE_G
zWRedis<3lF!|pd99QRvu_za`W3J@`m{k~(%2hSI+TfBvY|1I7z!y+lO7eF1EV-i=`
z_2{6+P*q-{6-VbOa*Wv!k5S2J7U8dnv>dJ@fr^t{oY$YBJGun9@O-xNkGh|+&kk~5
z>Br!H1tgWgX6h6^hdu1erZ`o4Q%J{Ty8SS3ub`|C7;h0Fgv5TzKyJt%h5@09>NAYy
z$0^#x&7VfN*}JIOx>SYttKpHED7e&<-RuX0=qcu_3lV~TxlF9BtB!4{PD@AYACQ$~
z-BB$b9sWc8D@189Ue5>o))`j|)J)6U=sL4*HaYt7J-ru#@LExyD&I)iMlpf3N+ISd
zZ(O;q?`RJ>tV*>k8+=|W2r&AijGoJUfG@jw5DyxE9dOPTF^F9mAwXbdP1DIgg_l;t
z1B;h@7&2KuDvF>1o6w&ezv7oAG(YnZskf-}Ko9v0QE}N*4gyG7-3n
zTBn{64tqvGw-{R**YR2$Zu2g3dr9Z22k(^WTfP9rR{ycRMFMHSp(x&^hn)05wV%_S
zGeVoehR)3GUuMGSrfzqhQF;~HGUKwP+r$_DC0hlDXuZKeT@cMRpZ{}oitlHA7dSoz
zKoJmsM~%6@#~d0S#ade=>!qwvYdGs=LG;@^vsjb;59^KYmmpz*F}0HxvlLlu+82A}
z5&@;ZJGY|?pb|iVTuQm4h6(!+{LL_F9|naQ|0M|{R^jm{3jN)d>
zHi^)eO@^=5qCT)LGp=}Jvwy&1Srtc2sm?xa#((i_)MrHMfQ!KRQeF4Pa-qdq_)=VM
z$7EtMU%C%{5w#2K(RPWWK^sBUkX&dQ+u?Nlnz3hARN3gE!4h&MgohDI?$@kcH=JCu
z8s%kWW7&Jl^6P-P7*&+h*r!5hEMOTzZYwWVN2mUT;`$Zs)~`@ap@rvYqbAy_#dgIZ
z?_4}1C2G%7ZB!11Y$q<)TS^hESMIY)y{Oy7JX&Y>Hdj${v9l#wFiJ~Nv7XKjfbf{c
z{)Q!O6EjlS!z18;><5K>VgD0ODvL7#XA$>Ndlb8K|Ar}p-EBpd-hPUU1}0PgBqiTq
zLO*J$6E@S(JVk?8l4jK9&We)JaG*})lU}M=GXR@fj>bnyGLuh;^SO}EFyPUY$td`
z=5r{Km`Sj%fI8}=E?Ya%8(?c(!3i?i;iFH7z$t3=O0xODnPT$?`f0?#A>PF4BSANK
zsFT7*lk3!fCz?4w3z|&REfFBK8z19?UtyrP>p}5+c=D;e(f<}=dsw}8zaj(>7iWSG
zy`*|qNMqYkc^jFICQsO8qt}siA~F
z1T;yxVzQG)<&oIuz{K!ECSr)%(PS}@($Kyh+@9WCbnYISMY^Bai238Resm!#
zRa-129-u0s9V(zI;G}eyzFCZkzi=
zdu&DL%3Y&H&t1eO`ew1!DvjiR_iWMH+e%<%eU8q&Avf|D+vt^7V4Awy_L4Tr(u31d
z@-Qus+cwB|FF=iqb@&Pg^+u=&SU`*8I?aT873K-GMc*(Sb&vA8kJ*HVbDiY}3GOxh
z4Gqz`V-~2OP#@#1F+nwKpdC#uAYRVf&XDtLDeVY3?xO+y=SWBrG72mHRISg_!*pSp
zqXyf%zSxkA%jke|ALFCn;x(^G~@5}D(Zd!WFbf6E*P?mXW={;(u}Y9kBiY|
zI_J+UW_`PpH*Ot{PxF=DcjC?XBv2Yesoibb{)M=ymOH0qiu493=B+ZUS=qIk&Jm{F
zL>bC9Gz7vWIpRlg#EV=#M+
zVg+v88M&k`9_M)MRkz+#_J|)8eS6AN9ilNYH+^f`tPi^=t`cL5be=rnXTH20T>}cNG6(8_Yy;Fm5*1TAD!>d3YTH^)MXHfUO*-!%hq_<4d-YYgr`{Q?nD{6Uiw4`wqmz-59<8$Q
z;@#A-=76e~6Q^;^*Otz{@_3cZ?IdhCx6qUHDnCMrsnBQ!j9EYnyE-RbPC7QS;ml{7
z@Rc*jV6SVRR_jg7LN`&`gcNwPVqR;wu>to;Cma8y`_VQHUfv$P6;vf;V&}Y#J0)a4
zD)r+*f3~W#6nV+b6Ray6Yj3eg^7oi=z~k|?LC_{>hcbJ8iqn@k$`|W0S@q#gWQdMC
zaZy)-H<|`ibJ9DhI=fHU)S`Vc9Q$&Y2aPoYYXe_S5=MJe)RZrRuvx+9@I?v)4f;YFv18PdyXT&ysYe1sYos}
zSs~k>{=s-FJPD9>E$yIyZ(`g_hXcuo_3M*`GDw#kb>R8(l*@w)0OF&FID#uv8?i`=
z7|by>e!I4X8hQ)iMFz?b)$~Q+t4${8N1D%3h7Z$rUb(^(lEJ?oJ<{JHxk+o_+nj<`@tPr~x&?0F4ghxRV_moIex`SK{
zjjm;gfulDP8LYykY!~AZBS0AYpW+zY7~RMc{AK16>s4!pO4!a;AVh$$kTqc1$rD9!%i7CNLQo!8M45p?I*`M;xx-pWt%}=mRD<^J)gQcld;Mh
z#A8Ydsw6cl%rxo1$sEsW1lG<2d@NyV_6-;2omv*ea{-rL&ftJ60fq3ri8n|rU>~|7
zWSD9%;JXkXy6ypFSdYtI&0sL-c3nd;YDvBDGjfebZ}UZC=#nKhS#_Anti~W}N#OY@
zuY`;B=foV>@~(O%$)AGEqLIaLs3;}o#8^?pDy^jy(bBP2YzmILokFv*CRTjeu(7+w
zYEmCAccf~1u%zFVwv69oDZ_aRtUGFe+{*-Z{)O1&fVVxhy++AVcp9Ba5>5)N(4a)l
zkHX)4*LzHA?6GI#t6Y6l3eFEMM3!4;W)Py^LR@LUxf0aSWKuw&mMVQZ2_%x#5zE2!sFD9t1Ciw{
zZTxjuPl-3P9Mb5WSFAe(yJn$k9)v>+BPwE5O1>_Q{F?U;d`MW@4vdzI4r)nC9{&l}
zXaUcONgm|@ARHrV!k9_9-=G4&O$rUvVsZQ!zh52&wLZN-uUxo4wG@4!f{65tTu2@v
zuzj&A9=u)lS62@;#8A)h=^4Q@d~9lIyq4DX_&Y;y9qg^0n>c%^vLJH#$wCC
zrR)W#g@fMQSp~J_@2Rf?-mD6-g@bsuX2S(9b%0}MlIC@i98|mO0G_8q@n0sQ
z_Q4;hQ~Vu{g7JTb1E9r12La|F>o1x6eiz6J6N%pj*&8+e!8qApGR!_b6yCt_`zna<
z0b$0EYXtjSTmSv=lu3kNArc@}oO5CZgGtH82E(Add?p1jTqfwXBdlxPn837$1=3U6
zZduuM5@4t_@N-u^BiO}i#>2t^z8*WJ1(R`K{tMQq&nCCt;Uq=$-+JYe-aBZUG4
zF@EJWhF1!eFoXd^745MqLSiQ)^}Qi*xXX3^vMu43GvueVVQL0QeG7GT9gHi^UVGR8
zi|6-O+Ayi`A6)RWRUE~2Vlz)3!xkQJ=KyHAOQ^B-()=H
zY8?$n9HdvTu;Bz40}H}3A5HBQP63fAC1lSGHfQ=FKcv{R4ZHd+Lf0o}(o)lp!;^k@9Rx0CY~R^5
zlu9{^=2>OraBC4hUobwQo0b@GoAPrBVLrinjY2QRFt@|&>O}ga0LP_AyTY1~L>cqg
zP*XXnti%a$4x5yXXEpKHKKkuhMVoz?@$>CP$SQd
z7y`0!O?0dNQ|wnA3i$4K^eE8fCZ-)%E%ZO{aDeCd&l2OByLO+p@1~w9&V!Lh6u#Pf6hNHgp!Tj6Zn?6@Iy}IBqkMZYva}MeWLYHZF{}8K8zkcOYV1hejY8N
za%(2AH6^_6XR7+H|IA$ep<8{{_kLvCdp^}#J#M(tdg*;H{&K&`Nk}B*A+r@c;JJr<5KKI)o!l6cPX*evu$))KJhWRqM8g|
zN1?53lOZS6nO$3Ye>-dse?*mG1^za6HBr$2@uv;A*qt}vcO)Y%w1)&R!;_rGq52KL
z+eoKxBblFYd@7d%;hx0}Zbr)|0f_I0$peFIj`?gl?8~oJ*cY$rD$@ACw^
zN{PEjs8}O&Cq3+NwevZHbnq##Cso7{CW5j1fs|^T`b2__TKQ;9$+hd9vFNN}96pjR
zWsDHZfN(qaMuHt4Ampi@C{U1!(Ki988($A&_Cpl~LNXq-U`B
zCk=ZCH?0S7%Y>zYoGAJGubuREPZeG6!qC1iUBW=Sj>4;ExW@zb;l0z%1sKo
zGXX(QlX?)JCAZG<9*o&kbhc*IR5z){SBw}98AT~aVJZWyrAq{T048zZ>G%!2{j)|m
z#1N8s1W^YL_s&HEpjYOh`i-bixz|UnRA)wXjJx1@N^HrYHoOQdtP<3ypq(gYK2~UP
z0=N~u0_Ba|2B0}c2qL%`8D*6nd=t$0=`g~b%hH@NEC_50h6ch5z#8dVN6(&L=(-Rt
z7vK%_ClqD@sxdF)SXXd}Go=JEm)%`X>BoGlVQ^V*7oydNh#
zRSe$J{xThtLH08qoiSO`2*(0-3{Imi+B{mKmYZ8cXZR7ouAL4^mNadP4W{=To&FD8
z`Z|%Iw|AbIW>}t|Dy;*3p=*M`rw^F2y2V1Lt?DmFLkc_j
zXIit+m&Dj4gg4aY2m~Qq!)h>WSu1B23@3HZ;H*NvVMz85);qQP(T(BQ%SuE8%Zzr8
zqI|ysDLb%1w#VFNG8E2!_MIzIrDg4MVYN2j_gYl2_1M6NhGlRXNWQB2N!urTN2g~|Zr)CbyC>qH}ajG4Hn7Uj{Y
ze{g*QhYW2LHidU-7tW>O>~^asY=^ra&7fvMY~qK`IOm5Oz>}|@CHL3|l83SS>vP2?
zAYCRLl?Y1OeBOF?otM&P#~yObG(pOmiENF)sC?&K_nVaBS^%D`yI;|AS3!T7sYi@p#7$RcfUkKm)7vyF<6&zM_G>Wh8tZXPd}
zQAid1c{XEUymb!X_E31u;_GHOv0_(}uJ4!&L8_!<$DGzOq8Dj>RGDYzSY6Zot+CJb
z`IVqOa3P>f=(qFBEF4oKJ8Ou447`0vYYS~E4-iucUJWw6P>SE+mM8!E)Bksrd_w^t
zzU{aFML)=YnSlN)s^xzc{xJb%DgBqv1wt2RZO@W#iAz0J4-jzZDNUKPr
zbA!t!44V5Qw;0_CMoP3$#v6&cE@E<|T6SW~+Nixn0*#bTav5D~=QI1O(XuflzGNG9=7
ztT@EFk=!f3G2YwIuC;9v)|4Wa7oDq5l=<@ffd?W0P=G!q14_9Vi+MXRSeBCQ|
zIhTGm-eqMf@y$@aq}3DsDbc1F>!LiU7wnx0ixr*Lp7S8Hp)8{F6^L9mZ0h#fG;x)9
zlV0NX89aWrT0Gr*Y8IrWC@M9)Xgw-r7Kuq$Y)XG9u4Cdws7E{MldITwMOd2wm!Ryf`xwMoRg;y`}xhu(yefO@sKriRg`FH;@pNo~+4F&Gt4$Xe&jscl8r)@dpWaIUQ2X7ru!EA7K(Fg^9EYaU
zzLhz$_Ybk-wAbJZ8EKr^@>AI{0N8m9^UTl+TDYWi8F55Hdfl`z&_R4*t?&?Y0ZVw;
zoe=Xrw&GoH2G}^Hd4S#<0}hiUFfTS{6WuBV9MYt+MTTw_s&^Fo3K3-K5>Q#!w55|p
zV|8weI!b+?3dIPoEMD;VYb6ge%5vJ(_kcwkxloc*Kt+>5wkc20>sZwsw(cx1VJmVK
z!8&Si74X41=}~<%WCTBPK;$V&|Kl?NqIq#Cr0}&cznLFIqM`AvglaabAicwaCgDc#
z5MxaB&IDpB`2BvG9HmV9?DCOIGZDr!5@6L7qFsLVFp&OgU|y{Q>($pd!+x(tC;e0x
z=l6NIMjn{r$UuUQ{?z`qARnOjX`MV=rNdxB9#QcN;}
zRQV+U(QQhpulR-G38!GPH1U)EoJ@CK#I3}DqB105(wc-x3_2e2Fmq=33SC9uz-e$G4{{3ww`L~G=x=FE1@zYCRBT@V#!e>39x}i>r#LwnA-G+
zLl7qdVO@?{%tuJN>&>H?4|$;U;N44mQ{^QDow!`dsH2387|)E;4`0IzKw&HzF(QJh
zckeAZ3+OReg15#B*-ExuT<=J6BL&$L+!?B_b?iYwxvN%+7Ryfy-QKK9*Yn`*KQ+_L
zjfnJxP#B9#YoQowx&E|-u<_e9q=BYZ?XI>AR~5vsVMu(0M+x|5@Pd9im>|0!cBNLh-ca>x
z<*-I_55^-(Pe0+tv_a&d5ysxYHYB5lh*0`?eHwX`Z4t=T8|Zgiaq(b$3E4>Z~@rl{X0yzs1!K35Mzl>vxN#ebT0QtwF5|
z8c6D?$z*_mv~$L6^Q?B_4NhlgB@pj{fijj`@Z;porr!yxKFIl}lMY#eL9vw7-MrZ$
zH=78i7Lf5>GBY{Or%4*42Mfj}mXx(j*6E~HFoRhhY(A!kZLV;itNq-OU|d13@9?%G+_q|;E)M3_3KQl=d-vBPEnJx`4ZE1ws1M?|92RL1;A2shEYboqi~tg
z1R_B-V0UdgrIyIu^SZ9k6B9C+1!H6h73%l;_g^mc0fj7wP~-!lQM`^obtMC}sPrL0
zDOL!?T*E5aDXZYV0ik)tkdfx^0Y>~~Fx77c>-uJ}u5Sh#p)yUAfQujohZ}XO*2|!G
z2;4(;V#LR_C`XxsYtBFhtx=0H=kHq4q$w5q4az9N%n_Gwmd*c@A_RLZ3sD%xC4cKr<{e1yTEy}p&jN^_mZ?+?b&9{SqGcrXnCuv)WI
zJFM=I#^gpKn2~G6pFizlKjVAj20t4`WqNI@G*YXgK&^5L(RnaVQ;%_v(WW3m{NRU9^@#hdOyz=co0J0QjVcA0)#)5W
zVW-AH5b-qL>w$9}UIalauiBkri&A~M+-&v)V`SoG;{19yC6hbTb;J-eC|0w(3Y5Yl*i<7iLc2chF7%SkV5jCaVU?KNFt}SbX?Jy}X
zetRpJI@|Qun(S1k8)fCJUoBp|Tz2{bXkFCWT&3>z^>wkSxq|<7HdU4DV{gaC@%s6=eE)nmExR-=t)IdtEi<`YsI27kx*L0@
zT5D4K6dMU@MR?LvB9*X?|K(lE_gNZ4`nn#QyY-H+`pWZ@^KdlJjlDq9^;w7DUdUDX
zM!RP3kp~9Ex(8s>X!JYx?K>9CTU_#!dfdem>IT=)hyI15p2zk~+Tb(=Zg!uLA>31@
zk(Hg$I8&%33Y6DoCSCpkNvrS-5`|{o
zCA+9GWAM-~Y@03ek>jb|fG8kcwj%;;X$lX1XwET(hnqb3U$7$8ep+QR73jrGx)ne1
zI2_xy3uaQx`-NA$d)GR7H!*h@3w8*wr$(CZQHhO>^64Ww%vXD`_IFD
zxaZuvA}Us8t(+CLGUv>UtQ=!ZoeFmZcSvwSN|DTb@uOmXeCP0Dg#PpyWQYJ1p@0g#
zz%7bbeyL*X0CT|5qVpz@11%&qDsra4RPi++3!L%NY*};22nxCN5l5Gf59i5AAKy;^
zbgi}7zm@_2>avTb`b-)_M9R9MtaEyxU@Q?R1oNjM0uL}n(>iFxU5Rl@C&Yu@SC}W6-*MuoFe~7|14Uh-QhA9MB
z4r=feHs>k?d*F-CbIHxW90S_%#s9T_IB%BY8wk09_CE5&h+Ff(YhV+5Y1S+Xt1yy2
z6@qNv^h@BeUZ@<6BO?4PV(6GyaBPB(G}1x)@KKeeglTuz%kh=I`|k2j3C&eOnC>eJ
zTjcw?l#{y>wKQ^a_v>TcA2sKa~6Zo
zJcwnlPT=NK*54MnSvqtSz*7ze
z0h`?OqwvE@h9wXcL
zS>rQou^R9*ji&B(ULgV-;L|3@3Rt2_zZqN8VvCSMlGEA22XBI?+zq1EY|cK+bB(OI
zO7Q{n)ZxpFr1C_J>?*nrG)^;_+?!C|WsCR2@eZz{V0{gGFm!}a>))|GcgJDSxA82`
zexD{-I@iER#8@s~5tkyreKDWs%bxPyNastas!_ViEhDrdVF9NMn<}%@7eUy_4-+&W
zdll=W)h5v>IjAsiwlV3ys@y
zN%9^|ZA}%OY^iD_jI4bHCib9tqcAkA%}o4ySH%kq9#o&Ii;AD`Rg4_+PlRpb`(AO5
zB7IWUCzG=1{2r#KdpCv${|hZ$)jRBN0t~Ewz6N>i;D&3Zz5G5JXEx(Dhy!4BeGJ1`
z)s$gZ3Ew`+6PjOdM|Sh=ltdeN_Vk;%qIw0gI{w0eQ0LfgsV~&g?8bdi=p@@|C5V?I
zbSH?lvPeilp(GQ5t4l_a+QS+vQ?~1b(8ybIPzi^)-Ut>rjbm$Py_^&
z68ZTDR{QH0p!5HJIiprkXr_e(0D!Lee_!|hkNDH3wwBugYohOt(=ng+e#acZoOE)H;#wOabsf2zP%~nq?@IQi
zj--V`@%zPP>O7g~q;0qzHTWk$8GTx*;PTqu``qEh%<@EkV#?2__tsQ`D^mb#nTf9|
zCuHn0z?RxXb$vSc!Bu_P9X)qz#ePvaU1P*raUQhZ3O$j~Onz)(I;X4U1_|3%^85qm
z6AMH7%ZXwAhWz~%GTsnPHI}6TmbjRmHxIx}Neh
z9nSIaY8D{))tN^jd!_J}U79I_rnoR3q~MP-9wgA2>u44WRV1|LNya`-Z_fC6c7HNM
z?koQo$dN`)9aHgbNp+rXLvh^BYZ@8U988;AX_%r=3Thx+xgfo7S~(&Gi0yEytSc!Z
zx_s@xIvTOucVPFz)UdZq1Zrp^{!I%=f(+a!n5bEm=@z`<6i3=tZ-hj#e)F*^2$xSC
z+mXipy8TSrn1uWz#Dp*!_&ow?L?c7r5)|g}H6%F;IuBP2Ey{X^9mUL*4lH6*Ej4-{
zx|$hL=)c1%gUvD&aPq8jkIe?+y>Q?TBH2+~iGqCaVBqk(y}^h`rqqD(i3u0q`^w8%
zEyPjQ#=_}A^@qQ7q1r(EW`k(KH1GSn2fndG&=|ZyPc09
zirT5r3g^0*SrFI;9Xft$lTLuiBs^kgj{mscF6i$9-ZH*HMvay_Xp52NaQ~+^-02QL
zMyB8EeU?peSI!*P!G+!jv!=z6ivu8n!bIA;<6r~IgDO(ZHKX$%
z`_7===?rEgpdiPHEcuZnx(8utxECVOSM)FO$*v$pM!On@*~b)(o%Jzrk^=T#(?GWu
zSZZNKW!d{I^B_D76!tD0-cT&f;)0QAQhiTYo0^I&OLGmWre&}UBtv|9W_#3s8ICx@
z6oi8E5($!#S_;1>Yb%r#DiW9^X9z%=rMgKo1D}$-VwqEbN1l)b&4a?h{pLV|`um=U
zgPq~Hq??zNRqtyII#qEuH8_Sspvy4eh&Wy
zVMuFd8B>W)zurCd8bN<-i;d+kL2bXqBO0EiSzIWJqNZtU@wSGgSy^a`Tn78B6T?@$
z^j9QYVCtCL2TwjTUKvV7u{d!*bt&T17?=P;tBOVGKUZtbsgs^7n&#dfc2-Pe!n9Co
zMHlKMmDsUNk09`o&-@NlBq_E+dioy^qAqqbVC7OE!dPPA@P?er#lj_dvVA9CjQXuv
z$z8h8N#LVC`W;9hDUP4oWEN^J*cn{=qqs{jw}{;Eqb*A!lowCLbB7}lx+RoOI5RB7
zi3(Q)F=Fk(G;Xz9+>@WKjfdE7^n6>UN@hC7B8X+&XqBaNfAZKkA<
zgSwpDK{zv_vvIsY*Pd#z+SS^|uJUAJlSRYA0KqY@mPb@X>CYO>1D6U!+-o2Fzr#y_
zGV^4GLPncJ`M(34mMx(T$hT?~WY1g7}2ucfTN1CA|qe0N*
z44Nhuhbn;>GnQs$feFpum3IE5^J}SC&8wV{YZo|7RmIjcv`N*>_7?+Yg977y&lg_w
z_T`(0`|0+qpvgCwI`YNAfciuiKF?(Ogu
zzL7_VL|egYVzJsJ`Axq);ZeWrLMwX^s$e9ge{^;^O;F&(MxpXDT|n67L<#ajrPF`nECrTlS3zlb*PKP
zEWXHN7<+;jnyo1%jZ7ih^{hf87k+!8sM#RYcp3q17ZTYZStskn7&n6--rsUq=U&J_pgjER|Qwp@+Ge%
z#>Gn(d6d_kE{nt!a6QVk>Eug<&ES%RF!{Ivgwk+Edsl^hByMt$wXR53&FQb_hx~f}
zT$;Y{YE33I@1YaYNPv8bZ=3%o@9nq0yabR3`xa!7R2Kbd%&bi>rf*ZinUoqbFnc_S
z!e_{9wFKK@Wo^2x>HhmclWql49?O|&%tCdE%Y#9hZRiFijIi4Ic5=c%W3iE#q!&T?
zg=251V@dYp`KYgqJlO)LmR${IW_~T3Fy#4f0-R}lc9GQ_fleG2n9erh!8sA{H_Hz1
z4))(6ZJ1PsPzz2UF>TmL$uBl@wZA}Od*uRBL4p2|i(~JxYeJ8I(b-7Ru{mve#jrp)j=pGa6
z3#pM49s4okf_!J^7hk@OJ8qVMzqmXspr-HU(e%Nx!#B7Z_~XRAvT<`ArT4?*_Y%*l
zmqa&zbuv4em&eQVbJ10I!}rDP=YIREVo&Lk=>&Ff5)`owRCPmM@lUI?rmKL^CqjNuXQ>Az9_n}NGcj5-$_Z6HW
zd&E$U7k64D_Nha*B(wu%q_4d74G1gHrI&9TX{4Km`i=fLR8W2sRsZh>`}G=mHB1f-
zl<{kOQM==lbUFodhiqd>2NmPoJDwTETqe=spbOk
zSh>8|1-5xwZJ3|tst$&bMiJ``ViI4z?LQ%Q7J3)49Uaqv;bA}Hd-=mm~$M5x5BP1
zu((k2iZx077)vhL+K;-z^)>TL{z%R>nu~VNK)pgsa|Lgm1js|_%Wx#8QxLI>ES&`)
zI{y}=nK053Cn6^oVI&o8Bmj70A?i~v_#ruQ0C|+~d~IvpX3Gk<)5gGGm9xHN4&VjP
zpMZR3bj`FNjMn2eY~BuBk)ZYtT;)lmf}gS>gXMXp|8N)Z_ol8w2ve~pK^(&+nLmjO
zYY3Afs*W2V<={n}x>6=VSiRFn=;~DsxJeWCzZf8$_|$}sWJrKGGfEfwX&BP$1)pM*
zk)mYR(_}63`h}u{*8+gREH#|Z1I`m%x}$3nkPpB^!&pho6^%5b8JH>OyY^Jj+yV@j
zB;fQfpcV#s^X}=7MreY)I4u={rp_Q7J#?U9NCu*Py8O_mjqq6hVGr9n1^l8Z7qEkX
zSxkJi08ArLp1=lvP+4M>hm28Qk58FKKZRDQ1tO(a62K1%0GF~Fj9_%OJw
ze=Zsxr^n@C;0|~Tu?u&^{qv0d;4mAR)IY7~X4Z>A)fdBHs+T)z&)Ly07T^6dLjP^k
z+y{{vVPwrDe&7eyvQS6~CBC~w|NKSn>&#_NIpE;?e5V|zH1
zEtOP2Un|MnbZp+zgrl`WhfktWkpF8RsVB6pvA&bW=S+IZyoP&+)yD|Q%gM`7Oo9E5
z2ibWnz`(t?I7NUmHUqOFxEf
zb=g(wXW0J^`1|ePDS5H3>=%Xzz(d+bAwRCay#h~^OvnGCyjEqr
zE43>cA)oB6KWJMk^?0k_5OdL4N$~aO+iB@DVy9aQ<~Nh>8$>U^h*pmRfIc8AJrR)f
zydC_cfixZi?YFxqklNqb5#*Uc!jQyN3a^E`8Ph}rBt)S
zuf7~g-rI%!3b3tZtijXna9=SV5l~b$kCy>I8FI@fdaG0~e%f-ru8!HC!X#J5KDcC~
zdNAU8%T*3!Rq=iA-8YcmRM{jhLD`R2o#|_>eoUAv*R)R1*3w4$BnnNHlDj#;`lY%R
zS?ZDAVevIjiLSd_$GAFV!b5~fc)-OOHc6;O=vBjY5!XQ`F;47bJ^oI|y_OwUswedu
zBS&8beA=j8JoW7|P0io28F0y4mPlJiBA7d-b2ntm;cAmgkUz|?dUhlF+VRa&Y9s}lToSr-844xL@QJFMm
zz?q&CGui|Do+@Q>tHJ_5YE`t39282g+AVSe%7NnlD4=v@sbrJfB>0)`z8Uc+$o;}F
zcs$90bQq=*`k97#VJmBrWW2}EJraCmSD#!t?dh1ulx3utz-o1r&^
z&+8	)sje(h4=eXVCceZo~$~)aazWs;k1~RQ$x?%FkB#HE=6C|FH}%g`ye&9fV|H
z%)t&0qq(1gHRtXEF3`ij+Pbsz{RM6w=Kf>btq$L|2e?B6|5659IOvbmq}jQs5rRuN
z+DuPL#7OPl{?#5^M?1Bz5TF5hpmb$~a29B(Gm+0A_f%8edSu8Kj14JOV>E|G+}Sx2GdG|)a)&Fy0j-Z
zDxOX-03w9uP+k`r=qyvDpaen$WZ_-5&;@vd2?UC#do{0>$UA;v5F(=I+?z!4r40@V&_qsxMi}vQoo_~ti(_dDXRKxk{_+{NYz%@KP?Z%gG9B?$
z12J3o)Fg$fkld(Vu0kcwY(<(~1Sle8uGK2C0&xf#oU$~QdLJHj^QUa@%?(d&{(pYK
z${vx}@$t+;#=;uX2U`_nQU}2_pazHn*0`%YJXZbO3F^QF@vHxsOYa+!=WrNA>k`<&
zY>G$!h+Dy=uz^|F#tbxQJsMkV)>HpyWjxA15;=^80p=86i5LP_7re?(Zk~AM~I_<>{*a}D>NAC
zloBcbXUIl}IVl+gySI_msThe$`7Wwg?rFRjIrNnir0Fz$z>!W#zT`O?;(v;PBCw>e
zwuzJ()&@8_76mE@l&0CTTy+DU0@?8l@pOuyu*ENd?YD=5-i{Q43cwN{YjtLKFdQvd
z@*9$EYK^fR_%B$ECukrvZMrCSziM~n+bbz$Meb6|a=3yhcA(C>9mSE(f<)_K4~6aB
z{VG|JiWih_b7!OgZm?Kpm#Gs|}dFTu_g11t|#unM|M
z{H?UM7v^6;A8FK49x~vpRvIa7)2^xb=tXXct<3QTDr*1V%g*48?g+9K6`!QC>
zG?bH3>$T_mcurC!sKi?ib3x%}HgGG-c6=PuS>5NOTl
znluvUD6~aRUnxj5mUIHhNY6f5i`5GZF#LvpF^)ML&}Vtg<1gL%JfSq9*$Esn2XaB<
z4b&WERPhXz3FoIW`#VC0V^=_8%ZO9kNbMs*
zUdtbT_ZqKWd=yPBeBsluPj8+>!Gxn718Mz}=dnIDJ#mNGJ#j&V?{E}^OK=Pv^TraU
zS=;pq_r@#TFGnNu3AK#~*;Iu?bD0Fpn3N^N@h+Oz&F4&)@P!+X``s6CKW;gqUx5vWuk*NQLJNV)etB7#=5?Cx({jp7J27z%Zy>T
zr`4{UnL;t%=H0+|Z4?uOkQSsL*CgZHbO5#{IC=P;OyKI5${T}?zDtm`7ic39c{*hlWzF3k
z;kn`+4p3Y7ISJWnlXJoE#$TRp{@8`AYyLQf?z+Lb;iVSKpEm4@gOjxQQE_v%ZFQ7`
z#0)}U1ut}(+!+~5n
zP@8;FEIBWQQ6>Bqt}Dh*$I-lc<}$QOLv|Y)iy9pkY6UI?Z%YWT!j#ShxcO(*EY!M1
zs1+!k1yieldbg4nt<6@q`BdW3db#0vbZ$Z0&pa9!oEU6i?ryXaQL~kGQ7A*$`7axl
z>Z?l3*)GrJin5=eT3JQbK#eI$Z;yx_Q~V1@JwYOwI>QmHyfun>+|7$f=IXLu3Z+D{
zXBK%n_L`u9HPeGN-yDz2X=X2H@J8?GTn_fReQ9QInWry1n{)M9xK8KwLD!*<_Mm2^
zVxuvz7vll+)^fpi1MUV!RjEzCi$w`>+IxwOOM{r4%cFhTjy+AfQkw`Y+iP6?=HLYb
zr1pJabuUFf?<-j~Re~s+gwH>!4~)%2(ysv5`nh9-?g4sS_I|gdRFyBl({Vz0{(5Tb
zzyT@7n1O+CD|h|8dfIR{itv93Qr(@@D;LLPxoWGg4?{=gLv&(aWV`RpVPGM)5&@?=
z+4%b~Lsz`$){fh$FHq~i{3kSzw!Ht4%I9s-*X8r4cWL4neS=@((^Ysq2!eV&ouB;v
zj}UXgQ`1=8)5kC+OT(ziCqAvqGPdN}n%
zZUdBBJ7(3q-E1^kw;5C5n7Wpl4zl52*-FqKIxbnY?f>Q0
zA5PqE!M_@J8E=*#~6vKzypxw_wv9V3)gSjeE80*OX@4`*+`5fxB7PWm$LjvbM;0u@nnzjev9E+I78
z*UnX00ntzLGOf);QI>1({H
znejuOsNRJ(Tm@F^mpv`Us=S5A6ncW@R{DRa)bAtJz0;aeuN>e7|`Jm?tJAZuA%c#tGK5c4{8?W^{Me;^Yz?X|C#6*A9w1nk)
zKM0lNm#1B=zEf`&Tr8w1R1`>d8w4ZZw(=$41L0)C>|Ra*tU};ksa@3l)WMq@=K#6J
z@@&I&&i!X4!@k16g#p7B3|Ls8#X?*VnVNS~XkDcCY}wXD$i_6@=L20JzbD!d*N&0_
z@5J|{qF#}*#X&@cfwYbL$zD0YzrThrpW?c1gl#BL6)CoYpX8+|GA&jNb?DW#K*JnW
zBLG3g&-pmPB{nKq5#9_ol=G`vT&3)q2Lvb>;Ux~nk{g>1IT1%|g7fSC&E;+#d>j<0
zmrS8oM2Lfyi1f5#D2l4>A!FO=A9N%H+#!D{RM$A#pM$Ew!+8XAmRnkiQ|!a;d$}GO
zfQWqce1VNK89y4lGYO5pwqjV7AziHM;727>Ddvj5p_(jrk|r-GHgOVBOK
zF616`i?)Y5=oJhPfe$^-0jwId3)7-^Ww6gka$g^*|IN4oa2@9it3WUmdMZ!HqGKZ-
zBc+1yScQ6{iUON$Oy47k-VDihJt}#71cuFZAs4mKo--qlhWx~%Ti?kk6wOTaD0
zF5(_=i?oM2Xcf#9%m!hHxJ}S4_UeDz;Gf-PfTH21mJl&FT-AQYk*uh~s?Rz&l|FgO
zX^hlff(6E>Tq`Yk!KQtxKruAhvyjFjz`(5gCA=LzY77l$DXh){Gd0IWW|QMmS@QsVE{{p8uz(%J
z%gaAXV^W`iXTqGcTtgmHa->8dejpyZvdKc~)dvfbWw2(%d$*W8>Nu+57I_P^$1zAT
z2pyaTQHP*Qlughr;2w1gx5qOG9vlaH*bReSJv|i+Mpq@>UyMS`=b}hKZ~KHH%2HQI
zANrcSU_EUCLW;l=f;vJ?qwMhicQ>${WEw-DBAkT5pwe%{f7H1FngC<-6co$C@Np#B
zRD0c-L!s|TwuBz6@%9EIXVGr{RmYPQL9-a%GrJT)bQsEmK9$dvJ|F`60(08G-PXR?J^%?=1p^n7_h{n
zLt8p;6mfn3U?17)Xe>^~N2{^u;V6P8S=!n?%R_xp`@}~^ya`c^k{~RYhGP!1!CI6e
zgs~7;V-uR{NjA}vio^gKKMech>6fp3^OR6$tWgw^_n5NNMWcxkrx#K5h$gb~iciv%
zFp~-}4RKw8x)6OXy&^?qWMRDW1KEL7EF2T>JbG|i{|
zHXz7oeYI-b>x!AnA;lr&gAwZc3J~$v`vbuzA
z3HN{?(NnXnoya`QbPDGc5{nLXmVw*68`Eb2TYIzhKh~VLNhlXoIlQYoen5vSo|=IMD@#YClwhdw
zi)RstM%rO5Q2&9m5?7B4bJv6?Ce#n~m`}&6h
zz2qE1L4guGH8aer4xla#kB6UQTIRwf*sA=fRR#8F8
zRn2v?U-@nGg#W392SL9w>2{mVl91J}5l&C$@oQ;I70u$XbIUTJ``a=98D7-1vMx-z
z7&qEE$Q=6u)&=W`Mki8onbJ+2`l$G-fhoE~YnK=2Pjs-C4G%9;tRs02Md`j#*#2mn
zp3&weNrlvyKP8$@*mmTKTD6C;K#SrAWe?C4d3&JOZ2NbO^QE?aSf&4X)?M{}iXB~X
z#;%~>%pQLf@jX1=srK~94c$GRsPcL37`J7eRi*XtI<$7Rah21Wy145kjT5+%i@2B$;N;Y51_IL;Pi)^sLpFN8D+-aX<+h
zyuooj>+OGwUMkoqE`m0AhSD~@Zpzx}JktZW3zu5pK`Dj5a_aoHnpz5f=L>u<{p^f}
zV+nRU=UYoSA`MVY>8%Jfbl
zy(Ud-tvck!@4!qStiX2gb9>Lq+k7oJM=jd5mGkDc9Uo)mlwZCt_DrIqQBl
z>i^3X#A(Od2?Egf_}U&%=!)nr6y$5z*kbpUMRQ0U
z95Ee@x9h4re|duY=fLGDx5|k&+!(u$E&uRzdH0XeL};J9{?*;+az)G&bo9dFM5}bI
zO~28j6tdTKRCcVPz$}vw&m))f9tYg^U8+@$o@wuIy%r9`5Dov3qqSNaS1vH_{1@Wu
z%4&?PA2T75<@7{jm(-Sm@M)H%I29l&8q3}@wt7Ani4CTypKgnWm7a_
zfm0xez(0V2K!s2$^2Ge%iR3`SO%;%VJj4+3GOU)fJ_-CPs)es+qt@@>v0L}|x8b+l
z4%;U?9Ah^=utnsgDW!~Nnl0qZlajh*=OhePrIw(biib{Ms?2wZ11OEc9AW6NjmC-^
zEGbOk-lVW?osZjXD^?!IR(`k63QtEQa;bdN3>#oB8~rOs{|MO?qNyVjK<%}Q2;d#R
zNd`Iox}%%V;+Wof|7L<5X9xE;A
z0>hhisH;fhQ$0q=;#N7!{wb;zqC|vQkE6YIHNX@KImjWbDgWKXP8<$L%ATu~JnhW4
z$gWkuOqoZ~R-qRe2EhX+YlM+qgp7@I&_0YHB!#Ys>Iygm1IPOufbZ3#JrBXrqnS7&
z^wCC(0_{{al>)6TPdegGW2@+vNR_FKFNyT%jt`(~s7?hULxb5=Mz*h#!uQ(oU=jQJ
zg8yzM_mJuyJA{+Ar4!m#-KX+)&xN0f*aKyyA9Fv!*a14qISG_12Jg)V#|T6QO!wAL
zd7;*Myd0eL28ktE&y&z%qKHeipRnjkZl0nj%XS{(V1|7dr)WcHqo62Dex9^w%YMX?
z-c=vDfYLo&gbH|nVfq;6GG?cwq>Bu$rtg$BaUK{S51q)+h(%wha0Ve0Oq9khO=sdz
zITA+nkBHFDHepDNUT{t{((N+itwNK!hyT9*c#2e{xqFIKue)t&RHm7KY6SSMOc|JJ
zq!^>(XiO)XB+Xd9&CUhOJBC4`PftiPC58O$<_Y*s8cgH0aCGH5f^}zCxw5w9C7YLT
z47q>Zty#}GAsJ^gXA`k0XSK~nvG#%BY2q*3R~jgRzgYoLwU0lk(0RJ*sn1v-+X6b2
zHw#EE71zOZl@eV+oh*Z;qVXdrvJzcS+r`MV6(>ncZ6p^6My~|dNe*-guE!VmDj%^d
z`-vk^MI@IobWj1^)~eH|Dm+CiRiP@3QFbw-L4XD9{+!;uaYwkbo9!MI8k=J11nChA
z<01b85gEDOxn5SI5@E5rUv5;SqS)=NP5|Lkm2|Et%*t>t8DEa_uHYY(AQ4NuH=Zw+
z)ZjKV9HCaCUo=S?w~XkH9jc-2IT$84i%8P0{Nv%gO^D1z+2GU8(!=a#i<*aYx
zT~2zo{u|SpT=F_FdHX3&hRbS3S;*7{`lCIdB
zKd7fm>wuBV%`qcPv}aF^79$uXT9_bDi~|V{nj1a3HBk(%4G^8mj5Htm$Ban@;04F8kZ_Pxq=La
z#NhlisrRuJxh0#Z%JiQyH=~Qay%#msrfvp)c33MtGus*$-!k~v+1>R-LTyDt?AhJ(
z+Wbtg6Cyo?K8PTQ{vfi?d=vB{L|DXz%wTEa2dS^VVr;UPPkrCWq4)Qf38_UMwyhD;
zb8YU5|B)`LNpL3g^bC1?Lo71~XOZ}I^H`BtikLoXv>Z`-{ABW;&!}ep}
zmUQj#{jc`=^AcSGxEPNHx$JWhz&Cq_c4IBZgUicXoZdwo?(Ob`;G7#-fzLT5XWuim
zrX*LH*p^E4RRLO1&ES~=T_eN5veYTbnj*Y)QF1s{d-K)Mn?)iK?Kd1Y-&(WRnsheNNQI#EB$>
zNNL0ke-fZ3v;&DgJJZL_{Gl2gQ>RUDqm#!gB-~S7Q16CHyvCr|d-a832YkG&EKN)t
z9XyN;4BQQD^?gh2TwV1|JK?kc-Rk4N+FIA!;H>j+9LjUycSGWVa2r0KMdj+KM>L&;
z2SHg?MLdr*v~D;72W_c|g|2gT*4fs;%=cam)J|RHtaf&3u5)E}cGW5M#uRK@2~IoG
zf?E+H94Q1i9!rdUZLnPK*YzkN?`0Dk?bUA_xqA3)^OIx5gdRkgcN@f?|^9bt_4c`(6?-C2w91H6@6YX3(>&%LGB62SvOZ^bbXj9?H%6@a>JFUO@
zGTm-tM=9qu3ZBWOS=-X0Yh~59KEDk@rlYg^&V`qQeUpo66UU_%=b@J3lxA)gE8O?Z
zRHgFofDu|YI+RDYZRpI^qubVR4j)Ej2+@xjEpo(g55qGWFi;>^FmLtZ`K{;Mp9`xM
zQ2t&+F+rZbr`}P6gJ%U`OD>z-P3})?zIEuJU}P|&aAFA|$T8VMf$%hXjAuhK+aX_a
zi8F&3`a^KVC<{kz1cCeZo@(0mORFL)xOnu>ZP-tHH)B&fGcO-scRPD4GZQz{8WY1>
z5B*jf`!)m10_VaGqj!->ai5KIK5*>87tJjU5*$jk#mk_`EG-PTdNEuq=*7D9OH40m
zh;z(yTQrPwYnyHk&Xw(j^|^W9`l4@3#hatnMNz62k@D%Ta15QC8(57LS$5Ynr)725
zVEgq>t-Ey
z*c9MdEP3gqh@{$n=DX%_-O4hT+1p~KgDd3@mr5n5WLgpo>cJ`TFiCEN&&LSg_w$tB
zV3RQS9t%?QHMUa^L3)zWzYa{J_QTSOfM|5wJ~Bkd0B$)vd77vqopai}rt0{G&lm
zgR*)Q4j0C$&H1H8WmWG}$G~ywlnl*p&a^haH#5DDeYfx3iqurG^>sYH)Gu5bwa(7k
zMxC2Eeqd@@7Ltc&s`he
z%b^$V!+@LLGtrHeg-3JClcUyH3ij4&;}Rn3#uRX*g;qp^8pz4-SOKFLE}5VhoV;P=
z=1C3MH+$_G@S|;8wdw^T+wJ6i^4m7!i*i2mh8)hEG^`&1e@z=SpR1pJRANn*glD9y
z>ZW+Co~G9-JbkTmm)qNRSQsrOQy5YSR51S~dG2-C`5r~-y-zmfeVya`9*v;uN(=*)
zX3COr%cBs`TSCgjL>LAhV~KzMCEM}QMuGx+7@_k4^mQ;a@P)xU&&crgzpMJW
zefc@~@Vnb<%k{s((vY2f)gK$@|B&~anwIA}OE=Pau;Vx6?NK6hm0Suy*lDeegV`|$
z0<*U0f$_EObG_R6zNhPZIWjBodAxc7h^G0Q#>H7XU*JRA-od_YvL6Nt^=bYWG3>=|
zwceW-R!&=$j3vjh(}uNd%Cbo-o3?BbPW+R*@z?y?Y1Y>61`ik4AGv1bi)f>Er1QoZ
z7fW-2c_H&tvr(tcbVfGX%j|fq;eDm6vUW6&y>6T_gN;5FqW5*MjXA;hy{Yfzldbo&
z=0vY`Lwi1+EhF4fnmJ42LKBA@E|1(F(bnY*8UI6^2Obpm?(<(2
zXmJr(Nr|nL^rLLlOH{0jOw5Z+lv4~aXh_Eh7{Op2eQZNvBvA1hoSh+Sn|6N#)zr`O
zwo{bz9b8LGvyLB_yR}*OYul~wC8_T#3;$;%50I>tSr4;gKD(JF?un%))|DovMU6u&
zqw!>-h>iVs=>j0hk>tvL<(hUiZpzn)r)dM%wFn4bGqk6vv!lMVt+VrQb9;>^_y+e%
zBldaWj64CZYpazS#5`xlyv{3I4tng=Av8?WcVD(OaSVlbCSF1$ma+Zf=%nxMK8mjA
z^%I(o_lJ;sa<5(w<wp!ftjUH@|GPOwO8T!Yo?6%Nsi7(lkLO8VpZ8n?LdUSZWzrAy?
zyLYg=yL+&2+1oo*p#0j~wcG4Y+fG(b8XBc3uRYH7diLZbclRuZ@|$z*>_pVn6idYg
z$PkIJ%Eve&pes@EU_LMU{VtA8CzBCbPGmF^a%@QiLQKhG1Bvf>&wD=p!FOd%CYQl<
zL%6lRFuyP{w>UbtFa&s2*WB`We^)b?aCJ0220qQw-W#2d
zXP7|TaWkJjG?Lq5;HDbix_`Td89Hw2xS?Z)N&wl}?AC*$-Gd`=pzYvb|Hx|DKRnpp
z-`n0h*aAFmZEbArstR^^xCV@AD!7?R04=H#O6xA{_&9%ln!R&sp4a5Jo~d__E4-I$k0&CNqnka$$);A+ycR*z4;N#=1fn=6)w2l
z)BMO>|MmI7YesS>8{0DDTYy3Epcr1if4hbOi>ne479u0S6#QWaNBc(>0N|dY;0(*G
z@9Y2o*S0nlS=ij#S>N0W`~CZSo2ne==#a<-!GkP|GLj2BJpm6E&Q8pFl{-I`@6;t|
zP)C;woGz1wPV+o%7`!SIJd?^AY$3<$DhV#um82}iL?I>#F_CYiIFpkzgWM8qdK*s6^j^d=w=>_{*K<|CEK%16pWN?kc}v2wnsBWz4!6z^
zUWXh}4XsO&b=kizhif=ENjyK%DkbW)
zu2l0Z1naZ94z4T~*kWF;SCm?bF%1md2XNLD45$$L02v}Dh6Mq=7P{1Xqi=b6`CY&A
ztM7l`yMN_QE|>TXx!*^vNDX?LdjxuzFB*PRDV(H-h+r9c~p`f3i<;xZI&PfJh^l2?~Qq9yW
z>Pc0oSF~bYJS|JdRk@^7g&a{ZX^1`Glc)3%9}b^M}d
z7Y4oqFoGYI$hr``DTQvyftx%y3q0Gn4o4}nDZq9AI_+KNJ~K!qk9{XhTh8WO&e`fLxA_z=KSaAp#HM
zM35xm&wedWtkw$k6XUq1-8nJgp+2tiCsqBlF8%Q<&%<{CakZ+X$#~wx3wcV<;EGHm
z_em*UNXR_=6X=8&8nyF({Ez>?_O7X7l=Do%z^i&JL)%p1P)YAd
z*lj7ksw8gmp%u=*2#pUcHAV=g($qIrY4!#2zf)l}gtbc{|p%>uj+=pBShy$!$
z_zwI@W
z{rah8mkDNhj8rDb;NmWV7GI%hd$QZ{Xyu+=2
zG4A|-f&IdX{}_~(6{IvT5~4^7LYn0gA{#p|keU!tHG*YvmU->9HkfI0<(!t!3dI6bC`#3e
za9UHVWf_wBT3)V}*u0T07pY>7EShO3H}fVMr7C991xN&;=~&5tutUPFE`9LrW%yq?
z6Ey{AMz9*(L7v%HiFGZtswQsAu@&$jxQ`2frt+b|2If(Zq~uO2gs!l)W2N~|Oiic0Aksq2)gl8QoQR8muLNv3207uYn<#5gv=
z^C_N5%4|~QUW+PV*(@4qc;%HB>$Oa|Al0i{t;|=;bTP-($}$we^%7Spu|+gqN*4_h
z5}k6EEgLu*ea>Jx19DYd6B|yvS4HA?c$%!~Fcd!UoI6>Lq4E^(20E;t8`X`m0h
zCU_U%9OCjtgLp!@7XXHkte}4V)bcD!$MU2i?Njbrfa@wJ!ood8=)4t}(Q6B{G
zs4}CfbVirp+%$zkUMm!2n!*H;D->0njE6#@YKaergVC_p(5P}zDC7i9rZkP?xCEp-
zH2qr52Uf_cg}iWFQ*{M{r24puhMub>u2z9x#Nk#@Q4AdiR@p<1+S*?mfogAls&9U-XAY{1NvN8;8zcAKb7LL0
z^`W$V8l`fc1(dS*mvQIZ8wRQ}lqXBrGiY9eMNS_xXd0`)moLUSEO1A4eXRmGH+r7SpzF*DgSIn^^e**iJbIW^Wf4Q-?Ycg{lIM>fC+C%}~#
zJ-aXkKgy6+gFMU-2RYJ~^lTV(;O5*AA33sbOpo+7$Lt&39Zi!%t@D$85$7%)-qT5k
zhFR1!`0)r_$;Tg<&7?pnVu+P8Fqd-YRE@=h{(!qy;ypfZED=g1!|`}Bo&aw~z@d>y
zC=~IA!+x*Ztt-I&STQeT4OZ7)8|nkg=OHW9$|dk1z)(G{%g1HztgcqFR6di^(O_O!
z5n~WQz^x}`s#c^cSvDg^OeJ2-Qig^ZTH@kW`K6N_Tg~I9;86wZ`pwbh<%v8_Jc+c!a&(vto#e1-^p|<(4PTGw!=Zhjl4m?nzWeKZ6ALc0ZqCf6j
zf)8MSce%IgdVA-!Gbku=3**1t+12tZ6}r2xrMsuq6#VYp89jYaV!Z|0lfmqA@{J?+
z<&t!ItiVGDk+D>keSVMI>+l8q(O5VZO-1A3WHJRF1Z#{t!^0g2hP-Z%tz2L#c`|EY
znb!^VfuZX7SgTjWvr`cY6$r=Yb+M31X+nxj`$;TJVL^^TnY=`Vp=_@eSwJG7uV7Fa
zDQzk-O-?96!->@*1S3-C9cajOd30%Md~SYVu7Sk)>A{8Rq3OwuWV`*@9q;2QcL`UcK-kxiHomb8ke@9nK
zcUMbicS~1CbKJFNkdB4Xb~$x)EO|22fu6P)#Djy*H4XmA)0%Kr<8m1SToVp^y*`&W
z5RAtGdeL|+6^$jLXy`r#{tJf!aJ+ZNOvZ!oP*)2y;PK+o`fFWRTVz_;50FB>|4YW@6ci6WVF#8O8oIP)x
z6;|WyW!eHqld>c{JMdSJ_C5agY^1a0(T>i`EiI3?wKui5T}MOst=GCc9`EhCGCFw8
zy|-{IduyDtLOHeM{{4G3tX}2nRsOujfAQJRg(G&S%MpzFd}wSw2oG;K;ztj0EE0~O
zX-(k}nug=^x%~m3Kj0;>cs>h>9^`$@{o6IHUIRkZz=?N`rMI4<@;PVVES=_Poa2%r
z8wW6^l75~Dr{kVv%nKDKkVDQ)XOwtWOQ>>K7b6!_DgcRexj^Oh)Xnvo`K5`am5Ifr
zvH6AJ`Kf`asa|m3{B+miSm($<%SeCA=s?@ZAadnIe=C47ayX45b)zD_=-Gvp8EcKR
zo+|#mm9eg_tC(+lcBreT9gR}8wq0v)zuMLIcx&60_V#NX&5yssjP`UqZr_}`In|>k
z_m3H8jdfJ$2LekqPc~+4G0#5xwA*WQxoj?vy;9cQ{$MBou5!ve`Rp@K0XF@9AGps0
zPdfb1<#2h>&@)ANi&@Ul9zY^W3@hs0Qx!<|{8R?-Pam-#?vH^A+YJBq&*jha5*(R}4^U;gHw{m~cJ=ZD&wA8Bv;}Nj{i==OF>|=P+
z<+eDSXaoz5+}n1IEEf&g;89hT*Iwa(ou1|3alU(|z3p7DmKjq|kwlVbQZyNQ<)v?Z
zq7JP42T^;iGLzy9s>-}uh6pZ)8v{b6hCqe1Up
zXUDZ0y{*fm&3tq_?Ord^Ry1-?K7hnh7K8Etg6wbo=ErLFjMM3~+HF?5)oynJ7$FLO
z{`1d1_0&^OKlO#}oxOtt3mOh|9NKILM;0`YAB}i(nY7rL1pPC+dv2c8jeF08BIu3pY#SoFmgUrysGuLmIS;TbGv^6)IHQdH&>vJjUprjh*7
zZ@&w&o>HFL++13@IWxaJwXirjJ2$d8Hv)bHJdTg|O^u(@0WSs(sL+dB{#TU)RFI)4^(F55Q{rq7OTx+vmfnS
ztw&ZnnjhwJ9~@dX*0
zTFacDsc$7BS&qXfGRjghmQ7WPz=;Vo
zaxVnIiL!Vx@%_p7WpixKWL|pth1FZLiz`!ei;yZJ4_=JikB>um>6;jZJh5wXq-Sif
zy)jF%b!D;xFbK5@GaO)6>@6
z^7uga)s@L!E^;se!N+}DB|SoDtBlzS#F3fayMM2SLAncBMP5thGlaus2d3MzSPm@~
za3?YZI?K-9?)J{%*51J$wB4h}?EJh?D+_l{^(W4>
zJ2k0VW}%2=@EA=-X)-`30ty!rg
zqe;#+M?2<7%Nsc{pWZLvJ0*PYv_L1kTRq)PT^(1B`M~mI@Ad1CL5!Lm?P+bkJT=q_
zksAC9Mc#1FwYlMzW7?KY@9Oc*H$2X|l*p)9Hj~b0F~2_mkFp@9_74xB9ax;9f)YX>}cw6(Q)dvk{(F^D-kyE{OOI-2qkl7t7ABiuR5)hhDc#<2ZKiF@0*CUXgf
zN%CxzA)-Voz>t0{8RFPvD(Q{Hd_0rLn~b3)A*#p%JkCIfA+a%NbLpcWdh$0u_%=wR
z6gB-1|L}jTtuHJrqAUlp#f8P8#m40AxyfFrpr=MVN5^{LK^`A&Ssc5bc1)5EG;9xk
zOdmclWSYZvjN}F|qk(M`f%X2bt93Qr)&AI6e-i}gmaC6s2~YF2M>^ZCw6;EWqx-t$
z=CF`*GX7O9x~WEQXOi3cgL6nUIc4Z*{-CMCbB#wse#?==<8gu$cMcA=_V%}S_BMC+
zHg*oSb`RILcGou181&}WrrmaA$Ut66mJBo01CR6hoqVMV`Hg-L0(4!yd#2Zmd|t;W
z96XL;DIb*%rW0W-5l$zgyg;Zjp3w-X^F$#8Aw@=+c3iqY1EN~}_{V?a3!i+Cp1}$x
zj-?#y>$5j+POmPHuFMZX3AixZvoPB`GtoIc+BG-UF+bkEKHW;%rzkhTaGG%boWXlE
z;+(i`Kuc}FmvP%oI(FFI_E>AnFZH1(`q2#T>1ltwyZzC@&dax#`Yl@%q5WAga8nAe
zNr798Z$*xxc|1R}#*jHw4)9c>;vcTC9OZB$C+;5{?pt;@w)c1Uw*ZM-2Zy(}_xAU9
zbB2({f*A?@mdHgo7LCSS-0i~7Pjkn0^UkSp_sqCc6VGefXzsc{3ZlV#
z+Pfk}koSLPq8L}jv?4%=0H-7}O7bT^`3aEY;o*KD;Kgw4_RjV?AaQFiqp?s&Z*1L;
z#(la>0&R(CY%9*uQHFYLO&ZwQNw!{9AjLVYi|5A@RONT-N~Or1)y-^%sFgKcCMqSR
zRu;1cl{Ik#Wts_9fnb6Ls#qy1a8ZtLIB{ZPBAd%T`Q($o^?|oTn9duR!FxsGKuYiU
zj;1#kZ^Or_@u5#hM(9z;}|8?K?LeerXM%N|(O+X)DQ1q=bUQ|Sq4~~~gd
zSxBJ4JRTw=RQ@S=xFTV@1t?D^4-a<_4y>vo-rnA}I;^sYH+T?DAmQjR;6-3kP`BN`
zUBix#jkDAIozon0+=+HvQBUi7y}}(=rDC2xt|*YPREun0C-PZHuv6ecK%cH+4c{er
zApzB)z&1Fsy{mI(X2vwLANk<>Km4Ave106C;L-=^AFrq@faq90%G`
z0Dx?uG5rC}eIST1NyZ550VE!u=FiUZkZ+$JYj;kvl@fDSSMph^R+dY74$4G`6OcaV
zv#FfPY6_+)gr=rMa3y+S4jqVdd{|%`(HSy?o*R8jOUq|xXYYU4JKps~IjfN+GnE(J
zDsENM2XcB_NuWV1DY}Bjssc-_Z-MkcsW%M(Oj*ZM)`|3kb8*0Za(IpNEnf`YGoFig
zj;qiBXpmY0(7;m{BlmEAae_ghx6QJ?RSFG$J@9S~o@ID~crMB_!04F3LK%xD<$x;%
z2ArFac(@W((Ik_Ia4~pKhk*oXGK>>}G#0?|0L?tWiP@ZTdX}xDL1*c-F2ND4?W+jo
z0`ub^{gbLhD@6%{FGOVcVO;?d#5f4b5>(Aea3%N=K2hd^6E9u*fA(~DboO-PY3$wa
z{*`w3Sef
z)FK;dbVEWIyl~v=#aIF~+OtHs7LeE6$ZK#8$FzMGTnP=n{F!s_->YG0QW715PSaGF
zV?rbq0>`1hfexb_n2B(xB@i^wq^B4fRKd`gJ(L^-9!jMG80M!4^yvM}3dKylo~?ls
zPc<}tf2$MA7BXc77YNNhaL7kB)H
z{hzU4IPn+uKZRZTz`O2#?&I&Sm-wrTrzu!-!jZ-w7P*5Qy_09R
zv(#oLy{4z2-BJ^)7Y(h<56{C<2wt>#A-Do0c`5Jh)
z&mxM_fmPOxmaN|I*F)ysTT2BjslZV>V8OgcdODQn;$=Pot;oVjvc$y-T)fCeOMIjv
zBuZ?w%*Tsdv0I@abXtRak3BBa)goOh$@PMmRqnX21`uyau_Y$Hz(*GN5E3}x
zLuhhIV~WYr#dH%6X+_Kd_-OAu>qirLNHpw^#11Z?+0Z_iXZ#BQM8F@U*B8f&Zai!N
zpgfDRi3%4f(!sy@)9+T8c%BRzWFV9Fs+e2DTyo0Mm|tPnFt-9HNtcjzsA(6R>$nfT
zrKH_*%B7|~a7BTWq*qFN70e44m4ru4`ZAc`q{1aWQ3p_}cvZpcGEtN99G@<$G!}71
zJXRv|z+{xyTRyLq3+fMk@coa!Q_g0oFMs)qs?4go1mKfoKpTLJmm$Vy;FDlYLop3G
zlMymHYnZ%Y2&TzpGH{*AXE{AXWeif+8B^y}RYdhB6dMwyAjp!Ul!7dQ<0A|c0nE`*
zjWH>Pi6LC_Nrp?ZT=Lj>AS?cv85&c_t0mM`1G-u%8s(w}xiOlyP?k@tnZ{%qu2zMN
zPblWFVxFiL0jX#%Lk?i1C2Iw)UK9X`kh_%fP>rODd9pEO2`^*;f@Cg>!*69Xn5k0*
zDBhF=01-~|@P`|iCMR-6IwQwS^iuApK>Xat-vh}}HAk1tWG#nRjYv-RmIQBscV-1!
zmfg=II^0&tH8Hg+B~~S*@Up1IZsMM~gQcF$rJmc%eXDbww-@@N_G#Pg0nEEV`lfOB
z1m&J#e87409Ki8n&WUHfF&z|P5ps3fx5WEbN!NV*Xd<#V3MX$EsCm6r`AC5YAZZEQ
zZKPc~=F$mACgsee;OLQ)4h3^uOrVfbb_r=FH0G0qR?~u
zu;p@cE~gX1%24w_m+@`a*7&WZ
z8;kQji*r4T)7{H6y&DVtOEcZelRXPFJ+nxyqsh&cj5ut529gvZ2OCYl#z*U~mU
z>Ch53HDysSXx2>1b^$mcVGSNFMqL{b$J*xNV8XlU-ksCZF6+%v*X`Nx(Q4AQfw+@!
zDYz3s7PHA|fG?U31lOgcgHPC~_z|0O0vrY0Ey6uxR^Zp%gF_6jH$kLDiB(j2m081qk!B8X=@kgU*GEpcTMk*j-Unmrkc{~&j
z1cSk1iI2rY!GI?O-w6dmey5p90tq!_dc;BwO^{KMs1hMbIM2lxHpS9$DCq8Y>p?3N
zv{DIxsFX^21B)84S{=Q6QI4xpwM-pXML2<*1BQ+(BB1aTDYYaZ$EZ~h5UT~MmM6+4
z8u6-^Rlp+pR*tP^k^V>}OINaFPQ^>Wh-v~&nb7cThBWk)nThIZq+q1c^-Ri8BF0bW
z^;~+Qs#f!CHBX)7iJFlpYW|$)(iodeAIS8+jO`=>%d1N_Zm*5vDcjt_;Nr}{!t9N?
zX#ijU%v8_pRM+fO_uOR9>}wNEIw!|FCnmZk$J(bx(A=l>`Tn`_R{y~qX1_lv5BDz-
z9t1&%(F6o^Xh9U3pVmjshK0Rb;QoIJ7$C)|N%u2&P?46nHof_|+9`BnS>zf?zoE+&G8*UpP>zEqtm>6oC8R?iE?Od2>-(Kp*
z9kXb3@cu#!giDklqIqR2qW^&zj;}Wrw<5IRM;YQsCk`^?p+@W$8Eb*E7}%k2e?Dkk
zElSbBo@>3m&E4H?sla~JdE31+TUU}dI69c=qCc1i>
z+B=)!SNsPn^TW-%w?+-tS)d#M^h_G=Yy(8f$)haezli&M{D^;0s^|3v%$Ltg#iClS
zNcAdw%+Tb!$I?k%;HX4084rd1UXMeSiGbhf^*g*ki;-|ViBxD}iBLQqMdCj3Xe!Z=
z_W@`|lM#SoG|-rA6o8XJAk_HM6;FCeD(dkZ8hRSyCcrUoQh9^cGk7Kg;hPp7oD=*r
zE0>K@L8?}?8j8PKwZxy)l=EY?T%yiuBAlPrWdPqPddaUI7g>c5H6|AVzEi3c!(w(i
z?G@>;BF57Rm%=4@I%+DZjFiw6qF`e1)Iq*jD@Zv5>J_Y1q%v|MBgO!NiipOUO*L-n
z>70h?0L`Du>s&goOO*l(Kt3)}MI)y3c8#?vto=hDc-P9!v6YpvrKOR@#o@)Jk@>~p
zg}K2+G~KR$X6DBI>7Rhk>3$?T)R;y)J<$z(GdWJB#!gB??V
zNPy!=2jg2s5xJpA1aRao)>k#ITy*PU1O79qBa^n|8dDxK7*te*Mz$#@||Plq#`IXpNNM%J`aRfm&@gJ+Ppre&*%5~!+=DfJv19IhL8uA
zOaUNc08ltj#4)6rgl4;;xZSV-FeSumz;xE&LO!?O@1XG@R0$B)fQO(&$Yv<067<(C
zjeorX7nX|%f~WONr6g3#D)jceCIAx7Ys#IvTq}{MRrb8bWzmGKfGi}kN{Yh03?5|h
zAcaRLB9cmlFf1bSIE_O;y@{wV9Sg8zSY+cFF#+{TxkLkS3z=lWNa|YD)ZrwpNnuqE
zLDj5qQB{rtzB50a8HGY~4MKjAtrqcICZezomG>OiOqPo*FOQp(BQ-F9J1AjR76@ObmB76o|S2f(;R(Ry3h;sCBBZ
zV{)i{cCw6LbYFS
zN6I`+J)PGoLZH9~T-#H}8EmBY>cqfxzh$9FIqI^fCb&){e~ojQkcOs@Ov0Y09+>X;
zdV_kiUgaU8!SSpro!`{6day|
za@%-dZu-xxR6?)vPwJVIW2jEhkjR~5v0Na4|DHI}Pip+xG1MP8n!u{y5|3#jI$@~<
zOU5ZIND~o>iLqpe!UBqxO2mA4GQ`t~SlFFRh7u8XMj;ddmxNSaC(A_&Qb|Yz4JDnC
zkl18aqfkT^BbpGAg{Z>cpXYe#UFSJ)Up7k=vv^*Q>mpita(i=O8BI}~T3i|jEG{(!
zauyawff^wwFU&ON&H^b;+?XD3Oyr*GnVSMe>~8QMnn4S&8|iNuxzRp?rr))V4z!J-
zX(wHy{jC%IZBWY0kG2wy1&GlXFK#XdUf|1%Zar*e%37ul0fHs!s7xP~Xba|9OS*5~
zn(G_5aec7!a$m>gt>xhx?N>Gy#vrBZXusUq@fee~x3ynxX}#LkeyyXuxeF+;1A(s{
z&E!MVE;>7!pnHz3ncmi49_?%5xj&x_Y~{(LD(|ZD?mF+R3eFM-&6C3)
zkRp7&)vFxj@->uBad+zcc~yXm$%Ox;mUkl=ADh!{<(Qb)1H9+~a`OYK!XYHE7Y&4f
z8xh(9(RdK9Kt>4pAi9n;;~*mYg2AvC@gLwffP}jsO9WuM93GF|@3#ki_5zfyCTy10UV`zMY($_zx7N*ba*P?JCo`~Dvze}r)kVh6H$_kvs9cS
z!YqR`REi-ZBAXy_AirQ%Cj>T;iUyJi4^4(6K}Ry_!_)9L97aP9o{4Ev8ok`f0RGUF
z;*1PI8Avgu0t5kwa!8Y-YGa8r*ri{8PqkJS3P@LxECQ>m(f5Dw-M7{kmR2VhSH|a;
zM&}nt=N3l*k&6q%^9utD^8+*U{ZrGulT$t8lU?&;y?^!mm;c9KefN7`dwOZ8d19bx
z{Koa+fomiE&BOg|BSUQ$iegB|39vZWF+R`NYa1Eq=?*4lcdxAU@*w1#&kx?0}S(SD`3
z{qp#Yrn#Yxss85R;WFmFRpp&0itj}97HKQsvO+s6^qUqd$0Y`8%;PfT@9cS%hm@aT
zXo8HoyjDPr)9q?BryEe|1w4hkevdcc3I)9ZzbEKF`qCG_@cGX_^)whdJoWTbpN~X*
zUa!*!WsS#$7}W1~UrYdYdtFWong;B2I^2g89wgJ@WZaWC(}tGH8jPu9VnavoVLLuH
zj*s>8Qy?Jm9L=49DvC$*giqwRo-37NQV|01EHPx9Bx4kr;OKNYFVJN4-bwzsZ+zpO
z?|AnMFTD7|3opI+;>#~Q|LvDw`tBe8!PiA08VmVSVQ)I=iw1nj1f&t}K)@l3$x@!l
zpO0N~wlIU09JKst}U+`>!A_eftl7>!czVvs4bPVk0Tsy|a63ZDVou)jcbAUo2cg{1aXKStXk^j_m?U$Qdf4Q~w^7h(z%DZ;``divt9vkRu
zo$k33w$6yj1Kajw+`e)wdCIK4#yL-DdzG;R9J4r@KK*kIa-%w0c16`7=Pt8_ER#1y
zNZ0&6uiN8rxaGK(BNeSH-lZCZObpxG(-xS?AL4{o1d*?@pnJl3c2oCCfQZl*#qY
z`PExVi}+rJJgCrn6>1lvGhE4#_Nl?EWN1fCZUg8$IvpZ~Xes^w_7~`;PJU<}4Qb`&Yho?b=(QwX{6e20z*QIFKkbz%dov
z(vtfI?OvYjxH;XSrS@uqv%(?y!5ndDr1uK+n^w)$0)Yk?kPhbRD@}wl99+E6+Uh%+pUj_1Vw<{_lM1*MIMKf9HMg
zee$WNzI1qau!m%)tTvkk%}jS#E!JI&bFz6jL#;tQ_;Q4?f5or;n~+~amYxkVFb
z_%Wa5p_b3;sSFaDOek^;YG*}CLV_r8aYg)TvGN;Fe&8R!`&7N8G{l6cYEk(9_y0x|
zlegBFmRFG8+REzO{Ne;qXP!U9y#V}L~j$GMToiGk&LGzIJ@|NWm|{g)qp_BTHS
z{5L+@0fjR#AJi*jL!HB;NMCUTND<|Tog;%tvvP8vb!xaZa5Moy8NI}DFA$Ak70mI#
zG@jR69@{MuTNQG@#_ZMEgTMIG@AwaAhPxlPZB8yuc64@KZvgRfV}-}#z=bU>R}sS6
zntt%N-+%RoKm3>f`d|O)Prmct{`lp8{LV{1{@x$AUVF>cYmYWve|&7bySwf3P+#j{
zZ__}})gl)l{aaD%N(r)rk&c*Usm$2RguOx`AZAj#B@!tS-tW^xR?6Z~8zC7pFgrvs{{D5$EV8avG~MU=H5AkY2}GCzV*^`F999C_}q)xY!ON*ib{}VGU)S&
zQaY86CQ}hr!SY!)mmzXmDx(1qqpAczOiO%1;n6JZ3z0goOTYD-zwz-Wf93a|tXHzM
zs*y#L$r|L&-r5=f@#fsj%EbKg4O%PIG7cz&3I+)wcS6XX9_(BkY4Poh0SYe~5MkOrja#R1
z%LCIxUvJs;c8S<7lRI!M;#*Q+jgRlGj&)4-Jf35nso;8dPZK1CP0f!twOnp(1$w*Q
z+0oqGdZi&Oc(t|p%C*OT`TFIzv^QUAZh5@9`EpnLwHsa6JKG+SQ?^{{koIomXz%7!
zZw7PU9P1*(2P+dDv7-gZO;Mdh9Oa2aU_||)8RW0GLIyL96nt`7BUR3l5Sler^!Ysb
zoM3laQpq@w;gQv1u^pjF`bWTNR*2P3h|x|fTy!{WhlfYIyF0fwwr_3htZ(k$-rC*V
zfeX8Pdj|&xd%%wS`*5~@c({**(GCv|4|Zc=m)*VxC6OT|3nrr@F{+3TU~0@!d)Q8n
zjk|Y%5zW(Mh|BujGxgrF^44Sh-nnsHlItZlo53_S38b}F7qjYkBdT3YRIdBUHY|;e)MA>{m8Q)d&fJf5<;N{?qgqh<)y8in`=WC
z10yyh6i4Uhp$*L~phc%MGlNsp{cuDlQ~mSP12YphX2$`Gy;Eb|6QiADV?A)390oXc
zqD2PiZBF~dXq$jLZ_jmM_G!jB%X{W1G$C=4cFf{7q#StBt%nVOXe8I+n8P*;_;v+9
z{L*KCb8mS-BkYS4t&8K`U7ZkNA8ToUEb6%xwJe;;!2<7ZZhoYt>2gYYj((yZgJ)wzl`&
ze)smyHcO=r4!314oHGbj3}w`m!bLSX#WQabnvZjL&T?m`>dCQs_cV(H=1zeW)jMbE
zNrk(20!%67a}3ACX)*$g$k8dNouMuk`8a{OXw1nFA%XErd@L3BWmG1k(TR8{l?;T#
zZa7J%LNt{k@DNXj3R%*~BpU*WX&`CzLR(HDZ8sq$b0JAcUab59yHqF?KK5%L{n$s|
z_l4hn@7;g<+T^(v~eGAksy*(`*ZI`cKd#o;o4bs!x^w>bx_4%>Rj+U$ABONVGs8T_p
zyyY=yeH~Zm@P1$GTcB#5>A#M7H?+jI5!=cp_m${I7Tbe=PK$4f;dKbm_xtpaWdMRQ
z4g>(vEu$vU+@}nd%b=M}Ry%<1;P42=<$bis!MT5QxOW7^W(R=n9qjEKAn{SB%d@$2
zxV3w5duMNb`*34xZ)5AoVs+ly+P%HGv$4ImwzajrjbORGyHUu}VZS>VaH%4Zk-gU2{0u~i5UNF(#
z5Ald|b8~KeefHL^nVUDKmX{~c!m4F7*0MA|xI8yBzc92gH!wHThsL0%Z_G{g%}#Vp
zkD)d>(lI^OIX2WXInp{iidMZWPqtzWc|~YUL$Z=~Oam7(&UvVv3G4K~ADZ>VmYLd7
zW4Dduwwl<=B{p-|&U??5#i7ThZ(JSiy)t>@+EDNH;TzZcI^oS$N{)wbpY|kN+=>EUXX7^IW{Ot5Jp32p#=H!8L?hBP}O{vuh+BZC)vBFGSn#N
zCuoiLy%QY`u2eI?lqWUmxS~Tv0ttqK7SX1l$dyHgrPE{@1#3YhbcKY9#8By2%u5gv
zMI<>U1_W6E2xcJ1Yvc)1_@}91OyVO5e`uOJTBacL$)C;4xHP}8RDlY}Fn{gI4}awS
z@BQr$+qH}hvbz!0dAn3T&OWMb9#}pusbwNZ1{p0y^Ob5|(Mwzdh9T
zh!8un@6C^NUF+<8G|zeZIv$6jxTojpP|sD@*8Gi@M=TqYeQl5RcV5Y)ZGpq(f!0T-
z2CvbfJ^%iqZ*v@oPzi4U3rc~TlK-X>*vKXJ1>Y?xa+?d>d|2A{^(G5Q=2$_RlqprZ
z$chr0oK(bAMnzjN!OujZL5^W_hG?-uuD7Sk?Ec}7B63@R&Aq+t{e57;wMM(O2@!cW
znGA04>?e}ZbtH?sxv{w+N#y>)w$J0$#AHTD>N6ljKK$VifApgt`N(^o`2CN(9c`heLs-FzMm!@0
zW!xrFR*7*P?9OhijjSyXudNK-S|0G)R&4vTw-#^Qn!j;-dGOXk_v(D-GMXgTvoX`k
z`d1kD6p2`Higit~?pewMmGTT~wkgU!McSv*j>(G!SV`+RoLqG4VN)Bjz5qKtz6n^&
zgb-HXV8{Ll|tWS#ZBme$_V{7_G*OlR(
z$JQph>CnDGxW~I69q)QHY*`S)8**q(39hmJWhHnEP$&m(iQZe1Zyn*!zsh@8SpO>J
zS$cy!@as($!?FOOC#gxe%*9k80yz+T002jkPoO+W!B7Pw5s8S;>9hnxfdeZ9?0s3l
zYz8zS-cmZ39VzcZiBK>5uxsSH{t8%kgQUm}!3el5)aLwJ%tWwFGoaFD_DFQW~oEUeIZU}j{ekE=48Yg3ZW>X}L&9we$<5-KIGR$@+yV!43!2rA^!HgW(^LnkvDuBr%v
zkghafm%IqdfWpSK^EjMvT!QC+Ix)7jt)urw-^9fD_V#u*n|<$l-~VeL`N#);^&P+Y
zfw!NQMF`LU$3iBa*TM$p70CmYJQT5g9^2v4+kAYJO>MIAbvAa3i?0chRVKX51(#_5
z93Na@12cSJRtn6C{#nVtB=}}T|DxbU`p2|$409lY#B7sr1Y9Csv`yd-t_OU*0R*+g
z7QhiL41{nQMyuS=0t4SN67~(=Qjwtanig6!qPJ7lDF7B1TBp3L@uTU`&gAXUX2#bbQ00fUujMKY?<6{WZNc5swV$e1;z>CLfwZxqsYsXdL
zw5}9$M6JjH3XyzY0oV$VhxU>y=b#SbswEMSS}d~pERlnPT}_!8G_(joKvU8g9SAQb
zN--4zG}6#ciXz7Gn83wZE{ddpIY<_f6g1eSwY81b_O{;s8{=c+larH~j8>~upM3Jk
z55E6>AAHx{_rLR`oMZC_UeMDe11so}9Pi7rZjC(Bi6b$+!(rQEY7;UxF|i@Vm*vDw
zDYlAMO-9hl0V%x72NuxEKmP(3Sft%^j2q3+2IQeM(F-TDv6|Gv&oSmcbmD6J&
zMFpznT3I)$bVHUP0&W2pv3!DIF^)rTyc?Z*
z_0oU%fBe5)c4s;fx!&5+-`{_uzwco0uv{qq>O0@{Yhz3;g9-nX5+{Z6@<;~IjW
z>57pqX_36(H93by9m(l^HNCH-b_IN!$G7FgrkK1fCT>g7o6wN_co=}P%J}B_;Ia^0
z2Jk_>+?bd>%Q|NoD^ii*0S?sIC}J+U^{_R>54PZj8lbSjh0p+Svad=Awm2AX>YL76g;h9oUYkRuXuV;YVmqcznkl+PL=O6c{Czy)};
zT0O!rKYfpQ@xNc#FYNzb`vnkxVgFOuFM#+9`=7!tz3=VEAAA34rNEZVR5_C<>(QL-
z$x7~wVAI*dEPsf$X=nEgX3ONZvn1N_9$F^7ro>m&)QXZ=mSf9ObV&&<-2o&~|bM0#eEwsH6Y63Hu~Wu}nTLDB}P-u+HJWS1ZLrQW8i
zO^^I_IQ)NbySw-bEg-1f+
z=!kUx(Mo%nl0;Gzp~fW9!aTGf8WTlY5Ys%Lf~pgWO(Ai70Xm%4$fz
zcs4;&DS@Xk?B@@wfGG;CYjiOumkWBSlqnbGY8jeXEXu_qq>0i=T{*7k$0fN^6pyQV
zrNq|?Ts0@v;U`OMV=HSkW3XCaDn+(jV9|u5EM}^4D6!GXDU-^h)y+h~NEM-?F!9Fn
zdn#+f6{@ku8G|e{t0W4>Ynvrrde7bB8QdLhM3AcGkVrnD(3ISoV9g2#Sz$jb92MBT
z9KEemw{?8Y#1R(N#3}+}9PQyCgcllZQ49k3mZZoM>x1kb8d{_WP=f-cq3bZm`xc=t
zCY>`-sWh&mdIAay9=$q-;^0kZ#ZLEkM(jIy$c6{35$BE=aTl0ao{d!mB;HVD8%H5o
z65?ecR^Xy#Hd<^bJyh6ONk|~!hlb1p9E(D{A|)@7igw(P@H*g9rt30wqR
zK`dnXN=dF&#gm#=%tF;7pp{U0yl6HyR4+j_EgKrz!@8R1%LM_wKFsofGgC>GvScMo
zXSF2!Jd$}Z@e;r(i)S-9+AUT~8(Jct!Sfj+r<1u1oy#zW`Z^%~=KIdiDttAIUiz2K
z)GIH4y`Xqa(Up}PCeR^&l;igD%x;d|$bOrzIOUWJPPCLqOTp2nrF|OaRZ<>3
z?KkjXj*94H=t8liv1JK4Pap}5%Jk~ZtvcD(-mF<
zuarxRT)#!q!nCONx-GTlTcHO944?yj*Br2ATrG`07^^{(JE%1jY6q@
znoZU8q{O``BdRLUp;|0xKls7-i+Q112F}yU6$OA*1E^Is0Ai&`)k^Yll`9rVv}U<1
z)Pb$aiYCX327`93$Z=&LuN<8>X@F+6$d__d(Vz-hvXDpe@8tqjFwll(cD_p~gO4DxGVdAgQG-zaKG`^MyLreMji`v!}I
zZy+=)_?n(xlZjhe@+O~L7UD}%43IaE=r9N)UMTo5Gu
z0L18vp%li8ULB+NFX$~Gdf|7`r-w}^f*CSY0Pr<*(Mn9D%!UyV$pFF`?nZ(QXjc~`
z>Y$`ujpl(Sr_m-a@G~l$r`#Hbj&NN~H{?f>UJ-N2aVKC@j=M5gz#xKo2JNF$*GRx3
zMDUtKlmy)5(h3ucdX6G)E1P=L&)Ce0z%+L&{JT%scfRwEq(JZ$potR03&4MXLPpgo
zU8hV#G*FW=838CNZ;IJ0e92}_#>g-^6G@IhGYrl^JEai1N+F|=`a5L&#G0ul%-1O#kE?m
zD2AS>0ymX}dX*~`@G`{Zid3%vI=M=otmJ42%1HPoFBFid15quYEt0Z&Drcl2G#9c2
znh2Lk<>AlKFu)@4Wj>QK6%5!hYYKoau>=_*A6rC%iJ>__As?KheY0!;#o`9-UF;0h
zP`v^01(pc+42ghnHmu=nP6E+)>V{No+uO$WQj{vH7@RbKq~$9_U^jy_B#8cfBL6S
zeDXKG|NZX+5ds87fkNR}V|0~9z{<$kEHuSLC=|0OJ}Rn4DH2B036{e#B9cl+2qJ={
zY8BEnC8Uj)<)Hz56`6y;Ey>Fy9~@_kWMuXKy(;sw8@o@yTzonA$((#(-t^3aCsqr14q|I
z(+HP}xzQ$Km|acTk!VxeDW
zE3t;2tYoQL0d0o_RaZGjm2+%PPoZQH@RMhte1X)kY%oBCr7V}t05#HRzcUkH2SkWx
z)pTCNbtRcMQLxUN6rA7h69Dl}QG|a0(#(1xUCk!Ts=pw*vywBzSu^ZWj@dDYO*OTq
zrf#d)mPYKZ&3A4t-&mgMSeoitnd#BR(9%Tj>{Mf`s)@Flsm`UT-kY->zTGjxg_h?5
z=K7TxJ}ZNCA@&bEag=(yMozt
zz)gb!r8Lq8QIh~KtB&9W-?d+WPs9=C8p=#|6?1C1r?H2aTP7|@6sb2M5MwSei3k!g
zW!k}|>^y)w?UHbhkai1EdqavTRuNO>H(9t22Kk>T(W(UXF9prW04O2hL!}9lzcGQ>
zWWWJHuvn0wK=ucG^=j4|_Qqq;NX!$C`h%fJFo>3z21A}u&=v^zyk1W<AZIM=8fhigUkYcSs0~RY;
z5;za3E;W?n5ekh9M5ZC)LuzO!aZ`(-ozUbY+~Izo0Ep*M`s<^^|-
zbLIq_#_XH;b_U;&(rcc*@!N|%OLIMovt0|b-AmKmfI?_XQ(X(=ofisBvlHD&vK&b<
zb!@E;FHH9=k2R+Nj!yLMh5$N*NbNy;++5VljR=l%MEEYMo!>k(XK@c;F-v%I0K~M*
z#N1jMIM32hV6v;w(nm$DA)+7^Qjt&%ZcpkE`91C@BF((*0R6m%aQczj5Oq}P^
zTw^!ipKH0Ckk6xH`M8>`RnW#gkPe*tK#;yA
z8er!|DI>&aKDY{T8MC7#@_wftGK2IQBruuN#GP5fZsImQWic?jOdvSQ=_3O>(g~YE
zTIGZl^KWf053S91yAS69d2q5c*$5k;HjQagSU`M1T($ExX?4T8fV>lW~r{Ww-035?%v?v5irUQNt
z1aVoyB(xWyAH~N4R2xtk;8`yn-aZPRinGO+2nZsKp^bqb1u_^|T`9j3`hY#Aqm%YbB%)Rw*!0
zX#l)XnwKZhyPGW9!4Sx@Xi^z90T|O{w0sTjUAj}2Dg_`|;w+Ds
zjbKiOGR2|OhZ4Ch5&HtRoeFI(FZ33T)Y1Z)gS|A*9gm-B*y>DAf7kUq8;dyC;RoWL+kVRm?%yXnLKuV}}|(%sXHVKS!4X7g+@
zD?;S;`9t2ISJT;OBpQpw2ps8wMWVr2ED?z&qA@_^g&J5GAxy$TVK0G2AZ3h(9FdU2
z>pets5sFB&wUif46Dpeoz%iqdnu-ZOT?_KCmCKMDD3xO7q^h6Pq)Lf7IhNrB;SZ39
z)WDQ#fjF-5K#gZLu>iGjk%sS{R)q?h@s-N!v2rd26?8$zt9i7~U$w*o1QC#+a4}Qm
zB2~>ZkUm2BY%1xpNoLh3I@cjPM6+czIhNIu8R@l7UOFzakZjfpfaOHl2;~%y#@Q9-
zNM#NrYJYQeNEJg1Gu?}`0}GAa4v`wzZ2#Qsz~amez$IE9fYiVMe+YSK!OCdY6fojw
z7ZPC_ZJQivpBe3#8|zq}YG?c_xMP<4>AV=Gp}<7C(BKN|Uy;LW_dE5FX@pZHtPKS^
zXh&JXg4Dp^gxt^KmICcilNQ{!>DrsUH8;@Hc|F5@LwLz08SVIW{$6(Oo^}9-j5DRQ%MU(CdMu5TJ8XQ=vhba#CRcc7VvU
zx|~xJs5B`sS+u2Sl&1qcJZ34ICmn
z5+2E*4LS|9kSduqQj!?e)z>PjOD9zkShrpztNC@vG(0-C|
zG6QY2Yi6{4ZnT;7E)dT9Dv3~_5FWJibK?!pn&5j=MnsyN#WR8jy
zu%ngqZ$#`j4Z;a%>+5Xl?7TKU(HnN%&QL*MuXOO>Mo-h>?b&w~@$S|~yStk@JDL-o
zt$R75v*TKKcWY;N^U6#=5#F5}ZN($|dD@+29R_x2;*LDyHlQRTJsR%f6GuY)h>INp
zDDQXcAD7K`lZv3Y)`+&M;@Gv%`+i6??#PsSkX71`x-`U5VH&m9Ohq`=~U
z!Z4Cribs=403(tEOD5C6kg-TS8U-NU-vcug@`XZyNYr1<5)hpe5lv+AaeTeya#CYhPp#J=I~1XCKC3II$0!{PlKuqKX(X0+K?6o+J$wVlfF=
z1pGm6R9T
zkR~14M5%v%9&M#NHQhTk1t&vrGCPe{@y(0_{<@~edM8KFrm!e354BH>AVE5SppC4|)8XFd0)GKguQ7=p072fxzBP%-P$WRUg$l%lbY1P~Y|iS5{(<(cZnTeVN7q##vzUFUt^^|olkdnRy4tUHcQ$o*HlM1|sv7I+
zYU${_4p?+q*0I3O(nJRpK8jjbkq{_hDKPF#+6FC8dEjW0E`_iQaf_6CQy>m@ygrW?sn+=XF0a=QZ=nEkYF~}W}5{|B>MJ@)R69Q#9%M^3CfrL77xPHG+4_T>X
z)T=rqto0gtYkgWr`-=kjj%(t1{X$R=t>wFWA{Nb*DkLN-CNeQ14iD
zisMNiP57~dKN)inF}u#CL?&qHP(edZNkZ0`RU0GD1=7?T1S#VgF#*+#4qT`tGg?f0
zJrK)9t_-zz=>mveq>sqiUVP!}tGC9NZz2V-1%M#5<&n9?p~bnusfIG*^h~1x1RLUr
zz=(5`y%3$J$GRITv0VU11i>N1h-ka#q4t@f&dI^H+0jnl_T>F!@n`yojp_LR&ZGy3
z#RbMJ2P?bPJe%E?~Rs@j;mc=S35ec1H#(dAICzw
zf$iBldN^fYcp@9=XuaCm)za0~G~D0X-`fme?d(DliBm%zbv<@-wkN}eQl1T+w3Qer
zjGzXxXvzID=P?L?qf1X68Kgswy=iDJmBm^ODN&>B>O{JC386qI@mg0coVBBT%}HSN3(xfugd_#Rre0#~^6
z8docjSv|%OZh#;}VG8%>GZ>ABC^AIgv2-d(;8BT7CZZmRC&+Y+qhjf}TbJ>?obxFUstDew2G5t^kEDptsH9y8^D##wVpAer(m
zub|z;8yoWh9ETPgad~cTU>=gi#=h7yGdJcSS)95tbzdB@7p)>4@0o7wAqj1K2=LcX
zMjUJ#?Qfk#k|S+X!|jV>T}j6x(GZQjU_@vDN4RpoQx935vgGL_z+x8LDAE_RR%drl8P2?RsUPE+v_gJWuNtR7RvM5Nn+hcP$tl@yy=X3jj9Q`OZBhl6j?cR64+>AwlG6Jc*~Eivc1LAn^c}K$}5oLd?*UkTvFYtdc{EObqG1
zES)YTvT6c_cqyIN(-5HV_X&V_3J-Cfsh62@F0G1gm2>=;|MDHHbv+ogqQ%Qg4!==+Z3GErtXUPzc8c9rmJ=NvNQ^Cy|DB&*Vra5_K5vYH(rO*gz{-amC1lYw2yooponB*
z8$<}lMu2YM6)X_+p&imgKEK}^@WXvPUXKStB$Ne}JW(*wI=YOS&c2B_B3Px8sn?9N
zQ@vE-Pipd=6G&uHMSNb9pE!k(&771u$U#*pNv1{{
z5tt9d{a8GxN~FLfq7grZhbb&fr2LYI=M1K3Vp%
z0)U8uGJ+!ju~9f*2o(bnBGoUXjM&jo00V05n7q+3In*&d+`2s3lRTP+0DZxQtPfEm
zW`9$?ksNtcW-JxPiXcc^P-Cn(g!S0rSbs}h_3x|M?P_<|l^flcd)glx?Q5DGX&oO1
zX6{UNR1ePh>}If31eXZXCwyYNeuWBks%7nkQp|1
z==ZxItfQUhgFY1B5yYL4_%pP(ktVVL#9R&uPTcR)LsqUR$50NRWNH-|fOz*ijC6xxt@
zZn9?*>9(W1u%XEb;DZyS#x&m00UHBQ4t1g!J=6*n^xjf0S|Hb$fYTTTL?eOsJN1y2
zC~FzXa2=K@K;dDDL9%rFOMQ7EIN0AZHr(9bd1ZB`fBZ&EU;AY-VPBgcYHh!a#Vi9i
zuC=#cZvnt{Tx$pLAqXOsu(q}*}TCZJ3KwkAjR0Kc6N-w_jV+IBSCc!
z)Ob>2^9Ic^UPGe@v{pY3q)6gPNg`Pa1!#r{15;LtG@K-3zC_F(i}_MY(OjS`wvDF>7uNhe*K
z+bgR#XP1yf=h))P#s1CEMv-*!+z4>t;>^I*bl>Dm-waaEzOgjbJwMsCGSxLR(mD!B
z;XupqjV7SLk^bhf{?6eWEyMjCql0Z@{T&niZ4(2n+88zk%Ev8PQbs|)7ss6t+Vw?OY5~8
zeNC+`kG8d6Zv__YxYpTzwWs}R2io`jN=x(Q4zy$RmA=l)71H`EdAzgrk(76*B7`Oe
znjG6e{jEv&tvizMlyjF*f@rO=?lJ{OPl{HJ?{aKET1Nj94Kz@FI
z!0m?+>~kV2^#TClZa}MEU|ERufCi7p>h~UGGgtu)^>Uh=G}Jd`M92%zPqWZ!74;k~
zut)Eh?wu-cyQ3Xfd0mO-%rr;E4V_`>s3H;>onz?)Nu($u`o3Se^Zau!zWm~MUViDj
zFTecVZ+!g)nhXQ@LLqkyy^4oF#tG$%Af&LgpJO7$ERO_$(Dpt_6pPU^*?0qmAzgyP
z<#j;3bF4tsj7F&qEUQJIe){(}wiZ@yO)srZqW$cb#}<|$K?G_9AR_7Fsk#2?sh-KH
zo+$w0M9=%~RsQ>5fBPT4^UV_#pB}tE4MaF}edxxuksB>Yw|D^JatE9vb{y;+zX2TC
z0RV-TLMvw5_v{Y@FMNFD+fOZ0w~IjV8iDr@0FyZ-&zv7t67mRnmd
zi-h||`&-^-M0MQS+tb|K@_0+@mFAYmnwlR2^4nWqcC0Ps*>wBm|1{WxM8jI!9&c%S
zq^0HZ-qNrVxIH&;rM>O(uC~j=ea%ySO$)>A3&Sn$?dd#efzVv%oRBHzh{FpwR{1y0
z5o<;Iq{7w9#A$^;t+0RhcYhlUxLs}s($97QCqljKfYi{_AViN3VC4w}oM;appCcCW
zKJ(1yKmYk>o@$5}KmGLQKKI#AdpvfJ*U{L507@MA&jTr;)9HZba#>tRNA}3&I&`~j
zP}S;MvXH~_8P3QM8TCzv_-b|a&S?(4&8|u3r&?pvYU%C?08y_Lpib}?%tT|0*96O^
zWQh{kw8$k`CI(N)*T44l7hZVr#TUPgbcGCH&{K3Ef-nakkYhV2HuYKW9zw-HSeD0I&&HuTj_0g85Uutf?51#c~IkB70v-zG_n06^QL3Xl@eAdQpZK+
zq{1H;S-1j3$IyvFjs-%r1A5$$AzGatyBpOQ9?0;3?L2NISNBW{PJiFO;zIXsb6&I
zVLPvzK!nF=1O=h+&Y666BHcMv-*G2X$r6T=(8Q$5lN6bTdY`3I0uwLfIF<}Q|NI|4
z{nTf_@|8dQ+Sk7Rp$~oZ%U}BH2R`u8XFmVTx1Rs5DAMs*kfMW$mv~&k_D0sxU{yuuzCyH+~U$C
zgywnR!llW%`LX%gk@?x7x!J*)nSsgaUbpSw)qnfvAARq;zxK8#-fE}`>;6aXRt+*Z
zI@C0Fqj{*WX>72eqXM~az17QwHg7=}fVPgAJLv1ZBkGHm6
zfz09NXw%+uhfX?gPPGfMog!@mIy`0_HQEMT2yisgd-uEbkf9081>&?!Lv~m#aBu}m
zW~e${5STqSATfu_Y4-pr0<2tUlL04$=_8=MG#0%8;%|KP*M9p`znh9CfBTca^Xbn#
z`^+<6w%gHo~V@}))Rm7%2!`{{*Rt~|9gr#
z6N@Il2)zB-PoAGtpZof^UV8D5)r>BR6jbr093KyRXeypexoPsv+fnR;+tN;2h|MVx{kz?_>j#eWXdGfsa{a3y*KF|zwIMUzRc#n9W1>pp~
zY}C)UhiScd=f
ztIxDt{m-q<|GBB@QHaj1%~#qxFSm9)4x~s2_j4qAPrkL-w>r~_2Q~nFW!6=oEairh
zdzp8X**D$ZqFkULJx5#B73pdol?#yDg@Z1)7s>g
zX_{Yn_6q>SU;p)AfA>4z`>uN@rGojH&prG3XTD^y9NO%MNXFe^akvgG7PyteW=2F
zNNIA6qk|+KV`z-0(Uzz@6HLb4ue|h)m!JRU*S`9duYTnZzWmG=KL6R@|H2nO|K%?|
z^UZHQ4`KRue)qE(P4akcPWyf`>Ins0A{!H!gv=Agya+XlsV5K?)wnE1(B_p=k{2Sv
z>vP0E{iENjm*gy3)dGyjJpbG`4y_xjw`Ku|3yV;xOadLEHa`v}Gc>^B%*-Gh54YD}
z{mH-m+h6_pQ%}DCo1gxj|MHbD{QbAT`GNB?(B2f<+XpZQ`63k2U85u2sAL{&2NVwX
zw@gCGGT5{*-k!2e(~ddbv&6d53q{Bj?|14UGgDh-;;@SLw%98X`%+{hYG1Uh4^0g=
zl||3);*Fsj?EpkzLEu7YZ5>UmP#U*hgWvtvzxvC+eeN5P-L2u~t2ambleWXZ{G%`Z
z@_+hYo136&c^rypNHIG)uD7>e>+for=(}DK-0tnsz2$+G>2Cl2OqF*OX{4K7Vr*Ib
zpmFl1KrH2Oq~uT(j(~3}ImVD;x*9XIHyv3yJ;|M)8I=-5WQfsd4&vQ2{fSfk-d(lvwgqA+Ns~BD
zrX>;0<~l!BL^k-!OJ95C#TUN$t#5qeOP~3}FMah3&wk1@GYm<6>l@F#^wPI~`*%JQ
z3nT&-(0ib+8#B`QUi$bbWRFFa>QudAj5EbV5
z|ME}&?Jxi9tKa{#k?!l0109o%ZKozjy2eMkAzVUS9v?)be9#&juCz`Kw$2W=V9q(9
zL(U0|c(KO$O+#~$+$$6NMSQzR>_A*LQ#*8My+}KB%2^itVsfV)p%BTxHsFYM_-RIB
z?oF@0`ak~dZ~x|p-~Hpi_@h5~<(bbt|LNcPlP^5|ch7yj`SSnX-29dyDDVf`piJq6
z3cBse(qvE4wc*>F%#pUWna-85cEY_{6I^I&MWa&5ljyxVoZRo$Lzc}X(N?jD7bytS
zzx%tNsFe$lCPtz@fS?^X(B`z*0X$Z;xq#gPRR<)0ZkNODvOe<+1Y(HJ&p!S1=b==A
zlh1$tiyIqTTRYqP`}>Cn7U0FBBZNYT#g?NzK;iz;rse3!YCEu4j(k3=E+(>SDrexT
zlHj>F-BcRzcjw$VJvQ#0`*%
z0q`{hw5R76P^LIPkA|M-AxzH=&CU)@&Gb)<4ZQsF3lRNY{g)s87{`LAOo~w9HMk0{Ec)428I3_I{@xvTS;%h;J3r
zI~8iDO7B(3qq97@yE?SBG%(WhNH5yM2kr24(V$pHq}Y0`rR8e-)oVc8Kl$swg!_?o8%X(n|Mx$8v84dCr=I@O_RitP*2dP(?(Y89;o$+`*J3@mAi_hm
zx4{09W#`bk3jig_sKc>msOfT+Q015|@-uW@^=vgwI}ZCcOWjGW!`#6
zKdT97XUPmLut|mnN=q3!&ar-$3>5VAD=$E){NjtxJr7~?Ti--V?k_z5!b>jzPkuX{
zPS7k)QgIwlDheKrdC{^PKAkfeh_qP^GjueCOqC;wkdy^9B^K=}AiOR#fAYic`ETEO
zx{~Aa23|Coe2&fM)!SPu_jmhQX&e_PX6A<$5D>@FC`)78pP8AV$(jD?*?}>jy@?xB
zqg~UJH%3RhM@Bj(Mv$2M&AZKi|z>7G-NAi@b@
zds8W}9JYfr+==ZnwOb^2%EZq9@%Mi>J=CO-PTST@U+=YnfwpG!QU}((G?jIodLcVx(w0Cs0Z?)`IN+Q6KAtQN{i$Y^21Y*`$)UPN^IOL7R{PBnfjx-&UL{#^HLrk=PZy2&q
zRf+)|6)~(zNW4_$Ul*D`{E-j*^I!epSskq%)H7tIk=bl+t*+l*S%SE{GC79=^!VJu
z*xbVSBC1!QZ~;;roSlZ+xepLIIo&fg-ZwqgGds~YHQGIiW;}FGjsOt5$A>#0S)3T|
z7#)Jz1#QGPJ=`%p(h+g2K!S)E(Y-)B=LtBm&EVF5Pe2>62&7mdwoAlLoh8X}GSywCoJG=pEQi-7yN$GKcX4Qbuz72F;9zA4s-j$azXIh;au%a;av>sZ3(yUPQT5JanJ7kY`
zsD)8s?64mk>_afVwYjr)dw+d%_x8>nq=ox?M+bn=qr-y(K;hBe;qKAl?%~m%^>9yD
zu*0J@xBEckv8034^L`vHhk(|t1&
zeQ1No2{^eiISzE#)!4GRG5cWywrHunGN>}UpPUT=Q1z4`LuXlKH`HQsZj!g$AeFAsD*Hs1L-<=I>s@4PkB?>}6K
z*p_R8JC7X{(g$V2q9=C{Bc^u#9Uz)&($t}$t$vD`bjc*X_q{&>Iy^foIh}Thp-^-H
z7A-ai&khLHZ~}>=-45TfL8!G_;d=nF?d_d|t?m8o-Gj~D{q3Fo-Q8Wl;laLbZx^t5
z1dPcs#O~g~_U^7G#f?ldmhh+|RLTieN*Fq!h?p$AsS3c^Sq@sQ0z_!uJu~i|Lui&E
zO}u-i-aAFLOA+!kg`&w+Mj_e8=2H;*87h2!qEV>;hX(~JkdY${?Uh(mU&q7#aKsah
zSwlf@FyM`Z{mEollGBnLFBjOXK^rQmDltV4%W@JbW#}Z7DFPpWlI4D%P>%SCPk#Kv
zANYrtK3&Xmnv%}zXbr?W-*xZy=JL(8dB_n_nuxZBL~pj|=7%8`qc_{AWEq;8>PPPs
zXZmL+`{yS6CntKx$9ty6ddJ70OzD7=G4uxKVn@hU;Khm2j{iS<{~0IAb)NZxn7zN<
z`(?FK*tPy{_efS#fe4d_Hq!jqIn
z5;Y?;B1h7Y)JUTd_jx0m9R37C7toj84>~+NI2jpfI_l&K9$wV%$02+q64BbbNc5vv0vKR|2Y{|1fFYM*D+CO#Algd&mFUludi_)6b?T
zAfCMc29rrL8jV^ILTb%PJQg`oK-sB5L%Iu-(KuG12`Xj(qQJuwg%U?k(B`(#9`|-P
zcMdjiYu-KB-QC;WJBBme-rd6S_3h2|?E{lu6%9B}6h}JUUN#ZLeOcgaX~C1^Ddx|;
z@AR@nL_AMloC|j^$hDw(-MLBvjc>e2JbVE(ij`6r+Ky*~Y}`YkNdwMM$R1_vp`bM!
zREGn`NYExk%zlrF4O5INm%|tgxgueg-k|olZK04i9CD=+)U}??_|g*Y%N~#$Y9YbX
z#<&T=mxw##Q5y`&z3+sE_|%h6e)#?G`}(KeeNl+Q;NW&%&WHc*@BVIUZ&eNrIlDv=
z`9^1;5f{d1=7*-|`e*{g-0;+V|Kw!vG-Tp*-}FTH6a}{E1RBT3x+g}u$A()cM!H5v
z+D8T<5M^mN2pm$7f#chKVdEU5o{H(_!s=N@4sU^m=s$VIhKN>}@$RI(J2_Iy)Tq8QL2kXl=OG*!VzG!;S5g@r#6Wu>Hnx?=8lv03hc^nzH^Qun?j!4GOxq
zMf-Zfu|WazeXls_At89>JCQ#ldGGCTkfB?o8aH9pvCVFZ#eGL7hiHh0M-Ig(}BQEQGicMrCAcJ>eUO-3E?8H)yYcMn2A
z2h?Fa=9M^i62glDYPh(#Rrr;4N&h5WTu_jeYFRixOI@DPrp0%t9}zM!iOR$0;(0Az
z$c7?}Baw&*0uu>2a@k0nu`>Zj*l%V0mh(z16tIN64zy9f$Kr74Lm`_FH)V@19!Jyk
zpy6iH@p7I^CvhEo@F+w?4#39!+L_=y_`z^72mgy8D@gaf_0h*Z_R$YL_3nqC`Q0Z9
zSvYN|%TS>he(bFeuW!w5Y|Jj*o|#)3U09riUzwdBo}L2{`)B6{W@r26r+en7DR%hm
zM9=(G_w01f>?qn|-^57U&`>)}%gZ1oE&VNA8WNA4u>?;5$z1c{87(F
zG{|$vLB%VYm9%$T@@$|vBIE9y^=)O{n+fOEn`?2!#;|f{x~uK}*476s>f2&K+1~iN
z=GF%qo33|vHZ(O}bD9pXlCIWUuLt=y<_Ef(ueUW_U!3l5hOH)Nb4`w^`@qalvvOy4
zpyS3=f0ONG)vcV%`VS=g0HZ)$zjng4opNoVEhb!B)D~UaxIy3hS}#iywZc$V@~1>!
zHtC~1H!_hV8_??%Cn|Up3R$*)aIk-Ls8o~GJD}itCunth2M4=kM-&#Tl~}lQxUqY<
zv3;AZagn`qnXi^b>d-!uE-KvJ^X#2-;h{6(>J$z}eE2+3Ekp@jyf>8y#iK5G4#sbb
zg}u~u7&M0ihG^8{bZQfP$mh1grZ9{PHaX7HKwl(+uR)vpWF&^-aHWC?-X}LiUxEvW
z6gHItPH}NN7yT6?*2%(1UspO>}m*-)w5S*3k5ZmRt9?G+v(^>AuQ1!j?na!5eSh
z-`(BZ)6>%2j7noq`_18w`Eoagt$7d2xfrQ+B)2ZnL1>`TgF5LzP;sJS4}lw|8{3y|)in
z3>+#|8Z^gEw8EV&*p$t^qm4cC%Nx`L_bBYt7JSSO%Jq%S?cGhS_5?Ugv5s6Cy3hp@
zi<~DGaq_sOhF|&Ce3rSqDpY7;4b)-!;#9mk7auw&7G9LOt1~D?@$R`O#H<++V%HxI
zn$h6kekhK(&+PXaV~ia)Wv|!bbK3%5i`QvmLf%+304d3G495nGIkuEz(^4>%a7hVw
z0!~@53#^S}Nj!*gkHESp!o{y_&~smkDs6)5Fs
zxNmc7c4K`;jyyHByga_NR9`{JIW
z6&P%s9%`N)Z(EvZ+nQ+#YADD`L^I83XQJ8}d3;a4L91qhuk4yZL^MQ*Gr%e1-a#v*
zOcBvYuFVZTI5E(m+MONkZR&5o-rIq@@NeFcoQj=!G_r=qYpqQ;8XF#HXnccecdDoD
z{+5;pT3c^MZ3pn(EsggdZ!fyl>jlniIiB~b))q%w1jkOoxmgGt7QOqTWsSA0#4YQb
zjWTOp`)8sGNC{AcB8#MiU{Zi2a!Lsr?9WPpZ-4t6aJ>eDN~JzJI#M4TQkX}05VXAQ
zgQJ7PW3)Jyjcn{5OR2>A&MrlsqJU>RtD8IP+uLhfTaP?c+}Pd(JU93D;}F7!TL*`S
z@rVQT6**@z;gTbtd1*7nh!Z!yd*A70>Fhjx=PFM@R!-A*ucU`Ag-e(+94X+p6fNZ9)I%Qk#KIKqjEx4IPID~m_xYTH5D5Bg>151l(=s79Pu3U+jFxf<
zxZaEu#%~fAgy*af3<8U`=;C4)G-wV^1>~mkR~lkIpRX26Pd)M8C*JeUPrv`ok6uZ+
z94W+R7BXUE!RMp~ywnsGZ`8EbJKj|NraXo$2AlXfN~M?tH{xd@z0l397>_-ABRJi8zh
zZjLF}rsUa9J2%q4^|W^j$KUhTnsH|)?%W$_yFU}r4R_t_YP;Ur{Q9Pb|IpWQy|M8P
zt*zH#W$eoJT-4mv@`k~lrna_g#=}M9!E9gqjlQ-Aj#oxj$6HpX+jZNMtaT&p+2M@K
z3F{h7n;jr%6edFI{GaM17bXtcN~
z!=oIcE$-oNeX_4LYc#r(t(|R?*|4?^5N>Slpz%@gGnkT%tv!$uhmMbr);BjS7QAhQ
z=Y#tP+f2|Q30_*7nLx|4rg%S`Y&`0W$M9LN*bveFt}gQzXL;(uk%L0gQm-@N?iqht
zh+I_oyJyLV&iPV4R4GO;P80b|P)d3uVb}{h-aHg=L?ZqWA%X&*hb!uphK%J`nV8|SdBooAt99b6pk@>jZVc6WDk+047%{*I46^?@hf
z@#t4S@$S2cX2kpS+?X^A~L-m}@wxJ_^GQ1IKW-F*tdw|%f8cO`-}yZi9T2Z>ZQqB~aXa`Aw~dlMY~w9a_MgpZ4atvu(8MI3D06=7a+e?;oIq3&y1V1MT#b9Et}
zoeOu)Q;%FE&#Td^8h7`MrpngJv=7+j8AV5{mLhC~#^op$y%b@BRyk}DT3aY722)}r
znFv)1Lb1e?J4wMZ2XJSg`PkHn?Zy@0&{`&?QznRLrtJ)cJU0>@E!jjJu}&IrG76
zRKE%#m_$>vuhX)B(@IRc!W-9;_MMoX9)=A|(1?O#^WN8bS)v%Qw5cnuz6;k{jxgom
z<4%!BTlD3VUi@wTWT;1D*&9b+9a&JpLV
zT+9>wRkJcaKEAegJDbhF^YOPo`MxLK_4s3-eB#Y#g;+7ew0$5*D?9O~7X!CSLqEq$Fgg62J!=C*NfdZ_zGU;F(7t*;ZjO3l`c
zO|dlEbwjZ};#be}mQBgN$y#m;mfND`Hr_L?U*Zh6BN~eElXPswO>+D*JoU;U(AXHo
z;-e{dF?WKs;l3P?)+0}O@P|qAeu~PJBJ*fA>EKrmU|tl85aY6%bxQT2&Y*;SRw&f5
zsC)mALWXakVQz1Qnc)83$;pXAuhsc{F0|<+iw~kn19CVZdo*HUf)soT9wi*I!RLlv
znTQt`h4XVX#C)}yy1Jx+X0j|*+?tbj&jqwRG(u8B+?O
zBQA6(1`eX0-H?0RYu((K@7`MIQEU%wt#qxD;93+M?i7*7f>Bv_(cY&slFv
zwvDu%S`uI>*fw06CEeldO#iLE_G<$zzvaR^kK-6p7uPPgs)?
zjTlt0zJ1Pr5bBaBhh$SI79_PoJoGAFF*Iq$w+HwMjt$D@Rf_*;-vA5!s%hSO8&9Qd
z>&Qtf-B@GB#js(ScWyFF7K>lQ@QDodN?(Za%*c8P*Q;&v=Q1P;*<;g@lDj%r_VZ4FJi<6Ugbj_V$e*~q{~
zZE{dFv`B~~$Sk1I4`fOSe@cYKhOG|yd{(XIP^VR+%~8L%&8$%alt((f@%Z@AW-%tv
zhx-IN7)9f~}pq2Pp|#7~H2eH`zL$GjZt0vBU3Se9RDh%IfcJ-yvS
z!z1(a^Myj;(MKPB_q*Qt_+xK*-)}$k$W^wSLE8_NGH8*mJa0}%)d@x^GKYe9FXrEg
zJGbL#g|5x0V~KUHN9-%CZ82_J=4{aQ^YT9LK*(&=JOe0lrunG6x3+wzo{7LXD<@%J
z{0iFG9gWhf7`ykSUY6>CARz})*8B77K_NK{sXD>7##-rq%9)lz+F4SQa_2LiBF%?7
znlHU%gO|g8Q>P#vTGn{WM!jv}F3cL1apxsnXrTR1VtR@Q88?wM#Br~38fPM-{?ByZ
z;3v*g=uLQ7Cxs@BqGh0j--KR78}dUk#v)FdjmOzV&YEOhNzsw!J!oes!7uS-Hq$~N
zlVH+GS|=|Fj;!dGDEzxU$;zyaTjCKkZVTQv8ls?(@F+}(mKX;^7KU*Ig4S@@i*|YM
zJH0HG%9&F+aQL0e%xN`w_aX-t<}y)8MheY*%AVE)y8oUgPOEIS%;6=c6*)R-i7n;X
zN+Dj#$BH>f#wc29E*r>Ye1&WTZB(M^UO;0Ejtvb_N(MMMHZ;mq6fTO3LQ6mbcWWn1~hIV@|
zXFO%WmWk-o5oL-|2;N=ZkLI{7_+T?P1<#7$TH~C{lx@p`eTlU$vlIxD%6hU4)5G(J+m6)PqIhmQ8Gk+j$Pc5sk@=5^4|kZoC#v
zP2`;N)*KFrccO&lgwT}#ey&8^%~1>sfY1?**yV=qVkiWp#qT!+gEoJ_h!RaO9QFiX
zxgq9@V)ZmrJCh!|%AdiAoTo0%_);-~+w|3W^5QgE%Hnp63I{r7)829+`kCMTNTtY@
zOEfbJy0BJ`7c$|Ge&oIRwC`s>`)N)Je&cJOPp1M>G6-veJ9ttIBn1l4Oj92ycD+9#
zgrH?v8rGwY=EJ03U{-#Gh&wwww^vqM+FSek`-g{z!{KnbSbWFZ9)IH9?|S?#55MhA
zwX+JFPlsgV;wxobrGzcVYE#TfGIX2>9PyrA&a=gPw*~h)=UEfntAcBVcP(@F70!+p
zu*_Ol>LFNSX52C5joo!KxDoqhn*s{rj*JR!&^UhYOT8?CYH%vVMe5k2xXks&S8ri4
zx!Hx`B+Rsp4haJ}3NCJ}XgWAT4J5(3%ty5KV5Lh?
zhp6Bn@QL!?*LqpvW7Ic6ZG~E)6Rr?81%D4vFcz`0^|nZ(aPC;tB1a^Zc}We+iu2KY
z@z(-11lH37}8oD1Q`eOjRn?0)BC
zPh>N`Z+_!T#XOM`2@O%+A{(tR04}Bzp;QVuXFx=>!X$JEPf>zNoQPhOawj5%QOB<|
z`isz{NcY`$-~YC=v3l*={Tc}YnZY7{6@6AKmd1ViyX2UZP6Kh<;~m+g+!^ChGn_B
z%wNi3a<9%ZmuHD;C4K?Rawc7#W@uOKQ}*mstW~*UHU<`=X_iaTQZXi_T!jo*DJAmh
zh`^aMwCpaDOoei3SmuC4%M2h8nWThgy-ATe8ex!eLE^YI3qFBjt6O6+3cMfvm5sjd
z`@j90|Gl-f#i&y>HaB!4^>mMnjOJ5PrBr(S@yFlsj>jK+)161}l+G$#F5xev0{OJR
zn6wu;Q#NV<6b1jG=sV!tdt6`#_h`@&Ip$o6f`YD%nEf{F1!r3gn-*|`j>1jr=jgs{
zn2YJ=&;;Z9`LKE_teFm}|1W|y!x5w9)zu+dAu4EsoRRnkhY`iy7X14~vjYX|6*?j_
z44K*%DuzWy{ZCsS%6k;lFZ$IKDg55a$a15^n;`orjy>tfdtd8iDHe7nB_%f%}Nu2kR(xoA2WpdQ2mUn%f~Z0OBzDipKv
zjO58=0>r`;SQtvDB0LAz5)gS97r!X_AxMO{Cy{`I_Qqq@2s|7t-LFmqyZ7IJP5+wy
zf13WaA^vOn|BLjm4e?*ozovgp|C;Wl``-T8BX57x+1sx2pML5scT4fpQoNcER&u^#
z+Fg>|6*-c4F=0W@aM~QJ&Bip@m@*$$XQLD%Egd__aVI(UI8Cv|_fckJ`(^Lv#!97hjcSAHWYAD_Tu%D{117d*^m}qXg;EcDW8eKn$tsiDr%-+
zsXpbnS22c?p{*rmV}`|;ZXpg!t);DNsV~U195*e;%qythyGXA({hNRDZ|=MAzW?+8
z^=}`%|F>>F@cL`N^?%;~oB#gWZ~Xg?n-5G3bS;h#DRx$!+C#tL#A7&iY4_dQ1CRd5
zr8~4~_Hl%8zoQFk%!EyO$(E>PzDbdd9vg+PU;pwlI`
zeq4Si1WJ6M$ooq|pvnhu9A!-m;p8IcFADwwNjQ1XiSWRxiAw>B{I=SJQn36QO*|(`uqaTtY>M74FoF=2>tQ*Vc39w}BF7{sKCDmRyd398<|$TekYz(`JjAm8
zI7QD!h8gq5X?Br3(~WE=O-N6%c8U{{30AYg(|o9w3lt?+I^jtQo@Bz4psx{>L|>9R
z75vedKN9gqqCO_DCli8pTz}9
zlyiwnK2<3uvl*^fBo_)VS}k+sV!TpGRVv9^C0WSDONDraqC`aG?G}a85`SLi&L|Kb
zUn_~VGGD{P8U=ExR%n}!(?Yb6^4Ie5(;{1~u+?JptQ4>0!=-$*kfs24xClkbSEV_I
z6uY8Yh*b;GYB5sGg-UrQFZpt`?KMTpD`Wzt48;I1XQRb*C@TdDS*Dx|;~Eyy{&JRr
z)R!~oo_pZ?|
z(tU4x%R_IuQ~2Z)Z+y#T^0W}CWQF!hA{w_G#59Zo(#*8t{8crTI70%B%@#8jLWRyUZ42Ai}b2f
z^Y!0qy7n7GZMT-j`j0mjjEXI{`N(NJ@LH8#!*Rf(@aqnPhU1t`E4odEh$|Dc=EIIc
z#95E6k6Z^Fa+&kicz>1iRY5@3TNV9f-iKU@yDF@^DtJqryApR-5P4J%z0UWQe6l4`ooeH5U7p#d)Nn|Q~s7&Y#6!wg;RhgYw{HYgJ%8C%fxAD~n4L
z!?U9Uoh=Rj`~TzrevgH6x_6CUbqe|efglrMd6z#F49A6JHkYqtvIUM8rF5oL%ofY}
zTsoaj3E7NL%nQ}5P|3&fBe^Qa-cl3aSP{=ld|nEPA|r@lk&h-g7F-j=XfhcU#dt!D
zi()j9pb`+IQU;$OMu0g{q|mQ24H;xni1Iu#>Oq$C##t~iNHpa9an8rGz+!-=a>N7i
z7!!^9sUCAv*jP5m(ad2F$GK=-SsdI1F@w>lM;>;w$HLZR++Ip~E^^_!d8U%0oq>4X
zE%Kg}5R_l@eDe3FS(%RN`|WQIRbd`C0|Ai=Uker#0cUnmnr{tHorsl#)Y=
z;#rF1m`!^td5YUz&V{O_7{Gc~A-r*yO9ZOCOxYO_bTw0^sWj}h{!S-
zK|??gS#VHEVaTmu({kLh3=R?yfkIguLJ87nwP~>~3FQGBio1)4fFnxKP(BWTE(4K%
zd1@K(SMNW^38*0BC6IxPj)H5T;#bkCYOi7vf)SO7W;U#z^{J*o$$J;+RVSzJz+*h}
znvR3UlYogrV0ewkahE<7u;xOxpZ)YFz+W-yEJq#1h@-?h3Nc$L<^m0KjI9v0=OcLN
zEJhvqs8h~3VlT$*g{UAX84JT*A);wd&hb&pfnhl%r!W@HV9odjA
z9k674=5)}MVvOmKF%vfDBKBOwQAcnw>Ouy8i>#+A_>loefbw4E{58=B1lNSXsTc+{
z>-4N7nS$ucLw@q1JQv8u{E3h|t>JKAPXDsYt!)`Wet)<;p`QWJ(kZ5lVnlD11
z2z?rR#m!`XZ4wfZY?jMr*kVp7=Yr(|1Ky!LEzvkg6$~vWAR&vn
zST^A=Wg>ZrLO)e<;aUM|9r`g2dY1CxVlI-EH&Q5MBT2zq&PB@kNIAz;Q6aSXi`j6I
zXbAlnDdoZ-BPdx)2g?~K#}LK7l>$(g(13CfaLB`OI!W>{o$%x3I5V5_<+2nnH4nj<
z3TF~bDiM%p=LECKe|l@V?;VfSKL3%oz2zc(R*XU+{@{Dh7E}I`9L>3s@s=f;jDdFYy->YS(-GnD$mye8JA#nkz=wXB?@AlzEYCXVzpYx<@jud|Ni%1D&?hOfj!HzZ@&<~{<#l){!<^2#4smBgk*$N9&(CB
z3En{iau9c<^?*MLT4Jh|XssNtm1AeMSf#||GQM&#Om?`yLSWXaT&>I^SBfkQ
zY#z$7z+@$$kd{By3P7QVr+`ArIe-$zHjqzxLA_$0DH0{`X+zok;)S77mI2X_3%M|b
zD#!-%nNT``N;H=aq(x^j0~ZXh?aM$9N?s^Oh{{~bOJQE*H-Y=kQY2C*o+VeFlq3Em
zX;ohR68$pW_te`ie&;=R-c(DRf!Vq6kAL)EN)*eUHr9heETw5iTSYV#SzVFSqbzg!
z0;^8P6(kb5lWhDDK+MFBv(deLcrP2?PJ}j6(1!jsA-I`JKa*!nxu78%Fi2i)%BxHH^a+nH
zMM%;nyc%Q?*+(VlCV16?d<0Ac^<*02h#Ga?t>S#B0Fi2rVo0kw54cIs@*a9ve-jXp
zb8C>nR=LD`;-L~$#Y5sO;0R)RbqPPRDH$+}K4Zdf#8aTH;8EkLl+Oss31mZ)!m}4y
zS4Hq5pNjtT1Y9{e@$*FJED^2=!7>-fvA!(pEsDXo$KuqTxQyzU=M`7BzEUb>MY!N%
zKKk%!_)q`ng*Tn?IVsEmc4FkCAN$Z--ttHy$sz-S03QcG%SBl(j0y+2CxBdJjS~rw
zD=JBBIvq=AV!1S%mbjF}ODR5+PGmA-HpgbN@pLAhNkfoEDH9pPKwb)EGMt2*lm%ll
z1%(()5*z~*p&h4X;@M0*mx)O!E{Qix#b~KclI9vgb;5?zcMza4Bk=6xwOQJt6q#db
zyIhuL__<6nG1qncmR`bzf+D8T%Km_}8!6Kv_NSgKI6Y4);NO&_Ts6u3aR`R8jzMK?AYk^IMcczDsjVan3QDkitY6Z9iG&4R>vVMtv
zneO}e6OX?APWGY{gIPv~jW1_>XL&HuS4_Kp{G&fFCXGeGP-69kxGoph$op1B4|Nox@W?OEKv!CXkX%OON?nQ
zV47oWt5MsEXkUR?^K0khmQ~)eLO=u!O$$NYOi)iVx*7d6R9@Zi0(^{N7EFv0)aufY
zo}w;7n)?mR(LtGmWRr=2IL){aCP_FKqKC9!H;tdjeT6_FK9{xL4$D#WT?Zp@(8%{L
z(yLB|sHGT&t2LK+ds%Q4SZkiO!tfRuOUAGL*-!pk%BPY1s&qh+bgKx69*yMFN?v^m
zOq6qyIHlmdO4faXlJh8lLX@Z@i*oRC96=pr!Vf+Il%O8)N0b!($m(QJD+bh%fifRS
zP6B_)fI+U~{eerogBq_Q+Tw^u&3aXF53-W=s^cC_)Td#IztEdT(QgpF(3_B=20oxi
zW&;||uYu&uLEA>i!dF=DsX)D!bu9@|Dc1v4U@_(^un>>07z68-(no$fe_jnI#fZp5
z_eDgIC=nAAQBGif_`^R=h;c!P$JvmOV1xvq!{Dg|2ndiR!x?D61k@j(7E5Q@bT*Mn
zb15(}%|aPLbruQ&d}67T0VcA!cp?>okB&xtE|)DB^6IoFCOKH5%i(a^of@q|r&k(H
zTD?K#3)l^KLa#Cyw0a8orL)_O{(uvjG?@s|2kmJ0xc83d~!c!NdHy#J|z)&
z^cAR%gZiW0V1TDmG5WVZ`{`+otyE*x8g)C+tkW{was0Fz
zJ3HmhYJ5HuDA6qG=vh@btw1x1G+F|5f}6!iDH|Z0TnwF+qh}SombO=rL{~K*DrG=A
z+DsmDvQh*PK|^T6crnlArEmp?SMrrJ!CE0!&PK{KcoL>iPZ>WnAaxOfkC{+GVhU-X
zGgiz(PBQs)B%gs!3<7*mpujG{F@;wJa0KR^+%f$LLfKTHKvAPSImw?C-Eh`rc}<
zOEVLIj*}yqLIcV@gWwt|M`TbB$dkc`BXbNCqG<_|P{!pPuQ;GLa
zhIH}~!Xk1iq?1B0;0BeMaRP!do|Gaf35FN)FqTennXCW;=J5;6
zv-tv7C?tx-R3R@&QY;$xyF50EfM_!rO?rpJ6bN`tCQ~7ww7X2jvdFR#DHD&z{3$77
zGU+G|tl4O@8jNObLiD&?CN}PMIc*{zbvjIOmNDp6THUeLW{5`oDIp{!L#0BzRE!k!
z@q89qGLlJ0q*RC&^CTHq@>D90?+FbH@yKzZXw(~v`Dn<6#G@x3^{`QIJm!wUVpGSW
zJ;YdpjFa*!uSEK_sgRdSr8LlADW{4BE|-fI3iZ*FM5V}`Rw>siygbkxg)P0Pi8Ovv
zqh0-JuUT3o5nGNXX7~^78zYsCP|B_Cuvl5lM
zDdw%WIqU71Y00`f@Cyk^y@z$z95yV{T0I>p#2C&uF5&pSi}b1!Aeam4$q}Or$d!OT
zA2Mb_hEzzO0UZ6Rq*sv$oQQ$rq)!PTrhUj7NjAlt?^yIh7@i0|h3Hp`o|BYUA)l`W
zm4LYvqfaurWDqzbkr;Ix2F*K+bua8X^659c+I6?;cEEh#FmC(xyI%E{N4*))?S{k$NGZBjM?W(blFJNJxlB4~>%ZuWcLvNgfq}7mmdF5HG+5N1*|efSm*j
zOdWi(DTY^#gM(5UjEkqU(1S5p;9QOc0dv`S5$>#OWd$N_cB{={HBro1yT$6T;uxN{yC__?)le?5evipwHB#hk
zIay4G)2dJ^@d6uk*o-E#-elAn^d~06aV+9Yr{ML1a>rS$43$*iOZobe3pSUIOZX?y
zM4tfuQE=rP@8fwt^rJk?A}_RK{cJ1{k3dMmJJTl8_pZ^aOT}U$la9-ZIGM??c!)}s
zx(h)!8bYa$q7<|7YLWJrIj;%lRq3oEo>pR|LIC)aI}K^y86fhk8Yhojj^dwFEwg8*
z33-(<%r*XLbs7d?NGrt%akCVL*gPx8&Pr^p7zGDwg$T+*+H+b8l|e?x#(bm-pH30)
z81S@)l17=KKqJ5rJZmmV429LDj>Qzs%PC0Sd@hhl`=Ipz#C(RyWx^7%lF5_$b0-9A
zF6}9111a8~Nw^>t3phF9N{cS)Ta+jFNTL%=ymyU$k?woTdFF0Oz<0%GL&R2d%vmW^
zD+JH;^);iGLc*9~H3d$WXSMmLIukig#}38tApw!uP5F0Hft{ppJ00Azsit<8JAIa&
z-Ie~e#jch4-le&2_SaXzS@i5TIpp$+AILMV0yB;>uNeRbtnXC*S#sYjCJA-pr>Ar9WVNUu7j
z{2H(?%b0*0DX0SwiH{)zp%B#bo#aAV$)`y9j?;dH=sOkyC!FU<@Scc1nBtR!|0L--
zO!$tI@YIw~G66-xs{l;lwWF>hmu@{`JG7}*w-$PDPj)zzYobSOKe;_S);d1WG}v)X
zzdxUk+U<(9xC<^=5j5|*lxwV0eX=?%c(mHRmD%BTmv+ys-SX+PkD@MJaX#l!axU;uRVQrBt&DpWu-hCk3S9cNLO=^d!n_L}
z4eL^KZXML6u-Rf|FilCv*PSM;QPN&@sU1>2`tQM=)3`AP37Q4f2u^E6z
zi^W(diWalRVASXhYOVeV7T)7B*)7Ic*qYCJ%jI~bL|YORve8^7O21(k!(2F%4x}M`
z(t&I`EF~F{lSi>dzmN#9yeAfgU-rZ!J~m2ZymyUWUCQVAd|m_xv$#VPA(`Wqic~8l
z&&tX3YU;F_f|RQk<9Sko>{*4qIu$PD)pHPowMy))#==trh3Azxa;?Ce6{EF$^t^~8
z_YR(cefdB(=?44c1@AG+)i`7(#3Pt^0f1(mwPFD3uUv@KU`dNCAbVO8N}2E(q#`s~
zFQ!C4w*4p(xF+=IseO~ouE9smdA5%r4MST+qS?Js5m83|g?2N{^5VG}ng$1H`y
z1q!94LrU5*l1CDp`IHCl9^Wv<*|Ib#$CVN(%*wrM^ow-gW9ONRGFK@?iPkv=+VHd(
zs$|?}Sx+TnEu~C(L0?E1GQ2L$YNUuV89hpb4|!%^V0IFr-2}6hjO;``8zR>YSbK0uW~=y5^?3=g2bm
zOpbKSPIS+VcTJCXl1Q9rpB!nM9_yt2KF9H}b7B-n2$aAjC^?f<5%~_lJwsLoBd7>2`5wacn%)0^Wei}%dAIL?m
z2`I;iNp~<8_i9pcTgai@SsWFDx(er1u8qcADlu$cp6;3IZwcAds@;X-_3@ZPkq(l%
z4%zo3j>E8RAFzWIC6vR|%S7fq$B6)3IgB&lcmzIj9%xvIS%^pQ5m^a~9rc{B{(2Xr
z3Ve)uRWZLR25!n@KGd`60~ud2qVOxFR4O8SVVGi0Ohk}@MX)a=@!71D&Lr{$C>;sv
zuTn}?OK@%QbOKO#S`{x&lc%+0J{t*neZ@@1?#LTTN-+eTcrG88H6vTAMvA$>
zIUty0C`5S`F9a(Sr)9BRpz-Bw(pk*9%Y{HOAB1uw_l?^XtZ^;`?4H-~r=j8LN+EJq
z0&V5-44^O@E~I?5Vi>QIk}i}LSZTOe^0L(Jm`S*^311#pDM2G7CCKocANb42vuc1m
zNJ2Phnwcm+ERD(nN=9bKI+(kz+s4
z`Bc*(?OZ@R3qu{UEHj{?Zaypzq=aVxzln-C;1cn_b1Q3BmC`aU&^C<2*MujA#
zTM>1g0FJCn!8#S38(Q*&_0X)$*OVX(ks$_C86lHRpqK
zmc_H0cuu>~OIH`d0)oQZYj83a59(I-sL5?;0eE2$sNW^0|E8-D*AsqrQN_hyz
zNHHJHXMx2?As3?wC7Eb89Z3j&WZL{W8B8VJV5KC%O}{pUST2eHB3b65gsWFACo3f~
z#qwU40$gnc`VNpfjh~;2XV8XK_Ot|v2WHW_6y%EvcUgnC4V+gZG}(|4#sY}6g(hfN
z4CNEMGbJZfg2PxIlVz8R`
zR&$MnxkV`rD0jI{hr=bl|2NNL-$J%BHg547%
zoztVJbRtiV!BbO!g2`dhi4#KrV)OWLD7!K+eS;Hb{SmI5uSs{{`LJl4!L&soW
zCV=ud9a3h)kYgw5&`}CfF?=M252esimICb_6e0?MGJ_mabIv1&V#TUjE%S~{*r?c=
z^qCH(M%w%PTe`cOTbpmj1Nw?!D{+=W)bvO>oQW9IA;WpnLZpGAKLw|Q;4@KZ=>g;Ul>S~;w
z=(TBfHs=R6=6gbx1FLF<_p5U;Q#ztfhgGSNG7(ZF{fAljed_&$m{p|U=zUPW%1lJV
z%Om5&L=TOR<0Dw-anx~$gCHZ0-@8VyI%Tt5Cd<)`nQXjJNaB}VuHe@T3kD#HwF-ZE
zk+`}@UY^r-%XcnCmC7JPLBsnbODQ~y9tF5l1RWL&IJkyhIYzUhtoou(m@8=
zX0zDrCcE7ji?}Rim}q!wv&9NNnmry9%XuU*5cC<$7PZ}aB8eXS^1%_>a+l`WF}buK
zZn}_(FN`(a>#L>hZnhk#M8ojzyE+ycaaTh7%glbu;m8H{a^71qTvy6*b
zrkOYVc`b2qCSIKJ5Qe8E23qf;BG6935KLz&a1*lbycz?uF00&SmA|Tqch8b{PQ}Yp
zp#ZZlz=V2WW~m=Q3P=gJz*^D?mn6D{sEucA@t}#1T4O;iA2kZBIh}MzLI&EhCdDK<
ze=fzO#b8?SW+)bnC!b-m*+?1p2|2`Xg+^xJrX#p*z**M{Y&IDx$Xlvs1Xn@wfnE8O
zAK#&z1|MOZT@c_oDM%4PATb0LvbfO5)ZTN2O^WAGb#M9jc)1*K!if(Px09~
z2By7M2*EOgiItoupRnY3y+lJOpy7!aJ5EH8P}&V^08Bx%z8kBX$>Lb)%exPMq$Wne3UE>>8i!
z#F3e)9?H;zW8{mcV426d0Yv0q0&!xvooGl|1|k&VP%E%FG1NLa)HXTPIyKx@XW|S=
z#rCP8mf7J((;m&ihV%=lN&Nwfbw~Wmv6PrR<*=SP>+LumnwCPEDc0~WP>67yie&I4
z890(c$5II3J4`dEAAy6wUp{=CV;~jxv!NqY^2|v-d?E!7Beso@W&2=tD8o5)hYL}U
z%44s~>OHnp@jw6)%9Z+)=4?ZLi|n*;6FR>xbF>tj;`x5j#!
zW`^4)`x@6KTFYVmSyUG_?euosYHPpM-gc|Ky{V_Od1rO@PA2e3&MPsx>5=yCuIA3J
z#`ey}&aRfu?v}p(wphSW6X%{vd1UPU^f$}u{@a}swQa^8D0hw7}nca2_k%H_CHStymnaydnnA`d-y
zdYU*rP2%@SJ1n0=4+?iqg{vxib;_UBVm#}vRFYDfiA23dlip~QNvKyFjT)3X9nG6D
z(d-$TQe!ZIhGck=>MV0PT_7U4Wzdhn=YV)bcFW1@^`i86{HTJDL{FKEG7v5B(bT_4
ziN;;^4P+v6KqoN-0tkSan*9->@*Dso}G!O7yN0BFBb^J
z&{t5fdI8GrX&p#H=>lTY}f0aHpO
zQI_Or!gDNaj7QB;#+qQgVZSNpH3mG!klzfM9Q0baunQF&iASAD-p6>2T*MU(+4#5v
z{x|H?a3QP2`tnjlY6lF!A4Dpx{UN$ki4#XOOn5CY}Y6(mXf`$djkrm8Y
z&Hx~a;iF_!kzf^U=!gmEH#a6$ZV%5d4NQ56;RQT$~vI
z92aH>X6FWFwJ0k@^3D{_bYh}+W@cb|8o6(NdSG_CcS?59(*WWybu7wVhh&zgWg3!Y
z9_f^G$M|3?(QvR8KpdB`I5yZiCP!Br8z4kNEshU0lUgJn-8Mhc;yjuG?*PI2CJv~`
z<0@2<-SNGyLt>?Ii8ZfsM%v}>-bH%VDI38a31b;e5kD-!mYEhtD|9hyw9N9-dvyT>22!n
zZt7@nYHhpK+J3XO^}+V`8?)m*Ro?Zcav&F0i=O>Q%fUAny)o%**yILE%
zAPnW)(Q$KOrau|bl%fXStsKC+bvAW$HMe&*v~@JJcjBEJ274M8M_M-Lx(`J*9^pBQIJ=d!50gs)kLi-P}e?9`(V#%@$+gNKT8sZ7YY1mKlAAi{rJa!
znGk*XWc2P8Z+9B?CI~=-POs7FG%B@HuT$xv4UJj@FljIuk;pe&NfrWcBoAdEI=nE%
z)r#cx0)=je%j$I6WJE$FdVs)cA?x+fiEfwI>F_%2ZoIzEL79+F@KGLSv4gfW`V4hw
zAu>XW%0ty89<4Tm1)pvL9Ca3x(quX@84irug&j6HU~VWpvRh(cs7Qssq;FtVXuh~yVHCyBL;<-
zM`S5FbCwqHg`lGg8B~0Qj4vno@u9U`lxA5cU73_S0Y5Hzad9#bm^8uAo912lq&J`O
z%K_?Lk}OvNSr~08>Eh#-MBI@TX$8u!ru*(xIe2~mu}mvw7}|m&A1G(sg_J!bm{L(q
zDy{+zGn__<81RCPjp@aek(Jf4#nsWJrLp<>k@@+dImpB1QJ@e^l*u@ZJU!dLG&2Cr
zI5XRir>3Ss!2X$;VK7m~B69ycbtd*tPxLO-dlexJ#{t2P>G4j8MDobvofFh=*gjcz
z&5(y9BozU~(f;ONK#(%{I6BZW+TS$M*E-$bF)`3OHP}i%8nSVyWqqPUvo;jgEyoPY
z@XPhNI6xtZ#9!ImA!c0m9Z%4d9a<;znt@mdtAWD0`YS}0C^O7KF0^0t9~8+W@8`pZ
zg~(BXJ;}3*Kl{&r_~G}x*?O|TI1bZslV)!=?o}OcO!jx)80u^4>AKn3aT89qudlhY
zv!S!Iv904~Tjx!bkaexCH#$0Q^mg9t>%2bD^I%`g8NVDYE6a`~}Gp$T_
z&W*HjK25|)M%b=e;hcxrz{#0tIb#i{oUs(u688hjv|k~4kMUF~q=JwH5TO~fL2V(d
zD@F`?Mlbnrd(hmwMz1=_8?J~TAlz{ct+W=0c!61iPPwXacWV6IQvvz17W?Br`oTv&
z^pxGAwOBNnY&@TiK!2Hxx`*#10wJ45tJG>#T0OL)7Jk`e(whvhs}`f#W;EL^Hd}q*
z7(@f~9OQ{TkbMw;s8Oe)(}VxUnUE95oNn18gME;e^pK7?Xdp&@74gvF0A$TD(RDL!
zv*V)xL`oKm8LruE(Sed|%wH~qJWi-ZwZ*KonosOzMOt*%r#crUe>v?ZKIWNXj#jPZ
zGU2Smyf_s}^qs}d%QU8O4qwfqoKrdoZXE_)Xv)8+9=OGs`%_0ZUd4
zLOilz>O2hxUE!cJ%D5sS7x)6AMq
z+EW}wwTETKJLD6AG#^OHp-8h*D9O47c{$myru**Hg!2-6UIY-s6&el?S4*Kv-d{>P
zv!X?es*`bz#OXzrHUmF6SQbQh2R&rn^77cy^7z8S$l~Jo!s6)sf~*i1hM)wY8KDsC
z4;P^jr+c9gLBRQ`-nq&Ch3UbW={}g{xtTsZ#KGywF3J;KbCW&wXwQ&`v*VD2G8soZ
zAP=WTy2l6GCWgB}Lujapp>~;o&7=)~!9=PIHd9=33QgWJ-q$+W55d?nG1xji*gQAf
zqS_wu8yEbV8JOsLA0jgFCyPWXqlRVY;i&y!#HX5eDPA$E!7HU)OaUdBVHDI$7~IbV
z4@=B(Ieb!%C@N89IjV#zEQU|2aWzgBd`i1!HP71)H%7<$Z;o_a(;qJK0nO%O|48=(
z%FU6Bq~lVwyL9Ul15LfXO`UBwdb^qidYXGWA5`qlUS?cpk}YK0>u7m{S-bv7&UcYA
zSK}JLX`{9A^{uT9Ev>g&T5mSD+-Ps3KE(F6Mq*-HV;hmN5i%2Q8cgiyXz1-}(j6_H
z^42$%{8_&uY*;@N?H=RC{@Umyu4m89wb@>$e*5J1s86?^@t<6<#?zSojMvv#ElT8S
zTnqXqJUfDCC*j#kc@K*bbv~*A5HkUFmeFOxy80!0^@-NZR%z-+twaNw0HQ1pX+-kQ
zDSrn)+DiPi#C-0vAA9kI=UjGUp%62fRR%L$vR0>8tJNnewL+`YKpCN7>kV3+Q7zkN
zXh(=gv(aoal7J(yfpIA0&OxFfa0Z=6G<1N5Kpx=efh7hEQOEhRBt!+;kTRKNyVGXF
z(=<^LFQ>_iHVeo4k_krUpo~Ma(PA~m7ziZ?eK@?c$zm|*z;1{{tL4b+JV_^<^1NkQ
zI9$oa3YoB!@T4FNGr?S%;@V_Veh8d<*XY%yVj)w=OSM|AR?D29rZ3Mk7iY;zC045l
zl_Gm_E?%DTm**UGUoPXnsIqq@@8bU6$;S4
z*i6tK3p+&K6AoG>a-x3emK*o^Y&IH{kfr~r+ZaoFcqF{m`AXCYNX?L7Fyt5x@hMR_p
zOeZ{93RDhj>?}xd&91Zn6Yb3io)qWEr-BL2ort@#32%ahowtgtONhVBGCxuiFDn9#
z5YZkIfhsM)4pwviY{Dw>Mlq%qqS~O3=1lBu&#&E{xVv
z=qL>chEIyW;NU$VhEH%19IVDpDlygH{_LmOxLLh9IMvrM+;eNZzgfLCbCq{p7JWYB
z+Lh#fDCEQSKPKg&~j~Kevow^6+`NXalgOq!MT}%
zh+E~i9Ing`wX{44>b0~%`avGvB!$@C*xGWdt+fHUqpcASAsE|Q8}YEE`DRPYt&Yxy
zfu37--ImX?r`@0L>%7s^dB0h?nvdCIKJ9S#_3?qmiT+0A_9W{(wjWN%?R$lYs>bV1
z1tVy9%IVGoDoW3tXcg6BG#2$5
z!9uguY_Xf55Uu2JNgleaG(p#O
zI1&l@qCuY!^TY50juFN#a-Ng`T7?+D8N{pyAIM~*Zjahw*SH;Kzsv4-n!H|%*JE?o
zOipAg6qw)R(mAYJkJAtjJFKSTK)@P{`VvBbXFW;5P1-ph%w>FNCmG3;O?zp+A#L^*
zBqc~v(F2_DFHBq_U-ahF7J^a$~ntz~}GMGAr$9Hg0|@^)tOhKt}RfM}9<
z3m-Lo?|aX^)uaLkYDwNP=;;e-7?=
zYG4j|vVV56zb*skr}}Byjm$(y!WlZ!J40~nngR_+JD>#XjDtaz)gRagNhp^Ct>7T2
zhjO%E7KwDc2~SbRaUc@M`$;NJKqn3~d5nAOkglUGF2$@@G2vHDGxE4|9fe^%kx|}T
zj0Rrnh`e`^UUe#l6_tpxQs*GbItq!2N9D*diNx^9)1P?n^WXlm->@1o-?pij`Z}(S
z477y3nu2HzJ5RcrUgy;96{41kUuP?@CS>Ppj&7YvXUWwmi_&
zeq*TX!GWHJwzeB>ZMT}5Zb0!hwOoTR1Q1)>sBCV2ka`>Ou%!V^{AC6To0}hKZh4@k
zWs!?qvrmJy=YMf9g`Hp$V9>{p_8olZy&kByxe78#M
zv=lxqhA(Qc%+b3w_AdQysT&KYxoieL>S26lgF#8_iw!!hR;$sdG#WKLaz^r5Z90us
zrPHZtfJLVVk^nV%+6^($V3Jj$P4>ACv(07#-{esd7cEw?!}b#894^9~6+c)T&bHcY
zE+|0iDzurQ1o58m#j-U91MwyfyVXgG5Yz+m%zC-U5`_->RBzPl44}3=uw&F4Od5kh
zgX8h2&uUV6orZwVP|O5MxgdGxEK|tPt^~zwIG2fJ)3i!ABfYjkl_IUrOUO%2>Of4L
z)o6jr8BN#}uFinM#KY&}BNvIg6sKFbx`09yAHEbHx)5qbIAty`1+z(flV}ohRdhvy
z=19m94tki7C&qZIxda<>6?0-J>ajCeMkh`1dZ7-XkYAM^vP4u?ev6b49plE8F3wRY>V$ECJePS}`>jXGnDU82o&
zK||VsLf*i}TX)Ktge#k@TV|&$6@f^<$T>yc%Cjbcv%)yTL?`36B(wS{h$i9-Ci;
zWhOY@BjY0VDuR!2&~VN3bHfX>1BjnVRgGMwaJb%W&*ofLWfV
z>DjXr9n)j&lcTL;!%gGEgul`LCRpR)K7yTGX_Wg4TgHdlhx^*bArkwV;f}}q>U@NE
zZXfG!C)wEBJc^ThnkELCk;ey`riWXm2O2kKI(@1+2tYdM&1?#T9292_^0J1m`*uJgQXKc(60m*7iVq`;D&lo5LM9
zS0{Q#yKmy#;vd!7^1xtsV_)aZzMfm%E!Xp10GE>YMr0%Z)$#k
z0M~M}spUcFL3m{FQC5F2%c$H00Z9oqKiJfGqq*rp)SH@s!uwlVZnQMrXlc1NKh~NL
z>drZHKB!S`PPR9`ez5x{>sCFS@!v^%kJrX01{z|1WhLc~dK9>|*tM%Z{c0|Fd`B>r
zqndJ5TZ`)nf~>X_RiUiLba+^as*4dE(N$x{5<{)%H6`5nDVL(Pa*SsGp2jXuqgS=a
zRV{W^BTAO!m}?%7&F!{^LRPQaZnF^dG#Z^+t5EAs)VgDh?!;!(@vKV+D(aEU@?eTZ
z4@#LWfFazh3`C2=4v@h^gP2wm4S|@g)G0~h9%h5eW>I_G_r^oaCLNxJ*)^JVaNb4}
z4UoVNBSZHYXvs5PYqFX_Lu3gpmZM{-KlA70ebSLdla
zGMe^#Dzq%Ch@Ggy3iC3q%>qIK~5J4vskZ8;|#4=`hVF*2_Ka|;Y6kH24
z_ISj_1U+HK7Yw;0VSj{i(T3y#XcYvDMUF{{@rUo8e)%h({^Tb<_}E(>lDi$f0ISET
z_Xn&Vw=Ev=*=+`^RcCh?ELNSzO(XR-o7QYOF_{#0t1=#ShC@~+V1XtTIfz8sUpANW
zWs`0IF^fx-bOVK`(?S#)O98~ZNzRp`c(@LMwTZk)p?P;dj?I7FO0KS8h+sK%7`y9-m(tom)g6
zL50Y;1bIkKd0}ywP)Is)XnqC;d0>8)DsvOPkcyL&-4l~t6H{H|6C?@eCVOC?=f+x>
z$J?j+ZcX*woF8aj9&Vi~9($Xr3KypB-*8A5Ml13nA4^L^BuD
zEl?Bz?EL}tI?BEQhg>
z^>;t|p2?mE@Gl+ex;Ze=(%aYE)pZLhZ)&nPCs;2to`PWOY5q;~;c_)@P5F;CThm}-
zZ*MdB1)M?gHMd-EXuQ_Ya6bqrL-0mZ^Nq&l2OAo$wY5Odb@sI1>}ut@iZ*RTc)O>#YnP!b*t55;SsD
z3wccQ&J$xnd3@zS>I1L7x
zX$a5&F3eOB*+kd!=z{lL==Y?+{kczl@)I1(;0oZ+)beK$
z^b7_a?Tn+>0>?U1u7IHiUsA16sWeI;5?WTPQ}_dBf%O&AF{43kHmY3?jnA!v2ZVQ~
zg}M-lc{ZC4rc?0CUi`w-FPl#M&!-w~b}hmwU!CXfT$C=(GN%>sv?^TCZ1&9Ei`3n7
z8mzxMN2X3gIOs<%6F_8zR@(Ve32Qb(o;1ur)49SSUohxoLS7~a@IeN8`FN0v(&n|%
zunU?IOa$8A^ziwIKk)wNpMUY0XP$rI#g|@u>H9Cf@Vysb{NDFo`T_DwFa5y_FaF1u
zUiyzOeg6;N`q*P^%$v)E1;Oid7+emE$i)I4yU%Om*?`%g2>ES(w>c8=y4_}{)8O}0
z3}_hVgy6#+qLOC|nP5)x(zHbCNrYeaLL^F}GbK7j!2uM?#@U`Ed1y-s_LS%lIV<2O
z@-G`y`Q#H)WDol}$DLt|ZIV;xS@
z@lSvBr$7I1KmMP8`N#k8r+@JGfAU8^{lk}j_Qx;%?H|AJqnEyRvN1l|ePeQ`}CP^H8ifqj+eNr6FmTn!(T
zn1f2}2)PtJ03UHqNV^i!-%k1tHG7jIJvZ>L=;>){Z@<~r3N!maXZ!W`mN#s#3|&Z;
zyGipyNlT5l?BAa1ZilS9zb*h9o8We-1P5<5K5(nyT2DuF&}seQbKm~!KX~a!FFy05
z7rynEFMJdE`(OI>+b@d4?GJV~zoDi1{^llPVr%0Ynj2o<(C|Q07&0DBLkJ{PJam
zy{yD9icttCoMSRWURj(jI8QwjbU}&O?0U6Ut=7UbtF?N_Li|V0dNtISN~bj#q0Wd{
z(1?1oPHzMOK|?SR&uC2sg-&zul`nr;X5Z6ac=`*q>gBuN`N5BW{8OL(+~+>=iO+oI
zGoSnHXTJE^&wuW7pa0@VKKhi&pw>h8=|MXc96ESMN|63bwq30`0gmNG%{Wd#RO4HK
z)S4r;=2)dZQEL=x)uBqWr_yYzHHTV_Ql&g(V-A;74+0j_eu$l1I+RTXQwe`s3c@>Q
zQody3wN1OJ)v~o}>he5u=PGx8A)Qvmvzh?ce0h<)bCtStnY?=i2OR?qAHGb;f-&)?
ztK{8tu2S$av?dA(z9h_PNdYM8Dse
zqTmWHN%TWLmkZH+HjqtwGAWu4iSLl1n};hYctn=w?m!GCc&EVHp&13<$+I>-4vp#H
z*?+ok(0zaO-A_JxCv#pFtHoF$L!rR)Y1(!ISS;lNe3aJYZ*MQJZ!Q9epyA5xxuw;~
zrRAxG#fkaFiG}6yg{3iBCyvc6jL(9GizBlO!?UCc2j^ynre_A`<++E`(*sk}{o@n8
zlT&?TgPni-v!DF@AOGPW|N2M&<4=Bg>)-u9A1mjce&RiQ)02kn%^DwH9UPkOZ2rOr
z9v|<%KGEMeJa7vf9O=0^)YmZ7+X(Q<#<`VLVQ=dYTr&+Z!!J_?97hMi$L6|y9`2*l
zMj#Id+r~%RCx_eShuah@gN$Y&teK;kiSm|WG3|U@zeoyEPiDE^w^+YMuRfK+N9FKQ
zkvS}d4vN78)Jx1E9f?rJvp7e;HypODyG|xELCwkb%wSJrPe)@%=YwrvVoO77+k?mp
z3qxTS7^;m~b`IAk8zBapueY?`YyziXjhk;aHr)Ud0k!tF#&_$vud9G)JKy}^XK0E+n;#HTR!sG!*9LF?<`HW-+FyZ!y8(`&|AON*a#-x
z-_mexp#8ewKDy$K4<+n&&FZaNzbOOpdUNZI&d!@dy*GE32C|Hn_w5@G#|pf@ESOd%
zTNImP0mFvi*{{UZP=#l_;go==K8tY4y6pJ;rq7%t}_
zQsBA5SF~R#q+XKp~Pu#DA0;wL+&<0g`&T
zdy#hNf@Ot!)#?mdon8rnW;Uz9K^bjIaOx{x`6^%tAb$Sypa0A!f45pJzV|(kfB4A{
zyy=m*eE1_DwVL%G|JbMaSmG0(eEN5P_vzpL%xBf=6TBm7J+0D!PoYm%>a=Qu0ZLV&
zCH$$tK^#=7j#Vn9QhB0QA8YZgG_%u+t67tb!}s}fX&+oO
z)LBw+q!KWNAN$VNzxwQRFFpVK?|=38z7>sy!i<{I`%u^1{+2P$-MUIuK?1ygWJsr#wHrJU==&Hw+F=P4&;r5DEdriHW{R
z804ve^Ge|#@xK4?-+%t2zx=D;|K69LeE;{q^re?R|Cuj5@$RSIa`l~0J@xFTKm7Y&
z`OM$^{xdKB-lzN9uE8=7^gIX`43P+}CwC^oBezm_Ax+OF>e1-RK>PS$2kP=UP4@;~
z`rC%&my8XxOb)hAkF?B>w%i_TaUD(imDBYIDp49;nGR`Z7#*$fLk121MSX}wz#?df
zELR{H%gC{lQuJ8z@8KNl@pLU=%|!I`qpgEoH~QPJkM%T-^fZkQv<&n%b#~FXuxyPR
znp$tRwA`fbzozTZgDq`DL*&LrSZ3Jd>&>^W|MahZ^z*;{>EHj^pZ@s!FZ}*jzxe;Y
z@4ipJ^S3|x*c*HAfBnZEe{^kh@X3cS4(DgyeW&&xzxMRr!ekR^!`C&DNW2D}h_{8n
zY;3&0wdMYfmg`Lo*Ql$p`FdOH_14xK!#ypk&Dp4RC!k$S`1S(ErKOQuQP;7^=#JKg
z6}Jb&mUS}7F?Bhrf($H2G&N*KQw^z0A!U_15LKn95*cKyU!qr^XgjI^$sv5=_7Fq)_2Qr#y
zTB1s=00DKnL%r@mr#;f^PfpJ&U;N^iWuyE>D8$cx_OoyM?RNw`>_Q9X?$H{GDjDCmIrfM+)#x1u+N+
z9;;P=;gM3YuT&f;P7W0(2PcYMh4SD;iHG}I&525-(5MvnVLR<=gKif;;9SaA%12<=
zWZ~n^WkUF=i*fwO|LJt%e?Fa_Nyz6HnTxCJAi6{1midEK7OM8C*;1PlS7d_>m6b1xfZ{?wC?ed%M5KYS(uh^2fOZBIlW-~art|LSLd^amgN?cbj7>HO$h-!j+RW!>M}7#?`f)v4=v>%aZs
z3;+4KulBdRVH6ycZ7)P0Jm!!*%rXir(o{q+v4br00L*fG-8+wyPJ}RQhMXMeX&CKk
z8tgKGG&%FqyVDSXV?*KtlhZiqVe$GWdg4mPgM_Lbtc^Mt(=Gfee0P7JjU
z^tC`LLj6GuwzS@Al7~tFLDXB@8gQ_&>A_nKH(Hu*H8$Ru9v!An{n_9C!=L@x&wltv
z|LI#_d;i^w;ad;%Ui*y-8`+*4e{&_LUSCnH%)jvYPyCl>zy1eb{rvs^;s0oCy8q^_
z*FzyTHePE2SmlwH`d~}lh7)RAZ?v}F?CrR9usk9-4pN@IVnmS&9&gTcY|eDAPIoL!
zwk=Gw*fh(MZ~t7N35n2&z#{mFT(8v4GEj(zm6(dY>T5~RhSlP|@EYZOsE`lJfh)m8
z*ym_IQ@6}Cq^#4ctF;7#mC>M9>rPY}rPXH0rGq|?TM*;f45!kbKn<$YTBtIbjzfl8
zfvlrp4SGhWSLk&6AY&}XKK+F+QP<%wEc4NUI-f2+`NWeZjX5a_k3II5C!YF<-E8~J
zXTI{e&wcsxPk$Mh-QC|iINU!zIXXEZt*2HWX{bCQNvI}Os8F1Mi3$b8;L(Xk6a`lJ`>)2M|${Ds8+&-
zTu@5+5~4Go3k#g@?o~0ucmTmD<4GsDNW_+90PE}>3f_Se7zsM^qud&@XYsK
zc>aawo_Xfm-}?B6KAufWckbT((wDyc#CxB3+gl(1;^#j1^yj}^$QR!J_&dJ&br|Uv
zo`3$u7hZVjxo2Pc#3w&*GSx@B^jhsPB%#Z$3;E4P{fS*0as!QO_kzNV4B
zhRMO^se$IX(Pq1P0ZuupotH;c=A%HNZXuwU@+c<3LC?vA^KjI0Fd|=~*N_UqT>!Bh
zJS+!~0K{T&rySZV1-Fa-y<*@n<=MeG4%J*Ptgdn;Ac+h76-RPa295)xtz)
zZ)Xz}BE%rTB)j8#s<5@~R!iG0JS1Q>-e_yS)zoxLaX^yu=YRkAfA^<<`nP}b!@vIi
zi|a%E&Hw)2&ULoB6^9dzH#m#oH~zQ#I)CdwJpJys|LB=-{@F9%c*Ae}+XjflTW>nN+9v>YagMA8M4x&_{0PApIUjh8pwV~obr94z9504dxM~c1U
z<3l`saze^cr8>a()azA7qtc*Lr#Olnf*)W}VsbEpyj|d|0`HKLft2{#fOsKK#=g2p
zUqKjK~($OpZ(0|xLD}RPk-u*UwHcJqWYCDf3c941fKoM(_cEPl)v)y=bpv6
zFMjXE7ryuGvo96PH8X92;qrK0xEg{Gx7$oUw=EX)8T9yrQdfw_VfVWnE}N-bOz^BH
zpN$u@EQM7`kT#S+!-Pu|9PrBt0T6W4b{KKoU})B%$oaS!fanAeA+*`}Kiz8gz7M_k
z?O*!vJO1hqp1vxx5Q(tNnUp_~@@LYZe!P-ry-sq?2ICRW1=lwhmseq&LBlBkv7Tq=
z0l~4^h2gnHQi$`5V{d3>;WZoKvIcDF}41tl2P&C|Gwmbww;OrfUg
z^KSyL-7@C`0N;K&1T5|Wf+$O&eHiC*1S0XEB=@6fwt$sw&GxWIyJk@>DR;&*5uNBg
zIozCRX}LyAm5GM%$k$OeG+u*RtPi2c{e~bT&9G^1z1h_C;6QJeMN2C{{_$r&`JaFB
z7k~G|KmMy9y!7MepZm*apF#O&-~Gm)Kl3ec@GqbF)_;5P`M>_b3w=%3Z{7T@>ks~B
zQxn5jzVWs1e&d_p`Nmhj`^~RE`|WQ%^PO*f
z_uJon?%D6Y@Ep#2@%iVz_w}!T+v&2Jth#VC06l0Tk*G8oG$tCOKe5{lR+~N;1n;<5
z%p3HZ0ku>jRLt}FOe8DOeu$8VQW6It3>~6?(k;Z@3D(DRUY`08$vX>CMQnDNzo?3pe1w8mrI=hQRL;@@=S+rXf$r`uAM7q~Y%Q;C
zEUm20EiF&caPtbx^3?qD6pgMd-XkNe;aePAf_n;V&(r5W1Ovt*p_btz8u
zjF0zBObtzr_KuD9jt+DkZQp+Xd*1%0%WBABTo~(Kn(mvK=pGwxn;h*J8EzjL0q;7-
zham<##%Z6M4rG#q!);^39i#Ha`~z5SCPdgoN%&56Fox#8v#Z>@@UuW6^N<^Imj8*LpAwzl1DYXkM53ZV_b
z#2YQGaI)8BEXryTKAMa(j4h7C>fY>ZYx&7fe)98w{KtR%oB#HYfAJT8|0jR)_kZ%k
zzx&}IA^-Fb|KKNo^!q>k!|#3dlOKKE|L5P{x^=Co>3U@9k+E
z?zy!x)4Md$KH7PGsN;d5&Ih|2e`|kbM6ou3Z@WC+c6+>IX}Ec3u6Jd$eQ$YK@Tsgv
z3o*G5k*3;&R5a~|QG<^_A@ElpNXh#4^7N3%c<&m$>I8=<4=GS&wW1WE4(?n4#uw
z)if_htD;^%98zf2N(}@hNlUnI+wqYqm#uu@gCG0+(_ewb`{EbA^4ZTk{rKD8W43xW
zcJ?>-_P4fo0mJQ`UGNaDd1r5P?*O7t0VW>H!jDSX9UmRhCq9=k1@|YqCEl6OhB8Se$p!eBJC*Py1xU8nI?4=r
zn7a#kc$qpoPn^CQ#^?q%}MW#Y~ye|gT|fnUCq-guRJ_)ZoF&&uKRN+h50
z7ihO?Uq%e1gg}&W$HM+d5T+g(bw@7ERLc=5=>UVGLEUK~9A~uWrNm3meE0h=y!ibW
zUijYg&!O_t3opL-{0rbC$`_u04w)*?0fbaO^X&6)ecL-M26HF?{b%y|U3!DcV$u3M
z_IQjzE
zxyV;4(hq*{y`7zvjjbhlbcN>MEUrw=EltcVP0g%KEi6w`PvXKjwBhXh2rTm)6yogI
z{Pf7e%m}$=FcD691`3h3x|x|CoSy2RoarYMJ=r%g**8AkH9FosIo>lh-Z?eaH96Kj
zKH4=l(lw6CNXO`C$HaJVeZ!lHVdM^4%M61|yV|smjJC^5_edK;7|PvNQWh0S&WtAO^Nk
zLMj4F_tV=2&yO|+_n1Y>gxXn3=cy7{0PZ#0vG1|=IBZavV|**4VI{iV--`X@j7FaPk@
zfBipy@;86_{g*BZQs>PZM
zkYVGTH@+q3O}h8XoUs(QtW9>0civbUZk-=)UKnXv8SPjYZC#mcTbXQksW&+HiD7Fh
z;ohsrU58~xT?uQ7AtfM491I*v-o3PMKkeDc1`hBr<=L%YqF0}w3JYmpHto%3e7OJT
zBy!NjOrVJ4`Ea=q&q<+geB*16KK5qt%V2`wQz$jiWw5I%l~Siv>ZmhMtp*tt(2J^L
zlqX6BYDXuk1BgbY8g5$d@}s1IummdAI85pi@1fD^4v&ua4-a>Db~m@SZ?A8ztZ%HX
zZ>_CwuWf8?Y;A9BZm)0e0gF4kpyA%u-rnB+A&m3U5sYv>K``Rs0afUo_JPIYqy1RK
z>2{fqj`mPLImD4;k@f@(F#(I!s)cz^@xBs%>i8uld?J3yoI5Gdx-^k@b8!#yy=(O9
zQni}BJj*|Hr*Ls8ot-DoYpL_9bmu%<2Vy-xbdh}IJpIU7<`L42$%n6KQ01Z;uNEjm
zQ!xiJ1`|ANrjH4_Xp}kRrI6DRS1fGLXJRqNCB*$qz#0yjnSg<1bdunBfGITuS?@>m7dCa^9p_A(%T>UTc*|aZ=vOVS224daP%1q-$oh
zXKJ*2a-^H|9qn_|PJ4e1k!+kC?wTC#9F^U)oQa8}!>z;pjbxc=02)jrZ8$aDHZ#;Q
zIn=U$dx-TO9<6jnEvpcQ$aR~1Z<38>j#1A>v@}l}COWL139DbTWrjio5RvN;EC#j<
z!JR@72e(ShUXj^Ld$zv%^v6H;#G{(+(U@D2X04jNnS9K2CK?~g+H$eO-L(PuS<-Rj
zk+0K|l4iLNv9&%?5oJSvPg{RiYfpQVEb$&_Xt=+*=|*D%^(}&TjSbhqM|u@-DMRz-
zt!p%qyYYSy7H4*MGz@jO^>*AG=x!YBx~bclt;LLQOuH*l}@aeagM?k|4?cVI#OxMDAi+&fkko9UrLtTf^gRcE@Kv@f^t08sPcaZT@
zrana9zU1CUCG9)Bca2_kl7j(xrGzU>QPu)<|CcDlS~(LarTv9WsE~C+w&>7
zKTk%4>Ir31Oi~O`9Oo#0+wPP|Sgc>7SDDVwv*+iT%c~sn#d$_vqmqQfg;|D9ybJtY
z(xSbGFXTa$OX=>V^zfbZ-P7blXGxm*MA49g#X>llVi?BBF#aIaS=bw49GO%&!nh&~
z9@--TS1{lV2A$!c9X=ZPX2a%KNH4@3e2k*?KmOZ~eCiV)`JIn`_8rNF&Ol_>{dNZ^Nx6ZK2s=cH<~mSv(aic(Oh~HE&3KjztyUYMT3$Q<-jtI_R1~g
zabJW!Wu!zfB?OZ~AeHorf1TKlR>sKl!dl|MWYb{KiKgJ+DxpLJFBk6G1}-V6hla%f?v-;>zmU+}irw
z>h0O3B{IvT7UhBFnfYPp#M!yA`Ngqmnwt%eJScY{j>*E1IuKC-5P?P6ID>{V2Pb=J
zd&G&p*@?bs+Ukb3L7bTEodpWvtjD@1#=A$yJBCMLkSUKsB#v~ENR&529KE;a4Il`?
z2vt~Di!CFAts{d?v!ksG;~g`!+fDQGc%yZ9D5{-_>1Ji{&Bn9~aUE@-9ahgp)N@hQ
zTnJ`aH62n+gOBxV^y*VCum_PyuGt5LxS92B76My&-)0?-H2NGoD)o$
z&&dky+2uRD;>@Xlrl;w3L+uYv4Yl>Q-apcPYqIawNY~AY&Kn`!ZZ2#Hn)jy%nx+R^
zW(QhkdYccIhZO6hLDQC3vz+qmS6NLps>=Hh!NH>UK(cL0_N{E-2-*+|G3my=VK3v|
zO?!3|&dvHIdi6<4xFHX7X@6R9r9@vQ9nPg;9x4805k4**pzQ)BuPDa;?(hD)%Vmei
z%SaJ}9>mi^C7!6^Sm8;PaHk*~wBZrCROR83`tVqFc!DG3tZ^nv)HG^6)FUbiO2-Ns
z7*Q!s=oKf*lY>L}+v9`1lfB)e?fs*j-J{*T!>yhD?cJlTy~Ax}XhYEO;CK(_dGBa<
z_h@HF$@5_*7zF#acQ+4?cEQQLy~FkGolUsw-Mw9$2hB=y@^Ei|8!YAoHxsl8bB(+Gd{O1
z9P+sx7MIKBbekMbZ7^t!$Gj%94jwt+ckl_n&7rs346(46i}`SSh(xSH(wWKl%cW>G
z6HKR&nPkGBOt?}>+R6dKkV*lj*hRgEL{B%*dc?Sgrv=gSLKn`*$6vN%_Iuy^-VeV2
z$&Y;KsVCp_&X2tNjeqp@k9_W_H=oy%rCcm8F=-LrIas6tmPjri#S1pKmo~RoVVu|3
z=V)dk4KC9F3jhm2^uCG2g%Mh>vN#GLLLtt9gY(0)3xkvMy)*M5Ang%b-z-+{NgR|>
zNEu|r5qN3yv{D5EjSAIwt|g(e5!|aTJ-ts*H_wjl)fkcMi)Oq@BKKSh-1F
z_}ok@od;Sb!OfxO$+4EBjnVbF?xo3A#qGYBd4=NNYo;TbnJ7VU)~}fIsiy7;Mp+dG
zP9_=UwCCVoGRmB<1JS#ka&JkVEmX4JtzuvYKtwJFAfxt6!Tp458z(OgKWILlSet4d
z?Yb%+A-Pqi8|IywO?=$YNFSNDXY9Ob4qqF(Ocwg(pK=bB&
zf5dudJzOyDFV2qkv@}9v(t5u3mTU8qJ)Boj<*iQD+Ui)h&#-@RduqI|X>(zCZ+XP6
z+f9T_vx5zmBcV#>Ll_wMJtdxCXcu&qn(oicL*od~m>_K|(A
zU!qr^HFcyOZ9sE=`k`u0u^@jsG;sw0TH;{(ud|M&#Qk4RV^
zE2%?Jv43#5dvLt7cLEyj?Cfvt9c=6zpd{nG1M2Om6^Af%+uM8FI|rLvJ4Ywbh9?H2
zJ|#vq_*SZe^_{g%SnaJ{k#(n&zMZ{YNetU9kfysT^9J|C3aeg-?>QLy@X{>-Mvc5)3XzI
z2CYnpmNwHG
z=a4O(3Pr2P>eHoFYauG*P9yCaX*F1^dauXo_Ys0AP&ErF>PRJmN#0-1#R^%bzFoFF{m_}DPD6J}z;&a5
zg)sQA%n9BBYb?fHBI^|6js(rQv9i#NJl@UoYZT(u`Nb3OdGAM_`oPCO^noYe_1K5s
z{m}DY`tS$ddRECr@sH0YLz3vF2nJ~i43;m@@_-F6ac5y|gGA!;+RP%YZl>9YAmH45
zy&RPXokwQohXBNxxq(>V5b%&P{gDPW8-9
zbPmDBA4K>Yl*wra{V6gnv%%5
zCEEMXFNvX);LD`oSA2v>ikB9Um#+eje)?4;L*M<*w|?h$J}wARjaChjS0C5_kB*@2
zXbLn9UmPCcA&#Fw#~ngE9v>bYf_`)os0U*U@Esi~_70Wwnxn%#SY7$Wc!
zwZFf$f4sSOw6S}LauW)1_lU+=cK6qI5AYBKgmPTp-rd;VTie=P--gxR-6w;*r%>)~
zY~9{FSPO@o0l#T)4>tOM<6TF`yT>Q{F1t>mab#aM$>86c;O!)K5*~qfu`!$c!=`=q
zV__@*vTaTO`6SOn%z%bh7ugHi99ufA%JUGI3a3?zkz$UKlEElrXBb;N21t1$5kItHG~!AKFt8E8I>tDnK~E&)
zP9;K2$m;XxLjlucj~23NcQjxS1i!~+2zc#`AAGchgATvP=J8k|2HkE`A`wRE^Ev}Q
zpTVf}_#95BNniuwc}xp;_W!`X~j%yHRtB%KW4rh;20?vx2yk>VD4M?!Qa1RqI4
z7EB~E(oF0)4KcG6xzNsW(5iMW4!`{CfLJb;-u1S}-~Yt>Km5U`KKQ}+zxN$)`p~=X
zKJ%IPKk;bgyu{}-(Na2+P5IC+Q&O-{2$gcg#M`&0H?|jcwpTXRm)6$jAr+TaC*;+8
zBXdg=^UJh$Mb1O>OQZ9&71;2-)y=eh?C{dU;L=>r(tO_n?W*0kINdjQFZUwPLL|~|
zvORMXz$I;?JvH7*8zv6XcG=^j?W3a|G~s5nYizWG1mj5i2vp$^fJnRJz%?s&XL+A`
zW43p0ta)j&IjCO@sK@;(&~PfOo(A~Bx*0H$Q9%;ko10xPG(ADl!p;NAr!KaUbuQ@+%eFbIrFv&+E{M%}v)^T5fc9G-66=TL!NH^H}I{n^){%~=k_rcwz0p-SsTQv&-D7kmD-h-U)Fyq`w
zI<`gUmS|t6?AXA+E9Ke(5bK$@Z-9xQVeYjr-Ag7yXvAF9ok@l>U_{a@axQt{fJc^%
z{!Ge~Nkcr+uKM{*_%pvtJH;NWjv^5zli@u+J1_@L2kMdGJvu&8DPVeHu>e?kcnosE
zl+*H0pBqJaJl#m2eFiE0CS!Jy}_^WU}^t(hM9E*CqZsH>=_?>Pe6ZQs!u6W!R
zk9+yJUrIy@nRqGBWu)}GJ$d$6Od^(U2JiLfIv$v25Ei?U9fn}#q%*|z|-I87Ucky@PW
z0TyQ`yQe3*rYG8`M_Q)F+DAv)Muyua$3Vu8i4nOQk#Ac!1NqC)ud9*+5r#+|!^fx`*!$;AJc
zz5fi7WJ}ZYzzelYTU%ROBME>Q(S22^R3)-xYAs76eL#USK41`*ZP~
z+4YGVlea#2aQnl1w?7;oeIJeW`J4OCrtb}X>EYOwhhrb#8vWqL)nAGnZJ6wdQaXmF
zzIN?bu2Q^zmDJ*|eEiXuJ_<@Upz-Mbh#1>GH&VT7xEy^se1$FunE2)EAOF(i-5X0&
zH}8yn2sH|S4Q)6&{K53yYqzfc^32`q>$Agb;<=RD;nUljQ$w%T9!`vXDZahLhF47p
z!}2Qt9eU8tJu@;-ob2-^vkNhZfKvtml@xy27gAyapd9SQ_&Q>6i{5_IB>3gLZIm6O
zVyMAVoEAeLLh3#*S~^@30v8nEseQ_yW!g;@PfVs_w6tD0lFFoOj;L!{(<0^c??;N#~zPqwz9
z?w*kh1P8aF2Oqz93A{ZCV)NNEh(YXW;3W`@&t8CxFCRa9@qBA*>*cHGFLr1g1`j=d
z&Qub3)4g4&(q|PmD-#W~7CF8GK!cAf75)=xHie;;RW;97Q!>f1U;=L?E%NVHF}r`}
z^Z~we@AXCP;-c2=+U>U4?^+kZOqEa0jW_3drzO0;Fg^{`;-`HL@w%&@x79a21IqD}
zK7gp>N?dT(mT3v;pwPchtL#@T5L_+#Ht!jnp_BwJ2k9qNa~zWuDn(UfOF6I)@|F>~
zQl*qB7Zb49OfkW;g+eyYSF<9Q$)--TnRv07Efg~Vq9QVqSXAV)rg5ezBV1QRf;w;LP=y)G%xMbPn$i{OX8?cezI-}wGFe(!sq{@p+L;g3GApV#G9
zo%21xv>4YcIR=6{qgPXu5WEEKYhCR$AJFRcFvXJ(u1!x|n|gF@cH+j|qoL(TBa07jEKXcoo4i^K%~vDv!qY$@g7hG4
zGW8zLRzq__XdVryMc8Ku#^7)PWUL&_Akcto1}g{m=(u+5ifz
z!c*Gkp979=?x{!Jix5+w=PNMufA~lL@bCOzeqT&%Mz-fCZ@r&CdBP^1rFWMfjDEB<
zF`PNxe6o1&_Q;n<0ldUf!d(-he{*N9qZJdDM&eq!|j;GNFPc_|8{T
zK}{#9g91JP4lObXGL{BQkAM4{U&*H9vQ!9iq@ffc|F%Fn*H>kUd9|}m!@e}kvA4DJ
z>ec@C*6vOydaUb}{X-gw-rGNZ{sM%2wY9VV_{Glp%Pmb@OOMQDR5~?$cp^GKEL9BeG5jJ
zz4LP)aduXNgYNZQC`2IglQ%S3<;{iGs4;^Ux!
zzMFUL>~H+~SMe%L;rPYlnHNvz9zUHUEN;$iZq6ct1qP-zRwq`MAFM1tTwZy&I(K(%
z;r<$l#Ct3AkcW3xXUEr;?kvrXF3;awoE=+Uyg5HRvM@KgFgvm|H?}Y{x;QloIWzZg
zc;V6L+{2-n2REi4UY~z7Jog9?yuLUwv^Y7mG(ECBbz^h-+SrNyjoOB`!6@|4`2J`8#id~-N?uX
zqoW@Tk9}}+=u6f3PD4)lTr_jIIdbJM-5vYj-snd+ufKnD_(K@&<;fdd@|jrJyM6uN
zxpnQYjE{Wz-st<~#7j?z@2uXNAAdi(J)1sW-Cn+(+h5i)TWa#LmBr8h!puICqib4p
z%}zg66B|lm!%9D~(odbtOF6bK#nzR?Ca?$snt@0hz!8>NPCgmjqPO2njk?1PrEKbO
zJ^1F&qK)r)Rmui`^rWZoH*Khtt2`*79CS63iEH>Y09eSU5B7Ic>1ZYsJ32nt-QS6)
zLqXqSFso#j{516tQs3ZCA{Apxnf=3^r!Sv9d;UVx1;Z4czuY0iOZa=W`Fv~R=?ffg
zK8Nn3Ghp23pPyNdaB>_obvBibKY#IZdlzK998}qO`V4yT)yv&@EEEbIM8d~MN3Tv!
zj`#Loan-!7RvfipDud4_Svf_D!`#6pOF~-a>7y%&z#kEi6rz|HxD3=H$G+Pr^LgJv
z1d~;$+Rgcy8&m+Z2Pa?mUFby6@T{v{oSPTt`bA&+jK-JcUY(^ir`pn+zVQZUs6SCV
z@2Sli&Fbs5#j~ywEM97yb>+HWse4S#Ww~nFv8vQ$L4iiki=@Wf`7P*Ww44^
zvUJW=89b`P(rT<>2(}?uT2&SCwa0*c?WWdhs10Almz?jGX$1whVpF+87Ei>tBh6ek
z3qirxj4DAD;@c6_D`>QIHQaZQbr>vTEh`1YppBmj@2*M}Rf1;BLUCW-qc67i9!*ZJ
ztSraliB_x8tk=Kx`Bz|?fBeHA{_gMn){npUjo<$E#eejB-}r;y`P!!)rB$P9=7Y}c
znp19g70=E(M%Gr7hDLLV{_Y?Bt{KAnC1cxGc`YOr5lpWIxZc(VR*efi$T
z>iyNl@zurK>+^S37jCaC++3N*{?_9B*!se)_1Rl1lcOusV{0?F7N$q%riUO8!AJPz
zg~^fmhd1T`zUk3&{H0M1FHBrrn!3I^H@q@={qgkm!r`o#SfpW-qlxPABzrPZJ((0v
z=eh6#oH8H?CbFkCGz)CZRQ&5y_V6g}H=WqcmW_HAQf>4ERvo|J#kV`tkeeR31|+4Bp!9kuMCDJJO9oPKG|Ixn;-x3
z!Q+RyS)GCuaf+T5+V2Ul)g|K)q5AB&bp%gIeNaQO2nM42jpmML38%;N)~2Ve4t
zp!W)Y*|12Y1%fC7D7cb7VzfAcwP={dT^KCd^nwIzU`KwJ3@CCHttEc3AcQ&3v5^g_z
z`ts@1O}3hP{_4e($1itwj)I|>=a0cqvd>R9pFMfCvvqWQl%-W!V!Qjhhernz&rrIY
zRy38oMHwLl6)sQ9$$U=Yld=$(MXE%=ap_>7HVthUl&3}{VWmYrU1r{G#jaq@02BCw
zBz*JQd2<0EnrA)xH4u3oRLq7pd`&0}4z1Tg$=I`=d~rt0G1H>2T?HJxfLc5=AR+s0
zsa@yJJ957x(Spu>8&t)swHsomDK&kCP-s?x!n!ZRN>dlGL3I*o7NEtF+tnc|W!vCw
zgR6Ox=kTq%+N#O$;LWnf>fL(74ZCRyej95F1g
zrj`wjQD{OQ%ram{c{T`H$xCuhQgVu#muav*FH2=vEJ`8_^`9ybJ2^EuJ3G6wvU0G$
ze|C1(Xf{51eeuIz`@xTX^uxdU+rRPSU;FlNeeWCp?)N|akAC-?U+L?e8b7EH2B}zc
zn3`SmoLtSxI$GRTW4d^32&Wo<$Q5_e(Z~Bc3oo8dJ>Gb9)G-YCmnzGZ2j));w@ltb>Y_X{Mf?ma3=iN7NRfK?k-JVU!1jLH&@e>H&h~qiN=F68I|~(Y|s_`muO0$s9~x-lVtQ05~nRIe_3m9@<&b
ziGT=UG5yp`Y?|pOX8!qL%;8@K9?icHqpQr}EO7Im{QJNDAN}R(
z$zzr;ES#6aY($!2HbIC1FBGqLj%%ct#WKljI4;^bvd%mA1|xX4WLkoZ5XMi
z1jodt5LqSre7Y>g*C7%CME7wfs@BHomROHLy@Zr(%VLTo!789v-!Z1WZEWA3{gM@pv
z{c?A2H9-))q+)A9QK`uSPy;=+G@;a$9Tx;?Ac
zbNVpC7v7r-kWv4HO2bl>2kI{D+i!ZtMVHoJhCA+c
z@0o9U_C?PD7SDS|yTR97rri>nb)nw|Kw-}vUUItD*NhCQgF3O`q+y
zMLg@Gs}NOOwo&JOk8vzox4?5)%b>0jeC;`Al}3>96{r=12F+9nzBNlwe_&tm7g8b!
z%0(J85mU0166LI<;vNf7qm2KD=
zS4*jUNUxrl!lBCUDb;B4r9m5FE<{%e0(45d%kveb9MX)fVedNboI{j
z_3_Q6o6lG8yn6C*Wp;RNesq0d1hKX_vOYh&IY0DdaRmFdnd|E_*H>q*C3h#e=#mg#
z6i?^)$gFUJ!x`ap2H=w-GdvM+3Jozl&4nh|&{Xwwmc~*d3%FQ{OykPx5sfvIDm(!G
zrU{70)1||y!u}(mFu(T@k=uQc-wTRsy~_snnUrnw0u5>hume!A*KsDfN!@J}Pk>15
ze|lNXqmmduO(u>8hjme>VSO4<--49Fg7YmQBj}L$Ob|4<14Iv4)mTsRsn>~H8
zuzc^M&B<%A?YX0;55rrNnZpGx`B=+93_j75PoVe)Ax739@#MrhI2fRi^q?BuR3e))
zq+euB4zG)+D_nSG(1D2GLW->+xbQL;BW=i@Ecc&!4^8+S(7DL`{u#@OdUNTQDUwsAEf&lK8Aj
zVp8b&
zJFC69sJ(g9xVWfyI##o(o>5H)hcdL!p%$HfN4=mmnoU}%nKBcti=NqU>z#&nLCC`)
z_V!uFqD2U(ZaLR&DZQ=^4}R7)&bxNEsh@QWkgo0v^%?}Gao(Y2?9SUN+;`1k+YO0U
z$m!6?1WkkSXmP<2ja2XtkHx#*8&h}4H*bSNJ|q~)DQ(-%W7)YGSMzW
zUE-e`5LDz`V2x>hA!M~6f`D1bL%>mzN}`y@83A82)cH`7KtnMvihrse;*Fu9TjO^g
zJ$f`THMzLB2&t&5YOB?%*Bf8^+Sh*cBLMM7Amb0e^UdG*)~CPsYoGsnKm6Kf9kX2*
z2GwMNbI+qm6C$Tq~Kbe)%>q=%#NG?dpB_WPa-2y_0
z&hda?bViEJO5tffHZRAP#OR_NTacr3anBsdZfA3-e=Iz!Vq58228kM`*#7?c2F
z*wDhI4~4W$!%9CklaC=J(SW)3vd=+AfYOD2jIHgjj;%cSVCCV5D-S>3S-l&2HvMFN
zEc#-$aI}`%Tge`+F`>s|{ME{x54G&BTRAG7K3;uvolWjMUmlO`m9FA`N=r-E&Xn)TWwxEGE_|vpTw_gjaw(C_&+Jy;fR@P&!?a!)xN{vK(1e
za1EqlbQSiQ4bcopx-3kq6$aNYi;>`=(Brn)`>xd+A&pt{mpw)bL&zO&N@P!UYqo=_eQRs#w5YJPs9y{~n;O|er0@*xtbSF!1o8&0w57VCDlVPsr6
zY)i)mx34q1X5~OcRWLCt)5&q$F3x_=1?26XSD2d{#~_$ccG5F()VI#ps+EomFBBN_0_;
zW52A#@iAT$P8XyIVpcdM6OCYwCxW48f*_)NFgehJXhR_)0ys{kUf#_gJi5F|Z@t0x
z!u%QoVK^9y1qy+=_JR&sfi6M^+bo+3_uBJ
za-l`A$;vzfyo@Z-*2+U>J~Pu#HC!KE7o(fi@M`gJu6Qt0K3+f+4rX$DGlhdW7V<5&
zR)HA@q~dF8@-Za_X127akXa_kr8AzMUd-Qf&uiI?5;hH_zurUVDsXP
z`W9cGS;4r9>O1^-hs-Z5@TX@EoN})tHfz;RQzi}A10rb@1tvPkzhT==@gM&2|NX!C
zzx`*BhrKpsp0w+Fv!>L2397u|$*r0Kf!S-Sbw_CWB3>U~Nd1=H_Jwwx2PL5dYhKxN
z%dX9~>Pn-gSa!8m<6N5w(rX|O1xx4gPh;t2Q!7I)LPZ)hD4*4hqN=AwIjN|5O)JUN
znFvXkl?6Bk+kd5GKFuh!Pqu8$1gx^o*bK0bc$
z-o1&*iPhEB<`>(yzx{2}i9h_|umAXm-~RgN-~GlXKm6wFAAIBdD;KqHO~NncS!For
zI&`ALKq|JJQp?KK)OcNvxx%q4oY>p}!l>-3rER0UqZVJtr576WQYk#=i%;d^GcosA
zFFw`sn__WO%&qacRWZ8`L_!{_sdY8GrlgmZ^pc!f00))SA|Qx{1Ry5oB@i&aEF~5I
zN+|+`I0r1sktLu|jLdTpIBSSXc+v$Sn2z#Af8rc_G{qi&AsA1nS26I;lLX2@Ctlv9
zx8AHk9zqO~NDO9cPz1aK+6L4ED+fzLgNZ;M&Y*z+90zR>P)R-(qifJyz|8=fgV!O`
znphuPk2AP_a5#7)H1LA7Pi!gxW#%c^HyGKF6C1Fxcr|)%bXAKzCi#YltzBB(=qhxa
z6p)Ss)TkiPGISqKQimX6ZW&rn#RZ{d?sx%Y#Kl$EVetBkrz6lF>~Zl=IXl>2-lMnP
zWGSt}V5-n@Wl(^$m6%h+H1LN*{D}jR*avN*p2*V#RT^g$DWgK>^Qu7j!}&lnmQ*E!
z*OZ|#@%fPT#86xJJ!F=1>Zx
zmUWao?63{tNi}IG^8*yt<%|JGFQkKMvqW?J*fe&`r^poZQT#~sWAhMz3H&-$HUS6@
zz*l9Gl}ff;N;6EN%*3iyYC|ouReTLpiiIQ-^dw&1qqo}{O{?Ctx_z$$Af7q>b4tMh
z1fk~6y3Sb-3Xv+`ocFEsGqX{X`d$0tjDUF2GtT--zo)dCe5Wlz<(-pjreSED>~@r9
zorlT&<3IkdyB(^sF#sZ5^G|;A&+(N1{BQrqf8*c#P2XkFZnyAsrQy*qm+w$&RHsQ#
zY1AsX`0xDZ|M9PV_su`}fBaWC#L1dR7l3;B=NP0M!WYwwJsnE01hJ2A9XM!1t;lj&
zr_9Yl(2d9#DyvE*UCe3tlOQLNrSHNZm7O{b<-90o1nNnIn}&DJNq;)+W_NdgV|6W?
z&0V>A!1DF
z*Dt>NweEL5?|#y^TQ#1B#;r=t#J=2gfyH9Y%GAwNOHbA1geQh<{ty8xZ7_RAbx$t6
z(u>>RqgvWh3eVKybG7hHD?F1*Pv!ikmfuiv8)|M1p=8&z+=h}~RRKpJGPNotRw&{t
zV5OV@FMx?PDX}cY2P@6P+%1W*B{*vY8=9+}P%2_27;C2C=F>U$cp7FI5af=hx#Ovz
zw#^KCNGAtCL{v}Sc?kg;MG1fi_DS(oHQWhje2{Vit*r|G
zOKd^_RRGqYJ)qUV*rG82-(ZixPl7gcvVf-y+So%Xa-k*YM7$=L$i-HxP>#_r)FRaA
z$pQiw515Ds_LukQtv9l|Gyw~|OG7O}`pLiw2dL$EAytJc6mx+##CcqkQ{=!g@hMqI
zf;EZ=Cek!Ad>A0p0)Qsroh30TiE)XKL1|KU3p^Bvi5G{a5L3ZR5nhALwG3ru5Hx9#
zHd9GiG`ToyN(GDRN@Z0sC@Mw9Ev*Gr>8TnsO^3)*w;=E>W$_jifg=`a7I04Fa@9(l
zs{nRDVG;Oa*&NGW3d0J)F`R6d&O`j^l_@w?yjRyNCfAT-K>$qO{
zo4@~8|HfbcEvV^V`|hWI^hbY-=vfybs?hjv{=t9cxfMu7$Ewz$v>eVU$i1zu=)$|&guqZsPbq3?7uNKdV6nYJDo~hyZZ6f>o-Pk-Mn*m{LY;_ckkYPH1TM4b;EV6
zdcEFmw!Zzfum9GMe*A+UeD61Z@N3`x`d5GOjnBXL)w6GY()#A7&GWX|^aPI<(q?K<
zix$(cVV`r5icK@qG!u0t>hd9nJGLMd%R5SCTW9ys(169lE3NoaEo^C}7Yg%SEx%Ao
z&z0gcJ@-V(t_DEdl)*&s5$()|l7e7_(*#Pu0;ry4F}@@vVXl|KM-en6GA`kekHMA_
z9J%m395nVphW0#<#w94H2gAzPGe^_qU}$Ba5D}L*>8-ax*P%=K*#A-$l6*^%nnM5?
z19+i5Xdnn-g9vCS!U6|&6=yC17xd!&v;lL95YYhINT6LhRx+&t69)`p0WTV>S>+)5
zzF;2$r~=dmy!$Ej295IZ{1?chD{+X6aUP7r;ZLuGex&m!i|o;SV5R9|0dNdaK}qUQ
z3}SG8@Las?k>IIswc
zoFh=`^sNR5jfe1^1d&cfZUWhee-Zq%27f<)Di855{Q3XGpZjzF#-IQ5|NEo;-Gl8H
zFJCo`|j7?eCw-cU;DK4l}{RHZTx!h&RpFjEH>k*;F%|N_s`ht!vpQN*aEU9O6J>
z0fkb0QH(Eg(YZnHAs4~NoBT2#T|j%_nycY?A(*`e**#nLjj~n)(tR3H2gvU62+(p?jnrvfKvnN;XDFd!{MNThX(t>1%va0*Bk_1
z4Hx`W^wBHh{P6*EQEyTW!ztjbNIJ-|N-R&p}2+t=%>{U9;b(xqWZWZ3w_mF33CgI_7!b
zgk?VK>iv#!)-`(#t?f(QIu9UH^!0w%>b7+NwC2*%cg>pIroj^#?ij3W)@9h_J8;2{@qubYnep&%E#}2`TZ|{bmgOKH?ED`
z92*)NyM5>O%=C0FoiTOYbDU1A^|fz&{rlkJH^240?|$byU;F%So6N3Jf>eB|mR>1^=W6k#
zQh1@{pG(DO;G>c!AcBl?20HOE+I)IL%s%E)>q2%@NN*q{@Fl%TUNW&ErGXxRh6E#I
zcQj%L14i!*$PymR$rwh9LwdS@Uy`RB04PWmZg
zkYp1~Nk=7%S(Yy}Ogpw`3Kq0OS2nAdMNy#c@v7|_ORgzpaTV*p4aRVL4
z1=@|Lcfs3bL@pmx&xZ)bCyJyc)m#8H$$-OslLx0!Z|KutVhMt+roc6}lEoVZ$fHAs
zNr8rFz!8_rIFm)Y$|UgvRI15B3CP14Sm^>&N|#6{(z75H2YWoqlxX1P@*ch2)@a!P
zqFdAIb*I^M`!LQOO2PT$b)CkY&z*kP=rrMl?el)ndr0A(_bsTuGa6Gi&U!G;;(1SP
z)%i|K=(PBDlY@8!G`nrH)lix>$uY_;k89P0P7}`B=(IF25w^GH^U#KlRcW}iFiF#w
zIt{huDGg7q`!Zbc`B|;ui8YtUa~-qnyH!)q1B;f$IwnVX-4+M-1$~H&saH%5hl1+}
z!8|-FW231Rg_85prXdv4iL@YJNvAHzphO6zC}cztUuHoMMj-qV_!_&sM_+93UH<r4O6U;OCHzx=Cz`QQAdzxaQ?`m2BC&W(>}
z@85pBFd091kw4ujgmz2Oz0C1e>2x=Lx|=)Q$((F6iDNMrl?ri_O}j$ADKl+_>8MOy
z$T!4dLn_wAVoNDEmdwPdEFAqj%X9*%l>T
z6y)m5ups!Ebpu5e|h%JPb3`;J@p{JKdCS?a#;H5$#D=i9dKSZd9;S~aWJu-cy1
z^5v!{_G`lDE%6&|^{Wl_yrFe#YK>N{te8|tiqjR&P^*eUWtnxI*ECjD8BMDihJZ7w
z!l^2*VRfCMI*dw5QJ5g;DUysmBZ>ve$dQT?m6OVgK_<2$6=Z=9b+O=TnVMPb_-wCM
z?fR9LllRTMNqHf8!z^27)zr$ChSx6(LP-$IoKUKAMP6VfnPaO=v5?6Z(#29bbh?*F
zzFXBVRpt#tbbZCJc*l|IuG;kUmT%$~wHt=#imit1yF$0Ew;E!rrFA-Xr){>IdZQ+_
zXz^jb(-h7+TDPU1A=+}ksdVaUx21PmO1G`{Iy&~gQ)&BL)2Xyvu3MLSZ57YzQzoO>
zstcZ3Zh95``o59xcxsA$00uyUw?2)n=_)bD4%yZn!0?o@EtVew8Xdczo04
z>MrY;#fDEcAey+$W!gU5bjoeFT(fcwyI8YmU7cVJ38v;TKIQyX>o!NFtb=8m9kWog
zicLCSrq{O%u7!Q+@*V{n(eQhpxBr9R{l@2gy;~RB^b?euZmI1SLBp1nX&Omii~3sF
z*G_He*p`ny`N)$FU2)G5w_Rx$Ky>(*uJ9_@Z+YUDBRu!S7lcCQu~pmv2NB@l0E>EV
z)yS{u`4ywEg1uQ-)3U1~sFz+snCWFLu>dT}$ptaCpeB~3#FCU)mQ$+%4OapVf`H)T
z0w5^Gmxbt35W$4J=+c0RLTDZ+lp{+*oKmux&`fskA#*$pRtA|jbF^3rRlZrShCob^
zk?Ijt!%ISt`0{hm@ZbDD{U5J?{Qk|W9}T_#OCSBxzdiinuiPE}cxiI{;Q1P0SB@Q)
z!h7ZLZaKD}3%$yPwo1_*CcI~rlRA_1#e&c0z`M%;yrfcFE;a!>x!6_9*#E21qLanG
zR_Z7P3blm5Wj&3eqtH|OdIeXWo7JvX?rKa=XL?2j#O$J>gO#|9u524zU9I?XxuLSI
zShV=OuQ0Aqw1lEiOqP=2RA@hOvYQC)XQM|#A;o1AY&MYzA3j^1f401^`(z`2w6ikx
zV0&|IXY1*e4}SH}{+T~>iNJqlySzv5vVm_^p0gcSk`+Nzn2Nx1vSHU;ztO0-4a3lN
z({;Ui-2wYtTdz4*)3=*-y650?t??e%r&TqLH%w7cc}*8|
zUDP$vGGsbw2nZbNbOD%HMO#w>8mjaxVj^&0i
zYN%9suqibgLbqo$np(4oFBr)u8iIFnudDXEX0L7b+va&&?=|&KLv1$|I@7T_O}W#Q
z8eSC;Y&g|!P3zV5eiN(|0mLp<04vvh2H{)9HogoRe5*nD!?O^rI^O^#X^pT-!!7z&
zp=Oureg*Wz#Vxnebg9xH9`!w@>9g$`3t}RgZn@!&^S94i}V}h+!
zTg$mRUXbzaif@-2cDZI2Jfl!2ZdO3>%X<`T?|tL5?sq?{|Nd`(?URl|G<4Xu!?c`I
z8v!QT*_M@VnlVQ?^3;$c9Xs-otsJ`Qp-+-<+mm+z#D=`vlwQ^N7d7F9E08vHxMv>w
z3@C&i97sZt5qqFe&8!d&bE^pGM1W6819po+gMetHmZbQc6q{3tg8-jhc@+ueKD@6B8@%?=0RW-U_
zJlU4BVXvC;*;I|oG=$th;x)y5ozJ4tkn(jg2Mz`hBmvk~$|L~QQbWd-`L>*IDYWk?
zg}zEyM6_kPKDfBpR!Sfs@lhit0)O3rgFP@&V{i?KiSuVhwWn442H!HO6dKzxxQ4=j
z#WiSBg;Zos0Vo-SkdK!VC-I~0T=Xy*+UE-?J`jp^=Iej+1rAYkGbY1T-w*&uz8+dd>4J%W?D?
zeZ2KnO=;KoPM!T)SN(cNf74XEHObN$RpSY8s;H}ys#4)=Rp(7ZHgpM!N!O(>^dPUR
z0&s>yO{+j25&>20aR?xyO^2W!t-m1yd=*GSiL_x^qUGO;B9+yviUKPLq!VT6L9xxiZ72^O>T7znr8yWwGE)K
zUK5*jsacmhkct5fyB($1G0woghTd&j?G~=rx@`kN6&b92ugOEQb?Ok3a<8fNYw~$R
z?Shg%>q3Z;7At^g-MZYPRBfr%;M#SeRTrB+2fc>p0(>5!ssvStD_aCUh%-`xjasGV
zL-duY?t@eGLBrsD3rf(Tg_wO8h-B(E+i*C~EV)J=5OlSIZxo1z7Spg8OUZ$`KyA&g
zcoyf=dU-UP@Tc2*-}}7xJKwqZ(KlLsQmsPUV*}8_DHmH_scC1LR>D(HT_xmdv^V7g
zTRw1Misfxz*>mMxN7}7PdvyUcd|4M>HiRvkduo(7Z3x5iW?+!XBZG{9;DCdd`!8rn
z!Z1Yz8ZOD01Oyk=o-Ry8
z_nzj$JH_}un?BA*NeQM;wlXI##l(r0jnud-@aGZ)0lr*QBpL#Obv^?c5()*JBpL#I
zO)*O$r5j?p6|gUON)}=eC~V5Pwv_A2`L>vC$eEU$8$6eQC>PQ0C?&iO;MfE@)dKcF
zA&80dkc4Lj3#oW!3VldLIBTWUQ`xRU(bHIxmRhwVSI}1g}K=ECgO`pTp6+yA>i3kUsYF7MI1Y!HUo
zB2(cNw+0T@b=`L0jcb0r>Di8MTbl10b>D8)WEieb+wwQN`nS&Pvzp>tRZFd?2CFK(
z0>DA;84|Him%u*V01d%7fREGEffy7okw=cW3git)M;DM~uAo6;5Ma7A$R(0~#I=Gb
z7pRDy1i%$!9Ez~a@VU95xE>YVgXb0KGOD{rKAPM#o?98z;{z^nnJAQat{{meO^kMo
z-0K>D0lDN9bt$LPgbJ$vY`}~Qw6-VD7c0!W%}ddZs_TlrE7m9zTdVt0-4|L7&2{BQ
zL$B4;Mnh{-*0k2{7@ZE0uHj29Uu=>9)H^M`*VU+)4efP^ZV1CZkk^*_9Xw0*-EzCm
zw0!KV?FQFv$=#;W2M`-tx31WF5x&)POP*cq_(B_BT6M6P>g7Nc`Zg83X}WN=6)+3p
zu~UZ~u5@vw$2C0`plte}Ap=R+@+%O4AX>wRNCXYbb*eW=>$kx3+C~sX}MeAWX25TE-&tNX^QLw%Dz0cZz_*-B9`h{`U6wewG@C-3o
zw+l_T&~&o@@W1(cO*=s-R6@RVQWs8Y!jT7^DDC<3PE9%R5%OM5*lCE{0HV)rK_Ob)
zQ>*$^V>WH}DNtya$R@)PU(ztYq6H{KfQbV=7@&|EQgTs>Lz+>s28cd2LG54$9t>>I
z14s~D3Thl6RstXrG$9g$^JvptX5bIL7<)DZF-TMNum=qhmvcD+OSw$UVPkb%
zU%d>sl5|ROXitwzm|WDY#(X@=XYdfn3t|qq*#vOqLg1Y%14<6|;A7vUUdWEh_H_=d
z4A5C^8cf4r>T(&f5uUoHuzWt5jvmF2cT=Z(sqjH59hEADY~2e}35xk(o@@@d
z1ktb$x*AJC&m)5dXvk9$vx3AGWG>_DnTuNK0xC%_=u%Rn;)z8=D^iUX{$H7MqZSb++B)V1&C3u18Z=L;@(pV_kt=t=rIdBpZP<
z{F6Z&B04p$)8u`JZTO;Rb9E2xDuC6g3FM$_Ld)S{kbScZKU?=%Dk)YM8gR{lW^6gt
zwpSe}%7#lW+cxqZd11T=YnesYVqCpcw}7&W2NrwSvkjYTI0BUiHp}?IY=iNG)yICi
zz4!f3TYvMnzW(`{e%_Ms2F)*wG=yQx$^Yah|Ey&v8b-`hLXLa_kyz70(1tbj(35st
zdCv~UPki#oF9F0F{|arZ`UF7KO6!n^Fvwn=przOGhfh_hzzg@e#v5YPIHq
zhM-uv1#j9Q8iIN)7v!Rqn!v%jUv1Q>^AR?=Ng@%T6q=B_R;A&TVV2>Vp$!33TKH5i
z(t>wZ5ghc*B8UlA(sEB!KcV6oLGdkzamhh5rt-5+`FFl`_Sb&>^Ve+!PPtp7$C@_t
z!*8GcxBtz5-Lf-(^tb=u*S=Y=8#IbC@XMYGop|Ib)NfeR4{hNUbRrEX2g1>jK)udFJKqY
zkcu0MLBHVuh6_J_4j?j3jdjJmFBj`7>%#G6;)%moLOH{vVoW;9
z<&&AygIDW6k2dVI>&>R)I*RA%IE1GI2Y>GeU;FWE4Tofh4MEXqNQ4LoFKj8;1AGd(
zUC2E^kV1jmC9Nmerby!nmSh<++QdGy>cBeLyyx&fl~mzfTLd_4Ted90vN#)-%Hr@W
z%i?WX5g)8X;0%kffJ?1PQW0=8Sin(7=oM3~n3|+3RZV78IBS`asWNjxrn);+r=I7r
zFG4W#d^VtA5l)%v-#{Bu8Rx+W3{~ah_&iGnIi*$;XKvv$zu2{4!{4newrO#s3TsZg
zZvD;Q|LfoX{x|D28|Q1j*s9abY&7h4%jtKVHY{^pX*Pn=tt|r*@2q11f1RdScS`Mg
zrPqPQ=AjV#U4&4tRT{NQ(`Vs!+fAk00YjyLhBS)hSb2C`s^sGG-MZLo3Z0rn)eP!{
zJnZW>3ub|6z!o@LuR$t;ebikD6vE-c7q>t|$iNy`^YJJx$pW=VtI?a)n#VbM*0&0m
z!_Y=p9ExCknTAuyS-Xs>Wj(uq%W#cn6desTgunh7mHpmd|G}Hz{$}^nuHNza
zmdg&#{@`2v0S*7)Z~XB0|JwH(X3SMXzIsa9P(5|z15Z7wsRy3CA9Nt@Ibb6Hvc|sz
z4Ndk5LSr_}@+N3#l-3beaRaIll2FJmiP$r5=9irB7wlW&
zFS`f{h
z25#VaD^P#1u?e#nHbE#N8nFza7LK&SF_@?oPe4GebbR?J!7i*8&^T4gA(a6lkM-gS
z3C7|nF*IN$DM7lDmTp>}%u8}X6pDgaAZ|ie;!jIUeAarmQ54$%M6^Z?
z!qE7KfBX;H4aawNIAsXKR^9v;KlusHblMi2a;Gje{A#BqH5+2TV_bBte%tJ|p%$Ub
zD$sx(nB_LP=59;qb;O2O?6mm6#;R@TK`Q8=c8P|PW0ruzwpVGo44iMTA$Do61SPW7
zrY|*XAg0*#IM>L*L^tbIXiuUcT&-24K0%K}U&~|aLDGy1edjSg^*@4Q)tVz1S}-(h
zmmvUcHCMCBo{1+i)K_SNm{_wZI_TAUc
zMN5H{g_8V}fBHYSobn(3{%`(6(9p^L-M{?@buHZ1V|DqoA)nTzP+dInl_LPrk#=2a
zoAM3CU02w4t1tX2^%&aKr$%|hs65t78+K{aDs7s~CYj>wvXWU6(hFi{QO-i~Em0%@
zLF^aA1PM1Gx-1X60)xSj0nyL^-9SAqw!lT_`55UwF%n3^_%dM;D8#ekOQoYnmC#)E
z6c=1VaPSJiC=;v-03Z@8zp&3xg`nX;7{V;$P>#?#A!=+*es>zyVR*%iFQl7tt|@1J
z?eoqb|NZ}>E++nmfArshiTz-K*9Mnx*|5h%oYJWUrB;N!4IBB8Sqzzg9b_8OkQg^$
zAEB^#qT~;?66`Q2iIdcnig|3(=TrFY8e+Bu@2r8NTq_eBggQgL5AQ}~tgeLZogp6&{y1>At>r$GY=SmKZ>OgN+O@r(+*oSA~
z2QaAz6Ak=G6-6m4N=c()w1|R2YXMWuF^QO%;V9BX!)h^5i&>s8;7pYYg+U}%1c4TT
z!=4jTEKiI2zWwG}TEjOQ4a@VCKlqz}9Z_?GV${CeZW?HSlKrmT=_n1q(rs`MZhcU%
zDW0{pv#!~y^H6!cE;y(SIs|)d4ambk4SZ{>!NT5lVXIqGw<8B>hPc&b*DiMIRnN%u
zntV6##X%wttrkFaz+AEJaxGu1+odLuN4gKHkop86@hH{Cqof=fIiW#a^2m4;d!IyK
z3G&d@OAUu}^L*&PZG$9WiJqOg1cXo=Nl?NPy
zJ9N3d_cwn0**E&ec@yO3;J`scoc+Up|2O{y^%!P;@{|9ip+_2WxGshoO1L3KYT~gg
zAHpfS>b@`Ucwi#G4H|mfw##mr+!M3<1gcPHHuOPXVSZKlsV~khLl{cw1(mEZ5m1QF
zl37m9Lm`Us1wJ+>(4Iy-NV^4@gI|zqP`wq61yYOQ1(_g7In{$b6PkhOt43yFa=9=u
z6fuA)^dRvx(1|~NWxU#efQUg#4OQQYuYrbAc=_kZuxUx@wvuT|>6)1I_}F(pZ~oE$
z^$&6W5C7_q8`XHT8vV&X`(J!E>@bIR>A=h%oB0#F5Ozu+W5foJvLU+|w&0FSM`{uH
zI|AKE8y1e`+@W3ykXN9?0V_%L6~n-m0@xLgaJ^ne;}Cnj3;~EZfy{(=4mu41zCk;r
z<^f93@DMLZfp;mKsHGDbl*Fr*!ZNVSMpW|Jfd|LC6kyE51{1@hPBrOp@w$|)3z-(B
z@|3!I87K^NB6DU``#RT@$`oRut+92rT28!Mw(wxPsL8+ix%zuwH(;7zhX*Hh9e|Vn
z@jw1YgI+>}rtuJ8#6cQD5p;uxgQhT9+vcDF5w=A#5G)8Jq2{>;3^;&jJF@EueqFBB
zbv$Z0aKwT}DTHM~EO9(^9LrXV`BH+ZWSL5?%%nlJ88$JL-K8#Sfo
z%dR8%fy@j{w+sOrWa`jJw5pa=h{T|FX^^QCEaWoCE2KeZ>QdzSav%($7D+I&)ohgm
z77NvC9?n{#Y?~ZkeYY{?dd+Oqjb`1fH}z&Peu9&vd+Jo0@L&AopF;*x26cxPl7}ho
zHl?$+bkUX1dL#qECSa)D;t7IHgDwv8u3LV!-Q=2n1-$FE;FP&OEjlUzeAI2{GrnDD
zdgWG~fsh0uDRnU@{u#C
z4HH+P87(72YraGDnMGSKcyQc)6`-`OeBh3GD0#)sfoKae#hlsIou1o`po8@smz8_UQ>&gBgk5QMb2EBVqzl5m|f8_t3rIS
z3}c&I5z-rSYE4aVHA{x}l_6YQ`7iH6dPO<9<2(NB`-6U>8rUGNjhNRXnnbVBd*VI3WTSNGF>4
zkdZ$z^696VA=#}W`p`(w~h0!HzaQsBM=n1YOYC8AWqLheWgaG9`OiBY~J
zjK55|JA)iXSmu6^$1^wt5IrtmSAHhP^)0t=e=65#=}7Pn>JM5^p!7h4`$zxy9|cK*
zqN2hVvq8EH3n8ZC0*idHYr&>TmQgh=!Ez+WQz;{d1fcA?DjD#aTCZ!3hK)em@t`*=
zvRbKB^67NERLq`+_am`TBpj)fnQ%CC8aYg)qQ{|qUMwaOr{U93ID8z5oJ7JWi9|SG
zNbo`#>d(?y+vHrEXjt>4x(DT`cn++$>XoW+bYD-d*Lg&{B}4c1I?|xtbuiY!(yS8bKAMiALHz-d5Mq=>?Xx8P8dWID{vg-7
zB@+sra<>klSAn=2lthFuY}ILI3k3dR((pb7NPR+?hXx=kpIQo;f(Ksapjs%tMTE_#2fLH26qq@bmlWAJ}fFQ$Pa_AQ;ea(ALY~;~v@r8iIFUG){sB
z9hwZZTL?4+3b98Umj#UzlZgZ)En&P4sEW5X%5d3-Kw;3~7~mD}SUM8(*q`vZ1DQ1A
zv6MZy>|~^&n2^SV6!uiFgp~@~P?2!irxt_XG3j&38lNJaNb->B>7|}lI){Cx`7q_C
z@NO9)gH2U<1JpA_KoD*hu+w#%sgev-C|O#gab#9EITIEYxG@CN1`Sz@`T=FzmP|0w
z5iR&BUvYiWBPf{lx&b=)HO2NMsw}Tn^M!aS9gW70V(|o56%>tO%EeqhDJz;HE5$;-
z)iiR2Xd)F+wW?bailtO08!4AFiDZPW6bkutJQhx;qUB;-l=7y@1vI4aU3@IzxM_UG
zajULZbsWwyIXHK6{gk#{pmdx;=C&MU;lMk~RLfQtDU$}?xysRE0NkKFZIwn{s#O}1
zd;6_c(}Q2!Y_~1HCX+gYv29+uUC^-85nFA^^En?>s!RQ@*6+!*>U>vi_*^hEPlPa}
z^Iffr>svzIErWyYI@fDRJ(__h3}}cKbj&=&9bnR_@icNm<0?8-AslzJMsr1)HL2-A
z2IjhTp<4%+#Wv3PT+Obu>H^?95Qa1}&*fXL(C{SJL|bb35@aBLB!G-^7|AjRQ}NKY
ziqyAAKDuHl#hOLEhc&BgYB|?tf~N#zH1HH2*U+-1G~)cTGxL7%S^WZL-sk=$4gFHb
zD|VfH+s-u1%hBYf7WL&LSE6J?MFdv3E&P4_JU7bk}oW`>uiN0z5X
zm!^i+=0@iq-B_fhBQv=Hw{2}d57M5Yl|ra2w1PiYSpO6
zggxdIOdO!lt$>Chiwzl-L+s7ciJ1oqj|{kAKnL#i3n~S$yX0MfJWvvrnaDT*+~DK@
zdDw%A79fQetb|PV6m6p%K(KNe>_dY=YJktg_2m=1wH3H&h{`}S9@1g{5F%7AAIha8
zsdyyg?eh4kf;aubZp(!e1@e$N1r32kg@sfMsZ2uk<)})3})1shD?2eG>9RfLDNet!L*1q0FZ4f5M`dH
z)oU6ApkJ374T3_mX?ZTL>mm
z-lMnM8dUq*ZZ?c|Q+KRtqX9=RQR+-f>$H@!u0jbk4W(HZ>!4d(>2=hzV5vON4H~N7
zk%D0prPm_C*z1TvY9TGMOo=EBwcj?oEt<{@_IXyp(lfyf6Q$QsdrgVvG6zcqG;4gr
zht(~Ck~G)Ysq~u)&NsX&(aIubfrc$gMdVsOO-*ULfFRd!g}M)UDA+osA41vrHldIv
zs8DVVr5rXKGSoOp^N}I?G@8?5t9e?riH4OK&ned25*n_>Iy!_rv|-+}e&&1Sy>Fgb
z=S{g+7s;R7mA23Jo7J|LM|A9L(}*?9SY3A%gN87Wjvtx)S%Xjyl&!ADs?yGEg
zb^6xg)adNg$n5m+{LJwD)acCQ4aDs9(CpOE()6vhxtp5{KxU6&nkb#oqg3E^k(pfCz-myVvPV~Y)RGto(O>z?SJhCb@
zqGFUm!-&O%As($t$Y!AvPgVK>NIc@b2*H8s9MD!{PNV`}-{n1eyRF?YeFwa=TMet`%Z*@S
za;HU;OoCiOz1KEioa?R##YAgDb+t1(iOZ@ruiS0JCM!5Rr-h>Ac9Tx_yZDWGV6NA;
z@FJbI+HFI1vNf;RYE*ou6bzdHh2*RV;N)Q3&h
zvNTP_$y;j1w~D5m^-Y@e;u=|9`I+yP_r8YPQKP(T2*b9=c08t2D|bAah|)rs@tPj4
zYvHZl=Grm78&d|--u7XQis1li{n_uQyHH_CwErd&V(i?6ari@Q(muPlr%&Orm-
zTAdqPUj)>~R%UOm&ECq#Ukas@&4pXX+e^vgCu@^8SEk42XGZ2`hUcb7=O%}Vj1!|X
z6C-m|V+)XtQzJ{$H|HK*UwU-oXlwrI{7~U^jf<}552k4qjv#rk8e8E9i-*LPga~{w
zEsYYSVbe((t)|sT)&^oQ;2u}Peu~n!=S~NWbkw{3z(=YGPTW>JMH5L&80sRVs
z8qkU0pj{2Spke96A&-1uRv`fQ&Em0LI>ea)4He+5v?u3x06PkBFu!Nv;u3gwO4I}L
zs;4Fk-AA|-vwK2jhfi-;)7zEAR`zh62|q1|p6BCR>60gw@K$DjqZE2xiM*;rx2lO(
za_&&d?t_dr7cnX%Cj)g!(sCe0111s~gP@*DIgkCZQUG2LfkGOmhK9|Pcod3&3pNEFJA%TXH!cqPpO$8BPY)xCBOle90gdUVl
zOVLdMG=vg#J=yU@gy%`M8c-*NOQm8e
zorkn^lPH&xx{^;OPvh|zI0#T;Un!;F
zE7?lQ)`eIs6pNn5qQ{Zb{e12O==8m6-DjJD52b{@y3(qvH0t8XzN46?sHADKO73y`Z-7+a5rls~e
zv@#U1SaZmbc3Wz{1L~RmwgElZtXDd%YOgJ}8&Yr{kIK}I*rGZMG~UwIdL6yrh6WV7
zEdh|K`=y#!YSw6g1((57e;QmuKLb$Cf4lyU|&wLeP+aI6O0TV{Q^OyfHg5GBY(aJ2^Bx
z0kt@^G&vGFTwa>Fxi)`$;nCHD&GE$UWGOtygy#7WjPtw@Sty^*F_9%E=qRMRUQx=g
z9%w*tbAUn`IiV5f6<`#HRU#(Pxgf{ZKvgkV&F=CJz4bOAAbM9Xyri=c+x$ixNBAp4d%co?*o)};lM5*4Wt}=u9Vvs
zGkf{aX8K^Y9DkKPeVRVr%!i+!yjobB7{+0EXYt_4B%9oJxL6tIpH7`Vn~pqR$R7ff
zFT&dk>4S|zXj94U0e=vf2uR34Zyu{4Bf)XN#CG6E(V_PI>gh?#w05l?aO4I!j1@6o$#Kp}<3gN8bd5vzd`Bu5-HWbhF*
zG^vY_QV2b8(3iZLOf_tpdb>@Z^I$54+Nev4oX=*W;m~P35s${A09Y&$!=~#RK$lEq
zQjmwaSU#7^WU`qwRACB;OyGa%RKUkL0zgb8W7$ly=}GxK&R`?Sn9C(=4Onal$XG0X
znoP#vtTUN}BywD}n9IbosZ-m`!mKrFY`q2n#lrf*J_C!`*FB}~NwCtE!RTrM_%mqw
z;GhyjPUI;)Ta?Nomk(At%|Rz#-lMnMAVnJut<^H1nu8h*TBq&xI(DE917+8uw3u#F
zKkJ(P4hh5a9%u+R&2`&6S?NG94#rQKaI!6$G(tUzZSkxvoq=~P5g@a)6og^J1Lgon
zzT2)sLiQjJadC@E1@;QWoRuqn2Eq3wzt4?y_?-KqzBM%gku0-3+
zTS@{%b|??=XGc*!ZyST@$q}|Bsz~ScV
zJ&lX%AkfU{;_S%c^e9j`M>ctAZfa;|;`+?Q@Z8ks^rIV~;mqXlG%WMfFdDNIfaCS)
ziL3LEZp=QqT8uw`u{d)4_*V7^@{qa|nd4a|yjTd&mt%`uG)OHB7A6h`Mu>L-2N5*t
z@&y)`MOwXcQA(0jl!IPHJmvBZz4hk8BLjStP#uLB1pWe@cnU-Ys_<~21fBAMRopYn
z`&xO=0O<~ZMnZ0=}7EkTEwkUH(&rbum-6_L(G1aSmbl02kkP|ZXf|j
z<0QVr)?ALpmtDc9?m`+W@f?Um8cwl|yrE`k=1Hw;8#!HxyH3ur(p1kz%LewmY^xcl
zLeh+S*3@X-`pbJ1Z1274XwZfvQz34Brq`&n>kPDE&&xIK1dS=HVT3P->T=kV4-H}0
z;`el6$Ed#4*%t=;%;L9PaVK#!^LXiIDY3=o_m^fz)>m$?F5OyLytOzB6pk;>-Xt<&
zKYwd;{T`R!LoCnUT$s5zKaHUNLAYb6znO{A*+(O@lcRIf*bjq=kcV^zu6c57=Ftd5
z;=<&}{KU}Q#Py}gp-O5?D{ik(Tq#D@N=FN%{*ERq;YDU(mIu6xt>6$R*@0^gx&;U0
z(Ue=0SQjWgd$x2mGw6lHHDKuF9eV4{tws>kZ^**Wo;sBfQ0P@oeD=tz0EPQ5b8Ho<
z0W88V>kJ_e+<`$x!>k=;ZiTnzLoeqSC$3H3{iu+5(Q_*ut5`UBmJK~=>p38=5PIITN^1G!`O^J+
z!yinJUw^jzpptl1K7GnXo|jIaR8lV?46SO|6JmBX1RHKt4z%K~nn!?x)NvUYXR^}4
zNH@VzriW;NMJ^r)2mldMF@Jy`?9xOBU6xvr(jleH{^dP-m(4W!V4{d-=%N7{(tKo?
zWf3&AY}KL8K^Q>O_l#zfs*`rw)DcEQrELVM!g{SLR5Qg~Qq%cDJ}dDsR_rGimMB$a
zRmkR2@pzJoJE&y>T{ca!FqT#gA-PP^6+Nmo=G*#}6c-;5!_oQ@buV!Js-<^C(Rum^D%K+_LYo
zP>8`2!;EPZ6tyU;1x+hRa!C}*@XI_~kob4YumJ?yZG2$}wYqFs97JNLV?YUlhG$*7
z-?dr|xdnuEWq|MEOzn3?ppa&pw9pWHJrNQQ$a~#WAOO#y85{grOX;`3LHWF^oOR@O
zy#g9`8!)*n4KcT%79l68U-GP@pS6UVoozMBttLfET3o?#@ck@t%6Jzr;VBaWUH#ap#?3);!M`Ln$W@2di
z(eT^^Jv2Qrg7);o;pqtwa|jJ6$GL|?M=uw`I}7VGV~-batvtHUgqE0-`6?~!JI50c
zX<(!hS}4Oi$CoRyWnd0`9MF)avc#8*p~=eWG|gI}8G-9SA!*6jJ5Q~pVG0&OK(W{p
zn>qH`kXH%Ss)r5(m3IIdI_2YlhI>FBw4qksG1+~yvad7H+IudGYxZsS$gUhZ)nlcw
z%|xGvUo0L!n@yiS-kcxHhBma~aVhp9d9-enPeHnJ6KHZa$1bOFon3r#*VjE
zDw+MJoH2?g>4P;#OjYwocSpW_@?yD^IG7&)2pF}>r!^s7IDIVS_oUn&pWapqhmf@R
z`Jq+e)=lU{$koz;Sq1_3bOvpJdobRDGvN4vLXvP_W(b8e_EMq|7_me_*^31-*OcB^
zJi5F`@3PU*uqio~W|)#@aGJr}j%L}K>l%(@dcIz7nC-UPY1-|k8RWq!y*6bLpLMY}
z+AYo2cvX;G+ho{6A(!j5jAld3WmDnP2*;OTY$MUgdB0Y3MbIys&1bWPY!!=L~)uz;_R|7i?RVep6(s^H@e8ZM-
z){$@$g7Km&)69@23olGvfgQO|HNMD1_j^*^FXPdEgDUL8IKS@6gv++sYiU7mAnWL<
zPP6Pgg>D-zo9lO!v$jl=_8>Mpcs1&m4C-KWRNsLr@Iw+-n+^@*G&aZ89zj)!FOtv^Jev|R_VEgzMpHDG0@PJPduPdI=1-(o!?ceFEw^c<92jr
zTP?p3O3w?a$NMj**H`YWF5b>2UW#mJe|LF)VSI7n?$Yd?#o6(txjXZ-H|OVWF3#Vc
zn*tf{%uU^#MH}jGY82XVVQyq$W{hYU01*G&FybY
zSf!9#i61DE+Qq0hb4WDn-5mdjR
z=~FUYlg3pz+bWv|74Nc)GDuER(Sm*EbPYhHq7Pv4(a`|4*Ig60^rEN0Y@W4gjrpKt1E2|QsDYA@
zgfO8Hj}5Ng~d-4J>Wh)tdf9r~3n75EBht==O%A1
zOpVP<49`x0iMOzyc{DoxaAay?c@$Y5X(oiLTr_duW*UWH0*&#rfx*a$a&}N
zYs&1SbiWh3dTdu91CQMDk;5L_)dR54DZ?p4_w75?1AxY3aQMn$cHHuwTZTv8b*g(V
zcZh2s#0=(;ProdLH`AdfuO81VOx(;zUuxB3Ch_Xv`P9j?xs8bt*x^cSZ}Gv9QabH8
z<@nL&!ov~0ns~7}b7%C!^vR2JtNfYA+G66)$onHBAKx6kHh=Ht-sar1)dv<6?P!H+
zdPibTW*=Oey>~r(@`6q6z>jn3Z7>eM3w{fex-VgzAq4xZMI3vm
zOEJ5PJsdPC&D=hv<79Eck(@gaGkcf!=v_9$0taP-OtJ3!G;_{%g?a;~&u#~fxYg2{
zExpy!p$FfbJ8#a7i@tWzv%4)-Q<;1|C8=T}8H+|wBax6Ol)6nNpO3|2AYnWfizkxN
zcrr$$%aQs6`*OK-E}Pagq1!ZakZ}PL^Z86JpUfB1xqLbUb(qJQTqX-3#xvQU(hwdx
zSuCbyfq`aBCTYkem5!uSv2-e$NksZ>)v?n&haU#o5JELvDMf7^pYWjgGigJv?h6f1
zz`o{D_^x1^tf7@*=x7GC4yl-RowBMGW%=Fu4ckp47+G@abq(Jl?S|HE8RuPxM08uC
zk>9q^?F#*#1{wxRkUT7`>qSRBZ&RGLr9L;iryddU14mHpmDONPE}`k)~PZP;(ZDHl2(+2p1juNe_n51G=DCG4C0
zJ|v;R?^@EnDedNB>(5s2y;y&EyuV~?>5Y}~)x|r@3%6J1?=H=c&&>t+Tf8?5VHlv0
zm^gQb_OrKvJhIO-x91@eC*g~40)=SIk~|!pnH-%Yn>-2>f`g#p^n(#JaQ@OP4^W7B
zbZzRvb%;k`apu9$?1Ss`6O_oky?L)fBgKn_gJ}|pUksiAj-VkITPYvUNx{Ie5MBK#
z1o_AkPg4U|gIt_<)`pZ8LmWBO85$P`4ZX?{46g|dSlNT@
zjjhGI`IDzo@%UtWWqkOQ?f_R;w5E6Y>2s+mKx8Y{-0^SNC%v1L^O#E`?ETGf5Cx`*Eg
zK(vdyc5%lnL-8F#_Ci7$`MqG6e
z7Md}gfSnFH7NHsmh^aJQDgzoO)6p`MDiqVHfQ(7XNsPqer_or9$tT)%39^xA)4t77
z^%uVi8`v16;M4%b%c(4$!+VZk=~Yc7spwdYu4N28Z(8rB4V!h93QYKh=SiJ5brkkG
z=2_1{qYdg&odxPB?Ds&o%h8gvmIk?f-l1&7i@u4IjavD<&G(x81rbnw-PPXo45&+7
zT&LBSDh-h#{dM!8oncD!uI
zO*QRAO^;a0ktrVP+`cU!_AFu75O&$Z*0YTV&o(DER>zak7nS1C`qKTi#Rov)%KW|6
z#ru$i3kwv)K|pZsHuwk>&dl7N3pg0WonQzBlJMrt?LCjmwhM?i({o&~c!;|;OEKfhWhM0VCeG&ra!SLL}VJO78M?-6~qdTkPFPCo&
z>bWvUGvFQcAQvQQ1Ap+#qz8iv*Z?9P9n3$GA}exqRf()9?>>qGO-FPf3rxL%HnZ=P
z_dr9qV5_oAeS$0m;I38KcDP-K1s}J4ZqH|lk{)|#l@8e0i{$Q-Qao{=PEuz%r}Em3bL8sC*wuTt
zuN`l%#Sb6P-MdnVK2INSl;STuE@le=BA9+;Ru4_s{L+qB+OtbEK5o&V^PXEdbXiI%
z2mS^$lnT_)@-)&CsKo;*`}2&VxSov9u`+FC*6$jxFU*T`^Yyt2
zN%+ZY?Byt>$9-tkGokn1o;g#d@4AC$H
zwU$l~6geb(>tP&NZm|DO2;RbxOP8;hH^9
zq^b~(VB3OB>#IQ26m{)q=9B$zZq0_#YU+(TzDulb+v&DVaPX{agNd!6#8$seDK+P3
z>Y%$2D(}1lg=j)(pJCs(V2V4<>P455Y2ca%DEy>nyy+Vtl%-^$*Ib(PM%7y_9dayZ
zX&LMtyOY%rctNsO#xK+HSm@P$v)Y9ytrhEbDp)P=)KyL_{>0!Z*6i$U8fBguhgl~4O^(e^-y#%F0*j;5lcQ4;qtg?kbB}J#Ox~J*1mk?0S8
zfV@GEVIT>qf3QT=aY!&y_H~@nYlPUEM5{zCsj-F2JM`9DF!*pxqr>bjIpWH`3o!@_
zOozL6WrrHoU66L}KdUfkJy*tH6vVKsYjXY@;VZ(g}M
za%E)n!{MQiZw!BYyt`J-9UZ=y(<@Oiv!6ZMXsfxpoL+c1dTaQ@+oK=f8G7GjPQU7x
zKKF~!-L;V$?~jaqG<4(Rk)bOi!yj)f+_TC@0MS4$zn^(UgFPL&_AB7y=;+nqp)12<
z*M^5be01-|tMy4PxgFVCn!Nqxwb`-o-l|?bs*9)f>Zvar*QJnM+I7miR`CGJ*JqE7
zG9>UJls6x_%^@h}@$zk4k
z-@53luLEoR$r%Mu*lqJNpReOXSt_KnfKWt~3Ka(WFnn>YheP2=
zxrk+iz01-5N10hwbdPW|Y3*2bYw<%fLvGTf-
zh86>Q_gE7={kb6`C
z5PJ=p+gJB0ohFStb$r=18Qh{^EWSXK^W3sU#SIzXDA`)pw}C=NS74Umj={l(d2}cIMuZw#$
za>DP3%bvQbXFG{waB#-nQH;9zU@_V~4pwW*!0wfpynq2q3hT)BSz!)sT+JT~&t
z?con^UjLQ*!@qp^Wa7!}=;W=Br^c@@J{X?5`DG!o)e|FKKD;@5d+5f8qoW@a?}o12
zy?H||hQ5YBbUT}mJRckWaO~#QQOL%zt0OnBjo!TW{OMd%FVy9fDMYr`?moKp!P?x|
z%e8w_`c;jMG{rFZZZmrnr31fuY8LjKVB8#Gl@5)-_5dJ}e##nugEnd0%^TroZkeh;y1TCNw;+Qb{pPCXozB
zVi13k)6>vt_&Aw94TZwt$Pt7g>}n)(3dIU`YqTDch_A>*rSR`8Tw(Wdn<>Y4W=9ZZ&~iD)p*2
zYD%YVb~_ftY41$y^psXzpig~MfDyjv>#uv%)zGY0yB+bYk6RiHCHHA)1wYm6o(ji`
zGjI9`6#-ndy^6{u9fMKCjH5G-R@9}GA|_QiBd{q`E-?91rVwSzae+;fLye8*$DQ&A+Hh*NxB~vch26v2;PCbzKKR2c!m2O^i-M}L~Bu3)0&dB%^cdQ{IgCOlDOZL
z+rHQ$XHH#*lyc}7>So4QV~%uUar*|ptBJdoe8?5I_qXSsZa!LDyT7vfU}a@udF3Hc
zxU_U1rg&-b-U7(D^Z<>eg?r0$cd@6gL+UXcpPsonJ$p0IhIi*??=8&To1cG3h@81S
zGjnf#hU6hMAb|MAu*onW7<3(u1T@6So79c?Xax8}3{)Wkjfs2L0Y~EFgBuWxc*^9x
zq3MU$7w%tQpB_r@PgRad27-V<-asA>4zd4N)uI}uQm;yMMTxz$Q#RQHvvOpyM>cy1
zaCjgc2M%t#G(58BRkuBMr^f9gn*0G&VT0YnLuzp=7h0?)pUb7gCrjh69#4(l_|@^T
zk8X~9JT`h&iGVnEoVQ-KN
zB7b&fecIRXk>=P$CK*YmqrO{Z*g`lOjR1$y(`YPwe0mH3g(=e|3@An-1j(K
z3#B6BzX1(ll#@`3aOTNaGL6G3WbTfRpVlY4Ea7xWvRpJ~0W(ya4cN=s7l?Q+&rUSCkgb;D!M
zf?R9FCugL-`(4;%{vv=QZab9to4(uyvYmnr0VtOorDBQ&v657T99xQ3icz){x73PM
z%~s2RV2Uj#IW{F$Gl*(2S
zXwcBJLGlo)5CFCGj4o#k
zf9MOtsXnoBd>bkR`vq$?ZFoVc_5=#-Nhl~VU62$E88_V
zg-pV}H%^{S&OiKka{QyY
zdmletxOMn^su+G^SB^dIh_lhElwD13ApJ&i=;RBM4~2(gw9utqu$P|Ic@{TNZGxVB6V
zn*4AAXUQ_>3y_X{wc^=kkZ_aB=gR3+A<%;XN9jdKEfNZYzQZr3Fb6b*U#5vGP>Atl
zit=x$;6pqVkDtWjN73*O)RT{ocb#ifelkRf(DeArIt4USg}1b_snLhovnz)Fj@4d$
ztKn<#$h~0Z$yv|r_w=*A-fk*D{&-ayruzq8e;Bs1WG(?i!^xB
zgM*gOI|3~-?3D~LML(EatQH~y6O)A$&n8r{02&HRx{^<@(6
zWgvUPu4vRG%V-B<;?u!?8Woq=lx``Qf_Uf8qPZcT33
zjAQ2NPSMaZmYMT|Nh!9Tg;Yi8V4LzYBCD5kh?2#1Ce!xNr9nO7i_}X9Rk*nP
zV1DV|+~Qp{mgeuSKrK?&;q7_qF(icu0!~8)&W+E^+?k!ZGe0{{`{_ILQ@239L9!t=
zfW=3{(_kVEp+F=O5Wzw0Api%$Fwlc!lSv`oA9^%?jre%?`tuiXCVWruh6OP`TT*)?*M#&
zAleQO@xsF^HXpC+x%r1f_wEgij(#+D>)OqmkcS^b
z1CEZqfAi**p`i~!Lr6Jb3vj$~<5#zz&6r$BF7BReJgl=PukE;&-Lgx&pStO~bTSPZ
zlISC+JUV)HZ0zc-(T|sB#-|>R0)<1=9eHhR6#JlY>)NebSDww^wX3HsHJ%MWd2sXn
zeE0=^s%mCCbF?OAw>|#2ErnYGtnr~)*be#-_sqg8G;pRRL~4~|n?0&kkLp|m_L-&_
zGWdo#fm*!0NAI#Vnrf%50)n)BC4D9(O7!i>gu=f1Nnc02KGV;;>fia#|C9gfzx;dE
zYS#C~WFnGCKn8{gH_=mUC!v#*ljD=nA+%T&QjxZJj0T%i*e79=bD&sYZzE85m^n4kv?lF`p|^{^1u%+JlFJ=AgtwKt-Cg7Yr-Y1{6{wok}!oT(z7^
z#7<-Jqgd=DmpRcSDhpT-%HKovw1eXK_=NjZ%$f6T9sx8MDqQ5dW!N;ERMeJcZFdJW
zq_L5HNAJ*b@(R(gqn&p}V6NW;^`x_|`lhG9?&_cR^*3i)yTmI7__{0h8`Y*;
zbo7ktNgCS
z2$6U%aLoiq&=6)haLS-z&~-TfV0P~Q?A+~{S-4{wPFa`&3Ly+{ElpFl&CDeA49-rD
zPCgi#o*0>$7@Z`ANXdplzab4YPkx~d19^C3de9EwNGOCPygNF3cX%40ymy^C6YpPJ
zdU)gI;_dAAv=CXVh6Y8z<_F+IpgkzlKygYdi;A=^)jK<7ud)vi5D-ZN?$!AN>|OR{
zo!M?yc57AGd5fbu@OkcD>sHd9v-#kiQF?EsCPiC%Oe!5b7<)gmy{eW&u<*H)jZ*kABw?L9?rHJ99PP@HI;0}4YCy)>
zXODbluf?6#h0|K~#3>&)g$V33uxOVK;h+b%=$$rvdcnbdSLwD@n(<220hBQ=Wvo?>5ft6$&WI6csbuF8XL3SBhsne2x-ZLdl@e(`7;2(n(9Z~B(gipPZ;Tc_8oW->hX@S_
zEeH-04Fe9QXkv7NdJ;347~a*Vd9|e!y{jAwV{A?u#W97H00xlV83)J$)-U9G?rYI6Hl7W@>C<`Zf(QPu(N}J{siKKo5?UX)PyYGqhOqZ!a`NVvpDc~f+`W45`mad&qf+d}#GR`XLWogU}2v2ZvHn@qL)BVm$;AYu&cBpI1VCBM*ilqwj|
zEtM+-GBHbihy&6=_66)CMq-1H#>JUTK9?HUeE0Yb$!nJR=;aB>k!(c5HEV_>%Q{Inew_Lw|tfi@|k*ZrqFnO
zU%vn@Asf%c^B&)C(c}=I5K65^{g~xaAp*HqspPAbT$Ra*YytLG;$TsET}%sHs#4Cf
zm14D;S74tDQNEDm%V|U5c&5NtN|{u&m`ifyJocqrf+?m1CZ$MF;HTMSOsbaC@e{F{
zGL@_@r!_TA1azq8cDF7-{nhPa%PCU6q0c&6*40TEI^brINC*WDxk@D)R8TeJ7$sXS
zxEkg05L;=~JFot0G^EKl(1vxc>2qD6u*tVTL#I%;Qigb<3rCK8>S~Gq>3{kkMX8v}
zADd>GCYccO9B8-j+^Z%782n79N)&fZxFvac6rZ{`qtbur5OT(3zUj@hs-hv_;7R<202Kyo_%y{`r+8rgOMPD(UQAFzyON?
zVt~T?bmrmRs}FHVXKqa20S#$%W%@1zY+_{E4yQ26VVW~wA#
z-Y*$>
zR6F|Q!ObsE-TCm|&@aiw<9y^P4yVVztQB^@>X&^kJpb_8!#l9FAC3)ucx&t`rO}Lj
zpfN}1ey%2jS7yfU-?>tglb`$9Gb8G_<(Hn(A6Nr<|=@QJ+$G_
z@W)^)>CF)mo|6x5sD*=1{QPSxQ$5|NS3@l&`EvdK*4m>7H$R-ddo^*i8QEIQ9&O0!
zmvG8`DRQPnddg{E4P)PxPaFK9ReWg_xAfu`?6X_m^SHyN7^M_+HdGUSo*FjYwg5@k
zA^j4p-rG}XHdt4BGeBWiIcw4PH?Cyayl;y!A%v
zO9mXoQwA6%CJulINtnwe9jltj#uJHjA|6RnA7V6}is(v#<}b%1@n|9v2}Pr!Ncbq1
zKTRig*y3T+tF&oi21nKXJP9-eC|#%G(YkRk%T*_sN-?-aZ@KxN*>1Vru7B2bF3wz{
zVNdO}<#rQaEyj6}pY-NTp`z9<^SY;gdJd^bD5Qk;j(iRW-2w{nQ;~hFJ7q`DHQg#x
zJgqY6N-4>)X~$xPYLaJDTqRv)5+ainE6EDnZYcvwatx3c*MuCK57PjP2C)rLLS4s8
z`2=6dm9jAyWZxDHmC5JA=|rTMOM#Mw%qiXlcZ@B;J{NQ)XK96QU25P1X{boHQU
zM3rX$wFDZ^s*^Ufw1_SpgNB9};!E`1{`}cOsT}6{Vvq)rCrJiU*Wu*Nxrv)I
zROEGZW@2<^a%}1$6=(no5%9>9_lJY-LNuTgM;_k2HUQ#)jF0Y;S_B6tac2C=%&np6
zJJiECJ$`NB(a`*ZYddQ<%b|tx;WTJC(1U|+L_VmG%}17shtuip2dP*0Q#%g_H|XuR
z8b{jDV|TsEj?WSY34()t5Kx7K1};`hhtHR9ms30Olg;trU)p~<1uVW?zkBj>wxy?-
z*y9Fw{PlX_GdH*Qc;f!e4_~f7$Q*6FT6;Ki_r}7+a8rqYy<7Q4qnJI}T$#RI6B3{J
zg|?P_v3hUl#+R=TeSCfBqw6;y58nq60|=5T95iqq+7SEU8&_^z|7d9F!~3_dn3d3(
zoq6MwGKcHO&t^}zW@vpYE&puo!Q}Xrsk>L^A6$*@EoM(v&BAU+3is4V586--0fjv!
z+?T^WDb%bUc`(lTJvH~rVUOJEiB~xujI<1H(K~H$L#-y)r#WE~KB(QUaNdPYR^Q612>3{^;BP^q>4sxlFuLN~AL~P6F6L_knb{BALX6^zgtJ6E6c4;v-!k<(Q#_
zY@EafnF;hIVZ%ug0=nU#?pNTH6X94a5|5w8W2bR&5Oj{wICm_1!c~)O>BKhj-3CV!
z)M}uiK8*
z2Pv)7BFjOsFKEUrBln^Rug|V-|(WP!sNH>9Mu%7alx1}+i>!Z8aJd9O*oPG
z(C_@#ul?Td{`#}Wv+J8vs~c0RD}dm{>gv?MDK9KMSS8mCI8Fe9(2R?V(1{P`=kLwU
zLoGg-o4Ysr|K;p2qZ>=lwSO?5X3ctM*80zy7m`kOmCGc{GBZkMml-747LzSzW@eeO
zsv+FzG-EoPW=@)m8p3?SbdsEt?w;%3s+?KL|HJ9(ou_xUwq;q~W&QSbJvThVope0h
zMcRa%CO+4U~4O!N%TN{FdDfcQ+SaPobf+Pw53y4fs%}zkF7nUC+XsPv$mHu;mbv-SW
zP)M#s0Odg;lq1F<
zgMbH{0SH6VhC9CB{N`6T-;{OO^qYmSW}V_B7z%}4CRa+Na=Ah!kx8UVW&yl)g~y}c
z%KOzCkPw8@Z)l+<0W3loQ%OR_BxXV(w4s*Cxgppwpu{uuCJQ~l$!kuTa<$Ej(WZ@2
zg%nWMQv$X@r_*bhc***P1~dc*iHx+@YIPeMTFnN~yrJ4ySAyU=J#?Z{qg+)g7QLR0
z%>vUGx&ZnFw{pHh-j&ahSx&|6=@_looK0V6W!`3dn`v-;u$MYINJAU$?vxu}gNBKt
zz4(RwSa}@pL?8)IXihe9(_#ALAilfp+uQMP7u_)R#k?n~_7)tTP!lOnQyotO@vxx^;=wsJ0jtUZ>V(Q3V3_NYD-%h64s>eFbkeZQb7T
zQxoiz6??ejY{FimWlzW;Lno%AR;oFnP_hvtl`tnFMzAs&G$(^r06iZ0S8bTsF9o*>
zUWjBc5j5P+yNYS($&E~GBNbW?`)Dy-sd#o_erS4naAs;?sytmd(SL2;kb&UHXb+pn
z_t&fDyUPpXl~rMxhQ4b>DHKY^8PE`4EnlDyzGdygQb4*1N9+^r1ZCR+Da0U67XpO<
zVnBj3IRCRBfA_Wv8TZDyQbap8!0B$Q8Sdc}LmRtEy;IK**<_`_`f|DE$Hhi*RKA$ovmxh|zr&~D{z3nwUtyK*TXV~>;*fkZc9FVR8XyX8I_0{mg
z?0P6f3P3{@k_H3>nLP&1u-TRM^;PUT?9VnfR<$&pZEiT-(OA)1cdEJmbVm~ma@|mW
zV|ROHUspA^hdtcGQm;*j=K3@%!vWLsR#3hjRPKfp`ym)-C`9E>NVyl(?0|-hmCn1V
zOGV5qNITX_{trV#=)r4)X{oZm?LXKG97DY9gv(BOXOrS50k3s;C!No_RO?cOO0HBZ
z6e=YVQLc=~L(!;9tdQd5x<;i`DfQ5XI_(CARu7x3)j{$R#3*6VMETO#GZA4O;7I>WwX6klm!G9D(#+RuZBE%qZ6yJ{TXIKXWQt+5EYyJ^7fh~s`g&o!~;cN)Qb;|I8
zP1Zu4Qspw#B7nHAmS@xcSlFb~t>Lr1S)c}4+q9Yz=wnoBkpV#R38hsu;Xb6`1@qCW~
zQjtQ;PEvv{ht6i#TCG}}Nn$PiUqbwA(
zgaYOmQ@D~#QK1el%TCFk%h;(VIzu(lG)ssPH)Rvl)in_{F{R4JSVWhM=wXmk7-4;q
zT1Xh-o#WAenK#^v?{9~xpJLu!!aqRXwUvYGHfCa405KKOxtU}!m3(n#nmawsJ9myd
zF*#UcHl
z0~A(fXht4^>x(sw6mDw`kuD>
z-Y(8SJDaR@JA1IRPB=SYkS+}OHmpu}(UPGOGRtlSn8>tjP*VnCd7b65RKzG>pbx%n
z`lUsW2n5{rlO((bLE4Kpy{k9?8B1R3<`On8nWQ68``S=XH9$Yy-;@e%loIB-k@l9l
zk7xac-GnjgSC0)gH?hx*^fwej+Vg4CepDN^Nk;}atlAqI*=M?1s(L8yT-gNhv8!0D
zvusWUtTB++05aBBm0d6n8W;lNAx0gmk`C(e{2STKlN;+RJ6fyTTdF!*Yg!u4v^Q0@
z)Su~Ut?6y8>1?g+ZLjX{X7#sMP7gQXUc&9HnHp-eX=WjT_e1c=s@;I%0ID#o0u8r=
z^4)-HH>BPP;h}0XK)HuelOSdmmM_tDZN$Ot5WE{W2$RG3WXxzHz(pYJXEQvB1NU5ylbFMODKXuGhmNn
zf}xR6NHip+h=&A05D*VZ_mOPW1ANpP8@MAUOr<9VhN$>IFpw!b!HWQk03#raQ{Ww>
zpK43k%4XNHSc6=DU
z=@{BDPK~*?L#3>{m<<#%fke!j%Q!=RZO~`(y3B+>w0SUJzj^`YxDVR
zexDW27sKl^LOF)~W|~8^>*66tB5e1$v@Y9*!@7}9_&rXY+p%G{YCuESVXIMYH7czZ
zrQN3XdvO0znhX+?L2NckT#og4)DiGPmYU(X^I2;Dvz2of($|(fVVYXoD4-lQrf71|
zl1aLgF?*SYQ2;Rt8tPMFT_R*mC!FboD-r(ZRiaMz68qbc?LuHP@5|;WsK1%D7t?rM
zQzoWQ#*BWy{wF{Akz6U5ogJQ<;=&+LPY;bx_K!1?kg$m3@jix+ePtBF9gk5^1$=~G
zrkL`?NH;h*#_Jj;2(|%y7`%Q8ACC+$HhHjln8$c$#xj#T?g98X1C&`!Oa$yey50^J
z%@Tr!9SuG0I7z~g2JsPJCAHW?Sfnojnmz4x{cQjui$`r8*cjt|EYm7Awt-nLQx61$
zBrL1K{}PNJLK~JmV4rlyC*AUZfNLe6c-s%12&cS;hd|_}U;LTfz`y_bPa6KVRsiyV0cJC*3NOVxha0RmVQv
z&{#D;-5(Eb$X6%o>Tj%NRj>iLhMIZ~Bq7uvQLm|i)x@c7;?!{15P(F+G6d@YO+3Uw
z-5DGMjt%t{+zys>k+(YC)7^NgjdP~0p>m+D)}~(e=vL10n)_O-7be@Y0bSCk8R=uM
zE^uudb7|MwZcx4zRFFXq6aIFC3Q~w+#cou!8B{A=%`^t>8=Fe&&ulKMUfdV2e_ooz2v`2D)%vu2jG%E7VejQmmFs
zE}TyW{SFn7L%nNYTFI$WGcTCZQ0I_98$bfO!5mcGFR0Z_{_Q6DTC@rK}G>I_O&u2er|VDG_sf
zJ!S|)uh$YJ@R4ALJW9}@W?K^#$nUIDd*E}{F_DqNBf4?
zZE)LgndMH0%52hrl{T}|q*s^>O0!vIwX9psx^&VX3K*?6rPZXeSu|x7!g@!8wrtA1
zTMAN!X2wxS+H$l=9#Cij6B&7E&m>&wxH}oKCL^X;*cc5PAQb_$cvu?`>*1i|5i_uO
z?HV!LM=l(spbZKCId?wq1ruow5mr2D%*G9=xcQY=UOYJ3oLd^7o*S8*;*C#o&rR~c
zKIp+Q%B?AzWr#$O5#E^&7%cVxi{m3bW5b=JLljCLALhOlStwX%l5ndZ_5Hth|
zsmtLw)hRcPacTL`A*Q?aKo4b8gNE?G5PggbuIuSwLGA%_-EFLa?xr4c${b3m>1^zW
z9_*;^>0l4EH}pa|w$=CHIry%&TI{)9Y}h?+Cu_WqtrJkkLl^9Dx#|BkvrPLk6U*b;
z75c#2c0dB@2R#URxanQn4v2t4oZRw@w*2D#ka#yDd+UuCKY#Pqx^Ot-RwW$Dpi|kv
zKGoC&!&}wDIXltUG~UM)Ji8Ea-wH+_KnSTrwMHo8>vz&mJjznL`8jI>Sinw{GDgnjiOtlADJ
zw*rdoAn8F2Xv3Yb5`uBluh@k)WM&Mv0`Si2YuD&{HfoYgYm?I=8%#7gaIzOT-leQJ
zXqKHK+2l+%SSZDGI)%e-^g7M3$SS2qu9V4?Vz~-H6sgqGfFBA^qtqysiVZ42fhyGM
zq1iw_7+NA5%^d=KR5Pd3VL;Zw<5B{nUa!$^C=EIVhRH;@)M?caeOevdE~V(K1FU#N
z>x|-+;e6qUsWpyXM<^^uY|6!eD!>qLO$8;04P;iS*MVrYTrSNdJ%NDDXxvc9#cGAv
z@7Cc%P9H-!wyY_>lf&tlsgQAQX1$r1H4!q0d`#?^8HuPf
z9I$)cV2zyuCX6=pdhI@+J>WBCQ?63Rd$gByJG7~Iu#`_d^2NKKe){X5`P5C@r4;ZN
z4LP0G4Xascw^Q1U$7$B?^o!*Y?fIarRdwtI?_pFK5549k0&kjCl{9|&&>=?oa2p84316=jGyZto9Ls&8X{mn
zd4V
zVB^?8K~>2IsVFP?rMm(0%R7Ggj$gUsQ|<&*TLGGSzTS;#{~4f|@=g#aJlOFb
z?|P4Re1|)M!>!O($&2Ucb!wwg1COcK!-T>ME5R2f=`JyZArzugP0?h037m?@qT#SZ
zyffv5kivirDyctS$l#w-7<0Ju*`bQ`gDwUKek5S2$
z*Qr=YDkxpG-N3Xp-
zS{eZ~Jbzp`KFm|`$!=|n82$nKSL7xpL{T_2L=<<0TKCjac8hXuleg3A0AGq_<
z#fxuUedo=~?_9m|9gMf${2q;~-+BAZAKZ4^=cq)_xj`#OhfGG3Qm0oN4O$aWXo2RY
z&fz+(T)!c6IrY(~)9u#TY?@fa5eZpS31>Fx-YG?a=`sy7NgL%DCTzerXqZX>h>)@7
zIB7#eDrUlfHBLtKi6~{*B%;>%ztkz;e3ClYjqVoxg@T6)UvgBiOv?+T&6%h!79wB0
zESQ>I7@eFNoSfoLoa0VR4Uj54H!w2ZgMkBrcT=5brO
zgDnHxCXD|6Mw&ewY#9d=d+SEKSVJAv7~`FFlRfqLOb+$3dEG!*b#G@)Pe*l6TTORc
zZC5Leo_4apqy*b(4w2k(JJceyBpK&{PMBz*kTclI>2GBZbdbx2#^iRfM*EwFy4n26
zHWyT(a?~pu4k*VkLdx-wYJ%Bg5E(zjydg~yGI8XhXAKrofwt=Q
z)>;my61uOhwvts>!Kyn`Q+v9Gb%s5z9covm*?+fsjq
zKi;F{kIfEu40PZw!W!-7O!RTadm8n!>9AeqT%XUn*A8MEdy)11=*C`9z2lK@`K4O{
z*)|R3HkjyD?fKNZJ{5pizC_ox;d59nkHww{xDz{j;SEibQ^jtiOrNf9jcMo_^+;r=EEl+fz?H#rz+z_{66^d8=Me6M{OuMsHZBpfIfo
zMU#NE(g1CQWoAGCDgi)xV@g6ctg%c9CgLQ{;Kxb*KI2wC9Pn81j?4yyNiU5>%;m@c
z#ZL;sLN=JCB3xH8h7UYwczt!sd;3)A4H_OFY#tvL;F@=~qSznrXD=LQsSt%J_l8J>
zJiO_Uj5F->(LrRhVB0D&VNh)fFW=zK|w4yxj~kJ8p}E{%JA*K
zwvT-3e0qO7vQ_Yv@}6SWRm!=kRy+;vTJi~F$Vauw^Gjnh^JCMq!$iZWLEvv}vJcu2
zC>$N{0U1ZHbnlyAD
zAXry_ww48zM?kEtgEl-{TUSxft~xg|$e$WgEzejbg0$1*(aU(S+w2>=TdEt`@Wl{=
zqzAEYV4WtUvMTV9+s<+-=d;!|k9>S(q^Yg`hUWUSY-$Nn(Ntg2(O3y3KGNrQMIVG-_zl~96*QO$l>br{j$;dW3#?Rk8Xf=9F)ghEtq`xINg
z4^yWM2m*+p;lVZzJp05!iYXs%2M@RX=>+B6fir
z)EtfcQzZ1i-S+p>03zd*i--H!?aj#Ub{Kp-K1@R!UN}y}An)&l!Nd!P$&>x)1u*d_
zezX@T=FEkxF`u@jUU^d`Tp*1
zE}sKu4OXMpV%)Ik*X>4)-)k}&6h_E@?YiA+vf*o5nT4|1l^z!`=S;-x#Vjqt2kBbK
z(z^1{hPYcmKBwZenrI?wgZe9H8YUygcu3E*^D@LqAsV7#T_mWxc8!?rBcH%cU@x&<
z2$!;fLYh{FCK^&bkfWHh`8-UghNbbD`4Q0Y+|{(fEj()Xvhp0XQnE-
zb9Af=dzvU@+F$dATe(B61A~oRZcBG>Lw{HO#TOrc|F3^|@3%ku`!BxtpFjED-+uJH
zzx?pczy9#eKYs7EFMaN)tKnmV9kqj9tp1Mb?v82@u)DRUryV-6s;86H*@lxK9pxKB
z5(0?K+#(ZB>84l;Of)Pr_&CTsrw^a%t~y>1XSln5j@x3FOnT&F9_bLRox;dNpJIgB
z4+m7^IO$dll`qf--@v|-XJyMr)))hNaL2p06uo@LdYo*8b-dz2?}{gziDndxb$`&eUr1xz;uSn5u9w6gl!SgW&r>%y^V
zZsS-_tz@o$p4T+l#TJaUM-76aPjV1ZABHKWd=S;_g_MUBR8azmIoE2&Ap{mNHvJ!_
zGH-XwySD`hQb3tmk;4xZ9&LvXpczZPgT2(Re)UU;Jd;^RZ4A|l&)j;DNxLcOTB(5T
zEHhCFVySSTkgF9kJfzCJ4YiV))YGa|1Tw|Ox>CELCfSH%wdmw{@9C$3!lyvJJMXyX
zw$I-4-~(U#=A(~4{=}1yKk>|?-vkz)ee8)Ro_Oj>x6?>*8%Fp2Lk7YTmm5Wp282}y
z^`Q7vYB_`<(NHdBXeg2?L^7Ea?pUr^RjBxKrBJRA%VlDtUhZ;kKy7X2J%yAlpK%q_
z-b}(p>*u9C*%Y;G00pjHqYt+2Zl@3SG895N&K?}5ceWu6Db?oaFnRtMK%}y}h0q5{=(qXl`%WpA
z&v?Rq%l=m4#pj>8^v1uW9=UWJnt_BGFmQSQWAbJZWKJVrFh^YG&x%G|5BwVhqMF
z)6^jjK*Q0o{?T#fV7zy9geDDPmWM~WMut0~3P(n|APIS7mfHupZM^>W$G-OP`|tk8
z`@jFq@4x@%4_|uz7jL}$%S*3)|D|Vt^XBWndGn25UU})|Cm!hHoZ@!Y40Hl~Ref!h
z{T;P1%jKy|9j9ByV&e}|ri;T|}?
zdYAm1UoqyE4Y_1PJ{8drt{FgtTJ(SDC<+Kj)|gUiNYO1Vnq{%)`Lp8hMY!j!Vx#3L0r#ML&ZpoMrqU&L+lvVkE
zAO=}%@Qaa$u*{Hz02aH7Q(L(_J@L!$fA>#6{o$|Px%{)&zV*}BUijg+pZ?*upZe)5
z&;97zPrvoz;}?qYR?cY_>jnUkXvhK$KhCOwy1WsVJZf1vifb<<^kL&dTho~aRu#Lh
zfI~v@9`$_AFWHZ&4`QSW_adr;uzH`#
zv%%Q(O8`U+h(rMK+BLeKZFk$Zz2({|d3Q>_{Z0ST79?Tla4U4M71}NO4)zP*`OZ5U
z)p{^w-z@kw8g(Wah{x=t!Wa$$h-HN+Q^}+NlUgo^93y6tilf->x?HPMVUWGmK-N*=
zicY6~?z!j45kLJji05~??z{W$`|rDNfBW#3^T%$7=ia*>l8Tk9E6OFl^s&dDH0bea
zculniW}IF`0q8*?s^Hnx1U|f`QUw`Eq7@PqEGF|VUz00DQrVhBx+0YcWeUDrv4-=I
zx8U-|hRkMO&!-%vJVXhspPi=dQg%o}2%juG!z$Mn<>JMcUVHW1&prF}i!XlbvB#c%>D#Zq^zB#f
zx%<9HzxmWFFTZim-4ESy`#l$K`OM9q_|)Z#(2U=I`PDb=4x8WaG#J-?9(ywB4f?fV
zzd@rE8Fi{y*yC{;fc)J)aH?RQ>lW~%V$vEB*?63(;
zOhQF6B9TVa7K;FgG-6T9zdGed?mWJ5P&Ui{eA-paGK>2${cJXKPL*N_Pnw?}pPn6^
zo*O+kJvs?_IK`uI$|NNoGGwG_M4)hNVsL1*n`j8jJlezbbL|@9wU-+j4su($-1dQi
zw!wi`;2tmg-e3Rx-oO3q=6uGtq5RxV(Iu5+T#m+%f7BuoRs6sH$MSH`r}vTr?N$Aq
zwLKlxeQi}eZB<<@)zE-Ut~KQqLK}9r!3a0tAv2RmSv7dr+f@KrL8iXn+r}!VXEWJ0
zOnADxz8^H~u3sE&Hww7{#h6D)1&UxMrXb3NhZI=xCjKUMt*H9r*$Rs#VS=m4olaQz({YG0Y=$AhAiBH}3xlcd&&98s%v!DI+O-JAO#uwjs4F>w1
z%a`BT-#_&E?JlRmY~0AEqYj%o9JawMdtGMOXZ%Z&q>t;(P+T7A1pM1FNl!G)^
zIPO!9;=rf+klGO7BldY#Fn~hnMC@_A6OwKP#k(QNE6;u7Gsjtnda~$~^G91c8&0>k
zR?~VWjn!T4?DqD04u`@ijg2*RtkYefc_+K6z5t8yRxN$_413)
zz5n~)|M^Eh{N>e4+u8kc^J?UQ4drn@ev?45ILxa47->(|84kO$xtX$>cSk{Jjf8ldq|H?PM@|ACX<&g(c
z!Jyk2`s!D{@wG31)$facWUDO^zE+O@&lq+PQo>-v}5r+wdQt%Ex1$&uX
zB!eWBt;wXTG~|4#j4zYpfKE!KBAHZVvuM38lhdj9IJG5O0F&y1Gw{nl-%3a6?QwdMNZ3%cCUJroi^!Z(ohe4lVr$~#a1YtJ^lPvA^q%=k3V$(gOA+%`B%RE
z`lX9ku3Ucm%H{7q`RvPjqb3lr*{p{3bp`HoHj^fk^qBMtYJF%mT5ak`)b93d0CRq?
zF&_4$W4=-@T*`&uj&ZI23y8@$h9e%qMRUZ%7|eBxm~iQ0VS6m(42PYeD7^MRXV_eN
z>W*9X6Z>27?V`V!^?-(j48>Bm3f|3H
zaiSrZI5Ghgc8@T^aDpjHVY*v)@~Gc6F_Ft{qu#Cq9fZR7|Nj2J|LLzk{?U(K`qp=z
zd+yR>k6!%dSMR_1!Tez=D<-OrItwcA8ouWYCs
zR`#hzd}`=KT9dw$;Rs1y)gdga**JJJ0Vm7189
zv)wIc+Z!te+E|^ON;v)APIhZ^HK!34wVDb`7y?oaNgWUgC0KzoHLQwiI9wJiGr4A;
z-SYl_{uMO*(+|J@qgTJ>R7%Zjf(LIoR?SY`lu6us^HEQA#p8E=?#%!D|M|{yk6n7=
zYo~AczX*l3r`R>8fJM0G>e@3kH8)aqbKPmkMpi9}&^k5{e73EbHPqGM)h+wfGroWq@x(VDd+LcNpZ~@;z9ACfdlgExRHc-v
z6qNGKXg!fku_lqN5awhOpinN8N+l~&iBKw8#gIsaVu?U35yC7hWiZZSeBEW&C8G9q
zwa{#kWMbA*-nU5$aysz|&m^5VNJP!?kR^4U>!R%LrS|sIN5}bt!|cIce4k2CQs)oz
z7mf<&Y5i5uFnG8hIe|8WO+HF};v{?1VUm_5DAKaUFq^5kE9AHN+}8i1VZiUj-s>?P
z9mJ0htKf9v_@p3WrG_uqZz
zg~MAPxaSMcKljvapTGUS+duotD=%NX^yXEHvAq528}B&XE~80pvl|^wqswj9ZzwUW
zCXLag3i=#ctwOI?db}pT-xLlI)RHl{*l-~efHtH%2PN6y-P(Y{ScF<!|>PEaL5)6S^-uZU%N)k_L1+u_Q>Zh_I>3i>d>b^Uk
zx&MyG?)>awJe0N?zxMf0K6&?TD`P|7fAPtmzWPEd*vBHjTwD9`>gpR{z-wzN$THIb
z9Qx_H`ZLTp&1tA?Xs8s<@QOa=L0p%#^LJw^qh$14f1OP=Yg9~646<$O3kkbmFQNhm
zi(V*1C4BLwUkW~APw|t06k{i%ECoIc4Yx`js@0`tf8d~Zi&oe5P>Ej2U&=b~zVnWY
zZ@d-?xl~kx42vpOsU=E{SfP?A-AWbN{wE(u7GJJG022e)OZLWDr6MLkSY`s
zkV~bOZLCYQ>uU<4;S1!G8K(?w`1P-U?V$%B)TvBvcj(ctJ}ec<)iTZPpZR1myYu*C
z&pi3m^N&38Wtd!%2y|P6?^Y;9wB&#sdnx@0`I;n`=Nf9A30o_O@xr=EKL+2>z){;6-j`20&Ry>b!S@CtzV*3~QDNhH&H
zohlOWXrS4(O0`-V4p_r}2!E2>Mx7$$H+kGzzsKNp853~IVee)!p3C^Cj5_JgCaoBm
zq%{$@#AD`U!kmbiC~QKK&=QW?BT+!m6bu;yVN)n#`ImUqM=n0|&=+pmDr-aBi_$4q
z4)QQdy~sCnUZsShC@!x)mT*brd?-XfkoE*b-o!Z~!9
z2%Pc|Bq2>2LKqG~BvOCFt}$MB`DefXm%seyFMjgdH!t&th9dfngIMU!^G9~cs!^~o
z$gceDTd)1;2XA_H;{Mi}{th-d<#twI7pJGIzNZ7EtLyJ(Q(v!ca>p3un&sYhPG38_
zoR!@R71>4^IsL75+%C=-ugPZ?dClUn&KmhlN129YZ5ULJ`Q;;U%^u}wnTGZcMMKhq
zPQjLEb=xQ0^{ry;`Nd3JWi3ZEeD$#CD~8vn2I>aes|Gr1lP=9c(y|-X>DDF&+G+sq
z*4Em(`bwB$K#+|+>lzS2Luf-B)YMcm2&=5CI(_xx#rNNR@7-Vh>Tf^!$#34i`qopA
z^;MtcajH+!k(SES(|zp^e){I=o{r;W_$RMChr7$dP(Q3O4008r@W$HOGpt%F)MK-l
zN|m|_CQePo&eYR^U5Sh4QqCrAE3mpnzeFb*o*Qaf7;c#wY8dXRmGQY=?M%@prWwPq
zvTT{lL1acPO5u@&1YFKmVA5L`5*u2hbk(+lSiVi
zc*3hz%9Lt}3?fURNTrm)M6F&^
zDus}BPdxE#*(sN4m`N3^W=ATPD{T!~&cL3Ly`rj7N6ZZP|?1VgfXU
zHmjzX3s{XC#jL-O#*a2Z?@)Fz6+~F#Q7SLXrmruGvbUEzI4CeQ%NoW!?F?hA);28A?rc*{xha4!TJmhk6V@aA*wWZV^}6$t#Gq2GstP|)v+#k@cy
ztmIbFhqvT*u3HS^H(q^|Xn5t))hm~-yz$CwFTb|CxgATy9((kO7hZVb)(f|M;j>?O
z{+So4Fg`))nnPVSUK`Lvs=AX6?_W@?392$*#g4dky(VNA`C
zO)i_|@rgmO4=5ZRV<0#-0JR7vj*Rw=ja{o&rhqa5k<2nV<&kbKuYH);IndYgowu*z
zW#9YTpWplSum0mFKX~%)JD#}f_Mg4_?Yqt&yz|TxcOC7&`pvKW;hl?r`^h`Q(1Wej
zaJ~bboB;}k)c17N^)ZcI`?}eKJ=Eo}4}Q6)v9G6@G0xy1Y%-^Z;wnt-N@x85RjSnW
zcGiv$a3%&glY{kYevc3AlM)a^lwCL;R8M#*qC)W#m}Qq@gtVNz{e)`IDzr6U8N-%f&^#7`X*RDPdgG@y!@Zhy)Va##N
z)TjWCuli;bceNBi#-uwfx?gZOv;C0EiQV4HEi7kX
zs8lE^7h0?&*DO0ZzWFIiwkE3#r~LF&Pd@(SSD$$F>2E&zm51)V?dxBE?4bwlPRG-a
zKlbcnk3apy6E6k>ft8gtfpA5zB3u)TL}C&AuuLjeNM%xqoQ`D@NI#NY#N>jN7yrC@?re!2P
z_;#?LJ3Pproa9c9a!mIcD%8U1
znFJNgWI)4&B^EWtV~~d?C`6_Rj{?e&u@H%P&mlk5qKzgKqyMZ8pL^u9FMs8>TMx3^
zg%Gr1A>&R#pQk*u9G{~4ym1havB`8i!37OT9*z%;
zj`o9w6HJB;oH8?T&`lzdTyw_=x5I8_(tO@~_x(Tq;oX1x*$AT~B8{Xh_HHtgcRqK@W7Y``fB{opmF#pi;IAxSh>_k<&QH51C+udHz`A4mBIf9JA2tx{+ltU=6v~1|On#zWH*0-L2
z?mbxL-~R4zKmEzSfB$=LKmA18sgJdt`sgjWWc~mAzglnjUj?^wyrqf9uKDS=pa0F}
z*Z5N-RTck-MS+wXIh^X&R#ts|1r#DU$l*Y5(ljNDb*8bA*6r(Qt?6m5o*in6J489R
zY}@N!wA5V50dbjJj6*TO3-l2CoOrz*RIj^
zY^9tNG=xb62dSq^)>$qTgFGzdTy7UFO%Vusp&TfeMJe;RELNMIdU-+nQAaOYDo+aN
zQGTC7CRf8OQ>+=tQ7R?CA%$9Kqudu2MS<7V(shjzs<6BWRmnfiQgL=@)0_W|#SbWxkLv6t1kTuC9s1Vu(QzNGp**6as~7Vkx;}sdNQ2
zB%6!_>8eP&vL+VbIRL0k3Xm?tVpEtKURx<~+w}NUmkPd8)>q1SGI2{ZtcypD$v6d+
z6H#;d5`Dl8O7Q3)b8?b}9s~z54iB>Dj|=CI(#J$Bz!e
zJ51}qTm}TuF+C2fL7(04_V~SCpVtuyd4fJ0Ex@oF!?)~g`h9M-)wp`)^~c`6`s$lk
zFJ8U!#^pC&edU$cZn<#&bDuu{?9)%(ddr0uo_XT@$??~}_QhMyA3yulv!z_}(yMP=
zxkxoCS1!MK>GIn;>H@Uk_xo@gGn%x1pUdemn@#IRgL-3QT`5;=tZO`Wn|@uDiU-0$
zD`;5Chq5VmF2$55r>v<2BMd3GhANRMr6x>SHOVN&Qh@bHkYXuOkdff{&mFzKde^Q0
z@$=VjKhEzK!dp3SKI2YMo+m9@2pT4%l<~hTm!C4f>czbVK}IBwPV`|v
zHVz;{CsIIpa=d4RXh_s
z>KA|e$q)bY-+uDvcW1w+S+^
zmzIla=8;)$8t7<%LIfoTn7B$WaLL4x2RhiD9jx9CYTq!}Nxd6*?W`GIqgl#>9fmw)
zvT6v30mUeQ=uwW4Fq98}h{`;gH}n97t1!!qU*?xw%S8`kpD|pkpFK{#{?gMio3P-O
zCM<%iPa#?C&v=vvaqUh-p%IPMGqok~s-PhVSj#%Yu4fAJm=@MdD47PZSXWmAg_w>+
z@N?h$^Pm3yi=Y4Hhu{D0o0ot3%C~;}@(bU4{;9X0di3q5AA9@h$KUwcmw)lfw}1KS
z%YS<3>J9&&|507_(VChYYHLr`*4`jk8kMb0pRM?4J^O4!!`X(qvyGf8Y68Zo>S(Ff
ztd0kaBGF9G6y?**hxCgDpG>h~-OkT^sP1P1{OEcPa1sM|_#IAsOeK*XO1rE&axND(QDPtyY^cmG%KaFu&N~
zhGlZ4gsib#A`_EBgI&e{mw)CnpQdV)Ya1*x
zjVGUkZ+?O~AVfa(VD_oVxV40cV
zi3A>*A}4E-rB%_ANW3Z*tpb-~F<40$)o4UUgC?8wXOh&fG@r5;((Y`=kx4u8(G3N3
z(FpZlDPN)wxE<_)hUp9EvnNMckP$RII>=o(%HMnpvz)$gOsO^}hpF=i>6?yHH=iVL
zI*A?Z1t1s;SvM1!a27KDRLq-<1t`&)+8SDKKED+XxRNnfJZyxEk3~#AHzcj!%
zedU$6-@NkX)ytPJzV`T|k0zsmM95jnWuAHBv5?o1ONC#4@%fYEUFg1No_g@|>ld#u
zl`3ysy!`l6&$+!$txl^{sPXTm(NGGf*|2UhP&uVeziu$#iyEiR7zw&U0o);M>4dMu
z2t!(LK55RTEY#99ZldlCF-tP;1TJG?do*N@g>1BzK-d-yneZ?gf@QY;%UY}-`Rd)D
z{nL+Me)6GPw~LY8Vz7{QC6o44%3aL)H}k>GTo6x^%LNdndV_M33873(@~9$(amt_}
zZ1U)MA4QfS49EH=CI?4GdM26HhvjlT>hZ;pk+IAj!y}zT!`*}ZT|fH%cjzs=_jgJ>
z{NwN5|NU>?|J|?O|NXDu`^_)k|M%Z+tj!H})c4W4chG>8Jwwz3@@NfZCU)H2(AV4C
z-_zWOFLiPHXt9(AhK6;09rfKE?4B-mH=K1RySt6L^>MptS6sAQ(4&vVZ^c9~Fz8e$(R8
zNQ2L`GSXX<@FfA_anul)AP3G5dZ7AFJ$@cupl3QGKuN6ErS6H4g
z1R@Jwan8Mlhu5yr^=z93a1fHv0W5CjT+oAzcXMN3%y<(ax=;H(E~8$xx0B9fT`spt
z22)HcqR6CDg+!{PBp0|=saQlYT!4v8tVklKZeLWG0(mH5LLU&15#-mM6xCY^GF^FK|_&bK_p&gjI%&25~x%Xr9u!1*;FcFEM(uz2MQ?%^iC><4>@HN
zXA+)h*c=XNqyOBM@4wxcLX^z;lgt4{QQ`;G>pywRaUQ-HC}b-0C=Ht)9wu(NkiPji
zK??(H1xgt&{9-og#R&OqL7z1lgD|9GWIuKBvVlhd?|M9H3i>u6zTEbWklXN`E8l+S
z>eV-|T)leb%H@l1Tzd7TH(vhM>o33f+Dk9J{_?k9dkM!cz46+s7vFg0;_H{LTz;LY
z*n9Kh#jELT&g#%RJXXD4qgKnc)CEnpp;2y7TD#ccH0kupV89cP`#rSi%6cjR=^EH7
zMnJ<{(ppH{GqhBmIT<$sh{{N>{JecdM*X6jptX5d8zX&gdxov
zQtLzcutRp;m3al%O5Vxe_6Q5kg`#7Lp`l>Yv$X9M?D|)BJga#dA5W9aw;Pqyy-lYF
zJF4V--rPttudBMNL{fK2L!}xk&W`CVO`a=nLa$Trc$-WOv(Mn
z-`@YtZ{Pj-&;RzrAN=(P-~ZEh-}&Qr-}%FL-~Quw-u&}-uKwi*@BIB|KdSoJ|ExOu
zv8t-mRn-(fsi`^L+FCm>*utqh)!kOt)mBIQ7FK%`3B&HDGjW?_FJ;{d>z0O_Y>GLf
zWHRqn=G~gPf!5{G4%HIZA)m}USN0;RZJ&I{tK9V|w>)Af!Llk$+4!5FVHu0w595?U
zz+%RM0Wnz2I3YmDIOoeu^rhl7;}Z`1a=BDC<4vYK@TK6IQYB_cBokBZn?xdmQC(dX
z3D?A{BC!-w5zbjIQ%R%>DJ`-rVSF@&mH&}A4XLP+h?SrD^zBTAGL#^Ve=rfo8LIGG
zv3O>FNief8yRfu4zYJxFu?U$6vn&$9EJGH8dJ?g?JWD7bF(_JE6Y-o%0$I0XU@ZP3(r|4%^W${wO
zh^RB*H--FmpU>*|IRZXc&~Fb1%(=7^=<$0rKDQ>|(dOc|J3e#x_T`Jzq~Xe2Z(hE9
z<>IAF5Pp|ly>#*7#W!999xq>liN19864c|BE0^B7eChI)*ROv2Td%8>3X|EOH|YXF
zXE@@rST>vvtI23^It=NI*KE-QLk^Qg=LU=Y_E5l@O?z{cm5Db=E70eY4oK;A5|YrI
zh#6B9g*W1Ifrha#tUbtxVU7ijiHHS$ITo>|lK)J@2k-j)*X}(2{afGo{Ds0+F$51%
zNPF^WZ!rU765K2Xc6M`bzy0R&(!}D@xmlv&*wpk0z&CylG~|v>@?e}t#|K8nF#1Or
z{EdzDjF0w@QbeVHe7ql6q=f-!ffOd9GSbBzXyFcZ@&-DFxm{hIjiUqI`&;?#eCjh7
z4or&GfezN}c+X&8Be$OxR_^VE281wd><0nil>2ZDk4y_I_w{f{9(FZS9Ui6ZHDL6#
z1BDIUZEP6l{%*?1!GOOW>Zu#C3`0ZdQa`t&hS$k*Yx%ngV<~FrZLMr+
zsAz1eqy<8$90fMH?2fOIk)$G#v69nJ%PJ>eQx0}@ZS7f3UCm~(fR}ymuK?n2{^KV<
z`P+|v__rVZ;4eS;9>$-4_`N^<;H~$5`P26Lnu;?YW7Sqr@Pu`?w&o0zSVOHJ8X79Q
z+gQW>4YQ+dgKgD)&1ZX>t2#KRhr8L*`N27E%SdpY#HMK$j-AE296wrq-s8WTDaj9!S;R;boE)pwXn@K&&
zl~S5nl*_2DSxo8ER6z_v;=5Jr>pGQEtCVltap!%HJq{*5_w-ZGLlS=d>yKqJn=|wL
zCE?1FV0B?}3A%6zE_p?`ELaw-EDKjaLn&yu2E$Ad64Hi%AR!N4SWNr1RiT*B47Io-
zSBQdsn@lWFh*wQ|mBBz$of@?y7Pe*LmR#IQOTlH_nS?hIu)^g*A!471{?ljpzuort
zb0jbWlv0s!)uHm;p3QQvAf2
zh?-(yGvx^p2lYT9{4#DfW#gPl|8o@Ok$dj^^6lsU_LCPLxou~=7~CoZAP;l2I+te~
za4h_U*2(K>7#nKu>22!mYwqi7
z1`T_An;;2k-Vj)%HANfxJL?9a93csN8v7Y6_H+V>4LzNt3jZtXkdhOb{KS5;$#vs{
zjpKcF^2IKiA7u34{~v`Ah6)HnI^)54Ij?+yKKNF23mG6T7hFpiu*o!h!jf08=@o2y
z`6Y&|NP@0{Pkx)
z`rY@wBbXUy)!bOa>0(6EBdu4rhe>gZsN_Hn|d)x1X*Hwm4J8INXpvbV9T
zwPv8XYN)k_*HJyy--I(0y$v(Gmhm2rc6EG1IO0;y6kTguLHVXzyyKB?`xIqWh<%xc
zd8aUCU4~7@arqKm*9L=J$T`8pEY(7Ib7@C0=cI5-!ClDt=wndI{N^{mQ7Tj$T7}uN
z0hK3L${_w^Or{@{AQRseOPRw}(aH)OEHjfRg=`edp%h`FDF&^e^`w}NG9(<8)OQe8
z8qbjm1gkK@Q}c_9i^93N#rdV>1^&wH!otk#{Os)f9L_+xF9HAn|MW>jK~ygThe4JAv!E=Oi$qF=AJnBt`
zU6FvvXwoPZVyj7=O}Pp=3ZA55Ht0bZ)lAY83!5U)H8E#8d3~!y9Uc~`v*8i6VP&V~oM^GBKUkcY>Kqr>R&LG0$E^sPsEIB1+a*b5);1-6TheA-&d}B-Q$o4z3QM_l}~xDzVY&#SKfH@%B8p8WIB0W
zeG}{}Gm%U*!$Ayy@yew)eNmS|FLv4Wfq)|#_4@rTjap$fZ-hcly+IQWy1g#F&7#%m
z7cMf9<-o@v%#j)g2S
zD%1lFt?7TRas0>^@4NfU_k8aAuYB?CC-2-Z2DS?kCIQ=-OVaENXqaId?FwKEpbh6i
z!|`*|BalGRs86q0UiW
z*Fd@5A-8>Sunhy24SOyvB;P#P*8)`tBMjX)(BIP6*9azZ`&+rau*rnQ{w~U<=7Nbm
z_5FR&jMS?J1{s!)GPv7B`*lQwiN7Tx@kdl}kr%frWjFx>X6=Io+pAOF(rpE?@p
zsp)H}=xMFtwpaJJoEh({?`=8T*;)xOwYS%`b<{C5tf--K5uzahks58$GI+Ihm9^xZ
zD_JZW6m(|Ms!tVXPNk!v?|I(pcHuTCG?Z%()~tr_G1ajjT(wmoNm4tKIAyxvf>RgRR{5s!8f>
z$QkQp&y6%qaT^j&rG9nXA)m@RS9ZdRt$=*XD=WDv!H||w^@^bxlh);&LjWLxj2PFh
z(e-SgA>45`W2Zj&L@X1@q<9KbS62=$gN18SKoW8h7^R_rkOSeCmX_z|7pLdu
zr)THq=lOGUOEU|L3kyqtBm6RHLxEsPAY5KqrLeLHs<6C4C$6rp30GGEL}DUd4BBvA
zEe(ZiV*08;B3fNrS+$z=U}8Sy)oW#P*(z|Ejk`)Ynzl
zBFk1W0C@-?2L1Y=&rE-g5cIf)RCfY4yLf*>UZmX-VL8inM<174&_TPKJ(_K
zi*Um5%VqqPMdH=VM8=D+zj5*Pi!Xia<#aNe40+5ZMbKlnTD7@+$mP?j28eZ9v1UWMx08;9Y<{0T8ump(_U%#x?~T@qNjYc*(S$XbfK$drGcbAM7)C;2
z#2Ag3BO!A*WQv50k)V#jBCh8@JLUWCz5Cv~ZhP^opZ)U>pFP_2?G{5@d0!^uO{BdA
z&@dm^*$Th(((||6dVX#c{n*RGBE%$GPNk=lo{9DKU%iT
zqkY4}-LxdYIL#hXgRh~s;o*
zJu}?sH}KW-Z2%we#|Xo5D#fGYF^`Iv=#dUN)&^V>o=be)+1H>UP)LCk7r!hFK|}1B
z;PO(@!_PYeDTm~bfB0S4y0$dhrWZ|1<_3i09a)be7mx>S{Kaz}?f)o8fhw%7IR)O;
z)Lu)6CS_M!!C}_D1O8|ZkzIu|biSsduC}VW^2R}k;p#Iz9nBS|{!eYyjZO76^&n>5
z*~+SqS5@6uT?Kh~rkPXS+F0G(P}$UYwuOD8Nj_8Zt8?}>;4G|N%(~a?
zDHe7@Mwe!JcCdM(i@i42=hm-`_OVwcyR?E4xAI)kwNh}cmfWHpuVlw3ExFbTjuj|D
z3;;1@;{%9k+j7?ZVQ5G#-BZ?F){#lsiWzt!M=osx4L5V%V%}d!dBXvMf=Vq{tJSe+
z!09x~2#6B5%c>%Ar(BasR>UHj!eas{kcSMaD5$Y2k*`Wb@X^%s20)ZbW%!TE=}0>&
zsNPs6CiN&12nEZ_OAE__>G@@N
z&>Y8Asj75=vY_v!yULnh@l&t`EBGH0Kx+InGbsG|+QA1)dZiBokWqsMC
zD-p55>*3?g)ZV(HVF2+uGi(lW$43~{vSEKWMF}_iRG~~ZndxD3em{QGe*Bh$3{!{#
z!I(MROP=f{_KLpkl5eZ%g;34sywRw|>os}2c8|yICm`B=J{yMHWe#}kE~mxgG5b8m
zLe>=xsxnEl-@Cq5h`sUp%U7>J170d;WM92PZM-PF^2Wt{zG$%;^m>KCAU7Me(U8Yz
zRGZD~Dz(^b)_T1bgF)eR8oXX>AYj(%B^x@K)oP%g3$*yBH=PV@mLkA(I!Q~Qq~o;6
zDkTF^{RyS1Q!mJ{F%dQ;s5aRi3)>@M8-N%N>F|VT`2W`X`b&>IeE(gyedY5P-u=z1
zU%&gfm=DmrY1Ws{!i@NFgW4{I@e+6{9K+%gOv4n@xM5^sYG`bBcyx+V4lzJLO0^m9
zhe)K-lxy*m-r?b%v9Z3Pf0Qai8x9P#a(Mt^$1tx8dXP8NKFDnu7;NR?m=;B89vN&O
z#&dd`NBV%pR$!4P5NVnDMo7Xk6Co18#6DU|lvzxwixgsSH?0;xSOgHMbg!6}*Ecp)*VRGm(exjHSYGx7ScD6vV@jy5tfhDh^+1F+
ztggY+DjO(!hTYY|Zf~ycZmsERs*0J{PU41JvJT(I;$Z9PXq0zwDNklddtK95c4%
zoNFcfp|oK>MGGWllD2%tiNAOnv^s}tGvg{@&>w2(i(h=`si&R-ytI0?$*hK|v)ir3
ztl#4@!yUtyu2PY(VpRkh0&XG-F@u9^QdnjtrXqqOWXk3s2gP`?Mz#1Wq_~RHZgN`JaT_RR9N9R2cQ-YOi8*NzVThU_v(N{1ZMeR9
z!-Ip|(J@u#9UT=Y^?EmXxSIqGsqyt;3N*ZM1R%zMLRvrXBzyiSeX^gr`7nL36{M7=
zqBoy&6$`;Yz~b>*Jzl5B>+t(+Ubmr`3;DcuuiF&xn!Rp|8^dJ`c#YAJF&(%0ohqkU
zT*w4rfsYS2zx2iXzWU{d@4x5nTW`5}vy{^r*3Bk$JnHbcj5dqTZUv#dCX*@}b!hc+
ztyZnwP}?k)4Xs9})41J+RKl&(D@vtwEba&~34^(ef2$bECV@o{Xqbw+(g`PplB1A*
z+BkV+s6PvnUIPtFJsR+hp^yP6j73b0(Eg|U%16HWwXffI&m9ln@tG^n-t&`hJ+ieK
z$>sdHd?1zbrc+*`VKKB>3gM~HhRgivg(cX9iRrn~iOJ!KX__>o;Bpy=BRtqcYs~j|QrCk%X60q5LS|7tO2!5a`#bA~J2{}?^bluZ
zs0R4+E61p%E7Qd*pdwWmR89CG5@o|a`G{M>^D^yi$`|N^Z!~Gh$it#rP!@&-$70?-
zUvMmtWp)d<-77_>;Lm^h!)DCLZN71FyiGXM)n50pn@WL$w0S3{bZX~eUF+)4u-K<+
z**8KSmKS(}TI_7E>j1x+tH=8r``cI@O*JizEZ~n#$g2SUYN}2He>hWSVq*iVrJ2p)
z)BuZA*G#6n0y?p^p_12GH$B*BS1+rDlMQG8mv(i$;F4wC3h_)|H)Ghl8!P&otHwHN
zHWs--t#D&?oY%z~Y^!zaSL0sw(rAlhzRxC`OgmP0!^)ChT5?LZT#~GLdD|`Ca*F{$
zQiV*nS7^hOZ8_x-T)Rfsvw?=GgavxAobm=kRLJ@$%AB+@IX4iA?s5+jg;FF}%HxSZ
zHWLNfG#Z&$B9zHRYf_0oBwZDY0YRx8gcGlcWNRWhO&Ss!%jc>6w4B)hKR{AUY0~8+
zYAFuL?XJQFFY^WXZ*_@|R+j{8^ia48AT9}4;gtb6fnbFoxFTAC@)JrR75RKTmaeP{
z1uJ}mNu5df@p3>TU%0X?027x&0h7(54fsGAligulUzeEml2pu;OPC62fDcB`MlHOO
z-c;Nj4N~TCB5F>?uWwzH{rwy`czA?;2{hc<3?J;qE*upu9OsCJN3=A`(E-&dUpSyv
z*x=*Ie(a`$#PLD&U@x?{6D$>=4I#nYp@7Tpb@@Ej{hf5kYYMn+evdgGb^4(hJti+P
zQSbNa13rB=VfQ+4
zYV}f&Ut>0_by~H>Y_M9O@&ZnWnHKHRs~{Ky0Y@-o3`I=gh$)wKgNC^bEhLai&~jR-
zq%E1i`=K7!@u)c#x5FTZ!jxdhbT))Mw1flta^*5W90~kW=H^Gf^2nFI^w2~1-}(8k
z-TjHbeD~>39i=vb+pIsG#;dz?Nq4CbENz8fc;V>>9=r!YTv$3cKR;eBSZ1n~Db;4;
z+|bBa-|$$^#5wK=r62YVk9LhRab$?ZkrArWqbihT_c!+RbNc!?{WMp|>8BDD$}t2A`z1xE)I9h^BNtR1+#QA
zYFye1$#;UXEw7~H6m2?1S<_<1xR^36gN7JM>vGykPC4t~r>)D^uF>^u>4c?_b!L;+
zbj%7XRLC-+!-Tbvc9bAhvfiznE5%gZdwouWLGSn2VI(PVA_pBMVj2AD8c?`~Qw$14
zQut(|A#5^aA+#ZAh-Xu9S*Dap6-@OAWdt$-7;Mmr)OKM_jF*xKg=@f^Kqy+|!x*oD
ziHplCivj?V;>!S>kc1%-kS`D|FXLxRlF1O9`mzu@aslob99&!y%r7l1^6@P~C`f2X
zh*NMC*fm)+P8STOFByYPwq>KHbkc%5K`d-ahMAV75l1*+2n9AGq3et(ALM|-^Tz;U
zc6%pwut#S3{9*n)X~P5{c(e!0oH#j39v`GH9HnnMOk6mK9q&g^c4_wTV2`QND|%9K
z8}Q-xSRz5Y&!hLbO+L374@-rp+XWhukM{eFUNFvY!khHEHau2&*rN@)As7vbh&dTF
z27MZzcf(;-dYwA(9d_GkGr4Rgn^|wQ8MS(u&8A5uy;_~x=`!1GdV^6FiaIv5idfha
z^4mb(Xvh+Z=o2YRsp#D*`m<>_WFtm0X-y>|pRI|A1=24Wx5i_n4dW5mYAVZ%g=`5p
zWj{mvUgfH=Q6IZHqsh8`p!PJo8Iu?eQp;lv&fRwf$a
zV2EjV2nd37cnF0^-LP?Huzds)lG{N}d9a;{FSqpdHgWq}2K$;I410Uvg(+-8d4-@J
z6I=!pK|rd^>tyl@uK}?h#<{PXEu0?+JLRIq!41*4Y`)tr8*8IY=!0+IVAiqBFmV|)Ogk1c_NAO-9#||m7q>ktn~s$o
zk0|e;rPd|0y?%qB7*xmwJkU_G$dk7&fZvGd$zvjG-RVzGHX-M4|mll7e;r(mV<;t
zFPj@|uj6*GX9imF4kvq9dhvuqbq>7S4$5|YiXD%yZkK_fnrKC$SXq;RXkzIaAc(O7GD<{LR?Nslu?)ln2%!yuKMJ3e
z&tuQPk@6JR)=2TKu1J^oYs&%>gBbHm!bO1qW|@GvEQESoT3P}q1p*0!OOexQ5v&N7
z_zU=wUxWT=hBD#2A@NoPq}OsrQ4ymn>Mxz$w(05*A?_xO~!SH(`2=3
zBO#~LsaL9`R-3_Q#cfXG54fxrz}MpQ0dtN>&Y=o>%BG&&sZ9~tW(9_bw(>lz;K{4%s522e=GnMY0;-g$&F
zZ`wwA?W2I>04#GecYqRZxc#jIeJ%a{ErY!+{k>3#js3mw(M{#WRY(<5DPC=F2L{s?
zo7&sd4|dlN^sz?=>lMpGlid1q{Vb1qJglGc$O(l^3$IZi&o1Rrx-}D2DNh&Tq)R+#
z6%AawLLYc53&V_UF>7A}2eGFRvmL^arV%%t03<=%zQQdRRWX-5E8n^L`pI@uIN7XS
z9pHAHof&S)1+`h9W_GHZ!#Pu5UjZ7j;g?xAHZ`0HSVV`>bwDs=ns+KDPZH)W|As}y
zXVsjltvy{`MXA*Fb!WO-SRJi3&CNCV_WIh7JM`kPL)XYeTF5(B-Pqm4;&pTS+pAq0
z0?+!gW{IaUQ`gE(a
zeXHQOZZYp%p~wj{QCM<`vNk~uO3=#B+xQXPOw2G}bgkvxGAhxMlMY~{_+`bA?3-Zoy8oyv%8#ztyZraEhd#(3W&*M5}Vza&xB<%Stwwq{2G7|
z0F)8lAP>ntuK|^$4T*GO5EEn+Ny#UJk!!0W;i_m&D5ACsYk;DdSPF><^|u87D-iLQ
zSC{z0d74RtJQU6|@^5izF_#KjEP9fSODlZX>opM$HjC+4$hU&;SY4P~np<32-q0v>
zX&cjMRvqz~6iUE$NvV>AeU^0Cnu)m>?%0_{-3-a7BNGP%4e)y9mZjnAr{T$QfmuE@
zv%4MM+YTM>#m*m<=M9r5N2w#w@PPE-`GXiu9Ujp-qQ`qtnB@!mbn;*;P;OKM&+hXW
z0s%`T;sl#uior6U$LMj>^2&bD(5I{W!k&q2{
zg;dnJyA{c%Xjwu0N#O5<(yeI?WqTs#EQd#8VIz}oNEOzxAoXrYPzj1564Hl4=5WLo
z4q7m-T_a}u$Q^gw@x_N8{^}PWe(HCT8cyW*8ts9!}7_VgJ}fFRcVXOQXOn_wz+k4A88-H%v<)2O=j=iNF=L~a4bX-~(9k6;
zIfX^{QqjGVu+sVpahEXfkth}i&J8qp3@ZVvgxBBD)?CXhZg-jmAhIhuTWgap^@Wt_
z){HglQg(4}SYH{JEsk_FmV0nfhD~+#jT5{!lXONj-{0JDhE@xxzM-?ZhTGB5&Z%x`
ztgWj(%c(tMR0{l7#fEH=Q*(-4d5Tj5hEk^nc3pLK)#NqUDHf(Ii&@)p
z+Oina&&CaNK;b_W;)j_x#9ww2sxa-Qsqv^In{wl?pIIS<;FzPXf7B&EpK-nL{4?MD
z<~NlT9;S>M2s(vQs?)2~8f7BoQYZkk6_9OBytYCCUdgIhwz7tYA_zeYu~EL>gYuPs3Uu8LrjaZJ9Ls+9#x%gZ8>0H%3<
znGX|i^yT*B})rS%TkFL1QCh(GMR8=U7C)2@<~@J
zVlFR$i4hIyV_`!&VN1r$VSJe3@0c{YYuD(5ZTkoL<0JUu@?y%V?ak=kZsO>GV#g;S
z;BoSBCwj6MKTmUo@tcomB>Oyfdj-5kKc3(=6CYhVkAqQ#KGOjuX*=vzb--)(Im|BTKC{m4Fgk4;
zF1tP$v|B71vsoDl+Z|T5!=^WzbvlFEX4eM&wrIfN_n1N0P{S
zW^Qz5esp|_J2g%14$Jw5BcsfIyazfFYH?_UP&hOS8g??Hdz4&r`}kPb7_V(~sBMhb
zK0efr{V2C(6f_)c86ze(jSb;p(*(C=WU!Un*E#@U*w--F-w2!B3rX1B)YH@0-9zq}
zGHl2f*TY29G-4OKyMsl-u(zJuT|3fWKhe(-jJH~)Jco3^ts3&cDXWJ4Dw2oLgC5l=
zm7}Of07qy>Kcf(VNWbE`>y$|hGI}s;UrqxG_QkwQP_Qq9hIz+A$%$ir$+w($3KEvZ
zzyIfd9_DR1*NS$9*VkIn+g91$aH^}ls=bLO4LO{%b+sQG<25gx>z*5GcBhD}E_q)*;9_1To_r$e6S&M)Wfw-3)*T
z8e)I#8ePu@*OLbLm~u1#F`uFJk}{Nb<1A)9MG7>-HB&)-CQj2h8jalHG|Lt6!f?Sf
z*$26|0;a(igK1294NlVR-s;*4qyDIJgfK~YH{hgLELmBT3MuZfDqLNGHWZM>mg3~{
ziipPQ+JazZc~vqm5G@GS=J{)j%WD*3UKY$RugubHpa?!1-Whgyerb7badBpGfuhm^
z3K=i+=a=}i>+9l3z@boxHa6DXZp*qFDs@dNU5$rrDXRCNTx%+@jT*`Q#mUV<<1i_5
zrf|R*^6TQ)9aE+?0FG#6_IFdXwERx;8JVfH3UHcaeqhEH}<=MSF%||InMauNd2f#Z>DzDcN@LPgGr`KcmdMtjQVXG9%XFMUF(d#t&T(*$k
z;rANcPOZnK&E-7XTi#UE=yz!&5r@xXaa#3u%SJ5ha@xQ|v(2WnSk_%Gs7^cdU@95Y
z1BNCo6k@<{k4IbqFZRADMl7(knaZa9xwNmGbd6hMDh`8e1MjH4Ya9p8c*GGa8|0`B
zQW19%SmSWe$RySnZ~%=78ixO+_w~WS!F_k%^YDWYJo3c{?z`jGNA5a*`KbpV`rN_p
zW`qgh`7&`=9>yf=%NBga0wuxEEsf1DjRT0Y^P{tK!@%M=6Hd9dItoL>;jx~f(JnY;
zpb+w~Ov8~8T3K{>q+@)veSEkD92_6+0Pl!~yteV74tQkR6AjyjxlNP2=Aqt}p@BAx
z!9I$a^!7FN67m|mdz*Utn)`YhdV46%kP@w_vjdDXbwA|xHgG#xLp`iXZsS;A-O41#
zrQkvpy5wBHatJiU@F;2CupCN;HY5Vdm^L=jA(xovkzV(_VbU^RreWGP4^@bRYx&sr
z`GRvXhk-NJ>71RPw(~cG3Vch(wH&nzdzwzI%=XPsw6`_U3Zg(^J^RM~j+%%=l=8_u
z27XuLjrFxR)UrNa	G1);+$ogFP!e_ZV6draL{{UomxCoRe7qm=5zz=
z%t%ke(qwl}YjsO~H5@T8Iy>Im)eh}Ry|tNr1&f;gQ)ffG6pMWZkZr3!trU(ys}8hR
zbv2#sY&gTCm6U5Id+H-r$%bGspqX%TdEDAXpv=^FqqH1T01j
zb7B4Lho)gVr3xaZkto_OK;XXOg&$sm!D
z7zFrMDbYnpiGY*@C{(B*7}cv{7~vHG(GW@y)Rc%MFvSAF3Lg-Jx#g2jhR4OXi_8|w
zib%RhVsI6hTVj%I=9bsy7KQUm7%THjqJ?F#dP6_ED41O2&(TQ%bRr!r3uZw>YU=$7E-9E1w@6N1OtgZ>1Hd89*%p|Ot2%IwHuscFM>&+BIjyc02
zT`-^x1!$dsFc{=DUb{vgY}?<@9v$Y+9~V!KpbgVITXF1<5Aqid^XKgmE-64Vlc=DTR{-;ct3VRC&9hOj^rAW{Q+Z&5G<1q(_
z<8kTyE{o4?-7LgBF1UM#!>;nUbv}>I=TzVx7LM6qv?0wL){X5_(q#uR!B(r!XLC4o
z4u`>L+_2h={(#$JGn&j=&=8U^=m*_=@mMex^X+V}_C5Q<`9tySp3vdpLtoi`^Xf
z<=$@c$dr)S&Gwr`KHbVlZ{65HoqVa=s~L642Y^BkW00W=J<4IPVwgNKHGHKAa(Vbc
zLk!uF=lY{4Wv85XLLn|>>|h^1ZCxnSFk_vALQGrci_V3-jSnT2u`U1Z*Z+3+r#D^N
zsp0OkDYq=;Q?@mnYHT>mu0I1BN|t$>;f>w+de*PtcGlF@-oRo*^qt|W2F2
zwkB46{aK(8Qnab5s;^ToWr*3cg@*
zkg9l#W=_Q5)R`;x0&-klzsWn;>vP0cbG*(G&~Y
z|7Eu8zuortGN9qfaS47IBC%8q@9n0J4syp(i+hQa{nYMO7G
zlZg)dy4|tva%#O!Z7%8YyYvpb-eT3+tcIY^MksU`6VZUjX>~h6f0xT?bU7_Hr!JQ8
z8cZ6u#|l3li+Lg;7+d&*P$?JQE=6fxHEmBN;fraF&RSh&~=OB;wSt3(_wU
zaVEkRyhCc?6*NPA$HJBfCES>z0eTn;{d1l2c4_nTpZV;=4?OtDLk~alz`YOL`Kd48
zb>UlIzvG@y?(G)Bn|XhM(i-fE1nvXO>QN=;&rT&=UY=UPt#Rqx+`>Yt49;Y;H&~R+5YZM}JtP=;5BOL(Z$Y=-HHx9u#$}B(6l&QczkH9r^
zTba=|JlHhMZ5$eC9PVov>TMY8ZS3jckT9gtJiz1|mX}u^VCE2eI;+P98ywmt$>QL|
z0Bd@%#;M@CWc>~)#(+-+3k;7ujAJjMkYdLHT0hZ=e9JlPd7JK)mGoY)a}7CpRTJuReSanyZXkO
z>N8bmKWbYS9w$sUWlj5G?fhsjb$?);h9l;%Dw>*V+FR>eTi8G$tM10Sy3@@qtmdYw
zw#KTC=Gxxo%CVjr(Ns6D3%)Sy%Qy>7Ky$wY+Z8ja57G>g}u8)+dYY+{L|
z?1lMjLjKwse+>kLG873`#6Y2d`Yqr&GI;6*0YECDr0Zqjl2FJOE-x%E%`LBhhI61E
z$jD#eskog!y|8!@2YzK(ys+OC^qB%a6EsdZKv4@E|I12m|LwNBojf|qpPVmY
zzkiU~-bw84rf6N1qwMhk1(dgn0g9`Xg&{Lh2pS%2hL3h)N4xQp!_>(EAriLwcsI6{
z^Je3YM97v)xHfZ;N^rzlpUdF)STd=g&!r1^O`C;;&qeE~z$x1-DoR51;0cDH%WN}i
zthNoCMeDQ~9adW2#9`B#4eK74&1%s*9cH)F76{txjt#HR8VI`m0aq;Mk44?kq1(l1
zk(o5iro9wLPFPb3b24VZof0D!HO8WbSd_Z|<2V`t9H~f|p`j%nv?XAfL*_`>@{bUT
zwOm*7U)x7^wzqe;w(q^`?g#I^?~w=YyY~y9dHBxb$L_!B`7eL|{7!5$7cAvy-K;pw
zIqt@3M=9^Qa8n-N$zL2@U7h9gCubQ;-H+TU~)wURx8afNp#sk1wFcgv&xP
z&I`y~Q!s^E*4K-JK+8Sgy}Ie;D824Ik`9
z&chC4P-0CCzL+Kxp&a*cCUt%vluSS&;yJseU?JnB!s@gypK<5YZm7jn%u&qXe9-SU
z(DErRV=U|rxb5+<-{-P+Ya_ixE0`c_QezSbkbhPxJxN>CKeWk7Z*ks=0U?@
z0C9Sn2PRHV4oprCPD}uWJ>wGt@XO=ppb)z!#=9p+x+bw7?K(HsL&|ZiYnUL|HZ%l}
z+%`4TIYtwR6k35hCV9wf8leJ}MqY0dx0j|4F=$$_w_yOLxVOHqn}xycVhvI6!urvH
z`tbqIId1*LK($WT4Gsc=81Tqm#gHF+8P}&6q6{0=2vF!Rx4%}6gN!%;8JP?lE~MhM
zEA)Xk(6F3j1LT!w(8{(kWn2J6^8YxKvo05Gi&=^_6EX3PDX)68t75#Xn%7a&*LHTa
zk1bi`bv2&tZmn$v3R|i=S}3~G!20;w(pV{?KTaAWHhDwcjV+CExNH`y0;8t-R2}v;
zr^pdkf4r&w%sj7EB^Vy>=QOZRK>*f+m^Bskb!X&)(S%i$b<5|*yJ~B1XkeXgWLJ1~
z;
zHqC~#Q*q-$P)k4r3Zt;krUe{F3^ajQzC_oxWs*+(x#MFNkJu@_HtvFA%EUdXxHBGu
ztJ2X|<91SrOjkRIlzf(qOEBQj>(;6Jv~*3YlSyT3G8qL>R@bD!UD-ZE8#1$mtIMlv
zu*`hu#8nERQ2baV(X4CYF&`}OJYO`wyr$XE<1@Xmya?wzx5$ho;p`HBc6oUYqHjqs
zy|4@>f`&5-3s8lbbPW1Msg{D0Oa+S&WaJCP`MgIem#&GRKKV?p>;hE
zjFTW>>|igrvmHF5)WYNmL?X3ph#qW3j(6inJMr_o>GRa{CVQS1q^IEWb}6z|i00G&
zVm@5R1#)RuGC>^!@vq}{=raj_z-w_jsU2+4=djuI4x7Q}hA%cb?IyR!7LB>#qvKJR
z&u#U4Z25FJ=(8FPO1r}t3c5T#V7~YRQ8q!6==0uEX2v)98E-wQRqPPm~F_7EWt`W0+WNT{+
zK-}5cx&8Lr@44r$haPy~o;yB&-)$EjyYCavefe{@?xl9~zCzBI&d|LVmN}brZ03EX
zoa5KO{>AgpJuVcUTUr7W$L0x$BeSz$;_%cocY2x&d3f$zKbQ!G2%QL32!%L4+6fwt
z4|m`Iz8Huc8R^8sv0)GpSnOn?C=_cZn>^4o!fPDna)t&uyuQXkCTh&qL>aD_(N?qJ+0Mp{;*Oo)&u*@so>Pz*xGp3s9JzL
zT$t*tsrf(cEj2C8HBfeN(2$BuSstx23fDZ%>rnA=U2B?a{!at@6yVrI9TIP3vp#NB
zFKq_3yJ4+Ov(VH~*;sd`ja}g}NYXB)MlhW8YLY(naA#$I<0<6=ce012TI9Lq)Bg2y
zQD$Z^VP3$98|UJt`IK=Ua0e4(x*34aqZ)@Egf_%+%Em7P5od5vzC_oxr4#r_*kTb=
zf=R%pLV~EBvCo!BNJkCdqok*pV4{ht_fpne+H>dapTPHmhS9K7tA#sWlSssCYgG85
z(kSz}phN;;xC%)~s*r550HP3BEN;d;9y>MuT3uTe$*Jy61Qf2!309Q`O(bR)t}ZRo
zoFHWvF8)Ij0)-eei;#gZ#fvk{{9q{H+Ac(NMm6>OS{B%C_6@CS5vouL1TO^wwpGz0
zKKV-3S|Va)ehUkj9t#6@`bf}#JwD_i|3=Wi9tvusVc29xz-J8ljDD{HA7h{AI(uIq
z5Cky}4gkdB_I7%IH*-{O0eeCVMeXnUceZ@T2UM_p!Xy}Cf4CimQ$E~|o!`%#-_Ksy
zOTtQ@KZx#b2llo@JEaJ9%P+-Cxe!%P$ISp@BI@!uEx~}Dar9=d+W=Jv2u4C)SYU_K
z9Eo}z4x`g)wA=JfyV31{g!F`bc4*0Pz!3_$`~geAkKY%!2X8XwPQ_fX#+$|XW-*#c
z`O-;GAs0#~-I;`&$;P)cZM#gkT=9qzD8%0eMV6_e(Ta!Uk;A|)^{Rp5E-#fAkJ@k?
z3)>%XY%k2syqVzIbg+PwXjDa=a4^z2HQId+I&p-e%nTwsCdXPPMq9>4AP-w7Mq0;)TgHc5Mz{^5LoLJb$O8?$
zfqEXvL-^%JsKU{H&S-xFubVyG#~JFW<8`wp1{=ou>nHj+=LTyfQ_UU~*QMwO?8?Fr
z2HDMM!=P$}v>}5+zkG;dDXL+oe9)(0%9CZojO^Nj^6_
z(vtEi(_W=cI@8{8wt;nHbN!j-#BAR
zP$xTTlV#khuua-pcSAGhOj}cBM{_N#F`IS6^l+O`C-818j`h}cG*!2ADw
zEb+#>>ShKwGeaDOaHzNClyaFXpX;+p#{f9!!H8it4)bdugPbtU<6+jukLzYKW(t)6
zdH#(l|Hip84a;Y+FF!0_qU+iq{mRSw;Ey|w+kO~I0W`$lu`wAp#hC_ncmf_WhT5J@
zx$(m~6dDsq5#me2wKadp=5iUu
zGJ58kMCx`smW4uQeo!#aU#8L$;nM8F0@JAhV`XM(X?|&8j=!|PUv)TKUXKIHadC-1
zzpw<=DOy`y<}b}JF3d0T6R|)t>PyE17Ng$b(8(1dp>R>DlqBK$BcQp3R(Fe-0hDk+
z8}=Ik#8}vpjMxG`O@Nq4g%jbhozk9t#(>Whyv`mr2m9IM!~F44fyQBRZzsLClcY{I
z1VlLK^zmVAyW~GUNSz#}j`pJ`hq2?`2o&P}X5eTi!T>QvlqAhaWy_mIFP;x3?rq2R
zcOZnlg&Y(vY_~BS@;DuqP}t@1n!R50=4Qg}HreeuAK7PT
zz=wZgpT}v4N8I@KXc$(&lgk940gGAx_GTDLaI+W&1Tm-rFYdxEFq0${GWpe%fQic(
z#f>vcD}~1Bj2*WS*kRBx9D$R-9n=h!9S-7{vTdMbqs-DM*RBz>ePn5gU(DyXilxKt
zoiE&e+dcQ(`S3#z-2H{mJ$T2bzkc^kFMst5H}Ax^^1(vRpHI7()`zr4UoK_IrcBv1
zDfSnhdtA0QC0HC;TpXF5AD)@v&CCoz8%{GooSqt-p6r_#?>RTsKR(tqGtxaZ2B%C4
z@!UwqxslFu!|ju!EfXWn#KEDKk)g)X;ii$HhOyzMQ3%7q#<78>p`M13zJ}r623}7+
zx37MF12~b0!8FMh6-uc$~@py6J&h(R6b_&2z~5?6N`VK2m(jVc29p3BY0O
zol+8vK%`CF=avp)PzEBS2MLH$T3y~DL#_DL;v^+P|D4gq$x}*u0
zOuoSFYB&qC%&Pp~oZ1^$bsukUIPKQ+gLYAS)9D84aC3&kIn&%+)!0(m)KtkoH;{6v
zi$Pt|rR?V1*xpdl+gjVsscNo2+tO6s(R|h*nTR>W(q(RQ?MItgH*_{tjt?|s{p)u1
z!W_48tgFhSTUwp!SmzH1Hx{DC#guu8`W4!R;f?9Y`niO5CTm%W=x1UC$N8*T5Z5n+
zwKMoCz!%cZz$wEWmk)3T-+S#EUC)LaJM>^W;b919fKA5z9GHlONl!6az!D3QS%#a=
zB&drC5sqr-R~$B5`{ua(}+sBL?%*br0R9W8k1qeCpow(rd&flj51#+
zjK=&LwRA-!fVV3l5An@8`a^3
z0|sW8sQxSp@dBGnffUdXA6=(?okZew)}nxVU>_Cd9b%u|-%Vmrk`0~7!2+KgCXe>v
zmlG$)=_3fkgZPF0*a^T_^d0Vmj&`F!Aq7$npd6!nJK?RO|6nhCup7a59Umldu)7t^
zXPt$t8$1fqlpOp%6r2b9NCZAQ>ULUSev@%G@Rv;m6A^dB50=@f?l|g6#sjIC7c`88
zoauzOR0waCBAcaXE=}z$vuS%F@6Dv0OlpBU5pgD?_*oE-^k)ET%*-%QrXdw0BDBA^ZV?%y2}4u2|Sb%?-o2&HS@AoSK?4o6MzRA)QRzdh^Zq-hKD|ci;2n
z`|rQ&wol*xx%1C`>GO|2_^Fev$PUvJoBEQcV3uvUl&zS>pPeZk(f!BY{`%9O{6M3e
z(IMUAs4aWvJ
zd6oZ|#E@ha3C%{)?z+k2=GXzaS
zsTKX
z3r07?+I&zmGt$bc{%C#O>Bh#Y)~3ql*6P;A3OMU&ZY!KJubtIY{n4>LwtRV{x23AR
zxu&&|y8Js;3mK1GyEf)pU!5Cj@2aopZLXLfY1Iga0|ud0J}aE)P|o#x<>!DijJR~8FbIU8>;LMVc_8{ZJicY`ob(_~WWXnry%K|)YIg#`k%mzSnevzgT
z=N9G{mKSBRHGjamva+x$;wzOhryUTtB%^kqFd1YKyV`#rf5mPr}z8y
z0V>FKz!!snejh2skl*TdYP`PdbIL&BJ`+R+3QuV6FLkhokv=)d;o-?){P;L=bOIn!
ze3?p>4-*UogL|8Ph{U6vFwqd;+oj^={oTlB!F#w9hH^aEjUFGQG4Q?nJ7JIucP5`p
zpH2Fb5hy2LKJ6zgruDHq;>0pE;n
zmcltoqM}J*+~KkrH~xL$o#PQ|xWL5C;D}9$819btL=3NKkHu_chbf?Jh*9wg@MjM)
zD5QMsh&3EAhl9>g*c}Pk!c>&<&ot!nxC;vl*<5CSZ)bOV=g!Z6{=U2KdGLYz?z!uZ
z`)|ADkuMy*@b%k2eVp1W`f)=55DOUxMV51J9OTm0Ow5pq>Rx>QQM^{bt6N$enVIFz
z%@57a@up`6r>6%1#ObO2*{Qy{X*lK1>B+9ivG(b)_L)&g!nTRg*2$69iP2`5<=N2=
ze1<0no6m7uCI*{ExHMx(@{m!8u*T4U03!cfPdc#9pY9wRteYI-OmOSZ^|2*0t^SQM
zk9vr7pR~`X7<4Q8JhB15W~^+MArH%zIj9R!9$OdzL5Yb=Q$(;PT8PK
zaozcb%*-H-kah~XiS!^K$fV#A_^eP^iy6~m+AyC14NY??D=9}j0Z*fFvs3WglMmx{
zY>Lt8{_3&LDu-%Ly3ps)EX?qldRoug%@W1hTvPp-&bGRxnLf9HZ`UsNw^y=jKh{w9
z@s@_u%?%%KZLA#VteYKc>uarSWuI=Uy#Wx6Sl4oXrPs9DTKh3jZ*8VWI@dkWaLTM$
zD28=Dlc=ZR^tr*trID8Ix{nTZRIZ-u+*rmHm<0PkbDAGCFGh9q5#0;~ZQghQs4kp*j1QnIqTz+Ya(V6v=%!f8lCrn4c&?4odX
zLAbE6WHPCBCe{4h(#*`VT%leQGbJcXi*poT#(qvDU6Y8#(XgMtvLq6VOeRAr?gP6)
z!&KOs3|pg6zEP0Q5~etb7Qzr8U8q05pAu`zi6DM2dE`)l(TM?r)1|p~jXv0RxPQ$W
zpFhq){Q-sLp08Ay$Ed>dN6C}pBv4508z`S9d9)WfWR_Hh281a6^JWL$#XOH%>2fK+<9`-qk`xc;!(W0Jp2a
zKZY-#h4l6U7r+a57dS<73rYAaP
zCYdqOJ`XI8w~vptOpm}Rw@i(;Lg`F!8_x|l31@r9d7M#h!w8Qv!sP&qlf0%$*kNAN
z+*r%nY|lAv-NJZ_O*LbXjOc_tK0r-5=#=+5p$cXF0TtJ;zm)5ikgkMaymo~?@CM|;6vqs+*q23L0S#RE+HkhH
z>1+qQ@Jugka?~wbnCxIz|L;j|v)8y9u&j1*K4wy$OM4|g<4SA&#~bQy4aM`9^N4KCFrd(
z6NQF(AU?P;8QeGrz=iZPVbydKi)ct8rp-W7Wua)9zp}cfFkAG{h6{p~1-@We
zu)ItyYACyKo-bUW5K5VbWS^Ip1)-2PkqFpr)?mOLiuxCp7F6rfB^cyopmH&jj(dG}
znS9k|*Gr|6tzs0GF&Tx|b6`N=M5&K}p4nSNBwNfuKd6V_$mVBaCKxyl1)vtGJq+L&
z^y@udTB_)SZ%6z2!@cYgl;BbB_#}6Dm@YeIMjNIs9Md>COu+CS?nM|NCaG(~L3npN
zu)iDJ*`jR3!@b1e9+Ql{8`~)acQ?bE1=5B%bF`lZ4UhM8M|){J4fb}c2*7!_OR?Rp
z#5ROpAq2sW8(T3OEfr$9bPz6hGZ)_5itlVjwo5@UbZ#n;Vy!Y-0@4M^H&wb+l
z&z^tki?`kT+1-Q9(00yO$hdP%IHj0%<-YI%!OHEKGFB#N$fI#LQUBkMEm4O%h+(!
z^jLGuqX^i~U#cRR<4bSoFr-wOnLu~nc+dBXM$KHPiS$1Xjy&zil
zNud!Hq#i}r>?YX;Koz_%n^|eg`%0fTulMeF@9p)OWndbnfre?In^ukzDN@pm%u`4V
z%}67WRC7XxWW)|6FP2F7gx0l<`RBt{f
z?4Ba+wtG_9J0V*
zvAcb|N1Bufk>V3KKDONudd+3d*33|tDMYA0oRZ>eU2!Yt0}8|=B%~#0rZm|pt)tsl
z`&*~<@~X?CviaTR+RYR7o2N=wkBOB_%f}x+_T*2TdiskmJn^|FzVuhb=9;hOeYLQ4
zZSLroexOslkqCvMR4U&(BUZ0Zt%}>-eCdfFd;HPQKKaOJYr7X*e&^=GGng~c>gcp{
z=kqt_pZ(HbIez5xCm#E;-OF>Wt<~oGV(!9=-1f3nyJTU7TU@n(bs)jYS*vuGMxX@C
zt4eWMEv%@8RV{y3&8_J9vqt$mz|g8dXhH?QBgd3Ak#Jsl|hZZ8PzA+I
zICt%a7aFyCft)JWv1Gn>@hX(zjh)?{wT+vXu3XsJz5%4Ta`~DfcSWI3+s$9Ue(l=L
zO{yw(t5n{_lHakI-xGQeYdr(&xHeS~P|GIOwWgSAyccN0%rXeYCsINiEt5$(ilD{1
zh=;I_RzGfLUJAK=JARqGD8a#P3c#L`TbYV_-94~hzC-m54`$|_nf=Ov_wv4bZ{NmB
z`R+^`4y5TwB}KV!fCQOZw5CI#oOCeO=%JZ=m$adGXBHexJt)V>?~R9Ynh2ATd3)-E
z94A94KCGkV$;jEC1mmGQ89UPvG@v?2`0+pje(sOe=|Ejx{
zKC+NFJe4fOY53Bu9S^A|P=P_7cCDc=gz=yL!RkH!Xh45;kpl$CS3k
z?)u)=%GFE9FQ0$u;<*>04KJ*|aAEbiv&+w%U4Huf@-ycbp0t#riY3{?6RV3)VSRUY
zjyQ2;{)w9xk6lMtjrx*rnKe9mQNlzfBNCIvrqPS7u3q4vUftt&xtw6
zNvw9UK$df-l)ckh{)}9h6ZVb^d&kI&lAFUaS*8HP6F@)Ko)9)q^fr${31;fAOABOl
z=(MwWtiAr?;V1N6A6QgE(~+{Hz?w@?bEE{DOebQbc7fK&4NB6;G$vM{Xfx3(XXU~Y
zR1aAdv2ezUyKzmgTxhSKs^2`;-CJBb{^Kt^_Cwv`C8NEue(~7xCx3M9!m*ndUV7@$
zAAb7i=TANVa5sNNC|}dt>(>^Zu5B#kE}uMq=BX#34Uc^8i7)@aOHX|E*)RWKclVsj
z?)HLOK5tepnbnJ4{ZdfBY?aR`Ai>fK
zRG|&cSU!tWwX|v!SM|aw>A}J|Wp_m>tjL8GsjzHSFBr_1BJ3?fAz}nAf#e@6`dU-V
z^hKwga4EswF*s&A>{x2e)~XKK*P6P_{0|28SxFLT#%!-kirJ1lAr55xMX@|qQ5KrD
zN`5y-6}sB(CS@ekHt#n#aK5(Yd0e|*$n9=p?AF?~t2ZuNj<&tC4Q;r!y;&-iaFbfC
zbo1u*D>trRx_b5Ubt+qU;mXx45&7ngb=&B->Wxh*AiG(s6u4f$TB(-HWm)Rt#d}uI
z1KS!k5UxS{SW?ccu2yxWqAPW@np#z5fsc@_g!p91kYe{zxCi
z@-WrMBV#tTr(=B|%gscX4dp?|?_=^<8zdsrhT?F5CAJhn&x8^yjYE3SwR_NvSQndA
z$(6Joz8;}3xwPp%{g7l)gjgD5;cV#ae**5EIkQGJiqYx`NhZ2oq6os!egtaA31;K
z$ho;kmrs6q`NWr3Pk#CG!Vzw7PAM&szRS-;8_M~U;@$~$Z%!+mR`MscJQm216KKWV
zm&84?35t7ja$#O8oB}pNT?$(iWFu~$!b%w{Vx|fyZx1c{%!~4TXXB;APw2ZoXpP*y
z>~=tT%(Ki|a3ATr)@8eT-m6o9UZyLt0)_6QMQH0XXiLg3LQ6tdLZa5yxOFvZUX44~
zoazOvOohT?bLVtxZ)xN5b5i+oGk3nebME@t7oUIPb59-p>7{<+6K``pnVIsVv>
zY@C1orAL48nJ;`_X=|yTJOA_}Km5#*&p&rMuW1$D+Con^umf!IBOQ^A@tFK2)heX
zaaqhSLHA`d^)eLV0+e7j_{WRBwy1(Je(jsk4mMj_;>VxVAFYd_Q1I>V=vv*znJvV!qdHZf@PAEai_zxYjXSY)vJB3n#*n1
znx&l`EVyrO?QUL%iX=1SwqvTE-47@luI1qM;9by*r-(vw9Bbq|)_{I;Tb0U+Tvnti
zaQM(|!W1G-``zMwLTn3MiRTL#Jp7ElyMqD@_rv}Dm?|~g8{EB{LO)Kaw3mMGuK&v2
zm?Eq1giwXF5XMTGwRfrYXG3!zAUT3U^zI!5Oyxnld6QI~4au{*Ked5}2c$_!Cr(H9
zY>c(AFdCSnk;V4sgJQMEu`o$U!R=3RLwzz-_D9Ny29DWsrPMw&WpF4Z@Y?7v<@i-j}u~`1_!w56Oiy>K;|=QuC)XEh+6D&n$^pCIb>PFoedW)$w+AN{i(`hTRZrVW>GE
zp^rr|TmOS)xYzUy$e0a#xWmy5E=w*7=R+H7XpH^OQ1-fb;1T)N>f1J
z#rDoZ?&|US?%7jM|JbQ#ehhd>MZg~W(HD>Y=ra%hKxOl6H+RA7?KIa{7N7a?`quKL
zxuefK{DX7PJ$mxlFTV8Dj~{#N^QG%c`73A2Hy5@q9J_StNb$-`{hcMgw4&6{8;uJf
zJG*)T`qwF+2mP58OtY$%&oRV`vgGTY3y0;8%h*J=vRyxb)7Ql=mG$2^A
zjK%V@R9M1=YMH{eag)Q(=;ItVzTyVxiDHjU6)R$@XJwI>kcxD&MJ1)9l5$bohSDPQ
zdA8Yw*0D|MkW+=JQOBgc1lXSw4}#M*PUx3Q#r2Kto9mk!+myk4b7OmRuaLK$e!Ej%
z+qkZ%Esk&Aym^C)R^Pa}zP5ei)~)L|Zmh50ltiIeEJJ&i%lV7fuqM8ClaiiqvHb#W
zUB7;HXJ^;5b-ZkP4Q4wqDNTZTgrMB9(r-f*Vri_&RZVKD5{1#=Z7N~~Do>JXcxzNR
zT5N~{XtAYA9g(YHgsI4iEES*}4?m;t?ih{ygM)Z~A8X_gczE|V@Gu?@ZRThW?;XTg
z%)Wfv1D!!3vdm=<3hoZI(1zA*Y)^*{QQnNnzJGh>4Z@`+HgED#se&|wP7p{Lva)+qfkvep0r^sq=}TqN<E09Lb0ryy|BfcS<$CmK+QSSFKl
zqzzT{wx;46!cmekv(+AcM(lX#$YV#JeeO9B;)zoyS65fIwl6)H^T#!cV^a-mByNfj)>t(uPEcTp9?Ypf~c{1E&_-q-_UE
zkY6*o4V}9wbuMfDYZiA)>)%kht7`9x*1ux#H@fAO;@XR?+(LbKu3cWL@6EUJi#ykz
zUBCEbdFxpD)-k@cq&HUe+LBgVluKuTgwz(#h=o&1=@hgcG$8b#0`3DX7SCwKdA$g2
zc#ewQCDcRyWVpcg|m4e3~m>yS4J%g;PgvEj?YoIoDi2E#_%4OEJ>Ti+b&XQ6Vp|
zUdAgqukS6HSmc823dDNi-dufCbY$`JbuzItv29Om8xuPd+qP}nwmGq#Ogc_Fwr&4&
z?_J-^x2o59IuG4vonKegu3dX$e_P1*%F67m7k0FPi^24t5)54Bj(Yo
zYZ3PvY#KtB{~x1s)W)CUicx!!Z`+x3N(mrArg_!5Pq9SkdW}jUl&^^E__k%V*t-{
z${Hxua6M@{{ITDGTeyt`uGg!L+m^=@J+*h0O9_jq(MZ`ClM3Mos#a9eQ3OhzfYANA
zFR*s1I6OXB-e7)S-}mS7q)|*vOs-hCKqC0Twr{_Y?;{35rgV9`X6JiI+_~cYU!y|Q(t^dRQr=Uac784_P0=74Gl#9
zr5PTpdJ4CMtEy2y?Rp8M?-^2+Kd&1RGUbqb2Pn+?7R!a1nPbd
zG)qHhYgF)fNEXSoY+rr#a|IZ$Gk8G@a43eIwa^Vz2!>tI`6yK7KVvpYt4Syz?98Gp
z5ETqj2vNB&aqTCS0GBF7mU2;J6vWj!P(8-6uuI5BQP6#Wb3Dn8*Spxq&^{~s{s3{E
z+As(@9bOZ1Qq0ac4r$cm9^5c1Ibv<9d2>3wcSmlMI@NWnYi3$p|2aRUCQpzTiNiQ4
zC^bjd=q%7+I!nILEwuv7rG3X~YK75-;in8}t#5KtYXrko|u47(sao$U&G
zeY8fVC;Oys3k8d))`V-5kYRS%
zZs`P^+Gvq9D8icmHrsqBlaxu@x7tNc$NF4JDvi?VFSSu{A7N!fZ8|A$h>73GmXYx6
z*4HZLnegEswxF3mxqntB?a_Sy9yd3C1hXcPQzY1%e;d!2lP8}S$h0QrBF8-DgX&je
zj9Z}aN*WK&=0-c&A;_EL0*!3pAt#b%Rt9JKmUyyqR6`#T8Nut$R7Mp%xIf^hPsRoU
zJ-O>88u(>ZW_BSX*rnmOcdX9~S>O*0#-LmYBhhD=u_fmN;8UP%a3y&A?9<1HB;KP0
z!90JbwWxGJer2MSo4acKCDB*to5_{3El)LRacQ#6T>Yec4!hiIQ=nuzPaIabqM}^E@8yc@81{HsoAjnc;m~Z({7aADFwHyS;5Z@{kG?
zyW9SF+6rSQ<9*-me%kUl%d+czWVz~jZ6fUQw1Zq^Kw2@(;8OJ*M4prTP_tf!a;0a6
zZS4v$X{5F87zkbMtZ=Kd1o+oXYP~hahB)mtE_DlQk#j6$
zKwNb{V7L+rh^&?PDO^7^LI{TLQ_!WtEBcd5y7dBYL3z@sg6`Riw8g~DyAxf*XA6Z-
z+n;;Bq?YdK#h0hIEossYL#ExcMT6#WqNLlylCd6hYv@&-LS`jcgYU~6CGiNIAKxV8MWNo
zzo;{qxT?^Q|M`L5{f~~$_hyIjd-As@&;PM-$Jph3zS7X%-rn8KSDjXX+@Slp{cY>@
z{<{2)ax4pYUs(}$eT;Yh
zUq0U=a>q8?+Ajx$xgJ$+_EbLB;cnn^e=hK(B`-mQFO7KGpaT``{xIQSHjj9;_Y`uZ
z-2)qSwL{n!D(_6e>{;v7{~gOxo&r)@Sg@99;FNy8-ZVpM1)I_d(=(KpKybyi;C`xM
z?vtcC-r-PDa7Y9_?IDO^D3PA$Ub0{X|L&Rz-PhuJ5AHc5b;>gKj0e6ogk_{4<5NkL
z3pXqH3DPvV>N3_DB8IRo|1(0iQffA}Sfo=HgeFd&styR=M&`>yDySC!St;1__fpvH_Ep3<)9D>>iqWl`
zxKq^yAzR|CWrzessA^u`dm;4bsV0ZM|LUe1ROHPSeQQe^?~#u>=sfA}{IxXprtBtO
z(mmh>_4D`D#)CMR5pyGT%oR~bC*kJiXva#r+`@ReW%XvRheAkO+2aP-F~5H?b9l;4
ze5=gs#n$JO#+RYc2kzFZs(JJH7&KUAjsL@~alX8`M$nl>bu?q%UTzzu*5}vsQ~`n
z62Ucc^*4O}7m_bV(400aCo?aXwMpr~GONMky(oAd%
zVH2)xlF8c1r6tSx9?k!+fJT+h+qwuzZq#>^8iZ%B|4mY|zyqtFQGg=8gN#FLbjY~G
zh6b&xrV6cI_@v?3%0;e5gfGKWYwW%7`qTa{y*KV5cP2GslSDWA2Rw)0hCW>M)TXoWNU~?`Iib
z84`+dDLg+c)nJ?$+;(1(jF3vL{;^L^A@ntASZWi3v|wvX?J&Q$_c>bX%=)xwhz8r4
zT#60qVy)v?rV>0D>A&erWWe5%vXk&I;3!f<-wWC{)HH6}8!DCOu6eEFx8pMQfsaWfgWvoCzN+K6L7618gmh`s(0bwDP9me0ENwJbOv%+>>!@xg$(FG~Mukmn
zR7@e^Da=b_3afwdSl)Q(V=acQ48=_#yA(QIZvNy8A
z;dnr|{0rqKm71xD3w!fenxo)|=-8*IOrb80lY8VzIJ5&hd(T6SAH?tAT0DeizuUMk
zT|8(FPE$6!p3l#!t=EUIBlmm*3Sa$^u+zk^i>+6;bV#v`XTE3!mr#EKSl<2yPtjd8
z6MAk26J2IItl?T^*QR0IW=vR!_4p*|6mN-=a*@bRk~*AEA!^WURglD#(&`pt*y++FX@+&ma`JWlbcb(uYt5)`~3#eZ`9q4XIJ5IR_~1a=^f7up?C!TVFV>)b^FED=SeAePq#8HV2iT1;2)1X$Kob{ss19o7{9vQ0
zDw!y~30zIkdr+7rEQ``6$$1mtX#gN8RgLhNSwWW_F$8)%JT943+%XCe>iHAyh@7EK
z(AU_!8>N6Gne_KB1e-@u^DlQGfUVKnm>EZyufRw@13srv37pw?rHPFhd#vI@&>W&>
zp`LvUj-Vkyj(gWwYJz8hNZ!lJdO2ZHGVMD!XOeE{7k4tQww3z
zvaiT&3BTy_6kpwri+h+CC>{eLzz*PefUGSXV8Iz{9)b}|
z(a0)zGDh|+m^P41Gn`%++EdC{cKbVv5pulTs=eIK6={rAz09^iK{i+0G>%(Xurv1x
z;9n;zS=O_#-AYG{%jHI-QBam*lupvV{^@V2q0MzWRP6Q7Vo>&BA?)3)prA%5k@*8Fqdwu-@u)D+sZj7c
zk=TvV;n!NH+jI35O$kCUG@daPJCh6cZ#z~83b8WLzVe^VO8hWi5${dD)8Q9va#SI;
zallKEZnARO(Kn9Vd9f+)4SIGULEyD}Lz(A!`)!TkdAVv9M<~$H(?bBhNhJ4JHqW8w
zw>S8-`9;mN>!s&)^q{`wbw{vry}@Bxw}}wCz2hIpM||Vq3@PM?UhQ>Pjo0P2p
z!7W{Qz5WdsF--Li2jk!GtJIC*ftSkh`}|e%*-p&!C5TR+etm0bn&!+Z@Q508=kGQ{
zQF~S>gpFvfQb`M(QW(8*(WIoSJoTERJzU6K_DA0Uwz+uaU8VpSIdn@nxjlxt+zo5i
zXeVx%&@x`gGTxOPAM_x9tTw){@YX}ZN&l3&q@)I){12vLvMspeNuhB|83k>CCjcKC
z-n4L2-J^K29@->Vr@Tw{!^Eca-2BrAy+V-i*Kpc&e{l8mK(170L-fx%X<5Md0yf#a
zW=5k()(OAtn0RA`CS_K(g^05~Y-Dmk*wae_1KFky#i&~VLzuK!)Xh1KGonCIoYP;5
z(UnLWn1M)4z;as8l8ZF6suxYWIrRc0PRyK&DzFjdj;+NMkD(j}TQ(@Q1mIv@SJFYE
zj+TMqTfw*(&QO4C(yS1&ze!$8W<3R4r?d%egs@&Iov^93JX`K6z}g~3$_hpQcTu4M
zL;~s+$Is4qQhl*fnm1}~E)t7lCUpcQwND3zKFp;7uO?n!Y-KD|?Gk~oN~9i2
zaQ-w&;#{sUfV=Z17W?MzF`;-KGor|CZ^jbI+U3L3;l$D7#KHX+UpAdIq!O9j(FTT6}_Fg&q|wXvRaWHMLeZM8AnP%!FEOU^da{xg3XzfBnK
zD>pkQ5`6j$yQ3~WDBuHU1@~Th>X+ZM^L2mpxqCQrIDNL<#=cD8yZ_x=-!j#t<#}D6
znB{uh3}eRP^UPYb1op|#-yiUN4^&Rq1YTw(w%%W%2)myymp9!X&g{D17t*ObwiI}I_RFY0;&BJcIpTK9wxTloG&C5vVugrHZ~
zES8~=4WYkfZ6rB5W}Uay%sQzP>2@XjXq5Q%>@`|I;*j|#ak{@E*=*%+8=3V?Qd;}p
zNC)1Z$(*Sx3dyU@=M)M{$lqlm%PS{T$yU`W5@$2kFn}r3iaOX1-?2$)%s?-}Tqx$M
zt+vp{FdGl>Tnh)#^Z66hPrZJLyCND>oa8y
zLqP$86vAgWyk^~ZncO0$6Yr?RkfiOC$J!_nQ}kD!G$dnOn3}?1Rur-n&>4d+iVUyh
zH)a*2jDE#{n~T&FsIBfL@ME9NHw1h#{Uq(>z^4U-3Jx1Yn*7bE=gS=d+xS*o9l|14
z!?6T-N)-#9i3MOm2=6})`WIP-#%_0zD8#laQ-zKYW
zmABC02Cul$HU2mY<2UgJ9dm|DHG>O0*DIs``jk#U;=2dry$1B&ij;JJv;Aj8Lw5af<_rjj&zF>EY&UMA#+_dsdjx8Evm%QpvCkPUZ`Be?olELY?=
zxU-x=({*xhi(|7*EL6DETWGJo@QGgJvl^gvuB()V*}O#F?E=a@TV9tLqgoUja>vyv
z6gg7
zYosqh6ezfQ1wrAirbB3t(<~+q!C+_Tc!2vI!uc~YT7?*+oo*fHLw2>GsIhW(fIxd6
zLk<4c4ls~Z;)(~!Wn{WE?u}UtDs@Aj5W~n*k|0tVWK0uX(L`R|;}9vqLY~5xOdrXT
zlGeg01{aWMf;pFM&D%-VDZm#zzy5=OoQIT^)MC@5I^W|^tUvht5IOtvR|~P&3IHeL
zK4D2s^B%ru0u~!~oPZMac%kQ8gA~CJjPK8hu%@8mt|FZz8-%D-Ndpzl_xPMCpH5Ia
z06~UX>;-hbd>C9c5NG=Og2_G%n{eDkr0P%ih>}jjQmtXX@89sHGk-KKqNdxA{RU!2
z1ZP9BWSK-^lW!qkg4=weA5SzsR6+&hu=u*=U|{40Fz8Zy3LaCQ(2!HnLGZX%yw8dt
zEbKfRursP+J+;yozIE>ZDQP4U(~At!DLy}a2dqY?e)5GR1LmlsULH(UL1#
zoJ)!;(PN?`T`L&J6^eI!w
z+WpVPA2lkPHx%ffg>8&NfPmi%XPDuzSsKiF9JrVTm1RW)LTNf$it0!Rj(YS(R*aumT5E-3~lDr!#LzOLz4B~%Z
zV)hBEQ~?h#uZeWfq>*w|O{HSQnpB0SG0f6O-5);pOrOeTd7kXQ&DKiM;b?{o>tWG=
zCT1-{q}k2i!VI6UQ**G4KT(Z?we#uy|R
zu@HkNJAbm`)f>dg*poq)-OlIcngjk&SKenpJNR!0>tH$DfJ(XPj(2`FI&a}zpSRw_
zN5mybq3p(emu{A!q;R?MSZ}|X#|=nyv*j`7&Q^T9$*JIocvuz8LP+_jaILpn-$W`k
zk_~cAqO1@q2qCp%W*$K+HHw9NWm<%cfSvIAIG}nwFbE_s2EEes}
zSNfC8UZqmM&2~NC6)aRWYiP7YRB!P0F;H5ezk#-u8-N-Ao!Qrr+2?uQyRx6<1@M6O
zC>7`7_Q>zO>08?_N`jEj@&0BsmiOj)PhJUccVfe4Ws}ra+r8^B_Pmda+w!
zq|##&eF+AsljDMbK11_*nytu9>_Rb9x)iF0!T+b#QIz;m;4FXL@(j&`lcNv%grddv
zJugOjG_pEdBSCFBIvoLKU#LQ?VZuETt9~m6#q`(;6YX>6O@4=jemD%WJxTh{%J{=0
z{>NMo6?aJ5gAwuxE(1kIe^D(q7B}fqScgaqA249O;CdMUjzNMqzLKvhtqC81g^
zA(^tr-(a*|A3LeXXe5UBZX|qPal#{_qfnsB6u*-+GQ1&Mq>y(|feyeB+*33pkpxb^
zbYQFtx`b4@mC@uj!aGEffPh?ZkR0Go2gJsyq=PwtUpMXn%OO`RB)F7KVhIoq77q$t
zG@iI#Rxw}18NLi;R#Ed3CnqIMg6x*8KF+{bE`D1k?;(zG0m`MX6Djz)2$>6~39S}v
zT`hZc<191Y1P90bF6&Fy$0vifE;eZtg#8(1o;_hGbG-cG`)AvJ=bJG3TZs}nX6Ks^
z>NvY
z?_)}x_eJ;jn)TZS(x%r{ciWct+2S|!?|YS_J~r%acNk}AgEiJbOVMLrj{LC+z1te<
zO3yx#plCl7BUs8Qnx^gaYE=vy5Vmoq_LRBVVcA@FoHHqXgz}=AuC<_z`7pxO?ZQ7F
zBn`%WlRa0gTr**9FIY378KdRMkt9(9+ae6g0f@Hl?gEiJV*PiA=IPVX>7ld9wQ8gt
z{n#cS`Ql-F7To2e^=~?gr|fS|+@BUu6|9yzCH%}+@?PI@BXp~Lyqr@5G-7Jo@-Z3<
zk;uB9D-dE{@LkZxTeC%8XF_dE7P8=;$!6l$4BucBv;xqpxOwW6PIOyLWT+C?av(GM
z$W`G?YJ*plv@LcS>)1USMgFjCcA+2V7yp*f^iF}b7CS1v+KsI8Ub|$TFcXUxG^QzO
zM(UI^34t&asUNS6q^yL@c5JO6jGD!ccX^rQMt+LPtBqOziavKE$QVFtD?r4c(F9t$1@ymr2hHMi7$WlS5!kb;#G+Ik{ZfnDJV-xsE5-l
z#BLSR*xEDO6IZQ@mIqaEGoV4;(B!6#V4{B>_p8;Z2aBIQ;idzw)WC037d*XTK*pX5
z7;ra!hny|H_K6@mHCCPK^lo0Uk@vv3`2Dw>;lBNllvfgnT|Z&Pj{8`p>u};}ccbM0
zi!b2NiZ~EooItbej$JUVF7Z%j;~oT
zi6G*E91h5u|4GrQP^v%3ni>%1KqO88Wy2J`pjaqh?0i5GUG?;+?KUroO#yqT
z?{LDE1GwU`opB28OY+aol}iYPhlH3(;MI;08FYA!m3!2oIW@S4FS=+K9ANezhUY4HI{0?h+A6t0p;%dA|_t-D4NaU3b672`;S)hSrwob<_L`J=Q2tcFWj73wy
zEUkkvI`9!&!*hiDZqbdH{R@rNh?E+YO{w7=l~n}lYtN0OWgiz(1$JQ@(xqjv1M%XT
zkkcB$c63Xtg-WY{jzg(suoKU69fV}s0Qhzsn&sJ>A(>cvVq`|K0rFnA&9mG|ElEJH
zzwg+e=w})8rm*bC$_=ewSy8rb!zXmyIS`$Eaj}csd#-8KONEO%jZ{~5tJZWTizY3n
z*r&@F)gy_2^qj4tTwVGr8G$VjWdY-po)^(t8S1o7=|&6X?{up9^o$B@wR4SXx^uL&
zS{|BJN-$T0bKG7|@pL3Q6L|&>JDLd0m3>YcVPOb`)2GRNePSwRBLIP?UA>-+*|l!?x}!hmmJ1ZwL{SN7GKgwt~m`{
zX3$;9Q!|`32i-=FyJjt4F0TdP`TFoT?6Dwy7qMGT+xzm~hb(@N@?RCb*GFGvS8ut!
z*CJncPoLL%FOzw11y^6QgfE{nA7f8n+j^h5gzuYQlV-hFUcTp0Uq=$X*XI;{((zGdYS9tE$6^?+b+Qbq0t
zU_^_pXwKyr1{4Jc(_fXVqM#c=i#H{fCC>_AOv#eM1!6LyaruL|r(dzt-<_3h2}lm+
z4l+{#Hm)%M3V`Bo%6N<{ffF-!`5&D?D^yQdel|{LjWrqg(_(Rfr3`b~d*9**kuKAq
zIA?x^*(0!+wvyUuw`MgtE7b$fh^lj!NA|2vtA~rMmK^Pa3*3iY)0)4U^tSBM+Kcbp
zzi~q@#Cn)XDl2P2`t-RN3%H=UJnU&{P{BbbrBXA4mP5tca|w?66p^td(g59+V(5
zwsI+|A|tKe!_BCJryrXXIlB}b
zBqGQhp5sh}3`l-;+>J`04YuxunAySWv|G(Kxk)9@C^g3lG;wH+QU1sJhQ%Rw4>2D+
zmRcbwE5h#FKj*Qwj~B$=Z94330cJhF4Ijh-|GSL4+vncp55T24yB4OB;uxpSqS*-{
z<X2&M|f7~hUP+^
z_&XU2h4X~m4}|+sG#Z=GTBbrrh{)
zXEcs_p;WTvL4MY{^J0T4&LXO46*Db78{(ZC<}FqqzD*moi>D=)H3}7%s#abt;yoMG
zE?$Ioos)4c>5x4(g|!i_Mclb4qMpg=y7{j?IH8_+#}>wjMs9dKdn*JX|DbagGT^Td
z8s>)Je~|xfW?h^UjrqY9^Kb*eL7LtX#6^mkT_K3czFEnN{WE5~F9;bSJ`8Q>kv>+W
z5~#4#+rW%3)Vw;hPMGy3vZpWFD4jb80;#`zsXhSZf(z#Ma^3Tr=
zR9_UhhIy%OhMc+9;obCB$Fi7=(h6oNA|Tx`+~n)?VE>w;cty6j@V<*t9S`(d#1_6d
z9+|yX?P9c#E!xhoeh+uV!mo>0vR?%s7bvX}rg)J-k~pKcoG22+0`NDk&($pX6J_g6
z$4EZXzi~tVNba^kek-^UzIBuBr(gd?=XLaoUJUpsTzLp(+96(Z*de1uV)t#OpUI$~tHhs=i0XuJYcwKk5
z*Jpaz9~XHZdq;k!4{o{w-7MMnhrUGbu*N%->C%Yqg~+1tmn$B_bANo
zn^y4LPU!J`C*Zh0D&V$H$^TVC__34sywiJ&D)9axaGTb9bSH4_gXH%aM({Nk$M2L*#TQ^aZ&RSne}mt5nr3sySUl8II&@zlU1|slDKh}vwFJNJFfiKPx(*^h$8v(N!-0x#Q6duD&{qo(QxOG7U
zz%{i703hv;P~wbBUIBAb&itUcIK0p(7h{Q`sc05DvdF7V!>LuS2d)*`n}?@fAFsNd
z&3~qAmT$8j_!7l^t29?a!)v6w>xWxtGXYD_sUvJ5rr0cS-k_8uowA;T|s
zGIvLqNB?s99S(<&ehWO^f2%aomc`|9-MqJlC}UzA{pS6eD$;u$c={;meJ=Z2$m0#}
zxqAIyDlrjlG|Wsb!YzdxbK-?F77c^MTVM?*rxh=wWashjgu-j4TXXALaVVl97#Sym
zH=2pFrUc>9iamk)jrL-JQyN4ix62t>2m)rX|KhMcQji1!u589+KZ}SOmDr=){7BVE
znZOnGuom&CW!cT&tV?)O7uUQjG0~mi=vIAI_DZEPC-~jovS&D;jV9A6gRf+yng?E3
zk2e~xsaeakz$52cYU6Ci*ce@Za{i{rX|SGch5+l5^qC@S@DEK5mViN}@5nNdW*^$7
z4;;%iYTU&!o$*H|N(7;$?*i!%1t5f%b-J4iu>_^c3z^GL#fHO%#_ZHMKxq?3uP0mF0LoPg_otTppBvS+4h{LC>eh-GEtu
zu~x+@HcV&Quve6JOGRAgitMg+*}>(KYf;#xXIDO<)qp9kUPec*rwrx#FZzQU@2kqO
zI%_VIi5+%sn6@qZ-@iVXRxMbj;ZDb?$6guXhZ655x#7LDNC}k-@#;PDLYSuyQ2^|b
zwFke&q+{y~L2wY?X90x81U+I>#_-Bctb$cRFQF=y{*m?3kf-M5u@WQh*7BvB#=8MO
ziRUZwibwSI;aA>o`t*Y(v`a)DDG&RnHVAoGfZi)ySZi&g6#M$%4UZBk(?qma%=oju
z(yU=~9yPNdl9v8I!y-~aYJ@E^PxEQ>H^0@`BDiGe$H*Y8fKA^+2kN8(W_%i!X0VLb
zS{cxAVH5{2amV}yA%OhHW;&H}HYhFBoH0>sKq#q8U>jtYfiN2kszo~BAb+kJA_>9B
z7R2_BC#W8CR=os5L)PI-1B=-`B--fbS(O1*&>|N8oTrcWEcXC#<;BnSGa7Oq#
zDB3nfQ4Kajo%Gin#dKoQ1ik&on{x*chM~zZtb|d7B*}231jQfVds3)zGV8v__c}rB
z=KAI<5Tv`e!JA%$c_8|%4mWf;D`y~1LNOo;`QJGEV)@6H3-A3uTt>eOIpE2D(DJCj
zSB(1CrJmo>AcsVq>@=A7E|FEChy~uY(eC;`Dv$v;i3MV8uZsk2LXVgPbufGiHR4vs
zgp8<~ZotYziwzQ;`8nikY?;mLh^zkP^K0tpd0<1&&oiq6*QAH#jF)S*VqN*gvxdM&
zak4*h$!7_U=;o5nq~AYW5DZ>E8II~bdh@Tu^>r><(V
z4nQ*&V`m_Eh^J2k5IEoiw`&L)XzJ5n!3c_c!JPr$LbD2I0oQvg+)5ar_=mlU783p1
zj8j8*PB6>`*b4GIOtY5_xn^--qCiU8J|*~^Gl6oC?fB@^Ii8okLq&14iE3i>uGYeyIMHBy;^!4X%*FvEV_B6)aZJ^
zWkc;uY7+@GG*hd$ioqW)1KYD=F08r-Iute)PS?a~kM5-t6l7A=DusbyHDKwu<`<$C
z;!5}zf;M0eEAB||X_o2p6jTe`L@Ww8;NI-RMV7chtOFnphL0@VL)0TI*k>C*iBO6q
z-OS~p|JmpluI8ND+>d(VrjK!(cdkx5NG+9_{dzk#0?(_;bNVOFt^_Tnu#XS%G4YjFkUcNoy+?QgN@(WC!xR$3>c<_bpM$=H5!Ib%nmMp
zN>kIgKo?nK*z{L(wMW(Thb1^;>tv^J(-22w%`T#r_Gx9eXIQ
z+u6h>aB+7e=JlUvXMK~?$L_RDl~)!=)yu^hrrJ>)-_yO(_oFuRJNEh<$oqm{Lh##n
z_^yJ;kT69DZ}3K+0I-SGmfQ+5Y95LQ5HXl+s!gDQzVXab@8Md@G1hA>^oIRRKaR);
z``zOacUR&_IKGEP^}Bs|qW_p4$4EHsDZ$K=l|I(VMy@chf7>E0s8cLep}xiV9M$;j
zO=sK#MYBUch6d#ma9*3ci{R8)j4`v###$>lQ(;M*K|@*%K@Y7L9h{dJZQ=`yxLZxv
zGWP`0MpgZNVr!TZ{z$ms=TKBYlE5FC4WA9V@lVzWJ%5!v-
zuCl=ka|@=F&bCZhx|@qG#Pn2xeR8UzvdRsC+ZU9!ITY01g)+?6K(}90Z8yri4WE*A
zY%apD6F%*@tgD@6s2pa~G#`V<;%lBz!Cp5MC7d*vmHYg$wNkmSETl#kq1Kk>0-PDu
zy-82?a&PNm-|J%AGg7|$k`>!h{$SHW7_|n7+nXY#Tk-fnb63x_n{JiX1a@Y|E>BTQ
z%Ts8aM+(cMydjGn61hvbmoM8b;p9=_JL(H%)zxxNe$iKS%cMzV2}a9$G%U
zL>~0>fA@zxKcj3jVGFYqWQII%cU^LVe>wJT7AzOb6=dH6Xv+|f<7Gny2L&l3V)(+#
zY&(GB`qm-HHuS%iNH0u_%`Rfb{-USj_B6zXLB5(+RwFEAMR?<*$f%>dSXSmcu_@O5
z#FS1Wy>T4+mF94T7hJFt;?IM0^J@TrOmzG-o_y^3FX5xE{Rhbu$SFgnqILdv%<{h!iPGsv
z1=t%w6eI7_`=-K<6~x3Jsjv}Qz=*-q;-%soh}{u=mKuE>glOrt4$yJ2v~=eB)2dN4
z-I6Zu8l9L)WwwbVv>}vk*3NU`xiOg;M6=N0MBeg|`bCg$Db&rid5MUE*C$F;!&SM~
z8hBk+Uh3!00KAr@~TS;Sr>q10|W(6^8LF9r6l*cozBNOMqh#P-0Y6XJ`y-
zQ1H=ch+o3&!uT8(h{Tpofj8CUtkyHto04`h_Y_*pRE=ej1-q@r#S1*f(Z=kOjYQ1w
z)8`3-gTHcP$A?Z$0)54Ud&4lBS|#?_d#}P#QIR5)Enl$nk-aT$j8N0USy1;#2=LFg
zB`qbmIa=F^H93Y8`sL{iM1$THjzT>J7CoukYrLjx=!;8_tN55X9w)qg>a>9rZ-xe)
zsaw`*j^5o1v`3u>-o1)wJgT5`wUITj>eI_kxP21?BM;M6m~}bYJv|-HCMQ$FEM-T!
z?yvh!^8fI?KFCgdLG3EKm?3_o)#{MxQRmoaXxQ0d}oC($ykw
za)mL5KAGliP{1nGy{fknbu(ZV%STJY%LL#r{#lVAA|Ft1k=?@-B3TYqr3@Hr$p!RD
zB8a~Pw3-1?=B=WaahJ5Y5!ry-b>we9~XcZ*UqKb9K1l4wYI^$^$%CM
zLx#2({=2LvJfb2gerFm9Xr*MK$oNKs2OY!MwhmjzkLwepSdtUUg`n
zTg1@|!8OODGs+Yz-&mPvA+Pv{HBm*@(S4g2a-&q~7o>AU*ox
z7YoMkkxO%P1AF8u3%WRHya(bw2XJI(jefJFR@_|8_*K!Zyv#RcFTdR%2tvLhuI*&)LkSfkPU4&b5TPRZY>blaJ6;tPH%aLTF(qHHce
z`?(dwzY?+gV)=WxXH(cR)&m>Xa7R&=Op7Gbhvvc`MjOKCrx+wLCg7h9ZR7JHh#Z5`
zbp^Ij>L?N43;;2gq((STN%?Rf5Qd26R$RLSfFlbYG$zBo^$A@L$6rwCV^C_8&Dfg;
zv%9W8I`KL2@4uT4Lki>^51LLre<#;HP+_J3;
z6zwwYw_aPmMz7wFzFfY&lypswQxowGA
zSs6Pm4$9Y((ik2?Hpt3gek?39s|i_>zQj7m0MI
zqQgBAkbe0&WCXj{I{sxtZ;zv$boEeWWXxa#US=Semehc12b)B{ms4?oi4v*1NGn&$+^JT*D3@7bkTX0}yKeooYvBy2M${TCz+`vQqLLARk)PLx1`UyS8
zSR}ZepZtYLx0?(fY;E>qn@Ie1t?XC2+%|`Ngm&3%t6kU1DyMGur}xFkT~16~ch1r%
z-x5RiYPV}^hfhsQ8ze^cg|5}*#(5eQczm7pMpkh8-IL$RQRlFWB&}OemGwkS_R@-%
zjVzMS#pTeMs#3-nBg+N?^Ru#0Fx$0e<$^K<+6qX?uP!SvSkNdWbEFTIQi<78<{(Mt
zU#%eF)q|Hw8$wk`3piv6RS`;1F9!C->|tRXWs}5xqS?ZLez<(A18#tQ@OX9J*n?yx
zg{4cr=}c6a`49=83uLvX49On-|Qhu(h^!>HNiox$|?U
z_HJI|8@1xr#`4_BpZL+w{)IpP=l;ZJKEu8~pX|{Wg}x~Aiefmf8>L|~ij#2^4{XOZ
zP0KJX-wTpB8K#3_8mDpa&;IE@`S!PeHw>L9bmGWOnQ0Khq6TgH=}P50Bk7f?`sQu(
z?K}2c`{t_?drFnV6_45TKsJskGN&+OIE)atsivu0mSNetX%iP(07Q$K1DQJ*Vj7sN
zki*vzO$r$#)Wa!+F&{Z|nO%@ffTjsdl*v=fxbTn^Edh*`aiMLKOPcl3p@&Qp50T&|
zxS?(1w&Z;_DO!=E-E2$}8>bX{NHuyhA^y`k)RK*mm`?{6GWW5ebs@Tf31pLF!H8f%
z+TjbWu5|DakWNuDM!YXtPt`gyZC%;UM5a2;bcv$0F&jTq;O254JSwSeQLZXtRTmqeMpy47c5mwU?Cx@C|{
zIx9sCA#)=u%x+N0>W<28d-w(V1P;el{6LLkBM21VlLxVxGWbid>KHl$+Nn(&B+PL<
zFn;HE{u2Zbz5o83xb~fQUX3D+c2Z)F<4h(adqO5dXE-E4q|H3=g$(3Dq)jMFPak5T
zG5`?*?@0EiWFwqS$%r@`>yZ74Nn32vHX-UTR_YF!
z#N03yrek?Ll+v&V#+nYK*-)O16mlYu)bYq9m-o=7m_;n55@VX0fWOf0Q;m6_Kq?J^
zSsmYPC1D>(ho_sS`V17C=#WXOke0Uc2XS4BQLVgm6Q
z3wlxracMhJw&`Bacly4|#hwtmenP4wJA-%Hh8
zqVL4UPRQsmF+qX1V&fKt8)|EjzDBLKp6F|-erurKATyzS4QQAuH&gjmEP)ZPlD$y6
z;))ks;i4~HMr-xYfewApA$Q@vH<|p%hX}|FgkZZ20U02!nw=HBwPa)g8cg1r!WE{%oveD#90oDF6WnSFac
zxudajt-W^(IEWSkDC9~T0_d=?*3aKONG#0x2fzHct$xYsmp#53@Kt~m5uQNpw}1D)
z{>nf6dl~A1!^V0G95&V4LmBke80i2h2$38hkHKGtgOFOPR3V96$yySr7DMEEEH@IR
z8OyamtOPGmNF-Jxp%U|D2s!~@4l!A*_sy@J!ryZyY?-F16;8o~SOQJV?+5Vu=&I|a90aJvP!SFn3|Pbj)#$>nhEULcn6
zT)t3^fR%D15^50oOqk&F33o>M`Csqe)P2=Fy&*{i($PDDQi>$+bN(
zG2YF>A7{Wy8#F0p1UWItsZI7#qkG#G4_skN!p}Tm;&4OqvvU(e7*V7n$HF(cp)Djj
zAF8~k^fkVzat*#&tnRK=cW>2lYmNLytGFY!%KchiY*vJ3S?SiLcC}M0l(ui}+_d|cb8FYK@6RWC1o0qBhC!Ivj%OGK1r>T>6h(t18765G
z#$gbIffIRF5;%j%8%O@v-+dbwe(?UAlYzURIxi3Px2D<$x3v%Ms_)#^UzzG;JBbwN
zZpY>>;s~&ZDdLou(0;HqOS#8;IK$ZlTy3&JaN*@HKNNrhas@d+@v`Jz^k{gQB0{jsdDt!gh
zR02eDJ+oaDDVC9pkwl6HL<5iZH1HyUW=&P)+Qcz
zCzM}Jg_q<0jH2*szFsyJ@M6={nubOj);VSuaBLW#ARXGS6ok6x(LYKMXh~=eV)7tQ
zhQWB?QN$_}kRl|bLvkg9t_B8{F8}PG{o}#V9SprRr3qt}eKMPP=#0kBWa1UI*)S@gZIViaZYcnoo+ypT!5YynO|&%$1f9U`hs^Lc
zp-a>;IiST+EKL(-1a=Ih5!(ZWY;^>7B4(zskj7G)kPO+)Q}8YsFNIMI9Hg+2QAiik
z<&g}aOnh8UbeJI{1a!#wuZIh1H)XpQ2U37PE~^{4T;Nj1iSKmoZ&J)t#)(UaiAzX=
zUKI8t3RvVpw|Iq+$l-j8^BoTFh=C(0vkyA-tbSxGv27fFf&Q@Lq4!^#ee{*l&;R6W
zf9q%7_}Z)K%lOv?+7lhh<472VgqGj>^?ymW)}Z?<|Mc(U^cR2rCqak9pg9a`-}<$G
z{_Su7Z>e2KEt1&Wqt?iQ5wifq*w~A-oy6FQjBNlS+Q`@pRSG?f^i7|H;tnI6DmQ%T
z8YGgh54Bt5T$ZlK@->PwRIUOFJ@FE8A$QK`t-8H)KDe+?!G$4r!ROC<{bgn#Jj*=G
z=g3(M@}o@T<;+rOwaAW`on~S*mdR>ZKLa5&tb_KJtopKEod*|c)di!zY}UbN5K7c#
zu2nJ+W-OQy9uXm^4$Q}FigIZIrx^uiHbQWlS^~G7Qp+o#)W$2%J*dfTV^
zd#C$_h5qiGw6`GV$do9vU8ypHM2D=2%(DzS%>2s$M41^N@j0+B&nI|v3Tr}jo3Bt#
zNw=`xD{koRq7S$M&B%@SUzujpe&J_7iiO%Q{_IES|H?o3yF=;F=J)Q)6O8v4k6sw0I$ok+m;2qjb0Cs^`^SF}JFF-(t
z9#;g?d3=%JjN1d)5#janb|>ewNv!s+)yWxXyL(nI4>8%P+1WK(+g5kS>g8-)1tMhE
zI(^6d8Tgp_*&i4n!G9x)tpo`2%%;fC
zENNl@6S*1rvb!^vn|b2I6%IUM=JaQF593pdl69tJo)p1|W0N1*;>eZ;22U9AcTX|$#9U3tENo`
zKLfN!dBKte@}q||(;{9pEm=3Dj1h4w;zBa-0shEX$U+PW=@|c!dCzra&n5S??+U&v
zvM@C{B!80}dTQV)o+k$$M&!Vke9CXYTLuwou8S9go5;S8Ig;m!xI^HHK21$m;`=7SC?)-cu}AH4rMMt=G4{QP7Xjt9YH2&M$;`Ln4{c0@{8wv$L5B-$v|
z1~J(n8Kv1QkAwmT!G(+wL5hGjC1vi^VZx0l1w@{XwDCZnQ1XfaOx&O7)3H1miIcH3
z9EefSO=5mDl*dC#Mo9yC6l1bU8OITLbom2t00Xjje%%=>7lR}rH3=a}94TaDHpY<^g
zd<3dysVZ5r%LpCvBMZY&$in+lKoN^Fq%0N;Mk1p_5pO?<$iaQ+M9%sIi&E^%F*D;u
z9-$k+j?zS&cH(vh%r_04K=~pxP7Yt?qAUJ1n-+CZv@QauvM
z^!4t&5$61zpZ#zo*GCGNul6hd;FmG-^;gCtr7@HmsaXB?@BY`{{&)YcfmDHv)y7C}
zOtkhus(}$ROdKfnNGgX?C6;mjQoxmhUcu*zzEBE;lFMbryn@>Y`4ut&>H)&QcC0<*
zJgd8HcDJnFw$5_CR2a{0Q1IhBLdnW_JgIIbceNO`W}L4kmy^
z@znGJ$S9ci@M8LTyPLD<>2Py;h)vEeL`zRW&(5wzpN-(f7YGyS#o)pnr<-#-1*-*q
zEg9`Sqn9)LIjy&=_Ht@Fr#E+v=C0k&*_}NGrUghwqM3v|86!i!N`3r8D2-J4PP}Gj
zWh57~**|au3T-5JGdJ~wk;9Lze&)i4WbSOp#N{WBIJQMr^rxTd?Nsk3dM~C_abZY#
z)AG<#LZv6v^R>NOjlxE!w#PM!{aOLA2xP46taU4UT)n9F>u4)m>+I|E$sXfTG#Uki
zfs0?_I5N`MN)sndo!|cL-^6e5C^jas@$yK0=eG9VUE|$*=G*tQdlTVBPK{W_;
z-_L5J7(swj#)TfJk*0wu<4_I*@FF22)kX=`I8@>Y&jPFjiIUJI0bU{RdV&XPq&whp
z6|az(p@04!RfL&VIJ+^>~mlC6m-e#n&nIz!&K(<+
zuO^{MNhh%nI?T}UTmR?c3k}?ce&%Q5uYf
z!D#GHr@?IEO^5b)01nFn4YkP_j78g{V{kThrz87d>fN6D2NQ2Lw)ZC%$PYLb0Z>A2
zJdhxxfi#_{(}^~w9AS-ZO|0)vwEd}iFjL1vfrSb7M*~XQV3;Lm=E?EUWPyy7=|bM;
zF<~Xkj3xnQ0gnJf<3yOIQtAVMdc#l}#VYe7Ytw-|N#$v(&48pS0VUz-kg`vP31y-T
z6Dakr2JM96H49NuQ=0qOYA6(UcH133v5oC0t|prH@`>jCU2)H3V?>|DJ;
z)`}!2CufKa6*L>^O|K&L9j>6_BsQ=Q>e;p&g@HgHcxTVx4+hL&Z#8y5r_EKZ-
zu+?@`eJ9kn0-Zt(Lp=*O+z8d1zI=`Bh#ISLsIG$!16Ix^p-dD8h!R;1UGbs=BBb`b
z#hrsVy>ot_WhnQ~qfdkVb1pEka~48eNNBjCHW%f_8MI1sQEM;httGtySX=}tQc=U|
zJb92Qx#Ua+h^&O+8LbK)0to?(z*~Sn^7De&81`irK0-irFi3X0tP&w{8(Hrl7?A*W
z#W|%s&jhSSf@#E9_v;#FcevldJu}ZQ^#PQ8?j=5VB6A$GtY`O9Ec4g>?(}!U;<4e{MvT(hfZ%T@H99gC&F}<32P8H*f7)Z9E0;
zi3^K%H*Wzkxjo1s4R;7eadWRvMoQ43&Fqc@i(Skwq6J@i!03L_!^g-M0izyQ^uX3a
zB>+2$WO*H^O^U75TVty`b3lYZ!~VX@p^tWAQ`sE?#P4KMqa~We>D1)+9cg6ni3&{Y
z`Eq+;@{!(+%wA;o1EXsQRj$6%DQ-7%>y@2bwY`l-VY^!{^eP1aBK!J$vPaFEqp{J2`f$e1Pi|ND3T)Boqc{HJfeYJK#o`qqKEpQ@p+IId{eg6Sx)zxgVz{a^mc
zKg!I3u4lNOj@I#X+s$y02`ejOF^gbEhs;95A|ng|kpzNaXois)#9ElBlmHt7
z@)YnQm@h-aOc-A(0T>Za3jPC|x`OM_DUqTllBEzY%##97@ST3(;b%;Ya4lUT<5r9~
zDM$|Y@tIfJwROiaUDt5!`^H6^Oo^E_kpdqb$+czAQC%046_@2=lO2(LIOH@pDHFvc
zSnOJ67W|h<*96jm7uANQH&v~nstxpY@*P(dxuH^qN>h;V1}6PMDEM+P}n
z$!tcsy5oU7Ol3eGKn^F%l1BYe)SC>2@lYBh{4fPgYCum4D@VuG94_F4$iV5TR
zam=S)8+M25oAVr`U%ZV9~?JzSOQqJ;WeL;^3%`m^Y
z9D8D5^Wa*y*t17Q(yV3
z?;gAZI^4JK0Mb)3%uW+&81}#Q>;D3izW&aganPHFhhY;KoTmK==+LYD_HX{i@BHWg
zb>x(XR$-v!DaugUP1IbfClD8OpaJ{Z?X7GD@hd
z1=7t}MGG{%8jIHw@kS_68j7b}^5n}7cfsc_xZShFf*b(xyxl{eSkUX7b-HJb?y8MW
zYlRYxnM0XOgRLdC1uk4r(IFhXpIlsB$Siq4J@VU9wL%c#8Lcv})#lam90WWk7lC~X
zdKL>8oA&-|!;xP5m48Hr!(aNV9{~*~T79C{e(7h)r2XE#K_Zqy
zA@6hBL4P~qa(;K$>+C?B7TP_(v+H*W3JG`6w)Zedj0oxMIqe)e4%yyzt=^%55Ut(c
zvB^w$2zEwi+aQPpfo3byo2C&&65j1#rrFtc2=X$?rV;-colVGtCwd_C
zboa&VW)@1^a~Ev}k$^nH%0si|AtN%-1aXoj^6>ucExomwy#Sn|rTZK*E14C+$7t;?
zdy&0@(Jfg0lFgURei41NCYOg8y*(4K3yAC&@Qipb4leJ|XXSP?b0e_3rO{J`KNt>*|Wu99o)ZFWjIpo})0nEqy)sh2`7-y{-x5B2O?i2u
z;L-o^AO2m&c7OeE{2WgIF>sLVVd}5`>c9HkZ~w02>W-_Cr})q{OdZpbArv4;u3?6Q
zCI%11GG*Jk?;1u+(SD-uX3ku)zy*OuoEL)jOlB#BXaQOElz=KWN^^r04bY)ZStB}G{yK(9DI=!d
z#-OgZbhQaNv@EI(S*b}q##$8@HB{=G;s!0t;R}IYdp07%kTWBZ-4uD
zqd*!a+He2XzsLOF`Op86@Mu7f{?ae}b&P!Y{+rVwIL`yjO~&?QW=zH^;AWTzQz{uF
zrI9cjDhFfjV65II6QIHDg_L@-KLLBmp4IZ57Eo_CC90c_DKL@PaYVv8&Wy?&l3$o?
za;Z2TfjG&6h(1LY4%F$8N+(Xn%6J6C)MiugCFQk1@B$b}_2c_|miV1C=!|1-0)EBw
zjuT9jS6n;B|bfk!40R
zp_c)|^PP@ocVe&|vjT#Ev$qMJ!&_#4WS;0SP?JC*SGX@kPR}>nfz@JF49U?Pd6ah&
zd2;CTxSMCULl@LbI7qH%X6z)Iq&nCw$ExF{{vX&5|Jp~d{jG0&ZgdOcKbhT`>*
zzY++ST=AkUUUbm%=PjOWgm(WtaL{hE0kXN0{|auK8mlw43sK)MBh
zox+^9kPOAZSj1a-bPh2wGv;M2gE^W^mOl)Zm`yQHfJn8h!I5A)W<)&florMOJfKiy
z6|KRALjJT^n8Q^7HAZhsYKa(;E@Ag)Cc}A-wn91iAZ;0U1KP5dJtMmnUJ`pf84Hr7
zFl#d$%v{F6KEPkrQA;a$h%AN7cBteQBvwOP#w#fK|2HeEm*t73s
z;OO*rnPGC*VYum%*BJL_4r|7RMtfIp;*}g44%z*Q2-#CWvge{l!HW=+crnA)9TV@d
zpVPbBIv&OQ>gR|E`-}+ryvFSrpu>JXdpZl;NhZu936UZ&6m8Mz7agu>_6rtYG`NDv
z6)dh`%SDslbH$>^7X!wNu~Uz1DAh)8(jGJ9gBDU#2-LpK)epZwpXBjMs{hoh?%#OJ`svrrcW#?QUvV7`
zbYf*zJxUq5A3=x?XvS6Ec=I(}`1%{KSQaz;v3Nm%pl(n!Ar+?1OoJ4Ic!-QNGh;zl
za%{n~W#3VKM+?Z)@RhY?8_e0$$B4p-3-(+-X016p0nwdnA1?)=_BEKj@z{HIr
zoEk}DP!YRS4-?G~0c|?VI{|eGs>aDOSf?+E?OwOi?Uh8S-R{)Nm3*aIloddjs_9az
zUCWnta)pg@b+^}V)as>TDYsYHt~K&~zFw;rF~3$Vl}mfY;x10>jS{AbVn>!cKqy@&
zYafe=R9ufd)M0@4C`AEP?~7wSj`WnlVjAm7tR*4DNbsgYyhqC?n<&KaJC;y4eG>vYLoEZDSA*;kkg1z*bZ5lCT77L+bz>A)4OS^d?$Xa~m(O585M4%vg|Y
ziif5|vNDPdL2Q8w1+b&slE_ksH}#+;QRpU=QVnp-zCWMD5rp`l@Xu-v1`bK;qysw{
znCZ}@3N@*bMrsmL~I-F>?XZpd6+{6b{LPM}r9Q5J{kSEY~DPsi>F>uTP(cYif(}^`@
zDa@mk_CcZSkf99pOoQGe757KVY#{GbnL}xY{!pee*CW6pJ@sU$4`MNJJ5fNn%%d2v
z)l2+#MsI_d8&QIbJjs$*X#W+m6lTIU5Tb&PgIFI#${=Jrm$02wQedCc2DFhmELBIb
z#46WhnJdyL781W3*iACCvF%cTSs5BaSe^=n9wr`GQyN7I1usTY5>hI3%5sfE4%}rXt(8vz+2SAwFu}
zx7z?amekVAN?V71-*dXI)%EONVD&;9pASoU0U81{DQBhY+I82i0SyDMP0&eI65EGg
zpg-(*=s!C}
zegm@ZlkrL}$k-p(+H+`yWvmUE!
zskD|zw?gSwAYBJ0W`TyDbdi#jd2$?^{j+*+1+CFtHM^@8L&HomC$ilntKt2CLe|!n
ztvViEHJU4S=Nww2zO2_)`a7p8H=Zxvc%i&@thRNknOmrCpK0zc)wWM}_U47+LMJ!B
zd-cT&XO3=Mda=2?+S)qP2NIQ5l=6~NA(1L8VrjXbKhxYg(cV7E<h*
z0w_<5`BOkQfEu4WCG5>XfRDs&d*HUr4Nbe@$;`ILu##w!%z=e7Dq}b@`;l)NggP(g
zfsAD2V>3@PA&VfmklV?8#{`9cz?z6_2}bdBxCtneo}J8u84&^j&FcA#2q75BEQr0G
zd46vJZa=Y
z(eI(9Q@;yR%=^7OpwRCXUEm-Xv6HhqI}Rb;p)n6F6Y4NJq!#i37LCq^*(EVL>x>!+
zA2a)()!TA7GX7>FAuf4)_wcC8=R5%@Mw1K&-*Sptoc1d*fYVDy&Z$k>3uvA
zBxm&*S>gllmng+sEC+lc7ORkf+8pXF%5fo2G{q*8DUl_A3>c3stm1NMVb90K$_!;wmGFt%L$1T~^u70A{7E=y94_>A+1=Cys28Vi0JqC)uu`
z89iQTb$iuDtI%p!OQmA5SZcRhvch+|gxL{{2yqRTQT2!JH6UMrf0YUpyMyjQIhE9FwDgnRBl
z0FKpKq1CGP`*m4t>S`P4M!C#3ZFA?lWI=?4KB!TSLj~+e0ghx!Q4{iv1A_IKeBZJk
zh@@I;2BSs|OO3S$pK9kT~0)M&rHrlz*CvWU9gxxcL+l}N;h
zBDEB;rAlpyFp*4&yi^y!j^IV1CX01Zs1Z97K{oHxWDBI2eSbcQgZ{Y_{Bv7r>LiIf
z9Qvb?KO9n$GXBM*P)TELIIxJ50Epyrr8+WSfBzL+`%Ay{bCa=3L^#n#6E%}Kk)l{i
zz)VA9JTzFnYk;FRn`-+rh%uW&C^T@G$e=v{BFKyh=2)yCwu7sv>fy`+Yfi^hwt5f?
z;H1ew+8+S~iNmG?Wq+iC4hay4(*96BpuW2QAn|#Gf91aK((Z6TH0H^ra?6yJoYkYo
zeTJB+0}5v&i{+r`V{%fH$#W2q#T1AZ`^qp>MiCjmK!=Ij8HW5crMzaA+N_Ub6*7u|
zdX!(BdORSHVh0aXPso)FNht}22S<)$c@$6%a_oTxsn!p$+qVI%$|zK5cSNR9kRFAR)as_oDY%koaD?}m&HDQ8*VjMR-pSx=Rdt+r$~RzZYT
zW7X}Px7+9B>T+Z2%r;n_jJhFO%+6(hfoST1a_4Lt|Q;)BletdQA
ziSr9jpPhef{`i+qAN$hci6cuVk1m~f46=Ok=(*EJFP=Gib?Nb&=bl+R|NNzeCzg+Y
z`P|%*o9CX}xO8m$>PwZKxmMv!2OL&e6w8ZZX`U~f>g}HB??6rpIVwyIsuTA>a;I?$
z8WZ<2E<{TPNa_^sJE_Su$lSrq;hS0bGKOPef6JJkRk~&~8E&#{m8|~&I$7$;9A1o6
zUXaQwYW1wnOoLKBi!5B^cIG-8#~U|a1oO4lUg~e1?romrcTR~rr>N55HeMAoAF^Fi
ze$NZ|#N!T!av4xK)f;FbL#dn!#Q|Eeln4O9Le_>9AqTwM33|IhFBkUrB0e8-dq6{<
z2d3m)e%FHt+YY}CJ|nd1?qC`&AvEk!3vpW8b`zaFJB#gukVTM4E(1YG*3Tpx$-pjq
zC~KK)f#)*pW3)$hN0;9N*!_X|Y&=K6M>t3=PA#H3%sjjhg2@l=h6%oy&n9Ps=+jO5
z1(zc}V}4`^85HsMvpcxB8@aQ0+#X&4doN_>BnzTVcE`h~a6qVFN6;`Zv9qCeH?;1i
z-rv$QcI<4aKvLjcd)sVnTJ0?h9SE~QX0}OYzr?3UjA(Lsi_aTk-XH_yp26>#AVo26
z33)O=as}4znP6G=fqPuu=L(@vOymkMk*WfTRc2Z2PK?f!ihBbJyZhvT?o*buL1n$C
zY%f7_NmHTk{`8Y98uH*U91xyNm0z-QGp_D95Y@3|*OFb6u^l;rA(Cs0HhEfEe#v)A
z36h-*;<}Xo%knc6&y_%aKFj>I9mR5F#{=g{5K8X=1!9g5Cr
zqDQe2#aa}rQG`>lf(Vn;FfN%I3hrwl4p)Se`DdA`+dS1Z+gv77^_l`Hvr
zqa-U_yVERJs*pwld?U0vwQ9Xkua|X0bX;AM`A)Ch>4JNDt}B7G1imQ>bxx>NYkT?9
zPQI{HEbR$G7sSkq^?IXFt>wz)t#Wz0QrTrY<8|?*wMx-Y1zqO*?MAa&D&)3zcejeg
zT(eQG)%I$&olX}oreheKV~K&QfO0ZV^dQlPsWwP(O0oHr7UPq-k+PwE!4Cw_=UFQR
zftUehKq)c`Bx85xiDtPhMqkUSb2DmW)f1`UHX}$vMh(2Ew-l9-kvX8-EIFDatA@k!
zU8shRDmP@YCJ9wRsPZIrUT6qpU#vqU=@axU$K*{04hG;twj{8DhLedmNX;OW@wttM
z7VU$Q8dd
z8TC=B!~ww*Zj$8!gVJVW;{bq2B@fXt_NTbHIvrCD>Nui!!P!6_r$7t98I>fQ4X7mH
zjC{&e?*>9?B~%2P1n}hA4bN_Z(g^ryQ)3{V#*$7boq0wai6^z$-hJ+5V2)C42o$3T
z!u}}XhoJzHo1_}E4vLA_4V?}UaF%Mg&luyBr;?SkA%;sM5eNl<1JZ$gsr(H~ULGct
zJu@N$8AO;S3WFt?F(m~uGPkcv7D_TwD&Wy5+n9vDr5wl%cV=AJNy0u}9tQEIAS~{X
z;t0WWgMc3bNwfOi#EX5}M%nJgF8QOg>|?YM2F=!WOu1CrhFsF@
zHBh2-0KRlM&+d9QnGYimwEai!v-}I+eEr?K;VVP)4sDpNPpGI5z?mvw4``bg3j8Ea
zPx)EepTwO>*c}Be03zrxb;`_eSR6Q13OhFUhBnb*YV1W+;BY(8w|$+e*aTF$W&>@c
zZHAP6vgXS-Lg`u}U(28{mad@nrAxMO!4VG8(BjWK+(oB-(QaRGIv3pDMXPt-?42`v
zt9JLC(>-st&nfklZec!m^Tn&nM=vcrdVTeYYb#IeTzjdSJ9F#OvuEcYS)D&}e&LDL
z(?Gx{7Ec^KbL`0cOAizIojM94ym8@pdH3Aj+Vc7Nr_P>!YU#ui%cq_=bMol?siSiz
zADxGsKznrI1mwul+!Ji@=&56mo;q=aK6S&nAxH%B>{QS`?%SSgZJ-c!KX-NLs
z^Ucju94k64<`?+gdB%k#LhcMs0e@gbAve$O(g^x;VUZCbIB$`iW~6wAr8b|D%ZuFZ
zX&@cHORNe0!=ucOxU3X`kK}r0*Fq>iMlCPt)fKaTo}jQoXb7;w<+bb2)mc&NtiU0#
z53ooTZOSWn3W=g2DHKx0DSId*!ps5vKZXv+N_8ZY;V>49p->2=qA%nFsSt?yKr964
z^Lsu=EC@yf7cx5B4Z6D^KRoJ-1&_}K3=MrT=LkFCGlo{6v>nir)7|#EyKZ|20yNAR
z(Qa-yZ59-G$a!Sa0|rt1d#DZwh085E-L$)#=z}<|))ubyI=JDMODIM(Mspa$9o`KD
zMo#A)vJ^6-V1|tJ+JrruF{R#GH#-|N6AwYeoG0d8Kwgi%Y@PrS;t6{YhKA_mJwD5-
z#!Rv!x+LJ^94-X>0lY9`0W|U656SZIJ>vCbu!}ZxpwoC}9|Zw(+n_^}+f}JvI9Z@V}2lPxKm_SB!DCef1Gx(gw@2dT6y_+LPvry21jC{d@Fpo1i
zo%y2K&-~XpqeHeyGEBC1%;t{QD^O7(N>Qq%a(%2(zR`s3D?=3-P1;&|O8Zv#W=?l(
zwTJc}rR@HD9TuxN4M?&)<~t@IF%^#XT{W;&&rmE~G-=;kipjI6rVJjX64qcoK&0>K
zzN;~|BS*07>MoI`;@XPmVBBy)ejXVD9anXLk5pnXBS^~R2m;DG4k4itMK&v@;|>@Q
zq$ye}O^pOXW+aT*NlfEtG2aigFtz}Hm1?O}DVEEHX0zIA)jFMevstNBO4WL))-1)T
zZ|HKhTCde=rXdUmmhFg|(T@k(bl=B2<+xUq7|GD;_1mp>%djL#?NtGf_m4`YTm^Gh
z^5s&lRL%i9b)z#H%Cgifl>mr4V8mh}SFM!5m-qm?-9|3AQK{_p`|V1lu$S8^7IsUe
z-2$YzTdfv(uG8(*y6v(mw_Ka^T>-$CMEKbj$CMrm&|y2x&}JCKK)}Zo(9CEObm+TO
z&=H@Z!(iQY6#Qd(E)^U1sbz(J9NHwtc4*TV+MPw=*&ZzvKB&+(fGv$;7Q0k)krmTn
zyREcTDvQXf=RoA9CO1HkvfL0QaykoQM-ba084)Spj0=tFNV`2VZ_kW_88}jzjpbp)QI;|8#_AWMLsbA%g|dvv
z`|ML5^u(Er&B>Vj+7l{ph=0Cr6tt75J4m?kP+~YGPKL&GXikQdhRl*(tl7xiA3_W&
zYM5l3B(UNK@u9XFKW9CVL~YGRgqNG?a+L0sy5#b+97=
zGD*Z4zGfiWfrwj?cN^n?PFB|?AqXQYBVZ0dmN6eQ)OFKuN_l7B6*)dlY!L@ZAdS2XnQ?McJbSRUH8oD;TPx+J0AMEuibw8z`K{~
z`z%j+63b*Sq>_(#+agZ!{->!h8$cKx#+^~vf(-ro$gPf?5+rp>K*NDmNX>jqmO`p!
zgVxt~0&_RewnJshQ`S9g1LCUdu6oN>uDjCJKmZg15U+>)RiD4=3fCOrs>@yWx)z;=$z9#XU*P4vkNr5?DejgtqWT7qFlSs+Fe?^@a*}8qsw!TuFO5UI)8L!?y;r0
z$ImW4b>;l?H!i+-?#z=*rygIKdvcl3@Ui97k5zK#B7A&GdGFTZxw$89UOH)rC0i{S
zT&}Wx@$9Lm&%6i1L^$k4uq(V2x&|2ZyJ4a6B7dV0a8FH5(DVg-LyNKE;{XX
zr?X+T*R3|tia5;a?|6qcOA^o+n9ma+pgIuYHjs`%A(`};znEec0c3LHmeg8PT5D?k
zmQuSRS8piQ8&c_-T)rt*Zt}HT-SV|g@d{tOCYEntM5^9Y>T61UU2ASal-io!+{{=F
zq)1-o9$6Xj6h7!#C}t3eCw*YW%v{(ELl13-1iptx%AG%GBBhwiZM}_81N?{aZIijS
zEpjwdMh?X+GQp|Q-O)PRS{v8mo+OkI)7??po8U{eyA5FxjX8tc13_j<(-^V%yd@M&
zsbC6uy|-)N=B;hDzQN)$v#b}qozeqXJlyw%{L56edrGkQM>$IVdmXN4ShlJg^8H$a
zif)KH+h|zVIMa}9Dp)NuAF!4;TkrK7
zio&U?(Cc-|)k>jMlw@%@Ogz_&Lf3VzdJ}k9E>#KdBvCMRijq`RuHGnCYWZrdRH>Fr
zl`^iyoMI)9Y2`}2T&b0-wMw;KsZ?=*DQh*5WfOb};w)DSRdOhkCB`Hlnc9+Lawm4li%CT<#vks9ll=|`n7JW$oDIn
z((r5mgct*5Vv3U+Qp&2vgpep}skUEg4^nciQnE{^MpVH^@oWj=TCzj`Uc`u0tdahu
z$nHytH3mnyHCA6|u4hf{stQ`#zD2(us%U7mH47_h!|HO&T?2Edup$LkW}aoB;U`On
z_zuKY7LJ)l)_CBKhh7w0L7?FaGZ^6eU_$`<86A#?COM18_Jcy!wB^aj8RLTrRiGhR
z!a`*b%gh8w#b|ENoCDe!&pDti^1z51hz;B}OnDY)2pqK7=6F=y28;-TWTNBIK|+OH
zz*Uox45kDXQQg6j%3>T%=84AZAuA@cWwH*TVK4Lv4MzihkWh+78uOGoO-llbZk&#k
z3E2+8h}!-TLgj2Sp+4?2R9UVGfgO-2a+{;LHyLn~lq%E=6Nx>YPJxC%)d;Xfxg)?<
z0zt;FqnM|JXp8^^BXLC5L{KI$j<_(R!y)CM@F2YJ?1_?2#E4#GM@ap4o7X
z8rsOsisL}Qg%mM~K}uV;z?7Yo!VrlgV=|q#0=wauHP`+l>m7ddmC@@H=arFld!SEZ
zaI3&FQRr=FDJc_xHvaijW
zWaJ`N2RqQHoK2u_5*o@kJ^6+!UU!A-9)HE~V~Yz--p
z`pYMeuAF{+`P5^pb5E@T5P^xO9=ovk%=Yy&8&~HpEIbW%gsh%^?EIOhR!%;#@Y0c`
zV~;H!JGyk@u`?$hn?HT@^r=VZP8~UY;s{VLvm>59{s?6L#N(%40u&xSef+W0#~wR<
z{Ba=T{K=zpC&
zvUgh8IVF+^{n06rjKDwb05(2qMBZ_DO(O^(cgU@72N#(&Oz7c&@3Yu%FTH~I2a
zu$@@B(aBwGY@ciIUg#CB^zv8u>P^0Wvsb!WT3cE_`$BDF731B#%Z;t`?Y+yb;?>69
z<$CTCU%91LH@LlP^|iCj&GWTetNF|G^|jT`?xpt5h1Sjmu5eW--4M$+yL*?~yBBc>
zp?pKC-qPEfWPk)KXD^I|ESC>ZHR})vW;R8<9qQoyl8Mv=1QRT-Gh7DtQJc+VW=ML2
z55ypkJmo|KRmtPr-a-ek2s#88YW*FxN0vneBi&u8vyE2ofe{N9`I_@OpEsF_5v`5I
zn@}Wnr2CMm(r9gw;NO=oKwJu5EYgNIN`1g~DLniFeUb;IjL^eL#Z0
z`;oB36sosEZeP#SSY<(U?pp`xAq?uSr#mjyHAD*#r25jX?gthm2o3OD5XzJ(94TR}
z1<@fOGWW5O#SY?U9{fbV=xnD7+S!8kw{S)SDsk+)0%%N@yRAm0RNO0-^Mz8bP}(a|
zUdUd(UTrjMWdgejwSYY$x&|2w>y28YR>g!?O;)%lw8Oyebeh1nDu(fR9seT^tk%nz
zR>6Pu3SCueQlA8OD`P$bM2zD>TwCJ%&6jT{2V*C6rDn5K!{zK*2`6zG9py%&DoGv7
z?1h1lB&r`M?M|uRtJ;RxYF6;#@kYw!Lb+6^*Gm09UQ4l2FNb2V{NkYRmdOn41
zb;)x_CLCc9ixhm8%EMG0Fz+FANkeodMjGh}1hgF*K*qok*(NTm)S}g=nu~VdVL93s
z+fQYPT#v|44ORmhVm?}yn}Ttb_CXm+)3M4*35w)F
zW_4=F9+_DsA-E8bH&PD96ov?*@~pb=HNb_Go*ecG%cw}T48)v{0ha`tU_{!BWu)#?
z#caBeT`rFzZX9v@1FF6W+-@4NPAclSmxST{C
z@FI=a_0VmB1%Z77mO29gCW8MU*^7b1ZYOqdtA=ORaJRsvr^cTN*!1uV^oJb}z4z+y
z^_hQfXj0ta5O4m_l=^@XDO))OPJBhj-$(y0N8EG4?vgRmjXhDarc+Hi7hS&W5)kwJN^)EpJ?n=O4a(n0O
z-bJ%_nX8>`6c)CwJbz>P$tw$wU0!(n;=6OK&mlvK~I`hQR{NoFA
zk1fm}1t~7fJ-IOV!~#apKmFL^+~bRB{@yLl|Uq*ZK_@h9>Q!gC>|D8Ji=*gFW
zjE|i@NfXG?eC$yS0w}2^%OcqE$inHPOJ|PGoqiPeoI81B;l$Co7r%V^#V@R1KCXAx
zdxi5`7oREKe4(*@qP=^%mz(Ez=H=ZpG8qxcKq%~<=5nX`!U9)b?w1#P#RaakAQaB9
zL}`{ZokM#FZ4h8wX5`~`=6YMF_+7FT;xrS+d0A{Cg#6dIP`qCao5_+?mTE%%Prl<#v%O}vZ@Qf|
zuXD@oZ!k<;2N$~Brqc&IZg{VQsmwb75`uh4r&9iM6#rttNUcQ7dX=t+ugpec|cS^)q7WMsxGRmAR)bpMIjY
zw#pZ7aQU0njf+=TUc7bwME?3xYxi<<=K|wJ!02VEa>K-%#S7+hu9Wwrf_vYh$!L$P
zi8jA$aoZ%!+RFGCbV!y|GNw|Ces&6i+y*`x?e#1{2PA5AC=!u*oDZ|4$?4qPru38^
zk)qMr(OIU8+S!I^Ju)}yfXEKBJA%>sd5Tsf`(lnf)LhQy@xfB@$P5!r@F&Mks_al>AT#BQXeh&*wb)!KRAbmd-;Qi;6GWRHM6ZnqAsS#ej5Fy{#xsCTwSC
zxlLO|0~6(r3R0Asn(_%|rGNz~DJKR3x?sWK&`A=Lg`bk)FikDs<9HlQC((2i%*H-A
z56cOny(yKj*`IjRkv&R5Z^~q(kEnJaIL`tI-k#dGC-xm`&D&%VG_z2`{i!;e0M2Ny
zJmB3v^EESLp-D!>F`4erP6rBLYYZY}6{-PMw3#0B0`F7NMEy47!rO;vs2+@!gAuu*
z8Qio+2|pf4fTvLcxYU_wEQdy&jHTH`JD`pGsH)C%NYRS>LwWZ9*-;WvX+u3BJnZZigp9XCcF5w
zmh7Rerh2t>r%r*-q$y+$c3Dm?wp((+O(5?$C<229891C@zUPWwH@pF@C8{`N`
z#74?RKq1SUU8``FGWi#(`obzzRVJyD$6>5m!eZu|loFB$8rGGNQuKqHE0u7y5~@|g
zwK9Pq?pP`7FJ--zVu*OLny8l|;KBw-G#60vfvOy;l_22?1+v5xDmL>&W0rq>SpB?H
zc;CriHPfU}B|9?ih*~IxbcaL2ZNA^+dyV+886P&{-C6|Flzp9|w*xdRI%|1*J#PmZ
z)-u*w+5$RkW^B#06=+yVomVp8!nbnr1ZbES-^tQDS$I?AUlsY+tn<3Sy()6AO2V6p
z_*M~K$K87uua=+hPQN;s57?j7^8Rw#Wj{4N1s(3q9PQ6O+go_Lzi?=pJKUW=FwFx5
zO<+6S!k&I{->|f2nBO2d+?u3z2NNcBo0^>sv;>H%;?RI;
z8-$WHnX#s6TZ_lPX=B>BK55#VGHy&9>a~a4lji5^G24;r)%v?#t@YJv%(l;y4sTzu
znmDt8vltT=eaxy)I7~6SK593_90ndx=rpi|+mw_M7zeN;D5QXuUCwIYSy>bn6PZ8a
z9UX!N)!-G-p~{hLggRLd;O_}l@bew8(l7gx>p-xRyQBzIWsZ_@vp#k~b(!y$&qv$J
z2`d?knbbgmf~z7pKrmo0bjk@^E#UwQ)_HqFwAXoCT_CCPHl{B;uOu$eQ3bmnMlR3+
zCW7-w4aS|z{H4r+Z_bL`MTrOH5CatxG)Q62@w0O5q#Qez6K5r!xDbO7MKG7Rvufg`
z%AHpe07OfLw-ut7g~&xFbjrD31uRe8=lhQ1-OJ}Y_SXi-8^hVtjf+=19`n)Zi%sMD
z*fafH)b;o;ic{k8cA>vQ)`pKlfgTdy4NmSUY;s1UXK
z&K}!e8Dq|uV(2&*yOa|)_wg=9QeMC=S&*~gOUZYV30-ERcI%tN)tQIu^P~G)bI#Kz
z5yuScK5c!5t{X
zPxH}}T;w>a>MM9i$RXihhyz$D=+;j3*_|
z>#|2efwG)y*0VqMwf0v(Yc?A>o{xYF$tvt4>hgjC-QJ+zUoL0b9kN7oTqxl8666KF
z^g##|NMIKV5e8x-Jftm5`oI9l4$Ox^fTEwlBTXP=RCgFb2EnJnU?dzYW~EvwT}TU&
z5P_h2xXO_qHuS-lIH!*^i+&f;Az7^bJQppO)9G~F?Y4NmWT&Q2y>_?P?Dn3=60TBN
zNGC(tWR#2fVj*87==8bIdCplX#wukzeSywoYwoga$rOS>yZKfFL`YRPY86(amQ*_&
zx%SujdOcCA#w!XWQB?#ru7yOAlrmSAW5q(akPj6Ku|hEcDVDf`9M5JWX-aAnk)(Jk
z$z_sUT1tFq6WP=c%RKyFxmBy_S}g}C>~u<4KlMhYT1~0SW_*MW7_rllyI4Gs4^@(f
z-O^RRGVCjO@t}OsP4eVxHKk@l=u$>&s$w_nWv>Uh>j9uJ%LM%##(SL<)wt`W2@@%h
zIg6IzTK1+70rOEkv_=0Q+P@%39_Ubm6brd5ml9%%!-|2O3fTW
zBultR9oDBx$_;j5z)FJ4%%H<6{&lkC!U#&HsA?)KtR{gb1GJhJk&?Oyy}Hz^gB>YU
z1Ju-^%s!yHD437=3zC;)t0F+!l%!B3QdIa>RrNI_Q*WgZ1r*jl#FRjAV5J-_%i&@^
zpvd75DsZV@5lV%KoDUUq0g5SMwq{7F7^=wRR#=ncq{5`27P3bJKr6*aIUfWp;(n3_
zk*wQ9ge9!rT)3Evlz*tBHt10KtXsJ076$E1zXd>)C>tbhD1BS5Q;QRcw|NGL@qRrz
ztVV~mP`~DHmnkHrU3S+C_D0^`D!L%ef}@tRQElb4t&%dUj)rpTR8F2MDRj=V=c>5Faa
ziRtaL4X_}HaF^OS(+&<mZXo6!gl0PSQV!xj%w&fcSfXsoiOuqF?!O#N(TfejEuJNwPJ8ds@3CHWI8`F=YE|Eo}@#kpf|eh
zg1wq@Q*aN3zt~E^M~(oogs&VsB}+ZonpOKUS)V`bsyan-&{TDbz(khl=PvJ0E~+Ms
zB>f_DUS#1f1>h-}}*<|N>3}{HC=yhf?u~JFo;(=hu3lIeSQ4@>=Ly^1gA8&zBC>#hx{DE*FL;7daXh>!}?STrE=VNnQ1Bd$ouvCCx0c%q9
z028Yef+~_WsFCYXlt#7SFZ_GJjj)VD%DDy
z38z%}Qkg5368U00n+s-hfm|*`*%osN@=zp|VKkefPErU%?iSET*q9MH-)a}|UeRo2
ztN0@IRI^Ers?}-+A9Z`BUcc1s7JBVG*^4{!bziyemr03;kLdLP?;F`xn^djcPHH&F
zL9T|RDFpCQaLFJu>?f~>S*)ueppXR@U$L@ygMNwtu@5vPb|lUNCU(=^rqFE(gKo0l
z0b>y+5(Rd15SBL)gqLL@FIlFH#2HfL%gD^5lmrnMQ{nn`k?9oE>S>84J2<>>MJmq{
z!7jd3D>Lk5hV5iiiPV))qY~=0xIr)3B+p0=K#6a`94PU13e{6C7Jjb3`PkZt29k1#*`9QuK+-WYKaJv
z1*wFAfR#dwrCr3=Pu66AK2q7`S~&(ZRDhCYoI$LXq>3!uEucSb
z`;i|TDDOM@Tih(XT2bTPkd8^jw?*MyUL=vl;{yMhREGR3S$JJey~|5)
z;{HRARe$K?c;7KL#FK7KZ$?bN$1nQX#^Tyo;BbZM=&-8^$
zrXA4Xf@x=-EX#UK02Xy-fgtG6xIIUh
zs3WbRaR&%Er`woSIS+lH9vD#tL>k!vCaT6|!a?SPIHPB+4kKIBx@~H=H?=!kGuvze
za1dNb?Z(vh8u21_x7X31GHg!o>t-Gs<_&8Tds|aJ>$7y+a`{$o+8E#6oOpAv=sh*W
zEqk10SFji*vr)8A`WqJe%;Hhpdn}0Lkh2;&n~`_ya;`lNXy`dexb|WW6Yt!^_?OWw
z=%iR}m5k>A$MSYV+^&y141(L3^x|x$G%FQI)m&VrG}U^hL^diN;&6gd9Pat(bf|{k
zs%WB!BxQ;_wg3>Tf~_Xn>w>Kz+UkO%Mv6mAT?DS3R{7H^2Sy|{VU@FB4%!N*^5R7~
zb_z@^b7Wl3lfLj==1$8z$nUfmKb8|GCG`1|l5kSwPOz)+=XK!%QWeZhYj^=PRD?_5
zQ9Af09eS4vl6#-!h3>h2ad&C*_1;?0{z8hJCnM)z!Q-c^=GWUmqH5Az&jysFC+d84
z_H;8DIF}PPMR28qm-bgi&h?JfgYmOmfEHPDRWe@R<9c3se(MX5`RVy9(-YIO
zetmjpdGg|oiSxZHCG1tfRVKuIcJXZU^0mQddG5M=`s(r4`uyn1%){rVRmpeJ%to8}
zSSIdxeY9qNrBC|LauJGLA?tj~11t+Wo+o^7;+|I#`_s7dMa=nvbH8Hk>vZr;CB-{H
z1ec4{mU)mOqrf{=E2x@oj-0?PJ%yA6jN@2@pdS{riYK?S+)k;ZGfQE9tA-CFP5MigIbbCs#tMoc5
z6v_jtCs8ET1)gO6{IFlV>X)vE<(pyoc38R@l&%L<$D&$IWi!!YUPw!v5RVu0=}a~e
z3OihGYbfliRtwowq9UhyoqW5KiNymBhr{J^x?CQI!{cz;9IkVR%i?l7U2c0U9%{8p
z18_s9kl;drfG0$R7zqWVp%5e#4hO^dKYAfQlVC6u#3&7*bEj7H2ZQ(s>=+FMqJdy6
zKyV3yq@f^=4*No3Z!qNc`5k12CcGnSGQ&!hAqfv7ksz=em)&V6TTQWC=1L`=OSmHu
zXC&tJ2V9`TP|#DaP*7^QC>;?6Q>Nq?Ke*s6a!JSrSw2dZyh-x9e%lVTNX@THz~7tRzR|
zVz^uad{b_@io%skiLwmgDrJ#XFr!?IWtlJJs0vFi9mbENB7T&4o6qIBOy(n|TWU1q
zPP^RgmRjw6y^(={6r0Ury^faBA7Yse29WYquY5D8+^A^SFZ8?FUI#A^VzVW-I>`or
zrUTTwgEpYjO`nor6O;9`S3@Gj0Vx!LYpU8$rM>)3uK>C27jOH8n|^lCPPS`_c0CR*
zWbTOq*lW;BGhHJoAXT{`m89Cok4s}(y&40rDN6{LmiI
zu-I=?v~stVX#%|JJZQ36iB*b$QqI#*!ktE}RgE+%;ZBnW|Fs+7RH;unckX~sRj_p^
zFokkx4_N^ioSeQjc~#;~hBVECcIK)>$^QC{6ifM+>C}^eIZAd|6Prq+1Nx*iH$3?i
zHuzeF>giFonpy%&izymGghCGlS(AD-vQ2kusdi0jC<)*iMG%)ML>f|)6V*bLl|PB&
z@)%hr8cIYd1e8LsCP!-JM77LU%6wUlmy1!Q5Ml~Q)#ETxEn+ZUDRGqDkk#nJ<<*EC
zL(H;FXJ{yD*s`D$xKchY=YFW}@Uw2=ww;6Aw6pmB9i|=aHl#kj6-#6@BrX(&^~6n+
zyJ{u?h=Y2lQ}KchTV>K6f(|KKIcINVZS}0JmbNI;MOi#6izh|tq?kM@Nbic$8wfD5
zD4ojUc}Y0SC*Gwauf@u1M?(|5X;
z&(?NL^G4I6ad%m7S~eM%P5Q-sZ?vQBjODH7y
zpfv;wZfGGJ8&m6>Q=6OGEyy~cP*pKbZm&-Q2Y1$|0f?Bty)m`3sbwQt{kqn;L0*q9
z_Ew%47fl;e#*Hb{=9Fn;@?b~%a&OLctdCj`64t$h#gw?z@fL$*-vueA(ArFQrew#i
z;MhwzOrS%cA@A7-8VV{GVj8QPoOBWw0uXttE^gI{u3er`@=)|0C4EOJR!*8lu8=ZP
zU@5ZIqrim_fehA^g6D4ee6&rbkY2mmmMD#jnW9NRX`H#rS;2fvWe6y=RnQT!
z?tWL~9U#bb^wM^`Yh0Z$u4pb^?k2ovuFL0GfiqM0W+(5>Pu+j}bUV*EKC6jeZ=^o2
zidPCJOYW2B+l$lp=Vl(xPLIq_kF3m&KQXL_F5eWR?h@zb0~e07L(X$t6}|0Tq?HMl
zc_+m?1KLDK-23*4VRn7?-rmNP<9I(Ax)cMaLHpB~>jme1o%A0AaPf<%NX{}TaVdEu
zGc;co!H8s$Cs>quaN$WIaSSfRF4^c~r={3g5l|RC&oLGxHDQ#j%;+$k;@uz{XRsJK
z&xFq)sUYt2T}>KlsRrOBh!AL)B%R_#CUQYZ7S)7{Oo>Rb(ya8$-2(cUTbVM;P&A2L
z%94(d496LYJFe!c)hvW5Y$#Zm360Rho3ay^yPZ;}U2Jzg7>=3rC^(?l?}7^%4h~AU
z*TwfY#oKH7{dMX6weo&gzUoqfx>_a0^M0@2=Jk8Bd4UtaWWHd~%L@T16>@p(E{{2#
z2{x)JKJN4TC@BmOkOc+1T^_H?O$s-s$LaE*%T$NVk_(Cpvhy$n9?p5U0Rkfo0CU;o
z`}gg3Lrx_H42MDyAR}YH03a|N_J<>ZaKz6Bu>l9^jQAK6aSF0N2YvJ-Lgb`~4uBIQ
z_|f?2jt=kK6W!skJ05qJOG3Mu>9+I5qJ%+$M|^K`aD>?XeyiW-2>9IqM8D7J_c#L{
zMlHkDrEZJd%Q{WagPPfn
z^4_%?=_aJER^v@KStKb02v}7Fr9`Elm6A{@a;0JdyGn_6!H6_Mu&62;8x3r5MaAmx&p^-zsx@3u>wRW&NnHZgBwuAlq9iHgC`{=&~T8u8PaK)
z29YiRL|Cr?m7-N8%5-({S|w7*d2?x3KIKvh{$kplmF%@rs8xxgtrUX{q10T{x76~3l$th60pEyZdwB*Dt!#hPVKwNtkg
z^dmJn*eFGslo=<^Xp&>~SEQOEvXaeo6Y!17cyB3^nYhAgu2jlcma$SHRLJ_}e4tW_
zs3rcG?l4R-F1cVa8q|LXEZM94T}cjk`XLuTG`!QF`AZ*rX>?vBZNA7{eli?NCdeA90V7d42wqH
zf{{|vEI^Fg^AHA(M1H$EjFWvCm}t-uERuS1XAb-aI#l(Aq!-+r2IuW;QbrrVA|TJO
zHLu@*kfL#CeTKCF$7vn-512@3sNGs)u7~TBJHSK+g~Wwx+U?b;?R9chq|7+#;Of-Y
z8Yvfbt5Z8Gle$$60piBwKFiUF_K9A5_GAfw2xt?@SiC3NjDl@9Zq_HvdSDzm2-IAoUJ%hI1P8COAyyrm{uE20^z4irc%$elC$@Qw$PkfgLocom&K8?6uzka;2y*jzNIJUAdv9UPy#I)+RJP{+O
zGX8DKc!4tK&(;st#}C&hE}v{B9Iv9*=kDYEsB=D^J9*)r+mm9biF;)FD}nKT%3BaHa!w^9#=$fzYx1AC$5!5Gat%ww%1R#
zXC^+KnHtefk5A7`KxU@Lm**xo7qpx66YC43>q{fg_m(1#*M*q9n(`NTSJ?T+V|nJf
zeD>z)_R9Ro(#*s4g)!6m^w~3m=r?C$Hqe+DIElGliNO;oL;`LrQf?rNB3KmBQjzQs
z1%NJD%i@%%ab5rb|MW>jK~xNt`Pb%0oflCC)5!X7cPz017Y2
zJrU>`GgBgN=BlU?;g=m17So~AEc)?_6m}`(<&Fi@!Si(BEK7RCi*)cT6C$9zTR0WiA=qgj>Q0lHmB2RcQ`Q%9ZbYgEIp0O=c9m<
zP}moa_(EY)0jhw9HXQOtBECo@5QzkNAwu~AWr<5LVhl#Z;Yc(ZjYMLRNHiS5PB0P;
zgrojw%pVH7Ltzh)5hn~sLNt$U5lkb31Oig9ONc^Vd_Yh9D4-%iB~vB(fr-??M_$!C
zk%1%8ArABf+~jxYb5l|sTs#4y$M1Coe6DE7Rmeo;LX?YpydIm|Wp}z9z+#`rn@#ao
z{aUl0&Za=K_Grja%Ey}(v4y8KDGRfmMy6dCDRh)VN-<7}MewOAAVo+6qi-kbB6edhm5^{;^KHn{%kFa&y#ZHSnR`F&6B2=@W
zvyc?LgeZd^c^0w=<L3p&3IyYXgLr8{hay)fNSRpks-Nk!gie!ZXh;=Mz*0ki9Wx4FlS?8g8gKi>
z8+HiOO=gCzBzUMHN4hm(0Q_JP9?b8M-2S?)6qsbtreZ2>N+KNx6xJ$KFSsm+DrIn?
zKcDsHQl5OuqZC5LjIY8f;8hAiCGV@VR4?^%v;-u|hf75)l1Ql#A(oO8b(w3(pfT}F
zcfC%H?|}swECN!&tN=k=l?r)-HbrRkaGfo2fGcc>gSt3qNQ8+^9@1|C2Zdfk=#qP$
zfUkhFb!rlsk0~StgvaV86CDbqGAu@ve5hK8wyPoq!89mOc)b*=76Xk^l$F9G_e5N3
zO%WiJUb}Xevb!utIcJu$W;tz^QV%RVW-qw#OY^br&C~VQ
zPqv;Ptvx$hefex%;;cYgr4W#K>zkK52d1S%)AHf&(%~Ly2M=9aX%0h4oo)fVXwWU}?%a7O8kjneREa=FQV`A=wlFep+?vyE
z&q8*#W()+5OmVn12Q*}nCED#R?G`X`U8~=i+1|k5ynb`e04^jnB-vS;W_m=XL6gu?TzuBjftHN&DPok(=SeKu8ivdl&he_N&Onysh!m+{f5@C
zF=^bGIMQn!$GV7hFL<%zJKcy}Y*WC>r4DomNm@-Q+ip^=t-`Fp67xzV=3@eIM5~rd
zNx3OP1#?o)gCtA1s2-)xSKST4f|vz!Wz_Q0_R45}w&OlI^j-qcgK(^RwgI
zE83H%diTXM_r>Gm#~Y^A@s0WWhBXaV_4?A}((KqGWM*t}ZftIDd~SYxabXNA^ZfN5
zAGnm0UOD9rSf8Cf+X&d6jO1DyM%6nvM7oso$@>A?45&Y(p;7T8*8SDGd-%`z}djDF$|@sFw=h9>3_wDMh+4OZ1njL{)JJ$;8gHv5Oof
zn`8#%@Htg;`JiZoP(N~(4pP#`y9M+yH>H{>SAd4O3WLH*Enluslu4~drOaBbVz*oB
zbmdknr)XTf&m}M(B-i^-4?)~+vRXNtq!Nf;j&uomv+ZxBI?a&qLLW!
zxUDYYB)h}qusaxyikHHYI
z&r9GK4ukf9gyBdm1mt5I2Evg*EDlWcha#jMRF#W=tWcy~Ul=WgtOSTeF{nm9Gp9pR
zF@}JTL8e(G9AqhS&>^)V?fN}|pf?zDq|&}tJ5?-5G=(*$dKDXiCiWIGA4k5YNbf66a^junChiOi|NMH;w7!RP%TlY3Z$G5RMDa2&y>%v
zDg&(|#dNTg4Hr^@QZASgooUHc$_M0(r!p+~g-|}@D`o>~fN%xW
zo{p5V@rEK+6)JF7FY}c`Ovy)Ua=flkcECCz8rOu>g?2O50_W9u(l54zb~WAwO4h|*
z1Js!5wNvE9*d`}SGQ-vZl&QO@=Sr%hBx}V)wE#}#YGp8AoT|3ugY{y#UEzSmkVcu3
zS}Op)Y_LVStm8EnM?%^`ARr~gp&W{}atw4^$OSRTw4rpV_(m86AeJ%mA?EZIz!Z3#rDY?)8m5`W-nenFsvS#)(#CThsKqCJw^bF
zD+jwPySoI43<~d*h$;~pjM!Zy%d$#`1~zC|+|kX04o!EFD6INk{(e9G@Lf=
z%mEXbTj89JWL6JAWFCj4JKUM0-7OZU%%V^9Ycu-wS>5K`_6ERl&ag2HIs_4t*6;%$
zvNKHUwkT;fxNvKA3PPl)^5O>R6t~tin``6S>l51>6QIMbRSjf&O=DnIX8qa}I(jCI
z6g9^6sU!XT6aD<*hUQ>%+_-%2^zm%WW=vT1oYerl10aI-R1uigP(?imaUsZ$OvY;F
z8m3ls?a?&#BZiM(;viX;86c)zhiS)t)_It5?B`quIp==fjn3ZP^7&|6A+DM%DHuZL
z&t#&*(-PQ@sQ?w86oe3kyQqj}aA6rN$aI7sG=--?!0H_Zf+>%g(5C>$x^UVQ&YS#c
zLpW_o7Y(9ARe+usxyW(K_anq1Zj8`yc6^4kcN*>Vn8$fs65Q3ar&;iqM7!vJTTEE4Dsf0BA4&($
z;?5T}$#qjsd{Gx}Dha`VVp^Y`pSZU)Gcq^xU}1J-PWxzSZuHgRrp!5pa_DPK?&~f7
zwicCn+u2Lq{M4s&+K2PAqjPhkTJ4B-YD_yhh8BQ`%UGD7z&lL9_CiTmuL}O#a`>to
z#g)InY|G7-jE6DHHb;RYoldUP&UC3vZNA%9(+S72
zGk)MgniGp9&`_`o*`yg7;$)bJBZ3i1c*8O&(hp_HaRNayJ*!vsfe}4^KiQOh0T+2L
zqE9Aqx8Fy$ag}i~jiRk7EjQ-4af_;zWUreml{hKoQz~2`8>=e3Tuk^pX1D9y?K*Qh
zjw4}9O7d0YD4zYKsiKO#ETbMP3fFE>;^kJIXW0|cO7+TJa_e-cSR!z+(0)d9t!wLgL!o*&u(5BQa*={q}0U~z`%-k$r5AfDS>mP3|b1w`CzRaFJ(hg+@9s#8O~Eo
z2Ga?5miNl(0LF1bDPc?TP6Z&94FIrk21#@#V%BUjs1*51k*^kc(l_VgN`WtC;-wsi
zPPK@43D9Z`SAw5H9)9GCKoxh&C9zgXwHq0#tx`!0m|I~JY}d;6J0N2M#7;BGqNG_e
zMKE_g+o`3S6%pU4i8l>q4#rmo>8hz`It`&yr;{`l9!LtvFVO2(#pctnxBd
zWacWRM5z#$^Aucy5%P#FgygIb&|J#-i4?0;qoq=c;j-misFVv=@)00!O%W+YPC1VI
zfZJHe`Edpe-YuX%Z37*WYM0`-@$%FF9gJr^yjzd9tKoJP
zfaq%$J&mHPUa(gv4CRvOFwFol4M03CCP{H9L(=EP)J2**@mLSvJX?G9Y~$IJjmHOT
zBzvom_g9}Bt{xpM@9i(|?yv6cukG)y9+*}R49f(C#^rrlYrOML3kU%tg7%n|nXJQK(jf$>$GGs$d<;6|U3*j+h3$d}
zv%V*(4=O{5Iy2=y$hZj>F@cic*!3y9F6;W}eurvunX+IdI^-@u8|2K&1Ng|`TcLpB
zQ;5QyC?Gb3}&=3*&@bpu_2jiK!8d_TkFXGPc}fadh*+~mW>=@H2C^yu=`{bz=SLd4uox~}uy+k*Eh>uHFt
zvu8WAlb=p%?$6AOYNsDgPCX<#oEn?a;sVBIwWEg3MfdsBvf%9JeeINESoHS_fo$CJ
z)U-0MeKa#YIz2NwJ2y5ngR30_%TCWuOwEkX%xPw3$Cp;7@HgVTc$$ra_B^$er<`YaXrsQPwSGsnRGP;drPpkGWKT1)<{_Z@!&$-
z+j8urlAy5ha*U#dz=(Ch(n>n&lB2?QA^1oQe9lMCSw16sO>)+gu8LsKN6%7$ciHf1
zI&_?koMyr&czO8J`ivHssFEUf?-tO<+*n0Bsa8)nnptKwF1Lsa&Rq4zetJ-5&5&fZ&h?g|J{`Fdq>isE(qOvC)tkTSAIJrU4``LtFqzF%rRK
z@--xzGFUGfjf6>y$ZW__29C6`ek>Y|Q)mkak)1{Dvkgp&zPjrR1U*4AH`4{+s&H+g
z5CP(s2uppxI|xklIow{m$Kzsv3xXslB#*|sY&cGz-xdtn`M570^?N*a+#i?A=E8k&
zTitGl%X#T`pV{rlPUo4+bsh@Ya=CD=%5{N;9Z3bm4n^-KJ1wcxq_CBCgX*5KN4r!n
zi**Y56oH!+Jg{q=0=@x59+
zyiy`%9&oKy72CCBm4&BNi=_4gM7Ai#g{v!xav@sI$IAJ5t;|C;mByu|Ft
z`Q$~!_wwS{_~P-}v&S1xAFm%CuI(SJ9UW~R9c~{SZ0_%^?d`1|9IWr{t?lox?E(#V
zR}azOUD<=|t)j)qo^g4X=?H1WunchAHBjHgTn|-eM3ZR+t!hfvQ-sRA&M>D#s{=1C
z>GVqm-4YNG2O6=fTiD*7-`<(q+L=MSy*;Ca6-E=
z>)Ow`K6)iRB0>s7A>$*Z7?doENPdJYl$b2Vs#35bohX1mbQm3yh$l6Oa8egf8`2p-
z5KDzOa&Bg9c5eJ&em=rNmLZfwr2tWK{iPR-AbPiaS{
zv|z6ZkmBSNP;4C3rJZ^-tySgzy!M`cb=>@FJ8XRtb3F5&?mphu=;j|j*`9U0+l|*Cqqd(D+ezGflwaqs&9>A`CeR^8+V0Lz5dUi}ZJ2Evrq5)Y>gA_GP
zCLv2J)309bCKJwPEpDnk;d<@i}8anY3Q?Ubu2Im$7XV<>*9<|Iy_i-#^N5s}3|zx31`6h5PeDCG*l!?;w8
z#G}q=I24bAlboTjRn8}hMIjXN+njbAnTaU~+3vKHjhKQ_oHmEuVl&$vHV17shs$ht
zl3f)O0fkKLG>$_&l+DKL^Rf^WqC+zL(#Eugcdmy7dyrrd*q2}uj{^S)?TGOr(NH)F
zSo8%Mz%jieaUX~<#x|g46#olFNli$nqLX5~J03rbQ7K&kT>`Gf;}5ukAzTwfzCcJF
zXGBPYssIzge}sTOFd}Wt;!GJ3y?{l^kLdH^+fkW5m)qlZxt$)b!|QW;spvB>5lGEg
z*+tp2t4gw1hz0_dSj<^fgj$7fHz-5{(g5*54!>zpQC;dZMbhpxnNStAB#UTHH)|qj
zMkz;2rHE3-13m$0AYLrsVtUCKP-F5f92L}R9JQ-rBTZ_YT0%(
z-|v(Ly-Kh3rPi=?HI#=#&|z*c$o6}=Ha+Omc=Y!>SqLM%JOjQw-dnD(fQe*Q2JJO!
z35p}8P-PaOGGO7xc%K;-@T!CPs&8Vylg7Oo^wPk=>t1%yPBApRllMbaz#BO-yizu0
zzEL7oSw0z(Q?YtUDx|_WDNreJ59cLMhI0yGOF{4}=~yWRT;pmoCj(wnzI-N7%!Tk9Z&ZY)
zBDN|L)n%?zw925B8n(0OHz@jquTlUCEt_Tqhf`w0dMVaW;_VvOtWkNuibAn9tnxAs
zo>OG5DhriD0&v_^xHkDFsyfAJDH~I73+_*aEYz`b4!0}RWVsA$a=4Bqmk&`D=2D`@
z(rW_^<$RDS3w^5Em69ov`Y^~q{D);(`jOAnH-LTt-=|+oc9@MHFHBvQ1o8tN^20Xy
zAc79t)o`;EXv%)jVJ+(f9hNhfWwIlmferzMh17`*F3enHxZ^0e@SWk+^UasfH=jM-
zc=BZZ@Mv}aaP{DD?ci_&Xt=w(zRM60T!>cH1)5CD=!5w{e!KgtroENjJ&@um#xV#?
zJTNRDups4KicKNQ@|~gCuxMmHh$vT(K^@bI_VU>3E
zi%h?`V8n=SSx<^X3Qtk19P8<-C+
z#2}E70#@jwjTwL-xDfoeP5d{xxvbe(##8(b4Ve)3VFVu$ED{t>fDt#)Uz^-yM=|U3
zBO7YRG50Iy>7Hq0VrBXs(0p@Avph30H}!B{`)FZ$WL`TqryZNsj@iv`
zvzb69?agHZp}^(--p10BW_EUTW@c=9dUR@X4CppFIRf^YoB}LD9!*a}9%v`;>(*xC
zu9IFa{FB}EUl^o6tH;veSMHOoWZ>mZIq(x5{>Ph%+mf#kdKt4Avi=wStm{_xe^m(&
zGB(ckcz0DhHU4mBnvBB0!8z^tjCOo(Mx!Mp9a)?oyF7iIid?ia-uIQr7uDz>?{B0$
z3D3#CZh3n0(KP6APBSyFnVuQNRe=$4dALpx?G)2N&dp66?XH<$@7dm(-W;x+KHW^X
z-w3`pKFed>>gd|+y{(0ZN88%7XPd6mJ=`nDiOGAm7k9qM0qiJ4_-TouA&V2Dj6x+=
zV5TBk8Yz2CFqfjI5U?PKup!!kfM7&)T1lr$iuI(ek#;mw4u!uc$4`_v6}*unU`k7c
z2QS)`gsmL26hh~@z-c~oUID>bQn43z6YT;U{U<)qn6xF!ntG+zw7Fg+6
zRdNu@8^;FLN`@-QE;$Z%UtEDPLTbKN}R^V{$wBum08V{-vM)$#Bq-
zlmc=wR>;P`_^dJP=NomN7d&pC-N{nXIGun#hn=j*R+af|cC*#S6of8{Q+Bv4HmAi-
z{)p;iz@(ct52?-|Zc@B?Nqu(*b-+EAcP8kg!C*8Ph(SWZH~^97`D{w$BBX%CSpkL7PzdM5$s>UP(33`S
zJ~SXf(h&wd0rdh1HpwZ`7w`jPDSI~SuzcA*4~3)v1DS=HfY1&8W5u66AVcgkH$@^y
z)g(<;X`0}q#5XR7*X{6n?LNOF9Ciqt$KyG-THiQq@1j9acnr)(k3aSV>`_RB)N6_?
z1eJmYI+Tut0-4ni7UtbWnH0$YS`x}KX_XW?UL{)|#~#nIvK&=Pv2y7n`W@Dla=TvX
zwX3aqvE3j~hJIHb_LUyXosM^vVV?wRlBKQAcRL`+Os}1%mzf^D%v=x4*H<9OJf*F<
z%G_LKZ-$h}rdtD(+h*P%A{5
zuW3#pRF=avCDy8P7_3s-&bXY90s+a0T#3pB5G_??#^h3#AQET0TR?x>MwaDaKiBJI
zD33ggN5LNkRgbO-UHnP3#9><)w8*mDt;Yxrm0+{%uNU3*0;M@rhz`vF#8UbKXecMi
zj$BM%7Lu1=+{pL=|M@@vr;C%rXHT~dj@FJIuOA$(A3oXKRdH~CeQ$4r^nXCTy;aD;
z!McixOxE^PQrus|eDEKs3Bik)Y*^YgEK(L5)AIiAir%=WQ=?J{@>DvcT~H&lGA|hn
zphE&gqj6Pl02(fX3xSL#5TR;@#)0}JL}=B3hcPOhM6iIPNTm~Hf8P3+BBgdjgV4M#k)HqBs#q7+>MYDk-(8uiPRE7
z>X?an2a{Jcpho>F#Wmk~C9X{|C&kJAP3@cA1>ZY8XWL7Wj&P5+8X=%VQUSWCh6?%s
zK_+)}h(T5E*ztn~5xXiNs_osN^C06o0w#hH)z$Oywki*pGgo;^I$akpssK9)*mt4u
zCyf7?01Bn!N|FGv2KbZ6+zd=qKdpiq#S=w%Tb16`lgAASjCj(J&RXfqb_!x{B+nJ`
zL{7ZTMPH?YucG$HmRFnlm4`>V$*}WzCVJ^JKY47J-&z{qTAN;5ot~c^o7O%gUp>Iz
z%;*9raPq;z%qV@jtXWQ(8G0pg=6k_S^$_s7S-g4c{x%vR#<
zLnSn<1gnU
zw=()-cgb^p~zGU
zOxanS9tu2m(FVc;9avtv3t#6!mrCIT)grH$J|0l+>#
zrLCr{*UYT^rDd6j4ICH-$;CpUNGux8q&YzV8B*z#2q-WTVJU0;WNs$D#6iAbz>mW)
z9~&Ss7LBBnVk#-BdPAl(#Bs53D2~$x1H_1|7BkS0OvyOK2TZ&(E~_ouD3lojPV{=2
zw;^qmIuW?&^|=B;0z_b`=C9b9;EpBuyiv3Bj#_e
zK$%jv#Sgp5>pqn^W&z6p#Pm%MyqLZnWYBgST&o%*G(=mCmU6yS!j=(SaxPje3u!Ts
z2-$LiuaXOAMRzXgk#nK6Pll3luN3!*3BSkz3jHGQ;}f1t
zDhzz25k4sJA&v_|Bq`&Ltq_JmsUQmEz3`6~|+t%~%Ok
zgNG%!q4Ia6w4?A5pSMhe!U
zNNoUL5%XEOVMs9>EM)uzw7D>QQK9f;r5q_0NrRZr_~a}O
z4+A5wh0r(KB)}(KE7cs)~Q8Xl~AJ`sLS43
z!Kq}da_XX#x-6&7auR5GDW}eWiN%yfik@eP@knQ@s6&|t)^6~>5E
zH-%J#n7pw(0qi5&F@*7=N`wT9%o*|SQ&J^rwwEatljpSJipACp
zT@b99*oE!b5O%z56~gUexS0>dJtw-AiRHPGrG+ub?93yIKA9VxTNqzhAYa4z`SF>V
z5v}&&{QT(rJV|Sx$d7QAWMX<67p9q;o5b$4mXw!Z!I@dj6uB6J4k2TzzEF#+1@g|~
zdub?~Wo~R?_R-4XsD5?A_DWxjnmc)4x9A%xfnGU~O_*OEEN?74dS+Y}{AaaHppg&C
zf+HKh1Q$kZPlM(o(fe8vEH#F7y{r?`%{aPgTQ_a*q-;&mOwm6Hkm3obmvv4d=rH%h
z(>i~FIhfg&?5(7|k+M@B%J?}Mpm|$Ua<-CA;G@Eu70Pf#T1iNmyJ#jI4gSv}8+Mz5
zPGmqKp0BEEZ~!9g<$B$$nihnWTewRm47uu)G46($)!q;CpVMQt`1ybs@s{NZx$b9w
z@fW^|GymZq{;#b@rCiDgl$hEYiBgDeGzxxlI2;ycFSdg5Qc}ELP3N+l*XOX=Emo`9
zV!5JiZnwwd@wwbSaG}c+bh!g=@Dig#RaCPwgz5R1
zt`As8AtrZrVT`DQ>aN-W?_qL09<9~OO1Z!%Vnmosk%*62aPpnynoh>%<5QMxn{}9g
z{^)}U`d_*vV#6iTRfVW@9|fI|S()t35Hc~dT|z)g&Et2o@Dx1b{lLdBqnOFW>~r`q
z%}Y*+tw!$sResP;Dn&kwL#Udw#qGAZ!HDilzt0?icrG%czftB$S=ba?HLi)rd?ntl
za@`sa>98brou<@oh@itpjjz`PCUIPVsu6+z{#&Z>Z8q>UNNR
z4@T@~D9>M00wb!nV+x`g+(jG%4Y7<>)gTV(0}XrP)gaaHO2f8z-A%s7Nd}qE2H9a-
zwIg#aC0++10f|bHN;#a899+Vjl3ay+SQ5OzyF|=g$V6JzWWB_tMUTWgC9)}_RT
zJ{e?|Rt_i0h@K=fF-v?v1OoB_A~w<&Vi)}|7Y}d=KhOEOn3s?HARH+U{X!yG%n8|K
zBrS#{&L0ce<6%c4>SB}`j7Pk&uqWhqpylI0!vGiY0V4D17+8>tx)Kp5A6K=Ho_sn&
zp)Imd&c)?)fU;QM1y!+QVdlJB;~^Ysf=E=6a-|K^MJ(|%at8hiV-;zC}l!5
zS*VwUav@sG21BwsSIIicX=^EUL1yKQrJS|^4I4#QF=_j2f8{UY)W81g
zzw+Xh;n@q_(UUEL!h`k0!;Qnk%>!z;j*fJP2iyAxn~VZgr^Ai?gAJ7hRU9-?49W^f
zkqH@{G0kWsFGG`w%*y-574kl$2xTB6rM5BZmrW2FSuo*KB>G!}g+XYu`Osh!^F-J$%
z7U+HFoCq~h6l=VJMyN^Ws9%uPK
z=@GwVK8T8j5I|wdb(nH~XoDU!QdiH%+tdi+1`8-|CNG%>
zA)%paBW{o%Au|&TCk>47$Bo2slSBKiE1h>z7wsf4@f2+ytasL1K@BcsyzPos_^;AFeL_cePw=0D&r0}`pWM8-N$hbWIW^cuF_SpW$q+5Kn
zJbix?K)*Dxwm7~tJF+zUXkPnZZtCIU{OIDs*viV}^77>T-1zJ)>EXzNJWaecHS=(4
z=7DzR5dj=iA2N2lH$V4aY5w8r{K(qe==#F=GO%*`!R+L{nTa3Wn7L!
zqPs0!5L&4|CW*escw
zC$w5X;n)lXGJ{His^f%)AV>nrak4B^FbXbdd~)jkl=i{Q+~~r>_~z=AaZ~%$IRAQo
z@%+hp=<=`-IjyJc1g64yA$AtDK3<#qbawpDug^X@*qpn3WxRZ4u)Q+{El;Ahry=v>
zu;od@`J8h-&qq%bj*^h~bIxnocU$z`QYq
zTH(*iiIZ~t7z>~&TAHG@CRnPX8JO4x{0Y_?XDLO`z=c)8QkQJ4qyy3rZ3<<~p>izh
z`uV6^k4kuvFV_Ho*vpc1^Sw^4k7sQ+-Rs~1nF1Q#P|*m2zgvcezhOVmq_gE-cmyyVXi6MBt*+29Crum&@vOSlyKK&q+yMye>B-!SOiVKBp%DaeGO<
zrrK@ElzXQ*1Yc382MZQaArB-+;VID==8!&*u_K@m6VM^9!~Y2Y0eN%|OpAueg3N%B
zJ|NWl^5i(`0~bcg${Yk8ViuhZtqO?j0!U@3MysgSVe&X6uS8FPQroz~5z3E4XQYix
z%=j|ob4d1Oa3P_gB*sfcp;+WnNdd=2!v0c`QqASFQIYr8D!jx49c^L1rB&nc91Z*J
zpu?2tDrNn6*t2|fNs47Av$D{x@Xa!%#A_&MsQ@koH8+H29U=k~YZXdISFH#vbv6W~
zh+V!y{%5?pem=(5=}>4COLkc3c1!)f0zmBEIXslEhk!o??e(BM>=wJtT(6buw<&Gm
zpi5yW6eERYd0qVc8nl=Be3-rMXZq|blh&}01zfnfF5Fz@m_K6SW>EP2O8(-C;*P&p6v6wTS
z@N#@e6v84O!Fv%XP2?gVytEiCW)g*TOcMMVDb%c_`i)Glo~#iax>%WDAt^?=cu3$P
zI93uu*-Si}j`1-M7ja23uN3o98~2IvfS3p-`3M&YB*H!^fs@DLVNW>VWFQ#gVn9QG
zBP{^)?X}yYE-iukjGp(iRz{GWRKomA^S1|L=YialL`AM?nJGOV%lCZ?JNTUjXR_)1Rb&jH}fWZM7qO8BR(Q)
zGIKX%Hf23ad1$1t=?ELDnviJ?$)KD%uO`px
z5(Sq~I&1!*;;zEz4&Nz?!o5leZTohJr`(~LPgR3_Q}TD+{5+x
zM{9Er469?dx5ixLvXOKb6V{mP&5Qk&jioXCzE&3}mX;=o5oZ8uqY#kd^vuY#_Tl{8
z*wXx{X?w%m(T-UPaMs~k1dq1!E
z`vrSC^yaByc6#j3PftFWoP5Y!7{Q=pnn~h9GFWRVoede6r$(m<3dglms;zlsQo}Oc
z00bEkQrHS%;=~l=Ma;xBEiQ6;WOjCRb$R0D;VSQY+se2HMSnNvZc4U7;4N=Elw40L
z+<7POsis|y^S#X#AoBf{*#~QLBOCK0`jrXe`h@wFJ{`F%aSq=3I&6LtvpwS+&*a!y
zUAXLL9oOK(wDT(Kx&|HQ99KoxFz)~+UKL!uoUNO&b}|pjsKPkoD$gwxM@T)R`
zBX&;}3TipW^)w}GL$cN+Yn8WFsE9Ve(TSTz3dOWb5v}U_`KVjJN6NxMKL;*UJqx>?
zOs}2pcT}xmhRn*WOzp5w>3^^L8D>x>#o_yY?(<;*?JdT
zw&oy+6|{%#gPKrHcHU=_
z+H98Vb(xCh^=gAbeK@FH4Jggw^{{etRlT{YTo22GegSK>)5=iN&2F*R&Rz9C_zsf$
zVD9!R_ZgF6C)KX=?HUg{WWEq!$HMJ38IehYs2Z0kpsH{?$X|8SH^c0EuwySpHst{r
z5mYU788|Cew9|tY
z(2&Ec1?aF@N#N$tD@ToMmg9|5jFMp2DbZu4K*8@-nY4zijB>alQ?f&)7_LHy3qhh0
zC6C=0C{W3Tm0YNl@yi)-VYrDmlQJdcsTLCDY?RP28>-3RSHP>knDNRvf?8`<35+t{NHc#)Zv!HCSntR}BfP0xFKWOpV~G%oM$u7VELJT<#412*t+
zcaOXkX@s&HF74`;_w*o0N_;~ui7aM?!j`x1N~b^!+jB<7g$7EC&E$>_aS~QrWosT#
zNcB`mo5<9JAB197RLk=EtZsd7du?`ml{^kv*z(-gDk%=PSEn|K`KEx3o1_t(0yS>0
zYDrnRdLi(4sOwwmt-V2r{1=T^I;RjNr^2(xp
zkGC2^ryIeO_3+td;CL-`y6Hbz3!QJOtLNiw_2hXoMQEsc6S5K}=M~{tA$u_kE0NCI
ze?owRpg`c@m%E@t$RAHjUVQ(z{{hbYcmC$jg>8qIuQsEu7x{#>Q3zCXe#<-4!sMS@
zo&6MaxVJI++_ZSGseNXgdwaBc_H4uaMrS)QTHoo94;O>y#%|X6wR-p`o3XFg!ta%U
z9KU#bxUw<#Xk%%7Y3||5+@tmR5d%v?w7xLDK?PJMR_8}Im&W40x9z;=Yt7i#y78~I
zB4503x{_lHw3TM94a%FJ!O?76cSdPL4951YBa5&76ERsd+d9cGQl{Og_N!
zb6p&jd22uC{j47SiN5$_ExwoWq&%;~mxqP$IZ!McIF8$&=fW3?=t@V-_S3_i)rqzF
zhntHdcv0Eko<7vi9&T&TpKkdtk0Mqu;^TbiT~oC5Q+A-?Fb61f_OrG@-aagV4oL<%
z`&EGkyJ<@glCid=i%R015`QO0UYBF<sk=H-#015}WYt`4VpL^e<_NJSG
zTzAqCJX3FnCDqsP7yr^vg~QHp(8#z3qY}vuyUk{`SS~CU
zvy~ZPR4QWpM+vw;pn`1zC%5rD`zlupVvW<*vk%UULwY-Q_rQSYNsAuLADZ
z8Oc>w;&^Pcq8${TLS=L5L7D8-(k+Tj5vo+5Em19Vikx7bSdC&7q(&uGQ=|_B87-H7
zSbXSz<<@Rh8jVt?UFmkKK*Mgg((e-*exO6;=Bj*sB@c%AZa>{6g?F9-BA~Fybcd98
zlaU|Aju0L8)6F_X=L{*Ab@nqdB7+6;$LRY%E%7QG1ZO~zQ
z&;~=ZXpDwP-kBg~$~zsa$Wa!DE2RX=ER#(~O9e44MI_Fj1Q+tYTq<0zh}AML=cAaD
z6#XeNB!L<^f<=i7Bon@@5X`5-BCwL;RLC4Gav^3o1~LL1Jy|i3=6xy7E5_XtvjU3=
zFIqnCNyI$@?<fKl6zu}v11`i0Iznt~SS-(skieVX7o8tF{d<`9`gl*rsYW{Z_JD7khOHjEFvd@k25$^SwIPuErW={4ifB=PYIIkbKfy03)WX
zg|t1zTkz_OGydoQ{GTq*p1pc*c=25S;V!zRV1=r(7z
zSs=4+a~f!8df*~pzLabpP`>;f5S^49X?_JU?>4uCkdy`^NTp`Z+z=-c~5obR~!4A1922!I}=dv%fa#z=(4rJIiA+@7rSHa!~Ys(Tsml4c`{L
zt)#<$ezZM5w!1MG@towMmTuPH$@$uOe@U>1?Jw6CMyDn|ogxq%n*x
zcx+fqxZfzet)6mp3f^YMTZ~&RuML~?k5*?MtS{WhH%)k7SJIwdIo_}GWl@4Eg
zV{v3>1+OR*n@f+jmma=3TJ~8V`>jV|+vAA!P;@`5#Lrqu>#*P%6kLOXV^DPV3(j7S
zFtMMr0}%UJFrw!w@4Cu4uCk6{#(9-?LHeS-BigF5^Gfur7(UKNj&p!T?xH4Iicu=%
z+z_p;q`fKG8iKXK{aNS^d+lVelO*$TpH-w~CBm*gco|aS50(?|&ZiJ8*iB!xQ~1{v
z?JZ+O$aOE>Z>PWWJO2bH{LO#x4g6~^CGhTDYSuF0h~4SFbUH6t^sx=%a9C{2aBQ_Y
zELQua#cH;iEucgjAo0R%J-f7?S?w1N(i&3CvekAOj|ZBKd?BBRM7?Bdrj#}mkHV52
z0;vKXZ_w@W`+PwawtRp@l>+Zl43ZuX8`Bz6ePoE5j}U+trY!batk&@ToOw{?%Cu$^XvEPTQV?;;}g%}{C
zF>SbH3v2xO$Ci)OpBw){mIcrrjyEsaj*H*H_4_+*byDg$0@@x7QVL;q_JV3TW8Pv^tqy
zj|J5Cs4NPlyk-uCpI^(LUll&P%71a4|NJ`7;z%;LYPP~bk>XK$MM}NYr(hJ&;pbN+
z9D-LMay0BGuZQVgn<~f+T2i;cwQC%3r%?qlN2#uHnJZ+&84IQLbP^v(3DJ}oPYH2}i=@R!E*Ys6#f%ta5h_7|BjzLp
ze_HU@WM0lhsztt`q{;;zr%j0g@a2abH)!3G=t-u$3Emdx9QZ2>2JEr0FCO*_(O@zW
zP5=-ifJk3F>PbX>*o{Tpey=q^6}?>nzcUzc<}zHREK0o3>pTm3ZHb7Nk5Y_FArr;L
z^D(y~i`jHMpW`!GE}P{tnOI2%84F-Cr4a4ZaEmC|x7FaQN~Eqt+jUNT@xU6ZDKRPo
zQ{!q?tfE+@7*h(sL9SVr>NpAda;#d2)a5u+8Ag?Syj+09%K31ug!@KG6U#E_&@bnM
zRV7-MLvo%N5kOhW1|h{vP|ksUfrflO!^znn=I!t!Umuh}hmc__J!~fN8wKn`+BKe8
znF$RCEuq)oyY&R&Q
zbps1JHX2s}f+piCKEeb&6-`-Tktkq9P~$4-a9_U)E;Q{d?dj29+1*((?JVx;mv?nb
z#%-#P!feM>6J;03xI^xSMi#293MTAeSBG&D1FNcMpd!m^3PTd&!c`VcLOMUv2yU-|
z4z*wU8mf>7uv-V}5#CL$6Eae?3Q&(^NwWc1T$u(tf(uDIxG>IigkyIaM6xpDRMVKV
z4O!CeENXT0Q#%Wj+e?$%%M_skM%-K*-&vbr)tR;WRgH0d;&5y7&F-xC?MC=?JAO%k
zs8-BVSy1&a{BoCdc9YJ#ev(<1(ZL)X1+v89fp=@s^DW-`(Jjk0?u4o#3#S0YHbLG+
zM?3}a-4P*UK@|skX)_S;juBO1gZ;F*m%bQeEd7k-n}6#s={-9{Yt2ua`>%>$>4D}>wT|8KC6UpOM#n`
zzZ88Jwd`45Z(Y3Fe0eaxz5HNK^MBWGjJhv(tD^b668Q0EbMiJ9%$Xb6=x*u(mXHpj&ylzx8~7YiD(O
zdh)@<#QmwMktxjx7!H7_q3D)Ta3SbWGx=yj^8kQI?t`p`p2~%43tpU^A!kHpTpm|V
z%xHmwXh~~0`A9SIaAN!s1bjI&GdepDJ1`fpPxH?$X|-c57i|NqcX0@{?KZ
zy@lEPD{~Ky^mC4rgRtX`&+`1@wb8VVW&CJ!b#!}WoQi|5PwsALY;O$(&Yq81{O9}L
zV}0;^mv_C$N8Z(ha}Z%aZ*Qk;{hSj}ILte)bIz-*y`Qo5GFHOGoE@Eh+R;xrhDql@
zq|PAi9A;c?(OQX}DNKo|=EPB`IyOZ*tAL1(x_&Z@XFG;7u>1LLqZEB;zth2HoU;_m_VHXZtt*&wtIw-G0A4;CJKsm(Rol
z0jJY#u{+InhuPt@*&USc+G+(1VzXYFtpG%`#Rg_{x*YiQ(sprazqDbp8l=o(nWIq;
zrS_GDSTsOdGNLEok=Nt(v%nNTV?@vu=?<}}io;+~ML=L86R@C~=7x0$5JMCwqjDs`
zk&a|^2qCp#$gheT1WoEgQbnpQ{fF6#NeRi?57}zS&GAl0h)wM?G^9S8Ls@DtQ~eKw
zc+f*r7%93uUI&#Eq$J@^DmcyL10B*lI+m=?fJkgkW?Y8YTomO)NUc&hkkR9^`Q7$J
z%q?&ZpZnNudlQLRi-ka~8g13%-8z*`>o!GJ4#pci5)9o0NmI*DnqFWi^Y<)u41eEHlNSLJ4bz7%!;7^%P&vGSpBO
z>p}7TP<{_UBmw*tzPKuW6|gugfDYfY@Tof)6ux?0`s#K0i>uNXH>5jc`tmeWnP*xJ
zu31ggm<=6YzflvaqALC-HvP_vLbNj`xJZ)?maQ3OgbZcO>YFhCI=rI~H(qA!j}l1K7o4Sl&)P5dy+;
zQEwvR3Hj||LP6C
ziupvT$QAPOB4AFAH>x5l3`oIDV8J$CIXYN8T&)tLIAtY@exn97qyT5Co-D_k3g0Nl
z>vF6nN2+qTp-`^GN--aUONiyH@hQbnDIXvsa@JSM`7y1O4U{r|
z2;S%AOdy{M+<`7e1+GDZg$Y3LMd%>u%*`^7MMcC1Ut1DvnfaF
zr9idltrR>eAeM8ka?VrAc+!IHFa7-2ak_u-8^8AYh2hzgttU^mpFG()I@$&WqTS!$
zV!5xk_V>t+4E_TksvR0UxEo}~y6T1uKXt+a#
z^)OBW%Ud%#=647dWTxahtsxk3ivi;1%H$3UI;L^eMod&kT0oWXn08RJu|$9f0V$#n
zGz24Jf@)B{b3i2j!ikM#2w9fd1PCTfWB%6S)YkmO_97`A@#)U;Bt@$%Yw&nJdA7s(
z&ZU6)&C#ZDZSrVG>w2>jH=E)Ygm=uiOx}m8zVOSAN`xs^XHQ^>Z&YwZ%M8tjm1Xis~o^InPwvZq>>
z#j_vpN;u&k{o#MEN#=C$WhV5ZCS7z3-Xd>3($CCmzXA%!tu}4X31M@q;J>N_uBwr0
z%4I*^U7h*lsd1r}^3_D=uo!r+gg&oFu9RRZ^!DlA{L1{p1?~NX=?8`lP1O6cnz7%O
zeP68vzEJ$1mAzL5Pdnw5V`l4X!|eEc64%rY4s-WO=vy^{7p0^
zP*og0!WqDe6XR4vWonW>V$?V~F@7J!Niu#Pq{!qU)m+g&oSS|)Kl5;Y_R+%Z2s%^@
zX669|-*Im0-t5%9Iqidm>4&QeV=MEc7+;F|8Czc&U0)vAS{c=?f)Ph_
zE2GAB&EDqJ!Orv(wI|sIfW@?ZkahLaU`IzcZLjecl>`{^SdP5S2VWOLZ?M}*JJt2`
zQMZ1Vpzw-P3g6KoDG@2Y1d^fxtQ`rRD=It2QX77tLsf1tt&?mu`2XcU{(GFQ+p1OM
zRI{4xwlmdIG?N6qS!_Ta*dV8gV4jPY2+F({BxADNXg&*u-4QzNC#!B1m(3jJY-pL`R^(2TSB0DeIqvo@3F
zQnekkjw-a_vQ*V3Sdeic5gr=AAGuJXRn>uRG7tlp9S*zGNrL+TP^J!q@`tl{9VZA9
zw}j4tj*D#f;6ev0MNMX95AfP)3kGb7m^CB$BSD+rdl`>d%f)c55^dCCtvc7i!?BLX
zB6%OSDrm(fq$W{Do2pc2Qe&3oMp>#+RTW7o2@rMte2lHp%(mM3J|jXkwc!
zC}ea<)$@9t!mv*h2E78%@McKm@*pbw0S&*PSQCbZ*A$P;vRLOozbU>awPFE-fWogr
zu1o0SQ?f3Sraaecr|T7fAQir=D@lBJD#bx*_9){|AsY}mm&6gVi6BBgBJojy)Q6Fj
z5Y32@N>QrI$-ETJrMP@X%w;5jkBL%35aYZM6@;)TMnvMRU`k>l26G^}Y+U5YB{3xg
zGEyid2KWT9-pk^YDcKD=WVYt~T-43QJY+;By`U!%_r>F0Q3$7{NG#$E1uU_!jm*%z
zFC21sz2-#1S1G6Pa+Tt|A)h(yw_qi3ad$cuO2k~iL7W69FBL=#2K*O3&#Bja9Pph5
z{paDpWg_m73t%q+Xqcv~jloT4(eI73bQz?N<_5yRMi*iHmG#+Hj6bOo?}GF`pg{6`~}w*$I++Yk`Hu9(IiXS
zjiqS_7;$TPdUHt&<^%Zw9M>=hL`VTEG=j;7pl|_md0<87a0!Mv6d2hKa0m-jPn*;t3!U
zonG=12evrMdi{I9``b9-Ph1yy#}oVOt>?P&%V&$6`+3Or_?c;TZSFpPQ_BluYfEEq
zo^RVP55k_8A?M52ha2m&Bg<0{7N_nX?kxE(UkTomT=XIpItkgIzI(c{xiB$14rY2d
zqq&DWpNiV^QOls{qndR&cR6txu|6}u(i=Cm+Q}cC(ERA+)Tf$>A6=Mv@N{?O?6v;&
zlQqM}V{3DdHWo+M$?tGvYkB0|
zv(2#MMa=cmeRgoDn*k=8HZ;dCHhtE|0qa3F^s2_4^wXAM#x~3{5CjgQ!}{H{rIRv~
z;xKFNWh~h3rp;)XpQ59iwYD>sPS)B#5>C(ZPQqP51GD~Ss-ItSmPRoBl)-9U#-
z(!(yLtr>PR!*04y)%PjS19nMkNbZJ|?CpI&^I1RlrKnDay{7Qj|C*ZE;afhB)n&Jo
z3c|3L$*1Yr;}6(EL6^&AAzwqlj@?0tYHSuJW;N@z)rwCq{a&-naUKXb1R0GWU*#&*!s>Ooe1Jx(Qmi7FpX!k?GP^5Dr-lg=FA}7YkyynwoJoZ_
zKMN4SAcI9x3zE{2d=7CEid-T0L6&-k0U`jEdIXOFobApp5aPjg(Jn4U4Vd{-=cn?Y
z+ePMJG8g+O9K{c;!yru{D0Fz4(;-7c2mOcKDsk(G_OQps0fwYxz0<<7!h=+P5Q1HY
z#qOfSkQDkuHf7xK%SgnPNyowgXTWO9wTFfVtMWLB0S>iYQ@Ten^4cPXPapm5kLQW4}~>3UeXy;hwL
zNq0CL6d4+p2i@YJTNw5V*Mq{%AP>&_>TT(3*JY*`EPajf-yI!Z*GJSD5AI|0c#e5(wxl*FDn2XjbNzfQ&uI4C|
zga;tcAMS
zC@dk$fJiJ@D}}ME(qV2rC_}j1RxTV7K4$<#b5jxO4jxFe)(@7pFVl{
zX8-W1?(tLo)29Y7;?dCn??4d04(O0f$p<@+5A}!4-H^0^`|Dst^Z|%OhpGc2Gb``1
zP!%R1MS?;I^H2mSl6~1kRh5@PhkK?q6Dx~nGOR$rg8PQmJ^hMmO*ZNlDNoJL{D)xV
zIRn{|7Y$%U3^I2^(4i`f4ha@jeIdlSGi%bJoiVUXBDzh|6ao-gtz->V##`5JuTE~U
zaAOGZ-{LqPtK>V#48$aq+K}jw%*RA{OkYS&huSreqUwOCdJ{6p+g_U7UZg$-R{?zF
zq{u#9nf{<|WHxAqkE;t~s|)y9nvMB!JhnF%$G4WocUJKH9s?H|Hm3Be6FWGgQ@@rI}qWt
z4FpV{wo_*v>7t)B_artac?M~TCun==%UJ3@ySQv
z!tsgw%&qVdLfS8yh91;P}`BrW6DqKG2Lm#32w6A<$5x
zQFVvd9l@OO@q2SKkFa=N?=8oz&-1}kIeeD!zE0SlUOwB{UU)P;`rpoKKAoR_v^GEb
zSU(@Jy=)}CH>KD${+;3-0rQh*#-;5gEV&8Gu`v_BXca=kTB2PFCj9UAwzT@S$;ZY8
zzwJrH{fzUyEOX~|;cS?-_5p%vdrJZW+WT4OFz@bW?A;Wp35OYHKVzdfm5hZVnn8pa
zYd7O)r)=#c^;@Y+LPH1`kzryd>1gtnYV2HHKOc1i8umKLL6;(wd+ih}Q=3wq4zDN!
zwi=|Iz8$3A4^p=*74T=n>}P`?x3yb~4Vmq-|&Ow&xRIu5Iw;Mt+FSwiz
zz>wWRUWRr%l}N$Hh{@yjfV{j;mNVMprSyPqvNKc0Lq>ky0LdR07a>5TY=Za*I2iK#
zA*3t}g>jJ6=XLnJPBz~a3}Two=d*jfc8`yYyzJ+=+#ZLU0zpUsYM@g}IOD^AoS247
zP~&58ut!x6vi#Mm01a_TULPiqD&l-69kx4#e!p}zAO+!<
zLCPu@s%Quq^vJBt=ujSZ%Qr*i_Da4XrC{;>O%W9M*>(P_xANC+%K*gB)nuGlwATfE
zs>)}#@@MZU>&+J!9OfwDT}!;~rH8F#O^&pbM7vIw({^3L-6#M@@_}s9UCIWkav~)L
z08AnuAZI}_B#LMQ>14Q&<$#PSF`SY@0I75`B$6Q**cTIpSS~A7D|rb_DTI?!EG@;8
zVmOVN$zUc$%EEjqT#
7Zo{oBId-)RXjqqPgufgpCWU&Hvr;dE*;^c9wF}IV^k;w
z&?a(zkunZc+}zXo(2MDkLS|sz9ge_$PS1EhTbHY`|V7(
zk!n>0fHmn3OA(+Ui&KfznFAtlP$fmQDm8x4CQ|N9%CcTel=HDtHY{g?N1RZ{Ug%^&(RWH|X(~9pm
z$hcgs@wJ-JqWXaJ_n=Cz&NVBMN-0n-`l`hMeIGd%4PE}bfAt&hGy9{-KWK0G+K}%4@iZ4plgthGAlFLn)eK=`-ZiBK%tIVign8rdZJs}H=tcGQQZ{EU$ebEr`wsQ#DwVU=67_n
zJ7gdR|IMpPLF4v3&DYI=1^0Gl_s|;W_6&3ThPeaX?C#do{`U0#_Kay`%D6sd1afU?
zbnD|=YvY@1M1E>aG5BwdSdDCyXjyOxg_x`_5;Br7m;*JEPH|;&ZBes24{8MGO#$x+
z@|f*-W048z2+0h+x;VZDrd*oZT)<>4vq5XO7AH3sR2H1rq@*@#t3d}Nl<9_YB@!m;
zmd1_C6Qmhey;0rKI^|YciRS2?r%|J#35ACw(EcXPwk(FMZxmo%A#3gPeJgwfw*T!@tGZ
zs*>yC*@peKE+4(Di7vtO&i;DWe!Tzc>DJ2P*bMM)=F#*tCAFT?KAfF?w6Q#K_Cl9%
zy%yc?{AWi`_4Au^BkXQ#)|Mt_r|yB4mbD}6a}(?H_`Of8uw2=5Gb1ya`_mJjLgpqP
zPEXvQns}h4@R5gLzH!E3dfn3b$x$M78FC%Jexh5N8yz3}1PDl>$IP2>T=NJrr5ytr
zLMEpkO|e{w+Ub$W$p@5M8)w!$)K1*jPCS^_Kpsw!Mvzz#XBZnJ?3);SI5zfx5#ghW
zG13td7Xnf>_cWTXjE{c;IwV>hr!&lG@6AsA=<(62;C$K^EMKpLe!Ld>=_dD?9IW%U
zh~=4SO*1q8=d}}`EKWZ-eW6c>E?Ozi=atykYVj|sG4wqrd%ES3&BaH%o0A^%Q7&OC
z3eH@@;xj+p-<;MhPdqlvxzBeaw#QNX<6P*C52{EOKSheD!>+()5@^M?4^^^H4ozx0j-zsii;+f;H0TQT&Gw1O{02xTxG5bK_IX6Vr4+
z9$90F%}D*|b_6^&zsu})oclbMM9fz%NZm&1C%<<63qSK?f8`hc!hiP*KmFrhyZ!l}
z{i&~hah*xW{T_?YW%1(YQ`Hu`>fz@kH$gm8!FiOO@Q&_)Z)Eue&N@^FO7uzXN5*2+
zQxKn0+%fArn0*;Du(7BcDlJI5Q-*zjKQr!<&35S^3p+j~{UJWGl8_ai)Q5IbEaEV)
z%OdgKTqXnpaJsCFaV?>c)9V$ONmUXp0q$fRGDT4U%kBQ;kX*AjpDI
zLJSsxiG+is-O0z*YRlD%sIH%nvGw}J0aZGovM69grZud+zp0}IDPk9ctlBa~F<%WT
zSAFGXP`$mXyuVi7Uzcu%gn+jU0l&B{e|9ZX6(1_(Q~V49E~He5#V^RREMpLILxms7
zkK(GE2HX^LzIr9r1R>PHI$Wg?s}vKpl8_Mt66a3x-h3vSrCKHwL?SUq!;BPcR@0TT
zlu1T_i~z?}Dq1W67DFNzOo~xSj7iM(kmIAG7*9$GNs5VLC@BV7_0+JF`RO0;_gjTu
z{DmL?rN8yp{>Fd*mwxdt|J-l={cr!)Z~VqT`mKNTPyg{h`R;eV`~B~I|NGzn0ptfi
z_}zd0yO8gH=b!!4Z++vJfBGkXsw@|hVvLJ>;}J(9>J&L|CLKwqfTW>th^pyC!)~9~
z?(;eD{zK8q6pw}XC1*H7>Dm1Oysh95ma?gPJZ7)k>~fw14ShhvusxX!$Z|pye9Y4A
zj)ZJ@!N6C}rNfz|Uy&17Hq2=?-K?b>Rk1+@@$M9dwQ`hILyjn=h@vL4`GASc+#FPj
zR57nq2$c%qaxp41zr#|V%+1AIpg>B*Krv5fSOOhVsIsS&^HzX{Sg-PB-VYSA=D_~h`CnKtAP5)z_)9ORwY(b@CAZ384@aF
zd<7P&{4f9IKY#V+@Y##~7q9moKhqsO(H%ZEfDZQ$4SV}LdjQ0vZL%o?3J=M$%sN}>
zfDYNnhH-BVuxQ++BFlSJPY(hLT;APX*=KnWO_a!HoyDN68;z@b#x(%qo^FLizp6SE
z9^B~;7k61@l%1Ug$maIU=FZI4_RNlMZhL2LhqQwW;7HOYZqFHY3;V{UUBle2eg-(W
zzcXXp)R;CWjhj=t)rq~;$-{N+!Mb)IvH?ca8aF2OYZ|cE4(M=wf_Yqxt}czNFORJ)
zjS>jXkFU-H5GPhx3mjZqByd#KiU2_js;-CBE;0l0q6WKb3)BZMt}PNNl5u&N49(!e
zt;MMg$O^?ZZ!S)5%}-MGlsRg*)x0(=wav~lM6`udnw0$+I4`wXrtYveJ^X@homvhY7p$Z5Dcb2ew}4-
zVJ~g|zjzk5M94{-Kko3y%ncD}c+yRsbeZn3lRWLGan#9m=JG0Q?qw~1^`|Jw@DIN8
zj~#Eex8^?GUU*+z->Kp
zTMfOh$I6oPD}!X>xgbWNB`EX@QC?Yo{J+
zfpmbji4iS@fRM&+Y~tSN*uAmw`(xv1KN+962U4V#5by!$5bXrmZsOsX<{{{Cbc}*j
z$m0-a(~iu~j?YXzoB9$Y
zjs93QHY@~VuGiZu6Pk&yXeK|M)_k%$`{?qeA?ZIW#cdVAS&UgDwwH(7GaCz!Xw@x^
z>6S-LE1JCx?cT=Z?&_p*c}ll9cKl>5XnPuUzf8DaaIR;$;OjbnHptj-a-M$DewA@u
zXWc`JJ8=%ce}bhgnmZEt6)>;Ui(bkMa0D9mQ^bf}$=pkt`zdEvuy#1hKyvhxj*evS
zNVZPu&m?Ar0Y)Vrkfph)7^IR
zAO6<2ah|{VH~*T~V~<1tC5e8g)bA8pwNyOnvfIzq9EW!Mmw-qcK@U~QyI`0|0{UU@
ziR7V($xbJpRis)2!bw7+Tu!FbF}KI*^7)XHnZM47ot#AJ7x6uA7$*+7iVVZc^4o;wqRxsCNRAtNHX}c#Er~}
zkTD{JlKU{5JKYcn>p<|4lW7StneLj^YOz``aj$GPGbAX
zRS9^P5hH0KD#Qa`x5Z{X2N?(gg-t}mcDM5+7Pc01L9!rMVs%ztxm6ciHK|!oHR_p0
zEmN;1YYN3I%XvJoW2Hh|kx5acloDmCv-}ZjrF8rG;jq;27W$q1uwMcZ0uA5aw3sx&
zh@>*?VM1}xqsq%yJ0tcfa?~zy0lRfBxBZJVphYSr7?@Bp2m)GUbm(
zT|S>Z;CF?BUcb+ih=pSzU&!x@f)0Zo{Mn|{iD=a8a-9eLwvgWz4%oSvHWtlI_2{|9f`$M~t>osznTC!fELNb&kyBxzy2*oUy
z5-dj&hfakO(}c?T0O+tHgAPL_QUnHz#h_da$wdHP5VyUU2mJZfY0ReVR|WktaiPDE
z^A)lXKj2aZQ09MFmZcy0*{{{V{$9aS7Qq)ArqQoWY_E&~90?F9PIC;M&6V-Z
z)v>jeN9)TYtBWIR%cCm`k5)k;b0fgPm3flYg$dFH5(`2m*Ga&Llh{?Q#;Rbxs!C)A
zXcp;A5zu5=#!)IbZp>>o0fmcGn>Yi=azPDw!FfneN!3%9$97gVy0t0e=ComL(zrhH
z!ZhbP)^T=bO1AGMt-C4fu4FbOt)`T1Hx04xp##Y{_ER?W_b>v%ZpN{faS}KtKiHtv
z)${Q-&>>~IX1YVBBRp&IrycR4Er9}0dMV;U5MeKU0W<_A0v1_>^5rmV9zZgeknjDI
zzmHRW)=IzDYxkBP9juL+mPU5wN47|_I|=MwU7lE69A8+Vf_SrFL@GKmy1J@Oi=Kk$
zYUcdyg1?qQ-|_NrZEoVvy*gORL{5fz&)2GJzig#8(Ekgo134|
zvXaWA1)O*Y2pb?G}nDc6&%
z_gTXJ#QfT*UzyU5ePvSf$)xt)^yK|%&8O27pUi1KU7s7vL_re)3EipID?#e0lvn!{~v(E6+pv&sn@=YAcrJrO+5D%@!&Z6O6A1(n+dIR}NR
z6rIDIom>(#wmxt$W9_8OkfwN!wk2JnL*A(5k7(%=M_PNLZIE;jAWHVGNQbEF=c8_a
zf(uEA3%i+Xmfd>L5rI-
zZkGkjWVc@co*b?((_deLU>L|)A!KBx4mlta;yA37+=dttBg_VE12$o!V#;>A$LaJj
z@MG?G#9}TMoI&DrJHdcfK$Oek@>pFii`xbAv-!MEpV!UAhKc01arhvlNX
zQuZsQU|9}Ul}H&K`o3H)O-ezDkAMrAD`5nvN8u*SYAgw0#Bhf3Vm_S^;+|o*^u=dY
zfKfghNhc$zR4kc{@qnOyWjiH
z4}R-6|M74C_V0Z6JJ`PaT?}CScYgOfzw>?cA>aGn55E6>U?RYg*zr4m0vx~d-QWA2
z?}8D35B+a^<5${kr6|W5^+cr-E#{+=7zhVl;eb2nb7qo!E-gmfh%y^3+w49Ihhy_w8${@vz4nu(4V&b$lv&x{*U4PU|8&T
za=lKWT~D{F$#y;2tm3-)x`ICy4veU#xoIegW|^xiczFsptC4y+oK5G2cO(NjGD@$fNP{lSrL|7eFX;ud)Ejt&oq6!)lICn7umHG&tJKjNLQ
zAw@3lu@pA@gp8{uRw4yZXf!RMPq8V0LjAnKxCk`V8JBkS3j~6?S-o*#M?a4apb)YH
z*`D3f&28??Zfs7Yzq2;=_No4TyZpQV=-YqvZ-4)P|6l&i|M%bi%m4Bpe((SI55NC^
z{JY=(FMsg+|J%R*7yqAs^UweHKlqpb<=_9S|Lxy=|3CeU|LHrw@;AQL$eir2ZOz|X
znf}V={3G4+gq~^~kK^gMNx_?sR+mOr7DrbX$+C==nV8XzY%Gs$u1>5jjgc&muP#lj
zEKaTx=K=UAmm%PfWx4?lPBV5K#~|2oW05lBkiKwriULrUwd)H&!^!O>Eo4izH7_wg
zMVe2ka5k36`)~_%xQuI?)U9ejhkKh-Pj+U`AFo9(4n+HrWZM%gCdpz{iI4!%z9(5t
zYH<{Znm3zj=vfUaFJ_$wX~(|kF!5HMXg8><=i_Z^xN(!!K_Nh7*{xf`8JUtL(iir@
zh!lNt*2|o=QzxzDaVLG+Nu8kIOPvD^8{Av&^xo9u1F+-K?#k<@J4dFa?X`)8=})&;Mnd+Ze$n~9
z?D<0Rea_n3lDCy|#GS8pH)ob+MiytsW~Lr$G!#|>6jS3%z<=nY!|3o%7z?6ve{}rb
z=-8(a&BTK_?fBf}*c1KM&wPIUw}0_x{_bD>x$l1Kmw)i9-}u+R_3QuYH@^A%zxl1-
z|E*vB&aeH_H~+>j{NmTI3sLuL)4E|vvo`&3b>`9h)ID&UX8cFT$Gni=_T
zrpEqn)03afvUqA$$Endgn3{Zu?>Ia4aA|IAg>rq5Z_bYxRwwp1wWiex{o4b4
zWP4%6w5r)%op_A3w>9-_YvyQu>S%q^@@z9^J}Ly>*0~En-W7{k?x!q}tDJ+%sAO4=
z82H7g+bRt*BK#&EsNZBtL-YZF-@x|Ezw*m}@0Wi0?|t)^|K9(Px4({(?7s4S
zLC>sN@2%;1(C^;vzP41D7|F~OiIoLO!OYCe%#o2y1p-?ZGcy#IszgOuq!P=rY*{i&
zmSkJ1+5300WUn{9Jb&C(eZ2kC??9Z4h&+|&b2fZ8tQ>^@9X@#E5NyO*MevOxZ%f1?fmqC!V7#6!mNG>WhEU8D
zikMBmpe4}0v4%wq&JN)|K7M@GlrqgyXxH)E$j!evvjsXt3Qwet}
z?MfjUI)HN0*ha+y_w`8F2#iSm-fzS*KcAjoNX`NRE+!T+<1oFpnq67REG?%Ou|-O3
zZZ=GM{6t8>G7w~JWjVgGoY=dXTw96nU5Nu4E-!{q#d9u*fo4+0yq_vhL9Oh_zLnT5
zYw=rFkq(#VJ#*9c*}P>oZ_XriSV9rE#sE8l>Ra}P!a+4qW;kH*y0t#i`^4ihdA(K`
zeSTvi>GpUHaCrm#MIvsu8=Z?jm)-An_}sR1Jak}fE*lXkMDI;5mPZ7q8XcsPC
zy0Cuv!ucx~F1&r=;?;|n-oAY4%H@lIl24wE#zA??;cz2$xVaYz_L2p@1QUossRSxDDuVI_HAtjeORTOOEd`4(hC@0mRS9VU5EBtV
zNj=O%0Zk~N-nfANv*kx`ymH^2w`BJ&$Cu~g3x&u+Av8A~EM$H8lslJnfe}n}SL308Z1oBH}1yL;-odg@`)*InP;S=-fxtF4{2?QPWnQrwA=qc1*n
z?b|P}{q37;U;pXaAHVqP=b!xbvycDw%Mbtj;X7ZwfA!BFyz}MzSAKW({O{gb|KmIB
ze}4bcS07yZ^8E{cdhhJVrw<-}>JF=Fva4ZhS7T8Z+yxs;yP8Tmn~OVIfD4OT8?l0+
zqoKIHp{Nb!B&>`sJ3l|DTWOdZOxUfEm)xffQX5V8wJZ~*mGpZ>{V<`r@BuG6C4?GpeBL3Jn0NpLsT4zW4bFJ^r11%rKLZi!J8?+xvYFsY1z%R
zlACD7HNtY|^;F!2f|LB>8OoSrX*8x!~k&NGW}k^*<^CNJ+~bA>B}!2URu}}^oI>vo5vl$>z?}$
z9z1x*Pw&ZPR@T<;{@EQ*?7!uqTW@>l*=Jw6=k7a#ekb`USVX*$HAp@ghSdKaHAX{BH;-|9MX*tdlCvo
zY@vuH5HSRzDY29RbSM(DL}D(UO@>t|a+y%8mIeG4t5vC13Vm)9U?1EHXR=PzA4$Uv
z8yltM5^!^LlDRb*$5gNcrXB(yV)qMdfDyCDqju{0xe?0(c1B4pFQir%Gpmc~)ur^x
za(ZPYxx9>3DU`q=#+_%eY3v;MYgOw=D
zk^O6N*tkZ*&HGjpx9m;bx>2waUMzTKvyRyum@^qMY!uRlE!ns&TDkr_gQpVD2DBUA~oo;LFY_9Je~2+Wj0>&%&Rr(wgH^XJZ9Jac;e
z^yzbF&z?VbZXL$6XD)!9J9pvi+4Zw$*3X~2a_;Qg=gwZj?dL9@Tfe-1{_>@ZZ-W6Z
z0yVz*)|D4uJaONB4;xKdc-!e@1m3pEsIgh}F1yig(WFw|V9@AsE5boN{92thjanfD
z)2XF4v)1RehJtp0ONU);G)SywrP-*oTGU>*+3&MOLiSh$Efg?CBPc7Ain&qdCh3`-
z4#DRI*2<>sMEei`5#!6G#2C;J9!r2DtqCG|P2_AanoKeX&A^DUkd5#n?1e4ZLmB3Y
zm=&H$D1&z!4jRBBA+#`9Q1}1GcX;)Ur|&+HxqU6Qwm<-J2I$Z~lSAJjT<+PV14b|^
z#7xi-{%tt&8Cx!C4tNwY$s~0mK*O=Ip*>?myY^sk8R&3iv}brnFVNxWu3n(Sk)6nh
z!#mJO#vz8Aks3+%AvF>wBA{W%z+e{v#P{6vA3_Orw2%}0p^{Zb)6k`JNmm$9y@sL+IQEk{q6g|
zeDnQRzyI#@Uw`-MCy(B`x4WurXKRCCm~Q4Upa1#ohabFG#h4gsY8dNky=Qsu(8Kq0
z`suP=JJl0olYJecvB78V-7g&L>!{t*-Bi@uTGoZBhuhH_wstgZYp*ZrY$^p(Y_2ON
zga>q3*3n$vhGi=oz??Yg0vQYc*gWhC8X!=4K2xcT#GIum$&4wKUK=uzne}
z4?6$~o2%LzD_R?9oh{XE4YYRTMMOgah_s%L>dyAcZmg=V?8Wkw(uu(a`9!x>IOriE
zW8goBnC_GS@FDhrdF8_d5P=kt2;l$>F^h2(=#WxL{K2SS`i)zF{|asnD%4PP=;h(u
z!z;Mhv%rOJphMoQi#QM2LV`Sye=$~Z-hcDeOGjV6a{QHd
zPae8@?B#ckz5L$sgYUh1@cmPVK78%SdnaCb@6}hXo_zW8t1n$X@zS}&&p!0i6)9(D
zEp1a3A;R*qn`mX5;9XUeZmulbTvmEhY1vJsr8k$9Y$EQ%t>q;**OhJBLvOH1c4b|n
zrI37YM0smczdxqSxCBPouJ-1VveKK82+Oz8FeJULv~){FC1z(nXIc+RNR6Zj^#qDvbcO_hcd{Cb8OKpl>#~Q6ZS^jF3%l5|LJW%z5UteUV7!=v8SGXI-5zsXCj$}@D`=OgvhUmWk8Mi
zaS@CG_;9?AjPSXn0?H#Ol?V|oF|!bu68D0kPY@T%gNR=NQ4~jCphV0EA{2?ixIz(E
zAmZ|c9FZ6dppZ#+@q_@5QaW9qZ{6xI6y$$o=!P$s2cY2VtRQYjcB-#+Pg$-CB3#nDcYnL
zW@7V&2#kxf@$2b^Sd0Q(xVi+e2>gfc!?}WIX4<{9;9p%1V}9T3}BM>s^AGx&t
z#>ES#FRY)wxPArz@#Kl44?l44J$L^6nI|4Uc^sctRu@)ssr-o(M_)a4^3g}0OT>}^
zw{3C05DlkqJ@E5WCto{!@L(>LoX^iJ%r4li{zN2cbr@nv*W-`ef8qR<_4TV4FTJ~d
z;awQ-y7OL_%N>mde15yhq%s+mHjCC~)>+Lui%I447=0eC$tbW|j!F5+PSQ=ATYS
zX7jPxd?cIlz(Ykk0oROWqfK)Zt|b#dA;4lhx{+>(>V_eGG;D}POmVD*0yMN@swIppbGal0b9&z;FkBux((dYjCIwJ%~f?gTtNlfp+>}N8eyO
zQsY3!@L&g3t=!*>qBa1Cz=Fhg*bFS#(~Cq1nAq3b)YVnr*`tiR>caQ97ZxQSo$-5j=o$W8)edonP
zubh7I#op>F`NW>H2VYuCC4c@<*!YBU3KHL8Q&mSpMN4BvGms)imPy|{?4*b6
zh+;RWcUaj529uVGj#iY;=|XTsI)v>V*l-0Q5`BlHP#Wm4tF^L^bouLULpr3lRt>aP
z47HUr>9v}vE-SCs$?pOF^8f{sm@=jzqQ7v^FB>LFhky4VdPV)ni!#(W1Sq695{&%L
zZ{UKo=iyER{}B)39H~LUk`y-wHp1kGU6^!80I}fX&iMJW0l}PKkax1qoO~J1bNfny
zIaI+JtuadntwP1Jq#87i@Yeidgd1GBkeRWYob!lC7Q7w>SZE;O)X-y6G
z8o?$dmD?*SP*$cIsIg*8PiHlIyjLUKr4#Q~@prIxchWnn8fvyx(9lhYWhEq(Olpv^
zvV_nfsu-4|;!JUI$!3H?+P3ma*pBKmP4!jx-TBk6zxe#xAO7&&Z$A6xm%sSxqxXM%
z_3|&zpDFmgH~q{1Qorq{oo)5wUCk!m)cwmdQ(diF{^ft^EZtu7<9{D%sM(v0s;0&(
zfBYZY{*V8y4e0Yf{?Ep;tpT&98IW}Izn7K#xV-qL@{&!MaaaaW_>~FNGrqV9Sv`;!4kmudvppnO)=&7sPT#8J&nMT`I1y->QCh+M1o$KpL
zTHsNqv9zdK4u}F4?OiZje2}r2I;%}u~92A8zc%j9{`9%Nu{Ka0@Lz{dkhRcg+%iZ
z01)G%h)z<8Kq?lJReI7($aK*pz@dg8>1lUQ@|_bkJWIPy!+9+V3d3)3?PUwG-o=U#f@xffn|
z?x}P<>M(fjzw_Sv@4a{L+HHIR_qN-9_Utn+J@@SM;b2s)alG*2(HCDj{K_jw4<0&x
z^w_IE|M?wK>4wBNygiZ;2%nN-J~7ZQkRBkN1aM6vkYNEbW@M72OrSS7Ob8@L8czeu
z3PoZ*U>_kr06v%i3-W|QE?}-m#1RVFFiK@?iHs$d0tg}(A|t|fF_&^E!W-rbI3gim
zDCC7h?qob*GHA3Kxy6hc%U-808MaR+J=ugSg>?gFxRGa5n1e`lxq#I;+^{2XBex}^
zj%3Uk3uDJyxK9HwQrFLoSbiu>UYbv?E~fXcWPlD=uh%Ru&Lsd1m*$dS%k#;#rS!g4
zOgaQc1Ue+XLtw<{{H!17aAD3*qz%LSRsjk(#IXSi(Qycq<=EO>a6admPB>>X{zBTH
zi8^Mo{sLMsoAO1&_L)L3;MEgN8I#v#^SEqoVkG0x=JD7AekTB;&tpo)96&S4Fe>@w
zfr{exZ~zz);KmsaSbQ#n-KdNQ%@-)Y1vLFx6{Lm`(&iOMxLi^AJXCE9schN=G+gb00bg
zoBH}%&{^2q^n>rP2P4Z37-H_O?dz%UXsHai?BD(MZ{$;dckQoVfB&aHUiZ$A0>
zPw&5T@8W!41?|4YrK=~7T|D^8`pYl;ypZJ#_Kvo<_BYgNSmOsD{Q0HB&)!i;RsF}m
zK6+s3cUMk-`QEudeQ@sn12diV#jUm5dRognT1#4+w_`mD)+U!@ZE^z;8<`*rqMS_!
zIt3Bzz&cy7GalhN%reB(!=_3ie~8<=T5Cu$VpUrskRQg5(O=k9-riEy-dx&=@`~ts
zM46k`>eklE)>c%~1~lw!q;)sadRu6HZI$%)iowq6f%b~wj>_TIik%%a&OnWc+hgJN
z*aW=@f5ZR;sj8F>*Wh(&8<@ZdEJ&%_;1&XiFd<*#4P4N1NZf}&fq;5B2a_VgjR`S0
z0HKf^hVDZ@f7;6hI-K?M^KR~?vzQLMw-As{wxwLcrMPY-X`Bt|ERsEa&BaaCo9ik!
z*Hv$;ufpPw#;T&$I`{=4qqj9zv^3G08Y*gPN`MY4E4Niv6;U$OC@5G_TvoP~M%#|c
zGL=Qu6~)z+#VAir%9AUqiUFR`gGl-y|6pb1C~AX7g3bVrMcZ!f?`pesb?NIr{_fg0
zUtjyvAOG^JPrv-|gWtdN_9y2~zxVn{hg|aS|F8eYcvtI=mO3WAV)!x*yZSylf
zzxBoY?s)#5+dV3AYw4DImI}uoe^4>8yZR^p_Uv7^uOEKl;<1+=+P~6VzJ1%K|5jG?
zlhWd!0O6IC+*Ary{9`i5v9$E&;*w3p81>!)^V;fdgY^2HLruGfn)*8{8Y;I{m2IMx
z0UctNBz`Dh#L}C~2`Sc8mo(Rxx7C%>n`z9U7S2e^RBsh$u-YOTjM+JHJ4?;&V2xA>
z_Ow{#dtwer%BOJXn3E$7tkGsUvroevFo|{qjZ;8%z=Bv}g6=>updJ`tA|T_uPr3kH
z=#?z_BugIgf?K@c5zo4WvmWuBS2E|rwtFNW5wQ|1@8-j6|7+-QCJRJJ`lXWMWiq-K
z3ZBIoFQy(A+zWZnLe4Xv$5!>EIWINw&rbXD8Sldn+zlr=apI`Wf}OrBMs+xBPp4c<
zbK&LL&~(Ocw;3op1Wuwbh(t~a{QxVWzYzEdOHq&ofsdqOkz6cRNF*rlj5tW>5K|A~
z_3#pjOo9r33Mt87M2M79LVya1QUx%IbSRgz<#HZ+LF7U(nG7(CmCGkzef7k#V<)f@
z8CVV-h<}ePA3AvG@WDf`96b2^^M{{*;m8XwzVgg-FFpV4^RGPj+{@2A_w19;JpI&@
z&prz`?&qI<_POVudEvHw2kyG_{+C}q^2))ZV26*qdgSPsc0E>WQM%(JeUYY
z44zOfu&qWZ&|xNK
zFJ#<>oOe2l_rdGEl}+)eF`ckw(VyZ>#cZTvz!;C1;YJ>d*rMTo*0t<^a#>tTEi5D!
z7n4hXiOcC#OghXiFK3pPk}FuG5?fwKEX~CM4ObRYdzZ6oOBrCqy(?M3#C@yD{cBj2
zQpmfB?=ZN!9ND`X-H%y@D2}~>hAW9%SCa=Y2`xCAb!TF>LfVs0xC?3Tbjm}e$Dsgt
z#vci}{BE1qiT#m%Zh%6Q$3sPy(Y#)V*8^tvc>oagskm)n*1vZpvbG#unh)i(&QQSY
z_n2~Ne>(1U+tiOfu>ZZQr{BKx*4vlPT)7C7GndYvxp4mMxifFvd*{!V=BJ-|^1;_n
z9z1#C;K`GRPo6q<;@B&Dm*&>ymtQ||{N%ACr;eUD{_?4SBbH4>49^L;oLyhPeCg7a%a`7!>YXoKeDBS(Z~H?LjZS4Ss@xuPIP5YQ
z)GDP+qg9yAdaK2xRVmB{b;xJ48Wl!TwroI6M2*#=b=i!tU#FFuj4Fdcp;n7ET9M0b
z2>4ANm)7Ib#lp^L&=v7J6A^4J17JOy59ibVYzpYm0awv=_aWAxTsLzvYK_ORDrz;J+YVZ;;)8-pQZC}bjTLZC)c5{_tS3x@2$uq_m{{PSz_
zM<2ZT{JXC|a^HdYt;@01h2+Y7VsR!in+K9b_aPNoh7kZUo3sHSQuWKz@CR|$@A0bS
z3Z%oYzWS2E+6{onVD4rxca2Yspo0*-gFQP&QSuP84|iaonUX&o8txt#>KexFxCK_p
z*wYVC2q1{*hByH(qz|?Z03DJF73{DFXh@nbQ(i+7Sw>}SI_lRn_VzXRA{xSKTOYl(
zn*^8Xea!+&-`NaJNkHsbBJ$7K_7pGtS{L)*0cxU~aU%vC<
zxmVevy)9K+IvR@Fn~GZ+wzo7C1ERH}_F)MM95$DCQjJoGV~^w%lG5V_;vGZ^Bz;y|
zNqq^Hn4lvNCRowjT!p=rsg2i@5eaAlZo;WxJLO!&^RzagLy@E#R&=(}uoqu5#=8f*
zD(D@hyXiI3$zH+kRu!Yu!tb*RdThcTw}=j0NClA*5HZ}`=MndMrF5^X-zDt>0}%8n
zM<{BfyoPphKNxx*k@wpZ0)t2!F#DT00Hu*Y3-c|}nf78-A(D3FAVH*yUDq>!a(=stw)0D@FZ
znH+;rW@JZNQEf%pbTW4B`@dcL%eUWu`KRx`_~P47KY?eJ-@SABlXGvp_xf?COi25;
z|0``VzV+-AM<2TP$bhEnW*_Lx!UcTq&FW+;=Xlv7d|9}4I
z{*}4+PaS^m)Zt&AISDkm{igqmR*HFtgb069UV3v`(M=d=F2gz%Dn*hK*#Yt^A*-mf
z18=xwYk3(a8q!eB8)3J+0zN6c?ah@{+bb%zH`JE3H_*oV+ieO)+#x7ncRN|a!U*bj
z$E=LBhZiu83->gS^;PcZDAx#f1nt6EBHmzJ|U%;UGU*+sq5#4F0<3F
znLIopBOOwHM4ZC}%|(GDpdqdzIC@bNZpJ@fa8GCL$(ZBzTd;S)>9^j1TZ=)D!ZAvv
zRI610IYGw0#3R^dBNnx5bux67Apr4F+7Rea46MVKhyYpyGGIFtaF)vCN+do&K^ZV2
z_Sq9jL_)wvF?tq(50MJ78J`TxQB(?fLvUOlqZ#N-GWWx%N-nB$wo_sJKDh=&ijP|6ia&_@Vc0OkM;h49q~(BTK4AI<|4
z*oAuqY%q!r`8+nC$KvsU4yOb{ghBzrB8+T4pCRBgg+exb+d6~FXwsn#opCzt&ZUX!A$Cl0W|B6%qetP6j?SJm(KJqm&9NZd
zvn|ok4Wz^Qg(Mg-;?i<@c_q8Dnq6K2OiV2=#}^kuqzQOvX(6^WA75Tbt}bO(7c;so66N^;+FY+*K#&pE*WCE@du
z95~E`1I|mv9Y80*d|tP~<1}K&WRJt+wvo0dR-#Jd@_XGruM_Cd>#@0A#+gF+f&2C@
z%!L-_g88gF5;D6ST89-i0?h`A$EH4g>cw~8K6~}@`Ky=DUA=tv?TbK%XD^;#Klj%8
z`|rMYb!p+H=bt?N#)&syJMqS;Q*WF)`P!?;Up;>G$;ThQW&i5h^7PDfIvGnmaL=75
zj~{;Z*wI&yA3t^S#M93_Stw+mef*)*Z@zK*tuyD(t*>9WeDM<2J72zd`SQgp7cahZ
z;nI8e-T#Q!=d;?3YK_Ed(}u%d_$)?~!eUh$u;HFWslXfzvq2g5SweoR#jI4R1WJWa
zqY~>h60KICRC3%dO)Bm72aE=j$eLUyJ69&@oyms_xllHVj>B}q
zPJ+wmhsMi^QauDiShOZ$wrIp04jI8>5lb>+NstPaXb2sI;h;GbG=&1N*Bp+R0T4s*
zh!QpfBL;#de-NvJzycxIWrbt@d8O2kjy-$NmDip+_VgVO{B-`na(ZzlI-7$(WEfwj
ze219?a3Rp4BM<)=GVVNfPeI?|T*2$}sMyTmFTeZ}PNdQbZB9)z?)Li49-m1hVF3~D
z*hwcbm2rr^L((y2qc(*k9l``~u(!9Vr?0h__z~&dje}iHJ_pjT2_D0@h2ZOaTq$rIB%dQ
zqEo(n|6P;4?OMjJPtU*h$M-LN_3_)EUVPIenrf-o)KOoI0c9e8jZ)R<=R=KaO3sjg
z9RWm=6iB)!mtza&4fi3{{sd#hl)n(HtF?w~$Bh&k0$g@BR}z0DoQH@o*Kf!uqUuc}
zt*5b~x4EhZTl`fFbXH0@gHAm+XcM~(oRRLz{>GBY{#qlK?vxBU#B`uTrx4wTRQ1XA
zP%_4m1DJrgvFeia+eN)LVXs}Z(Si>q4pAR|i#Kw~Uw0YKdbqPL&a|C91EZT&aIxmx
z+&MQ7d+T|4U~_Q5M%fCI;GH)v>*@_C)wBqveqS9@fIvVTY4;g;c@4vtH=dZ7Q
z@!Riy{p-Je`sr66zW^EwEic}8=WEYAe)-6YAHQ|{lQXaW>fCE*UV6H}se0>8
z|5{w~lM+IQBbXYneAHnzvx|nYN{(8i05kt#Vs=
z#nw_%i;ZQ=l|>CTMI$|pHrZs>1z09u2q|+ee#XfGR$GiIWH?Atr_fq=XSS3Qc}M#vlBP
zurcT6=RIgMelge_(jgr1UqOd6(|BK;#YPbxphIlA3x5(RZ(_k)n1+XE#79!6a@|NI
zdIno-xR)1EhV$KbuNn+$r3$N!NsyNht2V2_pjXM{0y*4ulwzquAeQk($VNhmRIJs?
z3x&wid^Df(+O1X~zi2F2$j3rKmqw=)Nr9|vznq2Q}kJe3mAkO}OSPG{g|dh{p&;jw=#Nuhj)2M-;7=Gm9l_TJ`n
zdHw#tJ$K#v;`1-q^oCqw=DBBIy7OnZsuij`e}21CseSm-N1uP{DU;S@v4viK<<&!n
zP8zI8y3rWV(E21
zqF4Z2C=dumNY9vWi0gbVAx?}M3-~NB3KMZIWC$e;82JJi*_81GT)A9oG-@0UT_B)|
z#Y{f0#%_~2?2@2glMDm%S=|n;Q7iX3jmelj9k*r>1WjOxnCW_a*^y1#GAU~+Va6U6
zAx$)_gPS@jOmQS)H?S&Yem=RdkXl;GE-mGjmvbwtxs{d7>T+^rIli|0ImT}kX)i|^kXUs(*!<(;bwfql!7{n%R%orQpg`xm3Pti*5Io4R!k
z(QtJkGz(WapkcuSmwGY*ykZHX2(xZF?*&Hjd-RF8HJ9;ZQ$C;9;&y>qJuaKyYfnT2
z(U8yYb^3h{zt5J4d!k`mz-J8jbRoYUz{7_IA3K+scU_lEIb~t1K
z{tJbX5s53&5DMu7L46=(3apXlZdoPhuC`DHJ9}+9fL#Nq!I<-uM@T-7a}Hh$4
z|E+oJ&GhQ>XMcXnAKqF2>VwOF`Skr`Pu)M%T7ka9`l2pmKBPc^!Y*u`hZqOk*4jdA
zX{~5)t?0y@LOh@on<-<7Nqf@<2m&3V7Z8&R(K_2|I$Ee^%BXSE(Nqc0+0jVDzRb;)
zEm+_}>DM3{qHYd>PO1@K7s+32YcAcFWQ&wJTet?XgVx|uLv@NrSv#*Ime1O1Ri?x^3~(_GTsT(+a9ZZ+$f3F#MNy0xTXF`}Lc$h2I5$kJ|-2GH6>YiUHKo60Ic
zJ(Q#=!zRc;cqCq2u@N!`D=EViLy8eAs!A%WN~vSWmZH+q;eWl9GS@
z7oS>2udkjO>Nzl-fQf8!mscaB-Sj_V7X3s|NA*qr_V}$UAHQ+zS7%QBdi{;xU0v63
z7&rg-|GlW_rs86(L@6o;ySW&H%dmQL873ocEiKuCl`*6vGc^)kB#y%h7`Ijc7L#1V
ziprug+V)D?_L|D#>Z+pJs-pJ#GPwBpqpc3v?x1cmX=NvE%(R0Y(2Z%iJ$k`_g4M?!
zZQ0XTJJwe>+FLc;Q#I5BV8X}gspk(w9nS4B{lp~XYq2o{@5$N>>;JjnUUL|>lCot>qAL#Jt;X@DIe{U)g
z&1I8`NYrBu-2L?ob2>D^fW>4~ne?hy$dO6HFB%>R+|%eiu>t>K;4frI
zhV<#EF_W~U0T7cGEF*|u1KeoH0FzYwpLH$!pIjCeGK-6dh5(4mE7{ex?8++8Ay%a<
zkb-4EL#mC+%2FEJs9;z*wYD5zBh|`#SEEY{{+Vgl@_YcBqYy2d1EllvzD3MCylrpt
zmbLi4)yVQ
z{p#h@?_4>5_3}EAy1sPz(uGSG&SP--?Ag<=y_pV27qhA3FF*D2^Uo$?@dxj{|Fsiu
zJo4Z(KBwotJNDgs&(Gjd>aII(J$d5jJ$K&=SL&_%_phz3sny!m<-KpdcKXa)=g*(L
zc!5NgfeukF@j4wIJapXQ_Q{nBHTDov*{mj;%|IG4!;^#2YSn4g5|>RM4Z55*ol3!1
z%6N#6GO-FZN7XW!La)=tV?j#L5iIDlyIm#^7H*qEA$urfgG(-(4i<9JnS3Ol31pML
zOwyG}I5Mbr2y{rqu}Q0C;-ED|!Qi5TIWnRFEQ(r&MyyZ?o1;NCZ2o`_p?@
z{`A4yzkT=O@84Pf`ok;V{rZEiKD-<-$U16@T5F3siMI(6t);T3xw5;7*3$xWj8Rga
z!nWq}&Q=tx!7YG>K#HvuUAU#PyA1#lC!KB89c?w89kre9HJxp!M?-lH0SDV!0Qkz=
zTWEkR9j&+>-G@Xj2k4M!+@NC;elAcW)<-v%bhnhzTg$=v+sj9~t1!6C=rW7@J&Ivc
zgMtW%wJAu4xQcTUNA}Byy>jfQ3=jz;Y{a>kP6d}8;(imabK_gQVN2eLzC*AX7pLH0
z6&whNvo0=>;+z|~Fz;l5&A3?w=TyPToN==8Fgs`3$w}FmVg1;%kNgbI^T3^ZH9UIC
zBgy%sU~vauCm7t>TiIE+xwpBrqkj9I{u+yHXV}6_xp^56KjRVvjU3MIj<))ern>Ux
zhKkxMRJXofYl5ypT181YjW`QQgA=e4f{d_*8sQjfJ6Xj#Ut}-f!ZP&Cm6sJ&0UgT4
zS1w<~j|z17_1E8h@x@<0{q);UKKb_JkG}r!{olWR@yd}`d6zx}Ix&**H>
zeaGB%)ux*?%&~hH@?E9dcDFQ)wl-J%_}_m%Kci-h7yqCCvJi0o>g=iC02*FA^Tnkz
z69Zj8{+Eo%FX)aNv~AS>KpAYAMU0NcUO*dSMKVo5sh~#n7umwfJZ$Rx3KeW!HiFs
zck^H@cm)L?+W#*a!YaB9NdXF_Xp_9IXaj~vx&^bI{|Yti*{rRQv1K#%T-J$zc%2bv
z@}AiodJ_v72N-Z6i7X=~E)={lFJzp_7_gm!I*-+6Or|0_xUIl#1lxQ7uK}X*jYf4U
z;m_rQKwNSq28cDxEx`mv#7%S`0wltM?o0G0@=2)&7WQKCGHelvLc!3H!^e&s0Xjs-A+=C|c;pBe
zaNbc=G(2?V;K3sYUpf5BD+gbJ|Ksq=%P${#`Q?Kzzx>MK!$_I0%S_5
zh^>&Y9S(IM1QejeZ$r!z@tGna6TT3=RtXT0h*&cTOFoUQatk>>+ytjn?tIdoh8uQ3
z6Ah@NVeCi|ix?7dYbxPPC0y5QQ*_kt{YEU<9B(1DyqE^~TU$x*T}`j8rq))nu(~jZ
zT)0uQ@&g?LI4&iyC*DdFlMYv+b2DDJfS2aOL>W7|Zza2bC9{7ybzmiR%Ubfl-V_`L
z9J#z0!Xu|KwJeu*0Q;t}K-(~rcLTlvbHu|ouiM~rn*j&C2#8LP%jI=@sA^@G(~{4|
z5>c<;W5o2kh;1(K+rNZeSZ>{)g!eN)ajyF!PCs%)qQI#%cqXMa_q
iB=g>=s*3Vp6KYQWA`X%Buyh4pYhgUAY
zd;8DsmMBn4Uai*X4SJ``?)KQMHoe)RvDpnSH?pr@qjK6U;jq_Y(RjUPx7&=4L)76!
zK_z%}kx7MmjofK9nRFVhN@lm{13p_g>^fQ<|2KU;qE^n*Wr<WytAF&7d*MW{yz(N0xoe8Ca~xF;!@w80;7tXdfA9
z8^*{o@LvnSBE5gZk4W5#|5&Pm$%p`mz5VD%r1v!ScGdTFHFkG4J@NP>)F;Q=^7ns1
z58|Kx@ZA@``Tp}?gZ=fFzxei(kH7xKhhKj99@saZeDw7vAAJ4sdw>1p!@vFVBOu6c
zK7Ri%pM3cJXCHn2>APC)7@%PfMs>?Nv8Dl)XgaU^0=wI4$)pln;k8tBw^mUgh*9R2
zidLY*w(9QInyywXK%qQ{-Obf~%{5)kBoh%|MQd*;1?~jwYXka()fOz9Xa&|JBuZoy
z%V1Y?OL=QEwr}oe#D>dVO=UezrG2dxeQlKhsXfgl10Ch8ktTz1(5c+vl5ZptQh-Pq
z~o3fb}^mApfR!xX5n|6xE)qOkNv+Ovh1A7IRF7!(+<|Givxz;^IW_c
zCuhdR1Uf7@8DP_{$-HxN+BKDTfH89p07?|lPTQFG-Clt6oH+c9TeCZ2Vx*j+#fS#*
zCF>G|3=F4gOv4)(Y$@8)Tj|v@rUQ!QxN0@2T8_yJ0g*#9+1p-$Ek;nx1#6bkbA~Lq
zwW4xkj!|RmgR=bxCn60d728OP9?4B48}R_*GQ@Cg3Gh})S!r>3S#e`^^&Pj|0`KrU
zxDLPj>$N|A`M1wL`}Wgc{`upN|NO!Gf4F+(i%S=dKK#HP)0x|{2^jaq!w2uX>-ZxN
z%z2$&nP@5KJM_RkM;>}0tW|USdd(c>%Xi=L@yQdPzVX`UXHWm(@`ZCRKi^Qcef!P-
zt+e>Zq+0nWB_%hPVshbTfWNxhk`{QD=&WsOC@m@e@%C*u0SK0tZ>y--LJa+gRTU+q
zaJ#6yd@GDKHKp}+WsSAPt#w88){2qNn%#YkgKZVP_1mTf>lMr%qiDz`-JxZ63wG4%
zxjioRE{AfDXuM;rzh)P`cC@z+Y)5yMUNq|0v)qc^HpxgpKap|p=df4GMgcO6#DEJC
z4RbF3j1N1b02)%52y_S|&>>|&ieS?oVF8YGBPNo|=f*C8hBGKyYfGoBxr{BJMMWDl
z;wilDEc|;|86(a)*Br*6-Px4eS)ZHP6sR&1Av-BA=9X38jV;c
zM^>Xkz_6WgAuysu1b9R|e#E4}d3+I{FXReD0@y`dhRA>DVG|1lLJ_WlNu*qfgd@Ua
zL!eA7Y$1ihaQlK0otL=a%}k2TMNryCsSv0Xuqwz;XHeA|8=h<|8<2=P*vA17sgaN(
z(Zs&KP#ZT45cBYfqlZr%A;l=ij-PtsiDz{>)2=;x#wI2vrluyR7?TVJ0Yo+nqs$x*
zm&f7o(Tm6f!!R)^IuVi-Ljj>iE)Nh;fT3Y33{6c$;tj7MZWID3V!9!0;R#qg*e+rL
z9dh|hE|0~71qhVKA$$qE$mVhx91epo0N@tOv1Ok~sT2YY7>yc8{a_R;W80B1oB&1LVw}f
zT4r?>CJ2i_gxAq9wY-GQm-nvb_F}qWYA?~jCYD@Yh%U`XU?e5X$pZup_b(^*FUNrn
zZ&^$1UybZt4HMrX3g0Zw1@ajuAWJG?Nnom_DIPWDvz|=Cor=3+VFz}}b31%4huigo
zmW>tQDd4rmLhhi?5yXi-6L(FgU8@VB)ur%k!9$4C=(I^~7O~YNOh(M--hAopi?3b1
zbo%P$b8la{aODcn;kio}&R#r!=KR^SCyu|mw7BeXIUE+*p_B
zgwwtaXo$Mm7cQS)zjAK#TPLZL`3gl9RmN=|wU$qibC
zPA$`G6A4v=kV2TgKFdc+3=y7*N!jG{M6VbJ#-g4h&Hb>rMjLH-*R_lJXQkx(1_|
z^J)zG01%B}K#;(T#I0xrUW`WmY2M)z58V0ey|EXY9w*LMbPdv0gw{JE&mkTaV
z2WK)E2O*9_dpvGUB;e9_Kl&P7tNLNJlu)Q2L7O})MK*ix^jrl+@|udiizs5hO8efi}d
z$;ba5?7P2y`#mt?pZ|F6PrtkNhu>ZM{co@R_BY@E=2zFg_|>)F{rdag{_4Bm{PNo8
zzqngt4id-by2_EGifyHCkS$S=bAN=MteW&?m<@
zazH-p718}f(Z(km^vj3+@*yzTi#?ZR8#T*b#V}4_{IBSwx8Xa?+Zoe##*B-aP(DKD
zv}3B^oSJbl3NB{e#fF2aIu)!?@o)=HPR`C+OQX;H7azW36!n|L117*+>5xq_FnO~oI3&(S(e|6@~Pu@87!O5c^o;voysUsh}
zcJz}sPkws(wNKxC?UUC}{^rbEUz|JryY+LwyLkSKOXqxA#ZUg*zZ7lx_cDOO@|#Oa
zZz?O>R9bp7N@SPav~x#?Q77=ZR34j5$lX;_vAuNrO_gO^tI9XmR&A@TECQ>mDypv7
zMyj@fbdiZ`tBc`5MaCKqnfcRx)of6c^Q(MDHg{(eZ)Y*l4M9I)*5W61Y;W0yk4kx$$6DU`dLo_6H(4gkdI>;6J2
z#Sjb_k%Gkn@h{HgTtE_;n8WMTKJmmuaGqmF4tngic*qy<*=$yQJnoCdJ+Zhuk?^E5
zKC4|X6!FCpKGyI8(ut7f;JzdfiZR$Mm0_iZP|OD^#3EY(SIC2r58#BD2zz(};6@30
z+u$rbv4kU(@WnFpAQGV%ph5|rMkteuWO9H}2~4ow1$A<;WLPEUiU)v5Cdh^VXh4A!K2j)2g3%{7cEL!v@aWM~hYy{+<-i?ciGs!E0}DYH;+>5KcDdKcQFC&-Bf>UWVVv|8)GRk#2
zsl}v>hU^$aBLyf_ybmpI&L*uWVw|=o6V@cgnjP_|JsJcO(gggfKu{G9YT%|$T|YNs
zS)2zD%n(bht)}+vO|PvcR!C%dc@gN4vee2#djCr9mX#d9-z}?|11qV0U~oK=Vsd3M
zM&u9UYs-mMqK3F{HNJN>zHcplU|)Ry-WUMl>SAzV*0V64!D2h5RPBUE{DQZ3daou6^y;bMIX_^UkI7S1(_>atWK|VQ~54`o#<9&!0PU
z{K&ym#}2)I;+5Bqy?Elt^CynJc;?Ml&%Al^t=EnoJM`SEM_+vN)X}qVzIGP9jIY1(
z+N;k$|K!UrJ^9vKN7m23wtoJtOY0YjNAfBaS-yDT%KG}{^$S<-zV9Kk&EyR@O%|P6
zt5A^+j`%DkfyV}!N+p*Q#dx(sV$dk`YPn9WP%0#_MWvK#b-;!axk9W_%ME%pka588
z@cS%or_STjxt$u)E5!tWm`eDjvtgjae8xv`3vk(-O_(!jVe5a~bb+
z7Iyh(GXB|o$Z1pk`q#gLbA?0BV9=IGcyqas+hdw!>>L@TkM0^8-H9bBK!;#d2{Yv~
zL`Ed;L$Za$lrfY{x}+c-cJvRR0%HGA+t6?q(B$Ay*9g)fkRpQMAfZF5NChUt!x()g
zT)2^vNIZx*@9%G;_qX-Xo4R|Od%9bDyIQ+i8#&CeS6+Ia`W9gM{`>E!WW?{k{u1ok
zpZ|neiGTY2_kfIGfBfyWKYsC-FFt+o(ff2_Mt@s%XFZmcbhcG?w3D%=ysH)Kg|R0x
z(jlTAVZ`cAphn_21nX%B79`4r?Nx2Ft)Z?_jR2PzKJIL*>LflzJOgry!w7%|&!Jf(;
zJr$yfCbO^`%Syy_7^$c+nESdD(L>ydfP=7$Owh&nj}sVeqCUI$hIi51}L0$
zvk(NGjA_Tjw0$aXV~|)gYuYh6?PTN}Q+X$|;AYQySTkN=O2!Cai<{Z5i5BE9kn+Pw3dwaRQ5J+Z>znzyK&p@{u&vFZdHxzCA-*TUGS@{soGkB
zF2L;-6-8AQfOkZs@P}@46vX>2N88}O1G7jZKDAlmToUC
z-C9>y)m&fG-_~*d&C~EEzyJPw0L1UV`qTGcd~xkJpMUr1r{8@1(U%{*_vL%<{PCT)
z!G3%BBG~V*UjF^tm%q4l;dfUq{Qm8Wf4F+-4=}lS{!dpgef7?jKfn9-m+xHu!+Vzv
zV$Mzf?fu>4QeO_%SW^O4UtI*qSYK0AO}n|TwcI4$opOj5BAUHf>%M9GTtw?pPm1=m
z+vQ^!w>;yPB^~0NS2i0^EJt+nL7iL4-qT$_+*&!*LK|(T$tJpOlARXekYBwgX<-z+
z!dVhTp7ToP+>&{>bj}5%7#)F5Ue>_|K%|He;BOxf03c
zb7Pn3v>llb7%^o-OWLMWHdv)_5cX!%70zx
z`9dxqW29^jkI4mu62KO$;Dwg~3u2Wrm_#lV$w)FHNjVguIv`cpLH!^y5=|Mn|4F6j
z*90z9$W}MYA0f#yL{A}L9}iHEi*aN;fGH5d_9-5Jf+rZ~0U%=i^2Qmc
z7XlqpEJzi>xLta`&mdQDWHL6~=^_DZGUCi8T{9U^0e+!LdoF29Mon?d`ZADCxYkt6
zk%~D}QCBkRj7M$Jh$$4*1^i(DtS`m?lS|8q#ibZ2NeL~^
z1(z4X%kzBD^!=1_`X%3K&(w6ol&AIOOd_HaXf(X9j;Km!{mWg6u4Pi
z2+mKth=h}OHtU(21{iSX(%xL!mx=>AqvH@55xyuAICf-`{!q~Fav3}x3;GUSRvsJG+u|s?@-UCJ(tfMf9K-atJu}#
z3hAH>m`K$ZV}ra)=g(a@haFMY&z)UA`{w$Y)8|j0TR#hHXV0B|6AYfiaTgXlpT4wy
z`T~ZNu@vPZycWw`E?$EFT>$31a^d{t3+q=Ne&{ioT&dP5feR&a(d^<(A{BAD%|@fr
zXj0m&IC`Hj#B5YM92&P<=k=NF4ue)N^9AhTh|lYD`UCDr)aUY;
zJuXAQhY~ZW93HjDqmFdao6iQPbHQ91b+9uDTPkYK#;qu~p1>T2M9c_u2$-0N8e3P~;Y%Y;mVp8Z8e+WIPF#}KaL5XP7!TQ^0aMIxhz0Z!zcw0#uUba}%_RFU
zWQ_e&fA)`_c<6zr9=!Ld`))t>#I0X`c=T86&)vU2vwtzYJeQcu2WE1f=`_%xGnI0r
zlCE6JlS{x8uxB>s1$LatduOJDsg&obr!ZXm)vA(yrp}V`Wr>CW>v!$o2c?dRkHH{9_
zy-w@nk39InJ6Hes``=OD3*4{&_SbK|{_^*~`ta(J7oJE3?0PZNZ&hkU6N5cb#-?eaT5aGwO04E*HSJ+*htMg!P;s%I%?b6YFgW?
zVeD+H?P;s+Y60>q$CO0C#}*=XP2_B_;c`4RWS?2Nb3BF{ro4=E6YEr5(L
z;;Iz4AVHGm%T5WJUDUhrCEc(kW5dWYjA`p6nT%&0Fqwo2j0NWupdsZxob#~ez3f>x
zbI!wF@Nr-jHqN*>DKq2Pi;u#o9=&%Tdsp)g_!7FRx*JP+no7GGig~-cB34l$sLuIS
zUITk#xUs(C$Mw~l>#DcZRs$MtuB_TxiRHRQM8yVB550zj`~V8Klviw_k`YVFHp52J
zNf|J4gBQv1MOe8ElXBuLtoT73y9gbMWyR&?B_%~$%1etXOG_L^({Dfj0^aKP-~a8q
zZ@>NS4}bg)81eJZuYLOIUqAlEUq1Ty+mAl{=A#e3{TN5!#jiei@2mIU1^e=YcfR`Q
z-9LYH^_vf_eEZS6fBV%huDo$#l-_yMfBb7n(WdR&e_UF+rFi=$l5R+G;pXzPt>y3$
zO1IG96P0Z)uh?E%j=h*`tBYD1F=L^*p|q*KxVf&VxpsSdeMv`sNgJ8B)MHG!sd5v&
zxlG6388Qi@Hc8Yb^=LWVT^&Om<)ht|dwQ$KdTS>88zlJFA8}
zDzt)8pMe7#l}x%>IPBN#N!!^4pKv}boAHaM-NJ%PH1ClvdS&x&N!}sIJGcc82Acno
z4&fz$fWU|;^AzACLL~YTVXq+X7Q#p_pBuaUoeQrw+l4K_3i*^XpL9&8(UnL^e&n(a
zF!U_uoJ35{lg&7j3A@Q8`Qr?N
z=#djg4j+g4;lr4T_;+MHcH-FaQ$U2zJbQ3??KZ8!I?iBEvbYR3Z<4{7n3|ZF8lPlL
zO)`)N8B7*~&4m9lSm;b-vcVW^4x7*+z#$MJ`b7yVl0?Ccu=4+%4q@c+7+`!plgnlD
z`D~#8QIgMNQO1LD0~Uc4nS3EjBIfe>a6Ah&5&0YupKms)qA{D*swRr#Vic}3sT@{y
z$Y)GM%;}gpo3P{)_+XGvV?db%j%~594X6k#8nh-Ns9uC>&*E+eL(n@S$DKa+~SeOGk3@y!vmlvWWtq^c<0}WS~uqO&YA)w*v
za(Hz)O18iOseLQSeM`w(Rx`J(W#D)Mk@4ll;KGatdqvI%=5ijCx=T57*#FIiVk<#Q
zI^qoZ4Db!46JEauSkUZ)(QWaf_Mz490rCU0c|F)GCFC_{Q=Wxc%w>dUs#ru9@F@ab
zl^-zCDf2m{>4HO6T7p`8qOzg^4Qa^I#!a7!wT)cD{4Jhv-
zV&D3O3+LA_oWF4C!bO;0xvaYLZusnQOgin!XT4dB(7LCwy2Fu8!I$aGB%PTA1{pGO8zvx<
z;4;-B1-qo6;}9mKLIv9>>mxy3ENqH}NGKUyhFF^tM&<@~#7gj>&k*vPU~eQ~iG^$!
zcP1{zNXU>%{?n?ICmz24$p`L!^8TMbf8W}rSML1gmnToZ`18l^m|L0&&J}`lIp0jq
ziylPyBq>iO4v$T4nB-I5nXC_WZDs2B!gY3S~2>FaLp
z>1yciX+rC6q<1&dI~v*>D;jG`JDY1->nkRA4R9w$=CwPJ`F*bxg;5H7KV
zxxIykuEe&QwstI1?rf{-XsZNkYeum{s<$#2kRlnYvClF_mQhl>tpSA(+ndp_(gjPQ
z$!S|EdfI7yZRNeKWxcKCeXV7K9pyXwDmi-^%_2H*9#Ei5-0zlRt%*yDXh?;Of&X9*
zBdntP5Dt?d5xTEKq(?qz74|yCy>96Z&pQMnr05VVYiDF^6F`Sq`vjmNjCsdo-ab(P
zKy)z*Zsv@ajiZNMa4`#R)~tsy>t?4cQ@74|fB)Oxte-i>+S%OGT-?)K(u0*K+ji4y
zGk#Szpqz{8=HmLSU**(t`r9fSD!0~EZ)<2MZEU91HE>&pNQTkDEPduq+{39p{x(J}3^J@TpEogK7YU6m944ZC~l
zdTNUs%5JW&*wk3Pt)srUx1prBwy3*iTW9UI{+6<#j*5}a%F*_!9mGc3Dt2{MkN4G&
zc2tkFRZR}JIMj@QiD#EjXgGs5$!J&)tk0hHiROaRIlpAqBbr0WYw4UzJPYQL6x2Qh(T*w4Qgvk^DA{$p(Yz`O5jW6N=
z^OEdCj4>lEf?r?aZ5UCN=1yx
zh%tfPY;9?{ohLn+gf|s)B_a-Bqp;sZnwXgq*yzk2kJw)2!MEC
zh18?0WN%po%k2l^1fX1vEzbKFX57p3o~1d@OwKx!wNI0O0=YC`jUyGcW?}%%u2j_S
za~b?@i_dBGxomE`#pAI0+;$&gqS5Cu`n`q#pmx-r0kX_EvKd=ErVoeJk)S%@mIplw
zphK@i;tuHsOLlg@ufF
zCg(2XJ=6JMBw~N`(fi?aPd@p`)YJ|JsZAl}DZ^m9_6&{g8lWP}XrsOTBVB-l1H-_G
zy#qV?26xi?hdT!W83((rSEAsEbT~wMr3|$X4s{F;b@ulICUy?>cMQ)uG;R-n$Fg$o{k!NcYRl9T}MZ4XJ=h|dkq+I0Rk6R
zcXR+C0t?o4w*wkh_q5lLI5P1gwqbcnHv(cM(jgWy(>jQo5O}ept-7rZ&=AuWsTef&
zTqdz;tU&=5Y^v;Rz1~TMC}U%VGCB)MgFY-nDerEsL`9nxT3>qwy`!S9rL4aVt3>zo
z*Gvx9N+;SaqCN*HJ*H5Ppy37=A~OC1AX1D7bm$QEJK$hKkg&xABVeVB?z-`Gh+ae6
zRG#SC5I~$H5#*_y6L@hPW6H#LNIZqi>;6LKES58)>dlOcld-aW%ALRY^(SyPvx?o@
zQqYAd;nj-YHm2Jf+EkYhp*QOE*3TecxNZVTa_ZakcfI`Yy2wX_w&aey9
z5PvW@3GTwm6%<4)+Pcp|Xe)H#RfBW{@U%$Qf=dZs15idl+
z8sajZVbk>x_hF`c&OGZ;ZmCoP$j6<9Enw8KL`{BcJI
zKpIO`;I2u0ikOm!k>#vwI_I0t`O#sJatHjD-;+p%-|rGpLS}F>9Md8-8OzhC}0lZofyN2
z)b(>CmZhcXrN!LJQg+|k^uDz`03y)g$|};~+-zii7P)YF9`g>@ma^C@Wtqw~yiSLd
zt;EolVtW_kx2|LkETwN*%G^T2(EC;sPAO1hCT5<^`fl4dyME^6)ywCvTsV8>!aBg>)k_yi
z&>6E5DdwX<@E>pxHLgh{8gYp@2Jt>Nb`{%vs0>W~Y6*G$~caE-4fsS~r?3
z$4Fyk7-OV1g+O5}(*mAk(G&6&^6KKJM{Rcp&|y^%mLylf3%lEDdjT0+
zF@q2`Vx3A`6=oBXKEGXUmF;bnZImk!yPm+VYM4;zhUi&r!YDIomx8-Gnz5xadJ2hF
z4zOlN6RoEiWpsMs$F+OSBuzrB2Se=TpUojckf8*g?2WQ-Lj@(mWG
zjObnW*@V3$eB4j!l>3}uA}m`raXY~*{B9$s!@zE%uAUpW02Bfp!g$@L@-8L?g?ZvK
z1RTuUCx8eE9Rdz+Y{6rku#uOsuzd2-JNM?`Y^Ps4Y7p;`vHHg7HSJY5ch?v7w^Y)b
z%R8z!x6*E+Hx#i)S}fAtCh1O%U_i*|nA+96qrbMT2@89hn=0!X%4_OS6Z?mH6sjQ}
z8ekvkhC=m3fn6lfysZLb%G+qP?G?1*s>%{PjC3C~9LUcBWe)n!HXHMFu)
z^avIe-%O!lX))^8YH_ascLMZa`^Ot(L-pYzJ224=w{U5V*d6UMo)HewM>^wo7$Z>865XAd@6#bZtd
zQ_CA=?`RuouNY~s8o~U+@`2`(J^i&Z_JEktJJeYLreF>F4LrAorQ-}~7`=AMNX!fm
z0B~}_LQpp66N438f*H3EY}O;n*?B1oGizt(ofuFCGz3OW+u2|V3nONlOj(&JLWemA
zCv9UPH9EPli@JVp=mNl(OIpFQNh_csw!}!;QVCR`fIpIjv=g{6m$Bu55i$B~pH2fQ
zx~B79K*O1wzmWE(Votx?eD_`GK794$aVfeF6>^zeDixDtc9BHJ7t4sAAAvCewgVB0
zMRFk@8!8J?3>y2y@x&sIfDcBBFOd4K8;~371){$VW_&SlArnZ7lcF
zz?53V@PFVwTz~_CP`Lsz7yXRz21KYcO^y`uF{u&GDa67N4u{QQGnmXNSSBYYCZ_g`
zPvW0`)U6mF-7~Rs&*bhg=B_=AU3;c>@0r>)KDlRnig*nf#GA+*2ZEep02(rZ23ag7
zlg(mrm@F=WA%{zh&E~K;92RjF@&OHr`w)IIQXq`@7T~P_8^WB+WaCSjWG`|d7{N!(
zI24NDU?z{lCRNN}9I=oi5ilh}4xhv1bEjldmO{z3niXz`)@fJkbt0`6el-F(%x%}D
zqS!+ZbF0$6eA=5&ICBX{DrSpEtVBZu?!g$&gZnoIniH0I47=xrgVvzmOc{0k+=zve
zvq72b)eYa_>T+sjIk~i$T$qb5EhHD`6N~f7rTNs_a(Zn!iBL$w%4^H0ceoG6rRYAe
zh3Ni;_<_abfrZp9i>U)kiT%s5{TNeD?p*~WdhE>ke*@OVsar^(|m
zdz}`K)8e$791f$~WpF#SUbhaA(d$&kg4$$63uC~ev0D^{>G(5GJ$mZc(JL1&TtN{;
zOdtG#4liFqXW`{bumz|PR$&TT@Tg1YFRY(C4_tWm%!MbOcsiXD
z&QRE_(+gz^wo)b1>6K=a*5v>=vxftYP{0uhx}qUBjIppQlk&|KBGV{k;KbsdH~^wE
z9d{<8_GHXXyw1Rg7Sysq9c)uLYzU*L5Zg1xu#GaVq7*st6h?fySip>(^spEOGaN`^
zGF*73V89Rx0x!aE1gq)8K?ADW1hMdW;{y86mLI+J{PT}L_Q*pI-S^P_cRqga?FS#;
z|LOVX|MuCN>xb{YbtyDI9V}$MGgzVQg$Jfg+LKIq<4JcS>4twEg^aI|_03KD=L!M%
z!}qhFuE7~ETsX&IqqGe$BK(yge=A0JkBtB$j_w*99-$A9ARzYd>ZR}O82}t4hW^4~
zEJ+ze9PAhzMnOc9cZjP%iqtAh28P=E2M`2@hB^iYI~;U(Q20FISCfRE@tL<2?yD5SPf`G_PXu?h`I5h#$7
z$VL{#`sJ1?3>ml5I$BZGnnFPIBNE>sNj*fp>vrNe>~6+>$~|qBy(qF+(brx{Z!6!~
zQ>B-V`b})3c!;~BM$K$@N(X$(5kSD}UPFXMk7C$Ovgu_1%XOC_jyWeQZAHNv;J+WdhE!yE8Ya{h*oDG}xSDlsI2{wFNvCA+
z^I!iGPPmw|`SlFHfo+oPR&WNx4tdh24%$S*@h&xcFyod_`{nad<$O#v7g6K_g1DP)
zQSTb)qE*v2RaOGVZ3nh1Dcg*Ww=(n*0vaOim2RVz7gbi25CaAa>MW~0e2RcZo<~dXq!t*x51fV7rf8f>XL>UT2p;hQ(bve
zO>tvQQA2HUQ(bXm_12c^E#iqjzn-0Q%U2@$y)oT#NR_qoBL=2Jx>GvQAs+8^s~Hh9
zKWyf^luXHZUw>0cSM?U@SZ_$jo%8FK!luQjC1IBvguAB(8uxV9j&@ZKwwI3$)a%5%
zjIyzbp~j((@}W-Jj;@Ny{yOCpJb~;8sK?V5*1TUd;}u|GvW=ZEO=Yd@dADRExa<^x
zP1|@mD>rFoW=H`F7?2``iAgInX<;NSaFMVw=ssiv9cCO{>iW5%OFn7OCP*8Dqy^D1
zX#+aUpgG{LJP<=RX@gtl1}tWrGw>8m3|p>cyjcuE`rzKd>1g
zpfc>Z93GRyV{=g352#VV<$;N~d@*T1f;oB|REa?eKvENpl_(N1@FyQmfbK~2RtkUs
zh3KZ_z$he*j44+l5tIP~NCQyg0hO^)f`-LpF{XeL8SL>XFwQtk7@V<5_MQnAWz>9Z
zk~INPI0bZwfJibCSyRkOsY1l&PB5911QP-HcuWQtV3Aq~|54sS1Vp4#{GqTLC=e+X
zR@m?#9)|_sh+m8l5SNc-I#Z-b1s#nPO>)^&XdEV&!%#^1v7jRrcLJU8g_C^2B$v*q!+OG}yMWo)dxvYK68%Pp^Du#+BZntu7{3=3@JolKYq9
zi_<x{wiF4wDniX>>XbSkdCtWD?GRSDB3I_pim`QN710b=m|@tH5oS
z&P|6-op|N=(Sy%C^~8zeM=q|PzjWck1w_Dgu#4Cu4=EAQ@$8v%M-Cr;;)y5r9oQd@
zMbv7!!Ju^5f!?%6z07D-8BI#PUakkEGis1uy;hx0YBb7iHnrX;SEz&2z|HO5|{8e14|!Kp__-4fI@K=-!S28afjZ2V73cs52D@WV9w?RErctG@^@yG_kNg7B-^eFpOe{
zU@#~3$k_XY>bV?7G_*y+wqVHY$L1(Hpu=E56AEg84x?dHC}0Zt5hXV+p#N<7(TmT&
z@WQjtJ^t9kkKBLPQxDwr3;^PzxBmXU!(Y8~@U^FZx;7J;osH!3foukz415`Q>LqlT
zOnOoYR|cP=yffLrOg=a}9ZDtLr%oM%lm7IMTc#MJ6X-!iKm;^|C&@kIBb30+$PW7O
zD1B%LePFb=Z=?&*aA*gSycxz;%Y+EgcZd_>JH+5J$w7oI^nv#N!8V{ns?RcTA!Wp~
zNQzO=aDpW%#A`^&ANInezZJ%w-bR$j?rG}BIu&#!qRWslVpmsvcTYnPSa(BjSA7rA
zUN;~h#)Sa^2LKJb00gnJq^F~faIgya
zuLp})FxE_oAR+>iEmVKJp7ttii;NNHDlp7VY^?+|>}aDLill)uHdeur=wri?MAxRN
zoQT)ZdRi-b8fkqkRlThh#A{e1VstAxy^Ns>$ymJu&`>=JI7oR7U9tf%bS08v6c{NM
z^eTpZvJL*D46B%lT((ot>k{@+BN*(WuAUpW0NbTWVM-Rv&Vb3ZlSy2IQ`c=WXB*F2
z$8vy)&Z+B|I8|^n^DZVr}!te#c4-PWX!tu9}4dLoHhenzswayUnUeyPl;I
zjtsV!jdWGS-HNPNF%wem%bNG+O{+;oKFE!_*zB?P8rsdMWmB=Wq-;}3+0EsZTg%Ef
zQ>lk#rCTZx1WDxz28*{<(Y97s71h<2*4LKSRs)BXHPx23)|a(4&|2$h%?M{@ja6l}
zRVCHcrNEKs}z)>c#2T2tK9QZdrkG}PPB)l6%tEo!XT!Wr%Gs+luh#Y$Ma
zH)dFg8s~yKyL^J)T-;iHb7R#_^%XZYR{XfB;wP=Ntz9)my>-Pswc8j24IU+cy8`I2
z;Mb*HN*Qx-u(iCuxon`dVn=tilDore?J8$96IYq#TGj;(mV&2II7EAyOTA7sl5Ev0BHh64c
z#7z^xh`8!NWTdX28@f;p3^EC9ftrXJfe}e$8H3AIc!-49oY+ku1Aigyg_M0dY0Jm0
zq_o*t$hb+D0WbDfole0CzxwJc64w<G8QD0ZV|!AwA=8#JDmh6cXbLu!;o>oWV#;86AF@yoixyAvu6ABm#&SP9{~%
z0DhRANF=6-KT(KrX@FD_>IhO&G6Dhaf?dIa}8Mx7QAYTNfrhJ01^0)i^?|0emoY7%VGj7
za$sb$aFw_Vxje3b%Mk%I;*ZCQ7I+UVhtrx(2GTKK(Blvb`D_kKKvP^%PL45COtn?V&iV=igQqvnV;g&rMC
zJYtK79f>I1!r|8LN+sMdqQk~-4*9^0z=fyrrZ
zVs3dUvq%7Ot`MFtgcj!_Ys&z68L)k87+*$GB*A4AuUU?+Er!>YBKwvB3V|2n`3AdWS>n
zap^oRjn|`cJ7voYVfZ%{4H%+6ODte@nPqN^+-a73>>9US<+3ZiPL0c^1msFY0Ful=
zU4ZOXE+U#XP`3ryl-|U7>QcG`Q{rquhFcY
zV(vmf#011qpu=5zhN#vlBct@;kv^hyh)_s$ZHN)28;mUD1bu`9!yTxA2!IH5h=Pcn
zef@3p0Yt!ofwmzcd4ty9J_smD)h{CyQUT@0fq`ave-oV!h6#xDzQ*gY*aQ?vKyZT&
zDeK1gGP)Iex*Pkt8o;RFGQF#T-c{e<-9YcI@9V1T?ym1>M_%kj|01R#cD2`bb=7rt
z)pT{&ws%&wbyjwD0vgr;|6wso8zwCFz`O;;ZV(W!>(mfuAyrC(m`FM@6KkfmQ~gv(
z2@BD(K_jGyjzhwWum#bux4o*T4RsCsnkwjRl>_axp-$RxXZdJ%=_I{W$7*$ndIK_a
z{`qBteoFhA62YcCg0f*OKp~lhF!zX2CEE)lHGy5iK8g{+C^UqTx_WNhf?Q~4>P6w$k3&pIg$ZBEY4e(mrxaLyN>yjMEe-CMt<
zw_zK9tSe{{MC~FCe@9#O=Jx8X62_oi!3bJ-Nsl1i$-Y^#tn=yv(IRW_mI
z>=@~;YpO1)t1POmDX*v~p_Lbtcr>~gf$f0gC?_Ime@rTi%eT?s{78zF;jZ%X?bTJK
zb+r{>6|`c&Q~1%;UeYcZU6QZ`j;ty#sx9B%T(xbizfs8+gu_nxXvE0Kdj)d=$$U@(BPCBW;}Fa`gtJaT-pa~Zm?`6A#x#|)vZn2v{Pk*O
zDy9r0K|^-R3J(uho|3jP6IN#2Je9QmS45Tp4O67SE)ro1FcEv9CSXgZHl6*6NfhwNfUR
zc|B&hRe>P_kj)pOaEpM?6AMTJB1VCU2a(U=3fLSW
zha={4fhhqBC43^Bjroayk4Szfjff{Dsf56MB;yc^Q{ZR9Ps1{4)KKJ-K6P+PbQbde
zp?L|=A#9`ok#!OV7jv8Q+O~UUQC7=QRqHxCz!VTM!!uz@d3||tog?y%%KnB2RZ-M5n4yS!1Dg4jo-4fig`
zR`Gx+X`m9@w-R4limfi8i*Y{|ECU+G_Q9@&@alYM?_y-{Qgn4Oys{WtSqv`B`N8IA
z0Rw<|-1)2n6D^WXc>ak59bQziv3Z~mVsS?JVzT>41J7LPeS
zZljBEq1$b8yA5ua&g<6sVdBt|D6=8pHBDy%K;AB3L5sp+kh#qYuT|x9sQpfj&#v;j
zG?}5cn?Om&15s{%mxh>AnUX+
zdR-QaMWr_=G+K#PFS5IoR=dpMRD}>C&1w{@mxn^$P|#~370rIXJ(mw`@>IX6&KA?MAeoj{6U6dfkxFgme;
zHOWuFmdaGqJaidSUPD+lM{tk9|{XXe{N8Ae&zYOb_gYsd(L^n_%wp7OEC{8imEylyVK!ifNQ$%-2`t9OA
z2VkNQ!^%#<4Og@QBK#q;OigkQn2)2hjePz7Wu1;EPl9>M;oW?#aT^J~lgM$~nX1gAHBvMXl9aI;*!x#{0ttQNgQOjGE?S
z=A>J#;EeRQ()v($oz~k#8*Hr_?Wi4SEFWkp8*VM{tJ^x!Ukhkx6z?zy2VII?2@9*>
z70w03ScyUuu;;y!X*)k{WaX{Af`gBAXlAAjlNsYwQa=^bO-2n9DdI0ok=A(`_=TFM
zaHExxv9o{(6P78Mr%5Ivb^YAXB^EKJ6Beo@h3bKk#9k37beB%RUqy@^rxOl)(ABTh-rj$4{|FSS*%GWiF>BmGEU!KBvPZ
zBYjd}J4SgiK1vBYvw+gDyReYQ5%NhYp_og`L;!ZE;$=iY!3Gy{`69MJ#O4F)31K@N
zLxRp|m{W+Dh%>-Mkw_{OV)Y5S4Kc?MQyvinHzZ|<&yW~w0XoDKL;;rz;D|p?#N!EJ
z1%<4E8Fb9AW^POjyK;2qOla0p{QU(liAd>S2hP$zd{i
z3?`3wA~}vsB&yD3u#hiFq#MtSaqUU=?un@>
z24iY+oXufkgqqEY_}#Iv$86H`1w3F;lA*{EOE^;5luE_$y49(eD;;;I;wW2_iJMaq
z?57-u`*Z}=iIdp$%$A7QVsLNv8)HG>NIL*x95sr~ks#2FD&ST7y}BD3Ste+hSy@Kg
zx0YX9&aPr`Ik~hPUtEkXE<~0VV@nJ1<%Q(ljjEK)zEuFk)EbJ{02(G%mk=LO4SPAh
zvK%E@i2#c*A|N6}E=Bh*MS%-f=7VdC5lm8CjP6|mOpL58hL;yZiwl97Y4=RQgUU@Q
z07QE_=>|sedrWSJA?UM({5Bvw4*;J_=ks985SLx=b(#GhyU%R}b7QWd$%O`hXz;kf
z^nj9X2g*k$Vh)c-54`AdsNGJb$0_$Zq&~Ye9WnVF3Xfgsb7;Lzo!hSVy0y`uDIK*$
zy}*moSU?~2>MbUj)g-r>l~$wNVvxJ-x^&!^jCliItHTQ1X->rhA-~gV)|w4!vr%g{
z>&<43*{m{|us5B94HF
zjEG`M)@aB=wL$@dN0De4Tk1t%72D-m!XX?ZAuHxK1T5izIqWk={di4=efp4J2Y?6%
z!!aSuO~m5maL^nK{8Ku7@WBV4eEf-LpL+V~C!c)$v4v?VBzV&Bahw%r~dfk
z4=0&BCO1ONRHibPFz?7Bb@+(m|sW?=KVu${e$fr9zN`8@fE3$1
zYP&jXyE|*UU_$DhDLQONy_=ej)@m$ghV7j-ZS5#tvypvB5)eC^D}W0rQY3yv?4gXY
z;|=E`;NwP;Vn+)$O6hE)b+(r=cD38JEWb%$)i4B8Jrl$AJ37mlLp2srzgsa9(2jcK
z15QzoThvR?knWca_+)giwAU-`bMSi{qy~i&$978k9THgWb4f{Ev#8G_MmHg_pi|HT
zBOGtzcG(0yHsKAYL&|puBcLHwo|3UmrmbTs%XrcXtboXvu`$xN$*jxOH}?Pl#(7CZ
zK~!xV7%^oXgS~ktW7@@-b8%-K>=_4p&dC8Q*jaf8>$X`hoc2$D{DX>3=kIPYOGkrd
zM%2bO%0?$f8ry2O(A&zS?16|)oN_CpHknaA+0#*3R(2CWVPzHi1+n{Z#a3j*$}Od|
zP309^%4nNt6`T5dYYej8aXT;X6D~#+Gd@w=%rJ`wRIJXherhGG*%vqLPncF>hUuW%
zYZC4nY%9gSc0VaCy_pEjUEzAU6%hDJlp?dpnR;KHVw(w5rd_PQd*NQ*%#Q#YI;6K$_P12-?rk)PCqp)wOUGsI
zXkm@Ess$rP$*4=UCt+m);M8m(`
z$ru(agQem~63LhoHYTFTj@cB7eULDVXBz%grad{*gDRJHpc66c%BEa!Kltr$QOsy&
zW(G)5r_-kZGrd-?&!*KVBt+DZk2M)WxlEQyM6$_%(V!=eKy)IqxjZ&c!p2%=FeE>~
zGccY2*3jPwjEG(2NUJzhmnK@-*P#$cScQ!o0Z^uZ3#^IUi93J<(L)H_giTm#5R14|40uD6CapN))0=cM9+%1C
zGIR#HLMh@4m@)~=VNoPQrew&RiP$r7_@%=y3x36L14h|7szfvzLJ{m#%$|ndco^=-
zy0A|d4wx`37=a@J5cT1JF5uM$JbLQ-xe?3aVwR%Ajlz@_6XmwIwhlMG|_B9Y8t^FU|T_=0jAH
z;=aWQPGI{|cx65?JMAvy-LnOMI_XR&UHPm(8F%?S2zlW!ssK8jI=|l>j{{~IV^K#m
zYz1hJN1Oms=s^U-JVm|B1r(^KP!d?s@6iJtdR!WpQw!#>DIGRxG^`2vRZgqWWfgnu
z3XfCmb84aiOT=&Xx-=fA(ruTzZDO}g6838SZmq>Abvc08j3K|(ZqYey#&E!uNd)3y
zC!l;hVh{RF7L!7&l^P5Ri$&}8q6(?Wq;xsp7iu>d6k3f`r9w1Rsbwa!PH#||&02>Y
zEg-#gN^|F6uZW1RR;a=SHc-a#X(~tWX>g>g`9`~CN?~cz%JC;
zhHEcqjt5PNpfMWIh5edPKuh%44S}F37(zgV4@;`)|7qUgefQl5fcW^Mj{zM%^VAd1
zJo@nC58nUyL-#&$->ok`xc|zDCq91T`BTr__0uKHMV-k83K`#Y+Lukb({X1qVuybf
zK#JLfGY_8`^J(DX@aFU0XP-kM;?rl|06Lsx?i!z@0C8mZp20n1LwoiN?j9QiKqOFz
zeN!;ROk&C;@33QFxMOextdpWc`e5t8FzO&u@n!lzJADASu!TMd)=VF0?j3CG9cTnh
z92f*BMCalF?4>us{D%=WZU7JmT7mx%0edmU5GH*a5oau6fh}|(LZHd+20%lsHR)~W
z>#Zj-<=VdP+TQLOdUqYYvla{!6T2|<+}Bmt+m1!eU2On=b=@6U?@X))0kN$T>9C^)
z2(qiawxg}Oy}i1vqpAaTHPgC*1*tB17(_1bXen(6Yc2y!#LU8GG%QkSLQzAC5iw7(
zwY<9xHWu}^mkxE&c68AO+DnGJ%13)>qn#y6MyEqU4`_DyRD%w25741U-0PJ9?e%#j
z{a`-nfKSrz7SWx;KD)3N`=&_x!5kvG6_8PY$%SCZg1l}R0S)ckZX=^bJJD!hwfz^=
zEdSs#Ok08cfD0!P6VX4!NLg?dENPiQ-yspWDPSiREKfnRv!?CLf}II~Sa2{4F6Ok0
znYOVWxD7imzjNin?%pz^Y&c|N`gCLB@%F*?($2bV!pXiu$e8h{WFD0y?BR6ayWW(Ke$ZOxewq6`Sj7wh7t8L5p}Xq&tu>-JZ4Gma*Jtu*
zg54<^Yw@bab1rG#r3mV|X2~ALXm=ejT-jDE9095;-@d(Q({|F!WZU*1S5<6lsVnPk
zsqAhlZ>=w?uiDyBS5jA70zVfxwWR3Zd%9|*oSjB7L(Lr@?rf@~6;;t-??xYIK+MXL
zt*y0XoL&7&?wDFQA!d#CchodhZtZWc9_w%2)!onq$XK<#t$KS?RZ(Txw$f5Gj9-_*
zNw(8Uw^fyIt)XqLqHUVm)8n%UQy%$TShEx}&IC0+9d}n}U1RCZopnY1SpQVfURT^w
zv%S5cWTdyjC})P93YVV4+S$(C-EEXkXob7S2O9cYO8^kf(%pU?BW~tQJ9$ff$&8Z+
zEI8v3&bmYeCqM7N!W3Y;42)J*+RVrT2wE6<8!Ka;ifVU<)H|cPJrV8hsBU+{2+spR
znJ8hCb@Ea+b_^iW3XI4E`lPO(8@i-o)>IrT3Ne@%M=k`yLn#W_7_q@$^JEnB4znqQ
z$Si6f5_U|WCF5A&JdNck&RoU;1~-XR+?GoRsFO#dadZ{Rq+%(s83LG4$Q6ruVyp_`
z+w8`8!XJAOha;
zv9bh#4*x3@@%Zq=Bs`c1Nf8SWpisz1VL%>|CKpAiNxci|Q?qzHRFU3@H5+KkT
zCIa%fLNFE^Xp4nSi`hITTfk)UfEO7U1?DnX*ad~j;ZHCyJ(0lzeB_Q#0q3y+^(IgR
z2l#HB!$WHPTCTen3+UV~npN(RFr
zo5`$VuqVbQ_e@PqphhB31YeKMA`AwVHk*paXERt#vspKt4a0rcW>so5VvSZR60vxE
zhET+D*!1y`Ga0hR1IAR)lnPstSU_rpyLdVYH*#|%qyajlnomSSMtDwuhk-=Y6bb0i
zRTDJDA~w=1#e&IRK|F@~72k+uX*s`y(d3Pc!?l&{>M~enWhps76Q0R?XQzGhGycW-
z&@zx8DM{J4npy?;TaF?8k^1GO`OxYDhK$!1!iasOiW$ZOtMLs35L}Kf&jps}f=Gl5
z5$Z75egN|nW2+0H`DxEg-c89LPG_-)3b38qp$Ua;v6$11nCOf~Jsyw6>oEd2CSvZ8
z-{y50-A=$k;6f5g_8J2|Y^LIM>j4nm4)t6i0^cXBdff)#MPNa{N9%Sd9ae?itZ>=X
zZo4k%F=XS|<$NX!{{{_qtJqBj9JB@f
z7OYPX0$IXn4Fau(;2*d<6>}$}PIz>j&IA``qPesi{?(@w)=bh$MmWZ@Ay^XwGz4PS
zlU3Mg1>gfCoBk;@%Jzwf6{-gn@Y
z$8JA&__252c;V=icPwW;i_^jBtRH^g`HVlG@nsV5pp43msTllqb79v-QqW$=dGk5%
zp~KI?54d>o{3L6~*wl_alS6wZ5DIsX5AEDNu$x4gca9B??Cb+f1S4A6*jNv2cn6My
zL#S&*Ld@-b{jDfxGuSye+|@tS2D}Jk-#~N!P)l!rBYm(5&=9PD0MHOiQmE)N2`Hlh
z6aqxzE_%~Ye{+9t1K2=c;~>2WM%Xw&Z^Q|ilU)r1J@tdVjs1PVi}m!LIzU5ucWr-f
z?LcqcU{BppSM4AsBi8qla%PM&x7T)d)uF}>D%}7Y0zTGscT{zC01j5RwgL_!J9f0f
zYE4^PO-CCBk-Go^TWD=9B$coU_>YEt`2Y>EP6b=@bzt=gPOw@936j>{THc9D*JXXJ
zrTrZ=u%XWK@xgkVVob}UtJxhk3Ed^7dz1qXX|Ge->z4GnMHC(OqWchI%Kbo!?(5lv
zScyW7MAQ%_e%Vk!HslurL=KQ+FrZ8w=@j)lZ+y*i#tsxX0sIGOn6yl#EC7ov3?1SG
z4fdjQ(Zz60m0eEsyR
zDGzr#Ae{D!(hh+|va7$TsIz`sS5xuM{<^8%t-A&rdfLib8j4#R%9?@CYKnjG9l{6(
zq*zhDrLufeOMS`saI0I(j#~r;uWTuzo)4%}RlP-}@%TTZf+8RpAfE`Ov0f$z;
zwW@4eW$D&h+V<9(($?ydj@t6}+VbYw^4jV$l7qOthPHjMt3fB847-%cfIb~G2JA}4
z9(qOTCR*|4@{+A+n41V60aF``OE#5~cGBgf_62L4sg%d!oBG;o43de2LzeX@b6!=_
zC3k5!1ML;fRa+b36V(>A)E9%b)t9!{l=L@OsW`hGYOYhq;q2+`X)5k%ECL(qpiK-n
z@+Ue?;^ByKDr043%~J&%8|V;zN9Z85uu>Lw%1R_@h=gIn49^3MoP!O&_n2`!ZkoWl
z6Z2$Pw;L>|-4)XA3Tt;ojT1nGR24Ioj|lc(QL|
zmG}`IDWJdvkOa0mfWP|ykq8z*fy8SFMtq83s1HYuckNr9gOmT|FMqMy?GlO5Xi~%N
z2c-sa0f<8hXfBV<;i7H}52#TrRH(!TlR_-T?dV?=a?3yx1PCZ;AQrcg9-&&1UD)D(~+o5g^)1|yflG8vT~
zugPQrIvgLL+@(+oqj7sEXjRC7cR4J01L%gFWU<-sEy^T3iI^o8V{o3so8t1Oq!PB%
zrin)|i7*v)=1>IDodWI;nG+#HJOsCG1JEI1K}{@}!*wpoNBbNF3?9x(pX*sjHlHI$SBV33AH!DjSs%&{-F1|PqmRMR$tu1HP
zme75;cL|Y>EVJzk$)hcE{v2;2}S}S
zXSHf97M01QFc_rp2r)e!$z%d9r`~{Fw$<^7KNbm?OnQ}CW-w_yUYir%k{9S71*$?m
zs&lk85_AN7R+q~V3_1e=XDIAWrGoivsE~tC1mNVK&IB?^e4ZqLNJ*tSNC*NRI87w8
z&=A4OVtqW0)yh%SuYtcUc1$9~bOkW<8luo9j8Onkcvb;+#K3VRWWiFEkTDe00~bcZ
z`cP0C3TT6VT@Z5!NkE`WAq)ndPa6)
ze0j$xovKqA-qAZSM5GO|W*L2o7*ihVpbxcT!7@gfkq*JAuyS926S@z95rO{(Tl$H!
zZ~$4bxxXLgXnjC?15G1?&4a*&-E}Yy0UGwA4bz*4dK<9`3R>d;pkYtLa9`74&jujE
zmcib-f!-Q=cNL%^y{85lvAbrtr*^2P9>s1@0UNESv%agns<*4Ur@gYPy|S~tssnQn
zv6)II>4vg_h8?x7sDO?6h#SI(Z52R-0EobXz=i)`-u^pCk}SXP1ZR0>YxmEc+1--B
z%yg+Pky=$&YOQrdMr359&Wy+mt#yR!&^kq=s;cgu?wMBAC0dRIumHGAfFO+!q)~t%
z1i2swTr&`W*{u=aa&JMq@9%k5VRjEY`^Q?r>u0Z?KY!sK8R6mn@t^Di6hg?wu#U>>
z^)&Q!)%Eu>#bHn5aBl1#}oUI3C=u439k3XgnIV8z9rAJhFPB$fJmA`R#Fe72+0Jrxu8x}D?$o>GA`%+OK6$s
zN+c_l@M?)X6g9=rGMF;$(`Ed6$*K9(U;GmL|EIt4_XOv>;$D>9TF>^x^uWEY=5O|O
z+!}arXQ1;=SL==Lj$1vQcRJhOY-_&J)O541?iw>I-)L%hqow|vbK{*}i#G0Ck9pR-
z`m_BPwqK-dxyYVrZLay=wKs2m{ocLnpu@(y*PHL%
z>TJH-+e%E<*LtU~t**Ph?m=5aM@xN6!`+5^H`|+T&rS3?_g5mG?SNzbV0Rf$DRqz1
zUDT~EYC(j6NWh#yw?fE>Rbb*0!J=+)S-YfLMyu5?UnSBu=qc09nqg&CuLD6+iIydU
zQL}E;rNrpvX|7a^Mq{4s?KO@IdR$hAbuS(}a65K(w(+MK*4K^JgFP|f$Ja_4WQ^NT)l|soRLzF8{awiop?%9$^j$gQQC*`0hxI}@{g$TS|0Eo;q
zd~qb5l(^HX^zbD6=oI)^q|At?=|`u4KR{uM8Ik3;&XkKIL3KSOEhB3mV=EI%jtFY3
zDJN8anbILwOME^X7kSEGlTL{pM)cBFkQhpxnvF58|O+
zmOVQlE4~EpibU+7J)g%cCVVL=;`bczao=$@6OXuqK6}XTiiW&CpCcG>Mx)+9z~T4X
z0s$LZpU>uTTRm=DFyQrh-7c5YFaEnPe(eVze*Cy_exy(V6-su0wVcbw1Drm6faR-(ZuI3
z-os)3{LlZR$z%WvGDe)zEKg~dr!|^s&BEjo#i@)^A?AfKU?K%C&kaq_4NlDtOhRS`
zCto=u&X5D*7(>H}>D~#dp#nxE`!WC#GEU*l4_LHv_arcJ`~mCqOiuMqP4!Msb1Og6sOo0dq7S$2r!co!`c1!{j!H#41$A{Y{(1J2CINUzo
z-!eJaHZyX6TAe&VfhiQfGSoiO*D})EjCQb>f>A(+eZ5Tsy)9%@1|1HxL3;aI`=~w&
z<-Y0fYwGKxs(QT-SOpZSo7|vAD-U)xkU_bpX{fJhe5l2!8Q#*3>!!P>2AU=Th5hwY
zgN;*z4f7+7yV`Eg=1^#ND7-ru+8GS*4wFrJcR0Q`n%EuX%;Vht1h`PGbi%6Pks?sl
z2!i<_2}*FoV3EZp6BJ^Q^o8Tmozch+*_tDpBhhVgKvd73*S7!%friZ8P@fM14wkaM
z#e7hc3uu|enKB^e{L88yu@q!cDM4+4ybra-@G@p*e44y}u@qP=2C#`d(tsCg0+e6+
z9{I)oo8SFs*|0trTTg}8c6EIN9dB%C2RQF~DzX>%uIpyI+8Tbgss8KDO+<%{O#rDI
zb@#sB((nz<^n;k&n2YTmDYip-zbcxtu^q?mY;W6*d$;~J<}@^1BhxeH*Ixr{)z@Ed
zZho`-K~q;peOG&3XY1Y0wmYp&7{5l9j_WC5VMD{4ds|xnfw2&=mSfgjct7noMeXYg
zlim03ym9;X^*eV+;n#HUMpw&i{p^6pq>Z^&XsD~9`R=ur`ZpWZ80Wi`
z0lT^WCZqxHq#l35o#v){jbw>_v$^T^mF}?NRznk@@H(g$fCy#ZoWlH
zdD`xFw%l5o?Tb6`C!0&6T@36P=6bpszuD7teYC4?s=sNps~$4);NHlCyQ7`A=lUCV
zwSzv>e9$}>*qMl#XHqW4aN)I5h@=o$&3SYgmp1KO%6jw}k3n&3At{d*@Ta(z&;btO
zD`SoXq&dz7Rx;k@q+5fp4_kqWm@m6DuNV<)br=HF6neUm5!!U5nPvL-meIO
zT#775xm1*57czk?g|ecJq?K?w&1{jB>4t6w1*)%4X*;pK^$tk*B=bQ8n
zC*X4*n09<%r*)h$YJxE_nRiy1B{1aODWBz;-Mla)O=$(NOaIR)Qc1P=f}9Nd^G
z!!XrBaZ?dn&I{ZDEGn{#=d2uOMay$Gk>UWbs}Rl*%m>G)=g;d{PC$OO+}TPgffSZI#SNZ!3_8$xwsRbRZJnW4}yj%>}6pn=L(WqNdBB8L&>oWxc`=PKE2pEevq9Gd>aij!K
zP6-GxdpKx~#oeM5@)PsfLqTUK;NW6jMGONFvA1Z*9SMT$!+2oGX2nc~kHsjHPCV`f
zxyE8XugC6zc2Jp78
zPN2VT`C9Gx_~KW-|IxQ__8cmQMT%dp<`b1{q=d)i44FSg1oKK9pX#2R>18byVy4X4EPfeK$Z)WGViK?jI%L|!@viBq-kI^Pneon<
ziTl%#sji6$GBHn%c219Wf(X%{7=JJcpd9NQAMG3)y$>N4#OlcXG2q}RuoC!qe~Kv=
z$>==XF-GR**3p5MvBB1nftJxhFkRB)Bsa-W!RME|5eGIsx#Z&zUA;
zgn%O|9b!ZUM{+vc7z%9;Q54JOF#3LDzk2q(zD2biLr6PFxer%LVG!Px29dTh%_0~v
z>jNV$7Xyohz*5!^eAH)Lnu1qX@~;%V`f|X44rNFo#TC805Y%OZ%inu?fusEK|M+ji
zrU{#IV6x}>#DnY3tqH-SQv$}A+hEl8-*3BdzwOQYZMWN7ZZ(nO@K$s4&Hk=B%hqfv
zvRji~C$i&6vgKnY$+zX)SsJ`w*Iak4x#2nhv99jxckg|@zV2E>-L=MsYpqQ;y4&w|
zQx598o$dGTw-OzaiMj4Nt8qt)y1R96fF^r78>Yv4X2*I5JDXbX-DtXVz2#-t@}1k?
z=zGv;*;-V5TUFjtOKwOHz}*VSFCzk7|G5%1n;ym!5&
z;buqMz1G%y9c^{(&3D^c?zXhtX>25HePu2OAhx#NxqrW*<9>Zd`@Od2TOF;p!Lq#_
zb$xBOCwdz^yYq3IK5jPz%uAY)mhPr+%#Ab$9R@M9m+<0*?Cx*7u{?R-f1r!lSG;?(
zj`fky-jw9fT&T+$svNm
z6rTHI`D{F!38zzmG?^E@>7<`QVL)|9BMl-`6+l#2#5FUYA%CM>#?K;GAkk8uvLXIY
z|I_~m2YT!6hZGjFv+ZzNao0&JTskR)!oH0yBU2dy(+CZXYnv;Ejn!3(95xy^D7E3{
zjz8eeC^3lF=VTs+YNBk?J_7EHRFl}ax1uSZp0F5k3j`6^~L*w@2u|atpG*%mF9_7%5T^Th;UDbu8znh0~Ml#aaIRj1t*gURELKoL>~q
z&htmdsiTwBNi9`70UeUjnKEOaWiJ7Rl(r`Q@H~57OCMFlZ^f~+Ch3``w9HC=&5VaU&K`7@~rzGUF(R?lfG|FcD*^Dop
z@=}SsB-xR1xuCq5cpynp?xd7LT0=Z+fDV&Mm!jAq$t1xdQv|wY3PbTFC4XA>r2eYH
zvRkH;chS6}_`t1rI$`STYaf9t!?-~QgSi=TUO{`Y_Q?ce;Rr@!>syKf&V508|S
z3W!)ZEG5dgs4-&-_!o4TOyQCjC}x9|Lgc6%ua;wnhurV}?!UnC{^39T6{BHx-MDD8
zZCNb1qRs1c(;6-4kN^>wr~xLvOcE)ywstE4zKet&B8!OVE~EM&5KirJl~fP-UXT*jtpg2>K^
z@ys`P;ldzy!O8iy!OnWB;hnNK147j`ua0~uNJnxWo?!S1_5-Sqolp%#AcHO|(r7)XfYv%naU}8@RnS-|F8U4DR#?cLqW`1HtV9#(%?6(QK3`KV-U|FTZ;QC-_gW^swqP74;RY6D-c4%f`Z9t7pQTx8tKK1N*eaowO
z6o4Q@Is-tk5Mug5rchMD@ro4D_b=uBnv`cT?O9BMDtz>kLSO|#S}2fW$e3r|Y~+I&
z(1SUiy;D?=RT6C0)j^AKD6l^lcN&~q(^LI*J+0UK$?x!X_x;;F?ROruym`O*)`QkJ
z$9ft8f+3qe88xM&=9qnTS2sRSdrn20u5R-Fj&4*x(=*xIFx+`ZH`VRjob&F^
z2KQ$<`$Ec#?`WkQSv!nxRVn55S~0Ym_30)1Lej0xc$RaX<#Nzi3L4X3M8~4ch!F6H
zZ;%1vBAAa55R(}oVi2U5VLphQbxzeds%VI5YO8*yuXRa^xFWk#vKoj0VhH3iWNQX8
zrWDoO6UdULko?jzsbE$K8nCh&55SYBmSRaSL|)fJ;rtJi5kb7VCpG*r1zMME6o6(cU`ut~oF0YPf@OWI`|Xn94i
z(dn0#4G_?wc3Ho?tk+YrLp?x|0$B{Yot-U{X=itD(|oWU47(jp^Twvmytf9VND1zY
z7UW)L5tN++TZj{%Cn5`}>CaML9OB-%@{Fj67m;Rq0~0x3X>luv~BQP@P(
zmWY8ZFz%Ip>Ye!i;&OJHJ2_6FWoZrz42dn%bhWk{Md^;>4qJDFQvXUR6(FS+ZrxC&~c{&n+NAR@9NgWtd!@
zK!4rxwWGtsYPDLaRH~KgJ8!@J87VqCfW|azp&fzx+#C46f*>R#v8T`pM*(LD{B?gb!%1woJ#q&s{tNy@_Zv7uH1L8c>|8R?uJ=>!EbCq)WX
zp_b7h2FHimr|^IG}Ol!v9}2_01E77BNTVs
zNWO_IH_c#QV}DQma39dHZnURVm!VFY9usNQyxM9f@qog
zkW_}zZPF}aPGpY^FmW&7a&*#9YRu`
zrL0?%^J>#RZN{f9Fbi@H6Ih5tK42jKHvdWqq!OY;ImM6xI{`1|0;_-gKmJ=B?uVbg
z=P(W$XWGX)Zw|LzAALX(6~hni4n4Rt&~+P(*n9u>VCUVQwws;J*Sgwo^**@U*KxbI
z?N(Rw&7Ky@INf)@uD9b}ciZg;ZMQpG-fV8T)>QY#++g<
zi`rK_rX~GcU(fwJ4fjBk*Bb6!YplCgUq>7{HqddfzTnx_?ypSF4Ytk>v|83?BTi%7
zz3R6tg{(`Q+aL$lW&e61W{%r*HsfT_yqxfC8Rq&1T5l{4G+S22LwoZHD{1vIUVJrL
z`YxDhm@-%6W2Y~|Q1I%~&ZQ(U5fEu#Btx@zIqAC68j|ABxs-A*iw=!oU*c`#Wtj5m
zGyWCq_La&IfQY`TJ4{$+)mA-!Uh5+9sv0T4T5>(iC}CFH)DJ*p`D~d9k_u@AvvMeh
zL8_Wc4o0kGK83GRLJCTG6Hxh5)g~6H7GGFZDCRTa?|$_Rhx^a}`9H_wQAvt(T*zU!
zP$`q$-L0K1%Yg~^$V@sEk2`Jltr)n34|+ZJ&5f;%^}US^)7r)+vm;YtY6CeNk`p3`
zk(Dwwt{4p~##Q|)I%@{1PmFP+VPkb=eO+hVTv^*Pt^)z_LdqP&!j`vo_x3I?j?2Yl
zBobIPZff-Fnw535%V>3!ywI?^X)vy9L1_kZ_gf@Vq;YDQS$UDTkN|N}zp}KVU()GW
zrb93y(H_W;uur$Vpw&PYmzOaCg9L~=gVk;e1l<9@(`?>Z*6Y+wT0LdJSy`pL*(=1d
zWZ>4VtnZmj{(#+L-Nm?WWo3J3BN}ra9P9#YSqT=(?c?!S-5xXOjl8(TAh3@VgbL|$
z*gg2l_dlBoX3~CH0`|EC&dGD+Rw$6Q&QDHY$&gG@$pnRo7$yJ&-Q?ZHfl)lN;O3%~
z%vt0~ZKIw)uVXnq&4K?;&vKOVkm6B_m!voZ8j{p%x#Q!^$w{tul0Bynouwbvk`HSve)&{+cmnbx76kA?D0t;GO>}sY
zd0flBb((#AntennNfPY*@g+LR(_`_t%2kRKlTa;+#Vl9I#L3Y%8!u9z0*@!6Y&w)r
zhf3LKkv%5mQjx3_DrGo)FVUclj{(*>ifazLVqteU=%)1Ap+G*Z6f((dQsQD^uiGB-
zJFyj#lH*(~pehJit{IP7qa`Va!a*zWQAqeelK{bx-xUeEgoIz>$x0iKxLo!RM)5S);B
zVqvjO6tGN#6p3u7>d6u=DgG<3L_D;pscKjmWpJUIC7Uu}O9AGUNP-6y03s{r^Hco}
zGnvfM(Glnn?eX#PqeqWE_~3)5PoIAF*$c>*Uw;0*uRj0s`O{B7{?1pQy!YKFZ~y#@
zcmClIKK$)p`TXaeUOcXfmsJIi5yz!?g_3y13;9GQ8_8rtxlB+EXGUAjM_Kk)%!yQs
z;eYe5e+LKtz2E&8JKGwgaZazF(d(y|m#4JaNhTAZ!^K6CrKRzOg;8|o=Z9x!2WMx8
z=H?*7)6;`9v;A{(12Z#y7-Vz^DD0k|?VFw$&IHpYj+6Hx=^96SNUcb&hva>zQln~CMhiLwN{$b=OpHKU
zM~9k62dRJ_tFYV*85y|h4EHw=_p*`xmQgCB(t_3AuDbrdy1wpv1ATRa{pjBv?5iK{
zX&CKonCx$cO!YTU^fyfol1vXZ%?>xsk2D%)+srH7uFXN;7O4q?+k@d<3O!NjFlri&
z?@y58aCcZWD3k7xX$=#5;6KQft(jwLMb@DZX3B$T8dEDNgAUOG0Ye*PO;&L*wnH{(
zAfqbk+4K6AzoNr{z8Ij`kU4#5*C_Y!b0?bT$x+Pq(v^8+%p1;P;>#TFRkKRhU;nDy1-XsQZ;)_zXwj-VhB^0|;9B2W0N&s1Yr6{;?CrSI)qJDB{Y}Eewp$NcZvhSOx7=!N
zya6<9xbw3H?Rdnqm5%Kn$Q7}p#5G)>)noy`i2Gq!F%_}
zK@if|a1*S?GSpBpy}NhF>F^GDuh-v0d!xA?uf1MZceAnaO$?6pHM{pTif^+VHyw+XnrzR8bQ^?kap|U0S#4^AzBQA9nn{L@o$C>!Fi1K
z{18AM9@!NVUkWTpHBuwYc(e|%NXFRdaqiFm{6FHLzwq%P-rO{I9R*Rn@dRMyrv3;-TAG4;ke
zxdpCKVwtU-yH9
zv$OKqS*cbloSfv*p4IZ_H40>YNbZUGN0*t)i`3UWu<=Dxgcy^LHt|%okwu-7$i&8ny<5b6QA(swHRMNwlls(KD(H)O?V__ec
z2$c%5ERZRgB|-FXF&{{g^o3zBU=b7;4miO?UH;kgK2E=f^Ei5ClU
zJmTZxLA)v!@^DeV%tumEJSE1`a!irJiHJMku>^hgc+|&nWG@!QpezRyyhoNnS0T`0
zQi?%9ld|AvnbPCgB%oHP6qLhq^02Iw@-(>?Jf*Bbot=Uc6_fG7NwVMa~aOzB+;ay5(zITbq(3l}e>@xeP`u;VE!Pjt_WGnwd_L4TrWYJx}+)5cgVGbs*1kYsD_oEq<#p140Xai7$UBOTL>5vRvG
zXP8=X>PkAtM<}(;#Be(a`oqoR!{EZk(V@nX!6vdV69Tpp0x}$gP%*u}W>PB-kdxvl
zZE70sYZ&US8}6?k?yDQ>y*DyYKibzYG0;3Y*gQGVG}YHMJJ1R)nI57nhD*cs#;GR%
z&Tzsq8Mll^O(W60QQ#n;P&Fb05Fsouc?=zHpJ-2|KtQ4DfXImODlInU#|9>v#yImh
z+Sru=S`AVmHK9s@DjlMunw24>L45sDDQY|l>G>#U4KYN4g{&4rtE3e4>(%H4#kG)h
zLl)DXrL2EB%XEiKtq3~QfEV+iM(`pj6e*~gl4b`X+ESP@=H!F=9BtLVT@3!u|LHGq
z++Y5|Co%hc*s@?>pV(ULUmR-P(Ts@hji_B0JXqkJI?irbpC9OMzA@HQZ{3;|16#?^
zt{mEpxi)mO{oO3pOH2K=79d*Pwf3f)9W6Hpd+Mi0+owib2fOb!-2K~kZ~wm=>%QLF
zeEmWD9Y}lgt){x`^>u(b@&ariyE91x)yD%SQuVxh_iohRedB)9P5n%N$g(PVcX;aMrmd!xVOu5od2e|7R;Wo!k%h3>oiE90R9eZaEp
z+?!vSdoa*(t)u?G>23MOQ0ujY!KQ_Q#-*X=&G{a?VJvpAlsH&Oy0jUuPIN4Y_Ibqx
z+FQiP3p7p5{);|c>Qy7CenkSZ|+Sj3f=+o@wMnQ)dO%`FnzXvHy}E&xQdX~R
zuC8qwR|yae4zDGhkLGfbq!Kmn?_jssYA}-JciFJ6TQM3|SM{qa`cWAY&uyfWkfD)
zwU`|C17K}1;EP7R9?wB2Yzs$RAZf$u5_s6_wTD6uMGDHiCoTChG8y>jCe2zh_Aw7I
zMRJIojWQSVE{S)rv^CDOjQIhDcM%|R2OPK0b5<6lOiqVa{)J+IuqH~*h+Ldtkv55b
zj(d%@Qb2^Kr}9Jz_ThQz;uL-5;kokgOi?3I9@dfkZZ4?qkiqHxd^Axd>
z%?8q`0O%?yMM42*B;u}ADBmHY9QvG-a!BAjT-?Jayh6ecOr%sYQX&-cg+ksC;4khM
zrKl)TSV=JG427H=7YK(bZ4Fy>MPuGb*qMlW_&9!~al9O~B=JF62=Q_3Dk@7+fe*xE
zE{W2_P+Sq{Kb?%`Qd};R$fTlKLc?gK$RAatYMJDys-R`&W3?t8mEKnSnH1GQQ6EAe
zxH#a4uc9GNIS7M77cK%SAhNBby2ea0B~yY!vK_N)jvvU79~AStx@>IC}hmapk_`rX~VVxhV5T1{OYg#LM(K!
zzo*wOjOYP~OQZVbaozIx;?f9^aba1sovSK?%C0Y0tp$%yJjibO~>qH`{a1*
zvU6;>bz-b_Vw47{!(EfqkS#oeXZkt
zWMYO)47QS?d7ycGplP(P5ePWe*ErtaG)A3<$$`ev-ny~A`f;G)V8hI4)6@VJN}e5R
zoE>VI9;llgxU)Uq7Ty_-?~jD{21C08p}nEd&LDFr9EI2ZyN?qFABSq^VgU;W}<
z-$J@W7J8zp2_d^KDIQ1{yZ!dSVV;Dzu?^S3~B7)!DArdw+Y^
zFd>Kc3c^7}vKDzuD!k{}T^j1Fd(d>Nz5aSj{TpqKHyZDLqqXrmq=D6FuCMoAf}<)ra&fD3dvWOgowkN=0z)YcVf!5li*CEy)^w|_=_b&#rSV2f!?m8aTT^`v
zX8nk7cP?mNv>3;SJKwzD@Qnw}HyZs09BO^Zr!Px5Y?mPdzL
zuMf6d>udV@O#eNfd6D<6yY}Xn##$DK8*Ro3*T%GGV-g<}XI)Uhg+6={%!nLX#rGoG
z=49)fWSJEYX43Y>yn8w8(j=LGq2z=tDvm{b@>%zC5?ehhifu`>E=YFrAOsGA`M`p)
zgBh|K+n7Gms{;b6f>p4fIt}9xRiUVUgRgaAj^wP8y{aRWS&Raus0HLv@eGW!pjS#u
zp_&)*h|lx^1chi{Djfr4&=hb3pnCu-jesZWNG?fUI%pyVVEIZrlroC;y-wWY|n5-nCF~4blk0r7O^HFrj%KF+0`598Q@;dl$V~yMmjRuNk
z*`Q)`#x)S(%Idm)Z4=WC6sHWp+%RnK8m#*pCRToL^<^T$WxejedT@MF$`?dQj_sND
zSlltG2FdulVpt|#G-&mJ!sVsqWmW%2qACcl48&|cC8p5<7Z0p^fsiv8^_li<>uY<7
zM5L4#@>$;NbJ65wgI254U{_k*vW^OAl=DMEmWZroYv4z2ibOHRbEO5~{^NY*-m(jW^I(d<=AeK3nNIm5}~
zYxFx*15M6q*~>F3mxA`;1tqnil6rtemi4f9oL1%ZB!l@XBhrMk{39xzLM2i_Z?z)<
z+;$GyyU0Ew(=Y+z#hLu*Jo(mX^5Kc3%1J49T1i|Si|5C}*%9dxAJ$SNrzx^NlO>uN
zqifRnsdRG0SBkO2a-w#`LyoJ7(_<04Jv#w+;<#xXk-49#HJW`SDL)>K^68kwd1Fzh
zz+*6~+DS912-pZ;ghV(Vz-JE5i*F@e(~!~)SGgC-2l
zefBB9@Vj4p@%=Bp`0l4KK7I1xm!Ew2-6!w<;K`%^?(=tl>zAJY<}ZEv)rS}F)KX^^
z@uVVFi(IuBXIuygg9~#h9|J@`=&+mzEPC=8cQNNJ<}vPm`qAZo`7i$kZ{@ds<5y#$
zJ=4y@x^ddDLjH(L%M%*yq((EY(M&8cEA!IQ7*?6-c@(RVxw+wa(BVw~!rb6IW5oHH
zzB#5!1O?8HcP{`9CwgYayV1@v4dV3JgW2(}sj&_~;rw{l+!)#ibK_X;n3)6=c1(}A
zkrHvNeQLaekzy-Ya1x9-3Q{C4R7W7=!_8yE)J_Z${EZJZGx9@=e$z-_<4|A2P+$E}
zfBjg0(?owWpm3yz=x}ndWum`nda!kJpk->Pb!xbEY^Y^&xOHl%Su@$Ox!A26Ynbc3
zsT;lPH1<$5$xdHnyC<|W5ZD&e1OieH!k2xH8ID;y#!=C{m$qZ9n#Y;-c}Q)8
z+k=qM?r>m>(jo?~jMP_w$rPc?L=8p(4u*C{d>ez_^?|_ppl`j;xAEFzmh%CkLogx>
zG$v~@_%G?!fD2P@4H2PtIp@=(0~W;iD=5TdvSt!8E@wQNoO_As4t1q~p0tnNMTn|s
z%=jsFVwUXD1T^YVfHlAUkADqs;D7#4fAMxT?%f>mY>qkB#`jl-gZuM>+rT>wyUWA<
z?KgYdZjSfYId*3wu9b*g=Ql0R^woDYz0uu#1K;xI%9L?=Vz{@d_1-ty>aR7{ee>SE
zuQxSbTbS&O+Ez26-E3?xmoWP*+R^^{wx%2Pb#L6e`;EG~YmkU?JX^jcecIxcUtcJowoX~cQxPWZM)so
ze5^Z5B8)pw_#;I5X5VjWf2VvAg9)XVVS5
zu)F!@;QiZsD`T8{E$%b~5417+YG_}#z0|+C(6giI!vFG6MokN{OPBGl
zrtw{PbSc+z%B4$r$U!je)v2*2qHSKX%t;5cie)ZkU(5m`T^h+chjFZ?ol9wlChyUg
z0~=Wv0ixnql57hSFwwej1&g-%_`wWkol}WW)gS@{RmC9=4K8GTt>o0I=g(_hm{XdE
z1uOVd5-#_lRFaedc#c=-LXW`^!@dAZKS6dJ7OH|LepN95M)W0dKcJ#mA?$(qxB0Wl
zP&P>^Eg)*RLq-YbGf@_^5-R4X_{8Z^`rrTiALBjzyMOnGv1n*-mtrjTOk2Bq>vrqj
zf!XBud;9^n$-EPddCt!AsZ_$}bFZ^v#cNw@tXK(HkOE6wF003DJ+SOY6ba@^Xow&*#|OqQY}pRxX(Zi%@Pt7EQdm
z$Wj$9XbcNlvJ@}q4D&3$7@IUSZFNy&0OxUBIH};K8_T3Qj*G0XZEmdZI9;{_%igNd
zIImfDd0d4;GR_CLcDKmftTPfXF6)=H6thCAM+S(?x|J3E>h{)#*K4!e%=_kTuh-&m
z?62W3UDp8|_sy2gjZMGb5sNsJQZOxtD1V_G%u0a_Wt^dkCW_*xB4euFg((Y};?T}?
zHn_ifM9v9JWGv|9(HA}B<}U>V&X8?B?o`j8
z*RcQ%L3=~o}Q%C+=q~}T8=pKEdTHVZT2C#31%L$qA3^W
zsk77M#aa5|3?o?zSRoB!@*&H5tpeZW34dCR*D8tADhEKkIL3(lkkpElADfKP=%2`H
z9~4+Sk${E}VB*<{SUcoSkA(A@%oLO9%QFBX$$2e#dMqDT`J)OIYc3b4&Llp6Kz1~2
z&!(a>_=fjUHSnPeiHOr(`qIvG#NkxVj{O~r~?P!0YBytibfB9+S&
zaZ=33SuQI4JSnL)B}mUuy&Q5K&XR&KO9h7`xfCTs#m^aU2A2iAd9_fAYCr%T0uxo$
zAd4d*A)5nLQVz(HpD`bmR8A#bvP20r!HCS2g{;X0$5fXEkBD9YEC^^8a3Kn$WB@MN
zz9r5_8E}NCz=5p^d1;)YRoo)ZbK$4?!hUUdbaZTdY<_-zeQiyWq-wPcDde;HO!mBX
z`oXuq^X$ndUw-!a=Py3}>a)*(_}#BQfARF`hu``1<8OcY(c9ns=uTv^$klkM+3
z%>DSs|3-aJ-~Hl4yJcl#ZEn>tyR-x%9MNb-A&ZN{5UfHL7l#%WNap7URauxDSeOMP
z_ASizEY9{W%=9hJ_RURp&rkQvO?9I)H`OyU);T-c2^^f6=mh@(2WQ9c&jAz1I%dY&
zr^f(=?K2bYvt#WvIMO~pdVg-TV|uuCX1EP9J=6-Bq;e@lilc)KV?#{@h$GFTBTXYi
zjiZB269a^R#E7`>4z&#TH;hq0Nzy-|LDf;U6P87z(qY&FKpE^}rwH&f&a&~uOKsYG^3gBabR%6sAMq43sV
zbayzsIS|?!^l$cqAPFKj2Yj3T{_O$vn|giAmA;Uv3{~Lct+W2kA>KAe^oB
zUj2<<`+4=9eE2vQGEGFx(^1Ppz&yV;+cnX3XR7C(Zu0*8NYnoMc*46b2X{o@rg?Ru
zyY1F+PhHTtE<_H*s4eU^jr6uO-2U0th8wNTH{089IS+u6tGT$jC>$iCyD`uD!bE2i
zz_I>~CU9ZH_2$MKjSbgYnr^hW-s)(7v%UT9{kGekEpK+W-R^FEv#0fTZ|j?Vt+%?H
zZgkdPYrXUJ_IuxKyZ4QSv9_Q^mkRI6f$f;fXfjR@bW)ze2d!^DXaOnS>}$O~-B-6d
z)!{OZyEdja=6kHh$%JDq8@1$PHrI}JsN+s|H-`Hi{$hPAow
zZOy=eVSHCRWLg?DX$CF&VfXq(XlGh>Xp$~1a82biupopbrdgI8TG>veO;R3h3P|T9
zYqAI;Bt0UDVqZ*Rj%5jwv}quUbt&gIr0iPh09?2zSQoj2dEU0jqEaX-IclDYm?qT-
z6&wyN`anjsDm7x{Z$@`0v4Zyyx&+IVS%WDNNfF3sFR1DiDGeU)!yxVo86`pxNeTcw
z>jOT>VMw(cks|7qm`m5bp56Ut@Hf|o&c07q;BCN5|Vi&{Y5ns%9XyRn7a&a%DF>LRwJDe7`3w%aypef0pfhd8jq}485`t6gl#Tdu2+FM;++MBEXSCn1PAm(0(vv
zibSpI`SUuKvs(K66y%oz`MuH$GA_(9!UH>IPfsw1@R6w)^A8y{f&x|Z@x@v4;bj_f
zaghQbUYuSDqqp?MY5LK5`fae|iFi>HFHc2QRXKikLYc8u_2K!kNOos%BwlrrysRZ3
zQC|TCo}bF6$6}=vtCr)KhRMg}_!(Y>z0n~kiskY&54j+0&0_F~<~7sjW3s`IcbU!i2&0hAuAtuV;m?(At3Y%isdqiT$;}$xonEh
zr4tPM5-Ax!u~;@8!w&J4rIc_XD^!Ydr6A&0#?lkUswLvW!-{-ZRVr1vT#*ish5#HiLs+;b~d{sF8Ov^CR@*_lqBLxe&ojQXeWFN^L{+PJn|!
z8R&*{lAsp&7*b@vB7+Voi;X1W2X04;)uc=oc8Wd`e3&ni_*J1jC_%h1DWgxiLlMs^
zEW(=SLpWD)LW+W0p>jU7+p81kuUo!0JUlTrIyp5pyD-0GFsyNL?znPzQmLLE9v+oT
zZ$G^J&#Hg3|aspYo~{r$A%k6hZ~6nhnv8Kv
z)V2^KVq~akVz6myxM_T-acZPxYPe-~xY@YS7d+7M-VN8@+`?Gn%uvHLS&i%07kk}%
z^BbC;`N4bo@kW!TGq61x2h3ThDYJrA1w>AfAbW_e0;zBkbuX-gaEMn)GfIb^GWTJ*&`9%s?
z!SXA={Qaeo`pK?q8*`o8nqKSLc)&F0-I=kijyu<tibffv+H=FK$
zeY~$ZWYeWWn`Pd7BwLPTTROPCyF8>FZQEMtUzxbSHq#ZgEQ{V%(X+az9ei-_XL=g1
z?<`M%Q$drWf7`h^H`I1>rnkX3OVsE$X%lv%SvT6(`1QW#Z;p1|UZ3x?tc=-LhP>-z
z;oTXsBU3h+#iVC3<<%xB21T24YBHo3)Fz!8pdr35!8Rw_=g?9ZvRVYsxx`uKgo9ab
zZ-(ESl@4Z;_9fZ6AY12?wnf=8pL8tcd@I-kZ=IJNG&z1S1O8JbVVRBXPpf)F)wuj>
zlWL4cNBzED>mrE0G*<#u7
z`S!yR?}2sKV%gu_-P_sOwpz_8B>^_|IQO=;j2k56*k@SXG_GxLZ0>IFYz0G}Y@W*(
z_)y5dvAMavy|c2msWWWoRyXvkoBEZ_6$5B%T?c|AHK9?vYFsw1YV`Ugy;f(?=~h;>
ztjwL3@?8@SLP%4n{i}dwGALg~r7+PNmURY7m!s3-j#aHHax%WTL)BeOJ7xfEg5%P;
zjKl5Jt>P$}B_JRfkad`^(P@`-+Qnrp-g`72j>ZBBKIHQ|*VYYwzdNb$Ua!|+G;D0H
zxm?y@5Vyd1CdsqZk7|-(QWmE0O$lB|l6?ybC6IHldUxKW-{Q$4z%=rh_9{259dh4?6eaKRVKHvSi%wto7FGtbu1@G1cj<<5d3!z
z(jxU?;nBmw!$-Nxi`@BH7VL-#Y%3`mA6-Dmp!|r+E)yf7B>^Cw0qK;B(EwtzK8&B$gxWEGa>#-I&Q2t}@Vu5fui>>!bL-D8>
zJ1!?`hr;PGsS=N?Jex1G1EnudbC;(DCi(MPwsw?cQ7oiQtP}xi(QGnImDuu$LY^xY
zCs&xgZp?Trrzqdc;U7iSNRdh}!XW7cyLl1%>1?6eg0(CQ1dVm=_CKzML1!
zK)^g-DT>uHRe(FLLgd<^a&m~b$5o24az0kbM9M|(uqsnNpd+bJN@U4`9IcdN#X`71
zUXoOI8>pw|tHSR+mkt+l31FpaR%ZE+{3*H)5C!5nB%KOm(!oM5l1}+kDIZlsp$rD0
zq!N>l2h+#*lzEm_{s4}
zwMtRU#bV+7?Bv-eREYVr7oWa(@#6E(Uwr?|&%XD?v#&n=_=``z{pkm9eg6LAA3S;V
zcfWY|SHJ(kkDfjH&cp2Gk$6((j>=?WF0)jK5ETtUifCD%)Q82q4^ql`a!GqiJV;BH
z6u+Mm_7%>Q5)P8weu_Vk5~f&i)9Wpd4wP9c`W)ZJHZxo*hQpG&fXdnCY-@Ol&Pa
z*w%EK_1znD&F;1SDCo^R&b$c$ZG*AB!MJ&dQ6PY9AhOes!T8=l!Zg5{hxq+rwZ%wm
zci@Wl)MCn{7aRv20t!KdXaRhY-Qn=g5NQXgP|9#tQ1LI50C^It
z?Rc}h<90{$jgGckt!Nu>JZQez({{_cGcSdAa>7AgI4DS#WNZ(B*jE2{8t?u$?G0bw
zUz-+vTj}6VF=j4A_Bgv?d8~Cu(D%aHD*1E+mp^sj0ATVgJz9wb84*nPW#=z-C6&Q
zuKH_(&A0lRZuZn)TN-W;9ju6+t+>q)G%f9GhgZfs76zJ(GY{;>vC!^p%sdM?OB~F~
z_N63+7?al^g%~q8(4=Eg0pY0`Y8;CY(J?RDXGHrf=nya`*cQ;z9;~y1by2b|3Fdjh
zJSXnYO9u4~58PpZCLsh^ExS&Ir9t-2-
zLe6NCA~bQ82O~1j^j+DED0>-p9%AJaSmK)$&@fm|hfC>bAr&s9Be`Vo-N)5G`tcvC
z@6GAh-QV9f?Qidzx3>4T_DnnBpf{IJC{oB|-gdj4kX$}ht)_V)YC15j?`*E`Zc>e9
z%3}zqS~r5T3~L+fTV9{jX1CdF_Cis~W@ETx?V7fAMuWz%s$uB~0eCE(p`IlaT+yLagGnnRM+wI!xmWZs7cjc#R`$=dp6B7vJI7mN9^Gpl8vkB1ZS053+O
zi7-%AySy9>xl`$=AcUL_n}LFqfr&(l+gqC+m)+yCc{~n>)3RgQu-NwYOdBq@{p_>?
zCS#vJsSMetN2Wd2CrxciWZxG#?*j^LB5#v8I~kNYx0vuqyqB~%qF>-B4GkHKnVOJ~
zdwGlqXbBAgf{;YS!N**HMcjayz7U%z12$g5AQJ3IfEbJ0;)&N7vwV77xHv6eoRu#j
z=OxN$b52E5E-&)u7rBee?D<9Z^dway_2CsAUY->mUz8q_a*;d^Sqd8lb1e5ExDB+&
z&@H9929idwM!5_ho=TTB;j$*45*@~B$BEjBa8ymyj)b!lnYgf)JUx+5Yswiz%*$Hp
z;#fI9l4}*=un<443Yf#p$2`dI>_o*-95j1@H&%Pah=hqiMwX^K!3?;e<0^MprsOAh
z?QvD99j4EY@pq|`IX;w*su<_Xg?J$oEo2f$<@9ki2RW)_D@AambbOdPIZU5al%tYx
zew;i%mXFHu!y;KbPZ+k=j!3n6ek>f7A{DBH9xY^}#eBR{77nX?J{L--JcWF)RE!i0
zQAj=)&9YE;Jin>h!ITmJ8nQTLHEn*70V27e00EiTAbAt!v$1SCL{*Yy@*TuaUd6sE
zVF_q(mePqT1w_FIA;U4{qfvp6o=fS0Q*d*FTaZ11;z>v@PIB^SMF%h1CCMqv9!d0w
zxc-O%SqKVzfaCl;@8>u#CwTauZdvZ@?;98x7#bQH865#2&dtp&EiL)|{^R50VzGF5
zcyw5<9+oTbzWvUp&z^%0pFe;8`HL4{eewAhpMUz|`6o|4{Pyz?-~aUew?BLT(T|?L
z^WT5(gJ1sQ-KXEGJUUitW&XIBsN|z6ATlK)MJ}_|Fc`61430oDOVY+>KqK%Y@6YUF=_vgnu=EvLT#@c7b+NQ@_<|kWs*T%xG)tF~(e`9iCvJKcb
zGukvehPDxc&g@vr%t*`JNE-p-7$!hk!G#Nuv8MUq`h}7Dm5D}+zRSDWAKnH3jYLT(
z;y7*|OHiJ|p(sTkkH+_gIn!`_2k_S)+a2W0BmDjtzYl^ONtlP@=E21N5F~CMz$&nk
zybnppMofx8^mm3MTSH*Y=nkQwstbgG^QgmeA2JXmjUe6t=AZ*23~Ubsm{+2@O8$sD
zq%u?;7JVE2V8pA_=d~>=0)p7UAF5suIH+Qr+NvWtuMYgDav?;e#*9moaV+IrfQ+RK
zDYR%O*hEQHSYDN%oc~JH{bMF&TDHstwud8oVOmgR1%z9+Od6|pV2cc!QM?{>F*v$yT~VB3w2xjxs{{GNVv}n%+VT)4lpO%@zLoO`yxKflx4UugN;=!!2KO=oIjlfhg%
zOo_7DeTWLXfeusQN;X!_#Y&WXn+p16lbpy$d>*UCvSX&mjIFKBb>?Dd+uhp)AO=I;
zXw2^q*i8FdYg=nZ7Q#aLZj7sXgMM|@Ac}EWj!Gis^ai)N9d3u+LiZBhYjf;w?f@az
zwoTiyMAT}v>cMnmcV5-6par;*esOPqTTz0UOgO=Xz=&GCf!q^8imQ~)kSg7+=vfO`
zTv;Zk!4>?!Odf>G26_+r&Gl7_dB^LrZ*Od2v&pm_iF$p0mvME?u%h4H*}~toxv^=n
zIJP!T_#4*N)=lO;pU=f}p)}RJ22Xo3iYueI)08*P&6I)+yP01Xsc8ufU6emX02kWS
z@MMv5q9tt~Fp&qclUH}0?U?yEmSQKB1nBSta9K&z4*AnV9)qQPq*9DySNUuN
z2R*EEg?t!9i1A`BTrQxEoSdATot>SZ
zpWoZti$tRNeEt}KSgD?#)ZTgg*8A^$=h>5I&p&zo;@Pv$K7ID(7cV~l?Aa$zK6v`^
zcbV^ZW3cV$=F^JZDKPO2PtmJv2CKp__h+?OeO$}TT$Pt
z%eHJaFF38srtRtF#U9;!uYSH?JJYM3?b6J3G4)}uX0CT}wtI1&L^IdDG}XB@*{PlG
z+|Ug>%u61dZfA9Taq|A+xv7TL7~N&EF_KiQYB#7mWSiR4sIK|e*McU#Q9}E+oaIbCI-$Oi3x&=HmNP5Dcc>+6>FIQuMFj5NZc)
z-lNO9m-C*Lyl*A#Ugq{^!aL)Etx@mhP{=&#-WfSq>$h!<8RqZnXWM-T3)#p{DzF){
zXnp${uUTUphLv
z2b!-hjWpRerUGWIeSKzm?Ed0Vt7Cm8YSB42r?-~+HWz#6hMET3ua9-#nH_4J8*1EG
z=&`R)cy?!ed$X|vaM-Nu(kL!X(zTp)>J-PaVp~kvHA&kNlSRe0Bv^?KS#H8v(Ke?z
z7Lv{-(K;vD=75HhZ61RHpb*q(nHLY{NcR6q1oOPAGK}v|#?1`=Y;zEFfPjL10WZW)
z1}*Kuwh%ucvvO>o=umVlVw!4b1|7aqA6}h6uX9PVO8+8HNoWc6nCrLdWQMExOYcLf
zuB+-1DKWC(PKrQ7ry{tL02EdW6?@UqI$*^N>!s@
zFc_Eo0hcUu@pxo=XNNopH`a@VbSB9QTqG&Rl0wvGJ20-TgHLlAF&^_;EPE6^LSobz
z^lKX{tE)PlUZ>Fm4OciW?Dsi#wzip_T8GKOpfwV7nD=&c%Xo>791eBMo10rshs|mM
zmpa$hHmnC`uLqd!$DK6=QpblZ`KVA0J_k9F5j|96avkH#*?ywpS+v71uG-iv&
z>?$~3oj|W)saDg+$GOwfqAHZg=A4v>4=(_Sm4^>2l;Gy9cyhwhVgsZAUZ?5H3zA2d
z*~gdU?f38;l6yoJ=lsQK=Jc4Xx>v!-6kkGluqi(_nD6u|E%q4&kx&*xg1J4
zIjsKP*>9hOsR^kC9bz00pAsRUPY^r;$WL$zc)XGQk`$DrkVsbJFe~B`;BdzBo_NBY
zz;h0<;}t$qyp-VQuGEJB#GoLAuTG%9Zu#1S?yjD`USh<-f#Kodp`jtP6B82vL<(e<
zq;jQPDwm6;5~O-~^#1!FK7IQ1#ful8ehPX1`RAXZ1t5O%;kRFW^xhXAz4N^%@BFu)
ze&-iId+!IIJo@l)@o_B)Mr5h5V-QjzUKyIhXv<*pLby^0RSSVi&Qs2MifMOVab!em
ziZ^FCbCx%y`E5D2E=AYGh*1n1WmT0JT}u)pZYr@2CAKMt*TleT!oL!BYP|;wj@_Aq
ztufQah-qVVP1|Fbd!U=SuV3h1)%NS=y1<3YGhJE&#QU15cFi=2Zno37)Vrzc_gWW|
zoY`yD>gFFTO}8&icPvb{&5gItkGBE=0fGzDZS#{Yi&M?>qYaB=4VtlrrO`UgSiNqt
z(Ky$-xzw?-)UmsK-)wkbHgvhRh9di8@dJ{CWjt;M-i-;C(fIyQY=4L|4-y^j55_IS
z@qwpM$Y3$JO^QSGA?RG4KCf*_Ggmeu
zLgr!!p3A-pB4JRd5*|UJmy+6`MPG4iBp1u5$Bdh#=yEJl)eV&k-Nc9>KQe{_BH1b^
z6RU}X>8NQUW}f6MGopPyivuy$W7et3yO#?dJzB74-nC4tK79_1s5&xwmI0CKp+)Cn
z!ZsJR%mhqRe)F_@XKG`yYj3$fWYIXbXLZw^+R2Vh&EUb>VIaq^^L{BI>-8W*t8JXopElCxwppy=9$p`Ox!-tI~OI24cFjvOFA`amp19Z=SkLN
zw6b*`!oo_(Sx~fs*k&LJ$~yy|BVR++(NMI`1L-)^l(;`H?vu$F6vzaONJ>P~BeD@}
z63jC(69t__%~RMLATP0xeNKba@r?jI$vlmYZ8l+Jj-&iXf@
zJ7gDey2L9oD}FB!K!}`|uJ5WPNF=o%xKK=ZAhgQN$4scaDTMM$u$*LyTxDbc#IU^Vt|H*hROiR5GGS
z(QwGMx3`f<_|MNu(WraRWZc>@Zf>t{Y;A6AY*?&jm&>xVv%0mty1oIZ+uYdPTHo9>
znYTpA$8m0(eRp$v)wrhjdL6PH@%r{nrfs_&m}cJG+N22N)m5k67W8=b_sr{*D~GB!
zuNaM6+Z*99NIDP;drZ6A>+724Yf=1#eOy
z^Kpv4jw_WR!8g<3QuHy0w`2#JlN~wX6XHHT?iCWGsl_HPX2T{fjtNdK;YtAb1acS!
zAd;FePU^sDgp`HgMS3cTdsu}xdo0Xs&5RM5RoWd5AH<^j@%TYJW(8|roj|W)DV5Sp
zeMl(}nRYNwIkC@+k1op(FN$a9`3qJz<@B_0bd&}iR;%*Kk#c^Tp{$2zg-4i)`KS5I
zvm6-l@+{44tP(g+jYXeaJFfQC_N$>H*1Ai4+h+N<<})RB*X)NundExLJ{9TtKM0
z604ztIry35fe<+8r8s3OeCOvy0zv%nQxww{#?^rEPVlNiIzmjK$wA^jRwWM?4WJ>o
zkmFrEI1+QnrzNNe5t-yFuMJ(YX#A&U!*0Ld(RRPRqw_v7Vqf3D@DOBpY;0%(^T&@Lf9qTCJbCg75b^o*7oUCh*^3v?Kl$Y2k3M+s>4)!q
z`oUXYe(?B*Pu~9d=kG#3eed+W^ZX^ADh?&p6A@p@OEe^lvnthm^e`7X%m*tuUnT7+
zDbAv7%Zrwrc#soJS;3Uyca`Y65?V_|*X7t6Fj0zZD3MJiigsNAFNO_bP%i{@V$h(3
zF|sa2)}+`v7t}{ROL4DO2(55|6_(7_2+&Zay@ZK*9GVBBX22Xeqr90SPDu4=
zhLEn2X$@7T97*g^25i+Oktq==S_K`9Tp5>lRH40Ll~LdoFGg6%i`s`!@@;0SzB+wg
z+oEPjrYy>Sy^3*Z-<4SzoCl;+2O%kpuuM0y>HvqCE=|(Dpish;g|u@C^rjk=RplZ?
zeIX_T1jD;yQ4>D)Spba;0UJ5Ub1s7yl3|*vy-}_{mliGU&8f*bH3bzG-2{ukR=itC
z4udRiS9B}|cBT$i2K5sy<6Spr2J6PU-t24nW`FDTzUFI#Z8yfc?hba`>}k6W92~rV
zOFz}Mvoxfi=vW+TK3JUyTUR2smEgW671%CC5Aq>%aA$F<*EY6Sw|Cb~`#amaTi`yY%kK7=Maq2Pwpg~d
zwv8Lx#&E7nv7k}IQlvx+B0@g>Z6lVUc>7>DnLfSbaA$cWF7ofLj#
zIHss%7Z*dTj(Ao7LUk(_zfuqq>cue4$wi%b`+VF@YCEgU{
zeqP3$lanmuN>_K9VQCQykjwKNDDd%l`tf<{>_j@M0HRyG|iQyht0W>t*AqbG-CDF(|D1s-8l
zJgOv4s@!oUQObr3*)ZPT=`r>olN?FMheEZ)K(LrN%*GFMiIb9aSP)8?XgM1_EP*}~
z)pERCiWUpua*1*omI?_lVm1{jWuujBw3?3T|MXo4iMOh5vCv{
zMkF(_;7#!E1W)dRc!~oEiY#nd4Lad?2gf@(-plh;^o19wHZ;4KkOMSnxc|?pJASRH
zrLFz`{kD$w&Ib=VJ3G6(dj4)EW_Wrk?fAIFR4<3K^(c3?G{_P)q`t8r&zj*($
z{OBlkS`m&be5DX$T&N}r3aO-6%!Vqta3vS0=KZRaGR|VkQA|2Yvb`u-b8&MzwwDvk
z$=H?$OCV^Uh&o1Mj!|?HmMOtD1IXj84m!ynOmfxhJ$J+=hp)SbAgpB6EirEk>ZsikOf0znfqXpDGt+)CD37p(y1&a
z$wEp-WEBe00%*X6uat%AI3_@dAe~ED7nOHQvt4CDgf1;eQQa*%*hK93QnF4$Lw0nn
zV4Dwak9aqRth#QyVZgmP>e?Rj?M-@iCtceUR^y0ocQ&*)A2iK7HzzDBLl)hD+c@S~
zANOxf26ktiYva2My=LuzaiVo)xXG#;@vKjqmIjvk>-^hz0x@I*8!6vvWPjeXJ-w^x
zH%xWzYKM21hgPQVFOD{^%-*-GjX5?aJv+0uwXq#-@1Aa8e`VOdHWt{KiJ0fY=BWtK
zN(~TUu^o~fK)fiqG_pr4xvA)gV4Vjdqa(6_j|9lf!qOAk7LwL^hdGfzbJ#=(DTJv}ld
zv#*IG=$zr`ptBGHN*sb2m+@Di6E{zbmcI$ha!LxN=ps(`O4V4IWEXTo5L}=Ike`F<
zXJ9LNwz(zVEl}tyWfv29Vi6X2=ppm8;Gm+t35SSBd0C=wjQQlcM7qXg
zRFNYb7w`w{E|=Nu-Zz^!wzt>G4865(wQh%kR)=+aYm=(a?e1*4-B!D8e|vjpeQSMf
zV`X#GXe1ROqeP=&4P%?z+q)(-2M2p0zf<7+fq;EycVlgnw28)b!%2mOaLU0fZn{8ZmNt?JK6x_P
z%j7=jP{@c(fJjQ#D-AAL_Jue;TX3OIOkmXy5#nAx=EkQj#yvcNAjOd|tFbE)bp!q=
za}DtyQx=Bp@dzcXAy>jU;Ufka|GDE)cQopZMjhN$c(OYZvaqcVU?PYRV2y`|Xv7{4
z+ar+7Cn#=IG
zDym_>r^o5@E0;lXLj-8D&=YzI20@dhe58~Iv_;9PTZo*L6Q@<7RuN7Q$@p6%J)cxN
zOr9QRYe%5Z)Nxrpp^_?mxsU*&WmAz#Q79MrVveg8MPf%L$E-c7NQWi(j
zz&sAIPmhQPB(ggLD8oQQj`Jm0iX~!1Y{IYOr|S;y*45vsudi=uYJYIQv-?4JPhWR;
zA1M(B`UeJjM@ELGr>7<-CpI@Xa=DyZZ4V0o@$~fUgAYD>^5n^f
z^udQ8y!Z5jZ-4s!w?6;i?XNz1`$x~d^`ocneDdzeqgv{u%G2WlzLEmIk}EV+rJN6!
zL5Dd)!%EI~SnyTzzDm|p&bZ1+S5da-MN5V=W%#{hVpEB4D$(^+gd`bW2P3L|F<_7&
zU_??P>IJ_}@GbMcWg(ywJQ~TnEO~XJcbWHSz=GgEKCmnXmO+ZV4nqBDb4(K#)-fP*u;Jo+&JeLDhj6wrz#rNKQQ(;9m=NvbfIP`M3QR;R+r~xf1mI7lM$s}MSte!cv}~P}ZJ0JL
zSti7TDRyU_77ivM;sH1kBj~FHIZXOUX0299F}B+m+35}M_J>)fYi1oLyhHnv^9F-z
z7Q^i!HKSpKg)lQrykbGDs)lC&CcPY@X3xGleO}v=3y=jFpaw2fDUjr)@1Tl|=qN8O
z#o#tj8o)(9m}UAx3PvG}W4goSOSPi92T%ym5D21j3FuJWi7GVBxs35|UzXWC3T?D1lCP$0OSS?g_y*mvU1LkECZ=E#m>A%>`F7e)?M!_p;>H
zimoMrdCrA*$9)?^fz6S?=9q7D)U!UiztnABe6Ty$Zd$l+(e~O`1|XK@Zu?5FbG6@L
z=yR_P+710?%>#?B*S$XGULSX^kGi(T?Hj|kwE-{Q#{LXB4%+5;Ql~9QPOahrTN`j_
zQU@~TBkW^}H&)0PBa7&8)`i$Ug?EUy1sNm2FHoIjj@S5rg=tqGoVAXL~najya{MH^Gaoy*drw(I+Pz9bodf0RZ*QjF^D#_GaA{Qz|n~g
zui{azOv$R3A>km?9jXF;~}_oeLumuPl&{noMa>$g>TYf@?jfjwf5B737C|
z01GXoT*}PF%}JI@=9k7uLRDFjU=`y$i+ezy-4*<74!I$+8;MV~FXPapn`EU9SbzoH
zW^fC^?Sv-ajj^y801(qA`chQL6*%Q5ogx+QQp+>A(@DzQ%L?~VbuX&aB75`60A=n?
zB@`(t2|*#@5BqH%r^#X6we9b@Y!0b@=k4vR+iiQhduwL%mf5_wy}7fyW8T@`IoLli?NPjp)n@kk?BS3n5ev$EG%1F`
zwaj&rQqNEVVWxmlHHGxfC09mvXCz;WSR72uB7W%4#~qQX6e?&FPKBd#CNl3Ana8J`
zaLV`?8F}+jmq`4|(WpBX!yBV<&>j$wtjRHeAW1xdt*%G}
ztryG(I>c*%k36Nqp=5jEkS!X;3u&CbR^E%
z#l(xt;^m_<+S40GAT8+5y9K=>jlgf}KM+6`;*TdB1dGhj{T>UD=M5Vyj4#8Cv
z|8aRnLBx=UXKKZ~>?LUvmE*%ixc~x-9ajYcyQ8EEf@dd$h71rX_8E+beb$b}lS3X*
zSSdu0s{CPvJ1lX>6%5LN%acRp>^M^+6`+h3ta((C56cQAqb^C+l1SBh)0Ft|up*ZW
zJm~O9)gV@rc%SHCwOSA>xx`_CJ1%j>Ts)Hu7qbbx`~=e~(ou=8(LrNJmBdj66C%ZI
zw3LrksN_imQpiVgnQ)~9R*{Y?a;d=Qvhi##mL~~kGr>YW%Cw1BX=^A~PKL{*C~r<7
zmmtqz_OzB}?!u}7CG*)ZrLbW|P#}uzlNFzm^vOxLq&Qjj84pI%DN1w5{0n`u47LmK
zJWe4zVbXO&#GpiJ*hSWI%#~0iOEFziSilOIm|1>os^7@W&8n`ERE!+&#-3%73I^3GS(l@0a%5Eq=@UVn7|=^T
zo#@d52f>JOp9aXt`}LwvFL<}DNAUY=m$GGGKK8_MWlA>`Ub}*8#jPSNGvOyn=i8e6eq-337G6h})7xLCA&N>y_
zCo5ije}dm96=Tdi5;u)-%(XGGKPK$sHaw9qk5WZumI@JVgy{mQupUcc6WtmLy^KWh
zuy7M>1tv05q;cOy9|Wt64*Pu@{ca=0ru+@iA-NK=bcR;@T-u!a%Wze)59CKA`n4xMCMC(`tU#77)
z2M$f8gcX+tZ|}-`&pyvHPd;+IW9IJ!x!=tL;8>36MbQC7)+soUS0}rdB=@3(zs0pA
z;%$>QbP1~h{iO?O*K*3CP1?1xZAr2%iFO=I!-$Y6-kAHKDg;{xjNuMu0d^2_F~ku~
zQ#1nXGf%6wV8JpQGfl=#QyAnyX)N^&=#V~PtnN+5cE{tGV4jL&KX|rLL6hQ|=VkmA
zOj*cq5d5dMq%Vw;8geFTnhZ1BH{m9>zGT6lbT`Cc1p8OtIZ)C(eRTr8&IQ+BJbY7*
z*#z@%qa24GnJN5mf#z|I7F;}M7m49OasWOjRykI64NvwgB=!ml(Skn`%!5ruLsgh|
zkPJZNr^t*@DWD;+575J&_`yAl5y?cwbdBUfg!cms0vM$wig8XV9_G~OQm8bXBPBZ0
z5?B@^?xaHXf-_{>@@5oICgsUOWKT{BpG7!mM(
z@UEx|8E7&r@gY9u<)S_@9uyNHna3LrgZUJR;$u=uG@FX&(^TRjmqtGXHcjKuiZ_=G
z089&tubA`}Q@*?c@#m8MOv;x@dQyr@)e(~ET=XP)cangcD$szH>CdNPvJPgQcTjjZ
zGa2)MzXWBSlqli^9M3-OggX(naZv{ck|PD78e&2!L-vihBB6sw)EXyivO6AegYZ~7
zZg)6L%0EzGl%h-=5p;+b0esF##Dz{IVv9x`F@Ph8GXc2tgu|dicQnl06Y^XC^-cKPzMe0f=Vcv-kO&z_y8nO&IL
z(-T#9c;$LXw&2qgg{oYn!E;9y2?TarO_J}RnhJ+`6H=J)IYtypXI+!dj)lVt8H-s`
z7$6yIMwVZM9alkF(1xl{iQ;nQVJFGfWJ_w7%LaKN#}@)oUP#-E%MbIc>t(B
zh-x@9+Dblrn2#J4qF0`XIp1N{f0XrCQ|?OAQIc#W!CDdy^4wmQ+sO($xx{ulx{-}<
zXX0C#*k&@kMi%FgkvajR>|d4r1}U&223B~cP?Y?72&onQ%L$^!Wg$o!M1n=%67QLZ
z2;Mme?_Cfe?ggIFAxIH|t)h2cbj`@_dC4^=IZ0$dq;pyX6gnpbg1<@0HASlqB1OSI
zCcDrQ7oyLok&sbzjH-R!Isq0GZ4;bzG|r6Cl69QlACYb2ihV-1k)}|x;1)Xp1QZU&
zdGiETx&843Mh+%{iRh38d7r{l#QjONuwG)9@?i5O)@NyMRFA_r2*}{7QF-_N9;>5rU&!oj$K^0apPK!Gfv)t+Fh6HO3)eEO3&l>QjLXphh&t
zI8tRVv={_kDJ=apC`2_Szv4pdK^43NGtp7!LsT;R$yJfUZvll=k8^Ogc0JL3M}f8&mgyqo~KiR`rMwbW|Z~d-82$r!ns=ABkLA3jnU0{EEDk26ih
zUaIlbX%X{O*gP3$PKTs@WMReRIB3R03k4B_(y%Hq76ccmpX~L^24(a_6R#N2;mh*ywb7g`;%Izmhb~1?DVU=w(mqCS{!Eg}g=Ljc
zP6-m^B{3n8S3>zzIG>8-lMyOgmkQ^oPGB&bqO6U%ls^wi`g4jWuXqYcUk+d@`?BCa
zW-?|hNDhUnC?Y9JlcFajxRbn7QR9vQeE4{IVsVku77`t*hJF#>0zSjIlaJelgjMA1
z0=b8}A$;5+;FAXwz6>8pFc(8Lngky^urCyHFx4PA5ym6VSQvfKp2~s{M<{HCkP#~0#f7>K`s#q2R%WbEfQq5=>*kQfn1$HuVJYk=8lewK*OVBqQlek(s3&>@84R4yn9;#n82*1)uh_7$mWQ}0!0BI9g67x-tYbk{1t!j`^1R<__zK6Q$Q-U!z3I09i|kNE5*d0
z{n>w@zm_fUy?a_Jun6LOyj;S5_@hJN@BZ=+t~UR~f}Q6x(WDss^?&rMS3@-T&((4)
z#eC>5{^CFW-tYbMKl{@^RyY0WpZ;+%7cLdZ`K_3X{`klLgF24o=YIZ+LM{r(VPX$)nyI?-7tq7h3U8BPbYoZbcg{W9+vP}6(s$i9F&!StoRjB
zqY{(|2Se#pB9ls})t?o${1Wd~5^g!+Qg~)Dp!|jO+{msH0eV_O{OM
z2W|H|9&~qgGg9pD?;l{x$jHd%=4LXPR2>kD#X_l6s8%a)zx_5C@sm$JQT2#`#23$>
zK7aPf$M3)Q{b<ZE
znzP|@CREA(W}i$Oj5yq_Esu_}agVqjSgf*O})|8ml&P5HD*?~>wO
z68%epZ$a?QLOAbq+&3fn7A4QT?41+cGZKif?!;2B`0o;lY(tR!m4dba)3y1N1qYxQ#_4N3YJNJf1I2VtrO^T<_V6f
z;Z1=HIhOT?KN#bz;}j50BJG$;08j(Fj`&
z?}GdW0$Y8Q2a&~{P=0LYeW+>{RZ@gt4_HO#>hyVSi&{O80Ff~wxRA7otgj*u42D(VE_8d_`>*lSg#p=3*vN4btk~B*EN1gE@wPIIgN_L?62XXsVh>
zibTP&Uiup1xGEi@gB^zP3BM#!topY`)DaaK)pw|FRVUzu*rcvroj|X1VNdWbHJTUz
zr%-u&N`nl+AbXU@qd6GGAtWefMSa{?g{Dy$1V(87D`XT&#rSdpg)=jUB$h)P0>mUc
z>D2`tgDmYf1vP_sfH)4k5N`%|9rgxr=OA0QibRq~kNb182w>B%L%S;d=^
z{h+{Hnh-E2yR)(XoEp}C~U(t&|w((7;(qrzHrDD2~ikIG-6|>XHPsH;1c0T
z#EbbDiA3$Bk9?hUSSlwghv`CDDU{@+lU(hrcwEaLon%f<(a*nRL<&85bWuWkewqgt
zQsTqY{An!)nLRcSH-gv>4K{2DJMsSgJ8tNY64^iIXX=I{_hhV9#y#)
zPv1u8-~ao6s{$hWzyEvx^0+Ghli#AUKu#)lQ!
zbW91c#ltf9kAIUY=Kta^eD|m#mhy4*f9GHRQ_MW7;4g~)#;^Z9j68kvu$T{m4#Azp
z99WRjU;ojM{|As_DI0qF@g?T``mg`Jd@hvBh6{znkN@Zo|MXA)12YqY2t#WA8a44X
z7%@-9{m9&$N`}eeOo^pJ_#LIl{g(hSDN{`pBFJP+mO^A8CV~XvQ88t7u$8O?VkjlX
zvPnLh;$DR;#^p?`~sDQ(a?yOM7c;d)xia&aSSmZpMh+
z-Q7LCJ-xlX1A_x|b8{BUfxss+X{A)mS4yQ~F8}D^!zWLkeEjjpV8o|SpFDr@^wSqF
zK7IE5>4zVD@ZMXbM11e9Prm)|llRV_ym$7|yR{GBt-brObbgp*8HOmFxyXW4%DH$s
zm#9#1P^gsll~RGje569QW`8;BEmPtfcO~trCY@E;0jWs#0(X$-_KW;}E&)c|W)|lS
z>cqCv;q_E#9jy{FCL`-&XjKlbCeaTWrLaK=>-mrlTqp;0Nk6qpK%WliQ$AhNx2$-V
zMgOwk*NC1u*)uJBW)$DN;$2Mo=cz+7r+61c_pIc(lB9QDcFju8S<)%Gre*iEWTzk%
zCevsc1p-Fb#1gHJq7pB7!EP%qx-h
zz%q5?h0HgRG9aqRcy;=`wne2wia}vnYzPV&8iMxlL8%n@3Jt-9KtRD%<0%UhWP!*FPLN$>P
zl@z}^Xbgx6{$uvys}UxkLsf~07Jb_Ezf~Wq$3lB`0=>?Ki-WgRvnD;hlltl^)`Xk|
z>8edJiJ(JDo&xd^cs#+oIi74fi3EfYP=!L31&QIv;;fF)g`PPq(hY#(7Qv28Po~Z%
zqcaP_C9Nb?>2Rwm3U-enPjHM%KSlHG@x4U00d;qS$*h(d5gH$=TrkycM4<1aG-JJaMH=*lYYjOpn;%}N;b04`tVAViCM8}4c`KG|n)Xn@5@TM8q;zDdu<=F5<1V5}NYDb@ygGqi
z!%`?Jhex^UVYXOO%9Zp~1NB(A36*9BAf8dNJIZbdIVuTN
zpk$RhJ(5nU^662UGFsPC=fFqMVNJfkt7`J;A%A+rpPh(D)mR}Hs1(9~!01r*1q9yx
zr@#2~|MZ{!ymlyJ@DG0fw?T^F#lQHAKR-DXs}uplS4xRr|3`#(*-W5ZjFt*vl2W8x
zrX1IxOzh#${_IZ<3w$Y`0NwubFMbb`fAqu8l9GqQO-j*fA%cR(_zpdM#{O+@BXWQhB^QL%lqGX2pr61WAr2=k`_OoqMFW`bTp}i)2V1S69*vT
znTj&ekmIk9r4+zJ6rJ$clqTD8L`jAeg(~SOGA9tcx@E>l;r@+
zapMsswn!@ZEEcxJ>r9|
z2Uq}z-CbP(#KFO#@$sphojqBW6-CZwvt(t?oh1oxw=PMA*62LkY6zP(BmKl~FB>egx-a}(RZt>XwHJth
z%G^z=A41W(9rVO1%}XSa>=El-X4il~i^prKaf}vUKjA8_LvC7bOX_j+N)@EC#3E;<
z@mjTjmiL-^;CNtzM&Jn+QPWpy+jVNU*NFzNg}KTy%9GMKmiZ)k>FyU@0h92n+08Mv
zN&(Ki%;v~!RQpu*VF*U>IpLjkHBUvGAtU<4BJ!JerZz$~QcYEnd~n5rs?te8FlbL!
zFmj7#Y1CL5wWP5_602MyDQPEDQZ)%h2=&?_T4uS`ajHD?AB9T0jMuy;P^yrE;GR7y
z%em1;qI0FiXUG2pWie!s5|jcm>T~e*NLaRec;(Pr5|z7Krvh}xslj`MJeR#heuB|^
zFC_d1*!$S~1Pa*#4^c%}iso5VHSDvaA2aA2KxX@`Gvsb$6EOy7p#WhycCQ-Hl|
zJJ3BahE_#Qbm$d|0ZUi2XaPS^%wJq(kclcVsmi=FUlhYYVJXRH3W`Npex&Xv>B_O$
zgr`dNM2d8Yk0p?&vgLq6-5u*)rf3RxGIH};inxbzq99884?sW4T^N}f`9{1oZyA>3
z(YP-XA$3IB7ZSuymHHBG!%S3ThfIO%GEx(c3pC`9-mE?nVRTk@*hzO}2ac9VaAXE(
zzz^)%M|k$C+gQPg^C&DLtUz`VJ^V3gkYGDX)UCORj<69dEJJr3mn6J~;2sh}@?;2g
zpe{*e3L9FJfd~-`LOa%U@uQM7i4nbll9POp(^x@|#s?%9Hn{u)BeByBE0-zCY9PWc
z4f<5Z$k(~6^KjGS;h$KSzb@Q^oFOnq|3J`ep?t{HBILh*c)|H4h+`%S+=6ljdF6z9
zWd!;G2uJrSdmpMLU)ZTM)JKD<#vk2je7wXAeC06SFtnjTnEOZFJkHK!DHDy>-0Hk&
z))Mn)%;?L-cV3k9gDS5qTpw?w5!6MxCD~i6rg;6?vT!cArPpQ
z6tk!qF&v^C6$SL~d}@62Wy8=0wP(nEEIZ622)>@?7FU5_eB8!=C+MQf_z0kW-S&dw
ze~pTae8UPpb02>UF#06Uh^y82`#@BP~5@%hdjY-fa}RP)IdY3-{%A2g;=
zpG2Wc8rEuMF9%f{0AMsEJ*u)^S&#ds+@&NxS+6U}6Qmq|CP9gBP7VKJZM?LNDPY0}
z$G0!bcuPnkZ8|k4hZ542Ga_rCdDlqlUotgRdpI}k)qh~174F$xLZXIXM;^q!rj{UZk50Cn3WcSXyS5*Ta^)oc=$gNDyW(se8xixr}{
z*lZWnt`Ll%CKLiC%eBEal46Uf2Az|YJrYFwu)VK
zDVzp22$|KMzVydQ>^HkqJVu2C;8ZsVXxJ1YNJDl+5!6>i3hs|8s)&#tR-*p^OpS8}
zjA=r3`n7_RJ37pO;n}CAZtWY28;CZZ$YlkiPb;AtAQ#C(8o4Z5j(-c=V&5gZK5Ni|#8S*sB4;c`qay^iaezIOfQB!{I0
z4Oji$H6{pcbdKkydnu$kRm1~)mt6f&r^zGglcXfHy=>{~O$V&3D!eQbAnEB2R2)M(
zH?mZ0i104jK>LUYeYv00>$PDm@#)Y8lZ6+HQ8bVXLhPY
z5KM%km`(?Q#h8>9eR9){!1i#DrWzsP^RvI^>kRMBnGBL=ihzdR7u)A3vou{7zywy@
z91Qd@c8#=vB&h}Ef_B+g+C|p8b#lESvB#3_-$mLlVKLj3)Kx7%n?H`gem91OVEg;D4*?_i!T}cWld6Ixe8+W8(*^|BxH~j>H&(nK=NkF
zqE3}cI%PCRR@F?D8l_abK_bB;uhanB9lINE>;<%JANPx#E4?aNMv)!rSC9)C$~hj0
zR`&+rLQRSHO=d~a*p*3y+UjrWECvETU@*-iWi6<9$VC^=)e;e$x`_-0;vPR_03*zI
z+Hn;f1{sZ|wvZl6{2xMcVdi2;)lx=Fq!I2@F+@F*oVe5+R`fyc!l(=+ymnFHN(FC?
z>iw`X#*g-lsf%Z3B_eEj`B5{gT9kEJ_Cz?joI%Btp9sI8HYL6xh83n0g+=UOSnK>l_77L`wDta3q=$a;wEPiil^13;
zMlswS6)<~fAzrfgk79TQhOt1kQNHTj)k_5A47zjSj)|*>u9RYDw@3=il^PiO?$_?K
z|49c-99m$E|C5FPz?ZIeo`5Hux!EhYo{%VzF*D&uvEUmmVZX)%;pbfMl*Iu!(w@UC
z!qU;N?A%Zv$1D1YmG
zeG*sF1>yx}NPc|!Jo%TZLwNm92K=x0tNzR3$8+!g`}R8vE4P7AGp3q08&|x2@OO<~
zhts{6p6F*SZ#!-ljwY9jw}nM{6~O1Fpt-%hy1cxryxiZ^)YxqpD|&<_)3#KZn}?6D
zN;SSZywqp!?&0E0g0R=)?WZb4!0+j>SV7S9ZvX5@yy0v2^ViPT>DK7XpU;;A2R)yM
z=`~1)T%VJ#sWsPB
z|9Gbrb)-7`BFKl;)i2D()DNHUp;ZJL(@)%~v_oYlaVuxDWZl%4kC@E*#sC~C0nFG;
zWz1Iwfre_gxWExeKqLUTvycRNn14q%Fpq;g$bV0lX!PaA>*d}s`$EwQ_lso*5=scO
z(*TG^Ly6tZO&0pj%%m)Xfb;5Vgn)sXL$ER+77FtBmcyK5yW}B%j?EWJV1J}M>|)|>
z^a#<~b>gX_SV?9lAd(V~l<(Y%U{f={vtUW$Njmw^(&@5wuOFjPysJ2|_9ZTK7@a-M
z4;XE=6-nS}Mw#-Ewn}iDurG)vqxZ+ozNmBi43kGCpdcddRD?Mi8q6jHaUlOHe_}9S
zwaZ^(CUB^8Rk{^zH0_mG;ZI9Gz}Y}{F&nBR#9yoVq__-YF+&%H&`2{A9y)5&5li`K
zG1WRtOBvV+0L>rYw-!J>$o4Q(VE0vkibkd`lZr3&n|1XSfSfor8A!@#0SrhW*t4GF)6~FjDYIUj=o~hf*Q2Pwspb4jjZKvo3jnJ`Sul)et47(K74{r9
z!y1FXk7_7xD(y3+i+kG-Gg*(E+z8oZ)*OI7zmiopuwi1_?DtA(2m+Ry{~<$szEjtx
zK{@+RSDB@-5CJMwp3^V9m)b?f`@y%!8QD
zkyrphoa|fdxH-c2O$$)y#a{kO_c1^l6$lu>jP?ovDDDqNN!nkxe1lPs2#Ij91#vH0S5*Td0x~iAB(g)ZYEM?C=7GKXvV2j;WSYP
z-vklMa9P7j(8*FgkPQqZSJn{z1CYciM%0YWoub255&eam0?XQKNFJ{2nCs60pcw$u
zmZ4BcjQmetTa?83ci8yuhDn2_ls5I^R_V4yy)rjVUjB}qL@epvWgaIl8Ic62(ZfAW
zP(VIk*&Ua?%kAxs?){YH`zD8`EWu*W>U_@=LZnr^YCuYCXzR5ktGfVa>UANRE#mS)
z^N*?vHbFVFpI;U)w?oxM1-d{T*@S0aYO$nZlZ^I>nfg)tlzI<01rL
zO&#YvLbcER{oD6_djuSeEnnc74hW!7fRvl07Js8*)Q$VQR@He^qRy0g^4|H#`Hwce
z`X?W~7jyJ&HkqD&WMm58CZui^kdwNk5$DXqLAAp)8dii(ukpCiVW371GtShg7AWzGuHMhUpH
zsyj3CU%XU4Qt%|8@Up7DGHa|URvD21(
z-{HUU%J83BB%wd$l1j+@
zYkEc#p$N_&_)|7RJyN|gSPDH-Z?2f_1%%V@&AkO$P>?W0|e0zw5_!dvIJZ;+C5
z`DhvYJ6}v6QV0-6;p&6s^-iM0E#X#bf;h@dvE1%Z!~SNLxno>N`lQ@?5Xa0>S3J5k
z#!PY&o*BDla0KKbu@MC`&Q8!3vFqMn#F(%|#CX6=s0cJnYPDvJSg$qq3srYecOg}M
zLa9|%56W#OQF`1I*_7sz7{-}$FYc{Po|_jCUVu>00%KS)wa|2>4e{PoT#y9fhbBvM
zyXvI%BB>%7$28@RSPPeXm`~~qdp36f6*U0@0z_0rwVI~XHikf$IMvuxC>ZQZ8ws><
zd7QM=Oi@tzA^pcp5u+WL$oE+1_o*XO4HI3-8B#I2`=4&31p9`_>qGjHUc11N39ZLm
z)9-A3@?OX~&0kH@oHO0RDy+4l%h(~Qfm~i88mGmeO=}aYUomddLZ6g@1PVo+2**lg
zQSVJNaf&!yjyYqRS+MBjv+c-e*?Ca8pw#ZiX^V36HvY9{%y~3lJCmu!
zTtQ$rHgys>JQVAXUO)Fm`?Vjj*_iXQyw^I*#DH(m3lY!Gf@3}boc>yF;3M)&4O)|n
zc+27LuG*pv&?s6JB4b0dHfq&+b#B3JNG;lj8UiTPty0#fltpj>U0bfWjo7LSIyz2W
zDz%)oTxG~c{0vNa#+o$}Vv$ak5W);_&aTRF_rySr=HkeTGZmw#xSea1?|e@|_P%dj
z&*buQ@^c@hcUNdzg&65V<0y4+U;4H;-@88Fer<2xfBHsva0-48#=i?*@o#wFL1nyL
z%=LV3i=F8|Vb)URHYyHKAxW^iH82Z9f-u|(>e%L#$NVvcMI
z5X&MPIU~~qA!_S>P2*glnQ8s#ik)ZcNVu9DuFPV`&)T8Egu&TP8%Y2*ppFJ4EC{Hrxc3UfjNc5gc)5KVZJqd`M#zP7ziwYRn
zzv%qPWnHUeHDrG)*yPvAc*V*^YM~DzZ4iw`7KFg(0SQgAi$|-F2DGFiq@uy@_)$e>
zeCxR!2?s<1My#$RY=!`i#0(K5yZ`Rz$7e0L<#*u7S{{k+@6O%AZc*nH8HvP}@T<%l
zQ+^i#gP;RHlH#|afBlVU#v~Rc0qcWb?*kMNM;;m@yLyD{7zi}skL0lNyh{uC)c+IJVI3M6Tk>HO6F9Gok(EMKbzNvd=w_0cG
zinJ$%1_qL&r&>@Ja{K*ZUsP{bVW{EP8Wz+<#(Z_f(fwMkBCcd$^}H`2J(DDyYi8vg
z``R7U7S%_(ORPWU
zMtrA^g_iV1ZBZ`6134Fi%C}|4E;C+Jk
z8X=l9SZY#yfP_6EOc>`W|+*f`c&jF6X>qS
z@IRj^8LC?OS;>!%<0afwcS`$Kn@924%aKn%(4a6NV-=6a*3Px{?JHX;WB##j-OI<|
zLR)5Ac(U&HSohSXelPE2t7o=v0+&;}U0X5sAmd0)U{Yx=8;34T`xe^ERr_IeK_@Rb
zcReyp7}6kwmG{1J%O1?9t|j{}xMQ7b6r|+eOI96QWh+(OQn5}LU3R^Lnqe`8t2U`~
zBOZ$h>dlK4%tdm%PBzS>mh%Yo3}oz_l?S%7(gWtr>sEW@H1xX7dqJ?m;Zj@TT}mbe
zX1y)qy=g*6gHF%}ae$8p}ZqNMh<}YZZe)-I_5r
zmOt+aLbTFS&6}l;k)>xIa>%f?Wg2a$wIO&Q`W@YKZYp?Sm^HN|JPG;14-qU?fXcci
z$RM0;UcmP?lT4)zHXzbQ*zoPkU>7C#Lu&uEDy1nm<)}n<@e1X0&#`&mgk}z@mwFTR
zur1)Wdl2rAkbf;6kL#)0>|UX0ePp-SOR9$d(|vxv!0XlIN_%gQ+x>DZt;;V;O3GfJ
z`&!ca?>mE^ob{l#ecS8(vR$k9{b}R+kITnUWOBKDF4r*8dhgG#%ih;12mkN>YkU2!
zM7eU>IvvCTaoy-(rplFHS9bh94~D;<$F{eBoM8~Xy=R{Cn;YXtuC7>fyc(L{9sfb%
zklJ5fwfyR}`AJmoU*4BLYdwk&g5R=@0{v)!fsomy8qtq{qYVK`#x2WHD?GQ_yt3`V
zNA_-&I)yD0uyVgJ<{gjEpSJ#@c>~-u$NZ5q41h6cGj)`{s$ooaW-UsyK1E`X1&-P
zL&$b;UDWHU%$2~(M`R`-m7*~#j`qt~&u*GvgQWBt$uab-Zef@PN=ffC1_6^Nm#?rC
zTPh3Qf%3yxu5Ouw+Phr)==(^{PwA%63^qmqN}c*3
zKp=;&!HS+Dw)^d!J@X=WyVs((@j4YBJx^D{T%L;re~o2z8qUP5v8HcvJCeDD_aPMG
zUENnfjv>9LfTTXP7$BnKDIp3ghE_=^!Dsck-u|97oP#77G704^sDoXTBEo!?>V#om
zx1(c|5qpz=Mh3qW+t*
z670fp?(aukn~zW9eD(bmzh@z>0y>KdAi#l0y#P-P4tG1>&S;F~9ZuQ^0D^qGUAEn$
z#{>CAx5pHtik=&U$#Wknrkv;+l<8PJid8^dA)hI0POY0H5qcu2!G$JQNK$-3o9UXG
z&>8Fp#r`9~u^FYNNsfa7fTrBjv+S{8FoaoE-3A}2o{!t^_dth&Uc#vmx!kX^v#=d)
zps$gxfxwR%ju#=){Ls4@i-<$=Z)c;~^NHLrx?3CHC@CPWlsh!hZL2L6L9X6chFwd^
z)L~G39mV^lX-drNz+!~27iNZuWn1pi4#EI-W7d4%xk*xx&<`7%s*6z4k;I$ch
zU0CL6Y{YD`Ic0vbNY0&J`Wv|-eX5KFTQ@MhR3?gt@x()`n*m2Wt}XevY3~3qR<9USB|@H#l5Y(3DmJid-<02gII(kpn?I_weGqc4
zGq-@aX+?eGedgWe^X@qbKzQf3=(!F;cti(|*cEilE7_%G9@I~0wOeXs
zkSa5`rlQTeeQ`SJ{XXf<>Kh%Z7aKOW{go}>WiFnkv{&NB@Fc7a_op%{W4&_y~9
zwvJ=N*4m7$L4a;a~vXBPP19(nlmZoZFBUAz{mN>(9kgK&gK_gx;{?V&21v-
zx6i}sKZ&>=r^DD{hi=acgB@VfKljs-2ctW@ZXXZcl>Xp_cKeWoK8{ZZE-RFEX7G-6
zxN61bJ=+n*=C#{rt^@*pEzdsr1XJ%b`GW6zuiM)$hWpzKJ(P&~0v+G7KdRk?*BAV&
zK3=`;T??K~3tk?Ko{sgMbCnM$^*fHdFW(V0;+i!-bpojWQsI~y(Q#7xP66VSx_00b
zQs7OR&&U5t*Tm24FSaXFuK)xlmNr6w$ih!I)fZ`yoy|HBBy9fovUd08oE|lfz6j3G
zNei;!$rJszg?XBY8*!^khy(Kzdm17yo0Y94=vw0G^N{>M$MyQOrIchPR0#C4EYWQ#O_YpQb@HjOr<+T
z&W@Z3yy%d!YYD8)UuobK}tnN$79!@VUmpfL+wM+))QnFkrz)@#ybpI
z1K|oYmhyIeLo(-WqO0-!kpVFLzr?QEzngZ
zWR+#b2IS+3a>B=%9vM?2K8+$*c#3~pS-1P91q$~&i#6?jjl5Y%?qnDC0Y$nPy~Vp#
zyBTju#%aNULaAC062EOjmC)Y4Ed&|2X)b2)jXyGmJ~HFqMmA8ZP{IUgb?r0AF43A(
z?k*Ibs?X+jjc^-OoKY{NH0g<5jRqTj{$h-4^V+ke<+d45t02B{vG`5oO<+w%m?@
z0rv@ea&?hlu~~xSW1Ys%W__svpV}-307pc_#)Fq!{l<+~tTW?na+VI_r8%6qDGHiB
zO!(E;!uv*#b(iobc@Ms|*jp~xW;q17bQ7vI_CIz~sAgf!3Ndx6uwbR7A*^H6szbJO
zBO>@h{!lU28nnSE>^BO2rK(WrgvZZRYqQYE#WThvYH#t*oaaxUHBK6{-zng!wu<05
z``ZHn5#351a4Gc5BU
zXeJrG_}7j%*A+42|L+!oAYrB|{(sxiFiX*(5_anU)3~YpzwW<5*jH1b6b7r>fPM}s
zF?m3ph+&YT3@8{H5Cjm^&oyEoKPEAf3REB
z;biczv)$Cy`E|hM>^H;xiWo(3$5JR41jHD%jEzT9R{I_8_1
z^LhO$6vPSiyW^QScXG{c*myhVQtW#h?yW!Rauj$HO>R1k2S66OD{;|=ZU4emr@iSf?CYv53A-a%xBuk
z_h!-P;nRD9Z_=0E4LFs#*2LwBVL$Ix0Rji2*S2M?d_ND|ZH#F3B!TbhA+85^13%p;
z@C!gzTE!{k{ORsXq3JmJ;x`KWh;=-*ztKbs~FU5}ty@k>WLJboXD(wS5??c83
zMCSAJZFW~Uxw_`0bqgb5`N7}JLpH3PKb_Thr=Lw9uBV>@JbVsgmE(q
zP9CBl$4v1JP75y+PYd0;0{n!`5S_P~NS&*71%zMtwdwm~L89pS)%p3>+;uL4J{xW!
zIfJ*+jx76L2Xp&Jj+=EyhH+?Wu>D!8B2;Bcu(t;Epv7t|H!9;$`t+dM>MQ~92DK7Y
zX1f-oq&}@A2pBCKw3}tk(*BWNW$3Vaj54j8QciT+o0skR;vRPm0^xeZj+2=}rPkD-
zjVaFj>yM!p41jRShrT4{kD=d$LfWN8
z_$&9?ukEwlYJ_=n8U|Fy0qXC{mlMWuu~$L9JWqHTH4C{_zklftcB|P
zGxaOy=DAxUUM9HP#@5JEPPxwO#z}4<-)D(H`?-%d%fAL184B3xRZBb^{*EGe{LPVd
z%q~?E>R9+^%ScF%uZR19qbQt-Kd&&ahp*^GZt%GMKF&?KC|Nl-g}nrZzuGNliEQ5$
zmU~6YQxvBI+G&a*0=lw{=<94$qG1rB#38)k{z_U-pS2N5!PJIM8m&$<3gkB@Z5mq%
zj$mkUSuEY@;`rS_;Tr3Gz<4n80%XoV(Bs&euVi6O!#0AJbFF$$d2ltX%6ky~WT>;j
zxVwg7c0{p`i&rd@!A=Sah7}FEq-9;YiyTVU%H4)(dTUHp+QOQx4;u12acBi^ATh71
z{U2*>ork{rt!JvEwPd_cx8f9p%>6W}-9N<{ZFaVJEVa~iyqYKyjp7_g<0)pj@ZqXR
zCUvoyD`+zWK&2~E_(a$QjT$)04_G+Lw@msj5By88=qke+H)PHwJoQxs$5|wkYhlS*
zhtG}UPF>}-?mx7&<8?<*xm#O)pa{6bRQKxNvZMG9&QgUXpx(JDrzI`O!#t-Gu5Fp}
zS^r9Olkn7s*8^Q5bobeJ^>1xX>*yfTb<=lyke5fF)0RPB)Hk(41eq&fZo`C6!i4YD
zH`S=(J#2zrqiS}$OL8H-#$2J#Vr_XAW!iw3ahGQMzd}f8)(y%fw`qzFdL*^f6fWH5
z!szslnSApd(dbT6XRQ%uCl1y6IGH@_Q0P&|LiqKfKaz%k2uM_^urjfSl&hGg;AG>*
z*;YoUap#HVeqE?A_aW=dt%xmDO(0E%B%FBwnd49=etPLzky-S{MH^D6{07coZxP5~r=Ia-vgrteZh|m>E4VjTcjvU+
zp5EhO!adf%{G(Zh|5>t>I5xIcqsF2K)~vmpFa>1JzJW9;YmL=6$p%6rFi7TLzo?-?
zmTpVO7LZANMsl%vHJ8{q1~lE$Vg0wVBI}owRPdp!nRM3Po1;3c!|tR~UhpIl=Eh{<
znfVIS)MNjB*x}O&p~u!{m{{VOp36(sc@6)2<}B0qsoWJ6h-%p<{b>{GCcUOz
zAsewR0`~1K1orLw)B8`6!fKlwa6FuFS?&9E19rypBD76VE?ap~GV8Bosw{c~cBI*H
z8%cHn8{+J)n*xOqQ5!4NN$pXm9da>dz0FJeRj|sF!qjqO1f8ZRlpuPYGSz$;9em^v
zWcVuC5gcSGo3fFXE5+7o(TIcQMSS8ezTLV>R5XXyYb`wY9(qMuZh^pEibJ@{;l_>f
z(yq!hQYDb*nI-T<)$#(~C7si$GANI53v7#kf1pJwOBM|0g+D?Zb-VbumXU#JIF^}#
z9IUg)qU%gCe^?AKI$hQFuTC(?RGZPp+>t%tpIGqGO{|@QIFQ~4bgbzNx
zELZ`q=Qe`aU4A+r7u20+0IKI!Q2W=dyj&Wh)dc^azH3}Tc})LZtHwb319!rqsq!VTWWbFM`yboX|jnE>g1-aOhn#r=a~R{
zINd?EbXls{HcIWJlEtu3`Hvf<%g4wT9m@F-cow%ZbAu$i23VyjZ*YbAyO!hBl#y=f
zRz91ocZ&$?zg<`C;XlDIs%d#6vjnIp9dR$8n6#uZ+5>(21B6z7RWruT1Welq_`
z-)lRXl}?5VtbaRTx!Pl~ISlKeyKNdZt*2Pg+_}}7
z9b>L4EPtm&Q(E}^hc>1o_E2%~=MSB>o6`KJ{!(ikJ-iBG@S?Jm54;LV=9}3`SjbQv
zKS^>6tc9tD)6^reixdt7x@xvUiUnZptMwP_`GrSAv@&9zC%MMvZpA^Bv%Pm4`OE=IYz+Yl&3x6n3*0cU;H8b%4<-U(X6M;KlIHF
zZr#vBRjI)$8|iX7AAwzoR63)>?K08%>A_yp-(cV39Qa@48-@!;s-ofFs8JO+{<$Qc
z)e#8aiwUifUNv)#jF~+QF$h4DYS&w8plv{9rcAeM%Oy5;z%|5DKnpZaP59x0#)L(7
z%+s7RUB?`tX=LM7+IKg9HXkdk!s#B~WPEz$rDNs!=nTLmDuzxumlkd4be;7?ip4bv
zW3{yrW3`xVo;z?3W-oWA}To8e1hbGUP~O901Z}
z90)cR+M>e5NI5}PTXg1v#3Xh#zt2`nGL>w7kgDyBebqZS>-lqxPn@z6lk9zZKpu8+9W%gT#l=t-1^d@>d+9+4UPdIOFLk>TLNj!%v=v&%s;Ld+Cy{5lkC*
zWv&&xKg9eHerO?4GyS8CEmRZjPX?SiJGtoozTbH@!3OQ|h}-#>-&x-+x>r#<$%mi*
zK7QXD`3PbU_u>28+aF(Bzm8_?*>Xv&(W;B_4h03#3O~QFMwL}(U35KvlR>M!WcjVxs
zD-(e8mHooz7Eqr)4DWaiO=XpmnfsrPoDH(Hkp4fzY$DNG-2Ji*HR4R}Ewz-2^<`;^
zpsyT*@TiONCE<%sywy6ilsbnssJbp7XMY--B|%s!=(h_ubGXXuy%_(r?tBecIa%Mq
zWfEohlOM4H_52FT)aY9|JBE_Zy3-7G#i+UJ`GPSsKRFJ<2`x2(B@^5mU8ovaWWFQ~
zF!azQaIfBX1TWSt-kNA_{47
z&-wb7;D^VY^wx;(g&lr8*(MTBp^ibG_%DRaDA56p>MmWKT>EX0|pP
z5!ki*KKR7yvu4KIP_#;MREHl^nfT4yi6YDji3zWWZQ8daXL+VDgl`$;dxzpdW;JFCtyPQ;^=NXBw|T~=EtB`^v%kqxL*L4bz@Y%%cqIL%e-j=}hI=7eIX7H;jn@=@)_(eXrI*Q}cSf|#Pr)g3T&*ah
z!5hEZESzu=CbQ9!#@L?qW(*hRu*iC`7#|yQ>!x;oc
zq}Ug$XE=Ny9pVg)xUvF$cdT1|)SUcOu|TJ8`DmjhjH3IW^E?LaxtoOO{xD
z;{aC5^)ZV!_0+_Rdw0GMX@7zwCW&&Q?E@9~y&2326%RWYqEi?D+`cermUn*w#J}rY?lVGRNV~NvK!5O!EfQ9V2Vl{c3)*m#`kuHs-wmL?
zab*epKYIImS1Cgv(6GhP%x|C)2beH)Ii9LH#3TE{TGA8`=5|
zH;47dOahNq1M$J*;%gR8FFFd@Gb1OfH*(^`O;+465*U_9
z7k_^vH5q9;aHsTg`*>-?605+EziOB8QMw5EYvGerKlJRhixsc4TK=KZLndb^zo|nEpO^OL?;t%7bL2h1b3}=rg~|v=7R2p(uQ*+rZOM
z5k6Igyt8RXNN`xcBzhzBc&+fO9sl#neHAo)x}G`K6*-~vFh(sBo4yR)ia@Z
zkulx2qg5|Dgier7PIcs+3oTr4`wqL$z2Fac_x%kD^#6tT9zq7>8c=@j$o~JsdmR6P
z_a=39TsFAU{C2875pno0WDx05z#O!B^}3}m)}~96WDTC=(yVkM?Gq2<7If}+PC%i9
zh=BBR{1%hg&1*hJiy
zoZSPy-baVsccgWu7?InvE(HYaYG2J;LnAhZot<8kVet{v@10&7wlB=vWggzw3Y%Yd
zJ;T4DzOLJ*7F}ygmyG{xTyQ>z(@GMs^ZeV27oW4_z)X7hG9Vi%EY^D*4U#jYjPl8q
zj-xb9l+Soi9q=KJfnTxzXzA#}{>slD@)S4O7>DU?ur%aV$K#1qBa;%3Og=VJ|8RLZ
zf3pw7Ht)f?sCv&fx`>g%fs?4OvjKfGQ}W%G@ke}$&z?!%+Q0J0_y@BL#rx&btksh}
zleT1I9xS8T4o}m(u`zW_imE6=h%0wlZN_ea!M5sejVpt6Y
zWuY)3`djPkcLy)uHe4|+idWnTs>3SApDmv}_2}?XP&8tVz|o-@PMN<0GyT^6X@oWQ
zPrBbz!pGJK|1imr)d}KF=0Al`{Yc%~(1aN7TN9)C+J%5IrUforW4}z9
zg)pW8)7xMJCDbpI?z7xXZzSzvq`h9%)(Vx+IxV4gNQ}am2>XHjWI%VQcW|-b
z@_Fi~Q22T3YaqgAY|;p_^O}eoI}Itw;&~x%Lie@c;d*FiY)(VRXMgD$pSmfRB|GP;
zo|Z()XPuWcNu0Z73#YYcPiNwq^kPe^CtIed7MtRbuTX`GXIiFEmrG)h-9Nm68!nVB
z@CO3NB-|zFoJYP^%nv5q&ulz?w9YH(-v$0cBg{phR_-GZx3u11UaMj
z^jB^hu8k)d#Ys-IS%{w&vU$;;ve4j`Ov5CF0igQyT}6ebTlNaka9lZ#J$?KB%Iew|
z#7J&CdMa7)g-U^s{+ley>x$HZHoGdrq*iK^e!aT
z*KZhO{Kj<@`9eU#4{~}|(v5!PCeuEXuXLI2`X;Zf108t8I8ty%IrTn
zZcGj+*UgKo5oSwJEot)3FH>_4yIN09yV&~1Wkf;L!MnC7;0HMzBL}7MKgxNi7o@l;
zk;iZ`awxdt{=4*&k}Gx&^ACMXOrSaxyst{?K)#oTfcaWyLn>M5S#ORYw2cbn;99Km
zm-B1m?a>D0l=eJ
z3%af2i8bL9+qN~aZQD*JPM+A#gcIAgZQHi(Z{GKQKkuzNb^e_0uI}BaUhC|=cB|12
zvA|RR*7rKs6Zy;4E52NUPpsIO6`3bK^>IPhwWU?U-|Jb+`KGD?^(NNDYek@2Q?mei
zhKP;x36VTz_`*-xDK`wAM@BAd?Kop+qAS)GJ&cSO|kO}s`3hy;2S0c
z#}OL(1T(NK=J_iHv_mo=ixpOF5zjj%__qqJ`hGcN$)!3p>Gl1ZDF{;!o6g
zBKgW9`Gv^t*p$yCTkJKap>JWaD-PkZsKr^Jrp~;j_`^<`$6(sIAq|79WriS!<6!IK
zXjH+(Pzt^tP#L<$#k)DJQvHFl5Vx`4z+&N|2|r+(6&b*(O%P2leTA((lj!x|)d6qufRN~=
zB7fDo_Nd=~+LdlEtu0iyTOy-5ydb1Z@}W@`yBya%762vB+mrZ|MLnG~9?#;FY0}mf
z@=U-G=9}J(GYR?iM*p3$dDOG*F_D6lvAK8C;>oAID?8Y3Y2$H`vbb;a{W5Oz3ZeBe
zzs>*oWOn~zdHeCK`q!&>`U@!=h;*H0`_*sr8vFhEFn(>nm+kwebg=bxb;%&m>HGfG
zS^whjzND+F>iFFM^}5V4ZQtkK?c?pK163Xxx_#X3`@5x82-9pF+}`9%yThE;
zxz)2m;i6M3!9>OzmSXq@Z*lKs2~+z7iMoX}Z_>gM-LG2;PBeK3cs3)yD4gN80#4lF
z#(c#C(p{`&SJy9I-2J;!IfgzayLA97!f*?Pl?A3xWVBCzXOrWSPJo)rm|_CXIU1$m
z^EmuvqQwNWDmg-)<3?s>sgFCcg~1%RxTIZ$a!!yg9OEQ9E8|i)OfZxynC>D78Ma&y
z{C;f0hDNa<438#rG-ymBACjiupprbH=H39+tC@98!)YDg|b?B_U*_
zK(^^=tXMnvd#Ehq{3#eIW)pPy{E+`?W?T+yE#PoKY+O>I&uP7AwHF%e9Ib?fZ7F<|
zvvl5U%)-nh%A6IdlkyD-(>xVB$z+m_*wswoe+IA{)oZ2Dr$Z$rhNsur=KE1s={7$2
zMxr+u-o5_p=U~{*Xbx#yLMMqO>RCQ|f$u)vhyXh-8-
zBdxbc`K=}agb>Iiq$Fl|lr&7CJP-S=ej=fJ=H-Z`nRY#l(RkS-wKvi9F%u2Gj$|Z2
zA{Krjp>`6+gpPXYPadA72tAI=I|0u}$nV96N&%9iKNE&0U8jC=oRO2S2v0=SSE`9SFA>41O%P!YYNG8AT~x
zkfT{bD(6#6S0_UOalBLWiv6E@hCNrBzw3Ic^7pG>3Igg==K`ZAx@_x{1oM+`HS4s0
z7VR3UVblqp)(OlX>t}H^=)6ug9KM!q8b7ZKJT)rDA9WwSjhBP6G4I<4KM~eSzF*%g
zU9~R(P}RF(%fAD>MK;?$Hk;BJ{;F}L*qoB)c*H4oq?1tG*d8Z
zA9x2keufD?;A_VDiC;5;FW^
zwg~8r@GoexZu)`rG$VpWyLmlN2;7I-HO+-HaipVg1yuossbqA}i98TRJ79OUKud4G
z&VRonHkPOA8o%OM5ZL;LUv|8;R1QCM?rtXRv_5l1I5`EfaBFtbyO%u0Fo&5>@|;M{;2DwpZ&!W<{ya)
z4W7zD>l6}iXRzx9-X(gGxhF+(+dpwKhzcZ|y*Ifq5snJS#WzX2?CA+hUV~;Sk!8`)
zRny?oDZ+`L2nWw+VVL>l16l-UYyixIal3DKzSc`2^bhcoH-=ynjng*7cvnLXasU~i
z`XFVhvRTG1zL;pX2EV6WtEo1Lm9Hbd2aYs;B>mRl7lJY;=nLCh$hXsbaXiZa^aeb(
z@W);O0q#a~n^oS*8JSXz({a$pwP&SFO-DD1wQ+%vEiv
zS;#J4#MqBI3FJcXoP%;ua9qXEjl?^&;kX<_Y8()HX~hU(3z+ZrPVDB!_R~DIaU={;
zx1awUsY8M@dnSqJMrf7LD0|kkN0i9DQkcINTFzm!q-3{W(;vJ24{l#$6P6LK@W184|
z@s#32TKX!Z!iT)b^5knRx3Ynx!2jN|NxKyKssH1>41kMYE<{&3+Ad|h?_qhM^h?Jv
z$=In63+9IaG#!vaRp{Ww1D`dOKj9vGeO2V~-X_#`*SDtPDt@G~dSe8k#u=%$*R8{U
zZyz&I_dcA^c-64pw2|A_8#_#lpZvqkx#!tGCd_+4y_veh0bFpyo{|4CdnA-GdP_C5
z_|kwUFs(!TBfNowhrpabwy&6z@Y%O^onXtqdbJuD7B6~)yS=ps9wXEt5^PJBVesjj
zZ`o9$?d{sx+P?3%WPM@#c|ZABlCK~8#^&(OZkR}Xw_@SRrY$g;!qzGqL(=Ti{?2I-
zPUIG#>V5jd7{)Gz*j$sG2;MJJ{!ix{=Ko4_Y5$fhoBQX`ri%Z6(_GB|p}8_OwVm_1
zQU6PG(IUM&ErB`?TOXrgIgvNAtY(g8u9kU_Xf&mP+=22snpuCpH_;owM;Mz^8(*lM
zpR1iKOE;KxUq$M?29$G?9O{Uwx0UTMlZ{vCOfL#_ZOHJdmSz;_kaJPp>iG0FzMVhn
ze=~cLFDiHTwkU$+Rve!dSvD!lmd_*5C%i@2IKt4;D4|P&3zRpi+0$gwY8DeO!|S>?
z5RXbFlgN}iGmcm#7jhDxR`rbWs=kPeQQUx-c1)9*xN8i7PIyzK&IimosLty)WtM+04tB%vqI}L!j0D80$z^{l
zSDQysJST&h47f{zIwK#A&dsP^dNxfMJe`Im!&V#
z*}O8*FfpQYekI235y?7vi@&CU-@C>s$qAs|{Q|Y?RX3ByG2CL53$&K*kaF{=Cw%q$
zr@W9>{*}DDI^qVeZHpt2c#OoUZ4an1)M;gZWG3T!`H?LZKdbt~MEdFCb;42Rd(6%C
zr($NCM=r!Kb_k};MFgrKCej>E=m|{lS_3THfle&&3MTm9u<+AeSOb>g`>9*KX}%_&
zBtQcTUI6Ww;vDI6eFQH}4HhBoBYSQsq--w})+KZQ@2pVt6!s-HK{%^J!#&2{_Hzn%h~SWU6iWzV
z>0?&ev?|h3!+lTvM!-2LS;6~Tt=dE*E%@IbwD10|2jp0|Z7|YS2jsEr`{fqr5*r8s
z!nZfgyD-7fI+mi5wUmHJBlqVOl8Dcu{k77__zh2AS$m;4#lo^9gBErPFriln2E9C)Janj+o4NChLK!l=IBG
zel^f7DVO!Fyb%I?J-Blc=gi4qcyG5N;NQYkfgo?lSk|0j&Pl|%3&9i^M|e#NF&n{D
zc&2Mr{ic`k!Yy2Jt7SW3SZ8=_r)e$*o)iTzjG8NlQ@!<5R@(|uwW~PFXuYgJR&|=$o8$L^XTcU!>c#B5F1vFGm
ze73Db@zwI3LXV`YMNCCyx3`B-%cR_?MUGM`$^5+XdHH<24UdJSVnt6U?7u?67YJ5=
z-C>iBBuif3xE46&@{ce*0TRCjRTi<@+>UTilg}Wk6@nJs2VbU05EfrGperh*Uzg
zWHMU@P(2l&AL3^Q{ye*6=WF@_4`m0hXvTV|{Wi(9<@X0n+rR#Qu|3acc||t2X{HTz
zcl~*9w|`aAr&!90c`_;XLTXDH`2ITGNIF<2pmMvOWgvQM8S^8GJ#{+#=Fb+fNa#Qj
zyK+;T)d+AUuzt$kz1uJTct#pbr?Rbg5^^J}B&bEje#kdfS0f;b-R>pPA_BFH7%v!u
zeuoTXaA+KY%RFXFn)&VLDSR=|;nL(khaI^nh>tbJy2IcSn1ZEcWGU^RgLJX$v%et)
zPgmPO#)!OP_&z#uW_?U62M+g=lx|0TK$Gac29s
zLlEyVLX~;CzE=~G%pe@WL~a#M_L$3N^|~Ic8L4B2w+VGdJ!c9G;+eO5av4Pg{G;dx
z5HWcvbQ>M-J!o4T!{DB8+P
zQVyTTT0(`*nI9$FkW_sytjIo(n*9Y-9WjCEE@@2W;6TKr0qRK`7n8`eEAB8$V2|-%
zt538h*`*g{rAnd}sTlPd$TRgKd$3KN=|&fmb_}`_^^YdewWT<^OV^oDX^e4q11|mq
zs46wRfQ_C`vXHlb@>CIm-Ye=OxC{9|HZGdR*g*ljCIUoo^CZxnTEIL0ovOMryDOn<
zJ9XZ<82SnsPUoJ>LTFA1M;N@O7J+J;?R_)*)WLIXP5Qy*Zi>OD?CjO!PZ^#O^EJoV
zs4e|HQytX;AYIP4a_P5;x_K@VwyL_YN$-3J#RvONGidiIjreGXuLY%?f?uzf+f9yn
zIcUq0F0}qP!TM;$r<)}$02^R4T5Mlr-}Q5Tp6O3l
zp=mOD@uEzt)OGRLfV^|qQSgI!%O3
zSfbf~PMhIf4Jf2O`4iCs$CP*s*W6)QN*NEToL=KD)$08i(!Wh!)Mkc-)o5QVPEXzi
z>NBiyDF~!tfJ~opxVcCjysM>SHonfC<2lcYk%i2g)n-+7QEcGoJ5t&854C5XbgH3y
zj=E;;?yFS662Vx0R1y1^?4$EYl>E+NACL-)GTZ2b>ZF8F+L#gtnTgoDsZjH7r~Dox
z*4-oD@t0@)R!2IeO}SV_RugM|@`L;2lUGP=CkoZHHiu0kz5FjpG1vfCWSh~SU%sSH
ztcPPY80o+Rl}8p>!9frTJA$${PWG`HiW1}#2HIbtX2?WK8K(a1wBTJh*iRXzsnPH~
z(brA=mL@&!H2og+M6fQDj^(ARS?X`P3(jQW@7RFn58G#BEFR5pMyc821GLnc(h-bc>Ur-A#dY=>Yf{Es0N*OV$|9bXby#xyZgY2uR55Z#qA
zu#6JgdF&8NQnitPc`K?N`e~xHH9zBX0hk>>)E+yQW0Zf1%AMu)kdUIAHC16x7~I3e
zR)LqfF`4}f0SRkijl7kRXn`+=`zv7rCc`PBUNtDj=+m5L@@oTN=md^TmI=RBwwBDr
z45EmDwf)Ih59`xbOq2^41qru3PxX%TFnF+u>)aUJ5X|DD1$3hW(z7AN#*0CvVdK|RD-7+#z)
zk$^76>N~;MyFiXN1a%=6NrFxp3@6?(@~Fnyxg46pFDr?Dhx0-N&aV8Fabl@71D#k*
z`!=Jq))14@-+A~G@e!0HsMEcKRg-zCQAOint!a(wl8o!IlR}K2w~296Ii<@Eo$PRp
zeQ)!~g^x!>)OIe!Z8=E@&H;1Lf|fFavguI@dX%ZrjA>~xfVCIz1;$QxBAC?|>{3G<
z8A)N57p_wv(M194WLzqsPhJ{UE26giUkLwC^#Ib&*jx-AJTC-Ht+U5DadwjQ0dyA~
zJWs-QbrxA?Xhue3BC9eB2#ysQ8$P{`(+Hjo3$!zn$BpSq#fT3zf`m-ChXz<)T1c$}
zmvGkqtdEt12fGU~1lifP!x1gPb!ZDmX%+}*u8FUa^jp;+6D0yxaqAghx5?1L=sZG6
zjF8fnx|uX8JtCXxJ_8b4kU+Xhq`=A+M=Ug&LxVW=Hp>e(%&fW8CPM%`bL$)#(tI$V
zBmvZE+nkAf{;OyI12sRYrU*MIKWY;Zf5ZgxPQC>Ag#vmUljW;gzxy~r2}#n`CIA`t##
zq?z4t3X*c{8+c7=(L_ku>^X;*Bg`AweQ2yQB7(N}ef&914PSZ?&3D(5?eOh50aK}S
z|EeA2b&q#?Cq%djDXwiwD|smOB=&`{La4~Cq*u4@N;-<5f>9^hcX1?#iawQ
zlIZJjP<2gMaPDUna>mfAha)*U`dU;eHB79x>$!@3J9i0*H>nVOAMiL?{TT80Y
zRAm2B)It&}X_+NG11ez%K}d0c6*8f7zz7*!3pH?sj!qouh~P{o1B#ZBe~k|V8>l~zr21J^fgbV@-VVHrl99z|n+{mGbVS*>TT(nFi+)zmQb}V;2@?$)}yJtgS
z-Xs+mQz{Z&gb%27ky^z1nO8;3-KvyUVEb=N>@MbIFt2QY{-Q?oLJHXMBElp}Z|4-v
zvYQp9p&Gr8WG+V%cVaqr+aH5!%W{w?>pv#-^M9vyzb44$-{wDjdY^u~e~RnG#h4y$
z-*5l3UFXNw?WfNDw0$@2{@1Czm4P7O{OPO8v&z@^?e$)WW=dbL$usWL$^F|qW9h5d
z#ZQ0L>wBG{9DU{Qfos0W_ns=j((a`|^zq5~ct^!oqgOMT%<;tmCK83qCDb-8(DS4T
z&^4*J;S&%d_=l)uqo}xG0`>#0?I<pKOKZb1X0(>F(sJ)(DN^vxr82}#$-Y!Ops-Q!LeE!(14WWKqV2PA)lyS7Q$hN
z^h7G4!b%fPYUfq_B1Cv-5#}RG3hF~ek^;+J#6N){EJSNSlVa~fRS$UTF~iXx4om=H
z=M%jJqeEW`&p}+{MSmoZkj_O?xdG*RGtP&X0(1I1_Qd+H32v06oK2_zNClu;uLARR
z$kycJ?rUa>hua%0=HbaU>BMe{bNDpNI9Z#5#t;wIP4EeL#BGF!($=$canjOb^yPNX0pQ<7uVnKv%=?9D*ns4;zh8ZTjuM!
zP5Qk8ANT$JxAb%{fkK=cKR1YVM`7u^`HI&sc3YHYyZ+vM<@?@#k-P+2Ho=u+t{L^L
zS%Sg5^ae}m5oRhg__&No7Yg$~e?O2s%zlr>I<%&4kQ`x)9iDhQXvG`|&c8ADLed|A5%)qur{Ba0>=;m$+iz+}ThiZOrFhl2tGI&Vsy
zNMYyqi+GHJJN{Gi-RCyx@_vtMbk
zJ*sE*t6mVGge#WOUThmQw!B+%0qGR4b0rQ*4sl|aWX`8X~B!iqA3)?
zs@hwU8n&l#qimu6tTo9)Na^LjSbMbbSRKuIH2Ec0mL#GjUamU>VGcevjThnSgkX#5
zYM%zZerenayXB7jGiwM@?uTR&?Ew4nHrvy>eL!x7SNd6500w8uOz#PXpPtRFbj9KY
z_yxL(pD+VSN#yP+BmnWbPO4epMRIH@}`aSb(0bCvS_&|>bkz$(gZbT;0ZR>C`w>TRW#7Q}paeSg23
z?6@4_NP~?1UD~Xl(2468kWcb6RotFA4e6_d?%BzzpC~UQ>Bej#6tgvu;PyL!(7>PW
z3cHz4BFNPjVQbLV9j)|k?ML#NUVeSq1l7lQpPu{`pd2l{3sf#55Z&tBe573D&F!=`
zl1}Qr$ukM?wq>)$96RI2Kz*)UHhgq9=d9di*He1h@w^~az3*a`&kzE);F@2c-U%a0
zqRG6OK{@uke3E~ydUKjcr}f_09eNoceH%-!U>IiXtP6%JePy$6o{*RWXZeb&vF*R$
z{x`TMB2L|>fCvKe^w0bA|BBvb{V&|Z(RJQuzxp)05;*yAU{D`kDkjsH)s#?Ch
zGUM3fr*1;EUT)Hn+%oZU{{93>KqZSvNuF}y{v)^SCWs6o^zXTQdq4h^dj*(#B;cEY
zKU(qrldI+4Bn=&2-PsQvoWZB`K*3|5rRN){?``HJ@bayXGaL+thWKhz
zLl?2{!aBCR{+r-X{gjDca9kw)G9T<~0$==8kjDys~p0ku`p{A+`D>`EcQdp1b%#pgxb%Q+1)_ftz;!4T%k9
zjl6PayfR-5TN-nQ`nJB2XIMr49XZdhX>R$KA5C4*wnUlc>>MZ4r#osrwNXixji(fQeXrlpMK_Um`3n<%8M}9q!@rDTJ4fj&
zqw6xD#!=h9yi&pKF>P6$8QWU7NEzQbjmRPi%)r&NLfWDc3g&fD1r8gxrMhIZQ#9*d
z-JQaEm3oK#q~|{`xz`5mXZYO>UXA_pWVee?F-ehu6~?4oROF9
zoa?BX>I0k$SBtE)2u)XC_i7>u+sr3alB$To?nT3}7~!Q%=JIlJX4ZtjTTlQulNKusMW9Nk
zfE^CsW?aO4&}}k=<3U(OL*Y^_y3Hf4Qh7z$M$TCmtr3@ZMU+h)^V3AIa?~RV0kM<)
z1*))LMRP-?5Rb;~kNc}DP`Jf!R%nZ=*p?n
z+{y*jU{O=}jeM(`ZUor198nlz`WTt@1fa`g*+}(TP8_hI
zNYx@_V{c|T%&f|-lz0HY9#o5!KD+G^=oBQWR9T;BqN9oTCZ?2Q|5Ht`(B6DP9bqOf>p`BG?_v0FCDNNc%>muR-;WF3OC
z)SynU7nGOqQuaV8F@H9tedFpJVT?rxs(-(i@NBB__G?B$uvR9N;V4)JVsRm(OlK?@
z`N(cjI;;i_*b*C3XtZL}3fhWO*+<|O@S>uO=+5Ngfm((|eBRV&9utzsFTpQPZOcL_
zgfOqJD#QY}^>e?Tddu-)&;db`jSe_wK5af#Gb_=RNAz)AenG`p{XHc^!6O7GpJ&0Ve)gP
zhPGi9Tf@=mcfwb6RCN+`Ar8Q4F^Ph{O2XVJ%8}dZX2;&7PJB{z;k>LqUz!k&XX$6{
z#Q4!`n)t{B6gQK@(XGbRkdQA94W$qiMUzE7-Fl8H4jOZuRl-O6>6wDL^DHCQy-$#N!L$2zLcgizCuglaX3jddnu2n2W*AddD8{tETc>G;)=YKH!ZU>nh`(_~cZ_Lt^)
zHr-t`!rG;@4pc9uZU{F9MMSRd9X45G+jNNmTef2S`2)6jY6QPXp9`5GK<&Wu6`nR#
zf}IP3_5~j5{0STWG+{a}uh9oe#QFuk6w5Z-Q4D$3{NX2Q1%%~0{Diqa)|wKDl%KoTOYq(1m{&$JL!a`X?ah9tM+v1DEjMDx^
z?b~W|Raj1z|C7O&rM8t`I;c^h%|v?%tiK99TApdy@_Lc1Q@NQ%G+u;CR8u)WNmz@>
zDTRav46);4LjJ=2SK&J)dUc$EN3$KnPuYsjWQ}OBir+ij*TIL*v{yQ*$Sn`${j9ng
z)NotzD*OZWHUC+Swi>`7+rhMcK#MHty5>(t?%#R=&!jc25J%Dm0T4}bJt?RwQegek
z3Y@(%{D9(+?;W*%YS{$QC-<|ApV5vR7th_P
z&F${Rn**;ev#&Sn%hT?9ai*_00$`ia#4r~Ar^b0n%ILg*k&4q
ziyibc`ab`#^DYcK=tpxp<%U|z>k+~@+)`COz{Rf;pz
z5Rr{iXpSO>Trp;;&D6G?FtYrh6v4HG>RQXeyvYmByN#708
z?J}N9htVf${>uCg!aqsicgi@MLyApXzzoVdm*&WNML7`l?EC#^l-s{7STK6_MX7$V
zPs4tmx5iG;NEt64?BxCgiI3zSsl5Vs#~Jfq{8N-bNu~|(4W7RUs&l?xQOl#20{zTB
z-LuNY(3ocH`OgLq_d_Q{KfhSSkN{tSVo2^Ir>=&pC#qO{8j5Vsae3WUv**X+*G6d7
zVu)!v0@loJlt5WEG@{UR@mX$p6uD*t*QHWny|*^C=atVkOgtC)2y+2&7ct;TZ*&LxrUDvLwiOZ()JDVO?AXC-ZLX++A
zV<3T6ah1dJwtJ7Jd+xFspz})xcV~SnGlj-KUEp`a^IF9b9LJzw=3N%&lFd_ft8R7lyZYaJ-qZ6J@Qye&9m*c#~Y
z@PD?I<@VmzpIHUih#weD#$Q98D;hD^@@*q+?DjoG=Ni5|&D0+CGWxsgRI$~E=Gpp!4=WwJ2<5yE#_%yc?47`j3*`#8)IgJO14%-*c_-
z?s;zXuyykBGb%mW06?|HB%Ys%ENiEVOsD=XtCWRz-W?_Xqqc4}uN_M&{o6}w#dc+U
zms@@KLB*@2jp5l!!Ros+N--1{;*VSG`etf3b%Dz?Xa`<^TwdU
zGX>(w5KE|C&RM^K(R&-BYIpEC>SolLYl`s$);E@^Li$Lu?gvQY{B82pNex%p%1`5p
z^q=5c-&EK>h19k*b0klDFE^Zv4mYbyK3YAA3oN9~H(NX*&B8lK_)0TKuP|P&Nhj>|
za^iz6glj;3QML|<(u$ed%t#It$|Z908Q`)
zEP>>Km`O-mo1c#i&C`}oN!Q5Kq&aa1iM>^nh{l>z{dj9XUS&N6VLDa|R{1G+%$t($
zMM8jV*bT9!vWm1G1iwc8m9WfxEDADY(egY1_|KG7l=1L`LZElY?I&^S3r~gwPVatsyr%CARaaD$?hw7>OCR79p`Vxf6z$O}7VNf%8T8q!n0#EdXVLMD@=V`n{?Ut*QM
zaQc)73C0v$ck+Sz$9_NDn@Q#P%}^mo-jFYPf6Q}gST6~7wd;!S_*B#;%;&+ianGK@NT_Rxi8Q!0N2f*&&~;PPujkyOX;aB_qQuV;qOX
zU+5ELjt8ObKs;?OC9ZBi5uaC{DyP@61G3;^O&C1fA@NMc(nu;A?%xfK0=|&*OH6$p
z#4ZSmR~qoN$SNo$41PD1ap)igxT&z7ZB|wGwTH3Lxv{#!IX?4J0^8SV
zeNqh6fPQx({?3`)Q1M|jwijb_1QXrJjYRl6dnh~1KmYDLBc^}Mmq<&969@8JbYjlVq)BVk|ms8^^DlW
zUOl_T7Lwr?OMls;rmZv-0qXHi=5ZZUI)MY*kBC@l9zab8G#n#Z1{wm?}#-G=)1np$H5^DDS
z`pc3@&D@C!77%M4vy%wfPr(4$O^;(gXjx-*dq*|kPaRrLpBZCq*nA_+o9!Q12QV$VCS;9g&GOVF$Ri}`>kj~aU%b&1?ZOH=jDgDB=xAQ;cC2$
z0wIbD<9ekUmX$O_qo)nwhsc=3u8c5v`c-6%@nqETWPHS`)XDq#oOO8ZdT6l()rE|M{Fz!_^vGWH2o1=Qw+kFm|que|I?RW`2z)
zqPvgi^bCJ2^RP62gk8(bSIcMyjAb+fJB_yVENF%rr-poC`j61hp%((nZNoziwD0b$
zB39l|#!M`S={g5cH-1=7#aXeW5GRRhpqD$aLSv=%j7Ta=!%o-Qo%PpbxA
z3u!M|M7?0SWp5L}F>i*H)J|5-eBzGaOPkE8`ZT@fo?oyy7UhJu_r)!
zgls|yu&$ZUEx`8t8Wi2-dHiA%GxTner2w8^Ez-R3XH;eT_
zHQA44n?YSaf?>M&&&SK1?Ki{uf$!Vr=d-aP-eV!b$L;6q;rml|3Y*to8NpyedMWZ-
z3XkW=Zb>--`Mbyu57%$oeF1xzIU*^uQ>I>VgacN{q1~U{N-6Wh0)i-7dH2XNv-^?SL{uqyb)8vEOw)rkCo0hslyn&Jas4;6!e_5zQ@)spsgzOg2YkUh@OeE=~?
z0TQCl+~QEpF8l`;ckpy0lMP(+ZWU9={+L`SdnV-*u(6cH$)hAF7l-W|O00XP1Yojb#iq(Q|y2ywj&FKpzQ
zAEw6M)Tyu5l+;<~K|`x7!aJnMnQO)!_CpqZ4?5znM2LDTDCC)?TRFy92asHePb2EG
zzJfv+SA?sAW1=G1QEQ`WtqP5FOa@d^K6q|Mgdvmu%I2WeXb2@
zAV_!j{f^&Z%n=4k@EifgN8wDw*93@^Q8DkMHO*Hpdi}2!+Rwp!Lp;A_+$Frfkv4_C
zX+rWD`T!Rb+E?)PFe6ee%s8DdjK4Z_E0jUL!reg6)EY0%=(`r{er
zQrT_CvD23t1^{aM46S;eIZ6!ml={Kgeq+pZc8emM^CDsXu`L1{u#YyxH
zRt$!^lIL1yJC3g3?Al?O@m;N<+DiFSmV4nSM`{+HlC{HpUT{4<;Y-_;CiRH$KD?2O
zdxJau!pheHmMbJ=3zkLfkiZstC5gWPRl*9UU&<7wf}4z^D}v8c`_pW>MMTs$a(Nb`
za?ejf^2^K0+9Rt};e!Bo9P*ZZgIt(m+SGSv8QeJe2*pn}ObeT>
z^{MjWP0aJ{oO?f?IT1$L%0_pkseT5CODVuaS
zDBhF*2?7!TT|u@3rfuoKxCem3MJ50iJQmtu2JLU!w(0%RmlSKI$R@Bq1o+Z$i2r(l
z#nJN8Ofj4BzZEF_;5j`pZ#tM2ChsLiIaaZhvMPpjD1n7JHNuCL8J-l#|Ea04!!A!q
zU(XZZ{!eS;e-YeZxw$8R{3o~}CGvk>g<1Y55<$n-dA+Un%h&wMPvJ4wnWwWs0?d29
zah?c9*r<4N^q}DKz&Fu!O^qa+JHZ<@TkhM7AdV0Q7&lSC5MHlwMUU|w0=cs;;InQ^
z(Ty=YU$n6;n}y@WP4#qsXISsomhpA@v$^l|z(wzpKyBSge?wM3a{fX7`s=;ht~+Iz
zq4+qDQ(n;UUqSxt>CjgjH!T6o_Qlg8UNo;L-jw0ZvnW6OY_sD2S`9uGg3BhB<)+V7
zyT(;{YuNjJEWqLZzL{=~(`Oyc({cJp?Ml^D-1kEVS0=!!{SnKleergDyjSZ_JGjJ#
zeN)E0wWtgCYUT0kd>3!kRdebyM`+bjqP_UX^x(H-e-RLg^OF7C*n^s2nj?p|+!S9<
zAYHV6v8|9b^P7?xF$*tJpTh{0N9igy{NOhoT{DT8Z(Qm&>d!OoDSdV%_j$irLimqV
z2#m>^XgQ*W-7QgmEJH+Hsi(7I$NI
z0=N`NgZpQuUUK7?0_;e~$L*Fb`yqe#U#mE5p#)O&{|p|TzQW^Q$?m`;oIAn2-W;1W
zqx^*o)bc6+`qG*wnu^9;89;H7J61O|iTNQ~sW10WC@PIBK}8nAS_vgLRZNx?YsSH6
zrd=33A06R?&N2ubFc7+|pSvp!=y@~bB9;XA<6zCZRtpP+tXw=xteKB!`xRj|D7-wb
zM8~0>rG9M}d$%<~0j+#Bp;**yl2tGQku
zQZqbd!6InRYIoqzDe^!_jttPd`7;iw7DHsl33|*L`O#1|t770;Thlz%mB&>hncI~~
z`bUlDr?mj`nNWuCy%vQlvGoVjpH
z&CTmHdxTV>EQQ09L~zn&`?T^Pu5_dfhR`**>-f@1gNcMl7pnt|N4ACa%M#}pohRz2
z2G1KCcjGv-o
zfg$pxxUb`uE?*;7YTYO`giLSjIOx;MM(gq@_=9C(9eC4IK`Jzt053wH?FN_%STZyL8XnZ4uKwk^9c1Qv8{N1egEm+RJBhZ?%6Jj!Om8{m4#tK%OS6~BV+@Nzr0&>fXra2
zuS3{_dL4TvXh%2qp|?XJ!l1c}AO!Dn2r{n852mlfoHv<8-IeT>t~3dKp-JF$72u3&kn!wVR?(MBy$Y?OfjbLY}B5q>nP6Rl(
zOI4mWKfnvZ3<3BP!fHGpT6|ZPgf6FBm5?qfl-K2zl)@cC<>CL)fGTkSdbGNXzvQVU%t_1@D#rb9&?C
zuuzwF($c?UMYOi*7bA5fat$OMp5jzd;)oA?8fDCLWqHz3VQ$O){?fe^Q4FQXX1uKI
zC<_RuVy~tiD2uf_RUoV1&a8D&BP_^X<6Vu=aJt;u(Me_hLeo(B`;EN8W6n=J|BR9Z
zH+T@G-Ui4LE(u*A>M2U?9snfKthOnPHCwy0spKQW%TUh}fQ!u*huX~7GViKlY`k-C
z>Y7hPLKK5FTH<|8QL`Db-)BU+$RPj7t|4{lL4xm^u)uT-HSIpYBwv$;VZ;8F
zx+M6Hv!wi<%yH4&XL0kdv7YM|OQ3>a-{0C%#D0&mioCc@|RoYH0XQNiBOuz2@a5Rc@F5fZ>~JAGHr-Y=!W)w6pd*e
zye9-J66Ner&rUd4O4F;y)CMy5q#npEm}*IhFetQF03CoP+xo)y?}f+VX%KmI;lncK
zx;tsM0o#?!e-e%(F|RVTtz1+B?#Dp=u`Q9#Dyr8Jl%UVi3Q?A6TgnVxekyfzvoYvk
zB_Cc$iv^lk7E4yczr}|0+KWh?IY}))@FjnTvGI2p4>Sp%1zP7}^zFX+5qJ#ak&ADh
z=B+wC_Dv3>?G?L`{Prx31+Cn~ANtsS{oGifo1~yw)Nk1!%`XouF;HkRAn5a<7IAJ6
z)hRR+z?SN!lxp4YuG%~8h>b5JPkSvHgcz1+_ii+Zt$XtPP@Ci{ICp8
z8|0@q8bfa4$xZ)p_|6}s|DE1=v1HTDAjpkMQDJvY*aq;P9Eco0=_0}i&w>1+w=We$w|+fulhr-Y>4*@$Mf^x!2ioa$GelCdChzCV;A&lg^IVm)2Fq~|Gex%
zgNZYJ>&yPo=k0!}>mzW|+r!H~Yl-belMt8ft=@AbTx!1Y8NL(w3cA!=%l%7EI^X6`
z=Hh_2^LoNUR}7`gz)gvG_{AfO#?qFO--IG`;?vNEyW+28Ru0FbX0Fn>*k`9Gt6(rU
zj_5M&su_u1&PqMln>xFwF<}4){82NnN%qy0y_OBcR3GOhFy=KbQ*>-mFmZDvlUehG
zK@22u$_;iDqCItgH$L$$mcId6B`>;Ic#tgv(PS@-V%sK9<<8S&}_9Ffct_8TJEVgYjQSBU0!{!kkwCF*G>{jV>vV*c0o|5Jyaxky4|Y1|DjclB`=I)O-ZEh
zdSx#D4^&o@2Ld^~FhSkk_&3_qYz(tDx`;A^A_}Ro6rxvOA`!e!9H+OjdyN<^R&XaO
zlBpISxkN<3aBV+L-f?F=N-VZkSmoFS#uEoEIn2!>ISHcaMG%_YZgMX5UZJjeA|mrI
z%3RMgQ(Uw45uzpRE0()XTxB`D?fJ?zB;u
z9T_8|w_vFMPMiM^y|At|G+8KW8%-vZ2UpI(WiETI8(*TRZG&D?fx*okqL%8$P
zx0k+Bo@E;KH^jr}XH!x*N-eB9*Yj;k_uI
zVg1`Hh>+?rw|}sWFoU~Pmm*rNi$ybMMB(0yGz7G%p^5kNf1KgF11X{uMkgdRvoIc#
zz^PS6MR0#wDmzG&gB1|$n_~~CrYnFHFc7Ks8{FATD)!zWjLA(%Z;wFRBTO?Y_#@3`
zVDbvKOINUZCdzuU80D=t}$eo7@!b6l1$#oPKU=S=k^7xpGP~kBmh34swaVH44FX02~bSom(;(kF?)-
zy8nQnCp$E&q0tk-P8Ky=6oESCIR`bKrUqx-nM_u6mVmWYV|}R;%dmFu?BzxMQg~6*N)jFR~l8bzp)#b#-i3`fy={>7h_n6M?1qi*kB&
z*~1wYtC@W){Vv2FjXiCmh&p*b6g7;IvYo{7%RF?(a+kbi36?Ukw<
zGwhFePaiIP_GhEIOivnF?3>>}iv#=dZiGIk3;Ypzvi7uEC`t*0{vz@m-iDCG{QzAF
z8LHx@-BFLy8x!B9J=8Yvmq)z=abaOOH)GI#R|V+2-LSq0t$w)P82hMS@inQ4SAtCk
zt*;kAu5(YviRs?ty0482uv2>EWpBT4x;sBnf&UVP*%rGzBFXc~GIYK=P_Vz**Xcyd&0+cakLT_M)fdGSkterupM!%)r)jvaFRN`p(y#84u&dUdJYE
zZ_e}jYHK%#pW&2@+osmbef-FOsU7d#>FJ1nqcdUQyQ1-K@CV$G2j4R5gasSc!kLcu
z@M+p@0=|KwE&Vic&0r&VgRm@fs%WQ`C;iWWQ4M{n+PITG&SKsDiMr~_9^Uz_`PeT<;B+xzvxWB)bFR_FhncNon3m6k4aYqyp1mJubsEsCLVk~8P1&_`kzD|v=yFd
zTxR38)9b~xyREWj`#Lk*BaS(@fM4ts*;7on`ky3v^>pb$;IFmYlN+rGd!8Pm$_S1<
zf(^cEvmf|E^lcM5C>TsSBrtRHh(}A(fS{
zQ&PDG9rc*?BW}6NrJhEvrb>YV0>UY)(-0H_4W+N_9g@iPOF1uJHu?$$*PbwTOb_)D5VQM}qLEAqOq7*i~)yTQPZ{J1;
z^lzcmCatgsaKcnxBD(stN>K@ik70*EiFdiOZzvVRFZUbJeg}FQ=jxa{U9Cw3$@F>I
zqdx+Ppe6|^ge|`$%yGojX)38#u}+K6L-%8gRdU9hYGgs@8bltcJCGF5<8&qSE08#v
zps1mo*|(C3Z-}Q^u9>HBv=qrKN}gAUR1!?!Q)6b;U6TCr(ERBz9>fb#x|$ETd-@t#
z+AV{BjF#?-
zNIGqVCxq#H^W
zhr}L*^w5a%4M|RIKZ}J#iMhoi5j1BlTc|M19i0=UvK*limt?^O;BS3xb9N!hoQKL5
zU0S|e0L(O|Ai>(%YE?p<1{>!RN>ti+QLJ-;dJahVB%c1#mJIDn1Vy&8?LuiHrd}Dw
z-~!d)rDa7cfpVn^R!*p>`RMXPsmd{oR9#jNgM*qY7_$7iM@6o%?E)2Tie?!_ihNnU
zWpTr)ACW`FX_5FSih|YOhl>kBZ;(e3fS4h(A=>TpK
zOf&afAq(h}@dP-8nKYpK^nG^V<r)vX$2R4Xc5GlifbGsdMS>;!3!
z2t$mlJ}s9e$7bE)xV{od?HzFzp*b{w&4qM_6G>n?S(l+5z58dqCy)?3$Jyi+Dr9X`Zt**4>2y;U>t|ZN7!xtjxaGp
z!LsmN-_QIs0Sr+k|FZx})89%aSVH8L<)2rhRmq4RyyW|8a$Iz96f0W14r7s5v6zDg
zYTsVq-9exn6)kF>iU&3PV)OS^yjIyG<
z5}q6@lybmYY~wB0wajuyf-xc$@PJ!cA=5({^dR>~Jp%?t&rN7Owy8;c8wurPoU>vW
zmej!nbW7J=@2^a!Xwq(k^_Q}$NF8_k7@S@BF`)*Gj#I30(n1^j$|ub7*6nM{>p71P
z?-zMd$pAPrlnnKq$nMop20!0MuTL!Qo^@!(t
zkp&^n4_dPPL7W$|V6ii`V+Z)Z)qz&p*Xn-K^n)+fs(!+3dRn&cPHn4H1@TklFU)84
zj7epHGW=lGKGM+#71L{tWsKOyBDZL(u2}KI;TwJI5f_JBForfDndL+7gP^j-g4G8p
zP}SL&32DE?{K*5ZpDL5Vq~_i^;P6yS?JL5V4^Vu*z(@<&xGb?pyz
z<4j#+TMnWUHBg?;@%;{zshTr@3YNIfhq2l20NX4OJVFV4FWg4j)xg#
zGXv8WxTH3*pFn_z0Xk?K02*axymXsU6So^c8Ox*%O!0R?l@`AmsB1R_59ub4%fRhU
z3}tv*L)5M71Lr1y$v{wtlZJQ=$quT5*gkxd@zynS26W;K*I9O8KRg&YO^D-1pzQbU
zzVzJgaJ>!uHQ}x+sMej)TEnN#D%Acp87atjnaTYH=zZ?Ftvd8H$mw1+E?a->2t1(6
z$l=To1(>y02Pyfq;BfVTXkJTj1h(a^GX1QpuM3hRnn5o%jkNdKJZb>is>V2}u_^uO
zjbgROR|S1|C56?Bo(`~lzL@aa
z{VTgZpi|7&3XYMt7Izeb`TV*i&_E^lkD{
zkNS)?ZhAAKg2y=Qf}(h%f_yKM`vP0)KZe7}T`&x`BA!im6L=50Oc#(jww8~yjxUDT
zALlb8hLC-B|D=(_Y0t1x-DU*1lvBzbmqg+5McWnP(PRzP`bHDcRj>E3i*aiEgJgzy
zo@*#2OQ4<48|>IhT`va;n$yQD!n-^2VHUv@&H`>wU8Ky;g
zz(h_=^64_a(?om&
z>E?r--Cc75AHrum7t=e#brP;zHR$xzqIiM
z^uJ{T6fr}oogx1C(I@zS@96%k&rJW94Zsoi>8)vG+9}7=IS+Q;o9~tcbtGn;s;H=o@Yo>6T)TV
z_&&e6b)6iFJ1d_-9&^{Pm`857G;HW2Jc}5*kOw!MlldwVUH87=Erc&f$j~77=5uSZ
zv}h)o#~#kR>weKkc|KO%w5=ULF^`L}aw)^R?k%UF&Ev{#ZY)9{H>o^$CV1oH;=4}O
z^;y1nH&j$()kJ+QU$AANeIIXhFKuI$ttFOZJ@0zyb)IL+YAA4aEFWHOK%m#ty7!3C
z+gQtovhpUvuDEHMZnZw{T4Dj|*!0z*eFr#l^q!Ed{rJ&nazk@A#0i{2%ETbds?a$Y
zqQoTA#t31H&`jACiN0AvqR*z7)wPMf!#5i)!a`u)jZC@h-2FWPY&H)P%fCf3iAEYc
zzq9yCinwXz4%*iGF5LsXLSHy9rSJ~YDWyw`nD&)IIrlFZ&AMT3NCPbR{5~IW6Vtr7
zUq%O@8gmWu_#OdMqMltwX#xgCsK``S2T(ZEsV7#61nd>k@{SojJRkRszO6QuL@u}lgT4*iHCRSq#DpqYzknU~sj7_(FE>7tzCC)=(ih6>}&
zMpaBZOrW`<$+;*O{)2{BTpmefCE0z&wWy2_3)+W6D>j<*R)J0L0nTbYI=yyZL~kG3
zXx1AnCuGsc(>TQG=&jyelGY=$T!xoX&nR%(fVC7r~IJ0m)Gp;ItapS_k3vtFcr*(vvVtD3^Qp
z{4u^5&W;);4ts5>NG2{`JKN6@Cg(uNUCdlrBz-AeA0)%4nlR~HAOg6(5X8Ej5~et>
zXMc@eyuT0v9%2Ym%)1eao>35rv$xg!6O)G3ae~wkyQdwm#-l-G3
z-=nxceJ;60DBD0W4$?L>wizT}%-d
zxWR?BNAZjMF?K(L)=H3cbw?thriDY;vAJT@aleih%-+d60-IMe0)*yt`b_-AV?)M6f2`<&q+<8M?KFAUYBf(co)^qlh`=D_
z!z(*!#m0iB!s*1u60IP18_Y|nGq4lTHZUr~69GJPGBLxuOw}&JwOu&0pw@1nn$Q}3
z*_I)Rk@W`kEGY&diKc*ha|^>c7|MVS-Fz{rr9YP1Plfcz3ow8m$CjX2bOA|F2dvx6
zl^%A8wYqy!p!g@y2pU#kEsl&3iJ`ct43)5SCWX|$>WIUeHF^;
z%*%_-wBdbex>nx}Jb62=8kOBX{uY42BW}`>QvPDE8GzM$g~`>h5Qt
z`>h|LB#)W18K0a?jZjIBwzbTfYIz)-h;u#JFg5CqHezwb*y7XygCHdgLBAW
zPT~%RLOjrYs`6?ABd82t##w&-*~-vud7i`pd&k)~B{=MCSQOgHoHd=mtvD&0CO2eY
zHsTh+L1gvctV_bp@clgy73dG#B?Q4z6aAh;ctf3VssnXbRBPTmWi2JJw{~F<}&Vm=+y&2r@jZPwN4;f-6V{=f-bn$w^4x=XZluVA#hqRMZxT7OlNeG
zKmt_pY+5ZQaZIYhfA`b1`x2nYAO%hR_9eH{Z!={++e=lMt9Db*sGtS0RD*rPr#uU{
zuU{%`P_tDwcP(#{797rm2?>Ets5S2j&ZsJt?O<`JB@1`$vJXqz(Z{FYPQeRT4h~x?
zs}V?)QZPWX*xTg6`x_G4YSI;*6iefo1c`3JaWj4u#vgK(m`lhE<9biAbvIo7?C02L
z&GHBTv#dtN{vFp~AzBs=ao=$r_Z`J|TDXM`S-
z>uNv8xbO;#HLAUxsKspqv7W6KB886xw-$Gs>F+2?>@sjMNPa~yZPlT+lh@(
zvV~&hT!qg3Eg#i|#l5d-`Sdo(wk1ejdF|Q|L@^=df5K2G@IAcnbo+`IXsI@#4AjrX
zy$`x@iLE_WX6xGTSM^S$=`r?a1mS5=*JMmCvv6>nau3ftPyd*YnI!i+)W%Dh%+C<<
zYlRP{2}`da!xAjI%6%!&tcYNck%Obp%G+GskKrjwd0P+d5q5M><<}tj`g-c{!fx)M
z?J@cpHdMfgrlMnCL(8rDmiPNhHMa`1cZr8`CI1y%+1%bCprwa)UhZ!B_StNC==S+p
ztHpaasn^x##lG{s#KZQh^-D~E-}`wBfB5q$%lpm3rL>ceKC4|$Zp{aYo;=)yVWs`+
z=FIXX34gI`aLe2C%jfC9c5`U|0PynOcZGdx_26pu#_;9l_VVcI3Jw^1kf6vpo10qc
zJ8dplaFpl6`&6g%@%hwdzEE2;eyTq}x3)iu+q$g)SJ+xx-}s91y+)!e4!6|8Q*C>-
zg&0XYy>5{#eR$>2Wck=J45hKbYg1ZJO<2M9IF+?;QYhL>XE?}KwGEYEiA=MeF0nCY
ztj|wY>yQgd9A73EgN{xhgC^2WtgMU5B`0&jA~rbl`T=Di*g=-?O+m|Kl!Zf!lb%A8
zeeEkDcOEo{5v<@3YA%sxds_->zC&)&As3a{QUhNKG1t3HUZ}Kgz%m}iA9>~w$Ho4M
z;<^vRyeDVBH>MxYKY+^aFZWJKXNGyqFwfGsY+uCKIf2a+m{{+dRa!J1hxxW|zN7Yy
z>NC@O^&?r6A$$TI#Tl0~S;P~Pc_m1rKUmDaYnq(-ab%{KUq6-Rk7I$|2%|
zcRBH#8&kdUARniu+s1}Ikfz%NI&D0kZhM=T=ZaeJgXJ6O({tO_S`m~uYA~hGg&jp=
z2=~TXFu^yo6pSr?I!BXva-gbo{J0_CDTYNN0=@X>fQkiDEID^5L}!NZVIbX2`ur$S
zw8s1sFf@qxxcKf-rWn&MHtB8oxDEkBOS~L^&ljl&b0+MEgNs7tdfLLl0KQjN=a``N?v&l#0lLVL{
zhwU6`ha&5{^l{Yfa@=5y>@vWGj##6~ybKKMLIy}mUMGky#)*+UQo_<4f;5UC^Vb>%
zD}*=O;~3KjXxYrh1uJ=1)GzsMEL-f@Zb!L+1P5!eFU;lgWTpn&s<^B3$nMh$t`lr$
zIx1!v)&g6zM~wG=#6%#FN3^rBM$P2R1#AhQJ{VnPI+Hrzu|RKkkGoXg87?)dBXK5*
z*{NkQX$Ou+{!Zb%Xc*S8bQi+xE{7Qg5HFDlV$~49c-GM~rmonr
zOux9;k|9DCF4Uz6c_Gv+_u@?;
zZ1V(wC+#PO2N=Csz_eRqo6R*8jSwJkJ7hm2e|#T=FiYMB9F%}MdoqRo8t_fiAerDr
z;}A@Ln{PJEDd;Slslue$o*eUWIOiYo|AXEi0!wL1FHIxqX-H^D45=?{5NBp#iOmef
zr*FvM&+5PN{5Vp70b!erVD!`TppOC3BPF^5afaZiETSOR43CV=F+1z`R
zYit4+1gyQM@2&sG6|zzyxJ_!2yP*>^@Of32>AkxL#vg0#z~j91ctR6}{pvqR0dL)a
zKhVDdS_$?w#_vjg!8}oX0U~j--8alJj`nf>6eWhn>jU;-LWpG%RE_$71~H7P3)p)N
zpUV`NSiO9h?+Z9SEQTmyRa3ZD5D-E*(FBlUK9mnjY;?m@Ub?gnRtS2+D2bxHzkfWg
zL}buNht&wXSuhlSu=i-Fiz~B3*nG0P%XvFR
zS+FM^MVniZA0zm|c}c+H_Co`*4FCKmn1Ya7)FBY%_zxP0Iwi;S=o+CnXAlcVD=LBH+P&_f4JItJ
zL6V^?wo2FV*TC0}XW&z+p|9O5k+zn8sYwNQpDBEM_NiqnG3BivGEIKfzcF$;-fOoi
z8jJSy#D+?-GVsb2Xe%gPhJS<|zzo4`-QJD+7bt)XLxCI*%uj5SY#}z=65$&@9vq!s
z9qcft^J}WXQxq<s0PKVNdRr?Q3vKR_Fmhr0;6@8fN8B%&_e)xKzR8iaoZ@Jw=
zZorrI-P|)j^YQ$;Y$-7L_q+S%Q(QSo4r}gqHORH8?LhJUb?d{kG5}X`>=u9
z`~5s%=jk#_&+W801E{9NyW?6ZxVwDSP7HXR_cqfo#VL{{1dmwPfDr3
zyp&}Dhj)lrR>Xn(j5_2mE_|==7A0K71%?WpQHrVYFUKj$c~9s*Uu);FiSP?i2!%g{
zbSK2P2g6Q`6$iNEL>7|KNP@|+HBAxys}5WgQAtA=4HXh)s|z*aX(VrBg_9F)d$QAH
zkmCOgI*U4x2};I^!t7VMNGRY=*FMwQX(;o}2V%{Y{|I>_ky)<$flH~u)3JV7A91NP
z{RWAtP|oxBI(Vncds%e)H@As|_H3BVGDZx!;$i3OWq*dSefa#+mkh&ja)NP|9XMXj
zb#!RJI2ts5&pkd!ohE}#rGqB<*~_ty=AB%iYrh@~>e;nJ_T3Y|7&T4vAeOaFJ8c
z*u;W^o9^vJ;x3|k@Z7A^aF_}yhrz2P6R*qt^}{p!-}3qy>uW5mxOO>Ee;)#cFuIXc
zQj6A^GS3T0Ah=NpYv#Vq4mNrO5hSy|31eF9AxgZ&
z2|UqkstL2f?iHKO?Nt)&&kfg*z(*CQVECmX+|H9j*+jaG2qa@e`$3T$@Ehkc^HAfA
zIix?C*c}HdG3^?zv;0qIS9cI|+Bu=jn4=X5XeMy=*M
zWbyndsP5&-!r+iXmH&CV7oS7xa+E<iU_O9V5
z^ogmQ{1^Bj9hUscinsi1IVjT5wbUcmrAh>A+nTc8J;EZ!EpQqPo6w($1bjl#JJ`FoNchpcBd!g8eO&{yEsGfw>!=@p
zA)Ju%Uq8SSPGj-IJK!BzD4aNwF6C@$ZzTWE{2-#C59pspUgN(@%HO=o94W-rK&~nl
zWR7_3u;^%_Kx-SHBm}ci@WgYCvM_LaO7_e&bo4V)y#5@*Px}FBE>8zZPyIel8{osk
z081^k{*4y2&gG&qe^wed;nW7lbgjYr5U9Q_#xaKbliu9owz*%4)Y`ldn$UiIL8z|-
z4VFdguHZb;tUU=HvDQmdKc0;hgzrh~$=H6;_53M|HL@a5uaaecOG@
zqgkhV2<=q;(o9O^JG(t7Ec#%sNGK928;gza-Ddb}5$JnvW8uf^je4Wo#wFJ3sadTt
zbM~ckR7-Kvh^--Xz)v3M*4NPj|JO`hwy309-QGrYe)kM>y1azgWI3z^ij7$&gEr|+
z=_}Pt%iH`_k%ddCghe|8Eu8}F$IG?gs-;b;uhTEQ&qk=Hr{}Vom8!;Y`lc(oyDOTz
zyXdb%`}Q}thWakhD?XpOlT+6*>Ti7J3x4{~XY-{k{LHVr11>$#0hcd(zTi>pg7OuT
zo7yy2NbgR~RM(t0@QE*Hm2x~#rPzJG3PM8#Yqg+DNxEe5}%l|MH12oCp8Jlw$fZu2#_@q*1Rzi6Od76
zPue(MldR``ksrRyOo}$42pC{Lg{Z-8^l2MXfYp^a@|{~qaZ7)|K=f;zcm^^C_Br_k
zn#t`Hvj~WppZewnKW+m;a>$|8`_`s^q;dz=0l_!qd7#(nSoKeul|UqnmJ|mZBupue
zjAj(~eD-UvK9hT=?NRCR7LhOC14!nsAKj5Sf
zeb8}!A({;EqZ_B~C%vTdOt1Iq&}X+WcV?w(rsTiwx#CjjCBM|=J+GG7zj
z>|p9b14yH@tp#{vm?wrWW)N~I^wv=6ULV{ts}MNs80=`1A)v>K9U`kcRJx^t&>00|
zjVj4~KvG;av451d1c`4vGL$I3%t)|&ui(megRr-VRaFG4KSUcIw-sb!#Okqlk_t*I^d6I?{~(Fw9`=@Hbu(AzAC;x
zae^euVubt>Do<$qy6$SjYnM?@GIQ?z;WJ(nhCxpt2k9L)q0J438h{ft`f(#T#VOFF#+CT_&=2l&Hd=b)i)GB<_cw#TM*j5}>>D4W1y3hX=
zNCtb^SI_(VeOZR&|G64sVfeQi%Gb7v-)&y_%q)EeN5@yREfw;o$FOVV9+=R-WMFQ)
zyG%;JUXNt{gSjT{YD@LSE7nLlHk)&?Vtv7K{XD}d)DhRek%}~M>3)UhU-u;c`zd#oAMfkE=xvGM9SxUI9X&{gPks>7{{^cwmY&24&@R>+4(aYFFBdkMpzgNS3J%^EUjz$dQj_^pga)
zMlckMsO?E+Hr%V2Yt`BH@ouMER{Qf9C?5aY&5=IrkNQo`y_?S1g5T|1Z_~o!H555d
z@A79Qi>h)IkbCG`zayDw_uG(gzxf-EuZ})f{10Jpcb*71yjEMpY$dR65K&lwNMXMy
zA->`0;f#wVtRJE_qgVte_>N`@`pNyj&}Nz2+0`i>J(hc}AORTS*z#aOke<
zY}^9c{NN?lKo8~IUyRWJfdO)%ZD!qWY?fYOIPnfB!5%zh^hQ~
zAKfrZMaJucMhw7(w>phwS{P9DGru~p<}4S}1Dr8Ke7_32T5mpQkxDwtN)C2g^pnAL
z>7TMctx?R*MKcM^n5kpaLP3d4^>H~3Fu#n=
zwfy%Ft06a5HNZZNmR_P@I?;x|^P^d7?Q{g5!E;>t|#8ZEkcmeO{!|$(>`-xuw
z00ttfDk?dTj%a0G|NjoBg@bS~Q%9$zgASSMV{!^$DvZr(0oa(UXxTyof>VheW~U9d
zs)!Oo+P_biC6>;Vic_9n^VvtI<%2|-jK`+cgUFcnho_Z;Oqp1caspv!P0UFFR+y{9
z(~Un+PyJzh(wp*mqr2Uv{AJ17)b`+z)=v#dKu-*}{WZ|%3g{ARR@-fv+x)DsDe?58pfOyQV6UC?uR-FR57N>
zBr?>cX-bMYWFWIY<3Z-)bBjp_X9Iugb%j5_&HPd8Z>Y2aEPl>Nx
zA!4jral6uaL1DIZ<;Y+D4Z<`&jC3RcxPS>#=NXOsKbsP;W(;agnXF`U=!|HM7Ztzp
zOMAaZe?MUDXPNw=@dC|T8lG<;QxSsNAfkzd&sC#ky$U7}`aKZTDS>Eq%
zgS>^A&bqnwJ-kPwGReF&Qnw9M?wytSCdA^t4Ei;0O%dHwv6?M41EQj;S|LR$CsZ&V
zK76=mVbqxsrY!E7Wt7s~UO5yzufe+7t|>u-@H+`+?5K!ZIep$~_LX&>X9rB7n$~cj5J2=ZnLRhw
z&yQU((6<0Sb;L7&9^0gz$yT@kwLLcG3~}xycB+c%)x#xNVQ0m%(%QEEr#gu%9yCZO^b>xUh!wzNE{9b#CQlF(0bD={t8e?4X8M|8r
zGzsqi!b}W63R{rfmD=U*WO@<=*o!<7CJ1Cb`%^JTMyMY071u{E@v5k^)zQFrM<81J
z>B9|VQ^zi)^(vcD@t~2NFv}7(c_61x;h0H`rSnwP7tm`+dLvpu*;uKJgt3x`k8WjC
zYLzlLSYt-&h1;2;q!B?FOY;#(=}tRzl6}if^HW1_jGVNo-n)DE5vd
z0U-^HSei7gOa`4ZRxSrBJq*eh~jM>PD+!g8#c+6R?tWt&V^_@N6$!_3f*O#fk|i3tfVJw-oafQqTdPx
z+hKM4&(+>#CP76mn78Fn<-Cc~nZx21zXs_3Rnop@clchdZ^!CgW0H1(Kxh=h74icB
zj;{eiQrd<0%$h5+A+wS=KjQ~EK|ub0TAjPByJ?29_G$PzrtHzo5E3-fVXDFehF|r^
z=3CKGrqyo;LB!|M8r?Xe@n!3*n>rK!DKi1mHs@FN;qQ~gg^Yyt#_2AYZ3dl$=&=UD
zc2wVl2*64qfW!^@`;3?x7)?&RkUybdManOvatPXK4C&5KbobAt_Pxg#`lHuF1})uK
zRM(+XW+Xqv8_a3q9~G{R1L^`)^&M#%qeQDA{Wy!k01<<#h7(jZhi;i5!8HQbI!qC1
zo&@czy=w&Rw0$unLy_j?LBdAN<@09B;e(16pjm`N#J>XAzyBV5GX|2=jw?!igEb$A
zRHYEg)@6`3{fZ{um_1?(g
zvLIpIZ-r=;!`r_VY9biI{C^609itV8AvMW|vKdM8C$O2-->byaO%U&U(raLC;uF}b
ze@Dou+4tb!L)fb~+VaER#saf4z@Qgp3$4?5-Njpr8f^xE$v#8+QrVzsT2aEPI1tFhL?KLxmoa+CAPxzZQF=@v*u<(q{b&)b1NE&y)(9{-wMPD0Xu_TtjNh+o
zy3jF))WyeL-jG6kJljdayLzYIpVHPg9BzvS>#gshMp1dQrtDICwbtnwqk=b@G%ENB`o1s5EofW#Y_$
zIvEZ<+V5AnzNa6C;N<;zJjvabgHO_>Pr>276V84eH3T7BMRwAoV#mN6Q>w+g%-c<#
zEw_42k`l?Fa4!L!NiqrWm~HStPzK~%Q1Q%6lj{RX2h^}+g9izZv&Dct1QeXiA~)v#
z;^OI6OeTP0Zn4$$H_odg`2YC&3aF}<_U}VTr-(F23(_FnDIrLgw19MXihb{-}
zjV*b#(6ziQBy?UVf`L&K5c(^CAdn6>BwW
zJ>1Oh=+b?2E@D$9Kk_VBCdNN(lu~eLA(l<<0-C#?k#xDlw6BiLhvTVmSiUPBj*D8E
zB$DB(xy0k<7`+T?L#Lu
zrba_+LsM)1tfR89AD1)+j~^B>>gnZwiU&qTCG?_XZQ>*!SD6^!A$&pD+TOn41;&{KmSAqY8GCmox
z;K47}N4Hm({vN9{pw;y+2;)2(N`_TdT3w@1;rBTeI>rO)2k9c{^=)#lYtu77xf*8PaJl1L28UozHTUu7H1MWnjh
z!W#ufkCheMm3~9eyp$ZK@1;OtTZyT~rUah5IhrihYt$?d71DkX$zN!FR;SD5up{s1
zSBX09q=ftR8U4E$|nF-xp&c}R0EP^>*3b6uxD*OznL2BJ!Ze-R$(*iu01LA(kIX@%=N{(uvmHc
z;BodfiK9mZ*&z4WhOaTMUYbZb8Ecz5AIgY(TYjv!oBF{y>WJZ(t-EZhz?M=VcNkTK
zy@uQa7d>|$V~Aay=ynOTSz@px-(BuZtLWD|XR?OjA9&o1nSqY$hxS{s>66cS^2=~;
z+#u8QrDWIR49HY}DJExJl@
zE-MgHe77IlhNHGVXnlNZ-{o+OUZ**Z;P5EPiAM2(R~jPOI19uOWlSip9Vy%3au>0x
zq|*W!^BkqK2qU``vC1n6+c%7_DlkYi?)lFrxM?^YZkH9$4hs=Pu`lOq3*(5;IQ8(3
z)Q!tTZf%&Vsj)5c?JkkQ9_?9KIUkMNfA9JHusmSZm5KlK`IR@ed(F?)fdB79&Q$pY
zBM8(WQ1I9Py=lYw*Vlgy^j%05Kl(3*LvhO~&#mG&G3Rr>2qV<8vQalAJ*zB
zN@8w8EE(2294s`oJPg!iek_EEaGJ>*Sz6AYXleeUf*qe+l^hLtH!j*5RgUJJOzWCK
zojd#>t-fu7`oj)snRWfJYHu$c5j&%4ZOeel3(J73%PRQs@__q=AKb1@lqaxf2)4aD
zyL{;F4Uj78j6IcWM#9hXgzE3G_*4ur3)J}
zK#Sd5U0wG#usvAJ0<)ujf79r%N09@&aYzTZt(^N(b?y*}&54vgzx>{U4`!fdZc9fN)upfEwv_tOh
z0KJhWZ1_|10NBayDk`T6Lko&h|C#3*mf3iKo(LV2uwZ#RR)fl{f!W2`(9|#NTfV@Q
zQ8rQkrkqAme@{p!a+k8z?sTlSW!t7R2|fA*+Q&5us96A^h9>prx@0A?R0kT8h8x@uP-0&
zZI}B{dd#Q_Mb27oFT38XHlD5TG$JM9XK&b*uR+hzw^8A|S$s`gCX$u@AF{>hvg_Rz
zM)l?2`<{o1IeqNsjGBSY!m9lWyJ<}6KXs~iA^Sf}xP3#(k@ybv);C4&;l_gZ=UycL
zhq21DB`-!?&ESM3b#C4!HfLMy(uT!7)u%gAVqJ)<{cFT|d<`#R
zOQRg8ESAcBmI_;^@6|BOErg4+xfegkXr-7%e-ulC9)%pa+}2#+fpO>}Z8jxWv!J5j
zI7%^;@=#2a!RvN;1vho;LV8MD!@2yZF9?(H;Ro7GZN8n<*2=9ua%RnB$le?JsRukY
zwv4JvauM>vG6
zc=NJ|Qx9_r$J#Dmum1pt<@n=}=9k(7NhBg>w08x$hOJr}&dS@XNC}V<&QV)|`EuY3
z`MsVFlr;Heb*)Hc&AaohHnFc|G;uO93E5m(bLkGY6WAId0UtG-9;Lj5?@CG$k$xSA
zgxDLrU6J%)<8jOVggIjHc3DypiOYft*uk!#$bN(5+n4bs8||HZPUvPGCbq%b-;!oT
z&2G67nDbx9e}-7F@p$BhV6tL=+mymPRHo8O8zk&_5#W~GcUbpOCyC|JM2U*DK^z&q
zDyhD+TTXFl4ErOGVuvf!#ClIv%x7b|gLbk%L(!;yhl~sk$&aVJA`iY~-%*>A{$LWr
zVBPrg$l&SvM5si>wS3!CAvJkGf_nDfo!y&?Or-)>8C6Q#9`cZVdSyipQ7
z%~sZL67hYoi-dYFA7$KIh61tolV4)tp@qaHgy}eg_^R3n&%>_
zTbi+gT74+wsvmV$-i1T9XDwU<4MMaU+FV)Cr?h!yApFqL9}o%^9@{CqA^y+Xzn>B(
zFep=)8GYO`$kt;e4~(GmmPo;&P^2Z4?$ui4b(1QsVo~=Soo(j&DBYjvQHU+II!r3x
zGfnZbm|%@nLC;@!4TrFYZr!OEUVUo-wIM_*foRS?F7oS)MUOozRUE!$$E_cNiQQxy3cRhHGXhm
zd@SZY9cfQKr{z!3j48YNY!P#K=$?&+ZjqKji9lOj#ptfw#~0a5?rkUtJP&?UyH(|C
z&?=YB2x{W@jfXPhEwQMZt`#tc6KMxTF=x(PtWfBGkxfpT*VcfcAgdBe_wnY0I?Eh%
za@x=g>Fho$rNw??2*ZD3Xp6*8NH(ys$K@#-->8v2;AJ1_mUpat4oZ9Xwl*1!Gu@D-WaUC9gyUM4f&gc7Ei(Qa&S$TCvbqGezMWNaA0V=juKXq_eDLEpMKE*e9H>s@c@+6i
zCS{*pN9XL~+jsCLdJVknR$96*x>uxHIA}T+9JbtH#kWZw!Kg7_^1e-jjL((Gk7CSL
zAZ#qEB!)SA-OfDjhacWT2EiN-52sse=AY(qF*~HEkVjL9JRxm3ex8SlE`!Tc);Ryg
zPLYOdJ4;9122WB04`2U=bQ))Oh&$PQsHB68)RCOPbd69#x@Wpw_7W6B7e2G2++k<&
zFgjqg1s{dcSkV_!3J#~BV|LGRXj^lKgci3>Fa#FeL*Av)>xDv>^1
zVP!K3U&u_I9-koUkmQ~pqtf^jdx42Q&05trBLzXG1!H{a#ZPD&8lJmaOQyYAObFj4
zj;5KQEsL>r)wEv!CJX3zTd2az&on&bU66==0zyi`9}TM++lq$%rSCkQuwU2|YaZd0
zYMLd@ppdG1ZFqrRO7PgO0e5%Zg_=kimDlJsh47a}eEJD+VOA0cD$wfCDFdjzlta6=rJO5N;me<)|#vQ|A+9}l?tY!H@0gUGUO5(>i5ovv*
z@kw`Ws^Nw<2Ux^6SBb-aT}qaG{YaM)sYSnX)UMrB!-pT6J+=-gVR(en@AC~xUz`Ca
z%97ZAGp0o$N+V->oV(;#+bmnn3C
z71DIm9wZCB8drDO{dq*P7pM2Vp!;78H^u-v8{ze{izN-yFttZX`!qru?ULabG+bfh
z^C!1TuGfY?&CD3fxP
z{1r|m9V0swzWV|sLHi5|4TBqN%i{po{5clJQ4FE@li>~?9U2d-#M@5=sy(6Ko^q5r
zEV=Ghi{O)_3y=1Zgnny(s*i_FY37tHi;YQ>kNu*}v_#)WzJNf0Y^nFVoH`yh(fOz~
z@@B7))_VqLZ^Icn@3viK3Ow52{&r(o9@}{vTU(3aehb@ytMJWlHeQJNWEZMMi6vb>CiZjs>$Em(oGGj
z1so%Xq=~LGvPs>>3yFLp|7sJd5R?QR74sNm8ztXDV>T)J!hB*YRKvBHWE!Crrexru
zAD!f-vqx1CETK;oNsbwmj4HDKm0&nG8SG3umq&I)@!S=yv&sB`5;5#ljLXxk_v>8b
zc_}iqP^66+`n=itz*I`}y)57V3Xm~{cJJXImCVaeAnwgSPjVZWZT
zy$IiUXv5^SFP%r>JTi|I5i><8u8#L|p~Pb6i?>RLSg-NF&(nBzVVGUlH6z_Dd$G4%
zWg5$UZsPUG|aA|1X;ofHa(3D6V|4_us61YfF{dX{*@K
zRO>PENB-ZVgOXZ*z>86)`$A7EmH+25u~^pa>$op|HZUV|@8G3%yUwV;Nj00&Z%N;4h^qY_)`i*?y+~7D!wIosez9COVha
z)&uP<2|n@FQUPMZHdl(nf35jIV9r9_##R$VcGH}mxnHTmvk<)dN5-2YSDy#L(U|`>
zQ32oQyfz#WjA-<&NV@Yb&hBv$gJM+k6ciipIFFXOJYB7Kr^7wO^R|zFiqb0Zz)D+u
zp4(4tZK5Rn$X7QjlWjHIljMeon?zOotf=`)vrwZX8?wb8AI^z`P~*!*+Ox)<>(yY26E7#@~cu(r}MDazp;NqsPL3m+9;5E%j9-(W=Dr=G~an
zvm{2Bat#{pa*eZ6UK_E0>pUz`wyd}G1;wcl@3Z@t^W9>Qsu!WhAG{%u5l|B=mlNQA
z97U@*^UZ1FGY(P42wFKo2SyH4IKzgtV{|Z+0T;r^;4Gs{#NgtIYj0m2x*;AF0L#kT
zDg|e(mB<*AwvKL2kXC-%82<%eAc6+9Zc(fFHR@h6n)K3?i4Iyi62$snNgI?>Xfpfj
z$B)H^>?HDzRU%iNX5U@DT9d~vC4K9`FsNtc!9e^!0cv9LbCzZ{8J=i_D7^*|g*PyK
z*Wj8M5d~l87d~c@8b>A{C)J^O0#>@8KPC{iKa-GsBH122+4t4=d#!@vD?Y_%3ShR7
z78#`RM!Ls%sd+S>G4Gl6Ln#@lcDFsUU4OXh&AH^z&j=
zUZ4kKnP4g&g
zeT4G0`=>I}@ApMWWrQe6szSm0s@ug{I6g^UhE-T5vgWVL;~uR1kgw#*C_ULGOQKys
z^Xzq(wR<7Y&NmUmobgdP(kqcY%uccEdmSl;oOvYJ!2dgw`11JBG){7vqXxCJ!=MH~
zja%!WJ9eGWrWt6sV7mAF&k_29Mh_zzncgCtSFr*fM8_UhPzpU4S@nMRu&#P)uEpF<
zJet(=j|4WaKYTtcau@L`?SGh<`W2Z1YdcT5+)42j*fBR#9%HmPvUj+dpZI6UoRJp!
z=HQ3zl@t`UmeggH8=GewrPA)h*DPCDCgSX27)S<2%SD7+Jub{1EngSD8wuAEQ2ZDg
z01H`BySMG=J$20y2xD=2#I)vip^u0l%^~zAXt$P6trwM7yub}ST?g$;^#5Gj>_g-S
z!uLgx77TnXPW!L~tn&Iav2y;BLvqDeF1Yx1o=P0~EJZJ&s-tpEvL(AxWOM$&H;jhP
z#P`uhPDA{oDR5i&__q3c?J`l{w?AP~=;rZYD4`Gnt*>|}PmzD}R6BWT_~kYDl{a%r
z^8$2~=#9pN7kpQ&lE~ydZgBM-DGmK)Nu5zCEBD}zzieo2G#RQu#*p}Nex=1zGIGY7
zRr%gXsvy!dwKXbm*nFlqLd`-rzgKYEhwv)V{MWI5FJ$St_}m-juL01OEin*bj3Q6d
z4l6XpuGQ9DaTfWR#gFbvL(_9gou!iT{*?s5XN>jqS5gnkPS>tU-P_rvq~&-5e^!Xn
z6t}B&D!GooFs6JesX61+rXeKdPQ|9HzVuTFM6D6B(uWiH4c|ZSk(%ys^z)@uap^Ux
zAP`M)ha74o%W~0lwrh1e3eARk9X|aNu?f)kA+Zn*W*4?{wud2M&p}ehGbuS++`ngg
zt|>c|7Cj$jBTEO+j+CB#F7iB7fQt%S9~Kv^_kG0(l)Y@jHUWr+=9njpM_&Jdw~#EX3&7
zDiUk7wg?xLDC^Y^UK`{b<2MBQRDpx6yP3=^dY8V7`!n}e(h4&H0~!=RK}I6BKYRlU
z^GSt8=lW1TU^_u(c+$kU8|RuU!9};?YK(k>o-aM;!*1Poo-|bw>jEyAU*n(S7F=N4JI>C_?>Ij|Kd?{+ghda(%<$
zcFv%ExhJ50vxDJQ=_p%^J5&Q>h3{-PTW7JBpE(cM!XZRZC}KhM$6dwMFTbQ360=@z
zomK$#9GpHhH9|K{wxJIk6mEOptBqLsax>cbNzR4}JM~!-C=V~c-W+|YFp*x|r@J2k
zprHq!A&F3zGV=r-48vpbZZo+!_rL}yon{;3`K$GN}
z2A92uaZG{{=g{|!rfh{d&hqSqxh7H4N6sqi3KvI}MfQB`9rDTXpl9M{^y2xaQ-tx
z!rZE(C9TU|Z^X&R6f33SdWyow5ogH#WMWR5NxAGtOIgSAXULz?{KHF`^MJ4T|GA(p
zG%p@3ZtV6`6G146A;K)Td0;LP(NXq7yZUmjhE$f9x*rR`~|3{+Y06
zub($z$$=?rdu|%{idMu2^#y-D0H#bxIiu>hw&oX<)s@(d
z?52r-jp5MMnAAh3xjRWJ@Pc{ROp7p&{fGeLXe*lBg3ZFa4C4pU6?%v#6yeaPi<8?z
ztHO=a$M4-^Gyj22CBeQp!X;-(6{-A){C0`F$`MbQqz<
z%`z2bMVv+4wA)_C^*2>~hBEd9g=rpAq+pDMIrQU!$cNelzivp8qHzj3CMSxl(bdR!
z@?|2rZKx^rwT7&dRs&rVUbbM6x*D<4WQd4A)8?t9?=`afR1Li>_4N#{eS}JWXC*2M
znJZIh$zzoUKY8VLf^+$5`X&+8iWh#%VR{`Ad<~Dx6c3-s=%V=_uKflcpYKs@qCBcr
z(hP6k&E0wT*lZ=1!z2~UAg(k{4<`7g#otKgoz(ka(?qo)GZo>qf-vp&GOhP%xDj&E
zr-xdueOwyD43tSfxcNgde)i^5J;A8bewb_rsXyF&mxW*5Gk0XdB4XNMDZRNuon$ZyebMN4OLjMqpQ>WW})(aWkB-`8;)fS0t)BgAj>Cz^5Ve(>Y!}_Q@Ve
z5Us1=yF$zDgf!V4v`MY7np63g!^ei_h=PwySp3u`50}UBG0e6I(nH5Wy+V6*u6qlY
zg-z1tIFdzctoZ#>!=3~4vR!Fgu=bQp(%U9TPmQZFB`KX!i-qi(%yfJ(FV<2NF|7?l
z-(XJeDjT3BG|@I_gw+J*9OXXv{y}o71Q*Yu0CROKKA>|F@&waB+%7frko5#WA
z>=f-s))tZJU=2r>Xs%UrP--`GRFR5xnm^b22aHugN?>KZC0!foe;
z%iXyvIICOF`LQiA>aN}&o$6(TPDYh@cY9vHDcb5a4owA!En7+J9$hOCD`t;;3S|Ab
z`Ha#7Nb{p+7M}3%cM*p(%P`v`B!~D4ksGqJvt{vJZ0t1NOu-!6=l$B69(VK;)ty;;
z!0oF21a=!#RCeb33_%<4wgBjm0y(VZ9j&+Lf{GgKX8Y<)>}IDbJ!R2|a$2lP50Thz
zpNcnD`&H5Us@7Kcq&Z#sT;<!8NIE;e%~a20^pghFVSt0f5f}PK3OEm~
zo0`qE*mzKRG&=Pb*}wE1dt}=bZ>Ze3
z^Ldd;kI#!+Wd>?7Gv<&6l_*+_^5$z(7E^4I`LX7e7HrL8^vd+mq_rH~3tW|M^KC%e)2Y{G$=qI77Y`$1g3P3i;aX7gSJn
zy+@AUyB*diCERY?Vm1CahfhxuQv3Fo*TB%h)P}z$fxQZ{GIk^P9Wh?y&cU~xi)9B@
zv)DQh;Xfc%;OL%4Hz`M(a36cUm#gWIw)r=C5_Ytvm8$ZKe_6@MbGJn}G|QugZV3`S
zZyRT~Yprarlq;jS?7iuqyvBDZ&SW&0^BorQn)xu}^#P%Ne*IaYpGh`FL)GQyJO_H!
znZ8SC%HDFdpZ~@ehn=b5CPWXmZ~D4(d;QfGEpM&G>~jYW{mD=8_JfQoEO&ZlZC2eL
zu)%CkF3zS%ux4TYXUHA7gwUp6d$-=1(`&*
z7W|~kOOu;J@eYg)Q)XDEZ&UFhF3~#K;n#K1m^nj(rC>H+!?xCnEM(!h#_NYoKQGKL
z+JZcc4?*8fwi)My#vblE=JX3~j%&#T3HkeDEZ-c_rT&nc-dqhE`Sa5{)Uj>W&co+q
ztREKOzB5o(*Uq0t#`h#$*dBxTI*tj$FH{R@3=e@tI8WAyoO*bfky1MfBv&%K8F^Bw
zo6n9jittrf5ld_pWsVHl**Mvq%yFj*!DBPf=lurj(#zJv2UQ3cSl>DqtWS?}R1kB7
zUD0zO?~w){!End=yts9A*lFy!g^VY?Z?3Kxm9#(g^;;kG#qRC5=m=B6iS9lQ2ON|9
zSD^+y)qG=`{u2cH^G5*O^R#8RGk;@c!fs_}VrkCF=4fvj@k&_^8-w&uA8h#-(rO?O
z<|zn-@Er{WxD%h5;0OFecYLAi0s^to{`o`jED&=Cfu4Zmr6n{xGj`_}-Ddln`Ibnk
z=7x$8t+bzHJ~PxS>AYpGRtrkPV9_=%KpY}OuI!wkucFb!D|u(88R!sw!j-Oi8U{jm
z_$1qswQ~23A`J&9taFL);CFK+!7Te&>1yJ{ty`ShOn^mEm6`(hsJWbRQojgzi}~*&
z-iUnNsPq0(MNMHcabf|($2&nyP=!hJ?9H_wc$V<*W*|@wCL&b-=~(H*B{4-N3inoz
z3;bO%qFvOx7CO=5@WJTAZrXT~uwOL3{
zPn@XFQgUc)FaaJ{`MY@2jEgyYX|*XcY1$MI!V}dh;GeUU%Ixed|84;S1y;6AYT^wZd(RLNt9lX5}IPCxF)JAmCOmajA=BcLcYG&g%WR*
zs@)Fl^k75x3--;uigA)4*s{>fM<_oIMJ7Xb69h|MVWqSSeBk&VMO`cAK-^+YoeG+7i_?wWx|2ClAc5
zVLF`4PYkQn735-XA%H}8!FFC#30rF@y!UjN7$L}?cbTKWHC`ydmN}H+R;cnIT_fv0z8^pT-u~aH|W=u$m(GuY`eJy`fNd={vB4DVlRAW&r
z`a8;vNNb+~`gu{}=+5`khOiFcjk&)|)O&Gw=bG-9J=9G_^l@;)*2PPE=`76x4EV1e
zj2n?>H~y+Bg(+metp4r*0vYEcU!$@Cmgc%RdpzIDM0mufS|iGQY*a4r4L%M|{h4EW
zkD4>iTWGU~
zDc)Rd#Q)HK5kS9!gv&uw5LPYnl{3fi!3EmPWmCTxBG
zc5zStJOKuy0g4l+cI^V5H3>sMyPJLIWAC*b93zoW3x$d8``$vk)gE42nfu;=1OB^o
zHsEhk;RXR9ifN2l^Pa{VM*==n?h7BV_RoniE1Kj3V(hEg1!+(>kxzyWZwY)7ET?2j
zrrYgq`X=^=uG*tF?rHySo+|P+VBsGy&gfe^I(}Cr9l9j_hjsM+{)flq-V_9n&l^kv
z-mVp9DaG5IC~7eW3F@Vl1cK`-Y>j*f*si?I1h}>Nc9NH2=Jzb*A~?wxaN^uA
z@A;fn-f!XoS(>N?wf?9Qu&_#n0yxlR|MH+xGfR_x7-}+n(>VxJS1D{v176wuyY%l&
zjW-C7l>!#vhHCO(@r2c7GTF`EOdFz@tGo0|(z#
zfI$(1x9Nv9SxRygQ8DL22VUmEDRV`MmFfy9M=mM2{;(&8az|r5*!DZTS1N!Q|0z0R
zJK^zc%PA*?t=Z7oefU&@)t6;E9eH5MPXlV!b8Zb3O6q520CDkM^$C|579|!QdCx8~
z*tabL7VZiryQf9{Z}Wp-Xl^M_E@7dwl^Q8xf4mCWLQK+{u4ebVrHJ-U2lD}7skmi_
zjUNH?f*5I$@XsGIBbm7xsT5ZIbL~-vcAn`fsCert_%vcvo$lr3SxQ6xiGjCOsuCTF
zMrsQ162{5Z%I@2(D!cXy#>qO!ek^C#yS3dl-RDzU|78=1LzJv+oJ#W-oLna|srq^k
z)R51Of6i95nw-GcUYMxh2{$!(M%??=DPGOHF6Lquu>-KPtxCRoo-1lZg=}si0ij{)
zmw02@7jLc#HHEe3xPw%EJ5LO8lMemS_l-PsLpmZ-HJmamH3cZCcx$j}U0Qd5!%hBM
z%<8{mKu63SwtxQIAtld!>n>CsrkfG-Qbs5t&M
z+#Ec+Oj3o~Vt&`6GoP1mGk|-kr$#K$ZVCVFjd#4-^~+gdg%JO{M#P_9KDb6@9b;bJ
z3<5?0@XbhNV-Kyy=3PJzjMw$a5d&}%K2N;kX*J**?z{&Gv|1!7mJgUs3R3}l4EY^l
z4huwR)YK>1J364KUo%KhRRh1xcA>Jc3INooD;NQe?5Li^gx23B)?KA)Ku6q)Q56}Cb8c&3ViS%o|Fs1n>1P$?kYf?{OG6f^uWue
zVkJ1yeV9U97cU+l@+o=z7Al^ukQ4A4`4`;O9R02{6(sD@06-xRkRUk88i0>r
zDrli_s1o{zT*nxYpq5Cs6#$w+8rkzsf*C9Z+@n(v{op#k_BsXO`3%^bi!h3^h`RE;
zTDheie%FXYA-#OuD5EfOA9dXEqJ}lyLX}E-26RQeDA;47Lphz>#6;r-PWkJfA{!
zKtQC&wPk|(-+cg_F(-?^nH`yPuBx!bU*L*YCDVAsY_hLN4VzB_T!9JA0R?)+q}7;mG>bz2M;22Hwx_x-b{Z}CV5{N8RB9>04N(%
zR}d>o+?Q)#lmiUuKDn=zHhTl301gJg1Wm!Id+!ZQ>`#XC4^&*ABPk|Sg1o%*-Ia9e
z+Cg>(WfIW#J2K-Rfnk6}vjf`swBS@xVaxuFofB7}-CYxq9uV1VgwO!cP?V?)2tsax
zK`ccc9WbrCMmf|${+<8^1iSZ+y4MOnu2=1xbv2XS8zZz
z?>Bj`O^TidBx-gFz!6PUU_PRJg_1
ziUqJ);j+;Bmv@~y0XG|l1K_eWwQHX0hFjJG*FwE}GQ&y`7jp#+aW-)R);V(`THtDE
z`0joPU_peA#|xJ!t0`oo&ScR;jQV!en(p}tUX>gwL7s7DXzbTC)LTF#?w;v)E&?=r
zkYt9HSt>h`;Q&xjQwUhs)da#TkfYp1{Z3{4%`kg|m}-&5!bE@eGE88)T!DLc4FWUc
zcADKk=hFU_jzSl|&7QCoxaz4Cn(5vbx~x1fm1N7Q2H)aJH3ddMQbK`t_o!5y3{pSH
zI%Fs~wan7AB)tdRnt=f0Y8%OX%FaA>UGzsI`P1)k5@@whQmi@(NPv0AN@*+ZMT~hs
z_Bd<0Zq;1v3)RAY?CXOWQmKo}mz~lrigQvNjq>
z2>$YlRs5Y{~bo_Y+h@w%=QDU
z4$$?rv%;>1c_5J-QcO*;O90$((FHlA;8sngkcbwdd^ba#7DfPX#KT)n;^4Xe*=lhK
zOSS`8ubaE#f$Cz#2dE*>N4q=T2Y&HBgQUx7!iETYZkb9`0|x6#f!&WUQbUhZ1;eAs
z*LB@E^7ihxztYYT>%PsVjap1j!_b6FH`WlPvu$j#~R*utx~
z9nT_{;T_uKzIdT6N^tD1l5JcNEnyclKLoskEhe`$kz9N4;p|JUveg2wA4t3?QV2KMZVn6o?eKteYC>Ssx7M82hAR
zaVzKZJLBN-J6MX=v%j={v%e4t3X0Mhy@DJCFU(E5`L#r>M~|IX2DG#DPQgxxuAspu
z=}9tyaL;9P&B_3ulPA9eh!Eh%rO3CrnP`j3&yAiX5lTbcFfWkIj6~k5uM?0AeUPCt
zeYiRjEFZQ1e7duZbvJ`c%XhgN(6G+)hnuLzgp2i*r|V`4Teeao`jlt^kRvJmZZt`>
z+3#0-w}l}YCp(w7N(rC<{eqE&z8#m*D+}tms%BP}10GR19&HA*%(r~*--AIN+c!}D
zC@?N(L`|B?8=i<7zI{8B#zexUzc$N^Bhmj-D)>Xq%c7%)fjbMrx96f8zGAo+Wed0}
zk>6!XPZ}@SHhfECP10G*X?U{V7bC*2ljNfgRyAY3Pjx?!iRk;o>TkQMb=nk|<{cboS&#mJB&2v3(LsUijSNM|_E_QsqY3QGQs#!916=TWc|^jM%>`;4gPkfD+Z&H_$#s_?4ciT)!IaTjx2rh-#e
ztz(1Ns=lHqn*G^P!Q2XBGR6MtxEq>gCM+3cWnW27`jJ4LypakGMfk^a9@VJJd%{cE
zF0fK(vD-Zj_44xi9valPYOZa
zU|!sd6zhhQ@pOb2?#jZ$lSUQ$)f)Yev&^Gjci3k3Il^Bm@z&A_f`n-Ios?x8I#T-S
zK$~i#SNsJ$0nbO-*E0@=F4S8URLQT{AZkC1S|6<&x#APNH|ALnf~k-}mIkf5!#%^R
zNr{F*AP!JX@9+BMK%$;%qJcdFjd~FxZ?l2o(Zx)Hz3-`jfy*m7nh8<#yOgTb2&#VV
zKf*!}wA1dEp^|Ni1v1(4&yUh|ble;q`otO=Up?ALsBwWtBqEa0KaB{Y#Lsz$p!|rjFg=l$xKlv$wCBGGh1R&
zeOs(m%xOXg&oD99siU}R@-=qE%64X40ACgu&m;kJR!IRi9oAX1V>1I-e!U>PF=70I
zb2@t~=w3Vrh<%eR_&viF1J3Y7Ty}nd8TB-)MIsiz_x}VJK^PsPghv*5g
zBi^A_K)vz0`(+2&+%Kzww7rdtlZ%J@v0)4xdNnNPg4&Pg2_0AkM)6o!8sQ^nn2Jxk
zU}8f81PS7Q_?x2>bl?p#fqmt&hxv?N`4Xoi)jKY(cs!!E(178b$}OFLUW@1`j|B!T
zBr~HQU;Go_0x4OMufzs&cs>_f=riNaW1Mq4tD{!)%_K+T|F)D_%eYE*Y3C3Ca&lvx
zLGH-J2`VH%!y~|D*tL?&mb~28v5!~P1=40osJZN*lS(e^;kuZMH;2~Q8$CoW4;*7N
zh9kg!agncdCrqp18u^@(qqDHL`qRpB*)b!}&N0sc2Z$y9RV>o-v6Q=xWV_51{OI=4eLy(+EYhN^mBgOJIq}#J}OaayxaIGeEQv`O2yU`9>_sg^`)AYpHKy
z?)ociH^uR+VV}H5t$X_Dl~G)_XreLvi)IACA6~}&o5kqgcxY!m-+sCoIFC@J%x!hRl&9%9!
z*QKoH;J
zm}Xsp*_!V)U~vRBV?aQk>co;4enIeUcd@?S%>caE=qIP!k;?CGLPKMtHQKo7GHOn^
zO#tQx`a=OP>`uPk@u3@J-nz|eDC4E2){lj|65tU(FBnyWxf;ju(9HmF)Mb}*Z2sJAq4Brura_^eAmaic==;LqzWHY
zW+^=Yz(NcBPrVr@!ULYorcH3WPl-zl`2DmP
z{22pfE~>V6Xvo(d!;wKS82~@-EaTjMK@15SWOvR5az<7enRM<8igI~@G11={ip7n>
zO|Qy>sQH~9O|Sn*fg73=dV0kS$(qi~^7qs3
zz9J)b@0_t#dm8@?7%iSbN93A0@I
z1(iECsJI}VA{`1l(yAh@!e^RgRf<#FmAtGAjmWQK9~-J@PPNN3B{}5`9W!fI4Y+^o
z{k(d$v-HUc+;w0R?DsV`V!9FYX3|T?n=m#bY-~^E!>S9}&GR%D&iCE~&|B{_%u)^h%eG{s%SG`u7++V0APo>
z{4O9&CF)qz7L~g>Txu12J1$q{yAOm8)E{UZvR+#A81uJ7?0`=tDW!;aIj2X2G9{sp
z^8RQ?BoVt6?w7DOT)%~NU5Vgv^1J4yvC_UmF;zLGD3`+0fmhb>t-zyC5xB_kz?@T<
zxR%D7{?Xgf`Kt?$-A6S`On0gsQqZ>iZK~DDd@RPLdo05;vt|W0hC;zbim?g2(EW-X
zL9t6{Fj{z<{;^8=94}^9{Uo6_a$BqoytK-vzc4#2Y%d-5tAElGQJekK!Oj&!kNFQu
z#%KGA9|Cnr0@@)OH8K2bMK$bY7B=ex8+k)cgE(Uyll=B}F~58lM?-n>S2+bXYOAvK
zR?g@EANrqX0dB1iOkgtj9BsBvO5VRlH&awrrer$iwk%ClQ5SuxR=J&Kj=7x({G9Sv
z@ia%YuNGQj{ZCrU##T!Gh9&j0>UZT1@*J#Yk_V33?XpeIC#u|>Do8fIuUM0_zvS2%
zzP*%%pE@d88?2UR&S|?|QY>C=R7T_6Y_2HIie774`XIM_S5t(${0(ok>Fp6ZLH_?G&SMh@xoJp%#P=CYi
zpu0VB^|(Dh=lAWUZ={RUYQp@=t&kC9tYN^m-60^kgYTVBBJZfaMu>0@xIzgx0
zs4}&_8Uhawg?J0{xv-&|Bt8djB2WTzK()4L6k1V
zSW!BNG^GhDj}$2qdPk&#^qK^u2?(fEr36p}0@91rP(_LaK?o8c6e0A`0|`m~SAXw%
z`M_HFa_+sS%mv%lODz7*2PW33C
z`TihACH4XM?)1KB%g@IBonu@ga2LSclm!*F{p~zIfn)K*aJHTKYC>cd*ChUWPn)8a
z3LRfT3`ClA(kc;(bB?UeiZJ`)Q%>HjNwuIS*#ka~G((5q2Xe=l<~u-${Q5C#^nu|O
zdU<>5wznfY*;=gnF>evhfMQ`KK6DvePlt`xbxn!Z$KcbMJvAj%c^YhUUP+lg0F&ubqjWdin$EuJ
zi9m>AM_|JJ-|ff`)vZu_lS>whbViePyLOxG;|rjOb5`ZoCR^vvA57cR3t^O0>*D*r
zISm!Axv60cAfy}KSBDyE*mSFchi3WF-EM3I8Pmgc2ld5DJwo~xMy|<~S+CKtQg0>r
zGG#ZLZGUi`H46O2^>k-p0E`C%F=*5s$gTi>YUV-_qm?UT)JZ$U#A@`1qkD}4k{!gA
zglm34CN9^yTsJt==x#CuAW=n}k-7DvE%G9@>WQ~}b-A47)7YXAs@XI#2m`#k3o3fz6rBc^%QesIm
z%BNb$mfuV3qdE!};wdR_{9yfs-s0!=4M)id#YnrKv$3<83=2)T^TJM>0W!?jVQ`65
zugvY^QaloPzqbG|OLjYGDIEHg%d!VVrl{VI%_6t4jaSFrLlcANyF~}h#+pi59*dU)
zJ>2LD4j}W&;I4kE>|qPXnyrYH5GISzGV>|D)je#c<^1b)4H4mx@lISwZ4qXt=-pwb
zu)^i!ps|E+nrAoUbGNJg^VLX81<}X&hI-rCXHJ{!*;MgB5AUe?i-ua8CSBtYYfPpdOr*=F>~;3cL*b>c96FKHeU*y{&stGD;6j@#fD+W~
zD$5zq3Ww==TY>=o$R|h3b4v%!aQm|lXCG4UJXOY7fa)Q~Haj~Wpi-i1XpOm{{QKF$
zcOyi646Nxac3KMeF#A$@6W>IuUJFS)kJWDcwO*ss+RBOY=60=SqeqBoSKVRee;=Qv(
zY)-{BzO<|7_wRPyM}K*Ta_c~zP(Rx5^Wk#7m2J}Ff-VGlTQIli*gE7i&4eUFL#3WlV98Oj)7treU3B
z>iJn1wgZ>2wb1%Ce8a4_J*TJaN65D0!`?XjKEIp_PT@DBa%si7s_08omBT^Cv(O1X
z^3o{WT6wxLhLByGcY4*fP>)uR-Z59Uw%=Iy*Nmj%4_*1O<9&PmWijoW^FeD!$`qFE
zz@1l0_qw8MFf80vCc~!vCJZ+3+%9(%rr>iK0C$bd?e;QI@fxu^C)M}CtUTz2Kuh)
zrPdVmVQrbzgYUFE!p?Fth&vJ7+}RBCK?`BmNJ|Yk^x*zrQ#>NjD(
zGo2kQx%2Gp)DdkN>XgmxeW;D9`_`X4s2lwOUYV}GQ=B|Y>?P#Kz&4fJEwReitiw<|
z_@z_~%TC)^kLTFl6;(Pk^~uFVx4AH0{GYCR!>8c&W}7wQGJ?i2lwtr+tzK#4Np+hl
zPu{QZmmU6ksnzB9qO#>lGITunX{7bR!z`fuK>e~rcV;qhX@1v0K_R-=#K2m-91}dVhR(P$@C%=S@dULrnxwo(1pA
z6sfE=t0u8D5hZ48`&H%H`ew9_+I$qHPG|I8@bE0`=hGY8$qA9J^O?O4D_%X`57b+H
zx3^fg?<_mq@{ycx`T+t~mjYY0XM91iaF-_tqhyKvg8R$sr3V1%F5
zu>Jj+W{Yv&5v~Ad?yt{r-be04y{@Db^DBa1{U?!h
zs5{KYYFv@M^7BL8P8IByf-RECSR&8-K#<|76LTM{Y@S9XODFCQ#YcKkh3j7fZI=}F
zEa~GFF0Od{4+Yte_pu!gI@4`s5f|?(X0*kelV-2(*bg(?fpc7MHs}=iGH~yL@p%?Gn*v_vz403CNQ#
z-mp_3JImgh5QLCjut~^>pTx;GM~BC2pV`~Y5ER8n9!({nKOY!u8h8htv&)%4;_J`H
z4MtvmOV>ALOB#MSf^#j&=?(?rlS|$C)ye+V#+pwaLkr*)NuEFM{;?jXMBdJ<*PROS)0h`*=*~@5uxY4mTCIFW8$+4{t33-+ZqE&
z?5AH3p7m+(>dAs6`>nT2z$#aty;NBgkMbFe>m>
znma!MR`eK5@uDgLJcCQJl>@dwTC;`~0Ak`2cq;}SHCGw4f%b$3<@;vgN9FldONAtd
z`t?l^n;;3u(X#n-N`_q2Yv0S37AzN|QeZ0otF^1wh2J%>I
zvTctazhmLr#G&Pb>+GrcjKUF-GsK-XtoDABXW4$`RAc=y6rCJf5CAz&zSH#io|OZn
z;4>Bz>M+7N%wN&7xA?&bD24(>u}PHOmg93uB=Q6V+WyM4hZ<8J`JQK>mbh>~zuo_6
z7Wt;GZDG>HJ(!6ZyR0|-`$!42{jLo1GKu{T+x3|*9Q5Ij#LTD`fu?b8Mzf?1u{)p{6lA8w;vU
zKj=x4CLq_7cA4K5QUbq=(?&56azj?#==GiD(C1HJ87#A;f(5**W
zl@w;6XohEe2tNn+An03r(MwMyP9AT}?}gr;A-%5w@+=wBYUR%^tr4D?+dtA@BJL=z
zu0#rU`^|3OXWOYogl-6O{HF!Pr6}@~?;BvE_@prfAO!0UI&FRg8RvD`El@
zY^FrSNgdbr>09r8>nRe(utB%bHMkwM3gQ`3fu*CRDAj#cajpNCCQ#-Ieq>zL#uXZs
z&U_$yb42Y@@o5V7Ci2;bPfTS>DF!Hae$bpuE#~
zf@XuYr@)RYKDy0hvlg&_26^#9b(JnD;Xk7$Ah^Ka+hjCLbvCBN_7>;mu&IT?*hs28
z4d+OjMmTMz6EaOzJef9fl*_0r+rw6-m4A7cE(>w@
z*&yy-f=c%OVCdl(_(pFZ5T>dF>fqeE%lcfQ4ZJSPm1jYpM{1@KWCgKzMuN8|;T}Fx
zGtU3DKOPBmbObHI>bXw$DbqEO6-FH4tw)iSg-iZ2iSuK9-bw^~f%hCKt2E=Ypr~hmTt;+;N_u
zjzUQ~AN@1wd86)^t6wkv$*KHcJe#zGc+yygkMJ2oQH)*6SF6cCP4wW-kM$ag9z&MC
zISf&5HLTjr!&97CXU&!e8``E0&y$z3g%JgpNKUD$&0|hrKkTz~#JQVV(yDqUQO%n>
zp+&32zD`ce3~)NKFA;C{_Iz-{68{6v`uXwWI7K_#mnY5#&(_WY0T@5Wa@?%Yqas)V
zbw+mPfPwEypNGz$9DVXR=Z@*poc-Y?gV5JyV;aWu2XM?vZIC-=t?lhO=gb8}ez>}aan@)ZVHc;MckD(8n
zNlU_;?GmYy4L-fBP*(SGhld40JNz#{-mGZJ-gvrt55?vL2Qr=lnq_VfNwX*G{lDgb
zc&pBoc~6r7P35$V*F)OSVFTMm_@Y-g>b5
zbpX9qw#}Zu(28xJoaxx(v)JX*i0Q^w*WxmQV)B@Hp}cZ&iPs*9sF<yB
zNqj)33FOpiP(;SnA+@xk)ApvViRep~;-YnIrMFK1XpMLL&a{+MEG(u$m~AxsEC{d!
zG=47DdtRy4TFS8nDzeqd-dpz?Eyg;I4Tl5IGl13l
zUPSv2J0nB8rdnn0UjRi|SDjy0vl`o)Rjigry2el`r;_)c2vEbvpbQb|O#9vMu70-_
zox`2;2s!c{E4&R*3Cb^PC}@7DJKIv8!1&VRZE(a*17+Bfy~kJ_!o#3c)p_Im#FnyZ
z7zkwjmETV6(#8>4ZMk}mFcBNM7}{7K*n-(Xw5Rw{0j?ZSddH`Y!q=LI1FQw4rt_OC
zP>m}ovGTv0%G7DrjMz~*1bc+Uc4`z8da%}wpEqFalGmf=7Xa}EC-evea=H1kyX!<+
zaA}rYNZ+w|{{r@Y{lcc=6@8}CkLMvIq9<^;p8|DyRkXg&^33E&U?*6Vd(>}^|
zw_E?Uz31N733JBuV?tpU?cl^o{KYmh7LgR>G~NNkstRq6O86+AUP}Z&t=ZG)>!((r
zGckYllP^Lp;uOb99HaIPY7B_>Ms!DQ`R{Bm0QEYHg!|Jvn~YI@e2{kI)40=y^_w#Q
zyO>9W-BDlV8MyuHuwgD(e(?@IyrPmGboT{TT0N{Pc3@kN?!Y<)b!ZXa+&l1=sDDEI
zjCqMVSAwLa&M$ri67Rc&jPtY*W^MK>fAk!0%u!3{rE=LmjcAQAV~A+oWH-`p)!;4J
z@wcBT8RZwHF?DK3{J15}ZDV-&nBBts%o`RXfaC>mG;dvck+gcMmJulBjTq7Eib34%
zt7adaxjF9Hhwgd3>32K-epue;yJ{Z8Hv6e2C8t0p<9Fyo>tZ3}$-s`lqzV#4ZQ}D+
zsVenCdW{6266SbIbu6%a>!VM*k65a-@35@^j~0|SHCKV>a?0addbM`wgO3|8Kg
zOwk7hl3vLv*sb1MzQcO_i+1!FF}(^EVqBf}8-PP8_3{L-m#HfdVU%kd0E96vgu*DN
z$VeFUyOM44AA4c_r*G`YO#AFsx>j7*FU68$E~7U&*?;h&@OdokLgL06(9OGnT(iA@
z9^7XJ1y8RhW1T$E4^4fvA4MKGz?Wt?DlSF?HHgOqgC{(;nqI?O`r}1(irokd|P`jr>tE(7h1Jer`89
zIRCnTGxS_oMeO%AW4tXYJGcZcz@F6Jc=GzrhaMiv#(K#&;@wN?a_7u{W&{2aw&BiUMQ8nSb^+s`h1!XI
zo4rM(J+QGeG5*Bv-WWXN_s9SijxB^r>Rq=q<(9n$u>0+(XXo3(G{t-H6^-bHZu|3pX5i
zMQzp(J~8Gv6Hy$%*8|pZ+WU5O8alR3B(;KFNR4FvvENeMsIa3JPo#?)Z?Y$U&gSN1
z@3R<4eN)4x=r#bk1U*%65(-B~r+R{hig^gcjlf6JC|A@pp3ij*B{9OTeCN}8I!5Sq
z5fHcsL6dQEO+e>~Gyab`#ES<84v7)vH3d$92J76pCI`@9OFWBhVr5E7>m{o0SY%*q
zf$^<%PjiRR8zZQ;De-DFKj55=@q~xWJv5$ER3kY*{wt*W$>SMwrt}oFgXLh5JKBJ_SD%$>e|-(xSORHu<3ChG`mK
zkMli~%X~&C*4IzRR5z=NjiM*>keeQPass~g-WpuII2U(>dACF1Nxgu!(0$}Fg%6~%
z`d-O4XniaK9ae&;^s}V2X98viAVPoSQ=ZHa2>HvjaoGxIytI`xt{2@8i|?3Lu2M^i
zpguIt+Vsx{cJ}&F3;qD!P1Cw?h+w3k9z3*(Ex^R7_&+&A+{E*->nbz7Xsd0$-A~9Y
z>9N%~u~fQbi3#8)E3gyc7dxJNUgOLMP2SM!^ExzTex}CM@9~9?)1AL26bqSDnQGEg
z3=~TLsupmeU9=OKK{P^dInw|6@PsQE9Qo(T19EuiA8!e6aZ5u}VzJ4LP!>?~u^jv&
znkrk-Qn6)4LYkeLBWBoB%bafRXraQ#w+TTrQl=7zW6sPCPkC|kdgM5YWaU9#Qw1*N
z4Gkf4#pAd8CwYoBCY5U#Z2l0SRf?Uw^^?TK+)N~hjG!kHrD;xyH)3NqT4Vtbk->ZF
zgQwXScgrEV6E&%5qW-n7YOgw`HAZNkjQ>cK(e*?}Ng*e_e!;+yft9=g*L#bbEQ9-F
z>;?1V;qmLKi#IYSar_syr0{53&%i_BJApdsFi_yb?D5ybCQKY^Jnw#+c%FWWFkwrP
zj6Tk0s3lAU>p`2e`Bb`2JijGpe(|4Ko($lqN#@RJY{Cu7T08GKQanlXi(a
z9YH=q_3s!c79q>~VaA*ALw*Heh`fZ2FCQjdERK}f+AdBYHd)#J!0r@7aD1^qw`ml2
zh9Q4>=xs;=;GHtK*d-RL>>kTI=JZ0-u$Z@;lOSLH%GsF3m2~{K$H-9|pE)z3Fa{
z?3&|T_NQj{K^09{H6?R!R^cI7E~)wr#Lxbwo+*<}fh|>#)4HL_Hde;{Zs603F#9l2^mV%)MMdX_aHXH+fh?;ozZj}1&Of_)Wrj)I|D!9tNt^NTWz~StHrj0Mk
zWmA$;^i}0$8FZ;ttau*vAjxT7kD(IH6LfqWi_?n@|0~nD-YB{ZzY7J5Vv}r{+C43r
z`S8mN_Em&}=UWS>n!~oW9xSz=?W7Lp_#aV%?KfPm4Fu4Ng{BD)Z7n1%(QebkH&?|K
zqglq$Fk0G(PW0_;6Smnzb>~&*;XD@f1NG-qS3k8%3>@?zBo3E0HI~r4rr%$OC5~|q
zH)XRyBB@p99V+vbQj#5LCgwj6kn_+7SVy8ra-Vq=vs9lCWp?=p8ZOz&b87iBeD4L!
zwtB0Rm1qn#)eu`c`J8
zF+Q$Hu8lU8NGPvJ6qIZGteWIt_9gLg8tf`*|1)Nnu*~@;bJKmHh5Bi!r>)3DFg`35
zXHhTy)K&876>^W7~E~q-G#!fA(F7?Us0If9UWAE>MG&H#cGEM=+;iR*jt1EIEd(Q3#bXTvWA$QAVmDA$DF7x5|>jvF>>&EjN2srVB;^-4+pa;@C>
zat`A=8?9G<#eJ4n)Ap;Kwq2#VbP2p&HJGyn^-;kAKfh&LDS4<3qx5|)sqiptErd4w
z446si^QwLs!p-UKh3_OY^`v83Ekdw6+kks(ri?n=?!hvB%T+Nwacck2lK@O|EmOqj
za~c%CF!!AAhxHZf6GT^;0{a!pZkvz4%cmc~gV>xs&+rtRAb;HSbB9i_%>6@$9gBj3
z)C|t_L&r1k_82i@YExHF6SQ{j+V~WG5ypIQmN2!%CAPQe^5ybYwInT)7bklH1{dVa
zuso5sn)BjE9g;_5vuv{l4xPbPLLCBJB7?+L&b_aDr}+>WmqQp$?0rsT1l3-_o^@!2q8
zo(6wg@5>5ePi4#ek`MpsJLIQ!8h2wOsNMhyy=1ZFR&z#RM6(1g
zkwHp$ey09w?4+%k>z|)s01ozN5}gKB=VwmBNb#FTM^-yi+&4vwR?s$6v5=FAXI70?
z*atEV-eRqIY%lp;GI90!PH^kmt`re)mWx0dX>J+dlv7)HCB4`eod?j=_s-)^d5}xb
zHr^`vH*q1%vd
zvyUtApaAhLhd5N&Y;U!*=2fn%N82?V{7Sw*Ms2JX)AGA2D}d;|l_lZ}Z=@Y@o$^6a
zR}}nC%5cLW+xpAbm*gGw%8zjCLsb#jmRm0|jPrK|`wm)R%e7BRm4YVzHiHoO1o>%?(QDG~lnFB<|`m~wiB($kc7c;?X{H2N32woBX6yQF(pG`yW%Ri3ln)fw6VKePEZnuI#(r|L5*~h;I&sJ3j9`NGN@jtS0D_5A
z%-y40Kc4FNALfHX+3UzY;@BHuk!dygYL7RORG@AC+IQU2?b}7Zw8q`WJ(@FNwqoJG
z8aa^j&{~kcxVq!1ea@6Z34^3F8a#JA?~nccckL{L`N)c)J{=FMnRM4nMX{a=lgO{e
z&z+VI$P*5^O0q8p5?ZxRsu%Z~+zdI>RT1DH&q{6S{DCZDwAs|Y^Jc9a{J|UAgUepf
zqA!JRJ!*^=;|@c~Pqj^I1d^x54TTq;>drNJ6==_x{RqIZ$Gq9zV|DPp&nlkbOh`#3
z`(kT3#oRz0g8o8Bxe)kZhX%!3&6~J03mrF+Bc$V3uF%5;Hd|I`E6w0Jlg>1sSK8mn
zbQ{;i`bNl})|Csbli=?G$Ly5LBUUJR{Wyi){K^{!6?G(2B8vv08Qs+>3sNyWutU&DX1#13BWX9G}5k&HITC})HYa0+(?uBjZ4hGn-pRy{9Ga=
zo;tqR-WDo4WXmQp0zO3^OlF`QMw5zfBKOd)a|4&TK%j7fS^k%RBFFh+j$a8ZvUT~!
z#P3Q3b{BQWjoEK&g8S~nbPw_RC-|nHw&Uy=R59~j(Df+F
zMSzg5=sc3*8Rv)?wa;obZkokCicFmhg3{-C7ovg|PhYGCH$XRLlzGD)Cl?g4;EtY;
z!^s8d@r2rD$?ji0SuUojPZ55*EGHCv``cLH3llkqOiv
za_T!i^_oglKW~U%sIcM;`}|y=HSir`q9B$7lm{k37&P>l-o(axUZu2hZ99sq^ApDK
zegJlU%}KEVvjDzeLGjVK(&+Ry^$Y&?T~=k>x1FDEa6*Qr57;3r=2*+aX?zME$hU!t
z@4sCcmJ|GIDd5;v^DFRK<+@KcB@Do+(TC(MzeEiuYpXHjSJM+&VGfVp0qxtgHM_#D
z;@}G9P*-0KLL@a^n)ZYpY^%B_-Vk{~2Z835E$?dLEaL#Ura|%*w|a0H=~m0~KFz%B
z8Q{-N9LciBZ8t@V9_mxVG`GzjQkzUxagRk-E7$VWX+*Dj9kr|5zf6~UWqiUG-bGJRJA&sD1sgvd!NkKv1%+5|?R}k|Xgj$P
zfa>O}ka1SAmTd?**$)UWS9KRB_*5|FL
zYy!8sIL$QxinzCP4n?{o)lz-qC!x+_+iA2n>5{T{5~(FQ1gGMgteLy$w1z1)x6X`Q
z4f}+0|AjuZp3S6Ie^EPmw|^WiQ#ByovbuL{mB|2ZX<{U?V~!MnK9|Qb*Qm~6jny@O
z7RW}{fd2^g9lpUzuAI~__r57i8p&;nb@oPBGRRXKoAOYn$7g`nDMA#pb@zp+psjxW
zvBrO@0^#G9`SARxy9^(`xo+jo`q8K$&=B_bw16F*!V>f=VNOnd8d+P-;!W^z00*$`7oU-p(E1v!N+#$$KBLIhxDYTimK{Yj?og;EL}n6ckdYZ
zw4F#31B0WPmHrOgVG2D%ic=o3JO9jTqw=2UF)-C)B1PB6j|Gn3_^EO%gKrj4AL*X_
zuIPPj`lS462)qJ93gXiLeV0?%q=%kAc2MQ`g7EU+p+Jz7Na~filrtZ-09YYKXX1^Y
zJ=ZxW1OoY8J8z7`NYf_eKaitI?oW&0Ez9A0rB9hp{1dS<{(Z94E$fj?%8$MR52lns
zCEK!5+AX}y-yuhU<@!GOYU_bP&ivE)b%ET!>-7jA_Uwi&op0k^Mw~04PSGbcUKZ9K
z3Mfj;&e>aPrYTZ4e*`MHRvqdh3$F3*jHRR0g7rN
zyOIX_%zK#9>wxrqGzrhoQL%Wd=u@yJd0E-8@Nq9?Pr{?mEX%l7CGIK3fvsGnKbHC+
z9abhX?W_!>xj~?nA`O(=H4ky9s+#dzKq6>aD}Xu$<6K5m0OY~(buauZkJRLaTeAsD
zl{u5wbJXze)!Ys%FV$(m!SZeBtiQc#pb?#X@KpX7kX>1R96&t)694X%@xVkNM_PFz
z7kG-&cx3ae0=T(9yT|(lREW84^vGzE=_56DeI4lmKqP!^*0JXH{~HK(7{ObvjX)_h?Z{-4DN?xn);8=WWoGWq*;&j(vNLMs3o=1siS%P#m3FyLIP3m`iO
zfk3>qXb(SNuSeg-tJAP)@7#7h64y=^uZ_TQWmi0bz7^m*+f+sOO*L(w1YA!&w~X}P
zCk(Y+xHO-224pvCq#cJGsVFioQ4#D6tU05EcZ4J$4j!GEHW>dy)rz_
z&!i}DmPb?S(@5>2Ih-6g)Wn7@xut>^r3|BZ-sksZ_3j}bzrr#7Ygp|VqKu4Tq@rxS
z8K(9%^E{+2FD%0qfKwBz4io`Xxg+Zf+BMHTX5I@c&TTR}rCekzT0#rk^4y7jsJ)sV
zFZHA6Ab7Z}s15*f@I@jIb(n86!|{6?Qm#^XS0$_R>>0q|GTFNE;L=in!ly5Zb)P+8
z&TSY{!|*r@F2SI23Y2x58)|!KIoy<#FT!b%90PR1K_C0vOjhc4hzKjX+Y;LB8033#;JnED;S$|*7Q`(
zRvuhBZ%;i?^a7rPG^kF6c9~C;3+jaw<$w427BH8u`{^8}olWzU-H0Q1dG6
zUY)C!d-6LZ^8ZiK0i*z>_yxI!j+CPTf(Z6vqxiksm+-`lysg|Sx#mwqIn-5jZ
z{M%Wfq;Tq86W^*oTZ3!jDgcqh@mess75kpiBSfS0dY+Leq>48B2=`k@WK-)vVS=k~
z%u2JiQKIstul(G&PU8>JiykrSq@zDMQbyW--v8RzBPv5nM{H*xTxtSlMPIR{Y}bp>
zcydwK-$&hG*oFgdwt4o-@$HgB;fy6(5ClR4pr#b?jvs*?lDcLNxELSZTj!T;^|R>)
z0IPRL>+pMRvi6Ix4y;y+wm}6FskRZN)zt7y0Wa@fPq)szgeN3wc14SOQUbg*|H&cskL`Q_fxyZCjQ^lsxt(D7p3TII(lCa{@I|DSlW&Li
z8=Ag-?o`EY=R)W+EN}wXjXH_03KxFGIzPOzeTCbYFJUI@PEY7^xJvuX=%3Oi{qMfk
zg`O3wuiuX+{5@KB%P_tUj1=8VjEc!KRBl)Pv(g-}Jy~+&0WhP$1nRM>XCMXxOq5>5
zgW`7f011pdl)=u=vZ~WR_NP|NYkIPs36p%`lS4?ha
z?Ik2&Ss4*%#SvOS`fG_Vu#Rvc&*PjTD6g>Kzb<^^akbbH24F%jj!${tqpkpSxsP1-
z)PjIu!necLcy2maQe?kE*U6WA*3J)smEaSJr1s4qU358RnEyn5YjM8WwWjPn?CGEC
zH*0~jH|8KTtNH&oy{;fTbyd!CU%1F$@wd0aeI?ofB)}$r0+&C@0;Q@D3xVMQeAI~2s{jaHT^i|7_Som
z1A#sRZIpf1OF1#WT*SK&$bH<+5n5}LsR5yo?|Tj%CEfA0#H5bM`;LD{t)qlh6gX-z
zB-Ed%ho!%0?MrTyC2xumHBi;;bzA7qCTUvvOv#-yppG8qN!8&8j8m8Y1mm8Rvve&k
z3pPlmmNeL$zm5-|{h3gtxitGt{$y?HpZ-rr7OUh4Dvh1T+3*W3lSx_u0wV$mo83-_
z{VOZLDP?U%UF`Tgf&kFSUrUu{1jwjNcH)lH{Mz{@w~FwyQnRdFe&Cc5PqI0w}qG2gZN
z6V>~Sp{I}yCiM4VYP+2puK-{m@-&y`Bg!}S*+_gYmxqF#S8s51S%%H5*68nqFXR7I
z$IB&&kap^FnGV3qIrV^V1pcDrSJY|9@T#v?LjS#fLGEU`XS;yYgJh<6^5vB=Sp&{0
zjd>qV&>RjKAT;}z8?Wk%K+BP9Um9p`fMn}k6REjuCEJwBX5~wOTNf#+8CdZ$MJP#c
zQ9K3#g5&aPO{Pstf?2X(rER&d0wB&Vw$tTP>CUj}#_z$;#+
zbbDQ7JC%GaYESJBuQCuh4~i&#T0jf~8?!kJ03@Vp4#6NR_*QmUSPpUfy&romn9WWg
zt0K4L7eVnKc(8l(SMw68YC9C%zll%FCl{w9L@Z2}O;uPx5lV`6nW!`z{?=xm4Dt8_*DdQcBur*;^0Ue-j|P6D6d=
zBFZ=eVQYPb7{nvTivhzAfo%5Koy@q%NC@Cr6EU4u0$OcIIHwz_mFzmzpE9$aD#ySJp8kzOhYUlB)rPOhZbItsvv~
zBq-zd`!|Pj)#31AdeRJe?N;g=BkjfCbMv>LJ*eWe0hyp2zlPC&&jGcO;+Da!N|MJm
zT^oeG&V>L~vz!U$J+;r#3&5|hNMwx%(cADC_FXldo8d39I}1>mC3{5=u6%zVOT`M3
z?Y16^B!v`p%ZK0Mv?h_Z&8{pUE79PHnY4HKNYZlnkcV3(5{WX>=JlccTcHRWfKY}X0IF))p41QMyCiiuG~uPkmL5G>>Z9BLcBwz0uXl9lysM%EAysl81NT8+
z*pT8T!vzh_l|VUV01Nu)i@JYD?-z>90j4tuqK
zg}~$w@O6JLJ|Gsn_sgdRgRmpTR{+%zG87O9ip|;Ub&(Iu(H^Jb08?xWh|6|SM2Y`a
zVMH{NdJ2Fg#WqE|ls8=)z#P#L)l47Q;CQt5dNA81)ePr(}s
z4x3CLfPd91;KOr`NPP42O?LyWCX6cPy&u)JJ+0zZLw!#3%7k_-g&GadH!1v2)$M?3
ze=LsOvGfV}%E_)@^9kWnd5(bw71)3z4qC<0)m9)BcYiv*uPPSuGtnqlx#-gl0XYsH
zeo^$giLp2?cvA%tk`I@O@Z?MN{Xq)YN*ei?t7wZd+13}Ck=lP(+wSns4&>b!(Z>MT
z#^F~~&#_(g-4eCNQ-Ei4$!4M8teC@p*6NEY!w*7%#dx1KY8Y*ZUwfX9ndMla`GK%M
zGjn}CmUHy{Ej8aqb3qpH;ganAUMJzXX`JL`-=YMX)9~@&w7@@m7~xGVkYMmk$R+tz
z9s&Mvy0KV=`n*dTdaseO{R4L3ieF{4>i3S|XsFsbyQic(M8{f5^o8zvPR`{4Q5HA^
za)3%3b<$oHFY?bZs&V+IzuYlYI-+I=9JlwX`flQsl-*oFKp8N-pigPWc$7Z318F&z
zGVJj(U8D#z$TBJ`|HqwhJVZoeeP1uDd5w
z()*NV)BEh0a&*iAw3*E+#CF48dVNacsdhW6p~0IH3N^Gk?Eap8;|y&{+~Tu;l7Fmm
z>NEv~yZBX0K#AsbjGscWcE4X`1WazbD)^!<>FAagfO>in4nQIlV-s)X8pLGmt;5~sZ-{om#cDpW
zYZkc
zNMX~(?s{T4Ae}SArz^YTse(UEsjU)F^UkCrh!kPdBWO<1Cts-aAZgAb=}rdd7vWb=
z{xb$7P7fM#gH!6>dG!_Add*Pkc;A3-G^fZ
z3IWVNf95<0bY$uO>4(aH&DsWU3(iwpWaE;_P3)&({F-)G@Zp#4&jc{!eO~(x^;J>A
z*QSj+>Kw>I?}?3{pc34uh>TM-Gk#nX@G^Q%PPGUDSglx$sc_MjXppz|8F$W?_e_Jv
zhXBQC&Q$OGjE^6n&x)$P8?M@p4XNAymEs1AO9Ej{HTzW4&r?qW%xrQtt@#zl=1<$b
zap_H8^1b+GkclQ^FH`C!vj8!j;n88ztZV8U;*N4*`7ZoZU%a-HUe3z|8W7X
z4`$Nc@$oj`a{KzK(=S4abA|S($e7`pu#m;`FcObwa0(Kot&X*`5W1PnYXg`n@60l~
z;xwAL075Ec<_nWv+UX^qfkp}?I2Oj6`niBz3{!pn
z!(SW``zszVioB}bFC2=1Cmki(!e6McubJ1rrI$j$|YT~Us^=Jhg
zIJFHJ>4R69EovA4$;Wqp)SxKN8Q)houI5utj
zCkpT^-rA+Qd?Kl@0olAbksImjAW$e5;mF%^@?~zxK3ds&iZIi!B)}fwW##H@=K;w1
zJHD!K
znKo+99PvJw4m8pvk4v2@+1ICi;5y5_La<2<3M4bHx%v((q9beoS^o#BW@!T7;x2gZ
ze$h4nY@1`@yW%2A!ipe$vpmsY|CsNl5zs6_S$Gc09xZMHw*=%SyZc?Nu2~yw0fJ}%
z6{`U8T_W!Ruf54!%
z6uE{0tU=97RD3%i<>I+WaoM6UJgqj9{YA4GC)x;AR3p3`)vR?}CG5m}hl_%D7)xu!$0nI6Iy4f`WI-u?QuQFp)a&W#_wFedZUg4;OvD9xk^CwZ>*?ZCK
zd7I<1Mmmha&AgKaOeS!>fqAKPwo#~4+$m72cwY9bXF+M;7vvq75?%@r-T>p&cAo&?
zVFLarJvemNPEDnJ0?tWx#lc?w0GbD$)gu58el*8E^9@dXN>4i#3eZtC03TMfyir||
zE--V|o^Bq&}JbaLk>|JoPle=1&f9iWNIA
zi}xu_;7$x9;K_HY4B*Ur;N_^^rGK)TeDd=-_wFu6O8#gY7|}ES3cjZ^e=oy5zLR#P
z@`#1KEq;wc(-X1&{8x*XY{3kg%ez}Z&elS5sNr+dQ!Si&fz_J;#&)1%IlwUiK?F#S
zX&+~JK)3RM{z{PZ>{KdKmzE-V{`Q7nZMG4|s}jK0IyhZ^^cP$sfFr1{y=no7vd$5L
zPTKhO3}@reZt}UJ6p2^y7fjv*eGC$(Dc69SI8gnZK^S%>b_Nk$W
zgyna7-nXK8X+DO<4dbIu+RE2l6$=$_o{4cI28jrRFk4=H7D(06$BBtVvmTL~)lp+5pn
z(zvfm^^rCNaRF+uOW8xj8>Gnrbg%C0g|*g2+b^x`nL+(Q?$lWub7nhT!l=yeJ?Z4s
zVv~Rtt2|!piI>lGUSJOHV){y@g$l}6rG|nL!v~6y-Io-9!x@!Gb*~8flLzyI14P$=bhI3{E`fZI>1m5-@LamMbRb(6U|VjLsO57~
z=eqQJd0duQ=C)++^#rXb9d??+d4YSE2so?T0_10dwc$Dt>c{Y^tQkE3giY%D8~bSC
z1x8|G++Nr+{=E5-)xRjM;`t@k$#_T0h(-Xn`zR+er%T`P9t76)P6czZA1mN8J;gZd
zd3^|$ec49}D3c)gqUcsS9@}dAIc+W4HU)fE;+yQcVG{8-3VXdB?;4KoKWHmTOLl8t
ztZbJB1ZPdFIXWi(kE-{MXY+mEhhx-esiM@@Nzp;I)ZVoA-dkIn60s$8Y0b9w9lba>KXZc_L*=C`Gry^`r^j=CSLnntwVQEg)b~mF;FWHlYPknmc`7QoqjCScsaA
zMCRmnJaeC3AMkOls=!90>bzSbC8xUZVux6rei4gi>1pMapzARxJDF#G$`flldZTbI
zY5!>_8+OZ5$?j&81*7<_Gqi74{Q#C^INlTCz0>g%iGgq{qYmcR71r8p4TZHsa&uy*
z6f=`DKA8{R%JHh$Sj;Gw!`?{-2f{|zcQ`o@VFw4t3g5w+K&`jR-QD1TZM!JO*fTa6q&eT3VRp&ycR
z^te<(=g~BhOg^+=e4LAs&wWNN>_DeCT0fdSKbncRFU?V{09*
z&qOBCCiEw(swoik_$1q>>^Z}Ew|9}MYPrmBjwewRWi>1h(gG5RPT5T1rWS;NpNIcg
zaz8!it}%SgNRh37>9ml1?6x%s^g~xZ4^VKCKgBY)pBgmr#s@5QYNzMl(Lc&yp0!c)
z#UYQPVpgJEwxftU-*EHd*zXbmwKXhw5fW}g;73$C7xuZSs5;U!_Mye$eJ${am$K1e
z#LXw|y{;M#kF%CwKx5wSKnp(9_gzj~c{%jirzMLGnb()1q|x_FEMV2<4N1%qpxQDXDs>+dxG;03@;58F({E4ltw@Aj*mxr+UxltNVcf_9IQoDO9r&t*vpn?ImKaq|(_t@GdA4nNz((uGS8Iaqa^cWiK;Jr*af0C6`v1%7+_WkAOu{&7fG&L
zNqW0=+grK_{XG+r4)DU>7!*m^;jCHhe0c+CN)TRRSZ$sZjOttrDQzRf>OS6VsCr`Z
zCPnEL6uNfG)c|Ph^f6wy+AS#s(~d`RSFHyEK19yIc_-{vmj@ebjua=q{V2)G6nyTE
z%mNg|yZnLP^w;0FJQQH#N>Bwt%CxSI`yiIsI<0CGNT3B=`Sq?+H|~!SeS>Rb@{WQ;
zpY_}yqql{7Q82u5rVPeh9wz$iU9Nj?!0&6559PnZeYSO8%R4w0^5J;BZj=7XH9IX@
zst+=b+FUcUZVng3&Ggzw|C_%34r6ghvY}i}z*(ee4I&3e?KivaUGZFp1D2@GhJOZA
zW;H_jYgx^q7~H_Y+o*?|QN_iThGK$rN0$++RQltUVDSe#XOK(3_bNA1C9yDoltwNGAH5$^HPJunbAe-n=
zw8nH
z{D8@kmaqJg26}SSB5gs!!yGqAx6fl3%~F*9`&7;1!wJsLbJDQ*!*L@`jm#2e9B#4t
z!}ssp`?Yeqlhmp5r)xdot(@l+3{b<*JJi;F*~3sOo3AbXS?_{SYR+_nXk*h8I-hcomx8T)q1j?$xlQ?VS*J910Y^{6+U)-h0U6qAfKEy^k?wLdgj*w12*6
z*(-}nH{E5+q%EK|8ttay*E0R^)Ge1Fg%a$3`_lQt$-ML1ol*vGot~?~kAOze6wIV%
zlPO1w^W~SOCyNkpeIFvCI%9r(@0Rm8>%Yb5yw5T}1JoUJ2V20M-WhZc{=)b1G(7p(
ztD6&dqrPaQ^Qp>AxdY|R{Xa-|_Wj{Vx82*@{dAM(bqsNz{GO19x^ixoaqCD*Hqx~r
z4}FoGEQYn{w%PCygU=ry#W}BL>yP(|nUP!yE)KIVwGuswK>Oafk95!Zce2zgJYASr
zRzIF;dw{OvJv>Mas@^?o0qTf%07vt1p|RQVsCKr~hrRFab_4ckU9vkCwigfyH;D>0
zB6F=wq3l*YhL85vmwnFQxiyt`G@U!SUwZ>e%v%;ax`n_b6z#cxa;Zlmj1btf=kOb5
z8w+)jLC3gqhLEYVBe9veWWT3Bd*nTurxs7nMx;%pa+9k@Evvv*t`K%RVZi+vd_qMW
zS|hP%FCpC-3fg@8o5@J+5*{UGmCG%i^59{H+EvjFFh4H)_YzRFiDI8Ila2$=eZ+du
z7s5D1%==dr2f0~tW5G4+Acwm-i#(+Lr%y9)^kWqbGBqd|epwITKQD94S{?WY0-!Px
z7MBzT6sxs>?b}TmVfSeOI_|>1k`vo|a}7>e#utPyr}>0vq!zhhLy-loW4D&+6^oX7
zpcH;veFyayy3t86*5lIDzpHyE65+MW~ZUv~xv
z0!ADcAK$ef&nSjSK4fjPMU_C
z*gvhm5%2BCjjOJfmMAgcWuHRNbP}*bp$-d>=#=p1aF}CVWB{3;mV3pn+NK~30xvB=
z)Ynv2oRACN1{ySjKwgf;mvul-MdG#FMf&*%xR;O8xJ{`{s_syH?E@`v>m5m#g**Wf
z?DO4LPe^6W3=6Ph2J+V75P@Rp>m+SBTIhkR%6zMayjwU$$WUA9O}1{;X`fSZ>?a6s
zD7Gt%B&adW+IJItE2>~DB`Ys?~dJUejMs9S6
z<9QeVS!DZtXAr)0=gXU+6S=
zBP>LyzPUHj+5f=zl4+3cR`Y(BtkR8ZcFQAbs4(t`Kt;Y_zVl=eb~*8nxD0C}wM3hI
z3~09|wk!nYFV+VnNUM;iIZ~?}SK9T6f?BlLRP+)eB))TQEo7)D%by_vD8g)7
zc3&d}Sx>K9Y?gI89seHe`k^C5-IMD?H5-D?>A}C9err7|@FU3K)?G6mslcLR=K>B<
zpT?K;@2D0Gq_7s=QClt6s(->={XG=e|d$;g4>Cq9c{S1`zvzJu1aTGaMfA>)fLch
z*>6>NrpY2OHEQy$5F0l*>3?;PFqKxxTw;9ujZ&K{~JC{5b!cw(`xZSAXFvIAte{UDF6O;IuP(*LFz
z%1<#%8&&npT2vXF{i(DX=>hicSR;}%atb#Xtn1caBfifwsz4!hN{Mv5LdseCD!Fmjd>AO(+s
z73>U;37Iq^_28ExkaUL^=rKUug!orrBhDItkNlGBMCO}N9k^?;Rsorg4%tEjxx`9_
zjk^0;Ne}fkD6AXS3}dDZ1-My5
z>#}{P$XSa{{BUFTyi%vok3XD`KT)kU&|a)sZqA$h=M$)dsIO!qy&Vf1+cvF|DW{GW
z^!rbHqV=;`jP5AWP*2!(-6+4E5RHH@qLM>MppO`O-4=v5Q
zyrxEJSzt~9-wgpe`2LNNBge)dGqGj)>BA}S4D)F?ytwtahUcNVs4=}=MPY927x0qb
z%^WXgq$tEF9Hgvz?l*!!T^hdi1ttD@SD!2LJew-FRif;b4Wdbhrk*Bz%zdbE7DLMb
z8c1%yg%w^k3|W=naPVANSZhI6(U%kjJlNksj2=qB7u@khuSSa-a7lcIn{Im&qprwe
ziW7GAsmZQh22ryuSTUYcg~(-T`0n!@;UzUT!9Yk)wZ5Q$2vi5L#&K=@LV|bxGu-)Z
z)x4l|dIPTY2epz0Xwxk}eKy0&VAsD!Av)QRebotZCS%WEU~G
zglS8REqnXEKkeV;%dVEZP6l;YhoymrjKM?vY7N;Lgh;R!*iWGLr=NoxQ*RM14Mvgl
zlSUA3-`I169?-coVZhVC0`k;BgqcTlN{p*r`L71z_~|=KIQ5~h0{;Qoz^`JX6Q-|R
zKO3+@5P@}>+^xm!+VX6WpeFx*ZEoS{6a3YEcL>7^ME%w*xA}c({+$F&AyGNlsxv4v
zp8F|KEd^ep^&rK(&~!wxn$?=6`AI#H>sT7k^X?NHQm$5A`$94v13*^D(>lJ-3*HD2
zDld5XQ62QlwanlZ>!-Z3W;3u|l&&hI@I)r(w}Z-{Ukl+WLky$FdJkpZ;kUapM8lFR&8Cm`|j+DT9`1S
zd+&$%)XH@_P+`$ryIQiO#6G9LB=ZVorqYiT2S83YEFeqzv9%p>;KTVx2&%do%(GWU
z^M^^Txdfv}C^3IPvDPs16t(J#*@A+Gw15=BD_C1?Zcuzv?KS`~Dg0LAQq3-K1tiO^
z{EXzu44!y>nR4>>e-|!|C27@7iYqkN^AN*z$7&dsXXAlHY0&3?Eazdr
z-KkIOhl}`R;NJTLA4@u$JHa}7ey0E;YPhPObN+kC7i%KW=mA3WA~~=b{_
zq_cz-ptkaKx9(t)2r##UvJWW~s@)~$@>L^a*V
z0K@I`v^*axOElyq6)~PKK?dV{C<-w%iowM0xH*Ccux(Fz_I-XwTzomGwJz^DRK@y?
zRp{u)?lC9kZ|hQOsok8XNi|U+BW^77wYwc36trCIwo(+nb_{tB^pZsjeZ+haDis9j
z>EJj`KN2vbv<5yNvnACGt<3xl?)XI3&bu-9Id)6hO5?%%L96&M5IhXu>T@CDvhw|E
zfrNNphz8Xq!%keCElm#gO2DRM8I+b*x3?yH*8~=qqCW*mB|J5W`?V3xuvq(!
zd;7tEaqz4BKN1=V|H$7w0xEhU-T;pL-I}w6(b8$*bgXVnn~1+5g*YHQFngBqR_2aT
zI+1pY?5}ZACPXjyQq3_9`{-+&6Cqii^I^C_;IAPqhuhEg3*GAc9&cSL23Q(7v7V6`
zx3u{40+48LxZbq$M$Og)x@ipM`nx4vZOzSoHN~Q%@@8x0#ph>I78sJyvfhN>xnBQ?
z<^Gf7d0@AFjTpZhNrs00Wwl7*rEDt}9s@QNr%QAq9=gwm@5rU~}zGR_15GhwqjuqX1x$+%ybr|jYp*3
zHh34(P@{9^5b=R*O`^8pw-HbbxG_3`h(~<^B=%HWiQ26hA%{uxhB0@_YIkOx=K8LmgCj(
zvig()73OsJk_6%hcfO`oy9sq(ZQV)had5%jp
z8*k>gz0dLboWhyl+=F|=A**4Uc&WytbU-rORVN$R973Xc=-$$kWIQZq5%GJjZt9jlNElPP9q8x89mAx
zAcdo_78Y8?{A%N_cbK$dz{OiR6DC~|e%rYC#19rY@uO!OGs;B0Bq~du!_m{~l&Hx=
z4Hqjr`enGoTbZUWqio%_KgwHad89!93#m}#Cs>wDk~P7b(C#@UGIp93&2QH>Bc$lJ
zVO9pCp#=pc%QMnmYtJc`ND`Cs%n4a-wS-D?O!ABjpynoaR7zn0E$zD2z>%f&USrEH
z+dBq10^8A;W=gsqoJFf)=r!R8EiPMviBWq^GjQ6K%{DEwL4c-Z*xQAl$L3j5
zndOWQ0l;4Rt#auRaDXFVKx}MNEJq7nI$<|lEzPzdgtg*LF%UpF{NLo@-PY;uyG<4E
zS`Wm#H6TO@LhZay6Q?Zk?X)xAvt7M-r}ep8GS`*X7iZSpz!@A63L&^3{%D|RjZp>t
zXqy|qZlRPI{HE6$g`6yzH|C~
z;};BOV0FpH+w!^Ffm@J(Vn=?`6_sDYH&h)^1uO2avMnh5J}SZ3hK1vPB9?
zI})Vh?DymT*loY{sj|wJy3)A?RjvpjO
zdl5|wBZ?XEq`PWNw=Myj+$Dsd>jT4M-{%0;l)ionIm|$thR_RZn#UC;ca4OiD
zy^Uw=pswXPGI4mTa9F8Y-xpPl*)yLzna#yt4f=$dmk%<-?qHE9KIG<9Wt7UdaH$@Pm
z3cYV?F_por8w-eeGF8W>V#Q*DHQwy}OFOeRSY6m!Ett;AT|;#>PwtxMwHWjQ%h|xqM5rWA^(-gbOEte}{9qj<
z63S{?-woiW)5Ute*wU}TqeM3E%vqiq8d7a+@0BbhLkD+!pxgp?Xf&^D`pwQSMn#uD
zX|+;tq08hX4nzT$$G-IoHM_&jw=-7UzMqy>v4K_JUlyuI9d(IyS;zJOa*e}41skwz
zT&g{AZaXpJxpRBnhU%9+FF&3{&~7OWpm1$b!uQ`Ii3+a?nos?REJJv+7}uQ$un#n&
zqZd1X5;EQrdd=~#_Nq)x({D}hxTyQrcEnrk6I62m1*NNdkKuc-BkUnNsk$wgXa(B6
z$DM~~BXTK$pD~Ko|1M<3GwCR(;Pfl@f&gPVRQIgd-ad$q89*qq9ud$`)t5|=nt8yK
zkAI;5#81(Ol@jf4_LqTPy(0_wAUkG>Z!gJ0e26jttT3Sc<$I?UNZhr5ZLjaqTk!;e;>YDhhP3ya7l?tZq_eHN3$_g0AXqp)h?Du_&Meb!A?FD4V)i9gxDk%buzos
zS<&mSx>~km=W#7$Pdb)bYw5(8N3in%TH4uP_r-a|dJ^*bwgS3)Ae3r1+U+BDe7T0#
zC-zH%iXE^k#4cQCaU=0lT~*O{$}kE2Z!sa`wRc+BE1@RH3}cglF`nMbeTaG{6ENKhnXYj;
z^R*CTw(2ggbGY`m#iG8}<%j!gvrRbDAcZ}9jU&@7f+tTJ_|8J@}^lz81ndVD5r3Yxx_5B$OL6etyxNpN%5XEbdl2iOsy0l$@~^OH06Ff
zzQ*=@_8PKOc(zd{U-PL(6t7d*%G!gl%L*u{7iEA*Jy9Y>1(`Yl;6kqD(O0g
zaNKUAW%rJ7c=?e-%vszz-jgU3_@>dTpYp#$@;HI?3?^Z|H``W2y=OGK38K&dIwrYs
zieVGqv#<~voovZJT{VJ|pW>I&K*7}=QfK}U2$wZrD`wu!-1i-85v$I(kHr>OeKBYV
zxpAhzc
zu%}t8UIZWkLBUDqyh*^x=Wh;FN&MQ9r0Zjt7Gv*nul
zzV!|u-w9YZApGe)gXtSU3X4rKLFZ2Zz4J%Xs(ad^;Fxiu1Adf@?otljP!p$m%I3ROa2fnLslk@;Vv9g(Ty}@<@hxJ2O7L=_+PGM
zG&b`8IH?zZ!Ml?)TtD~fMO(=Lg}+jYY9;lw?KRP6@{@&B(Im=GHuKUnDScuYop_W=
zzex%XXz2p*f>_Uu!%@1E@9;eqA$9(Jm{x1@BkJ$7_5ETvfX2D;J}q6Ez0SQGLO=Np
zO!yAA1a$LKq%Yv_|M%Ol)PXF9eE`0wnlcNP%yhMB2R`vttur@l6tj3c#@E_-Dl|(8
zAaa!z6tHhLFbAE30YQSo=Sj-eR4Qc})bSMiTnNBO34Uy${qZEl63{Nosqp`sA}!7C
zJ7k%fBCBT0lp4h7hpG^L=X$;uL8cd5Vz#pB%!^u?CIRU8L4Gm;@W7H5_caBG#if_e
z_(OgRiiu{uE`Nf``i~&h8g%}~Z7GAPEIXa@J>|yPy>s$i=BACmK8Cm~Qlb!4#%-Ob
zUiAKj^(&RTE*g
z(MSr*Dn`uxfeNYv33z($!1+Kye?On+9Rsz>uAX?5Ov8Vu%9zo2$Kj_%0Zk%(P^b+!
zsy)7=_c`3b>f*njzsNUsX_NQmeg8S2k%4xA#5pIQf6e7RkSRt8?B~X+E=|{3z#eJ$
z0aWVIMr$>|%LUR6LoLys7mDn`tn|P+4en-@%;3U%aR7%V9bj|wx97W8t<9DICqyc+
zq<2>E>J>b7P4C^`-F~oh!eKD$aT|gH5PR9Y!mJe~+hM`<7g4B<(nmDdQk5~o(vMwx`ObRfQ)GpZPUP?t$R2xJ9cwAA(x_^zr*iDRP8zZL3zML!yT9eV?v8bL{gsT8
z!g|q*kqByCZ2zk1bOnhj1qi`iSuYDf0M#5UfJ9#BA#_#SU5bD#4?s~%A3KR!JC(KQ
zHg&nC9+CX$(#0GGo1EMKIiZZI-dX)NE*boG${+wS=0DRy4@wu^;en<)6k(?pQ!kx_
zG)NjE{Xfx2ps7D(AKk*q=S;Nt`($yTX6X8ty+Dgzk*k%{k?D8Sm&aonX@P
zwEOh_u{r1tFPzlX)bX}G-LD?%y3vi4;;{sfw1Bk%Bs`0!;o8yWU_@k`b6zEiy*Tj;76}>DE*e&h&`W^TKfm$-y7QBZRg3`WV)FBMuFDC;
zvs~wOoK{GP5-ka~C^hDSdZ}1lpDgbK5LYDj8>Cbj;AAWUD8yY}neq$PV
z+p6{<$Yuz~G+;f>hXaZ^&pEf+>BCObGdGUL?QubDLtP{EOpYpzXPhTeId{iJz(ORO
zug>RpuY^~$Q+i^3S2(12y->UfSA|!PKfjGZ)`08_3Frv%xzN{LFCTj5-(cl#s;e5#
zP?a1YAt`vcXBtO1NHx=W)dJin1qI@T1y1%rD}xB>l6yRfZBGw8+yb;3-H{TLi;1Zx
zk<^ms&-}0UB&qal1Dg*5sw*+G?2wxP#TTf<^aJ~B#ryUM(P@iTNY9?XO=g|n@N{L;
zHnE??B`+Fm)`|;A$LDqmyJ$OHnB8S1VC{o*&7G6599Md-TB+viLjr{XbJ%g6)S4I2
zP!PIbsApbh*{`Mwu+Pt%iacIv5(mV+|AbKsnn-v=`Mk^|2Jl#Dg@5_t;}%**e?CCj
zi{!O$7;t5HlZUCaN&8Q&AXiiOlK9V@(Tr;u(NwVnao`^zDZKwa?JB_S=(XNukK8YU7h0IH!P$jE
z{+ZW79_rD3h~1uoQI>Jq9R!fiL|MQ;@#T0q-TSWWpO4_i3|j(IK+|qnPqCQVm{($v
zj)hjEGxTTZ5ltDiW=+HS2%;1dU=T9Nb~JTQc6)pCmZo=xdY9J2nO>{mo5P@C>*PooO^PaA{)hVESY@v|i@e3UcyzvxvNGikH`#cs
zP{56t@A?&-UpOOssM_g
z(jeA!Mul*rFgu=l58fSCW2LLg!zJ^hs48B!A*u#1HCcL!A;uFnVu#jA+$w{v(pVeMI1V^SC>
zBBfJz!Ds5*J5LDxey0fe*=K?(9-9(Yl|;AFZYEhuKAu~WOkq~li~^)MXlZ^ua`tCz
zQz2rJ9sX9tk8t-
z6Q=n~$h3@qNucygA(MalU*XS!t}?K$)FZ?A_I6EWaS|$=5BuFO6%yUCQKjgb1Cc03
zsk7O7#__b)HF86qGI6;@>H>A`*YEB#>ZfP!l9%)5Ny!yc&p41aQLg@ujlUNTA^`%(
z3~=C9&@6jj_KT34+jEpMZsq?vOx14wcpWDwgIf1M(?9w{0piGfi)dIXe+Q0idlV_u
zSHj#!#&Sc7cjO_@9*d2O_)m*8k<%0fdfk2A(DLlB_5+R%2hK(>Tb5;lmXGQFB%CZ%
zlkSa8{%U;qiDJ*9QC;GR?D=H`(ncj)L#`P;TYcPK27UUq@z-Z9tMn|6_o(3P}eX$@PK-@u+3;vjdu;!tf)07m6CYW92fvX1B1O6>Q=bIv-
z@RNYRLqbV)jH&ibk^}l>ocwcYkn-PY;YcAI>!!G0J|{aXkp%QyZcjssW>4Y)fpXy2
zfcJNgpCK1uiD1*~BYtzkP8}c5TG;HyE{kNg8~8lys{42c#`iqp?T@Q^PG67IDBNG?
znVTKv3N24)Yz(E3{y?soG)@n6bppy#;kKk#AD2^kr5gX)F*S1~%Lqz*^0Vuzz!!(M
z4q+RDsrQ)aRt88=H}29~BUUIW%n1e9vv*&`G)ZHKm#O#N^_u9lZYf=RjsZ9Ro7@OVOXOYjAYjvY@r(tJ(KwRrcNaL1y>=
z5P1!zVtgycyqO;jKxEd}u=Xoi3!O|WSLH@f(p6sWiMEX7DvsUX;wEd6w^VOb7755PgPu54vC*ic}*qQYEml;2BBZa4D}M;A;M3%zlRm~iO+HtRV1
z9iNT$OUTnbVmRyY_(8V|tReYq^D;s|=rF0wl*M2xXoQq{q_%Qwmy;rx-qVgs3SI2g
zU!n}6ur>tS&zd9P2f
z4*_m>-ix0MuV$vY6D6=IzMm;b={m)A={Q>BNw)Mmc>pgKPO(5Oad0*U={7viB4{GE2zf?Z)f*c
zl-cWat_6AH0sng*<@_Py5W+MiP}c}oNK`xXQFbYuJMiCd<&-1j)r?JQ@_eCJMiEip
zV1XvlCZs`GYbm!H1%h;5BjyM%a#VL9b82+;MJeOB^hjI(H`_qh_
zHPY7)l;gFV!9BImGXg7inB3b*&y5`>n^x6G}hHtA0y&%H?yRrz41%&i)4iv-4p
zU4bx>K<#UXCN|@S3Iw*y2eq#0*H%`h$ZQA;RR;4_HcU@CAl{i40Yip6GSEqyeuDx_
zbpcniKjcUfJWvt)uP=ba&;-BYIG@JA0Nn|lL`P;7&j7JE$;>#>f886$`Lt_l2=#Kg
zsbXQk)yhZbioryX>&w~u`~`bttyHUiPZpv6j6byUcYd3^|97KAm3V34E9iFO-Yr{M
z;|&U$U~lfMvK!(G7s-m5>&zy8CFUxDMx)o7+sn)@o%UtOXA!w)3T|d*DnlB3)`(I7
z6Y~Shp2D-};oePs*3Uht94Pbyy}*^kFx3D<*M%@WvCJEU+kNb&bY;b9Z3&GL97{*tIc2pcR=aZJm!;=l^1%wn+-QDKi}G
zvoCZ=s>1}oPpWVx%>0YQL4Nd@HM;Yrw)$n3>s?L*d>8R2l~SgR7Um@1un*>u{#56^
z%|ylMg5zaY1k+`E9aVU&>*QdXtOHtkUJu;Gc)$e6Sjotbq6vnR>Mm4Qln(kc^&+#NVSv3XEW9kl1v%_`Lya
zZiT?BWANv71!!MTYOUu3{H3R=L1IxA1KnnrMa%A?K0?rrzsit;sf<-u;=R4_1O3aR
z91<{GZrJqAW3gngmLj_9^DFoZD}zJaKUKVUk&I52AE0gN*>77p%pa6zhk1l241XaE
z);{w7_V_=`eC?7QbvVc`Qyiw@wk=Cm1UvXgOLkw%*ct4&J}!NHul;nqmbz$H%*)k4
zC`T3MQ_|P@pkRiWM_uGedcQIFBTp$$a#QjX#|i%Qd60Ee6tlqd+YoNge2bMp=H1ar
zp!fFM?sr3>MRo^CBgmZz3#{~;6%827aMga45Lj)z|1zit!qZ8+9A_t1dMxoV%8qew
zN@!iFPo!JEgt-aE>(uQ2k0dWwEFk%
znMox3Lc82s4Eax5`kiVx@u(G^(SWTA4fos2Vx{D=vj)uVC?`go`g+S_QJ#|RjrKkF
zyUkFtSv_WyB6t47hvmk@
z`#+X$^c~%*^{<&$LDN>l!jl(5M+5Xk8dLmdtommChUBB)qbyp5yL-F`jGd({=|I7~
z8XYWdw`IjMo?I^G%(=QIlhh(*{lGl#QHGrUDH>W#S`baL@`-)F@lQ@zvCy*E+w3=a
zGnHyIhpcvaLqt>OAQ8L2$=a~^-mk<;XiIIHYgHCyLA2%pOfLk^UOQ%*(IfpzK4!y8
z1uE??^oDxzfwkMiV_~Bg#6i;l&q77Jzs(rZPY&H|18-CuXZL+>e9H)}F&!^=1H1fW
zn7T}BjRng!y++$n#SN_9wk4uA5!GQq57IY(hhx>2o@2gs6|<$424i6lO78y|)c%RF
zKV5d-Y`q%SRWU+ugAn1LFR`SLh*Z@W^R)?GZ%`=?ivF=+fAS-!KX|>|8$MdO2_2
z%XJ?ub%11_=3*5*up_KtnAiTxQQ~^
z8DsnDV;AbZ1t3XWn$}1{h;I?rUqucl@xXhj%beoMy?2B7>V~Zn+X@;vBOznK?K7L{8{BZXyuy
zK(Ec*hQ!S&$`OWe)AbQTKH~A30-A-liTs|k@X@_zZ=7Vt=#jHY>7vsdf5JKw-c32wIo^VEFK!mv9t`cl
zYc@#R9+FM(4N=;u56M$rgb@QHL-uG*kdABP_%1|t`LbeX(PfgGC0a?eT_*1K4OkC!|Gqb#ov2wrdOI0iLS_X5amZ@dhA{h(LcoF3u^&
z&O+%bLy5%H!!3or5Zr6Z#)^8oMH87QN7?EF9>l)Iosn7hTdwM19`|QG0=jZF2hL7g
zIy)T2g!*zD+nv8K|YDT$cEioD8V94smOE#-M`4)pX_0Z9Kc<)qT<
z?ibfzG_!WJfqu^cg)ZSKu4lEEC@g;PvujS2t>7}p(o?GXdTNT{lye#qfYk?ugl8jd
zDbnft8-5GIM#bep?$dIDO>0lOo~5^WTz?pPf-ZrYH~i9tUAIV;kw25ly=~R9AgR+`
zWuSxR^=kRC(v99vB8++nWeFefz1!+MY1W{)^o@;^vIW;ODH&>CzMSOczHX~yzmFlg
zxS~I|n>HFgvjDA5R}@3coqkgtkohGp86I1hReL|vNfzL7-{E=KYtz0}-4|aAdn3f~
zHI(VRJtjlNTm_9}W#20b{j)vsm|F0!wO?5zO&s#uA4_)TJSgn`-i}$ge|?SHpX7m0
z!~?@kUgj?c8CYYpjq^GErSa)wKtzH*Mav_4
zQLP3E>Ev*~aPRhcNc-``J=E7lHhSt+gY_40Tn?}Nm%J~sL>pJbRUg+i3o{s9tK6fy
z`hP!2KrdEEy>DoqI7QSOWpZ$8Q;F=iwCK&A4$mMheoyx!6w-yfIF}gSJ=Q;#T6{hw
zpMZ3n(Je#X$$LkjjGGBqkJw4Jyi!l8#2Pvz^>+E#S@H_^Hys0ffxztB>aE{!N&1GBOdsEA_M8Wuo?Qm
zb;sAVF11aQBJfk*4eVupvT*<0-s<(*6Y|UBp@wx3xjchu=}`V85n2=Jl@t6g4DF3A
z?@|d@?HnJ+h>4Mhw==hmR#-X>XS@5e{xMu8MeH+rN(uxqTTHHUNNuI%%43UH-D1~!
z*Ec0bc`SUPC0gR2^gfL+Z+S`LQT7pF%+{T~h;Cc(Uf^x(jQ}b4gX9@=yhDWFb`!;$
zZ(Uh$(s8X1&tgQM0$y9EjE
z9^3-K-6245cX!tW4esvl5?mK|SS&zrUz~4~=X_P~Tj$i7KQlGeGt=GEa@%#?cXWqX
z_0ujDbw3KCqg~=zo}?&D(#K)I+xA?z$oI`Pu6Sf9c_OnK;KGA0zrhapmm;wPcih>M
zIq0N>EaAjaS4(8yzXn=Z!)l
zHROCb6#3ocQOFKBYfO@A;0fd!(!&UX3l41wG2j$$HF_0x2Hysrp{qW^7EXc?ekx+RZKW(_3{;7
z1Y~|yd_uzI*_g!?`J~9CS$-$E_B0zT?Mj+!1T~^u)y#whz25Y|19gFd0Pv_np{0Jb
zsK!QfUU+(Q3;Y1ly49CL^Y+V^qePHy?%|X6yMfb4o|~|p<2o;BOn0bd+($$9ey-;=
zQtyE3DA}b!wKWWIzZ6J@B}MROZ-K?#qB=M$KMy%BWM2e6tOmKHG*XQ80K=!%>540D0P>|U^tOC;J};s
zOq;G%tZ8V!Bzt%8VD+I6RUmY(Q#?Pp)^tSd2Y0;V$k-qa#Q}>8rjqD#(~=Le1?Nll
zHOyVM!>40W(hq#z$labFtsh=jZ9M6rwaBNkA#u;ln6AfGq=OY0D@~P!L_85@Hl%A
za+4pjhZff-Q#0Mp?ZrsdRNob+2kGZr&n_;{3cA#Zea`D*q44h*1r5fZYh66dwIS;#
z^gSHYg82Fy!lLbc7@k$J_jy6*>!~!xuPP$suan+&_je>j8zs=y;-FBhdtgb}lD>@h
zZUca7Z*##zK?PJ$7%KlSj*1-7HG}{bI(_X@{|GJ5kNl^;V)5ZJbnuZv;SXFq_
z=8%Q=-t_4`)OH3Seb2m87>Id~cc(wO!k^^#Q#R%JH$ka|psK4`aduTwo+`3g>o
z-402vfX8o)0Wg61yo=vYNr4FfX4Aih+n+}MCPL~`@!Cg(Wlzp7m68;{tbsjm7*urC
zY`MBXLvIF&LvPz56mi^D`K1Hz40hJ8XkVYeXrPJSxe2zn`@UK4eYAZ?fX}^wfGd49
z+0GhG?e4u}cg}D2{rjN(4BxZix^qLeGaP4NH|F!;k>>p!g>`Hq!qkRu6c=sTxoN#y
z++W`b;0GlmH0S%OdbD&$^n=CK&%Fa!0jXY?`*`KoJ&jb;@nNlgXvgJMKkG)IWp=QV
z-$4O{TtI22ykUOTMsL1&(MlY@iAp=H+Ub75ov(B4TwX7Fqae-uSA-&_
zlGZq9lp4hWFAGs_YQD12sCVo=b;{%le>oYX0f`yR;fp7~`XLcmBl9hF_w251#z!jZ
z{~s3t0cN1_y9s
z;6gorvh>z99ncY=okxc~R!!?M>iDC{twtmz{$-zp8@V!WF`^sTFj3wI?d!heBIg9?
z<^9-r3T@D1#v6A=e+N>ndh1BIL}{V>Y7#R_adILsRTrymLqq<-k8%F@lXkI=-WisP
zoF|0OKjPL`ANTcst@vGr6&Md>?mK0OZfQfie@0t#_-e>ws%wFXV={tZ@eDK<)%kJh
z0dhN#ARFSDKCdq7iDk29nilsX{i^RCiK~W7;oAorP1aL%Wb!Z0Qp71l5@0Vtzq%K#
zB#cq0Y5W=x8O4^{&QCZ4&XMe{$#QK9kU0o}D-Br&K{F8`4gNsi~OWCKG3lF=0o`v+b8#o|yP2lE}A6?WA*=?*wb^K_Y
z(n^HyM$vNU1X$;@YY+8bi+sQeP;`O6pnjw23W1$RkHhwlAkB*|3Y+#
zL0+0M&T8T-Uzg5-w;1}=KlxXZ8rTWiUDUzLeKJ(W=0O4+
z7`E(jOr3F_Q_mXY)vGjWj&)nfmkxMxfOL`(CmjLh4IhJ|MyI~V0V_80R_j}mKx`lp
z8qw8kq~({wQleQ+$p`EBCHeZ}fq;8Ipwk0meDi7Gl40^O(aYImTKW3%)8+SScE}n=&u8EC$X}9x=OpBMh~X0&5GD_tJ+5D^`gNlU
z_p6xXl(9t_Sy?B9s(5jV3Bo<-vmsX9KcVMBX{~?
zqebjtM&dm6jAO&{GB?y(Rq*$zD~z$c&Rj
z#R%Q$RzP2Nh{&YowP=bGyxA+)g?x>?@L;&R8A7+7FDc)fc@6PsA38~Mv^*uyAbKjm
zJlB#F0j3Ec;t`1o=1>2I)ToU`%wd^)>_hyXl0
z#A|ROjcN%K>Ms~y$E7(|f6?4GoMu@mn=kdm8rB`xNgfI?oppa3@DXponSutduzs=K
z+yM{&wTLbX6qSEp7?sokdw%I|^5w?CDV~uZAE9%RIS)9LX4ZRfPDHux_4=e?ks8%~
zRYm758+T9&JSefXjrsZb8q3yl+*NG!nsva|*~Y3U!1oB-XfNIAjsBXY`g!I+aQ{m*
z!<&=jQVd&xo<)?7SBpsUzoof-b}*MGp+Xm~bXv7sk3+uAm28@-T0Y~}5nz~XT1x!-
ze%pFL>i)LYxk*%imk+fxoK+Y=E+;Ma+Jh^3schV%Wn3{6XJ*w|P_aX5Uj8eSzmq%U
z=vjQ2@2G{Fep}VnU(Y8;Q889jIZL>E8M&ig`6rbv$GoA_HD3jSm?IPX>#7S?>6)Q^S9{@Cdze6{gDpnI%NOxSCJY5y8UHKzjU
zjZMfz?c_oSs7L86FCpQm@OoOgAQa4wCw(5g(!$Lwvb!7~0nQu9X>a
z^vVEz$E7EGX7cGJj$FhGbb`+0OdBo?^nsy)G2tu)y=
zg4j#2)IU?dOr(;qR1E7|z{fp~Q-@w8i^Ptpl5*&I^TyGd+m}pALp|MLvl(1VXgh^c
zGLJyWuQ5_mYx94}w2@yeo^thL<)eq>x@zH#S*V{UhH)hQ@wSWAE9YN`Er4GW@z(uP1i>Yc_3d40`E5uu
zD$D`>v^>1ZV3ykhS2+U(qV*{UvR6F67D*LD$YUVcUjoxG8%(XFuQ%$C71$>^y4IkN
zy>~@}V=v6}Ju%N-e1tyg8t9r#�gT!VbaxP?5J0i_Xb|Zs%gFXJHG+<)&fl^*`r3
zjrLTXG~@btuO;O#ElhEU{>wexY_etNp)*et!oz-|kl9BbBKE>jmGasf9s%`~UzNrN
zo!mT`bq&mPMwu{LOQsD8l5Kr@
z7h)zuNha!HA8KX2&&k~5ZH(TIj~XO&Uw-3@em3{#8LEsE9Pj9!AQNKQ7t11Cn+Ox&
zHi-eQt(al6$G-~c@Je?_yGh|`*yhHl2xfoIu4prk2~9hr#k8(-|5wNXtV_;gG%Ofra?aoy=^P*
zv6bbKAQ>(JuYLHh^$4kC;%5d~W|ef#1EcX}<_F)29F>pk9PCtqj3c;OK24Rl>-V$s*4E9
zi|kn)I^O`WAZTp9${8qO=QF6&(YV+y8N%FoC#Q@}Ms(AL4j&DT7q&+j0&de_(Z_iT
zIWMw??AdHXPi;wAq+LaV{@pc`_Y)#?Y3BmfPcKi^q2Gj%MboZtcGslPJVjSUtA&q-
z$QF3gb*wi&J!?)@oIx9=wB>AH`r3U~=cOGz{!e&H!N&CjZEd5Bgl72sR4IZEg;#B|
zh`dAfy&2UJAXweYte6&S`lFeh79uH^b}w-9#a7h~`zGDA`IHA^t?E%wtrQmEQq@GB
zN}vBY_Rz*wf%M|~aj!?E_06PLE|Vd_Gs518#|top-{97fw)nz##okR(O@TnE8iws_
zm|-sA{}GsT?h54Hs;v}^FYd(kb+0qi1EPa#07wrkYE5t4Thv}Fv;!GFc;&^1a|)`b
zBmXfYt*9)dAtqByo1m+?4p3Nu*0<(J$S}N&Dr{dx08N4dd!
zV^VTS#LZ#%5D@ud*LND*#JzS-2FL~bz|<_+hcuX6qX|%Jy(8slU3|JoLB2ycGxa%1
zza%N>j`4i?(G=E7Il?}|dc+sPJ0|;BVxbufNenqe9076pbwV2OK!h>*`SIjN
z#UNVfbd&_n_!;&jg@fpxnZtmSln?#gZI1i%B4*Bc<}c5n9lp_hx&KrnYeJMX`07^p
z_M6XZP$~cokY^Jiwp%K0@hsU-$X+SVv=naW;6?UyfN!CK}kj5jgZ1dfdh4p9~cG
z0d^BEx|Z7D*unBWitXmKlL7zO5=87v2`4{%l_VtR<_U1<+oJWc+@2Lvx3k=xZW7h}
z4T2=QB;Q7G(o$qab2uKpVCA?n+0KkU(EFr3Pw1mbBhVs>6`Ome)V28|P
zT}AZnW#Ff{)H=+rG@dEtyC53903BQ6Kwg(^%Ma=gJ;>{RUMOh;;uX*p3~_^=M^=?=
z+SZyn0rJU=H+@;SCe9!jKx45esHKvQfa_gRucHNB(bOkSx@j`PFLoGG)%`q;Zq-J%
zDBVC<`>v$~;IMiC`l}w->s7}=jjiHIHun3SDBSv`W8w-F?_x=6e~33{!*yD0!4J&C
zgZVnePmW^Hh<#?;X+&X?D&K8Fy+I{}@Jzpba@W+9C|!P_U;R@g5Sgjk1me!k@u)aI
zz%75VjCuGLqn&k__;7b!y+CUrF}&4K0P9=@Q+Td2g7&34=lYOi|E!v?B|6kCU50R<
zG(l0lv8M|PZZ|KjRE>>tKtasIyyz535oy6_2yO88yo9@I&+Mrmx51u
zg8{t}Nqy_!lG)*9nY_pPnqzLYt=w*8ta$Fvr`)mSJoVs%Rf=Dlx(D`$J~>RfZP`r$
z8{kdXu?<}?!TkGr@*U?nC4cG(!;%`8;z5tMPRt|pww6IHpZzDk54O9HYB6R38iBT%
z$GUH3F`kRR#x-s0AEh{M{d1b4B^mzfnijp#6xk-fUz8TQP4vRSnh{g-U$m_cbUG!9
zbPJs-BtP3LB%#H^$Ew=&f!ssNXK<>!c7+<1CfVA@b|l;kMHGa}K;lMlfN2O0>F7s=
z%%ghWYnvjMH=af$w(KRMO8C0__}I@T==kI;copG;aKRSX^UB=aE7X^ThfeX~0HMS7
z3fD<4EzTY2A=fx>999;W;<1O#9MS%xN?V*{I`NnBcHsARp&TN{FiYz%m*SNqxa@8u
zN?iB9m|)+bT;nli_vBrpavL_|L&xdM=Nvtwma*Wo8{BCl`**rC&fMb8E`mriV3yuM
zEf@J6{zBo+2kqt$cgDU?`Q1>LS_15SiMSrze@wEhw~M@+>lbqJ>0W`MueUzmJL&y#
z{;3H!*IUJH(XFb{O7B(yv>EWUlik+36_
zb?jr#+4^d6ao$<)U|dJ`tP%6nBT~
zn&oQYYs{61mRfgRHl2~FIuCzz%`@H;rdQVn39_^=rXZb!5zmQ_Bg+DBgmP|Qa*jKF
z(C<6Wf6!00U*E`|%2;GvC^=saQc&!E&nOm1x)Euzx~TU$lYM++nty%4YHbL*p5J=T
zYjZseVo_uRUZz~`THpo_B8`U%AM@vVY`~o1e7UndcIP@9&GRkjaV0D7keOyG*M(y?
zxa#`md#4H3-%gsS+C#eJPk2i%P!`pglHx%pJ>xyNT>
z!JTree6UW@Vkuu1mAHNbAS-f{eDLSPybJ_|1T#_Jw8%%+islMJ<9QE17=Y<0+)gZ8
z4xz?q4gV5QeP_1{>%^;XBRrOE4SrWk^S2{`3A7<48V`bTOdIMtV(+J8JtC8APXFy+
z+ws4@io>nyvD%kY!cydQ
z?7pTJ{Q+E0l7t`7s(L;!Mc=G>AU&NA_Pwn-TG4sEp3njRbcke1tL8I^!a`643tc=8L-UQj72*0p2uvdjnim=JQb$*jL<#8U>O4eajJ+ZK#6_K@
zsSS%>0B@nqF!Q_Xw`p~=#>_f>cK#BhX(scXQc<-j=L7A9-yRy`NY#oyyN@G+Jx~Cz
zuf+f(vh@%lo}=z(){tnG?GxgseaPRAev6{oDD;*ySaX_+ky?-E>TM+Jsn3P{Z|B0`i@*ZxcjZGyADIJf`UEh
z84zGl4y)*dehZRl9cJb~yrw3goiqQg>TvqerBZzOhj^*~OzrBE$u~%@3|#0reUb{z
z>FW?S@J0vWu>Y((+~wfA$&&e-r=bQnXo5Sq95LKw$ol^C);t(5`_D2#!5Kv?PlxrT
z3G%tn(De)?NhhR_Sv^7|w*mo-UKQ_8-fZdAff$7-ja>yK-jnzo_N{PFN^BItjHUTl
zzPJ5T^I@n+Kr4&GNOEC7?)f}fx~a~}{OzP)v}2C?R{Lbs^k@2S5bfph$Il5DrYnyb@zC@OGArR8G8MV#cq<;B98ye9HGs`}bTkdY+Bl$87&qoe<#{rCPm|WyNRY
zpy$I+JhfI;Syr`QE3qg|ZbWjcQbg5T<4o5Ikw_B&SRuox&8TbM8YW8=nNAg>4TvwK
zfL<#)<}XaYc}53qFA9I`dW~S$JE)^Q0H6EF8ekz19*gUldjw$9vTuj
zBzM9LYuoLp)!61C{|zv`B)-o~u)b{mv5{t^#VK5zY6RyvAA!De9*8Tu18c5z`O8Bn
z^SYE4xfZE-Dl)0?pq5$*FtDwV)Y&$Be+(pjgr^ZLCUx9FD)w)z6sU$ts*OH|$u1V$
z<
zt-I1Kh9HL-R|uW5RL5s{U7w^Ne3v8nBjVTU+p41Jes!%J?tUR40k3}=+z
zQ-}>|yDLYA@;XR6zRC`)UV(wKxfd!va
z+?EV{Vm1u6iNGK(5{N0M$nshA8z63GYkdsZ)0wuV)CE^cH`5pQ%
z4H%g>s_FgEDEe^7K&&jam&$o=9a1lT{A&LzbTD$)RZ}~p>kB3$EP$Mrwt!Y
zWr24{a&M~@+396fIrkBg%bL>+V6R(-lDDP2GgxYY~
zyx6J7vPkG$GwRh+0axPuW4qbQuf+!bSnrl7^?}!4f_o`U?9c_nTdZs9
zJ<9zCxy^`b*t*ngbr%wGofT9j5?vb|un-UZI#hBdOF=gV5J*7|(d~K6>r45hq~pI~
z8<3h@S+**y=k8VNUxEk&pUcXhK0;q{=TB_%yMS~}z5LR!@lyaNMwR;E@psy@@DXfe
z=6E9c+@3WzDHaKmUS0FakPp!8d5=3d>&^h`m
z)GC3&tI3@VsYadwN5mwvrs}b00WNNIICvf*M{`Os(PTvf>11M!G`#c#pn=P8Nyx|;
zf1nxKSx?tkhX=5|nz$+Ct6!{cQ88mvm4VwZsL(6nL3Jk_^8)w$;
zuBVyouR|IyfVM=|4eSEtUUOAt)*!zqYI?slqOkZg0F~{AOV|dkRx^&?eCv3!wMd6e
z9uhB`G_n&-hU=?Bs?XMVX|tWr(UI`GZ@uQmZoziv`0o7DlDflqVh2b1zwygS8Eo~~
z3J>DMMh
zWm~c_p+OU7+dTvSe8I36Kbu?pa^K});?*`;|IX6J83<+Uqi&op#lUt(#{3z;{x9_9
z9mL)%6E#{lfpK<@6GSdTE}t-g2zHOd@Hd5YoZ&rdX>imo-dXZUGTXkc$U<#ht9sLy
zXP!vzIoQ>h<6_M-&e72ZBCkM^x4*pzNRT;!Ok6bxzv-s~-);*Y5_eHN4T%~q3$valV5m$ozD$9Yk@r<2+A5Lc*x`%DmgQ&eY=1?f{Y(uA7
z_o>5yr;Qn5L?SOs_7XkC
z+vq088pacwt6;J(@r&RbB(w^0ae4*wl&1v$o8)ae{25V0Wom+
z0qO`$NI$vbKq8l_`7i-aOS!WC8S7J}bL|TcSvjp&|F`V_bAANkJ8u*0gE03Irtub6
z<(08p2zvBeRG-&rCk+4T9slzI{Fu;#KnzGx9%S`C;LIirgJdTAvRyEma{)jJ60EMzhDt}35j{6Vv_dni0Z8DVRE~z{r7}pzW$nzKS
zW?tnQoyd$`ZO^dmuZum%vbY-RhHMe?Pb~Q#4~q0aa>4%`#|twjqQB-;Ak*xd6LF1B;B^#9kowsUT6ztOS+lK#^6|!{u>#od+5c`uf?^tQ
zRYbcFGC%zyvh$<t2YzKmt6={rp
z+=U)rj&CD5zG|NhVzJ2XZ28;}n-=uwKLd08e9{Ze<5xg=b|Zs*pnaGsy%)3(SIqD<
z7Hr2b4|DE9%0FbkJ5N;W=9EwT>9bEe6MDD%(HF*x-mN#$|4Rwp{_X9i6?
zUKo{O$-(dFMksf#xvI_g9TD*cq%0m|Ki@(sj`6EM4dLA70Htx=<{D?po-1vpzGdgo
z928)V*ZE=(fiCpA353@t{F%B#-^TlEJ|fc|Q27pgwGX4tJDrm}V~acO;&{GwPQe2%
zQ=$T;-`cwug>`ajCKIg%1=yP6_eY0;#okU;L{sLzKE6dncRiN&b~z7PKZxD?Q$M$1
zuiG&VF%FD=8|8f4qHUNn6W#?<{^B)tjRJ9W+hBmM7?2c`n4JDRQ)Zi%xKNOuNcHXz^-Y(oD4nzH82Lf21D-1+)hRoEOfHqg@D@6@qV0SdUx0ZD<8D#8gp#
zLK!1}A$HNc%ADKP9PEKp)id?s
zlh6FTkCzi=NM*}gdyskOhkVKXneG``l0f7x?WNP3Ha@MT
z<0~tPsH^rBZCfv|VVke#$33`QYf+wGdq0J)aNl-YpiENUV9@92JO#-flzGY6@B@X@
zYd#fkKKo$ztHfxfOKT#gK;eyJ(ZKZ3I|?~EwT&cNYE?qgTD4wj`-#(1Xt*oXY-O7m
zxF9eb9h7x8H~_uOKN`dfvX_YZT+K_D;o;+RLlU@;?y5+TZ=cK~NRGP9H
zd;Su7^KfK8tu+_5IXocft{uB*p^tGP%xNY5aeG39(!#IAUU})+zXLNW1~fP^TkJB
zM6;s1IllrmO-oBbvwsuAfT
z*77&rEN$lrf`5j#P__`t$kmF-A6l!uV5J
zzgO@$P6wRAwQY9D2(I?`<~lDG3Ee)DJxh-ca*2{`b-yK3IHj~tZpew+M)o+f#ql^Y
z8AUMcYZz9$#gux
zB!WNsE*0P82Ix*Eb^nohJN702E`s~b2GbmpYR)cDKsh7_OGI&N4#BNqaa_dSV?o*&Arxa&$GQ?#=blOhUKQ6kU1c;KTF^
z`g=N74tgEzj?RFeKdYzYQMK?qDF#xoXM2WF`*OJCgmy{WDf|Y~}6GQ^!YV`d
zLKIELv7Q`cQgLy#{jr#>H7-mon||hfq*ojaw{z%Fnrzme>G1JYkF$zCxr%xDQK>g7
zU;Zs4+k03$+Qd&#mv4)JW98)R=AegtgLj6BJA-5w`_(`g&M!Ze);Rmn4*a>3oqm)o
z@s=^ktf_iRY@7M0e1TiCd5rJ1KhukN>+R@gohFIhN!$6i
zRDBv4F;g;AAPR8sqDnHn|8;krCq7$Oe39s@iy2m9*_v
z(|3YYV)3MMl&5mvPd|*vIa+JFB*(V0T%o|7+Gu-U`H(GE@5NWrcF#v?+>#hp6IHKx
zz9r#}hUe$RMX5|1ySNo$C-6B`1+6cN{lVVvtt%%SMgD{7K3r;1P$=KBU-1#HeQhkx
zr6hi3hE0@z&7rRMmsc7yk8UOO;Cs~3nFL~zDAj44M}v)Ek?@ls-X?NGcy#0Xk)z}n
zo#~gaF&lBJ$Y?hyjS!kYSMbFj%m>#(8#=sC!6aFNXKdm8E~S;FqgY9W6*Bg4hf7~=
zGD>&tNf{X8PnH$7VKTav2XW5n4NkGCiPR;_V}8U6;TF0S^69=mDg8(m>u+t@K0d=vxh5UZ6hkym4rycFl@d@$4Q7<|
zQOMw(QBFfS9)hoT;@&00AraM0gDKypNJr$oW~D=yec8^opXft6;Xo-kkisP=w~rN2
ze*QZjDWF+|1+9TV-13Q89@jbO@snHX2a%A@8|D$S1tN8T{p$p2|FgjfEuk5I!0vg-
zN`AdXd261}3YnHY38zwmo}$GnY@;j6uo8)mrVCT~)=pNwGFIGY+~RSI`6LUY9xqJS
zUNVGeDb24+avTxTjKNBr)NvW2rFM>q0eYiEA~oSmElN*6pcriA4pH8@dv4>KN)GU^>>EE1+wd0S
zs98mD7GtZb-l2rO%@2^(^p_#=6(en~rz8O0R-dY1OsX*t97o&XHYE~Ww0yZ!6KpVVxmxo?!y5^48>
zH+bJuH8NgB#-PCf>|k1ZZfTgw6k?qS^V`S{-|IlnXilw8Dd9tT5RU&DritixygY?N
zD>$^dU*_16Gvk@<>X}-~xq9l9%e+*o%G7QqOaaH5!;z>J;V7Su#Dw4#7}*Gx$s`=$
zd%3#Qod$dZhrS^K0UX@F;bFdX(no+dw+SQ<3ZVWBtF+Xcg<*e!*H!Z7J1G5%eGvl_
zu+Mc7gSb*BwOe3$Gvh$4JO&#ZUoAfr_;@bw0?!$Xpiyca8Fpe4U>=7Egv9jS$_-rQ
zDWaa)BV@7Vt`#ztvrwe*`@OK&HLCPD*phIyeCp$X7b-O-pFyKoeef=VpAaTP&;E|A
zw=B)6+*Fv|u4z#l55w;~u^27~FK_OmmRODO$6Kb<V0Des%FllIUbkerK+-Yzje$nbtH;CEyJ!vN`#eZE`&)5Wb<&Y3Zz=Fj)_lu
zCFS1A2N%34q8Y!3CJE;shJOt3pKsP=fcq*T)?#-e<)s|1;ie;2#`TD(E{jeZhSto|
zIhM_z8q3`o_*(rcdH#s$n&sjWmjTNfX-P`rbhyF5$s0xCT5
zJmJC{ygT~bH4Ziuu)yK;u5(CMP+F)BAFE}49Rl#|uRV-XiIdeC{Bdf^iZdF?-tUvEWwbUd-iN-gU
zpWEtQ{(=D07QJ6{#FPa2Fu(=2cn_yuUxbfSx0WMy5oQ6xvO&1BMB(>|_;H=3evKMG
zi1BBAO`tznfe(HiDA21!DKVN2>j3BLPkX|>Hbn9`SqT{zHJFOje)T?UgxYwv@OX)^
z5Up8Qwc*Zo=IG>OXpbJWCmuOi6>*=OtMc%(5e*6vhW=9>(Vnk5@w>SQ9#xdXRueTN
z+^r@Wr%6otSyo@B{UkYcQCGaki0U12(4`xXQxMqsB%#>LrAZg9Cb{$Mv|PWfr5mFp
zb=(oJfEC(Q>B6ckm^mkd@;4BC-g{fJE-o^kvRU%s>M6a0-#XX4c@mMY#F+y-dT0g8
zkePKhYHjAPA?WFuuhZ$%Yd{2x@B}{#aGQiy`exX4_RvHiX5_6|#39?N3*Uasr_JzJ
zU%sE@AK)iU@Z}X`xC!;}$|zy~yWI!O
zLmk17#64krdPcxd^08r-H)!f}Z3x-smp+
z@s{h0o3rLws*djB^<3Vsww)Kb5QtEaXVk|&jB7@m+v@{5y6h+2qtSD#YCTlt?_XCn
zBHdaByinI%Q*etI;0@$QakP2~+1^*DakpuPa&D$u^?CCxd^PXd4C~8(-f4oDlX-GW
zXZFnbJZ>gX`{fsFRnor87w*z}kNGoRY-NNwxa7Si4$jTcavfvTgj{=}AJTc{@HvOf
zAg@uUk5X3vS&45o?CD7B0WP87VlD-rb^cI5Tz7aEb(&9u?vmY{Ti#~dxzTt%n`Hrp
z>Z~Ykz@h`mr+~%eGv3h6WD_EjBrSw!E-l8ikCGidlni@FCQW#ePz!8JX=QN|En|@s;n!3QQ
zr}rrWH*4!_r|vMVsEq?`d0^CTw=@#e$aEcUyFx#MxCS}Cpe9brBHDi6;S=xua8mWQ
zIo^O2Gtx`v09R;B$4ZG-XpGoUQ>3?J4(GZUXy(;hxcdxWLKOKn;I>zerv{(A?
zgpXPwE52L^e%h(YlyUgia*FRKzJs6rnZ-(RD`jyfdbP3Vj27kH3(uTb+M|Kee%WK7
z3vL)P5NFqQILfnv#SZLBv`Y9&|LCN-}s-7I633vha5aDJXu
zdTY7t7lZo+=ZV2^y50yT^SaX%ZROj-J-%(+crzO9UsFtU9RT4P3
zDv|{BY}?rRZjBK|CBzTl$JCF5U+H3CF0uHxJg%R5GZ=?6hArC3W+ra5S^LPV02(pb
zh{@5_zg!QB@71L*SqWe8i%#_UWpQLV@oyVLEmi+;>);;AZp7r+&LwRS%IfkWK>v9y
zA|1N>3Kx|!TTlE!9@Wf6pgHNN+7kI%^4f#AS~R;(8J19W$R38S*^Df#lp>F%b
zJr!=FRQV|U87iE1kjQQpjvnEk05QCMwy_2=Gg_)U)
zGt0jd2k&2tRi?(8(;7F1@A;QEsQ&QoMqHMBW;IDO;_=80n(AHMxlU1XI!bs%T!7@q
ztY>dLa>-E@!QBC>>v~wUDP}Y`_eZNN=f->$Hsygh&^56HGUa;>Mw5frv&qqAQQ2L}
zK0RzsH*Ph)ns35yoK>MdY6L}uP-1ysY3JHATdOGvChLwOf8btFJKZ&?I13z-6Lk2^_EUsT{+iyn0WL
z8^h66my0$wy62?*E)tLU+2DzS#)4@Zuh-wdBc_S0Dv5(K^nKYGRQ;NRkejd*6<#9R
zpXE2azWY3eKT$tX*G1ukrAEnIwEEC0--3<$(I!IV6zEe1ru+?_+@ak;dYy@YMx&f&
zP&a>r@QP0EHhOz}9OhMDCw-i0rt?uX#_sU#ysf0^BiYwh9zApCn
zd*pWLl~T>f6r`xV)YF$Jh29|#Lt}S3`60!vJC9#3dbIN!mLt9TJhsro`g&LVIx%nI
z%*Ma;6N=h%vL;A4Y$0eSaX8nCD0<{m_kFn
z7Vm$+b#FvC0f+aat-y_u*e{3qZuZgvJb9iLM~3d3f7?j)caWVL$M?@b{rNWE+GFBt
z`jbq13e2QP2c07xwY5tzNVBI=3k+K)ADm)NuOSKs(ajBkN7#kyGh1+h(4X>!8LJ&5Wv%ITWBf^2?DY@Ke(>N+PdcOG
zE`G$<>NUx|l1YB1izDu?k%lEFc}gD7($m}@IOh5EUuNqq@%Dc@*`XI}`M^uZIP}R{
z1X5$&p=JWh^kzB6+QbU8(5=oZZJW{7Y);R@fW<4tg+Cg0FjY*z>k0u|Bat65uGjPm2wIwQjccGDO%_)s4scpJwA2Nh3iTGH^5hc;b^NuBtM|Aozm*3=r_yO3wq{ZC=
z>J(`5Q7f+x>$B*X$}bTP<4^(~v>S{O##b@bl?Yxph{PRSWRpw9
z>YozZQIqjL=!tZknhxNY9%RsEAbb=rXwOL+nk|eUnjrn%=ID~A$5J_6yW>(Rtl#3@
zPZJ7GHIO+uhlRmMHSAu_{w`w-NvQerk)%Gg-WC6SD%knj?xJ>j7)b2{SyeCoe^ynVf2*qI|6Emt)ORF5P?!H;
zZ-01CTWum>m&g+VD>?9?4?4lLZO;E3x>E*smw=WuBPpe~udi?W%OOGh<>uVGebS*7U@<#Rx}*U_=5a@Jy(_*W;%b
zzr*@rJYxnoy8U^=BaGVTx3wyE=9Y}&n95uoBWQwkGWNak2q>s;CoRmh@0YxklXj59
zkFSW&l48ip1!mj2TkI2LJd(7g+E5q_=_+kYx$tAZwtw@R6W6FLgA-48Fg`inyKdEJ
zvJ~uAC9@Mc(P%Mt1lXixuC1X@^bQyY&u_kE7}+fCnaV9dk>+OR6qtIWrZ@wRUp}OP
z0zS6gJBSz5UDl|-xNO-~L@zknw9Y%az5&x>D3NF@-9mXIhll1#nSJ{+V;cQQ=~f~O
zfHEI!+^7BzU2ho`R}*v#2MO-(9wb2U!96$xcXu1y-QC?GxVyW%y9`c%;O=(GbMN~8
zyx;q0)>$)sx~pq;)v2yiz1#fO?*MWF2Ho9JFbR5r<==z-fA<%Njqr0@F6tQ_s6~75ThF57I_y`$bW)1O
zIxvfYrRllRvjV>xd@r4Mk)FvN;Hhv_0!;RQcd7iEOwWPBD)uvu0`Y@4eI8Oyk|EH#
zgE(wEfsexp7#Itn^~wjRCaCle2ipWFA)feoj6E|-x{2NV5Uv7QHr1JhBrBIxS6=&5
zbvV#xTcsDCuQgU5SH%tu3C^kG)<}6+)K!k;VXCX3NsZ$#b@cr`KG4(`O&+n?#~UCWo>KS%hjQQnD*3rBstyG
zz0uP{GsB-}&o%_BI`@JB>cf}FIzY*
z0hV@q6E%Z17{a$&_A#vxQr^!<2xWYpx6jhd73EgZEMy+>uk7B+{yLJjt
zh_2xHPut%l_w($fo9l|-*#S-T5{U=U%01Rm-^)@kW~95cmgsO7Ao0%+G*<=2)t#}o
z^dZLCp&`@Ca_c<(g_Hg|C!nEl#LO7~peVM@C2jlWUv`eO(55O`eqMj>fOX%K{neql
zK2zP4(B(jed%nJO{-{-DIt_HQ+VjxxpatoRVJbNi?7Ekgv69$-5;GLGLWpp43Kf{f<(Th8o{L*0HC&&5anJrUV`x
z&fXF2xsWa`%N#BNH6rhL&xV8cy=8GZBhD=}W+H`U;=m_q^y4$k{huxy63=b!@slon
zgyVk?gaQ9t_PXYV%^m>FhkyGWI*0hY@Nnh1$I)1QMxhj<}bpO;T%b+LyHN
zLVDY>2`-=rFTkW4-0}UfCUZZ$gTP5Jg%Gl^A0yjtbwN5B!3vUnSsN_blDaPkW}ROY
zzxnteLG5{0Q}4ZTZJN9ot@->4e~(f1c^lt1O!i>_NGRO<_IIV;vm3jmB7_WDB%JQ<
zl5tabn6-{yYisrK-@NGCjU>3raGf;?d$HDqv~z4c(1b{MBgLGa|Iq%X)5LWi?b|L?RZDAt0PX+R!D`KM*0@?DVnFtBR^3G>_AF=Z*v~6-
zbehf2%6m@tIFv_kMUc49L58H`%1uF6y<45y;q6F~^xkCr#5Bah?KPQkxuiLHo}v&7
z(#2bvgb~ajCjFo2Z0KqXeFK5!a+J{n{kD4XgggRxJ7D~{F;^LGE0NHTQ7$q4#ys1m
zgZ)WRdH5t{hRk>qNo9+Gp(vHdZ@Wqn@G>bubj{c)SBu8ky!U#lea{#nI9{0mKhn5D
zf<1*kJcAbm*dnhD|D2kMuiMC~MLRl3#Idyb;nYdy{U#-)to==vb)+NZL4EGmLUG+t
zI9ZI10tD)8kQ6!hR)~}uEW{bVJYa5u;VMyvyME8CkT{2hs-pT~vhESI<^veINy}Zo
zGB+gV#!9eShM|f`6M6#zn$vrmF(8gTA`D_Z*A5TZQ(}VxUD0->#7Rh{U}16lCXhPo`rEob4(|c^$^W_8xA_arMk12!d_8)9&byx`!sqB9%e>Enj82N
zW0tP&y3#3l5bdyNxk_8dkRpT)>df9F{|eVA(m~Rwbvp|Wx&U4Yeh7|CyV3Bo3ZWLV
zxm)+jpJ}lJ*qidz!q0z)-qRq&X$YR`A-fpeDgE+6GV5sj9W6o)l3jPOB
z&|F%au;tBA-Ae4Rv;;wHCRDbRu6Y&5&jKdhxM7uHF#u)h2ahF+JR3|Mrlv}Wxo3U;
z_fFDqzX)B+4ItoK;}6L}+Bvl1?pSkH;nY$w^NFEX&u|>TwB|e{3mnb`Q&@R&O{mn;
zajc3qjtBKsP3X(URmD|x5
zu2GL^ysk=%tG0DfvqYthggIOiG;k7)oeoV=Guxwv_2GVPq$&uJ_O+ZWK^aMSM|XPMcp6_^>E!bgbVN5f)H6143{$!2
zm_xvpEO0Ga7BxVSDlaIA^j103_7`}kRz9x;<_U!xEcH0L*)ld!%CS>Zi}43`@*lKF
zN@~S7TeAMVGa1({v=mCyy5m_{9mNY3JFS{f|D5}_r&d`pLof!O4>z~p
z-}!^$^8lR7U;Pvv8n_(7j`f^wbQu5i5{^$yf#E3i6|1S%IZZ*C;B3>@m10=&u!RO^
z5_f2r5BJ(=#58s`9jm+n(3n%W&XSlLDp(m2|jXa&Q&bfCeeKU>aNwmgM}$-;NP
zh~v^!vg$O{g)TH$A0%W}f`YerIu-8K#>GO(SXQoH&)MH*NKEd22F#^M_`I;pqEGCP
zHQWmG3pI_nfkIn^h%+R1C9M4t4fRsBBIdfYfu?(cj?O9?=prv;C(jkjsucd^s8(gu
zN|mss&2A?4N|i$BRV`ZtbBv4}YL(o(%dl#5!P!bk;UmP8vmCk^GKNA%@%!hNKrii;
zRCs$Djx!fUH$>$m>1TvF!MzsIU{}bBwWpw9`0u$oZdl6H5ivMM__rF3POF6+>NB9Z
zgs(nyq3|LcP@L<$A^+SA3(WT%8O&&Xf=@pt7n}#@pI4M>uFrHFWy~>GsBLK^XPM4=
zbwDCpbd9@^O)0hdq(&o1dNN8wUPiLWx__!QOr1M1)eh&#HR%sZA+Dm-u}~;e4WRyH
z(9gphf}Rc6c0o~wPx3FJW34b@+eM1Klb(jpvmdI`EXH_UUO
zcCDaOoyCRQ?EFU=Q5e-t8EqR?6eKOQ?^=jKVqo+bD7@aa-BM6~_)wO0=}&<(*&SUL
zoJ!1Grh-HxvKbz#az3D-_ieI`v(qsV*Fbzv^R$vhrY=^eoNDY-OI>VkHuU|2Acp3=3
zg;jNX$jl!k&P3+LlO`A&tNGc7Ac<-uoQ9`y&KC_vQn|>_Pn=Q>X*1FtiJ38J2q(c+
zB_@E`)o;m44NSSTI@vE?HEWf1*m4rQCyJ@$|(swnL+Z@EY
z_bz`%yFMv9KrTBFiFrc9`z#RjGAt4Jy|@uX{fLfbUnC&a${Lr$t*|9tS+Cj|cQJaZGn$AS}P}+zSYG}oD_{(_x+t&mCq&*Ed
z>563km_vA1USx(YhWNejKP0aWHmSOg`!gt}R5L`H7;b>=GS~Woz7aNqJHx4voiu9f
zU5&+wJ~1vKK2r%Vj>Konqw|hGeRJj(xjHla5w53WhBvI@6~QAEChjj`yt!t?UnWV_
z3x_uxfdPC|nv%_i?`@pw4G55qSA6u-Tm`;cIt|S%6lWLcEd2D8II@=;@_Q^jNFNNA
zuqRL58sj3vxBA0$nm>@{%lR|FJAQoi1#1AXSnN#~ed!hkYx`PC(eh{l?|V^=sTXB(
z*cSO)7zSu!4`UJN`}5aG8nfDOmEpyE3X-0M?5TU8Hbe{n2Y1R-FP+7Tv3_{1hn0sB
zk-kRj3{pym-jnVsr$;KK^JEV|<9;cl%&>-SoZY8;ROXU}LE~-SDCwSam67j{Kelp@
z0IKotrL&FnGjCneE1Ev_GmIw0DeS7j_WN%68ejVQJ?0aU<=O{~Y2B{Pqu0+)i_0S+hOW**
z+2p@snmD8#9C$p(7L6IPSlF_5Kd<&2vU33
z2_n6Q2_Kt|QZLgj04^og!Jcrgp%)1`y98uLvmiZ64OW5;!&_~6Z&f6}{p_RJypf`+v*P=(o
zn(UU?#9zDqB{X0x%((qJRj2meC!4lS3mxl~av<^q``64B8l?ewSpQKYnjVhY9gz?T
z)~1L;zepH<1gGjp{ayN-q|gN0)64vRO)o>p8Ijyv&R*YQh$2d7#KW+w)b{ZJJoFOi
z)dTs)iq2<|_{g`*4{y4YQJLpJ(d4pKm59F&I!sGcrW)ng2BrEP{{L^e_<8EYjMXQ>
zOzS6E)c;cG%kp1>PYGnP$B5#kyW)f5?&2lmN&3rf*Oex5qwdt(_xpHbQQS51ZDV~7DX{*)m
zkY1ZjQq*FRxoCVe;L!6Af8AXmva40vQNT)F6)n^nT$tLVQ?5M%+{78dy!fo_tdgUp
z%|4#QPy=qy<18z2)#Rvq0Y}A~2-jdn|IxiLj~2)^;|8H%5SQ_ZfHAZWhwoxaYGvhv
z03bPU>+JyM1x~=36&vzKSnOh7bmiqkg<9=EV89wn^xVFqO@IDTBNhc-f=qNVlQunA(K#J66@%a2%7%V1g^W7y`!8XtRXTX8?^4q=yLI+`W``kR%`gF0
z&*2+)V~wY>-713%hU70=ex*bd0eBm5&m}V?P4u`#YPq7KY``EHlVS*+Ups(V5vB`n
zK9!DuE7G)D)7Fm$tb|>Knc{3j_cg>(E=`WbYk7SNmZdEgv!sqvdeV3r`m~}-FyNO*
zs@N>0Zf?497AA7RC{gaw=%~OWDqMkl!)X1B9DM{V8c&F6n5IEt3{Qy`aZh5=K%r1#
zF}qj_2QOK5(b8LXN_QiKZ5XA~+gRR2FES@MKkrO8wHq%E^I<`6305Xq>4ia}X_o_C
z)3?ukBmXm_VV&9&osRPP%jY3_|J$oQw*N4yY2~oj68D~6_JYjiB|fPVjRkh8TuV8q
zDv@%USYN*?bH=VwL|^$${@d8SYt{AE1sH5R3E1j&5umAf_SD*uy$v66``Kp888qwQ
zO~*dy4WLv#a80~W9o#VaV8s78Ib66L%D+xLyQs6Ooi^QD?jZO$yYYEDdM@PPOFrS@
zj}p+=of`Z<2}26E2XrbXkLZAPC1#(1(uwtq{M=Zhlh&;YQH-}$F^($*^8IM
z|GGA4%A_E_?51v5GhNsWjH%??h`owk`7G6xZo?ICm^jgm?Y=vH9ZS$Kae96q$T2EU
zj_3M_7(ubLpU7cf_a&rx9{x$@EEVBAutH36&@j-_7Cm1)xdD9jDYEep+?ESSD>7BH
zBfu9t-U~4X%Vy+foBW96*WI$x)8{LnW$Mm}f?(EWw&Z#8)aIOF$apPGd?!je*){fF
zUw<>KpWcbO+`AB|eQ6tOdcr;r&~$C45$?7>d=tCZ;K|~sU0oTZemDl@x&Dd$R=~#D
zAJ)fI+3|e9(KdcjUwlUMy{X&!{MX6qN_Sqi3@~JE&*ZXr*Er6GXo*T(pjs;)SEySY}fm4c??;1FBS1!7@tl2<4x2()pCT
z-&s?GX4%brHANu0zan1rvyvE#K*a4KkMF?aJ#Nfg@>igM2P|1Qr7oL`0OATXtpBdj
zCAIFICVF-8VKI8aU=3mDVlgaB8w>RS8SY8Hh+;017oFZYRD@(u-Jd^k|Z!GMCHNpn%D$DhS_Ot1*>?Fpg&+|9T$S%)R3g?)S`>hZD_*
zFLeWtDPAC8@HL(~R>^Myb3{m>pmmI+)2-J&JR|KCPNl?ZGdOPP;1%B5p@MT%4ht8j
zQ_w*ZUF3JJXckt3oZvX#PmgyA>2ghSUhT^kb}f75Tb^?G_d(#g
zo1Gd2-I|Ps-vAs1s?q89Th*zw@8S+$>*Pqr@q|vtt~*9MMo0E1lyBN|^$o8&S!o3(*4AUS#O
z0k_CKH~@oL759fy@OW@?rf|uIOl>n6qp*aBjOgBshQ#DVAKp(IW^?W+L5*+=g2aSt
zgW9uqEki;q2WUJAJk&O`l;fWyfRlurlOUWGYr8m<(CFG3;dLo=Wk2_H5zMk=V_A#5bB56yY#Hg
zbYCN%-ui}4uZ?xv+uCGv0=Iw5RB}**+S)#VjN8hD)#n{Q{DQ$L#kepr%76d#O(i&0
zYG{SiDEVFZ+3D}+Y+_v$-HusWAgtP_hes55yz!|noM
zUVnR@QQIu_ho(LDAfFD3xxen$s=Gx|elQR2SJ;Aw-5e|#L|^d9`$Cu!OkqSnQ%KyQ
zo^eR^CV#U$y>2z2VNOYpJEt?swlG=j9}G(xJ6V#}yCLgX3CJ+-hVt&;WNV22YHPNY
zuxkNo92dy*e#Adm5mLYpYRc|ULTbG`SIdfjEIi+}jTaNga*
zlpUk?>lh<(QDngmwdbO`@3k{S6OhN5ERrhfY?5M#j|wa#x8wXXEXW^^o~N=_*nsd5oKX|C5}ZP5BUhAkPhWY
z9p=xdSS>>0b$gYZiJ|1v$bNrD3~}BNwj{za5w+T$vW$+!B}!D1@F}4UdHhpVygq5H
zFK_#T^xn8@Lcd$>HOtOdT6yVz*Dikx^&URoYb3sKy*gLY4LZ={MulT76e5NU`41v@
ziS%VN^LSCQnD17Jxcu_tOg~|hrQGy;%A+fD(>LUw~?Aktm|{I>a+dD9Rx~T
zZGQ~-f^3bic5z@ySju84s^tBbEIuBtxy)K{v4&+CfX(n1vq2T?t4qg{cQqjc#w*GpE__&^iE~?`4nL
zGrip?3|OxAju<5H-ENQgO$~TsZ|GzC5AS3ZK|S%#RO6x~OZ<6yhgC2L$7b2#c4+0x
z-BMMqLY&L3!8poOaoDZ2+G`~d(@^Ej-z#@k7ev(T0)nE161EbsD5+clFt(-9d`zo7
zy@x5e^sM%mQfhbV4GWiLHsXt_CS@QN_Tk;c>c_$k`6e&w=!|*yhi{-AtodaTy_Hur
z{j8)D-MTY$z5Dy-1=8;7_w0?Cv;OnL_7~keG1_O{7~T)=m&K3ky8C82wJkoXKL@L?
zXJS4NDa@TulP(`_1quC=yBANm4<>%evk#cP~?R)*qZ1f-^u5H0iGOca8@g
z?ERa5-FM~ns_ywM-RwHNqncH*!TD_68Rn;tOTumf6=j>jvx`)5?a`!i&m2N_kvj$)
zlN4g&Yw9iQ@!7KXE)9HowRNq0#r3whSxZ;x;uie;zS*&?YwtoXG!!2^lJF98Gq_)d
ztc#9YHRitQk`IXe>`5Vr6u)3HDA#NhA}`62vlb8(P97nbFj7QW~@>{dNh^=P;Kdh^Q$qtB$U!9Na+(Ni&IxQt9
zdQ4a)5RO3$HDp>GcZOTc9juO>BjLjQMISpt)EM$2O&F*ZZJ=^_|94Ldyp?Uv;G~~L
zJKWjEj6$a?G1U6m`Gq47vh*Spx9u`+D<;+TSJO{Nsg*jashU5S45Bf)eqrG23)#vn
zF_HJz`ws{-XK2ug8zvXIi>?ebM52^)8&goPPmBOgIVf6OPZ%Mvt$E1-yfL38$ff0~
zP_mu$A|-8wBh*uBrxZbOc?>i8w@DNx>34Q*n4VVL%#yXiqCk_u->2OUvz*DtCeU6lze+bmj)}r3d;h2Z4q`kRWcz_>*v+j
zZPx2kRa~ew?rW6C-_hR$O~79UO#Zft!sP`U7u$XTF(anCQrK!6pyK^a-6k7sXrq{A
z793n)(mz1&oazqgK|cvQ(|Pu&)q`&x$IZrh7*-f{vA-;L?IzqTGI1d7)8;=}La%3on?
zvB77eJZLpXQHPy9nFyY8ukX#XS-mVq{I&_`!L7b7R#wSAen4<@)~ckc1E7bqL|{}?
zZiCmPUEqQtmI#(uJ~@wcQ1BVDK)-s-CkhV?zUHGykzDF^!PF1EmZGj%TNKa)`G_Lv
zOXMlD^zj*_5Qx-@a}_gHpJvH;Gn?SYCsBvm%?PUQ>C
zH>PV}R46dV1F<+%F48`O*fl=#(tXG^l4J#)?z;mr=mgn;^V-_I1v`RxoC#!^n%?@5
z8E5H=FXIjh`1f^p@QAH#$LP-A69R(6vZQQs1-YX$QlV-y2Woh7aJ&!kj{^88EVW>qksi`Xdj%IGD=`yuna)t7o>J#1N(k23J!uY!;
z!13GwiLejwJGj5T6bs-m`40?4s^f5W6*}<`70EMX*s*hB`$B-E9xZ}>$j8;9L)3#|
zo+%L(hns*bocWR_ei4~QEh*w<6+})A609O@sHnSmwS;6Q@{d3DY6nQ<(FTxY)CpEJ
z*oTb{-bP25_R!CupGTs=EkttTD2pPr2uV!8nE>UG!zjNA{ta4#i6s2Ca%(~!5hu>ktn6lD$uk_(%cAi}(1Pi914D;jTQ7@oSV_DX@4}Ru{_Ky%u4ZcgSn9#%(NR*ZjS(8F&VdhGRM$QFRrHYN339#A3K47uU|cm
zue+Z#6PD60;fxYDHm{-e?$BE#QJ>folRdzw&&6=2iI4|Pe7=8}DjhuiZI}|nY;@13
zr8=g*sz8BXgY$GH?=QQy%E&EnE@3k1{lZnXmCj4oF
zO=j7FK4GOQ=ny;K@C{Cq+xa`vYdI2eOb%V5{obsVU0*^m3&paleCnPzindK{xlk=(mW#&Hf%Gx9LvG;BHWHM$X44
z*T?@%XoN+M0y%8IeA)V>BKcnu8q7@p5*ig=mI?bUcKZ)eD<5*2y35TO7h=P=96xji
zEl1(h=f+6A%B#9qv{iW5loxMe`#-#p#Yw^-<0-28kXqZR+(IF*Dg7pdQJyyVKdv8b
z@8+NO@7|w|_MBdSv~_XuZ}9qb`8;3k-F>{w+m=*S>ug!)@NMz&@MrPse7Jjez8_wE
zJbXN#A0DQ3cY1T?Y*o$l&7TaPFxc4W@^|=rxIgT_y1qQ0Kb<_ms(QP6yLEW=`*giN
zzTcgUe^PEb&hPcVP=tp+#56z1E<3;z>j-U8UK?Y&#PggFG=I@_^^LJ(s}ch
zQXJ)9D�`iZ86aB?eaf9!hN0;qz?&c)fb=K5m+dZ=y$**>VY~kPPW(l8hHda}u5#
ze44>p^wIVC*f{if?Xyr)WjG|}(;?nNE~cQb+WP$ZkDyN%|HrGv+spCY_{}ss!$Xdb
z$A@DucVFDc`|IoDa62gE<{}ZDucwn-JZaC{-TOVmVmlB?WaiG@n`4UxyUqPgHs2~V
zsp_F%;=Ng(M|$(^C8d1&kl4DLx1(_y`NR9;>1=%XAj56vSOAC?ZsUCY5(wh5f@85ZM@_pIwM+QrP^aUnVv*&
z=`OsGxz@{@ueGI#nB&Q0m!uP$%2!nwIaN@*4*!CeR)-%Vh3|dRf**`+#bOSYyNp>D
z0iKjIFC)Q+pE5?2CAMwiqG&lExhsivoVWH+z4F1(pw
zOa<@PHccl|=@ertECK_0jD2^=G!@;qlOVMAl0S@a*JXXo%TOQ49R7WfCi65O7M99;
z8Sx>zD$K?P>VGYmq%#P35XoXV_L|*}ur@)(?+{cEFeL-HvZaMgk<$QM05K)b3q1aZ
zv))>k!4yHzJ)3c%HLS40v9%pB=I>dVI*X`dh$7TwKQj>I2>U8IC>WFCv1~
z6N_%#%L!ip$*rV3F5UYRc&avbRy*A*_*wt3NUXi#&&e|UY#`%U$TG_YAL;F=yYQ5^
ziH+E0mMLPMPM4o4B4OlG@k7yG6kwaA+7k1He(zkNjgvTANzwKF#+*q{a$)Qutyy8I
zFiDNHCbHic%MvT8ew$5En7F#$xS{f&9MvK;*#;Umo-6-}D-p5FiEu#fB$V)NObc1)
zKv@eh>tNC~xz^4-Z%XV=V_^7b!)K8odhBB^JnJSZyp4)|!z$+n1IM-IhS>l$V1qctlOj8>hexE_rQS
zvaatcAT-_IVSv53dn5w{M|$aXF3L~|xW+-gVy55cWOt1#c@Ju_bbk}
zY*9Z7y-|$TC*+hDE1F2qj16Hl5+saXK@Z2zD0NkpQFq?P;f6357RUlqmj%i)gI;!5
zYJ2qbT;2adm){Jq6`vndT2LgZxK6$`9~_*8>BD4Vt_?XApagfgV$ImR(nQOA=+Xi!6jiXyzZe!_c!#?+{DjY1<_~6F~p=q|(yfRkRk(R}8z3Xi^
zB_~zZd7{U`R*O%+X6Z4}8w2P5c(Di$c1)i+qg%#WwNIo8gHYs51>iSk@a2c34~KLD
zf@y*imU0KQ5pDeC^0y)quq2YDGH>-R{IV}cz*qba;*=dkYdf1xk^zEQ^39hHovp}}
zSscQLwS>2Kgqo7n(t}gde9zCa8Wec*qXN!RrS%Xd6C++N3Al}hlV9YDHTxn>>asRj
zyDTPKwM`~j?TKRWH^u-Kw~ILq;;fXi4xvA?ZjkS#Jz67o$+NcWob&$xAQy1uG&BJ$
z+Hw~%JsKWF9J*We>M#}b^ctm&C^6b{b@RO&?Y){HlX`yBf1ZjJM*h9=*#n0rBq
zNtwz%+lWKf6P;de7#O>YD-&?A<OB@_U&h>O8eBB7x2
zYTY$~5WXC?8HojnAB2?IP(kg<{KGD<`{`Sn%#ciI%yKK7FC8DZ6IM~M?RdumT-~qO
zJJH}Ipc|Oc?nGfH{?4X+Y*tCMI(
zizwR*>XBay+58%JTx0th&8e-h)jB#W{7usnxT(8*qg0+I(R%RgTXDdhI`?=hW(QhH
zZIfSeTyT=I6z~QIm+pe$hg7w7%ezof$@^olqZ~h2#7JJx@h382ZqhjC5eG4
zq*~oAffzk)?AJW>mm|+jPW&h^E|grZbX$~sek!*h5}W)v2{oO&DMz+Fp^Q+svY5XM
zQ{;dh5(w&APaB^|*04(tyUmz4*rgj{=Ux_5Fwd}8QJ+F*Wyg=Hzn?7HLT0H~w&n_}
zog6Z@6FE~z)vuZANyTi08nSimz^9oZtwXP0Kh+|ZsJEI>uQ!{3U)5WD8ihVH1$_g-
zP=q{zQn($`R)3W@>cAog*89|Q+##4)Zv;jyq+2yVsmxkqUw2s$r#_rM6X5rrPAx6z
zq`0{#;8d_Mnn-NK5oSlR{*@R&)OM+gDOdv>R%ozN6?@7MRXK0FZ63r~1{!qRDzzRN
zlT?wf*9{l2GqY70TRd<8+8R?$CD}vPTKVA0WHl($&xG>W7r|OA>~VwGF)bDj@<8cL
z&dDbEvv~m}*!OclTac6kj77n{)mFv@M%3Q|WRF0+>z+}XR#aZm$sXs55`0i?p1ir{
z>I9*hu6KN?320sy1Bx^sX;|4rXu@!0EjTmCF_2kBtH*QTMHg
zI5M)+y>w%N9EJ^!>rw0%_y&}})%f;jbf
zb%S(6Ql{bd;w+H1U5uz)l=?oH&q=qd*{@}4JJseWd)qB;Qzk_-Q?0>dm!XgWPE*cxE}T~*K+`D8_arJZYN`7{w8aI(h{{41r&1u_`U;p9&FJh3fB@~R!kAnEDe7GT
z@mAMBTFK7ADM*QkIe9sEGIf;cR?pr>!xRL(CDON+6kg){N&oYln)7okiT9Stb
zD(-pEn{pfA01J>-g0s0vM94Xj51dQeVK11oiJZi!MblmJ5Bl`7{FpM*ai#(3VjFSb
zCTkN81{*jY+-fZ~anJf0&Rxo^XF*2H&Q}-cZjftND)URx&FQvNV+K)B87t&z8(ODU
zS?~c-ko9LRQ$G%|>&DSHo#b;?$Z;OzU0$^Q!Tum0t@G68H#wq*V&zVMvmLq9AmD;)
zE7PHC6%rz0r4W`UFGg-6bd#@*QB907;((=&Fg?b)ktKX#Bi{iX3O^`1vq9Q(j-epi
zq5si3-WzJr>}v{=d4L?Dc>^_0ygEi?oRuP@V2S*U+Z^+3=&v93V$b_rqbsCu2$4SJ
z$6od*P$%N0y!z?UE2zpx1sxDHE9&70-CeNwrNs9vd|Thwl1+czM&fI@CBP}=fMo12
zG^G?=s)7Gx&rl{=o%rs`eNtlnvQxFLen5!;faB#bPc!4@R3BqAZkIvCTL7@(1Rf)V
z(=&nZOLM$DTyK^_=ZXrgdN=*z#Ae>-3B!!Cco@ltLbL#>2$oF!25QDljm+;djt6^L41p#n%
z=#7UrmO=G5B)&44)@e^lYmH*e9u3b)-GhwI;8pC*0F95$|M&FZ)o%b-?--=Sde(kI
z$}rR829ovC0pg6XGQ{g-0Cpm!C(hH2#0i=u)V-S$cuW9us>Op;2
z5k4S;+PU8pU6pIMF6_U6%M(zG5_;yE@j1BNJj;WjCV1`X#0wc2!V)fyrsCwuhZP`>
z^|YYHuO+U{fT1z?yGzqEz35K;OOOWwTs^&>M>%n?v$VAaDA1{h&BPx4dQ|hH1fr?*
zP1dDPkKCyTaO?i6s`IG68n|VQ4m-F~OlRNSjX2;0WvZEEl;KHcUL)_c;~jtxg)dQT
ztVN#yK6EYg?$Ot-7}(AfD*$@O`?R-6^`)9El@*y5D?TO!0NO;;9@oD1^+H)H
zPqN;}*M!!Lxqtr)lV({}J}tNASBb%U0u(6xQt~FZ!{|`!F>{-Kwh{=zdv+wWF}DS6
z6#&XI>XZRS6fi`-K=X`Xh`(PTa3?{bcsPG1At5~
zOur`DQKNutRHcN#B3*OQi~OGv5Pcc}YgxkfseI%yUD=VHVN64F^-NETawj7#!cv?<
zgaO4W<)Ap6YvTTu(Wep{){x(UXtQlRxp~mK2^*jnM5%x^^$>r(Ec3}CI`O81v?6m5
zOHd;(%>M`Ikne2x9Wu;#7+b8{=ZgqJPEdm?gmK%>(~f!fckhlDaXP7IM>pm+{;V26
z8_nVdskFK5fp(>QLAwaI`QPH6+$B>DgLIUIBIoLP5O@B()oI+_>yW#m$6;2zciKyZ
z31DAmc<1TcAqxc0P-Fl3{gruO9Z8yRK@lPNT*QJ5QBxFt(2viFl9ABHLEBK)3Jcid
z@>9>iDtUpUnI_4=CkhL+y#(R)sV8QVoItAE7y-UfZCgXG{ujx}j_$~Tq-d^=utIz(
z(s(rpz1JWM{--DJVX#4sJvKA=N$!z@h`)jaCczl-*;L~eIhguY
z%@ib2!U`!#BQV34Vg>+4)8`33=h#n4GHCq>`RCJ#*km?LfErs~zk8x}+iD6M_Z3)W$LTpV
z>>mvO-^gNaK$p4tZ^PfL^*RSH*5x#s<$mr=($nntb~nAXPjsWf8o!9fwf;2tFQyPd
zf3ms`EfDaDJ|POI|L+E-W%ABrp(>BQ3#Jgrcz&AA|H2~YJ`<=uCZQ1!!KV!%My^_A
zO;s@z)Kk6kDT*^@pR~bh{_77EPhprA_u$1kAkF!e{4*+20ItZgcMI!5vQ!S}d{
zH3c&xkS1J!T)v<_K56B!1|`>e5OkYINaB
zD_{D_1nIJie!1apP<0qp?aQURE;@R6WqbDE1k@qDlIdFA>X-ORTaN;teH7oUll<1H
zS8FdRCweN1gcW1ij_NQ(i;PM5e@Ld}61HHuuwUh|&}Be8pQ`+?aff9Vca`zEE80b!
z8&qSb9pk@Q)u$GDo-vTYGcfnjf
z8eQ#34lphv!)2tgx{$cvQWLmlX0FV
zRY`Xz+7KJ#iUdQCD|$N0xT}5;xdLG@kc~ioZ-jG2mmo$rGm{Y{rbL7Knmnkpj~WG{
z=M`$%Ck;?H`DSc{P0W<;QWjG|?M#&>GMtBVaD&dXKkoejT0Kp~aVH>Q@e`E6mj
znu?=PulO#kypaU2l|-+C5|(b=7G1JvN1%B~vXC(vV!gc3Q3whK9bdU4UDZpiO4d){
zTKO+DfB!-m=+r_}eXyl@7qt-J7AOc!j4Qn1Y~Rb?O76I!cVFvQH(sDM5Fe_3ii@y*
zN=OH_uUgUI-1rxkTaYBA+L`wR_)U5=uK+ScEZ
z`f~+-Pf^kFO^+C8TlMp@S(;~5kH>icRj5&tzIN*TZrG+vuo|gP9}ITT=^-+Es7R$;
zQijj^JEH5+XIqmyC6|im6r5-E*PE9sHKWC))uT!-*v{G%9}2=<+ZW6<4cG(!^sKf_
zw_a6ZD90TaZ*7VGwS0;bP6d{XpyaKQixH|PBHeZPdtk4gay5KS*(g?!oOzkxh-IO5
z%H*5~e5-ONVtXx(-w00s3U5&r;y`bMgLj_{_xObHh1Y_$wLQ4y?j*$V8y2`cp(x6I)(S8%W0SO
zC3R_~&6(4Vf*KUbH8$yqK*f4xA9DIG{)q{x9ulEy{bFQwdO~8|(k;VnKZ&{Hdr+@~
zixDoEd<(
zv$`uK*7Lq$LF{xx<)DLLrR1?8D>Chq4n^27J4*`UW*_dMGk7Lz-B7y>K%t%PSoevL
zoda}=V48*)zzlp+YL9R
zR$ZNd9WE6Wvcu>TP1Xp<>yi
zgX(e__V<2!!Df|q$n`u=~h=j4S)~;{rT&V2>o0`1!#}^Fp#tFukn9_sJgnB
z!I~>h@X5nPr=DT`n1*qgVpFqjS~dA7Sr8z2UAjO3XYMT5Nw>c;
z3$r<;YHdzgFg%3~77M_d>H9Vg;y_qNMQQ}cHcZdZmoAOGnrjhW^(cV5Gr;GN+~B~?
z{hLI)$ZS|fHrj;GF>PJn)1vAQJrNA9FP=4ED~z`T6whfcK4*p~+$7zQ;&1Y+DcC|*
zv&R}sc4V&DV82$fm~-x3$yYB?IrwFZ9~|I!NJn)D1^C<{!#6EmdBJm`&yl)(@pXb5
z-uOnR1(8^OuH*WG;7qEebAwyyeD0mFW9+h~dUo6doLsB18mh)!$Z5y8egXc)<U2g|<8bLphfI+HU{{kj+L=79
zs5huit!WoD$!<*DJiQ%S8d&r`(1Uo>T;2a5y=&n0s~%>5W3Fm$r4qIk+BeO!k#SzM
zi!~_@qXb=1$NnW!x3PDDUz+O*X%udt7f6YyZ^9zf`ekLVr9S>~%EY}LF%b97x+k(;
z?jAse54UqaxR$}!%7C@#s2fPm!+eA(mC56uGX`Xa$WSuAGY3SS6!+4b)S0D#)s)Eh
zX6q&(!d`?I<0Zr!K5Oy%6NepR2L=Ro*ac?FrI!640Ixt$zYK0O^rkqWb8LsZKemYp
zXfxGhToW8
zFN$G5BMf8crz(HK(`>5$VMEyRDFu}s#8XWfp?mIPOsE}(Uc?CuJryEcw)+i>61yt`
zL%-4)kD(9i49u(J!}+TtXGY@j;nlR(Y#%Qih@Il)cAJET3K$_Rte<&-A9fO&m-wvG*igVehFE
zjKTA(#8K;Pj|7q$_YkZkR{r(pu
z4i5G;5u(k2l5m^7r@q**I`_iWFdRJF^o1E&N2|gYr?FdSbl=E9+&$I$-1A{6RP|mG
z!p0JJPePl!C!wv`FKD*3xQT;BCGK7eWw*VQyVn&y`CC1KyC)p;+rnQBC9=GBaj>bx
z+>>yJxu?$T&JU(H+dvpv;_j*Xsj%~BrPgUoH9)tydx9|s$oy?+fj}5k;_i)bkGrRv
zorKielNJbsK_&K{DxV4lbxWV_&IMHZbDJy`Ynu9J6USk=j&O{IqQ0ypuGIPt4HbqP
zrCywjP@EX1`kj|-d8UG&%)I`d=fFCraTpHvH7vWmppnpy)x270iw?G+`EUKjny0n@
zMo%hwYLv)UR@sP22ygZK
z0dF;#n=~14YM;IvF(p2CNK?6*skcQU2nH(};+%P;5i*Z-k2|4z^_J7bSubz)0I;1=
zWCvARDEr_FZExy#GA0$Atn*QF6N{xu3-=V`Fc_>S+zNyr^KycNTekfn4j<
z1Hzh8@}-5cHJwCjN^L6Y1V`z>U_d3tmX)LRy>uj^rqh-
z)@3d29oQJp99wIl(~uKJ`$r_lrre`@MzZ&|mVh?tCj2Duvrko=qTS>^qt;0h5yyRFwV%#QxTxMPTkpAr$w=cxFeIdqe
z+7!m^)R>&utWC1j)L`5rTd7tfwxldUU?y~$Hh
zJTASl$yP$z^Kr6z9Enqkl2&n3Vv&)pRI_oDY$enV*(%}$vX!bm+GMNP6@hGB>5NCV
zhIQr?Q)h(j&`#~iAhOjIp=2d8JhGKgPAclHLxI39HbA!5k%T*RD{0{=yB~c90^!Og
z`m`e`E%XT2Wz>8{C@$S>GTq=F+A0vPgyV#ucT`Lm4#t?}6-KOqmp!Maj3OTulsm2_|;dt3X$a4@nI
z%W9!)WG9y0rC6xUshzfZTcruL=fP4OD{PlC?eXcu1eG@3O2{3$H4F!f8YOI|n1!-M
zdE`2ut^wJc8w}4ckGELzW9;>u7WreWOQ7!3t%Te2TeFj769>PQUK5azO|||;Y3huP
z6L$87;b3OzJpmPm73hGKQm`?VNZlq|3ASfU^FCnDmX9B%5Il^!-
zrr#Mv5_&_6^wPzx3cEiG7;b!HdfhIQvh{`ZC$DC>VDSH#(_ZC+T=Lwi8sO(wpA|cnpVEM>V}+mD=rX5
z_Pc>ceilkKt8__H?_&W1+GL?1gxPiQ$VgHu
z^J$ZX0`f+>9X9magbht-Es%v%QOXNRQd7v1k)$MK5NB`hIIz+X<|ZwBz5Xz
z29czuQ06vCN+>(17S59h!*$parawiq7itpjP^6^9_Ap^bY8Y-@I%7vZ`eu(HUBUsr
z8mLp*FWN9U-4H;K63#ZgaGpdM4yKo)OcJgTq~^MMX=t6U;htG~L#^)sVRR|n)Iu>h
znhKm=LXlEM)NP8CVEjF_f1*Sn5EhoAP!evFq@-kz{tpDg&{7ntg|eY9rTVED>n2S~
zs69V6k>4f`R+fl<652E=33q7HFdQr@vHMymTh#edV3%^zg<5xMQo^y3W&Sxofk0SQ
zBKS$TLzI#h8&~%#oPTAWj*;S_ktum#iRO}8@O0{mCwcT^nKp+flQXPA7BH;>CO0Dz9xOOW>
zQtJ*=>H=Y5zZ)kb6q!<|Sgt8&7gJH$g%4>RAFJ$S79<*;AWrKdykpxcxRUZeNITo3K_3xdz35TY|52{HswmfZOU~;u|IX1z|lUYS5OT58Dtpc>Qp*i)*>B4G0K%nf^Jf-
zgxaB8MVvsnYFx>V=@q*oP_8ST@dBW*&cM7TwiGB=v9#&VApoX==r-j_sGSrk42N0F
zgq?N>Pr@C_m6SN|JiYgJfj~?IraNrCH!l=e_Ly2*vYhqc(#dD)C!JHx=@
zAZ;QMV*W53j4ws2BwQg~sd3H)`sexw0%3G%mx&fiA%8NJY`q{soo{eiZSNR>1!n)y
z{=U>eTt_&2&*UQ9q+AyrHmvqG{|4g5MXlx8MkpKk!dC~0E-TB=0C)GLE~xDZBoGH1
z3oi~9p+&eZ!fnDe5C@A2?+T1iwy5H~FLGOTgX^~bF#w4!NXyHbNq%eE+w^bPRO7hc
z8sRqGx^%|I`3Lw0;$UW@mpSe%l+DcF6qrCFG4*HJ0_PpzyTJA)0rN&+&zJ^hk*%a;
zhiqLs!?-|?r3%Esn0{wYMkpKe!j}YzDW1!@K==DQg7Nb6S>%4-5(3vgnC#H4i7C*_PfYdprUv3*VWZcI)fV9<-MZ-D
zp_=#Ubtn*aHoal@5CJt8gdjW4XnVbJIE1Bxb`g>Dnx!R~^`+-*pjbQxPcK@l@Z2Be)HWXd}EW%B?
zb?J$&y5{bZ-UGmP0_AUnvIp{wT8jtjtYdF)YGO+6ssrGb4G(GVytQaUfv}*Ee=WjI
zx|Lx3oUbhLEot5oI1j%Aghhq)%LrwQI;mE`-qb{wm*t-7odiHIzCxv?@2gT)h9gbg
zlK`ki`y_xxC^N20Hyp;*Jr67t2qT+x%X-6Ngc9SL$TfGHS?=sjb%ZQ2PNtfwKI1ye
zy@qsnJ=3sGLrx^^Gp>oQG@2;(k{*@SoIP=ij|LpkJKv-BLQjmd(?fw1-rAFyQ0+-J
zf4WNpq)!5nQz@W;+P7q
zST5r31TxL-;9z0h-ck$27s0|aYS+RcFj&~t2@B7n0-yi8Zh~=vZRZYzc+(efH
zFTxXDfg@!pc2PMG+R5P5A*-Ifr}`5YDV>-0=`{RhA+DT-0!lSbRO*unJ0mqqn?3au
z?vxFs8Ye1MGvq}h)w8T)UMC-bQjN2fzJL94KEHLhZ@1rnH~sVXFVAo1ySMx2r>onC
zAD>_D-@ZKl?)LHg@%oSB@sO)P@XPJ%mp|V=e1k0h`%lNaQ`CLxyZZUJ4>y0j|I1C+
z^!?}0|Nfg#U)~>o^Hcek`@VQz{LA}as{ZAN;_c?=)3^HPbZ9?)ef;4MRr`{D{_9V_
z`Sh3H|Hqflx4(J+!|Ut6{rvGGEO7hqrj=xI|HtOx?+?HG_4Z$euYdiwzy9fur~muo
z1p0da)INWEQU?%3>i=+`8jm`U;OhC)e_$YLA1TbRtpR`!wtC#Z+AFuIRu=;=metL^ex0q{H^kLdtVK+BlJK}Ba2mCRWT5#^ed#B<9
zUKUL*?p(v0_u>QoknS7QHN4%C?o)4vRbQn0dK`0vHnH6L{T$S_=^P~g8omHm;}h?L
zIKef9xYF3m3S-A7EdDiofLCGcFtvXTA9_{jr+D9>u1%jJN&UpN>601ZS_QL+Rym^V
zEqaMpgi?-_7q6z@6V%1ONEl*0)`A2=3pah$;*^bJ=!9Cab|4Oe>co&i@z@tzZ|
zoWy%hDNG9PM)1K5E{KD8g}&iRhcl0bzTrwQ-ZS9JDBg3zm6LeSF^xVPQ8!KK0j_lO
zt0336aHSXT8E|D3?>XVhNxTPj4KQ^{zH^K}3{ua=7#=EFGx^X+KHViBZY24!{4hv<
zam+uQ8fapg%=5283*sK;>SDO3-ka1S0o3{bj9WhF4yyoJj7RgQ6_x`$Ui(oBJC
z9ROkvajlo{8&sR4eBVi3!yjTl;|M=$i~wJn2NQJ-F@Q8DXKD=Mvw})FY78Jtr8ybb
zP!mSBGpWpCBFae%dcP0FAw)me|xq5t%Cv(LN6cg
zKYzS_IekV*^2^JIZ|cAP3l3D(abF(NypIoAnZ$>>N}~gIC?k457EROk|E+pKjq3&x
zicy33_vic9uMfAse!T8~K_}j>{_ySL{Cai!^!e)a^!oO4k3a73uKsX-y?=eXeY!he
z{pt1-5LQp(qA#j6Zw_TzHHWNEqC-=s$zkYOLcYo>C?;kr~3&s+u{5R4D_T0&p%w@`t9GoKHsBL|8(_wK3~0kIbTh!
z&0(Zv8Y}|nXFMG8sBRBgd#n%D(3J>?(_>QSO`BGc)YAb;4W>zz0nu-Tgo8Solt)WT
zQ>8^zwe6v4qW+LIRfQj*C=SP{h7(lB=vZ{JmMn%A^|pw#Aj2RnU*6unzJ7TB{_+0q
z-TB+y?d#jS=a(Pfzn*Vj?!LUYIslW`QI>aywymN=Rus{pO3LEUMqO0q_>q#TTR{7{FHF;5_YSKnX%9_ske_f1|_d39_HadO3Ts~lQ=Y_O=Y=e0CtYT{zZqNYD2
zm@A+5vI4HEU>sA}Mg8he7^M$3~S%3?Tily!JMTg*U}(iOE)KXjOzuv|%_X)ptQ
zX!$gx_};~-El(@!tjs%D3(PD$4PQB7+OM)ho+U$*!3*#an5+boK+7iqMR}5v=v|zs
zss^;c7G)hLEk+VWSX(fw;^Aqt`j8|;KMXx))qYJ=sWjOWfuaO0O_8dNyeK+GZJAa5
zAuR^@bXlc`CO(#jB9A)^4f8}JuAdF20j0>E3l!&PDRM?M9OE{t;zLw4H6ES>?p8+w
z7SFQki(}SDgXnHhlq*H{bf7pvdqj$urxDdd+;mY9ABH%_dI0j`P!}~O?z+XqSL6wT
z@Rc7)d4jUe5~A4CL4*^JY(+`Y)+N095Y;)>*Bqv+(+0m*fmE_ekC+?8d8fg%14Zls
zQty~oO;;CP+O}nRfLE(%E60QoW&NQ*!SHUV+v8A*^EDJHw_}fx+F`tEx*V@f%KV6k
zrjHOzb#-!R$~Hda2x?St)3n)2#1N}zRXN&XIyNQb_RJG?NsZ^e$Lty7Ssjio0uwlQ
zTBpN+rJ*b%F@#cY(v%wJ3L8@bJSs=!(?cBPC4L{w2FJ3&bd5DG%G$ES4_@Vg*WvV<|=l>Sd_X#O%f=g*^Tz440mvz8=~nZ<|Ae5E2nW-XD$w
z7QQrUk5Swn%f4STor)0D+_pFZ3lZ2#m*G&gvO|zlAK`Qv!jeOiwh`vj7L$434NWQf
z8wR8%AErhvdzNFfC$&yN0!NtS24n+=Ea`_sofqvPPMWOlVb*>vU18y=ni@#OZ||SZ
ze}8_s|7<5CRe`{5h!61qiy`)@4mF|zOyX?@)k9Lqi_nn=Au3QHJ?;62=eOHm?jO%g
zQPwo-;VJPaTpO!Vouw@zh8zn~er(D@Tppmvp59c5Pl}F@&%fN?-9I1|w4-axi1@Mb
z!^A0uR1WQ-F5~3T6~{CmFx)m5*9R>5cK)D(tQ}2#R2FUCVOBUsIpW2%#E%sBnDp}c
zh={98+7(S~wNncPX*xaLe?32)A8peOO;WXGeuz3`3R&4ATEtO1hZ2)qUtmoyk87s0
z*E+TEk(&PH?bg+U-93`cBjXl@F4hcZKRs$}Tf@mScwCAU
zp@#}JWp{_VX^w}s?(#k>i>QmmIRU>98;(64NW+QnYY$o09fkrEP=@W?SQ?V_fZPYs
z2%0f{j1k;}EbW`7giods
zg7QpRy^4`nBavxi_)wY3Av2zCHhg;;`7;QO=f_{~*u#w&ugH#>iYaO+ijm$nHA3~Q
zi_)r1ng$cGOyjV8R&7QkAN|+!%d`6|3~iMs2_}&&RwNCAS46WN7W^nH;K0>T4dRcA
z0WlK7o%hg_=o;imJ($4;g9=^;JBgR(lsj8vyc`dUo1$d1x9
zPUMG#1zf6xAnDn6-eb}q>j-RSmmogM5=?=hm=Nn>YQhRtCs;yO@>w+tsZlMonmr4h
zdOOgI(eM5F&H34
z;&I(I`TytaUUwzAj_d%xiohR+2bg2lH8X2W38<{f>R)3FJWtRXQW7DFBq$29{q+7;
z_Dt1|qn$#N5I|8PJ1Z|cZYx%-um@EQmiWGBOxMT#;Pfdn=JTWi?fwea*}gOWS*0gWe`4v!;zW7tZM
z3+&v&3Rm5$MWygI+z(9h>>G(zS5@pj)so
z1PBki49Ba3XyCd&D*Z={C;Ih)_^
zR{>9VZTEJ$J??LZWxm26u4hnt|14!N;nh}Yt>`uYnAKp;l4EpQB=B--sr-#`U3{k7
zW9xmE`)tkVnox2{8hiEFr=x3L?gt*~^0;zxs>f5`e-soUEc@4y-@(`Tj<;zR;ZGn+
zIV$Yh3ELecFl@Ddlu9!p+TpLaX`CLfYNr7v=AEFp0jcGo6Q8-i&7iiv<1A(L*cuVw
z_6DctHLk%m7DYP1X?$CBBK9Jx9HrmxEoEPnyPJri*>GQyy+NB*JnnM2$PLaXruo=u
z;`ZZOijCJNZ%t_C$rLQmd6im9nv1w53kUe_29Ee}x%BU{Hs@LkI`6=3dk$`TxL*CqFN
zLBRpvtIIief4S@+d_3prc$f~;so#{nX4B^D!He}QyZyYAl^UUQmr6wig>LffV4kls
z55-jXF4Kc}U9zyoYY@HP)^)Z5$R
zmaNdZcP`bM_q$CAkHdVQAN|rcS=;N9t@Y?R&UeVd8-fFe$y?|GJlynU;@VDL$E9zO
zS$h1sWNSSRrD!nS6)nQ9e9IS?YQZshw)34$_EF?(wC-P*Y^~?8C}JOrZX#>X(MhR!
znSpFc4nccRn*Qf$zj*Z9UjFj%IDi7x?J|sj(7d`r$a%l)a;JCK?OrmD{CSsAF?(K;
z2N$|9L$uGrynxKkene|ky>Qqs3yF;WB};3)SP$>8%+QOYqwNq$u4k=bp?!DOIs?((
z`vw_d_San&>$y!RGMvTn9vicbQ2#F53@+n!uLs|$z0*nNdEDiL
zq0cuJ!EyEymm@%6BP&d}dEI4eJy#4ztxw6dgr6tcd+%*9bx`@Jo|s0lk}b{x779zn3zC0py+ozo!Web1bSGA-3g;KQ3%
z)=sK)g->)Z85!2sC0px(mw`>3ZPcGxrYxAPQIsxQ(
z;pAKg=-`RjJE#5E*_wGsj<4fBpP&o_EJ$$@xC`2FIk{u3euaxLC*$mY_0}lYis)rR
z$B9j<_w=iLqkZa%BVL0eq&t7T59eVc8IG(;^YEn#+7I(t)O)*OsKv*{&Eu7DBWE43
z8;owF5~wtf=mNa%RDh+T9d;5Q52j{DNA3g)x#K;KI{OLrydkLir
z!UshiWgqF6%QLS^tF4Q+#)+TUTvSCpxwQ$HCI%^~LlT5UFT30AdL9m<^Ts=^oSl@J
z&pVw}t0R=$!O!FK_W%ms={7y)361N@jrOaS0%{{EloJI_7~zaNd?N2O-6?0)@jpz%
z{(3|P+5l2ATm1U^8MJ=hsWd|Z0z;C`C@s!$PMSBsnps=NO}pyGofa-pD$OQrqSp;t
z(DQKcPGKi71@H%2kG}T<+hTD}x-tUzDE9i?)d)7h#^Fh&OV_E$>Jr~Cp
z*yees0JF#87PjA%u7G?w)xkw!d^(@iZ_BXXsMt$pr@hf0DOG^Nh$CIoWNjpAGM9?;
zx12|5q^xA)PV13sElLA+zufeFAs*f-Z-*fw0FF0Zh5dt3OBh7m6Z9`gPu}!&yiJnk(+2uiGQEAMIq1+%VHXY0X7ji+Y$ELGqQ+YacjL
z@u$1#@U}lAl#c+w>to|cl{#dd_-H|`O0YP02;57AxC!x^NARU3#&|NR<>
z8ZsCT_ry{6QLA5IWDzhXQfJzlI~~?JSktae}i*l4z>GH|bnX8@W_=88mlVpoc4{_qc}WaJG&s
zPT<9I`f>~$9kjImou))?F4|huI3gS1bG<2!z0;d>KQH)37j-=%3$&@x)4p)Dx_7$j;Wc+!;JeGH3dd!Kv!ue6qeCK6>2uiU
z#pJ=Gf23An$k#=KjJ|Ry2UX-a1;6q5XSL`Iwbc4T$w0_}h;H<{l8`qSEir1m>s2cq
zP13sP2^(Nq`%@Wd9geuH*M2UwDp)laEmf364{cXDa=Hd3QtYH!_F}zM_GK1h>z$Sa
zEhz5u@gIO+%||9Qgu9L4s+9uUxFO<%kF|*ttrBp}owgPQfYC%jzJtvNH@GT!7B{|E
zNtoXexDQ(&s+ei$AJ040_3?pE>GvpfB%^wBcMiZg^->eEA6+vwvGy;w(ol+Ez$Rbu
z2FP_(ITn4-95VNA@#Pz8uEv1jow;B7tLFSnak9xaH;Ki{A?>l?hNIWR>@-9*j8YMuOi+F#VB-QL`=!WJwT-?G7(UtkTCu$GveZc3x;}kn*
zYJbJ)nY%8A?73-$Ow=9_CJz
zRL5>MZQdX(zVbsX>iImM&4oG~uEXVGzUI2ZBf9r#M`@hi#^sJFpgXy71AIlra?%JW
zM%=ihVPvL&aM|a|lVHg6GRh&&Irx|R@v`r`q(eC2#aE;`@cfzL_a0|Vopt`?lpj%|
z15mF1A~Ff4JGA}oVSj{4U;SQMFV7!A`Dq@715%gg;0-EilXdtc>SHmsJit32cS=x9OIHMc~^5pA4$W;wKKD#Ru47zF)EiaoMybwVjjU%ygl`Y7Hc5P;h^z9`cGnj@F+xGrX{?)q=XrT;94%%c?#
z6b{M8uQ;ga7_t_4m*B&Ah9y_Z~O03o57EicNsk7=Rak5Yo1db4;PUP>eK^C
z?&jR@?g4vQ!>yYPW)QH>0glC&w0R&_pK_jX0HU;HM(hA>>yaA3K}6S@u@|=gBl5sH
z)fm|06|LIT%o~&X`&5TxW*Ya3ipd1Yo6b0TB7V(%=pPso5N1YO>kG5y`6K`R@K0@p
z0qEVSuM@6tO;1CZRVZaj_={}ASQ8pt_gPNPWudX`)Bfy7UXX}0E^!`@{Dv+4rT+<%f6YvUM__eFLKc7dK$gkqZHQ
z3^;L7Dp7sVKf)-~`Ra!9qnZ47XZ9EQA1qA`Yt2RTe>rH%0DmWOK8CQ1CAS;;pTK$k
zP|tHn5KS0kr^qJErx_+s|taT)VVlx%8hHELpXR|ceLzq0i&#OPIi1Zs-pm8A}hdr(ZK3cx+Kqj
zr}&#}5w5>e%IKT+*lw?fIgQK!{t)VRm|mKMhuh-)J^ItyXD+9M5Nks!n_=?khPLmd+ofDaR|VOVeD3jrVsEp6TQ`N}WbTtU780g#5nx7V~E
z2+1k?O_Svq_gnTOkJ3w%2Uo(_AGbFnxx>08cTvGO9a2U0-5x9b
zP^~n`Z}TK=HHIH^bD+*)45gQnX?^f=xRy}cyKS(@h
zz(0NxW=ZDr5B>2YDgpoU;oU)Qt>1TO%M>30vLJt_I^bj(*D)=vXr_5#>Im$x>yMdJ
zIdnK%ACq=NWBTt@I}S)$M0+L-XM
zC!N;xOY%eJ%cDPKlxoBm_p}aL-vNvwXz9VO8^GTEPz^ac5LhDc#!JK}7F~*IucizE
z;AUh7DYid|Hu5#4GrM*`wx3C-3uNjbJ7CH@!(zIsIAD6JW~ONYfb6?YZ4}!|4|Lra
z)!1l(Q`MzlK;tSJAQ`XG#X+h{1|po8y)cN@N1{ieE#<&7w5@HT=6SGO+aw1(9DYGG
zL83mPuQkmEU-tx^G@h0NkiY*p0$ZU&uDgS_-niQ7c_z`jUBEU4FnXEu$wkJBFRyS2-wy2puEn9;&s;D
z99!|zAeW1oLX_7qPcA2FAZbskKOfTUjrx$w`A}TWy13)@D+M*X;ZPt*@;7+K{7t55
zFtABSi3tpp>Rmrd^EV%=zX>z#^(#e}3ggB$_g@_c)kI*HHFQKbl=#h
z&I#u5I?17`Z9I#4lML;q&#HTay&*uG6riRvW68}Tb)ORQ;AcKmKa(-3*RK?mnRXXJ
zFry-r1XkiI^FQ*?hgte0O~2jyec}f<^P#$#;O84r8tkr;5dtL7sg2Wwy33wMi8`5y
z*-&QJnLS1sM|Cp6&!4|?+_zEsa6j`c3eFMImDk2xE>}h9a`m4F62+mf6vo4Rs2-+D
zYn880vy=Hj50MlT(@>q!pJ=w={0274oJjxc%WJB8DcV|}FS`IoJkG&P)r|q55s>an
z!kvZ@=Z5dt2h;hU57qY+$*sewO-2yhj#q?Z^pOY&YKMj4iPvxL8h4C{P(K-=ALCcr
z*7T~e-?)Xg#C9qUN+`|$Bj^S}%d<#B#K*9{lhaEF(5xam{NS^UHP%aRe5
z(ThWo<7zQkqiH%DlE@`W97>B+#-0POlAyvo?)?k>-*E2BM8YA2>esPrF$q{|&
zlO7!|RZGSwO#faZ4jbW=uBT#LAKn?)FG3_IZo`+2(~warXjpef^hQ&eDDsT_+D|PQ
z*N1n;^@|WmSP8*4xsB#PCivhT6C0Fzob(-yRrs6k8*uJF)N@~SyFT0SZk`zpOANYz
zB(S?dVsb=N-Z(9n`*qmhAd0oiTMWwUf
zl#-OYfnqR4?(6gE1t7-5MRr68o9jUZQD0z=9v+XoE{7?RKDUu3o*QU^vsGm07kK!A
zjsS5mIbo<^l)xYoOaUm)FX?&Gs_UNtR!~i?sDqi?Zp*00eL6(WMn>aT)&WIzyOTdt
zb3i1z-23HcbjNR1Y+x0U+%BZ<3yF=$F3s9de1|tm#lTY`Ib!yjNbZwm4b6pim35>q
zPh0fC-UHLPa{yebHJnT+Jpc*iXFec@LbF6{>{n8T=<`c08o6qHHV;)bDsQUUSuTYH
zh*yDJ0sT(CcsD+mpD|+AuR?`wzm#OXd8WVTcoitui5rm9WYU=uCuAI5k(G0Q^PJf0
z*9|rqmHWsal;5iOM|~<7hh`y_Z*$%9ct<_bwJ=wFBFsTZ;s%Lmzw+>^vSXN-+wbo{
z+TyOL(t>5?PMfK*^qwE2-LQVmANO0orbY5h<5Q`4D1gZEaLoE5Z=G
zUx4N&9TLGA7zbI>PCpQFSfru-dLriRcj~7rNNLqk#xx}LqajI3DU?GM18TXJ_Ra(1
zfuOu~{UB9>{7(HoEmm6fnsHfme_%<#2{rhTkY`9ziF^iQPKKHK8MXHoN>K*lUZz}V
zp;bxQ*$N#L?thE%Mplyk%$|P42*%blGmo+HJRuboDV9~`=vAT=hSW%`ATm~5`KqSP
zspAvr0vgaTu{4g_>iyr@OCr{>x#oEa-)m?Ku4#9jQf)W~5$DC(gqO?KuckAv=ldie
zZg8ZyK)+L5U?GM2KBapqC-madWw_)d=-aE4bpqx=9c%muPio`Mae#iQIKV;*MdWHN
z==8`iTsQ$4xedKgEf5{cJ(?{-%(RhvsBiN-CH*O!(5e%E;aTZGm>aw)P*3>%iBKnV
zANa?2Vx81=H@;9TwYu3t3a!s$oZGCV{?)j4XO1#i6Pem5rq-0IJ0(fK*AOS`cZ#JJ
zR_JGEQwDktLzKfG5eG7Ms=RVK%(R?tIPC{wUt6CpMqHh2S~(41)7ItE2vS>We#33D
zHY3SiuJm0+WTJ*&*RI}prLv}XKDN+8kEf+MBABLT)UYIQYB-A%-rhA*SCMzd$^w87
z8$|U&{yG$uuV|{>j*AaNJ2*CFkp7x~}ZIUU}WQm>Sl
zQG<J1jjK4*y<+n_wlZ2yqN}7)-e;0(43;QX
zw7x)WbTu@>u9px|Ocu!$Be8R}PGQzXMl|XN;;O)1+XR|53f}=x6MoNK6C7Vy<`j)4
z*yM285D{Moy!wl6*3v^>fW~Y*p;`HUYs1X-0
z7B1%NNJ*D`{EPX#^!q5bgnMf&f4LxlQOeoSd2`WHm=)2l`;4)DgnpZyOFLXOvbHMe
zUY#>mWPq)YUaT`&&4>C$Bq-f5z%h&g+ds5|RmF?y%i@3>F9a$j*c&guSV{T{uR%T|
zU{WHfB&C9AFln}2Oi2yEAai3Gl-$_*tpYz9v9ItB9kWJqYJ2Qn8ydcXPXMl
z4mNkA=&`X3#DHb%g^O(1(QZVO4lYGxJuOi2Vp4qSuo0da#|$C%@3gw1A{<7ZlHSb(
znnc?PwOS^3HGHe7%Z=Jaw87&+l_~jEItGo$nDo(jbpyd1rqRI2nHWDXByYr!f>Xcr
zchTa8(gkRy`h*CaK`27nCMW=^d`cb$vSn)5D}C3E4^`bzK>yc3bH?F3Fwy@=*)IUj
zYerCM>zKy915`Jz;pKNOO<3aAf(9Vursi$}13A`#TT?ZSIKgzNV_K@pgfTpVz_YMgwK~
zjf)od8Rep%k7jUA2G>k?J1ri`<1i12q$vVRv>wN7WZ3xi`XyTPjZP$BpA}GZNFNBe
z;4I3jX8
zi0WSN@jtwCLt)fCFA4~uq-Ie1=8B%lo)$1(KQ(mGdZ(>L`9=h-xrXHw
zF?*9_csSnf;;hlOqpH!L^LEktPFstT@enOzNAMT{QR;#mh5Scx(Cj!;xPHRMPf1|$pJ;Vb^947b-Tn4BeMf)WG=42jhfDv
zxE#B+&WD-~9d~VtsT7rF#ha`6V9Ck0%vfg?4IyDJMN!ee)4H_9?$##7+}m~~7~qwK
zo`)$16%4P%kf9+xYyJAWBHU@~rBE!|BL!1jCSwM+d#H373M3c=BpI^Bix|xYEz?C?
ze`>u$dr`QD4-@Po}@_?HGvc;&SLbZ#`0LCC8$G7N(-9`561?zFt&qKCF<&}-OY-BUm%}P^%$kOBH8nx`S=+`U25rz1mujCQEy#B)cfcI!Lx+
zc&A{zSfCt)7*^mI@23CwWzfbbNOMtPXXTYToq{?vI!Z$%9Vj{9e0ZWETPS9k43KrS
zkB{k+9*6olEJND1`f1UM#@DgZ0ld>^OnUs{+=?EWZZ|PO#TXPX$s%UHKw){+Q3qhc
zasiQTJbtmL%w)f^rA&D}LhD4jPr#7aL}w54Kr4E0YsSWUw5+OrL8Hf_hel=^nyql#
z&GIlp^Yl8;yu3afI>Q42Zi6uT&i0EQT4L8No9S>~-RT*gDIxdu?Zi=+Vyi40or1^=
zyv}LiJ<-3s<2g~oBMtp&lxCvgP7O~^vlvR1I`!Tu(Sc(7VOG7WpYaTm$x2m+GMY%d
zt1djC19M1=8oICn9+ib1TCweiBHR|uWmQa=gM_urm_
zAK&heuG8mKW@Sb^5l>cSR7KeK)UT>eiOh@S6EFOx5jN9X|95dml_3ek>-|epH(pUG
zZju0}Qmv){avb9@Wj_;CJIVg3PTG-|*f)=l*<$JJwl}gD7`Yhb|1crv8n2I8?W*x(
zI>PFuyNpnHD2;vEqJ=>?`B&r+rGw5xcDq^qVNu|;A-KIfTaRNIoyTir1b~^|w;n#$
zVil6;QZ7Ut~g2Hkw
z!-5cTMWmbGhzW()7+WxhR1|FV$>337?ezG3kcF!0J9cCu&kucn8MO6LzKnw@%16m#
z!S-Oh>L~Y&?^JOPze$#7m~;1@7WDkVwGzbCfJJj*X2B0<(W~k;?W<9I5O13|D0vD$
z6d?$ToZX&HP+h((_%YKkhuuoR>YgK5{H(}5eX-8^k{vQ|wERb%0=KW^k1E+*}LmeaPoyffmLBQ2#^aT+oDE)!A!
zd7Ox{n_tVjT4~{?$v1oKT6%c95-J+kFRLLGS=(A
z;F0wUB7s-@MS{zdD*I($kvn#kEi(^va$3WAxL9({D;iKGfhqPjnW(K*#=CyM{~UT0
z+lS{fH(*wyo49n`6X)i-Mzct=jFx-h&WN#&iN?<{RExS~`n1zlI?z(~UNaLFO*H%8
zih=b%B^VOdhWXJn79%(EqIq@BMRRD1zbW{|H`IBY0*IZdkz#clb{kY>IP^CD(sC-s
z^DGia-deL^R5;U86uGR_MpvX`l)wte0KD3V&0{5h1&E5t_E8eX;^J0prJJLUKEL*2vNUcek6|8@+mmmp#LCKk`CZ2)
zSn*xiw@(MOd-yn4g423tO65D$Vm#(sN}eE64LEIgaNN|Ha_}YZ_1zPA?ii
z6;JXIeWoaHjxYKVF${G+enusC=}1P3hCT_gr)FlY3SWmDDGb>Y5sW(`akbQmM5pCEWFW1zZ}uM
z?G}tlKI3uSa{^3u0*dfc7#2~RMUe@w1zJd8}EscQR0Dkp#7riL?4JO4H+_C
zI{9LCCz|TGZzEySMY5dkrA@)zn2fUC%NaYJaGxJ%VIXj=1LV~3hseK46jrSc_Qozs
zuz(HvxA$*?iWv{0bDUV`3x3@`IWaX-a-PKPoHes$^hyYq9wLqCFEt!hgLjdY1|tQW
zGN0RJ*@f*t@5I1{!|#|ma>JLMB_3t!G#|Dv%j9&nY!FM)rQrh-Z6h&Bibom^_TK
z6vaTX5Ak7K!hgXv?iRb3i#&H1y!H8jz2i=teA`K3{e`vYaPmMAb8;=aferP>x3*`Q
z+JlX5b;!ZZ>(tFvt?o3G=_?=|@$&{&+$X4?Te5z^92e7i13NwRpa6`o5Bqd;&gsYH
zpFC<1B%y_9zX}^um1gW#J9D3}b-isefvcZX8**>NXMP>)1fUzVYibwu~!dn)MY+
zy7u|;c7g)yJfp9M4C8vu1?JoMjZAk?fX}zte3|V3LEK1V&_JcJ;_0xwqATS#`)R&LloT5gpiW^
z8^0t>YqzROr*mm_`fB)!MiTh6g{|r+hNdb!q9nd-Z1m@=0galay6L3u?i=RY&f=Ab
zIb5YzFh667r15*QiJMDC>mZh`ZkNU|WQv7f?)3LlW(TF7u3Y3x==B~+a6@Qy>rVbQ
z-8~NeK&UlD4k1Q48`amOt1ynAOtCH7NC}=%dWUN
zuOrP9k~<9f2_w7K!x@1dQTSJiv&1z${at2kwkL|j1@(>5QQAW6uVh3DV)~|XK*Li3
zlnHuYy*Q0+BGU~wk>7w~j}{`i4yf!cxENW_`#V`O?bl}ww;cbxh)4_PJh{II>&bgP
z+4ro1VSu0YuS#%)CC&U1oqgYfM!h-fRJON63N{1pWAcO!wsW#HBX
z$4&xj_jr&(qV)BIG(Q$Zr|8EA>Ni?bB_eiz7hj|ZtxPc<+b%Snwp(RfQK`R{iA*db
zfeMVGeQb!A4&`%{h=YKxTph&VFkrFqe*4KnbhfoliAKCp(l5wI&03RgO4PSKoX)gi
zK5XYpt8iqwf7;UfVNeZWL!>Hc(Hy;%_D)D#zLN
zxm8k<|HMlV&layi6$0v~qoN6U3M+%mPZQWb_+Zn}U-&e}enZJcele%^C&lTkpVIIs
zr{NrC4okSOf~@m>r+)Xl7k}hX!Hnb|+jJm(jSpmF_1F>@O!?GD6b#(AooC#G;*Cf1
z@(^2PF*R^Pc4ec?RZ&9s^n2XJ3bVDYjt`L^Y*bf)3-*bQ
zT8sJE$elTa*4)>m*ar
zcHST%avp+bRwM0U)3BztGF6wlIJse`2)6r`M?wKrErv-bcQmuhIf7iBW`j&F>v`{
znR}M`^0Nsd&zuV;H?kKg=S6E#Ij6nN49>)K(m@ldHxG3{KxdL+WuhQzE?xlXqtvss
zlGn*`cCkQMh16ydx`2wa)Pp@O>DjV%)?$>atdp-nJ2eC#VclPIz=cotJWXnmSVP*)FIn^Y?Q)24Gi;hX9P3V|S0MsV+@zm?*}StbcCV@D|G++Q=hWHz`w>A*?!2p)2bS4F)G>WG4qRBJ3t
z&V30;Y2K#(R_woWdIp0rEn}NZFH7Rba{N%*NDo;n&X?REte|}h>Rxpu@_W=X4DpB-
zP6sHahLTY1{z`Pv025@HW`FGcmo>qPzct=&@aIBA-zR+YK!p@g*^Y;>aK60NW}t>d
zDKeP(bxVmV8W5Ll47OO+3vEz7dtd6~dYPS!?vKh2a_=vY&x1yZK02y^VI$7%)B3S~
ze;B=`E=YNy$2l&VCkOU?GjtiCPUI)Yg0AyjCzP_UCvIEW
z+Fa@E8y?uwxns@0eNps@GizVM8pktpnQXadRQ10EWqwmf^T8#kfNT^5BMR(p6tw*o
zBK?4BD8)`CIk_5l1<9|NJM#8^^+|V5%7^iqNye>;S1qu|9qExle6cs#HO_py)uG)e
z{59m#KS=5h-usbr)|u_15-vvLV5{ULe+s-+{&QMSEEIjKKot!AFLj=##?+#*8k(`)
zZ!5tEnJuVBVj%bxY4GkkH8zKi0erc{b_--;FwFUT{#LUG<^+5##EC3CIZg7!q?_Gx
zF?1T^)AIY2%#n6Cljpx@n{gz|rCi5TzQ_gjp`Ys#mH%a~3s#w@N7_vPT)X+j^FYrv
zhnguFQ3@oTw1(OGT~9{8Ra)pYuKx6$_LO#H7?Wh6(Ml3fDN4+dauSh9p-(?oj-OT0
z^j2MQI@#VGJp$%fiKyTbLvE|qL0oacMv|eQn==kmSDZdR#`pYv3yF8)MyX8Z=-^>L
zzhLF?5eE_q+h+YTm`(-*2z)gH((`e-;a9-gsgMoK3`E&KUHa5NO?@&RXak(HlP-B<
zu*g_2vF~K{e1hAM-0;?0@~P{!|Kn{tli=g_+|~DW+_vj^d-t;YX(^WP{eA87{ck0o
z_f1Ex&)eXIuhD!MaXe-$OYkM-%|@A9)LpZAB*`|r~&nBFY9>#gp$_tM<1kDDRV
zkE_Yy+U}=WzSkYq?w9wMT;8|y)ZB}st?sAeTE5ql(AbNc&*r{cug?fEr}Q7!*Rt<)
zC_|TBZ`bsEZ<$;ly1s8Wwl^>kr(PesEn8j>^TWAaZ|@ztzSpI(Ti)l$uUFEUL@zB`
zAM=;Ii@C3ps$0HqcfRlEzAul51n-9*Iv>xry53LEAKlLl@8Ja9A8W6>>;xZ=sk(2&
z558|xQuac=?~fb0eDCIO-L@Z}T@Na^-XDi`y7rK;q%mT>HE5?
z`+haa&i8ik0r9_;8w7bRsX2jzf&GF61H%FX19P*YH*(N-HMcQ!{Ldejf2s{;DXrOL
zF`#(Y{`ReVm1%ACONqW01yWk5D!+V*VeCcJGveyN6?uAyK|Eu#CaBP!N?7}$c*K!OwVceWbzUErj~8Dd&Wi&b2dYJs7|wGc-3X~fs)
z6!!9ZjA@>{-q^b1!kh$T09>+E)|1n-DNWOeu!$-u&~}$v5@#xz1RF|if8SrtsuGKs
zr}{BuXE>co*7Hy}ld0f8-Bs^itEZtQFy9>r9iCc}<7?j)7*itFEkv%q6N;&#x`%E1
z#|iQx7Dfiy!QlGIEiOzI3dt+VV@@EJy|a3tANjsW{*OSt_|(+1&he<=bOPpMGfkj$
zCp}3i@D?^1os}&O$@s-2ZmhjEwoBVyDQOz`>1YFOA
z7ugO*s!h1(^?IFH1Y&hdgi;({iYTM0b{Oc%1lMFzVTWSU`6fm`Rxn?vhQgD`{)SEf
zGvK#gQ{tvI$+RU8wYCUJ%Wl-hD^LXIrt#fq;#+>Hk0&g*9203YEt{vPP>3q{CMH4LQSSIYUX19nP;sr=?Up0A0B)3eB`(
zrE_$nL9@PnA^vxLV)fJIi$A2mI;dVdUFr-EKL-LYi;MqgpO1IL)}*`Eo3
z_gO9d1ybm6<@os9)BY4Pgl?c@`&a%X;N>i>X!mxW>bw!ZDu-L+!oZVGvGCHqhMRp|Pc-`>LyW
zV6Kc|9G9#QtmCK+j3Tv1S#-t^Wf@d_zl>C+w_Q@xXRKVYxx08S2&=&`cd&mtF)roj
zt5zj=Slu#x={O&LvhjYIeAb7u4#NLv+t}=GQ@2ssg8R14-yy^wyxFy3!v_nF5Je7I
z`DW4Bj*7#w_QA$rN!)v?z&QWG%V5K~@AE5jqh^yfmo3zy<0<#u#7*Oi(V735
z_7}Z?56aH@5u|)Mm@#9O6wxJ|VK!LsFg{1iql=$Xt8?*_z?4C@YWm%tGE3Vjm}pxT
z0KP~sTKn~zLd#H^>j!@|C(F5L93^D-X{1saNs~VE<7F+eWI}3cH^K#=8gDkJB8;6H
zb3j|}JRolpV%&eR6Gk4#C4*w5g@*z|VGcS)4MH=@Oi%+QCIKaBIz)I%;0?h~(9w^1X5`m2w9eFAN4OU9X5JnT)kAKT;f&_zx
z*TeEi)?p{)TNc;nf>5Q?V-a@f%3K7Z5k6ZlLeYMWBSPf3?3P4>q*O%n5XUoD`4iBJ
zP@ye1ANW<;PM{j{I781bs*NP!)bY|WP#6RwhN;~No{CMBd$!_{UmZ>g4{Itc{9TQ?XwMsN`17A=JzK-MlK3i=?l=d&dZs%TIF9l@8CbvgM})
zRhWSTQpFAAp%0a%u!`F=%mi91i8KAZR+V!GG=`q8IBs}tc)TzHDIgQNiel0d9}S5u
z^kby96gus`Fm2`svu6f}YO+M-TSyT8DEbV_B?GK>r@YOAPP7+L-BfkuGl5$Fu1;6{
zUF#i#j<{NaQ;Ox-T&8f&6!^2&Bt^&kvN@kP&Bh){2S+W#=#+2Pzz)P>TIdo)7aDiD2B#(_1Jg4{c|3Bz~bZ-8ToPEH=~eEE;f2cr22_IMs7Ef+(_P?G-UJbLguI^P}QPwcN}4@oVWSoF_IXlQBSBW-|&QqIYq^U
zGeB|<%W5V@DIt(fK;ohd(zuzBb<$zQanyE3@zkE{hq+N}9AWOn$PM$$1@N~(yQdRV
z{+ChuhD6z?tE2V@19Rv`^+CTtwA!|N)Fn?$Tz0a37CdMFbgC?U%q#UoFCeAL*!A$i
zTan(tA0ES`sghLSj2?uc5n?6v=8(wGNGZ$E4->u0FDHF?Vrg1r_6rUo4PQ$;a&eS#
zA>)kdl3CJ3lQHd_M!TES?kZPxqAN=wEG%%GJ)kRd7C?aetL(J*6t43yb~m`pPDwhD
zW}F*_-RQ)B$1iEy*E;Z@R#S6{0ofIrgUqu7T#7A7W~L`9!6ggT@c;Z=8fc3(Ki6C!K4{Sd2VaZ0cvY%~<66+ET*9gwj!x%@!Ao
z6Q(&IaXWv~4sXrd;OovQa%!f29P$f__0Q3ZVZ8FJs$yL0PD$lWTOfR6C=-3z{`Rg{uxvtp3y3nHg}8`Z0pceyq8i
zTa8N;F%ylS$8*_7OG$c^S`qqGO_Sti7P}avt|r#4`lr%0_$=$hrw=9o(yfGZFG9kF
zWhjbgw;B_xDaEyjv6&JFV#lg{ZJaT`b#p*fej6$qukxLxW^TMyV7hT?&9+J75H}B>
zK;t7Ly!KDn^uy9?__BRFwC7k^Y*<`-BcWCu`XSiYDabrdL&~z^!@GfqCX!6rOwkmg
zEiJGEkwDa}|Mi_W&1(>lp`9i3A7@y-d09?dUg1p}V2tK!e3n}P(eUbFgMS+X`4U)R
z6)eCw5(ioMoQh2Dlt_9)0F!Qd4QY`lU?UAeS^~`81
z3pw#S+h7(w^bka9`2=bRVvTbkklysK3dz;mRjbgr043}LTK_DJkl5CInAR5o8kkLS
zgt|ge>EZKd>jE)IA6`OM{9N-Wie?%@KYE*x0s^wF!oKNSyx<|vFZMg->m}kC7&zXh
zlly*NFC;A}+a^q+$Ptl|K4T39Hzc2ZptIi&*FX%~fPJ6@(I_8!hizaW6axRaB4L5Y
z{`W8Yl5#|ddK*S=Ce%}SQ`5veTk55Gnlv=
z`}_%#EtS+x>U{2Vf1+>t-UrSlzeww4mf#iR9{q~gzl1R2ncE`PVohSasQvZ=s8lYW
z0#b0Ha#oYt#LNn>h0?BJs}oFe)v|5$orTYd`!)}<{&5|lv^SI~mbwsjS@t@zPeVli
z%!ncXsK9+-9+#VR9H(jiY|CEGnNcFXaes;q;w8i;{+9X2@S0tpCiLB9bP|
z!Z;z}$b1?(*Ll?X)n+|!o|lhI${Y98sKS&A7bE$or?ELu($ttzb}GxJV#p@;d&_ju
zKLjW|ms!#8DHgoK+=4TE4@WAo&!TeLper7yn)WX0#GUkQ=pyy4IsZ%rH-^EL)ee9|
zpmy?&mNkkb6lwp)QIew^`+U1Qj-mF?>&B7Wk?85_0Uk46ozpRA^uoU^Rm2w6yQP*~
zt0vgk68*_F`1c5KH}IcX&3uFv+%Ej`2N=igv~u)Fj~0Zv>8|6bqYrgqmg9v&`WdPZ
zDiSfrRDm=pG!bT7!B1htx>31Ae
zk_#+^iyWK7qL8NW!Y>k8i08=Fg+&L?!*3tlZd1QIJ#cnzS|k6RirqhWb7|pS-|%he
z9Dc*GT_p}16ti$0f7_59pG4E^4kmbiy1L`_yy;n;Jk?!dc~AF#dXrr^t>v>`9DfQO
zbhVOx*z(fts^;w?d+8wXeR?j{?ed}+=_srA@$`BdpZ<7V@=9HJwSU>C|9E+xueII0
zy5!T*6`~uT6krM;&HUWbdE7pSxxcd=wMFJz+UopxTD#;b8om>1_Vz$g4Gr4ibCcEj
zHJ{A0*3xZ2{1!9uZgN+*Ufr_MP1N6}d%js)v0&1eyK#Hj-@|I>+br3?oP4BwLVqhe
zQ{4$bWOZc9FOoqsJ5O6${sl)$}z{*gFKjU~?z!P#3Kg9l$6J|TQO+^BWK(88l9f&fJ
zY1AwZQP>*fs`nVA-3s@E}Yl%Rsh4uq7db
z&3&qoutw61W?Mf_xeD$t_XNPJLQ`Jh(H$11@-*#{<>Se5q8}%LCXzKVc8N6
z)iAUD59NhA;ifZ<@PkE@r}j$&v9x4@z{?mqD3c6njEW|(Ku=%B5c>QoGs;Xo3Y2U5
z#8A=xwGdBZxkpA(2MX$$Q$S}fF0V29V4V+Ho;>P@^LZpgY*L5_SofE2u=%j+3VQ;-
zL3Y+vy?16};(}|U3GL^J3GobcyLl3XhADwY_-x83#lWV@sj<%M=Tat_n!Gbk^^M1V
z%zWOfgoW?6CscXH>O!SKPxAr(QW_|3n?b@pH?iCL!f*^oIxQbp!DU=SxH}eOJ2dp*
z9F5R2Wc`Tth?NjB_5Rs|(pVU+L{oQ{###Q6M8q3VK?NICX+5JUBL0IDe@wxl$?^B(
zMFOa#slZ=i6X$I4Y1%R}sh-v82+JEwick?80Hs$DReb@Z=5d%3Sc^2)di6Rt1E9kL
zkTU_p3KS`7K8g`wAZr*F5@Vq^du(Pbi4zRnQ0{W-d@ydYGIG#YN#RjHxZT)ss!6HZLK@*p
zGf??(D)9j&DI;P9^t|z-8;zeXk=${+sCbEb#{Q;!M98SP0z1NbU}CcK7er~PD8Mxa
zD3Q!Be)ng8tDnR(8le6cQ^N1_wh{MrhGoY|YE&~v@Y+CDDmOqOb1JL+Mav<@PlGmw
zYDVFsgs{kx2=#u5qi?-+l}d5b0np*-uapJW1D#Z`_$DamTcXk2PRxNatjgl2gv5x#
zfw-u_8A}3_CuEfw@Mt${4v?A{x+5_=jD6pq1P=rLs0iB&2gVs+&DsNq7J*O&GHC#e
zU`WagUor-=#7LV7U-DZ7o+368a9>?Lo*f)3$%(=;p*?Fj6)K`4QI-czGP3pD9M}kY
ziKL!CX-?V5+i56v5nw**t$amc>e3wR1knvN{U}GMs#858stVW6K|`eIEzA^_v~gVt
z?LqDUBrZa83?uo804id0C}WD#x$%;4Y`nN$Xd@sl&MAO8uB#Z>^kQ27^+QUwP(
zXrG2k(#|}LZ*(D52QOK57b(6}8T(KGz{Fu=CKqQa0UWT`DQ1C>WVogiB)SI<{aA;!
z1SWLDe|OZ1u&RR|rJ0hK>j5fES-K^XfbQbRjwHyol%twIhVnlZ0Q%
z#~W93E5ddib}5`mrxO~sllBFKura<4;i9|yhfP~xsU_GyYSiA#rzLPKb0qMfdTpy)
zt=|qy&-4fLYhY_BOt;+)gx5L+
ztpoa{oU_^FlV993S4rzhO77nsXwhCx!;#t9{nPR_Vqb+8+8hipeCDh-2D7%6mw;_eX&1@{r5SqpTu{v_--
z&`6BErh^x!xJNdM6b_`(F)Bs4i~jlEq0SJ%D-_?S$gGk#B~+ZMyouf@Y%P!794w9!
zD{7|zq`0ISNXsHw5*Q^k_<^G*0pFL0n)T8FD=v0m@HnO%v2K(lRWS`!jwq#1Eua+%
ztD_nQqX)dI;%A6JWiKQ#2iE|KPLU*J#ltP6$D!ZH=^riU2rw!INy{CKY%vWrgat{*
z)FgIe2{M`})fUY0B}5vv_7xGrQi1knbf^Y^y~AwoVIxCvoT5I{F+0vS=(Ps2zD58Q
z4@4y;Gsr?Zn=5C&oi2*X_5t+8*eI}L_=h3y^(+6HNSpYA0Qn#9_`$m9y2&00aMdtM
zqw*-Eakx_YcXjCE3|0vg#9<2Snd-@mRdYw7VOmoRskKoyssJo*|YmhSQ6Qh&%Ty+)u|?8~}VtJ2uNVX-KG`rv!ZA!T3$&HA$@
z0o)_?x@MNVVxLO*OOTDAPm$bW$5}yb-jG`t<&?$xrtGX@6;)9&4O~2RGCKPU$^D*q
zIl?X0s|kWJ=7pXUzbL`{6{0)bFd5G7Q3U^&c(yP?oZfLFS%)1
zte|JSw>KGzo7#=!kZ!yvPJdfr3+S%ZrR&|X{wvgfg00eZ`4&M}E=YLbkw(OmTL$|=
zAou(^7vqYT%Zgx7lZ4kt-fti7?EU=SZwr+}@GnyLVtrrm63SW!tyAj@^{S15u&qjH
z>F~-fpybu$jr^zhV7}b7A;J{>(>(GC0Wj_HlG@JxocgA`wy-!S|*<^rU~9p
zeceCK-JTtMR;=iF^6WVHHh*c+)gnJU9G0d|`gr@edTrqS87$Jqvh+T0{{au;wQ*e=w+%Sbw*9!3^X0{pJ&omhyttI;@;UM5>-|u8^etJ2b?Y(j
z_U8OHJuI8*%Ky}5?)dnW_%izTETIVBohw2%dMTS(t9iyRMD?p$LL%S1I7H2bq&}Z4
zWQUWd(>j;n^4**8OUIZ&mUa`3}RhL+#+y3uH9Y(;&8f*{Jvg7#7N~|&s-f&mfo#h
zF!5cycX@Ypa&Jm+7Vi>MhM3!z;=g;ns#yQb)uo#WIMW74&e@zw-PM7JAD*{|$%Xj1
zzt_Yo%F8^x+&OFsu}kTs77e5k=sO&@Evq&E@@;u0VI57Pf(Tp|3iXjPJc@JPPY1~I
z7c1HcU=7oxHshDu@NKv58yr^tNXu7J#GdwdTH13zl?ay}SrJ133y2`#j091FUn-*p
z+r*Fr*s-PjP!xU7qD}2orlq?`u$ddP<)H`bH~r)sZNlpAN7g&dGTVuZh$b#*KXfSy
z^)-#$%Ra)^;Gthuu7bIz+ebXX==S}c+Uzt@IFqtT$qcINJFeSUG6m*$Q{~N%%0r(Ug2x>z@%dm|2HQ@#^wk(bz3QPaCW`e91lmiA>
zz)6xB0GdO;JB4mNe?2HUeG8-4;|s`Uc}t6V^GPy`-nM>bgiIzfLk&nFG6M!wpeRwt
zrA2*f#&^D8@#;TqLTQ2(7)NP>7f^<+APqZWi2}Snon%z29(nDCZG813VbwqDbA
zQ*)G{l(rUlQ7aBE_OQ>_H~Fij!7y*l+YCggBtBXKu;DFlCB@X3F?!T!Ls9<{88#j#
z?~=w$S~I2&Zys6H!(O3Eqt%3n98C#SRzFwewuHkK>!M>
z6`p>d?D4c5a33K^>n4PpvvQNT*To}A`qYm5|mvEw_%ljRlVT!R?#R_~vLzsl{%;&*o2h|me9
z;fG=68eE4O16DRrV@#1$ig}UIdtmF_6MqX6Yls)rPoeMfOjIr_E`idTNE5QtVQGmW
z%9YN3c(ue4E|IY{tv~T45y4c>-CAQ;j0C1BbB5y23q!%&S0zBlvI+fTguoA%
zJhPBX@
zq7n6;Jplqv474xX5rPq+0XWnZ(HJSHB&aoYZZ&FZ$-%|V@_pirF37439jIZ9*9idT
z;00napvSlf_^7yD4hEzV68K
zbY!Q^Kwla1?Gs3EP+tm5ba9G2Ltc!Gk12Xpu|!qVAZG;wiHVR@IhkE#4)(WEC97jDUQLo(nlroddH+=Jah1>6j%U_gDNyNdg<~v#Y2(bk*G0L
zjPw`NccDu)UMqlgOxSZJT?^=G=JjIQ)&Lw-h4%J
z8KuO^udNw%EF@zdO`XP0o*f?psg}
zU)Xq;tb1t2gy+60t6lHWBUCnhA_muzBl3@4VRM>;;vLQ|7ER}Xu2v>HwXxJy7~dP#
zJt9-$N$PQW{|l^tyzV=|##;&r>&E=Z<9jk+AwR))1PDhFYO3?OJ|+jys|Uuv+~Kwe
z5FM+3F%TwuvolpAhv3Vkn?1v`O?YgZ`i@YUq~?OJ*bH95T))bAGY2IlvTSWEXWS!H
z3DU4Rk+gs#4qo;4Cr-={$vw5|&ZdnPHzR*=l_MjxqfYLH#ob{9I%f
z7TnH{lIL@I{4%m;JQO1~U~vkgjTtuOCpU>8O#>rMKb1@%J`|FK{M$R9II$8^Cctg4
zmV>Ga!&-?NX*MZKWPBuEty1q=tG&xkEfQA+M2Jj5
z1=Sn;k18kx02h$9m?BWEzUWcyvb
zSb#|ow1d4sgQeo3{#{9UK?@4oPIEDek~S&|+JXvUb_o1Z^!ZoY64Z
z6h--+Q~c^ZDh>N}oGl(DHQK^7V3k@^6cV5pKJqXkSQ+(mT_6#&f6ybf&2n)?M+X1i
z&B62^JnrZ#7T?=fRF=9%x38E*
z+%!2?r{8F~K3&+3j_~>VqT!K!6}mIEqo$M^WBsr}!q>?b4wb5-3%p2G?r>-*Za_Kd
zs`0?(Vbo^
zbGyg!+U~KxTBvW-I)(wl@HHKtUxyQdfJVW&w~1;p8HCuLYK|Bx=5vS
z3ak@TUqC*;TR({ydR)9-UqUk8E~Xyxd^JZ;3kELYD!?mupkXPkDiD-G+lwxvhgD2q
zbDV!29^H>}lJ6yZ(zWDDJ=pGkcDP1$vn*amBraLkp{d34UZzQNS(`M8zL@-l#yn0|
z>aK>g6`C(}L?ufQFhNfDi{EH=IN7`sRs9Bh^P%d|17;ZVNtp#uZGFZzu%lL-
zZ#+a7U#m)MiQUogCSNr+!(?EkQ#8P_=lRYrgKrX8dcY9bUzG}53S{?8@Z2&Kga4|m
z-+bBJSbl|CT3=IE)
ziA@;Cq}u3zfci|2=xPwUk*#(uDR;MP8iKA8iI?n%qdofbla6s(RC-fraz5!^Tz;3FmsatzjhUU?FJ$sH7HVxOUS{(rX85ATDJkplB6XVeY4Q?k
z%N_jqRAQ*|^$8kHNpc8wN%K2&PW3}4LH+gBs?n+f7rRv_L@AX{pN7@1TQQBPg!ra)
zO8>gMF^T%0NpX{eRy-SVJ&THF0zwv}=yNRo(S3>}Tq=W+s-65?9AlD1D{vEpABAy7
z1KTnF3W+l=5`ycF7O%`+DRc{jFnhc*Z+2_ki&G_#i20%e?AL`CgNQr85B?lEp9aXj
z1l_teU4@2S34+oj4j0-2$l^K}aZT3+iZxW^pZAV&RDni&JY(G>u2d9fN3CniFHQ7L^A~wc`h;K9+qEW*25dY0=_Fpx`FAE8ld)Xngx|{7JyrH0P@lah?kM932h=
zk7-wF|BtSB49}!#0)=C3up8U9ZEkGawzIKq8ynlUZQI73Y^;;r=e^GP^L@W+W~#cn
zrnrl79OYk
z7!&oq`gPb&&u#g;YRBHNnSh{<0Y^Fq{M1uYRTB=>>(9a>Bj$Pb;W!kYGVuPL8Qpwv
zUImnf+~n_LRJ{?PZ@+<0@QZG$veP%*N@SodaiwJZYg7cgwTS;#M?<2d14uIXk&>)Tp7>js*g%I;K2cUYnpH54@D&zS9;SM4WElWJRXe5x&Pq=z4gH%;Rco@hi
zknbC$432FHO#r^K`2+WBhgx^L%;EtHjDfl0Xas{GBZyjnzhOWsJ}$fgghFBWVCvuz
zi$Xq*CH9a~l+fArSe%*zCbVdcqTkN)a*1o@kBT$Qswlk>9d`eMm~vlT8UiJ#FIE4E
zP<0Y8uU8!i;%Ke0f4uhrz-ZTT5_D{3^uY+60IE_~SY%FTbQ9*xuJ-)+a3mV?a8%7w
zjXjxL&9v-;O8Gz$rKtSPD@SYh!lC7nJ?~~8rNfbfDu%A4W`?I4trhK_yzUInPalyn
z?cX{rg1tVxKpis#uzh9Oh}nU27GpKMxf%@^^2%s?CN`b+eWi}}ST%T9iawfN)AYi4
z^b!2@Y@>$4tD3)J#ca766TdtPZ^N%>=D&$ja7_-*+AcaFwKH7RSc`JsT+BW3#kD;e
zb?y=r_T&$(hACKZ
zh%`aA0nLFqh{Lu7%G+~@u@XD_2ei?{B*}sKk
zFT&Rzsj#wP<;#_vBTC@XNi6aq0*BFrCwIT)!$13%VBxz@f^MN7Y2K`h&}5maF7%S<
z`;!SRjG@^6XcVXymTm#q!Dl;hYrsN5!u{ng&&IE@5J>0KUZPC9@c{4tE@W4Nx1Z4K
zYd5pg#1&u?mOhes2j#Eg_~c(A)P;Wr@iSuW?s9gsLwjM&wn-!l>@^yZowyTVX?O-+
zXVUt?noeSwVAveV5`sUHe)ys2DX_#?FQb$ifZwJTdw^3lp{2=g8JhRa;Ho!Up8tD6
zIH6P-C^9oxpI0QJ86KIezJF-nvcR(-K9n#>7?Wl^Fv>uK*W-PBn$eBe;skSIy0yTA
z{I_24w6ArUrp+uIT=5M2REhFE$pL3@8r-RQ=t6u!49I^HUXXRT_rGkJk75b}SsBc)
z9pob_JxT6@D+X(dN!5ili#wETMMWXDpit8)X3|j8pB**4+swf&xA#Tm;#jg7Sk=xCV5G$EQVQO>q05qT~xT38?q82G-tsI#}CV3@HP2#3^F#YO-ftmVTW8t
z9u4B;#_H8JvPru$OM;NaE@c&P6a>EXP?0|
zZK^!en0I^=8ypyu=xGEY%A&dK2vE<1fCU($Il6}m_+U2ZSInX#1_+cniJ(vb=tjf!icfqFBk~R`S
zmbFUs&DO}a<2hOK5V@8eb7S151S3Igv(21-U!3aQ1{Ti7RMqpcJalm~W1#9oSc`1c
zo-x7EU&!F`n{A+7w2~6
zDaIN!k`gNwPnde`7Ufqv-%@(;Qr)svSMHu1re~T&xC}o%pRqb?&UEwNJ
z363y84Ukf9wSkIstvAWlIL@9x#AY+oX*wR;Q4^#mr4+wq8LZsN_2Y+2-}~l4C4_8{Q8g1e1(Jl@ku`t!
z$j%(-#Rey6<+=!@q!a|G0HThd!kT;>}sj4~tNrPmyqhdv0JhUt+kbyx>XGLL2R
zBDFx0>Jo}wg>qZtJ4h5odwg^wWLW3)3H9=HGUs*eMz9VIN^Ud@8XSY))ma
zC+4o|O-juiONJt8mP;h7BOUKtaC{FkId;=nSNmvXP8!(QavbO$lD3^ob>7fz3Y?
z10XOhW~jp`a|`l1JbABWFWh?XO)j|
zra2bu&FpVcJ5Zsfrq2bQ*XTWY4wX1*j&i|pTe*{$lP;l~x0;pyGNzF(0Vb!UDBJ*A
zFlje7|24BEvy@(>(hN2*iQ6G5ws*`0*t1_OnqXynv8aBS%#yhz>hXpe-if2WrO_)y(KO`rW{XxKPLdHqeJG2*eVD;%E7C3L>2(
zn91YBppatu`huD|_Lv(Gcv5K>yxn&gsq_opzH?AFX22BCKa7&gKTIw6UyT1C3+-Pziop(-J--eq
zsjus_@_%JO8Pk|oy#kA|8O`fnp=8O7=8PVHOg(X@tMQKxd|l$|4E`RyBI3>p6;Id{
zbK8MU_*<_WI<7SLbzs@X3?|TDj2$T3Kd{e|K-wImuyHn)pSJfPP5O1SGv&c5
zZG%_XA{n+S^A|n`iYKg#QP?Ez%nmU6{FS9?CC)4vxT()y>ysA8$~N-rm$zrQRGzn0A2
z=)AqmpSrDbYc~xG*>=8qa$D2Uz2YsuPVR5gEjH+ernz}}Kd*Z{Le$*FY_5n
zq`b-cyzl-&c=W;eI2@08)_-{&Kl->`_INgbd_yR|xc|(2nD75usXM>^zVk6YJ`OlM
zY#u);zC6^u`UHf$=G;E#ocX-mSKoWrzBl{uzTZ3peke?zZ;CLkR*Txo4!-TbT>HEp
zHv{e*cwRN-S$4_%c&q2Y`I`{(9oMIo7_O2Q=vF9%XF8OPKA3y}h>lTF0{*
znI5*C%vtYucWj%W353`qQ0nfqk!io&mAqTJGih$Mx@g7>^*;CH76`}%K5rhkZ{5^p
zB?BCvKb!+@&tLX!h@b>uY`ZzUwn8Buv(u~nceX$tWin)AT<8DjlS+KBc!1K)hoFGx
zMB^3ZFD>=wMBz!)mYnn!pPuNiZ7^N(jp8L60Qy7FM*AC9<1hIzco*`2F9$5|hooB|
zX-$9B;8V~HA$&W7YteiMw!Lo}Tplq5-mb;(27P$vU6Ag~*sgNAmFursi(PYglas%}
zY*}DVAq+^4v&IGX8PN{Z(qno(0DdS{w50*0tqe~rMUY&27K{l9D^NTQpKm2k0063<*Hbkk#b01|
zj7(sHuASG#A#9$v*L`SyJ})<)*q?seq?0*kvpam)
zHgF*vZ7%7YatjL#-aB!&*aY!!69fp^r*H=ZkRhM)l{qA*pbO6$x#9%9npax
zZ#Y;WLn~k*n;4_2>QncDU(>k*4L8O5*l&Sb%=CvaJjGpa>G!I}hRwOJw$Eg|G3WEF
zKqLZ5ejH(4>`t(v-k~QDgOa+b`Rf}XSbT(16=>Owa2UcX7PCd3i&XICew$ET3BW{7
zVJk{m9;J)e(?3M#!`^v8(xFXR4tafje>mMdx-|d#XU~<*yZu?Go|CPk=hBiH-M)F`
z
z8G|OkvyTAssM#OLF+xVXzRMN_s$mI(x=l5ZrVgTnJw&VbvD*6~-N+Y!&OUoO@;WZy%Wr4K8NZ$Y?h+-S%np<+g%Vo0{JWSdT*hxo-F65ymC$ir8qYh|Zrj1US^caeiG
zf=Pd24^kJe&{>%|4979!H=H7qji9G**e4EJ6|bP`e?65)Wy)?LHUH@l^7pFbAeh({
z*_dIUf_2;?y(NAWQ$&4YZdXM_D4q++m_aB+ObsJ`gCTM7oxM2iFTBjW9L=N3-@MV4
zU4K8ib?^+zdB0n~LaK1<%h_J;#&gADy)zT#CmzncK=+{C>_4G4AUt-%s5ph@8Zs_-
zqek0_Z{8PWeGZMwFa(sFcjAQCj*4AuVpkKh9N3Pkjn+z-^5NX7acpxGCW=+;V3!*@
zpVw}5aXqVDEs^+0R#C>F54R>v_4j>TRmPx?9isbNiE)HHoD7v@8?)bquD4_c#h@P_qQ^7Y$g+=`vc{w~x`<+2Y43!QnpAFX8B21RRMhrtlyJGSP8#x-
zCfp7BMn3K`q%6#~{%~cSG{h|}FhJi2Xka-0#EI%dj}c=uDBHz!lT%vP+JAuOLH`hA
ze9lp%%~0EN$ppsY;uN?ZG+;8Qk0Z*M3X2Zu8G@&!x9E(LwtBWs?8%QLV*UkVOx6=#
zf)irZ$>d_kC+SL85ZYGQ;#meshRl6~Toy_bCQv(p9dXF4zQJTzL6ssh(E<{YG~Smc
z(pu0QilLgq>-q<^HmSw{Hr`K$Ilk5Sg_>~41)5rg_S-M!PoHK|xd9VsRrn2z=1@}F
z%&q;Q0THX@5oy4*3;A~(uV8xozSipeR@JM-5L4xF55t_b<`
zn0Wg%ly`Gh^an@wKSg{~w{?8!{9%)B%xThh9HUUp@0g-fd&AzZZ5&n)??_4s-hqpQ
z_ghUk1%sZkk#*)itkUz|*>LqARt#y6#do86oRcBr?h-zjiFg{=*6jdLPnG_^9v*;v
zJ2B>v*kAl7uMENM2!9l#MfKgBS39wO)sr!cdbHZfgk39bj;Dc|%$PUx@ST}v+?$sI
z;(gSO;VNd%h?Tl{(1E)coGjXeDZbvz_Ym-Q+VXj6{_DiLd#y@3jb`26Jl&ezIB2Qk^bW8ZzNGUm8ko7ZLe)@g3yoip==RhG9ON#(B>6C;0NY
zl&xu7In@nKyzF21z$&qM@fei39(=Y_>vzUpZfk$i#|&T3$BffV0z`b;GNpFUlS!bc
z#b5h@7cl#JG$xqp`ZL-L&tES_Jix)_{WtFbr`FvZT2rXQ?yVCL`;4ci_$}UD)VZ$w
z0xuDDnZ7*Q(PWPChH!Y@T)dUF67PU3F>*D&&*oAdo0MTi+jqde`JFRWET(`}mr&u7
z07!I>$BpOv;eAVx=zH~+d;O`l4l9p9Whr5^Mtb77L7WuXyNCuq8_D5sK8&dF53{uC
z`dx!~fjGiN>2X*X1ngJBs`G`cpbaZAci1kGG?|1CAP3-gPhcDdtmvY5r#dZowEaQk
z0g+ojjf9Y+9r#Mqy(WoCXflAK+QG~M^M+;)r&P))J67b2aTgE^dd%GiG0o7sF)t39
zoMEN_Ly%ctr#9td+egQ(II;C2YThW=zoImJ@VT)OF-zVji>ZZ{SZR2Z19aiY4nn~$eA
zY9ExsZ+sCxJ{~@{JJ;8nY&*zt7?eBei!T8R*UKTz_cFeRO~J@#pM2R}e`+ee#}sZ>
zcN;P>A(QIui$a=3^zjSv8}9fu!nGq@H|HP>&mXzlbK=OFK2C2vZx7%G47#m=?gu2<
zt+q6ylXVV4bsWn>@F{xwCyA+VC6L5*rj?il6iYipzfted4B!H}z~EB91zZcLr>o&|
zgmR|p(yqjwJ}*zY)|!Iy9&TA~zBlimMyxCVcKLw+zmhub;F?XR*nxlyh=KqAb{1h^
z_`9=6hu3)mQFGk!V?@hmUNfK8N^RAt2j2^`!$QJAcA@gmrsXy|tW29J*vcyt$kA*J
zcf-%eS7Q{pAh9~ArlH~*F(P^@q@O@xp1{wOc-`E*T3%}x2*qUBK3i?{pzC8Iu4Q^lW(BYChbU
z>1H;zkoK62;rrdmEBCuV-L30~m~)~J$IsoPn~v>@>(>}uJR8AnSzFxY_2P5j{>v@!
z;j8!8%gv(I%}#Ec>}b&V_al8T;ZFp-=4r^VOTZNP=Dx@0_;|f*^Dj?`aM$&aOTaSj
z>HXsV=H*%cyiK?Fqp!UW^xpmEVhYa(+TLdz@qDvpB5t$m>!$wW#}h=VZ7}b8Kb=i@
z#{FjKC~h}WI)2xxEw8mX2$|CEc^fh@QI(w_YA2#PCn1r`rLAt$qiyx)INGP%lPkZ^
zQ?~9L-WcDf*ZU>gJLj{$Ptah?v-f)_M+xrIyqa6D#(Of26(5by
zwqG2GbQ*I|p9{*O#J&@qL@E^1Y4l4x0&SH0z_x2mdJ@wYjh+oweCelacH)Z($a$SW#A5
zE}tIl)d_4X3ZcK54hu8Gdedtp_e3g5|HqHy&*AzxbI)6((=9ub8l%7{U|C2JR~kEx
zU#&wi<-JeOmdj6E>py<}2HXl-a5VOzKC)S|MN^jCAY{6uL@&3Ojf@Lp7NwQRLl)+h
z$x{~UYBZ9w`LLQnv%#U_4Z&^>IZptr_}JnHnBDv!VEgJy4ewV6tG3cO$`|;b>f->@)Or6oG8fpbK{YE(I_ll44DM`SIrq3?WOe@s4nw!
zHX30?)E5ZK&c%kD6I;i-8ENjn5zKH2*phe*WD0y?UKKk`y{y?-Tof(YoL%PoY&6!S
zsa6+qCfE9gPQ7+BXVHc-SEVaA7gnXewVRu>RSF|9nHn*p535GcrW8`}PNx(RF?b~s(1&^YXO#IUl0Ecu=Kwfx7K;AbSX?oAdwspsiJSki^C#VC%#Q3cJ4C1Pk4+p`6_tH4}Q#yAdp|tlljH&)ovM#<^>tfHi$Zb&>M2dws1A!;DMw65DH(PU^!vu8xYNMX|C~
ziiT#{p`C`7ZSDF4~b)@_I@L+#OJjkT2qr@a1pZij|%WCvw5IvVrlzk85SX_2^|#=
zO05<#CWx6b%tKp^%4vtOCZ}b(I|QfoY0UgC%1c%{XmDEHmC=jxx7J9xRZL3a=8Q;^
z(US~5lW3@|V74MbGv`2uTZ5;grf~$~q@wLv`~N
zG1>}b)DV}Oz~nITE-*`N($YdC4nG!{CUfmES!EN46T$gxwVJH@|4QtqLJx-;TPdtt
zMo!|QwdSE5(%w!AiSvt;^~I-By8v5|=Eil`ecSyV;zHZhTTdN^+-n-LwG_YgtCp34q0y@}&(%6FhG-CZm!nVXSeRu#~B~ZIyg9P6(*SszvmVVL?9y7QE_;ZKaVq9?o94jnw
zyYhZfZ}cR`ry7J-e$~A=9z_sZ@=-H8U~CaF4lLzJG+4B(xRVZU0Tz3<9qTo-L~07f
z@VWtQ#i5W2yY{8aXSY^@1+jknGc!--CIu3|1~}84i+{bu+HnZcV0M+P9qWIsPDR%o
zD5x)DR?*Nmf_R2a$B{5#;9j7Y;WmmcNUa>4f~~A6Y4A@4NyK+GxB|kwfO;oKs8H*wVf`r;gKMr?
z@8oCE2W_!OYzQUJ?)4E_V88oURYd`wxoJc193{n~b|!Lo*Eov!zZVOHeFSHNxiP-a
z-a%~;5j-gw)x?^@5?1*>qr?cd&`O>wToepE%t`{!p0B8kMfKgyzXap!EHqk-
z{PG`JiuAE6OUvO94=tg?WB%W*cdfYPfU>?p)#8ZWy9n?~t
z>VjGOB*){;$xi=NeKN_doRLDUJigfTZ+xYsoKOBJXM+qneN47HZW%qTfn`hk-uF{r
z^O>46Bjamu8N(JN6RxS*=u~ltbsTA_y=E%PVsM;+E&VJ@%`mrSY^w(;Cap=gp=bM_
zC9uJ4bL{rhJ*|uiu5lPBPkW|OOGc()3WPpvJ22)q*Kif(JVdPPLzEhNe10k
zZfp<$OS<}MMkbD!tZtIa5fKfu8jExOKVrt)TYiwVF=FgLlh)Z+h?D^*ISwrq{Qg*K
zM7>JToZg&;@~+&RmX7UyG#F)H%x~kNiG`tvCk`UUg(;H6a^TlPK#v@lWhI3;C`;Qy!fHl^>PM;u6E{|+%@4c?0d+B-1R1|NMHyoh@TL+Gn!{aQgwxhkNv
zEiGu#kiAUqB$sh&H6{Z^=DAv;d7P@~VvBLbu1A=C>HvRE`Wq8~s0NkK^lHVT`kN9FR6GpNs5xm*UQZT$8FglE
zGVJ7+eOWbI(eF0rKq!hM)fOCI7fA^bFy>_$1useSCB1?9HiwNbuKQ
zm>B3+ORGqw{-LL~*>?%?Rk(+f+~MqD27!n-))-@?vuXp`5LZga8;vAw2ckK=Df$&l
z_4T9a;nqyGPdf(sW-Ve=;A$`8vM}l7=sohwt1>v$?HXwg7t}i${NItJgS#pLfh0bD
z55Xi2D&(6r{^s=01EfV(4i(g=ouaP&XD}zmD;tH?I6a!0Pnk=IS1^{Fu+$2Cr6-IG
zG`Tr5(rjvJ{<_G**&Bx_k5S%M?xsZ_e@ER8qkR2#?j|8cK@aSZs4(k}Ggf!Tl3MXR
zjwr_Ydg301wmsHO&Su&~Dm@1stfETeS@lw4ve5KWVpu;UZ(m0!LeZxWh(Ab*Xx<^JEsx7O4M>sLpN~kmfHC<+
zn}xxDozCO(8D`(lUE4Pba<*Z<1F=M|R{(^yp2!asGli&U^PhJo3Cb4tKHEg{s5})k
zEczVSsZNq5_noRs=|s~%j3ZwmePCRsb}M83m1Sc{{dY8rUNk0CBH?iCxB618KWM2n
z{{~-B*OACl`=+(pk=aA4^B+B(dRelmQZMUTaDLQbVV>eA>LYk(vhk)dw6viJf0l7w
zg6I~MRoN&bqTC>G#N<&e(uxAS5`(5N()ivu%4MQrgEU<*5a;;MW>`k>^#%?)-Y^`GJo
zYug{-oCtd{5p>$JZN|iOB~xTX(jz~Z6IhZI_EkVN9@eE0)6$c8nkdv)^JyrQ*g^{>
zV&pjG6_ZT<=ZF$0vvjH?#w*@F6p5fU8zwEMKu$7`Cj3{^>w)IuYgTPm#8=2T4J@W?
zaMYu4Y7=TsdB(r7w0|I-v!;H17c+hF>*gc17%iEt1P21q8j6Lnvm}(EM-c?!QsGVO{qHwVmAr)8Gx?%RSI&kA&ng-o%C#&L3k(TRL}ScCa-wJB%A^}yBInpel(AA
zT7AfSYL5}(YnH(W1~$_wL0jc1gMYM$kcbngY}r4KN;T&#NvbzT_`asv63$YgBz!pB1-6+Taacg)AC0F
z%{@`X3-rjkpMB*AOq_fDFIp_b22G26V>&IwNVthho3>R!l+a8xN!=)*-tEd=;UN&c?v-bb8Cie8*S_xNt47waFx=R&ciIl?oD^fs)z7xXjqCF+B$kL`@
zB^SlGT=$@N&;vhY4!w3V!ZyZ#RPlwsh*_(A^?2%iuk7uO=iGM8+c{4g8U9%=HASbf
zqlytyjBHev0VN{49&rxJsr=K#)I_CeM#UMH-N-cE=%=E$&!h{K`q{hj_vv@CA}T)m
zge@vylM$cu`;%TIZiGcBtu=+Lj_G-)G+6>yPqGQ_?jWp{xvL=w@6j(;LfPkbwFk;`
zV91#jfZu?62ILZ5Pb(LNUuy3%c9ptM9kJ#4$A#bq%ZsHq*@aEzRx-Li8G?p7|-Q_LG%EbgO42@IqE>Zqo
zb7ehNRo3Qh!Ar3N(tyl=7Kfky$5q{75OwK|54^yC`qk%!j+!^aBHx#D*fdYf@}ZUk
zE2^gukfz)tO&5D{#+@T#@`OF3pf~qK9SM0P4m@VmMjyNAV_=7}RCWrAs0X1b4Y~nc
z_CpR+Q~h#%!Q4ofB|7cVP}?^dhvOT8r#=#
z!e1WOTq-N^3PVKRv&3D6@ow*HPOAW9E``(9L!yP2V!88977T}*-nDIkocfO>h5EFlz@p5x63Ld#)=Au@0tHoa87){Hc=o^+C;uc%=Us(>@4h6q^^=Dzi}%C*rFe`8I-`oV*D
zlr|GSlMUp^(DPGMAgAftja`#9le0)E->~aolZ}k?5VI{dR{#gb#!;pp(o^uBGz`?D
ziTftlPiHkayuecB`69Bl6m%8A{-R_*N@q~cOTi#p|2&yZprRKWBP@w+Y5RfFA9zxM
zlQ-BB^MJHfQCJ)-J%215_PW_NQF@#*4}F$xxjCP8u%CnKlD>@AZImZrXGq`Iz{Rw3
zdp`V%ro2}XqTcHO*sobTJs;3A`kyl+Bz+KngiAC@m!E7j48R3BS|w@7(dr9p4=osXk3`USiny^{@WlVsJs--Fr`G_uM5t8eK95
zMSMaIE10Zg9N4)%<^l@k^qd%=FvZ6EttgZItC?SQ$$ZsS3`dlE{3li1P$h6VTL{53
zFRa{DCRS~56fBi`**qC1^Btq2K`}wJugxyjrI$m6vsZv!$_|DqL^L~TgTzm<;`gE(
zr6%-s?P@%598P&nfiF^KO@wRG~6v%1$^`(Uq
z+i)J5oknlaHK_Jfjc|zp$UB1GR|RbI47Nzm*U-AH%d<*-?7h*$uL86}Ik7f|4!CI5
zqE-J%e;HxznHqTj$WT6#BwSfqwN$eL)5!!%l90KMzM{N|a)a2xn8Bd3hrh~9H2CQ$
zT{M{bq?~D+a~CXiO65G)(GTPA7n4?hWK61K^$wnAqjP~UFBN5oME
z^=*;EdZ-g3J@~i}W|m#RZ@zD4hMh+Q`Q;I6Qf@C)Lvp4;|dO
zq-m9cNI^Kc#!i8
zXLZpZ59w&kxsG4=iauwfRU5qiS@KWDz#7uKcvy=iQ=#@cyL&wJ7-NS1R}JX>xk)Gk40L+iJk7$}CBB
zE%nE>SlCPKXdJQ5F3voB8N?M;$B&0bQ7j*8>z95d(vq%9MV4%>g2b7t1(MGXr>?s`E(*srO9nJ_
zD@J~oSe3(Vd3dnc`GNSP@%O1os~Tq}rH&$oPAssJk=rew4M{ZFKhp~6#y%(NS)h2U^Op|AE1z#F-1+hefRB@$JEni#;N(#!)R!B{nN0yV)~b8BKGWm{xq
zI#GoiG`)Z)tRzDRWS29tFe|#9@#AL%^@STRJl9%Ow;5P>Dn6)aK{H$a__@#rZ99fk
zlOVrq%%Mx_M}9KCq|+u51T$$7Qg)Xq#YE=pNE!i^mF+({2jsapo-YtH=7~ilRryY`
zGo>AY4lsu)CeC+H6^p!sIfm{_?&Fw~yAqY^l&2LN846^?pXOu0{4;2MXn~&QC9w}X
zzY4+%%DSHhyXr<7^HXV+=iJd`7d_`rtx3l+>&i9_}JkBt_cr+8_vM_^FCou_9u3(4o3R2|XQH)2DKO%Q|p!qDwBi;!1{-@pov2fu>f
zK9NYaSED0NgbmGbwiKoQPT7ex$nH?11<6=ZpI>e9i@`N0dn^kt)k1rNtI}up()dR_
zt$tX8>NAy5o)Qheda7(87|6vNfS>{U{V6u8tlMC~?dT~s4Xv$UfS1>*Z^eRDU#fH9
z#Lcs$ZFO~je}ZL{UqxY2Fxk*u-FY6vvMo6$n~yhejt!3_Fc)j*Pb|qg%GJ|OC_RCs
z-*x08SOOteKRfk{K`Gj`Sl+bx<0{d35mJzvvc2IZ5Hz+g{snakxf=Jgaq%CpRdyd}
zqc;~+SV>R(ye*_;Ythxa5l^23NRS2v?3de8G)GPH_HaSeRmu{eeAh6U?jE$rB+FV^
zS%1H6kPHo4ix(A&tJC1`rr{S`*xK|PMG=Qov=0vO(3K|@<@fj&)kA9m1@wUx*b2}k
zH5^=8WH}kokX`T$z**Ho8QEFoO3_*O#%;ZR)$t>LHl`$4>!L%ua?b`mQ9fLp
z?=qGLK-4>x6)yzu+9WTbAhY3x8z&qJ2``ClhDEL8CusZ|DMjQhXCM$dNQalXL>sHgX3H(Z#GJE?ffY%$GSE78@*5Q=
zA@?70O@Q-6@iY#MhEyL}>hFi@NNw88;zRV!t-NX+4B26XLX#nPgA=UZTVw)!_xqwM
zHyW*ti70WYTJsRobac7vC!pEb>DB+}5`aK+C6LXdNp{Y#QNUE3$ugx~d#M1c8ZOCf
zeVGlhpm`nlNpx%+Oxex_R&Qc%qN8y(Q*THnjOJ%4`_){!2oDN6NFkvl9g|CbI|m?6
zBGqY7znDJfN)yYGzS=e|l=pP6Pb|%CaM;YuoAK9
zx^7A>`JXl_$>c?pC0WNN$hc}lAv1)(L9I7cenVE{*_p#Gtiyt`qF74?m9H>>B&S~`
zgqh_uH0#U{w8AehKZEH&`H7@=7G^2BZV_e)UlPZkPJ>_jEvF=DnZi3|ONMHR>+>}}
zuQlGfg8t+@3)2AwfoU#cg^Vb^&aAxY6tvvK9G|MnVifi$?ivV8hEXNy?S_~v#1@Qf
z68}bUj~l?nZaxb}7Q&jHV1%aSCOB$PcE(wk4Gj;L_~DXuS?me|N@qN_pwv)>gVpFL
zA(+ikoY~VOJC&MV3iD0&fC`;564u$=Ro=B_ZGUr8qF6m`1fHKUiH
zMiHH%UT>$&cu-H@VMxgcLy-uaA}BI8dQ@@iJ#A70>G0fl61`OQ8zn4_`o*a
zySm)63#vs6ef%QC-XoKjsY?N&-iYs>7LnsJv3ggU6|m%VJ;
zcSVi);esxoX}5a#3mX^fFh|!>sP+kR!d0#%P{GOHkNmc`z}6rkcKxup_o98eaHeXc
zlQgVc_@HfPJl5by|Mv2yEl6CSxS2%C85^76SR|EEg|lhHPGPT#h`513?59)#5wTGu
z5%EAc(SavS<`~H_M?PdAPAS*)51y^F-~?P^=Rl`yA`kYtAH{dr@?#l9GG7$m3;qGs
z;I#iMxCF*O4#=C%f9a4d9sdCe`@i7e
z+NEE-OZ~4zgw5%H--wVb_8(yT4=hJv$v7Oa3w}xBZu(Cklw8+;C421#++Ct=;PKcp
z4C{HTy5EaF&k*qPig()-Ze0a+tF+SRS9l4hw
zy1aZo%`d5+IT?JNG2U<8uezTfx7WJf@6WGqcikTfAM2Yjd?Dx8pZDK+-#s=yHmpCI
zw5|7V13rarA0N9tJ-43tJ~OtxR~OVby-R)G&SkgX#a^0o-cxQbHQB%F7ZW(J<+IJN
zc^P*AC_eJWl}*k_}t(`75g;ozuSDa@GfP9KniC7BA%`{
z`^Wba)^5L&Fm7_zi~CJ{Do}j$27%N*UOHC!ta7|Dy4tq6t)j8+%kzxi&T7^Rgid;1
z4qMKf5QZnaKBtc_i#Gw&=dK7DxIZS=h9^Jzi>_}LH|Z(aeGEbYC<$pWP)+ms*`}!-@L%
zLj}kq))Vn%w)2zm=!bv!akEllMjAs$gp20fxYk7GtgYL4^g9h*&m3=muNKaVTo1d}
zD3edWD#8yX<&{PjDI}!|t9Tzb?tTh(7Ah@zUOzn-seX|6qw#=U>OR
zO-+(z%jTx_T4GM<@E3j12#Q?r3Ru8-W0e76V)s|>19jK#7evti!C97NHYB*)2W<=WKoPuRi|p{J3EVXa_A5xmyhB+c
zK{+sZ%~AMN=fK%^xtP$KV%PffotJ&&Y6In9Hatm;YNQ5*YE_;YS0N-Ju^dVfd^0|w
zs%PlR3>iiW0wHh(#rti^$`ZJIO){p{W^I!{FP1B
z()p^7(71Ej(pFr2{6ltV_T%BjT=hDe*ZKjHTtN7G-))D=2Tw*~?66%#h2u}f`z5N{
zL;0_r)@|Huyru4kX$zm#?XDTR&qXTor~dv=!xvB=s*uk=?*d+cPt5|hxsfo4hLbpm
zhMKrwSFb}+&?&i>W3Z@HGk#4RbN=DZOi^Yb(AWH;ft5Irk|^XJmS*`}v#(EQ2Orkb
zaS3rCPG{p3xkH2IFa+ejuSDRHroVT(fq9zcjT{|!=e1@ucZg6bs^eg2l-LNLvEztA
zelW6%5vu7S{ZPeRq=v(UGG>ls*4xpRDah7tNxl0Bo^AlH1)Z}W
z7bAS?wH96DAS4JwlxWWs&A)PdTnu6hmaW!ULa*WQ*qVS?yX>lHlseM%MLAR
z&q4&?xCaY)+0ZwHj|TD0%0Ir9ITtcEtHMChmTfT4%DHwj_2Xa2jwO9)mq2&7ZD#?d
ztp?%iT=PbCG=Szwdz+jzdU_{l1!}L?yW$_2VXd1DY1(H~SBd|)?9=G{P(niuB1PU+
z1B8Kz&w#hbZGf-|KlHw&*F9wrrFZ>-KNofUnwQ=hmfD~P0qd0($Es;sGYvB*Sgc`2uh-*9D
z`XfR+-8q+aSPNp7Jilbw9FIeWfsM_6D#w%F%qtFt>uqaX^(
zfkoOvO@$K)BU!|Ybjbj4OT-2(;*p^Kzaw#eK5)sQ%tWOSh6QqcvxdXE0(Z4S1sT8beuZPTtS}
ziG@x=bBehxn`BP<>G)Lv@bP$jKHT2ieE$6T&F1B9eK@|^?LXW+zr5>L4*Z{o|6D)a
z|L6Vg?&WdwbUfVb?{6GeOfu&m$OE|1RPC0oqFn5=N#@KRkXYy>G$)#?#7kzCN^J!aq>^)?X1r?}?5T0!&fcbE<}`x6UXZ=6QBmcNJC!+yQwY~Ands9&Lrjpc??0W
zlTo*@bBrpTvmz4cx?~QGQ=aR)*LBM0#JWD+u3J}ZGu|>mw-Li
zoMm%{1EK}B7A>I2_{h@V<-d1T*RnZ99#j@O6;(L=F35lH>iNs&yh#PDEC}8$}fI12wDBc|GT|L3r$&p<0weNYes*SDP`Pvlfa3OHDQC5N3Xj?;xKO>Ewq|
zhT*CR6K3*RDDHCil|AbWAw$3<#2xdG+dI|$d)Tb^cOPB-y!o7b&EPQ0R8Ll4Jp9y1
zqq^|Bs%pF-s{$`ZPKj6I^=mJSlb}lKGLHO!%U&(%{-wf9H5QjQDbnJj!i)1R^Wq}*
zy&^4YuPX8+EZQiFqnyQ=s{Wn6lJw-~d)z*6o;Hu(9(RA)T`pE4TG+%@~Y!0YSMx3kdG9<+aO}oll-)Px7%AZt0+pU7W~Sayz=6t
z3qU=ny)NsDI1IppqGD<40+t?C88xn;sM9)0TF(!Q#*3pO@rtZ%ya+0FSEMy@mdB~j
zhPt_JZ!(tOS&wqvM6jKKV)%|daBH@dP(_1e6}$}GbOti>OBRFzeX
zC)BYt`97(-3NkRiVxO|I3Zp1ZG2Jov6y%9lHcjM#Jz-PeZ)ta;Pg-WAmYp25an%$_
z<#lmTdT|?PUfG4Qm*+_qH7SB?LCTL)Q)9HGxZi4<)EVwV`9T&xJ(%$K
zx60Zs3yKcQD(if#vJxx5O&Tw(qoDJ#E84ncxlcn=2C538f2W+L2i$(V`rYAfzu7z~
zapmX3=H-6-g!_$;oBQpM5qEXC`}nZgzTfP(SBNB1>doD5{ow`Ka|exoK>{8&UYlj$
zUlT!QLjFViXGvXGb=t-JCe_UDKE*}#-NAErWV&S~S2`T>H
zb`dW+HD6SpUE?$yyJLL6x;zduoK7C(UQBFGyeh16Y|kiegCg_Gl=ty#IjVgD#B-~3
z2q%BQ)tB|t-DV0Pt0sK}L7W%4SHNz?rb&ITf~U-@(=6$_u
z$pBG49k=h^#zFu4PtTjX?aSj^Z}`tCs_nW5=$B$@JxDjSuRpv$Eb!i5s2RPG;
zpoQ)elysFbtoiLrngbP+EEeXH0Y4^?qS+6
zgGmH|RYks+z;$YM51lt)2!@t^5)r$+HTIH*{hg%yAj}Sy-kg4m}N}
zs$jNXu(ys^Kfd6melPb|PuK@|8vqGZS3ho$?0qB|cQxGQR|OpOxTJt7(;ct4w}-dN*ts`+oov7
z_KDd&vcg8gfrs-CqU4%9irl0~Xtj2QbQm<*@H_M`;Zn6^+&mf@1wUn8NF}uJO
zdkw5nD598zqJajUXK{=xuu+xy>_Lx5v*B#+UqDxep*ywdk-PDPpnEVOihO!u)WW=k
ziH8{ppz&5&0=)pMDrTp=BSORT>Amnpdzx`13Ec?p{n
za}{961x?f7P~nePlY*wXeYYumt=p$dLS(*X%ig7b|oUYV0a&a(I&A*2pt(J+874%N2)D1HMN^S-|DN
zn>~gsr01$8Hxx`(NCM-8z;XopL=%5nhUss0B0$HDt2E27
z6X6kyn-KPD7v~<1vNpsK+-1BfS{lNP9?=??!jIecP}{e-p`t3iNfk8>m>5Sbbcj5G
z_aw+6b#Q^IXrK?*F>fRpyC2WfoS_6S1u{MgoHJDiZ7eHc9LCUtJHL&6+`98&kFoB8
zzU1E|(C87baZLObgSv)|*0xYL$-fv^dFquxU3*!b7x*QrTHalP=N8CHqe~1EJuUZC
zPV8Bic8E<@#trr{jtS^y&_SxYi9M`Rc&xLsge2!}7F?VkDkdmhc$HTjc1DrnboVkG
zTVyOj;^N^U2$dp)Of0J;V?9xj?i8}pvX%lZ5!IOs4Z@a1g)QZ0C01AMLs;fGo*@e%
zaUk8Agq8fb-k{HcLs*^Ef4G6xH}{)Qn}^*qC6s%+_ud`6Nw}x*;3>+Z2Var5x!b*e
zkCgLXy<9(RJl=}{KTAWVLz2S(9VcL50hgs$=NbH5l^-QSkGxUe@pxW;*nGF%!$3Y<
zJ#60716^<6jzAnNgI3}PNf!4B$lDL}(i;2QaraEWOz?h$Tm#B%eYZQ}Ud@TmK5o`<
zB8eBtplA1g#VaG!qn|d%m*=bJHSCR_w*SCWB-ly^um*o4pU3;{{&4&OaD(MOyjk*o
zd;IfmxfwbNAUxRy#tKCq%K1GIJa4oO)4wJ&^rPER7ry;wcYiPb+ME7A_J98H&CS&Q
z&5i!We)qW|ZT}$ODucT8xc+~Hoo!CTFbsyT;v3Mfq!gh^ZOIA71&TIJ)1Vb8XgmI%
zHysinRDLvd6DLkm$xR&l?f5yortBLmn+Lz_C7w(ODCoMk;Q}_BFEzI?3#W~te=*43
zvd$rWxy~V=?{yBWzyGpmbNzQKLhxV4y?Hzy#wqT1A;u}rKOb#=Phf3$b1Ra(stv2N
z6h~fJsJ&r{!-XDNpf@C<;M5<+jB^|=vhSS%XJP^WqEMCG9T$LIF0&`j_Ao~n3pbvr
zy|`-`dkbwXtR?8Xr!BM_cV`{#^|S{J)Pgbrb%U-kh0`eUs=Yvuh!26nV!}RCT8GBz
z5z`^Aca-3t5gNqe3=oY(tmud)ykN0
zb#k$DO=Wi&2uZfA*5PDc$28VUda01Zh<
zL{b0%0j&T40LKUd0003}E31A00004VQb$4nuFf3k00004XF*Lt006O%3;baP00009
za7bBm000ie000ie0hKEb8vp?RrAb6VRCr$O{Rgxp$$1`#UJxXR!C)|cK#DSy9w~tY
z34ri!Ffas30CWH`)8@Lmq1-
zFB~qecU+DhJP_ldcsd$M2z)pgj&g-+jt%)jv2ePOEjP=VVlI*pH3of14CKn$R6gD6
z)VWAVh=r{#+y42zR6dg_WN@jKN;ThTKJCzcSTR8S1Nig~fsNRRpjG3?mh>0W;L
zVyjy_ymT1PliNL63bo`P{+mDK1b?|v^s;VVWZQ#gu9(OaQYuav}5zm!gKmmWUc
zJAbfy@f>a0vLv$cY%ywfn1mQ#tVoa(h}au<^k$RVN-m`_nY0We!>BYeu~bZNQinyp
zR4Yt&#x{?&P%Ttj6@6Ss6a+C*Fk=k*q&
z!J;?Y4CPYH?$+VBe_>W>)yDffv}Ma;apGo-yNA<4E?lYS#HdeaHmYUdQh-@s*{QLoJ*|Nk^;^D>p?Y%)H#&d$lWVdQ8Cg8YPq?Pmx
ztyAb21N6Ydk34vAVXx85N8@2!Y9$_L8Aj>#IdlfCLZw_&qJ8R3l~SQrVbGzYmrc}}
z4Md7o6Js&p785Cs7o4MMbFw=dZO>@SmL*$CN2Lfx^mw}$%ZMtAQEfHhNMJT53x-z-2(ZBQu8_H8y;-
z;D|qItjzAgXu3U2q(tx-ms+XSa$cV;BC;5~>xwPX#4Y89atlpVYBegoT5Z&7OjnzT
z-!s?@W|!IOvA9C+d@)rYw1ZL7BPUCxS%PYW#%c8%Xb0_LN<;_`moiw*GOTEv)=HX)
zBY+n35w_7Pvb=BSa2uCeF&dQ~ug&4ID%9%Lt*tf1*6OBmb#vpiVsk^WzPYtJ*_owF
zO^s2bHECr!8Vxq1!C^6btsc&u%qBYHet&yPTed7NzXQGO=e=&$vm~6#s8ecn3N={1
zcIBBDpL+T^@JDSTEJEukHE};4*3loe>a8-^j7zOFTcw1=X|!9L=wHR=*^SN9>xu`~
z)=r;2egEm-yz;`g%{Jc?PksIJ@BLe)P60{dE_F7u(P?Ac4oA?NE@mU?cw^Y3En61!
zaw?yk?@xW4R}B`SeFmLMr{7em&u*@M<6D38?DH>PdFHv7zy3`OP=MZp+)$&{ZOIps
z(B7?n6PH?PHj6sFA|wRXw$@iS6|0+@r-8NgQ)_2_=YijR@`b@*-cW0|HdLD%D#eCk
z6XIM|tZi(aJ-hZhfA!dlk3IQ{)})phX#lBp4vXGlH+q~7)+1(9Y+P)QMzm$i0_hfN
zrBpH1>^1Pi5F~mNP6HaM)*H~QzxwK_Q
z==N#LmZjRRqm?)|`VFl-RH0T#cU!2a7&=@~!Id>OBPwJ#lc8+{zY|$080Ipi94@t@
zQJpGRAjMUUZgWekK(jXF_5oY^MH6wO^txc7)@Ie&tXhZ7;`PK!g|r(xI)n4r+^8X<@W>bGncU2yDJuE;WehUrEOOqfQ|n
z^BGO5P4)VQc7rrgv!&1~;YJ)c(V%CbDHbe5`*cnaF`CIGYlCjGR2l9*NL#injb5iW
z83^$RBoURO3JbGgHY!a7M3#&}h6znqn;BHr%|?6yU?V&%YA6=VRZ2o!_H;VUT!^z*
zO7T?OZ(?9ki2M{f#g)_
zQlk+`CUL2iYArh)*95^8V6Bm;H^917Mim6Pu2pU7HJdQmM*Rl4BBL;ww-^VSsIgo5
zc&u72cPD$J-SZ0N)}43#1Z~-}+`_EI?$iLq|K&0y8TeynMf
z>srm4UMt_XVZ&hBFfdw&!@;xmV4&V^3du}uG(Ua%^c{EJ4bYY?ORn6UAMC|axl$XX
zEO$qpL?-U?`Jl5l44N|h;hxk}3)!W{!^~XQ^
zFaG)MciwU9ZFk*q*X^`r%aSXV8=Y>mH*60^TwKI&w+5YPDq$e*oYCyCMw2lF1MqFl
z4vWj@m9l9e7BSi_l}4plt%Rb9Y^n5XpZOdvwbB`O%MDzw1V^A1tUOm2j=OHX?T*`SzvqrS-%4AyEN{B$$3OYW
zj|cf+xmJ#)(>9NX75I9mh5*Xqvau1g#tyse^#ww)NII9SRdeChMQ
z^M%{)xcydKgS78X3fi(|dE=XIy6NUO-F)-S_uO;OJKz5EjK$>ixxAb|D6ovpjuuDb
zNsH5IwmU4~PBg+rIJ@8V`Op8>XFv0+x88c|TW-7c$A0X`Zn@
zWrLY<2Rv$nh8IJLOfsEK1%e*8-xG<1SJehS8a{LO6#f5ixs|jJpcROdwrp8m|N7Vc
z$dCNUn^4|-^P5R|6MpX>{nS7Fl~3OHOTYN@A9(LOKlH)(eD*V+e(x{6;{)%0*GE41
z-dk_I<<{G8dy8DqI2>=e^(~7g(kuSYTvk}lJDK+Ow)=?i5$C58JSsHWPbS%HI)os4
zFsRI@&Do@$%Y=r*#-)q1YE?RSarDSn&O15xXm`H2*ooo|IuSmP<^y;eh=_L&W(ZHK
z^^!Lb+&`ScA_PO+ba#e+o9>Lk0Vy3vY?>_<(3ykjP?Q8IC$)OAr&Di~UVizd?Rmdc
zk^rC2HkmX=gG#GW&NPKm6r$g?4rC!Sl3P
zCrb&z@~91$5s0Uwongxpa3Oj^zyLLAvRa&8kKOIc@0ZkFkHrq8n?~`&#
zDIdH1Wn#2e5ZL0M`MkfqJrG4UkqD)dY_%LOX{Q
zoyMefc&uh86N(0$9#gH7Xg8#8JJanI9{JtF=D59o`8Arjvp=;uOo$Dd{Tf7qikJ-h
zS$8}Y^>KcL^lFn?XSE5*sNH3*HOg+U1AMsn@OgK@6-$coe2NtU<*IC5B9Xw(&KT_*
z_A8|V(MoO~;t3-{X@yoz!#@B%1e^)0$82?*YqcaFvX3V<#6k68bF@z)jO&Wa#~>C?
zq@xI5B2gaERwx{B_}nVS3O7Oqjq@3}5n7`eRs-f^?_e8EthK8TK5`D?gv*0VA&w3w
zlftl7fq0}?z-%=j>RVI7*&%T>eHwwr;i9rXW-ytxP7f20xdy{B7j_`v-9EZLh(2%7aViG|r
z<1pD>7PM?#1y4*ZH*pb1A2$&Zpvh>5`7)*RVYnUeKX#9{yYnG!*2y9!!eS;C&12jYYeifN9qr5IVxh3#Xfe|`8lgTS3=*Wu
z?OQgHL=_~kFq&*etJjPGxzWm&I_24`o|d2>_H%e`PQSw!v=K-1IFv?^k0Z{|j}!><
zDR7<*2hr(l$hUVm=S4Y=Zq*BsFl)1$V3!f(lQ>_AqS;!6`Xr7<`{c-%#6Cu=iNyI{
zt1Dnjq=Z}}5AT{b>tu;a5sYGw;OE64{ugP7{3rqyv_p;u2vA3Czl`$%59_fwtl7MT
z035>~ms$x1oodax$!gkAs@Bz{eW=g}CQ6-(1TG}Ry!t2tewxW)LZ}}I`$3&>Ix^aO
z4b_dYf*=(~Bf_y0eF{;@y+L9Zxs@cs*O|>Y%CRMB_jKNY`h+G=<>lc*T#S$(ffbGO
zDG=(P-8#FjSXHRj{?mVX%3#)#P@gu`YS7sjgVV(LY>8YPj(4(rszeuIuhd;#sF!2QItf*9v7u%O7b*%oeQqdWe~5DgeY9C83nJ(kMsx&3ghC;r!mv|nH5@g7e9%(?TF%_4-|lIA67iwkkARTe>X_XSgKtbDYIk
z(c4J-5a%154hQE?7xVd6Z8*LDnG;GplSB}mtLCmgxdSPW<9u0Ki%?%{CBj=q(_77Rv{@$$L@4Fc
zoly@kdt8X&H_gVat8qS2*9iO3Zt@VqOdbRPMwb(}gjfZ>U=%^zggjYYnT_kgfTdCp
z?GB^Pq}kMLDzpkJLd5wh#Q8>p%48r95+DYvMeDE{J#Iu>0Wn%>Rv-B{f1=VFXtPe1
zTBqe<19qZ5`2X^f`w`g5xx+QC$iakm#}R?$THOwaw+b
z=dC|Un{~28QxbZr*eDfirDP@pRjjdE)^tV^=j-$vdLx2-1pFl0*Xq`^+D)Al!M$ot4`5H~U
zCZgG5u~ct(Ij-IB7HVZq6cFcQ{6b(b%`UIc?y}}G$x5RZj>h?DOv-0n
z9`{E+^5NTVyA9DQF13O?%a(F9+P8ZgCL6UmI9i4{pB7x|{|`d_
z|M|Sp!PR*{s!Sh_d;-&e~`N_r0
zhmU;a{B&=eZ&eN-I=_4ITxWXyTZdPd_Mqtvx+3vVA{%S=>hMV6+6N+`Tq)D&)-!oT
zw;?){z#DKhIyoU8Hd+jf&FNu-9P2$mBgQ?K-|6r=qf!jY*Wqy$t4S`*BI*o91)NN#
zV_YbZ%1f1I8R~7kJxS$KnPSEh^oYsGxyy&GUK<~IF_bTp_ZcWFd^j-Q9e2A`eE9aa
zzrDRZfCP7ThK)uc7U%1Y0_2;B`s-C`JZN-U*;XUdsON>SKOA8rB9}-A31X~**<2(N
z^%jaE$2np3Gbs*|4f@Rx>%m@oIx08oNuD+D?~gA&xZUcM9=v@1(!)nPdy~#|aCG_T
z;L=g1TB2?GE+tpavb^`t{hwwrX>{R5tqeM(QrHh8`d6linT(%
zk}Fj6QAx~}GC|(AyFc$wxQL$GS;ETUb~#nM3YHAk>EMb
zRV^pV#aO8nmn05IBv=!pHd^(J-3V)Bwiz5wvp?uYJrWH#oF*U^_ot+w(}M~angbv6
z87}BEjEALjN5gs}^~hH)Kk}6e{ZXUPDji)q+`hP1?vhu}-@R-f&dJ1@Yz!8=3s$mj
zF)6qM4ulZlxByXBnx$I1Qf?HRoocR_O6L;e`Jhy%3K0D)qd_Z%?L0m&d~L
z{%WlVSrjWdgqoAtu+wXXMV=Re2ulXjo)8uNybqq?cshtnB4anznnhpOo5;iuFCI+x
z7Vi{S2E%qd5soL=-C1{gyEmV-cjvvysN8L5I;~tj8_r~eFz1OUcz?j+Z6*_{Rbn=WIu>zHru9(B-s}`F
zT-u);&Dz86?t@3Ko<#HNGTs@1X!%Muk`Q7kara>63%c+Tq>IFO3|>5!^25x%iq<
z2R9!Q^aS0I7b?we&F;0MlORDa>%kbGZZ94Nt_XrJ9_I^%WIms8I!*CpL~qm>jXJyC
zjBsj01IB4iNRT{mq(a0fh6Jw@;;|g*^C`#?(lqL7K@XyIyL!nREW5N@wAc5
zg)6OcZ$6lx+bg#lv`ycoqzh6w9>S%zcl#!{wLfa-WwBbk)?_I~#RusuB?wTVP~cCr
zvXtX>UpNW1&FBxhV3Z#E(nTQ_YBsCYR{2X`I&!max6fQ{WQXH6ZPiM*RUY-~7ONo|
z3t8<9%XxJOMfGa>fDu4NmZN%IqgJXk5TLyhO2-*+*gTd@F;T3fy#f1h+U)NP>b>T8XS#R(H6G_*SK!l(<^whyfHuSs%M_ya
zpzFa$j!X{p77@x4R7_Nk%aeq9Rz@p7)LNcgLTkaFuAZl&G+2!Yn6iZwOgZrZ@YD4|
ztyN|Pf4xIym7uJ^AB@GgN;M0wB_gs0vteDiv8B6IDkrlp46Ew0KP^aA>qsNK*32fefkQZvaC}n%O{ye
zuOlYH^POIQ&`2gC2N(BYSl~1ECJT3BrBX@P>yTiO5BV93L8VtIwb}&@j~~^pZK~H4
zo9kPO4dvFx*48FOs@_5bt28JLCWDbNnjkDfKqHQFg;0_Tk-%mka&(#vE{oA^X1rFj
z*BZ-2LvbE{AEM%Nv)UZ?%Do%AIN$=@KzJ~aAe^KgT@HNxzgbS6g6
zm^B8Y)}+;&(VZ3->t|ecRH*2epch#Rk;;)?6Y8#5iANKmbT%Q#Q*DJ9Pahqltn~ZU
zN+o49DnlY?GV9d_)#|3=tU|H6wFRJZW@C%u>;{=ec4mG3)Y|KkpLfo=Mm*1K{n!b`Ca7xtp=5aJUj)URiLAl+Qqy%
zbU2w{ra1lZ?>_S4OW%0(iKh!G>B*aB&8c#bfgoonBEa!$06Q)T>&P#_qP^x4}CZTSTCn%B#=i*Vay*
zId%W(&wt_m&z(B`*{5Il+ee@I=3u<{=;JRvdF7i=J^StFzxDTO19=h-XpCC83#2EH
zJ67+o8eKNC$7%JsEk36gURWlXuNL!-a%VQ|&aa=F`RXDSq*O6gY!oq~3)LKqjM<5s
zB(H+NeJVkaPNgH$=BNL6OCX=0UxEXl(kwh4y2V)sFy4GFHy(W{8Bawg@ogMalW`$rEy{?s>~dEu`$R=dim
zfE>X`Vq_Qt84)(C#$pEOEJDWZuy|d*D3{12vk2a5l|&(1A9Sm|*LaeDU1{_iAa9{w
z2u6aq2mJSHrz($1D#ykB6X#!k)K8xFYt$R6^);v^%^KKu<(cQ7coLF)_W2iH>J9oz
zMy)aEH3kD2L$U;yDiz%?>rJARj4n&65TET$qEZAgH3IGN_NYBNw$2=9uh&vR-lf*B
z>x?Rw$8Io@S4xoMx@vu0xxTrzv8hx5>sy-}N(Ij2uh5AK9npzeqt?%Pj8?`7D{R%#
zxk310`M1q_t5t8e=ZoWDTZ^j!*>
z7MF_WDusv?$=7nNeiKnGehW8D1~noA%R-do(f-1t)&qLR1Tm5K5eOW>EE_ZoVgZZ%
zo?_8p@_((1OD#u_&St`Y5mT|zv;!rGp+M$~w(GO~ZP-KFs+DA#5Aya<&{oVvqJkd*
z24u9ZTtn||syA@lP%9|tEXKt|JXjU^HO$gFA3Ha+_lObH*+4yr&qm*HY3w$=+X*>3
z*#MZB%w)sabUI%u_o}IKY46<8-sLaTHhq^e+MXnHsYF&PH7Zg*9m~Y)y+*2#!Eb4(
zgR<}wi3GtWVkl6Dr6xxL9cX(!ATk0y>Gg%|09=sFmbRFLco<#|)NyYzIJkI}DrAfG
zvM9wZPO|0!Wo0_9wHj%^-=@{BIi31wjP(Z`db4&zwYH{OgUB{Ci%FIg^cBpjgh;dr
zBq;Yb5h4KDQSs3!m>Rp);C2F@a7fIg*+e2+$_1iAyWiVCcfL6ol{z;zEVWLn+HQC`
zKQt*=$wvh?!uvx(tKXqOkjI!Pl%_?UOthfHTzHF%x5x|iBKtI`P=#Z#T2*Fd(_&Is
z$$KAER16bKBdltL6VYbBJ>8onvZ+{F>WoG{p3hgwqc4<|dR5w0kT)fAE^^k=~J?*7RMk9bNvq@zoueAWkPHlB)Y)AYoEWya9MyJHlw#R(9)k-U2?#8P
zf`T!wGX{W8C&fovp;KbXOjEOo&NqdKX?=+evwoe?E&n@s9Sn!k#cU`R=0q`DE(?h5
zqEX1MSg#LeGmFbbTeTudT)Um8$mhjmhUdagtIbICvQeedDln*tDCHToARwWk3>x!o
z8FgC*t-_#JkXKp;g~?22ubK&zW~<6#12lHK4iTl->yO34DapyPg?c$tLZ~}?hlCN~=}tbmEyz
z5%q3I%I9gTRw80>Fl^Qu=?ol(c%aeB7D};5)Jx|1hTNWjJ-~TPc9Vudyo}gcxuHY&
ztXkKq$QwmHnM+Jw3X*BHCi?RP7DBAmBQZ#z+Ce8O#e!iD
ziZUSZp?H)u&uD_+SxqiRF+3l(Q3&HNb*e22zhzffYa|qrP6AE@2-F^
zkV;(VvhY#xh2S-sQ5fL4Qotx*VxOp-?HNYYich
zEjGr5dUy5g=4XEWb9c~k=iRs8anEbM@w%=wy1mhSr&Mn>dfn;XZoXW>;PMI~+-+|%
zDpt$MOxodb`Pg7Gn{2de)A=ZsmwcQTBW7Jg!qyEiK%-hyE7vqidM}|^B$Z7$T=rB>
zf*YuY>GpUyF_I~jKs~459}I^>F%ds8+1`n#bIEK$%4Z4EWQsY;N~Kxx^L|bUb_cCW
zy%?9oL^@h;SIYH5I-iuXab9FOk!2%6XTW80Flt6;bRurEo!Q#h(5ekChtcf-8BJc#
zX|R~Jn`H2pSt7DJ8!$=4&Zizdt}^w
z$DKDG&cFT}pFO?0#tLE31P*4g)~t8>9+pez^YvB};Ul!9#pO2I>?XSdUaHgQiX_CK
zz{0j7%m~MYL?)3gWVi^QDQ1OOC|yXQ5)vaOm_eh-?GFNcB$6vijaH@EsdJ|MWlmr{rbz9pq&zc^|xdF)U98|6Z8*#+%>tCW4!8x#i}2@BQe{|NPq&iVe5d
zX?EHo$ylmb;A0}jUA|h0N+~`9?=9d9x}r%mAylYHsf<`DOUVS6OovlhF`f!ZnMh0$
zZBECQO2vypIG%L){60R!#lm7b356RB`W`s-J0E!eyFYgChi||A&RfZw(p%mrms@YW
zm9}c7+3#Z5qjR>js&FD!td+`*O1_eVqLFebcp<5L8e)y76Q}?XuEl9J+8GQD^d17B
zOgho5<$PW{7YQSZDpsNIW0pWLov-}zFaPrD>guhx-$o$M^QKZm{UnwGrEU5yk}PgV*N>
zvK~*s37LBQ4!6(gf&=2R0yd|`?l7Aeooe&UZ+zyHANs(%-~Zls-TUDWf@t*3GMTdu
z$=!0x>tFx+n{RnDKtH0;R{ik3^M8l(Lm~d4<%bgdLCeZ;)P|Z6qx|-EZ#-`9%(^=>
zct4G8MA{{3I%;;Bh1sk#nUK{PK&6s$It|rox>8AwN3}t(H0+nh!)mRT8Vo9vQLWc0
z%qDd^2M=Z}VyQMJ|1cj{n{pw@Zy2LL=I$l|azFy*(UHI@3{ie`hkAL5}TKtF*T_E*2$$wT}nY
z-QC`3RGW_L00c1@H1LIPw<<}YLLu6yr4lhe5Dqz`5%;KH>NGOpkYj(hyEBKYU#L~1
znN;Y~#rfsS`$y-7-G24*!@JFHp
zGF^~5!xn@%+nbmydY9kHh6BA(+sAnz!E!AXPsZ})xYg@`nDiD~tx*YbfxUxWxH9AI
z5nKycKeOG|88kb+8k`>V0VG&!l*O2kEoE$OYolAUxh-DSm#-9JWM-GA+N{{z_Q}p@
zx;u!a$y{xel~Os|@7L#Z@?aJcB&%+=`v(V;S}i9@;ao008nvp3skb}e*LYazcPiOz
ztW=Vs(O@88i^cp>0%4^SN1jE5xJnk0)YB2cIiEJ@`XRqhckW>H@a3KJ=jZe7#_rw_
z667PU(X4m=OBd%CcJj^I{QSXa?*gYK^uI0<|_4qO0V_={A3*}LS`*_x#kT9_(&KoS~j12
z!~WsXpx3JmhOLJl*^ec;cDHfik&C09QGeFod+_`XC0K6eInkf5<-Yyb-^ND_;aoWb
z!3}5qa6BZ$_};h!Q6ix72Al}+G2FmPP=pg)<7q1_`r{JcXqC2iN6{EpC@06$emp6r
zvt;^5wN-(dlX6LnaRd|?=AB_1s*o4C{-oFHH=!#XUic-l=So2b^Z
z7{xQ#kewlp7{&WLgF+z@2-q=-InEW2`oyqX6urqLn@9wG0S6cIU^J->NGVJ?p0A9P_XN1~x_zXiqxg#cr-
z;c5sR>@I76*nxcULt!a&@zMc)%f%f(@+w#JE*CSIbYMepoX`6h#nVw|G;F|K}
zo688fOc*LJ90_1_+r2i2-(hvzm3p<-N?tW+Ogf`kt23z$Rz2fnoIabyp-)O|A{mIr
zyvev<;H`x$zdfzxGMtoRFJ0a))ndB`kl=-b3;Uf}Z+f^h*tvlol9M6jYA%9RNM*tva1m=jH5CiF0}_K?u=ftT)s7tbn0?bZ&HbZd|Tsk1hZVLG!*J
zJoxaX+0kyb*M4;!a^XO`S5Flrh?u-l
zB6F9B1ecH}B@rPWgM3YCWRyme+2N2fanQWkt{oih3K6bU$v^UY52IrOA%DByjKl@l
z`a}lCDni%qp{z6-`E(|}vpZ=w3jI!X)Ngc}MZ&&pI3{{I!R_+c$=fo9%)i;vY2*oD
zsOac?B|1|HM+k1&&qRXq)BwF%M^^8Pfk?z00bT5i6-9mzNEKmv3%HkcPSqJ|fmNA+X
z`~kDe&$K(4Ry!+1T!-gI+lT#TzlxaT;Ntn&(f$oR>Uz5hryA5df9b&DcU2mBsgQ^!
z1dLp_&zi}{W;?w|GK!v4k+)8Z2{%+mOUUo}7O#xuGi0{h@n1nnQa8X$3pzrPAX*OR
zrrm3xhj#bJ28RU(T28mXPG*a|ax2NCfB*w=NVS;G780Tu%x0poNB~}*4bBPLp*Jq)
z%uxw0g$O1>f+vM|+!P`{lDNsDH<95r$>DBic7sX8P9IEX(rDEqPB7W^^;W4+&R|57
zRo{CjH?e1EaFmspZsuU0On3%QunWpR0IRy$)bXpMF=Nh+gOLs*o6vJg)aaG?jO1gZGs
zjwKSLZcj-YfXhS)tS@Xw5oMo{mjQuInlQ#3xU(Ak$u#C$GWr
z=mwVb%$0Ki-rw$4g;=Om%fnG0j61_gw^%=x;B?fgma+oxhoc?}vs#@>p(PX6$;$d;
zA!6hb8Y&kYRB6;|twyEQK!PWyGsr)A&BS3UL3!3N1E1dPVt`mW%tr%oj9cAeYg9`W
zQ=QRZvODXHZlDJd{7Sh*A`=4#;Sah)ftVDM@=-YO^cNRYk}ER%7H6pJ=#gT1hF0iw
zLNYnTN-Fp-^ho}%#aL;keE}D`tyV7*Z&CI@d&|jPe!rdN+(10ZgJkeswzMQWA{8IS
za@H^*ph~%%HLRA!2O%P=J25rs8u7uB5IyJs0ZkUS#q2U$+~#CH5eWM+Gz#^6wbv|n
z>TqSE*~JsL?^GZ-3?-WE1rp4cGf+&p_);j8J4;X!;iS%N)-hyyD*$Ul=1dX6Ev5_u
zbRyES0#GK(CmEy7I2^aqnJ7shJ7@((^3VZ}Cv6qU#agZ9_>h+ixh+;Q=NA#%Qi4<)
z%IPK{M3Qk5SW1wlo}?)$AS^kgyE=-O61+O;+F`PJZB~!P8E|CEaGs=Ur&8%QQso>h
z$*a>pURRDDJOBZqjKIWJzX4Gq3Wl1$fdu7-$*sC7K^Y{kW@I=W2J#
zJG;YTH8b=yEpKtxd=MH1tCIksFzy#T0_!Vu4+KsEtT2=$CIu#&`>6w4&7`q^k}r$zet$WOAF09*b8Da#2<)NTo(GnNO9QwfdlQ!{>t#9|Sj=51@unXB_5syF@vN
zTfIs;*`^UEL7p-!Co$PlXf~C)jb~nX<%uVsdFtuso_+46>Fy4`eA1J}6=+YK1TJp!
zTIRd`0O#+IYVfWR?Li}Z<#fs@E3H<+ZqW#lpvkN^Ta8+ier=0LkWN^qbFCLx-#D|r
zd3x>4>D4cgnZm1|`_k|KtN-%V7ao1$g~y-y*5gnAwTBheBz2;Krg>b>S*H`$^-ina
zX*PLmCXd7Hx3MA{iih&Gd~MVe(uwZ&$Q}&RHhrf8YX}9z$GL-ZI|xhmFU(>ok@84s
z)~V$=>kIM8bFCpeD4%tb$z@|rdFG{;zj@`E7cN~q|Jc`_eCFBbU-|mCFlaOeNLfx@
zdScGH(rln+gqjqc-Pr0^liA4bb{``E9;n@8E0jr=Dio44CcxR#3C?W6eQ)R)!}=Ee
zRRsumdR;;B!0P&`_4TuBtEbP(Q~u9jY
zHmLMlN}U2m2CPJDaC>w_={Kw(#zj?{*{+rQ-VuPN@)lQ=1S6J+$mHu@akd5pa&DV1Z~xd)vhlTl8jxi
zF{sQA1`?!N58}hmuPRiOfJBIEYiCx^o;vfzFP{3XFFf#>bSC%2^MCV~U%m2IUwa-B
zeCpY6zxc}ELq>GUKQS^8qO4yaJ~Cg}VI@=k<#atZzb6LxIm{RbJmX~xRB$5gGQarguz>^WcQD@6PY;1L8V#7=%KAzX}8NB
zuaz-tq9X6{J2usdRmGZ2K$>?)c^2Z^+ynthQsC9I53Jt*g;Sq@;M8vz%;v{m_}l;X
z*mI9Q@!V5azV*bFZ@%!#|4)e|U51idR
z`_jwbdg{uP5V%i3Q9*w
z+WT~@J%ANEmS8N#nQgjcQs6nCMi1+-F0YtaESEUBVnSZHvvzv@)cvdXpE~oKXU_iC
z6VLtKzy5dsVLUr{^zoOUe(tYd`PSd7En2k!exjTs3buujyOB(6CPKszX50=4(aHK<
zoKJ`gLOdds^6&(kqke02gJmb_Vmcy4FnluQ3@X7$5Wdk;g22^bNT%hI;R&w`oWLEe
zD_8&T|MHj5J^wOf_tewRKo7q3%Gb3R_y`B|a^7S)0o8YsU?LmKl`~MjP$TtD4NOG;
z(N?XfRHs6mGaf}WvIX0!(!g2Skk_1$Bv1+^$>+U6vU;*PnUeZ#0YsvQryXM0_O7vQSM7Goo`?wVD0pJyxGr%qE?@KT|J<
zQt{Sg7|msO4{z{dlZBK@M}JQ7qPqrFs$8FI`Iar^C+V`1xR^
zlC0D-W}8-LP#MiykI%V9R-0_BtJctOWVOlhf)l#hWJA3Pe^5o{sc)%`8l6c?R+yL#
z28+gICXZw3f)m*jw93mR$bu7t!-i38z!3JiAwI9bM^f=*F`KQGi>+E`GORS3v+Wx^
z<%jrcoklX3%2f&&zYTde34e&Bv0F-T!9h8yqvB9o;a4qIo6yxGdb>$)gR6hdY7;g`Ia--H2y_JA76SBq}WPg}Jz=oWRlRj-%$7@`n_@2OB>6faVIttlbO
zMNV&poJ(s1+F7@y(l6%tlirh^RrxkfMkB=Um)S=$erv22t=(pHyBLq#>~rx_Oq3GI
zLN=U9R@*f%$31xI!3$sdUD~GaR75ETA>znKg-WXyPKE(Ulid8tr!vQ~BXO}TTzN1q
zKpQ5@j-HWaXIo?uhsfx-Spt78RP&d=e5qJ3)72U9|4C-@-f>*4(w@<(Pv=r0I5Zx+
zc}u&sE=!Ou)`9r0TdzYG>nxX=$j=nW5CCLlM4F5CfqgOo3H6TG>p%&*OfIL33;4o3
zACLRRNU>GtlG0>nI@v#W;rIWDw&^<+v>xLZqZmSj0`>CVaJjk>0Az@%LyS`
zd~QAwg*GfyD}`pQJs)iEAM8E&@FV~B&uN>!Qwb+T59_OUn;;;@GQz=BArsFe0|JX5
zQptJLaa6-_$r4;Xn>h)}R?4qs1!IL)=zmvQ7(itu6~<}JS8_D5J$`gJ2LYQNHjt|v
zKUtWJs`-3eqgit}bS!I+h(U+TL{iCXHm>4Wh|9H3*Gh0<1gZGYf%5TKcCT9Qhx>s{AyAyrI?S79GhO0D
z*E-R}^yJr%$w*xSnO|Vs;+XSEP%D=AaP_hoFDLiNw{l
zP6plCM8wmnrHXlx4VW!fz22x)Xg1d6eEc|)%CY#C57)b!v~MXv(ond8PCFGM
z#ODr&TpXJyF2B@kBNaB{-aq!Mji_oGs@e
zKFASJSuD7Jdh=UGvbbpr-l)7_Y?<<31|kPp#1=DQoGfUPAJEJwj{iFaKH395^b>ju
zd=CgbFUI@Rv6l-*lF49rvDeAUeA?`Hi|uCC>eT3r>u#UL7qGkBR-;9~r6sy=xmxU+
zrDDWuSv+1{N|3bG%qYoD0*iq_SBq)wE}g>#37WiaqsJA=q|@aRpNLKOcf0fL)^sOR
z?=<@phB47LeW$W>bWmwEAjfRENRp!sI=DTkMGR!n*=WNMCJVg)#qlCBT3Id?14tHp
zjL>VBiqX2fTI}jdGw`5?5!$YYVlf}j7iu+&%f*Qz>|U{6&z6rz@pN1-6j
zFpd}7$;+=6Yw6@AZP%@|ql@jmGlWpd$2!~+@@%W+jdL`A3|$h0#W
zrVEv1;aCqgJJnXVmd+)}aBh_#KAYWOa~dJRP{eO`n5-_d%79WTD^p
zF2PC@A#``Vy;tk>YMoYhI1&@dU`%wf!GnwEVV%i-4Dp!BYDs33)n+AM%w!AcK*(=$
z+O}X%(mG9HhZ%|eNA(U{re
z@68X2t-i(W+fu7;C3#ory1ILAyZ!Fl@4W5Ro9SFvoL*l{N|6P!c}koZk`j8Esa$H89ZdCo-i%P+)~vSOw=nOI|DL&Bk~-5lh7r8M0i{U@^G^UX4-f
zWqpjz>IwKmVium7m*TXmxGT%IrO{3ezsUB)mzDIAy=;@Gg%X3dDpw%MO(EJ
zPsdFbLwC?_w5wuVkh1Yotx#>2^5sk>58q$pqZ}I!`gpI|X;$c!I;+VJQQD1Xl?tWF
zVDez7lBh#%HLvTn4!;+j=8wR?WrEQ#LJl}knQ9|lX~weETDwbfx&Ov*-g)O8x66xV
z$@0!SNe<=P?*I*Npa)N%e&AD|`nWg9iV3M$ujVVY!F0Rc?ZwiWn3U`cdIPu~IeL
z?lq)zf)ygETrm=t;7Iv+R?q0)^PYEo;C=78y27(mFK0{HMi>07*E?i?5UokGu3S^;
zl`g-N2FUOS5!)H8CdOfL2O%T3&EtSOZSy*nP>$fA&t-PmT>+m*2I!%x$wWX9_+*0dxOEno
zHW!Af!DMDEwt&FlUV^+&O2>2AWU*2z*K3{t8&73uwgpj2CQ>Q4&-=gw54`ui@BM{e
z`1xCJz2)}XZ@=lLn`o<6;E}Rn&R{X3H>#}~j=6Gyra%Uzqf#7p-Qh(;Y<90R5DNPF
zfXZt4{Q4=4N$2JKR<|9a!0q=~{O(Po)*lwa@lZU8I6Q6j2b;rPZ%`<;I$u1qdUkD<
zW_5+w2aMk2|W
zRLH^g4aK6o81=H8!)@mT*3Y?vytCfQXR@(OHk!?dnM@>|i)HfBTqz+$d2i5dvY0s`
zlq;7K*_^><3ne0ee)5wa`{XC?{YU@!r*9>>nQyt}mN)jBU>0R%*_d_2%d+L6@QD?F;=x>C2oESnQ?H-3G5Cr2OSx=BuFfsxx&xXTZ
zmbJS*bSo_n8}P7x4EaEWvj<#WpIf2a{PZV3@hcy@?|tumH(g~+l4jp_>yQ8VkH6s!
zZ=kD;X{#W?rb@3d*%)|I$y^5FqwBQk3T?;{Ocaw*S_jakb+y7^Gnwr+4qcTLo7HSG
z#`6&#)|LxLn%#lYWG*&(M#ggL)G07uUZ;I^$B;3V+798QbN
zZG#Ok+e{`#r_(FH_}icT^e6BA#kc?SPkrLPpZTZ%1lJ^jBkQ!^a{Fz!L3Su_hUjE@
zUX>seBnEG1*oB3LG$BD4qi8Y_B~#;bpdMp4LuxeVGe$Q=nayW1xlA-Bg!ll<1${yo
zylXZ(foM`=aivSuv#aaB`P-kp_ah&>^)~b$-P-JG*7GH3`g4Fv7DA+L`cCByZ}`#I
zy>8`ouX`Qt1X4RGL3uYclsDmbaBp|tdDkz#{TDv^!S~(!q4$64zK_1^7vJ`tcfI|?
z@BgKbf8+!Ae)Iz${mA>@_uhAX=>6|`=iA@*{$F~>eINedCqMqt_r3d_ci)ZXVWi5L
z)a7LAXgsd=`q#f6T91egg2VMs9yxs2>=hMb$P~M(3E2S8YnH1M;=N`N;jYqw^+wD%bGMhIpU)~K1?#mC(
zhP~=!RDR@+9`fP9?g5!BCB*ndCKgEu>4JoM
ztwr_`aI*gKY|!bq+JhEiz~O9=E2f+tD}uyAHCH65@gwC%5k7t_DfC9wdb4IQ8T-?r
zC*)V@Ou-O>Ed9j`2U04gWlTzgF;_2Dx(zo^mR4(xBnM-$T7eaVX@mP(f><+Yoyo`w
zLLd}!xUJ*K5Wg-a$r9~!AqC@z2oBzv(`_r3b3%kmq+*_+yHL#+YXzs*1K@(e5D)u^
zYr_A4p8T@{^sh)n$n!LTs4#^TBi>=?=IXy~=!l+a2_@2V@7RWm%cdJNbe%
z9CiDHRw^AEPkI1d=m`$(?F{FWE?5YFnmE~P7F+cKsJXX2l8HFjnGN>lL;ST?%WZED
zP&vs+pjea|jY25otyZ)6?;Pjo^-75ZMCSzOy6t?Yl>-->^>nEa1+
zs^vtxnMKex9oMSmI0(lW*LUVE0Ce2j=@j#kgT3C-(JUm`FI<=vi!prj!qE&dLoZfHO-C!%^Uc&1RRrM#5P
zMC;As-oeBd^jRHNwNCBuIy^y--mC|`TKzVnU2xIna$22mh23Pni&49OG~L-9UVdFM)!&G0&}>hZY1K@u%6O-fE=rE9Z|UB&Wkse>Q36v%;l|v$VvXJ2xAT>wzG1
z`JvrryI5;vE*GB5PAZ?QHp?_;1Xv3N2_=g2
zrFtP#Oyw)t@%G4MBm1$VYr|2lQZMv|t$Zn+&LyBP6Dg983Vf2X1*knCDuR(va*1@x
z<@4IzZZ;J1b1c5V*sS;yfIpcWPA$XOTn=6cj;HmV{fU3kFv0#K9N2lIG3hA_2I$_in&KknH*
zwrnYb+m!OLFaNu-Pi
zaBl|Xhc8jph-1HBhr)wmi;yLZo@y;uEM@YA6vz99gK91p84asIqn7S>OWih1Z4pYY
z-6(Y1W$40WQs6kZ$7^*sjN!1KdjkB5^)jCS--C0Si?+EjX7g7D$C<
zQHRch^+YJ1D;B^%tJ5h@a8ve%jZ!Hwo3_L#?_*u#oxT_s^2JQI-%3bPP%vEpb<$qe
z1FaU03x3|$9&|iGFO=Et(GD5|wH-}G**MQf`C7dclf-JP0+S7cPLeB#{L%S+i_;9<
z32HjLb|3G;K(e{*nWBXIm4&n@D{ROYiUi4;r%_`z?>zSCSNBN%3PRQG?H+*2eBK?8
z8#_DwTrQeUhtt`Jkx`KS(i&N((@-eH;&INxD8|Do)L5&L9dxVt4D?wN>;cM!M7bz=
zeCB98=yV&QcQsl?NC>#x79rwsxD4?mXS3_W5x>jBBqYJ%_r4Z#5o<6QE4|*7tfE1d0}U_b96NKdd>6g
z&cz4!$J5s3hj+j7dyhn7frq|y0g{^Sj4poZ;$Uaeopg^bA4StqXvCcd&!uan>A4#$
z_q$emNKztpL+&0%9k_v4wwp#dRaHP2quAfU?l3`
zV!cxh$3swu4zCRa1uRZxFmAa#HYp>Hw}+mf3p5Q1{!YJPb(s32c7IX}MSU?TQft*J
zjgro!=0(=-vOC-kZ_wB5GcxvKbxE6`+7a2{~+
zY(53&a_49pg8_D+R4>8SQz_B1lFLikT(Z}1?(L0-!zL6Sd^_sT;ml)?eGN_?T)my`
z0rc5?+O3r{P?@PzB%K!Rb^}$4@i^~w8DLW3*yXcfgcp$rs1pW_fOMKqXF>tiZg=Ya
zL7UCZ7%b{Q$gMFd{H)V#)%t=C#-fEXcDl`6$m{Vr;FtsP1Z!lrync%yc!GXwG9F08
zd}g~YD!Qvx$z)OG^5JYw;CNfVQ{aM@em7q#MCz5;!EPJJ{hij~elI4v_jWtoez8y#
zFF&;XmEZePBo@5<@Hw#X;N0xumo5zV#(U>?!NNkjynp#{|I&Flg_Hdsl!X?TX|&Ty
z72=&Hya!B`w7XjZr1A!XwM-b)r;b#NY69!z?XxN!O53!pe3
z3FEK$6<5H$5R+V1FhD`U;i%*D+d7>J-M~%Wfvh{3wBaVoIaLtw_I75yYAL-l?ZL2?
zN)ng{56|f|1_F+3HkM6?prW7)W1<(~1&pjbB_bG&2EZX0U)+*Xr|_{JwL#1*n%r=9|YttE3umTAEtWLAjW56baM``mfQg!9ZtA>B$cKLIboWC_A3@qX~iL7`u4+
z$iQd{<@CY+C?03arKH1UneB{i4klMf@!?=LFM(&(c2#dSl$%uq4f$#z6cds;iH-0G
zN?L)2Cio$8sb8MTp^7LJUoyolar`=gM~%+aUzc(rraol
zwV)tq2W{FLv@5kD^dC$%+{F1lf{AuCB^K)iHWCC2L3CJc3_Pgzg_z{Bf}bqc@(#D9
zQq4A+#rd>{fEPrRpUd+t!kT>`srxY&WV+YOPs|qe81TSj{++g&+nUnL|g8dX<6f4o+v-
z8Ep)iX>8W&EIN5Ttj^&!n{7Hj>tf6*pWhl1JYK&!l?mCM+GyMlI(j|&YAKvbc&I0k
zN(Q&b)nv*aPk1jJ4MT!sd#8Q=!ld6VmusW~8*b7(&B5Ag?-9{}TvI0oOhJ8kgm
zXFH%83nHS=5N5*vLvRhViz6IOT(j1$q>B=09SjG;38C69JAE#v*K4vbmc2rxnneZ&
zk{E`h=Aa2WsM#bF=|C_2rbY$Mp-x#yb2rF;
zGAea?wGnbL(5c!wGg%)(r+TVQda_%F#h^Cpp&j9>>lm%wZH^@ZR=YYZx;;TV%RBRV
zk%lrZheqJ-<6hqF)%N=NbNfA(v(C3$7cNdioO8C*1Pcq*?1f8v=N~@TnskmHJe=*#
z=jRT#FC4-gZ=XN>!JilIpWlTsg?T-^FfWvou_QO$?m`73WCo4U$Ix^ANf$O3#Hut)
zaJH(=e6E;8ms{*6^ck!N)C|Z+BN8a8p`51(|50Z)I(%-%L1sN`Emkd=)O_t);bVYm
zl!)IM^lJt!Lxit0gQ*6K!x>AFw`Wkg7y$V73zrTVivfBL9PRX)h+tryhGP=AKzTz!
z!f?3*F6c{_-w6c?MM$=P>6Fo6AtoTW-Z|WcImYPPJGTpOav>(Uti)n$wVJ8dbK^-b
zm5%X<>v`Yqyx*$lVS;Dl_IS`3_3Qmk8394HjA$cSDaFCUVqVOoLrIAXvUZzI@ABEL
zPR3}~8ZC6G1UN);gn(`9sx2I8_LVK24s~ELsZ)nDgq^742u8}{AWMN!p#z%C*FK)R
zjf&o)H`*aqor&xlgrhDL4>Asu(`)estns+7Sd3a7xGcxZ9XS}mq{r&o5MZt
zh6U%*x$$7!>j;tBhX9{|bbB;3d8vit$dbT?n&-
zLEB(8S>1M63H6B;ZInjW;d}h+$uCg8o&-2*b=l#@87#WipaxIi+{Jy5oNlk#slsa#
zM0WRJ2A2cPhLMFL1Pi%vu-&a^YuU-PZ?>Co622qCWW+sSDtYkavSurbEq!TO>G$i1
zHb$e?aM%uuY&;Qex2rCvDVq{WZnH*d*sb+QPW&9m2j;;LBT9{nB-3Mvce?z5=iDE(ThtWf_VUFw`AcGO99C;T9_DWbWlf^
zz!sQn7`bG3TtN(2Y?^oip|{@SW2)t-*KZO8N3UCeg3K2p(^+FYsijlg`HM3)3mz$N{i-(5~KbWnRp%lNDE%?5BF?%h1lzsTi4M-tpIuSuhm
z_%44XgIQiqc-m5n
zvrvd5o=B&JR7&u;P0_HgSWMNZ`i#;J
z$`7=Y>l&KIhJvP{LPbu>x7dkwNyH@umx^#HAm9WAaU@In^cDljm?pz$gMu`e>_&LL
zjNRa4?PAR530kt5V6hb8!!9_E-CjXTvHf0gIIfmziJfzU`N3c?gE>B!>`w->;rw6^
z%6|&`y)&&2u6eBbeG~+e(0@>Ja1EjDKtWy%_NMLTu;~ie&tIH&hD|*>tXoAd(%ubl
zuHmE=OY#WbQ`vA(@Q!wda%vD_5P-!ZnPY}sN2AvS{)@)CAlxF&)A0q5zeDV@tog`C
zIG3_gAf#N{YXWiwgFEPkd(dcCp#0EgDDPIk3I5>-YT`WfB{16^fpeX47v3QP7Z~Ug
zbX~0gV-1?pBysQ#A1&VIi%{9~boncCu$6qIkCXv8H8PjC^(
zg`vksst)xQSsgACjTrS-z13qSNrP+#s2m)FA$z_QWkdEpkP?^;N#xW
zC|5}$Haxhn*BG^SF78c_w$s%-v>^P#8z%X?VS&Tf8MfdE`Zy25;S^$vlxX+c&s~_u
z(-BW36imEL`eEnsSL8?M8>!M%E@c8E??y2{3?^;VU&M$l0p(RH>4PM7`r_
zqd%^S61#mkf$vp=T|T!xIh+l4C*%E{{?2UlJ#0n#-OFe`5R+l3!)C9J_CPg4>6RLK
zRtSXR+-TZ^74rt1Fu{mU;4FGs_ul!PVA$WCw7tB??senF3G?LTs&q~DYhuZgCFm~X
z0RH32^UISbuX*wd-y`69A$&|1q(o8}&-!f02mLpk4ulAYz_i|~VC+Ht6+E(mBXp!6YRSVsi%r*935K4vR-0;H^@Y2L+>Xf1{N}SdHUwTq~60yj(VGl1rQB?P-Wqg^_3C(MKA7Ej
zN8#^Y;11H+3G_uAEH8{Q>QN~IQkLu4X0Mva#@HA)+wO?5pxJ2*#d(X%D(m=b$hX9T
z1lN8%d1eVpL0kufTT=NtPTvr(d1aiWJwnY9>~ACyMrfQbWxz8i#l6EhZV=iXL_{bJ
z4-(9)Hj24oDlSD3)?io`kF)vEva&nxcbdg+tJG{(d_E_~c^O6r!w(azP_7$I8kfi6
z^td%fJ;L5~m2z#1*k9QMFD&vB(2kUa>l%`jbg>sdg&Y@CXmnb&yfr^fQwpf%Je$Y3
z8YYtm*T;tVyR*<_W9TOS28&EVmxXZA#aKNShu?1VSbV%QAhD-cJh(J9p1
zd8rs{&$@$oKVL0&MuXAz1lT@2*gJQAA))WLARK{VLj2q4*6Q-c*RW7fkYFJ`G7fDr
zCysV|*-FYC@*tYt-W^%pw&iVJ*Y^}l+Pxb1>+x`1@DHH%SATp>(4U~J)mtni9gdki
zhP)2fQCVv@i>WvQ6h0ctma?<$J|A+y6%jG}@W;rXwiD*}=|m
zKJAQt(03=>2QxT)%PCvX4KUEPb_MDXo?@w%C;gF4Is?u}zH)%5+32$BPTbnbo(7gw
zTh^B!m!M=?5{_0*!f;J8o@+>nkCcB)7E+u%dEL)ZsL@(@K~Cn<Ni^5IuztWOmbN<8Wr7cITi~hlDy8iA;$cvOjwBc
ztTtni^}2k}f?9s2RIP53?1f83coOSd%cQO(uPbn!U0zybrA|dNz0zc_OVHFd
zuLkAcvU@0&`~wgplXRvsXkuN)$(UW>pBZ%o&Ni>j?z08L{%}(82;O8q0Rs_D2#5^w
zwOpc@tdBaCezVxAb+$*1alba~c6WYIiwvQc>ID*!)Cdhqf=t&y!a^Oqhvh(rV9X%FE)7Y-ycafHUzRz;LVXhaOf
zg_z{B(rT4*Ie5qpt!^uojzvTc{B!#pO7*72W`ftLHybxq;NMl|9aD{fk`GwhRBtE&
z{B>)63zQ{9+)`?`lq#iK3AL!wDAigOuxZ!=6h@`Wq|q7ldZR&SG#DA9L52>t_;{Sr
z{J9j@5%DAo31kW)Kq0Ah9cH7`0vMbo6Lg{1%D64Apv%X5?LNDlCpPI9e1#gB3CD(m
z^=>U)%qDXwL?^9LuR9x8x~(64ej&61ne!5Gf^)z7hhK(+2o~Z9^5ICdqaX4bEy2igIO{uhT}r5
zU5&(rYO9tz&eclG%6Qx=79~jvM`Ix|%9|Li$7=@#oo*XkLzPZR@)g3{QuhQBB`Nw#K^ws}LTQ2=V4QlnED869Bv`ZC3`
z&Eqpzh$moV^ahhw2Ss=csuZtdAu2=>qGHuU3Y3L98zCZroaPxswD@d{*J}3JTp_QJ
z48c>(l+*D{OiV_KwE_@L#cQ2Lqu1(;`=w5Ew730(zek2|1X~Pk2g1QLgOrF@=;K3B
zvpHzC+WBZa&>pqHLiyGhy1M{W9n9QGo&hI(Ww~xJ0&2Zs2^C4Ps#WULB!{12OQ~Pi
zG1_1#_`m$cUp)HM(@#G8>=Re6Jn_u4zx#)O2nqXmcERdef5~(d0diWNRSqra3A*}|p7%KCGA$%$E6;mC`g}%2
zbnFYbUGj7UvLk}ks5ZcuDpxl*S2q_y$r4bCt0XHg!I_OMT9LElD$Z_f0n%BHy`aX)yZJq5+
zVWd2~Cm0FrpWET&8H7-TgJ~~aj7zyF+{Abq0ZU}T2@81zs+MygznUDRa)Nm@F|vYe
zO`(DFvjN9_OSP_C+fb7v$^XZH`oHD$sxLhA{7dH#56aoh;~?XeXPl$pqmWTc_4G0XfI;nv4w`A6Pwo|C!%;;LLA+@zie+ocT@V>TgN$#N*HZ
z{nwuUoB#5)XVclD7)d?$#0!r<{q-lVeDlgPfBo#sfA{RS{?_g$nL9K_h03s|(UY{|
zN|P3$%ymQrs5mGW0ZK%J!)kKbNdgt8&Ej=gJa)!o=A#_ELoe?E1>@N`D2Ph7o@-Bf
z(QK+c=~sKr6l77j=5_n`QKFI<6auNdRBo3eQn=D6f`$1?b~GQrNQGj7?zoxE#N7cG
zOegJi%0CKlj`lr$dPN~8^Iat7rWD*%(calSySaK6V_$v7$GIPS@~M|z{^koWex2l+
ze)7tf9=iO*SO41+k3IF&)6ZOa=DFvdfAOW4zwyd9zB!nURc4ZO8Z1=FDZDAbLQ4H5
z{}wGd;TsV5;5sha3>LSgRL`ceky15NDyM(h$NFF3*)0|L%$B|Mt;mzVVk|edb^O
z>p%JGqc42zu@@hI@|7o^`ubDPe*4PvfAiwk|NgOOUje05(1LoBmt9WHuB5ww$m}F@
z6KVfZPno8^q{(6pF53c5tI2IQy6tAK)4}?^VbLvp`1x(6Xiz9$9Ykq6L{f^2f~4BXOSs|gKx7RHf{0oZJVn`X083|?*k!0g3qb8M
zQHOHscEIX$yEq>k6QY@fhxO&FMNx{y(n&#z*81&YtHvk9a4Ip}-R{kQP!>Yb78^w<
z+Hf)qIu7OoXTS;O<;t0^ydx>p11tF1NDwZp-j0?p-VdE*A)$h7g{c-?>cZ<;s92*c
zT-!PYxBgq-`fKPySmY<4dhW?5pL*i)#~=IZ*RDMABv^Rm%CpZu|Kjs6z5MbwzxC9!
z&zbEGO2H)y0h;{#yRh&C1tEFDKMW**aawRkJNx5EjNjgy#HC2KM3$|<^CqdQb4i5B
zu*u5;ZQJeBHcqu^^DqNXAqx4{gC|Ma`3ypwTM5C
zLAbcYnT<_?^$i$hn*0CM+L=>p58QwDcYfzIQHS@R`t{Rieq(jx%$1kE{rGc#^VO$c
z`A>iO_<#NCQ-2AI@#Kq-J@N7rPk$4-5G;KD<-hyW|M-_SzX!fHNzYESASk%Ce5|7*
zTfq@Qz(>~FtQxC@WDd5GgzY-JjihZyq%3Pe#_I%39*2VuI5@9A!tt?irj$t)QvrdK
z^4Vgi0SM_tpgP
z$O9CMJbmUW3n>rCJ<<&dfMX&;U6Hp?@;g%UzErJ%N4T~H7M@+(T5a~4U?E&U=)R|(
zeEO-Ut~~MhQ;$FXBu&AO^Dn;ijjw;>+eVui9u6@q@(vtoJ-ICP3zz(Z9z;0SSlKd^7T$_Fzv$}ljk*^DkQKFlU!Cf&R#0T
zt5wOzI-a>PO?zW^-n=E{sZe6nj7o#
zZWJ^wk+FXI%-R=EuYTdw+0Q?4`Zvz5eg4eq=l}H|{i{cx{^nPoeEBaQeIDjmw#Y9(
z^~^V(eEyryef|HNEEKhjQf*YoAREn4{%OrH#E=oAVdM$M$0|_Pf~b?6$~v<5f?Y3f
z9srm;PLs=J5BOaiYxdX?f^ab*Q!P3JGAJ7eA&dwh
zj5?D^V_0lgpaw6Y#)xWED>U@!>=w!XtUPOE3}5})qfcFV?(wIddGv{=9)Icz@Whi>
zo_p@a7hZbh@ca=xezi%hHp`nK8FXs-f~b%uWk&t-*O$+RfTc%BHUuRTn#^({b$m4H
zWfq#87U=j)F(L2&?kQCBVBVZ$q=*jZgF+==@7BxBa;04@HLrbYJsei+^>jWjGK|U$
zx5}nRup&lzmh-yYR;^yOrP@#^*Vh%R3knio*pcUh1a!*;0tLke-3^G+^y+_El68H3
zYn5U{xwffXcY8hm{!jncKl$_j_#gkz|Mu_y{4cWks#>cxFj@l)?zK;9D0E~lH~I-8
z0NbGa$QFw<907EIyoZX>N%&`Q6D~4dm)YyF`F#M4Zy?GCM2=5J)0JX8pGg$6zA#_u
zwF<3TXF9I;dehzAhaUdYLPFnf>5O`{P9s&wNcnW3REOaD3lAxo1wf4ayt7(Dsi&U*B0E(EuBh57T_&6x+Kx=$p_T*
zLEx)FpAljRQt0J<1CIGeHeWaiIFukF<8}d7ugBtXx%nUvNydZWP%JG;g`8B%!wXE6
z3)N1o-fbtc*?OycaCrXQ<;%s^4{DL&cOvfTO$Oy=wbCLF#zV1id)P%Ko=NgC9$q5?
z7r@K;>HaKKuPwP(dd(dM%i2_!7%qLbNh8^4=Fq
zye133JFcV7cLGN8b!RA+?E%RC8>m<X~36j)i
z@KqKE3rDCp}ue9qP
zo-MaK^K;v+VQ;p3Fx@@OH#&dtC;xlCbA#;*Z&+sg+vp7F15gmEj#?;i4!#lS2xk!|
z@mKT~D9A?zd;uz)bhepn^+Pud!IAP$C2!7h9Seys_$mv29ZvG~m{?aU%lh);^2^|*
z{C^h%0Ka~9=NGdPEF^7%#dq1obR0fzBq5BqM<5~_4q(Xn_yF#x)TpHjxll|LlL^qV
zHyPDBEq^FfzV_7=*{5hctPFa^ey30^#%twdMhf|Y4ue^()@`V@s|J%oqgyjF$U^$$RiDEj9f}0Y{L4?#%Roq(WILMXL7bprjy=
zY3x>Kh{Nclpc^7ljYxK8hzKDmiOAQ~pKkWRlF
zyp)P5M4D=wyuk@{zzJ;0n+7fG%k$S!Q+532ckx%SM}D?KPf}%u|FYy30X->K=#fDF
zl})p8(_&igU9<$*&B;Qp4_60{Z!Db%Cq#@fxV-Q^%FRl1(6A#Sbh;8*1ZUaSpw}Mu
z^VKR$O(+(NBw-D%onMHca6GJL)1i3OXEtqyc!%F(!qtF$Muvz~4
z45AjbUI|6GFwJtx^<@aM1hv8^S-7B}%tFxayR-0EtVB#ub)XuQKLti1h9EuCosaEd>f%0zR|f8%)H^0iP=z5;N&!Hk+Wuo(e6e&Ay#>!56ohI7
z|3F6&kr(-Zz?ofkkU+uc6=nl?aJBmpBbyn8(LfnVxG3)nrX*W25s(#n#~>^;Q!bK4
zcUxo&B%CL#g-EF;!;x+|gv-j5B_O*xF~&{Cuwgc=nQ^?P0TlS_7Gv`89K4!HQY_X>
zgBc=^X0B55aseS8b@{nSB8l4S?h^dc7tRhqTw?hH<0b1<47o-cJrzx&63o~d_xJ4d7KeI=B>PWO&?ykjAu@3(+|
z#d;OGwlf+a0FP%Rd
zHJjk@Wl9CyV5*SwazRl_2E#%kn?;0|%;kJMFG^7Je6CXAqfx5-GNn>$Fu-}x5qfbU
zCb_KiI)&|73mUQ8DRer8Zns!2lU;fIezV1*G#WQ-cC|)xCLDINoQvh%T*w{ZJiegI
z?lN2KMy*M6HTb0uV&vV)PO@-;*R;sTZ_rg3)-smct1W?1yG8sYun;QHqLlaIQdw*O
z-H{8>*vYJz7l*anl2YTAt4}yE6vJqdsJ!Fi}m_wXRp}mUH+GU
zlxvTN2Nx#$=k!L)`ugT)Kl|Cc?)iy3f8wVW68e5icRWUy2=O?&2OS0?0%V80dKKLk
zO(nDCBF@0afJKJMhK}qG2bn@4kxo0jUT=gqxNw6eg~_l1LNJEat2=>R3%wCIxnUHr
zWiTm?42}vDBX8eBK=l6W2U#!=Y=heCj7A7YKt4fAmO8CWwbJPKmpiu6vND>~2cv4G
zCb``P@|cFR=kp@j+_#df%L#p{u_pR5=7(wwuy&8%;b+}mveSTraWEjF#;DdY+9ekW
z|7a|7f`up6AR8#Q$o@u}O`{fAjx&nIFg00^VF3#%C<{-5vJe3I2p3(h0GT_U5Ta3p
z!_bI!J`~Mn`tyFiT!KV~vz<(_`q1zGVRJMaA3oUKy);70PTgsof=k9y%x#!Ni
z?z#Q$8*E&2!-5}zRzN4gD}p+N!J6!DTiwobvkp=w^HQVV%#<^+Ox(-)MJWaYohxS<
zJK3_eGi(>Cg>)fJUccsZdb^DZ&VRJNOV^N#mm(1s4>GVQOa#*hybgdDV@|S+^UllNZw-5T$U57WI(qQPQe)6aO;obMV
z_3nFqlJ3HH!)@elSf+b>uqo&ONF0iRc19hxrd~(iz>xVv2$fRBMlq3zkLJU2qg1R`
z;wedpikU(l&SI_8fU$=8hVJxZEcrZ2#;ky4)Kk)!)^tWd-n);GiB>4+)^wz<)2`|?
z6w8yeay{hj>nP5U&CqnPOD05nFh@EK+&kzts5B4`F0a$?g)T=0u0?CmDK#p%FMPr3
zc5|W#3jpAL8=ZDI9`g!ei!Z<>;!>$tYPX;ZcaE-EXuDFW(`s*IW~y=p_F
z*whj&xT#UD>Ez7@wQ7YrJ}%`O?NBlmP8SXz`Gat(
zSnEyulRZ6STU*~$C=_?yb;q4|z4eYe-+I^G|KP5>fAaP_pbPQwo`r&3D%FQPD2S&nG8t=?&oo2mT&(}zHXqr0}ny)|U)mjzu`oG%*5tF%8t=saj
z0Vp1HJmawW1rA5X>w#*d(gPz;GVeN^QR|mDt5IfN)q0^?na;<(
z(YP}h7Aw`xU@GOVeRm?lz9+-|QF}D)bqCExyHcqa;zPW`tMdX1P-p&Qtc+BkeIN6|>PD_P+
zt=kPtsaU=MZzEZ3jQ1bx&JNO*X1O!0cLr;ls*TO9Q>RbgcH3=a3qusLiy_%W4l3{t
zc`rj?A))WL6spZuf4qHgu0NeLdc;T#=d^7b?(69+nFV;Z&gzPDvHS8O=s>(8majXVUpW3XRmCR(m5}j6ZO8b#qJc!4H2(-U{swx(y`R1M-f0pao%z
zk9RX9SV-vmEh#9AZm-m6Hah)Mt=Sz->+L>xnXfbwnL;v?8_wplz5VuZ#KO(zgVAi7
zjYR^YVDovTQVxXcj@!9%rqZg$)5%mmQ)@SUEN`;f^=7NhX>oespgW;B+XGy@o3CU=
zDH;@5FY9yq-R^*=P%Zj6zYvS44ce##GVy#g%!^?U>v#B^nPS!x^x`|gaF7$Z_NbH2
zr?Q1ifD1U>jsP$4k*GJwSzWGdsmMjb7#rDYuH3Gs%NbS_bQUugMRcF=vK%i);^{=T
zRA}}(JBRz@?Rhwsj7sU4luqP|(KIxDwc6^E2qqTe#i&BL`H4^7w-A$DRzUgopanxv
zEa!5CbiSCWHPDHTZodUa=89>k##}K4upu9q=knSRlz@edRqyuM?H;SyVe$lBjNOC)
z1xGb3vz)or;wuHDcr~mP+MlCYP@_`B-K!
zKg`!UwQj#qZx$M@QyYrkzW;%>jrE`Ush5@H|}L>(mH#ZWSv<-(C@Qqq|i
zr`IPYl1i;kh=xrzhVEkM#K;xlW4V1S%SS{%$1^s2I1vF^$>upxF&N@8n2WVarkI9@
z5RMB5Gvf^gbS5Jg7I4i-A`z2Pkwg^qt#=xwdI`+w4Emu+BA&`ro9%3|6buP)Inu>K
zu2N2w3(%|)1SK}xr$7D6?|8>M?z`{4cfISKx8HuvzOO5Ao|-)frQPf`8{K-bR^TG6
z%TMx;NVz2Zm1?UZZ>|YCFZL0@c_9`OlMyfLf#!1uT;8CEEVT^zJe(&G4g@eFIlqVX
znVnX({D690wRuLhaYngraGI@dI|cr#w_CQ1I-SjI4fwQn>lrm{w;E0{nS~YbTjc3j
zV4jEP%}(c*iM%)pMg(+QLXt|AG8c^`a|NiDT&?L1MViA&wKwLI#blvYZS~Z8{pUeG
z#nwB1>D_dfy(MH7xB#)gcR?xM17GlVvc)Uem-GkMg*V^yqd)Q1JAU=kpZMJ8e(mEQ
z|Jbko>ZeVN0VMGAfi!uw1>=%y_S>mKR?6mUtxhUeNaagV*ii{SVip|4#oQaqiHX0renk7vsjsQ(09w?xw8@dN?^jYjjyPk#L8e(qm<
zcv!E0!Q&>gm|f3QcQ_t@@9V_{ci$)A@j>GOU>n`{amm7y+dzVacij0C
zWNTca9sm2VaJhBq%{Si!+GNI;XxLJ9d;4o5Z|;zjg-JQ5968)bM<$yB^lDZqV#9h0(g5ICJp
z@Zq4CfMN@p?Pih9reiz*4Og336=c4h5l#as^7ID2os(~J_
z<{OBR!mP{f(waVTJ>-J)^EK3
z{qK9{JKy=ykAC!Le&%Q1@|IiP{N^{kBg`OP=obkmRh*pH#I5R+WUzP@zU
z7secvVy#`TwrX%1pz1*y71>mu%+bOi22)`I#AFom!k2NR`!oaapkt{xoDzJ&;^ymXA))WLELnIGH{VP))J0D~E4=M(Z-aSy?|aFvx*z%Q2S59n
zU)@w}1i=_KU@+-@p&%C(06rFuNYQXIiZiYNMCX8(^0C2a62>u^FPDM>C-1%N@&&wh
zryVevjRunev~YXfb_{Zdm0=8Kvk50{4x7#Zou?wJcAyM}7o1PPT}Z%R)?YSxID5PQM470Q1U?3Rox;v0kW_
z0Gt89vs69}r%yfbz?s#vKlk>Zf6HxzPPg9y4#~_r2HjWqBp@IhDch*X
zC}5rcd$Ex0g?@bV&2PNr&2PHr?mOS{i*NtvM?Qp3ef!V9?Ong{
z_7A-0-4A^Jw@;sWfF!io+JIIw*bIpIaAfQx7mvehx4ErOzXMJYLPJN;>EfaB-0qOq
z!MQ_H*vYxQoDYs*PzZWhFFsoRcKp@pcY0Vi94f#Su={zpk9Ye+0S~?$aNB)OxMa9E
ze!^yFj3%v0weiI-{?;cx@$nCS@cq!}AN%;dpZUzMzWbNn`PRGcy!9<_25!6cmRrEN
zTkm)aWP95kx7>R3&9}Vi$8Y*EkdJO64BE+i`I23OX<3L#E-QoCq%#^c``z}i3-3@?
zgt=U$6pD#Ho&~pzRuc$;K|u4%z{7>N%SCwH8@L7FjMZhs_<$C~N!0Ou*k25qGaF~A
zUkp-4lQCA{pfXb#DVn9HZ?rA#3k7sCO+*UE7|HpC0b1RoV0UVk=MF1NbHX2)QI
z_ha(H5S7dELRzWSeBx7|{_JOeePey|gCG1LlnVR|x_$P^ZJ3uhNxmiU9g34Dm;Z%o
z#D#>u-|{0rvhuput-SvAuY&=4;~U>d2}cXzpS-m*#mNG-aeTZ9w(Pds-hzngo$vgG
z_r34k?|%0?f9`ER`_KN_KY81~_}O3hg|~g+{qO$dC+_|9r$6!Qzy52dPyf!@vk&NW
zN&}g(pe3{VO*%N<4vW$5U@TxS;giY4=qy&F#b$y}XfkRUlTN2qDppUgp8Dc%eeTyj
z`{_^q$|vr-@53MX(EHx~(T}|U-j9CZGr#t!U;gEffB3^6_^1E$pWJ!pZInZ|-zIN)
zeatFa@DYE4s(Zs5-thX@zaICCkK_-x-TLOY+;a0RZ(eRGO$aELg_z{BviSFh<-d1%
z6S2QA+dFDA^V8mcFUV@d&`?|
zf6Fc4#!uXR$4~#%PyXUR|Jir{!rMOb?stCpJ@5M1hu`;!kA3Kq_kH+dAASGFKJvc%
zKJxxg-21^_zVE}I`;||9^n>rc_e1Zy?}P9E;Je@Xi*NhcpZV#3^pF1GPrUV>J7F`Z
zc>vyW+gonONBny`1~xw2PI1d^cgnbf@(E4Fy}aQK7-c^S;1(8*B#J;L9jGa9X-+{4
z{SL}POmg`l3x8Pt$Cn?n@Q3ApaQPtxe^~wpmmgB_hvk28AzME6`ptAE;r7^?tx8f7
zyWJ|?lXfs@?C*?rX8rl3OLxNq$d0ws9!~Dg2LLMgIF~oDrC98nH|@^n{qeXRi3Fz8
zULp}fU8y{q&&P|!STyQuxAUz=WT7qk#3{!qC(21~&N)d=
z6nmtpnm&?jr{DJvaB*|*8A_XA0w)5=A{u5wwNOd7>v
zyk1YIrBJt>9}Ozgajo6V?9E!Ss0Y)NqXA{x-rsFkN^x@acodC#_x8ytOLuo_moLnG
zjQPst$Q_!$-O6mgf8pxIM!z*Vn(SZP4+-Jj
zXA61wGk<)M!^Ir=>k;<}2A$KI!y0viVfLloZokM2Px1*28)I
zT!eCYgk=2a;(jKbaFRprnrw_Sl8Sr6fmk+aFq`#e6FEP;Q5#Pspjx}(_IcSb2W@Kf
zMvKwwcXfN6bRiX!1W&+S?=)zSquFbf8F%I-IlKu
za5qnY!9%*EUZq)WbemR(1HL+wkB+IdII%;H7kw!Jss^^NiShXb8
z%BkrTbk+xh8Xh_0(t1`w-d5!i)Ts^2Ywwz%M}
zRg!=P3WXe#ah>(sav5I!tyXH-FO7#4W#;IhXSZ$v!GpaH&^$gI*6W%5gZA!juiZ>u
zzBpst#{Iq4l`Fe6t-XACHrwlur?m^0rdPjw%yOdmp_^riS9{fo;(dBb+@-f8SUK(5iCcqbpvcNGI35c2a?%vSq
zqHG>InTnEgx>ob#=;UFal!*uAvu+P}`kZ{0#&WF?4Eu|fbfKK8)Jj{r?Z%+3F&MQ*
zqd&xYS*BD;4aRMTbu&RP8wr^xOQBXu=d)atk4t1%uFYxh47-$z-qMh7w(~JTYqV&M
z>e=2X7LQ~~X$M1>>P7kM2x*4(ifK`lVsSAVjfHEiDz**KgK4>56~s86GZK&X#(gto
zarxYM2p^BM2OVrkd^{YEaiDO#I|^b}iss6NTBmYwVb|et)jG9e<@&++?ih|*$yCf@
z)dN9_HV;P~xEDOE->>h^`fxZ!im_oTieZ@F?z9JkoK1Q=W8#H-vwpi>ZZrybENl`|
z9C0Yyr`u!O+3C@=5k?q|`r&`UAZ@j7gFH~!tfwobM5z#qMVUdbR4OInaep+*j7Bxk
z36GS|InM#LUMHWHf|*okXHsX}hS{`neAo|%=%a%H9t9UXIhpo**=v{g@XQC~>KLF;
zr_IY(4|fkbCl@D}!TP&=?da&jtXPpQUAxr83!k))t{jz{wY`(0@!?*%)7&{Z?C;+2
zdz?S-rP-^e3sSa}PNZXSvP!*BYnD30)@U{Wc334q%E3^{Y@%GvGC{w=Zte{lkp$lv
zwpl(9#P13DlUd2`q`?yt2)O(XF%{jJ
z^~6*{YtT|oYFo2Kxhb2|YN0KqdI_$!q22_DYP~L<&l#@dZxsLs`Dc7J~~=+`ruSU!)x&NXZ4e!DOlRI#Rac3MDTI&J_OEI|Q|yi)o{o4ft(vM3$u*wNxg>0Y}tOkOwF+56)0(L0&!`9&`#&
zqmqmZ44xL`Vfo>H*X7Xe&Dy&=t%Lo><%>JPfbGhqX{jJg#TsbPWYqJYSD8b2MZhCw$+@H-y=$0;k
z4`rx3YFArj+GX9@AEU6Mq{7c=kKG&eU+g(U#ezM!my4}@=Dblyfa@)
zqZVsTYB&=g=Z2G}l!@j`nQEhS;mVGfjoCd;jZqB>H3pM~a&7DMK|U0TppbilT(HyY
z93CIk+EutOuyFf54C{-Eg5608qKNwFWdq?D-x<`7FHXCImXo0YStK4tRSiZ$p(saA
zhQm1Qv}Lk0gtx&XN3&tEMh<|PuaHB};BLSX$c}d>cxI>9i9(E5i$99ZDG>JO%Gpqa
z$9Bl_!8#(}py>(tB8m9dfB)0O1ja=PbTm@!ryGt-<=L#eDMVY
ztl_W$duuieySsxzL2S26n07klez!av)LM;vyOkdxu}zy0YU_Adg%1J2(LlaWuO1FF
z`Fui>_;fm|)2)}wsdyYLIueOMJ}-E^7T94pnX%4kuls&7d)8!$ORF1KICG=Ce6yL_OdYONyA$nT%pO
zg{g8dOef>f81y=uZ9}a_a6CF0_Xbse$VYozjaIeUuCXCsDxZ>aDauX52+2kg_Jg)k
zy^Q1sF5z}UGK$C;DKGHUawjz
zrMzB>q6{qS;v@b5>*^2c*=z(9j>mQ6Ii$B9OsiJ}J>6EJ->&%mG!Un0L#ZTLEb3|%
zwbJb6asc=Cm;IkxRUhq`RM(Sk|YSttNrH22Ni!mUG
zS_~rhcG_6dsK+m!Omdm<#gh>VbhlHucI_aOw>Me$5{G7)tpn^l;qU
zKb*P!F1-Hks3Ro9=+9^m9TlTuR)D9<<3uiZ@KMB9y3?(@ToxoYESiqHFv9PC_eIQn
z?Q2*5{lEV|QG!uPXS04b8!r?kz?VuzpfAc$rK%UjJ1T(Ddb2gBl*zjC2a
z5)Y30Xhc%k*zu*wm%nzY-YuV8J-YDKE7d{c;L73TXm@(NkNTUfm3J>5Ba0{lbZeIj
zSC8R&un?p@;03C%5M9XQPd?rmwBd9A?%)64SePlM%8g=}oHCt7Km@q3Ok9O8Dkq`=
zvVadO3@A9l>^_)a%xuhC3?*
zh07htym(9HT0WH)P;I~a;tN=c@CO8O75etKA68Nzrma>948i%hu(wjpNm8WQEP~xk
zMu6?1dqw^2w#w;b81TWp8a1g}N>++eRA6&?QK#R;U$NPZLX7h;H0?0KLBqVy7a$cm
z6mt5!R+q=cs9ycbrF4$$$e14P_IF2U
zM|#uV&e6{3V7Jn3VTweo4A8AzYTX=2Lh{==?1|~P(LqkZ5BGwHegFI4M|b??uU@@y
z`DC&;0(`&@4Knycbq2UVDv}7p9l;+kMO%X~XQ55QX_InToo+f`7E!WsH#`=0h{)LP
z)lr~Rg`~!$x6*C{=`%E&T2(kMIDI~w)48rzskPhNstr4Zjz_Ku{o)Fw|edC*X%Az87N%tz_{Q&6w8?`BK(9@
z;fcIQ=DXj00aw5FwTu7!pa0{XoldJ&m`>aEdN!HlQkjSl4@6_WN+o5pX~SVpH0lEu
zu&!1kQz@oO`9!UnM6HAhxmY0^kH-9|48N^DmrU_)4;AJEcFLsIt^_%kFF;vr8b0Eq
z90uBHq#Q<<$0Fa&%<~>}ElDYez*o#i(TJeWKv=}zg3x)O{(4;cRwLDIrBkBsV7D0;
z+`BvVMomn_J(n)+GK@VI_kQ^+m->Uog-f$bR}MuasJTP=6oe+^s%8lwVjk`YBTVIzsMqL7z-TKZnpbBuT-fUpQ!TzA#?$i@vbbo)EEyQV;1>p~l
z6-z{doIh7cgCV)q@Fmjd*#)&h1r|XS3=j5Zuo_bNw7h3Aj)aQ342!k9>}WU`miS_$
zTSs63tav!UMgBum91%Dmp3Wu<)hy+9_&GLLPS@HEU+DTlGVe%8QF88Q-XBkdr#sz8
zANdxRJ|a)yg~)=#AyQxu`47DaED-h7=XYdt3HVB*Q9z$72y7w|LO+XQN)Er25(?QE
zI@x@dhq5V1h{Zw)F>JPIFm>UDMp%kA<7$Xw@N7=E6=n=sDTCEUzGxJShkbqu2qJEV
zI7ckvL07;*mf=!s4j?o4ccc!&Vmu8|E-rw)S
z1zYX%(FxfpBcJA_dF`v0Yt6#(<-_Bv7iztRg5Y?6j6%G3=>%D@F(jGfmM<*tyKrs4
z+RoS8m9P*ryDeB4jG%3mq=&g
zd^FJMR*R(+Di6ndlbJ}dnu*1EKg$3?c$L#brwb|A9w;O&MT`S>sJ}oE^N4h1Bt<8J
zK?%(Y2rD-#h@Oa{xIZd2yb#qEUU+=@$U>W0J^*~dA|DME%Q+x^a^=uuGv`YAQX}u@
z0zg?AC|vFsjyl1R7q(QZ<$xM0FUUj9g)onfSV6E+&FxNmrF=4%iHE~plwc2Ir)gs(
z;)hYO0S6igLGCI<5kv-%3neL(N{5mXD~f?|gc0H_T#$<}D#HfLGiFMsHEcTE7B^$F
z*mWMS-D=lSw9#nQA@p#O0PQq0UMp-8j}7|iloWy&Mg{y;ZCYYuVvr5mD^<~A-7J?A
z@W^DsKONWH4)xwneKIUTmoAKQ8E!VMefi7#9>#QV*h4Kw-R`!c3AWuY#}WeW@AT4%lwhHZ
z^;U(Cg@icI2EAC7`9g9uX{57!yIUAd>Tbr8%0|;!IHe!8YdC3EYUya4wb=C}_SFGJ
z)?m_dWZ#N2Cx8B7b67wRuEN-m1v`V590%cZO@uiI{+_d`b{siUNmPm`rK;d#n3V+OPcQ~zRd;9$w
z+Fr~6yYaZayW3ZKWCG==)oqmq-5RPY%R0kh2J(9CJnt1nj`3IvITT8-B(fln<3v{RZQAXpAZhw9c&2n>9LD
zh@o9phs(nFDA_5U(I{GPdt79lE@L9*@v*d+43sMgt8J@V72%PQuoGPf$6ANIe6=LN
z4lf+{V^LSF62JE4Jr85NaB+O)>VcS!o?M=uTskDXroVi2eDyd}$(~$29v+M*C$qu+
zxZG{dE}jhcZtK&LL_zd&L|jGPh)dBVEHfqaN9}A*tT&3~
za)$BR!aU;-(6vUkT+6~B!%=^=kzj
z9WTTu`$N0aib9Y2UhC9i*%%Vxe58ON7xo*B>Reu$PCM;(S+T(3umJ%lxqL26^){p0sIfS#8k5f9acB%0+D&T>+a{~d#ZW*H83u?kI>LgF
zqIE#f?X&R_SD`3Sv^tUSBPM!1#!fru^XSKeVm=e96r;z7T_>$-){`d}$2+qo5QGa>
zo0*GOcMeach~y_%4*IixW6(Uhbl98q$HzPUy%7-Hy>xN3w?7}DTe`S855?FIPIggq
z5p@!oxPx^%(BW3HaKXW(i@*o|V1#UhY4)pln^<9R9eE$J3%7a#E|lg%HHT1$TZLrg
z;CPly$50=@G5U}FqaDg=>2@nf8v9!8r9Gqb~8qs^eiKClH(Ma>0>*qi_*-U}y$u;r8*#oo9>KKKrKOZ6h$vDQI1
zef_ZgcO+A>R3<(gcQTn6+S}=*3;$C@$eWU@qhV{v%Z
zwWId9ldI(~Ub|54R%e$E#)mVpklDR>VYqu+2<~4wh)R)0rwVA$|Bm;DQc0rSw#jS&
zgBKEE7#mt$w6sjn(H_>Zc2jxD;xJ<+VRc#^W~4xrU{Hw27*7e1mvzIaV18I-utV4t
z1fwlhbL6D8>9{ArnCxcMN`EM5bI?|r(wU4Zlf_`CG2J$rG2PS~bT&KX^K9xh4m2~I
z9~Q{RBT+GGcbJhA$iX(sIXi6`P5Nr>7Gh#39KaM72<%W{b!HtK4u#`vDvz|6K(hj>
z@Ur&~c5IZnP|BWMKEge5|H=M@jf8TD?TM(xVL{6RI$@mn6UWEbi_9Ikj_q=1Z|K4R
zO*-V8FY>+^g+k>UG2}DiL2b~j40@GLGau#MV%!hl(&@0*Yli2E306w5z>XA3rwP^B
z@2AMot&!YZ7TQJ5d%dn%w>T}B>aFGtjcQ%JO%6AxBZnc}Cg+DChwwMpOp8NR8!5BO
zsM44w#5qB)%r=7Y~CQQ?6fp;`30?Kixm4zer+PUcj
zDO=lVNV8ch5_KOP4=!Jxx!s1@etWh*9!*;pt{s+I=~BG_E;Gdx8};*vuqWsa$Ac(*l-ud@`E;j8OUJ+}#}t)iT1aIu
zsEoLk2=kaK_jmcdxk?dfG8AS}Of3$>&cWDZH>GkJRHWJd1XUi+3ZH{Pl9t@(9*nzI
zy9vz-YA%u@@InL}&4y@7kSOqy(8OS2vtPgRl}m6U5SlVH@P&!CPQ%aXdH~KJ6)mWJYDsfIm!i7K1XcC1=-A
z<4Ir=NRU>_h+>2^9poI4%VPwB4ws%~ZSklx;IlMp5)drqBgH&VyVR3Gu~dpRnrXBn
zCnw`#DRz8uG@kWmd%X*2kh|6K!T9LPQ832uU%fa!*$<}@v&$!w;~NeS_2<2y^gu43
zWB+6~#CttH>f)6HDM!9@Q14XHOaQpSw1--Zs0V?n!;AYNr2beaCWhqiB_t@9eK_sI
z>fn6XW&)fST%thZ{>6I9;dMsDh{mKfSjnNh^%j(o8;)uFvIr{tEr~n?!;Y!hYPQ%d
zh}ED66&BVApF_o0j`xSM?sQWKg=lYgcE=vCQ;6}{NbD|KFv9Mi>;X7b+g87cR}Qxu
z?hMdZ<*R7`8j6yPfeH>f;hK{@@J)7NntmlVPLZEw>xFazTW%mI^T>KlB+0d@M_aIkzZqZe$p@4KLJUH=3;mBZkIKe$=Hh
zkt6G<40=rE!w_nKAf`(Q!VW
aKoUuaTJ}M@wIfDLK`pMX#|K)EIG_0p6f9YyGU9
za%i1yLn0Y6+qLmTz~Ml%9LlCS+OF!gGF-?W6PaN*C#8a=avX(tGOnYixp;ZfN3(S>
zIKI5UbF{N}aqr~Hak*XJy>ha9@i@>0yD*QGMB70N=KLX5h{{dNk~RvlS(bd
z6!)2r6cEhk#Z)Sa6j&&xtu{lkl_Zh$lK5WIDiP}(<&AS1Qq@kl84~>86_c%
z4xRxsiz(35+vf7Hl)<{~^4k!n5UUds2OP6$Hl7Un1GYv(6eTvq(ZhZTRXEH$kqDcO
z^l(_YczG6=!p9e;K(O2@?_E4Nx^&zeb!V3jQG%5w6%JER)~q)W=7ySuxQjv?QC@8{fKbI;vppMBO|do9|YKEZhkb+)sMJA)Cw!0Ba!
z_%}L1lC&%a@Iy<1cmKGAm*3NKYhC^a-|skMi8_{jHfxOz?8=19EP9OFXx64G%T@jL
z>d-i7_;itLKhSv3CG!dcYGGVQh;!)>&Zo+AKt1dh2vZbMtgdE
z!HOiZfPv2*|9rv|C)Cz8iY{0fT*+&-tS6?Z%SQ8@;Vj|RuYVov4d^ulUqGJ`8DJzvlOE_PCg6IWNxiIB?R8*hzey<8MRC=
zWx82!O*}(g8QC44;@owNO8)+d9W{g1Etllj
z*p3_;u<-u88DGi&dUHp)qnAYj4Qmekin#&n^ZHB2DsWt}=GcrnD$N*zf=z-Mk@JQ>
zKzw;nR;MMI!e>Dd|>N~fHj;?{`+0}i|g2Ovt
z)htD6*Vfnej6Y7Ew`ZH>g7(w~Vo>Zn5^9>$oBrE+x1&IZYES(=d{pRun0G$kATt*V
zbYFShO&IfyYM6W|3MQIM4)f6S&NkGA$N`p%Fo!?i(!}LoMYB=~W)d$qivL3rK+{ka$Z$>adtB7!
zG(ABbTnYRUPkE7)0lM%oZZjRSn94VPB@<|)%N3|UQ0(R){N^0pOyQ*8WE{yq5d0xC
zIzN;&s>K6ac~F3iNB>%~E&lBqxZI*_hhcrFsB6GOBFqDAwF~_Vrg@o>&3Emi8eI|e-Oz4uV7)cb`IQF~ji2%V=I;{_i
z=nVm`VabAq^0O^6wL^Ig@frf`So=eZ^O6zz#$K2>R0SDNJ4O0L$3RRHfFya~M?0RJ
z!r)8^S|rM;7|rlm-ve`&Q3A99KuVP
zu7BUN-MsDH1}#9la;vBwlBVcR;qVHFv7=Mx(hH&&0c70~3CQQ>iiI?1ugAsX73no5MK{RPb;<98%}ptQYX=
zVH06l-F=NWWKrC6XS4H$(Bq>JNoC`IB7O#OPJ6IA+(6CIAi$C2`V!y4=WRA+@z|;q
ztXnl3{bZCpA54_G&gI8vj1?4D-OD|&{(;rXj+dBm{CE0DVD7u*$h)=){am&gP8$M}6ha2)JEp(nSxlbJ3!A6yvw;E4=p9!T-+$L=1
zNu$V@maGG}+05S8{U!TBvK8POpYR&|ezccPk!#z`2QQpY-(D8=mF*l{>H^h2`~~)y
zlL9RPH62642~cV*ft4LEQ?v>0zHuMI>gu2N`!H>uBD6a7hPv?#YK)Z`%zq`dC!dr)<8)i>5)p1rV<
zBYsd-wFr#+JJFNIe;h1)(}%0J`A9IkUH6yKls4>p*T>=+cBTTS`Z!MQw;Y`X5g(Ot
zjMtXrl)DPn_!2bM*i7_rCh%YXD+iT`sCpioi4ctv1I&g49+qDmq=7NqizEAmdFSKy
z{u!e``bci!q$H75ARNe)M=`!e-^Gxz*f~1c2S~K#>k}~c2-dIKng<}?E2FP8L9uXo
zWUv~}tyjH6@>RlW))1r%``SnDi`Qcnv7w
zc5gi`-4ihVF-)bw;(!PJGD7m-7VZ-3^QcUDry#btU**FcF|88k@93Nk!LJ%7UG+m
zo()PmCH#6(fodcKD4$6)x!J}kECgt$v#(SW&p9x{e8IAgANX1jf!W#D#nma>h{sts
zzFnJr{tp1iiylMppBk2Sq@m`z+Qk~LLfe8RU(4_jm_H#GCx*jyV^&M57o&_SKXhWY
zMNVy0A<)h@vu(&Y1o4Dr2}?%mP$Hl|Gc@8d@ezQQJ4M^H(V9idsCyZ1FF{&=*uODm
zlaR*U>78M;D0zTNnJJGR*!m$oVwU_%%$z~##}PL^V1bo)=D()J{iGty`~jGU6Bjv^
z^3N?dZ|+0I0sgzthsJAObmOp(Bn*ja+u~@jfmPW?V@>G+S^pSL)oyEBTz;
zb1)@65MIety$h>3no1P*Lhj@F)#TF+&FGRt42GCTy^wFZ`+8h$eq-XO(Cuf7Gh<>f
zv}nR?HvLMS5gF^eh9#w9#nCMkk}{`Ox-&7<;)^G0shq-Huf;-m(@7sOLkX;Fv7bPL
zC-LkwGJS)HoU%uG=t3;Aq8_U&~45y~65jW*TDBR56x-qkiq1zrUxaq^e)$K%!8}jD1M@Q|4LH@F>uBH1(Qg*Im
z+?}S`-}8oAL6TR*=LVBB=f#&_X{jal6cGIu%Tk|7imSi81FQBdlt0ip3|4D}j*Cyv
zcc*MQV$};G$6l*Theb9Oa~m#$J@0CW@n0?ncU+1u<5$cxkMZvF`P2mz-&5}m%|Ju1
zgSIGzY&^uv9#y>>yJU0|k0%O@ONp=xk8Ruu!;QpK&Z%Z>izfPGWZAq6sIC|W)#s~4~8Env9V2sey5I!M0Lr@(#&^$?`MQ7f^a
z*mp+6FmxYS#*8GE-sNAQ>0y}2k`_))d6M&-ygdeM3FIpu9OJg>IV+M>Bi7<4Z8TT!?)zgq
zLZ?}7W%bad7(x@3Y~aLwkV7R)EKL{L17+@>QRnU#5~WTL`*iBQ#9S-esH8@$YQbd#
zNtCg!wLh%4`|0^A83rX8-OvY=tc2wZuf3q4ebYky3I^HG_tEmkm%b~@XV
zGaYsRTawH4a*MSQC2SJn5|O>lS@D+X{V!}nfu9>|r|{84ZMG3Ia`kG?ca+NbRBt+a
zY^jrD#Bl1HG(UO^7+0wEZ<|wRpKMQ-tB>XEyaf8+;P29-qp=JkVNE#YP?c)c!g7RJ
zgC3FHMPLaUJ$m(tQ-`tm$cO=o+}Wf4;hUR5;)RX8rgcfIxT7WgaK4#exHAoO!%~A|
zSg_e_0@IQ~iLoW>O!)&2SebmQp%~ElsTNH^mbv@$
z`u-ki6a8*lPM<`&do-hZNaZ&>JkI*sIi;`wd2T5C;KnyQ3+Xz(OKu)4sc>S2WJmSg
zT=aHqsPV6zhc$+s1;4OZ?hSOk1Y{)#M@2uTnBO!fgf;5}g{bz*02njufvH7nko1Sk
z{ykX->TmHh-2O3@^b(wN#OVi<`0my+a^hC4Du3s5V>6vH%0OC)0Do%0y*=|v#F-QJ
zTsp(DW$1w4klfw)*K8zf6~Tnh!~l-dJ)yK9?Aomzu=)69pscuDnF7(oD-Nb9v}H6vaTdnq&CZC?eLDT~-zuBB_CZqioq
z#+{;#LizG>ukDJ-Fme4RXW@`vHEhEr6*;&+7-3fUL7m0YU7yoXm|>@q=wW$^I|9XGcm
zLqm>`Rp@d-GwMo{^nswmBviacWyuzbXli=G#l+P)pIjn>vHTgZ)4r{965@uZN!Myz
zS34ku@&jry{r9mET^gYzNx?wBwJn#(BGF+4GV@!Ih6OZVzGI#6J0@5CplQT`Et#9y
z+AF_zMBvV*A6noz4YA`*|8oMl$RxQwOt#(d;jHK!XFZ7itiNQtFBE+7MIUrlJp1~Y
z?<#e0ZzfsguzfrV!0~6DCL{-jb)gteh%J34DZ?kM=#ZRI(sxiR*A46vqW{{U^HCwq
zhMNjpo~AiIKBioqO{wP^L|m{Vfk#pYd|WaRXok^G
zQ^U}{uCV^<^QwUw-|I5D2?kE0cp+@hj+b{pY0J4z17qj0l%!thL&BWXRJKO4gu-l&
z3;Hs1_lQH+ZrvnDdMqIK`6r8c>}|fT@}9H+&3zKmo~S@pE->N?Z9HIRac)f2y)Q?<
zg0N7zwwtRCj57ixc)F|rMDq-9
zcut`$@v%1CP;mq2&sgS?w)A{)^QbW68$_de|Kr^pH>`?DU!JE0Zo@rK&3_c=r3z5K
zv917DuG-}h-!dk6oi>QkGX|)v3Rn23W712zLt}%Shx-JL`^|H|^=aQqy%%S#;oMvk
zr7W&}m1+5WzNPfeD6Zz-SZk0M+p9JBik?R_9oAQ@6|IfG3A2n}r{5uFePd{zts+)2=$
zcOvcJHrw>Zk21v{$cI_8Ub6ww;;z9&fZbosqb2-{=)otMT~8DL98{acWE-8*j-$Sl
zr=t2G5m3GQ&06t3dAfyH`8AH)%1&7eEi9dtu^jKiNiNB$@<)#$J?TbI>4f^G&vBCR
zoofo$lln<-2PN6<@h3Erp`e25R1$2*d;Rc!C1O-=m0Dwxsb$wj#|GVb=B49VwAM8=
z{5z8XB)kpMOkL11{ga86gz0#SKWN
zm8BiT(#{wCx$(RUm@$S5t2h}sIifmO0BSlu_t4sa2*xey(z)`FQ)rF$xlqAppyUQe5ja!G=tWqs5^-(
zJxnVMS!S?pq)kwpUcDzc2Y^?1i~e*u7m=C=gK8ExD^@J{#ybyrH)paa=4oXg~Fe%B4{{}pJ?FX6$mNpQdIYX{OZ
z(0e>c#O}22N9-XET$%S7V-b2MUhT2NJ2ELtgK}+Z0pGm$D^7UJrrHZvj8^oPH0@>^
zKbNKJk1GLK^}59^f+Tc9#qOz`tw
zR!MT%#>DC}YF9fsU7bZ1z1Y5-0$k91?nMZiI1D@Sl_OBNO
zR?Qn66v)IVX)zZ}T4OcrCLy*Bvkh~w*}>jj_;u7}>S~j)EWx-)p_9f$CrWNQa5)4%
z@Z31O25m<7ADjs`A_j-0X8S%P|DZc72Cz*Uk?+j!HaMThepq*{=5Q@7wMVH(q9mjU
z*5uVcoIT1{Zl2pe9mBw^^(k{p?@L6sU~X}Ou|C#=ntkv*Xho1t06J(t0b$Iu^5MU~
zYdC(;$(-)YLo9!fL-PeI^qh@epz=onaI0FnID>#4sOkDAWBuD3XvEKl8f+qVBO-Xj
zcGjghLK*(fLm-XVE0C4ud5b>3GDzoink%VeN+SFM(a1Nc|H+%C
zS?K)pT)o<(-$p&Hf>mtu7E=TOC4U2-JPz?Pmny`7Vp*dJc%Ig&yE&4<(EVBSWzCJO
z{*49XARAUi>8y_cCK-DW1^7Fl>pj&x@fRARIJ#1w_;cZ;6->WXZJLIf`n*^IiZ11f
zwJ*{4&3c}$-hDrNKcI4I(kPzqeWy>AV!-sNGUDksA;9>EXGZ2k#!@aLnN=hEV!#m=
zoq7!GU6H3{lwwfXbCMW(1Q%mhjC0!}HjV3Sif+?mJTW$rb&_#2fp0bc`ta^nps6{J
z!TjM;Fu>9=uLV6$u=(SE@7!Wo^d;Y@vW2c
z3ZqjK3Vw4Byb*+&dY`UN^
z6_*d&A`c=v7^3%z>_khHIB%yeKExfipj5Yl0`+)uOW{o-z7N!+BV+wMIiojv(17k?
zY&|}_!vIQsXT9N%R6QF)#o?>_E-5^5sMLZxBe6g3WtcbLg4=yb!)O-l47ic#L0TgtXg4Ki-0svfDA`LVJw$NR&)$Y>Sm
zo5_z65ew;(uxQU6LXn#iduNE2C-kA!>P_$)qH8C4%S5KaCVNPt67t
zYH7z~2O7Kvt7gF}T(GqFem4g=c=@`VBz8tA&D*ST(f1?CEs$ie?~(}&1nBsljsSVg8dkcDe=+HKS}LqOa+hpPkL^XacStq2rTOqk
z(4eHz&b1k=7D5+aKBy;2{x&)oWi*BgAN35PgW$-+3FvCoh?HEv>zQ+53a%+>V@WmD4iP`>e83)d6P_~
z%r#Fbhug2`w-Dm-SLSP;hjC2VkGE@&Dw68lIu$%yTI0IOHS{P$NvG4pE_>>C-ld5(
z978tW(mYq)oxiAm*;exjMnlXUP6<{|FdAduU#xY6^GEYU-XlGCzIPB)ml)rv;UN!}
zhGKs;!k4-vnBB=W4FEPFg4w)^9~~^i-zn$n=ZhV`$3I$85zu*gWVbgvH)ijUv7#ef
z+gwxQ=La#DnLS)&EZW;hJsW|HV7xh_Hg3NNjS;=|_r3f9`$vSjN{UkQRo{GGonqS7
zm9;>Zw)CpEwMjGOBQekZiOr`-z4R~9Al#P^ECBKqt+pve%oT@dupQg(Yi550*Ghl1
zd#c(=#K1OBXSZdmJ@(^`RYGr7cBxS%VWSfmCiC<;no!^;t_1C2rCESON5b^J`kxgJ
z=}k&}@$ZKLw8Av1q$&86Dfe;X}KRy05TF3$Gf
z5FTs2o8M9qJ>RZX5rGfW$N23HoQgagyR1F=x5J&j?}aU~h$nExkIAHnlN%=b*(?wk
zvj&TcB;f_mJ37`ysEcjh2ZR_L%k9A(Ee)^^@hqeUe&`s~S9O;LTmOBjZ@i!ozavmKY
z4ldNY>}iil>}gR8HQtXe%y3rx7OiT7$Ij8*<;!I~<}(@Hk)jx?GeBlSqe-E-U~*KfCDMRm|r9LOg(*NfW1-=+wl#PE0rWJQ;i!eU*h}n-j~Hk8e>bT
zfvKw)-N$Yzy-dHXMC6@5ensghy5KXMr2S>MmQ(C`dn!icK6ULRHL5s9?56vTirDqB
z3uo)u<}LN}O+Lm&f=DLD*+HFc8{TA2*pRx>@FqI*pI2fs5qag+E7S@A+h=*Hj5*ObkkP--8x>erf97vv}90RnFC(>zLRbl@CE8x)DR*Zi`S*
zQ=wicYHmVsTV`Mz!~j#R`Im{i8^lGoc)Nl{sMh&8H|c}*sQ-Dci?PQU+f{SusJ|EF
z+C?b;rn>m~Dvs&-E`81GU%LO*6^-9fS}2V#GNIV>w7>U#^UHIT{{s!KmR^IzOoN|P
z{+enWTIpiE@IHF53-O3oBG<+Bu*Lxu9~ERqxLh^`ms{XOtFo(8m9Lkh01Xs&k-}QU
zg$k@i7zZ))_8N+@&&r)FRwY!-<)s~UR5k}=1Gj@>19M%H*s`)C(Bnc)q7akGgFi-$
zATOOfz#E}9Jl9v@aS}_!E6KVM2e?N@Ul}_G^VVPA@oCy_`YhR6{F@oMzNFY2b1ctT
z^Rm&XeeR4{^Zy4wMFyv?na7C7A>8C;A135z{O{BDa{e>1@LqdK7_Ev4Q3;k`
zZ83k13f+z1LP;EKgp~-qmHDFx#Z|fEZyVPoqYjE4(g2(V6x~=&on`{HI}IyDXRP%s
zH|hGryRvbqJ#9i!kAKUkd(>#2_!;mvPEl#s=jGE#neC~f&Z-ki`K((Q?f+!H!e;4~R4@?=5qJVb12*DYB`iUxB+um>NEcfIw27pf^c
zkB!K?puckc343GZ_99I+D57OC@H1!$#hh-Y_C|fHXURox
zhW-7v)5M?h`;3}yX8g^#grD~}tf~Dk9>&d8p3gPLp60BLA8E#XU;Gd4@vcT$Md@xr
z=#r=lJy(lNQVB1|SLd5DiOnbqipx`f8rHE54q^Jn(-
zW@Y=NRiwvSPl4b8bhzlBgfXp;5>8e4O&z!+9K>WRqZyQM{w
zwy|DJsCkcnr0E7g>j&4?&S;@W0a%^Q=cSpm5p*4U9_$_4pSaEZ^+#S22t+b4L%bVq
z=zvvEdJ?w04edArY(m~S8hr)#0Ep0N^cDna8!*`E@5UE6#hiArjeX8;+waz`+g*1x
ztVdT7dB5Xwf9eH3Vf}n1E_%Pr|9tK5akr%MG|`yld;H^+0IlP)FGl>DX{_~ZE&FNp
z1qZO%pjICVa;6pJ+ijI=j$T)n;rhaY9i*oyt&fYR9!5KO8c>ci(%ZFa!}T-rm3pfV
zr}evF8!bh`$sLD$Ub1=Ltlg%y%+=XaN7a8Hb|O>XsQvRb&Fh{IFeT*{2!U}Gs${^BO{MT=@HIs
z^d&a%BsSMU8io%0cgzeAbo25#vur%VpWj(ZlPohm6#SG;N1l-weB0MTzvJG`EH(mm
z`L6=9o$B4pHB&s*aklLu-a@vmm6#q(FZ0Kk(V_Z&wCYWzs;7H
z-Iqs|uJesX0yG-$^B<>=?}0v>2jaf>@RytA+vh!}Qyc6bn)t_j1Ya$%_$O%Nw(8>X
zulk)3ad0WAs7t#Ett0w8zhAHpC2kD7Xs(Dv)uQ>>BPA)2rT_z&AE5nms-GL?{iM#4
z&1~_|GBvv0aDz=}nKv6K?kZApSM3@}0!Pp{vCA6jusfbL#1P=(K6AMqGNh
zp=c=0*lKKNj3nJ&v_)0b4H8b@wqVv-o>&|upgTmY!*3cpaM7}*Mg4G+?$QuuQq%yk
z%T4#}m(|n8e=beh%)FjM)VEF6M@9g8IWm-qZ*p-T2l7x+
z_BI~t#@@x8@EF>)a^C4tg`_Foq^XlnY6#?pakG*0d4{^GA;*A*Yu?s_{kvCgLuTkr0T3Jjgb
zdwYV3+Ve_SMdbQwYOE7I+yA-8+Q@@|L#KQ;7TE!YuEGxN61x?bx29hs2*B=5Ah=|3WxOD@EvVrpV`t`8y>3gW#z&kfr
z)SojIypy&AG(pVjZVv-=EvRF093Gd$_xEX0*O+R-J8sg%%p$kz@K9=jhn|PARsWa3
z?3c;Fj@$LLH5ukd|Mu%lCZk6hCzzw?`HJ}Ctj5cu@$=Hl)mcJ}$W3P>jV}Sm-S&qU
zGOyj1m&@Cig_mlGYCgTuub%Y56pE^>y56Y`(3$Qu@rR<=QHKOe8K5RGafu*w=A-~M
zGSKo)nul_0BJAvkyZ{G7&4F22R++X4WxAuLxA4@iQ%1$g>U+z>U<2MzNZUMf-anm;
zWcAvh$zwb(x&gp+rYo2!o(}Gse!L|^SH}VDcB}vXorg~00fmS*$FYA+GCsYhK1r#L
z-g*=w5+>a*11ITFz&cM*5xvHIxxzo(5z_1@^m^KGR}Do3^wY(MF~3{*>C49ky-9uC
zC86sEVije{4TB3YCz+uQM_P5y-E5m|KOv+ED`9g^%@0&?oP3x(lAp0dBJf!?Y$94h
zJ_s?PXY2{L!4k{PEV^DOj~xS4quCWqFX@*Z*;&_zK;8*f{iY@yTuY=~6Op*YXVb`>n&q#Lm{Osf8XEp0==>2=(tG^(9ozH1aBaoC^g%=65SD0AA2+Hp7
z2A%?qL>2~N^a;F5`z+CpuXvYZVz+c&(bieM|0epf?`FGVMBv@-Sw5Skh+lYK1Ux-W
zuc+a-FX!T`e6}+fXm%o(lwix^VQy$d%tvDNxUmu=YH(R!FH^r@F6+o^@;F+-LP8Qi
zf{T=^+;;hCIMrrU=$noI_$~#1O~xxG$|pEnbe;(`BJuBiIRZaMEf(v5z)l>AR(144
z&1Y9zP4&1J@0ag0_gR{AClDVMD`V#
z#KacK)@GH{a)8|-c%6S~`lXnI4$Nqa!b0jD*jZ)1zG<@PSJSBGsHA6(05z>6(YZC%
z8SAn9#0sYPRq>5TYh-Y6_waBQo>WmwU5ROQd-Y)~pIH2STO(#bxR3}fDf(_JIyi5!C%?-5BCE?886VkIWGgmMlBV#A62)%Q`bw@%8lMo5z(i{
zeC%{`4`X*iByX;y&BJTgT++*61IBbWDPQW-iGvz+DI>)wtCa>Xb91}Tc)?sg_K-5{
zyZ&OxTyUB6-mKORzNTuCHjGBvjjY`7U>MGsC5Xs1*5dBF%X_1htBza{vFEF7vBx|2
zm$T}$CFX(>o%=GUj%`j(E{VV8cWiuiM8F^wk*WWc3A7?Es_
zHO5RzXxzD#>p!+Z7PS&$a(GxpQ5uaZ=4^2oR)J_LFZY`*g8ZPSI~%-cW`Ci=MlxKy
zh#t$0Af#dZzsS;eYaWh4MhNc8W@ZthU&q4pC(8aUiQaSM{K0gYrZw}Ygs^IsA2An3
zZQ$VP2tR)pJEF(Z`fWLoN2r2PQ?8A<9o3&#;NVeD9qF)TkpAA_JsCsqOjPZ=Bm7Kb
zUlYp{SbbC|bIg&r??W}>w)(swXXJCYG$wvAf4dG<5qV;IIb3@TRjSZ4@5T62kxIj-
zTX+|*595Jy70b*4)|2+I`bp&;Ea7aIfFsD
z4+E|h((p917NbKxZ|_>oLXr7}W)Jvl4PmcfOdqL78H#o`a1x*+g?xu
z68FJV@sLWAxEUsG0qJX)WUm9qLW$~ol3C`Kt=7Wv{b`{<#CYY4BSI-o
z1ddpI@5hf#>-jNac*5n=6s&D{N?E;;1dMUJjHVtbFMn!~*Wa={h0OK
zL_?a*R-d46-pqk&we8J$Hvjxxa(OC$mnC+#jEB&nw>N8KiCGM=X>0M1No|ugX!Cuh
z@P0rXJlVcmYtL)`cmLf=IgH?cM*el59Ym35s&zanr8W0E=&Kjk?ZPo>$tlS2CSTOG
z6xD*0B<-D4CC2xQzTr^->$s_FhYl=!6$OApZxPp`*tm870rk;;-||UHZx(kPKE%iC
z1;SQ0ChTt;460_on2ZM)vLzw;4;Ty{)^(9@K*It{hU9kuvIFI$1i>j_)m6D#$OMGb
z*Qiy=?1zyhoqF9{w5t3#;LP)OgPT%d^Z6=b
z;H(pg4ku@Vo{Vw>pD<5J)>BeMj!(|pA&+fPzoorB36+Tx4lFnh*YHBIeD#lID=(o?
zP9Wq;zH9qUM6)2vWW3Z#taEAoz{Aqya)xf{~tcJhsnOrLRmFT9v(5*S(ZrqucWfbQ1&w2^e4ifedzJmDt>
z6iK#%4AQUIvTyyX!%1mHRM4Np;1#8OS_HU_ABl`?)QSkm<~}n|U3|V?{9{G6sQLzC
z%h!Ok7S%zem4M;&JfoSH64@^q)>iyTz)lNz(QxaYC&Xspkk^pKgnVs5%3hGs7ghET
zx(q_$*|MTHWy!{6+TxOAq#T|J57sLcl|CrfVvX90NLk8PEA-XJyb3G+(T2>a8aA0A
z(adSJg3LJ^G_}{8t#NNAK=#6XwyXe
z31I_y)9CLlR}2v;1;fh>I{{8#Bf2oKhx?hnubY|LI|FDv=28ceFH>PN2e9ETukOY0R0jvhGe>m*N>%(gm&UpGG*6?a+6HMV~oRta&W@E!QoNyG3`
z;{x&fhTYi7!cQ3ITE41z7l^>*EmElOre32p?%bHsz6M8b%dy5@{7&S~9hTzu3I9!B
z;=>{v{ax$r3(KUMn?VmDTty`TWaG3*1Zg3B-X)zmz!|yN%?%F*h9FuR5>Pg75t=4*-7tcP
z7z16;`^&CS-DbHLNQ_PL2p-yJt0Vnw$-ZJL)_Gx^ZHG`A;?+)T{y2zwzFBSfEd)Yn
zoSL1eqOHg4pDM$m+8_ZyMFA#R7?dQ1)*jKo){uwZ71E#BV(kc!TN-c#4wb#fK0Yw7g_#9!f^Sw
z2YQL_VH0b#%PvXa4}!nRY3wPekCT4j#<}vzEZ(Jtj6}Z9W~?-M+07uXHy45@#7;Se
zbM~M|mgnMqMqz0~quEY4A;gA1M~MnP5LTWdr+Uys98bWIerLu8s(}w~56qi-wcXj4
zU&=~LE%4~<=eY6|PMcADk+$KXE9o(yV`NB(a~-5VL*{^1$9~ei>O62RTsWmRT0V_*
z$NTNWyGDJ3=TJr;@?tt}=!egSOlb8M1K@M7lt4UYEXk5OiS}gn%s3P@bV`uU&fVvE0I(BRyNs^@<0W&_a5Wn_YQ={ffsO
zEMC9wfYq2bK$a+V()F1w!Lvjgy3v<+Pjx-NWN|-l=Hzuqqb1!(u;v{5t9`0kv{n06
zmE0gDp?X??i$~634EH;?&yHB*)t)H72IjPGRSq&Xq!v7w03yL|p_%zO!;@(=04V-u!q
zo9_tZgn%j}5>ZRP`3WbkM*
z2NR5gdKhw-%h#Xi{MHdP8cT~T$%=S(lKcT_uEB?{T<2Or-Fw9J5mN>GZm`=s?caX|N^0!e!713r)458VE
zh9_>QYNeY60M`Qv%&>r_0VSQza+0}Np@mKSXJ)lR@KOyoSF;$kV#esB2K6hlTzyQ@}e8dW6)0u)PAc2lU~IChn+@lfz9Vw5{t4m2ECV!fx_XB_h`
zCHC_?w6)kUGfLAn2zIg_PGI+Wo`+-W@RQ9ByKK~tfa}usk=}fiCSM`Ps&;n9Y^CaX
zIKK%1y~ewfa(rhsRj*veyC2ZeJ$Xv^kMu^N!t0lw@>%Pgy%xkF^L=`wJ>R!5mvaKf
z;Rh6ilzRht#UJ()maxP6&+wc*ew%>xcs?He!GXUB-pg2(>zu&QS67CUCxNIl8)W;NfxnUsCbf;T?nYQkUN^2`vmSJXOH%ViyMvemej=
zh_@3@Eo>tHFKB4wS28yw?fQtAo((w69wCq?l8=--Y<{UP@rvC>acBgZN
zYl>6Bj$e(7u3Ff`_!%2L5)@ifQ1P%-S4@x9
z>L}u~KNu#LH`jzvG$bwlnqKgPy)ABOM;4PA0>safdZkG|asystRUeq^8wlB_5$mrW
zq?jeLyn;GE@itK+eN7YZ-*@w(GaWpYda8eDEjT8wAe>eRrbKq)y
za^}Wquk7WK0zT_n=PqdY=UM+qzX^nj?!iIVtL8gSnkS55Z9`GrshVr@TE|q!r74^Y
zFoI<;b(pL6%%^tzcR6a2hn)CBgr^ORrjB`JQ0WtHn^ENsSLj=;ZkJ3B&Ey0YW;7qh
zP1q4PWSrX{8x7fx?QQ320M)&(j&K79I9x7Xq?Ai!@1i;tD_&r61q_KQRPXVkdM0@t
zWKhVB;3)1p+cf8_obt{fu3Dmo12UJ}(v`U;fB%^eQ}-%QFy?=(FEv`4g*g0uu^?fX
zEU(NEqI=&%VR*)g1y;vPCP?JhHS_a(N(e_0Csoe)KRZp7hl7d_l`OaT+{&BrdSj@pZ^vILYF-~
z@W&zh^6j=q`S!01ryN;Qbbl<*3ni@ROZ}1U%F5L{l;q$(ArwEx{ZQDuho$rT3C9hk
zw=Q4sv5Qrl-#3|4fXAuMlE`s?n*Pn6IfyKtO470uQ?J3+!faD#B~$G7;Rxj*wyY_2
z;vm8Z8)yEfhA#)C
z3;h(w&pRG6U(FUDJ03lN;$tgKr>o}`4bll>Q7>ORG+#%6B`0Xer{Y-y-4}u#AO?lP
z(Gu+=_o*2@|CfFydE=)*e_g6$S1W`~9?6y0)8OFYf0Z5dbtH!Bpmkik6iSRxaD7r`
z^7kBrU+P>q_(#D6H^ov&zv|e0=r&E3^*}b0Z{E;}xvm5Nfv_l)Y`RT19gkn=P_#;o
zbTl9R{zUGSzY3;!s9_>j^7E3#zb@oPl`4VDd#-ac-NU!1)mVjV*#xe~ci+_}86!iqO)oD&V-
z9X&T7bYUZEaok4YK(Mqn1@0G?Vkqbn7hTTCDSEI~?@5dd{Q==GCy|t>y~zQy_V>q)
zp@H`%suYp0dj@CxuT)xEo4lovbb{-goZ#JN~~coXut-itUc;Q;RSS50gHx
z3*rr8iA0VLbH>32lRyE5$0-59RdGPXbo$?LzbODPsw@Xg9L8WkevQ52`uVGX&DR8O
z2L$OA1BI@D4d$C1toGSzc38+}rXcCt{oIatwbeM}Ck{qBx+4Q6;-d)zNasDq@4V-8
z#3P*z0=s0S31)~Jn5=5;8K7li(NaXe8Bt0Qy0nYSOC|;Yj;cwh_^JsTJ3%#S6Kv15ar9EE3PSBwWCjg!ol*tTn
zZgCY6i)rP7Kw=Pzm?Ahgq^1m#*c%O!DVrc4A{eJWLk6Gi5zztYS`)W5;-kLq4Z>v`
zXUN=+GX3g>ZIs+@fBQgA2elD~t5zxPofv^fM@M#cc8)$>6#wUGXqs|i0=*LmB-m!l
z`h%m4iYIMB>4-vSHYXoVS`krYxdDuE`smkRTP_~B+sYT9%DSLwM+%icrx%!1$C^b^
zV05lY>O_O3lq3w){vokb=PhG)HTk?GHM>e<?MMeo12e2)5Yd_(
zwoJXkx&Fyt${poplGgk$X0KnpCFSH!st+!J9@~QrwWJ?a(6JeGfgrv5I;B0(Bkb`?
z852R2jY1M@J+WbZYoTsN`x&CWh-x2sR_x`=MRsf~(sYBbH-(5!Vx=8z?Xe@*MFfd}
z{kHwU`u_{cRctbs9c>y^G89fP)Jn~U_OnU|DO4HV6J#hInkbnk*OAvqKJoLaNL17k
z9tS`PvxMw_8!rNPw7X`b+n#CK4-fh#29IB?B$A1Yg~O^CYU$9y%eeWhANF|E_#&o0
zDslu6&LeqFSWHr2eT0jk&{)McQwkY_0Cx5_4~cz&(qW#O8?)>8UlTtPOB02>@TM=g
z39q3<95^v-p2K4ww4!>yg->!treS+OmIvZClX32x3mV{9<`0k&Z#z;C-)cJA^5vuh
zGmb2m;(AUkU4>9G%6oPJrkA1>^j0=QX0+V;jqH5#mi6z{myVItq}24t+p4+DxEM7CB1h&Sw%VOgqN7OPbW{Pp|gUawRtC33lFp%6=@
zxlAF7M94+mCbJeY7}aXc#1=`|Zf
zWa}h4EeGqs(P&nrASjCmUHIznm-^FEZ<4JwH@4IUo#B^$>6hO0rnlVlrk}azjko23@ZG`A
z4stgai=qCaT49}u*|g%0D93_Cex#GD6cGW@NMarxNwe3;6jQB!BP>QEsRZJn#!6ZQ
zg+emD4j=4FmW<#ESb=mpMXOpJh(UOQ7J#n8QC_O$hs(lM@>s1-dH4crn5f!fB;UD=
zgb^gLMU|U%kfbr0Ko}52#>IP-cS5ybgn$puhuG)x`*AnaBC(Jk?C-^LSs;st%twk8
z;!(BP&LQ>*f;XQRIL?U*ju}u0G_&b2`eGsCi3+|@*zNV(eF2*BJ88Gg;kMZv7QID>
z?nFM$hDz~5#R6|aP&qfOeCiRvM{*^!rdLDj1`VWCfrVrQjT=U*qL)Q*As`4B)H|Kv
zPeaob%Ld|cHWtIUID@P&5%Wf3g=VSJEN6UI=$X%3WV8IK9eow(X_h!UN8r%Ly>_{d1=Ot<#=~Mus@x`
z3y}!NdwZw@`D(Q_8Ua2J7YfB=ib2jt3JCTGjlrXZOtr&lah#AGsPGHqZCyQsX5-oM?De28xDH|EIDB@$}#1%SSh2%u)S>{ZLgdNx7Jh}z-~>mwW8f#
z2YG7M;_OT7FYTH6%isgudT8G2raU=hs
z3qgZ|HyIG3UY_Hmls&+*QG~!`z1^rZ8~J)8-)QG+z0v-qi(mOiz1eZ0-mNsdE9;wD
zo$fvFd+!_G^u{;5@n@iW?tSw;Z+P>3gl_4AR8;G9&<0_PN8PWs$p=%Yyp>iH>j^Fb
z{$lA^Z;E1FDb>sVaKOVd(FE$WRI1h7ez(i-Or+!aYCf72gRv-yaiom^N!k@HWQ10A
zrt?@sr&`g45OANpU60La7J0glCH%i?jzvYBvF
zOqGc{VsPdo1q4&+NWGc&vvhAzuGUkSq88U`DMUlKV4)OGrb3~xlMT_dQ>WIRQ|rzf
zDUHs$y=7Qa>oy_OR(cq6nx@a}uxG#{Z`x}03SI-JeGA65g34vG;n
z6OuR#009y12oOkQlVP7NwnE50BbiN{=i4;o~5z#EKm?tl*^4+Nn1+At!w
z!KhGw!5=6z+{n;e=g4{jN%B>#TG8@CW&UPqG>Xn>Rp)h@b-m6&Q`>s2!DdkzbjmJe
zGfm^|C|NL;O2WJmWR-7V;N9UqXhC3#D8wkf04QHB!UfPn_#zRkluEZ#?sht(5rXo3
zq<~;B*Bf$qO1UKXL#vd`N||CdC4a>b84-#mW3Wuvr-$`Z
zJ}((M#AU<0k`gC7#qOnGVaZvQMp=#-Wg%v6nqNra56^i{qh8U#JG45p8Dj|Auo+;A
zcHZe@umteI1u-o(YUu8R(TL7shV4OoB7v5)NQY;H`XAPT#nV7D8y?d0;<-uYG_qMW>#ejT)5zhPJ>Xg
zrpNXz>l8skp#d!$5L9l$JaNG-3tA9#!EioAK=5aw*?^M`I6^F&OjtY&Hn>0p9a$FT
zFCwM6M5@y5xk8cVR
z@g31n%%$?R65zx7MqBOWShK^9B51H%4Q?k&2Zj#Af-v_(5In2Gl<3U18k*Dg0}wnb
zBM8Jd^*X)9>TokKJT}6EKV()xidEaSbTOML6{_tf5H#8;E*AG9;H5Ll4nNp@GMhyc
zW^=jREXyTRnR2DptaXRO-e??4N}a(-NapzX@(I8?)qE+PE2g4x4)d*Ut<^5a;vs*)
z3Dm?SUo55a1*uR@B_uw?dxb>EA9O)3#%6O`D7VdE)tM=BNE@rms<-J)v{7#*$Dly-
zv7+8mw5kDrbIHtI*TM*wHK$PCryytKIe)|p&1RS%ED#AD5fJ2|@;ZFviwLO2@O&YI
z$XqBlYKVcb@u-yNlj+@)tEpmZa(u1W9)x4bvuD>-D%CsR`OZ55;63-;eeXSY-}8pM
z?*V_9&NUyQTe{TR!~SHC^tz31x|r)tMmvZ5rFtuo&O_n2=n4h-l++jvbLD(*-0M&J
z`AQzB!Snol2spL}&3q+W?^GdQi1BmYWF{R;CTX{acDvCjtIUQ?gLcEHRrB3w2TmC})10VOzAYh+#tbzuiXbEOw2R(rOWTjK~(%ove>Bh#`XTh!30(|wp41(+uruJdjKCUnB05M
zUHFFx_!op=wbiS&`>psQ;Ie5E?v*@OQj
zvxQu>EPrG-o*wKsyFGB0DHPGdGhxo+aV7FOC0Zf*A;m|y^7Z|Q80Vv5kJmjPDIi#?
z6_G{wSU3_56-wE5x6y3ZQrPA)qSx<^i6~+*U!Uh830iynMD;utKA&rLkHz<&W6SE+<+IxSiSMU?PIa!{}%S?GHo~@pK`VD-~mz9GVX?
zUkoLrN`KlI?@5(b8tbh)Slv|J|GEe-}nV(
z=B~Q|BJA+CcFJ%kA~A(9?q9cSluom
zEzv%Y-Rts(gXvbD#g+_q^}j^N|9AQ8A*V;8v#&
z1QSUC@Fi1m%;bvcOg>p_ma2^+_{$cgcrwCrUbmM<7i_d>O?CrPAQGX4CZ_
z3#lwRt=a9e`@EQv<8lO9lwCFK(CbA6jHIMOtr|;7=|X{*GLcj!kuMGQjtb3QeK5r|
zRjzHQb>~*se(&?21AKSheHXMq@Xoskd9T0oUVygDW-G45rQ|w@H!I`tP%BhI2#XkMxhwmc{Z9(1_T~4v*f)6}+<~Kh6o9}zy`|i8%zWGQ2!D6kT?3c>rQ}A{vov1g-C#bOcVmVi-7vz8_
z06ve;5#s$oP?^^nwqb!l(B*TO>_)9gqcdwaH5)o~C-NyU<F@_A{$4;HAi
z+YB`24h15T7|*7Y#eyFtBuSbNAziGrN29$9*sw}1^!6Q!@qO+~51u){^0AM7JM=iiuU*eR@y-h7fuv1Q)a;D^10o958M$>>113got_Qzl*{e*dHh@e
zW{D?3x%UNGU_=fFUBVW^qx5SGdJEE)m!VuPtHaS53~@L7U35{^7BS#bt(-4c(Job+
zExgCD5F`6y5~N2#;pXB(fC~lKz`1khKJbALy#M|0|JcVq`q%&ZUq=@>A1NRx<&siP
zGTBW=i#}J(v`~mU^>V$K$)~&lHxqCrGx0nsLN!+?qZVf{pUx*yPoQutq@35(&-uI|
zCcyhKWkO!7(`Iwq)h5k`eoKRm(rz|;>{f=-*!8H(XExT(Zmw_WG#b0rUHvWikx}}y+Zb*ZmVq;it$*Sw8iPLxji-y;|vB>R*Oky5$}yp2$@oWiwUuGCXBd{
zEwC}M)}O^Pl~l1=Y4!@W#=1)L`3KH`zrXXgx7`Ko?t;DD3(g=!K^Z|5Vx<<7Acz^I
z3g2cSe)oHR_58}&k9_35`@i^ktI8L&yS3i
z$>%@-@?WKemb!~p6b*;n%{aZjNJ2y(sxlbVMw7v6g?qvLz?PItWlN}ZnNpn`!WwIn
zUiY7oGM5hCgZ!hU4FsEFnUjZPZRAh+8ta!4A35rx?1aG@5P
z?KBsSvEc|G4Q30;YCT`BK5_Qk
zLv|O%MuGu82n!)UFe_xTyvt&9sZPS&rpTh$g5`Dj3=GSgOgq}^fnvR+J$v^5apv^FDL
zKxZ}?ZB}x|2f10)QC6+hYCdjBM~VTkq{IzVj3}5^7?$CP{`?Y-hco7?|%2MLLdF;hu`|vw*tF6@4EBe
zd+&u2y!zFzo{tm|Z1vmNfbx|>p$coQRGMY-jixr>hGGG9A#!hL%te~Py*Vp9n*}H_M%NeKy+dWx@L?K5TpW(
z$xW~6)#ue)>w5K;NoQkRRu`?enrX&uhkRa$e9Ka=adhfJ!_@=)=1YiB?
zSG?vmuX@$1Uh(Qzz2cXD`E8&5?C;)p-v>YZ(GPv*v!Aip&Ah;Kd`QYjrAjfGNvHF9
zF`Y(sjHT03E-&Rt2}3LDVcBpjCW!G&A=m14Qu!1-0xJboE0#)l(Q4Q&Cdx`PE~L6d
zMuLwT?RHEJ>t6S|*S_|(a?H8+ugRDBNC83oZMZS~
zyxD7%8>LJ!4cZj{1ApKW?-^WT21}G_wuF&NiWwCASWFTi+@DL3lWB2r4jsNCc%g?y
zQMQxg1Q@kCvmQ2pPy!+~Cf&J>6+}I3f>w{y$$A}Lr`~F?dl2zx8ql&{z>2O}Wi}xN
zdQdguk!XxBlrjO%=i|dXI`d2}6isAHi1Wwf#LHqTRjMLyf9^{Uec}EuJ@n8+f8%fb
zJQ5$IAgBQMQUpPs{Bg)%B!aK{=~plG+Sj}qEdK1z{>(={@*$L@4}S3dpZe7AY;A2=
zEGD1N8(AGe3YE{SBN3Dh4aM>
zo+mCwGdZbP%Jllp2G%v=Rx!;6{dS5n*liTU$h-7P;TXaIIwUS6L?U7w*omnmwk14m
zAn12G>6Ml9pZLUYyyG43K;{F2Z+zn$U-Oz*zwULffnb3^@TY(JrvV=}%^M1Fv)>l8
z68SY@Jc76iO5{%}VI|dir%|kx5H+v_w_=!(BoJMJEQBG$a3JJj30f_ngLHy!%S2h^
z1VaNsgb&;V>{M3$s%{H7B2pn2PQ=`7Ai(n>Aqpsy*(_3HfD7wPW~Ybt
zv5d#(;-YMjCuiPwcx;(`tXPq9iOTdhX3*moPoxnad9%Z*x7nONzl-%_U2utLM2ZKoQo=!Z
zzzg_jhi!9f?ekyw-4A}?Jsri=r>Zg9{
zum07)3JSsB4G5y=MVWu6*$xhCk
zJNxs0>#YiWFN@%U!UcSa7W^%4nvc*eU6x&NA&kCq!TLZ~h&pxOefPchJ@0~k>o-6C
z+28vN!kE+T0FmUIGGR6l39(Uh5FtO$28D2d=PVBN#UURTbo;!5nBbxje+V6h5RReU
zVQrMnPTMF41(~fTr<*(*MOh67t;wV_TTCW2d`NyqorSh($vLx)X1k3Ihq-8!4U@uZ
zq9~i&9tK_(MTkLLO?f;_Fo=9LjC7z%coggm?!6*ll)0p%sgLYNBwPnz_e8{=}
za3m-QAxRA5&!(if%S$k2Laft|6euR7RJK&D_oim2Uu$s)Qohz527~!KKzTzhSAmyU)
zhl?`*nxDokuYCRMUh~$U{~I6t;QNr@-~RSre&;X$-FLm??VtYb-+JgvU)a%O==@$G*c$GpX`*S;713P
zU|m>(n{a=-+lJ=S<)b~U(;aYlSeKh+oPOjdhn0N$#Ey0oy{6M;*J!s;V31$Y*uLjI
z?|R?+-t#-3{_T%_?8ATitv`RyU8u3I0e__4zW#3Lbr{||U;7#q-q*bHr(W@s%kTkC
zWk$KoM+yj*n{dG@I#AdZHaOs7b2pTT(fj1Y9Cd68+oi5fi7VgpH1@P)U$1Z
zxZRTBosx8&vmc_xJ(m!?twQ`0KXJ!T{^U=*@|Az>)o{ZbFLVB0GuQG3H4E$J&2N4)
znrN)-cfb2rf9Y+%_=|t%=il+pzx$Do{@U+;=C?op*-vk7oY$x~)S6A&Vck}(8%;=t
zI=w+n(H4i(>T*+z*FkDhG`w7fDh6S|_ezhIRl)+G4Yt+#cFuHyN#ZOifmU
z)n?Se8H^gOYHjuG{r7)XCha31eCONW_ABpr+lPPc1Hbk0Uw_ZL-uad{zX30jxZUYx
zURh-ay!YOFUiHdXqUI{_{WR(@YV+&n_m|n5U*;nvwaDD17CXR!3Q7w*`NJcy!AWpx>K=z2>D|fsRd-qQe05cV&UQ;
zkOJa-gl_2q{y^bh`6~oORH8Y3@=(cIIhAVNU{G7FdZR&Y
zw~(`eTa8+$-E6k%Z7@sPY_jOh7Ckt#*o=sV2EAIR-QHebSv&XOmp=Eqzx&DG`kjw|
z?6-dXBlo@U-S>UqJ-_zB_k8MiKK?tuO%mQa-u}yPdegmkVt7$q<-N+vMWG588${yKr2{mWx2J*=ser&1#z*5U$j$mm782{|ewTmK2kjj4#NB
zV^Nf51O-%B7#`YK5Q(d3MBt;Cf=i_|!v(<{Y!Z%`&ZbfsDVY+}87Z9+(O|_AJhn!+
z%NYm->~3cyl@gMo!{f+h@~uukTWzW=)SA`=emOCd$VwKw{kMPfQ=k6iXC8Ry{x5#v
z{=fBee;cJ#dGom3grLIKUm}9=zn}W4p9F#c5isI{6@yfcbu%aN2e{zr<<$^Cgz)aL
z!m$4Ee&6z@H~-=<{Ox!D>aYIV``-NmE`#$pF58U@_?**^--S__Yz4uq%|Gsy<|J}dx
zo?m%89`fE_dHeg{_0Id=|DKP1=mVel^^bh?L&yT}dfVH6@y&03Bgrp!D#J-C%<`Zq
zJmEq{{&m;8-B-Ng6?hlQP0EE-Xj${C@t(;hYa}o8#|ZxT^8fpnA0znV%U|;4
z#|ZxT^5e^oFaK}9{MZM7eEIR^$Cv-NU+%~k#dw0N*7B2Sp9=@nn$28Z@-TF@R_OJc
zAw~!Jskd)^^67y`BES{IH@7L?~yxp#k$3xw2mFInG
z_3HZiLo{vd^(uowwOEW-tCG)WEtL|3L8Vre3c2W@SDK7!6wMuf>FXKu2-Qsvy+23tX$F*K3
z-|rSM->6BnUDa-8CZj5rA070yL|2F%9oEz)l9vWpYC>#FYaHwdhzJ;#eA)l
zt>R-+u1oe6bso(x3zomc(^}njR&KHy*WESzWn&|
z|1Xz2LSav{Rq79#VV;e}`CLBb_E4#Ge6~A^3ZaA;fh~?F-NB$f8Z~8K!?ZaZHn3!O
zr@KGv&n7T3c-&l*2@DHv)q-_GxbtM(#(j3=>3Gl>_G-O$xzj8*Yx!m^S1Bejk6UGR
zrqd3d0e?t-cter$gpl&rAnWHTTn|!a;ILef+TCg5>dDcdT244=&7fC=
zOX6y`o#Q#jXi$dWgTqmi=RL)eaD39gcyT(Lb-9ppZ&tr_VRYrvZnKt!FYoU*4iDN_
zukOK)qfrKLDxVi{XZYZ7+^p8q<7w@}<CIF~L+oDhsBBfJnixpWW{`9`}EiG_N@R&U&KdTHE2
z%89Lh1M~GxHI+}c2TeRlD9UC_X}jCT3G8sx!qr^0NclVl$}*k}qp@JKTbFXlV1(_B
zyUkw1<#P(jsE>6=<6OR!t~QFPY(mP!t&}k;^2J&{7zua+F8n!6!$Qd8bvayAr`O~K
zwp`2fhE*{Y-rb*ZJZG1G)*@!5U_7j+%xb++r88`4w6xpBhJ!|%(I4{e?F~;(_A1qU
zG|ubHdX-+grPFx1KqwJmIKPk@KC*$$50sLtTW#?l;p;}C&#iL8de);E3cxILl##0F~lf+wyih?iX
zPZzMptDF#uBzQdG&cQU1jt3*bbRm_<#0Jw|ARLS);@MI@5ca1E$!4!@p)J9PKb8tl
z_ecFn-{z!g#=*t7TB|agTtBMT^5u@+pxWtH+ns7An{2kK0hSSy(Y^giI+O7EUGPEV
z#Nmj9J2{RuWs@RK1P|KV>A}2~O%Q?^!Gj>#wpzGbzhA4C(v4~s>UXM0e=tNmc6Zu^
z;G{^DSO|Y?)Npj#$jsYUN;IusN7uuT#Lh5b+=w!W<=$#f;x;!A-a-CIZNk
zcwjmmMg$WCc&><$n9K0NfE`YnmO?N=q(Vf(Vm^x8*J`9|6>-=v!T!X!kFssot4TN=
zybn_crA{STgv7mB3ki|+TXUH(9P{{Scz85vw+q=EzcZ^N
zXn&Z`M&g2dchg2lc~CBoFSL9KZ+1d$YZh
zqv_%P_;9Z~o8%f*#CT-G=BPjXOZCB0y&z`d(9xv>*jc$zgaN^fghcrAwG$W<43Ucj
zD)qwN@r<}zIRj%VRCBOP+>`d$VTK*$Rh$Q0AbtXOSTI{gOYcZw;Y)-2I3YrR$W2R&xW2z!O?y8TW(xi7@vYN?v_
zvo3$ojeB|nP9eb^U6^(HwRA4Q1e`{@L2cAfUZ+&bd4sIcY7x^Z%H>q+byk}4b8M!V
z^!V-7M((SB|MF~q04H_(X-~kTHfp!!0~Z@?;2m0A(@2P^aiJhAV-l
zRMBK~y>*33rBpgCpiza>p>f`y4bb`4D%naYg)rEv=Zo1yyHS7x&c+CgogMj6*#7a5
zN+naPW#MI~@sK1?wAiOF12ggxk`3GKRwKs&txL~
zeg$bu6xnFhD@47pzf>{^J42u&$4|}+nG^?KD-~i`80FoV!rIt?T{#AFHj8H{BOAg-
zF@r}jZX@o4UKJ0452DE}jj=kkReyv}68d$`|0*NjLA6LhqrJm1?J_6R5yb~_bu#PrhPA_!-IFUP7p`6D
zP6x4kVs>Ho;L`r_)#HPUN4W|)ire0W;~661{%mxx8&1ZN2jPQo!~X8hoSnani=XpG
z5@CcpL_7q;d?kx42Jf@j4db0Y6ppf`Y7T-ABB?P*a3T-k{+Nf2x_k~qLKqfo3x;L1
z>C>55chn9F;gA?}`aLd&Znnz~59Rbauq9)AZVy@rN1lMYP|hUNF?cTikaEw>DiqcPgLWJJ?ZvN+-nmP&fdW
zsW&U$AcJv341{yx#n_xyEWr$F2_iOTV2h|RScoTtQ^OWvg1K@YFPnU4uT_Kn#iTg?
z1Z=U{Yr)E~3SfLFNU%bLbkrmiw(;%&h0sDYqMs16$YR}K!Y9_?K^
z>h25&d(+|m4915kTI24{7{ZLQCs;w}FXa-GqKJ4%bI5v)ZVg6;Da-qzK-h;aNojat
zm)Jru57WdQ?8t7ND!S=pHUZm;r-b27A7<)cC=w?fW?W6AV@8_+8z%xC{>o&3ggfiZ
z8ax{WkMjmSc-mA>#M9!b+WiLpD4q=uv^vm;v7_0bR4>AkU;)U3jdnR#Oc^cObWVgX
z!#87z@N9q78#a+xYprrBD>4BWqL2nXu7l=dF^$2fGg*8=P7p<3Fo=W*=kkYG$m3)3
zrD7<;n`~At!o$uWB%NR+oXTeeF>ZC(wI)67cIwSWwO&hpo91>IEM~Pq2fstiw0pb`
ze;}HaG)AM|Z1%GOw8O!$^YCOCPX>pRc5l>4q{OHgx6xLZTBB9X7c){i;quVrI6qC)
zgAS4!W-vw5`u}C`KfL6)4r^}|f8Kl7Stf}%v2)HjSBL6Qopa7{dh#HURIv4ISq`$U
zb+3IbTM`p8NRR*+6t1nePo17ZPh$wuk}Y_x@9VW!&8h0@n(nG|erNBBaBARMAnc=e
zy8x;xjS@mV4Yu&AfF@Y%NBfHe99}!tXLr=WoPafkHjgz~N@c1!twrk#`^xnq{uk^d
z-oiSB55+3oJ(`1_AYeQhh2Nac$Cw8Nd_6c&WMphF2pJh`elYEWk8p*lJYs+J@Wug*
zA^y9?VTosAkwg&x{m=gL+l!iX_I07&C~aI30J#V*=N|`@6py4v||Cgb`GmvsovbWebHk3iEllP>7Ywh`Omr
z#GT1RFzRyYJsy+6ATyg)2(aO>yIAC4>tOC0ja)t-rOu1ea5`=Fd!%sVBTi5c>?04ph2vPvn2ER3X#4+4w$
z?EY@|V7HGboy+)I&BWn;=lEban>5&n1OD;opnvPe6cEIs@Ewkir#ElTv3{yGuG7tS
zd)cGo(VK4_Rqz87{!%4za5T92=FZ8@ottkRIo!rr(tmPm1`Zxw->tPu&3DfCsW5O!J{s4vWI4~?2
zC3dxg2poriJiE(WsTW`&OVu2vASn;V9b{^c-vK)bziD&Z$Yn1IDQKnE>(lvy#bHNo
zk0V5IFJqnOa~uPz{i13m(RN`mB>^|Oyn|YdVwxHpf?nh
zs+C((vB_rE8MRE%dvv^8t|l|NNN+#_dn%VO+Kn#1Cs)jrEBXGg1EXiQ8ZxkHjhcFA?fk7~RNYEJK=bIfSlwsd6XR%hw6tnPjaCrct)}#U2z$rM*Lal(c
z(#>|QRLR>MW+d@2%M2&I
z&ajQuj>TfN!wUm**bs$kwgmfB$sXR=_XfR2o5^4`pw~|o;&A=grnDlhye+PHP%-uU5AT41O@BaPY|23w({q_kA
zAkD%^&2VAV2EutIlSq`&YBdXY311eEGf2wmG#d_kQ|TD~dpr@=80*K>reKe>5NgyEnAcmb5IUozHK=4`Z1|oL0T`$%vS({CVAdG*9f<&?w
zjrtLj5t(5FEf!5K7snL4UGH|AoDMC=`QQOz2@#eNNUatHydIDTGw5~eopv>_2o4(c
zV#aUwdkg`e36%7C3}9lp7!3!lYULV&EeZfxwG=NSK6CzBDGmaHiKT294l&7j?N$Y5
zfQ5wnLqV_If{O&ffkjM-M&La)_+5MR9)dFy&?n;dooVg*@p#xP!vkVAa>)321Y;Nt
z+mTkm!IP8e-d=Aws>I^Xb|-UkeF6@)J0)@h`)(0t5FEU5YxnxCgHFHd^yAy(5xX2@0=WBI6FSb)hqCW
zlfylX)(6j@>-xKY!SR7;z!P|cL<}~8U&y2&BWxY~+E3s431<73pZu84k5{u>2gvXi
zK8rZ~`RAX%^WHmH$nmX1@D7IY;5x#Tr8n+iIWU7*lu{=L%P@)=G)5JM2)y`rz#sk#
z{v#HM831KWL?A6UN@$I+JQ$)iBKpDoWyl@d$-QD>2CWVwfEZ6k5aE4{3zWoL;A6R#
z4<~~7GT;b(5RyO4(7Wq_W${!JECbqL?i?OB1tJj1M8e=2;-1?NkLp4P4)%p(QItVF
zOr)Q}D4-eT68IECu~;Dn$Js=v)+ihtPMXbpr&HeBAJ-ej1Q*sCl)j)F2D#KMjwbzF
zK5aDX6e?*l9mgo>WA``!L6;v?icR-sfd~W46{-ceHuzr%NJ{27_%bjZbB1DJBxu+%
z43TqzDx_>M4nr^tj;}RndLllZ!%%D#W9eA6S>8X`!N0>2ur{D(uK})shL}GZ4SL19_7PK_RAm
z@WFea9?CQhV>&(y7(w-V9$6R*G#HgWzr9k;(p&p?x>ev3v<0USVpH05uz#Ubon8=K9@gtDaAD!A=YK%L6D7$)WXBqn4^wQnhlbT1wTcxo9ll_E>WH
z1QT>=v{H}Pn#sn2c!N=GvFeklC_Jy-VY1rvCW|^25BLLix5pe{9BkAN{}^PfT-+OD
zU4E|-aTvVIW(VEv56=Qri@VTQ5kbkbN1A2g>@fqXuU%nPFBvmprl
z!f36MK)yEUM6iv>)F61J6gL?pco%O0g7_iugLDVtd{S@KlZ;RAb|`D*=*eMk*e@g#
z?(wj+zuP`J>Q6>xyH%FW1orm2w{GnXhjs8h9Cmg(`QwwxTi?9i>o>6BhGXR7$;plB
zjW_p?uI~qeE+1o`?e?y}dGPkPZVkrWQZ<9Te0Y8T=*^>}x2~7kwPYzX*`Ms+*x$c#
z(4P$=$w+J1+PiUxEIhw{RPD8+*%ZqC`LsP5(rWNZUI*8Ai?tlUWObQQr!iWp=fiOZ
zDB*9us{B7c{wK`#<~MJ_tbuy%LG$y^KYQ=}caeV)LL1%M_y6XvFhhUbg~hA3U{A=R
zU@Bn=;TJGJ7K_XyU%s-qB;BnxCkl@e`fkOBc
z@D7-3_v*Pq3QWuvxJ*8QiLGv}j(-X)^H>CZOmb3iQILBC$0}VZa03x>2>rtpxTN05NK2oDL
z+Yyje_yXAOVHSxpT&t5uU1ifD1VKOJPG=MCUadcFCG)XpI-)meVYtYhN2_@lF_de~
zio;6+Zz98`^BK?($v0idfJBXM9Sp)6KrBT}))>{@Q7@TGnH?6)4|>u)mC0PvXfyD;
z9h|&(>yo>JxXjT^%wRXL$;fy%U}K>e$BuS}Sd*oC5uOod5R5}%Fzx|`kysGH8KJn-
zYr4G-rB=?c0nE%q0(-~1m=h~MRY-8T*v)U=z;^=&VMwt`bLI5GjXjt|z?!c|tFH^_
zsn9hUEm{UPb=*m$*zu&zB|}Ai@7}-s_#ZLTcfNUJbb6%t=Rf~B&p}wl7CpxWGkoyD
zyC~2@!;MBB@8YdmEn6rg0KsZClg_ZEaw@`l9WFy}0Dqf`B?7^a(`wa3BA#+Ng@DYm
zUZ2mRQEh+};6*MIf;DS3GWBYzQO)%`m24_p%tz~04xzGIjzcIw#eA%kj~BA>QXv_N
zxGgpg7Y0ztcB)D_zQmQVBPP
zNBbR&1_Q=QiJi~tH%^9~R@&`UHR{}K)<7=a+37KiGnEP@Q-Q;y(YL;R>+oo2Fl;v4
zh2!hf>o;fDZ|?0K&YSIWt6QGzbl&>b$(wIqA5RBWY@^-b@y&yiw@&6qdyQdtxHpMs
zej5aw?2bS*SWEajtw{~EHG6e15z)I?%L93!CuJXyhtI+lB3NNIy+sSoq73q4
zW;jI5053@oLz^9jMmx{O14^|lolSA6Sd0tClFa_~ITnTgiw24Ri*h6p%9YZQ7z0+u
zxNxW6XtXQ%=IKI=%SDp8csL%3r<2KSPGc}>j5=5wgVpE{le?DqLO!uV0w#itFptot
zM2z?hX?1F=%@|KaTJ2gJ_O#n@I4zA9vU$5dYQ~dcEDTtQB_i}5-_T&x#T2XEL=P5c
zOBq-#dM`%=Uf4G%-2jjuuy-k@G<N7(-Cm1Kv57LgC;Xt(zR5+C;Ry>=!UcX?fE5O6-N
z^*h;k)Bzi~zuP+8@01E*V6oHA931u#jraG*ydQM!?RV$9-M8Mpet0y?7q~_%4?hSF
z-ng}QaJ1X(R6KsmaMHZ_*5UPAN10r*)35CwOi*3G!QJEiOtlcrCZ-3|gPR8sjA6c(
z?@xPs*AE7JJG(bdMhA05;~8S|{=7MQ{+RXO{Yz(2j(2;-dM3gJQiZ6~Z|P53jaC_%
z&K+|3o)0k!P*PlK42n`U
ziyhhG3Wc~1x03vK793nCqsEq`zH>s@-L#tPq%$xmjwNy(+
z6Mm=19Adp5#Ho57+ipDTbq9@Fv)E{ttBqp5lxei9)kZ0qj!oyIVkK9p=D1|o=`y2V
zy!GZ$f6zoKvb*$dpCz7z=R#OUIxh7F?RK{j=UA7=j#`mOMnMxq&M3zsoWg2Bl!FNV
zaC}I$)Z`$LGwGK%E3zReDV*$|f>Ntl?nP-=FkZE(({5oX*#y)z<}p4^@PoiP|5w_(LWA
zYCTu3WJv5i&BZ|8kVj#^UkBrMcKRqoSi}#0@O{K#h{ohXo*a@mL_g-;P`yk24rDjKgVHgMA3a2&eQ!mIBsxJWwsCQXCTw
z+VcQkCX`MEGHE803M3OCjz5)PQi)&+pp19{T+q;F*NMc}fHovPcU*XKaB
zLqOIekC@e7za6g7XhQ6@AVKR43YAW7cUuskGzKN4GpS*d@j+nJ;WWG4)=X>P3j82A
zc>LD!!Of%Qs1wU^#d_iJ*5TosN5kD=rkt4`PWNsc^mZoGqy74zn
zI-07EJOYU9AWfyW=((61-X!sk(B9y
z8lV$_8b%Tm@o~iJ7TjF726VzGg(8g3pfXxi^Zj1E1#gJz?f?ftPrw&*!g%6e!&in_
zKfEfG$&<&TRhuO+vDL1)J=Or@1kM`G0(?WMlI#yF`-g+W<56!=?qG|Ls`I_xY~CG?
zoBN03@wC-y!`vkbB`%$fM4}!x=0(s!zTuL={-9QCWYHJ)hK*zfnMN+6dz;KI*@U&Cw=Jlb?`0=LK?Gsyyl
zkp$Zrc0K$}sp_3NdJzyUkpV^-tx4|>gjDrmXUh#1(2l*Oa54?l*gG203
zdH^D#H)aDRhqD2Os0ILWD$60WgXSPOGBp$QrE}bkw~yhq!?B1b5GYnlFq`dR17846
z&>QrX>g7eXIQzPg&crj>M1;j$_Ti|5{MhMK(VXB1=`KGil<7G!U>pkI;17RD&YSrr
zA~XLM_=wqn$X>gG7z=vtOuEHfqF%|i8%2%_frPG=UfiVQ>
zYL!Hcb^E_y4}WT)Ef-i
ze10Rtn4@uz)+E>J#ZlIg;yk&0Boy_SZ0c~to=o|xH4eW*r{4}R=1L`j$d4TDa;V`J
zk($TDN+#v^xiyVyd}mSx77>;~N!UijCR>Of-`YQV^YF&EZ!%nnDEUj7I4r}h6_gnm|-~S!X7^U`0^xQTcFMEGKE-QqgCk*T66~#V21?O>{JoI%Jl*{D;Nzs=y5adQlsn&xRUu~
zIvXpOGu2ui;Vi+03`V8iph%`eT#89$!wB8G`-7vCX%BR3=JTawGQ$qW%~rRP&c(QN
z1pVB2)`1~~`zuv57-Bj`6G_(Yvba39+3sjO>%%!(oi>$TYj-=F-4>gOS)F#B*-)zF
z@Kw8mCQJanDC|w8!sBtHRN{KQ%6QzIOj^@v8$(PS4#~+e!y%9d
z6n6RPFo_NN)?)gk-S3o(x!9mvnU0#BWDgnVr$PV^FcDp(pb^wBrh!X{tb;n{}3?VEe6mkSZ
zPP0vCvT7Y}vqZkBP>Wq&tJ$WPsw5)$md2<;Z>-SDBubG)B~}@fM!P|x7E9F<6fi2+
zNHuz;)nP(UE>nsnvMr0vV6hveifx?{l$2vp4z~qZwAc+k#;MWE@n7)oAaB57vFouW
zZFXZQ;xSv*cBeKHb%j`$!J^U|rEJ6=30YDp^p94RP7F$>(t$#e^#@E^-ImLv&E>;j
zUo_%i{3e>IdmT{I8fHwDVr0-o*HTU)dV6&!&n8vGvz`
z1`b}oF@bL0+C93y7YI2barg1f>CLzIZ@hWf8#X69oulhJCvPDaAMIV=o!{K+OuF;K
zox__4u!PlqJypq!k7o0m`~AJ~^kgsFsKnt1PmcS$VB)LfV5w8Kp!c$BhdcdJjrc5Z
zP-{>k${<~Gxp*|qx(EuDF!lRKJAh6y69bRPInSdu;FZY4O7#M~Uaeh0+3B|%Y^q!(
z*_*VA^&G_YqQIrt4tZo`wcBq5
zLtZu(Y_==eJlANIQAi}i=}e4`1>o%PGxcVT!J<`Yq*|j&suUs6grWhIjaFSE9fbw1
zw=2zVz1pad=b9zqMo!X!=
zTFq=Cj$t$zo9$1~2lzuix|0#*YOCV#*hcsdA00uC2KSOA-#)o+4pu%%cg
z3P!sTKMI>eZ`b={ex!lf!KBC^zQ+RLVX^Hn8V+&h
zb}{JI5Uv}ILNXaf_=OFGX+j+KA(6Pv27>}agxOp!p3f(MV24fZa%i}?m!8ZV@R?#!
zHz4Ts0+a?8l{{qk`AiH0fO>*K7ffX^2#*ObW^rMG79F|{g-)?4+0a{bSSfOiOsXO>
z+08n$Uc^5-Yg;asX_Ydaa$6;p>Xb^8R;-q9Dr;_oCbQ%eWnhPYH%=;tbf+QWFyM$xjVX8w0HPOeRU<)SEComMa7*P9Irjmqu!_!ysBuQfSrZYCgA
zD^&)a)$PKlHx$&GO(ut3qEhNCW(+ai>~uK&o^T@SM<7WhY#!G(>bOB`u<4Vzc($Bw
z4H^N&(^#O=EbblcV2yeF4y@9hz42scfbIk^f(HcVkfu?FQ^ODhBuAE8Rm4)*H_Xr*
zcF-bNj<`aVUWxUF{xx68YfT2b$ANW-l@F&jn2tOQjJAdDh(x{yH_>1TF-zHGI=;I<
z!}8%S0YnsbkLH*SX&tzvNg3v`*eH8~-cqd;PsVP(bu&}S%C!oIj~ujtorfjtjyl+y
z2;Jzw&|OvP1@xDTnsoMcA*_}RMz3841o@lCH2R$?qH!h}&ZL-HCE03ZoAoq*KY}zyOQi&q
zPKTmVx8HBE+0{;`HqN@!$v~3x!}NK)1}0=f>~%VH4x2U{bOr-9kJI4un0;OgQmxZt
zcDPM8r-2FvO=DIo^zu#F28^D`X;c^#+lp=eaq=pS$*?7pVDn=rQpiws#7a3vQIMz<
zm?Bon6gs6;BbBHji5Tx2R8o{xQi&2%WNM>^AW|*Yn6z@8T&xnwbuy_&qB1IVR-FQ|
zT89L!#y8QMlxCYY5OP@^I<;10wQD>+b0q5a1*{k~nicq6Y|Nd?1RXA|-KoK7G6gIK
znSj~jQb)tqaz5B7hZ!$9l#H<4ZRY?-L}vKJMkO)o6~-f2e^6Crx6AA0*wKC$9E8E_
z^^3z%1ssGQym4bTo3=e(eJbNWI3B$H?ZeKXS*()%MEggRlQ)SUtaWRJR;e@T?4Rr*
z`pu8_I@3X|-=3ZvOpf-ZNBbaPwbw@HwsUgW8uthDS9yJLBpvaDJ!Ti$xzQi;!0`bn
zjdleM)#5NBljf_rbU7VKM%;b}Y!{pnTD8+_LmL2qz^PWh0aU^F`O)bFoG=viZpj~U
zvB{t}zg`52a*@Pu`a?2L|w?u*D3)8t<`&4qFfRKaOE)9gTeWGw=dM2rFORt1wOX%G8Ky1RAPJ+jX{YogS29{8xW!uDv{Z$ak@?6h}Z5ksR
zIN9l5f9v4j=6-Y7j1{G7G?!1Z@To|$~A}y>LIhC5fp8}UA4-K(7jYf-xKO_=DqXmz&CN=Ue66?;v6iF7q
z0w{q(Bwv;b<1H)-vw>xhQYXg{AOpn;Kv>Y{3wW?trw0hIj;5_bncPbTISXwS4bo^c
z(0iYdeP`tiz>&rB^Bi(3ISY;TN5GL>0{;u20&UxaW-JpkI*jh1OKDJ6J5@Htij*Q)
zFnkUCYm!~mN~uz*&}h+ZqkE=3G%b9&)aQzV5<=l6!V=IlQ1j6cP;fJTCK@q-C;U_3
zl4-6t=(@cwuqIz6cP?O}J`GH&MbBlE#cJ7P)g$T8_b2Fb0DZ6qeG(`+70)}aI|fW)6&E$>?CV0i
zUF-LoEXx$~sdlU8_dEN;Mm8UJI1PyeGe+9&R(q{7p&q&O6^8JGq&yrpXavR#z#ljW
z8cs3KpaSsqI*Z#46mpSbo-G$+;9#|!sFdQEQYu6-Os9jHOemFN;&CtBpWknGIdy)w
zH4^khLLQd&S#3I{N@RB!oNlYxqSs>s7&SVB3PLZWf(&Z8PDxCh8e35TT7hxv;w=ib
z4aqjNDP2$xG^8A)_@myCzJ-~2lL!tfF{F~JQIoJtITi~6e}Ew6AOuzdnv|6?jS>|X
zqnNJHtME-Ar9q9a2TCfnar)M2g9s0kqp>f2r5#i
zM;~A;h{+%zz!wadbD3bJ6r+AHlL}Nz(Qz+dEdysrRtuYiH#<4#&c;D5*4-J;jt}a??(FzzQFmU&YqT=}r+_nXke)b=
zymNAMFP)3#iir^G351-x2g6Du2hyRnz`Fr(fE{p&kH856OiiqT<2ir`e>a%+ocwu(
zFmxEjJV2N)0CTlOqQy7xFLs|TpNcLMURt$1z5ODEd`5byCXO|^vVDM<_Si8
z<5?g71xUr$gMTd6@)*UO3Z2Ro@c6<3oyFkrxilsnDvT7!Lnp0K$#fW^BPT=3IKEP$
z*1ZgcXQ8%=!WSpLpp~VOe%}t$BISN#ae|K2ly}r)(<_6$!>(X0|epnU^Cl;77{ex!gi0PA_q5iyQ4NXF|1|2
zQizf##Dy>?d?-97JsT00u+?wE9wK*R;ftDd_H`l5cp5d>w^}w8%cbMBN)A?QXFkXm
zxKxTwry{dSx7VtaipfejO{1}}Ly+zVgb;@jfxE3T*&9gix(Yv0p*I<ooKXimI*N)o7JGxDXliW&0#c}wF<3Vp;f4W
zJgr=*Q&7o(KVBlWY+EJWkc-x&Th!}q$w>HJ7XyN4sE2nk1*0en92ADA0V0KBORCtC
zkteo^5h&!OM};Lk%_h$w$eTw}L21>Is+3}tT&$6cF&k#k$YpvJKPp3lR_GNPvqo)F
z6VIrV>n$3GTj%kabOy23Ahy_5OxPBTICW-~*{<^kVHN#cGGMhSJsw>u;VqY<>2$zu
zQ#u@~c+}Obaotv$VN4#ME*!Px3!z>sGZ~h{5qmZl%H_k9gZl^Fe!qmSB^LMW?6yvB
zPWO*SzMv~i?g2G9xw(6Eb8mJyZI9c{aeIEUdvxOfesHooEwyWi!1G(jFoW}xqkN+p
zNpqw9In*5WUo8g#sr{2(WKzUcL@EOUfnA@>hOgh+DU{>QZXuJ8>>l=}yPfu+0jO15
zW!N#jMeFiAz&;?4o+JpfhJXye1~LMFCc6Q%0flfDXgRTTB$bP_x}`!n8IJn7RFq34
zR2n6l2=5%s;5dLn2u%*nRU+RCvHqj$dk9}TqbgfWB9fzJV&TJCA6^gNS*Dg?ip}E`
zj2_GvdQb`aT8*BUPOR06b!xFrA=ZAS2YfC8f?or9=W2CVTl};Ouv*Y;~9SQP&Z`gthM(*kK8?9~)E5S&f{;CH7lj%4c3&95N>`q_|
zoo-vHQiw!@AS2u&6C$^?0rFsk!8Q0b>ar25LB0N@2j2(NM}bK9+af{pdl*Bo6tMHP
zPPsE`_`~GXPK%SAsS}Eky@!Ax=!p-e3n_pV5QN9nnYHvjH;bBd_I1JKGBp|ndH|$Q
z;QIYK8)Yn3{my(;DrY@jdpP3ncFEC?4m#3W9z(h-klzD{cF_R)070nNMtCZ>8d+-n
z8nslX1xrZoY9%;9dX)%(h>Xl7eF@GBGl)Pim1UwZ!Wo
zlR^|jluDFDlySTbg!_Zt1K?yBZb&c@1`wlCY6Bt4z88gsU}*vq>5}P`W!}-UAWTHH
zrlM15EvJRki6oxO$&O2n6cEI3(aBXth1IP$*whN0SZ$P<9okUbYjWsRMy1-Q01CNu
z*cY&9blU;Ol*{<@`A8(@F_;xTzbTXQHR_3ck&Q&17OULrGt{cwXi$dr4u-6;xVzp+
zO=pdrc?;<{mnA1!7K-e_(ct99&ScgZ@AT@O68zxxTYHB$cFA#)z42ggv~vtB9v@sk
z9PdtRz1HM#KD)l(nUQ8re+#OOBpqW<~uPQ6zvR&&)x5wTRM
zm$6)Eb})&iBIQOQnTxvv4iF8#4=xOulpe+f3McbnG80SZ5^!*SP_j`Z4lWv?2Yg{L
zfk^mGlr#B6zLdgjuzQ%z&$tkK(eia>4d$O8?tsE@k%>%mGl~jaEs{v)s2q;AIz)*sk!;8Y`MXh|0YGt06NTgN>dilqf
z*(yjtr%a>45dOemwJ5Yoo7)Dfg)YQk(|UpqU)W`Lnc)z*bhKJ8?jP+$6Cs0H6XU}D
zQ9GWD9G>ign?{QkGlZf6aFbp_W47rNDYjV2!Wa&weR>etVATVZOeElPS=-&3*=cfz
zJ-KSORL$+q$GK8Q$)9cwIN~Ef9#Z!1(HsN>Pk~o@bPJ0z*vvYM(d~CtYhQAog;XjO
zi}@OjY`@*9ldKPNd(_kM2@a41QoM(WK9QsK3=t(d!)&(=j@`piePBbMY0VmiPA=EV$WVu{DHH4%ji}pl5KRQA0d2tFnrMrMAn|(ZVj|#=0`ZiISr`QD!v`e;=?sH@
zr9UW5rgdnx(`>i1rBbxn${d}H$mwRo8k=Ci!K3T5!;{(m^_}jdldI*1`{Vta2Y}%G
zaJM%ZRJx7%^@H)z92y?XcJq$7c-|M2Dk$KMf}
zv>d+!`4>U><~Ofnm@XuNJU|WDn(a^E0f9NAO^=CMgA!01j5}zGP$C%#$CykZNnIPb
z2F!)y!S#$^ZzzG-moxk`NARCGY5yaqG()pypqSG4G
zN%Gk4gj}nFi0R|^pP(iP^jVfrbG}k5AEa8D=OvP8RboLe{rCz2sp#HDDmsdx&E+I_
zPDD|!gqy>fk0i*MOz3R(4rl0Z^d>dvh5~{!xk>n-NfC(^OAp1MoAEI&Y?1l?1aD!^
z$?gdJg6V^swCU{Q^}`8kPglf>mRWikr}2BWkl&*
zISca+Zy1V)v^Im_jK>`~!Dh1}S5BH$!vMAwVF2W;}U)X%jWMR-6sLHNX0z0j!UtEE(>M66#i&k6)wxWBj;LMR3Y
zK|=VE?9WOW!Uc7wsJ)fv=ky-KcEBTI@@Qlv|XMou%YNFky4J0&1F`T?|28%QC@
zm!anzJQZ<^l!F*TUkSnAo`cj3(gG3?x!a`{9Vs!1C@XX-1%k6$O3%E}7}aWWm_?>G
zskCO5FX+T-QENqZrzR4yr#QFIXEfVX4!0r9I*a*GHsd##B#_mvWTVbzJp~lH>?)gG
z3G3HtXGh~IqH!B`FdK}7?Y%*fzX+k4%0{w9uF}jOo=lFe@67gxkz}~iu8fan`!^54
z!NVIzrAB46KbxKG_xC2##T#<(
z9?sy=^88(}=xq@|y4|B4csj5Tp%{W|0}6q;O0(1*wVhrYJ&R>JABLj=I1ykG{tn`zY@O_MJ0PK@RN5
zR4N%hsFK+|wqmUSsF|!fg<693MmJCsi0D+Y!ht!gRp1Y6erIotci|ARhG8MGQGiZ#
zPEwTw8J6yLKtKk|Q1FI5Tqars+IEI}2Qw^RZBXJ}uo6+%!?-)cHrPim@1xhE6smc6
zNxWrsSN)2`&2rEE3Nm5b3*fz4+D!9Y3*0s?;?j&*Vo
zXEbOJ2W>&W)$1|2oF<3UXm=V7X0=AAROu879raD9F@z?RMBo&Kmmolm8bI)lCSR)a
z2)HWh5UJ?G1$#*GM;QkRKwO@m@8oE*H=myzA`v4FPY(Am?9Rr6-5FBzqVBwk7n5N8QNP1)4<|yP6-)#g
z8>}2aMnkK~ZkXUcAMr(rUuc)=d4okmF0BiBkzoy19X`8vFtOV8E}zZI
zxIj#NiX19oT&-Sx|9B^!3@1{NcCU_4p{uqy3|K-9?Pb!5rN~|2p+LmzVQe;!(GzrP
zEjo!-DblJXdYwe0m8!8twUAV$AyR7u`YcPRLSLzs4^pkn^P*@agnnZVBGxQVp%YIz
zsFEtxG8Ke^LXLk2^Q#nl0?4W?hc!QFf`EV>HWNLAlAOOXXkrxJoOVS{x24^0AT|4g
z9w4&bLGC3N^R@cT@qFYD`@pqifh$&XH*Xy^8)b5T0EaQig?wQj3?TgAWOod1B1AjM
zJ+7mG;BYpe`veh?&30p_Q+fNX<6gg!&L$Q$>Fn!5vsr+8y=twNtyI$d9b)1m^3acB
zAYdntOsi&eI%zoK84T*#Y}8VsZ%@s4TY%-h&`;*~ZitGVI9L}bL
zfFPV8JtPtjJ7ZylVn>Lv2mE%o$Kr63n_rpDI)hOI4k{2BHA>Q}oI;QikXkuv`lu)b
zc_xybfE0gUNkFP)4pRIHqR6B0g#-vf6lyD4t~U^=XJ5rZ8jAUXd>MkL1-Viyvp9@E
zAqpCU(n@YG>NVQ5YJ*H?lsjBHE*0QXemh#6Qxgc9b6I~OA1IU}cDF7Nw&e>E>IdNj
z>y4D#qw{!lwJJBAHD>cxBI#qo)>c11KOTUCJBNc>rvM`}n)mikcK1$pXNS{5y-@2m
zCVR8l!QRf{esj=ERSLuXoypODXEvT3?UlOC#^C%X-TZD|uzm=q@M6fh#abRg2}A1m
z8r>Sbv;*(f+U4oI8%KhU2US*`%B0Q|x&Ek@$w#?tG@Onq%o<{?9i{k^cBh(tYmNsycX3*t#0)K!Y5;4ODU`_!?xW(SM
zi+>6nqcg+87d7eZ>q56%sn>G=U!{^6kK56x&*d_4TnIj~->-2TEMdgwvsDV5&8%j_
zo^H3AN`+Nwkw|=v2{=MQS2W_w=i-?(n?nB?XV{P{;I%}8&RE0~XT4A?;tn(RV8G`0
z+dN*I)nT;QjV6oEXwvHSYPCkGR4WzeJh4!Pf~HrRa|MBY!cM>?ks~1>AT6wD8Gm$i
z8G?{NK!JVBTE^eGKwR1UR4eri-j>&bfFur6@qSP^_D#zQaL}MYG*;;4a-9rii`#5)
z8dN4UGlj;avbl}%Bx85M8_KLM9iSGE+biX8JmIptwV|jplMO=6RtAbEJi!oVaQAz~
z*-o=uO*mYdbUxG_m1l>&ox^^ml}qN?{?pxn|yF@O_4ey%LlCm2`2ZgCm+4+rgTA)RA01yQJr-MEqY@KixR6+<
zq7tSo>&yqwR;RBNfzAsHgoOXNtS|XT0@0ppxt{a8aWrTVD;zv62+LWB=b%yo@{+3(
zR8fu%1ikR!t!@n~8Tl79L~ss-JV4U*H;>`k5M}|yK*SF>2Y#U+Dps;cMUfbT{t2o1
z_~t>SRra%fyU%WMnq2{By<2M!Tc94|a3~f8O!4tdG2Nf^4zBNG)MPh;stCn^Ad)o#
zIF^PlfPcNHNoQXdkcda4RxB1k7Dl<*EDndwMx#(Fr3wWOqwRLNTFyj+?o1+7$i%!J
zEAlJ=A5AcNgTi1?+N^rBMeFxF+-^%KxG6Bl%&q+1asAeAr=
zEq@&jF6%#wgDQhYsXrY(!$H_Xg;K9nnpJY6LaLX^4RVyVcAdhck{c9CtT(e7E!@r6
zbw-88AhWr&e#V^31+uw-%dK(yjZw~5EJYED;RMqeCcs$2tOHYMMuv+_rUR8max!mD
z_dBEAc03bo_AAYPb?0!rd$hB2IIH*SqutSXZ#p}ekC27;=dDp6Ss00eOEDf#M~n`m$)-n}gkPYSyV1j%kys#CP{AOBN8kO)Lm$m%$mX@#zLFmPL
z&X-p?h+Mq1oaYk3(5T3zFA}BFU^d1QQMcFW^jJfzKb=d!+<}HDpyL6p(uEYPTs#wp
zeM1T+Ck)#3Y$6B;2UdcKCpQoDX06#}Q<`+%h`-b*rgE`TIoRa*=q0-nJ|l_B&iwl}5fT-jHLBY2+%cf}BHS
z)!Q9rtKEcx$*R@pfsaZ9q?GfA$m#ip
zDx*qeP^x*E9q8YjdW#lq-e}dp0Q!QKR4(N7>dkhgCt%{zOuiT`RTAYY7m2zoHf1#K
zX|%GvK^YUX`A8-g?)FQQS#$TWU#uq+*-);+b;phQ(PVx&>rH!+Otd#2OpkZEJN@DQ
zxIS#ea$JvpgfVDHA68dGO?#!!?aUNY^s2b-s0|dN#)F0+BRGgPgJ@iBm7P9&wOz^7
zicBJ`wQA!T_TXfiNHOtbAXiE;5ueRzfKW{2C5
z%0^%b)47NzU~~H2TC)+Gk8V&IFR5-Ju;yG62@}uNQvF%&M^_|7U<|iadzoSqo7)@qqaz$oTg5_jZ-3D0)mr_I-DUL$
z+;NVb%!Vm=w@AR_cO{D%Uo;fWCf#3l|G{cCt=CH%jT{QSUb)*X7mJB>I*d_FtW;9j
zESt-+*(4KZ-K7G#6@tN_P^iQR}Y+ur82NwsAC=uwfc%fYh*Bzlp3%UU5I)mP#V
zTG`}Z!oe3IxZvP21o^!D9D)GiLa@(ZqETganb9~=#^%==6*iY9mh=U}Hj_;O`9s!V
z#9l1NfkHOsw%S!LkG@cf)f#CCSOf<_!%nX_o;D_P^pJ^Q%w28gr~8BH{t%77+N~Bl
zobauvr{T&SZkkZD((ckAQvIQW}fJ
z>IFs*uJ2CfeP7Vo=#*3WSPbkQub
z`3%Cx3G9}>z>7NfzyFsCiAQVJs|}>PLa&p`!HknTLe6$a=#bzI%{F~+*h*&;(Ej1P
zS}&Qc1_WvZ;cy}hdeXByQCAt(kL^W{+UGg+Wb^&eaNNul;x4a^TzL}l7c04Ptxzas
zLJ@zhS$z=2KA%Fk;7he~Ug6H!AJfPQWg$?ZRw^yjuaz>+y<3hPy9F{Pf
ziDr^an6df27K=q447t;pcqr_%*o+#T5?>cX2s9*@yQyV5y~<)WxV;XC(_%8~lxo?!
zbaM@oY+aLVuSvw$M3Sr9;#2S;?LN1J%j^@7Cvb3$A8txTo3itF3qm~jND%%VaPVxE
zJ)eWiZRS+xa}d-61c?nas!&kC2^v+@3>x?o1t3%-gH??n9Aq6jlSFTp!ViX`PIyDW
zE|m$oy#_eJWSW67tT#~=98R|mSj-jJ!KexjW{a#RWc7vZ?O}DYH<%ra$i-@nBDw3#
z;k3UuoE*(coeDJEUmPi(9UnAD{c@+t-*x6yUQYrDf_jx^3BCXx5X=I_;1Dqikijyb
zw@~WjFov_eJ{$Mv%E|7y9gH(_&@kxQKi=6t+Cf0;@@EL5?J;35etv(_#X?H_Io0?V
zXlZ7bxlk{3#vO0i>+m}u(m&}nN`^htIWgaSFPCE08
z65d_;;D4PYI`k8AiAJWiXx)BCyIZ|+V{b5OTkHn(Nglrgi8WtJ?;cE>{RZ-KAmj_P
z43H8E`!iXN%f$FgeOzb@=DYNJ!FR5Rmg2OS}sV(ngAqg86POVvhxveQdtVdt&Q
zPH8Z1b^0}bz&0G#JKfS-Z=Zj4`~_rT5U|hRM=P6+`Th1pB8Wn>S*%ntPNxwwa9lVR
z55^K9E*W8h9-Uq(SBUHmlig(k(eWFsb^uW=SIR_^?QMxzN**qwgtn!UEwN}_1b8iu
z>QYn*qc2JT;_}1|(e|>oBw}b&EP9FPJoo}4Ie{9`_Mgr{s^yKngumxnMxG!#oyXro
za-CAf?+OG2$$mqA_kvmv_NlZc4W_90vc{-3*mPdjrE{n>7Ma#8^##rGlsB1WC`aCWda+1pvvomcUK?*pxXJYWm(q8v;YlKjP_9wcQT
z3=TqLR9ft?d&NellqsdM)m$ja%JfPvzk6}_a7ON=5@+&wtH8l%IJ~yW?x;IznH_qo
z!;mW>KzYnwtHPx6MFWjd%fYzhRw=C^KCYZ;f<9Ap`b+YwDgEA`x9P>m)0OxVT71EXo1TxnjL
zyNsSPU4XF3hO9bH^x$@;$
ze^l#D8r?}VU(Y6rTxZ%F@1iSi4|m3$QLoafjdv%5*|;_6?HukGY87yBy1zR=I%vGo
z`|^WyAYd%Tc1P`GE)j_MFbwmL;Q(`)EH
z!E+^mW?ARX@Rbt<(XX+hm3dyG|y+^Mx|4zJV0c&#qmq9&bvT>$v#!_<4dnu~wPFKl4DT}Cv98FV-dk%%`I
zXSgIwAA0HYJIxlIMk_a(G)9Y>T0*T}sZhxjD!D?f5X)si4>*N_RCziolf8s}!dn9P
zRwNKm;N6#rA`-$s6?AScUIE{Vz77YMH!9W3*|)4S1f0{#;GkqubFVl5BAK}bm$TAU`>I!uQ>#FS_<0w$uh0E=)Chd1`&Cj1d^
zA{#B$^KQRWZBUk*#hc&0-WxYVQ4frR+hpS&_g#D!PwFs#i-+CCs@p`k$_^|FwlVm)gkb_t&U=A@aOa)NOR|
z^d4E&Rt4ljMjp@l;b_3_G9xUbFrE+L_nW=?(ai&FQ;kst<6mtQA+Qo3X|yUn#+56k
zCOd<6uZ{xvcyxX5#+yfAB4*~#Dy_g3E^5-**9GL?G5_=>E)fd&9p!R5nT%+4GKO(g
z$ivsOF1OieR5@H`I6)8)W-!7Af+4TVZB=T-Iy7AsIjdZ)MWfXyGztZNA^+HX1kz2h
z`0C~cTp|1*m9S56Ww)R(WrcvJ`VVk$lh+mq2=<*qkd#+BxT4>TgU>fGKl)p7P+?Fi
z(4+7t)2MYyo`Zyd)C|&43_qwwa5kycW{uvabNL+(kHzh`8!ak}U1fJ^nJ~Z?W#b+{
zV}&0~Bm>2AqFT?CDoLlu;Be{krC57V1P5#FfF$T{C%`C#Z&dOW5+jUtxho<^LECFx=sh7DM9Wra*K-P>9+N0y=$mlfzhT
zmWq{ZhJUzKshWd-1n*ki8kdd&j&OwlDAXIa;>k#+luTq;E*I@jzvMow<3Y2O=c=W2
zyHOl;Yqd(2-0#3{EELmDmqjF5$0&c_p_nh=MpBc=whbn&(`_@FbvC=n<+eGTR=rUt
zRS@5|A=wryB_f4*Q%a6+tckX-Zf&n^e{~8L^a25iu1Ume5>nU@OSVM|tq_n%BHENo
zRs{S>WKxJ^WS)SV3L<*7vLJc~hx2s)RmSHX5_zs=X21BK8
zk%%b)=`#Sx$uuT%Mxnv3H#v=Fmq}~YYAtGbLx@cVBOGJ%n4owjk}GnhYPMXXF`6~U1(%Gvu?Rl?$3JZQaW47_oqX+Kd^7IH){co!!Bruble$@
zhO?dV-mBywg&KlzXV~hEJ1~8)d!A1+09N1HVU@X^445w-~IX$z6SXwr;wFvwSts-y~<#aX*A1oewkiEWEe)7K_f?1H)^;X
zd3K%2ZgBWKu7ICSM)Q?SH16y63e#!b>9@fKG7%p!eTC#VzjgEYWDgJo0Wk#-L<$B6
z(|HbcV=(QZ3xxGURlx$$N5Wu&r^87X33^eJ&b}_R8~N#|+3%EV
z>>1p?wk5iLIK*=}C{h623%vkA=s5?MYUlYJq@%R)KooF7D_RzPYef`=AfVM{(-^fV
zfP)l*ARvSSF@{EjVwKLSg&zb8F+|y5*IM0rU)aG!-DaoO;WN1zYb?d&OYwXu!Nz@V
zpE;QcS8ADhD_3u4F+G}MvejfHT~$z9UAxBJ-HH`=D-I#J6?cbX#TzJ4EVxtLibE+B
zcXx`r7AfxTZfAf0xyVH(lbK9r?RTy9sJ+(22lN|o`z#v+a1^c-`j^hQNeTwCc_uEf7Z9FsyiX|Yq0=D(!P*En*F@~W
zKb0p0do!8hcq>l4(oHx72B+yy=NrGX)bpiU_doS2e;E7KGI3*}P|U(44>FC{UHP6X$B~<3oGHTU
z!R-Clo`(FTPIXZ`~`CC0F+oZB3;ybcKw^io^;l{2NSV*Fx1{1rk@F)4A{NnmAvpY`>lahwMGGLbV(luql=Ry~lDSGrQBHq>ao
z*uei+IzzXyvOI!+zHj>v@jX~l;FW+>vYIf}gA)0#YAl0kfwIxYdV{U2QeC@m2h~5k
zC}})yLaVi!*9=#+Z-=njEt3Mgopc9__I5b@cifut^)n^0gcKWIeKi=CiF
za}IQym|Q9tK{OuJ`xv#^5|ifd1%`=PwejdIT6^=SN*k@tZOQQpwMr70&l8iTKQ;-e
zIk+Aj_V2o8ol=SF!r`FaH=rKtNZ(;3_(Da`xLP{eWk%cx@V>{Xu|I)*hO8pGMM8q{
zTtd9uB7-~MUZe09kf+p#MZmT!)ITO2bn2AFz}M^$u?UkwKBgfBUQ5o6D}2-g6P8D!
zVX|7JX#o*>NI~>>1YWWq%3X7Jd0Sy_O)qG&s%nZx?B~
ze=V`}!V{4rx=iA_(W4#g78@S$LvA#DCsk;Pt_`*&TV8~GO^j`X6$xrWc7eezwh!Ci
zy*Y)o*4yOZgdXV9tR7vcKME7z#T6?5Ck?Y~*1V8Z+qyLm~|4WTbpWUuxcC3&l@j
zM9uOx8Tu;Kd(LN&fo+Jr7Apdv^9ZxsX>3z2qDVT5hwvHk$8*{gRL7ZA@)^3xcMlmw
zk5pqoHGv36A`%=JT5SkNEDDzUFTi4q{%zImH`(e28_;lv`*_l}XOpt{b_i
z2`|3e!!uUp#AlDRn<^IJn-n)gI^vNo#6p5_{pD4doB4(Y-TLi&li9x;)M9T)`M_TF
zHUe(PJm&4D2@H}A>)vQY-onV(q&nHHCoz_FPWu;~eX8sJbi5A&Vj)mhJG-=(tej^D
zT=F!EOvvld%N0M(eoS$_F>n2FfQ`L72QK!2PW|yaoEty^uzy-@F;Jw_0vl~P7>I3=Gq0P_#{Q-an9Z5*2*RoS4i$Cl
z#s{D`Ab(5??t@MScO_w0yR_1`&1Rhx*^t?Xe4P%$Ii5>|@=@24y=Mc1-K&T|ohI3O
z9&F$#
zU7lpcbdySbCM)aK0+(oRq3C$J<`+9bN;r*-cG+qjCILl~Fp2{ai8Kb~8ZSUsb9;eKP%
z>_XMlp_6dYPjX@fKu|(e36|HC|-KbdD(fTBO&pVCVELs
zC)!=k(FNxpf&{GiXtbr+5-DHH2R25Wo5T(|IZ7$d(;E;RvhJ;;y4c#zoi_0EaieKg
zV%^=-J)4!dszrph2q9SXT20{xC^kieXAtjq{9%i>yz1mAjtaPOjr@NQ4DBbG2W>ZGR&lqp_K@GMgqZLXD+i)H
zC7L}AVHxEG!#P#m-{QkKaACjY3gwZ6T4Gaoc4A9nGE5Nm8Wy*@34c5C=mmR)L=4NT
zB5=Iz~o1>IWu8)2ZNETN1L{`_@vij}mU
z^eD$`(hpCHKn>XWiU#pi!2&oDx%fJxyrwZ)X6ARq{oRdT195Q
zr}@d#6~C|5vu{zXd3ev9mcw;n@9Hu%i7K2E#5sz@UP%FFy;4I3^8FxcpQaB-?=KY_
zCv=>NX42&u2EO;7c+#dR%ls(EBft4nr=?&&Y72Mhz??PO-|i<@pw2?1A>Plf*JH_%
z&Ti#H!`Yi3i}B-KiY3SYGo%n9xNb%IM3veIX)a0|xM;(IWF;#@;KW99*^h4y?XueD
z#BW%L)@fBJjE|zr$XL%dqSGEq5(XSfiA+h$8jDLrfI4m4SV&AlnSRnyf0kXN_ugkS
zlmuOWtskd=4u#V`B6K;!aC3}(YIpvYNV3{Cia>^ZdE1j`>R|E1^78b_$3CLD6bSi}
zPShWk2!KgtB}7Yx=(CKuGS8tEDsspb{?QR--6Zogs*o?P8372e)VlCqoMY7Fp4wS@MX(+UV<1<=xIg?Ur|!@+
zvVY;F0)d)wNx5Q68uP5;fdzkx%1^X(pZbM&cZy?nP!A-yUGh0g<~5RAFOfvMGws!|
zjqWsXpy^HjyUgUpDlIB~P{Rmo4qWUaz{sdR&n(!cCI
zH{NeM7#Xw@ki|$AXxi1YWT_O+l-wB9gG;&Mw#x0I)UEiL#*kv>g5g4=m>I-SltPi-
z`OCk{SHtOg#6vapLo|P5#v{VYdX*GGglEmcR^+L%Qt(b}Ek6W}I3@;A{E3YJnGtcia-zEHCJJiMsO5VR$y&GREbp?n|
zBD4$7e`hy8-s5`Y!7$2q?cE6Z_!Uk4RJXUxFx2e^TG0>Co3flTU_Yv}zejc;q;;SK
z98+B7-KV(4Vjk``Zjo)3)3-~%5Gah6@h%FsDI8ePy6G95jC(~bHw*#B+5q_J^2PZEiX|fE26~`bkvWKfMQ9`IN9JR}bWc`ZWZYN~oS3&x
z-i~tyntDF0<1Ae^V;=dNA{H9{Z_@3NZN&sD6b&pzOqO(Yc7e|+!RpC)<$v?ly9V|6
zSX?G6{t9E@FfZJ!7mRn5ycRW#`PjilNlX@1;u5A8+WMt+`;Z0mRG&Ixc2rw^9&D!^&c;V
z(MNZi%6&Zm?+bRt7?%fA?qA?V>_pNJ{ozU13z($^f0Z!=q}Fu9juDD<>OIhKE4$xD
z?;F1vT_``E`CVhbokL$yAD5x`InL0#iPkOkk~q%U5~K`mdw%9{*4fWvvYxU&u8NtJ
z&!}2GXCcnUPjgbuq?B3{f
zZ#9yR{&3;L*`w_a=hRi6GL)^kFk_hLYvNK1FMk8lj3RK%+)1YN^Ar4ois??k=<%dq
z{r-2;{$mlKQ>s;NjgE*FNaZFtiqfe(DaA?4pbB5LZ$v4QnJeA!QNF$%3F}9hS5Wdl
zdAX8=_r=*{EiwouQ~C?-%DR7LbOiuxWpe5xT6Zb=5soPXq6vAbKqH5Bu#NzR6Z2>38Q&lid``
zzRi2Q)+|vLDvfzIjU;
z>;4OG5CxSYn8;p;46%?V4m!&cCcb>^w6
zp+9KcZGog?^XPE>e*H$Rc>`G;X)EqKthBVTo=nCvoLW9<7t(G2yE=qu3wbA9VmH@j
z>3V&|!kz=SDvc3O(jtLl_76%(ttO~PANdF1@Yks^(DOEQ5tpq{2k|+i46;2rE~R-O
z_`t>w#Bwq(0`-Hd2~I<^c)vB;zEhfZbd>AiGtYyinq}wr8vvDgj_>_Yq8ybkWN%e!
ze>DjEY~>B7xAl%{rTOXnb_E%mQq1r9q89ovBr=mF2KkEnjV>+*FU*hCM`0s_Q|Z2k
z2|doh1Us*VOCs)i<(zZ$o)jHr;)<<%+T;%Be>4l?cXa0D
zWuC>*flpuwj&1yOt%aldCL@L-^oIb^a}=!2l0`K+xbtp{#H67
zBx?c;mNb#w81BEV;iz;rHW1;xAk(-_xxak8x^k{4bC#%s(YeIuwmKQ^*WN$u->Hvb
zWo>ErvNPOIzkm2x_@T@7YWnu^Xmc#;yq2gn#C$P`-1+r92YP$jYjY;DDBp#IM$%m90AA4O_vZg$N@L&STA28
z8L;ZD&Z03w_hXNOpiAzdNm5EkIUlSfqZ!22!e&V!PRxoJ5MjqUD8ITXg~L
zr+%4gojRsazR+Qr_!j8Y{?W8#N6P%pWj1Zp3!|C1ZD!)}BNne0=V}qBD~{uha;<4-
zU$X%NN+`@&`q77p%kOrYY%2us4Z+*Nyn1MUjT5^qw(t+uAKkuwbo(X+vC?d5U|+f9
zS%p4dfW)4j_pm`;mm6EEXJS5=>l*_eXJU^-s;e&>Yj67lZ_kOq|Lb$U&izZ&^Zx!d
zC|3M=f2aT(^l+c33VJyvrux@vdRDiA7C`=ZBW>Aue|02>h}yXsEzz!t%4$h!*BJna
zPSLUQcgYDEDur}E4kUI<4CXa5jjF_qne$`}t(Y8^Yp{`)@$oELlup_!sIglMVr#hrnBw<8Kl
z_K*t@sWr-7)IxuJ;Rg>!FA*1V9T8f;ql$@0A}Sv)=~XjlaQ@9E8?$2RwtUTzxav5a
zN7T&jZ^lI_ZIAq926Zqogn9Rw`Q2_030w$WhL7b5}@iGPdFw@xCBQ{cn{HQS4zq;Yb_#F$zCyxOFisIg*onm0#K{CkX)`5(9JI2>a=a;}O{xLPI8__6FZC#t>3I
zOQBmvkni2l%mm2mnScYkH!M~h>EKlCdH=NC+gqeorTt$?lCR2y2*~$swH^76O4RFq
zzd(*k{B{3=F&5-^Ih3fHBl>bYGtqIM(fJ~hwHW-^4Xol|jgGoN*ehnCw%2K|gT+P&;CpIygK&cZO*k15p&S`FH6fz51JX)WpUkJ2CXH#0}Sa<~k_M|>N
ze|QZxS4LzUsp~NQSYes8xgW%o60bF(o%?QWCWHL8E~(fLuuWSpy;C{fVsA=2IafU~
zX}tYBFV_=I+uzo8&(_}hp6)t5_kvVk|Gs^DdxAc7cHX_bJxqZ7&Voc@&&2PqZ`*Ae
z&!Ap=Q^X!rFVC+*rmMiRm7{uF4pV(Q8Jd8;>_K0!8B%lBdSfCb)tmZ|Q$9raNYSqS
zr1+;3-rapdJg)Gw`CcZEG3g2!lP2BdDxXNC?b{6U?@=V$5lK6Yhj-h;Vfr=#pK%k*
z$=apPP`~+lZ?dWZ6DGoK5eU$YhU3@eZ#
zlau$GL@=-OnE7q)GaY41H;DX|4i;=dL*J#!!~f&
z2sE+G@dv>MCIykx9tcAX5EtKSo87-&EhWdWl9-ru`Zyk4{<<#dFAo0v^1AjiHe-_m
zy+i=OG_>w+Z*1`v-?NPq5f4=?Y_!j(oNvb>XRk*Sr>lN0Pvc@PI5IG&`&Km9GZYoxYJbVQ?sy#>Sj&KT??9l
z+uJ(O^_BF=jfBlf^H*GxpM9f18Mk^P=W#fY31C!bw0*nxawMneV0G;(n?ZS-BWp$?
zktQCB8OMwB-tW=J_d4~)seI`-5S+4}x&p<)Ns^zBi-MId*C9h|o;kqz^97u8^R1m<
zfFf^(4*BMuR}UwwUbt|~DNtP?sZ$s^82&G(PVe@$DTV+1(fE{;-P&+DV0=SzKS#0Uf?
z&Chb=y01wWUava?XX0L$XJ??tMqpMRWd;^m^{=?DTm1LY+XZTBObDiRAcE%gn)lP>3!qer0{B5r4N8-nE%Ps*)f{7~`f;+gG(CE!?oE
zWCuPlmz*IA;Pm*!KysyP@SrD55dCnOjPXkj&%8YZ6gO;IUOfu#hUZWU92*0D|JuBm
znEvprbhZh;fnaICO}qBo7X<#1HCoZ@tbs)_X|MV6aL7<|{z2mWaQ=vVvtF_G_4vxv
z=kofhXre=65D@{_Gu|fx_{(0fo!+iZUmsp_p6_ob{Jic~me<#_TJO$QpeQIkcxXVH
zkI(JF-hbQu;sof;^zB)7pRJGVpoU5`HE0r=7Nq2NZiMRRq8~_=M4E(_IBX_BV7I6?
zOT3llApS$8HW`9sax!1uYbSR0i9-2LB75P1)o!btNa70abMBa9b#wV3&_Iv>J?uw2
zQX5UE6g@zW?9liFS+kYMYw|?6pgzx3xeQ$sdOZv(!(q7hc5e`8H!}#2NO#
zwv=r*EAbboRQ6aCDs**xs38to1IfE`cYZ#=!ir9SZ@p$h{uGhE1;%3<8>c`$tBZ1g%KfP&n4@mL7*JK1DL<9vzz
z3%o{jU)QITogJK_-i|r_&i9Aj+TVcJ)4eX0=;Jf6y?1z=9jLB)-)Eh@Iu@=zWl%kD
ziJbXfzn-XyH(doEt_DryB2&GD!e9KbF`1`B9{3A#I9H|FT>6reJD50x;K7Vfcy4kKm2e5pusa#$r=v%KLOZK2&m(?HZ0
zy>)6Cny-OMOwz6r!=S
zC$P`Ax$fQG0Y%$A-IK3AcdN*aXYJSotKR49xO2eG=^1sD`ucb#7Fe1Gd!{~*!1{hZ
z))&svwdE@gBiJ0FAogz>m4*!*F)$`Ht#Ebbylo5WM*G{1j1!OFhhbN*{^>?fqglEz
zJ7fF_c|auDi-rQz^BGI;RZ=KXzWPR`e9jrDHRv;-AwZ{v6KQk5{vKlICrY)!J_1h+v9cOd`tItKLIf7JOF^A~zXUilX5+;;JXhzuNB-{7(O
zH~$q3n2O%t>)wGL8e3zb-|j9rfl0bJaq9D&ct_dpu~(4O;r%A}c0c2>2K9M5)!ZL%
zx51(IL_SE9qXC{ni4De_*T*eY=*tkNpYZ`!LlRHC2Az5oEI0yh@IBMN1Sd7D$Z!F=
zzwb1#rjH(&kkxsM%W(vmWXANCgqY;*CMWa${WK)%EKpNLR}8k;7AeI=ESxL;s)ym!
z+V8~wl!?@+?Z}(fcB>}58-r+!3#EJKfhg+KPp-r$(Iw5FzCDq7<62E|ve%L=g^yEs_{s3!te7^KdQ`!A1mAu-k`ZC#~U9xQJW-T=6
z$k5r-=R0s}e7-&?Qq4|KQ})2pKoR%6pDK`xJ^k10dUo3W;9%oy0~108ecs+GnxF*v-lE3#*qA=IiBK@}8B`s6^mh~EbI(5rO|x`?+vjl1
zUY-W7R;$uStGGD`qVJpBl1wlG?UcU^S%5iA04OEuzE>QkT8mTVjzRv>##JC=5U=zw@ii5%LDnOuLJn6Tt}DOI*Hos8V=58r9+L4R)fvD
zL(QHwLm-E{&(=NOYkGI9vM$lu}+sllsH(&O<
zm5!%qh}wCOhdC;h@0Yucy~)6!3BQ*Mn@+#mQqzg=&ON^s_{=iHAG-;$E_?n|_H`42
z+t{{ZLzJBi1-s#(=^7kA
zB3+xcIt(xvXm9;Re(a!)p(Ryp+rL;h=+r!jVfE|U2`nYj%#z(biB$3s2YHmH*8?IO3-I)Ypw(Uve~8~+>xC+=JFyTwr%nd
zwaNGM`Xwv|ih$B_Po*0Znf8GFVQ^@QBy#dyNTC2r)-7YbWYpPnMhZv}`fvMeMX&d#
zdTl1ey&sQVb8(tUaDu52kk3H=q-{^D-e>Jk<08=4EYMp<=cD-Z`pTVnlj{>l2sKJL
zO(Bio{ZwL+s`wKH95S{_g?$V|GttK<3*pWTs-e*4r2oT|7Fm{Fyn
zhzCY2YB1>b6LEg
zcgE4ZUm}N|KlXu|P*6-B+W&IARCAIvKTYjofvdegah}5qS&8iy0z6eWyh{5d3w$2(P%Q$sRF|=A>Dcly`EX(sRG*}g^H=u4m>F=
zmOO=ly+;?JLBAn1hOB#sgapG`)-_22-kH@#WM9&
zE{sVK=*tz#^eJ4ubO4Pv+`~1wjCCF1)yOZ5vhmLFjP9x)+T5BSP}-w7#gwoa~T``NEhJ`xo$Al<6}b4#6#U
z4{Fba@0;_h6CXu4>UfbzW5t^2l1S4xx63g@=hwNr4(Qvf)c#ahENC~D7?@^@TdLXO
zewV;L3wk>y?tDJ*K670x>$jzw)yxfh&4Q>kaU2<8C1B?1GGp4+&TOL!_Hsi@4TpMQ
z_#@}6hfZqA*_RAzgL&YbJ!WBHOUu!Uk+x(w@P!7T`x16GzI>uQRz;c^EZZn^y&PnOE(>cbP5s)_F{
zg^eV24DT|rptqy*E#aU;Rmeq2u)mLvOGs%8#EW3(vcJFZ=4(mer$2%7Cd1vJd
zyZYh*^1QFTqlAe%^F6;GHG0zikIt)jQrjTtEPemiy1PA*?tX*PGc
z2P3-|tPB!Usp;w7c?9#oVdR>~(NBG*S&vQOP9nYTY1L@gv8Llr|GBP7LtyV<4OxvI
zL-;)u@Trt{yO!H2YT_UYshkqIhN~B8E8UZgJSb*3sm3KlrE`E73-aL5q5m=ED#D^+
z;WGlBdRFgdOlahZEIPl7a0NC}d)A6W`9@UMTEVN6iGNnk4SdM{g89ojf@U89{wFS=
zuL&QBx#I<5wVycrpFyUZM_U_1rsXI=e>k`du^m#Z1Ezrb~&QO&D$VU{+ANj
z`Q`zATHFIVobVx4_XPvzL9vv6^6oIJolomQcTSyer^t7QPnU#`%g|a`b_q
za+88N=l+>$H8vF9G>)Hv>I|ksge4Cf4lvI$iEMfi9!g^xHvhnVFle7;489qgkregi
zPxYGb2MDF>utwB$xc!J>42-Z0k3oc^DH?F*g`2K%j4?oZ&za&Br}@}WX))p$E&!Hz
z{pS%V8I87C?O8$(y3Y?65S?3kWSFbJ!34v-2Ez}e;>4&5d0s3PM*Ur-W@-Z_rmm^?
z%dmZ=>1)3|@!S55!0Y)j%$d)9-}2fE
zY_GLz-@KxZ2s6vgT&@ZkrV3vgAJ1#!C
zErXOE$V-9woupUT+@Wib)p^i(9I@Xd`K5QDI7bFXpVW46HzYIyiJLxs!dj`%sGef%
z*E%fvm;v>;*Fqd{t0GG25_r=HXp1%(vhYgtDZC8gI}j*>!c*kDX=&W
z0FL_$HOfpkdj8cNVfKZ-jX%@suHhJxkcSsJQ=23r+ca}W+#P4fUAs+=AFL~KfKwL*
zg!_`yXRX~Edr+mP^^RL{HHB(?;C)ENGdMLBh+bUh8MPyjs9Pq1tva
z_sf!EL?DIqFAcj7ld11GUxzg<5!B%{+B1V71qRky_KvcNBbIgKZbTpOZ{Pye{BKeZ
zL$tDwExZDE*vqX-LpOP9K0fou`xxgXO3)7dP^5>W_ocLt`x4gc2lVIazmv_17nQX2^?tXM?`nEni2kL;Fe63fx+k;;Gy#qb|2W+oA
zobR2j`T~8DHfJjj_w6F`0|1qEH`E@Mv)XYtbkeH2+WE2#Trw=**28kvp3bANbDj^U
z7(1W0Yfay-RL=~=Foa%1Ou+Pbr47=G0YPwR0U#i;Kc$4e=w9k1K#iI(d=|+?4Fz4e
z##QZC5g52rvTcyEW$#*K!CA*qQo`Pp$$OYl(d14`r`ftJQD?2#VS8dYMGZN^Bm2fn
zh$gxqiaM~6Db!$fvL-~!%tW~Tjw?;dKd@}kKtN_UN#)&_li;W)ulFljIs<|gZ{0Sd
z`i#0=JcP-|{y*Ux1|0W&gi$R|U4kN%>N>QYTEsKVA7cRdIWL;|#^l{gC+|7}{zy3w
z<}8yLT9bln-Ei@={*6~@yovs^Aq1z#ut!A-oD>RYM6Jgj5L)GJh=&X1=TK|v;4m>H
zzGx)CEw7B4{J~KfRaq9n;T*wV^Dv6s=nVSyxLAOl<8wbX6Be6IP2Kw_<{4b_1S9#d
z8U!TM?fjPx;v5R>K{+2itmS2Zn6ffF=TezvG6-Rpk|4@6P17XY%N%Q`Z{KyhG#rA$
z7!(ybJ_<89NHMX0o4+V(+o1?$z>~xVJ&W{>OOo{sWlOR455r)xj06z)pLP7*`~?md
z`YR0yKRzDFYsCu)>&zK6vr)4nQm2Z;`2VC6zC(VpLcAfXQf<sO(P
z#i0bV@*DBzlBYT+f}QOb_IC(aCM#{Ss$%Ueuc5iDz$6T!1>vOwztTV{x_O%^gV_vu0msPtv?wp};zzrn{^m!LxYQ)>$?yp*@
z{BG}Opl?G@*o&63Ka&(bIb9
z@32UW-A(yMtrK9V2o(EaJM=g(y@W}q#AJRgIj0JjA6A)?Uef}h915z~*ezQZK5yC(
zuI!D#YA&%Jc$&Y&M>{CQg?EDiWbH(&0rmKz
z*o&oZ<-|MNw
z0afw;aBr^op~G^obXk^}d=*7`#9jK?1=kQXpQWhES34Hi@VKfJBI750)a1pVG2La3C#?P69zbr8twDsXMK<$SuMMTl}qg5t*I;EFh%#$4o2
z$--|OF-Ec#QZNXgWj2J0=Mr2kFrr*7g0DUWNA2yWbEnaMh|3Dn;*tIY2QKL9w)$Ph
zP`>i3!9a_scJ)AlRH|TLBl4cKsWVQXOD6Cjt?$gO7S@zvM^JY>jF%!qiM})hhWKkW
zm_O(H)f2MP3WFBa&CFa0h_bZKFlf<%Z+Q_U-u$pz{y)^@)h*mE=F#}`91I}+JFcU>
zlxt$*5y!_=r%qrjy(R~$pSgNaX^HZFyDUmG5&gl5L32dy^$KG{ZcdBspE!w_EJ>yJ
z+d#vg!b4_8=laR#qYlTjFREp+JXnDa|g-qNHi2g=9ayXl*22TzV%4ug~`vjusA9pvmE)Rh36LOz(b@kfPP}-v!)`N1M
zJ|~}jpN^O&dp)C6McOA#W{%XOnEu3v)2WM_-hxE;vu823&J5yW-Qr|}AS^W$lt5ox
zj>wkp5lq3GxXN0BBq
z6T2XtPqQov(~PmNdKAI*A6#(dLrm-7T2tlkPbOWF8|xqlsPkv6GM#DEUU2x9E_#Do
zb$B$b%Nk5YhAVdE+Mlrvo*2DRn%!eDD{wMmDQSZ)1{%KqDqzAN$%*d9qs7UEp@s`7
z#ye14?d4%;#O!zZA53Cfzl_%RW9--E6F}zvRtvYT$&>C0^UnnQd0(i00hPUI3&gdu
zzmpx61pY)iVl>ik&ujk|;RNAEs4+upUZmozDUu3KYs0!O>!#_T4$uc&8)Squ%+6eh
zgLn~ti|6T&0?*Hina&0kzE6*RJm44m7IH{&RT+N-lrhMv=>1Y>D~M6zr1-2C$R
zKF=)rE20m7ENfRNzW$%yOb`(&gc}D(%F^5;Z6iE}C3l+OXwIwA*s<|F1@X@GZ!JH;
z)x|}SV8>T`cTcsGuUKns&HoAWLeiwXy_+O0E!Qgn$pIV2vw2IO6?zqTRP$(lrZAfG
z_)6xPqd%+Ma?uhnuvteQKx#)JWno`>HK{Glg_RMeFKXzMJ`b%LvaBlOD%^*mT?pjC
zu1Fwg#KG8chKqM3K(VGaNwY0g2d6QVMzq4eLTK4J-_d+GlFFV17fu%c9`v13rJuQ2
z?;>XKI5d|3RWy~L1Hy@u#1W5D*3Dim|6wG@q}5lb_yj?H^SW63J#MJPTIC%Pyc1`2
z89`#L<~V;?-mfQY;;5UDes4RUL#5mfuADiu9O~6o8z
zaQ}kDO&B+HaKxl?YKxo4&xUS0C=j-B!0N-Hw#Afiy%tvx2_9VJ{NKjx<#zj`)7Vbm
zNfv~>n5(+zPAeL@N{ZOkI43p7VSYqZf?ZWJh5^>W=Cz`tGxK{|WCha!(_5v`ZL`x7
zHB=_#&W?_RAfH`&yqc;}`2^17xDXl$9Oj@c4=n+DPw}*aB$|%lXpvOykItXcXLXCD
zl|x5$_bUM;N9W(Jb!u0RkT7ApJsAiU|KvBj(e>)TIAN1pG})GDu<@}pD^l`(zHMz*
z9O^?D9mHj
z#1TTacHHQ@;lFYO6e_^~K-fk8$8E!w1w)ku%cwB$-2A~-Qhv-<$)8$05PP~k*bSXS
zK-Zk{Z!_NUYE4RcPHytI;*_kU+`{*$d-jF0FLL#D#k@BuidEht29JZTS*J{AYJLhAQkTv9SC-F^i^cZ8Yyo$6%^|tgF{4i7eSSzY-4?`7e;&~ph2ZeU
zA_#2JXzymwJXEY+I?0uc)UH?>Z^-5qH5P8`P@lo|^DZyG^yjrOewDL6V9sd?Jsv$8
zz1D1%TWq9#z2!$or690v>NDNB3`9Zx-PKL}H8f(|0z01&OCw8xz6d|{>u`tF3xi*r
z0my(lWzx3Gs|cSP=&U>c&1P*tZN(K2GI2n9ZR5}r-8MqrnptGCE_#>3)zkOsfKClX
zX>g~uLal4t-Lt@)&eZGCt;3|GZXF>*nGeI(ODfNzed-++R_tADCDjMvtZ^5J%U1b8
zcMN1tdo`A9P8i?_|9U3|OgSO#b~!l@#sWI*5^*vl>Tsr{L52&C-2tYi2p)#{mipaX
z(rDy%^J|Phbcc>!b@)DLWqd+xMF)Bz9FfOE!mWu%tn`@-HIfo68^-eYgU$Db*`5`_
zLQwmx-(6bMwXG+`>-X|=Vow*YIWyPE29GB{-{qxuMa&dvBV`P2^1=I*`?+$RXp&ik
zS77;3875*KbeK7)UHfbxM4fye3yTaG$94v%AxFS!!%1lYQqOdD;*l}ojOT+djzdqYu_oxC*GF`KJ|%)6fvR
z$!nA#(=qJ>9#*~vhZ_+TJ-|x~Z5!7F@)}ISLJ7Qe(@OFHY^LiyNS75j{BcE;0n}rI
zOf&5PT~v70V`l-^Sfx`|jSv4Y$Ri3h@;pb$QTtp;8E`+e01_6~%hk!VC*54LXXYdoMv}EdkFfQf^R7
z>6qYP@d}ac-tzf~%HbU1uhr8UcOGxmg6hhlDyqvW`p8bFwY6vPB@l?cIY*4T`&xIs
zOiUqt2cOs4<9^NMR5~)fKkvQ8F(PwJN&d@>+`P8uvHLpDzg*Rr@_6I*23~oio
z3tP{7G}H*AH+(Fzrf=sm1Sd{EMd|<9e%bec!EB?d*Gc!lZCT@hFk-uA%~_VIL1gwk
zDDAs?=U)<3Av|@{%$pEWUB2zBZzud=-3~KAnPen;wZkVRWsZFKn_ycud6>;+23%#I
z=9Kum{PAszhk0}$7$7e5phwAUtp))loAUW(n(SM}O%PE=&bqVt3j!?knnhS1hIXhg
zG{kb7t6JThn>pgc6g+UM_9q(`^#Jy0q~KSwZsUR0FIj*dkJIZbNF-ABHDT99PJX`
zdU)gdJD88_JUudBiQtVQrmLEY)djz~enHzi_yipSL+gJimI(pzfhk`(kfBQD)Vqzi
zhm1q?vJj1tk$SD1&I)ORn_K+|w=|R@g_K`>c1glkbhu8~26H-v^A)m*4z&1Tq`_(&
z0;~%)3xE@KA*qYX*7i#9D^X&`#ruogD_NV^rl6(eci84HX!ViEgp{7q!95Y4d|7Dy
zYT6y!f(raYU6AkIR@4*yQD^?kunixpZ24M|HM(;*+7aaakC(E38hetqZ)
zPva{Fc=$ovq*f!O*nw@AeKi+BV0!u`NLIuvBv~v}vop7mb4PFNe2l3l;Ik%{V%q}H4UfJt21)xe(g?WDeJ%jg||6#
ze7m8w7o&%Bl=>p*^Ehb?i6}?R*dZF?R=P5asXQ?Ru(q=9x$fk%5}XgjvGeXYwF(_5
z$L@+SA}70FZO{{CDca-m%VlZiJ5rSt_ER*3{OD
zQy8*AMbsPbeFAZ>YRgAeiz=Vpm&6=C&t-7#Hv{z7ygiMCn)&q6I~}4I9X?xE!;u(T
z=s>WMAZ5O8Xcr}16z+G5nE|98B00`*%*b-mk6$7j$fPE#mYf1ZpDP@Z_$PP2m=jP0
ziz0nGg&GYq71PA?+63#W<
z>(>-6_p?Q5#44uIc6~Ph!9s0DsX3FTewR29g%e?L6pfv^hDqJ}uN_|X+~t*38^ln?
zir}FZX;v$lQ7qD*1d$vv6!(fuR+s^_i{OV()2-jG?3A5MLl{
zta7U|JDd%7M)htB?#~|%!V)skh|}){{=hzj-%P2{n~W0KOuATbGXW+VE!1kDp)VX>
z)TFbo3!_1~-z{`n*>*F7VZEBnWg?|QJedfD7)LnhbUAb;qe8CS5=pOZORjEh)QiZll?5Fj#e3lUk{h%QaFFNW>q^b$dDw`-=|B*61es7W5zVF(xlAmbOgGutKL{@I
zFXXUKRueV~IyP)0A@jo8V;kiv1%kY072BfJs9=Utqul7XV(ECTQ^%IFc^&>p5bO&l
zV)0B0D1fO&8^Fu
zqAOc4dfQjw2hUi-Q~W*W-KifuJ8?sx+Y0rlgm;&9E(iH1gq-R;4xS|-)z{@9LE(!x
zj9EJNx6DCm_h{W(DGO$hOo8~lffx!vq(?|7?*Kk3I*NBuHu*g0tjJ+3kINTjJ&~~4
z>(SY5dWRjOu}m_VOC>T~BA3oqOW}0V6Nw-!dt>2Tqf+U%M!P#8V7Xo^)T+r+xwkWK
zk7w~*u|1map1l37zy9I;Ti?yLC)4BaGzJHw-Rq6+NNq4L>dvcp1=ui9n6H*y0Uw5?
zM$PQBqvfE%z!idG2u;vrZ-%ynb_LQw{&2t*@SsJthu!YDPhBCJ8D;?WFhm&*4_O;N
z(d@L6{f`xLwvEcHmyo??=mcYS%BjTE>RGD>7GQz_KR8q
z?sF~8Anbfxorf3v7ycbBqd;P;PK$ydVNPLmxd0~8QT+A|9&Kx9N%wUG4q{E>Un8|}
z#eBI*_SnM3V+-o7#zZ!Wm5&X9P7D1Lwh^{hxlzqk^6e3cZrhAfma$cfu}UFYEksMXa3K@SBz&p3hl{!rh|f`1IOGTftX{7P
zvRT!3yT)Qw$;jg?#R@n<8F_M>NV>UANhcPQ5gXZ0;kEd@W{=y;MnYVIO(o-*WIUZfMqpDM
z-ZFZ;j!-yVt5tff?rhxKnUu(3wd!!bQ|WZmwMKI?W4P?@jkmw`S3kJ%o$pnK^VZ(=
z=FUlDbTFD<4}@Y830Cg*qVBwk7b-fcJMfn+7s0_qHVq??%x3^WI17u*3a3E#A^~=A
zh!l%}ozZTFJ;XdFhXqW8#lX8@A_$14h>ySz;v;lso5$e|dW|-dHwbIVDA76Tv|^2R
zORL^kXtjke3&9YWgX7x7{Kzy)RuP&TRPewJ+u-!yD&gQe>Tqaa0
z#WN|!<c%h_wEO)Qx5wac>P%*>(Wo(+
zG$P{Q#LqVqU-27iK1Bk*s@K|%b!o<;2;nBzt3
z8I`a<7^0)dw)8E!hgc8=AC;J#B?IaiF@$7BqufN?pMXM?RW=KPu-0kE5Cn8aLX?J(
z*5&ZTSSHCu(y2%)g)G4FPv*D!eYSw#9SNtal~SkO8Vx49JN14S9dbCG=1P_R{y}%X
z*PQIdi}mAg|HZey|M$6OKilXH_HR`CJA?UgzS>l2^&-*s_U5`mE?d-{SMjQM+tdAB
zKrmIv0f@Ou2@cWbaRp;h01H#P;~@;AQm=(iL{lM^I2yq`D1_oHD2Y%E8Ul-;Ap`@6
z#)h^B6jB?4ybK^>I+`WjSBSELzs^Lek%?6@!WuQao`Sc2sx`IZMd2;78&RX)P$|w8
zwT)jUN}m;Nf~1sUFlBs!I8$2Sg%4s#>f0&5gjx!1FU=`P_>aqF2n$)B4O-X81+A%N
zr&|5t(DKh*SIX&+{r|W3-rsIp37)6ATvaY71F1e
zz<@v!OdtpX%sIZO=uoce?&|68nd#o0+1WjN&hDQy`@Ogn_4FiH_v|m4bEa^<=jsv!
zz$fC~&;5P@5FihLciPBL`n+y1E3L?60IQLMeNbr){*iopOG_Xf@~@Cg`odwgQpx1=C=rm+3-IpEZ@*o-
zc@yhmu~AF9f7;-7&caDF>p2Xri^J-T)%NOg^ZH5)^?tY5ZEJWdD{)|PPK(p)Y1pX8
zAF?{V-Uwhnd=
zYP{qck^9|`*mpPf60IX3kzp_Kh{3xlR;<
zl!nCm`TQm?LuK{_sZ2gU;AjbuQzh_#6oM!{JR3sh
zLMQ<{{MTR%B~_uoOgIJV9}%otgAR~~%%xv|#sY|L#v6%oqaQQy
zVdOF_Lo+f!33NhmC0NoGAip*-A$z*u`2G?H*RtTD8WRVkcu+JruM_64U6F2QEvhgR
zC7K*^hCxT+eOp+w7+rVm)*!S)v@1Fj8(FvHwCkRxoIs&2hy6i~S0QWN{hP^M_?`Ah
zjI>6$Htejy%2K6O&uaO4wsV{BvVx5Osc?vxgSAF2>HcZt2ho-qHMyXQ
zP&yfc4MadzWC0MwfQol}okFLjLhy-obg^P8pM&|}qr8V>ok@|&q_CDV7_j<$4&cw_
zwnC_w%(EuToRK`XjS%p@OJ^S7-4E#j2ttpPgAS5wsA$F^LoPXlG-_&N2tw=d2aO3x
z>mv^OVFt&!m>wS_l`#Qr!GJv!KpaK{#!DDLibaItL_tld`IL-IsN}1aOtBD3iry&C
zrp02dRBcszi~Z%BE5nsxxlwNRI>VJ4-KEv;()H%Ts$6N__~SqPr~m8!{q7(CMXt7o
zx4&<%++O_VPm5pwF_xALb2HZ_u3Wux#cVdeec-^(ojbR0-!W=Ck75GgKs|a;9N`G=
z4=Aj6+h8I}`R@UryTX50m3TP1_0n?)z`rt#-c$JB~VZ
zj7%7!eBmHG9nb~?7>PxJzbvARnuoswynrw?W)Kiu!!lqW%pfct5Q#dHFLi%eO+y{?
z0Y0pP6b#rcT)&QYfk-S2GQt~Dn3kK(AH05Wb*Z_s*jO6Y2Hny^ze1egVtrw;j=VM$hug&SP!Xet-7K_tN?t`%YXK)YE0}zDnaqvD_XQ}3Gb8CdWOk^MrR@Vgr
z-hBeY8i9cJbwW!TH<69?_*N;SO#CPrW
z(sXQP7+Wxi(h>+b!eM_b24Rkw30Oh_U=C3?q2#ceLBJ%?P%R`B#mAx>3qm5UmUFdE
zxixGp-&*M{4YX=mt)RCzItxpk#no)7E|(iOzW?(-{kQ+;Pyh0NRu^tGmTnGie%o2P
zdE@KvwNl;g@XpN4Pfkr)ES6KJKYIS>zuLOv+3nB%eCv+qMs4R&OvBX`7(IFctyZm|
z+wchy|223$pb)7Uuv@)z3%EpZhVKaSEGNc9DUB?q$7d-iXVgj&Ue6l}NNNr*wJOYG
z1?dz{|!2fYr_Ty}^Kx77NX)UkIDMhywOGy(LULZB�BOIKv
zS?&sTn_g0p`i#vsYqQaE76jCVmqe(nsl$+h#nW~G5%hsbg)Dz}MY<8P3PIs|jaPy6
zm-ZR*^4|P4f1YjHW}mh>bfH2tMZo7=13}cC`bNms5Zlo~%swx?k|)H_Q~dNy7dYq&
z_@unbi^)c}A5TlQb{DF)yWkyw7|*1Ud4a8bxfEa{sH2@*TrO1L>|p)y627m}Y5{`4
z-}0?nFpQF>0*=6|Hxwer$IGQ+qtRVj8m_Lc+`bKAu~AF9f7%d@`s(!@Qq;n*y1LR@
zS#B;bHHk
zH{9B#CI8=hJDeRw*|sond?N`XVA;
zzFfdiOorLz>q|Fomz$kLPQCr7KmWtO{vUt$FaNc%e7k-9+y3o8^lyBYv^DX)OH@lga&>6>#vt?-b5e3P~YhF
zApHjed2}rx5{{$Nf}vOf1c5^O8w1RNfJ=BoFcAxj5?n@4b+3`uIp7%2|AFa~xhh?=t
zLBT`&>N*qu~5!v1|)v-&`Le#ZtZ@>u@`h#wp(?mIFwi)PALI@Rl@&x#!_3=!qG5*G<
zgNfD?kZ6p&Im=k)d8_q7&Dt#^+00ZkL>P+im)$yM-^k<>ArraQ%Q=GJ{kq4&vDR^L
zL`JWEZX^((CrRM@fIL7D_`^$kD1?`sBndgNPfjU{C})#-MJg5fOxhU^c{ol~R2c(c
ztJ)m27FLIiZZlsh$^{K6WA*koi`Q>8dkbB>v3mQ@|M`FW(?9=9sXeIlmR7$1b7gpA
zaO>MzZ)o>1Q**}IS%bx5otl_@rxw8iMKnq78D%SYl-g_HL|xcDAP-BnheNc1q$~$m7VJ|>CDajnG13E$`Fd?|
z^G5IbYHMjRQ!MaOM$E}@h*$u?g^L`ur2D50E7!XVOU+iN(CL*13-y)jo#mD0U{KB}
z(L^!`u7$!5kJrF)?rJrQESyS(6Nw-=2vCwkgtCy!@)(RU#FjL2A46G*LYXW_kP6Ck
z&M@m@LY`pA!vx*1ih-cp>$kfRkiE!WHoMzuwi``014N&2WFV(gbUsoVlBZwJ&*>Uh
z@YamQFsp0MVjOGso=kUTp0nCU(r=gp&7xJ=%v3XW%UJ6h?nopx(BN=a4xN4Ok({H-
z98gH*a*s9d^4^tC7b>8k&PO+x=m7z(fgl{8BOC(qP&y-FdngEF2pZyLAR6T|nP@f}
zm1RDYVUsCID`E%=qv^mN#ssOPErPdq{daHw4w_a>iFnCs49j)5vF9Q|}jo#Ag
z?eG8YpZ@jF|LMN~lkKG&D_?(K=`QxJe_bE0x|r~_S@M*9qZvcf{Jy<=pMUPzojZ5#
z*s%)`gdg0teHU^u)u`<}is|OJ-@*x^GobUp6wr$#mTq1jt}Y{OAsPdAFch7I0lnNB
z-N_#bMq)y>-B7E=M!ykFN7bsja%ZKp*wG(uC#~FG1^a+Pz!A|He2k?1aYs
zW~GS0hj}if=?QG5a36&GEWxSAVFcOqQ{x%~q-@
zlXc2W{xH@DjAfgUoAjEt$3BVCUV{d6msa8Vq
zSU}(fB9r7fEHo^etaAv<5GscIe`GTL)!md~W_&5NZu*SV=J_eB5t`PKH+n2AsAo0JJVcgt
znzr5xCgUdi0|NfYA((a2<1joRqVXD0W9R@1!9*(0oYVh+yvWN24+uCq6sQ|Oax%mo
zV$AyG)3#v1!?SEU#if!_DTC6_bJ(@1yuzkZjtI+VvrIIa%;ky|>=*32{$OdbzqC+m
zw-a(Msi^Jc)#1&rOU+?QsSH-X`Qv~1*Khy!KQ{WS{p;VXeEp}^!u6$F-?sV-ZhvrM
zdd_IJy4>#RxtaZMA9(ip=eFwr+_7`lj-Ag_ZQBkM>UyLcy#0qiAl+m&4GkJ71P9R#
zP(epZk-LeIL+t1bP`%s1lISpWNhnt=a$-EdhO-)Zluv(U&|YY_hRyCmr%=^;i(PW7
z>RuyXR@AbZl+s$cq?U^Lq9%y(R8|5R8@<-j&6SKw&bPP%ZdbqqfM)VJkQWpNc7-HN
z4dV_nXd6He@qIR8rY5bx5TG-H;99L^4fJpFXuT}vYZepLUErE0OqQ|MFRyFu0%P5K
z*KB@JS1iUWR?~#lJY_Yb`#`Y3CjF_+7MBAK4ug$1#4udM!-VE7HdlbLdAwXap;c;1
zsf>6FqX&~NN@*97Z3
zpMr*@Wn(acpsT9j;wU9v0MWx#>VGcc3NKT=Uj;6JmDmkjy$Z5r-B=cCT
zT9;8rMy7rciirXE!DKqj$9&$f-4(R53C10^o85B`#%%SF!-a029Z4A#tHTH;8sYc=
zL}X`&aeOT_{b3yN=Z`Q+IqePkQHL3vwwWMc4jcplDF^9HGT#obXPO2pEs&Xt?mw!B
zb8yY!l6zWvJVh7fAWB*vk@uzv+dzxk)%}XFa7<0{x7%w_z%TazqfjO`Rngni>rgxTeWuI?GIhKHa$5#YcgBr
z4TeL9-`({rkVo7fw0*}ec)(rH{sP**<2j%ZB{;Zs`>s*jc@z`I|2yA*Pmg(b7Z+(z
zLK>ny1bqV?2H6=i0Yr2sdiw$x{PWx_lE~Rprgq%#PX{D@`8$~#~&aho>l$2r)
zb}yr(bL5x*>0~z5UFeIML{^oBM2z0d28L14@7EB|B=n$7jy%HeK!5@{{#a1$fq=>5
zK}dvV07Q~%@3k&M#vgEDbj~_LQLSCWfH4#7r
zAEC5FP8`SL;kXzPqCrjw@B+hfekjZZ0wE6+jQB_;=yv-ZcAwqhci6l(i`xPkQq7tP
z3h7nT)D=z{XD2NNXv%DuHjyV`6PdtA;t;8T$T_=Z-eFy52BEba9FL-i3DY*$1NyXYH&-OPCctim1eoo
ztz#zOm@gv*s~{j~C>NASjN?Rs9{xwq2Vv3qgFK7gp3KWqQDvfBFv=V6{@4Rf3e60|
zEp2tzAVQXh&~P209u!?hCmJeL_dxbgjo1A*m%M5+jWy=rq}c>bnN8DX6Fgc5!fNYpU
zUIrW}?Jgr?vcWnxZI~o?VKC3knqW(&4YqlU+dgHOB}e+q22gL>I7`f+ew&6FGyM&T
zah{y|Fppy|P&jFtho;QHpZP&O40-o7es{_SOSm3((D(?;ee=g|@hG6A0B(y4@&XOg0u=e=Ci%L!pI
znaU|zxmc|7%sl3)0ELJS_)i#Kvg(Q0u{PEOCw&KV4biHV7Q`}S?$zI_{}?c26eZQHSJ`-plv_;x&~
zQQLVGQ=>bmG&{8pIJLBJ{pJAKf93jcb!GL=?S<>B-~R2NR&L+wEDW3dUTM#
z@Vz0OMU!bZE+*uxTq=}Wjn2}rvosi7Um9Ltq~L>U?P|4Eh96AlQb{@K5Boy`>`c7U
zth5HL!SbNLjDD-6k-h5Z&ke1jm7A4VDh}tERx)@iDW}5G2%m@o5CJyg4Fv;{u*2)|
z27`F%<5{1;8Qd5hG2&W)MHs6YG%za=2`6Y7Yr=ewSr65Sl>}RW+In3vn8sQQxbf=u
z=B$;$e9dT{G+8EzEyYLRFSJdXEg0bE9OO<74!_^-@wx*{h!Z>kCMqTvE^Kw%odJ(O
z5~N306WJ6jwp^4YO-jfKKFQ}wa;~JniNh_*1r_Po%>?XTPf+00O7-S9-{s3yF_T4{
zgoo0q^?J8osMggo8uDVRKjahmN@I+`3#pVl6!fudMpYxC$R(56awT0Tc9&Ng{r>9h
zTis!Q<>u+Jh5D}kygBlX_V4=|;*4y1OQomM6qjg2&K_SMtz2*R84+Mccs}E6+
z^~95rs2CDc5mYjAES-&_l9GgUR!B)a>b%H`nOGzmVq;+lm9P*D@LnJ5aWcr!4!hrK
z_ggF;lYR{#2uN?W06rRL%;ezU=nx^T==SiM$@maGZ~$ek)^Kpm@#8i6%N!h?Oqb{Ffz<=cPyhwI<|EgGF%Zq@oL<<4S#
zu-sl;jc0Px^XAE^xoeZtX0!Fml`F5j@(Sp;MW41}+P3vB2e)t83K0(ots@}SsO>z8
zsZ{SQUca+)>)RV&e_v}4)N-RxZT1!y7p^0=bV`ld%I%xo#o_9mTVP^;X-O`??ltHY
zxx{YdWVK$)mP?U@h#rLuRUg1*+~_U#p;o_r{mu=PQa+o>=g?_sf!X01*a}LyF*$nQ97P(lu!^Uo)7fCScj_>Z;NB7c^ls
z0c{j;l(x`}**tq!GbYol88Xl6^Wpnu%qFwTX>i!x3=1QAz!|fPe{pP
ztz7Rm;gQSDDr|CABNriIM}T^;dwM`lfO-y}mro=(QS?V5@k|Ce7yeEumEhK~U(m2&
z*z;v_aciMgE7qFHtP&RDAwI^&5(z1n&Z*8IldG1Ib`wfY0pAuEP+z>UihVs;S-Sr9
zZG0#=3rk*Ybud`w3gwKVL0Y9=tTig_c57i+X}8L)AGnTsu-E|#0XwxQXXHdI!GV34
z*@c)*;JWI`^N2kdi7*?24-(h9JIdAyZX5~Zq=Q&Z(y
z9u=)5kSjR
z7$=gl$wBUuI&U>i8|RUQug=d*7-k`A26Z7O6YEag``8SU<0eL`F%Z{k{O*JqF9{0Q
zA#WWAQPGcikFGPIW{}{|>7pkJXY}jxk#hk%qnDf%re{>(2LVK{AVBmk36y|{!1P85
z#|i!poYbl}n{MIRut16=RaD)ap{P0^e6^bz+&kFA^8C#f2N+-~Rre
zZhZR>xpEs3xY1uOHhZ1r>$P^@>k9#YQ`7Tv^Tv6j;rzu5zy00sDEq)cLO?p*;~@2e
zqnNxFe`Af>&ZC%`z2V~ZTM%5KQmm94?HgZzM=z>q4~O`cItvSfl@)-m(yCYW$D7^!
z_V((X8+X3{rdY3FJ~|r1P2NpHbjc};-u_8u(qDpZ$U3w;=-VVWQ*gT`jfNT1Na$8>#&7q!;MelS0vC_Q
z(@8O%VxxRg%4F4CLW;-J(e|K;|B+fIFYzC&b>Oh77&9U<#9?whro-oP1%fU={%Z-l
z$L|kwYPklkAE>GlANei)pobm>QuY^Mz>$@
z4I27I;Gl4&RLN(u@nS_Olw~=e65`=xCW?}a1`)2Uj`=X>_c2bF*Xn`4_S>C4yUA{F
z2gtQrfr!s&o42{GXa|6u#c4A;twy^UuG`|WIs*QPX*CO#l9krguea(m(SAOCT1{kv?bl`S^A%U{>~*SpKN5aE(JbD9+Hw6!0m8?5D5627k>BL^S=TFbw9XPz#=I}
zZRb%;=t%W$2fTv-zWxfin+U=b__%WG>sB9uXjt#`LCJEXRjfDR3-YB(EG=OU-n#wm
zcQ?QO23oy!yV>oPYIUVp5_7p|R+37km@Eh5as7AMq7Q?z7(?HN9|QzZ7OLgtn@gQx
zyI9j;{R&l0E$1^zMk(Z#f)?hv2(p_PcX~Y`j`airZoiL@$6P*NB+8>7O8H!|td^=;
zwSir$6-xPBJ`)qUSW3{nB%Ce~SLVYb_B
zE+;;M{_fLYvw&qNVG+i^3WeFEcSJ|s6AWMrAf2QtL7oMz_=Jf6m!xKeWHgmaBhlx}
zs+djsBY`j*R5j)L%@qasOU298A}Sz=lvkKY*y?oJ+%A{Ti@(Pk3~_PM>~uw9agM}f
zKEQImFadg@R)k5UTds8)orNK&hrNap$n!8kPcVpzC`t6nL97ecnUv*RQOjz1tyZRI
zT{;T`xXWALd^=oTfy(uUTEh2OZgjfX(VgLPu2A8{G^`(tB-|gp2`knuH|y9GTs-+E
z<3gAX%^7As`~1^UOS*sB&;#%8s=LsswkoocX?5zAT2U)1d^D2Hr7=fQv$aOKKkRgR
zh~DjXw}EBKwL-N~M0}1Xk#l)5C4{*^RAkdxF`0=mVK3aJ5RY(Cq+=nGisB_IbS4&q
zA4C?0AA}PG3K`Z98hRKvXy^{OP`US<6a6GIJ&$a5nNh+XTK$mS8T8owCH{}`j&qyK=3oRh&vV6gRZEE5&<$HzwlZ*AYXWAoN65FFo@ZJ?m8t=l$lfp+K`
z1z`v;?^ZxfJth-G?%29r*CX|Vf|yiG6zu!o+W;aGGN5%kO5`pws8_27Ra?c!u~e9HLrQm13?~
zD`ZtEqohDdkTI5uX4MS33@DsY(y}H=Y6d|H2|b;|d^nhDquWf$cqbdTY*}e%jNWW1K|*y
z6dM(yiBt$3Hzg%9Sti0&n{8NQF_UQa8Ywx2;9qOkWKAwN%H?)VsTHferd(E8_*@}8
z2X7Pfxk7>|S6e+~-u7ToDON>EiOV?*U2?giR%?Y?y;!XmDz&^;N~W{1L@JY2z#6N=
z_0{=HCr+F=c<`OQd-fhWbZFF)?w>XcR|X&;@P{v5%4hHuOW4iT0!RnyEiMnn)a&+J
zrHY2P@|v8M63KKN1cdShIL;*KhGbo;s)e$mXi`dw%lS0k$|?xR8Y*-?DmgU+P+~sz
zhnR`MY@>wWw2_XvIQYmzAs%E5c!M4Q(G&7m+!hd!(hyiQI*s!#2CdtL@^|&KpA9%;HsG#(aL*tw?q~A0@
zAtLbFnSjaT4nzezLmn-{XHp3zm)6K#67scLsoj#xrDR@-<7=x_t$1-*i`QX3*C={no;=R&RlQ&EZliUzoQ#&R@ND{>s(M6BBcW`AwfW`Ms4R&OlQxZo0yuiIUKCO%Zef<
zlVOfUT&=a*^)_5b7aT-=u(aGBAk+*InovTGUcbArh%O{+rF2du4N)zkk}p@3l7`3(
zbF_G4W#RgYekYsZ;QDex$p&M*R8;v?LakSFm12k&5ch&y)E8!L9-qbKF*%%0Ka!v~
z662F{205|PY7}badaqII)5fh0RELI3Fb(`t8W6(7itWK9N7&O{UbLROO}Jpws6~C=V!(WC2P<;1xXtCpb{rm$1z%%~r?W;XS!n)E8u8
z$wZ-24nzX7mhCQdf$37c1mxkrrk0CJK?Sq4a?$Q_neA2&<9GOc^f(|J7wukeI2y$q
zJ`qbRSz6)?uQbVBZ=3x_qg!i(Y|9ISr6r7B-QgnkV7^$2r&38tD%b0^RttL;MlzaA
ziBdKO=T|CWXwj-Qtx;1drFXJEbz|H-iBRVGn^n
zGpHK$SpuGUw|&xTylS4iMowhUTU-uTz~>Dy2pR|-o{;_sO`e76v-y1ifrs@A>zB4W
z^+&B^CKiA<6lE!`$eDZ&Aw{i_8>paVq}6;>&IO_|J|hWIR&BIWS}{{7tJQ9)IUKBh
zvvA`(t=7wxTGjRt9;ek`grm_a4Xew0{>rs4FI+l%;o`N~*^5`M>_4z?$4&&_ja#;C
zA_oF>5BTrrpq_t;P^aE-Jcnx3b{@rKG#M^mzI5{B2d6(g_3_6ae*XDqW{U|uJf2F!
zp5(LwDzRh=xk=|y1re#%X@hb4m4oH9fX9$jHaA&Q4yV9&yTgcc2de9Isf|Zl0~yaD>rJasjEZbtpkSx&=@b^8q;6Oi&di-t~t;G!dNQ
zCGtN0;vhLd0_ypUYo&g&^@5pXt&V&V%fb;
zH{8cOa+cZbv|?S1z*y1gccXQ}
zr8|RuPb7$n1&+^Yo3WCM7>r(zJsfg?WkF`1+)B$iZLwaOoxN%>Oj%(1ymp2m$M`sQ
z{Pxq0Nn!zYkRVz*O-a@s;u-uiYsdJaF
zoWFAA(zR<7Q`7GqfB)yd_|<*RZH@E@{1D+SJ@anEzxrZeA2}LGS-FmYx^|A*&ZC%~
zdHV4k+c)ib>-A4RId$&bnKNfTI(72+2d7Sce)jCOsj127>Dl@DP$ZJhN+P~+#1b`^
zE2`u)qJ9N6Fjs8@i=Ap4rg5NEt62>g>U4)oy@eHwF2!mShLMXW(Fvo8WGX8ohUZJ=
zBu1uk1xBw5QjjyGT0?)3e7RXw%jg2=HH9F@2G~e6l_W!tk3Ho6z(MsVfVIB*$0(N*@61AEZ%f!i?s)mk6
zdl1qaVlwG~^>U?A5mTa8(o)$}tJlKIQlo-SA?r_HQA%n~f5N?5Q7f&Am=UvTR!9g)
zvS}r)-|3#UxNHu;2kgclGY4}pH|O>TxOhA)2o8@I--E$wbNLvP-R1BGJWMdiad<1l
zb3BImP$(FQNV!}#uYjACdac?hG&`kQQ>!%#-2og@wL56^7QmJ!fDW=p6EP+dWWwky
z$&{?+OEtAzEj5~KEXKuSf=Ixe%@-x5kS|st6*03^!afz^G2{UFQ+#fajaZ%5i&xH{
z`tXBy4(@+z&l~&p?SB8nu~R2c9DIBKOTT?VKMcNU^TwyQZP`q(i@>yTYaU5RDf(P|RdE
z<_a=k7f;7ff_+HY*jreoSSw&j>_t@Y66<0kc!Fzy$=>6A4*;
zZkylh<05{ZbA>~mNEjhEB*sy~?#446Gm9~TY?Tr{0bp*PBsoRd{mtJfRl
zQYD>{I58fH#WISTQAj(`%8j&AaD~~VT4*gUca~TC*Kf6!R%-pFWWJg$H4BYituw%q
zVLm=FHFNgd`LE7hxODmI%$(uVGhe*;yO*}@0Kcfed$`uJZ>{jw4{>nw)~(}={67f?
zpL+7A(9=&nPPKj8rZ?Ys1uo$H`L90tFG9y$(v4osulq+O{y?4g6ps*=<4Fm5nYA&!IwA(dbgF(=~#cRXRn>Orjb
z1_h20*hoC;=fW<==V!ytK)}zk?qDz>%T|xa#V|8w^Ss^a=ORX@-Qsagn~f-KKF>S?
zjoCDBK?-(T-Oj5sQ#Oy=?(?`q%$&{Q4l-u9bILgHW&-eQE?>au^&w)T?qz})w)M~Q
zIs-nV!{%cAHm}u`FGBPg+kq8@4#PeFNR94ejvC*zH@HN)T
zwFZWgW~p4PH*3vyqgt;*T2YI}qnyC`8GlTSGjNk>boMg7Oq5c-5KU%;R4Nn|xI`j_
zFH_U&;*M;`wdcwrtw8ag#n#_xI+TZ@&EU%XsHcX0ngYBu
z>^h9$U>Sjn{JMx<4@E(S3g!TXFoVD%1aGKcAw{o~A|*^BErB+=I?7loiY;J{kl?W$
zl!)HcA>u8R;3@nd=3u_d?+o)n7{f?BLVrvG0y^Q?gkU%pj_8*c(98GPIFCvQUrUUm
z6$qh&mT2@o@Gju7dmLua(`JIKZo4bs0S6f_gvH<-odI&9dCF|KG&6Z|`r6g`8Dwgc
z$KeQg{9Gs?0AXPt%OF|XeJ;=w$pTx3yh!cjqxrBH_plM8{^TvtP=Ay#lCPUjMiW^i
znRGlQCNbRR(#4We!PqXRxmXN7UoK!!DTo<4s}@r-#uY7=%4Kq;&Tw_{);Fu){Grwx
z#n*q`Q*=@dg=+3x}JFQ
zsVDIAi6-)6h1{#h%J&e8C?Ut24g?E1}dd`5uK~rtip~}nw3JOfUc)sU?>ZTs2~dd
za3CT?5M$BIJON)I6816y6S{)m7eU(axZR3#OdqZ#=L6qch0T+#@
zvlu_1l$=+Jl~{_L6b?rPM!%J`C`qw&N+}lcwIg)vAxTbT&}Gnh#0b7jfde|jY{czx
z8%%}^moA+C@btlh2lwa`Dkn~yICSXH%P;@_x#xCm-VBrXG}Wd}&j5LN{me6@vTfTo
zRDSx?pZ@sAKSqgG^5m0Gj#|?F(}rfhO-?YS;&kMkHq6-Eh{NRi&v-hXQ8M&dqEzH$
z5DZPdq?Qqc<#aBckP@iCW2fX4W)grF6|Dm6SH#Yy%Y%t%1gI3M1qcgcN!=vo$HGjM
z*cAD-lafZ6%B2ws5Xt!jPw@xA?IYC!YLL}svw0jAr`6$eQO8GU7-fS(BmibbQ3k;~
zxJbA~_{YmrS0Q*wSV)J@jnUZ8VlfU1ML8cE@(|DHh5Qje6kr1o!v`5Y6p3TR4*Nky
zuVdOg>q4Lovt|!@$`VXpFeb$0j3}q!XQN48%B4#cty-_hxolJv5d7srE}=+lDixJ;
zQl*yC%8^()DHrOU#qRLN(&{%0%XjjnMu3k2e`&Q?XmpSzkdD2f$koZ2v*#~;dG5kj
z7cO4DI`QR~U+&qv=h^3;*DrYi!bYX85!BXVZXE|7T!2bHR!ICHae@SV;NUhQLPjFY
zA8XWh9>w&tr$E8`^u$w7KK(SB_lS>_iBCWM#I9XCUVZhYx8L4>{P;0gh64xo!8;s0
z`1X769R(;q`snoK%NKntk
zeHgA#NG4HHD;3l;Ie@QJtk!C+4k}2IfiMeGiDYeeAr?o1ERSx@$KyhbRbVW%Y$_8k
zq6aDIVmV)}7uAAXsvsI_StX5kF;go^8W5o+3KgkP&XlThrLHvFrCLoZm2%~Zq7|e9
z2vtQ}LDEQ8;aiHbrb>-^p;A_IKJiZW|gcoptRdo6Mu|zr&jVF~nn@mdN
zx4rqKqKLVipM%*Eg0Uz{`Y3HNmrbb(a4G7KNua{F8cm8~65k0IW`kiiq?bXD&owtU
zec{4a*g;2+9^SWq4~*VB?;JRCC=1FK3!c^yQ=o7`VF{8B-}#ABA#*J*7%3eeXiEveG2AZ!59MJDDg-73sW5#mvchU
zH=@Jg-F#y;4gLfX0)-1kqK|_*5mHk*0p4+V6EyiP{m49pfW)4rND4(nOhl%buRS1<
z7ldSDk?jSGee5<#?pNH*K+p)$ToEw{`~lcTSx@SdySLDFpa&v>K@^~$Yc6I
z=+5P(m5>q|fVUvLfC!R-Rzl)=riT(YB#8vbnB=x`ZdgO%K#GqQuN`?9J=gN$+`-y#
z(i`mbL#0R-5`@(iA<5hw%-2%q<)9jYOzNaz_6yUdOd9}AT4+(%gzSYUsm*F_4(~;8
zMPIMUxB=Qo_fmY=u%;`^M7!oM{YKFo+Pll?aJ;-IuEhK!r_<^Ede#&^)AO-6)#7@+
z;__U(30lhk0M~)_esTNQ}?J?&%C5Q+AP>D=(|(wD!w2b7;4gNcE48;JnU$scMYh$|#kOw_UON3P_E0QVinX$$wAQZZuxbh{FO0GvXA2MTcOj1fV4L8L^M(b$Mg2zaPpGxA+__wzmK+
zW_penAg_HKjuIR6v$#ADb}AV@uiA8Z=Jp=Rx#x#vwR2a)pgKJ+zAT_Wh+g@hR*VJS
z=3;k%{e>HWrF(B#t)!miaZUntth2?t)`I{Q*<8Qpt3b5h3hAr_ainLf`A!4{NsoT(
z_x>0+s{u#o&)9_xE-MFk0}i+MN%jo?>&aeQLxb{i7CQ}G+?0(YmyHlR
z)_iPNo@POC-eI0c-s{}1W>P}gY+@SkF1g1Il3Be&R5$G!&RPQl+D$=mZBcBmYAq8#
zl6cjTFfFDGF*^B>v(`^@tXfu*+d9s@=Jo4mh%|R*aAf5lm`r~|iFhzj2Sq7y!)tAb
z(~Sa%LjNA#zJdH?1ad=3_a
z6M$EDT+N~HzRSVmY9nC`xvQWs`zr)^5U!I{)`x}KVBI~`2y@^87_bdb?k+evxJ8v_
z0t5sA2Oe4K}en!P~21pKABG*zjRA~NLy{}0;L^Ti}%*n2yz_O1791m12d*T
zQaX13lZlg}z#^cL&#o*xEr85F7WY4VrW;
z8$NT70USGW4VhlWmY~6#y?rGm=2V#p$xmz}N#OD0Vv8(Td;dJ7Jrt0E1|4GLa5AO(
zgz<49IYB=4iWIG`>3R4v1@cP`{v*h;ouT-0HN;tOFt?%Bp5oHck2rSQ>z`M`#b{f|3
zoQQ{W4;T-^hXy0zzzIE7a)Hsty&PGM3Cy&v4Vc{763@b^^Jl*@$K)@dSFrYdC>T4b?G0%($Zj444LU~9FqSZ3Z}
zdLSO|;V{y)fiR-m!av2s4^35val^#Tsv^6zw`_pCa4(#BFRd~Ju1SUBgr
zU#kF(%icbRl8u_k$rI&LQ5OKfD~Jku?M3WqLr3jUw!A-8f$m#sdfx7G
zHtjm^pT69-`P@G~3kkBgzrM!y34ERJ#up3G_q0g5iV*yT_CDH0*r{@gt#N2^=Hd08^sD
zGQY_{*fL`imzl=feRS6@6Wj`Ig)Iki?=lE6VvrB8pCi@*Lpfwd1}lmO8N`hYhxaQ&
zkPW3yQa2t)6OX${fR>M9Y2T|quzy6N+ca7k`kHzA@-^TU|
zF-M&qklYN2zPh;;+%L%%rZ|5$=J#}RYG|I(Bb-)G($FOY?5+V33PK77?Hr@7!VOb4
z{FU?lrKhl)C5xa<2$Fj}5+@8|$qXTU`azsZ-g|CH(!~BI5WccPE~=Yviz1N{7mD*KGsOgY{D@hazuNML?9>AFt6JCWFV(YT?|9rlCS0uKJ&`0mc!W#yF}G-f~F*sOm!f|hxfrm9AMg)v&+Pxn20fbt9NG$hQI9asS{`>06gF+$%X
z8;<3(zfKBc`9JR_YRJi<-luZ~{BCyo^uO*>GdU7b@fV(y{Unru0{Yx-bS6re5|$jT
zem43kTeom6xo0{nQ;y)2uKzbEf5%`*u_j}vV{k$kWfiqrFys6GS(M~Ii
z*D38`oO2n$@pwC>Fzf)7p59jKf9@r#>#cRY!@Fnkd2MfW_&r~>=y_c}ruu%*!_Lyw
zd|XX&=y`lLr9O8)zQqsNfkG1aIo|<9!RPMulwro#^>zH!W8mRoa&WLo#_3+!Y@&0H
z_1syri@$WytdVE3td*}eT`hJQAs@t}3qi?E6BO8u^1x+ZHx@q9;{!pU_n^tc+tsf3
z^l6nSb>!-ntIIca-I$`koxgM<`j-(pGb90WK%g-%ed^R@{j0ZJ&-SHbzou3;0<3qy
z5Gx0Z3jq1l>3BNl^=x8>|N8;p3}n4s7=NfE^mti(*O5SO@iktb?1D-FloRDa;PdPD
zIVOwSKCMs70EQ+FJb>;)OII5nK*{*fy
zoXB)>2_ouBXu3OWWW4M)dI)n8;rUv)t;yzpeBvY};0sXTzP_z_khB%;3lhw~BK~hf
zi=-s#>#}7El?GCr5>-m)to{_(mcX!ivjgsZqNy|IrXUcJ9!8#LABQsRsme-@5P&k9
z+TTnMm;wuy!~;qTdReUxhrtcUH9EbxFFcl
z1Sva|e~Irv2x7x6O>S&7kcfF_Q-7KrNEdFNz_mwKK5iNP(Ydb+=-W+a)q+Q8p_r5y
zRAH`>(yCjrAgiw*AxO)~d_R~pmypNh`@B76=;8Kyx=>H0*Xh1lJS>!m>3Z3VG$43_
zX&aWxWe4^kd8(cx2ZIRcZ|W_GE70QjX0Vv-ZqjOjTXf&IZb}LN$261IUe}F$9Z3if
zw5+8-{hdv?88dHT4Y
z0ZeH3dlZme|23m+ceUMeoDKTE`$KWH!<=L1WsRoC>+o>9`)&MM&+oB#S??22q~G;$
zbY63@c|SZy0x7@^FY`$M+wtw-HkRM}`<{g$`*SbRNk5wlG5h_azm4IK9;esgN9r;P#lI}icBvMU53T|~F
z{@HS#&0Q1Z-o=glp31p53BHRf4%VR8qYtMP-ltk%X3oS%4qZ!fg+o^q*Z*#*?hLiY
zA?@CsZK~y~#gwAbdMhxer2Ksq?w+%3eE;?ENl)3vc!Ka=mN%HC7W=z?)!IKnp>TZx
zk&yk2&MC?<@am#+G1XvmT5AtlO%+8DkKzI~YRo(xepu53QktMH
zA-Djw(WAy2VU6(;=5#PjqnkQu`qZD~K^kbaa)*u$2&rTHrtU)HG@4?67RI~u%x4K6
z-Un33j~^h-X{VtJH+Nt-u~KBr5~YQxQ-Hfo=x2rt%qnm182}L6pQr>mUpJ8~`Z+va
zx8tT*Ju=5Lehv?#`Ivt9=f4cbOX#$r)Mj0m8c}_SujK6%ieyg@#ZACIk;Y1~GLiEJi7weGJz!8%*Y-&xzg%&NXmIm`430%L@{#*N+TB*|yvu!i7q6#OojI>qRJ
z1ZHCSN6R4!B5Cm;U+^(TbEBru;w(pA@w8)ITAHZyN0UCo;SCacxA8RpT5tL_anIB8
z`F1?h{jgW_+jspeOcCSj_!h`Q07$(qyi>&BdtQ&O+iQnzuf9KR
zaXejn;2rY3yArIt53j$w5v)9u*HbhCz;?Y{d)|)D8M+>iXzWe_$mZ{#R~!by`aCaB
zTZz{MJhj)=n>%aTHT#EN5{S9{4i^Wvg#?|?SMMV+oo)w&K+jvdZgM%Cu5W?+v*pj*
zUe}v}kcfomJ$LgH4Ba<-41Qmcx-{r($?JRe-7B_-GA9+sjS;(
zF(UcYEcn%a$hFd@0$L$o*2|!mTNPG(0*$2YKrq&4Z$=kk4VfvF2+iB9Un+-XWGR>*i)XC-&Tp<#i^8<@B>SJYH$LBhJ|G@ab{t~>h(po6z
z7D7&9=gWEKv@1))n`cvIuo8{}>#-=1>Dog(Jaqd)st{{UOv!alKRJi?fz~5Le}Z{M
zVuaaQx;ATeJ#_jD%QlNyqdHbd38RnNmu1yAO9`tn1h1p=2>AV0pX7=&SvXv4TVbxP
z;18GS{djNxOTM*)O?kKYE)!M6sMGj9lcVr9L-wY_HP_JEGly85=pntwfNi%6-TSMx
zYE&V6eJVoKCn43tNoAfq%wvItw05#EHFb7k`1g(LA6XsL-gGJyNAc^acqicG+fa^s
z!8oBU75u$Jze?I6rDc_KbTs9b|f9on5Mo`v1E3{X|J*szefxoBZen!G3APklK$*^+E0XhD$q-oR5ac{O7
z;)t>?5D{%Vb@t)p&s}S7>YXXwF6;4wkL4aGoh#`FvpS#w;QHY~5B96#uC@e0Mn&66
z;Onckqu=t|*h~}1bei8N!Yrgv`mgM4qA;C6~I-e9ohtvYkEsinANb#N=1VgB&u>ZU{=p(~$~KaX2LfRS{ZqkeOB&%UPSu
z>v|avJ=MeOp{GuLxz6(4wf0M_ry{SHI!~#)Jxf1`AH&YJBq^B{V4pk6Txb@v{xzmG
zm(Q?A#%Ic2f6}@4{$_2*eg7z7QDjd&(!mR3%&zVKnb)C3j=>7blJ3Wb7`Jry+pd4$
z(+WS&bON-0nB#mG8UJSU_NH448IKz+bCGFti`oX0sYDDfx}*5=ijl|s+0Es#pf@k*
z%Tn$KjKdpFJIaf^747j#Qu&j)xi|Zp6qJ4N`(5iWMaJed%*DTyyFpiqK`(
zUv{D^lY7s5C-1q<%&nELB}@B&E$ToLyQtFUovP9;Y?y2TjauBT9ooK
zPe_uvChF<6S6o*`gc42%3M+d6g18aopP4~Ua~M|?;-`wSK+7D8kndrML-`q3`0Zcu
zdqtZesUlsIOdsm-A@%!V#&iGp7((uX0HAKm_QAOo^)^tgsvKoCNCuVL)VOVE
zlmysjijXZilC^frh*QP8N;f9o_u7_;qEKh9dsO+Da@9d3M=Pulc3aHWvNzIA&jv02
zs;Dhweh0=oO_9}lOb|lULghVECoY_4IPed~Krd%~P@JX@oILb_g^?j7
z+lhLtrxH1KS5TfQ=%XKwnms*oew^SvKa>O*^JfMUAfP^+d8nm%Z2sSQ5#Ec9Z$#Y*2Kiu-q#Cq+
zODMGQ22_2t7r_I`^@c>7bT>lnXpO1=udj>NoSM#>RAXJU&(*$!g)sH-j~H~zx+qsK
z)2WDXNEsuTprh(L(tH0v9ipa*S`Z^=D7hA*U}@PNEbAk=x=^8G)&)*3-MKR~AQwC{
zXD0oevz=I#8ecGGO6*Zlbi7z64;@51UE1Ml9II_1
zj;y5@d#apQx=!2r(UK=%xwu}BGd(0qNs7dSNfI}tL4CzItYi(Hf)thBP@JUOp~3P%
zF^2N6f{{q=F>4f6*C5}B9dWki`!g5}yD^Osr?C~a*QP99oo*Ngx(|ZxYDG$mc4=dH
z5o7yjWownoEHiXN!h~IwVa0Pvuq2WehG}UqnsI~G$d#*FGAw$11tn`dlq|HF*M5CP
zXSevd{3QZ-gNc0Y`d?w;2iv>Bk5H3@gH<|1mdG9@HqtR=a^M(rI4|D#GaAYS6z26r
z(iy`=J~NWPgpt!#3~LbAkwIbbRm}qoKyFpGO2K%Ggnq6x+csZGqYFa@{2|owqdx(2
z>3m&ivu*ICR8?zpG%x<-RmVDzjBT-&aORPS0VpJTCJ8j_XuOhHfF{5K@S#t|g9)o0
zIu&tcr8vLV1n09GHvspo*boX6`LEc_G66oJ_nLtI!?G!er0g_!gC$DM0T`{c%pK`k
zg#a-W+7tr-LnUjI4C<+fsj+*^0_%&9-6;8d$r2U1QtP?RY{m<)66+~DGO5lZ6!=Z0
z{zv&t^OH%&q|IQRypq8>vg@Jdyr^WP$xCR3+0(A27Lk;f(8XSo*yQ4qsEJExoqL0x
z2f1*yA6E$4>#1zBTdo1YqL$1QyzgVQLOyt9_g?)A*phO-EIz$P=%+IG^?6WXI`E;j
z;{fqhnMQ0qt*xCET_H1E4E1UGTU;as((q1R$_Oq2))CX`n%8eRk~>(Ze{4xSSR~ns
zRsb0aEg4pXc9iO&`I-$o-Lv_!7FMTG?Kxs7{~ty}7Sw^Fb#7D4;cRQ3L3@KHHmB9tmo#E7O6}}>cy91&lS5@y%;Qhs+>Fnpmx|~o&}YqtZ#o(V
z`;3Rz*xab^kFU6wQvDo(PKc3(&xB#K$NHA&m2?!m1PF_%Q?c(8cKYm1ngj%2+5B{=vqe?Bs6>7tJ^Z*oFGJ7T>V2UD
zIPjX`o_ZQZOZQqU=p`%&aXW(v+!67}>}IsoV*P|gW`82g%KA>86@pG6=7X
zqIihikS27a4xly?k;mK7?dW8HxnbCUNzJ3U0aNghK3w&u?#6fg-ls(2&qH40LdgZY
z0*L_$cfX+D8H|Zagvc^s4{D;QZLe}sP-Rdm12)~rD<%Ar*0RWeCBU@tj_plEs%f^D
zCw51X+791^mcBrN-+>+%W!9g=v(e3OHdpT%yN)ZR7dc)%n0
zSV?_z0FoCjzm~Wm?Z2LUb8z-+@#8sk(ZtQ&{mK2A%_(qD?&&XgxqONdvfpeWXZqBf
z#k*h+^4(b@cT>%t>Iiv!zdN&hA)|UEJx6)$^G9XmPIfG3CnE%;MKCGVr*4&Iu7>9O
zZ{Qsihft2Zssk^FwAyj)jq0*snBGekI$66Dlj=@Xof7UXJPO*%tbhR=wLe(ZPrej1J4)oS~hr+AfC
z%z2r=UD}Pdg=kDMPR!AG)qdf4(zyRC!XmG;p(O(hFI#|QnU*IQM=OYc!e-m$D{$?C
zv;KIzDsGzcP@y^$qWR%|@uXoHev7oH&9no3?aP(?OQ+~cz3c-3s
zDHnzXN{xzqi&{lby^S(rbsNqKv+V4T&-%4Sj`oy9M1>{RZ$S>~GI2^;lUO7ne$1CO
z^-8rbnEX@8-&P~yY5dZS8}`+G7TB3Ie`D2C&cLR1nn1Qy_yn96EdB)FQa2yP?@Riq
zaA2GZ#SWaIsG^P;b+I;nQUbA*)m7qDfP1TMyAivXhVJUzXCo1M=!9&?GphCKCe0dbR7b09>K!NvXC<6x+f=#rcR=cl6U>1g1D4}Zp%y^auGmSh-QZuaBMZF^M)1Sl
z2i)v~DBHcpzQadvs6|Hv4R6pP^-4!Pl-*6`r|C}c2!)e$vMt9L8#W47-X5}V7dqLq
z+I)N)nhm^=TDKb6yCrMrDPFDM83T2WCtJGUg+-s}32^f#%D&xMNy-pH$I7?hCDayu
z7@G@$UKqV@>I+k^=6Ub-T)YLCb5hJ{mx7mqAP`{wbe;C&njOuLbQm}-DA(5&mnk1_
zGZ*%6%Og+s#~qrn+fyNSy_ab~$#l+F!23sWcnq4W{hL7$M3zS3xxM_)o1<`coN6CJE$
z^!eq4BW1Vqtg`91b1Fhz9)xk6jGKK}Dv7|wB46+IXY)8=suYcG4ue3ZD5l8fy5w#f
z@#Hke7u1VUOTS**dTiL>H@-6mwqPNS-S@-gsl$V*7w;v)`+DWc)PYsw<~H7y+q-;=
z`u8!z`R#?3Gq>H-bLPl^ub0>3`IGZwsoVFy-IgyOu0Sq+^ZGp$JRJyuj3xLm9V1OiuA
z&4;^Jhn5`zEut~&BU3-t{5)6qa?zSfc@Wx4r*7{j?q9BM9^gp%FYw)t^}**V=l*WW
z-dp-{+Vb=EyZJ@VPi>y8BY(y2$``CawT_%xy1DUYArQ>i{l0TqH~YSiJm2$lT2{R4
z$rU4)u8Cb|;JFZ#rS{cLET}3(w>BE12|vVRLR-E)GIjIwdL%%7-Ny2jcrj+q`FR_9
zyX~jfOG$)H%s_ady_m;Z(
zbUya-e)3@dqJ`)7{N1^3XIRva^?hmY{`P8n-};F>a!eBS5f1(N1M*40&X=zvs0${c>b#V&B8V{bP9(fUoyd;f^{}PdTxFA32H62=t5XO6j5PQRQBz_IF_AS(Id
z{DnSZoh1a>+(`N?nP3&(t1JZOD?|LZk2OynJepOMgg)T%HwG;Bjdru~Q40wO8QM#V
z&OA`n#PMEWgnC3)(g4MISJ|A&MwLll^-a{4!qQ7ErjYR|kNd03
z+Zz|K2%wj&9F8)zLL3W}kC?(3H=cg51T4-5j=yl^lX%^nBOG<_yBu&8sJ%U%kp(B0
zkC<3hZYb9IwMI;oH$%mU)IPK0kkvj4hk;fE3ypcKp$0`jQNDy0b;?}V%gR9^GeAlWLA
zh4GhCh4t?!B+&rfu`1t`NP`DJ7sBRBw_X%1jIu39LjQZU=oU*-^;SX-MTffYdE)+6
z`B{@EKLRWL0ojH>NT~Ztr3|;xu9qjCE0ERRvulv5{AEu<(O_c18b7CA5jL5s9-X{F
zc~H>Img84h9gf-ttQKT%U$Tz_E$PnyLdlhDolO6vlfl8Sn}&xad9
zn#hqW-jWNze*wZly%iC2Sr%uEgmH6?cQ_oe2_31ui~gVDsK05JU|ow6Y^-Gu2))T-
zf>{}j{+igUHJU~ymdx5zlQv9ZC`cKSDN96EV$jeuK4~k8WI}&MTm72wxBP=N?MHnm3(yLh-lZe~{94Y4OV$LSOO|rgQOPhl@qHwsQD?5f1B5&QN!Xb%{|=0%w%OETlvv
zQGJD5^GK1(G}5^+!d4r^kYqOzBRZiK@^#xErj8zWJFg%6%&YRl*5SjuY8^2mefZ;a
zBxp;rx}9*Je=Fsu8;y6>t=Bh#(P|sU>Xs%hN4yo+t)s+?tf$((1NwKTK4FL=sEh>e
zQT|;@7Ic%AM{skeV+?^A_|d&(AH#>1$0hyP`nZD)r~>#2CDJF3Lb3mB8f!Gz~8xf
zhv;OX9_1*AtwSmW0L=h%62l_gP##`Ra38MrcPW@ki5S|{(n8bmczX}H&Ny5yUhDsi
zflj56+dA;qg-C)Mor6J^C9y-5_JnJ*Jbk;@dPOH9(~^#1@(#^e4jTEp3z%(UpUJ}V
zaiu$*;xeVQsgz@7Uo(u)b^~FtuuzdP0(AQ(6k=jiowc}I21^_1Zf_;#vpY`1$KOV5
zGRnk_ktAs|9(K5%fzc&!73^<@!J6}d#;uKWX3w&Cab7SpI{-Ho15#uSrJSKew%}Fh
zSGbv2)0o+d;Uz4*!~R-l2&=Bh$0+-eARJt8g!)FS;cm2nsZK~WH-cI@rlpCN;-WUXz)4d(;FXp%Mzey)S7nih>`REimpJrYfyOu^mc
z1q%=ED;88xGfWrKER~QBH->0dLG2gP+yrB`wGfEG%j`*st*$j>b#U{-2^SwvVJsw4
zhpbw9Gyh=zlaD{wWj40
zE=HEUfFK`efghyFW16bta3M*B4L7}l!4yBz%;Xsmq9#iq6KQkur%K*@d2WVBdt`sW
z=K0hKCRo0!V-co^F9$nTD$tdl3C-TCs#&
zMDO!?#o$slsI~5Dv{e~9tCCn`k}B1p)h@RY4K>*EI_Hu`!7Y`XlEva@L6kyuZMsAG
zst$2hxrQV{MPQ-tJXj*mZY3lf&|*ZvQ!>Hm%nW2PZSFEiFtZw+*=@CI8t$C_D=Ezc
z9r?3b{5jZdHz=Y2rR+#-jtN1Hci9vVH`St2+-qsTO
zQ&e%YujNyk&AS_953q0JuC1_1N*xf&95zL@{o@J2s@NKyIj9{Fv{wJaG=Tg7Xq)vk
zvEX&+4G9}*j@RD|TgXs{saQ#Cg#|T`%+U_4nQ8!jK=eZOI*O>YeQRZ6vu_C7L}7U9
zE9G33C4V{>sOwliHCYPVTyaa_wEgkrU>nDrDNKs9+s23aP>!!or92z6ENNKMq5U$s
z>Yr#+(6;8H{ux9kP87fx(_kXrhX2ZMKpdF-1o2GVr
z7d0qVWHeG{+t>aiByB5?pit_WD5)R}!tpJ^%xJ$w4-O8W;O;)lMqr**@k;@-5lgs7
zfYLQMv#mgZvjSNH1j}nGL#W%^*2=20R;E>h^>MW~B^9D)>ndb(AF`^8aQi9;88#t3
z<(~OOS0&UnM6wi!4&T3
z#Rhlnm!ayYJXZ%1L_&?LIkA`INend&e^pF1dKkkxx29(yo7Jaklf-*2DPsUuddoJH
z5a$22#`z}sc+FU$>*HzbXW$s*S4R>3XFpO?sLls}$w&>b#*>v%l;ou+GJ(H4T)py1i`E}dP8n}3&Pr%*HY8b#ef3XEzc^HP
z|Fvf$4MQU}BsM-dnLpL%#W;|egKv_iRgM_mM83R23*J8+P01t^`GpO+rybFXmhV+E
zRD}}J09CX`UfJbeLV&?*hR=J0phhW=~|1~TEDfEa2>46
z0mEAd;B7${n1qCv+6wkiG^lp&nKch@HNpO>PprP*c!?lI7X{cFDk13l<(SbXprwe;
zsKWL@hL2XYZOap0XkzfO*mG+Fs$+?|=u})#G(IEVvt=vwW3#N;Vpw-%#7>*-_PBN{
zb)!eqN@^psW-CaRdQ~3B60Th?HO#d381%kI@-%ilt`y^B9tcZ?UcOhFfRw~)YD2>j
zY2rsNHPVc04JlR{?PQyfYYknCuyc)D?0IMS+XhvpOy3iDM&?PYY#MrA)rItu{7IU=
zZfz`*<9F%T70#uWggh);I-z}52Rxe0f@2LXxJ{PYyE;n-NrkNvFs&s&{tZ|3n%`Ho
z%9R@i8H4rnOPyU1|5^s
zTmtQu7Oo?|kxM`HidVH!`w-H_P&qQm?dCjHJBrN8UBOvYJBTsWE?Jf3o8Es~uWor4
zq_b~w)T;1oou3R(-h807xjvP-3QdHkOKE5{$rSM~$`!m;=oV;JWZQ()tTC_-s$TxP
zVtOy~Nyyhu`H)6O75j009-z
z0SKtb&A$Tb6Siu9uHLz))uVS5Hpoo3zR+cDGxpEAZ8;YjPsaOr{nKmt2g8%NM!{}0dupf;zyVl%P6tWq
zGuVr|v}xs{)w{*OS;kM%c%r&V_aXqyoTQP0rWp=L>cNp(U}U&>)*#!~98CyGZbY;hCpKdBp@l8G-0$-)~Jqca=W+Pm;b2vx$?*LXTw#~ZfCV|E3j
zRUOwcsS6G3g@jW69O36-HC+KFxN*B(u$uZ&xl)t7y}NxU@9?``(>1AfDF6He+=oHFh7Oe6$`D3;chyPczicd6#
zuoOo~qH9(^hH!d!ea^l04@`3;t8R9ZLfj01QX?|CIE%Y%^aRM}`ummu>Vu=Pxs?$V
zUyoGL)V9fv;s6YoY6gXkc$Q0Ecvd(*Stg59U89Q(Pc&o7
zfc=rOe3%#*rG_fLR@Om%bcTp_S?<#c9sm?^YdaJ{7z*@Wia(V@OF&}(8Ox0Y?{>ek
zdrG(j$51SazEza<0TT|W?ra2*oFejL7Sw&a#1`gdC)6EdSTz6@Q!NyOA8bk_&{2Ne
zkzFMjLJK^X)l5+H_NCwA`8A+Sn@~Jf*9W~1BhCD#OK*WW$J*4X9W$=)MBQ*Zt_d!<
ziPM76DthUMFSbQ^h6qxGwZp970>3^|)6ecaD?!64y5{~XDcwL7K`WJxC&SPsjtW&E
zu9Kd$1vo|2K68A1B(_k7Fs(wDk|+=*p$dz=wDmG;eSwOx4fvXZ^qp|-E_0QJsM{x4
zEvt~SaIB{AA1Z{n-GCX*!rmP7xHFL0U(dzpei_O5w_2{|335u|w=_ax0;s?l$N)i7
zq$htLkzG}}2Bzi!e-0AKX^=g6#NjfpY&AsS!Kd0cfn-mJB|#a1|b5p7xURaJjG^=aMHTBBI}H?HiO
z;J2s;eVFio^)v&*c=K?JuHYig$Liwp#g77BiGi{uOQ3!O)RM5>@WM2}vE-MYR{5EJi_h8{vPBN`J&M!uVr5>AhnS
zxdqS?pQYxJYy1`jy$Yg?K8=|@fj{_gMrNy@E)^j3;13{OQpa8uWPu<(B&mh!|9$WZ
z1*RXD`+!W@p_3^c+q
zba*7}6MxoYKxCuBz5snMW;3F2R&>i>I@tV>*&^@9{uO12@dhT=`w@vlMS>ArfNE|(
z3&G}Fyzo+9fnGxkMmb2N+H6PVAQqgbOqJe!{2YElftUb
zB@a@du8J~lEBgdY)Y96;mP=R0@q(&71^;ID3Ll@E9`q$uhl}{KdiQ~&LZPX+GCR7Ob@{VMCN*BxILao?ya+`U
zbK|@e46nj^?P^m+aqA|D=Ev{EV5uLn5LrH=-X5@HDd!Q#pwJLGzx>s
z@+!J>;bB*(EtVQ|tr=TLSoo5*m_2OlI2hOlr~n9+lFH=yovjnIf*;lqaIpJ-l#jg!
zTobQ|B@p4+gO8CTrlhjd+f!kC`!|ikx8KZq`)NRC20)ow9wuRR+Edbs*;r?F5=d$|
zF;Ed3!z0*n*bLC)9xC+}Uzigf34R%mPO+?M=usDb05Di`3*
zVi&a?GvD4=O|9Y<`S+*J(NOC*UvqLfeU;$UJeW$*Y7n7{R@6sFwa)`=po(D#q@@I-
zO&yMfXB-5zfp|g1{;Uvnw1!ih=NO+Z*LZE$v@ocLRl^omK~mQ=O<+0n(`aJ-GH5a*
ziQSs3#p{amz3lVoLB
zTn|ZKABczav$$PP4H{gH@q!R30$18KUfb+b%uJ)A-F(9*`WLDq*k77&u*Xr8FT0tQ
zgFJs)whShAs_SrdXl2w3%~RPW{F#0%uIJCS~1uD}c;
zg~vZlxRxX2joQPN;m`;vxELwmYapk<?;SLn)-Vd|KPp%5Y}uTn=}
z#*mGq6-`UiV=
zTAt!7lbg+#@vm&O&zkZ-8f#C%@OeJgMWp^rA1MgmMcUE8e_aRSvRc%c7&9>|l
zTD6e(wzu~UU?@srf)BHCz_KN}k^&5-Q
zbmpthkeh!p)tChGa9T{vU*gr@|C1{`6EGaaHZ0Sfur{+J)cNn{q*F7u-9|gQpN}73
zW~1BTx`E&dpDz!d+hJ%CA*bT%YH7~tGgmKMdFc4@wjM_;<2Nl|o}^CiV!==M$Hid>
z&C8FMLie1(O<(?xSw=!%F1gWG!_WN>QMUJ*H;)hZFT_Qscl!C~w${V;%Vf^QLnqq!
zgI?+SVek5z%7bF)W9M71VZ3X1B+v|z{YO-{Cu=m=+N!ON;kT?}Gd&rNFKrj1&Vy~!o@gb-6
z-NK8H5k3fGhiI--z%Dkn_5JXn{PleIp^bghl6YOKs23Rr9Db=S6Y+F?*TW0#(|f~*
zJM**V`Kk#$h$!x^j^B4B0y6eur4kf#_FHVsYHXwW?UN~SOoZzZeOr_r4UE9#p9~ML
zra2FzY)Vcis%4WJTMPP|9U!=3nmg!RRRPDn0_bHJzj&&mXDzU4%#711Vvr_#qih9d
zkb&Htg))cEl(X8pYPUIdK<90AZUoCYT#NxTi-B#ol1$hJk2VN{d`8+bu$9R;O7k$I>5g}^>%cI{(RK@p+Ng;M@-^`+18$I*yp%oa2i>|<9Vpv)1VJ9RGd7wB
z=|+GZAfD9#!dq=mE^U{y8}TG#OP@-Bba2j)1EgQX7nQHu6D(+KJEJQ7_op#};=$hH
zM8HaBrWUPx4M|SddI={v_sEq%1#T0rzvVjKMtb5q!tWyNp@2+s_c{ClaO!;Y4k*FD
z9iY`cl(VeghlCGjC%5X*eTBUu(^-wK$uI;+7b&e_3v?rz?aS5Y-0X4)5nj(d+#Wx^
z1G_%f){G2PrQibh-ySUeGzcE_8U|6Z1eWX&*GcT&+I4VK&GQKDT(3T=o1tJfV>lU~
zDnF4ZzQ1Ah=Aij?Z352)=ktgC0CW46R!ZQor@n5UzH4uuUctiB1kVc}dBa81<0y8Q
zmpJf*Q`P!T{#ZyKlDvYw3o`WD`8!=!t2R>pbhRhHc`jf77{yKx8#sj-?kX%~`
z;*$8*XE85tjkgY7OLo~ygrNNy48xWd)d7ev_|{uoL;VZ^^)BJ_2Q7@CjAcgb9$=dz
ziCA!3qkJe^1{081n<0p0n*P0X9mxIMciv#407b+LNi<>%?kfL_1v(+iUdaW%E|Ooz
z0o8QlJ(+v%hN+8~qoaHaO1>(@s67UijdR^>+rjuJvu57)ETN(c!7RdW1L)%V5CBC3b3n;=qZ&UtrLm5DD$uWRRVl9{
zfD7iMvUwKuRiTXu@o~XHuQXoyKvOh3Ca8seZr#jMX-D-tsw&6|;Y+oYjs7undguy;
zC{U{{9#EZMDq5WDGvQZ3l<89_5PT^dh$@s4UmtEFr$``9bL;)}+cvN`tSJIiEn`~6
z0Ls?e;24F?>!uetXb=mb+!ww_YL21dKNa^JnIv5b&h085V!>AYVvybC6L_I^{V}pu
zbwL{k^F&@u>KCE(2L(*p7#z%4x1=GIHdOH5OVN
zD~CX6&5>l$*PmqOmO>=CI12|`v5bLWW0!t7gT|Ud67#QKn(iAX+(?DG!=GXk%sMX^
z5WY7p=V;37voib9sR@IiqUXT|CgJMUr!ktyA1orHg2y}0*6bv85(5iBHERS8XNgHm
z*+k6pq*J(IkQ294BXF3fuURAop%rmG6K8VWpRK!H2%R15ovn0heK&s$UjN7i
z^n*i=kJUZGnTGBj#E&x=8vv0YyKQX8r=7zs++4`{7N1^Q%C}HL*B303xF&E^PAT%{
zK@v^x8*7ur^c^$`kO+HCBof)zb;krv=rN?JNWl1LBB3aX9-9_E^;*g~SD55=S8eiw
z;hng6o()_0Web$yXS<2hpp)5Ar-Ez6Ja0%jKjm5OfjyVsw+ps|moo|7Ap#zOh
zvCdQnSqlE~a+1Y&HHD~19}LG>_PboVCN(LJ*UH9Vo0&wHR`dae0Cu|E_;fdp)#{in
zivJ3LePePh6lF`kcrGVO+fj%yZD~}m%p-k=@C+x?)W9ciGkRV@SBDGkRhZ1L_G#WK
zyr~*%l6Ovo)cDuF9BP2jhWE&;q>|3KB8=X7HmQr%A*=k^P3hxN`#lkY9s_R+$Q=+8
zXNr2;4E_r~QWHjd3_2F9V|S*kNrgR)8$Hl4DH(d?k>Pb;JbR(xO;oh*b6n3xWq^P$>sTJTDMG~N5r{fzhb|N
zG?Fh%Bofl9xL(%pd%VzAa50#->4W4JAM
zhIp~-PmQKVNf(>fs5O5ea(qnfGYvsesf$2%>aug2E=8g{LF%Y@!VkU!44<*Pd6qW=
zFTO8a*=o`B=J~^8Yb!j#A$K&wVd%Mov+vTGq~hwk?Wcv?M%IUJ)XuwsAcf?Ob4^&{
zz9qBnz_DYd#Ia$U)QmNrcqEGL{=|Yu3yJtQ;e-*Ggs}9A-d1k;gn5>j!(GRg5JOUtew_-kNs9tztqDg=EeUqftqTXkj4^li1jX$=
zSq}Xo^>U??)k>ISHvYJHH4TMye6+ep+plVrz}%Et=)0o=s)bv=Z244YK>)XxdwCTQ
zdR(?<-x)8J=+T)uG%q!!p9_$pgiXKWQmviHhTomRBQ}0nsn?mVX)wu1NH8z-{5byc
zv3ZH;#>gZyQFOZ7&V4>>!kxt+gOzInqL+#}dTrRD9ZNZF`I}(}PozqvMm|NHd<6I8
zGK%t;Bxh`Z`|g-a{-BiE_(X9qvY#gg#m(*fxu?4
zf+3y|jhR>{<)B->6P1#+PN?>mUIBBqpAMJumU~R~$?ylnv1MDfsZzFthk)kPy8%uj
zGQrWsLH7wR*=m-gV0#yJ74neJ+!--5!bFzvpO>Sea|^dGETP+~l9$357VfRfPlhkw
zIPJ*e+pmsOxV877D=32yV-x+J;thrTKRCZ&+946ywy^|ZSU=4zX|z6eIKqE4nhIEMm<+$)jYC>
zO(H1YO6SEvWWG&rUx71yxsTnWy7gZat1;m94^uhQGu9Y`DqP!w*_Ea$Xy&&x
z(gM7M+1KF%Ib_J+VJNmjzx=7Vw_L6Cx;il`LiqCed-s6|a|Qd;zj%20dJyp2>1V#R
zy~4-PbX{?;+YoHq9ewv%!&f|f^j`$(?+6c-BIB(F71N5jc|nM@g<@tm0tKum9qPOn
zf9%}uj&nLuz6t$G@1;MSm_jnIe!m_q)32<2~`pV?$=wy*oF5XP*&&R@H8
zWuN)QD155pHGta)0QT+im~*1H3S?je|Da8F8|RCExqa?8t{d4x{P2Pa>94~o-+F}c
z!@L53bP{ua+mJHN-!H?WN4a`SI5toIg`EUCjmB5PhTXjfQVX|@+z}tMl?MF=@vx!B
z{HtjA`-FWIhJT0LEV4EhlrD{cCdL)ive^`#`3MT`cfoI<=fR!A`PJD}Z#JM`&jeuE
zEI~Hwg6sf$_Hshrq-4GrPy^gDZPgvoz!i?
zehF~oK~SD3?yMkoQ~|M}o5@enH-Y&^SNY!%t~lvnVd+P0F_69WKx3JBtr=Ou{RE5#
z#}xgReNjU_47}5_=I<4fz*LzCC-o5b5zestJ~@ZXFrfTH<3({V4?|x=}T|nzJ(fTs0)4DE1zUKV5g{`6rNqzO_JHby7RUs1CXo6^UR8uKY1vLzm
zAsI3jROmhR&UbG=xBK3UrzSzZwq^u9h(-0*(AD16_uf~|MZXV~MyiTR0>#zP#?{u|
z-iz`3)b-tayUvfx&+}43#KBHM-=%W}b@T1*>+$>0+2h^u)5X|ELf6ODLG{qsRwzCX
zH?9pk#i#qHkNe%hUE9|NzvGV!7c}tY)7SHlZBO&Dd
zVCe8y;J91lPw^)~HDk{v@nc`VFT+5vk)@lrzbKk>zMWb*y12SpP44xkJ03KAx_c4Y
z{^YNsGCkXZ1~k%|p3`{i8>p#f?ylG!FM40)T>L~H5`=xjk09(O8R|nkpY+r9dsk(o
z^yAYN#&X-VzPyG%X+2-vd%0iKYhT~pjReudce~usR^J|XGsuphe3$iGzV!8;`|!Dc
z+P>O7Y4Ur0eeXp`fWiJewr~2paP?|@l^8n2Clj2?+l21^cz+n(o|R^MIN%vnA->)u
zMDW9mgO@=0{;QHcLWlAC=xKGm^}MK6#i{9a@qKkRlyh;v^siJeTjY$@{ncu3?CJW)
zdnl?WQb!LM+t>YE^z!=l#Fz1aOw8f6`SW!!FN@1N`9K&i!j(W#FUVcOz}Ls+_4wMk
zDYZ{zd2Z@^hw0|`kCf;=Io!0<7>+CCR}K_)T%}`cF#e0xuFV?4{{HtNW89t;5I;en?cu#KZ&KWB1H2TIrzh&wI-N5QV!ac#?LMvzM-cIfjV&hriM6_!2-<)Wbmc@VanQfz_7p2LV@3tfxjG%gOt7
z`|op1ScMY4`zdBA7ER#tfl^Y(f{rEM@~wn%66;wAs^!bukLxkz@1bk3PSu*Iu#pRZ
zw-h)qN)M&}Fn=C;9DuC<`nw&-13@#;paw<-Q#9GqAdCya5=^mYqGE1vIlMZ0Ko={f
zVt9dg>W|d20?E$tw_aElcWya18Pwvf>Wg>egJAON?nPB;r5u$)^Dze4q+vj?XZ!m4Tju22i&r}vyRjMl&E-~p?-(V)o-
zjmSV=^fB&2?C6I;ekXBWyNcPFH2B0n7oDQzad(JmV&J9NRr(k50M!7Zz=JxL0
zh2QVAb`_{ufzC?tTuKF6xYXU2ZB+nxS)cy>?-?D|hx02VuvX(!Yf>5*M+3rG;;hQF
zXVM|H`2k&6i8Ge0az!j8j_Qx_j|<0a>ZB^}IEa~QJAJ6IsVHdS!A916IVsz^x6Y&~
z0$#I0cTW4E4FuCbbcZkS(G)Iu$OvM%2@N=gD-zt)a$$v^INkS`zcM8>R^gC?3L4k5
z>dBC=`Zza=TF({Tquaq$BQFmke~fwNX}5nWbOerz&qtx!@HYURl+xSqFvHJJSkIyI
z*->B@mo{1cgz&?)Z#2xSni(+9f_;So#O71=VcJVHpNKgICCzfhq${Xj4~_<}{v#dr
zsLNKXp077N=5Fzb!w0|HWq9IWWVJSBS`z)!a-IjuY0k9e18fQQ|@nB
zjA@(bFae}$1lV75GGu|ZBf>NFjUUF;)WPDprMY&b1T;8mGmmiPwQxb=1_j;r+u*
zB2+27NW7T=1e+`XqZ2qOw!m=%sdIXS(VbecnddSdgCod{Nx9o_lOY;1&KzzCCxKVebz9yG+k^4I|(DDibWSm+!DQ6
zKMWzRvOXzRezjZqEbC+vPtip2z?~+P?p0`@IzGDgt$mI5lyj1}AfyskX$o}pO+tagui8s!V{fixFDH!3xN=#&mI)67hIKi4QeR;*X*
zOt%V~Q6<(zOGdIZG6?yZWX0ZB_xEmPH3AEeRE>R4nidySA
zsO<)@`%~zfjn>OU*d?kZ(=hr83|e@FeAbdN7XZEK7|$M@vfv~PIvxeLh8GXB?Y{fl
zP0L4t^AA2~0OJTJ2FbJuiHXvhucCT_)x|bdXrtix+v15b{xU`J<-eH(oVY$!fcSFK
zDAvH}L>2aZC8{(n9G|KMQu(at-V8k4-BCB-*JR_1fnC=3I9|$o7}Vn|aFt4?QN)mr
z4NEeX)rYW8SV9{;4{?c^$>pWphKb-LDr=ZM{pG_=oofJSp%PN&m?sS)PmW9817WSo
z>)Edz+!OancR>q(0G*&Qs>jG#yiKa6{TsSIUv6=RwHSn~fp8~K0AJq&U+Q~6IFCzrWvBmp9U*(8(B+BVn!jn^e
z92sp5C`c+rA3sx(%E?M$XRw}YJBgo}hRxukg&d_5w_ss5&=raU6GDsMbB*t~{^MSZDS5AU>dFjS5x
z^d;!&AJygV*@()ean43E-Bm+!GSV%m3=y=15vSGn(*7JMDcH@WQi{L5MO89%Y|jQq
z030Nd)h3v5<`PKZPgBv>GO;5jY;rUXOth4VLJvZ8>ngr5@NC1F)#x*?^?mi)&4iWv
zyK-jbYeLupRl@_L(eE0XqXWOJv>+cgzMCkKW;oV5m=EgbpLJt%AZSQ@#S-d90zwgs
z17yj{VR4~Huu>wH1YJaT?~<*oTKs|sQhNMtXXa5RwTI20VuWGJ*N@|O3V2gVttohV
zlqqSP$m7QpWtpbWQQ9B@wNvywQ7DwMx#JH&s&KkiNH;!_BjlO24I81E^
zOHP%a2`DHptsafomjC)m`>!pz&oAAUFdgk}ug)A=hwKf7rl(-xHcde=u{UqhRc1{a
zvUSstONyR6BOZ1&*`eLP1_*GZQSnRI+L$%)P8|QR9V9J)QcZ9e%x`>_f{eYjpv}R_
zWaZ>3Ga1Y^wJ}NGJNj=(RdNSO4s@++U@~d#@MTmB!<8WPoYv9)kU7Riwq01t!54kdh8RDEn20rupa(RC>aypfv{Lw#)
zge1EkfDMR0I4ngNg0^8+nK}4cD61jP6R(29`yYy*Fw5q#Wr=1evc@n9gLvk;iC=5<
zNS?U25WINJTb82ml)V;&PYJzc;Kr50(-ZQ$(&CpP2{-k8o{;>6*`^*hDkD#r1svM{
zt!Hp>?oP^OjW?ZtiVC(60CEdiu}jc5&nU8D3_&k>)U`TPL_fs
zOkOQiyyD6=ll*x*bCE|;_<9Y9Rx#TXN;M%%eL?44zfO{Um$7hkp`Tv6F)s>LLaj|c
z$MW9uCK&bliJ$iS@M6&FSwlSurLX4N@e*>dw;U}v%(Q(TW%NgqfzV`tr$K$hA0Q36
zxq_;~xnqm{zHeK@u?<<6$@YGX9M972KvD>~SgkpEI&nCNOP5a^Al!K9kF!bN!c0?=
z_;2>2LRR)7ysX$o%UsV5Yl&NY4wOg}hSQBPT+!k?`lvC)wHF~0F_dxsLH;(}<(O{u
zh1NW)=94bDpfEllGRgB&+V1U!yl1o9Y^PzN?TT#UY|1
zlGpFm$!y!`zPFvN#Ud?bNT~4
z6KP&2v#wwe9WA9I)dEd?d#FCE%S9H)!rVDLsmlzBobR(1>RNm(7bE
z86Ew7c&Jw+Mb7x%;Xa4$z;Y8?vL*>OAX7pGErxb)=Ic;YTmx1s$1bmaQm$aUY#)J>
z-2f*Ow?!>KgVNgflVDxx1`nJAWhGo~
zOB9{;;PltnU=As}g=CVnk
z>ecMHrF8h9kVgAQN$-D;eVYkpMEo1cSiM#fFKzkXd|)zHvY`Ny#~N5
z9&TPi4hlMuo(HEWe8RL-kM893%{-go|FZM`Qh@@eAHR;cMLd;t*#&E%&V1X{cIN^W
z4dfW*R;Acdn)~n_*RGhJe?0F)bHCGmZzS4H0w8c#8|R$G-@{LzzM@$Eh|-AT3KgZ8
zj)HxYNK0Yj=P<*vb1wA@p>i3*`ePMxWNNLTCt!-tQXTl#7j*ogx)Udzwo05Rb%@7;
zG447vU~3LNYt3mLY7Hd)S@`N=%<3A1Y&7sqAkl#MLZMdSBy=vLl02O?X>@z)Tr}Ls
zoVxNyg{3wPbvpO(6c8a@-jh`LPEGLKywqct%7~~{0c3whh@JJD1w%_8ONxJPE-(yJ
zjkX%@freJotvNnZlJy%p$gsXA_|UsMKk~w3`|#qX6x{{a4_^o1D9}&*$mz97VL~IC
z6;)VEIV}F}PFx5Zg<`b$Jc+iBwY1CMv;q_cSP5Ff{YcY=TCWC@aRhkagsuBN$OT!c
z`pqmay9MU1GC@_SXRXvPUSL-cx8cH+G_oK)jx`-+6v;AAI#v0_|rz~{0
zyl~hJ7k)pp+ziVp%cMg>4>SpCln$QZ)$_Q@TOG>eEx#@g8d99GxQu14Jvfc9h
z;sP89xhZ$biT|Bqqtzqfq>x6(N98XJncT;pl9F*4swbohviJ?cZD_Sv$ds4Y-cOj<
z&dOQ}M*+$JfU4_8czyOtI+>$;{QmZSz~L`wzF8z&`uNOO0z8CjpRdaRQ(SGy@%v?#
zH?rX{g%tG)>*}IqR149_Pnd(3>0h#iLs^Y=_mw~9&G-3a%2-F^@QWL6rU1(c-ICZr
z9E|vlYWT}9a&Ulqd)xVHC+a=iGNzYSgpw2aZgQ0ZHHDEd(=*5w9_9K2F{}Co3VLpc
zY)Yfy(&l8n!v(nc=%DH`GKS>A{qkVA*K`N7^g7DwH5Dxhe|$AX+Er#TNB46%p4t=t
zB<>c?|I{gPuBhRr=`0d3I+{QEPRll#oh^_cb@6+gND~s+H{DDnY&Ir6{{)9QY~-n!
zhEp&g4!uJHSLm0fIe&4Yhb$R+?#Ni^_vR776vpRoMvXGdDb_od0>*6E3ry{mr_XC`|ikuLIxG18zgUn*zK8=BjI#6%AQFYnl;tqh}I2x~m
zfX%*2V6`bhhzoPUGEsYu=a*ep6P@|Zl@qFTV_@9Il&ZMaX&_A@pO>Iv8Wc(Q5{;<*
zb@_s%A$11=qAVAaq-FDCBx)Lpq)1_`*tN5=dL!2s=xm{CSWDKHG2dx11doBCeagd#
zdqWlf4qSLYB`)xw#*JYjT_y&t*vYcYZksVkzB?FH2z|oTFZ>;*jdw<_tDw8-vLKJ?
z?ik*~e}|k;VsK8{7=f}Vmnf=LJQrD#_V%&aiY!flhW$;UMW)sdrR18HInm$ot^8>#
zFu2E9REq}}-MZr}(Q>6Kx2zQQC-1?t`srP}$n5PZdQ`?3F^BEh@>$1_k9(+N%7}3J
zl<7h3E3-Q_j|2>=bXs6)uk6Vd>^d?9n*|e+>PE<;`~^HywwGe{lLKOWBS+d>5R?9y
zhSGi{z1L9*1$Uhoe{h(m{geO5h4U*6%%nXAMeYH;96ir^Fn7;Sai^eb_)uM3tpt@w
zT?SDsB&&wbXY-iFUWywHkQTqxGZ_SUm`Ww}`MC&Hjl(rag2@M5v}}hw!cFv5r?gWz
z7kob6K+EuvvHb`Il#GT=Q$l#QhPFFz7eOT_O*SG1+l&eI88WpnPRvRZOJy3icJ2sB
zANIWH>PFhB6&+$?Pt44YsO-*#!8%J`@ycIjJ~G72)=3X*h0ZAt(36I(r9Z0}
znZ(x1zl`t~h70>Re^Mg?JXhGz1huLv#b4?ick@b&O7zak{LQR|pHDQk;`)uOg~QEO
zexaDV23JFv@fa=t^34+FHrv-^YS7m!NV@VW@psCj=TZ}%52h=~GYD(M7aGtm8Z3F6
z`XQwioLoPu&rL*Q=Hz@_-|<6Jz#PdfgTcK#fiB8el1|*)o%>8SQvmlf*`?%GuwETb
zP$jc`+A?EDE?(^?OOBKrut_~ozcYt=0wXlJ3+^Je-H-|RG%K!?z7qoddxnTMf*oNa
zzP63_r2oq@M&1Si=_gR3qvr+Sf6WV+$2n&(km)S%;gyEVZ}5gG-g^%GDGB+h1yLx;
z)~GtH=4euoUc11Kf>Y`<%wpRjBls-vqrVJL?!&W_si
z7)5(oZ79qWO7m~h3)HVi)RAI0>y2eM#x4em8~dgFjP2KnuAiykpTr2L&niS7FBfL3
zlMXZ|qo{tcv=3&&Z@0uK%CuB7T}
zvm-4huCyg`FPfw1TliD4dr}U2kOmgF_)@FI1t$wD7oWu@#phqxzVhFTStH76erHSj
zLTmC3IK{gI4|`mLueD8ij64{8v$})q-5Goe6+5AsFEIX|^okBONgj6qaM6@Li>KDHKGSY(Bk62@#%n(jy%5(Vyw$dz=zV|hR+cy2{)QRa7xp}($+Z1skNEu=cV>Y%esne|m>9}SzR
zAr#T%j~!EYGS1K%XR79mz8i|V5}-oNi^lyH)uFt7u!@TurKCyVAy>&1TnvIxcD~$+
z98Sm1pOQr7WCu^5o?loTGPk-KTSZYXii6Gianw$_rbN?Us6wC%FG+O?
z)Ki|p!>E!KH#^LL;{!B=s;H(q+Tb-st!j_`9iSU0xTqWO^#Z=?yNNzfRTB9(0!g_<
z532Qe7l%>c7|2x>xq>b
zqv&yIjIPh^Okg%v03y>jm3XkP&sSoIt7FIwYE&Ui9f|T-QK~`j)|vpEx=qj^_Pr(0
z%t@p;asFt}$ZZXdIg2%!vRVTVj96w{@@$K>8XbeE)!!2u1Lb;VSMqZdh?Hk?FY#1q
zw{?g_vor9KV-YZsf%!fM(H(A9P&jQ8D;nuFnF95H1oJF
zwBxM?fI&iR_QY{F8>bc4(yCX@Tyd)@|6I!rl(rstS@sm08f|X3r681%^%Y!c^LuP{
z1TE!U4+jwEZCHeU9nQ!m34^Z8sIC^AWUYigb|gA2A%ZB111Vw=(lCKm
z1Wz!?!plLbs50)EE@Qf60a%TYa#vFJ<4=|zBvk8+oZL^gI$GH-bCZBws8rn&B
z3rAB>uy_PgIK%HKrfXvPNaJsRrdkGjQ4#sn0zCL@WkEFuD=LdUs70Zi)~ZkqGjd9z
zVpd61Occc1JUIxy$0(Frh?M$=Owr_imBMF-3!9rKicPen}ma!{t5m|{+mXRliSaz!GMT;7;{YD&W;%aKN#q$9J^RFi^u%d`?i3Bq5&Bn0_Iy4
z^QiW2{?}{wkK7U}YRM?<2_i?s*YDEdd6#WISW|%vZa9-EE8#d0GRE;(24zU$o)V1(UX@&_m$~uhv4-6o|9tz@O8mhO
zpXN>&8*UJnkQn$DcooLFdohv5yZu%^(O@f~BF{aV8}t#woPiba+p&YAEtjGEy5BA&
zD`nI&If0?QuPaJ`svjOKFTavdC!18vPtYn&LK7T;cgkiVcM{$13@k`LM1M)|{2w$$YtXBp=P?H(i&S(JYR#Ou6wBbngW2C^CV#`D`!d?8VW&=E>
zEaEylx-GSe8x5^mRDnC55m1)>J5a@2K5MGL73JIapa{@
zLkK8)^srsO7729z%92j$|D9ADwzQnGL5?PaV?VYJdnw5hlOG7zk{|Iwb@+X6?86kg
zrz-yAZ0`<}XC{MmZL(Wz07|+3=Q<}*i8`uu`bH;=?}+dikq{gCuWS|~gEnKw>>n>O
zc+9_BWua2#;U)d3DQ&is!gegtqxYSC{1@&-!R@e%q|i0y8Dq1pstX{Dy^*^$mn8#h
z5g5ZtJ#n&{Lq(JM*|~97V}K%Pm_dpeZz<;t(}oV=A9OfPJWm86rNaw?g%S{I58JBy
z{7fjP65sToz|q>KoQr$0PfmT5VJ+6SwJsknU(x8t);GpVMO2BBSmsBDe}+M-oO{+7
z1-AYA##<;^V1^J~sNo_SZcyZGQNU`N%!+Fv3qE33v6Tfkyw8!#VM=nNXID$ms{EsC7xggd
z!7z%v=QB}4;BY?`0SHZa0armqS5s16o<6LG2(007Qf?{-kYw^M@ubX!5m0KzN*FB(
zCcU1?!65RCR$w&&SaI-Y-{bCd9={*FFxXhnxY3r%p#Q~@$u90tWVG^W3^;0q7u$p<
zI)2r(C=*e2kcq^YBb_??yGAhOABTe*7PBJcJogO&-{<|wppmzJb@t)3^2P7t3paIc
ztN7a6JO6O;zTG6~)AVWT)#>H*zTN^T*ck{xTpdL8Ti);iJ!AB9e;mxQ{d_2zw|RW1
z+`oME`#A0Wd>5QU#T}Sk5*CPLX-5y=HdB0S8eP-;`^d0^HB$t{rylt=gS#*?r
zJ~iGH`B8t|7o9vHb$q_NecHV*e$}$>COF@Cx!Kl@x3Q5$7T?D8aglMwsieUexw-an
ztaE*_{pu<7(&T53kV8OJ(R2jwca@EW=-b}m`47o6esO`|;p|T0C%ER*;x|RSN#Kj;
zyDrFg5mO`~ibVu&@V>u$;oj)?^m?_hy1srNsT$NSLf
zyY>a#dAE3dU$3zH{>QD8w`21jzoP|TBA6xs=jo)$>+zr^!uG`1g>V|m9e2Hq%RM=m
zb3U#>Xrrs2l{2Fohgh*>4|rfxqqI>wmJ#*t{phg1a=#J@ddo{H!2VNV4?aD?y
z`MGodczU4v@;ERyQ>Eo-I^ld8QjvpI@g@VlOype!u1&nzC2qS(E5F{gDK7j0OL5^0
z6)m?DIeE{92R}Q^@$w;&C)N&dq;P=Ghl~z=PASW$iEu!_k8nh{eEqYD;Q~_dg*>5+
z+*YKy8`>ZyrHL7F(jEkVwiksT??h$RHw?p}EzQe{8qkMWL7D81D5!xg?#Z5QfctBk
z1Z8?kmMojO9c}VOj{OxoJ#a75n)*VM?1klNZsF;QfaR>|(OyC%D$7UFxHZz(5oIyl
z%*T+MQ=l#!47)7zyXX71jD)gS#u4QsK}o}Am}B8sS=V+WE?$k{A?L*g(&W?QmC38@
zbsC54^-5fh)V!+hMi`IYn(Pq?!;xt=T3S;Rc+RQ!w|Qa)_ML3uwwDaRl5nKinOSc(
z4qJ&m9X4~faoN&v*i4>26E6glL&{lG%2t2EzIZexJ)XM+*A!q>p%>=zr?nOOM)4AX
zv%6$cml0ReE-J$6?}cAr%%>{n&BsuAM|M?v+1p-soH!1fU@CAnHzHWD!njFSrxqSx
z0HIhy1jN?akB3;vB?!c#aji8_h+0h9*NoFpQ788&12^v=WU`P)1MRDNKg3f|@0Tk`
z1-`N9-Eo3wJWjjo%f{EiShrP1y9&%j^_*DFoW8`*BY3nojjd0yx312(tkqB2u#lop
zizyYh1S~c&(`hL%wWWPFL&|8msc(o9IJs`z(S5?C40bs2Z#>HW+kDDM>itjEFu}%s
zgej^dzPuc9EW#__TSas#tJ@pzhz_92Lq)xrHWpTo!9UQ
z8Xn^~1RKy}wy}(nKwhzpWd_Yr#?a%9xnsWfFhToY3ejK&gQF3t%^C--`*4S^h?77-
zzt@I&zmH0@F`z(5ZL!MbPaU>CV%q7Tk~dlO9lVH%>3gzrF-H~B1N?dTzokVbvWQ|NDsRyasO@)GoDf{tLuBPGNdfg*(p?Ng!0gpm3|
ze?2VDof{q|Fw01^qufO5jO8DEK;;7S$o!gzRS9`Q^#|_T~Ql<6-_{_Wa@c?!?~v^TnZ&
zf5X@Pd{j2IBdD0hGxroHzR~xYNe8EPhV{#mCLd7%&kY{hx?M?~isnf4?@p!S(Zx+4l_b
zrO%ZMLOVhOTD~?xpKoL8=6GLNrwJGxm3DBBpna#C?&_B^I9efXLIb%qJpf+9-gBQY
zLu}c2I}07U17dHap{NGJ?Up7`oK5VvhXB?=Qq#b;_%-o(wh|uR!ORHLb00hkVvZ-!o5Pb`mO*-0>$eY&FT&@-R}E8XpMAjaUcXbgSuwnT&Na4h{1kh$
zGz!DlgPetbnb4=>k+7VIZ||dq;@944fHS5LUa=lE2{O5|Sw^b|^2sBtz8EP7^`x!f
zYTTzCP|Hay;c$H9bAn0q3}T+5f^pRZ!=>JPuM;!OZ&6o
z(FkjdHe>Orrmg+bFHyg?9nZyp5DG5GyevIsKAOH4P7^4hMuCYuFA~}M5sMvP&BIOu
zyR|ltD254+!1oUzECBqV0wR2vP!ZUzbc<~WH2eP6zyqpj%DJF%Y)KJKq}
zc8HBR7jB3}gNuWW9j^)Dqg+BIQzKI7D3WOd#S95k?*r!m7gQ`GNZ$VEf^f+1FVptr
zrqZA|o&phETem%H+X&9&2%
zrpKsb7(2te?$%b+B|!JM6tl;x+$I1>Nt&3U>`pE{T
zbR@76VKj^9%b6bI-Il4FySH1@=db>E%g;c&$E=p|p(#f5yDLJI(ot0}3C;+eM+=hI
zlYyQ*T;8zb5wzJ`SK0nS>iiO8DDz#eBxpF87;QvQo$yOsJZ;Ba=QakTgC*lz!(Sz
zrxFV*i}kp?GY9N{IT-%9)o{BMz~6pce^fm#=bVN
z(|nT)3?^+dl2dS?AGm}6aPGVDc(H#9>%@%xG9}xd_-`*Bud~~>hqx6qI>$NW%C>zh
z1<>8HvTWfAW_QRksqsoX#%WDzDn=n4BCj|&g|yu$Y-&LRky=?f4mm~6!5ZHQy^Z1u
zPwAK$zyowq)8$?x6uC74EhwN6$>@0`93gsh0Fuc!{!tH#V$p+#Wq8*}qYGUOZjPhF
z$$1f0cAzOrMl)%kPjI0l{jVlrAhWAQU$i)Cv>tlrL)L9F?Zb~9jnZl-(hAa_-1Y6K+~Xo*D>
z>E6#u&2iLqlZ$tw6W25v5sJ!}oSR6ET>EMZ3WIH|%sRAQOIaW!f%sVP=t<8~?r-%o_j+YRPE%~Nnq;ehcKCoV-f8z|Jh@`Ro3i5Wi{6{-v
zR9vf2dY*$BOQqTdhr8Nm+tz0h+)I$Mfc5R<`k`r+UmKs`qT>yqxN5mup|vx!EUshR
zPcnSX__TISVs{HE+PzD55cr=*Cea>@Lcm=KK12Bvm+m`;fr^5cF@xan1#
zp(qs0aXeX`x`5Iz7iK7m#)f%$HheU`dLFjFaY}8(~K=nj3$)2RNx?>C+7=iu45kO?7
z!x@d7?(PnV&AMW!;@2c)FK@AGZ{`gwo~W!2prqRubLFkY6vrrm^J&67S5`9?KXT~9
zm^Vm{sD3YFDtj#E~jYyZ{G6cUF>BJUwZf$&&4StPBnJ;ZOS$x=B5&^_ktQ)mXuBJ1+G
z9>LD4A
zFIv$oz2z3ojoK*~LfL1m&1k$)603L58=HP{P)=5yoQXEXjaIxEz>{3?BrC^P{l)#P
zBD$FVLTY*69cPUVKAEt;JaGVw=0if4#3DS23F4IRLhbC**$dWC+EEV~W@3!yu1lhn
zWz!JS44FT^Px!KNX)Jmes2b?x)J{VoFNBk+{!qssxML_tFWAekETTMO*p6ck>eTCf
z5D!XcE1YPkWk?oJ?<)xuGqffa>@H`6hHacpcN?ue*Q1`{!>bg-?_*Vq+*OjCM1(^-
za>F(HBeKa}aAPv{*e-uYsnbf)^*4C8JjJ*=c%-5_-7)%bST26Ob!5SSaSdcdXMw$*
zpXKqUu3BC!*5tzA-i8q0-$elRc*HzYzdvupV;a*bDZL&E%~Hrnj>~AiZy*#^>n}aQ
z$#rT)Z|tBc)85(K`+&e5tUX8VB7o7*+XN*b8=MT}XF_SxAatlQ+B7p5pX$hbnbL0$
zZ{@eCx$X2E>A+K*HWGe%BN_T6@G5&8=<$FO^uGG39jgXR@Tds(5S)>T+R?U3+~{9$
zP;^Xi)T_oYAKIk43mTK9GjJ%kJ9J=T%p}7IGs!OjNtE~ISQld4LlK6}H-4Bad9lnH
z{GqbCVx9}6rKtC<%moE+PfYtsJ8ZJPY~r!I|orWY>r?ZJ~pChPKG#pts4knFE;eGR%=}+_5X5uuYbH
zah=|2n3L247*Wx*mZ8>I7ZcX)3*tbACd6o|VW?RVC+L3iJ!cN&sklo1YODfgJT!b{
zy`^?>W0d>>S1d6j)#(lkN(4OmK)B{KdYq8t5^?o`ImTxt?~w@3@TU{Ti+OzfXc#-C_VVBB7HFq*-P
z4~5fyuk;Lt|H%a7b!B(hAFgu31gQn6~cz$@XaN
z=S8E%Pye$ShYq`qn7z7z*G^qDVj)z*bvAGqFR%HTnNlX=QP;glla8b&>9>au--i)U
zoUsP4rZaK$%wlL{@SdN?_#pWnG4vpXh-h5!AkFe+B6)I^04y`X6ywGEI%fUE1(F>n
z>wMB8sv(mTM?U#L=mhXW`ThAuHN%HS
zPV4Kr+z`~!9bJuwG1PysKUAs{`0Abtt_tL~{fps~vL&fqF|bXl>!lxLGa1stTSHFJ
z92#Hn7NVd9B6A>@Hp}J0tKUt3#)fqn{A9XwaU#94d`suN5*+kOuBol#+Q0UgrTZa2
z@Oq1fmnZPU`p$9|SHFQ36I4a99xPuk3r$MRHmV@+m!b
zOi{q>2LX8s=Er4N7bTp0A;Jsxwa4G>QB6_GcQ?wO6H$PsD~M?HU>l}jThELP7E>`J
z3z2A+j~jsA5M?$e1&~e($bU+3x(7ARe*bq$7567=wJMF1o+UkkDe5qMCcu_{Ba*w+o@;eHJ}{aa-+~
z>>6&Rs~s^luRDLIP3|Ygxzy%QHe{1q~mbmilvK*!`Gf_VQA_ZPyZ-V
z{*}^lHzT!USAg;`AzeiZ*@D%tg4(F(z=^WD6PY40R3e8jb^Z!|<@<((wx-nz5%kCk
zScgYo3cAz{Ri!mT&FVZ$5=P#=u6`goswQ8tQSOhui174c`xM-&BQksG@$t>>4KJ27
zbjy>><+GU373?wC-fHaIK3La$GU?HIV7h8@BleRJ8d!oJf#ghY_~8Y93W+1eD|eO$
zuVF?6Tm?iw_k3ukV&8jOcZHn
zvxX-z>A%{mgBy+-Axtp{mg=
z1cyJ&8?wewEBhHUCOfnp8YmUrfz&Yay=!WBAbtfu2)bQb$PDHz^7@>KkjrJ@TV!*;
zcGYkr4?P}tAr!k%#}4$=82O}1iF9F=I3JPDN!1zHvZ=)SQvYa@E;>ODVhvh=M6^#S
z&`jr*utmzb9zGh;$+md9pTM|0DzF%PS{i`t%8V?EQbrw@|BvCa
zwri1k9whg1EZsNqo`5n(Dr^^Y5b*({G3I-fR4aAWi8sP(0-`^iBPxlz$6x1GpylnP
zkDmrkyXLC9XDF*`06jIr!4)?a0uI=U?y?nPo^vhcVYjg4=kfCjk%a8h94)d7D%^2r
zDzU+!Bo9dfu_uhloF{Rdj7Nkg*(f#MuOhQE*LY-vMNy%j0mEASoIN-=~!Kz07vvOM5P6kQCt))U}^vI?dt^VQfp-*9_RS)c}?^R@kzQ3Ec>NC*euw!U?tJAACItJ;$j5KBn@nU>h~3r_zPv1B6!O8dIYIh$~`*U
z$VP)jORK<9U|~p6Hjx^UR1Mibd|fhnv^8C0zHyJlmLuelu{08!lWHqA0f)1FwnZq;
zkicN3-5lx2(*^Sr2JmRA+A4I>=y*RuV~(FzCPcc8L@@FEt|_%KV?r}E-hPd_;m
z@w@wtNKstnCB$;;8`5%h1ADkISXE8g1R^=9eYEuj>2dc~#GIkHz@KT^5@IB-iF^9w
ze_0AE+821w3Bd;-T79uzJ2m(V1Cc>uAdz`dMjr<9K&<;Lh4<5^Ir!
zF2}6C&Y=m70mU0vRCREs)|zu+oo_HWhD-8@jw~pa#@L}*Oyg&isKIotBPtNlsGrOX
zK2@6amkB!|y*a@(>!KI~u~VWgM4Y%jX!zqXBq!;p91Unne+!sA;@}4WYBi3O5YJMb
z>J}uwZLhId#tGchV6X~y#xtzhJQYvC;StyH77{5dZXK|Y&da<
z&4ri+raL;{Zk)C|${vf}tv!5|X{(vt&%Hh#nm@ab(}+fa)9t$l((YYhz~4Q&g3BkH
z&ku(z-nz=O9v)vfObREwI`v9D<6@KRUDN+gHLXA6neyrm!|`<-u0Ry1VHr>BVwsIFhuA70L1POqL{PT#SzA2pfO&N#h$KktOHmHr(A
z2h)KcuI+DrH+Sz|_cUEy9oz+YKKj00+{)@S^5erk>6JdcLZvG`exY*T9G?MBw4(aa-(IQd1q`=S;HvW={93jpfu
zCMDh(8lF*<150sC>(5Fa1d`F+!YL7TQz;Wu2b`I|zwH|597E|zZ4Uh>fhBu`6UN+W
z+4Z4`K5TcfXwJHbie01ZIBz;G;b-*hYOxHL89x$O?o(-k5isb@wou#do%ytSNx_T_
z3oG`a-GT;b*c2J~tWPTxC4Ia3i67IUQUDcqbNI;)Sxp+c98V;vDP(D6b4Y2&j+`dD
zf13=?V;+%95RhoTR;;C@$nD8(
z;B{!fD+V4;8Y>WbQ|Jtrim4N`Zu<3}MS}0_#o$ZZE#!F?r0yK{q6kap@2{lwzrnVS
zpJTW9-KG}BiP~4Idsr*@qGXg_<^mOaYripHh(>Qu?|T2AXdaQeE_fzHARueu|6kHR
zj{nd+s`buY$lIL0ax34F=>4Q94yT;-Ge!@ubnjDiBhdj#W^en19Ui*dNwQ4oUb+)s
z-hO=`VEOY+lZUGmvg9j^!4kcALbKW1UtVp0o<0BgZ(Lk$>r>Y4O-4U{JYJc*eBE9i
z=K0|lo!#x-)_3*->^z>%+tPb$h?xApt_;2orb#n3%3=
z4Ze2wKkR$GdLcG@DPPWB_m%}drEkBcx+P+v96Hx^uRY?skis?ld^o0g$a{M#>ok_x
zN)tXU3Z(CmDkB%-6zkuq%V|joCfaO7X
z>j9u<@qujSrhVw9f$paLxqr8rosGavU(vZz_p|$tZPK!6l3BXu^%gbEt5wtI;rz?X
z-mUx7q~_c7^q1|`GO{G}-SOttRrop3{i6nbfMJMlq#S+YscVxeatA3xiC$SBf?JZJ
zefyHh{x6Y+;<{+t`lqLhOS`W(pjU=2F@h8${V0C>+V92d&&x0GKE4Ibk_75H51lEb
zub%dGDPWLTji370huJ`~Mx7XrMdZ-^uV;A~fJ#a_*0N%J_-2kDpio&}st-Ms90~_F
z5;{?BSeg7+j!4j#HF=?*I;B&N(cZnB0&zbbrE^quW0O<*NP=3abzs?{(&R=RVwH!(
zzb*qt;ybPM(ePAu;&Gc7uMX(@cPdJ1;+9rsiN&+2Dg@z>;V1Xb$Za0a8iqe3gN((@#ae>sIgN;PjCi3*Mq`Z%*%hW0>X}Hxe
zteO%3Y_Omo@6Hk=IahwLI5HZPOxb8&w&W|Sz>a$!gNQso{t-kg*2|=le
z(?GI2bVbH}C7g1ic$?CFVfgb85SqSRPXY)8u_C<Vo`9D-(DSsRQbLmTlWi@k)X!Os$pU>Irh1s-&^Dt^sdw;G(k?RuplmPl8U78;h)kJ~
z?i3^^$-TuHs30sb1zHKE{R<)lSV@c3WjAyzK^Y3bX_Sf4h2g{$q_j^SD^=>1(iH*3
z=_Rt|l*A-#SX<(tWXnIC`slwN_=`8)r(%Ji26B;beuxFhOb-YOB5o|1`931z66E#!
z{mwx({)C)j`^iv3V-#eTitdqlX(5C_$$cSTKS)yr!<4+hokl|#rbh2OMQu^?9sVlIh%hL=yegrS`+DYa~O-
z@Cy0mZ!NElaDb+CD2B|7S)I?~dL01Zm5>lW&g
zB#8V)5-=9wa=ipjDd1vjO6a&`+>~+_sivBAm5EJR&m;a9UA0)>5-!I_+=%Ew{xL^<{Tk|b`
zOt1Hc_Z0~N)DT
z4ks;2OLUVy1r#%VfL0yX&$Ci`V3NPoY`pOjnUR8UN0|wMA~~DzW|y#glv4Dxvtqo{
z#=c0}1;)ys6tS@YO1TtEcwSLYD{mQ5HZb=n>U)KBZ!dT;z+2~(0A&o1GL15X%-%oP
zi8KvSlrKV4j9IXA0Q2tiT?M#BY1kP-tg!00lz2HJvC>K-smTa7odhW~4SXXdCk%Xz
zUS;P^5_8J}O~o;T37>hj#YmWEOlINr`*BcF1xdSmSz$@>Qpk_dDlRxfb`7)sf!A2b
z$>AngZW=U*J|4nIyCpQ?IQ#_r38dP;m_eAe=B9*N3iXeWQx!*u_eG33(q{+Lez$3n
zpbAnhBN#j~xKL9{xxR%B`lCUiPJQ?F2$0p4U@g-#NC-=0KV&QLateGzD)7wuu|+y?
zqrO90CL@@Y<|CnSt1R>Cis1U}<()cE4x2yRtEHyhB#zWQf}VjtvgP;qCB&9{2C(!f
z^|>|R`zVR_HLXx&Md!tMiIb~hLX2MD6-Mi_SZ3=)M6sgyaL|N)FU*a*c*DT_+XWrZ
z=@YwL+a*WTt;+iG&&*n9?&L9p-bnlNG@t;ni8k|NVdE#0fizbaI%I{U($;M#31YhT=ZNJUD`MXC5saDuXf9;^dhEfyZ(}sKEx4ZS$dYh!eNq+p1|4ND)$bP?zVb44g(}toDH_IuvgOS6nxZQ)
zKNPu?Z#Q$2=eNL;#biCn;AVbomco241L
z(+xbA5tA-)g>14Q^Ab4f=sJ~MA*X&Igp;mkC~|jy?@pB<$EB_K
zVfS@?oKzNQeuK$%A3f>BBMcAb5<#-B>5!gE8|h5gK(7mUG%<&Q?F_&
zj}qA?ZBBSNW?YD#;70B<<)*cpEY20rjvo8Z$|xOb^3(|oYU(a(T}`;TS1ENiGvZ(=
zkc@z+9Ys+FNv;{zsa|J~oS^as*kDM*u={|RQL;2dGb_98jGE#joLZ&aZV5RV!Hi`X
zF}HPN=$hx@SCRg#YC8yz*$L<5cPlPHO5?_vK8^j3$Dk2)4+ilF?Hhc%HihR?XGa@&
zhn{#~c?k<9fHH?$j&|IR*=I?S00BoAh~vw;inW4A&btzA%z=-U7UqW
z{_OXbpPS{
z8-xdX>F`}1zQDI34{mWUGpz6yk3ps0(5gQ0Bmht;w<%&4DTvgOA%q|68p4R(t`-?n
z>W>@crHI?xU}#jl|DVisaKYL8Kxp*`6eu>n>me)xjX>#&l`d5j=N~Zh$UTvu4W6hy
zm+SWkp_8)!y!k_x8Wl_GK;sUVeD)P#c0*NRIdPajo`K#&<1tRw!%IX-Vz4_Gj4_jL
z=d__N?LeKRpkFOatHi492awrK!Xq({Q!C8zq4o_sn}xWgW!a~yj$HM5}TxO
zn4QC(*0rPh{JXlp^G+)zgD%mvtyq*AC)g|$cR2?^vH$4p227t>j1bTLLug69er_Bg
z?>(Jg%j~8FjeMXDaY~rCq29HdDw0wZ_<%1%43j%68%3>7EV1r*W{fw@0ca`5%dOA+
zL!dl2E&h0)X#b{Ed;HteAH(8sQ}d?*?@nJ8*_<-4g3XX>ZwjJbsNg|Xz&1t%hwY0$
zly`dyOKwkd-a6z5Y3iiV6#Mrsm(MqY$T`XJLCr(esMJZ%ZQ%F-FIq%MlITK+%G-f#
zHF5!1+VKh*ITQ{p_&zn!7)+|rTXNN$YeH#1cc~4kkhJ7UyPE+)*_zkNfSR=IISZH;
z%WTjF^7|IfC=!&2%sofxPgo%&D55hEdeCc)(Lhb1nl-9_?JNv<>X|NBuqjft=?{lO
zj>6VW1qeuDru;z2Xv2rkc}+D1j>$sB*1*sH9P`@9R1gvniEd|aVi7VmW{2A8cRs5l
zV4j?*V4aS%%=o?c?h`Uj&!ZalNj?fx}yxw3KbD5zJlV{;(jl1U>HAE7n
zA=E3y-7&!~FM1e9rN8HS&<%Y71vae2D+-WtV~mMN)9^N=IHg!i&qiu8x-w^YfDQ24
zU7wtae!y-DVUV*ATxGRQw7
zmrWDTq`)Vx8rg9`wg^#e!Wf;&IbVh&S=Fxq6v6B(_crVod19Wu1Y8NX{vxi{X(h|#
z_7a!bO^O4`o2Up^k>kcJC7-hVi-RzEh+gI4if29K_r&~IeK3~wjYAoTLxNS8vUhyk
zv=8DN*ON)sioG0C58V3E^iQleknHJwFYKa3NJhxDu_mm5zBqh{UCVh7G(32E!E}OV
zcNfYN{b&ObLUoK-v2N`jh#PT6=gBV7V$t1t#na-Zr35nrr)(-sRmeIQHx$tpvwS?E
zpHlquFt3G;K9~L+Nr)oa=EpUAW%7bW10d@mW7(U;BhJDzvx9ymZ<3!Nx1CD~9rqMP
zq>53t=-AzZxefF;wQ2$2*B}pt&#c4Pe%*vadl2>p?t)U;#t1038y>yZ3FlFTz@*)n
zOT#f^qtnG!4?e;lbmL64PP!BbJU+;&y5>bt@#}!;yUNiq`Na}@Y7SK|?kmhCG}o%W
zjxpZTlE6D?p*MPGvi^Xa`g}xA*)l=&PZu>S*gsgU;(2$^@Nun=L|$qPnBpOhC?Fs{1aXda3*FWh(FR4+HAir-!@m5armj
z1@4J70vIKRMI7|m&R*ybKJf}antH$^8=4XS(#tx<7)CHbnP-gW;ETRSnwKg_&>FdU6P6lZ7o+%pUx)Y_T7VEbe}d;&ThRd0hQGAOB94)0zH;d@=<)!~V{|
z(#*G)Z~Yxcb^GG^`~crPrr!-k!pj3CIUUV%?uZ-<9O&;yWUcwVcb~&>rK1pZDDQ+T
z`#}>HoMFrzL6aqHAJwzpEI3-6ub(m8T)U|MP`tRiD^fPt@1!s~bq(miKwRkVV`by;
z!HpB~nc@MNJ)L9IO`t}D$B)<1$wutvkgUz)2ik>^hUut2A@pG)mf_YZ!
z_<-F^gON{e$0N^}5_*>jtxmV=!MlWX}7SuP#7;^rXqt{xfShg_R*h$LSj)#7)
z;ze+nb=~L~I+c(IvMM|ji#Xeu{QT2V(^|H<_nlfh!rmz$Oe{DDo&#$Kw8ml=yC$#f
ziN8j(=4r+(WcAr2_>%sl?%4IwWtIX`eq5_Pt2GJ~Dl@AKN3P^YUWYQzrbFbK%gm=`
zxEXtpy74jOz(c;0O~6>k)lMxk(rCL^*?E4^{p7f3Vdo8sVCl=eclRRO0j^Fe_$KJ8
zdmw;-lLiQA)qFU#+~0xi)KHpHbqr~dBX=q^5;69A?Z^~I)m4G?c7xcgvskR6Woew+FQ-X09xD8tZ$_BC&-XGV)vW!=tC`TH`hu__BF
zlJYB4sehA$pKY@jzcRR=tCzEgj>H7{|J^`n6OI^36D&;Sctfv1dHQ4O&JG^3O9i#B
zuS|8|9&G?0a=7dwpUrUdqZ##wh@fu2Cy3q;Y=e*pHhcOf5~6I8hxR*V0Y$}zkrljd
zyGcTMSmYOb$=r{WbEuP%orjTnDCapftu|-=ON0(3`zx?<8i>gCo|wl@%mXuH*L7x=
z9Q=>5jZ<1aH&(3xI8H=8?os57Y0^?rc00ruGj_#>Oq;i)`sd0n-rOA``2LVf_B@_;
zdP_FTn+8T94jrG`=1F_1XoKlFJG>7K2UoHNd3J1R+0$0!9*O+6+4s-ghX-~+$-Y5|
znQgh*$q5@O_Qx8Mb*qK0%dDwOJc0D%5CU+rCX9XjKNf=8CEoC`o^pR9%Lis5rvmo1npLcy+)%TkL&ei2@mEj88%y!=k|D+B(6G3g4QmH&KLo<7@+zs?KWek5x9*bL8`@O^6Q5@h`9
z{(8IQYWsTYGNKa{+|c)bdnvo_eL1TOcL-a5Jf02j^}GMr?)kh1mi;vNdStpBb-quJ
z_jn_!Ma=VwvtaqX`7q{U(D
zy668(!7mQES6^SwfZ*cqIzz;W!NYaeq>EhA`DqRa*b<%aNSsx@olige82@(K)E=I#tC#V9I%S&P7L#LTF#26ePf^yJaay
z?wMX(-b`^`@Q6Nh3->;pV#6^HB}~~c0RLnSJxzP|aIin7aQFLrFgcj~wtPny^!9Tj
zVEUd5qN)%NwfQ)4mHqKM^Q46}T8w~QFt<2NIm=kI3a^$}9ss?zf&
z&dD=MBNUmI>@w(hJ`;M_-%hh{w77hMNHmyMSR8g)V)7drR_a`ZxNL-ELE$)L7k_g0
zwPK-{?#eBbSSChcUBoOx%Ebmdx^1c&tNAdC=wYU?`-^e*sn-f)leq^-+Bhe=iX$tr
zxBaFjE5R2lt;Zw@$&NTohI}kya1^pkhWDr;Op1KQvdS5jUnhb3GYb
zAUz0**fGhPnP*5U=w&>6frYM*rLwmKXNY5q`22Kljrf&8lBdp+
z8n?$Sw(CxEcgkWo|D=gid~twgD3UpShCho%d3NB6V_Fj0I4|k-rX$}9r6x*aIy-BL
zzuBuf^n#hP3-u!U3gfIcZ>WW<#7`>~veiv~n`l3?LPO75Ln|AIT!|ZSXc;J{z%@N^
zU!5uFN48VHf)eT45ucWn8!}gs;7-)y-l=t%zsDRMHid
zR;b8f)J)$1yLx7@R=`3Vs0A()TPY_i%L((@`hH|5iY`SL;P1PFEUW5Am?E3Sc2o(h
zLK{in(OZkbraTYWsy$gDeI=OPGCu$SH|A0~w2j<)k2s?&=W`nQffuC!&jRJj>$GZl{eKj+@<1=;}u92=g9vfFAD@4ATVnp`-#uStX*
zXN-%qcvdZTg2ue_%tt%Q@blIC?eQZ&TG?xMxzimdK!bD2swAO#)=C2`_o5fHX5mk=
ziYJL>r|0791D$3j%P!I_l{>9d)FPn5VH=cx_E`;aC}E1@#*&eeXL$IaWW~pt4jM);
z01G>guO;^C@jp1i(CBU&b+?L=klfOwN)jjd0Ql4BsO
zR^iRZGAqeL%zA%l&$UI$)K{5G6v|Fhg9dCy4N}UNRK=$QJpJSs9BJ32c1kTOhRH?>
zHwH%k%=is%g9@L}XEqDo9tq*3-#B$gt7@2Q6F$PGlEw~~aXh})DkYEWA1P9JxCl|5
zQJiZ|wTd}~MPLEzWWT}5>xxJHg|XD`{4LPAV}koiD^_$yQm@jSWj}?KdA3P-C+TSw
zdssBy(;a})LMoB486!&4D6IA&;&@V98Y57n9aU;oLJ~w1Zf|agp+-Rc_QM?=>M0x|
zzQVohl3hTPd=6LmwF%K3>jzc0H`z`K%Jcv$2ZnJOMBDB}>4hP`B3ngY6y?YPZy-<(
z_Z=K9W{0k7k5R(6>kv!R#C}aLBXg
zd?I4<)88iITn8Gp^=b(SUe$6{ff-uNeL0GgL^n~26RNtC{pB9K$ZoJLEC`3{dveKU
zIV_RYhiq-~aB~ZI=nImGhR>PcI~bJbB4xE=4dM3X8W|Tk+dZpnu5Kb1!bk)eKq-q2
zAnLChs}09og(sc=0ofVpX~5)-vIC^&gQ?%cjEMDI}U|
zU%@`2Hn47~sQ2E=PQ=ERos+|PzHc*JYOaB#NkJiXN;M&SqSg^pJdHp`verO=qckAI
zZ{XHb4;7~Ai=Y=tfxpx&aG~vl23UqsIsjKV_!VCMphTngw#(G}t!&g3J$`JiSqJLS
zM}(HMl{3Sh--IXp$Y|&m--)-D#Vm7Lzl$b&t6oj-oX{mkVyYAtqe+u8j|UrQH5CGu
z*ww#E$28&?FgRWYr*yKNjG-8DK>S9gkD#BDQVdxWVJ9wyi0>3MaJF}TTSMJT6$tCb
z5BG{`>`%(t?>VKMr&)6Cg@bYeol
z&|M2Suw{ive+G?l%mm!)CqQq{MiKPW_SvI#a_rxl49h*l>@)o}NMnI%ZPhhSuJAi*
zMeUa~v&J&A>+oD4AN89XDZoC`?7Hu_X3(PyGkZEVBY^qu7bjO9+jHxUQEn!qAZ?!i
z!?@Jlfrh1!gqNuCP5*iXcxw?}vT|SFTX_TJiEXuF&F)e|gQ&vmgk_@oRtx>Xut5;S
zGJQdx+RiiE@$DZ)Qm^3mn1C1amdCWIQx3qrS)7)MFG!Bmv*hZ4MtiQZ&W$cA
z;Q``F41Li%L3~dGG16$~asyQD;Xhl=ZTGF)y`VN9y2e*nD7-{G65)Gz58^)%>K0TUr3q205%M%SsYj4)J`Ej{3V%jVmEI^
zXI2~-eak*YWJ*~Wi7t*1kCb(meoaAlg$67J7#c8MR!akU`gJ@Ux{wfmA({fAVo~b#
z(*V0xOKy<)ZrZHV?ifh$s)9^)c6<;^Om1hY>_r!YFfcrV0h%w{7+qe3n(hV!-Xdc>
z8ouh%?m{gR1nL|F!jRia2dGwcf&wKiW=k5|<*Ocgo9izftb(OZsi4ZX0DY(lguY3p
zvmAyC@$gNtU
zW(6RejAT2&!D
z_xZ}}ly1^~KB24W+!wszf?_GyQXRMXbyO^IiAM&T*CZ{vWlya!>ZODu{?^bLvfq=6
zUNRnM=+%`pL&b72#Idqp#B^wrqWBt4w6kArGZsBrWpIWgA64nnBjn+iT46|%xIU2<
zAuXutGb@34+sY@I(k4&*GYJ0M!Jw^Dm~w67}X?eAADG#m0Pm;O6u
z4UVOc;Rm@eC8@?6y2vyo{$H9zf?u6)&K{pzF+Gb`+%B6)n|Rm#o{Z3Z{=ZHrG>Lxd
z)i~4^0*5bwPdB5NkMYq&RTt~;@04!|nBrI8e3%YTKPB^$_`U=mmVf49E#6|oOBVVx
zNi}zNhg8y%Fa2i7E2SH~eJ>M1lmXnuF`>~1nIb^n-xv$$roHSdDuFAO%$+TUK#v?U
z5o@$7R77Ys26$EYY^#NgA+ihwsp>*9a~T3~6WsvgnBwyVvU#Q*-C0uk#-@&wB;OEP
zE$dnpq=QvS#rcO+q(}7Q%@H#~2u=G!4dz)N!o4=y_Pu-osJK4CCZ8f3P8fZuy;VkcX-9O
z3S%Cj;eYtj)MO}WEL#VC60dZB3hzD4^1XBu;B>h&$DmvBfz2E{?7~_m3M<#W
z$GTZHk|)}3C4tlFYKPD&3$N%q?E7)(Z{@+Cc0>Orc
zT>$|O@?S&ye)7wf$atTn0flJ&^;7n~U>BPO4
za|kaD4GKQjDO;6hS-zFmVTREO2MitD{OCifHyK?V*x1;(do`K;v%EQ!$>c}$`4iS6
z$^LI%TrfHQ6r~g0ebSKPqI)k_2I6b-maE_y5?}J_FLr`wY0Ge<1T&{Hw3c-ZWYZ5n
z5B@7esN~`I<{o~r%PH9I{N&3eT6=tZP1;av0Lyfko!Lh%nz-BKLsEGu$2Y`}x~CoC
zi@NBtZCmvc$0!X4ZW&MjQGIe-*-pSZ)pZnpU3}Vop>_ML-0z?jiep{9TPq%w?2292
z0In#1TeG`-*VFy4Mz;_GDMO6nxflNH{=Bun12fL7#$@p(?ySY)VNiw}-}?ppYgI6C
zYo3IsD;!F?%f;tW#)19ds{|zT_u5avLTvS%U4K!`_j^Dc@XSrJse(w7RaL^8h{0UC
zZJiJ?(Zrt@L8s>3BCpC4)|p6ws?m&9O?_BKlnU0m)&A8U_&0|grLk$Mu{JTdn6ol<
zTDzs3b27^KwP%+n)qL^JchhN;n{rxIpytY{oKIM~E!(~r;#Na+F-Qt&zw;6xt)b>N
zgX>iJ%V;rvqO*cKF4as*qu}lvdD{r+9K+35bM7P*XI18V_}cQ~HT<({V_jV30RJ~W
znJz1e<=QD?85>CR%C>lf)al8D+0ek(%q$&~fuyCH8>H0dGu2OF#^6(C>oO2F+mZ!3%S
zHdU=1MeOLKt)koV{9K3u1&1&4lS1uL6=Z--w~1-UpxX1!UC;j}j)RXHZ!6oOx5%r2
zz#_C1==z?&sEKcY@KL@A{3xGWQroV|aA&)jC<(|RKhBlD?<4(8+%Sc+mVJjmNsrE(Srf?U`!Xsm=-lB
zqNmA2+A?iD3=hWZEDx6JdM4Cj_bSK}kr6JI4pkP>s8yGz@x*;%q>0d2nn$Z)8k%Fv
z9P2%pWPC1c3SqQCK+|dwCcWrHo!^<5St>s&8bmQzzQ!rADWmhBE@RLqw_gj2D0DC|
z5@KO7$kaiiS#P6M@7@2-=%j*kXL@6($Enbq=BF!Ql@Sx*8ppnCFqa7)c?bR0rZ?t@
z@24;`%aF{S{!%f
zdDl^{cf+n)bvIe0fl6~V_C>kE82csr^FRX)H!rVErzvvP;G5>!QDImJlAwvle!;KA
zi_`QvgMEvwu65{?{qdHn12SY88NwYZGiszj6=3GSdOm$Q5OaqOxF%wIs>u(aB?~XV
zc6^zM7Y+(z(PFIm;Hfb?_G7<8%)?00@YZj#Hmd*h$;Y$lNsoQSpC_!eaagXDU*4j{
za#1fT*<6A_<83j2Qdl}W{%ty8Yn*wX1C51(1uAq4)
zwfNnC1`i!M9ZiUAgB&0HyytKjdJ5gyw^wU5qo#Qeq~gQa+h{SGc?!Y3#X_yTV@X$#gV#mzonQp7a2&ua->|vu^{PG8d>%I
zFV)GR6HXId?Lvf%DtUwHLtd}i%BpZgb{{@>VO{f8NSNB;Z6KY=8HS^T%IFRR!e9q5
zU#Z9uEy%vje{M$N;Jg4zlQbpFWZtC>@398AvpmX?NqqvV>QEL4YvGXv`}LFckmnm{
z&>r=?c5*i8u9>CSOAs4zL1FMN*}l$NBHPWbs=#3>3s0P6;$EsrcL&Cf2KKeA5HIZ<
zTpHh%&!|mv0fE6w`;wT(5W4ZCQn6S9^nqg2eeIl>h82bDB>|5BU#&2m8VqKRrvIp7
zZ5K46j^l&`k(dYDjeSyNy^xe$r){IuQU=$%Ay0O(i9ek?7lB2}q6^OT>6akn^0$Mw
z1=>)^w=|7iH{-?Wwbeweksp(y(x)?~$c|f0j;ln(&OOvsP_AA?s=
zv%__l2?s6_uU1!Ohz-SB+m)$of_@%?_Vuc5t!g}os4|p`Eb}OjsiN31yH*!2b`nCF
z2IdNR1T*b~>5Dt^5Qb9jeE+L|C>AOfq9XG5P<|)gOslGuW+Vp_QlelXm68#|gaTtF
z}h{Gtt0aJH*9X@tz$(xN}w)zoT03ygh5=_9=9iG
zXZS<<075q*`r!O!YYhR633hX=!{w>}k2g{P398r&@rLenYdj)}*Snal9JtBWneUbuKMh=LE^zy0oeH{W^h
zX4LJTD{P2rov{Z80KkRj{|~`w&8TS!qnZrd>J8v70uN?{N!g3
z9)9?c_~?@#zxB4C1UN5XQ<|K@irQU_XF~r-4+X9q#hsK~xG(F|%UncRX_ORo8`&Ys
z8z0=hbMyY~2cO)0@VRCwO|t4iUf>BSp2@Ba9QKY8oTpM3Datp^`}e12=|+~y`n#BI1P{S+-xs8#vTPpf+z
zHn2{eq^ug67j4w&+D6R|E2?wr{;%G-`SJIEa%;3Wx_$pwH}C$U09Q7e&?VTcm_}Ju
z>A9G$_>QM_Jr4cx7`f0-!RGGaQP%4LN!>N$cJ%P0&)<3fy+8l+e|!JIM<0Ird64?B
zTzAk%aPXrv)Zs?-57bFjXGY6WYkV7YH)>U-+-PorO1k#{`n!L;dFu|S
zy!GgF!v>WKsN6ePA-?tA0)`c~RO>6gZLYPe^jV~Xn20ZKZoF{e!XLcwjbgd-!Hrv^
zUfb2{Z~pYHyZ0V)_Uy*Sh3)OlQVF``A4Ye}<7st|!&cpFI)NP|Sm08W#ER-Z`0$Gl
zZvFiK`um^0bMw<%4}SIDonIDJ1tD%W8XQY1q^ZEgx*ygY`?Rjd0aT)Mpi6oy9h8Vl
z5WbnKKK$sH^zJ|V^FI~9{P+`4iID>&i70wHyR@Q^?5QY`Bi)lKNOXsty`w$NF%(l(
zw5nxPKDhVUfBa8>`_|hZ+#n_x?w}zWLx+w{HLJ&i!8ntu_(_l30=Sbk%hmmW3?=*neA;nDOXt
z_zh{wo{Jixk6XU^XMgqQ_wIjq_wN0>_wI8Rs3jdyK=kO@2$Dsb!1Is)^gErQP!(qu
z`zt5%glReI?VlVjcW1e#c8D%6a_nTCY`)rcLd*12C$uf@l6WHw(AA_jXm>}QRzDjr
zzG4g&brqF@#>D8sBgPE6R4o3{CR};(?8OVnkqBMhc>mTZX16wBOyrKvY1+1x#9Ro~
zo>uob6q)IG8r~&RkxL4{gjO++PrESh~}l8Z8SJtp0uziVMEKp5+t527O;oBcB`yw$Wadi
zYQP3Kt?qGX;zaw=b_2s8E@{SAO~oFo5x%((yP2wH)hrQmYi#qd?2!arzM0sUCyh}_v@yXSL!;{_Fnz}GZ;RO2lS44@U
z20h6R&apKfp@m4`lL)s&+Lc0}WsXFM6+b8Hb*q|&0VqI(HLB~U)jbY4hz&YLl;SUj
zt#-oCUW6mUEcceefr*3Jax`Cz
zUVZ&IY`K0K(w%`M$2jv3c89Cg=;ZQ#chE-XtoA0oad$B7Kh?plEI}6ZYh;QdE~)%i
zLWf?g2_Km#ZAl^1O1X@$h;JGN$QrY*qN;f1;=NJ&^lRFtp>VEPzErD0qea6gW1?DSyVtIpxCw5F9P??bpgkOdFVr!R#2SGF
zUw-{H;j=t;a)`(ac#=SB`^Se!98+g~xQn>ZIlCu^^l_>>(;l>ki(Y5cULWm&&F-)@
zUyX)SJfun53eqeLB4@o19}N1F&SXAZ@6Qq9Y&neD;dnk=t|!yw2&l@I$*|pQY$~uqC>VT6@-QP9k$Y~S{e7wO(H!&+|6RWUTHRP8S(S#rXgOZ
z2f=SUj%7Wl+o9%#;=N?lih6@WO>$*>9^=fU%ZPO%x1IQ6{0~dAQa`Ze{%4~cfQr?w}2|07$Dqbff8^M|b~POiyjIp44Dhv%u3eG+8W(7Ju!mUj=;Q)`SL5TpbV($3?|`pJ)i9^+QU8$%<5p#AGLSav(^55?{Gbt<9@)ChN&$^_342CEG6BHvdn}u@I;kM`+K6W23u`
zC`7Sr<yU2az~tfFSqLWjAMxQA0o(chyf^Ljr#+ZqeY^&b$JZ~f4tHhCWVoOxZl_Z;
z&ARWGEbCIOg1rJiA~
zwSY32Dc)=v70aqw_EufIxiFIyeT@dweV5AV+VpD*G~B2e#f9e623C7MPeb0VX7Bn#|cA);V&YfPdr&oQd=OO}pZ~;jiXY*-e2$lp^71On|
zc2&3Nzx*`f6wi9A(KG__jSO?gX}6JJQPuL#xxV5Bb(cgylg#8RZ~F=9V6=DTn%8Rc
zn0xbC8_jca?9;^;b15byJ6WwTKaa0p2eYK10wOsGlmvaKBVT988h;=D--q9e^8cG4
zzL5>4BkWI%co-8%3mYPh>C2PZa6BF4akSc7;6=d^L6*TF5HqB<*x!#@E%e=KWsiem
z>Y8IUUCZ=c@xs;Av3{^`=)%Q%74@y!=4NRp{}3iVF>aMhhG$}d#@*QT{rvSz8nwUT
zK5Z+eo%O1gzpWT`CoHM9*Xr!(UeN7Bf8@ZSPODec9QwGEWLRTG&7xlyb=_%o&{U9s
z;(f*V#g4%qr2TMOcQ`;hBLuVxIpm{NFv#b-b2SiqWU~9{L&$j^(VFriJyMBu&erd|g+0LP!&n=(M^#=uxHyv0_Jx
z6E+;b?gZP4TC?0@Q>bh`jFH-Ay=f+ymA2}xht!NDLCf1&3ptX=(_djpaF8sKd}#?`CrKEc5emA~dhqZ8#yLfi?qYw}kE70@
ziv`~ubJ@5(!1)<<26*NuvV~A;X@&$TKwU^vHtR`HT$MMmRrNzm1z5blTYPoGpHJs8HDuBZ1Z@*EBC}y1}+kFL9xv
zVvyT$sz+(f4pHS+lmSe14%!1qqUBNCY8ax;%~lJjo>rF!92mqwLi}sFWdj)bzmOop
z+C4nrXYP!5vR)fU8!recO9P0bw9F|_4dQh#SxF}WlE{&wK@ub5`JOO4sgAn(!jYN+
zNhAm=F;KbvXgbBK2ex7Qw5_{YEp68;Sc_q|1Go?za=|tfpDoh_krk>{)wY5xZWyZW
zy7-a!+9YH*2cdwGd!1I7hob5=eH3)2N9|I>ZkRzuvzm^FHNI6*^f0k`PIaZE+nD8E
zD>Zyi7)FK#DlsHEqQtA#R~%6OS^js~ufYUhM1t6iB*>9{mLr*zp#X9Rzu1+?PI{JP
zB2%go!!an0WiCgy;179G&>8k7%Z1_Ci5Q2~(P&I3&U)faJyjq+T-2y7UXF4t3E8YC
zLGv9jSZ+2NhK@&=4|IuwR*J==`&Kpg#4&M7jRt;qE;TWXjRf5pywmX!G&FizT^^cV
z3+^jvPS_jc=fu4c){mFA6vHnmn&x=8j}_e%!-le~3YQMYbawm}9Pozg#e)&R#0EO8
zE)U28pvdowP#yq8Oaepe73McsK};O!&LsFx>3o#rNE-YCMtGA1Rh_{<=}iW!gLQY*
z0g}j(hqTuX(x+YHs-a;L;#LPP9=qwyWk2&Ssd^
zRljVQO*`7CHRS81i`D98qmKVmP*s{uM?sF7@AKFy_&jk8LQkv91M)&fvbTZ{$c}%C
zNG6h^M-%xepp$>U1&PQJnIb+w$`R4;Up}TPp=W?3(&>!ES8o!ymSHQFWY5tGJlhw8
zGK4_WVE1UBWdojvIgk;(o82f0BO^;6&uuv|}&rC23a=vXTNk{f(L?UeJ|`7fbnAjB*XJ
z?x;B98IQlv6fcwfb_))rYeSu<)#U*Y(8G`>G6H3YM!d7gAtnUZ6=OUliAkA~$-hhv
zQbvMwd5Kf15`+Kn4!fgVWsfK~bs{mUQHU=eg+T-+96<`w?2UWl1zbBzyV+nSzSBPS
zS&>jun;X^QMzzF0fJVkn;-AElSNkK
zd)@9+ctmhgy+C}351E2QBJ#p*vUfuQbZV|btVo%v&QMfPq!^{v
zMKlLTySfcV4As&sR}E4hUFIjQ6S|@gx{l?!Csz*X{)i98Y!7=+4H_W0tqfr`eese4
zIVRn1*=UNP7L}3^V*aXJit-Z2atW^yyQf$Oa1j;~a>R@U#i!Nffk#-g9DHrX^$k0y
z*`6GKu~k>7jT$znr&QQ374hql<94%&<%rgT>r0x77hh7f(pO(8Aq7x|jF1aRL^J@9
zgs`K(^vMBPlOSJYb_7C?t{%7goj3mEk9iUZm#UCs8`B52qQqh~)m;kQJ5efbe$ubex>O~`M{@#MpsZm%tmO)~Y-}mo_MHbm
z`-{K$>svQ&Aj;eKKXW4JtfrW%;abQs>!qM_yqva2!hrg6s2Zvfith)s9$}%Zk>*R6
zF1>K!;)@s0-@I}6t+(HQ=iT>z@T0fS6}CBbu~0zn^iAxf?Hb;Wy`!s7*^h60^L4{d
zgR~ta?d^uOSu^Fxi$cS^|LBX`4}bmsozHJQ`1P%aUtn_4sihq22I9yn&4&0kYr9b7
zX?1y^&!Vh3UVHVGc7FhvoJb7o1};%6{qUpD?mu|+@ZpCf!YuNl5NS%a!zEW=xegM+
zBR{F?Oprw>#`(BEUCrjZvxcEn)Jnav{qn0<0pka^9(?fL&6`4wpBpZnT~RDCTwuLB
zo$rdV0!SZl~{=>K4{ot?v>M!1X_x+olm6&3S4|MoxJy8FvC
zY-h>f{o9}3y7$Z8bXioiEk!|;Wz#IyDsB|fCyZFQG^f?&0bPMCh$v#LWf*JuxGLKg&be}!<)D6hyfRG
zz4N2*fA78bJ`nvnm*b_K9b}4Wg(&IcJOhrW)#ah#2Ac1BN!&D@vgRYlLe1D|s37lfanm!
zWCvE5$!@%XGV)jk`E|A0lBe)LJ%UW9li9F0#-@7OzplIXPE&!BP&if7z$$!U
zbL)i-G2r5lUVQPr_iw!W&W*R<`QWX0-xmX^wzgi}+7wE>Sj39N?!nbD;|N+ftu7DS
zimmy=n62CHRs%I+ZX?Quaj8_^EL?c_$uIAH{>7b-etB{G(nhr=<%ktoHLc!wj2(`D
zjj|^Hw7NXt>>@a6!Js7Y2HuS(VAhe
zn_E9BBBO%~J2@X}A%!dL@JrE28cFnPP<&cl9#l6mL+l=-VewqsD0TRe
z-hIAQIlEQ-#-)uHFP(pJbK`8WxK+j4kfWishT{~K23BD>=$W`o=2t${VE4!o&Dd~=
z3CcrK-~8imOW6rI=AROgCK2e7Ny)3PUZY>1T))EQ*I#?})Sp=&?d=}z(XXL^{$lC}
z?(V^2IvecmO;P1yki}ymUcS7$Tn;DGUYrK><@s{5T#w*Kh*dW0NhqQ8b?wDc0U6=I
zAQYYo)*03!KHRx#iHIEKC_wrzsKHLk-w9#yS#BI6MBsT^T^g4?v&1M?SS`}c8cdpB|Jqe@TlA8F*iNmic>r#IXetdo>rHK*{W);x#_77Y4+v9}n{
z`t#LjvKUTgeb+aSPxgA_4(V<`JviB&E(XiJ#d>c#o(=LZyd-*04GSP_Hybrad}x(c
zBq$5oE$l(nvFauus*+j4BLtEHj7ltqk-JuiinB_J;$@i!D!=-^r)C7Ymz8v@s#{w^
zC3!W=ts7RMfvISoE0&Swg;HgwX>2y=1X@j3t)@vVLKEm;n+6f6lj-$upeg+uf
zli6TA>#q0bqiJun82PC`UXGCIXx1N2TK!SG+e^d51A~((f*ub?ojEeyU$&?H-|p8t
zns%X5s#vEV2vOV^-73)=wn(yo=we3m;0D{M+=ingj)N1_nzKR`+
zmUI^dO~1C|%um}!5H%fdvr=zbrWuDg;HVvP(q6A=iEoeC9JnT+@b{Rw!MP@iVsXTULH3o`
znsnzvy{QJ78787fTRy$pj#E_pcCDcWk(;(G-`T8bVx(vs5lc-RYRzf4MW;@Zf^IxD
z0y-J=cLCIT1u932MQbovA05DhNC!ehDI+O*>ToukEXAvG`Z$1v5CQCK-+lwYVmTdM
zyGB)KhVwD#9n2h*yo%*>cn!v|7Cc#WG({=>F5iXu1&MTOCYidjj_3
zB^Q3hU?!+>tb}1fQOc%X*2Vir{woY1d}@*wO4KS&pnvg7~
z6xY$dI(SMA(rtwjF&@;mM6dW{)`-II32)UemT{RT(+FUMEk_@;b8NnZxG
ztAl-jKVB}mgsQ~*M?{I6+@B7Sy%@5xoF?65yc(zdq}7Xu)9x6?oDY&-GMow<#KX0vSDZb!T{!|p*kFs2>`Ko3I%1Cy?&`ku_;EWI8*j?FAY
zZ<*z-}}sN!>K|TWQ+CyBFg$vwj~U=IG{Q
zKP7|Xr@=FEr;VP(Zjt81JpZ6{+Nfs*+#I46c&cqCgKnvbC+Ri}4SFxss%1q{1iN~5
zT{V4<8a9IPr^-dh9G??Q0o#A4R-sH)RVZM1IBSXgU`~`@EveH_g>Qwog-hureqA%L
z$FO(v35HtI?H22G`?qEQeK|nIRV(0#omNya(gG6OicwH3%}pD2gxRJzz8*wc)GanF
zFY8nd+s^tT48Ef<
z+LWWv2)2tV;o8$SJu6^<@H7{@V%#<+2_CYr^zxZ)7w-pD$Zqhz|LqS!*nvzrnh`EX<&RxXg9uBAn3~((+
zZbt#xD#4LaC&C!yW&po88g~Z6uJ|0-Zx02uxd6}*-7w%v5}knK(^_bp<&~*n@!i^h?xlm
zZq=&Tp_=c(bNK0Wo9#+TwQV@8P_24NRBF^PU9l*!Qo~NWq&A~=?5CmXi20PJm?G#l
zEzJ&Hx*zU;O&2ps;a&0OFct5L0AH!mfMQ8wsFUExEzlUJ&3aa-n$b?v)kAFC7(_yl
zH9M?op5eFZMqq`l9f&uGHIEyUHq9{B{TQy~E|BF$xuN+k9JU-yHd$@ma`4EHv7|w#lq}>9q6yq#M@~MXh%_&(SkuE_R
zHsvT=bq3ghBv1mXIE}x@+1_ZB
zk3ZNS&ZYp4|B!sn@{dUbQx$h4L8Hl+R8N#=Wt*NEnmn&w8@QlAIhK_=KRM=u1I?1w
zs98D>5?5Y#1=UHgT7kb=E{S(QhAu`aS;DJi{&;Q-OBeU34KrAa-t53J0BBfIXJ+b*|gZy?5qVw
zAxjX6awo#3{KVZmZPT*?Ph5f$RPi8qjv$O@F_BI
z2~3T^Jzpv+u2a%fP-TaH-8CylGi;?a5}Ojjqp*Bcmk)LIuqeoBT4Fp2rVIQB(W2!!
zMVj()zqeVd!d^sFHUOn?_FMy_VuX6wtyytN^XitrqgV~cQ~hYWt~zN~_2Qt@Q(Q0U
z^b3mNMyVDAoNBtEnC4p*-$ukd%4(g&Mh(7C*7SV8(>)!b{M8X+PX!PIB7p_0A)y28$RQ0-02Ze}Bxw?_eDigl6eWQg
zPxJWd6%dB16&6}cC`nF9h?6NbJN1(Z^2ih`tK_z$tehI?005Vo0W^^cWvj$H-S)7H
z9ni{$@qxTBi$-%mlg!q0pgCSl8M
z`E;?GuXdL(E{M-pY)F!>_>u`02b0NUfh{uP-vE(WzXc!5Ha#=l*{FLN99CC7d$U$X^MWl5M9F#E`G<|Pk9JnzV|X<8RGRtFbPs9-
zXFOwk7mlzdE)FgfyvRRACOH6Vm5<73=*m7TUD@Ff3mdJ`EvQm@j|5pE;k#sl5SNjtEg#sijW27Q&o4G
zp3@qSuwjC3hyICt#EKKpBpt8aerin4Qvt>TE<6JG2~6-H017YyH{gTFbCFL6|3*Bc
zd_X8ANq}9_Fd_wH8F@KJ@;OR;QyAEB3vNVVega4C3uLdo`U*GVrvN?H=E1&f)fsdv
zIu0y?6}SP8ge-w6bO1$qvx7rQD+T|NQe+G2ZJ)`w9&ck$vFS&
zV}nj?L2~3GV&JJzEsHf{R57k5VLiWxB7
zer`%Szr9}JmjeU_?SUAc1+b7NAWw$`Sb^1eOcIV10Az3c$seP~Nf5yh9>QcLmOhja
zlt+*U5CI=YNRb>M&VvS^)I-gXB1id?YAFMQayyJy*{U;({ardein})%2)-P2pfo@!
zmyGR?J9~#qKS4o=2^*4H;16OB&3wg+B$lp#mn7mHjTq7!TS30InuMn3@}JLEbcpdp
zOm7qhK-`VSOQF8e>~TARAW6tJJu}oT6W0VU+s)#wS~)-BLWmD(M4kt@;W^>NPz)oI
zXDLxAV!qG=Q4VI6QRG+48vrz)m`f#5w+mB3hrm?Qzn;&nfQ-Q?nf>XMvwGmWzcpp!
z%RzO$x@o&fzpA+v)u|}Dor;xA>?o=0cxLHF&DhG<+BuDNZKJA)0XL=6R=K=U*x4$U
zHp=C6(7#wJT+08Ety+C62j#XRhJ=+=t!kKZFgavtK#k%{gKI{y>RL71Zn$2>wBX>=
zHa#l<4sZi3IKo&`M}rmcBnc8qlShd*&I&K0(@Jn;d)@XxOn4EAe02q&DbD6P9gxZL
zfR6+@;QsKk7$k+R@8w8Yr8#xBR>lbeXCO4u2wpO
z6?lL5-p7xA@x_mC-mhEnMy0Y{-QFl}ZP&`%N^`pjO^Ok-a@=gga;iE$P-44|CKk+X
z3oAKI=#waJ%*x+h1m(*C)d_pSi!h%A6W}8OhUng5tF=5hpiV!D!6itguml`#P10_+
zyZ8+K&TyFZPT|OrYb6A^gealRPwvHyz$izc4--oV91RZGgqF?+{18q(8vsF#`MEaw
z8r_P@hPR+k#njP##B#GzZWe0wg4QfvzIs_K@^$ain|D9Fef$2+Tla3(J${j`t_{`zq<423*y}me|`7EJpIWp2jiu%
zmGi~kzcbL=rxBG#SZ8@gv$zH#~5)sH^@*~3R4J^JwDM;sr0^zhLqKYi=nw2RFr
zhTP?^2*v0;uud9ik_MWx0~}mF#&6;7;7uBrxJ@W-*(y0oH^7FIbcNyQMjoIf6aNO)
z3^i8KgKD{|l&ba3y0WS0jav_Ye*3|v5afUU&wu;RKls6qfAr&{-TAHC4{qK6==S~3
zIZHj7-Bk1S{giyHx#k#YHy(|<0G+cEj$&BNu*7{#WQ&+Cl<;@twW#a#mLQIH8e+H)
zww;sVy!&bx=#lu4bK0h71>lI0Cv_`F5Cf&bTL1`ML|4QNBXSl+%Hz{)6{7jx4}b9R
zCAZAK!WSDTuUv)5sC281<%A*K9$V!)dQS
zYA^QY)K4$Li&`J#xB_k$n((+?Np@sGau-M8O<_x%rU-ne=D&fWXyWeG=#
zNYd1UJ$kXYb75!a+)hCZ+)m<(q05&_VXrF&*ff>XW<4vIo>y$*1^Z6gx5K1rSdf_J
zggc5O#};qan{sj$NG)kb+#21v|LfcLe)ZOkkJksU{NSf|-+brpTQ@#=_x8`;zx&Jg
z?)>7-4?a^&zo?m#9e)#>P4qIYQVcC$B{Rn2D${j!%}z7L^Pigc`&5wlgSWt3yWa&d
zPgo6_Oxhhhdg-tV1I#r+q~)8ReE#c4AAk0D|LgDn;xGT~#*JI_@B8=fgUCl82}CaT
zRy((8f?yUz9&
z61UyV5t&C@r-z9t5V1R+;kF;a?ZACJ9gOBn+#tddc1z*0fap{jPUCgKOy!3}JzCg5G_x9}vAo3r+|HB{u_{ZP<{ty1I|M6ctQSg%=
ze*gXV-@A4DF4o%g3
z#rsGAG3gE$L##TXMq_un8n1STM@P#b5g&Ysh9}laP(4$1G~3Y^tI@yxi+}sUoky@E
z@y^{xH}5^VeC1`w$EG(-N7Wrwb2agA_@*6Ld19N`>$I
z<-dFQ$uAy#^2OoFYyane{O@nSPxt=igAczrI6B%YY~tAn6z0mBC=ppy#Jc!aBT^@GH5Qrk^JU#u_bx|#2$zDFXD;Je+=CZKLHUasN74i;*E)a?%1ongDx
zPbaIj8w`3o1%UbuAj+~(N}TbC{sHa9CZf!)W5q&8wcO-2ja
zZ6}Tt&xOlz`*M3+c18m^fo`^*4rYV-66bu^Z^y$?``}=)T#sJ=
z)-^x&oHX)N3|_(HIW7NYB9n|_CQiP1te<%Dh^hN0|Hm8a{rO@&>Gad-Vu%rWaCv{S
z%*S(#`>kOo8Hg2re|w(JmqR{3L9<&ay{+mBgaG
z^6ig&A1Pn)5XJjQ`AR7FwPoazOQq6wMNIjjD#!!H4fN%Z4kCyYgWsECsr{$Mwm%hA
zClL!OW2^+>b`5t}yap=PlxkD=;siGyWerVA^)1$oC|A$!lwaE1IeYN}{pZ|;^Td}f
zTzu)`#h11&y@WYiDs5F81*}go$yeaArh`9R+6e15?zF5}Obnz?R>T+WNX&1tEEIbE
zt8=}c3Sa^?3TQY24j2pS%DTdx0FG#LutGi{lQ@GiiBE9W?unP-Bt#|su6%(=1iSDe
z`dXHxHt@H9a)7ULa{V#};VW;vc68;ktd=%V^7?D9PV+qm2x5lzd~Z1r@2;nm#stJ5
z1uI;?Oa8dC+@0+0&JPb(CztoW_3c-pmY`)f3r``Kh(&irIz3&0m*{40kRg0`wHjT$
zx_{;B;c_*Z%)86I>Hf)HXWR+9Q6$KCwA^3p9<9;cAQJABZF**?IhGa$VYdVL%9dfr
z5g3*FlpHt=^_`7|+m#Zo&!uWPpIufuUoOiiUr!RnioO-GsIPcKUM_(}j#XX560Pf+
z7|)i&H_7+lz$_yl%EXv1HEJkv-Emaxv)|eR;mbjok6zHQ9B8uP`WSOXMJqN;attrf
zoly5gPEEHU%dN6N@VKfndPXzG0NWuxIZ
zre~u}%erZMw&HkX25E|)R5r~WUBhy)vzFpNZ=^-kZlkzyd*L%VJYu|@gA(C$%*U_)
z@i*nz8gf7zQTpccJ&uf^4cHO6wms-A55zzXnS;8|k=SXgqC)ucb`11XHi*{)di7(_x^{n=o)Cl;^a%KoJ1MNV(f+B;ZW
zefjwCc&|5TC%xn`DY{7~>JGA_%X_cC@$$jZD$Beu_Vx}|0B*IOE%#=ty#<%7cBd;b
zRel1v53e2euwQ3lwdm(_ft(O~Gw~YolHlleE$ltNa$KW%Pg(1scW~IjV?wwQ9ahkN4H}
zUY-hC5LPq~?cA`%3U_)Kt6pFwY12)tBy;0LwOlU=iw#{5!?J2`)aXKubH$pNOu17M
z(9Dlw4eL?`yk4x-HtPyiHC=2|7gc6BD4$d=Q0li^RnyS}vFn+YW#M1|UzYQwTx<68
zIP&D>mwS^*mM_s9cRKvUy?_*7e*HCQPkJGc965lGQy7KP`$;-206O1Yw8f(7V)PJk
zwps#2neGg_2bYh4Ak+vi{>h(xM-b$-t6UCJse#%+HcmI0+y#36jc3!F4Dy96lKHM!
zloW7)(e7B7cc2^4ULz8Yf-u6Jj6Ct|7R-TuMR^<+W>j
z$CsDO_2A%Wc672Jy;uz}9M^jbF_E^H?H#Tr%MrB^QQzzR#opm^?`REcVlAu>#cIi4
z7mB)y3f^uuh_Im7Zb{esd~wGTb85t*y{IrRNdP4Pbz1R`TE9>#k`FGq1pI-jjcTP~
z7{hul1eb0RmI0&{MH1lHfuxM;R!P
z1eI`{u4X81z$acwUOU0)y!y(^R0Y;4Po_L2TXhB$j^-n%5pS0x4*zs_g#$iXjxqj*
zlWuR=8c#Z__2}Sm-swfXL4sMigmIUnb}t!Cd%$$LJ5AeRf7EWZqi!$7WP}Lki~bsO
zad!-e$CDl1czvYdam0W?)rh1le~A#`!n&bDf&-yYp827kKe)J(0|tQQ*9lG@M%*TG{=
zlCo0YDwnwyA{3+4TxY8)=Il}@psedUX>sbgT3alt7$$|LwNVqZcy&KQkLQaN8G4ZJ
z)RaK
z3hU3?%Y6Z8;e8*jhburmoUCTQJyZG1VcXEp)v7yMv+jy5PHXn*>lm1_mM=~RA^{K%
z3hoXxNhFiA@+Vd%dKpEp`JQSSX5f(^2e#t@Q%3mjS&H)FCu!Ib6pA4`zK@YAuJT;&
z=(WWMU%-0WtY-!AXUCazXy_ka))983qG?`OXqsM>Y&A6b)^Mv@_gfusR;bmgn%U5e
zjcS8T%+Q({Sb?j!9)QE4)NS#xk=81XlMee-uGlUtiva@=wJ4&y;$P#?kZAg8#c`{@
zwKC>YVYphhCu10Q_sV6twl#J$(3eYB=ktE&{fQVz22;NJ#y7!`AiT9$F98_AYB>?k
zCW|E$*d2*)*79|aWJ=IX#73krmH_3YF|f=haEtZvubjyBvM;~#3Y|f=O00!O>`%q)
zVxWnOBR+F4FenyDw-t1vs2jI?S#Q*t?Tyz*v)Q6E=8mImI`7PvJ$YQL`XtcTvqg6@
zYY!)F0n@$l$(8lq;j}-YiZJUXD>!mJ>5jXjiNpQWz7h?
z!<~jv)t#zo*G;#msBS7|CTuI3nPx^9qn+JWr)Ii#m^EEr&G%)lS@w3lQ8i6F62o$X
zR$6E@`LE4HEEWt3tt>5@R?#rLPQLVV7;QHVEzIn!zpXs4=fs0ygblfOkPb#CufFD_
z>3F#UnxplKzDfdBj+IF-O&pz7R9oE^g>k326faO*f85vYU@;M;NADI;TKNZI%UQ|EW~u;pote%xu+q~5>0s0_YuHliJ<
z+rdy?V${J&q9FPPsB=h;xlT^xSPIf9d?@bhwTDl+beGhV}2U
zB?HMXd(F;8Rd>a2`Ae(wcWq}na+LG@6_Fv{l{yu}1TM=azc^E2i~QBP$l?hL2_3kQ
zbLg>{Hhk4vEI(t?BCmq_ac)LJ1dOY1f*X1^RI_-11W`3*`n(;UBxVGC`ipMVX#tBz
z!Sx|&0S*%fCs9e5e<}KGty{<*R{(cqpY~RstYq=VlhA5g;r3?69MUw<>Pu|&a824k
z_*~3_WX9u7?AwX$cHElGST}!&9bW&Q-WK<5-Dwwjy#Sg;bSm`nc+g!vh6J%qpdJZj_mVhlmPN{K~B
zgN+ouGFvhso?AqQvxYa`zTqeVAmY=#Y6WcYP23St^UmECkpfnba}(i1SmsuXOrlq9
zG#hTp?2LDOxCM5tG`_&B}o~GtfRpMpH8|UCXGo!0B=;s>s;2O((xz;8ZS`ds*7-33eX@dHK=Bl|s
zws#DmC1I*QSEma*R6+A=VXJ1fW?C6eL~D41cd^!$dTl(!DI!k(o97HG0adX!jL-WA0Ju}tqUz=I!a?))jOIi%v
z|8WG$Vs+Ikft~1WVmHq8b@v-q9NMF95?@rZW{>Hz9+Q>6P8m;Zk2#`4WPB-V1}5I7
zzeljhf2%{7T#u6{-VU(V|H*~(B$n@acdiOyf3ME=v`~Mu
zpWtgVKw_aTtNnw1*pOHI%h-Sozp>JQ4J62#_{UNSId!F$9}?V;$ebDhvYWrXUmtgn
zFrOm6qGImpmhF*mlJArMgxo)-Nop;Al0Kz~|cFAYk@IJYIt2zQ*!0%tRhJ;7v6qiwcu_5$Z+VomwWX#|lx2W12eUJ#$L
z^(S~6H&v^&r-wn#jWtsn$|
zxko11y5fZIx~=TbuuCymnHB`^;bv~IwQzEB7|Vv(wZ8{{BAn(cwUV$h=g*{t(J8)H
zY7y*NtbxBszJX2Nf-{(sFv7b2oLnFRQ90<#(Y-pkZ&?*RE7`Fh&l?}vX91fG{D|SV
zc|Qf5B1tAKpZ?To$Q14-1en4il-(2`O+(mIAd=U1VsM
z+ec~9#!89&zD{20r2B2^qj8p#p$*67WhL^{)Kg|wW>XU$-ZZbZ42GUoJQqprvh##<
z10>G8FoazLv3p+?w#Z}Jlqx(^5evOJ-2XM~
zK@{C!DAd$bm5hH43JUDvQ$L|n!F=)!XD+_Br_NQZ`C3GPAbduV
z4F?s%J97%4xyQ_P3lCQ346z!Jv*mQSd;W6DM+7UQhu{b;pW!_cmAUm(TIEJgVr}N9
zpAnSMh7KYT@qYQLk70?vr<5bNU48+#@Y}7rN0s$wWg_dW#S;WK+?^HDg#Sv+CK`j3
zU&MtCuo3WPgP5cm4e;43OW!fJh%;g~Y)O83fWTF+?fI>@pDZM=6ywVzH%25RivQw@~vh>k(4<;5kJi0e}{a{gTK{86l)O
zfWYsn0|4XhBS=zj6p)R|G8)s^eeYUm-CUsY_2
zWae&U=4SWGFFMiYEI!heUM))v{R|*n#^=D~K1RRP<}yfCVd^H5G7`|-1oWmQlSyi>
zAlGP;$Xval@YSZS%thzrS%xv>Lw(Kmz1RIl;TA}RNCeA?EhNZQY2#u(Cmsba)eEDNgS{Q6_tL_>}BDKSNfKjDs}
zHO(QFh7$?(zmvu=j;$fl)>V~zWLzGT;s}trJFm@ysQ|l3N;W1f*ENnO75Qa=)M+1W
za$XJA4YNs!*zxnEDn$IUxBDGcm+zzCUlY9HTd<(`T6AChviCvf1Gpp5llkaD6>Rb;
zULqSvD{6KN_gH6h_yjdXsb%)wTlCw7gU2bITf@dW*3^T}NfFXcTXQztRDhdMrcOr4
z(et0A$3%mp_x~)v?OtalcjF{kgC(|JDd3LBN`I1dZZQxFnKZ;_wTXpA*^&iC
z=$q}PA8yTx#^_`e+k0w>Ui(W^#&e27iwXkAX_}1qM@>|`uc(0
zh&A(9mGvx#yAApd)-$$FX$q}{wTImpc4ECubD&OOE>cITU>1Q=jmivun>AleftRxO
zkqxPX4uOR=Nr6k^;MA?qE-FU2za(?JG?57SLl#r9K<_eBg&cX;3T>5l83W}A@TZG9
zY{xpii-xmv-g2$Sn0-fCZYY|ASb4Q!Cx>gfG+j9(8FyU1^XO5m+*m_n^Y9xfhioP_
z^O2kG+|Aq@>BIvYm49NkC0D;@=Cot;sbmG&mj*Z7{Oy4JH5+I#4kf^nZ?z234b}+`
zZ(r%ZC5FPm{?!u;2jv+kONl&<;P2r!CRDo*hk;7?vxhSAIRz<={wKjYv0^a(J|7Ga
z`>(XPi5Yhx+EgZ7iiv={RUqKDk%=|k1wkW#uZ~xZ|D?GWxQZ|Ev^jr!vsW}c6}F3n
z5$ZNe!H)?AW7H5d%sdiIVj$M5Sj0Ql1zkHg&Bu-S|Ma8#}s6`))
zI#`PJrLEK_B0=-VRgXgywBBm8)0B7B$7rimNXko~*~F-?TP)cE58o+3|AuJnZ-AxY
zwMg}Wd>uPGCkuNNX#U|`$nQNE>u8cupXFmu6+qO*;RZ0%0W{Cg|LTrWe#>kHCL6ad
z;kE!A*z!5W6?iwmvE`X~C;gzlNA5YKT^YQ+F8#IGULblj4eRci&YeTKV{r)7kbw45
zY{v_zUa29ao#@bN2ktYPz2uU-x2)NrWYZ{TXdz~@{N-UH7I9=(m>!&!e5VK+qOFDB
zAC~cgLH^HF@)AWw4!Bd{y{$_1>v}UH+dzT+=uozc`pXQ=-
z)BM_sDUsJ6{HdOK>?};Ml$1h3Y~Won-Weun3XtCE`mx-J-6UKLtF4^b2}D!6)Fx|78o4#67&<^d<^nOV@J7;BZJ((iMZ}o;
z_OPks^PQs~>L`@Xf{~9@->>XV3{`Q;!~<*W*;pO-NEnKEM0Ch%_wD*?|F;*Cn8F7C
zLjwkdo?r9br$`!I4)
z_HIs6fLtJ3|0pLn#*PtZdfa(rBQ2NOh*6e;nn5O8JK;njU7HZGejrk;)R1)_(HgsR
zPzejDzq2&??owCqOXVBDr~3C)WvMl=QC0{2Isw-4%JC45fKgxtg?eEiHdvKWsTP}D
z5OFx%AOwK)fwcvxu_xo@O!=5d%CUx%UG3YU8z{G+;EUy7|2@?xk?PGjOtOzv1$sTL
z2+>UXH(wk(9ezlu9?0PJ*X4~z=U2AHtGx4Y+o0gKREAqjg9`UX)ie|2$7|-CcPh48
z7WZy(MD1kQEv>x%tNP*Ff7RH-la~skIV;|+K60TkkBK5G`Pc(Lec6)BLII;FhJmc>
z?~R>vdCbVFfCTfODty!6_pOd=xF4~BF4y+)qOrSzSpvf}6MF`I^i_G-yy45?tFm3l
zl%q76y=`HidMVe@P|{M}60XFV44?~kJ+U#(7nS!
z?;c7|g18BzJ;w~u{;a#O!>9D5AW>e~!^6Fh5^8ig1&cjR9U%iwekkzZ5#ez}H`(9`
zfp{4D1jJZ_$Oy;esBqbj2|e2z>L;eo_`8BVierMJF+TO>X<0of&*ECV;=ZVyIz>5t
zA{cGn)(F9(hb~Sh!ydqa%M>K(eYF&zxJ_i%uA1Vm%039X%_dS|3Zw5h9y7KVPsTm1$oyFWflK}
zL#d&PD9MDH=xx~OTg!^sb*IWH%{m_Vf2X!D*ZIuJo3ea?A8wZBOxTdC_jl(m`ht8#!cLjX}PrFSc2
zwC)6>zJ@mza4m9;5eSII?Vp*sZk))*fx}$$C^w~Z(5eTrp4d3-H+vo$bI60j0!$3+
ziHf@Oi9*`Kr?(P9zU+Dayq4|ID0ldqG!YuOP?zxV`Q6s@zjyS;qX5FLh@`+2SWdj5
zUN%>LdvALUZlg)-^envH6T%u88d?8T+NMl!0!7qXV=&RL>|MVTfsJ3*SwwMhBtMdi
zkx48<{!6f>m)OO9OmKBp|BcB2@Q~7GBfzK%kGVkhn8)Ee)8xfbU>}3-3dZ`%C2xVQ
zyHDiS6VxDag>YUDV9JUbZMt!l|6z%pR&b-#+z#Q2MTT*H_IJ(QI}(4YkUxdXdiHkj
zjcKuVyzY32<=agGdq>p4rWk#E@QyeN?alpBCuy-9l+X(6=}C$;Gj%kT&Dr5lp5yt1=cE
z#$yO*t)6dKE3?tdT9odQt1H4QRaVom``ebmkA%99iL21id)uJikvB>!YDBldqDkxw
zL}wsWG3Y?P7PP|VfJkMgO{ektD3pO~7?J_1iUEb*(_ZWD+HBC6Gr5AFG-%zZPeVS_
z;&DDrf0>3hjlZN&s2K>#pORplz0>pEflmaj<1on=j4GJ#;X-+1rzJwCna4w=Njk**
zU`ThNsn)y91Nj!4{haBGwHu&@LTM8i?|VxSO8paa&6PgD4G+vzGohtAh50s()GG0w
zLYZ^BKlbFotzWS}b|SA81-7|A
z$1NAKFAN0;)_8v4xEb1pD2Im`79U)X;4P?~#bVt97dQf)d3{4+qsLUSD5N>@$GA6X
zi`FA4Ep41GyT3=BC##(psdwaHBHUh#a|#V);DUxb;9P&6Q`C+=R$3CP6J1?4RygHv
z)+K&KPx2LiAPwF*Q;q#cGYUx|J@WE#k01!Eg60OaY&S6>EpC8
zl9c?I!Jx!ZA_XYicomu)#OgY^Z7Gb@VIkvMXO^XX$;kll_s
z3&Uu^i0q!`Dum0pFoxmtRjHy$eVq3F>UFp1#i(7%bd@L;JH$D(++#86PoZ8&L+Y_!
z^;QuCON_gTbWQ!ZN&Hhjle%RDV%-O*Ln!#vsFh
z_Nc7LSSu#7w|jG6U~9Foc6)Jd3M_O%>h@%oX62C+GqI_h}Vl%CmXa{jW@KfLcy2FxdR$M|ctj$k>1
z%FPqtNP2Nh95KB5TNhD~y-j%U2iKmeQrSEG>TKbP%lELwsFB9D=(NZ11irrjM^Jdx
z`T*X$kJyw0$CKr6c$hL=Iq)^;mhCr_B@;0@rsrRi9-l8=IKsan&?;^E1M362SW1D%
z_!wxm5&0Cudg#Ka?PpPi8;U!DAHiK-9VS(x=3R
zf1#QRlX2D{*uN&;LnZaw;w}o|R(~0R&KFJQS3j<&4ovK8WjVf+Wm#4>!gNGaVn-dlRd@3
zeZaBz{nzP9J6m8HQd-f&giM4a?ZWXMaM^1yaU-Q3%$ewpwG49;puplvF1bpn?G2FT
zsa>)gcjUH5ts3|aA!-|aaz}HLq3DrLZ~m4y#`cM(@W?8hvw|~V*gcJiBw}9ppUX;C
z91z%jQr*eWiXQHd;V;|9^E;S%OF-d5AJbI3g^BVWOh#nDlB<|_=?Nn*%4GU{eNsK5
z5ITERzTt`PQuzrSUx2%hw0eZGi1wPO)R*)bz(s;A=1lF(-kd!i3N-9^(m7Q%KlVU)
zthA6QwVf-9#4LNvY(Dp)#2=p^7gmvQX!8jFMU6wtH@WMov2=!+5VuabOP=|tU`
z_~$+N;M)&vGYBg*H<5Dw+1d`D2~TT?@C&d!58P|oUGg%+;{s|Z(7w>)s2Y`=3hK80
zR)FK02R~1U(=U_>UaRxMC~c-rJ&D7cd2N-dnzU<$oYvCs34lbA(IxUS@Qltbh)jwQ
zu@Ew_zydLrN)NW7O1FQywrQM4vRDE6^gwjpK6gtcjF0E;_qCv@?v{rqf{&w%u4cnI
z?y{Bi!pchdU&1s1B)YFkFuZFRV{O0O_{%KXiwb=(
zN-cmMfI!;o}(`@~X2bkgl2DFxQABWbRaM~B*5v2MUbc|ws7Lx+<9MqlBic5zCL
zVYG`NF{RDC@FX*vtB|Q}9Ddxw2z=}%C7t9=)+Ft?v82VBN236_QdkfB5HP=Jp-itZ
z*P-0A7yWNL#=z)Aj%wc(1d0BL%>TBSFve}0T*`0L1yxYU`<#>#C!OG%f$%1m-4&RL
zqO`q)c3_6Nl>KRF?7$~UZ1ij6Z$DtERaZXzWXN{Y_BI9BAGujN5F6Z~L)X!u&TA}a
zs3gA(vDK)UC=W6hvS<@@>y&3yCr@cA^k|nonoqmmeD$i~shLlIA{@2j1lxdxQU9E}
zcOhsGaF0|Gvf+PK5~$lz#52}1Xf@0YrjqdwAEJtNm1@l3aa{dzc|`Ca@)EeyKP9#O
zPHX%+@$nj_Cb3k7+l3}0mk?5XtVsFuvFl)w6y!WpNY;W9n;pqXDa|7n%}E9J3ad%$h(hI#(0_2#A{kMzZ8rJ7{RH*R!d8_<4%M1>`$s1Is}!8OU}jb$EGt
zk6(mW;89hBuEWk^yozhPHtNA`{BXZ|KaeT?_D>%S;SB7EyxnxazFhdKJhP+|{wk!5
zd>>)hKDadBnsF|5NQ=i3qvih0M`uOWlu)Si^YG+f2cM1${mP;`!jxdg;zU_g!>(4D
zKJn9gRt?oVSBd;{zn|~TU{KsH_I5YT`pf0QgYfhAeZTR>+hx>)gP$JYIFB`8V5mG?
z!L7myK?d_@LwwOrWSB)B3-BvBPwZ1mp`atX@iav(%zx9V@#FDswBz7K@uNA@hamBi
zQ51u&SXT|RAcL=EDYZh`fb!nsG4aN(
z2k7Z?lu^6)E59C@SdHDE&;CpOwWQ%+c6PUozxiyLlNj+4O$?P-12yfFll0{1=a1nF
zb%lBPTJH|c!Y|J|F+@Bb-iR;!E|15mS37+U_F;Qt-G!f@%xnEA(k;7!TYlpdSm`OD*C1@KHFt-OH^_^tdF}Y{*{CYnh
z(svJmB-yFjNa&(+ks@rPdbENKYiI(fifH$7ul`-Ti^dAKJv5b0F&3sPft9)?oZO6y
z;q#VfF6r=Mk&!xN1c7#`TS7k{HX*F~kNC&lwQN67+-ey3AY;
z_W3Gn24(So6AF
znvls}Yx@}K^df(M=zd#i-thL~&wAhacs6c651LVN6n@^75%JNkPdCAGON?6Px$+gX
zZ6$MUqjwMRAMnav3Qr!H^pC1v^zs~gU`0GMt=Ez=Yy*D&<2-$4cQC)MMJgj9)ZK}0
z-PzFi6r=F8+;TAW&&=|%8RFOhIzNTr-qsuY(Eq4WEY~$j1i+W99J?v?7Y5
zazDnnjPr#2IK6Ofh>@muXTPniUiujn^eC^a!fQXf5PamV3$FasSCsw;7;}7xRO+nY
zbC!A;s`hBevpM4&ud{>z?{C^Me0^TlS^b`81vZ}NjXS>IB#1oibbCHb9_+5RevElx
zbU$vXoS)JuU50JIlG}|+ow08z)mtu`3dfXME^Xr_9Z+Vc+1i?}g5D0|+~F{xkia<=
zVhEl%Xt@>nTA?WMO;mhVHnn-3RA_7lfe%t2QFvzd@mO)6-VOz@Q@o!Tu9787K*Ji!}k_2Et2
zdS3G#R7abcDqpXq$!KK*E#vxf-x=p1^!Qow@%=2U*-@nB`_B5r!^LXr!{Ojt9K?cj
zJ1Fs*9=GjQV#X^Rnr~ye!{*7{-E0zFfS&2u~xcS+hKNL~|NFcpmGe?U;
z+?(aU0gr#?5xjL5xX?&{!r@2wdEB3pXZajq7-64;<=dXG`Q1Wqdc6qQ9YHKJVUFE*
zv7);#JQwR;)LV~mQP{Dn`$Z(J32{(E`V6HpF1-H#5f|x9Q2L%n%ZLN!z$sS!e}j?<
ziUb-hHJjNe_Yet3Vt-Pe>NqSbt#tqRIOsVaJe#WSzRp~-ddqKiXcBm9cJTGynVfRm
zc)`2sOwYzok0F&}G->5YRFXRVfkZOU2S_G;7_cI8K=C|o`BjrYkJjeHPEdR&_=1>C
zBo&7U8xSCcDFMe{vpkbj9lwWQ$@TkXNtv$JZg0W1>JqXE{s2AGD%ud4~K$!eXz1oynv>hP$-IiH+hJc
z$dN=3M~nt&mdMCy!rqr=;R=ZwbcxL0E__K$cHBXA1GT$X_=_UgwP8c4-|)(eWKNS|7SUuG$GRodMsFV-HnyL}RCuK;+ZMXu;@$r&2~P*ehr-I~xSm+pDyvwD(FZzn=xkYeWwG49
zV1iE3+Au_(`3xRY{NA)TUe+IcuM?WjS6iv>Uxt^i@~3=R{0U#cC3xTAMk&a6^J2wz
zZTv1Eu&^EJRrmxffdB;A4{7crMebp6`=NIttY(hHfP06pSEtCDh+at(z1B77F;}CW
z7I+>7oM5|fE;w52@sJ?kPS$lb*zCC0_I>BRllUQ6?8na5kPcZ>{@y5&c+b9Hx@{5xX@#)pI{ou1?(eTf|pj1_V&FiljC{Q_9!Tn9#OBWz_w
zG5>}1pVCPYajn(tBm!L*Ds_O17ys|J5j$E7^i>aOSBsjMz*`~cQubtG@buPC8ZYXW
zdGNJx}9nM?^rUy&|g{+d8Yud^!UD4_?7+35mn
z^m#V@LAcfH;EN9RdS_f6e$!4SVs^+c`z4#MFW7)2ucO6)InqX%K%y|JZ3u6#02Wi=
zNxDW<{hz+IApq8nmjZ?ccWAIaxd6%YIQi+%JwE6)2=(B*8*aK!#>R5X_m{3kul+Ok
zk0)BkHwas5h5UV1Rz}ld;sO^Fc@vz6
zgh1ivn!h3oVcMQ$LN<~(v|MS`etSsUK3wj3lv5Z)YVgIN4?v0Sh`_6bOLZ2@j>%5$
zxcWZO&g0kAF8sV90(lL3b@x=ZzRVCbpTFj5sLMaOp=>I8a9qcz)JN2X2B8lr^E0mz
zP-$1N{ntmB${m!m#fN$M@9$AfyY44_^lyMFbS
z{U##A1v&0!-d->+);m8iJ}wPoAqhI~q##^YCiU7Z!EiY9)-#XiTK%@mnjDvO3WWxC
z8KNF~&p^BQ8qzDnnw8KS>tx4A{tR^Ko2~P8XI|`j6!!I89^mXB&CXn_ubPaXJg?Ru
z)xFb4{m1>r$GIQGIrsiF>7)LTT*OM2{LZ;{d^RnN&X8P|M+C%9^yy;KdL#fO;i4KR%OEH{gx=E3}vivOF#g`(w
zi@Na`^!?k%tlzu-;?>%Nus?<0>nsoCz2EHnJWJl~xrZV|{MGj@X~BrW8$MRDrxU=m
z-6+~d=b-bMcfWdLK-|j>+pO~6nFo_4kGwJA&ddrxOV`m>8i?rGz_A&3f1Y*#&
zR~30bU2qq9-+s?G-e`L${|C|3r#o>c7yJD{?sK)d!|Ha7_x$BPkL`0|kps6vn-R}x
zooO3jm`X-qR!}G7T<<@y_%}>*IluLuyM_gU4hG>_vB(x&w!ZbNqsbl(y1NQVJopYe
z(e5qXel2pJ*QNfj?A-i|jStM?E!K}~)*70RH@|mcG#O+WASS9!0YVktQ0(I)+95PK
zTm+UJ`KI*hCqtBHiv;lXxc#s-pFO&MrV}FZr+%#1j7b4RnR;!bcA)2cid$yy1YDZZ
ztj27t*U8ots4~2zs^@AxD2@bUtyFKD>+xuiqX%FYnCKxh1d;Z4vNVZldk>)0=RgSC
z$z~)rN5-@4|BTE(|MRDS`GiYHC+Ql9$AK2`DGUAfNhUo7Jjg-7(gAw!Bk#Q3MonP}
z1vnp^3n5((POMyPv_#ahsMO(j(OkMzgjuLLn7k*dw&Cn%sqwFo`XMa5BPj$82Y#y{D
zE_|$fynbmT?(%+|A3O%qTyFP+M3oC`B!kJ+b`
z_;o@VfwZ$p>8Kf#KlRwPdtFr0DSVPSOQf!=iXoXv~5i)Tr9+-v#Q1%ALHX(<;IDwKr?J=kvG4H^finGQ8IVHwRr#_l1rStLcRw2sIGymt*(S`^&|;
z_eEzqkHaeV1<_s=hrT{AKdo}2KIH7X06ddat%iAN;@t~Wr%l$RO3(NI@-Pu7|7{lW
zHDux@ed#^K+ARchS_%M<1g*Rqu33APNJL0zt!}w7gPo&;aT()i_S>AF$8Ejw#?xuk
ziwF+6<@<#3`-{Q~0gIjCD%07fsvmr;QZ1$^EUFMvzv4J64i)Y8Fc>w~jByMcPBz4N
zG^Ou;J33ZfasSXu?h+yby$>}6iA%XjfWx}=m-VGFyz12hyPk8(@c+)-Wb_4B-ZcwvxmaaF~2C@Y%Ciq82>4w_-n!_1gUJ$TB}f
zG&H3p-`d@WElQny=TAh?#;HH`Ymv7*MlGz`Zjo3jujz4UCU~sI)R6WL{7JUfy$xAy
zT=!$n(dYzyMTYhzHJT816-Z6<10CNB0yeO#Be|o!ojh>3IOe~$MInI#{Gzi3+JijU
ziP5JV9SKhEzK3L@3P?dS$$6x(V6)m8@OL{My@)(+y6;Wm9G
z+505RYHzQGhX7?&Zo-7pEJ}+~p*`x`E(Oz%W##bKcL)<@s~66xUtG%?(l88NZ0j!L
zb4Ua#o&TLUW6&Ar5i283*W6QcI-pd3D@Ty1M0hj4ji4nZ1;l!)WZ#XAu0kmE*92w-OsF!G%Vz?sMKZezUeFC;Wv?CT{Wc
zaE_;|)jc}fD^i>dE&!T-Q6W0J2W!M#6ec#q{_e)-XQ)pt@^FsAX)O2wFJQ(yu?oz{
ze$wQ{w&MJL_OYWHUii?%$HHKBt{-Y39z2o;mC=)l8oR=
zc$Fn7%v~oFmTHE4(6OojLOq&vc(qr*AmRsGf>GTzc4FCpizo4z>Sl&v<*&*s_Cgov
zP-1tNhOeP}X}%f+dg*1iMQ8Z9jnHPLY|lq0WZTkGxu01h7P1c}4SCat2&Rm^BX*V)
z4j?-KGf12PZxO)HzC9n<^`mWXvDu|0`mh+kgzcMM?p=*I7)bsmoP1s|?nJ}aU-J;WxFD|t
zGrJXMe%Z}F%Ool2SLQ$cgA-ew)s^OF>EFyo!m2f<<2;>|K^1tmI6Sm$q6_2}gOm}#
z0+Z55bDkY10imb=bduEp`HKC>iC;(>@oRwN=?RVF(B>{X{i>QET*tkcXQ!e{B7kUy33y
z^6Vg9h&o{HsBzjly&vQ|U68+X;i-D1%ANijY57>S9o}j!h$`s79O+^_UO#A4vD`H4
zU}pS0Wf+3WpV)>yZ8DWxRJettohzNoGbtWpf|@M>6RU`wNULr{cS#${AO7VV8y%D(
zX=E?XVpJmZx5_Lw7$=Mx(wP|uN4tl7!I_l_Zu#=LxqINuJR$g7C$COL+`O=~6;b5d
zmh{>ZP|!Gn7dF2h;5Y5+!{LVo4;PS0;_Nk=VjP;E(@zpY;*>G#Q0Lx27A=5DtvtRp
zat;&+#r25Xta%NPCTi8=`}ww>5-&&?v#raO{6`_Uao-!mRekR)bs>VMZ_h+AJpi
zTWQrr
zg^(Z37fJZdO{u(K3Md#x(S&Sln?L&rbctF;;IF@6o=BcDsK{kRBe09np3{~~5O)#TB7^@A|gjV5GR&ft^7!137(Q_oG5`QW2b8Pf84a3nrBzSO4i-*sK`ZcV=AmQX{|8+DcwY1dlVGCGP8blBOT<(LyR{D6_`TA<$?oMmp~{FOV=~w_-*mm
z?WBBtt!_1b8oCF-0hM+~+by&_;~ZHgF^6g1rcgRRjn!y$s>p0?E+j2kCkXyFAJaB%
znFwu_n%!?9j}B5mM$$h|S{hon2%{{==!Irm#d^fqc?o|~ny3*Yl%_s?+?&`kT4m~}
zY0SJpYi4!}WlV+_h(y11MIMT`lxK*t+KZ
zS^=g^O*Z=OzUa4?UR@b?U)BBo-)~rr*BaD8FhR@FC4^-CrC#JSxgpLZmuQL-c9ttj
z&P~kom1hlUD->_L?yA0GJ~fF-*z5p^&2DNRlHY!Hr;XtmL~ZvYP^lY5M&w|i0MF(5
zsCk2zPneK3rGKsSD5*T`ac1@jsSECVrV#?^IqBrk&6W$_U@Z0b4nnb?|D>CiM2_4x
zJ?!T$Hd%`qnAsAa+(qZ|G-KHO86xj&ym(g!MR5}_!GeGvaN!5GKm#fW=j2otFokrpC2F$vEQPe^&JJIIw`blDRda$0s5n>iNDl4}Y6k1=&;>1=U3F4To?#^%p
zo8ldx1^3qSg{~%;{OCE1CgIP7<`?3b;KK!q9nhinmhV-0$FNJ!j9AaYRUGIJpKRvH
zqpV*rcddklJDlOB#n^5IH*m(Fpskh)I7)^mOI8M)bX7pXUlfRXx%^?NSkJzl>=^!q
zCc<}!!gg;I@Oo-wgz%p>jxYo=on(ljBx{$Pw#hOojD6mg@3dJ|iiM)bD@YL|WJcEd
zE&TotBJlDqlPY=57A^)bo)rsal!Q#Lc`Qw7&ub1kL+z}6XF2A;nZwwkzCU7p3J5@y6)tqP`^
z4jPZ<)#5eby1&f;<2LrZ%5q%b63W@$^iO(N;%wmJ6w3*hpemg-#IuSa_MZcBSSf<;
zVx9T63m^-cay;RQ=R>4I}cT;YZcV7>d{{)sVNOOJ1$3XD@j%+0@ld#Fs4VaJWl=_1@c+zX5ls;+rcyMv;{m!g;P5~oUdu+|RotX9E
z8|?zd0%BCq&RVC04k%`QLnJk>cx|g-CbJ#sXzlwHez@%27_4OKA@BbFw
z1SGfMjN9qzH2x~IG8Bg(nlEgGRSv(?4(65etyfYa1tJT_#@kHow9APb89vq3Fr9F1
zYc-+;IqX&w+J@@Qa0m7()WwJiZN)P5*ijSKIr_~Ic{f)xKx5U~H8g18-KH%KRvjg%
zY%Ma+d!gJs+AUV-$xC-PqDb
z?YvzjF`fkVFF6ZQguM=w#aR;Y8bxmndtX$T`_Qes#uW#Rkc3A~7%aTp9Gy3a;G7tl
zh>b#UgoJW%0)4+MNlLr4tr%P-96cQtPsAf1S)|ydb$Yq>?PkAcXrX=d1_FbD?=zpj
z!F$^7MsbNVOzzOP(gEl2%ehk65EA(jpa}XxR-O{YnKYsh!;3ID+
z0}64ET9LCeSfs%CnyE(g}0DEHV
zy1r;kk9#W*ykFE_>aE@ShEVF1`vHJ8{ggRbM#1}O#95F~#F6AnsP{WRY}m}==!0(%
z1z=k84+&t&qxa{YmaaGEF9n&+SSa2^g^9l`N$%n35_XoAVQi6F^NBGwwbPhp-Ow9a
zt>LlCUPA2mD{QaIw&hxP32@fk8>h+@P}m@XX_D
zu^y%~*k?Wu6Q211T~8MQWvr>b@+k6PHu|4H3Jt%!lX0Qwk5r+RZY0xB3*G(lPQ6tG12)0UnBD{vJ`17z?O#NS^&xuNROxJ#~>b%bt
zQGA&w*&~kP?*V=Vd&~=#F%i1
zIzKUy$0ITRFZj_%k8T>a$AB;hVqkjfY%tw91&;4EMfQza=9C2fyn@=REINg~f8@?L
z_;fq`&`Kn7r~z0X$2x|sYgIZ70cUY2t2#HVXE9EaXKD;9rqa&-UMHn)NhLO}*#wM9
zV>;}c4U7%m7~MA9AR;fZVqkbBAnSm`GpbU`y#*_Fxqpi`ql8%oD7i}gT<}&rRYAzX
z>4TW`XnA{I4am;}MOvNVo)(PSm7)JzKm;PiH4un>xqVu0UhfGJS7&`N865%zwb9wuKHb@LG_&3#B1A>)focyY4>GrSb^RxGF`CjRJ#8zd
zbi>qVt=+j#)SO$1$Viy+%dv0;43)OsICaqKO`}E+PL6;=zpJHRWXgN(8oWAGzHNT|
zW7t55rix{J_@~3{l1qDL_Ls3Uy4PG>BE4U8z$Gwpl~+iVUzB29@_zg*vEB@)WkC(H
zWI4bcpe|Oc`=X`QYlf#F4Zt=~i$;-yMdEz?H?|<$M$JWK&0`#(t1J2>wynD&7F_pf
z`LZy|Z4fgUi=C~-aiT_+F;<;DGgBIey0nUb_BUx$q*DJaY#Ji#AAc7%=XyFT_wqEB
z%|l*SZ9DFu*yJ3Sl{ab3qliVbTpOV&HvdGIG06ot*mdl9;cP~NZ#G3rhn_|nNdOys1YLos
z8|l%{>N(wc#0I{5c%1Qe@g5g+L#Y8)iCjr}UF=c^j4ieB(NI>2thP;y*~LPeNA3u^
ziJn2Gwwz~7^Z9q@aPz?*&pV%nW;E>Tgh$*T5d(pV(osApzVI`+8uy(2_q!A3Dd-~$AKnR_IDGz0^8_-R@L
zx26JC*wGH$6(wu^-Rl*$PcWN++$zy=Hixwa=n}jE*IFz$9jh|*u|Z_mOf9tZNbM`m
zq>rewQ);I2wyiLoexTntbpQc$;lf#DgQb0`9!Df#-eTv65`4(mPX3H1-h&qsx?&HV
zZZ`%*Qo;e-`gSU1Ew(1YaO&eb!4hnfN{Fg;Jcvl&ZG4`V=?+Q0C5pYb42{7)iW
z3+PLl9%25A*H}>Jxrc|#+35NRyAf_UxEFG}@Y08cXV3VyIuxjQgZy-6`c07BgkWFG
zB$!f|UoVOvBY}lY&-79(FW;>=+hUFI+V`-UI+Zv9;Dw(oZpSo`Ba0c^$
zC8SQ1n~&1#pSN=q&WMYsUmG|dIll%$3UN_A$jB(yT;F17T{RJP&-pKTA{x3eu?zPN
zbD5K{>a4!Uggop}2vwQj@x!G!$f<`#H{F$ASdX}s6$e}z*=Wv7_F?3C*4zl1
zi*ibo5rRDRV~Rf03Op@_*ZmI?LG8X_Rdw4E`_1^A+Nd?K5erIF4?;JMt70P=qh@JU
z+f;lHb%DJ|ta;v+s=}0*l65Dj*?!ZHX@ed;@AEpEZhmx}42BbcvX}!wu!zvG2U-)c
z1JLU55RV&$0M!kqlc=3#z0P1N7EZyTIlg)szncVZ4Pd?c%F7aVufFk3{AHYF;0P8m
zK*1bOue2A@y18}*}?93caaUc
zK^A+NAGAZ9lG*NfDIDkibkUwn(bU;+l8vXWIjlEr?H%BHk0!JB6eT`sk7wQKqIYmK
zKf1h}%zHRPIMhUthrXWg&1bu_#lZ?V!p;0ldg){}TRnG;9ye`4AvF|}>t1R!F4n4c
zyLF*bt{8@sr4X3V#lBb7#e#RztpSAq2ojaUCTgYuy}4ORj^?{qjT9i0k}xItL8sNQ
z%`Mz(+iK*i3{VdRpjZ-8Ut{*E?(>Gp5Q?f(Ho#)KSyzaP7u9U9qFYtXsT)3stQZ!i
zq#4Fl{NEq}j*9CSRb!)C7o)=c@sm8QT^4{2evqhRUUisu>;Q1co%b8%cU
z^rEIWd>_e_bfW^Nx`CZ_X#jRY)q37LDS)^6db3%3{MfUG4$eSYd$ZwU
z*u#%mPukcg%Q1!{&eMEv#;GSGf2H9#f9`AWbB)H1ZDUjwbiHI*%_sttkY&jRA8H8`l^6g&qzLZ2Je3d{$CLXB{zKxfW^@E`dXN<}>g#2T{bP_Bi7
zdtDNuW?fT2q+?U_X`8+#fGy|{Fo83t)d6ruoZ+MFDAXX9@2T4^(Tu~o?eC~I3b*En
z3D@9kNBGhBUal5IoAqYh6<=0%G&LO!fnC^XiSLAl5p+8`#1HKb`(i^bPwZ}FXKgd>
zpsB@13Q4=rG}PdEBYJwP)%f6`Go4NL4~Sm7Gd(zj8oTou9Jzn_GMW^{jVA|muqpY8
zuLGDs3ob9j3CW>z_b(q~4vyA~;c^DTR%p`8C+VP%0RRP#mrGcX8v0YT?ofW2BohVA
zS=@Qj$JZaP4UT1sGX)~CQu{d}lSZ}A_m{nCe>5LpJ7P`Z`HmO#1F@4jE-?Pha5hN#
zt@fnf6>E{f;r;fY)k1yu(tIuF{*bsBE)Euy94)DEzC2ujWBwEF2+E;G6!c;rbS_ti
z`%hNneP+O0M9?LAzwe@#RnNbuHn(+aqp5Cd8p=)&#c~mn5h2LUY6TYLr({a_4>$Z`
zsR&--QTURxAXR((E}d(+iUg`3E0a?c;1u4Bm>mXcT?gaR@cn}EJ653(W4xQH({7`A
zE2bD+18%C8gV~2qQ`NkhF1Ej{J7P#87&78i3>cHUt=q1bwLx=HGyGo9$})PO7DWYB
zY#WaT*OCnX!^)EFrh;m=(v}em+YwC-^u-Dxmfdi<+%e+L^VxBEbb?C+JI)V|;@+S)
zTTJ&3hSOQr>+N5=ii?9X!7athx$^3(csV3sN(m_xE(k-RLvNt%;K~(_yT``>^ziCc
zP)mdYIZF=dqiff=gi1gml~59N0_c-#*I`GN
zEB5o39yh=OXUp{n6-=gZM+Ug`JtB}LhXRl&*u@7Dad*1dUnHFvtarx)ECKOOOE_p9
zR5Kn-ZXw`d&1nPqvQ5tn*ya@nHLYCIG;q0NnRUm(b}XpPi}gB=&bfR!D8L7dF#Lg?
z)Uaq<>5c$6j#B4}&uh3c?G}ZJByd*1D~NTw3
zz9yJqB6dqqa71jVYezMAQ~@=7ZIFtB#)+=GUP*Uqwy-ZH7D+T*zpR^h*`-`l|md6Ian^H`+Jx}@G)uN1(+a6SPe?!2nvZn1(E}KAPn*oQ*aIs
zK^|l&{d9m!0Wz_6)<;KV60_l;Go29UPrg~pKfe#Z5C0m%@8S6S@UJNR9*(~czYo6;
zzYot2;zc-aZf_z!oyVP)SOqs<@($-@Fdei8JuiuHMdakNIA1ZEV&rhj^nDCgTqrvX
z@wC!>+u-qh=0#z5I2g?*^WABG(#6%0UJ%|+yPplmz43I=8?;G?VUxX#bhqCcjJoY^
z+UjJ3QJ*-P45o|W1ixI2G#bm1<6$etvBPxcju^+>H0$?qfBA`(jO#{Y$iWliNE#cu
zH5kw^uEN9fl7wsJiwhFu<0;~+Jo&6InmwEH&(0r@Q2v*Ore)wC7VFhgqlW0}x~iCZ
z(-o7{tvG1dVm<3ZwM@(f=vsl-FmxqfTe(td;>`#zo+CBv3jWX=wK&2bFRLjw3?xNsW&n3!!LHqFWF*L2q=L6fMYuItoBd08#j
z?&Qn-HVi{HgEEHa(g1Ev!VE0Kvw5;RHStQ9Ti`VA)aqe7vI3{3if>q46=W^$$o~a|
zxQfd01BslaerhK3R7U^uP-t3K+H3l$8f3U?a_dokk~ZQF=^Zs+oY0NyPDHGjVupz3
zrW}ikO?kyj?5uBvspjSYtrW|j>kqRkHKKGif)=}0<
z+F}u%o#8sLGk-=!>aLm8W8&E3E$XDnwqjpMp%@yxy4f)pixo8Zr_j~S_(?#7PQI=d>YJ+kTZ3X;9m&-pNf~g4k;sctP^HHw1z8Yv~anekD#V1$;}f>iyGiK=#OHs7?HjY
z3C!2KhnK~!)8wCAyGpCL9mQx2WyqHt2l-F~Ioz6RX&(91OfedqH+8~Y_?P*~kxPgW
zG5M4^l~EqV?lN#9osbjUkADE}gAh61fAByqGA4Fl&G(&?4I=FXK5428(}de&Fmfku
zkYHtw#U9p}HuNrJVY&`A%V$6W5pYS6#D2a;YVep(Im()840neGJN`jvuBtYuP;;!Zrow&acM9i<1vy&?BhiUGPQgT~ZNruD
z(N0|~Do&&-F}N-idpS}VYQqBMSk3pe<5)KhF(oM95^t+qhA2rRPY9ZZ!H=jGISd&Z
zr2uRQ_r;w!$l|(=rRiIN>m?yX%(bW=8bDQ)k)!CP@yO$FCB0t)Z7WCBIYhc5@gaCE~FUkhd`-8nwGQ{5`%V6Wt4|AkOkZ!Ekv&T@lSq23phbjdXv$o
zpM5%{EA#5um)gctgBV0mLo+MyBZa|NcU&4oT(LQuY5Q}|Dh!o>m?!qw_lc+=z
zE62Qk!D8H(YrA7%AxaXI0wThF(qHBjBuLlg>=VbCQ_^e3S|LC0&TZ8)KKb+$+|RnD
zzy0pJoKg%8YfBi6p$}c|C^ZTVw-40#u2y^j|!%dZ@YUe}RF(fzh^>
z69W*!_%dZfhV$
zMaNmw#&C;ZHwdU|+J38}PEuB^nqh^VzA!Me4ip)62OPt8Pgt57mSgC&hMRQ-
zn-24^?)W&!Wy6Nr)KE+k!93(h5MaOLIe6o6JF31X4Svs@0pP@a5#!a-C514^Th-o#nz)B_~bUpXPx>8-pbhMa>w~+Z78McoSjPtEQMsU3RZ;^#qxw6xu
zW=^?bh}(|3Ad{=GH=#?;Vx@BQlDIP%qB{II@mguz?``9Yo-o2
zK_V~+JPwCKH+Jazoy?4VQJb!!bwrFq`34Zy^E+)Q?^2}F2{V*W)b2$_#7i?8M%v)&G#6IP|T*6JI{mX++x>;`FYPH;>C*q7kpgeu7
zMaiDxsw|~3u&tYA(5SRSvGIX5X}FTR^HA`<3%_flsOJP6Nt|dbwQa?~aQlbv{Q!Q%
z$Hc3}U8O)3t(+vvsCLXTe?kbMIqi9@(<18#t$2ak#6>UdR8@5YHztwHJ
ze$eTQ6+-F?92s2tnEEimJ#s+*8$!}G}WI~ch-^=vCT{3zCJ$f;AtvT4GY*p(c`
zcp1ZxtASOJZ4i`g+ep*g*>@ppDW897kc0vkNQ3Lv?c1^!eD<@SVUG3lfv9vJTv`gy
zFCY{yfpK6=j$AA4LAp6qMW2FV=vc^V9RN)gE*2Ae?&-N_JUgsPxL7%(61+y4)L^PiJ;
z*6MdL>xT1j4D(FHdbJdTLj{xOi%g1rAJPO8luj}2ki^U>$_QsUO?uL
z5W%MW7ojOR5wUkT2(y&d0FKeq>c^^~Zr3Yj?My1iLtD5Ecy5lGoSpwER
zSB{n#4Q8iWQf!@K#RzYe68I~tN;>G|gW-tLrl}0SY*kgZt70hiCSBJu;UmfsJ|f;B
zDaw%_f?o&iDZGC5KX_;KcPt2{qUPc+<6`4fVvq~;q7eV?>;Itpnc^fhBdBVw8K#CG
z*G;$7)Qe4Bj7t-@x9VD1cX5#ID8r9#+8#O)h62ixV&F$Bj;}c0PF+)-6h&!9o*LpT
z=bx8|iDEfH--ufIyMiX!wfqy5y6raIfD)`YGNaH*+F~9mLyR(#jK($F)`6X-@t@$+
zP2x;`-UK&^jJjPTj4Or>9ARS6@54*rI(`*Kz-D-;$3!VSq
zyQtr>fDAgRgo|Vuy#QXo2zI^v+0Wj1`DHo|nubVHl1wIGFAO3JP$NJ*JqYd)18Cq5
zWzwxM2|n_|0ol=@8`&v`c==fidyn#QP>5;wAuN4dbouFOF`7@72YUyX_iwy<fA$
zG1)Fuh!|RdG@T)Y9ZYwZPW0>Pa47$@1XKxqk2O*hAkJ31v=>b5j>q!NVwgDH-9?We
z80mZLqBpWjYDs=VBq|4`Avijf=g^eQiEyl8{=#v4*asP$ASPi=4duTGzn`os^;x&j
z85g(BwO!RCw1Z}4(RQ`1pZz6(jX9p)&gQs;|S5N{|kZkgiW;gz$=
z&p|H8OC%MBkNhquM|S1+9EDrWDUb$wuG{GBOViB|s5?!kq&wS9#2}6*{wbOc9*G!O
zRpPhkTV$)=bh0*y*@TiDj-%Hs2R`baZ^lWXX*BEz
zuRIy``K{~J%Cx;iJgfkYz)tALZkI#EgJDV20iqnh!SD58A`FF+BtU7Bp0$-_xa3~9
zqxd2E6n7g#x8igI;&lU^aRDxv&?w^(|NNjz_5w(ENfhtL#ni!-gB@oY{Wh0Pa-A4KH4FB}Vw;+ot
zg~MQ!h>-!%;ADlZSbPRM?1D&q?ZFfk*6U9OUJ|fw!yhr#pty49(vNSJ56bNu(B3usAgyWKncxuJ(%9_&@Gpppk7RAyUFcglj
zTj-1nY7y~>ghVq^Ro!z?VW>j5#=6+3irJ7od$S5$Dp|jWUrYdLiMx#>M*McIT(@*P
z356eBF5%dcfS-wSaF!8|@*|p>sw<|wS)@n1UMnLWui4Ggi=`rghHa4%Z<;WEG!jpY
zu7VRM-XaoHp{V(HyW(pMO+3_AEgOoV7GW`%Gf}B(lM3g)ws?wN*H!7NV~`Ppi2$9v
zu+qfuYc!-pC4gHE8HpsZyk!a8!R5M*&c2j1f2(d;$$)m;Y8Yk1V{Il~Hc^xXRlJuY
zZZ)>wD{Z_{gVlU1tKPorXor-FU0WrF|
zpXgpzsM`&8_lC5vpJbbrx)r50!-jO47oaq;ilJGdXZaT8ixF^Y&7j>yT!(3^W?QNs
z7ZgNdr*4=A7*+MK-8Fo?`v|HQ6g?dd{Ct2BJ4wa&E4Bl3;UEsRG@uD9^GDv|{T}fQ
zJrE!7LD;$@Vt}LmI|twX9SdCmj?mHQiJ*i&LLVdyr0A+_f(&A0hoy@FEIJMeh>_5N
z4oV_lDZ*QD3eY0(p3oq
z4eCQxB@;OiStx+xKW7
zHwadTyI@qz@_@>I0wV&lST;FHc_3;`TNBA%A?~IVI3-V*u($$DM-&2Q5!=Jr*bdz8
zNIY!81&+I7@*Fn|t5!yo;YZ8I7bs%Dt=J~$teRR$1tMk8L;G)6OB>Z<
zO^iNJB0IY-ly=IxLKmv&8oVPJ;8rXH!>8V;l<8MMpB|k*L{`v}M3Ry&2k#&wDiT(z
zo=bWRF-YXaV)5e6&V}u5xJDMzY}Km8T-m`pBpzIYZuxU(G3qmQMyn!1ITis<1lVCn
zbyOi(BqKnCrxb{gl$2B~yl?TXFbOCSfU=3w#|K}x(b<=(8C8rB6}h9Bbth`L(Pmw*
zm>!#IkT$&}r=+EaSw%PXAXZ!-4%$g8M`3rX)@ayX!*(&v3yX?gQ4P}zgS71@t+3TD
z*7QPEb)p!}D0121R!yY@KTfKO+H|}^Q!}Gvt5#QB0mtonQw-~1+JX2I->;bt^sMS8
z*Y7Y%%cfq^pn1k+$%zvyN{Wi6`9YXvZq`zLF+!}758#6jQ8T$-ia|;gY85FwAt;fSGYQ>Mf^YZ9=R3Q%)uMadMxQNRclpjfgHPfdvDpcFzz
zVkn;@lAUB^zkL1Lx{dNh=tluZMA^8H9*kNsXp><-4#>~(XfjZUgoKZPgK7~8`%#X>
zhylr$Q@Iwm7bkru2_}2<>E1ja2xxD-m^eu|-d%WEJl$Ke2}2JqA5LcD*jH7p~$5UTYmdW~X{iZF|kEUVL8)n%nueVuhM!e6Pj!-F!$1SpOxK7z
zWz9%hJq4DT;x3_+w%kO#H0rfl#im9^IAua2MT55TT_PB{Uv0Sts?sI!6Ue~1&XbRd*>_r>udc*a?!Jwe3VwkBWdNKpX
zsvCM)TePPuymB%3WDq6&p&7)@Tt$i}?5!h13Co(xv)~*_KsDBFlrQ4>3_fYt5=?}QU=ckiDTzXyEWutc|IlB|ze)_dD2M|H
zA(qbwEVFA
z*V8OVv-qE|71uIC57CrlF>t(c?edE^u1seG(7D{5gHaAA=f;*qo^iPR=cFO#2YWcz
z)7>RX5TkC()s)I(91*zl8_2dGG2#4&#P1ICT8Sxlyd*$1cYf!ziN9lU(n$Eu%^GJR
zhm@@7O+BAf5x~iTFC^?Z@wnf^`2~@!!2r1AuWgI>tI?Zw6yP=Q$)+WyoZyT&FS1CVTDtJ0Aq+0rgtl?#
zcTH~fyBDxnR6W*u*sa@1&5F0{7AW-6LC#07rUy0M!3#EmpxDss;#rN?FhiW>?Yek%
zF&T_I!%_S0EenksA+|okrNhrS{KUA3uWb!n5jyPz;vNp
zm21c-hjCvI=3dc?4QoeaG*Pd16mj*n!vw9jqbT_A{J6A6kY!wK;A4;vji5O`0#-Qq
zVvu7oghSJdG%vE_6x9iBVJ^axK(VPpNhirlx+#QY5Q`Vf(-wTJT2FaPm(EKUpx0m!
z0VfoKV6sO54)&5pGLZxXuHJZ2N;VAWfGq$7#UK&6$V-4+>;(>_WEU9`eR3~riXxs|
zK#;K1ZsYkPX+yWGvK;WoaS5RKWDk{`r8IW2mN=${)Le!+D27%=MUsZZL`qdiQNWaP
zN37@k~tmPO^-oIYeD9_oi7p9ZyHFcrFB{xFsrKP2E`U9_<4Q
zge1;5O@QalRiZx`O;__azIIzU^|TAk!H-9~^J}$wJ$aEp6r*t0Ep*1EW;a#ezEmk8
zB^1xajl%7n>E)z{xP`B_?;hyrUU`{f!7B;C
zC25E!4Mh>41On_LBYlu~Okz&P%NS{ryi@?#Q6|Y?A{CR*uVp=D`S6bHIe!I(DTgdn
zo0BD()Vaj4i!9jc=wOu3VgoeRZImz1^d`gpbSOsH8}%d{(_RZBGR9{eiHT$3AlhoW
zn)JqE>JP{WN8l+6&Wrv1lY_x@fcFY37ki8Dq%Zc)hpU4HI*x9M`p^S9tB1d!x#G4I
zeUI*hxHu)_Y2edF8YjZz3vE9#-N0~s%yxV)2;wZ+JKEblSczF|j`!w!^U-`X+np^A
zR^VQYt~#H{SB~(w<;5!hZTP)=S(nS8cpOA~g_*eTNz>ErX;+|M-d%0=pVGhHtQE}2
zGo#=_5id{-u9iP4sZS2hNkiR?G#I453K+N)QgWrIPBn%%B
zl2zTri`VjZ%jG*j`A}lG*#E(7Gyk^*Dgg+X0vTEJ&yN8M5J`7n4PxX?J?I8;=ss*h
z8A!w~G3Rgo^adl65{M)j{Rl9@9oeB|3`WA4IZX6o?Un
ztf7a>&MUb_wUMsuqBPR5iOKr+M&e1)wVO96K`KXfkr9}3ju;uKBzY-^lw=`>0Od@?
zc=O}s;r?W`*w0^*KV6hDB?;m9tw8MgcA)lkeQPed=**}d_X`r
z!aA3h^WCGp!z%}IJ36|0uy?#qyqN1%Opgr&!JK%$DUA*z*S{5z0*AzCOxn@*J^qfQ``CelIr0m!)tIa?~u}(v@*>N6A9Dk;^ygWf+r3=
zxk6-I61o}LPcIL{`FfoHvo0I;a>Z0@wr*$9j#6W-fb>?pQ7aKyP#cJX20nHEu8*B2
z8@1|2wNlXPYTzh=4Ka~soL$&%BP7=^>zF$7P~Mk>bW$ox>Bp{8vwpr<*s9kGO0%qM
z+l{(>ZHTpeM@PQ*Bf}(Mlf)bXw3VAp*0d)$gLmwrGU6p9@%@bWv@!Pt9r*+XP)bE9
zpG~6^<(oZ{mF!|ob
zlROjyG|IPp)(v#V1xUdT$bt$3CDO+PD@4Kz*hh@Kb4SM^&B4jBRBZqV%CJc%l0=gv
zWfx(|rc)XcNoj;hi9r=K8Vr)(ba2Xp{9ypb(J2R`hjLKLhiJ$;HYq_unE+*S2+|Xl
z$pADor!rIzquLOVU0_!pT`Ee>lvAT_^1=YbAtR?oSTdKxacZO_a@|Jx@=SZ!hn?bO
z?|!#C5tA>pavFj{p(}@I#TFt_szvd*V?L521fi!IfaS#
znu)^LJPm_CX(G*&cmniu{6rZk)M7p!4{}DbRYuYwKLyiY8!>(og_(bFS&V-HsV~2H
z1!@mx;`>FKjK=DWx(MOL{xa!`Ux;%=R{~I|3QPyH5lpA%FkM~`IN$E?oRR5wEXYHY
zV?CdP+l+i9VWC+oDs?xDRgZ32HKQ=xCT~&UnWD&05F{pY
zGoNl7hl?_imIP21WR#D0Sfe}GMKU&}LBsV#$~EBtVw;WHW?g)g&9US=J&I}4SCO%D
z08)8x6tp3DRo6i?0z}AoDjwziO4K6F4hM-RfGnb(oHbU
zm0Y*c*%vjR9#q_eYg)yIRX2l%8P;?kbCbSi2bvdcCA{Aw;*=+iL38>}6#nV1v94VS=*j8Ot==@$3
zYL3k>%g>5_v|=%nh8QYeH#kL9ButdAMzXFs4xrTISd0FH>EZrw3lISx^bW)n?2v*B
zrbu3}hKX##9l8%;A|VJodiC?415$7YNKtKggb@SCNG2edr6glbM%L&Luqcg`L;@i3
zm0kWZHAYd=D2?n;OqPt%f7z7rtRWf!3LzdNOfD)W!_;3^n;6bZ%1;86Ace3zSqh=5
ztYt<{ig?J#CY&V!>DO(PFJdTrS=XG5;#(RZ0y2=3$S4Sc3PW3g4{>i%xYd*Hs1u~V
z8#%+-q?3PQIbAIVQ#2#~4wpyg(6$$`9K+8(xh(|**6Vg2fGm-8Y(0s@dx-g%U#
zxo)8|E@7_=u#j)QnEs~fw^Oiqp|p*Q%|Crb7gOQjTvrUens)|x$0op{Z-{3&`J)d`
z5I(YtzDN4jcm%d&KNJcvCnnuhxZzJscF|Ki3`;YidPMPIc0L$K~T#-*2c4j^76SYyFe#E
zhrjDKI{PADIjkC{8MGQ!SXP{x;pdcuj43+NP1^-Ap-LnlYi!jTUf6cR2rs*$gK1m`Tnl!&}oX`J$r9|F5nC+MHhjK3*&nhK$nkH>kvv)s@X!eWO}q
zEhVI+ByikpG~ilAH;PSF40>jZDKjWvrawh#myz!X3OHIQj^83flUjMxiVUVQl_*4JOU
z2}uD8>0v8KmE^+U3nhRX2*oC8z>VAsQeX>kM1ip>Q3z_-l;mNPloEMzFQk)^vTzwG
zH>m*0s2iG;suC%sCA%crFzP^sVWJR5`J06hklK=q041D4pOdjXmzt4s7^JDxg7_Mb{hUJ@>6IyQMx}opKG1pK2OZ+(UcroNO#W@ao
zX;0iSKwzRMxhlxZLw~j&?fJOyP@
zRfOa$6{YY*&~$M^Lo-b3nz(;gHyzCjounlvKPxshzunciT1Ks!74Go=
z7k4VA|64%(E!(LpTh#`3sZyn7XfepR#g(bV1xeT@?awCHr^5DTsUU5mxPyt9f(TqJ
z?OY&nt#S!I<_~J5Z8nSC}v(>C}Ib<4bOwQ#?!uXPhSHTzy&Ny83ECt2K2%ABuqSEIusCrKG5Xl
z*FH-;WMmWli;v7DFm8(no5WxwmZ-w$R-770A%+B!aiB)pDGg-+qDi9y99PE6HQD8w
zO%ebv)-o4HeNL0f1Lcw3YcE{~Ryc*%Uw-lE>M5>IAYu>=jjpESI0HpSh&+34`f5eZb2
zpHx?LVNFw5!_cIO*YR|bhAm@g(e8l%`i-y!pTX`CD(_esK5Ud-oo_
zfA``0Z{2$E)vy2W(QFR>0H_t1@KpCq%zhp@KR25C$gVee>@QhDxde904E6kXK|xj-k=`=c|apbsESM@`6PSk@CXM
z_H(73=gS35vhO0w<%xfX65PlG9QV^EfhfIf8OB}!sg>fnYQC#f+^N?t6n4nFSt$c_
z4u^ik94pu{CcGCD8;XviAM!&BkKTNdRYB(wfgHYp25Arj%E
z{ODM9gQ(SOSS}{Uwbk)MEhs6*F|(YyZu?<|2rp_5_>&*oAP+yy#82C&`A8GdVw|k$
z2E}RFuQ%|gSfH1%RlQ7vz~OgpS8Stysc#cv__D6-dZt~CkA?fm}ZDIamP
zrLSF7H3QIFZl$Ren~Lr_ot{u0G&^wQDg_zS;eh`N{#C^7j{NN|c!UDA(pE{g%BFZk
zj=Q~XpffIDMFIje$UAfdprqsl>J0sbiwaHXDQuDesYL?9!^wEGSb#`;h%gh+UMPWG
zq@;7P8DNQBLmHOD4)q
z8KCkU>x+N(r#OpvgmnKKuik9+TgTT<#tU(u4P7Z8J;@u6l*UDZ@P7UZdMp2;n$2|^
z<;ydzK}S5i9uEey3AG1{uo6%bhL~UoVsc_sh$i5|JeUlp^U-`cX?N4nwAUSUNK?1y
zOJcOH+!U;$)XPe(s8%XUsj3v3>Q+h}3LVwfNUm@_??IC{tmIrRQd7j)f_n=|s+A
zZ!($n$I}6<9E`-gP2i7)?v01@{iV;(+82+i1;F#qH+{*wzch9RjRRA06O0V|de)z?#EtqBQHZe`~~VL8jqM~n#Nk>D~3rmV!R>eTJJBqnc
z6NC4##y0C9@;8iKxuNd0?OJ2IQr)bT>zeu67ys;ke(f8NKl#N6Kl|0ApZx0aPk#0A
z$G>{`i3nr&KmO%=KmFA^4?dXeAMP|8n?i4*E4Q~R#jUD%2)6Y^GYTNWM^t3~xCUJy
zp}EskYo=8-tg@!-k@$Qdh9*g3dam1P73vD2+w^^|Lv_Qj)1<6x;<-&oN=NgfAU=s-jK7a+Coi$8(<#Vq=Qb`kj{rtvPx_5HI6$?rZ
z=W{55&H#w$6%d9Ch%ZPuNMZ`{kp-dWMm~MbPrNqh6T{Ao_74xg@vU!t_O;K=m%Cs5
z(w~W0PxD9N90emlt;o(=24t8rsTC+k&&u*~?NPy`r>fMPU1TR9ImoW7H(r$Qlaq$C
z0EHw#EfOXTG?X_qhx6&twJSjH_}Z0q8|4dpluvA-I~N4;RJT7FMO3RT#;L{KZV!85
zE5SRa5#h^XZ`B*N`=jo7Has}q<+Q<*_*Nu;v978%%SySdlyWOpaKai}^rog#RMetj
zHoyIy@7#O%)7y`JeCsg~{P@m;k8j`q@Gd~S|K9C;kHz}_N4b4?_t8hUAH9F;;fHr0
zfAZ&F{wo9h=<2G~%=xIPrmolx#ct+?NI~fcTxu>d(+FZ`wLjZCSZ3{bG8@kKrdcnu
zd}p$p!9F>wGM8(lC6q)R<5tTFmzRgTAQD|1cb@XjjuHAmp>7FnDDUXy7k?e)xYMZG
zNwis|^NM%i&+Ul2`xVY3iM%X5x3f)WgDfae>7?UU%clV^>=d5c+Ie2CSyn^I&D>W=o_`_rJRXEHdadK
zO9HP_kP1VbVwJ*$oYy$uV3E_Ia6Rz1Yho};`Ym2_dpN8cdL#ch2X7Ra8MInP;9n}0
zs`(w#s;+zOmX*Z76ow)v(Ut2qI{UKIG+>J12mG`pMQ>PsMHO#Q>s|z&OHFFxs*aC}
z+^RMUbz`%v?KCZHyJ=pk0!MLs5veFp*fd$^OfbIHS_{)TiVa}YYd&t}eEhUYKJL_;b<^e)#O$iNPUjC}I($+UuVEPyj^$=kbH&IP_##|!ONu7u
zJNLtqCZ1x$N6KF}&>0tb0}(_b8srT)FadgqhaG|!`Fqs4#uQ&4lIHqLFZoHr?>^hx
z1&+82_ypk6jlw7&&>CQYMT$a2nVxO9mS)puRm0UR&u}9TF5bTP;PHnaeel7LAHVnU
zqsJe<|G_5@9z1&Qy$`SlkKcR$qmTc`SH998!5@Tb9HbGn6@oMoh0{dTgenmuBO#!q
zCjrS&fJhe7NU6xVa9%{hO|C$b<$QH0hJBQ`BjwFXd8e{F8cbJ9_L6bkM)~p#1caI>
zVW<(}N>7KfHnbhJL{cHOg!Nj})oi}EK(!jK30Cm%QJM%hDH|c9w2D$IHOs|Dp-|_F
zE)0jGsch?}a_7OLdyhW6_ZZFi(Vd4M-g)r;>)(I#?!5;;`r(i6-+y@f_T6uN^V>i8
z{txfmd2si^`>05gNxS{tPrm>5E#Y4~DtyEgv)MGOO{3m46s%z=ilt%bO5HIa>G9Qr
z#cCR-!EAy1+?8JeK}q?bsXOYSz*$4d@nRxwI8KLLCvdKzBoZ=eKP4ZPz)?fD;hHEB
zHJ|+$gejgFDisw_)KsJ#n}pGZ5ae882dTBws3SHjx|jeSu|^vCLJ2zVd1$z?fjxKe
z;`5g-VFW&H&tJT7ZsYv9jf+vMef8SSTet7O_4e&I-+cG2AHDn58^YfH;al&#d;7a@
zy}8|Nq`hHxG*c}1Lb)VgRbedx$Wrl4Hn%*60OAoi!d8PmFzC}o;UK=}#ho4MiBWUZ
z4PBZr$>c|e=!>M=t!OHhhr-g)7EhdPYu!d?U!t@l?#mb^3bCT&b%r$~&>i0nV%AN=
z!Sl8JxKvkzw7XT+E>-lcy2UzwiO1NiBOZn2p6}Ywj5~0xX%tkW(9~m_HX!zs3c9*v`~TtMXMPGeXy=7hU*vs_%q7QhUvRb6f`VOS@&@XI!KYiRs-+TY#_ul{T
z(c||YzxToWAAI!q@%zB>{r5k7{N6{HNbtcYk3alaNYNw+(h&1v+Us+pt6BAfo_E{&pm3I-_pfj>0Th9xTSo`KS2^8Ig^pW~tIBRjON++D5g0
zsn*!Qy#Qzb=bNwJdHmDck3YHl@DpSscK`mPzxXeI{y+Zu%U}HLt8c&g7WUGOo88!Y
zaOd6o_ujkr=#x7SKM+3n!=K!K?<4a5&#(O>r-y{ZAfsY7upE)~24P#lnx?ASy5<;Y
z#=ZT?Y(C`o&V=t~_wylH%VyBg
zrpVQL|7OtR!I5!Ay(x
zk~ua5w~~bbeiK$xTn?U?naH}jwa_wKVwdzG#?54W4UcZ#2%P^Uf&Wg%+ns0ad%cND
zJi_enfaIENok_gtJJE@R!4Xa{f&1{P>Zs88Uk^cpk@t4
zso!k^X3yxHzE?XOm*QZdvo$OrXevCv^A&AT$AwITa<@hHvxm5YaTb-U({7I=X{Ynp(?$&XXs6`CIxeAFQNt}eQcL|vmn;J2i!?h#pVT0l}T
zD+F-#FG9H+crbo%23c(*i~)O!JrWdf@>2+Z^HWpc$`mnFN^th|
z1kQJ>VYFJs&VQociaiQiM7RT$g`;LIx|xPn>=|}=aV&XAs!Y+wUo%JX!S|9}(j3Qh
zTGY~n%Q6Vt(LskV5D9T#cC(&qc@ELXsA-93XwvoB-i1F;zV`&WNcaWm*WWjfBtX?M
zKEiCd$@e#mtGmS~mIJJO7g-i9auXd_uQ05EnK9{)c
zlV*@6Z0%Y}%_WEGtTD%M?1B=U10_MjPM>COsrP;dn>}{rGEy$2V@#^xvBk$_ISeuf
zmNfn|_k@!6B4ib0nn!)ss`kC*8jtS$p7a5o(gOROmJ8|Ry?k)|C$>YcPtve41Ei$*
z=97Ej*9$LBqxzN1j=8oIP{$~?pN(`6|RgsDlirkm03K5VbLPGZborlkItHk!Tmeq3@O>9MYCI!wkH-I
zv+E_z(Ovo1*4|ekVjJp;!EM{!ro80#(hciQayDPP0ry&obEckPHB8F0u%t;xOprdu
zesdadsRy2BZ#f9umvkliwh{!=w`HRq3K|x<+GxAIPN3}e^l$^*t{!w;trwnc!Vor#
zuUIYzzKmP||7WqAx4VnAN3Z?%;#0!S^yFmq>hDIMBH~M1rDA}&%>ynRs}hEJoq%vlBD^LpeZPnE)gsf_JE*w(H+95tOlK61x66h=!XAy(+aT?jNk;
z@e|F)Ttg9Fxi!jwp@sjBv2Ta54`3%vyBbSNSOS@N_aGAf@Z8T+5#uKxD9^bC~UF
zrJ#Jic+pYP1FJI&M6NVgLu^yzDg8RrC#)ubdKP&)Qf={uQsr$sl0+lz&y93qKX?vG
z%K48_-UR=H{1PdnrL1TegZw7kc#|lkRGntCchPjm4r-@dR5hyK%Yv7o>6DnnQe~_Y
zlTz$F&uzc1P#*(3h#yAt8o2V^{jSW&f&sem=U%INAZCvgZ+DvmW-wG*oRP28CP(ny
zI)>fNS^b
zqB2Jhm|ySQ*EI+-0eyYASo6Kw3<6(UT>1jzDk!B%s|&5hf4Yk?PCVEPeB6(iA-?
z25)IJt28{lwrs+R_ug~T-|(=cUYv)GuE)2FHLOkly^UJnLDj3z)Adw1OfB8$f{o?K
zl%3C#bYNaev*+Cm6}_nVO3fvY1EvpOw#yBBHF2iD+@NP1WJ~RC2A){gi=3$YZ)n>6
zCYNVhUHvdQ(kLj5BTHh719SF${rO!+2H8L+eB0~)j(W+j@3+-y5Sgx_2}NH?{kN6f
z3d;1)LOV=q&v`3jSvK$CBT85gwzzxT9QJsQIIwT!iKeWgMvi16gHOKqB*z$JJvGsPS*K@Ow&9MpI^fiORSUuOTS5OVD
zn*@Qa?tm+JH|wCQ9V>yD{4M-2Pq^tF
zZOo54x$kG7dlIqQk8ZZZa6$MAQ`R_FJolB5`IUp
zq3-pmtLOEpC-_nwx<=G39UL
zlCUFJ9k_x(TP?QQ!Km8&HDR-jG?cFjSRA~kn7MGVybMqYf`yPI%VVB3
z_(YF)ga0oS{}mur!=Y%P;BQlnCi7Ylp%!4=NhypEF1c);V?^%W@7uGjYiPoKzKlpR
zt_dkFvEC$!h}$^z6^E?Uii5#K(el@i*E0bCST^m$&nmsz?Z2?1YzB3OUi5T5Uv^xB
z-Vmv&>mS9z`gCu{Baf6oDoC`HT%7`(I4&v|YS{}hVwnM9Oyl+w~8f5QV3d3
zLiCOAE~VDAfvDwaB|&+a(xelP917$RWgMb~{rbidN&^$@-&u_PueJhMFNHSSZ;J&s
z{a^2|ptlmxTW9We9|+j2=e4Hi^~%gN{<(X#F}tY+2!6tX-mXh+~+^vHDu=n<3=&e{+bvbt;Pp6ETndNlB;Wuca)Duz)|C~BjIG?IKT
z*R<=qYD@lVcUMe6XS1+TO*&Ls^VEGRL;&)L|0zAp#GeC4QXa(xbtITvsR*}vyBH)B
zy_w7dJ|5)dMrzt;(Jy>l_*1&`lJ6RX#cky4wW}1if(Tc$Q2K=m&s9*#^LFQe
z3lf^cVA{ZQFaW0m@EC^C-mZXmbFjaC<(V>CB)&f>7!2+Um;c=Zyl^smeQ4>qht;|+
zAf28tHYz)lVCy8b(E
zYT7}y=41}*Nz6VPwNAt5^#13!i|3>{)A^WZ9(N*c=ON3~eua5jmom5xu|Et|noh|f
zLy%2l!R-y_dW43w;xt47pyf~D?>A0LG>qApT{E1H-Zj;3e!A$fk-@mrcV0Db+l6j9
zSK?0<^N|w%x0kR>bH=ylIUEXV0X|N;zMdUPKpFF&U-Dt>!sCa5M^~|z?Wutm+k=55
z=mQJzO12sBA&l^-Jzb(mlhx)+Y3oJ#s`Q#uVl3d!$`=aoz8^*n{PVkDLAh)K^ae6T
zeoE+=8)EtrXH=DAoBXa}LkR8w0gg~a(sP;qWj+x93Ke1S#gmA++Ktm)Izb~)lO=yv
z60MMh43hB_WpGSaq
z{hr8-j4du39o}c`>S|HS{=XT>N_zHOoGIh2E&HzFl1iC>@
zJJU|AgM=`D$c6sFv##qi_O79IveW9rH&@
zO;|DPE7B{Ij2gDD(PqFm3W1AW2Kd#lo{TW_kewMu=V4_1M%_egrYDZrLgQ=J<-GTt
z*9nh-!OX?i0SBGQnsS#y>dkWq8*1BPl4Uv?$YWYfm4p9}Vob~13^9A4?`S1?q|gUuE3Xvjr>mUBRuj`ktDZYz~D!5
z|Jx(iPEXecebz;#-d_cosUaeFT12_2HpHWq1^>>_Tu`penWWg&4I!a6Ok6yuQs;Z(|b9R)*}
z0xm5DD((HR^;R{@ESrBCZhQukWTC`|@d|vm#)Az3(aD3IUj%}Zcn&dk8>e=FiiV97
zz-;c+lYmQJj`i4(fs?a=OoxgO9_1@SUp#=L>eT+ORoXSbh35rkKokzjf`R~)`*p|sQ3VU@3XXsDoWj>Me
zHTRUb!XsXjj>--+4|=qV5Yu_CE^L9e%43&xIcY+j+5$t_N#URdyVqd#i>2lb4WF#)
z>@^+lI8wsqQ&m`5gO-itznsG;fPv6GGqFG@(IX}F<#He&2%UU}o>BJP&e}m=eiHRu
zuU0`1rlIFB7!`*^Ab7KuLR8N6Z5Mwfez@BsOF>5Z1muZ%h$MeLr+!~S?NeeVi$qFGwsAJ9#i&?
zJ@>_{B*OklBuY2xF7q7m{&@q2ys8@e@p@@5&w;QPHh`b
zoyGb=Z@f1OP2+eSi=q@uNlp?sf8E}BMj7jQ?x+oZJ%e6Lf|ss>uE&y~hb(4e?O!B7
z11jA*>?)(fjG>$apDsMSDrGQH-Hc-t9A_!9aD??-jk`SdJ`&gxIip#q2J
zfR-y1aq-@(?pJU_ZP3&MpHZN3xfLu{Ja7n|?N8VXTlH@Q>x%YovYww)kk5v|-YTwgeKk{BHvOMXBq38BzMJ3~5!WvFvq=Hh
zE=YLG7T}pMqr`Ws^Zrt#1qP(OZZUf`oV`#Igf;y)F@HU?$!7DmR!ek`4R~EO9h`N?
z=O;%Qcf#V!74%~enau2u;x*!;WfnXYr%Bu$|5BFheysdXY#8{jUNjFHtq<#d;_F{V
zv78*j9l#v414|jZ=zFi#W;Ww7H0RG_^z7`d$Ovv^>)4R(7%V_*F6NVyhkazXD)~6R
zO^}JKk*yiSVjae_H{On4DWRt`BR%OHp|Gx34@>;%;1vr9xehlIf4kO8Iyl>!r0;Ng)Q
z2ZL_$$WP|4d^|febuT
zW{87xCBxgajJeu
z`(o7F63bJ2MD?p5Ds-8ha4->1M0dL-QjEiUWAwoinRYhOd66c-T#={H&O8=8T4-(A
zxqRWiI50Ic_O@`wSOZIkq>Eed;=DMb&2PD`Wo+1aDju*PdsTqd0>^$+>I5QM2m{3V
zK7HEmqcL;)1yQUB)$fyKvTxi(Kmd-{>P;Fk6RHv%{VZG{9KMf~I$)5UTz{e2V)3VR
z%9M{w$MyNoNr_Icoh0_y5k3e@veUoE2_p8``&*(ZvsSNq;($AaH&
zg0IxRi0hW$?Zw(vr+Zv4Y#i!&7?Qxz|LULbe}NPQs{
z|Ci4K2w?kn?BkjZmOL&KF)vl$wFL$ucl3ilYqc^|ti?8&%(Z+ZeK3k1Y#z@7VAdFS
zH#P*h$8DKgSv|iDCESu35mntg)*JugYnl)+dtIxA=J&ulKgi8iu(#kAo50;I*&3M<
z*|clt_4=XbkpPGJHAu@nJKwp=aLbPyyyptSDOW^1z?{$|uPwKS#jy>J_*r~M-T3g%
zW@JD0QyPtI(~Ag6oqda;?)QaTMY9A!<}kg9!t#FuG>J;7V#nNv#P@28bL!!!buso7arvg7A%7biG?)Qv%LTX9GX*86X@~e1;sA-PxotykEjg3@L
zW@ie-&WksG2NJVYr}Y%ZOCYmHX@hog+V(XIh>@(>Xi+s#N{Y!H`x(Yi@Fa1yb}YoJ
z7L;pYIU^k1%>j+__36`_8-b>zUwIUUS}}})C#7D$D*kV(`!VD3)g~N60B;~Xvgw94
zZL^iK(Tc_El~vj>O!IF{T)U`#GOnx-pi#K36L`Nm|*Qy)Y3PNs;f54)@1$%Yf3mcs1WvJIs$4^iJJdpfRn
z7@d=)<#r7Ql^OE9MqgWP*I2F~i*yko;%|vvAfe=oKr
zsE*3+geB#3^V5@{qD=JUTijZ{P0}ocz-;ubc3EjAmFE4Nnnh`NC5LeJ)fFg|gS3o8
zq_T<#NZbLawf_=8R3EFdGO6lzzIso%>i^n_wMgxw|K&U9lVX(xfX>tysZ~_S8I-Z_
zc9kA{Cn%)+`8j>MR{cu$*Ol^jQldBlt|{7!I`5P9VaP2}e!$Ml?a@D4>8=pM5yx9(
zZpStG!^;qnX{(nS-DWG2KF1f=FNAT~-?H|L0~rRM=C+8G?2Deq+liU(i*yN?pL=evYF31SP&bcSfq3leLtyZR)}mL>El^3Ed+
zlFM-LpBu-rTb-1~qcr@uOAdrX0kWpV`h#>#K-FG#5Y8>nv@5mf5WB=}xb9yHSQ>AD
zudC0+aNmK`b1zPAX44+X3$9}(lJf(IW$Rw3wR745<|?8})xJy!*q!m|5zE8~V?{`8
z=(2fsxROA_*Bx)Oqhp{-uiMV2FpbvZ^}5h%D}Zo%iGc{CsktoHzodo|YauW|^uysE
z0v(RpW~Un3#z4$!QRT^d+U7(zntr`M8sq4>%#+At5x)7?8(U(ImUItT6KX2F$wWJv
z->^7y$!KWCA0T2YVl7z{TWgab%%`n}1(eHw;nM%{9@#vdeUjk>Ri=x*><@`M4MIVW
z5YPIL@39{#Mtl2GZI^BWcwN#@T|V=4W)bX7XIWrSs&X|op3<}Bq?FHb@bhgjCIFmp
zVcd)*$(MAK>dLY}eAoBRSE4O#koBLp<{<5d^V=iwa8%a3XN>G4c5w~}Ao%v>cFkA~
z2CQs!{7*dAoqdp~>CBGXDB*r0X&YlE3bjXnp*oOwuCnsG7mW2(N!(bW?infz0ZMm(
zk_wUYNFaRLRisKQyrIPuBWtQZcb@Q%oAW*Jk7g`G$2yXG|4Sk;4Urg}SI!S2_%oIf
zESVPw|DGAyK;aWYDh`Ja8xc3vPjZHnu`FUqx$y-M^_|pbTlHlDSRxwE>}>r&N+Hl*TB#MQBpk_hgrh!mlWN8VGo)*CVq7Y3VHq3d=j+V
zuY&Pn?k_$9&z6jp<#FG{Qj*?t!)6^{-hEjdwbRFj_2SA8{kIGLgmQlDUG8KWiHBB@
zF^xBVaDmt<#?e4y#^r~rFg0`GEX;pa1^Ua!kPmsK#Or-cRn2WH)fJZ2+GHjnnFw4)
z_l7(`<#i=XKSptqyQP+WF}=-HMwJlj0#$4Htb^G$^%PKg($Nh(1AF>VT@sCZo7axE
z)s`i0?sn>+NA1h+=Q$q=rLa-Pj&i%U6`4J{4Hte=Y2hbFS?#!c{{d_P#irh)cu7XF
zA9uY(Fi_*PASja76uQqk7&Gq}oTWuN1^!p&nbbb(UR3VrG}WDe{g3s$8f;@*0?{mW
zb!sgFNT>L8CWM1$`|nFD)rbS!tJXPB3H^1eqIaeSv&G6dUX3ebPf!nXc#dKZj(nA-
zUBBgTtV8yccby)O*i8YZ>vNKlc>(MKes-`Yf@ul)mqYsf&bkl5_*|-!5!@L?Pv61j
za>paaqG;kug1g!oDZP<8JgV%;SysHP#nopvISGHUj2!Sthq=%+I|ug!y(e7S#YLNp
z95nTYTE(*#?}GU7vFzO1nR9yEL#J9%JU*P$KJ_BUVukgJqw={aio(+obW%~IQ>`d)
z2n{_Qk8QVFUtzq{;=vtbS7OMM{#%HozyKeG!yv+p3UeI;5XjX~RJf$8THTr9V}Gah
zYs>h^`YTb0t8+lHN`#08FoTeGJb7#zFT2b=DOvRQ;NU+
zmSj^7VaX3jfE)aSE_(X%9msYi>LV9DKV{FA^C8-||0hd=ITE4iuPf&50!HNQMQX&pMdfVoHnyuZw>R9?;oS4{fz8W!c*&EGe@_i&
zgOs5DWvCB>nFux}o@+mPb(?-0)DnE=`VfYMHjchu*o^H0+l2^wOPyj4u%PFZuI{51
ziA3MUx%Mem^WiEVtliNUZ6Zoe7Frcg5K(s8PJbp7JlEK}!3>ld`naAj=bQ-elviO12TuG3wxq2p~
ziQjCfddp17P&e<@QrQNv-$^+{j?HwTt{%6LQPp>rmgCwW2)HQtWn^RnZzG_FKPPMZ
zoiy@8QyivKN1>I7sukjj{sO<#>d#pJLgW7uscs^qPu6`7AT|BBM&+Zqb^^_H(tPjWU&17y4CYe;d|qiV4a}>UA$0TcD{prP9(P
zXBpk)OyHenV^WgUTtx(oxRX77jZ(a_<_uJ#Zw5H7m>v9oYwgk!yEw&r8i~=&<)Po@O#7^2OTWO{%Ow5!Bkopo$fE<1O1O3`o$<%Bw_9o)8YmMP`x-3X{
z1xFGy+I5`~r7FnP@2MV~#1F~6sEPsHo>{$puOo&V$E!_UFzD68tTJN;2glLv<<5?m
ztLyI;2?_C)VuZMjvCF>m{f|qq?SNm?J**hNB?BQ1`4<$_)KLZ4CO>@A
zRxZ=ik*)_}TgA8x!5h+c#*T?i3)QYH38{slAHBXOM}hM`Zt8aJthTP%3-96>So*80
ze&e|Ne9MK0V^)ydg^-nCn2yDb7E*F*O%&lgUj>*vny~cgnj?|7kxcYw*{~)VE(ykW
z0pq#k6=`R!r`J{wbWdtk#J=O@^}T#+r_HowRSWKzFwtO1b4vtvONys2|(4HSXH?bl8y98%nZ81hW+YjEZ#m`+-~sC2268WhrsUOU+~UNgu}t65=Zj+rky
zt{55l@W3M
z|JV7+^*0ftKWDbr2-rfJ0B!%k=OY;?B8HLvD-F6llH0PWco$Iz6WVH+sL)+6}od1v!*5{MkH5WjZ2!k5w9NiwD7CQw95g(G{
z5mNGVXF@#ptwD=z7#dt38~(Mq?`j)FPUDI8>IjPIjl$nsVzLPtW5_FWVOU=Jt22}0
zxuV3Pg(h_aRy#zLk#h^u;vY)KIAf6Ob61n?p@2v5>Wmkkcw1)xps|=KJynpZ-um{1iu
zq4F9qWty)$^5v8o<6~(-pLV%0N3zy8$Ei19MK3uFl#w>Aj4`OI5Bu0%>MHC~Sh#?x
z=RK%ASb4x4c|iTMf%roK#4?g3*mr^d)u(yGo
zjd;`*jX+}Xis5>G+HQ5g!Z&_EaQx}@&3U*s?cv$@f}v{R66C&)gXk14t0Mj`^h0?w
z^#+q~izl90S@pvsHF~)vW+By-S3LzY@?s7wkbgV<+eKi>mtT(twcZEAI?Gx2gPBeH
zmbKR9#@hX9#nmPbGzRDboh)*Hq=?ZN)ZSsERzxGS1vzSfS2#K!X6+=DBSM*(kOmBAK#Dr{@)qTjW&bC!O&66e(K0I`fdfl=Tg}4
z{;*s*Seg6_`v>F1s`IhWd*c0`
zkLD?j2&s^ixr>&;GrkR8wQ$adqQRsFZ0=Y)k=@OrI5ngcMaCOi5m~4=jU^1Y8R(0E
z*5DKGVx#JV0swRhAkS@Bcjuf_vSKA3&iT0#$@)p!L=L#Ci&o)`yXW{6wSMrxS0kYo
z%ENpfm;#I&s1QCIJ4R~Y-W{b;{d!Ojw#vMRKK}QLlAYDvu~JTb2S@Kl_xC#IcSSKv
zpT_b(k=d1z^cN!sv`{C&I1*Cd?U=Pjdh4=j>fZ?c
zY>0J(*9ldA7b9h(Vj!pKAzhJz?S4Fe<+p;lhc!0-n3jQL50vVEs)Ua3shs}OUT!02i>62EM_A!+h!(564
zE*6P46{%dAc*OR-pgTJ55Tn_k1(Aa}c8Z=^d#F};YA;=s6?!dxY>NKVwz}yxq35tt
zOD>$x#bE*yo|(|}<00cxlG)oji`mnJL_;r(1YeQ!-Tl;S%`UMU0Y0bG^B=1UnE&Ox$F`|rzSL^`d;bL7j
z=4wMYJv;~SDPHT_l^$X`anO=$AL-p{;7tA`%t;&2CL#^`K+eu#Ce#ZZg3niZ_T+37
zAXPQ&c-{*i5SqOKTYE#sFIhNDg73evWT=0ib9g+qcX#7Fd&Ki;TBYv!5UM6X1G*;`*7F4S;K)yJqdsnTHs%}^Je
zYgI%`%ecYgf2DgV%2!}U1}lV{&zrOq#;uU{Vy2X|X{@^lGdK;>*3pUtgwl?N`w}Y@
z?TxKvrACfQ66-ng`cx8Jqis{M(tH+WQKnH=fp82HR#fh;pd!%V)FQPUm7c617}fv(KH#Cb&45#;
z#RkfFthPXS>gB0sfP8&UiAi~tZaNKJ0u|w>8^P{FIb(TizMdNdmNvb7vII*Jznw#2q@qNtD&egv{g2yzwr*+M48@x)aj4c@PE&J1>H8c8
zO^E#w2gp1%DMYLLFD(NrZ?)Xpdu`2y1iA_l__CgV+pWfh#ilI+`Sgg?WJ$GV5}p3u
z%`J?wHbCJI92sD+^Dc+o>t!G%;|tst9&5jR9fFyDaSwYB;AeKy1p?ErF0T(9c%P~7
zs2D`U1RME#i*TapR3z1y5+u|lhm&!4aV
z&Dd-A#{9o|L@o>^*2~2M%I|mZht=T;M_pr`0%n*-UBprOy87p}ZniTqyYAP{e@|>o
z&E<{Xk8P@_xpWHapI=UXuL6NU?C_F8*;w!gfLR09s5A#x?hEPmu2*IcS6?6+5;c{z
zG3z@j4J~g`6d|gCvbxlH_TCL*G=gw=U
z?yr5x$;s~Aloym9+w4AWomt`M5nyu$XL$>O1b>71qcHv>FYKg_s2=z12WU`ApqB_6
zKKXl&Zl8^&!jhNrNQIZn@~tYzkJ};cvt6=h@F~u`)^koVWQnm>pD0DOt&7hcdVjHQ
z3JJuaZMG=;zqL`bs?dqJ2*TT=d|IOUrA633$i0J~b3fNOU;asK!1IN7Sfm+|i=_4g
zxblLDkiFsE26lKG#oz$ZrKhZe!eTxP0lV&3goD;Q_7iQVW-ECd;S@AaY3D9uPDf#Xio&hiBzJ|#~@`XjD7)iHBT1C#mZT)xaB=POS89BO)%aT
z54`sR&`_r&RC8>#hVIyhk8WCr$%`8PVc%-q^yA)c4$%|`WBz`x6h;RbL|7AB9hea9
z^mu8Lfb5<;#|SoSd4w_IcMj#l!9nj7Wnicbjo;tYQ3Nv!!C#+QEj8>H~Cz%%t9d+&VwPR4Nq?ITcJ*RAiK8vW|u{vfSMrlDkjE8f$Dv(#1AP4_QxR+
zv3bgrXibvq*zIpQ|HY-N!}ehZ#X|qT$5fy(+Is+SuZz8z>9P$tW&zDu%uep=;+I;?
z#}@qY0P<&Hy-Q<%s!CGH^9mSPv=;9r>>yVcWxl*?a0t%F@ok+`XN=pi^lb-r3U^}s
z(sUVp)U6_uuZa4uKHRU6VAy3*t%$ByF{ziqp>P>Q=v=n`rkMzGtFF$nf4S{LMM}
zZuVr;*@yFL(jPqEFhsmQ?Nb(|hrO>J1jQj0hETD*)BlWs^{PLw0|K`i+TwXoKl*r-
z?<_y%`e^Emw>RGp?hMTgOMDS*CPDXhkfHt?>W(5Qd@EOPe-M70sb0!7Mp?#t;?UZq
zi_2@=a7k>7i?qRd-jb_J-lS!X&h**2zN$o^>btJS@r!D;?MbZsRTB%q)gVqS%jNhdZqHI<==*;n~_a;~w
ze)Hh3pgYu_0S
ztXyx)1md+xE?*`Pb>Po_;E2-jxUvQ|XFa6+m>AmxZQ6s#=CbZFL|
zy0@;B$Jp^@&0dpRUI%ItRv!%fC=I76r=gRg4wK$&Mou5)nx&Hb8!{wUTzXcyN7t42
z=@Bu}LPJw$R{%S&v`vRiK*f0DRPEEBrj0t)Nuso{1-3+bYx8Bs;>UL6e?PIQzyS-3
zNhnWJ*&FubVHy5-_xB8Ltg<|rEuv0v!>jFI)(rDDRuosWjvh;UIGNK>Zsf(8)Hnm$
z`$>Ig$5A=z%gTf-izU@*MUge{Arx(1^S`IjXR)@ttX!JyBqf*=sH+=U7AecB+`ll(
z@9WmKWE9#9Nw&W=YAnhQmFSDw^Qd5edPkPad0(pcLTo`K@n$oS|Hz`{xibB-u05F&
zKWYC((L^5UG5w4my#5kCQBYD@!us)JhL~Sj7&Pq*Zb9qqRrO9mAQrg>g8U-i+DyMa
zGLfkOsg(XBB7MBu^jTuhM&P)f(&I1F+uypb;#eIfJ!`1XU2wHNg3%otZ_e$&12lG@
z*^B0=PoGVfmG;y`q&#AYd|k+Ma#Zx<-mF^f|+;l|sx)V99lVD^#BkQ?tlK%;|+Wuv?uYqqr+#0T(b3cfL=rue@Mmdf$W;R?mO$xU5*ay73ijtYQ~uFZm-c|p
ztq+fkRV0;uHioX+0K0TtxXn+Bd$)xN%a{m~?C`_BkZ#7~6CX
zI7L*07B-@zRbIF6F*5^jR<4TL0=Ggail2yg_)+BgfG-sq>xfxT2Qeri%K@=a9l^Ozyx4^sWq#C(tTS2IO{P7r}9~Y5_jlpkH
zc>WpGpP;u@A{E{GX&85Nwal~L3O{wMyF7p7Q+EPxH`**
z`4=)~4KFt0mLdN)DTg8z$j%KA%e@5$F$F~q9BoJk$6iRc6IL23O^yWq7r~Axkv#o7
z{|SNt<=lJif;+k!KY)O6vU6AFom!qIhRmDrvx{*IfAbNO8@G9QU66M3FA2HDw9DAS
z=sA08PVRM4a-VYR736woC(@G~kUfMA>4JC}NblznDFpSHYzWI@@-s0fqA}
z*g=qB{Tvk|~cP&^%$y|C$3FG8UbVuE!CSGq#MuN=N94jI@1zeBpS2c-x+aeb>dkg8xVWLjK?|z}pZ5SkFU8!ftD~~d{
zawOaS)8c(3afMmX@@vyM<{h(RwY*I_Gk+JEv8I19mN2PVA#{@YN&0k$UG{CfY;3ki
zJV+c-GR2`>0f}Ks5M;^{=WjBI(r(2=c_h8*NJoM?`o3R-{x_1JXBuaRf}&Z|F1Aoi
zFE4F={5$*!dW;w;{)kb8F&!-n-?kEdg<44BY0L_hhkLskEKy!B{$AU4TnfdLb@xB!
zA`L=WQb242stTy-|9`YFvAcZI>Y8A$J7d1Ha$vYIzguHa%f^3N9>>Tu34$9)DWx@n
z6#aF!t81!(OA6>#JqtP;aP<22<;U{-C7CsSAjf89RI-I9pPC&y1D%nkL}pA3lgh=l
zJ%>p*feE+2y?&2IY?F^m^6s6|pQQ9EeDj7%vx)x
zal^a?RCz95>6a->;<^`K91Y0UtrMPhpeLbcrm2mM|m|#LT`Fn1jVx`
zcGq{@E~M~M69^|RW!49gbQGGIltX9iLqGX60uR7Hr@OuO7RW}H5;Y^-&|v9@osA#_
z$d5w$LNblCBqh3&Co3+(VT(7uJJ14);#-8EUj*yq)@S5&z<3=NN~}l{gxIEpF`-jz
zoVxta0vU(2^=vYF6Z%1I_Z_!WCE8_1R1}IeJ6z7*&O#OOQ5@jq%PZ3e*FcCga!gjh
z%JwHm#VPI1p6(8nD6!hyWd~xPh5~{CZ2{C-DPiOHa#cI0fHokKK%a*br=zN^xr8Yz
z@~v#ok~(Y%1rJHOMF7YfJ9g~XNiiB`TE+JL=aQboOA>}DOT#TzDN7n;^G!xo#`}D2
zwH@WITUN8FI6eQ1t=gPwur5}N`UDe7L-$~rqJ6D%m-M5X53Okrb8nqk;7Elj&5kJY
zyo8(EEQOS4+nkF@`H2}gb*LLPz4f9io<8gXC-MVrl`nv&Ba;kM@l|hOIl`7*-8BxG
z-*#Zx-hAMV8ym$T-@=$(;Z!F{?EO%Q#R9Z}rSHK4tZSo3?O`HF%l`?FMPOZe)=<2c
zBybo-A)j%_j#W*?35ORf*W+nwr@uz?6C#I43vHugc*p*!eKIQ(49~qAau&MgrBeHC
zIR-$ZqN7NAg)xdOvtQ(9Kx&!RRYJ|0@1zVRJtEck2UVI#w5*WQ)%b#7JG)YSW@@+m
zRs5HkhW8lrHS$zQ7NFeHFxW|hXp2^uegOff^##77(xs4Thf0uVfEY?T3olRX_>+xA
z2~Cxt&a`@-DIXx>6uMe^@IL@0LE64=merzaSxLr;8@|thI3mZ=gOEa?sv$OwlB!27
z@%*i3dtSS1N4^=`ikn~O8a4RX@EoU|$rpD7`+@)zLdlA4^RH62ZTt_&NP?i>w_D<~
z!m@62?zBL|jX`9^(W18JmSE9{&29KX3-c0GxEyrP3rlOk^+IB)}Szk>nx`w8da3{xZajTN&|$
zk*-um-dH3(CAa#$?ikTCTO1q!M9z+CbAl3)Xk>7|cXGm6@Gre?qkO@?7LTZq%Al}2
z9->0=G|^CC0)r!jF^N$`C1Fm0(}4Q02C5S8C4rprsypiWiFkyKC*B#f+T8?=*&DRx
ztKt69?CA1xwLjTAoUuMUSuA%)yZe))lO-g@j*ju5k)k6~?jLbU6PwuKkpSQR(L$)y
zac4N`wz^T$3TDe8Yatb91K5Y{p6sF%JL3+P(W>HBK!36vPgi0V8Zkb_v^UwEj8|i^
zUJ4<}$#QD)lEAru#pU5H@x-iK=#0xoy}40uSXp~V74Kv~$#bO=qF_r^OO}OQYBcb{
zi7BWmszD3Gt%ms6#z>;AX8vs-KC)v&oQkF?4j!To_2^xI43lhKaA?u#-t1aL10Tu<-LKUh`
zST}st4UvjX+q2^gwHS2=ge$5IB2~|$<_*ho(-z<>itn;jkjjsRa4Q=Q`m_#e>rGT)
z18G^;cN%J4GjY0Wrlo+_roPos`JwsMtQ#A2{A)Tc=DC=AdA`fW?
znh4@-*Xu=HFPkR2@FAci=K^X807{rhydHtVR@L^mHNEEfb#$%^5TPV)J{8shC9-UFzREbR2gyZe3dvfC0B8TSUG-E7KFoAi_0NKIG2`-tlx(|z-agQ==l28lNYav4?Onw$;Bm;jPM8M
zhyg5~e0ePbxsTi%iZr;r;25-x(K9EPkFQ=kynN;4+I0eZ$0sK*z6jT-3C99WRb5);zWZa5k7$ldTr-a3p1Y1oTN)*5%c+u{zgM#T`~;*(fKc|IF6oXh)0B^8pr5LaJj8(mz2h)
zrk<--kQFt@Y`8Z4wr&~cwzmK!4megcG${#TjdKRxM3Mk_u}M*+q-0s_X$)&R18K-b;>}8Vr&4JerWFXs9CVVB
zVoBz<#L#UVn)|Nff>BCBDHzL!S2n~QIwL~s
zS*5121qFiyo!GG4{JBaDBI~9DXTc>Erdh)FK+MEYx3!>Ur5(@%fQq_SF{l%q%@~KtLGMzMPScZHyEp8^}
zgE@)Dp-F9=QBp#36vlyS$4rNwIro_1yyT$5f=ka7B3q`
zxo)5{F7PoKkAWlW&SZvuOoT5s0*h?ocVoTTf|&ktfp`S^ATmV0E$0053>Rpl8RBuW
zTuJc-$e@f=XM~{-NP0rR86-k%LYN>+&|zMZKqXKWwOgyB1DF`)14lwe_C}qSk62tx
z!hRdb!d&xr44uN|At;TM1TeRikw8A-p%C$;HBI=BB$5I*5vn$BW=tmsj)g{}k-rmOZZfNYf|wFBr)tVqL?2}
z52A*PMAeBG-$6T0&Qo3b!mRNIh
zBi77q
zxl*R1;beagY22Aj;sIXnoCH@t`wGOA+6|aOIsy<1DuFX7MgU0;)X;ixinV;bj2I4j
zc=akVWC3Rc;4cBhDS(5>LiFW25duPC7$=!XBuB)+B2dmB!OtKgn`Du@
zsB?Qd;RIJ#e)IhvunieogZ_9q1ALPe`EfkOEZR^Kbh3HsdJByy_Rf=TzcU;s`BVSg
zT45_r5y+F?UQC5~i?nwi=CQ2=P|_#SSzSS#sD3
zeLCO8iyzN-C*XB;Fb9|O{W&xgk96jvw3oGp?XVq*DaP7icifBH2^S)+Q7GcwV>JI1
zh_{F0@!5QT7h$-2vcEW50nP4c03YSk7>LPPbNcyu&NTp-(gN!iI^$BbtPMpenC6zI
zZR>^-M%$`>uFx~QL@@D?91+Uo*0xuPwFFH{GNLhnPJlb|0#0$xA^dJ-pj!h+(rCR;+z
z)znLxTQz;v56mR3T0S6KKk{y>C8T7ht9w3SfLPMSw0}6`6~nfYtd5S0Q>X`Cp`o3%
zv@pWg&dCT6ah$^{oU)yre56~+Um}6sR2VC~wiQ(kLM;qUF&&%Dk6W`G
zyoV;O9l}=BpSVAu$BDS%Xj$k=_)eMPduqoufMyuhTm-Dmp-H);>Q=i~_oIpf#1l>*
z*;scX5MR>miusg$#G&p^=d4$kuOx$^m$mn=TqYM?FBfw~L~5v()Rhd&>pToF5&wC!^M6>~`8t9D7Kq>6HH#
zaVs;2qx5YNeRddvCx`|Ui3g4lP-2cie>P3Ky~Y0ia5e*oU=COVN(u=(ZPtF4c`fnA
zF5n}cy_5-vPfH+@7zsxpD5;tb`a!!D_qzL6ugne(;CMD3QD>=+ue|c|x{dPXnf2e_
zFTY=Yzx;mr{qmd3@A>%q<@d|)m)|e{{_=Z1{(kxW^84lY%fG+;o{zs@e!u*F`Tg?m
zFVD!g8nb?PFq^n>*c}ggV!r&g=^1IS(;oK2R@xf$y2F7VM`E4EozcJwydX=me%}tm
z_HbwgLDX*hX*!&X?|xD-3|w!z8jt3K&agF@_WF|^#kTsHoKTQ;tCNU%sQax>FY6CG
zSX)fTns$2a-k{s^Prf=Ho$;V#gA|=+!U%Vn2@kCh&mIF!TA6eHcN`snMfup-7KYG&?b8N|1b_(@IU01x+Q!Vi>qgIMse0CD{r-~rWeTXg*c-8ga%u;
z(HR#xmc%R{7`)Z%9$mT2|GfClB>!yr@Uoam1{>vbx{{JK@_Rlq(oNVTa=yDF=J@Ir
z3SsXg|8@`~L6F4q{q5bu19p*MnU76NnUueGbjT)qSBJ~J>hd8k
zy&8i}tm(i6=omBsEkXmu9oQ3tw#jlLU;Pn}ttb8Ie1t(sX&@3f5*UoS?42#9!|`A+
z>W`*_@oc!*ov*~a{;8jYaXSTYVLl2IM+A=aI@l+kN#&EAOjaw_bV%Y!3Am|}d}Dw#
ztjR?@iOEHPwRrqL8T0$mIv77*m?r#k>*hK80+pa11O$cP2~L5hu-DQ8r>r$)40~1E
zl%vdwp?7lj0U*`3NdRFtiaT3ndZLw&prdb<%Ww_i$oIo96bpLbb0B_&9I^sxw11&4
zc8M1is}%|dh+vLtY?cZHC>D%j9E)KXBCk^ZnfQ#D2re%h0E9#IKuI(sLvemF%U5qiI7c{q^
zIW;jvMNiCK6K6zn6!C_+8ca!IPP^h^HvUPk^J0)WQU0gHaGkBxEF#
zUGUM(+KTHHb-kItJ?{540h7m~&Ysi>?
zb<>JlE$U1fxW<|?IU-zRQ+~=#eK7KpjN@`F=r0T8TsSG}K!EfdP9BR2UwQGm{L*IK
zKu;DiK5lmm_D1q8NIK+TG6|9dqic;8GqgjNPp-(3I51shwzndZ^z;f?GswqhXKng^
zkfzkhi$YR*ap=WCC!hIyzBk)H*_*B=a-3R8L)HM1b#KrnkjqH|!^v#CpmB~4U@-#9
zaGfa2(oQ$Y$;c7ubr>k50$@%mK?EZeAV6g>IwZRQBFP9tNwTmeJ7A?8a!I!GLvm`T
zmr9z6-*VkNXI~%@Vogp$KwEJwA#5dKQK@g$%II$5L66jxQXxtzfh{CEXK+$)*FTVV;k1nwK^3u1GB0KI%CwZ)Tnbr&esaW
ziBJfo(ei+jV`tQn26-^f>~)7Zss4BXh4lD4J)kaUeiMT
zW$dE)So^K6c+(r1=Ar2V#fcOrWD{;`eke;LB>;kw928B89t2GJTbAt{zJi`Wka)(#w?o4=ND=
zVSoeB&^1U*r-lQkN==fENF*N6kqn|YQ5s=NCNbrJBuK=j>{+s8N~7@o1ny?F1QTHv?1O_Ca0E24uc8V!88+4O1pE-W`fE@W1%f{`9YRvRlZZ&H
znFhszFn$`68J<8=(-N~D;#^+>ph}aYl$C}VcpRwIs42FXT8nFjWER&Fj<``QqVIBt
zy2)PF#L&F(QI0VV?EDmG8Tn~ns+8oR3yntDN}L$M2t$NmC(BM1omh3_h;!tJ0K_yh
zN1=Q`$*-_(ptCO&m-Eq=N-bwr$eE~qT2M?}>7Ay9d=sCPSU8>mn-#-vT9N9e4J)b`
z9vmUB3TI6r7%O7xt8Ueb%bEv6#bD!Jh~K?g)9PaWuL$Fy_~Q_BtD!1>RJHKC1Inpd
zK2o%x3MmH%iNyWq(5&%@(T_xyb+eB83!iJJq8FGhYuRN`MZ
zJWsqn=|^y|q??p13&+dGr>0m;zNrqW(U_cz{J4-xuG{F0i_}UmNb*9;I@a`A*hhDO
z6vP9p!^w;avYnuK+JLe{HLl&fK`sK+1T4~FWw(`i$p}C>B8Q+FL~^o}
zERRk=o*i|T#Jus!%Os#2cC8!e$pRliiMWQyB3SdU-yZhA_k-`dk>BdK!z@a>!u^yN
z1P&=r8{ASA8BZi7a3nVj$Sb{aB7qJmIZ47KlPRf_6ZofXhfxS?(I{fH_YQQRN_1lk
zoJkqTTJjFA5%$xRNKE?3kd6SmWF$snk^xiT2!rrj0nK!GNthaT^HDRYj3hV}lfMur
z#fcDJH_zD@>Gr~xx}{@gukrOXmtZ=ZZTO1Cpjm51+k43vB0;n&Jr8bumeU
z{45&9SItN0!8?|l<$TB=60j-0fq9}{0hweaP?I`0ckp8_Ka$-rn)*;H>38S%G=&dN
zO6s;<5i`sHS+Y}k1S!9Q93qz(h`DZ{voAQLus{o2U1PB
zfP8V!O|z!$?$q>>g6kb)VoC-Jb5%grR1sgOFeuhEgSzhXGbnbfxv8IZ4L@>{R#mrZ
zhP6{u$Wk+G(3xvey{Nfn(niW5@jzAG5g$h@K0-BwR(Rq$#KkQ_^kd1e>VBv}Pg~qB
z1ZtSy?QiEZ5sL2-J&}>303Un=ovcxa(nxvgr<0w-aa;oIA|vr7-Lul(f9CsZx;cR0
zU!5)wN9YB>0`%OzbLa2>@gL}nFonKAfCTguHd&JklT48`p%>G4D2LMMHIzd#7$j*+
zF4^nl;ba!F1H1lsf*vFbMahiBfWP4sQX?CehnKJH9v#!EfdK!3$&xf7&Zkf^AB|}>HOlh6M%Gt>HJWDPDlX3$a=h7O85CR4FPPjTG8iWD{vtJ^`XOq
zY|e|d#JBvZI0boV*_!eh6zw2e=P4G{A0UR3+s$f8Z~EQr!;e0aq7q?ssagb)8?}<+
z2|hwSb`=z4nBjH!@3-)dOPabP=8P9}S|R8l3uPiFNnf|Et$M9yndggzOEodl1i*?q
zTu#K?30{)PCoQZM&#juqX01wrW{jc{gG*8}krYm#n2#?>Jn6wAcU<
z2{@rj73O-Lg}FcO8H9xN{PsI1D$;-8xDGnHH1~`I7(ze^~z$4NqFfN}?mM~5(g`o9{nkA-bjZl;}zygS6!$$O(X=-Qq
zygHjGyP!7!d8AY#{ADqNg4^m64lq4D956unQT*J+wCR@L;yu
z#g&d)LLo`xUygsp%Qvpmmnny0DU(y+D6%vdM>$lRj?5-CgfOHbCA(NtD-KNzH6*}Z
znI1&SlVbhi%Qt2FoG#CZ&j*)cY&DE+@_+T~|Led0^_L+O5>o2N;Y^595=cs7a+CI@
ziUc@Ms%3dD$3XqTIJ`@lo=5`3lNh6XjKsvWb39QLm6Ie*^O1yTf}Gl7I1m5_6X~Cb
zM2t=FM-1%4iKhF3MF@gap>vWTr=dtD9cogx1_IVFakK!n;{GXGGV6((q#QaI?P9LA
zQ(hCvF4;Oyv2ZL-0k~|}P-@L|DCW_ws?7%vAF?hqYw%HVt*WjdyC9~}VsUV(T=3gz
z!xkfwNs$=0J0KEr*M}v=?eofUm!Hum{`N}HOJ&cXeiwk4}U=3X0ZerCF~%z>5DlO
zp&oDqln7xb3ZXgGkT)FpU67)r$GPTL_|NFa{OJmK63US?{M?uR;(z|Hzpv=QhaY`h
zP@EsW@s=HR(STLWt7?JaXJ!~{ff&1iEcoM^8`^Q!Fr8vPK;%|aMc=8eZ^vQ?alh5A
zs1AbB41|8n2Of7Snu&fyORD+6v?xS0EJ(ut1zwx=CZZBNp&#L$k&oZAqprm%R<+%l
z7nC%vQckY;{QP-~CFa=DG?Cs5Bx?0Y5Vn$!hO7Ewgi4X!a?p<$tduGep2}O05|R0{
zBjI8j@l)Oi0uT@lG(Zjh?LYqbV>;mD_uhNw-FMmb5C8a&^a6}9jFV_142h%$#OSjU
zh(uywjx+@5O>`oPB_OkNAi6pIi^Gv?G@l+{JGuPg6{rFPC_(ZBQHgSlTZk3-AhaX~
z1SB7U<7{t5&x&(N%Ym-mcoFJRIBQA$OEZnK`PgzS}7A_jI*
zF=9x=b%IE;tQ+XbBJ`u=5iTvN>M#HL%f!C^{qKR2zx?ul{foc)OZXV1QFkQ9dXOXL
zQcDOZzS{0}!5{4+pM4Kz6LxX7K^k*lxk=$|f#-gdwF7jd5Yi(l%jsq$AY<0;VV%LS
z4dz-cCrurY*Xy%MOVMzCEC#zL3^8$;@tr{cJ&=w^+kryjQJSwRBGVa
zin$r^zRwqSutGjCk75}WrNITjiTtus^3$+km<`=B+@NV#<)&aC1O#wU^-`sbZ_XNB
z$(k4r2Ye|6((#MrPoHtI#ls~oOBF>-*$Pa7EM>wwFA2QV$DvkjF&#D%iCr)^>B!AbgS0Tf~>6J1;;u%
z&X4MrZ^oU?N*zBPt6JhlVc9Sdci`BFd@*%b{yGj6bK6}d2up^chM}EAUMsEU^L$D1
z81(yA80q-tIVEwfK_u}FS4_^uCag>+6QF6gTEr8h1VPC(tyarwx676VGz+S(265AS
z%I7ou!_x(DRQczJVvim@0v1pPJ|gk1-MIOUZ+(mYxO;d=S0!Fb2MJS5booIarjQpZ
zNohub^fKJl9Cj&vO+G9pF))Hb#ITE)!F0Ub-^EU@UB%B8gxXu>Z@G+@2g?^FJX}g4pcaet`7r
zOvjj&M2Kx7B|77lcw{u1&82vRgXj^~gfYY;ss}70UZiX!hKrA6E=EIeL|R9-G7T!*
zTGXM_ra_74Tsp&ke%~_#_v_|4`%<@!lGd=3aHmoQN>V6e6dnM3V;%@B6MFqyR?`%P;WL}v#8d^7=rmktdL7ihXAlZlJJf-RZNGV
zDdO>qg>s65R#;JLhG(Pl8itORq@kq84XV(O;*MDU5FEB@ff#ca^@oy`
zU+k=ph^sqc{kk^We9(D&c({4ImSu-)!3%piGaXl>v3MxbkH|kA4Y3Y858(z}v
zlBzdsF*GEC4nxY}RyS^<6n^sZP
z@uLx*5EK7e!jW7gLuSgc&SW{#0k=CH183ZX%N7|~KlS)Mr~y!d(KP@f9UnB%FYesE
z16E%C>}!Aj5C52VIx(O(fTNp$6#xWT=qzM}FLWp=C&@?}GLi-)fm$g?=u;Fcu|;~=
z#3u1_7x84l*u_yMOOh>DhhokwdMg0QO+1jnU>v#Vus2_QMLPb3$t4Tqpwxu&<*_9G
zB$TNhc}Yo?=;_pry@W|mUMdVCX#q|_7PxMpC(AS70PPA9pd{ODvi{x=e!%9tx84;`
zW=3LM91!V5-e4xkNUxCW3zC@1^@c-Y$cO_w$Q2oN!bNpsVQ>}>_C{#tL1)+#>GP*R
zo#B98&{jN+$y)6`O1qtPyZy;w8NZ$jL@*xZ{c+>pD
z(K#op6>Eq9F3Cu-xmFkVO=xj`34YPRL|j;8m}Zhc11(6*WI5+VIB{x~H_p>6$VSuz
z9R>loSu4RfB5S7h(Z?U9qaNt_@WT)Bsa40^s1#u+_(MP9lY$Zq=-{i0r`v|=chZJq
zpd!W7@GKEJQKwfofe``moH~C{Q>aw{D4G=b($q;e(><-!sQPJShhjQ^JZMm*Se9zp
zs%crCj|FL}J1zl^h^H*ED4c!NVXsru>J_D4YN7hQ9$L<4pG>ArBoNH<@rr(aDZ!VOB9cFYB053Iy@Bx9eO!3S|kirNdq(~M2?~cCF`D7_x-YM
zJKZkQm7~K)GkHo!2O`i7p#ue6n|h5?sIGC<#J;
zfhKfb5(79kK^4#eG$bP<*n&_bkZI^*B$M1B0g)19lB(>Y>ye8!1dLla=13?pBQ_KR
z6j*zJg2`sP3zQ~CIppGq6vaVhGO);T*`$WVkbvXLnn-ZV-pwhHQdUe>n{y$a1ca$1
ztpQKh4fJGrCg&F(e%c+2p&rptuoBTHeN1STbs-ut#P{&8r@KqJ*Np-WMjJs%2unFc
z`bos`I4ZTIFUdD0<8~HiA%1$)irLl5r{n2!lJhAr%6j6C11Lo9abm;SaIwFb@6WqK
zS`cCqiRx^HSqAd>$3mNcMS36(HG+{aLQ)9N(a28{V&J9#Xr7TmXdQWRz+^+PNwe~A
z!7o8063Hfq_F_cnaJ-yTbJ;piv7i(60R3WFaRB?EBwn`S+GVXtq+*$O@7*ga4gBlP
zYPn&9JOz{>_fS}XlIDU_AQGf**DDoG0k}eJDh)Kg6-RioJNd9N@gK4>aU-U?t~;XDuHY
z!OC?5oqa+5VYt}2ii~iU@wMS&#S{~qe)!SH`FlJe>xyax?VcH?xYc#j#eK%hu9_Z7
zQ{1}@1U>Pr@u0=y?1oxW43a@rIYXiDwd-f5~^^`@AE!SkvX`p&N452T5cq-9lyk3cXS3}_rXNlW=7
z8Z;wVl-wlz>7gNskwef+|JrP|v^YjWf?&Vfht5X)ly`NZk^~lfqzlsp=&(?O$eXW<
z0lsk8=x(b6@qh(t$Sxy=A(W94jJ`t_06hglyjl>@)B!*46LtY}$C=^9{z(hPo
zMp-!N=ezr}6)vzK@^nSfi^*bk`NhjuZ(cpRdPpQjB}q?4308rN{Jk8iA-PNpML|+x
zfT@g>Ye_?n4xre}S&&kup%JKqtch%&)8(1j-l8+^bSHguNB*L?P*vpo&ges^?|EUAGJ)ULY^Qtfg`O3
zTR9vaI=R@i0}okB0tzSnc)mb0wo!ulJz6v)5Cn+wxy^8n+)Gd>M4}l%WYSsBb_V-6
zRg7Y(Ax7Ogpn1@v<{TZ4vzJzr>1EAHMhtZ(X5BnzUyu^pwMx@5<9Z`ZjCLH5E&1h`XOgkVQ!sp(kdn2Gbmu
z0>z`7N_n$VMxRovtly>0NkBCS(BRaN#FBtG(VPYK=URoybK%!PwBnU>7XO+1j}0f?
zteJ9+Lv1Eq`3VZp{NbB#5vb)OX>Tjm1EX%!jJCM8*fC+`UPUvluvKbW@KN)^
zd>U9W7fr+Tt)Lb61~r3SVNDAgW?%$i*lC$!6ye}fwOMQ!6se2RzkRY$0-JUc>wZwx
ztwO_SIKG>;X$RbM)%8h_kVP=^(<4_ahH1qy|6NWT!AEqWcuLby+T$s8Xu2MbGm-e+
za1c1kXX1oO%$iN0Nfs+>p&8X6g3I|UKBgSAa@|H}TqL>Zn-VVcUjqEw6Zrdo_y_vr1j>s4~4gm-tVMnoKAqJD&q*x+JK$oOUlC2KJ?LPtl6lRg0WUSf5
zDE#Q^(ZS`z!z)LNJ@I-bk(5RjN}#t=8r9&q9G$|i-guEnvU3QM(S^xEfvkxqC1DbC
zI5HBZR#ct<)Fwur3q_HaG=O#8Ku?xuaKVNPTwO8QKqdw>7muH$H%f&#DhMNgXNc!J
z5RbE4II!YT3;_zI63~z=FpdT#F&Qz-bJ--LtcOGo@$z*`O7Ii$PeXj#5zoFk6E?#v
z#Z^SnAVm>?!zto!n&mefUB}7N9sJ@-
z*-GM~st^eKJ=g(Iq=Zy$6A~c?!HQIroSl5pr_>PW#HGa@-maC&Ub9R&#Vh4t9OY8A
zvfZfHg^(=cZj;zYws(TC9r&5cI_iX0Xj+jOcOy9|E^WfkfeXJ`Do_n%CcKkRZ#V=f
zFE{J_*7>1BDRto^aD;$_;R2T^0#KC`;Rnh&?yx3OW+5f(bpxG!;Zjr9gQDsc6lX^<
zs+QMq@wKC^hPu_z3aZ&~!*hohQhYksm-6H_=eY}<|^WFUt~22)g_*J+~%#pC0q+7#dX`AyC)
zZBc&3uuF<&_?{j{4aaRdVMTYHEHh&97E#T@p9t`o>?o|-HcGJOII9BO&Dd%@%-DDx8CmC5Vxr;PJQo^;HHz-hcOrSvtM3Rh*
z0GC`8NJuHODSX{PPnKumP7<^NWFzA7;L1^qc*@^!r1oe={NllM*co&t
z%V}?nFD$;i#sx!#!7>_-nn52)QVtJTK_q8O{V?L;CdmfV0olh3{Ne#@MIllSdF5%4
zk&~p}_}Y`z0)|pP9(O+H*?6*CfkM>cWVNFE`KkCA21nb8P(9+EN9k_E5&Uae4Nyx%
zNYY6(b0BKf9`)(x9KAmgEkz_PLNe0Gwxde&^w-UE_C-Fq#yiG$cC&c1TEg9q`aSt#
z4MGy#hb}{%1>H8HQds`X7p4G|ONDI|BCak>fm3*<>>{vPDiOf*g=Jhn@YD4`-20_x1>Av`Yhl>`dg@DvYsz_2oaM~QCvdM2D1up@lE@VeMQXrI+%9rrEfzG~cRMBX7
zqkd5pGxi}E@wM~!vDcpfq9~hQO1zu&iw#TnvQpC#D$t$^Mbwp?#Pu#ZS1nGy3AxL%2%UV{Hsb0L(
z)F`1n95_jav=pDd`>m3q2Ave|9zK>3f@uODp&qIbM0Th1VpFxE1a+y!k(SR3hU;B2
z3>XR@*(4cjHpvA&OS*W25+=%bfRKk?bO#%7kfavOpE1
znLADpWj!c{W8M;uxxlNq_)uZeQ!>93Hq2+vfvv!IFczv1>xfy9Ju
z0b=-dDS@NAQGj3H9`;GOZl1F*c+>C^EW$GCS<2rHM1Qe~rgPFr^=u>b3ym5_k+&Lg
z#>-mMPC~`CE|m-7W5m!asS2cnP-Z9uHJTB9C!ani{hsD|bvc^`kL9Gv`N9sU
zB}^`QFRT>rIXYs>t&K_re-LOwH)z-z45}zr$9A)nNN5PxfE|E?WfF7racWET#O>ow
zOR)^2c1767pB~kH^kpw^!+*1yPW00C;>jpae0vYkFD@Le?T`g?M
zw;;EhCWyqd29fgBAHtf8`yB1ml|nWtMDC~9`mSu)TcO<^ZKF!FnL#;R%s|g#^-n=RoA8Od`ob`LYms*2F+n*6gL&
zbpt(Fo&g8qMaBG09ZXV#q{zU|2*)->SNds)b3L4mpkCU|AftS)jnj>~gp$;Wqf$92
zNiygu_U0e=P#}d*hK8qWVtLwaPj)5w{Diz!Q%!fj
z&h}QlhM_Up3%sIs`!E0de>V^&hE7p<{l!KDy1_D#2gpc+;Zsv{jB6)hs!9OHfhKvk
z6rG49q_op4NPEh`K(M?mAn!s_vSL}5|CBQ|vp~k06>m4}ou>GdrS60qH8r0FThpUf
z)$)zFUDCx^K8Q5{WQ0jcHFl7V?XKoWMMVd8dJtQ2R<~U7m0?4Lk50%h-m!zoi`$ik
zWBIY}hfUkxsTswlg>N3Ux=kG?pi|ZiGE%1ac(Fm#*kYbF0N0A`C}3~H_E^Wgo*%|$
z5NwLMfJ_7_t)#eK!$v~teyeSTVLk_rMP4(G_=#0!~B%*^|vf?dstgz38EffksRZZ88-vbn?)LVY%
z4T0uK065YvX!|rtT7-3Qaf>#UnMx05Vc@
z0raDMZCz?qKq2}O8iGjJ2QCqk5}N2oip2E-;)pa5({K%9$O>m8AWshUC<(^p$T52f
zvqoUTDgH1dmKmTJlXdPIQ@?_@UTxwR`wmw`9!mGzuLxI~!^tW}K=2pGIiM#%
z7&IWbTu#Nbf{PEn0)m1rGB9W{fnL!dV>p}4SXw-3jyeeM2WYe4qyh>pR
z?4X-p1z2`gR~6d=g``9z;=iL!#Cw%wg2Uw(GJ>i~b|D^Hj*72kVAfI)iHS795NAM5
zz6HVnpX|bgXU%odl4L%3hc475DzaFwLqLv#mBesD;K(K%WRoywU>E9=T^t2Nv&QpJ
z&XqPxS-TR=IZzTZ+O;-yv6NCFV_d`0E@SxJid%}Sx=}1cLlCJtK2$2UI%cVo$m?Lp
zueXZL4!a^*)hSlck0#J`ebsam5RM;lw}X@m`ikcj+c&(TX4&vjbPIR31Bd%Gh>pE3(
zrCMe24Ub)^X+eK-qf$X0M)P?<8B!G7>O#8<8H0~!O7M|1a1-ZR2|nKrE6@4Xi{C##
z`;%wS(C7e%DEe>!U!-J_cp^aak;X1s4Xv0k4F}LbB{1}C0ze~aOXDR0sKPE>ei
zbisIw)#=t6h(r>)B@aT0N07}btSr__@KJix)QjM0P`SMc{%>_K9R?L4o<-vJifeaT
zPO%_k+I{f_d%fN44F_&83>t)TV3c@Q(br1rBrP8L@l)Nms^c$Tl7U2-7|wXMWiGEJ*j0*Qm9niViA2>
zgqzexTaa{CJqKT6xL-w25HJw~e|Xl2FX2S%dEIjmgSg(nF|FrA3E{w^D>ctqNs5mV
zV@gJL2_g;tH4wycUW&(-Vv$HXnbuUaA@M7zB3|)NRV(1_*YvQtr
zuH)jRc0#=7PV3^cMGVgup@-84v)I%Nz7aewL=~>Y-*j3_oLaw#cB<;B0Y
zssfSt)JffosoY2^NgZUA(mJj&Qq2dBY2C(OjwzbzczDNFsRrQ07lf)2$tYQak`_>i
zc}qMPvi*8I!#&BeO5)WvKJ`)}8_TGM
zwpOfEow69OEbkYiidvy5b$U75(Oh3KEl+$KR!N%<0$(fmF%@LjA#zGLL+MP$b}Zni
zs;S@+q*bkn=Z|9CAUEr{?1i3iQ}M(Q6_|XTJ*%SwE)pdm39=BT`OsM42>2ijacIr}
z1-{TuF<3)mAp!BA5V1xwni5S9%3vG_!e9uyIIRpz1S9m&Ly`{|jT9q5f?`#60tcGH
zrzW1Z$<+fm2#G_Cgc{dEauVjcY?46c93#Mmh~%6cMOI}&$Oae1h{PZ%VIt-ExjN^U
z7^P?gI0;#uRnY!2>mOce)(X|4beWNa7@HgqH#v0!kF{9^h^4ytY=}zX?3@%nl5A~z
zy*KX9Sy^h;DxG@0FJ8#VQ&n5_N~dX;3)SH1jBDoo|Ur&3nL|183E9@I`ej7#BQ1%wPn}
zk}oq~OtFGL1_c$>l@Y
z+)^sDoX#r9NmUb!!{ODQo`;~|UXTSno
zMspyN0FoAu9{9zXX(y*p2W8iN%6~jnGvH;THwkm9!Rm;Vt_Kpk<9!YBgyr$#6UoAP%cs<_wY5ZTpfRy_w_mNSV+F0GfmjI9$;
zeVcI3#fgq9j_uZK7Gw-&`bR-Tlx#xF+r=Wd!M#;2GZ~CSAs#qZ%Ew|+oMH~)Kn^(?
z2_r(KnnRo}BqAv@&*e17;wDEVyD&Ur)=&vZK|?r&=S$7{!9elyFMm)yzp5jy?&?5eAp}E2-%MENfsYDec=N9romz{XtP;AdARyDt36l)31
z3Zmk&^C`R=T@k=FzE;K)|5{BnMC$&b;6G
z3p4k%pSAX0k?2aKDxjJ;(lGg9^;*?V#=BjoAMQ9Vt_cIvLkVcA0u_5~w-|~#8V=!#
z5vdNzgQuX84K_-t>VLMe3LP{)s@Q7_TPW@U6^0>#e9Fr{SVVpouivG7T7WkBT
zUfZ&5g@S6;tkJxDPU-;nt@e4(Y4&V|rfD6KPsRv0!C}qe&R2xefaWaN2PHeZ&)!2(
z=3-I->+Oj0`0a3{{AkihBO4iGY0yH+`e9^sq)VDHX%fJAX%<@AI`W9p1g9UBFoP66
zfT58VGl@Sm(RX3)gRqFfe?|ACWGk%p^gE!UmnBvaRMajs#ZN^9#V`xX>MDMyFp3i>
zQv#^5GT5L*YvqZSg0NW+*+wPtX&ad-j@XK3(AO~~8PU3u*CWK>`w{C;dawni?$Q+%
zfU||>9jf;D4%vR)7#|v>YY&D-6`rXu03%wOwepY|T>6?v=a0+3z2|Uhq4g$Qom(CA
z7aa*)#Xlvz!hO3OAF+Dqopb$u%;ytT8GUog`)ch}l*E3cY8JBb@t28Mz~!C8ww(5t
zfF#IPjw*P>ON3_D44
zvJ*wS1?@i7#zzL(fsGbD0f
zN4o6Ifl?yVlHB7-LJ>uIm?spJl`*pT#w$fWTysvPx*%?j`!jGx^Wsy6#%5H9`;7Y+
zwrQh{(X$HMC%h@2AGO~c>I{YJ3BLZh_32g=p(D{wu0Q5-0*Q#_@w^zP)Ch$-zyAU7b2W;J)TPci>IsZ+G@k4cbjE;4
z7MM8f+C-=pt(LTIAim%L3b@=zH17gyFIyWz~*}{=`p6ThSMI_8f3t-+@n{4q&
z7io#svAhfuxG5+oz~}cunU1ZlKw#!YR(XQgic`i>v#
z&QG`Ny(C6AE@9zU^k&L>qT3*7+!l8M-$3ILKk#0p{&w=StED;&%X9nCsnM8R)erGz
z-@a`u;qX5A)0`8o^d>vKmzN`3y^a^3$0}V3`WP=)+6TIxJfg;P#vb$9x9U(+7D2Vo
z|FAerJg9A^F#%JYERHcC3!ALpo!W6X?h8Q4E;)o6hbY6|!f7gwgJCoeoU(lXdD6(@
z$@N;s_31bXxvvq^(}J0CPvan;>yHd0mAo0!j7&QM(fK5F+f3KIF!2`6x}ZtdDLG4x9Lau#LEaP(oI>}GgEw|Kd2O-*O#^#ND>l6TuEVV8p6HK=
z@PbP?1H#kY9J>5(qE2s&H(OPxNo92&{op;cV9AZi4_#pv7!U0tWs0L>CmIvtaNM~j
zXPM_mBP`d7M+p_RYdQask0#3BAp2z;-+j89!4v!AxY$`@cfpKozm|TKJo@xui!X&(
zk&*?k_^$#*5PQANGKlTe1YplzomuZ}PqFN%4e4{B0vq4Z!Vd-pJ2p?S5#DO>fCv{u
z@cq^rGakLjQ8X7LzBiu0+j!s~`GCA!WPql3Qk``I{U#G^ixRiFn88o=$yi;f_*$}1
zFVQuY(-1BRY#ffhyviOD2#zs+(hDSDfhg!vGDg9)$Gm{#A)F;(f8b6=d`%~9RZGXf
zhN=|d%_~i|Us_Z_=q$*CRUy%8z(@})()w-EiU*5=Jk5%XH)?jHoP%IfL;=d-x5>vy
z{}>PCT|c+Yo}=m&)F?VhL|SdYbm#fs_=Kc38Yx(YiDS%2tJx4#z!P~TAr)=o1>)x6
z@?se%HY1U=pvM?c#TuV$#uQGMY&Ky}G(c>)P01VF)U=ZiI?@irl8=|+TI|D^bD5Lu
z1hLZ-O_7{uS19rOPczZ$&YV{}Ab%!mcG+csCTiJRS~8Ry}kOkT-U>g
z8Ed@%$m*@unBz+POu)3U(^A}4t62i4XhYcclhWC5>iw|>gga!J)8#*uT0E2{bkd11
zL{!ve%I1#g&?VdGOJpOtixYr?UDf8<8Ow}^Wj;fd+e5UTN>qF7&VL|=%%7a}D`S-~
z7*ca-A4SPU;?h7Qcc#GEC=tyiu0@t^*W8)!UUpPJ$jN5LxRdWJup;7moOM+rQ2}Ea
z*l0NsLEptK-zaW)=%V!qD7nXTQuY=44xtaTCl*;XN|3^#DNs!et=W7-f-KtAGAiFSb
zZ*cC!P78naBQmY+>Mz-QS3LXTI
zcMvA|6j@$@AlKvp-b^3{{1q<9z_Y{)Y!{vuO9o*k&BCgzSOCB;6#%5{0(>2g0|5^O
zI^{*}^Kjc+d=>c_zI5aT45DdlZ$>^Xs1a}~Z_eHGkuhdnJ<&$gIUeaqc}TkeIT24;
zt=0@anZ~mZQu%0a!$ie`$|F5mW$JBo;0Bi`EnYVKXGgnwh2R`Uu3jW^Oo^lEyu4e#
zbA20x%z*y)W}^1*UWIyCfSyXN1MwIQ5C6A5hEyRTW#r
zbd#&FHYPs}FYd++QX)=M1xOj)EQ}rYEP8kz3?0#G7mJx{T)$hjZ7Ph0NHW_%yVj50
zS;ak6B7sH!4aoAtJcbaKG??TmQs(ZQ*mBIaZY>`yD
zNH3WnY>Ywy&I*QZoF&#Tc#OH*C2t^SB@4Zj&YsZw+Loa_&R{K?7~w@rKOt^;!sIKV
zPXMC9x1}i&$zaZzv{|uC(f7JxumrFr+$GU&t-?vf*7Y&Tfi-(BkMt)hOLrwf4;MCd
zlw2WN85_67CP|S~m41s3oJlx)TqiCtR*~XtQ(HmSKr~
zVJRKpz}SO2Wte)?S#V-Q)EQyIBzKmWDN2bCphaXyE&%oX^Q11%<&#@P{EN$HaA+G)P&JhI*fc7LyMCt7<7AAHM(2T*&<=IvsLnGiTCr5>4Yzrb^j7m
z+L_PM`CnR!D-V}DqVa0`>9dbMCJ7qw`H>UWwV;Yl6NYtg!*2(A_rGB?o-
z4Y*o&B;w|wCJJn_cTsDnyenGTIFGsykF0Vs7i&hkEA}gZH&pd``DM3`?F++K_k-F<9Wn&v
zSSFAifBAtfxfyM#Lz*|Iv#4JIUQhR`$Lr-v`N;R>8LbXz8&X+O8
z_yQwwx~1aVNBTq<9&m&{Oi&3`MM*9UF<9YasQPu35}q{9HFAW~5N*Br>%ngr}T|u{R7_d|7C<`Y#G>0u*e1RQRHTW=Z6cvV7W2z&T
zb}?3wlL;FDyGi5b;)!Q-6*bGXTBZ!N!lIRuF1ESB$cUt0JnBV*3
z{XF|RNAI*#WRs+v
zr#gQ>3Ijvovn=p*vn5NqfX`!~+YQIdZrcKLa^iPDR4@h{|G0<{<}YUq<4S+a)^&2V
z=W4EkKNvrEJbcH!~03az$Wbv{G`~%Z(S#Pa4^Wya>+ZkabJ<4tA!_Wd?SF_`r$_gusk%f!XR9
zFq|qWbWVn`o8OT08@Z_0>fH)6lFXzsRV9ik=ji_C4^WX|2Z6)trT8puGi7|oSJ*XfW76#l54IeJF%@JI+&9;3nZ|T
z&#Rw4kn!;+op?C2kO9<>F(`U2m~C0?d)NSBhbLUntgzbZUG-iL}CD$%wxluR+GfZojS+3zE#>tv;eY=V0
zW8qZ+O9*N8uypS7rt4d4`1YD=LI#k@i*OP{9A1?JWC;5y0{Cslj$~Y3(c@P@R*F|T
zQyQ#C#+Cc2fmv^C5rb+O7vL>8bs93ECyC9#WM#7ZO6peQU=$SPyrB#`V*&@7pa724*Y9Qhi8fFK|4Y8xPNJ2*%j6i#5hsE*)Z+rwWnI
zRn&AXKI##lBA8gLLb0L)?lt05GwK2jZZI1KEoMVBObKlfG>$h>d3u5rr5T+YR$W8k
zIb6mo*rS9X?mUW*gmWj#fa`fU^do^u)!_;Pz-hREpbhWW`Ri8az_jBg;*FAAaBKyK
zm*UZOI(%Sb9#YE)iBSbQOOSZoooY
zj+4?LgIv7D@vI{yJFTMIcLqaIznRc8c9m5I`W(U=%5H(8uWw8k_~)`FB7@Il_2$!q
zup(7(t~|NAD%>S0FWSK_o$ktcE#lV$w;K=FeHY&^$*QeZ-85I)7r}!w7Y@8*6RWuU
zxR$C|v-`L5rK7dNa5ob=S6VAp0UKQ3Q=e_|=;QAbew8=3{SkQx$H<=g9Vk*apkD;JkkfH!FC@0BS;#<&Jn4T(;BkoENx^XJn&=E_i)#bQ^
zqwFXlbtl5nWj`vuC*DY4%;%d6hRC0ql#|90hv-fYH!w;}I2w(5dq$D%8xu53ke2_m
zg91o}Hnq`VMNY=Cv6rZdoI({jkun6#!P4i?VtpAzOXaakr8PkYV}EI3mn6(+-)AEl#tAQ^XWd}pK%`wS>&
z&PreLz69c>MaNv#D}G=&?)Js_&bKz@7SY2Sk9cXOXG+5~o+=yrRPT5kahzh;@ikM$
z(*|vg%eLUSfDrVX1{aC_5MGRgRs=B=1z%aU)HV#83~M@+5%t<~539h63jzuP0|zu{
zsUmp6(Wd-14-7*Fgzgm$w0&p-JW_mt_3iTZPN0^FF8)Z+9(Zp50w?W89i0h~=#ZJ6
z8Z0r<0cJrSQEZ*b3v5+pjH@<*NyAI?T9Ah6P%7O}jRV8Pr228fCMeJC{mc9WPPN$Q8xD=A;VT^p@7yq~HKS<2oJ|7hwwLbNSdaOOUbwoJrz>dEkT7K?
zAJV&Lr+t5c<=A@bqXu;jl1q~+g|F)C1RF?V=C&Hi*E%}zIY}FZL
z;c0I>jSF5k#f6axYkg5j%uywSd(gsj_r&y<#$W~61ea@wmEx8?IB;~C78FdRqYezE
zVF^z~$l!&KHM3m!%5KQY_L&lL8Lmzrfyt>7(Z@5`p|%Qe4$|p*on4DGOrwVenG+ow
z5<|rIn_4*!>`MgMk5&`}co?+mGGECf!7
zS3G@UQx%+6zeyFj$;%zVxuI)(;T^8}
zW15jZDCntjD;I0g!lE&Rs}8HJmysfI^6_|b0VfU_k;d&#;jtFDl5ny4kAc5=u9g<23#Z>K*1u~5=rI}T%KF2**(NgJSzcdL80T%cmy6e`P~xb{)uJF_(q?ej9ft|>>i?xOi(C=ZgLa>KYls;LxD@gvZCdR}rMz`Z&zz2jngUm;Cv8WjL1s2&IiYs#S56d$I!+KDqy9cxJJ&`a>
z_Tk#5MLeb<^GB&fEns#2&~pFf#3?yJ1|rzv>yiVH{c*NDoiO&aPN=$LkSq;QPH;1A
zSIOc3EggKdoMMzfo|wMUJxQRON3J{9e#v%bdNpe-;7$_j>be&R%vVETI`M;&ez{Mdr-pVEBZ
z?9uZN%&daBCQxReTYJO>!A9?JQHgFn`tP-D94XNh9?-aGpC7oq%
zcX~M;Hxc5T(GCpc0E&2-vQw%l;%l#!^e%cOyD{=0NCISF5FR41t`T`hh)d-1R)>XV
z<-;{x7FeMD)<~iZTNb29q0n%82)I_O!KF|H5g8FD;;!Bi^iXvp1DI4fY+=O4OQ66q
z6QL;c(D36(gn=+E6xb2x(jFfsDWQ6=9}>NUc^Xl`sOOko=XuR!@3cC|7xnvw+32X^
z$&oEg{QjT*B8Zj*4e()=^C?pwUI?FBS3IsRQ%k2A==*E99O%-@gOqlSt55XxC@KBt
zw=1I}Wh;IZOcHiUXS`%y_OzJ!xW^wh8I1l}OEgEj(n)wY5e9N{%F3ig`A2a@_*U%+
z%hHnMi0&C#AlT|8sEUs?p8uWvhA1%O
zKI<%oDR7W{W%~4+UIophDm-lx#-U`(={lA%+w0u38uKa@y960&FGxu{r`Mx$gbCBM64CeekH(ocNIOj?9^_zT0JPn3
zfm$F_8_=M3DKwo6?KDqA+id6fZOf7iCJ7;(pWy7Tl4yglAOY}Y0Xne~+%+Kg<4fDg
zMg*%L6nT5BhOUB(X+3@szlv&GZ)=4Zp}#mE
zk-n0c#{(Itvq$(oPMl`BcGS4zbkqGUf05G)Q&qm?uRYT97kS_(mq(kmtAy=v5M+|7
z1!~3-?QI2D7A&x6ff&ga>t3iFWVSu~fKlcO%!QT8`#dM(It#Z)&(1uO3ZYXOwvLs@
zFK=Ws(C98X_|jZyIv7~wO4*DhTGi{L?aG8uBzJd|)6H23SR%kEU7~fy42w1fff){1D(tQ=^E`__A1q{1mJ{{Cu4miE^fdW-
zf7t388cbov0mynVu3B>w>`8(=)hshiejoqi&bk|UeZLTpY=t`iP+v-2nYDdPZwM8)
zFh>TxJYJOL{B`^_b_U0O;!5`$4`(_sl-d9A^ioYBI4lLJF`k60Rn#c^3HR7Y7-ie0
zChhb$nN!OyZfyNur*UAZ*s0pLD*30iGJ}8JutPJl9V9geMEMy$|9fntJs8~t7+(^;
z@Vo*uqbqv!RSX2o19g-W=wS7oIvtE%R#*$17(lqXByf~y(CN`qEJ1OUQ
zSP2GF$Hua8Bs?G<4!$(TI{M+-5u28vHmSeCp#xcyqNbZ|~NO@_Q;J@C}7R
zZWt!buyPIbh!8ae1T#|+Alwqq*ykZwRN{bg)tEC8lBZw1f?4L^t_W7qsP=OGI?K8<
zm5gUksEB+w73vI!3l|JECJ3ktd^>=`xymd(mxSqLhWy#O!rz~CZko3LbT^dHrKO^l
zQrjP!-k#sE82SGH>X-%q=eqW?TQs?PP65TT*y
zH0Y`PTof6s`)<^Z)dhcAf;yFRtNm38uAVB#Q<8sf92W
z42y?>U81KL{y(cB)$TAy;bDust!ER=r&tp$JfP_uwPK)k^d!1$|&hZ
zCh8-r$Y(;yC$Yn_r7?^N6ujk`InSP@Gx6SxV&4(k^H4=a<*d9WAo7OKBWL;fy5Rk(
zJ;?LmWt=Y+t1}Oy^QrKuQK`4!1weqJ2m
za0M9H^P6u;SqQP)Jt#PfrYe0mSkaFx0%Va4z{=}G92gZNl#-}8wHM0UUbwTqi<+wZ
zg`ZXc`N4`4;UBKMgtt%CpV>l|192`8q2OYLXtl_COq<@xQ;RL!hcV4*qgAf})5A=ikV@edxfoZGPn
zN4t*rR5eMrcg5If)<}O)Xih~Dc-A}oie(r<7Z3qv(F>QkskL(B9e(*L%ql#pb`lq^
zH-4_OBq#YL1B_4f@O>pV1E&DFi{EJEcN)bA>M_hw`%oH&g(sItT5km{jPl}MdeZ5%
zSGAV-$Lh{Xp>7WywPyvgDW$aK6yN}fi1B9>^`i
z*p#|hG9dgm)w1vRUf#*DoB(dsfYUItR94Pz(|A(YN4RO5QsW4$fU}+7zxaYRb$+ym
z7jr!{WBd}a&h;GwZvIfEQdj!BU2v9)RD5T6J(YqW4>AnYsj|^d-bT{0q`;f5)U`AF
zd!Z#5VUJAe7&d8@b^xj2HufwbjnYWOfA>3_^Vr2!qM1=lom9eiiN96Sf9rtDgypAE
z8|$`H&oWf~fX-h^2p*-OhmctECdy3scd{A9y&U2!vEY~U|97uom0Vaon0f4%)VQeXdPm;3=q`D+n4ma6c7Tww{
zLd`%&|21AaX8WeL*n!a*QNl}|$6Fk4H+8a
z3zm{HT&qleonR@x-yDRz&;As;+zn}Oi;)=Ue+K_a5|byxa_w;RM^e%CYVV7Pq~*R{
z=Yc0Y-N(#+#wh%-FINx3{!s_@KoeD9rg(h~h_*WI@5q?l6Z?!5X;k(Ajp+_Z%pm6-z1e
znbDf$IL$4ft7lG!p9F+g(}Lt@6UTiKCIC+7stOaHhfmy>FaPH7N8?%^x;$3gc8Zq<
z#DwaBaEm@H4HIjXi8LNsuQabjBT_>oT9g=Lf)ni^*Znylq1g{3jtVK&<4Z}}YiMjh
zfPJG)_?6AuQ%6TT*NNgEt(sH$vK5CI-AxA#^;0u`=dZ2;wW0}ozJOfQc!2)CtU?*J
zfz`5-_`pNw0}939oMJ8AfssI6Zf>6pO_8p9sf&Rca>h!BlD@Y#*kG(F{8zLQYflI3
zUPhLp)bCfiC!Pc0ZVNcWwwHqBqfm-w)sOaUSY@ya4V7-S=VXqUx$yD%1jG%}3!p-M*z^nf0iAslT|k=>l0%qMTh
zb)3DKKWS}}oI!#b%f#R(<^^G2;H(f0c^vtdi_h-_XL30gb$eo^A!{g^TyefK$hd@7
zWT12S|E~}zL4dCScX4Q@^3{$Toy|--MAVMh2V+KgecF~<_?t6F;JUVt@M(7bTA~Pk
zqUU#bj7ivpqc#tLOg((ZU~Cl(-S6^}DVims1MjoH`dXgBuf6xbdi$R*3wL5xT+svk
z1MX2FQV)A66bR*oYZr-jUT1ndJG3QxU&{?k4~dIDfBj~e-M74D(YMa_A<&RzLg=I7
zZM?_EpZ#tb+%)0coDqL1lDkCT%?s^B6Oj`w3b?gFIjNCsLyh6X2qn1oPD9Q%Q2b)`
zrLl^i4h{&b1GzWJhFtVmlMa@ZP_~dFq()Z%yF|bW`M1>f6j|koE_?*cg_k-Gm3Wn;sGi$1BFX{;zP%cgvB;}h~=
z-Za?pe943@^>n`bT)gvs-A4U>fAxba@RLX*Cop|h*(umjB)LXjyOD<5pytv0`gKkc
zv$7nM8PdVP)1n0ANjT~|oAk>2olx8I>6deR-izHG-M)bu9t*YZwJO+PcrhZYT-0p6
zouvyJG_TrR^xsAIghs--+4JU{l$*8^+Hyy89+k+AyKfSB)EbG)f7ry{(&h1oK;-aC
zZ0{+8u19kf3QR&q0jwP^Qk4rFmmp;LV}J1VRI7?|9S)vmxANK92V-Vp9`42MLqZYw
zI9o#yZsfEtbD}SRfhikx1F`V11E8aouD@~&Wm`@kh$8o^+k62T7<0WfU
zw}&1lVj=V4iyC99KFuf;49uvZN)-&AI%-Kcb5EM%Yh*{u6A1@%cL!OVRu2mt|TAeA0y94*$3zNO~R6AQi
z>=&1ptG&G`oC7cMdpW5*_RL|nxB66El1xP|Wh(Cb+0%)bL}UZ
zw@sdu-R6F=`@}+Os?1c@-ELaW-Ci{08AiBCfF2#m#KOryN
z{8OhRZS3TcMUBb>%EM9|KOtPH4G7)#Q{9r2C(Tk!1Di4rWzrqPe;;u~WRc@1r)y5E
zV`GhO+sr!D`JwEE-pmT5nKq+Y2AvkPSyX}2_*zFIyiLCtDhw>ipAE?PHW=&$3sLD^
z8$6+AuI(Xr>F+PIYrQE_PcByxi(iU^1K(d4FZ-WQN3o^oLvfWK^50*Ylncd70!4_-
zlB4wZE#;5i#}rW~g`qVCbF3nhs;5Y26;<$*u8$30(B0^5QA~6B)SdD_;{MGQ#AMH!
z)$Zv#wvRC2fB4~<(e|GPCJh0Be?W(6Y
zmvbI2gj@+O4|K{>5sZcxp4~HVS2M1e3i|xWPFI;7#7}#!B+i=QsMFUH=5fsl+Ya%M
zj>uv4kDw=qhJg@Q=Of9{4--b^)C(*!R2p$=JDpaBPkGiUSa~n~x_#lv63PaBCp7z(
zeji^m9{H8NinoeV`M8`^f(w}Xmp8h>Z(NHvd*vF4URob*&yjgxBGnoU6m%-Br@A9q
zjL}hHPD=)?WSKv`4Zb~(-b?vCT-x9NdcNBYD3$^d(e5D_L2;bz%?!H#{XQSYDR4B9z`z(M5Eao_F*{ePD(^hBaVH8$CP$%UCr5kPg#D$PQ7Cj;@fxXM0pgpbf)_*n1qu6%7eh9Z5
z4YS79-gKN=Wd6?y!;rQ}Nqmq9=_O{>K^xT)Z6Qf9KC%){Ph@qZ_!NmW(ZFz=!=q3N
z3qxQ7_eRi~R(}1(qj8*Xa%pBy>#*_&=Zmi`DLs|gnCQ?E&+@XocoZ~0R`qZ6Wf#+8
zq2gVs^lCJ&cB?y)cUd9=wJz$Zc|x#M*uTJadntBmS4OK@meA~&zs>pLscdPZp^2pG
za@bpyWxmZd&h?P`+hlk&mL^k9jtQ$N;HmAg3p%oi|NejOnDD!V!<%^9{9xE)vIN_1
z;;m@&cw2!rPCM_9Jcac+e6wr)Gdkj(AiQ7Gk%YQ|gtr*fM{QHNl^yOwlQ@BDqmz1~
zbsf)j0arnuSEq{C+NqHK#eYSC-|h|TucY2=?je)ViHz$W__P^hRTTJi(!Utr5!@za
zlH8;u*;uh!YX88TS+17`0)bMxrVYijiJ`YMaTJGdc^Z`j9|#6nkzz;BbO#qpi=9D>tj6rR;wTd=$rz0F|Hq88sNRS`PPzOQGW0Y&s(4Q=(Q|*j=T7%qRvO0t2<|tM7hfvFI*E}jCJzrBD9#H6
z$Lx-MBmDC7*E`iFV8{xDlF86~XNopr#5lo#aXzunUEAabqY
z*ek}a#seWFN`x3}g-6u-LzVA@L@A6-=DjE^r=+T~_gml%Nh%Nh4~Pq%@I;0?D+haA
zpmNM-4p?fRE2*A#(7kXSdTGGKFJHg*zr-Kp9DePer$)Ln}e$snEt;
zWz8&e!g8r>7iX9AOLO5Nl4$RXq%<{?Y;C_o6zl5}MsK1JYi+e4=u=|-_*LN7!|YG<
z_kZ{P<)=Re9(S%@!HQB(kipx0q+~5TBc?W5lhX~C_#gC;Ah{&qs8{+g#(mfHXnhsQ
z%2g(+cv2+4k0?}dhv8{xj-zRbCoC+H6$eX^hXH;B%se+qtM%bn1M+R|u*iIFM5-b`
z7f;MsuTGQQh-bdCJiR(RxK-wr{j4vy;3?-~ym=ngJXw@tR9har4N<+W{||{gcJJo6nK+Lz0N)Qm>C^EqeYe
zv@d7wjO4K4zUwy~bCRURN7jIHuwk5HO*|T%_EA|{ws?+JmsvN5F%c&I$+d3UU|9}`
zFX5=(k?Dhau+-@E?fA-nl5d(;>CzWb?$o3e@9FJ;2^y7$LQQ=o
z;d^(zoZjCbgH0`&1r#s4nO?;nc|
zC>gTA*IQD<;^83OD_QHvuFbE0Ebs8Ro&W~UtHWV9qSD#Itf@)B^#8}?!c#J46a4S919!ms?
ziKh+yAzqOqcMmoSzPYo!b}}Csm9e1(2mIpJ-Z;G?Q3|z@$(?Ek_3N3Y>&|Y!=f&?1
zHoo5Aqu&?#K8-s)L4Vd}A@xsxItTJQUytPD`Mln`JA(muBdPJ8x(Fk*t*~R+;kE6r
zRVTF(zVfJ?vf|S$o|F~#9}A^3#*`Drgp&NTtBOs`j6z*>XFCWF?i;g
zu~&{AhHFf)A8`SNJhy|g*BJfS(|6s34ivEP*n}JHz
zuj$mriFaYRFT7lqMv;`5N&XE}bjnM^a2fv;!!sjWbde7NwU<8D=*8&g=jo6ajBCql
zT$F{!SbL5=C27$ey5ZIPkbmZb?y5!RX{M#74@$37$t&O#7krxH!z{HCZ_nrY0stOl
zmJz7zQQ5gzAnfrEYB1=~BW~&wfd>xDFrlKP7p1rRLvdP<5GmmqG>m#$hPGskd(d|F
zbDB0-2cw=?tsQ2{NN&1e^{2&n69ItYIB?9W%-Mr3FAhbrN>*0fuFR;wS)%_Ie7bM|
z9ms(+QF|9VlY=3zno=*v)WOeZ<{`I>A>CfL>&3edqetk+O#_d|Vm_BUJ@+I>U2RNe
z?!PtzuKq>b|9ZF;i0mKvv^(H`@zn4<_;gVm{2tRO7Qyla
zF&vUPZ9wk~vVA<6xoKHK`yx(36jX8GvG$FI^0A^6FM<~7v*sKo4RssTal|s?@UflL
zfn?FnQA&P)*2@4US%0bAOJ4@r+^pLhvT~Gtp(FA&{80A#C^5$X9Tk;s9AP~Q&3%qk
zgVAkda=Z(ULXMOVT<-gunOe-s>)3d%CR5N*kr#>c+XpAJx2O9r_mbWBVBPb}*A%y%
zXO!NccWXx>AE`dSt8#L&NU821^AknVl%Bq}`^}x_Vzu>e^tp%cI#NKs?i`XWrkKHk
z@7@HRcDa>6`U3qq6^^o4#m5c}bjdR6M`dtA1^;~QcctRC9fCo8o^Ex?Dv4u*3kMo+
z{2MgUse2LxfYF8vBK6*XcdhC5Z{O*GH-7pg;rBi|scGjP88HNTgNIz>z6$%a#D&~FNVr@<0keN{4+&6`j3f7heK)qRMPUjmX}?k;Qub8L725
zo1OAmk24e`TO7kX)uM|68Y$Ukao?4HWWSVrdiWWfN?wD4D~E!#>c}MdJdTIM_&-
zOtvtW@Fxj?#5QLqQ%%=Sq`duo-`?4j6A2$V+gKwvXxi@cc)k4V?9*66*R+#L_xhWI
zcH{jeo9%UZtWJ-JKFykqZN+`Ba^AW*%H5ZTl`2A3$01o9;1*?!nHw?49v~ULg8Epf
zsj{dmt)i~tpoHu2PoJ9|=crQSKkeL+)carL{Ga(oKd^1*ZFW`2fvj$mgixn?{F*<3
zO}L0$sheHI-j%l+w7B9M&iSiRc1bOAC!b8P|oH-3X0lhpyQ_9>wR^nU-Rlb
z*!zBWQs^qk_jULA$K_za-`~$y+rd{)e`DUCG^GYTZu`%AOKu|quqA(XW2;G}hZP1y
zN^y4TABbqwjhrYkDrUjWmN93y<%Aw2f`-edyBh7;kx^X?lVgN7Yji8E0Hz-kdq${Z
z^OIg^J-m)I4)~q41&VnoA^huvrZOUX|DhRagbi5wt{NKzEXD<1OO`Q1{NTq916bs3
zfJ;XF{%A}IlU#@>VshcKlIV|c5cCuIw;)cluvp9wg=~J^b$iqA?yekJ^H<3A$xaNm
zdt>o-hkub2u7w1k%vo9@4r2yNLTFEb~99q{YiCHo_G&SQ7yjJMjiY&@3s?k
z9R{XfxY_OXxr7~H>g~nmH0yep|6$hu`QYFDnUJPyv8dP0Ve{(P_(0q9!@vHR#cN1^
zK#HW(mw=8hMP@3==M}}Q!hTWBhk<(tLuwwM@ER=#y;)=;XtlCw&^RvDfr6SP5
z;>@@%D9Y~}q)?5&L8fTW*<#F}W=gZ)AWN!4kf{+!+cBq%1f*i0u@yoT*ynNaTkOiD
z*Yl{Sz0RNsUNLOyXD>9MyQtUKkMvlGqNrR;a{uKe*UmzobKHtqvGqdWPiua%laYmX
zFhX36ZHD+bPnpQdp>~GwcU%QE-y|};)+xf`Nd|?^}9qaQy`R
zV+)asVHBq)#l)c15)(r(;n?@@@FRJ=fQN36k5j}*sZXxelEXff0
zvD+pq{$e_3kk^kMs<L~RMTXkwI+{knN#P46`hO>>3jH0ZgqXYNff!Xer8d8tB2*<`O
z{}3B0tEL>q@Tvtq$q;82F(wxbNE#+k&`;ghzTqjYIEeT4qEuBps9k)_S>QZQ8e0r`
ztn0;=l1JL@e{cMr;&Un0|JmoNqbcZ&N$TWZiUo4%IH~PDS
z!soK`hr<5*EAhaP%0V#hS$x&Ch1vb(&xi+xq>8+X|u$igK&EtMNs%bfTL
zG6U_Q@IU*rR%g(N5^!8tr!;leeEW|RxS#LyCGG!My2_xqwr+`gaEIUy!QI`12X}V}
z?(R0YYtW#>?=eXxHpn_SV@vYebwY+4V^}pBn^v8Wcxw4~7
ze++`fCYUfq2hsoxJxZs~LdQeHNf7Qf?
zu_>)ydi>r#3m*IW7C;E!ZP(;Iws5lqToH+Isy!QRZoUnq84lI8wC^!`Zgth)
zLfXhiZ)`p#a>;hNgIl~_udQaQy^?UI_79)IqKfJgj@Ya}YKOOYE3U#cC}9q$cgwJV
zvdeV&n2UX4t%nL3kzH@HF1Ej(uH8gSaZLvn_ISX|nXgJ*{{nJG8D}7L3gLeI#8TYj
zF~l+(=_d@s5lw1MP543wPG@lZd5)`~r24w?W?W)^SKOrAAy+JsP50u*^f$J>*#8lJ
z%lmaR5|HoL^tj&z56Iu_nRaq_I@-Ks2>`}gb^${J-!lX}Jw*45M|PhmpH&6J{hr^8
zJw?2p`(*O^L_16AV;`&1oz}X8iq$iLs)Tf5_o-5yEQr!TG1h*`8#G3G1ZpAIold{K
zF!OxJTBlt8@6WqWQ`Qg!(L173=$*w|WN%=`B}3A2q2?0ak>Tz?t3-!GQ#)J2pz
zCj}5E(TwpPnF*#nPhJ`Icz*0`4+aC}ZsTw%8%^
z@wZ^DrrrtUWU%(KmzL)km`AZI`t}T1s@wARdE*w@16(EJ^SUf-mTNf)`=32u%CnEv
zFsI^1p-j~FK!WRbGM@0~N0qscUe`Hzm>79x9=&?o-Fv#gx~lh}xF}B;t{$
z=2+MP3<;|u(oZAeCNp>2l;aq}6eL{@FC8MUm%t8EVZV^Bo=0?H;n(?s&CV82Fd4U2
zryp?evh{Iv<$qOhxwVz@e&6*12sr|XiwJ{9`*nQ7yIQf9xXL2Uk?;
zXs@&#R>dFKAfU6udAk48Y1ulRdxYur^-k*&QPWPs2^rnsMAr5j%9OkO-T4?za+dYX
zJU2z2T>zS`@WX`B$LYfWn#Y51vftpKXP5xs>Qb=N^<|UC@M(C}3-n_2Ay0O5`KH%_
z=Clzg4<$F(fwqY^A`CKix04tv=Th&>P4>C+GK1}O6q+yec7l!}^v{0~3&iIQ@_8+5>}y$O#jqug
z4YSCwQEbiCHN4H;o1G~-fL*~t2xYk$``rI^bXZg*;2`s^8t^)>GhpO>B6Ut`_{w1S
zYR6T#wdU`2#9XQ3wfGOB`rJ>Yc{;wI^}OadoepRYXr>vx9|d+k9jY<$(2jOcVo2N#kWRwypaSsRjoYlxE3$OUTZVt$R`AE?I=H_N}
z%9>NxeMSzC)B82N$n)D--4)!#W@zNK>S`$MRS{`@BOZ&l#nz`yqXC&XI7U**xkSVu
zZgy#5v2;Hh2}hmcs4)&-L@bC$-YJMwf#7|b;}P^BZ1ji*1!3QV>;D8Mg)ve+$Ax>S
zn-MP5Q
zev%@G3!_i5M`3`t02KbmC_{nA{N52THM!B=cDq`-#9g*$=hWl=n0^fF?fW=8>H7m3
zeJm{YZCeQBbu}A#uQc)N+r~JeFriN8xuP)jU2!@>t|OmhqSvVjUUh7SlH%fZ*@S`M
zc|B_kYi5Gtbh7z=EvsPxS>le_wJBq!o&CBDeam|Sa6qc%v@_fFGX{e6KDYc(RPrSJ
z^x>|zJ73zL)kRh3tOP52A)AWbzs_oRBW2XRl#tb>r4o!29|*(%(t#4M*YTZ!M2we@
z?q>jI>Jf{+xZ_qE81_MRS1mafqHp<}UGRLomM%Wlv6DR>?akzvQpkFfjuJV4YF_)bK0R*xXi
zKX4@+zp{EChx!*PkXaVn)&lBEjm@Survz~*nDW!~=xW9Zy4!sl*Iwmxt!>GbZyfHK
z@(%A^3Q&5BvO}bSfT1htf=1=UhP)QbJOuQH5hjMq;!Ey|m&Ul5e+rUStwYmyiB+x5npr-yPb|5M&ofUh7)_w7{LTFceukHxFaG{4Rs
z+ICSSJb@X&HLxe}RHeps$TOZL~Myg?yi_`CAZ**{c_
z2gTAc0A6YoVzz`30F~oo4=?Zyc~k;~z*G{4*@%_DrS
zS8>r=8cFjx(Givh+wJ}^6zLYbJpz4yi0pAZ124PE!Swq^XWMPy`@zTSOV8V}mB>2}
zsFmYr&**Ff3|-ZRtc8NT7Utxy1EhtcG~&#!=cJ`X#;5IP0Q1dLZZ#r?q|Gu8gOpD)
z73$Iqgs8h>JnfU>&C6((1e9?d@%H-xLFDBB#R#&1TBn^Q`B!CW-EjM3AhMAMM-v2&
zt4k%R9QHZNRI)3Sc2!*yt*LPZz(!$1Pv-u4C
z7$2^E+)aygI`6z*1-?`*1wKCi#G?JUekOw140u7p#1!tvl9e@%2@3<%`M<0sUOL@i
zq<~YX={T}!@}(;Io`z7J%O%A}U|lku>GDjm4x)-8DquR)%0{E)Q`uq5gZ^8bmM1R+
zB^<|6-ka&O?ecLHof`hE7O36HXk|M!ROK>wJ&@eg!Ss7&{K)=FPhOhw88Ru0m{-ER
z?AvWkRfoXi_gaymOOe;}!zmda(tx{%_z|sI5&xIP6a}M~o#(}&mb#6=qp26CtpLEi
z!!OzF4M5$x586T0#`@c_(fdWlS^2b7sy-cZ$OmDR(XSu?#y2VPVJR6|HVUeEW+$B;
zH(cRU(^YD=)B>+e6A#ujpORA&A2vpFSB6VJ=J?($_yUS4F=HPFjvr@wUT^|?g@d+u=YGBhV@#6P)z
zL;$e)F)zTg(O{#?5QROidd)_37f2;|wpff`a5gee%Ts1I(2P|zDW<;Zs@>8NKMMoj
zq3WQC4j9sv>rUw_Ni5lFEIkNIRdCdxZ>3iJtxmE7@
zxDPDYF!ViGKiT?t_H=rO)$u;yN4kBU%xUqsJQps^2Wz1U5~-QrEQIBG#iiS%=Z0;j
zZGiMeruYFha9ESZx#UP8XtMcyIG(W1h?fTn47+TXFze)WpnqG_<#42h*eVY-7Rg54
zMWnJb7lrJ|Ll^AHna_?=?=Ji)qbol<8OvJUF-fV3kE96|I}64#<1g=;o!;gzH%ERP
znO!f!e(~O$id=H+3Vd4xKf!)JPibIG8Y$v^#GmjR9nf;=@Ah{20w&y34al4}KCs`s
z{Et$AtD5@V1!ETCFU32|R_xQ+em8WVcw<(KxI)*^E`Bo%vyDA}m5feP!LCzNMFENx
zX*nDRVCdLtFc6n!O!%~AHZbL${kqA0Z@$aJ_^N^#ihK<<8P!ign<&n}jwsf@i}Uc#
zD^zxc`70Fi1Ci2QhsWphU-l4i^(Byy3?E;t`L9pM8>kCFBKR)JJB3z2f%$Kf-WqHV
z=6~BBFRuK|9Q<9L|3q(WbUcDLs@QkOz8+nnQSL-r1dk`@U9UYAM2^+q2ApAQR
zBouJUQLUPn){Sas)+|Rv)yG$1(}1C~PuZoFS`|J6&5-v38~UFWBQKP?HmmO<^B`^6
zju}xO>9afOF}AP7sG@TJ`A%{z{$k}34@FLgg|=XU@<%0d?flfbv>{0CXwDmk+
z@Nv_;WVn)<5O8~D)brl4wT;#!AD}uN_-I$x`F6y!>3z$x^)%(_xV6&O2zu)}gUJ(d_HR#mAu0>>xVNeTrVV&~kik``0U%+#qC=UGX<-Rl#yOu`Zi
z6gom>nPb&SEuCE>bR){1kAp8+8$zN_CzArChF!qR93B!UN26A^6CymLxA*%zG#JvW
zKsR5sqvwH~N8wKQ53{iS_&l^LVbGv+E)4j_-GK;HqY5C1b(Ij29(v^Pz7%SDGL=IS
zxZ=sN`Su6K4(>K?#O0~U26BXnoiFoswOX^W_On_;eJ944(2+VaJ|wnEk}(u#5Do%@
z5fyQ1Ojv#)Jo#|;q)X!_;oYEhWE!U5;4qP0!+h(j3%DWbOh@?eqSKNHAUT~6FyC?l
zwLXgav0~kwuXOmoJWK~X%sct*5w$K4iYm_Hsa*p%ay+kEsdw}TBv0n_(g@Z1{8aeFa7vVx}3iN+4&g#c&Zm>4L|0<7O8q|nn7U`R^?u$LwhZ8Pa@KWpS
z#>yX56k))anA{5FT>|v`M}XPK%h`T%N>jZ}HOaFLe`kT?6-pG|&A`XgnvMgXzNXfq
zm`K32D#kSF6I*ID(O&r(W%nyH>e8sLbxp|6N8nWSN;#i;JY*sBNks1E6V
z68E&X_CAv)jPoo-vSuO>A24R8S?}Y0yfFgXKc-Oq1_NFL-`|v-47_h^Ji(AN;C-0%
z<8GJ;d`w9VMLN2kY9=xw@(v3OKQ@+({GW2RUbDUATsY
za}|>%u$jMT-U%SST4=CRe(($NjPI#cQzvnaacJF=b7FbgT8PPoQP<4fyeNMfx_O+@jp$asT^xol>}_?E|<0
zUvMe->=t={Y1MMs`8d*}uNPf2*l4r<5S3gYp`xa?Dj31#j9s95w9sT?=?4CH+qS4h
zSZdjME5z*|{=hQeNm}~0#1U&ztpA|<1$C_5Q1aVCh*xY^Zot&L(2YN{XljtCoS59=
zHnbxq<%UBmq7MYRBax|xC
zlt1Pv*skAQ
z!v8oJ-poW*K{*t|?S2H5Ei9Zibhj{U#rm2wbMZ&P%vN;7fzM>&Uixt{NsdYB%L-$4L}GV#_7-zMy8aJ5uC
zDY0s0;7<>KN&7Uy(P=7JE`|Ngb0S7Z*2Yj#@!)w#Yk66op(i=rPlM9t6K_L8324Z+
zYiGE)yubtubvhnZ{Mfx7Ng}RZ`>r-ypD(W7&j0~8XDv>GVhkapIRd2X8!!70U4Y9(
zOT7GmMAdi|3haq83IeWbYs~QE2%~LEbL_L+YEwU9K<0n8vL|bNW;>I|2t~
zxt5>VRHy#)A15$>%-~68Fv07nF(eci@Zs~hfIrg)Vh}n!4vK-;~!liT6R1-dfkj8v+>!Es)T&g#OJ)Hmm)v6yB5iwNh?
zZrqXIiMJ^tT+BYR&yEc%Vl=7#&z5RH8>UxnKMRVK;d|d3J{W!Af0X?+zd|ZKbcYz-_
z;11?D(mF$lwe!tYoHtUZE1~|HO>dB+lVG#{*Y4k_n*%W1FTLuSm)4`wCLWt^@wNj!
zZcqECtvp!|Ey}e{d4^|bL~p9T4KXoH$yV>nujCW)bJh-{gnbClstLO*{jJL1UWKme
z$YJ9|MRyo6h9M}*|LAj6OX-
z%6>dEvY4>E4Ja7(B}8bp7qfxAw43ezcpWtPUpB>L`^Pw-$ahBPz@5iCb_Fv-W=!TIqtay8~1Zj4I6mC6>Pw4I)rrErh3baa%V!70@;
zqc0b}NcS8`%jHR5I);W+|HL7KvO@P2B`RkaPg4r-(wsjxs(k*brFK04w4dS&5b1h^
zkqijQ4FhJW&Z~9{`h9wym>KR`^6og&*q#9euWJL5S6i$8AH!3{db{^${^t*QzF^}J=JE=d-hMA$LnGPh`mnwloA)U%
zUC}Kz2nJNHhBP;M7Tk0-xejefL8#*JZGuuivDe+XT@g3{nQ9UX$y#9e=W8HiWcPF0
zzz68V_hbmHuYnHt42k@m_`L^jKb{YKfZN^|3$}c2CwW+Md#(qrKIS`%K~tA+jYljI
zyTD?`U7%+M?WnmLS4IM_8MpUb{HQVG(`{>B03yr2k11V`!oJu0^BeHHl>IpZ%7MT$o}S0h
z0{>fq5AJg(`|7;6%a)J(;R~=p8#^!9<1(<-^lt1dyrC5MngZS28rs0@INY?2spj8H~T(7p3xTVU(S5S{E0co`})BwwoX1uirP
zk!yuI`Y5^95s%4w`6NBE`1v7vc2(Nx
zWw2?(K_y_4?J&J%NM9F!oX*ZRrr1!!InZ?#;G*$9lH_eWA_MNWeP>h
zvc2z3g>Lu)uIrqHyk4J)0@;}6UA|5J(XMqYTpsGMVG|z81&n$X?K`j;quFgAr{_*$
zrTo3W96oinv(t4-^PR8VV#=gms?y3a02+30)^PcXV@!}JtW!l+70<5Xv*gGZ{tBFa
z>GRBU4
znCvWT;U>URs>2lElL$Zm9fZ_4-s?i2p^^i;tvR(&gS_2+JJ)y=?nm>{_vME!63r7+>qmRC8HyKG!H7RA5J{=+{2V?y~+BLA$
zS!1?(gZ64G@Nq9vStQ^!AD`f{W9tKW;#voO=tZ7)00HkuEmAy%@XEp|q(*zuSLaWL
zlqdb=Y&GVn#NiU1h9{`$DYueXSo7(r4#{@(QlJ-#hJr+F-^-y`-wBt2RaG&-|8h?1
z#2T7rvDey>7|Mq#pEp{P)?`7y2&E^+Pzph`@DMLgeC&w!`MBOI_6r6gaZ(~w!Xt@r
zz};p`_gj|@>xOaBxaw~`%&k9y6EZ!!FBWXp=y-%mwE9u6STxY)(BF7BmPKFZeyo|g
zY4!PlWQRvZPTJr{Thw?rQe$_~C4hDpmR)Q4_O;3_JpU}Boe(fdk;js)GdU=U@snai
z%JX$NNg6eV$c4uG-5kd{`DSVQ9lN19mn9;^p3|Lv!*o++A6qTc81(V@8)HO{hOUk2
zIXw2Tja`0$3(wOZ&wL>mrJqQxDt#YMn$JAXCL0V``51oXo|u0&YBretX}gt%3+*fq
zop6&EcaYU3=KHcgeE5*PL>Kp)_TD7rJdLmvoQ$(t`3sK-rDHMy-x^vxt2C=Y!r&
zsa)J_PKLs>{M}73GBW1)4y-eLYeRi>a9J#LCyqRC}$z+?zHoH~&4U|%jaNRFXgaJR3IZ!qp
zjVW3PF6mww7R1SAF0u~gS&6h3@6+c_nhszJjC1&|__lnS!7EzyaNguNQHdgONzyMf
zuFR$&*(ZBcTM2?+2uQ)P3(;!TCUh)q(PKa1S?hEwf9JToi$_mo!H&4Nn4bi`KeE(r
zc6x&i?>Q|_Z>Kyx`L%U$+4T^_Y*0hGvy9*zkzUd!_t?fwK{XD{2w4P)8G!CElPR0|FSWm6bEZ8
z9g1UOnNw4@5=UvjU+Z~9RyPxs>b9-e)#d54a81;RRYi|%&?$3|Xdc{-{e*6G9_uj<
zx9xN0tRi!Kh`_&E`GwrBHOpkgxTIix_4od-OSAsZzeoqGWAjH}rdh)qnZ80NwHIgR
zd+~gkyhhoWFRhRMjdP=^_%<)>ZrQO?i*p)o+o5*0_-sn|DX^8lHz%EAu8IGC)@`QX
zj*8-YeQ7RLFtJal!N1^47eNd?dD`M9Vje&6_VwDo=oE<*t4=3O2u}+;YTIQubkBbx
zU$nXpeH~I1RKxP6rn9N@=I;>oIcdhAsPIjPeGvtK#Qy|TFENtP?RGb+g+^-Y=_B&I
zL`q3yAw#-?cT-ttB0A0
zW96hu-~bB(Q(?*aFI6alU6^=sK)?4>Fu&9GmZzg~jUkNQX|_p1{)E&O&;>hq!G_q%
zj^x?>RuoXa+@ySk>`(|gz?AbN`S4qDrDGan`_V{4gkgnE0J+sF2HRu$ZwkW+zgcl-
zj$a2Q4fx8;k`(Lq=@JvM8ggE$s?G9^FH`Y(v{!+@UpB1-t^z&&xug&F^{)aSKzq}M
z9}_s(XD;SXpc~a~x~Eq3SeEiR#*+^o(xiBu2{{5winCjk
zI5mt9N)vqgiE-X37n&57m@F&FI4=;LF!O@KG~dS`Yj=l+?qC5}dRA>{`fakf%%1&l
zfo&AG5I~T??gT#thCa-)6qN}Su~IAkAMf~`Dox$^KZl5fjYj+yd4m2ai?v
zDH=(A2@kTq$P_yaYlM6kxC9D_j_=nyypakSI_*!%c2p@ePYCNvzquiHz5JnwRa4Js
zxeebA?YinS&vUBOMK57;BhSAx#QhK(`;TzfSaV;Xu+vxQv>Bz7!5FDIJkQnj2&?{G
zdGlmezUAy!yirxa+sH?}SC4l8gWl*`fx};quy7DT8x~&9{)tzzOy?I{)v>Y1Sd#)S
z&9Djmis7saQiOpEk8;898182b*C?jl{4CAc{_b9x0UpUtCsUz|s9x1y~O$J=?<>|8*>tz}dH9b)&q|E5@Cz@M|fPd=VIC=UX46?Ed6g@7S*bHPv
z2jBUC&8i8!CFc}zx-gmypZOT&W$8pqM2d@qM
z+Z-`bH*0SuRKoc!AP<>uDjpcjV>K+?byXjlyRlU7oBYtd<|rdoIzVpr5&uJDAEVRG
z&L0BK+F^W?!ioMe(x?!0TelWX;TdO2}F%)Bfr{>#ikf``w+zkSEE5NBVe2b-{DnXeSuHFh&>bl5`Un>gnkG
zZ~%nC&F2(a89_KY5m<2PievXpyw-G=pP|P_RSQvSY!{V)_XEm7n)yDJonDUQ)W1H~
zqQ##rG8>jXT$!k68`4e`+Q_p(G)_@#i`i^-apmbgL$*D*AQxPwlc3@bTSN_;re^eg=_=>|Z}@6j2eRM9w#>|vn57Onlx1sY+j&3A*4I9QN4}q2YQ?G#Z$Gf
z-^QVkR{j$Fj;MNj*YGPgkS2Uooi}<#xee^WKQNtg{ZZ*6h#UO*_4ug<8ZQWe3wupJ
zPG*2$mM76j1Q9)%3=uqq_ASa&Bx!uhK9gs6=fpOQ8b+-nqk@j~e5%XGBr)U-F#jHW
zUtc;@jEpRkKGDu3*onUC73@S)pZjd{
zQjE9@IOYNQ2QR_)+<*XKX>3M^XZnG$RY%sb=JavB2)zY;9=mLBc+*wY!Bit`qzUJ}
ztj-;;q^6L-&(nIQyaiz~ViL1GGIt3mP-0#LAB1mopjH<@dN;q5Wnk%m44}u&9yr5h
z>v;m|pR4y`|J~~6_ubp%`^oWl4DUP8Zc=e<2p}?Jhw}M5#v1}@1{OUC;YM5s*bAKS
z8`NxAFf_b;2|HT0r>jljbk9YzCAyyk$N&Y09_JIFam}(LV!tZtV__z%
z(_gv@2c9QLPm;{ZR7iP|`$j0Bfdd~YmV@^Y*(2tG=4PLOvQQ|($q?1(WI~9AI49%^
zZK`Jpk>VWU(xNm^bQmjOA#T38%-RW{p|vTO+I;A-R}(Cxe4<3NLFwO&eb9W$=*Rqa%-W&-4BQKY}~Aa
zgT282$n@u`H|ZWo`jXJL-(4|`pRj0&)XUG;sFfdU7Jmt3CO8j(Gb6BZm5!|)WS@a0
zo;M4_tItvEyi!|CPtq#|W~$k4Yf@-Gw?nC(Ozj?g>;miV5}^N#)yKiyoX@R4q(tA6
z2}akSv#+|QL&QB>lC2mQYIsW`aL&yIXO9T)T8l%pJ#H{>pbu!`y)Z5ME1fejOsN>fFvdphyg%MeRSvS6}4pL-^7xpuo(AfoDyHEgP
zlH9yBD`9?Qu`zCNp^+mJOInZceY&f?oHW#e`S@?wZc^3THgQNifioo2aUdyQ&NuI=
zI&RvWoFShskvwr2ukT>EhY!!Ll7J4+g9U-HMTAzKQ+3Q@9TWy5ar3#QgvyTCFq*-f
zCgEtpCo6w-vomX@+0<88oEkuc{1*$E0Tu(3VR|Fb
zUl&5#ZrePt(nUW`dC&Uqc4SLi{NfLx2e%Rln+g$n!Vh?~EG@5YRxE^@Ii_{-5fre^
z&~!^6Jtw{6ke14U9ST!od?R2(2=?$Hho2i`t@>}q`~E}Rz|G6&Mdt?YW#KkRV&&Y`
zFu>m5V7CJLJSu_U6Pg1;HFH1PLVD;8)um5|^sWliTRJQbgkJN)=fD4(@bp=U9O-Fb;Am{h1OyA6|QN(v;kc{8Q#
zws>$LGOVLVAyufmiFy8kyGlzbxnmdUQT
zuf|(NJ9zhmN)mYrLY%}PMYhEGd%NfT<;dq(gNnm(LY)sRo1n5G;P9?g(t|q9>}`qi
z89`6h9C!DpnQA4!8!z_Z`*-sb{B!7pxx$?!GZr}}%-+KNqP<7}6Uh)dU|pj%{>$)>
z*ys|!_txaGQPiEx*I^G-nZ^3f+KzmD{f+OPx(2t%_l7NMb*hoC#ua)2;=7a!+un|I
z=pty1`Zw9}&dl(Ps!8Ciqsppx*MQ^Z_AY~~U9N{UIS5wRg~@J;dn=V~
zdex7GV2{B(=vG0WBA`XNK+yYgVMXDHTiJnJFsUF2IS>9`R$`ccfVmXEHevWoy#)Bv
z)rv>2%UF`%Yp^8
z2SZvocg^HkG8KPlvlNq_Z5&<2g?NR1U4Mndg4DqI0r4pu7a>;ec~5pU*DPXgOszwz
zGd10sa}WWI*fWZvzOC>mt+7&F@sxke?>&2B+1h0)Mfy>qEZTtz
zahC+8!5W$t1k%M4^7_=28+t0+(Vv?Cj5^fCFO>#=Rt(j!Ty09-2DR9nya_hGox3Qy
zhc&sq$x5pd^OO<cg(Txn(qgrwcP>nJGoho`rQYwYzcsI70H>lT$w=!E
zT+5KWQNc3R;Un$b$wHQzJVS2FRXIeWNMyU2)8KS$x%6iu4<{FRUl*bQy
zZw*2)k)(c3qEInR2#E{wZS7t?cMqa0-$nhe5HNhj_cR7SYk>aAu`LQqNS`QLi&G3u
zY|*-Er$hwbeTkc9(xiN$_5`+r&$@Z-V6p~yc<9x+D)im*qJN^?XCT4|n|EO8_Ym*-
zOcOE6pvYeF`8W*mP~#{>>qiQog_WbLwY(V?beVCNHe+s=^UdEnqgBCrBx)TkqM`Q+
zpjE*2hYKVAGOp5K>`wU(};#EZ3f=ihsAo2;A*O=GY@
zQ~pbdd!8;5iDYHWLHK+OuAfnbb}gn`a2Oz~GwCnbooJ^?UK=HosLfk5`DSMm%ey3Z
z;3eqINhm@bO=2KNVi-fBtLtrJ0=x#A$>2ISLLRIqCXJwe76<@=`eTu0jCA<}yexpu
z)=w&#BJy|E#CiF;a+c1gLxs>Um}>nP3f86+tZag=eE?4kCNdlsXhLvIHRA45xD|cf`jAJ0fZ*-yaRS{qN5TN
zkTYOv$(TCgOrEfUymiqr7$=bmK*1z7Ohc~|$_BD3KadnBZ4T&MoI
zMDR%^dyb&aT^A-uE0Djo3HW1(b}sj0mocM{!o-{f-UT}Ym6Kk#ydK
z$7-9Do?zbzI;9?D$yTj2W1rr^FD(nIafD|d_vHHjFtn7(Z}_u>ZXJ8U26w&G%l+!o
z5@RE-X_f@$g+tE+Q(pY&{-*rRf3fT~ZHc+5ZSAt-
zP8Af(Nle4A!4SO6;?B37$laEH_L}WIz1eqQ$W%(w^jnj3EnlvtS1$X
zd0CLzwuM3;Zwnvk3L_S{o0Mmek{f`>Qg-XT;T}5)w^A%=j&E9~!IeIyJw(ALBPhQ`
zK-uDguQeWJM(2oTTRUS*b6a_?`0jZhxL`0@Rl-S|&6S*8?vrmSKrk`JXGj6Sr!7ll
z%WE>BZLqChG_P5yRS4)*W6Cp9qSKjI-oJ2$6Al@ghQEhQh#mWr3y={XlbD#zNY^sd
z*XD0>e!c#2%<2qURz*=EL3%F0bVU$m{sLYWVB+c~`3d5dSE^5#a)Up;~}
z$GVrBnWhZ9J_Mv8t2j!lC_hSKpRgN2$4oNoF}R$U48g>dm5%0n1SH-Z<)AEJGmHsS
z`^JGCqF?m1(QnW^(+hHhjBGDl^OND>LWe^Ur`{)^w16npaGnIiSN2}=TPzpstc+1R
zH(fgYeR6Y2TDWNf9;G}HFewp!!9jc7EH}JUk_yfiX-8D))#?GdPf4)J1#SM1J|(g6
zUB3A06CY5#SaV+n7U=W_=b(gM%W1Wg)dVzdR%@J5qpw{4CC3mXRPrhQi;
zSgOg8{^r>8NiO_KA1;9;!u1RI{JRPxNlv|;vGif2m=8t=qyu26h})p?Dg)Y7DV&Tk
zCZk+nW@JZwsswe2?Cq7s%!>_9;$euZzK};o+HJ(A*hM)zLSW}MXMQcxLSy9@vr*Fq
z>bqY&jf{jNM+w91x$wghP*!5jYpj3MfbN$^k_*EjhNP(YBB&w?y?R}fXr{LE9quF<
zOZsP@OfVlhE*_@Kl#ER>0LlS!BcFONE;INszW%8i_Rq#+YbdMMkqb8YyP8GpHN
zaXYdoqqqaq+M2vse+W&{krF7t;p5NXiOX#6aE#kxC!LJ=LXjo}!Q)9!K8jtn|R&3a-)
zY)c#^j-~!ZIlEl1aysgAe(i$bYxDi73OROJL3YSLCDbJb@)$P*?Mq$axongO{A0~A
z5azvk27sUX3Pn1ky;X)aVcX7fcm!k|g=Kq#>wzSMjcP&`zT_B%PO_QjM1lq3YjUPi
z_K>2;w@;SsQx>Ao#~9S5c>R0+sK^ST<0w%+LlC2jF^EfZ4=Dh)CsOJHU-ahV-5>hJ
zDh5@nj}j>$8d)J2N=qg2?Naj;dsmjj(%7lXE#A)MqWTV%9=ABdE(EC|XQYFg{fZV&
z-FqpN$Q55#TY3U+*6BsPALiP|hMR7bgnyY2-soxvEIXXvOrB!mekI1_$oF(Gc;)$$rv#mc$<#Xo`T0e}g@u2H%&tGK7sZkP
z#LELY(&{xe8vNlY+}{DNe_V^3
z0-cySRf_Axy*9s%<#&jFe$B@@Car~e=F1D>on&s-!nBuS9ZLct^Zw<2$0@s8(E(kBkzDZh-Ff9Z%f*rE*
z`gH<=h>361l`shL|OKaRC<$S$LT)*=i&o%W}Ol54)V4;){#1lle1RWru2~xRDf+
z3=$>X8b@zdT&F745WBVOjw22Ix=Xwq>N?%(N8McvTS_nMU;Nr4_1xfkOlG-h%X&?+
z7Gkb{8p`!kV6-;4Dw6eRv9j<&n}J!Iz|WnQt5~aU%*w;QpXO;9gB&q}6@3gqS;~OC
zla@&_c&NtEmaD{EhKcC`Nea1z_vy=1^=COrwmAjpnan{7Y3+WD&{gDF1jl9&ranq%
z`k1vXFM$zizHYKa1MOxD+-xSFSJEDn#~CTVLjqDtJ6;bmcQD^{q5X+
zUk0=0gW$A{t>su@+7^}U$E*S`Oh{LTnD?npQQ&diBPI}tPy6(tsfG`Oplz#ze^Oy6
z!X(IYPbsoXt{+8*Lbnm;u%bTEFR?1*TixD`>Gn$2Caf_B%lbsy$9a)Ok;Y^F9{>+Q
z@V;GX3Y98Pj$kBX^2sBjQogw+^INC4U;f(VjgwoX;Z8tiYMs_(bG_N`4uc7@i3H!X
z3ff-;AE6R(?2LNA(XSRMJQqNe0!jiPl50>Mz!6H4lJxMDONu^*gVx%{q}8c*aL@;>
z)wRLaiP7qMcYU*e^33|>*UpVsalJk9c}$tRqA4LL-Re31WaP|Bw(R&l-|G}Dm%}S?
z)*TM(-~RUH%a>1`IkUdKJ=)mlk4BA+&B^N85Izpa-NCqnay)kt4Ld{z!n;C6jQ?0^
zmhqjNz4~->Jec3B;Z&;WBP8fUS$oQge8NQ(WwOI4-hGUcq|^D
z2QX;(EE%z*385Tkhz#C_&!y$F#>toBaeQao;oxy$Hmm1pB&AlvC>7m$Eo~ZzN5BU?
zg^R80AQJqMTU=?%6-p&Si5P0gDHZUtf-I?0~s0HjVh|;mr;nSTOwuN^AW$%l%m;1)AcOBhy$L;TbxI6yp?ozDS^;a
zST80r3yG9`1S$C_4HbzuME-D)+S%SCgF?%IZH+P;Ubjb?Ltv7DzJh%T}GV7#pDsGe^Wii&CCU+27%d=F!C
zxNc-DhdTj9mfzCki(;0ASsfj40gk=Nq||5*rW5I70vG52eW2TTV{NcH0U!MUj?y*8
zW8FS;0u*eX+Pd`G%U}P_H$Vi(f|VKRS`ENj4!Sx@gmIJ%kO1(3Kh95pqwsABpj$7#
za+yu3Jvor`0LS%{+uLVPlLv$zYLs1IT0%`K(9`G738V&dzyPJSt#!^uR-q)sB&(=M
zXfDMgxy9oqFkYXmZ;NjVxgzPilTmj(1d;Ww@V+m-`U>&03ff=9_l4cbpgruuCfEmk
zIVo7=+8AL-%z2B!E^5TDSBkBAwbynk#Y(O06A)Q|GX<9x4M!l!mhRj)H>o;@{r`QqmKYHNM9
zGak3s*82T^ZMr&ukAq=*b8A`3mKxG*qNh7L&{fbs3AMa^m@;@LO$rC64CIrt{+CYtBH44DljP
z43BCT#l-efhq5c@yAf3Z>$3_v_!7gu=zvS3*V{OCiXWAP
z7i0lgP!e{47{GMu!nxM4U#g4g3_+40S4S8?K(7G=3^tuSdj@Qsxo}>1IM-({or8>sM{tRl8>|N32ad(3kQldtMz6DaViP!?IC~m00&5C8tDybm
z1)zXy*`JD!MuG{iafEHZ=1;e$xZCw^6PBSXp)XhEG9*TDL7&mu$gLHfs^}BmSw*V0
zw1QS@mtYP4>6r_s&YefTi$2@9+v{5sWL>pU1YSP8E4dzCM#YgP-@0IemHVGv7t0Q+
z6Q8M4FTh;+tt|1Mmm0nL>bdpJ>DlwA>MaC|UB}H6RP>YRjy}#Ob8wIE46AeA(;3Oe|bbArc?
zhMUOQd8d+8ot#xl88*B?JVum!-Yo#oNG7+EOoLIwuO?JGlvT}AMfbQ9mm|qcB$>?_
zR;5-8B~&zB#?(`J@m;LWWWvhL)pPT=!13xNeDoA$0mXcuNj_7mt1fykacVl24w7&P-D#@$h1fg?8q%6R(R+0p8h014!igjogcFE4;IA)|VYT0o6Tt1{jk
z*Sa;UBu1AI9~1@?pO)%nG7+fDCZcS(I)Em%PHnI@9C3KJQ#N#~
z)O=Y!t<-o8a~IGbTK7Ty3hV5LtAF;~o%%iM?T`*KZ9+-NB?goc6X(QU{ZEw=o!X
zH@8=Dx@*nSVARH;Mj_&Bi$kWp$=0OQD)%SdYO6d%icUlyavXEg%&O<$OUALVm24V5
z;t1nbL(HV9gGiu>TP;3{2EH(|#M^3_SG_qAGa|ZGsQSe*ixYa7YLA?&#!RV}l4!&eeI}HsrH=eWO
zIg?9fOdm2r2UH~Moa=|u*|cfL)x72xQ<{@=%1OhHWOH_@=#^`DuppB5uR9bcm_xN(
zz)4?8=A%j;sDU=@XcR0afa8%!;tPD7hgpBF90SP-STT79(T~TlaDK&u6wSz(p6>YN
zW(_f}S)Oh?x@|cHhYF{Ps3^N!vdiLA88NF&R>S@0z^rYd8Pm3nJjB1Y>vh(8xq?{c
zmJp1FsSp5^Tx(WG2VBlwzT6(ta@WD)V09Ha+3fdO*E*fnU;sXV1t^rrICbtUumewU
z1h@bcv>s|}GnfyHHEAp
z*$A-fudF4gT5mUyiX1D?fGdq?d-a>Iz5KPykP$#}PR=HC$WfdeWRnLZC+CETaFg?s
zXZfZcl2S(E&t1AG%Q&l`{pAJu?OlVK8Mm=YTTH0m8nzn!#$N|W;E>~45#aZM!VkXG@I?lcvX0;XiS_|x8$L~yTh(ius2T#NC`1mD?&8%W2xc?
zLuR_HB^jkF9Sn*oo;j9lK2T#_ZI&h*BP1T&L<|DKZokEWwMKb$eZ0Chu6JwYT48H@
zZEbxt7&ceedehZzeqsVzgapJ8nPa(@pkV++)(Atn=A7VI%0>jN
z{04@cAbH$cl?+5_y1`_#%dr^h4=%$v8j@Ej0Y{oTc?iBHD4-%^nGAbDWGXMls*t51
z^OOiFlvLFq+c@mc`KFa6P>xnKW5pFQcWc%Rx_sxv=O~CZqg>4xc0$#clWC(+QY_SE
zVJVKnD*KI=Q!0hys_qmG*Q<7$%gIcf(-n$twY;3jt|anF-Gnl-7tZl`2JwiSd^C!L
zj7cU!zMPI$F$nUYiS)Zc4>6>XLXrfm
zff3qJiax@C@|ACXz0|1Tw%0l>q@Q0YAhu?%chKX9^jrn5$(a(!fZWTqga#Z7O}2G<
z^Wv))zx#vlz4ooIoqPE_l!Qot5_Aq%X~q3k9}bEP%bbum!sL9sCi*i$M!?M_$T^Yh
z;vPUT*~EY*MVM94{_;Yz*Bq`6dy{r=+G-8!gY|B2((R1e^gvW2C%V)WfV8>9ZHT`arf
zN#Am`cBc-TMw8z9=484ybPCq$<^=qe>xKTPHJo%#p5DN}Zni5Z&}yU53qFH6e;Ktu
z!f{35`w_ss+V{@{xHJYyW+T9Atrt70lzg4VyZrQ1}E8~sP#)-9B
ztI`>?#;b$r+F(5Gb$Z-w(8UeTIo%v@oLuM6fcTwN&%qaf7*a9`LxYmbnG{$ov|H!}
z+5qclF6b4gWJ@jDY61@wFwspm|b0JYK
zp38tgU&fIcXRe4zkJZtWncFC#|W;oRZZwU5w`IW^`RSzTWh6qM!VC}T`!flQmPG4@z4`_Ye{@alUYuS
z3A{k$k%-WVFi}35lza?6(~cdFCx|%~OR#Gpo(iS&5k(U($Fm%pL(=AbB%!YP1rTZZ
z_%}7Kp2?eAu(rB!>J%z+y0wL`jlPDM;IiInPd3&oO~l${
zZF>vNg#-g$AO_;V7t|IpV03M3W9#(Ea-&vhicX0A@vu}EP=kr=MZS?9{9%P^Sqx$p
z^!hH=${VM)nmsWpEu5NetRXfLdK`j&Jah5I9pBl55c_kuSk?)8+B{
z^z5bc+hH{%&QcX;cbz%+cBi2Uvzs*j!-tLyW{c5LM?hor{
z&uwjPjZdChyKsK%;>8oEPpximjnALo-rOAVH^PseOuN;Z$9feMPC5imonAk2a&`N}
zwAn7MZQ(~x5wN(@`0Pl<_01`3Im30U-#{?d+Lg_d>%@0@$lDs2o~#YJgJ!p19}FAA
zQFAnIt#6Hyx6l?k%Z@&*XVr7?1^I?&4H@yK38NX0MkC==O7}cCl?w*P6_4i>@r6mT
z)dX99qn=PjA8aY&%u+G$xeMViE-h>Ve`qngQbwH}kA|?MmOB;+!AFFrRDbMZQ=S3H
zBHXY<&_g?fE1gJSoDJa_%cKx};-y8YfTv@4PCT1bEsb>`PIdYI8b_Yrv0E-8RKaw{
zFk*^AwmB_OPHA})fs@U0PA^QkI=_UCndsQh}Q#
zN-#p^EekA4&6ssvESk@2r4sQu-(SjPR&sddD!EOXVyF(qEv2pJ>>rM!uy*=Xb2Rj-
zmC5Gj)|oSS*}cgGKH_4tMo98^48GBBkJeWwn_^CVXocp&U<#DMMV0SrWS7HcFsp&|
zZ~-F30aAqL3XwHoUJxA
zVL7VaZbC+>BBjGFz_-47`ofu0=TDPElF7#f#6MdQHpPpYU~n@jFlQCCzliw@i}kWo
z6d$F)1+dtk^ze>xx2pm_}hTw92V>}pDPo05io%PM$WVLH^y=p3
zfOu>?ZLK4Rr>)VXxw_tE%^}mZ&T!ON+Z=ZK;;r;#b%@7}!(J?V_}%4dft;+LSVa%k
zJJkX33|#WbbhxoSMe4#w)`9lq{@5R^4r<+6u~F1STFaF%dLlHj8QlSg5?LZ6y(6reRhJ
z#ZH3;7RjY$SMZ~eFiM0&GGuc?p`6yhxBOvvFD
z>owLGd+~x-;&IY1$7t+2Fva`h>YR-;YXx8Q;|aQL0^E$IS%rdIuaR@g0@KMbc$GQl
zir^B0Q*cUWRi3|pcwDovq~XL=BdH;~5Z%baYRYt1GHTiquX?pYDQ((W+g%ABM5o%1I?sqMRG=5
zd(K`{z4f(1tBI|jJP8L;j+>`XpSo}XIfi!-R!_)4c`5=j1E7tw5he!Gu}1fG20i&i5=Ik=%S_6xQzzuRYyqoI8@!T|02gJ=
zd02B%#3Rl%k*DHN(cl$>mgyW>`8)Mz62hV?#@aM-}=
zWOdL1)!mWkFo?T7UKbjM%4>qWm&_UfflyVe$6
zNyW>V^%Gz02KB#R6pvWD@cH`$@+LSf^bXZ
z^EllpRn6PB=(_0IR>9MQdE5bF@U}-0j4M|FhvvBC3IQ0rs!qel|37>G`D|IT9rl6!
zm(Bq1byr<;>^^6E@6GZ4`dhx*yayvniW!O{MJPr=4k=0?IEJDC5CjSD_yKtMNc}R`
zts+KfDWV&p(w91skvDhd%9Up4UHQvxa^sKnn{6MjX#%HIFRCgmAa)R8*cLogS02?{
z&N+E04hu`oFUMonm7(6vFsS|>_ph@CR2=!~G%i?KUyR+bn458RZu(YQVDkEgvfNE`^;sD8rI#vdnn{8kSIimGmzsFi(GmrcTee|W>O
zS@_!|Hnm@*aaXCua+7{Mws})ufgD8(Z5+(*KiLErVY!t;z1C$li
zwTZ&49(q6W`JOdk@aFaD#bbp9J02lN_z^=1OWwYGiItpfHY~d7kmY{6yFOvgFjBHI
z#bM5XM{Ljry6UR+VS|aheQ^i$VMbUi|NPf~4IIPzVEeE>_~gX~Vb?I4Xu}=v)uz1a
z@Pi{2*DRkNK4;ZT5y)V|w#VaarOX+2jU~D0R1X#1T)%n$p7r>v_pd=n^-Q>acaXAJ
z@>4yC^40rS=)v}p>+LsRoBQ={jsS~s@Dm7Kt-IB3j+?KW
z)po%Q-OMWj*t<9HUcP?&a+Wajy)N`hG?OnC9Jtf8$BdaXziyI93;Rd}c
z%;IdnT3ziHSF77sx0uwm-eY`w+RWBJet%qfV2y=RGVd^p@Z*=G!N7AMM{H%%HrOv5
zW(BjzvXuWKj1CJibw%H{SirKB=D&+nOea>4g)O#5p0;70$NIo-*gNc6tUnA35;7Gt
z$v3No6_X3gi@8+p`KZrg92k_FDg%2ubWD6Z3EeElsc^~?SVcNXgvo;+wd<2>WKGAm
zGN8q5mejSfeYTAy4T}O6R!}@1O&ka6BnfLy-KZpHkqT2)sUbFqR7~en2mSD$5tMx^
zxtNC2sAi#!xx`%<77OZu<@$Q_9#*)3m7A(dewauOduA~4)pkC1R$WY)SHdVS;->AJ
zp0coI9Te5b@xqcbVqJ_TCXFakSM8}2L5^RJ#%AQ3Suyqkbh50b6jyDeRy`ZrrWe^^
z9At@?Ca@vq)rt~M3e!fI7dE(;s|VEU`JA)Kav`60hVP<~^PV)F5e4ug@o`;a{=i07
z(D*E_38+28nH}|)6&Op5C@oN6A1__+%(RJQUC;X3$$uo3r|m53=KH$`m=WVxFMy;Y
zmQh%e_4Un*7q7nldUZHpAIlm4+AAyw@CdJAP%u&ius9f_H($Sh$?{x(=vBVfpw_c5
z@A1Jmu$gv{`vKLW5CVg!&}?9|2+
z5GCRDK|Ozsd;hcdXnXNi;UR2@P263pEJAq8?Us6C2eGPh@8#XM-zro7fkOdFtSYTQ
z49iGczW&+IUcdkPaDBs?_o;(E{Jy|AVi8XF*K;bjnqejNc0OykGOu%So5LCwJKnHd
zKdKut>$Y1|vR@AV&HWLpMCwd$22pnf)@`|&J(n^Lr|bRI
zt=j#U3FGgxzGmiUwr7b1NWzR_C4nzlZUa+B;DeB?eB~_~R>$(R2WxEtaN@JkkO1Zq
zNmi!np0ekukE|L71_(2Rj>|H-ihks13&;P_=$Z5G{rovM$R
z&*amR)5sfn*2uF*zH$S{BqpeHav352y@5Ogr>V+kxs6F>8H%wZh9v&^F@+S`H>c|M
zLKI>mG0+G=VbqX{@ehV+5L_jRn53$xHZo5g^uvGCxST`^VvxsI%`+Q^|-<#T&`r=>$$(nu)Y0~HPj}@mq%eLaAU9D(rpq{v_
zAZR9%Zna{n<2<@~hC!sCFU{%D^@ag+n%Wa{sNaOa6w0n;7(~Vog9rQgd@^Amkt8#2
z-}BBa`?+aN(#*+o_;Kj5#Qu@bKW=XB^7*1%t<#yh5c%-_-R|y|Q;b0rkWA}(cYO^`
zzW(O@_2WIbw>c{N0;#j3Y38%w-Y1T-Ce%i~up4T}R;N{)AP8-^lLDz`mb))Hoe$Qgg3i6VwhL_
zTV)N`>w`i<`jmcT7Gg5MII3#`ANW@leaqT=2|qr(yhXTOHV8a*&kz4S!;0}grXE-;
zVMfUDY-&VZ14x>g`n(^DWwpN6--f=JPJVKE!Ae=+krgokwdl4j{&`3OE$#T}W7A?2
zF*Hz~@ESfbtdy~R>U9^}1Q^eaAq#N)s3}>^rESHUTAs@hPBeUn)Qic8Lx|>bI%e5^
zJ{g8;_fNH1Cw4HY3goepJ^g?;1`c~iDkYNIpH56_rMJQ*9;1or;lB$pSz>Fd^@yaB
zVk`eX{5WvKNtB&qgq!)uPxQA8)n&N2?m$SnEu+4p;P_6Gv(6-ZLF9MME>N
zee9zf=XwwDc*054@Hh?Bn?-?sxkx53*qJ_|mpHRnNystn>XGXr%w);zl42i$ZcT`|
zsOuOuSV_T2ET);J_!91WK9FOo>1ut5+-|OI<9E-1#MdkA2)Q5wGNppx1`_AGWc-)4HYS#}C&A;|09_6nOfKi*#-A8x8ev)Hdr4_EUY73{J)n{Va>*09^d35eSr
zX5Bnntjoh`v0PWDYu4Z$?r@qDzP?>OJnU|7*H>2y4CP{7t2g`(i#>d&%-`nfW_@$F
zCGYj^=5$5ON-c+v%lrGo&CQnj-(79*uD6eOM|pbm2K#uJ9h5fca>hzrUEHKs?~V}e
zeBJI&>+KEe>Up^+i&;UV=G(=5v$%hGi_ye5o^E%y58x;KyOg^ygh*%knrmKO1c)~c=;4HCa
zp*=87Tmy`Ft`kRbRkEx*AC1n2!{>v+*>EuNoUi(qBejW+gY)tQ28mp6J*iij~jZY-5H?_u&
zpSLrY=_kvFj)&11`Vld3F6l^
z#!(yen$(nk9ef8@7d)BJEtJ89~!46jXb_zxl6H_!bF|1Vq%&YsG
z&5>p4>f!YZ49oudc>QoY-z*8-zPLZ#ULo-E-Rn2synFE$Gxze%H*e%dGiFY^JL0b&
zV50qczj^WY)%~kSa^Y_d+uhaSaC3Tm^KyOIswaeAKAi3_2V0V6tNCiL_VmS4YpbWe
zDnkHwyuCTxTz~!Z?_OgTPe*`vtsd$;zIy-ebbH$_m$xro+`WAD;_ctL{+Lu*p*N?%
zII^a`eR+4dVFGCv+fH^u#D}L?cwQ^RF|U{N)p5VQIq7$1IN|EKZisKS?Vz@++uafC
zcD35>XV^Oe`@{Tr!W6c2__ewXJwKdCnyt6>_4Nj~-LzOk+%+vaE!XSv?rwu6#R4MF
ze0F`Ulw4o0SF1{ETdvmi?fvfhc6)obySdvzppYPRiLs`(MVnW%@^F8wS5397U_;i+
z`gZ){o^F4617ND_o4eV=OAfCWyA=%wjc;Gxck4Ox1TjzD^TU5%jz(@#dS!)8G}Bm&
zBUX~NHeq>82Y7VS1ha_G{|tPAHN;R7kMj$4PxDegYyD-vhmRSJ>I%~dj9@YOzv7UL
zm`=igi9F&%E-}6ks7MlaQgxXO6PYy?F>*%;opRCBj6y+IDnq#lpa;i)KA;K;Vdf+Y
z^6JWCo`XdnArZqz&8Zj_peEQ#%0;K0#8O*7%hX%gh5?p7bV+}EUa@kRyf9$(1
zVKYg`L2BnUi)$lEr&(^L%DF}LqxrE0{ocQ8HfsXQ(~)`Z@Nh3a6$2aB$0G>I5}VFx
zSF0EA-YxfgaF|1qWYPWd{afe^6N!(-5sGA0i=q7bXWxNlSR%DBKOGLY*AN_NgF}Et
zE|SE6Ba7`4%Lw`bhHxVA$iFblxc&8xl{jk2f{&#`En&!xm&^h1^6~EO@$K8&moEv^(x(pk@KgKu
z?5+>kg{*(fr_$11P0Y}MRkQtR@YHcVDGS-Ecsb?BSWFo4M%OMDmro4N_d2}jP+}gSW?_m
z2mSCL*a$+7fjHYW<5XXHw7jw%dJ*=^2vfDSPgx^|j9N-pjeg_MVNtBOvTni8OVcLF
z&5N*Z)MpOU%u3QTV={6*{^$EJBFJw$=f?E;*of+8z}(SvUk)eJD4wXxlqGhmXSo*!
z3+*_{@-Zl9I;{QA4AY9$jhcwrE{?FRlojhYH91X25Ye%A7KL?5xfC&QVC;}t?VPS=
zi4e!Yqddoham1IKGvK6rkW0Tum|!0-UC*iNX`YYtmTnj7gI_=Lt)zChU1@B5^|S9f
zNb2sk-EKJC+}@BRyPwG_`|9E0{`Ko_y~b!_J|N1)Zp&PoRK@zZ$I`J}eaUJSJ~D@>Fs5O-rx&WcDR4`*^JBa{ZIq$Z_qfGMuD7g$kNe}M(>FQ*
zOzdN`o;RC$yItTg{|Eh)jCyl%zbv|kft(->gMup
zuWmGB^{{};O{cC%Zo2uZQT`G>RokiQr;gT`Y#=dfGWA8)Rom`n6>-PK-5ac_`fw}D
zf0pVu_gKT__DD6F{mt@pzmex3cgGbg=z2Zd-JK2(*VsoU272IlceOd~u$A<~Q}_Jv
zUoY_gufxGFVR!Uv*I`=?eRqJh=^79+tV(bUWRv^I2$^000RQw!L_t*40&W6y7&5R+
zaO~sFYvIa#J_GKEhwsEEp5-}WI8<>6!Qqn&CItZiNf;BNRBy02mK%q52zaW^c&Gyc
zq#}bbjv~-cq%bLAd7Uw9nyhUhN7O3ilL_EMlDg2QKTkTCuqs!t{ovzhMY&ucjFCkx
z`X|0Gm`TQ`4*KCg`MeCPV7a`=YT62uo)w%=z2{iptcfZXxhDK5x3F<)liI0wF|o6{
zv9t1g>S9dYqQ-bZaFC;XNb7Q9X5CEDoQ7hx$yl7apjoOO=4Y)vjdOICi`6uUu$!2|
ziJz#aqtyQ1YLPn*V(ca@P3yvsqlx1qf}p
z+LNo**g*o&qTIa3Vy275xoHx~azs7j>8qR9R#A>)waeK=?Jn+6y{A6?YZg+PJ
zJkIvJySHz;-4>Q45+BQmeZ(NH4hO~ne1hG)yTen)kYZ#_xsa``wMtG217&Xm(m_ID(=D_msumK_OUp=6W#V_cm@0_T|
zC&?uSmw3TL_4tl{Hi!W6KqZB~|L$AN^xJQ~#%dEURu~HlLQ(goQ7_1s>uga_2u>m!C~1Ac;j
zSMtr(t1TMz14B)>Zn3Zpr{ijuwrZ~+v{iGEaDhAC9d2LVkdX>tOj$Bx{#a#;h25WE
z%=&b*I^FH=-`t-bPUXC8mK~VP3i@<^jcZpkriT^vzd!D8_f&x9Gh0y4r|$XTKkVbB
z@AbprtI6a`!}#fVJdR=~$$ok{FhgL+H`7F3t-)M^mR_a40*GdMI(T(I8MI_
zLjaTdlgkUNCni;_9+70hmSIE1JgHkHdJ}RC6aSfnF`z`EO{^QaMy}=MiQzkbk@5eD
zFg~gQf}%eMgiO6}S};CyP0{Lm|FVl-Gey{UyI
z!X(LS%NUfQ7hq~JviPj8Ny6}jmHHeYxz45*78B#h0(`74`K3esYBolbb@9YY%&@dl
zPL|pWoh-6JhI(`nstsc-@6dyD&7tL{Rjr7!Y=WY2($Fu8xbDDJrb*e`2|EZU>W3VZ
zO$?fb_4O!<%siifv7U#C9C)5vmTJYV_I!+bHn5!9X>FzTr4`5x{hhVuIUcn6DN2Ujd+)e}EhC5#lN>gsBDJZ|>8C6QOR2k38q+8nR<_m4Ms
zk2hr89#^wfgR8n6Je*+wck`l2k!&I*KW0d8tH+onm
z-|L4cF^RRNBDYk!O&7V!4vJ?4)l(?)>t<^@oFz;y0zb~y9{
zkMsiu^r?G(`0w1Y-Man>)~YO@O{ZANf$xJJEYPB+{pqleO_Xbq@*1Lg?ni%;ffX5R
zUc#~~&zB!Q#(;4om9;91HS8Vs>-lI%xLhsWJi}(;Fh=;S;}B-utro~p$ZA(TGo&}K
zWfe>oD+%2q@ypCk)#5#BYSc3HDVh~D>p{fGdpVu18h
z)EC5xoV>s+t9W8qgJZafq0Xp9mDHhcnmxk+AsLQO9rVM0Zqf9eP;E*UV+wu3J=<5t
zuB@HBJe!!9KkSs970S%%ohGo4UZFP1orZ~+PV6a*ZojDPB)gcH&>sQT+AMfcf;<^9
zVM+jav>mc2BWt@!H*?bbY;2ty?vy2T)7fE2SlmLw61@}gtk1;K~*}zsW
z_PA-9%u*|Hr!l6y;Jh;(a^C&A#{A(}M`Hxz*(`+9S!m}uzLn=3VmxxuXqwtqVLYnXWXB*9
z#?E4qHKkr-=&^n4Bmeu05-2(zVd2B=Ek5mdpe5?fP_&-P~8}dD5!O%&AC4Uk60)y7t7?POLvF)
z{ZZVhY$|L>o_qqNE4zMP=v~43vE?pN}+4ubm$NA;q
zkfD!R^y?BUiCM%@VjuA_I}pDomKA+
zjtp5`1N%dVg|m7Fo4iPpr9buTxH7^7dDiq;PfEcbd4aq;*qfL}7-A^hBoEST8b;W!
zX%NIMRydsm9_LZ56|y9rwTuwV9|*~4!9+rfgc&eaQ81x`kVGQTcU>0R+S~)nK<=D|
zkAn>$-@+q3;%R`jgNW7{2@RXdPPj0W5+&X
zUO7Y?MPLfCfYcc)2`$2pR9lRuSa})(6eIA|K_7l!Y_HVKnWC!+U>OA-g&$W3jF$Qq
z?eYF*aoWu=9M^~SX}{R7)i%g&na_))O=tT>(PWDaWLvCByxrcsJmKFx?l${oduSKy
zVzcWonwxFA+*Df%+%@ZMt#8hh+kN}-_3Epe6-gWtDR*y(Ty5&bS~>NOC0ZS^^!A+7V
zo^|?@GKODOz?Z{PRNZ?~-@nE@DeIFYQCaq;6FXKLps{Wx9-~75AJc}9B@*L^CB;IC
z4|tLtJ+jXQBO4#TCihsz=1(M+god^8r^z?SdqXI=P9Qww;$3
ztg^klx-ix9Tu88I+G9WJTk1hbFcS#na2h0+hBI*^K+^C-D}qTCqH>DeqMSxC)CoBb
zIJu^oH0=o6$04O?lpc8=dLT-GnhC62FR_N?#r(0XW+aS)u)qZz%fA{*Euk~$^
z`}I*h_S`PlWjn9uvzy2J>j$+-?cwHbdxCeaU%q>D_wog~Fo;+8w~Ot1iOtYE?_%H%
zH`k}T+r!PxgSyS4o>HWU&Ee23m-TFR`}o+hBtIRmAMO!A&%N5!@eMKH;Y@A$bKSCn
zR^N4CX{a_RTJHCn-Gvm{@)hdXTF5g3%iZq-tgt9#m_cH9uRJS<_!+gG>SD`g@DoM{&U
z8bZwdYx-+DTmSgyANy+i`^?JKUIS6b&<_~m=e7++VkMyianHa6{aq0-;hEk#*N6ge
z5_5wcgyRg)>+6jj6aB0lmI(7V)puq@1~Y__B3>=7eGeOlWyCPy#D>aqIT$Rok@xv<
zp!~n}Eq^(b7}Uz`AmXuW)f~ODYCuwpqcOtiJXPv5(kF9M)ue
z!hEPF;8**#T)3QVml((84r6q^+AHH&w3y2l_RQM~wP0E?cJQz^uPlAse69-
z@7(vlG|gW&j6iQx#eW@ZDC{Gvr=I6Mn@%y5_-B^&Q;gJfN@Up9th~M&5AiScnitD5
z)E_FqVBxC^f4)b2I_uyO;1Mw#k$|UMXY8}2)z<;>iBwB%*Vq{bsk0&u|
zsSNQ%q9mwFNqy>|AO3^pdZrWBEw+gzEo)&|4-<)@WQna2((OCp5bIe~PL}sA|7=W&
zR6EfC7`l0B#_7e>zL?lSRnu7b4z3*7;kn_BgH&xI8AV=M_8nJos1ulR;%4e5wR)E^
zE-<^;$EkYKTYZ)q8EWFv-b@)a@?zbF*udpNcQOle^;sbg2G5k?J2y=`%jjyl1pyaS
z%rfj9BV+)}s}FC*I_xoQlrb$!?4vS;o{z&s+JI`3U`D-iP6aT~2n^gG`P9^k_2%8(
z{>6)Yv8*@S{ljBAoA2%)PA^{_9v-vVyjZTbclYa?+qi9Jhdu4u+}_B`HrSCj-+l{!
zVFYoQCrl6aj#W92mMP?U>hB!Cz-!FFTvu*g_I1gH$9
zV;>*izNM;EOkNX0k|g}QSFebymzcY2?B-JkefWK`yFOvpG20kQ!qgaYY*(~)F1CY1
zun`kU0MuIT7OY-Dv!%L;tlrdCk^A+0vpA^D!?F48d^2n2_3m!Jy52O~c5zzH4vTI-
zFIROk%ZpW&&5LZ7x2slfkER|nSKni3bM?iAE)$0l)K3U4b~pR|{Z&4%S691syXbby
zV$l@KHk(x(o?hHyH|u3Bw_JT?Oq}7iH4cNj6^acoxND0$4DKy9Sb^eJpt!rcyBBwN
zcPSKi8KA{oKF+zh`I4Lc<4q=+pdi>~X15ku(R6KUc70
z9IUk_k&@S{IYR3OiY>Ws-$5wTN%!HEkiq)r3~&iU;VETU07HQg#IMD*&Au
z>vLbExQ&kHH40#?2uuwyqK<<_8a*NsAi0Q>6!pb{^{gvU`J?_)!{^>BVa&R~*IIl|
z10P}b2~M`JX<5ek_B!E=5?6{ptqmQOOAUmYQbH5*UwkQ=+2RC$r1g%t)xSk(E=+9+
z-`D;t{n@VCZru49V<&sNFDBMR@5iO=%pVIlg}xZwcAz=9S~`t@&~+g)(;9c*p}EJX
z*Y=PO?JRbX85pE!%2D-E@<%~K)`Q&NZzR99NMzWCxRujBmW$igg9?hPO?noVhiknD
zhNA+uLl#8u1T10#C=@&UO`7yR=R__B%~s~aC3{C8kt!0Q(O3IPZp(17eYWAt>hS-D
z%v$urDgpCKM$Nr-T?GMC!_-WlWogi}>@P8y5_D|I>RoRPtEP?#ac$p5*Q%h^3X=ly
zGyJotzI_Vev#XIrh?ie)=tYOn){_?0LTn;%27r)AcE}B!Nkhef{>CePk9BhWA_Pr*
z-zExHlju4*;%|+dxl5z&-WB0|FuNcXyk4j7VT610CZu?u6ZBXcpoS{Qpo&gGQWkK!
zEL}(}37ie40Z%U4JpSU`VcY0ZHyro4y8U@u;!9S>huN+~tnHjjal0dG5?>Cq?9xw=
z2fiM^TKxzR(x0y3r8f)EdMe`g;{nrmNOx4)XGr~O5?h^IrF~H&P*hUeFrBRHomk9p
zZ-knkGzGq1yCz)n3zF8P@;inpRj!5z1-@TI5f(5Hm%h53JXk3J3GHjY>Ir4@YJXqb
z&Mp(1-MRQ%+HSBOF^n=M1adEz%XaPX?nwIiyX5IZarN2ah4b6p@+Pxf+PRGC^P;I>
zbOKw{Xnh$;!%dHBwMNXMcI2)qnLffR8%7iwA93KQvUGvdupcNyY>Qw&jYF|bpcpx0
zBwld>Zzz;qD_FuEAw-rL=QlEi0x(Cq=L=2%(4E5v2)XB%%+|m;pwO|VzA$#GH4cme
z`Z8YANQmW&RDDkle?D9-YhzMuH7-yM{m5*thyT%Hx8kSdGD_po$FjRRT_*w?K1XZt
zGuO%RKZ@uy6PF1OcihsbxE|1XI1dA5SX^6!wXv`B1P1tSEtM21P@bw6Ok_-3;_Yqe
z)>4}OJq=`?e7?f1%I8{Bv;3#4K)7_$KPz&e@QOBlpDq$H&>Xr*#H6&Xg{s+?PBO?@
zN0>dp@jI&ZJTj@*8I{qI`iR;LTX*GW_@qFs(t0)i=nxij?*Ljdi2C~Qt^RsK}Xu0oFkgKmLrsZr`|T&B+pCZ
zQ;k7wlg&W{$;qrXTWu1td?oOH=u5_8^IB&b#jOs>phpQF9z1-oo4vBuA1HLsZ?JSl
z1=paTcNA9#6t73jAf}`>Alc_YwsAc9&XAc(`rgm43;j{0Z3&Ng@4BM_B!en-p2?qB
zLRHB~Wxkx&zp3!PjL+vO`EER{}F1Q#J6zzkwuJ0YB7yDAfvXE
z=)T(!oKB?^HB2
zS_`0!?zypAQq2m5Mb|sW24&3KPz!~z0vJ81IJ)@Y664obpzoZ$0*GA*JvC#y@O``2
zOfVLo*unA|AHHIdnvlp5;5}@+gKsE-J)vG}`dsVlMr6k!|KY2
z-5V;QzuH{xWBSX;iSkNb|m#ztfUWERS;J
zpA;8FG7PTjQoV|+KaQ!T1hL$rm1vD+dsv6cS`&_MSPPqEjkjf-lEnkRLp-T8>Gu6RYM~x1mlEdwH%ucPTDkVnyX76Z`Ui>d7M!K>%4&rgR89>XMJ3z%r
zIag#N^dC`OKiyS_hY0Wc9->kebHQgfkY7s%UfARgc7!y#Fw=z`@lSWN(sqvR{RNEh
z-{DR#g7VQ)-3@w?1!<;`c}SQf0SN#v%)L*`*h({USM3p~AuIbiE>*U>N|)TkM&Q@`
zd2#)m;pa^(JVB;Ma;%)>fExwmqh36eTY5Mb=1M*k3*Cd;e3loI5Bnn3%iPZQVdn;Z
z8xYqJu|06_P~KKOQR<=c+;<)S$EuVUUCHPAMn-F<*>1ze_OFiQzrP>jZIfNC6yGuF
z#>NJsCOHrDQ`MYpu;L%X&Cs+5RHE72EP
zeOkKRZ^9#&`O*K#L4mB!s{aVk^j4=_Ol;
zeuSX!jNkn;^m=L3Qyz%JftP0(DbNKaCGo%+OE`dlDfYA>@|TaK%td{}L_XiVSe7Im
z-hTutEv)aLU|d5mJthK85^$_oBeDGP_|spg>l4zl*5=AEzjRra6!0$NtX9QbzS9;o-Oq8QsLF=ALr6YPNl`CeC3E{*Zt--krI_nuj9;o8w5hagMztr(bOJ%Nq2A#Q!|5e7>
zX$nZJ2RMykeK<)!SUx71Dc3!xJoV=&p_gb8okmecwkPx46qyB66=WdxGh#Ema_f8Q!XflNxrVQ
zQ0b(`y*Id}$ywN4YR>dKd$%75Um$EfR8Jwe2s$=WuQ5w)Qb2P$&Q>IwKwU!yc$nD)
zk3P70KvJ0#beWN*5WS7Nb@Fddx2*F=a4<}V^JFw2zYu`6*gS|!V>R(;?`e@-!H>vyAvnS6c3%>S-
zEOLWx)*tQ8jbrRzBLpUv&+Qsl>&Cj=Ur@i7^8VImA;G15r|U2;sj(Xsmlx1pc=`B8
zIiKx)kQ*U+?4-;5zL*&(Ymiw{S?lD=h}yhWrr$PDXkKVskOVsQ`y?f6ozX$fca#J~
z*i3__3R+%{NYUR+##zFQKpJUvXViv#MQc`L`>GB#xfikBvopoc*H8ZpO`f#458m4t
zo9lPa->Jm-sb~@bVF>M^IA6oUAe@%TClBV$D-!dV`TQxC#
z?;7&?`GNOcgIvrP%!+@jm007Gki4uFdvKsgs#K~&?WbQc%}-x%iXU&~h2Q{lf1~e~
z_0cc1I>qY^p?6O5nn(Ez?R7^BQErT3JfAmU_u4ytwcWstV-g!9G&eu3pE-2Fy8TF%
zdS{b6*6d
zDK#iQP30(}pYCeUA3Kf1F%J9YL7tu2`7@L#F>^2JA19Ce%t)#}BufcsXM~u*h9!RB
z@uj-O+zpBuO&H{SE7EDO{vECN3AFeT!*af~de}Eg&OfGqfpe!(2l*l|Sx*NNS*asx
zZ0cS`IJL53K)jm^$}cbP4bkw@>a|~BA#csOTC_MX;&^uCKKhiLP(qa4wreUQ67PJk
zIUbd;SDDCG(xmPTPh=a_*A@o-eJ*xzZw)m_&(mIT&93##?hDi9aDKT8bI(K9v#sE9
z#8fhN&g_8gjid}qpJH0%+KZ(*0IYi0s%`trqW_ses}1m8SD9J9`UT8_5~1QqgsmCH
z4GQyCt=Q_4pab6z$BLI4
zafX@Mq?tEv9@DM#+Pd_A3$ZzmV`lJQ&WZ*}=**$iE1bw|^k0hxXG$N2ZR
zn%#=c5Hf2dF`iC;Z~qs3`~V^V`$?
z!`=Tac<-Exi~s%l|9>Js3-9h8ZvNlGx-W}in&6En9J@}b&Jiwp2d7rr5gr`7*v&w1
zp05vk^NnC>t_q5Rr97VTJ^>0WkSr+%^~ya
z4nJ2$zVfw{@DYiersQqR{bAM0c!+l$l
zW>uSxw@lu&18fJak^c^vclB8@5Lwe(H>9vrKC6qk1Wn`@PVBwVKkNus>Cg6mHzsXd
zPgu!fU_^EQ=F2X8mXw0p_c=woZbaPGBS02z4;N$3@?|XbEm@nc9?Lg_?9@0BXE2-=*}`~Q&JfLa58+e8NF?j&YyPQ03rW-88YtJ1s*X=y1NuA0w@932#aLoGuuKOgm%0Q_~V>Ey5_+&bdEaJ!QV<(%_{h5LQTQC#c76L3EvB!A@}nJ6TE
zV7NF`&pDq_Hv}Holct#G-;!KZv}#Y8PUGx25EaMxSRzWU=+gY8`u>3WO=fXmoZjHz
z+xo)vWNu5Q+oAgYOr)}6{GXvw(oa*rK!9=Su2ycxj_hN--A)QVcZsy}q~=RF!_o*o*Pw0cNPT;NcC
zvXRV=R8k6AxJ0eSDetUiy%|u@6%Y3Xf?m|EvRrQvN<`-6(z0``K{Fv*vwgqn`xNMF+nrl~KIxEBj~
z|J)kZS5;J_3|_`_73G1ZIB3Ie8&#h57A$_$r&Fx+dx
z!k@dm<x{!Knm_nSZCiJ~T2On@ONLx*@W`l3VB1O|jU
zJOm7@$D1m?U72@L#x7yJI#zT=QgZSi=w7M`k?C5{B;ikL5Xey*cD{Gp!nKa7&=kDD
z0@59W4)-WxIN)d=c&2)@TS7#CmSr)8C@>2<;XT)3AGbJRREklsXj)3ZqZFQ`NWP_H
z_R6c94MuFz-`9w16OQ$Jv6cDco7rqlGi3N3yV8D9jbJT+dXUeyQLG>S@mJD%*Q;L)pm5?c
z$W>rK;D9#1vd{Y-wOV$i|9FSbhOyj#VP)k1%4aTeG9{bWzm~`?i#pY(masWzeT~RS;l=`IS|$1oyBnCE_EmvEm2jP5k4j?7Q^xDJW`V
zD3uUFDgLok!OTZgNVP$)IVDrhY!Xp0(drY+I~qGjPSPLc5VDb`N**yL0Tv@Qy~r`X
zKsPw#F7|Lr`kn2_hztAE)r-oplq_vCqJ#UiS&*JuazXW_$wP9t6e1lZVk%|u-zm@slajC77tQ
zqO8pp*fd0AyXKI=ck6(zm1y|~RW2DU-Pk2mC!i{d-GiABV3#2ge&#;Ukhh?QSjKER
z%p+OExj&3zTUH9})lpSR@a8UNXu}nIJiSxaS;COgcKnhKVFT6VX3z5@;|=>gcF>g~
z2>2;dsMOJA2hX5-!q{#FD;ZEx76!2k_tm60lX8N91%{3Ien2_j0%>pvJ38Ox0urB&)D2o~Juc)#Usg;7
zEG(AU5##c=U07aw##2Zebm@g~AmcY=X#G&jR0V7i7_)#Cp%J!su7aEvN
z
zoyS}rLi6dds1`&eide|sChqypOyAohgiBu-&-O$*@4`g~k~1g>%6q_!{@C=Euqi{I
zjFY{V?ce^gpe6y8!);Yzy5bB(W}T-V^(Sr=kJLkh_aPP9ynD*mpG-GPX)fxzE)^DnKeWU%6borl@)APt&@m&>
z+nij=nB2xc-2eNCz*hb};fV#0DjsZesoOegfG4WDw(`aMCTbojdONr&fHfFW?IoZD{)=%
zjc>_lpI@AW{lU*+iqHA6+7RSy>+!GD`9)LCOvp$7`HeX45$k(-(einG!
zuFdygUeH`9?Qiom&iLkxKk;9F?RMm*tPDCf!f!81Q`eA2<-5!okVVlV8PhQn=_4H5
zpRc_h1nYTx)QlZIjV^S?5tc`pVKD_Jbs!i?n#Ka9$vk4I2q3LTp}f$ZNG61^j#yA%
z(Bls^i|D6SSPz2X8XB;O6CtsyGW?dJ$ozKdmc5iBS}~Kx5ta&2bhJDn7cb+D%fQiRfQ0(8@U5j_~
zeOnr|bPD}wAou!Ir3!JZ
z=o5h0dD1h3#noI5FsAnf7X62XIsMZfu;{EsYfuDKUz+2#k
z-uo{dbfqvy+ch&vzwtpBwm%~K!&dcUUt1DfT$~gty4U#4}Q@&#}j2)ng
zg!75TnTj2SYaGEVraVB~Qw?RWN4hL@lx5vXGelA0h80B?LZcIY=~c4|g3)1^k5a*e
zWt5nU;Hw_hYzoH_G1!U?SLHqmph1)4=T;ZId4Fls61c)06qSY^CZ5?F%`4AxetH);~`bx*`Kx=r9>
z;n`dQNXFL+JD>nCvK45ElPftZDmsPoM@~quqAR~Vo(T3>`q+~!1gILmC;lPs=#Y7y
z3~oWiBZD1LC@TBkQ(0EO?k2oXJ;r?t!V@UIkKcVq1@>Xzrhe^TdXcB4weY6x4mIrR
z>OS+Yx-&~;jmh6=tuykjs^U>3c-&ZxkaU%$L9H7&IeWpr50hJ!rA2EX1%bpNY+Y9t
z(p2L#v^1%$DRY5uuFNZR74pC$%43;l_9zl;43+jww$j6n@eI@>@JN-dX9d%;tgW)u
zS))*$wV+-Z;y_r>f$VghO0Gxv-O|q%M@^L-W4iYNX&fRF!DA*mmRyz*uHKf8?_sbb
z_K2sY%``&*>V&-#h7g3*rnK$UR@hITm?=*}923{r_3YHTGpzzyDy+JxbRs)6A$wA(
z8qWEWn=jR=9RfU=@=Amq(eM85-`h`^7$>;FK#p~JmTprEPXA+UGMdOZph?7tM{#lz
zI%S{ZM*;OvoUosy{5eqMp3z2WBpB~$80KK}J!QBhHZ?t+eOEF);{GzM&6Wn7LJ49H
z9rg8YgUR7+FG%Fpc-(g?%NE`j_{3brWoHY;Y>c1qKcR)Hb6TL1(DAYrlY4Y_@)*$`
zKbr?BVT{tqw&qnX-w}q=;p1ITF&7~dbf8L=9x0hF-JYa087wxoCqj9otPR@Rey)!&
z2aKe&f=~`E!Is%Iy3~*>%2f0kXj_lV5rnCcUwJiKikufsptxgN@xK00Vy4tD>NO+n
zm4K_KzWDbfMyvd3UGDR(9s=`=z6+zMQ}81m`M2FT+}u?WbX6u~
zq8YziNI^J;|0%=EE+}MB+SS`KU^C>rZ&}pYI2W(ye-rF1gV*|^3N5BhB+(=f6m)#w
zT^HfAZoN_>M!1%DQ&=xS%J%(LA6CYjX0EzjRuSpFsB6igsK$iosriEenpHmCo}=tV
ziMu7SMH9HaU?w}xh+d2yB8&Eldb4h&bwXgA%NNFoU7-BFA5a3ns#*{qZSoW#|VsA
zM55prRWL)Dk5zcN@EC$YgCQMJfu-=do_cS1$V8kua0ud9I&QN5$Em*HYj7DEHQf*e
z>q1}i1l&aGo)q{1P3;DphvEnD?||bo#ph^M3XVidFZr~7j_1COTYS9qZxg3KP+XB8
zpAp6|G!ZKInOM@5F&GG2_JN=PUy6_D=j($Riu4)jhVN53jF_6^pO-9qne1
zLu8Oj`Tb^Se403%i<4Zje%@Tp+hg^ts9?w!RUdhJQK4Qe;%FthuwopxO!*hNB3o|7
z)EJGnpz=BUoiYIqM^xBN1B{=CN==cN}-MQ9(xrO&(RLF;^zm$=Rv!dDZA<4SCvzcVULZ<
z+mlHLv_(}GCHTpHoZ42-zk;#O(Z?yVnrnCQ^|8_rA
zbU!iygT(DcQ}rl2QlnKa4WG5&?&OYcn0M#6FWui2B@HSk;ZvH-L;=wUPxJ(RVG69+
z>u~%-Q*ab!=NA~SCG}qO!?|jxE6f12uTixheeb4jl(FH
z2{RETfiUKy$g#e`mxCFnEao5vRm_XTdd#YFqO%3~l_5ulDZp;MSWX==fE~{W*^Z>D
zq6(@=A5MC+Zqsu9$6i#Z^YbpYJHVtPz->Ltk=byOp+DpZqb3xX-n6(q}&I2mC|(IClJaf~ff
zDBPoU+3^rd7yDVdzlJk9`k$~h(y4BMuwH5+ZDT&g9wSXT@l|2I9ty4|kV>K(XZkp{
z_lm)XsQ3r3gNG}76dL6m3KtgxU^nJ@&lB~F06dm$=~MAiMoUWY?ziye*T-s~ixr8T?psHqS_O{dgF^vl{0u(_6ePK&Hhv2Gn=?^Cvt-OW59
ztACb29mpdlC(DsGjhs!7aJS*nKST5d^wnwAk`$CT(ZB@!)E
zS)i7Kc^xW|nk$W2lmI*D>k;T{Tv-4`3qz)(z-1L1MoK)2Md_zai{~##zxY(Br~-np&_)sh2`C2P5srIi;c+n+gD3_La=bZ&!eHtEi7>28A6#^(<}4wHGE-vg@urjWPwDfR#XtrA0D?yERV!uEk5$kTW=_dFDcPT`1m8=
zE!x8%`rA(EWQz3`9KHybBCi6p^R)i{3h-TUH?6?h_5VICBf$;s>xrb1y-s-|>Rt;`
zm&txbzist6G>LDlB!ill5h@%Z#OLejFOaP^&3rhQY{dqm`l-U;d_*MchTchw=Dl*V
z$w86s+z<}>f~sDLGqUI|F-DC!v`;fC?56q>FKdm;#b92}cj`YbR0uan&zHi`;`V&|
z%mpQ`u+LU0n8_x8tm|l!Fw$SI4?ZmI5T!2{6*QL3C(!sf6Dcok2bRIG2s#0pNqrD;
z>=raLsc{iS9#c6qgrPN+VOc<-n_C??rx3%9!IV(Ik?|!0xn;2gyi#}C+i6ifIO2M;(eq;66
zVYdAA0hQxSVLW6GWL#-jc2OZP*2_=vd!nND^}3y)$Q1TFEBMLUc*o-r5ubmENgjyf
zH1}?tD8h!^gqA8EYg9qbWRLJQp_uC#ThmsH+TAuaMg4=EisR9}*E|)Vfn4yTDZ>^D
zx?fW|IoC2uzJHEA+*c#5P1O|QMpG1}URPV)^hfw}(GLwjEdQ9N-{}AAtIJUa+harq
z^b6+_pAs9kb-{^EA8v-kk#RCJd9?V(Gx+mbZ4;YLXfp-)&~8>YeU*wWYugD`(#Nys
zMS~Ke7adu*N{X@y?NEL(-3zDDodNqY-_KEp#}YS;-i*{7pT`AK_R6U3!vQgdkAu0d
zW4dN@_Q%N^SPI0E`b!=lL$HXxzLwfYftHwhz9Oc#o)5Pe^KB?^7Zh(7Y_A7)uUlAe
zzOu!D1OM*l@$TmYkr(y82_lf6`N*K>-8?bq=*z=SY#nCB^sod
zfLoT;k3LXtkO*B|wAfA!qIEzg5An!<<=4OgU{Q&ts+GozvO_WxQLu!%yxm{y+gI$O
zo3+Q++jN~5E5&qRV1fcirB1Zkg)j#KN%x^Nn2A7UFd!_vUplOx%*!6?fyedl-7IXP
zX0769Nl^B;GIWB3CN9L?`71R|&tukdsuwvJcMlj6C>u)=U#JYhpRmG+b6A-@oZZ6E
zf`TKCW6=g2>F$yFpP;w|sm~!O1(`r+M_EGSQb5RkzSvOz-D{T-T$;L
z*y6>ufQG8c^{y;|a{(o0k$d2=g+PR<7=fHz-i%*3$1k<0$zw|5Kw{K5DmG)XVz5$~
z$IYh-#@{6T;ds#lc_FxRgC#OYl0qsAOf+g=`!d-D_{M*s?(z;x)PHgI7Am^^qN;9w}=(K^2V%}HhmTzc&9+LJ<(^TibehDi+U
zsnNQJ0eyj7)UB~Vw6d(%wy$c*4yySHX==YkN7%t>3s=QEo*Y(wBhtOpx(hDD=6T7;
z1I)r5VbUiSpOic@WLK25u?v*iihW3;=eVvv)F>5_^5mQ&Z}*zwO+$!hKr1Nc`btCa
zKS>vZwm+Hgy{-D({ghYh#*gfo+=UN$+sk=Tx8FnW<$wOs{r1FOlrdC8lZvuTg@mN&
zb?E+v8?8YyUTOCZe?26I$y&8meru7TTf4xw*`+}=(XAEq+qf1gSg<3hTQ7)nB$&{N
zb2PB>#TQ$>$Dj1@N<4OT3>gq;U#OS<&FFdakir!^YH~7%$C+hgl?7`$`#)tqy6$+e
zC*uVfm
z*cw@R_A@CbLDyKRp_-HFg1>Ziadsn_muFpfL#ZuDBh-{wgtiCSXskxBg
zehJTTCEZV8N0!{PW!oJ>nX9o5sH@FK7Xgvp_$f=dKwqslUD=8WD+~CC(6~7n1sn1a
zzzZ?BO$IB(Rc$>2j{aSi$^j$jyOkLy+D%+Q3^pX7_
zp?!yn&=y?dE_)|CIqKpjM{uSmEZd8-$x8i89?`q{67A4)*^X4m+02}oPaLvcWFz6Y
zKn6m%L=YmtAF_V9BanDYX1mWKdt(<7%ux}^qBbl<0R
zGjJ|@4s^Z#{fg=HhUHC>4bz=U^SUkaSRMK>{8sJL=j=<20w+ct)&ZuF6&H}@q>%s~
z0fR@0AaJvLrDol2Ij$BI7MIBi~318s>U|1blZuELx)myf<|UHv$Fi
z(SY3Xa7M+MW%C+~@(-1TX;`&HG)j
zIC$!9NO`?u$a7aKgd9RC(Wu2WoG{|^9P_r@eILcQ>8ZHo^O*DY%~bM|;#Fk9s1KRK
z;S87f%YjX+z!_BPL&~vreXOtEqj(ABmUTr{_$(rKJO@1)AbsZhk7@%ISV8^Sm?=26
zIrITyv9xE^EET8
zuMEZ))~VkW^OfKQBBPC&NjY=A!AAF`INGJVwZdZt@5qWHflTX6KT3gZ6S=bBE3LMm
zVv%hBxE7D}N|BlQPkif`OG5Lu(MnbCKGMVpr?>^v>|)8J5=#T%QDEC-ktpsIS7i4c1{{oMEBFPgH(5cTv-|#J9h9Z$jfca@XN4+&W8;it}%+o4jx
zKya}`)hJ!^rNq#SrM-6Tw7z0RbM)DnedRDhCGd;)#Rt<_(|aPZV_a9Tkc}-0r^D!v
z?j}K@WgJ5cj);WA1%4(mURd4V(ozntJu5%L6s?sVZh^9bx8@0VEYTq85{SK*|byz3mO)PWC2a}0Ld4-kCJtJ2Vhwg^RT##V4aR@F$wq
zPfgeNO4{_oe{z(z;74FsqI{r;ll{U-L=z?x@535aLP3{JA8@GtY9x7tZHhp~LyKT<
zx*4|jiwNO$|LxB3ILhP;P{x}P_C~bu_)X+(R7AqasV(IYXWpDVMIp+0`@xNoO$H0R
z6wO6Hn%8OEln7*!muW&~&X@GF{8FJ1@3EVmn|`Ob6mYhK&R3(i_0Q2bYP~0#lS_6c
z!39l4ZLsu*nRr7UMeWAI5JkK9%9JShgU7hS-YOvAea`y
z1(wR>2|^><*u!MnuC_0hs|g@elH+|jog{O7wXbeJj@(dE%N_;27F@o~GZ>{$nMYFe
zJ57R$r{+Pt;$C63_;J8UmQXm9rFm+BtLG;
zk?qC=`1Wv*i%+<$u9#UKw5n^;KnwnP%ww-er6Q@p3b_i;VtvP=Mv-P$N3q*BdG-qv
zx$hUbzv{k6I~6Gd!vbF>H=iddUbiVwH`ls7A10^0qvJR4iMm_6+srp~|6#o^8#c$>
zah6a90QKOYd46&sbudKNv5fP4>aFKwL1U8rnNq~C5Yo$h3fqmM4skrjHSBnOoLnD&B6>Hw>-Ol$
zlHER^{0?RFD8yVT)73e6!BSc`BM9l>P7_4w=jc=eT`>o#HC)4BLcWO6V+XTYvcWAN
z8@2@jSHu}#dZ_x2;*#Y>a#0(BausnU+5VB&RPxwvFRxkHRIS)_NvyPLbY3355{_|!
zp6x3CK4ZTfoZNA`b=}<|-WRb7PA$^p*yrU^3DX?2z4aR!KN5X%F*~7nU3x<~_Idf*
zO}oSp_8hhOjA7iiXx*jjdwbGfd|IAgAu9d6egmof3K{-AO#aA#NZ6Z4hD
zBh@G7K`J>bddki}*rfIis)+b5@7fF?84-|2%I%y0vSAb%Mj4XRPmW+!XA7Ea9-cq2
z-!nu}OAN6Q(_FI}_BaZbp#IRAMymoxIu;~N2pV8V#Em_PCL7a~bBmMhtLXQG5q+5b
zW-vg7uFH!i?dx%x;^?4}J5K-=SHOoq(>D;NkPflVJb5}Oql
zqWm_aedee-XGbwbv_4Lv&F!;x0=YW&P8i`z$o&V-`mAK$n1%#V*Gn~_mJvQbdeXf8
z`S!X=V|nN>ot>#HGaT|2^KIPc8Y?FT`LJL3@8)~6eEE~}LPAe!dMuWfkcZ>`r>?yL
z{o0=Ymf+`hem+e1ULAGFx(6*0es|mFet^kfEcxG
zgxdKiXH79BDW);}?%1N^ksu5i5V-;8VLXM149*?3!^4VAP6wkQzP*{Wqb|PjPe)jU
z^G>=tmc52uv^s{E;K0;1tN2930%1-s9bcT^ID;vP%*U%tGbPV|p4@e5UivjX+ckFY
zMz|c1JX^AW$Y-KlLK&U&Xu&N7-G&N-^EVyAxE}%^Q@fB&17c`o)&+fdNq5GX#JqYI
zGBGCs9`|>Nw%a1n#eSE4(E~Hs1jp?v%zut!8C-N(Rg9&ew){HGscsykv!GT#R?mq)
zuy_KBfnj@_du5~9-;lRQ9R7Q!WMWy%ZNS<2v>4F}?w
z4x=qM1JyJKQl52BWQXk@%)=23)GV*&w@I`B*(At@k0
zyfGoa%kO(pxOu#7v^N511ZC%4;YILkIm`S^;U2ARu9ZC3;D;A9X>~M6nTUh1WunIm
zO*$*A+3|l%i1WCkrDrS3O;{OAeh+&V87-R0KFiJ^^j2xof>RB$jpI*?Kh@oEGC}<$
z*y_QBGy}wT;qtO%58Mmfm{NTAuCt9ZM#y9iOJ9jh$UDIhx?x0zv;U}qB1UalV!6?%
zgj-@GLjfI+rHYcm1xaoX6V>{OQ~OD^sHg!becNl8p}yjv1fXo~ba>EPSGk%tpBF{G
z%h=_d%do>KE?zJ~N3laida!5|)bqF=rj^q?TY8%Qp_hVFgcEJ;h@KomS`46rV}7%H
z9rp>FsD6H|=D>l$v)kz2J&$?Yi=ntd<7;_4=zg&adw8gRc{HxqtY7u4T?V0wg@Hlm
z$gp+rd`BhtzQG!ac;>e0@E<6uR8Yn!v35{Ky)sjMS&UONQo~}YK4D9U8DSjtQT20YctqRuYHsgQ_o@)9enUzOw#M5aq47x`AEMUNyJHDnAiu
zSN`^;Te5FJniUQ|yu8Tc&KvM)>`6-{m#$Bfr(&KFqaIXZHeO|X`s?6|$7&JL=0T>9
zp2&S45Vr419|sD=cgUqmAQQ$!O(fQ_cM=?hkDKs8;OvaSik4_i$TCt)i1=E-y1%>wj=f1(61nMaqKofVA1ffjBg|L!};OE3;b6NlvrYQLq7>+*g_y1jlV_2D470h{2qyxnfTd!F|DNFzB~kkJQ`Db|@k3exRsRR}b`#~r?)ZK=6oqB`%wY);2p5|3PkinMm{
ze~3ZBk7&&ra75Pq%ivSQcipP-LAlMp9Ok!?l|?8wT~)$w_umKZDFpSOZD8~owWCuI
zcASV)lt)Up_HyMxDrvie(vX*5eD%T{(yD^kOBF7dp|Usc;2I2{%$
zeqS!bylo9|wP|n-_jj4is*33jC?fvwa6d4Eax#_#1owpQ+{?gViwMIqERjEa+ZI7X
z*2879|C0eW1$vGdZmMdpU)OuZeRbCQqD5!d6O_b)K(X?%q
z85O&W`T9Jj#;YceJ1PBD^>+VpGX>01+G_I?qBfHq25L)l=$uI=4Y-A`_EEiA1mhev-SXo*DnarG#{rHOZpPjT(ZDnKV{^$)Mys7YVbT~EeGN0=Kco=dMY$LL>3xOJ#h=VBI
z9(RNg=ulpI-OZ#r<}4i^2}h|E5^`p*!5%HmBOn(Q7Sj(k?UFyxJJ4^7u@1)RoTNxW
z%oLa%JpQ6=DeOn8x5h>9KeX_sW&8D{OkIq)_T=`l
z8hc140B*GcK55Bqg>$=+X~oykrGk|Hu0P57xme$1t_FQS
zN3H`0$mhxHa7YO$9yacYu`|H5k42kU`RdL&9O_H8s{H+6zro1Uq{bGc?C?tU0$fNV
zBSdzLO$RwrK8cd!d{=3sGp_jVXK5AurN#>i=ZXndV~qAovJK^$
zMJZ>(>xLt9-=U+SnCLOYZ1E1dLkRjk#$a*ZUc%vS
z!P5^EmO8=kv%RK%2`rlGGjL!Op;R;uM<})o2}E`{?@b+JcBmB^DEnm}yEcw-Rxtne
z1C^-zH#&D|)ZNpm%#M*Y{XK^@(bBxR>q~p^h@Ux;R@ff44GWHx`qWb-6!@oF#5x0ZYH6-PRA#9
z^P2Tu|ed
z(5CO`{=Lx+{YUyYTnz}%5@e)E3!h=Mry)L462Y+78)X*8=FIBFOr;#ZnR+#vJbVhr
ziC1Da%MAghkBD;oksf+5d<#kQ)I3RF{1v4dg
z%A`-Cbc5>drayYPGcg_h5VLc}dS7?<`0md*np4*wa6S7z`1<6LX9%4o3AoeQaPAN2
zte8W3_M3b>0IBc^Wu@x&R4(VbCaG8!SCSy3r76-vhd9eH?UjlTAmQS!I=Pc?s}a$%
z#%$!a8f!(!*_YUQYWz0~CBRI?(muW>Hd!@gcam!G8Cb&6Mg<{w8uFe&)~PI
z>njL4UWXpke?Rtfb_a%hJ9qyzTW`i_igVLx>Gwkl+1a;FVRedh)01Z8ILy$%qBh0@
z!ELUjTNPiQ;7LX%-%f96^b;&MQVvE-y{T++jzpL49aQq;d8cBi8kOmRk&)yY%o*Qn
zY(>efH8>K~S|I8I3)zZq&{?0R=>2abozYwpe4f>`FNbdgO!f8@fetA|E3M6a^h7RE6hTQ=_*qb|&{hkd!wg
zPik(c8si^M(*o9C?5-6sGHmKW7&E{mO!$cw@xVj^CN3%Z=~R^UBue$+uph3&w%)6!
zT@YE&Wy(;B!*a66gM00*SdV+v0hAA~*Ps_AX{tIoIu&R?&)=oOp;Yg>47fQ4-gHh%
zNc&xCAYy_@CBT7uAPfng!6GE#6jJamr-bh>|-$``w-d3hJ_LdPkeUI#r^&
zk)vd(<_Yr;g+dRBl{%cPz?`juu8>EekkuQ
zlzbt9DLpCN_Soz?C@jd+Kwn5zV`cRvaQ-ZU@n+j-SZtW6Jn@9RL;#ukR9z#d)_u0L
zS2WTk{Z85Kwk$KU>?9M9KiV|QIqI%BWmY|295`PRJNbq1Rs#8)pi+;u3%Q(Qr6$Hn
zIlz_>roa&cF+@T4N2C~@V@aHTePEDwks(A$RmHazEOSy~j!--m>qRE~V179{YS37*
zZqO&4Ne#yK~v6}CElzi4yv;jS`6i8hK0?qq0!6RcyQLVRwfD)o>7URqKY89EYRdc1u;8re#my*yj9@og-^n5)z
zOyLw3F5~ql{^MWK3ecwD4|mg=o*&DNffZ`P88O}nXtH9KVGc5`*TA?<{bRZ&z4B&c
zwjd8*6@<&&HC~(>@)-NXRSodCw?n2rRLiFIHX}(;_=q`H5Yq@A81*C*V5U~(%N1D;
z8s=c#;Dlq^3bU~Cm7BC3q5thReWHOAUuT?+#)DQArfXrDo7nSL)KjabLKtr=xord_GuEn1e*WVw@+w{g
zVBSztWe>u>Uc{IJmvP_d?|`Z;z`=0p;6d&D#z3EO+I8>9-==YQfgj{O&kr4H_$5@7
zRTd@d2aP_OFvPw))ScvUJ?2eJ4`V=ECO3emO{wpONluLYKmIP=4h-{Ah7IflhSfR|
zvAs_5`LNC8!C?xHVZ<1*_&LEkFTC?&-E%_FY--jSeO47a$fcvS{$7T7nGUr@tLbhY
zbk&pN;s$KpNhjOax{j4T^!;jM7$K=kvknE8}NrbxkbLg#d^{6h;=G5LEbP;{ZB
zmMs}h#lcv#^v}Lbm-F6bE4bboNvT)ymIFS1niorj=SPmqW|-d%4RE2KSLyrUH2fBz
z-JctkMpo9#yK|72$?jzcmlCWJq+6i)K^R&Jjk{QwFf8C&+J-Mhd
zrKS{U1kJ37;SK!ixl?s`>}FTXQIn9rn?8=OopCQ3D8KEow{P{KIU^@rVXvz0djVqA
z>?T!wV1%4MnsL8hJiJys%J)S^ysRlxO+ZG;7>@i5wDPFx!c4NIqSMM;|JZ>~ePrOR
z0+bSX5#vBi&psP$gWJ42`UN3J50ki^NAK8az~^3eQDP2fBPaE?9`r;FTiSPoN@&k9u5ggf!B)(E5)^qa`cU{!phdyV}Ff>e(%JWJ-Jhs!jJTp`dB`p
z?oH;icT0hytqPuG7p&ma`#tz_K~JcV0ms29`uIy)G9>@Dtj1s3XNR_<>{1ccPt1P72_bua}j4#pnd%3^ofnZcxM
zm-uk5g-+ACc2o#39*g?j88x`K%}o?2GgYP9Y{0LOfpf(B`Q-?5xr8^p92j3&+U$nF
zpo0w)KAO?1$_?b#{q9`0_tM2q9vI(T1Qt9lJ6f3g8As$NE4=*&r{6aBEevB
zU{}P)faduQ2#`2@=ivR_i4TwyzSMWi3bTiRud+0)>QjgaCKbcGij8*E*%ZWR`M?C;
z5n!VD3bQLOF^~Q$nNcRm2oR
zQQ`HWA_v1xi^HOu;ItpZUMXR+k+CaUXP;PU)FiY1tc&EA`hCe0ITX4R5>U*6+VazU
z<)cgLF#c@zi4AVkzRBd?WO6UxkBqY&_e3nJ6S>t~o%FGUbW!%QQVAWGe54K-5FBhZ8TL7s?Wso^w5!^2@o1_j^jRjox4F11dGDgx`1OB^j$q%hU7ZS1b
z2@NLKc8gq*g=iOlktqFoPUc7`LN}OYCGIL*vFo2^r-yb>_4)+v)M
zAb)^oYg$Ud<=x9TTf}q^7fl5Q8QpPq8Y8X=?NIz-1%e8f_3@U`DYMtCqIkftQp}*l
zd|S`Dw=nwTPlOoJNsW*hZq9n$*NfW9Zn?)`Nm-_}I($UP^n>d{O>8~Yy^O?dbAE42
zqmAj=oFuIla@;&{H(|8$#~X^(-#ZOYh43g|+Dni8PCnj$Cf9>MKum>M&*%vdD0}{p
zbm?rP6GU<6nd%l;MlnV)uG+}JR?V~yi~h1^1IQe7)1fSL+6h?JbCY!$M?_jqS9)Yt
ze}2{=kAn}>ksJ5a;xI_FA-G;-zSvY9sxTQ5=}o{!?RB$$iIe>&3}l7p612u+Vo$~c
zinLU~|HND!s(w1KVnt;r@n9P-s!-egrxrX!BzvR0jvR*&*s)eaJ6H;$ne{)F-nuS(
zq|wSW4k`txJ}=H4xmy9-pRSb!ws$?xJgFik0n0L&vuj3sqq%bw0-6l%qiKxU(CvFe
z-A_DjL1rLRO9O!|zUHe}qFsg0LY4*!?~<|tj;mrQ4hg1P{7&BWbkE1VXkJnm
z#BBPC;1l=y6Me%`OSuzh6Npc
za(Hnf(L$wkkM7fENL4AUXt`^(lJv98PL!jHYQ>6U>kku|AF(SSao*)q5i_6g!
zQPpu)KI!JFXfo%!>iU-CQBfVmwSt=Cz24z;x=j09-EJ@%v+zV7;vAjze3_G;!8oNm
zfhpR)t#w8VnIvhFAIQcrjYG$*3>L+g`DIBHOc|N%Boa(XuIu{2oMMZtRB2c;Ief0{
za5xE8(Vs7uu)>b8eb)qwO!hMYAVvrccm5~N2))~}>JN!Rj32;da|0bQU`&_*yew89
zV!JJ%A;5>AOP-vzA(oXD0UV~Yw-;7M+hzzu@ehR($R>H=R_p>1+~N
z@(u8UMVC1>U?M9ORYnEUV2^Wgyn*w-C+FLL_kYYrnA
z9g+MBYqnawMz4{sbRjLh4ip0oC8MordC_tRQpn|J;l{a+LZ;39bfuanuuDHNdD!0<$yq#X8bSK0bAp;N
z1uJ|Wk4rNeav$$MeM~s|2YL!voTiXSsvs!GY-V2`XvZYgiZI_xG@Yl#aMhtC!ym!E
zN7+h&rP;q7JK)P}%%v<|>sx=dM1-QC|WBkT1o
z>GIZ25%g=qN6+EMJW;ttggH5!5R92`06w1%B~_)y2FB-t4G1tq2#9t2YWavH?zY-%?;j9?L@d4@(lG&A%lPX*A1v{L=DFLGvp7g!CMSzVQV|e9R>&E5D>^
z9K-*CM|8MlUaGymqITUQqq`+c5Oxp>*;j!g3i_+`m6
z(Z6`js3W%sgpkuwi@Do$9qw|G#3NTp2%pX3XS%mLY$HtEvP@y-TdDz4uPgq3K~=D;
z6$JLX=J2%0sAJff+X|szD{q`fAEN43-&Ir|QFkzP+fvf7K?x+w!B%bMS?ems1)_|C
z+@00dj~{SzM6P5D@BR5(1(PC03&{W8G^no3y6t>%W$}Kl_;LB1;tE
zQR7r6v5+)cZ@1sTulO#h&hy$RjHDoPOA+uEvCy}*Hju-{=g)pj|&SVtcig_-1yLi0y~58b#two0rp#&@$r&?C!82h)s1y)3g>|yxz5JBz>
zG$Ud$DwNV7fXh_0H2qh3IyG~+fLts78L6tGSrV3dIh*K&r
zJTS!Q2F8q(=5?sWa9Nhnw1+B4txrrdU!t#}e?qOp*|h+-0nY_csJ%8lrXQ>##OZ^u
zRiLMyV5%c$??xkrDun#g5w|4y(6lQmu*Cum0zG5?v=SQ9Ddny9=H1g2ZSGz*K&q0}
zC!Rh`f^ALYlG=?Xs|#+7IAz%e9^lN#iVyy0l!G%&H;_x?z8s>bq;WODm^9Fy5eX001Yb0}bIvDZF>o1*e6cBsACKi`ID<
zOb3jpwk)fQruQp~xRpV?>-blqo^>lrlL_sNMnZH^6a2CSunwZDW!SMr*iu^C6+`F2
zLhDk%3n$QdaQ!E6#qY2P&@na8(O%mtstyKqR*Pd*I2p(f7CVt+`27iNB^~f8ntx4T
zM#zSvXAhDf3y^NBo*#cicmz4PvSY+pnU6uQR3hA}nCZf#I|mRUTe)k&2UK04TUWy;
z@Q`%ejtXZO=K?|dk%TNB@=sNgk4S3uy@=qgPQ8_M^--FC&?IK@FJ2#P)>KvCJL0}S
za?u>N;qQyZM8|0EVesILv3}JpgUztFytggtWPzSpRksG83NT+s*u5LZknD-xZo}1&
zPn&DKJbITz2rbikZEJ8{-pqQ0TaFPddGMk%CA9jWAs*lmn
zK#~PolMdLR%RmY+-ZtU#knVbb1u`<(JuA=)SBd<^J;tr1U~k0syT+4NZnyPU@;}YQ
zW4Z%YMEZP&>Aoy}NfO}bC^20L#(CfB-4Q9s`I6hmQLB!2|CihEwTawlL;;OSKFP{~
zJkf#kR;S~Pq7DWVhbVv2v$O9^1%VzuYw4Uux_E)hobD0~sLwQ&Uj#+?{xr!YD!zBF
z_KIz$s@ZzcV-Cv;`Ffe?UHQERcN6PV16q9^@FH)&z8ml}CVl4m4k9t{slF!2Xo4d!-Q{@MFf3-jLj@xE&g+V$p?TUmr?iRpi!HF@aDg0a^qL2ni&VtPrSN!xs
z_I63j@R2=b{qy)f@~DQ{?J;3A;s?bT8qQL(H!eGx9Nx|W2nK@euJfEe+(9QrVU?cv
zKIlm4C3Y_3xploIt+K%vWwOMsG<9l@I%hbR2&7JWb$K_tHsknN^_wn9RW1n4tzvd9
z?fL+X@YLQ!^r)7SiUC52F90JSO_RY=gGC^tX^{qGsc_Nh;6(AM(YKSSuIV`HMj&0b
zNgWvSZg%x&9Z?-NTKqkec>0eH#jJioXuM=;6mDT4Ckm*Lj7}(9M^liim`4nmcB*(d
zQ%%UC1Rk$H47EjegR1E%mBJ$z=CS$gYODI3$I9|(GbT76)1WJ47%i+?42uw6O|y7?
zw!qv2R<4ayxWT;zT35+UE`<0l8Tb;A>k&*Ppowp2Pz@$8KxU6w$}`R{ql7}mP11)l
z&D90VDMnaQNe1&rMfZ;lw}W@XxbYUJCL$qTAnFFBqr^!*OPmeUY5e<-A*Sll7~_v9
z*cl2wcINH#ttss!1Inm$jKpYQ_Uttgpc|~PS9(HRYd`~ed8(r#mi{)BS%G*`vE6IQ
z8}l|4JPE)=Mw5W5nZ4;Jl86|mZc9J-@?!+601)I+&{yMm6+OokuZ=yh=k{pB9
znc)H3{iBnPqz2lLfJHa_J013gfJ%A}9#U-!RlPw-zP;%Y!u#&{TG
zl6^sOCu|I}72`bx8z}t8+Q*w)P63mz>d$z))witjcYR*G;VS76Q8}4%2P?k7jz85M
z8=!-#dJxiBX{pS|%C%IC%-V_E6e?LZih>Ehjnu?pbVf+QPVdx0eyt}52b2Y!uC+)=
zZo3?nB_aj>(7fo|@HaBe9Qc??>z5^AuCycQHCR9D7sy6idXLvCFaUdwoZZ
z$yW1DV&VwNisrIAxO6s=b?;A()WQYc%H)cY2L2790ytk^%?mqSsbD*3hn3fqY5$SI
zAj~^}`7Jqyq^BPLVo@6UC?u%?iw*A{yW6Isizf#9ym-x2(u?)Dp6JOS|A6;P=*f|5
ztWc#I>GHO3%X*dCPZT`-;AN=<*V`qotmGCpdD}M#xLVc@C*{^~O<-31i>dKR;+L+G
zM9%R5Dg|=CtRG30`S+PmD>d3h9vK5%Qw{4DIYL-rp_$F(emBz&n>uquB^RRnTjm7hTYwWxzXC&@C5U30#O}-D6)U7ApO0DX;)Amj
z%$%6L|JczlJ&jLS4oh!e{W(Liu37yzPLbhPHh8f#mO2e}G()LE;lQB5{)lz+cmt%v
z9MnJKVJWx%?2SD~5og{l^LcRjxuM}?QW>Z^z{DUk{G`hz0vBoEWFWx7Zt={oRaD@*
zey*FpcAD^OY)4f6EX}+AI`L<@9v{;k>PRggiB&9~ea0V=D&f#(T+ufA7@nUAUph&w
zevr8QITog|UQhch#{xc0oajpMXDG4>?{2$$7i0jvX!Fv|F~2VsL(t@iCA?5u0}Icp4o~bgMS7RDzk-qkB(gcj$;sFCFP>2q4JT&j7iksA_`^ds;n5}bY^xSsG2
zf>>8i;#K*wnR#28>(!J++RI}NqSI4mrZ@ji&2Ot|z_66{=uQ%#u8Ruc2DP&CaknG!
znHQVCCOIWx@2aYp7>g9RG3vEZ7mK=HdNeEO>X8GeuVx2Bmte)X1)l#lBcfHV4EO*J#|3b}b|~8-?R)
z9QwqkaYK*c_7loP8bD2Bum2m~Y6~*(+FSkWo(^Kt4mxcy(i*j~=_rt?LM3yvc%O;9
zerj%=P_@-&@Lus}lj!jA=|yJg6UmiEq}v;)3m>L0zZfeGGIvGlDxLbYeSMfmp}0O=
zkcH~aQpZX6hIhdFlk@ilsNjBU#`6`4cu(&wRL{-*ZhPx
zb!tH&qZUo3X+%0W;YK7IbtmbI;YFfC^E4kpiU+S2$Wl-J7*hV6R5pkcuD5)t{oHt?
zY%%EN+w|*%p2O9Fwk&UsG(&RbeN%Td=-oCG_H=vaHjVckxh5+(+(frN0CJ;b2imv-W
zt(4+Hg`VFkH~F6(pF-uC(u#@iuc|xLq`iE_X}7k>yWSFH-EiP~;&Vi(mVIx&2(D}r
zlXg*5p%f;K$iV*li^f4M24_%GE$KA4TZ5!!H31HwPZS-zQq_?
z0Qc%I8{r{uzD$exKX22Uj%64!2CEmPef{?qVqjeTI++mU$0o6}I*B3-
z*hLcW5dHiqku~n+{a05BVOOUWro3AdE=Ie*XO7k;7`y4VlUzLI^`GBCY;Z?MrVBg!
z1;1S*hQ0TeF2>xk6)_CbbBJ@=Qzr9TSVTBg{d~nSM>9%!H$(}q{C29KWh3+J5$NyG
zX4%y2;I(F<^-6@F!%OVKjz@j^uBFx~V1>Q|&y*O06~%Wd>n=l51l8Y+)5>gnc?MPg
z>b`d?c!aK*6`Yj@Ht-xwe^{qh?UTUTmSg%_dKPnBq+Q5NR%qmCQK&sbxcubgj0k^%
zZOLg@T{p}*2&^=+`x~WNo?S^}k?*%zEnJsLbx~FFmJ*|z*v&tjoKlBxm^2?H?RL^;
z$6k+RBCJntf*L^K_8%VL$ewV}VTEtczIo9sw2m+G#8ddqMI!{9>$urQNy+Y-HfGls
z`@kN4<4w21_OiFwrLO1eYmp1qfzJt=B5J+8$tzLWLjO)pz<3VY9_nW(5@yT5d!pLhG+ol@A}f+y)}gR|%ZmU^fnw-&z^c4@32u^=3tD%OiE
z<`{+e{w%sgMjRVSxWS9+vTiVjl~RZXlr>JYq`E9q&zi>}qL520&UE8UvC?WY`$)
zrDU+CmUrc{)bY{L>4W>PrLZtp;!Y(c+ix{H_DQNyNj*D97#
zy;9|1A@G&w%JDhDe)Op6`i)5zsyrpJGWwSv4*|>Z!6o$#6w(&>=;_nhC%v)RK=QRb
zYTGWq+RyFVdl#Ty;f(Y1#h3%iF8V?fu=qzMb8ly25ZaHqlT=
zbZJd@h`mB@XHahu-`5SV*0`$Ff^k#Q@gKv1t&#LS0YQ>yG(628>hfJ%H^p12+uxnt
zpI`p{J32f&%qUiA=P&S6Y`!s5xXQ;_(s;)cx9eoU?%H=WcUeW%%fM@kwWj*+qRIn&
z+Sw)TD>HiE75fK;=4iAM=s(jcF(f!t8=@QN($kc?qrn8+-HM%#jFp?&j`|O^rS>ONTmzDk3HDb9Cj~ms>)6oWW$K+d;dA8#zR=egiE!Vlu*aC@ABQ(5yE;2f;V9CQWJHxj&(td!Q>FC@fm_X5LYG-L75ObgC+TbL02Mcs(|C%gL4?tsml9J
zMVr%nU3sInRTeNMjYp^K?ZrzW6=#&&OR0hOx3jU3Q7gBb$7bgb9m4}rd4JVD9@lXw
z;ecJ}GmwS7k=aJYv?ThPASfse?lYe|(2xEdr}(R4CGWYESXjkJtINtCaVbN1asCKhPhNjdY)#W#tuB)T|XjOQjffTEMgV?{WBi~
zQ8U5-j7&_DdYdt3fX@Ku3{V&Ye?)<~6jvPrRD)UNiKWN641mA`N<`_=M7CM!rV4Si
z(7YoMM9V6XV)FN92+x;jL5+B5LgL_CPUeKuEVacgcF|bHYVJ2cb#Q(B!-U@wLA{dX
zI}OarDLGNfDRA8S$G~ZKmuju}k?RtKvDm~d0>bku^*|hq0fM7>mC)G4GJ?m>HlrT9
zuv3YlTccc8G#U4pdI0gg^bnyG3#U(=OH*DTsOMu$g7(11otN_hshDdXP=n|uNZB^B)sQ&*bsZB=OqZRfd
zuxnHCg`#&Uet*9SnpcA<=lSFo=YETl=6o=#=`=CW>a3|_Hd4e43l4=9YN&+Gq$m3d
zF)A5LvUwHjTawtaXGO_y)&NOjv=Q?sV77498UIfCbCR!X-r{%(2WNpFzn`w&dJmG*
zWewOv1me(1pYEU5cb`fmSz~ElJKgHJKlz3JgBD+Vx9G_{pQmO(-Mlo|^Ik3XV*df9E4@Opazwt#
z!DztfUIFvh1WJ&8yhfFux*CsoeQk2QibP&DuUUnhq*2pH1XaHm9&>YGWA5GGpJ_PJ
zxv7#m&xtz^ISvy95%r;)O_Z!e;fYDR7+KiQSI(26#CT8p
zdeeKoK?nqvDP2?5b5TjG5=D`f^#p)%y=1hHw<>S)nzNwIFU>}4-Rd`eD
zBlRThE-;kP+eA2B7VWK8v9F|0Kunb;cI&gq6PM|u;Y{pGEO3Q%WP;tv-GBBNQY&m~x@UT)=T3rpK`w9lT%2RGsj_KeU&N{}&0)5K=9d{y
zz9aDyJD#HO9FMArZ@2>VBRk3{@`N532UAh5468*|{fM(t+npGS<;MJg^gWa}@jpwg
zC{2n57n_SZCOj7xypzq5S%dan{|xJTkEPDH6o+=Nerq$CGxiAOuCscdocu^VZ~Z{5
zBrgHR4E)KAlWLtp1XH;Hapa<-9+*jzgQ}p+fl;KRf?-|+RkO;XOghD{pd26Z;(_3k
zgczt!Hsg!r75KQZe@e)|r8fTLI)>mu)@7Ya|daHbULkgFZSts-`4vF4z>6#
z_gcASbfa1@RRpN7YwK`RE1F0S_95|cR!T2w?qiDE3`wP1S;T^wY`YklD6>y1@DaKX
z>D<}V*^z%a6Hdl-M2sRvCBJ~4RoOvQoK)bF!dx0@S6$JSurMnE7X~YpT&}b^#4%-W7Q9FYkDY^$K@U6U^Fj=Zquu
ztjw5jUx*L?nhRGpGj35^DlNAzsTy7)fUP{GcaJ4Da7sG>kSbWEcFjeJp~0N+2Fhg_
zY`37WH~j8xp|-GwwLbR#j$SHJU^EQBR2$O>tyikS3V|4^u4+~!b=S*Bcm10*db`0r
zO*9(^ZKfZ~P%%7ZWN$zj6n-NZR_MxC4;vX9ko~vf&u1-GXK!7o4v7nqyd8vZ;(0Ms
zG2@XL8hRUkb#wa`FNo{JTy1K2P~Jpribje}(Z>8CRGGt%E1^N(&UOFv-~rsiB+r^W
zbWQzhOe}XRr)kxvXKj66PXpGz$rn=pXga?t*D)=)yA1qy#Rv_3_4cGAC|5bOJbq!!
zAo|0oxyWE@4L4bhRbe+XS>CPJfpT3*?MsoFb4i;~0Rt3BHY8I>qoQpl5tpA|;cI>4
zbga}jIRbbdG(5oWx4!|%Zj^1~)*Cq*%rOosi`@p1O7TFE
ziWMuqW9s`kF`cJ#wU8Fe+0~kmJ}ZFG^_gqf@QE89kHj^-ea*PzOB3(<%?uVCAJ$sm
zS-LWjNp;=&wD)l?L!YpBqsYCkR|xzX99O(Q_J(#k8tb(YMUfcn-Ha+@D(&P1;U=tS
zAOFu*Xw=&8KS#{z<|$=d!bvn$NP!`+(|>ABw)v5Lg6wCdmyv1g&teAGAVo>iXE#^8
zE(~fQE9~21V!RioeOq7&lqis&XtygA+w)Y?om}Ew6=R*Y6QD>yV5J5~ygCMZZAFd_
zl~AN5Se(`GLWKg0BkC)dr3Kh`U5=uf{m8Kt4##eJUcPW`Af4cnh{k^hy{0Qt`TFd6QvT(Wsb)(AL58cqb>esgS#r-WnvA{D|M*9;+$_0YW
z6xNK`>h+;&r{uc&Z%IsAE7{5miAI<+72c%z&D*tcpqOC=QN4_Wj{N!b2;n=4G81|_
z!<^^0CR>EV=!5NB^6L)f?CRr>PMG=Xvo6)=a1@DHS2~B5RdZU)UOr1eT`atv@z0$e
ztd}aLV|^ut&D3zt5qRXsMOpfnbDJ!5bTA1Z6lWCmy3}H>QYl}hv8CgGO(=N6JM6Y=
zA1MS8fYR!4;U9q}4Vm0vGATa_375d-QV+ZM`qEq<+MJ{aI_=(XsVADluQSOB>?Q96
z+XBP7jBX)K1
z1j{co`@OAGic851kZ+&FJw4{ZgM~`bPmijRd;+Ipvt@sAexP!1ASp?!aboSM`SpbS
zaCdH;`dMB7g4{Ot9~a|p5SFmc*SwG^96;aR*KtOU&JSQ>?Nf_s!mDr8qOzS@g>)w-y6f|`d^h_{oe_dy0iqyl
z%T5`OZ4mKdixjh#Edwg*$tkOm(9F0FdBTEbyV_@cT{B>cA-HFu%dm(2dz`Leq|lGg
zy*z=wF)b}A2OXqO
zY5E!Ad+R6OBp}Ib6VnYOD>0E8^r_rp1wZ5~GmbdOOV-H~av_p9eUAq((KLfN=TJ01
z&A}_)eB=llrXDQJk^p$7EZe6oo9f4`j>CyaW@2-}6ei%iS+U~|ugE|W)1m3OMY`Il
z_sdHD0!$M3%+e$1Pl8_4pD~IjZE!dGtO*8(e5o|XmD~wuP$RJe(1C_kaaVbJDyIng
zQb;B+w?VNH;^W$_wLb!kXQ%c_vW_9sqkjCR6uSPV;VuT%(TiGK3-}l$UbW<|P~3Y2
zVIelMY4_r@`-+=m>+2qwrqtCRsEz`G{9Tuz5T7@w`|Y!yw?99HKHj5-i77+KoR~_q(XhykxuDr)e&lw$I2kHCFB(a3+
zCF0~np0gZSr9i3@d6n(Mr0Q)LzM-o%(g!8Eb=yu!Ihj$GG2
zy8gNsQ>l{KFPXsdBL2X?_7)}=6Z20-0%Y-EQ`hl{5R?pCGa)N;GJ{Mqp`DVp8!WR#{VNxBly^Tptpi>!!n_}XKXoail#=tWLxs6(X
zpdu|14qF*qkDP>6-Y)p_NoMQ?i)X^zd;WQ^5x7n1mjzLx>5EJVU)~)O7bh9d;rl0JqSj+a?@fircS;^nTeDphJdIqT1!t%`_Kl%2_mu8J?=xCpKkeXqIdeYkxqNAE4M$(m36%aG
zXzcP6zTOm@!O%o09Y=$-lqU##F-WA-mXr)~BJ2GBLN#zs%bf$=a{q8<_mo+gg!K(k&X<8sRVWYhIO|
zcWB4N!??EN_KD2p=ohhXNbSV3vlQ@CUIqyq{_D=-h+-4H>e(xAJKbla4JPUvvBwP(
z-j9_X5B58^$}-ojvaVk>pZCRwh<`xJOZwG{3;LIhVOv|`72Q6%cuIMdFr3hDs~#BE
zO5}x#JqeSdfAp1n@Jj6sTa_zGo}ZoUl9H2XBwVgGQQ%GmAYaRirEm(egw2Fye%~y(
z|BX6N?u^(?eWm%czGr(gFJf>9{Y1w`(8N^#nDCvme=6D-af~${vRsy=rPBR3n(M~^
zZlXD#5Q*fS#P6hJHkLX^${kj9atyRndEm5}S~(n5Q?LhNg%rH@dHm)|FVx#i1tm1Zz+Mo0E;Kq9rB6hFT@WgE2sSWEc!nL5(^)0MNCWgO_}|7y13DuNiAoLa+-y!9HfM##
zLYcyJx|j@2U0uFrWuEjAL=wG5E_6~+fn+oRw>~;_sN9fS!4DHC!kh@L`$y>YZ<|8`
z!T)Obk9GggHGrhfQ6aRw1=$r8=>23~G75u&np(WM=d=ZsL)^S)Q#h7c(W<^_+#QrZ
zcA*>)T4mf(MU^A&Kv!#)Pb!+)X;m*%$fJ|~)B8eBJ2u)P7m>TyR;XLmJF28PYOg#X``x^JmVE-Svyq#!Qp)Pv6}ZTavrh$h9qLE1PtwMW!ZT2I{5X=!R=DE
z`1mKVcFRSu9HzWjSKPF6-;C?Ef*Pe~G|*Owa>z4B5HtSP2dgvR?FuN!KSbg6S|~C@
z#HvbhnD-NAOOh7WpDkq)m_&Hmy}&O`?67#U1#F2w%ZZ1b1PM{Tv)eG?l(>Cfeb1l@
zDz*fcPo)M?y*um-mGfpzF@X4HRsx9u(#-U4fWZNiogH!m$!sF*q&sHMLyHdr1?R}(
zxZ720PRCc)r0+((<;;8)m{#!WpQ}yz2DX^{b{JetXIX!5tV*<1{EbprV~~=U6
z&+6}9f1h!ieh+OiUnIU(mMH$Lp!3DOYG!5eDL3R?{H}?D(X->E8jUuah`dUYXr{P@wYg9W?0L63+-4W<
z1`#{F+;byq%hzd~`ct+QGPL`LIN18)M<9YV?4vyiYNu
zTISJ0u|-TLrv+i@_6epH&`UjT;2Uk6WjLJK!OrX7MAx-01*7g|TwipG^C#?%_((O2
zA)l|DWDLI{E*X;i(h-+?-j$GTuY{o@H5Ts|7BQ;q67fUK66*P~z`ya)#{}}^`sdL$
zL&25m2R?E30`fotQyT2Ozmp2Zh-aPP3=a#C?s*)K_dm{z2q>G1_IV+^D~tpmG8nG!
zppk6i&hd2rWyAwBw8^*5#}dQrJVlB9(2@PXQ6VW}(e_)WZXsh)G1^*FjQ98m5N&8@
zC}l2(7`*YS#Tl#9S#ge`$5hBGbo2V+9$v5jtpO4llaWV437EG>6V@)J5h~`pA}@w1
z2K0(rA*?scqpUlMP^H1lcj>_Y2joB-zhETb2q$rhLry`H5aih0!a)e8E7
z<@u(Icp{eTJ8tOtrAoD40^=Ih`QvlZK*{;3naSzdDFg@xg@=LXxhX+#giPSU$t!Yf
z_V^rU$y>>d(J8fv51$2IXm_qUw-)RP?Y?L7_TQ`N&C`ZKHmi^(qBHp$NHhCtRdNNQ>-Ogvg%JL=t2UCB{zb+X`EIlJgoOMq9v{o>DN4m(5Bx6Zk*&ySEY`Hx^`dls(&6pt(!}qels|R{^m=9hF>Q&9N
zi=h|wu&aG>`g3W`wFTq&j8lji;T_@oQVAFle=v@81n+PK_yn^QL8jt|6Nv+{819i&
zQWl2fNn@EbM0GSC>j7#D`Jkp&(jjFpn)^&TP!z<*?Fl|oTg1vp7+jf*RgG4X;w&O(
z2`^?y?h}sW9-z0ZVMup#)CX+~KGHnHZJfoE-wS6sg!2&clZG5mehySlE)7JIl=R?}
zEZ9e|WS-krJG}EFA`uyyMnqB;iz6jMFfPsIxCg;UWuB~5lnt_=cEsie(2JhSGM62EP4pKtj@#70dCp~@?IrjxJNU(5jL`RMHcq~97WVBKN%;b
zxs~=%-gfO$EuOPuSqHZ-ZDfnSTWva(y3PwK2s)FaEmv~`q|_RWhT>IowjEdF2pubI
z#&cG#7?c{#pjt0Lu^G+uYFW)wOY`_@D?exqe2k2I#s0k6pDD(&Y63V4SL{vcy=nbu
zrqdt&E!jtY`?>JIKK=Ve@KHGOJNT%k+9-U)%_fg#Q%Ct-=L*0#IG!++xly*LM#Kgg
zD`-+hc@Kk+e1ULSFije7oA*QD7m5Zi!%)rLZU*(iq^1nFnycCfUIl6di(?~xqmE>w
zO+@kJjUjKCu+`+XQyOUT>PQ*7SRZlSTGg(Ule+HLn>ou#YDU(yORcsV3gxLqe_%w|
zk()#(!|i%qbo>P<)k;9YL!EgIf&dl}1L(jDA55Vc6~w`nMuC?<%?B29W*XN
z80cLK7I6U}bZ~?gL=uN}NC#@+6me;iNR1|m%MqS1gn#PUXYhxOxULALBUIN#F+91M
zC!T(aiwdIQLx3~U8jS=dO>PN)E=PE7fSZ)0Bu#FfD{^%%T8q*o7XC!x9!QGtk}Sem
zbOLk}6a`m=C|nm;4oR6CAfmLDB3uYc6SJbADhiK4w(z{<2@&xjThPf6@`^BIDd})&
zPVq!iI`|WSEFv4pa8l-Gxe)n=LNKE6_}mg93C5v7DrdP{
zxfb_H@o~sSaogjgGG1PJbYN`c#Mv{Q+Vh}4HTIFvFec4O)PMy8qk|(Lo!Yuk
z!J_Iu-rM+umPz2W-c~~-E6pk{kRhN0_W+}^9wf0qK-_jTs1bZ5u*ds9>JuM}#?=Wp
zI-wg>L%?Y6#Icb{sI)aUJ=z*3*&2tXdPv}j*+~)sq@bB{qud%+TkwgMg*Le!M+8Fflzm0|U>hfuvK%c+9cc<1?q8I5~f6Ze(gCXjTTNMv>9E$r4p}
zY_L5sOrBf5O}3M1WVRBL!}e0F+dYC=qy6up!t
z#X%vG)WC=u^NLPZE3BWLglijM{n!x28q~_2iu17kbl-vGvX)_$1GiRIOF!l_J?TWo
z)Il^OaA8Ea4SGu%1x~4LX&e(B9~9p5AQ$9^$hwKV^h+(?_$L0~AUrCK2T_`1!$biA
ziOVI9rqtSplqt;;qyo@DKWdS}XoEqL!i6tsW)8(;03rkiz#WbEiyZFng%t6DX*flO
zi_K50eZ9#z0!QMLGgX4LNl}BOA+%T=>b^(f2zMy>dpHrt?Tt3??vJ*{<|z_dfiUQR
zGU?DL5*~k2BL&(&gW6ju^NdcV>{S%5fp@gHz!^_RyX!`?Q>mq#LTG@kFrB&qRx;c}cM7ID>DOVLCnc}yOPCu)q2s5u{jPi}~Csu=t)EZmcY(h6o$
zchs(fR;ZO)Ilq>+)Fy;6&4wUB$(&nOG->#TSIb#^;?@gJ1=PzF)uKN!wf(f?*9Q%+
z5>#8sLNV_KMhLZ7dD982t#Y-c8BS2CJ3-lW!;C@A@q1F55mdceXL-d$zL+sw(of_q
zxYG_>nxp!rLBnLhNfew|G(a=1gRQPi=sB8JQ(;7oq_sUM9L;9G+f{uq8ULu
zUFmx67k+Lc`$8rUC9@)jQ@JB)m{rLhN_M0tnx>8P<+X%iCW{t&Ol@Oh!)?@3+@R5l
ztOkC;R;%1oi{w?z@3%fU=vAoaW!?2ay@bYV#7KkSe%Kryrv9sslW6p$SE;0RJ*k%R
zQ7fuyp36@OmtQ(Re11?=HW|voyTz-kYzH5?dOWX1!|3@c(8a!p6w76J7jTRlMQ+MW;w!0qXQBNX$j~M1|-6hbYLd#2izerA{>Uo{Y0&p0y{jpABd2<
z<%$v#;S^y6Hvvjg#s_~6D_~+YtVo2nt_Y>f+o{%8^YnQ~4UUhGM&lO+o%A@yLWEJg2y4PLZHIBX@|u+&})L#-nj9
z@Qz0&mRy%uPe1o8sc|96NdgNBlcrpk8zUIWa_6`_J_>=!SPF}qA#nl=HBvNk!%`O9
zA#s640uYQ#6AVuRa08q|CpFG;1Lw{^&Dl=vdC=bv+;RvwHirj?CdLNGM}k@jWDM(N
z$PZ{39H#))O4JkpG%ARRw8w^lKWIY?ROM*r7-$209GxB~1*9JBMuQ9DfQ*F41%2Al
zgl=2}AKa;9(-D0R432@K_2G%3>G`SoQ;H@>r$%ANnT1(IES-KOh*7n~tPOV{iHHci8d4_=u3Ei0Jp>BO?BGiLYMYt0wGAP+-q4IpRKo1{dT~l8wpY2J;
zfj=ma_Ngb6MuZ4udGLg;rD)6|A0ec}w7yXr%(KuWb0?m>=ix^Z9
zr?RuE6@L=ZN(S9Z-V>d02&gwypbqZzhW*b^R!qsA-8hiXninwxPH2LVUX!S?#us@R#
zLoyj|S1YaYG1bOL`)-pDJfl;q!p-%O;oyH`>Wo#YM3X0+q@j2*QS{=5oA=5{vgoEQ
zKkI}Azk-|6-L&CZrG`~%7K57ZRkCK#lP>n_8ZNiQ|2;!BJdDAX63T_2#wJS9v2sO_yhSfwtO+bN7fzhO97o2k1P*;rQ%)TsF
zQOFo8xV>3xPt2nktt;5kw+zB>0G=ph?|O)1qCqG-KZJGDWq(7IlnjLye*yf)3>-
z3R&J%vys$hhQ+wry@q$-kW?_jQ+26_y6aM%sAkkCzT)^*@&l|44VvXrE*b_6P~yXP
ziyj2JA6n%qIiJvUBPjWeR@$=izV9}hNz;TK#rl}B)lM_qb3t}B^wbKJ#qvX)iAWOw
z7SJLHYyk>z39itO@R=B>aA`F-1DYWW$#RO2BqB6}r?9EG
zL?;aVL_0;8C!T&vsFXXwhrqN=T#ojO=m@dUIg5_J1j8jHSA>2D&!L2ov)mHIqx1+L
zg&I*J1KEVIBSj28qT>#Yt4Yw@jHJL-crFxqE>h+m5Rx64P)sZkNfb_T8{7jK!Xpz4
zSDr;4kfh|Eaq;P;gDDeIRidE_u>oZpMQ=gf;Gt~$vpydEdo$LgdxY|ZYdqI
zj*wiD%;Cm3grUinT1(j%5rW}QNGSy=Vxm(<2;q4I!bgv$=)V>1MS>4exD76P_Q`YH
z3BkCHPVITn-w%WxabZOA9a!wnlEH;qfQGPMk?!z_;?-Vuw2>fSB^vuEI0$ekwyTEi
zu_2;>9i&5QDv?G7$|Nw*1MUEwxH2G8kVWj5rFt2B9G@9OV8_|xGjL>NgB+cln*x=B
zY6v)bW#0)qkk^&yP~jji0)aV%77OVfa`t-#K2ZIA-IUQ0S!sv@pjvb}vYY1rNYuUg
zfyF1O>StG*BlF0OR()WQEGQ3+kIpX0M)FgGqiPJ|_|(Mk=ulV=28LSWlVdZ-W+tY_
zRX6wSBpCvE!+Bw?-z}Ac%F0tr&dpMe(o-3&J+8J=
zRBQA^BNhbcA$5vFO0d+ZfUQy=D9w?nhrMu*5xBbVIMtF`z9-tiI&9T7-|5S#-f9Rk
zp(}GEVIV*Jp}@G7%UH@bnb2|&2CsYY4#)tZ#D*uV20KC<_>1j|xLMnf=`VTL>P)nc
zW@!im(Fj3HVZAPtMxz459fQuBQ5l;k`NmnuoK4MDbc@@>=@-dZo$}9zBCZtaOyS0j|X5lniBO^l-
z6J!N!2U|m&WDa#(GD@tH@Lv}hWuYIMXRlJBZRT>)NsS_%)MPAz&ToXk{1{2OoAc2C
zN3~XYTGz<|zft$ax#7C_Sc{BwBg@#{^=ZYE4@+)exTPkM&
zj-_VX@Jk8JaH@@bp37Ry!eQC1P})Sid(
zN4o$Jz!tOx=zsz(!l`IZF2q2S0jAIZ(eywPAdzs4fDVvBFoXsLKp{LJ0$~uCL&DS6
zkOCY7f=D795`arcL@tdFz`CE^LwwN-3jMBQ`=LqCBZ2F8(|zSK&_Z;Vid}&P915xg2M?
zC5ZyM;Rbn*LGZ3d_GCqQsC_EPlayfkDc>za~<(4>0sZkuA
z+Vh~lACSLdf}*vHP`!z$2`l3?5^As`KRI&0IouwdR$K6i4U!T9{y+_ZKV&qTqB}l2
z32M~ZP^OysK~ngj0Dr)xU}Als-WqC69h;gxK07@>J$GVmY#OYYJa+Qf;OIbD^=qx_
z{K+}+QKsP3+f7fcVB&j`-4T4W1GRdN^e>AIl6D%!DJg3r4V4uri2SecQG9TfLR=mn
zq`MCv9k8-e4%GInp-agBLwr;>78V1p5|OU&k!Gn{3ah2&U~6W678e#A92;)5o72Z;
z<`(8=kIl@^&rZ!u&Yw7j+a4Kg45~e5)Cd8!D9_mN1of{yJg&g8IjFuiO0|lrwZ~@b
zZPklS_2N)o5Z#@uC+B9Q=qcHO(V@XHwStmtjRWXI>XaiuIXXQKI8uldC@6{EsW=bo
z4@QLNG*9h1*q2Sk3)y1m19o1$0!sFzA+4m0S+pym->BkGcnl$4=^8hX^_#Ot0z
zcqyM?h=*o|rX^@Lpij3}B?S@(
z(fZO!uUe-5P>YIQXF4{uNOP=$ZRV|FS}#C~aHRBEC-PZv6L3uAGVxr71_>AvE(HEa
zP_R!F(d7^*>_{>pj7WIF%DAQsmc2B+5kU%B3Qgj#(vRj!17v_B3@Y{-Su?4*@x0xW(qlPG0cFnW`!Dbjb~KP9X$Uf}
z*46=EgpbM-e587(lZSyw@R4u4Z^l9X7x;+8@;rM1
zh>R7qXie`@-d1acN@b%qQppRJU26~6q2pIWDp&i~5nvn~L!%%~1BYM=r)VPp5p=);
zAtb?w1-l?J*;zWENsU-w2WJThyFeQf3vw;
z7FW)qa}^Y1|5=qRyx8bWwXPu17QVQM47ZDjr6cvh!I7yc#g5SsFQQ92a#5Aq9#G0v
zx}GAU6PTP4AHoQ4$tiO0#F^6)hG&;xB-l+E7oBGz0C8udu4K77aluN-LopN5rV|oZ
z$Pa<=$ab=qlsQFNz=eW?($G_OB!UkipM2&#iBMPsrYz7;o>iMAN?gJdmupc0q^lZN
z{0Tr{?u}TT+Vh~lACSe($e>6@i^+sG4+S6m$@)mte%Ac(!f4&c!SP|CLpTEgBH@f$
zw5rSS#0c)h>?ACLQs#Mwn(fhna--B3tPhU0C+8-{rbnAYiX$7*3gH981IJE8yR*zs
zA3r{Q`po?N@tK+VsiCpK2o@C`B2Zm1nr9#aJBr}{U6CmFNyL{O;ZTAp`{LgECiqMA
z{UL=xzb(9#zME`k7B=miytYI*{2rmnj9^#YPgo1;?b^ib*pttmJNL{Jk3W6(^tsc=
zPR;}6WHp&dj;Y}RgX;5<&x^2Hk&;Ggtp<5TDS(v=r;n5Q@E>p~!yI`uo{?V^x@^M(
z%~NoMCru7XAB9U$9I`JC3WuuyI$E`d#EC*M%C}Q-9@d}WR3aMxXOhX)3NQ4Gsaxd$
zvcVNnEQTK7sQZql_Kz;(!h*59!ZPp?$fFHFib2pF4N1ENH9{U>M{{h{tJetJr8K~c
zYti-qMqZ^NrZVJkOf3e)&5$O@LNi19AetmdyU1D67aPTuRdt`FzGO
z$k>#wbGJM@0T6P7d?sgzg3d)H14)M`g69y;ws9dy8fKVJgqjR2@>y?0Q*EgHD3WO~
zA~`86h)72{q)5%rTWWQ8L3~`U$en<>pcr8YKq5dqx?GFYNP*(O2Y;B7BH+e|D33{I
za<`q@^AP_42qaUq^0u3^94l02$h;LM@=mhgq;*est7g#1nISs(h^QqSGetPk3i$oj
zol@1SHPc1A4@im@)+V}FZ3p!sqNH_KiRS92U#<-_28W71x#t;vy)R?u-5L}a)7*?z
zP8vZ%_xtiTP#Dwf{(_>z?-!v)A;>)`^rSLJlj$Rg)IL$B>-*$LJbnN`1PTQu_e6dU
zfMXXKBk2=4oB$|AI>h;{dY(=l&SZ{cvqy6|T%;$T@69WA6zQ^~5>4w$jLPgfIoC^R
z${0zB;F@7s_X59K8yp@EOJTWM$?*&JT>PwPb~ddz?Rq+&!==46eJ>UbqUGm6wdBnp
zm6NYi-Z@#Tm?#u7Md;kHOKQ%URq`{Yk+rS7t2(K}_7Jd$xXosXOII_$T0!l)b
zcD;_9f4KMvC_oZoz7isVW8fYr2c33AAQDf`f)0d40VzO6+8O~M!jldmArD$20>Bxh
zz$q9=Y+59O4+%d0)RQ2QTnMJYvrA?uNYr?#WW`5}n)nc=>yM5<cMhWqbsvpO@Cdkat?nsYNlmVfE2nr&gu|}jPv(#z
zq`-A~b}o&loaJHhC&$P`uun3LWbs7d(xk~*m`^S$w?RlUkffgf*^69GE8Y&(vBxHuZRFaCE#is5VfUIW~Fb$una!6HbYb
zcx7@BOx%x*UFmuX_I3T`5ZTXp50ow@DnsL*zF%ks;X;~27y?1zP*UbBSVqJsDFQ3F
zl<-j)1&9KXT@lakiXHe~*@x03(?+8??;OI5w9BQ#nwnj;YcYm%2BR}pa7BhAeCL4MCHwKoI>n4_Aa=dv57c@xYMU8lipyr)
zdadBOMi^*;uLnM3o_xo(waqv$%cYo@1qt~{zVukeUeXnj$1%cK$29NXa|)3H-#G34XKrziun
z9Om3&*luKPGkTe*QnpmPP_oN`9lUjyHO-MDWh=nJhkXNBk7Z4a$~q8iz^Ar4HF*Jqg>9NfBM9k(*lBc
z5|Km*29FYqtKh@^5SO#u16f31$`1G=!?`G72uxDkGmpjyjY;o!axDKZTE!0WLo(ehIkbFS#ruN^@d%0-1rKPt6m!+^CcqRo!!G
z28=K?l!@*eqvLm_i;UkD0mOX*%yq<3u&8*^t%ORVe(G;YXZK;XX@Of&8}K8vTeO!Y
zHMcZ$)OH~IDYJu*UFmS)9yspz{I00zGDpYrWTi$b%2UsthZ^Tj91{vhhv7NRpxJPJ~KsvLCWTQFP_`9{L4z)xb*+@@1g>D3Xsnw#T>Ca_j
zxg1TS4DX{F2oG6mZ#SP?3Yra~h)qT8bHoM3#C*spNmC@D6}W#fLvk}mqAM!pJF?#f
z^Ih4GkNf3;`1nmkl8uD)#YicERd*p04F(lECHI*!bY-&L%P6uU@7QD%Pv=xRYYPZ9
z0(Q#&7cJa_4&LRX#doOBxZS>NTroG|l8vMw3@UcSzI3Ojo~u(*T%B^Mv5vE{cGpX-&%(4b5|jOaA+`Oe4eP_5e5BsXY(zFK>Ig7l`Q*Hydq0Vt6$(
zXn57Zf?e*<6nm0-!LDddMLMs|poyY6)w~sEb=$8t%&?NPJ+o5n$>z;+m2_gcf~!U}
zR=ipRJz3D*pq|q#-FCo7uhz^vm7G
zH|JP<_L!AQoJ!to$)Y@BZY)+R+!#QKVpXdI=+`s?SbQT@9x6UU1E2}e0Cqqav>;Fd
ztqDpObOe$JCV>SR$rHlR&_EK&7
zqLdMZ1s#&5k{UR{-QtqxT;=SOPjZT62?JktYR`lI)YO^r+37CDgO9Kgo`_7B5f{FM
zCdqMv5qMx^NCwFvf-KMmkO8;=A}FASECwk(o&uMR!6wokRrbiqsiB#<(UDQgKNuRW
zkB+rw=Emy-O*OL6b7jwfqHP%cqCtwjr6#x9c4#{#$1S_x
zNXhleG=plXZLd@cDz%_e<#4|QYRF?HsMNhu#fKf0CohWtH;ScXU-+_Du8KHexg*MK
zsUQ`2-OrkC1dH6EAY%s{qfwOzXGxh~&hgVH&pdu|bbM%XW^8I^d}M5JYG!Qa*wo3#
zPXUzVD*U%_`Z%s%E!BqyYs1j`U~6o6e15huI#d~`)!U$ayV|PYPR@&@E%wF$c}wD
z5eL5@KgdQpSiugs0Uw}&wgGB9l8p67vue=QzAwHAZ$J
zK}i@?Oo@OdIyi_M)@cle1S@el%jLxME3qmqwV@&j5=(#*Az8lbhzOo?MS>BfQ+pob
zA9odrS9C+uE9rKSHJoUIZKww&x7IYnYTk5{IlUN^buZN1AZJ0GCEX1TzYKjEK6Ek=
zHrt%#urHgptM!cK#PfQo(dL&~t_{S}g`88es{?)Hep&5vleU7C>Bn_=(THhk8SwpF
z_}`JfoDs|E{aLLqQ-~zro5~$cXOCpks?J2U7ZF2aZ#;(d#A8RJotBQImD>}89hLOP
z<9&$)(wj&ejU{^Gsoq37k|cVc+95sOlZYLS_sbqj$kAATCr!ngN)D%xc&9$6snXe_
z+)`vZ{T4NLy0E{&$F4{(wg|X}q^T8#VMj}!$~!ru7icmHw&gb(eyvuC@X>P2N;H6n
zU$J~US>+PHWnMTaxV$bZgKbXnBa$CGUpu^u2+8jSPr^W)d?4Xd3`D9mlTMwTIhz4M{*400Be-UH}RrJU9#iRlqA8qC;;01Uzx>{L`l%KP$E?
zScCwu4(JKipc9dH3LkI;WF#ahLnLyc*#*_9Dukp$HX36yGu43se#`O&Sc*`o3rr$%
zh)c@29oZvAnypGSGe#MzDRlLVubJGJLQe?Jfmr(gi{p^35K$??JQQ4XbB7HRI$1_cI3Mx*GI54Q_y
z@JQebu!th~7*s>?hi^~-9iAMf3~MDG7@Aav^-{GS4vn-HPRyJ-On#r3NWt{3entu~b|`FjEvibZq3C~%Zs
z^=^N<>iCWjSunRNU3^4`CV|MXTAH4nn3--kf9BpOUjTS$e01#Wltx{dRJt^^Mmc1G{GQulkSdDrlDM=7l
ziV|?FwA5sL8T<-9j?O&nnb)w9SuO!F>1budgqq`$=+Eb}YN_x{*lO~=#)klT*9-?5
zRwd}kB#x%z{e?`dpvFF`k%*Ql7z7%U;Gt+28D9FhL`O>Pfnq6)74iq8LH*#A>UYlP
z0GC?34Xl7NKnYBP-jhl8?E~MNKgos$3es-sj{8R
zMYE~}+MpM*!V1(}X>tjwgWFWA8O@2276MOz52O=3>
zhk4iU&EyNVr}j=69Ob{>te&=fJ*=fnPYbFE!%i06gyHn%i%3sa@68$iLs7d+_vH%8
zycbE2^jv44w@yu?KFAkBeo7m4&(7awuE
z(#6N4d-$ljwn;gg?#amtKH#J3UhjfqTvyBPfRF0%d+|}akCkE=I&BIsUcTE)A+F&%
zcB!1ubRd#;jkkSR4m2YlRMk+H6dc%W$go;9E+Sf~$F5dt!$Z6=c#|Xz-Kka8NSLTM
z!;The<wH{oFvF*=eI>2ON1
zV5`Mzf#34NnKSjlK_N)|;gzSKdzR}8uI;BTNm+yjYyXNoB7{V^c?sW<@312xaE8EA
zxLl~~v;R=;0fltL=YhgS$%^|DA!USHB`yz6=5S-=54pivJOxSR=_HCM-RA}AfN#<9
zm+-ZL=IrrV*a@HlAK}GQPnw0Pz#@=JVR2C@Qwjonq*jPglZZSHdZ+e0=ugeOrc@{iDHt+(Vs2)9c3RB5LXAa!
zZjBncm?447QeCY9?tqt#3hW{x_Aq2*Vx%^}7lSfPf+L(lfk-B!ja4M%^s(v5S!yR`
z&fnr0P{f~i~%4O_G9yohP%Y^Q)?
zd%7LirCMonR;^P7G7gT6P0h{!@;9%({Hx!*`LBP!@sEG~_050$>z((W|JlzcXXoaQ
zpLpuoXZVd-zU`H~paM85`=wiQ5GS=UQXKl>!^@Mya|tPHwBc(NQODA^op)|!>(K&>%Q8yz2>o|{CbW+xki
z{1~XFd@Au-GYBG&&rDIoBU2Ly_{g_7r3rLG`O-a2$`qE2WR(@*!N;MAk&&q}AaZze
ztW$9w)}PFkfdYAtgO9KvSO)hbb&a<+E}nX1KFpZ35P7>=@|(4Uo(Ce~JmQLxpy0W@
z;%N!gkVLI;C>|pnWhN{dP-9Xn0IAiXK_l>KIn*Uo1DOPdKoh`-7at77VJw^J&u5ZG
zA!QT*N3lMpO=X(fj72P)XFOMKsmuEr1X#C0Htf{tvAwytCPzhZ|C2~l6
z5UtFt@DY-WKuYyo!+by{aTfS4taJ
zG(orwI~E)t9T#?t=XJo*3@fF9!Hns|^19b(CG=vVVDzT4SU1o6h$n2}~4Kptwh3@S<8LUom2|Z)aaB(a{s}SSpDCon3r9
zoKjy<>gw4{4>-%c<&8-8+Z{z7fRBjGr0H^G+%QrGjfL%&)tX0|<)#aII4gE-8R1TmmSmG@!lKz$h(F
z4IzINJ2usAbm*{Fg;%&PtOL7{IIbjxkkoha5gmVoOAGG`hj9vYp_vnx!`ASSz!1XC
z!&qWq?Mfllpt(4XqO7A_nZ9cqoJj%i9ItXIKA
zJi9Y#@B}p|3AY@A9r%w-jzJamb~C7z!dkS1p<11%F6+pQMvICMjj3mA4mJVAN|P!$
zFgQ90N)Jb?h!2dm2gg<4Xsz9Zw{*wUXrCe}6pgNQ0Wnw9yOQmQmNg1lBOggFU(6JY
zOre;`8R;A^hhi38H%0chtZm+0
z-Pm1T-(FhXLRs0^K?tzAd24m!=F0kwwXK^MuPp!K*T0)xH~}&`f$fA)qiF|*pW}0ak8qyK$w__~jq$1B$=R`)V-w?3BTYWW2Kff64vwi#2ZS#egvvB~e4bMF
zt9&0Vzd=mktwWtw8RqZ2ueo0s7}F-_&0|5DL(84nU(1)8jvUB+mcZ)
zDsONZM=1SD9Seb$i{
zkp_Uo2~XmxXE_!FP^>V_s;zbP=J2prt@P($sSMXT6jy_{Xz(IhRb%+#TH#1a4f#S2
zCSs2zV~<86UDAlMEbc*}Af}o$5UtKA@+~x!p5>?sM-lgdq9)38L{Xz^^8efTD81xd
z8n=_$K4v8!q??-z?9ZxM+wd8HSZ=l4ids$&o=X<;+ig6Z*QFq{BP%$qLw2s_3K)KW)t1E*9i)dzsZOwmT9
z&pM@>np-mbl3Q({XHCbc)Df@N1RwK`-=8H11Iw>uG}~}WX)_S)>n~W4BA6%}+lc4?
zH+<~>rt`Xkk80?lT7OY$UHWJ;NlEFJ(-;`Fy=p97NaTxdr5Ut_`t!wD-mQ
z`l%rm&=8&g9l${tf|de?0AGMP=mGLWfkMCtaEDm15z$XQewI@b7%U?IXT>B*vZPjS
z)Wcde8vRucsudEfx7!P6&VY|HY?_wcgmQ(&NDRw1mXc@hLr1e6=$R&+z%1Ed6bVg5Q
z^kh~IlIBJIjc7*PFq5VQJLbH<8uN+sN|zt>yI_
zE9*PokzLNNY;abEB-qkAG1&N(Tc8)
zPth$JPEic2#=h~I-4UGo<(spvrTdm$@+t$>nT4s5@pi2lG~1QQ>9O`u6QD$yni-!x
zHZ?gjUT&1CtxCC32IZ-Us-mk8uNuV)9_mN2|iW)xwhC+(nPHKdZ
zP$P;g6^={wz-Me`V)&s?o#{y_3nIXWpa3zT9>6CfkOaj59p2qgW7af|B!I<2Pdb6y
zUBL&!>(8YN(T>;%o~40?D7~2^2zWFV=e^&b&Cpbsr7%iO4VqNU6b*|+fIM98!Ee-^
zY6YTF(@UdM3Ko-n2NHdU)A2*8ev~7b1Oh&a97x5xBHh!{-Q1Nfu8E+lQHjy?=N`2R
zPr4_UL3$$t;r9r!M2IT{d7pGqa=&mnk**O`L@ZB;a3onl%D7|#hhl>v7P{PaJlZKo
zoy}y#3@MfdD+o9g(;&DBJt!QE=3;}4@FHhHL#UA`x^2VjBuoBN5Tr?=xN3vAni_9l
zs2$Jo;d0zeAM_usUQV*KNr<3or}jL=zn-j?EZW6V#Ry7fsbs1phdkX4tWp&;)EpmD
z%vrqXe5XvlfP2H;}
z4Od`MNKr8HNLuTf9{-#8NPurku^*095Si;w=XycLtg_#$<@)ml!}0vE`uMqLpM2)$
z3#Xs`?VtYn_D7d4ENyMy{c87%udjdc_4d85H*bHvb?57?yOG@adh_nrn|R*)dh7GA
zx4%%z$BSz({rXRK*f`XmDmZR$h7#oat-mkb-<#^|Npz$)88Kxl(WjPlRVx+r=5l?q
zYEPFA_l%2*4)>UHzew*k$~T~y*AjWPy0{sXG?(mE+YEwtMKysv%&S@#)CUG=xhnPA
z(D1PO$S(zEwVbsbyHw2?s)|xSsbjTv8-?1dyXq%^l-mP}G7UW!v8G+FQp9=N)xE$B
z%duR6L)}TwG0G-BV~9TaUm4|1%GlctX9RuD3~Y;F9C9oPrIRs33Ty^Tt$K41R&v6O3;Pk
zjc8qN$WjE91RuF=JkhxXo(fFWwG^8oLS_hhBU+YjVs>g`W|H;}z1*l)p*Q%fQJGS9#BMfNf`2zV4RJzT_s3J6S5>C;Wz=XgDyXvDY16)NJEB
z^35R5E=Ot(AFsUZ96PlAirXG;j86@oQtM*QojP;;*uu=j)aVd-JlY-@YE+tK1bpPD
zLgiCm9%|!rwe5Jw7j?S<0**|LP0URVM#CjR#^Gp;0r<`j3`Q(BtAHcnqpyfT*?AJ5
zX0#V2G$|I!PQ`gxe-KO}+NZ8JmsM`G>P>&N1&dv+Xuc;st$my=`zcd1D?!#Z6GlE`
z8%a|u1dde=_0T<%jvt8k9!&K07czOz(gFuhzg0_HImSiJwySl@keAl5HJ#DkGN5;+h_7a~Oz2S>Oj
z#D>dlfMTO_vt4xK8BvtGC*%XSy5C1cac4%Y{wUC?mVx|^Jdi27R!p8qnJtBG$ze53
zTiH0}K1Ik1T*<4>ATY=Fc`XhP)klVLzX}yf4H0;`bhww%%^OV#>oytE|Jl7z_e3)9^zlt
z3F5jH*Z6Aj1s}~YEO>sw3-Yd?v7DUis|}iMSMvjqCFi&~$G0oZf>%jsPSyriDiV@l
zC|;wbVmW@iU?wzMtv7BWVO+NphTUI)4wXS}Z)u)ymfaDbzPuXL*ww!){e@yz_TyuJ
zHV;1br?UN-Oe~YtZEt9Ndg9peS6=(`TOVB5-2LLl-LH4=e!U$DqzE`}-Tr#>)>oT1
zzuvm__2$j5Hg0nG^=5>U8@ImNy7QI5Wmmw>#myT(|J|SRZrGP8WHf`%i9R*FG9HbR
z?CnddQIfrCQvmft_&$781gWf&_f5x67`y~bPIVv
zqEW9oo;T1QDAlX#8!7Z5zj&@tbk%m)e5mk!QfalM_VRgSRm!}G#N}6DghAHkE210@
zw7H7f|GHFmYW0F22sP$BuQTw`b*rhrmjaWl=uoMBx{D?9{3D*cf>@
zHZybng%@UyA740gX7bo9$Ot<^kbvXV{9L7}7!iIzWELqdKBUj3QMyd2=CGDK3nZNb
zdz@|8g=03hI$>irXk*)U(uR#~+mnfHv%$np<0ffr+qS-W-tRZe9Q)qa+H0L_Ju>K9
z{!TI(ZKEYS4tA2Y>jOv__HLjpzw962Ql(V~Rpw>14eH4aSw
zZCMXw<%)9LVIP*EVj8SX3_z3;f4=bJ#q17H?3K1KbQQj~JuL!*g=UOGOQePLhp9`U
zi-R-X>z1FZ93*M6Q#gY<^jYX*_Rp%kwJB0#rjW1G{iEoA^4$gErAW0ws@-UQq)I%f
z{!cP{oWs`T?l%^*zZ5x9SX4eC1ZJa6X%quRf1R&A5_D8Q6(;V?d6lozA<_`U#h4=9
zet&zs!YSQf>1XCsUz`8lp2pQ(#}P#*R*1k#4J12*%+r!h$`ClgEGdtJE5{`3Kr4!Q@u5RJN{%Jc@zpbqN4S@`2f$8b{*x_XH*OIt0Je~}$
z>l;f3zr5}P@FMZWc@2+uT$Emp!fIOTi0DsmtRmM=^-LbGXED-q6>c}EN`a3O1KPa
zEOuea(FB5}x#zD(y;oOBnsk*4SaY}8;+)WBR1ogYIW&R6mD%hVQ^BYBR(X5DXz%VR
z_QG9dUeSJ+ZR3isYcGNzy9c|;b{A*VF(--oAZ(Fg{LujhF>Wi^&)1j6RYuiq9Xu+M
zZ8@!;
z){&0LT4mE5uVB-KCP^E?;Ek1)+wyPfpYtxA$HMliCvx;BCQOLRDcfzq)X|204&L`?
z_%nFyEcXOVM+@r~KOxEPmE>UyAwhGKavP59g-UJaB)%We^vs!mM
zi8PNB#(xfPDKLN5^o*!hc)HfR%2%sTjBF`|i$q6i=WG2V>wOQb#U-er@;q-CO%LuD
za`g>KGI^(PCI|5vU_f>2>h?ymvB1}hO%tPh*f^-4sbmkR?_?sA`#A6hDH;sla`rDt
z4%GggPvW_3JXC1t@DHE{iEzR7O}4wqvjzmnj9-qr_B-CBaPVIDnv{jgJvBYxOdVQP
zbYhjE{c=!i6WOk=i)_qK!RP6BQXwj0RHizm!?FC?78kw#KgDk!mLLzYENDJm>=!*|
z0D}K_xNpL-w7K6gO#j72cShL+ntY3n2L5d$rdwaV(JCiJ}b=HBw
z{af?*6BDr~Co6gv{;yLIa*h}We+JUzM1IhKE*kXpKP(YREGNk%UAaI^3uwWgAi0Rq
zbju%dGAVF0T8@!)>8w+QxU)UViX-2kWf3pZns^FJu#QjhU;G
zqiTp;Co3tus1i}EP0hoYehe=`lrlbbKA3(P&qS^647i5y7|+$3oca24(Jwlf4)R~X
z9u=5l`@9KTRNq&CqJ<{M8vd37_1oTtQZ<>=;*HL>n`Dv1?exh1k#YJ?exQ~BT;<-t}sAF+1RY;cl|+<&mdfA{*K)b>SYP4jKdO1lUV
zsQZH%VwuayAPFZM`V#hIsP*ZnJpJn4*!ffL(G(;&F5AE_2#Y=+J~%fj3lotP@z=l9
zMfQ#(=dwWFoKpVlawS65ZDqdJ7FFQ#S8{~mt0kFuP=+v>aBqX)<8K~jxR>}Uv$8vp
zY2-sT;>|K{S?E?{DZ|wc@D}nn*rrX}I1CumO^ovZGrCJe2iTLmP5MPdR0d)8XqG8d
z_-<9Me&L(Wb^Vgkc!7d@QTbqcNRerX!}n=g6j7I!%c=FxaJ>Ap8~(p*FO2PLonD^N
zZ*K+XXA04~sU86l;$)J6826yQE!a0H^jm-c?!``+%&P;FV+-rLB}Vu2P&cX2+hg~}
z2ZRu~n_?}Ma3ppWf)xVJ$I|T$yc!t^-4WG=!ngb6H_9*rTI3keq(#A~xt;Ag;sc#E
z@sVGXEM>xW8TE{>`|MkO@ukaPsBudfD|w+zQs*IcJ$FXt5VAe=l>tjq%|dFai|4Fj
zW0EqgGWdDuZJFWz&LJz&E4xWYD!t~5NUvQAU}Bae+1bI-!7*ysdlV{0hQKm+Fa5Sk
z4w=vsWu_JUlw$Ju&vvP1b~-GZeKp8nH2p{Yrg^lL
zX_1|`VXL{muS4l@3>wwOX6`437K=NfuQt(+D>&xGOh|C>Mwdw|;Fxm(
zk@5#$fS^WWLR*Hg7<^$bI)fSOEy;M)$qM{8wp-Mc^dpE<&UK@
z-=({w&gpfUR)DkiD%P5rrOtjF!s{!h^DBJCu{9YM7^A`+!vNn9zYCl114Y8~5Kz)!
z#2g|}wdKVV%{M8Q-F^Ojr?EzXfy%-|!0v*EMUavz1&;G92hW*TP77zKIS*Y@_)C_|
zmU(Gok_L)8^h%Xs1$H}*C~+CkWA};^-3%574o@A)2rVB^P5A7&UENlotA8gbx+WcmOn#{85jOMJ~UT
z4E>|p;Lc9t(O1-lejF;!lf#Cg1I1i5?Gc@y(4art=rkzdv=doj^xq+fGkL6?$cfOR
zFo(PUonUlZq&_A8rZW2^FuRNv0j-ajsiw^e`?3qaAl!0+R96{KQ-#cd;#Nl2Zw12&
zlN6sUOr54`r`}Pov@gnx1QZW=ni(_|wD*8da%K^)6y5F!vu|=?giV~pX;PT+;U84M4yhv5W=@do@l-PN%Lj&a4UitoW
z^bUZl^lA?SO%`MwnHMnluCHqs62j0!|DbpV&>t+a8G+oDIg1e@RPdv1!r1aC-ccwE
z?dH`v%RoI4Zr+xON;AhL;+NwbRN`su!$75gchPePhO4xC;(LJXAMo(B3}umwaniew
zVxU&l$JB5a5-JL=pw})E<+F(t&`*oHr+M!(Feez%3!Uun`|ILVzYe&giP&0$t*UqH
zN{L1P`F1-Qm7vy8N58A7!|!aFxW1#&?{0J&JTO;mZ5^$ZQlsDYybgKzJk>T&@W0Jo
zp31K~V^q?7{@Qkt3bECeyV&yvlWKT}yOf-k#XU-^qo2B#`%`(G-*sFN%%K91kK&Pn
zL}8VvWCaslpODbTV3~E|h9XKTsWdVFA*j)X&>oC*c12u_Xb(jHP`=cEbxdq?<6P3|
zr3HrM;=M#;Z9Z+Xa!t2AjRB<%zS~OC||KmG$#jpLdXWLg*`K=?{kfamRnsD6n
zZ*%dl6al`y|NGtk`GMX-_i7ik2t(#J@!w`z#uX!mz2}8WKBMaMn*#^4%y^FipUA3n
z@p`$(VgG~5J0zBcTK~?Dx2Nm-&g8R6=+OtEuKU>rRx=bY`vf2kO{b2AhDXB?mq5u|
z?p7g;GMWsL`Gnio5(T2G*|#ahCAU_aP$-em!8x>7^L8D3F3vF*MzePHEk0%o9f`^O
z)^jBU+=Y5FB97?xw3YG@oBW-@gpc
z)zSu65DHy6L@qDn$a04WTIvT9F0mK8ugKRdc*;Oz=}@S6OwxXe(q$^DA;m09bad#r
zA7IUjIV__eKgs)vXo2G}K@Jj-;{r($-R91}kc>GIJ8w{{3c0GIX(KY}ll+$*$(P_o
zEJ6HyNh}wGamE0$>d*xe}xx2m``>-^X>nT>Kzgn1Pu?Fw03#aXvM_+bpN}zg9nPcKh7??
zU!Pb7-!FG!!LAvHd&PTM+j2wZ=7xS-r6-Jxm5kQb)>e}D)6XnZG9g9xwCx?9
z)}99w_1nYkN*}joITLUIU*B$MY=g@>V>1-m3-7fmWi
z9P<;aqwt?{O(L2XkBNICL7;!P!cFnp}XiKxWajfHMNf+52uQs@Bw>&1L3MDJ%W
zuV*iS?`Z%aY5n=(g>8HJ7(b?^rN!&+_!^Jx>Uw&6E_sZA0CK};-SQ8O@;W=-v({oU
z)amd#8%-XN(;{Hi@ATSQ-oE&F9#os`xSVG7zd1+D?Yf%?w|_rbvoLz}1arBt;VZyK
z^0-6R|R(Tq|5}uDggW=XR=DlO4j!Tk~a|z_THgB-Bp|O^%
z-9&Yjl{~y6-C;b$i4#fiw{fd%K#{RpZh@Ppsav$kt$Tg-Xn1g9p>oBD+1{5zyaipv
z&Ua+%+FS~M;le<#I~<0b#n!L2C9uHK$rC3+JwmpdeAa~q&LUL$6^oEq;@7&{AOkH{;
zmhf{{{Hc>^DG0B4%$2GNcutX|xyYK%9+=z(y&Q#8#Ol8)RZ9fN^k^==>Gze-y9lub
zCFt^Zs4_lU&Gcm*m>Ddru0YC(@?8ImZoy(%{((lqoePq}mlD3b#R2B>dn2UvAXWtE
z<`J>Mq~%qYP9akL%f~MhMVP~Csko1^1BW5$hZ0*5!~ukS5!M)!1G`O16@_sf;FY2I
z3ZSC<6BAz*i*I!Q#$)2m(sj=DNysqLEkE1ooy!zu}a(1SByj=8x
z-+i=Ef*jiCYMo*MJS?A>qM4O-UzR*f1AV7ti$4;>sxDBzY|HzZF?id%NdcM*pXqaO
z;b`C$C?C}vcJXLn1QT#`k`^F=gx+c#3nj(L$-lX}c{-(c08+JiaTGF4TrG;~t*>-O7gT
zT1#`2v%A^B{^)%y;`Yw+^L;qL@3{|E=%xR{$onMs!)L42!tmwHp4Hdu$Ii9MYsB}YyA!(g9o5)3`*Go1c}=;IBmKt#tWix_4?J5?pI%D
z`$lxq2L-($F%P$&KfP?^?{s*EkIPLG;lvPzaQQU#xMTxANj>UrW0u&UVK~qkEW*~8
zd3XLr>|gu~$09+`f){W(b-0KC-7{2o6!|}W6MiA8i2xO)CP;eRIjcffg7g#$K!JP&
ziv8Vp?DbIUV){
ziXq0`k}8xW2zfv4S<6+PkgUj!Su>82DDQv=@KzxkCIs;1aWy(!Tq&1Y!(`Cmb9M}#
z8z=@xr$Q#IVY`p()##kH*2C`To^|vX$wErAV0*{w#e<;d!JE?i^6gZ~FeyNY)CTAR6h8gLScA44tY2vOokLs(6w
zym&83N$K50awo66stL<%sb3n1&hwS<#JLLw;plhCH1Y=iP3oAJPc_OFcbH)b6rM~w
z$I9XM1>@p6PH22}wT!JFD9|exex+Bqqdi_1Gf-4|H+;EcHS*eO9m@6aaq#(Dqn;?y
zZp656)4d55=hutQ5tca*o5yVZEwrqE`LuJH$V-R&*!r=IB18Rb{m`P9|Ff46L@zZ*~$kJnl_*I(&yx4pT+J9IdyERJQx
zUpQx}S=G_)Y-n^kSRP%ow$3#&XmxkJ`&=5rs@2@3`lnTdw}ZA@AL!Mo)zodc7G=6K
z7JD}NaSwdBDOt%KFP-}t>&4{NN{b@dk;fD&{V7O&b`cA_|K!iI(I>UNkAgzUMU{V~
zY_hCQnm)f}-hZue@Jm_KQ}
zQFu7UCB;{^0Ayv!mV5yY7dY1*O8^UeX)JOSb2FU5GM7hcFjV+)p(`G
zs_Y1guYRfOb)i@nR4D@*UVK
zP)owZ#NA3}k@L>PczbTGt!?*nxDY2IVtyx!Ai|veR-soJhpaRq_)OXYk#8XM=Rb)d
zn*PvPWJ$+OF{mkIghfz)!Hz7{ZC$yHGVr=!wr9xsAQ$0XG3&d+BM2FcW!$+|6j{1e
zgVuBF43SDBL`8Ngjxep@4=H4zC5yfc?^>e}^oBQNZAS;82j#`<@+UKP7exQIXP9vrQE7)B|^|A
zaU8xs{M-#}0)k%=_G07}l;wma(^;rs_`ckH*BNE6E}oN?n){J0znA!ndLeh>wzxq6
zL^`q?R{?KEHG=1L(_s;_y0|+#y*#lz0eKC1gT7yqIH<=HplPTJELW0PSCaU9oB<)`
zr`U_zpX1Z+FX7v_xs1c+r^XfnwnZ#%?k_m
zqVWs!O)2vb;nWUAs>W_T_VQ}~`u;5Wto?-V;r;6Vr8*y^TWM$)Vq9QHARa(Y}SS(rZQ}YS&9~_exj%=M*;*
z-0tg-{PxFK$~x>OL$X&xL5`Ce%XCDt5L*NVQui@&EviHiJ8Db<9|RYPq~xL+Ozb&U
zxQToszNJuTlgY)Z@>c-=;>mFm1RLpLB>17Nq~y<=&47zCWzG;klkW$w2SgFPCk-X@
z_u0KviX+v;B^*&ghmNL1^!K@B2LZ@DZb>|EK>(rqLnUR<9+_ej`#T#(-M+J)=Fy^twu;nss;$f
zki%%Hsv>dQmiJ}B--@PwHmox}G;x?ca`LuMR^pR75?zQLUIXPJ85U#mU!sETp`tKS
z6Yv<$WQwtunBYYy$xS*1%CKVwv&vKWp4sveq<#M<2|Nti``xYLSbX;1{(BpV1J5c?
zY}m0mSpQ|S%-c%jDClGlS1M)4vw1VAT6GRZtXbXhRhHL&x!B6^EQ8EEs)}
zA0_TWBa_X;e^C0DoznE7jB8cQ1M=^P6{FwSVbP3_kG3k0gpA@HgiBj!8X4(CEw}#`aG#-=lIs;fYGWp=AQ3<)A7tZh$`;mV6@l@B9}v{cN)iMvHc
z&Sm2>QXbx@ji^%6n@+QiaFfv%k*&FgoDmUL>^4_&#;0lY#-O*vY;?BCDFo}HaoXA1A!
zKMy{CDQjs3w}U&o>YKW{BI$qv^{dOvc-Cf|&5~O?v6=3@L)9mnh4ms%`AVz?*;(0I
zdHSeDskN(gk(8N>6rA;q$vvb2xIO9BkUF?&2^n_AZB>*_;wWRvRuTI6#93hxNheA4
z5ubY0eEoniNE!&A4(?i7q#gt#S}N{P{5wPJ43hebY$aN~UmX5>1>yF#wpubj4CQ(y
zydJC%`(USHz@lJ*Mxhd%^8cUJVhn!-wgIArLIjTp)O(Rc2o(V)$TVaZo&K}lyb
zN+0>XZF=zGDeNT{%_NB!kfiB-w6fODpu4@z*WUHurueLk$5XF*s!-W}#CGh@Z+?BfYqnTV{bWGPK(vo?FnH2ezUrx^nOfG`?}>`o6YBIW$v^+
zx6#p75hlcNV$v9dK`G;Ubu}@14q21=D)}C`-7X9ab@@E+9WOV~{}xnk3`NuB?fQoS
zUm&*^xgt#J?n-Qmj#_Z!)S~5%D52X3L_d7DhVwKFZU+>Zpk&!15)c2!O26$9BCh_K2(E6_QST>(
z&F$|vcpgV!Em_ysMA*XPZzkc;90thHsQh)J*Wg5w7oYeXGxUe1(bhp7-Ts5y>QtM8|Va&2u?Y4Hw_F9U(8PdTmiNa%)L
zRTX;!O00&h9(R4A(FCl9s&BL3rgU(zf<)qxPForqMO7g_6&V!5P}zm~<_)id&OFT%
zxyslI$PevDcPdK&XrI0t(%2*%IFqT6@EJDcg88&um{#=@+6~x*NqzD&{Zrt8E^N6W#}_H5$u6{k}N
zJd18d%!oT2<97kkL_y{B*Mh_U-0t@#{`=k#$r+5H3CqGTlqY$;sfuZ~u(UV2Ypzgn-g{mR^az(qiL_4{)tpp|O=JumY
zfOnOcC_|u*&C>?of#2_*^ZZ|nE?&eRWXV5?7L%9I!Xr+<*!k6zHdQPW82`tO@cS2G
zzAU@&mG>5k2MY5N?h`bsY6=wGE%`m|Ce^Vrz)G?$Vv(FC8)CaMPAZ~vQib9PrwuD1
zC;>v)#c5=@I%xWdoQ@hMYbtV1#@DPf`Jzu&=r($XR^(QAT2`;;*T84(
za@H%QxgH5N>;lJ~9K0wT=L_8cz=P(^QwbHxR`V>e)n5Q0R|q|g2Qppz;;0JGL{M0C
zd$BNaCvcMB4(Yk-zBxq%p~3_O8`G2)r7-R|Hu4uSEqxW_8)=3Ub;Jpc7pHK<7Wp5*
z<_dYtq7&;ee4AbH7Hpa1wO%(cQS@T?D=$=uBcn4q6Pmqu$P$>I<8tgk8AqvtQnSNz
zOe(m%;>U6((Lbzd%7z_oZ>)raWo>+2dCcDmWZ
zyHR6psiBU4w>AT|+YdC_vN$ML3QX0*{$gAn#O(
z1FnngOa$t;F9q55!b)64s%m0bmM85I0^IBce~YdBan%%}
z6;Ikw={2MBGyE#Q7u&E)6UZU^tr!x{lGw?-y>fIQ`kDbxC-MIy;;jBuR>Y6`)z2Zu
zHtR79+J%DpxRntXQHK=g)Kx9zic}R68JKq8)iD}4n>6?H*6tD`8RVV
zFtq$yn_K$_sjlXK>)T5{8OwYqc;91P;7%UE`Yo2nJ8W;Zvksoi6#AG0NQE8b2tLeg
zyl=Y)@7<@HDEZtTjSi*q2zGSbU+vA6PIjwblN=}taq;v2eA(N0y#g#W2^y`o5ZqaB
zV1G8y?TjX&sYI91G3<=~*uFlijPA(2=(w7f+C>)H4M~Y6sGkmfgRpr%q}6m*B4&*7e_1DS%+>+4F8vIZT%~2+s_Ao$Y(vb?pJ~PzLtE5U{#0uO
z4tI&xaL#g%?xmS)&qKjVPuw|y4amLacPp->KU_E_=@DsBBeNHD0TW1)*KKXb(
z8TW=PpeI;@=c_GnYis-NxBI%*)~PL!(Z{uxn%dWc
zNuif9qpm*hMw8&xWu1*h5M&fE>zqq1k;4Nd?ABf&M~uP8zkhqAE7`RVxC<0w%n%`_
zNb+{La_T;*5LpSs5t9Vh!(BWblxC1USQ8fD^w};mO(mKGg-VsuRFEb#XfxQMf&}WH
z(A%FKjslPiwFr5_Ps;h#$WW6~C3JC2WRVHdT>DR8V79smDZSB?bY6srzdp+!3YwQk
zHKiP{SEfjZ|8@Ly0|HRRaH!@2d1uQ`Lse2~JfP|1|5iw>{6NZ?M}|31Zr|F^+pIg1
zu?%iO%G3EZ#g_DA=qlauS{-eQ1VF8~HL$cZ0~;K>HRaZ+LquxFrK^G7Z
zZmcveEi3MFioQOH>!yD;Y4OGmCX*nSUjHOq^y3Rj>@ZogMYwxJb^f`Zh`FMX=2G1p1
zpIBS3FjkUSUEe*QPe0!kk7vqdT7jkKkh{W*ruqcj)s3De3|KnRJM2#RAqWu*f|AU$
z3X-%E12!^+B0{VpB)C@E)|dU6GFQq#8`SMn`K~SRG5YVx<{sO#v$va%DC<9RsE=Si*Wf&gC?q6J4b`&%M?
z4kX(L3QFjhq4?zUP42O%#*It<*pqFquB$K{=k0s@B0=oGW(KP(QRIHGacb2Maw3D$
zC8)Gn2T9Y~N!?wD;`XMDW~yEy)ho3tgv%%R3|Vlm0YXpg=YE0YKcuR)Pk}TZ7F9Ji
zszVS%H7Hp_+1~al11}-fU3pn=XSSY-|7B7Vo@SFs3@<*EoSd#^SDGi
z@%lFD|M7K)1@-F(YI)nEF=pX!rhl7j;F
zw?ti{!U}d39Uz%$WfULoe{6+nLBc|za`etAxZjF?O9%dxKoUDb91qh$DgL640JxVz
z_b*1NHjbZ-LhhGK|G{K$MlP{7rYAC?$|zI5)b6A34DNsx%+MKQ4|dY7);dNT!{8{{
zS;z=GyHRUiRb9V+cJ`6WR4h;V`sT47g@5jNKbhc}=W?Zjq&n}C^!bd6sFTNnn(J%M
zkcQqbDw#F;U*^3oXL--jMjwuz+3p!X+vj3y}*1mggw2sDdiHN^u%d
zBu~=$zo~2ko!#UApOcB|vkvK85`s3SzXyz&kCzqYvPW1$9x|IqG!Rt=3iOZq$0j!a
z6$J_mIDku7w6$iRSjt1anlnS#6ud;7p2qLCy}Nlx_-lN+n
z>}+k_msBK$M=yuo=A}$eo~vh+vVxQPEZ0Aw(NV6=BPm!BP!@ZxSvzQ~FbJ}lwa#ye
za)dD9sR6z#=>#O3(ic+=YcH=5>GRVQT<2yLVbWt2F3|2p;
zs5mj_MOfW4mETy@tsiGtIg5Q7#^~{jaG)^+FTFKv8F*56v=o_GN-%3kpGfs%pxb`p
z4)S_G66MvBHba#Olm^Mi*(M@nn`1(rhg6~0_cQ-j+o$8?yJD_OM}d0eYTHv5
zEY+lOAr7;?myiiU^T06WltgkmO#;PD;N4DL4J1XhTj7=p9n<5Rj10^
zO=fnIY}}QpilpgpvW1Nmx5UUc!=YV7V`tHH-mp4Xt0?~`E2v5Y*FFVfQT1V(wgbupr-PIBKmevI0Bc~B-+JLlo*9x=lfeppx$#_-ZmnAkTwl+mf*Hny(TuCAy}!Izu-X&BdHtv;?t+k3@wskOe(M|(iQ*V{hYT!Y8m
zzUWCoEvM5!V&*gw-g#~B&DqyF;D-OlwnYbm#)0dC2Etu&at%_N6LLuNF)C~4YO4G_
zbz-fKYl@a=EEMT!i{
zY+~UDi3xxVaLj1N%v#be)$lKeSch;dJ-tBh(-^<#a$|i;t@m6^If96}0$1Q5qZWnD
znj0r8-LskBM~;!}tL*yyPb=ogAe?z@&#&c`p3J`sGd#2Bx~1-Gr}}>wbrH^xOIxZw
z-R=!*YnLXlEIV?g5`9y+reh+l$S8Kbi+`5U
zU+0fF9w_;|>^4ew?5F%m?yb>KVy0%+DUNm)Nrbpqw%!t1ZE%>a^r
zB8b9pk|F%xP_?0m`r?ey6ofuO??F-KA@oo*xWHQ?G0g_aJv&fjVQOv-qhQj@J#j7v
zmwxsSVno>v5G?uvw=^(RWBpV^zSAs0L8b7cS)_>Tmht`HBU|lYrhC_F=aX3ou(|o6
zM3+a-F2_+x}VpxuNL=*
zIFrbHR@cw(^%)Bx4NYegCnwDpkuMN|QZs`~I6e&GUMTW}Cv^;^g7m%b;xaQeM`1A6
z5?Y$?&xvjag-wT|aZsw9)2DU}Bw|y{d?O_#`+oPRgM#Xh0*c5=I5(F?$;Qst&+)oX
zznK&YXZbCi;~a(B8-z=m4#X%%CJ2hm!VZlH$~2}6*9UP13aIA&gh(yH?|y9j-%&`@
zy3k&^sFpEjsMw&LHz`*I_QpF=zBp@~ucORD!S{2m)f+|56Xpsyelmq79gD@r3{E=E
z*K!JzL_i4F+uT|F<4~xv=iubl7dvkhN<5I9V}0q^U4$oV?zH^&n5Jp4xFMf`6|{>p
zb;GHAw+$}VFbn8tXmYh6GktBkQ)!Ba2Ba?3)YhD_)Y?=t*+bSUzt^qM))5o%Z+=1k
zZ(rG;9~M3!-q^YhY4Eb4-iB(lprjsw;Yv%SPxqap$-|9M=X(i`msPyIsog58Ny=uu=gmnVE(liJ}X7n^ZWuwNFEW=1YRSzNIt63*eRkS~=NL;F;
zxGY9UhBReh!13pg*Q2h|0PNs`|OpwX$w(%K#yVPA@d2Z?F|mBE|~Juz%F$
zVDYa>u~Ws79N6Yp5*2a9YFSei3Bbz^ByZ9TSBZsEpU=)HbZQn8HPwFSQ~s7YM8S%}
zo}n6kEbI?&qdfgjbA`muylMb}#1g!lNV0;@!@$qpyHY^G=@r1soxPz38KdMvr0>A@ief^u-N758^*BKkrW;FK;fkWJp4o
zjIZ{YpC#Y`5)pJIL*gumf*JJ|^4u$#vQvc7WGXfx|M)3Owy8$oV(liHNDY%5t)nUTLWZq>{v@{?JDSH)TPx{-4QLgxf=TOyfub+IcnM
zTxV*n)q9rx8OK|DkNG^Qm!WkA!PZp+8pq|e+TNBQ(kUK_7SBHLPE16ch5=mz;UztLZbg8?sSXllyK&*(Uw+$QHAqs
z(^{@pZA6f@24Y5-iFfgDbu~R))f0}ADk!aKY;D
z5UA*%>NuY$9nYZ+aUH1pTcKHw!@9HqAj?iH92zS$K7j>k(@4(Mgc(8`$af_iB9eN(
z&1-?6RnrkDy6-Q8pgHbkbOdvXUP4T3o)Vg;drK)lr277Y^n7Ctr~#RZe3(6
zUYxKNYM6Xby6UPv&8T*0W>F7?DEk$SFzyd8MPy6SSpB$4@&e_I|969V;B|8^(s3~q
zOMWj)Eo#RxJ)LM)Hrba9m-;f;BCN*j4(B{e=a-MhCFT7aSsN-ZLeHtPTGr$@WJBX@
zV2h1WjD=j_|Nd3@`#D$&0WmyNjEXsJni+9z3;1%$p31!6W+yor1k_?Vr1Vjz
zB5!|;u$25u_a&(QW*_pIVf5($xA{8T@-3TR@;ydW_4!-3TU+y0GD3zlN$rP;o74GP
z^TyLqroUcV=G)w)e^-4=eN#b6Z^g*(N~?-H|4?A_oN0D-`xpsCIL&Q@U2$b~TilETcM`uAT6`92`pw2Az{e|yb_`~y
z9`)cXQ@_u=Vl*t)u>&@poOzWUyI`i{4VCOax{<0F!A}XxjB1tim0iaod{fQv*xr_L
zEtM6Hg(SGa*eYe8e9S}c!rR91{T(P+E!W2`Lp~D~6fIyYv5CG;^&;UyKyq3s!t#kNj_6z-*k0*-t^g%)#M}wbwhN4qzHvKNA!dW{m
zXO_~-H{R}(fsm53H~01D$9{|r|A#f64Uab?fB&0m|JS$V-0s&wqmSp_7l7|$FN6d0
zN>BPULQ5bRYk7@LjVvn(H`3fvF%m_FCs<=|o9nf$zs^}1Y`f;XCDhydB7GG|`AEkf
z>mn&UI4dg
z$>NJEPtCmVtI*(37DWObF3uCB-JpY0nC^W3GU?OIiM_pn*4I3qra2B?#uJWLm67S=
zgN6BX1D$r?UwiWddwK+^c7a~el@BZi?QbJ<+5Y~Gx2w^$+=wNTLl8~sX%1D3Td=Fm
zduv&t3@f4oV&Q^Fri_@o%LkMWyVv_#Sb_{zt70Qalv)=C2A$sLuVbB&t5c?JLaEVs
zC~u=stpK^8phl(^UFxZ$U(Wt9Q=
z;~MNOjXz$sGhkVRgd;e+K<@+f3XK-wK=BE>5DG0|;E48fI8rEo2)zj6V{m*+2-Z0@
zR9z3*C5(0;O3?u>{-1EMAc%d}1k;A_hB5iKt_Cb%j{n5LMONXV30AmbS0oWE+qp(e
z4A^rZub1fs1&->`_DOMFviC`;HB$_u^SPbT+buz_Ddq^YJKvngt{9!Kzy5rA?yO#0
zS>fYweSRL?N3U(aiya5Yx~^xic0I!Qci=%zE479OUUzc~IeyPFyQ$r;1C##m*X_3p)x4~>FF;;DS6+4p^u2!FNw1i(cigUw+)bx@5k$;VNt+0
zxmF~*AXD+JuTT^s=Rg$un#5;rw9i5OsyjgKzxk0Ly_INR?0A4z8!
z)>hkWVO)!Au~3{sffjdnindVPrMNo;cL-LXxNCvp?heH@xVyV1C+~OuX8*~Ry)%2B
znYHfqoVYx)uPdhzRI%bwZ3lBYbkueFJT!E@+KHVlnh6G;H-}Mf(c*uC)1Jx<+PkUX
zm_vv!&(Ya!vk9Zk`aU#p8-YoN{f_%lBr_++`*n4Mz;b`Z6j3>neg7jr4z@azdIo>y
z@0{#RDsr;-q@=cUWP8>fb5z#YFoz(uze19_WC+O^-3N{|*pj)3fGHG_OneuT@P2i=ErBWYAW=to>o>4cm7KW-
zXHax@i6FLI2%F-~aOxEBNGM3O
z^%fkeA__UIQxSQ(-BA&FyY2lo7QL9Fsnra-A+R>~vAMD3ZisiCH0L+})CMXO;9LV`
z_$`L%L^FTYGI94(1fG5XE>eyJ2o%7QN=!=pZLI$(Kte>&oICTgEw{K>8fd$K3z=rb
zz}!3rNo8Uihj4qedr0bo3TmIfG6}ha-R`y!qTxsgR*BvC)k*P4YWJ$zWwBv27@
zgX}e}cifKbohd5vRi%r5J^K8kFl}xIg#NXz
zFMdBorpf4VUS~eGkw%H|uKmRP$+Nor`$^f%oTYX%W8X>3Hy%Zz$C=B%%)K;Y@H+*0
zNw;X-hIH-9L091eFU`tzt>G6$tWUR`amQV8Cl(IMLudabh7Qfb({R93BOJgd{6z?N
zM5Kv9lh1?&%4`m6V~=3n4*M3hmdi52I?U{T0s}njK)FrQNKETY|JPHP-=8;ZS=IAL
z_2|8jJ-<|t4h-ESqk5TKS34ea=zhqOdZEM}KKOaAajgMdk@LUf{bKI`ELo(pr+~VeE=jUT;s<_~xXL#V(ro7YH*$Fu@?7Dv3
zvGjjv+ko6v1G6(So(9+r)&pSv5;L+`)^}cS&*N(+yx()0O@?%b&nq)jgx|AWvMnptJP>Czl^!5M?6?ytQ
zlLoV@#CGH`2?9OMg1MeTyaVDB6?Ize+f^*?@1!y~it7ePp>*-k0F~qdx-o6+|1ZC#
zjTONJ!Oe)Kh>p8c{Sp5fQ|QSPtfUIa-l4jPkxrp-z!!6&oK$WN9umIdfxFX-tQfu#
zb!G~S{Fmae6sQd8WfKS6Vb947qJ+!ni2ZwwY=K#f@3Ic~aSO%F%p&K^;q4M^xd`!n
zW9YJ`limv_ESSD;Fp)g)aTXP~_WoC2w^#mfdNZk~)81I)=VE$rzkL5myHJ;XAIKRFgyq*zwEH!d+qjXF@CW?(vEhdwWx5@asGrE61vk&|KE)#Gg``EqQ
zFHdCMWo2|h-Y&d$)jy#rr2ITEmK{64HSCL%>(N}B70WAj&pjIDJ#B89`Bl55c+fyf
zoi)V}KJOV&Yv(oicsqPa$}V_peweE7Oyw(UHl}!4GgBIWvwIKYT0QO#!+^~5RlEh1
zR=G0h1-4PsOvq1Is%B_KN&(i2enhw^j)l!-h%1%4TMw;
zO;GmC}v87R4`6g@v_HM#O*r{2J`ANwqZ$J8kp1
z3xBV`4YRJ>cb3QTZP->}_%wDqtRO5Zy1r&ifTZ4R7-yA#U!g43g{|YaAu)M#vk8SH%CKa#FfqEz*bljv9CobXXd(e)Wj)$iA)$dqF?1<2W*@9R!&5v6SZe)R&#{!@#NY1nmfV
zA}Mkjg6X3yYKr%(UDlI`MQsr(hUuw{a%glcnYMj+iXXMft
z^cS9FhKW^@Nl4`HQ?x4%f@AM>U!UHZ&*B^Z!p0mz}rI+yhd|twAZDTPhqyAJouzvca-{F1NuxRiy!0vxFqsacY
zg#%n#Ue3Qug#-BAjyU+=9Pf>3{kn6~+S<8~)m?PhfSlQM9T*2&w|rxVfu-^MM8#X_
z*#+jcPo`NyKW?uJY$ZD67sOW}*d=2U%7tkVT_tOTY<+fO#_m-mh6UDRD-{-6knHz}
zC}0TevZl#lG{blVD8kILupO3o;vT-#2O2fiQn-*15_B;={DeGYlK~-@^GH}5{hw^(
z_8~ZLByV4iz+I{bnYhop@7BAmmr7NoSiK$wI
zJ^8(QU9^5OVS0?_&GhwvZ)Yiw%?QbCi^<0d0Rs~$lg;
zvH8mjsHcyqVr;-EDcZvy5SmEznBW+T;MiCO3roi4&hc@vb<>A|z4@`!YF0M&22HDh
zD@je>MjGGtPS(fA*fpm~lolr+)0cArS^9+XcnXf4W#Ubhe#T
z=JYuIKcqM;2O^8;beca~nCJSQ&Yk}2ox9R-DN&wO`5O0coEeq~J#xSBSEs0N=S;p4ynsp`913%2QU^s!S1|_|G0x=K$
zzbNjfDkXWDX7xfJNar$?tQ$YMn8OuFzP-^c0V+=kKs*XtDBncy)-!F68pEieoW8Hq
z1t2Da)o>8>Y8V7`zU(#)$L@Tb8OzacSE|&Fmf2wIb04cv2P4rKLRU6`kkJc~j&{$V
zPVbXnFKO?>UwRmGI-t{x7r@JDRDkc}dK=Uq+TpS8bFk6%GGC2a?uG&7?egA(&2e8Y
z`*3oA5U?rdj*6(;{aF*Vre4Yo21aOXt#53sZH?2@*RjXOVX;2F5S%LU&WDyf$`OVr
z3F6yH5KLP1$X;WSsP~7rhmsjP>F7Cgr;JcUR@8t{P2bFDi)G4vaAmWs3d)3>M
z$o8yHDEypK&$D5*;xg|2FEMdA$qq4b8?FW!Z@;%8l$f;efIBng9oalV`v&gY@UB;z
zhlO>S(1asAalBl;l~-@`x3N-L^1bK^YvW5F7!X4A;guc4o@vJ|tCHolUuFq>f_1(y
z*{oi>`y0%}U_)83v(}JRUEpVvOpouutrPC+_jb~7SG~Z~`D3HK$z|t;ak9&?uv#?b
zT+xi6OoAst>*S7(OR!2?pMns#|Ll6(uU3?fW{xQ;z%j&HAVLZrO4!6J&AKik7|Fb8l;)OCM|L8uPD0EJd7dsY#oL
z+N!b8dR0ni{iV-1IKSrSeuo&F+jj9jsPcXaA;iOl|BEX~U=)Y|M3c?Oks5nItEQ&t
zrBM-afxxW21kJ)4RAB#gW(r^koiG*_BeDqQWSao>(YF`io>m}h=-!rXEfxbFk-^SzlMX`7A<
z4FYZ8?oNCKXX1LmrjO3^gPavCC%U?AFu%g6ay<&%pARf7HUR&}D{=>zuVm%I_j)As
zWYOXDe0>$x8#Y3~?EXERiHP&X>He(%K-(}=5F5n!>u;(N;&Nh)7Nnd&8;Zn0IAMOJ
z3B@o>4Gd-)BLPwp&0i{&Wmbub1PT8bG1}$89||RFuD!%YMhV|55Jf$RVAy
z;FMVoBV!w;2jka8wv=5dvM@KYb@a4Oj;J(l==pbvWX8|Kx1dSDhjMafF;Ea#`k16q
zQ0J0lIg#zT-%*Mmtm+bsiy&)
z!JtQpQS9>}#q?1!<)uX^){q>?<1x){lS>9~>N30W4otC9SrmH$V-u2Sc^E#e<-kn9
zqM2T=WriKs#{lTXs@@{)cV}qIR28izp;>gLF0%!)p4rJv@8{Q}B*uNQ!J3*L>Ux&DT<&iGGMn)U&^QHo
zRu%w|MM{xDnx6h1K=BhR4o7Js7Nqo%Hvjnw2c#}&9$KDz>=FIbNa{?Ni9sF?&k>23
zNMtnSS0Cb+E~+e=^Z!M+(e|PmQQ)F~$w$PchT)-C12EapzIS^ye`7qV6d|j;mL$z5
zfa7A8B49O(pv$IMS7hfrM&
zXhGB<$Yp{R?k=t9x9dY3XpSr((wuV^6LUN-57>3HE^y~kB9B%>C~}iKdW7Sz86gsm>rOn!gH63XS$^M
zErS@t@`$DxCA!HJCf}vg@KYgLnh@OlZZ&4FcK6c&y!a?1JiQ{ix}z8!n*{g+9E}^?
zXb2@bNHmbyDc?i!H^-x6<9{OufKo1UQ5wq95yo<@1#n&dN(Pg~g8A>L_0IcoOxLDA
z+U9E*Tw|a8Cb1FMNz#kf$x;kIrYTPZNStW*DeQ91vVg_s9a;ReMFLj~@!}cKn5-gL
zXekren9oV%t^`f`owK9~%o}QM^*I)~HeG&9Hy6zz}){Hn3=NbtS21TCp
zPkWv@uFrY*k;_YtIBdx8=Z%K)e=}VUTYt||npSu(oy!qv&(EK+7*xQzH%%92b#+|6
zSN3(KEJVESS2Tm6##L$lqbhofyfrJ)cLP{LkQt%Fx|@l2&z}^`z>-v7!UBrpBDjcu
zUjEC@QG4EcO+@21Ff>=|oYfpEs-;RM>F;#1tZe?5+gTX2|DCj=N+0f~+~PG|%15bI
z@dR+_Qxc4@;B?>rn{hH`G6p9WXPhd>4y$4d6ptlASU8sO7=13QjUki(F{>X!$3^r@
z+|-y9ksOW33P(zr(2JzeuwE6jqt&ij%$ln6Z2-R;&o7IKqoF82;_kJMUsW;mHa;1g
zs5-XSd@Q{uU+t)?bMf#wxF6g4F{LD~23hPiI9$hbIHq~zs
z0Q9jWs@BKG<=}q*{0yd1xY`zS+PAF-zdIywmlcjeYSkgc0?0Lfj2>TsjW~zNk0So^T1#yMFM2f%ny1%TQp)^QM@K=U<*BYb>B)bhU*+
zFml9Y&*meCn6|wp`Ly%);~Z)Rtp;`Ra#FD{Ps|M2&r~w&pPs23GW9FQm21?RF3s~)
zlvY^0f%ve20mGEiR}gI156H+d;1dxPF46BvGb*KrOL!paIxvG*3IZOYo$seo1ubfmUPYStNY44$r9UeT3yiKr(
zlqy&_N>^RIlZVsW;QaT7lg-h=^W$`#bW1A<*#+mrLydg`ybN^mk5^5-dt|yJ^vS8=NuT-+%x)+%#p-p~6Q_
zjIUJaMqA$(uNYaO==J>5bs_ihXX*Dhz{u0Idya#|T|>Fy=$V)v1xt
zy_^FM3C(Unhj8t70n^43H7%!^$Kr1X@m-J0E2uQK&@(_S4Iq5~qktc7zEYY+WVGH!
z6<>P6hES0%{1ELqG&+?{uN6Ua^xMf8Nwx3&$bgFI^X^PhbPjBM%n0i;7B-;kOj^aV
zLy)_st{a}yKk#M6??Z{4kAjyBg?PeHoyAp<&_3!Z8Ie`&nF~zGK{5t+HeBIb9it;hvTln=W
zBQ?d|*WLVO2UOMZG}zYlHg1?B^so))oD_bWQ-u1z^ji?i6ui+DA{eoNh&^tg?U
z7i(#*utn#|HT{gF7gS3SSNQRIx;FzA`o|7Dk3p0;nh7&7
zn}!A>Hp5s9JTBPQNc|Y@doX#;*l|&Z?e}3|1tGul(^IDbnh;dO2o_>)
z*FYi~43Z#O4uYs$d@u_d{bo>Cf2a`}h>=%P07+6VyxYAS)a#;HMIhjA>rryG>_38xXA5-{?Fgaidh9`ry2SzC$hYr
zpKcC-&;P)T0LCF$e+r}91PRfl7RH32L~iIux6Q?1GOD~nWx0)ca896tBcrKQu`G#yc6cLb&!SWrVcIp8;$
zJqU*@jNG)&G}%a1D+|H6;~0r5M^JL-Z(%LcBFaZtY?@{eNFu({c(fGDWHe2#{D_JB
z!!d+-rH=IsN#uH5m9o_1<3!)H2IBjlqWO3EfkK}JuObb}tmJ|8y9rYmxP1v`2u!<#
z|32*OVh_yk(@Wu`$C}hL{p+!k;UJVC4~Re~AXXb3vn8H#8Z%#o&5hrQD;IXt=c*H?
zg*6+M{&`^vrj~AnB|iDnf+!EScR+I?CpoW&H2~=4G(dRS<(plCNqT|C?4;1kYX%U?
z7{Ih3i)41XOdU#w3}Baq>G3*SJ-yV%#~|;#+kNjwiz-M&J6!K(zEAkSj)eZ#`npVt
zK$k13KN<8JUeV*36Ob*b#UAQ!yj~`$+{j#YClts&KPN~EccA)o2KK(qdFH@HyugxV
zN9Z{StwUOhpk&sC)8o>*y~CGq@puMwTIOU}Rhehe_l5lFswvVDITT?eBi2TWcM47E
z$z;;+RA=Ngd`+|q$#7-l5}d!q@|sgtO0o@FNO<4r{I3qTEetOia4k$7j%DafMcCLY
zcywdOOWd4h+F2XKFJwv76ry}Vr5Aj+>RfjC?5^shIRD3fKbi*v_xE&Ek@pyS1u{&$
z)$wD3wV7z#K`b7<@2jqO?Qlc)&_&Wk8WoTUL4RWpmD{HT>hia=NnmX8rQ41@QMhgW1o`
zxB8zLv%Sj}(yVYMu|RD9{$)zTAWsg4-bW8zFKZbNoliZ#Ds(HzbE+Mf9h2AUdxl^O
zsLS-MEZxJi=)3#7yMgDIZ9l(A$i>jmi|3Vp!sSLv+90jX=rfuKab^40qf%~mm$+0_
zOuv&kgRXo{n!;&hZL8ks>T1=LB_IxMH
z?j2;jT-`N4o}hRSfQiOW55`mxP-hFe?T!rPb^glCoeBPuq{*-B0U=T&WGji5yK3_>
z`YC2{N{Te-2-Kvw=qO*c>Gn_N56(TDuF!0__A2zdj-M+HvNSy|8agM$#~T9Wdg8#J
z!>r>Y5a~{2)as~gCS{+vU*4MgNZL`k^BLFJ7)asm#7KwVPP8^d3uTo4q9{gw89Te*
zTbT@-{h21gzZAfCSw#BbZM(^zAj#1Y=iL_RyTs06d3kB3DZ1iaMkRFN)kI;lr2q|l
zuFo}$OiFA3`U$DSz{$l=aZId{R?3(2rJrw88WY`{y!?FLE`S#g(BtX>;%(I(kpJt!
zChcaLn0~=+d}HjQ~d}DM=0h8iA6;UQM@*wVnRC;7%ze6VvQ(xakuc_cPhjEfIk+ho8x^Q
z|F~?iH_@;WW>q)WD#GvfEPy^<56{^+x3QL1$#*-oD}b!b4pFgI+$41gmD#+BwrB$A5u8BP$+VD}mEkf5sp==v-fVbOl
zZSLnf0OVGsf8A$W&xj4r)$6Gb5VglGVb%G1djNg*06sv*Px$Ptxp*o2oM8Y!+b-jl
z2y20;=3A~Z^0;ekKwh86TXbAGBx+c@+c|Cr9zY+B8p)e^TO7S*&FSaq=JoKms}&qq
z65u7I8%MID?XZfzl1C}%Z6vkU|24R9k*b=cU_j{S)y1A@X5pHd5TNmenG5HObL8;Z
zhtEUNSJqur>36DMR+rPM`e>)OXyfD?r=3e0sF(_6bXb1>>JiHK({~hs*i#^2mW-X#I-f|MS
zQ^wbE$txwhQ)1FK#JKV5lLHxqKFz8?*mL}!fzPoUo;{0SQhDtTZeWl{59lHgS^~T`
zZRwZ*yltugFM~zj)*l8STlf_8s{R)*qGC_y5B`^^z)O83f!B!($z*$7xHNFuw($gizws28){DtUqk5DB0fQg|&>QFgs^l%6!LE@k{^j;AVUUp6
z)=T^2k)W3|%`Wq)r}r}wZ?n)i+V$xv7|hH7FEaTrTA}5gutlBXh%mc6oRbxP5E3yS
zf9t2gKV#;wMCP%CqGZfM(!16)->^XGC`nf?ixvpXOui7F#etmFV4;&3G))&RxTmE7zbyBTwaXlJ_yi|&GW94Za{yVH8lo0Ju-xxsX(?#e!q@)JvD8-d2~S;yB;V*
zJPr(@Plk|j73emJ=qs2Va#{ksDG`0j06<@1AKVzej)0)F&p5#6Cedf`2IQ8V1KN}W
zooDa7=@8ZZ!#;UKLcKG6G<^lW8hN@p8W{O`ep(+d`iW?gR$?p0%Xr8r|%pP*4g^b6>$cGZC%`i
z4cK0ij?5aYal+JeT?ww|RHa2%s!`!t;qcIt9p8C=Xrp^E#We*VV=cdJc>_Zcq_*)M
zC5=>j#T}U~H;vJA4=od0FF_LO3V_eoX~Xn_|7^91~ry(9xTEal&CRQ++kL^
zf@Z9|s4achf6ecunX7|2lnFZTw0N7KO1iV|=)mT9}y(?--JHK35M=Z$r1=1t`gRmQrUEswvOM-uW1
zEiMJYXE+iF`14(Qf##};&W`&(
zp!-bVspZL$iC_-vkUV2b!OWU5=4d~=1a%S^7oKLX5Mh*Z~;M{6Vic+s>ziBN;QCoB7nw)fZa~dtzw_W0<-K;cgh6m+zZ0LP%
z#%)w^TS3#wHSQzW$w((zf;as0tu8qI{JnUa1!~C@s62|~_s*Ue)36E!T|t&5rU`^#
zFF(JF{eb@LPhn=pjSBl
zw+Et7oUTW(A$%P0r4A;q1wpqR{9gf(dq!xE;p-tR+_A33X~}glvZc
zuP~EyOm19^A*ZnGu#!&#>tCRLKp|lP{_<~_dpa;c!1T>5N!sxA)0O=BEgjG)lRcYo
zOzh07C@g|M{Q__I<*%m>(TkwJk(VR0#}6rIEN(+BIN3QJTChQ$U?Id!?eMYY+DIUK=05{H)KkL3Gws%yBdv|U!8
z>-*Gx
zIb^Qndm$0Eqz*U=!Z@r+#rsakD`z$(6Jrj}TE{BAUD}r`p}2Phl#0yPnwny5U~duq
z@%yIKDUuPy!M|XGi@$p3ntfoa2E&bx7U0`}?sgEuR?Qz@KxEFh*xK*wt2AP+QKTBh
zxNqn4iu|Q-KYTjRAFx`6y=!zw{H2h@PUBwG1OsWahLik~(C+KTC8&&1nG+Y(+~v@Z
z_SNy}elW|59%Kx7e%_jiTwN~|+?cR988P7neA=9FU&XeJuIWy9Vz)&$IBxm05kuLs
z{!voqfm)LqTkciNNP#(Akp=g~MZFtLhdzcKz|n_|#Zv#LTj~^-q3(3Jk#;PSTX12u
z-&Mo5pR|TR$M_UE;RG4G+FsOEZ_?TKwbg)v+~Du3zPexKl>4PJAI<9n9oN}#y+q$T
z*S^Isc$_50JvjZhU;B6qBkDs_-lv(&j@wFOZo|bT1k1k^uQ
zlJoA(j_Ft4uVX)%mK`7qqK_RL(24)LS+m80Or)pqjknHSIkuku3%>_Y*A421EadP7
zh#{Wu`_Kk_C+m#))B|_}KXg7YZjiuX2tW>V-fp1l=miCO?ydg@cCHqN7q@qM_D7D6
z7)uyYpBN~9GpkHY7W#U-N9D%Pn^E#ddg*;k3{+v8pjPy}YX3%qh{wM+irtq!k<*I`
zP{eY|=JVDjsw0&~a}?z=tW?E71K29T@Tl+~Xql2}_x7$7C~wOUo$(8)P`FnT`&J+G
zm0)K++1CyxCPpIRk{?*?Y*w1e^Cwk?9(rH@i(1RKbYw+#Ld?50C=HBg=n$0Faaqe$#v~{1n`Yh)6vCxWZH~sB`A1a?L1fnRt
zl*i`m(As+TfKg}~#Kk1f%>}PSW!!1pT|b+T{cK>lF(80*&p>DiHBk
z&krPzSN9DW5>fa{$3~%4QDbXlG@;Y+-j07g1whBJmz_%9Nl@HMGF
z;i9HB1K%*u|!!$lx
z-ymTQnxI}w5{+ew)6n*vkMC(|*wJ6LLd|Ys()vCB%KK0j3LiFw`|;baoC;^p$8h<4
zGQMA_^nWo5hS7h<`-9_cpV0cpk|Y9mQ38`H^zdo#(*md`r90&wm#O
z4VUE;!p26!(nzE?phI>?5$<;KYe_(t%pF`Chd{>rDkcp@+x*da+=
z)6J<*<$j>YWToMvlIuHv#;BJru@jp%RS6SX$gX~gT$knV!3)I9lSGf;;CsKA@lHd1
zs-Rw-zm<}Uw%v#pg{y8>K}yqt0*t4N7#9#@J8EiKOYy1ErPQh6x9xr1)gM99;Ef(z
ze$q*))Fq21Ur)cLjx}r&$)=+dgx*e_Rv<2V1OQEyWzWd;Id0D@f*^wa7B`K>UEJez
zsqRY+0hC%ZM$X3o1ADt)8CO@`Ge_~tWcKH>`*wMDhfg!;g|eqPVQ*jpb$c-G{fY%~
za#kw{9~0wM>~tz+j;TlOd2gt^yG%ybme2+xQ8=Yo61HAH$XeQOG}&vwNs&cIKES$qFmdvVY_l>m_XZ&=jHBudwUoeSJD`
zb0Evk;S%bbIhX@{+Pi@E0Q^M-5pz%%CiDS`RW1L3ao$n}sM1ZbAeBqnW_Tht&hq~Dk?XH64
zK7BB%JWAsHZe0?C1!20eQFHy<;|+?rw78M%wQ8JRj%9`vLIQ5#G2it!o7yaz0t%dt
zv}9y@x%b*myOtUs)Qr4G<7x*#^TeANd{?$1vX&m;nIv!6Q8+4nHQfAnl2q%jr#^XX
zqOYjdG{!KAOpVeCSol;@n)Z}#pnjTuZo?(^Hms6lD~MlXuA=YZCdgc-JaFqARrMU0
z#6z@F`NT%5qk0x~zUYRN>YpiKtd2WYbVAZ?B0W;ULo=~hb!bU{S6@oa1aK9A=sRon
zWA;B0iBK74!um?8tZYh3L)a96DoaRI!0&o{cjRWLWD=C!$@g^ocnTf?-~4g7-aSR=
z7ZMZ@to~?S^{taBMVZa{U_ia<+s70|S;l7m0(((W0dFT?S65$G-|N%E$D?U*G$Uh<
zzxVxa(yR(@x7sK?K*jlh5ecTU#Fmp1x&RW3(DW)wemb&Ho38&OWnHYl5R+(KnjP>G
zlz%Kv{oE^A6YG-pH6IT5#3YBZ%jk$Pw*2?tH(P7drL){&ZDO~fk@)F~mMSw@KKyjo
z6}u(8p3dh(1}5@3j1OPl=>DC#{`ZD?>WPaUC+4(nG#VO*9B+;5!XY#U(BY!(Z~)bM
zG3psVTQ#iYD~h%IJ;D9x1{`wiLH5bm-YfM>$?J8hIM+hoA!kS$lHrZS2NLDeGNHvN
zZWW=Uy9pG)b2P0w_{=6C4H@PSK1dDT1zz&0)A7jbNI=CBl?9I*W{s=)Pw9i%03LMG
zty9sY3U)Y1d=f@8{RUMm(q8pmi?JVn_0iL4^b#aEIDWv1koaPzNpU`!ET>qzca~}>
z$NK{xt&{Gi!5f4))tyrh);rUBx$~{_e5sraknYCQKG!V7D5g*f|B|pX@OTUfYahTg
z#;3kTXTT>s63-hp@-|A~30~bNP@D-+RKmNvT&!wGSz|bf{6WAe_xS@#v-rK7IR4GJ
zEeE9(*IgZ_oRQRT(AyEmak1l%rLTTez*U<#fi#n-HaUmN&+vJ_e*A<8!f+oY#1?#LjU2h+jI{#m>aB`=8dU
z3Jt$n5xLlIj4XN$K@u+48Tm!8PP@~q7&&V8GJbg1VA?>UUey(_uSxO52O8u1UGYyg
zSxzwg2s@cC?bE!Cdv)pGzgu}TwrM?VY!z=Kv13oY+&*{q^J_D7AlW&BqX?muO%h=O
zlQ)hS*QU0w88|Qr{#DuM|IP0GnK{cp>E966FrRju@mEhZi7n61nGQoc=3Sf$ve8ru
zGj~2o_Kdn972O~dlmP()%3P=fL{tmq3A@pC>w|Sw+1RG3KGW6_7o4W?#2r7#?)bgS~Uzq&G$b$4YY*9
z6{FC_!k@^h_;OScXzuYT&`}kGdhsa*T%V3_ec*%vwo!>+deu|Nc%%Y-BqTq)?~jxJ
zxgA3m1bcOY9uYT3%Qbl4YOQ}7{NQH&>`YlGjV18;21{S5aaL*E2@6CbN9P{u_LhD|
z%q59qI*x<+SNS_df+Z4OGOc@DLsp#vQAWD`$FQ@ZuPY!f-eF!YLHlg2!G>7!sRQ+L%+BO;%!a1gn#vdrI}&?LhTaJ*ox^+Ck+lW(svkf(SwcXVjSBhn
zaeMZFT?7xw>-F6Y7}E-WPrF#Cr^gFh$=4azwy@m+R@iNL;}PW!)4UNJj9-Jp@ZGB!QfN#f?%=!pXbEuzBpO8gUWeT#aaZ1IYqE
z*ajqmt(kwyUlTAi8Tj23M|@~Kc@g9vW^q6-Vs@1ZO95jl_$1rwVl;y@VhU;Cu@ela
zgnQG$Yr!N=Pv>l)g=4qnH~$KjeFW#Hzz0L3)p(;!zh7xeg;-79CO>Is*#Uv8)STvM
zOPi#`L!b5Js*2ZSl?O5_51bp^ESaz)7{V_$gxa63&qy{P*G-V=rV9hn_@rG?Y4-@i
ziy7hd5Bdspgk{FI{%)y#Cwm-ZE?~gKV#eB
z{YTjF;YDUfaoaxges;kBvjKW}0EbDl@9MA1z;2qPJ*3)yxbcj1k+9j{kC6CwBu&I+
zDOu_$sn`MgP=4+4=Kg|y!oMg~M8+$Y(vO
zrO0?3wbRr+M_!l92+&0&UzqwR5Jf~GD4EBkUZ24)*7yCL@y>_y=in
zF$=-_S}rGAt$&*_wedq{l9`)3CYXy4GX_fVc}=L>bI!|f5vTqs1ZLtRLs2(1{zgO6
zjUJ#w+JA#w#!{rcHciU4XQV}u4z0x0^-cE73yJT)PbxI%D>DWb@
zoH-si3ZprV{j<8iJL1!*DUAmH!$n{v7XWbCAz{mB~L-%^F5Oof5
zd3U*ZRzcg*tnn+Ywl)3dnqWUHuBB9S{65nY?IqyWZ4;31l&u9|SA8LE|k$Gux~@7uqjEnT5&Tvc3VFz47_
z{*&22b!IKd+HmeR-$X1V3Rw^(?BJxTnonc`qdZS`y!@;}B=&u!y`T(fbd~I)Mn~?s
zH&gdl1KaIcSTIQJ%&hZx41O+ZCQV3`F%e-$A$-EKwl;rt>A`#q<$y)J$qUtPVLrvK
z4Qt(vZ5+lglF*r(cD}I#ZRKRQ1%1Ek-P^;Xk?0aej*TQ3>)r496}>&;X%{RGC1mrx
z-=4*h!y{)_$pJdYs~8F;TvLg6dNNE13-~$tyR+^K=}{PF=Imk)6(8yNpZQg00
ziJ}4$+ROV6rN3*ju3$^@=V{;iuDFlyf~v*t&Gip7%M37Q`&9^Z%Gd5-BSy?x>6jaX;&vPdWRW4Xya3@N{PoKCO%YKR)Ev6s(Q_-lKC-!~K
zzHy$~^N%oKk15h$mMFCKm`hQ)!fkRWVKjk$?dYlK*x
z8^GtBN$B``FA71;-8K7+EN@OyKr!;Gl&+0x#DHy!N}{h=kkIFsDf8jMnz%3DV0BDF
z+cj}99S>n|^0f#ijge~N-HLqAqE=#HLCA10#ks-|YEp#AErcZqaW}p(*ogV&Y!hFR
z%CcoG7xzp1uw+8tAu6ieU}|MyQvB}<;r=Gb_y**Y9G(~u)+;Tfk~!ca5%2gF?`%6@;i91ZsNoI3~K~OSJ`Osik#cQvpste
zZS0b0`RI429$`D;z@-fKGCRs?7O?WB9Dg`I#=CSp@j!MXjJY7?&9SrBdwU#l<n8lfFCd#(I!PxOR+X9E};F?_`5d9{?
zA2?qzl-HpXD(BI^wfU%3c-~JafIO1{)gAw#kztv{Bq@qcBqT*XXC;MuTRgIWUXNtO
zO!x%n)hNXt^#jYGgIY>U>T(qq%beFJxm^i5H+ipgzl>0G$TqdfLAu1b^yj`>4;sc-
zKYDZHpszt`;-wfHi?Y(2gxIz8BSNA7kXYjWil@fBq%GTOGCBGEYJ5n;*T=Ze+24@g
zk{H!cPn*QcJ@qTJVj>|73F@X3_!9evpgYxVA@Mg_OSq}fwLA*e2RV?(o}(B>ktxL{
z<%8$q#u*?ED{k)=d_BYlVN>Gvk*Pk1O%KVHdTH^8KZ~AP+(|vMIer#tP
zPX9;JSvIu6HcJ?{;#%CTxVyW%7J?Kn?q1v_1d2oP;_mJa#UaHdxVyCUwk11cUzy(y?9Nm>%ubeJ^fw*L4V-dwUkG
zD*6F133LyBpQt$2{O0a{e=>i^r~pUyO^=RN-0x9s8lJD$B^ISX6nBRS&Tkd@<FD?2_T$|BP5D}&R$uHq2ri@a
zRRXaY-=2bZxzs^RArW9K)7x79dPpbnt6YS~ZH4LnC#QS^sbsJ*(v2A{;h@4#!ra~uB;mAWi?Jr3O
z@+^MTB=Zu>$6&nU!j4t7kv@qdhc1p^P!JBee8;IUP=VL$5gTY1?J$dfAr4Jh
zwfd<j-|`<}0GimuU5FlxhrB9x
z+;^$1AkM{^XuuA7P^&lxHf@-z!!v!Ivt}f}fv=
z045}aluFuY*QX^@9RP3tjM%ptU@{=OX|tN>ju?AMHG?DM29d8g-CVV5()ensE0D}K
z034TIBUxPb((^GCmV*;zSJo2JPy-0jjRCCNDLY0#H^C;ph-+E{Lxg-PA0NhQ1DC6x4M8704Jn{)e1c6!|z
z{W7z?bFalN)qr|6Gy&;TqCN}=&Y>P8Md56W2
zJAnuja}rrcFj*h_8Ij&Ty!IdClxL=-1tiK3r9>}#cP0Q{cXoG;*$+SRA>v|@RKLW9
zg#I1~(vBZtTQP7%xW`$*5(
zf9*BXOp9VsXZy*(k`FJw;@DKq_o*yO_HRB}{Ynv2ojt+2e4UW<=AB0+!%qo)$IDUr
z{bKJ_v(4@8-e55!_OAUK&z|g>)eFa69!0l)Stbk^xGQrM_R!deVB{OB4cxU9@;D4z
zm<%Jc0z(CmclMbIiVY#({+3;cigZ8iWZU~d+b$_K+HEQ;y&sOLe4IK7HhU}%VlQ=^
z%fI67(YIZ88u*l3JLb-_-#8gmBsB6aauT^@evD)hQ;xa@^hhb^1Z!#J*qBu6E
z%x}ULC?rS2LPo~9DYoyzl$0ahj}6yU;Ap))^R>!gJ)`hZ{l0npy*_-f-F^ja(8l|!
zDjjSLlBpu_QD0LY)32tE57>pA-d>^^x?l+#Jgri#EN{+SzPbkl#VX|wCEY#Tp1vO*
zLP?6VXoDYp9RWdoYyI)WtTx39+%#zeo}!s*uc)l}HS?fm@0vPcY{42~AjrcsFK0{2ZDEMyvYo
zUz-2U2rs+{UBh!|{rJ=&beYHy6!TNyG{K+=>?~yT>+Md%_ZnOzf4y^@u78u{0g67H}%r`J-1%RXx@}UGD+=`CR4!&OBNP1}&n|Gnp
z_eslxMV|i^w_jlhQ_3be(_TI4P#m}t-QX?I@+X0EeA`}UAkM-6ZciaO>s=WJ83H+f
zAN;u~n*%01xy~^@hZ?TzyDGi2+TB_=f;mDQ(=H3Zq}oT>;PyMw&$V>v-K?!m50Gw=
zqQh7vU^8Y#3a^>nN&;b8;xVH<$k_w^l7rE$?SyZLfzO+(Fw+$)LAwk=Wf%9{y=~3Z
zg@R>v>{ZGogrq!Us*Ds4?^>B6tvMme&~OeWq=4Pid@!!Kd=>G12bD}EI}HV{U?)Un
z4Tb!tUbHqDnnAnYai48Ej-+W%i8j
z7&v@wz+4Bbi9IM41ro*+0d%7^b!R3JKS~QDj;eHuXEX53V~VNOtb%;{hp3)6-&1Be
zMl2<-w^>&XsC6K80L;Xkmi=tEN~uE*J^s#n-e?mR61QJ`aOO~0IFO{Dxx&^~LQ+8e
zNH15%f%?Gb&Nz|Nby&r1j;h=<=(}uq2CVK
zCtXeK_7Cm5@0aWPX|YOhq~$~6$5Tz-C**d)MlUD!Hxo+li>dJ%8neBAp05-0H~W@#
zM8AGe^hk;ay`%fRs^|Ck24i#S+-7l>-X0*{``u66+-ax-0{#8(56+*pW;G;w+9mT3
z?ZZ+1^jW2Wj3blw75@52WM|s5jUCC_;{9XrA~e^Q;QDy4rt-N?&I#8_G`*#y5hd#G
zKgHh0+Gl!G<#CS|#nnrsWwW;GEi3~`L;7EO5vJ*MimZ2PlclY2)SFKK-e2g^&4$?MBI-M@P`sG2?a=Kl%ufgiGzudWuo7MTHx=beO3MOyMlEpYb8yGR2l7
zYJe?TH`*6fxW<|W&>RZ&n)2x{G7!Hf+`MDQLOa%$e?f$DJ1K!NN
z9mhc%O~aFsRhavWGR3k`{Wp?8>Z+HfTNje@9~%}ma`I534l4}Si4%O^Tv2tzyL(~j
z-)K*RMRPqz23DHhAKg*K_k0_0npC9x`f<|65H3Y{*$y{fH^iyaQaFxzKSc*W6&@P<9V}?5M?oE$6xXmBJZ?
zQtm?_OY8$D^td79xc+!EfmT{_0CsnW2-&Yx>bdkhS4^n-57`>rEH^n~0zBTf!f2mL
zK7OQVBy-bCTJmsuVF~)R0mPL^XlMWJwm002fUD@QdT?TCLi`crW-7bPkdRVKLXAyP
z(ep^w=3~rB0=QYrJ=`&chsq6`Hz%{5s2xu(>KW;)VE=H>v;_@lSBC~aYuy296H{6V
zhZS}Y_X!^loRs0CV>~ma=;Su2)@vL|4smeiP>Ol_&$TjJzQ3ocF$%7&H9&vrt}HT`
zskij4q`b8=YRt=qeD`cBIK^1a7(-ei{}qGFt`<7H1z{k@(%e@OKD#PkV*2bFX%?
z@up>s6b|s8`bSb{6e)i6Izs{WO5;t;n9hRCVfHfVl>r4vH4-y_37G-O8W}q!+tfp`
z_CtSC=J;aZu6^zEdC~2C_x%CuS-9xbE0vr;iD27Zjsi!oU&M=ZP9@PV3doCy-;L^)
zFbV}u1K&WGTEPLUh3wvbleAR*m(a@3!k_MvL5|@V+>>7i0C}M;)0X&6GIDC;B!s!9B!9!6Fv1
z!z=#+!rc!RwNdaU6v`}R(ZA4UoX
z%Yuq`cl#($gTnw3Y#E3%
zmbk3#qCZDZg`3l|aluO2A>4(>f}moZhC^x^-WqK}8aM&8pa>H~(Fld-#vs>BH?6lC
z^zXY$jvfM|@J=UPW3N+rN9|Ez^=__hK+8uTUcT1fLTu}5DV-12c%3<$3NM<$@K^{;
zsfp00;1T6mybqCbqae8hwsFOVy{J8SVtO?Y40rmgq*U?#M}eYN)!f}1{b2u!`#w;9fi
zEox!=*^BJ0*fFHTC|s0nt8en&;%aKgkOm+NQ9*x8u!71jFl42H{W0I#+RfN9W*Ina
zihsR_;%wV0fct!b^~6+~#Xp|i7jrKjY`%4M1$cSxPH
z2;?+Nbh&(L@8||wu{1{a(;r@eXcWjUB+qL1E_eZiOb(L!@U*JN+xE8i6MR+lqduG^DnPQwwu
z4r1E0D{`NIs}GiNTl@Vw8@u&t#(6{P*4K2wv-CMv`TA&l_l$Cm%4NKMmi@ke5;r#n
zZ~wN4vgi;{L?UQk$>~MXDX!j4Z(F2pG_^7L2OC*estaOf4cr_Pj<-@xg9-|X5wz-9
zRx6JhWh}>|{k@~wH?GT_KU&KTOd0W`v)y6Xy1#yzv#$aZOSd>`>5Atl_M0AS5~BGu
zjL9;wx*OVbp;VecV+RpfCGr>iW`c)M8_-L06gp@Worc7JQBx2Y3{5@
zb!TSr$-jQF{F+tP(DM_jhPwq6e5mz{y6K$9J$kp(^t7|L9ORwo`csh&n_gQiOB
zD2pLC0uDRh(C^-#S{JWPJHFs!8_g~IF8va04CUZMZ&FtvNNUbjQ^i%?3sngtp#6P0
zCgx?s-8*Z;3uhIANP~(SN^SLx&bc4+SPF9x&SD1>(<+&282+pvgv9mdIn^)%-&XJo
zA}e%28(LX|SIPt_xG5$0(gi93nF^M7wb3%(&Z?$zzGf+EGvO(LV)D8ch+*AheU!ck
z?huBiw#sBSe%57QNjXW`rCsahSh&^V#{OgM9cZ={t>~A7g_N=pV}Y>K~*C2`(&
zv&x3B;mXX8cP$wGwpUV>rP%64z=N*o6ai^x_H-P#%+bv2;h3+NHXKBs9BbQpw7zjt
z3|$sb&np%D#GW85>c4$|V2MM;%Ntg06e`;&eU=UOMhH`>9T5xeI7k1s=@9Lbkg*81
z;o4^J0;8@ft3U_;D9&iS}gKz(nPjv
zPmJLw4oGSoD~mUdK(!^>Sht@U>NeqEcbE!QqQCFus9h)y9e_;}m$n?RCBHETRK7)xPK6z#T2c^RjiFg{&tHfQKfKQTs0s+2j
zS5J3mX9S0KOU8AKQ_EIOc~=|;SR8eAF0JdEmOXiiWi=2RPE${V&zW6(McDE)1I^zu
zc|zbgoNHI_rXY4aC$n!iR4uqa`A$5K;OhuFW?*nY;c9I72kow?a`k~&fp<^e*yIcj5pq9g(fy+|1A4rZ_P
z`{Ph3aU>r~i+%?ak;aD(?cy?#^b;W>aP8r(XKs_f9wsHFfwG};Nr2e_@~wm%ozA-{
z%~)4yAT}b+pc~N(2IvKqd?FuVXpIhS>q@-+HzapKQk5LmnW*{+Z&j%aaxR>i
zd(&lp)V@ks#XY7_%N`^UAZ^MQftYVhsnZmQL#+x-F;`;qAwB#S`hC?Mi+nmz4e=c&
zqtcmJs{GAj$a~~wvJ${^5w#D|yC~5Xsbld^TQaG$GPLB*g&dGn692R``8==UH530?
ze~l}gkWRM=MauDS@f+;9-Ai+vJzlF9rQ(axJjF
zp+D(ZiyK~zl!DCEKTIk$1nX8Rx&{u9kv$uRFmU}aIgk+hB{pevxtMx~bR*Y_68Q)C8i{o3p~>KmmV$
ze2a3TW7}G_SZ+RRRZ+4B6m*J@An&cR{j|wk64(+-D;7N9bYc!R33(gBW=|6lAB-`^
zPc6ybAIQi=#0Vpr@^P<>BJIcF{4SQAiGA=t5TShYW-%>l#Z|noyD#JI8AcdH4TDLA
zegKM@pdUu^8VCbbWe0J!IduX6VjDC3RrTL7ZSc$ykztVO5K=;9^Q2sYI$rkH&E5}P
z{t==h+(@ESWYX|u)f`D;IRa-|De1|j5*v9`!^j!dkjL-@;efFde(QYv{lN2bTD>}n
ze+i0GWNRo-zKnU#^u%lZ7RTI@WGdW4i6(9d7|wKUvC;m>ewhnjqTDReikls+AFsab
zJs!pdX0j4l;k0$aOD*&hCMRPg%Yf>~q7;=FC#enL=)jqD=DkKhA(#ayB>Ha%%IsGC
zJ$)c@f#lA28F0`G#1H$7I4Uw9P++45g<7qjkGgVfSES-)}kD5gZ=}R96md&pz1^lQ~SUuYHm9L)=$Yx
zyB;$R{&=uM>qdXt-}z>NEUfIj@=X=sj7_hxMq9zOyC{hlXU5cxC3xFxw$>%x2P@}n
z9pWtkHk);!V1E+GnXmrQEJLR%CgJ^O{Ensp4k_Cc_g5VGfehL7fz0#N0lYx+?bHqv
z1U@;2R+yHJk#PLDv^Gt0r+CxhrOD{(*8Qf&r3ZRg2p9UYp6*&aoi0P2JO8$v%ct?c
z-jCF0GYMqCLq{&MU!6S`ze)K+&tDwcdvfc%n`V|tLdkc#%L!f^j_55#d-xpH1QrJZ
zsR;Kxiw+C;jMUPxcP*FB1r~!nGTGV*^M<=3$ueh!nMdaM3#H=B>BpHSaK#*vB9g_d
zloA9FSH6tA81{7@NhZ2;*kwQHjqPbC=>%NpZ#HN^YJs&L+Ev|5M9O7J_`C$9w75CW
zWTO>RQJ5(FWa|^hz^Q$0oJ-k)QIldoi>gpuB6L!lDq^@aR;sp|;;SFaI5g~@eeQc;
zpxtbtuB>EF>KV8)Y6&Bi#vbamPO(8vVFEEXi4U4t4x7eaAm&r6%($H7-gyUJH^Kxp69r{E_M;n?B3~%LzXDkXEpKQh*%$N
zDQ(&YQZ1$v%1|j(*x_&gDK`Ut)>vBlndkNjcQwY4jbZP}>4P}Myi
z!U;23WK$mOtEF>V1}_p-1JH82wTk$mi*Z!6V%H8>x=8sUDddtKwVOuT3HezG5%8q7
z_fd@*dz2-z(bL;F?l$f#XQ2xR-VHVe1DtZxv5Ke|M;ur4|H%f5{))9`&k96C6!(_T
z|8~dwG_x4*QuHJ5n|tslNRF+o_VDe6LI)KuGj}so;ypkev8v6;;dB`cXoO%MxQM(x
zHkRA3U`(YyXRo6q*%K&JC_HcHxhFZ@fi@z5V!~;{rN(d9HnO{#UL5n6uO`YGoWFR^
z%eEbk*&^xK6R{)t5Xcj!H4Vg~cdc{C$2vB+IUB>LTtdN@2D+APpF#LIxj6T9o#(>C
zviPtZwexkB&tYU52tOx(f$TeP@MO*~ROvNsUnR&((j8u$t?oO<6ZUIqBO1cnhG3c#
zribA0hKKJu{wBtFUA(bu3nedPy5IUphkZvoK>MeN3I@3xyA5vwwV*^44bkrf%)%~(
z7!vxK3n4`|!Q28DZ_noM`(fbT;?>EGIqYO})lT#-2mqXjhP9}olVWwIfr+U&4e
z3m>N=FnHyE`|=K0U8!@(D(uiLaKNYV)2Rx}$PR9K31A*kO(`B-iT
zu5jsn{__YKg8mzH{>Xe=BY*mNCbX34nFB>bl0*$`JbI=Wq>_9U7e4()yFds$u-8%~
zen#KDMc)`vYg*mo>IZDNW~k&26y#}94q{}-X2|}@8sguE!CLYNvK9Wps^7G1)3E8X
zvQDqctRG!HyZ~f+u$h{-TKO^SulNlJ*sONGYVG9w&H8oU*9f@
z%}rL9+QYWh_~@<&i1(jU2!(5R-*#BS6#c*BExRQ$^c%C+w#-}@
zpnK5=@7`QGHIjM#w77;VsvH5-yV&__LKt$6)h2HNay4X2w#W9>6F%Fin?OEX9@^FY
zW$&nszRoR^`3;<$2lTRLixr9qfm?zjEtF)Fw9vA*>m94<{*Apq0vU|_9db&S2E!DnqTcvj;1eb4
zGj5V99xeL4Bw27`&Yc6q$a_4_d@P{|g^Y=-X~y4GXMvCQ`Y$h`$od<*6}*I2!8#t7M?z<(%NHmDQ#MrCliNZZIky9vVu~@M@pMA87(`><&PRwSz
zvnbA9olpgun}t{mXB_Usx5@xF;|L$1y>o$e-O_9Hp!
z=L!N}3_OQ6SOxLj5ZW!A(4Vzm1a#Q$nX_?+m4s~KA^%GaLC!1}uL5PDUVfrvNSN2}C+$I7USE)JtWUju0=7(?Y0?yw_<>kD-$^*#_zGPce
z$8FM#pq_WCtoZ3IBTy17{xV48gjla*g32xnol2Tkk$6MYniOTwl6(3u2^1sSMaHOe0g&(QhuTAPnsHgK&-gEh8=T(!N|BV)`D7f|
zorR>jXb;h!#h;lv8J!F;aK)6N?FO`C#Wgl~lB~p*2Cmoh%Ac8dahXi6wK@^V5@nyI
z#cvmg-v@VS|5^6q#N;~h7e^lZL^#3>Ppy+4!)}DOy@G`a46)B)f_Cy>Y=Zp01-!jN
ze3^x7^)tFA9AG_MiI)0dr(rpF$%BROS!y1?QXwHKhENv3-T%FSth)puDJK!>m`AP+
za3HvcxgfyVG+_y>W}H=tS-~scQUI$NEY!6(2axW9BCQm$(=t%{W$P`nfub~^bisaH
zJoUW+zc?td>ghaCY>rnV=dVajK`$7_MOQ6`FUoVYD4w?iK$5P+{^PFX8G*#7j6`pX
znZ}Cx@rf<7eLW&Agz5SOD(h-5>pqLYwnT*Z#Dyay9ASe#4o23Qv$dPpFr*(
z$Ne64N+ZHtsCsG1GZ-wK>rALr7ikzaA-hd?nFDr9Z1BZ-dp
zoZi$1{SC{Bw(&S*-J9wh0>#leBQwFmr_pZ@AyX>zo9%`!W&M}_GuwWR>oXGn_LeUl
zdQ3FN7K7`y<1E{jlm5(IS}Q#CduZ|4Ju#!tuYN2Gww)vS6&*hl*ki`ur4(OuJX9e1
z9^3`r`9^2%(_(yK6F+0ceU)73N&*Cvl+9ZSO&d>=*F^t|Wu}fJiu-T!Lr)OWAgbjmVeIOu%G8#J1W*kYEFv+uD;HZ4
zJCLQ3-TAe`k?@1abz#ura!Zj-LqUM5SkxyNnq#JoFo_Uq{7j_F>TIO??};HFY!e-a
z37PpF=u0n$EyAs=$`Rb96l(_hRd5+&2eK=z4@iJ^C$i_inM7Wc6#^MPL=x@s7zJwe
z#>PrfN*662vHzZw&J=lud>
zXV*}|STpJ;q=3r~a*LIn0D;78i}JaAFp%x
znHH98ZEcb`r!J+itZ)T_(lzWcOf5Wj<-AE4|H%gpw|`$auJ;V)Yoac!bFPN7N%cLu
zDn&XfwdT7kFIUwX+SChYJxci$>g8Gs6W~7|;A22|&zLiMacTqSIV>vU1D-{v8D1v
zGX3bgyi!YLr;jl{GHE{H_x&)a8@R(H_b4Skm63lKr@>C8IIZC4pYqK+e=N{HKfpab
zwtpayfeD7D+c)WULS&*`D|7CMLu+4ZYiO+4T`0BApR&{suqsDXTuFnd*JT&8YcJVd
zu+V=u)miZ-wRD1TLFklUX|trpb(Li-%Tu@P642oL19>Lxx1EC4GN*EOnQuM;W88jr
zA!P}d*<53po~j!Owj7MqiYiIz0V%!8R|a;bZW+ftCtqle#5
z31SZ+Q?{#N)YYnY-wkriG3*0NOztG2zzy3}NFavsrb!LQNPWwB5Q2adhGqrN`A^e^
zx(D~JY*veSH$1^ybc%HSGpi+*ds!M<%@UMelo>}izN
zGR>S3YNk-3@oV>UM-(V3#VlNy$3?P=HK<`d+9SuDs~QAm{#5FU#cuC!udd_rp!%cS
z8oov6IMKiDbWi&#n%ttxHUhpWKK7=g)o$-{5Rh>{e
zt`|Aq#mSklj5CMVX?Z1wilmP2uFJ$>OK*xeZW3$wzs-c{0jK@GoOv7F-F?|cdY~}Qv3jRe{E88h
zMn$xE!9+v$1bLuwxcXWgjva0c9j#)|4+Qsmk)Y4ehndZ(s+r)M+Znd&h{i4xjIka%4Cqwg+1>ALA12@Z!BIq>jM1$$Mj^l@
z_Flv-S2LGBW-mNSjZ@dtX)wl}hdfPPB2k;eDKgKQI|pku2mCPO%}**F&0z-kb~7?`
z^kX~d5qwc)kg>X|VkPK+p-|)lq$_3nIFCv_Xv1lwwg3>$$9Nl>4dh~&nem=(np);W
zxgQPpiOzdShdYy5&RAU^LE9r!ErTygZ^Zv>kNJDEJ&$dMdOf2na+)`;UCgmXo{iCK
zNPQ{aQ-AerX4AX1^kTfP8D3o7VE?@&K2|+J7YoOpKUhs!{C$US358=)CQ+l(n(sc(
z8!t(;%Ai4Zq5>oB>FI{~xN_b8#Lc%b#(LhZkC7M$mW!IMA4d_S!u32_K)dE)F!f07
zlT$$)>5W@FmFUY!&9(uPhQi(vX%?YECGSl9*&O9UZ2*s!er$Ub2&ZRx^;!GE&U>_Wv_xOAO#I_{UTygOrf{z-2Mg1iDEg1eG}-0vhre9zV1Cbi0U
zrUF(Fquy6u13!1I(P{kYTaE|W-c*?%d#iDtAurMA9Vnk1iVNxS-_x#xgA?+c81F$@r&bP4bn+J<8K$r)3-
zfk~)p?j60IrwQ_Zf{MHYnhjO;S>D5!SUS1{ecX7a^n?5HG-J+_b8S-ZG@($2SdJXfT_-8el4b^=@(GvlMow9gA|n%JS$+$I
zAHzK6L2qYy7rOIIwGdjOjbHA=#N;IS`HqXcttr&xH;;R{KIWD?kwaLTZ6mYNJ`e8CZH@qhQ$M2E%pfyA-Y6(&$W~V
zzrQcG?E_+nvf$9~mT`lg(soSTL$NUne*YhyvRy;M>4!r_3peT$IYB>6w)wUqW1sxn
zUcw18yQ+$yoSMkGtKsS=bs#Y>EeGn(xZH}7+T}PpNajt8C24)$bp_cvM%tYYN399K
z4y1QLgneF)&*_PP2;f-b(p0!L@Q(kKrC_bbEg^P)^E_Pip9F
zKIq}L=o9!w@C0*|d>U+t9=-c<%m3w7{d&dm`8D1k0Ojr-#Hp0Oro_0eJvP(&B@OL4
z22N1fTNb2_-!^0;0FW|)I-S)LW{JDHG}2`sNDNVxoA8v{6B;4h7FJKlY`#yI!4i27
z7BhkvAe*&|wtfX%`CH>2Pmi9hEk~j=VnbAN_Vm=s1lb6xY
zbIX>jUm19A&kxP3lr6UAX00?`$jcf5q9ibA-tb9G2NX=PFva+=Lb2RLjOc~&7u2w0
zV1I6-q>>4?m>*@4X*0|IK`&?O{eL9(3_P3^8|>`dBWb%)q$e=A!-9zd`f&hhysWtseU_xu@sR(ScOO;>WBq)%m`^lh##^bPIS@x_nr
za#Zs8lU>>eD?GpMI!uZ&$Lxr?KcyoY!^&`CNZKRj;~{2$nV_eNI!e>sJu3p>4ON31
zDY%X_Rwuy?0wE+PbiAR-hz-akvhq}*F~2l)0i3k(_s|&0MlE~Qd@aDFVk{>044us5
zjwQ2*TfeF=F8KA)kX~a*d+|K48!C
zykd3t#zNWGxHdMF9I}PNNjb15X0V&C#$Q>>(soEqY`mi*+?f1wEo%~oTAkOrCrDgI
zicNQ~q?x@>=&%eWqj0{(Wm?*$^HvoYc693T4P_G$jKoIb*A}Yx!b|PLc1lm^8)F@dy|({;?wej
zr5b#W`B-I{0J4|}u87;=SLF%|LqImm>QtNqLjERxz#L40Ey3SzwD_;qLz7j)nkvfX
zeADRr{R;gJ5uzNDsd}pS@QBK;Y3}WT+wbsUX}!U*B-^Oelo?+czY8B~p$11vWY2A^aQEKc*4kJ`-K-|}HNBNd1g_u>VV$|sU(qK{$hb2|O*C2G-@K#3Y~S;JFc%l_h_f~l>d
zx>QtNaJEy1i=f|Rx0BSh+xfe}@@ttu{I~mtL9sL6Yx_L;W>~8Pq
z1(*Wjn3JbUO=K2H&^cdpWPst|^H+!plTITo*@S5c_$Z(!>Qe!RFN!NHw>c5mG}_!R
z=o@m3`Bq;rV&2Zj=N%o)-W^;-vaA|?!Kg2iykzEB%((c5v_n$;97?&z<{0M6tlF+o
zVwbUq!Eo%`fj2_t_aiQU8B(O7XJ~V+$8KWTrycEMa^Y!_40uRjRp=B3KSlhI0)z+YwPU9#C`L*|o3>+zexSz>exv*s
z&e8jqKJ5Ma5pq%0bz>P8e(_K%aypQmQ|0uHd#6zXXKic%yJTjLF6U7&qT#M%wI0~WoIf3OX@<~pI@U;daTyNl~U7BX${dAdFI_NaN-
zSv(jRg^%Tjtbh0CE-{3F3BfQFu8>gZiwp0?eH61O@5eTVJBkS2d@oxSL8a-Ci0P0*
zOi3X-udz*=tAx7Lx
zhR$jmjDjaeJ$(bLD>OKP0xx+*;SA@NJH0PEDuuL|1e$9
z(WEP=y}Nha<#B2z*e$3JIjrvTN$~6A;z|MYX!{pr$%Gt>uGL)j(Sj}SKI2+j7)oYh
zHKZDKnxCK0GD%UBC=|
zG9jri*ze9*_AZf`C0T1-#r%JeueF9V;kp!--pfRLS=z58w`=8E}EdV(a=!35rPK#4#8dN_7g#<6^iBD|?cu
zorQlg1fex_9i>rfISdbiw<5>Gsv<1y^Zgn@K3b+K=S?^r1a#OGg;F#IM{50r
zwW7MSZfynTPn~b*tf
zWg?ks!$|n{RO+ASS!wNv9C%Cq(5Zp+&*`*!=b4rgEr(|GW=!<()>UopIAF{jf
z+KEP9@4`4CWW)Q7Xlr5|l0Z1*Z6a*!z2QJgN_q~81DJU2#!Go2eN2(bYb+k}7RQyB1>fNh~3!bcV1K1dvj{$K6MTYmRwVN^|$razdIZegKAe$gq_}@=RqV#
zhkg^4?7m&oq&s{ZOxqBy)iqbxchG#E`b{P
z=kxB!i%nBsSL#BJs-%*tq86s>-A{m-Dce(kQkDsgWI~Djnp_y7AdNoYs@3%)0&OgI
z_HH`eM@ahj|GJOi}CbIdMbtZ!*CO_Z*{O$<|snU%^D!wV6Am2bG_F=9C%6OgnhCpB1(F#8_id-@v^-d(PL)NPP
z|7Y~;#ks`4Hhp<)1zBv~i#MQFqzjPx0tRqEm32JQF(lcd_16cRCESGZrkh-I8jaaS
z5N!|G)vM`@WAvncpI?UBK7=%)%L-Xi$Ox{)Qr>j58V+O88Mm$Yy
z{#<0oXa#Vjf4;aL8Sd`d#u*IU+Sa70nxDC_=^#-K5+hxt*Ws+pXdk{3Ax
zz~%qjP99c6jd5Uf~#fK^eSqIY~@yj0t06~2`+DrV5>i`))xK*jj9RRocgusB4@Hn
z)(j|o7@)6?;z6yGhEdbQ>CU;xk8$5I#+QUH{k1GCHT>tS1?k{VD{VzsrAbO=Tuq0X
z)F?9-bLTSFw_#iXxP@zlbyki?@=`SNexPOrQnAOy0)dnGyHCh@?Tfoy>w#LGrr^>_
zlvW;DWDR&2$8ifgmg^UW6vhL1G?yV~f&@%AVJb$jT%mKJD5C~aMAvuJRdRhJ~q(N^kWX^x)8b}QMsXd
zP-W%}!^F4CGUm>oyP3Id)IFX>w{dI-o?SfpbKu~m(+3tI(W9D)<3Dn8rNH%;B*LJg
z84e?v;S<}ZGY@2(Z`0GzK;zcXN|jMNu2Ax!bkW6;Xhr{h_1}pr
zmzYFwO2q*QO%}%kcI-&S4YDp6>wk^DHIo(7_2`nhu$5iT_$v0Nbi0NuCy0bEA(NqE
zFb&jwl%BCewKAy=$!k4MCG`pjCsY*3_dcA0mLcS_A)Q@#@?JRm#6uhwE=sBP1G%zi
zqM;E$5pK2fOu?~kXtPw$I$)c<_3Z}ofG?FbyMAZw)07jUmTDi+Ltb1bz*`1-C<;)D
zN?v#=$;v}dyKF0d@E6SU*00)~nE^?xK0Lq$ai48$)YQ2caF|_b)z%Va7CqT^?`J0x3TJf`6>((p}8hiQ$YKk(XG@^$yko^Jfp|1C&=%aDG*k@({|rXP^v%
zv@ENdD==MmYlTxS&ml8e3()cZ1c!J5@N7R00)WWJFiJ7xR-nwOJO2l{2C9(hiI6gV
z7Jibzh`4P3Y_@9teMRBXC~O!Jw(F68ULQ4h0hk#rty}<8bfz4#RqOk{U`BX(KUKje
zJH7`;X@Z7$J;D4Obo-fvXFJIEQ~MTQlS!iH*Z4iTTI$iTm-F3cIqGleY_Flth^C0*
zTyYH@=gr^8LVqWa{0OgEMoTZMY6QsOz;|UUdq#}j4aQ>=V8_z*v&gV7^OG_dGKbWa
zRYe`aq<~)LMr2h#x6hMJ-II&lyPnAQUK-a(t*Q*G$6f3K3#J|8$wEu=RW#d?mAFuK
zRGp^FR1OKG8cN9gY3s%{#I6yaS1RfB#BG%HAd);CjL{ujcf=x~0L&kuQWEE06LELS
zFWq#Uc`pCQ(p!eL*|lA_xJz&??(PJ42`&UOnU_vs)^P%sGcSXy8|WOC-dEf8{6Q7Zkch{CB=;#k8B|MU3=W=8oyt$qt{
zYVx}Vo@9RF!bEEfE~LzA;XT#9?F*|&8|;GQs(`t8@^rp%{(p}COdPD?75g4%66t|M6Hd=|6Q)>#pKv^p9~;Pqs{}rbVe=Sc
zcH5umVAWW`luK7_{Z9)m2q>E-&T@?^Q#w1#)iG)9;DOuciZ9-u|K=fnSPHjV$Lrn7
zn;WZ9XCh28$J5s`;afy7wrY?<{;`>aQ|+hsJ62C*q|6G{;mDw<)&G?!GN4AKClWD2>sn|JI8`WANJGENKkDc0pf=P?=faFj}bLmxMVa
zB~{*q5A*+AMsR+#QLb8)zU#nGtT4esYGN*o4)-t9EyU7`Eg_h8VkX|PD-3yI)~Xdo
zBQ%*fV)gAxTRhUyw~Z3INl^it(0TTLn!Fk5!5u;nO?QU1-1>DPY=x*e!2LX
z%#BX{`wQj&+h611qjy8?pNBeWH|4_-Dlkz8gBzntae?6Qy`T2Kd1}9z3A72La8sqA=9K#p1j@{aBbA9Dd
zs=&E}nrI{}?bE@VO7ikzZU;GpV-da|NNwx3UuMhsQnKjwDxA5zU;}0a)0m&%q|oDIg2{Ck{^QIQ*N8`w
zQ}c=9LM=HrCHdyEN++0l)nUpHGj@5iq1+f2WmcM7i)7Spdq<1-&MQvk(XSR#4(vgP
ze=xB>lp$wYrCz^`@gHZW<>E>p3CZGkMdOBGqTA>6ATrFeHJAjft*TKf)|)~1yY-tt
zn?h0e2&%46gNpiPZ$)(X^9IP*0Mt&QzX;0)+Coxt5dA{aGHH)3P}7RXw=%lptPb4yzVTlSa!PF*isSqw2sSJ=KwBst965XeaG!`@UI6)64igLuAd+Z
zUW(Sbn?kj!p#lwB!&R%>2trqva09=mG8prLiS%W7@p1%!?r^>oHecAEP*ym^wB~o!
z#dzyB+GGjy&#$VN)xe&&Zx|Xj0T1l62?p!_n=ExFBPc?InOqOMcI_2T@DR0sZwS~>
zD*-~ql5eK~ATTY}3T|1L!38DdOo1v5S2g`GsH0F%JO;dE6|G>P+R=|ARZ2>W>%(%0
zd5iZ-vYJ|0#O2RLK(|;{lKe{h#l+Vjh3kll4Y$=x5wG&KD<#m}S+DAm4p$)o5qAyi
zu+Hig3dr1XHE}i60=e8k=GF{iE9g|!kr|<-|4=w!D)@UAn3-nSeslekeW6zv8M+rd
zQ8B`@V(2pv01%A;02DLn_|lo09jzFq;&5gCjrk*`gy3=9>jGuRu8)4FoO4uFaEr&r
zslKg}W_Ze7G}(&PICmcInKxte*8c`)(siSw`2hdmXxUUxLOd=EVWh+klJ5l8-7
zDM^>6=HAZ!L8ZPU{_D6+N}SVe?uPiK4&+0BQh1nw}HBJNWT8q>94L5XA+|%$B#z4F#z3N-AQjpCx*F2;
zrs+Gb;2YC^;35TfVa+(P;yY>ECaEsm;e7Ys<9&I5pE6+&nks$
zZg?#Tm_dnY8`peSs%8z(l8mBwtrDUajOL6gVe(c=9I7I|Nimu4Q}7IXd;V<
zS2}a{kzC9Z{A~UMlfFR#d<^71{fLkj
z_Rnf3@c(ujM&8$qt!F;9F7X*7t4rNxnhttR>~I2stC+;oGnvjeF~-NR`Eb8SPkzB^
z?d$~`qnutk)p5zqsADqz(=9H`0Ma15!Xy$U$y&`gYK1A;1N(qfMAi%se!QRT@ka-|
z)Bm_zR#uRe5VYs@eNu83&rOV*B>A3nf3^931kT4RAXfzL9Ltt#fR!bwPF6NvRB0LUq4>h08Duomo*4)9j;>
zme9acpZPJY<&)}M4TZ}%$I@~pH?fNBdlOyk8KCz-0RCLB<7KyL7VvVbyDat0)tDuB
z5t&lD*tJ+)f>7P^;b{xh8aGui5-i221UZ8qN2#h7qQt%bp#HIiV2}kQpU2r(^-438
zTCz)c#vHP9^LX40i8hd^%drN-`=??N(hLM0Hd;4qTh-!YNp{yG4c8vEXOm)xz7^gM
zR9UPdI(&Eb*;lG*wGPCfLsc~N;s6n${u>UbVA;_dxE&}f{QT6O9-_;iu-ap&@-U$+
z*xOeIEJ7+lu{P1Ysv_+)(@KA@`C3-R7Gf^2li*|`XD;f(>v&O=BACE_?ls~4&
zXHZuY=07DQAkv*)N!D_F^$;${*s9Bud!^T;O2#IA81SAArtT$u)&Dk&yOu;a_QYj*
zy?)-4Y-a+IsWnZ)Qji*{$X%wybNTlS@6;}5m2Ns>FDnyQEC*vJvbZh${6fi~DpISPWcY%7Vw
z98>U*o}T=AQAn*P@xE`*+qG_6k46h|mw>pcorkEe-gXPGKM#bw5Tdsnc}V~KG~V)L
z+nE|Ux_h^zee|?Oql~DsPnZKj!upLQX^mMZD{p>?Mriuu+v|4y&02_1v6sqQ&1V$H
zsFmw3y&78qc%ER-{3i9T0AGB_5I7Y47Qku_~_APgi0e*c%>F*~oD{u>^NWl!QoGvXWWESm9Qn_~FMK;z@Y<)APwJd}L4Fk(5+@9XVcy
zQ{1kbJ?#k5n|3UVa>{6em-Ez_<8~c6Q?t*h43*)8FCc_Jbn`wqCpe{JpwJ<}>w9F-
z7^oVi{W@mY&x$udv-m2z7&a=usFjx+!JsZXD3Ocbqp?l@BfqdFgZpPH?Ar9r4rK?&
zbRNv%s!E@oc#T55$qZ_Pxkc;`V@|m3`B;_a2+b1V2l5hfmf+`Kqofg4((rfn@q^S%
z<#ryIdp~#lZD__br;4|5Z_8}%5+sbV+>y1}k;iQNyc%g8sL`4nzlSdmzL#q+X4;){
z4~Qcg>37?~+G@G4;WWC@u!A7qzO9{J+I8>ooX$>r@dVIL!VX-dO&dpG7eV|C8y7e<
zB=ylqTXU?Qh{d(**z*0c-z4%BDA)XYZ|=GhN9gP2)@87C`;DDlsD{{)t^vg
z?6d?%^Yo|PdKJ{4G2$m|mRg*hco)FHLNhn<7ZKpoS*X2U_QgcU2A-xz@%Qcz{lD`)
zTi<~4*FdI!B<<(ffe~G-K8{z$C!l0))`$w=flsFG(pY$X!FeVzoxCecuu@BH!n|t*
z^?1fky0V4t8bgs|lY`Vt>^UikNnN$Ih66(u6H2JMakEb*JJR~-tW3`{GM^Dd(*`Y5
zeO95|tlDg=$N7Qi+r!L{!895b-u8hFQmiU%W0gy?uY|n7;eIBvQ$VV
zn0TU7%@nzoT-Nod%ut$>=r#JAG^=!+l#7ta>bz&y3CK
zvugyaNk=8oi7CfOpNK8M86;6jY@Eg?0CyW62DBshZ^Zi>VA@1Pc5Pg<8o~5bHkGKb
zCPbY0E$&2k`>gZNgZxV_xv!xW@0hP*=*LEA(|I3$>x-gSCU1O`KCn%viLLJ-@o0dA
zm5c2g)P#WXH^OmKttU63ape4vlA5p*}A
zNg=^g(saS$m^qT-@wM%$_2AY1N!-_3(NDK2=U@;8Py9v%Ppi&=>%$qtGs$-E(ql$|
zf_A?DSVMrcP;E8)2%*tDR6QocsMO$S;Ggcc*wIs#r!S0DK7-N0xA%J9uKdJv0DSY~
zXF$8-&ehk=ONuZ;+05Of5~fgFjd*wncfQ`p2p|9OwqyGWEMhf}ZQV!OkC`w}&|W0N
zr{wdQKHcchMS_Od#r8Y7EixRA1fuy?4DI~{4+SF+4U6|2XAO^}Z7g^U0Ny@EUhkY;
zII+YAw4-uDx;7#GJLayfmM)}#9P{N*_ouVn=WJ86i{RaX0o2(Np&drJoy71+F9xJ&
zRc2lx_i2-DhdkZvhvBAbgYj>H?_4bdfx#)vayRb0@#pZq6?oV~SrMZ(=Bi
z*GDw)kU3g_VSq>gOJt=;R#gP+fT&O?9*GL+yLrM*zi4*gy`q=4opaN)@_mB(eQrVK
z(SkWrBB79+!u7QHjt!{DW@bTaCZZt=JOx%e;4l+Jkxp)p4}+aJwT6F+9@={A;~g^g
z$4wYP_tdiq+@M&Po}eE9g0&D;plKjc$ynMHP?v?W=r)G>|Zfih2UXQp#U
zb~()iqVPhAB|kF0M-&}1erF))s}m%LYNSmjqAVa1>O3^6hx3!?8>A3kw3ZUS;7B%m
zQ1Px3&rPQ)Q99y7KbfZ8D5KiSqxf4C;MfjsaSICUHEv)v>fYu~3a?)~nYSCv|Jl4A
z_g*CM06{?E+xD85bnn1kGn-gx%GoUYkSc5ZBs2V70$cCx-846eUd_9Nf}VLMbonJG
zDqz$VAYK|CG^nWBD=2g&cR_aUIfx(SI`!?OOhz^Qnt#3}-h7MUTM@6)VkNKz+M5Sx
z2vcndS<0MZBSLVpQH$QmaNM)kMltt+<8WU6mf_X6metu`=lNXFtZ4scdqHMI&Hfwz
zuVrw^oX6*3I^BmTG=?4%yz7=_R8IhHWbyprD3gDW5e(ji@g2&r&=JP{@9>=rEcn&7
zK7CJd-cqk40$Na%HbuRy#?e(?c5p@AF=B^
z3tW@+=ejE7M#0(ro?6xuLLNSPJfGW^ZTT*#eg@%cB_K{w~@6-rh{UW^}umT{)t7|_6>Y$;}xv^tT@@q(U
z{3vtQ4g=c`V2Bc^m8h&|?yIRGbx)OynVS|ui2pJTmMw}_MCzeK#rmzPn7olYl{PT-
z@h*2V_gJflY()96kOIx~j~$8a97|4mF`(ku@g7}{RRJS)2|#>L6g|L95j3VsVvuIO_gP0>$+@mRE}@_!G8RzhFS%%M-~K?E9UHi$
zCuH77cP6G1Rd=F8n^Rbf;I^!Z_`Q?_X*36=jlW(K>HBg>TGFYK=EroAom1xd1gAK$
z?5u3(n&=qH+gA6^{kjCX=;jkjwF!@e1OpwHwZu-kj`R+f93@R(GgoSWBdC3m^U&+M
ztqcwhqmxIc)im|V5d)=p9?l52uL{0pX6W@cUAdhnCY0uTi_*C&Ch_1eh;bM=y^po4
zwlg-&%=CWsZ$eTw!r`@ad_SV8@>hRYh5zZBx2p2klNP4|JT7w+KXIBVT*+0B=$$gI
zvy&;D)xi*#XNQ@oUoJ2_b3+>H^e^SF{fo_?LQ;dgIaC+!SL9&u5Ywh=UG99E%A4^n8k)?`WCwF~wA_~haHfR#6}ZEiUO
z`x{2ihdQ3NpJV%gQAz>7vB}(tWUiuB@!TM;GO>+Zw!%&Bm6*mOj0()^7Y3rnTI^bm
z+3wQ;&=eyqZ)sadx-%|3v0TC(5GqlGc}k@maI*bIc(XQ!o&1h@vP-CbFvqL?+(AW`
z)1brW1tJ{5zXJP&=xi7la;%7+b5c$dY#7w>zSkfo>#nwwiJrxn0i{J|wZLIt|0pV?
zv*lZ*^fICzTRq3k1;m5m*;@%S%z*nm{+x+nbJ^u9
z9%3zVy^C3?M>%G>@!5Bt{gIBtDwt`7Bh41#NB6&6qEkmCuWIvLNy8Xdu3@X^h;bMd
z7{Y3q;{q2VvG8ie1d&ON*g*`s0&SLU1AB2*G}mU5*j=F?-33Az640DJ>CmrQs~3s6
zX|nh|?K>LG_?lc{_z!Y_j%TOchf@flrgi*K}7mIpb^5{1&RD!zy9K>
z{v$_cpceF#l*pi5)UP|@B@|}XaW;Nk4m~=-7Lw@kuok$isxM42Kf~Xb=bIwFl@1}-
z8T%p5Ukke>k$n6QXS6knbh;Ab
z4WS$1SBUm%3xzdH;rsXBJ_Bjv(p{hOJFvRe^Wj`@n(G^G3j^mrr2IQOnIj6;dR=#Z
zmlO$Zf@>SHi=3``N;|T*ksPa&lUMw!IpoIib`3kLgyy^&v-+ASW(9=~@l$nL$S)Fn1t7
zrg_nhNn8_23IG{3sy><@=HR5!r`iYzhLdw)a*P=wR+Tj`&)VhLeUxg=d{zv%ETG?s
zF8E&tW7@)whw{?jqPE|oqWQN@1S5;wrJGi3Dy+`16L~k~s!Cr0r{AqNj$k}TNr_iT
zXg6j2eXqD5&qB)q;X~OLTWt&l%S#N4q0bc_T@6rf%x4knq|cg4_iBI#4TLz~^L@6i
z0Pda%vY1|@?5#62be-2M=&?c3H6hYDui~D#^N?MAiAi%mHyFdqdnW_h)#*U70=7CC
zFN2Bed1sQyKAdEVB%n9Pg6b>tm5~P$;f=8wR>u{_Y0hKwY@KDRUJ4UFpclv95L35f
zgMO!%82EFYHT}k#VkP~RlpUtI)WEIhb-_~MOvBrv6>IpYF9Qx6q
z)eOd_Ow1m~D8vN}ilF00y^j`bI?2*w
z5jo&)Z0xd!QADEFa55+Y%qJ+|p?s`k9+F7+p=8jVNM>#FR)yYv{Gk?oONNoP%
z7n!VzzJq$2CDE!Wn!JpO)xb3O&lU)l^bt}^J{IKQrI*)GZ4$f|3FIyt%e;=Git?zc
zXTOVxPbY|X9v~-r*9t(*Uf>5r;+YxeFx!Gq&JfBaGN(K}R{
zyO=9DK$|_W8|)p}F$Zgs&iaHR$hkE)xmylx!P9g94@)M!){ZT)-f|8E-TL|AWz&HG5w-&jo`b)u-%wbFZ8H((hc@mm6hrf3dV1R+EK&&M=`ul|><1ZiQ1A
zI^`&81xdr?$a+AOZ@16abT#KX
z7)5MDIV2mK_bGVytdR3IZ`T5T^4X?8b=qVOLb2G9H+(x8P$}g)-F@=pEAG<$n!&==
zZ;W|4Ut(y*KaJ)J>SEeI2?(1bg+v9kTMk#cbFI+|#hBHN9G&9DOXDvl2;0
zuj)V;aePnQa7QheR0^^}?NazXJf-XC0r(yH?j_2K_XS^Fm0&tH2Va`%q97;*p@RH~MbHWCV5=e4Z-WFXHK2@6Qg2gnppFBHM>@Zkpm?{kznzqfyVj#4-S
zBN9@CUB)mX-gIrrBAkqklbO=SlSK}~;PNwUnr8n*N9+}iM<7D|#R;`Up=((?PER0+
zpS;nehgeck}T1bD=rwEPT3n#nqm(z(8fw@RJk(A>L@A!+#3L3OtT
z=~k2;T(nv`xa_pTmJr~&`%AI8+HRE_T@j5o{IraruijwY+e~xq7ssagWdl9OA7XkL
zV*rtO6v4a@_lJJTva#$o)L9Fz351R-_!@ylBYxFFzWs@fJD(;qsFYk-258hNs5Idc
zrMvmm0c;c_?&JREOGWxeN#SKGa((c{C8XE#`(BAx6_IU=dDyb8U7!G7So}rDmmC`z
zb8i0L2~K&g=G?`WSUS=5^~7Dbp5nIcFdsk3??eX>_)Kr
z;P>f=yb(iru;tAJ#SUk<3aHD;o{s>F-Z!?47Ed)oACs1-snFdJ-<_7{XV?OKy!m(e
z&x!Bd&X->Ft(WlSP<@Q!zee+X){i@L^0o`#vIrqpU3m*`
z6NT^<>-S`?p1i%iZFdV%^+=dB!$z844@1kPu4gEcLMY3|3yFh{2{SVTR!FMp7e(p1
zfB*_7Me#$Oj1Yb5Os?c`M3YmhVUq&3F=hZ`X{tI3TW-T?6sd1sj^`JsWW=W^44?%0&qIfV$DHci6(-9>&rqu+UC
zGO(3H^`F&zUdvbsAEUOzL|m#KcpQ56mI9m(vB}>>Oq45{%X4ZGPImGsOMhu^PeuA
zHs2-omPXN$LA2W$(br!m#LeC_1^A!68H$n$^^y}}hlcIW+kNaESKo@q$hAWb18#FU
zh|m%1`0ixu6Z1J*4QHk^(*B>KUW%7Ah4VAaG|5PE)OpuQWMn*|iGjo{2sxRvlB`l*
z%QfyMu&q+i^S|3XPLXr=8Z1jn{>OqssgH=~wr0}^u5IpZ2jV@5`LfE?vho`ULK_8k
z5?l;nb|iY3L0@2B6ymcZ+okqG>0FG^uFW;uKM*T-ITl3JX9_{u_a?
zwVtdVJxEd@Mf(oQE(rMbLGw|X)JeFEE@&xsSoeQ(ZY|jAtD`RCcS@x-HnxB#XfB2Z
zHMuT>a*cPr%f=>~k6!EF#2BcaF5i4b;k?Nz#z;cGT_(q7+^tFHo`)kJ0;p3>q^}XZ
zl}Pj|3p*biw~O+Ym}j^$zN5%WFsn0@2X4P^S9=;Tm1zDpE6(g}s5y&KTc1TzU8nu-
z<3mD#E|J*-T@TZDS;Pb!w9jIWze6_p7M-790-wJGnbvX?xwF>hNLuA788FvY+*GXe
z0H(F}C&;21a3yzysI~FSi3t44?NF;L1J>XHXdTzF6hhulYER0wrTKE^hBxV_#JCu3
zA*Qvtx=1lj$yY1nw^E`w*L?djpX)^n?9`tWI3m~Ga-qi+@qh8NR9(rhB_tf*zA@<#go^$p^@7F>Q3uDM)^CnFahu^r@|;P?$A&Tb
zww^WZyrmfdvONc=hKPeRz&an1gu@8R>xhWC&*CPH-UHicq5!tb#44|BAsE0qIWMr0
z7F+or71y)5=YFPbD$Z*kQlsqp?fjE@?~jsgFcczs`$M@<1c`;J7NAKX4*G=$!iQ(l
zhh>Ny^MxkM5}FI5wTt^WpQtQm#P~ZvL`oo0TPEDZ)4B!Ed)K3tJi>Z}&%*@&QB3?DH?;I#)brY0h1TsJTQL<4ZAA6WZ4TgvNfVxs0^$Cj3)HLe$1|
zjh;UV@{QNNwGFu9gQ9~wVZ-?|zCk7K`+Xy77
zWIfJV&`>KA_lidUWU%%ruOWi?D7!Al18E^Y+`49WAw#*yamcL|78-8_bAe1&+L5;b
zy&HGy7gIkD4hAGlpJN31`@OoT8@mKIJK60D@f?VKU?KG?;*&xWr?a!d`)vJGwK%#G
zr7TkyjXjw{pbt6j*)5DgFaOti%WF?Q1sx38sgbGAEY4D|t~-YcrB7XTos4`NE+a+t
zOe}_(qULesiX*9v`b@aoV0$4|hO?MfdIm
z$w0iS4*TwUFGU&)PUVO@X6KT4@R
zRM4~nFo=l8;i-DsJJ$7)DH0}Tg9hPm14{`jF*noPesg?s%YSQJ0;&zTo3}O%(|oGT
zlmSOZUfNq=rEZ=&Tyg?i$>!C>1T7%Khl!Hl!@~Eg0}%hlfBu!a4h~wGJ(!jO&;pQd
zprj<)N}X}?yJ}&WPyXR!UOES9j}@{`Q5I)(OaQpn;{Da8IcPanu?ka22*;BUgN>78
z6+VL>YQUc+*PXkj_F_Kd>EbXJCBCC2nMfHIzjB%fapaR^)cQ50s@-6C2i_xQ
zNPszgC0vC^MmwOffMzNI(L0Z0(l9pr1*^k7x6Y*lbukxib7hcRI}ha_rLp%BC>~rA
zZp&?Jz>$W4km(9$b}e=;iYzwv-MKi}|M@RZREC6A#(orNue%JG*kFOLf9cQ+{Y5H)
z?{rg{-Towsl}vN*$&?&lo>B%nL?+O$L&l=nJkUO2=q!j(`9VW{(IHxfLA+$?lrV6L
zS=$(4UbqE<^c38bwQ=c7FCVYDPh1mq?cPMY2L~n$sWFiaNBzfK%9v0@rhSSLD_X7<
z!t0~2gB1}}bTBIm-z7wn@$VISFMv>g(Y@PS_FXr^_`ODZ#I#tb36Tf)>%n(l_@_^W8R*Ip
z62a<4vXMO8;W5iWIKY_sb6rz@zde!+I(^Z5KDqk?bK5>9`6!itECNuG-AxR+7-$L!6h!aRX9nvKi%znphvW
z8)k}~G7Ig2OtlKe{?aaZrjB1Id|wJ)AtLlYR9yA8i=P5vU`~lAf_QN&$oNO7FW=8a
z5!h_(o0lL(vvP)TiXcPU@STH5P9rNM_BMb1M;;61oOoXIpD|FojGA&8>*u;}g{}^D
zk7wI=mrl~?P9ujm?;j2Ar26N1J}m!8QskfSn%#60Hoj$w{1=poCm#7ylZ*HvR0MG9
z#b>f8KH8e2074DpLR8xn{oncf69zfZ(08^*kSIe)Qvno}(i+WFBjnm}TJL+Ax^-JD
ztzr+c^??bce1g`3TAMuw4OhpNM-XNx^hnM$6H7T^Iuk|FO*!Vp-i>#{NGb@z!_kW?
zAfGC1jj`+)QTA?G(q;PW`RzzQ4|ZvJif1UM4rEmPmXua(18)e9yZMb*Dk?9Fnluyi
z9IJX^f`AC4bbJMJe&*>oKNwIVcz4386=St>Fz8b`q;r1@=&WqGSL#;ZjMGOShV6&DKP}F2$+}0@b&&CUR@@nJyXP
zZCO*i>^id3Vc`7I=p$F6DwOT9t60Q)y;%&r_8caLq{40ni6mzPBz8hs2n<^aH}F@c
z)+lA^t4>itp$2;-8hcVpLz8f+>@Z!3o+ooZ-Ox2l@EBa%QF4y{Q7+~S*Deq?0b-9md
z+ep{FT=ucn%&^JS8JJ9=40+t?pr_(d@6**8CryEfC}A{T3B$0q3LE}2n5*EbbJ~T{
zY3(7$#Yti8t4DrKallK{U28)<^Y@%#)WM*W4+nR1_ERNR#p_Lr_%=MSgtKsCQ<;xu
zwj3ccNBhdqb!*or#gG}e4)4ksJr1~u6%MJr(#JW2jlE@+vC%h^Q=Gyhnw*K>{x2>4
zW!k4d`u3ai@*sbq@*sHW0w*g7?|JZL$Gv;Z&DTFT_~r65^}y+u#qXMcV=p8fd6Jt0
z0Qi%{yK?{!^}?B3I!dEqs5I5w+5AWe=DY@L`%RThev;Ab+S=Ovy(fl#)4Fw{yVFjw
zmU7~YhxARdO8+)IRM0*+bQ!-H82QhZFrIrPHofUMhpPYu-tqFw=vVhGZ1>6tK7?MM
z*t_%obZgz*ySBel3Kc*x3dlgDt?ghqxwtUZF=hAzHCuP;-Ms#e`5BQGNm48YrOotsa^2L?`RKz4xrZCB*
zOdJNcJDVGMeEjCkVUh|!IsWjLiNe4wr%{xq5}5;65Iw_5xx~pilt4W#U>G|AC}p3$
zHI%fo*iEq?{V)p5k6{Ujc#xIzk#u8#40i_bsgCYhP!#B^16
zqV2~FFCUg?m?ZGIH6%c(aYwfB!{KMn&2`UC+|%sUZctw1=L@_%sS=KDDfCKw$q)VX
zGo2gxQUD&2S_0~|EL7xXKVr>AGh*_8%~PL{3kWdqY$xl;
z`q@%VcqO0&qDXqxZzDkkkES7lSf+;cd8h%wjVL2w8@Z*
z{1N@2o%Vsi_
zBA-d8iY=E#=i7SxEr|0s6`(lnrvA=@KWbJ*ec7*MXL6QZ;5&~|cK*pf8+WRrZjFlT
z-s(EfCg&t3`QD`tnDUWQ<$c3@@!Iv`?Ab+iX6Ytyy=%2*_ZpAmpTwZM4n1zlE&pZR5lwlH4Ke?s^+NN$0Gl#(dX71f0wSF4V)Tcx{3f$;l;y&8_f<7?(9+CNzk87V
z@Gt5QyG3}HN)Wio$k0!9K;;!-U@o0Rsu>FWr0#X09H6KYmuwalFNHZAv(!Q_TQI$}
z)H+gxK;VJ(l|jP+zp!LjV1?Z#yczHVwP3P#s`u=sI&l>C5)dK=d>lftRY-hqD;lUaAK${B|Ib8IrkQFpMp{l+^n_)bFV@^P5*NOos1=s%MLGLEf(`G5%Nu$>L~8I&thj8GJh9?%_JR3b8CgQd_1sptXjpAbHi&<=IL^0#
zR!lk#e+~3;qHR8SL$fptgh%aWwKLEvxk!7_QPU*L?P>xX@>We1pt56gvmBqGIslgq2
z^VmvqtkF?+w$4rJRR&936J*W$&*nGGzGZoL2fPmI>F
zB@}x!0#VAhPA@E5rqO;goOJH${fwtPxCw#!Cq?#rKT6pw`t*yJ7T`eWkv$l{gl2{4
zBb&+w+}`_sP$En-k~jFGfs^>%JVn&`-};V{@)e2Oamh2JJ5p8W*iRI3hGYjNIsVO-
zUE~ol2SFHx*-^OMj^i0))=!~Ge1q)OE+xBvO|cQ!C2MBvHbN46&5sgasr}YZRIqZd|}V?eI~GCm0VRS4t>Yf
zYkz(J_EU)Zr*tyi7L_!5*?Q4tOZTScw385RX@#hklJVgC&@QlzLQKXBF-imyqh4|w
zKZ2s(P{taTsNeYMTDGP1|GRPv2*YGziNNM7lMF#y2otG@kQ%19MnX@Qu~qT%m8{@O
z>xhjk{hn|$jxXW3>MEjQ(R$yPFE0{u`JyS~5)0Spn&Jp5Q)sMbJgs>K51L+|zL{uy
z8T&9WAqI=5m1wkh?i@gs_fIh#_1%qTm*F7{-dI>Pc`3~&GXP2U4H(B0(QMua9IYI}OOq0Df_Hl{hBq0M>C
zLe3xNTRp{HXIIZJvzYoT<{_I_1%GFcFJCKjnF^S)bQo#O!w8FF*weN-{~O&sHU6A0
z*}Ov0?fY5JE&ri!C-XueDbWwJgbL80W2S!9eki@J)y!)|grA+SKFzbf6(n*kt6WCy
zR^o=L7?ILn|Ecg0P4+$RxACp*q=#~mqSKT}MEtA1qw~iB$+m4d1nEn`L4NAdwCfO;
zZW(WJ&GoU9=>@ZJUu0hVJ?bw)SGNq!8P?(-eks)7)xs`6#e~^xt9(H
z==`8Y7Zq0%{ei!L1ta8UvHFdUUsZnVDOL93)5c9|st^A$o4?hsv&lTK+P`0_7#INa
z;QjArjiz579DLVqerv(#w|PJ|a(VHZ|3FB=wV^k^0EBBq9UAD0n#lmsguEa7P1}mn
zomaTku_MnOVRws#F(iI%9o=h}$>yWZ2+XVJy_pAWh0tWvPdWkz#}AAZZ0hf3cBC@#
zosJ}r9(5TD+V@eWKNs~YdcDgDyNb|c$JMvynsAr}n)^W^h63Zr(ue;2fg$^Ls00Y5
zIN@PHyH1B;x21Q{g9wTbv;kVP*d;u`#e8`Zf?E`MM7^7X^JO2|)<46jM;ivh@))rg
z%f~vi4=U}R1@nVI*A0PJn~(eJ0mzRBVoDmVlBW>d8_?>=0#N8dE+EKq*SjI>>L~&$
zWVw-{V}I)?&ZC1-$Fa`9q_$F6nvyJ4bnYkYOguFpuN?kfl^|QO5I9nzyWgi8(l=Ja
zPcC-sLFY`Lhc#<$R+lPQlheMR8IRq9)ZZyxLTxjWM05cbQwJq`{R|w8r4cRd*hg;D
zHB7EpF{^tFSTVSAc$V*?SzXi3n
zwODaeoo(-y>dg^Bc0WWfbFB6+#aZmz=>-<*>9!`0%>3E@)W3kY=hvSeG;<>|Jk1=$
zsS|f$TkyUngZi}>;`v#Z_OIN(`ax+nuKtqBb~N{nCJalMpUSwa>5g7bP!DzaP-*Eo
zP(%`b4-{z1v7zh%_nKm>u?4=r7f`h0Wz@3jcjSqT8*@ZDrk5@9ED8vdoN@^z9ggU$
zD|`~fyJ(&xpQR|
zIZ4&@<`{b9kT3{GBQ%N%!$`N}y)~IJR~_@Hw^C2m8dQeIZqui;kNW;iTmUwk)W)P*
z4kfKe$Zj{#bs;PFqCP$X5&UUi2ARl!>yQ^#vGTIoMHDp@sMK?8|2P#`gM6m_aFLDr?+qF<=(@0e>37=h6kfo?iL&@Z
zhtMw&@yM2J*+P15h}OV5+v8eN${mD_8s+isF)1{~1cpzD5X}{?)IvDaFc()aucaJk
zWJf3R!_MBcKvX~jJs)!OEONai%i-r_7%cR;&4W*}@H3_&HZ|FG(+Wh?vZ#)P`mZNk
zGOOG8u>6n*I&9|poB7tiz1we?3yo;bZSa-6Pm6kM*BeL
z7Y;2CCdhH3(Z(8SMdn@`6{z-+UqU}W@+0PHE?8)mRM(klfh{?8S-tB3Er@-xLizWQ
z?+~7bKstVdE}o#7m~)S2HqQ`Ux_klAN$g&tJxc`28~$H(duiEPMG5anl*(goAr?+!
z)R#H)gsED-jDaASyY3OkzXaBn)FjyPy=+$Wj<9(0c;)
zWqF223YI+Q)`F)P$ODDh$XaYg32B|KIka_=L)60UU<)ZEx=Jw6_;FPYN3F1I(<(H3
zHS=(tw@dj4ryx=Ui2>pUgxVew
zu*Pp2-k+4Wf9BmX_Khz*F}I30M*10H3CR$)B(qlJ!sd}ToIR2R;@;J+&5#|6
zpLhay`7c1Lya>h8EhZ1Vi2J8VY*DMy4}7<$*EViNo66`UoA#q!Jl}s-PN{E3wv`_K
z_$}JP>|S+~!o$~Peohuk@KLprv9$ct4`1o#?!Mw7F|oXI4D#dk=5njz7N)UwxHK;T
zr?KOY9%aeggLR`Z7G#uAZa*nQcpnial0Rw*wXfKaLtpBT6*(us6sV0o>T;M@yRJ}-
zccV~&b^>Fz2*@pLN&0+o-vjahmhR3ko`0V+>IAK{OTlVB
zd5bpD*t1Wh_=CCEt>nbEjluM4SgRX|B~dUzT!F@zf5&WlYBZ&NHF~x-@4JG)ADCTY8jyyq77m=<(3^PlxqVDS|%`
z77ynmVb6glH`)J*M&A|-j@29{7E!$1b?n_Ek|?|~#@l2V{URKv%x8c0$fUP$;pfmA
z4wA-*_@4F;j?^7?&p!^&1wx>yh0iCFig=T+HHWd(l-2rc@gwqqI7^j#bNVM#FYQ#G
zL|XJY$3o=o%ZOkQf^0C7n=2dvxs`<89(G9G6R({USRDGBaYu~zgNltqQ#SUJg9et-
zkc>GQ8@p9~3|~o^vn{elAXMtc$#(?ovRB3timuV?L4yn^g`kgw0mA4rN$8EyX}WSG
z?&$d6RWk>q0le*SD3D?%GQHRSnm;|mB|i7-Bp#Szz`}$W3cxj{F=jc>5BSz$NMx7i
z4Wao?VfOBY08)~(dDt)bvn|2M@kbhqatUk}@vxex&X~(SR*F;0zzVAN|hdHdwYF;v&16_nlZIn@UQ(W@ihO`UDw&
z43EFzT+8jsd_`zMRQ*6~FB-)2_5tJud`TQNS8rW5>u4<`y2y%m$pJ*zds+GmV}aKky9-jPWk{r
zF_XV;l?G+cNH*0GplN9_i!g&0{i@06=yy%kKt53c+n+lCkQ3f%caUr
z5-?;<9v;ON9Du4OAt|$|pZPWmF*}AM%bcBdeTZv`g;Cdmv!I4|?)m8{$l!PihQxNY
zpRnDye}P(X?L#E~dl!Z
zmd^CpJ7c2MB0UM?3QxUFJV7#2o?9QwVU$|R{m*E@N}4V@KzOodz2$Yo#m$pDzy}A`
zv|CAU|Cj}ml)LCYkclmXNk4V9r(xA8^)f)5503S+5OnnUqCJE+c50~aJTK+?vfAz^%}$@o6JEgIlBD!p_ln^#JqH0`ULonE&{WGEFiWdf8PF>QJ_(SYT$6bhwTK08+%BdvxRh?9-_2-u3aVyXyRA
zB5wXQC%qI(L(#JkV1HLqhNk$X0|rK?1Ffk8rD0n9*DXj5@U|9{Dp$%@H&j~psVz5z;%li-otS44I0o;EHRm!pt977tX7h!Hu1=z9-;BNDkUD
zhruXB290{Tc1&k|F}Z8+8T)tMnoNU)Q2cJgkIDSFnzLYp+{!9M@Z6H=dC*tqD+ogf
zKk>~^!&sKnyGU9}wt|Zo;4Hlu+ywSW;CP=|B)_i}8iOcl(q(4$L>o`Y@nQ>$u&;#*
zjIhqcca|L)Vm<8a(Yf>B+M;;j-8w@FS-Pwj~M$6AEqF7yVW99DXA~
z2P-O8UT!4QWQAI9mT>Sw7w{DAjz^j=5d@V|moMzVR{)?W|qUTmqGtIOg`t+M^>*DVKs%AEW(9X+?GZ;>nZv}%oSmcJU
zTGgL*1CnQRrG9_)@peC;>IPO@9)1j4iu0N!=k4LI;W4Mm}=MciAMV4
z(YdW4V)a@&s;}hM1#*wy=NKFtnvNHfr`j(mBN)XqRiTh6rm;vHZt?Yx9QU^@=lCRW{!d#LgOl%ywa&;1S(i{9EDwO)KT&747_2n9G!;-VKrzV;70VymDo
zjW`cFuwCCsd2$2xAf$9_mUkyxgZrrqX&RAGP@3_T-ZgJ}ggsSVu^u6FK?B
z!Z`LCZCsdRP!vF)gosE4@fU8t2T8eciKzxO3gS|8k;a-L^o5!LR2r(*zYmp*?9xSlu0f@KO0F4AU3jvb
zk)@fGs4<=m+rvJpt_9*6_NN>MMQL3ER9z*FjFT|5Kv%8{Ka3Y|D8JT|_Fz<#VROAO
zMrG$t@2&guJV8U%W*&xBR@$b~);ihPfKPJTY-zdhm{<$mKCR|0m!TkHj${c|8STi5
z-4PYecjaZ5zP1wGQ+Oi!tpw9Y9CuD?EL)cSDadhQBQWEX@yXk1CnB5Ax=Z$#pc%IF
z78YKl4<3#6^ZUWMl&>%+2?Z#YW4EI)>8Y<>_LK*Z?y9vU@cAP)6K+Wy4z^K8)(7rw
zRRr&Ewcz-8)wF$C6Y|y3r8;W1A|0aJlV5T1p`x~3hWM+qKBNhzwye9HnCL{jom1J}
z9sTc9*+GzH%@12@jg;IrT?c2q16iM5R!6Q90!zanJ`xY;5+m@+Ne#e6-m$>$)*g3c
z=`IP_s*9%y1~4jF|_
zoqXrEibG3SN@R3!44Cr@>9<`mhbHxDH42g);lbUsaj@G38sP4rUy3irg^l`!T%jo-
zH513dh}K2k;EzBBVG%8ENpy1+6f{USVIbXh=rNsKsSw;<;P}D75AAeAP7zZLs9Gj*
z5r>?2WnQT7dolvjpc`shK_!I7F3X{iak|NE_txxF9Anh>j!BxR7)$o|=%m9n!`%DF
zjy=&~wUJjaVgdfE>nTpGX0QDQq{YH81_8Gex7g%i$RyZ5+0kpqVFG>7;YvrScW3M&
z27-mVVecTXnm*u}Wihb8?GFbRDscrYhn7{E%bXX0{
zC7vul)$+}MOx%9w$W)AfE?LjXU%0W!IKB7wTCILqaBS8gT6`{F&URZM^wzBZwy4x3PkCn3r380PRGprktKidx^JCat+4R7o5-N99Pv;p
zOVz*MclwWQ)U_b~Cvth+j!B^V5t6TMgXKfsjz>0eoJYh?uRgd~Y_H$p-plM4*8JxcV8Nq~s>xX}>h
zBB+D0HBQ0DWwxB
zZf;UPBtK{WSVhQ&%Pi5KovId%AD}oMr#VHTM
zt;I!SL?Hxd%G(`H%=!YqCxDklI|)nc@J8j2K-bnBc2k6>Pna#{_Va6^czx?b-)6@a
za6Zo=0`uFVihw{nCq_@Y8=UA=KV3#5c&$5S^Gqr|9sDgVKqU9W3zh!?I@^#q$a;J)
z9%(~(;;)wb<9W|v(>oV7)bsk_898o0OCW?b>1}S?Yz5M$jR(tCTp4oq$?D=pzFeN_
z>AhfcTL&_5jAv1*IRz+>;$
z;&3WKI=-1-vw0-CuXP;lqPxtWAQqs37Kd9>me_AkQVU?$srhlIa51WtvYLPC?1Dt@yE2~7M1EJZNkT~tLkqwM
zV}R*;e^A`JdV`g*lznur10)!`aLFB-n48|N=rJ%+D8g^Un1U5Oc}=R#UTOKWFGaGg
z=EPL=UP!+wDCNLjTw
z;z_aPC>W~po$l^@CHJ;dyp8_$Gh06=Ql=yyl+B?IoJQW1RRh6W4$CPSC_Bd9qSC{c
zITsMOu@A3`nktI+4D?A{_zJ3;ycP?A=R5RfmJ&$r1_m1o=;I>=j#ca*c$Q6;-alu3
z$Cw|!IKDTb*^QGCN`wcWMka9>A%ut!Hu=GqMer<^1lE{>a?t7X3Psr)8Ao(DraTG@
zVT`5HZ#0~i71V|I*0LN-%q^p{|E(a-+`4*ctfos(ziV4hPp|P_XGYbfe9rH2@Ke@h
znIs8!I~>{)0(hNtnv57jk_84y+9M$1k{6md<82
zxdl4iCR3<@I2bu+(oD+;ItO>2_QulI5?Yu|!AVm@XYJWrH;vt8o5>LaWmh94h1>uf}fVnFP#`c8me@)lCQ!^`{0YCx%1(8`z7?!DIX#T>-DkMqIGQ5$Ni*
zf(n@@<{ZujCQsUJqSNm|ku>F^d^co7$rb0ZUD0=N=grNR-GG4m7n25%DHnVCow{=E&|$~uWQ|xPr&!!eg4#qDnHXS`+6^Nq3?bA_%BHo<3}rJ
zd$Wnhiat-(R7VUuOt1K{7>V`c@|TaCRdB-ndxK=*BG=P$GvQ7Slci#B?kd4@9p1qC
zwb%)leD?lS)uQ6Wfj$w@r&^6)eWl_#2P2*yVJ;7Wi$``4_38v7h)R8c%N2;q33O}{
zI!r+EHvL;1GMGE{+qKN=@-M3pWD>D{ur?-qOn(vzdeQ`Zi)+B3sB^->AGz=o;{Jg^
z-2MSB@-X%@^9AZQ_gXovt6Z905_}0`EEARpeIt~R!Y7A1MMC?=rr2gMMF|#vcD{%wZ2>A)7vOL95Wl^Fe@~Pm{2&-pe?7eAnd7G^ox3<{qm;t!8$7jsTzGZWk@p>}i5r^J~}>6OsGf!^j#b%ljv
zmvlJy@QK&CBJC?tpGn_1Jqc~?Sd^RQQuNO=dP%C3l3oUgk1`O+y&bOgyZda-xEgx*
zW^OMleSNmM;*WcIad?6K`HOT~N(a-)oxr}G?xGmYZU^Kc`K38fxh&j)ijHq1HeQ|T(|1F)l+N@-D<5vgSZIML5-OcE7HxHR
z5E(*(g8)k1x}HkMX8I<)_4#p)9J@v87H-C`KjG#Vc8Wu(sk^6RrV0*RzK_U5bqjdYm!aA;g)tL2qSziDZNda&V)IN1-spj(qi!eF_
z5_JIg7=;+?TO?M=ev+1q)5VX*Q4Bc#;a4P>ZOro24lb
z2DIJ~p~OODLkm-#K!V35va}~%z}~MPKBhe7whHTd-oNNWZXWZ<-8O$lMn)3tw%Bn_
z#;&gRERWsjq5GX_@s;(6UB!3jYTFR5An!4rPj2DK_ehSl;=!-(G6x89X0$iF?Am`z
znzUZTi9M}`6Tactha7x8HY&Y!Dg;&A)J$nFc=0)BfZ<)0zG1=^iUW|$E^nA`e;P|K
zjZCH78@Ld?)<5K_i8kp_4bR3O6C4eqwB@eR2aA5`I1nXnn-lfxG4+bxA(f;o_(>7_S|_Be&KEik-yz;5U}FiZ
zE`YGJM3{gvlVVgOk01
z!ai_|q0dWYYXlY<*DxktdRH%9;zqxk-sZ1BAaIwf`WocUvs+ANuY)C_!(q#yCS47=
z-l~?mn2j`Ctrpjxzx$EWI^E!P}+6B=A
z74T3Q&YE}zQ
z`C?kJ2;}(HId>izRx9-Rr&hcd75U+Y^)g5OA8f5V^h@
zR@yA`eFgbCIJB{3o6YAM$nexUvJ=@PQ54aiey7w4c@esRp!&$43+?ls)kaYnzd5ew
z0YUzJIy`Zvc70uVCZ(<7-^de0IZ=?;u`Zyaq}1M@CZ
z>n;d1sMG9o4O>bbxUTIS4Hn2Ot!S{CD$$|S(PVMZqZ|{jTg&P4sbV+c|oX*{r^zXq&^}maBs~0*;)IW7~^Y>wmsqetDr*SrF+R0KS3C
z2EsxJ!C>v%9KR4ZNg+TW$7=gX;t&yckAN}PwQ$P$FanGT
zX%S<8pcpx8_xkx-^W{y)IpL}*tQZjzNfw|KM5bPLP)eM&B(LmxK&}S_1TtD$O!ymN
zFG=s^LR^1u22G*AY-=7>05Fa%<0y_{kUDN-F8Nd(RAh&#z}2;1am32vGRIEq;JDSZ
z&FjNDanPz8@uqvA=ImFC!I2UVa&1K#Ac@#q1Qj;B1wW7pAepO?);kcsIzoG#mQLR?
z*=C_!;)HXE-yabZJ#~m4F+PP(DXmGLS3SZe<*0dz^I4fC5?6~Z2B{wK0~vcgw1P}L
zY05Y%ynDs+`$*c+1jE*aBLP~+N-AETtA;8a+SA&|QYyns^JemxODHX?a0ad4&IZ2_E#0l$&0njHZrg$+pfDeOnxEB3s
zUld42(oJel?ev(5VFCyyK&WB>aCfasiFm;pbs%DCIAl)9e%_?q})NT)5Gu4wYAcC0chtTpV
z)IC3_U%Dway1SZf_GaX;D)}ihJ3q^|Dmk*7d@Y*=G&Z_2)K+=thOTESF;!Ws
z#)Is
zVvZ;SwF<&(BLw;Jze~D_VwvPxF~+fl21IS1fG(vHO*&}7hywo%(x7{oI(@>SYD|QaEKlIg0`?>cUSsd;ptM8ucC*(z
z!v`2+0x)p19E*(p86P
z%(Tm?rsl*j4H-$1%4+j3^~kIMDL^gYutz00k<->&vq5YmmYo<+M%u~g_S!qhK5H{Q7<#ay7AU(aDRi
z-${IW`<;eB-fXBAxWveK?Rj2eQNI!eQd6+p-Y(`OEE>?oCu-2<*ad!BG6o5jDwN0v
z&bc)9;QI@2g1SxM}k@1gh=b+
z^L!|n&#(<2&6&Au41>QVneDmopsAMleCr~e6zDzkpOXCte
zL(zO}*K)vcw{ftz>Pvk#egE3mU3o}t-g-Ru@!HyK{%`S0WPSPc)Y)Nox%T?-@8X@Y
z$<5pQf7y9$ePFHe3UvN2yAHe0-Se)G(@&6820+b%Uu`VN*GpPlL9ANDAW%sb90DB#
z3Iyx#QIqp_o*n}w~J)4$(vFu2=TXMJ0<&0<3KshRhy
zeN$js0@31tT~QMMx%$geu$!5(1vJXq%&idkxmg!rU3idxGIkMV#&?*N&YT&!J6*`H
zt~FfO--FW=9xKQ3!y9-#MbwyTScE`;w>lP|`jl?vUHATG;bi^IVVXB2ulpCAz3e&;
zD@JFH<`8uG)Ly@2c#{gkynhAZo5T!w5}~IcIr;s45tohg(4UnFl=k_;Pi33DAN|@x
zC$;{^GT
z&c|x?lF>r;O7nl>j~Wx+#494OOvm9a*aoZk>-Zy;unG)F`Cy3^`!x^
zroN;&A;FiIz+=zKAeBroKsD7w@Mf|#I;cG+2
z`eTAb$54bGe(L;XlD(yaL!(`0M`8{)K^afp!)BI(akMw!G%aczEoyk~-S@8q#Si$o
zM%WtGG*xB=JHFfBmu`1D;t6`=Hm~G0VA|m|IhOwZWbFqI0`mC@4)VWIdL$g5*#3pk
zP*@NUoPVLz&Cb!v$=t-m*@^L=1slshVXC&~xW<9(b1C;3&==Mz-M;lr8b{ZtwCVII
zIY}Va6QRjj%Yd=TV;OXEGO*GXwSN{F5^GlP(Hcv55
z*=@XsU-Q{ONe^T>>$h3l*l~n|gUsv8E(G3DLXUttCXoCCvfs!BI2xFWa5^NLr3lqK
z6B+feFz&{G2Jk|aO9IPh9c_3UXv8d4$>5i#45sfhirf|EntB_jiQ!YFK>YOLLNBMw
z@65Jo`U%%cQfJFS!!f8MmVruhzh-+p^i)IDDE8jZo`CE*IB%_2hvzBE4~fY%2`r<>
zT6dr;vssFBik1B$$ArghpSgh!-jO?0q;T&3j(*VzXlHfn;AxMMUnyned>J^*r8!tW
z8?hp}bOvwrti9%Ph{$~zUEjs+cK-b4%37^s)%Rr{>WdNzF;Ro+JB{adfP$N97!)ne
zg%0HPb+)?-bhX17VUUUzjw0U0lBrljPkxe-sfBP@8(P#Z+kk7xuZlAuV-0LpnWvQ@
zD&EH*UUd{cH6AENy=P}-X_v5}Hf?wlVo{D7FS;BIKnu1txX|02zJO0`NAB)EmkbD&
zvw%6<=~6~nan0kntE|o*ygv6uUdbVIXjztmZL2i4mtZD~(|N>O)#qw>~1Gc!Qe`s+Y~ZU
zz(Emr386WPUHdJ~XfK2c`F8-EM!R;y2iO)iApf{?Q}}uOUe3@lb;##)RKM^txA0d$
z%eT`voZ}J`%PsXZmNC_C%eP*c1EDR_o5$()w_o{65mzSZ4xjG6Uz^pKMK8vrBpLBf
znL6FQ8rje5cli`Zq{~Txt+?0Ju^2YA{rNagi8ZaJPI^CLg&2Zj%nsH`d(E$8wLT>#
z+R|kKHBH@b)3HSdX(O7y-KJCQ@FzJCOexBUT)u_M(p@-Rbb(N
z1`UPsDLYWP2|_~LlrfFfky;n=&|wR6h}iW~A3X*PAdgMXjMB}C-bpXqt`Y+X2-Nfc
zm-3kZNqOTwR!+N8G24%kEuVR}VUgJ_@e_}I>K8D|Nn(=e+OV0a`k9&{by!T>=nWgtItA5_=o%j@uhhB((4)1rCmQs)3Kb|3_yq5)R6t{Q^
z)DsV1*B<6<{WSdC11~>tDNkQVmcZW_13!lny?Y0>&+P+<---&F*{S8Awc<%JyW%xCkVPE`Z1tOw+|)l&!aqx{So{3~
zEtGZySN%Rc?l;;L6n**Rgm5?oD|7Ra%1iG>JzQ=#+QR6a1$?jeYMk0aL(pC&HL0&ga5YyKsHF`rFaf}h@9zN>HkFV7GeL`T!P%5|UhA5DJz
zBz0{S_&EiGe#@7B;!<$>sKkAEVY~Hn?&eQ@2fHu#$81}I@AW=h{F}PTOUm(~7MR8A
zH#>^2j1#7>$JY?_;WeV}_Me`7=ef|tH!WL&J%`<0iHG!vD$^79OBaW!IrjK^r5?y(
zQcvzLp)a__(*gWn=dsX>JV~z_$iM_4p+mDlQBTC7pMbwX(DU{Vzr5+<
zKwjDk1U+oRRm%Jj&raEnbi(@9mKOr2)tZ+KXQ`vK7L)*wZe?zXZMHJKh=)8yOs1qO
zDG@Zg#`051LWTV4VB2;=60+XE8`K2y{
z1|b_!jmzCcVo9@DmQw~9$;csbRh&zz@R*W804xSd1qRHoh7*B%}W&euk`=V*DbglRQ3z9jmCD
zJNZOKHV#(>P8x2NZF*E@j*Z?Tbg`(}5r>1}OA&U~tOH1I4j1$Rr(T)A)q7WsETi_b
z5Oq_zsEu>+jQ7$3)ycY~j5;r)_otI=R3srS{dcsKZ)m-293wSH5*h@XwYW2*5-mJY
z48Iu8Cx!3e8oeOfrF~kJ62)t(z^GW9c^YdE=qk1P5;|J24Mt})>wi^|t5wqaZ`4cl
zCGcs3j)A@R^#KKTZ3{lnr8wF{)2yxJnB&{0pQ$DJKFhJe{Obnm4vEpvxRGr(u<#KvU1-LQ=*il_xhhqE$AULJSQM#>&YM
z99l0h!VHhh%@u9Ggg54sLSegjRjW5t@+i`okD-g%f2qs0OZ2H~(FB6YWTm)mMa<0)
zZ*p^>voMJ8KA>s5oW*M#SRwwVnY0X@U6pDSVqsHhIm?R|JtCVP+^6*M>hi`DMyg6o
z(Eem73l%engTMWQ!7VY<$kFSy#4}S2GHO0jF5(e8VmT>X4ym$E(cIe8hMWh0&q4iV
zzVwUq<|-o~Oa{6EOae9uKspJ>);Z~Y{Bu*AQyf1e2H|{WJO)5t!88<{v4CQTzKqt@
z%@R!a14?ul)pRwj8|R#_U7|MnhwkuuTTxt3V(kJdEQ4{^8b!tH_sahzS}R
zjbDwU&di5X?Kb#!@_rWMNT^4)obi)dghqzB$~=N~RQ%1bRZ7?*{SVFAwey4=>X5Kw
zJd2fQ1tf`R0t?ja`{cT1k4h8qWx{ls$(;JZu2M+iM*mXyPzkw-*bz@=oM9Im>WN+*
zDTzJl`LS*R4s3#UsDXl!CaxYF-FqP>_&7k$+JlZFh;^2YhR{8VhtIdM2zw9q>7J%0?j?f&!RLFgrM$^U#WG)
zD#?xluy8-*wHfHO1mslt$E!315)X<6Nr%`{E31o*$*7~kXd?M0&`Jo8Mt-+yNTM9&
zyx*ZS?5x&CnD^F*4rT980F(GR1M9=}BMAUO1{@OJjJhW0kQ{#-$R1?xq?5TU19O
zj5?u<_T|4QAYOrY`+g-SdS)W5C%T$Xa?xwx{by;t;|H{TabfLj%{`BILdw?8TrE^0
zrJ*N{Yxivi8>U*JAp)g*cYU7hL$CT?6fN=f
zW%tP>e8$HtqgkgWryA6;%j>#--ZcIy>%W*Qi%s>KWIpCzTM>z1CzVV&tejDCB`U8EriI@=@gjm_`xey>(tNi
zRZ-y|Jn8Y8GTcStVbGF&TaEvFV5CAZ$wPfg~brkbjY>t)fyTIJ-;!SRN_*hd898d@b*pPRS76+rwg+5iMNRt
zV5MP{CD?Q!)>C;$O>yROO>EWhiv~@WVUekO#zeD<-0mh|RlG>_iK8nK{?(Cj8h8fE
z+W#I1*o?9EsLJd`OFUu?=$C^c;sP3=`F^qEx3KM9!QrR*}=HUU{DaY)ljelWhi95bNtM
zgNz{&#F_ks5HBk|$|$J(V?R|t)_7QPo(JVdmNC|(Rh=n?Ig4=3BT3@}bn>eoDh>US
znB-ypiz)VQhs3*(?+P2V4_r+ZkhB5pEGEDI1wDZ2|JAEQV?j84HQmw|5&<^I6szGP
z^#wT5DX8Qq6aVRgS~~k?rqWbN)(zS;ANy3JxiQ_Bi)7Y$y2pnJxI%m9ur{WQWlfBT
zkW79)UP^Yhl`?iv?YO45i-Gm8yb(tx)em&}a_9BA4ne$3!wURGE{aNX}M^ywfhQ{WA?*uzD
z?Zj{ui?vDTr0pjEL4Jzx9q2jJzWcL`kPO#AeuolG+~9%Aq@!@vjLHvkOfU^T^?wn(
z22@WN+2ELu(cSUcGATUl8h46$E58c|gj7-I==x~J{NJ(*EV#HokPFo@`WeRARUiku
z!!iTx3~OrsKp4|hub~ZEHRt$2R|zG9Xmiqkv;;~X-yp+n{J%qhTknEkH$Xaua#bK(
z2p6r;*`Wi+^6N(>+rj_+UtC9}@(yWUCgTo-NE_6o0qFb$B7?rsl2eHFG9OH9ImF>U
z2WYhl`Afmvbo?;y;!>gA-r~_HdgycPdruae7FW;{Bjnyh&eSy%t==(z!d#6
ze!^aNl@*~*SL>hL+0QMR+SXt{394*ug4HZV=g0LAkkOgA08&%L|2?UhC_$LN{%Gm?
z=$+2<8qhjHbTorC#%Pw(`bYr%BFgwHi~qurdMMIol_T+3jk78s%!$QIT=U`Wk>>Q`
zE3eQjz1NZ4B$&;3gREt%1(8991<|mF{3}jLlLb{82gIB!@es?o`|#+c%ay9+Sp7ZN
zLGwMB#rR^Pd36<*d1w_?=FaNNSJQ3yYe>$gk(U+^Q%m97)GP5_FS2Zab;DBj7d~2%
zrK^sEBL0m5|q8t40(ltzWCK$SEFHUhhWqUUq~rZXPdemt!b$LmM#t
zkSU!q-&afRnCvYB3MF^J&;wi&5_?oQWb{Luo~yW|qD2z=wLuHiAg_{E;moEkFeF)R
z7{z{M&&VmO3Y#(Yw}qOPzd%=2kIu*mFV>{P7fG=7Ov|A#AY1u7@9!gT&`#nee{TfF
zjRW}_kRmf~r!5g|>_wo`QYQ08R)+Gc+|3bs8owBjgwZY1X_Q_e8&xU7)ZH?lKy|{y
zyfL&SSlWG%&yki;OVr*5G79}*ztcgX$jhlzPSQa0=kaKQV?IIr5-vN1>^^}N_$KUR
zYJH<8eW>nw(_dnCuo3L5!$>m6Ud
z_g}7POoAOk)o)d8@G@DZwtNB`*#9$qf#FHr*wX*~fslXA?0DRupP#>K*UgRH^QAJ+
z6km|m@a6e8zcu-kb7+|pSk+hqN{wm2kFPmhqX&?+^3euKMnF%Cjl$%|L>f03h=MwS
zAOVqq5*0UL9~A%9r9mkFLSy`BYTLNGL!dUc88ac6G;W|3t$~^tsyUq;t(g0~yJ*USpVEAueCV$FmgqIZE-mteI(pwM^f5J=bN>yd43rY*il)>>
zLlN0jKa@UTIOpO3)m|0(*x@f5#THQTTfI-bRN``)EVVVv08Nagh>I;~>xhuGcSKao
zhAal{#36-xp{8PJIMvQxX}i1k3qFryS@f!vbX+X=FU*&5wpM$v<)xqdKb2u_pK%oY@e-8jQe^3Ojzq8%Y
z5!jF<uVGMEq;Jz3H@#FBg9(AL$y<_5
zt49e0p2}1=-dO||do~C`cM45^#F-+U{PV_+#{{5aG_KXkpWgQD1zBwiw@S2*RW=okk$PQ4GlzZY
zC?+lHegN&bjIK`o3s1kuUj&1UH*8c3=M)<*w@Fo&9mYF#tZb93?Ghf_@w)8RwMKzSqfVUX7mJgsM;*k7!0*M`d0IEbe}
zk4PVmEWn}Ut3Fx6xT{F{?A!)24mLn0&x=^=0+tc-4Jszk2EVutMqC-!e2(M^-v+aQ
z7&gQTx(6&s2y6yDGz{wBCII+80qXxCph=htD%s;4fha{^hmUR>saPt&p@t6GR39AS
zpM@VqorfMRx${ReSm+*OSTRbl<_a6?k4lJHRU9fk+8eKPEx#sdAWX?YU%3Z7htMN^
zUF~$Dx{*C~^f7n^@{D?OUgjRXR+eQHUL`XQi1+*iSc?TxU~X8>7T=2qtl>uRP8K|@
zO5i8YHACrPzCWDGV#s7BFgE+8{YwDSZl3>JrSc$a4dgdSS
zCMJamO+wzE4cXL)%|Z*m0NH=bI6(y$aaj?YCoq1|?NOh3r29cuZPolG=3x@C7OOEB
zb#&S$L4f;JZAdJ$I5Z9sOBj{`-4KRDs?$Sgfn*Y2K)zSi8kteW?O-Dq{9u;)HZ_fbQ)m%I14{aHw!Wh)VIanZS~`yl;_y
z8zJV0r6u9OAtz-u<`g;JCJ7+YlF;;lFk#!LeBvG)GlB(Q7%VyT8#VZ&omQ%O;7QeebpP%`RA=pVjGY`l_aLC%gOlw-AZE0=>w-l`(}9mNCunQ`q{U30NQ)uIM-d2>FOZ
zP@_KXWqt&VvX~XH7POa!UGIuGCbAI)S`y7ORbC9_>A)no%WPG{#phqeq2?N3aV7c{;6GrW@kL?o;ox8F
zgsFFLSC{i$CKP4|ZPgX3ci=C5DgtU%+`XWJgb~T=@EO^541WwrcuBg4FRLw{!+}|m
z#Yt44W!{dXzUT!rtcdaalYl%IM?oB{8Ds{T2CfhLmExvsNe-rngZdZ(p&CF~AU7T=n(od0&e1Z>G_E3=1mRny0^
zsnbC9YwJzgD65ODmMQOo`HARmX)`+)L)LQfv#dUmIa&PyklyzllUDG$;2ejJ4A!;O
zrToW)1wCCx&0jY64&9Uq)F28&N@|qN%?ESK>-DMwTGZu`46%=rY3yaY>WU*(u40M=
z%&Rx-dHJ8{knOJP1}HVqM5NxId!_za_N$>vT*Ja3gG9t|dE~DFS;mlpQ=%s)x)nw9
z&ZQ^a{hatUOGPL7*Mo3tpDZEbTG%Y2<^&%g@2H(v&RzqE2a{03z|l~`in!^FW+PWY
zyUZazu2{moQW29-gLl~9=}Pp%u=SnB#@_i#Kg8}xfGxcSPBfy9#6Wp12jbjU;y?bR
zkF=qHS2E2~@Zz`6u5Q-2pQ@umsTmzoxHR|-8t3$FCGwc&``agK=q6J@=qUm}{z(u)
z?2;0h#ehWe5-cEok37$?D3mOk$}kBzxQmoD&F@N9*2}XCnA+u1@~z{{d+jK|R}UB{
z!}?{E|KW_@pDa5|VHBN_AqX0$op*AD*)4B5++8#hl(ilnL!D%{^_u1nI)8y@(Y+%z
z5asxcCV!3R%7y+gN%vcpw@g+BrNr*4yjb!bT2(eeS=X+DrgVQDwlxoXy*;b?7ZCyi
zDD^XI8S`E+@EN&Z$%z#O*Wl`^T+z*9pBY)4>g>eKF4Un;(OXGK-|e7=Yxy*U;TMgX
zGpqH`Ghah-5%LKO5#t`GS#(SZRk`-IU2Pb`t@ebJ_sA9A{X_Fg&wd_7)FV_!LdUC|
zgr#&2^SMn~87MY2wLi(-L7qPkS_Zk?ZeU_y&P~7AS)8yvr+I`(z*?1B8`m25ITUTC
z(Qngh+?1eco>2d-UV_0@jto`k0=uHfp9oZWOQi1}I`UHJ_Ov>i4)Nh#)3A>gRu9LAK+4CJJMuG?FJY%vSC>3O8lxc;iz`eIoU4kIt0AM<
z$ikzVd#3urn?l~D#Y8*v*nX~|Wt5a6n?<=m;bL9lvc{DPEr@nPj*7c$8laD}MARtM
z&sd|wA0`)jfI>Ou>>t7K#J^8xHFbS+mKBE?J|x8Kb|`OFH@AK>99A}@4Dn&v9B}@b
zGk^=!0gW%h+>T30#Yj9eoHSaFC$Ny8Hg(fiHP!e36;6z`3j0aP5pFi^9kfqHLgqb-
z7(<~zPExC1T=W{ktuE}&U4G@tMHV`UR`Mk{EmR4SvUb!A7`wnMSGY=#Wm6bzJQ+9#
zcN7{bxrbW@*odL*B2jr%?%?1->k<;+WNv6LGeY^`lB%O0tf16PpQ?$jWR-iB+_!g%
zs)~6_ArRBFqztrdRVCJ_mGXI5%d1H)hIZ4!AmLB`@kr+I&x21^HM6Rzc4$3q?SFAQ!~$MsL6J6(lB5S){WBdR0I=L1uY10DD;MP
zGN>JGulaRuX9ap>g#~(uEr{V;AUoeB-0y<(DW}H~I?p*6d?T-+&bwZ6a=y@aXI`!a
zfH@ygJQo=#GG5zZY6urK?fZv4-?Y3~s(Xi9Mc%Z^a4?<^z}SONyIv}}-n4AzGhl4Y
z=iPOx*c#=xmIIH^&(n2{#bsp9Yzo?E3&!4UZti|M=ZM(F4CB}|K@AVn*Kt)h&YoRP
z*7m_j^E76YD|M9xhC@}Qr|mqlFbN)~rOo5|L15bT;)N@rZ~4I~P>v(|Sd|0ib`|DPNo{(o`@%>T*NYw={b
z6``a2)6j+VUr7?yzmojMv7&$46a6I;*Ts;odQ9h{822ZK4xSW()_v1i+r3eDkEFpACc>eb@68g-Ync-j3e@&*5
znEv-m2a|cjJ0wkF8tbZekTW4qhWb?B5J0rXf#qKT26Fnp0vg``?unK6UpE=s#|y(X
zgvtM1#t!~dKY76TPuQmX@Sn~jJ-5rDESUdp42=7~8h~SNIM>A3M@OfQlxyYAueY3g
zzuZ=Ge?FI9`mk&8d#@3+l#U(~EX`zgR_11|vR)o7Ki=Njo|mfmecqgJe}8;3%$?8N
za(#)py)k{5PESl7y+8ABeLTKvr15{%zB#{tUZpjy58lqq_`W))&hUACo)6mI
zKl{EP-p>4$d)3qZ?up(0=B?E2sjkeu`kvXuD@s|Cqv$^XkkqX+2;buPzN64Q?%o-;IXQWDC^=!h&vLah+<12j
zUsB)4F0LE6vW{^1q3V!Rt*KMH=AG}&zUKz_O`O&btsZ}Fmh64~zy(2;YD+&I-ksKP
zJNWfla-U0|&k^J@V-QLCa@a%VGHd!1-@hsee=qkX0(ONr|I&6;cTg_^b%!p`T}A}V
zB&-{^-Wlu;$~?BhwAE;vZYXJ@x5~7}8FVuRvYQ;>G+wk6Q>xsE!lf>t@a#b88ejAI
z!`-x6>yew?+D5LoRBqSr+Pkekk?pxeMy_K$j=*lE#oH?16kXA*(P>J#&Bw`A?6s5}
zH2blmlctK;cM|r3j`Q1gc5xG>a`afg-*;VH1FXV^yik`CX)7JBoQwqLxIYS==}IpA
zj6PVn8^RkLLpw!I(kwIwc#K;@KX=?=QJEkK;fz>!pj=tX;1S#jqAt3@cr@bV^mCb8;unp0j)B(1`2rKiZ7n%YGiMpx0*(VZ<#twB
zKIl23qUR;uma?}*A6$WCg1R!_e*?*(AE2}`pp0;rkKMrQW(wW-GjWiN?!cB!iCe(9
zH4x@13si@!3xwGQQ@DAv5E1364$9;Xao>PmgOUCIv55Y=lICR|JK_hF#SJLKlRpK!
zh3Mzi=ES~FE2s6fFOMHh9d|Q=d}&Z*BV+cq&gIkn=hgj@9q1^;wihnB`{lEb%MjO<
zR#~dQD?+PQo`V^|&U5JH?V&j!-?W7X+p9;L_b|ox94Fb$4C+_z4*!kT-)|}cuy6C5
zM4kdnH~kOpn;&v_4*1<#P9b9QzzCDeusnX-eIPyI&vU@aky$q3?19VB7A}XGw|#I{oL&4kBH{0iHFnTlZy4~Xh0hV8DXn59hN5_U4?zrjt8aNi+@N9#R7kc
zAdS+(m#Ag?(}&%+qVW5%evQ73$1t`=Ael_lbk=fMgrEj%om3!w!#&Z@D(`7s-w1Xk
zsglO7;`OyYhz!r309U-W4+e`@wP%q^`=)6XG~GSNgOfiQLu$Xj#W%
z9bdyt(t!LQgo1z~Xp-2mkk2x3nJdO9o+m7`Gw+~xgQVU%Uc4s)J%sa3
z^H}QFj?QiVULNb~<(Y-p(7rXexho=j1mYX&aN)meJSDl)vCd=uUaPCt+8I}+mj0Vz5Y8bGxAxCj1$Er7@8e?(
z+Yc|jtc1Yx@L|)l`{*{_iZ<$_%>B9^Ev6mp$`x*c-HL{SF*enDS3aSI8Z(Dzl?xc6
zanJ$O{d?z`9K4dDo+>cXiDS3R42ur@@O$@{d31d;)sp1d?$0>9{Gl8yGbkf_<0uhr
zQ5AO>K9rdx&~USpgsYugL0vNym4g8|Jfj&>uy9`Ku-zW!VG(xP58YcCtu_sTxnpq1
zdei_2a2i`)^?W($VG8*g8H~UmukH^!FonjyhBi
zU^zM!x>=Hl9j+lR{H0&mo+b%o2NY_eJ1(dh>--)7{&tBd@JCE;wzPQFX)`=7T?
zD;Ip(_^*wY7xf=?LV;MQRpd$o%h5`H7+ej%a@|Zo)GzvBBgRJRoq%JsQ<1TftLb=9!3pC-H%
zc#wEUty8#lA2>Jn-53h?yrFL{>uU`S9nb8TLCDOCd74zA)b$Q!x(qw+FPhppt4r58
zEygSf#UF4Hl+Q>E&?XU&!6hkfV~Rh(LROXEFA_hNv#Y9?
zZY|>2p9dnMW2W!-v;W0rp}X?I(&U^#pJ3IZFL8&r^pyjf%+
zkK>HxsX^T2p0K*4pBSc8LX*Bkq*=Tq(jmR??zVvzo$3`SBwE1NE>22)pq$=WTjsct
zGFX*9;FK1A+&tm%FAvbN1J)v|gfP)Ve=_Jv3ECm5jqiAg1nf2s&AlCVabs20Q6wwv
z2?Be9P&;26`YLhlxf@^bHAI34s&r+=WT_zdqf}nY7*F;>w`r3ifwqP+#zXhS`pbY5y?LE4ds&M;aXJjq?9J`B&z
zym6T81#DN;BLU?~*#u`C!jT4#%+dX!6ZoOtLWgAhFzy3yQ7^>u@#72Jv+Nwt8!Vj;
zXq;Oieih4XqF7q98c*BNq$!cJupiWi|Jxpo8&&C;T&;W#hsHHN`6c{@G-X&2bi|mP
zaEQ-52BU=xRiKClL&_m549W>x*qXq%044bUt$ttptfuGGf{uTxFn2AD&$i`6P52
zY=ANFf~>A|q6JdFQ=G~I>%<^WrpSF;1*HKXt+wlBrD6X2N4^5~4;_t?##OJ3WQAxF
zmf&y-P3e8B9B`}yKXlf_^jEkJ<98gV>#tXwDkSqeNo2+Z#&X#SRJwZ}kj@s^iqnFD
zF}mEtzBqdBF+tr9+Yrwuad$GiKOQ`p{Y6+M`m+EmheXG8p-%FgS_Ax^IKtfhkdPrT
zxQ45wYrc%~=nxk-fO06Dfl{C2H`FBP1ac38$)B{A8FG-#i1@pTd3S|jMo)$_=m(gn
z$EIz$$URNMP~h6Pv!~YsT%qD9*_JVJCPL868!T
zbb84(3&Q}BWh3cExULQffoI$ubT#pzzYC0^@R9*-Y10A7ZPNv`)yMAbWn=z2BK?;e
zkbR6p?5ihNpf5a+%mMMp1+o;zj3DR}sJJP1=;+32lZJPWgh9h?A{f~=O#}KRnI~@X
zs`pkuqlL4~sb8$Y@dsFgiHF?dR5T>GEhi8yU0~BsjR+d811pnN8{5hf+%%6kqb3T#
zjdOw{PYr=&&ER4iA|AF<2CMPkN~D@VjiyDh0}m_uJAYV%ILr1`Qz_d0*n<_Fbx2t<#>-C6np^K9`2${jb!CK)
zxd#muzjCT3Wb?3UrQx4n-tS(0j-_rj`#>x<%2Ijc&X+5=OKOg<|2cPHQ#(WW%%InE
z0>gT;V++6jI0aG@ajj>UlX=B2%OngGnJA}ZU6MYK#Iw0^&F{mrh1=0?_SuvU-&pts
z#dvcMJs-MYra;@@t#fn(r7sZ(2I{85TDeztQsh>M!P`^CZ{4Fup#S%n!+p(b2oHAI
z9x72e4#OQe$UG-+)X`7n!*NFT9m7j%7b1^|Y%xTZ??SHh^ByZ9HuEuXh4|JUA<>~#
z3s{o5UWDHkZ~#VPD%%S=zpZazhsvc=6%lqJwfj!3sg4q4c*zI;_HbrDpR$qA=*hivYzhATB2g;G)iz)D`W17<~
zyIVx@UkPT7BrNF!ECJvlgdYSJ7wBL+NvB0;5yHFX@TiV2IOPHR_H$O00)g9k0nP7ldSKvj-9rsm5^$WwB4NLzUNi=_u|8xx*p;}%o8qQUjefjbkO-7$HYd39(X~|niAMDh9SFiX^$xCRudR`m&Kh~^;->!NA
zaW((n$Qz@331UG2hOTz||Bs=w{)@b+^1gH=X}5oVRzCFIDMX+uMXuqvE^5%k2o-iX
z8STlk#nU6(ZbNn*&iXY@>fGsC{&D@v27dj6iO^f^N%G9x$;bmc`breU?fc!9VJ0w_
zJ#^otx3gDbE7}G;b93;^zVqF|_nyF419p@>aNoS!Q=9+VHS;}F@8@Xdw(rZRuiLk?
z@5|{+(`puYULE(=Hcz%}t!r!RXlUuw#M_I_cgO1P*zxDCvG+i3C`0S$@}SA*AM9?P
z?UF(T_xFaaD;q9o*HBFC_nF*QgiMp~o2Q1=Y%b!^sr$E}FM`~bS~0=PL!yw4iMN}D
z_46Bp?>lJZ+?JX31%{}Tshz`Jn@8hT{wjXn{qA0}*EfTkOTX{p7hm!f#*ZT<-9gl+tv{I;hc)QYFhI+D;5G%7<4G~vk!nBnJk
z&n@0vy|1}Q-?m}7P@gQ=G1zZn@7KPzd|jpce`n31ES=S^Pc0Wdz3;p0P#XMB!6GQ78$b2;
z=4YMTUK}sS*rjyQR4Ak%?(UyrD6Ta1VO*HmUr9S8K;|$Lzl?<|V=VNU8nfOZMmr&2
zKzK}=?ND5gu3U-%)1bPgCM^6|dUZWLh42`A^Un+}6$l-=6?g4OZf0pPom=^hH5=>Y6}cH6bfq1xp0$#W{S}R$?8FGHgGrMsBLIG)lT8cO-dNc=l0{kKtI=DF~a+8X)J1bUt
z(-E}HtY%wYF^mQ0sJ2gv3dESwhjKQ9@-ZBiV1n9snC8GZ6VAA9vkM^$#5_k_JBS8H
zTrr3_=Pyrdyiqq1ub~%z!Q73OQo}4nqIqacgi9s#^kQ`2YDJP^01<9>6@U)Rn$nbl
zM=6uEqlM9gOeh@4QtTWOWClMg4bg~b#gm0H9Hr^R5+c7m0ygzO=(+rPfGTd1^a^SP
zf}>ZA8JcY6eQxT>&V9+-@ziDPIuRO*x_UW?dj+h#DL4le2c#ko@ZwbYZ`z{(^fyxT
zWE7=Lbf1tED$Nd9t<+t~*?DUP&8W{Ml5!kheIvsBg@#x&1)dra{n&}z9!oSA5GOrc#ZN!dArr=eW;NfONyhjNsw
zR!kfY2xJz{DCXTOtkVo8D_->^IOIi#M{M(Yc*Q
z$&|>=>}+_s=}_#naSctya+@wA7b8H1H)6w;%Jk<5Dx%z!1v;PW!m3@?S@sXt!Vz|}0AJ&;Gw3x|$JM>f%rw+y2txz&tG#oRkk
z@VEV?b;TRbGPRXVG<@-4wvMX_QWWyO>h8xoA0=do%0?!$#jHYNM>I?BJ%3>Bd7~+a
zP(eRM66&735J8&8>KK7DGrf)~+lJD56zUqED1dYRa~tn4OC7Otw<&H#q2XZ8k7<&#
z$~H|bzd5VCJe9}o_VjQVX*3C0hc)~JNG3;}PjsrDvJx%LlB1l(F&dJO_0>KuKN5GT
zGSc3y`lLNSQb((nUQ%s$_jpj8g)U%=$Y4(FD$Y;EU80%b=u)j?`%MLm8!L4c
zZu0hf%m{Wis&G95Qf8(s3!9VSTF|A;V
zv4|ph1#-eIWjN6(*c&;B6cNYF(3Ouj+V*K`C=3X;W}6{i;=)m~b|iHk2b9D~b+~9L
z3566b;d|{-0~TzwYy~r;Y^=Lhy`+U}Pf6VtTr~(E2Q$_pWr*(N}Ni?(e93!wd!h
zxN}+qO+(!T7GOh9>lauh&+f|HG3QhHlRR7
z55@l!bLvz7SyLr%OSI;!u`-}b_mg0KqQ2ULb_yOMIk=`rBBQc=qROjdW3{+$Q9?<@
z1$LxAo4Oe>+&2
zJ4-AaJw)qfJXqO%9Ag5ne4Nz-jAu-0XBU?1&ne{|9i74Y4>D+$TV*}BhLS+hJxZlh
zdq)vlN~h%tZ90&iC}B%BR%5F6!gHJ{e6dyvusC}RrR&SG20R^q<0It@b9402B{MV0
z6nwR1xoN7BaA8YcZ8hAZzrQ9{i_1wuPe90=OfeEz6ex?1Q!lCaGK|s(r^Cq$>Hz&`
zOwY;kL2WMX6Y9Qs1$C!!JA3tlzlY-J<;k7NSW!Z7aadskP*Dk3TU-ICL$KK`_1JJy
zXB9!_oRyRofWK&I&=GLQf^TQ3I~Q5iK}YFMyj&6qld{P2NKnRA(S##4AIRcFgH-lO
zKX}`{VvLQ`S=Q}F@|&?UShH}C(DEtrV-<16?X#1K<#MzXn~txujvodUolw4G0Li<`
zFMfn#(hvii9G&S!t!eRU5!8F68)g56}PV^$)mX9#&XycQUx
z@c(8A%@S-B^{vdO3O;!C$`#VZ-#pN9(pRP~CNWKg9AyUYr5VMn617tn8FGY|jAuv@
zEC@=EDJBuGM@4+#*NV!xX1Rhrf)PBXZO
z)QxW-|C0>kh(;a7G@_ox0(hcMsb&TA~1Vlm0fy*@##Cm3zxgLjUk(70Np
z-=HA?Kc=`e2=6hv&zv*{l|Hmcd~SSIT>q3{+@v*1&;l(Xi3Z}8oOtcXYZaVmDIg{G
zA%G-^`zdMqc3?L~06Lf(Sqy3xkwXtU9Em=uc{o*V-wJtKx+l5{~u>BT&nc
z3DlG>$G#h{P-K`5DAA#G1pNt^6z~#7Q`?DXVM&k+Uk4R^tc^NKqR7b}vIZ^L$H4o&tQd#Z(JO
zHf7XhGq$+S*C&^wRVUz&F1lz#b+8$#8p!g!J4FA~?WqJ=Jb
zwAFA_kwR4%iqmDALZXPlYGY5-lP?8jtVq4!Qgubsf|o0ZE7k!Qb&>%uv7in8TVh$z
z98sV!X;i}#m9ORuJvxy&99lMDs%m=%hs~yY=6_I9I3zvr<8%I&FS+qy|qQHd?d5o)2t3Wz0n3U9Umb3AR;x@l?9dDvhJ$=e-L
zJ|cs>n?$w5m@G~n>jE?W1(Y-64tjrn|4mngb`p{^RGc%V+cDKsE`Cq9**+@C@AMdu
zjYIV18kh9Y^el_?klA`zD;jkHEfg)WY^C6VG?GLv(NIRB$ilhusLsx+KmN@Sh9Lt-
z%Z{~BePtbvy@g`|iMu82Kf^^gTt)91s)169x-e}8U8SEtK?_|uS68G&VUV#KQP2Xg
z-Ml<%xT-Fk=7U5v^sZqVD1YW?0~%SRfh)yg28QA2&RGA2n#DTe4m)B6|MhUI;h3Zu
zjnvs!Aw#aMF|OTfEFEu9OHp%jUJFBNp!3}0kixB=X@arnFi&NiYLapgT<{4gw_f9w
z)fP?q77gpN%JlPfC%N${|UmVjiq2Z00$;
z1+RV%E`@+BJIt)Mrd0|-1AjYye-~wcSXo+UnFW@Rs!T-tvJM!pf}AB^i4@QJkp{TZnq9h#lJPk>$0*l@0yAJ-n$IR4CVsNQReXf
z=BQ)a>*3dZn&(JIx=i-M6n9aMq^&G<6u_j8yFk6Y9bgYSVhuO`b4ArT9b&(5^sYo3
z$zAHxy0Zr3--al8_VnQ;0dbRMUgkhrzizev*I}m-v&lx8?&@AKd+##sC^;vr2+VGVNzsVHq93X+@Yp3r!|@
z{=ngSxf8+&V2f9A6)gd#h}M&q;V`Qa7J@Kc4ezSNMHW5zDoMjU+Tiq8E(pd$j!`{>
z4-Ybj4=2TN5}#&two%(TzrbEt8gwEX6X7H!MbsKds*h?@3TC_fP3_bPSj{F$B#*BI
zx~$9JahtRBs<$qKkNne4Lr?sBTn!0$_MZrv@lFqzSLa$F3!G+v9FfH#1@bxCa^X1k(UsM@O)(qg&V
zWLj6_*quez1er`hzejttR7^g~ZI-eRDuxu8ReYLL%<5wUk+Yo7vscszY5%>C7YA)P
z52RZ5lPT1wgmgM4$8jI0#uO+%)=%@wM3J-@fjzbsq7Imo;*nWid7Ycy+Ewv=K5~9M
zIS5wHDHa@}k>o@{=_I=3e?=6SE-h-y*Gi5eVzSM+7!Xh((Ox8SNCqj4StG#Qc
z0vu-ps&tp^o5QA+=EmM+g_AH1PcBl#^~_(fCeTWoXp1j?Z5iPNIlwf;(PaoIt&HJD
zs;DyB-3P#GfL)66fD&ixoi(
zhromg@n#tiY3L!LNu8d^Bs6;r=Hj0K}GHyJBNbT;izCYYhC_}I5&kKbN_XT(|GI`=%@
zj=79F-{Q0VYh35jYGHxVIC`@q7m*y%-?AdbG36G%r7uuS^%*-idifl1Y1QTZ$tVa{
zVfK$;V@&D7I7jcwMm&ZRIF9d5+#HsW1Qzad%`hO>JZo{-ezy8GsTGZ@l*^5MlSGkEIhA0>97_5!xM8~S2OpXfog>F`=Ul(YLT~7bDH~mZ%?6n;791>jhQk#{`96l
zZsqdp^PYQ_Z;UC|_g0Nt);CMGeb#r|wEhKXmaog@NwHBV_l79?Lc5rABh
zjU8%w9X3!)hVY#R)#GI3SgNqTfE;LAnYsZT`qhj`Z+2GJC1FliigtJ@-{hf@0C}(!
z2LjGN42v{8jy{9s_Udaxe^r;)AEQ2fNW&JN!kBK7^=go3k;}ByO!aD)O0!C(ek
z9OO2X!ZYeBB^mHu2G~`ODHidFe0jwU_3R{jwv#EQm+_bo{Q}BVe%LEe!n2_Ei5gn;
zwS(?a@;xH)Or`c5wVmj;O-9T~{^*vleV0{yy1K!m@42BuT6V#fxNdTS1sOee_5$M_
zyiFF^yiG=ZSx+7#w^Dc;?9i+68U8;|R
zmx2IUr7({s!_UA}ca(E9Msx5kndz+(WIcY(9+*OD
z%n+$$Qh-uMv~7^Y+R-JMZh{wHalt(Wp_=bjC4`@gJ~AE2dN8RYGCg0yI448|oko5`
zm)Xj=mhuYLj&A>*O@iq6Cu_i!bs6kIc)U)FFM;Z1Y~mh>C@mizF5rmK&MbE0$O9r`
z#t74ptm49KOzKm1L@=SkfUI`(pXG)R>O31C96uOsE5DnT%k`pbeSWh-=tWwXe3HH>
zl&S-ZbRYao#Fu-?NX+?xotTri!gBhG)tQ(xfw?_q9Cb}fDJtuc!t(KKMIrIhojy`d
z4va~Ef~x+RsCyj!BAWKZI+{hDEM1VFXT#2aSf{B2fU~g_t=R?5>Sd30kiet+-s!$$Jvh{_x9P?!r
zAB(qFzj0-OGRz_u(fKR>s1~~TZlfG&^-Z=UR|azZ?|cRfv%XmeK~&Ak7mHI;ujj8r#h$Z^@$0QuH
zwW%1k(b;=Lo~Bu)R~>nM(A$AT;b3!wa`nIkIu_M_AuiC;I^5YfV9M)=*q{|<=4)dl
z(6ug_NFq_D6g8TEn-|J|&R-ev+V+`9pkg0Tp@YG?L+266HG3hlW-*z?mD(~1Y15o1
zQ@GE$#O$s?MsIgoETPM2C$70)b=0jKS$6GUWYAGDh-s%)=w
zw;8~2D11BqY4eOB$QXBF?1gJ1#zbnZKYInD5JwdECKp)zae8=XLlh}0(^y{NBVLR_
zW)cg9XzeNOC$w;YRfcKkTCK|^=qwn9pRG1+@DTpopyujK0Sz}k=Dv4t28<>!2o9+q
zD_}I6mkTX}LWwZd^|KGUy}*h(R{O!M!Qsk6a1%Lm;zV(>aapdvOjKVm2U!ZG6f&;~
zW~JbdL7Et2Fe6?G4bVNp6HNhyJwYWO|EeiAIj%%&sQJ|*<&eH$f=*LGDZ~M9)5t)f
z_s_&y40Zatry+?dM~z>h{J+ORD06*u?SZTZY7N-3JxdYgb$76tqge!Ly>g@q3#s59
zHw7yh2SNC*&^5C&uy6M8HERW^$lGQEA|f>(72!-v<%#P&24*N(As3@{j-bo5W+?+E
z+OC@UdT4+iVmw^F&x(N$>w^pgvxWbnxMx?XzMHkP%FFkx`12O$SW*%GxoYRzX_hi?
zenWcKCl77#M${qz4l=(Fp>$VCvjuw&=rqs2`1oy}R3sTKdrheDGuZgLO#g7QyU%$U
zoThdKlRRW<62c0U5s+XTd*uU?1g}j#&4SIS(b_?i}HIwRW4}2|xy#
zcW%Qi&FDRaUY?#Fc0NuVeH|Hb-l**v%mhWr$#W!|CLnzt?49Q
zyS{1l-7=UJ!)x?{aCzdbF7x=`7I21jPHueXFv{2S*XyNmsj$zA@8#FVRZQlfc?ppd
zB2510p|d047*n4!O1&Hg
z7
zM(~Q!a;m!Ijt)0B#4Kab9r>$oH!C_R{}}3}y233O!SqmGYck+kuDV(Yu3s{qkQh%RT?#7`atQB*&VvG!^)Hrhm1b!B?!<-Qam2fMGhWEON}x_5@o+>Vvu
zW4OY_5Z`;j@Z<+h@OTmOa&>Ip7p3ilw@!iDMg-D(T`TR#d>R=h2{~-KD?Z^E_%7qo
z*gQXEJtV7$c(%>4sD_>MWzMsF?Ek%|9^JX=Ud5F=+M-~~Vdd~!TM*{S->=~H_FF8~
zHJ`lwedP_zG|TNQ_ORlRA<(h8aW2j{JW9;aPf?7T8@aU3%R7{s<c&>1baw=bR=
zKd+9bb|Jq*w)P~Z57(|YN!3ZvyM$$b0PXJDz)*+&B{|`-iLISE*JBLqExi1_4ex6E
zaO0cy?(ZA&;w$^T(^~Sb#Do1=+ppLl5e6qN_4B5lG}C}Kb{dFl5M+Gq@2xn#oif95
zyi4t#cPuO|Wi&k}VZd^5u$cY8IIwgb2{ePydI2d;+Y&a8=HGCmKosv&{_9TZo5RyA
z@G($5O=cqN2qS-`s_DkEK47GP-~QXR`U=^mOodWAr0!v~H4FO!rEn2(a=611CxJ&)
ze3W2@7IFFOipcd1M{B+|VMr*N1WM8m`CS=eJ$~!{E0}+vY3H$8_K=f#7
zv$wkup?nF2!)Wtg&}(vH7BuKb@-cXZ65`)dX)qo4(oAy@%m?VjS`q@^=g1++HP1@4
zQ3kkEB&@{Dutt(jH27~EF<-d(L<#$Bl(j|bJNK64u~&C7C`+t)YG6GOn^RS70w7NG
z_0lFpD45c_x?S0?er=AtPRSQ5Db^0}`RUz)TU93>i7dr|KX&pSu&6qf>7;H=r|bPAmNUw(zZD;BL>`qs!a18uYjLR4n7Y
z&S~FGKJK5b9{0wbT9^3j+gD<+H>H<@`%m}0Uo&4HSC@wiN3%qzcq2}(Yd#&LF0>&x
zx6b!<-k$9QO>IjOz`a
z45%oZy2a+KiG8>Ye!`usxS9?ji}U>~Z(!Vdb^s|pl>g@aLO*XY1-j>B
z+k?GREf`7!gMD38E;-Q!mwqx-6clq-iwN=!CIw!?7O~D)nw>8y;`d(lUFWmPjb9Ga&-t1`zs;8@Ac`5D@OYTk|0W#zKInR;pN`Ejhy1Wr4-n8x{MEb;%)_0I8?
zHO->%Oftd5wr$(CZQI5~6HJ^P+qP}nb~3ST&fW7o@45Hf^;1I==Oii-o7sZ__V;RJVIT?n$#}Una^jD1lxM9|YXYild~#jZEL9>7|3evfEal
zt-DYG)XgI83=Z5@CBmzd3#GC@GiRQmaIjYo`5}BZRu|0);HoTKjj(LJpE7lTVFo^U
zY>4krDQln5)G+AEWMCoNjqD}0Cvhuy*;rN-5{6qEO9D!^a8H^~T*YG`BwG!PH!k+b
zWFS;5<{O;XS~49Eu`yMOC}2!T7H85km_c-(J;%D~#DMy0@H&53i$SrE
zMktGb+g$j8nN3wke>{=;s(jl3C%|lEq?X7}l-Ugfm5_S4Y#n9t*b#-v`EU(O*B$5S
z@~a<0M9vQaLG-7gS(sHhHU82q-XA!>B8y{Z3$=Cj+AtZi&R>NWrFkI|MUJRiUf=4o
zJpH}dNy<`EQjd>G`D_&VyS3tp?Zvl>_JyAG9`{=hX$}%Un_lSl=lWi%yyr+;RJy2d
znUe_1Z6#9RuEOVFa1{O23LvXoLjpP?IMNLBE8$tnTqE-_bvAzm%vO@0&Yzv+9~)G`
z&|MMD$}am+;HiT}np*fkFOoO#<#>H}QOs7^eP;ij>ggOakQT$#avT9KKw2xs;YP*n
ztD6s#<{Kz^ey#&f)4ghc`&u>ekesU`5TGi`RVob?S_Rggq(~ubz%=XJmrNU*KuAyt6(hQ}NAdF{LsfX@vnQ
zK_x0)&LS83S46!~HUlMo(Oi8kjnGzuB%fQ08Xhn(nc-TDo5qv{M&JmJy>
zLwn8M*jH_^OuP69KBEhm$Ai*SDuafLr*>b`HmF2G1aXs>ht7)WfYs|bn7(7Ffts!NLe@MsO5d^(|Hg16*moLeFY&5FzEPFO{
zFyi%;1M&V(9Me|sngy<0WoH$1oi>!0D#l|PE%aiGE^{jRJ1%R#Rdasy-*i|8bBz5^
z6Q-S0RDQFV``(5j8f-i+*PB2uQi@GkOE#X~P!Ydl(IwGKrVBG1Uxon~s~b9!xNAs#
z9dAmFwyR|fr(&U7k*t>(6J@TrE$C^kI(nu<{iKXowTYDnhT=Wrw0&FpW>Q&hr&n9X
zwQ;V;X63K3yhc?`wnv0rWEwu3C;-5KjWl>fbV+mKsxU`TOhl8_A|bsj
z;t-xcF1i$(?lydQXL;U%O+N!a+uSo~6t+cZx-&HH`5iLp=*3g%4xcXA{2>>w32rtB
z;|AGe!8j2?f+?4a-(O~R`@&&8rnr;o(KhMcws6l>L;48G;2ZrG!p?zOod216Dyc{k
zb4X!r09mHVmNAhNut*fLiaG6UvvD8h0%q&A<<1KA#Ew#p`)6AvI|=Qr-{9k9-tg`&
z37sj1gl)UV&ybu7n-Bil`(yshH$v{??03s*&Xggu!9rVSf|h)-M7qr3^Rp*!=}oRu
zO0ta-9D2Tqq6soa?;QWsLybS~D;b1w=jzAnIP=n*$i?6l-BauBOr#kc0dM?q-DUMl
zXjLNQAPHt37#FlSEMtDvgv9#7D$VrJ9Skvh$ObuPLOxBnp=J+>T-*;P`i?Qh{^TAD
zrj+A0Lx$0Dp7C2ru8PAwC@FZK?4p$Da2Cqp!GhEzu{qa6M(C1j%oY0-!Ec}7;g<@RHqx_+zgmOcWdza6hTUSzN>w@u?=dNo+9
zZWWbOI7z|a*XbJ;*WS(>{0hmT{1QkxgFKj@8~8IH>CMx4ZI`0Gi!YCO!O_4r^1*-w@XXfw0A3p=9f!A#Bd9T~BhTgE_5Sx^Yf7d&@`voFC
zhk{pQ3%l9Ws|~yNYWR9|`+4to*OA=7pKo7nZ&N+LY1e}_s{~a^2T$byj9$
zrr0MJ!MxtR!Eno1kP2l>9zE22lQ+e6csDK^{A)=MP&g_CcEm6j~g_^0E$GnmT0yt)R
z)T5DBID0feAnT;9X@4~$8hYGU@Olq+AGGJ>6P4q?5qid2q52}}kMJQvfB5}d>TbCL
zx{?~4Y$f?~-0C-!8`2wi*Yb5zF(dp~W{y7PnM&vt5s6N^Yi>8jX{y(<7!Kd19B6sW
z``Qo|QmlKmmCf3MXo004!>6(QSrT_e!`(JrwaVZO5_Yt%-aHlEd14Ce;Wo*~7t0?z
zw}=mn?0@afCw!!xi8{PV?KE}BtpMABzg1m%mJ6@W3h(4Zmz!&EDp_ah^q|4aW}gJ^JJAslDB{vHR`5#fPg&25voM67j(A
zrNzs)b_4H<chUZs;nz88m$Rd~{OVcvpEOKaG%kh~9j>gMNA2J=puad#!2z
zGk$3qQ57!tIsNf@6Vg7}|5#lX$d_~WMDYNzSpTQ)#rDrhNy?@k;6~N;#r^GrK71~R
ziZ^k`HEvJJ-813c_s#e2WT$0?|9$xK^ZDk{>9r^WCSs=qM{g~9`-*>geKRClJR#>#
zQBO#_JpJ%TK5-e(mD9wH_oD92w!cy`6)2UnZ8O5@sF@%
zC|hRYwK^N^E?czC&&9)*m%|IgKQAEp7#DZ99g5CIj)6ow?wUWB*u>VkStQtB_a{><
zT^gEpS(GbcyhFE-3F$G=x_y~Xx;sBnaj&L+9)hdfyMmUxL?oyb7MMzD6&AQkl_@LD
z$AJ^ybE(he@nf~t=?Qbmi5&Zcg$nG6s!$y22S7$z-Kkya`z**YySC(#MdD}j^xz8&Jc_CYWOkW44UN_l!omT}2b
zLWVx;YjX}EEmfv8
z$3$95BU#Op_R&U~XhO3@Sz23=gPaWNTT#NvnD>HzxvqGj0?7TI*;d?G9G%=O@NG0>;MXK~eyWgu1vu1@(`aH#TI~gg(~$LWY7my}
zn2$7ik%g+p5`-w)0SRh97g^;bB+O!v)G`zdKtr?WS&CqSinlPod;@j*Hxt1@8X;ES(~?-IiY47uUTws`pORSllE;o6~aga!4*U-FOgh!sQ|
z9Tu{T0iTwZFQ1fxi)7PCoh#6FvZIgFBS^83a}+lPvwK;L>S|?aP*VHn?P7?s5YU(v
zL=5!e>7bbmv=;+GlmUx$>Qs`(FAlm)OzI?Y4QO9=-NpoW4=oH`JhR2D=Y=?D61IP_
zNd=YS3_;JL5FAG)iT%PjYG&(DVZVdL$+rr)&8$6`b`u*q#^hKhb0audbTfr3$CD6U
zzal+Tj2Me}WGP~5eef~YSp)f2XRG=3v2A84OI@xG5RYEL`hbyG(!Q#U0UemYG890^7*_pCrl;dn_bf%%!
z8;O-q6>w|R@C&02)$qXK1y$VS8bPm%9xFa1oxB~J;}s%$8+t4~l1N2VK`*ii
zK_!w1Svd
zbf}{M`nKY36I+Qwyo{MRVi^$yy_m7>tm)cLU41^JDsnee-<4NA6{Cloq1V
z5u32Kh88!uHF2Ghg|u{khn;kXk%M)x8gs+Y3^?%x37mUB(V4KSFlIpNMUDDLgGG-D
z45h81qd!K4XpSm5ZCc?Vn305|b+G>A43@C*AVMnKniJRXYISojvc2CvLmKu1rF*xj
z*vAJz4CfPon+b;;{f9brh|Z5}K5ewY@mxgDukmeG(RE&usJlD&0QV2L%h=s?pVD%-
zKUkMv6GrLXpTvNHEk8{`EcKX$Kh-uBRdcLX-Z>cZ@c^sDj|#Jj`e+~6Ff$ni-%IxQ
zw=VW-k&PuHmA}N+YQa=U2wdI;Ys1Es+L2g@cSNEfsNHcxv%V#gR))oM#Bg3$h%JwOqPKThRpEH?Uo!DZm&*16!GaY-7v4P4qpjFpf7
z1(X8-#4^4Ek`n(R^ZXrfW{lnIL3st9h7Gc-LoKdLB`dY+_J{$h|I6h_
z3NBB(Nw++Bd8!V!urarZiAM?QzRtGwwg!m`AyEaix4`9jH$EmL5GLz_u~pl
z2h6K-NL6M}w%{SC<~O>CTf}0yV7>E7#+sgBz(UEdFUp*e=(*blg#Em5`;LP)AzmF%
z$$xa-rhQwwyZYy@y883tMf!Qy1~af_j)Nh68ld5jDd!UVJrG|n5;Gt#=w_&y&8}NR
z4{z6&X1wOHgpIh3+=WZ**_476xHjUL0PJ$KRPFc;z)dmWHjkw+#|{gzx$!?E8mny|
zoo^lz6z0_|UDvmG`flv}z7Ufwcwnr$J#*f^
zGK`>xXR9N|e`)o`Az#`%oRO>4Dlmk!<;O&Fg5!ND|+x;%d{8D-Qjav2`g{h=sjiN^dZf|h-
zykvz5EZz_amQZN%+X3lwn=5l@Mf!GrthF8_{P)9=mAVvd6*~Zm0aeINp6LW`;Fx?Y
zlEQ_cURCul0JbZyFyC`9kPogb6I+FCOynnULmXdR<1}GjObP=$Hw-s@U;N@WFND;!
z$LZPHg(t;!Y`1?*GRBH>EHXNpxI~iU2}a{cEDkUZ(|FU|KF~RZ(8&v7w1p%1l(f5grSD
zqvVA!>tS%xb^%+Ca{2-d&1ON*2*i;>!4yC&t^4OGk@o%QJfzgdhm
z3nUA}L2L09#%T8>lkzACARFUMgQeAK1)glFo=*V9GW@L(>#SLI_@V|yC5V!k?`7jr
z2^Q(6PBD;w3kt%8f_!SdVv^eyga)6K3ypXHnIUM4kAo7f+AGy69kqaS20e$N0figs
ztv}e@u(Dk9)XF!j7>#Pb00r7_3v%>~Bx>H9uu-{;geBkE0MeZ7CC3X=I7xLey;Kl)
z@pp5xq3IFk$u@7J2CVVcK>0({zK-3mb^~ZL>d3ZNtacIYCtgRT9dZ|4nv-ZVGO)bg
zW1cNCaQlqpTmG!S3Ll#LE#~AdZEPVEnnV2C5iHCW#L)g_ft+2m4>E~3Wf&K
z$21~V3$+@Bq>0J|%u+{iZbp5e!F}-;P+ZTmL^V^xQnim0{$1c`is}5Dl`bq;Yl+X1
zq9tiL8&Fmj#1z}LbUdeavd1KnFzV-J^(EdS0g$SQ3CYCug@n6JXt`E@l?x3{w`R(P
zMAMsI#NehHmNpxPhQh*G)4=~AE^Vw6pFi^LnHNHwrP`q|gSp{XA(&AOHspY&IZ*5>
zZKUm}|CP=yi_R#PSLWPjEcqS}G(Q|m68tkeD8?uzdSw-p#Hz!sEXk9m)tO}JBBYor
zZ5w~^0a1^q&E7{ZuT!4Ou1_GWUlKt;#Yz|Dh)#kO=zXnGKsKMaRKBNCIxh50KPa
zZ`&7W1btat2$BbTl9U~BwcQbQ+9WO$tK>z@n7|ouAD;lyu$;C>1zec845oA-mstBO
zkygb`TN|W|cO;^rk`aA`=@d_~FkWP;jp!u5lF}(J8cHB>6cBWZ9S-$v>|55F(cC3_
z_$DcEyA;sNS;CR-%sv&{sdB$AB^gC?cZm)-ghpr_4EMnICKOV|I~eLD%#10Ol`zpl
zn;mFP`e_9LRLoJT;sNdJgj|v(qVjQI+W`x`U!4Y(aX1J9Rlgk$o(5Jit#6T$W?DNa
zaCBYNm?nZP0yW69GeV7)mcw+1)RH1xber=H9?=9eD*%_mEZ4
z15}6TM73j+b4l{-8P)QH|o3@l^n2C{%p`Re$I2R#;jbBOHZ
zWV5eFBFm*&(j`vg=gmg|S^{#;Uo8bWC-)nOOG5>=eo)!>vF|f8Vi{jbzvfki#chDt
z-9Pkv1MDR&TDqIQnv!~8DRc7a1#I2cG$aaU9tZq0EdfJI$A#F0$X3=8q!x?bNOt8f
zK~PhDv!P7=Gf7EeiJ0KcW)}a*6=kz)iIC-!b6w-3t&f6KQK`(rSy+dVe5aZpe2zQX
zIs_po&1TR4Oo|$uN_?}E0^aW_dft*|F9xOHc?X`sHzT;DYN|2^Sk1Qjp%
zB2qhA(5-jn0h{X>JR?i}vA@vK_eDtw@-
z0}8F81B`oDWt^<)s6Wc0=9u~)fl%5ab>xnByWJjOX%;(WZQ+@@{8R3vgNA0&QAyM>2*{TVq*Gu1QU0CzO*HTUnzGc_ku<=)HeN4cV8
z{(PRf*vOMB8Qqu?by8&AIUpT9PYS)&`OkSZ1LqZ#<*qdwh%*CE!*MI8Oc%I9LJN;1)AS6F(PBg4{~88&4ffbEN-1BE0gb5wYaqPBVtY>RwSM#1PJY!LQNnz
zOehlJK>|ud-{O!6W0FQzrNEkkk^D0rZk@*|Igye(h)bDOPJOquoX(E{Kgp52Mv>%2
zet2l`Ed-8ZII;FBvNUWvqhQK%Y{!Ia;jZ%!(=IYa?DEnu+OugcP_~B+7Y4@mXl~r#TIddJzyb1SxZ&HC2wHazN%lxhTX0tHnmIs#9;qtjO@5IU+g6DX>Fw`B910u
zwO{&?H=;`JeHKAd;z=zC%7CS!$kEP3`u?MDI#Ue
z%gk_)+*FhI_&o0tG>!z!|-y6E&f6qC^!
zt%N%_eP-%Gs@i6Sz0_KYmnBmG#Nbw?!b*(^gmk*M0<@+v9!nc(L|No|jPhYoq;*!M
zzE2q)zGX5E%-bP7)Yn41Rf9W36Za#%{=ajgj%FKSwbF
zSjh!IGB-?V=0_ji4jlRW@12t5?C^x~b77kD1)A7mB7kwkgKQOn)%!0NEOo}|7e-g}
z7`QmoB@x@-XTKblNIL{@@W!4&_aE=SuHFHrang(D0vq$PJ=|87x8_3tq6`x-Zq%V0
znMYwN^yKiZ=0y13YZ>C-nVMea%y(cFEf2y%g!u!uRC9**A%$Mze5U$3tK|X-F~YR^
zNgx76cqgiR0T>bq^)7J;6w}v1BE0O~;OX8ktj{p{Lmg#ukL3)=7{p(jq2o;{NQGD^
z5v6MggQaU4O-5GnLrB!cbBGHiXoQ#SB(sBQ@7MQd7oL9%oKt2FtbzK=8Mzyd2$ryE
zAE-btnWpn-B*QWS*U~^+25=!IK>A}S2Yd213GnHUsupn$R@GU0d#R-7_Nbbz{u-}S
zoEbe0NDl6Bk-LbE$QR6maDR@A3&~Riod_Fv#AJs
zmx6q0Zn4m85)mdU`$G42F2sw|}(ZbZzWZ!Ig_3}M$$=h%|8T~*|O73twTKNSJ
zI@mI{Tk?2PM}W?yp~K&DjY>?&wM09xXxSA-D*6?a*FHUDiwT!=-m$c4mQ5r#`YIy>
z{gUxPXX3iA|2AC_i@Nn`&d0Ik&rGEoD`kO
zbl9q*Cu@0Jlwl;k
z-UWy8ICG0_6wduS49EcuuJAtCk0Ic_kde%`lRXbCnQSCb@cH72DMAMOBMu`1`P9t4
zxh#x}j7($vX8Xo73(oL!oI;mUhPQfe!pE=fr+<1iYdPNg_~_&p`xf%41#|bBhGhIh
zmO^u25u@2+UB{4|0sD={C0h%gAFD)A#LR-}VB3y~v9qq3OiNIdqZEu7B3A?Xds^e<
z_Bqb>D{l>g!;LV`yhyhRJq(B*7_sKk`v;hqW_hWNtP%k^3Sv3niGFsS2%Ut{aHp-Y
za8_ad0<`6$S>a?zem}b3RhLXoxJBlJ1
zODRw)eu72ESs*AuCki4-W)LCis?#2QT{YG1%D7Z;a;`bZKFar5-lDCZhECNhUM5}k
zZ4ED~;XNHZ%=D}1ual2}_+rl^UX|ND>|3p=vAYEI{PX-9O^k0=mFQ*r+(fwN01u&@
zEu0^^>t#M&3sy{;HGvYHx^IegE!rxdDjCK}zXWrJtn%Qixrul&euoNj*q_oj
z!PEos&;o{_o7_U?-kq*VYhgbh-j~EdZZyO%83sB@(~`e`m+$2979ZJFCNx2W$0{z#vUBG~Wk?7&;#-ozH{Z2dqZ<2=nI6aV{5
zc>l~NSk)k#+aCUEU9#_ZIw$W9p`R1aTTZ0BqFx7$+~v;@TMbfy}d`s16#Pk%oYsNgIw%??+4hR
zd0*;o$RO!btEW*r%$Y5!fc;wT|JWaJ;9l9e;A!MF`9HAbomc++6ESU0Mgv
z|F-wP5UTkJ^EJ(fgsXzRxSCO7A$@)sgXnbf#2Ngbw<=!v9qHm9p#MBGXP58W$90#lR5*n?IenrC^Zq~2NrY8jylw(oOZzt*=b35D
z-8_R(RB;`r0pP=VAdQ#}IAz)=EV%3Io$lxD_ZD$+`P;F2
zcI(4iBt$aw8-e4>-$H`_SI8*xcl0oSX>-r|7U!Vxw_42KYX6q}i&yYp*6^9+d&6G(
ziz~_h#g#QU^oKK$6rrgXN9M=YkF8rZ|9c1T){nNE|8x1d^{|bX`_gg^pUJ!0O?+GN
zvgq~rG5TxnqTCtmv*|m{X10+n)SCz;IsZqQnReF+>}}%0au>wdtunHUx-X`ecK7y5
zqW%zoG@5VhEWH+f^eoKD7qeZO-(|V63)4%i`+X@<-^}~ieY)*-JQDtvDNV;W^+pg6
z9Qlsf-l+DD$`eI;ihhrsxLPoCHzd>98Nx(xi|;gU?CguK(hF*XG*$Pfi{!7Yq*TX}
zZ!;l5Bkwd~9%aRlCOnI*;6fyaOoT}F2?$|sC`7YvLL_U_p(xF)-Icp`b(%s(rFeIq0*XIVcVv}i1Oc5RP5jM
zUHIShm*9x0s{Od`3C?F@h?C)Inv(*
z>h2%#@EFv8{uw3QsLXl_6|_XDh$Q|Uj>-bypTs0I=4h0y&G)5c6R&*I@orN4X=j|!mZ|kE_%a?9z^Wy{f?Zmq5Dgyschwtl4HopuXyI*GexHiH!=I@5+&3CsJ%tQUI@bDl^pwJQGyd7)_x|CX
zmvHrzz3z9JrPma)7w|<(>RXAQ*A^b0n|yae>18wg`d(6z6(!x`_~%cM+%M_!!yi^p
z4jXv){Mqi^m(l!oTf8=`#3fVF>-`~>bk~Er+SC{hLEerlUEQ4-iR{j}^#{LcJE`oK
za5^zJSza;hgY*;o)3HLdErw`|7Y%+WHz#+9SeoUhV-8!hwP>C^Z$NhAY|?PPd%GxG
z`uXV;&B{*Bn&f4(rL;5V(Xjo7@=8ui<;^4S|<)Qhz
zD8R6{Q0Tj380r%&rmTvcj`mKUDoR{+Y8$vjVo*HqB{!A*eH6FMbP9~!LcOMp_U>aG
zcE-oiEAkd@o1(pOP3er|%k5q!NWt!%(B%C?G|cdcg3m7V*@=BdjY6;zY7jEh*0*-W
zYGubkdM}Az56LgVbQ?9g81%zNM#kpEE<2bmcy=W@$L|>m0DG(fItI(37+P->nJ3l8
z!Jog!Iz=#(yfLo}4Z9}@axtlMNxNt~R}Bf+&jrLFGD_e^VB=A_e*IVoI7usOKO5KP
zJP{PTPGaoGw`DY5HwvSdejLYfEn5*}5Kn`;0%0!fM}G)s=+b#xyiISO#($Du2O8$I
zgC@Nc8#_m1e76V{r&(-HmVX=kJXyZj0h5Z7dYPsDy?^C)pk1;#)jtV$0zb*i;mx_>
zt@P*BzEbb^FzP3E34SMaq0@2qdGnv|EzLMbU&S4g9c>m<@y2WQH)s+*&&IxYKKMS}
zzSq3KhJ(?yAtz%`fj#i^B@;UNKb|`IPf0t?s>6<)&P^XMiP6oN>(Y(fbhN=RwZafE
zqS~K0`Bz;yDU!8T5cTVzftq|pY^6~sy&L$oY^P_N@D)oGEU8r|=l5H<#2Mq%0fP`6
zLiG68A#DYCOR{*Ka$${AhY);Ag=k5-TRfi0eWvqmngzP9X)sz~n|FZ~tLCjdGXz#g
zD@Xo>zG8THGI$DCXjbYoM}iRE^$APHvE#T7T<1%!{4Q*?)H?1?hTVBM|ritT)Av!abK6E=C=to9mKiuH-O2mhJ;9M&9>|;wD
zjE~Ff!+bF|>We{j*N|Gej$9wDAVzA{FWLF&3JRxbaG@J*_g5i=wa56H%}Sm|dEX3F
zq*srYA{01W1R_kcwJC&lW@>57vb9MA0Ht&z4zkpjDXkA**#|d%Pl0iTCqmDg5@p?m
zZ^-zcRmVoOU9UAW;||V&^+kTwi|VVKrb6b5Njz$}%hNq%5z>jPVEX=p26xKHGm$e2
z0UXOoQBR4S{-CDttjWP7A=NPodY_!V1usiV#3Yaje%k*S5Q#=et7TZGk%_;^Fmjp+EI&
zog1Av@ax6!!_hgCrm>1x>K|WC1XYy>u3oyHLShC@UQvO$cIqF5CW49DrlqZp&*CwI
z2G^*fv9rDE!W_$>(t5bcAHrdI81h|tG)zr>P;QG{HRTJli~I>R!TQckBPlH9gkll~
zpQWHpel>QCpW&NC`Er$Fd+DwQTa?ie`i+AT`a|bhQAHzxWt^uhmQOs9uf0|_<&IZo
zxG8R@`-hmGCMZpd7}QlzzAn(MPPnl=W_^Vf*|W=PH9^b%q!m2ke8}&@1zh*eV{2c=
zO@BWsb>;IfeMyPz+WK;Qq%zhES(j7A>`HPS-KaB^7vtt131|N#7c{
ztnn55o?iNeXNW)<8Kave53l7e`VjG1dS+4d0mCF|NYlWfq@SNDDfO2_(Y-P~njBcIBz36vQk8yY1-;I50CjxYbix-{;a(Dg>D6cO)zsU6$eo1ONoLmMV9T9C(HgE2?$E;4C5EaE!@j8Jhg^z&N-c|H{IDkbm7+
zoR;mOZ|@)#_z21_syG+byv#@y3Vgw9l
zdSOslgh@ph59Y_-ixpo7mDk>`)lY(i@)I1tsA5&kD71RV)-<5kctHyB>~wzd^0MZ#
zv4cg2HmYjyaZN|oOtpw|BgSm{AAx1f$MTw4y={5=g>F2x)y$f5;e;!t_=`?KPH;!+
z<%=z8k7GufQ!h^7UV^WQX8hCeQiF}|tXZ&V>Vbe<%TDrNm
zUV)yi83yX1$#N;wxLJ3DCX8AMd(;WobE!M@I60~L(JFU&X)+=4CjkeTbp_Nfx6lDH
z0Q7CYKEk$$$@ve_yC4q)ob`UqpAlC;Wi@&4@Wjq*7O$T8p}cIzf-NPg>ag?Wx77@O
zWtCYVqS5Q{xMgd~6L~qQcK2fpZXz{quXP6M%**E06(6r%Hh|v6jS4E%mZ2q$=C!`O
z*91%u<}JRw3_~7$v0@uLlDg^@w(L($_j(C)YICyR;LSv`U*>G(;^L=6t>@Ea&4+8T
zU?oYDz5~JUQG~}U`fDHH?(Q2R^szoT?&jtA-qJa7bu{pN3cHvE{wu+s;YQcXY68_@~uo&Vu+?&gwY+0xFAHHBNcj0f!T8D1B|gB<
zF79`yTtF@b@~Pt;*parl52;MfqNe)7B2mI0mS~EF3wRz8Uc05F1+|*rmsTixnzbMV%o3HbtZQyDG)
zL8iv{p3k>KtotJ3J*va1NYas!AA5h
zs~JJAA|nNt(D`7!IwNL_K~8xfoasVhzAo$|=JlnQc6Gxr?Y{!^r7xCB;gtaM>(Qd7
zSAnF~f@N5+2um|81+^AHWC+ROBuJ!DrB!t<9iy~7&o&V7Q7BUUYUabz`8q3R
zz;{y9jSnd6p49W*@STNdS;VX^LDuuz!uOpe2f97~^FR8d?=pWYrN#O3Wj^75_ean1
zk3V`{P3OIlSl{i?4|pBE^N3_3N64ZO_U+`L)F`ZzY>w6n5EOp=Xl=Ei^C
z%$9s=6%0K3k`{hd*HN8~ltYEF`@Pp~%ktR+if#Q`(#6;#PE4FNfYF5d_crgV`8TJ>
zPWD~&aPidIKWkdkeK#|T{Jh_)|J)un^80e}+Oi#eSK!FFERsLEySwoA)#A5(ET5PC
z)4|yjAN}Fj&DGBz9ep={=UD%PAn~!?vqNM5?!(F}MG2~T7y;{JIC}k|=wg}vZE{B@
z42Qja5%bmW#~NQYN8<-q(1x$;`~5AC_S2g=!Hr@2dR8}5-u$Sq&)enA48A(PThCK6
zg>EIeKH$0=<1_o(Ormvh&bOWKvG{ZE1)O5qG8;G)Pgea(Fw*ot1Wbxt{C0fyjv%C^
z&uw&~sX3_9Mx%)XPJ%EYXC7~LJ}v2=R{aEvR;?@ahu_{
z?clLBfQ;sM_4e`hVAcGBhkgu~^eIH^6HWcLzPS8(5IJyJM9MQr`X~2_-*A-Mz|N6?j)rhqt;-}(@WTI)vHfr$Z)GzwG?$eEkI*rWKucykV$3P!X=sM&Gqmk9
zkj$DNSlNJ4DP3oaf^}@zr(oK4F}}%DnUE8YV6tT%@Z85UnE^i(icK4%Zm1!<6=efE
zkr9sA)kqu){;Ac*pqPXSbbTNN)v8cJQ&dtxbf%!qjR^S|iyg1>^=oC-WF7-~cz(j@
zgbW%cI2&piG3T|*(7tl1a!oTs5_IE5MM7ZS-QirgZ!R(;szw=eJZ+?+J%&R
z4UAAD66vZ*8?p=n%Y+JNc(~KKx1uV#dCgP78cQP?q0B-R&`QY+^QR@4n3M4OwC+Zv
zdIh3t$lB?6`CNkuhE${0`OEh&jUBv{Y#L$l**932n1Y%Wl`R}mvcVKGx=D}sFveO-
zIE|&HnL`Op)<1@jvawc;p&
zg$ey0q2MO$i$@kl66vF8n`IVj
zQ6y4w2+g`SqTk?7G(<(pewNIuWm2|sQm7>tkzxlZR0bf?)G{rTh*4gXL<0k!rTt(B*h>Cy|=bS=6Io7HJDZg6@IxFlyV0qG-jDYt6Ub;{*$5Z0zH?GZ+2fRwdOmY`uj+g|{I$3-VB`6q3Fj
zs0axfDsEtqZ+ZB#uR#Fa*&H>%^CzFSBNxbWE!>`+V~?Cuh6MPHTx}mn&wYq
z!vMB0EJsZS1`Y7bekFyn3cy0;L4@wLrUkaz#Yj@MKf=`1mwoAb-G>JGgqw*dyM(u9
zcJ&Pvns5gRTwWSX5`C{CsCH<%eD;0?(zb)s979x@AKMf
zl|ZFD=bL;5P5zmBbRl55?)%*sD|{2vB8@og^?=2TXeJN=5o<0_tZFmlWOck$JACn%
zMH_@NRfRb6HE44Ay+xZomHfkTF*B3Ud~gparFtmZQRK>#eaj9%IB>pLL@N?QMUA@w
z)RJX{qlWjxn1DDQ#aFqkA?}m!&U1?r)@E5TEHDQT2_Ou#_Oh<#nyEnkLlfwu`6A2L
z!&$OJ%b0@29jVMrh6!Q?CLxD#5fGny^Xb{AW92%ViU<*m`8!zj2vrDeyfTNRHFq&%
zBhr0hM|bX5hpCkMEd-(oQIArl^1CByO@zib48sO#79Tn#fcqkK@
zil3Dweo?lx&9J*gvTgj0Lb$NT8x%mTlwFSJ)1m1HPsr23UE1DxrdE-_}$bntt{qA)7!nWiW8pkhU2@G}Ya3C8{tkz-)Xn6#O5$zB#&*
zCulU;Xya_Ov2EM7ZQHytHnweNW82!;*2cE|?*6`a&iBuI_nf)aQ!~}m-P6-mGbJW*
zO13~#dnf~~kZ@Jnfw9|&EEa3fJey7wx!)M?B4#p?0oM^r2h?!DM5BR0AjYC{zQfj&
zQNL+6>2%WsA!2TC2Pixks`7~2459X`S21gtm`6Z8QqroC#68*!lR7sPqMBD$c3LB|
zZ?I6BVE%CXILU1G3+mZn5Yn^b5Fdr)B5}A)0aT&grQxdQA+82DaGIWt`;}LZTM=Q^F`E
zQNko7Lu~0y&~s(H2XY8vK=D*g)IenuXd`kNHshHvEUSvPc5yE~ld8%H*D--%!4+fO
zrQpH!Hhv?1WTGA=lz}(RK%W?~7F2?0ofV!fF)^axXJ2r?H`EdocM`VdY{RSqH!NH1L8*^4PsD7x!U(t7
zXSBF^f1=)-zLBgNPVMxwX+_*j5tb8uQ@nrpsc5E8O*{N%T@=B+pvr+mmMbf8T|$bl
z*}}wO(@TcLFhquA8X?;|_D%MsUmIo6KJ52HS6t
z&a2PQZnu9x*vpM@%hPJ2>$DX=6&Q#QdKT8GDC*2L(#M&4#~F+@op7{=OQz+H5%9Dj
z|KlP?hWeo@)Fad?N<&$scO)qRkaTEJ|HEG@m2a|l>l#E<)9r}U7}bQ_0V#oW+?0(Z
z(mJ_o{aD)+_~XcnCe_NnoI1&fRW}0LTquyQI`ZFTWVjv2Ww%q~hMqE2@mFs=DPn*A
zz6!l%dVo;evWja^!}=YWh4Skg4AMl==_X5s$sRoQ9jqDoAM^>iG}<&#b{q357eE2v
z6RjWT4)sPU=KI7*`hyw0JH;Ypv)((w2L?}|ih@%q@bzqClgXH|ShzTZX=FDZ(mAEJ
zgn{3BAT8w{wZCmldSZe+SXzfnJFT&g11<6zXMoxKCp{gKmghMon>+r=#m%Bu1JE655h$t0y*|7XLa<*N@z{p)oI_B3To4GA9dM
zQ(Wo+9QvgxW)*roa$R8lz3hqh$+5o+X|cP=E>PK|P3vx&BMwt`*jzb5=7LaM?(y=v
z#!?WSO#WBR<8S6AZ6k_cYg)aiwzOlYl7Gg8?l>{f|9rQFw?w6IAA=RIv>_-4t1A12
z!-=cIAg%;um%Rd0RWBQVwv69_Ra7d%aG^6tROuvZp=G}TyvH#KQZdPSUd4xy@rplm
zEmoSx9yXXOL=dym)e))eI?Bjms^EkafYN}JgjolNcimXCZnb#|CNoz+f{L=UeMu#VPuI`Gx@2B)|OTQWV80lRgYIfvaEZAd~7&)aU
zo(REh!kEoYpY^pB%PF&TV~9jrGsU^e8WHF)9!~WeYwOdI)_$=?k{oG|Gg!_wD{Ab`
zg0DZs5V&zAG{r0h&<*Iq&*%6Xk5Y%6)-&VN;%s%w=g-3|;X+YML+5j!`@=e&zE#yL
zOqTajKw7zm*=s`YsGp})n-X8rWWzC~TTOIq!S%J(+!4@~mQ;UG25NqcoY0BZ+MKx*AIwD*9)@+8ON7Bd&b
zTTA#~1lj0Nk|`ST%#5&-J*;%hhJ#9OCzt`1n!6NNG!Xv&q;7b5MPNpvZF`S!S?ba1
z=rp#e)VJ92LF&e#63)%hjW!6ThpK!umdTfL!)?hHx#5ZO++(OF!5dkdj6gUOvops8Cv$p82C5eC>6iZ<*nH>n?$4nWN9C0xt>5qDD@u
z`)PrDFcr#65zf8NXkjO^fQfD3YI5q^Bz5zTP~W)D|fPuKDwyN>LA;agp|+
zg%=a$97$@XgcqmwBTGYT344zY7*WD&pva+w?%QGkOV#AMF4~fa1NG9Pf((Cf#&FeC
zT^fYgjrXRDEPs1^5K!06btHJ-WAI*A6cJ!t57}{nv6}X$t+^ipaQ!BMSFTxLR^z52
zx;27lAWJ?zcp3>{OszHzzJ%`RcQvJ~Uif2gM2dQlmk(`RXXAI9E0JF!gE8MS1w8CG
zq>FGW7~8bwA&NQSH_8Gd*yrttRzoX-uI+Z~8oYHxS*;>JrMAGs#Z!wQY|xt;M0s~`
zV_fs60_}!H9Y$Z&PBNx;P%ChySIDJ!Y1ei0C8_2+`kjutl?YmQq=BhQiCh`~h4^5Y
zhhm(v=1juf(Ab8J?#}G3i~4V~=6R93-fBPGhy_hPj9SuiO7A*`I_8guV+Kdux+L{>
zGq$T$*rawX+OPP;TYrB_E4wnxLd|%u-_>C%9Zog}DRn=Rc&#ymNmrE&$8;272Paq1
zh9TvBigDG_u2NXz|HK`1;gcAC4#22))9Ni_(i5##imiq69Hb-|pgjM5^nV4#R4Xgq
z+?P-*3k{XvqB3_M9I*lT(sa32Z!|4g=FhgPSv2}8CXX+*VW|?c5gjBgalvB#672hl
zX+u#J*DS~1Ey8~?(EW2Um)-guW5uM&>pXV-Za&AC=k$a9fo8yAbN=-H{?6*@8@}vo
zv*Z_Qm)}z=zsdN>?n`FsYmfdH)7NFHum_LN^FYT%yGNAo*-_0yOK9%)=9kCK_-84Z
z2iJ#ImhYvXPu9pHKc5fw$8ycl<4)51>s#ux-)Hydwd^av9SVKS%H1rQrsqn}_svJu
z*Ylb7)$VgScbga0Pj3PIzLS^cEfoxK=#T{cCCK}JiTaWS^5L-N)UY1V1SY@I^R_vT
z*P~7%^%qR(K6ib<(s?je78-<>5oFujXA8%DeSlo+%&=iSi`|M=i^wYbmDuHbhIUuh
z+uOxuXFv^VAAfF3?%SRGvm=Yp_e0AbPCh${(49=(AZm%Z0@Mb3*W#AzE^M@^vGMoj
zkj$hQa-`hWs#$1vo{IYQ4BuQ~mgyeoW`A)2(S89&@pY81^hDWma^yNfHQahr`)~j0
zsM*w&38|H#sZG(czz2fca{|qj7F-cs9C?D;h$aa=*or2K5%a0OvB-5SJq;HI-J}-Q
zPGJLnO9LeBR>*xopm#vNgpr~cJr)Nb$lPJ(_%~En=yj%7f#I;u$9Tbd#?}N=DHCLl
zMZu2-!~@&2-KGGnwCCknW{cwB0s4{W{TaSa@ryDrc`Z-fNgI5zj$n0NTvvleZGiC5
z4LG_dEPFMsa}Ie6E-vf
zFs^y-9*kSNH8>YW(^Q*SfL4gt1SeOm6!($Zl|d!<(by&Mzf|GG=@_?j@Brfs&Md%J
z+lEebZJm8u{u*@R&J7;_@ofcv>KRnvmXIi})O}vK=N$2zIYZ)3QbO~vEhR(mORZ=d+Z3?$D-S_RUO|5&&Z6YbI!X;z
zg}QGU;{rWJ3${0MNr(dW8eZYGP5dXUf$ewn-u{l5;C&}pX_inCSc4M1A)!-4!b$to
zv@#i%Z+`kCke$w+mU$@vVYNmO8cJFaWkcp{uhyC4Uq9U7Kl;V_J9Lezar?kT2t=@3
zhx#=rd}L8)g1FWJjXt8-$))f}ThcN*gzQc272B@)-V5DqR2E<%;?4P2ww?TFY+BK!
z$wckCyIwo>Xs&*R@VHCEbIW3IwjiXdA>Biab?O?_RW)cDTF)ibHV13ATOL}V>j>an
zdbDvDW!$`g%k)lH7##)dGS&sQg|1KDXWo2m2>uo?$qbesGH`NrCZe0SJC)BO+_>~j
z@UG*rMnlBgeF6|_28Gh1WtXo*@OqxGTE_9>f0my;qiqNQ2t3GL!_FF#OfKXic!UTs
zaZ*ewG9q|w@Pw?%BsSZ%b@zWxuF^)j&;inn6m=QR*;)Eng
zR+ClVveZbZbqS<$YFa0I|sKV$d@iT6-_evmv$c|W1lI!2(vTPTPZOsQaYnA^A9=OC}$K973uAis6!IZ
zBHZ!=1>deuvKmP$Bma%!MpBN~B@i?7*OK`zN_LvJwhPMDFtBslxqmC;&-N2)FROy9
zs|U&DqS1xi)piq0DKbq;h1u11oA__YLW(da+ST)RvoR%^U5rWj0wThHlZ?*zK+r4b
z+?QFsJNc7fc2;>ig77Hi)g(#u|As|7FCoOd46OkYI=S{70KCWVAtn{%Qyo1hn0+Q7HF~JP>*eW%Mz&1q=xQ
zHeV>;F9CA0-zl~_XkQXOB@}HFwAkM_Gs@`&VDmpoOLS6A77fIYcV&F)RmkywgDBU~
zsH(%s+0Hb}_!OX4@i2Zrz6grHmsENOgp**lQ!3|@3`tid6t&~#P8}W1UwD7MzIrxz
zXx7LbWqv+$`1!unu2-uA@c-VoEbi>sBYwP^_Hbs&-|Y?XBuVFz$Px6Hh2yIb5Y^*!
zcX;1uwEBlJa@sD{tPgaD*#t#f*y^-|`Xp%KQ@X;sJN^_mtxFSqQe>4Lug^|)U7Fgp
z(%f9O)fIx9az#+JHiAS@RR0oM|c~?}ppYZn>-Vg0qMvNhOrtW0gofGhHx|t1EL;JlBTC
z-yND=$A85YS$jR)b48*PNrvGD%>+ud;&e)6Q`jPH)ZAQ|rS~e+StIKM@fBTr$`VS#
zrO72HbZI4jYd7nlOE&AMF)L)OjGJ;+Byxl(MrXh*tPoi;kxQyp=gHGHi#LhvWWd$NoTzXRJ
zU6x=p^L=Pn;l1{H%_lB~B92TR(IyK9%})O0IOeSl{M-Z2so~>&(vFk*0^Sd{#JhPj
zp|aUC0hlY*_Tx3LtdM%0sW~#eexq^&(j`}qT=!nDB$TbAQ_%Z6pel0n^!fWQ?p0g9
zUDuq64o?*W<5uDktJziHbnHGHz8QZp`8fnFdS;dsWj
z^Av#2V|JQ?Ss3Lceb2L5x`z&SGcMFvtIjZK4_V0gucDVEAy12T!j2S<&Yv9TN}w3KVvAgS3{h_7SFkwG$x$1xUZvG%+k6}h$7z4q1^?jZ
zt9cZcv~4JgTc<(D)qC7Kuxo%q##cLAJfSA`WL~4W>H#K^#zn_p>V2}#qD?7W279Lu
z_$sZ(RJ&|!)TBl1*tiF
z{E)68NqHJ{XhnFUuK;$oM|8J`@jd27oF&GPuGVkV+^@&uEo3s$J@kjn@a4!5q=`b+
z&saxa=cmWXJ(!|coLGd-`2ktX?G{P4KA>xLO~vK7;@i{lbLZRbh2g`qeuXWRG8);7
zeaGhEhg039?;v!0NIAYBrQ9iE$0j++HLnYsP=Y(cBxmNrOv}inqSDNtk6qnVuo)
zw~t^HxybcV7Aa#AZyui^%5)h4v8)seUi2c4AAqs2UVA|kt~AK+F|&V!SQ3a<5RVxP
zL3>2`%}`2-H4%8A(nb%$_D^J7#qjMosi1#i;VY80n>lKA`Z%xnVD=&ZGK+bGpsIYv
z8$ljsyv#fdG$kObS-n^wrbj|mqKZe20QLRl5X)fB-;*u7wc!)O*?^iS<-eOW3VF8J
zNkMPW|M0NOGCi3Q9k>JDmrIiV0w>%wcs@|oas8DiC_Aj=YS8E&
z*6gQ8U=c8!(;|&mq)T3l;;ehsuBc_d3r3>F1v;ypBDKZPbqD^6NkPcA0f>1M+W<5e
z^-=&^M6$L@hiJ6+!Wiq&3fn7$vFQ_adJaB+5dX$LgGR&=P17MMlq}4Qz(=o1cvFIv
zAPh@q7HKriE>$8eog^%W!mq3mpGZjN8Aq=a3RjyN_MWv=6bMPeLSzan-|R;Nxw1E`n#3a>C?b3M*8ItW8a_^u@$MgVWYBpD
znHnSyLA(mxHvC6cVbKxi)DgZ7n*o7Ew|{Ugu7N*p)#B
zj_^JgIFn#iM-RpM%#%W?eqj7CjonJhJTd=92r{WoI8C$kyv7-;!a!QManos@fVtqk
z`T@#d23dLWRU^YFpWV7j#$aqaZg_b9Y_6#wffKB;bgMd8r$en+#q(<|y&X9A#lM$%
z4sdR_D_Xb70>wL{!;%n!(Ka>e`BfA*x5nv!2tbkI61;2zX>$WPoa;Bw@)p9x36Vt(
zDh}sgWn#jVgf|&_B_WwU8<8B;f8ygCZwyl?%EZ{dM^UE$Wa*{xVhIsC!fJV44s{Kq
z{YV9NZfYd|k);$l?YuYqRo1@IwN7&Vx@^e2M{yK+D;
zT2KtldGvs?PYG-8nyn`#?Bz4{r_#vD3bA5I-MDOd2&5w(NCLh8(|@k#P!W5lleaw~
zmJb2j3)p4tQl8!uAUUzc3qvE_aMFGwS!aS?C_W(h2%RagX3>fuKjCjRL`2sp3WoR3
z`d+egm_?yel`sMs@(uKPA{=}IN0#KNc1OXVq-5mVE0b*v(HI#7C6<4CARYq4fPFvQ
z$-18yLaCd@*A+w?ChKtXNd0ODM(-zvoTtTee2a3^lKzX4{gGo_>=L
zR9m^UZbX&umv{wW*^wyM#5c0rBcrjslc*Ht|1a8b#Y{|PGA34P0U}32ObIvw$YOIN
z^Vhm;T(8Hnr$S*V0awl<17cK!YCm!z*^1d
zrbRN<`(W@6jTXl{M;&&UBH|{aGWC)U;gxSD9Fm<^;)XaI2a$iEWx0GsPu|7c!Yb5_N$
z{)tlQMERI!D87p}t`=4%o^2J2b|}e#if4@w`%dOMyr5dECZ)L=gg3X94_^}W{5ODO8j7~bA;^3d~G|?T6jIfjeG_oXaXr}hLP|3$JVl-tT06w$c$dO2soFD
zCUb=|rN);wh2ZCbFKA`8FBgIlg?E?Wa-I27aoEnzQ>##0XvE%({-XbP0vG=Y=|HWF
zz~z=DGAC5*4Aw%1eM7~PVkGs3S-BTV_i!|Cm5-NX?=5D-w42aGLoEx<7)b~*(gT!6
z4RuD<7W+hLOJd-;L0zQ66?
z$Wz~jcXM6n6k*+{lxr1aR^uICZTxXrv=x*xl0JDJuE9P
z%RPW%O2HFau~Xu@%ZZR{rM~u@jUT|&Hby*NTxMA-)*FRMSy>TVzO#fzoH(_au)!vR
zY#Ks&E^Ur%Dw1^`*~%+1$!n~9(U8B9?lo6`nm9&Gid^}_7VBuFV1oN8
zWL<4TH*XIi6?(r_wLXeF=3TCV2JGep*_3&NSEEEl6F*Gxh
zUG`w7+ILYU<-}dq1M>zz*|RlQ|9j~|NfEudQ7_KgvWsDP4kqmi09|c>_)w#Xc7(It
zhJ7As#SJMj$E2f(y=YOU2OY+=?KB#?uA(*+?z65XTM*b)1zbh*Sf&M&0GwDhO4>XK
z;t+ow7w@d6qVEEZhT-hD31W%gCUkr0s%`Rbqow!jW%O5XaWeLWk5ZZp;$1Z^mPNQQ
zXuZm%t&zAS(a~gm{%W4`Y2_488EzF{))7g%!6xo(NTYJH6NOmPWLc+vGd&Od`+#+}
zMhd+sk#t)sDv1!Fv@ReUYLBdmHaj?bs~tFnmL{(#!_NQqqu8o1}Ji;vXjG}C4MuJ_P_3y>FIE4izlA~RVbu*U=v04
zc)_$IFYW(^W&VP4R4LaFSBOmhSmlRRIcpF>`{V3^Hh-tY>2%e%M2zE(sDo+%xo>ZA7W!+I;nI>hCOb6k67nrhoMq~{d&z~ku
za9H-q!Xi>P!09LM#xU*Y-lkR^D!BI8>nfG;sPD-HezJT6@{=;(AK^^i*pqr90BQ5T
zgx@NR@Zr~|DnN9N!q=Bz>9Z^vQKg-(PW2LU;ah4dBPJ7kIA{b?HIO0MyaV%Qm1wei
zDx&BG5t9?hkF9(Bv>4le%6m%u$325Qf}c>c!`U}Fci$e)<$BJprb4jU)Q0>hnC>)E
z;!4Z_QGFPn=_oH}hK91V25r^lZ%nevPx}(s?dhiDE3>R=F})$xeu-+AILUt6j83U`
z-@F7bKPO?G(Hi_c&>GBJB0^nI4+jr_T;W*O)UGpTrf(QSBJO%6$xZN8+p{ETQD*rf
zEYD{p@7C3+90t8Kra31ytxSa2-AvFKXW$jC>^3>Is+%{_0Z$WadkrH
z=$fg&xRBnidb9}ZnW>sEJB-ZfI^jXw!KV3do6-Wz%&wuN%BvZiV
zHUb2zUmp8)?r078?sQwbM<324Y7+p_X<*8F$v`rMf
za7=M$mZE!IAw9{-S6533V0Y4h%8w&>n+d-=L}N7$X0nEu^wb}}7#dJj20W)jMHs1h
zu
z)!mIk6`m=7s80&^oeBy4VI=c3;8u2cfN$%LhE({m(^%|e4C
z|G@RSz2Qv0clO}#HF(Y5w(m&1IXgbnac5v+;<#jB|FK>-^=#t2Z95eUGL)lwAO>yl
zhElaAe{S}fPzj9KL`3Q>I^D(i2gP#zn`5DShGoj4(k4_kr)D?>g@H6n`P7JMd}@U?Q}XD9;j2j+XK4yB
zIg?Ds0artkqAbwAZ8WLG3#lt7(#mA%a~h?pnBJNM(MMBe6NDqpOo%_`bH-%;4-IIFbV?)Ht+4sL3q_aj?yfNhfNp^bZONrKvs5kZ;GZ
zt`IZIBoO&V+=+`EP8UEaApi?PNlOq(yef~hZEAsuO?Q!cPJf6AJ9$aqlujagtRCr{lC(EEZrhHYa>6U2U!)!$Aa`;VJ(18fv84|
zw4rGT%25#YVM8>+%L>CHof?R<{i%dD+O!FN!OEG}2m&xM3g1xwfKF!a|8yFHVip0~
z?9`Iz3a>iFjyaRp$LQM1VC*9Dyo!Tc_z$VpCLaexuE`d1
zcg|n|apzNLqm4%KV^ll%^>xRy@(PBlW3i&}5&~^JxnhY)=r}$k+XyA#E
z&1io>qeO&(YtF}|i3Nv&rz6K3h=fbT;r@WWB_bMS>feVJ$uPm(vHtiEWWKOuJn!=S
zkWBf}?IBzA4^+wg2ekeNL`xNh(|aPv14-V(|05Z9{SU00{RgPE{|5-OWB_Jk!brxy
zZ<7+v{R2+~|A4;ae}H~=-eNb}nJ9sVxD)ih>ujBn{yT1;h-{f)8sv^0&Qi`4cr}7-
zNd};fS?~;O83~j49fi!pN-$S6M$rc=C6b|nDX7QKBwHVKEd)`O3vdniceyKcq<VA5!)mc>Ix`CS~JhQQT(3n}XREp3IgWz|mp6gx;^v_>&?k(`7*lk$)stjDh0-TIjsTx{4=r4Z3QS?Jlx;2cSng)9h41v0V
zjbbKRMDX53OG5Kfc6qlzsO@SJo)e}IK9TCkx_9UwUW3mazT|AAp7ZKwsxfuZdx+^~
z7Qf^10WL6!%4V-Y>U6Q~LcPtHH!;Fi2Elgl6Ns}ui{(6ogTW7TqmzM&~_dVhU)!BZdk@Vr4&q41sczV~eP
z>kIWWe#Q5V+WEr#3>(fvT*Fi{nA~`79Wx!;Bma`f725aPcs9<6~K$a
z@Sef4A}YD2AUNFUEUb!6D_|`KyATkFLt<_kfAGZWTa#xFMz-Q=BLh|?Q}V>Rg>|YO
zz-d;AfP`jS`&Tr&p;N|C&v2Np39`@qB(v{Cz`F2z6DSI7;lgit=lne{gGRM61!@!v
zh>}XHA)PZ9z27rLKqk|$Y^}om8c0t6NVXt>vttDXd|A7Hkh3d-XX{sqAoTJXnol0%
zS%AT?@oiAAE2#0*;3AoY{Ww#NDK-@~n4PhJO!5pTG+Q)vVh7{u9Q@uu1U;UG7D#MJjal_P>v48!gOwSFQ=sLg)`Gf+6`Us9D*jX$DQXO4L3@ez);PS
z0D7T?RT6eSJqT*5WwfQcDE<2j8H&X`JX{-9^7a(EY!taCJx?M*UEW78F)1Xu-@2IP
z23*C!5`#2qXI298Ue{8C0PZnf0;Xzb*$zOk8cX^*&XPcQ5JH|BLE`$*EA4NN8;*SU
zN|~^*2$uc_j3nO}h-U}Mb>oqrYuo@ZN3*2~UYI=}wC-E7{A&MB-nyIJ?w=6HWRx0(
zCVL7aCA1dSRXjI8h(sOz6vq|FGJ3AZ<{jy$=Fii$F53b(6awD2dxzUlot412&x&zZ$O%tcgy9sQ<
z)dLnKPR(j2ke|MM^9il!o$`=FukFxW7ceRhF5K}R2jfUH5>ORD#$KS
zw|-hq-_J#f?)WU{n8hb2zK}={pV*+sHekY;C4YOc(wa6m#a+CaSf7NMA~8^D1Re4{
ztMf2^QrTBcSC?e7BX?z+Iz>*S$Xvx3Zl=uyz?i3nyR%G?-S--It>L@LpKYEQwXMZ`
z!hf#t`{~l_sgKOsb$q^FVI|&qFNw^*m~04P^*XYFl8t-9Fq?7NMoOkH&kyq(M_t3&
zvA;QHqR$qkiC=K!l)}sOBZKR*+;D`}G_c;mtx=HshTI=S=|3JzHedHmwMRJ&CyjDY
zCwS_Z0Udjk2J!?$OP#+kPORXvwTQrpYj+BJC
z>nS(PDV_)Ds5-(svro>MZJ{e>y-+j@ICkx=o$o+S8^?Spoz8>I0euYc`Ec5&sjF`>
z3OA{7gl$FpE-k^Qf95`Rpi%UFVc>Syxp-cRMPcIa&djGzm0-f{p^E)b8$Tu1L%8AN
zzIc2V*(qe1g6S0fGIZymDiYXt`qvwKs4{-@AkRc=X65^Pod)*J}GIRFp0ORTcu{wicX($~4lX?=5%
zxw%*PeAGk7_V)E2{^9*}D3{#R#%$gDCV&QWKw+=kdu)Tgo;s9)78yxQxl#M<@XXRL
zEYd04tl8QB5YIDI2hO5L3aUo>jXw}wtoGc;_j~uopx6E5LlHBiYX-y
ziXgnN4$E&RhAIz)KS2;%^FQ!NqNq45tCgRPAshWsmHJzG-b46NdIy5PUpv%=!+nB=
zSd5Fjeg=6bjpTNyyIn!X{-Qm+>^?`xT^Y)1`9l2P%vCTzP4d4VAxJq!72VAN7|6d3
z1&9II(A%1tSQ^q>+8UahGSfNOnTIRLiNnKS{iA`Gln_w@0ReLamPfvS0|5b*xAFl1
zcR-z$#Dzerr*KYyJK*MmvVtHWb+NGTh7iDgXa@;RXAlsC!G9ZQGBpA=uqDNkB7!Oa
zz4H(AM3UurI=IJ;jt>4E-G&cbYisL{$F;7jV^G5OSqoLIvjr`2v*V}*t;n%Ct;Qe=
z3rSD~cnPFDEEpt`Q0Ae+3=BLlO
z&uMG(dlQoMaMA`NGIDaJSs6L0gF%}gBNklv13x}oBxTWtO!U+e0uvSo90esrgdG`C
zm-iNp7}E7uH%_*%iprrek*CA7U|NdbN}ZJ2%St1yN{UR!xr!Df4l2aza%kA+i_Mty
zb(r<>kQ>6Oh3p5qoQ(N3yV
zs6#Gv31cufA{_A%Wb=%R-z78j!=c_
zZ?mjkFjDPBactvO`E~-a!Dip2&ZUVVnsz6`+2&_#zVyhWE9Q1!E;d?yKH99i
zK7PF}S=n}JUa4Abx^yL$H9bh_ma7&UNsj$AO1II^gan2{DFPQbnqLblSr9r0Mrl)v
z2+V>V88_-AIw2h`qY7_Nu^V&@7+#<{BobmHN)eHuz`Y@VuM4EuFUXGq3EovJngkHt
ze!guR^)P{N7BlYv=4!CZKdzlF7QQ}u+IB5!P<~6R(rcfUWm~%u69!|D9UL$
z>5uyTV*9cP)AVKp|ML&UsDNofLD|dqsk|CAa1itnfMf_>aVJPHWL}>)OBTWo#eR{7
zU^sfgj?6-C#Ex2#EbR}q2ZE1!7Y4g$lSM+Q7=^)02YRipJGHBXP3tCrY;_zjs;gy)
zKI^;K7&&7wWOAH5v^X-1U;P{Wnu(_hGADeE2UE>23MW-u&!AU_3Dv!!w_Xy-9UuA@
zX3>yI8QKR++s{S)kDrmN$$!w)tMzIwY*?Gsu&gH^t=c-YENV>F#z*C-w=OZNO4Mpb
zA2O7xDFiIo$W7~wuv8L%M5~})p9A}M0>P+Q!p^Iglw>qPA!S7e6MQ;ELD`6r9LZ>a
z0u#&@tV5CjE!=++rV(c}gt7H%K!r8RWV6c}$`)N@Q1s1e10`IuKXCI>mtnQ^XQi_9
zVYtWoeU_`|5)-3+c7x{xLJcPcm&jrTsZYUa{B9o-Di!2&;-lMMxMGX-ul?N6m7hk|tf!y@(b_GHBXgyZ5e-^=y_Z
z0xJm2(|M^GW0_IWMQ@cU7%9HMC*9FtM^Gp;60|TgpEC;&54;V|W=_5?Q(UY(>|7kIo~B0kCU5Nga{aRQ>74y*Z|Ty^+`YJA@z_>Xjcv?e!iLhUXaHbuG70twrG9v8
z)R64YMy<-5nc6@K0YjQ?cAWffk~nABL?Q&DM2lbOO9%M?eL^5WRU*X5piLJ@oFsv@
zzzf)x%s=-=)jt?g2>HGb2Oy#HVi|x{f$W!NTR!hJwF2CZ{oP+l97vslN91ATcpgla
z{wWqhCm)3%CoiXIPJTEdJ5?+&h!tPyw1JDxYk0ui2(7y7BahZ7Bs#(!6RThaA18uF@AA`VOSl$96ykjT
zEvTJ`H;s^t^-k>;CK2~*kf?pzBT#C1
z7NR3(`)2I{ACPS@=6@L_GT2EpcmjgkhQd#RM|Vc!$M=YjLM44-b=z)Nf~8}1Ti>6P
z`^ZDZr(I3a^~eOkO^l{Sh8eF}Ut)|wh&R7+rPR0QP@;Yjl#4$|1EG=vDH
zHSk)zhH309oQDsZf`%Y!+^3A6M!$VR5vZjVde*$3u=_l%{^S-{=MG&T_oAkLyV!Eu
zi?r`am>BjBT*R*PKl^E$h`#)ux45e+p4@j%8C(W7%u{
z-Mx+MOl;il`~M_66aP9237v+I&g$ZMK0X+a)x+|=pPO0T8Eqg&k&li+n39W`lAp>j
z@2%~tRaMcczdQi)lz8Z|A;TGFQsMDGSH5rBTWJgz_Y)kt!e(#9oa28Jod4`&HF<_k
zR$G=%(@Ofvs?AZI%NHk?H^KzV<@?nnF12}9`7~~GZ)kDqklWfVR`Yhzp9Tm_*fq`5x)IVW)
z27zSy=j$Vybxh`NwcRa2;jak8vVApDpMv0lwf|frA(ItI?o*h%n%w}#F?k0gX6#t*
z2|~O(T-`Z|FBO9f5G=cWKYniO+o}0Fo?7bv%3zb3E(T7
zC~wZX>>oW{e!OpO=5BsG4|tJGU3cm?LZGrQM2`zWURXadS|qSVkFp_L?b($41(`pYC#aFg6t6)R<&FuX
z8u1$He)&+{bA8L+^ER-(CHl3NSrg16PjQK&B$&I~&nn1Ja@dCm>56FQDi*g9Uj{Y|
zf?sk-{ufRc10Reb7biqE_kCENZ>!_uQG5II$^LU+UOr|j3p?G@+a$=+`E+bQZxqx<
zt6#C940(!w^*$Z-YS7Gv%@0YCw3i-&n
zotKOVY8*{z{^Xhy=E!H4+}c>Q^|-ow3Zm!PTlU4r(xV_Qx#5i924SD28y%g7`5`Sc
zvvi`_Q6RTP?5H3(LbO^5XljL3ue!9^g3O6aZ$yjs1T>)O%9->PWOK*4C1CRE{p_me
zV-_Escr5nI;Y#07qDesDCI~sef(S_xT=@5L1sACNU(^;OweL$*2Cu33A4n@WSy&xR
zjB+bDSiIaEkBIVFn>`=Hclw`y@u#!>i~u;DFN1%;_1p}cZ5-!Lb-#m8#HXQcLI0Dx
z;$%|cDNw~Z3n5iz_kRxCY(a~I*uR!7etlf|orUs$4oA&T*Kr;pW_bI?BC|@3TD7cb
zl=mY&0Qs5c2vk=^$L7c7n6L3&ZC#tT?xiWLDMTISXL(NC<_UN|
z!K53zel_U~3zua$`v4j9g#xA|Z8
z{rvWGKiBy`_W1c87ElI^WyGdp<~~)0b|?YKRi3pp-ujS
zg43A*e#d)((Dw;P(+)W)ld=JF-nz+t@aTD<0nXMHU*Sg8bU+mIuJ*J(*7T8Fq1`nw
zwdU({SJu|By|Py2^L{gOl9e|IcAWwCql4e%Ddgf9jFe$}(ye(*W?*NMi8|;Q{YC@$
zq{~uN!0~f3xepJ>_iJ^yvCjeQ+T-!RJ<00=
zYz+2C>l|y3{`5~g&rKA#ZtZBpjhq+UVy?*~C4x^VQE7{+BqlhE2_*k`m*?D6IBw+j
zHtl1xDt7nYxE#TZ)0t6l&}^1ltE^#@+MHhrVpFfVsKlqO!Dm^1{N2$J#(-U69lWgP
zhY-)vIi9wQhQ@!LPcE`@NySrTR-zIv91CLBoHe1E;Nbi3eQ?mz;TFk%K!f~Uuk#Ni
zC3~L7Mt>zQ2eYAmn(MT7r*TZ#W~pZ@8zG=W*pVJw0MY;`zyQ8!K8TZQGZ+n3m59Q0x)4dI_~6ooziihBT?>SA^sc1Vm%(=WC(7tjOdZQj;IwcvN>pSN0uDHS%^Kn;1TUE
z(H=3#tH-PDlbixx`M3`z$SpZ=t1~gli5NxXyt*;#gD0#-Q%O0WPE<1acCoouZ?834Yqj=9ySCEk-|M7p+&Eah
zw!U`Q**a`(>{PaPD_c9|)%C*4Y90!0cT(+62GZ%~Tb&#PMjY_0G*aYgmgA*Lve`DO
zpVB6ooec9d(?NR2lL5Qnp!Xd{#_&607C_P+b@(K=M|J|3k+|Ozvoiwqz*~Y&p-pGh
zhFcLf8FhLU-3x^JLrZ3l+3JRUoW3{?`#wA{J$`Xw*04cUh`DRhi8B!)5OY6~$5lQJ{E(xN{wM*4rt-0Q4
zZ?@W7jn+oHx!$h!$Yg)AtsL*KAFXU1ch(N-q)NzkwYQdET`xhQ%e{PeIoDk-5LdRd
zm0A*dEI0B%WxkTkSJRnNvb&ORcTd}NDJS4H2M>D5$E3F&D)YfuD}*>xV9BGny$a$B
zhexItJYx7mnm4F=V1mMNzaIgT=D|
zoaC4tXRF)VXf!uEjkQ*Ft=-sM?%(UAZQeZGI9}a6>h^ZZTl-Kb
zz2?y7@@fuhYIQS>b_$TJwbIZgfZ6Ee2$;1D>^NfF49t2Z-dj06n8I8lddFd5aKxJn
zZ91Y(pAJoVVC6lkAMZZ&2y%qhpw_VN^JyNqoIoh>3vA*7+={R%Dgjv!C|W=_LQtrr
zx&_f53|qV*i`@^LF4=q#v(sY^L~Iek4qqLr6jd*NR**bV+52e^Y3G=tX{e^Y)`9?Q
zmDNUVwOL=IBLp8I^^JCWr`Ouz)3+PTIz;!?mN8&7=0}er0
#9Zyk2gm)R1
z9SZX3ZWn0~(T?9Kd0e6!LAqVAK+zD6O{mfxrO*f@+vm-w8h{-XRUcOJ_sNgl|A8@I~X|~S>Af>h3hZgI(YVI^Xm4>{(5hB
zwY|06-C5yBXt}k$+}P|umA!*?rpn%ZSvlNj?yRuv(#HJwYn*SC!HWcvzRzv9En)_Wp*|N(Hv$LU>yaI>PPo;Xs1y)YKOt20!5l$U
zJ*dTlP$*&yF3_Ns2;ilbbw56;2EN5d`jLnn2uHnwczS$u^O;w!zV_yg*I$3`i?2TW
z+U={iuN^;kZTH6h&h@>`<88?5!N%tGT_~=-zrK99wRXIvLDDBK-#$m!K45+o%`Zd(-Ir61x_$OHwMZ-lP^QXIXq()1hybMUinT-tM`#co;1L}PpEQCqegv^_BnIdIv`v5M
zE8o2O+EZ|itIR4N%lGg?bTF
zg@uF|O{)PtE@sk#ae9PYO-5rCw0@q67%&48X}%;-yBa)MOLr
z4O*Izs~HHKa<$~A-$y=~e&(4=dE>d9a-
zD?k$Yh>{YttSlsGb}X7we44CePro&^93iQE=l%Eew5TRXmC1|(Jt9EPRY-N&9sb}k_4F%N5JHcdm>*n*TN86><4#i9DRHK`$cjEPyUTdh8
zax7mU0UDC&C{&q935irVo(O+>;x}GZv=U9*swL5=$$E(`^r)&hsaHgN8!yXJUQpQd
zFU*u!hFfGlEbQgQ+m?a3-F>Z;JlpC;vjz_L)#BjeniTNO~b^+=I9~
zB-moI4{;9cj~sVHp?WH!Wrc_?gf$^-NM7~yuxmUc#?#uDzVcQ)qi|uP474I4SEY$I
zKABFllE5Pr%BIfQS_A;|{-T7_|DpS;+iRcmUEmfor=
zm6}{Bi@+vA%v756n99W1iUh$(3H%QCTcWHb%7m$SNs80dxyV-}#7i-iOpbLG|>kw49LiG_CB=Qc@z#UU23x1A}}y0$-5;
zJ>m?G9F?UO6TIDZQfsk!+O__t$IprB&gP9bHjWNz8*A`PTdTF^YPQ|Wc30BN?F3X=
zugbNm)Tk@v5^0mKNMOqmV&E~D)Be3qTC$=VB^e?WqO`=LrmDH9UX0QTq@oOk%GnTJ
za{v?C3?}_>n}lpc$O4|xP$uLvLg9?~=j8~J7D%K+&?7?0aMbDwn5@p3CHvfhb!v3_
z%J}@qtYyOFT$;1YE;$w*eoI((tA-zMy%Z1lm0(1n|H&ttno?+5?awPa@Ltn$gk(`k
z7xhHmNaR!_uOthG0d_7Yveh^+2%Tn{=z}OzAj)k0GzFJ?hmKfc`}%Qxd!w_x(%ERX
z*GlcRLU$ETrCzCPg|bp8iq*2*sA{#ER;_7;lAfd2oR(F6=6tV~$D1pvd4aS>Q@#>F
z3Ow?~9ZDglHUhQE*@&F&uh^2(kytV)rb5w72wVyE`3+wrLu)$VLZL$rX@*uOh(%_0STODb
zEe0b?KmN(TFfh(c%uigI9KA3)`o!SnvjYR?1}>i;zC1WR0hu(<0G`f(4KF*W6Aq@R
zpI#wDvuVuo#4|E9Sggj=MFSs$YSx`nd%gI|YtJPz5%|2}n2iq(AfUiU1jJ=pDw8Nz
zX{I+ruQ}M}G#AB-5`?BFi!p$XCMk0f#E~-8$`&G!_pZAsC}Q&&LW)M}(1|43>^Uu%
z35HW_6#~LUCGL;JEdJ2ql5J{cX>4MC{PNV;`B9qbrFrv9S01}EaBg_`{OIVw)a2mI
z#H@LC&NA%{SR|b$&4o`b=pe34sqlvqIfWJ*l?+&+s2=l5F-J5uYFe@cqvnt>>-JkB
zk!gp+r-_0gYXz;);LBs6%}n-Fq2A`L7n+9$o&Al@!Af_pxx7*R`7eJ4e?vlu61G6x
z{-r>~7K%E2L7OOhfx%kcsNjVF!{ilu!9S%+DHFzv3^NV?9Por5l^ji7K&^1v;eLnX
z{($QC$&UN65WZp~o*^E^<4yM)1g0|xV1kI)!zO$%+2$q|MlX#GKQ%lA-JKm8`og74
zk3MzrvC9K&a%~hcFf%bYHBN(Xjya0ZB?q+0p6bsHFETI)LS*aTbofJhIxeRTcUYM7
z`i9K*QL|&(85ml$LZOambjogD@_V8Q2{a1Qtal65ZV{HJf4h^`Ilj?3K5Xx=^mcn|
zd+pY05flt|as`*{-UW+m7O#}aF>Q6v`GSr>1okroQ&RzTRN~n@EkXG73l61_ual4J
zB?-6#9-%?N4SgsSeJ7%tnAsj$aK$LRfi@BF;HSU=_v$AOgw2!jg4j
zdU0ZOcH-j1*i&O;&>BttT)graTY|u*%cstb(pN)sQv>5ymaGd7?~+7g9H#?EZgvb>
z<4QB;Qe5`MLbgcM91M;*+#?qEl?B_tq60GN3=A*X?6fvU5fboAj8ZdIZRhjte5pkw
z_{r8jKI|OtF7L0d?6=o;8ujH&A}@ko?B2PVg-e4I7k>K3JH4ZW(W$feTby2NAnJi5
zS%pEX#PN>jN?Nv{_wRMmI}{BR!yNUe%khGT1dH7@yI`8SGJ5ICWdGGB433O_`xp1#{^7^(et4I!
zJRlhveR6bUYH11(SaQw5;w$mfBf;@(T+e8*;F(eaulcR#ZdrZa39Eg??7Td0yEtq4
z+Bd)a{&(K^>bq}_+Pvcq??NEtRpgK^YuQAhooy}`8q1aX^65#m?(y-;wf)|~T5qql
zw%=;>vT(D)qRZi1n3_HJ(Ve@me(eW8zk7FR?D2Wih{J0VVm`QH^=7)(Nb%|NbpG@*
zQV=2yS+emVDIJ!8!tce<_BMX|99s`XZy8ZPhjp^J=AlYap<%mEHoV}pzz7tX)%6Sk!4-{~0?}c!n~Cq;Z@uxQFF$wl*2aP_
zIBNCId4lF}*ssExtJy}X-m8?F#d7zwDtp(DdPf_p`zz~vt?h$GXBDc9f?nMI#TnBu
zu=CU3-}~s!oxzE-OZIthz#f&onVi<_^i|1Fd3sQtEOid*gDPp+P>kk$$hJUPzqohr
zXZP-X|35zd#!r8F^x8WgeSFUqUJ9zjm>|l~$vO_2N8=Oak*EViX|_){#xIN$
zBpE6vpBkO{()<5$^Yw3i?S~&<7@y;+JUce_)Wqb_+{Cf&?BFp;OgT?#)-iX?|uB^Ki>J~hrjvf5AS^cKkohTcOSbYcTfpL
z;)F*b;RihNvO|yfAK+GJ6xgZAlFPR=Zb-KMSMA^Kq^(}x?HsKx
zAJ8}(RJp!YeD3yPIv0g|821Ch$AF=V`=~nIrNAZJX=)pcBcv;oYPa}
z&>esYjlhz4WJk#8uhR0!?vMWXN4(lU{=?nFm*4*GukZZy<9i&EFydfIAsLFGue$>Z
z0TZ`61E&EmIL(*YrluDr2Bya^jDjwq%CX0<4F2`wkN@{a9{KN&KKg|#gO3f4Kmf_h
zvs05x(+l=#Psj`}N?;?&pKKsX=rLK0=W0oG08B?DZR3b|-E5c(-@Fvbx`bD%rF|d1bwT=ukJp@Q&eBBGL_n
zp+^tAT^O8Fne+&+w$h*(U9Qdky-pf12qnUBL#KFKeb5mDCaBOEvw$c+ymRkIzyJ8B
zf4XN1`+O&}Jlkf>iwj`4o-ZP38h{SAo$KU_%djKZjc4>0_i9uR@303~>ljr~D
zi6{Q{{P{;N4a49-u1wKtgE{l8**W72nPajYMw~y^{RZ9fr3P$NBAY4_LxnWOC8^Nn
zxZMvUK4$k0o1J*&VZ>*>0goc8rL0j&6cKE2w2=Eo0vYx_-7PYljZk1fs3+h%4gv-Y4B|AUxJljHoc?zbeH
z8HXx!)hrG3)N)!jxpR2nkH^h^!KLbEA%>TI)Z$qTiosOMAJ?V4k*uf6u-)rb*zRhl
z`f0NRRIVNLHV#`Wdo;td&8Kr$Gt0d!Vnn>@h-b1{+5=E)q+8u`f$0&Dga-LigJ$!z
zDuF4$5R3_|5%C!TuR@>;>%O4sc16u*&y>|SWev@{qc&(6O2k*trc1I3G_UKyYmPo{
z#RJEnh>Idi&)mMTWSgH|m>QZI8JHNqFf#na;FU)%UV8M>rHd1z7p5kL=f?1ABMi5A
z5gpn3OEx|=EuN}mjADYcSGDMe*>)$_?&jf6
z7HbCZNGr2w1R&mSYk+Y7UMCH&HrFO}gbtJ_q@q66<&m9!*<}hWIARvJ==4kEQQ8Fy
z&eKXvBM>(HpicBj=>~JrK`XR^UG;(TV2%%twk)p21_YUW~;N+Zf(}vo887*tG%<@zuie&xw^S_&{;pIukDd4@pi9ol-4#&
ztG#r0IR_;!_llivo=kQtQ>u`+U#w>fHJa1~Fd@C(X;qTHog%t~D#ctBN3bNDar7|@
zKXGA3cRRWl*9#rE2@FwUl7_s<5
z7H`mOcA0G+6Cu%$GxksvZ?pq!fY6)9gxI`eR5~4lAKg0KxVpZ)yV~09)>cV7^|e;1
zSF7}z{7iL)))qkSuPVT?wN0JIW~aHe3_Uitdi~p-w9V^V8^_D*2kngmaAkFKi_hN{
zp-R43gJ#2<=|(39RW{fZZm|wk8t{P%HK;XJY@8k<0S2K*vc+kdbmVb&Q1dPZ%sw5;
z#mS&kbh{)P+Q2&w4dMtTk`JVL0Z)8{a&fCOF_~s!IWVEkcp@w#p4U8Ni$o_t8jd-r
z6LUty{u&Jg7_v@31^*)quQhUdvEcEGx1V|K_VpKU?%vwpINt8Um&>S29rze>y7b}M+hp~vMl
zrbSDt_4;Fg|#!CU*cU;N73h0WtomJ%97s?OVq$+`9VW)7M^l=Ef_}J^SWM{o9>1sB-(T
z2d5IM1Xn`vb}w&Mx=ikqkR4uw)dU)&2-;{Amx
z{aPTL2nThaPY*iqUdvv$0^<{KOCF!(0w+SJj;PhE(tC{#bc!<&-0Ck&3jWgmS8V-c
z2Z;Uk1g&F8rem3$oXUuqoRlfZG{2M;@?|AckdiqelNSnQIg^hiGvQ1=n#c)>T$Fb7
z=cDOjG*_0hCCNyK)A<-Ak&PKyQBDd#gbJSVw9ssIYx6grIR@i!hx~i2Wh?J+D_lb%``<;s-;_zrT
z3=s=arA&M7gXy4<7h-uiloq0S*=K}=oFo=iNH86uN!yI%j)!p!unZh%43|lg+t1&4
z|ATMgNJ}-Cq_Xsv>nUF0+E#RAx=nx_^6`jq^r@7FWLSIhD^QRgIp?{eK+CWjw*;Q;SkgwPZynNYNf}!bGB?>P1=y0OZAs68a361VoNY
zmPaF&s%bzZfJoo6?e_|sxrNAuD9+=M1Rj*niz!u4bv`i$H2&$Qgni3*PB&3l9
zbs-oRfzE*1f2PlCwC)2mNhp-Gln6=W)ObcVQnX$UVq|Gm2tawCCO^5r2Etd@aAaWZ=`a~Y_SQ-1TIg?&{~yD{V+$s)
zQ0VL)?QPzAW##zB`q4psbECRJ3!rJGd9T{))tkLyix!IJTD^38Ioa$Ot!{!+v$XVD
zU1>IWJ`q|DRj(LR42}R_Rg7cwN7$oXOSL
z5>EzY%>z1A51w~U*eGjo=4lWTT-e#qpSv%2x^
zoZY`<@h&>UR=3|QsR6`Ow3avtLJh*uONLKLghe9~l)NE55>P{42|>r{dH+*QPDpSG
z0K|AkVgj-hjf|Ae%YUZH65)~!__8I4HIQW@TLue)0uAsV1RzV5R7j$vr7C*9nJzT}
zO)}*iwOjyAj!q^p;>?2AlG$qF)5{)Cwb5CV#}zq#;VYhS1crJ2>eFjiuQj)~>sttt
zS7@+dquyFAch)M6UbekfXs+Zs>$C#|hy*U{O$`F31THJ3SiK_G%2KPYq0^`;^{P^<
zs@0NOtf={t49Vu@TtR{B1vr9SK$8T`tO&Y!C|~Mqor+$O0^LWlaX`D+!5kSwz!SMF(z9>g2@|N0`dSvlVf_xIB5m1t&`|
z;?z@=Lkc7+Aa2!zk`bn;UX29Rhj>D2O1UpUC&-d51yO-ZSa4cfQ&s^)4$4d^o+#*g
zR#7sVoL2E8q9KY2MKS>H{!M7QIjb3YEm@4G%iM|V!;wLgR?~75UuxwTH2dE^)W5Vl
zgawZj(UU7TU){KItFgD&*xqRDY<9L+JKHPmwOVJZ+F36%DFT0BgNj1?)zjoN4$%|^Ud*U@M0KKYu3l8V3}ot1J0mF5-l3jVE-
zhvG5-_JQRs(t=Wml8
zke;OFD?lfX_z~P6);yRDAX*0^(MKng3c&l6iZMWzkA~0%wA`}45{(uJ0+gx|mUTFb
zekg(=(k_S=Z(z~QsBva#c*#yvKtSH*@hbzWOQzNWMSsgR7M^tO3Cu5$zygkg=L@%epTjd&GE9
z(8GaGjm)2FDvNt)$s9B2kaSMZTY#9TaD%IT5qcYSzasFTFJM*{BpX0=o9n?
z!{URzg3Am|l>8IebNE16WhxSTYEo5?9i`T2Nh*
zMuCAs8VF|82(&?9wShSz$Sllv5XT6^F+@ni%Cn`Gsh~%7`x8W;{Hcg987Kn)rDk}-
zQ8OeMS^DmGzhkmaSR6C+mZ_Pg$yw9P$kgb_)Z~ScAt3Vn(BP8;v_R&uD}#?;8F*q~
z@bODm&J7Gf&JT^89~!zcIW{y+E8qsFhi5GFfF@+#I!6;60b3|)k1CYp2+@+Hdm@TE
z5OoOJ=>@Q-8jQHkR?Klw8h}w&g-;0}7OHVbrVJw=A!J6C-gkhIl`t#dGltj5Qq77NwzL3qUjA
zOGG>XCFIlVlTWpH`(W?6m)eInmk$ow``exUt?uD^XSdhcrFEh!JB{8>9ZU%${`)`t
z9-(1^;!7Icj42){N01zW2>uJUpkSvY95H;f(%>lGVc7$KA_gdxm1->xp=FTuc(D=(
zE@9C5!g0=>iF6da(|@MVY49xJK`L1U)T&mJgN7H($E`4e0i4(Jv9G|>AId*As6abyIF7e&HuCJrXg8
zgmJ5T&L3U~geUEeF^hY_CoBbo5tD7w?lp%*n;Nx4d=SZ)^(n16Z;!l|}*`<2e|t?u!)?$sln@oVK^ZF#4+yxUyafi#vktId_n
zvoBoF6l5bUD9I3BPIt(J_tO|
zUlV{6Qj{}H$`L?4GEL0#>Fj{waz!mJVaX%fyg-rWak6o8LT#FU1aJqB;z(FTBxHDT
z#LWTFF!+@cIf6UGzW50)1<5VMoG=pt&5T=sORIB6kUVfA=gc!##x9R7Ob<=ddYE&=
zlu-+arl2tG^iEiv-NJV-YwTUrAn&+boQU=b6WT6)9s^co#TVf@$Sme_A(jq-s(Z8
zx7X_KH9Ff>_>{OTT~gF!1b%i0Yx>ogQUbo^%R6v+ZuHc+AH1CZr
zg>{clCgKE}0*L6)0&BL!2xkc5Npe8Z$7>+K2T1r~(D_sG^o?#>fe|tL0w$Md{%c?V
z%Jkgm%;MD4{P@@mCB(ZhHgs`f?Cc;YkQQ6tXT-BG-?l#}mFek``6)ldq`Sg0wQ>}Y+
zvwM8Je7xH^-0mK(b@x`*4tr}y%d3Z-mEFejR<+hm7pqz_E5$T_SRyyZ=3AII4UNs7
z8=JiF@AvNg;?BLF{psF^e?sT(gn4mb>cP|g9^bcRmIL-`WmP#6ROICKCM&=}AOGYxA_e3|a=6~Pe~Lxf~lNcuy1
zD@bf&)swcW^JKGdtffC(Ly0wrK-~cO9%sc2&NqO!978up8$bK%_dov9cmD0m@Bhc!-}~*?zW;}JzW47qe|BUH7xaY|wU3+|9X~%Yc42&E
zczSqxVRGI)Yjw|?J#(Ib2_zkrZ7}GdO#V!t*T9rUE>6jvvy?54C5+S4ABg-k{r^th@r_DUCSp^)eLZ1?G~EL`Nndg*(+Du`Eu(axa?iK
zwS0|m3F#iJt{$$h9j&bGw>Azt8~e?bZNg=~tfg`y^bcML3O1*Ae$g^AKK;bt)Byg$
zAN=BX&%X8UM}MOHd>{SpccbG^j7^=JSr{@q=NukOAZ&*_#MiAIu5}0g|B_T2ug6+lyFMsoEAKkn6
zv%B|xf|uvcy&wMZ&U?T9O}xE+`)lvwnmk4r>6lIDZ2?F%l#h^^4#6?N`40`+vMRa&{CKOaYOw>HSRt
zqhsgCCoWEm495J}^#i04x3ZXPyhN%&5s)k|;hb#o;d5szy40ZjxqzL44EoEo3I
zJhw3UZ}({H!bf-STz&rb#N6fa*&!&6W%jhf%Zy620t_*0p_Bkq(w2r+s?IVn@r?~&
z$|PRkv}~jvGOiB%0UrRLn2q{1uUDsivOoy}9l!B
z4Ei|jQyH9iNO^w4i{U6O(MAx;pXu`&%y*(d;RvmQFBxFUWRd6CjEiaGh1Xtz
z@pTE&DZ3j%x5*zGvwDHcD+{iHMfb4H>l4-Y-hcZmZ$JOluf6oG_rCPq?|<#3S6>;n
zdcchapzerJ8ZvwG0nJ?Ly7G}d>@E1UU${?PZ|Ia(${g017_|>n1@sLmPc}2=K6wZk+UX$
zDwgI}u*D=NNGljxaQhb`a$w0eGch|3XpYZMKRGxsI5ly8Wb{0sIRt2OT#i3}W#k_&
zoc-HJ9{c+*Jo0ys{p~+I`p92@;S2xp#FJmRJo5P9IHyUH(a9&sppRXgo*0;!8l4-T
zvCJ;o=H_jaF5f~hgh&f~N$cIC(nI(X_)C{ki9$S8Bv59`NgPQ^DK(>o)#zJqf7vHX
z-k7xD_0M|3h;`sxf-i^79vE~Shb=&!Z^8*6hDXhTA&Y<5AS16%*;OtWlI5jKbG+yAa%j>`tG>>RNRAtbwpAD7f)eMD|6MfE*72
zlsr+BKdD4RlK2&YK^6o#9bY+pD*
z_8r!i8*yONE4t(L(yZOiHsI0jlArwX-j9EG@9RJQWqNt%_3!-nN57{tR>4MYWt_~k
zo2A9UO?U_&)Vyp}wIiAca5%#I48JlQ`Yx~Xh1KL5ewpZQStMBgCclK+$dyUPlN^d3i+H23|^U+L3NU+&p
zS@nw|rNs-&z$lsQh=>pe|D&*G#Iyv(;BX>qjWjqCwwt!fR*h;i4fZA<3q>k%zgKqHLJQG^L_*_b5_C-GEmh95`V3ODqsE|+MPSjN1NfvAY~
zrUXuQ)3O2pP=xGdJ4+m}s(_~3Yl3GzJ~spmEm&tpCPznR#xISIQB*!e=sZ72gG7{I
z^vS1y#lJcCB#wXkR%Ia?&+
zl4Z!8KWr8x&>{Rt0CCz49`zy6nfFI=9JP6-+~4qW=xr_=gZw{
zrCV!KK9qW+SFd$zjb5X&e0nF`sYbbDuOF-)Z*Cl~t{!yP_PXl_t@WeE+ID$!hgOI0
zvTX}H0O%fVP2#&`$`vJ-mor&0o)C0{mK|yaOgtq~N~EIMypk`f#Y(!~qIKl8Rt7)>
zB6;4wBCR7&b1brj(0ZnlELIZLPbJPd)i_gv3kh?SN|jtmuqIhp+6v+0$-#UoF(1yb
zEjTVu%w`JAE_z07fr)v?pd&cz49zdOMoqqHdw9VSHhbB+ey>c3Bz9yAehHchpI@a>
zPl0yxxM9|XIHd>O^!K}eG#lVZ=D~V
z86BCWRH9cVC(d5Ee13R{CpviK0%4I0ka`}$_|Wi^<0I!r28ZURN9Lx-O;h;U$%RRi
z)3oSXa`-6ws6T9i`35K>Q3se(RN>}61eXSkcqNr6rzz8GHI06zk;}CTxmGq^&!Uf$
z5G|J!QySdOST+@itAV)YQ{#98@WRor6cwM5w8lWuQJ-%3;)XvScgnIyRehQiNl|Lk
zcqxT2Jl9AUJNZhl1gUka)#WPqvbsVWKp_2R`kY4lxhS6>!kzBw5h9-U>TZ2?s{~wb
z?b4>ht?eqHxw%~eWv;B|H#W=b8>Qu5767d`XcnhZ)hkt_T#najsX8K?R)%f1p{$9G
zR=V2CAoK=D!jvP{p^Y~zuQXd2pk*t1lP=TS?L@Ql5L|NW3=|^7fx$(Lq7+1!a+p_~
zhY|N^Zl6Yr&jUK`qy;*Iy4Mr4du69BVs=H$_TZw$H{*;fx}qj)V8IikEoQh9G|4-F
zGW<(m5gow@gmjt;LI*A;jtuB-+5wrQO+Ngo&PZxd)`Kz0tLj08^4n4_R-TR(#EC1c
z?gg{+1fAwN_?@HEo{YIht|$X9{g(lOrO`%jeG)3SP{K%Wyd6
znuTN~Q|J^5ol?GCcjb$QZarEvD2$
zQZFTO|5QC&=$6X8Vso`p@0GX!mmtg5YO}H4=F)$r&uJSs4uH$GtLrOA-Sw->8*nHO
z>ToU@S@sk10+d@j<=$F;eXG2>R)9gr5zy>((?BOaqSNVuN^|WF`m~ddHq#*pVblnp9((1A!I6pwSmYl;y&yky98qgP^8_i}2>{SkHUUAsMzJ{p
zApBmMQpZWQjn^Ze#N)8ze18dzI~XBZ1-Xz!B|AL7P{a}lEP6v01c?^cqRFwaV3`L-
z=S(x>(^C^mQ-jmP2xSJQM@JWD2d74-Oo(g7XP0Ic?TZi)GN8(S1)xc#df*SDwS92d>bGH))o#Q96^$Hk?*=Jw9B*!
zvsFqribf?1*vVN#$|R(GN-1XKVnQh;LPjdwgFV66%Vu`EOFk?+h
zxC~KrA)bm*6|uOFlKD#(K{N*ii#N3B4KBI;R;$YlF*|_1=|$V(lzC>+y1;pHe2yx4
zQPOMYlEZIz1)YHqr4|=tTST(LNsu%*+e%4@WXYOo_ZmLJ&3`B^SN2wWRP$`PhA3p6
zcCHq>6#x`)DX!GZ%Lqqk^D3m)t5=q55Q1{A2FZ8IKpw6y_DUqHbx3)=R$Z?(H)_rG
zR%@f(+Gw^nsng!?VZ(6?;bwYwr?G;-Pqc^y0$^tjJumh
zE#Pu%zs@(ra=zT&t#o@SzMYe&-|qBs?d2?O>SSr7Ppo#f-p(+|!fL~z_Lbco4ddD&!-SD{?Al*U`7K_6Vh
zFzRAQHz2KpFFdqh3T>{Fy$lU4QY`jTf#TKXi$}HyVu)YUEWz~Z2(LiAgQ%Q+kmOF4q&waFPvwb*Q~8I>lFl1~^m?knj&EM0pl9=HkL4_{uN_o3_N&{p
zC6@SdbGx#!O&epmtgIK8*9sjN@gAYGvz%u~O0^G95s^)U9V?9_ut=Mbo9Svh3;dND
z03{+GGT-@XGF_y7pScR9k%#C7ZF%J(Lt4NbLUQsZ*;qF^I0A*laG6jbNuVU3l4W0W
zDGqzg1r+}Lmp`Yp=z0)Xj3fnf*yhzJ6@**%Qdq-i@;*j67P%h@@ru+33ekc1`?;1W
zzcM=fsm{n+gjrHQ&jZfUd7nE~1Go$Vpm055<@v%N+77LO=Uk!+7{Egz4*)<
zZ#@0#i_g6F(zCDKzW&0Eqi2EC1IX6ZZOG>FHXsXG*;`}SU5D_GfN$qut$VbwOa&5G
zD0lnrN^5tG((CQ_Pj>fKJ9}&VWcOf`%ktq?zq7xwa=5i|ZLj}KpVL^T@{RQ)kY#Th
zLC;ZRbDws^ZtRw6gy^6SYff(EMv?E?Ufn1!ujUb>fF_q$3!q5?WjELE(UI@s1}F;^
zz1GPUL6+Tor9~;YAu#BWOv!)+=iJFb8PBPuR<_i72w(c*9={O?r$e+p*Pvk?aw}6n
zTfn2bd~82Gpb5mVp&UOz>6AQf#s8b%{>CN2Qv3e-y>ABCIv_{Pb@cS%4}SE0^bzRb
zJaM5+(GNPVn2iD^hC-j}@~duq^s!Cjz%hX9QJgNR&rN3t5E4wPpKW|54g)TMP6kR?
za~iEUfo6ahltwPXv>Tdbl;C@!`G#n8fIr^B5oQ`4egO~(IO4YKcMZ@-Zz5LqM*Iv8+<}0_}c=h=&zIywMue|uBSDtz8
z_S3IC`}E7tTzme;joUY_Jxl5E0onaqhX+p|?cUf&AII%$yEu~EJlMXuzjXu0!>t>8
zyuWq*VCNd0*|~MJ`}8s2%D#_Vu^rhsUVG`8{xf|}TfMrwb#)WC+yO3+ItY3o+Xqye
z;65&aNS2Txx4c>It(PdR{&Kbnr;ufY=R4s$D@9oFHf;bZRGX<%&1ftafJKny{XO0H
zw{>%xEHwzYpi-PK(Qc%N#N&R$=hZz_-5?dDb>ln}7&Gf3N-RVIjPhVP827ql5)%v~
z+Yj!B9anr{N^mER5L^#Z><8eKv4DVR4VxTMAdf6Kgiy%AD%#QK)|~c|pUg%7W&ikJ
z+W(5}FSz_m`(Lj81(bhj|I4*Ae7{_ZmFG_7q)c9>OaOC1jJ_K=F`13=og%C@ikvM<
z>3l3x5UIEaTbIQPec(tnQ;JHatfdNKswk(+YCJEi*_f7!smZ9EQRIvojtfE}8coJ%
z@;a$R)0$t^LWU79CPPLR_exb-M(IJr)OuRvX*Se^tR-dK93Rn-XC#9?c`{4&T=*K;
zM2^Y`B=PWUw{G^N{0hy>vAU%tDtU(Jl?GGbhv8!xej63Qp#2iLdLqYni&MT0+8&9M
z`8u!9k|{K3Gi3j4uWHdn9=FcmFV)%lS&l2?sFJ&~>T
zi?Q6#Wk6XESUd{>78x7~g#abTCCmMi#rZ-r^XYmwr&=G6XU_bW|N2+wE)EY~8JV7%
z*P886C{S77T|Itw@A|dc#!6+q(^zZPdNnqalrFa^_Y0)frra;JhT7~H6`sqWLWy7U
zyjD(5z!92HW~jysOFzM(iDT4AQW+fzNfT6&2>;gpGksPAq$ptl17(7e8Yt+nBpHOo
zliV+2q7q9~Xh*ruaLF@m;HOf}c%rTWk$^9LDwYiclq&F-3ILa4AqqrNVUA1)po|q1
zj>2#z20=fN3`O(NNI?td6i6uBUr|q>gy5eFXeL>`5U?ix!elxMf&?fzK_;_8wh+ZT
znqWZ0n;K6B5~)xsE5wt*c$(6@0Fk&1*K;0Cm10yFDIF1wh?*9qlpInc0WBPg3!%6e
z)T6PK7EGvNBOWg#LOQM1;?MM%jf0Z2BRsN~kTE6C025B6s819_yIVsL{z#wM5-f#Fydvu$yqXd(v)WEo
zMJWnYI13Q0%5<_K8KBR8>LQg&KvgKa3vijJ5{RX|fS=;4?xUna
z%wA;k;L%_*?T5sZem&t!q=T~NQsW+glII=7^*E^|AORy2Qj`$DqBe&+j<%2hj$6?c0rKf-Ww_kE};-pcQ
zL4N)1W<^T&!UcU0r<#w%OH{&$U(by@FU$js;-tXx7lc^a0wEg#DADog?g&*hBA9|E
zJ$is8$|B<)Oi_NKP&(>Qoa`3ojtKv7^0o=d4CpY#3`7Kfd@4gJH;kk=k@6WykE*-y
zk#e<4v>HuPyb;kEmED5qjY{}7po2tlhg=w7HPYck7SI%wbXZDKDk3=<d52k259NYqpvOu!G^o@je8>i`7ns
z8*V}*&NmY|kSI(u%Rt1z$9&39VzDng%?5v}&uf6>e>rpJ|NX!J1Nx2an?Xe_FR!c|
zJ$rETxVq5;D61P?fU>#@!(C|hiV&V33ryMWQI;&2Z%DHu*GeL#e`%=YVw4I8mLzV(
z0nJQS$Yi4|*-Jk;7LFX9040Q5aQ;Z2*?=dQY(NS?1ib-L|N5(6CMqhRrsM=AM~LKE
zhrpMFOG-r~!u!+;F&KLAE8EU1>IEW8P$p+h*m1y-5@t|6s4yrK!ZI4brpNpV%HHOX
zJ)tz^eqlul$*iNppQ@iy5PS)F|NU>_FQK>XBtO>wkRmJL4M*&<=8eScEI*bd5Vm@}
zRhi0Ws84CL7
zL^Q+mV=vP(fzxuD^b0)XbyZ`iSzIe7&TWw!|
zX7l>>+QvqGYqhc2fzX70uMFv|xm5KuP(rSZ1tGrpTiFSSQ(t`p@)P4P3|txTJ(c1(CBI!L+6l`4vQ?D62pxOF{%!
zlClSu6}>>gO_En3WZooxkaHx!jbk_+gj?y=J)A57N`h%Z;4x4rC4{r#P$t5i%U}x7
zB(mgBbw*DLc%LX_W5o)ANR|O70MQK}uqY`uMRm%GQxL7eh&2$hJ6sDuq0O`42rQZ1
z3wED*!8UJkTWo%d#cOf~Z4R&56R?M4E>ZQ<#G~qlHBV;zS~{q}pU{0c%1JS#hJ$)A
zK+udv4Ee#JXnzM<_<|4J;^k0PmZYq{3D
zb$k2hMty68gR-^Nt#7pIEA`G=wb9GBSMoHMvqE(%fymBsa=D#ow&RdiLu=F(2%rgE
z0;9Dmk!86;RRjUbY>pDVWLVO+lhkb_1~cFEpM7AU10X`QJSA%5xCFw;E*B~B5CgOLVnhFR7ZN?pm5wuy=(Bv=9=N~!K*8QUD5d7Ec`W@!Y+
zMcbswF>Q9wFFIyyz9qAB*6f_Kcoyt_lhwcE5$uBO12kibS55ljX(|(`8h%0bD9I=S
zAio?8>2wUL;c((XpcLaVp1j~BV;lGqWJ$w7KqUE*#eV1wP-aSM0Rc@dPSC6-dB!&G
zFG6_6wp2w=mh~*c?G}OWzBT7Uz&%OY#)g3irhq2m@k}j|dDxK9=)}Cq5%$Ze;~O`Y
zZ@s$r^zHWU9;|k2d!@az+T3i_*30eHa%+WU##%2zSW)yWr%9f)4Q?fs0D|jaZk@zPvTPN_ymH%`5&-7Uh=povxh!VIEfMdA=)q((o
z#c>{ZrBp;w2>eJKsoX8YrIZN*i1=}qOb`I=gA!!PLCKeF;uy`a>GcHFCxanzL=b5k1K1I8bo!SZ-UW+edWjW;
zT(Zy1n#SkM6C*PNGv5j7x^%O^8x;K(?V{76bag!qQ1Yb$G6+IOZwQUxuM
zXM1)j!&>lRXRF)YY(d&Z(HOOhA^!5>*8)lwd2!gM_{2*_=5jx$SEtG|fgbQ*MFN-@eagh0xhVWgpp&v>WkY@EvKWm~9u5K}u2l1sPYVK~4YBfB
zJckzg04Na23*mw9N`Isl_SC*z70}IcJ%LSls3X
z*Sy8M6fw
z(wK0jWLQ-5Y*jW0GMU$nyryL+jUZ3LAtp$agiL9(=?tZP)3XXLOP386X!qIigfG!a
zo#YUt^$i@dg=QMgW&g20r@ipz5BBzVGs`j-pveMoGT+?e3??aiAghua=GmhvT#z_SPbey
zC>{$N5(EKO)QHLmn-In4!JY9Ota*b0@ucGMNu^!_DY!hpnBR*6v1U7l>^0^2nV{N+8(VtWcEGOMmYN@73GM3_=IW?HyEfuL=)`)l8-p
zfI9s95Q6J`K`ND1z_Ha%R;p^LtduKSsX|%W@`&(Y#EVJ_9LaJ4L-3!4^q=Xo8V_-N
zij$(|tiW>!0$b!$(gaUGZy+M{7$W6#5ML2YvsBnxM!?E5w!!|g5C<0vz-WdNSOSOu
z9PkI>SOh4;EZZuss{+@$e>9%0lfBM9RB@uU($S
zdCRzo(g;qE&y7=J%gKSknTgBeBP?&*5X)*gz>{s98@MnyMR@}UW+p}!X2upLM&`$-
zm!=Q~K^DDBCg(grNm`D3l(03re%fD-h^`^k)&$;UG#gN7to
zWRqiAfFVW(ae7<=>{KD7M7@F#lqGA>?-8Sv*iwxJ^(dk%3a~UW8kePnCZ{w#qo<0A
z990TSlshai=dt-oR!ayawrpi#*87k3Ij!DYZrym}+U?t&{j1I0?bhykdw->~x6I37
z0g)@a4S=$+=jS#XOmoqpX$>W=e!Fh*}UhdsQb8DdqZB80RUnDUuxrdH_Kw)89Ex!{b?jK4v1g
zCYmHCGLoe8=zt@`sQ@1d0w^O4b{>s(T;QWyb>S=AhkgXtvml*a7G@KVCxMR47KBTx
zTaEkJ=%X_jfz@7m?)mG8X{=88juQ*k>4~|Kk?G;_*{Lg&qZh}9o*cgN)X2!W;ejUx
z2Oqm~<%ug7pB%h$erVvSk%7w-Bap$V@!{FY%M+vHOH&hzlQ8ALrPX6WBovdJlIE3k
zfYJ*uQ&a*GDrV#J#~!rH5jK~Pob%C2io`QAnQu0=U8v}J@+0HvLK47Ll8P7?!&=NM
z2|-OUd)+=U>Jr5{x7(}AvrdOS90-paCjrQJQdw;iku+`e@wRe^~JDugNDj{;G4sWux
zlK;aWexENZsa!Okil|0VRJ{?=5tW^kMS_VSxdn+zoZ&0r5@IAHfFPK%)lM~<$y!ar
z-(DYvz*r07a_g7@%7-ZRCXfqJokA^F8#03B)uuj*cdFbO07(SQm4Hzd($!4O0
zEaLXFK-=UGEe1l?r=PjHXqhnCrYMJ?X?l2KXl!P3U~K&2*f8Y$(D1o|5z4SSF!1Q5
z%V)0)K5=;v$0r9toIovjbOe++j31dC8l4*l%OU`R9k;nnZl4KCk1BTHQcuz9;E3W8
z6#s)$t%4m1k^IQAt+D|iT6F3b)$~%874~KeXn42-T%rS-d~l$n<|8x`$%ZQR
zvI5Y+jsr2wMhlecG9M!wor^$#Ed=R2qXt3E@JA3+1AK-zpwn7izP-V#P=P#Lz*n>P
zFJ@cL(ZR3a0T4chf$5we6)5xpBL56Zwv)?4GlVCg#DDGU-*|^oqg$uoO^!?sOw3P=
zOpguCOq?GXxG+9?Zg}uKjP=kkIP%epmmgz0!5;@M2Zv}U_{azq)g2kRFgh|gJvlTx
zIXF22P!3NG&spZo?s=PU3Az?lM_9Dr_tHKdsu1i4F8MQkX5-NbrD)6Oe8AGkBIu?i
z7ZiH4LXOFt(dxB;$dCp&dR@_oLx?z{F;mdD==0km(uBo1?ev&K!i3GW7zjYj;qZ*x
zJ@4_j!J4|nQUI%RR*NHwuO$IT#*u(yUvMUmK&SnXK`|F*9
zUU#?C-D@uIx7K&t-Hl>>IrGJ@yqYP9@oYp+Q0Cu==nO=x5VwEP8#KdG;Yca$q7JI#
z;WLX8aOqLB09X)QNQG+aM!lY@R1LrpG|2-Uz!BdPSw4&@X;>!{LC}rh21Yqvk`Xuq
zk>E=RC=DkO&ET3?in0-f;TN)f;t(JV)EHxY8PdHT(QXf$!<34Rw%Y=89GYI)1qc$A
z(r(EJfD2IKBL_Nt#kXW6d|vHj6Pd!QyYVeJfv^eU4Vu38^{<+&GfTFGk;$R)xiN&;
za2&6&+O9mW3rqex`uLSmmihP6;}@?ycHuH`c|Xr3OM5wii?2+L@yzPL<-qs=jJV0U
z=n4QKUO}S7={)q2RBu3d(B?)2%K#;WI5JD~ikvA^lou}!IO3$5mTo=&bVL_|N+ckK
z+(LB1W?S?}#%!)>H~zPw!G*o
zz?VfD4+1Dz=HE=EQ>=DNJcmrZ_mJdl8&BWr9^Y&q9=4D6x(6HG{nh2&mF1oG+FpBg
zx3#=kMd{gmbBIrsSiQ{b%~D23UX#l^k$MgXCaG6;W`U2hNn>Maf0M
zmxyfSToe!lo&Z*EqaonJpy~-z8UnXhwD@J4SG4)rMjS9A@COt!BOZW>hgTq^C~>A=
zcLSg-`7g!na5u$#)T6rt_vgNWNQfXg!Z91q{EHXVY@3D5n`bBH#-|o0FAQD2M3D_8
zNCyitL{i!eFeMQA=u;QJaQ-3(B`@R7<*CsrT=~@45Xf?LZhCZP6pTAKF|c4?u(%d{
zVH@p}l${)utepCTm=ZoBXp)4lRU^Yqp*K4koIY`xpvyry7Lf3-6I>C&5(>?_{lgZ=
zq|19{&OByuj$1vm?$C(IK5DkjdjmE>vI#OSn|3%RZ003D&>0GAf&}!F9jC#|ax-1)
z51gq4_=W3wLhcIRL=;_YU_0BN|{>FiboZI#SfIk&FR<6zG(7
z$~Oexx};}v2*Y8=70#5Y2WD7}rYT_tAV}z>VaNzXEdZB3c#xn*AdehPmem~W$l-`1
z1Q?AZ0&dan7A-!-=8Ku!kp)L+!5&&bIL}QvzY+k2OA0j8@DMu&;vN8+Dgk7}z$F2l
zHU^zACEOGU!o6_R3Yv6!W`Ft1pD)_y5N?mnjt)=3BSgFcY$2@qA97Kj8yKccL;piA
z>VYQ)#`@XVSn5iW;bGYN!P&{7`RPfP#Q(z3Qzplp-De64c2RL6*yKiB)*oWN`N%nh
z@&;11JeKn}uOxGEoD_ArxzY)%(vsiji3;{mz#I%&!@`^^FiOdPoh%o%W!UV#vS1%F
zxh5QeF`IABCoF~Kd2eva?wYdO7yNFgDEO6FIIe&!)0H?tS!$%}-F&@U=2GntU-lpC
zb6Wf8M(60La}3+P)7x8H-e2wRb$ffQ-a)Io+dzm@X(zK4#QTDpjDRD3f)xhJ?w&Q-
zCg#i|v*yt$^U$nya&m5XVqsw3G=lT6>1O8wjEq0z4oBhb1hqsootKL>qgqP=
zM=wFHJU&QCeknov2`HZ;W*r1y4$Mr9FHX?dkbPlfYQXH8^Rk4$3KiOQGXLR0poHND
zE+If9IE-e!^Rz52U4%8)aq{M~w*pec7mLg~oi0fow>nIL;H2F-?IBPOEZPT`960h!
zsyv6_sFiZ31FTaHFC0y0H0qXPFycU@Ud-zGc&28Q5Qeil#npDP(kkTJ`2tJg-+!#n
zY3<{q?$xURW#@2vWuJ0U_YPJ8%C+6*$~MK_zy6PZOPAn^LoUxo8Y;L;OXvIl0|F%zx4E^4{Fy$pX=x2~*mo;oSPN{}9OgSmwi_NNt_i84Dd=7B`9YAt-<&5rFmDC^
zcrNNIOZG9V7d$#)wU61{l#R{m8L_yhT)|miaK`H!cQ_E9!<0KB0gz=Zp=$X=s+y{{
zGmYg!Yo$a+yi=@oOO?(;vZE|ty}o?B*Sos6a=f#AwA$P6kt?~^T-$H0>^3^MhE%dRMPQ8DU+>dD(xJV1YIt`h}SwLSnx{cA=xWAC}F$dP<9Sh)(%%U50_UD
z+UpFIU`kw*%8Bt*REh_}lH1{3Sh7z}%|10Y^~itTyZ5E<{^*_efAQ1*yz{d=cYl8G
z-r0e3Lt~GQO`o5fAGCWH-9CFrpi<+K8U`p!WxWosw~->}lHrn=vItOWsT?hy;*a#1
z4WtM(04@L@LJ;&hU#f_23N*EYGx!R)0fqn?j;dHX;)}~4-n$1B0+c_y_wmo}-GO{~
z@8gf|{Rv2Q3pPh+-W^$r=!D2vG8B$e&2_+IllauUIij7>g1GW+&-KYsgz|M>Fz
zzy8wu|M9gS{_&k3{OKRh58n`fsiF6
zm?&R=oKg<)XZp+rEOJmLvYL_ADBK2FmW@Q-0A3?;F;U2R#fT#swS>Y`PDD~fmcwT6
zr8(>HqI1IH{MNVMeDB>az5A`#{`uWkzw`c=zWuE?XPn+iXAsUM;nLw-3WRMjDWJkx
z(;|kd>h5d9j$>Wdnft&*LKN#;~H3A
zm??=e{CYfrC5vNfcIooi0+geZ=a=jVfEN5A
zdnD!&m4IeMz=gF&y3xwsFC_s)LUP4;mW;_mQub41lZQ7+umEV-pbvo$Zl454GaX^R
zCVk6k641d>&Z-~X1^({+^kYid|HD7s{lOpZ{P4GTva5SP{v*(N_oF|3>=Dd<(Hc-a
zA(r?GKLxl4G8NMJs`3W)TXSzBGOX
zwi`kB*#R2sIX5&xGD6wTpB$U;s;L@AFTVHhZ-4I(M=yT;33kE#
z{L}C+&y9}b`b(1&=f|!L&yFuxr@@p~ugUFO@&*^+Rtln3R2+zP_%nTG(-B{15E%fG
zdLl>Z&;dtCJR8SXG{LPz?ctz3BANWctTzIq4Bv5t@}k=>FWMqp@@%3-K{MHwr
zSy?SUcYE*MZ@u;GOHbnhc$VXK|BM@PdSEFSv_v9qMUKRkn4xMpJyl7T+XWVSSIVq{
zM5R+HJuF{;@A|dw;XdV`-d|fiURghabT{{#n|rmb{rbu#neTjANx({yGwp*1g*aw*
zacF$@k}d51$sh0j=s*AT(VyT`-u>{--QlUTBa>IiyjW*Fep^WJ#N?o;`VwiWSdQ0Q
z$z~^AZKi6BDQN)!g*(ir%o(ZdgEpDaiVEP54T(eCk`o~?Km(L8P||oLA1w!ZfTuv*
z>ycezvGNm+$UokRH#gt^)gQ!C^Mil?_*=jD&ma8e&W9i0{pjPn(PYRIHTxuIG!b+}
zt+<0Gr`}-~P?Z@BHA^ul>u*U;Eh?-}|?(eE0V+
zy!`_XN{&dLxc}Vf1jrJg9Gag1DA~N_jLA8VKnK4R?*l+7sm=$RZy*nhNX1RkS~70{
zl&NA80#M2cIjo5x73>jpM3q@5zSt;Kx|KrfA%RZs+SOGmZnCp_
zwAnlCE$_Bh_F9_@~B&uG2*aETyE~l4<#-=XHsU)oS&+dE-
zP)^NGjm=zIu;5Le_66)L(G3Dq+7Xt{spV<{h-|b|wN|C#iDv
zgNjHftj0I!5Xb|QDFp>_PXI0^qb}f;9|0qmXb0QjV=x~0)-QhXGxoOp==XOcxyJkd
z{wJ?qc{7>DoZU5x^Z>8z%_j{xoc!q;VzS6|VtK
z`t_4cSCOa#f9s*6lgQ1?exHa(3_x`wX
z(M{lyQy`_--Ey)m1QgA!LxIK8uO56IFjt6@!z
zrc|wv1XBW(RjU3}hE%)dVyp1bjOZ&@50|g)FCT5JU8M>V>-(McgU-f5bN7gFxw4sW
zE(1Vnz9e$8lyzTJcDsGnC04#B;J1IO?%ev$&+mNjuXkU0_ov_d$*;cq>pMUG>A0HVx$7-5fnj9OPogSPWom!a0uduroJONWUY6eZ>7?o@f^C{s$!fMls
zT|TUxsU&esl@fZ|2x`*pS6*@oG$pm@4Z=~Ka}iA<^uDs-8eZ~@I|ASN?z`W4?~N~g
z`MGcW^K0Mv;O+1I=skN_1Slae-xCi1nB6_)bk2FbOF@_(A#6x;HV#mhS}@<0=4!3A
zR)-NUwTllex6?a504RIMTgwM4-Th^Na&5oOnG(2M+b(w3GGBS;^{lpVb6b$^>Ky>H-SU#}T{*2y!5jDQ89;0jK+|{g&6j~lFeS6#
zcW=M*?NGY(?O*)y&G)|l!{6Nfmp|P7;8%B@F*oH6l>H%<<(XzcCs2|@=>d0AaS2v8
z*P}Qn!>{4{v-wtZpA6p}
zdv&+Ac}TXKEci}&btC_u|M}}`UC**wJG4ba^7um*fX@}Mnw|4Yo`nV1+`MJV>RzPe
z$RS%G>JCdjL7`lYdNKmXu~>-%kvJ&WFe;PQqYyvmNtZ?k#8{w`n0fv*HP5Jk}4uW8b!NlJ~*B5nvpIjr0cu$Zq>
zHIqc{LD6?mC#dmhM!*qf6rD(#<_3K#Xfg^%5J&<|0+%38F&W&rzPA*x|L`}zrD34E
zcM*Mmbmz|ZfBo^b*S{u~8sGWV@4x?>kF8OvKpIpj8z3JE0v5vt-4+5+;;WGA@gw?1
zxRVTeV-Ec4KS$qGVn^`-7Ty3nJowsFm2BQJJ#PV1UKyIDWj^PI1}=?HoF5&fDeu8i
zRsd@F(My;A_Uzfee)J3f?VtV;^4}kM8G8%uT&ulQ+u;7V2)z^W5BMS{mtCA_F@e$|6gcM8a
zu4vRJ%ZvViO;Cr;E>4-C$$>=|a7kiuLk8GMRu#(2qHkDm&#W&n=MP#V!2p3$6SHxn
zl*%^y74j&v%5ss)M|3JU_8;qW+RC+kHf+A$JM8q1x@-H*jicK7er;pBvb{$sDtY$Q
zmtVPAsgh?Irz|TWHaz6ziMRbByDvz4m%~x`k!}J1BiRFv1R`OhL6fyc790s&^0lN0
zaUkg;?U(~)Ci9da1Z0^hJt+DH5Xq9J0u=GUxn#>M5cE(d8*$2%KavH@G!ld>(V^6m
zg3T&;5sI;q^Ls!07|^`?(?8w)$sg|_^vNu5+67Ypp}NX4Nh>bggi$XQaOO7&#{IC`
z5de_|-JnT+8GkDHlyK|)fCXY5h}%0aNPajmaIWE2PAyCfOb%a~pkg^svEtx>;}Ziz
zk6#)5r;C^V{;3Op^TZQ>{rKbm#}^*^o5#=o_1SZeTpD=f((n_*BaaOZ0ghDtX>@FG
zW@>PDVrXu9a*@U<7p-$9$BfIr6hN>mTG@<_ll?^Jg6x?S)6ryO(AK~AD#1r;Vkk{hSz-pE?I}%O%UXyGdSak%=rWhun?oV
zqJCWhA|ZMynXYF_opQZfZLT!xs|{ZI31|Lim~#F4{tC;Ux_SVIvH_-q`R;8MDf#&x
zB~V3Yoefw5mzhjBl@g2u)qRqIKX_vx56LZvlxi7plvGMhuhWjxXtt=9YKi;hM8S^L
zW}2!-FvFdz7%5iwDOXA1_~1Z?3^)8pmW7`J@T?GGOC+V7;5U43)fGunl^xEMI1k)_
zTy2p#kFd1pbw2;qul@|6ym$A*yEMoTgC5N%?cqsVXvrS21T~rj;sQ|O2t)#xtgaN?
zR(zxtMs5jlJ&l9nTmDpM6fFRO_2l))d_k(LQ*T!Q%0=t^#O&Dk;?%`)T9EN1TPO+7
z5}D!KVH1@=)fotd3I#<@u6YFH&0DWJ~c9UWqN#getO0{
zyI`3!(JG-?mk$AniN)P;C~f#RNXkRTDdR<|#dIH(u;6^3VWE)$W$M6XDqdag`W4A5
zi9SiA#k^K0$P&&a^BQ5VouE&^6diyPhMUnO)w`YZMdtk>TO>lODpPtao6w4hR6Pyz
zU2T_nEm26ZQz~`Kkp5$RPFuZx0H*97t^$!O`|XXx*2W>3?{!vLhco5wUITp?aa<2v
z=JIkX%`&GMVVEybp>!jNX&^A`su7MSX)hQM2}Y#a5%pBLN|W8Z$_@}oBj;5kUDN=_
z96TI`$aK-*kMx<1TWzw-Z0!X)aO`NXCPg#Rz@Y)0t4*^wfSMy}1r~uzARC?~r^cYpikl>;8ZHD^
z;sX9uXXw>b{S<@CcE0S~>tDhb3sxGfgn%!{sO0S+aCvcp$dcy4uM9nY>B=J)F8$qk
zDn|CVPoC$M$R0uTJun1<1WjI^nz%4N!uIRTPMYS%5#=mQEIAg|FC^ai=GUW%gd-Y-Yv|Q9ON2^1
z&-tSF0~!d7^-@RzJEAj*mm?Ilf+JPkqo{$nDi^Y1Mpp~?E!je|RO(b3y($$WTWP>*
z*SfXZat(ahf2_}G2y|AiZm%4ytR1ZM_5jE3`axr5x56ut?SLuwD%(3$k8ESB*zTl0
z{P0KBnwBrbGC7fz%A?%g_p=EYNg$$yz2`CTe8Cjh=>P
zc=5c(LqG`u5dssy93K^e0Ged4$rlW`C68C}MUsSF1SN0>gR0x?o3lmco#APF5V)MQ
zcqi?FnI+el**{|oE%;dtGGGyCCUS)b$rA1Zi$0CAoeKs$ON2OHUXlzQdDI*>=N
z4A26$krB}3mFY?R$l&bc<>}FpxzSnM{2Z%nV)a0yu9^i98B=Bp^*lb}ns|;}sDO?DRkuZ>3qHRsB-&!KB`Pii!;4`7
ztjW;nAGLaBJYk!tI%M4@iXL4HCG|*3mGXvBO{5y>0;1a0GNj&vLrH#QeYsX?S4vbT
znT0EmKdK0VEf(<9vR$R4U$%lHzYjKuw3(e9TVmf)g2Fl+Hn
zEjmXX!C8paH)RXWdqgXu95>5t-lte2;AKn+*nxv_2b_r*KHMi92g=>QQIyxVwQsXOC*?Y!O+OcXsPA+?(4aKy!7i0M8Of*m2+ztXZq;wYpIQ
z-~hX_QLm@#jZ}jL+U;&0$7(Z?FOe$=bm9m^k~eu$9xq+eN>xhvLRnwh$!h08Ov&L0
zpit=an38!Qv8@Y{5B4WYH-s
z`9y~++8+kO#UM-E4N&IU`N5!oBhU%q_{K>b@h$M`l5G5``ZXKXc#t_UZjte2Ftp$c
zEdAn_KQ}pN=Pk37b7Ko8bmqnvrZ0{R4or-l9~!(oK6ZX|gzwII{K^0V^T%l)*_DeE
zqfbqaU!Iw|G&wYBo|#&jIWIMexNuF%Zon*}(3I0Kt&6jEv~`RZG5gcEuwt_Vh4NGE|gub~E0ai^@#
z`2!0^=2Wx3XWtj}qyS9g0y>uanA8JKc?zp=Jk11Nz=DnoW+xHq;+z118q*a%SGuZ`Di
zr8?bQs|}21I$fN}x7rkI1Ca=~OEsfdNdS=`OCXY5Nj40GW40X6l@q{Xy{WZvpLU|w
zeh4UGtbs@fI&k=4#A&%uhL!~ZPmxU67e|-^5~Wy#ha)uB6SF&GHY$u4H9KPtbI|0B
z*u0|49x{2!+>?WdBXu;YqeB*4>lbgNJ1|cGaKsr7N|<$!C4VXcC9SR30<5@GFe*9W
zT!y1mH4K4Bd%4W2HO@`V!^NCiu*^>_PF)@u8k(6t+b>=_etwi{Ho{V$8y>toHI9=b
zvr_|8W8+IR6Q)_PBUlzz+vZtx`pur8B|rrmtpck|&zFP1g`i=n2b%9}tC#``>pAdc
zqSCL{NCa8S<(kEEuUhO`lrnHz+_0H1Ef>nY(*1&soGIZ`cGlbVwN`7hi(~(>KBrN&#^cSkt0zo(P>1d2
zRYd#M$9AZSC~WugY7XX`BN9g-5~du`qa=G`r19_PL4K$ptH|9-3X89-f;RU7STseQ63V<^X_r
zVSH#{cKpip=+Nxsta*0MGBD2l9hFpAj2MZ0WiFEfqIv8~M{
z{Fy$p<=UlOqkymjN1zbsOgHk$S{9vRvk0c-WLa#NAca;bThGJARI<91jmOd&M9w6X
zToRG>eUb91RK1XHW^nUjw^CWIR9C8v^?G}=-P&ld!~uX{y|dMAZ+3VUv-)bYyj(9X
zKg4`*-aOnq-Z&|V*VsI2uIyDdcKe{@ObKZAR;d_XZ?(L-ngteDR)IgF#@lY!IkV+c4EtWDT7kMpvpQWt+SlzEGL#%9+b>OU{$}P
z>3$(m5F`)=APQ{dZzR<(k_QxesAL_26)&qLO2x&TqRp##?NOT}W=E{;h&nwo4gKH_
zJ~l!LIN}J2CW738pNJ=nuV{&eKb-KpCGsp0*9Y!L-+%=dB_7m`kgWMM!!K(t;F9JZ
zLl%F)?C_dw9-wo6W^roCwlHU!nVg%NTAZC&nwngiMoi5|e8%Q+a%Rpn2R4Pto?MtT
zyUYNk%Wro3%%P|Q4lBc=Ga}k!cvjgR5ebWYxER8p=`$OQCZyOdLjcV}w*n*qk(p+p
z&?q4C_+6-01cn>vP)1js12(
zlgxH!fy+O$Bdm6Ry#*`PSWOg4I@pn-?`F1G%K?$R#1jW)x(LclrV2W!lm$<@2bU0~
z%sy-v4#3Aji4Gwt?v1e+h&)1|6V4?s2FivTAvg)l;fyJ4_Ub;T>;f(!1lE`hoa$Am
z*fJ3+V@e8WG%vy(FrrU!5>qlDLU^6VpyBl>CxH%#io2Cuw1j}88uuwW5HK
z-hkQaTQGY}Ci|k-&+_rP399I2=+@9<~(%m%J%t`j~0O@Ol8trnN7u<5`bxU;xY13Pla
z;wxN0z-as@Re>v_P@sO6K5Vy0Edbt{CqwFavnN|i&q+shD;Woxt5
zWHlav#p+sL+B>Tc1?B4Xt^1%{hg-Q{gKX?FL^7rXF5y$IuIJXb$}8(+#8=i!?PaRd
z$cu;an5Naq(*oXBy3xUrhJiqnpiKCYh`aNZegQltMuu`ACX#u|@|CR^%}yF92Q>T7
z^jVGarLb8Xvezdy>A7&Eg5*T@k*&`Su;QUKslx#W`t&M3hv=pXd6LI2P)&LW=Sa8c
zz-6%DKq?>zH8e)*;I~J(yA0PynUWtCeYrr2!NcdQ{66
z!U^@hAWXhr(H2Ku)V8!*Ew49AYt_m|y|E5^U1ddWTfCwzj5Urp!$^^e+V;zmZuNLY
z+t&69r2kl-(|X4nYlmwHakh?^Hx4^MBx6ce&UUv#(f1YyWu8@NEHYdcI2`+(Pk@qF
zv;{!|k$@vdCqP-Ko>W?9prpLo#FSKuC0ou^>luKu(R@G;;__VITDO0Xa&Jal5I
za2N)cE%FWML0i-b`~gXT7tVO8zGBc6vN|OAk%UWp#m*CDqJtmAecZ&3E`lA4lNiK(
zZV)PmujX=t`!p|1Jb$V)qC(kxz>XZ35Ek?V;9u&A0QeFDj0%*fl6izdtHZ}@g3p^>
zi&poN1xGLZ&IPO2Wbv9DJ}PtT^wJJmsz4uu8-VzloJiH6%8jy4p%oz5cPK?yFhT+&
z&Y$Ts+l|}T_pa@3A8qyamRI)IyE`igILNlHwP08QQ&3uMl?v8YRvYM4R~pq7oTSpW
z_()&%8u*He)~q#wW*l)buU6aMS>|bMzAAzybqv42<`scU9PtsX
z1|&HpB1M<%wZ~k5BNbkjy;i}&i!_2t{W_uGF{==VZY^@i-gqAx^=&;egTWTkDX^D@iJJ1gDo9)w3Bz+Zc-TVHQcweC%rU4XTLZ-HGdH8=pD
zD6@RO!?4(6g_Qd>mhXeIvkNS;K2>0*GRs{0kM%ii{o3~C@%rY~-qtbUa(TPFzF(oT
zp=80~Py&}VjzuP5$|5)1u({~8yA*2!luZOT?JN-4?B=UY3ba9)1&}2xYD=lFYgA*I
z60!E&=2Z9bR0RK@S0&mhlL;wmw
z^}cQW=$Ai-5yy`Q;~|&m_G$sDB`U&j`#qWu{D+^ykKlUXjOG?KJ
zH4=5O1s1NbK$%#0K*KZH0g-HRHSR#8^zbI}TljB`z;GkVk$i#(%6yPdd2svot=FD^
z`t=u{d*g+tUw!WIx#Rt34!5uGtRHQGIG1-Tp#2sXVhI0J+Md4Lzs
zgU?X7(mPlOFMbl5TzDTxe7kzIiGCgC8@79Qt+@kvNbT>f>pL6QRyVG#0F>KTyRhBc
z2Mt!pwz0ie-`pv0?^VE&yzqB#y|l7X?({O9UK*eTS$2CxLL{P`ZXPJa5k4hA3G^|(qT}cP`V0Q!zxnNN$g|XZ=7{wNKl;JZ(?`U4fQRA#=kI*8wo<_boGb~N
zY;7;_N;8Uaf~+%Ybu&j3-#SI>pQjo7_)tQk9J-H76=68+I9StQW$CH>H_R?8=dHRK
z?ZG3Y8uJ`~+&WXA^7T8=!5Nn9k7vK2wf?v**bzrAQ6(TK!Kf4nN4>1NvNsTZkoms;
z`d1E~f9c?b+c#c$<<@JjzVOA@pMCB2t(TuZdiIdGlgcLVZ60s+c2{|^@B4+n?;ksx
z-7dg-u+}~7SN(2ociX$`{Tko<>%8hWq`lWa+4&!
zwbh-Y<(*@g@9GvS{JpbZg8-BenD0I)*T9q|21+vDonD?m*)RE>gF|^Al!bb-aZ+HJ
z3I?!Zeh?rM)R--ki^(NdOJ^!cp2V>KOrO=l$$(pNhFEE3o;U@dp%J1?H~@Q1^_E$f
z%yu*SHLpjdoP9t4<)*P?{
zQvEcL&W4IqMDdhwh$3+|{Rm+LO!v(d+o*BufO#4E6-kk@#gV!R}Y>(I(X)o*Y(~!-iDQ5
zKiuSkj~ho@0O-cm?Tu?YD~D8m9{6j6Xb-n~hX5SBz|FPeEt({}y1RaTpC5T=<#-33
z-KUQap1Z#H%+>y5eNF=?fym9PY!lwU9urwll5Y*#oaAqh6i0Tja+g8gF0n~KgGpK5kHF#
z;OJoGyuqnB;v|9|J}`uDd7O@m@w;&3Peq^vL}FT)m7?z(@qWak3$iA_xr6|heRQ(Q
zYE+7zVGhWHUFN2l_xWCC9C-)V(3}nNF0n6e9*Ec|=VH_q5W4{hP`nRYQ{r1hn?US1Hki8p6_e;_9I`ojk+c$U}
z`lIJ>;@E$z&uQB?_cpJu?HsLaA9c14+na}tt)u47VI4HdV;z8UeT(>VWwQwL4S_4!
z<+V$CREnO1lH;=7E3y?BMg>7nCkI4AK$GQWAA)=}208#G;v2x!$g1ULp5?=SP|{&o
zZ2-~7>d*t1IG$K)zmNtyqL08_K!8l^&44O4DugHpkqr-b@DU*nf*$ykZiwXdNW_%n
zI7)002E!tQBTf9+h5jTE{74+}5ntg9F2j*O)tRVFfiNLb3j;Ct$&&bzKp6oRPsozI
zOhP2p-3h62LYSVUCDXtkKjI@$2xE;t0E!Mi!fJDZgs>E#a5p^>(F-`jd~@5)Vx9hK
z_|I&)m7{~_-+1GlZ$9^xuO7etPI>#rO|a&xuU&oZ4FL4!8?W6WbiV%L7hie#%dfup
z#h2;$#*2_!FF$kR#akSy*Pg!tutES(^dZMD+&H{_4LCczeVun8SD(9i?e;Ao4=B9$
z(ld}7uRQn68!tj`zIyxFH(!GEAM114_KjWml)J~P0Oj^!XXBs_Q0^WzI4HrC+}A9v(%gz0yQ4qL=b
zTnqYSla@dv#2PjMojlM1K>1VsrQY{n+W&IxFQEKO`%C*v`%8Oxql(|Wm<~UtShj3h
z^_-U>ylz!Li#C;$ZdR3?U>
z%$DU`RZZk$nUb6>N`;Dw3-If5l|(YH#IsVeASUu+vVe|~Eyoi%C7Dq<-2}v;$7ozc~5Rb}fC2EL}SV9WxVmPh{2`!e2N78yIq5E_klR_%3
zSITlBD0c*0%QI)fIp8K{fFo-0)ypQsNc!A-r|~_0uYUW_Cfp
zrT}GdXUVcDbpZZwUQeG1?`H}Mj`Xj|$>}0(3!{YEd8#4Jrn~zUGIEvp{f}&-QNQ1Z
zlga0OAbfC>ANd*n@qds8Rkteg;?pNZt@6!OwwdI@PjbmqaX_k!#U)#f=j)W1yU5EH
zuzcK1cpajL6nlAaVwh1-GGbb?&CV|Nb`IoX!xv9E
zL*Zv$dNJSXb`Nj$j;{6g_7AQdZR~Dzw^qw5&C+_CCar001zWL5S#n95opQaMueCCj
zMzY?fD#MMgQST(m4XxTXn!IXZORv{h)I$FWqFN)@qOl_0#bD;1e3#&S&3xkx4-
zOJ%8YeuALauRaVhk`Wp~hzD7bR3X6%8uC$wIIEM*M;Q>B@fZ!q`@vdYLI3|ZwL~@E
zlMOvl*NmD9!AGqur>c6qNXJBtYT7W7jGCCJOL~=RY#aYS_Wtw9k>pJG1u5q2p0#7=
z?Aq>su=`=ZuGxOLwrh6oy>o`6NVce|?oz3>MrJ~*2mpZ)2mk@CRU);ll%=|=CA*vK
zZfe<*!<0X$4SZy6b=<
zQ!Z}^esKJctvm!{PtcEm@j=JNrKl84MG(UoH8vg-^rKx?AR=1)>>6w*0
zl{*78omDe5;UTSS1r%ChF<*c(mnS%~QaQ!S%b8*X0{b9vkl~mqL|Iw<2jn7&w44Sy
zGa;lXkm6p818R#Cw&%As^gPvn$TNlRo^GpzxaYCNJQRXwE}
zX#<&9&J1-{xer7VawI8-laWv|8cC@^lqVI%GNP$?*s}0Bg9%eg#8Ty=S;*`8oSaNZ
zRw|S(1QIz!vFqDcI(O*(Z@kbhAZUnX((WfFQ8GnuzO&1?q*e5d`&o(ferPf-!AhQr
z1;pfatXRMzi{aSag_wrOFg+QI-Ddaq>~dx7@)D|@wWpUrz0=i%PGNdKD3PK9!IaiY
zCvJ*G1v^Xk^K;NbbRAUa+@lBDI#B$R?V}(4=*K_)@xI~7|Ng)JRbStLZO%45V_Us)
zHCA2qnPqQCy7}ad*4FOY)my8_PplqZ-@SHa=jwiId$qFO0wt^Kt=ejf21cB+veB83
zGzUaB+O+I-Z3&rlwH2=|naviB??+l|n6+jMtc1!Hqg2+)6}?>1z{+A-fx4?;=U^Rj
z_-kiH=+8c{B-0`Aky(ih(s&YB1VHI2E#jk~BxS^7ge)c|3#{aBh0YCn{~IHc!GsKU
zK~Kt*!8;>SHev!>;2H|G0-%O!dJ?IiAq$ujB}B|*C7P&2sRV2VM#0dk3RW8UI*SG4
zQO;MxYjuf<7ZnRI5_Zipy`mzPyNi`Hy%43P$MTU-Mgkw1l1PD0y{v|EA%IfKNRR+!
zB$AJ)B}2|AQaa4bBa2KpS_BhuD8_5d1Ex|MNL4~voDyY90+&cbc>}vhJ*jssWI?_%
zCVsWxD_P7({BM2x+pmM0{KO{&ViFt+I#OEroXjI=XaI=96~g#LIFB@wr)6=;u8AK~
zS_e3XX_A9uo9^jk7D=DZ@-B&E>_e3;+MZ*iUsvqT%RU76s!~$
zQcdS#sjLCfigFV;X8UG4WHvd~DMimc+Fh$%_B=Q`_Frk;j6_vnGP4jSLRef-b<
z)BofD`9D4Kc;8b`Ju^Q~PnPYS+=$mUq-52ng|FYfwY+m>>&DZ|Cr_*%9PVB}SwGmS
zZLdL<&6Vora(%Pe*lab{>h+aceYHX}My+J4?G)5p%Yl*tl!+SrW1G}mNirPCQ8r^R
zk4S3`qgshVwW?aHYJg_fQ38}mIiJlTjKN>~DK7ChjIUcNjBgWCP?EWc6zCKfr6r1m
z&BPZ_=ECmx^nPx3ZqWPRk}z)hFxUigbyj%KM^lLTDrBkP1pnb5f5G0VQ<>X*Lq%G1x>1TNot>oxpubz*Sg
zE@3C}Uu)9C@^U;C5{{B63F?7m;93?QFb8KUfs6u_;Z!!1NYPTc0A+`j_=`yd5^;Yr
z5j2xjXeN>I8%Zy(!5mM?;G+qQWNiL9I~gkU_aVmMI#1-w
z5mpi*Bdvm!YDzP*23Q$NDnTY@9PxNmGL=wVk?Gsz?H~OxmeSw)_M3*K0gI@H&|8SAu@bn?Ia=3&Qd+B*mg_yG
zBneCe83~TUQF39n0y2Vqw8AvRpk(~flKNdU2yE5k03}jB3Naiz;dVW7s*d06QnGV}
z4jEI-++qukk_!PxizVBTrmTG9jW_ue#Jxw*aTzvJ&
z+;sIpSZP%a1mM6HIXk>1fwnil`+BS(P*8y-)c*B1{|Xz33IHWYrxijd2Nq-a>Ipcq
zy2K<2Rx%|S!HEi;i!10wVjlxB4gsT;SfZ%GUD7&u`7k4rUlD~6JSKTh;Wxu+TKkv=
zw`D{0_~R)qIRNJc{sYK1@-G`n~^101@!Y0)Hg_c?1vz?0j*{
z4U|<@gZp3kA
z8VWCrCt{EQxCsXuvwX>{l*j<4WHtfNWG)oTgmp{SlClyH!feJeO4JHzStXKy$BYDH
za)^i-mgAA25t3qINKR^D*vzCR#q~f;M^qk3S!N*)Vs`G(``_Xj1lo}<0ohA}l}1v1
z>)UUb=_rJ1u~amcQc#(NLa`g=UAB|=IZASosiM|dPFl=r1?4ITvE%7tj7Fc=;!Hh=
zog=`<(KJes!S1yu_mFZO#wF*WE&-7u;%1Y0UwjQ3BIqV{tRjiZ^L13{itF58(t#;1
zf(!C3da$j-NO;MQ|Jg@B`mulf$6x*VCq8MLch1<{<>uz=-}!-7Y)NYD*%v+c
zT1}I?Y$sdGN$|1RPBew1Y_t%Jn~j>$sOj~p27`&9n_DUYPzu0Hk*>Q0E0IE(YzTP>
z8K5(hjieC95DH;05X^N_h%w5D?5b-v>D!tLcX8RdLGOPv$^Ds$GBp<_%38dn!AP1S
z?#5B#SApVC#N+W2p%7s*OeFxP=V(pOcv;hPvQY?|#R#}b;?P^f+MQh(Qi`utycS*}
zSs_OW=|zHLr#`t+9pEO9SyE{+MgdK{4ZH_bMj8S=%CrEXcs!iDM_9iln6Up3}8#d7}mCxg7+V`04)y
z&?%h1_-&z*)6hT|Ll{OJB6Bg{az3=*a`*
z08MyLfD&me5s1UFrr|^3Jz^CBkN&P>9m}d@4-kW=jd(W3OGlEgOlw`mQmUR*zW9|daDNWcMAk^A
zbtsX7qa?vyA{gfuOtI|Wy{5_gog>5%HzdqpN8LlG0X4Zx>~fxkL*1iL7ncx~H#(*g
z$~2Qux{=7@;`bpBLMGS1QH$#cgGm_8)~rk|ooi%aB;hXEVA6U9&Fp`;zU9Bafs!Bl
z*q?pmZWH)2Bk#iVZ~{hd(PD~E#*wt;%da*QHn&<(^C0=5iZy0ff4`TR|k
z5GV_dEm7f|+5VPYhMNO3tp%4a>E?&}N2P$c)Qq5d;i*<3YsT
z;9xKn@+T#=q|1OZUamlaIb0`rsuXlUll`XuJ?)h+@Va;if^bP~BJ@AO{~7oF$8-cl
zB7%m6Od^y9B`rj&KK6{UxC;U$b;G6UPOvhnJ0tV}kHZ(BdEJnaA`YK4@0S;ldTF-r
zIhSw7<)3$WVGgE|y8H`v&m2lz(xM|U54nO1KH1?8EaH$axEPQea)h4FjT#=!^dVH&
zOfN!pxKUV6h9;#ce=-Y1%34YSG?j!O86A~jGp&eZNU|9QE@d+mj7xq)_UV#877D~7
zz@?l}!ODQ~@2&gs?{8`%YNSNRH=9c8%z@L4CbHmWr;XCElw{6;;I&-v6yJU$RC5sW+#Uf}(#!xg+BGbhvS6~8i$~ZMoDl
z=vZ{m&bp3oy&SOWQoLAMTdpj%c5b}5e&dDJt5Ko!g!?hYHxwKwwt(O|Bxzr?vk&4cVd6|7z!8u#VJ*uV;$;Y#SdpS&ws_?7P_3Zg5cs8+2w@@1j}izqsa)hy
zjXP>$CFDskkMN#+Wet2RM)Z6LX|jeFQnjpvJYEPd0SgH}a)gcy3!ubnA;YYcQh`uL
zg0zwfAbL#?J=&9&z(i&xqZ63`0?I7hB?`k)IMYl>LOh-h%2_#_4}0R?NL~$C1kFf3
z3JIS2Ls_5`xQyaZ=QfG$BMeGrCB(iGd^D5vdj$*`2|prb1j3>R#t(s&kP-LjrW?^T
zQd+9Xa7I)I;24THq!6wA=nK*mgGfDrImqRmUT{xN+6Ix@z0>px407~k{
z=>o9;qbHPusqCsoE0+Ua*=n4XF2|r$$;ed9BGpfje`H@t4U{mI2;p%xMDFBCK~je4
zpNg@_65%=bfb-ZO!XjRdkHSt0M@ci~!E8dEd-Oot!)MO_&wu^N;n8Wk-5a&4jh)+)
zS&5kOy{r4HCr@qNdSUJAt?e66Y+gNS?Okc@?SYj%rG(H5O&PV_XlzwlYbB_?flP5}
zqflSTv^OaOwbt`X>$#QnT(fPpS2N3NX`0%PcEe}`msP!4
zGoX4!Yt*!6U58KzRZG!&1q?N+6}?Obu&%)-9TPBx_w*-xD1q5zn1YhNq)*C7u#?_|7uGVA4M}jI
zMJ13Tj3SlNQaDe2=$+dnHew}@JOD1^U3*UsUo|ZmpcH*CaB7lhH*_-}0ZOEdNS>*h
zR&5H~Xo{>LT;!b7KWF#OEPBAlsYTcLykl&^ISx32iA=_cxq<%C^T^CO#*m+yADXd`
zO)ZR#+eW7C6H|-hqq9Tc=Dd4$YJLp3v^l52&^gyMaJk^0pYzSx{I>bPyhn0?r2dFI
zr1~PNPm2Ykx<49oYH_!~r9Wl?oqi+bQxi}itRt1xq$Juj<$xBXNL-iXm@FB=pdRo=
zy|9^5;$2-}?`wmpWLzR8gLxk%|1A+E8JFNAyGUkbwrt*SDuv==Zj5_@wip{^LHTMr
zQ%OSUGIg+|%7#_aA;6K9sdQKgB}(x`Il;23NltSWYW)hzGJgaRQ{qv_P
zG;#>H#ZaLXMdH=CXwb|+`Fb{oV7!?xv}nrr2i`7T9+QKy$$8(w?Js%s0s@WaUwkr@
zNUvT0?ArC)2iI@xoLpPp-*4>hHg>lVcQ@!+ewyh-XtlM~YHrn=TNO|eT3RoIm7pZF
zyj5zh<(9Y0$TwHBU?t-cpyXcfdW#TA{oQpPDpjJDnpQ@jEyf8|sz$A>vKmzo(`-~@
zBJJQ3gD^-j_xkJosA(|@~xq=P>n(Qb=B-b%6NZCtLiGU-662c!3)VV?L
zf1_|1bb}cL>B_K*FoT+!qnMgO3BVx(oWc5mTwoUU%oHg4)(D82kplz?i!h8RA<|_-
zC_#{pU7(PK>vXVKQljD_U>sPfW`dmxg(#RCP0Kp2Q;2X3jtsvjB#WhHQ9_6meiJ1~
zIbaW^C10G@k!OzyP=b$YG0NNoBEe8@&;%kwxezGH2GbMwxMD68`Ypd&R#C_uM3i|C
zD~;19X{o*P^p^^$iP${m)naa75iT;33cyju5;Q#<_!!j|BPy*(8w}a}@|-s~>kZ7g
z;rRUUfaDqN?n#?{bar9b<`|z|7@L|OMLIbTERIahkB-j{kIoE^Ob;M4JT-Ko|NPM8
z;P~8F|5)G1^e{3YCRjPKFgiXrio)r|sTuq9gpDR-MT*^7$IOCf-sYN{bHb(0*?l&L
zZ`K{O1tN|xEl=Z&8ua9*YI;CSGZg?aiTf6Q7`)M#4|P?o!8m*+pa~H)Gck}6kvPO5b}|>U@&;}=`^v7JM4BpUgu)6TGS`_T
zm3q2GHx4bumMj=7t6*A%crqWuOF(R9O-M8X#4_5cXhDCmL{ZGl>QFpqSVa?;VhPC7
z!fu%g4=E?N$o5d6@Sd;C3FTWfK)ujFh)pSn*h2IGI>b++vk;i)L}1>zM-Q|~ekH7C
zc5Z!seBSxOi!XS>diCJx_3O{99$&w5`!?)k^U7Z1%9YygZhd!aX>W5$%)Zm!U2E?w
zx3?Ngo3)jlW_!D_yj5A+D781sE8CS7!N=8|%F1RALHF_orJauNcCy;g%XOnzF^c6_
zzNBXIkyJJWv~l-zIvY-&=M8h$E^59E
z0*)MUBLisiJeELYI65y!<`80k@ry5g{!5=*^iR#x)NGSe^TXq_18|O@$LsDEm(Z*s6_yuW9Bpm%(rZ-mr8HiY!?-V43M{linEy`z1@
zQ^RAkV*?WdfGOxXI599V-Vb7q%>tlf(~FZM(?iqt$yx90w0nBeF=?YvomM=Yb4&%p
zi(sW7raPiL;4zIP-oHPV6us(+fI_p$(ELUqCKNRTAw3W>BuPaYg4qn2kOQ&J{z-z`}fX4H&1jt)7
z;Xo0pcZn&$cVDw+D>t+mt~7VHTDu#~z3tZCW_x!XxNHkYxw^Zw
zvRhl;sgkxTt2?!o?J8KgDp=WCFRX0lxj*OX&279^zM^JJO0E>n79v2T7~4ouS1eAW
z+~UcAVR~b6zZsX}aXDtvh&Sr_v}j12m60>~a83-XgyjSlYqeOTZZ?~VrB<@hOw{To
zm*-1STt8oo0++&O!dD^yr{_NMMbJ5hOqTqn0Z^hGzOoyDL;O{R`2IY=hEN)S^NZy&
zW1{Z`G&J)fnl41O48_Rsn4EHaO-53X4oBeu8HE5PxTcpBP>h=zyY3GaP-qmRI1#5n
z_fF4-qbW%PC@tb6bC6FA#67qyN+6sLAflXE2|gl49aLtd()&jooeF}9aF@U(2jdXR
z0YRjIBNRybn3zZ-coi{M42TJNVs4x+r)Bs`;1a3)?i))nIM0@WNIaGZnModqKz|UB
z7}G=Tk~G%GaE7CEA;l&~7NpSp+6JwhV0TX0oQRPp=Uo#v=ftE9tQ?w}9~qk)=^N|q
z9l1O>**`QhJTyH#Fh1NzE0Ydf81B6=(szES=kdYI$UipN^Y~C7X|VVFP~U~&{io#x9Tc56_N{&W#Mu42{eUk4}$_&Wylm!g9iF
zB8BY1xq0_gAY@l)zE+xuD-^ZkgAn=?zL@1T@NsDA7N4xTnV1pK(+mVvUr-JDG*7^I
z@Mj^|-x-(46~JaPl4
zDJ*9qo{q)SrVh*zg*Bj1iYWm->`{V2BO1^Zk0QImLBFO1V`{*l;rBr^D$;TBsKRBjV45s7o!4bQ>H`;FwO
z5U`U9t#ocFm2ZEb_DXz>u0D0u9gUfd?X6ocY+k>;dHv@4wd+fVv{X@RZ>M!-hbArC
zUvFPor&;x`EVp(V?Y-90ZgXk3-rlYNlpyBXE+|mlY6sLCu
zN|xX~tFdY=UarK7C5pZarC1UF=|zKuU_6skIT#l`JkhSxWLX*N1ZQ<_(EH!wB{fmj
z5i%z$I*=4hc#(oiMp2E5HR3@!+J!?zs7o<5Y^KUWK8nCrU=hGdlnrXQET~$p(_sz3
z;cDO-j_RmP@wK96fL(5#M2TeNBT7m_1_T5Okum{s7ETYC9+U{t+-&RUhnn6vIVlj#NU})ACochgg{&jh+w&n)JyFFqq&wxJmOF8XcR-Db38K`4rem
z%?o!4g$=(?@yPnWH|5d4zrpSiAFU29DG(NUWb_0*r9&ktm3?KpNY8PLW=FG7Ar;}~
z%A)s%#!e=zTs&1sS~;R*EFJ4mGHry+s5|5jnR-B1U18Z9jRe$4P*YrTVBY6h428V9
zj&#!FoDF#G5!s_fK+=v>s?7BzJt`Y&D5im-p@bF!e=S{2(M!;Bg!x3OXx+CKAwBF^
zZIWuOOce&ROU$JVKMDz7Szao1dv&N|r;#ln#qQDvYOj3i#TOlFwzl`=_U-47pL}}n
z*6rru^`(7;-eBdGrTy*Y!=3iQMr(g{X>VoaV7rX;srQqMSb^^nu-QnJ&I
zDLf{JgM5D;U_&?zs|brnqj{=2++P#{sp(c=0BNYB#!O*c0;zx+wL<1Q@wf>xB2tF6
zEGPh_O13c!R^k+Z373L5492}?Sp)U7Y$ReyiY38I!bq~m#0A620Ag@j>=@WectOc9
zEm%U(RPzyE%q3d^U(8KWw!j%oVj$sTIEILlfoMJwO3T5d-)DM50+B$TQ*%h7`BI!n
z@C70vd=LpIrUJAG1>Pi>P9eOXZKf~b_b22~mL4jHwd~v`vC)_z?g7WI6W#h`fJcdo
zK|dVK
zWC54y4lAR;B{y8&FGSxT)K}8DaT*(>=OaAyCtlH!!dJ@40IVfohv1rVi9Av$k_yrz
ziG>Ji@<1X2wxB_fxSgcV()A(j2I6knFh#B|!
z#k{5vPg;o#u0Tskh-s%eMKv7aLcR#65H5>1fV24Au$W
z3sXtWmr_c08=g=m40LvGlh`N*=cg5gsN-9Wc}Svz8=#D+v{1M=Fzxcv65cq+j)>bi
zG3S^XpB)~Vf{Pp$Es|p+Q$vH31H+R;17kxMhx#uL_k(5Uhx%b2Sz;l*-bZ`-9_{IU
z`10k4E?xT6g$s{dxXgO^0~@^RdCf^TWgE`iYnj
zUZsCxv}bq_`LVglk?E1~x$)kS-qD#+UK4G`F>Q0tEO_VKvfUe;lOpp`7-ZcpN9Ut4
zrylnhiO&4R(YR06TyU3C)E6RmNIKpjiqlBm(@bm#52%rS}Aa1o3qs_s@4lXk#
z_L9`uohhbL`D8L1H#6odUwq{!Km7^9?T{G>8H!&CJ7m9Gk-ciz0~yg7zh}fg?~I1s
z8rWxyIoyM``59lp71d?~kr6wNdgg**n;e=61d+}LgCh>dsM9&+^DTtKE?Q01a7Cl=
zp}^~6Shh!kE;Z!QBa#sb#iB|=S1rWmrkRf=@IEV6wn{cLU#E7-Q*;s>?-zseo@jy1
z2Or^&ZR6HUySHCFdh)r|YfrY0uC1#DjboIfZsL0Z!cxD13Ad9L7K7^ipwGR+t)hwX~$iE6;5-!LWigS3ElF;=Q1
z%GCrp%0?2Z)<~6Vq9np_AQb`)QMub#33W|nmz5u|y;23;G9hZ6EYdVTMm|KN9SdSi
zc!|am0bURg!@)R&3=tR%?fZJg)Tg$HaEcz^BC_5aefF`VEz>RP-_wMJxMGrXriX!45d!^wA
za}htDh`6~MClsOOb-+ruZxSbnxO;Sbx_@+f5UhkI<_0I`MnU$_KZ3iUp6x&P6g
zfk#ofPh6qD|J=X;M47(+i-W_D_YGVg9_<|)#;YJa?;RcJ8||A~m>QlM1|@rjd%(@f
zg^9_9v03NTyl2+wvH5}v__Gd07sJ{@)O3QF{KF8#FA{$D@P8Hy%Bnx8c!5j4K@YG2
zkzH02E~$Z%_{g{f{*aGnbOhkQC0Hr?bHpQzg+#hwr4aV!5qc-6TH3$`z|=7N5EIAjY-gEsr};Hq|64w12#wR
z%);Qjd)gPCmo=Ltjl11Li;EK;54gD)iGY|3GArjs!f~48
zPD`tLHfj~)>2fk#O=YXp^TUp^)I!`{C?Wbj4ZtCe!4Z;|+eLu#1CFoUf9A!TpLuTi
z`qN7%Pqa^Nv`(&qmF>eTVCC{LOeL|heYoB}Tm>uJ`|Z{J);(5UAyy(1=ix!^%@Qt{
zukvJo5jaXC71XUjH11VlH-t9?7K34G!0|~ow|~YHfM(skX}ga`dMvmnUH)0Oe-_^e
z5Ys2kLr(9s+izQhYY*7z!Lx`nthgdkT2>sm>@LcJkUW#421>9JVK`D+X1fwEmSPYO
z9umH?LrEZ#!|-mCB^8R9Rz9GwMEIO2YaksFvv{x9o4a4)B@JYRfECaOOo6pz{GkLX
z0&pdTsGNwYror5(ky8+)!_C3#L2z?`5l#svy+3gHmH|NAR*vnEmm<6hGZYw1r&i;>P6JG{{{^3ga(e
z*6F2oNz{&N!Fl_n4H36(Y+`n7a&COeHZd^KdwJ-R=*u3yJT}xfF>-#e?_4j!=brO}
z1Mq-MI#@yuw<+Sj+zT2$e5nuVr_W!29uoTWr?K
z-k~#n{qUHN5A|If9qgGHxhSIYOCtl9M`;mB5OaEQ`r^Pvgyfy&`y7)C?ip8L!4sTE
zFs_in?6g4PQ;R|Dgda_k?nU
z+c1($RYcsnr5Ee88feH=LM9xg5=4LuY^fnH9A!A-i74}uv=9o-OW~mf=kTI$G9dTb
z7NH@BYs?8R>6&o+ro5ryMQ`tn{qofO7{1CrX~r+lNu(*Se{kO3J2T%myD+@yoC^ei
zOOL905t18**HC@2XaLqS7L`pkoX`|YQ`3en;_+0`I&H!1%-B|I=b%a}Q)+ex4^c2)
zT`oekl@jtO;al`z+rcw0u3WpZbbNF9`RsIAbN8u^;|mC8kvnFxX^9o8o1^+y&J
z)904v0*W1S2W$@C3}p9C&%-6SCT8uUHYf6=>4i}zSm~MK^67A{#h89?kJ4_0!wwJ?m-_pRr`U=vWK7os?;8)5^0NIC39h7rkx5|E-5
zafpfC#qC4{4c_?#{v@$LBIMKTfTJri=hqhPfpK?e8uCQvU5d@CExHvO5mU&G{~EEN
z7%oonwZJ9di;JTKyWk+0h|l6dSS(s90Y_L!;1U2uwMd#G@hAdt;Vw}Jhfs%jnhtv6
zoU96
zIWP!6H!})WPRxxX?(QG&?;YtMoEUkm?=p0@_tLq(-pBg;ptF65yZhh=*&dRw?CX2@
za?c}|5N^Xr5+6ayPd#>?Kq)*X^r`a~IUaws2PPDV9E8qv)BfRe10&}KkOzf(&%?bA
z_7SGXM|;MGhh`=(5BGwVESu&?8Si#bFSGr$J8u9@0@l8YzUWN86ujUIy7O?
zl|_7TP!hz%Zq$^N574)xB{hh|Il@-)xoaRlt5HB(ROxpMwD
zzx_?bhY
z_8}m0)^Txi9-!=>a}F+e2IpO)4&Q`3IOz>ddSoyZ<*=Ls^GtwOH;rK2loIi<6<1R+4Zi`oL_8M8b&O3fj8Dx^OhXIf(+eZxv;AYxOrOm;
zKIa&lna7XRw97l^#jmn|krj}g!H`3WxWZ9d%12RydMson!f=S7VWDgmD{)Y=f=Ilc
z1Tle2_)4V0U?vJB;4%hWLa7Wusb}&=26>v2ip2Nl0X85;D}=!a1lQyfPY3#lew(P7
zr?HSc3eqg9Vwie_0$$S#8iJSrQ&(WBS`>O64ijm)}&)6T#YDLB0lm}ZZO(--8qK+Nll(fUu=W#NK&Eq}}nP=bJr
zNRGSl0r7i4OY;a;cHbdaV|R%twa&n%kODG(
z7-s=W5EFI;RVQcrhbQ}H7RRRMX|Uwj>?lYCN}lV#cyXk!XMFI|*x=(sU}Dc>gJdMx
zLY@&$kS(Ezz7bjXL62POp`aTU@*?R|7cP*_Ut&=q#pC^t^b9`QKh)LP!4b}!89?~}
z(#MB};8?-pOJl?5hx;#&4@3Ra?9AUr19rj6U3y3%M2W)2JtlSnNpmUDj4K9
zvt~SJs0md|7?BwL^#_dzw%;udNpkB)a$#`v{Lt8A
z10!cAW-g6PT$o!No|@~QT^L$$Pusn-kXN$%f-b-04#*w}xYYd-BcLZ}P%}tJZ
zSXrxE)oKzMc9-14L(P|n%8>y&OR;RhJXI`H(6dDYY3ByL|1Fx=eI`BbLW5?+QrrL>
z4H(LW01@zoo;yT5o(oeSw}{Fi5YwqFf_+>c++jP33}}dQ&T}E^2;V1#U@GIjfZ}r#1LgW7o=IY?vgC?)|X#>^OyhprSJV%&J^bY4lSQ>sSc;S;0e#TroMa8Pyp&-mp=<2$e`rzby#K`WfO{{Qi7syd{P`mHKc%S
zh{Esyj~{Xy?^?d|BcUiTLE{@ld-lE1J0Q*b0&_0U)PjAq-YUHL=4*2cB;N$(Vvk08;5fd@^!xyPP=gfH!
z^E~v(rHf~J271P3AGu6N&z|dlt28};wvAawcEC>-g&Z2JacodE@kx$tJ
zUP;%S5qZYvh25JA$b+_pX`eh7(uNj1eY1{Hhkx7!%mo3yi&KjO3*Jl9c4lJVw7X|!
z;nK|9#TjSMyr*~G3-#F$j5`Nyu0c3T0oFd73p~9vz1R!mX?Kr%gHwUfTqt4-hi7GZ
zMv{PL?(p$wQNK=Y`WMElNr4VjZSZsJdMG
zfWC71_-6a~+VaWOwQGlK*A7-ruB@J1p#@)$Hdc-WB@b3Nj#k(Am&j2bQhVk4ezP-F
zXs6oVEY_B(!L(QfWyp@1Rz!*UA%EBoTzcgNS744NC~yqh?1K|C7e{8!j|@MCzp25o
zp5=qXpWVIt(|7Lv^zPlC{PCTiymJS_?l11#EpPAjjy~Gk|2M;9kM$0p8yW{RF9Vlz
z;-OynO^4U!^eh0E#7ePBq@o3NGaR=NO2_i0B$x<0S!<-Kb?aU{UQ1H9cqPu1?1~Xd
z55=B}@6Q8lvLy!*9cM$1sNEOyfReCXYL13Oo|-JlKnyOPx>D7#|!QAHFc$f3EM+`N7`vgZ<|Q
z`UDn-0Yv5_)P*Kzs1SaWy23{;PrIM~(%WzT^zLgvzWeHr?|kbgcfR@K-@o$hpWDOn
zM|wuj^b9@PJM?Zu{)vEK0_DJ2;W1$_FN};_7#RR7N9V?dr^x^EKq8pR>4mX*7d=&n=F7qzSjwGrfrK;)vZ3dw70g9;}4mAAw7-
z5^?v)yxs2eJ@NGMB%K9QTwSw;ad!whf#4PfcXtgQ+}#=6-QC?Cf@>hSTW}}1ySv_b
zzgsou2Tax3XLqk&y&h|OpZ$qT-}7dBzx!K#pNc=LnfGnmlmW5`tuSncBHQ$mI$g|h
zetpz2t$fDBQ_f6W)F@Q<59L-AwxbUG$xH?ey)xuk;fE@t%5YVG7aC!OC1QKCDhC&}
z%tteaWJ(r+^*u7-_A^1Y^xzd2oz8l1#|Fm+h5U{`-QFF)Jv-Vx8x{m~LMn84bwrOk
zT}u!ZmCYv&y>|0qG3ni`*Sjvg394oiEyd%;wM3A_01YRh5HfDl9GAJ-nt;rVOQJj;
zK|TjNi#?Sz$w{AQUVF$WM!#2h`?n*K?%P{G--mH~-$T4^ZjbFKK`%+~{>!!Z3r4?t
zjj5IKcfWPcw~Bxn$=TG5)DT)G}+R(_Cq>=`3
z=ZxGM98ayYSWUKbZ58N1yZEh@+IQ^~dT7f`+ISYy9HG7c;NRdzBMmwYcDl?wyCC=E%O`&s%9C9tj<-pa
zLxM3EmWw079Qa!m^rw5+Jj@(-R26(2;s+3}ZlU=PUym!YZu_CxlFbdaW;Tc+2S`JW
z@shtC*mvK6W9s{~yFYe*``xB=zrL$?Kf*6A`FSs4
z%H*7S#pS&H7E|&N4EHcIII1_az_5old>XtCsOR?VXXEgy&D)K09zk*h|I-yC%Nv0RxprU0Auu9SM(*-AYsiPM
z$8O`okv*1SA&jW3?fO_9+K^X_d77_N54ntq=FYxNw22clgPz^$Fa~Y#pHMC9WrS&bw=qH{;oq7@UmcAhF=D@hH8{lKo7noLuS3sqC^4J|D
zjw;is$R28E>?jxfkwd<3QA6gltO+0EEp6!1sbEkqnB@1&x4mDTNU2;(ttGD2<%ggN
zkS$m@6&?jQ-OcX{_x&j`Mf(%|CDr6m;7xC9r|$YLb?xt$EUv`1@)3}7z@#NZ<*cwm;MpmKCgKfzMpBAZ%<2Zeov>H
zAMd<=XWk2+S7En7hm4PYfBeo8y0#U_4J4V+)FO!oHQUWM_H!O(<nFTPF=L#%jBz~EaGo^E#V9B<#Iwe3!WE;YVty^#u7n_EWeZD<*!;@+H
z`IQxc&%x`%db?nk*W)>_o9|Vao9`QZ`b4`__pL%V96e%=+r?J5fsMl|Z47T<(#3QY
zKhtp(5YF&&$2ZOheZYbXQ;(izC?n_~fa`n*^(t)VF(@unVa&Vu`h2~HdS)O3n>6?q
zCmOn_!VMMh7M_q_va6aiG(q=^9!D=;^j0|HKv^3UJIOs{o`YS^$u1ZQfjd9|IK3pg
zAizH*NhdrZ_?mCHy(KosSu!;AH1iPRG
zE;hVP&yPYF!4hoB`;?8I-~K-5$94sy&nNQc$HLOa%Mzo{Bf3F(rfm)pU|7=+D`=Ct
zAvMSxE}zt7678NGWmx+Un*b9FD+>!V7dvOHn*cvJ7@yr=f$cC?<4T^}hgJU4SyAs!
zwo%z#UfCvc8v=L_;}Rn39Ykz^{Ua$@*36Vo6g7EG!g3!gXY#_EFC(tsl7%Kgc%r-{
z^ao4Io!AeyorsZ15Qtf~nBfJd70E
zaDOlPt>^W8Z}0Qbte&^ouKanjl>5AsmisounfJL^ndkK$qYh4?DB;xeIc~P^JVP4C
z_Ju7!my8!U6v2;;2gp0k6QqOSZ4!;j^wH<4hrK1_Saux&k>cM~WHTTrpT~@NevW>F
z3#T<2~{h8DEj?t~_CMVDL5{v{nCJ9fRp1R!d
zIM%LxMAaq6cgMH+iqFl-498#D_YLnONfx_q0WZVVW0F}VUQ=FUcT^R4?
z=RL3B)5QAa`^)6x=QBEx{B-e?yJ2<6JP7B8UgV^m0Vpy=kVx(8Apczp8_2
z{#L_pDx?=O+^aKSP!jl6vIbT%Y~n^jDD#*Y6s+K0wgH}jPpQGHu6)+;PClt
zh3)>xi|^W8e|q8^eTCG>AS7uf1}H2dsa-KFL@ShamclhfdrrlBW?rRwiIo
zYFZHkU(Or0IDGv)ObOqqmAVu!Orn(WF*f`3YunoD>PHwDx90eGq2T-YdinXH53YbF
z6)w7gOgSYP<{-_D;
z-ef(H0iNOQDJa`mHFTLVFuRH9H1$yN$%T^o%gHXIfw~}ElLB4g1y~QX1jhJz)A-~o
ziN?rmW$>X{0@cb3dpw?RZa)9z)bIS59p7|+Ewg{$CFy#s1rtLm-6Ym~n~8pJz6@`6
z-;eW_cjTA)-g*5312#5#H3dBmCpkYq%uAX>iToph%AbiBp|!2%%UbIaVsVbDB}><37C!A&8ZK1wk^eLf9xem);FcBEM8
zcA&uS!EWF>>CsL9W%9D?qhFB2Esu|r?fIx@xd^)dv0c`rbt+64
z#V9ZZ0?dW9bAQ?yxf+})h%$zTX8li4lQh3Rpbi+K`pgVI|ERI2nCd
zomqStJvfu^uCra1DZ&?{GwG}mHH70jrZM#1YIuuaZSh*g&
zs|d+hdA=U4__)>td<{&%fo2%SbZdu-lE3Vza`(aNQtJZEPsJ)n&D#F>%kKUOBbuDDVSY-{G@-}^5LDI^WiBXG@#ay
zRtSU+1O*zDB&zc<|7N^M`5vjzi}@=ffu`@vh1}>Yghb-eKS;ZtuU_uC>wsS&bLALF
z6n%o=lZ9!Gya(xb`EBfD=JG=AxBc7IlG}U5DpB`azq;=g{qh5+-^VNG=XRX^d;dD8
z-*wpK$1O?s0o4skYCK45cX1&
z-D64(AvnkDUYd6Fj30=7@<0H{Y*y#A^L~GI17Bj7T~`N;g0B&$l(s?z?lp
z=dnj$Fst%?d))7_-TwV52aK^gSIF+{2@0M>jd46k=n@WRHHQl&xw!N*G1$T!*b3UC
zk4O>iPm_?GL`Q#+i`FG10b~*pmC~-mnV+)}q9yBqevrMmx|bR(LEShDiVCvm9>5!+V&kVY6947^{Cd=^vUN|*#eq4
zd9_x#tn5fyY5*<5(nI@;DPyayzQ(_obqd(WDp4C%7ovXV;I-^#1V0%DD<+qs#ghZm
z+=%@co*Ers4=`oO1slWbJZ;uE_-skCbnr=6LP@>ZOYtO>AQujFlPoVityBuHUNL_gf|ma%T?wC#RvFL%1qFu&|XO7*v!v8d9x;e4gC_MyhY?0X>l+|dc)~6KPKprQ
zh=f9e=HaWk&>_=Q1tVSp6qT=u#;gV3pQkSRqE*Ig@x_G}Z@juc`r|%9kFVWbuNn5<
zoLXQZens8y<)1ycN4(IO#GC4T*G3xZ{;UPJU+ui*4-fX6&)1h1>HDop^Y6^v>Y@J7^J#1xJLr9`|2-*)4|4{*j1+C`xX4|Xj*9ln;sdr(0a_Ep~@yP8Rr2KDsNJe&Is&k9aXZ1F0NVj7;33rUR(
z8Z!RnMAO73uUzS#|J)b-xZ>-VT|>HU7L-xO!>_nPMS
zb|JWqNT{FIUgs;^is*skEj=xcxC$+o
z`?>D@MG;1WO5yX9Z_Er0cLDcc0W%CU^w@MRSICvOw7
z77uomIo-Amnh-<<$MqyH3GRawfUVSdo(~Vd_1>v|Br(gDI@)-`7;^1^;dz~SVXt1p
z5(QDBL2>u21nsVgB97M@zqfWx1F2@i7*V}X-b%W;y)GC@e2;1c-YdF&&StuO?+UuT
z_huCMZjLf?1G=B~`u*Oo^gs8>{hlMjh+ncKr+jX%qtG8w1m;F{y`&<3M7
zC4f?cKpD4JCWQF9csPLfzYMW!8$R`kfCvLhg!GYq5iDHDABu?(T2g_z$Bty`vZT)9
zq?|eu4D43NGZfXt#7tlu)xBjVb=6Fv9j40|yugb%gnR6R&)e4^#wHGz^35)-Tmf%DvgLEA}D4x>DzQMANh|
z-P}LCo943LdUguUajE8s>e{_;^+qFJz@F4usC)`~t4Kt2hLfk31|V!18aE`bQcs9Y5?HF1C7RFk#d_uAe&&s
zlQBk=f%kAQf-CM$E0&(D_jhpFT^SpMw
z1To12ESNA@+(vW*(*mh%s4mQ>tbmp#pHH^#P;V()-R8Y3`
z-v*Cq9WU<98piJqIw5GtoN+|{w?SP(jBF7qh~)x*MUHU--tZhJ%C2v>T%KOrxw?D1
zOSZKF*%%l!`MDdl+S}CmIXW8{MHAbeb)p1$I2asxZ}zn1ez4YM`1sr%$)nd}g$K7f
zy=}|#=kfS$*Mj+Y14VHk&!Xt>gJqu&Q-aS+RiF3vpTCkm=gS1Ir^&Zy!3JN(JLqIx
zUc?*@H6;C&rO#!ilEYB3u&3#*kn4mf>?D5d-S;Hp{<)%Er`_qhox8ohrz$6;#o2>Q
zuzkum;*T@ei^Q*4xgpnUlsMMt+Q^+fqB{s8w_^}RF0iECTQ03yjxx8BaReOALr0hDU@{osEZjl-zYHnUn9UqPqnJ2$4%K*FiX~
z6f*^z=Jn7L2NMSEfx$hWn5fTb>~6B%%Vsi{z+SS^gw6pI0T0mdI*?w#B*cB3b|^A4
zSbnhR5?Ano%8s!Vh^Q+=xZPA>^4FczHieZb<=L!YnNBUW+y(1bttyfAPpc}O0==Ba
z{|$t|v(d#`66MFo(T&xG^_1O-g{1qG{*vb1{V#;1O$}X}t9-$=Rjl-!=vH3vF%vl~
zv*(>B8^X4SGNxX&;B&FE46L?O%yTcwC|8XU!4w8E_>m}#-MKJfM!)8Vrxz&Cbn=B^
zlo=HM`@MCy%=aO_$M5UKv=Ev|tcjmUX<9#xRB&ppS
z9xLGqOuZ%79RKb2IH^P7dSAlWeI2F$4n~XzNO8%Gy#AGFPF{@hyWRe@}
zS(UO`ey7mGqa~8w!?YleTiORw?GdcK3D*&YCyA9MDfGQY_gcQBN6&{_Dp8}0O@DHF
zmk2An=)**ZuZlBm9B&^B>^`lYZt84WO>t9|9!L(ETZR@ytVHC_1R#sPcN*C>ZPag%
zlZ%=&J_;=U^D_h;)fbS~-GEKNDaH1o-~xG<8BfijYh
zCjF0-g4DUP$^Y
z?_CGEK)V	et2WvGnk_3>n=P
zjG(Lp8y!ZC2qUVWq>6p2xM?yA95MM6jBU#MW!=(WJr}v4T`p#zZ4r95X(G~@QilIo
ztN&JyRac8!#Q?SWLP%@-2dsB$g!s9~#;fnF;Hf{}u)
zV3+~L3`knx*x76(F5>5j0fP$3fI6LK;5W@iif73ysH%A+Oas^_(XntbINCW@2>D*Y
z(!gk0rVu4qe9QiT5$uL4bp~&V10>}JS1NzWH1PdLJCjnrhr>e_H0xUx5EME3Ctogd0
z77bMMAs}fQg?(=N=wdsf7c;yh&Zd2tj(mJ5a$
z4)gR(*w(w0dOWBfn@
zepYdE9R}4#Z>byR9gS
zO>pMcmMNvvQEdZbnh0d9yr?BVuj0Csck2!0B>66szQmQ1;^#TThvBVbU-U!^vhAnz
z{?HJCnZ({;Du>Ub;qk`Md<_se)5~<#$t`G+N^l*5Bi%>op#DV~KkQQahWTwdmhlf}
z5Y)BUH?y(P)?^AXx)loLN~PGe*-pv<_U
zbosPI4vQ7;Ka!)iuZmbAV8y*gX>$^+Y@Mtc5*0iSU5~-lH`IG92e)=&9k1G1TGuu-
zs&_h;pegogiKssiO;6gnc$EdZd%MJ#Ep+(2`lp>w;uWrBXUa$>8pY&j=mdgTorM&k
zful?!hMAb_MHV07biv&O{gN?>W{RAm^6J%L2_^
zLXc(8)4u9?QK|2D4$iwf=6&-gkCFYnzWjXJzx*usaQ2yH@5IP%ewN6-8HlzXkykN$
z>i9##coMhWZ1IhHgXvY$H94Dw#ft4~&sVVsRFB2L@~9&MJC${0l8P?Ud=R;~ZB6<(pw#3i
zV?=wVxAuB^p0=j3hm-FMVC3_}GqRu8_G}sOPQbb1b7rGJ
zLI1)~ESHFohnLB{wEOdVdmGt!cjPWQ4*b(2BqGkv=-^rtpT%o>Hq8<=DXIuneL4~s$DZr1j8_TqQPh!ohU4!^9iiR$o}MwQVW
zJ9AS8qYUm=$%Saq4f1fXQKH*W)#B2JXEa2PYLFI~Vryk)o(ISpGA;Pmz#7-*6F1V2
ziEu?b3*cm2g}feON@Cv_U
zV7WRjZ{sl(bRp&iPiymG5$B*+K9pam;xOv58IGh9NDq@|w5BR3J-X4R{4!;^*QrSe
ztN7kbzptjGAtkoCFy`3&2Wla{;LQs4SC#5GNmVCSa&U97TC5vK&3QGTrkbR-ngnPM
zV5t529jr~Y#I8b6u2Iso)$8l7(_R4PIo-zF>r%ZyX@MzHy%U|QAHvwji>@BVjdcyF
zx>j>ywzZuP3o`6#G$$d2sS~snO^Hnw3oBwQ09MK%uJC^f4^V~Pe8od16DR~ibnQ~A
z^5WG^W~NOxq^XS5Hyq$=mLmV)7C)u>
zgNnCCS+~z>z+kz>X-sc`RkwWI`z|bCfP=D-jpkw3C$NVw$rY#)6=3KES|$MGxy9{H
zEdqZmmy8Z>1yi$F-=h5E6OHYKNcTM
zcjA&MrC6inl@TI=0zx~~YB#ddTOJs=OJweZQ(?uHQtSykT~qmxLaN!l2lM=vw)v`$
zxP2*vFQ?@xJ!4Tvik^=+(#RGWeh}Egu05Fdxnu71pp<2eREkxV-4KycVUx7WitSSb
z?UU5+lVp7O;%Uf4LUbni0xsx9(}34Fspf`En4#owf(nf_!hTK{4nj$-&&#_utO<@E
zDrvya^N=WXL=vQ#;%+0mf-tXFV05g202>6fmtFql>@vpL-ma*RkIHUPBeoBA&~D51
zM@0eR>m8GKiH0;(rrST8F3m7Mv{)7hbjAZ^k%1W1@9B_?(yoa^^5TG}6$EhsAum(X
zjPGRy?lXaZjmXr(%T8A)-c#JjuF;qiYQGWx9>}ae7U9nevuabNO{vmo6)8++cD&yF
zxNuVt{LBFH5l0Wd*Do8N-;sfJiMG3z
zjPWFsn8|w)Ayge}bJe2q{0A&3?Z0>oblI(n?x3ef@i`SGSP&_#Pdw(nQ|>2T6yOHv$7t7mlt7YM;K?sX}m%9t0K&Q&U-R5d!L|K;8h1tog#H+MGgPQ>iS
zR43iX?A|Z*KOkj{m7MRkAoN$BhBYs&&p!B~GCw`&f$1>fJK?<{TQuAB5xHJJ&+N`|
z)E8&zD>V^_Zx_#fI&kk3=a7v4W3x&qAIEFd@n+YFTvOaY<#*(Efzc4zWhr~lG*PC6
zCVDi~^!IX|DfZRL;fb=EdcVMFr!c&uA!j_6LX_+(RCD55!oeZB%-RAWd&M$X_#vd#
zi^tE`R^)oNd`}wAby$UP|3!u+?@j+yOw2u7L{^#(<1-5dP=-sd;iy!Sez7SOaEJ?S
zWj~7R-Gr?hzrgyI1VNQKyma~VtHAnk82V4#GN0Y38eiVcnNf>*^hn&!=I6!};&9yD(z~*O0`{+?HARS@6|xFVt{w)NoVx
zx~)tsS5HEl`w82((C=}2f1dF1d8QStn&4KAfrnaOQ=AKpaqXcAA0T&Bn3H$?jlSXK!GIv;DBOw>9uK
z0B(_|_okzL%)IRY#{)a_+19HU87`jYYXX@atLQ|V9*X7yg*;@DvS>kHHb##7l%KYc
zjOg!sjjy;g5dZy@Ha~5XW3Wz{)1{Qf<({yD+tI^Rf@eRL7ItUDB@zEIzht=GyB
z7^3BTV
zBkGU)L+OSbBg3J%0;hj^F-E(H0&qh?+T@!*Rv+oi`;T>Aj6(ZxPsg!(wrXFSFO?Ms
z${o$g8d~x#TGv|rRU8v1vq7&iTM7lu`29kLTt7T$lBt$^)u9r$zV0|MB_9B=;IMnY
zzp|eU6&z|q1+?n7n8Y1~ECn574^VU@wzDBB7?gl#cf-%B@M|Tq4u43MYccL^)xyb$31N8VDK5)I>VlTc?zA#5d~<384GbVlRT@o-&sLh$ktgQTRY7Z*aQs!x2WMLb~Pu#18`$aoF_rb
z0Yu(b=K4yY0|=>$zoYBZ+Ic}JOt_4u2|Qm|rx}(lqLMG>464)ZAZRIktBEI5faJ2N
zFoOqL?oE3cffnM)3ID2^dqXoKLb*`Sho7(=VMUfB^QDIKdiy@MZ|ZWdW;@L$zcfBb
zdwNfAApRAeiqH%`OoA?Y$9CE!pCeC$^MoIg0HUEjC`9L-w|N_uf9}u(-sufYqU&F5
z&xoVzcikOF9Zucd`$tdrr!kU6f)_`mI;F@rEL|e6o!&crlCYtZjE$X=(j?)BZ0B~J
zj19;-_U8NMqkS^*I!t4Ey>DIfCcbEZUJsxX`Gw+MfHIM&W&}s^DdOU8W0BCHVoEmE
z9r9WVSf6-&fC;3L*rg;|#m|;}RoLV+|3q73^E#&=_TGQBfF}L*y5zLUlmjLq(*^s(4eyJRwp|e3Ma@9>I>|
zMx7|AWObY_5RXVWW21-&N@es$<&u7buJWElXveH>tBwCK#p3hNoLH)igGs
zx`*`u!cFP|6)}(;nuyxKMKRn{csYPT(56%!ejKWo>uX>SyI3pNQc>Fh6o(?%ttl!N
z+HVDBqknPPbuJUpodquRR)>Kh;fCFxMSpG>?8
zC73oA5I+U}ln}W)NjrcFHxJ^_Ayb!OY&9?NIQ;v!Z@$CH4pf!5%6wRsU*Rz@6lBbb
z%`Xbxks=QtejOV29FmxP(1-i52#u;I6~b;G>F0w=!^3C(YoBk)=tbEF~^VMfl=vh7}|S_G}}rPzC7(
z6?ujRjcM>K9KRBIHWkY^@@pk2dCGjIlS7sG%%Wr#MUDdVT?t?W2CveXP=%Gi&+%Q`
z-HF40`!`yszwFou|HT}rnOc^?G1&k9Q2jer5`zm`(Xn=(t>ysik8P~pT%4?az}@_p
z0!$>-=5vd1JhT92yzHL5WE$)*jv_TCzILg*$+8)QLtQ;KV4XBzY5n^fkTQKBpRtV~
z0~MvK$U+hzj>~D`D3RRV@Z(nz{-GOAgW92WP8@K?0crroNj)1lyQsI1Ej%
zq(35!NmfL140XFKKpZK18zUbP0m`Y@z3iW)%oawWV-nOJ$^>*(E7YVoY(6$Yhs+^I#E-u@q?z9X#_jmfECLgmQZl#6bt20=Rr^tm
zA`8ObXo`<0(Xp8Md!NPgY(Q+abw>T~{RzrOc_HZ%Y6<_W~u_W+qbyq$a9+nZ63EZP|~XKdV3AuHOM
zPZ~_)HVp{M*p966x%J>w4OjZCWpS_i4NKokS*^Bo>hjI8
zadFk|`#D>|gB`Ngs%?v_lSBdU0;>1@{80aQ63#JWnv6{$Sd|A;W8&{D?JE+vgux*z{#Y167>X>9q}qDKr$k>d&fN`?c@pe{h<2#~Dv
zO2A>L*;05)_J#o+Z!HvBd_@U~$E2Ys297vE0Hlz#k(vr%=7Yqf!~6>ejMa6VW&>63
zg<{KzZU~v2?M5o+xI7TlF`%h^>dJe7dLf+@%78(7GSs0C1F|HvRv5rGAfXqiW8(Ig
zTe+_WVGlFH&Ds-{dX3Ua#rdqYT>l81>%SwtfCg+Qvlx2IFNU;0YDCPc81|`$$v;+O
zgXjIh++?AYco2Bw4c<$5vYn6G$#Qc)I9N~OSYpGp^|hK5fSv%#D@?y&CyDO%@3QV1
zvlbytg;Bx5mxW?T#)X#*0AtYZ6k<`P#>IOjk7B36aa9GWHc=DFImT$DkeSCq@5G6#o%FH@SYv1Z$8jrdQhv5Aa
zRq6{R4lQH;d!7Hyf>{ln(&-Q^YStyLC9T0DnaS|SFgHDt9J$42m=p|*y?(f?_kf!-
zN+tcfn5}`>UNOYj4aUF&Wo}svgcpR8Ca5my;2vz=9Vn7Zj@fZ
zmX_45DDG)Tyfo)j?@m-FxwuPPmEu&bfeYoYm_S&1
z>#Wz5^Y@cUUl;XoA=*C<=_&1A2t$Sxx0R>dFk4J1QcE1N)_e3$Sy>(?YKxAx1FJ%N
zNJ7mb55z!8e&Mci>!VRblvr{s5~@w~pul@AA1<5-(UjZx@a%
z!L@BPKll&8xxzIwo8b!#(2$!T4d+)BJfMy6rW_HA6xw$skQIe$D;iT;5xbWcNmxh_
zYC{8}swsdtlw?f|$$|xYn;zVwL#nCI(~3Aw&&BC>kkyPXVJP4jSFU2J(gsv-IYQME8pIEpW_UT?FlW%FS
ze(7GjJmH*?DVw#A^#KQPa6O7k`W(5JfF)^>EBlUci!LSEx%VAcEjiDWiK1Cr4t76lg3!x#wC)(p@l%#vy
zbN^*jp9?rZDc0oL^r_qBR`sjf>FKU;Yi?)w{Ei(_ZE!_9`S;2W*1;r+X#3x{cyk;?
zDo-;OV!pr1G^A>a#|{tLRdi-*YmIWGDvva!vW_s;?kA8fuxnc@fcE#SL5C1>hHFWxj0D8?Q8IZj}+!S16;xadb8;
zT2lHCpRMITc84^=NPbJC9o2{~j!66(F$^FGM~H7j>nS@R>p>m+!fcB^&?*K?iwUuc
z;Y^-`&Ips3DC*M2c9V$4{7N8i?!1E}0IhMy5Q>|F@CUUv>N_!7Kw=L8W(;D~%ZMn~
z*S?Y`9te^f9aQ^TCx@B(eqH|cxofpvwLPT^HQcr|M9NkuW_39hu}&VUd*p45KsT-TqeL4LJegygw8S@N!ns;^J`e`lFN^g`9<%2b?5DtfEUf;Zg71{Z$MwNn!+Q
zuO>%Ekfb7|*05vy++X@41p)W3l+aY|j{}_}Ah!l0Xy~b1ewq(n-oaTu-Df=E7nn{lp7lP0wOnO{l0h
z8D0G9&#UB!wSXI|>V}yrJ2p%-l|Lc*tszbI>vrehR6(!ehm?hfl$3{FN3Xml@4B@$
z+h#E51H^>vKUS<5daB=ONitG!&*>Y_?SXm56d=hF4R`MS0Oz*g_yI^W8wz{)D0
z-ajs_4KhVwJqLQ);-mE`Jb0gSY>^bS!kqF|msDlchgZ8j1xUu(B0F+h14>hEZO}6i
zbA1lSDxPrt)0}N4<7m#wB1QXxd(AFlAKOI`g&{|F@5yLteGV{Cw=1m#D+CZ^7@Ae)
zq=wYJKXC64i;)}%ZS`6bxfK&Ts82w*ls6?3XmrqNm2C@Zh0S+cQ$e!FUJA^iD#9yJ
zmjg~~Mlv#Hrt09Vv>+T%!hnIxUeU24&30J1BEFmq_7g65aWPC17cx}3aM}TQT0%ga
zCc}^d3M8Za#Bb;WABy!qQzaglp-~SqFqi&#Ac>J8cg>ZR(q^7AHAU
zfCTmlZWuCac^tC-itkjdcM@L(CiX-2#javcsr_ZsWOajk!3al{D@ff--|1)aZy|-f
zT5usFvKw)-7gyW44h8-h5NwtKI$&c!G$ls$+?7jlcEA7#KsXExIqU;@%r`@gbHm%g
z?THt_Di|!DXNfjlTut=)@_08!hAD_WsNY~6lR*GhDB
z&i_%&?0gRpk0Q+N_54m&w_}2WwAEc}>@M|0|NL(0uJ^5L^EAzA=k;#`3V}&9v}*)O
z$;gmnJ2GFKgYDnv9bZ*$x%pL2_Ee-Cx?^m*~{TOadV*(8OSs6i!EUD*BaPIkBj?XF%t+~-W}qCSnCS61?3u&ZIw
z4-%Rz#E6!6cqp#$7sI<~0D@F%C*}9YQik5E#E5D8KpP=yi?f7O*#D^g2l6o52pK8lKLM3biVt3}`+#DJCm5&=1%nJI|B~kuM8mKB
zF_&*?Lq)eL#Blirnk(|!;{s7>;qMASVA94<PUNsDFXt%L(_8p3fnJc?^3}kNl?W8eAkVq6aP}@wjcmKs4WaV^&FNckZN-^MB#E
z!W4VVqeSEqMAl{`5+)>Mj6e}6g{#IurZo{mK-n&jhD)@sQH_JdLZ1Xsr2g9rJJ2=+P^LcnU%zvYxk9y&!N@r9jVF7
z*8bGp>(#`37nF3o^2Hbj4*b*+FCEm@#R0Y+iv_EAdA>jH$+BS)rJ*8kUb9=3j`Cl`yOi;JUla{CVp
z>|2hPgiu$w;cc!O+M*x^k;`)*qx}sfAGgn3Avt2ZQEwB;|0C%vgWBr4HjKLj*A@)~
zf;*Jr8r&Uj!&OT=^xz~Lm
zVLNhYLuOJ&zM;JRolvh`?JIW-=MS|+BDvjPk^^1S_=9xq^wyO9C2##Z3*-({FxQ%%3
z$U$-0hshMgc&{-RK`!#(Cl85`m9$^9EiqKV3w^N?5)bf8S}x$DNHAX!gl_
z{%K$QDq^Pl8howNgoWyPk;SrE0%K6Nn|y)=a7}d%4iKGALX-wsxjiaWm2+kPEA7lZ
zfkKcf6_ado%|A;I#N9T;wC#7fs!~y;K_h?)=}Ttd;EpQkiZ+Cf%;I%%j$N$CF%@SJ
zDblsZ_`RlT&)Tc}s0O&|FBk9DJ_y{WzA^&@AA+vcq8GDHvPFZlVtoBz13|*h|05u)
zF1-xCoL}QaeVpHYDX+B--QW098ejVQuD4d^&(CHWFGWrrtCtbiN0%EbE9Zw`aT3IN
zj#bD~^WifGvCMb-a@iP_47f!z9l62AXlpH!=O?FtD4;3+dvYIAu_%-da{j%2Zs7jR
zF+j-bk_B78ANYgJ0J`KT(UL@{5TZO3@i2S8`pD53{uaBL@w|!g{2gf!;(x9Khue>f
zzg}YPeKgq=&os%0e+LJ*^0hMQO_Rv=zWE@Bwz&PmWqB<<2LAEQd*Pve8+0ZU@oVWN
z0AbHS864r@E*Vdm17Akbm{)?0_d2dDcKg-Rh70@*%IXcm-(sISu@v*ne=p
z#UDXJPn`$ejeK|rac#X[HdDSH}U+QEsYGE|QD9=hU<+gGCtn(oeUa~H`$TgC~0
zI{#5V6!OqH>UzNXHdhJhFv6>%8pI5u7rBaX;kH>z2Nd1+=vWBoF_rfbZs^y(GaLZS
zmaHguJAK*z>hdC32}?~9nKR}5=L3jqDvwO)MKKm+wp1O;5J|km!-pI{1hcbLl8jDgl<Innfv-Log(+%*XXf6*@}CG8C|psc^p?coc8df`~T_WX3Lnd$uFf=jR`ZJNkn5bvt32{_FPs@IdbyTHmjWQ!8Sf
zIK~+Dti!%NU3_tFa=h^3?*ihR8SgGO?**F;JAwu}P$n;7Jqs9{NxmjhS&n$^+Yby@
z7(wy(5*i2}Tsq4Xr(EeRR1XKw(^~d}{K@v?6!P=^72j%CCF#s;?D@AhN8r|G@8Tv8
z8=KvMzP`{v$3q9#Z}+QHda%JeAHPjeY-#gO~;YXdsarHdw2e0g6sUH_&lcVT`
zc1)4|#gdM|Q_5`P8m!vT){lw8O`1TuIVBCe8?sG)M@X~C|JY19&>_Teu$y-4DJi=v
zu@K&JobC6cNj#-0%5sZNIbwlXO)N`Y3|c`@Gy@|>tnMNfyV@j5g)hzKbGKIZG~bL{
z+^|%gU7~cBsy;Kq5>xb?*qVRDD_cD3*N=$X;2Fl3zEKkNbO>S$aI|ELnH8Vk8oPBy
zDDFN;U*Vm+H~EjO1K)LgbcD=0`ih|YbI1}^Ht@=
z8!ucw%@h}Al3PE1+8+ndyO~u@AA{9HmUjiU6LH^&zB)1I!t9cnc}lb89KWyToTxCy
zVNXVxTLMU6v)L6{w%j3!(wD01%*xI)Q1uDD7Bnx6cr}zWLjk2<#s?~giPL8_n0abf
zkJ+OS&hB(+J*=+<06~d{vJ29niF7z)LLz0PT*T#2i3Mt4Y07zc;NeK4U_JKl26Dfn
z^}oHEDRZ-mbheQS-M?$(9}2nt>+C)7bBm$u&Hl+8zs%L@&C<~Ima}!lRY9KY!_T>;
zmp8M{r4grF7W~qo50jj|pKhl7bu7d0r2?+scYRy>tn@nMTgcPY=;*>Yc=OMnS6wX^
zqgi7G7goE@{wd_tLGmBogjTU;5_S4}dOvJ`KKb>pnE`kC_d?}4Lt@o8+&4Om*1dso
z0biybH@d(@64?hfUkNfU0^C1K?1UeL{MbM~=4>Ls-K~DJ1+ld)KX!*+N6qJKl9cr=
zy8agrstjFE!Ot5%zS!I#OYkmhx+rP-@r*YoBTp>z%tDoTVy|CS3kMi*49I8~rYaJE
zua|%)AeUr4Sm4cW5UtH8?ijec#buH5N*ksUE83F2{jr<2h%qaXsyTabudzonS}M%e
zI3`m=qBG?h0|h#XU5#nw5lzaxguY@0Ar+o0NLzb3rTlsWIN}nX2veYZ&353#maJJH
z-64f3kaK6+kYCrCs%$PHY~@jd_#c73d|83$d4SvV%j{1;05V!Kbe^5Jdm)Hi6U(5^
z(LltqU0xAK;2`3;48Z|{k&A4N-8~s?r}BYO??>1SzNNzFd@Pr~Xbt+B=X>%B#eEZU
zb8DlD6Ed&yudql0HhfDs`V&A-wPuFC*-@@Yz_r?_gn5%?)8@QtXx_~XGwg)i
zp(m@-qXnM?C8+c&$W)vBQt|24hYa%f^2tp-m-W?eH8Of^S+>mW{=9$H7t2yb`q?`4
z^81(4yV=dMr)}}F$1$3+uw!^F%9deaDV%LMNPl~%E$A@*qs{AIx0899rIDxGU#un3
zQGw4``cnAC{TG?wo9aBT!M_L1c{U;Ug#0g2U(23m{~O)&*NJ?bbe4Vk+hG%e&L!~r
z+hi@G*827Df+d-o_k=p19_P=CmR?>>5bAsmdlVZr#5&gSUo2FDyS0Cp$|0{FJy%C_IHR5g{QOD$^|n4k?j;}kLq-`2{(hI^T(&pA
z{>7{Oa@*O}{uuZr9B<@LOUsYv%@@zR|7hn1XKq_0
zicm3h`tN-B+^TDTT;GbtioRfAtUpac_}o7nJUnDzzSR<7f9be_zgQmZFR9q?9$Mv-
z&7({1<6zldj|vyMj8XkrJcqbeC4!|HMBJK#LGr*Q{15wgc4G3`T%;j^1i7NdE4#`=
zIkHmDcKT&AFDDH-Phle$)BhO?rMrMQOff-{w6z>F9(Y`pImjf~0$XjIHh52Xh6raq
z$^?_{6mT0~h%nkTxj%@|neVQX$nvcdiJK|!E2c+!hUi@+{1W~L2tK(bvRoc!UV7n6
zV8sOV3B#+dCoBrw_GW{`QB1hEfh~!)W>9&Kz=msmK$*;4EQ}>pn){Lq4LsWmSax`)
zu(SX9zjmYAmtE5C|JKvf#}Ez_MO5xIxp%N8(So-(j?D{@#hefL#y1hpLT^Hur76o>
zSr=LzM4o>W^{tj`{pwd@mjt#V!
zN;Yq!SB&?N%;qXcZpxi^PcF9GHzIKBb1@GcpZ$i6u{{bDeU@HB$@_dGC#7H`t*N|9
zRMdUu%7^_q{-lB%!~p8XPDVUU1+2dd1lkoqW{GMwCAAFV9~MGpW?e!Df@Ygw)k^x1
zn(6?V{27L=>-*mkE$^E0WS1#ILhN5Fq?`2>pxUAJ1+K9{Yv$65^|s1wseV+A6VFAd-LaN6rj*gh%axE&m)!h=tPR?|u%W^|Y`xIZ_%&Pwa_OKS
zL#j$rKak$;0m?;0eos>1+6E)hh
z#zTMQTN^e(c+A8QhUv3T_DO-WsCN{ng=
z^W=72T%cOc0aZFVfoL;8@5c7%kczl=Pv0p!H)o8`
z2hqzGf)>Nq+v$0g$L|F6xhU{!#S4LIXl2`GRbKK~#+uUn~sjY!hq^lbC
zqb@Io-3fsd05xpxSG9HU5pv$y1yS@nlJpdH(STGGf!6p4==^J=q{gBE;hC&>U&v
z0c_A4o`}zwXB9bkAJpJQrx0+gl@qw5eO%R-(oVNsP8^VRIqk-Nv&_Xv7io!3_xvEQ
z5gh?juq)}JoM1DT68{?gj)df?`MmOj%f|@@(^WeT
zL(M+AIX0yKs&xNmQf4YM(C6DZ9NIbT>)7AEfojEq-50LiD*IN@Q6Wc@M+@~gUV7#&
zms*B%&B_ut9?sdo=4}B64diREo_B!~vQL{%9tl~mdoL2zZfcwY#6~zcUfbeD+ST(!
z)Tq;i$zRGA=}llb3&j!nB=a+akoMoRzHq*9Nqd&rNkJNQIr74x53?AhuKDNP)=m%&
zAyRS}nGI3L1xC-A%AX5qTxutqR3ho+7aC5}6y8FwoQ={$xC(jP+w8EYl1iEFwboK?
ztBkc$DRe|D0aF@sAy#s92Y;ewub>!{Q3C-0e#kLUi(knVrmv!px~?WH)?e)@(&K_K
zLU~PfwZ*vDdR++`Y=UFW340WN8VEIEsYb-NgG}_u-#TQ86dSN`QNY^^mr?}4*{Ual
zh>1^MY&dtk9`9I)~Y<%+TNJ5=}hF
zi0Ymw)8?1U8_@^DU85S0U!MNj2*ux{=s92CAHDzH
z#A{FoY?xcId-19&sKvukV-lXjxzYN`TC%S#C}2QQN9x>Y)4cjWQ|oQ>#-Z(ord@y7
z-vHtW;R#CGODOWh@7;D>p2#;1lrXkRd6xbN7_C-ko(Z3&ms4+OP(nV)70l)2VFBYy
zs)j>#$s_-!&0M_B8Z)%Z!+238O-sk+2%UgX8(hC^LRrcG85X1~NbumUSNecdGV6AW
z6HaP#L~}6W4LT#v#t7s2&cVHhC~V5wrTl6rKNUhHL%Apji?Ze6QscsWGRnmVbbumF!JS8ITgOv))=kwTt4RR^~!e@@j
zA5uc;x^xvT;UARgXI13ZeYEk9@n9aD$EXUHCJ<8W+v{KSL9e|&4iKJ$Ok9`!r!)3M
zN5r8gl(8rL8gn1Z4^ypkR@aKJJeM;7PKE8Fe_fGM@&qBPj5r-cej
zQ`~Y{8K4*v^zBeX1$E_=#A78TZDxx2Q9~Ev0wn=g9CF{tRp{Dj2v;7T<2bU4atWuo
zir=<=i?q`vkS2!F(jRScgIt>e2vcW!zB%%`B^l}pQ^R`#q=4z{3zyIJs!86>Kyev^7o3AH}$o1yR*x!#q
zf&N_sZI+)rHpB{vUAn9-nm3Fg>0SEaKm*U(Io`&1#a=w)%H{xonI}txxO=l{M@gM1
z(Pdk5Prq$c+IpdJt7}(-vGTIjN-B^_VPXL>e=;@!siI6!z3Z1FmlxO9B|p&Iv>G#+
z$^k`>R*e+f(s$z(%CV~+6i5H>xc)<@!fU<4h0_`XeN|1O>Pn68CdWPlq;+E^nBtRv
zTeU+9A&VMUi-8iLfTKdbS#1P7XKf0!z$3bSFaw86ejP>L9dVu6)(mD1md!y;h@R5%
z6~SPI*~YpZdlt%A3a`nLw(Z>rkkyOTUhm2xVq)(SK7$$WhD5_<=~2FgWOVH_Wy^m}
zN0|(Z7E^IChvdP@LF(2*S;=E23D;7L)v&ce<0}86%P+VR^p|%Sd4QmPmFv9Wzsl2h
z(?Akry)wCtxzGzN$cjjPhYl8Fwh&*3a)|z4F11s}2<0n(`gmQaChm(_UB@W?Y-k?_
z$ly*_`dJiTq)A`Cm8<#twy4>}KS(=_dH5T!HD(Zjs*z_}1|bNHz%O|Guu
zD9i&yJ#Vq(f+5TaR$AH&sQn#`S!qn8h5ehS`Ro2RN*WdY#IprjNA4AKBWyl8*dCi4zKntgcU#fohyadc
zR!oXx&fN^U#Dts!ho3M|Uw)qNrQ+Y0=P}UrUezCwYlH-XsZrG!85~1Upqm5M%IEtF
zloM^gI2w-=o$9hrl8RtjWfYrF=&){#pTmJN)JV{WYxXde=z8OnAZgd$G5(yLuc%>4
zR~46laHY-^#u$%s^gOU)iEll+Wb}@zrNaSNVk;xZtyEZh-M#@7>7VK7F;
zmd>cT7MS7lupa8@H}Rr|<(k0yoSpIxr~7GB7G?g>@@*#gu#O5?U-+b#
zH&_nCKSn#oeC)H7zh2op@lu3p8_eWJQVujc&Zz
zmvn27kNaTGdhy7N&`ioV2diXFrM$1VW2Rb2^^W)x=%AZOqW80z6=iZ`M9Is^rhg(q
zpU}o&&=HxICu&LU+U}MQgngaa3#h4D7noQNz&lR5V0p=ePK^%fQ44CFsic>q)5ew8
zc~<~ZBI2tB);O4aSm&nK1ZuL%;oHzH#*c^Uk~S$3q4+@j`>Na(erDirN&Ri$YDHbz
z_};h0CKv@-#Uyt*^2Mxl0Z
zwzrFa?czq!oCuO&<8RYhmupn$z-)w+3eg#rnm82rDd7}IM1fK{rN(V~mAKR0&p1ve
zY&mtTPihqJ*_!tPEUEiPfYuG0&i-LCy^TBRIvfpp`2oqbTM9B7AJl!!3
zYI?k^7pi7fHp#O*ElY^+rH_2fLxivr97z6jz}CFs{F>K=M_a-1^1~Ai;_p|~ob(if
zcMrzd(?jH4QT9IFG;4DsE@XXgIr>N~}euJLs^W>#*oSyzGOdl;!77E#BU_
z8(d%cywPBDXpWdomfr7k$%0L|&%?S(JX?;jfWmO#HT0FEyQr2*J5}rlJq47X#J^AU
z69^t*kj9E#fr9rQlxvH4u-veQ!oFIW0r>ss&3nfRc)3d0EzzoLIlgXbP>e9RoOD$s
z8I=DKB+uF-Ybr}QMthL@w6QxF{fe%K@`7|`Jc$~3^e*kF(Xj*1FVPAaYe)XnliUyN=kRAABdsI6GnU+E#Q*AC%Z04y0ldNLK%
zZ!8Xg1OwBOj1jRhc2?!*kJ*C`phi|4)#pw*8DoAY>ppseM$fd4i%U6
z-{PW84E!j2I$29-rJosf=;7B0J&*3k63aANo&1B#
zK`4boV;i-hbd-81yT71!lQ6&ds4Dx|mKlC=Z1Om5BOCB|jR;@)7O)H`Q1Tb2tjjLpEI1bmyro*M>KK$ikuGa&
z7NZk|sv=$Q8#RbJ2#bQQkZ-)!rO`gz{dtzjaBTo<-*rz7}GMP2fXU>-&^N|K&3%3;MP)Zw2&nSDLW5vR^193BP
zFKqAhh&A8ab(Sg_2A|gCO%iH=>=Gb?n^hV-m1=8G6FKOH36*ijSj1a;V<8+u@}L6Z
z(ZMk!^v{I19%KUwEzF{tU^`99PEitO5v70=aY55?h`2PvU$AVYVFj3_#M=tc!7A=n
z@g|75Yzwi$yF95yH&I1sz=8>bMl}`a^=X|;NgBQJQL0TSc0DZv1@i0$=F^RS6|}(uo5rMyd5TLF(};<_?eIn80-G`wwORY@WQI{-Dr^W!l<{Th!8P
zH=qA8EIobmj$ptTVQ4r`TN2t{7qwDm+_Wmi$@@;fJF`h
z|5_Jfy*LvJ^zYuNn|tFbx}X9jOQxLg;N={hCE>H+Xj~U43ar#ycQ>LZpXhPOGy^FU
zRBRSK1L~8Epa$Rk3KzK09Jz^Yw%T&vGMDggpXOx@Cs-w0F;=@|$|KMI%UywUg3$sP
zK)R9k-=xETu|JAO>CYv~BWrC2hn4{`23mFqIVM%K*MkRQCYx*1{$B4#uO`P3&?@tBZj&Ocr!V{al$N4tWmVQ
z`u0F30&{eS5iLgG>zbI)5*4RO3XHJ+lD!=bl4$rNdrZI?Q1w})zQU9}PApy5e+g_*
zWaa1A-?|o>sf!?wHltP)!}bTV&q`_3pd$onId4b69PR0G@ETc~de1oH7#bI`$@1zfT|
zbUKwvI8xxES
z0XD49)$@(_M`;YEoNB0)cC8>npiuj#q#lMK^2O|6vt*uMUy4tVdMJ8AG<3|3q=gRl
z%t$MvOA_-FX4xfNQxOLUQfG_M4tF#uxvywUWDSU0Wu3s;mY_O&t$0>(moxU%Ds_%t
zOBi%9hUxiC69dL{Hxv2L`sCct$(o4recvp7Q0RR7cQtRgaNfy+f#KU`+2^6F0(j-O
z7vdQ~+P^=(v4A&I;W!4mSNDA~v#V1`C4qlyjNgU~wV6vlqcUXXX{kX4g$VV24GvO%
zTrhri#bLjZa3K|OL#|X(Tz?aMU0+b2kL$R-aE^jW5(k$K9WqsoaG*_!D`B@Os01~q
zs!rOQ&~f>WcIHI%2**dALNgX!l6Tmb3d{AAjGkho`nr^KaqDkZtaI
zcjRA1feZ`>ba^?gx6nEQ%%lz?TUvR=2DI(cg#9=T!30z*BO5MtNe@=CXKtcRR2tIn
zF_fxKsl2Q*Z$h9YNmL!QSA$HED&z#!7&D2&P-Fd3`Qdz5+MXj04eGae!N?{DFTdWT
zp?y&FSl#qbjZ*=keM?i`MpiXdwC4wSR#+#U3~$Fivr8&}-UHQF$42H|MvgpDBu!+8
z-WM>;91bTwEs^I=@TQ>w-{JwA(YTK7DLJ4Kpwi3w1d4YnNe_qW>J)PdE`paC90Gap
z$t*WgFrVc2EQL-dZCyWX$2>;AN&)7T!i>=@VOl@c_feF;)mVZ-2kA=x%y|IDR?><<
z5dP#EIXPS{i*T+fd1h4}0XTqa=aN+MN>N2Yi^O7tQQlI6D|
zKv+^+7f~VJx)Jc#9{97Z@MwQP+7wzeG-*`F-VKmdid3(^1yh=`OK|8H!plYAg8Cvs
zqHc~A$vh;d#-Aw(kAf34{g#OZ0b9bX<8ltZ_^S^rNuT~?WqUfA5J47ok*+!<%ek%`
z*5baY1L6zLZbKu#jDAUGR&lBL&SCYqzH_FM~}K4{oi
zjy?4O|AX4KIA#09tB<75Uk~HLbeojImtV7xw*thG_|#k~D$mAj3h0^08uheR^wmd0
zhJ^1E@9=!p7Ms{r&61$J)d1`CvJCarcJh|XC);z`{3D6Q=E%!%HnAYK-x}X9IPYv~
z!HVS1X*WN=@t*6fcl!~Z`A7KD2?woN=_-Xh{i`zg^$+DxbF_{x$nUNS13$dtqCWbv
zvi0}%)z%8${*o-vaoT4bKxcKubv}V$7LKzR2MGgAkt@luy1rSlI_$sOULMStyjvTX
zl+Vge#e~I@|C|q?jBZ|)ufYM@SF>vZ<c&AiB^5uDd32u>UbE
z?(!*=2;#)8+Exe+RE(hoslFrQHX&y-BCE5fgX`8sc^$Lg*Lw&wuNsY4Y07D0=U`2|
z(kD_n912-2qg4Egne9Sh$DCkHKyaD_I>Za1C%e+e?(<^ZRuHvzRqOR*#L3BYih(oc
zRpnZGRbLCh1I?8Eyl0Bxcdx}P79CRQ>Or-$u5<{VS}3-93&<`zB{2ji57J4u6tpEAu6ZdrK@asSqKL`O
zt~`F{Cn88o5!11?Ul=_nTgK&UKfXn+i0uVL)y|-%+ut=xK$%n|R
zWuykFm&|2jGx(3UP4AmG&d%q5x9$vTy)l4#(3UZkO+YCoQ=T|=ZvC3gXU1sqa~YsJ
zxJXNvJPZpc2|B%qxWECSE4}q|ZR=DDZy>honUBr{pxwU&C*BDHS!n0OjT;tnS3S7p
z*yCh4?K>7YwNZDjF1l6!vooTp?fT1#^UtMSxfXqsdSU_u`#mE}NlwiA?yP9|OJy7^
z(hN?@X%$$G7c#ngRa-e(IWUVG&g>`cfK(9Y)%2K$UxFsWfK;?A_}}#cW^&t;tiDG6
zV7*&rmkPlPzW`U83vHU{YpI_)Nq{JhLmGgwr8^4O)KG@{0FCH>M}c`;+EQktcXUH%
zg60`xk_24=5vI9CW@0M!6|u1ZIpjlSCVphZzyMlLoCH(vC4bw~FJ+iRPnE(90fXC-
zHS|vPl^_nBdxh1*UXbAUlwi*m$Rv-*)gN`)i5G*XX0nfV^rVmP_)S=E`W
z0Mcg}?3nvl_d|7*L>kdqd#P&C`2aM&N{quAMskDfH2T^QYse*`!iZiB{4c#Tf_=Q&
z)I9|rM2{|w>uyH1tUt{0#m)5=(p#KOAO!6(!~iD46$I0X7R?G&aQGvh&_9jw+RUXZ
z2G^}ZbhusA^79$L*NDcuuLJ;#m!_=uNAynJS
ze^&t`<1e#mvi7?YD8nID`c@HUNK3094Zcf7rmf{2?W&wfPy(yIdvcn1Z904?kB}uJ!Z!Z1N}gvudkMiC3_3S5Xcpg)Idk
zoy{XMg6|kvjCokI3A*mAMVuO1y~}EPM6K*_H)z4EVR`Ao@7t|M1+b|Mj2KPj7V2Ew_6@BKE)6-*q^j=#*GWbPW195eE4c@G126jhscJ%^Im7
z;pga}-u6%Ez|HQ5Be2;|>n#_)R&ir-dPbOgV^gSSYbz
zA|k_%AN)1Cr=Pv-0~7BwM~Gmz+WKLKAqH|kzV_yD$K*hH#-zO|U2frHcI%FKmB
zfupze=vg6|9T`K@#GIdtQz1EtA6s&wM7zHO(IFa>B|B47TAtk=o7GT^9_o?!IsdMM
z2$pnINp(;_%^FG{1cd_}+0^RJi{H;U^>=<{;DZ9a3V)r%)H8-_q5*B}mt+IN?tk)+
zKGMyKqEX^blFyqPy-IbS(T;)YCda!cY1!tyR{%At*s>VVu{)N5-b}zuvUYq|2q&?0
zBrXE5H7^j7#Q}#_iTm+Q*JOiAD3X%l_2^pEt<}X
zit>kfQ%jOs%0fKuWyk5^;h*+ojNU2hxrSbN>rM$~PF$omW?Ix}v*y&ybCmj9`sRxo
zr+zAYHHa!GxxcGm9&*Fa?|7qw$SWkgYs}b)HCEh}$B$^XZAvv{pB=-nU+0@=!|m|s
z#{Q+RdPH91ON+1bRQ)%IBNs9fwr7cK+vd3CMedREEVileTam=-HYtA}#15yv0B00m
zR5>%3bu*E#-6L9){mR7sP~{PNadNBs5xwK(BYDX7F(&Lh-q`=*-Nx&u-6y6eoiI~_
z*BT(oY4P)yq_RwlLD*e?=XRyvTbX?vddklEBi$KzS1KI5I~d^_eENNBQn>bujyGS)
z)}FcKV4vUX(7T^w2fuwn{pFI_A;0s)Ud&lob%H;>3_zrxUtH7Qen45@V#3&rTh?>4
zMok+139$oi4<@U(c4otDiEGGBi@`knuw}madJPHOn1y2SJn{Q@Gg?iDn}hEHvW!QG
z;XQLSK<3F-cdBIztD$M
zVm-(_her~5dT*KS+cfI9+x2|{8e$c&eH@ao(ES%EYuWDsrpYqay)ldn5;He}L%bA<
zqeDRivUs!@3LC$V_x8J
zOqFEE5qdJ8prMAh5|>`xeD&F+X+tkT1CmJnQ*mBCNRY+woOoezM35Wj7;iw16k3>Fw9FB%bhc@nON#D0nz|wWd5L9;-
zpK6!j7Y|r#sfr*5MiXDbp0{Sl1%$6A7bh8mW()2;)AeGYdu+~*ZRqs+zm`ZRQlpvw
z!ZW)E(dZ;8rk@Ex=e31Y)sJ&VEWINP(UdNrR@n{07M{fD6K6w1t&v9UopK-E27N4)}!dn@MDE=#O!W7r|viUp_Bb>0a-Qx$644
z@6VrHZ!N(6EnM=n*@F3bOABp2a6nqTmiW9eU@!4tmM=v2U`oz`m0d&YW*@PDMTaZu
zrCs~L(2Em_9YTNXo|&y^3}*f8Wr1nmUJ)Hp#XUCJjK#4qSFd++^wdtclcR5E$dDg{
zGO2NIp7pxq6@=?vt4*tpTn>{z6M{b+LhbE7XH+V=;T$rH(UtI{fu2=M&58AXC>v8D
ztU%Y9fSmk-3^IE1OmGaFZmx2!m0{Js~mpZQfpk_&S7*kPWA3ipH)3GR2;F
z_(9DNQbQ$61HxBQ5L}@k8<2N6%LmhT;qFn78+WqZ(7ubwG{5oPgR-om1@vKZn0&DP
zV^J($1a=6zOMTKx1E$3Vm=6BOeTZad2Fbm*psC8)6;
zz(IpFv9mX(cE>MdY6b3r;N(^wP-0_NcMDQ!D
zrJ*9e3rjF^4;aZ@crx`waGUfT8j_Kd%?9ljug3^l)CV(__H|YZ&J?@qA}q)>!GexUbwW7%G9Pf8@_3@<%euWJuy1
zYgKG{R(VK3F0*qA&pX8+yU(Qi0xXnGo~|nuN#01%FEph0R{N8xtZ$!oaNeX}AN0QI
zz6cF@xLz-Lh>SQpgHH-O=Pj1V?^t6oE>VC~rMlX~++0uJ|6Q#&(F`$u0ANQ5%R+v|RDYj52LaV4
z2L!u~q(w19ZbAnzL#=MzXb&_x?KLd1trnfG-EM|nXnFj^6s>k9@PsFkan4@0N*Av3
z^f#SB(Juy5LZVt43+#WVO|Q%L0$Jn8EClzkCHfHOFNai6Mc>R?BkNni@NrY*2*yVV
zVS?J-3~KC{B_K{}s;%SJDVbsi)q8@j2Sp1-hesY(6aJ?X;IcU9qZ;y<>4}b8vVf4X
z2S|l8=Xh(^oCR981aP8vU~PfLw6GL*d-co~4Ia
z%GV0-T~3EZqk_s`ug5N4?a+{6Tp7}`Q?-uGIL`V#LKF8*6vtJkWZbcmbZeK>H%-S0XD|HeQeO}5HyW1-mF+Ae
z**ea<12WEkm2j5Hj8I6hA1k;48r`lX7UXa_k?_Y+XAHX_-w&>fe4WONr2}7vwLgVF
zO+NgP4gYf--{Jga(aKWdjnn>juEoX)}n3YeiPs_c7bbV&!5fakhQTgc=
zcpc_Kj=L3!)H4EzJeIwAu~KBFKqZ#NQMrFRW3GQEp7wlcj?w2U>q%`MIA}z5
z_7j@r5OKF!c#lGRL63%$aOxrU2Sr+a_6r$IN75;SYRL-i8nltFBaAUoP2lav@ugXC
zAlH&p7V}#u1%)XV$d-ZS5g=7uI`e4)A{IDq@_oc4;~$&O?wveIxby@){a~n{6I6D{-3@^U(Rub7@pKbb2MvAZ
zKMd@l$9&sPfFedbk;1~?Atm`44&LBh9gBzY6D8&NihLBlE=vDx*VrFsk)f~c6pMbf
z`Y&_(`k!Wt&-Hx0hx6V0!QszC_c#83WPMI9`t$gUEuR-Q(~DY5@L~ls^XW;~j<%<2?MnBR)vSwR5eR&-3qip1H`1
z*pW)k2FLFQx9*~6Ki5Z@#p4!=dFA3}CJ8zxItL7ocTlQ8McfX@I$4W@2f($c_Xz7Q
zchL{e87^dU@?rYFf7M}YICR`e7Op8*w&pO%g-T;Js;Z2nm$gM78Zo@QxJ
zKcD}@Qb;9zz=xO$H7~42`Ud#WxUiA5(=cg0bawm=ykrI7rRHdOC<891%VrAj_Ah8*
zA>kurtth3B9WW!dz7G#?mY54ldSmwNc{fYxkg!LKbbOc=;Ts=;^nMA7F-Zj=(#pAy
z%lVDjGKJ>=l+ufvlUX%+iJn&u6~MZn=8utH4Y(L6COuw~LoY*yP_glV-xQm3Sj_j-
zxeK4MW8#&0BBoHK9vonSW)T1A%7th_F;333+i!DXz8s{z{0sZ_vu7$f<4xW4wLjNX
z`jH3iXFRVf#~pr|rjxLlzgjsEbLXWGQGZJw9E!V)V%1CzEGCUJ1izsut=s#fYK06i
zT~ukmqqPSLg}@jcdCgi4
zp>tY5RnuN|3zE$9=X&iH3I_=)<1ilg-~=jbetef^a$*nyndbiMLs;+pTH!2NjWDfc5%1x`{nS?
zfZvaThl`Ipy%LcZe-9+h*9Jo_<_~%ez+c{(EO|BQ6YBCcmzG+|3J(W4c~PwtMMK-5
z-`P!jJ696&j)3y>8pesK)fYVTY*;k-PNN4`%0dNhiYgztHzy!Q4Q$Mt2ET9|`G@Av
zJ;%3A-l!dS@W6$QTX;56hw<#*4R9MTyaf-HOZm#|X)u%;;4F>4T3yGYWnDS_nF6?H
zECFz`iHn4#k<79XyDK=qr7%^Ln`+z{*vccs+28*x$i!Fd1$jSf
zD2JItFUeU}=*V}5^2aIOZA(j;jC?04e5t8jHi}MjDmpG*Xvu+@^+iCAzCU8BM%8($
zVy*C(RHMAJsPJlUSU*;0va~TFu@(}pz+t>3!W$RSF_gH0Y
z-+fd+Mdx#}-eL;2W)W1w1lrp3XO0x_{L+4JBf8*6pp`LHRpB(uk_*2#CC-?OP+wc=
zr&9(rf#ux*(~fq~7rYD)
zd2vs3ZQJ4mevNc%s?Pv^QxD3UX8pbj2efGw7MrC;BT*BBH8`V5O+`CfX#6&#fpzoo
zSH91-m8Krl2y$sBLY6^1yNw5`+;6S~Ne>Y1KHqYnYwzSq7^>joan81Q8U>F%=KBLh
z72WY-)rZwHyBG@oHhX;R|K()K%2N7G
z(B1s+)m~u@tXW>1*=D$KV`FWuoI1*5aA$0`e*gYdlJ5fKYI*Iz1XKEn1C)Il=j4BS
z?7i^F_?>m(EGIZb&9G4(^Tb1SsmEg!XD6xGGGm!!1D8tXwaQ`eh;`e8t{3ElVzJT`
zR9ZS&RQl^)GcWz_Rw3g5>7080yzF`rJ>!#neLBCko#X!jENP@k#Alz$>@ZlIW`o_Rv1xUnq)j(%*3Cc`{iG3n!-PRQWzuUb`V;!;BQq!PsLpPh
zGQn?}4Q|u4MPqcE&2F>CqBXjV&Y;uk*4y#=ZiIIe(1{F=Yz~8oJRVF0{4rNl@}#n1
zH6K@tu}m&ZC6;AcX3hs&3sow>%$0;xE(U0FWr>yXR9=*eB>w5#+6}gjUj(99V;6+j
zpWDF^zO=E{t~A;uwu>6y{-?r6B)N-3r#D;a&sCuwyOslOq&8cD->f5ibt|+p8xwqD
zrkqQc)NHkoDk@?wjk}OsQEyUqUvxKB&2dp_JpfwEs&zHjQ1eZg(?YRbEO*Pb9&kxX
zygdhBNu@u49ofcxft7QsEr@fIb*QqEBlRXxkvSKS>Z1?nmTqSrcr06=8!m5@8qI8X
zdE@>^Ht+ex>HF?JdC$E|=XRFQ?Jl1?zkL48^7&IMXQA!Y^P8*ZH&)NAaKTHGojg5@
z7I5T=dkZ#myT7{GUES=!OP=4MYb8DV{BJu$wLMU1LoBx6N`?LxP@P<{k^~|P#W)xK
zuDJ50M6oPFWq6LN%$BibTWz(|RlB`he?VBAUnnoH)R&fPaFl$Z&R|&V4}j6~>|CXX
zB+(-#j%RhK-M?BNAF}*``2Sfh{t?~6twxKu3rNI5Aqot^3Bm^E0mOc;&{Ipu$aI&?
z9p@u7PS60K%F1_uFtnvE9z|d$p9t82U!0X_l}<`+r0`IooyBRCwHtD#DvUv?G>D84
zMK
zG`USCm%;2ZA&G;M?vTqH@%W>@K$7a%<8n~WM3h1Vf5&Mxq!yzJQE?itTT);|r&ssg*Xr^23
zELb@^N8^>;Nb;IW=Tr-_-XLDdBUKS*6XL79+ULlVZ&!RW~=^T`tWyw+$cVQ=SJVncFBse}$
z4~iBdjEuxM1nRLjWQjYCK2GL75$wbHqhFz$!3*Nm@Z!W`<|~txIG&DkIDa!8y50`j
zbepDnMjsO&qvWQNGI%9jsM6}`d^rI`@^8`c1Wq>R&(LJIUy!{ozVz%1FFqTMyFxLl
z7`J(}PQQ_r^4Oeyo7rhJyUfVWI-CB4adO(KpSBujtY(-;I7bN1anh(cuA4flnS`A@
zrk#e4>(J30*J@AbHSm>3H50IwQzm+f&W_-1);KI$r*+0*nKWz6KAR3d#bZGp=d6UO
zbOoJgJu$Z*89eTZOCg$J2cYEY4hWPKzG!-<)EXdh=c}z^tzE6P
zYlUhlTgs{xRVioTB2&d|s(?;5kVqsIMJ^QLYSt?xg0h&*D{?t67E}=oEoC6iO0kqB
zm9uc8WJoJ{NUas2T%EjXrCot)-CA={Z_hS6bM5Y8wZB{gD*;M^BNHF89D|at*trRm
z?ZI-77o3x$T&j;gpj*1xg0V**c_N;vls9)z-v8+Nd+s}b&%NtA_pDslUB0mIB`<8P
zT!fKiUh=})^4Z0)qg+MSK08mKJWrt9Jd5Z(1R`N47gw8)JoZcch~8WtMzYaS>umrC
zluUt=Mf?|Fh=i0p{v*(SfLSiwEz(^jPg`MumAO3Oa^x;6Vy!MWTN(Ju4%>;6ukwbM
z1TpBv#`6221nt-elnhC@76wD)lXwV$dO&`)s9@b7DoS8YK(Hz!l4^2%R
z)etd{%uJy@ssTo)CXLh67VV^IX4|)m{yn3V?!!8c`Puk;}RmY
z-l!LO95yp1`^9uHl?~=fiL{Cg9#cz^LKUoJI|NtZD@C;+X4EA4N)k+EB31bQ1G3JMGErp
zlEqx3AgC!p&7>;DWL}MCQbIw+T`{KwlCgj+CklnAs(J*$77cmCL@cie`7Hb#CiVO-i+OV_$`b9MXPN6y~&%gYZwxOw*jD;KXUpWj(J
ze}3uw+0~0@Rxh4npxl7SQJ!00J-4!cc4^}bN8}=e&epkkMwV
zx;Klcn`?HFwMlGQ8vb8MYB5o$h_H=vHUKiR%~InxE0c>c(I%>hDQNK&s<@~~@Rblx
z;;@J9E@C(hSuQMAn874g!c;CSz*?63bOroUk9o;)u0C5=?JE`zpQ$lX9Ej-#J}69n(Zpac^cDaE7f8W0bDJ_kS~grB#p(e!pVF&rsPB5qm=eQVv2;PrLtjKY!k8hBe0Mb
zkkJ*eI{j9=*Q_y3>a8wsHaZIN@t}`6b0gh9Ql2ZWX
zT~kvBriqUSCXOGPoV@$#gEL6sa7YQIa+Z-v8Z2Nr{lJED4#S
zkjzH;r*mt!AAk}qd?iI@W+xdaX%ROs65=I6{|8Xc(b#39SFLxdqbD{?c{YKQE~dpo
zDpSd)%Y{%%ieyq!sSwMi-LY^&$t2ZmOjQG^lr0kRNn$(?!>l-BQFlDzNkpUBl#o{i
z;-(_xSesX*0^2i*rE;(`Tg%bZP^(mGmn-dZwNq*I;VY?LvbRWcII~O5IpFdpP|mKl
zzFz>&HVtB+gqLh{Xabb&#oLPB7w)+?R%k3;dhqmpzux`juTS26@A9Q9D;F;>U%0q(
z@xsc*bN?Nb)H%1Zb_N!51WIbpEx=B$p6t__oVC{ZOY3-XPDviO$CLyg@izm3dSco~
zMlv7CZ0+cw?8x}gl
zQlDjTL~oqTttHFg{2HiaC&!>14^TqK~6EK1O9
z5g|^-Q$SdBxF|}qIv%o+%@k$!o{A2Di6G3oVIE3DsyQFl~3
zjX-@|t2sOkX%C~L)o?G#1yCNGoH{%;eF*LJ3_3@qXO7Njj%jC*$B*jZDCu<&-e;^P
zn)$JsU@(#2&0ebotlS4B1V_n}xIg9#Cj-%hFDd#`R5L^=DU%Q8%25tVR%MA`C4iO4
z;OTsvW_3zJx_Db-lssi~3&}fUK8}f5>u^&^73N@Ni(QEul;olcN=n?7I-k0!7n)tl
zt@&D>C2l2E%EU5aLP^WzqEN_r5;0FAktpONO4bpL!bnCGC6vj8vx+?$vxLH4QHths
zk(}yGCTy{YJsRg
z<|_e5n93f_;VjTq#+t(#?Id)2D{~@BO&M;Tdf?IX_dj&u{s-4C-?y@}yL#yoa`)<`
zbE`Y#DAz8XUcI!nc7X;cIW7UpjdSEEIVCsFEkL{~h&jqWUU_k)$uIWFC<%i`l!Wky
z!NC_7J^0H>DZxxGEN6pqHk?u-Xd!@--vubSzGo$p_)PG9D?su==_<2W->h{p2~bnqxx33PHSav(xDh!!VsEJC=86F6k?qti7B)|e~P8qJUAIvJdX
zlL1gTO`wpON?=jsl4veS6l;=HCzm?$OEM$rmePJf
z^5Z#yu+{B1dV^M97>FbzY4e!v9*e_gH`$F^lg3~*8toRX*)*ZmoiJ!7jav9YAn%Aq
zb7V$)WLkf4T61uE=C0|P1Jg4Hr>5_koPw!5G^IH>IelOPteiPCH3OugJ*L$i)#%V3
z(ayk8P8wlO4L~GVskK>VEc$8FjL~he`s}<|-Q+ZxoJMEB!A+$<>WL-;;h0;>hVbW0
zvpS_PSjhu;sh-Hw<$7Q$=AhK-S2-w~J(@4>&UdpgeK|Q@%t(c_n9m?YyW%j3=|o7j1Rn#bEdB}6x&%S*_gf;7KqiwYmLiJklT#i+bjA}9&W~gzp{Ph@Hp5d<
zv(2t8YG<#F$vp3C=m&9KS93t#wLh_=MR>QE9N!goHLQ*D_Rw9Dz2O@=3
z0CzbtMSRRum$skEb1@|sQ}c1Kl27j-fHP21=msC><`KY2^9yLpvkTS!Y=w_e!cIcm
zPBz#!YhWd>qvWO%;?etdLCN+i=Z>;ITSTlzTbV7EhXp_fv;trFXd_xckgO&8bbTth
zK(p9XLWJical^8W;w^KI;2L!xp$XuUbYKefL>`|yq?v|}=ycFgy&mmht@gOlc-&-~FzDbYCk$G&
zI=khBPGfS}K}oaAZ1>r9RvkL7pv&QRc%n{!+!K+4QPGRPV{!zFFIxzKl}agGtR~BK
z3BNLw0V{K0WjtGymC|jk_2zZv5D}9h@@7z0TV)7{r1gtkT89Hx0+cL$(*L;2
zzn?uOnu0M$T=L3kk0e9BRLYS^m_i{y6aA2)#EZpf9)4Se3H8fzC@Vp+d=}hH6%{_u
z!z5LHxCh~%F
zbhyY!?k{j0=Wb~98U6FOd@Bvi0d@%8#crB*32I3^gX3VnofgV5cs-6tv@n=t8@n_y
zLbX9`d=o7rW)8S4w6nkvfCZ4H>mr_o^C6|3hC{@05Gv0Qh7**!oNr~aHM$-_3Un*Q
zGyAh3UgXOOm`b`1BAdNQWqqI|
zB&B_E!G$MygJvXdzG|D|6`XHB@Ysc4JbdXF53gVS`O5CS%R5(=b}p@6x(HCN
z?VerRJq1w0P6CwFUR+;0zXDLMU07PbxV(B{@#OinjnfP3r-umLY*RG~-Tk=|yTGyv
zI|)kC2Bvkyiv$uh{$IodH#(ps1U^E@;6lnDO}b+Ok_v4hn3Vl6mADI5a$@4c7E_^6
z)Rn>4Rv|fNCEu3|faCVCHz>nPf|83%^`+$o5D8EYSa}c^D-r@Ui{qIbPRZ|y`9A?l
znvH3v+0}1o$Dn;yrfBVUpCUQ10tOKr_orwe&OSQWra~WD(@j&@cp~+|FYemV^5+6f
zpc{?=YUqpuwSw$iNoL_I;R@mYN-?>dh^t|-7>g;PWIiGkqG;tZa<>r92DpXftQ@}-
zIuRuZD@t%=9OSq}2c{BF!4JZF;K%t15cilgB-)f=GbL7S&L+xfu3W0gksJ)>O`Bq{
z0m{(?pHhgxbMdj5Y%a)$Cgrp*DY@f<^ZuV-dH#iG0}-1iU^F}RR=3gSF+mQW+3tml
z(@yDUKuLqmHiOV@AV)c2B)|cVM|FCd*VarQ){H5e$uVFztH6m=z~U_$aC
zI;r>$$OluZA060d{@tKf#avZR=LJ~>E9oN9w|x8WpadV$B7>8cMDA|VvK+oR2Z-EH
z-*A^T@UhXQ2^@aftFQn5?RVcEjY}3&Qa&x_vO-Sri=s~u;%d$jOIX9er9vq?BZbl#
zTO_V^gwQscMD)oye@X!v&EYT{r8AifWYWQG7SIGDqpBLq
zQAL*W89`0Sg>1H}s`Xr|8=!DTLdM^PSQo_Bv3M4h$zfUB5{L~NFn%gjV4_{+UO39M632HI2PKFJQ&}uaz$NpQSwIkul32M=rShOz
zQlCxZz*O>8Cs=7rRhMVSR+=71j=}_{Qbg{|5d0UZi{TM9a`ZBYEb$vL{nK>
zenU#(Ytx%xqm%xS(;KjR12&i6>G0ZgW{ttFGdOfcTC#1?J8i($G3_)fel(uY>mV3F
z0B+1XK6P_&+5p`(slD?AKsmw1aS3kTd14Y7{NS{P93_DjsMT{F)fu28TGLUm(rB8%
z53(30%zBtgWbjF&*5r1W-8cJ6ng<6r`0l^SbR?dl)s0m9Rt%@rAUZIWBVWmW_iQ04
zW^b#GvQYn?k{pzrm26Xt;>`;g8@dbxb
zD2L0<+2!`^a*I|suJk}gE>Lp3s}Sz;&*#=|7k>WOrT_Y`jl1t%-hE*0@;$4&msco25GNC`5a$
z;-Qc=7;%fKsFaQgGF>Attt7KKAxn$Ik`&s?a=D^ZYq@r(%rbZxF`S7iC}&|R*%&3n
zW^(eK9!{%qL;{+en>>1RP(rnvuB!Ua-imzwnkvB4#ol=IKJfzp;$H$SA#-63>xAoaW#}=paeAWYIp_w2)rgTK1Uv>
zB!GyHP>O+)`L2@dX2lAxF-poc%G!A6G^@kF3Zw#*3LC6UH)WBnWfZESR7;1|o5m>F
z6}xE8jtyPMi6E>DBCQ0$N`&r6!XAv-;)4InFTV^$-M*mR2{-S$j{B}j5^N(J<((%c?qa(0IMay{C^;+t
zkDxrJx58{5GXRl>6DFO;VIfvpO%O7;#bW~{VJB@~8{bXC9ddcXE`QV&N_fFaK3J)i
zB5H}IGV%LzQ;A=nz9dRwDo0n-zvUY%c>EreFp?aUd>0Hh-(6_*;2-}%&3<+4H@PQ8
z=w3g$mMQ_13MeTT6(OHVD5<2HiKVlVbjB-+VO6z7lLmjpC1gyI_>|kH4@NAZs3{n+
z$C9q3Y>&x0Z)D2hH~7PjxQHV(j3TEzqHKvo^}ZlriidDA5J`42pHCJ`$x2N|^sGSYW2F2HAmrF1l{BvM(bwFE1v0uLFyoT=8-T7xEM06yRna2(E6
zK}ob6lq`31Ygy^`YMmaf^@fY&?($|w$v}DQ`%%I$0(@McMviT40Z^8@u!l7A$VV{2
zL69!0hTz~pA1WJSvozoo7a}l@^FHt3Oz!x`?vK%vyySSUMs1{|VjQd#3vsa+j%K~d
zd@!DIM`TAL>xqMyiZ8DEBUz7FhzNNavWzJ~Ad+)4U85J|KLRa_I00KVb3|;hw
z)^tnmnBYX{o?q;{ycRf0f5_npxKDt
zd2qg&m3K}~B6{C3L0u#;(jRq4#Q>F{D?zmsRtglo(`tx&NeHaWSL96L
zHpeK5kL4Dv$r;apgMh4Xk~YEs6VY-b$)Mlf}T-m*}x_f@@(wX&3C)akifk=RoX?^1YOeO5(GEwpjLN`%zd8P)+
z4j?!#*whNnM<>E~CzTU2sF#mKl|Urx6-$vw)+eaGSlR_#MpMp^
zFG=y!GJh-shpBLSp$Nck~oMYP6@p_D#@hxxj%rw
z06I$USvcP+y==S~OH}>=loIU_LAiidvm$iEZAlq_LUchiIw`utaR*NI1#O_D$8R%O
zrcHJOKxh^%cmOm@YJ9cyAn(MyJsoqP0W5h!b`oDF=jpxv6EtHor1OEBA@I})
z7{n#NoQkNqXbz6D2uCTD^2t(OC>7;uHC3x+t2wof=v^*xM>%YC=GzpyS6Z{H?fJFN
z!de%gTv#1d1@SRT#BJbmVPh8PL}&B?-O}ys{l8eh%t3i&br(YJ1|=^7loY)$Y^}jg
zUffzczriTEwsmQ3?cCzlh2{0L3&`LbXXaK<4i`7N_x^n6v(GX{6LVl?nTp0iy&lpxBO`E06W=$bZgV!ZGLrCv01Y~s
z(d;(4NWhT;3moJc(-Y9)a0E2@5q<)Amr%p7lW1AQ_9Jm8RKJ+>C$pYN%9+S`BBC=Q
zIMD_rcO>n@nPMpx&qu&nU=h^D>j0X3N(Z7;&SrJ^7XVT}XCf1pE?GY3vg9h{g36JaWUcH#tt
z&RFC(Cua^$8xG7E4{6O@hjo@wM{j@*YIR^Geh@M^O@*8FTBjB6Qt!5F9WaWGS4&ADP06AK`p5
z_K0AQh~{8iABY=*i78i53j+G0lg_||BQWg_YrIjklg{9bC!+Pmj3L1gOrnJ>QOPZ-
zP9f_{=RIN?+1wJ2n*sqVn*?_y6J80vNQ|hNxSEzqxm2Z)sj-nt_}`nhVnYTeO0IR8
zhGWgG^ygOxXhBT4OaA%X+HL*rU#wofe`WXXmCILH=)Smm`TRQR+{UF-2;J)!x1cqc
z$_vX|muMyj(R<_K^4j^u)$>$j&Z~m{^4C9|Jim(EUF)i)My60p<*Tx+Mi9C|N#yRN
z?29H{!Kf_|v4&!Hx8L9i7;S#7-LJEI_4p35`Sp&F+2%J}-3F6GqqChbJEvVfz1^*G
zdUbdfgjWdAPBEUS7>r3FL5hi~xSUC*6d|1#l~O8K$y6IzV6N3GbZ5)M1w!OJ1LfR8
zo!d#yN{DY-N(=w{<#w;icL`_!nq7XirCYyfXbP5)?XRQ2KX&0FnN?)-+W9U`bJGas
zeg@}bmkO)S;f@lV8v9Bd;V8UWKqohSN+Xr72ngDlsw5N==}J;8Nbz(eraFTem)a@2
z1-D#Jg_Ll-;0?;|Ecz5@U18A@5?n#S9u%z6lq;$FQk7UF?N8>2n0RqePpr^}=RhPI
znvCP;a*l(2fFM|j4t^u_({%w<<)GxhCg6w;pRGclwjFBH{zFi*^8KVP)lpVzsX_^6
zC6>wt07tZZe<0XNn969F%)0VAX@~-mu*lwTF`axadn~
z!&1t}w}GMk4%kTLJ}Yl)jFJyc()yfc5fPPBl7TW`ZIkNVBEJ9*Qwev;QMSs(CJ{DQ
zDZKpZE9HR8k*%nPe_E=Ky3jvNAZ)C<3*7;-T
zgP7B99E^dIAm)^d`Z|9cErcbAd7EA1>m2}-8(@oX`HxGkw+uremNK{~eZ%xAKi&V0gTJE1cjHdv0@-O~<_7HkDK5!C}RS193$O2}ssL5@LE
zCZ0knD2hle_^(%OW`RF|vOiY=9|205`)28T%u1>jLJMdP%We3|9#~1@=maQR-6H>p
zZs8_3*wwgT3|k{(2wcKl^5_asmgvfebWsPjnL@wJw%x^Pp^TqX6^P_a1c11|Lpwe=
z#%QJ{rU12aGE+-sYB((@m16B1kr
zWY!%|`NFa@B0Iv8J(_kU3n8f#4@y36At~VR&w3|IQQYO;HrL6F12{klvy8i9IgYo4
zM^iOPWmXywanWgP_YIkCI}|U)0L{_I1W@Km0xh&+%dNP*0w|NxD0k!kU?}GJ!yi8H
z^ef&VLWfmrp3+-qSQU;DPR(F9BI-^UrjKhUPtb^=;fNkto5gKC**$I{e*ntEQySRG
z0~3sulfdHCol{eHO=@W#d;*%LgH(d9=N6J&q|WjKM+qI#8;7jCLJB=?Phaac?Y17ePxaA@Y(%<|}ElEGiY^xEy^vw{+u_
z$
z#s!ZcLe_9ZABMZL
zE*NvGw8p7DTdMbR)lN2FO=Svv2dN0WBq$k`z3`F{T%^M@ZE+qq*^lZihcxD6uBiLf
zPd@r$Z|~!8uYLIKjd%Zk-d-KnKzW?bb{7SO9
z)QM(&;iLmG+!r^2l~6qAPnGF)qG}kX60FQ3P_wJ(P>5zR98Qzo03#sy2!NtPrV>_>
zO}o<@YmFY|B!#0y2Z#hHfy+cW{tqj2GDzHP4L>dE&xOai8yrapo>0W*4VrMCFKBc5
zXqwyUvpc-_%Q&I6Xbd)^)@r2n*B0ZHNsq*RRHr+pHy+cQI2Jh{A?_>r5rFdG6eu}$
z=)?@#gHw|SCMOQh%$zVd4ov9|P64CZL&vmtotU|6YUZHE#5JZQlL;*jGJ~l5IF=0$t}vN(JR~5R_y)B$2NK
zG-=zx@@>^oj%U5OsYHjf5;WwslU$g%t9LQGJzLN4c%
zl5mcAf0kg#8cBFliZhwk`y$3b+#ZuGQJKZ<5Rcg0IqE$LjVnCm_D{Ke)4rG{kkAB@
zT3-Tu)OsQYKP7bJbRd$E6weLm{83XR;Sf@8IqOYlJSlXjE*+5{1{2Vvy)#(!&NZvK
zdMV#5SGx7aY^ycj?$BzS%>A+M1nmmKw{ut%z?tQE(=*s$)%bQm(0+Ab6
zF0AjIp#jRB?e!gm?v3r8&8>?Rx_Rz~wqYvIFY@)>OPigYyH9`i`6rzL_(D}R$lci@
zZ5$6F8DB`W1(N1y%IO#FLD`wi
zg``3}q6DOJBEbT9ss;kW%u>?Fn_;58Hn`IS1c6Zqztk9%bfuk}9A&0O6FxHA(Gs5t
zzB~ZU(Z|FlbL1Sm6jxdekB25{vRm-P60QghX4`R|&8fFJO`xRJWi~rZHXm(5F{PWH
zq^*676GqxZ@`TB7R8JhFLh+j@3E?gm$K~N^&A~~{p=r|zz59+6)?<1vz7!hsr%qV>
zI#2YjN!_7I-N8x2!71}Wt&!_6{s46#8oegEwV6F&O(uRY8CQW?*4}lVt1S@$5tYmO3H~Zk@
z_o{bB<>h6*KTs|I(61kQ(lRX2Kc88i_fhF}zn@fbz9HhR`i($Ula_
zM}%meuTR+hFprbqCJjf%O+i@EsL|&)1p?-9+!{$5!xXn+Bw;@RN(jWnU29Bo2(m39
zLY7#}5DFQ?VN)n%i$q+B1d@1APR5j!SX8B=lBwj>da>B9)&`CGY_ql49IO%|k-nkj
z%>gvO+F4jb7zZdx^XvV&wcDzrTw|bIzjF8L?hYH8Bv7thI=#LNom{=N!9lsrK)JQE
zhTOfivkFSy49X{-dE~cG{kq-HxBG=kT>&K#y+KKsN>Gwl0(oI4g9e*x!t6L^v>dcp
zj?I{kz53B7fa6Es-T3&My-&U)ef%x`uLe3lyLSEgci)}R9@pycm^S{zU^`-VoUpqQ
zz>The2?@p*v4vx!^vys?m6f@oybsE9Z%9=^9Fz#)&<{X)GcEzjn}#fl%u(L@WRA+X
zR_LkV8mt*d9v}i@j%t7yUnqm`UsjAN%-Q~FXgPH7tg)};Ba$3d=-?n;4V`Qyoh~QS
zH9;tfu6W=#ue|ipjT@iseXmddPx|=!wYUHLr*Jmr7o8E&8WQZmls7Cnqxc?2058N6
zN+?^E#6nD|$!Gy${9MqP3qKdgCU7?;m`a#OcuyS1IrKi+enof)2XPu7V}MdHMO>cG>4Gyi|rZ?D3T8rVR
zcIudJnpkNv(A0_^%%VZbv5SPpxa3EU&CCF%KbbK0x9)lU^S#$U+k5GQ8!vu%vIT)mC6^XJX6g326P9baX$3RK6h|gdp_&DiA+$L^<
zn2;%ef4N|9zW?kCkG=ZV?_PcLx#wPb;>yo2hf<<5nFJ+)%dv3R5(OUxTS78Nlh$|~
zf~gF!wL0;9UanSQC(|r?EA>*LSt)nw)m{^hvc1shAz8D+AU;OPLCN}k@{+57<^Xo`
zHXY^q<@?vK+{;0^wtJ53m);q6Xz5jf>Pg5x6ngU0e&c{=^7$_;L(TL!o3*^P^F2Bz1o-o^vnr#OSmb(mI
z%is6*-u?U6FTVfz$A7=^U(dY$=I3AD_t*AaOnR4O8VA;Xa7f5!e;*A#-1Y?
zj>v&n+T#=KA<+R=ifTYAB_i1X9A!)m3B_2ZE}@Sfjh~1gjZ_Zm;a9*<=dl{U2$+Z?
zcyGi+Hb2e}W~pkOe(OXb3bHf5NxNo@J|=*Ym3PIIJpTQt$ULKjSnh_Mbiz*hLsoq8
zzW4sSF0a|?vm$gu2CHtua9n5AYUt88`e}>dgkF18J9AhwearwLf{&x<&B@5QNzxgi
z!y3bpnW;&u_qVTo_WXy}o_`;@{@lCYJ^jx0XWzU2{D;?{|KR%b@BjU-8Ow3F#eYO3
z*BF$rnd9-wqk5XyIcm@!)$8CWXFzq@Ovvc)(T?jjuNl$X6|nlFE_c)sOwgFUgtV3N
z({HT?D0Ek7BWtRWy1iL%2FejD!N)Sc-XV1gb0C3mV0H{wVjfXBc`h{JKh;XiKkO}QdwU!u1#
z``T+yzxn!aUwiG*H{N(0?OU%s^2Y1Ged+g4tejeN39>0F=|jll(L}igUug)&P0VkC
zl`c_oNiskgQizg5AupB+a=8df0+*R;0nr<*9D}m6L^C#XtDX7P?jlX*kgvQMl$5^L
zXCeOi+}dsZ@_h`HSGl7kJGpy~K)HK*?b6o9?$*}M_SU71?F*~m<0hlz7K`2-l>Q|PskchdJw&1$q*c6Dx16sl$k~wIl9uHrE$r{<<|USbL=Z=r1Bp@36Z1h
zl{$TZ5?+$#yIVB9QyG0m|NN~y$O8&6Q$Qqlg%KqPBMIDaUkNV>n!tI{uI6l{5{@#*
zwx@&u9h?SMay&ttm7I?}1*3zIoA0QZRw_|Sz4rO%AKtkB$%u?&N?!j2>3i=wgc#2C
z2@P4^_+;U&~XQC-jK(Z$lKUgWK0U;krm6LpJk6cQmD?+A91{OaZDCBMz
zB380>I}q*D(NSb-ju#Q<{1mER-82HStTPNWjd;-EhYiVBU&S{$ju{1
zB*P^QEFRHY4{0q24dx3E{_gn?_MU$G+h^YT>ghMXeCmxapLy$>=id2_>zQ}Id+e3Z
zesXAL49EYUq8P3}tcOg%<#7w#r55RX#%`Wr#h!T2w1UWGb_X542ppxw8+RaH#RN}6
zq@h?b<)uxM^1*zCuGg3=$8OV6ax8KqNt-#gDwSp#;y|o4OSMk9F(@^MXp8k;wc4rR
z{Cqv1tBtG|EjjaQ$1<@b-i`r6}6Pe8wa^|vp-^61Vz7p-wg7ZMG@B%W@L
zNKB$NCPS`d%9)^AbZ|M8$;6eckjqG=vQ#Rz7H8or)mky%D3{u`O0U)!HrorW-b!b<
zN^o4+=q+vZA%;r=CD;7g9K=7LTf1#sy>H{{J!@BX*RJerUcJao<=XCCDHscQ1ZIX6MFd*KWM^#W(N&`3CgvpT7C{+IRc^)%SKE`o)y)
z;Eefz#`rU%?Xbyq+~S;a2QBzw4#xbExGyP%#Z)wvO>j`=OX+eWU2m&!i2d0r5V^SA
zhQ^L^z@j&FGbKB$Jcx@1xS3jPsq3xXiu>i0Fjn9i3?{h7NdcOm|#Yvc6<40zQ(;N%%*+ZNeNI
zltc?A;z#3`!WRJE5`GKZP1UGg62C9(Bp%{0#X(BtExdU$o-`v=7cy*L^wGxzP!`H!
zflYj?`FJ)P6eUj*xm%!F?{M4|h`Ap7?IRl}R~1nTW
zGLkwSTAJymsqG&QP>wo!(@~@4xY=$?R9<|4@0mBRKljczzy19e&%OP(r(XZd6R-XC
z={Nt5Bfop+Yr^Gw-}YB79yM8bRnX0KLR{4ch&WK-d+5>Zq~EN%*gTuI3%E2dCl
z!r{~UU;_!4aFjGONweFrX-`C{R$qPnx39kT)N8+g>h~}I_NAA9^YSZ?u=cT6e*ZW?
z`O-^|{Qk9PguG&nrz}y~6c)L71~-Ai;V7~qC>f+t391v4$x&9M5|7^He7jog)XKd^
zZP;uswA)MV-fDMtwKtF4y$&Nuj*^3NaUHq4H@n;!EcJ)Ww-voN??&{#d;RL=^(#9g
zJ9+iu=GF5n7f){PoZP&`7JBb&ZtbqYLY@R7cUDOkmrf*|Wk6J2+eYbb5G15y=&vP#4?axDwMvoUN
zWC30~v#%EqkLyO3UOit$O1aky0gGGaw|eDfUj*a+v$)n*Y*rCv_7BONY7Bgns6c9_
z91E1OCUn6|Ex2T)cf`chfS;Vc!!Ex#oFOhp1QC2iVa2q$lS85zC$;bQu;q0?vmUFF
z>clyLQVk@|7V9C9pw36jD;8fV`tW>`fO%nH_YyzIuA7?l_4s4y1tnjsNVe>dF3w~_
z-KFpT?D2vK#fq%c%fnMlT;-|X1+#5e+hxyf$9-qp=L!83?Kor@lBHT}8DV63eonycLR28uu<`-@
zKSJ+UuO}y%(KG$a))d^qgKULO)nyZU=(85E;CslNtCPjkPw7$j%)e|LGZ2ip^(nRV
zgzwRRMt4En`#w4T2gAIb-Y12kOgXOueUt4T=Z;2Rhr>-|0k=`%+0PeU{`Xs)RqwY;
zyj@;bF;xMm>R!I-qQ}*D`?}{D{Um$XuqHPVJ+iq4+b%oK`O*iCsi)FyE8Av_vxfc|
za}}8VB-zcMa-(UnEnj~rCTfER6$CZ#``D5mIhdyj|67Q{-jb7c=xVBVF0)L<+MF_M
z2%+beyED!yx6I^?_t_e@D)V|kV#E)kL|@qpEw(`4bon!rw`eF{5+A#fIkfwqMx!?L(1Ki%rSYMwSQgXca3WtDmvh04f?ezt<%X@qHImhcR
zkHF|1s5t^KN8kvg0B&Nh!Tg?Ti3Z%5%6CT}@)_L0z8O7-R3prKucKih7}Z
z>6iUn$+JpV;)wMI@qGS;vzc2bfshZ9=NMxABWwA?nQBY?AY`rB|4Pa|YL$katzP$Y
zF>S0>XPIlfNe5aU%FvLNKWhX{%4c>!Mv}jyjprA&3xqDMWR;Jzt#-}lpo6z^)uWRW
z6rALXIS&?wml@VggZPbU0C)3kjJY+fu}dT}xBIvv?2m~1ppBPp$H~seaF6$!(|lIo
z58JVC9IsnX=oM={BXbysin+VU#WLrpO9s$&tlK{n>ctUG3Nj;$lXm|oYt8AYTi+he
z^w&kjkOe0Ex|i?+NU#kjXkx?h`F1Cc#WU?OhvVXME&$-h6Y*b=b2qw&et*`bD^CdO
zQVoWoTXKf{CNf%YemDBPD^@hIo=|AWVPKMH*!;|9l8VT)rz7T{9V49Fm(641^Ox7b
zXXEpZ#}wP!q}j>NXSw=C|MSuF^|zJVxULmO)~u(^3}Q0l{6zZFjYXgPGRK4l1EHOm
zLg5k#zBEjQ>d-N@?{&}?ABWYhdSqIp&*8d|;#)-+G`2saVENmcf>!3WD{*Kp@#=O`s`Bx!4~Y6;v+=tJnZuJ#U5
zCNsZt*nY;^aQRMCP*F)VMIJ|x2If;p(OzSRJcbUx|6SSKOo{8bD$)2P@^T^=*ZB~n
zksWZd$LfE%>(k|Zwlie>h-%6gD&)UQHg7}edwAX6+
z&dU~QY{$x}+!j@a=UlBX7~zxK7&9Z3Du1ved?eT{zeo~YvB^KF>jp@plLuP5^sKOA
z{u^^^PTB1*Z?sZy`Mv&b1gA>t-_ggRnUMmqG4ZlJ9rsw5-{sh<#~ZhhC{ZLY^iHtO
zNp(Y^))#_LcIFFqCUMEPCQ+%w0dEZ
z>=nk0rtnl51!ftvRW~&Fc)NJmx_IpDPT(^l>xsBwOM@S8CT5NlP%T+lGCS%c?si+2
zZW94fuJ2X+5b4P{zO};jYuPmZB2mE0t3n#N7@-{B7GsBa;;17Vf3fTQ4t~@A@V&^x
z#mcec`(DQV+uQii!^SgujI#fP-Tu%5FrPeS5Y6^SA7R8C!3C$xjaSMNRk!%fH)Fxk
z#J7pd;kQZ^ifP-Fa&g31)T|UIMO{bT4kQiE*x;t?1Lam&hzkH&x`f=1Pq)oga4#oW
z6l*!A$mC3m2JGa*!A;{o^Q&UQkVEiwtAESezENlQr(sj|X%=6OkW9&O4xE%?+G%21
z(oDgU=E2wTwdC5VW0>vozTapEUiAr+gX7x%Y_wmw+wa}Hs&qWPY5SbN*|X}NTDD#X
z(jGppr}(_iYOg;XH=X+_CF$h&d+f~G`UEVkp#C0~oX^pC2_{nfZKBGdUijrM0;eC-
zR80VSaC%(|J+hIALDD)qyhF3LNmK7PEcv!a59`NCH9}f}Kq{5JoBmgH?zbK_3vdkt
zXD|l|PF~_Gq7ETJW=$v~iJSl9T#6dIRkgKiGNCF?3-OWuIfurKYS%fA*(g}zf`;p@BJl4pG7wfEiQ
zfXD&;0
zXNzsW8Tl5mRn_^XXzPC%fBjN;K}piQ%Mvft0UaW0hayE1+5d*$byS_+L!9`-rszun
zsuUNhhL_0i1&gxNFoBiw6c!qU@v4y2zQ^08mbseSJ}PV|`7ps~UWD^`w+*AkhJM*6Xq2NzIJ`jMx5}wx%3I~
z(y8;!PpoK|`D$K5n{0z4mNqOE2FZ!jc0hTNxkNF*wU9avlW>b1`Hu1hp-UayD-6&omcg;xh-!I*$iYTq&^N1mMV49%h
zK5mW*{Be)Ti3R**BB0Ifa@{~7GDjAiP~_13ufnt;KKviB^vE}B*sI@4m2XJYz>$2b
z$@*31+)!I%U{D%ms)VJ(2QTA9q!h{aK5+g^v~~3E{8G+AS+2go24+l2Q+>qgtj<G*Q=Bp9%9oYi_WVj1vu
zA^7W`%)*~=O22T_M-5&4IaO+6D4GEYMTWsyw0JS2TCC5c;VT2q^m}dyW;Ms7~Lsz#J0;@}l
zl-F&aAEpl5+@L`1C06;p_Mg9hck+A8J0SJB>@yaaU^EuG{AZlwy~9|I
zQ#3=Aj6r-7{#C(^t$6;jOk9*J3E4NI2rMBnSV!JN9)2o6!+V
zH6$n`{hdoBcI>!rR8@rz_R_p3ht_Ou`RC+b`>Y>TQTft~zGrxZ6FyriQgOaPoU
z-ziWTL3nG7G{J@s
zCQHJCY(S&OYaKD~`pZe3t9XNetM@ZJXjF9uojuLbq>bxQ@Y`(
z%8_eXh;I6tkpZow1nTJRV-m2~`estY-ZcdU0-QWpOBQ>HS>i2A^suoF7M<&qn#48@
z|HYuMI@r1eyRiYXdjVsV+Q|2&gxYbt@{jP0oc2WdySd_{LswIlmNR#_P>j*k(R4b<
zPfmvgi#+j1M5~$UIXUl;o>-JyLdK2vr@@Xm(I)@B1CheFzdpw8PvPhLlWWht&p9eS
zxWMxBK6$FtQ?!uJ9;_C*gPs^=)&)Plt8tXj?wR9>vd+mDrB%9lPx*a2W&7a2
zt?(D-?G4uKy@j7tMw>bFpSAx)>VC%d0d4!fhun{#&wXGMZ0BMRM#Ioj{zz+4-fCUv
zKl3}IF*Vl8B6iA`mn@1J8WL_{_2h%r@L6w^ovP-ldHQ-4F=B2*seY;*VFX$5fxP7gs<$R<=9YFBc{9q1AWG^
z%=F4vv77Ark6g-$6Xw|*Ds92aFYwR#4lj>SR(0G2QS0lWNb)mbEIMIWK{#Jf;{jkh
zEE)4C^c$3Xb{peY^Cmb+o^aQs%Kh9P-C+a}V|5~m;R(e;+IiROx*(J}2d37HsGJz7
zlw+2tG$*rK{ClD(maM2kXmIkFk-EhyT%Vv47Cb
z>)%;SU`zitN4Md5UBbKW&0<(aZWYo3b(Y$W*Y|3Y#S1sy>?@EHXKXk`63e%9sVXmD
zdZYmu)yr(MDxr-2L5}-uY-1~@7mfd2oCcFOE-eGO>Jz6l1kiI?-%9lQ%Kdtm*ZtbD
zcF>=!aYn)8l%>PnvyuwKdVT#AUfzkS%;hz)81;gg#;gzf(MYu{?U4UY8u%p**XSts!n8brGZ
zHUTTgN*
z*UfYP`$zQBd>G0lt_k$Os{zcnt3RXX@BapPNqyhOdEb3^MyOcZA9^-`g||o5yYqQi
zT&MqW74Q1Pwa0mY-)mM?=i|jn2WIC|NL%}RiKPUXJo~cuhFwrD7RPDViuT_JQwb6I
zq=Q1ZHary^I%*UXB6qXSgf1^6X&fiaBI|L0E_NTy8z=K
zKS>0Q^HtJwEeY>p>>(5C0h#w!hhvV{b%u=b8`GMB-^+bY_WR>(M?;q7`pak{;J<3|
zs1&}xYbf4$deUZXznkW%Ro=LNFRr=Q*^W(<9csx)%J1%8PWq54xU5}wD+ESfCwcG7kGGDMF!9=FBDXJ5ah+HH
z6015cPcj^ZpZ9%Omnf0hQo6_;#r6LoQVu#95JaR?Iqy0I2%IVu_KL~o{bWeFz~B@!
zE6Y6B*a8vPjqe-exA846`o>mhk)V1|0CJME`xHl84$I?gAD;8hcCW|nyCj9)EPJ-kKLp|}cPA4z;+*Oek;}r+-4d3VSv}=Xe
zC11zijnDiJ3`ct810N$IwI;rcDYAdSkc5)24ex2jd~kt3!N`Gk?mw#&fORJzzH0Ot
zf3DrkWT(k%Ci$Ll^t&8IR|}^A|4SIh=|3%7`f(O9T{BonOkvX9HaH5k2q#^?9BtnU
z1F;+qw9>&4@~vbEFl{wh1f97vo|!nMQML$uz*9|R%rXfalpgV=T4bgQ%adG9Cs8v-kmD*JSFqQ-Y(ygda^G4Tgm0-+q+on4udBORneTA)m=k
zx7Xo?_orRk0Po!am4L?^pDwR0b)7%Jx@FJUY{C2}cFl2syg3goWf
zx7pNa6?T6WCi{QSht~O=?jeh2+n#(ly84WsV_@yykK}on){E=Rz12~{Z^
z4LG&TMilX*{d0<{$*VPzI&v~D^&&%bjLA;Dc+o4rD4P*}1AZP!3ssKF%l`VeP?n#n
z$KwP>-d9Q5Io^+RL&n~FYQWywcWb~nr=$Am>O9Bu_O{qK;JT%0-RrVxQg{n*hAlzJ
zH6#w}3?^&esy7?Y5J!Zl_30zfOk@}~jbsRA7_bY`IQ;U-+^=%U!0KjEs^3Dp&BeCc
z+@m@8qp}29y74*Y{DB4U!Q%mdD2CaaTdQD9;qjORg0t1&qrZ1^bt~G9^Q;wWKF+sz
z0t8x94yR185KC4T0CTn#n^1V(GoQBpPwV>4*x&)Er=cB0g|xtk$q|g@Dg2$em7#b!
zKCqHT<7~qauo!+BB;f
zWde@Eo-~cPYKeSqd6VYu;ajy3!rqk);%P6Aruqak7ebxuk)8t`ah5@yy50Rq43GJ#
zRui1tQ~p}o!zwM}u6jg{xnn1BA@9fX`oulsYhXx{Z_@AHtVdo&7NyBkvf%Zi0J&u_;-
z-pXwG@n#He=(1hZ0XS^+!fV&E>
zaTq%6{*YQ%*y7m}N>k~+>bH=ieT|Pt3mY0n8
zpB1cp<1Mx2-WvqtK8fpo+>b^nm`cz#+9R9K4%O1=)$V*+`>na=*~;>Cy@FBYMCj%T
zmCWFMZOEtV`EZbt%(&~O8&^~qd{Su*i@6LK2HlyeuUIPXEL3~dNO{wAZg_07?g+!z
zPa5=khcRbx4dPLYOEPh11Uw
zmZ3)I2_gtHoQH}!*bPBjiQq2Zhn^H;ul>1&Y~S0tp@8c@bC%hDhmQpQ=&Z=9op1Yf
zj$QZL;W?cd^cpc5f^w0>PP-Ai74!*Hi1|O+@%CC)NaL1%MUqFPCGW_~Gnp6G{^C-g
zAu1}b(RFNX{y4VNJ9siP|8jK)6N+(0`Mpo=P8$L1-Phr?(QR_=IK`v!e0^!Tqq^3|
z;q_`MX0*7G#nDB*#oyT;ZDd?Q;hSo9NBtj5AaGR;el_!P3vt)W&}Rxs%4hTr5d9(-
zRm%tZCTC22hDrz66hm3!aIY_>?b8b*mklU5CCk`+@joINFNSro2oXj5IE%btPobpg
z2(T7`?SOwQUU+G+jeG+z!UhNCQfCZ{pS_VnuA@%3NW^r>#^x3U9Q5pmW2k-2Jyg%p
ziL-!8M#WXu?}xjh|F~)Tc{%yzTlxe78;{1v~w4jN)X#^eodYFZMG--pV($
zoP_Zgn)yq#E+w`0o*2(t_<85Eora13rz2wir_V(01wA8ioog$t_j$%|7;1-W2cl2U
ztT{fd4dj#(wvMWY8lWlDgOmH^DUqB<^1rejw8zXu-snD}$g9
zkRY%SFn3A!I?T=UUZ!d(C3)O+3)l$@((loS2^#)H1JIp;^)S<1fdqfgJ^J<_$|lxV
z^X-UrmI6#Uxwlit0I3o3#}lF*E+^|+;xXmw86i0W02VLPGm7S{q-;=X>I>l^RKHH!*E$J>>02OX#~LAz_o
z3ihi}2mTM;fRmwi^|X)fr<(ObgIzX4sq}wtBAo$Dr5&y(F2lZSZdl4WSc>mW-vOi0
zXI#1+5)xJ(loo06l9^;(U=pe7*9;qJ*lkz%lb)Y2k7!3@_{%h^cnljk@LPT&S4`hX
zNbf~btJn+{9`p2{#HyFGIo@o)(}rRrzuU9}W6xcWNzs@7SNVS0oY$&a
z3J{4KrkI#d#Y=#|t*9ye!QV4b>mH@-h`G-V)i;~v)8K1qU55ot2R*=Hz=;5^fY2L(
zr#`SHzHZx(a^Za{=261GSl$0y2*WN&XBbzn%}Ey}d_bN?kofdt&czXurGgE+cut$b99yFZdFQ(e*B}H?tCA2qdw++
zds%A>Xp1j*TYr9T0@7x;eXRcE^WR%~wpRi=F87Tqf%|UTbN}15jDS3;4K;3hZR(dp
zPZnCd1PPINRqIjiJgme~VDH(;o{X9gUo@-vlN}iqnJSW3+U>}*i5nThRBz>sk&2}C
zOKG<+;@~UeeZoWIriIIYWLVb^gB%sk6Cb`^s8gwqI0Wqr_~xaK9yM(W`Nq$PjlJ>M
zCNAUZ)x}n-?bIvlk0na?6+|X8_sW8`uHH=0xk_<^F~&b)C?8`g{yXCny39d5f4JPr
zm$_{;@VMOC=y-gN>-0YAtIF};QJGu1eHZfG9g@L#843~%06#2F(sCm<48n4HH)>-k
ztvP-Aswp!iUhjP^u9y5x`b@-x{Sz;7ad{DanfL+Eks)p30*ZmaXO_g#&6vekXCDnG
z)CA0~T#(npM;cd75N8X3qlDBhnG%Z#ERpmIC1ck+|BTY%*SDR_tN1mk!oqcBlmD}1
zKgahj&4=`bAGR=k>_ae4wAmoV)W<@K)TtWg03f1nUyZ;-d(X)iAxCJS(5#pmGJUIF
zyy5qr#k=9TRncVZd0k<-;eUVRA?kfQeURNsuPs)G;1UXo>|-&_KX^M?CS9a)}-W@Tx?&%Vzy@HzgpY6JG(eI
zfAe=vv|-3=8Gqb5t+-upZf^t3N)>IafpPVp1~sd%ZUzf)D@OHg2^M%fco$eJ9A=a|
zP)Q&LP&BNV0v^t!xk6q=U0$_yo#OgPtW$jC9CjGxySb~pNpk*S4ixB%1HVkkS;BEj
z*xLBA=s=zw$W3(n;86QrmOi13wqQ9G4Gakh1UqzDc>^unBcT&&vB;Fy>;zwK;3Bk3
z6%il-ibx~N!vLPJNm10LdmN*tO;?
zxCOD{OEf;F4|>`CgdAT#l%$fNnNADRXqwe9nJ;R7Xo=eO4TYlj=hgk;GwToJ>1@H2
zIg73L&;{p{_mwptRu?Gt86CSdC=I&q!m9?P7g)?T9=4bD1D1VWqt4e~W*d0lVFbOh
z_S?FEb3BFj%x9aPLV+
zTRT!$e@X6;8;;ya8Q&#$4X2<{X$!shuabIel(iEVe&$UEp?+T^;d(IhsF2AcMijix
zr`iQ&NHt`K=btc7yxuwnd_XBx{R0azp~oHHhbbxNrv$TW4MGDIL~C?`F}<07jNaz?
z94-WSTb-N!LU5bk-POco!0YJs{h7dyv#~%iW@P9eF`VG2eiweHO94-ATc$nP5e$mG
z1derAp6-#5P}4|9HOu%P`C6titWUv`-}dQjzv2;0f=xkytxYa=mri84f|{iGdwmJh-4JhS<0-DnmY}(
zHucesOeWtXac$d+R^t#+#VyY=8bXHLdHtt3C9(zUVv}vfqHj<%8}Bd?)U3niriBtD
zkX_JuX6oZ`e;yeb{|lMN>MhlwrRekYC(*a*EYYWX!S_=c(dWy6^~;_2ho!jp*Vquz
z*6YQ|Sdzyj;7>G
z-l??E`cAm58RE1{DXuqARWp|q+&8{F%$}eTgs$>S6r!%&OIj`wlr<=tersE_>5qjp
zv^qPK-^>Mae{&@!7Nf>QCIuTX7XB+#%!fE?GZ^Y6_lfiCoJ~#}+4Re(f}In$?_QRf
zV#g|{G#*ZtPd4ucLA+IG4n}$K{C1thxk7D?J~-~++uncsX9&y8feCjgL_y%^-c{hL
z1ogUjax$x<*>nHp1PNmKv_khxtgrDZ(xgf_@t?v>i&x*auoMjeI|crEEJTQ%`T%y&TUyJh5(D7KQU|5@`%jkSL^bYYdj^=84=7T1u2Vm#
zkelJM#aLpCeW?r&lgm&;uD%Sh4*Ww^$eDsnhz8=2ygV$&V0Lv}_5hdcFSi-jm?9z`
zcQ(zc#!DUN9%OIWu~%7LK+Er(7YNx3`>f)!N^YT8GZaZEn)T&!x%I8l^rNw!)(mb8
zMl5TpRj7YxHHfBj*>a^pR!;*-2TE`xMPSEhNFW!FaP6VXOSE%7r9#Ow@UfyWbV_lW
zbY7$>D5?eJk^B6Tn^ad3^}iZRUvYFpG~j7cvYk0(7RX;KXh^$_ShwigI*LRNabGs$
z&*LOn_!rlweP*1T9H$Trz(F`u(*@~@{J|%S0i^s_=ZKhZ$A%s+E1yIk7jj-dKBeTm
z(e*!xzBUP-KV9Zgi3)qa6w`5eoEn>=ne9fHHA~u>aBgyiyT}%c+VmT)vGd8d*)Jbu
z*62mEv<=udKA%hk&JtF)^|`Br`kG7L&`4H6uC^JW-EqpzT=>lB<|OcP$3XG_o5t~5
z85>wA-SfHapo5>C+m?$)>HZ2_-=0a7ac+cG71UC=r`gqeYSpM|jEp>!`Bi(J;c+H~
znTe38Lu6@j$1F~33TQGfimxKJp2Q3k2!?|iqGQ9_&{Fax$Z(WV`z?K^)rQEj?j$W&
zkt;L4)8hIf8v9U=pHky#L}8cmu+skEhlZUIAou6JUyWTBkbUdgcsYGhxd{N9lC1r
zlE}PjCsQ?!t6t@2cA-5P)C~F}38&cUP_p2FXw)7Z4kUTnFW7Q&5lbJtn3yGy+kWuI
zcwSARv&to|t<8LGWbcygi_iBa_Z%)9{Mxyk!Th;jrt=fRo3h0gS(H_maZaBv&ELZh
zHd){X!`;!2|DQ5UztY8bs%yrt$aTkK>TW;qsUEb|nkv?vA4$Z+N
zy|m2hqX_eFRc5=5s5E22QZwuqt2o7k!*Z
zJooqdbn~*A(b4qo{<`K^+4XvR%X)XWom6iOmiPLx&gH01bUG1b49&cbERbKec?FgI
z&Bv^I?|?6uH)M9|;8yH`dq4uOAF{<|n_o&!k}^V-|3mv>=+ICxI04HkjdALBV35%T
zYNS9iLuS+Xen&+FjL3wMlQjH`d)!JSbSACsh}o8)Fn-@IW;o_`L1JFRScyN%6xH5Ppx?s|#Vs|;w_i472S+8mOJ
z+pf>aOzm{h^I3?-P!!4yYTzRI3mpq&m459)$K0h3M^lC0(x%_?{3|Azw+^4%3{K&?
zF7pXVs?1&cQ2S)63`)JAwjMQd)XN)oKx)=NWhcsKl7txC@BoF<=Fwcz>m*3I*Wtd)
zYQ##%fR;xdv;j=|sV*gbIQ`;}V!Y$9JJa{&2HQvj9&))z1D48CWKDDnj>-Z&HH8T?
zgd^g!xT@#u%WhzGj4`=31!3ekDrotXAUX&yuk1rb?OrsGI1$@U9kp&{eNSG$Z?#IK
zvW#<)Bv%abqGA7K7RrIH#G#5`SHU55?vT&EV8iS#Fxnwvw=?pSwO4oXquBMa-^iMs
z2RF%X)_+(f-azp2nS!0`6{T29qYLr?V2aT=Gv3b*NvJe5P_zKEBf&{htH^GC
zV@nT=LHc|+n)bWApBkP*IAMa0kVekaG*4o0&(|tp(%1uWuEp!3W_*aIN<^Cb)C&Ka^>G(&Z%VDB*`pwYxo2WS*6q2=t8)>wLcKDbH
zq>8TEfXlj;w_zZ}+tq?lJbZT6aliLp1u%)885(S;mzw
zce;l-qK3h>9q|pr8O~7}G!3F|rzV%h-B!~5b-XIg588nz3filphrBzRD_2spNz%?4
zWRBtKXZAS{Hwt*vj%$GYo_n>7WGvi{Pf0U|O|sek6^*&}kjQ@HRyvH4DdKhl1gmY$
zA5U8cKhc1Bb&yphp!Oz}GocXQU#BRbE;r7bk2n0i54zrNVgsI+vJBq64-DVk52xZ{
zNnbB7cSJL$B9GC2$X$g#3(NBj2H9_(s-EiT_P_
zkdyRVcQcaEKy1}h6XM;Yq!#76KoU-niw+}t+n5LzwacQb&E;rbE3_f(WH)FA!Gm1a
zs6tm4=NarQS83Wcif-&!Kv`em?h22jBa2goB7x{WLxK%lj;nb2%+@Q(@~Omr0TGDF
z0s3dUQJa)IoifbjibtM|t20dP$VfA~w0yH7uxw|-r(H<95&*VaRigxobH{B^dv_lp
z8THV6+joU6iGnV`!c<7K$*mMqa9D>QRZHRkdg}TbiiUsO1=Z6$b)@C-i$^Zca+-~>
zq4m!n+-axXwA-Rc?Gyxxg_)7vYVt>(df2;)ndhu&T8Y((zN!gzA9`K9w!g>ke%Q}~
zHud-O4{}F_A+s)_Tw#o;Bp*E4b;{#ulVv1m0W5>qO+L>)NYiM1e_2mp>w8cq9Ea3k
zBFKUEf4%h_kEhz<>^8~I_?6G~o2ZUypUw6XEAT*s%#sg=KjGuH-KGd@61E}}QJJ5B
z4r(c!1fdGs>GjCfv$6l}qY@-^lkst8ux8x%U7sk$_g@7sc&(N02(8F>*z_+QpVtlT
zX$oV^5rV12gR>{6XGEOdHifdBY^iEF?SYOGxnE*dIZC9j&R1KKL>dO>-bYU*|NZ~;
z5|?wuyW3DSPIA{DyDyZEfV%20XG`j{-VzgvO>{xw6C6V=KJKQ0{TfB$Vp_#nU*;Xi
zIC%B9C?6-hNG&7P3^*%aAk<-8$3sb3{YHfSGG{3E{qT?-3L6j=JY;#i8HfIXeRn4~
zBYkT69R9xZM=jHRs37(js=Yu9k#?P5xQ}3qWd6vycEw7dd``JG%bU)6l6S{BMC-UZ
z{o-y>xlcJ~4PA9+eILWPAK%m`V@L`!p|HKn8q2X~#1%g`dW{w&KCIVeMErMjO}@l%
ze=9vIq?TU{t@vim_}3`z)yG(>P3scf32lXvQg4g!2fJIzi!wWMRy
z&s#bE`Uy{>epeJ-8IF*@XzIw&S!|I=3z?}{O=)bY)oJ-Z6fn*0rKOj@CrrAoY}X$l
z7@@zQTXLv{;j0e1c)3q63*9HE7U`<#&4IhrNdMYgqwk)*jeM;Z$keC9V6kVBh*}xF
z){k<@K%Ek*Z{Rb?c_#av-~K!!+r7u~L9KGOa=%`kb%P5D*w9!bQ%crGo{ziqC5{0<
zo>gVAR<>Z5)6>{V$!uR@F@os(08Kle4zl`^O>v%uLJ1{(NGe;%2f}yOKXSisHmLJ^
z`K2XkGFkeixM5VU!XgQ|(}rUV%qmm2Q@lW$b-ow}KJvZH6AMd5HU?Zlu<{a~5eO_P
z=}&By@z%{Ee;Yj(<2)KUB1vo5KcySEbxhH7F!q@tSGW{7K
z^3IYRgSNr%Ox6SqagGKDrr%O{MLL`T7RbVAR8){6HKfK1*E?W_bTTYoo~Z8eB!%BK#`&_rTmt;p%0paUm57XN1dtu^*`GlF3$1!QOS>63o9TNH|&tx;+P_5yFfOp
z)T5`I8bhauaJV_fwK+gSW1RVU)a^|W6x939=bIXmP;=GYMHVwx6#TGl;Bc`{>qj%aXD5Ej-25)1IXZw!B~P
zUgk6?l?uz{${rCJLMZxxwD$wM8mEg7G>ky$0HAi)%Tj#ifcCz~LczG30}PF&xn<{C
zdIfj*+`L^w+tdkbk6v(6%pGw0YOT!K3A3h@TnQPL{Mn<_NgHES^L&$-X0%|+3#B3P
zpiyTVoKGFo3ZVL)p9Ay8Wp~?@jlxj!g!pRBi@DE7I_GJ9N=1NihN(J(U<*YPZ9}gA
zqelu~L81j_c&^ldu}{`QUsJWVlaJ|!sG&vKzH-jMhQbwd{(Bz~RK0!NtDwOcS&C`t
zd9n+zN7|Y`Ls9a&*ZTjvEx@4BQf08gU*~pv@~?3Gbj__gf#?gd)n;bfgM!qYBfz#*d=WF-8lkdJ9@AA>`BOX|*f~i$&!*`(e3_f5w%U?x|
zw=5a|#-%wLIoH7aOQi9rIPvDoOS;`!VL$)ymq!tQ3Sknd|AIQUO@pU@zjLdR+@Drf
zUZIQl%P%yxo+0SkKMQOQ_0m|mTji1fh64RMGNl>ks^4Bh1P78?!)5r1iNS|kWOOiT
zbh7>S3=w!+6KZ0_i@e=EWduB4T~Vo|Qcb54-O_%d7$(9w&2Ihx!5gLYx2i>IlW)5K
z-qu(;!%8&%EMyJ+tig8{K1k+7ztHfub?pKH7Ps*d{7
zqZ?lJYBdIG!Xng~gN{PrXHSST;>5m!vF=_=ND9g{&7grrR-dm1C*b&*n>D9UPK`z^
zDmJ0p0^oV6K)F;{f)^w=?E@x)3*}=B;Ih~Y>LUR@UJjA&GvG#W0WMOT1)7KAcwqFZ
z0$6MNj6HGh=Q^7ShtkK}O@R89!8YsGK{xJQH?;p1VAu$Y6STomofI%;y3$d{{k-~2
zm^9A>){=Or*!uL9!4VfCJ5}gV$Yb}Hf=8imK!%~EIp1!Qn_M-4<3XaXO-w3FL^P`;krf-fu9e6Cp!#avVS3kL$QBBSK&qdC=_h__TJK-X|amLW{P3%wCf
zFEo)6ljFz^r20652&`lYF{3=`N7j&a6nZFRS?KqYX5-6y_uJ?_4qDOAKv5muCB|i}
zTv#1Ld*Z%0Wq?(H8`IZ0H22tYpo>7LPQaj0e+wKUgs)G03vniM5qwE)vs
zT_V)p;1aYLvW(Z=3CP>U0IZrV%!?@_$GMr2b>M%`=ih%~fZcq8DQ`a&Q&X!q2?a^g
zYt_KJhUcMBUVxD`b8)623wJSNY&LHIO=IEbG?g$Uwd$1|l%glaDS%m#kyy&>p+^dn
zCRSm_4+0bX*qn8;4S&0Qzlu;Abjee`UUMO*%IPSn@h0a;Xs5Pfx=MZ3M=X@r+{^Ev
z?I8k~&$iO}$>^o%y`S4Fv3db*01PNh9;X~Gl2Tr$G~&{iDH%1+fZD|c;!-A8k{JO_
zTkSId`qjkffL^?YZI%b&PH+6KZb5eX>(j+x2L+8a65p4YU>Ou0DtC{WokZd6P6+ACBvojgD!EyOi3J}Qg@jB;gKAvpdx~@?O2T%5NvuiP>#}n
zGD#MIg&<^-5i&b5|GPX2jFC=
zx7yuL1z)aLRuKYc_NWlVdEzu37l=tL5@+34fAgFC&0!H+v}zY2Jl5m7vOFBG$D7|L)Zr$<3Q3HM;H@+
z+e+pAiW~)`9O1xCAKbqbdkEIMNA=iqHkW%BFP()yhQYgg1uLs8ZbdCak2FVYAa!Yz
z)B8ZnzZA)5SN8tiHDT!UN`;3ny1LWacP$0XAMPc~RlJt^<0c`lxHNKo-aeH}S;aT#
z@?cYUg5UP&#Csw-x})4>vKt=n+Xr7tevTa=rPMP^!N04&9&w@TGRThbPe{%WmNe5b
z5PwGQRwE14jIOgETS6*g721L4`c}ji7y;b5!(vkea{QG~PW`GfqRf7p%n@WqiXaFV
zk~J!ql%P?VCnsyI9rY?*xY4~J=8^|Qi`-M5UX!+*%=wz6!xE=Xh>%T4cwGK2rREG=
zu9W4k7Wjp*a2PJO`?`Pg@Oi}%lPfPc_Au5H_OdpArsN+vRX{Cv$8VY#&u(QKVgM0L
zWM+uAiAu|r3&|8+y@VBVT3V`P5jr@y&Ch25rT~!_$X=3kfa>8bYL-Lg5&~nAUY3(?
zNx>!ysyRJo4V&`%uY`$|*_JP*szvg{Uzjy}(%cH?|J2y~TWQx%CwC5zPVg^!CS3`+a8V27tvIe@jNw=(6pPud7(y61
z7jkRouv?QJ(#R!KdKIQ)M3)_}pV-PnsKgndpU*pr{g`_^SmMOYfTKmE8xcBw7>svL
zrYN~Om=P2o-G`TKUGRl6F0DI5vBwAJ$@(8j)g5MT|H7sf-gg~BZLnHk$P#090)Az6
zi{o-e?fRH;m%lJpjjphO$lcK1#S)rU$GYj?C3IYbap$bF&>pAN-{Bb64kMeK=~T1J
zed_6e&*Eq2IUoCDV*XG7nij`pxe~(lVNHOjFC0Wt=zWPg3xVv%n7>Y0m#s7`kaOv+
z?`BO)-O8t1GL@z!jHrZ9QTL_ZAN43~5P@!6*2F
z8)`w3bL~;KQr0PSW~n+Ik?}uQ0FM=@PM8SLht5Ef$=brGdIzc09kxL&|C-D2$lC;|<7}ZV~^QtM&1abJVo7}wCH>EE!X%#P#S5PHok>L83xW1
zTG7tfGiXaV*I@K~uRERhEv{Q6{uz)NBGxxB-cnfMg+o@ds`C|>?|N!`aQht&G^|hy
z%7A?T5}vi2b$^ffs?xw!EHRw=ZWZzNz|+z4b<4w;s~
zHp>b0CKb1ZdEzqL@hrpI3l-s4Vx7?*wv98hl{JI1iZlIDF5EYItCIvf3+4gM%0g#?
zgTEQ_Wr>a+s98oeD^+*j$9qWrEb1GaihZStTf9gWZajcb%7V=rQ-Fb}I(EXx(Akjh
zQ!-+;C{!nq{`x}EjW?ODFZrv>O*Pots}UTJ^rtcnR^S2(LjkzO@B7B5vVnz0i-<)k
zai)xya4Cet0>g?^$)sszi-r{U1&WpCAq)q)2#&27Zq3=2?et1vKJe?00y`_%;A!I7
za2mlsACv8@D2!KkRrFpU&CDj5tj&onNRo5=NoE?zJ^aDuV$|!^e^`1_;c^wYP%*8x
z)mnHMeiR6^{s?r7mS+XtLhk)yqLKKy8k@m{ykWkf7`6P)FpPC&`Ek~0@}wQs)f{9Y
z9j37EcnXhNoxvwcKRR`KL+BoQwH*8RZ&t=J{3GFs?M3$*GEOXF468hJ>6E^I^AntrSTzBwDdBgLk&HQ281_Tm|9CUXa$c~XqR9dPo>69HE*O93*?aoe}v&fTlPh~
zDIcG=sdKWg09Ubhb%rjC_0DLN0f*$|Gxad@k03>a=IH$&mlA{(GV*N&(X5I0MJ{({
zBUnFX2l1g93Rfo=kT0g=$1Y5i>RHs#LHx~DAU!526nLca=-sQ_Y9y)_(V#?oO_x*C
z8g2Sn|NWSG)3UnNBPNe$+t;_{ug&b48<~d7M92}L`13t7uJ{L92e~~@O#kCv#E7>z
z@4eiuS@N>lXSKE~5g4y7>2x*MH`IZ>En}93TgDZx=~!9paz14X@Oq?2>UcTu{h}`4
zdxYm3;j}!MFfQ29rxUa#Mu)q&jp4aD5DjqN8ALZSUOGN#6Ru7eWNayQgW1M}6XDUb
zsmp?;Y4d}#X&xB)+Q^e?JI3mkto1y4+%I3?ct*lcGrbi_+$@>X{cvUONkq}7
zZd2KM1gSE{U#KWrAZi>?K7BE-1sZjQ$TTS=i#@5`j7wpb@6hQWLQyHgOcaT^(1H@+
zyoDr~F(}jz!>?DX7VX&4cz%ItW<-`e=b9Ko{;*moK!N0lX+olcEze%fp%%UE2H3%g
z^9xYqG2~GQ3MDH)?v*Q=`(dGL$piYA8K1k={eysqG2+J7kUw<}G0w|pK@IiL5SFf$
z!{C&Vs(Pi5!#7I0Qr3~oa#N}GQ9S3D591@7aF?*60R?a@ON|x~8H86Y
z6_e$XSS_U*<#e;Cw9C0}HQ%e3hn3nwqrT8+E;V~A?ZH}iZga4(J>YcE3M_F+Tv0jG@oBA&Mn;f#=XEFIYb(W92Eee1$y}Q
zYe3Ste3J8&gOVR%wh_=wr)y~>VmL}R$3hj9KqS$MMcPbN1i})zFpL{aTnwf%0sOh+
z8E+tIi^wit+~SRy{RuND2}NWF?*s%}C>NkndEq7TtcV%_F7Z;MkBN^_
zDy*=UtYul?VmnPmGr6#&(1sC^AiLrst&+xbq`c@2JKaIMFXA%Ubyk-d0i3Qo2Ak=%
zPFpm3hhfI7Ii{bQFwu3#CXI%}(^E$^GsksWv`1zTrKyzij){poCMJJ+?8J|c9D}<=
zi#|Li`f!nGX+U#I$BNbUNA!lnM(uHn@ql)E(qfsmS+!2bjMb#EnG8;|#cS1BblD
z=hklg0ttMgqdC{A50RruU?1OZ2g0MB#V&-D4Ye0q5bk!DdUyyYG-fG%S9-NVvy!Wq
z9($5zX7lYvwqBOXc_d=7QbZds=x2KS@EaTP+m<|%i+B0k|l?ba?4r7
z^Kic4%OIy`fKh8)G)I$=Eg^6LtdKvedehlhAr~*^g-S`TmeeM^WUbU|)(1^MpC@kG
zD`>SpWL|P4T7)wh_ydDVI9AaAsA$s4|ew5o+FF>1@&z-#I;s#N2dwX~N
zB+YlPK--sAPG4F+d0~+*yLfJP>&)O3fpW-KE}pqSaT|h*Jacvyd^~-2aOV6FxIBGk
z7Kq$F*#{+|t?eG}0+%bR4QOe(23E2O@!Viggu(1|b8vILezDstbi3tVuhQ>V2ZQSD
z9Eq-VgEUPAl5}})zLXp7;%aktu|A93Fr9V-ZOD5~H
zrS@F4H`iEPZZ0mDSJvt)YqkF`dw&{a*_NK?VclpD4245lB7mkrQWQlJ
zK!a3}fba``zxD02^HkRD2D&a-Er;*!_pV-h?X~yW=hVsfJnLJ-Znxo*W}|C0`d?;I
z3>amKO%M*45xZfjn~s^(
z8I7}W5z4^7i1nyp3mc+TU73r{!0%R5bF0a@)x_*dd}cW|HM4pZAh{HsTtynYxdOY4
z-&%~_LN%Cd9HJyTd;F9<;fXQBLdMgG!?Fh<
z&T#3$(+hzq@%$NjHVBLo&2U=Ncm5{qX<~Nb?Hg}jox1ks_?2HCyY%Lb>#toML;8#G
z%FAyf|IJGjxcvDy-xNmac_ITQjU4*rZzIDk?w^0-t#6IdqC}w4UwHfNZ{4{1%W&Sw
z8^1jE_Lb?Imu`+?+U4uBljDnGFwnv+SmcfA8?!63q}AD}mFeZke2C^OE<_TG
zY?Po#CQ4bQA(Nm;@=D(*@j3hzG`&e^rCL?Tfkg_r4HC7f>)BkZkZ%_Yol>b=EOiS-
zAuc4f3RzLvt>>(APAk|-&V2Uyr?|M3wWO?_$-5jqL<1Rs88zu)X
z+09kzcBMgs$>Ei3l*of3eVhbr`r*q_qs)oH=k$n(j@|9sot_2t=y_yrtMAl%w)YwR
z_!}$_LdzPi$MHu}J{3R{MGS|8B~iOOpGsxvDC#7fC=(@=$|WN_myw=>7znAbEt-nM
zUde4_@EuBEWMO%Qf{c0)7oQH_1aiWd0;ze}8m#Ir=2?583{NydposKyY=E{St-
z78>0kP&B{;GIi;AACniOG-H}YD?w>ijLl*=-8Cc|tK0x5qr_idf<|lq;E(_4{-eA6
z2%71IoAWEPlk^PRvFX{H(5;!tiRtmTZd|%DHU9dIvDe4O-nw!9jT_hByngK$-+bfS
zV^`pn-x{Og=;V@bJm-&aMhIMql3%=Z8Tntj^7gl`UZz;*7#Ssq^37WluU)_N*3GM9
zvlG{5ZeE?57`t_SVqtP>;nvvX82k}_J-0eHADCYVF3bk!7DMzX!$@K&mRu5}g64Sq
zlW2NVziui+o!$767(TN%luUoAg?kAeYrNEV@D
zhaOc}Xcu!$SQ3FJomkHCL$tMGcIW62*I(b?5v%yvk^syUyi(I?JhZOGYzryg519F8
zBz7xGL`nQCY0HX29W`)O+fF)8%(5annpjd$lW72uZN%xC4lJ1aZNwO$tcCXie{7fe
zJ{csNgGOt!+1_gPx7w`UR(rTuZ==1{X>GNe-hlIVYqJA&wtGnV^Le>#``#Uh?DF2>
z+VST084=~yaUTLv0xjW^(B5&6i4y6~fpAGN#hZ=N(_wvQuR?aYSBFcoc&HGJ(l3F~
z3}>!{OQNYO(k$E%wg{o5)5Xy&+QL0JW3K?OWQ&A3_SQ-sPEr&S=4hAEFt1aO4LlJP
z36^A>3dZlYc9f+#DkmtPbE4hS~nhBmt-
zcnTf|!GO3M2mS)6OxW}+Y*e5rjN*~sBtWGT4H>}%>gzBU5FGWcz`xiZIYScbLefA;
zBearPM8g^BYGz?6IUC3)7jiJL(Mq^LkPDulDp=mu0m)N&tr8Y`OKKuDUW
zg;clVkm5aVEGTR64vJT%qy@CT;gv8-z)C1e3$KNe%k!)BTtgayvor?B&^6SI?V-MBn9HSy-PD{oxAa(Uv$+Y>k7nDELsu2P5iFOOY@{{HKpC!!4w{lZ(9
zp#SErxBlxl-ulH$mwxHW*e|~Q<{RVJzJ2Y=n-e#FVeInjljCpQn!Gv#3x4ay{7tar
z0U@LV{$7)>n4l8f>5LOipOl$M~3ir;`0
zNe!l?)ij`z1`LNNRYPC0*W0bb;|dPi&SaDnZ4~Wj&mUQS`?}c5mpesI-Abibfghm_
z4iDv)d$wM1s_;rzLld}^)r;;Q|LcF1a;>Cek}NIdm>C!DmP@)0TFqfy3z=#JZS$-Z
zv8{k+EJ?~tB6%}{hIW{UGLwNtfwk-u2mWvwbr1~*>1xnyW8ZC{q4@sD4S4!r`_4=khZ(+EfV|@b_spSruT?Z
z9t>!0^UbYO&nO`n<<6b<&QWLgsIz%MEQxkE(hEk(LE?R;-`-gNqFcDHA=ItK2ix0YL5L+jpb
zcCBXj<%v=ZmZV8IY?Nq&QxkjGnFD{}b~j4YvINxfB9)?38)+gNPvz+WWZ+6EkH4ZI
zxDqFF7?CruGq^2yEvg2fh&Z&EoSTWZZu*L`FbA{j8f7-k+e#Rta~HRbu$hDvUtRdqSGRku*)R1!RL6oj+Lhd_wf)z~~KN>6;VR-kQ8|X>#KA>(}1CIeC3%66Sbq
zYGQK!7R-@_7n)s}nVg$g49?+}#JYhCE7AF2bRiO5jHi~-5+#?E$tcsxN=98t$*TZK
z2!~WX%2PQ-ug;emM+pRjvaKRy)nJrPww@I_cS&D`Rv}l<7Ml5Tw_ICmAT4$Cm0q>n
zsfY-s=cjhXF^evw=WQ)-s|8od(?Cn0B@69kG{$)a@?_QqA%=7%Y^YGg)Do^0b?sQz
zK^ic$Rb5@tl$m5=Rml)hq6zQlsl1Ucm~z?C%eGN*#9Ju9B@5khd97AouQxUTlC2JG
z5f-`Kf!21rA`heN^tXGxt!@VhDf+t`{d!#t9zxR_V#oA8pqJX%C6NwJcemIm&o(@k
zB=vX2qCq=HtqnLJStQFdN)erG03q2Z;gW#L&7I2Hps=x3+S;v-nxmiR);GA)Z;T_4
z6qt!}-zC@9OCU-XEE4kVvelvGc;ShRirnaCoMf(KmppHAi#dyEXcz0W?j(2SlTrZRN9zu(hg+iDGN@5my9K?tkqKfAcb#<7?Ni!XJT|$iFdu{TD91DMtTX`=u*yU7n)#C9h6RzIOHP
z>od2;rpIs0-+F6eY-$7P%ar#a)FGORKTjNMbP>Ux=rcXwG70
zF{LcRB~$V;h*H8wrUcO9PD(5AM;3b}e>yL>imbZWWUM!m9DD)+0bQm=wKsGM!0Igjg5yplqec}L1xa?Z}=ZMo>CvS>B4
zUDDdRa7k`T!!gr&Hl;o9`&V^{Ur*bY1$v8bvSJTTmy^_^La~m#6{!TbqfLG?)
z#ZtdoT`yPHE42-@yK9|IZ;2pCtkGL-iS;kIvzy0J!Zf?vz4lO@ojy|U1A3`#=l;>)
z^kDbF@%r)Z_Sr6sa`SZE3s9b|(~}pEXo0oO!#WuyEz{c&gD8g*MoC_|PXS6cN?7Fj
zW^u4xW}{@5^o8;2zaY^4O
z0gMclEZ8Ny33SQ)=noZQ>x46+5MBu(k3%RIjuuSVAh>{dT24G52Vy2ooo2z>Ky6V2
zkQkni&j2mqgK$F#CMb+@N%Wz^Qpr`}iR_gSPRFaz6+{D^^T=?!n??xnFd#vWNsD%o
zq9pCcptupFXGPGuYO#>KjJFI%hEayKRa8SWoMN50G0|U-*TU<19}^L!8Y7kz>p{UK
z*(@|8%0>x+CHbjaVifvvGDGX`#1ae8C!c=sXMgr*3xOGU6NN07X6BY>W)`Q$r>=u2
z;g!(%%#9mU6XVmjUc3DE)u~$`$}2Y~zj^sh7$wBZSp34J*S~%3GRzSa38Q?Sp5<`k
zTUSAySN)|fu1-&mPfv``OpZ-lo0y-PT$sKwd-LW3C~}s&xo20V7lQN4k)`?7nLuo5
zHM$r{twyB9SZXnzTuh|sVa;Tb$|5WhMk#3l7^PS@kk%YTbDJ%a<$XLawZSC|-3rTX
z7EA5g+TNyHB{pOYS+WRbZ11df_BQ&5TkE&C%iU@b?%DPhoA6cYl&LY^tYm9Nr;@iT
zc_vDv8DL<}NM-d@78!~#LhwWwB6}tBaK>a7Eo)aTQR5n^P);s5YTnWcmQix;Y94ZH
z#cZPl5XM_5^=p;&Ms3inZ?;-H-Of%O>g_fAdu@Q^MeTH%C>biDE>h&-l3U&VyN7H0
z>)oBc_W`}s2A14BJA_?sob35V$wawBZSWqiYR*QvL+ka@a%w-!D534$GH?=5Nk+Nz
z1xCpf$wcWJrC%~?l>IdiC(-owjnZp$!xM**N7y1ax{-%VvQcu2n=3#gMoA-tc-XmB
z(X&;!ZNA>fHku&HY=7MWPI~%sM9CWUN=|7vmw+L{2iYr;0w-aPoU$__Lqth|KU$M<_HmECUG<3@nN{(kh&7gEOBd{
zuK=7(IrOLr?_&~8ZyFoK9p6AprpvS(fLEgRO^#_rRDeUc4~_ue^2b=FIrjTUXz>aS1R8JiIbZUitQ|
zaroft!Uutk+{8xtTQ{%0F>&S6t!uwD_Qu%sVkioPT!|#+Q}Pn{7a$o=FN%itYDNP~l0S-NS&>Fk
zG8~gu|3{iuaELm-y^rUmHuz(adOymQUai!rKww6s`F06_3F{Q3=B4CHJQ0v;mM_R3
zXH)K0V57oG%h@`-(ltxAQ8eW|Ni6^jO(|!v0EzHWwdg7ZC!MpHH+|6n@`3{n)vE=!
zNw)-M%ykNM+c4#R4KKFxGe
z{XOzTAS6-_P}bL*<$klfKkz=Fm)f@P9q-&f-oAf0IN9Dg-QGPLY#yPxy}omZ5PBKEadWCY+EjROxZnfSmml`=(AySke
zrHp8R3wcJFtJsiegClR^vc2`f#zr1Q*;|8Mx*J=0?=$-GH&`J=gD7)kln_TDnJAN4
zn#%}df>(-lC8A16N}@5IJ@-(ga4UEy^BwX58J0(ni{SC+Q6m~s>1nYz1b2g0BznXR
zd~j7>Sxhbjl+_h!Iiv-HY7luey;m};Y_+f|oQTRHH4s!*L8%d)UIj*p)Xx9_GY*A8
z(WVv+XEI8N1Cc15)ndF8zH=?bABI!Afz+@OGjrv>#qT*J)kLe4I
z5&~T+)Dk~8O3e(T4bDc%i`~K~W61@yYNLsTmFV1JczzLfxk|%^=2xa~&Q3tni?nzT
z7?XDA&{V!QcI(F2t%E`%r*WMNn4Zn6}
z>c-pS*RG4M?d#Lya7OmW8~EQ68rrjPOt9oa2(Lb~7)Cm`LXU!43CHHq(2geOlhPtJ
zx8QR&wU?Q#j$)`RcVDbuaOi5NCv
zkr1`YhenB`jeeuHUN3gbkl*emp`=qP!@{~Gm@lqLw%aPX^}JQfYb6I#3f8#vwq$PU!s??PSV
zhbd)tNu3>3>$J8zjm;Km(5|gF>l-ajAsQaEv)0;K^FE-L+P3ZbRh)qr^Ryl)kA}o~=
z57x$Ph+P&c1VyJaT$M}UZm^-C8lH_WET&fiY8dIN5`sXQXqAg8j1fzs4!Yo*9nkdoCm`N@1DD09ReD8@mcGB_^>=L4dGsr0CVzJpsd_EAHUk;P_
zxl2o-naSC4pe0-q?Qz&8yzcSm#$qRIGw+FWt_&7vp
z6pbfOz|ci35-DsEP4A4ll2%ayez#3|64Ok>hjjT-=
zoM_3mKy5H12o?!rBI|6Ift(=9+FE@Gk3u~Xmw+yrD1D=Zg!$I8tunw6j%ie~dfA0(
z!XhDfrB;M3!W{E3O10uZS`{GanvI;*EI4g6v2leeh_cWni)5n2E8o{GXTGV2kW=5CW
zr3|dZb5dcHFh>YAae7c$;S^rU8FnS4sEHD!FiLi-pdMOLR+pq@WCB_cT9(lg53XdE
zAs8j9!4pvv;2F^)V(Fk2ycQcJgjc~Xy(n7WB1{P+jKCc2Xh4iPj~O)nJglz71wRI4
z8hXjr@5MA}1!R8Xw-rL_|4sNeEC0r(n8-R~llpkcwTPr3s@%
zAwQ{+&@!Ver=_Jtav`3WizgSO33|#Bv>KUT3{B5dC(j)9v@A`-DA_BgXw9Lis}t95
z&QDH=g>^68xHLIGIX-=3Vs7Hsqaf<~FUfOP1H!?m*ogw6fuJXifX-iFP+YvID^cd%J58tgyR-hItQZ
zYpd7V7TW4HH@gj7aI4oqe)~(sD7Wt3*?V|AINRO6cflyvc29ac#~m0YxN>k<-@aYn
zz0=&Ihvbk;jv6KW5$W!JeFqdtEapKah;n1A0>|0fLZiD3t#7~|^Sw2+aEsl(KueUY
z7dpKhjr-}rLyIEgHM-FvCYKa$2*DQXEw|pvmT1LE>g?u1YJkH-yTw`yIO#RIUo^^6
z-6~Y+VK_XO(JkrOvPsAZ8f`iCmer^Jcepu>va+%H@9Zv7`a}t%#BLJpSu-5e
z1Mtc)?1pCV(5jT8g7>&uHcB`P>a&Z9VUmk%a}0(MD&r6nCCP||^yo}%ekrp`EU86E
zVmTr}B}F;Kcp%s%k7fr^!Y=u0xDGO&>)}=8mAFO`Ms8~pRC*(R2rZ-FS=^_IJn<==
zVi0dKRMPZHu?QP}0Jt9I&+{&?ucsPu8h>thXepk+wFtUo
zv?O*D3;jlui;?(3C_1+snO%%b&!HtAoS&XYOMI5)H^YIJ+%tZC`o?tt;_@_h;eBJ1
zV`x_MOhoKLvnw;#r>;#c-a_W;%`sZuB0&B~BPGL&%i*OU1tsUA>1CowX$2`7+LFE!
zOV7&2YFeQV9C#%+w2^wF%FjjXtujR>C9o%Iep#XvmT?YQO*BQt5<6f(_Dv$qwK~`h
z5XT-$gb1gj7I)n@K|X}ad^(@#osMR>fJ$~-T#7Tys+l_w5TuoZD=*}0e}&=-Rx|)yE|-@6n4ZrTH9ZT)(c(l_jcJRx5*+&JIDR)BS2+q>rNA*H7M`2
zkka!PheipDF502?wU9B
zN2tW2#nZYusNEmpq!>dE%i}H@SY&6d#D&NsBl>N!7hF<^h6fdDX08I!2q84Rvt
zG;B!p_S9Pr?uxsZ1o^&vjFJtGD02A72l7qENg^>ZLb2J^
z`0R3cdNn!^e_U9dTMW!Y$TM9|OjE0z0CQ>P^3AbZWS|s(WOIbzm2gZntEZRH+$QnR
zAGqXlWN9(9fE0Eaiqq4bsMAJT1~$SX#Q>nCjJBLsDWyk-DJ!Z8D_m90=rArBX1jzT
zLTr?*c$ymKU(zVo4mY}c{oY=`v)gO$bSXl&+2P0?RE6cOH(*Rqb)!k`Xm}#*Z>>?;
zY&Ew!@ImZSn_U#1pCvT9i#jk|wndJ9A_LQ8-{efGU#+ael*xs2y-H!N#>)4RukzYI
z)%9w9(4a|&TWzSZS#NDO+B?nmP8)B*6WkxPxZS}!LdrFp+g)GqO7=}SBZRg#3l_=g
zmo&=V`$yaNZ^J0JV3cRun_~Xr-sw67que>}QBTfc9qIN#-80JD-b%fGjFQGt9@0eb
zt)0?fi$+jx@70jPG5w)J?2_z{T|nh}q20@}QHl~8CdvKU?2_#+h!W-qmLyShQgrF?
z07)1kcXmVEpMwl{e4`yL0+g`JEa$~8trY}Y%$D_HotB%-mW^CR_Y9N<4CMf-y*27?
z;?DQpmlz(zED7)P+uaw85}%|OXl2Jtz+-4JwX~`RgIWlc{nMicoy7o%m&Un#;;OWST^5dV
z8-F>yz%}Dys1P^9*;|p~ws9`%Q$t%`j^RWxCld8Z7A?gFiX^BMd@4k@;eAZPC=;@l
z;0Jwtp;2mPTDMZBo6v3eX>jP3A=L;7qeR6s#~XcWa);U`{Vh!x_hCsM7|`YCt7g+3-g+x6w#v
zki;%5awWPPh_5b3mLrLkcycM8q{k?NBH0|1@&Z{Ta8g}{MWU@OQtIaB(BuW9^l=i7
z`B!3;n|HRhk9P*QH^E=r3(T~ImMPEVLzA3cvNoW$IgWxlVT(n2f&wib!8nNwKoTj$
z!?w9C@0Sp(4(L)y8By6Zk-;vjvQdSqgDPCOy48k|sckp?@@kj>0RQw!L_t*RJCwG!
z8?CK+2cEbMitK_M1r7rk!IC8GinoBqH6QBsM0Ym7m*!rd)!AF)H%N!}HXt}-cYgr&
z54Zf(`+#0*Bcr@`8%^)c)9u~UZ6?Z5qoe@kU)m@)HuIa?#ZjYVuY?BMRk$Psmt?zy
z);G(@x4N!qi9bh_UucvtN8c#f93e(a-zY1s0(5~W*(iaKAW9&oUC;rQC?TAzTltz(
zsu$|5LaRd-38U=x+(!G$JToUvekY6%*oZXkdfne}Ny>;$9+blY;Y6?-b}M#FIhzDd
zq76&K6^9|nxRn450xAK9bBV=>83!ujT;Yt=!^2mAPl?W%cvy=rBo>#YRW!p_6&NBh
zsUS^?Z~AtIQ-VXUJyK|7Q?ZnrO?b$WOgMw8;Ha2Zq0^frdFnA0&}whHqktvU7Dsb
zM!}ic)v1}4>6zf%Y+!bB>DEkWjt2b%=a)kBE78T}$U-o_98GwNCzn%c8n*1bI*-Jdv0AfDdvA5^oTBZe_DeVwWEjg)}9Rb$TDqOKrDL4-U@`_KtUV
zZf|WJ4hDDDM7tHHxyDuk!5pcTD!dOC1HtuB0tbXSA`jsZun|63-)vV0EtI1gTV!j4
z3>U3qz9yIZu3GO?Qyt)0*=Ueg3RA{KfU7{ihDcfM-9FUahpDai4%Yj(H~NPgYj@WA
zx7Yee@2vF>d)`*w{j(trHJxltZ8`MKU31dk=;*(irD
ziDtNGl-%xSyX0M;D0^!q=1L*aI{Xdc*H{P-G^bOgM15
zSkk2)?NpXh5ve5PWK?9g!YS}OE=)NdQO03U0xD50ZUE(AQX#nBLTY)~riMwyL$vAy
zYz_t&6OVJiHQ}wv6)CWkVWT|n^%ldx+4Z=g%?QaX8P(~@V&tA;EF}4z
zP8~I9eWMT#i>5c7D}s_M$$3-=WN4&14GaP=(__T~v=D|M%9yaxpmIKynT?WK-_!sf
zMkhy&Qq`k8S4S-D9EVGygpCq(39n?aW5Tn9T`t8_3qtepI2>~^7@G^k=E8{uC=i)h
z3{NkkRZaoNS%18`7~%szotq0xEre!0Mdnvxi-G9UYIqKYi-vY6wg~Qnz<{yjB8*Z}
zS5nfVf`399Lmq%XGDRZ8E-BI&?9cD3!Fxo8cex}bkWsf~?t=WI`m4f2}aFKv`;j*u7|^p`bC%CA%J
z&8ShrCEKE-X4EKsqC`q1eHfwxi+tWFbJaF*676m@sC}b!z>;WjBZEeFp@wSIHW%a1
z;iuV33unPA3zfFhX}jwiIo!7Q8U6Shyu)j5=e&nKz#<`98Y3IySKx}#2n*i4p;lG@ueGJP6hqP*);WWGTH0s0`_`pcVyMBC{%wi0<;vKT@B3y!f3hAFN>qm_)<7J4_i#aB9V&8+9~RG7tc-9R%IF;xdN|*
zIf5l&l*o$=K_ybWBN!#85S$TWi=>PaVw_CN(OBxs8s&oz9zJ^i;e&VYpFTP{esE|1
z-tNJ@gT1qZ?c?3eJKM0!^@9Nb6I?m$FQ%3(tPNmD18chS_!=rRc)}<<
zTWj3wLQE>~lO)KLNOM!1PT@k293h6sQQ?{_v5O4c6V;F*U-Qk5^`beBUV$}ym36<}
z4UptUH_Q8gUTWKUc(QS}zkBZhIJteYwSBs=cXzOV=6R)vQMNa4H@1)KJIBqPJKn$`
zXzwlC~Rmn7#U8w~}?D8oGZCt^jB
zuBtG;$TFNuOl^cBI>0R?2Bk+9(u-V2JUa|T83<`1w8zC-lVU+2ucwG^0Aiy=3P*#x
zA%jC9EdWSlDg;9EGjMnfA;F0u&WHg+t6_!4nWGN!-su8Aec`g+#{{EHt5M%5VVZy}
zmhY81?DBc96c6wOQN~RtA;t_vWHq1}5#5d|I$4#Z!7G;mddbX!lwQhYmQran$;l!U
z>17C(2ccCS6pv>JC*}z`ql=-$ayYpXPAml@v*Fl64BQ@>K@%P)CR58X>ax{P2SZ58k_f|Gj(1k8U47K03U6czFNz?&;pn$sX)->xhDw
zq92(|6RGc>z6d<2d!*OhTO(8)v|*i4e{a3B1#hK}b=287+=Pd+w?gE$NMVkmi4Ff^
zQyaCpA12_WfXa>aJKMbjSQ{)7{>Y-1HSCf#tWWvTaHUWgY46e%+5t
zB7=13l}Ib=G+hU_2xbIGdPGS^36Sig1Qto7g4ig#Nc$)+!YJX7Fv`wa2`L*TMInVz
zqQq}^KW~&kOXRsH2T)1MSJCdK=RJt=K%PsAX*uUzP{;^^5YhUE
zR>T^w+^>E5_!L5m8!Q=+VRrGj84qfa`Q#F{zU3f~1j5l3g=XEvV2{;CLe(QAK&6oIN@@ke&On#k9#6}(T2CUgOj8Nv
z0D&PKGXXbTjDkATWTUYJQfgL5Y3)d~-&qI8j
z^*dWs2M9T$&cS9IzIm_>c^}YAZTm3F)BWAM``ag*+b8R6lzYS0_x5pT<93}MR7+!n
z8qmRUYoFTPEf(6~y9YH+eUOAvB4xnb*sihwmHmx;cP)z)2nh+Jq?IK(g-dd0PH&?E
zXQXE<3YQ!TMCmp<)Lp~f+-#IpxF^6<CzCHo`q
zR$2wXX1zorFuW1OCAu{Q+JPnUhB+FiQBNcMtG5GS>KPe1S`_ojf`P
zZ*m^C)f&|AJvl}Gzy00c#tY#TJ_I|%E;qV;qvRN6k{;=^M9vN~6^{&~u5Iyv2d;^>
zIlL0}ftD!2r6O7|pe{v>02J1#BZyxG+t(y9JctGRVAS%(UU_bp!?lHAk>E-SR$2+$
zO#w4ul-$}St~B6Egq9Fo5)E@eANBTl(_?r=BI^8s@xdZdNGUg~)5}R>#ud0{LRyxU
zP$IQNkFuc=+s6kTga>(47ia_773%=-#`h34Cj%e92uO#
zhai+t$nv~@#&a~bNKUz&eT}to1l$7yk~1QY3dr~-_=V!jLVTUglik7b4ty3REi}~+
zHd!#r-tBE+mtWc_AD(QT9pDq&J=@+s+kkfOZSJ2@e-3aG8r%U+!W>&{lq}yU(FUhs
z=eHX>`yNHY9GNI#l!7HIgPj`aY;6E@%n73;m*h71+D3(q5+KPbcG)F;qvR)uHM{iG
zhg!?2Ha(n#xZMqx!bs6@D
zU7U+@dQKVYgER#{CM=p~8BmsJ%?^VmHDVVp#M{?08WH8NPKxs&
zN-^It2DgGy!m8kv$S_^1@G@bPGMO6e2_{8TA%`O|$vr&-g%6@lE&8nCiJmQ@U7T4-
zOQ=kS$VSQLh?n4$S<*L3ASC-E8zlf18N3AE4qGIrzEMI63H}&?M6Y)wmi$r+_nv(4
z{>l6Aoqg~D^x)%Xk3W6?!LxUseD=Y+pT76-!$(g(etPe{`)BXmJ$iI3bb4^__C7Vt
z@1RuVnJHGZx2JDW)P;$5_|@9e-IA!OE$b~jG;`*-#r?*n?NZEwUVfs@eQ
z-M?a^WTG4~N+L>*RDvSmkKE|?x$-Y>lyF1F$scZ%+^>yxx52}M#ME!Eznejlp%S}R
z9!GQKZmH7A16|v_oc9_1_*>Kpqk#;sWT=GwA%)*TjFaqu1eL?aIISjWhJcgtEUlLz
zi!L2h;F|Ct7-d8U=*7@>M$Y)u6Xz}_=fe8Rs=NpSg;Ao!dl?v|W+vevY#fT7l(l$9q4DRwSE8-T
zVy_(aP2EXQN?w^H-?U;nA!p36$u!|yY@P5g&LD;0gOWxJh;oq^(MAm!Vnzssa6qIa
zotzOi2jfE_UrI4oC4I$k;l;p4@<(Bmv0+0ScSwWhVTi~eMV?&}DSR`f#$uUJT92pI
zSXz$a{i3bSJvqo=H<~z)O}xZ*^ufnR?|yjl{)fl!y?65dyZ1i)@X;rqkUo0<
z{q&>9AHV&JV3hOe`B2QRt{ZJi$M+`SEXAJ9u}I}eVw&kpyfTWp602AvI{gVVwOasS}7
zw|CmzfC(P8_MSINw6*j>1pjJDieRp;b-}6$Vi*O98a0;eac0=nwwr50OH6-8&DC
z|MCCuPhh6pz7EJRvKR#F45=_F8YF~rTtCP}xnBG9yU);|MxL#cXi*RT;Sc_R`)W`P
zC3xM{%pxq37U*R+6!Ay#TnD(}BKPMYMICwo8Cu*la){dFWU@5ab7e(ZgwYdw8Y4|_
z_Cz*HNsVF`Da0-b{RpFk3_Ix?B?l{Mmkbo`UxG@3c;t^KO^-KJ!sNMvAwkC9)IUIPe1zX==~3m-hcn(gAb11d;ji7&mMjJ(UVV~
zJ^th)=-tmrPd<77;YW`ie)RbMhYyb)pBz6qJAQii=<(^{!#mVGe?-mmy}O6IX9sAZ
zb0eL4&rkNCEx0F4Q#9BiF5xD;Ut#-nZ*a7|frk9;O|*{Tm1rQdkf)N9eTWT?-HohM
zm?`w4QI3kNaOjMz!RZ0S>yYorU&bic1|`yuX_S?QRc#SP!W?0d
zFhSTQ=h-4*mluq3*y2Wpx^yZnYGreyyV8PPQq#NC%sOQ~TeZ;W{wp!cm=lRP;UH|n
zO~NACD*>47m=F*WgoqSPY}h5CrFe=CJcW4^_Jl?{`w>duI1us>ymD0u^Mvk&)GACc
zphh8B^knYDQX;~oPC&VS#KKlIG>Tnn%UaPfH15vV3;>vhAKEy#rMndj~VK!uJ
z#GRlfWt3GYEU)+vgG?B-usN>0oL*pug-{b0;U|W}D}kTX@NhO+6h$ta$cOwI?{PLYS
zjlI+S`t9by{fFQEjXNKFdi23Zr_Vk;`RL>0_uoJL@Pm6FKYRGuCyzgW_VCjWAAIt`
zdvMH8KYaJI51)Sg9x(IahmX(Rxp(jV2d7WZpyS7<(CIt(0GrSObno`==|02_b~M!i
zlGsIt!4ny-z$LIwq*QqC5ZXS2XHh(nu@N>$u6KvzyB>~io$jF;#2KXYuo|JwvqN4(
zm&Kk4u|Kj`Lde4?4%1kvda;pJfD+;hBmyC+TBQnMfL|3
zSR_kWr)QLKN%l$@rEiY#L6|1QdAKC;a&ka6jlxf+E+zB^KN@#kkfG;vil>cy}gy2UBUG#vnS6WVzdvy#u0jM-+@DMqg
z;oy`gHO!IPF-X>7d6XB20DZVPnV_&yyd2DqstqZUP*Ff7+!lNaXQU=S8rpD1oC{MH
zQ@LS|Oq67l5Z^yCa7^4h`zBKOV^WGFWi-RdCAq~7v0cWJ!IX5qYRF4$_dogGlkfdb
zb^A0wIO?7}dGz^joPPA3USSb=K6E(Ci*9zGSbqVV5<5{_C4faH8~6&4wU
zKN^XMnM4U%**xZ)p%N)veRWuq@B20&NOwsnIb@_D-5sMxH{wWIDd}dU
zv~-uGgfzVS{J#Ia$9?R0{@=4*_jR3douFR^`))izJRRXbbKt%Gg?6;wDZvN%gV#M!
zjk*;^91^$gFuPy1g12w?6Z1!Gk#zG2rABNqnxYFo{33Kf3)zZw#EgM{xRja^u1e65
za+JfAvtj(`O<(AvMlC%;26uF+3ObTi2
zk<)kNIj04u0kcRb-i^P)El>E9W)EE@m`jkvyznhBjs1c}B^%a@;oIjsIR;g?
z*q5ImjsVOUAO9v`*NqCbV0(y3dOPBimMtN(fsq)jHX_+P>0SRlGaQic->vl}dC)kn
z{U3(fiB8jnTPQO_#cuy*w+C+a0{Qw>@;xA!6SHz^9GVh%)vGkcErhabpb8|EDdcQp;8C=C7Bk3bT
z?WO1m(1S*Tc{(tOHiM5N(dtea(f?DssgGMt8Vxu{$yI3v{iYxNN`4_$NE2|m>7;Ee
z7qzM-M!_d7p(NJdgwey?;dGdQ{Uvy4O8M*GjapBkOuQpj1Xl!ZAdh2M>iVSjPNivz
zKKhVUfEKLxzO^)MLBXZ_nmI1aTGWMG#fY7DP~)|18qsMa%uWku7tvWF1iXG98SP+x
z#5EC24c7AVDKjLH7$nSrW6D7_YN?SQ5%)VeuSI{LQxvFvN^Ef{DhpdjB6*#h=mdj$
z+r!S~4U~r&3qwW|-263OQJa(-0_PNJyPV`8I((Ls
z@T+abtHP_x<5DBy-w`-ItTg6^G9xCD!aK%%p!KWmLkp1Rw-^*@BgN5AkOZcWJRdNm
z#4_}rpmKM&K3)Gd9UlMrblp>(`QG^8i{DKMuRmq4WtS$Ow2cSL--tg{AuikNZL8cY
zv4`X1ZM9)m@#ov;_qh`BVlR(VRy6sF&!;uM|2AvdxO#nxx)XrpFR-DAKlS$Y6p!3u+Sg_$)#+3bGKx8=?!&SX)VA5J`+7ii58T
z3`a|C^@Fg-6o~Lk8h3f}<4A5k==zYE$ANZB%fn(3x}gDVa2MR$J{ietpr&Q=pLK5TAj!@<>6
z@miPE0BkLbnfECU>l5)jW@-@{^Ar+(c~3D(7T!Pf<)CcYgiUmR4e^*$m3G9QJfVJe%XjIJzzZ
zpfIiLO?G&x8d3wk+Paq`y+C5RlT7?sz!joFy@FfONZ{vmy!v!A_5SSB%^@PT_rHsj
zld@P1Hc3%TJJOf*kDL;~z3j6CMKt?p;zS1bafiga2;svp?ORH~r0LatV>)x9{D=&E
z7d2kG&=sLuy{SoH-i#z@uGiK6t&foH-at~7^A6eBh*A*N0IoU>@a%NtE5>g=3Y#h@
zESiq|T>MiXL0EXxkEhJdCAtuUJCt+_n`EV0){Nhb3A7!hIxA6!Y`kZ=yL|Ev1so9$Q|
zznR(N2%?Co3<;8QYD&PXLQetwk=S!ELfVVX9eT7$uub937Ef49
z9&I1~|5LxbaBMUPS5gq{8zDS$w7=yb-|
z3IMjT+d3V8=xJiRjaQB608eyw?6l#$KcqC}Ked)T0LgxUrpmOT_8f;KMD84xtz7RjnRkdo
zrN-Eq>a|;EnSU%SxZ|MV2*2wT@2-g{LLK@pSC%&(q>u*YbtgoR9E=G>}dl#bHrYhpDBBL!1hN+HIAXX-NNU3+b3#4!j7to48?Pb^g9(*}{G)9B@;o
z2p}YQ5`@j#Eskj071_h7M+nx*cy*^Pwfo53143F<>+B_;fdn)xv&yj4uz09hem^HC
zz7>>VcPdSU%|**7+_YCb+RdcuL`OJ>RioEUAHN_1A`a_UPm<2BBfvc1z?e
zFBTyUQ7WashDkG9!K{-ut;S`pQ40E@a_-EtMdVUZE*%b&tm~cs08KRkCtt*$u5*c&
zO&^vP0`|lo*Pm&mFlFZ(#2<1W_iF-Jg6@|E~$p
z{dKr-M~9?Ko9XJYPSelElXs$KUkbI29cKCe#KwAmDa86K^3kLVsi54l!@NzGwBm=)
zu6xbzg2v~|*tq56pH*TzKNgO4)@`rGyw@$Y+nBVD^slQIkKb?(+cj3n&6LgY7D*po
zml%{Q7K12l8abqsGmNS|SyH$=v38ZK(}EH{?S8tw(`rhvq&wSzy7Sqzm22p$5=jlh
zOa5XH0L)1>OfDmtFlaxrypOiE!SKp(w;1H*!k=^1%<9EW_+$P=m=oCzboa~ePrW(0
z`|scPvU~F7v2fTLaWyf?4v!-vEAC4G(}+A%IfGx)E@zE2WCbfW9b#te@O&e44e5L7
zNKh6WQ?Mc+8Do2Z1VlQt?)i7p@80E>fhT%*+#^neWZxKucd)Cn?^sSR7R7v(LH#5|A}zBOY&V(w52(X)@wo&
z>gz3}P)*-i>$rZmO|uwh{$e1ha{$d}PfO9AG{`g?ZslM}--n
zMpoF!gE9_zHl`;S$F)X4R@91S#icyAL~VG1V3j3<6|JqXEcYwr`C*7k(P4Y~NIJYS
z*|D-r7DB)9^XTOrKf0$@2e(vNYFhbwe~_E
zOC}|DLie`nICsKS%QPl<&OIeE!3veGZ-HXYdY62lG^sNJs4?sk@|Z3KbFUwW8)b28
zsB~WVzLB(rhK#IlI-I@LZ`7Jy^Xp25=pt}bs*jzofglb~ma~U5ME9yww8r=H{2ahf
z0Iz|B8Z
z2cJU0177siJu>xr-M6kRRP5g7N0x1kb2fMx;xWLwWs@4$1ti$6W%I8Ch`zOd)5D!R
zCwhrpjbsq8O|Id~g0N-BR~{jq2CL@7vYAtTwqKCKs)Y>ODn(|@N;?lb$RFGe1I;O{
z*D~{zSp5=S-+=Pk6(a*tJ2Q}`1XR<#zu&ov;B=;z=db#=KA@v!KP5
zi=7smBHIRpdsVjV=bYt$#dN+X-r8XYE@d<08%9}D&5WlM510=Rv**T^~CHij0
zHO#h(phz^XA}Jwb1r}084lCMnm|T=GWVWJmj--fLGFyudsB2M9Kj8AW_N^)zblA!f
zi)Gu@38NgWxf2CtQHV5Rf(#a@avRG;awIppYQ$R2d}74|TtdOT>Jda3q_vqqoARJ6
zV7UMqDebW{OR^K%EdLIcw$h#kM=6$Vec8YzsDE6dE-Q<v0O16O@~rxg-{CkT&XIT>g?9x8EK~#aImAU660X=~
z!6S^bY*F2i@&X16QVccGJZeJ!v>8D?Y3+BU;qTKK(mCa&p*X2xwD)dVQj`&x(scYi
zz;p7%ZwrnpFJM_QLV(%K&zu??eF9tAiG^8TtFbP5b-#B`}OvOdecR}M(AFxXXR2yje%R*O?vOFXQRkCD^
zha31Yy&g;3nwibVdzsCR;C#cq1MxPG8WQ~5WVFF~vAm#;2XE@$qo9eaLGCMQf0
z>iuuSWy%(@r0G5u$0r+olgVv*pM?i0Qd<)jqL<8ir@4e?4q{c4INWAnU_l?+X
ztdvWGdcqceKp>+f5&A@$+?h#A!et)dRm$|N&uJjhc{k@SFc)&e>*WI{7
z*VDh>k1Nv`TYs*`wsvMwp6lA$
zOsnr)w6|}h3LZ=VvW_LbP5ktYGt>I}#(GDp!*#;X6aSRnB%~3OrbUsn{!GiNYRNpsiCL-)wWQ>XopP2tYW;E+nIwyH
zy?@q3Th@Ry@Gv%5O7PJ{A_$mH8Gd|glr>GBFcq(UFG)tg*td(ei4K$fl7%zSRrSj{
z-}KbVAFPb2VD1i~r)Ed?yaSTX^Qgm&7qY`P`BaK5RV+xPEw5xYvQ5U*+!pOC6u$W-
zyh24inS)RnVO)H%RY*j{9F=`D{aq0fqph2;f6vBoUlSnJ^G
zlM2L<{*>4O)dQn`hkw8W?;8mPYhtObgrbuY0v2|~ACAcA{-rF2+|qyOIclJ&6Gc&2
zfx@~gMX8)VGC1R94w7I5lkHQm;z~RwuoYKS&T9uUsB>#8BeUuczXJ5Y4#5WMOf3Z6
zsfwi23Q1lddG13Q4pN?8E`GXX(sJeG8ClG7@EnXKkcc3i4A2cCu;Ml!N+^lmP{`t-
zO9BEFh`j_k5c^@(kzpGO1dIe9jrr1eH34s<_IGMCF|80cC8A(xtn){IzNW6edFEp?
zcnsH7E3~9|f){_~*$C^ZZ>29vkjtCFwvqxQ&0OcPaDMBh=?EEoO~HcgC;X0}Dx(iu+xBFa6pr+NL=R
zo&xv$K5|~`$qzYU
zq~_n;Nm>Nc8%7BZw1fs6vkcdFwQm1cF9vBRl;H%JzB?Qa5V^VwBYna&YAF%OE->n@
z;C5Zg4B!^9EZc{yzcutZaSb
zA*N_3k^d_oS%?DC4X=5b<$u06eK~UI5as(V`izhcran)sKOt5z{^SAwEQ^~8SYRKjc|Zq+t@
zoCz7AUO&f6$Emug9!Yy-TZjysO}yELZ45i}UWO`TW-#WlSzLr_Ctl<(si;;S**KfgZxU~}miPDFW
z(UCK{)rd?x#_Wi~!sNsPOX^!Cw#-57VyvxQ5SBI3@h~dpHy{JY
zCxALpcx^Pv9YisHXGfd$&@VP;y>pNnvt%cR#;*ve=!OCGc59y~KsF>(?8{PrhIPj`
zhD+H-brgYVJ>}Ewy$SmOB!EX~Ft_~QsrOQH5@g|w`o96Q(yW?4gjao~uB?kT$p@m0
zDv^{UDKY5g#%SZgi7nWtNrgnmc_1S##Ceye9M+Q!v&{(j
zNWCqy=DJ;yNvrS{HzSI}6M{a
zjgDk#7*RN;&uUT_LhS@Cis~|(0J%WFVrsx{8Kx3bI(TW0TaY1%U(<^atilDDV2~YOe+cgy+QrGpqB*wP_%*+Vv~lo7;op9blGwmVy8D`$`&HNDFo6tN
z3^@<=Ic-0(LTcKyr=->dX&RnrWuom85(E%5S}#^ImVJIZ^L$|GKu+mPlyVmU!A&>ZhzHo+$M*J)PQ^?la$o
z`U-;6ww;nDv2PF1xakIeNzIJ&yL9$@?7y$|%DPSc?f-|0B>(ZA-~YZe;NI#PF~Tgo
zT;K$xjo*G@9zFOKAs*oY)CQuE$#z8u*MOJ&XIyk)H>_LZa=Us~nF4bL{)Hfg_B
z?JrY#O|_}mUT5dqVJW-EB5;9!%0(t6Uz&W#whL?c)azxr6fh{jnqT=ybP747dB8s;
zkrDg0iz_6Q6ZY%in+hNfPLi3d(!ydKcb7f^lu&$`*Ik66P;fP6paSi-bqGnj^@Razm)aobys=}EMNAV5oCp4Uy#h+h>0v_epU&6ckyzrFo8B{~s!)Twazd>h*jKSFc
zznukw!!OYupB8>N8_Q#%d^Z0~`>H!Xer?eR(zG@^2LehaF@XQPD0pNL2^>C-~P)
z90@-ZC_mDYCr6mf7UgYxQTtu|aTL}F1QpLP@2M$H=OG`S~}
z|CGt`=${HCR~w#KBu?8ezXH90TPDz?ERX?59n__wH{{FC2Xw||w%
z={agqXYN=RbHUc{_UfhadmVOYg~%`1N(}
zb9(Om;3NWG+uPZFxy%1_YTM&^yz7o%Df-*M?nbQPWqta(u%Fg}J#%c_
z>SAnqRftYx(cIJaYMWa8<@mp)p6sWG_!}CLRUscl7xMRhYIVG@uP@x=<}CM@bYZ;5
zJv!C+iM@-*E1t#Qi)MM1U#s|=7P?{T*h{v}e9LAaBtUI_#}uk2-vTQS)LGr8n!G!a
zpq9vSag8|;X!xad!kf&za;F>OGk#b(GfPdwoDQV=`j$S9nnFU~p<-j$(h%K<$g}_t
zgbEVlEH+qpL+{5W8HW{$lWo#Ht;;pO`I=0`6!mTUIul`-$dJ68TrP$@{@qr?$|i;q
zmG9w~9ho9uUK+q1xjPKlxZgJL9~8Ti750WzUpGDF4K7^+NDpYHbgrY{^gW6-Og!k$
zaqH~q`Ai+%$@r%MUP;b|RB_pVf!-I2<@qtgM8#$1=R_zH{_7
z#v~#=uv`g4?jDFmMvY`U5?U`}Mm?LpRcdFzGu$Fgw@4&!mgIqZ3?nOHB)hN^e;CpI
z03zZl-jLm()nvE?1h6Fpkerd*fJMRxHzJHVB+(%1=*);2#!-QzWM;sXB^QEB-IGW_
z3)LX<;(*EghN6TIXo--A2gd)_w#DiX*DI&5`z(T8Uo`P0@7=+N^hri%kzVdFX)wjD
zLiQ4~e1(=9#V|9=HXF&{3Zy?S`k*A{!c|c*1){^2i`Rx(i##+cQFlD3WS5s$e){64
z$p?sTer+)l$PCeC>7~0{VBBIvK)j|vSbCOFCbx)D{Zj(|&=^?ZfC{gz^(>wJmgz9`
z>%xd-Hh7*zIMiK{b9d{t=)hZf;<#6pSDjcj?w^?%H>kLa@uS7?g4kLwZv0Pt1b(y%
zOFVmYy|g{+8(r+I%2St8t6u%99^1;$QT4cBU_LyQ%9Qa=@7tnqwejRk
z%fmTmO~+tw!$S=(W(CDZWQH9N$(_9jZ-r2LBH2URoUey-vB!C#J`P8
z57KmwPfivZlxy9`Ki|B(pR0PD!hgO+j3_UM*ZkG0suP@Ss4r9E_d_pRrjMg~a?4#0
zEqns5Ld$YrSaXhK#-+4$-0^NsMZFGmM#jfGdOB{J-*t+&JU}jwr~VywR29wy``qA9
z#JQ{4pJlC_(j4>LG*Px?5`@41p6RFa)u%(O7xoqMx~c>nMms9!(lKvT!#6*2?Vn$#
zgCy@<1_h*XFCR>YP?23)d{-0QcqfndDutaee@DQgs$7REYADsXVUDXC@ugr;On*>?
z=Z_fhYF2@$iy#?SeF^?$(2t?!l&I;%)R7|5QfU^BJC3t6AL0@?!PFt}$Tp
zY*O|)J+sk)-Xq2__C%U^8blYH(A}hB&gYBv5%%SxIENgo?V)Ab4*)b2S%HMlDQlPk
z&-?2y@?E1q_4qJ$zOpL3N|`V?5z3(ChF}%6Bq1M3cy{03A_2fn9mXRQ#u?g69yvo?
z$A(6NCO>`kwj*SuEN_`tn^O_VRBM>qm5=0IKPF5j?2rsKayi&n=m+yLmMfV@PR{@9^yl%|
z*;-J9zvFzWLCrC-H22ZFq{aRRKJ?CHrIL|*$;@N_ulyO=&)9#b&!@pR9yB7$KW`@X
z7PqTr9t`E*hu@sN6BSq$?f5A0b7pb<>xq3M^M_WG_8xix%TE6~TvSn_L`uZ{X0LdBHN_4@*CDGYzT3)fvj9>(lIdnyJ{WT{yFa2cO
zJ5D@lsDz?w2ZsZlnMGB;qXCubRmmq9Z@JbuZPl#BIdf@aiB7q?0uhSv{S+ud$@z}4
z-xnS#n+Fj)+#^~vqEA)Zy(p6&*#qa)vfg*z-9!iM`Nqju?v$Riqx@-T>8}~1{I`_-
z(kqp6^tX8ZXnc!v^7{&NEk6Vl&`;-PMgH-%go~a
zL)(i*3!%n&>hwx6naaToa~W{?#C^gPGZ10Zj^ZxKh0HiagKTx(mT1?4R~wwPW$UX?
zNCB9#%Mrn?Au%n8UUrO|80PoaGN}@Oxir0-n+#XJ6MoK}nejNyM=gJ``qw^99x85N
z&y>O#a9e1oV6ey>q0$)i6W2O=5oN+Nf!8XbAOo9;mECGlwJ)-UXVYYGobC;P6)%&>fH5S5%^Fe+<%^*B}aW%`{Ib
zdAo_dgfzrXr6CU6t!(%f=Dp!OY25k5-6pZx>8FgIWsKe6nDOxxlP|UE
zy_||AXq=7=QnIpSY9+x_e~|zLC@81XS3(>~W;#UU+G)jX$rDD#U}Exde>nSKA{~Re
z`Gc1|8hG_ZBDX}!f>;rqkLvVaU}#Sfg=(?MafWBRlush=t>nw%_gfZ;_o)RL(j}Gu
z>IsISS14jqVjXv@ze2-Axg|3{5qekWdNXHvB4gzeS8pHn=F?PP8V3Cj_8{Eno?$_Wf^1{VoZ#q@9&{}30_`*IeU@U`YqzcmMWz9
z{Y~=t-qOZuytsAsjn6|HI{v#8ao>Q4HS|oYv#&WT%VHe?w;O*qpM2V^{(xZ4HMdJ9{Ocd%_Q?Lr~?9b_M!4i;CtGZexTWRm4dHm@N^A8qPs?>)w
zj50GFesPR2tweP56c&WT8PCMIdpcf)-jwiZ!(TA;1DZLWJ~6L`>IgY^rO{fj)XV#^
zec4<}`2q1D-;q#azmk53GMYk)WSaIXw0@HHY~7#8qm@`KQS+~fP<~)mP{nDYRzLk0
znv(l;8DKk8nyw0M$83H
zIwNzSp+G<_NWQbtC!y@PToMQm2N9D}n1a?T9faX{m^g2Nq?SSaEp?QjMlKt2VwT2t
ztTZBDcpnFaP&t1)OwuB2D|a`)^gwi48O_OLrCnf`oUhdXJXk#F
zakcbJ{nhTn`V0EwLXdd=f0aNT@g#p)LzN6dQKXeJ-4{iZS`5-#N8X6AwU&&Ub^lz_
zC-bJM;oW1T$?==Zf|IbPG3zyFsgk!LIIP2x@)!s-8x=URR8fRV!d~>}lRmB#5tzM*
zif}cizz7^fA()V&3yAIJDttWyqAf(>>I-6Gpdby+X%Dq+BrxtN(Dv41C^#Uj!-DiW
ze(naHUdzdKTX09$*m0CB<|oEohh!6rZWp9d10nlK?sS`EnmS?@mYQMK6SnqXT1zQ+
z^C+r?OJHHb{G|!
zfxIdAx!fTT_)_??`l8Vsdam#E;z|W>)4z8js{!YyYfm>#XJQmtYwIF{%i_XuXSNwimlU-MTxZkC13?yutI~5{9wv&F$9R}{+*Y!jk*HSdtNH1^j)}Q
zjN!gY5!{jAf^kOmB%&LcFjJ39PYwx-I>poYEB+P6Rw~V1&E?TtavT3Dpt{QaodvRB
z!;3J(D!5BObgY+7*qbv<)jVBo4>K
z4Z{g-VuOv0#RcufNKS1wQm`&9Q(@0$mo^`VQ;=km>6JG#M6Q-KIT<3BgftwL#w;%_
zJLLTumOc!)!z!1ew4qP!mEFN&S0HiQ@?}m`k;`JN;gMO-CvU28ntj4fCqmKmCY>Vi
z+F!%>KMzOzhyu1=p3Xf%?;^)w@Nfk$%aO~?7%3iSCoR6%z?e3Bw#?Z5ZrGxLMZHtF
zxxa}+BYtQ`E0zhW0Jr>-eLspv2J*O`>`1sWL8k2LB8mO1uEkfh@~z!qC=p2Mn~bes
zj*(P`a*d-{j*+UR&NMd*5+71cXA<&A8tx
zDA8)1GiR6m;hKw3?ABz@)7R*WtP4!m;jnM{Qb|f
z#td>r-8+JuP~VcBKtQ?bhNonnP`9aKEkhpw=LkM8%bvK4_pxvq&Sx#4?0LUbuwQT@inmZ28U{d!$ZIm4a0DC0d(I
zZJv;|z$eY{+4L86cFlHIz*)_UPfdqA5U3w;>G0HH>i_k4F!r$9S)iRHC*45VqO$GG
z_ovsrD$Dxwsl#({z{C3h${9BHFI^8)KA8^>b8BY%YctvClTByh%R&!kj*p&>&P{$d
z);DXL&xhF^Ny1;yg-=$;|E*cN1T@sO&8;ljMj^w@O(uS-2f&!9GEeR;zjIl;^BtWa
zvy-Cc*;S`5QSDA3p&qi!!X-fl;q|#^l^Tph1YR7HNh?n(%eB~Q)lZ_-ZpA#PWUYFgZ&d|F&~%}P&Y@e0+IWg69B5+B
zS=0C?7aY-dM38h&TG@B~zy}r*OjP}SamXZgmlJuwVc4efo`R{7{sCGEiQhVT;Klns
z7)jE{EJ`%s+bB-(kN5(QK6QHRxpv~`$H}hCBNB!CRm3>5$MU^^;PvD48D&9@k&%q6
zc62wL>pL`(PvQ}M=?bw>{xoQBy3`7tedL;>s^IoM=kbM-qbE_DCmnWz?uB`5CmTV7
zUe+|_zcW^gb5kPDp_*vyEg>CVX%8`KL&Y0?!qNq6JYod!6&+H9!XYRH*HAkySeY#3
z4#6s*ymor^@P-08z`q-MMA1@ll;m<`%k^DlZPfXe%UKN)>#M+Z4%x1N(tc*f@Zie{YMRdny)l3PXV`@7#zl
zArT_1fkCl)p`ZcQCvzCQ2o6qn0IaqCw;!IYS*NN(+>Jb}tMQ8#>E^JaXf2dI
z=%Wayzs8HDvk6widz4P4$`6^xx0Y0)D
zDijxG#C$JPhQRw+iM_e20R;y1m4k)DnG|Lg%BjR9OcuDn(ucQO%2`g*aa5q`-l^O%
zPY^??v}MlksfoMPMY6MO3aj&ta-t;K2CZkJ
zaO0%D)5*3)Nar`3W_v26XpOo;^{vdn^6snQT&n8tlUT{3&e+^pV7$^?q_
zKXqhfL2k`b%s9KU*q`7UM5?+oFjOQrRJn>JzZMMNu(Y%
zcOt=y+Ou9!igA|oX}CWUUX&8VJgeV__LYBUT-T=lyCL-4bB)mCI=&M8`$2}L%Qx;(
z3b`RL%$9Bd)kX`#b@t%#rplFTcd@8A;y@@5JSbm*10u$$KrwZ8Do&$ktSWE8XkhC4
zp^r@HEjr;V-V*e_CvhxKOvm{(k<2hfsLdPlO=2ftJL*hDe7un2p-pHh5**7
zT}0_Nj&wuI*Pkwk;iJUGNluwV@@@NDUle9kSLYF_aT1njUZ7Vps3@|M+%*Po|1^-K
zCxSYD=QpE5qEft(^&_
z6a~cav-dw^_Y6OR94!Suyv3NLr@@&-@4d`FF#k|b5W_)B9LFBIr8GL#ntWhH+gVGQ
zDNm`&A&-@ljVr0**lUyFXpUf_>(KHIb=10^{M#iJE{rEPozXP8iHKbtI!#J2HvNL
z&*e$1?tZ)2t48@r(w~ZxtTcuj6p4^E)ItZ<>_h{q>;V6xivdzH|(f!&9b3+G0^&8Cy!0*Pc=F1Hz=U!*OH|Tj7iXJah>f-hMylb
z;<&1f5fbuqW3+QT-96sBqjj4~V)4%}NVd*$utM1~SHAlw5|HoD52oF+z+@!(4TfRp
z7EHQRCVxZ0z)nHI{ulI6h|?0$#zZ{y>-+CO0T)O^Kjaex%}3b$d+W8fzLj_eo=0B@
zUU+3|7S?P&&L)_Pr1m05i_A*inC-G(c$_h7rh;dyr+&PFnt>$V{mB#4
z=9nSI7StJP$j4+wGfvl*MTbY0FY*u|l-0^4pSd)WSc#KJq2B3#e(^>MfAjWqBVAaC
zvZ2e%*{Y)G=K<MoeGBq#vi6-qVjUGn1nmqpxTr~*O+pz1i$cIVoZ;Cx9tnszAT=~}q!&5Y@EK*(L0XJ1W8=4Qem
zyOu2OYqi9oG7q&xK6;oJreH)7`|TPu+g
z_n&W<-JzF(0}^&|B&B1{5O1JJBXy23);N3Uero=3uQSA7?1N|nPa{E^VI*6%TuQ2R
zv{KLA0MZ|}O2!mjBG%}s(9mI#kg);*t~aK503BKgGmRmh9GSER?H)Vf8Tpu%PiJe#}rnU)j
z9n&NJl$Yg%Z870CLQ0euDRJw0U=jBNDoFtgnYN=b$qdYhd6yDte6v@=ycbuN*(;SH
zk&R>4*c*aJbB&VXH4Zq<2Dc4(G$8p#eD
zf|&$(_@vUq-l-tyj(FfQ(#R_fR6UqFK!>{OjU`QbAuMIeE
z{QnO_LA<^SfJhdhUFJdcQ}S}*zpZ@dlnt)P$zh+r9;DL
zrPd+b)L5gT${#I3nWDd2fTPcm(CAV`K2stC6^cAT$BR=UEfkd^nvp}GgnW)1jhp!L
zj}j?f0IUkf4y(dE8GB%42#5z1b@VK5XuSfM#6-^N>|L17B#7y
zqKSY-F=P$P#$~9Q8Y+0!Q^Y@`sF8NK>4WIF(|P#Gs<98YwQK
z=2J>O#gSBipeDMi86uexIpRnXAxu%82Fv1fkf=w%6sM%laXyO)65{%}8qP&VD<;h<
z4b9XAHR9g*K9Lex4wpCQ5(Y|s%l_MEaWw`_I#i;5@VFC+IS~LK$PZ)*>=Tb?q)9g5
z#gGvUn<4H8_sNpQSjnMEl%q07E|a-bG7HvBBO|yItVtSPAKXbt6D|#ZWSZp8Zk{L&r{-%$Ts6R*3DZqlS^Qy8jE$mh03hO?^C>t^j+Ysy0g*gc#+R6UBj#cc
zm-6w4KPvi)tgT4uvZSm?NCXm%+wj}oK{!P$kt%wmwh6mYp3SqQ|I
zR%1&mvBj0>0_p%#k*>yn8cPS0N<>m4iiQs%W>|4W!v_+lg*>g8
zVg#8ihe6G_7<@_7#x1cJyXZQP+qsk}Ld*1z=p;28R2q?uuxv;4Y~08tbvLCsDb-G?
zj-=RfN=qh`1k#kAqP&*yyTZlu#M8jduoR8TIFyMgDJW&g8B65{_9QH#Oz(^HYB$g%
zgttIXuoRu(+#AkfMubKo(l7K6`5CSt22Ijq7>D>Mp1z2m0r9v+o`vH}jFqIRIoUF?
zBM8!;tiu_|8%#+-O0(Di=jl+X36%6S3YR|Nf#(?bMp2Ka$XwJgfaj~&wEg+itX$22
z@^#Y}3K`LGS$-{sNPZz?@Y2r%EAk*zQl)JP(Y*mHnN#_6);V$hNC6*5NbyH2I|_(A
zp0e0<3k|$|KZHq{GCkUxz!9qT%B)JaRO%F&K68zq*m%mn_Vu6n8~^@)xEPGg1VaDM
zzx`jlapn5d%>2r7U}-rzwUlt`yGQT*MzMc)DV5J;8)!$Wj{f0iANF^)^3Ao)(|30s
zeL_#fx&L(I?B3?t*};Pc+oxxnCueK7kGuPao&9~NwYLL^Y!gAU)`wc_?e=?n{k8qI
z-d?x6+iveP+FSMRpw=1CB0TTrKHVYeDD9?c-{a$a%Ks~zyUhG-Oce-Y)O^Z;1CVikp20+a1?d=mIpGN~Ax@8t7AJ
zHR@Wurq-%Tt*X{5TCJj0t6Hh76f2$zWqJTxi5{ilsaR3{r@r|a4nQKqyS}n{FZwvD
zQHb<@I)}>!K^%|tqmr!ALhsx23O8UM;a5!qhk@-F9|eR_w2!z@U>OPtC7<}=fQAKG
zq7IlcQq2!)!@rWHBj+wzBUR)jJ
zKu@F)4xy&^HF|#Y##8!C$)QRXbL8{mDXC}BMoNDb-pD`0j_N=k8|)ZE${Ca}L0(`=
z(ByE!4Xp|(I`9_#RIwwn6_%}-ihoV8rju5kjN)WykfoJM>G7l%Lz>VNQ59)2X;Sbq
zt|t;kDz2v^GRQK9G_IjM9amEcGo7?0@ksG64tM{%-Xt@lItqs>L6*qqS#5+V!Ha)^
zcu649OHLUv=?7#fI|VNu>5KcjL5E;OrbY%w-sN(}M^1e)YkEhkYQCm{EK5yuMCYB?
zzIgUGtyMlc8T@%t{L71(GF#P0<$-36CJE)m#GqmWw*hXGa?|PKRbs5kVqLK=`26YDIUX9VEIc96`I*xGn;QgImr9=
zyz=co{=fgMU9A7TUwrKsUweD}=G^j9IIt3%nGZxW)}6}>P&w0C&BvwzUu+o#TM5tVH1
z4!ZjV6enxI1h
zBlbI1uWkCs2%!S1k${pUDgjFRYSwTmWV9d6l$EMhu6Y7PBCXVQL6ZcRqf7}QgIyN#
zFEFLYj^bz06USfp=W_Uq`33msj69dlFGL0J+w%%Hu#pdoEHE6=WF6Qf(Xx)Tj1K5Z
zF>AU%g9q|ajPZ_3I0^`QBeEPu^&sRm8Yn4ig^XDSDQZZus~5fXdibT02MC&Cq$ZOk
z?ee^zs>+NgFj0h2#jWzI`}Z(YOvU2r?kZq#Fe|f+M-h8!y4)$~c5_q{wrfxE)S75n|0@EE9*2f=Z)S
z2s8H-0Ld6t-5?INjDw!-H6o#x&*bc{Y
zaSCMOIyqWmo!7|ZxF&W{ALpVPcc4>YA)U-gKa?r`I3-6Y{qMJ(P5X^4{%e6uJEdDG
z!}ga#pfP{cMLQH@C4f>hy|p13BAFolJj65!fhHLxkrDmc3(3rUB0bL>8A~igVWiF742g_L&}y`bZBnqItq{nlGoC*PQyy#jUwR-zCD
zIkj*NLI#DbnWgc``5Tk-*Qb|n&aB)7N&+9JmnTs&cJtE2-1Yh33`lV$;b9xa-
zdTTj6w-lP2TLHq}nip6JB!!k^3oEe&z~ut!14dCEnOlg?FQPoY7);PG&DF>p(v%Vw
ziYP`*)}v`9NFxyJgrw1QALm}Zf0X*dG-j!Ec5t>puB2_6^F1=v0{=D
z&FE3pPH8Tfk{ZUSgJV{uYjQM0~q!LCl&KZvLa}^uE4fv73Z-&>$O#(jJ1sN%IWDj9+
z6d#!#`Os)NR1j;M`}y<5gN97W5;03!nG!129bTdmq7qurk(967Bl1Fz%!n5RcJ!HY
zw9pex?X;Ylc|kPmvupW)!HRhQ?8AI_l#pi&Gw>rAt30{EOIT5GKmpVV0XFg$z%J$#-FMj^g<(tz}
zE8$RPX*o8(k}R}#@4okIrL{XTqZn7Ml}Pyb?D)xhPcnun<3qarX#M^N8xP(e+vgpT@~f$J;9yg4iJ+s8iBP*i@yKq=WVIVQ1a?F!
zLYU7jNYuvZEfYWqn)KnaS=Z}TQmv-f>PEG0_)N(HQ1W`og)%{8v8+L*itas6c*vAP
zl%%kwOLGR!JMs7@a#YNkNVCInlMw%~a?BE$3&K(F+w%%HBCWDyRAgQ>$Eu4(C<(v#
z*)zziT3J?#vQo$xz{Cpm4toNDiPe0NrzdMyB?AJzmA$@TAQZC{OE062s+A-KuvkJ(
zoJ))Ts737JEL?{c{Xt$Sq>zq^k5Xl@T9HKeOanKm=bG;ad0i|FM0bMw9NwNg1}KS=s2fEE5zEY=kav-Ra0=&BxOgF*$bIo>4T@9p
zw;Y%Vh*69vgv^CFrT3TPO=ys5ftxH1_46dUzfFfCl$O{P0ZV%JjE|Cpj}(tw7NS0G
zmIzNSgC>(1(By)k$+=i^A(mW>CKke=Nd`(0fLsdCKnuYs)_maB{OYZR)td_|lk>|H
zb4%k8GV>zn2s8voPAx#!kYRj8=GOex8&hvx8GmDZ`t6CCE4StWl;cPz=f;M*c588B
zX64q@(j*A-`t%smn+xM81Z6@X&MT7ym%z$};4CxyHr%M;5Lt5M5*c3h($2??TwKe>RXeI!P)s&KmNCi1&sP7%n-_<)h-ld=-^F
zKm;#}hvfi+yuNP=Pcl=|DQ>>%Xqq8AQKJAvy0J{guZj{!`tutx>4H>
zWZaoxth2HH?2`}doE6jc`u6S3dmjz%f4u$R!_Bk%yJx3I5AGk{J=?!~cm4M5=I(C$
z;GlDO*g4p1?-Ni0B|FgJM(^;PDLZ=`-Mx(-w7&tS?2RyGcdyysYp!iKSRAAzZB=_)
z6p{ouZtT^Oa)h$CSweozi&jzyv%gvD`+eV_$+avo<(lhrWXoHS(rmUV2FV0TC@DCy
z)}SSUDm7UwX|C4l*j2Dw8cv|`=V(_dq6=HdXG+150LOE6TNe0IgfNW`n6jz0c#+G-
zd7N@YMzd~0jfN?hQa@+P3fK`?sa0wy)Js*pTs3@}%ohQXJoAPj65t4k#P6U7k%WvQ
zTFG7B&}b*P&zBsgfgD^%I1G1&u>7O=A@;sKuW$oCT4J^h_jg0c(3F~*BqVFp`70Y$
z9nt`Eg~Vu7PpsYJ#RXY5Aswwl36LUA5;03;i03M*QNn8}kWSs%8I*9i(Grgo=K!Q1
zmBh{16?(P}3TapLjH3>OT{)XjvNUU(Wr}A!BIVd5%RdBC1eh}R5#0jv%9%_qj<>_o
z0F<6m{5fz~RLLdjrSXcxL6-bpcozbpLQI69Ne)Tkg^&R?GC1NWGbMKY3Q4dU@XijS
z0$mFHT9vh`0)mWK;jkIv&?ETLA8kp1I5HU=aETO!5D(2{)?~6|tfUg$7;bOKi~Lj`
za3KdQnG{jDs;}ZGI1<%Rf^y`UEK$M&P~u!vOW;KdG(Ft=8a=;xYo2q<$^YJ82+R9@
z;wo@ck7!2Ju$USnb~ZXXvzrG{`Vh$y10_kSv7#6N%B8f-!N`SVdNH1yj}b)9N8+=Q
z*t}S^XE~Bs48*-bkUa2lH9ET*nOO-
zV8QttH|MTT%v_zAzB)Az#H3xMC>fi)^wzaE-n#zAwOdyv=f`g@OiavPzk2HmbYuD|
zm)x8mM`mK~+T{GzTZ=b@z?V2QJ~sLGm5Iv}v*R<%)3YlxQ;WB5&QC(qOH;f%IX8h6
z`MK5Eh2Z>Bco9NoJ}^gGom~u)mO^u(#7ZO;Scxnwg{H%)g_yJ)%`By~U`h)ml|V`j
zs3vefl9W~?Eu`Vc$d1#@9ycZ@f1WZX-sm4=kGOeeQY65A-NF$8{D3v(N`{KOX&BsU3B;b9cxx=pET}I?!-*_!
zYye%y6qM=9fb0@+C(EbLY}EqGvc%I7SrjELyzp$sQ3=kY?r9E8j;h>o3*DiHYY&yE
zKI0&FaQotsl%vY=m01j+FRr@|mD)L)yF+kEqbj{`&nw^1WQ@nuP$;>u6v4)uJe<^J!waxXDcXl3ru>0`6!Rdp+>D_~ej}9I_*t>VSb#~M_
z*l!=~w+?SN4sJL04_fIS-ga|sr{3RYjwB(!wo~Is^8oSaWjRxw#>-+1%tn`4t##%FFoH>Ph~y*UPCygqdebtdKnS=GEFjB0yj~PU1m+}qQY`y32-^HIyD=-HIH`}nSqd5
zjLxn^=T@V@&6_Kc*=TwtmRU{6!HgD8E30WG0IUR4rsM#2X)2E$rh_jcZ8IMJiS5i^b69ns73<-IHS4v5S|-sIwDO6lIAG`(MMGD;1UvX
zP)}LhbIk%rawONNbWcecM`4h=6$cs~=0$9-3kOf7wGFR>9k(S$@xNs=1=Ew_u
zfxxK+Pqgrm_w9M*TP7*TqH-{z5B8tl`{1|p{iBJM6R3jK@b=u%>LnLEecw
zZodC7+V>Nk%sYGQ2e30}~kE3B(-cV;qAWQvbwJu!F=6gB@`*vOr0KSKKh)hB$;*
zPpXA9?tyM2mk_(emzk_LCKA`d_4$5~_u-H4&3`TAQHY~_7KEDtFLDf$RuOU{1dGE6
zCEqjG$1cw0%J^4633dT_%!tT<{8p4@9%0Gw2LUUQGE-7U^mHQ+A;araCh>}5T_JEJ
zO2i!V3`%$nOOy+;1bW7BS?*!S>ByrHyNs2*o6INuesGRfA``a4K_e2jz8D6)wS-35
z@kQ}bh$>Tuc-*jfu6Go&#p4r4=im5qZjf?>a@fGE|$yrGaoZUMN
zC1!$&nLvDIH42oR22RZ^ff29GEL|6KXlUvTjerzP36z{&ygnk-oSXzQPK`~>UZ0%1
zag)ID#uzYh>e|(r8`oyXkzT%a_3fKumnN@VxpftXP=cdxO;*1$y2DW%^M}h=Z5&;ko(f+)QX@IygNQm_lYYJUd5|et?yWf!N|wXcn1B
zYBiQxPD;zN9_A-Tf-F^n%YdY>C}w~jmF|Rjz@>O*I$8xZXPic1Iy7rXHX~weWh4zY
z)xt?7h`emZ6f5ovyD2rCP@+kdmb8q^F=omnm=e20mZ^mP6L{DIHh(0gM%Z*7o!3->5{8vY&qj7$jEq8IsL*rQfyhWVVs5$bq9>)_=W1-wGj;hkh`%4k|2>XSvUIt1IR~;(0eqwRT)u<%f?Yr;(
z&hFW-N7VYnT(D5Be)`!bZmF`8F*BuJ|Lon}haYX*-04pytW$$3KPx-;xKE)|}+nxSSdu_L|zTaHi
ztFP^e%zm@KLmUZ+T;FX7l=MYFNi-??zPnqc?q-pJ@QtXfgN^P$ZKV~F}^*)i`03Io3Z&3
z-eMU}Wau8mDn(Q$n?Ni!jlY+
zaTkC{5lYApSPm;B_<~?Z21=ZcLLe+&3mIHFBhWUD3^-Vf$n=y?C33VVy7x7De)Iai
zhgf-zk0d8!I#eR2cqeV~lowtqh?|?13wMZWrWcHaI5sI1P>mHx)|OL}w*XL#y15A@
z~$ut;-WLSCPL-qaLqL
z&R?U<{Iy$)H;|c_8JnEF29%tf9iNyUzkU;dI5svlc6IvN)#>Y(!Fdyx-x_}#>Da9s
zmnW~ib>j+jX?$#`Yj0j3d;RL=w{BcTUTEyi8*jgM_04aOz47fUufKln&C55hUYi-e
za`XC|*DvEJGFPX@ug^?gn;z%uk4;^>K6`_8b?WNn@weX|zXZ^nU8XoCg+iyU;wCws
zdUKBMd1ChJ&G~VL%Z1=Ps!@J*mioknmcolG(Pe0Eb!I+rE0~yzrWX^LC0RV098z@Z
z*G`Lv1|dW1T$&<6Y|`V-nfNJkj7&C;qr5JrtkXzMNsXpt3SKfz`jU)TTn$B~)s#VV
z!{c&<5L1uGv`9>iCG;;|lIq{}#<-&aA8myny{H4EMBd6#oRT>bsgF>+dL=(`hcj-$
z%9pHM(d2a~&sC;Q=RB~fB8Es-sgIkxxdD#;ZlPwB>lRdPI;={=E{O*%0ylXU4l;mC
zy2x-;B?l?9CCe=WC~c4&;16I2f$(Ho$ylmHbf_VdGGr)i0v{m-k{qOR%9Nlat?0y}
z3HU^|&U3V%6MB!Ic3h!ssrwUKODMOtb^772wsxK@$8+;5$+P?SPVOFuWouQ<
zYwf+x-46!<%17^Q-G8|E=)vy8`@0VxY~OpZc68P`IO!gq^bYTI55$^52Ya1^-R|LT
z@AhtQAKK~dZxciwZuSoc{lks^UZ2(5?Lz(i{@Q-0zdNMKy$15Vo!S~oL?1WU5#r8n
zWVZGiz{K^f3NLRiR->diC1{dSa&4>ho4@_tKl`))8E@(j{_vk~@3)FIxlonz)l9yU
z$(2~r@VN}$d`&T=o|?7zbujFhX~%3kW|>jTj2K4P(8H!4){U@g@?#)qh>nKe5wwA=
zsA(rmo0e4L)N+%y>p%N9<>u(&8rg!BFUqB|QmJaynqID`^@cf=7q$dnc0iUw$TL%N
zn3F|wz$+?W1Q}eXRyQj(Pen8`hx2lv!iBjzWi?k;+>)HDXhoW4Cq}uTEh^%dqASlE
zOiAM@#Z(^1i(CqEC-?>Nm*-V(1blUk=ABez@q`-+o2A^CB*J)%Vzgk8i0}y}qi7#Q
z+(wH~B2U98fs%kr$Q!>n>?P-}XNayNN`P??N|1u&l%f~&^U;km6G*1*9mr
zlgSbg1}tNIMC#}H3XF7oak|4{r#6H2vdIZVjZ$Rj4>
zZVZJ$Jq{~!d{N*dF(ontf9Jj7qMI97jC;$WayUlyL87#P5ndfBUJlhz885+*${>r&
zLdbaViVvieNr|WLB=SkQqDU1vSxCjR@kEZ8GUon}IXXlb2L7I(>+iO6X(uOHF2qyS
zc(t0Cu!#s7nlH%f?*>+?Vk)ts6IH#>b{_ygfPg);MVL@>>&ENaL4ZzXnpg1YUe={K}g*uDo%bN?yNq
z`HkyW-vU|Q82i?hOW(Tk)@xT$$mLg%qU4*G-uR`r0hgC9-@HCHbpxlragE>-ta<6?
zRlL^N)b&dfSD-7nhnex~vlB=!PhNfN#%0u*T$sAGcxz(z`i*IzB!Czwj2pf_K6A|v
zWP&L{mfTl9w>rz?FCkQIyN-4`cVv?UlNqKEmz`eH!
zD6rCWBbpu3@NY!Rsz*VVk`~IS;glLm$N@iQ=`p34&674_2{oKhBWXPulcEth6gQ%A
zBOXI>F!2o;ztnJJxu<>oagThMbw
zBVRIE&oSkYAR%VTQI+sxQ}xIaKv{)Ekdi`}BSA_CmvT#@pS{3bYnoZyB%vf^5C?lq
znFdN)GOgL9Ws+b@Q-Kni6jRbMHO*;UlM;rUuoRN1#7)^3$TDF`;^~^BLJ5hV=gv&Y
zd4HEE)0We=1WB&KQgW)0rsj36pd*F!qG1#btEk&01M(u5G}_XeoDP**ScY*A8bDSaP$7VgR@7w4<7G6e7Jr8{>JHP@6J*G&T;SdN$22BXaAsk
zaL_y4@7><(9`1Axw>t-$pvm6;76m4WCIwI)uJ!l3{k?8)4>Z|>km>EUeVRmu^GFB#
z4d^+h+^qp9H@2(1wmC0y-rJz{%v*iu^xih3Gfq#EcDyjY=8jLdV$Ktwb2bR2IzAjV1-PrmUB3F$;okRc2&
z!Dt8>C0WUV`FIkKhFyvy0&_)wG@n8=Hk|&#NQVq0Qx`U!OUi>LL9`%C4=%xu%#<9J
zq`;)uVbf^ibKfrA@Cnxoby0H{(Nvhe9sW>if&B6H$)$i
zAWjZj0ypuZKu=r&_sn356uW|Aqf&{Mq70d_sFU=c%@}hNAj^2}izioj^S&7Im{Lr~S>P!+;n*yE;ZOhc
zPw>J|p570FCIiz8%ac>{;KDJUlszw2k(^tZoL#;tCg0F(o5|VhA`(g92m+g&n;f4R
zzjXc5n^)g_d;IN7lW$+XdFAr0v9~9$UbzX9yFszWiED39Ttgn|o7b;=`|8`@9=r7V
z)l1;QH^7TmFTFPQ*0-;``E5avuU)77Q6O{X-g)mE);Q{3F-G;)X>Ovye=
zv_MQSCAA^DJ7)LBoUV}75io}mo@m+^O}a7#KWH+QBeKM=b295m=e_({2(s+BjmwnB
z6D-z(r8)(~i`6LLGFzrlILH!MiB^h$XREPHC5C^3$znX7izf21L@5?6hGT_jy!6-P
z=tyozBFHXHqGf6%-0VsOdGn<%O-fivOxdnH43t&0twHc#tqn*TArS1utT)l*gPySx
zP!d=P4d9;&{{65m)P6WmygpcN4%MJqy9%Hz)l0=Xg{N7$Y7WX)Xf^h9B@ZP^*|J%4
zl9xn+V&z9cli;!ngzYF(D@e-Li@8QA-z-A~2RqKXma+*-r1vjW{)mI!Z%4kIeTbf_VE1d;knsEGc)_A!Ibj{XCW9u
z)ARcYC?%#`JiL1e5gqSbq_l^K17xqxgKshzroS3e?b@C;q$qzq%cWSmVI4&HM
z!vM;Bb1+L3HIRW(Z>Kk-B+(=<2_}G&nUcV<7=UP&j*!HWkklhRn=J-$pNzZZd=c~+
zk;HKMFkjMi%!ZhS39Njfm{;v56Wa
zCGG$pC9>pAFlEPo$%W8`U;rqan-akPR8nxf*-iHbM@oTjh`&6K^U*2F!-aiXLn
zV}ce!EQwGr$SG9x@oYGA19EK1M$3}68
zmOYd}jSZ&8!eFK{T7WR11abv{4s}ooNQ6UF#tSfjaX2x&1W&wRw50kYR1W6nyhu^LBfWySvU~R1pR@$2bTz&@miSs
zQvwHL^(erRA&-F%J?KXdpis)`mLkzGc+EzJIiM$m!PsPW#D1`eSD`;t3ZfIh2gJlC
zp2brv?18T#UlW`p#8*ZlOD1nHB_9_pz)>(Ic|&oMe4Y@WMi^w-1Wo3W?KDs_HIPZu
zs*D-V0q=Z`9)5Jz`(|}Q-a@rzrq;|>o1D8tkyG490$d7Zy2XU>lfe>pXAY(CPB&^`;BTi$-lysZAQKMXNDuG$xJ841iPhXk|N8eLY%5pHAJc*OGK?K}glFzu4mn%_TOj6$CY|xD2V|Md
zdJ`EpexUQEKst{eFPJjl&7CUJgv+3qa2YH$C`p`Zs#ER`CGOBXOX0Rm7b97)W|t{5
zm1L%p0#inFp;$2-%|m~spAx(Xl$0EhXhrzDROtdGhS5k`t+C8l$-^YFtcwL0i6e!8
zl>@_|$?AW@l$+CWm?MRsvL;j=7^yUdN-dGxjXktSE6w3jZJ-E*Eq4}>ELU39N~2b4
zR6&!Oawb(ur;2G9nQ}H&%)|?sNG=)9#LRQClcv3k5yNXegJ86thsYlmlf(ikSx}S;{~UHj5oag~&4smK9>O
zWpOw@S1)xDvy^Xi+^ZlGweU{
z!V8C2PDE4nNPf65v3KIwtBcRSyZ6~Qjy(7Bu@_%ldG6UmC!SkeJ3hbi^z4yiGly4a
zkANu;Pai%gfN~$ZCuffkP0k)&g1YX>h54fkb4TW84$VxHlM*N?X=a`@#j$U2-U#lJw7yE;4pV&JDpB%nuM;
zK1c?a#6HW-9!hdjb_-Q>;ruJKQ?P4dB4)80kETP2#dsMi7QrI{{cDtg7E*(z3
z83R@_S+cj1_rpwyL#Nw`U@7D;hN5*^6Fkw%gsbsnJDVNOr|^#cou4vO2xW_5QCOR1
z+Cg2%BrT8wRW|u1g=k%zvPkO&M+$s&L!6O=c2nJQPQt5L#G
znGGtF0i8^`7@)ITj4rFzZctmbkk+n;^iHGBuGg5=KupPJ$%tw9+1PCf`J!Hb%EqDg_3%!o{u5?q2Td2Xd(xQ=)jS{8b$
z;7+Px*{Mt^)e<6{FOGCm
zjJqPdlC@m6p3j2Pss*5AIFt0J;=xQRUM|K;g>XI_%4NLCxFZtu#>0^ug}h^hOf;Vk
zXH&rp?j90Gzu(~VIpc9(CKE0egZaEapY~)Dj(Ei2_dw=wz!41vK&W_OS265|g6Ww@
zRmk8FtVAi7DCLvoLXu+Zz9HsFXnbx!044BopgVQ)AxS7Hj@216EHpAZ
zjJEUbdF+o@-+pUwdM22wg)1XU^_C5R7-V-k!e)grc7hXQ{+;e-Mer9Iv>6x`>
zW>=2Q9$A|?OioHLrO=_-BM0V=9++Q2yKj#CluI*57UvEx&K_D2A#XBf4$jl&p}Dz3
zv-5{$77p%SJTS@XaHL?$uFy|Fi54iyiQdzTgS@o&?zz@0uRnv+zIE&7iRX?CkC%qV
ziUTA0)=(A_K$)h3#I1A}C6ncP0{EYreKa;Zif
zHhS2Ziec!_2)dOfO`@fEH*k$Y>Zx=yf%k=1<=QFqFd#xWIv^}s2@;Am6BvMD@oFSd
zi}EH~2t9$EH(U&$pZAk&#BmxpH1CZow(GvT+EbRvZTv`OTniHrNGbwX@D=!*F;+!D`W81z%{4VG}%JojVH@?$o*gvgWl*b)I*m!MF@n+zGJ|H9MzK>Z-_**sDf+g`
z`-l$Z@@;a(Hn|e*R)tK`Q}TWx7;+W^<&*vWPxkdb+1s~yIz17mKkD`b?cSgz9CyZ(o>az%+j{&W
zr*bsClKhuB7Zpq2gq4!0uw_kz!bRmvkY%oZOqU`&!!nu;@b~61
zKNu*f?J^>G5gdtDBFHW{((FkVZ}I>ks&HN(1Wgu1jUlQiB$Bc_$=xgfa?IZ3lH8$(qwU6PK16JWY+4Af4ZIti5IEbLC0yOv8;fp^JpE*>qU66JiVT8vZV
zx&V}PM#HvH06+;lTFl3agb*Wo
zDC|vVf_Zv2kjn!!y=na6g)Je!(eKrJ-R7Xr6_5Cm@jyBi&SfL{T(p2g3TjRlxr6AtrC$XgMPP^<^!@Er)apCWZ4N-k9GyVl=Ofj
zCAa0n^C`PFdngG~VUNuYLIBOK=MvmGfTwV{fvHA&ceA7Ezby7$Xbt;v^;lzKaA|Gt
zb8qi^?u~=bzIyDXH`ZQ$nnOu}?=D%A9x&xJg}FhK4>*#XlxUeRmk&+O?;o2LG%1Ri56vtM
zfhPAI+|7~hGatVLs(jSjx>b$%%tq
z`IA{vDu>^t0Nd$YkZnfEPN!f>E^UE!vjIJXm8Hld@o^50Lrj*ffgEU0M6OH2BNPy4
znw;8QotbUS%r*%kXPPs!EeR`WI;IGbkBM5F%#=e9*RW(sd@0c+MZ-z?M(fcW9mzep
zS<)QJ&EhZ5<9vWAE23~?C-Y`VBt#FSU{GofsZ$9EVl)BDKmaBY`=-D*yBHb%K$DDv
z58$%9@L;AH&$qGXPA#G0V47{-KleZsmF{{XnNzV_0j30hXmMPLESVaaECE%~a)<{o
zLcwOHq_}oHnrXyE)_E!m2y4W%U3BC9;N^G;2IJ5;T&x;mKP6*jtP;XgjAeNHXmKow
z3n6r(hj#)S{d@xaEM5y+oC%E#75qE~t+W$5v;buu$%CO}EtaT8@unD3@n-Q9UPyG<
zi1Q9%V?XpZ+vJAix4<7qZji13?-qkQXNZF~;~4>zJcp7QG1W~NM+;jd_asuS46rg#
z423JvL?e}KrW1|MJkHM7=;23aZAOUQlkAWeKKW#|(WxcI1t7|`XrUYgI7+_B&B_)$
z?4A@JN_#v-iz`NAj`2yFDSzX}Z}mpj?bS0%N@XUUUY%Ip#vlZyG;-;3prpa7R~uAH
zokDBU=q);I>dacLS*HTDsT93RMW0gLuhPmil(kJM+rlHbOC{f-p!oGpr2^U^Q*G;4
zZ0%EQ?Ny?EN+y>??AYJm;m9scKGE0r1c9S$Yp?97-u|b0`nUA-L9o%YwXdUX{c>n)
zpL`p|#2;vzOtxJv+oe+UX_Wol$U6+VLCZeN&Z+7(3eh9etNU~^xlyUb`*qP&OY&J-
zG)7U(lF3qM)k5sElqOt)ES;Pi9(4O7o^aIT4>S{~J>HSr_$&fR$*OEHmX;x|~Rr6Uo0WN2f^3Fm~9H
z@e%E2Pb5Ta*P!eiX39rY6NS*b)y}E%xe%48+>Dj~jwzwRiS7)`PO$q?rfdy2FI+s2
z6aM*^p9jYWQ^gdNDQB{kOs0}amQ%@cI$6pjikWaa;fsZRiD)RBCWsXCBY~2@K3gON
zScKfkB=C`(k=d*(k+6h92A|Iq2sq<$^gtNkN~FE1EN&(ov7{{$GX+9gk5A|G+G0^x
zD(TH;{P~B=hG&{1bM3KBIXV+G;gSSf
zVoHjblfx42z~~GGxM`)FDOxW_EV0uXoNTk$Ps!pHbOuG)bN=!?{)ay|7;Q`s>^(7m
z;;lW;y?OA(*VkWtZS}bq4m|z*!uoTw>(9-sK0UX(Hovkmw{jGkIdXXR=%Kk)=-}My
z{{NmS9{}Yhrd&KUy?AhH@c@{zpUopxnJUFge%cVD}F{UZ0w2
z4Ud-ql;oZq%u=E60S&ix%t%BbLHbUda}b7Q7aei54%!FuVji#C|$VDX_9D*dj!p??lEs
z!EyFk@@hAYRtB6mFqGXq$#QJGG_|`jJp-)l&?Gb=a&*9yTuOaxvOG3PF$!Siu!w+z
zDIxY&3OxvgGf;AZ4y*Zab@a{NN>;t~Xk|(ke|a9~LsTiJ+Tc}U%1$y3R|}#-KcXIZ
zeXQ6RFV)716(Py#MKIJLXC8wi!zFBKlYmBSGGzkhGW9s+dQ)j}N|!+oJ1+&Z0yN2a
zNfR8qp<4(x?-N7?0gOOkfF!mVA7Mb~K|j;gW-_CvfKz}xFkdZ#H^n|nF^94v9tnEG
z%kid|k5dh*9Le$GWIf6*L$r`T>yfw+l*Y%xanTvf`y^6i;aO~gIN8SG_}O%mJdPO5
zm_IZP5HznVgEiS#t
zxzU;&JY5pvEN`O`2nBEiL|SzQ2Z)N&qO}&S%BYfQ6#Z(NE(st5qEWnCrv|a@=!Ubm
zt7JRW@~#xym5PoVQU;WSRA?n|WSS(b?CXE3SGJ|6|H)l_P{)S)WRHp%v~P<{@@|r`
zRiW6fQn9uvmD~zLxl^s~(Q0>TwL65-tHGJ8rPC&?r2HW!OAUH}n`*1U;ItYXW{sI9
zjGCM#qbP*QlSjG7?z5X+X2=;J=Orx;8L~s(h%*rP_+##13`~#TYY%?hGeuu2@6HrG
zAWIm4OBh_zlH8V6&?J4z^x@)@6(4uD6iya`iF^P|8P5ixbTO7GC9>rtlrH`?wS>41
zB_-d88Ivsbkdk~zo`&)A{~M(8Zw`BbQo4j0prQZ`n}#cPFht&|f}E%S|Xsa-9#
zYvqA@Ww2fuu2qK{wUK&b463yz>jP6_9mUQHitUkUj#CeGvu!rdp`>R;M4K701B;+W
zbW&)WRsipWyd~jT*5FjT4cz3VbpE=v8PlW7yH{V{^W4dUFT8!^`PYxV{Km?2FE5{X
zVQ&4z%!rZ$+a4x}pWWT_c1Ht;JE$NvQ;NU$Bd4`GA(
z@H@}&Cs81tg&j#aV<|U&h~mJ<@DhDA;ffHGF9#35c!xF(iQWV{<3E)9=XM#pR8lMSKz_(V;bOvzX&
zT$O;!jwYuXXvMIq?#-%=Qg(KENEGE6%Fr0G8hBaM9;ynm1gHUJ!leK>hM2EA#}PCM8v(@Ivyjf%$-6#BC7Ri1A1uRL8|g{n#yqeTgj5
z&#;A&{HnZgz5--%=vXP3tVF~)B(g1#CGC($;vE4rQw;!L1TA|gBPHyLpew5CrB6X2!ml`7{4#2@YNn2px{+`;r8
z9D2x=fQ&S|j_*V{#!+p8FFUiaJA7FVN{KiR`zf(W?vi-Q8HwBcA)_y77#XM7(~TRy
zMG|he-v~MVoXt%FTtX&?R%4QDOfrp0p|_|FKuN2?WH*`|My*B7i_-uoReFuaWKf%p
za-+6Sr`jcwxOb|k+z+%*;y2
zr*BJd|5KpG-hLQc`eaY^^!=@?hq02G5ep*!
z23@~SD+(B?@s22G+^k27_aZZBG-f^1B%`EAbvG#V3S0;DLjX#f*Cq<58|{9RBVcg`
zL6$aG*zSwDLJ3zeYUdyHLSw5CdHDBLj;uQ0ZlSca#2ZkSc-%j
z&?L>9l++$+wuT$cp*jSh#GZ*|TjdvCc>yQ+`_12{7pC*oJY{p&vdKy&R!l|n$#6Cq
z&8HLPLZp!OBx3e(&>fHX(}_?n9WG@3*^Dm>V#|e!d2c3V2?uo^x7OnXV)`QFkQnW}wXGDNlT}0GD9OD%Dy~F;+?y$cIKihXj{n
z6E)BzPovzV#?iO5=TmK3GtWb
zaX#362$GW~I0~SoRlK=?xhOUXAWIYn$)^b6Sw=u%7VnqxHMhkvCg~4pl;CeJ(4TCj#h9w{mEuRC9h(iPZfQC2|pdr&C
zou`08yh`{ZgPd|i?}ZCkitCnY5GI0gncxYa1y5rqd=#`&c~OjKKP3j^<*?BM@wLJy
zLOX26IKI!vfU7t3zy@mRyN)K^SdBkM<-Ejrr15%
znIZ$w%;6r$DwVs`nm&!TN2T4RRQISg{W`teV2~U2K;%BHN+ukZo%py~
z-mmUwuOy_i>hw0EOh|1~gEC=&GSS-oR)a%h@qjD|E8Sr`S+bupo^g;}!iP&AD`O>Y9*VVSz8cBbVugA2GrmOB8I8E(v0yeE
zEf)Oglr2s7(-}`H4Z#4?figYmge?-$d%Y@$Q{(cO{9#)-t_0){0bt
zs6|yRivy+dP^mIpu8x#yBV_<3m$U>^3bjOJytBF^#m9xj{L2RpNJ(JI(HREK&EkHF
ziL-YTot&LBGE3qw&*OjWd+D9SFTHu}mDitn?e&!xU)^)!<=Nve&8|N;xBd*dD%Xxp
zudYq6u0XR##Wc#*!(ht!wS)6(2j>_o1EWADc6m$mvM&w{PmaJ^KB^|2QAA10VMJwSXQD6*h
z8rUZcv^bx1BL>AQp=c=(1LRf15%Nmp-9P3Mwy<9iugDb%=>&9
zH;#gX0wN)F!e*jHKU#hljFn(Y9*Jwn^Eh#daG@Z=MDf-jbapAQ%u)rZcDbIa3v@diUPzNNdTog?ehbp8-E_O
z{11`hO*9FnWcMUTz=gxI;K
z`|w!9uWB&^Co?yOP7ufI0bAg`E4h$}vC*
z9Ap6v0fTR?^J4f)VdzE
zb{F7MrR~*Fp>?@I+oMrJ3eMm$Y83`mzeXmA*^ULwe{HG)l=RmpF_F*?*IMf
z@AbhtXc8z1rAt&TC{YrNr01bjypWD$lhIrzk}E{=#b7$?h(rx;k3Ad-WXT7KzaLW|
zta14?Zl5_A#a)^`7PW*!)@Z~LPq()H#_5+?Tyl$B;|!SmF7@a+_CXb)!`|13GWS7>EhCWfF2F(~v!$G>45|0
z2!=&H!c{4}q`8jr*-$YXF6AI{QkGz6qor)B{D&e$-3;-3vrudo#dQK2kT5E#N
z$Dqc*L`%$oglK(5$y+Hj(5(>E@mBICLnKopgr4!ak%{?Hw2(9aaM_-0wI-Sn4F2*w
z{>QwOF$`@a(-obVP$EaqTaBV=0xBd0z{I!Oi6rsX!qig>7~OnO9!SG_D?PDn_Sor
zjnD6+%0asq2d0+?UVi;qoZb&VULTq)4~!QDP?D2U6rQBnlhxJ(_ataCQx0Y;p;VE4
zlc33TAxM~*aHR49&?JSeg<}%b=nGo{Q5#`m%nq`|rY~e>d4gs)I5LF$Ub8D`@kZ_5
z2(7^jSOj8v@I?+=nJfXCK~WVXAPR$kKEawk+%5a8_)Uw%eX(R9kq)JE(ReD5Ncoa!
ze=0YkMQZp`0sT_6IXgf65uod3g+scrlm~?oU1n05Mqb`?DSxfJim~e+-?lF^1m-&V+mL
zEFcfUo7#+nXu-2=0V11|J6u-U-ClADaxUxLmM#
za0L?UC#Hm3oEJpi~+(YJ*k!fc4?JzlTK;U
zLo&SvZyax5Z?~A7R-@ghF>7>Ioz-JC*bTj^UWHy^c9~30qg|}NV{x0U9*fg&16F!M
z4qwC-jC%osp@c6=%Z1ZF1~J3kpB6JLVZ_s1d+32Tx2vytV%0Q{oE|pq^
zVl)5xTd(58zWnOT>QFsh%}OaOi88Huw&d3PGMI-Oze$86PvbZQtu0^T|TA5t8{qeR+qx&Ryln-Z^#skNz*Ys
z=|Uh!C5muvoErqP6q!ItcQWNlBwWe3I~Dh)kNl|5;Tl7evIkh-GwK##6
zzdVosvG(%Gqc6R2_@!5tPdu}D931)V?D})_>y++2zkYmfZGCoaWo~_S{@5DY*|j6H
zB0Fb(<-q*P{zU*KC*>SnUR>F;i1x_x(vjuG!%GW?7UvJnEgS|=c9?R{k=dm~)60iv
zAlT62!QBh{Cs>OICTI7KO)rhiE)N4JUwumgN-AGKUisldYbf6w1XF@+vb9#a+(;H1
ziBdC}uf@`(P$KV#VCSmQNZK7tIItPZdSS=2zG&LV-bb|Iq?>JD#3mNnrB!wzr{C!C
z8J&KsOZ+IggODAzs79>EFuV#c;a7=u)Xd@~hVCN0I(NVvj(KCrU?Lp`Rt6*PP}Bps
zOlHEVY*e%~$x9!tc;gR=}IMAt>tR$FE@&hjVP81skDdqr*wvgcS_HCi4^a02G4=zv>jxW*|ckQzL|z
z@Gy+wVR#BB1F&O*(`c}_R4o=O1S9xL7eSDrL^+(ot16*r(HkjvVkI9N;hfu_Fb7kX
zNY)WZTEZE7C}j=j93fC<&K1Zy(S{2iY(_91Z(M}Jp=iMe)(qvnG3>J(;>;cxI4hh9
zTAVproNagW!TW;2Po-NA3Mw%jf(XHjU`OyJJ|lcm{9*9`MoB!yKnXU*e)vj4eDU)`
z8T2z&(g5M>h46Cz^!X^*Og7`udL#@&#jtiF-iimxfiQ@c^_FxpZq$aoDaOlWB?DxYnr|mAi%WHJF4Ni}d
zWp^7bPP5Ub7xN}{dW%*VTD@JPwP=(EMW4F2N8a0`=<5^J%X_rSKD`?1rTXEj9<6GJ
zQn^hoNc3E=m8n
zqocp=!ho*2L2$GXGbLl?BPa=hBOl(>?ob)FD|OqIz)Ct>G0##1h}@x;@6;$5DGm2z5py)I4~7*kcc0BJv%3^_LQkNf-WSq&gBrIVL}>8GOu+-=FXfZfVxm$&o2r%4wNkcG
z&f*d^3nBtuE)G=6L$%6Ktua&sO+p|`#!8VGUV}LH&3s9Sxx1s0sRl$g&Ac4o5<<|#
z{P5($$Y!Bud~S#f3~^DR!O6zJM4i7pkNOH8@2vKK%JtXvR4xo~6&Gzq4Jv2bK@{_uRqPq{L?aCC-&5-7R%
z=p2lN15*%Ca(>@9G`nYXW_e_KX?SwJb#QeaC-%=@f0>*E(3e}I_?{O5lt4+YJ=uv+
zHIms%BvlM13xR0H1FVD{&-nszJ2(OEBVu!Z9~`LQz*Vf&WB+
z%V0d^hY}f@g-K~W`JhCWxniVPN)*e9ay122YUye{Q)_f0)Qo^YLjWc4k)fxmz$iNFL{Kx{};AsJsJ&;(po
zNAtW24hN|@eVbNI6h(rFEJq8VOiG9m1PL(W;4f_SaK#@+Lx@olCjc8QHX#^HRKz`k
zBY7Aj5%UmlLf|m$9D^|io3NQ9(c&o#!&8!t0RTA3SqQL;i%gv~4u=-2&BkHIOhUQ22)m$WhiX}Q^F3WZT_^~o3uhOFwB>-LBX6mnDvA~mc;-oT<|#)
z_CU^ygW~AGN_JB6J7sW`-Vrt#k-6o53H3mV>~{q4!H9@j^!!QjheZ_Ft<%m-nW%LR
z#7DuUp!_OaF@cQu#Ia`{kHHWOhEyJqYQ+=a)J7~qYwCnx#GA1oE>|@Mb-qRqKbR@0
zJVc=i#n3WemO4or5pq-IXpNSrU`L)YiB_6JiOo>V8jM;35lcMny>Wx0-kE&V<*_*2
zCbLbeHOTcQrNyqZI*eAQ+2S;@0GB$mMr~56OmdY;!IK3wCan@2sa9;Kl0bc2W1JRF
zB*}NFltQ9TkV3YdN=3>AM|M!M!SnZNs}r6tEcC`c0KS-{tX1#
zQO^@QdOMQ*l!7TGKjr_HDLD`?iJ5YTO20#;+o1w(GFB>xAa$x9of23H8w9Bk#nNe#
zrCy^l8`Kt~#$r_HRWfZq@X;(LRst(^RvipLq~50M*YxSET5?r-%yysE?ls%J_?af(
zfGc44hMnQKJ3$lPoe;1ROeusPUmv3+-#p+Ght1wf_EYA|#F~X_GGEQ)DydBAugUw)
zRde}T9%RW($*DPiWXcX!cBW2Jj9YR{vKx}s9ELiMNvJW@iG#CW6Glxe(p_tHW?^EV
zrFx-I&F8DdLalV>P`%|!#=7MBSP^Mq&
z2?H6G4u8MJ-Dh?|GOI^n_W?sy&H!4iJA^S>4-uy+7&C|B5Da4=YVd_M?tsGXky%}G
zn_Eo2q=a#HQnEXf{gmEJ$2}P;6gX3di>q_x%TO^d($Z7G0+FRJoAPFo5Dc(ps7MR>
zMDy{@Rfou1DLyi;j?S)1T6Bk|R1#2fcFy?Rz{LFEgy@+~Wyvf5(*b5U}#-zWF0G
zhmulr$V0hASb2DH;ou_3a`79xFCS3XQ=+a}aQosWww0BQwSG=`-bUBJT%E0xrRnU`O&w
z=6vClE0lD0Xfk5)gvrGSnq;4%J7i&w&>*U<8r_PD$X%un2zQ9<;C-cd&^TTm>-*
z{!!8}ypRcOGnPT%C-w#MQCJwjFTu0GJG?4Yk5isaF_-8oazN90Rbp^9d
zf5t)a?t+JzGG1^)ph;icBw?j5YKHtVOCW9yCTx&DVe`a6me`3Wm;sx5afn2fido{I
z!Mu+lo5j?~pox~x6Q>=@Q?d@8<+nyq*dRY5AP*l910_BY#zz)5Gp$bPC5((!L*bGi
zB1WXNAv&CN5lFPsddCw9^z0<}2!|zYij*B3OANq;?bJ2`h2vCXIAIvI1l0K&J^Y}&
z?=1dzh~i$5R6@2ub!BO_Rt|PU?4e{QCHW?Sl2MC4Wb_6N-k{k}6KE_SeewZzdSqok
zeh7FuoNhXf!R*lMEE<_s1_07p$T0~Fq7saDgVttLTXb@RS_X2`t6<2Dx_+a+N3Y$f
zQEjSEPWZ@Tf+UDkP>~>s?fyIUE2OePXd#f|-*)!==dN9U6yfHd>2JNAiIq?ED!25j
zw)Cr?lxeoewNEJ^ooGAuR;7NMN)LOB90N2@DKuMEkQ&;eP(oxA_~K0gE>*&3seysF
zEHmlkW<5j;JQ_3#TH2Ayr1$ESeL5vBm&IcRP~rmeayxdP4R)`p2hi#8+3jwt6TiZK
z{K}i~qwEdad{iCXMXQ7-z44?wmGNb9E1#!o_AGqX_@MFOf+^WODcw|{MNhs=l$rZC
z?(YAuA3T{dU(2C|{fM^`n=II17Zx)mGa?%jM{?Q?Z$iAFqHs?NxE!QlcXhB-8K9jP
z$wOJLv}#bUUV7z?*Kj^(FPx*SlrlIn6UnB+SzZw*9W9bqB$UsGv)NFFXwsjE2U1Dc
zc-E6l*&|U$EY9gTFl>>iJ)E$IleS>o8i*M@A-y|j@!LJN%FWyyyu-F#2uY
zT_$I*#SH_SVoX40_xD;ntbUsho9I-!LTXP$D6H{DG~Osn=Z_mhDMK)c))LJaLrFt0
z0bvaGhJ7j=ex<{waR(uRr(uIXDoX0(w5g0Gg~bc`aIp|Amtxfiir31CdL>z}WXM%n
z%{8m}b}iqo7X})|!Fpw=RvoU_M;fBQP`x$T7~I{I+>;N&-@;EhHr;wy1LHHptjW1i
z*3|qMBpDO4Bh(LLfoPH^S@M_X@jsTHetG`b^PtJuwP$A6PRy=7JxeG_k?y(mmAUn!
zbL&Uu)(@lQjPHfDL(A)j7LV?oKfJuOvS)E+&w>biFRkvKKSGr$=MOI|9+_QUnOj}~
zP0n^EQ$i~P&W>#fg6hW~<9$aawS1YO8Cyez_Hc1vq{J)u
z4~~^bXl^ArEV-xCGKQKgkXbvKrn0&`H2N-ARY-}
zn8cLKh|Ek(mJqM>o#=v8wv~iUIXd0QGK^r(?@xQfIe$3k3uaxRoI9NN#fl+M+|IG=
zL>2Jl2U%j1=1^vBP#|RsrtO}%*^9e%KquHSVGG19-iXl~HF+Z@Pt@#9*xWITCvNd2
z?ZJ#QlJ`amK5${Y5)S6P{){^!>Kp}eToHn2fhmET;6HwkILQd*27x;%^9CP{U`m3#
zlqf>U*vCMLXTgpb02@ygMri#ZY@#z<^5Ipu2z+t4dTW`5>0f-ba??3w#tJACXM4rH={*Jt2w*!RSP^dpiO$
zcA2v0zjpQhiHIqCH!-DJFeMmK^OREih_M(KzEVV<2D-1jULtStyvz1VEFCIIYkfA%P}+
znJj?P91KCWNP=Ywk~dN34QM<;fS}490#M5AK5!mv03U3oNd`?u%pS9Qm&t_|K-p)-
zQ|Jd8c32aLDN!am88jI#wZ51zuo=<%qWVA_0$f^XZe`k=$$GOnf3D!m70?Fqg*5Ir+|39oN3U+%Hlw|JXEQTR-yWM
zwLMuMoUCoeN_JIF%@2`p@*!{K$khDk?gi4s>~KeOr19AyHpXTK$7Y7GDXI=pVM`eN
z<$3&%`Qy)nCTSWaXtI-$v;JpHd3a%+GQJnq4=t?h2U9Mu>|0tPjs#OOP0k)#m_M?-
zu(G&tWOiwFZh3WXUgUQ#uF&Sz*AlMIyQRtF^uwFKHsDU!$qXkFHF7&PgR*+NMt_%fJqkgHPUbi4fqu$@0_fdSNW
z`E*XN*5*<{76))pX0-MhZ9N8Cuff)*xAyBSGQCBivC5S;nZhcQnfv7ydB0KCZ;&fY
zO0`j;GRReiKBaD#O20#G*r_x38Z3P}Q;){5Q*Z7y+vV7^-K{a%V%&lw6gYffC{#nrGR?Q)1Hxstk_QSP!srxQvk!&a&Ma`U{vc
z(V%sxAx_K4b{DD!c`)PwK7fE6xdwJHtf0*ek>|27oGIhZq+4AQG|AaEAWMK|eXPh&
zRfltcQ9wzk81QA>FnG7jh1e8_BZnm)mq1V)U3lq;0)biRgn^c+i-j?0F@~R|o>nT`
zNTk8aAV_?Z3p7zOU5lqG$#^M3;8+U8%fVPF63F;{DN4Qx<{iF_#hI{q(xE+1ADcLM
zFy3e++wEuGeYY_?n;IBs%uIkvqot5P?QicMh*x6%tj80#2I7uT(jLGschVGyTYYi6
zCt~%)4CKO$n;;mWv@MczMvLBf*`KOKqJ@Aj3DCp|P{|>lUI})@8%G;11%PynjJVF6
zM-Rfo7zl5$^B!^Cgl7>D$t~yQ;Dtbfd5YLmKOr`)CL
z-=XZ?q3r9?$a-lqrK(r2Wt!|}aLdrLhZ5~3vQ$cWFcMsD=1a+oNsi1ux#X(kh&Iiq
z+{Bb!fgt<;AW_c}qFI>zf9sJy(W`n=rV;MRKS(M0DW#r{lXA1RtJUC07QZjFJ2iOk
zYR=c`(RF;5AWH~XskG=-W}VWcmT6@gvznLH0aJo3DM2UTuzPJPy+W?-bNDQ-0J$pd
zK7%`C15^6Kj$j1$0M10xok#&LUHEYE5fe=ctR$5~yr`q(uw=6A8h=%ePRA1o$dkl9
zV9M%1o{mZP$Ol
z`8yuarAj{2SY6LQ}
zm?Hs~n`sg#sd9%wlV~O46e4B?t%6zEovHK3Od*xie^9f<5Kx5LTc
zqNZjpT*^nv1t?l6lDD#2N_9~ZZMIp>G%ERawLDlY4^?X;_1b8yK2~c^)CMNGco5YR
zlIl~A&kjhbIe^QqhQXARb0a{>ae$)`g}-M8#p>RJqw^!9bHgKZ!=qqIQF~}?mhyNy
z-=4?*m_PRH+_4jkk|Mu*6`K1uOgSg2ofA_MP(tLMTwK}1WXTT8#g*mdmHDNkgHh!};n!
zrraVAC4e$li2)@6l)%b#F&s&|**zIfxfm!Ra3s44(E{=u99^k=
zdhS_IGO|pYwhFm3CsM7kw<$AK#%77`mPRh#g
zWNmD!J~7oGfhNa0q3}nvnJn2J5-H)EX%di%c3>E){XxW(IOryzEVPG8{N;I^kNij}
zJJcyg7_NlkKo*eYAmJV38WT*OR@SCycy^Op3o4D|io==GaJDo;lPp=~kz4^gX(jRl
zDLjSEikOJWU+KlaULe!jqs+VRY*R
z;qBzJ?M$*Bj+8u+vM*Thg-fAmB~chDyD~mw*y%{e_B{LCS(sp0m5=_`58FwIQ
zaYyu?sKFaE!f=Iko|w^_viw-TFt
zCdp&qb^_m^Nu60G*Y?UZeG0u?WmJMG!9z-e
zLavv~bPBmaqcmw1z$TrlM=b+f(rVoTA^}*!RSD!$volZ3Q|!dPJFdzuKK{>{5_*ax
zdlG=y+w(*pV6o@PzTPML$bOP44N+paB#|dhwa~l506EnalB*w3V^@ME4QLm1W8b2SJi!
zQZOakEWwn2P3-%ROu4y7a#ixG(;fW@Q$7fScY%_bveFtM7iMFK)>>qyEVrb?p)D0^
z#d8q24BD&j93M<*&=acFrxMZl`g-+=~ub~8edrBM^6Yq34COrgqR&cihX7e^;(-{zM)gED&nt-=*zTc9MdqtY2vxk74p7_FQjwZoAZz_Xl8=>Y=l-Y&&A96M5VyFJC%`v
z*5q)$Q7jEqOSrIupnE&J78me1s{f
z4(0GHX=HYIbZ!J>IWD5!6C(9{a$$_WJdgh|f9%BEv8M%7Qo$es%JtQSW9#!omPcj<
zP0kA~tanz>StP97yKodhNi@lVy=QID^6K)^%Hs0M95W>W<YaPv-M#dd<|#vN+?4vk@_&eSU$mP(sTZF6aDUXwd$^M)NDONY-4BM@~5
z!X61L!!bXYGL{O(GQmVHlFUa%5ImkOCGur3WwP4LGzapn!NR~WaIiWw)>(oT)HpU#
z16EG$ZbIXmvUdI`VoF9#wBuD4fN~R4RyPSiiMHdX6jAR^5d5!+eK%4`P?}hskI9n#
zPwd$uKHKCe%no!)XOjlVxdrCPHIs!F)d1o+ID0EOD?HyyQiY&a5q(;`7s+}}BwE?Huehw*rDWULrWRin8ERWc`sWi=Wr
z1%t&vs1gc;%<9QVIg@TShZpxQ9((5W7hhkyeedUujUP6|w{+v~_51hnjlGU9Eez`1
zxPJfM_xJDqu(9!z5WcY=U%mSF#dEdkkzTXXn|8;`{z%3djM;)QE11$3H-RSEPl?u_
zv;;B^5kPlE3%*1-5-&x9S)VuU;(Q%oB@DbZS~N&PNkMqH!n7%<8Z9mw47xz-F48%m+`5Ha^p!t*{QI3?NI_EUCS!93H>^g}iJ3yIqM2Sd%m39b5C}Q&kOir)v
z@XPJ`V=SvV%Ufm6JVRCrQvau^H_&?Kds^eA`9G;*a*tx6oQvw;~AV`6U8t6}5lK)N;Wj-Lwe%Y2jih6J9k#Fr&J=Lq+(xZF|
zMxSb{OtS?>zxoL(Fr-qLy*pHvzxAsB)}wr~U;Sjia%-P*TaR+qh3N|S#kj3h&;c}l5b3CbjG6Z8yL1~m5@jWUyImsZzr)F~_mV5QQcmmAd@
zs}=-Fvr%n2pt;tfvAE3+zn#d^t^>-8n|K=xyVp#~Iw89wWOs$_-U!ux3ybwFVo6Uj
z?Mr8Ui8QT*R44~>MSrmp%9ld9Vz4N%689BkY$8kk-aO__5C8r*Zb;xeQRLm<=Xlo@m$?k4Lh(
zP=S1Pu4KX-3>p0aYdG!|wV18ph|1{!N`e{~jRbjvUUGV%dN{7_@2j_FH^%n}9-xPww<7TtuQUlx_ee*}zkcH>?6g
zl7xHG71971y)?0sW9R@@v>fv0*f&rTHU^+y=?W-Z*txgg?v^<`FvR}78qj1oY>Gr|
ziG(YYv8PfVu@*Tc?sT(xVwFmwS_VgQ)EjNKS*6%_y_|29imhs?RV%e?)uCp6xZN0S
zwED(D(6PQno^n$
ze|aANV}9+~`L$=}*H3Wqp!xM<^XqGi$Br%@I|3~T_aqF8dV?m{4lb(dp4kig=*;qw>7~Q8#&>6#ZxQ=u
zrktE_afR~_KYnjyqAXTlq#1-Dm|8PeuBY?WI4|g*tHjd9a5(8sQM)T-vU#<3kH+Ryn5?~KYmeT#OJmxu)@{|Ox8mkkr`x5`?^5dJg@M7J?%cuu
zUHn%DIDQY^!9VN`{D(#lb>8jh`dxaK971>R{{Y0iaicso@>Jj7Wa_8Xnk^c@rRE74
zetI=eDzs1POgr@ET@+il$}A40-J^5(44m9!_v)Q~{NkD10jtMn2Udb6BXJ6X6H_Kb
zT+$NCMQ(%KYVdoR1u^tR7=b0lERyz#LL43E+eH4_MYsoyKNih-w3I
zo((y@1e!2tGQ@0N9VZ7OG8J(@
zfsu%k^U3otv}xQXl~b8YJX4RR>)}i@CYDT$XB)XhHEoT0UD@QZciy^o=MG>I9Qj8H
zj{M*2I*AbTr88%|xwOV@u*XcEgvp;W2NFhqROgH6JW*pH>vG5Ko~X$ew*->5P}&jA
zxsxS-vJ{LJ0^yuLUJ5}GQO_tL;`LPIvK&SyXqd3LPH&CV`8wc=L3|OgnHNi0
zGG#I;=7)&>(TM>N6FJ6b+JuroMy5&r5YycS(D{?aNQ~#>;%Y!5pAIo4TLpMQV<()af+{doVAZ*IK#>9;SP{=7MJ$QaCS*IGfG+dz#n-By`?OP}_sKK)a2
z=EDDxwkXtSx2m+8I??lhCfNp4?hrmp_Qm$-bim3!1I?=JH)_C?8k<37#?@1qoCcns
zii@c-Dq-7wR)^PYbptDPVlpLw(rot`Z7{+Pcf{eLQgF1^1uvKuCvPP$t%>^wSE1}L
zltX|>4u!M9rP0}ES*-pweoBccL5+`yX_7sc+#?*8Wif%0mRQ^@k%&XuyvZENl8Oh>
zG)nSN7W1_{#7@ekLwh3mWVDcu6|;#_F`Cc&(y@t6n-)6!D3kW?^4i{Fs9
zGUv(^0F(*`6_Qjr0~&Wo?~9s1nSnT%637US+?-*I?GXq1j10x;BFzE8>FyXhhnesE{_l4+7jrW=v(G+j
zul1}Ox*%7Z=c%ow;IIaN96R5A?GylQ`s4TA%*@ElC3dx|3l9)}##JdY%r+JgZ&#O&6WRBGV+^BOD!5#Q|hV(17M_l;L!}Crk>c2e5I88<>D4r9=wl(#8wZj~J
zV=edpZH+nB}P&yKpDAqBT6T8Hd0mM-chhU$ppy?E-_4|h-OkGZ-X#5|B!g|?*{lUkIEa;;Mo
zoXBkQB2WV_Ha#M}TBdTU58`ts<>v2tAXEzhvVa%{gv`RSFL{15YcUC&Fb%%6MS`;x
zvJfybXa^$ecA-lXDgHnv8v|n2!`yGQ!$INvN%4l>BH@|)%ZmD07*C{W%+0wIThS*v
zA=NTcM8(i^_=Bz#`SrOpbCYzW3LSo*bMHGMcIiVOK1~(oQ6Sp|>gk9O+Yod*U#6Tj
zBkkzCo%Q!SKKmSUw(1+oq8D4e-8p*`?W+S_Zx4V1E9cp>zu9(Ubo4W8)|-0(d^G;L
z&f83jMI^3TjM38S?@4r8Hv}Fkm|81eTPZu8Qecyr>%6wFA~vP*E?&0%;RyLy2uops;el41L|783Wd)fO)Y20l||a7Q#$xGNP{%*ZpwU<
zeA1T6r*yS8=-Hhrb;@ul09y|4K~u-wJe-D`rv5YNc%pzf-m%a!9Nef`@q!xMc8@7|
zshLnfBgE_4YS5tn}-|wf?aBMz}O4KsAR01`!eegqs&5u{u_YiZDfH3;F;z
zTb4OUl+*WyPRYMhAzCL5;Hyqs3kNYuC+<|&9|K969=gG>2Hy(&>@X|p9QViJFE&>O
zToN#|>IYNRz)&JqWJpbcc(U_g!rQW$bS^KcWd*hq;o;z$x2TI
zP+vrEBey>sPHG(Be0T{u*ebls!6995cZQ!v?yt8vZ|?L@u1h{WggbR29uHQUhN06B
z!<6g~EW%HmyZD_siZLPK^>E$-9NDPNCc!Kr`NU-1nPenAmeY~~jznbRyqi5&!)9u!
zVSY~32fw`U>3=acq4=8f;0K?Qsd9+^oJOlQx&7bo1~=0lZW)G2sG1=mny3Pzt{x`W
zUy95_YAy+!6$3^<@sH0^S7vz|qK7U}
z91h=PZML2EHinsYg2@v?8ZfqZK**)PT~S^k39=9T7*9~gA|d^%Uj`5g>`<2!MDHF{Kg`Km7?W4LoT5ImLlE2!4ow8hX$!|zUi~m
zTBWc=$^0`<7~DyGP7NJrnD!#@7q83qQRWk^@$+H7W_BjxXdjAbaM^_ltF?LWJu59#
z!T(&GR^3THA3>oRt*)oH&rs-lYA0s2au|HRVzj1Sn*~u;I2VR*;(3^HcC|{dbH)}7
z3ipsyys0Q0aAW7f?iRlPAcB1xk&kvILG@!YI7qG^a6dPuhOKZ!){^-w>HT$MNtQF+vEAMW|p+2qy-DwOl3gn|~L-deTU<(balZ7bS3WOU|
zh8~l^iB_oH0(q92r2GRNoDL}x)?7eQ!#QMBt`LFqBT_C(ff0zPkpTo_WnfSBzzH!9
zyMTet`-_q91q>p*w%2$3HN&o=c<5b&HOXPLxavu1hIApczf?7XIpV(#yo%AKLI^m-
zH$~4+M9hp-WaTXGy-EGt@~}&Oa@-p$u~93{R16>>kk}R#v6fGGkIMDaKGtZiwrVae
zmjOh2E#ga(hH+1uV3l8Ie-)F4I^!ciNl0MlT)A?Y{Kcp!Ytg*+<~oj_()?Z02ACW5
z29Q!NI<1ODii$S(vq7A|_4|XPfi$PHtY+7z5FRIguig14<266T=(;5Ah{Pel`)Mpm
zd`jN<3sR$}B>Z-5kyc36_@P3`{Q$94x2A8f@Wvi
zXg5{bXg6K*uM~n>`18S|LAjqd
zn;K?Ka^i$N_@k!#&2kb3lUBC%I~y3Z(=F=qu@!~b&9V}dqgHtj$|5P)=0sWMV?@|)
zLXDC*l_U9K4*20o_{B4uLifGN&OH>;Y8t0_BbgEt&GEs6s~;O!v48D&3HQMj>dB<8
zSU{k`WxI=;rEg%Xe+TD(!}Xzom-EdyPR1gL`CS~=&Zg_N!pZJOH+9Zdt2f?=~J>V9Pka9*Bl@d~ulx$IbW
zP-Plrm;|%5ZbC02nlb(t$sVghWme;)k@uyN5)HI>fd4z1smWIw1i{9o7Q;qSr+OZd
zotX-^)!Te0vy$3Js)}ZGLaZ~PG9-cTB_S5q(`ryrfMn49$%t-yGQ1BDey;@PqIMu(q
z^!rKdBG~Qx_^ffj&01kqC;Vnj7}0ju-JdN1zf2L9e0)4MKKuN93b!&wz@`@@H)vru
zzMiy?u>pbGOPQ@a89t3_>kCzD?3$9(RsQdbp3}hyw1O#kw5w;7xXQdlWFm(iy8}%=
zhsjN7##-Dm<=01$N;t{VCQ9;!7H>TMg}yk|(;1&dt(Mx~-x)7IT@hY^Mtikx+kiXM
z$~%5K8{3v=`68<2om}%A7$ew2Kx4B@>~95|mP5q1rdZ`3o7lhi|GAKmIv6&b>ZMc%
zrJb2X%g8`vbVxBKm>!O~uhPjPXjlj+cvB|`rjH^~ERc%wd`xk`35m6toS2f#ODIXq
zdFq_eHq0iZ;WjMHIDfZBo8Ey~gCb&MP`@CE#&dRyr%*Q!PTq%@xUqh}Am4ND+cfm3
z-T;SZ2kej2o~<-{Am9zr(PeialW`cvOTU9w*6VlPwBkKVm9w~`fZQCfc_k*a*bVZ_
zxKFrJ?O1Pmejdm?ru3|ISm~ud7)2~Yhkd3gJ;P@voaZSmWJq<`0cU@?M`xd`pAQ`W{_uU&cpbh3jPFY`h+F4$n
zYOr=0h38XWdi8VS+7d
zpZl9pIZcdvMU_cIV3
z`IBExH`u>vg$!Bc8>sAk(jFTZ9@aIqm+ewFJHm+o}-1%tk%xgEk8VHnJ$q{=PXZJI^dHr2`$%e;N
z>?*$#qn@2)4FD2y6wjH*vw#OgXzDx5YhQDrs-?p#7E@?Oz;4ezZAK@cqJ-UXXGyvr
zt~`-WW=jOZGl5b3Z6Y(Ul_PGqwH#P!Wu6un8z-~;pH`X^voit%Eujg_RDyB|6oH1T
zE(Qrwi5WEb$ZXS9SA$*@zsaSja_6W|Yly995+}U*U(j~2Eq>!kxw05GAfMQ02(vGb
zi+qh^G9p_@#PK?Dj?XHv*tY-c>r|r=;n9AN3S}vv^khl5?#-I5%AaM;(_kCIrz}c}
zOiJ?X;yD+oIR0;-X;q$>YN0pGugOeLjgV9l-n@cezf)s0^LkPp9x=(_$3_o&3Yhrb0;%9$GEOaBu~3D|WcAe(UlJd+9?y}=lc@5#CdSrmAw#D_K9UCn#C
z>d>6~GBbN*-jbO!Hg{L|zGaTEavf)4zOJ8rU`cu!{=2=?bHcqmB;GB7D$1jd<+~Tc
z_x8>7OqOsrUe<>|+49H`Qm|FJ-FCTayhg2%AbhSf;JIcy3!F!hm3{_7(YeMObd`$L+tM){Q|F`{VC+iH%AokmtFjU%)L+tRH=
zc|Lu@D*;3r#7ETdox#$03h9NljZ-VDxyuVKkL<&-L0VJeSF`z4P7O^_0Fk>ybLg)>
zc7?Ko`b;@Ea_B~=jF=^9EC)g^z!##eFq^OGpn2;Qf8!W`6RG96E5tkmWLT}ggn+UW
zK#kWjt}&jT(uuNIs|0FAeFQ|UNR1`98Q)f|To3$)gLkbajFv^*cF!H2tB;mp+AW)*7RS{h>3eUq#50d)(2W+m&-Vb5-zE`QV01Zob
zxLM?YUIwj6*vezJXk%!=LDn+NXM(=?iFfMqR
zrqBI(m|00rB3xG@am;G_L0Jo8f@_f&tjrLn=mA&Iu+d?NAQ5ux#O)3m+138{Ssx~Y
z-&ei~5lj&JE}i&={64`J)%&SD^WkO}N-+a9vPOfk)&mKWqo|n*&R^aZt(nKKP&iYb
z0#Z3lb$?`+vXq-=k;VmvG$1=;@|XSAHDo-mG%q0|Un>9!`hA%O1(N1GhYa3tIp!&Y
zaTi_-JE@%m+)4bHG5px^`2T?Y!G=j=kf?-&URNSB%kLjb+&-QfYEhtQs!pgWk41-o
z1})*WRGIzT#P@qA8U5RXB-s*woHI<fWYm{g^XL-laBQcAcQ1h^uG$uJIfK}VdTQko!MBC{
zj+(Zfw{}mi6_09=Efs`u1R->_)9308!x(lwos`}AbOYCsTo-lUZ1t3Qy1b0-gnRjJ
zhqneM&?6VMU0zAThGk>zTlHIIN&+-We7+57)P1N}FPev{AA25+`)d~us9yCS4ytHv
z3W`5_&=&69=V{%p&?-G{m(W=!^p}X9)cs5f!TvUJ%xI|U
z3`p^&D@0YieL?TZOr^MRxs?OnM)`Kp{+DfLM&>yG==E|qLL_zgr|7pfT1zkqK3>ta
z#fo%|smLpWS%PiGTY@iSv=ri-UfhyNzrXmgEV7;Y@7;SgItG(gIj*$Jy*b7Z@P38^
zb9VjV_I9Dk$#*aAC-T1!4{(k9BsLj5-zI1nv2gfpV$B_7atYN{^kpN={GWpzp-d5RUkm~Y8qN-%_ef8kele5tfq?&~q
zl+raYXY#90v&p)N;=-2r9`gqp1s~y7T@W=FM)#Q?UE52Bbdr-pKWDODj0B;@0oAFZ
z^ghVJ;s4HE7!@PBg#94ol-DZ*VQ&3#>bxmeZ`8pxP9xKV0YDG-8G)XC{omk$t(ojj
zFPbM?yg4q_QmRlAT^o{V-5~rX`NCrT75~yK35U*}0v2*X*AM_%c{W#yq&USL?bAwR
zjVT3@{7^^JjIzt+dAxM0%6{-LcX3~@5zY!cUg3a#mT*4{Pg#3z6RNG6GRpXOwUWls+4*pI=T_!~
z&z+Sj0b3fS4S3qzM?7wzIA85Or8sp4KFl8~39q%D$L=;P{9(si{xnd*jyk9D3bw>N
zicrmLb4qqL!q#CPFGf@GNK2@8O-I)_o%-#2vlNhDsZ+I967QsWGos9%*_+ed@S@hh
zog`%#9C7PY*K2a6Yftk^0y9L#!o$`OxsKJ|{X17>+>7tommQh8WUou32Exkzdl+GH
zXo~8vL(%n6IQU=iEWH=hEp^wPeZT?A8}Cyeq>>XxD)O`d&4N-u$rV#_#T^sfx>g7Y
za^KXr)asXvvG{c_5DPDbZ2PP0KuSLGVklXg^*L{YA-*jw5z_c;cm>x2{5C)6M0iP
zErharzQdiXsFlgV+TdbIV1KZ3`h0(KdX?Sbwz+b6wZDd{5&)Z4!oZJ`xP!s{p9YNs
zb`OB@e0wX-icg*8vpsIcQFc|l9(Xt=U-b^rlk2(e3(riP%z8L)sLO8mzkrF8{J
z%IEVZq6ZF9jQ%7~HiTuA=D6W0y;)9h?GnXT&2{!vKfNr;kcbw~xk00E=ZO+ml3}xr
zVJW`|eV0Y7pmLo0#J{L6K?~Y5V`gWSjSN~CZT7)J(IYXK1N4od1nqf3-9`JTx%BPm
zTP-tZPhT$|=dW_*$M3{NM1^_#-8iHZaq1Nqn^_|`Yp{GxZL^BBzHxS^n9cU)&-OCT
zGUoFGjw}=A|4a%pyt`PuyIU9AN~|$Fl5T#7hYkHVj8|oV47UdUKHB>qYEJu>tNhf!
zaJ8=fkLRS=11KeiGX!*}t^)q0*6i%%13h{x&1CIr;lZPxkVqdEwEH3f5wIqEddT8{RMDEMPWrIxJN!*!Bx~S+Y66Z4
zVdYzE(v=>J^_>oSLtK~d?jz_CJ9Ba%yjUVqxYnj=wo*9-Jpds+xo@Sej@F3iwk;YJew{3VCt+AHx_A89os`iTx
zW^J$C?MP!d&b2opJ)KeqYVYT3x4k&Kf8-XfYTSH#%9S?*b#yW$RaSiJWIapC@ulpv
zw;!W1z|xuRKzq?4V3{|4JX)JSeVmD&?8
znOx;`eLugb0xvF)o{3Q}K}b2__W!@$#b5MmWSP$^eT+3M&Uk6(W&s92lDJQN*jOgQ
zH9(P$l(fbQweQGzF3xriZ;l_51$8-Sr&H~S^8YY&s;5FOzAyi;Ce=s4U;I;hE9Cjv
zRPop-x>Wu-&ZC5Qc{lTC0_W!UPyvHolM#95Zt|;)m;dnd65=-M9Bkd{MXrz1swD4^
zCJsl1bMHFuPZtwO!&4Sw+FdNI9o?Uk_-O;+cciLD3R=b3A(1@U9hdXPk{!>BYR6TX
zRVtM|UUx9bwRea~zz+e3@21oGxg1~bcXoPSpfByK8lCVrXF({lG{`^LG87b|eF#n>
zUO2-}R~r#9WTZ~_%UU6j`8Hhvrem4j@xTk~oIaa60ys0Nt&>u^i%wd12d~8io}c9k
zC%(*xkFnQG6|$+?99izCnuz-~#R}&SzVf&?b95RyEBvcq$0R41o9FT0fZ52skb
zUiRVo%*6NW{YtZ@m8AdG$zo&w&QM}@yzeEKI-|)&KQPO%jBYI#Tag<&UmV$E0nAj^D0!+T_aFnq3zqPP;uDVU%7;=AL-_@%9SNYBA>xPq!&z@>
zD2yd|Tj~SNJxZR}4i{V`tYo?9xmo|xOf-D&f*ksYf3jmP8<#C43?I26KmK#FM^LYsa>TX{;kwA{U@5PZw(g
z!kz2z6X139d22b5wA1Hlh14m#6Sh{!Vf^f~{p5QW(5A+%2grX8*In^movX6|a=vs#gf=I^b&^R}huWKjOH4?L&zo
zxU`oFcq!D)>|N@X6_R?DO02k(rEImFrY^BF`PiG}{N5ay^}~!@9(g#u3)4U^QW27@
z*gMl;Y0T6far5+#-_?Q$Fn*&P-}5mmwUoC?LD*;bVCTRsG(|MS&Z%wH=wCK
z$LXHZzt`6~?oKPjfsbDL8@s!+V33+|v+2*U-WOm60;bIPsK{iLNpBfb6lP)`pd&TH
zH8qvUseq7RujDK98i0@C{h6j*1Lej+N?xsKXI04LBg))(f8P~b90xFm4TZ!)@pG~r@zihK*R!#R3lzMZI
zVD;bQzwTt*y8TQ2%I!o<5Y*ZbS}?9KMiV23LSMGvS%LbIej+N
z58MwK?dJ_5cMdbo=)+o%Ax%N?7zZmfb!1YAN*y~Il3eH$LeIH#L
z{ECc}7qAa~zIdz?sRETFTt)f)oYj08lW27|HD{*t9Bm0&y>F@VJCnVz)9*Fkglhuy
zvBKsbqLG=e2^R^65_s{Qhj|AX`o7A1X<(({{#&$XHIWqvty5b!DJmF_&wIX46gKkp
z_kaF3Gg?*N_B_GAF=~}9e!g;r5nDO-&fgTun%#j_-WSyVH1Hy%!~g8$^GJr
z--^e-#q;zxf4l}V8?6L~r6JkDjvG1#C5np~ojnk9mhmxu$t83H&!K;5lGgiWh!|U%
z*S_XABcVHM9{lUuR7Iq|?Lxy^4TVp+hDBMEf;bN(pQNjB7i`U<_sn0}LLKoZaihlH
z?-UmZWQJ{)^nd(Oq~n42qx1!#_6+dTS9`4&$+F1FvnVOED5-yiU8MAP0D?HWE>@9Y
zPS@RI&&Aw>Sz;J>ZZ(bY-|WKYR$rp-ZZ?qDZz!RUyu%or;?v|l%U3M)
zgsxGimwp2bB0uBUv=nu*kU5Yc%E?_L8qu~v&Z`9A^|8mTCKom|>E!>Y#&Lx__AZZj
z9@!Ho8ssOg6@_ZK>$$uq>bAZ+*lFFShQ6B*w9pke)?Y7##GFBMAnh$dUKGwXa8E0v
zyz6KQL>Le<
zZZnmV3!;Fr1>!BFl@lYK*kL4p6U?Vm(8F>sjDgI?ffx6+Xqp=rcmBKlasGC64c5pu
zI*;mjy$~w1J*Kj#=yFyDy$&;TNd60LRlxyIVS0eBEdWAhw(`Cb7|*Ra+E8#eAv4#r
zAxKI`{Xj(_YhVYLuIS83e(B4W#)ym;#mM__wcmUg#Yo);4=IdDcB^Y-MT*-9P|Umw
zC6FvU*ief?@it7#A$^8DKNww@a7pYXzGBF{=zo6_foA4#yPW$+kx$Rgf$!Pe0N3=I0Eq$>S%Gnpu67`Ua%h?%LQT_5*J%*R>sSBuyophtGh@<
z6HXD6Gt6PTZ#XuwqGs!#a+_$&B^-Oc?fS|;Zr4*-STz8?y7Gua8VJ9!!%kT@
zD?+Q@l3L%kQya{CEZ2d%o83e&00pG!{&KWkpksWCRe02L_RR=
zo~CSTCA0^itqqe7Yr-Ki)djOOIh0;r8uSDH1#qEljk(~j9;Kh%Y|K5HIaCXwRZNux
zfiIgbGpifUMYd*Me`kAv{WSQ|S)@o&LO`>q%V(3|EWm?zN^S%>YaOfg|2VA8L;oKSI-7WSpzRrVLJ#rWgMG=sprats}nhUOegNsq3PU9s)ls<3y#*%W0%-`YrRU
z;~|Dh51oVNK~8Z?!rO0ZAT-U=n`OZk2isNr=nob+ujOtt9xog3K+Ai8n10q4cyTvN
z>eS|W29?i}Oe$3qW+A9-yN3g+dU-qS%WvL~+4_MOe;0~*o=5OUJtq;DYyHN-2}mOZ
z9ZfeE3wLaG`y;2t>td}+PV0HRjvpzqHOR%374<}@7xKS4ruXlIu-^5^fC_^pM<6{8
z!1+uf#4&|Lx8y*$BuS`(Vqv~~x$sCQO^_sI@rZA;7L}uULiFr#@zZeRfe4!g25lZ=
zf^%5@tvZ^(B9}P(*()SSo;ovgP+fL{L2#0m(vMNBi~k_4OdA{?q|?ZH-&n+HP48=NZqt_I9;Sz(RPpDE<@-xaV{SZ$VRGic*
zo&?hK_o!NVJ#$Y4S9bA$Zav@>OFrK>r~#{bT^;nCSkZ*RmqYUH)zPsN6{?8D)k#3y
z?yzTe$eQ2r;ViWC{(`m2Y%DAi8j;fGc`$pFp~+Q0}O+e
zEx!Uc6P-eZ_r<1i;P4c)b8CvmRU+%%??DuKnG1Zd2dCex9uCe+5tD-4T0JTE1R)K}@%XwJg?!
zR5iL2EB|(2JAG8mtb>+vdinhMjCBRm%{94)U;YQXzKpO+0dTJO*Rx8jS?KB$6||q<
zcC_ptnkfxxr^HkN^E%5woVT&1a}@G)S5B*I#9Cx%_}S3N7}&~F_&e?@xwxyw63Q+Q
zPT=`hCL^e2Q=F)~*?i16y3N&|)|NF5z8x+XSCarktpm=Pn!te_48oARJl!;OF@4Zu{Ex@21(IG
z=U`=GwQvKF&Xg3DAt3pIBO=YSEbomh^P-GjHp&wMh)@tKrE=mFqX0^
z^W^;>5wX4;)H7sFbXTKld`%X81+anYU%Km!Pa=pBc#07mMvK__rF~M0wtS%s?)KX$
zhMfrwUBZPs9Sk2Y1{TXY{myp@s{Aj*ssyfQSW|f5e*3W4MsAo_ose5KUkwy?v(EGU
z^{V-9(*OQuk~E<0>0$D2G9d66rsmlJTWDA6Txo$#it7ZRst{GUzNN1JnHlICIpbpj
zYpc1~!k`t)Gji&Ar7W6%f5(1lwl&8l4x-2ZCXW+bjVZUShi>h(^g&7w`@5UbTi`Ia
z3cl3F#vK>f3KJS<$O*8Y-+p8GJ1@3(Ws7g-6gd#v&mlPJ1Ss`!e6x;}5?@2ah5wU8
z-n_goDZJ|#7QZRBz5DO=6*IK>|E6?Fxnv@NWh>a~xg;v~1#qAPuYp-&b;n4s)BOWN
zX7fFL=wB)9&g@41)A4QU?$(Aqr)LTz0$oiOaa~jT0{%-K)FYqYmBNjp^K|kHKDo7A
zfqcJeDOi_j)D#;3DMWPtj7;y(8Vxtw3QaYzDb(Fkn)fISNE!H>F9=m9_b837_GF8W
z@j84U=n(UD*bd0cY^ME`md
zM&@JZmxf>F%1-o?J}nm~4o8FYN6lRf#!SH+5-(Vk{1~`9=O_!>sDS#c7gC8>o=ls#
zA2*gM)D~a8Mdh^tY`7?F%sPc8;J`}aA#BNA;~^jhL}XaoB>&SQgitgCZ|?gDX9TBS
z(CDpKzET=7)nMw8N%PX8TcIw`ejk{(t;NJQVdb+V{FxQsPiESbTYpR*`@uPD#L;`!
zTa9o3r&UHxJ>#!h`2>$H3lRrQ7U^gyIgk7905s;bWpfV`L(Gbm;BF>zw%OO}O~~F@
z`8;WyT5FP5XI9zmZt#=z{Yee%iA5Z!pAS5fAF%wn-JTLi`rH6YIne5Rn(ehaHwVn@
z>y@i;eA>*wr_6l`al~3NaNvB0SbK;p<}pG62Y5YP9*!Dkw7_oUp&6oS<-+gMeu6Rv
z9^U2{&}We8UrYI2LeOb`9E5z-WJ1<61sO1eK%>Qz(7|A$VKJZ_W`EfHOQ`GD+`I?F
zHi(+`Rf)dDCmwT(e#6!T+TX8jBrH^ZsV)B6cz|$8?fg68{TFXAztck&Xw+}Kw
z3{AV&>N@K8hfZd4ZLFcw&Hfx$zOiE;{YM%W+wJ(Dw5@I{lxaoy{Lc@@a+4MrkLz$D
zoP_YKf4g|vZf5;d)SLLVu}d2nNQ!{zEwd(*~UoJ}m6
zY0Pviq#*?#Mql@7+-J+rh4~%&@n+o)CUlteZR0JS8vUvt_fFFmj?bpNt2CPuEItQT*dd^LF7s-eYi&WH8Z|h8?jrHP|Aou!*WE-a
z6eY`zLiw{Or2e<3D*J~;5~qQ-d?O4_FJhIH>s)(Pw5{do0pFDZ7>
z+!}OS;(ri_#4~&%{YeZ{Z=;$}M|;bzy^(~
zeI9LGlX$v{CzYVm6MNHke@#gncy|e@hs?2;B5V5Dv2E-dCs~*w8MqE)JRODufC
zx*e;1UDTYqFoKP}H#&N)JRZ2#a$YD8=l$~>BUEY0zaG{nXHK-i*hokk6Cnp)pQ)S1
zo|;ZX_5YW__W!*`=ID%qcVXIiO@Pro%J8b~FQ+T(My=?~OE$$CCqlHUo=SqmRf@8P
zL1ajf($Cn)H*=4?&aANWhMGp%H%xzh>OX+*L{+R}v=wVV6dV>;*xa6%j4aZ8j^c9`FzyK_XT{>WXlN->06ybZ330m|d|a7-L6
zM`W9keud6NGe8`Yu2AQCq#E98mBsu8-M*W)S7|^mGGGLD_Fumg>u)91QLN4l%Xb?MM~=CAxk1EGYnT}r3L*fy
zmskPhHn6D6v))os=}GY7mdmzQdz$#(Ut}3AQjOVL
zg1Mnx5=vzEiLr%-R6Rt~=O$Vrn4cxe#!*lBYu?hg3ZDc8XH(bX)0*!Y(?=ROxl&$x
zME9GSr>)W{Nfl4*Oi|d|=6^;F0WS6zS78h9+pNg$sjog{1g9?3x=**Pz47FHh07|P
z$ooFRP$Z3@7&~4o%MLx51;iLWik@U!GC?&WbfAZ{>+JGU3N(_gBn9|Zc=?6dYTXow
zG_hTtuLkOA!v4sW
zYwJr)rMK_;UInI$_x!?+KN+3h=8Xe4tEC#)!XL>yM+(HLYBWZFG+1}iZ2s3QkUl7O
z_2&U{jPqW2SGQK4T#TH8D|cQtG9lyi@Wzh?Q(ovxuFyA8Nn0Q>lF*CbjFeZ&7p_b6
z$ku#D{h|fibINSlWEts-f8-~g@9$_qJo{&J(NBhyKd{kPTklpgTd9x{k9(^;aQCN6
zNhf3Y&BWX?@4vvG5~lr_5^z|-7rOKmTHx~KLD+WE*(3G!kEiQQcP2cmh3CD-Z
zS@{}7Zq;_@!;a&*b5bRd0uxHEntm2Ba(!uY(f0bY7tkeHC#cHkN8rEvu27?RpbRupjX^q9*FH$r~
z;ogs1PQc*58q;Y6&ZxIQ#wYvX79PI7^1Rd9YE^~81`T|i>qIZUdq%*ohFKqX)JFd1
zdBu@XH8&*Mbbxm7n*7+3&;%m;7oxGzO@e+_c7vch^TVOJ9(7R~|PP=RyD*BIyDFC#|Fc
zKPdKeGfr5)J4Fdce*do8_wv9HgAF-F-YP}AC`G5J8}g)MiBFR$+Q#SUwEZ1pOHD}c*yP^8Mt8+)l(q>-C-nUgVq2gn7d-!s@?~WB$kG+
z)!mYGd?wz!{+0UHIz~W~RGjHB`p=piiyydsZ@ZfYY2D>#rK#}IXU!Q%H-*w-i-hKI
zO(RC6wS+L0v0Ma4g1@M{zm^*Q6fE-a-9NDlOk!4euBUNycW;hLL0%RU6%0DgUoFT8
zj!)3VDVD0+I{?4HS0!va#-s|_TDe_9KZlnQ;Abi)j
z3-ZwY)tkwfY6L|u$Wb}E8Tlu;?q5jiVfpF;;de#d;d6`;WEh}ahuM8V(rIeN1RmG2
zvPm!HPlCnuG+0CO%}ui3BB2v((D0VA?(R5qam*n(^=rC2J4onFhOs{oRQg?n==#JT
z5&U>t4Q$~?t%1;^RbQPCD0uyS(0I3tBWm`y4|CDJ42S8ZXSDt|tDi|GIkGb{#cEqV
zIf=Sl=1>KlN8pk|F}^Jf4%TyRK(0NF&YoQI#+z5%)a2yE>hlyMXKBhI^^XaqVfV
zahYz^$iNRf-r13EdE&mVL!F)s6vh|^EY~X9+ta2Z83a8h
zI?M~N6R>f^K76F_NcE~iSq$Ee2U;JQOTW}FYNI&R6PxD@&JEmb>I6&FeeKTwN6CTC
zFo>ZQyTSj0@BN7n?rXp9Zz*jGAdEzf-x-sghp2GVKFl=EQ39pjK3o->Vz)Q_Nuvyyro@e@
zmhB(PW;o~?q)Yhi>RB4rN@tgE#9E~t=0VZ=ztn7|hN6}v-sykNR;`mM{Kt~w#2hc_
z%CE;K&1VQsk7WvRvILiC`W!`kerMp}@GyC5fPgx*QcZ8AXB)PkKM%<3IA%XPZr3>t
zi@0AjYNiDELboK1p6(yTN#PF{jerC67S5_8EYbYuV)!O{vT|KA@Dw;mAS410UKB3!
zEEs%Zxk9wNKdnD%sr?9bL?4vTTTT~dF5gk5s6x^#&DL^W#J$l3W-&=l^CyKVCJR64
zl(p|yu`D$Z|6#6Ch_>YnyMs?s67T01Y*~BV(QFM9#X1>t`cW97f3dp;
zezy6E{*dX6|H$}1U9d~e7RF!lJjU@tMT@LJITJt|gNB|ClVq&?cKNM2rsje`;zRMx
zh9Y%5E6TfmabdS-Tlcw4(9hGz(BpO@bb0;->o{Is*^V^!
zfkuVXU%LlQwr%>3$(VQQzx95)j$;hDUL;8Jg)0~v#u7DjgWxPaXJA`$LETp}XF#+j|x^9;s6-j0%-Ccd^l4~$$jnN{HpCpDc%%n&5_
zQe6oPb1hVl
zOdgE{0n}Ja%9G5SAhvJ-=BFUr&abT4^P_z+<+;N!lcX=xjw-*yi&1}Cp~~_CJT>?X
zwrE3W^#cnC?+)~mGVx&xq6v{_74&d@v9;a_K;o6;Fmrv<~w_G3d6w{}-cN6_#v3o6F7b{um%GMAj&H
zi32d{t4aP^2{?&UtNkPv`PLU`vK0|1hv9KpP^n3s%r?k1z_*BnPXW7!V6UGA8+RT=
zdkn#Inlbp?{33d&Fc5Tojyk?CBeKSCdXMJ6^y%LSJ~S2(#3Z=nnj+g{q$6oy$LZ9m
zoVIerJ2g(Dw{h};$oaV!NXYE4uA<=}wXIvi>E-JG`he0Wd
z?yM!87g{}%5Uc4pn9JerbYw~4y3Z_|>=@A)Z1F=J^)0ljH^(XprkrJgdfj-c)%+5I
z7*-zpH0Q^szR0;TOBdgFz!c~22Sh_)dU5}!lXX}me!p{isCo5i7U+ObWcoeKG`Wec
z{dpYCx)I&rzqzZK%x-tS3jd_iLbeF_`1<6KX02O=LD|o9xeP?wkX6j
zmXD$NxcpPNit@Zz2+WAyIJMw1yvclvh<*|{fG-C?2VgYwKcl+GxQV^}^cLQMNm*bj
z>m!#p93Ti;HKebgH_svla2nadjPDjodvCH7WK5L8sD=3Ef8%+|Msl;0BJrx|zTlqs
zyy}4%SZ_Sftn-iWDPR-$x@RdjYNKhhyaBu=w+o`^2qxF^Z{jII34h)EI^
zsZK;UF=oHD6?HH+-ve`sW9ptr6N(dKk}&WBHQ9*abO6`YUK2#}2DCs8IvY5_XIk5>
z+{88Cd@>6u%7_f>FX_<}l;MGP1ZI=aqfJt3w{{%KoZWeD
zLSIM1FmnQ2w|m1=BG^US-LFCvQbcf{cuUv=u6p*_MO&`t|LSx;osQN_etkN>sj2?)
zbUfVb!G56tDW?yRI*clB=Lln{c24{Y835_^n#a%+`F6#DeOHq@So=tz^lWdqYk7S{GYt-INo`l+zjza<0#Jq-l{0?fT~
zBn=7J^#jf{yHRwo{E7kW{M`FnmmVn_li>|o`Uyb~0qQkETMItW
zerBOkID8*n^YxPVAh+s#9o!O>WGY>%2sE$ZKC^nwLhBq!f&LcElC
z2TgZ@U(}Pdi&rM#Md@V=1L;-OlRV7q_i|miMA@KM?L#OKtP+U5X_&TCaLqS>n@k?8QOqId|GzZGj$|U+c
zFZ$#5N;Jmd=FPL~IpVIFQiJgo_5Et};+-6@pIta~*X92jk^?4kxG5klv0a#QkYP_jdHXE*-QE(
zmYVil)aZx{V&i<#v+MpdqdFV9DoNs}ND?-S;?T>OT`6vmXhDf+V;nXV1zD;1G9bRu
zPH{qahN$Sn5=##nvOIi><0hDxYG=AdNI%@bj$x7bthk`L9J&<;{q)n0eNhX7{6oAf
zL&v(1C5ik+dnS7>aJ02;_Q6qQql4>a3)(wYXltrol&W1uPZ&7*B-p^!Y(4$3cecE|
z>UMJ)ha?h9STLsOgd{JNnARezlo^p
zsb5<}Fd>C&k`RBnC7prR9Y&?%c7B}P%+`X`E=g*q&--hL^9ZS~5?=&cxkZsH4bw9g
znGf8fxXAP?8%$K$^tf$Jida{YfO}aIu&KU%
zmxlf7r&uDNbcC)j3A55`aOT$$t19!b^#S_*
zfOO-ver58HtPW*_ft+
z`Mcewn8fdBg9pRU^zcP!-jp7B3S#J=U|GOv;okSnTAV4jF7#X^Jqdh0?D9_;Nt;jW
z56->;51yj`?%}k`WDI&irRs4(EJ3hkR$O)zRBegrLP0{eKzjb1ItCN$!OWhP)&Ck-
zI%G;VPtliEC9LcI+%;O&NQOva*G%s$kY*|n)%5HkaI%qRl2!c|@Glrh{GDjT#nR=-
zp5llwQR7>Y$)Cs)1^o_Kej@YJAWq@2Kv^zbnA9^IpF%GI!k(TVDh@-)XCJ7#uH-6E
zfU=R62`NC9pxnJb158PZdEGaX2r%@~>GE8X974Dv3iy
zpLry>R818b5wL_H{KS|DNHXKK9TXwSrL@Wf!+XzWn~40Id=>&WGjB_L=01PU(EYd4KJT
z^OyGZ2zVW}O2gk7*b?dkgGQ{NS8@K(3eoqg_lUXVsFT$o*PE)%_d(wGbK}k%cFOlV
znA2CyJNo|LfF~TvfD?wU*M_c_Wn*aE`{R8V^tcB4L`-;BJnkg|-B1a*ddvB7o0aq9
zl~?rbAEp0Y#TkPNw?_!?LB6o7b=e0c@7t2~Zetq9BZIn
zHl);Au>#WXjn=fdGfzQDoq*TTom-aWOj{64j`(kIB{yyxy7wudlB0rfrS)iFSZ{zE
z5y1X-aLKEGpmh_azuzw7;^}ccIQOtRr#+0k$N`EC+c<}arhL&u1_9$VQvUt4vI
zo_Z^4{GnPT>_4_gh`XHcieQN(47vAX`(_dLUJ`Roz*7=TWqyQN<9FWxJGgX=p2sS5
zL|#VjCSfbnn2V0>e!GLrp68veFsthN3UJ64`Gut=0%4H8I0@5miXn~pIc@D0Uv8iA{DaT|Ya6kK>w)Gxp+zgK_
z0njE<@T5yejA_AGrplLyR+Jd(q7_decvn?h#5tDejtCEUQX?rrQ^ew3kP>Nr#4y5*ax2#m2q1SSeSXIL02?
z><^J*tarip;iI}x8U^LU-~k?-_%E%5+MB`iHMQY~<3V~FCNq0KOs*Bl*0?nYIE`B9
zo|4TYVXhr&z_70MAi#z6qXA_!SVfSmi6QY`sy9vXPa@EX=?rFeI-Ck4%@-2Dfdbe*
z6l3kp_DGQFk^+luY+_AD3~48WE?k?{kF+XAAz$k^N}PF6JNK7h#`ye-%X&^OsB-6<
zMowR(S8fJvZwN9~TD|=R{JeNTPW~+(7`bcS6dH~W+0%ZYd)4b1C(}wC>uu~nSBu?J
zUN{yC_EAN2$!opXopo2sk*vOnb5m5YR?nrMCTKYpS+%YeA|wleNnH=V5ahRT(PziD
z3`dWd?h$=1_rR@$($bd|uh
zMG{-{KQl)_f1YhdxKIi?IWNCEIptw1*fOO@#MNP^bh^5!P06ulV7J)?+s!zzK4o=X
zMyFdw2d`6J?p`UDITNFQ7Cx6wVMG$>aeF}Z1<|4)(e552Yv0VNkuChoc{W7Lsd)6;
zh7t_-1wvy4zOcJA&LHv8Q^NuJoq_Rcu9DiT(%MB@FmzX00{eoEN|xW3#0o!z8zAY?
zk}$dqd@dYw57B8JWEfw|Ly}XZUIjB4p2Ilbyk9CZkKC-2R`ugI41L!>_>TIi>S(Ap
z)J9c1ld39dcxm~MJW~igCOv~xd>Bi?K}<6A*eLcz!V9^}A0JZRcw~igJ<>l3W{k={
z7T5}ISifE2_&*lJi9n}icggvK74%8i;P-I?t}43T0OPet8qoNA*p2A~iYFV1`~_8w5Na!htx7t`9e%
z&Bm|eT|bcC-u`y21RPc!EP(Q}U8P_XF;~+1i}>A@V9YB%tXRgUqe|1n|K4PK90!#k
zulObg5;E}sNxJgSOFx4fjTqo6v7(Z;Xd?fhvYhIU7wUwwx;E39{rE+mpFu!iiLGGTi#
zsptd{g%5{%m`jPhl!iFrqcD!#T2|gHg{&*-dXch_BMY&yGG
zKjPH&d|hJfeWdqxKbrG?meK_m^QH6kD8=|~j2RX&>wTErqH(A9%l;}XK3jqN
zHnAXzzc{7pNof8$MEsd1a|RkreP227MbX+`$!tT3&Q5Fn0?TmQDhyjnG&gk0C`;$5
zM&*ml^s6$}*e6O4h`BK_F8^4Hm+7!=hh-#dq6~ob${JY3gIPY3MU6;tC1UZ!ZNL}b
zYUnfig}^6lWLohBvY294wmYj|8xzyKI(*o6!l8z)w{PLpbm6Hv)v1?YR3ZV1)G*{(
zyu>pfbG!r%Y>V<-1-Xh56sG7B0A<6
zk49!G=T7v`|L`DcIxK?#m?kiWtX-t2FVDRNhJ;_D63o8~?eRAG3q-`D`_y*W#BT#OTAjTDrbDHFIH5RTRJD@8c&tF3!1*_Hem=TSr|y4YX!h-p)<0l
zs<$uzopI_CKknzRm$*OAQ!sWTXiId1etfn^3$p=PaN9=xB(JL##QR=SknKK}5h>Ye
z-hA%UyC$?snMrA%eddr2
z`)gtA#PRY>@Ss|m{GD$q5E7+f>-i*6_g!$sRI`|m)HBML}gOhX>ROsed(agGl}APvF3}I!OTtPS)V_ohlOD-K
z1JoqY^GTSA^E!O|H~PFL-^>Nih>n6O?zyrnAA((E!s|#Su%d}u8aj(kD*GaACWgX-
z7M=>E4F-yz~_z$I-U!Cp8OV0cLUlUmnlavONtfIX4
zBYP&qZ1SA)^;Ku{>4?4aWj5d)-eL9e${^sf>WsGwd}`lsV3%#!XKXwF8=LaS8;<{B
z4Q$ad;OPkGJtXd}y{C8ilRKEW+
zO?PDrH|s1Orsq%@dhYF^HK65xfmiaR)8?eSg*p3{PJPcK$P8VFVwH_rdEq-;AG{U4_eZR%+g}aXyKVylt}u6>yNsTN6da$bU}^1{j?vpK
zEH{ODmMHK#`d=MXu?GX4)?aqkQQ0?h{#=_J9PhEv0nqc;f3Ug#KpBz)>r3(CVdQLU
zLfTt=LzCQS30t3Sk=mJyklI&D^iWqQ8mi3m_8Sg
zT`U*saaJUcb%Vkd%4b$nu&`qW^XK#-9&tTKysdtZ&qI)IHl|E`KuH3&ZytOmAGuUxsxK!nGv3Mr0+?Uw7F-A<-uy7e}c
zI{%NGGD8|T-e!ZT>n=2PRSA+OzfQ)}2<ZIyZnyG0(V;A{?)^1PZdOL;6ETxGPwZxt*baV&o|kuCQ@;D$h5PhurPh&I4)jEKMi(cbt8}+bd`au=wm2B7Z$6DBy#_!a30LZAG
zb_oBhKP7;fXJz{-q3dQ5R@iSs_rgWr_i>G9ji>b-
z7}nPJJywKL^eId97msbHpYDl9#;d}8{PZWcN3gO}riW@_8pNzO-xDbow-!858$o2y
zZy%@s${)ui&dTX>P1|RJKM*1)bFS!5y+*)eMCLQ|XfuMkHwv$HMqyI41VSxhH$6-e
zX0%D9Pz4TYjb&gF{eTJ$y71u>xtjmd+VlI?lHbC1Mh&$))TqzlOm=Rd;b6d2B#p#V
zsSTu3jAyI)`2j^~18Oj#dUKQWE{HO)Su8M`KUlf<$L9%!~2b1?)Hhj44?$e^)gg75`+p*Xpbl@{VSIU%3+Q|6C|@b@3Ev&Z^(
zJHB~ptSJ&z=R(w^IP~gxJyPdl_5(U{=8*U{{UN)2-d2i0|(6;pd_84C9s`FPP029qv}wNo^W6
z8(k5Bk~K=KhFO`Pnl8bY{J?3bzt0K6jywv~%$KesesI
zHG_8gTm{K+6lqOZe{9enh_*CU=ISc_ilpj_Ua9$Mey^On;tSD7q+%r1bVGqe1t)jg
zaki>HD_k4kQ4PX&Vc`=NixC)5J2Q4e$#?vrKN@h961a&Nh!1#oG`bA`5syn1R|gIP
zZ`EfG$E_uH_qbNjQCrgf-TAng(`Oj_(cO;_sLJi
z+TY!LW(HlnFT7kltGlQKuO%)}0X}j*`F%b$%~$lLGm9FioF;*yX$acH*>|wpV$dsY
zLstGvZ}yQYgxP!`z
z$(?#d0$ZgKKpipHrI>UdHGT4~mL7C#SHlhRn>HG&BMMzn=R?7S*9*wK5_ltIxWT>j
z@$Phr{v%%fSuLl9PO1e-1B9(0AeBWeBcqCmi5r3+qgKb1xeeCCMSyFC7eEfk
z{fDZAz#K!3_&B3<&S6FcA13wd)Tz(GxoxdC_``Oo-!DHx-oT2$zDBk?@K=YcPvmMQ
zY12esGJ;XEHcu5xR$gA--xx%nUgAWd=tI}A&RX5pkkvrj_XfPfGd&@^6i8)&>+|EaP3a6>SFW
z+FIwiPv8$8TAWG(YqsIO!!Sch0qv55t@wNU$6e7UMBy{;aZ)=ig+b{eN9DXME$c%q
z{V@F+^`j(=Dp!5v^vpk8TpV?uh09VAwP$_{xN#-^dIIk6gh&r`v_55QRlN`}I!%sk
zq$Sl}58gIbo@mS#eB|Fnu*L_C{BiZ%*%$Qef?*jInw`4bPZkax*B;02PI5Xu&bV}H
ze%v41<#f27aUrGXh`x;^ZPMf-X&XJA=~U;A>|0H3A2)5nJ~&&`ai4a=E8;6@Hj;9_
z2Aet&Mu9OR(OOJExOC!sNs(zf!%_UqYl&`)C5KL9EbTnP0e3-rbL}F6p5L&~xN4MC
zHq&#uN>tZ07@gQvB}ROsq8FS<%i|V
zbZiwB=o&y)3^+v-#S5!*^d$>B3wpvnQ3`ei|G8h@rL}jDz`P#*z>PSMu@HTmrbB&2
z7bhoWDDHQnN_T$E>4qrA?1>OErm3|
zOXb;C83dJQxweKmc7t4lXSAdq1rt>0>LaarD1hpn=S~3^f-OaVox1i_7=DyN*uyxF
zl<1L+Q522hbk*32mR|absjN92vHI^iQwIr9s?})RGl+jrP$D*u>wVRbSq)uqH@5T1
zZC1=U<+40%pXar@Qu?$m){QFgx#(;I{C#0BXRg(eHT|N@!DIv-{Fc4oV=Oxqah<&o
z%q0J
znJN$D(X@}rt!pRZB`Dxw^pCUo>D?o@H3NvzJ?u_%o
z24F$@!uQGzMFGWYLYvD%l+{_44&(%?*xiu7%qOzU84M;PNqDLr;eSm=CKlwaUiN~4
zYV{mTb{{;*41AShePG|nDhJC|krPBg?x}Y=u(oXHaKS^}y}zLB##fn@g#+Cc^^f(1
z_K7}|@w2p*SqiGzNsZ3S)sc@7hqOw3Hb&bIvP--VEkT-!%04Hspxd3ITSYkAoF^%3EpN^_#dIB8>U|r7yRsxX&
zRnqN42xX6$#1ng`Q-j3fS;@b$)%#wn<7W0PYl#)+%F9==I9#sFrChxi`jl%b5EUT{
zXeMVg3dllQK^0V!4M?g)Cy=L1*onPHR5!;phn-$A6TED0c{XMa8+_d~$AR5>v>S})
zU6wQ|(j(OoM&Rl+m@obAxt>C2T$i6_R*3+1W&=^-
zoy*eGQKX>|cFL<_Pwe24l(z$~2bT+c+)ReaW&~(Z>{RV=>=gYS8Z(Ur1>8$!2b%64
zptl*D(8ZiLDf_XvO7la&$&8v_KvXs?yMOS%zwzw4Vo)$T$+R#XZq0pQv(9p(&l&mm
zwLS>qoamA#xfv`y&A>|LmW+oqO!y<3h?>$
z@Av8lEWpKqMR1Arqmu~;%A5#g7weQqMUs>loA&unOa^y|MOEDr6dQ=CQ?ziPYGBWl
zsAcoJqU(Fa`p!bd(
z8O$bn62ocTFglGZck%GMob|kYn$>_CF=(VCk7+<)EVHoxz-K{aHcSD+_UrO_fD&J<
z{WzLfXJ6~Qc`|4g^}Hc!!F?Y4ju9NEpjh92ZICNZb&zB?Wd)bDSRHWRbdoC%TT3!v
zUq>laZuj$iPV$|F12J6$QNc$MPFuS0y}+_XL0VHc5x0LUx3}|UX^WPJHIw6;!Ix4R
ziOp8U3`B>Nr9|h<2j^^Kij0RP$%L?HfKr}?OojgEQsTSg)*|nGn9bYLgR8u~o)p&y
zMO(4B}iyLJ7P6m37mH|l1}(r;H`N0|Sif{b?Kn8^BEFgxFLgFSS5
zRU}>oxBGKQbI3KoI$%C0h|f>hFUV}Klp{fcwA0Zm{2X59HW{QTt
zyMt7!VRhwLN9T({6a`Dfp>zap=X6L{+9N@g~9cJ$PVo
zvXJRoqzG=f0~TO>o9`@&K!q=CZMcvj>6%XC+RPhmB>VPJFl5_1xtljh
ztx%zrG<+tzgdk`9FJAWfgRYfgdpASEWlct6W;y6cJFBa93?X;BciZTV^cDr7
zCgj74%c}xL$$$d7zn!Ky*!rJ*Kj^1RK838by_~(ho%aNB=cwPSf}FjVR{!R`O`IF~
zS~Vj(TyQu4{uE*wGlTU5c5L4~e?k>%uGfy!F5h+q&>_)kvq;0G^rv_;rj8?XwVH6A
zB}zAxfV1h85KU`Bxujel3p^Nc-H>*bldWBlXdQ#VND$gqmtUvR<^$kPFQy@oWiQMu
zA}OZW4R2W(=oHU&tz^VUjE>{9>`^D4L8sslZgP9Dba&y^~MrX?&LogrP6p)Q_(AB6r_2a))q!5MH7Ao-=&hz
z$&eOE?=-5lq#DWpi^OL^K~z17qymVTq|)
zlsL+_#{y%haCDsi({7x|bI;`a8*F4Akj%4SuV&)7mV=)DCX=OLb6<8E1V}U}tD8Jh
z`|!`^yYfniRipGJp%>A^KT`3~TX!!u2v)>vt(d&y9?Swt)6|WU=n}h^+CxhMPW6~y
zUlK87`ZHRd)!2cGTKD>Y4Ug(xU;80yVhn?LN37_~E^2tWsMkNO7iC4A2^3j2M1w>E
zXbrEWi*lxCb5yo#6fpuYALu4a%)$e>^@-ioiO>XYkPIe++nyf2J}
z2;R)*4zId#c^+7ivY8s^_)*o5iZ;JhBQm-+a;maPnykMECFOE^G=x}SOQC6xS
zvJNpf@LN%YwLz~OuPt}G(GtiUumaGLZCrLMX;8clzDstkUU=C;`2RMzHYpEg5Wbs!Ga0l
zW^quEdNP%Q(UDVRN#>*Q5C!O!j_UspYhETaIgfmJRtw3wRXe|ix|WLIz>)xqgo=8t
zN_V&@h;-@Ph{QgR)VzL;t})w}XA3lx@=Qy)(|So0454w&hAUSAeNcFy((>M>UrKut
zc3tS3
zdaS20xP`Gg7C!59cUuc@6GP$E&r8bIjqomDNU>@^e&n>G!K)JjZUV@g3&JIb?ItNU
ztl2QLqR(FCZZIOn%Co90ES*@MZb*p6
z2&t4CFbb~BMwzYq_sUqt^pK{)*H{aVXL|}bJDg`u|jv!90vcaIFFf$Sa4Sekb$s>C)
zZKe~IX=7cZ&j9E-l}=HFc6chDv=|FZ?~YW=BiEPhn110cIS5$B&XF#i5dK_hFlS8l
z-W6n$jcIj_M?GRb!9C3X!;6&%k#g3&#Q3-x(nh$###*B(&|%hQfXnPUa>ge8$1X;*
zBkka8S5Ze-*f)FziF&7Nd?ocqgIqd90BVo-Kr@={?AXwVZaI~n-#>6DaiV5<$dOCe#S_*AWp`8BKIwh
zH)Kjdpm=gO$SGSWB{p@PVxVa)4`C4N4?f$9i6tSzpca+KKwV-qxf5+m5TlNA?@@$q
zrdlp|HvC1gb&aEf)|ThxyHE291&3bnUX}aL6msg1MLlSYtew&s#uoQLr5*sTE!C&r
zNJ77JRZJIrXNQkXtahgj#6;}%N8lnVlYPEY;kLRdhg
zw28rXqw9C(2XiGCdVl8xNpNb^BWc@yeQb_vG=C^{$Sz8hMJ0KTd%ul?2&}LKCFa|W
zGojrgqU;#{BMSkQea+OER4ywn(Q0T=h-y&y#UJCU&Jo~ic|15aH=YJGSs*bCW`R$b
zt%;o9R7_qhv2Od1e;F6+w*?M>3lN=hvEh4kF6^Nm%dxLy)Pz{yK4rHk>ic2;17y+y
z^bfFoM^{|DGKeZ)yi|2-cpxG=
zXJ=DnVOvYjLQv-dDYF7E*v6F0i7mg|s?w7&d~Apkn9nz=GuO1~XJRZK##6O*|E4&s
z49d{CAoK_27V=t499hqka#KuO)e!D7wNGIS-)XHT-E|>Q81V2RU!3
z8RPggoj-G|?iy)a8`$MuLjnsDB(ajCqNY6Jiajq?6<@ip9%ELlH?$Q8f2~0j)uCR*
zY^e_OnjnM{opiRH{Fh4yB9d;D?Hn#%q6*J~)asp9`DwrIdS6lAD{(626FMqv7YeO^
z5)oSBTQw4<2n6z~@Psp*?B$WSGV#V~4;ks7T<7||YKWiZ>M2C@(Y7SRG0GcOGT5@h2eFJM>6Vcr
z8y{epqM3W=8R7;Q)4}YbvbWGv8Xsy3b=N*ji*y46X#V?E5?p64<{>$#0S}*`o<6K*
z{fUuO>F`^cAB&D+t+m0KT6D(1(qE`FuBlTK0(voB1Yztj&D`-`##!c)g&M4WxXbXc
zKHd8RBS>|@ERQ4q8+euD=u^M;$uAuA_{}Mk$ViPh*Xb++rBB&QT?&(D;IU!hQ4#d==|%|8<%j-jK-VD$
zoWKjgGiP;!a*FGLpLHR%J8PvASpL*BjmpBa*>eh!g
zF4Rtt&*i$)kKIS~;LWEaVsuzdgt{SOD5zT8GvA)`XSogjOKX1mNOTcAEMn)vy5wi;
zD`$mC8rX`BVPs&4erblQV)bE_iX@)a_JJ-E`>BdkX(#Wp-AfnulU#z0`tND@9pYa0
zpc#3~BH<|xh%8H%3&24UwiXQ84#wFc8T9RI5pz7F3k#sa6#_G=CDf#KA1Dc
z(Ra!F)RC$!bW`tT`qw1ukH{W7tQQM)@k
zU^9OkQ_vS*E63}Dxi>*rwQE&;F*dfAmewIGir9~2jKEu?BJAbhy3;g_%4=mgSg^fV
zQsM~5%}{LI_OP|Gj?PxI(Hd}f{-(oUFg3nv+~N{-_mlzSUW>TB4VFkp`?e>n?#J^6
z!m_&yIGBkS%pjYCDv|l`T2Mocl5&^8)mG9AL46`P`TOL=M%G_~@tvR2220i
z+6xBgo4+r%-)msJT2-nh^TpU?!C|FLN3KEoVmUo=MC;*Q)XkrPG{8!<%XDt$A~QG9
z2h$>Nd8>I_@kH&ajpEsrFZzNGc9yO-tknQlm0$oIX^3=R>DF2{lm9?+10w}kmA%ZAi5Sm
zHn!HvzHRf&Kb`%hhX@w-=SxFH?L4iaFV3IRGy#b$7Q11$+kFIU8|(p3qYKaFqKWtP
ziI2Rqcs+t2mJ8H$XoB$P_T`HhjWUN@)PcT2j@aQn5R|S>60B+Z@Ptq{-0jmij1td5
z#qPgLs7U6IAtW!UuOtGbsIpLL8wr>wp%eyG4x>_&nI|Ri=2&h*w@3bhK$^q`;xD@k
z_r8kJ4Ir3CR{db@C$d8I_iz?D_>Y*_A$lu*ux6kv#li
zfHYDlg=N`$`75F)$hHPS%%u_a`BgLs$cqd@VB8-N$T&o`V^|Hj>DXSLIJh#o@pAL}
z)B1ylghG;PG^Xc@EYNk=In8V{+|EGOu5q8&VT>^o5;!`$LF7L7A4OBR?|6@6NWB_`
z`)`j7!IxZ_2^y&tR8@@s$iL^l(VE7YZGOWZouK%4liSp`N$#k_8@?YSZsX7~WjtI{
zNwnde0)E}S5rzI074d6Xw;s%3W$ZC^0r6}8G%HeX)Qu*@*cN)^WJu*CR<`OZQ)Em+
zkCkHno5rbD%;_JYU+=FibQTpt>;2?07+!GtIJP(R5o6yaQoT|2m$IO>W<}gqbrhxhMY~Zut))|Ub3`dL8Aw*_=cS7wWuDzGBWKjow_TZ%o53$v2y`?T-VO!t{r?SO{)6ss>Q_Bgw4GE&yUj|L@yDs
z{);7>13fTa9$U-Nw9+)Z$T=yCj!S!6yiz#@3I#X-8
z_?IPROo~J*$e|dkAmMDC<&fQ^BdJs#bDIt%3L{ze>iHk
zl5oG!f)SZNu*Gfcb1Y^35q%q^+(tOW!BOgUC~gL7296f-7kQ}V%j=nivo#qNO|eX{
zOel}5Ofp(AXf6xBc1#Hb$O9V|H;OoI2zau_oF7G4R?kpce#=60*U+kJc70P!m?2*fdDZo@InI
z<{C)1vD+Rb9RQNN(YetpL-Tmb(rDGlPJNO$s%P<3Xa114=}cZZPRIib3M;o5JDwU8
z(ZdQL^@Kl%Sfw{W5dpmHkBG%%7&O!^grG&&GFzhj7-;#CJ8Oo+Uc;lPSDP-9#%};k
zJ5m^@#t3U|SWdm_$w#}68Ab%7st4P7Ws7zzyw7t$!WBZd$uCjMK0poTVx}i4{ukKp
z3>@zh!{%#)GtZ}q8PTc@O$@Q4hyg_t*%9^&UepjV`6-fAe1yd5;-$1`uC$&2ok#7<
zziA5!0r^L7c#@yZGWc<)d83x
z8vZ+!1cmn}SRlagB+A-ZEkJG;(NMylge)h=M*ZaBBt-lhpZzbXu>{69(4__(sTCL0
zFBvk51Wfa$*Btw)zz>6ERXmxqDi{s_DO7Aob<*g~Rc}^5*J2)Rvh7k%ume%d*;h8D
zpEzLng&^<>WPQLjxAUGl$1%Oc7Qkg)HvKMbo(Zc3V1s7u--|2bF$oKzbzcNrhkQ?l
zf#3EApWxy5ci(!J?@_q+(K+_FkXFbu?d@lLvY^k?*D!v!tHp`6#fucm$i{+;j^#+q
z+kr`qyzggqpBtX4cDy<#Jy=2W|42H^uqGe(?b9vYAR;gr(xX#4MvopL(jB8DM7lv3
zqeB{Lq*Lh_ozl`sDhNoZ-{=1QpErB4SKG1UzIMguJkM;#0Dp64X24rl-E
z*DDhb>(!In&49eTEFi3iz$zs;$_$RDd}Mmet%)LqBd!ioiRAc)mH&
zA?ot5FRHm$=*?S#1@dL_~CA>IQc&pq(pHk}lNv|3sl!S4}N
zID{#aw5JUHaasvQ8rJ2gdf)~h!5z9BqH06qaCrMNS%|R5|@2i|iX^a*22Isa#
zfqo&QPY+|Ei2V@9qAR_~w2%Bi#c>9-ul*QtZ*4v4NEjMH!SRhrk{cB7yL&7Ul*Z=;$O5E4F$8SRahH*S-D}#YF5#%FPq9~gtMcvpZ@0kn^gEu
zJrtV59-eXa4MlFvmdk2l&#R#|4juHXZijAI4^^nmS@p)Az>wU&riE_Jy=femO%oo^(tqRqAqlncf=L
z2N&ErLab1$wF2pvNq6&<{qMvu)C9_YKWZ1JJ|`E!EjhHFWQ48^XgKoj>FjS*_3)+5
z;bVpr^%kvRFA_5<3Z->(Ro}#B^*E96O3B#RdM7vuJ2lZ6OlG5ckP*_{3mhM*u?k&!
zDEdHp85C6Vgt^p&lg?hY5+1r0kq1q(IllIg3pd)UeMBnV401vU`ta*mUg#-UFQ!OO
z=qZ0W`+-&qGT9jM$%WHO1LT@x$e!m;gV_EdX4+$VLd(;O=rpOm<+)jc`_#?BJ=?_L
zNHOz*DgS`k<0n!WP~&$i_IzXAjDhKCaGIU1eZtk6MdNzu4|*
z4xEJ_`ANnWoWF%?jx&!Zeg>V3hsSHBH-UNOXm2<_%diS?K3((lIA6pw&q!AAew!|V
z9A1}9*=~BM^ZYw5{^dTl_rR?^t2nzu{Uyht1?S0=D+|S8nBXg-Pek^V4a`{@X@du~
zA%#78_lh`_r=g0`Hf5%nvT1}LVVV$Vf|F<%33DdZ<*Cdg=X$S8`>P*yA`h-p|KPTP
zy`0z}3FOmMt@Lg63XM2tfWV4RClk`Xil2?+PCVdre}kQ3H@e@k;yxY<^#Z2rRdOtw
zLzi>6$Tm8G`r6FyUW@juAAEGLeY;vNgDSJ4)_QeWk0kYAw+2o0_zJPxFEKz+PE8D)
zF}x*BZopG@u_USRY?`BqdQb4w3rEJHWc*#2;`KhIQT{FzgB&vrb1dsp%EsR#{CwuY
zT6(X8UjlZu|H)*AqI8PITk3Urm?jj#4RxG!d7qsxl*mM%)l%v^%$HfDaB9r(7w$S{
zP3Uy?xSmCY@zbXlx4U^1L8JVSzG5LmharpO%3L{3hS@^|Buizl*B
zRDH)P%O}%uC1*dbv-*xHS}|`L@g(U{*~k$s%w9el2a{(*??(m`CMZkyrYRf>#?x!eM~$wKsL-_dJ{tl
z8WOMa9XIPcXnv4$*_c`pk^;0G#GuQ7G*##`?*H%oUJF@D;e}8mvtb-{`-T+pEnJ0&
z5m+BISmc->^5yO_IjBJBP6M!@dlOx067&bJUH8Y;Nj^(~k{iK4@o)clEDm>0xd4+r
zN2Aj)g;bSDN^;4X{6YgA9zSB2)beac?nYQ0cBc1sN|!yw=swMt88PQ3xUav
z?5=m|w3m|`ukzIhCAx*h@i+4eL)~q5*Zw|!t*r3S)inRH!Pb=DB_u>>S<0J%f$p}3
zLN2y~@24%(tiNAq%8!`0tFeVBPaG+vTSF7xe^WH7z54un{;8twb@*Fc+j&me^sk&1
zR>6W#_5ib;mi4>EN!JDHo6nLj16)H{ZZq)7Jf^3$z;s+FqVJz0k{%PH^Mnn4(>hif
zCN5|u9G4GE7PzR^bhHbK_KE;TswmZ^l2C7$P!%Lju-%9_&X68ujRw8uc>=AohDKTf
z$;R3`y~E}0K_tcvb35Xa*qpKNWl)7-n7cAZ{c&avP$BK*GvX4LWKcmG{n)%JlY^cI
z_n#Nc*L2Z8jnS(Z)<1t7;=Z%1;BA{Y@W74GcgyO_N+qaHz}>cal^N2E!TxH74hND6
zFNaK1R)>-H$63CJRt~NltM=7gvNEG|f>GYYDwwX0Jel>6=pd5Ru8~X_phLzhLR4zv
z5MO@dx17q#;gih_4u^n0Jh5AlBYMKct(vd#=wlWjb)W+}kIH^+5cZF8q4O_etjW>U
z>E@j-!Q!*IU30>PcALaX)?l`CE&IN}Lnl<}{EK$;bMJ-a_3#cM)FM6=`wv@^#gCUU
zh8|xAjsbT2u#P|1%GrC`eDjysOoSzeV5N*gsNQkOV4YWxM7ktE#AYX%*?7CkTxeC|
z8W0t6R7~C>24r()?h6W4`(YOQu*Xg5m+*!L%<}Y@J
zZzozah!#z;^_Fu_TbEUPdslmAi&h!Jcn@S0P?=55%hWFM*YZ(Gd}*EpNGd$h$0^k>
zs}{}*d|~s=%(hJ2Ua-JB){2#ar*{0^eF)-s$=a)BdMOX4JzSNvn(T)5S2O=+^za^P
ze)5wz(2T8ab?Ri~E3H-GX{ATQK(H5T3CM0Ct7>wAlCn&j7MPA9&v=liQ4Oan*tH5?
zusjv^lxcr{qHU}^D_y^7ldq*)gbzu(agE*#^$TqM+_W5qf%@ATS|3?^*g(i9Bgx#!KZ
z33U|sdSMqlai6g?k9K)&4{Gm%nO+j=z`i5-Tk92qjebVPTGdi`dYU$n4e>S=R{ok>2K9YedBq5~YZXKemQs#(|d
zmn&X;5E@oT42$n&y8UjGit$<`Hp2_6*q+FSnpBrr5
zFN){poe>QXiQQ?1%pUUC^_)4(G~|pCLa6JlMkO^S9hVJrkB?ApBt$J?H608zT*n+L
zlZ*n&J^1i`K2`Rw?4uo$wp*)7Kw_N91jkOHw6Q~lX#W5`A%
z$Dy%{Ola~17t%PWg*NN(_kTYFyvrLx{wft%4odf)@VaDfRWIi*{i5kPQ{oGrGFKlZ({
zJ}83|<|<2;TISAuyqMO~;hlZpz_{-5(0^?hPVJZ>{7dtfCdv&~iWgYppbrdR1xEPT
z^Xu0^d9TMy^mCTrJX3`&T^N@wd1(u_zJXf&ALh`m1;e8q=6Ra_#O484df{(
zTXEHFgE%O3+g6SXM`m~?m{-#*WQ3Gt#~&EXSwO7R-`)InIwzHjeLrmrg3nU%Ij~13
zy~M95Ymsh}IR=n%DbS%Ar~Jc+yy?*s=Z$}$EZy_#>H?M(DNns0WG4}KYXgU1p$~j%
zzGVy3zRPK7^F3!x8Fzx=mVb?FRExL+Yz|LLvi(F{G&!6!FYM;i6pw0Ub3Tn296Ak9
z$1^EX2>BsxHUt-0ejvYA7N-Uf&?!nY-otIweq?hMc$M#7_zpzo%~bs9G!)DuIe_hi
zFp|ZMY8et$<%;-0zV-3EpfP`AE8^F*!M9Uq9Gn6F0{`*#ga=uJT(a;~$0EjhBH%pv
z2(EmBJbX2ORp8;+jPHj(LB7uWj~0*`o>JILJd=~@5oCD=oUCDRbo0(nw?;oP`a&3O
zaovLG?${m;s>xs1*gxfQU2VcVwzpq_Zsb;<4yUvA8{-)=9Y$MO67_~@WK#)VFo@~l
zuZrH4kihN#%{aS-c@LS3O((jp$9<=`e8bjhLVwv&(_R$UIPp|W5
zbZLW;SKr{lohV44##B8k>f(8l#@z*;?ZgE-pBA{iW^}~Al{3pDrNC-|Ap08=9v)Yt
zPU@UV&CLwOV9Bq?RFLKMPN=Mbd+P7B97>y9yCR&QJLIR7dWtwGHX2X^PDDSuyzY+<
zuzR_ITLn>_VbyRIPxFn==T*MzOya*wysmz-@0-5r{?1$|(qOxit7=BNE7g4HV|=<@
zq?Nq)c|6TWpLdnw(mO`ci!2*Yf*>L(9<;M9Lx9&FcF!tD0mA>Rj|I(^Fq=Psws?&e
zcuN|P0+8a&;~$l0b=wqL@i66HC9owS;yAp#&q(5_c-V^}6Gv9tlalgpY+h#sdHwzv
z(pcJ<@`pvQ$E)m~J)a_tQdDKSET5(jS-}pf(RIC{a5{NPjCaIF(yV5GNgfdKR9mif
z%)g2&uIvOk*KBv?a`rr(-OW$ct^VTzO?sw^Qjw~~BF}|EJ;b;KS8Nk|MQ1}2D$=FW
zXzqa4RPdrLBqobiavCZPXMB#OmlXM0g#{c+lgiWp#x}i%_y~u@`pBWSaHb0PHIrr+
zlKofc8N~1cRO;$GjQowT%yYQU^@Z_9^Rhx!b>FFe@>Iwq*KMGV(~t>A4r@uSNn;if
z4l-!3DiZn#qN#Y|xdYEhv**tj-e9-*j~*xm*T$u9it^cG4>l%y
z?>oDFngKHKhrp!n&-vryD!|Is@|_?i_IZGVqsRQfQ>X)BubAZhNpCR37@`(IZQo>P
zXD6f#F)OjF#nEoMTq{FCe#NNwg$8?EO#k`gYLISH$tj=SPIr{e{iBN3Q($|Z?1FDv
z#}(!CP+kSX#j!Q6>1r4JB`+ymX)t+8L#$f9*3)8Vfh8;8MBA4}zD;RV#E}h~Ewgf*
zV>rVruxw~OB_S%F>GR~Ac4`>
zaj0+@()8ge$+``p`2VCVT++E3Ii7UQ+PUHYB%}wUu@X|
z7ckN6B{H;%fi7i043D!^OGx(=b@QWrMx*BtbvE^8(_+w^APVSLqAC|Tt7)v}t$*8Z
zKi_-)8*Yc(Aiy6;X?*lLP>$@WGk1{x<(-#rWbzVGy)j^T#eXzq_cXqYn|k^2@>zz-
z`4u?ds(hjn@u)wre5cr_=2a}oD6V3YDhuFBNQ`>af`rSj!Y$9@5{rmtEx7+OR>j3+eQ%}Bt
z*olJI4egt+w#<$__}ay!r;>GCOL=N~SD8%kLnP0BJ-)kqReQtgG86}=V{T71Q=n+{o=Uj8a
zo88o_RX^$?Y~UKfIUYmLJi52JCqJ$z4F!O#xP1y%EVM%xf?|z@ZmO`h&F4mkR&V{)
z=-b^n$OKQBj=-v=PQR(yM4czKxY*EK#>N%AxH;FAzw&fbm-QAfDn*UtikxNt1{v$BVg!IsFq_vci
zQ2!0L=woR$Qv{F}qIg{X`HP(a6}3Pg`T;%M{C?|9`+UlH#Ksl}!OY=+zIFb0!m#ET
zZK)Z`ZOS%w7w;%-<01~Qu#>#=t@CqNJx4NzNx9_lZo5m@I?Mu4QFF|7TWUCz+-QiP
zU+^9?OG<4hia2nWKVZY1Y<==M`xco8ws=g<_Ey}vGL{bkU*lX{=?12F%-0B2-$9>Z
z)ZnrL#WGpMulW|{b$odo*ipzEk-6QXRte=~4-v(Gwd>O8@8h1>gC+ZKq=ttSlHdG?
zdO4|LEalpbqOc}zKdwUXeSaw*WjcGhO>J3uOk)?^nNXw_uWwg%lGjjOC+PQEWzFs4+_
zcgqkD{ktN-c}1+ssz>^zkIz*<(9k{p@|o@JT*Xf$PESx-ae8v(>G)CPcYDy!~>pM~O+OwY##pcb_ag`tm;^wao
zoDDPcg$c8k2fIT^8(8z5yljB&?Uv>6Vy#uDwN>sM_hHM6a{Wp{CoUQvgX&I|NSHH>
zFJ~N7CFJ@>z|)Ikr_`unv1Zo8mtI?k3ND|iS~<53VJrwrr`oO$2z)Xi?wpx3PX~Ea
zR7HBhBG~nz23)pndQtwDc+jgJjqr@9_W&WpjAalC`{bG8O}Bo~Gv>n|{HzmQ^W~Rz
zf|}1N(`{l{o{usSWs2Y~xgv7%V2=3_H=^#Ex;u{IrnY=CE#o9O@CvdkpX`F8f-
zj4&t=Y|jNE5j-GOCGQ~+L8Vb3pI>!qaeG&iS3``^cB`+r>ua%yh{+o%56~`wes#c^
zBB>*ZltyHiJiyA5C$U2?i6{uID9$-?1OZj^`kTWzi>z3*R?o077cx{6z>OIVV$GtT
zxJlKz{>P26g;9EqC#RkjG6!fObeBD?(L{B}BaNNLT#3Ii{4FfCf1AMMHF7wsyk!N1
z?E@IZQ{8;iZ>*Z;9yylZ631~6G4ma87V*l_5aCldts}vD5~2)m`*@t9NLGi1|$xhweykt~Lm;DUi)SB8z`JY~J#>U;b`KPod-|Hl%2U&`xdc9%AlBzYy*
zu|8n}J_T8+l>ts4dC%)ptx);0RYu5agz6ZJm~^Re61N>5k}~F@HKlR*sZY=zi!PS9
z)*1L)o>nH<+3r)CI2A`qiUB81Qo83BaZJjp9-cC}#T69mUzBcIexkED%agY&cwtyP
zgSap2<3{(}aVP>3FqO;%p!pMWnqll8sY~ON3Q_TdYC;5!u+K#Iyx!?T!i`8S4~TJ>
zvV*pT;{PhwJ!)k<3^oT5Ncm-tXiyIZd5
zR3_dJ`$Ngc8jX7yj{&bbgUwrHIwXbtT>Tl7O}H+sTY?jtf7AGYfACGq>ha0xaffHm
zz8&5zgGZlSBN0|L`IhjGmoG)DvMp!BIYpsc#`;ms3aQL{c-k(Ln(#zC*mv42Ef@Hd
z`@+ebO+}WiHv?-rl~z@ISF+gq@e47@4bJw_vrBkyC~+|O?elbTyPwg{44+=wl=!iF
zo0FR|2mz=Ip>(+{unhCM3Jz9U3{cF@%P)`@m9@F
z`T
zQWFl&KD^bmA_G$y`G~m0t4z(sfmnPh(hEf}vK%z<#$au|HYdwW1+9y;jEW5^21i;Em~kRbJyjs=7tIJN$zQyP0e%X9{&CBCI%0d&X1fc
z-y_^B$-F1fwCJU!x}~M_jHNo_I+DlP;c2P7-a>-FcJVGg^fP6b+BOMR{?VcGS2M)_
z5sY%U=Qjto&4frwtgp*pYI~5)wBtEO_OBlP46*g<;`G_iHV)8z?4e>uZ!Xw7y;-a{
z*ut-?ixd+&;Fmy}?CUKC1Fo|Spn%~_$w`zJkm7n)SLP=vojg^y_E3c7PEr$j{@_)K
znG%)FxSHtF^BVcKB$HWO^w{!%rMSO
zho&?Uq*d41)R|GQCmu;{T6jt>ywbUOEYiS4T`v~7`1jL3)|iRFn0r1Pj@_ZrT;z|W
zSx%q)Q4aE0wB61KeM%R30mrxYN3=E4^r!PZVHRhBOgf(sS+MqrJHnda#%)@2CPMww#HL5QG)V<<^Fgm7(pj;1vQ
ze~9~*??EqRTz}U$D5U6Rw$Xkb4pfo(D=8MwI7q{j5J%$=H1VKZUFsD|m8wv4tuT#t
zt=sw3D@2;%!DoO{Y)AC}d~!b|RQ|c7#_cZl+F(dp3w(UX$|>+ShLUZHe9#{9go)27
z02@3ggccdnVqmbJq?OZzzdB1tmMqYwpxnk9eBSu22cL$VPt|=MuNPT0!dpkq)l&dO
zilJgq&4_g|&2DqTao`f~81fTLdwoPto;gObxuYl--#B7~R)n}2Eopr)bauV}=d1|6=wZK%=-tYBy}YKK{sM#v31`~PUSfF?Y83Yd-uqRa{GssZL)TzQN0F?
zYG(9ZfH`EEUt=QDDUDoec3)>&M6$TdZ^NK^*sRV)QRtnchYP$ed+DP?Cat3g@voqz
zT4V2b-a$~&20`AcDR`^?u!4J?3h`${j5HOr#IQnP37HRU5dt+@WrVWHuIGiiA4r_9e!e+{#PEpREWGL5i+0x7PcSCJI2
zS8ihY?c0V7vw!Tw!2vK78k?6lDb&O}S7y3=vBK26QO0=cH2m7z+i!!AkEDUdwCV+j
zDIp7TNjW8vln|dGgDJ!xF-CzVA`QWjuE4%;d8x)U|8r9FnROZ>KK)fXI)sw|jpK^-
z2)&mN&zuNj$IR-}4wl(fR}TDKN=K4ASe*3ittt_{$KS6{@K}nn?$90nX-7~U&u_L@>;w}hr44PU7Omb3vHlIryrX;
zzoD|PQkgTm*@VkY(|$2m-~d{ruR;f2m3T!s(0UKlve?8V%3OLs8;2KtHYVhey4xX5
z6&scfffC8{79}Vpz2A^ioFuN;S4EXXCLx>tQE82ftXlG;yLrWMsR5*%B!&EAnrzxx
zOccKm$jxT-2ou!$GM3wU#v^l#ZHTRjSG<|N*g|)aDc)bayDLTwPoW9Feb#)sP5M|z
ze9B{@HF@B{fdX!c@A3{yi{XWVlR0haeupeSrzTN^=5aXIXWkuL0@YM--C4|&aJoIC
zwXbQH`qn(1FIPLqBtWmr<0_S~T&l2#o~~dx6Y^q{@LrQEKkH+|!OpV9XPH(Ue?Pu?r!zYZnA`$yjhI;pJ*Skxm%olYg6(tStQ6xA
zmrzWqt#IkRKT>E4izg3AH(7tvU**l@NWex<(=+BM$xdrQF#G-o>TgP_u(OZy6szX0
zx=<*+-G^V7ew*x38T@>05kox4|1H<#Xfz*eHR8FcY<^=QU=BSkcjBt%zs3Wjvw0QL
zW%d$xkO)&w<}h_IwTgx$ubK6f-XbMQ-rHj0Cf`RA#fRTp@6vx1ZPw&Im6}D)=}bn!
zewO3OciN>^z$19+vJS(LO*NF|%VpukDxftI
zuY*m0G$NxW7O#9}k=H|vgL8}dFDye|>-*L&FZwIz4~3qKqg&?TCd?F|-@;_;PdP(I
zdB0M)52Kg=!H4zihzsRIpQ@X0C@}40v~V))Jk0D~^3h0#`|x5?tIuk-M&JH-8M>^%
zcuENxnP9S0v|p9}B9ds{tQ_Z%vyx(dy#=p(c^9%GqdHqQUfdo$H66A@BO;B3N5?l*
z`~=YxDhQHb5nvV>mv^R>ceaUBW=MjsXb?(A2)d8g#t7aTG
zRf1uHUJDlcGw!3oa<|mBt&uRWGqwlqxt9T2b)r+^jR{zPsvM*LiJ&+4*B6>DCRgXs
zVuR>A_vUnZ&}Xa=iWaq9_10DgTOfN&WkbXSVevFqXtk3gm#1?nSasqI`Nz-Z11OLO
zR}G7~JMzFD<6s&3E;u7Oqd;_pRrC1kuYs4_W8PdKH^GCSZULtuu{nr0q_r0K2Ix@q
zc{AXQ{nO6=F*^*ILkaqki(OGx=SwP0{SS}*qP_ihq2f4kGT&5qA4)nH*kd|C6M}v$
zjDecjWu^tH5O>xB?X>s`38Ucm@jy+ge1)=Dtw`nNkk{7)-kN9smnhcxwqqK
zRm3g~S|=awUX>;E$Kg$x*F|p=xY&__utD&SG<{0EZZ1M*+@yiNcqbHoF`v(f9)d#z
zdZE#uw%^Dr)^xAhrKd~hQU!~wK(wt5>$J~a*qNVSBR6o1Q*hy)ayLA*nSrHH`9>wwO<_LRxN<)flWmB5~{_c|gSw#x9@Q>(Muqy%HA7
z9BV@{BN5Q_ErpOWc@i~QKvF>7Rh-Z)Sj4C3!&CQKQ}8{-pL_&?FTs7YyzYRqjv|Mf
zjYQI*QonyCbH4dpMi}#VLc!K3a3z_*D&|Uj4LKu1CRfu?A=4VFNf7%T?@T{$#g*c>
zt}bRV(?d}u)pxN3r_!f<5<}u)KsWnu64iL`{!`_+aM)LsHjqJucwa+GqMw{Z1cARI
zFVFmh?vI>IX*TotYQ+AKe0|4KRz;HLl~d#KP}I|JPe0oTmYeT)MulhDj@DpoavoFr
z9vXP@T?g#8sYGyeb=~24&&nSDOEb!L8H4NYxy010YYQNy=7kdM?|rcKPrmb+j@d_~yU!-_FrzU;a$|M{P`|OMB1hWR=4rP%*>rCe$4S;dxi`ExTubnUd
zo$YUSR%zfKwBcy$@J^@i=~d#%VFB59X9oLPd(3Syz>Fv_5fl)vxH1c%abG#Z-%~Ym
zp@=uAxJm#3FSj56dQnVi0IRafkFefp9d#vzOaEN
zuayB|AciO5??o(O809hZT5Epr8e`WbdS(&J`F%)^g=*rc8{(vnKXT!J0lPXMh7ZL$
zuxVcnos4=4**yfm_nu0D*hTTv%+#a-81_|X47;oXL=Y9HzV}g>Ea~I@o
z?Bs2D?EBSGY++*(uR(KVW0JU$|AUSPfxlI=3qroHHE(}fP}z4H@C2Mj8<#KEFNei!
z26dY6O&;AFe_G^ASNde2kjTrdSSpCVC;iz1A26G^fsqZ0B|e>f-I|~oXDy!HG+$~z
zkuj$l!HWTEP~dE0&I{3ao5{3fg&hEMGa{NoeAY*cLc`h&TT^Q>_Q9g4JVYWaKwNUM!Hp{>(K-v>A80zDNB}Myoq^3{{
zr`gaZWc-SE!GtbD^(yqoMQT=!`4XG-%be4a72C|lFh7qkK}B+6RYl?h*sR{vDR!cn
zYS&z90E2#ae|V&h`A6aJ{_Q~%>%AG97igUqT7=*m5-8U+wbKQJ_z;s
zg`u^&CFSNB$wP5#LJp|mm_F@%ajmTivQ>J+5oe+s^$H1MDlMKU47U{2VZsyb+3
z%QaZisOfrYCtsrL_qH^Fwxyvyoc%R6Z6^~evPM^^{48ca2Q^XJiKJAkH)dTMFmGv&
z1&DVX6yVeaA#P%#lwURDZXcsE`?yeS(QJNkU85J=xp79zRG^q4lZb)Vsv9N_Qg8Lw
zA;3HL|CNN;lQ*MeI-x$vVGe6jkQP~%Du;JlcxEYNE(JBM^IV%~)|{%0jJ7_(D6hr3
zL-@(Iw-siE$_o6XqGTS|bfIS(v>zw;(y&QEY0|F6OLG(GbcYL53P~V{t4VUnt1&2w
z$V}!iV?XNKbwpvjb9&8$H*J5S_{`&XnHOQKFzFwxNqt&hp>U;4r!2ucNWM_a+IEkZjeD+N)9=_4)tBOLl3&lJ
z95yD~$wVx+c3%SaCL@0zlUHmGh3dwVhJ0|_1D`c|X~g(^4$Hn9D^yv1Lb%Qcqy98O
zzPXZhtSzDZPFLPe;z;B$v{5vWr%E`hUxe@aHnK4$
zUi_1T@asXCG+d%5Wj*u%w^$VBkJwjtwRvA0I$^waECTJ
z&S0ZSgWAF^Ap9=cJ&G2^v%GpNe!Ys$decsa7t@;`N>p|eeFg#~YK#;XG||#N2IS|a
zN@mY#$WXtih^|DjgnkH2Z&9bSGd!CclN)m-yU+pz7fU{5sOEv}4~A2lmf64^Qnt=m
ztA_SS1fcJL^8ji&Fjy
znJeWkDXBOma(btIb=QH^(*4HOh1*&vrSdY2rN?lQNH`BE=%z|M%Mj`y!FCG0uR%l=9}+!cR%S5ruX*hM)6UK-+f(=+=3t7Toc>uHa4Uz
z*JVns52d+Ir7K;fD{HzPXVKH#?m5`uoZ%TQZ>RNROSWR&(IKHL%q${pWc>Ku0`ZcR
zT`LgBBnTjHkg-JO$JxqDZaB+hppzAR8aJ8U09&j6BAFGiB1sx~fhaG*Yj2D_4T%JIk=cWK&4s^(y1N6-7XN;?&cmP;Y*DsH5ZL5d2u+
z^6(oPFceiMaIl4x+vIh!&sc*qErIIuedj#Ub&AB*OX
zk5wE$zjx_cR2T1B-Ewh$t7pF6XOOk5u+9WZ322_7H0_k+C2QlEZ#cpYjQ|OPysb=!
z3UGhT!92{)xXZTvKtr|MgZ3TDrsJPgQ=buF>rsvcDbZI`dpT}SqXzSSD_8HB%0g?r
zlwCXm$x$sRHCCV<9P-dK?8L=}%+V42^|OehXDpL9-^{7A%3vO6RU4NTe4U`+oJ8=Yw5
z6-rtukpeOyOFGEsKJXsx$>U|LE%WP^souTmbysce_7
zeO%05loD1M*H=92!Lh)SGEyy9Y{<6AF4Ui#5~!lhG&I<61H9*|4*k&a(Z}lxzqx2D
z9pfcvoIV&&B~q&-rW36>GJ}DD;o1CUaCo+O#fA4XQghpU+}=f*Bi5Y@e
z6y}01v3#W*(9G+>z)#N(@lbw^rFu_l@#1i5F!`gWj0n`2T-{U2-^AG-oNY(hMc{}D
zNseR1K&r98<~8TH4(+Y0RSlSS&g}i)igL4+2}zc;Szt%}c1g&jdKvSN}=4<1-qv-F2VkOki^F$q^Iz?i<5r98kko
z)4my4@Adt-u;8L`)P=08NotTqWNRKUOU;|mEhnN}0NVrm&G}mwPsg``0i|Es36+3R
z|@?hcjT`Ez)HIRrkKIAG$n1yQ5LE}uj(mG=F9C>qe>K07&V?Ce~kpS44y
zIl~am63lwk=9z$8h8BdsFJS<&DY2`or8EG7D1Ph5Xs$AFpGs;0O_c?8=LJm;P|uQ$
zjn^7KY3sXTl;afGj1C(&^l7br&*)353$0tN5$~d5b%^%=JiaW2Yv!b^@d&nx8|kU_
zub-dJVnh+hzS2fCGAR|mE62^%I(R`Sl0ci=v3g8rd^ta4X8;6k!Az~j(|H1v*!<=j
zdH)7kZN~yqicT^H@&j6esL>KqTZu76;x}=+;R!Yw#US`jy`$ckk)1=ym
z`TzF+WyY%t%VB-)0JR{FNs149UZEtnr?B`++V2kn|4G&qHbC3L2OT1H
zf5hz+%7UN!(wbwY8PJkN$c22^`1U;Fj2M9+yxt-Jo{>E*
z!dx7+61%3B(McPJY7ryD|6TRc07n^SNqapX4SKx2;OKjloBa!NZO(xxB9i&4(1
ziJDf1vuT>K103EwGeOQ@g=PV3k~`nf57TNw-h%0?2f}NcHkQqnt`)tnopOXb1-b3J
zh(erOoPBBQ6ifAv7p1894lwmj_~7cCniLEs0t|hHi3Y!#6J3@{RI6tB_+98|TNC@H
z?#u7vJ0BO&&W0I52N4dTI!_+*N1y8*7DVSfCIphY%s3e}OWmMc{%u|35M&U*N~2Ix
ztCo^vP_77s>+F3k9`J-dQNH7QW{OEMN}aom6W<-rtf-5e;(S50qtG)
zyvEVeY1rDCD^{jyz%2uKV7zxL$~$M-LgbigS1wGH*$~Bl>e60%QO$K}IQQI5vGF9Ia$Z2S#zBA>w3XdJukwPGXFCcK`
zT$6Nyg=Fq7ME1PRA`N?aLMazt682vpG6hl1Dy6c5xGJ)L?TZh%ZRVo#ov9gNM7OIm9C_FdZf1bo6o@C9QV;-v=#?&TtG=*uWG7
z8#IRazubty75Zh43g&sNg8rf&QC?3^%i8JJMf=~|CQ-arL$cGT4KO9%-z;H!Oc6p%
zP)*AXse6}!Como}X9P!Z1LCGm<1ZUln0inxvs2Vco~bh?2=tA^@JFV;l?3;@^w=~A!dKI^<2MVa-8FvZu6R5T@rWi+rjmb|7
z`**dt;5!!E)kb;glT1j&ktRiwD3PdUrp_^n6%!R=r}ta8?UA|-%G0oq?J9l$L0%8_
zTswybu7aFN;3SyMqPvYF%o|Rm>-ieuc8QX;6y5AZ|FDhMp1ZE#N!s|UCEaC=Q(`CN
zVX{k2Dp+8d{Ejb|0UvkSY>I4hc_=wRY2iN`!Tl)aAO|wgtk;H;2Fqw!`rz*O!A(~B
z{LQBbmDkod(kgw??MUN__YVGwe;hE1`qOG)xAF5QH)T(72rKNeIL3gPE}88f1bSIn
zYV+)A5A6Tze|E}VqKdS>>VI;bUg(-c?Xk6k#vpX+_L1?v;LK|^sx8w5tOE%~T?(@%
zC)d$3Ao)GoNmE{U4Cenj#+DQQoJAy@S6^`}46_YrJOYz?@^kD1F!@`9ej}$l%Y2-!
zb$XYJO>(jf@j!a>)=LUW8N6W?BLo%u?n4>P3C;-j`H}Z8c3)y!8zv$U-Y4ORAf5J)
zf^h}GzR*@v!+OZa3YrCB^eXPuK!iVLQPq46wbbz9E;T*1T6pm+QsW6BOMwxScP8?y
zD>1?{>~-U*3McDY()zv#aGZzsVi}cU&$@|7Yb&y9)~%NN;PDow4y)ieW6j?WI=}gAmziNnxaYObASmO2Xnf|I=C$MGv;e4jUT-
z6O)fK$HRE9F&lSdcMetm38}x#r+dUSx&~kRHAu4-IeWHn8%@P|WyS835P$XGtZS;)sUoRTbyWiuz$@lhV&zh`Fm7$gt
zFe#*@YUDk%qzyJL4yn|tLU9Sh~gOis#|
zRJ}9M^YG@bWw-jhV*ahhF`RgD-9S(dvD!)Gxv@VOK85Luat%HucN6Ofj5#no*ff~U$>+02%MJKjgQV){9eo3#oeQd
z#{ZV4Ork`_VHgK*7K1%MP!@XrSeA^QJ#6d|0+Y7Am`p>xR2MAovBQtyH7tI@dT5M&
zu;xGmHxp3$+e(REN+udIBDj4hib1A$pt4L7-&%uo)0oZsdwU{W{49Dy8SciUdC(_y
znZ@3!I1sVn0Y=n~7+=%jn|9_K;K_+9{5~S9!rtm*tF0A>^D7zqz&;m+diLtKCGC13
zo%3^@nBhB9k3*tXyLw82<@E2YA7I0+U4bvS)f{Ml*ts`jHQA{N;HZ9Mo_*j#{om+<
zW%G{>n>jsyGHXw)FQq~!p)*7Gk-K~-^E>uHA9oQ%gBeKTHo%}TDcVjn
z28WSWTp!6uP*f5RmHBR5T~Q!^>e+}SX{f1KTNdT98xr6lFkb1M%&%|vbl!-N=Xn)TR!i-X`a7mHu?F@ylU+O`NQ~W;R*0{Rw4O*xd@SRl
z8DAOK&G9ynDx0&===;Fsam0}PJk6T2jkt`!x8m#qB|tdK-Nb0ti&{c%_rn6&=qrzw#`ID(`s1mw;4Df1V
zJVHU1%x*EKm5yh0Di_r3VB9TOn)7OwXAzHvqbJWLL;X_ti*kH|d@ApghrCP&lyC%R
z7ONM>(O*pNX@RMJ`3xV7VqCTU6s>e}x8{imK96OHW7HoY-CG(a_{PI~xzq3NQ{b|H}_HP)`YmSsR{J&s+Qm
z+i^nd!{)BA%L#A9HdFTBo+Faaq4dg8(Q
z8?KfshtdT+?G(kCUC?hSr4-kItbm}}e;)7bJ?p+`zQT9T6YC8B?yC4WjYeO%yrVn!
z{n)D!H5)r&oDSx}5;I4l@0lv?}O^I5$!?FD~0|C80Soq`#WxBSgkTJv5
zivWs+3~(xHd15MaqR2Y&AEF}a|FLwIQBil_-=WHDwz2DaafQGap(7qec?IOgta%
z(mpRgIp
zvABNTc?*N2qhSc(_>lSBmvCv|MvgLne=Tn%s4Hk9-%OWDTB}UoECJRJwNFvDI$@Qi
zBpS~cMBHLcqU|Y0OZG5FIb-o~A{(P8@%qVqJ7>{#%KIEX(FEV*a%Ez6tT+i`$)>2Q
zH9D~g)bx9zaVvQ2>#+#Bb@PMv%Ob$rylWNE#k1@9_+&6Q0@D@}1u
z(Lahy2JjF;EiM1%C8K1pbCSQtVD)9r<15{IkBn3XZ(jd3k>SZ8tRCN)Hprua4&gA>
zwT>Q^3NO5{g(hR>45twFfRJn79dCwWhj4kvXd2$N*=vOYhxhGK!ln~s*544bl}=9e
ze#)l*AinU{#3fqYuSxm7@1PS5hg;P5Xt&bv!6A+SrC^l&4
zw*yY10=+}#FuK&9OlklVGHrEa8CV(-kS@?ZDomB!yDZRt5NB)-D4gu+RHbU?RgP5Y
zNd_sAs*q$xk(Ndw4W
zJvA-NDEaoyNo;;JXg7-Zjg9dRxf_QusF|MjK!7A0g~luPbE1;3LxOeMh$Y;EejtHg
zaukhh^Q;?tW!};S(-bw5gv}-iZ5$ROn}o|jY)pcnq==HSdkMhh*NsL|$#{!unZ4fb
zu*o`tNx}xj=ycnFl7+=^qfhpr1A@i89{cRA!nq|Q_MZiA^ZTEY3*3B+DXL~IHjGh@
ztED;`m45t?a*p?O_G{?qV40<4Y2)fteim7Hr+SS;kwt0ai5#zU&o57}EtxDZg1%!b
z{BPtdnV5Kk^ndtzGzYf6D5sNJq@Fy;t;(yb`oxbIZq1do_hPdJ7ri75b*A?cCE`37
z^G5;}c*{yB~9#oEegG1-@70)kMOfGAa7=dDW!{*1O+*+t=*qh_6S}y_pZ+eVFj4Od0
zBO4*4N!3f}N+2)-*mU&KG7gLOGv6bufzSegZu2vrd)E6$Dfx-5GvHPS^0joV6Oc`A
z2nCZ{4Aqn=Rm>j1Bswk8JQGGCUcz=XBNRElyfP&to=;!upCT0q=jP5A^
zc!rPj2T=>+KEw#N#6^gO(6)x3i9?h0#-(+~5167+Gu@ECMR1mZf7DmC8v53vWQ-+J
zLE1+w_kI?3J&7Y+Y)7t1GEZ3O${uU_4hST$Y1>I0%NNq4T?|ho>e=CP6Ls2<+;B>A
zabG;G5rc~qjH9D54!!9do;psDBD@LDTs&)?>{Z@Zj}gyktcmve<`KKJu5kOog~IVH
zzPs?fyV$(?!g^}=SnTYZ$D?jf#pwMYbY0&*T>dh??9-u?5CPN|d}3}UwFNqQEC|hV
z^sf;9v=^nd&k&i+@enZm85`4dno3)$gO|KFudX2u50eI5nk{raNgU6pIOSH5TnMW~
zN!CuCsE0qK-rW1iw@H)3`jj|?`n@S$tYnAYuU9)JM!8tABlhJ0KHu0S^Ut(AykS#C
zuP03)c%U$xcUWl*g}~{!kK9I8>J@eSzu6nW)w5KbM`aW>oc{4~k=@EHD(kE^cT)$!
zi92O)R#?Ct$fYWW&-MEv1I?~680IqerZ;
zYjz*tPnPO%5)0miN(8AWb7hg%*RYc}fs)yhNX+d*dGwa%gHxtpdCTd@j377K6{ob8
zl=?#rIz>pZ{WdN^D1F(lhEbSBv4WdLF-JdS7z-RU&k$1_CQ0@AK2(pBj)RY#uqfxh
zj%2~g%*xT$QB_G*)mGI8$;W2Y+GWF)d5%9AHh7bzU%0R#S!#oC+>rt#p2_WB84Cs+
zlcku9@&twSK1O>8h`ms=V8=`*r~y8XiN|J
z_?F(o*tp~R+Rd(l2t9Oa>4@)y8~ueJ3=J4ZV8=lyFu~t_xla-~tE&P@D
zC$XLLqqmy%_iU~0~SK3MOkmNw1(@Wv=0*Wa8n
zbvGR_T}#KDJWvS0L|R4w
zV87YkNi0bw&&Y7pd72ffFR^q{SE=D+rV00}iE%ve#&hb=D};ALU(p~uufMf!lDZaShRVfg_o}qh
zdA_^X<<-nxh9ZCZudVJuLn$dQH{)NQ2q>C)N@p%q4^I>Hu-{hu~6Ulv#HlNe1Z;HljL^sbYvG*c$F&$5;S
zQ)lez#a`QH{MngW>PVrJ2^%XBY7?#x$-rn_!wr0W3sKhd4LrLE>>HGB1^=JTi%~j
z)TRkPK&;y#F`Qct_vO8;pl#};FSR`Q$_i5>oYdP9tDxa14r0#;E7Qj^lDKB+z#Lh{
ze6?fNCl}Mh-6`W;qBSwe0DpgEbiu2&&964h?Vlsj;Psh{cdfXX>6(~<*&4JvqqL#p
z1rBUDYPeItR((+2$+{hV$(7X#P~TcN_>Q-QcB^pt1y)oNeF3-8IEz%_tVMsJiO8J9
z(P!b!gJ!bxjc98L&N)|}yK8$$maBHcJd8J<iaHRCWnB9ZVv1-}=W8>-_P)+>AV#|O_Sl#He4+e@Dr
zBu)Xm_|WZ=b9FZ>Mi(RvcmfY&IA6{4U9GtqvKD_{@O5i{x*uNOcs}(<#?8DQHpZ_P
z8gtd`mo;15ThA*S6Z9jMJ9;djnde_#OOZ%8ePV2CBFt%1ru^$h#X0o7T?v|%qVLle
zjFKQIDfqfJWKb;-+-Oryw=bxRMnTQF02rq85lGch>{~D}%Ic~1I)0Y
zA~H*~$Labv2VKjloqKxnHPg_W}HY(F;-VRa7dyD5wQ}=W(^f@w5>VL4afFyYo0@e^sz7&
z&xedZ#Qc(}3@Z5;xNvLE(q$0&mw_>2$$P;-B^{CuOu`f%t1_;Qo?zcD++BI{s~y2(
z`Jh5Jp)wS$3ZV^GJD1j+%@GGM*1jg$fvPCC({DQAb=OlYt|a}UL)tJg$~>eKhKJA;t^e#}eK6q^j)8}j0m&SDP72BjN!XPYPxF|C}PzFC;foT;13uNHGTSL{U4N(y*Q4(h&+T
z;!*(@MQahW&|1|c3yo+2B^jxeVMk_Pvjj<5JHva>0`C-%UB=G;LBk%|Ws}Q7dWTR;
zbh$G;?+Ds`jVKnYU|*H(Zm7q2JBEvdBTPFOkHH(oz&be>fzkP!L2z92wA}giq
zDnIcJPbtcL8^O~Awfdnoiy1`_-jm0qChE8>B`G;2cfZj-Ke2U_pWF3xde)Z6*!8rx
zVZ2*WT|g%-A?5Fla#V0~oa=lf748{Xv6M5^7vHzBv*F^>E-kgNAhl>DOI3N~{Nwmj
zWzCFQbB|UnGop}MHG3NSgMa>fkJ7fNj@|q&iUdDS|KOw&&$BjMjRF^RE-gpQZQCDzb
zL$z^#DD7(rzfRy|LT)UE25fwz8>+AvCFz}0EJ6wg_Uubd^ud3)o
z@$|n43of0%{J7#@miM(ukn1}lz5%|&?h`uK^x=OU#dh&toTL}#2?6mn(Sn%BZsDtqqt}nH}RT
zW(B(=FF##bw}(+Nh3>p%f`Owelmk7g6a&;K7OjhESR&#+-+LF}PtDI&m2+m}Vg*vb
zvvzl43ZiJ<{|tElC-eP@C>5I0$I%@Xi9DdFQXx;*0Gu|NA&O=Fnu>RuoU-g|d`RUI
z_9-|8JNYXKaU`@MJdX2Dx^N(`u&GC+Us~J9p^1UjoDixt03$jebtb}BqU(@%T7BV4jz>(rVm*-<;X*IF-6-73l9(VuA=r-~mck_4
zd5JknPh)r3E7o(FRDbF@2e}`DuB&tV;DE{%EtJV!@Un&DpP3KN->wX>Vf3r@X@vw`S+k@BhL>;D-v~Tc4t&orm16gjSoC2?MiLNR_+ccm7|qR
zJXB&Nc0~tg)E%g;#S_XxtfW^R+4-=b-N*ZOdwu<^=eeY>1ByL)z0Zq`A==?|O06=`eUj@Qiw{G6;L}$GrAtL<
z#&$$b;0X_-&8vz`;M1L%=-zTKh1ujwimi5G)6rGRk0{j7&?#zED?pWma2B418MOYq
z8KKezi#-SfLp!X8{jdLCI*L-CglDo&z34*|ZQ&R*Y-d}L6f6I27m{{$_@)IRx{Nz+
zBuhi6;Weas*3x_Qz89|PB7?a8Tal48Sg=aerysQfKmJWXfHy_Y|9(SoVcWmO)qk2H
zXAV55u&!~{J7Hb8Y2Vsm1qLfv1AHwbA7R99hH0sTVdAM%3r)eySxJ==Tq1VN&HrdE
zXj!D$q`yojEDEiPKiawX{4ZM3ooFnEMtz8!9T;edA%k~Wl!%mJH%Hv*^ejF>oY0c+%<e%t7I=4eQR6$2OoLr#ZnpQYTwY?Ip-Ih9gex14Kn@;$w$wJQHm&c
zSd>iVT#Kg)hpsxy11bJC|3U{Nby`|@AwM`NoD*Aky2rxNOZU_y9oA@;8<~Wb`H#so
zQ3c)OY?XSIa0RW<=_kjDanVtRe!3mUkxnY@7Wdh^#s$@zV9g@S^@UHW?>0P2WsoO{
zm+cLk{#3#@A_~8^{@zXho)OB$iNYZgZfBX%ToqqFo})
zGfi4JlJyJviu7rcK89Nsrmu6@#v_a4$C$-*hg#x2U!RI1VPOaBSLGbBICdHH00d*@AhoTuELov
zuRYNFaeMuAW3|UhYiH`2Rg0b2J!sd_%SD)u!TD3cF{p2g`CI!XHcXs>7mB)v5g_O*
zFUTYq2JdCQWUNlWf65|kL1uAzNnX)HlK5{;d?0t6cY>ITrYw!SBJfI)al0+cHD=oH
z*y}a;iLCY9bg6D7qdwms$h&qtsZk4FCKON9`CfA~q(79vMWt2?8rqwFw#zn`KKHmF
zTw*cXuq#WI=9elFPdxu?3O+dJJIhMY~vdruP*lrMxN=&25UN-Dz%^(uI&S-rgA>~!+lnzkLM(i#F=NX|<6
zWc1Xb-rw@`x3>~i*ShFQq#JIL63OidNgQbs?(h$w;7bA?qUZ2NLQ}6Bf}o
z!TIi{l`E%IeM@i)lI9!P~p6a1rV$O{LDnnDQ?Kxpj_31Q!^1Kh+&Q`7egS!UE8;#HA}e3
zmbj%7LM-=z>4SnQ$tPyBU!(-a3Km=wC#6}*7BMzkq|IEQQa)?zC~H*SXd2}UR!m?k
z6P|7)I!33_ASun^gA^N?M|UA1_;kf27Le{{?V3Ws2>-25NY`N
z4P`i_TuGI~*mc2&oPyY{H4j}dpmtSdND@ly_q5+vG!?{XX3xlAP>F)JGZr`t=?{;K
zW>Vn?To%}Y#go)YLk>NP*lloVP;H70G-KZ?&RVn!>Hn?AW#b(>yTspsnES`TOu~^WAp)$eG&!gFm1IbLwQ&&8Oj@Vi+
{#D)KCkNQ|+%q8SZWU4gB1^s7t8As*(XL-vJ72I7$q}BK=3Bu;*Obt*Frr
zv2f1<1-5(Fih%28uEeX47uAXc%)K{vU_|8dW_~$#rM@Pm3{NldVl1$t&idG
zY&-^Vn(V}@n^}nX-UKziOaEJ4?zL6HjlE>RYQC0Suu
z1UP*e>FEzBS1A76g=~XtopfU@;kQqP9Ko8acRTW`Z9=^9iL{{TGoEJf{5HvjATtB?
z@^Emh6Q}s;QIzqKfY3I?z(=}SbjyW}Q;;wky8|gQD&r%+s!4Toj8DkWe}HS9S7x%e
zSiiS~+W~NNygBQFRTh#}A>uKKB_sx_x4(pO2f>K;!=I@UCAGmRBy#Ce_`3aYIgROQ
z+w2z3lzo&HG5T@?N8Y17bS#7nx9y~PKi)DyxcYNaGF<_QR=GqY7-E}|
z3!2f$8$1!qUJ0L!BaAgjZZ!E35Lu8ASwf@H9E!%pT&!9Ing#f$vU$FPJEs3N<@^&OuKjm7+5K
z55o`6CZ~vu@gnGnRA_>!tceBkZuQR6Lu-
zcRbmHu-tw4%!A@Va$$wDsb*d&`q>|k=ogD4W-#6jo6@?wp*@Gl%G#mq(NU`S329l+
zx)Uej*-=5TJKl;Bh439ih^AchD?gC-InzI&1qKthhF#9U4RDQl4fjW7$?k)J0lic9cscaJRqbmu
zbveDT8*HAPC`>xs9fjZdF8q%^Gx;;3QNW2+sf$u6^R|=c^)@L%-jH+2wSR=ZzQL~4
ziCl=mn)EO4{?6>9V-cKhoCHR>3xslo___RBXzC1kWk4*7UXNB5LNkR{ct{up?7Cj-
zWHCt-MkSxSuj{(S`hn*5G%Smz8olJg%hts2TD(FknBpvm6r=$yVyx@>IQk?`Zx2|Bg<{f$)9fMEpqS=QC_lHqZI4?KAwpcNntiCe
zJ&CP_fi^{UCh1wECj~{+Q1dX#Ea1XUDMCz?-0P0jTSq_qe0pY%h7@lww6+j9880XL;uO~)b;qVy%J&Haz)3bQnqAm3_HL44iM#&Svbd?uu{C;y3#%2PZZjY0
zlAVV&usp~RVNFWdADY+rDjG@B{6Ogn4tt;-@gtoWz8sw8q_v`{WFXZ3K}TT!=}P9_
z9D^bJTd8zoSrJnf;ShkajBuK%)Fzl!LTeI95Fot)E;LKLr<%hOzxY-cQj@Hlaub{Vl6zDUK5Yr8%`KJ#tw2CSv*zLW20Z~nMV$K3S
zeB4gK5ERtvO|K{X-JMKoxj7jDO^G5-2{{iMhFvwn>HQDeaaY4Aq&!iAF{TPB3=mr!YMqh
z!DIqJa^A5n482+?DI^-7L@)iZS(ph+DqIfqg(~DM3W`XUlV8Ruzbr*nGUu!QMI4=8
z$Z^y(^!^8IF6V`cPmraCT0fx#vQoIkb#$MP9F%=J2@hT)MhvHt<@!YfnQQ3B-Pq}<
zhQ#3|PI!jQxe*H2U&110y3Tmq1O)K~?*eYy7z@kl77l-iS_A`ac8i<;c%7CuV;~og
zqP>L!t?5Fw-jwiIieO&0pVKsPNEp+z7#&ewu!?J_YhRJv6>$)#D3;+qXoaFN!|`Bl
zD6lE&tqWihk7F%nyzqn|@6q2qbz-ygyh2(tBW~Ja4|ys$#cNdF1zfzz?GsGR`@>z`
zpVmzI=V7uSW>As<>ONajnbdHKQOfK^ipza76&FG^eamuryM&UI7c$AF<}DD-=M#z4
z%!MRV^k>0UFSuAvCb^EI(Q!0cOP+sH
z;WX@Zc5MhDX3nOG=ie0cm--uW=0nrt-h&JiVqe`C^G92lLei$6PS-cb0U2!IBo;}g
zH)*RpT{$@8gQ2325>kzX13biH#N7m~NBa
za%R-}rMyog4xT>pd#+#pw^FdN<;56uM8ptqb(6Syx4w6Dqq+LDe!Fs`u@>}iyW=Kd
zEr1s0bG`b&ankO0zv`DLbGtsQ-+4bc*LnSCPR2WLJq2UZ|G}&CysSFt^m=YB=;7~4
z2aijt)t7Udav!KV-Eo5In;$eDWIEQ0$-`H*!`Na0QAo%ZE^N{D)Sd|)J&M$Ad
zaWPXdB4BIdX?Ydvsyhf@t5mZd<^WqIv{#rE6S;C&P;13y5)IPyAk3eM2WVcj;B-`l4pwV?%p(I
zoJC<<$H#IXgX%B+H0w<)!Bk6r;fdzTDk6<p`kI?00Tx(TP_dXTj`m%FEgTFZRri2kdwG}7-=e6`t6n&yo3!P$H#AtnwL;+BmZxyNx6Irz8d
zGS}>(>~dL$UE8GR+g}FMIKTo9O5Q3Cm41j0&xgwji8dEV*p?YsP=!C{xKOl)jbPHRXS|PU=mWf!hPuk$sgr*)o
zs2M(T{n0h(gQ^ams%bKMA4Bn8BaVwPGvB0;#m&qtB!k1D3F8Ii2bJMyCfk>R*f;oC
z+kcBOS!Z4-j<$2tH`+HXS+d)m&s9!sETp1^@$MzLh6kknWE-oaQ?;awl62RU$uPDa
zz7_kS=8`oUP2Z<1ck0@_{Z3MW`UaUsHgoxk)QhvuqZw{CbBrtu8I_=okt#Z
zMzK9DK
z*Y!LE8cpR3I$F=;EAYSLvNL-=y?i3lSjDsqyxYsW(aP`m*V7V}7`uK8tqwZs6YacC
z<1o8Br!@;W;W0;?1m3Qm1YN0hT_8leupZF60mNjLcY{!~P*ZH1z`L=blP=fi@vYRR
zab~K-)d08a>yi>tO+r&y32!%?t=lTyy}hv+*7cpg9N3x(Hw^T(o{S8KxhD!JJ+7`L
z%Nik{1=3PET;=(jUuhmIwqTmSd`HDyuO_jOPHVVC#i$>IvAPIt9KW%KkrUt5PjX5H
zp)l2CbHAm&npbKGWEm(iq)Jsz|M{*FyF!>IRyk>ijTqw~-r?^QN&VC9t&XH(pv>v!
zmX%D5`;ecYt`lwuy{M+AcCT&WvY(sV>EObYG1313eTVIV@;5#jAk{$l1-;SPlS|E$
zi*7z-SVS>LIKTRntjSVfee09Gjd!P%7(f>J3L)BzcUJ@=WgV1cY-|DuiwEM0xIe+}
zBgd#`fQbqWNkQG-`Gtysb;mlarCv>O4A){!GOP>4eXw4TkS-dh%`jKzRLB$TBW;RR
ziru@~4!q{&N+HEstqAKv7;=0}%IOmgM1qu&W^9o*@ucF>guJOZRU9lvq_k*38w>38
z4|%9$SH?AtlFV=d
zlh!3>PM3UIwVftZ`>7V-YPLkOsB|}RQeJpVX4>XD_q7SBy6s9WD;csHLXrf`Lvj-i
z?X8;tv8qw;!`4a5m0(O%<&g0R!UT)X9%h_8o7$ch!N~J)`Q;kvjhey3>(ZH2RJ~Si
zk{t0vevC@a_dr=IKq>(ImWPCc(9p_BKV@#uoNhVO_^?6cogEzx*K7GdH3Q`Qi2k*PiCgIEb!daAi}KIS_qsRL#y?jtI%Lab+Ti
zqU@cacBL?Kq2R+EVh)75X}-Oi=I5`ZJfh-os=yR2G+4x5K8VWB6Nr^W`rt$(mRP+`
z-Xuv|46TnQO9{%7tO;$ghmZRcZBD0f{clV04(1{kV%v|=_H%n4b}B_}E?d_AN{S9$
z7jK!)qHNEHTGbE|pV9vo!!-@5xDIhPN7!!=N^(b7=_J{3Z;;+i^JS)lKx_r6mI(zF
z@L6fpj-#EnAj9(Sj)|<|4pf#yrc$eWNkvh7`~KDrOgAe2p`K7-;*^T*j}nU^%@ZKR
z>{KrLFon(2%o!;^GN8UG-;DZpK>)W%2->3Cf?pnf>KpNW8aK@N^n5Bbc?yjdf_s)h
ziensLAt}yICS%r*AY6RX_CgjDcpQl4!S`ujHfb~7r!DWD$p#r6|2v-OtA1QfUAt45
zwElRa>hRPoAyq}FdCyUO(shwG)b#*$erl4Hd4SI)uKqi{46Dw2ls(F`)2CCdjlB7H
zOdobSslL@Ag(J?!)`P=ke?nhB0FSfXT{{e5SvzE+sp9MBP@T)vlwb{fPrygmm6)P$%1+F4`01Z
z{f_HPo-UaKg>+8%Jy$+xWOuF}bMIYJgK;ZDNj#fEx9u%8?*W94M^4%t*NRy~3mOF<)HHu5>knmME&HKlh0m!IPX
zF3taXQfT#I=9b4R`#yYNJ^)O)7Lh_qe
zW-6&vs#bT|Vwgea4=MrSxuBx*n%||AI&XuWK<{tqQw|8jlq-~Zh#DRg>u_h*)EKfs
z*7lF-&;DTJ1ETOMve4TT)CSbe{?q@Kzw=fMI;c2U9@zZTo;%elva-PwJFMHTh;
zxy^WqnBO$PwzWQ{&5s7nNWP5-S-fwtp=JZ^{*2O2y`H@&-jQwRZ_fP27`rd;B|g3z
z|A5fV;o>XE*P<*Mok?|T)A^7VJ4OlvPD1pBoP@L(S{yEsI5EA!*um^1fPXZ{`>}HK
zF@Lmyx}V;>yaR3`9lXbvmC+a_+3x>zU%jlsQ>{)0s0Y!bwYNgmFuW(1)#(q**Tm_u
zE`B)~Q7Z_I_)!yJdK)TfElv!UhCvSB-?xt9UW@kxVTUs>XaqLD-yqU(WM+*?pO#k*
zmlM((S2+XgAt4EZp=J}Je9pScTIYnCVi!&v!)De)JDs{+22O(4zM?-{7*kgdAS`C&>JIZq8G$BqvKn_U3)z6>5b=!L>O+<~N$D
zENTT^Z&PYZ{GP4hycEKi+;CiObVm#J
zM=ypd_f)REse9?floh-{>9v}9SJ|c>#j#+hQik$_?Y&>cgJKe^ldKr%E01I#X}j?T
zfQlqaxSW6wpEGPsA~G$O6|6)m5{TVQ&eR(bthRPa2N9QOq$?K}6XI_Lxma&Hh2JJ)
zc26}PnhSwJSk4ySakTGi)Yr08umFA)SfJ6KmZ^}1t&S)r*lSp_}=amBew
zsk4#}-LNmtA6(1_Z6}~RN|7r*3bij-RtUsg_BH5hZ~k6tT+fVDWG?&pa(h!e(^BQ`
zGiD?7l%c!Odk*K%j5Dm|1Y<<;I&Eylc@h{+EvW(g+&N-1&dQiPt)iPAg+Au3Hx;Kr
zs4kXm8!bJn(fKkcQ|hX;zj-hq!zIKdI!gvi?lW5n#BP6CIh-xp6e31(PtJ>uF^WTo
z{{^`$jYgy)?QvfaAAHAEG!7UQg0Mdc95QgfyW_jwn=jq<=#J`!@?%oljK^z?L(3_8
zXX&XoAGOWnF?zgxIQp%qti@jDzo$xdB-u5ww_SDYDP}8&9SxIi3#T3L*|lY1Ox6X5MafvCIcJZrN(O;?$wPt#~}jsA92v{`*_c+
zNtW9v>?&51B`0JD$*9&#}T4~$&cEO)MYuSLu3pm
zv^iAkA)4bTvCm0Nl0rClh9{@qL7bM!-d|W#MVK|LIpt4otl`tYE8y6dXSZ7w=Lo3D
zgVc;vYynDgM#P2Y)aJmT-2NHg*M_FA9Bo-cZTq5Mx86SJZk*pN-|Z@1NEtaZ{RbsjRAyq%vdRvn3@Vf3u@3~SvKF@tAAg1E#+^5cM^_z)Uo+!OdzLx$3
zZCahgvY~V}Wwy=R5BeAJDLj*vlp$(kMKj^AQ`6#XCxmQt8&lGfzwZeC=6=s<3Lfa5
zlnJ7ao7rQi{e5wQj
zyKk30t?E)>mFlyd=BpR`>wHNQ>Vd8jdmc0qn0;y4b{I01CEUC^svr1cwT~Kt~*3
zoA9*HC)UCRQC#m3y~vzRjc{oBqZqT*1T4MCLuXvaa9FO;eY!(t3cxfFbxOCUwni9D
zF4s{o6d1g5o4wrKeF-`VSI;9FTTpUjAe`r@?EfmoqMlFCK$_Ir?Bd>i#*#=#6v=|S
zeoqs%H%%-MM~q1v4I7`W!jdhi9$8!7p)E;wLS@l)XZ0LSn%RCdP)=t^RZJxv
z8~;*B86DV8z(qN+(i%XY>d<
zv3E-f0L1os2o=ns=Bdq=79g#2!(&=Yf6Eh34O*p-<_)}a@lMn>!{xOBxU8}aQJ;TZ)9vi?7U?yEene)9rb;)E_K(hSAWLxUBM;HF9O>l^i?>z3sHuo6wj%^QrP&
z5NrAJ-BA36?ZnrM1isjKou7J@!d$=g8s3Vwx#UhT?xrm&PI7p*W?w~~=iw*_sE9N)
z5(6`E<#fU_Wejp(Np+Ol_muCKh|dcLzQs6%OzG%Iyb4rBeMP^Afsd9^-Y1_+bMMhe
zw8vQ>1!pgAvF0x5P3nhT`g$HJDQydoSTOx$Jy25Zu`D;0-!~%3p^==cw5GNBK#kXp
zgS?{J{Vl*v%F6C*OHR@VLQvMcM3i$6%x{Vh(!v-Naa~L+smvFiVwwOf_;_s0p&Qr(
zcPc!D1o;)h%=|poe>oi;<}j8oF9tR@Soy&9o%PL59&vR$7mWly3jiYRz+yV6mSBRS
zZAO59>9LbQ2-Bi
z5BIi*d5bFk4l~OMGML#1)3z>r>zduz>hc_dis{EV9(lavcniI73o%j}+RR8R6h*9F
zmv#I{>jn5P!H!`3SsN6vQ2nnjOyU)>ThzI`fsXJ%m%zP0Z%-!3nwFQyp}rMI0dc}X
zagX6h4q|hVCraPyg4l{?Ty|6W{kZqHgOcZTAm@I@4rJO0eu$+l>F2Hw7eA7Wlf`4uQcArgL4suW}3NKWfc=SN^9@`ifjx&4|ZD+U9go(
zb}n^(HhoqmeO|5tvjbjXF42;!d>yOCVl6B6r55sEhas90Ryvt$VbgyOn|{pXS)Ofk
zmmmhZ@^U8@@qt?G8;lEq<-(T)EN{vv$g+1<9Ybt?MN0CT
zc)UJ^Qb-s8>BujrDbf79a}oFojkRRu9(|Zm`Gl|gE0{5p#qRD2S&ATGZ(Ge}Ecf2T
z%znn%vhd8$#5KNC8Js>0Yy?^F)-zp1v0g#DsreDhlegqr^OOutv#fDcF$Cc({KW!g
zzov!CzN=q;V<@P-5l%=Dpm=y_SGKzzURr3#gBnNMVK2nnTgaMC2=jiY?E3RVra|WE
z&+Szc{DBC;m3eM;efeskJxX-^BBQ`PqoC=$A+2MyZ)Fs&;q-~`-zNWsT5F2+Va1x7
zeiwVrk->{vN2@|b^goJYigj5ZUZ;$;hUYoGe*av{Yh(QSVABV`U#i9N&yVb@o1;Of
z?%~0k4z~{mxMpbCmg)xw`)9*GRe@7q-p_vAE#I0kYBA&y8FArYiImXivZtXZ9sBJF
zUcpZ^TXV>z;XbR6{w(n2!|v4d1Z-=>u@)xM5|NKnS=wkTo+pJhi&mylC@Lh?K|TD=
zZTK7DAL%peQzh~6B$MG2FZ)fk)Qd&ITse!Z#0cm44kjuYeGBffW!r5Fga*J1xx
zw?pT$1UE7TH#A6MoN08GL~mNpVV3Zfy}|3Ld*dl<4$T(YfKJNyl!|Dulg+=DaOokK
zR>_3ArvM;o|FEyZDdAyi=lWph8vbXzq>A1O{>ch_L2H>kLsHto?DE2D<~M!0$!Ex&
z`IdT8>9Y65>F@H6Z>~?jS2CQByB5!Vz-pjHaXII`C;8Mrht>d_@B1M-@2P^|utc-v
z5GKazHAA6tkLtU?)?4SSX*=HJ;Pa2=1dX%JR$<598z!zk;G6qgKojfG7MxWUx?4c#$oS@!=Q{0u6k&`f9tRXqT~0jmwx^V?&YK8Xh1AEiSR;voJ*-`
zpbFW>NuC>b(HA_4r}WXU!#$>c-K@!QrRmzXxep&xT}|-
zo1e+Bd~2`T#uTR7yO<{8$T7)@h07+}Ztas<(1c=vTlyk;LLlAWeRu34-I-WrTs6nC
zS1+r%2wLBz@ow3RmiyuJ#cv$u9Cp2V#4y3MSsZO1f60R4080ko{MAV_0ywm_NPgr>
zt14y4KdxI5${x5rG51&-87sxUlYf*Z2_|Z!-HZ;YO8~AgC+CSSsK`r`Fl$Dalg4|8
z2j3<`9$TR;N1=Fnb`Y#-n71!gL5&bNjdW#rMOGD^nLf
zreyNc=dNL!tyx1LeSa~B|8x24c6a^r`tW&$wFFpl1>d2XK%pe%WODN6vesh@ulk8$
z5~0d#i!hsm^7(jo_vqQllKp9~__!p)opsDUn`3=bjn?QFR9x-XyNBm;;#>RjvALUd
zFkX7eB=nlE*G3m!Qp0gO5@0%`KV>;(ck}ZFT-0lg-%ddwXr{dPZnME>zcI(SfgJd*DQVA;{CHAUnE~2$BV;=eeyp1
za6MQVIqcKd2uBJTZi;hJs8_|1QmRC1
zp$Y0ypeB1V6P;P*G40VoV~+oU4Va|{)uuD;QCN)`%~+3K`UFlk;zUdfcLl!F>@m{ePb4A&zdfr
zuw%g+GHm;^8G<}DDC=)?Aw6W-3V*!j<|r$@=GG_|>8VF8RSE#fCrw*G>^MXCmW`6zcC=)%mS160D`H<>r`y-Ayh*^Ha>SjMaB`JeHso
z(XfQ1{pIckYJvNUKKvDEyp<0VlKHI;6PEbPnj|p@TBAeLSTenBJ3xn`U9XWZZ7&o4
zZ)IK!ziaeXxJIHi9kv@{vXGfWxYIvObfjA?!L@SMYxY+^r^UO=Od1vo0Iy;zp6e=o%A@U!q)>E2ph){;LY9@c^B>e{M{p^J8UsIN&!z7TCR2s8X775>
zmHd!)jam|7#KwTwf}9C_0UH#PULjs^KB`yZtI!5;%
z?rz7zPeoGe#V}dft-oGiB|g0@O)VzwC;|4>C=oVjW?PBy4?-HnM@ihWu+-%VWva5T
zi|X+xCM=Vlk$5A?;%%vFZ7t=HqYI_$7=Yn)sFgk2i3bpS;5s|q=FXRgf+)GyPv=9w;KCrS|Kr(11(f(+oUlxcJw+t#RXixp*U4jrjN?99bV^SRc8#uz@w
z!%9?})2q5l?8?T%S}GQnN4M`~!<_xZwqPnZ-b=iGAunuiD#+R-(R3lLO=%_b!51o-
zCjP`|)*|#JuY-n|TC+@PNQni$rVaV=O2fH8P5I3?A_QYvr6eyS2xGAVr20LtFmfHj
zfvzR(rXaS19w5<)#kIl8yGvm)%7xhd@2%$&@s)^&L{0IMEL7z>)MFK#gl6cY_bsrb
zlUPnNCQ9b{xo+)|>`gVB!7LNgOo|8q3?WY<#c>BYhW!*1(wCG
zsQTu(1K*VJ5WCC9xC-Jya``gpcl9~NZZ?ARm14isk9-$rYG6aJ(}%;1y4JZKyS_8b
zey|dG<;b_ra<~AXi6p9ucf=M^zoi}`=GKr-2d`bPV=JgnX2mf2F&5b3Zyjj!RCdq>BqShfX3m@CaTqn!9Z*oRmap;ZLaFfy3`HW+}VKK~2
zJRbhMx1pC2tLsfb5>-iNi(?>1`h2^`i0}u0)!CP)Xkp?A@ZhgMY_*i(A=0;
zKNHbOGiunfk~|vxg`P=&V?R;t+@#>V3VIhsE36v|_AZPykQw#pM%z2FzmHekhTiJC
zaOk^VvaRsW6^&E8cN@Vlu|1XzXOHG~`H#TMtZgmQeP&4J!n~6bdWq%EMJ;U>cB08Q
z!!$jpw0^GUZvnvi6(GEIj@6co0M$t?DjYN^D(%r3nxif9{$^uKn-FywoFz3secTY(
zAw$l;?XB`+^@fVbaKXJLY7?C@Vx&k_SZnEdi}6E!J)%-q(tf)r;W@z0n5twN1~9VF
z1ze1Bq>*ddcn|sd80S&S9PmR_dMwg5^f6WKnUg_AdNVr8MgfE@;SDl?G%5~k3WxLY
zkXlG0@n6tV|8C>SlxDna@(NAh?Tbng<%qiIJ~RF+o{-<2x+kewdnaU2Tw0f~Mb?(gVN!eA4ip;;*NVvO+EAw~
z;{d1pZy{=)7?zII3S6vmAUIhD%UvZa-RG?KBwhY@?-}WNmH?#&1>=c3oa!1jVv_%#
zl(JF%k$3)ZkpQfJI2VK%;>3|e2ld;{(Cun(34(P6Hj@3{EJdVGIotvKu|`I4|8+-6
zim2Yk(kHr@y;Fid3pKQ(OPub#x&*aLtR^TETIdX5t)_mEG&yy%%LD1~`j3+FCi8}+
z_@RJ_0cL18<|`1bA!e5->CL)zE_0+EH8QSuUP3wuKvFzxiZ1+sY!!{uLr){r+AOH1wRzN{D&%LnGR0E
zgPIAH{{^?Wf)wsAO+j({2rcGSAdm81AzkuaW-8{g0wOEg!9_k+CT<%k6DCuT5;t6H
z+&Ingi&~9se<_;Dy?D+mz^(gB-?HxEs!!T%r~4_&myGalM0(Z%vJ$E2zyY|y>H2S}mJ1Fl7u
zS<*=h;`Gn|;8A8w*%-QjIY89Les6OIl?V96Mnk)_4vo#=tXnfi0s4(pT+lkPa
z@AR?7+odmjSr#p6jvgik6q#msEW7dW28r3~lG+9o@3JBrvhJE9){97j>nvM6ilnAC
zaF<$cDY)PE_Cn+u2Ca_&`s6*-AFF|@yFK1+!lD1bmuwUs5|xZC(zQ?ISp#P+Xi25r_~z%G^VqHQ-`SRNF6lWQ=H
z(5RUtnLQKXvV$@w9Db)Js@L|8^{#AO==p{>?G-#YQ%MXpGc6ifXvByWFm9pysxu8^G8|QU^yuVC=7vW5(6qyEb^sT5S6nY@@`Tlz
zl9GxL-xm=pxFHrPPxVZJ+m6Vq#Mb_1GPo3&^g4D+r>SYcTl&FiIe~hg!*O{lvik@W&4-^S=4hEoDBs=d4pBsro>44)b_fZzk07qhZX2`Wdbq!inbw09~`i1MQo
zgTm@u(Xp3?V?+N$qqQ{wXK)de5i_EtI*+Ulu1EGAwa^)TpwZmrJH~?GVSSW7T**$o
zofsG7$N8J|&Pa!-Q{!NVCI9bJRa#E8Sw9YChVQry%W)ky56PiJ#_DmL>VrrXSuPd4
zK2@c9F2hx-vtBBtDemY+MyFMT)lFqZif;)8((7FHP#0-|mgLX+tAw8saC#JN^_Jm;?S!V@2u}BtQR;K(n__9i=wxZb6
zgpksqu7bXR(x0UN7wtWVCxbdv-^k=CHryS+MYoO=Dr(qom{N2b%!l~M<)lt`sL2tz
zkgMVgH3|4*O0<5!<8F%W5X52(G(M^=#Sa{c-Sv>v#TGdekJlcJ)SEYkh7y3BX7e`2
z=2uL>aFw_5(X26I>!=@^HSG2BojZ+6DQqg4kheO1#jmc#aZcAi;ws6Yz`E^-XA!lm
zo5m)bxk*ntkBX+;;kRppT_>gw3))#v!twJjbbV6&RL|6q=5+t%6kFEc_?WIJ0|R>x
zt|Hv}N49<=Q)97u<@`2r<@?0Me-!GUNi7G9+N^BrO7FMc@*f&84q++$u6eCExZ*qy
z6XM6U79NDmoteIoRfruc2PS&H2Kba&)INRR%s)_rn%8DI@l#RO>|scS@8jduH)_m)
zi@3nbxQ2Yi@D2yDbO}EgTdPKQrso^&!lB0v_YX!0#dq=GLY$wAv)#yeSSkNE=NkQW~
z?qs*wKtuHrCD(6_4Lyi9**BmJ_zIEck$+}96xEaNIxzLPWtEGz@
zU0>-jJyrcrJd!oM>0-EOPzu&Fz_+l^MoKXi!*+dARjxBzT6SI2VTt!HZD^S)JHRg5
zf^S_f+wa%r2k<{Gde(*r6QG-!!#fMBATT0b5TR4c&p5mww&RRxM)>HstS8T
zHGY1lgm>lfm-Cu7M^Kuy69DNx;VF}aIqn3H_lG~)q-UVmxcIin`41q5Lb^z5fV#Ex
zq$vcSp
zJd%k9LpqL&-CRE|VSMlw9WiN+_XHC>QM8_qRx~%VhuO%rz%|s7#IEYb5To
z=#4lSqb
z%E_ZMT13D{%=qJ|!CJRRT)LMyQ*^zHq@}U4nr(2jK$iBnk1s3|+wNTdFI?_ib+dft
zhndap4ZZ1AinZGWQdXHCd>9f;O!!mFKR_kd-KEZZMuWuk~lY#rXwO+x&7}-nltafc)E(Gr5t`Ev-XYLW>4S*8{
zs?{~9(JDuUKAg$30NAN|mJJt~U>fYl9%h7eudOucWdf@#u_Ir>1IalF6?&`)*|L8b
z&?MQa_bq%SYeHe>Zv83D2~?}hEw0Qk*SL1y61{uC;z*M4OBO=?j=>1^lTV@)g6$>&$7ALNOM=5x)jbOh>2|^SP1wPDAgb7!h
z9~V_?*&0VNCyW~dnni
zlh>_8s(};70Xv_qrs1U^J0JIFb@>Y6j1GWR2(*QUL@F68Tu2Giy{I`@?*d-_B$~u^
zd5fy5Yb5gcPK065;!yUv__=qvb*N=l!_cHBTaD=Nu)%EDs8r`0X@zjAO3=RdWVzaj
zs3GbVZr=C%GD*E3*U)z7CTYzueSbBC$#YZ^$0srlCOhvaih@)lN{3c-#9@>hui)5a
z$sV@~kakoUjcaPBk_kOS_i3A^3UG~R$ODZDqLoH^sUqK(2tBS#h``FsturbK_))jW#buP
zhRFI?B7M0=;ntX23PbTFe&F_O)?pJuIOa^7iD{N1!@2REPP8=i;kDciRBnI!3dm%8
z_~_?
zm4Bp6=S0tn9D}PS4&qv1jEO@=O_G^Wh6&Ck@9z5L>h78YHNA!MVqpb0;F=?DTYeg&0LvTDoE|Ih>kV$=c>&Q>MWZ&%i&!;iRv$?%*;*c1dJ
zlUsl4t}!mWQHV9iovCJqTAuuP?oH{~>>61)96+%{phi%EKSAotxXh6!?bZP_Orc^ju`6XR{P5IuolnOjk`TsJux(
z`^g(!h%uyWBULLkfJqiycnRwWwO5dQR{O7sJtXV<`tGVXNveU2=`bT4FT+x0Fr%J|
zF)kZLkDk~S4NHg?0gEQaWt?e5rCWvSUPY}k>WL`587X_Mpv&c?f;3
zk=>2XDFz83kcU9pc-oz+_1CaS@^5TJ@*F;bIys}EewOH)q5hho1sKdKKjOaMyZTl8
zrILPC9Z{V(ihmnSXsTmt>@+!4tWsq+$b(HXZOo_Bq2PJjS?iVe&W#~`!6h1Veq>9f
zzXhArS?)c5PtvR%@dvq9ZO`S}&=VeBOnj9n!{B2z%CK0t)j}+d95|=1w88#0NbU2l
z-X0y2_V~cTv=kP{H0|2u$_=L}$-fPDZhHg~ZBTn4xkb`-lGIY_i(z|bvr2O6F5HykiZjklT8Z`OjWj;J!4JOZdXQEd4{WVDJ?nAwePCz77~JM@NJo8V)7j)Y#}fRQ(wdZ*
zg7oFj6R$o+8AieM#L~d}^q24NID(IfOA$ls*W{og8(K#(-ulAw%vz(~RBZtETQMP9
zAg6MaLSzFY>qp70)v_pX&*bJgGv0P|ptgg&NYa=$(1|1><7N8r(D!&IVxO-iKBm4+
zJD%TU8ruUu!r&Q?1BB%o@EZ2c0W;rkLWFRwz)oUvkz!!IMY_0JFX^PwzZdMzHxu?(
zU^U2c4)KV54_4i9-G9~tFQrGXG)Jt`m2!D(rSOLFD!-n2kBZdJ{=vQ`Wo8+g%&WyY
zGoFn=I*JbFpR>CM!v#oTKFU-THQ2KYwk3(DD5~*PfM7h$e;+Hj#)G=@K_Sjx?JCBC
zMhEJSq`~1wFCy}zTEJCUBu*^cb3#L0O!2Oi4*ESnA!v4z5`-ILR{x;yvJANOe?oY3kob>j2*KS1ws^^X==^^WN^;E>cm}XI$P*%!}je
z*xJ<-cDmbxTZ;Uy`~C3g<^1hS{`0VA%IBr|s@u2orNbdjzo~uj^Jl13HS#Cq)9zgu
zTjBIu|J_l8Wp;K?PCxp~)yMqVU5v8Ns;|vg>n46izm*V{c0_;8=gk~mc2hgUh2GPo
zinH}!J$kY2pBsd^LNk7oXI9-C{8>1hTG*d2bsud4A5Aa!3s6FaqSKSRdC2et8;uI!
z!%C>P|1IbSu>2`;S0(Ed(xWbRzr}GjL+M4|-D*JbP+(8nE8F|zt9R$dR7!Q0z*f+}
z^G^0Bl9y-Jb4pLq;vH0|eNI1~DMpz}da9<|g~=A4Zg6GJ0w^fS6{Aa3@7AuC$nT$2
zY?AHpKH=dEHbJKk%pNms%wULe$0s|QP3o7`g9)M$>N#EdGla|2HtAj44N&`FM0lL}
zG5S~s_tuUSw}>V8B44J}KB+nu8COs2N{@C+S+e_6FRz$#vi&lwqt$un_BcOW&c6Qz!_r4Y{<#cdC1fBW+=P
zZz{pgjV{7HCK**Sgz-U2;O91}B~7b)aiwk=YbYWVIQs81s}bX=kw;9c{a^er52}TZ
z_`y}zuChEV``DC*2lxncnR#rq=i5GLD&D$!ffp_+raPG-j<=TDS~YTMcbm<*mQxfg
z=w2Opmm2oAVH*sGnsNhZ(LK!|-9$qqnKdwc+(FhY-}!b<0+0W!wpP
z<05OVErqDv(ldLKdQLwu6+1=p1XM#pWJIeC+v;jx;xh{FyA(pj~s(m5yre0
zNO@j5@hOa~IkNjYVEShIU0{_F9{A`QHynO5C}a>aW*h8prCf!c(CWV(y3a|LE`pc|MZ=s}XuwGYSh4jh;$OJ@jY7CiR7?axRjdRhIJ@B9dsKQp
z#v058ebTeW2jcOEO^NN_!Er04-YMD%r`Cp+T$HY{Cy^DKdm(!!5(V!#cH@&+%Oitq
zxITk><=Q#4B=7wVoKbr%@ECmHhvt(kXaj^w`t6_2ep}Uy+`I0#WQ|`lb{Eskbn*)q
zc@15hxEQx@yjCAd7w*?Z-S5n^u$659@D^1*KEV#G%G@gIFg7=O4OKyq>(dMe;m@C9
zyu5v3C48NmNJx)ZdYv;Kg!U4MK7{y9hh5HV(-O;hOSnJNF)lG!1ZV9D-U%Y^iea70
zscj{SXe#6hY!&Yi@OLBzj*TWvX6!%RxjSVY?6aHQmM70PkKEg~2npZWrSW-ZEbRFJ4ggvr(A4)Jl@g2
zBY(Z0JiMqlTVl^8n>6v*32aiJ0zQ^gj_luFy?CMq1ja9JF5S6V+e7C`XN2D{;L48i
zwovf0pM4_z1AdWKpun@d*U3o0aQ8eKVB~!IQ=~F{k972APZ^R=#(&4j!
z%DU%baEtC#99@v=Z?LiTSokyb{lYlS5H1M?M(@@{Y6-m-I)d*ocnA;{?8xo=s8&-S-?s^PQy{e=}_ADWZ4>k5a86ojyLbIY5|
z!ZYL-gJKF=XHjo&9U^vAoYbJQ|JOBW_hP--!NuLv>V
z?YWH)7^f>rFrh++L0dgMSAOkcG{9OK`(Y896TQ&0M~T-j>dM)khK`WW7ZiT(XvaeP
z*|*@-_FHFh1Dse;vjqyR=Grsz=)Ml^Rg$@hjVMFuJ0y!6y8m
zw5m?r^G`IoIKPe0r|WNEX(4o#e_~{0WIkzV+~~-BoEEq=EXG`Wjj6$;OZ*i_*W%{d
zs_-7tWbcKs!Ns$2%qvv_%Q+hvR#a<#Z7ceyww1HTX`7C}rZF$?8$q5WZvNLj#r0Js
zsyS+6rYqT1?h!>(L$;!LE|v*zt19?LiV2;tjZv-yb!?W+HaPr?8tb77sRgTdVNpAv
z8MAu3u+%0FZ*I7y%{GnaqP%7fYfWnY$CI@d{}g^;hx*!yUag{9H_UsDYwCo(f}|W2
zWuXx>5AQDC6rj%wCf6EA2Gg(4uD&03%2|^|2rdf2Qwc{Q9?mnl>QI0+#nqr~Rs_>8
zU+S;6&>D8C4n#Q1Wlgc0oB<%+2nV0reypp%UB?C{l#t=$i#d9fd$ZBZJgQk4;=asG8#}{Y`rwKFX(0)U`@vkD2U384EbBBV*+StGKuyydQ+g
zmD)HH3%%3ZgY#@mrEiIJ;zDV^N7|~Ad&sl}GGStA3Wk*zsDdx^H)jaZ$G41!>
zZbhm>NTenIIEF`E#SnGM_d6pnjVEnh7X3)sI&0)2MH@zieA84i&F*-o
zLldZS;1g)H5RN^#agGvh==9M}cy)eg#kmdv9fQ1@eJpJ_e60xB)#8cJYMYLCM5RRT
zx+}$m09gXlP~PoQ{n!QNs|P7Y)!X4j9vCCQjv?q6;S%JdlfxN|C
zaMo-b!Pm)1{#rsxw8`a{;=o68h8~ASB6loV@=q8k{*X{qXN%CX%oUb)2a<_ga>L-EBvSOw#Ckw=w)?D{b1J3f=Jyww2ro4@0+F`{u>o?2vCoXz%
z*Ho>y#PY{3GOVxn8pz;D-pEK1q8yAoa=xqcwhx)S{2pe0uJ{HV93Q1oRhrko2<@7$EXExP*f3y&U
z%Hp~$WRxmE9%ndmmt-786Fg`M4OQL*9`UQe0hQ!i^C;B$dP8V#n2Zy6_{q59_3C2T
zWpB0w=5N_0Qnn;tq{NT7^LjKs?gN|V=Zk}v0TE9#DJW?ZIdYOgIJxgs>zBfk228^A
z&Q^^v=-8Ah2K$%gI&cu8nb|O6hUU75=BI=8!NI{g8tH
zZhA~(+%hOP6oH%s91w@+r+bz$kb5wQ-CJu=ft}d*E;jXhJv%~i^>OB^uL~eF`zh~#
z1dshDe0+Mk)lf3Oj(mPQM&t$FYTX6<@gfj%;xD@bfqKc_V0mavAhPxg=)^wzlSU>tr*o4^rk=I&{5c;ue
z`Q_~R-o7HBh#vcwVGp>4zEoclLUBIQ*AWU^Oi=E|Kr*7%kUV5N*U>`_?HbjdYR8G`
z+uIzbJkN5o05}TXZYPQr0L*DbZVdzrhSe6RT8ckC3`*q$dISi-zA$Bk^k+N;1y}72
zf&=r%X^Hs~uFbcEuM&wQb_=$yp`rzOc*Z3#4(}dRq0{#(FMwvpH(`E;SJ)pcC+&!k
zi&C57!2
zyqjh7w?II1>*0m`H7mmiy|xM_edbNSOe1*KT_XfrNoil+|5MkR|tQR=?fs5Bq)&w+Gv7
ztO@;n-eQ34@4fLi@gH$c8@Vk`KJ$EJfTZQ&eU`X8NyzDEWWLs8
zct12G5F5|Q=7Xhl_B09x^|kVJKVCz`P!AFaT&;J+URh$zTz747%!!WqZNR6a8RKRs
z`@Rx+-9F5q|K(^nkbQT&!Y`-qdE@0`_=(4TH0}Sw^0lI{JC~k|?5=GI+5G75VfFq_
z$L#A9qA>HNw?nvZ@jU0YzvOh%3i(Xye&reGzPsR*1=yJ>Uta11XzU##cV0(z6QudR
zJ$)tc-D7|7e)yWkgzPQ8C+(Kr!oY`Z3>AjIJZ-IPJtajdIZ?!%aqB;{Qo?@8-z^2#
zH-O4~G)A^wyttJI<4-R0ecWXoy_Hl|d!ALY%yz$QMK5=FS{vwWdy6sLgmk)KxHdky
zZ~m^}dEkkA*i5tDg26jOuxWVha1$~$s<;q)h<4`5Eu!hZneBS07V|A?N$C9|Zo#{Wt-itLiq3))!ARGHH*eTWe*0%&p4SVvj*@JR!r;
ztX-ZJabcThFiL(=fE_PN|50KZQlKNT*!A+&au)>_z57(!!6YpxZX>pNiCMXMuai(e
z(hcso>9yqv5Z1`d#Mm)^>Pd({U93jkc{AACTB92Mb~u-v3rOFs38>XH%WIhMnkLji
zohZIvO2Ri{siwe^X}_hw_c#)B6(ze;kKxK(pAA2o-~~hkGa-aJqHvCfO|g7?5CvrI
zRq=r&6d(ws;QMXls(5k@iy{5^=(%|;lp7`1#Yzu_AGg5)t`HVrtVz7!@r-y2U+^ikX5*jQ5VNyIx|Z*(mP=Us%;
z+-j-{k*&q`7|E8A_!g=kaF%tc@ml}6dMG;9Oz=aH;NfL)KVnmjWI}6rdHQ4icXESRN6ZLMlZ7oeZmf(Mu_1@%Lx$vV2
z8}Cb28tU$THu(iow~Ja2Kg#(Kh%c=SegNeVz9CtV^WKj{_)%khHUfNHX{utb2KQML
z-;FureRjUMhE$POa_hnt2~S+|V|Fi9OAc~oLfx@zIOZW;oGvJRC7me|UQfp{SF$2L
zoS_vkx;h!A25qTn<9=hJAMESPsDtVUjUNhjS}ho~KwY?>?zc3}L03)4A0^vv2&-%+
zkEmX5-H({c-1632CKfCOkQQYY((wN5Zod%>l)c?xmND6WFI2Ewdk!De#mgGOL%GCK
zYu@>*X@&hjjtd~uk|7E4^r#x>
zf$}^Lct*1?84fQvFKtWyt!Y|0$oy(8$sNekP2UwR#zyEbAAYrwG2mkJ^|VEgdxfmg
z`^mlo#q;gzf}2VSm-Vi+>ok2={k>$U;cP=lO&p(~h=$(F;(Y7jWMb(e
zql98QvrNPde$PfWQ&Ti&kOTS)L=WdcFDWS12LRC
zt5}4
zoLMN9B{j5Rn$5t$M$1{fUQ)_S
z+?;-^=R;{Ilk1ZtTm$lid5(RSx7EkUx`?GZEm?pomgC^gRRdm&CglQ?nsBL0(a{;f|>swBM2jk-@TpT%x~4H|3u%&ADguosm$q
zO>KbegN}upQSQ}OMh;!`Gla3nt9^@=6x83uPf!qwWX^B3yEZd}^Tqk(WOVvOn@R3r
zKj)FQC7FTPzq%+kGXpOI?plW1ax@oU#uadCbd{t
z2DYZ^=zhPJm;9IXP?8r5SSLbD8wkM6dvN=z=T
zGr1>0ZoEhfS$Si#@Es6b@lbzOjWTVLN;|NTrczk`L`PMMF-$Tx
z2(n@e+UF_MR#^-4vW-whIoT;jQk`WiKMOH{tX=RS^%kKq8Es7PYK%ttvGtQN!cjOP
zjVc5k(zRj=a+@Dk&w2UwI+_**N80z0CetK(-4kY)@RFVJAqWu|)RU`)GxTD-{X
zB?32S+zt8AR%JfNm$J7Ipay63C9a?I>owMa{K?_7Qh>TRe%_*F>Va*5Ft&5X^XcLK
z;Fcz?2HMaFM9+wa#K?_I)HccsA`*2@Y=C*f>2=(#
zwZH%xbDCol>Zq!cu!@r{8nbRSXMf`_c_E3Tkd5VoyL&36b6_Er(*>PU2*!sfxJ-ud
zuh4C-X3AU`?mRlE`WFr;5fN*Q*naCo*4=5i`SXRUC^0kHGxylWa$XFV<2mv|F4++q_$~Cie5ZTvl)sARNhO3AWR4!-93~VGRjq3V9db
zHe2MPZTJnxC|=WRem91T1{gTTt{iHDvErHC($%CjIWm0m3EYbV{>$xJFk?8a!`7?F-NbdiV^VFfi!Vw^wydZ
zEM|e2xl%vEon`I1bBVyA&?~-6o=N!TsK6q^ct0#LSLqG#x)7EdQqXY(u1^=rZ~Gq;
zCeKHJVte`Z`>NC(HYd7O5E*3XoC3(fHr6uI94lQXww7|Az~@&`XjI!o(wKii`f!5Gv9lVc9dBc$Qe|#;4ZU9v3gA~!7Fp`9ozNdu
zs+e8>=zZ}N&NT#>$GzyPhvlI^go(>;8D-f+7aha5T5q+rXf954@%h2sC%(npZ9KrA
z;bGvExfej2FS3~y+3J`kFQBh(IcF6q!mHZ+IQ<p#B=
z;Q|Qg0LMkf9!kY^>#>Ue!wJ?~Ku}>33Zf3A%x5Chf$%79moi~%m0!~+m
zM1Y6GvOk3t@W=L9GMy=#Fo6VuwYk()V@{l%Gr5S5H~hr}t`x<g=1$))7ECXFAi>3)do~ZFN}f`gziouK$hOS9qA0$iBJ@I~cp5kyVFAmwaflhS5ei
z3#yV^V^FHHL7W(Y1WsVHD=Ee6=|${|FIGJOJ{Gw11helnj7X{t1NaLoLZ5g@a#%1f
zBOIGvGgbu|LRY{JkR=(;5dyHBZv1iIB^nC_=|f{E2n&{k=#DTx7sQ-Q#_AYGa5O}d
z2*)+87na8MbjPm!^{C>Mp*x7Y6x~)tH>VP`Qx>szn3>1>n-vKiXZ&3IgYV
z{y7>jC`2R&s{_f_vtzSR-9D)!&vDCys2ZJJCEV+Ni8)n)z;aJ?r!HdnGZnqIVacvs
zT|Xf4bBjGlsj3#;8;|X=~YIve?n_J=vdZ8V5!E
zxCo>%Yghxp2uz}P=oz$xD1#!8QR5%s;OB4iO?rlA#
zC#H;Z%J(yTL}+s3r;pQ*9-SL#Gq5^}UxyekeoI#XDIJ5Hlm9Mq*Wj5uxm6P2*85BS
zLqqqqjr>|yTc4)lhqp4oBiulRq1vdHdNJn``4;og#ciLE5wLIr(|U}QyI0Ou?pB{g
zoV$otaWKDgf_k2SCXXMPh_ut9dW7&!I|Y^yD%X=dxQ*eR6e<@>BAH2K@tYTAs#$fs
z#)!w>KyqM6!X|1Hw1aanG1}%0*N;9&Q!IP~g;!LPb~;GX)z9gmC;X_CP5~Jm_J~ct
zhMHkSE~nA>ioQ1|shD@n6;-3GZEXo+@@T*)6a)f9?Yzw#{N8Dg9>zRnbCAu)_*ccI
z=NCNkMJiuAb*NyX+n=?_aRwnSAH_>!oX5q(%q24-~d=y55iNvX20G_(qu8`
z84GHlV$yM@teCxAO)Is%ObE^hw>b}u+%FzJ#RT|I==St^(GJN$HNSwh=uQ=Zt{$%L
zLFBmiu!GZubLeHnee?qrm|R)e)8E*CxV~s%t_pT^-_M#{^HWZWSA}UbkPes
zx=@NIq3!*l*L>b-9-Xy9w5&2X`yeQKN3JwE`-z_IZ@e>igx59`Zj4}04aWSWmq(tl
zw|1zRDpFrbF@A}xc*k2wM!;T8P2^R$fk}ILJ!0CB1_liFhqvqJNZ^>G8M{2-2=Z|P
zB$>Cli`0ytsK_WDAmfgUhNSnK0X05BkhX5WdU`2qCk-vnrFkkFC?k$o;TeHb{?2!
z5GdNGW(fQBMF447(v)aCDRO%lG~kB9I#=Ng;4lR(FymX(;6!
z84CiGJbauIDg6W@QZ!>%RB?#fpj<-WvH)}|K25=u+ymi2op*x2-3ZFx3klSPDg{1G
zk!mFW2S7l-zeoVAZs0)|A$=B;jl7h^NaEjELzEI*ypA}J7ENP;>DH-{<-UZ0IPKroYXYri}W=fI_VJXxCLH|l+8JSH9
zVJvaJ;kO|%hys++s{BlvCXKIJXh+>S4(2<^c<3b0As+;oaq9Ru;6n}(Ibich%y+)`
zGqk-rQaH8>SiIb4^TL7XB6u2Z#>c1_T1}PaQ)cB3v*ya-UfxNai~Q~_?5Cq$FqBYo
z?rNyc*YSC#?5k$~zOh+-hM8_SHHe0Ni~U5JS{xz6C5?L`%V
zRgeoKl_}#Ef&+1YWUusxWH2tP}v2afC
zdtw-1)Zf@1bZ9DPkj5_NF-(Z6AkK>*X<#jFFz2Cwmv@qa?c6OATonm9M}|Xgkb$FX
z;e^~Uwypec-Yl?S4^yv&ypRDd6%HV`K>N)>?Mt^gPPyY6o!-4Uu|BVI@%0{V2
zR1oWNyonowNWvx`BT^#nYlKiFgA@xrJPt%(M0#LKYR<2i)^ypn|47%#D65%kC3z^CKq~2onntQ<4RAii@
zeWwBdtGH&~&UJRA>PblhGqp$dgz51LPKyexEDW+pDO7XM-e8;axij{sE2wP2?T`4>
z$u`y$j7DT`dJb_I5VuVP@@AwkN`5?Elic{1q)0+hee%^4rc-qW-tt#zQ;NecjpfnL
zkue5kOFAp7&(_4Za~7P!Wa+%5yIx~r*mVs8oq3{3x+sZCGNaUZTf31f19=b7i72Ec
z)U8OkS?y{KJ%V)PMAk$rV6(2xN2+YX-Eh}6J_&9|x;LRRJO!Wyz)E(j=(2u@R;glN
zf7(&_b)(AQC#q<4WL7vV8mB%o{{&qI_+(Uy50*;-HZyvQg~ZveK2-%2L?+)65GED&
z0d5F7^b1x(87h6Qz5$9CMM`FrNs_|Ec)V$&wM+Ru`lRB_S}dNek0X(`SVf%-2+RFu
zt%MjaohI;6Q1MQPiE=Q*g6~59f_=@g7|4n8%{4GMBRA3INQEMWS3}0SF@EoU}=tzq(C(=axmH8(-<
z%bbPdL7K0TC%L4r$jLZw;^1cPyHhUpybSGl>Z1s{YpaTyqcY}Ap3m4Y8=)7j5UGWh
zM1gRiSi@|_AvYkh3RMaAr)g@}>B=8-b|bF#dT$}~;iJ|BD1JORKJGYMUQ-h#Ygefz
z%FC`ne5J`6nRT?Qi6rbtVN7ebT%q85<0>nUlMqrrKh@~fe7q6u3cxspi9*N*A*?0+
zK+Pmh1VrRbn(xp`iKWhuKSfBHZ^)K`rPCu_3P!6986IhI>dvyt8Wr|euGJHSV;2Zs
zV$+bCsEE~Cj2sBET>vl>0m54=a6}lCIABb}MEqBnVR(I#e_&u-vT;^^mE*?{R3ZBj
z^gO@~w?y0!u|nxL^0Gw0A5d6@B~%tM)O*0vLxBqpX%38gg@MT3?IA9TAhCmT5Jc0Z
z@HT~sMFAwd9>QHV?7NA*R0UwntdeEGadE)A&?-ZzDdel>V}hYTNf!`OIb;OE&nc+-
zT=Y`>jEJYpYWN?A;Li8zilJp43h>(jrB7^)C53SpKbQvky$<|~QnirO+LhR$XB
z&{On(VEmTNAM8qs6eqmOG$5OfGfispiwly!A&w1%)Sxp%F0X82%uxoQAKeRK`G3$gO?!aUOX+#ez6@4&$Q%2=On{
zc>5Aog9Tws9$)-Y^+zyEL~9iqnkn#-MBPh39j74U*Jng@C}cgS{SsxlMBT3Rvk2`|
z*pO5kn4yZ80|tPZ7EFSMnkV&<*b7`%$Z|uha;&X*nehd#zVeeppThZRZ?b%76bdU+
zDfo3NP&6hPzoie3SemfSKa$iI%d)7&VUbc3_@{`bfL2YIYmuj07sv<_^R~F^h4>QH
z1FFoko}AVKfw|cu`}ZaJ=CpW%)W~zJaQIYC_;GFf0_Y
z=_FBe{fB<7QWHim`=r3EkqY&oH^6S*eTTSsMbp?Lz
ztJkh{Mw%#kZ`^~bY4E9frSWj9vt>f3e!r?Ksv*~_tzszUeGsXLxLHU~BaJSs_3pON
z|HtvK_2+6E9GHTkGxNy!sHRgw%#ZG#TPdV_nb5z;yKu1{m=Sff#|9yxm5f4)-sX*nhC>K
z9h(W-mc7`|hN(TUl0OL;8!Qa#9=V>4C7DbXf3WY=G3gF6L)VbzQLY$8Y_DDaPS)4f
zLxsifG(z$BSSdS}#j@%ab>~6|4FPGLMaEh!gz`8;^hlmWz=k1u2vXiF55>urP*6eo
zC1*k=-=Oa!um#OkuAGi4@nG_^=oCjq#uNsMD8`d~{xL=IO$6+r+F^OcDrf~C5Ya$U
z^x@voW1ldq1W~GVrh;_U+Xkx5P}nNTe^;^DkM;~%VO+;Z$mTB*RH~}&uS*i6d^G1)
zkw{2+gVy3<33m#m?oOz6xw;S%RUMqC2r?ls$Saj_M@kH)rAw6+A`Ks~b<$lOjYeUR
zNamzB8IgICC7o8+=qC#rJI)kxt!4D{z8^JB
zDUuDhomIj@3xVt9e1#Bs!TKo6#dZx+>A-}pfgqipPjxp`f;KG%x3Du6k-!h@wjm5;
zQq>1DAp)_Zx}AG}{jZrSLr?mgLd~a=_$Pm*n){a`q6z^H9Ow)CmxJK}l=n7rg?BwG
z1tzfd&+DAZ8o19}w@JtRdtL*_xz0vKW(qVF6d|AiWJOjG%yG|1)nv-$ex5$LEe62|!X-kRc1aP?7~%-9v3x#2U}y;flBA2m3UGHz7iv3DfglCUOtTsykVZO|MXq`H<=-
zp<)UbyjJHXr?sTh)SQwM2xV)D4^XI!19=rs}p}U_8Sr%uMP+rfhax>pb0;Nmml>>B{`6zlE|!;3g#{o%*UlV25Iu
z$n13%0myuUyvDt{LzM_K>tx~tBKQCm*hO7Z+)b3d{f!956DUm4c+bJ+<$B2sG?3kf
zLzQT-#P_u55K90HEAV4*JW~#iEU%P;4LFN1llq!vthF#HDbvzC6m@Co5LmBF8<|w{
z)fpq4?isypJh9vg_~&vh9+vO|2t`AcYGV0J;0{^DigTW6d=_J8mQs4PSjW>P^*3AG@xj)_L>qI-tzaJGHy
z3GFS?7Yd*hlt^unKa9K-kd<%k!-uK+oH0L{1c$NrQVuY+3XK6$$G=u!2`6-IT&z@L
zR9ycU>yp4DVI#S;W7!H23I5;-lMoWqb3GcCshtVE;iuE_E;52ih2W>BPZAR;p+@03
zxgZ%v41E2A?57XPKVhLLEYi~XLd8nIO*zsP4)MX*wY(eLM49Foo`XAx4JDD*&MW@o
z*=3TDAcSOH5cXkjVK$K~8aQ_}FXS80Qp79J+b6X+&$v7?&gi`_huDKuA(%^0@p$Gc
zXST3p(k2#06D6RjC8xqFqiy?8LNhjoa>lS&@D4pC=blrpKKyq#BAM~zAZEx*p4Rg4
z0r5;$4)vN@;=G*y_Lu+p14lWO{1o@X%ehfevSr`d59t$8JF^uMe?gqLVlDd>^ESR0&H$Id6%#Wx--gFN}jLI}f$H~~xu@N
zKKRQTi)1-GiEKmI7)dHkDaJuxf}sGNOd#;|$*RSdt~-*iDIIK^GXT`0(mJ;K=Fk6w
z!i+ZI<8Uq1B43?-($_-v@|qOJ=7{uv_g!esldsR$0hcD-;>!vb5H}6k$(0ri*~zam
z=kpe%4cPR%$_8vR1P{6pg{cW84VccNNFlAW8{EgpmJ>A%`Hcj=Vkk{0+_J3<`@p5N
zJj#m0(#ynQ3F;~*l~VQ@-}&V{QVTefH$#@3crxc=0{n@wCn$ZCO%3pEQ7$yH2gbWw
z5)dXw0JUYQxr`*GSdAZ1Sx#~$0!H;PB0+_A_UOpGeW^3dk59@I_vNo>(m
zJqah6#EYV-#K_&XF&rEllm_#$AbCpy!AN5zl`P!iR??63CkacTthEuoNneEFcga>hg6^4&ax_OkEyXdDF|sLLk{`~B${eu=4nT^fh<*z1kdkZR
z$2h2hF{X&UD2YBGBbd&w0MEeLS$;#+0eLsL5izVhjZiNs;OyvZR
z#~+Be!{MP4wjxcHT`n3E6!{71P5yRP^E2uAkukQS$-E!=eg2O;Js7Nmiu5nz7UYX$
zXI^?xHx@ZM(!~HyEvPIr*r%@J_plaiks5l`V#k=
zT_9BkTaNIUm#84Lj1ohS0GN0gK7Dd>WV|^tPI+g3D4)SR>7OAy4momf;&{r=HD6Ak
zXcE*+J!@MU*SrGJ@9__&DYFWy_S)-Bqo5jxNLq8-*Q7oFa;eKR>uQn9A=W)#;Obc-
zZfnXGty3gYPYeYkz;ef3Y^A?X8SQMiF$6)w3jXDQ0iS1_zY>|6DNDqV381&W!}Wuy
z^ACuY5V{2zRYdm6a>yf9$WiAVZhYF9MJ&s*A!_ex^k(DnI)m2z9L?J=B^Yvq1
z3=EV&fr3m3qk4UT=(_H<@?NQLZ66uv%o1f+rtK_f?gtx?tu4&~yv8{C4xgtLwSMlQ
zN;|C<+Z5G8X~&a6P7WZQhAd#31jj-VM@zN`3ifc!Ct-o}w}dk<=pKsd&<)vUb!)b(
zZ3}2MU|3ERd%hW!+vUn997z%3Xrum6gd|cH-d-(hzu}*5*c$@=%azfX`sun7M!NLdf4j9_|V$YFD{qH
zHM$8)lqPCtW;_o4lu@dQW7K4uD9-ks8{g`7&F)Uxv0*$;jmw(ng!W?y#5yDT7N(`{
zG|Bpxl=`SE&eKtP=rq1z+LK-TYlcHK7N4v%x
zc(N&nQq(`J-=a5v9Z)cb%1wT^+NoPY#RUe&Y0CJXf}PJH9zjiOqKlTjKn9Zolc5zz
zAtSt!0P4gFCI~*Vc&kHlsGx0eRa1&;wdJ8HKp;{4*-9%B6~Jeq$4fpkLJo?-`P`SRdSSJGle0|aP4PZ7Yep(QvE?m0b9(0a(4Y5Wfr%S9^IbG
zi>BZA3Eq=tJK^_aC+(b;I
z()~b(x}w$jx7@Q?jNC)dzlE8%UJtc7_{)qGpVeKTO{Y8wJ+Jdq_MJ7_B
zEKdjk!aCp#Cgim=Bb6Rc&H)87p#(vVS2S|XLW6aEVvxM9sNO()4w*
zJkCJP#W8{dCEcV{i`qBfuG@U?rKLZze6`94aW;qxQYUcT!ge?jHEy}+1RW!V;~do^
zj2?4B5!wqW-H!70CUeMDQK$*d8;&Mu1^7hfr~0@cFC(8V#z%$xQ{`DGCj;vIE!h9b
zsh6q&i24?p>=_JndKO6y1gI1vvcVDtakct^Fv11>xN@Xo!U{zL
zxVT0^tSM7GlIkhYFZHIS)T?`HE*xelSG6CU8eythmpc_ODtc5eJ1-4nQXNu(#XTNXj7A
z?(D5DfSacF5;E_dLNupAJh=qNar}p!p(^yoeo`vwC4Ot4N&@8>Qbw9K=NWAg(M~jv{3pYvY1@ax>C*BN>MN6nbme3uTO1e&7B-2
zCDnAUQ4Xq6e
zrWp*z6uhh(>sS9?@6GAy^X8^4sj$%cT5ND7B1HqGb-8dv``v1Ci?LK15Fn)bx79J`
z*Z&b&z;8|=8P?n~BrqqwC&jA1BN1C_)J$KrXU5dWHFIAflbSBR(vjcXoZ-4`?YI}~
zu;n=;djNcrR`wbl^TX!m3UVSK;sDBN>EJ+bUN_hqQjWWYG){X5VP-@%dB86r?hIv-
zn&;>N3Hh}ht+0-kLI|$qDQe8FU9JK+lnA@DZ`z*yOUnlyDbRSNOWxj@_d|211knSP
zxfewYtO-Bs?6@TAI3n#DsF>reo)9V?xqqJrE3J=69L>Or}b=DXfJ+gK`6y)a4Z
z^`0F1x~?w!j@XY);(`#VD;$1hB6zDSRx{yUljQSQN{3_fPPrK#(|M#5;QLIaQ{nx#
zt5GMPZac+ZHC|jp0juT(*FNRgmVlB~3-msQHCAQEm;mxQZbfNty|(+rA-3-jt(oE`d)|jAIT!YVu)1G?
z0wOan8dYshvFw`8aU}=0RI8=>kV;h~UiS+G;KWe-gXIY&A*#V&5
z4$~?#qRQ6s;8megO}Y2nSvsZ=?EDTH^nN~9?HofW78F>0Ydl323IL+Tx)#JOMp;Eo
z9c^W}hEHKo-yMF)Fxq$v^HLXL_0C${Gg=5xG0W3N)8xnus|>5-x?IIrKnv{ai{
zF)wf!3uhuzt2xD=^!t54PkGh3YVkEwRKMfH@adBcj>A6~zn)w?`|aey_yss!xP+j)
z+qWhVJtD7Q>De*rFgVsTRI7-frvg~MZ-pTuVoa9H-j@#ot(l1Gw@6rr4b;Y&(92q=
z!uOj|iL~OtF5-msD<1^2@h=DO-yh?D@856AmNa!j=QT)0?A9<{vFWqiFW=&176s3m
zX&D&?v#vhDn%z6Bt@AZK|0zY73s1Jd)
z=%;z-RBvuhS@0ps&Wdzi*=E=+HMJmPU!O~*0ZAyNrxrrrtq%_?O<9*NJ@w+SP&2F~
zOI7utUx+#lN^IZ{e=sJOmse-7JB!LM;SE(R#yaNz0Hz&JBG^;8=_`5d$NlsU&cV##
zkNr_{Ugj^JBe8>^1c>NxS-sxUxm{$hRf^E_`SGA{Xt0;M2E0;`5k4%d(kL8RokSE4
zibADqKruGd)Trn)*Paul6u3SwDU8uhB=JB=>IO#;sZJ2ol8MkWEL0RHO4TMHK!}k=
z>0KwJT6&Uqz+uJ5nTuFkB%vLNd=&Aj5iEj8ACy^FF32lRg3I+-4y0NV@35#;LUE^X
zg0g=eyR@1GgMEMN1RPjP>Kzm!T8=DQ)WGsFE>W8B6IInl9FL?}@_y16K0kXS5H
z#MQy$P*pd*KyjAkAu&{9#<4Y5;
zDwfONlCF_4{Au`OSqzrsob5YQEDgy3f$1Wwl{^|%E_bRlH|fxrQ@jZe@Mx=sjVMEdoKSFX}DEo0dTyg5
zRCYz4vx8g`BsJ3`cvVtQGbmJ!Q8i_cm5YF)w%MjkOTHd_{lP@msf
zHR0N6Hrz`
zkTDXXqyS5d;sq4H3H&jpzbf*~TC6ZAk*3O$tKLc|MkYULuvj#NR-w6Y?Es#J*$GUN
zti1FSD6=6nRbfH05G61#*loC*5hGu<0$1E`%WuMd*1*=}=tR!Uo~(!qOF;xsw+$ZH
zDQeg-p_a?ZBpR_i0YZ2i!{$IbFda)6@YsILHMYY!4LgnJ)M67G*rHClbz2W__s;)5
zmLfqA%JaBpVtTzW$0tOFzBw*7-D=rRC8!#4((L5=28mihCePfuZ-5J+sC;X?{*v4>
z-ULo~!-}>{Sp;@~z}Hm6HQ$mWwjt%bjTX@R=1;AD==<=e(
zfR2?|qI_43-$c!f9sB%od+fQ?dpum0i#7nX0p=0-*RD_5ULu6(+PC=&iE_G}@UpbC
zFF|~xxD7?jg7+wj4Q;d?o9^t?zgwj@vbJZD4LWT4scri9cXRKd=3YBD?C3F7SBOlo
zSk7jE{3zbcE*A`Ys$Ap2WVV=?@*TM_DH5K$@nd{XnEpt>0+-w)q?BUK2~M2kYEdc|
zJ)p=&KzSFSs2&v@0Q&_f>%d^79;WNmVvP03aLBWu(r4r`0)HiC$OV;=A)f=^wC|v6
zfX8y<5XXdlAE#hy)*RGU|3)W6p;`2K3G%hjmuvL@yIuXL;ZGn<3AdC6BPkvYNlJfw
z%UoaX8L@ic;5hJ7$V^z0Bo&(Y4LKE|vGQYTF2boq6Pj{iPC*Nj9#JJt+?&K=c@~6J
z$5cEpsW>n7>=d?tuKjOKFq74vIYq7{aBlVjfUiSL+#@>ALjgY|=iDL~>$>*|r)`{c
zZxW4VBcy{z!H1h!y8wW`EeuqbL|M7eSsm2O-<&Zh`hii=!J|}IhiJ5Pq3jD>U
zOEr6ZWc0oqilAnS>oI?fz$4&hw~X#pulA{9!5PN&HioP7UkAo#T#Ugt2Vu~p
z;!&{xRPRzH6vW)V=N(tZ%qj5Y{E+){clYDyQ!mIXSa}I8tPQ{k5uU8-D-@Lw1_1bo
z<(+96#4tFlV1*DkuJ4u-fZiegfc&N-x@I;dy?J^=p#_!0-mqX%EZxvgCvELkS?VUFq@S$n(l
zRo!&cp~Mfu{NrEh>WQiSG%~+fKB8H4-n26_%4$tJrekcmRnHbePOt9OuAaJg9t@JC
z?49MR9KxCdD>{X?-3I&I4`xWx$9kFAmYOLQnd!(Xuk)5o5!qmqDBulwthJw_4;lNm
z`9BYp48rwawpcStQX4j(LY%1DAoaj~@`DWLueYJ*!&7wh6r+=cbHjm)y4$8GxUC5{
zsmJXDcn-irDW>xOQPVc_EYwJ%c~ywN?85=7%dfx6=^aOn+Ya^G{ANpbbQ6i2rvu{#
z9OXbGe5l@z@BQ#PA&WB&xShb0?u2XHEh^tMZ*A8~4{>>=HsSqNmshzxsdd!P%M8lR
zQWh|63RaYeWO0jP;I
zigl`ZK3FtXXFIP=0I%J?k#nf2gzg%$Pg=dQouvn049H$g?CC=3t%o6FQ2jz!cVYLf
zTMhzSi`v)V*3DC$%C!qeY&&*MhG5D>P1L~6#Ari@|nfti+FNjNWx1y|tqBP82
zI8Y{W=o7`!wyq?l^nO8zv|cA&L$b>p%iQ#RplJ`f=P~kn?k1bW~e>;2XURAiT{&@O5s};rO^6Zj5#)|ISKQ+gypFTPD
ztr=+bp`8mkKA_Bx`V=dTag9il`q%1hyY5!p+isY7sIT!bP`yK)d!74nL9A`hUT?T7
z8%kD4Gw~cxF_e4Kbh8k!++$C}+!wRG0sIJ;V`zyqR@U9nIERJhv|kgYRs7pIF!z9R
z>vc)PwrieeT(Cm4bDx2olHs$DZgbJN*~j+1wU(%j_5axWw%xX|G~N3Ec?Tju&$g>A
z+mfAQcM))$q${XO+Eq?XWAB>{N}?pTDN)UX4|UbI{SMPWVPp6G^Z;`+mwAABh~w2_v+bP^C#uNHyL&dz8y7uP-bVTSr9$z9QB^&4*S+
zVy&=*Sq^xY%OG#S&4rPIJKp7N@h#+EcK#-JiH%it5G`f{?J|3P&R9WjQf|Yv2Iu!B$5jB40l7_e*>q2`Rka0YXL~&rs7jIXV%ol)
zn|mk>$khh1eCi=glp^}tTV<-)_I%h9+bPWQ@uNKwsF^~8dwh3`+Q#cL@3rqB!M4kl
zn@YDeXv>YEX$v{pc1!8nCM~S>HZos{b-HC9Igp$zN#zh9
zT&)LDx<1JAsGc!{j+9XdY0KYVG<(c+=B!Itq(HhGBLSs8Ig}H(2lp4&atX30!yzgq
zjA%OLf<`c&Bf%Fi>mnfs4!tAxmyv^`y3^591>M*o#~xBD1YQq=CPl2-tOdV(GxB=S
zycTbj9A2bcATC5R*`4Ac#~zdlhY%q5A-mM`BB&GMMg57?4&|F5X&Uh|NFE!nOzMx*
zburWyDpXS7@a)r%c*mrVjZgIerGRK5F|nYaErbB&Z!U89l4&DDh;Rjx<_2jF?{%ALQud=N5Cr8hudCSF^K
zlDXKn6hjFy2=l*NR8yV(HSAqiG(ekt_0nrBx`k?_qwp5sA>XkXe6A3SFmWn
z#^5>FBBtQIS8JA-l_F&8QTMhY%U(2C^^8>oxbr)hRzYo)lraUabUK1*RN0}s@O`hi
zf)-w5;ey@md3cEvET$&6%f{%oKL279?t98aTHM@Kg|H-~P5Gb28PzRQvL&!ODJ@%_Aq
zSD0CDZj5EaW(`Vw>b#=upN(TVtYP)v!nqKMQ>exNhJi=nmvOiX&S&TnE*2vwETdor
z1mg%YkqBXehL`B>r)THf_1Ji?#BNVJm`Mg@6l~$x9+DX#gbQQ1;BxeF@onqkjiQE_
z57Ggw-L6T&5G^rpf-@E4mDYEV}r~kj`K@RW4-Ai#eU+;t<{35QSV6&oHrRc7B4vGkh;G_2BX+
z%oE|3h*!$0qHI4Xqe^z=6Z+JB&P7p)49>jfUsTbOq=2z)KfrSK53TAZfS=Xt#DHcpMF;cs(dfH$n9|S-YEKC
zOLwBBx3ug)I$qnzyZo-!U+wo0NM8>RsOT5|ibtWi>HT^KLaV`4MO1=V4DLNu?pR#?
zmEKdF;3ET-E1Zhr@LdhU;4cYzvyw^ALYIL#K+rm=ihYUt$4Arvtk=l-UYmC)mF7fL
znvdNf&@IxIUOxTAMUNkSnl!CWol31IYFds~3KA*$&D4?piM98BpYr&{PG-ofQ~!kW
z??(#OhzZn4E2?}$|vi-c1Xepb}xNp
z`o^sf3F^3R*!qTSt6*F=bVBXV@*a4D#81XGJWcN%9JQ!ubA0&Jz;pDHE|&n!KgpRF
z9#|(&KmW7+`M=H&toDn~|LlzFk=vC0rdP(P!aq*9l9;!kv5--rke+0j1sTdNR2zW-
z8TIeTZ;idrP#+;1G}r-Od+rSz`vznF9GbaTX$4c5mZhals@sNFAGS64qwftzaB!pj{g=P~y|SBD+;H$ouG4@!L4{_uqq|Z`aPunJ_o&B0
zz=6!8Q5Nz`UZVl2(zj6$Pm4Y^_0-U2*V$k=`*eP8b)LTL%uBFuCPQZatfodc7r8}s
zx(A;jvY_t56o#7XXw*>apY|&XTI3r`r)~k(FhvxD$&YH{Qse_4f#~r>n7DG*et&L#
za=KV;6}EFQKYKcN)a)`^vc148YHfn6J!9uuYH3;wi?Ub>-MY9gzxBtDj2gREI=LdecD_b5KJmIr|8xq#0-0YRr}?k
z^*TqDacdB{G_qWokJCzl{VZQ%ihtAb-oqIlat5KS_!Tf7IT^l|6}8v9y!`b3tFJgB
z4w9H}9rOW;KuXK9o5f-CT305I4*~UrCA83
zoAS)>bvJjK@(i{dKo`D#az?#)>aSo|_JFnEAF?C$5g$2l3!60M86Fi)3O`MG=Jy+Q
z2Finst(0djK`(_mE|?I#9%#bC^Fx1)=4GdSG9S;HaK_PyUtOt2vtBi&IS8ABP#j7X
z2>K6ApJMYuP}8Sq`V`gSUl
zw#LJw@2vm+kJiVtH((=u(|V^Lx7J|27L+I}vO&DL^FJ{^wYK?%AuqB(Qi3I-;pY68in}3o`t?3ZDl|UhRigc35-FJ5Z~MPZBq*TO-N5
zMHCs~;+3ls+9vz*>_XamuT7X$p`}#@jc>v%%^`E0J=-SCl7UeZW-Uh(l!xl3TH;NZ
zHD7|?5K{&XBpArZhIeLv>KZ3h$w2EF;RBo2@+PTjQ%)gFQ$wArM11`^%P9>Ba3vC8
zbEN7%QXfj?LIvCgHKn!Gu5SpEquX5FlSbAKp;Ba0^Dfdz5;AQg8xfcD_6mr1=)V<-E&)#)p>%uxFa
ztaP)O`h019g~~S{wUAFp{Y0u?RzdwGR%`NG+*s&c>csvPloX9OD1HU6&2E5+bpR8a
zwno#|Sczh{1@uT$?r6##w`2cR1fvf3>nB98cf)JPlA|b!EAd}lIbvDAvbMd6LOed#OS$U?=IakYseCev<%W740hbo`3?d)6clAnIM
z6V5emA0|0_kg`mAjJ*fMUIO{!0RA-nDE}BLz1|hfrK~4i*XfO(>~qbq;D2NN^0$9j
zooCi~d}#gPPJ<94uQ?D`B3^S_#O}Uz36IUGdMglvUGr{wzBd@GcsH}?+w@+@V6G`q
zZGiEql1FGnsT
zvmg>ys)SSzD73@!NDU}-BmQFJi?C1xuhAQ_e{V{GwmE_t`Gy7ZlNY7ZLNy&NYv>K_
zAhDBp65zrHAv`y!-+=$a|4#sV*A`3IKF!e+nv2+0y^H*_sDU!Z~ge`Ju*c9PAb$vWZm1?o%C@!
zp0=Pg$K_Q1oEZBYJacCG!40G~`#}VLE-5>%b}QnWAnrMLCkGasY@NRQmxN%vfk%#llA&y@pH$0~cL4Ih~`t)q+uMh>a?>X?g^?JBw5G#LqV0B?h
zH^I;7%amX0IVcyiyRMgd)E8-oBQNZ?hVBHT&UI$=&_|9RM1UNjW-|jcYQR0Blh(u&
zzv6hp+M_i#^zVAX6o3=2??zVVbflfCQ68-|9oH(*&$UA-(Os{B`z-bZd^>@zbgBY3
zaNHiWQKI_bJ}bu~>v*-d>+!Acjr<^V#?uiY%K{%>wyqP8NwXU%IsWZUh7jJCKJziT
z%TqKV;))8N`3K<*Y*XE%8wT;n8hgDk=zD&`(ZYxK=TO+ke4=QDesaKuz+<=XC1Y!x
zL@~+xM#*&QyEIM+MOYGh8u)in5OxtBwO$-kSKF}$9Pktzfob%P508&KzbR=_$M)M>
z1dFltL*io#rtpY<(4#N8z#9tUyQwQDb{_0~=S{BY``-R|es=kZe`CE%a17L$XZ>E|
zR?d8HI1x6ScxE@OP^ZV#AqALW_vAME}=*w>!i@4`ZMZ`n@9gHTPSj+AdyCi}F2<`FO9+AU?e}~G2T-+n7Z=`>D
zm;KmJhW%vXP9phNQ#VEp=PDSan?&Sb3x;oRekE)pzU$>5=y{3UP$F-Pjd>#O02D0L
zIK1+)(VWjyC}L&@y@g>hcwluLm4~RMrDvS}hpC)Uk<;se$(BzR&6@|ICxvzcg0SHo
z*UOv<|tOH9AMzeer-v!Y?B*IV_Kn+pz2rh0tB0N@sM4P8Kb`81R`w3W^
z9;IubKu-D&R}tt{A{^vbK6dUb@(HKfs%8z@@^^S1gm)8HPDi9t`tox-nobX`Pa`kN
z&K%0%IBi1F+?mAAFu>M4rqDqh4lE7GSjKl$T6e6mgFFy+N1(A%PiqI6LkSHti=?Zjm4ODUa
zj8$&&k5u!8bz+?x$HV%j(ZKp=Ne_y-Fj=P9FL)B6f)3br&qa<*V?i~3XL2`RqA=j6
z`S?){GOYBbCl7!wUvbC)q53gEU*;Tf)wx!&!}n>Ag>vg5Iw;h8L6--002jx>ub3@g
z4L>-~ciaQr^4xg4eQ!FVoXIOO6r=UGM%iYq`b>MB`pnz#E*?P~h>F+Rk83&k6nM~#
zrEkrZtF=a^ARnqbka++j6Laa+=^}W%_V{oVl}`6|iquB_pqS$e5)hq9w98@h8M$sO
zhEBzWm2Zx(m1-cJ!gWRd#g(di4Im+#dytL1bSkQgHI7!|_t3HjlAw-UkTMuFiA1>x
z!C&M~9pD9E+($hQt<)6q$-m{@F0YeXg2hLZbH8y
z3Ef}*`gd#ZJqp99FwDqaEc5GhNR~-ptrTIU0zPQ&k}FD+E0BNaS`4tApU}9IdHey2p-!0pnOh1W
z4&3Y$t2l#bb^@tKu@(@oxz($=#kRC!FQ$rgbuxH08S(bE{fbSOfN00puj!N0GtJ9)1pP=qq&qRD}
zej;A@DD?B&cGV&tzdogxM2>Tj)$X)9$I$e&9OTb2B5Ah?n}$*d2v
zM_ce4i%^GP5ln&!2m4|UVLM;ky24o3Q6Vr?N6*&-nocvWefidibu#b>Iz+80f+Q~P
z9g$y^>HP_fF4fS{(JAMk;9rN(tA7nEaP~Wu4L!nYg|3IB|0_x2jxBp42
z7XU$ObXwTFCo#7{xmie?0{W`}ZlQPD^{7pnYWjLUbym5-C=diB_=KjR#3+id%mB6d
zgr`f=_8@Nx8#%zp45tlUU}9XtEBHS8m--Z8+yk7(FwJp0t}AJEzPB^_2YY9D^MJR?jhrU}9pRaII*vx~c|z;madma;9E
z@!ZZN+jrGDRwxIT7Xlx)-`s=Rb`8}->#={loY^VC7*LWef!8YLTk_oy84^enTHkPA
zQG>Md+*Jo+3AJF;0fsd{ApPL>F5M4HA71sCtV-O8ZjpCrsZ&f;zny3iKMX9{pFF?c
zBI=0&FvDDDBYi)*38{oH=e#iY9H6K|fdE55yuX93h08hzX9~zw0cW%R?EX2KEJ5O~
z-=MS0n!JSYP#eA4x{Szoz~b>LikGwKy=5Sjth=VG30n79RJYuOXibj@Pitt_bTn*1
zo0RR(%U^5->M*BMM$TlI5CjqiUW+^PyFS6;0!)<~1vRB~VBWA&LIkE;$Z$|eCqq4W
zt_f4VX$uA%0_`#U3)^cq$v8LnV-b5-G0_;zp#c!l=}C9bSLE)RKrhN
zr^Mi%WfE5dT0fx2Gw_33sMxFm=G<_R?B%rcywzQVVS)1OqV?y^W8mfh=tlO-#kUyS
zo#R%@r!ENBJw4vM2fP`{x~fOse!i=B);XRZG?Osria^Oe$9yCHMrrS%=4`UOmk+_I
zjs|eZW)tjWojCK{1NU)_onWd9*u`9E3
zjh=B#;LUjgi|fq#7WNXBKs_s~lr~^w2H4A(1Ql9Kuaod<6!?H`K}G;-nn(jnN`d+}
z1XdDtZ`TPZzk;I_uYrDk~^Sp|v1?QRpJvq_QQPZHsBmAE4Wy=CTB=
z0$K+oTxmYB5tYkU?;q;wHHmAem|K2AjEhi=bLti0GW+=UT79Ah3;@bbfjOQ7;51{f
zN*9vmHsa$)H6Vc-U>5e^>(v~kzBFJ~`C(TNzLODX0hmaD@sX$ysihRv?A
zho$n`1BBw+DzoI(c94;SGENEE*nAv5fSO_
za#4DBS^L0pd{TxRj)b5*KM$nq38T-_Z$LTW=|m8fs!$pbbF3&dkQ^L~x?Mnb!x@ru
zX-)ieGlFY)3=#$-b^KbQLKq_||Jz2R)o=rD@2NE&9$gKsWJ+)%w3X3tE3(UeYjuhr
z>TvIQcC*>9yBl4lC4^qas)CCqnrmW;CPQxmNX80U5GL*+x0`sig!g6Q+ta2l72UM4dih&0$pkXVnC{pO$3#7^;Pa6flyX~Sa=X=6LpX^2oNHMbP$X|
zD8s=7i8zwZBfStR-vDn91#zjjC!`or62P&wlo~-qGL|B7df=%I!7XF<6vXQwJW6pG
zNwq;s)Q_ol0PaJOkfv}dIu5uI;jvvl2zw+9VYJQ8H>0w9Qe
zJiy{(K#ZfI-V*6?{s^8P^nZwVLhKHDGD!oJGpPs2fb5CwVcai%+aPp6RRX5GC9r73N}ejqd&mEe~VL=gblSD^Hq@SFT+`fvc4L
zWH9OdrHJhJg52eFL6Z~O=-F1!sT9?=<(99^I%1R}yO&`O&WG%HJ4m&G)04hSGLM|_
zV_(jWeN2Aeg*{E2pDeR+Kw2D-m4xC%Pqo^=ONo4RywNG(^siZBk|@Nel%qaQzc1uS
z$&`RhJ6z{#8bF^Is1EWXz+sletza;qno)x5NL?@C*-m%OxE-LFL573Z*bO~Vex9ew
zs2_a8OK+eI0z7`7Y377--U|~2~B)RaJ;)=
z>l-X4UA#e`4$cJm}eByY$!jCt!WZMZO(<20-qqN0uUXI&b61ya3PiRAeLoeF`rVg
z=R5sFak{ulwa(U6zU=1}kwhUG6QJh~Vi*Vfo0kRCKArFXqH`x!vY=V;
zrdMEo7vQYgrJpYye=O1<)3XH?g$l*dnzg0v!iX+!J=6#GPobeEk?2(@?+Z7DOxMx!
zw)RRzrHh1&&ioEmw|m^d>w_xj{)_~)e#A{h(EggeR|57^t>aZOjE=J?KME)t@9Psp4eWznF6cewAtjySP7K
zM4NkMZ1`q5`ogEw4#TY2+ZKc3=Tr*TmknS2UFxd!uGm#rtB_DWOcjd1D>r{e4ArSgY7C=BDJ15Dm|A
zoplY9PDkOgdM;*)@H`po37K;M0lw4&mI2Kml-VjaQrHW
zdCKeGiXq=UH;gZDq6uJ}!gSR%nKqG{salGAFLsrkj1w!{C0Y=
z!gkN8>RaSB2)^?GriW;iQ)A5drlaM6TQu(Cp%P$T##3K-yIVhgdJojAf4A{0uj%gf
zFHbEuz6&eyATJpeYf0^An@2sHY+n`kRelnFaE05919MSwrrn!**W>JG`?_tvsv_wF
z<0av_FW8WxCe-E*taC4haxfRlYAI`LFUx=HyWPku^^m!Do5TM6GbN6&h1Wam<#YH4
zCjh{Z@l~c@0Y8;)8A+AzXZiuei(%BK<`n_l^VmaC6}s8;m`vSjnAyD-w_XkT<|aFD
zzVXkv?x`{{^(1f(oFWK4FLU}j_!Qt){Cn2WKQNA`ZeeAYn^H5
zE)YNnHUSe}7=!8FN-Ky^=}D1qw8p(yxYMxb-h%8N>)x%tT|~jT|B10b9|D;01FiY2
zsBNPyZa91G*|!>V$=ZGRPanxd4a*fGwl!=--VAT3V+&B0_99r$u!{dV#RY}fE
zo#W1F>$r{oi``s-q8W32H}6BY$mJ0T#lF`A{a^8An&DRvHd7cZyH3ouu3%GWE|vao
zaK`bb91!9`h7Zuy2hFE9FHNJ}Lnv#o)=`!>Ugg?T-Lu&3?w7y)e?f6!i0w`0`;;0)
zf@Mc0kSrb$O^IHGdgxCeC4gf|mfWCgX767$3q3iuKL01w4PY5dEQ??M_K)^Un8wy*
z-dKZVTdn4edMn`eNgdv9G(e&mu6Zw5D)xB)lB%GFp*0EX3|N_xMyTS?38x?;Eix*>e#j*pM3?&aOjmZJ~c0F61|WP#6nzVyB@?9o!Rg%9w8CBBU`9yKlrf&Z*Wl2Na87i
z6o*4XCHRfY7`j;yl?))I6c3`~*D2V%he>k+>N3b1)NY$)}aF%rVh(<9`
zUAnmNDKGdxlW(|Usw=e_^1EjBF0{I{pHzRPG2P+^D4SY7AKp(=4K&47RekC5O_7RB
zkG7-k9Vw(a!+@04Sg{NVc;68dDvP`5Q&v8SSak!hX^;ug(X}{MOC>ujQf-0=1d;Z8
zNLDyak+Nc$JdUzM^3~G2n!8f|;%T-(R3gG$hSXDETy}(n1`t(Fb>(-6srbrzLIs8N
zdB!kdgMSooC77(tYNJ#M8rWgnLgF-LohfI^ai(yp#ZD7oWkgVhZN^g{Y>l2yTr4je6TSCimof<0OH
z+O=Ps7sa@MKA@0PQmwDOr!KcBj>ThE&~hrcM}Jdv1To3WfCVef}Lk2(D7G
z!*nU{Q3dFYHHC@}#0Dq9WM51_TK5F2l2VD~+eDR*H%aN6P8Y1Vo1JNzliT7EDa7wk
z_i{}SLv!%@Uq4wteeRf_pI`bJYhX_;4_01l6~b!v)N1$G9oths0MmNQWf~Zhzz%2x
znT)80h5IYWWGX-nZ>a1~LdHo%UQ2tj+eVpS-$8I5Ax`JkK>it#^qM~A_O*v^AJ895
z#!D>RH<$CW-a%~9>vMW=21k1^Xk6=T2zAWgT2Frina+XNC98YNfRJFIn9xO-*0=WF
zot?G5c`e&GQ;}NdHavY)wEHl*@~DRwAW(ynEk4694eDp)YW(!`ze73{0sX`qj$)R)
zjja><>48wsq{xqSXF_+3k0CFkET;_td~dR^Us~)v-(npj{-O8I3Bd~OTkXSR?epgS
zq?dGgq|MJAIblF=b)gRq8AeK75AYIOC(l3s7v5w0#pi!^M)i~>eh{*b%VhR9Uot;V
zIH~4J@(s2e1(#XF15L!gME2P-sAH0791hVOmIXr<8+akrukk
z3u+Vh~*L1_X$o`^vzJ50L9NQdBp}Q&#J!B
zAasVrrZQfJKKpcj4wH}0i>D^|3g>%6Z0G~eya9KyK`EL?5W1L
zWK*|UPP=qzdXtgY^6
zRSI2Gs>$TEWqCf%o>P*s>c
zG_vEVaFv-;gG%H|7QE0$X8mHwmIhLVrtvryKu$c4>PKWfciAu&E>h<(R;YMmk{UnN
z22|Hh>*<^3$C^b%CT5ze#2TG}RDH5vw-sevrcd
zEnB=5HsMmy{X>fd*=aM7Vx;umTxc^=!(%VM%OVyHIJ3?%iq{8pXQlTAz#B2cSk@Wk
zY`(qxKu`qUZ$=)PC1uScVOx+cLzO5DUpvH^9Q6J2*MIv6z{@Xx{rkdpW$HzcMr|}~
z7~KOJDWalME(N`2r{@PD@-4n6Z;-VO_a1p+$vEQ^fLAUW=YR3z-z^#Fe;LNV%SXDTfv!55+yl6T7#gCuH!!TEHU&q~
z#*5@%Oyl+g3J6%RETILGUvY6gxx$j(p#vdO^rIYsq43+Za!EN
zN)Xr&kdINb51&_7KE`R_#ii<|=kN%j_82_dsD6S~h>a7Qr`!Zm{88o*^!O3h^Vqq<
zEx}|14K^|qOVLSU%58t%j=^uk_l)k_Kd(fpX)JD($ICn10X>oKBWO&n<;IsEf
z4;we}ppxC^f3};F-F8ZL2$@za&rxut`YNflxG$m#;4K7F(
zqFNH`2)s+$`D2$$`Ug&ZiYxBmxRat51^kLI*0Bd7foQtWVY1X9P&!PJ892EQGN?;_
zW#+tuTG+q~Nm4%b2u(i$+c=I@9L3HM^#t@tQ7XIB->|6xB7uA}%AQ;?szoeD2_!gd
znOEL4@b97kVQ%cUUL0F{$WV?uzoDp&K8f+7nky|`VMx{Yd_e3l(9+}ecd!6M&u#X{
z*2qD&L~oeQ^D_7~(yMoDR3)zNOcG>rRQ3;}|Ap^Ve62XoBTQik#Jz7tcfc}^qq;(F
z^QDCh)~n)p8S_tSpDLcX3f0?p{4R<%>{IdyIUJW(DnfM(M2vDKmTNEb~
zwRR_R9Tx!NO6pJ9n*Nnr12XX=Ea8ZBXvKF^Wb;OK)q4N7q;Oh3W&W5ozUqL=6fE}YkyR!BOyrWHEs>8X(}5K#
zemMK*s5kOm4{c?gY-Ss2XdS2qdZ3<|fC^w{6(>)3K&(I{7tQO}|N6_9oPIL9z4-N~
z8x2w?m&}hz)93XCypRE>5U)MAqx;r%r$X1p>59$__sEcfp@j-qXo`}Z^p8+3U^*NY
z7S&c5oKd_S+jh0hN35ShXgH$_4MgwwRh0OMp6QRb0&pX%93&zUSnXFRp;@X?CT+NQ
zHdITfQ7loBz@cSVB!pEDkH{A=L53@zCR&jXHu`~hPU2>wTPGo&)PY${(!|6?5(*5L$DSU~QuY1J*}@gzyZWrLy>J&VJ<)4+`N);Mi%RL64(VE+WA6;DuC;EW#7QQ$pC5vTHaxl-TDLHs
zPHp`PAgb>ZZ;~KfCfH>QJ*EN0&h!Vd`F1CDif{CKjusnaGr-nqVytunT)-iLP^OgFOb!Iy85X
zu8m;Ln>ul6RraliVnP%s1!zR@5O5g@mP*=UsyrN0-7cQ>%8gM0q)c)Y$J2F0^yW7h
zjAWSf#1e5qaiN4+64vsPiUbXDyI)+Q4gqDo%n4?iZE=`8?N&$5r#&x89oreq
zyLC+nAL5BR`RTBOmdcFBX>Z-Eq0&g==`OoO?X{opu!q%Nr?bO%_jK#lLgn6HRr%It
zW789V>bYvKm$ol3~PK@VKilyt`)C(H}6R7)Tl`mcK293al
zK{O-HQ!%pC-cp8jKtLt&S7RrNfEnT1Eq|6Dp8pGW4#NPLP*M(bCgS6u45k-_N*VZA
z;>Qd!4RYyf{(S&@m69-R1Ni?1{$X;lMObZU?`eO3_Jdz+*~swAAsve1Plm8ifF4(l
z)vn`pbzwQw?284G6HW{lQO87Xf&xbzVu(>?-sVoQ^etnK}^L#SW
zq36vf=w7q;M8^Fg#2oL&Aw*e2m`)J)37hf2!3eCttExu^>+vJ4R^SCdxN&}6=}vB}
z^#j+=w
zF3qTvije9y%@OEeVPJ~FcFUF^g)Es}E4j|Z
zH(>3;UL;j*FL~vxMp$Te@^tjm*CIAxV$1Y0!E&@3$m3ZwIz{VkoS=hBZ&4WZrn<)n
zwOGkqc2!L8`!yOxND`IpUe7Z+V8Uylw077JKti>ii6g@W%rfhA+1gh
z+UUqgS@dPa4M@X!{_4U+lCt>vW9Y&GQTOsMJfb`zp0+!Sj)?Z@@-w1vSz5z|K&jSE
zzMjCSxQFX>uqkfWbMK2b>_sn(Hf;IE?zj6EcT=(wmnWjK^;Q98YLFZGR}U^#)F=>O
z40*R-T!gQ^x>196;TIgoZ#ha+;`m=pu&#Xt>}=S*d!cpJ{@$4E-ruXCf<9j2{$arV
zf;@KXHL!i?E*@td%6*FW#dEk|GZEI@1ziKl`%N&NU76Agj%Hl&C2wg<2_<
z>5;QI(*Ew9DEbjnm4rx0m7v;ubp@#_N~cpR2r1PlEFESb1?belkRITDR4m_L{*g?g
z*`pqwPS2k|YqeqHBrV=`zQA+7rIyqGGiqb*yfUhRmb1>=pE)OaV85z^j`8?WW`d>j
zd7j?3H{ySg#zx
z1Ag`PVrzP~9dIBdi>?P8E{T6s5ME7BbKXYrDSQ+jDpTK$U8<=I+v^Cv^^pf%TiJ^j
zuJenI?vm|sk&jh9qrVkP`5Mn}(FW6dAlmoN4Ckq!+STFpP8%rPkYkhiijYQM$gi4|
zvcl5k{Ukd}On2<8FV+}RoQ?G~UJRU#jRuJMuH+t^qPct6Vou1Zv@gDwnMFkU82YE^koMOik0Fid4z;itct_HPs3_ikiv08
zRVsMuh=^MO?58y=@sTbypy0nFwTV~j0&Gr;ujLq?w=;LNv(o^g6e-5o2EY5yT+RK?W
zcnQCo*)~*ld^WSn_6pjUB};|4H&IO%Wse_eb-k-FDZ>OHMn^ot0n;lSKH^O?zZ?W4
z0Xr51bZnM#Vp&k5S#e61*=lYS581WuCeuUf;$f_v8aTmpmQM3Mp|~3`pM%dH5Pmoq
z!O2QEj2=W3S2?RGv@zkER-vLoUbs>m84c$W#T(5Huqf$av6Xz!W~)J}!5ml+^vIRh
zjGwb6Y-zw0rI50Q7-6cPPV~k+fa+{k0)=%sog2r)UJfZtaxTrzZiK^>Ffa~aI>
z4CE8g^^kc`G6tQ@3UqOWY=usexD5>jcG}`#q=?nZRTX5+f*uT?QzamULu&>kkOe@q
zzl(hZ2c1e&{r(()FG8GI^YlX#`8t_XYfaNDMBhK1pIaTu-6_1QBf7s}A)$oDO&yIu
zpheI3{KeCgeXcq%KRBIDxvW4P53XN_%l>%&>D+3cyf}TPdsf=xUf9ZY%F{lQZv0uw
zAvHjYoi{GIzl^Y`Yt`-Lqy?y3zAPR;0&BR269|H_jH2z5!F9HsinLKObxFAZ*#l&7
zLR5eIr9(}tmaNH8m{2-T-nB4O&&cY8gA1Yjv7uF&(Q&7A&3MG}BgRUm?rh24xAw{)
z&16%*zt*v?tF>4MRN7!;upUHX17N1=^AQ*9g;#6oGTs!{PE1-f1I<*B((L;yo5Jn>oJnDo`*5*(L=}NAf$7*#RC_k?svcrc~fn)p7
zI%~R;#S-7+N2lgJ9X=@)2jhkqb$Nzph2Gl6+O~S*9@f
z=DX(#WR+lxP|&}1dfo))neajY{2e$|_3NM|VEx
z+2r#>C1*kZ1R#icCLYzP1BvmT-C9J8F%G5-QI+7Jj1nghKur8%I#c>NA)f>^??bd9
zBRKse2(!6W;_0`*iKiM`uJb|rRuEO%y^0!dIr
z3=#|oNTOG>I#p+T)@PB$$^K-j&SsYW0rMmBOV0DW-vs~(NTdirvYVMn$1PJJ@Zr0>
zm*-+UkF>Q0{8+*WB9n{$JY#fn?5yLFxRXUj8|z7&lsCY0Lc(;%X}x*Er3)J;yCl_u
z&2fiRpUGHjiGvY(P#`BxVd)jdb6MLcOe~7^sR~V$*izJ!OzqlV;YwvC-{xUq8^xsh==M97D(
z2i6x(~sW
z+aKHKC~<%ww^hdynA-MSEYQ7MTQ{b=Jr}Q$ozYYP2^cGlfZJ{5y$uNY`|ln|-dik6
z^}(3Z<(oMgk6%3Pyx2_kyX+)uLc;2U7Fddnc{XSVkQ|Em4nP=v1Q6%t=jTXlA)H`}3P#}uxYD5?jkQ2;*3o-Ll`+&RsPlyC
zzDR5ZZZC}7IE*r+_gZT~4cPp>a;@2}>?>wu44ocBgJSKXU-#LvyaH@k;?uytoG2*C
zECG2Q1totP6Ty9dlI`JdYUf3^PINS*pA_=}n((5irudNqKY-`~CX%8}&VIWfY^s0k
zNV%IcSW4cA17L26eH%5I^DuxDgN)#vE38@fYY)E8>(
z9Of>NA8V#bMDB0xTbKx`;c2fZ5k=kXO#hdh-vsS}NcoU!m#K<-g%=PSxO4*wUASKD
zQ;R#5&#g{2Hk96!lm<2yP-&pe2j>l=ast&a20`KYk;yWAQ3_0O+LF`Q`zUUr%xXlk^37i%r>!y)K2Bzp4Z#+dQ06F
z*@W-E+n(3k^SbKuTG8f?U*KqN0!mtcmFQ9VMU+;{s~3f-y&kpT8(mCr-=5do^Ll$;
zZ_n$=H*eqEeFSckcF*5}ingGlO}nMr;_V8>+qZr{3ZZov_TYZyO|E>H_`)v-UN*;_
zFMscR`LDBG=kOSR8fC!r!c9W6HW>nj;1eBSbgPE2fWYU0F0is=3ew=|AFzjxp6`YGRe+CDs}@}SQ}
z4cmjB4tW5{K~R)ZpaE>Z!1J`~p;x{_PpQCbs{>jn&iDv2+Rebp>m2o+{c5FFEOjTOInb_s2y6-lIMIOnv-Tj#+KTlxb3SA%?
zy=+-`7|N0}sCL%fW9Z7%5yN&X0}K>ajp_n~FZ(^#Vs!LYSXY%EWeaGBZLMuvYrEZ0
zW-C^+ilWaZr2K81vW-*1$v5Ji_tn?h3h0kDMG+-_@Kq+R1dT50f$lCcwcR9u++#(3k
zwzDXT9h8``64Kkw;s*7x;uHL9;i4+(@7F({onCx&{_V{9NZsI^vdXsxzx@`@{AMWh
zTZqsWBBUWgTg`?o0;l^gH5jVBpLxk39ETI=>;rn9T>6u6=2n^hD&5>?&rgn;!{1cT
zfUI&vzQOYU_CVZ<&d1$<$+|z@zu~<~9e;ZuZV$v?%7G}lvPyz;5=Wu1u|yMgGV*&q
zbYBIPjJgXz%BU;!yx471NYWh}jI#Pj&sVN*vy!B9OJ-SV6E7|})D8ICp0L{!c6-9E
z&fRu+3f}
zfzHC@&>j0lRHx$j;QQ~k<=kyK_YTJAHmlucwY6lmbt@_;rN6@$hn)tiycM%7i}&p_
zAGTx|g-~DkfBd1*Z`3~yk)K_*g
zVr;D~Kw#fMSDFCc5dP%S86+NUAjG$JHVr4x%kV;obo8Os0n?nA9`YA(#|;J?EBven
zzie3ef~zY0$5|}yH+I~Jhoj{PK8Ea8N2QU1oB3{)IksP=Gm&Av=1r2z73ViglrWQ)y!*k)rqkO%A!TZ5+
zKl|}03di$4UhA=V%k2W7=SGAB$N~CfeDN2xL2+Z
z1D`;K6Mnb&qd&tvOtjYqXIlhEV|&?RG++gc*n*}BUP|N`mziY;y?d8<%R;1T&%bU{
zA@R98i~WJm`F}bQ0VmHn<-K-ZUKUqwzVgNjaMitg|6nHIqJr4bN&D!TD2OfHLb8z$*6|@_!Rmgl%3q056|4O?
zt+E((Ehj0C(J=P=o*Wtje`svrcy4;$gaJrik%S$AYyJ&SQ=H5^dPUhvnhDbY8&mb3
zOpB$Z+6TJgpz9?XD3IclkZu^cmp+c=+MhvTB~A{XpU5k!_>s3zcY3}
zhdt@Ws*lcmfSvK*xO;Q})vm=K9(LM?hl@XK9Xgi|q;lk{h$;{EPVj^L)t@*w&XMC^
zIUxoBR(nXkBE7cFSCTt_`^{y{kx8ardnlvJ-oNggpC8~q=jUq=rhabRL=N=)m~S~H
zp=aLz>E}4|0I3_d-7CNN-FIHJ5B1zhC&cM^YQ&oStNa|0SNGAs^t2Sv(h`4w*H!TB
za+}L`j1AADf<-Aemd-D8GBkW+>BuZiaHjbFr0}&?oMuDa6tZCm2g6A)Ury@RoJec!
zmg#1_^!zcl;?F1|wHNoxhuxB%E${D-V~*dlS3c6AT;3Lz^g1>^kBeiK-Ks0H?_t(!
z!P523kWB)UlBHHWKySuAgaW;Bn9IqQ|lmxZ2>2%AshC%oWavNJ1+?uJvh37f%!kDcPc&;~b(i3ygPkJsH
zrvGxSG-U#hfmhad=WgD2S?<9zQXkw#2
z5d>iVyX^N;EF1M^{>}`a(|;?SP?TG6*h3vO)3)u2h%wXyOs{c&!+ppWQyU
z9XCArHz|gi@o&t;i0^;je*X%%0%`iQESGpiQ6j(~)xC=1rKhH^m1jmrAQtckit0Gv
z!hYEAqXP^T_+*Mk@UHW6*Ey3q{_pro``&cqq5?k+QFjMSL_D%REU-a3&6icQlNo+5
z2F-(CR(Y4E_&E>vUsh?Q+5JeNi-EFHQOh<%QNha3uv7*iqJ&9^4%Gl1Dg(X2u%L$?
zuN9fUM@9pUZIM22Hm#BR0JrI-`M7qq3Cn-%p)S34CH3WUQW|&HuOc58Rgv|DTvOzf
zdi2w0C`j9CCu`9iv`B_wfKV4Ryf=4R9VuGpe~o4A+;1J*3ieT11-k^NRa|pl&iqS?
z4)-4F*3Tc`q(SX3!Yr?;+(pF+TNUwA$zvT0eapGz^Dlot+~$%roRCEr$LM!@#V;&^c2BE1j}BIVw7#JX?@4?4PXU`#b|#7c@Thx
zvcOyoX@zVh(5qw2%RX|wIFSiDbG$2bm;hKp76`-4{;;!h|3_s(!j4kD^tbexu6;TDzSHo
zpnE2Fwnv0qFh>H*MWltd1c}?C?B8P!D5dno)+U(>=w=
zaI`*p{SoYhkc0o68S&QX$Dhlw!E0bDZo7x#pbvIODk;M)U}|7SHZmTZm6*{|6tRGr-@W
zs3RY?IT%`V(51aZ@@+?)t5tF}%+zd}YE~Rp5*DaU>826)1X;W3k_NbmH6AQoFTw}p
z7Puf5t|+KQbz4PMf^t)c(=i(B+5iiiNU%aauvSOAg>j}O999JvG;)E3w)#?|8w)%_
ztsp3zsSV>1$`BmYWUuvrfi}IjwO;Sp?yKcYy21p1vmtuSukU!b4D6AjoZ8rC6g&!9
z|EB9XH%yjxq7jH)zQJdJ(F4+aMdk`RsqI;
zaIoy=)hLd?44K=Kds|L#n?^M6mfqmWK?QfW3DWSiG)8`l+-n$wTx-S1<_E)tmqsgJ
z3j*~52vkt*lLA5&BR98yOM$-aNsCJW^Qtk4^|SrWGa1N!BuGQdYbQ;`Wu?{ra~_
z(p?z4H=r>#GY={o;KuKKy}=a*CTQ614HSEw`_HSCHi$QsUhnRkc?4^Ig?C*7sp&ra
zCRKK4taE`8prpq??YB=@_Vy4x?kw(Pnh^$@040q7`_2Wf73B~zkhgW*3GhmSein1BS
zH1DP#B!Jv!)#Fp4G-r&~KUyKPG1|ZXE~pMRX%&x{ZD5o3wCMkb?*>u<9bM-i|MPDh
z$fJ#)IQ%*+^qwn3L#4KMJ%S2w2IdQx!6#*TD!qJ*!`MY(n|CL7KMH~T5J5MgziX#dcY48G%`#g#Z6Fvl)?v@h5%eJe_MEvUkCAT)sqzDlN#ANs
z+-e{(5~FfBQyUE^C1;hAJ%Gf*E*yAQMDWQ1^%Yk2)^jR7N$%c&8`{ubRXQw`y;^4X
zsPof4vJV;?rBn6clRa}NXc_^S2LU(i1eEFo5ihNjtVNAszPPNmQF+B=I`I<9Rk_V-
zjMO6jvKF|ctX1>CCBo7U(!=M5Wl*8k@q?$WYw2kG5n>ifEVydQS#hG4Y0+1yy9U^1
zwU~|)tq6VlpcXyWrtL0Qx~m{pK>DW9
z*yR1{Bm~R{;g*CTATXgo=>UZRVeVS3_IS^Etuhl^iNN1MxDmfh08#ou(nb~|tz8G=
zn3M2k&P&gO^e%QC*J|$Z&lW6>-^dV%71IRJI$fv)SH*;Cf~{926$64-TJB5Ho`~+E
zsUkvew-zj@n}BjjdYdS^m@jN(W3GEsO9#!An1t=KG-N$gZ7dT&4J%YI^$2pREd1qv
z|EDoNw13L;%QHKGb{9a*eFKHgAUi7%fD33P00EtH|CxUQzB2t+Wy}~PnIEChg{*Gk
z4%Ph4Ssq`au7sQs7~NpbiWTmkZyH8eAV%O(=qKSb$M$ZJ63|Eiv>_ow_)rbfls|vM
zOq&^I>Use6QcO(HISS`xZiw^4m;0-wDOY{zv;z)i3GY4
zlQ_p!pw~_!Ne*l-9?6N`U4)>O65THh*oMK8#txp=7%f|)9r_El64e53r{4q!_
z2MG*=L4&P5f#IuZC}_&-!Xdt=q(kWK*E}+div(l9H3X=ls+M!5gs^BQ&S*&2pm@+IsaiU(1l*
zx^{aW`#n3;s()Q|zpXak7M2s*%c#h
z5my^3NG64>ct~n^v)w01h<`pKTiX(>BM<2fDi=@=n9pJ($sj!jcFx%tmB&{}N&gPa
zat7u2jmA6;RXLkIZk1;dTfi2UtKt@V?XAz29(foTH>nZj6C>XCR3Jqm){#zeE=$&I;{ycMF)wh9AS=V6ha(Q>Srdn1_3$j;zmEws&fa*
zAH(6!liO}*0_2Cj{)!j3SMO2abn)uhY96x&AP20BN$Gu@(VsI!L;#+CPGhsJRAm=X
zGc47jHlg4xi-nSG^#iSd+(N3}BCP=!5n%@@@=rmdmJb4yb1DyKi&G|?h0~cwBp=}n
z2;dTwVe!Moe}@!M;Q4U2^J~xIs!vb5cpx2JRq3wQEpx$2yOD+a?1Py&ee)#C?Z7{J
zisc7?sOo@|WrSTFS{TczULHA+-cNNQ3n;GZ6Hwza=zqq7Oz*wx6Nc*Y0A7ZJ+#eT>
zbEibNTZ?wv7nFa4D`6R$8-R@>>Eb!C>#VGryaAWC_`3`8&duxImu>)01K(X{GFEP_
zChG6bONwb4O?bbIF!rtzjqnW-JG;fatP1?(35lt_Zo7z+cN;;;L*8_4m^{*9+u@h&
zcm!4dV#s{S&eLfE_D*LHLbq+Y&x&`%e;}1$!Z-Jrl`=Uc-hkt8Buka@l=Ro~kg9Sq
zMQsLv97WK;2bl+w$3tJ#VvW$N`2=d$0vK^|C&vCd72<5lCZS4zc=2xd
zGQ)^s@&-u@KZM6b69w6Kdnvvg429bBFjccg5^oVMfZ?PFcMaH69a^%vX7t7Adt>0s
zGupZqC$II3EoF#QgzCva#jow?>$lJ7-1P`bDCfS~UB%<}!TY7`KAVkR_wdf6wT{;#
zn|&olE)PpdD>+^tscd9E`}iuP5A(NNO_;lhYENgkj1&YT^`*1)k$6H^B#O6LdQe8p
z={$YtVJo<^xNH4n5mx4eP_D
z-f+|r1i>glq+D;OhN|zWNwy9_mSIHVF+hOg~}TOQVD|OP_7&M7-zP9
zGn07F`GbdcW6>1|BqO63{}>JvqL~DE77o@Lu{z?1B2c3#z^F0YFf2OF5qZS6L_9NS
zwdeF;94J6=png6n2NDgSQMMf}_yyL6dQS$NX=lDsn|TE#*A%=y+&qxaPH_hYwy(d6
zuW|XRcwG>10@#`_i(Vw`TsAzxPi_hL?=ity7ciqqPyi|6V)6-#6QCGg-@q-@82~vz
z#=rU)^I78Kf$;}!Cs)3AExw|lHz;y6M@#+ADH&Q|L`(<6g5R9NRgvxyC`p74Ml$d}
z<8=evK12&y6tVfj_;%9o-lbxM^On@FSvUk;J@PMofd2@TxQyH}EMg>UxB_%llAN-c}WaCSFf
z86O|<5nARg1sAx6whCLv{QH3UXN!Fm&b00dld9sKsAOZP2M9}c>ZrL5N6~DRXUo2DO@YRD&JUA)BhS&ab6SwK5Xgaj`ZxML%lhZO6PZ7
zAx!sqdB3i*llPT7L*oqDjV*9E5=}GZ5ib}-h>C4J^1l4lZWjrfk(sdDY98>dX8JF(
z=`3r6VGEHy_m{uo<7R*riQh82<$%K*v<7nAzEaAvdleFiEO=NY?&l45mq4#px)0Gk
zzEnF&)|MG{I|mKCveOJAQ-lLBGR!p0ZjP-TL@>O(6#a`?&F){`We=a@FX1l)CSI^I
zB=41k6mpDs6YgxLJ?t$hL~cO5Fp+ww3!%BHH4w1^S$ja*#g44N&#jp!W*4yJ2~rxB
z$?Q2lo1i9taao*Zm}J3dqE;pf3jJ&Ts2ekJ>JyL$<^2s2RUDG1&W}x3Agnn;?Li56^4UM`T(uMMrybO*;
zs_d}J*qUes3ndkLU1?yO&Hp>MwWaUz5?OIaHA)?eQfbOL96PViemXygal#a5)!2t-
z-le$T_LI0B4u?-@my4pJRwHHZhrLWHhb=RUQL#p;2qF4J;67Fv(kSFUk+N5Mh7LR)
zjKbofVof{;98=h+is2)LGPnPi#AoTZM4vZ{8j;Yz?SJxEN=DSDI1$+6)T3#>G8df{
zZPaQIa#A3d$kaX(I<+Y9
zG&8CMWqhXfR&NsVG$T?{FGiWd#aL3;lsG_aM)JmmQi9wZ%xrhA0Y@|1vtq-jEhy~V
zB9vQMR9H3xie6xj*F|6r*MYoC(M&3wfh7|Uby789^0N%(MdEej;KoZ(!!7PSD&Ua7
zf}u>-U0km%z8Rp+gcy%o!&|~)8v2lf;@ZX4Xag?ARtohX`(TmPBg>6p0#XVnP|BO<
zYsNxNW;mq)zXKptYNfn0&VJNlKvskAHt|QsM3HA!k!)DeWRf^cG3a<(`XNz=wkq2h
zaUL1o%pfkRSATF|My|0i;Ea8+?#vhbnm5aFw7fLXrI6C=84O8omYNVrscD`IzD;|H
zTRch%0W@mm3}qCih65D@md&wLG%XO@2PuN6vExmlq{lP8;TA=w;wIdwVpC=gNQ9#o
z;4=OnN1E@#gq6A;)q4Tf1Pl_Rxr41AVIBHKJK40W)ej-cGnmjoE(5Rx$^{-ArV8jWm9CuelTcb{V{e@g;feu**}_XcFkpKk9DpZ$W_g7BiUl=
zauHz1X}!TLOc$KFhqgL6^P*Z4hS?^QgGBo(C2B~xJFSZ+HSW5{4J39#w&U@1>-d+QH*1G3g%sJhu$@IQ)~Tiak616kCUH3t5d^UMq_cLaWu`wuuwU(l
zKbv2T=S~aq%p{>g$J@?U)xuJ1K?OAWOkLoplCp=tX9<(aWw=dS_Q$E+M{<
zY}BV~yw+CN-C=Cm6C{-0*6vivV*-4Z+W{VE?OytHlc%hUH
z@uv@Ycme0K2gdU>K!uKPZUKOxzloPsJ7!1imVA*PL`%SVE~Ll5SNYt!xOxa5h{?Ub(7oy~vn20(P$)H_MUml|JmU
zhG|9vSZ$Ed*k4U<`W~tAkFGZss1=@D*VaGZLZGTFb&(gHHK8%ledQfwR3yWg8helr
zm@v3a!DY2KKktwSzsLJJ1=B&EqxO48rZnBF`~gbnsC`j)=pk*#v3UbORmipa1ITUE
zzY6aZ2B>Pzzf7V}qcA{VfbCS|5ke^&Rl2QqwNeRMZqNy3k-ZJ{3dqs?S5d%aD^4H0
z?!?7(>LD3cBaiz+oT{;jXy8e7(T|e82xf;ktOHhoZ3>MTRFWWY-eP=8!LN9tOVo)X
z`$B-L_3jp6i!AwP(hf>8YwHpn9;z?VVT!76nO>5S&ZQcbzIr}CTWpxAFEa2;4umQg
z-TF+pC4sdeR0R#qWL7$wqlFAJLG~FMPnDlFfRu9nol&~$483bMYRSh!`C-=phOHc#
zGHYW0Prr#?gt1kSp#hrF(%(&qd|Jp>r8i1JmWTz0t8bWtAm0&*KJd2{-f8Ciq>^Hl
zhL~v8P{Gts@zs-X(jK}fVGe{uXESN_>Wltng=d+uwWe;F^ekx?&2BGh|47&v8@K$a{6a7%0B00N7^z-B_zrR9x^5A$kIdQB
zGvRe|JXLW*t$W>GK%rv>25aCWt<>*z>`sy)wrao&WHDSONdNH4RJQ2$AzSSB?WYyt
z&n6(McCvU$Vl26?*j(Z_5hEFe=rgGvM-s%d8k52%I`}WCl$D*{vIj8glRI5#!KcUQ}_1>5%Au+>d
z1~DiMcMclFN)*>C2HVGehpIy#Em|~RQAG9FQAVjtx)xAd)TJ-ZdsUoeWl_OpIhifM
z+O8~B#^@_qG9Y)=FX|IT%NBwML8Dx!hbMjV!~#)L{_#Kl*HWmH6+^g33?>p@DuTGaWw$9s}{?VQv$um$Xv6
zv$CGAOHM1n%3D{WB2j`Gq-hYJOFcroY9Vf@Aw9;x0Np_xB#bx7bfE0E#5rO^$Z!;$
z2{yQRDyD5_DRLst@%BI-DLhg(Q=rM1blrMjRrF5e^snzRvSwYS0&klm>vx5?h0<{K
zPf{|K_YlP3;SiWWy$?t^K=_A&dqsgl{A7U8RdSm>2WmoSG`o@h?8uK?q|W$^hzzNZ
zkKyeZ`vnPn4QryXPQmZlc-ls=b@eB(qFFWx*i66`V8IDsF+e>MlpzMHphBQcv77Be
zm>xqdot=MO&91TBqcV!{XG14sletd(nPddsW*ECS6^x)_J8wpcPj|MZIR{Fy
zdjqh}W0`eHgwj2VW&YKscU0%VrLIq`k5@At*K!Xod85Tq%bhY!Ykl>3kc3ePaOni4
zOmd4;`wXGKE@0t!b^}(YC2NJZ2u$VUVrL$pi+%0
z9y%oqR3^Y;*rMu+1BSc0peDbioI8uEh(v@$Q!vR>{7qa
zuAHApNYVeM7%eQpvI3ixi?p;)(D9lv=6F;qCGI`~AMm5yGXL~aH?9>3mrW7(v6(oI48eCV`S*}phF^n%*8(5
zA#lE^S$}Vy_SX
zs=0JC_;-MGd+D^$BRM>1AD(>qzh@2$T@x`PA+$Yqj`-8vv@OXjIs(4uiWxW4=?-jv
z{7LohhTS)E*NwcD{<#|ks_uJI`P_Ol=_e4M!QeMAzbHs!02ton%8x>1N0WHhIqrP<
zd*{o4;Z+_U<4>bSN&=xN)sFx8wPnxiK28mH3Pyc|tOZbL~n;I=;k>oGXm8jo?
zV@X}g#q^7DY@z9Ue9%6Ap1p8G(z_a3@k8yRw54S#84qg%B;*LTq^BW{d9GnmF@oui
zehJhyGL>h34kc(M^dr9{;$IdskXf857YFc&K$$6tk&wby12$iTHIWsa$I=jB&vjlP
zFW1m3`?q`pzu?tvR<1ll86WU4jTHN{2mXp*+RCl!Bsl$ecIF%%ojg4#uS3Pir9Qh8
zuYE^(qw<0tdLUD9{DZd5zNQl|0Y=bwslmX^j0cBc4KM@4sEw+32t)|s;`XCuMLv{4
zR<7LS9<3H-+E%R(TV|DkdWN!j2dp0(Vzp^(x1|7RnY!$gVkyWPd`v30VJK>X@(&el`ng_~`S9xQ!3*;71I5#D(
zdYkQ{FVXvwo8EQs$9R+=n!WVJCt7|op7*KSQE@-0yocY^E928%dp;=F;Ll8gNU9{d7mUB9t5Y3Ii!-rgOhB#xRg8+3U{!E)_DlL<
zf*K+qpbD@oN(dtTqkc7=18Cq9vI}(v9(zK0S5TP@RyUn6JTxIEfzpGXEH0FVHU3mj
zLV`5$=ol0-2?qmTBe3-lLlFX$4Djt+f}!D|K?NUHjtTW2B5@%y9Asl9D3qPk>Q^#N
zWvOwdm}QN^x05=fPL&c-ISG1xNQp%|H#8>M>VFx&?Re^ncm`L9y@FMN(1RiK3~94|
zKoJN~;;UTe9MxjYGa=MNTT2sU$HFae3;4N*WwU!
zXadYEL_IO&fR^+`CJJ}{XGt{E!BE@{xVn?{k9Vo>vX2+Z&~yUoE(^~Jb1g%BA$kn@
z1&g#>h7!RUML*kAX^98YCG`N(AyKa;-90SeU+N??NjSyW2WVn7W%vXFj|X}~q;f60
zB0D8Y_cj2LIjPhAfYJztc;Vf|y)gVFbKg(|_VdW<^j0}z0q|i@ql}ikxP7qsRkYz^
zH9FikLGHEQ7)p`|5VRC!=EsQ|7O0$wrBbR*m66<0au>250h{)LV8ArM>`MT96L}?R
zxhXMG*^QtzWp;a!*ixWt)lo2Daco`~ZxjUj3Fd~JRGh(l$4HW6H1OzcjF^(sMm6ku
z!c*n|Wt4=L4(w%}_sxM{)%WcQS0STA1+S8t4Mj2?JE~8JgQM=$(DCB!PXc1
zM~9{7CSXiV{PH@*`X&M;p|sk(87Tbz{h2;KGL~B@X$KUI2#<~vYY<{S*j1mQK`Ci^
z$doI#&qSZ8Tt`NvZNgF${tFPD+WW1dEl*ICv`H{2IJuWO_&G#>MejYGS$WJv2g}Tl
z8-+`pmeh?l?J2F*_J6s1R&pCHflx1Zf*u7FM^whE4o=@Ae{`*&mXQ*Z|p27!^Id#!QNYL&(}yX)Njsh?EV25IUMrd}$%b
z%5MZFR#FiSN)U=Zn7?}we?*T=G}j_Q80krzM}j*+igH{Napy9FF^n&$})z
zc?A)naOt{LPhy$0P+})Zi*YLEpcptxgg|VLBuIjgw|~ib>ju~ETy#PZ&ocm(ti_HM
zohe|9ftZB-MJ2AW{4G{t%LcJpS}Gyg-h(C$?n%+SF#qIMgCv*1$}P)ZFdX8I2@VN;
zCt|Qw3lvYLv}z0(Sm`8X)ob^hS8zZ<7KIs{pA#CTlzH1~4QTTO|B2kORU`BD4+5|a
zr0wP5vdC;&$W$THwTtkt(>`**{&YTJO~?e(3_hNF-q^!ZW_pBwNkzX9cSxtrT%BX>
zPuiw*Nfl*I7{((;09l>_eFWJVbl91`j+qaJo+{oiZepzwM0MiP+_^%uY8EAwneF&2
zuXIiNOFuI3F6nR}&j62%{SitXOt>;V$37y?U62SdOxO^HBnZyNptOVHie95GN-#D}
zH%&yL>JdGphf2~lz)N?b#_(qZ5TJTeFGz$u+2`gPQtwi0FyeX2b|jfJV@5e@m&lAI
zuK51<3g4`f7?Cqp_pCQGT-Oau!(FW(GqcAoAZ>OxM$wtQ`s8wvG^tZCJqUOh^h@yY
z@GfHVBaZ^fY9BQY#jfQNrO;i1R;=pq8&e<^tz!l;nUl#-F4q1g73Q^bN76z47Mva%
z3K&MNEjO5fyQyZgbRzQyoov?jd{YmZrn2X>N(mr{mVY5eOwkSyZ-cpKW?s<9B|{yS
z2@RYA^{v?G#_)XdoEI;Cwd=e9tO7&#;^0@<
zra<@ijx(nML~TjtQQ=|NZ577m`O~usY;cBWZ-?11m#cgpDTo;$j+{9Q^GTR$oE3{|
z6{6#C`oU>b{|K7F>Pg91Je{Ddae`61
zagGG|R#-f)X26P*3OkCGPK6&?j*@lC+U@NRRXd{bg1g(QkhMA>mG6NM@=(Hz$2R537xH7R`A;o;
zv`LWgF~XccPZWLDiRu=iqmrvtpu=#Vgt-~s>}^GziUMJdVu?52G>N7J6{^-;-rf~;
zAggDSGKZ8A*5jB!-CHb4svMsC
z%@z3PU7?%EZY>bvz>H;P47?U7N{1?JwOLH@u5nVOXhZqNbiZLrIbBVxsp7l8%~_(N
ziF8Vevz2PbT;Mjnq}VJ-O5n{!9&N0&YvDb@zO59azfSdn;z56Ni4Xzh!YI6kG_F)9
zrJ*_n92~t2p5$!jVMETvyfeRRQNLXrS$qLenu&YqK1faCqQBtke$r$2@4ZF
z7-DiwTV0&6-T;6SIy>%ofnW#?WP_zg+TtTO$GSpQ*tQ9C$onTd8G3l?2fD`1=6M$Dj6jvDJxsH1JUW>7}yRi5TT@*N;rb|rW$t{
zdB3CIF`~QM3lW=VB=jjWtF3JME*dA=&o#tqKd)3#N*^lPk(14B&{v7#SJ*H)br+Nw
z*3p*Qumsh)W3kmzdiqGB0vVZbe!&)+&jh8@w=@l_F1@`Lkz*w+fIiwX_qBd{y8z>q
z128aKf$hSvF>m0<8E9eF#2IIXVfw$mc=-o~XC^KWLA}=e7&s8UJHv9jV0dEvU?r&0
ztS{w4L4jL$jPpw2;TDd-qe!SK$B2iNjfx;UaxYJV3RMSok=d9k-`LXL{6b85oh&aRkG4Zy>mZ~0CPbdZ%#lO8Haj>1}M85MnATi*(kqOY_+)l${ozf;?*j;}3?
zoBGg39Z(oDFyuh~1oU#ydLS>@ySU;}yl
z5Ci$Lz@dl^n0Zg3aRPyP%+RS9Vf_=f%S{K;K5gL1fo#JM3f+FVqulP5Wv;A{AH=iq
z)f#$L%BPfFrpRrpz8cqtQN%4itMxUoR1`79HiLXAkA!ntYJNWf$$(kAgw;4zfDiJ)
z)=+*<(~w11Z4k~Ma=WL;cq||jgU{zN+D@rg1UKuA`Z#L3cN7y{07&jnq?lXwGYe8em>ad)SU7f0GK(t!h4
z85m^q$O0jr9=&r?)^(h-@M*j|Wh;ns46yj}w%p#`^G^ue~jJF9z-
z>l}fHg3?UBZ#}e*$GOc6ueMEx2G|N>heDqLO=ZAz@<+>9$O1`MDU;MOOwYfrkmdH;
zyKwSJ;>e6}ASq7LeQhHe2IYR9>L7N^hM2h8TTu$cYU4r9pXx`sZp
zexAE=Hk*#R5oTOyD9TA?#ag#1>rO?zrbpdEzx8-4(G@6B?!P+^-+b|&eg@+ZRGK-o
zi6p-5dB7)|3Nou9sU!-Ss;qPgrPH(-$YlkMIP#5zQ4?Fvg&RN#2~?i~++oEknIGrV
zkuOP9BM*k;qT<
zB*E6Q2kcb4?{t}3Tiqk0Td4Wp|Z4we>0Qhe2)WzCDI}pDwJ^WWF%Dv&CS~mZ9~ha
z(xbWi3$3v=ftmXLyF1Izn+F&7FE(#nBv?z{r~#Z^y}AD8uj<>t(5;}M+5n3AEsZ#o
zAyOJrr{a1nB4@an*rr8W67hEv5#}jHNMoadUtz41B99b#6p|BfUK6aORZdi;3pG^I
z{LB1~L=w*oObL^NANP}
zhyA|KAUdsui&RJ+T_-(lcoM4K#zHUqD@4855K&fJ_iMt5?{@)&)~DVyMw5v^+S!-C
zG9W~@H3H8)Rcy-_p)!J22ta!UJ1-g~$a$?!!S&9VQ&G8nXoYeF1M$qgvYQk3N
z2kGq;skT==jJLqAZi%L*+5*~A^!)q)|Eb35z4o&22d#(8exZigicGEu*F};w&Ar$H
zY1JvT(1I0}jhwW30ji%ksU#4wLw7RAAp?Oh{gsYsyQ9HA^rfNCOG>JxZVJ>Rl9Z5o
zXW;K($OF)f40m1wi>7{rtJHnWljju>^LQ%=x`n}f7NRj5d+p~3j>v-^{>sDvgp+|G
z&d!9|dn{u>?OU_oLWLtsB+x%rMIs*lQl1pO1@iDv!#_`zIUtprQ1=Vk+R^NvC=(J#
z5NVgX7Qa%IfFh-KKL=)PTs@M$MB<9ZqIH8|p=F4w8-*+q(O&`wBbh`LlcQL%K-3^5
zj3MNnh2m1e01D-aYZiRd9W7m3GOsC0A)6(8-POjYUF^T9x~(}^DlXr)ErRhfdtjy|
z#`PQ+I{TFt2us8Z3~@kFB{aybj4{y=j=9>(PGvPg=Os+R+qS@_5g)9bN~=Og$UGvz
z&;S4IecN)|NS5t;Mbtka95FM}9O^>Kva71Q86nGdwPVUIk1stB75xB_poBI_uyK(r
zKlN*W#EGbwn0`O!;rxIy)ywMfJ|O9K}pSyt}09B1xVy&@3q%n3x)=rz!_ZE@rM?mT
z?sx4j;xAeteXI|xE^0@;hvw1dj$O;~iq4_VQP?8-MTyO;xNB7V@;EB1dU$rIiGb1)
z5wcK#y$NdWTvBMbyShRKFCeOBo?*H9
zP=ETlCkP`BT$Fe?YxgYHBssW&eMXo!vCsqptNh{sI389u{rzX^_G0E4o+tD&L;J6Oz}Yi=$-0^DRDB7e*$*5~vSR)hIzd1nv1O
z15u1(PKlgb-Y36Q!c)#*y+B{L$t3u(NFx=`(s>2gcw=Q*YmTvpE0
z0hqp_{dnM@#;+lEXe4EJq>ce>!`RHeT0zZm)O$nf&?og)8QYFYbm`hXZ7$L)DmP>K
zi!BEd*hQ04NtZ|laOq?FDV{CVUx8?#whQHOI>l!YS%R`)>w?$&2KsKq?5)f1s8LETcQ?vn;>6{#9qj6P$7T)?
zY48l-V4nLMB23D=WC2NQJ7@9j%jqL(#~El2iFV8xXHKH$4>Tb={+5&$i*uC_M6^fuz$l_v)_!iOgXKM8pdvqQ|!}rdmQ$->Ivdx
zXIrVwiZboh_OZ>W68DiErw^U1?OgYhg0{SVbm1olw`LJ~z-hE%s3@Gn3%fA;I@9_m
zxKO8Vn;n-+$oW^4a&qF!Mm{+G7HHA$$RL>!0Mf1i*e@(Z8Zk6eX~@@0NVnxJ1|0L&
za|eyK0Y~SImo`3`UyT613nL8#@FK)*2JuUWwjDxc`9oP$Vg9FA4O5?MN>$R=S1Uipvj11i5TK>342_)$p
zRH*v<6`m`SNtqaOn}j}}1mu4m#^De^zVtXnuS1Svg$kNXc14#^MV19F`N>7TIWL35
zg{ax=^3fF#ToSfabcMC)qpIGmzsw?CD|101_RCAO-nkR8mFRUi%pln(uNGrn=q|Ob
z{JlgnV`sy^uSD4s_bc$u22F+t0h}7=eRQ-jH}Q3bze*q~Zv(=%yhJxjbI|T&KJ=Hjz{5`Y>
zXi6obc2-~GCc0=#3%LtT?N+P7ug>t*2CABCQjuo9>LMU&L)LHvl*?;ckM0j5nbL5y50A*J(bruCe-*M_&9y)HWXq-CY5)>En?MuR^h)j*v(m361M
zehb0H-O=<}f{bgS>*(ymM?}-(0DZgE98Y>DAo6_YPqjg7;uAgq^z*MhF-(?{eofpL^c?E%Us
zoovKaVw8z*(o!ff1vh9Ie$EXit4TB$80RF?qj46+(O)xYGl4co)+`CqRL~zm-?j{j
z(7r$=Qtuh&a|_mb1^axnWPcDsoDcvE)ybzF59?g{iHzp*zhgA5_`8K*gR3lFAKA8|
zrE8Bo!TR0XJb4`fY%NG2>A#|`2as3%3tbDNAsi9Y8Yda6yHv~@SwcqfUCfCNh16yO
zZX8-JK_+G2M)HS}ZW3r}$L3WP@~m|)NeeHL{;A3aV6HEsmZ;^9>XeeQ2+Wh?4it*U
zNGyltRE7c0=jfDL&sHHDCI
z*qvzx=^aMO(|A!|;7WyT#J}Mr%*lq8ZZzak!Z*F)tu95y1Y@*eoy{Us?5F3$1(sEe
zK;gRei1tH811U}>gvGq*fRd|P<1J!GcLh)n$pVvq7}w>
zA`h!oAxgq41)T%*#7W^rYO+(Mgdr{mu#i3e5HJusAM|s+*n*X-{Q!pK^&zCbgT@8N
zXrcV4i!a@Ig&C{G8`8OY3t>!GO{j}EFDKueZ)funF*i+^c_%zJ1TZ(DtQUjlPo=gw
zjqw@!Mx48!RyA!e{0vHP(=cr2b(XKD&;1Qscof*oNdp&-qp~%bHt6~}#QW|1r{ny|
ztmqB2;cg(M7;zY4fcz8VNNnAhF4*kyvDgoH$m~jhg>$~8}
z4i#^4C}qd3?!IPy`utKobe9f_*5}*3PtoCsY<6}P!2k=21vuhT`~;;?-#MMlNz`!<
z{Rg)jW-Jlat^{TnkEaFk15A;3@q>sS?_~VY6J~3>_@V#%BgU5uEvdWs!Aks~KOQNl
za876>@`~lE#d0u@`oQi^y^@R^IP5p3IsHuC4Cnt
z>;i?b|NFH6V=#;0SVRmHvHBAHn*ISJ8G4?V-e;Ka5WThfw>Y8F{;L;_1q=8tJ%dyg
zx?%kBA08zc?8T^-Jxj^cX8km)l+P*Jj?#XOXdSNJXV|ZOr}%cuylMiOC75f|nz#&Amo!%PwpzW$1CpHI+I8o+NR+5f?O{C0b*I{);~1|YMc
zCjeDHA6l3~plgspwh)v+)GBcqSsYIN7}ljRt^jTCsE=V
z8pK%fUwVyr2_9;4l-y3B%rikFCp^#CvPJctX50&9&rj3nW?C{6{VCMMP@V<&3ruo^
zZxsbfI2TW&7zs1Jl_+>HzLv^q)k_vmG4QYf*^FLkWWANddpsVD1~<7?nocKWk7;A>
zQsbnn`P(bLt)fm)pTc+S^7M=0OySy~!9hEY>#y{C^5nKMGb1Q@P)G%nhCkMUnT8qG*b$--ehkhq~&Bk(bVx84>L0^Z%;W&UzUG&L&`p55u
zrAGJoU%a2so}Y8fLRNR_EkYj%h?0J4V)tw^DZ9UdyKpwnCYrl#RGe2rg1eu)$BkQ{
zk8~BLGJzfTJZ
zX~6&_gCV5&L!`|oPrm-&?$`fw&Q<)Ul=OhQF!XO*T5Z(E1OBqrJ3kW=BggM$AeA?au9i!`^3u>GUnZX$yUR5S`Sr<7$kO7D*+Pv2d8XCKbbz24K__stD(BRL(@iLug23bJv|bP}p9uoHy>
zq|PgvoY)2BMnVxUKAxYw|9}aIZv6lp;@pm!$w4}lzAnP7$R%zTE3fd34Hn58qzZFf{l$xX_o?h{;mTT~Y)`o{m?;$JJmtzwJY>)_aP!<2Y~N!c1|VZu)4%**w+Hb{Z9yd}EWXYe}^R@Zl76w0|USF~?+9}j)l@FuuH
zYg+=Md7_bV$;WpM*O1@-_TOHkV2Q27@?G`c1<2r#0wX>IRTeH1!{wII5KO&k#G2i}EeLo8Z
zRK!)K52*@1WRz$)KMYuZOE4wav;`^6w@$Yqk3>Z0Cu#QQudAEW4=C+U<&o*_seR3?
zI|Q}|I+X}jn45*HvFA4fojQVRYjF3)E?mhuSRa-W$BICb=9NujQ{!9brt^1x4>wPc
z*YLomtalnjaGH{OulWvtvOv&njhS(`wsQ3dvmKArcC*F=vcG@UBCXmM=PKS(ww0Fd
z@my(}-Wx!c9tQ3n%Xq$eL6wc6pIl+JTVAq7fZ6^H&$nka>{-q5vq8R7RZi<_{^IR9
zu~0{D-(dCM(K!SC#QLFGnO-!pXo9_Zv9DKzwGiFk|7k`vQv=fq(4=U%v%NNrXx2PU
zl#OsH{T(WaZd-+hj&awuWT32572OP_mc@hR5@cJ&tlb0KpkemVOMH?ky1E6ez<^)w
zmfA}Y3IvD#EQWz5Q4>f0Bm@(HiS4N)ByJ0KBS6~gey;~=
z^-G=AyHFWJo&&>Y@|jFPn*l2e6!%0RA;OQBlsphm27k?nkFPzd98^@R@;h@6NJ|^L
zylD^(1`&nwz(OrbC-UIFHCt&3F@si181f&7;a@(1suac3&^HWz8^w1m*<>Y#BL+@u%;*oGC&1mBz-i-W74-_luOGwYi!TR8daODRRux9xr=3o2;UJzoA
zjBg^?XNx~)F;R}%8Dh>J-RuX~KF-n$NOLGHL=Jncy;p)JC`ni;X@luWk`B%QuW|^q
zvH{X!V5S-E|Hy5jhVl?jygsvRumC`xqq8bWVZn^k3_8NXjYK|Q6%?nT5Ng9L_dpX*
zoQe2=5LP@i2|=hNgb7+%SX)^LJOCQOH}JeJLI_u3mMMR+UmG%`#jmEQ7EGiK9oC8e
z8Fj(Qt(VOp?-mTLV{ZB@$uZ>i%PDICaSt6tcUbC1r!!CQ#*X9$JfB|=O=A$u5ed)m
zUx^eh|At1XY3}B3uk?6Fst^wqjprH*2S0bW*4U>x&@wA#Zdvi^(T@*jPxRvpe}-L3
zCC2DciT;~5Np$+gKN|&#cK760g(iUaNUc{rLex3|Y#|5?rA?xc@hrRDAAC$w6Vy=J
z&AneV#Zj7se-?GFnkK;B3U9p|fsmQW=#B~ZmfS}maT~%jxZp_~oj>HL|514T$P>IU
zGi0zbb=mg_Non6UjjQIp^HZbgraUcESrwlJq08hvO$HV
zYA{OuFOcb}{czx4ht%NdPsD4&3#b;s(yWoWYzCPsdcVdr&sHUyNP%>_Ft7Up%G&|%
zThf~I62LG52A_Hi09CLdyi@w8)89k0JtML?jimaBP)aJbnuKGs3%jZZ0=%<)3z-NI2k)bXPZf>s&l_7yGlDCZ4}6G%tNTV
zllMYpma~-rROZWDEX?PZw&C>-P+|zYt2CV@KO7z1+}s=n*#J%Phf#caB>o8aZb;6B
zLkK}|$H0+$FXz|(6f(EUD3tp0jmf_m$6_%B*V>}OTvZQWYe^zW@GCUF<3>_G{U=A~?t^+TM(jV?SrUM;Foo&;gjD&G4(6-+BcDBk
zt1%O)nlvigl1uh=SV#?F5c!uGn$O(JT~uKao_v_Pp!OvBw1vfMZgIxaO{{mkXeI+<
z(Z~lJdLNO$(pRz#Jb}et*ZcbaE`?bvAL5mIVa0RyJ;}Wvcf5E1I)<~^F?8Qs+Ut=i
zx!>(y8z2Cqv-q6UGB*te=D-9$(2t3h(^9ha-4Xg2?428+Q6p4N;fh@N>j?k_C`wBc
zfKp`V2ceA#5J@Z{S8Inpd3^>f0R2~2GJV#V2d=uh%>1A(xs62(wt5
z{3;|2*%)ytDqy$>-sbSGAMz`@%`c|o!AF4jV&2>HcZ=K1SAQauTO3hP?tIQ7q!Aco
znM+}lQKr}uvRJJY5Xi)*;d9^hzzOvz=!q;NdqYZ~ykU|4j({l3j;aD@D
z-%@`T1}121!Xi&3y%{hA%$KjI85bA?bb>2I#eC^-fs4q_5VM5`35B!DUV!U2#aWwG
zolbNq8-chkRIMBHYQu`z6nQW0sbtC0Y|M3a7k{MGa5P4{+814Ckb{9Mws-0MVmfo=
zfnYoY=Iqkeqxin2KwvvfW-Kc&Y|3^4k(79|EXH~d(ALGdXoSimd4X^Fr_!IZHz5X1ihZO2e
z5EkbxrM6G4CbsJjNXgI8t%`OK@Nd6qA@d`Bd;u7NV-tJ9@RB(n1QNkx>k2J}h(86?
zbOWvjx^y9XpX%py6;*;tPDKb8Wy>JBj5usxu;;LMw3LyC8#^}v%u|G{A<{DG%&e{IO
zIEscziWMW`QSr-Y_G@2gBH!H@Dl*RG;
zlQfte49Sd@Zq+!_i-6_xm{q=o&_Z&q06&EGo9Ok@u+K*iUpq(8t;@KpKVZ4fi{`vc}
z{c;Dds?!sI?L23EK|E-Ga4So(*opJf2L6ag1kn&gxQE`0^PgY7LC3+f
z$HRm4c7_2>B4Lun8j;mvhCldg7E(5vhbGVq*i$)C%I{^T3toJ2OU_UpG0p_%>UXtr
z3zu%YD4-N2Wt8f%yH93-%0sL!@8q~B2=9x-qy7pycv2!JQ+ta7D>1j#Il;8wbN{f_
zri~u}fIuvZ8mvDP<($?5rz^Y!yzURQ{-0q;KC#7@CoPAUC=Ka+ni+LbZm2C8xz~+Op=Z#wr$(CZQHgv;g@;d_q%J|
zb^qw@vrg5n+B(0gK6~#f+#Y6>=PBcth)0OgA|mb{^ehROpE=(|jk<54R}lK5^>JvWxLOv~rG!dm5C$|>2l8~thN{UZYR
z5g?3DXehF%!939R5Z9YcZPik}>5aXMM`C}hds)|E!m--iK2gxP@<8r?OLsONe0x#(
z2rFD`@N~cE9r8fB!3_TZStHLyBCt8Ffa)ZA2puqBdF(^^wc*68h_rQ_H8c#ECnlB1
zh)-zWAVX?4WKQw$15SqbEZquySiiwD)qU=emurJGPCgDOcKBSGATi<2(1zaeE1&GB
z;wb^WQ(z)_pq;`R{G0P%c$*P_u-1SwGK%<+bX7#(jObV?mQu6I8dz|IvR3No(WLU-
zUt*0-ps;iycgMi^ra%Fh-4`VZp9BO8~&L18}zHn{dQxI;zFi-goy8W^?Z6H?BSJe
z$5r(J?>-IBq3-9a_#YQFg##gfi5~#!?J%1?FoZpM(1pe&RJEGTn7QB5jWS2P_mlL3
zb+~~>`ib9g(&xeEA^c+84_mZ}fBq3uWJWWY6<*z)X{38P@Tg+Q&!?e#O4_pqQ9bU7
z^ZN>#0TSaIT1~-}-VWA_n2lbEhT1)~#CTJ*0%J~7tm1HMHy;)^m;$hQh;5BJ)(XC%aaU+=$;`;m?$O`
z)*3UnFwV?wn>@7r9r#ft$r(I@ATF;l#Xa~9bpD%&1_D0yPZ`#;3@Tpr^Pf+Y-L>!*v28Z4m3j%i2XVdOBW=&L~|+hd!9=F?#5<}EkA
z^B*n!(8tkaHyDBqhh74riX$v2k^JN2#b)YU{Y7OAi7MR%%V2um2c$Xs@X@N81*$qi
z*SO?@Nt#S-fqC`>vm_v2D@`=ax;~h!CP5xRj2^@owI?lZIITat
zdWqs1SIzsY!_6|x2OY{c9I2G!eBWCFBGc58y3OEw(d+3$It3ajASfjGBCO$PQ=wAT
zyALaJRc5=a^s!=YJZ29~kE#=&4tMbiE#uGPB=*S{{DwclF6CJtC<=CIjxC_038(q>MaJQ5(er7cm
zD_6!C?nlZR5gjXyh*CVwI08gXx@Et)V=6Ki$`0}_qj8;>)Q}{5^XSPEB++07SH9)o
z{BI#bI8E}H3`xxIgmJ>w)2{+lY!QY5RL9YcRvN_3pX<;is=wvS|G;H(aM-FX>}-BI
zPM&ND$4~U;GlO9Q$yxS9NtE`9Ncbhaj{ah9
zGzHRxv0`ha3so4xSLmI($2JTd#|H{J+sU8}yBfzdW`+B)5$z2&!JZ-gMwi>Z-OZfd
z7o$<7SZohJ-^@`{DqRi>07oXa6eU`IbI$6}P^bo!R9ZG2FSv-apSe(L%eFoe&UgbA
zV34|DMDLj#zVQ|4!vzX}*I#F6K{D7Cw5usrI(9yAB_~(SuwM3^0RlY?ljG@TA~{)u
z`j?=XWNrNO#d#jk=l=vT%93_Jg$*wkdxg=!_n>5J*t(tyb*@0a64fp&U1x0E%-7+c{>L
zo(!&2iG;hwwjSM5UjNbPn~Pn*0$%|&o(OW9Sd@2I6^S9X%|05rW2Vpw1#|1v%OrK3
z8oA24Mz`Y@T2`MTM?VIIxoXB_-8op#1g4jbhg6lf$Af_)4tr5q`K9fa-O{fYkMq16
z44qTn3PYHhumnW3XQJYQ36YhzLvcYyi}Y8;X2CkT
zc^e5G>ltPw&N*=(nLYj*4)?aDs7s>t)_(^p#OhWlMCVN(?WOB3JH;h|Ai8mb5qkk5S81jg
z7tTfMqS(%DYx-u+PcnC^GU-icDwo?u{
zFr%6=blQ?%f7II)v%8?*?O{fLlpXh3nDYEYDKw84WtbJHe44%r4i&aACX*@cZy#q1
zJ!-F^RFQxkKK<@f{e5vsgX*Ww6Gk-wX?B4XZZS7meC7Ki~PI
zToWR-3(o=Be6KYtqK%^yjVRQ{WC*CLEzZWJGr^e{;36xEwB9{ecSr%k2hG*Eh|;_0
zUAN>dCMi#o9zA|>ij8XJLY@sBO5wvx+9>eE><>li`y?H|oXqfHfl3jn)VQKjR>VS*
z03-eY%SE{7+%31>Zw?qOW!l=85T{6Id(`<^xceE?@{Y8)iYcDJEBc7|3vPn@!YWU+%~&X&3%
zsI3v!bREIyoRGm{9POu@(n4q`wqmXgTKA12*-r5>o?DhZ=G8Ns_ucyjS8fClwO5(Y
zr7st&__FZWQESPF`>3r5dgDq9-UZRjUyvT^r~jBaFT(p@;P&ZRRh6DaGM%=be0zr=
zBZ2UZFi=}DCxe%^H_
zGYoyg^Y2|#AqL1sx;I=-6G)~SdZOeT`eczMpzr~tK3Y#Eq>2DsUrsQ1Q26;RoQeB=
z72xE8ljEG8!=QG#IIi(lr+GZNfEB?F_qoq61$huP7+ekXr%N(sH(n=69yw?J=;>VH
zsA#0@rQd=)W5J^AcjQMx4XT*Y3)$NoE18oA_+IiD#T{cby=U#gyp`Ulg)_G<-qkT1
zMOZS>Lv=QmiHUg${P=#HZUzunIWLs&rrQpmm_i<`V_%?-03YbRm@$L~LpA8e6h7mf
zLN;p?1SW-_oo(e>>pV<%R8w~wquEsvu6?E?jGD`|Lz_TaG1u@?C02h|{L2p@4w1tN
z@)TTz!^_9#!eE2(Z7>VBdxpo6jv4XnhZP#w9RE4
zBI;@W`RR1}HO1JoG{Vym-M=o7@wETdHA$a6e?BoaA_QMi=z01%2!H+ftST3?WR@cN
z>MKu5liOKoWkHtL`vV-LZ?9Knr69oil$bxz=#K<-dvwaeMW&E&c>Adl1MU0?gztJH
z5i+o#&W(Nt7U^5VI?E_IY))#VTdv>boOY;#d%c}OkcDJ)9^{pk633qgMT8P&O&tBj
z*hC!uUWH|poQC)&8{b;V>2Y?Wzii5zsG{2ju#fI@3*)uCd
z*6I6c2?zG?LZvn_`aOs5BDC^G2F04{y&*Xr6c|^!%KF@rkum6tD+U`>Gkxv7R1R(ndqdD6
z?AY6k^V_3<{=xM*`d0G7ZTpT@lJS==7EXTUN06b(%Yo;$fkZrTDd^Tc>6zCC#8wjR
zun!Y5nsTptO^XWp2Mkp|*u+FSSHPG-e)Hl|^N-D+rpnY?9$qo4*=4=mg
z@FU07CkRO0P+x%)U(A)d52Ktyj>G2zkATp1?=0YdV2&}q;RZ)+OAVO>^f
zbhV<*~$)QA$YIo@y*?WL;fC`NBA?6045V~1!gCgsQ6Q4t2gtB&o@7@H1&XdmD=Fy1&CQ~*#dOBygzHWEovk10`f**8gXZ;d6T7FuFnWT}q>j6M0lKpB)92(boG{<6#{NH&hul20+4k&xqi&uCT2jhUE_-{oMtu
zQ_)bs9@l4`Kk(AwuOyxvQPuW!_8XhfqB%F**Xwsck8o@@4If@NKqM8yW?@YLS-#Gt
zfnxRdl1gt@%hrmX$0G&hk>jF(oF=7>vA;l=rI-q73NyS&{k0X^?1%|S@=I26q_4Hl
zni0!5M!%P`409H4m#iBimbv@);OR%{ieTy~%U2IQaPV=W;E?y#LifOv>MocvT
zVSR>dQhv34lf(o#sKQ7Tb@$b~*-TYj85BvfK_KL^=uLGHx+t
ztzs{|4upvfXRAcayfT{hskTg>)FH!JZBn+B%!vttA{cS@`37M`blzgb_LvB;=YS++
zC^KcdPwD}xb6F@+_!TsF(n_k4{pT6)?C@P1imUf=Oe8sG=N@RV*E_$}MuOT|i`HT0
zV_8h<^5$*cZ6hx5p>eW{gK4B`vYH(-V6CY6dr*0VhbJ~hq0L{2#%|752J@;95X+Ib
zUq3iKU}2v5N{uV{jTGQMdogqgPZh@Yl8{Kol|^bBFCISrZnrSRGrsS{6yQzq1srFw
znJ;WLsqnXac#6Yw{2Kg9VCd9D&us;RhzQ)#p?7Z3l3hfe&OqvJMAfTTFtGj6sh;H{
zKtMB@Gj*{fP6tl#vORX2#Onbw<9wOD1zLd>kI*W!Kq9k-vgH?*$bJ^rXaH#KD{H62
zW?EaJbp~QC56iT36jxqcm-6%O+9GgCy$`vxoLI=VkGeI_`=Ybm8zxke4J
ziA$Ak$Ms#o_S8qmoAlRi5%Wc_OpZ
zztPol9Ub~GVb=GubKXy%9?uVIvzgTXA+gtvqh4)*ZivU7yu2VH*jD29AK>7YvK1%nzG@aO3l|6=j4f1iZG`)3j{ekEA
z$4CR4^PhYAYCTtzOQ4B@5Mhnz0)LU4IuDTwdjq$Fjhd^ikqhc7p$tw(5=fdqQb#^0C
zk=wp#V?8!!=*NEW713XOfOkAvUGb+oP5o%6Xp+-AsEn>557;C3?XV}$11?CWsA58H|U&CBEOrXT#qS<*n?|tD42vULtJ5#-K=Ym$hvnFbv
z#_o%omKrDrtnCBsGp%i5x@~LiUf<>8D^Y94EMkc%M9anEu5FRW?}8oA&;5NFZ4ETT
znH|Dfq$@(g&48MDZALwvDjfI5bwS%q{~@ieMzq}G$?lHJkH(|y6CYcA6($4fs3!Vc
zA~m!3Z}+xSx(lVP?(L0gY&}dw{-;khy`4y?}CJ9p2U4q
zELg`*)=H5720_|?;`ZH=H!D_^7VM;?ZB#m7Gt~J{JTv;Ph{XLmvZC7pwfSLfhwKqJ
zs+C%J+=1r(36+{cVmGuE@fX->gvZs)$=>%*>=Pe=W5p|Hc7TrfWUYtcMlP
z-)OiS=*}2Eq?{iyb~9@2pjoRlA%k3XgMSC#DKZDr`S=0oetcyd()T5WLgq>4-98E*
z!WLdNhf!7y28{gWO-iw~5}X0$4knKSagR48t@qsJRL_I5Qbdv<`He<#=~7_K&ND7P
zBb@dM2H0GzbN>##q=*|n|xya%B&@Qh33Q~)|!M@%mxyytj3E6So+Ok$Wa&am<
z>5dvZ@Xcb75zoFd<-AE*z(cU@k#io*u+5nS4z@jwv7^*D*nQ{sm#esQk7l!?h!(8Y
z-osTtC&_57RK~t4Arq_$-(kS2?aYPjY2*@RGm@`kHl@nreqZ;PAA$6#
z83pd#Ajl{My5~i%E_miJ#3#{1DfK?J1!U497WwhEIlJSXerTDke&2o@Uh88(H_1niHvt*`!R4r|&qBN#SV
zGXa3^;B9p`1-xIxtf?vPJIG}mg0BXyuKyn6z^R~aGLPN2;~?2#PZQG>a&2DaEkM5yn_g(DYrIw{V5gj|H;upkMjH&Be
zQs?ry`-1C|LT&TgotvS2rV14J=7LnRd`uLREY>3*0@n!dXZFdm{d(;PMLj00P;tZL
z3EA@fFk|uMuJsE|ULN>z*|YJ$ID3@W-ObHi)H&+>PlREUa4
zdIl2NqUpqiQwMip-tJ`KXK))1DP_4?fh+wK!b6j3dhG6lZ7$#{tMyo?jncYJyc@a-
zey?w6vx}CZi=%s`uDT_5=vr7d#OlxcCK9c`3O2-Sc9_AvO+XKm2N6~;V6dLW{kP*W
z6;EXCj@3?OIIiNAOYK!_MdEe{V#WMNaZZ++olta#U<}w5SOsz7$nTe`^|8X{<(1@T
zC(d?$FCZkwZ;v)R9cGcSVjij3`p-{L5RlJLa1aG)a0m<#C=eJB5D;PzhEHo>M+guQ
zbkwiU*BziW!*6pF8YP5SUJrNHUpe
z<|YQ_Ld33oyz}x&)f#iju767g9fZ~*;qUa!W9Z~P^5u0bs1tgbf91{hAFB>#PIiNvh`sfR
zR;cT^L18}zHVZ7R7}&Zu^%Y&K-Ul%Y=|&hj2^+kz90~SrbY-yxgnyysRNyziP$u;X
zyG)0EEoYbQF{wZ@pKaYrIft$=GAJ#ApfZJY+94p>y)4xfexKmAeyQ)oes-YgILe)w
zLA7k*x8lfdFv;)_Ik)G(_UtXVPS-Gw&lbr18afqAbw~t)Nc?9zes=@bvje1*m?`a7
zITgZw*}0nnyFwm6V6wnH_{z6=FhqpWbrMCjCFVjJzQSr&q!1GfYE61!QG-N7!kaQn
zj!TaiVF?lGm4w5N`O^2=A^o+NhkRh8>GWJSm{E1
zD(A(vqG(`rlemG*RfoJV2MmoC;%n!A%Ooyk^fn{!kkx>Na%7kJEy_KUPs<9RU>@A<
zc``TpF`VyE@}oh{Wf3CjO-01kbzSZ<5TVe`7c$?JwGm=-%-Z9F$uu+WRHe>I7_^5m`U4_iLo*%i3bMU>RNU%0c~x~;#}g{U!h*#SSz43(38gU)R{%hsPe(>v
zSxQLtg*7l0BFYt3cZoU2KLo%tl_L(P&*^AlV5j;%dx5j<3FC6!N6F&X#P3rf
z@TSvEiW=YCw>+xkho5lG5}$}vgTG(`y=CF5jg}gCBVEl`Cv7YA!vqCXq{5*47Hn{T
z#8dzkI1twDgfZ_!m~A{lF?%|@X^kr)v^I9N$#mSo1k<(5a%D7BY;8gpQ_i=OhawQ3
z5A#KD1e*M6^BjlDe5t%iR8|e%_>~79(dqwk))K%Nps9r~dpua=$Y=^+QqR#MU?A{(
zIjfrbnSnMi)Xm7-Rl8A-O9$zBJ{B2dB`qUpxy;AnLDM}@qcHlK$c;YT&25kfD=-cGz
zKipn;Czlffcp7cxTcKqTCEK!coq0Auw>oB>emQNYt@x-2hP0_OYNKZwq?gbACGcI1IW<
znp>IJ2WnmsEXlua9DW=&P23z-U45K%b-X)yKc76i)^W-H>AeJc-~IjV*3#DTgU@4=
zw<^l+ks%GA_ir;lZ%|W#WKN78O>Jp0y&FElMxQr(j|Ov>
zgq^&0&P6f926y#*g0E3oO$_3a7k_<(FI_#KPsYaX4L;w%0DRV2jYV5fxg2pvL2Vy%
zw%+RAK;NqmT(h&FktOiAr0&lWW0vk8a$hm5`#zdKfo|aOc0=s1S$Z3)O=r-eBcEPa
zDV%LTti4tYp)Hk0&QdXsLRE7^3aS9Al!la*eH%#^d+!t8BD+%H$DVJyBL;UjABB-uFMz01E2@z0ZBF@MZFCZT+;1)gU+$jolg!+Pd(*
zU|*B}I#=X-FN=Uo(1|DiY6dAnfc#4FjQ8w*+diNOH`?;S{r2VrNFTJjWtK7mc<{al
z!lms``;pT1ct%H&fXPFXTq~ncRTYA6a8C~lvBpv_Bbna_fO~~HkH0zh>j!{sDZ$|W
zar)4ruLsxUst5Oy!cAC;E(ckG#zpf>4A)W4XQ9Ka+cJ3qSPUOq5`)wUuLDW#?CEB1_u8VssT|i{WW_Ln$BZ-7P`Vi;mGd=H6Bw{c}}S50n0cK0>bSKR>Gp4CVO8t
zrLQQ8q=)0mF7(@rc!+UgLZk$1BH9Q{YJrqQg$UTe!fZt8aACu=dFzJ;-p4_caKqSOILOF>n52zNVTM9tvlESbXLueyV)McY^OQLIr|a
z*3>Y+89w)V9&;~#+f==|)KV;&{7ogA$ZPQG96OGKp*y^i6AR}hj%ge!}KNjU$K9e}L)lAVBj>Y-rgLu*56
zS_MD?*^Inq)~|BH!`%JU*rxV1I}XVn6p!LEDdL+4M^tN$SKO)vhkM
z;?mCfnj(F`#)9MKqokr(T#{EoR2vn^4h7L{jm%^UF(@S(9BQL_l<2Toyb`~@;F)-a
ziS0c(=8*RXv!@d~R=oAQh_{>a4@8GP(!nDR#rB=w_
zeayU6c0A_NdmZ9iR5;z{!?4tS*}x8FjEKzL!My>-><)+Hof$)&*eFV=asoX#PqTte
z11Zg*T!(|}A*1L=Ch4j(GrM?OqqD#9rXK|~MzO`x&XHYu;=I;f&)qnjkMkBrh-i$f5*C-#`(+}qVV4PC1#m}73YoG!IT4-G8zHS;nSf(i#X8+<+lgpS=i+kh}m&uQeBhBPtGaq=yy
z2;VD1N=d%Pt{z6w(zc6)uKZeFwOvoj|WX-G)Qc{YiV{B0D=~dd#`O-5h
z21;5W(a)Zg&-wDa7)}3ciE8M2183&ryjRfjOG9q34lUJ}2CCX=?w+|>(JyYGr?nq!
z9I?Eq?5xA7dXm_7N~mhf2Pb%u3a4ghE@UDG*?4^Jm>t=g?ZiI4s+qopEZ#{RGoUwB
zI+ZdPR@vWT|AlKL7*Y}jf4(_qD&2415aJ?xf5Gjr|(vJw>4X
zF)~~|P$ei)g`}0bgNaw&2X=(Q_=E<6iQvkQaOfC*pruTxAJ{IHI&-W@zoG-u$3=0}_2FCiFF
zoZnIH!1N6opc1hv%mc_YM^_%nL9nJGw^!i5u|*XwwGH*rWQMkW)bztqZ>0w;;Hqmz
z_F^~gQ@-zQiXK6RDlMyrKA*c4?IjflrU6vn-sP}Wc@J+YnDQu)M|CZTOYZ-
z3jd94EWFrjR3PI-v(Em-I~y|8iaVr5D`f+w9K(udf$^@86ibzcEA=MWKgINCckL`K
zUn$XcJ1pdeJ|HHh-lcXiBMJjt{d`11r_l@q6m9
z8I_`!sz8lN)@${@>
zx#JDjHzqbmX%_=2Lr83fL)!AiuTCLTg;1YYr7i!j->HVqNONWSxfAh>s$_oV>U`V!
zS-45Kg)0rO)H{AN@!vFOsg5rK=;sqvMR_wTLK|0B0%Dp(`>PagEB3!o*Ky7(_K*4*
z4cb^L#0D-Nl2TDj{qvw{>~0(1`G|-{3{~f{&IY=Kb4(xuzg+q(Zhbu#T7nF1CJmPA
z|2%7Z4~odG(zdwlCF{qE`T=T^U!x;7D+KT*SfRDQo@~{i`A;TEW)#qVsyo3ods*{&bME9DTS|ss4WR767(E$Y6}^2SLPiOo4d&w#mG1IPN`!bk!a6o0C-XK36Bx
zHZnmThob&}Dm16zVW_6gjK1?)ft3BQ-WrN4>Z0kBMw65}lp`H_Y=jdZi$k#Gb$xk5
zcVU5N>hwZOX{#t_@HMCNwtgWOjT1`)D{&rNL7&}2}VUH(I7S!;lM~DZ7(n^#
zT!ej-m_xK?ME(&-uS%l%VlED``d>?hj|@Rsc-8s&@Q;Fmn1Kf^&_Ff3CqQI-A5On6
zNKMRGKT*?hB&=QtW%Wa8g40sr$wqk-u$!vRy
zs=mm)Gmd)mWsTqfzX)4E$P@%idJ!S(`j2h(v~Q-l|Hi!J2kQQjpi-iD3>P0B&O?Ih
zC5_bilqJcS;q29UWR=@BkC>~h#!B$lndZdOq|mfk+<5rHr&G5l?5IDttn^OO%#eu*
z{h=G0nOyK?nCgdE(E+|VR2GnRfRn*Z8Ujsm`wPhMc)-?1KqYpASMy2C$pS9JyT+sy
zafTWT)%Ha^mUr!PRN_~SP6(Su+
zT}jq0S4?wNAEFh6E!VG6T5>&L%U44rMgq2Oy3&bkE|lVyuB+gMU?R0^s8{$DL~zEu
zn<#44RCD{9G3e*-v}`)i4dY_lf#q9jw?E)X(okM}p@t(MUG4wCyVwXSGHM5X-!yWS
zK&LO|JH4Lriw<|@SlJvJIC0ZGPvp8Ul#laBy|iVag&JdDJ&mK_oL69p)hcWueowvH
zzItKD@3#ztCq#*NHc=UHx}imQ_2otQeCftakvp3Xfja9SUzK0XvIw?1b45H+5%$p1
z)6Ig%({(@|c1)6joDCo|!&3b+Jm>}bfk`8|jsI(8(@ATT^3;3yu%;b|KZkb-u~u6u
zJr5HOBx!#&EYo=yZ`XrC!__ymi;iLulsrr1;ZP8}x{_e29@U*g7E=b&H;TG@=0GGO
zx=|6!TR|$BU&y1ueU%vs4Z|3pS1;Y~)p}zoh73)G&FuISL(<+Uk&6cpm3}~NMp`9M
z+b3Q1mKd-AN2?Vsk^&()5k{}^ztA1N^g2p*Ky##PQ7lqN6TfknamZW0C@^P~YMFE4*~Fx?g~Bb7hn
zA}{dc0v}sCHf!g)FFy`So-c@F8yvPq3|(IqvyYv_-96K+Kma|JfpSRE>kK7zcq^
z8()|vE)U)w>)#3&ckkPS7(*xM=GX<&Ep56K^-yedI=TJH`==K$|2yiTH!`4Fu}kh#
zETituG!2lmqJmNs%kwls(YUhkvDaCWm7PRXg`KG{yzYWo7=RsqZ2JPa?R3{%x!xaw
zohgz_?3CGD$Q5kU^?0yHDS)G~7|S#U@dz^4M_(^NV>Yv;w#h!4dKX2VD*>dc^qj+I
z#VWZ>)xB6ZT@A=MTPEYYX#w)m+CGL;H1mLya?0eLa!N-*vjYU>B@NqT$a}o&3EAKn6f7
z;eW{)Qmmb^6E1C8TdRG`MCt0WbX>+OAdZxN(i3^C0MLC~K1Pq_m2by%{a
z;~|x0r^OFxF%gVQw0Kz0jQdTYCS{0(4RKMfT4p~B`>+kkcegISo
zDfx#B4JANx3(-{)m0u<0MKqTx4sSEr(#x>J-^fOWpV3s@?BggccA
z=?wkBcTBFipe2F6kR=R1-8Zhm%J1?_fm-o{O6D|Y#Z?oM&#GOq2%n;hGjvBnivVuuefpR$4^Qy10vGJcw<>?D
zgUID3WjZWy{lE>zp$dvTbS3buHz!)5L5!+NtDJI%p7KfJ%r}}Wme_a(>P(Kpg#&y&
zo?=Gm7Q*Q$+b3hmJaAc@s3CzZ@}r;83UHYD+uS-cw)F=T0K4A{2llrX363EJ7SGQ<
z`V|aIMgM9l+zFIhnEU__Peld15c@&Ci|Xr2A2gup=1f<7xDP~cd`=3nOh==^xyUba
zj_DoL38}!AB{E+)mTCb%vP9xlRFSa9mxIV}^vSsI>c39Gi(O(0gHwcRN&(J2yb@A@
z<{=A68@2F*e>AU%?&H<3qiKsbmK;QAUHxV0IB7|AeFHc-#6t4Ult1@)emC+J(kl;?
zVU7G2onA?D3D$H0drk6#tq+^*Y>l07#s*r`H8&4R@oQgkaqnWE!n3A!C~R}RLKrnK
z$2mS?8fDg9ZKl46hh`c%EEGFIG(rT9ApjOd&Ga@`EH|iRIA6i0oF5ko%65K#v=^&*phmeS-QG+8p%)$e;M5-{4kE=D!4hnT0Sk@7FWhfU%ctgCMzQZE|
zPTMB+IRMk=^_c|5ikZTz3v45Na(Jvlh_9Qmm)}jY9_qLTZ@XdXx^4q!h$xbAV9ydfzGHcyJ3Vg(j
zyht`{s#})aiTXsnsx_lI*08X4SSs3EkqX^mZ3HfvoVz#j8KIOz;11NGCGX7^l_GpC
zA^W4YaYP}xK^eWWS!I$kaYR(m-yjs$KrV_-CH9l@YWbMCHySGkvp%K_0yF8p1~eZ2
zWCe-CLDzzFpDwo$(V3yq&d}+K0s&u#6iqGiljVq{kv#X&7Lk1wH?F;-z%;eaE&>*d
zXx_o5d+nfze`-<-Sq9=e?T$RVO71HezAlJaadd(s-(_jSNSjJi-7K0>^-dWWA`2
z0}A2#HyIw%|BfBeBq7;t7JTMeAUX&cLNwk7lqmwa$+~WPMFY(GV!ux8k|prLl_-XoZP3fh<7BWt5RU#G
zZeyCrAggH=Vc}&76{$}c3)v_DPP@QGrQ(S5nwiFL-UXy1kMvjV7_&nSMp`4(bn~qH
zxn7J@YFk=m5Iyvw@2yVUX<#OQD;cjPyi&vtI(3-y=SrASZ3@ynLAWEg
zFw<=39zzV&0NxLlC%W-9IFOks4Em}*-=h!AstZC|(Qh>vj}yZ%A7=Z6v!&|#q6%1M
ziSTOYoLJEv|2>VGnASgPU$^rYy~@>GpUxOE)}gH!O7j+v
z>4L`}MlI40>NehEBEcRMaNzompXWr&fWh`Kr$rqvacI4LjPJ`F)#P@yd1+wFP+@;Jtvd-ickpL)shvTmol47zBGDx
z4YvSRH@c|MbXb{II{H>b?`4!rPdmplL9>q?$K_p9_sTNTg`Z-i2h4T!0ea4j`m0!k
z>!xMjpD)Drl46~6gCqK}&6L=zno07(Xr#(OAMH}T>l%4vml&pDP9*;olosdZ1U!k?
zmq`BI)_f&=du`0c!j=05+p0aRzFnp2QeK?d)mtzdj}@g@j0Hl9PLOi^D?C)EyFs@V
zt5J8Dc{tv+T>Jo9F^uXsNbNnog2NW|~zv_)k(FVpTjh&6C=ZA2!N}ghpW?YS0IsW7l=fMC5}AKwmOc?)qW|9hYl|a
zB_<;*5#5X$g!rwS3Jup8fj(qWNSNpnd|!qi6xf1!pqJ82Om92my6a4g;KaAfy|#J*
zJwApenxLyvV(X
zcF0S~WoWRHX1;&$po|!NRLDx!Qd4xH?XcJkRr@A&Nzua{HlO`?sIQ@zHwl(c1Wy6@jr^T+JBUhG?~;dd2#3||KtsA-IyD?lK;mC`2HWC4DEk>pkn{=
z?YRJ1Z_M$@|H)29|BteQ{vYKIVI)We#9c*ugYlV@(UTcB&ChjpEZ6$U8H9D*BmRE|0>gv_@Cfe4g%To
zIYYxQf|}@mIu3~cBMbol({D%>MP3QP%=A_Lu>Ywf?SE}&lpoFi5-GR+>xAs-kCGpO@_6`A7mj}Pl)%~q~C4Ke5;{EdCddd#@
zb?$Jde&dS#tVsT~@A3Zc-?WFjuZ3YxHTgS(O-(}n&t|U|uFPiwa@plpe?oc*DXTRwu6_pHNrHY
z)AL%F%Yx~vU76kIO|6!-Gcy0%+ef`;<<%82PKOsaEIFav!O&;N^WQajZ;is6DSm>d
z&*vfj&QB)+x0TDoR|Xz+`L8`T+sI#u2wCtZt{uFAx><*5MHG|?eiXY;?{i5<8L)qC
zKhK`eoL$!OBcUSMOwY%3^
zz5D6)SW(6mc){c3>|_4vili%Ze5Vmb?am!`b|^I`Lf;XWhOiL2{-dvs=I${e9}9HDaA(rD$FGIsAibNlF2(RVfDR_@*!vo^FoYBPewcnGZtV
zDsc@on|7F@#Y@ch`RVZ9uZ7E&u$wP{rk3Y1USS&Ya}K8X{yk&UuX`I<&xO}_D`=Oq
zNNWG#oyoRK+IVNjkGJU9x(=Ew`~~eo&@z%*@@OA?e*5U~43YCOvh%lBU-?B~pl3%v
z`gWNTM>pj}fX**UJdn4SM3uKUT8%gVn}{wR;UMh>X~--tHIN2!$LF5X?3jujL)77)
zC)zGffwOH$(F3$dU|)e1RqKNk8Zc-AT<(H@hE&YcxLKGf(7z{0659x+Xr+wEdR8Ve0%*zLbV0|=Hyk1^{
z`=9aP9=$jJcqeZskLSXMA#MWpxe*ASJj~$WCPy^sri~3iZI=l_+n)dgnviKGH)I-m
zx#ARzW=be(2GER9oOl?v#PP=+U|9Ba-L`1;;$jx%zYaf-LbVa~F*1+={m+kAUB4r
zg~!gM9hcG(Wsj6bo+NmGESFW%RgyZ=(=2aLAm(IyF>vTozb1WizgML`rh%u_l0{$y
z@9~0*32~Ct!2;@rQ8Y|0`>9~JL4#c{P2Y)FvtOjXo*ZRExc~@t#hVCzlt4BaL1Qg8
zs0uR`e6CIr=xG9@{5}p?bIb@m0%;#kQZ*pfJi5V8i4UUr1%QIbC5Z2psjs~2*sTX=
zld0X&fA&;#P6t0i;k`#;orubI01>N8A4JcP@BO#zQ5yOA(~S_^hW=nvCh=(0j=f{s
z-`i{Tq8VwOVpPBx0-dp^iEYHHBL_SaZ5^=!+6(Ht@H$&fI6{6*Lm#Dyen@YiY2
zD;95K7W=&0|mgCh>30i^D|MIZt#!_tjxl2-x2&O|ei
zGHe(OR*4%RsbTO`YDnL?PIVmSbPe88NhkbdRuiOK;@`4~JUQQvDre?dnPq*r{3sD(
z3B48I;uf_wg0V)6ZxH{t(cdJDpB7rLLRZk^pcqJqaE#()7e0Z)*4ttMHHu;TB%h$uh`ZsRLcca&7($Sl@${i`g|EQVfgdaeH%t3a;&t^ea
zRfMeZV)PGQOFAYo`6#!b*Qx|7!bOTBT!!BZ8&G-5Q1APX_kf}Q?#`jA=*aLbdhQ#-
zCi@vmlgImaxr!($BJ>=P)bZCDqQJn7qc0@>5PUxj@o>_gKTGe*&R(!!+oqehGQNc4
zeV}B0=w{~N325f)@d9t1Q8Ms(YU$j{hZw-|<>&KCGpJd+=83e6nIaaO_GJwGxa$E-
zm0VVD^VxN8iG%Ivw;;u@$3OQPzdU9z%n-7NBmW{~I@`2--|e0p-rnl5A!ydmzAo7~
zr9qN~D@xxU*7s<~0-()f$`4a^!<$NB))4{5N
zY?6(_=p-k7&7cXzy@Hx-uu7e~Y-}Np7!7mfplzuLIuxSSTCgR}TE`&i?R69fuHbvN
z{$LPV+IGTr7&eVDo&jcxno+YT?UgJJ9fGSf`Q7&3EX;D&(;T!^Z
znxX|y;~sTHOJzQ0lWjO~XSqb5nzVV^ePkX)
z>Mk$L{w@o4g4`IU>(JxZ)G4G?4Y}i0;rCGs@SE=u9wmm6pv-F(?}){WD$xTXQ)xsGOI3#LNs$`
zVT>_nnQ{7^S;PrbSf0~rEx3xr*?Gh%#t$*qPU_Aanf~qnBa?{NO+8GX({$*fH=O|;
zBMl3u@SwgbHmCyv=c9@kdsS+bfhQ6f7(JP(Tozc&N^H~zw|)b#uK$PZl$
z$~v3ztsIghqt{&)(-SgEXZkx3c#z)^f&;^ysP3@zS;Y<-(G96Bd$H0kq>O2BeJh~I
zl{=@|0Jmh8Y|ce3$f~!+L^GMfHff19sZY15dr0T0IgM3Qn>JCDiS8UchC&CQKkHDD
zPqv~wVh6Cx4oHvzU|GXY5g9oQAOxm2aE#K>6>v=w--G|9ivmzl3UbAsQD-lT!fpLr
zrIX&NcWTw3**@CHniQN%)Z~k;5CzLh6jh$Rbpx10gG2hQ{(UG}p!~@f@Mkl0XsJ=}
zwU(+)ObF
z0kY=zO@XMvt75P;2
zo?C^5i6BY4`Ch@1mXLcJIwSUXtDt7PPFls%SParwT#LliC9Z7Y3|c0aokdjv_t?eW
zi6f$$)6PF(V;pKzPf=pHv8K2!0ivq3^<;d!y#cBgeU((G*3BmlW{Apu=o~|=dgP20
zEd~i07F%-B^>*W?e|tgB3pBggXy)~oa@fDx`F}SbaeA)#4BCDJ&0vRrgEtdL@8RLm
zu!8L)&m1(&e?n~kdr`zOH>kHKCwwZI|9piXo5^@ASQ&Y8M4Df!EkZausuR8DC}Cho
zN@bJTzHaFecH|q~d8zda^511%9l6}~c*D3EX8i|5pr0HN6P}!iyC<5ojlb!i7*?U5
zrKp@Be4&R*x!$@WBpeb5w|MN>y|&-pvU*w9en;RWtmqrNqjX;p49;HeU^p)Up=C$i
zdqgKh6p*bABXoK51fq|>MWdO*jB4y5$tFOjQ6m@|d~(GE5;$U!3~NE+Kp-g)3Y=}O
zUzTis)_UsTA-)gHeY!e*c&-RQuZs_#rHv5>@0HrHYsL)eC5eKF>WlJg9x(bJ+@Q9!
zkumKE-YP;0DEChNpqSV(2lcoSxR};dodX{R{h<8;m0fbv5ONoQvK8pdSAlXvQ;2Db
zTG|+v3c@8!YS9bt$FRGd_9>AFvoh1c)r-@c4u&{cVqoqRAUuo?9ViSTurJB7#3=*7
zj$yI*4HgT2&S{w&Wr-MTzhm6%0)ltaC*BV!_(I5!-=g|kSws$M4eVN|;CS}LjFu0)``uEk10s;Gf)I9lt8xK0|=&ggx6n_|4xy|4r^JulMuMoB7(A$4&qL
z>%Et>Idy#@x*tE{p8o$q^dNKQ|_YI>Ud=4*}g8Ah2Y3J(3YtHai
zJvqH4Cq%5sD4Du?ZQpnBme{TPdU14bsd{$T&u*S6i5oL~Z{-pM#v^s4792gfr1oD~
zI=_4znmV-jdx2mOy2W?Q+ee)~F3xXWzRll%*1q0AUjylAINa5@5pR0%KJ_h_q6j3s
z);95zqMy8hgZbefJj-x{421)p4;fb-Q%*8WS~a
zv(oB;%hXL^$N3k*KYy^7tljusgOwemr|mDD9{-B9F{E%BiAUb;BH5PN~vY-MSxNy}v#_;gi04_$ILDBD-Z)B`@Ktds_hL
z(&D+{7mx6O4EX$6x>71|@tl*;heORHlEMKpBgSS`x(ev*#w^MZazN9
z@?)D8P!sB&hYMWwG_P-#grkm9ZkgQdTut0I`ZJ6Cb!_nufgPBsD8YXcw(!faKYLz|
zb4=*Mjtv(Li-|AUu9ZBRFFO+b$6~a|6v$AT)@yIXd^H8epShVw~Z(R`>wBE
z0o%ez{DiBgJLkaO-Y+!8TRgW7GFAny&nfzkN_e5Egq6@gYSN}(mYWIVusF$OmTD@=
zW#zNRSDQcqSwE3`0$l)9k!toDl16tU;>7;kl)hZ|J3TS@%82R83T&)=Hhf4OsM
z!K6?X)If^JV7+bQ9QBa-^Pi(MU7IsZ$eM#2bRj$i2YT-=tmDM=CT45vE@^+2AxcjC
zS+Gc~hd6_);Z{;xZLt^r*G_UMeDYeUo$93DC)n3ShD=u0?W86?3Og0)``Sjn>aGz|
z$W2Notc04V_Nxp*@;pu@#VW>G3)*MuAQkF)_acLY&;ox)Tq8Dq*l)j<(wJRH2|qFA
zR~d|C#h-<+!X{y-zaRsY>R~v%`Gh`!WZdRLJqrJ416OhC-d&;VsC6HB_6;{3c*BLC
zwtjZJkmr)8$Uj~U#E*08X*=!Ya+zXIio=uJ@MGJV1Pi#gVZ$S}lAMeQQvieE%~ofy
zHYR~vt&Ok{&3U~|>;RVEa)jsO;_5MAqtLpwhv5IFBM4=2oQ
zi=#Zav*5vcTJI&{MtUZ|x{7nH5}`XQtvZ4<$GX~R?*Tf(WLYx;Puljdr3mM>SuN`?MJDL5^IjWoYSwcTt-W!dXtK2dOjNF7aDqaY?g30~^Hmzc`L9
zbsHHFyHP&WMk$acaHDMpSyDy+?60hUv^?T150A&<6xh4Pa!_Nu_9h9C6$mj1nqg)G
zSz;#YUXUKiAyyFS*7=d`4|qT{T{nIwrh|ej(pi)6y)2pu8vg*HbvXLq@VhlzTZQKE
zq;o{RjS#<(aj9v#8Bn&fd_|3kR?YiWbo9rQA<)thX!bhO6RM2AP|oy_{f^77prJ09~ydu^{{(6H((B+O9ORQ*F{
zQRtCtF&z#;Gp_Y+C$2S)eM~{w@|Ak=*7q0q57IFsAKsQDjF+pb?*(ZIKNSfC*P)#KJn1I;Q=o?b9%?o9KEhi*+F|W}L;vx|
zOpbA@Fu0ZiL>V_mkxFrvgM*|cZ|I;ZQGrf49Z{aOY~UCujHfyX=lGG$PVwh>|LCmyYZHDn0ZAHuoj_N=qP
z+Z#`)`ukPol@XdRsMJVwo_Up#{dZZah^>_q98OVzC)svY)F>~gpOu7p^jO)XDpLx>
zH)&cc_8X**+GKfJg5S#N6NU1;vYP4a`fiU~Z^tACm>Z~&>XLDA&#b4`($DMv{|bx?
zThu>C9UW$^^!fqiERkSLHWo3DZQt~flCuj36aPs~vUDl8(o`Q+cEQ-cq~&LpoMfrFs{%a9)zdy28xxcfxjwox>zc)&8`R14=hOrNOag
zVea8SMZo$T=%!c~Iv<=#p@&rQ1FXR6wf-(ae^hphmG>{`zsP?p+%uWqsVX&+L7Ke_
zmDx|~=(jj#N5|*LCy7!6i$4U5a7t;g^jap`{&VX6|&pr?C*1+|nz0q>@HLYpq^I
zl*jp|=dL`wm5K?_??0P7T>h82n#fmg9!H3)LnFu~5KTdv$fCBHE?d3^=TW{!NwgCp
ziSb@XDn9=*Y_iD?=~4kQ#SfG`MC(U4EAvFp8k7Pq$t=i?oa@#*`%N$
z#el)|s)H?1-R|7Wl&h`(lt)^
t9OH}C~DPy14ex#M_nDYN!iugb!Z)2dts>03hD
ze+F9qEqwSyUWp)PT(KS@hYagRUt&CF3of(~5)Ee$uB+093Um}j9an7>@FiOM=6cc=
z(p7T#zNS47pIbexG*#*!Q5+S3oyS7*lD(q%6-uaj0M9XV>-Q+df*90Cu%2-J%}rx7
zd0alA+YDda<3l%_Lfm0caEYDwsnkG}i*8{pn{g9(c%gJp`7jo3xTe%Vy>_X+q?LwB
z*S#Q0G-rbAeVv#WHU9`zzUWr?nN9u=?`%)hkFM`%frPEk{fU$RL~
z5sMRzi}|QLOzbcdi^u*h*ocA=?f_PhbGmqP>{H(_Fld?#Y6YXxtH!ghg)+sr_M@}U
zxkU2edFgf*T!4q|UL61vA{k}Y-nYHeAOW(7VKNd~4M}E;jKC%{vyUV9qlq-rK9&fD
zdd0p})qh(T{Z=Q7cBQ>iagU%x^ubbAUK5N=3dFB+3FfFIVUsjTeAdx1Yrg7M+7HJCyE*>#e1%xn(DL)MjTd
zC6YnME4u{06w%HHZBy9n8Zl9U}^tJ5miA
z3EgjX>~Otfq^qcgeIWuf+`iTDX3ZN7XZ$lV<3OT^oT@orQ;&m+o$(e2T|SC!QbVaS
zuWkcGIGTJ2=P%7dyb5?;6_Jarg`{L%^09D*1|yx4qG(s4M*a{9I;d`xiiieQS(??&
zr-)s*Gl3#jS!P)TVOgQ7i7hn>`Ow}k6+TpWl?0;QS$%p^v>bVul&=4|yz~K-({{qb
z(PRIap|JXaAF}>%R|MI!kLIR!RCvgJXxDftmK>CEzSYO+(xSM@I1<~aJ-k#l|IrB2|e0Y33e}-mUpT^27Ixg-%j~!
zi7pir=e>^HOLznPzx^;ticg_V$lEbm0d>;YYkc)71riNvYr_
z@cr{qz(E$m$P)b~D#HNwrMf(143GUnI($GudnX>W&@JOPHw-Exo8b$&EAe6N`of@o
zyV8adM8z~!?o!ZXtu(168ycO(cFOwe>@>OS*G5I#-Z?>&>YMd6Oxl`(%|ww7G5{W0
zi+*u>%xMb9MQe0kz4-R6Y2-Tia%4cgN4zSO(yE@Unbdu5eZC`yU>;nO=UGM9zg?U;
zETJf%N}X%5R_UC8l_35CHY#~0xvRa_YQ{`MWRO-
z!Q0UWB5E1Km=+C~Vl-kI!?=`@1;QjNM%PqCPRM}`O%y`SZUmXVa=98$#b#)I3y{X^
z^?yoi%h9s>zAYTQsg7m7>J3jV3sCnoaz`rMm?khEwlk)ziO~$c(SyI-N=qk@s&uI{
z+xE%&zlI71{!lpZF149QgvdP0xuu|yij5FfF}8tPyz05dL+EKiR#WGW5Q!tSRJA=L
zG2$xk=Lw&W(9Q@^)PJx<(My@s{y#1Mkv1~6?j!f`;hU%qI*Uc51U4<&w-afB9HU!n
zUH;32LE=TxDTUGKbe_m556MJ|D8uoOn#sp{b+g?$u1?zOOj1T{U4@j^cn1aD`8jDn;t_Uf&7Mu8mo`5$pXT(%ozND>wJO&~dx#tb<-yOPH$$*eBPto@%is_M>^X6**P{l17(JQa~01}qDvni3IbZIS5x
zmcDC65>~4ngS0l8gf+|ng*<^VS)S~gQ^g*(+^nHUi#`;A3;s~w=YAT1~sRll{*+k4R~yOUK~?%%kGYA#3c
zS!S3xM5HF2C%=RsMlaHE|u(QHl5i1}yKmW2S{*
zduApNx-X=q=ijt&oOEvyIqK9lTJRR2SaIJb>&w*uy4n1jLrLQG812H$oM?sf{{*EQ
zn#^#&Al)&X^GV@rEr^KHb2?|^z{Gre#8Gz~(W{o?e5Hg7tf<)>a(emkSLgBqfJhA%
z+clsX$Q&=0(n@_IZXT5cipqJt}W!nlH-!;sZdA?hpiE
z?{qjP5LLZ;E9g1Lmytk0bg_5Tf~EwNUmU5!uhMfrCvtYmAI&KHwb1Vn3`|#ZET!VR
zF`8qmDfofH{;g3oi&-Y6=$k{qFAKWk@!KMULoMx820RJ$zFvr5$Bv^%I==gLPLzg9aG1fE{AR==&@>zthHU{0Q#(V$+l|1|t8e2VS6V!!j*YjEzS)^?a#KFa7R21M$j4tFyu
z0}ULhI%F%lwCbvRXL>zdG>1T*b%;3gRwzRyMID8_*;-
zn_*_+DZljRPC6`YrN6s)(%+E^I3w_0yddFCsuNnSFnPPjzG^=S)$DlaAvmW9^hZxT
zlC}7pz*dXScRJ98TILYLiiN;6(akN1$>MXLO`>^_&dn6mZ|90Zyc#0P|XtSONHwaKTqM>p3{
z^Q10jFM$rACsZ~CE@968rU60dZY-9Zw*0~)T3MNgKo=5|Iof`E^Ey`9jy|(ln*gpm
zA7_cU7%_O1gb_Z=AtcBP;u>x6u+_qCl@YZzH60Cv3l@8pd_LCtkMb<07I1Hsb!)O+
zWt~ZDF?f~`%cTXetL|=d&PGd_cCf*P>b??reko;3gl^d&?rvVS?1MRHXJTW80T-&IP?{&_mDT84guj+{+pW8zJu
zQC=>5x|}$uzH1>zAuKtCRC9}l?sN_aKC=Wc%Dpewe+D`xfACXC+_#+dACs&M8LIAQ
z8mgjZeJ2L^iu#@2M>h0>B>u1y_zHmWUhUbG&R3mbGP#T40P;D`fruWK+E`x~XQdRU
zrAARXCr!s2_YxdeM(uW8ba>}@$bglSX>Qf|xWvF24SD;cYw2`ZBT1g-Jes5XQ9fpN
zfNvCEn4Wa}stQ=bgWn1x_mb&}4a*lf#DKCNVoFS>I{_+cRll(AWnH9A;)HHhGQEG-
zANI7l%QD{Ua_D>$=OOBFh)8w7a;UZoS4?b{(6~R2Fcx-U;nxo04@r7f1*!LNNWxYs
z(XY-gndDnU2ilJVwcz%h7>n;Eg$&sM%Z9$|m-EZXoT^o+uUiCu$tlfMOagp^h?cVP
z3vyLPxBQ&E86(iSM6fd_lbPc)@-|?I4RExdNIm4TC{|`8r=~-5)^VKzdGo0(vd(fU+0et#RB!?U
zYu=nf=;{WG&I+*e1qe1=#vQL_#r@nw+J)
z4i~0?+Lp=hVC#MP%K~)uXlRsxAe@X87?K`6=$$qI)kQBNmfLaF_icus?Mtj}i`~Rl
z`4x_vhTA>RDr7|a4}W|Dr9PM_Yohg60{g>Uj$Dv)jDIpCOY8o+<|>tgPLCk3xI&L6
za@nm)GF1RC^T%-=%PIMNm?&UxXcLkON~+uehtE&<+h{{0JRV%)Gr5O~q_g`a#ohYr
zZ;_{1sdS{3WG%qC0d^66w}sfsByPQU#%}e$&7|a&7U~d2IeoMQXNRcC*S|F?ZbPoW#5u`h2UvoE|^?}t+ThJ}=eNAYgy4$ZN
zvJi3Ylzt@nk~kRA%~SC^Ac**ArT8-*FQ%11Ncf=iI!Bs48Xpf{_AweE^^vLlhVptE
zeJSGSlTVsVC`%Oa@uDM0EfAF>>c^`hcPKtrIvO7yRrWy)9BAXDN!Bm)FSX8f`I0>p
z&jTfJwhu>fyUgbCJm0`irp`ZS=JGnTX{<;6nH{12K-?|>EehVOs_Q$iP9wz7&c$!j
zQsU*j*6CmI`8r_ezqXa-_I_M3wO;}>bocUj^Sf{Kbq6Z*;Knc}Js3Lsyu?rKW99;v
z2%at>Q@J>JTIPlt@JZ7->Y_rJVfyRknn?Pmn+ui^yoF}^r8fjy6g$-u{)
zuXde}8_y46H97y+bKn$EfPd2Ob2&$Vf#B;hHPs(z_w>F^V1B(N=+f%RoABqoWMJO%
zYhr3Ud!*v6$1bIZ*WW$uBLlSSA{+CaVTQAVY49r-uN&#Z)A#WkC%%@6u|6V><-H37
z?DGG(dzhs9J|1=RzsinZANZz&#~%V~?CG*Witjj{(Jgzw+<$63EaHx$a@`=z6;cSC
zN}cas<;!k{dOV)ES_YmTPlbSCR8bwJ1_*P6bnDH
zcNA^^CBbHwzApZ5!9K(AiYW|-?~zR9JzvICIuX3yL}(4%+QlY)p707c{}VxZ3NwGF
zn5|+5nXaTDKiUs-9@(a^kZLz0s(|SMsR^#cHA;ddq&w(Td&3ga9&s4J8)&{`DaAeE
zOk2WC2daCF-W_}=1m@e%;sIqUI^bS;icqf5_`an!=X$s#^W&Rf=z
zHc|t{s~KgA;}JCS3+63=!h=12mZtpn68>uVr_~R6tJZ2#pZX9A={gxO`I|M=JjfgH
z>z$ugjP!Qqo7AmeY&((&;wNxy0sp%NrQaCyZw{1+NwHa?_R_%`5Z*p*`cRzSq#}*t
zKnf4ZA_XvyAP#b=wREA)g^lEGt-OdqYqc%*#K&~mTtP{FXHarEuXq?%^1v;b-cCuj
zP=1QtWfG4c%UF`W$nA`k+pzlG0ZT~d=tAqk6t1ax`z?MR^=K2UH-+dEmAhkFv<>vV
zY6G_Q3corcrgVJZ*fYb^h?0t~l)
zhfE-d>XY(U77LXkg3lxUkS$VXO*q+-}3FdD(M!%V3{{Q>1`eBm)gb0
z(pE`K{xR~}nLliBal;Ko6a2i#Z;!&V@iUU{rWlJS=5~5RTx!xueSRHcOUL7Op
zBW;sr=+?L2{ZJC>7$PHoC+>_!+Aj3J;bjl{J6kPfx5*Sb)}CG#3tN4{Ef5rAKs$J3
zsUQ06q@q!uw(^r1)HrCM9DTsst3G1og^Bt%xDOOfKmOvpfUgO7;A@_?M8J_!rXv0p
zbs6SS0&?LPInluDRcFJ#-7qWmcbRIJFEcJ^;(iHA7Qg6j^qaVfLz8P0d@4E_B$n%v
zk62g&?9%imI3e%OGCnFxCR9(VZgjQb&!Ys8
zLXa7gLl5#ImVAnqZ!+wE0X3~oK0}G_E*o;GPkhA25@6YnY9>D|dmGf2
z%doA3!dCp^7oLeSC=p24!l2e%l_g*H>L-L<~r+
z&bTTFkhQ8zROS=DAtQ!-mcFDeM&l(N^<~(()Vc49E<0>a^)Hu5$0(~nFsAr
zYn7y?_cb`_1WVieMW)IPo5>kYz0K$30#!0)j>-v|mho}XYQ!<=zK4{ChFcu*p383E
zd+|k6?0D1>Cp!a4gV`taT7B3|%RtgIaI1C^gHYhMz{Fp&DcIDeoh6&2%!N&kGcu_bNY#B_hr&(zhn&HQnI~HEOpQN*jFaH!}C#<O!GY|8O(`t`!8=Q%>`LLEW&6Kj>bIPNJvI01|nFT{DH0QOA>DcA!;x4ZRYv&6T
zJyO6hi_r~{(-qK6VkB3;QEs_l9DT6}rhsY@}D!F=H$s3{hu`ZO`7UgS`5q7u{#^^tH&t(Lk|aKx^;e`;wIwvM`L
z8GcO^jt&J7e1DzQR~&)<%BLlVwP|0qZm0#hwV6}dc%>Z9N-u9a4Z^KEr@fR+7Q3#A
zk#mk9mAq|CWjQvjoZ|Ue!wYOfI6%omUCG@Ri|TYtTh*osmOkY-7ca50|D%6~MmyM%
zmHTo=?aU>^0BN&|RjK)8VMam{H*cJAvYY*xghQfeLKDxhZ+jwjZJ`WE)-w!Rn
zI@dphoe+$Yz|v0px2P9k<@2{_TGd;3re3$4|QrhK?ZcXgr2E>^LAPh=qg
zY}o1REtzmgDi_5}mYc&u6bKlVv9-SCq{v#mFdoRg$^RE
zX_{{h6bwC<9LV}9Go~PioS3lx9@b+|j+pXMQoP#m6ZDPWl_q%JF$&?An0nBs47u=X
z9|hBDn+4a8PV`l#_w$Do;|Z}%@Ky{n%bQpBk`%$utU9R4+?Ny3rl9U<%434Pu-0xm
zcj}-;i^5QxjK76U{rcGS3=gqY&}_?04(8UT4=`uKpR6dx4j7t_9NR2{Od0x-CJ(SuL)ev$VG(Vzc=IV6yp~c!B5_
zPnY*q>c~Ofgr?kU>N1F%QZ3IjiFu^NlpPmVi_3C>x-G)@xbfjl9;>ozs3f&({!TP#
z`?HN74`TRukOeDq@nrhkh;NgV)4VjyTz2TdOM^N43uDSBq6@S!iS9V~)@X$`qw(LCXp)3ojtkH-olQCzba@=s+$<0#gm?9@McZYkC!>0>;
zfne{}v(3J)S(^EV_BXF(ySb|i*u{7JhY@Y*I%^)Tf1VJVH&ToN^yTBJ-xP_>_qhP%
zAq$B0Ck^=wnDHX@%h$0cwr0opwEBt($gchTpCQyB<;1rF!>90g7ISeJb{@?|`O+}w
zUvsI=Oc9bE3VfK7aYk_7uJ=Ffg5OKGb@%V)Z?DaLU`kdAtJw+p@tS+C&`ReApKvcY
zyvX}M_tAN`ef(ChbCvwtxb0eMed@ZDHrjosD~m;!4pu=M6Bb|b_&=T4(-6g9bFoq<
zyx0jXKeVOK7&A!8BMm9E@3-!rwP43pC_M413W@A^iu<0x9h@Dx+I
z-}beTHvB0~-6_YZ(`mAb*%#JLr@s^2A*kMPcc7TDa!!7IJ~g!>6~QGW$E|08-|NI_q+^QY11{eGwUq}?
zUf{>oJA*u7Em3u%|3;SIR?GS~)3$W)mXAf%!eH*|23UA%)%@kcQdc!`Z27=@%lo_c
z+ws>HZ`a2*;o=P8)|STGI&KR%-X!ygo5w=NKf$N@qt}Te#RSVQJ_4Nk-J4ff_t9Of
zmv1?B+~g?-xq-y;-0dE+fg(jlkT@`N#wmn*>IWD=6A9mVgk3dl^=$fjZ4ov*Ul;Kb;nx)*dkpm-EIbx_uQB{)q*wB_5-U6m~9N?w>NaD}ShvNb2U#c)YdOxYue$uIM-8S|H{E8f@%3
zQ`-b=y8DeNTKqPDap^yY&z#kUJbw}X-=cYg`uSXUem_Bq0sVpSzoL0NyLj4|I{yc@
zzR=Zm+UHF4+m7f87P_X_^rx@re-cTpKwn2@K}FYY!o8=SXq=)0(uumSH!!uVvRptM
z8Nn$LLjb@NexUpgI`lhf-o(iKff6~%&?BP*JT>h)0}_zEdvvs2AqiwYd(WA*b;WbU
zF9W|`_ysyHo}W&QoO?8EIp$oy*w&uET<&YWoSNkI)#qADD5bn@BBnmuzy20?$OrfN
zy`oiNz9X&cHX42%8)j5uQoXZ#;$65)Hnwh?6Kd5!7Tn)Q_jw`Pzl9_7SEc?DT#7yz
zxxcb$)4j&9^ueszdtf81*w$tc06w*@l1F!-qduB)YSMZ$3`CnOcuPhJBz`qMxi8%^
zuU@qvokFo+8NA>8WGHBFZRoS9)yNhzA~}y`%|x6QPj2fW1(3)>NVSOLNOsli(XK8ppQ)sJmGy)O_3{M#Ur#Nm>x=BC
zMK;Q-07Qr!e~rrh#dE`1#Zj;$)P)SE>X(sF-4Pjtq4S-C8Xc=k)yc*@1HEX=JGOa0E*Z@#Ed6e_%a<>W
z(6`APoBQwZ>pVR!scMfBRMTj)V=Z_h0QZ#g`Pqlm0@cSx3u?EB^K0serK91XZ@;gu
zK7-py1?F70`r5MRKc0I_jPb7L>2nV*8)7jjCAk;~(z;lX0M
zX*3C&+7~w2bM%zZ)s+fR{R57Gr&Wr`{WCcC^pZHJ_sk^CiM
zY@{+x`@qq;A;9>S+KAoz7bLy%rsbg1XnA!rU1RwkGb@&Bt$%ST!-g1EUfj4I2IBBo
z)n6)r@-~QRZkb=?-Ud?;BM#nC^g;d4Diyh`Kz-PerL(JA!v|F`(<)++R&R#@)L9w*
zf2kIH;Y@moL?y*1Bn6w2maxK~I?>U0sx^
zJ8|1j2BT(R4(&4#=!U*+uEe`_B)Nsskv?PYnd$BRL0ClMoDl8{CTCFU(BI=aaWyPs
z677H9YMtcA5Zf^M@){oBuzKO-;ppkfl@Sx3Bze_XCh_MQdVQ|L)@g=0T6Egiqc7$D
zrXiz3_2Ex_B-!o0^3%3U$3$_Ptg;wWYg>CfX8ih;QL?T5EzD<9j9VWT#xn3Bl8F>{
z)bKXbE?)CRkp08a<@EZ9`G8o$KRHrUf(p1fU=oxT-Gk1+fp5zNSM(;?vbjW6?=6N@
zkR;%DW&|piVj8OYr+1$ox*C*0>?yXqK%1OetI&vAEBT=c%B5Xled>LErfD-xoFl*!
zeZr#YEk*as-fWnc&fggC*YM(`h4)bEq&KghrvnM%Hsh@bp;4Y4
zgEJK_|DyJVTg7q@f6aBiNj3}Ty+G<0tFyBFw(m54?))>?sTKaAo!S@UxyltDq8@?Pk>jsS@rjF(z10>U
ztMdDjw0$a#WA;}wez#-YTp=!bYTd={XLK+9Jau8*mulf_?uTk&D9qvPl3Ty=E&0`V
zDsKVP5=P69D`i43YD1Y)bZJ+zM3Ym5Scyv^JT$GC0&TmNCrfw_m)!t12gZRBO^p1C
zefX}_aI;>+#H=rn3Z|X&YOPvJK=_ImQW%wg8?;3qJj`vG>}q3a6BD(@=%;Z1v54iSFm6!E*ctIui~e|E
zkBrW}xHI0?vBpKLQOz@6$8PJyggf=q0CYWePvLLz8gK4Rm*l<~53PQTY%P{w?xu^_
zSJzc+Q@Mwisi8%S!Bj=dR*O_c=HzC1eD4$x`fo=^9Ep`{8sjOk)sGc?!gU1
zP^07;yuY96oHP!x8JE@=L7r*mdFZ<ReF#?dk?5)T$w2G
ztNSJH_uGYJ6&(!5IXazbQ%w*5c<}PMDn819L-TK6v5VNqr_@gc@(5Q;w=m-A^o9sI
zg@(M;h(C%;;eK&x)cah81ToR}$_b;nb`e_9$t^I96LyqV69^{2%6$%Xp~R%G7|IaT
z&c@Mo$e;_#D$(o(dI1Zn+&;H$wcH4~wSP_00ySs)_Oo;|q|vvuhViWK8nsJslK*(%
z@V(owSZNLYJs^-+no6B}9dfwJUb&%PIe%zsvO)pSRxwv
zUN*I2VvTmg2`#_U5NIDJU##(T$kXK5T8dtN#@cXR!ZxA7Mwwcx_(C@p%QPg5nsB1f
zNT0n=91wB84?7NsaxtJuEohw{+xA-^M-G#gbYyVC(BDVjAAhy#L$zQ|V>2S1)(CjoVX+99N1lLBmtW>lSL%sz%OH+GKH
zp47^NCx6{c0SwfQGay!N?9e?5+7@&}$-#vK7vYKY0xWOH;&+njr$Av-IE^|jm)pY=
z@I;P^<@sCO*~tz1JfNs1K%B@RRpMl*g=dPS)|{!Q5I5;kmB_g0eFiX5QG@q!jw(`YIw{olntkqx~bwF0f2136;wH6o;5
z9zMk^Y<{ODXZO@V?PE+r&!u}`3%12=L6NDVW+3XLgg~-T9^yP$S)0XSR>%Z2oySGN
z7Q>p8+)gibg2=aiRf$aS!DOi-7YK!O8T+!rcgaE5AvekcK
zUeYd69{tsOhma7(s%JK?5p>Kc;E-ILhX>Maj_2i(iVAxLQ)K(C28fu@u4&2G7OV11
zWd{`V8{Y6b^_`C+C2S0DA19H;D9e-)!O{ZR7H&j`G*{@aTDzb0x8nC|{PI0QY6X-Q
z!c8i)BiNE~;W=}GNt?-H16^Sb?_xyxXh!4L`$Ckf(++Yl&nqT@PSRu;{lcHZ8G6s5
z(V(Ek%6Evw$&#?zBLWNOx>X{Z6EhA-v@dE{y%w9vq^hV-r}H&ANvILV+L^hhE#tY2
zwzsJw1f|epE%YmrXgWM^g_k(D}t+UuY^zH^$j*I@kplLI?$J6n)tihFwS|4Y7o}_EZG+d)9DaMmZWtw@mtoJ
zo^;Q`T^v7s6MA|`TR>_mK@fsW2{l!uGjdQ1
zR?r*Cqa-L@9~G>RIx$LFx$c()cSJzrnK3oGP{1AyXiT;i+x}D$Ef|Ut>gu
z?fDXVL5WlX{gQ!g4WF$FzIjePK6J%0O`+{KW`~I!CMprJ_b7g@w~+iOt9Gc9n@p4G
z`&_s-(PUEhLJAW61`p5C$(wA}q4D8|%X%b4%nSqSJ78$wLPF7B!jL?rOgXy<$?;=7rP)B@
z$H6)-FyJe9d$yZah?RaK*0MyYZIO-+>0)*M6<}GA^_k4oHH&lzenfUetrWc=vIOx+
z-}v*I`+pAxKYg6vH;47{)S0&-HiLpA-wK~`sj|`wh*%@&_t}JCV@X(1^d*k#-JG6J
zIOzx9dYCIf2s4DHi!0PNAj%LO|MhV8vos~F5x!FrW$FulhnLKY9LVdBxz=Y1>O%r_
zq$$V*MIIW8!U3+-=_A6FpMF-{>JPtWC8o_|VrC@56SydnuaC-qG>nn6KH@H*)Zl(X
z;!`P;yf!$oM^w!u#|=~|?R6)_MfLw8Z~Bd$$>^f{#^Bm%PsD|UY!1VR;%iAfOYgF>
zo$sXBX38u^FirD9GXl?K`{lB+rPyu-mv$e>m6wnwEas-jEDm9i%lBq!Op>549q%e>
zs7PnWNZ-(>b6ag>8l|Kx$IM+SFvQ~<)IaKrS|>hJaQZ0iO}Cj6LEM}#zvp;g&`1jk!zofWYuud
zWLid?%CNd8s~}qhElfZ8OcDN$I1_|nCB0tnWB|ITJu`A_YFIzyW4NdBjGWcYV
z$Pj=I+}vuTS-)Aq7RZhGz^yUzH>Nc4qM^o#Y%!mP5
zPC8#hP>}T+&@h%9KBl?*qi40s;TKU%|0$l^!mer!+jT#*lrCt|r8&s$U(H`*_r)^{
z8)RwlYx^_2ykjkw=@_%ARNumXn50L-Lf4L^{H6kN4J9<7WnuJ1kAv~z4J!c$zIH+?
z8yx{xP7>Zt^w}IEZE-Ays(hzG!L>)RR^gIMQEtGLPh-XG)oFQnF&v5xg44iTp;hi7
zAaWo>;to>`krbpng){@hy);!MqMZTARU`qH7@cui-g;&_15g;}xh
zc!~9jR=;ZS(JUJKS>LqQ8XrMc2i0;%UI(?vPg^)Fh>gQdvK9pcVueN-_R9v-aS_64
zQ?ggNl%CQ=Hdu|PZKx`Eo_tC2O@y>ur4LLt*pCii9y@k)eF)fGlHY0xDX|1u3k-G|
zC3Xfh0iUe<9=H{LN|jL>=s{8ncnA6w7r;4@vJ%$XX|sZ1@+`>AjBAKMSZ%jD&Hd)X
z;pkYiYSwI(t43K)T50`Cdf4#1&o-Lr+p9FIx{Z*r1FwvoQ!o4HH5rc;FeypqeuHY0nG{dLFGf-CiJ>dLL7B?3!&
zmAIJ1Xmr6Pk_N)rpgdBczpZ=NPys##6w&vge&thg$}vndqJ6?_unG@u^Qo-E0<9$4
za?OB}3J2LUMbJ^%mj+QjT^dQab{QljUL~n?d@sPzCnONhQ(CWCS@U3At?cOXYTOU-l?}*UaoA|HyI49HyT-|_}da2p9i}(
zIPKC}FcdT4gp_9m0!a}1Y0#TFAiBLIVWGhLKlizAn8pZv`65sc_e*N(8WYy(<#Qccy1tp)LWQLP)3*Lt_Rdzai(=-lnxec+3?A|ak*kzaB|la>!EUZq9KFD~f_KbGHb
zO?A%mNp0zb({#?*7zPf-Dh~HJ_*F!3q&lU&j@9FrYR_X{0kR-TG_d|{<=i|VJLdFu
zN{reZD*Pw$4%x<%5g-0?_r)
z;C2s$e+UUSIVS%?fATt!%GCPOD>z3hX5Ez%#!>~Qn}3649dg2WjcKIVl;;vF4%uoG
zw}xJ2k1+`;iCyoHUpm+8AzwrB%7R-sbW319kRznCQ%}KR2sWa3B
zmA$e|>L~gw&U5w7g?^(8y#a4r-*qvD)uUy0mtaht@1<4uFu9}nqyM!>%q*=)Cf&6M
zgFaav0Tfs?kG%x&LsnQ2aDL2|WDts^MNeC`=rX)^`!M_KzkcFPYK*F`m2ciqWX~`~
z_rQv=lqPOixTg`t2D%d!r@?>B^PKQfl9oy>38JSe4c+H&(wuz5P}L~*6xA9oUJ~w2
zoS{xoDYwd5#0g==Mj(_#$^>gen#EteVS$|GJMQ2AKF9uAyauU#&R_7YXHAwsnZYkM
z$V35%>JjI~#E)H{@TsSYMGSqWC}jbEvBAZCDGNfW6y8eoNc@nQj|SaL06usU^YBiZ
z&Rc$H2_xxlws1pK{UHXeAnBC?H#rT9e5k-2#S@opToXC6`sMdx>pDD`t2L3uo(7)j
zG_PFY5&rZv%;&D4lt8VQCwIFf!=8?zUKOudFyE#eh&q>YM!6C!nD05DmU&%W25$JI
zA(Xcia2$^|@wE70Pi4d3isLcHK=+EO9)N==g_gcRDS^n|M73ol7`N6f
zo~iuU+6*mh3?=tCDw#riHSD&@M1;vbZUiP0aQK1JD&wi?CNw@_ZGK(JuB>RwKuu+c
zKRQw=9B~Yp7I$~~(@HSW@Oa(j$ms_0NxV?kx{_~<$C>a}1~jQ-{wU*HAbI6>ZriCM
zd3f3(Vx#Pt&P|&1T*Dc#8aCxM9Zw}f_q??5f+f&mxcr?T<<_0$dh{9y=Lt!BqD7a+
z2Jn5Y+TG@3jWKD`4ra^I!E~-fa12>CE`0vH|_cTLB=3XVcXb?cM}nf^O#4Jlb-^
zdf#)zWY;tEg{6
zyckxnw2++&zG&D_(%fy^>fU+Hu$nPTA6$`{A3Wc;sQCzBoR}rvtvWeYklu0GfquhN
zJ3@TZl>$fJpn!is>_}GywU%)FMm3mQKnRB9r7B!J@`gwfMOCX5@c5Ns^bYR3=xV^J
zu-JL@akQ?ZTyHxpbt3fH`gbdcxNr=T3J|*Xb(=~F_Idd21gk0mXzMu#P%MQGdH_0yhz1uk*6)X%`5m=fary!AE(!nEon5tioEO&mq
z5A-;c{FE$5=sX8?_pxAcDlAmjrJ7y_I@T4q6?vcxBq?6Q?&nO%94w(9=R$>h@O&pO4nq^d}GBTqZHX&h2BI+D@p`m2*$f
z9Tt89>G8VdIGnL`L6bIqqo(pn5T!rrvYi?5SLQZ^t^(}3#Qk=6r_Dg!HpVBNqgAN_r6Su4_OWG8Etu(-EJf*1Rn
zNffpgkyoW?=|v+nL%@lRI&Hb(H77!O^^zKJId`=+=xwOiBq9D5WB90kxli@Ht@+d%
zardubz9GYTxWX5E+d4I|k9ZgVyX~#+eMj+vc2dRLV^=1AFjZ~j?{iL_!Yi`KX0^=+
z)Qt@>cR92WBL7hRP5MCwn$tmy5E)Rzv?z`sCU_;(B>OaMgc%=iaO$|XeJ5hyvufUD>wL3w-dNi?UM78Sux(=dx?j$ez7~w$A!PRt*Qzks
z(`oiUp0KIYtKcmDtekRBqzFZ@D+fv5{#=UMF%3G=2~>Gw+Wnneomm-~<&@TFQE{1u
z2N>>IgzvO;OERQ0Q1taHp9Q8sG_x5T%P|fERdLi3rGFGR*SE|Ut6jX+9{aYIR$q6D
zwI;3W>47z>vQ}s5r{_cct9Hq*)c5OF-=`<~DesqdlY^TFP2HW1CUd@i=l7f2oI0|O
z3LP5m?2k~XKHe^udnd0?`g=(#&pKl$nJzMx=``u1t%9AOc^1Q)OQkbPSc4@bo;
zI%4H+N@l9LN-uKh8a1|>WQ-Ip2Gx^7v9?Q+YcKpCLHz&Pw7aESpBDiX2*?5&2#Dxk
z!u-Z=PR0&4`c~5BHkOX`|9-^yx7dGF%7*O<2kg)WLi2mir6c*mgpFn(*_R9(?V2iz
zU+W$45f%L!qzb=c^IE#z(wgC1U_PBvGE#aEAc#!!y+52<-4+-!ZJIh$%brMjf_GeH
zs=wa%9kAmcQyCw5n)jTjcg&T(alBv0I=*H(-%PJ#ysPDg$<=xM
z?ckRr>c}3xCR^R)tBd%0W-6foXLO3WZV&4uzL?7jPHe+0{4{zXowVXBR}j2HdO@^e
zZ@ilPMhu<@mbAEIDp?u+@*U@m`Ri+MADhCNqvH3u#QHjqPki~JYdD?|N9=CgL*F!i
z7QB|F>39@|)27Ce(B6HY+l)?Vq-th0Y42z!Mdj1aLQ+xOiml&$bd^ZO!*P=k@uttJ
z$L#gHrw#{2A92gpl_hw&R}ay*6!cdN=F*FbbKW>8`Qo#rLn})sn?kNS%Sq&>9oH*P
zmH3|4JnB%!h9udo!&QPMbQ;OvV;y<-o?x&Ml%PJyA#V9I6CJzzI2P2*;k~jOq<@}m
z>87B&cXX}t$VpLKq*$2R>al?*N|rKRb=P{4xPL7S_G`UK%8_(R8K|Fn%Szp
zm|DC!fHjYyPgyJs|4Hm>{}~y3Rgs*A(53?~au!wWYr6QN%7ET*VDiT2JmEl2A{8IB
z*fjO&hVCo}<4*a$3C=-*pE}~wHMFIYgis^&y^EsL8ZwMJP=%lo@|dkib878vbouCB
zC@mFE$^!&DsilpcWp|cU
z_Eg{Ss^4vGF+GPC$)jFr4c{Ycx(rV*FrOg@eFp7ox^e7B37c@3J27>2QM*Wz^KCd!
zQ+8}PFH?vwIDW@;SjM#P{N(@&
z57WQYr_g6GW-ws@s?EoM^{=OlV=-mWCxFFJPg^=?Xjia%+vuL??;d7|TnQo$_K)|^
zAq)r)_x~i$1nM3moGudNtVbFpA54((Da_bE>RrIEYGYuAUO8MJ{4>l2%vR$t`sd4Z
ze1DQ*5GO|ZMXR_Y8UgM!f5c=kO2{PyMM(WEX51W{G4_X9sPE!TiI#IEeC>n+($d|q
zYCQwph^N@w;M*_^V?e(}d(5DsLc0IU1=b6y9nnPZ5*F@K9`a6wYQMe1eO-!6KIrU=
zPuRkgiZ-vU$Qt%t9X43&Jl!#8i_le`++}Z(&_FLGrX_lqHI>>=TD4K4uIfgm;zq(r
z&u8K-+|)>VDGhwhm&M^jjp)~y>{#o_$=bjd)bnJ7uU;V~9`xn*E_{*t}eb3%6*WX7v
znN{Vy&uk}Lma&`OWt!)dn6sp5c4g(LCkkKlv8;}>p)h#=e;i+4MkJS)o9&8tN+2y
zLQThpv&lZ=EhWNOFJGa`pzMR@;Emf%)ur;>vl3pat;WE6*yH-qh-UdV`D`VNm#d<~
z5?jZRR0BRU_L*wSI-a`uq)sW3_v+*Txzw%B{`?u6x$pXU)3M0S{c<;pLR!O}V=o{ppz+Je}*VTgz3FCe|g
z2VaxU1tBjj8Olpw6VfKqm9YAyGfBzz<_3fMbm^o`ibH*-~VpTuUmZ@+Ld0rYbk^PEn2cT?J`>dFq$Q9Dz!(NN$E&
z`^o*ss|!3)Q0Ri;r_0$9SyfsxhzLxc%eYvmx2Gw`vaY8QbP%Yf$0)9ZFltx9>}e4G
z2&rb%jokXfWE&1Kq*HlNqZa!)Z#^ckUPUSVK6sk7s(9qC`K0HzTKN_5~czLaiJ9GWd5Ai6-0m~v5E
z!-|BKEdl*q+K|}1W~j*79!w`Px>~P7#-<#9gMC1ql^4IUvz)F9Te9i+0TF&auIML4}#ZZ?uZ!Q
zI7&xFLqVfBY229Jn0rJ*vNP@N=_qd}c**htd+pt)YrQaFVhTIOQ6`f9ndr-LHXFH>W9yjPs2UvVQMjDT51SaCqHCqK%4LUlL(c4EN<(%ds@Mzo
ztC=%LTL-r3aWbSojx9R>;T*P-Vk%#JJhAxebIAO+Z`8lc;jh2XA;f0eCU=nEko7c<
zu+a>-g1(?&!MD^UqvepI#JK*#=ezyyn*p2V519Lz`i*VQSEoUgZ2}oh(Yvt2U?*m?
zFZsUftM(}{ap3q+to(-iZRbxG&oOwCxFd;?>0g6u_mwEGbi%C2v)3GfhZP=@*{z3KePQ+`+Aw8(ic1!_ArF
zl=Z+sXe<3coVgCHCo8CrSquN`Gsp68GZ(iZ)h7V!w*meh>ae-vVV#^i?PBHFE1=(e
z-eP3^6xh(RLl<-2#f|_C50;YjP6!sDW4e0+m~E>11GRPO}S!RJ8~;KT8E+u
zR|!=9p!lHVFC6MKC{haD_5!*Ix#`X!H3k){`utSP5Nmt|g9jl)c
zP8YUV9*)E=Z7ewTuRl6L$lcC?UjO4M-2iKtJO7`(jDKGi{wvUeQXfDEUj)1p!n&=J
ztp!G~Xd|MbqY59phY#1oS(6iDrhd#QB=~1AxjsXa&U=%LwbrriFv@2EtYb-kf!ZE-
zES7dxxlB#ObU03CNFg}#v1&_t`V96gxYRoX6cT23o#FDhDRQb4MjZ)__HyBi;f<`8!MM)T4Y~8eR2C#W#sj;
zA83W`ewTX(^N+rS{}mXbNGGD22#Ytpt6=i{CC{x(GZS`6%@=Rm5cam-b1{y
z!88;W?YTHwG!;iX6vG1Je7HMJ7PEsBi2)Ovf!J1bS2)}L}t)ytU~g2%fTEDN6bwp
z`@*o@i|ZQp%5L9239LP}Q;7Ly^ZIQO2?sou&zY^DHq3BEcEoLMes6Dpj=!lj^k&lW
zN~%qQQ!Ga!zaoY<`;I!#(W+%&%;(*_y7CSpjZ`&_h5inx=z88v6}FzmBrlacsuwbX
zd0Pnk=~v9!J6+E&gIFC$g^hBZwy0d<&Wt5Ji;7UMMgN)&Q{2|*FM)%ws}RpnIjkE8
zP=xp?pJx)6hF^A3nqr~xAh?3(w8*+vn#UceRFFaiI&KOqFl#19o(i$M-%SQOsq*V$
zYGx*C3+A9ppA190tGd1_`^_%1t)!r(d3I}MQ7vbhHPI|-eE}QU<-1eUN&k{xY!hj
z;%DP+@YJJh3t~(ahnf_{T33u2zeS?Zi4mJ9MQ+U+aIN4&^dci)mk#(@Fy?ARm7p_Q
z^haU2zlUM68hmuVQXn>&{kNYi$jn&bn9;jmWXH@%O#U{?=4Boiv&~_?1iMQenGsQZ
zeI2cReUw$5=z7F-OaKi8Y<~f^zy7(~U;h_avI49rz?uTA=|9z){$F6p
z2EY=4B>>Am4NG8ZY
zWCUOd2#^2*B!60fgqabbmH@Q`sO2A~mP~-tGyt^(sO6ugmP||lwFIaoKrR0;wPXaC
zSb$mr)bdYLOGZHQ9RN!JmVX?UfaE&>mH;gOI4l9lcK|E_SpIQX0+R0lSOT#8foYCj*9J^xeb
z>i;|jEG+?40;v4oqw=p6m}drfSOAs)EdMwx0h#ImECE>lbFnl?_#~(d0R)6W0tAEz
z1O;qlYbftvYv)L>Z)f+nI^YC(V89gLfj+8-|Nr~1Kx5oyg#)pZzWRdTIYEk=eC_)o
zdIZeM5t+brg?~W{1gwZ=g}EXDCGq+5Y2s<*+0R;I3Bpo|d(?p}TN4(XiJUYqclAiK
zzWOam9oWh38U22euav2ykz4nnUF*JBqJzlk$hjnK7&hscKA7)snoJ8+rppc{M0$kd
z0}OR+?>tzT88xhoj5Jbe>J%Mh=x=kQ@ftK7#;FnLmSks#eMd(_NS-y)MKseQc1yL&GGK;KlvDnlWAWWyuOK*xuf`(j@u&1|Z98%o=7kO*=D2
zvoGu|#lqE?40!Zm3^bUyzT#Dwl+kSDTAB8>H97228imAtz5z=Up;OF^70L$&&4d{!
z=7N<86;G!3G!BNh4Z7C^;>e{9
zZ}&M#!|dW*-0!>SU#T=ZSPp-&4S_ZVq<4LG%&Y9ZJS
z1-QxHl7qcMd`?4RTc;~_L0B!>RLgD~l{r_7sV#M7o(s3BtjaYVd-g~#Tz9T$E1C0|bHG|oesXeAeD=c6*2QOs9fMZek
zBns;MD$uR800eq~hv(cNOx(_^Wv?`JSUACfpA%e;_C6`GxcokWmaxQX)%I9;cf=17
zVVi40Kfitjv58Ub>r~}eDKhUj;V9!^6QSk~WAt}De(2#G6UMK-w5CNjDz&dt=$7}T
zkxJh_y0wjW`>7LdGISTUYO}D}iNe4ih<^Ib5>D6}z?faneg)mwQ^(;CcbStc@d7f)
zd~AH6BYPhEqVBk-m4Q4Ge3=z%4tvElBe3n$N7)>^iI@+|9-rx*r7D&U)wAl7GnlkT
z(A(kI^z8UG1cZH{X%T%=dIltFbLv`fuWb>0OGZOZxHWt~b*j$9D480{hLB1_P5kJa
zOtE^4dNTH_!LG%{;rCUavhN<3;yi9*_*)W}6gf9N*b~2~OZPCKCS=Hu<_s@tyq!Xc
zgKKnuwpZ>n81C~&VxT-vX~RJ7a=_wjKaX?*Zx^|PDv)C&uDWpS0@;O8mAd6|I@}%|
zPk493kL6VDfBTLa!Qsr4k>&o&Ssq8a{1Rdyg1$A|$)yb6KI|vdK9tE26dzQ`ld1>A
zwU8TQ7IO?`{ziMSj~FOX7-6EXy}
zqA47#v#wU(rI{#u(%8gs&#;*Y7wRtJ#hct~=yG8U5NeUE0mj)K+$zEBPw(i@L4x>0
z<4TX+yuoy3ktfY-aLU!|(Ct*VlV-jc<3q9_LX>5v^mf-cv+OU>dW6LF;bwtL45Fgs2}LeLCrf0VUGbGz
zK-m&jLNnI1ez+zx1kNGiyu$u5giTi1J^^efhcvSN?6^KUx)f(S-D}l9tDj!8q4o$WvG_#JU@t
zkfO^~Se=C6;6?r7_9$}r3byHVdKk?HPcq^3uoe^BvGiDjv#*e{j80{+k|GBq1fNZ7
zPX$lO;l)p!o;9+f?{<&=DZ_#pJGb#`?b@Y)3UYq)_zt;41=WivCxX~0s4Iae%H37W&g6x-R!PyD
zXGaPy^!;GQ;8wlu>DwBK`C8=RYEbjuN7J?ggyRG?m*%h2Z;UOIVJ4JX!lky^v-~6r
zcDcfl2@=i-M7+P+bto>nc~m}o51Qid%<#)@c}VRv89B92GruAHcij>G+HMjctqyQ6^1=_zxB_IbLKqY|6KaEPjfiVD;04o19Dgmuc08|2~{L`oe#9aVX0;v4c
zs01V_0H_2|`Ol>?q4H%O9tsHPCm|5fU)$~Zd!Fs7s<)l;99kC%W{JL;6_Tda6b90a
zkf9%mpEy_BvrApu`MKv(lO<6R9lh;^34Xix{S}|kHY&y}B}2@2lqoO;NJ-pkwNBAv
zRG4Y=P-XcD19MOfjh?*v9!#NhO17hxdutbQasNi~e2uAQjvU(q@xzq$RR4Tz}aBv1T
zbkyD%=P#W$1USr?$*cv2z+U7%MnHUh_m2MJ?XcFAbXcw~F9=*F@B12W*gxda1qXN1
zY>zvj3{ZPFejVt+&%*n^`o6Wqcd#Sa>ptiTkJ`R2K)rAmHy2_MGUC7}+Op?Q81N&@
zQ$`TOQI??T8xf#Lh=ZpCIfCz^dp0tJLvpA_SZr#-&$E_*EUEyvKclccDKYbwOrsvc
z6ir~s*c(=nkA#f+jR;YHq69o^)D{~xQct6?xJ5Q$LnbkYAsZ(-OAC^h@X0DoSA2k<
zA#df+{acW|(<&qyQ^!g_p$xTMk13pd%OD5Xkbx~YaLW|O3_{f)6kfWX%uBa@We|!O
zCP{(V;>jvuJ_%OFZ7b~oYl>d6cD+7}(1q20$w*1$Onr$!A;p!t!GHq8FUoiWKfey>
z%}a9!!o^w($uJZuc49!OkF)P$aP^7)2RO
zaf||ytg~TqC+{jLOM`w|$7C)u_xVx}Jl-oR88B{;L4#S=Ho_sC;>N0>_vH-dDsZt`
z64boOfcSg*qTUSh><~He36GAliM`fgcVvm}e
zDM$8ctP;&5*hhASB60H)mf26pw~9u3DyZx^fDYGTu?juxl4Lk_e*L0V%SVPGTzodn
zW;7;|5;WbKrLsjpZB&Z634at3_LYX&Nu3!6dY$VB8EapzY5HmMm`iADJA`Jh&tU@6
zC$3c8OYmBe_@9`9pYw+1pkd9%Tg2^vo6IOvvSj!#twg(6%{38x*j*MAG|31TkGaITK-NvBj1ot8n84F|!FRN(c4U=>J2
zYew7wjRJBg35f_G{6U7|0)Lfe%N7<;utYlAKc9x6c5Rb7gd$bVh%7ZL^4N@MA55vR
z+W*T9&aUu$jc4cq%KcMWKamGmoB;jjgbLS)TCfs$Ha8tm*~qt&>4e6^p1NZr@`$w4
z2-eY&HTcpi0Z7nR5a`xGFS->7qVB?!;BrQsyd>}l@+0#VyG2$sYfQ9?9j!EULA7bj
zQpkp3X%%`&%$a!&(OQ3KJeEAPi+UO)Jrzb$<^nd19LC)~An(qw8TAP8(TxV?2T
zt4mga5ZOHuZMZyHs2w`ba;;e7aU|?d6D{Z{WM<#DnJ}9@aXkbEip_?QU)8bG9$}lI
zLK~1(PV+Y4n$E;C^pfToS3Tsb$O4jcu9wQ7nfW1Ke+I-AHX5)O@`SwjdT2Hp6+}ds1L7QuG*0Q0D_LG{euF{ao%cFmK$0
z3wIxz1?d(Qw|k?7EJ*12EN*7w9{(TCG@WiUWsIJ?hx6yS!)K%HPR4A$#v>82?03V(
z=f0MG0`437uRS{(R@PK}T|1=`C_A?BNiY8NnB2c6d3{Qb8rV11>Ugqzyx+RXU$&VO
z*()iJG1D4srdo-MZVu+pZpSCjo^9?Mo!hXyoA}i`^?Exxu)n=N_gJsE=yE;Pdmqj(
zpOa1YpYgxcx*lo9(o#Qe_Qm|djZM*B#BI5b9_xJ@czuQ0ch147TOY75-grOr_wl^0
zFQwm5sdGHeo6f0F>##_Cnf^UtO#gPgGReDBb+MPa+IHXD^TjcimWR#awoKQi!sB-F
z;6jTBzhmcsUxV#&dm@zo*=Qa6EI(f}cGBW?#TpmC;7-TKY<+>B=l3PO&T`JV`qS&w
z!N`RcxBi{y1^?yx)DE{Qx~$h8`0t@MU5P617gOD=b+6rEUnk*Y?IC)Z2XV}%gLCUU
zvAG}4u2oqc23D^lwKC-ev_j>muQ=G
z@j#Gmqjz?CO0={QpVf?H|MrSUl{_tX5S}4M5G#P^&jaEP_8V#!=_hgAf4*_)8`#bN
zktFs04hkeM1qy}=1OfEnBY+5jK-x9ftv{aRfdBy^{rdzfLt6)9K!(-7WtDj)=vwwN
zpbl(6KEsnnOJ972Au{1e>u%0sWQG7Q^ZTS+c~%+&#?jKETE{;UM1q^_
z7`C$G2j-w`MecUhXB@6DYD4PtzB%;feSL4^a_`X-r#uyx|bIxHltytTx*ct@Apmt4s
zLzkITJL;VOpM?jcTq)c){2(YFF&4=~&~pyNY}@F|JQf)-v>GW
zTFN{NU^NO@jRIDq|J>E6%Q8ZJHt4^sM*kv~|L)i)ls=OW!8_ckG;9`ZU9${_A_fNL113>gnx7LG3Ui#35d&c_jX^Sl5L$p4
z89@p-(;FyotIub-E_u=rG%cET`k)muO|5QIAFu=xm|p|!dUb+DbwFo&5JJkxMK}d9
zz$M?j{K`HX5fgSx`&;L0*oOj9)-(r1`V%g)_rn-v0QJEV*rG;-belo_*GqS3H;g_6
z#N;m^1ZO?`LW7AF&9|lA7-TE_F>X~39lH?(CDeEPl{u=oLhq5&{ggt>1!FFpinO>q
z9{Z3Xl44$Z+}Mh)U)pb~KYxGT`BrrjJIhbQonx5N+QO!AQ=4(o?l#P1d9uWYT~Qfr
zJDPpulaTn3)Aj-M}nG}6@4QC*|abe1T2_FcB?F3W9F{^er-)6Rfc
zw#^TUnTpx%ajp6tCHPVA_r2AVGx|=>hVJc+F0h=>y5-BZatB^zd8qg|Cv6uqC@4+7
zx?VB&UYq%7cv!tNC`A*qotP|wcVj74GP*Cs%=zay9Ui_+8_a9Bax_ip7T?x27dt7`
z^h4K*ZDSE~a`0+;iSyt5WZHBLZohi^bKfnzZ>T+-^oRwIdy$nwkF4-R$hCJGx)-IN
zgSKTeX=2ZQuGBIa?Z0dOqS^GerY{v3No{hT>7#6MwQ?&e7>kb6)mm`nb6IrmyTGrL
zxL0Y#!hFPQsClXI?y{I;JAa?oSg%5V0{8SJOXIN+v0doQ>Yt4%EeAW-P@cHfenIQ@
z{?hwAM{UF1xGJ@1fLS;Z|s2h5gQz?!AF>FMP35`n~Inz4uNf{N&qG$=%4xV|mlS
zTS_bf=Y4ig3ijjP%F6q*x^$EQ)1=Ml91p9^u2APo0BbhCuI^hy-=jgXYYuCmZRo|7
z(q!{fq-z&E^H^incn8;8;tT1WZQJ!(F>k7FCb?yc-O78HZ`YtN_c!bJPLuVM)@e>n
zcexYwEQinNL4GZ`-@1O_-|;xB4N;xt>AUJ04X29?8`Ng%j@j|bCdIXw8V%<7!lE@K
z&*d8r{G<2xAKU|aL;Rc3`Ts(BnE^3Vfbs&A_n)i0|8qmk3`j5nUjSIjM
zfaU)lmVYg33aESwpb|jk{~ncpZTE;7aG(r;B>>Am4oiSq0$gNc(0t3dDvLVeM))3!iRLmr7f-B>)_O6gVw
zI;EU=8moSaP~#UbM?BU^aaWM&;|X&1TB`qg
zhT+6#`*iwd~G(+oKGp;Jk5cM&CCzN6e<+
z{e;u~z#~q!8)8oHwUTz(EX}jv6*`N;
zs6KjG@cUYu2n$oMIqg=G40`S~$C%7okR{X=^s!b9$Ri`w8-&|A;5w?o(Io8=Q-zgyFNEPKA-#bJOAx0
z_ulig3{7~~HD9lwbgX;Y==rISZvEOb^=R7iu=mN=)&-g@Z`cxSIV4icX2*{vo7d}|
z>t)~bQ1`Hy+Wm*BrY&&XGr7M{Zq&Zp!^_u=n{2;w^=0eoF_+&?D=^#j`Iohi%!7g*
z(lZQq&aXOe7}WLjk{1~V4gWCdo7mDarH{#or{OLs-~N%JUH;wK+#;W1v+|;{>8GEa
z`Ric8+cq{%@qZ3o7(D#x`_?a_cg9vm{dd~+E8}aOMn0Y~>%i39)H`!mo16RlMP6Fp
zx;{Umer1B_^*rM(T#&9i%xmpxYVNFB`;~zjnl?2TjeEr#ir)AjU8q2q^;xo
zGjlh+YOqR6zu2>S)BTG*Yc^ThS=TPu*Vl7`??YYk$M|L0-l>Tt&bx|#YdiBN%V&QV
z--;OM6aF%G;jN0Wn;4GFD!6bl4t`L
zp^gZd5f@fA$Jwj8HZdmdhme?yN`ajiQP4$-9u{RtmGTpS;+P$b0L;lG?%HYk}sF~t>H`)&e4uxFv@7yxD^DXLas
zRv&wAqgGAxx!(zlQwt3Pgy_hG)od=&jSEz`8vmF967$1p;1|6lfUaC%Lt&u*U44Yo
zUeQ1uI|-l*7kJHcW!ej9Xbn7=Og7odO#VVUM8bm
zAvV2!q1}9ZfCLb}ubmgWw(GYK}@tg0Yi2QKu^{m3`F=(8hKoj#PNfG(+*zH{S;O)8yh0LRgPZd%`
zT*H{YwtjH6v;y+)v(M<1Dg8l$$Ok%Y)nAo|5c1GS>Y6ACAU_(73v7(pz`AG&AU|PJ
z5^g+c55ah=1w!pXsrq;sgMp!O!HE&kQ{wGD{GzJbs*VJD4t!Xk&x_U!n7vyY2`AZ)
z4vWW_C`D*Quw6t{@Dzn>Z)Nlp8nE_4q5Fs=goKj>)OOGjD!vHdq6VmY^5n7AX+lG8
zLPN-|ENTM=&<()}O3PSQwlB4$MhgiiDI7$b~PJ`6L&0|aiF?^c%c?k1F{
z60kJs?82!u5ObNb5}g{%f`GCJOiWU)#WE>4FKHwD-84!|+NX_#vn|oMuo;*lGBUX7
zQ|zllcWO@T03}#CTf^J!tlBWG%oK9@RA-l!bG4Chl0r`Pz!mQLK
z@=IWsyTyh%K0?0Sw
zl6KBj?*-$5vq>YiJRxC3c*Th4=w?sSx4eewWC@-_O^-x)p>T;d1eLuy={
zBSqu~V_^B^E*vxFN|=#90#P1*v6T&Mc}4=rA0!>Bw+*=qZuw3l6!r5Yfc$aX;Qhw#
z!V6|r03?mrD_;WGhaZck#m>2G;+F+dM1JU`e*WIU*qgnd*99lqLYTk@+(qAewol3pLe+dJhKnxDP*hHUY8>B
zE7`0xgDFEnqbV#!k;L*FQbc|y7<_ejRy}B}Fr_(O`w
zkMOkvTU7W0u@Z($WUIT}l^{Cu>qM`cpUqnVtv;_YIyrn_ipZ~JcdxvvF$Il>VE|8R
zocBsr949qis+1z~qeri9$m4ZDysZ)8
zrBzZye)K4lttyIvsN0U#xVKu0$nUq>4Vd)G2wI%~7d?GA_BSSe8aICU1(yhVs#jk%
z&F%u^$az=|A}1m5w2i4Tw`$pxHN!fbZrLRUqU4MYO+oE2h1P-tj@D8=!p!sxSp4V^
zdfK_el&M8kM`=vp*7PYsMhKaVp)s3#urZ>!xO!T2rr`Cl^wtQScA_zM{g@b4Ueanj
zDg*ZFL8EqPU|I}kV??%5uW*bVd-Z7ASsf&tU}
z51cT7^;S0;bJLrR!5K_;t^lbn4owj2EMJ3vFhRcZ&txZu#JT?jrnOY8^g5CF2|OEPoY5MyVID6
z)ocvYHhJ0>Bg?_zGa&ZJ@LRrvjbSEbha2-JCV`sGBWTR}3?>F1{$SXq^R^uqnpq&U
zFpI{F%4K7iNogGr8nW>!Lc&QVW%50Y5hW#a=_Sv+`Q6#z>H!&a-5itIp0)JC^mLa7
z@6nxMCE5_G6=_@T5=;?|y>Sh9WUu;7oNqM;Ff|&OZ!fYj%nG4nHnZ$sh`VA}T21S#
zYz(tP{5U%6valGGrO~DIzt1!cGkT-f<)&n*ej1i@h6RUr7n3MMJbg*rKhHZyF@5r(()6p^751f|5ee9k6X%E%B#1z`L
z%qq3g@Mil%Um_F-cV|gIAJ8*r^|j1=+_`e?S`h9$d$(`ZG
z#1dLd=yWE9X&1%$)7iq!E|`N-Eqa&6q=<4_?POg?W79plI!HK4Czo%;6p@qrvYc!%
z_2eF5sXAA~$%nRDu$(NCp$^$f_te$GVs|nqBSSWDJEqW1RxLcz2~?HW>Va=>g!Eq1
zm=SxJ81~(X$#q_q?tlsWhsKnavoXx7U^Hi9)jhcP-`R-HLoYo`R?PKbhD*+r`aQNV
z!@aVGRuk;Z#xP^oY}@YJ&0%bpy`9Dsj$va&iKGsgJ*NA6|MN&22`3pa+OZfT3K&OL
zz^pjn^UZb0#IUEd4y(ZKOsg=v5xv1hmpp3WeofVOKLX3$I4~|oW`X$5(_bOSX
z->xBYK^(-KF$`YFmh7C?LlBY>u82~oeu@gDI%qRpEJHg%n2dfyx5R4}2GBvN6}hheSlv$$e+SxlA)q
zc@zdiq{@eH8&Sy|qbV(p?Sndj5@8Jh%r80yA#1_^WUE!Tdc^;Rsm#X)PFl71e+Iy*
z8t4VhWTA1$GtsBa-bA(l>{1PMww5e3E>%qQ9i3y>VC2D2-9|?i8V3Ut&5ww$bupTX
z06Xe)AH1Os9TE0NL*CdzMCe1jlM!*J1w*jdcg%v#SLxGQj!FlnN3jlohqNY+e{V}zg#DuI=GW8Dt=Z&H+ooF0004LBHlIv03iV!0000G&sfak;eW7vQ&2UJ%gRpOV=m
z)Cw1$gJSr13Wqjw8e6Wrr*Wtw+wxIOlh>QFXn$kV9Rc!9^Kq4N>9>>iI^94`y|&yx
zKE$9@a$lupo?;AVS?~89=6?JQ!V85ll3h_vJy%(kt>jXn{|z0RCdLYW<;&4opKoPp
z^w#Z+)u^STFX{o}NpqdTNd&N&K=5fSVhCw{r~oF~PU$kdhAcay2VD4aNP*Zj&WTnt
zxpv_A#bQreAA8{v&H}}g@C_1oVwoJ
zKQeadibD>PX9Flm;^^N6#=3}FMG|(;%kD82n#$@^JU
zSLzy+0bBv;CeZ_z>P>LJbm3`Oif-l!0#=Fh<|v>Cn3$k|`Jrcr98XZ!JfaIgMlVqW
z3c{Ie-u_pb*&l?QZQa7M^zj6Fgd=MJFC1lEXYQDZqQk}E0zuAEuTJ#t7N6qCu1sR?
z?S@n7UNj~zwYAnUn6Y3*fqb5#kDn6L8mb0++8!tXvcy>K{Dhl!hP!Xd;D}jiwPE^T
zPAlk7l)Mq)vs~{ZQ%v~4yV)|?7-J%ChIm+W{7IKa{=z`9+dUb`j>mOWtcP?+WHZ~!
zV}U(RaN#=WoAU}*fN#B@2yPEgEKM+2ThyJpaC&QhVDv@?Yu;ED^i0M~>{n)96E!%X)-@-wGG-b%I&AOC4`3dq;+VYjf7-OvG^hDwaaH
zSRnOUorhx-H@bJ|XZ0U{(g>LGOvRu#Bk@#FVra1V^=COnQ7mxeHSIuu%|
z9y0^u^MY`-fj9C?cU~@+OJBhX3p_QxKzN?qoZ_PU{ZJS;>028h&F~4}HQ%{md&#q!
zSFIs3I;4&wd7xUlNXHDH8~Eug2B2rh|MTiBr&uq54ZYI3P0O8y$~8}lOJY!k&wuS{
z@ZM}pU}&7SEuM_=PtcVb4__Vd)3rDQRxMh=nW7n`=+-5HqtDaqk+W*>vve@S6(MX+?f{(Vv%^Bh(uygFYTYAhO|-xMI3w4%{KFwUW3iQs$(IJrrZfS>
z_${crrJRmeWF!
z-~wXl)7ERvO6CrZ)-SCtGp0TNSGF~?3zuQ}6vT7bHNbf!LQZQhhYAQ&Lv+ZRzH^$W
zUCfWcU+aj9F_@hKif*_Q2}p&f%~LdD$7f+Xx@Cy|fU;)rtyhpwof#Blyah9008qQ~
z3Im}g17k%_LeSRdk_0ZTn~Kd)`6H_;VnCg!VFa>VUqz!=0sux9RJ^o?Bp9(bh;M>o
zS?fr^oNCuLpOmXb%b5fW942iYlob8VkJ;+O3Lnp-g{t|ed#S+f}0$%Gg``1#*y(k@rt}Z;DmWM^t>!PM1=H~k&
zRCGi$WGyZ;E75&&QVU1M2^dk@FH?^%6w%_ll=<
zAnw1ZNK1e#17@LGCV7tqM%~FjZG2|JZz9hlP%hU^2Uj!c?H
z9b3O?vNhQlK#DU$l}-CH2n^JJX_L{3Qei?x86$b8z|03lU2!9a$!8kr`tUMaxw`$D
zV2r3*v|X5)Xkw$_JQgkCUUn581D-&VoTjc=3OJzPAVgXhti%@;0^aJWh62&ul?&r7
zt=A7bIpGxzaM_4&*#(7NA#EGG3{LyMkt(5Hwe55
z1|*msIGIKo<5ye@1HT|d@ox8zo3y0VRr|^O
zwEX@Gi?Py{3>n&_Jl{{y)~%R_j9C-ZzUmO2eY`Yh?jPrA!75T6vVKFdZ2K}!^>WMT
zk0`~0p`3lv&AW6NFsCfF(mb1xL;Xbl!l_!-SrgHUq&tF6vw>fR+xY6KK-)WD*moNN
zbhU7%RY$%H-NZKb$3hRLPQ@ulg%wtgD?$NzCJqQ$x~k+U=>m|YD+Jo5efS;$Q^tYG
z-r`1jQPqXt*43pi0RptZ@K8q=nV6}QESSFCbwVzRzAuN{L|hTGuIL(q|AEdL5*xgx
zuFLIiVTN^~&DjFH6rAVFMZn3Ja~Ix^^2nIM458U7;Z3&-G~wSoq-@yGA_b!@JDLJd
z4f@tHd7!aj07%S1X`l>cx`#O~ra_3TXwwntB)XBawi+NWyWRD{ctAdXnfx7{O9fsu
zFl7VfkX>mVRXumAxjR{6Q&o@TqvPL9mE6gpANz+~%IzL4P>JNJE?gJqF3}E5C6aEt
z-5G=WLx;Ci&W{4awtNjw_J
z4RCk%r8B!bl7}OZiOXCUDapeBUazMuL(1siGcg*jJ70OW8l$=(e#)Rc+4UQdOTU?nU>{PNx
z#k~8J7fIJDJf><5r0>bZm+b(J<35Xf^@byaBTHX>lA%;0qZGgkzA~%TFQH`U%WB^_
zNtCWEjPf;vfBix|WtZ703Rt|?5kT_gE|Xa(yEUj=Cr(LHMGDY{0V}6kHCpCDSbZntLgs|w-tJ=UlJ_~
zkp+dFX&Ii!rG~A1WByxwHtD0!#Hq&GW#ipVg(Qxq$fZXdilya2k
z_bCNimUra)<#PUBuG$ns8j>Yn8o^1p_m?m<`WWfFd}f;FJ@bbq+?G;)!H?QlE&bf1W5b6cbJ8rSr+xa>4Oa=*(Sl+B
z&e@TX`?t>F+hn3lyIpMrvieP7c8qKUJ?ENWS%Rx1jy0bYW}0=Z#yjx@AoFywFj-ap
zIh@b&a{{&VmtJZUj;1fLa$o2!#)12mSlxCJ`>(K;@;My~6
zvrV#+wAqm9tT_-Z)ieyN)PfTvG}Wh(kz*ZYxty&yJV{kaDc31AgC&8B*k?A?+PY0n
z|0gwagRs!?EG4M(9!{&n^z5Dm){#Gj#)$7^I(8_$!@(4?o6F(3wY;lPsJ4!+Cgwv^
zD0{(-kMTTi=2PpV)d?c8Pyo1CG<(A2o-3a>j8w!om$1099{#-n74Dem^|Yr2Nn0)E
zl4xd<ruQuU17HXKiOaj}yc`a!Ivd%ZJ&2qf5R2!d`9c2lGX0rZQs^d;d!k@)?OgI=CUw@i)0X*!Sa^*HP1xdeM9F
z)v%;j|7_-Z>VO;f@`jd)qy%S?{@h>U*xPWQ)S*>f=ns%&<|0DOSv*EqzXcGW`K$N$
zhUqf|Z=e-kt3Ez#L0f~Yv>*(p`>yo#4g%vvz>u!I7Mx}Ghaw+Fb=NV3}WMd+Ta#LY}JS#QE~3d!Fvk6&X}jWsnwCDZgT
zKH;+v$(ptQyh_vfebV_}
zs*+pBSj+}^Fle~$XS`w-BDq3;YLBMQ6x}F-O}`92&@78zmH%s%z!*caX1-HygXY}T
zM856a-uuBOB4yK3mK}GmCg8({?P8bzNOd9KP<0Gk`)jGyQvk7ERt2^V&`_?Pp(Yb7
z)KGd>Z<#?P-kq4vIe8^+w10?AaBbo%N6g_PqpJMX{Bdi@^KpWVt5;;}ktE+M--|R0
zn#D#iX@Bw*MX=t|-NuVPpdQrHJGUc}tNVI7R{MfAKndR&WnbGVNMF>?JO^zCJ7Ddu
zNeN|f0SCPx9LdHLpu#%u>Kti0uL^*oKTA(D;D|+%!vFG?j7y)@7{p5=@Sy2)5N<`w
zgSer7dzG8g-{_AOX+@Cl-y@h*Jfg#FVAQ6oR&;#o
z#q)|opMk6{Je|$TzYr`3=d+fM$_!X2t%X}1!7hQO*FlL#^D;{^u^}lh7PWkJ7$y>iQ!`D)$pjUc1fRa
zvrE(~smqu2I@b1m4cVD?$>?-BPl8lIRGzsN>4XLtdk~Ad!Y#Y2g$o)#|Drp9l6E?-
zRda~wF2ooVhtej_!d44gmz
zO|b{AiFOE?DxI~3@LY==XoJGz;is^_7g{O{y?wp5V$_q~D>L=uTq?aDh-$p_4&s(~
zk4#U^=MBOTSEEyx<5;YDam02MtnotU!=%L2f29uMJKs2nk3YUsV4Y2NK(mBz;k(Y&|<|{MA(s{~8XQdpA$#)|?#GVY+ZD
zDrL7vKSPLRLOkg@vcOBIa&|n}*}AdDLKMJve;m&$biQ&bw6oi-Ouy`#K1f*)F{g*+
z4)!x{J*xC=QKIrJU{3U%wDhPrlBVNSZ`45#BD4zhG=kMwbEU`M0u^3yvh}J>OsG=c
zSo~4pSsU3}qI$lY6exI6j^G;p<$n=Yp?od~)YjF!K=GDCt$mQiu8*E)QY5$l8>NSG
zsNn{?OsxILqisN?-!oYxt@u5^PNj4VaxR~AXfU_W+syc@TgN8v>cLd+c;M>Q?;b}G
zNO71ZLq-V35EUWoaTG$N5Bg0#R|UhIGnK?v=!SUvxXgdPv1Zrfz5b(TzS`An{oe6w
z#LV@x<^aDy3xSUYTnRlE*WR}dsBk1J#+OKn{CN7`GEa)Of~*XDYmVlQW8?r=1FE!M
zNIs1@)lleAvJT4c1c2$J;pksb2xsf|D)_pHYcp&}(qUGowQGf&pmK~Uq}-J^SUh%K
zNKoMu95&9lz?7=XONX{68ZF9W|LM7-c+3D1bz_S#CgOv&U8F1YN{x)Ah!
zpSPUwU-!erVz$6LNe4^j0;-;By&l-Z`0!oEVdA>JX!g_8DvM>IJw-Qb#?MR6E3KTg
zxv|u}7*ADiAqbV#9loQu{vSp6KV(dn9LH|yOW9qIJAL^|$v}M-FuOdh8G&~^+i{yK
zk|^7&iKW$jr%(@LVZ69mrW0R~N6S}C*eQTvIm^#O5ivdc1YOZ!s#gW{AAQ$Fuwy(d
zVaaujJ4K7GMfuMp#t+#kp3EK6V^dE1cRjE3Y!EZP6Pd(Qf#}yNpf@FYXK(uQNiEH2
zRwq32<=txl(xaTtzJ6_y27hsvDF)JMZ%A=m@+sd}f>hw^W7ZHMhV?GlnlS&Mzir(}
znTVyetHVsZ#2RU`$foBq9}N!!Rc)aQuzM;{`qN5^An-Kb=ckJaozgvIDRop!lw
zzr-Kk(>T)jD+L&Uak#wB*2f$k=z+PRExhJIwNWoAg=IR1={7(z=|EvFLc{HE%+uzW
zhm1$R?``k?7WHhlT9i_fs&nDnS$kYChAUn%;_06t)dJtHpC5ZsCcGF_^iPC%W#9P<
z6;5y^vYiIrwrj1DYdM#fY#Z*WnWY0F`Iwa#RX~LmRRJKIM@-tgz(8S3@9-d8zG!(m
zld>|AQWF_B$^p^6y_P*f!jUnYcsuz)NbyS0@lY8*7s&5wr=Ip>nmK$0g9WM(BesxN
zLo22iucwN=cUm!9E@PXOP6)b+c05zoBAtP=-5fqZB7=+SzQ7cvw^b}N+$z)Jp5wr;6L_yMq08@RDd|m#YhN1
zY##3sM7c66j+*^IKoe&wj_-0y1u|4)k7bZ8Moamz3r*h1u}x5`*=!~e^AakVD!{H!j1d1XAeB4B
zt3a0(nC9)Qo5_^NbI(8x
z6I;=+`ur#p1GsSF%yi=N?O%_i*0qRe;cB*L3m|no%%T%E1K!K`>3%^~3beMmXusBK2AF5ZDu0r?1^HgQ(qEd=cX>%7BA?f+(*^+r9n9|IAdUS)8O;
zZ#1{4jGg!w(x~Dq=4CQRhOJ~%Y&r?#3;R4wOz+Ga&3j^^Kh7Y%_mRjGwc-Fy5~Z&O
z@->B&xai-9C!20D%G3|<<1jWot=DvJ>Y}CTA<>jRDywzPlN52%M(CUadVfCEYMs|i
zd9LDVu#A|RZ1)T(vu%kWz1lQaXB9bCmXecU#
zq4r981~CQ1H)GdIal89~_y3hJ(;?6S^uzQZ)bbO&6p4{gKCnwkd|cmYYpBWswN+Em
z0gm}Xv+4(v05V+m*Cx7qvmkbB6m9w;MQ|?j7(4K-=#Gj`)6bEvW%5h^hN52Nnmk`z
zTFpQ?ckRs}xYY&}vx=DIV5+5s*`dz&^-s+>H>RENKl#H5!f2-Or{5BHE8absqMR>
zi@3`XBV};~_f
z?h>u&xyTJE7BrkG-RpZzkAsBA#Zu9GoP?32Sv|bl<-mTlTAWA#{iqd-Ew=Z0s?z>K
z&P1rHCAXS;dAcyv_ucr<;cl&JeQe#s#}1J**-Lr^+xRBl%l+?|eJ1K`Kj?H5Na!QD
z&HZU%f5kgMBF&k~q`e5PnRI#M{2ei*yoPmUM%=}C&}WHUiTabkf`Ye8w7;%9C&
z`Ms~=%%=Nand6(TLiKLL7{eu}EA3YEPM^-Th1IM?N~dh3iNQ2u@$Nt@)s9PSWmRNhvdXV2|9bEOwfATlFUx#P7P6B`W5(aVeXCpUL$n0
z+dy4|l{|nUMUYux#H}~@_5G8tC|~6-*LaEJS%+gq8g;k7MB{#hUu?Qx!GC1@SVTjb
zbnkI2*MCDDiC2Khv;%0vj9|VeIG}X76kETjZ@Ltt^_wroKKiG8;5-?ayP1{mr+ON?
zKRCb!mS4=hd%y(3?&kbI1prA>G#nuWHc8IL6Jy23&}OQ+sa4U?(02o=rT1PaImFhyn|_&lYF-S*1eg3?4n^2X$p){
zLv$pz<&HVBdGTyB-8{|}W$0w6erfAjRn1__Dt=33@OfG(as{j{ob%H&8mKQ#U_9K^
z+^yafm1M#41YSdM5EHsCo4yr=6R&xU#WrWBQFq>>81r7c3D|P8IRmh{OXZZczO5jW
zyvITrjx!K;m5S0xZ`#k{yGrkAPjrydD;2Ta)zTdl
zStdO{T~eb%-wYH^oX4)2nsq9_yKHxrXm9et^zqiV7z|E0Vqk}^Z3tffYs#q4cbT9$
zE#2-jiT$f1-Y`l^>kz3}oLEhe?9}xu!Q-5_#G^Q{l4LHJBX1vMqXQ&IM&om^NdhJ!
zzAR2X%4Pl0v{gXO6Ca%oMnI}|im>ysQhcrb9o8Dn@a*d+Uo~hM>>C=cN>gK2YUShZ
zsJ5Ju3yzu#oaI2jxIgt#etx-JBq)5L%(|BOggh0)nvDGyehs&|*|HOc&!utz%s)6-
zrjjS6%DVWo&^W$c$J`Egl24l6hixW-fR4Y7kkwJe`
z>J9wRRBL4~zkg0+w;PmRqUc9fm@dmcO=M@#=d7EiS9mshCN(p^O@6<1KK54k#*MX(
z)BDyBbo|OxlXd7;ax0%rZ5yri1vGpDhU4TTh*&zjINb+U5Vd4k5l0OB%VqO>HFro)IvgZR8FMW({s*edbiUsZcw(
z-ToN!R)Io^N*@1;GV6ES>7r}DNojGdp5ceN3|~2Z#yK_MA=(i(FmMAvIZJG^@p2S#IxoBy%Yw+PZ_)*`9MB
zIuVeIRi*!6ul_6xZ32uo7l*EL*#j$nqm>d9EJFz>JogBQ1a@lqjQL)(Rl!x!HjX8k
z^Xjk+gdzd#3giOJ5p34HI<4(hT(v=L*A_ze)7o)bf)I|3hTz9j@E-^BJq%|$o$}MY
zO8Qe<$&zVE?s1lq-Vg4A$S#Peqw)c4&+zHF-(S77C29=n3Y$d2Jze~+zqOhkNjTw&!17AU+0S4
zTfZ~WQ7LdR80i=FD3uDMRI1NVQUCDH(VC}=PQ7Kr
zFKW*9P*L`;0ad#JAoH{1xQ9UQIzqw+mGsHK=_5%^8D)fuQ$!1nuIoI$QNc_JGCdq7
zB&^O>Ubp&^Mhd2BspQw>Z~(XOWwC!R4g@q|9BP$62Mkp&|9*ndSf+w<+!*aqE}KG^
zKTXYM`B8`#v@gh5CC-0enOr)9NS#(yr3uye(~GD{Q0kFA9+{`+Jx<%SALCeYSb4vW
zDlt|YN1T_S&I^p&a#@n&F1N@#o?jg3*S2)-2;4y&>M4C!P@}6*{pt&r8~7}TS@D^3
zs~eF0a-!me!M3FgvHHg36@5MJ^7MVM4$&RDM=m^HbedtIql-(nn9MTM$l}TtEgbL?
z^X19B$`*#(4~9N-doRh2<3#bFyp0D|$<3SgH*8APHH>G$@7+fXyqQEy3(VIa+%|Cs
z#2Zjf;Nva+@KJ9yY1e;~^I?t$ROw__28V+a79gcophPx<>S7)F3B4p~;;euqr(pLJ
z)Z0eG{>*3gvDr}{*}jz=1-VI?hxf$bXuOiq3@#cjJUUBn*3tH$7rUmF4HQa{c5@ge
zz;Y17rh)+n9N%K~OeccPvwEt&@bl*_d<1o8Ega5Car?x^?!7#0E*THf(<-pf;z||km
z4<^!@MWB$_eu0d5IqdSt!~S6g&d0sDO#>r5V6CguDdp>Bv$>6tDi0e-Z8qO=`JI5c}JEB
zD9iI-I=t>_Lj-fd$xzVMj=7qt8vbIA#pF74aJE+gIzIGbesDxn6Q69i|E@
zMYRdddB_p<(5jS8wsL12XpLoBY_chRw+kpFRl$;vCUbvJOF!Jj@`c`#
zv-RXKMBpiaTCzQJ7diBQBS&OAXLJBEE7`EN|kll@ke
zGjhLs@J+KtzQn>c^^;Ehmet1TY~qR2oW^
z^%=4cV6rULEmQ8@nlu8ND{c4}FQ$HKT62f)yfx;RD3(p;D+zk$w(eSHhScHwdGu{4
zl)JkXUL^B1*!E3pXkmpw#-uughmepa?=ShMT#M5VI`nMWN7d1=k|q>h|)XcCW`(r4`Y
zOFn)@wew9AJjHP5u#0UN49P43Djq_90Bj2Y}
z!x|B6gOmGSMR?3(mMvty680~gt5Y}J>8v(8j3?t-@!E>9{adqQ1`VutXz%gJCNX8I
zzfA2fzYQ+W^Oc}YKuG_oQX5f)fnk9Kqs^BS3mY83;IFNqCM0SVfj%}#f49hwP!bMx
zG1Z9nZe`j4r?tBe|}kONfvMELZKRWZFhG+wC3dZVzGPTQ^0qXRD!
zu52Gh#%go8aO^;tgFuF!UWm#-yT3ku)s9Xk)4|nG?p$83V8)H+i~5lMa7JTT8ENa)
zm!%piYN#RR81z1F<2%l?uN~*+%>{e&-`AVQ`$oDn~^gHy4$8jzQcW@_RtGm_TNsCNE>e8
zGIhK~FyK5>k9#G6ewU|#t8TUMHhscfau8-)xp{ifO#5!x5GeNHGwLhFZgB-m(cLXa
zY?}3yka^~G6JDzWpZ8#nK7kMYO#oO0Cdg+bc5Ow!GVtm|2}`^1#erITYS7cj3&&*k>1{y4T-+=1r;)uB21^F{{X=
z$cr99YamZ<$1BsW&ItvpUts=0>d1xrN0b{wWG`shCw;#4zS(Sq^>C
zQWMn)f@TQ%{`YRbGis_mJ3ppBQJL!(mHk`2Y}6`2hKS1pe&_lYJR-5we~frHJu*2!
zi7H3Am!*T=aqlCS%Tx3qPAA!EXya%F?=%h=BlvSU1vk8J{!b;Vm>hWiygP7dgv
zq_MIt?Of*h(X^lkjDiJs6{;8dd6ly*K~FAupLe~DcLFz8jyE#6`t1X;!cdnK#@@dx
zQO!k5vZz-SG0WA=nV`PxoLocu>eUvcFB*z7NAD$z-#Hp!Rj#)Cni3{&J-q*CU@yX@
z?d~3Ubv97FYc+Bx;~1a7{kL1^*UTGuNRs|p_L5z;tLk;epd@ub@WLi`
zU{xFBB|z0eB}#(4Km!s)7umh`;nDaXV%yenewi|@*gr^dM2A=9NCr9;O6LZr5;HHm(QX6@-qA}aoo9}pQEQe4hnk{l`0LdKM%LiS{qQhuiuQ0NgmLJ|s
zhgUAofI;#Qc!r?^+bdAa$gkskH|k-BDcpFMS%S)6;gu)mwy#WBaAwI6OZ9!uM+ds7
zTjObWGs}E7`y)0}(>_hk%JL~c&>corfeI%*tS(ak`mu(`o6#?{9i@MaS>DGO3b6uo
zT8P4CA!YhaYOGK$(1>}m6w$Ut`TJ?=bqz67AWly5hIw}W`8wP(u%|WLEI{9nU6@Ua
zC~cQ`IWa!~R0{h>0AvWf?3z{f&h_8HWB3(EKnodevgw`~A<_LKLQt;Uu>yM7J>4Gw
z763-G`sM&b!H%c1eIt~@stk=Q^56t;Uge~>5T@)g>(hSUa~3i^(|t-ZUae3~`TG*2
z8(UmwYI$JZMJ!xlD|q(Ka%I}Uh}9#S@5IR{?ndJ*fThczmB0%udCK;{9OTZcFUs)R
zMKOh!cH!EEsQTy`!z%IhDUnKOv2lyLu9^|Gp;ZT3uUtoYSB~5k+BUA6@wWrc*enQk
zPJ2Cwb)1=ERFA%pMuohcd1IU<0!#ASi=>MD*_tUV-MX_PeZG(5-p~FUXS?#gqvMI{
zID7#;S2P*Fsh_awZo*faL306j{gWBMLWI#qwKWQOGmtG+27!1()G{Vem|k?utOUx3
z>eZpGGhxE_Fi^J*_R%~9zo^q)xX9*1DGzF?B1EQ`a0R<{!sba$o!dK^JUdvIKlH3d
z@)2c!OiA>+dYUXstK>3F0w5Sm_Q#W#V6R|{ss9jHWoYW
z_C(w8M4P2Xe`RKGG!)<%?|jYJ?OP8#W2
zk3AifAF?b}@**;dx;MW-{`WIpjL@OOj+^qO@pIOo`3_4`y&}HJN0Zf&4VKHfE8_n;(6ed!uAw=5iSPrcDH47FhJSl)#CnloJY1p_fCMeO+F==#ytedw1
z9!3xTIv*E0NTBdLW=519)6Y`jutE_{GfsT$jqxvjOARF=a@h9NGha0ZN43Tcvm;`a
zN(oeybi6f~srgI9VpuB+u&ax5BsV6IsoGfQEu>z)$}@f_7zA_S9#@i~yt$2pi_@$|
z^d-+XD*Q1Q_z5-!(rm!Ix!Vw6A8^uB!RTrcbobXNwW0^06(ZE^&`m0?lItGe_t`0N
zI-5}ryNK%+87FJ?$x)h|^{aE4p``hS5fvwqmGD+Sek0i1o2<|0HkhJr7p9H_lQ>I+>8)ljEyK+8By}w_amPC%5!gP6
zUa(YO5N%UiB?gS1`B6?8DF6oy>|@#jussk)Aeb*B%K3qZ!*APwaajzY48F0_?$y|ga;eFL@Zx+vLZGpGbpXpQIMgei_e*ZK3zH5g$+(EQdc
zyRA`a7ob__{Z^!wOBr-fpfNfcJb|T5KW)5jW67~287dD-1Mmie)JbLwP}-_PKlN@~
z_#L-U`Duo~d5tqy5IrSLqoMbZsI_kVvLSEXOnWy(^nY&K1$ilzp=iJOt^^sjCvJ>r
zz%e4cFAJxT8g=awF`PBHhC>b?%q;4W7{op_EMb8ptjNH1y=K`5f&SWfhg8i{F;y6+
zQ2mu=)8XXebILn!YR3-pJ-6M>?Jo$iQ6v)^O5$e#uL-ju;5GXo
z@Ezw^W7&I6g;8>WQU!P;SHu{aM8uToZj*eZ;S+3IlC6YN{ao=ei~(AW00)R&qZ>x+
z5Zj0Ko54+K6Y~T;c{m|^9I{yl)vrDDTc-Qw)3vy@=hZ70P|qVx4N?V1I3JS&`P#y0Sw502
zI32l$A(*P$bZp_o(1szS;hp4b7?VOQlgSETb_%vg4l?*e3*W30YfscDyCJm%sUb;V
zLVu34hXbeypqt~v#5*jZiV05@olEdONY}_@-+o8syQQieX@1HkS1Y{(Q^x6Ce7kr!*G2C>o=N--ljZ0_of`F$8`)d
zgi2GMw;80y(zz2|@2FMuG?fye9v(u?8*@Bo<MBW5AC^jd#3SrM>%xb3}5`t2Ldk!
z+juAV2l0(Qe4q`zB(BJz0&ty$QET-uj9Jd%Ely|CkoF9lqAX@pGoILSI%M(%4OHtD
ze^E}i!C&TS!8Vhom~KaQkvE)E$*NVjspGm*3EROl2ws)n2=AEAZ$qIXpaM;BQ8L22
zVC_S?uDkb!y=Z^}-)||Xh)aPw?B0i_$5rJF=v-20cA|a1pt@dBi;DKI1NV5qWo7t@
z%uV&eVA{9p#UZNUAn)jFfx^SfAW#GV5#}`rVgedkT+Vyk&gloVDFKcR-!Uc6oudwb
zh6qax1@RC#*Had-wOKyHEOA2H;wD}Y`5m+gChfXc8npo_AnqR(0#EI-Yoam%&lH)Zy7&Y&O~yEtf}jHi#|OFMZ48^Uf|!z0
z3}_p@voU3q7}1Zn00ELz3RJ=(Eq>lHr+|P}>LrPeYQi#z5CB>eEL;*L;8z=E?anq!
zEEO0ht-$u~VF|{V+CoK~@4tJUKS#12GIK4g+1H(AhPedJ1bBB(-=T%LheE^K$fZW)
z(Z4TRS5rCRL105TNs^P60cZIA8x^bj=Pa`I;mJ*>qvTkSsDq3LWDk8w_{h85VXDok
zK>$3$imiOq-jo9DdGN~U>L7v8?hSd
zIAJ_YUPmB*p)J<%63Tb@Vid0P0q2}~P}qel<9Evc-CISLx!O%!XU{I52u+U2o3Mwed*V4~J#`FGHYqo<^tEpSBh6AeAQf(jA*TwyK@&PVnmMQlnw@L@^4He*
z&ysb4cjyDf0L?C>D;i;RUBodXw@cNJ<_2
z7xHX%W|cVJM_q(wGJUIvkfuRnM75FKhi*ykD9$+qKj`;AZaX{r*eLz&m3f0;+;^I!
z6;GfCVYZ-It$IFnCFPVQ;~lCqd-AQ^BPON^whBGTmnby>xwqZ68JNm2eB?V5Wqvks}A`jK<`*KF$@-EJ;s9{CkQ`
zoBa{t_8?W$?;b}|XGEoo+N9oFD8WZr^nn&tcG6C4vmR^bYRR_IpSg?BQo&V*@EdP|
z>_S)!U{SCS7m3OP$U5AkzDi5BO%;2a22Vg5l3Gl8&a_m-LQ_PqnA7Mz4j@=z3qB)VHd*;idHOaTa8bXO&-uqy>f>
z@o0A#?sSNAUc8ooMX-Eo$ZQyl2M*AjjplektxKjT2(nLy9p7|*o25V8kn=1KJyZ5O
zNyA7DC`}f;=;xSK(YF%5ayp@7E^2Zna_Em`Jd5$^m4-I1xLiyVJd`c=IA=mnt58%$!E^5%JadowadfKWg+oeGQ
zNvpSh_K#@Y5gW|e@y}Wj`-^5PN0vf~_GUh!k*#TM7>D0XCP$XP~UBRjDk-#bcl`vSK*EYZ8=XSHS)*mhpj$z=uY^Bmm^Qj
z!k>8?iJ>8$)`t(UF72YU;XMWU(1!(AgQJ=$fRIaP^y8+wcPj;W8t7vWl
ze?gRwq%wYIs#Ydk&MY15o?j2XoYMA4aJJsa4HBs8dsQ*KpbtW_>}dX3
zH_9z3axc|YyO=EL8b_d4e&Mi;XA?;=VQ@t_jPZQ=l4iJQ>_BR6e4>s}cI-Nt#?{Cz
zcGJ1~kdBuHEQ;J$t1;V{x_ru{ib{&daLmB^05d?$ztg$e31lSy#WPHc*86ulz$0MO
z$f>fO`ufOH%TAV7scdYV@-#Hi8;jAh&IPw*|AR1;pp2dTmy3!dyG}L-z&tCOs>Kp%%oy<<`
zEE2NfElDo~Hk8sYEUj+eh06>oDY2|g{cxvgM=#SXjL(8kKH+9gp_8{1LHj{|k>DJj
zl13XO3FeW0UhSz>+-`-BLgqJdD(xiOD8hS*W&cz5M74|o%QV~;DC(dH)>hKV=G@b@
zf0}_RM`t$4_o&aGvAGdo%PSuBaYaTgV@~_wlXc%CI7f)_9Rt8!QmSN0QpBWNOG!#8Au3J+dWut&Lh;_(#p(FF)=A-Vo;R>c7H
z!2=Of&JvEAd$zn&^Da=Tk+SyEOujZa(V~*72MVvGD`4yJ)?|5~UFUA=bh$5*1%Rq=
z8)42lP__*jzOgcNb>z`Kh!iTWR>f^FH$RD#_YlfIkRNV*H>&-Djk6s~{s$F}rfD;B
z6aBy1YhO=#^I*x+L;gWE=z5};l|EF@i{n6L)ESvvL^w`yb&G`=gI61o;$snrdK;6m
zdWE1oES`TAAW$X~i)^3jCMCS;GjV4p{jH2&P=duka>z_^zGO``+<$X~LX
zufthQYC=m$P!k&xGsrJ}d{%kDEkX=`5Yq?$UA{yX{5peA0~*d@D(}i9PI%Rd(M&O}
zW8V}8*7NTsD*<5m_gsOTpd7{U2~R+n5V$oBf(}(8V!*!o4T6%0Cw)k@{t9wWZ?_QWq<20v(D^t
zF`Oipx)mYc&20zj4Qc_}at5F_d#2D-dTY@q_Oge!PDB6@FfFCIL#MZpG2WLoU=#ws
zsf#4hRcVSof4RRO%?lzT8wD~@>B#cG)0h0Lr}`k$(vdQ
zfzKqC1@mu5r{_BrTQc)bq}!$|Z|L8#aJcaUN`f5SUXbo(-*3QdELH86IUKv$wBk+g
zQi#lecaSR)A}$r1kf?tZ9S^@nwkkWUI#{+Xxq#f@U>z0F%ab!)tR5%YEp#RLZXon0
z1!PpclEAboX8DK+(VD_(?bgr4krpeB7j&ke6)z~{g)IjTh20#tIFSUSASpFL!!TIs*abiTz!%Qhv>Lp&KUTJw-l7_sxPRi*#X1yf1ARQxo2`
zxo*&(7;5upg>Gmw;|GTX0*@sRzwr+w%pm<_&He^k?`#I@C__>^Qg;tr5B^*q_HWv6
zb4BlSz}|#*(0zkrm$wY)T9FS44K41B>sx-W|h#>-65ke
z7g6RXP~PN6=s9A121gdG0KU)V>$a3ZooRWCQU
zTI{zj${q@{RMH_l0PE0m0JIugVO?T9KW%YX^Y})V>*8VAejzIH8?bmC^NOY%m*_)_
zvr%7_1vO&k7)F8srLTty>(QyB49`1l`)Edt$NYmh+S02m=kLZxyHcJFWT?=&wch`|o
zp!TL3O&I**_m)jZ=5HKrbHu3WhY=gy@z8#Z-ejweG_TS!4;kC;zbMU6Jtg(%U{|*T
zq|xp3I5z6Z0n8b)g9TeUH@$*FvrBwEvb!5t0|FSzs?zqA8hwnUC}gI4o~*~LRfiVo>R9
zAQOKRNve?oXQma7PdZn=POphGb52AG)K7#g*!3?>savBUzxy-}Mm(f(SrWF91}YG=
ztNNwXX1|=Igyn1iOAaA-B1by{S=6n@2Fh?R`}
zN0Mzn_TQxTU%(CrnIjz+^AMHFeN#&5taYC3h0@UK-^P(e0V6yxHMF
zQBMfVx+?l#@)gsRziZ0M18wDkq~f~F6A8AK&@ie3+<)0qPCay($GpX%NZ=3sr-2_5
z#a!qtP``q;Vw6Hrv0L&4lVyThgGL0r9tMVGsW+b|MtUn<@3m^SJyz5*Hz%ecVu%~*
zw)E5U-6nVyL4F}v_0~crf|i?fCr`3Wtapw1(D4!H5M&tGd|co%q3!!oGnfB{Xi9r+
zSCyHC#34o&WFl(yNQ6V4j4{~yi=@cgUcV9l=<)%wO@S$P5w||1-z6!>;EJlm^2M`g
z2$W%?newaOn_EMzSPWt7YPW^dY@Gc+VVMeH7FX1=G1c2Dv)wXxU!9M?Gk^eRbFmiL
zu@fN3_P*r*NB2l{D?pFAgL%e51#82=+-OlCrw1r@VPZ77bNB*b@hJW#AWJEHW`S7}Upa;OUtE{JQ
z!!=jAV
zP^yeT>q{cEGs0*>xH4}X1)6EWmFMEFt3PEM?q?j1IgSeQs)<7U=4r*c5!3YnyBF49
zn#woe#4Ny$)Ga5CHrwei)dE~2zac}q9v=M91JPDKZPmLc?C!#>_7fD8J3Z=vVWMR$
zdFwn^7x>44lCRr<`5d~s&{-c8PUFTtlFYi4RXGjb!8H?|yhO-_I?y%QN^T=K4mAsv
z68|9H%9`UduB$Tvz2v2o+}wLP@TvCVt`M%C^Au|0%}}_q$dpX=|K4`Ruo#7KzNqu@%%KVNQhor=1dU?%uCEfCla}>zI%aZ$M#}t}B8$TeP7Y0ug&su4N$gEEqB&t&h=bYO4BKkC_
zgTG$ROXFv8eghrHE!e|
z3hnA;9wNRiN{z9cGh7g4$#RbKv?!xr)5@4Rp~N)l90Nf(Lk?b)*R8wZ;Z7gwc7Ik*hVY!N`{7b3qe?tZz2)dSDjQ
zr-&F%zVbSmit!KSb>)>?HC`?WGt2qjQQPIF3_kc%-H;ksvU*%r9!XNM2
z9fT@0DJCD3b4^ehbz$X1VP+`#-vj9cKV;e1?U~hBtp4+6)#K?J&Wgs~0_ul$QF;^g92nn?EBUqgJ6L?5
zQi_@g(v+r%fCOMh4cfFu-0p}(Yx}@1R8BzB6Q9Rat+s#?DG)gPbMYD=ZuvZvu*iCA
zvZ^rlN;BSG^E^16M2$qiYl!vPmK-7N8xrHUB}*yqj?NhfxE4ryHt+ZK{)E-}0~Y|r
zHp^d!$8v|B5u^I)ykklnewQ)oa4k^*gDCXifMykuVr|O4f7vl6{6So%&CPbq=-B{e
z;!%SpaFT_RK+zPmaBbs$5&tyQetpey#O%Q|-vJe&?iv*gL-qlNi^=v|p=
zEBeQnfs~%ogF?8}3nDnd(ld4Klc7lpW9zpqvbD#a!(3i5glX|8bGo;KH>>~3Y
z_ZS`OzgA6y>M(JrfkdZA-86QWg0wvyy*8eGkJRdD+WAUCWkS|<`Thz=Xn8jTU@uLR
z?{RANWvYgnG>573oHAYED4pgTJO!aOr-$zxu;j$X~G>;2gTj
z!lFNNq2ePXSNBIvGRI`(}
zEM7bP0DH?Dzr_Cb(<_4+*O_o1ED44UIsI86*8=iJYBVu(W7#w%o0eUM0_3BJrFG~K
zl4h?SJ##5dcWfC4%BBcdkx_9EH15Uqaxl?e@idtrF>?f4XMb6upai|tr|0@%O6&+ZNSj8uFLxXuqztv7wYe-DsrO{
zlD`i0O+s(zgseHTY3hxq2B?qa$G@>$|GrMs5_2u0;Mxaahk_&?vbXa8KLGA8p8Ks&QboN8^Q*SAb
zZjZ4P2*5ST;bu@?dfeUu)Rc2W`bjY<4*Rq#L6N?e-nNSsCk*Em!Tue84j2;!rtq$l8DuL_QJ=z`A!f!DTiEo-yDr}r9x}EZeVXacsN>Ba~u|=@6
zvatn+H|C(40bevH`Dl*O;en7BoqR!9$ndJqVNOzp^gQrqy1&!~Cxa+;mp8%OjMlTr
z<i*ir9ef5aOCGBNqSHY{akzq$8Tse&Mf*`dR^S%OKL}4t1{NqH7~M2`!K!T
zuJYNaJo<;xl9UX5)9+`|i8tI?oj4syYAtdf5#Q^XcrbF}ZWxD~j*8a^4mmDUbWYh0gTlT6B>x$O&ty
zh0QkDibBo5<vl!3p7mJy)3o4aYAoi?FvEs_WGlN
zr_~3Epcu{oE(bQ1I`s)PmUx&W9p*LClm^n62iB|3g%$b0;!${@Nc%jI0uSTIJeOYy
zRj9URqVZ)xEee<5QApSV0HH)=Q--eT&Y3(509tWKmempp;T$gstK~)+7;wxsE|#0z
z#VZcR&@q{~tYXj&m5MG)WLrL*TxTr~L;$y9;pC^lA!-+gS*YkpP}e)W#9mttO&fpK
zn`d+CkkJwO3!yn0DW}CCd4y8{>Xr6}YXIPHi(RjWT-o+@Bcu941Ta$OJn(16vb#My
zQ0{cYK^%_X;vT*`F9T9MS>?B=56bh^dUs>P3O+8i<7%;boG^!|N@|)iD<;f(V)`pZ
zIRj*b>$U;C)GY_j8sF_pH*IO-1Y`KcI2bAgL5zRVGd*Q{JzF3)fp5O5AHG!`dkjYD
zVB+CUQh+%+$I1EA))fIMvQpCCTAltsO
zX!Rt<9Hz(W94z2Xftjkqh60l_Vlg?*keIpYoVWk=mmirsU@S`IT@s!poNSYIpG*-^
zF6$HSP!6?Qtnt{zOtnI@qLU#!lL-a961eP9Zm)M;r@W2!C`**i_e(Jnbr~C5AUcY1
zr+~jY)Nx2){y|5iIC@J%2{;yfVXGB0PA=M=Zx%DF}&o8HLUXlh<<9w3;->;J_Cf0>1
z;o(z6EmNiio#H@|@!cJizHORpL#$hyQbpyO{Itizf_%ddh72sun|^GhzdP8w|SrkGZUf?B^j@LEgI{_c&5glX+rqY9H%hCJFG7
z#`_r?=)wKj*ndpSADq16>xvy9`zha*o7giQugSX^7
zj(A{-|H3)UG_<)7|Ej2R(ZlBGkpyj4_c{BcP&8E8-gkpK054gAp%wsbo
zz`A7^-rdeQTe)nxg+=YzGt%KchwZ}mg$#~m6eA{xPBs++rQc!M%gw!W6~S$vEz;Qp
zFb{jA`HVgaigvp9M+Qz}X{BnT)1`0NkgNz*C114$0&+>a7<^$zX6(|oyn>K^014~|
z+sA3M%Bv{XWz;5%q;dMaTt8wbMFZ#q-TV$bnVeVhl5rS731=w*^zowp4Vv-HZz9(U
zIZ(V@0&-7&P1>C)1a+bC=xreb4@}dVR*%Y4qF?(lQw>K#qMUS#u1xBYW#ryYo;#KI
zPd655CFL13PrWOM;~QpUAsGxv6uM71lbgn#l+8rLL|j59$lVHnJ2n3t)3<)leiW4Z
zE#LDn2nEXUxFxFeH;$+m1nhBJuqjG!O>O33_hRr77K$Mp&Jda(^#XdI4$nx}4m20K
zVkENed@d4to2^^BLT6u$Scac3O!gh;KnY#qPDr`te8WDJ8AAJr(>Qn{cHQ?^b-bB9
zw}u}RLvqn80NW-LSQyMN
zl!DdDi)q_#x7zEn*YNvKSw*F6$;W_Far6lQVEwa}UZn9_v2Iq;}C81?!&tI~r|-b>{!?8hx0gHDNQ=WNC=
zF>3|WpKV@KqsPAvFpk(L&E|OSN!SLbTOEOvn00t*Zh`>n3;S?jPV3z129&g*&4|ta
z%(Feq+M2$NEb$7$fO$H5ea~KrC%_NzQ&Fc1?<6vgD2_8}xC71#e3O2nXuSzZ06vgC
zkrxaRJ4WZ%Dtx3oc*1fa)iCsuayh%$n`7--bh7@Y?$_p7f0rXEG@(9KLNA>tf-RbX
z`{`Jq{8Om);|q9Clp;?|ZR-TvnZJFF@}yH1?xBfM
zp?$~|%bj=V9f~Z3eByhln`HaPhow$5eAJ{2P!yG6CfvIjBiFfi4`rUN>umwuHo})S
z6k;Q=F31>YMT0`_d5F4*Ub;sj(q2pW`HS$C3es>I0d}s&wzm46N6L2n_NmHCQ}V3p
z5CmVP7{LYMOkn+@!6+f=haoU<=pB+B4{<_qkq(iN1OsOleZ3B0)B`L!{lfFHD&5Ka
z;(vf6NRzRz?nSLXL5`*}`F81JS9gPMt{>RH&IBL}OA)$14yjBR0fA0e2+{v2qJ095
zBmNp7$wEeX5gl4DfzOzH_!1Ln%6f1!X$DTpYgX7XX-KR7V})q%kaJ%b(o_YT!xr_l
zaudJ-fMHK^eGeylv%)J&ZX8d{q0U%E!wT6%aEl}RhG*7&C{D~@A~Q23kVf0T-tWUn
zhUb9?lW$)nP8azPuE5!3ifFXtSd#&S1?g3w=!=%Z)+fe!TzO8iz$|l*l)p-&7$eVn
z4_X$kGRPoWRq#*$N~PDUlx|k#!EV7=ZcNBc6=kwQsVekefzn|qoy|aSN7+?zu9fZE
zWrVN+YIK|;ziKd3BB>lFvf{!)8s#~{qYx@Ccqd(|^qUhM81YP;CaK#nlC>rv`%tIj$d58<=Ef7w2O%!_H9`7}kij}LID}8Dq)(kyajlXR&yFTw6_Nddoq3p0Z
zNZ=dL3_=n&Hw7y{3zE85;&es2>V&3q$vqPj={}Q&{S@J$HlL9^WLuS9gYH
z!i`-cL}F0X`-pkXHPg432-Bn6{+nwWJPdFU&-lCEtA8oS`kkGf>$~s_opoDmLvxae
zWh-)B;d&U)E?^#qKnFlY)UAz>?+WY_!AIL*sg6xxZ;8t`8{i)w>+h(rj(8Y!F&;RgS@RcS
zH@5n87=)#ZTAMe3Sn8d)8++gb5lbsF!-9C_FS>c)4W0P
zRad_N_rZGnqD4a;9&80&y^=XI@IqW+)I*<835k%;6M67vjNABG#kKj8VI6qnTZXw0
zp;2^PiC9+^^b_uLmSxjGXZuJ<$hV)on&oOjosJZp65#HnMMObQ-5iKxZK9CMy)j(M
zt~QQOu}{w;B3E$mzJ^owqu_!EhW{LH&V<4j2`Rq`#WfaW7aRPmxR%bv&BAqPvf(Eq
z%0Z{xt9N#15|MBsH;_SnXxd9G7D7N98$}QL!p+zJP$NsDt(=xz~|PSiW@3
zos=<<_OQ3?*^7+5?SKM>y42*4`VJi(36U#TN?974x20
z+)RmM*NT5@=3x)KAd%(&>6o)L0i?R0*;`(vhd}G=wZ|OeRo!#95%5AxOwrNmIL<4Z
z!r~LJbSFko^*S(c^AFrhpuV-jWyhf{$hsW{d3zuop@*_i3odv%4KC{{*R(P6jMCuvXrPnb1>^OGA(^>wmQwR4Z%YM~Zn8Ri=;uu^2bWAWaoBCA
zkg2A$Oi_(8)0xt}0?KD#F3?`orCU(kNc#)fb*)kXfd(1m1;VX%et2&T)OLULEy6Yv
zRLrw!)%qAQA=D#s6D5%zcrKVedBDxMjyEFxR|y(Kr0CA8S}DtUK3flF&T@Mb2i!}4
zo90q9GIP58caaRP=LS}-rQTS+gtV?4NQSsOp-N6)OzVVTPQ>Xps3$~#l}7Quy6`PF
zM0BP5YAr&%-Ll(_>Exw`FBi;v1t4-#`ekbIAboWqY4mjLhDgGytCb~e4LkKJG%6;C
zXMFrHs2Yf_eK?kjfVRHI`Hsxmjm`u=?V5aNUp9l$ytezoRqO6YA@SYxB#pc~Co3F;
z9kv9{(#bTfu@ho%KQygOecT|$sBUWDU;iURS^?Zps0e3$CjYTh;)((d6E-xMq&mQG
zsu6(GTxd?!swBTp&BXY6Xw4^(>Re}nM(`;0iShAH?K*MorEbmvN)`I2)ec;#S+Dlq3hR4O>cyGY-Nlm|LUw>Ai<#yVnA4ZQ6Cjq>uw2QnTDs1x=)%m3MG=n{i_
zRwJO?r)U!O|4kZMHI0@2D}bbAaLpQLj^AxBdI3>*>Qe_gY!;D$LU~%@PZ0qh`2oGW
zAV`Z8FUYIALn2~gM?&Di8nNO1sz
zZaU&F9S|0(J=3GxlB(A0un~Itex**rm)PkeLN9@ElOxT|Ha2uLpB^K>$zgW+uM&3!RvHW!PWG$@_FVJ6Whw(m*Y&b!Giv
z1FwiWR`ui6c2Z#J1X7PKgp{mOU)LKh-js~ogmhXq`zt9>^Oy5iS!k-(muy6@>M|(O
zQ#Lqi&gLKA$5ecaro0j>BU#SPmZa4OlFXX1h&f+4!grYD2z>f6z33`TK|O;J%Q3$>
z*|mm&3oTC|_X*OBnR}P2rSA98vEib3=#6N)6%m9o?4KycD?30PY{FfAtRgg)d+Xa1
z-EC7bjdB4A>NIN|M%(rcc^vAcl>4^Y83Lk5G2MH9;omj$w(a`HUv>ZVt8=5vaBgy>
z(fptArK&*8C}V3`wQ=^0ZQn|fB~nDhe2k0@wO&*DyDLGoSS*JVvqTtm}moo}8
zFE^v0^qzE$&*kR&`{nuV#2T44ODv)wPMtKFjX-L6;)1Aq7QINfR*8DPe-^yefr@me
z{#ifVl0mr8yjDf}ws#a`gN`AYxThsydIA~4yk}_(u6B66Vq!K0q7gP$4IucA;hQaM
zw4n6*qI^YV!L`Xgs~Y9b{|$?@+KrFG^%_CQ`kvu!*kg1OA!dgmP4NXvz8fQ=Jv$owtGcyl2wpdcCW2~s41s8hCe
z_}979)GT%c({kbOF{gJ2A$%ics%d{DJKtTJVM$h$n$QE{9W23yyrUPO{ug#JG_05PCf(Wj7Cj(y%F2~#ZF
zJB1I3NHy7L1+cuApB36dm#1HXZTC9o$l*w`b6E2kew+&5wE_!L&9!>%O!$aM3aA2xJ~_xA=>ewTCg-@`{SeAn1iTym{c}^D1Z@7Kyy^H?Tj<{g
z*xyXpEa1JxM@>YOVi8wn%v4R$_Z|+B%Qk%p?f^{%QIDI^({A;rA#vjC_l+70j%KgK
z^{y;5F#i^!Z9?0}jz3Rh$1NjbiuQ1l>vjM`1w4}Ohl`2~-J6`skCY_rX9pS_rnZC!
zB?a=($74ys%1v94d7oSvByeCNzT6WB92&Gl*q$3()aAAs=&UTSxShgmQc`4`dZfO_
zt+)8D+7FzSKfTr9KDqI1cWj6f2E84eWq+VXa}@|tHe+GTjezcAPU_J>4IVTOfjDW_
zn_LcP?n{UHx$b(=SlN`d9H>N=DxJ8
zn@HHq^M$Mz#cT4@izV|{=62Fk1JTL5=LZkVokqGhdiv0nVBe_wuO7PEDWBY?Ht^yP
zQG?QlGVy42L!4O+SK@?MOQQfx&>JZ~hg|W9A-`J4`zb{|f295849NR2*d;xID?m)I
zcKQ02<&vd9uOTqNo6MbYpq(7XTmPCJf(Fz15Gxl0PsjL*KX1KU6|EzOuN^$OHbpVE
z>FAy|YM&|_?Oi7adlJW^a;k1A*LC`H^l#YW`HT(Z{3w0F$L?2dCSNLTcw==1X~tjF
zjdYgux
zA_?ziNFczhn$~R!#eXw4(`a@3tE(?JpEo`Hy^T!Dg)0%aI{VsHrL^V?(J^=Yuk}5p
z{9u6Wn>rrLY(Wq~1M$J1j9Q<3
z00Y#8kyumBwCJJ9@#T{6SdGdSZiXII(OGa_aQS&5s;pHj@ZCnAbG^fe=dX@0Qy#6j
zy@wi5@1UvYI-lo1pdQ*i&`6r2zJRfR%H)uZX0{9Fgf)wmT<41I?6It9=Ygm%B-CJ=
z|De{!G%x=|1Q7A8Qy7V+8jjzhj}hlwo3oYN+q%`;JvFH&F}Q4$j~}g>Qc4udd>Ygc
zDy174mvi|zkpPPM)xqxHQkQ^%;)_c^wA9K;j~Cy@7cg5TWknmb>8B#qmOYy@csyU;
zlgvJh!z>un)zuTa@0flJ%0Twg3rvKyPBMC?{?{F?IshesNZy@)I(S_Cy^o_^<{QT*
zmF$wI>tvK~_4*#x9%`v~cRw$}9M=~WfxK~$%{cUNrs${$9-`dW
z_j#w;|K3a66>woy^vI`=+=PR|%m+$x{BH2XrEnl(-cKBV?A60E`c17vP7|p|o8-c|
z&3K~Ni4P{RZ|KMQCFN7R%K{8wFV9z?4f6Z!5O^wJZ)R3r#1_cr}N(f|r&3n^XLKn~PnQSk4%E2LVfk}h(@RoV%
z?0yBeX$wYahRwxpQ0GDr5UlN5l|J<#lq>M1`_rJW#SCDs9B}R^u$gD|%iPqJB?zu^
z@}X+T-7W#)B3d__v3I+7swT=>?(r~|@ug|L>9!eD|7VTfS$l{WP~XyB%fhC^UvT#s
z>9w0vIxc=r3Zd=Dy@O)NW4%W5P``xQi_ANcyJ}0rcFl+(`D3
zZfh_bHnadj`T0*LU$g_qaXY%$7J6fw(Sb^&J(|x&)8^4p?oLo~Hg~f|o{7Fhz&cF&
zk^w>V-_TcDCapBeWgy<*g&{A@9_4;F>T84rXyC#CZ!zHmqXAinSgzP{DBjl>1-39k
zpwK;OXG4~C*%7lDX%!SFwJGz&tWM_W+UD#G0BOF;NqN+~?}yaUCk}hL5GKa5Ji9TW(1Lav?Zj?`$~YK@0Y7;0?4Xo(NeHc}E^G$ORaN)54A={3j4M}bxA)VRaXYy#`(?Pw<(5%A|#Bu
zthv);y1+HIb}xkw1P_{>DWzohAsG7v=LR2DoGt>5NxqwUN8U6(RtBSvQnW(8>B{`G
z{cIeWrc3dL=}0%OTa$j=eMDo($b1WAQ>7Pq-($bo@f$(6#MnB>VrkzAHjz8cCz
zuM8tq+#Y9ZM6p{OEvXb~XQZqTK-w^KD$`dD%~!OjI!GlzKndyKIvbz=dqo7}1HxU@
zvn#NYxk20rzU=w}aX=#hQ@*gewvlMQ=ibBD93$LsS?ORKPK0`!(2ONT76ZzV#Tv*$
z2AE3DB*_^4MvlvTQ!C(eUB>*wSwPrbfnQXoDkJ7hVBm4-fBpl}z+0DbinfTelw#d-pebxnhQqpBBeTtD
z!vT#TczJ|82_m#Gr{HOUJsy_7CWb{P@`rk8t~_5v1LEn@pmx^)B$8Xcoko794@}XG
z>}p(Fg>{D9-6VGVJo`{AKcx+(*cfPfP^l$J^9=aPqigP>MK#t3A$(+@8hM1`6Y%;I
zZ&Wj>Sssz?T@aw3`g{(I;19gjnRAI`6_|193{|Z^aCFy+V0oBPc>hcO>LG!T1U;dqww1sPdr-uYyUzR*G@=st(J*PRRj
zwiOG|vwEF{2`g$85@E{Q|L|RVVUl*hf|zKu5(O@hvCyj2xcsn|2HbVa*tn>iEuU6%
zl4QDI_yXaqEc8#TS=odB{UR1_;2;yz@}scMicCo9K9h7B5wV!Bn_1P1HC)+<@7FI3
zp0~TRO%u|(96%mht#%EJnKLbrzj4!Gl%*o!at%N&$qR7VI0kf3FHryo5*^$SQ#)Fr
zw@nx6o?cHHe1;sEdcUGk{ACrVw!TLmCE8)J|I^-&!!1~SU=JGwdn7&`IA}c2^3t&e
ze*Q8N24NV;nmGs(SG-DUJUSv(3#;xMxg0UStfOPazkMu7kgs1m5A?HQ&vK%R58wH!UH@Z#d5E6GGYwq%4h83;12P?Z+ObxN
zhOI6LO_pH@f^x@ZrEN?_t%U)cAx#_^UM-||K
z5yQwz0;{L#cf3o+Ss-2(5d%ljWb@m$A7yH9;G1y6M6k8Zty$uzY#L#(JrvfECQ<}p
z7;}r#Ywnu1<>&yq_<^lV#^+vdmN#3-l3$f!roJTy?t@Q`CKC8M)v3xnxQ~ns1~rsS
zm@52JJzYyh;D&a!UGyZl>`IMW*A)ir6ZpLhj-dmkk=FUh#Py|zOwflN3E>ug8Rq;D
zTyfgHD5ie??4h2-T5u|h-!lbgfmj4sn<$a2@#;&2X}SQX2D+ec7TxHL=@!cRem;F6UI{<6aoCdXKTjwLiWM#qC3bbGjCd1&^<==&$3g(qT%bffIJ1vOY5kFoqa~d
z5b0-!wcRDEN!7X8)3^kpZ%AI~antHZJ1{O&;lQu)$i1`gl~t5xilaJX1gugwNS(R&sbutr9fsZB8_
zc8nW1f(qPYf>%e}=otNG*zMvncDN8m&}{(z{uscRN=;S7k0d4eIG;+?1|pFu95u{a
zK%I*9-X-1%q=McE3Y}j!4c2X0H?#D31i79;gz^{bNK+Gv-3PNe_QA*wvYLER_
zK@CatNKA`18G_8NiHTF}L!5_Bv&pui=63RiDVh
zf<}?sBSYcvs$r>}8@s7+u_CeiGD$<-6GcG1QlOJr`e1OQpR!NX3u&Ap
zV3|r*p;!c>#wE|$_x|XQop&g{G^@UD4A+W%3D*h%{jWJ#ZOj#_%|eU^S*F!Xf8>W(
zVKbGPj}ncCTbNM}cF}2lmjsWaLPQdlhIF8NF2FKr05CXPiI#+Aw7`Vp-+|s=(J|S%
zkaO%XpJjzAv||)YetNbcIqA)WAlQ~X|w=EE+p2$?2+op!5$i-SYiPw75
zLWjwnhi$6&Aq&QR6VX}`S
zNZmUdm!YydLj`XN$_Lias{?KD@XkGtfr9&*R9gQ((z1H%#t?
z0$jgKS0(SM+QwR=v&TG`vAx3~iss435Cf?Cq1B8$Ybzf9dev9@h+8D_DpE0r!cvRl
z5!z^R@tFpVTRob*TdLQ#=5beYyy(Ro%G*XYqHiXojClym_}s)jK%q1h9qfy)$-MFR
zdP?P_NY**PQ_SNN*Iaiq*?O#OJmjWi3}a|xc@f%mis#uOsMdc;t)xI
zDrkX478Q^%hlA-S)T9lA;dns=G_5HAUZ^IoP^<}=y&cH=UYv2DKZx3)nG!t4oEa$8
zlQ6rRSYc(G!}nKBHS3`5baZgtV9hRcxHgOO|8s|J#rCIhurGM!=V&7~pYaHR-7^I#
zs_;p_Dj@4AcRZe~2l`Qj4jNfuGjd<97wM3^kHu&?#a>q2Sui}L7U2~#sDO}BK-WG~
zn6##=gCpdgp3b#(D2G*6PF7kbAO*N1KExq~5A?8Ok5D9@t?2wpA;j?l!J_t$PxNea
zikiUIphE4Hu#5vy-VYr0uS6(H*qjL&;%Ucikm;p<7v)Ku!iVG=@M8$_(Ss?7`bBC<
zm#S>nTg%4C$ko?X)DFnxI2bOVI9SRo5X7$_oO9NaZl|Rh8e#W!=?)cSaBixDr%KBo
zm9L@GnrnzVWSuBFQc?8g!!9dqHjHZ;Y?@|jx27p61D2IP_A1X{4XPySlH(f?;kmGT
zF|bC38*2}3)=^0|sro^wD7IZz`1k?P>EZg;1{x@wgEHOMS1|KVqfY9^T+0$d{kc1p
zrc-0N@$K(#Q&}Mi7Go3@q|df~fJ#h>SGz+~-x#vznk9D&p=fun3DbdaBOc7viZWU}
zX6G)Wt%4)DWKz&6EriC!m4(Tah#@5tA6#LKsLl9`g;5LbZH;UYdrP~evAl!JHI{K-
z9ON$@)Sati@Wxi;E7?G2h_ko`G1{Tw+YCzd1qgk78!VlF)gsJC#F#*6IFvRf&=5XRhaja}0{KQ>^YAkxBPSj}AB|SbP1$2TFCY9(p=Q~u
zqmUkT>ZJn}TS>*>@29f&ZCM*v86Ib8<3e!W)j`y=8>2PW{F3JA&F`{k%~SUKwgJ!$
zivIG~EoP_FD{yaM3lf_-1^XBt3q91~(MQLH#7i`F%_1+$e_h1%lK5(a8#0_Bx2om4
z-GG$sJ!Y%11Y(JxgREpN5~L@7Fwh9*LfSoCP0We}?q%!0kuP2Z!czb9j=$=-Zh9qe
z)$70wEO*_aLi5CS<}LfvRL%Wy!#G(nv5xA6!N3$4Km^LZm7NPH1J>Io3M2oCs(cTx@)4$PxPqY=6{K
zM&Ff*l+9el%^c$x@52=&)sBWL8|c$_$(_&7%L~$yA~i^G|Kq(_|9ww
zfNskDwon2^Dy@ObE`5sWku0SiNTi^tEI!u8`=JjfT`0P6>g%7)E)!W1TiSEi>KMB;
zcrdhY;SRurfkVMhpI7(=?=ID{sEi2RPxS7X|a^==>!-I`c
zP?4A_sYPLlbVMkXPQ{pSco_Pe5yW^MGMuRGXfX2lQxTJ#Id^GQwqvHukpJ4I7Xq)1y)W9axQNw$eH^&RR+
zV1b6q-3haAAsNe!FNMA@c1>5B>}LbS^{>5Dx?7XZ1uB<%m~Uq|h6~HQ9+u{twHo
zy5(T;ta?strWrYMY~4sAVMZt48on3dhi$EOhNK9KzNI_|!1YpG2fruzwaBsnNJ>-M@m0#l`YU
z2Gb6Lft>+S{{5TyQwh%Jga$}y@IBZ(dX$}Umx=md}_TTn&hOs6~wgXFR3&}%F
zz2)2TJcD0L)s}(t3@)2IV@iiWfC50FMpa<401#u)7z)lHsuB~dBp&x4{c`-dRunZw
zP1uP=u>OydGFvQ`?p{7CiNiUtV1Tf9tN@6AIpv;OomO)2R&Z0_l;Q56|ggL#<
zxjG`1RTDFSTjm*5UOTCxNFU3(NS?Xi!tp6e&?N^0ZkjNG3Y)1iWs4g;&r6H7V%;Pu
zQda1)*pfC{3^uAwxj1@bovj>~XY3cwJQ-Se`Uw%edk4}hNbG@=H<$&#LZbh5c*u&D
zxuB^j1RiD8ozjdE=vBJHKiYi{y43!cHc9Q_D~TWU)e$+^m3J<+Ad}FKe@&1KfG>_w
zmjJ(|JrKpl^yjAcexVW#X1m%{fj)(|V>@xTqvjcDQz1-wp@6v!}#
zVDDMA`{#mnF`}`mjDn3EfG%8_(NMRVIMK2AH4B-KnnV>H3`*=NJ*@BT|M?2U_*Uke
zY+}hGzhYxeRx2{I_Z~{8DYejIzWwb9`%__t=D_6B906?iL&B9tb6%YQT#ym6o87Pu
zlfEj9eu8_Y7}M|pUGaK`VrPch-#bG?upGh{EJV7-*knSwxuU*y72JLy-EBCC6gsly
z;al3$p@^5*7@->x3jp}6pW50XUyh6QK_#q3lg3gKeetz
za?kI|V$okXebvL_+4@h^Lj+FZelG-Yf6%DqKpsec+o*y1R^J5OY6V9gxbVOX>lO>b
z-qoMJe#HRNYEU^EsxsdK0Iz`}iGvjK&)<`+L>*cj@5SbumywE|Ce_;1lLZE)j%wXn
z`|&_^=98N>T+WApzDk}p6(_op{}Ld{Z#IYy+WN|
zzWFe?`C#_z&h51ZobTuot$_Q)!c!z2faU#Glr_R5gq#N|H=$jFXd;2#GxM#TrsM%7
z3r~45B7EZg|Qrq{2VWrPCD!ExFi|
zqg@9`NjMasEqDctNumI{-Z66fhqia!cZ*%)ylS+eF`!m<1eC*`55{P!(Jy0eTHVc$P2%j%4Dnj%4
zy+F@dRAvx=Jx|k98=?Q|&S~G_g6+W5ePUnd75aK2sik?35^fMNN9vyMT~5~TrWXeSGvC0ngH_TV_kPcWE(TGeFzZVFQ>3j)zXg}`R07V4#z}N9;Et#k$9S{>
zcDXy%#r~DUl7qPu=BAZ?*14U!e1aeh^&35sN*4lapb6W%JW(2h@a9<6Eb@V@WvUD}
zu_SPJiz6{0isP}Hq>Sdv+^dI%#XCbypcJ~a|9@|P+q^!IE~;l8{3lDdkD72Re1Wa`
zaI~L;F79(xz`{NFUW73Lt{(W=()?w%Sq4uQwi#qFwGRfIcb}<%P=?yvqy<(O_#V+q
z22W$JAHdtvuzI!~y-y1kg|Q$ge~Muk-ICwuxkxm2K|LVYqB|0Bgw-C2^?2rsmMq5<
zCs@A7?lpdJm>JAySwoHtqbl1m4vu!IGhvnvdW@ZsJr{E=N%KkD7$D}#eD+oqRK(l|H9yDBdSe!BC2=r|BHDm446Q-n2xy@i7bgL+xm
ziMi76v_wp3mZLd#PEho+MUM~V@T8eN-`y6KS6pt_TC-m(!N@OxO0tI$
zlf%O6NK6|>G|?rpJ?(@L*>WqZXj1WXXp_F;nJyl3@J&4|9Ys;AdI@A$ZlfR`FDL#w
z*3(WB#YvPJWq?f0Z@;^47CDTjFtcw{4i1qP;>1@n+K}hZwf?&4e@6U+W4Q;JkVF`i
zWHm+URSG#^B&MP!Nn7yjXVZ;mr(Zn3+H;#{#}x#vGF~rnNzoS5YkS`{VOwOW3O+sQ
zzR7D&Xi14voBOPvS?{WEXHMre&GDLd&qSy5A@&<-?LsXk2i^UZ*_Ps3x9Q8D#n7d^
zPCl>^99@3Tzc{zBV=AR)g&74`%-Ck=wP#JG8m5~|Yjw8R
zA2NbedkV?gUXFAPx(mx8&Jz%09bY~^2T=|!3>BC8ecsJpSLVBerI|T>1_nCrW75aV
z4vHuql8v0i6o>DFJN;gMH@oZ@?V2>7xpub~`jmd0hAWKRp|e{ASu8_+IW54hNj;k<
zT?vuRB0hZCB!k;Akb*%Ceo#UYOyyZ~l5n!r;;X)({0)NEw(%A0-gM>+f&=!SC0HQ}
z(=51+nDk;clhkm~Cy>DNXqi_4|5E2$v?VwDoy#Be^FDgtT6P_RPE;~4y$4{?P)!m3
zPhrK7Z?nT_oDu{1mBDP90i7y*A80`}iVW^qw#qKG=9#7&xb%d0&e!hdm}7szs?>uRkm
zHzZWsvB8l(qz8G?nE3{%H;+|1wrN4tuVk4axlk6KTg0N;p_u;=A&*&753bP~Ju!!c
z{7A(8jfv}p)@*w3$$hAz8xqt#wCH0oCq8?Cm+E`Jo&gU+Bt0y6;g;InMmBS+ZYpD^
zyupG4CU9+}D2GeyPK%mq`Jq?(FwPwLHkH`;uw#BTgjPK0jOq?soqEL4idow{)tvY=
z2sfKjy4f(s-2zI*JAJ}zkBW60zV|*C8%XIbgFpn2Uxo%-@IP9Grx=rDh3593M5da}
zG$`VW>kxn999p^xYFWk0mBY;+UU##zh%V+rcy=ccs!wSO$^iWFF+E0~ZrVk)+#=CfYlLj>@`W(ma3;T0+t+}I3d)|@R97h7ZF2+6}eZYmCC>qkdy|c
z3MNm!M-(X|Hr*5DJ^HAZDYXww`GKrG3d*Z@A3fY%(2pk7L57+t1q)ihbwi0gaNYmN
z6jljj833kVq42Aq2tD%J{WQT|1O*NX{sSM=ho3X~X(`3P
zWyTiR=HD>OEWGGEW*SYhUpUXTO3_F%h*mCpx*p37U?qrybb6ufw!u>
z9EoX$Zrf0eZ+B%}y+lbVo?CANTLbrVdDlw8(R?7x0^3CoQ+WLSBk#tboDQCWEWPy1
zL?CQU8r|k|wB6+9C0F1Xk-c*|f1EGUsn8#-x}z!OG887SD=}
zPH}nGgO!34S4FG_g>T4Yww;(iq8Cn@*f}9u#$4<_L+%Vv)@Wbg=+NYWfFd){
zrNC_1WOr&#CH(n0u^VoQEoi5W1ZOC^B-ISIVbxukOa%&V#OmuM<#kNM&tN~qUv~o+
z?zhZFRogtI=&7MkWzHEld2i&uEK+OS?_YCqdbnY6fN9Do#;LN7ZD^Oryrag#Z=n`S
z4v{O5(9oGuG*bzf1hN%9Ky7*goF0M3q@`qURDL4$hcIH0R<7k5+WV~9$ho6Y+7aCZ
z=qMUNRmn-&0FNPj1Vf4Ud73?R%Cm7u8#clHx>PTY)x`!66}uS9_}hyHykPLhiiP)@
z`>Xeb<<*0fHESujXA&mSsvLjP((<8%YZbd$i7ZpXYNd=Ru(w-(m#N-8C93S>rQOxi
zAI!p$@d*6Zc?^z7j^skEv=<^9mP>62!(w&e4dWbf>gt1Oja
zAZ;B8)F}E*bRN82O9(^}Sh9$|@!4a$Cdc!ZIL+#+cn}GMY
z;So5*kcpD6JB`3$bFYYwlOhJ&LWOU6*{rC-C^q;BcGNw+?sWIRYwdsnr>J&n0=ZO`
za)6vm6MGJbtM^Og{0I<5QLKG&p-hUMG9rDAFoD>Sc~;jpOnO?9Z9_;xxk6Qb*sV!#
zrbh5HoALGA8J(N~+847Zi?S!Oud4u@{dy5cX%ZI0YvqDNba2uGHtnPMEzeM5okcGc
z$KlT*_)_I4yG!GJ+k_3F!L(ZfyTL@0H5U%M;qJ@@|sG6hDlD_(hVF;0lwurSF#qd&t1}m_m8tUFonfUqcF}L`*-`b`eRi
z8+zKy-Qm`j<>Mh!8u%Z!$S3QivH~R+j|W!*xn_Ld0IA3SLucqtcw-fl<437d*>0Q>$)7BwFX1>c9Zouj|XzcJ_7cp)Np&@Gj8cI#=t#E|dLP{rhF
zU-9T3oTf;KFRiZ3yg$?!4Ka?7lJgui$`vXhrBvXsxh4U5N~>A3`dMhPF#Qx1wLu%d@!5aJG94!h@B)M8kBR+66rR(uX}8csMY`)_
z9w#|+DgGx9xF!5@rRW?MK0!IMu2$Cjn)VR<566)(jf06$cI8!teIOW~#&Ukz3V(6iA7Gqc74Qyz5kk`QbwOIl`Da>|_*$9F2C>mA
zv|Q~^7a7id#!QR9*RMcos7Q5=dzOnuX*Ct7Y4TJcrsS%FqY~g@Qx>pVH*i!#2)~0x
zq;Rw7RKVb7meLI+trR(|<=}Pj851_61hc9^H;ixe*0eDotz}O2|C*r%=74(8;iiqj
z^G21SX8BTmRIxxFq9*-84|fjOV_U(A^;EAOJyg+fQmM~JY!oNo52ZZ43oO>Ud`J>B
z2Za0DX3!9_``uw1iwNg|*Ud)JAJP4#R&A#Hk^MRE56@2n#jCwnT^A{_5j!f%D0e#?
z_srUSEh-6_zd6TvpRi`a`kS@sZ|d_MpBfjCDyag0puqrG%F|=%TWc8l_nn$JX-7XUIsgb#?N)7D
zh;fE~AZp}674k&X5qxA}$pyt=KzqUhtc|H>R~G#>%c`$-pnCQ_nm62r$aL6%vkLYb
z63?p9NaK0|HmxbIHBFYk_VBm2QlR@Dg4CD%#aZuOn#L(x=6P=&aTX~aO-XCm1RSnj
z*J_xG4UQ?`;NaZT03WR}1{|Ob*MZ+2xWW-oioC7L72~g3-d~8G#T{4%4e2UUZM$#H
zwTV2Fxo|D}hSTaH!NTV-WjujKg5CoRQRvRMR8MPyu%HH9Y76(DvJ=nt@=*|aYq&&9
z2I(4uwk^V$HE+)yFXC*It&BQ>|FnJ(1Qn&N%2R8rr#BF*z03AcufCTW9;`B;xtICB
zo>NY;FCGg9kc?|eYY7-rSrp-WafWhTN?}5^+ZN9WbS)y<;_lIFtg3uj>;F*-k=qjj
zuD4AVDWon!f&Ai(@~E+1h>_bgh9@S>+lnamD&(ey2ovsSh|&a3`=*ZQBtAb^4&z3~y`J}zBlQUZH%O)bqn?{V
z8|0vOIWTDD55dZ%>#?9ym}}^Q>mgQT*?M8S_KWn8GXADWB=NucM!9WWxBK|@qid1wpj{)_m=uH#bouX!Z8^S7#{A$W6rk^m6G&*!s%wyqgR0RSo@Fq6PW5NZP$w(`)St$)~}
z)6J8#GMJ0cRnfvb=BC3qioLP%{Y+w`@H_Y_fU8$ST=(f;p2u=8bwg$1r(-xMjmGU*
zkoC;aebyNn{;D*!sI864v`E8rjiOo1M?8bdOC#Wut!t>esOJTF)ErDNZ{~$ZpVNNp%7OGg%L{+c
zEN3LZCd^@CsQeZ9MGd?ZfbHsr$A>cNmfE$A=#tcjQ^QAv-P@Al>Hbk11Mr6{9@8hq;;Zj
zO6qnBDR1gedj$TV9#@pw=rMAm*b$urq6=HFQO8$goahS|JDZ7;QR}DHDpoF`!=Od2
zqslTh>0aewgwuhzBO8hWbskaJ4rt19Hvq-O<7zU4E~)YOmllP5`m^`sBS+F@-lF%^
zaFs39Ih-1LlwKl>sX<*UUEwQBk
z-@5YM`sPz;EY`FLMD}2d94ehvz$0}A^w;39a>)Lp|HfL3j!%o2PI(b&4;I%4CKG=o
zCWwJ_2JUa~i}?Xhjg8MYG7|>7QQeL~4Hgf5KV9@PGaE#vssyqFG5`0B8^L>rPd$lE
zqNaVWS4Z48?JiijDqtECdHE^(*grM4LEc{6c`lm
zuEa%-%fSgj6u#@zM)^;b-64SY?*9AzK79y77gi=Yi<{2175Dc+I~2<`C<{{Z1%aqJ
z&duNN*f2k|+PD>;j%BH2M}+Usl;qR+8aJXyWu67V0^TQ=@JDC~+*25J1KAPmP_`CP
zs2wsZ{OXaMgHFQ3sJFX#RW*{fwO$XIN#oQkvPgOr+a~4cu9Ojs&K0o@O^orm;{U?s6=_RW>&67Gw8owxmS#xmhEj$b
zTt8*YR1b{^P2xn#H~L*$Gh950PZxULJiTACvW^v6tOaUed+bv$`~A}l~k#x;@XvxV;$xU
z*CA^OtZ4?n&o+S7PV;Pxic8D4C!qP+<_x5_*B6rTmmE+Ub&YhM_Z!FJ+?Qt^*@G5m
zfwSbaiqB;VQp{fvXfEtTa)OD#++KdDu?$P_G~#{+p*`b_SqvcqOXl*wn7-d)RK3lq
zc@BhH{LTZ(UP$HktPo%b7wK$Hh!8Bv_n5Et3{9}2ypm0H612s-gPUP*P}0k21I}hN
zTIG(er39;6HwUYcVYlh1ktBu-$VN*%qTOQ+Pl+Z8_RwdGoNA?u7Ufe)d172ngdmM`~j7y3r&2H28&i2O
zw)8ItJIEqqUurzBfieAdA}o%`{lxPXByc{bungNKot=QRXSrLs%2vmpU~0e4kCmFJ
zYZ+)WzL>=o`;2{opL2S6NpnySJ?S{|a$>aZ0!e@``3r96(NuH?n8x6p+fdnQ#A-*9
z^`JrLXS(ZdB(A?PaIcwVnUc~H#th?OF>DH-FHMV*kL6Ti(7?#dl9=6>{%z{_H#
zM1pXd3;&pR(d54@!#yp7Txahpg0RaoPH#cc<#w8m;}($f7#I1NdSo)BFS}OvC5zx9szeHW)pO4UAjW<39!wZ{YM=L&kZymfQK>{Urfhq%&o*ee$g$K`~
zGIy*naa5dHax(-~Ib(?nD54Tu`xx))qt?-pU)mT0KzA-(ZZQ1KOzG}mY?|bgs{k*Q
zHYP?^_#y|4DCi~Gpf2}g4{tCEt`aoTa0wJ>bi5ptOyZ{krw+**DI;3M#<@4XA~!d^
z*9zrvyHot)D_XZdpn$-nuPsYPj`wHyW4E9`8q2F2gQ;C+G_zBzb%*0X9l_B*9#Jqo
ze7>LP1OE6GNVO*MNsf>-HoF7^Q@}8e{#xdY=9!gHDdHsK{uf0;NG{Nm%<4#1YHWn?
zV5S1U=*B#Tc&~&m#z)3T}V?VA;8qfqJ;O(
zyjM1I>I%>3;3%E9(_6e@O
z&HbU)1M#4@^V+P6>F&J}>p%G#^5KE1JmdgC%NExWc-F~jNI@}IGOc&PHyeGw<;uly
z_)n%*+N@mwHnI~GJf+fg^&?HAZ`_UW&%*-aG%50Iq1S@Iv)rfYlP-U4OVDOCPO)PW
zn5W!y;`*i7t#Qsn%VnX^$~Ym+6E(gX;
zk@fD6-~WeE#<2YQgJb{rPUo&T(f%tA{}zzZ+tBB9^aSBl5kAYy+RpuTv5nqhW(VK%
z&aJY;@}O}d|7xttUi7j-Uso#BHhKn(9_id`Au$g?V9h6?oW{y}7vBU%*2kO#KAhN3
z{28q3DnF=#n!*C_@Ee}}To%yt-O4ABPKjxrn%2_%{{*lNs03k2NEy;XsL--!B64>K
zG)n)kUq7xsbodYRWsfn8?Pj}NC7;n5%su5E~NiBXOb%?V5#3$fOJ3EJn2X}JmHd3S0N@O7^reh2<*
zxOq<4BN{%yUUlaH}A
z?cO$nm0bwkZ7rj`N$j~Y=k8*dMvBVBMi}THtg!sGeP&eCwwdBLqPQB8i1t<9&S~j=
z6OvmXjA1Wk#Edc#{jPjD6LbOg+TFH9LsLfB6i@YU%6f8xoobv5forUGT#j^n4{K#t
zbOpta0jC+?eiT#$V6!0)iiE(!LS{3=AKm;1f1lgxTMdX3WkkazD5;+SzhV#12^3uL(S24D<=th9`60ws=HdOxO6NWl2Zii+gr1{k|
zl2}vgm>YfAl5x!urKJv3fN`$!7fd44b{)w{tE0*?eU{mM`_-KWIUD%~(YXyjfv&>a
zAYfTtN_`8*cGMK(Jx3|E`~cQ1L~nDWGiYFRs|;`_MG52(S!e5(x12AC2UDAd1N`Pm
zJasa~xrwOZLaTbGxLONfFC0u?uLmyy$9G5d-k49S5Yc`+O<1D~iu1l->`L9cD
zH)>9OD9%bGIn;~t*rJALF+Y`S;t4Cy@{eANbATK?`*=#Wm-rZr>}O
zp$?0?KXE8+TVG|0;%C(Ve}nbDTJ5)|Of(XOnj8x6LLi1!ZAFelO~WX%M=nwv*=&yT
zHYg^H9QBS|C|7+r6#;dpR>syUNj4QjQ;5Mh-6VwLYA+st6;_|l^Gjis3-
z(8i#`lVRM;>*x3b$!riLhB?HAb!d=$Gld^WD^olNtfT&P8{C)zO9Rv4jts$-Gpnjc
zXE-~VKgsl1OkX<#Z{e^mU8po-!7ZL|fV|x4U@;?XISd3pr;7hy-D)g#L0O5#cG~JN!S(V|h5ZSX_A_aMz
zOUqs}fM(X4I8R59x>BBJIpfC!wJ(=M^t+Q0@38vBE^&Op^*zyD=`XR{zuro)DcA_;
zjX3G}{hK)8yGmHnj#Y1`>Y{ZOpS^H0;|Zu808_DqA2ey+XD_VOu-{2Q!0KsxQ+)=lDAlFXr=LzxbU3wo)4t8(g>pFQ8ixNqMFzs9}}7dmp#-@$z1>_5d>d$
zG$XTYet2c%kLti93)FHHb;nkZ6d&sy(mFYXBt!nrIIxiuA812AWL#9Gpt_5+r!
zlK9)`SKoc?J`_$}P?YS@9*bA~A}dppME9u$w1rxgA=g#|#`oURr+AUC=QB>x5
zGodSkrUUJia2=lvWp~8MF6UQf9F)1OUU%`>3noHlFwhynH2+8!x+z>F9FS_1h2RF)
zy>6g4(T^s6=D-HBBDlmI|Azi%E;V)5`X#ICA|g+6JY_Uei7c
zEnfv+oKQKMW;bol1)EIbppv#V+t>O->NR-m1qVF3@Iy6bi4#l8+=A^jz#J0Tz}+@j
zklYio5#&dIT)fb6NQj!#q(w3P<8P9iRpC_`{vhZpd5s)=4m8T`6hdZ~<_VbTthh&Q
z;1!^)ZA6Ca?CBrMJGbuP(+sV!9sSO7w2BP!k^J#8D(bc@KIPtZtna}C5*$mN4TBGz
zfi)5C#j&D+J4)z_`WfJ_`7nwG-oTVlmKfk#acGsh9wvZS+H+&^x=1-T==fxErd~wV
zpnT`K<}n+uK0YVUFlW7;`2%8`E&D~Z{@vV*?h^fba1f>@F;H{HltxH>U4rS+vQ&2UJ%gRpOV=n
z2LrlYLx69K3#_U(S_h9PQJbSw&FTmGgo1t`MNsPG8nlfSAU>X+bwB)FC)V;XCxQaB
zefPS5DGY;+0Ks#Lt{nLU>`#@A^Zj$?8Et$^9qUW3-#cxSi@{9+@cR}Na%Q6;i_Z0?
zo9D@M&tb|_lAW}S@wXeIu;8s{kxsyx236{l05`V3J@tCLh@Et5OHMAoxwoz2g)
z&xK8&tJq4U_D+235a1vyp4GL!c-byZ8a7Ws?s0twh`d2O#FK8WU_iCRiOk_kBw{I;
znPhLU=m^zW=sEIrhB1C{63<2XZNlT#R28$oX4#U$F2Wf!Aru?(u<=p6<*+Sa;
z79JZ^fDMN0(X2ua|8&Jl-oE5Ukr-9OxJu7iFAClxg-+X$IYjGJZ{1l~C^F;~#Yk3q
zKQN5GybV+rnk|le!*2TcSHdep&^Q8|qQSPTJnFvkoA$cJ((OI&=l022x>;|xny+&M
zuar105y#+UYJ@QIw&R)9SO{3vGEcIvCj&G$W6xd%GqLVOL^H{pJ$o;}K!>v^4CP!C
z;wYBMJK#y};RMdrI8NgE*q)6jgoO#`P>-9aC}cc`sy2Flpgq81f_w%%$7wG5+|wb%
z%_)Whv4-<(jfXg2HjwYUrkL7BKX-T(OfpRqomdtysuS5Y&wrI(65Xh*pM{{ql}C;P
zg-TJ%)LVISe_J|`oYj|{Ld!zNrxtbTMiS_os{ekl^@E@X8fZY7!un_>LpoKgesG61
z_~WKF2UiZ7F9jacIr&NaD!PiE9I-cNSwL4km|yGuI~NBsH8nn+JM&X`8hSQ`p1Nsk
zDs(XfH+TxVVE>S$ikQ?EyFG8SF7yGSRbsE67MAJ((d=-sA@DXmv}71oT(@6zW0DgidwWogUsy{E
zo>%@AP&P>FwcnV9?wI4ue*|wSagdvr4jT?
zAv#sKP6Vci@n5XD_b8JTeh4#0jjdPT2H-U69oQ;*@)vOG^f2E
z;YmTjLPp}Z3Dbo+T@%WHc<|(M+WP4+5P2!1fhLK)$&g8`G1_QG2djIgjOwI)n>i%v68B$=48_PA7
zInhjV_In|s8mHv_fRD>7s&VGq8kqNmaBAaq6HVmxO!0>wY5P~!C@4zL@l8XH+z>*;
ziqGmJI==7Jf$n``jlRiA`eSCz%1awl{BDXR$?gd8pB_%~bSFq749b7pwP|G^Q{GQD
zEoBxQ$e}Jvf4Sa2{`;Ww+~uq*53$Y`8U@6BbtNA;)|d|@`<_GUr!8MS4!x$S48|1O
zo)|@GO+UwzBCw4VW8lPTFcW}o
zGHqfu42pJXyY+CiUOcGIq?Teoe`Uan+hH9$1_jKoL3gwJx-{Z$$E
zcYhvO9BQ@ZwyB9dVOv-x>(U}CX<(0tqeZ1D&~WJwT#Ox9H`5#VP@bwxc0DB
z=oR!)7fEcrAx9&$+O6J2z6~%q44*Ky&mr}R-gwOL2H7P=$o^w9#^xFAmb)Fyfvt;k
zk*_Yum5i9!AWy@}WqmFtu+GBuOF=3sRNllsE-sN-^q0#MB5%ejR_1Ua!Im&@ajiu(ZKTt!@5Tw;wtgue2TNjgq8)e)?{+^w`A(#eg5
zLkiEa*`R?pmuf^6Xhzc=nvo-h)YZqLXsIpLk3?hMTx7fl75QVl-RxNYf?KU0lIk14
zSALB3DR65Q`W4WNuejE`q>WGK7GKn+R^eL%Kg488byb^N4T0vBqlQL>G?g
zXXCbSh!8Dc9DAHLtB`t0OWOlgRlz}94~iD`H8#8URBS5#`1%8AH0UkJjI~UdOl7;0
znENfImvRd4>y(qtvjHnc(g^3HVO2g_2w<4(7;Ee*2M}&Hpf_!yWqEr^QJrykiI1Yg
zrYt5VQZ^+8xje0R3{%197+}4>&9|>-Tr1~X%(CqjkzHZpWE(i@Jr=ph)QZ}Y|6Jq<
zH|JA`ty=ZBH}@WS{%i_e`Yyj__ojI~{x-4bliC|qKmuQ_%I`;4Gq`Ugn~-}aYcP*P
z=E=RwPO?5yJI_WK1~Nk>UJqLqTvEVXrmm+JnzgCv?K!S++cuGrD%962zO?Jp!+!MQ
zJ-Gk%W)ZbDIXbq?&kS*y*Hg?JjWk(s;I)c}3OoY}$(rE^(LTp{z|sUlcAJFMfK{0X
zX$w1kjcUJ(qp5l+pFrkq9b&B`KU)0OTJl5KRr~p>#IFGk9Gn{hNjogCzwo;{nqhIO
z2?fM?61!H@y=^S{TEe6uCCG)*tf_Fg_6N)+xRii@s{{!jS5o$F!|+*NO0sz=i#QSt
z@7>0_8mkU8P%5GQI{<1$YNzq=5?^me1S4H(ioGKJW+-5^ry%2aCefg^nQkc2lllLH
zrz^Ae*8n+qJ0m&ziXotlG!2^qc^Tmrk$MdbU#LZm`!y~&M!NkT9BS~c?`o(9%6&KY
zvy4>v7KAvfbC1u5pHc9Oo7HJNG}9N?bFX@WHLvRx6Nc5!UG9j*x+o+AQpze+D|^Vj
z)BM$BV+&J`yO$=q)i-40)KypMlRCcVM+BaK?pIxUM;D!$s(;5bPHeGW1_PG{20%<9JXZ5%~6PC1ho7kQhXE;Pac
zaC1-#sEta1d9#E65LJS7`;Jl+FX0H7kSxl0J7BsS+o7{bexyk9JX89XE}^aqSvs8p
zFjQ=)Yeb*S4;zXvIl?~RzgL`Uu`{C+BGbd)SCjYz1Oc`tpY0UG$)6-BjC&@J!q%i{
zU(-&;Ued#I`y)mc4bS5WL~Cx2wK1Cu()N)nFY%kr(AazF5lU!1{?xB;&Z&6BMB+|!
ziI#BsibGrntgsC3JqvsZdDM<=Zn3E2d!wB;jIo&n?a({V6zzW1xbU;7AYYxPpD-}F
zg#l9<#XAFCs54|*N+HElCgK2*quX0RWpS|0?E7*i1F^u%lr}Q|by1ZP#4L6b@Fe8A
zG+XIAS2&6V{XVr&=ffm;a$g-H?hBEb1ul*_kZ-N&m*j7F^R7;Lwb}QI@p(fz^~@ET
zElL-RTz%<|>}|r!?0M@ZpVkF&U!g|R_zetReWe}uAHP)6!q(i7;|C&Y#MPD{UV$2@
zanlN*0hXP!4CBP^L;*!Ee)%udz1743M|G4UHsZ3c9Vh#kg;xBeJN(V)3Dyj_VO`IQjoZD!j=#1J*=<;|XpRxzvM0zTrgIpsI
zlz?;#O>Ek97Lsh**&UDIcK!kST9*iyyPSVW-nTeg<6l0Y&BIPD`Ky%l#3WENWwX?fk(j
z*N3r)Z7p7k8DFwH?EoCB-^nXEk*;l=OYaZa1BnAA&`6$1Vb7h;2d^X(4Z#=HnBFR@
z=a{UTD{y;G&ERxe%+uW~TE_ZH>CS}~#?P}iGtas-_)9dqhG~2Xo%WzwlvKgcD>A08
z_8y>a`
z7bmK=3hLIJ>VYDmiLR#W#c-pKfzGC|DZC1ZFErpuyFWvr4{moXQUcM9bhmwNEJvo@
zu@9Mg8fc(cv^^Rdpuo;nIDHg@>N04Jge`Gbw*bwz^Bm{i&r#sweaTuaGeSWQC6T#^
z%1Q~Q$mQ2N@D=_aQ8ndh0lKxmb^ZA)4^J$^4aTlqoFFAo=suYu%d4C-YF#cS;QDvY
z6%Ofu$2O4QKyrsd`j?k70eFEcD9+D)xp_S0Qti`eU`r7g@RKc69tbgZ>eKvI3r~u7
zCW2jBgjVIb-hmhs>choW)#Tsc9DdHCG#7QlhMe?b$rz(O()M;y(xIeuEuh;>r?MPl
zV^XTKW;X0~4D`7>PXj5sNcb%{gKTl}7gr!{$ZBcv{U#
z4NPWD7bm`Q^-*vlqbbR#WLhIEeQrDF>PpXSb38*0lUelhxyNA*9i|xs`Cud)Oq%VUZ{V+z^qkpLQSgpfK0=ok@a5Y59Dfq~JrmM#tIahypHBFAVY$Foi
zu}AVc;4jR%S;vFD3!J*j_5B#mx)|tND57uxm1UjA?C1RY_u7i^0s|qz5cfDHY>e$O
z1y=H#$_%^Gp+e=y28lj>!KLFk`k3}Ki*CMp8w8{|!W%n-KurJW*bs%f!!9-a8TEjO
z@s|Qft`m9_gfz26m&JbkA@QEDJ@tKa;(%zxgt#mthRX0}3nm~_pc3QT^nPN8M*h+R
z{Q4){W>#E}_e^5e>elcJY|fNp%@>tw4(364&_N6(ax@Dp6UMh2NO}c>!>LyqvkrRV
zkCVX0dj(v)7i}qK>{Ui)oaU%-++<5bhtSRZK=IOT>~egh9r+y=HSO6u7`*{U@9%c3_O{P1q#W6J5TUTe|!+y(+E#$(i%z8(lpSyL#VA_ba
zHYBenLb5y6Z;bqS0+_4Hh5%pD>n5?xQ)ED;I30<#zuN}-fnHK0@`4$U2mKu%(;sNoG2z^##WVQ8n52yv$w<0X==#l}hHJ>Cr&XI2y9WWP&j(4J12|5I-
zU=&Iy%eFs2f2;XMixc(+ma(h5<4`6om5Ou|N-H!8w;jTq1vjeKxaEK-?XAhUaZ&#R
zs3S%mr7XP|vtH)jVjMn^;PuhS0H=7#>d26??Z{nM<_n#~lr?6X@^QZxnrXNEaEyTh
zv2m1rbRXc0*6+sc%3Ee8*zyHUe1g#W;5!W!nabX8cDAlGAv1ZBrohId!+UTn^g8A#=%f|F0^E=sHO!JQ$J6Z$&NJs6)Xr8{dcP#zVA7YU~k;ESVrr`SEY80(uR9;yaa9
zffn6m=$gGNknf}HMs1Tuu#&8h@gSM%HL6!GgncfHWt5>HaCBv2RIvXzTv%1N9K`lo
zCn_nAv1vbo-^FJ`S*mdI9=I%n>r)s5OJPA|PB4Y*XG0y)dEfs!O<`PAkA7h-Z;o4h
z(j-kep00w??O-cF6Y|4rOZ@r{T~SumV<5)&P#PwVBK~XHlHBv8sLP
zVit<~^J4jyea8ok{uPk!6Ad70pvO2zP?$SbuR?PKNzR~jHsl0tt<)LuK%)T6*Y}|K
zxO%sWW4QQtAk)z8!m}ld5;I^f|H2j@Xy9}Zuv!#J7FcPd9q?3QyFsX2)RYo(a9$?m
z#}isVt^Z~$03*8hM5YG%(PyD)gP6XBsN5%6PKw>VE!g#?D*neH6nS9MTdzhWmV{v{
z^UXyN8kQMRv{}`-Z6GsBq9MN;-`i1i)}c3BJVykCSV0`F|8YY4O
z8z#M|Y0*epxC>J#z@?%WTi7BS6WTHErW$HW2m{CNWMdybGRS&7spMv#xpE$TK||w-
z@TP^E7IRR^^bK?dea=vKGlieP01qHcXUA?#X=Vm}Js_fD%eEv9s3B4Y8&HM^8=-BB
zYR6fu^zn8e4J$vy>Lz-R$=`CJrI#;DLSsAqSAI#2j#pXJ1U8RyxWdkyaID(t6(I$NoU1$H
z=j7wnYq9|_l8p-%+Tc{`^#HUE{>IuYV7FUoMy?uGhgyd-QR!^=I#EI--sEfMv7$wf
z2nF}wPvA&osT$OF&duYho4Ts}8bI@gp^X?xk15`3tu(eph=2WHh2
zprCqAM(q5zxEDG9Ze~VW=$xR?_Ud=ub&?}l-;*-zENfn4I`H$JV|)|eIEq)g0GCh9
zp-%YbCq{zxo>CYd~ut9)_^h4e74k|ZP~Sgaw+I1zrGl*HFwreve6Wwi&vDWxqbOheXxMJK(Wr{)#LT%EFDIfC;2N0KH`
zjv0nm*)jSsCOqv0*@$n*Ri*}3@qT6=>&MT~KHx7Ny;YiHmdV6dF-Gi+$Q(0>e_sR=
zY@Rb+YM?hjJFpOg^9iibpd)eu5i|{q6
zb}wi-<*vm75eHva|CW$Y^m-v2?&@21lw%3ULOzCr?Ao0^LhQLew
z;>2QPGS9=XFsmR!?`4&U1OxKv!ZG4Y{Nop90BTJN`^7ae062*0$O{)G{mz5fiElQJ
zPA%Hr!kT1=;o)O+=_56C#Y`ar{|skg!B@&t8=(DKHr|Z=;mj3)Rnal7C07EIRb4kV
z@w)vQI9lOd@BR>(`97T4RvqXACrXcHxjS^6vydXWMn!|YdkDegANVM8m
zB1fos4~+)~7gJV_wH!*5KYA?^Id0dN%@Si8!0q4%cj8DiTWz?e_Vh@R!0J-eOb1qh
zV$#nlXs(i&)H)bazf1;&b2*|B%eLMS%|M1K{q
zhTR#7q3O4UXpn?es1P<@Idii`^mMY~6C@i=W99xm*^Vav%O8^Hc?{_sT}ngOmC4OX
zFfNm%;qqacH7Ob7l{089E&ckUTM
zI8Oa#oL@C-N8|%8Sb9QylOP1-1CW@Z*6;-CY#a`&DErLZ4fegAL#y&RAD1gXEm$hA
zl$2;m6_ekwI5~807VnoKiXVaZ7f68$W0Y2$U9@`FBqi8ClQVs4mL!TG)YjQ
z9E01XX;;M}=BHV{H)uj}XZj1IzlrcGctOp<>$?yxsC5oJDmzM}!hCkf5>!T#dBjS?
zU69;f#&m@+JEkH&ndV{szk@iB4q)<|kZHroCoewH^8o+AE1xBR>pW2#%7C764-*_v=
z*mooz?oQVqa^+MdquB?x79@<%B&mv532woZGkO}`+u}Q+P6*KeGg*)+DGv-9Ks~r4
z3^a3`ODU{H@Ls}WDVs4mi-itc36no(8kYrI7|?tDz)p&;Q=97+H7opUz
z8(3k;el>%{USyCd*4*sPS_wfT5IdV}?X0@VCw|Yxl%N(u-dZ|J0)%D+E5uhD{}-$|
zfjdK{MkK+RwQ#i8<(c6as4b-v8sq|ECcS}wl#qCytXz%Sb)O)oY0i)}VSGwW+tuR~
zuRXf05K%4gK6*cMzou+LR0##S%-~iYuKBAzuJ)j)z}-qOrA{?Keo((`hap3*XGVPQ
z9|z8KX{2dO)3EVY4O$q{Re4|QUAAkqFp8y0Aq>%?Bvx<4UCBanTu!}vTl5b^LD8YC
zMzAbvIBgv#!lnZM@jjh+W|^PU*&O9Ig{LVv#fnGz352ns+a38kgj$Ry`J&P?S*E;2
zN#M>af`pHlPW1!!X)69_*DQkJa(-7@rxTGgC1GRF8cuSzo~
zm#%CXjifSM8{Y@6Us<*Mv-Mw-Qd&oIwoQeV#m;H#ip;jp)Z_wn5T0SW;=>FH>V1Th
zoMoo&jTI8{3(2(}>u^U0DWMSNzYhAB(yu>?X9QgTf%}ZEi6EFq@88pu6U!RQ$j^w-
zJrV-nmJ~EDdy2GK*eU^v@)`1?K9*IYc)t?=ayxulkOWm${9m4VVRiKg)G4z2>(`v-
zR3C>5+olUF2y*!=C*_n&!hazNx$C1(Hhpv$H3_AAL=Tz`)8NQX6eNI}duk42
zhqt{tIkWyYu5RoX)=fP}
z>3yw*PRbSK=N(a^hqCQ?+1ZH5n6BgHJz&C5w+SpKj|9aDApgdz8Ztz6ydtY$3X+hl
z4cfT?(@20DqNp*M0%(9S@_T7R%=yfz-8zd@zX);aAN@tP3?SPr9Cg)B&|42HcYD{Ytz-H(um*Oc!@Jeq&COja;pAMpuFQ_`iY@Z)VPD!5IO)Xw{qjl}^%P^GTL
z&5g8!Nkr{Mvo7t!VUdh7u@~kliORw(&$*-Zq6`h@_Q&96q&k5o`{g3RG8)@hxR=vf
zK-c7ZMNO^u4HfNn{P}mli$v*kOSES15s#HJp{`C^1VXSkb+XJ=Idj}qh`7F2x(#{V
zh2;dQ1ay~S%+9)B+i{hG*PZLED6Nk~y#4X_MrGtrRF05RPvM}N_M3W-L2PWW*65_E
zcSNDn;9YzvCSa98Arq-=_jneF9DaqJnL{{*r~~FKHg%|E6oGd?I+rF#FJda)w>C>2
znu+8P%oV)q{_;n7{GjLxMtavuT9qnlFiU4K`^FT^0Qlk)3SCVGcYb8ZwgYSCu5G2N
z;>!7Mu!L9R>ZE=@sJ}6fl*DbS7NT1|REMAg^vy02;H#*G4~V%EX-6TlLS)G=AsS_z
zvd{RcU@CTq)~wl}QNDq+s9uQtq+A
zjt63QK&+R6UG19{%A(t!e|1X6o5>Ro6#ETh>c7&OyW@i>ww#-=O<)5JbJwW>0!hGO
zXUrWOON)}nf^FuuI@IByg_K$mlN~VR06H81XQZeo=fwyL%KbsmI@`BX*z9AHOkcUn
zJW(=*u@Zo5`mCDMex}&CUcpbz(gInRJ_bV&kb2Px7epmzl7?=@6CBMtP(iSX)9|}A
z;~5WSKy(BYX(W`8F_D)*%?I<2evzhGaZm3mM*1$*=>HEZz=xP1w<%hM%Q(w&9wymE
zCmqrIY`D>Y8Olms8n4~>;?|{(jCM877BhsE+H~+J`~*5-gnk@$NgpkJ;P$-~CD)<-
zy`qfDYo%fwL(IJNJr@22CDj`DB%VtahL(N+lug-IoQs$SN>3D~VyJhje}fFHvL$3+
zP$J<&jX$Px6Rd!urEtfLXZrPyYDS
z`2d=A=3&;z9`IY-3>xrF%#d}ItS|pq)>|r*juqi{5#o!?o({z}0=FQZMekbMUeuyD
zU{VSnlyz5wMBi;Eo=ckmCdLKSd|__WAZ0Es*eBi^L3c7Ca{rfO%qe6X~bD6x%7YZgFJEt!atZYDD2%>Je$GC4-~O
zsY%52zqmmdee%A)5<5gqMcY;Js{}cYG+@7A1jG}%<_yE)Wriugm=mZ}0~6n!hpekn
z;POl=G}))K09B;jF7ZW+T8-S({^#Lk{+wUx3dS5Lf{30=kebuVaz6ST>+Uy6djVUk
zX+}1LJ~$$+d}9Nmiwz&gy-Sz_{zn5-S1lskKmiEEdGF~Q)}{(ff`mD2GZf{AJ^MRH
zL7?vcd=6C=7QDAvKB;)ospUAp+IHDX$f6hhdh#+`{X{RhDQ|d?%)bC-ZGa{LT<%$P
zjtmmn%(U1J+0{YdA7XT7&ZPa~Lv)RVb$MHP2m4mVPY3Qs
zaE*y0UR-i~E|4u6beCP9w(KmLstaV4xgBxzKj53t9$Mw|x6p0?&gSZ0lkA;;
zmsaypd%WA_7CKS?qHk~3IHiN&n}X?OXVp&R{7w^!alC)Ot~ML(t`k$vzjFqTOlFvw
zz`UygOrO?e`=CXu`J}aA=A^wbuTA1vHp2|Rs~J^noXWMC+*zC2i;PY$tQY;jtdK=qa0$D6>mf-#lP3$_R#*R;9rVk!QV2A1P%hSKcb29)pwdy4X{;H*oYX57BNj2h`Bp1(kqBsVGlMqqaTzAQJYQ1S8W(Jv$x;+3ALp4
zAA(TG#p47wTP|ery6uQc71zM+BOnvg<9u4AA608M()N82uo>0vLS6s9q=b)`P0vOO
zYHj3
zPxe`1niji-bhvbs!%XaeofVs3cW{QfQNC&|#Zm~%N6fWj%i}&O(m^XRsv2Rw=~bDr
zCC@~C5+Aqq*qH9#u_
z#+wLp!VY4Z
z79SmZz|$+=baoaU22Ni?jqpjOT<)3H_?(L2H4wYg)2VGU#wXROsoGyNc(hfo;|a;r
z-DR-Ml^RdLx~xUy1R^RYAHA#)OGLql54CTw0A^o7pV{4LVZcZAJgc0K{@O(CoFTpf
z9;nLDT4{Wp)P{&a1+EMjdXvl=Cp>YO`g)0ySEy&AWW_Jfy5gZt{*7bZjCH&pxb8qx
zZnZe*kA)cV-~ESsT|hd7zVoWBkn3c#*MH09HF@G8J3ZEsK)KF#Zd>_RG9TT;V<13p
z%!x3IGNULY9rzWYN@zj(n#BO=JD?zXqI1vdx5@(I^));jX2*K%Ad>AAgIzl_H8;<9
z?UXyE*(M%J()ATjy$^4>Wz$A29#-lo@!Iiv2g!kapv9HgNm-EePOSt_%@HW-_rdJZ
z+O+cQl2%QLu`$gDZ_{r8UWRCqCq?3(o$?MTlpAui-GOCuds{5byNW~hk4DcP63}wZ
z(K=FxY9h0^E_}mZ-Uc2SNI>P{s3nt>O_vSb1nFq}G14>cX!_^af
zpQN#ion*rLT%hUT*-uz^J*71y#FR=+a&0Ze+=iU;=${mi)y?%9r&!*naQzQP_*136
z>t5E6ogrWb#7wEL#@IcQ;s|(xL{VM0p=tdipAjV6YU)&~pEB`*mayegt9Dgcm2*8-V0zn$b@f!`^DT2(%6
z9ax!#OE4uaQaaZpKGGC_N_gg#V{w%Jt`M*_h3N2G)!BxD!IFc16&}d$xCA3W-$ztY
zrZ_Tly25VeRmlce@LUMkVMmce&8IS4`rbdv6GM90bYOhSV;!h>T-YY&-|KwC|2Jvf
z%D=2v5c9jaL8>bwgZ>*?aPDc=Sq@TrP~2GMDEIwUcv+y#`D#H!{W5(?^IaT0V+31I
zrmn~Tz`ype$Li?qR5efY0*~Z%yN?KdHLNIm$v|nt*=+&aVai4L9yMu4K(eoox#HR%
z;sRmz=wP-^#kpF_Fbc$gdc;t;e*Cm6j_UY|#khLA^(r41O-}dAsY=y+#_!LD;kQaT
zTu(E`%4c^D)-)Tm{o@(D7fY+yWUtDJe#5reE4B0uW4_G?m_-MQ7Y7wuTKfIm_wmTR
z(^FG9FB0+b|E=3J=?~E?pos2kqjA&72A|<4<+vs>eUM&bXg+>M0;!$%+ZW`XvI=(4
zc3r%_-X5M%fFoJY&soj9g9hp#{czKfi%%
zKg~gy@QE2*hi#4L(nsO%Ra{`>b#q9!AcSHHAqIu9(>(dZzXT2E@a?)K%X<=k!#A*e
zJG(hdU}L$8;v{b%&1d`7QVm!HE#vO@Ed`{HRf|#9BT>YzbWv1YZ%PQlz9Ze0n>F|u
zlz#VPI>T>x$f$=3o)3x*;F!|#gU<04DT4aH*@4szbP7)YXTcp6F6V~D{$;XuIX=Fd
zy1#gW<2SE5cZ=44WrT1|!e(^WN@NJq28yRvD6SYkFywf&H$qyKnkBa8f~E3-D+wcI
zSQW#CqNijBq}%r(}LT(@JY#RxAPi*}VGME1*k-Re96ZiMLa~8QL
zjwf!W`qxdsLTI41woiR*a`R3+$EO8
zN?s9imT^F}Q5CqdBw-+1O7JI>P&0ElJxNK)Qvju@SJGusWez6f*UR&N98)}>No3C$
z!m!CnOW++Hh=-Nazjm?V7n
ztVhb0iq`w9ykXa6C}7Ek?HZ$!LjQ#Lff0Iij>h`iHVR@R8@@j*CKb*pQQW=-n=0SY3MdRh5ZYPl2l?OeJgi=(2#>erIsC8i;pGwdSh5*
zB}u~Ie9OJ)8Q6?Y=2;+=X(`-RGvL<-e4RDM96&!7<-B)dmNd8pg!1b)9iHRjAE&KT
zD*?Rfw4Pu&_=r*>-wekCXv$Al0Z8@TFPzFYi51k#T
zLj`~3B1r?$bjw*2ac>aKg#s;kpyH`k@_6lNkeKGdZEU%oa%jGGrKB*1)v@T94EG)bxJL$OH|wBu()JmejnT`9XJ@0-n#@G0u%p
z5fF=BO0tO^ma;f+bVygK6+_=*^t(YNwpd5xl7UwaVk9tL4OM66fkV!F;)s*Eq0BWT
zEhCF$-+Wc`_^+5vbD(HaqxrdptM~Uf=ji;-gs6WPf1c|M6bqy_)&~DT3#6|o=WnLR&th)cUXDIC%vqj`;8sZ>ZbOv?#tkj+eb%F|
zYv)xvK!k7&a)s(xRR-lwpBctv19?KS@AGwPm(_vRAFXvq-QOjtOJ*fCC*eqmA;|AcC?hfo9xbKymXI*v#ptE}GBNW6ZlpCDYhz$k%&
zRg8D@1VaW{jdTdT0EkV7x_=0<$O^J~?I(4PP`YWtrZ^@!O9@oGRo8?0g8^p*z7>9682u-Axj4rc}Hs48YGUiqXKb`
z$CWd$GcDwq6YtY*CI!Or7Uhy?;(y5GAA$Hw;z}L)7SsOJ0z?*FtAotzpVm`!VEcS#
zx54ws+!E%`!j_ZZ2f1|Eaaq*mNu`lLGViFM0D6jCuuC6sDSd01I&ktpD{{Sq)C937
zQdOIar{uI$LGL`MJhBa8u^(Y`(yYSzFX`0pnRySHa=2?v6
zN|wfDlnCu+8IGX&$7aJ;BSvYA=|{=pzMAdV+WBgAg_VzzKcfEAHU@|sWo`5lFJzHQ
zSZA&q^%gZS-^nuh&lTWC)YSdh`L51(E8%uSbK
zp=*J>)OvC4lQ+QTeFVDw!%3L4VTV(tsEW0tWRw4SagsV*{)^{cFsNa{!fi<-xZ;;M>F?$QSTs%Y~Kr34&R
zgCp5YSk3Q+M?nKA%HwoQhE86VU6FdGYE7*L;GGnpH9;$1^-VZ+*LIg01~rtvQ~ILg
zgGqeWzxJ>8VxrIE0PcYdSsAby1#7{OE1ACg(j#nl#H+cS;2gkH7`s-fM()@I22s9m
zLTHW$G)^s^$3`2Xs3jREQx73Yh2XyAEKI478`?i5gqptta9P78A1mE!@BWI1oT!5G
z{#C4wZn^l^41P>}2Tv&1dc{WCmIG;+odu9&Rr7#8pHNe647vbxyedt5XWYN~nVs|z
z(t0Qkj9NFi;H0l5WVt~p4?1P=e7)h^Sbd?ubUa1l8k)4y{mI)oFrIK&{)YCjsrKVt
zX{?I5!SS-~RFjZB)`~*8F$xY^fS_Nnl?I~N2Le2!3aB3OHeX|Wl`A`qf2(ag@(824
zHZ@DUufF9Eai18-rD$}o+-Bw7V3)JwT#1@KiOcs%DRxmBMg;
z*@d;_kqizb|J5AugVK+I?p{GQPj?O_4i-`Pi+Vnk!*L&y?vi%fEn6-fl~;hAWC?tP
zaqT|Sp@|5DqlBl5A98o1z#4T~57oy#Mr}UJ6B@{RM^QC
zzVJeqMZPH{hxBtX_lsQGwyNgdH8?_);r_%a0qEOHCC&!5@S0a^y)dOH}(lS8$TvW
znzCIK0Aw!6fM0fu{Ns03^Ab@GO&Efuf;&bmI=I0j(|;|i?znOKg-;q~CAk52A#7r{
zhaHR!KHdi^_41EqtNB`rVB9jAE~v3#20S;=7L8tsH!#q-jL{0#7IiPJoDB@GxRyQHd(P>Nx-Mobt>-{Gi%JvzH>^>x{T%TJVeu?$;
zq)&I|L?R-s2=RSrQ3$){rs?OJ(Da_^2v72UO
z)A(0lVI}T67T$cI4LZkiJt+&E8alF~AU=A^&%KU06<2DGl5e@g>)wr@y@y)zdixsz
z+%d7#-D<)*#&@s!@?AoWoxl06_D*QzsK*-nFw+X$XSfYV?0MI;)hw)wIUb3onKcV@
zd|nhm7`)SI57I|1QZlCQ`_;o5{yU(>&2|V-vgj46KJLXf&AB%DPwzCKYz@PG_WW%2
z%0pz|&bu4wXD0*WhG>OYsq&vP&*4SxA=e5`D(mb+>f3O*5YDT*>dJ(hA^Z$Jc<1G@Z>K;#G@F=pHlq5=%Ah;LJe1BTiBMa@hLdtD)hhTTU
z$HGVAZdKK)ir&su#m1K*KiW0H+sBYRUfN)wXmY###91t&*3@BMR5F=X>Y9yOM9Dqj=%H0FKtcjQ*H#XwpE^8?DEH5zJl6@^BkqJ=hilgDy&
zQhMEygRv+eUk*{iPu>s|!v7AZE0wDKe{jV7q1^@(3%qB{`g&1ub5QHgjVKlWOk#qH^o|)hg$@HzyrPHg
zDk}r^v$}e6R|PuYKdB$Eo%O}x11S_HGV4$iaYby6Wq2Zx&_&)u%nt77^jX*(Ik_vt0;p^<)p{zlFFO+w%Bh;ciYq={c35ZI6
z*a`_N_zyu1{OyTUXqlmf8BL5jN(IxI&PNVx!JS8Z8m9(J&+X(r+g`w`ZX|E(bld&m
zUcymA1Q4=(h0cNl1V;*uZ|xVZ5t&6mkPq?Yqc%!qnqX0EN6bTNRYQ5R;=*TFdSb=Y
zQF0P1?fh*6k3tz_!)KlRKXxYn3poB`vJb!P5nl5h-E)CBBN;A_Jq`QdIR`Vp@7Smc
zHY=i%<+YguT2eUV_;+?0wBK;`bBN@Tbqf+oL9?)V`&&UP;5T0-=>a?T!otOw=0V&+
z?A#Q|gPy;US)Nl{OlrU;xo7_C5op{5PP9=C>NoyF@eo+nHN24cTvy~}phymSe>KRh
zS;0+0e$`Jd0?V|c#4o`5G5Ie-ZXiqbJCZ)KYW0`C?CT`9`IzIcF%MzN+;~T=eB0H+
zCDwgz_I@BiNKxY5k9y-73-8~`xc~_?5U2NzcV3lFxI9mYdSc67w)fIZnI;aSDik~eN3}XLm}0$HPMO-qQhO^E<(jFOgcF&sPNGv~^`$Hn
zfSB#JaK@9j#mQX>NpHEN4X)ya?Mb@2pi$C%U`~$?I;!a#2v?9p2_h*FbsDR+q~6V@
z6EODFKOKPh1B*_F&TR;mIe`$PFufg~vB;nGu=C#4FP$oruxhRG`PGc}-_CR?2!V
zv^+;GX*wkP@DjfxsW_C7w|spz02BuNBw>s;b*fB7ckW^`VLetno8_pSeNfBM2xfqj
z<+{(=^1G6#_nxad{I`(j!!Hb)#n*b>1*RsNnhq%u%c#IeRo@HVE^HJS%Fb+5Jiwd3Klp~IL#(1J_?xGc{@f0^n&#C5jgQaR$tf&}KG|)^z{uc#B@Vssg%;*ZnCnw{utu$pta^1L5FcO0{dUqpULQOA&6
zHCjPA=-=BRX{3)fJf{aM)awEAs-`j;^_p6qyeagtiVOpzAAm^LsJ(OhCTVWN!!?sf
zWd=S5!(Hm4=n+dz{_sq#(yG{`@n_+D2o}Uwi?Cn2#q0dhlZlP@i^T7{b9qu@Cn0E4
zMgZg5i&|EKB4dpcx)0Z<1eP0_9W1@UK*+WQ+ZsB%B#{Dnd@Q24N{{FkkM8lar+C$hJ>Ob5Xc{g1^q+E7&a3^j&W0t*i<3&XIpk(;QE@WtA>_I7^-G$h|Besc0!$`P?~1J4D&!4!?14
zS1=dqA?tiTgkAmsPY%b{|559caDP*R3cjpHiM+{YYv=nkft>n<#a~}u{8@kQ{lT`Mkk71
z+}FVk+c9}R1=i=@_%ri70e7ojeVy7HmOCxDxmLC69G3b11Vb^MdSP|5AOGeYp4oqo_-D<|yn2=fV%PUBON)j(MchV7LXz`?`ucKE^
z%!(M%^|Bh!`zea6!l*7J_=H~xmo&Lg&piL*69y&-)egtL
z+OUfq`m@RoC(rtqh*do}N&e(t7yWgr!=W98Znv8`kYp;Vd%~*lePES
zRIAPG)SzY|jJ(1FoFfs%Xh}r`8Entb635vpRY6jz>>euj#X(@6`XzylY#b;V?i`(o
zbuC^+0^~U1=dzi2)i=|x8|p#JSnn>`(A$_k!a|o{-hD9ZOblgkg2Reb2_pK?fUxeh00j&|5ZX(}(DMf1o@e
zHY7J3R7h&Ok6lqE3jw4Za;lVjEOs8e294z}-JgeoF6AAOj}+bPLDwU2fSq70(dhJf
zc&!kGpihuPVPDO!J<=xV*#N&%X|xuTVSWc>C{h|9FodJLqu5j?a@NTGax6S+7ymkCL}We8vU)_ZmwLedM?m)m
Nt$f~{
zp(0l_<3cEE+LJ+fNflSG2Yl7jX7_xAeCoANmNgLhvZS)ICIoykaVv!%TD&l|^k%mS
zBXE1@m9v%xSOUj!6Hb_&YF9x`Xssik2@6U%N~aITbl!DBLhenYd3*#wniT(V2M}qx
zcd4pZ<^WKl+tvPv`mHhCvB!6=6^ANUrde@323^#-oQBW}Ir!4_f>rhT_3GEIIYZt<
z=E^y+5#b_pH{F^V1yXjJ9`j8hZE^gS13<#?F<1(L2({e>29N8OUR;T1eAa`ObqfjL;#
zJ(Nh$9XhX$wy})KL77h+E$f^R8;X}O)pS=C6N;_Dc}36D_FJYx(bVz=ve?~Ztl}vj
zoOKkCbkj76nOW`I)-*)x`fd3Wepxmw>IrJ7K428Tm>&Bo9Hh@#Abc{|tygqEq}1
zo|@;8ne!xmk$eavG7jJ2$yA6|YoCz2)JJIM63*9b4KZ`#wyW$?9l((nm~(W_wN!wo
z9`>{e7D$vU1_e@#`=+mgsI~GcXm&bZe(5GqcX#60655u>ua^2jyTVVkn{ZqjHXEPn
zCPZF?qs*(5g7nKg|4bjcCxQj`oPOJ#O-^#SFb%5eF*$s3i&wv=+llMG)0`g**g-F){2Wn^5
zqCy#PgeASkNAPPX@ru}*1jO$p=yNb3&!p0xHb4gqDnnK=1QvZ>vcC?21Ht*U=5@l}_j!th^Hp5W$1{jJSp?QOCH%Gn$)pX<1#DDtLAY3@an?BcX5%=$k#Z@F?1WEl>F0L0eLM&#x!Tkl{
z%6ynq(Vk`!P@w|rx5{9iQatKT9J{zCWsR{jhW>GT@*K(5D*=U7xrZv&w+Ox=?!~{s
zRY>5;RK>u%3~_v{F~S{-R??){0gBUw(q>cx#?U8SV=^|*?P3+NEFWlQpaerROH?=gqd50)5j*5
zml>Sc5XSO#QiG*3+5oauJ%fr5K!+mZQIXxeAY@~P-n;yM4Yi|T;v+7pz1L{hICigv
zzL5zj!)n-*uX=xMUr(D{ezLV0FBXQL=kgl|AtL}X(xVafL2>4bu7#LyyX4!@W#LfW
zzUbj?v9}oZrOVpKgjT~h!!VOm>nIhpJ3!RutIGh}1|z2E;Jp>PFl>QM6!Q5YO;JzS
zm%-=0mwLGxH8bg(w+*Btfr$*Ylj9V1OuTxu03d#>_OkeFa9o!yk$VnHgIgc`;9${u
zh_S0zEp0Z681Mm&I=kVUx=2i%P<-thL>XNy|HE|Ol4u?lYUt#m{?1yU32EhWg8;;G
zM-jOuoC*m2dgQvTQZ=I8VQzD3ckN;8Xsv+@B7NA{OP7zHmE&@S7^|9IT^9Yo054El
zpQ1qz2jBPY%@e=o92qXZ_XyWAb?@{Lvk4H@7MpnzM220buq_O>g;ZXMH*GO4%)A^8
z>!~T-%2n^|PS~cQw_r+e^7{o|DzO2~U%!
zq|f)}h`kAjLj~o{fYI%*!bJ|~=(nsk#%5L8MZgZ)x>sIj)t-g8x99(KzuhCm`2cal
z8}PaJS`c6n5P1S=o~^Z1@@5w8IxX5}@f*`wkl5{{Ll|YSzL=c8x
zZfLQ;c(+C?fIy816xd^faAl+S{)hk2FZez!I#2p|5Rh|0&p87mF7roglY?J};#B)O
zP86E)W|@XNuATa}m!Cydgu!}Lid+%SQlEo(S~45^_n!exJ%Y#az3Vg#UbWK7X1)@>
zfbjqbgSneO?h-#>wQRkV$O*+s`&**|UJd~!56SRle4guqF3F@GxF)f1`uKHl=;%kV
zf`d_)kO^%M0vE?Ka!t2EVg>3)@!T0zL*766BlC%TwY(T$gR=&9EI~s5oFgP;Jaw~x
zX_A$%TTQ`oK0bJ@jDRqPyCB#=Nb;9&=-3YCt4R&L-)(rwd~15bS^Ny71GJ_62Begd
zh%HYOCYED0B2>4dbcZF&vWJC^*p!2CMU7zDlJpFC=q0;R1%#bffLL0y7s=vcq>E;=~fZ4tE3_L8J~-|DxQAb3#^-!FOV<~|0p@BgU7
zAzadyLZ}u?5?&L47GUqRW<^C9(u_s2{H=U0k#34c)R$tkXHl{!Ly~H#iB79QF}(P0
z@}WWwf~E_iqE3hJg{o~Ax|eHAl#hve9#@%tGae-2cgtCFpkL%8&eo_~y0(%!9mKoH
zU)J4S8YMnRE-P6zTam>Q_K2qbt5;
z4FENV6|4j4>7!#L1ea#UXI3aJ*^LW|LB8V$OR@mC9%=^uS*$2Y+nKBdINK=zltzNG~fFcji#9@aC?{e*%n~Aw`
z4E*oQ-}4@#-YPQQwu(oa)>0`fuZ-|kaWW{y7@u}dbNVUMR^Bsr(y37L-C)^j)ll=p
z?bi-itnY3wiycmy^QVJ2qw$WMh#Let3A%s#3dgc`j#B@vMNsLX4EV~Lc==w`za=b~
z@2T*D3hh^#OF@7L1$&MB83q@v1zrEcmuqCG-1tQOJ@XO<@5Ofuoe#oJeA{4yXp$C@
z#jHWH#Lo4*<9^{9^&5rU-JQTfwAxL5M4lx)oxunVbP+kbHc?-_j2aA|Pp4EIbC0dB
zN>U$Iu;tLkrh3M~qH@KS0S`o^ueNG*Wfpr^0R{YfR-FfAJQI*aX2eUhVhec7UD}GEIOwg$(XlGJ#J)h}~Ws6Br1E$jR8W+WY#gp%|#qr6pT6AX7S1
z%LnsQNg8BZnSenY)MDjN9>bqOcCDr3td3BI<1sY_%_pp~tM|2N#Nk7e9)MPd1BH)z
zc{+qo*Ni|jSiBtRO?cHiwQz#J@Yxa^?NvNN@sEo{Y_b+OceOi%MpFtVep8{%7-UeC
z`1{7A$)BWYIF*_$he&-`8E}$~e?gOQ(p05^{u`hAqq(MvF%g(Y9+1C*ZU?9
z4;$D_h{_zf+T?wieBj7U`UTAkiMzRso{KNM`5;W4T-znclSFfj*ZkHixkdTVkF-dE{3tP`E%Z;|KfZ47!cguyR>n`osx7Q~nEo*`am+9(-hut#dgQnNR?_
zmB3sv@zZ}*R1_4!6D!G2PxCvjvgM%H)Lt=unsk57IpVU(LAEhazF!S5g)sBt{ul@m
zZe1)}2~I%c5d-d4u|m^Bt}O@#&4*V?u3Q1P2+a7&*m*?8MH$f`HDB{jS$Q#!8`}#q4fFo&`Oe9el=>p6>Z}8fG
zr!aLyx=|2F?3r(V&XP0oZSUeK0Rld*=Jq8eb7K_ovIPyp&Jd)QNa%NWyn?*n6;<#m
z9-MNl2teziP9iZpxP732AA$nWH`*IQ)h07Eye$oSX3@c20y}~0m->__A6LP9{z{`^
z0DbPs8_;F~fINA{AQxFQSvA&s>+-}C)GEd2zRNt4tg`wZsNa#@f5zMm@Ej$#@wMt?
z|NbSVgY#E1+}w-n9rQqf{eK6H)Q!Fovek2T^jSPgvR?*Xx6`+aS&+{jPK0WSa4K=6
zNdK7CV|HH}0Fa6wh~^#fM8PII;lB9Q?(WAAFDUxVsE1q#c(AK5OOH+y2|mYo^-1bu
zPJJdx@-9=NY8}PT>jScAc?hzMF-+ByUO`|eo_03#;wi5qho$24%Q
z63{~nb->)OI)-<&NrRH_M^lm^lA+6RQkDqcOtraWJmVr!sx+C!A+Aur
zFC{evHpt>(Q-%KUG)@$*A?rHUbfL`x+?L8V>)T)ff1J(yx@-J~RZjK7>6Iq{`~5H0
zRxT`?D}OWQB@wS>mp)8l)!Q1M$c~v|0U?NiEcN&X+0>pQ08-8tO6q{(>or7d(O!Ze
z;JG`1qj3jsSG@~n5-l6uT}b6;ld^!8
zGRBJ`v>PAz3qkn*0n%-Nd9piJ;-qPBOPJaZG#6&6~W8wu2MyfM%P+qjjX
zp+|V(FyHO>j6u9ef$s%}n&(@Jzh94n4ZF|45^P0hi+{~;lNebyzWLDqQr1>u4(s&X
zM|bARY**-7=&uxdF{*oVM5%8jvug75=CP-q<1d#?-waN<++c8_Iv?sXnk*LuA2cW++km{{snOxPsgOs~O!P3u)zzSstbO
zps2}Lt-uEih~RCzRWVoDJ8;FKNAfr^D(=1Xfx*pJR8#Nn)VZFJbMjO3$nv0i^O`4$
zev0Zj8;lYv?WO&_Xs+jEVFv}wa9jJGoa=efEU&Ccj$RqvbThNb`+_-evB%
zQLZ2FkGuZu-x5y~^{nFEDkXsxF({%}`Nl!xi^`?xC<=uTP%w)X5Ct88>e<0X+0u`p
zs0k!(Q5g;{hU?N!H^7DKi>bY}LZqy{yyP;T6?0VVCR6=lI
zQ{;u)83@oup@&9i4$|6J6C8N?=DK`l2;A=$S}D)BJOT4;K+2~Wd8jb-F80n5<$+Il
zqQ`i}t!wIrRw+x1IHn1krT;35O}Qjl
zi<{)jcul(=kIDWIWSp${_?}24#~MN@b?XHI;lGqt_w6ouYrcq8bB
z{O2QR?lu#NbWn3wU>dy+;eNgD*c99Ah5X@&=Khxj>Zj$;OezvL=z)=u`qYF1Q}nVL
z-g7*F>ZElW{h!$`LlWBc89*F^6(dlccRv{YKD|M`i!3>h2pu@*(5@$TPOa$GDdMuo
zg`^L~;6%Cvn6hU})wQnCtbwQyH0#wEJa0N$zpyo+jm;?wNJ{b}vOJ(wBM$5whPY)R
zF9j1+eJ%#+M@9Pq$o667K5Ml^>;l%8YZ^1(uC$sUZd767l0Z-QBzOu7`tdOPTS)Q(
zZb}(Y7$>Ky((nWNKPRG0fX4ur+}C&sIT?Q|qUAX%5EK)Y2fle==Oe`jlwuT8gHmtH
zpRb)+I~>pmWLNj-w`_bopt}#{__~Gi$i$|k6=7^wnlWNV5>_g5otINKSkuQx9s41)
zE!-xf~N{Sp(?+xNs
z(tsvkeEm0%**~yRuza{v9ok>FE6tv;A*BmDG`K46dmOA@$@HcA&guN3y$%Os^D_iW
zomH&DujAImYzESm;CGBC{=%0m6;MppcjNs}m-jiMlGgPV`!s#JxZk5LYw2e%4$F|+
z3a-np%Xj{^U?DLo9?%zmgN7qh)$KFJ!+}Iu4HviPu3=0YORY026<)b>G$Zk-kZ=;B
zsq3BXA7eQxqp)@Pj}imy@HeM}{&Ym?K_g{lWpO93ZsyVf{`&Oe%ZqeoT@8cw(;MMU
z2JYZz12Vyw&sS6}6=PYkNdh!?#1W^T;djVfYrXDE
z07&98@#_mY(|Ay7o1waqR!^@tVIc+pEA;lNC$Hz(LYmz4e&Y`q$Z86_Z4S7G_)i}Y
zA;3vI3J#DS8Lb+PeOm+M1aO~iK9@)soa3@N2=b9-0%Uq&O^I}WSeENoO(-0PhHxw>6aFi=#HEWywwAeyOR4Pn+52hf4#=>&wIk=&
zVmTLdyPE
zb6Mj|2@F_gFo(3xWOMqO9gN?$h7Rno`t_Tmy#q4xRBT1_wkxPI#=%nBzb~6F
ze^=UZyU=Q3$P`?D6_DIJsehosBZhajYaDq#zxRU=mh*aoY(x+~lhOWeUMVua+Z+xP
z!=5A#x$h5|Pl?O|Zh)0LL>G;G95k}3W`#~vP`qmY7LB5ns(hS!4LkF<)qCIx
z5h^BxlCnkOC&VbbiPKlU>j~X_RHoZ(;y|h!Q@7h6ubEkN0AyB&^p)t?c6$Llf*3|Z
z+Z9J`vqIME_OuK-v0y7RmV#7_e4H|uyFsAIM8U4~C&-Jw^DC3PD8FZt({G_P;(Zov
z^%=RH!eIO%MsPLf`lWQCvxMWw{uOP?b8XcrF=iYF9-!H^HAMhaN&^H<*41X&Ojq)|
zJZ;z{S=ti@E)qVUdJh0}L)pGX?w1OgB81}hT3IagF0=D4RiKxXme7$T>S4$<%A>jew7E4-(0wgC;Rah5~S-c#wOkwTj@T?_V@b74Nc!#Yp^g!ZWo
zir>1onOgt5dhAGU{{qcKo;t~1Jup#!W=BOmHNq&LYvJL~QI63uU(YEtW&0b^iEay;
zw$5;xE|1=*YSTtzHyUgZN`fV|jWPW*h#fsU6iLUolqTKwzS@iY8&8i49bk7(AN$Uq
zioiRDV4O~KGXwgIwrTfwXbm^-P)$WDWtH-DG$X<-={Nfo
zJECp2Xrs2$+n9d1`&yF!I7R~7a+iH=d1RhtO=GL4Qvp_yjQLbPkw+!huKDfU&y93o
zg8-HG@xIO*dKbNRsE2&0K5;++anwM>xsP;_9ruuL12r2WO;Te8D;XDCIwV9svEUgG
zyz)+sW5%0x9RNtfW($THCxF(@)&At`3pqEE9NI08>OiLNJa_~O)(&}?v4BX
zb(YE_FLbj8m|CyP2$X8PewWDgd<6@jcO&tq$qE-_gotNE2dquoW(QSj1FRSyxA1oh
z+R;UkV0SQ;xG`mi7s63*o#+FRxTteqvoJomfa0j#j!?BTwCX@bGkX5V~si7JdFBQV{9%0+rn=)C%yq+nzzMz9Trw`+y^0q=ztch0OTvxK<d2yVy5&@0aoZv}@-q4d%A^B;upyvSx78vsO%tEn;
zl8G#A1R0%q3dxGkfYZHV`Bp-LS@f=ds(c!yfz!m1NyRzMi=y6(X+FX5RP_$@yJ^Kv
z7i(3Ecb2BKll5H1YOf1=V*FK$-5Zp0+;^9-zmVG_-nu4@!ZW|O%8Rpmk!lduX-`7TVFeg+h|qzcT!m@5~Bmj*F-
zJEf10iaN9$=Q)TZ+*q&9Lz#STWV-A=T9VvM-!ZR3Dqzjm`O1d&95okXbq%K*)x@mm
zRmmuB>Y%yPSvIVE{z-olRR1C>3$x&Xb!4ads_R&hiO$_Q%a1jBiN`l69YMX;ls0E$
zo?+^~*83BFUTudFELGmKgy(hx_$n#ESMW4Duwx;(9;xtzL)sdMQhf^vider^}qaGfS^N
zkQ&&Kww+4;s?gQ&pN9*_AD??po!gdSgr^KI3#W@TBAEriI>2JouJ`3#IzjCf(JPVs
zONcEr>Jf*6GhoysL@aP7?RgD0qX8c~S$714iJ#apcc@8;^4lC2)$5XutO2T_jY0jY
ze(i|1gv0`%z2cvFe<>4lrs8rjccruU1jm_|yVv2Up0VYDkL*nh-=7{FR1vYpEIQA!
zT$E}ap;BTvWGP^=!xFORthKOtXoT2GX|Se&atu}#2?d`J~Nqs2rUMqalb-rmdjcz6pD`@O+cxOb%f%(7LrKKBO7cU0%xwI>g@&G$gfx#K$3u8X9r%AwfwoBYS#Dtoh7>S#@(E+?9|j0qto!zE@+
zGP6UHGnrvaK4R$15<6-BiIqY$ZC;RPa*W14od8Pp+{zI2y}7@AgO>T^L5E8YA{_}{)6Ta1WgMPl_}59o3H
zC*kQr?|p=#_-d0?LCro?FGU-V
zEQh$9`;3SMOy^)l&{_zvi5|uq_>rs$(z8mE2kpcp*~2GG`T!
z_rLWf{i(TfGTZEnLxZ=|s(k~_X
zb7()Fa(evAB51-06Ig+wr~N1qjQ6z9)Y);O1M)(k!{NJ!KzXo#-Kd*lmPc&c=
z1;*?Lce}Aywz7nd4JrbmC@#`{S|)UzSvc?{kW!7Uh}QPxJgoxuMt*VC!3eF)
zfE#0YeS=(?ZG5q`Tu5KhNMFOIk}>A3B2tZp9`_F1jGPo;LNz=Dr?Or*AhWf+B%%X-
z+0BSh+@&tg=ZyI;3wkTJRMXp_QJ+v9qBZXZe<;|!X=nK$Br-nV68cSTUJ8@A
zy=THC{(0StGBaMTjsmKg4LpE(3{@xfR%OWAKBiJxfdBp7m4cM+pPlR&G4&LXi*LV-
zB$oyZ7=sF4_{0muYRn-tj*ZRPuL8Onh>)oDkmDm%lUw54hNJh3dI*Nt0(6)KrPN68
zR)6m+0cY3zK$9$5eC$E_@1{XK!idV|Buf`6T(cy3CepW3;Y#e`yibTE7m4@sC87qD
zAuL?oG9TOJL>I+@v5Ui%)`+@fqT(XRTpA@Mgo2O%1g1GOlYwVWA@sr4BHV8OFpC6H
zxIXlKUFM8x5={FN_nele{fJNVk<~4cj@mmXf(x)NI*eUli`S(t14#2+WmnP1`Xr!z~
zVFazH7XXtZ?Zcz??UgvG(o7M#Rv#mi{6*fpX$UOySQ%0W;LZIb!0XHs(JzoPkafjA
z=j5SxXu^f9c_#7t{vt^jL-BDd>?tN*<s6%)WrZS;%>$0~|XVdqmobQ|qrOs48BGC-f$d&;!|h|6FoZ5)=Zdq7YTNM>_<
z`6&=78=~j&Fkg=(N75I<$myYK;+R`Aeb%&DqnZUeLL@gs=ae$swcG{VQ+HE`qx{tv9J9gKr5Xh63u}33BMPQReac@
z?`*<6z24m54P%U&`vp~B%Z1)ubGj1K{xqr&835*B(8nfozujs45|9hL`B&5t^8+kd
zfSCIWFRGOqEJ;A!6QtS6AF0=sFR*8(Gmd60F+6ZIchbn2pf?2C1wF9Ge*BP*+zmsA
z!GplP+Jy_{q%2`*n`gA$6=?L=p&|~(wkaorzSik#G9f__=tBrVbo;k@p^c&J&HAoc7SQds9s
zn{!W#p~QP52SdmfPXVX{dZYniIO)Ji;pBiI3Z&2gUsUoXO+{fhFEEh#zGc+FXFLPk
zj~F*t7ErBBCe1{i_5Vt?BSBOVkyc2Rh=?8^@Tu~aDPT9I<=$f#?+xxnLsvlXyC_v^
zVFpbejKkvSQChh}wMzr5-m`Lvehk8r|2_E6Crb!NY&x4T(G((JQ-787s{5wf#n4)k
zXy{wCSFkqg7L6-VcN$BvZ(w21{NIQ#7pH(?&JE1i<92qEdtdJ*l6=Hx|L
zgLg|X=5KrBb?~uFQS7>3>NI;TzhSs#>AXGxf5s6;0R4nWO|Dd-ZG4(ysO$9m9pe{0
zWhCF7taHy?%9Jip+1I3;_BI9bo!*JD(E6^t1v2a1bBnZX0UGL(e{awotPb;$+^^$(
z)ebdcu7sIe6GLnrxD+MjkhSl+>8O2^vg#=@xdlD#5hWG?CkqO#!
z8F+@kDfGsQm0n2JF};qZC{)Pe{`j<1Qj@)^bGj?YD81B}d5-~vc!*mFHbil`Zwys!
zzs%DT1K;Ow84P+`GnoFD7j)SpLsyCSxhHo&c0S%kzP91&c|0!BbMMK~iq0aci)-Q9
zR}~qo%Kbtu3(7nCL?NqTamjaRuR?rY#6qVIT2S3~jfR^NXOJT|&GFWM2TP~T0HO9O
z2-H&?WVPQ*m7Jt3k>;Q0k}z1mCMg+-qO5IimK{!L$ik)B14Qm)i9}%Z@J{F5AJP3>
zH{lxY{iII+T5hZK!rXRgcjq>_O5cT||)B6*;@<>mfUI86h>^JShk8AR;PAI2ik(}5m9kKB(
zkNGvZXHW4j~ter5jHI
zJuQ4Z+^>{N@2I_5uIOUkA8#VCdtq2w3&P_HaO`#nDM8jp5x{<<6ws>G(VbZd;*|wJ
zUjyi-a1e=T+E&tBYK|QeApmj%uLkj(U|L6LV3dtTeihm%8yw<^9dc#KTC`X&P1Gkg
zkN{)ZUs!QJmVb@R%aJx$q&East5J4ekXtA8`%9VIW~P_a<&7%3IwZrCqIkHLOX>Q3
zf5;mwW3U0W-9Pqz(C&hp^UF+N$M7vl@}ja*5xZ3uTBwn3o$^lY(o9cWn_V%9dkFxd
zOpQjj3de`MR4gmesHf;Oqk}j$UsWL`)YNi(zy}*d0cqXRMod2mAE0l5a8xOXQw&2%
zRN`wH8KAS4YC5ddd?I^)<7@3rBFI^RTR=o!ro7F_9!BIe{OcrOA7D<@@*T;G2Mav=
zv5N^@KtIR4!cGSMsi$bj@O533v1#{N`L9Mcp`FYXIx{<9gIC_C$;6=+(iMIJ0Ijw#c$%3|8Hm4u#z=1)B_?XzsBRT*en
z5#2(ZbwCRBUdQlyXr77JSVa
z@XNk%@bOeL*-c*y_aOGt?p~+MemBE?KitJHZ2_6&1it|S&e(r7O-52CMEO}pWKWFT
zoHl5uG0qE76a*oUm$9Z7tXoE1LltxLFbG
zdOxHq8-=`Q-+Wl=7@MC9g%~tcRX}mP+#!Te>LX}uI+cBv`qh5k0BcqI7if{zQz8*=
zOn6`FM@Wl;=a{yax2fO+>)ezjX#q{;r~w^Mi^^0M=B{_`BbQc
z`iB?l<$bN^MS$;%;L4|mw3b<^s>w6%r%M(Fz-0SmpZ+-ew%4|RnR2XIG+F8G1J-w+
z0FT|$&;WCt1?bk$r?-f!S4#sbA8i}enUyU~rFnq@?8`phL0@piv`Xv81@U2yWg#=0
z!>Nj}Hw*ti?N#X@EcBoI;Kj#sp8jhks=86G7tf__4wbE?;D@
zo=5|=B2`Rk(Oz+h=2QO+!KlB_9Vf{TNVWWDf=cfu!h77kUA(zjcGwh_d*sp2EJ
zGmHSPMqCJ{#-695Bfjci)6CQA&*K1;nd>)XRL$|^Lsf6l6%O6ZbL(0dc+aU!4rY`u
zJ`72RkZtfr&Cv_4f*bn`Aa5rbiC$VsA2Ffl@V6Q>U21IB!jYlr(cnahJcomq*zsuv
zOlvJ$Y9;b*@&Dc-7qJXQ^CaZ5SC3R|urgao`UM3wT0RegwW%X>imj#{0v%jZ?dQTFduMy~6nVny*K)@8WGZFoR
z2cOTn&A&&nN_tJkZI$P}bkM7=jfack5QT%17MiMDw0P?Q1fyc;8C|7SGq);HkR^H#
z=smCwp((!W9DzOB8=pVu{sl9h4`H=0@&ww>x7JQH8Ga4v2Zthz>?)Kc>9z9J8lt)HxUm)`2+018nji81%2T>+|Z6*#lg{
z9W%aFk&1>-v*kJ!i8s{DO8t2Z=)z1kDR{bS*S)jA^P3x;(r$Hnyq~y-)+j3a5!^gaHv!z%cX5{P}>SitCXVt0}(2u$pF%=P;gFu(H%G_qIiT>&-(JVz8yv7P(T|
zQd`!E5t|Emsk@x)vSItM!PEY`#E~*Ehlb&e2>n0xWrj8Vc|3hNY7FG4Ak0bCs*A;*
zM`LL$qf6+0e3x4n^iMC2ORf$n{R|(LA-g|l{)vtu`fadj#TQ0Ct09RzD3^tQYVeC070)uG)X6tY@#^#W;|KT-A5OQlH
zYJ^o++WFtWI10MPo;vDMwAe#*`c%rRf!S=NVvQbw)?-a!oFWYd;o;*ZF1~44m6}r%
zzrJW{WRqx`5cxtZ#<8LzXdY)Ca
zv7v3IlW%?RL~Tqhkb(3FcI6_~FjITF%LBK?Kf6B&9I6vzaDg_wEjYnoC%z*x=v*}&
zq-wlmpY*t&M`<8W;do8bld|MLte1c*5&L>50R%Do&R&B9%qnXlW?`$41-vrsL
zz36{m*#dSkW^a%C2IP)_9U%;5lp)6HiF)p+ZnArO8N-AU(mr>hH>>_47m76b%JQM(
zvpJo~O+#;bdh(q}9W+<6%=ALK7fRpWT)8%yBGETQEW;f6r4;3X0Pv5+@U0>h#!f)i
zTTeZ#(9CUV774o-^2{B=vm?6SlddH!yr&8*etDC-43@^vLi8<+)|}TwTi@}A3`nuE
zhgsul1&%w;Tn!(YBMmZ3@J}NaLH%d^T8Rv33}?1|HZt4+#-sK`vH7YbU5sX=Ju0_
zPz{J~~lsyXl@c3GsrJgwXe*hq@{yyhQW82%e^~9RL03q|3!-m!|4+PL$s3UIqag!pCk{fF#8`j{y1POZh
zlVR%kx1XWu^Q%e6D}BMuljBe#06%GE!23UxT21p_#p-;+=C(pW-p2MjX?Mic
z$1dNZekR%nU~_q*nNqa@uFsntr87mx
z%*yFd>hv!~7F8rH?^aFI;x={jos6%hN;Zk+rS{}l=Bgn|SalvmqmbCr5vDQKG-qM}
zKs3iaOSi{{PciAY5BC=T>u2q2%JLx%au0CxF0hEASBr!T5(ZXhqN{c!O1Y{CFyD@F
z_8B2ldE%8)z?>yxHH>!rD0ba8%Pll(A~*&_r0&J$uN)nyrYh_^SZn!do(u?CIc}Kh
zG8b1tjo-*Lu@w{llJ)szmFJimb27}nlR
zNsZM;@`|-jn$7xxhNRQnWCZL*vFKx_)
zMnQJaJOlxWbR6K}C7-uQxCCqD!BdQHSf>LFG2aOLuhOJgF5C0)FM0Tuq)li(PY!*w
zYMN&8@oTg2=?9y}+B)sDIJwiN|0m5+TF8DSYGsbUtnAGam?a|`7dfQ`M~T5pD56Js
z(&T5=L1x+??4ZtK$)CP4Vfj@vBz(bPQ|^$qxOjZy@}cHGv;E{#$MZiCiSyI#VdPctfRK
z;gvk%+Y&5-GtXssDqdQzi11!;g9y%y;p=Sa>|LIyR#W8NU#4(G%~<@bK+qk=a^RzX
zu1P12Yi2agaWWt9o<=?PJOKC_#oO$harliWkt|9SL1oa~IiC+|g}^&U&{YFpUm^Bc
zaxdJgor3Sm;B$_eR{h04=o&m+lva+PcNiq&F|!~gcf|%9w&*BZ{
ze+f?#rfD9hbARe1a|d~9UGu#2Cw`k@|CaKOdOW$@tVSxDo8_sYix;9Fcbp7(JhKny
zHtP^YZ4Mr65JFxGq={=iZIbf1&iM-ykluRGhq%RSmCMr%&~kP2^vMH
zh!?qUuK${0#c-dc(>D_7ruBmz<|o+5^dYDk5?)ue&WBheR9|x|jrAEp_BOUmimu1*
zos4AbAuE(;GE;0NwW#Mqw8Uss{h(eS-X2qn8Xhc7gx|kW4&ld@
z+)C;)Tsm)b&GD-v%41DU(oMZ>svzq9yJn>I+=b}eea?)#24|?sxF_3{L=ogmAxO7e
z5oLBIW;4%?A>CzqNL#YSr^g#$kO9QaVPuV!yA&fl7+8)iuZqPBn!H$99W+Dtqa(2S
zFuZ)?GY6z_poXb*u0F-6lciGx@~MAE77{M6hHsM?gA%-D2(9?andkg@-DT|pt&U{P
z*{aA9d}uwI@jirM>@lPFTCYOSL-anIwr6Q&Lby+$aToY2XP0V_FpOuFh3QT|vfL~1
zabGn6axr{;EMK-WfLf`edANs^QqIexD@w_Gy|CbN@|aBF2!cTP$kF1tHLw-WEf^hez;mG;$c_8{X&n5*QkdnD}yuLhZhqOo9n>-FV7(>9J^GWaj(ZVzI2NP>h`6*R3wBXT^Q`*hiJNs}
z!qxtudi>OlQs%gYZ-@CVtn#7EQdTv!Mgx2k3oS6MPh*`tPyXw=hFxGUc44uWw+9Ox
zt4Vfe$E0shaD(U`8m>&?UbqZ!wVV6W5ICY_+@zTG7Oqif`Uvl^Jk$kAZy{JMHspf{
zZ^@Z#hx7eKOQ&A3x>K?SS8+U-7J}APk7ob2h!l909yLHAPBX+Lme}0vZZ|w>DNTS#
zTmNx`&nNp@f6y?0a`Y6EDXUb2n(zv>$O`zF0*m<3EjvXaAWcORv`GJh78E~(HK}NwM}0Dq&qcd&*Wue}
zGu;>0tk?ViW~~fA
zVC45+zJBQUxgzHNz_6zQfwP)+V;>YDSwcz(YrAj`9t(8VMdJoOr7b``JpCy+)y5`v
zp~d^S7Ckz2o9`Eq%W}Bsyk2`*%BBg~JW%E(GJw>~C!t+=`4aWYF!u`OCBa@x{M1b^
z3CE!>wa56I;``DAl0GkhV`t*!Tn!+Ok0c+qM3(7IMb)#A@tHUcBS4AKJsinARd{Ts
zi8-x1JQLhxQ_G2x@9;$K2{e{IaU0W0aEP4reEDoaP*NcBKsY@9%?172Az{~$uh-8h
zmb9XEdEMP{x=CJ`x&|eSixur{M8S(zs172lSJnV10JJ<44d<5IaR#yj4yYHmVy}Sk
zPxZXZ>+1`*Bi1eObudcyd2n$TY%CwZ<67xp9rjY_%sW-(i4xGoqcu5M?8Xf
zgo-_4elH!b{#Aeob)Rp+&e?KI{YBCT{(PjTWkB{lfxq2ISL2lqoceJW
z)`(M$_vS<8plau{4Z2aB``^XP+~v%_U*iDb(|U_7@ZM*7B|=7Dydc#r
zt#b)QKWF*rXp8PZqseK`0f{hb9x?pZ!WJc{WSte1XH0pFoQhqP%}nHiKC$0KY4ffj
zO(eBwG?|M`|7ks2M>BTvO|ahxg3L{7p?y(jp>7V!MCx%Trd!b0ZbOL^O;PYQ>LRsS
z>^Rc0*;N|%zXNg9sp+!h`$~vO1ViP!WMlKK2Y{cZ9V)sr8TqS>h+3tA``@5Tx|#Kq
zQ+aP?c)||#*QS9EgZA?P4KGq($NE(el_fOB$*)OlBvyQcZs(hcBhNvfz+4DPTMV5e
z8#4^R)}(PUT4B)_4u7MtsZdalB7^`
z1szRCo(Uza#9V`l0O+bO15k|AP?`d`7NX=kkkM-e#2i{Cx4mfgit%g33j0Jyag<^Q
zTwr0BnkyE#LTVJ5wPHffrK>aA8%)=vNg|}>snLendNJ5Z1|ck|?rYsp3lV
z9q>{Pj{;NN${b6`(}b*dMoa^80oB{w@_Vl{p$B4o7^th{L6)~=E`K0AHs39Zr7ot-9QhWb)w)_}Sni4s3Y47Ee
zzQWhkhlj7F+gj~`7t2&IB?i_70YarHn7&__EI~H?lzk?fo~c%~ab~_S9Woe9fsnAK
zH#b7btB}aWtl3d*2eP`dvCm>TqM*`;}#`?Z?l
zBg<@Sf`H?iU%}D(<%K2he-Ko=M3?;zs+LFrsMf&I`jSn1pVX{uCf`Dt)jr4v7CnuyzgF|}#nrwCwI
zNO2J~t7|_7tXBgxA5F;TUGX$LwKM{D(0i&vJ!5c?=IVa&SR)INYq=K`aR!2dU%0>u
z{_1P*u2Lq36$-(aX;U(G>?n!phT;RSwhaL_)MRKRE^^vN--T>UI&VFkodrIcwI5OC
z^&Q9cac3l@ra$h$yVk=PlD}DYAKiV+>IDy#t{K;s7QmpbDpI`EALdeGVJ4PCWYGLh
zb=N?wB9Qz%ml9a<7bTV!-;v!W@5mT=6sje
zR9qg5k7m`y@kn!X!#@*G%k#>$L6xpeXUWPqi6CE8RQFgl^F?+P*V_UuI|3uc&LRS1Cj;-BCrU
z;PrIc2}ajntoqCjhRbcS5{I~i)Y)j~qn0^T2!td^QWh6RV2dbWbb)-XW&dQp3YsurW2}ry!%@iFtULuo#xic>s;#t-Q)Zomd&9_;j=xNW(
z+icfDRMjqXSBd(27zmYmk+qxt!=*H~E8vVfXIZZ>C_D8K)h+tC1@Oevt9Dkicyl)H
z>xa6KX+7j-o=(dy33~B
zmj?&+hQU5ZkY`Y2_-aIWgPgU%2sja#3#?G*Xg?#zXbxxB+R69zO@
zmo5aRv{prW=pE>r&*?^Z6(u5YX7#30kMCd1WiL_k_B9Y~=Zf1=4Z)MktOq?rnhskCm#y2T
z9qGZ@(aQemSXhwJAr#1rE`3Z^&s4z!D3BvkDBp*;3H&}~bC&S*V*!FWdxZ~|Fau1!
zHADOuiOS4q&lR;qBr$&K_nN;JE>Y~DWkM?oOwQ%5&;1MGgRpJ37pzlwxeAhxbiHTD
zs!v;xWA@vaH?yzL*xA-ZKBM;
z^(4t&QRD>GXO6*0JlYX&GLrF|gFOSoAtEM~{Dw
zS;|6#`btFW4=B=Llr5=scl#dW9CWozJbFrFoowhsE4H2b%6g$QNGGpX&HNiGH!lI$bhzG5FH#xY
z)g^Ez7S{UQuswzb3FAX^o7UthL9)q`j!PeN4H^HCm_~asCFYI{@O{^V&E2rLvcbN=6-;`y!W^~sTFu|^BboUF?m)=fg$N|!+8W6m~L9NP7H5)
zAojZE^!8-~S-H3PPa63$29;2XX<-n{iedBi+4?@o9@~)ydi3Hc$@Y>5dpUb$PpoOO
zi}fp=x}%EGmJ);j)5%H@2`1$|_32w$Rl%cyIbt@Y&XfF4Gp%*p+_=_T%6G$b^5UXbq_c8sCf4k*;4c4C>p=kDU#y|wl#j+Yn$=}
zc#1$wQhfk4L-r`h)co!LUyC&j-CuZrQxJWus{dC0@i)r0Z%mJ)=D{pc1{IJs_t}rQ
z-F^J-OJp@X*{@>r%XkmHibx({wkoUa$E>T_E~I>#+*n4jfNgtJiMPigGL~}^VbscN
zU1J)Ri5NRQ$uRZ8P<3I`g5eO|uTac%2udBF6~fiIu8Xs)VXgAVjEY`Ke7dPm`zXha
z2BZp6aI!4Bk8VuBQO|vZ?fo7pLUXS=oz08$v#62=p2P+#VmW7`3_RR7htpMA(vpRJ#3e{mePmCZGPW
z5_mYR}Gy?MMKel$~}>bF)t#dscHO{x=(oFvO7(B;cVo${o5tuSpU
znC-GDX@g0ej`YmY5f?-LK2DVjxWTGzUzc$woKGIO?^QsfN@=K|zm)QRE`+ja5P#24
z;@K&@R|oZox82*ItgRV+I^c($aL!Cf)^L)uxMjKrqw=max@BWhuT9A!P`2n|$SNCQ
z>!J8muK>F80SOm^&Y8Rb96Np@XJ}!@D;C%znNua*F15qF^Y9H=<$+BJKN;lcbK6
zHdN3M5F}@*$o{P|okMT<$Sp=@_4}e^t>)EMQ-yKi{N~&?!_&;{qtJumzl{KDaDt<$
zAAuR9xDruGzm9^7_gt;+n09}1>z2DEk@TEz^@{MsrKgbZ^cByKyxaOB|Qf-W%Yh=(L6hycG;n97i_a_pzsTd!9rXuic=XTh}p8mIpB$1ql$k
zpIT~81eNR?QV{<>rPeD
zKp9qIKYuR&-}MNW67&dGdYS#Z>fpS`s1&Vo7
zEYZx~Yn=o|;37+pV*mvr
z{CB3(II4~^GVN*QhsG}U-)N4Wb=
znlrnUi17t;EzR0d~rK^SB7>ft^f#&ntx5>-PH1UyH%5zoFH~
zg43+o36);-!>Q*gFUt7%+PIy2e`hUSLz1NPLZm7Ke9+pP=maqz+^smv3{sMl#9v%M
zSZphVZ|}uaxUQZn)~f-v-gKamk;=d?o|ei`g{C2r%-AZZ?<_+QOc`sOZv&isc9{RD
zrRqL>*ODy&#wxHuwUYqm8Hkk=Eea@I-O^+j7uEb4Y?sYgx0qo(dn9Z!e?x<%ro@uO
zj?uOqCBgXU^VAN{6)Ddf-s&s^t##}UQ8;97O_NA0f=$OLbWZ2
z#E$mNf&5qaMPPLvTb5&VKwi=^Wv}iHP_$S|w$jN`z1Unb=R>Y#@+hdeCclhprAv*C
z+{zBRFwd58zLbD}!E^VvMq`z&W7%LmMTcQJg7BizbZ)8&sILr3`y#LsFcuRd!lt?)Ne^!x
zS;3Np>3j3R;(@c6i7j;VWW&2%X65?Otftp@!vdG!*QEy*uiVq>JrGUv%Tx1?08~FM
zWIBcoTz-Yy|5E8hgK!TR#CMFYLQ^PF)ZUxVo-!4tChh|0-<*dol(4Ik8a(Tv88=pGrD~Ufo!NF^TE*vTGKitwMmo8#{MDn@
zMM{KntUD4sRo;9D(5GP6c~d`V{rofiH;#Tu_V=M;L8tlK7IL87{A)%veBB{^OUH-N
zqXsK=#SjBg%zIyhIvs-^By=i+2W;4%iQ8cxqP24&5o$c`2CN5)spGzmmL40K9i;H)
zfn8!S1R6si2ccv8yFVu4mUA81*1~tXzAZw5(B!%;vy&7){U==mp4w;kl@T|-fr2!N
zSCJ!WX3qZHC>-lRClJ(hyF0Z??TzFfduwbu$|tqUZ8^5ppRP_Y-$q-h!aq<9n(}Y%
zG3Z*OrUdr%APFTsoF8`RGq0?i4QIjm`eSq>Ee4iu6?h@0grt!+hbeA7E4kHE6AXG&
zSJq0&M2mjDX2;|Xf9$UVzkb@qM#oTz*{
zQq04nwSIfFY~OJ*X8bK
zSNlUb-Rw5@`{!FeISM{f{|{0mDDI`Quj8P^%}(2*hK~HY+V0tjZvde|{M#_UT|~M+
z_2K`@qWtaAm}$3w_+_fglT3yBg5Lg(HCATNAApD+);!+ooc8^I?@bnBUG6g;w<)`E
znJwA&jcHjxd*_W-Sd`nI*A$vnX*0fvH&*2V0evCx?RdO1S^i_X-sQLxCdHVmTy@a<
zY2GQs%d-3aSI$$fhNd(+zHCU%@u|NDd@Lwxu@|@5h(32lh7k0UoB&-%9WMGA2D9g6
zF6}9Qg{Wz*9f)527`Z@UBX8>I2T)}bH>D4*8PD7wh=y&6UkB-OeiXW!rZDAc(cvK_
zff$C#l!Jh$@AK^e`5A{<*}^ek}@a
zz@x
zcfl%xQO6z}=!Wc%e0vlL$nakY^tC#Ome26)Kex{s5takC02Y;PMym_3m?b{nac`-Rz=)Hg0FT9;
zxJ)M6flln}5r_|U7y%2iqFwaCG?LLDn!|3__W@W~!Q8QwxVL0SK#l%!-*(xw-psP-!P6k80O+QV}Ys
zV+{|gfOSBoCt+yF0VU}cz0$R`{T75OC(>~42}k4`MkDm^q&ktc^z-BA
zYeSV{?>SWAY~uC$(#;PFD`yL8zI@1P&3C%ndii09ZorTFMd
z=4O7s@q>itjU%6>C;4^v{svKi
znj>~L8VdGdVVBppDys0}=7yc=i(8E>8OvQ!z#A$bG*^#6z8Pbd_3#(i+ZJU^DD+ye
z7gg_Rv)YLrFIPw)lB?WGlVqc4d~VG;9{9uj^N+4$HgK9du$ec_4=TzE!d&TiLhv-n
zOE%hpWEP~d$R5pmyN^8(<$>fStWjR
zQlcx_L1b5!VuT=G;vUZ@G{DevyHn@&d1U4VL7BMG&Gn7*eQY72mbg!94Jj5H%ScNrMhom9a
zYbW58$ddcxVrn=Z)6_&thc{4DTv9;XN;|GAuOAa;)t|ZezU{ngWgTy#%?~>N;NZS<#(U|E^$`*+|^N65!TD
z!x0spM4I;Vv?r1?KP1b<$RB+LU5IQ^SWORQkPbU8k>Z~@Q~UWUX{D--2y0z$-iSd2
z@WTmn!LS?^M3mzRvts{?5BYdcfnM7o7a(rQe(UOtJ8~w4EW@%J7}mk*|E)05r;~K5
zX=Z1e9?ZKf^!2(-lUCncahl?>j(!^6B5311Um@4%^tEeFXN^7e+`eJj=fGK1V=PAt
z+2;B#w^)nVU#Yubwx8u3TBkS-{m_O}arn!+PPuH-vAF0n(Kyw7_#A$1
z>@}iO!rYrKNk_WcRMkM#?uo(K{tOE-S`#G~J9<|VAxml;^tTO|Tn*>%%delh>i?WI
zEZ=()0K?Uf*!hLBWr~*814_Qoq%{B8QF;`a-b0oa@BnS9Xyeaul5na4NQ6JL>SaXH
zcvDKve~4TIO%*XBS{^ym$Q)f&U`
zbf!!M$A)`xjbDddoan<#L_3Xq9%khx{Y*%)F;?W{?Qw8(E(b#J!b_mTNSo_$f3W*+
zzn9(TD;#=#s%q4e_OXxP#i%w@Tu4dmOUHV)N&|$Q6$n_+9Fr}#KDAx}XtIyMzdm7p
zqfZw-85U_~B?Z-5WO-v2W<9%PT3E4k0--dcQ&9IhcUH*~;7UTYk1+%lskV?_Bczre
zzXEbo@cFJ_`E0x(>J~*{HyutV(bB^_*pJe&oK4}-Z85joj2}C(AqMI+pBjT#GYZwL
z%gD%cW|d5x;jlOWJ0*x1G_BC<9qe}!kW<;JefDhsgvUF>To`xZQ2C!V8q-lgb2lfB
zKc>YQo!qi-mWbSM?J|i6A8KS=cFAztYyGwg164bF9!xL|QGkTLdn{6{zFZ^{F2K
zC5$$m{)2n3ix}%@A`O1rkfr)a2crfjUw1Gpg@#<_0QlB`S)bCDosD$ag^<#Al7gRn
zH;xNWY{9!bVOC>!MLqRVdiGHS1QyB`nx=GH!DfmcTn?Q6XSt`SFx73({&%KF7IHZr
ziK?_dXjU01P&okv#9k6K+hS(%4V`^=LC<`HPDDRjO{rtQ!8B&C1
z>5zOIAhvaX<7;WIm&d}Xd>N5fzI*Ic6|3j+WY2G)?JMM=s15l(yPX`+5>-Dg;1Be2
z1=m<3s#d*X$~wCz1G^sJ-Wd2Ni`NL-piNx0*Y;>YQVjaF`c~+nf9RG4hP~;5Jkb?N
z(8+`@i0d`KO~7Cbw)viUjuI9XwSUPQZZ4Fo(pvb|>fN%ab8OyzGeytr+{cW5khORH
zb%o)PfF<2;KUMEe!xB06SEu@X5RKznLuXrz&;3h=xPH7^SD$nSa#QvMZu>)+Y1!eskL
zHbUl;fdwP2B<{cr8WW%`dFoFd!AU9Ls;z8>(4%}wZ$A{>>BtgM%lcPuWQhllSXwV$
zx6R?5L>JmlKZ2R_7(s&BZNaLC*bpY!3=S{G(v(}LcU-LRACN)TBc_ohX9=a}Q;d%i2(((THO#;|-4<9L})TFC~o8pe=&;t+Tiy1-}ph)ErjP>^)rX;$LMh
z3<2H8p7_V+x@Z@ZwsaEuwn573c8J6?sKVT)<7}HWeA&-5+Jf_OYuE#xs^Q+jY70^q
z+w{99CCfHhBb7pZ_^$jgfg7_2tLdLcV)(=O=&lSU2XejXj85RI(Dk_>AofZb8*hX>
zi?sESARIn5175)x-pRpM_W3Cevt^m&$9`hA%(VJ%yzuUN-oj
z3T(q-+4DCR%&*6=icqf!P29JxEVF6p2m1gwS3h*-M1I+W0%LU#3-;)?OIF=#ixqVk
zfU|=irn4$j*UOlhjsnjxr{Gp(H(PfvQi8Omvoz>$WBahvyoe
zfu@q=t+IT9Mff4En7Fal8-`G4n88xtzI}tzeoTg@?*hr%^;iX6K9~1ZizlU07^}Q-
zn^h;JlvC{&b=5{EIdr=Buh;lJHzsS#2GlXiy^*m#k^yPaJxvveIO`)iC!DK(hJ4z$UT{@QUesjA7e?VhOjwq
z;W>a4xXkU9$bGfL|3ziIYV?s;nV?>7^>}a(c6R~Y67<=lTH3Oeg7v<}
zAeT9ayp}JpC;Wu$u$g=*rAPn(0NAnt+5iEX;sSuf4^Tho7CtZyivj=u00045TI)qf
A#{d8T

diff --git a/data/antimicrobials.rda b/data/antimicrobials.rda
index 6c28737885d0310333aef39f2096462aebb9e65a..f5953720fb2e3b3aac8083418e1eeec66f7ed04d 100644
GIT binary patch
literal 45392
zcmV(rK<>Z&H+ooF0004LBHlIv03iV!0000G&sfak;bgHBT>vQ&2UJ%gRpOV=m
z)Cw1$gJSr13Wqjw8e6WrwhVr@P5m+HhK8~`%Q0mv*PCM*owI6Yp)+R5I%=k5KzvU^I|#lNfby;cMrL0W$xVOh
zi5@J4vF$Rt$g$SdqzrzrY{wSFWqPDRK-DIQ2&3PDgeQ|gu%d%Cf8j`
z6RrBqeh-r|PfIDw15#sIn9zuyj!X;nxzWy*$pPIvqB;}t0J%Lj*Om0x-|}}4{BB@s
zo8NsdG^3zOorw2&%N_C<`uMny?~N$km_!{8ozJ`j9A%>8f57tE%GGSjQ9EBXQU6l?
zmJiekw6Kb>^#@0J5{~f{od($3E3zk^yJpokuiM$nUTGXtnQYl&3!+{*oB!P+Vtk+Ro*#wFO=mc9Cvby#BV`$^m
z+FIjUh25&Sc7s^|GCE=DZ;tuv;zol^@2(*o;tbpX+`$IEQIAQ4kx77PFz~f+V+j_9
z^}+sbw;&+OLs8VL<5_)N;J$BpcDY_wV?e~2y)s%U@$-p$mp(PUk3FWD%@AD2BC9f2
zv7A<-csT8m8k_xRd_V`#vn-wq1TfYp6@*T+ik@@uMA5k0nbXt6TV{9Q
z1AnTOrqpU>Rz4W#U(2Hc1h{Y1?!MbyjAb$vR}0K(?WoV)Ue-SBOOal2%8W1R&G4Do
z3gx2X2&Y48h%k&hs1Rtg27_FNnc;1^AZO&{3Tl+r3^hvjU5JM$SQ%bBY{Zbk?Z)mY
zdnwMqjE=Kg4S9+x@cGN#D+I19JSfr3x#Z3Wj=Sb
zdGE?oYC?kAGPF8aK?~XG%$~p#&RSc;-*dHcj>Fe*qqjun`g-lT5q~4n+Zup?^_Oy&
z0(V6vzo89XAM~cSeW;o_v{|apu7M5Rz_XzC{m5l`mSDu+N9zQPJlj_X#axrL66W>C
zrF2m63e005P?uYn^=!Sw##eqMBjjErk|ju3{h-6d_$#{=2I}bupSEzvd8a|Gpc*mE
z@x>P@Su_>{I;P%I2OCbb-SWiHX
zxq;Cfa2ka$8djjBx6d`XCxz@F??%NEbvhgv_K+lvu;OKe4VIv8
z)H%bd{*G|`^@O5Vqy6}xK|H-5T2_wiZT3~mln%A6eJ3rvN8&xQ(2|vPUZz#~O0=wx
zmm>M|sW@1kzBs>+UZlaWk{A({KO+0s2S-eFl|LTa9NEl?C-ab9T0pP`6-+r5~Eu>JMn13XDJFl~pUrSKONQU)d`qP6&T~Sj>o2zFj
zARo81f6-9-(tMmIxoy)!iQD3$3lP?LEuL7C=mBpzip5@DO$%)m;2~S)ZKTJ_W%=cE
zih}#_akhPc@yI@JtYmPVl9R^HTDD+N?Vl?BkNGdtrnqd@4)CG_RMq0nQu~~dxCT2d
zqs;5O9{R_dyoK~9*8WSB^Ef#+>FXbS&HA7UF`RP{I=X(odisR-Cylil6DSJ})>$B9?++&Dm5-ooQJ(w0Mdk|JM;)$2p0
zV_n|HP8KTr)4wZoK4?k$
zvd?0_(~-I*4%U#$34)j-jV9M+A`$qMzeoh(c_)(iEvr)b%_)57&Jc*_F|Rhv%(i$1
z7bP$Qwhj>-khcP=QWPXQ#b??)FGXM};-@mg<3)Hj@wwds-d!W0LDhRwA^f9TxCjFh
ztQiRWJqHX%IZM)ugZ!O08WCH6eIo={wjj=&5x0eCo3K~R09c^fzSVb}MMJqeRp5a{
z4|L(FrA+=ezw+R4gxao0oXF-2~Xq%6B!Px+Rd5+Ca)?VZ=7EH0Q(~xvkni=CGW*%uY`A=*?-@X!Q3f
zc$zqhI)HifkApDZ>gr7@n6gnr;;AyF7=mNvxe8ZzgHMC1Xk&zW+hoQzsbhVduSd?o
z;f+Fg#Ew&ZQpCWoWYFJ_Mqz8)UxR0Iu;pD@WHCWc0!@sL6eEj!?GzpOfz{YHPbF{FOUO90^odc;-ZH(srb*-~6$un!Nt&r3Se
zy8kuz^?D
zwx`MC!W0rZ>_5p93^^^-s!`~G=1MT;La<>lIv@9?J$!*oA+uO;+dxpYD;P#oQ!Agi
z6J+uaY`rg^2I&u9RiMni+-c@de%Zu<(ndwHkiSkEUO(>lI>)I`Ha6`5rI3oH5^J)~
zq#W4F+?$DMR1rQ&KdQy)EkRD7O%OCMy90sf&$R@bvowi2Zoqgl?!O-g4-H6oWFnN)
zalWKnaVTIwuN}jM5>q9oo+w%i%w%(503T=shmYXh0Gk4a?f@9984tvXp=Wn
zIFuX5$aB)$m-C2;nWeq!A~uJ*unN|EZTs@ml;Qm(+R5S>k3Nj{O73T=IQy49?XsaX
zEv+3}Gz2+UF&hY3bHr9}#kg|^!8hMAilJPdrYg4%O?&o=qW_Z$5OeEcZKXXHzLjXm
zZN?jipRCekXsOS*$QGgaxBXztR!gnlnNI~4dqz3)iegIPKh=8^_}m)c%>bA30E-?Q
zD|ewQf1nmw8OpBXi2^JG-$WcyM8O&8U~PwZ7q<4;^?@~CE>ZRbPSuPLeR2t7`4jPn
z+g!S#`>=$Hj>B>8>d+FT1b{?-t5ptphoF?oZG8=K2WD|nC+~2%+Wcd#9>yOmK7AQF
zFz68kgYQe)(=dI%>k=4T>bXVTBz46!;Nj{cY4<^~u#@|enKv$^NztDH0)i^gb-gU{
z+Epttz%s3+{RTgFs;CDh&*af@r|ip5*J3HbIt{_2_A`4qWG+IHIYx0%b01Dbj@3dy
zjJ_Gr?#RU^2@|jzU#?XAm@=>q>lC^Shm;JccJqbdI8?0U079t_M&m=fxG|VJGX9*+
zi`GBGG7o*7uEP$e
z^CWRAfkQ#>jA!6r!#ua?=)Qoj)Fsn@$T;)(53q{pgD8JPt7>ye@wb_PDp&lbb?Wt|
ztOtniPbu;Fq5R!pY-^0e=)`H;g&>7buh5Ps&G@yP{qPd2Hm>!TcOj1rSFFuz{fH|`
zP6x#WZV0>i5I`-t#YjPu2A+0h!AJ8i-~t6$2o#d83~qgZ5!meOpq)#F@iZAC
z1#tAheue4XUuUwoxCj~a5gn%Do@Tu8qNy2G6RbH(MOaHar-Q8v1|we;4?wLZxRxF&
zPbcw2V!{tX)?YR3a_gV%Cmkc5%Qq0<-l~tTkb~?y3W!`6+rgV!
zSzNw~P*qzxuA{*RvRFcueQAA9Gfb
zq=XYRGx-u-P9tL_0ViiiQ%sBUyp|g*{vEaf8fOH%&OKd-f-o~UB=1d2edvf+#x^P1*XRO!V7zs>tL@p7wpSCK^eK_
z4PYiD5B)LV;TJgE70W5_QR<#}aKzqpLYdT_{RjR$b}nLT??~fs#>joxBZpko&ESl9
zNwf}@-qibn%jkQROWc!goD5RrDgeu>X8^I3p@X9PV|LQNY?TUqv1x!$IzCL;X
z7@CU)!~y1?H2i3H|wv_av~3in@yox}F}5jlk{#&B1!J`6F|$K{XLrgZ==XOv9WKhxNhw
z@5rQ>9n$Mf7OXNh?&^Z3nrUBUoHk7I>&Phc(vsTX?XGEmS7R2Qd8szb3raMMzn>HK
zLCe_Chf~Y|WA3kVoZW_D2;UVpQ`-L>1y&0xsc0SVe{B%kNTRXasP$w6dtEsBUBv)2
zD3;iHvHCg8_*u(A1Rov%MyDq6;ul7NGwqc!DfX(k5{QX0Rf&_5rGpBQ8p@LBh)OY#
zopeP&PAwev06Iyl6L0s?*HVXF_aK3R4KS7-H$od}q6p1a5$qX7GXCJ-IBEiDnNh0EJqE#@=*Q*{JeaG?;ios(&#uu_U`U@N@0DgA
z-rO9w^ul}&$4(94`B*r4ac9(F{oISXu#De5lkvUGRXecEPDQ;YiRD1AFHuPz=)c=e
z!Xc+#Z_K0LA*Fxm@bS@9Y{WQ5>Vna^f~?;a8@YcQABrC}n0faBG&C7#9zgjke06Q8
z5H}0BVFNb~A%U^|xg>(~NMJVAbd9F5NAR8hm;8A)n~9}dIFsIl8;zc&`Ki!hTh=Ze
zTEP~SkP|56)zb^wO+UNfgPz}m_uXA1J6mkyy89jU^pG8O0{^G<3b$H@vwL*D?y`xM
zXgemR)1VE98{qQA{34xY<<36a{irwrchSItlw5w#MQ8z>%dJ9=se?j}o8Dpo{WoIp
z0y&&+5O>m_uI_6zKM^n8$%M6W9a=WZIFogA;B>I&z6hIyw^{2(6VG`h!uF5M&dz3g|YuV4xYP>(Xg
zO%!`xEUMPY7lZ!@bK=FUlam_aG(G8Ku-^-hqJctC{7`#v7y1?IPh
z_>gScCskzky>GK>Bar_$+I{XeMOWQb2Qu(e*_|v~pIZ+BU#W6!LY!X#PAYbK@PW6i
z)dSLicYtvKFge8SMCT#-N^jP7>5ya3u4Q?iVVJ};G
zJ?(qWAtjKA);XpzB0H;QQsgFOLK5J_!A)TM5g0`y!Ncl|uCm-vJaLRH2`12^?;e{o
z$USmEWH*D9;D=DYie{86b+16BA_L3tqS)-mOZFg&#QETO#UPK5VV)QHnx;5>BoO(h
zN%WO`QWxIRK~xRll0)*=q)Z>|Q{`B28y_G+&IhoFwec1yN%)S-*@j2Ejl3KqQ4$=Y=VFj!{6fic#hosJ
z^8#e?5&lyjR6(>?=Ssi6U3S{!bCM$r2fXgi&B)OqH!R*~tQLwhaF==CspZ6c4mA2DGA9Ug>V25g3Otz3*=><{#OgsoRJrO4Y+6$kcb`0
zn&Cus2)aX-(PrBo_vmNkhPn95E16pxd$J+?K^avezx4D&F)|fiMjHn|yc#(qWc0$zLnDNc!W19UrY>>9YPrcCJ0wT*ok<3;3sORm{#sTJ#9r#%P4&hDX0LD
zq~>~xGJ2H6e_9?W#y13)-+wTJEjYLDne}g1=*XT`LsQV{|1H0#kWwBzL&*-5s?l~J
z1GZu?=(
z{UKk%CN?_+LB^{kA=AB>o7NKiS)=I{-j~Xpu0BfUbLh
zt6cqOfl!yb(B6}_P+PqoM*&gpv^deG>Y$^ErzXi^a`DDR7#6ZVpsQ!^=KivFlxSK?kqE?m49N7TPHFP1C$IW|e(iY83cKGG|Dr%NJDm
zg1q;cBv)D{zDYY)|DM-RE;!_HRASf?2rg4U*bafxK)Kk*Liw7Kj((J7vQa&uqR?tp
zn_et>Q;lY<$t9=D1t(MhT}3iI*jf8Rl1>_&rJ{UeA%!*@Qrz&Z!C3fuOZtJk=FMco
z%6mZLxTM79cMH5PD5AvZO~GQ56b1Y=4$d}%N{z{=09O;tk>*AHbZ0OZHIjO&vkX4C
zU%cxg4vR=Fa8BL{b#0yrKyLS+jiHv)h8iN@N|=mb5BnTP5g$FVDlrAcyddsM1Gz?%
zZt@a=}C!_7wb%M8E;Duz3n=Ga1-*&aF)*_+~~Qr=iTFO+R7oZ-&s$L7VT~aApq&J;d2&}e
z>@D+(7$|`vN9=((r?3&xgjjObRvB+mVCdZL}PwH(-U+@kmP&pZ_|Y1m3r%c3oa&#o#x907`!#j
z_RV*<0<}IK9aDrZ6%pOTlr2th4P1eQf|%!9S3RBBCLy1?K+|YIN)8pzP*ZC$Di;+}
z6qd%VM()}Ud=cP9omvFizgIgdxg6wAjo_%0GHb@I6_
zC1+k4O2g2<2h$GI{A4N$9E98M@w!w2pPhY}#rM1(G5)q35o5{pKxK6*IR6K?xU{9$V@vLzgh~LUK!~w&SmjrB(*)Wx^aPSw1F&
zrI-s1-Lkuu0=AlJ{NPiAq7)F#^;2bi1ZYo+levx4kex`1O$8kkvsYfGu|Dg;El5?4
z@yDRzVbf!aBJZt`rH@lZUZ&>ml3{)8>la>7$`FV(-)UO}G1@NtdnVwH4g-d$4E;NN
zLC2YE)Fr=VAoz%%fhuxr@31tY%%g;S7ZFNQZJaGxblta7uDZy3wc^TxZ8v6|Log;LNB$7}7kR4=`_@ovl=
z5Hepvt-$$w5N+%qkz(2a$wE38jUb3mm=56ZZI!RECvo>Rk_P|#W??|MLKb+@&7W%D
z1OsBH#OH;iZSNOJ&Zob%K+Xs>S-0o7GE^qm0-Yt!k*TMH@?vTa7pKB(w$vfM9{<8E
zN+TZgH{`&Yi6xkKa7V=t^LSK@mUCI%Ezu$g_xKM9lwQKkiGkj$$%$VmJsf1~isk59
zroeq+OaZ?i0rsp@VvGm$vH{Q*IY-{@gm%Q7(!TeAXX_RsNt}}pTJbJSPuDLD551YQ
zndT&I?JkolCwr-<2tfO*AXOvr8A&ux6XjCbGWohWggce9ZMObr?IG&LiBU84EZ^(5
zR5d7jlLM$(=KIhYif60lOC3~xLh*!5*`8mA{2PSO42*~{ylK{%bagjEmTL`-P_89g
zpZ@HyZN=C!jH)EWe-y?H1Y_aU&Zxd)|AWUP5+7qmjKKhF930f!BhhAgQh9vW>Eye_
zc6x+VK;ebUY2`ysx9xhaFxp%{2i4C1K?^$M({ms?e0NtQV{8=6fMJcVL%>=ej)P3k1Zg4$rRm)R5rwvQ>Nz9ABpQiyFE-oF8jA2s$i$#ayC2Y2_tL^F7gBJS-W5_
ztZL>~ZQhI36$()?zWFgcB9H;W%Gg|ToodFrd|;D5$|0;mR#M9wl9BgLKKMfdbZ#Ic#>ZPsa(DZDRh6mC~*FE
zw?P1c-^=7CXk@Zp8#sj~*bng}B3~=qtd}UyYrBXaiVJ9xgldLEv=n(wQW6BjxgM4w
z;``qH)DBJ@)1H+0%r7iAwwWZm>QjPrf5BEzr5&`(yj#ve-A#EKnctyHsn
z>27&zN#JdAD*$OGw*DVyjwOEs6flUVl9RscrA8k+`tD^?!njVc?8r9R1>;obD1vsrzp`Y;?7HnJTyF*~jFsBr_CyzX?6
zC1`|JW+veRYg&C79O^b0Fx*uEp>y2*!W9Olw~$VbJ&|!Li4wxA_PjwlM!rF!1cR2_
zCP`&zy%va#M!DN-Z3R{4iwS69S#M!uKtM<@3p
z#D0@|-kM#CRPzsKD6vorW`Vx!|d6y2sB-GxjV)DF4@>^>F+EGaW4&Dy_3Ub
z(mV4YwJ{>BTJ&mtP8(x+miSfY&wRf0F-KtVCPKqx!#eBoj^#{y4yMK*hVA}xFaId;!?G*wZS^V1SU
zoIFfZf;S&3onv1S7x*b-0SU(@w3~Az#Hr$A87|(y+w-Gk9r-a0>Jl@ZbUgP%>Wp->^!I7X@4Xe!haFtw
zKnQd_5d|VkdGbBbTLVA)241RM(s`8jQYVGXh>>y|FaB`dLLwbCYk
zvtKL`YSk4SHSNN`3&{Gw1rrUf_E6z)UosirrjxXxJ-P*0BI?~nwS%e?9Zk3jkqIAC
z2%(DKUik%}AiM4^pxX+#8kE1W56HE9ya0M?gBazt+LDA|ETIK}$pLNMr?+>h{(!Oc
zAU?xOFQuS8b4U?Ku0w(CZjlu7EwI34>&9j_`Ygjnlkzu3lSneI-U_M*y{^uP@FFKj
zO7ND@9333(WrjC7R9{z)acd&k##J~(M4TuJfsy3iU^(v%Msud8yyg1%dY;T+GtA=S
zxZe^{Mn-8;?u@PUv+>*6OpcvT`=}kFNDVj&0MiF8ShYvB68|+5btw(Nb>|KsTORf1
z}sG6Rb_942f^hDjj{WtNfjhhl8d+?GM1gwS=3EfiM6$xhXK`sR7mx?
z@O9*Qp?J2Al`8^!lBD2#59TkB@<_@
zgQH#y#*kl;zIicL{UXJA($HY%0(5T+_umGyLMQ1SkE@~Q6{i3*T1Td4U=VP<6fYSO
z(+yV!?Rqm)xQ@tI0O`^*BC(>1qy0dHBr-x#&i7S0-`jX7W6Cxf9}*E`mj&-`hyG5l
z*$!gHwEL&Hithva!{rh+9`i~fl6J)Xk7GJshVIAwMQ9(A
zoocb__3FVZxWI2bggtcc*SEJda8LdCh*05iMDOot5YcZKOiv4I@GA0LU4}?-PiB}X
z8ZC2$M?}$_I2`b_P7g%$yb`z^TQ`u$>yG-_a@q0sfbMD-?4VMOr2(S9dl%+gGAo_|;v+Vm?3bftviZ;_sq>F~Js1Yu}
zPZ}zms4RWFHgbK#y{R5NN0jg~{1A)L7zGawiQ!KashoHbH{Mmd1}n4^D+8@V#8RaY
z3xeRU7(n`U-81`Kji$w;VyXV-Pzu+W8}Jl!4v01537`DU5_mC82lR>CH&72`VUcp&l+?w_wkoXhSU-Ue1N5ze
z2Pru;N(8t*MVty<=S6xutDxkGf3`i59vOV8KNG3!qgyR^J$wX%H-uV|irfH9Fcn4*
z#xIdgf#{9ztzXoOaB_=;6ttQc_62$k=){)gpD-;c<5Y
z2VsU>Ep4jS(GF+tW{%m{kV6e0CVX)i61vtY4uQ2xE9*1zglPkw&-*6|^RhR7)CEHQ
znS-^4xbi3NzEZ59>xxCW+Dz8wGlBen6#lD
z{xced;8{(2We(wOF8JhsdeKD~oQ3T5VDph!pjEQA8n9RB12L$h#`sv-THdltIY0`s
z7{X%r^Ig-^t)3iNxv9BBiLIKQqMHe|2-pZ#_bB=Jg`+yfjO{~MX(*6jRP?5@MT+tL
z#`J>fvozs%fY)?LlGZiL3=`hE7{m@qylplZ0d~#+#NX>hTxXFgzr~M)Gwrc27`43g;_|azwfxuTGs
z)BbU~3owGJl}LK9*>eQ>LRYU=6sF>n(eVKCS;c)tP9*2`@CLaCsOOA#DbY@In7!6N
zT6)ShqG>3c`^?jLQ%KCKX36)xW6FwA&7=;SWxKC9^Hnbvkmcy|BExD41tgyZNgCmx
z*>H_{?j_h9b{utph%J<=Io-elf+a6R1gM2c_~9m!bUt`Qtv5?}6jx0pqf=PCnK%NvSoS-R>!)h8Iy9kREp9x$*?Zp294{Q`P-@=K+@c^0?)x$;ZiO|9Ju(z
zel@9Zmg2)cH2qikVo2l78&G*#c+u$XSRihCLloVpS^xXgkGAT>>v&L|1rE&c%FlQT
ze%$zSa+A$7ZbNAL235CJo0LebU!Q&|=1zSImY|KqmME#Q2z|R##e8B88%H&)mvhfU*qaDO5qZeIH?2&X!7S*
z$h@tEUD-1UgL0^!<2uGdrd*X1L$=Gls%?uXjLFm6=sI~ypNE<|zMgLgd6Z2BFOwGc
zwz~6Y4LHbaC_n5ZPK?>TAozv4(nJ%R>g}c7cnKOep_;Zp-?Fatarp*3+BM=?kM7#X
zn&QS0FW3_&bpy}#zuXMR9HY5GP2$=sY;*5t+Mclh*8L7{iC>!W)qHG85^r$uj5cNC
zHtR0(Tin#wm(SiYkydz}MNR$y3Utw8{{?^03jH#WCPpRw*I(}9qJwVqed!w7{Lp|Q@e$xJ*Uvi5QuO+;OlDSnD7#SH`;
z!o_t;LmNHmBVK)iJ{_Q>X3EkX92XXPnOCBKx(r+_<9y8y24XFJB+9>E?EweJg7{tMA*C9$IKs#KRk((5ebO%Nx8m6-kDvnnl
z-ZfNbheltZ(460#E(Z_d6k}#d)dJ2n5o2)01eIeB0(7J}Y#grlGlbJ)a-@@390lPV
z4cP`X6OAXv8G$L!t^6BK6$IClDEG*4diBY|9G$0KRisN2b*er0lG}nS@v?|z=yl#+
z?DOQU4?0IIA64&F-l~DVJxK$xooGDir0yt#I3VfvPuZ9yQ*NRA0-pO9;v5lx?aI<)
zgisJAfax%(5LPf=A|sL)C^x-BndN{N!veWws5XVUU00ZvTMK-T0^Nr}zAcxDgwA3wt
z*{mO#6-waFQvmUlP$3^o!l|}`PNM>-l#^9%A*s+HL+*hkHugK`20;jmQo%+361Tl8
zRVUl94i62izhVnDHZzlhBVjc$+}OInO|}8W%O3!ms{{kkR}0-Xj`DcQoqK0N&VA1`{blZpHU*R{cYQr^2)O`-U5gzK7FB5v2Q4otI`&4W||7zEmd^$(z
z0GNSTh85|W^D9^&7(p1OHn=AI14E#o$aIYZ^@F4!hPSr%GK&Fb+ud)oQ&)43GU*^;
zBLfcFs0JH(LzPj3(0au*=w6{Pv&lr6a0-uoTp@o2LR1+?^0nu;mnMneg#QxeDRfVmvG>=Ps2vXNMx@9>bVL1&*%Df2Ib>NtYf1}N
zZ4uTBKuYTg>)3n#1%+`~@E256boHC%VO(K3tgNGffYLSXfi-e}&u5NxsNR
z1wcXOr(<@9m!>)>wroXx~jvZ<&I5&1%_zI4NwhErk%c%G6%EGWsxpg8ae3^
z3gwES8Q-?NMhI#Zv+QM=c&s!-(IRP;3A!VL3N(Y_AN6i|Y>(N~^%V;>TRFb3&7V1&
z;AKFFJmPM8Y8#sE?!-bL74G--q`P!dn*jrOI2!tvsTP!s%eZJzaOzd1W@44nR%!7D|)Fh?K!kMyD~?06DZ
zytxCy{c&LJ3mRm_D$euz{p2&mW(Wns=z^p75SN#zWM#FPlEkDyaDIx#<5gbvL3zOZ
zan3wxFIN>QAfb-glGAI`BlsNYd1BM)wuK)|KlB7xI4upeh2KYSqt=(FC%Vmg{$5H$
z-hNM>
z8`coLwv1^Pzi=04PRqA$EVtY^*3D(CXG(%t96HGAm~7V9t5zl~)CK2;o;lq$C2==gefxJ^4_I!(g3mwMPOXgyOYPNU3Y%b_7knoa@Npxj
z8u}r)DIn8F-4Af+$hk-43#Aljol)%;l8#KE0~2vvkMn2vVHokl8l%-C23zBn`TTky
z;8}!ig%qu#5)PuB
zN<=wgbrco3YwE0A#)Rm@mX3Pzwz!vc%m#CdxGqBdzJbXp8YTd0v=8>P%0bp97rikd
z6!q_u@#80^G1wZ`c)icF<@8R}!IZJGH+0NJ?=!Bc*Nzl%IE@%NI{%o7zMOfs3*T+(
zUt$Uwvlr~k`E^YHV(9v(wicfLH-6tzEeKkBjGe@Frp-W7#PJP`^pH2JM)gQXR*8yU
zoC$R_fc~Ii)8>*bwmS#F^*P(cUx5q(>geA{TWdKdHQGhJIRGp%-Aly&5%?cWNgEWJ
ziFl5fT_2SQJMSltLuhd8tsWCVGUBR21sNEtAcmXo{MtGH>21c6{XdWlwO@|h{w11D
zpyHLqTQ7Mb>SVYbp^?x~+*E*g^58-S7Lv(X
z&+AONh^g!BKVJ}wA#z{qFe(-zO6&UiLfD?n4HdSsSZm!s@UtcPcmYpI=E!AyU{9&
zqe*+G9AltMf2uQuNV9Un>pz2BUv=wCQlUeKP_1cnH(d@F128hEk6Yb9OOc)u4!-n>
zF5NraT!~0_4uG>28I2X;4*dPYO;20*5PVI8O*7qo{VzQg2Yz)0#MXVoIuCX55(wm)7FV)RcSGz;*hTJStduBaTOIl#FaiSkxN*Yd
zX$t9>c?J1N-)ZWLMYyeK7KPZ101M|FrUQs(I~mu*CMp>b7sBlKJ_iv`2i+MSXn-o>Cx
zh-x?0=mp1d#!y3cosFTP
zCVZwG${HU*!VX#OI|0d(>8kkMWC$8l3twH5CviSzCB=WcJJBS~y=n;W|FiE-7>!xi
z^YRh%??5i4<3$u!G@@$K7w_)f>N24HdvO30e9951arlpRj6i;-OO5AN?3icYwy9h8
zF=^smI1+EwZ}A4Dt)g(!8LU!83z6>2FZFz0Ownj_d7^D|{y?UyW%_9z47zN1ic4Wu}oako>!{
z$NK`}q==d4KQAy)X|dtRF{K(i`zg}!%=7@ZRqrb{j8h2Nzk2eo=esbpt361|h@^3~
zmtr_E$>fyBQctku`E#4X-HeM7lX5IN8g$Hqj@e#EXTliNtjW`zaS?lUFc%{=)=4S7
zFf#%g64B7$V7X{a4GrnFY=97RdrHYy#ww{Q{n;Rg0kk#faja?%j?(S;N6xWuiZ-~g
zNdFU~3p_D%Ksgy@#Gu(vxv>~{N!B&NCuu~^9om0Z
z+k0j2*d+Nsxv$YQ_ZmNH9tX3vlL-_@jIws1S{#=0W1E6TR=iUKix{Mwu{@)|PD^0`
zKO+428&BCw6)?W1JS7bhRw4}31UGE2KxyK(rPSPjkRpmKL&umepzkXm{y{G5IHSIU
z<(wzkY)A>q+K#UL;f1rMIZjGZ*La;sm1EkQRyy}j(|E#~x6K*&TuA5PrCuWvt*D7#xn%D@KnT5B
zK|Z2gFy8%r6(H4#3Hg}GTGRc-?OitJWVI!)ER%#P+e*5=c-v0XEjB5ig}su3bK!;t
zsv`ur&JR>F*fPW
z+Lpk#6s-ZiZVQP3CfoZX3U6@g^6@L?S(ofGR0K-4#`i6$J=C_%`owBT`h1||@C}GA
zbre4I-4MDTY&tcr$~Wp|lXy98zm`Wo^!}gU6y}m-x(x5U9C0t<%0HV@eiHrsj(KmH
zFK%*jG{m4_HLc-nkEz34H;}%Wdqewmm%qPcK#1sEj@_m{@sN=WZK;~`{{3U
zQs8G`f)+yAhF*}8;g7`jbb}XPOUq<HfZuP)M8$VrCb4}OGAmiQ?G$hz~A
z5$Y%=lu&`QCR@`B71=usg$W#Ff6*7V#0=XIeh3E^*tr!7!s%gh166LjxadpkWP^N*AQGWM8lQO!w`Bw6u4aq
z)Y-N`Up1F%V3dMW)72-|pY&2kJq-?aeZN7H#I$54&-5)}%R~esgoY@S3v%7%S!t^_
z??4^Ec=R3xpAh{Xv4$IrQ}acQpc6m}coZ
zeY=H7eNQqN{DHM=6lpWK)E5-12x16B#5;jU`bT@x==%ipSl-Qh3D;05L$$zpNlQmJ@q;%@`HbawLGC!4YA0
zlR44V5aR+-z~Y5;qABP51j~h=uj`%dqpFSc$5Rz*K-Lqgb*c>i9C-laZgpme-#fr<
zNeOrX&{TN;GM0UArTCz
z)Wc&v_$W>d#{!mJT(bi@3#odoOK9u`?yq9g{l?4t{V$}Sipf??`lTZ>-S9h8qbmyx
z?f(_wO2aiCE&&u{!#B8Ant`Nh3Z^*10+PzcX_pt!4ajI^*px$nw}4{y3;07YDYM#n
zdZkN~NarREe#j~0uiQh~))}MB&f4RH@zu&}wc@EuW{7rPh;aD?eBB9YrMQAz0DRat
zlX!Xu`#74=)?$T@Qf3E2ij$&8PukKkiF1xvHU%LfNm#P5s}EEiHUG}GRV76NDc(3{
zbB;U5GTr}Tw}Q~pH!J??tv*-yMmp<9AN%q4N`ND7*M13vAu9vi;Pi6R$S&=u{6T4}
ztHst$GZp>o2bKwar-Q#6-e3%CsV%-(l|5c?)-baBtO=l*uC^@@BZGvM+QVN}UX;$3
zb1#--{NZCvvF4uXp+(>&u7c&a#^r3pftIaBt^W;cWvHImy89f!ST%GkKfIj(BlW7z
z1XcM1cPHM3{{LK&*A+fP-Qu8~#FSxqv*qv7VBH)2yp8*y;OH&M0@XmL>n18#5YN%X
z5>lw8wOBGUQurpKR_u{RIHg?@PfFL+40UOsFj99hX*GZpLIc!xVI<5@)M$d_EM;e=
zZ)OuIIBa4ntb<5>W)#09`O0RXWYXn
zBkD8tD98-e~YF}Z(3^vr;!lX#{EMqXjGCv2fO@hl8?
zE(rUPkkFg=!S37S`+XG%98rtZLl*~1WHGbfCTHE6T~}2vF&s3>*-WcUAe6V<&0s3@
z$CM+PTrmF)A-PXC&9WWAp!RiFgcDCb=STr0y+-cT^-)P6I7hAs{(%!sYWmIiFnriJ
zR&D@oZ(fEcGH_;y6e%iJaA$g
zm~zW`ERn)mT?kK+ez;CYd%+*$Al=%tMWKNvCu8KY<3LZ-kLw+sfx=Ppu`ic&$fDh<
zQ7YuxLNWt1YDiAkZ>I&XFyR$ouNN%F{x5XOh=F0fafb`7oO3i=ABJw=*o&z*Rxwbi
z9kK#JbRymz{Cv{aWphU)C4R$Q%Z@}gs?C$|@^6V-!KsB%JV3`XO@~3QV>&JXgUm3K
z&F!bsM)@V5;!HO_Szj<
zCs=kw(~o+A7Mm(P*-L&;&%y*}
zLv>tvRJa-f7d?i|lnyVR_in2~MP+@%_4k4UDK;m8g-nG9^W4tuyc>tSR7gF%$ITxP
z*Xz`)3p1}@Sf%=C*|Ekcx8`AtUYW2<)&PF9Hi(RX_%~3Jz*k7%q6K?DDYxb}0=!X{
zr$=7kpi>U8Lu|nG7vc8;&hAyOjHvWqskRpJ>enh)t5O|2jP%!RWq)K~1iC{6wvrL*c=A86
zGGQt;vEA$3=qUIkp=a4kN+kzv=IKZyOLZ_o~MO
zlZL)HQZ~i%e~73;LuIwQ-6Tj5)RFw?;DMx^rEab&$eP2Zj8%{)d7-%XfbVaDQ@!L3
z3&|*;x(RhmK|&AMmH8HR2UcDk=ZIl@P^x;pdb}DtKQEGJK_K6vhK+xNd~|Nu{#ZGZ
z%@@04s!7C;OWW9nT9;jDj7R2Kg`QAl57WTEMGQht*r6RffcS|jJKl^WHk_Z-(OiEm
zwX8;ckxYg5*TYoX3T>5}=I2-c7~#;aeb^U!QxI?n6YK7bRD^3L8q?ojW|jH-rttL*
z=_sHABdx?)+YkMTO+)XqhK=^9DyZ)>*$OQcp6wR}qa-<-)^y)!vVr>*ACD<$E_n+%AF7JMME0R70ja
zlTvX9W>^_tt&*@*O8%3)Fm}1R8{0bkb7x>$@0uLHC&{*d>RyH%oDO)W9Z)T^5wLTq
z(!C3s+`&oiY89!|vfN5gbgM%p-x;rM{1yWmvYAfuH6BZe61Q4hRqP~O*RgR)jl*Ix
zVx$p~YhKR7nwXXi_vqK&Jei$C8VVHg4JB`N@7%P^gIvVp|DsEx3S~!X)KjcZ1;^sC
zGuAi#>)@{ZrsG+Q9F|>?vh4HzP_9ngylE`1X`a-&@+!eTcF!r-N4br_C9;o6H2*mo
z#3`x*YO{OK7L^q?H~4n#zd27Khaz`%{BnwZsX1GP)?~|?wYW?*MQf;bkHas;v)W!4
zF^Q!xe_1WdvmRt#nqwqIEYnCLRCR?lbW&KlZ6TTR``;she3O=Tlz6e~g7iIu{0~M6
z-*TcqK@~7+6&MxDa`O$P>fonWNKjpO{M@u7@@;)bb^A(E5cit649U%uF93!3k-OPT
z?!LJgYwi+v8x8a25UwA>_AMfah!vcLyE%@qBu7SZq?&4D8-poS-1xf8!
z@#A*LY{`PHCf&bQMo#^Ysle)YP(Bqk;+d|Zi)s_L=}gKXHjBQgK(JvE=t*0(-B_54
zezyjHfqw$f3^Am?4={kmt=#(7XpOr-88q03Omfala}oCc-{(R8bDb
z>}DZ7qMt0sp{%7W?&9_;K@1z2Hgj0(!R?|(Gu`VAJ!{PG1@?eyAxfjo{pq&uIbgZ~
z)1O=Y=w2%xuhIbba%2BXB(qQwp8Ae^7l#b>Jt_{emI8b@GjbT@s+9dYDKx>9=k+et
zXwZRN`F^01_DZ?-7dBQqXwF2LLx*e&M+gI5oCeo_o$(!yDOZHMrhFqUtbp&bU-_ol13(N|bFzujML>@1y
z_XP?XHRFdbE{1olQ|#W#PGAl;o2IYPSZsfNs0w?_G}3P>GBMyP)@#<3)vt1iboruV
zn#lbHmqaU$vY)p1MNF%+q4!MGxu~300KvBgzabH|r?p~5Nm8F5w$_cr5p=*WWy)&i
zPrl%Ui+0zOT8?@_Y3Ds`p&{a93hTsMdN)DGd$lx`r}SY5&!MT_?Gf4`mRc#5zBB_&9fSIJ_D8AS
zy4(i}Prizqqz~hNf@yz>``7_d+_=od6}bVxG!{+^ms0EUs%AQiIG5YKqw3=CT+Dbf
z`0`O&Rehw=Nnn%L=Hy4n9yy>??w#Jdh4eV;WX<2#&^KX{{$~ul!(jlgf6IX|MVIVr
z4LcF*W-klo+4Hmr3
zwaJNkLM~QILQVnl?4!_4^R0CcC6whE8|cd_
z5g>{fBoAgZCt^Dg=d6C{N5D@Vnr;>kY;#M|N#P!9id(r`0MWxfSc=LwdGtA;z+z_j
zVs$|={i2oT%(9irFL%$KX=``}fN?jh%Pl00t-Cj0fviT)puwVb$EJv=b+80ROeC@FDB2`b?F*TbX>uvvyiGphK5G>^;N2Oy(wunPeQ7*cgD7%Y+L%#b2xXlyd5ct^tV?jUyZA?wHM
zggWd}VG_QvD%9@F@==ivglEU&o7q3aY+xbOl5=R=VLPvuIyK@MbX-C~7C3k=Xx|t1
z+wT5K<*92?MaDMj<9L^7kXfKo?MqJ%ch7okqDsLfa?kN%usIXSF1J|)9z#6&h>`JCIQMNNAYrnKJ%luSHZvxA
z&IzHu5jUUsvplLrrrY^8Gzw=$r;R>%K+c;Y#u2E`Bo}lBC({n|LSGXdRY8vvg1KEB
zNj=)gyc=!rI!YsVtpRDTdkOb@h(p*nFSjZakgS=C0j%mtzc1;{%P}*tCp)WQt(XZ(
z!*UA9
zN6&C?hnQ~-6rIX>pmD#jj*cp!=sB_U;yZ<~s5Z-?tf`t2tH&{pF1zioGdPkgAa_vK
z_YayrS{xlgv-E9Fp?MNPa*Y@xj4U9JlOs@FcJICbH)JAsH?tf+sJpL!)*8*GqBz@-
z9(s+13EaWIStEuhulCa0`?Ny}Ufq+O4e{_tyy+T_KEyKW1R}Q7x{MlzJ`~BdI&q5)
zF~O+AduAzUz5(fncOIxjn*JiGCL9rS7ry;>Sh50)gk^egrVg>l_oWQiO|wc!>ewSI
z?|W)Hc+Z-=P7Q8v5;FuE-*>q1$CyAJzWX(^a3gx%PDk?9k3Wkkmg;TH_BPmP&yoE0
zfqc3g@)Jc}Pt;52J1Pc0UcerC(@>Wx08US`&+^tBmPH+nHvCnW*JU$7oed6a^0t4?
z%$`-gT)^2)El0Z@PoP@-fJ7)oLHDwnhw$pt?PTc#^v`{d-p9ecRF191Xb&iWRuL(vZ;X$Ifc8P<2##l~P@TzBcRtl1x0LXzthntBQ
zHd8Q?%^==xH*lK|jt(4c_NjEa$^X*4khfm<6TFKGHq77r4m2Z0+2r~C3OER+DP
zPJQa}QrTDGU%7XB(B`F=K>P{h@4{rBgLg~ez7~xp`ijRRu%~{QMt&7OTTjA{a1~|G
zZ&@NS#i`uYt|aVl%ONXvAGO`@x?h~oKBMvg}n3L-skKAeTL)!b11DOt1yIT
z1IUkMc(c5S+AEK*o_);YECvfzUbJ5{_7PiCYIYri+HuKj=tp_opY;#{Je2Ox`Ftgd
zS4C}8UE5Dv{*TP2331@4?tTex`_YIHq;~mxz?y0}Fc8wEpj$8wX1%fR0i1|qla(^)
z9+PF9W9+od*!R)$($-wMPA}MjjD*kbcP=;0qGHW2dH5N^a8f8capee~mtaKQK+mH}
zNPCs=4(+oL(8Xv^4+;FQTYzb8%-2qj$SJ_BE}z$7x^Gk#zE`v3>$YSaO7fq^PYA*D
zMZtLHPZG~+uYxbe1fDGZ9MWk3+2l7t$OE&YdHz1J-nD9-E1kvQV9IJmaOExbh=5lPW4DJoocCoRBz7FXxn{@IguT~G
zp$CdzLvaCh?#g#k+BCNvB)8hr6}R3^MVPdg^0Z&p^~;_KC37hKv&Q@rj}U1DD-oWK
zaSldeOFY9dXM;%vwe~E<g@`}03kqep8Pwmv_~{K9TBfC8K5P=vz6$oGR3M8^9q;*`O2ywZ^SNK>upiG
z-0(B~aW%hU9pkF_FS$4AL_tdu0!E{M`#;s`%USx9X{S+v{y4%`xQCG0Y6cki@Lgt%
zCj?R1S706|m`>&xF$49`(o%F4A`zu?$Xyib18lh;`5&N3DVymwX(8gOk@n<6fS;>M
zmOZUp>`m}l_6B-4f2yHEq06i`0w*GGh`)9kHLQSf?V@9Eyb
z!}X^xo`HLoqUmU2E6HTS1m))tEpn{-OQ1g-xp!BsmA0?cFr^#Gf=i)bB+K)^K$
zQsjxzgTtYt)cV!`9-Z~mPpQCc(9tg`Q*gAKYE_w<&d1yM{0&rCA}+t}GY6^6$^Vh_
z#aFzwv5zfxan?dn6H_F8Oj?WaI+29dbXQ*#!G~&p#ERh1Y@
zI!$M$Yak}op3xf6pIh5=B%}$d0C?K@GW12N$8>joa#ORIvcv`uFhrGJ&YPmGCm`ZZ
zmMW*Ok4xv^Aj2~~!$MDw{5?k!uCyQ=#}jY`@YLKMOce)=+noSr
z%kGGw+3k{Xja&$pS@{{trpeh2FyhoT3tnLK2skP;IFV6Uw=c*yzppPVq;Jo0Q3?|V
zLg%oR&j1o~BTlLgfzaSy&t~?UP>o%1UQ%?FJ9o3!S+#kKWcM|(UPJ%@9X5&O)xRB`
zySR4gmHMahZ?GS@Xl{lCCLUyyV30Yj04(I6&Py&{V)X|OnVf;P@ZYZru$%7=JCsBq^12p6S$1!ht!shO}xoe=-<6cO@
zG#$l%2-Lzs2qB83kalU$DLZEsBNI$yl#_&O|24Cd4!UCb)l21j^3-bBsH`W5F(=i7
zx7uMyH25_MyfAXenEAG-8-50B=4J7CKMhX;v(;4=$akrC?0|2wXXfh6Q=#^R@1#RL
z`#0IO;YDklrU|D=4LWxXlRwf
zTK;x#*X8e4+)~y5)iMxjW&A$v!BvUj4jL^ks%c^`HX#$a|-tAigQjTQ*DirLW)gbE4d2GEktXkbM7QchRFKD()a|JSwsQdR`k
z4a&9IOWId}8OVMf&s-cZ>6ISlGhuvqNSIQz6lcvV+wThxII5E?)z-tf1TY>%$nx=U
zOKe{Das*%PL0r)~iB0Yiz6d8O+x7Ad4rK|ax5PuTZ20c%g{^*=^(7i^9ot{2Eh}O}
zwm!ZLM{e(x9}l%F2E+C0NFvoxphA!jowG7+u!_bF)CbT@=C)GcN0D~u`u^qb6;F>s
zuCS6s>9hQ=yL#jv3K$%Fc3Ll{@92M1=Gu7t2{M4uRdmK+_+^|5+l^RKw*?qwfi(bE
z3Y(DwDD?YsW@!tQBvi8boX4EUp=UDO1RrCM@o9{`jZ;wY`+9Ebngx$YGPXRb-0!)NVZNpfb0BjN8EWj$ZCNT
zUUA3HM=(#_3iV;gc_mnCm(OV!#1%nPSGUMHVTJ;v+c^mOvlxBnajz?ajaw`4eR!r>
zJgkKv!@-#2ns-tFvF$Iu?6mUuHCqw0rTPlGP3Es$rW8q00zS;t4!Ak`*zZQtR?+yY
z?DNfIu()UGZJZK=GHSaJu-brrgxyHglP!E6>k1uYn=-O7ce0YbXbZ#;IIv_FA6ikD
zg-ZIwmolhss-|o>UNbWzxQn!R^Bb8_$BiJiUIBIiwZSH;MK`$+PWGzahtG!;s}GQG
zOwAk67`&?U#=_zvL$>AD#2gWj#K&e;SBNU|FWXu^-j&3lU8nqxeXo3o*Qm
ztzMl526Ot=aMlvQs>qOm#!T>8C{uLK(5<3?T8kj{h#(VOqHgSzm{DrIw)AUAWN96I
z*&U}GN;2%alRnFF`_rBlPPe{ThOE@bWFcLgVicHPC_5il*}IwOJ|0t&jPpVzX@twO@h;4u9TVJ+3KXGoX^o`P
zY9lwdp8EPyo(dvnWrSYU-oDkRfk!z~L%R69G#Xo(4_o-Sd;i`;>QO2kEhNwkVGCvB~MZ}Y^jrOT>3=Cw4{V+?wzY0lkDJ@?8b
z&Q?9;VeZu0XwEKdrAd<_bVU2)LwZ=>(adUABWQZTPs=$@BwPr;v^1v4w
zis9Sw6`3<g3-
z?GK#dO&Tzs=40a0g|VZ-OEr-VI8zzsT&}8K;`J5||P)D1m7*RQxR=7__QBVko*__{o2#dbSB9zCgVOBQPrgV_v=JAN2czvm>jUzZ-5HGX7a&j44@!lB{Z*GjjL#FN+aYg^i+wF+w5BIMyC
zoEVyqpSXSah*G)yi>;HwySq*}+Kh{G7>I80-inKK?;CDA$eNNC!=|cuN<;47u@}6}MeCGV907!72;|ur>QFQy3DjJ34-29Ip$_yll3sJ}z#l
zQLZJ+Iq3HtqGWI`&5Ds_k~-gv&oOFnb}k~2V7V#$OqZ5769|1C*{jzU7w7SVCEP$&
z8y0YTL%&Q03xSj^=}w|~m7
z&$ek;t+djSTY}ULNmY`?<)3LKH?9%XQF+QA#w&x?+uXy$`eS&zezk_3FK(=+MehIi
zF_W&uK^>b40=9HM?h=yhyT^?$LMBcT#m@T{NcSNwd*8VIl>H}BG6hOrGH3ehsf;X=
zA;LqOfgbyUsmoJ*rN1nj;*Su#y=Hd7elkJ#qYc9=Bu8$;io^+w5^2s
zH~|Ai#=QzX;$KX|?RvtP&rvMaZ}(ar7&6GLWYOpFd0QO!BuG4mV8gw&YICqk8Svfy
zIp6L=IWU0eN}>*-@+EbV1~Nza(>;h3?2sorlp(YWoRHIxW1*`tm%3~l4^B1Ta`}fC
z6As!JvEDTk2Q_f=t#>J25f8Asra>b(Yfl@}3=khYZXM5*f-X`lb7a<4^USZpL@fP<
zP;Bbm27^+Q|J-hWAHhM!$XEGz8}?LXCqq6kujtOPw2Oy8o7wBwa8E0!!qv8j(Xgcz
zqu`kFwfUSn`|W!kGeJo-8pi$ISmg#0lCeg`x?d>HaBmkOcKK?%GQUs9LRHamYW}E|
z#$gl-_C4H?Ytg26F5c>(ma0C@d6-l1+_8TuWbtdsl18f
zeG*mQz^D?u9dt*!PXeLL@z7swcEP;&i$<(k6NPCz`8S_~5t-iX={-|QllU+d;nb}m8mC-A7V~1aXZ{;K|4(i5&~g*=8>$X
z3&UeduYZU|Ba7(s=ai0ZM=W;MXt|Q4nA#P+P;-Z*@S`<(z;g=q?%o=_h!vW7V-~zg<;8O
zZ|4Ds5c_G?l_LEsEG{=o5R9fby)%N3NA1tIi9&yH1A^zGyMiVH-<1l*rh{wy_3+`K
zoTUBQAgFal21_rQK?@sBk#^z=j`}3a_{qLKM0J5dS*-yq`DKF*TANZ{$Ptq!IePCE
z?RDcKSJ4ncMNApb_1NO?@648A{pMI|a8VyC9wCpBnU6Qb5PZf}oyFF36}46Z6Z22~
zOSK^W%+I^m(=DAOiM74d{U+wIq}@waHY%2Wvq&vLv?XI*2oxXwNYi5t&4FJbJbio&
zY&WK!Tq$edDdZDdrvpG%#PdG4?Byod{L(p{LQg$mhmp
zKW;;Rlx{X8#CMGaF#n$L(9g~`{*@m|#8%+Fw&Yh$&hqc*#F^k}dn1mNjhJRv!x#*E
zAi;p7{A3wSBrNR#EIKj5u%RNr8^uJTa-Hb**k0H{^ka6WbN`-MqB35If+
zP1anmzX{lQ0O7YqZAdBNr;HfsR{ZCqe(i-=PAz46wXuAFZA;{q6VTRAf=(4DEFS2fT6rY%wWjNx0}PkCCW*l^ksb5
z?r3@f*9%eP(Z)w_KGkoKFBH|2otJ)BX5&B-DZK!1jA(->Ui>hT%*T-0V2`dj%;`*%
zq~Ihh;XGcAlK8BmYs?7$&^)VNi9d%G8uSmFup?Gjpf?cM!xn5k*evT__69n
zxHi_H^sG7PD{(-%WqY5gT{1l!KBsDhRWJstrZ`i6w_cFFF5_9gcRt5n?i16aJ0`|@
z0K1)`&{qZ2_4)%znZ~3YJOPz`sMtq*>H?2Y5Ts%)yfAxiKp8
zl~6F=p#xT{H>0*nM7!B`hK730Jz}5BT&Ia)?*8J=)g3|_7eL2X!Z4B{1~=INHzSA5
z)u+@(rtgeyb%0Ql$BYPHw@afY
z3g8tgX}Zp2SKNKEt#*3ZBX@%j@U0XAEoo`m$2Q?5|F@Xg$4c4~Ze
z`g#Ls)>G9HFfXymT&(z
z%>GCKWaP_Z7F&>ibtfO;1hwO!9bZsGm8uGfL7*h?)`9;a{k08?o5sh&zjq|bLHuXc
z_j&q8MdE<~7L(2Dha5zACL8z*p3cDP`rstn7^*3r&1E7?PvXz=c&foHy+cGMfIgt7
zP!W|kz!+e^BJNx+bb)CD06SvY3oJCv;fU#AU$_?mUZ#d^1c*+o07zu=ux90s9bfY<
zl|;(zaI1+T*x4=h_sl(ZNXd?g9m`ciL>4d<*h&*?WL+GqdG$+C0XCWWRg*v-E}f-~
z6`*=hVtm|U0u}(?$BtJlQT2Lg+ZHL*SY5LT*r`}?bP0hK-38275Fndhd{dS(@5xtr;k`*)KzQ;-1khUU%-~-Qf8QdgIUFAj9BN>R#T7vYD?`zfW~B
z@w9UO?T
zQM?!OE9fFr(W%#P%l*zQ6e1A~O^GK$-w5?YL0;qy?_pFAY{+Y-oCy$bx{a;zJr`
>U%Fa_v@3x#AMjoAvwYK@oBOE|{+OoSD&UXGcS)}(2r~T-XITv`
zTXX=xGSBiZgyhm16klKO=D=~Qpp%bfD+JLmV2gUw8xh^g}50D%Tm94`h24FxWn*4`4a>o2^wE6b=?TNr7cK
zaFp(dF9mX1zI?EzEMkJoymyShDxQFH0UjpT}yQgX0X@<95nSs
zEH&fKQWT^LY9DQ?a|-p6i(}7*mW2}E;5#31bK!qfC9At4<7{Zry#wQ1{28w{AeAmT
zaH6$oqfwISY~O1rG<-U!k}jVWmXOFa0@{my@xb04*c}RS+Xz~g<~b3>psF9AKAwA1
zTK9|64>mW?4_qC5C^)L}Hl-4JG&5`PiTxG40DsSY68DCB5zEXFnT}|ZMS2Rxo4Sk{
z-fPQK71g=lU}B42`O8d)1dPNIoEHTI=k)$FGeYO-J1xUR>l2N^x{>HW7|`+bxJYTf
z|Dv_O8A}nm_y|xEP9n+kD6c#I*2|vr>L;`X_)3+OIx1N%v1J}}wNh`HVnhuYlet7n
zf%Ng|UuFuoM7kZ-KtWPMwDv`@`+#|I`;bVFo=b!NIuB4V^YePS6Yj27oza4y@%i2Q
zejH#hu1D&?sb0koUM2ppn9GmkmONMY$gA^l1ov3tEcmWV@5nUU;1O+fu`8S7FwTPf
z5A2Z(H!}8|wV(^8UQU|C3>7yWp@LLv`}?9}d(T?gVc*!y*op3mLq?d9Dp^8^V3}@)
z-R?Vg2F9qEj6o4QL+qj-Q5D@?lMKKvg*0!TwY$EJ%>f0%?MWid)gcL%S@3C=!-)^p2p~PGU>hXv=9QnPUHdrw4Kg2e(XXsoV
z%Wy{e^KP`~a|L5G8OMptG}MtQ0GhHlyVJSxFXPHbi_8Egxb^B?B3)>!vD$B@?7Ui
z!0obK!yHIMFLBCzvb01Z@ikK5wH}iYugO*Wh!tg6eufV4hL|5Gftj&mo;?B<@RIg@*cE*Hc!D
z>=+pV%M&jRm(mpS=4supE6>6>kkeDE@}O{02ZM%3G+;4MlAo3#0-9%VQ!-4Ab=z;_
zn|jL-Cg2A#>=(CPvRAD|Hi#$(M~{Th%I#)u=QP^$h@1n!4NjUDCNkv3t#yT38%Y^D
z_Y@6=izh`JFUHZO^@yD4|AA4`w+0FtyjmJL4>!mb#Rt^$+j-79FA@`4g(0tX9MO&Xb&7ar*JCk3qaU`X*jCl5PZ641d
zd~=y4VDVE+am5IzM5DSzR`%JbDr{45cz*g0Mc>`=3Wi&9+s`2um~JvJL&qPuJkiB*
z&)wW3B8v0tL5A#r?!WFHx;$rjP=5*+Ez^qd<^kGT4*B90j#O-#PZB36OxLAD*>gRq
zGV99`UWDJo_;jZ|7993UwbT)uLH_C$6Em-
zyZ$EHKsGnZu>;=bF++6ZxsquS>cQhvifjnYUsg`&sI%ckh9y#iVe^f?ApR=_0MzZv
zC(%VA1Bq1~fp451Tb9mp8TnN1#>XXnT5}9Zj$#zYyeljiBc0Tw^^d9IQlVf&^rcS^
zYiXw6oBgSt_4_mzcZp^(D0-~dgFgRT#8YZAx-=lFoC0E$nk`O3*gCS?*4}knaTk^-
zl^w+)9%lnQUpkS!icLUWAbICvhc!OlWL*l-wffcvZ5;Zu51Yh+d-&>}O>o>!sZ(8ta$`$I{o+SLIEz}9@_h2BnQy@dd+ib0d1+&0n(6NT>0
z^DjY~8sCtH4Rev8)Hi)U_x)HwHMhgXCQy{f4A2M9TV0{um*(tMKQ67Xsfpl9$5rGH
z=RI`NXX*#`a&YN`Dq~=10ON!PO!O37fCvNx)0#9Q-!!8fWQHVFwx`q7PX5*#MX+xa
zQ9CGHay8;^&kZl0b!G&|}lOh8SZ*QMXpXv7N
zata{SqE`Fqm5VRbr-FhBE;&+yq%@>mDMt{$xL!h*JoPRbY6<*{e0Zsa$U;hA(vrcX
zjbSR#5Z{^8|FNzTs|hG?I0*+`EWz|Y;2u)|FF#`knzAz6j&~d}08&%Iu^v>rH&UNu
z9?_AD#L8J+AICA_Y>M|{5H26W(MQ(uJyH#FFGhkvg$}te1vLuW91e%l_)@NA-Z#ed
zJZOY1$kiX!wLY!96S{gw?D&|1{rmV<3`f{=II}VKyhbS2{PXweuMeaQ(8KdiF3M(m
z!$?Fu4DOk(BIvLPEw%*@!L}SC_aVq?9Lc#^fFeiuNzZ0hbQ-KKKQ+)5Z$_uuqATUz
z!$jiZ>n%eqq}HHcw|)}pigtN_N+ylR3Xj>>#IO+@X>Eu2>k&!+G7ai%UGC^bj&y7_
zT6$1h?Szti;i)&^k&7o`9Q+7lwc?$LtM`A=(o<=2bi@T5@F3w4a5*6Rd1*%gM@oYkK;k9yl<8CjDT
zv1(MVOKl^)!@%xgStUxq(?~mH$GWh&6wO7L*hTJP70`Crp=iN@O}!1G{i))Svc(5%G)8dyWiy&z!K`VCg7Fnz;|{W_
zF(EhroK+-=%fJ3`&t8_&1QGZjnn~#ucOp%35P!+pkQ`)-qBUOz;V!oh+1q^q4zjpn
zrfR2N0bO=h@RN1}hgXCoCK%~;v=@RFaAE$kk6jYh8Jhn~2!E1Vts6_(eUoIalWCM)6@w?Z;97bl3`rU^o(N0
zJP_%zvH#kQk=nwwsvR~Lr>I!(7OgP3vYI3-$WePDdhOZ{ee($Nldy;7PeVX1-1q+*
z9zPt6LypremrGzlrG>n`C
zlvK{E@EFJLn4R+tBQD)S3kQzSC^PWhVf}Z1Aard@Rgg+oB!8Z{zJ7xd$9wag#CzDwNs%w>|;Dol7dFlA2;J
zi)H-i3u04S#55x{2J8vOY-0X&|Iy0Is~1MQRuVH`CnSC>Vsyauo;En`B<`*kkkOws
z0%}7xL%vq~*PJ(a6ba0V*o|^BKwcfeeF|ADB0i$#mFsjBEsGcJwXmvF~w{}kBBAhBbeJ5;wHV8USXC)gi{7dshZ_6BQQ)Q8A5uvI1j^H`$
z)<3(`Fn?YTX^7kyI@IJbeJFiyd#~)&pDYnQj<`_6jMQT+wCzegs$poOJX-|Rby>mITMIgTb9C0QtVwgjlwutGZyo
zp?>SvIm5r{YD7bvI2G7^Os4Sf)EmO%y8;5S{`peast0J)ExyO2=?JV~)+c3p!(BVz
z0J8!B&_$|DvzWE2Ut3R3>Jq5+k}A3y%DwR=EFUVs;?X%Vl(dYYqH+Y%wM9yIlKWu7
z#nJ|Ocx3W-9ys)7LGXk4+MyG9hQ^2{JHlZn(t?r$OOwCF
zwXv(9G>WOlI(nc7Rz9f3{IUDI^QWE?!v%N7tzGO+FM4iXmo=YBMQ^g;`nb(`JrD?Z
zL%tePPn?tUbf>v)0mfTZx;ucJ{fYjxq~A`D#9o<{9{S#;{cMnouGshIyhk>D&lj2v
zX!-Y4HQ*7$rnan2=(|lhL>FNg^W4k(+J*!4wJ^ZZ_
z7{S(35N_rzq|?e!V<0lk-BX|dV)SO-(B?_ptpoLiui>oydRslH*P;)*p7J`~lRoRl
zNT^#6u>($eLHRS;3_8_W{&E4cMRl_H(?&-S8tJ44F)h@G
zosw0e^KI3DYT~Q{)=@?I3{?
zn(Cr{LaT2_j-&VsU)XEnhS*BUagKHTc~SK|=_y-92?Q^k{>hgs8(AnKPpBR1eO#L!
zjEV6OF4g^Y^U&N+rCr1mq9SfKn8Jn_Q$R{w3V_uCcdK7y+Y=xi}+MPh?u
zXiCkB?GpbUBmju))Jz_dJ%;p3J+OHWgxo$v?t~P1GOn1We=5#MSp}`Na@6?6<2Rr}
z5tw4lC+)hDmww*srbd>Fs}L1n6=sma7GzM_uIlgzWwyBiis|<9EN6EAWy0;UL*iN^
zlN*HI@gLlaLEeUqhZR6>Vi2NnZ)X&NZ15RjC_N5kxy-_Tis9ubG5~Y#i<7{dsrqGS
z2M(V!+EQ!oJD=ICXGBNscERY;>e`)TDgj$79=A05RsROmub?v=JdZwk9P=Rg?tP@%
zU-lf?N-zcNeiSvIxW84Zlh6WnyZ(Zqq^bfISCM(8W7*?M0Gc~M*BAE|>%grzY#P@<
zAQoj2AM0Y0@Ytm#j8Kg@61`li@j)+vN!<%}Mb&s)zSNPfIe&&H1jZ`{sNkf#C
zuMY!wNWQ3h(aOY=?w5X%48Ja|rkqZwnE_F%gXlT)#7~Q9PNbKrjyvKN;cY{7?&>TY
zy(Azx294CnMxIBs{{D0*18V2bPQ(_Te17C8NShR$*+Ey(Nox2pR>(~k^W=~>u+UwI
za3d2?wtk$%d3C{*>p09=5(wO<_5=!_j3X>brB@ZQLI-I1n(~6lczHgn5ff;~pT#lc
zJ#f+Ui_Eq^>%&t(1!PP^b|wk96s@Qb%t{%861-g2Ec3D;#GA4D+1qvkwll?<0;HMAcVF9^x}(ED6Ae>!(e6(_Eg2ewF)a!4zq^S*xYi2
z5)nj+Qj4(m^h79ZX)CO8V?;K34Tvq_eHHd^+5gNCWk^n7lrb0Z9*)l=^$r`A|JIc8
zp{doAPyPE)z$XKK;?*+Ywc>Iv8D|414;FJ!p0R&5773W!If59x^tl?J>Hq{4L^2t_
zg@=z+{=#L%kP05IpD+EmYOh?>1$9xHW!jpqGdhi+n&998>};jSR8yw>;}XF|&_aYMov~$?*4HCZ=Rp<}Cb_
z^S@LamYY!9%mRnD!hz5S#4f`oGQ@DyNE_vsB3)as0X8>*4|noy0>2FCw9G&-tWn5d
zvvp$ljC_wd`+4qJ)R;YPT#la)X}XmZp?*Y_Mm&enry6-Cy+W$D%qED5lfg4j3WRB*
z{KMgaH)eD(uDd@KgqKZm5B8G%!>(eLGW|>ix7Bb~*|BUrp7;h5I45?_8UWH(MlWf{
zy!RqWwCX3MAiIgbg5;r}aUJSM&{`~w3q1?y6su4h4I`VMJT(93cAP8x1`9>8np)x2
z^+5pRK9G2G6ujo1P&$o5Kfv(7%;!&9!RCbh?zZ|`^rE}J7u?<-gE~rsEBW94=POiC
z1cGD)5bbbV2Y!+T>CXt8><;`O
zHKq14dT6(snKkGhGI44w8(fZRzM7L>l9kVTuKE!l7j7Bl2rnubA$_uwZtHZRC1S;<
zh(#gUhFcjs=R}GOKo@_r%~d+|^Q|hzF*i5Lp4Z#Y>Y0TWyv3F2FiZl=;p=z3mGT_t
zuKQn5XR0c`BEb;2O3S+y@T{k6JeH&r(}{~&diC&v>~e64ZNlDYFn#^z7xni#6fK;;
z9s5Xw9#CN4qFBcR)0HGw5}qO)E
zi)<ipQDYICtG<#tTCFo){1CNzvEBYVIVZLri~gapt3Qe#(%Zzi$qD6H=oOCjAwz
z2=VKuUfjSXA47wMF@8+5a&ebl%R!@*p-4xcP}CYL<%_dONktcTorCoWcJqwGUxx!>
zT67jSSxgDuR&t3kYkSg<4>!oHL0=I|$sXmKgn3=NDRc%$@0LWb^UP$Ls7lPa1Z;Uz3L>m2>Zl1mLe6uTb%A8`7BPFm|
zr=7*Ol!Ir-+&U@`X$+Jbva7$rei8RTPsXsUAi6WwHIuH46jdYxL1q#t$uNQ@)R*FQ
z(E2d4<^e(g`0S$t5`grmTM<&YEY@FG2#Az09#{FXr?p)RfzrcdZX10A<@jE?`s*ShmH!JOc5^8
z-0T6|o6b
zr&v!yCB$=BF0OBp&6EjKs?>+twDkJr52+%xuI|W3mW(_a|1DZ)2lDa%6pP!tY&SMK
z^+Z;1zM<_OHP4fBd5Ni#(*H$0sz4p9E~yS?5wYV{{njEa;|muu?wsmKy1a?qF`9&N
zUWzGzMZ(q;ojFam04RO3kMNGp*uoU*G0vQbj4#7OmvdyRqB5<8ht<=Di!QWD#o(da=
z9=FE4fPE7M`UW_q_RjDvrB})(K>)($>CzauX7SF3xI~A1%R_okz73oGn>`5zg_x{r
zeUw{ZKD)K~F2C#w^6EE}wnf(p{l)aB_HY+Igl4ZPXGDZLL?u>=k$QL^(W@%|b%vQf
zO9Y?lj!%{Cs}o=?<(9N~ad({gfBU8pFUf>j!i2x>;lu}_7~GzGDe&re9Dg&XRQroe
z%^Z_2d673df-5gWRzi~Umh7KcETgbkI^*kgcMf;I%f-&(sDkr@0=okxVjrt_>Cstt
z#DHg!0vjjiPAIYSc`VXXIcJEgkc|HGTzXa)9#yyWSKzX)pceD|~@~Z`vVI4-Q6imt%c%?;Y-;Kbo=N(FP=ACHWt@
zo8Jf?DnNFsFgmwx!(B2fsTdGft?vx;9Fqgk8
z12}&=`IbCbCT*JCT1$C=RYo=*V|?*mlUy#Qx#1>i;GyiUJ=3^uI`z~Uq!OiRm)I(|
z8z&vNm(gguRjnhm$6#X&5hhiZ&nN_j@|0HHM;ao7HAlYEB=96QSuj_KGT{!nBdhvV
zt|eIMyuM7%Jo>koRz();*X2IahMugBX}BN|ZSCS&!CP1u+)Lvi`qH&jp<1KJ
z=j2M9e3VopdxXg;ediA>iET)-l_%*Vxw)I1zhn=`utS$c73^~XtA$_I-Y^+2g8wWb
zr?f~}8(Q_(_U5|tv_w9aMlOfTMX`N?p-1=Fs7NZfI8#Hmum)mSMn+KaJU<9Jq^e_;
z=z3Vvye0lAg%KQ7hK`eDwBkrlC(9DK!v3u{86Rb1-3cf?@jfX^k?UCGgSjiQVTVta
zqgfTG*gud`k#NPyunh`f#C9**(r9#W*RSIWmT?wwfkdDy_{pR#bAxME1>Ep@D_GU&
z5&h+De0S4zvqCd}1uh`n*;ieonj}NDC@=n^NWw%^tfTpf>4(C}yuK8qBYRXcwg{U7
z?T2SYM=|GqvjHS2`*4ngaq!4-J6{lkw?f?`iVDr+i9)R}zj;NfS3>lAx{%qSw2&0N
zx(1A6zckvnlPCgEAtaBe6$u@X(fMe*5r
zM~`)<4d`rlsw{408LTh5zEsxAj^4b-)7oqg(q@%@@qdV1JLe$rJjiyeM1o9|5?9aM
zKqgwGQYB!tOYd>*$P}#obTUQf7U%OMj)$^kFbl~sOu$5)eU|1cxDaHjFLD_62c@L2ch^?2tL;t3
z(|q#nD-`ra(h=XY@NEf2a!olu%oj@t1ArfP$!5`V-^1P95Jew^>qK559YU@BZ4n8f
zyk`cvZfqJXos9xs&{Lr8V2ZWahCcEQ%vY-p6TPm!8ds-hC#@?24VT%9Djq`jlt1R3
zNDe}xu5&aOpk*Oc+_a2*3_Bd;r8zx8(IRnS8Pwe5Uf8}X^cU;q2|D)SX8!blh`|Gf
z>IgTa&XURwibw)i%fBzS+36eUw8@VXKhhO0$(knP{VA7WjrsavMoi6kA+CbgxoqfK
zWpoxAPv`1X!Qv}^UCRhJRXnZ?v-xf~F;puC_Q61sSL+D>YJ5Oy3DryNGfg#_=|;ib
zW2eE;GSf0A@`@>hEq(B!`8)`Etx!C121T|>Aq4R1Ecqz7xby?`gd$3e-UtGXIiU~5
z(@e6>KB>OuyBEa-xW<`(c&Scdb>Jp=$J_-SGbaOflXST^sTW
z$12~qN+;)Lymzlx*cP90?yL{Q&v?>jnjnr;e5y}AQs@!pj1>*idqBU{Rl`ijU@Hs-
z=Du~6U@kHh2}a#EH|Fbjv9M2GxVzUbKL55rx8j8bKnUZ|JqjwVIIyRhJM8hW9vV_&
zWee%$l_+%+#q??GzKQbt=F6mqt1UbY^>Dd#xHb~tAWLb!{)CvrmAet%6NPDlVv$6J
zO*z7lsEtcMCbPn5@3y>*0Qq%)U`PM*yK3s=bM1Y4=YbElN12{hY;7i(22?
z4UNbR9`Q69x4F2UnEAc}Rs>k#SYI-fpUoUDHVvB*UHfYxE?N!V25ljSZ+(dUZ%_?!
zJ3+-OcL$?@U=u4JNc~^%h;_6!%0InNq|aZ7#iVK*ko2(>3)znLKvbjyOzCho3AO!s
zc>-#D4sTwUqU)HZHZ<+lN9qO=($)z>*d-sIZZUOx2G;^@^~%Kcyx9I6cBFyJh?e^&
zKxlX@Brqz=sUEns`sp3b)
zJdJmg#&C9S>i``s#jmMk`NI^AzbSLV&dYR?aVm{4W!|oWu2o^QyWTy9P67D@JR3P#pMz-#?
z8)vZ{(~q}I_ff~=@0j9X^dws{_dbPA>_QF=HEy-FuUZa*pxJ;1CYT(9zdPkhod?UR
zKwJm+gwDkjO9lDz&cl>JRkX@t@7slW(LakFdv)~`aW*m9<%O20u!2onj9GcRLsi3^
z-}Do)Vh6QEK>tTm()XL=8On$E3BN1388>ZG_@xQ!-WAX}b&%2xCC
zC_x864n*_GLxMfKoP!xXNRFw^58h(B7`9FO+@0-?7-wZ7{5zo5!H#`eeM7PrHbSi2
z_FXg0%ccS-H!ByFuUGDl7qlS1QQ@`bA5^MA~KU=Rg-#{N_pBw2|7UiZT^N8aAMNnk)n35lV_W^cp`A(6OQw
zGROaT#wXyLq><&}tLxtcq0OnuN|_PzqFuVhE0Ma)W{=V?UDTY3Z~!?fUXZ=h&dZZt
zw8pNWmDS3l%rwtV=wo0mCf6g)t;nk5vj#o<^M(9<(!lW&n)a_5AA(divRR3f4On8(
z=zT^9iVNef67U9$0&+VaV~Gqs`C`$
zL%jHLLDriteZ0lPubdUB3hEJ=+(%>(4Ya+!rr?j@z2O8=8Okjz2{dsLd|`7v`J;fSsILv7)ikQbm+xv%@!y74=W$HDkVtU*64Y
zTbhcOFG*>4iX@iYP;o+;#;fGkP=f_P#)WD>E)Yj0DX;FU-8IYVOakFN;*K$7ys>8N
zTH5=^5Y;z~ac@mCk~Vh2Yw;FqanO{Xg7NnNI;m1Wm=IMv2!0DmgBBn6Dl(FF+2g^T
z12tWpDOJkE69RE39K~>L`qZ=L(uZRcg>r$30Y5m}S>m|zw&dadLF!IU>NW|9BO?20QRpK3;FM{_~mjEd>x>{2=Fz
z=LT}HTwa+XXPSONwvL|hqHgp(ru*g**D)XpD`
zWGXix)dCJOj>6Jl@P1m3FbxzONR+u)8kK1R{l(n8yZQhxhIT7VkG8Ve2#J{=laetQ
zR;n$$y+shIn{(jhbfV~STPYH$#TTr{fJEF((-aCsdE6#Y(YXf9SI!|^rl-t%R6OsZ
zN3XvG)$>0re}VvkKPCmrSG(a5ldz61%7s3MebH_>l|quqKFB91y)#(A&!&v%pdL=0YUTmFRXkcLPtDCDP6+
zwYnrUKsTUV(2~{MouSz9U&Tww9=Z^)*4DsI4PfoSR|1F#oS$Vq6@42TKrRrqyFPbH
z(vI7Wr{gjc-q>!#C!2J{UF$m!W0irxg*)?LuL=#4Wa#5`+@nmd1TmVukGa{UydThZHuINoG
zTl>C^&nKd5D0+jtdik>)9ieW%$8eb6W_=RXSL~}t4rM1}Rm4P9Q5^`<*Aj1ATlu@L
z*2(I>{Blxz690Ip!GME~q2WIv|9;0vNjmi7)C9OCBWG03Nq0~TW-Dc*?46%YWh;Yo
zaG4|HN9}KqnvQ!qM*r=!|9!L>3}V=L6ho}1M4kZ9cunXlleWAgQMO3C;oO?gA5A}f
zf9=)i0gxcQG4C)Updg8|pJ6HFT+(dsUdtR5@#%n$W37O3Q(0uk5evH96+(tqjpzA#
z6iA7ATE0}U_BFlKDdv{b4DYwd59VIlz9Y1Ql!z`?tukgE=nTePVs{tZO~j=9%4Jt_
znHz~-Xg`i}*dCB+9p({DL7}T4P}plZhMrW#`_nbTk*7YLIviYn^^i%8*>z3D|3QIY
z^h*FUc@=FK|^8%$=MAD}iqQPYb{=#8}E22U(^5{aqNd;xU+Q+$j`$c^@KCSWW
zsN0PUn;@oJ89Rx`8kq5;&{VNtjbu)CR#+qA07KX>wGO0jwIyhwE9)vMQG0?xcNyg-
zw0`cokQOv8t9`s73;_59qrUk@Zz?%!NsXG@u^jE?sih(ezq?DNzEA4_48vtY861F*Y)jMy`o0Y}csYgJ`J4&RCg+V)G
zLKiZLOHn5~wXz<7_6|ZIF~@Hg^+o3B?0S9<`k@nR2T$gvv7j}iHK2HTdDmTsj*~@E
zllV`&8Cr+LNN!N)Mt4!WzFCA=Ax8gZvUbenrtN*5)jFJju6U01a<=&+fROt|eugSy
z!Su_=7XvMmXO{Bl`v9lWZ6>A{`b!9Uf$g^cjCCoxWN??)Lg@Yb1l>k>XhS=-wK;vg|EDr`c}
z>3-s$a($b9*-K7&0l#rmWK@PD{2_G-8fJPETH)D}?4^N~Vp8QCYUySC&M0jM9E6@b
z>!UAu$lmZM0mG-_MG!7P&R!w&!-K?-K#x}E;=~7o6#C1G&S>S3kU9NFzk;7INJ9ps
zqM-XSI>44HHa=D-X1&T^LiM8P!Y&&L-(FOUDaDgmUle|$<^&2Y`+#C!24_YfNN3rx
zbP5AvVN2Rw0!QYZ0&Sn68Z~8t|`;K8w8lf(%zG7|M!B=Zy)2eC9n+z
ztYz`22%VTi#d)7VvG%t(5in1`te$P~5qy_5pU30&$Jrib$XJ^t7sNxLP|uxtX3R52
z%ilP6e*5TKtLsxWhCYdtNO4fO#%qtO5S&hNP6!h}LCKU33)Xv!5+a&UJT>$b(E&in
z;bt7&w!N6FlMQ`KUW7&NbpSk|ygzH?WCGUC(KaRc3$fmyL}GvWf2+5Rb^Gr5Z4eW=Y=7+E1o0B<`?39`7<{?#*p4O?sHgE40c*d7pBQba-U?bbMRycb{NEJIX6k&)9elr+~Zq|8_$~C
zZT9BNG)+?^N?`%3JoixLF7yZXZmS@Ub;6ttiYRag|NiVJj;yQ?nS?1a=Y)`U-||0(
z_9miVlVZ(WLrNI*79!I6_xnbC>%TdTRH!m{bl6z)hqy=Z2W9)mxE`d9+>Voj>YinI
zJfHqr@grx^(ij*THr#_>xo(1yZ@ks>om%R6{RS>f0WeE^8o@MIyO5+;Bd&Dl
zV-}EDEf|E%bN!`9F53T*D%!mr*~WGKmY-M?FtXDSbXJfc7%l0-Rgw?)%mlXlV&R7H
z`@1-?&@YRiA`tOdgolBs4gHt6Gnp1xRt@v^K(^YyT{JsNnyPu=1vr4U~f|!q*r)upuK2NhN
zSx%2J<31=;rESBJ5rbT4v_!}djo*Fi-C;Az*#4${Sq$46Mt%Norh1?@IEJcgcz^~1
zGXu7QCkF$32$V^SPOp5E*YXe)_%*m~p5q@mBhnDI%B*U&L~(7uUf!8yXU-B=^V&Hp
z{Nr;vlsr$-RyeP#0Z)>2BJ?-x6N~uHhj(Wdz-XP-&DiS56joYDRqQ2TsN!)(Nq>e7
z(EaBG7u0{}>~<};aD%*dma&x_m`w#qm(J>&yi#9_nfXJsa;tL16zy6e_5q6*87EA~
zP;HsYzeSf7*Ty)6XJ)#)G&pin!@W5tLdzpRjXDQTRN5jS#LlOz7qte_QT^E6o^BuhnN;2f`OAAmdbx*vSbmU(&#(Nl4!D%$m)b&5V
zi7Z{{9PMF)#y~wqJ4`2mQtlAOxm1-pc()RjDG^=iVH7~3piBil=c9c5t}Gn8!(zFI
zsiMzsR7RW$L*ngSuy739XIR$(zhE!V28cwp2e-(-76T!F!Ezab4f`xRirIB7#E8k>
zamfk}L0f7{{4P7kZ$h|p?
z=vR|p*m3MRc=I^p4;I|hVNSX3ppZ7ap7Ff+;5;2Y{%|)|T+5LmZPu>d^gkSfP@;vF
zFoMlkQ|5_CUpd+-JSd;ccZp~0Y2CFq?HEeI2%$MI_(cHAq#z8ob}zMI}0p(r`6(m10*
zc$Ru^$0@!S1@*e|H`0buHHollL_XFWFD>nu?5SkAA~{wg65^8^G!I
zdGuAD-t8ZBEFtSGj!x|L=%ONI?>Um~o9B{Wi7NgMua^0w?(l&i%)??M%#p|AwvsM7
zpq+iY_!p`4wAA4Aftct}eBS(}+Md*&lZsLnp8NN)vo(uoOwjlGI1Sd#G#BR3EXr1j
z`n9eqWNq@DIG$b^+iD}r7y2MpO#nsQ{Kf+S6K`W&)W$@MFQ~#|#k)}rNWisP<~{X6
zkbQqgzXzS$$S4=`r=GJA84pV>nUp22o$D0dz_rO+i!66Y_t7eofQPxWAID`
z%|fDyjm=NT*Z6YosC84bT4PsB4p^P@RS;v(@WD>^p-@R5SgM+LkwyT;11bcI#_GB{%DDRG#ij2zXo6w2d+u!OMImuM|+w2N2l
zFhP0i)#6vNjF$8|^2mBWD3gl^N5g&KZfo0_G2=wsLgpa1A^8L6C{TwdeQ4EOZ0d5p
z@7#CdFN}dasU2IxND~KWXzc_q{E#I!zrXUI1v#mRHk*96iWU2R)aG4D5wsiMA1tO=
z)DeYxaL0r@cd*C52o?I{-`ODTS7)&YU8ogRyZ{9E<@=8NO1X?{inq_>hPkve-g!z1SH;qC=3e-`Rbc-5Lm4+*$A
z<$g0xUZBmOJm8t3zC|M9Tgqw_pKTv0Vv7;SaA$U$W?xz^e@u$`x(1`e+nAT}Bm(pC
z=y^OE{ms4U_;}l$`PU+rG@@=-+2-J_ovvd7(4%@RDgLZm49pN_F~K>u*)CEP;gT_4
zd`PPiBEBQdyclWVFvZ17S?*b4*t&6)(N#@vBBG6zrm&(6W~H*c8iyg${baO_ttrAU
zcmady{xsnJ*kmW(Dp$WogVPx8Nsfqi_AzMlswvyxA8Kc(Xm1g`rb=ZeX)FkyB
zA_59M<|UUDGGJ>Dq9#{JqH(%&`v*+c8QjdSU!27ELSS2T_;6sZYsM0%690HLGY6R1
zxXmvS;Hwn0U+`OB!|BL1Z6TAPd55>5gD!(t)-w)F$$zJ9ORBkqn?X)=gwgL{PS7$0
zB>Pl{57>efsRb23;~R`MPh9_$QQ}XNu&hZOS*U@0_p%_n0?tSk`-RwmG=o(Zt%LSO
z(MGhxZbu?Aet+S_&`Q5iUZttGe(dtI^dBmlgB9aj*BHS+Paj)ljoGQ2+~DgMk37%(
z&l&FP5AGA}I9yWV2-Bu*lNys#0*F3dmS8nEZBa37hDbSROr@-35jqO4Ltnoyv-2h*
zBH!%tBbC*pe`p|zTvB1>hzt{Xr>_mKvhWvziI_%eK7$BmMpiogMU``OG8Uq^V;_a#
zyVTHC2bfA^!Gb95h`HbO3Oksd8PlhYdh!Zgt^Px#8+u|CAP(p%AQD>I1J2=P*EHdp>h(eTBr^X?Ph|zs`dZ
z=jG$IUGcQddO2Tsp;)`)eX>{xd)vYh%eo9S0Ox~gYd3;4=`R5~%Y9DxL};b1Ru)9Y
z!K;K4Ei>C6W?U37$3o9*WTI0nRCgjLSHg76Qc&JR)7&?|1((S5l`SBcn6fGd4P59q
z8O>}7qa6OF=*cbVyveX;5Y36)H9nB1xlbAHYW$%Ni#CO9{n(Kp_mTwjrkPUytkE9T
zC_jwYT!u{(V9q(0%SoS*Bm3{B2%egvqBcKYUEw&7^y80J2bVW=!GkARV$jGnkhIy9
z`|;0<5|N6{1_3;5XwpY@z3(e^uC1f;T$KwsK4}}=A?t?cU&}g4sBW3jX-Ck8E1wdj
zg%@>tbGP9w3*fW~ps!uHB=Dx0p#!E0@8z^m{u1qo6;iLNdvJz+#gnMzFMwviS}#DS
zT}i`<(XYPkrdqKZ`7u+Il!rKxhrj|*aTWOwpOMqK0$l!4tp0ZvAu)v=g)PY!p(Cm|
z%?3K1=ONkX8vzcb>$*3vd%WN$TVj3C(0gA?y5d!*I4wa%#NuaZP}e%?v^7@`i&P8
z=5OXI5uv9o@)n}6uXVK#a&k?_N`TZVTUf5A$Qs=pIhr1_$Ui6GS4>p*U?mb@5>k;6
zNO}66Ep^eEvTK^*;!=(1LIeJMI%RBtGHiL7BVJ*l316Vl$SG;#N@S_9JratT0jtTD
z$8C8YvO+Lkj2EM37p^jSe5cvHzC5xO%K8v9&lYU%MUIf23EhV6EwbpYPk)l|+&Ql4|9g!?d7WGc8xCkVPHN2NEEssg;D3`zb3zpF`H-7jOU
zEtG4kL+69Brz;wSx0(Y%nXW4pBr9PEdnX&W2Au*0V#xM$Es+B3HHVvJ07SoQo8=h1
z${lK9t2K{mO=smKF@A_@~EbCIT~)Qk8=%c
z@fxKFYF3S>X}hcOm+V`|=FZl($O@T=r8M4VxJ<{IAEsNv5AQ`O!-3#cC0dA
z$*r?x-5*k@0R*pDG2bgM;7gP%9_8Ao(|M!-P%B1jI_BQJ;R#_V9R|p^0%xS5;m5oL
zkuMtnJ%7S-kt9E{lZ`niwA+YzsD4$G!HAm;8NUP#~w55|6ZIda8!$gr@lX
zgXw?G)Uqq)vcY|_&kNo)^%ChY8JT2^0$aFUPl?ug6(+;o$dglr%L8bK)WwV-)jg_kC#&JQP$TSD{+FwqFc`}hc`sd|8+keaK
zIiPH2nOg-{@pI!OCxwzg=+1yB)9^2vF{~3A`@3MbVU_%rCeQ1;i}$gsSn-H{ORanm
zZ}1kwPO9~7%LHQk>P2{?QFwP~i2lK3c;RnOgd$Ce^vRNVWGhyzQdZh#vg_IF*$F)E
zGwXc0Q=f*70ROh?mPaQ3H*hsy*G$I7@adAapP5bGI4`U@YpQz~r*g%03;1EZq?iKu
z?#sr0Ra>=dt`4CPQ>(?8&QMp~zhUyPzz(R&0{=@@2za`_rc>20pSGtsF)F56FMU<&
z7JP-VO%C+^usLbLZ>cfWZQQG{K$RP_$M1f=<`6`h=x*MoL(c1)@l34i^@6!%Eo0Ce
zHcxEw;qPlcux%>w1XH3wg4ku3thRra8_l}$mVnn!*TQ16jWY`H+ooF0004LBHlIv03iV!0000G&sfak;bgHBT>vQ&2UJ%gRpOV=n
z2LrlYLx69K3#_U(S_h9PUtKLlAd>g5R*bE}o|tWpayH$mv4pB=g+ZX{tOTp{{4ofn%|~Xs4`_W6s?2G1A`%9>jNs
zD+o?r0cKnhm>dne5(>+yo0993%FAUb|Oar}bT7ihO8xI?!YnU$YdXH&Y@Sc^rqO-tbTL85LBr4Wm
zi2;v3@2u{iy!&y*ghV3Q!hS1|Jj?H}s!PWXc>NUmwJuA5cwM}7Q~g^)Z{JB$2(^gs
ziFmW%nGhZ;K|k7bEpOJb0OibK8sIyDb~`FdsW2!%JV$-k1L*XfKU|Az{&A$+m3+d>
z@IFL%(I3mSJ7WYBsUQOxQ31cJ&cotwP6`2CCv46?<6{*nzsB!1G7V0bc+;!@e~&V;
zhn8$s84yI>F+~nfp~%6ia!U5NxPQ5b*m4BG-i9Be${=A(TDs`kK5>LkvDdVo5ZQQj
za%=DocR3ppz#O6lHEVk+4N`D)wDqq0=LP1}V7qEA;S2`GkeIw{y=HQT|4s%!lUv4F
zA&2$|sv||ei}bf-!BT!*EoOzFVYC^xUxh}9gE!h;Qfhtgs>})+PIp4&2dz1k&f4HS
z{WBlG`^|mS1jzx%O+-F7%_+cXVR6H7iX5nIT}KYNm~w&N>gmm4NGIAavG;
z{F!EH3g$l^9yZRn`vo7y^D{`ss>`>;4$Wse9IT~_gQ35{u_@cgbw1jx&M<5T(_uI=p
zX}t+T*#&sp&xT;mNfE_+(72R&T}y`6=5hgI^ZyuqT%}0=YyOq2G?Cx=)rIC^ddIC)
z+uEL^G^J5ZepA7SPzNy8oSNsbrjH14Qw`=m$uiXL9e=Wq$*{8kM57&>hQTz%HK;?W
z4BS>#n$E^Y5Xjc%`5bRh(KF51zq@*Q>sRqc;b$ie1NRnJ(J^bwWCz&%7SfI?@`M0f
zcl6uEeWfz8#?7koX0HPhS4Py%Or#yqNJoS0G>vn|!|ic1u9G?<^ToI{xuCeEL@6Bs
z_gOq6D5SC5JB%jzpfhaI`ruizQ6t3NR$DP0|6Pd+q}|E;R-Q!g>F0>L&#B708SpH8
zpbW*;%rm5Ln|p!KuUG5$|u~{^+li8ci6f}z9fPGH%7QnKN%+s9I!kHq!@=sAm`^L-39X2N{TX%tm
zUSabFC+pd3u$7$2JYFEH8vTmXZlOSmT|E}j&S=i5KL0JCr;}nl***mY;@#D@G{gX!
zCCSY}k828YLiIQ)e6?}#W{I_7#0&dV@h*`P+eFkR@)9xgdUQE8?E0jGNbO|L1avdKlPxmRAFULN
z>xmIT9n%g-G)O8TSoP2>;x6In@89r&|LkhqY$!f8NaA|`-u6D<^6M-TSr_Epx_K|W
zEy_`FWR9Q$LeZd3qd2`uX+@so$+*j1^@XY2gH6Jnc~kATW*#^G;Y9vvh;vHz>+?!?
zITGE1Ydi#vkbPH*IrV-iAj2EM{p42ovi7;gE0f>Iq`CX2DJ^68aaAVGANp2ObE#ef(p2TpS*7M{S!
z0-Bza$v*02H8@=?Q>!kwz0t-us@!^vIFsa6IZAR=nF7IsK_Ev9FzQ^Lo4cJM#deB_
zfD}@^vFvYYgg0=R3?`a_tkz)TiU_Yq_Cn>a7Wwps0e#Lv
zU7TP@zEDr0(j?7IX9Pd97j6Sue%V3Z8KQ78<^ZZK?bkg4ED^#?c{I>Rj2q*@{7!9H
z6=*@c%Gw9PlCV5M-BjX_I3@81RXh}%{=j=+9*NYTiLen7Qg*k0B#-;S3{~_PMC08b
zvopwip&Vb%C0p(j#L!rqRPvWsx03F^q-;Goa@Z4zUVV#4jvZ<3Z6p;p-5vEr4=0RO
zJYj4;DOF^AT1WdO;`I}2qsi-Z3HutMm4geDaAA1%R{pcO3Q+_2&3@rSRJJ9}dAs|y
zpUxZdeMxNG7If6tPD2T>^0fLrti<^4e9qg8w7>5l6lYPfS
zft)ge4$h5W6nhL&r`wBbVgb5HNAFGCNW(CCLd54*jIIm^^*i6H*_7)1qgaECVd@wp
zb7&Y(CIX}KF=3>5=EtqgXtKI58$uj>mODatWaGmribip$)I=j#N>1n-J;&0&17o-L
z`hi@Jm?U;OEV+G=kUQU%)P@K>|@HO+Af-5<33aR!*U9
z_r=HPZr+C}{}{Y^UJq16rUp$IlBX~Ej;v7kQ)NuZRJfpxj&shXEdv6_;VhJxva86p
zz@!kk&JY(dkXH$&@tF5(PVS%#5yqR&HDp1u;I9P3zy~5cVsxC8SE{BUtAAMlZZ(=p
zSL=gN5yRi_$L4(5tMd2ul`BRYh7K(M1dW&{f7mBW)|nZcG4Y|D<;8mBu~Hu-wp+p0jfMDQ2kNu{
zh<+XK7-OQU&TztoDN^_TFy*@!E*Gt`G
z;2|q^gq>~^gg`r`DujqZcjtO>^}zA3(|#M{j00mfM_N$Z>+75plwQ_Ovhj3WlmYy2v5Bf)O^0hdQ?bYCeLNdzaK4L-n#Yps-xb
z)er(tkTdj>5()N}yD#A)HN(IX04T%<<@(`AcL0Y4*oYsQ%}lJ<5M?ft$=GI}XRvy^
zCSOdU;j2cLdWL%RaF)G
zinAuA8O6yjMJcg`ga5}geZLle0^7T1wo-exoU+6$CB7AX%A24!i?-?}B=RqaRIW(Z
zDuT32A6`Bi27gwlpZanK!EV$$9-|DFor`g2Jp{mZF~3S@7)|Wr^<3Hco#hw6Z5oik
zWy{F0)}og3q?riX*Vkd+bm-4Dx|f-(yqox|XT>d3g0o6f@$rg$d6G^}C^%HO(@vd>
zFmyQ3a=Hpz)X*x9Z}dTJDiI+bzKD@3ckv=A9~9c_FpM_WSOFF%Pxltxg+5zB_HZ_EAyVd7_CGU!DFJLx2;kcdoprizwHh}^9lg}jZv)A#ULy$a4ha{Heg
z_+U91i7f8e*e2oPm!(t-ulVDJ83XK%s&DpnL1|+nurMd`B|O#<3Yz?5x7a864OX%F
zUO1DfY6|B}bZZA=MCPkLrzoFG*o0mPXcKW&LVi~x2|Rr}1uZGkO9$B903Y`3TgE2(
zTTzeN#0CIH8|#ymj?mirqrYUrtXFpibcE4w@28G%(?#4Vf7bmZqP|c;*)X;a7fX}p
z(8H(b^a;4OW_lyo$SObCZV^=8)#>m)B$E6pr&W2LKs?4qa{#Q{34Z~fnJAq_#8JcK
zq!HiVLhl!*dR&!XVDLl*l^AA_N_m$kv2%G&42^sR4g>R_y)x(CETY#U$Ad+GNpIon
z#XUU1$mYny)oGNsb=Posq@^xDjY+A>$T5oPMMXQ!21T40P>A3P1M>C`W(Qh=)SkXz
zxa*~xCcvG=l|qP06Q2_DiLtWYvGSMrcZ5M2vpA@Z23f}x+jDz;Z@*%SXwV(b0JbHt
z>z4#9cCzim)Dy&I8~h_S`-RAiY8s-|*Xnxm4qus7irXdFCpq%E)6q9B*Db6i;92a43gHTQszkt|YvI{rmG1ZHc_9jMga>8o4
zqw9Awv_Fhb>Hv^Da8L?*)mmAHS;p>-M5x4kYBg;ZUlHM5jH$2!24xf?ym4m~kBvP{
zUEv~_o2PJ+@*vcnyodou0AwJSo1_5wOb(
zPEcBwkBI%NDT$3nmDRdxrAlQPqnGFGf0f>8t@+M6yO>eU9FRmu-O<(AJ<
z7o}%4D-Hw$D8o{HSMhJ
z5B<1zF;qhxVHpD{GX>@!Yy!?>D;Fs(N*f^1R9T{oGSd!n6Oc0*bAVnd2lwhL4Vq<9
z>@PwR9ewWCM_jsFT*@GQ=`3_Iu>(i*ucyrE&0hK!fC
zU-D*bdTza(YG=@meAZmXSecPDFm*{BML*4qng786Llo^RAaC?{*Q#{yaE<^0ZEtZK
znYss+Yh%LdMPn7!5aCJl89S^ft=5!7->W$sb%Snpw*d<4$
z5SfSCf%DDsjl|woN-_x;PGZ*Q#MhW2;8B(R(N&~&^?_$YJ1d+I_R+sViFT;E1qd<&0pYYsv2R-d`VxY32og*w=2Oj_*
zmw74ctvG>kM`Rz{L4m7mh568PPOw7>vZln!DO?Houq!2S(H}BEWcWYf1#&qX5f1Bt
zWSqD%Y}P|Cufn@UrtdyM`Vz@x`AFOPgI2KIN?>=DeTUPuw3nrtF
z46Ry9$6gM&yI9RTqJX2iRXfiFtP160T;WuMVVPKL%S~K|Tkd&1$DLNH;ln*>|R=
zZ!X=jkI+;8k%|I^2D182*kBY-048C)QC98alDkpVvSxIswg{-isV-;^%z|t4+3nTV1$t;hgqK#{ao@COmtn=Dq+j2W;W%<7RhKyzMw2Ko$%z~v(&8pU3cp@5WA+6N
z;Vi`@9I`4ddBA|k(ihkn;_YhuIXmAjBB-7OIj;kwoUvVCd11p}!xF}Wm1QiuQDv8F
z9#Dv_INA%K)OVo^J4VUUS==o4r|a^8Fw57(BatHz{FePUM;qVAeuo}nk=LXV=hyh!o&
z3I$|@`m~EfsjZlblF6XQMcMsnsHjr&G9{7?7j(%^253RqoONn02TT-_`|3n$d$-lg
zuNVO=qNPc_*0m8A+Jjtv3_ha%F$Wd@>#4z?SD3qm6}2LYwRi*o8)GB^9gUCIvo!p!
z3lZOxzoyAE;q7TDMx6{wwj1|T-E1z+ygFDwrs!qbp(_0s1O7|11!3VJLs7v6%pv7x
z`*Qn(O66M3(5Az23SV=tWEA+0C@RTEmekXF}C
zQ#l|V>A-uXn0>U_>97k*v?JV9(?#G+cyT}HgIdqJ*HJP*?qwr-i!}zl#Vw*fTxo?+j38A
z3ce2M5M2woeuQQk-7nmb2Yl*>jYGXZRX2>%p48FW
z!TCQxoo*p5f~+O4D@vH10vE)g=nT5=(|Wq{WrR%Am8WKGx40_|9ZzATCl3C4E?E}!BkO`-~XU#Xc5mTh6O`JQ|{+MA?%q01O
zL)evciPyZ1L5{GqcA`Nto>GdP-DAN!N0r#vM&V7#dE^F_yWS*Tl|NtPtPgAjr6J32ogEguF~Gt-U5}*+0Lw1HT~;GuHpm^`#9GRrE6vIUOvhz&%F&|wodRXTaRB?E|S=E(XKfYtZz$W
z>q{er=c`}9Rsv7UP?Vb?%<^1oSFd{{HL&
zi}z9afpN>0fz_~PzqMro+fh<2X_+SWdpXBN8>3rAOj&r~8H9`wBEkXIUSxrHlZA3~
z#(E~c0;}zOy#j3;
z*K}{fa(Bv6Nt&&X;o}K%11kDYZDZas-oWI=;klBsg
zQBKH4^EJ7$;MEgVT9MoYMq+e6=Vp=hd>a~@7)4P%LAd!kk}$(~G<$+GQ(RH<*q2CtKyL_lHNQZVxlz*~*o#mlTNG!8j$@#U
z3s@qELU*VZBzB%JhfdeYEybToTlN@Mek#xwsvkp)
z2=U8O*r&(Im2zXGFi{Zogb!QX_^2JQKIz`sI+h`o=FT!>Rf4bW$=R^`?tDlE9anP7
z^>Bw+zAc|EU_dz^CI73R
zYxB%|HhnJ-B5Ng>mY%X9myKAjhe}tl4*aFqNfbSQ)A$)ujC-OP0^_!zjH^y)5
zo?s?0jYipbxSuOUdKA(>D!!in5&^oh34ZAZ?xHq#qqjmE!b-myMc-JyZSoB+h1|lJ
z_EOq{c1mCRz{9-cC|2?Mf37=Y2mvkm7Sm|!9(n~JS=jTjJIcVtJQ9pn;>$!&=@_%=
z?Vay*fljO^Df8T{mssyLJ9)kpGAi#q9GP-{Jw3v8$srhB6C#&y=CTA56C*AJRJ0s(
z!VwX9ww+L|%+~lCuQ!{naV_up&oBrCo-GG)?RtWd^pCzFt;L_7i&o0H9sI9Q-x!No
z_X`8xPfA?i^-y=M@vR8|9T!|I73-0Bl%p<{)7*nk
zSY&v$m1m8kjH!KYIwANlhG|X^Z{Pdo4L)62_QdTaAh#3yf%j*B22-Iyevi+*(giDX
z)hE)K-bLE6MBC~f(%z`Z@oxnA^*B2_LsutKzF}_%CO(5=I5-js=^ke?uDkRANSb)c
zWBy?sP~ou~|487?PcAQhSAE(ZecniISD&arX3Ycm)}!Vdq;KDuN!XwBrRp9$tz?jR
zEJB-(93E)DVRtT
z9UWr!w-Un++bfas#FnsTw5r=+^{Aedth1rdn}`
zZK7nk#3%y`WB<~e!&PvL0I~vr9?@7#u32!>RrvIILAi{n+rVvGl<`CT_WBWMJ@?)Q
zFSb8$Z#OgX=nBGvP{3by>3oX|87kw&!n
z+YBBqjx%|Z6MK0mMEx_`v!x32{=3c{rzE~uTjH7nZqV?_sG?+0ByZevGY|Ext-*lt
zFzJ*on60O(9<0(l_I5**kaNVslhj$4%rlI`JR-k#;h)Cc{>HW9`$Xdrm%V@lSjKQj
z2T*jC?x`q+QYK8JZCWeSI?TFUzGBWs8h$t$q0QoJyktZ%_e~QNtgqO%5kxfn3OGG<
zDcZnIDitk~wywZmY|<3nvgSjCg&OWSmzf{;cT{;QYkB}$DbX-90aqRSr$8b8*Zd4P
zZA=7DF-zz#C>GfLFmuhSKy8amHn$;3$IrIjL&^2Fc8#q4tfldKaEUYIhB1FLfYUH
z$hWnN5r5U>JLSMel;b(3ZWtLon~2t&b(n>v$nGk$;g+F@C!e&aFSJ0dYy89cPg_aE
zE4CkT=hVLu!Av3mdSE^gFBk6MFrn0ji1L{vPjX9{p|1K(Q<1B&3GTI#B_%hE)0j
zvHUJZp0;mxreDhKGE3k;uEmIgQUz~Oq&^sPwJnJoZ4;6t=Gp}#VJ*BoE_<>_%g=b)
zdLCe1rJZ|xOBI#n#_5f~;B
zUfoT|f{sS7#MnUv-7J9$i{{-n_rTcXhkUpgk32T^utE;v!;RDbF)c@P^$0Pxov<-j
zbsSx!TuG7~;}E%|4Ef(DYVFwk;T7LXT~(u%sZM75wY?m2S=-DzxBDnZ*iV36k4$9=
zKd5IqKvg*Fgo7&qSbL1_fMZ3KbDq&?uXdQfLHgU#K^Zy^;rYbFyYCqvZr9c6_NLJ8
zwQvEl0nb`N$~rP;Bj-^!*ns4#Sx50&k>%)rD%vZmVwQPD2_G$bgcG>E3X3qT3qQ;8
zU1gct7ay`*p!mq42|7Rmpp!^=eoaRk_u(!7zv6Ixxg)U}9+cd1rs3Xm;uAlsgKqJf
z*EsD78esIkH*|z
z5wkggJ=Ig-XDm7KPp`QH|7K5)X}19^g^<2P(LBY5&@n(5gwsIo6V)Hoeot_BqAjRV
zpneVFN!0#_ssY*kG9iJK^4>#sR{rk3t&)KM~Y7*A@S-EiWUa9Y?o+IScz6Tu_uRjt4Wd^=Y^E*hlK=j1
zWK#FO0`@maG0>anlGYBuCTSRh_HI&hqKeI_wiOyeN)qg|EY17Qj261^=?2zmk!5UW
zW;Ii0GLUm2sSjh(F{tuqTs}SF^Z`)%pLKZ$w{V45mV;pMj4P3{0Sk0Zh?mVF%D3Np
z_7=^%bl5iEv2|)h_cmq{!%&w>=GkVM@%eOF%6+o`<&i=k17#^1JA~U{)Wh
zvxN7C79mq((6Xbz)ExK}Gaq3D;`~E9<&nQM0yI=%(%yHj8YokTatUl4ue+tHeKuec
z!%eP%Kr(VOpJISVMmP6#a76dwWs5x9%R^$rI#kFv*PA*f|01)-I8Cg6{qGPs?
z+~_cj5r7I{p6|Kr0$ft1E0fu$&qD@-jaR*4ZlKy$jfON9^M2IBqvw$~Q03@yb|QY|
z0!|QeeUFnqOHiLx)`eXcwDQq@?^?jioDx<2Iu6E=ydQ&HB(6x!3LYt9t=g%EH50;~f^v8{K8w6%c%7cm~k
zI7Ku@n9$0rFfaZl;F^jQo{hxD;}nan>U}(eGt(xSV(+&=HTY%ro>Mux6zO4u>pdezr@HW@J5N=>ql6PsSO#HUZ&34{r6=*ts*(>P&el1g9vHdKMs2
z1CPS1czMz&;G@+BDlXH8$87SN~rD1$*#3lRBAE$8hhOAy-y(>C?tR!So!2YP`c6%L
zADanoC~>YOr&i|c1HjjQ&`%$$tf007BBxpq{yp$c<6@&&KI|fnO53k_kO#8kvPB1^
zISnk0FSZ0#;#NWNSkxG#!&x0POpD{DlmSl$HvI|i+-%-6WNSD45^CJoM?bf&R459>vE5*eR&AwGcMg
z9F}X+R`dFo68Gp+^kas!dKM>zq@*&NW?@?rs#7jC_Up*=LW8A29?
ztp-%j8BUDd2WTzs`J;&daZ`ZdfDF%tfl39D?HsUJcR}WYzhcr%MXM9e#)wbBQs5U6
zYkH@)wH@i}r{rZIDfh+~j!AlyutD%&*D82tXxG+l>hxL&vrF6gJEZd5jNtJcS`_TF
zd5M$@(kmO-tRz151xBC2{Lc$Wj81uDQtq2?%+1J47%BjLGAwDDJsY50P#yX(Xoi_L
z2u)SjQ#WGvo{zyDt}t!J>#Tpz!8=mkUa$UQ#dj3q44Wu(we^!tMBw&RV7ZAFqnK1R
z1be5TvtCm`&%-zATv3=_`@Nh4^@PahA;pywDeR-Jb}j8cYlq
z%A5nhup7CDtiO;toW3jEfTl(Zfe<=ss0cjw9j1m62hwmHs>L5KNaAyuanZk@2=gO&
zEuF*1xeH1?ICV~*uPVP0HO>0fo^U6B#ocjk9)VV`69DlBDLNS1gsT04
z#4sA6zfMM7=>)eU9|&guw31rjQN_$fY}7P|q)djJc_R+o`CM|ge*v@M=c`2Fk~K*a
zG_s3LHD9To<*xyp1IhtfeNvYOy!+*!^^UV;N7_9@G!MJ-ww>>}?dOf*MO}qwCH_mI
zxO=z-zC@z+Pi&q~BMGptXxR*p;Q7Db+|}fU1I#_MAVg0$@+HEnp?=$#_yEc+xz(a)
z4A~IDM^GO7WK+QtZPrN{vvTU|e3dbbQVxSZLAvpw-(Dr9hDaSRxrO!OLQyz?w)2^l
z(HrQE*BX6Kb$fpmV=N)gC&Gx0twu>3cBXVCy}CkAh6jJKN!p#Vcl?!T&y;JA`0`7%
zCMlB9#k+Y1;HMGra|aZ)(b^97%;;>_XU
zSd{&mlRyzJGdY5Ly$F3REdBV=g*IT+a8ru$o=iO&JN(uQ-H4_&Y)NA;y<~t6#^RgK
z>D!pH5+u#N!C}o#hx?G?ueG^dvh~#i+oxv&vx`u|u$df}tev=yS@vTxb0@iEJ*0hT
zlg=Y!NRz$^cTHD+xfoK-_m3JAm#~zq{K|H8yM4?qz*LbPrYD#_Q0$X(`hPW8t=t(L
zkeL!kdp^FYFDLD^9!eAq)_tE-zHyWDiS5H=jW&4PXVjZ&_j~$%psT4V)5!B7T*5)j
zaRZ?Foq@f-q=GO#D0Bhe0AgUi!PY-l^B52VU9G-bn_Z$
zQ=2jD>J(-QAtZ^bd&v-ov6qfLdgDv!Rq4TfsxCTH2FamT->;nF0+8!spg
zM{vCdeJ1v5kwO4fnXK{odk~62WT5kR?s|ith&!3_N905%Lm-5q!Xa*xo@pt&8s{A*
z7dWUy+ID!LmuTNEwbMVb<|GuS5DI3ml#a8u>~%`Mv{0<&cuZ~Z*digW-h_i`JnO#O
z0bJ|rLhFKh=R8ZabWl{aI?QW>6NT3mamDT*wa`+Kv?@&WADPtz-s2`J*ERAcsOny*af
zc77{`H*Op%nfBJIqUwuQAkd-N1kJBcHi2p|!iF*Md}#}{5)=R9fx8H1qUGkkF~5F1
z2dEBDldXDn?>9}TH~liVp!Y4a-szaMaZQtap$mu`k**XW*yp
zYI6vx#gDo@CRIjBG2@ZpIp93lImr;C@>=-}!5K&RZ{pFNW{dBg=Ed~NP^x19uTX~Dle@xBc#2QY+K1>q6_x7_}J
zMrj)J@}0dIO$7AtP;z;le1>|}$m0_YV*mp0myk>Ny2sY*EWUNr1DwdX&ll&Ds96=n
z)5m^8fdXM0Jw7QaEO*NFbgVJv$7<|6aehL$gZJ
zsf!8aZonyI0$EZo1B&533x_uF?2{%xKj_lE#)=cx_FYnMr}Z9^PB+zqks|kvp)s>8
zsv*xLu)iv!FP34a4b#$o0m&@*u>lhWKAHnaVWe-)D!nrYneCARsT_DlKfTACXU8&O
zGD?Y>xp;N#_&4gBS-N1chD(M0F_mH-pWcg6#&SJ+c@Cn9(ZJ2$N1Y85Kvb-F1
zUqXZl?wAzgTh=<@57uQ}aD`~3h7raCg--jhRqIZZrhAim0|
zjn}I^mi!ibE=W74nF7MQTPgKl4V$ekQUlU;Yzl?9Fw2H$EgqWohV1L}^a1Y_l@1*1mMFnKHjd*f0wQ0E6Uo!d398;69c_&#Gg72mBtMIa|hk>%09PyKkh
z_>*@a>+^aFi-;@gqE@?}r|#Meg|!2NlRqV%>E9|YgU6V74hgnXxU0wTGkz3Fl+)iBg<7OQY+ao&8OqDDaM3A#auIx!Lh#+v1~g8#E^
z4o)St-IyDQR)TJAP<@|^-<;7GccUY{PTbfKq%&z@XBNTv+&FcB`lGYbm@|@KXcQ6_
z*XeUV*kf6q{lp%j7@khWa`_C+N(Bt}V@Xd3`A98o{uh`B*5P=;ni{m*n~W5@IkFtZ
zIU+`RZ|?83)3)63zt6`~D$Jua5-jd$+aZ_1t1nXw;O%48s
zY^NBh1&J>6)(e}KN$^@x+dxT;ceU1hI8aGD0DpxlSylDDCUuR#l_PZ
z)1uf^sBDH5ZF6LxMwRp?PSZ7^lo*HbX+oCty)D+$hT^|E{3f;(`Z|J}IxkMKI;7A2t*{N)yY~@43U#>Y&$jcPLcLSdjp@FXH7RH9u
z8vE5x0>Zj5VR&oSD=K=GavTkPrN~|KGgxyEHU1XkKD7KKpcA|i4=w^B)}}S1o)N(R
zJ`oe_Y}D>plR%Uc`?U|*wT{1=od~HZVk{1kxcV@Zna>dJ3}YDj<#)Q0KOP+Fn`(hZ
z?RXo?w&6fT|46@)k{rxI$l6y(3iqzeBB$qCoO(VxWEUptOO|ZqTX8hheAAC4f+jn5
z`4kv$*JA+GB22himUU7Ev|XK|sZ0AHe^E%G(3t;;;GC^b$rSz69|`<=OW_iJmy0Um
zXeU+3wHY;ho4&k`U5WY1&l$a&Jbb|RTFVWv)LiPD(zeM6OOE1DB#3pS%yq!9B7z6H
zIa;*@6_vBh6-jLQE|yEm=Qi)t1gm?P$nwrHm-OZK?$ux)->^Hr3}p_}Ddlm+%~B)j
za@Mg?@pYQeY}h`B!%?ddi-p#>e()Pm8g4Dn^832>dMBtsUf!`Gzp2~n*Az(3ijVGFkj~yPs!ISZK+?b76Xx6xIx&vz16EduDek?>A7IP&Js3;!ljlahKHw?f
z`?8~l?t@IAnG&^rf8Z$BA`!b0FiaX)YS}xl|3R#RN^-Go0VqO=X7iO~$Ir`Bv{Wo<
zzNE&}8_q(%7%e;PdNBv9^I8tdZmFylJ|#-^3G#)vuW}0%$Le$;|7@*7J)|vqt6#_B
zyRH3(t|w-;Qh&o>7_jOC
zcuAUr>@eA&oOWg3_Um~1$G8p*CQ}e*ApYpctd2@5``zkNNNuOPKrhL!Jn~kh3>yic
z?XEJ^1OiOToH0v{PIq?KHkLhY&ZVSZiHT*s~YpZdDSk+b@8ySdGz@!i*Ch&&NwBXufsol%NgH#CpXe^2Ahm&MnX+A`;Y4+UcPBL
zHz1HLIhD+QWz#t=Cm4bG`mt2u?nLdAPDfDu2fU4ZaM=ni|39HnV>+hWNy0s>d(0~r
z-2%-uT(knJKNzp<=G}iCCw)ZI1#Yt|q{C;69t@?2$F4F>PVVIF4=#!2EbYA?lM5hb
zlT3i1duRX1lXZO
zZyNQ&wiAg8XttRzwA0Ek<;W@=2
zaf#njI{;=_A;8o#odKFjK@W)Kdz6dV$4Im&Ec}ot4x;se#=$!d21fAD=z!DX*U?Fh
z`3ZPJ145+6V9PdcJ=eh@;d(wxcLw0`Z@aa%|-Ok
z5ul&Jr_<9M%w>P@PHDu-amxj=K>DAeMUw_Y4
zAkZl9*HQo!Lg*QHSKF-5wBjX~GvfNh?w1s_-(BSDZQSdKZSiB`H>Qc+
z_hjuzt8m)4CGi-~1c5>~x&|rZjMgkX<_u<+c87Y#&v6qfm-v6`U&*MgO~owy=jfd(
zYN;P0@hzvJ!4FLb!LA08FNdmRE?|O_@-F@$leG;20S5h!v#TuLeGkbNW~B;2%!q^h
z{jR
zYgtO46me%iK$jy7_!%1RGpICz%bZwbL>?`n9sk;e`Qf^iI?UUN@U8Sc8vVePhbZFd
z3SylaJ=%@^?LK}+ff2+po?=eNi>1s?k22IFNND`lD@A)+kx}O5aej3~TcHc>vcGQF
zQ&_w$nQqLx(RQG^9@>Wbqh^Oe1z0$dx>d2w@jXdSgA1+mr^XWb3>a`ff}1L5dAKQ?K|O|QBa9`2Me
z2aSHc+x=wXqz%b6H1cO$a+FKSB!DQdkONdQ8v>XLbjt(VUpjf8caCGaJBq4tn$BpH
ze8qjNSq5wEpnQKpyZcyWhKjCO_)Ouh&XN(%2BQUM4U=&@<@Cf56l0tdn^I+V+TTp=b`vY=p
zxo)3Cwck1RUX)YWGQi&|cJ>9%3+fYw43LSEr1_GQYw=&-5_1DfB)0W3?iGCdaK6bl
zr|{UF0uJbZDz%KRFs4C}NGLk+^yznY=I1}we!@y*nEVISy@cfh`*@*YenFNybMQMYE+k%1~2wKdh^W+HN#qM=nuQ3YrV;1}&ig@o_Xr?J*
z!o^f(1=Y_wXsg2^1<6i*RL@;`UnM&xd3O?s9pzL1M&huK+
zrwEgA#6L*`I#Uj?0)WNm>&RO;IBOXq{mLC2pGZx3@acI%c|OrxE!c>kOMh}uaTdH5
zo=I@z@;9g?VS&R|99p)Z77kgvMDmNiidvdd$Dm~#~QqBqqR8Ai%JiVwlbaO&~z*i%jpKmQ^#UcR08EwNy?hs%<
z``g97x+Ptg2f1eV4sZTB_HbnN7c^p^LR;UWP~U>*Lzv9ZzL=7v^Wm9aU<_W5zMC)g
zTOWkl0aQirX(N+%>R_D56nyr(`xB2Zb_)o>AF;Fe&b8=@t=0k*BUnSZ$b=yhn!fnC
zI#+sn&u|&bOg)ic(9tVMzcKJsa(#w!qYftL^^1`Z+6nl3Mh}`7Yn8Y09sO}Eni~s1
z`J2v5cnV{b;ToG+{!F}q-V3H>H$y(5PA3Y4`Y5-!%h)#AtTyapH0fX$@Q{8+Ol(zv
z0ixUFP*?!X3o}WB%2j)f%7D`CJ7i%TwakUA*iS^{F&Uv|ah5of;8Z33VhPRU10VCe
z+MrbWr?gMBF@ght#SmaQ56cIO^WCj&wft*;t!M7amuy$Vds2hWd>jE#b>e;5Q~Ycr
z`*0PaGW9>Cg_MYoyg;HW<vj!Hc;oUpwYo%a22#{0aEY@X-RC74GBLx#OvsIk!nE~Z-OgyXFl2!O-&=khW4l&4y
zz5XP|qE&PQU*z25w>^^E3RuJ-8|+DFL9Z$gdnaH8TPFKtK&XRiWAT!1IOWOkrF<2<
zSpg=NU1nVAEVL%E9j7CPAozE74We)E%QEUBc#Ap=q*I%{X=78*c(~el#9_)SP$Nz?
z({~?+xV;#Bcm2=@UQ1t!H>tu}Ot004`V8tlTJTtkHyFI~N&mEv^08$Ng
z0P;PKJzr=!swNPOCImI>DA)pcU!t7k)BVR7*|-atR+tJ#B{k;tsQgcga00qK@p1sX<6+>YT{L-Zfu$;H}6v@G4b#q7NClCFb`#bZst!bcaz8*{G7RfO0n
z$-IHw&cs^BqSeH&!OO><6vF6unOEZ7|{PiC$zTzXQJ{;=!
z{f;PQUmF@v@69WUvQLCZKIFSwTRCG>ov^H^jmDJP8GXv7Cd7nCK-AgTYT=TAkf8Sn
z&!-y|`_;Jv#!-elqRhkKiXf{pMRtLkF*2(1+~Wv7Z&wlp%D#w55^O`BoS2Q-PD1HGix2v{a^z|<&
zm8<$wRK4=k(>s1(K8M{G2a)r<7`0#artGY}YL|i<4!-)dPb7)rZ_5)cVZb{zUqR^+64
zK%)!A%LS$7`
znu06inYBj5qeiZ*T+ZS~#Ta#A#QEGY+r|@|?#6sGdICPL83fRSDlMa9^Lj7-ZL6{q;7z`4z2q7P+0^C0r!(
zw5y{H^txo*a3lLl@^zm*6%y}3B~%XDBkGX70$@)W9vMq<#m`qk(afY|_S%elr~C3z
z`nH)Vf_JhMRuu~X9GZh;yvl?362AjfTs9Nb{m7Xi{Su%{MF`XtdJS9`&DE$bw*?sM<50R3^xN`Wmy1whjuQ#W0RVN$cgsZf4O*q#YL#gFVMNf8Wc2*nVk
zC9zX%Dr3t1xkj?!*%DT5zw8*W`wlL;-_rKJ$~uW4wb~JOoMD8J1AzD7#);kG-HY2*
zXDC(?9elO&Vama%+d3AuUyWaeK&&4(&EwsbNZgXsx6%kMuG1xKMN*H9%mx%xFAztx
z?~$iu&x~=s$yIEU)YnwxO%mR>f?LFaGUQ`HzBEbXDc~CAL7>wrC$a7@O8CF{>U7(hGx74Zo@gYkJJk!!F||?ST5L^lK=D1iZjL^
ze?)+7XGe<(Vw($stv&5zlx&!Fn<(M(z%B~8fV%uTzAtki9^3xO@{YzT2sSa-^KZ4v
zxz4IoI-vPL0TXVCQw!oGmRu1YplL?*z}sS-Gbij5vA~pGx{Ajd_S2_xLEC3k6d8eg
z=*Uh?XboM1D2agxL$`Q|)}D3CSl5XLmrwrg#3uqmh8JpINj-XT>2P;X2~&Bbfd0yb
zMeTHR!^I5(mKZsW8%?UMH5^X~R{@O0sKAPjTk
z7_@kzD-6*iZfR;U5mETFHLKq^fc7R>HmqZ4a0_HrIgamxv|B`wdr1LIes2%+obz(z
zGZ1_*vKdi~v>ko|NTTNDAgrdh$V(-JEK`m0U?*ObwK`*W&>VnBZV$?7EjH5Mu15_^
zSL0p6Q;dJPq>4Y(1-vF+WMDlaLZmZAEr_XA@5au;3d8%D!@{l&t@rc3(|DFpiZR%#
zxdF`hr8DwR&dR)P1fMI*Yi*=p>Y_4NMNpFo}+g>%CJX0NmI6wq>>*+`CtL70r~D+L+woU-s^e}|ua{t!!?sHC+d
zZdK~o`z{k)TsS)-xr9+95<2&5G6{8xDil>p}U2#g40LvCYVPC}SGH~|;c
zI_8&NlJaxax~PI!R0s%hDg0oZ385J<*e9HZU-g9vj_JZN#_3snoH}*^Z&6*UZC2L;
zKr+_|%G=p8dQfIL#S2^(vS^Ww+C-trX9BrtP^dplk0ZKkBcb*a;r43O2nLTMO8CR2
zUhu=b0U2ho4LMf}UJ>OILT&X8N0c8&i7mP~C#_2?ytH+4yi80%*nnDecuACBQ*q7n
zf-iQRx7G=!3OVMp^`!++KoX|t)^dleBBD`Wg9k}E^U$gp0?5^FuhU~u@ANKchuX#c
z-=Of;&CVc`amYw>jq?Ln=RZ+w#Cci+3i>M2s;BO3n?4jtaq^gZ5(-=`y{Rf
z_xPcj(-mu+wbPBnA33SOYp?C$WOMcytfsQXOMO~(biO}#5V;j7jL7g&>6O1QdPIKnF=Yg9QJoS>
zFNI1D4YWxwty&dTx6b;a77w@$DDMosP0A$;RvM6Kw!9pg#=0%WGe
z-Zqc6160EmUw>QFo7H`N?8IT8fjaHm`30>2jo{#xRN@*ftlPmD8K`PTmCDb>ia+$(
zvqUNWl(AeA>QyB!eE#PB*ON2n-yVIHhezCM%m|mu%^%3%OQa8tX8Wrme2Gc{ksS|5
zQ*_^06uu&j>_z<%9~Ras@k=1g*T}LWi|7UXtAH_PNT>)D$RvZMRQ*gkpg{=qT*Ivt
zijcc~)Kq4W`+Ft3lycW>@t3ns#(D~ZTdEX6CANgR)$rhELU$m7w*-^7RlT#~^kpPN
z22Pi3-t+~4V*Zo>wKcQ@mtFf_{#uUKPQ|DDR+$0kOm0Qy_#fs62njAlX-fwtZ6EQ!
zsDy6jof8OGT_x55==15~C&_~-(t9F9Uk4`L&`TbJ39_s)TV`zYLi&|2$iPg#JXuq3)}R(xm(;Qw7*
zcSdsZC_WHTuRHLmoJ9py7R^sh;>8$8cf~*^!ps_{`UUE`RkA4sy3G<5kGqCiG62op
z8No{TA#zr5N*j^i)@Y?k6M9hn^H2CjebqQa*1(3U^pcsZxS|oWXyIKwOhQRcJzQ$d
zx=SFR2-4RTkXUq9)Enas`W$Pb7}gHtxSHK{0l*s4c8A+chj!*-Gz?nzs
z)w&q9IIg_iXBN;ABIkjAo*K;kl#t(?lFQm%i_
z#b&J0;ef_~a(>$@X#P<>+B5i;vCbj<%+U0_P46boAoTklJ&y6iQX>O#C3|@|h7Vis
zm@639$O7t_^FI}Tc~S)qim&49i$yO65>1P6R$>Cff{3s0i2VPMwXoH%+yiw;W6W-5
z_c~wd!$^MQvx(-X@cK^?|KUj$`<`Z?ySLx9zIMRPPPdH
zJbVjX{x=P0CABs6Cz9Bb2LM)g8y3nnC)&9AJAO8Js6l+#&M@jmX`m1YtgOJd&uAUn
z<=Z4$dE;7+%vEtmmQX%x^HuB~VBb3W0`q|FqbR(nu2k0r?u-NivXmm~HktpYS{oRj
zG6D&?gqW~@uC5b&HSX3}Nh4wZ=Y6_~Y<@!^O6Ch<(+zkAY6IgY*j;`dZY|A1WLR4wAKCijr7mpmir$KmlV*gBQAtH~){Aa?s4{lfCib?MYyvrlK-fnuuW)&c;o>hOMd}pATW?@w5%Trh}96RPp
zDsIN?9uwPBu?X5vn|}0xgI}b=f%}A^IHr-1YN*cBCBSclXUk
z?3z(&p;A@Soy$jeR3Ub+>Q_Gg?kue_5V_{H<>64bzL2#{_l%Joauhn@Xs`+~Bjh_h
z$oy1weQSxzwA>WnZP99SK!^(3;W%xMUn$W5CB()&b{5?3*2`p|$^iqAHJT_UN%M;`
zcG&&cbVWsqLB`P9DEt4xpqP2asM*<9+zSN)1@a}W#$_U^;XP2}HuW#+NhlqOH1eo|
z1n?7j-ac9Yqz{xgT;^3ER=OzD=?(|uk
zMS5(CNDK^i!pwrZIx)RjhY9rievR
z7xXdZ`Yt$OaLhEjgaGfS%%!C?$qbkokC%K8!Om-S`z
zkBr+Z9AC-iEz`#Ltng}Ksbe2AK)t=turSgi9N~~mXXoC$7#W^`_Sq9}_E1{>VkJ`&
z9cR_@AaIkiWYs9|MV_8B$Qqr{f#eh)SNJ7Xr>=Z4<2o}e250uzM&pw#vJlHAO`8e-
z08ZG?WRg$5n3LTRj-m()cJ0(}vwA)!!2(`q{?$5j4=SuweLKM~_lI+QhfO|=nTU3|
z+~iF(drJD)BI6HN5U<1tB0srhUve$_+GO)|NWD4_IIw)2Ie)&rWp)Lxw`zE*Aao5>
z`+vq`CZ7=t75bCJzs1&KW8^P{=)=ctAOi+jmrc7etd0!TX;j?l!DHh?Kod>Cn$?A?
z6@Z%mx2fv{nEsPDIvm4R^*rHg@Fg@*3=q}LykJdSoBnd|9tDksz$1^7)gtZSbDA6L
z*1r#|$?8YHVenkOazOLptgB9F&(>!Ag7ii5Bkr}My}@?0aVEJsu+$0!cCt5*=kCr@
zx+Zaa#{dI;8N8@c*n6DK842GyJvnlVw+^0t+eWeriVs&|`Mn5MXLw9us7Zkq1+IXRCLQ*Mb;5`MJ|OGdK$2iUd~Q8QJIV!z4k9px%Jq{TtkyqHn@mY
zvO^!ZsBp>we4TCU_kz(x{~8dx3}zn%`(zAb
zvY!I@C12sPG(?TKAXroOkVCLF0=T%s&e$kdl(t3~x8Ux8g<^0sb#YI}`1Q~DDiN@m
zP10f$0${ad8X%4T1t(CdCUryj)~S|f;Xd3fbjhW$iUvpYTB!jO3(N#pERH~87<;}`
zvh-xoE0dZ7$Be#t&Y}C_J6=d>X1ZkzB}!o06hjERW8K}%JDWC30O#sKUPyj%bYnc8
zV-~rtd|vQ(j2V!q`*Sq0h2kfF+)+bu&k^ayrW79
z^jKm0E&uTkLHJ{10W$?J8RJ{&+WhHvv?4D0uwFU2u=W_fX@<`;5E4V&cP~kgs7beh
z)zVLDUiqnI*9XhqeWL0fE(2cDaEVP*@e$MS;V}5R2X;uL)g`J0jkYD43T8IWgPh_eyC%n@CS&zVmgod!91YAk{W{@8ikOVZj?2mI@}gcQ
z0yH`lhXYhpv!~vZ^diDKGK?;wmKvU6`)*0t9jS$#hSX+xlJiU6lkZ^F7-Pq5jKNeP
zP-asU6f^q{?~Aqz_Bl2A(Ex*+wNjJSfXVjEG_eeT1Q4Mdh8Y+}+JcRtcyYVvU$p<9oP~_yF(D*=~ee;GMgr
z6XdLlBYK@aCg~@JM6U-Ifn25SatZrLPol(dqa1C-M2P7aKw>EKFv1Vw=RJ-^vYf^Y
z>7)pfxH9iGG+YPSZ`m7>ns@#1dmDc~$gk=KUyi|oW%lFyYzzrihvErq@Indk*}Yyu
z@~`n?69sl8^73;VV?L+btv+{Hy9RZ88dYzNOmhMCIz@NnX>50kno|uY+qd@y=gZrm
zjC|;8-9YFL^NG%x(O8RWuN?=wU}wQAV9&a6g2PL6v~`0BlKW!M=4tg!il+K)urQhY
zE6iC6=fi9g_Y@?ZPmFwd04fKSAv&4qjo)u?@~GmYz0S&Y5lN3D5Rw#mWE5E
z@F1j)0Y?B#O`15C-cg0PRdl9}TnYmIda!SoKLG@!Ph_-0DBh_>dSdBYv>hed9X5Ci
zZE+w$SrV0NQj#()T}4-nz2X*uwMGZ-9?$FxPDfZVQaJxKTDjVG=|hOlcImy3wXpfJ
z$V#ajsy}sOmGst|0OdBr(EQ*jYG+sjFwj_lYq@WJC%J8BAAC5y-Zt1bsOB`Un%@S;
zDlk*}LcgTiwd6TyMr9eP5Ejlc60+$Hw!CVyY#jD^oavVb=e}m7nK?KrQAk~N9aP!b
zVd&M$M$z-+^iVGT#!8bl@x6JT;Q~_6Z-n$kt(p)x-{GgyJtq=aMmQZO>EJs-$39I!aBl)wH)4UfxPgbDMA#&{K)te_l_s|)G#c|sVoZzjV0&v
z0S7iPY+sS$M7(IAvYu(oT)XIZ$uD3)I)v(e8!EQp9HtbR7){qE1I0|n_w4IH-$oFY
z9q+K!Aizy_U-A|(k%05G5-3NnQ4y}B_$>eh%rpY`=QmAYl>Mx%yP)D2@)aEt=@tBH
z4hmEYL{p$be^AU5bfJQ!1L*zi!I#5Dm$-@&a@ycS#D!snYffzyctEe%lnomJ
z5nNM@-ZFks6Pd1Fj;`t?8TVeUojCic1aq}#@qR_)*Esb8t*AZQ^|=QqeOwpg+6aUt
z_zHP4(n&5s&0*PPn11F+x;1;1^qg={8#WkR4l0Kb-h>&B0WvlvmL(Ruv5J(e)5;##
za>;t!W`r{0=Cq*Dwy$d8V}!F$EKkbN?Auo-BPM^IP7KrKe?Zzl0A$%WNi_;(yGU7>
z^r=928xa8{ek)cVMxAcLbY~xf>nPl(1$QeV;sk=>Z>_TYDsH9Dxy5^5O|CR9$^uQx
zvt+CHWz9yn)UcO_o+j{LtJYHO@cmi{5_M@_366{CNy?vjX1gD<%?O&PiQ3&X
zF1__(a?7!wl&DrK5|vTMeEakrj-*^^cUa&9ubtJefo#cvNXQa5pwQVW&(G%Eg1pID
zSNEm==M$u$kBu?`_lT`-0RM`=v8ZVjY}AK-CZQqHoP?+(+7fXOY&8n&VT9^-rJ|B)
zQlMz$@~O0bs7-3r-%tx^+tFe%WWSs3FNXS^BJ`wntN
z7_09pSwOWwlu~@cO0!okV9^>x()(eGPf#uS4MTnVtp#gG$TJOYoklJR)r$oG2#VZv
zd*C2{@i3>%0c9B?aea*@ny9j*jVf|YK7k1TM(zF+0~p!?@2tsN^K8d+6h=_{O`F&U
z<5EHiZv1eRr8O5f`q>R%0O}8LrYJ&-J0AwR9ah`o+Y=QCOIZj)3FKWo+Pm)^*JRHoyHrOwlnGlx_y3M(j)Z2ZOVSkhl
zzXp=0^1tF;<$3D*O8N$%RvgOqf5LZHe1G{C_dQ$=n)3grPMz;(!qtv)v`wM^^_nvX
z>-)lmpcUkY8q`6Z}ff51>22j0-T3ja42Z2F?AVw0{(+2{`(-LbVw>1qSFwS
z7p+s(%o!7%22YzX400NHk=+=V_CS1`1@)|qusT`r53xJ^g5Cg+t6JkYHD}S0;6CcL
zSmfYStqS77C@`r*
z^tUOv<&=CK6irQ^QSKGLY0<7ukSe-OTzgbSmLAK>l?a)^tutIKtQD#%nlj_a)RPc-Vr7n;Yc_t?77vl(
zUS*AYa>h+_PaomafFCVH(N6fL>Z9A?2N9PV1^ktzvl-UA31etp`dRwLsk4Aft1oRo
z&UznHU2DuQ|5I%tM+yNTRIAag9v24>)&wD_s)fF*diq(q!!!$oVmPX)i-f`akTj0$Tk}
zoF0PZtgA*LZT|Yasz@9zH@;A1?C`QOC88TzzkvW8TwsX(K9_*KDDalQg7lJ+S4D7$
zcs!x9^#pO~VlDy#Qc@xNV$BWZ7n)#k!VyAWm|(7kPlK>1C=XTbvnRBAN&+KbQ^XIy
zpYw(r6^FQYJzu|xIU|a!Wu;jSGi$-BT7mCXgLges{iyv7h~qNB7=E_2YP?D_xb05P
z{h8COdhVShjAM+Z&J|oWqQe>J*y}$JIf1V`iYo%*h8p{NsVde4&vceE`7V4a1Bgy9
z62>UvBUcmQ%!oS@3ZbSlE1c{g`n`%sIt4FX<;l~rI%*$3HA}{4p|7tCIB6#
zREZ7C7LiI$!wgk-aQQcg0*{4@Kb)vJm~~co%g!WK>Osm<+Iq{vl%n3tlh!Uww27a6yL$HT*Y5d%2RsdYwb?clw(J_XrcfRHI(5AiSh}-
z`P>*!j3*D<*Cqe80t*}yU+d-FxcC+=tXv33Y+G}&G@~?Z
zN3lzod8-!;9r1U^&SAffoC!klgc`v-1%p=>Nd)Jv!s>lJT0U*&5URa2GVJ%YT2wdV{onz5$Ub%p3UqFk|g
z=pCoOhV;}TmD$bv1=l@$+vKiG=EK1VWO`ja%ZmWSl-ZLu43BxyU?f8EpiSPwOI&7E
zdc*nssM;+gd^+cVaGmTmN46vMc1Iw8VAtf^#vA~x5eO@OW4_GRN
z%Fa$9#Gg=VZzaKpA=KzBClG937_SYjyp*5}Sy)kh}NR+M9Gt^sMQ&HyMUI
z?Wuf#^jiF1)vHTP%B|p&3KYY&BM>Z^CQj%!)rE2!`a08Kr?jS{ArKinl%DJzehnjf
z6FKy$vLJ$!Gh6c!*B`?OB=?ZrELi8QGrWXTV55z&QSd-5EXjZ&3BBZc+q_IA^a|E3U?}b~+BMXSouYTUz9q-w
zsUV`B5!4ns@`$dcr~`K<@TBytjPR{O9VwKUW&%#8-6u2Y@j(b0PjQb-L0;I&(&%k$
zeHU;(&QY!zrif)D892c?4P2>cw!^;XG0Y|!>
zQ64CX&tWHEp$DkD8gz%`m++92DM`|lFeo4Ya#{w(mefZitPo;Gfpv8Yu;zDk)SQs1
zsp}0y1+rC_vN0B;HXfmcb}CZ>XbsuMh*5m?!+4b$VO)|$#Q2azAB8hB!9ME4UHMxe
z$b?h5hS2?Zw-`-WxeT%oKLQ^O4{>Gh1=Ua7YkJ>{X5Z`1AenhQ_mJ#KBcG>}@d*by
z?g_DYS4q`Wu!_kbv$e{lxQC-jl$O|R`Aq6RlUR99-6>He2eDKvW4yu!5V_hm&`@#l
znWc>MGiGsZ=b4&Ih$?%I$h*LvPj~F_caLw5k9o=fSTfVOe0rrtu&Z+S>?}NIFpc}kewv`96QMEA$T0UIfsbhgLA{$r(VSYe40&J+7^|{X~QgTIL{mG7n5H
ziMjADK!)r%3iMI+$#zRiRsoI~so+P(sj&VgkovRZI*36!bQ}tex0+IV9;+x)NPj%;
z-*4o>nKrHyG)=4F0GtvUB=<9_XnLVga08}y6h{(~O%C$kCGuQn8&%z3*18d~LP=@O
zI14D3E>Gs^S)Dw26G*l`+=?dZWDUSmMYj|QaI8afVN29^%8Jd>j&jc;2Q0=0+Q7;v|J-Nu`5IyN*0yfO`NqMF!Si0X`awB<%mLY_upE}#=iFQ-eij{a7Ysfl~I1@48m*c%sqfQQ<$VQWK(GPV>YeD
z`#c6hjZ>{A(n7~EzMd1z+D!CUy_>KRoZTCu)Q|LojP+N8k8krjQpz20?9sz=e+=8Gt#&0(ImswWyA3OdXu?40h)szTA@JK*s
zX$hOZXeG54H;b`;RGq6he8<@kMv6dDLn8KNu|!lBJ0iyG&$oM%kwxo*4As!Y9F_K^7-G-h72rXrig=EIMURuoU<-2o#9hqh3Q?aZ>4FTTt)*kkUg$~_Cf(j
zh=Ig8tN0VwPwgO(w@Q{5#waRjqmk5~hHNwkzC}u~-U0>w^#9x`ZnIqs{{d
zweAbpk6X+!AeQ^Fjx4W8s2%|G-HeW5iD@3hDj?Cfvl@a2&@HQir)Pnb|5TXwqiM|6
zHb$7FqcwnbD&m%3Vm^u6w)L+WkZ!WFktCyo?E>d5dLyHl8|qb6DN&8(0lLb@WdE;W
zrPb~9kShPnv}CQ#;qu+_xUKH_Ly;*i@zI^Gb!5~
zmM_laW|72YPk+F*tbYGYxgwF*KV^XunrQS+^DjgC53{>~<)twi*+8!^&X{VLUUMV0
zwW(+m%;tfp|L+gCiLIOomwNrDqr!hNlRM9Xd9d)
zv?3CvbDeN1I7jH^ri6@DwR6(L*~n-9_$~k~h#ILj78IwQXLm6R8O`(Dv>zB*G3WqP
z3>(JKBg!eIIS}SE>`Z*E<^4J5)IZ}3(ev&I-1_EN(5i;wlbhbZ&d-Wnv~9
z&X!;rt7*j~QFKfeTy`BV2(1
zePVN1^iW8)niF8uU1okWQ;bb|-1w68ZKam4>AhLv
zwlrV4jedu`z`4d{&t;tH5ky}&wX4BtioS(eO|ZRIZphndURRGQ$wvz%x`W{1Pnl38
znV+QS7Jm4=JPj_u?nDIG;!WnTbvE+~O1Nivjfhl{cHvz!IGs(yb#4OJv~yz1!sm{$
zLabDHM;iKPe`!5fI=vFS{
z!$Z^65?<3AIAyBa7TzDAsrrvRnyT?K`*tIXDueBr2Wl~lwVD-z1-)=nS96W7X|K5l
zkYk+wO&r9E<|MWn|Fx2br|VR;g>_X@ObW?N2ntrE-V+#xs=D9gX1U=sBVj|^tw8e=
zkxHoi`1L@Y)Dju(A}yGjvgr!ETu~TwEB5GBx_3%5pn2O<^5L{roQEytfLNrawcpnw
zY{+{aN9RpzR2FHzf{L8iA;quEW}*g%@&XYx6~winUrj)hvAW=U#CQ+g?O|1u5=$sR
z?3dLO_%|nOHDecgHqVI*Bwfha_ktQurRP*C=i>gCVw^`)j<1KCjOOr5y(L_ka1!aZ
zcls@Af*E^Hm7+d1GR3?0tiCsPgS=)xIEMmsB8m$IVs`sg)0o74JaoUFEi~SMg(X3m
zEG7VB76N~ldBVk=uibBimaSf_Hodz`O7Esu2@VA(qk{27F
z4N2-Sa2U<7|I(K|VOg~t80%A_*@8`*U7%4rnL|x|>0{x0Gvao!Y}*$bEa(-PU&wF&
z*qVO4RS;G;jffP}%C#4tUv~DGt8IyKlRt9WTGkPM<^rn$RFb!${Eb<625Ucj`=d6a
zNkRfnp8ABlu`(1uv|gu{f_V+E>~A3Nzas$VbnQy%dF)r|+y7!eX#&>%|Eq5&3jgw+
zRlIC~XSa|lnx)*_t^z^MBP^p^72y6yh1nL^-cK+Nq*!j)tv*LkVHyvy;|FzpS{S1p
zem+6)D4j~DIt>{qzuA1%0U$Bo&ZS2;w$=0zv*4obbh|N%u+0k;D=+g2S`FKkl3~Kh
z(ItfMK`fK|@P4uwQRz5Z7C;wcXk7-#cYu)4YL)ANP4$m9Yr}34Biz7aR8Pr1|4S(`
z?o0fH)^FP+d99e61KPL%YhTA6~t|B-LdcNX_Z|sLCqfXJ;QUB`P50iHV
z`RzOF0G=rUuO7l`JAfo}(Bec|JP<21{XV5gkt%7jU34C@+8Q?;Gm4HThdL9%(b~
zC*7F#AT+5rT9o0_C&88aS35sBkJN57y~4A)!kPV7qoyxWVw#kLfJ&xE`y{+1ucs&r
zu-IyCrfvk47m{u}f1PfMY%;su$7g8uPr@puo@DHCF3{KzNSsx`ZbuzI3BAS4(86|5
zwuC?{n4mORMR<1To~Y6Hb6!2g*m$Oeo*1~D+i3Uh4&PpBj7WX($3a3~N~`O!m?OV9
ze7%YtXvU4Tk6`Xk+E#zv$#Y#4+d1k6egVN$eYEXH__`%
zb>Stv%j1Zq@qq-2T5yIDPNHXZGd4o2n>`U;iYY8;&Y6+Bt+{pBwG2}ZgL5!ssi(RT
z!AC%4N6g2=^@wWRzje`N5E!p6>PTX8-8j=u_qv4tr(!{~aPg5L#kYv*dJ@u&Q;B2I
zzxty2Cz3MSU_bIlV?N$EVfhd0W|T+{P71N`k>^~QYT5O&^PfJ>HwJRb=Pj7^$86m%
zO}0g)!u}k>JJJ=6eB%HAHiIu_GZ=#H{UR#3W)
zv@Km+&^Vo(lM1wHry6L-BQj93nO~w(^jitO!ye)G#e6!g;-^(UzcXOTJO=h8IH+
zhWVs~Y)2qX!H^|0ZFc&V)x^T_yOa`{ooh9#{!(%J8g~4XBc|pEqeH@3Px+F6nj9;<
zyAXN{r7@yP*ShLZXf-2;#6R5y%LW6QmppLM
zzb-14ZgEFJ^3whnhxDNsK(G4QClm#YcDOpEi+HWf4jL0a%dHe6*u^B!9VZy40{<)M
zMsCUVVvRRSnKMDJ42LoDz_s?jCiOQ|_bAM5*S1LD`@t1ue>^#=au_
zDF$wTXJ0p|{>IMyN8Ix0CZw^w{U|c+y^1~kRHq`EIZr191#z51$_HP~
zJ)xkaT%Q6|dw*H%ptnA!N32O~KwAtdJ2;kgK+1wAGQca(ITGv36HYpmZ|nTJ*D-N7
z6N6Vy){Km_!gnep;m_(ozu5oRz1hS-2n^vTDQ^cj60#SuQ;h@dK0POgj`S}~vH7mf
za#jRMO-*+0qbusB@qZ!=zlyEZzmZ~igJEuM5>WHp?(~vW!O(fsSUJLwlcH5~mkfv$
zG=BlLI*ulYUKkq?!l4gxhhOagaPZAdlwiA;W@1q3-%c{?8jQ1FyMzR9oCOaxvDtW7
zVs;nlVBF4tqbC-jWC$(K3*%H0S(SmQdSMWUPlq`>UZTFooSoN(a?4Hk8VdG#0QJhc7e=>MPnDthj+iQGU?Fqu=~dzl2O{b
z0SO2=tF`1xowHLYJ+;%kyidqIDjz6mk>32g?xzmN)R+B5?krZdpWdKZy8D$0VR4ZL
zZpj+C2pQ_8vdqG;zgy?U-xEmP>Q65vY$gsrtgS+7<3W{Gc!Z>-glOT8`{G^8EH8QL
zEOn#z#RGv-)2ytdXP8xfunUwYdL;EcMMC%oVX+Ja&*VDmbuzxd%I|4=_tMLKR;(11
zXvml6gA8<2U<#xG)ZQglW5edZ?{k)%6*si`@$zXjm^^ggegxfc
zuDc$QDt32aB#qLcqDoTR(}K#v+xzfg=1i?vF8^WDPtM9nYqYB|U(S=~
z1+s$U;i>h@Q$sUa$-!0B>ioBO2}_FfG=Gfcx$?=|<6~r>Dc`SI3m}vVjhO}?2a=CF
zhwWbvGPI*!vfUJx0bk|Yb{lTU>W|c>sRIF&uZN!nf71C3cw5Ynn)0ts(y=3&!Osd)
zt&RymU4A~=xjBjpr~dM*03ZU%MfBDHCDk4Kt|3Igfl@(mL>bko$R05=c}hRF6{obC
zXnH}=zIeP_y>A~|4Cbuf#;r(NISzzGkUQPSDJq*RyU;?n>ifgERzCV2Dh1`qzBjEf
zV*6(GCrm%_Cjt8aehd8UXx8H^hL?(EBT0nipC~hd;ld9Rgo3cufJoKRw?zx%
z_R&;D1%!Y@joFJ_m{f%=(X`a{iJ7wNi-CzWw+oz5fUZ;GQou_OeBWXBCv0ZBQ+3U#
zV*z_-&BETJt%H5pNB0zvQ_M-s+ojV6_3(aHuraupnVKhV!^mb`Ss@5oC>L`OK}u#-
zw?AWo!n-?AavQov6}(w?wXoB`+O!WM{YspMmg8mP3GYO3k%c=_y`n#SdDd@BUPo`k
z!pB9H-NLDIfK<2r{Q!%bW@bJI8N>JvTasMQDTtyb!=1noPN9XwkaM%Y2Qj1+Ot}%J
zc5YsIAPtg|!5nJp>m~wQU-Ax9>u_qtGQ}R&(L~`q4gS8XQ+;6UaKHIZ<&h1o%n*34Y^Q>COBJ$tm(=ZiK3@piW|G`fiYf2KQF!
zox&1{9+O{hepV3)i}}C)zrSL(z4Xmx(zH21DbAW=lxa)HGq{LjQ0U^jfFZIoF)8Db
zQARy9QW8n~pG4}6IR6Dw-Uem-!4@=xZw^D=577BvV}5@uXq+zf6=9U0-}u^qhzb0g
zYO|Ht6v<1$2;v{?Gvd%twZwd~cAOQy|KE&^LOV;H@J6X%jkPo6dgDJVKh76AwtH+)q1HC>9bo#h1XbaPq
zOY9U0(*oG)R@LC7-{++IpS7l9eHbBuyM~GuCyBbxTLc0fzJN{~4HHo_HEjNhE+;Td
zmzybL;Zj>&D0NseERo6G7N8T0utpaj00g(#uy&Y$(O7C{|M7)avv^V`Iqj2<$p|e1jaAMXc?%ZIp(3+(;)(e`-zV+BzjqQ7IhD)Wt{rlW>?VkFJ{to)
zx6M5h|8qRmICC_qI$TmKhn8{&j7A5HibnTyvTy=mf_z3^H8lOxOZS;J4p#=2sz?H!
z-?3L&HVPGuD1+bGrJ>~9;yJsL%vp+qAeBK0ERP9k(bF|JUgnsXW-!E{e{~$Fn$NPq
z-+TMdIc8CDsG&=}8G6$(?+N{o(poy8Sn+v{ZC$$xF1=GI!90KSJJ(445Jm5c;*t>{?)lie%t}S{O
zm2&M3outl5@UB8-S|Wy@L99sUftHs>fgNNGPfA2^2xv8*21CT7v8c=hK5a(V?-{_%
z#rU>NnNMmDlQ(+r}%M}%cQWr=$%&j`e(?C5@k39#n%KZXmeGGnotBH@M3P6RR&$%j3R7Dp^{mtYz
z)*y*S6cvzzNliYVe`F^7)ug+8*LchcCCkI6DF$&jb(LA&g+}5NeGpnMp39VE!7aO9
z9|49WpVN|E%~An<;>D(DI_pPeAd_vaJx$W82z>6^q-j{%(>uo+2g!Zm
z^~wN)3bH62Tv=&PXV*y*o68W^br!0VZHw&PcY?W4yfcb*-TX=r_T5z~1@^$3kq
zN}mZA+art`g&)gQLf92-ckzzqB2LY?EKj#DbLyNhDqA-_R@-{26k0e9D&-~c{4Xj3
zCB~ExlZ9Xk6X`yVonP6PFRi||Mmc#>h(OZRez!v*)1M6?f&@?l#2~GrIf7yuyN()u
zW@IVG=$UBd`2$JWn?2%6!Yr4jt@JW`LhaAWf?K5<2GM|_A6lGBRa7@zBWndMWzV7S
z8y11k81AqpMnLl#WA-lwOJl)6)Oa*?KQ<3&pEoQ5SAPuEZt$A$i8aPX>qN=e?x;+x
zMf+-(k_E~3V!P{0LtpxRR0n$COe-Aw=WBGNzvEI7?4C7P;vF79B=YpmI7un4v#^A3
z?0V`-PaBNdGvp59AW`|JKfD=uP<6MTd*7a&3SuQGwNqw0u=N%`6>Vx&VcDYEFU0}D
zHX)yd^9G>AyJx)%fG3H3ux-ddF$4ae41ua62YcI^ep&LHcLlV*rqWfvC@KxLRo}tR
z&EXnqWG4NPvtn+kmdZz@x1d#zKZOfLRtM5QWqv4V+Bxiha(v2X;^U@%V#p>6si-^ZaIY)j$0xu^3k
zz@X}D*btwY4P3e(-^?;Y6cMmCxO2%nev04oV?M2zgkGxgKPfay=a|>~^n^Rioyipf
z7+mWo1*HH~kNWEz?~}Zgz5!t`Vh~x@DqE8MlA7(2YJ+KY?b{Zi+dy*HG$bFY0$fE%
z_hh1B;o~DnG8cKgjWrkGiahY$IqhWnVtiDXJe(PMh>TdGN3$@e=#`1aBPw}#E9~Lw
z2YK}#J~Tk0-Gi{~_KZu}2%{lD>XAK(+nhSWdb{gN!!876)QZ-okL3>p%jgF-VwG4J
zp=66^1PX+lcg5b(bHZb5MG2)rbBQGS(asj+)ue2V
z4J9kAnq~S3^Ruh)dy##>r5+zBF%A4SxW!L1z&paHE^L+#wc<_+gD=MnqA*e3%pb}X2pD(2ea
zHFKltGxoY*_YeC(@0e<0FoFNDITmw(<=rDJN`Hvdq5VneafZW#0sV}8c(O(kPy8pz|X8q%NN4o0rEs
z2a4U*%)SWt^RoK8BoH7H3we@EkN1zCy@`roS+@GhN#v`Qm>fH9Jv!lILK_7wguFSw
z3={7c4X*Ym)QwsF)}@emb;_i6S1n+pr?61-?;5w%AF1qlMI{!})o|rv=_~3aMC0wu
zt@|m~KuZI#j-24WZ;WczXtRLaNwuMw0{;1iB#19V3Ctw*myD@lIbm^js*wD4k9ZD~
zLzL2|+3X>oLUYWQR}4BPxGUFHmt)+WXQQvh$Bh;t@2F%jPfXjji7DQuSMY}U
z`sik?^{xWeFA=d_%~;M!L1qZHhq~DYmJ375fYTWuXn#9<-DLr8P2qPVDS-#NOQ{Y-
zkYG(}(8ji_9468bPp5l)Z2fz?!7_+kEo5RAu2bbAxZf$r!m+Djgq!Ya^hSXaOqs79
z$&V+%*%7riFlQX1ix$xKX@aUR$=C+RTWvrqb8M%8gU<)_j30Bi78QivOCz8
z$U!9&!?*%z4BM}664(XK|I{eI;!#M3F3&*%C-vgYy~~X7RvuD^<{~ACHuIyIJa|UP
zc?i4QoR1(`j!|A1khV9fDj8x1_P&R!xT~ZZgeKK{Dv3Q?aT_@C3h_p;74~bZq~iC4
z13XY2lel6P{_Yf#<=473qOmD+Hkkk@GM@}}T>=^cBs(;$A5XMr@y&c~b0maJ1*xUD
zndg)TmS8t=FukJz$jhs6OTa@)^LYZuo8yn3NRwU7MQlotTZ3~vHp^prEnYw@7wvc`
z*QK~9w#*62*X|I{-3038!+OpSYdclK3ITEe9|kWZun6L85`gd;a)KidEH08cOiU3X&*-jk`{$Rqo=qdU>^<(85-ZIzDrm#9{Y)8pH;zd;>{)+ZCd@P2fLv)
zm+xbfaRI|hKzKzw{fQ8!K!hT0{n8aD0pRbujGkT)44VGPz$l@DMSS7lkK#4BJ@Ltw
zYag)`XL4AMb%$a_@a^WF4bYU|qm|G~YZO=AQj}P>J2*bd0kPxO#)J?mg)>sE%W9g{
zzjc~b&WDwYu%BR>JYk%SOc|5F0*P+gCr77DZQhFI;qdfxggIqyoZrnnIzVPHW4EaW7hb)YPVaEBb-KQHe00}eBy^S7n%_4uq_qgbrU0tYsZEMR|IBl$<6QKf
zn93?NveZ%OUy{ZR-~Qgy2}nn(C`(x5GRp5Bn~ERt37g5
zbsAWL_u-pGbqk@|8${V9!xMtw#1kF7LTCw$E}N?i(1VT(Nt-*P9AhZZ{-I6!19VU8
z(PYiE$-yxhp1dYI;$-+lay#r)Q^8G4@Q8KUXjMGIXx1U>SV0slV!LWcz(VyAT4DQ@
zs)|fp-LG`*+?+nSpO&LlGvb>2%VV4m1jIxn)|KzWC(83Se6Y}wf%S*sFh=_TJ#D`5
z%H5`TJYHHhl0cCeY5EsU_&050Z$JL{WACP1yjbU<0?UaAlgU;|q57uhQSAUiQ7q1U
z4<4Fn!bo>*g3rFOaxc^T-@lpFcXqB&&x!;TZ{-|tuc|JEmAvz1>FOaWqP_i9$s_r$bS#)pS!D_@y({d1Q0!Gc^TVU0(EXj4jDwA;n%FYX3`aPPbK~2a3Qr
zN5y~#9R8Cq-ABC;Tk{3kLt>_#ajjEhg;7YhY5)+(7VpeAUu!5GKG`<^*et*=$flbR
ztBgS0LgVI7FoUkDp`SbFEL8QsP7S+vdEYTcLxH!u@&Ls^2$$TB^6)tS1Ar`_Tf2~2
z;Ivm;b8wv{a_L=ixg1_bm&bk{fdEegkJI6tkVzgY{;PqJ>BSSc%^Jv&0h++cKr$LVTlRL8P%;%nH6s41YimZ
zf206tc0DG-{o%b%W|L1V>HcOryMjVT%j2D&6D1rh%^XarZ^dj*F>ApkNDvV)I4Y)1
z_OD0oE03l@MH-ypvQvyVb1rTri4>Aj5y2MLUc?kw_}^0_UK&USr=!u(YTw9TFBkuv3W5Aq+pzQG4v1RC>c0
zu);_AA`HlYQ7X$!MY=AhK1e2-f*t6PPn5L2w9txomMZ}ix-v(
zb5H}2PB8IuxItAcnWWm6qJ
zH3JYBcSfbnroSd4MN}w_-|7USZ8TY8d0tKd&UY65b$==+;qUhxIg?izOu0tIW&ZX$2Cy
z#zr{D^{CuQ+I;ie4@omXWpRwXQGr;tET&N2P=ZNu0406!Qgo%5MWW08VYbxci=bL$
z&5R-&zitUak+Ex4i}a{j+=jLWO1j>zWKE9g)9AvJ*z?Oj*T``L_U5PwJe1sDXq0DS^H~;+Z}coeyL*f|}YgD5R?3JduzE{>bSx*us9C
zyGuoCDv0N8bY^#wi!&fsgJ{w#4qLp&++*`2iQphEk&-Z^CNY|>CA>(7hh|ViUH%U}
z%7*1rE57QKUGnd1OMbt7N!Shi(l--z+4-IKwdSqZqZTnoV)Xbf1m?3eT7P%wbsyyI
zjmcEvqw-X(8k>kG?82+Mq6$oK!7{VfB7Kvx%?xXN0)g4200)-)`qDx0vs(P1x2&CA
z{k%($GV~)JX$U4ZDUTFOghjp@FZy4mV8zDpmpl3W=e1ItNnr&PiN2w4>o~hC#rjfr
zntJ-;VPOF?VBP#d-vgL_BhYC&mhVjD;~J{Y-*vwI{;Ep=XmZY?M@=6hX9^oi6vyCG
zA>6@Ghtm;$oKf-*Fh_dp_3%pSvw%3Q6)lPy9p$KCB52e0QL^ue2~BWBy4~rM_(EUE
z)GWRnGcvxwMcdkMY36|-5d%>%siGftjGo%UZdV`@o1^^}wVC$UPZ*MB2LOh%d)2N2
zydIr~QZn`9Dv!cU_lxVA#s4j3qjqA0D(~8}(G+P}BvfKhX$p89P*ppoW8zMz@0^JO
z*ZpeZnPdz#(`KAu-&y;Ph4n!>2@0((43A^(R5q33%%9X+autW|IUIH--i*E1o;TSP
z54kq;MceaC4TD3@TgiuulMY~A(0~8Oz#IU^#K@k{GCzY_m7@^Gj(h!aw+w6i00e1&
zp`f-i+KRUEfW>81E{zE9zOb1Dey4S6fnILdsSU;r$p^|5g=N1?)bN6trzm%1t_tpN8I*Y@9*0k+#G%>0yZCNbQQ=JOjvo9@
z7b=W=nbq515$U|(%1x@R<+Lr}<1}Bu=VwzQh0)>_pO1c*9aDLHIP>rp2BlCAKN9K9
zsS+*QISUywIS_%6N@>0=WwhS_XZ^TT!2{erZbNt!iz9+JeC5kZE-!xT#QhEEVd1C$
zPh2aav2jYAQIh)pOPvggXoSWGeY4)app>g%`VdYUeG^DfPq04j71(3=eCV6vtaPx!
zzMPYaJT%uI5BStB5sjP2ltuIvgOuhLSW#F<25Z=)P0?4!H^Zm8xfEY;%7o?G*&&|F
z1~}ct)5KXC!KV6mCZa9f#PJu-u+jDx72u}sjOnqt9PW=oI#@1WM7gJ7eW~SEKjPVV
z0~RbmuVt0p63ylY?6p#aZMNttl#TL@c{?U~r_b^MiBFP_ziqHBk@ozm_7<1(!6b-3
z!84D+*_dQ{m0|&@L4aE{iIe#;)2*w@Vh4jUn`^qrX&CloR}+#t&_)FG{~Nr2aZaSf
zN^3*y${x(#x00*CTUbT0OnOe==|)`SvSi44t8}MbK^U~fj~*7kggW
zA7mzaX{N$n=$Dx@q#1naUbJ+n;>jQq7|=w}vMIL;I+GLi!^T~xfb&-_gnco>dR3Snh^8X1h$fDu>+;ZO$
zT&oa}<1v3x1mX~(T6)w<-b?Br78k2~8hE!H-t%3+?w=?&a4qxFnNV@vrbF41=lEmxO>nZC(9P$kPw$~A>~RVJ1CD!@PVBjE4rya4uo*f
zZC3_j)%~#XDW3;u5~SZcb6*BYt(}k1%|;Ll_g&~-@l;6m^LZM?#?*i6cR5{}lT-sO
z#5*}l(}5tOKl>C&?X)>K_E*mqAL!MJjJYGkhO31dggcJ=`RifW?QcTA=}ee~o$)Ov5$Am^NONh3E2AyB
z73i@<5;Vrk(7wo|s;3vi>`rbovxVmc6D696+*0>W`RY0GH9&4x;+E*}i^Ius(UrFw
zVS%$;;ZbFnXrqf?dag|gglTZRn%%}B07ozSW9*c`i>)QT&T~Qt9u$8a1J~@+Wj>+i
z92ejND~o}bi##)Gyu;{p0T>yduIR|3ok}Uk1^4%f-+HLzis>J9PucEqiSM`I|3+gl
zk5KkoV_q$>Iw>9A2v_eV_I+ZRSZIYqk=-<7vBJ{W0Ed+XJzd~G{yT~HlMVLWF0s%X
zQYBU&UQ`?(hj_0mdL|(+<_=GhnHxre%#m)-(*)9SvdzJYWp-!obwMnoM3ycJvy#D|{9
z*HR==P2W{aE}Z!G($Am_8W2DGP)R~P*-Zn=Rs+hg8Ov&7#+kFSXbMrx=XJprt%6*9
zc4-gqf%-?_M}A!U<^n$adx=9i^uXH-TJX$o%%ku4?IcQ?(3_4(+ifvqWqTP2%hX4c
zsQk&%(R#v1^r_0j$3Qaa5$nAXec@LPWWz(khk*@g8#tb0cjac*Y?MB3lRgv>YWKC^
zp^Yoql=k-t)kEY|URAftD4~!K6c#IGx&5>VAIB1E=t}i=t536bpc#Lv2XK7goin=bUs9l}z#BZ>QF
z`&^+oyVzVZHN&#;d_S_qEp8}#=S8M}(JF?FAIk!Nf@tP~@6yKdHTnJLQE(Vcpj{#eDk1#{FdPOd^V+9rz<*tW3m5J?BT0RxE-cRgc>W<1-
zRm^AUPJI8Os|du*W9DQgcvb(MS)%C?gJs*1u_WwG2ik;T+n{Ujy#5euG4
z4XBjGcV{>3b(vKw7w9RAfZhgKY0T~jY;<^@KPrg_<>=rP@r-+V+e-y%!lVc;mqwm~
zBT>_Swd8)kMDWCy+4EkCWh2JuSv&abd%{zF_+i0Xf8#Zl!mst)XF>ix?_*d0N$(@xQtx
z7i&ZUl?<_cQOGy?-26ufJRN;Rb@!)wV_#0S(um-D85Jm`#X>gYsF#!RYw=i9+^DeQ
zBYHmTfPj*y{Q@uRy+D9OakztQLavsoDA_5cJA0$Zj)HVDoj0pZ!M34~A@{6{Co)zh
zVMBsA;EWCah&tbh|B`DKC7&CNPbStJk~{Z}NxkZ@YX(LUgDeXGk7+AiH
zRzv7l*j)@l!N7)Ou>bJQ3Zvf@6q&UUe)uw2xeXj?dTQ2sw>jGHTF#U>SXq+bLvKM7
zhkqX-NkM?4Sp=F@%!za2Y-f)q_o%(NT!3rc=DpVxm{C}$4?^ZyE?oZ!vn)ZcsCruB
zuS-?d0idJ29YO768UDGFk$kNcTw`#D31Bc7Uhg}&s+Lmv29ejZI;|aL?D3%?DH_wv
zb}O`#r{C3Q(#>j_>0>6W<24+%Q>viCyTou~Xx=lDj(o4a>&3()=t6|Ha?R9(R>nPO
z>5k~I?_efaAnPbvOAFNx-)PV(UBLL%kN)>9#2Pm`$^Fq4gZKg5gH?>LX@A_lBxTSs
z*vmv=eF|`%w|1N?hqF9=v~8i1X|{>1)n1{MUOWrCR*9Q*c0nD=kR?WCKY8L!s`*
zB<`GXLD$hqOYQ|zfFp0gvz5CKPfS%|+m+~=`qXl3K|2}N&PQ~lnEux(hlv5PQQRbJ|djbK_=N6wkP@+_52|)ybjO;b(UIrWOyB#G_
ze^e(6cDhZ1yPe2g=o|%gjrOc2j(^teh%1R^)Ev;3GXr2f1yt1Hm~1>{?6ZGO0*cuj
z_^!BTV)q%Z2ko7LjZ)rF9nYN~=|X&}g69JWQrgAdn_nIb9Fo$Fr3kCAHau%)0f3#%
zQrJ(BiWs58e*#CMSoevxQ_h*18iFLjg1(%LNWe6@^`99<)2j5)*&_!wg`^^Z;^e*Z
z7KVgVR=W-VegXsnM=+g1G
z-P{bNCo1;JyKh*||5EhP4ay8#rOO*7=oKaA)X~uvCPo8DaW2LokpplU)g=?nQY(c5
zoWyhCCNp04i*c(x>N;Xy;%TH$ted9!Ci3}(sF=F-DGPE@eO&Ytxac^c7A#Ks-_mfFg8%gz>mN(0)H|`?`4SeAWXxmNdiQBbh!GN
zFR(g1YXalFI+PWm0uuUD&svWY`mv8c{NV%`fAKn*t86vOc$(q_S!^uh-;%Z%T+_x?
zQ{@LZ!g9<_*#^v5o1z}(`m13!;{(7h`iisB{&GvIgz#b7APbEHwDE@ZftzHsSEKd}
zCz_XqF&=ZzY|0x7AGxs%`L4}|&u2}%4zybQ=I7Qf4U;OMkZ{u9qoN5D+ooz+U2bd<
z9Sn$PCC$2$+E*Hdt|wA)yd;8A*Lh3R6%ZsoJLE8tp4B%RO`M9KLr&w}4AEQ+hu&8A
z?r?ebgIu<(K?Hd_jKVTV
zHvdo%j0hf=`hj~DlM6fH>&w4GV7JC{p4F}>%Q{2M*5bH1yX>|K?DAXpBP~sJCn#0Y
zx4E}WgkboIf$gclzLvVo>$0(R_wSde)w1`qbZ%Z1*2Mhl=d}{1^$wWK#-$fp=2QKl
z&96Ng1_M{EDo@S@aW&EqjjH}a0(J54`nEVdLuvjTqn%H}!nBoO$
zd#{!HN>Hq~oOT21dRSG9OR<2vy;GWtX1KrcW|1j2
zTRpI_vh%+5J9ZA`dq^tulH8lLf{rNlcnbl&V_>E$1Q6l?0DWRHY5)PN;sWKu57N`g
Qjy^CAivj=u00045T3h=u%K!iX

diff --git a/man/AMR.Rd b/man/AMR.Rd
index 13406b27b..ccc786ca6 100644
--- a/man/AMR.Rd
+++ b/man/AMR.Rd
@@ -12,7 +12,7 @@ The \code{AMR} package is a peer-reviewed, \href{https://amr-for-r.org/#copyrigh
 
 This work was published in the Journal of Statistical Software (Volume 104(3); \doi{10.18637/jss.v104.i03}) and formed the basis of two PhD theses (\doi{10.33612/diss.177417131} and \doi{10.33612/diss.192486375}).
 
-After installing this package, R knows \href{https://amr-for-r.org/reference/microorganisms.html}{\strong{~97 000 distinct microbial species}} (updated mei 2026) and all \href{https://amr-for-r.org/reference/antimicrobials.html}{\strong{~620 antimicrobial and antiviral drugs}} by name and code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all about valid SIR and MIC values. The integral clinical breakpoint guidelines from CLSI 2011-2026 and EUCAST 2011-2026 are included, even with epidemiological cut-off (ECOFF) values. It supports and can read any data format, including WHONET data. This package works on Windows, macOS and Linux with all versions of R since R-3.0 (April 2013). \strong{It was designed to work in any setting, including those with very limited resources}. It was created for both routine data analysis and academic research at the Faculty of Medical Sciences of the \href{https://www.rug.nl}{University of Groningen} and the \href{https://www.umcg.nl}{University Medical Center Groningen}.
+After installing this package, R knows \href{https://amr-for-r.org/reference/microorganisms.html}{\strong{~97 000 distinct microbial species}} (updated May 2026) and all \href{https://amr-for-r.org/reference/antimicrobials.html}{\strong{~620 antimicrobial and antiviral drugs}} by name and code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all about valid SIR and MIC values. The integral clinical breakpoint guidelines from CLSI 2011-2026 and EUCAST 2011-2026 are included, even with epidemiological cut-off (ECOFF) values. It supports and can read any data format, including WHONET data. This package works on Windows, macOS and Linux with all versions of R since R-3.0 (April 2013). \strong{It was designed to work in any setting, including those with very limited resources}. It was created for both routine data analysis and academic research at the Faculty of Medical Sciences of the \href{https://www.rug.nl}{University of Groningen} and the \href{https://www.umcg.nl}{University Medical Center Groningen}.
 
 The \code{AMR} package is available in English, Arabic, Bengali, Chinese, Czech, Danish, Dutch, Finnish, French, German, Greek, Hindi, Indonesian, Italian, Japanese, Korean, Norwegian, Polish, Portuguese, Romanian, Russian, Spanish, Swahili, Swedish, Turkish, Ukrainian, Urdu, and Vietnamese. Antimicrobial drug (group) names and colloquial microorganism names are provided in these languages.
 }
diff --git a/man/g.test.Rd b/man/g.test.Rd
index 8d072b379..39a42bc1f 100644
--- a/man/g.test.Rd
+++ b/man/g.test.Rd
@@ -46,7 +46,7 @@ A list with class \code{"htest"} containing the following
     \code{(observed - expected) / sqrt(expected)}.}
   \item{stdres}{standardized residuals,
     \code{(observed - expected) / sqrt(V)}, where \code{V} is the
-    residual cell variance {(\if{html}{\out{}}Agresti 2007\if{html}{\out{}}, section 2.4.5)}
+    residual cell variance (Agresti, 2007, section 2.4.5
     for the case where \code{x} is a matrix, \code{n * p * (1 - p)} otherwise).}
 }
 \description{
diff --git a/man/ggplot_pca.Rd b/man/ggplot_pca.Rd
index 671e01287..bbbd83e87 100644
--- a/man/ggplot_pca.Rd
+++ b/man/ggplot_pca.Rd
@@ -59,9 +59,8 @@ ggplot_pca(
   }
 
 \item{pc.biplot}{
-    If true, use what {\if{html}{\cite{}\out{}}Gabriel (1971)\if{html}{\out{}}} refers to as a
-    \dQuote{principal component biplot},
-    with \code{lambda = 1} and observations scaled up by sqrt(n) and
+    If true, use what Gabriel (1971) refers to as a "principal component
+    biplot", with \code{lambda = 1} and observations scaled up by sqrt(n) and
     variables scaled down by sqrt(n).  Then inner products between
     variables approximate covariances and distances between observations
     approximate Mahalanobis distance.

r|hChsgP-dtR&
zPDwq~(ps0Aw7;adHda*|lh~P4*k4q!cwl;DU*|+u_h56=bZ6(Cbg?0vwa2SqR=c?ub$ZCzPMBcnT4hSYUu|<3ao3`
z6Qk;jON3wJ1g=AfiB+n-TcWi?nuBXBlc%828>Di`T>Q25lX&(a#+F51LESOQGlgaC
zk?|RJu702F0!pUXI7&@OkOf14lFS4lATlzCEvTJO3i&a%O;M)3G-onw%z(blcowr$(CyLa2RZQHhOTf4E_wr$(?
z?Q>3j|87=Q-elEVl~n#@%{iVqhPyaU6!;mo-p7hN6s91TRY?o90D==j6H+t)5jf6l
z%B}#i?T~@~Y;ceRDMsv0N90wIoM>z?R0VsqzpM!mCL^P8!s_5dz@jwB0IR&ANFX3f
z-!3(-)dkSb-YZzoKh6lo+TOWXHECaK3xkx;mSFeT*pv_$4v%axjyc!bXW&
zQCq8kQyVy@xW+|+q3!$>Bn?ZfbjTtG5(Jvi%PQ}o&xD1PYk*Q2Jq=MJPihWgd_1MkB+JW0&T?p
zQZa`Y`D)8V85?s-6E2(R8OIev7>W;w0FsZUl!T3yTER8iBWw^?Bv3B7mubTutR4o2
z*8o}m*Rej_>Qq-ci=k470~euUm_lT~2@`9(fG*ta-0N^IG<@Ylf2y1@K2lzYzCS=0
zKhR+tRtAdha0?F6TAT=`4^eX|Y@MD4zXnI+wGQ9!^M382X`zXl7##g2?vlQuGFqxU
zMvl|Z{&@K;MG2f-cl+O(mfFYG#fn~+yT|cqe_EZc_uc+k`vG*=`^V09hmVzYH?3!DyBoyX`7maJAbx|nF5yG6yN^`Hy
zAJ^D7QlQSN~c+FYB4P^ThKJu9>g
zMCFb-ABV|UB~i~>rz5O4#?A}ku>i{mjZT&KNA
z_YBaC0}3(*vx!LO1WQ~+DyV=0twiPrhER!wnR{|heSmwh_-P+sL%WD5JvoX1kt%yB
z3j!S4NI55lc!!1o6-_Cuf(ZvCGf2Pt6p>^s1@FjnlY#R=MupyCENkic+C@W|4E=C}
zgy{JkY_>WU)et021L~(-?x^fvYLG)9AE$U+&u^b(glNmhmZv>z`QrPOoud!TH+jV4z8uDYe2o6?*gXKIbm(ZkRc+#8Sc5_c
zS0e0|5axv1YF)6hasY74?_=bjEUR1sf7{0li;~
z8i0V2F2{MLILs}}=A)6SN`IzT+j~!CifONip_{oYCVM&+$A2;b@XiJ^keJyY!n8)i
zogR+M13?=ipUHrzK6(>;enOLoGCKD%*c*6{E=L&5*$7dDx+{WZ!i?_bk3cZCIdXZf
zYJzw!5zz;N3dN{|~QaJ09Y}68w01?B}BwhdOpt|2@VjhL`+4T#g%+Db3|
zm0e=3iQh)-Y=>q0~-39p{x>VNFt%%Z+iUYwaW?tD@qlV$tw2GyIb58prfhFVLah
zs$vCUiRFZ7i{`O5l|@=SE3&4NQ}s?2FbE~9oV3f!Zek;UB~XhbF$t=P#$WNkJ>i}6`nkuAIgaO4ov8`e&3tE6a)0&!@w9m93O7@vm4u1
zobZ^9K>Vjp&Q*|XdZz?@%#LV=uRnVKqXLcOek+2~o0ml#sbr?p8R#k6zo%utK9T@(
zw=J4p!o~S%Za(U09pEMB=K#6RrnB(WS^)1BYs*i@6a+it?Q%KfI=&~U74(Z@mNk-O
zuBiNSDD&MX(j1^+#uoR*re}C7fT%Ik^VFI+2Hbz3N?#q-5V+jpyzjOWEJPo}yDf1x
zC_O0Ntw_q=p58tmk`2liV}UKXF9b(h#2^$wnnczah=?#P%oO;oe%pv*ks`5dHt<$_r=
zt&kAVH-|sJz5MELqHcI7cz~i(94yryyex-na1fiwuWNyMFDZr)72n_R>7;p^BN&OX
zEB{3%Wuc><4)Ej0+tHwhD*hg?7eC+cw;R9rhn=5yJvX~;K0n8|^Y*2QvT5&^{ipK;
zBlP3gZB5;7XXoy&dgID=CkyZQ?e(Lg0i&0dI`4+#l5Ttayz=*--rhH>V~KO
zS7|xbxwG1az4KJ+k!fi*H`-@dogD7<gi`
zsJf)6?84=qXBidcIj;5;hIGFfX)e@rg@brXrH~MftwF=qi!$Ek1sLON8AVc$&M~bm
zF|Cd9EQUs%?Kck2^e%B{aVx0qpW}+11PCLe1w7^yud<7F({>`c64W3nsP$$z5=|D;
zvLTsd3?=q)L;EUF
zB?$QXBl%Jjh#6auurhz`VR~nPGm9<6Djs2_njG#|TdP*-83N2M8f?ftQCn&ePZtoB
zsAsO$0l7k{YH>Yp2jOfgLQw6QH?y<%E~i&mZ&#SgVWA+I2?3LrMy7k5`VRXeZ+_Uz
zM`W-Jg?KO)cbEJe?JrcLTAc=1f^QgV-@+K2dBJlU2k+x&Bf?GeUxC==6B)`CJ^;jH
zdIyaML)XG?0li74HKhRZPq{eyN%8Pigy=Uz%zPbF7a?m&e2|;NRySUWYmGC9*^DK
zy~c6FJOO!26T!sm!DdxaZ5ey>PNrcybWchrr?$q?34F&ZD1HN&6xdk#9g2xH-mRf2
zH7$4q&Wuho5?1noKHkY}pmCP5VMOy){5+sS`dAAcREjZ&dx`z^C>ZIvPn$;`My1hY
z()Uu*?tuJPf+0BOrpSZUSBoO>^)jjIKncs*zr>4B+oCa1{$MAbcVbI2F~($imw&F?pwX_RR?
z5>%4QyS#Vny>DIYY?)3GIPpamw`a>U7ypI^8ljY{O@K=0{7erY14-Pp;y?OYU_q$?
zelidebNC=cqhTOqd_%sN{#dU8R)>YOQjl1FeXuG_G!FtR5fpcCG?>gRBRvC2wh1_#
zJW@Avn;HXV2gBSYK7wGl9svNLM=yOazjc4~WPBWHut*5I`_cT$`r?;vsEy9GvJNCb9+t
zBU!&Z*S(MwV|`%CO2(YUA1j!UGn#6SU@(ZY_ZB>WVG%U0-s3%Pl@VhWi-Ur+G+b=0
zjimEU2qqpn7`xjLI7k?PN>Hb;#_oJv<}d)5VpB?(K_4?USYIS*Jsek{cq2LfT#!I)
zI+RZR&$=N#HzJM~DT!9L-&1vt-Oj&{&$*_s6+4@1?Y3@jS6BVVx2q5K6*~TIhlj7A
zuo*f%zQr|<`~rjOQaUXXT&fCf^BdmZGhDaXPf%1^uI=Xc`&*UP$;t?~r?30-`FMiS
z0c}lMT#mcj$M$eT$;O`vBN^J4>ALO?r<18Judru$oXg8kYnP|TY?+FJo8lVb%-(5#44_8~vDNnQ!
z6*8D>Nj5p~%XFp?q7zp+DNI98V`ow(i|Q6b2m;K!ALcqf|AHpuW%rylT>f=AsR>!y
zgcmB{=@3HNM5&}e55=2;VP}$Ua8Z?4uiJ};aL{b^`LM8-iQ*~kB2yGKik6ZT6iDVM
zFK1;h6GTng-_txoAz-D8&aE!>BS;tt5{70Z3FZjmVaXVkad#YhzT(tW%R1XjJJ<(^
zprR0sGC~OSEypq`RZ&1y^$xIa1`@G00nH0~vqY&;Cq566soaMc5;IGv1;I)aOE~Wu
z<+lPBKREuzn$iRqY3-vgitN&?4bRzy$-;!NB4qI-#+No1f}frS9l|g%$TmBrQ_?(d
zmrSiJPdwa8wzz@8LVS=hw)*D;RBH@12C!iIg5Cdny9g3ye1;2%e_fc1S&i5Juolmk
z-YZbb_NMjGqjm0NF}@((1|%#^^|k@dv*`rY1S9IwJBUESA~56-f@FaqVh*C9VE{}9
zAu7Pb9>$?-01h1sM{+W}j*T{=ZY~5Sb-=I%ZQWPFkvm+x)MpYF5lxybC<>3xH3p<1
zKq1O}2|Bogkf1_JNsp_S;*j7pq#-(2Si9u~$=_9ZWwH~6F~yG^>01rhtqBckFz|cu
z5IUEV`BDXM4g3=?+wfdVdEK4ax6t*;zbOM!EEY-xDNh6kbOgCe#Mf^|PVpuvWGQtC
zfWuDR$5uiFOvNZ*fa=Y5cWE$4Up~SO1~G6#)Vn6d4vT4^a&Vv$7{RkjlpI{a?6!Nb
zth<^Ic78V|-XC8}Qakxc&BXV0+4ncE$E(@l;`}US#qF1h{L8hr=2q?3##>fT%>6UG
zN36Hi^|O%0?&to!|MP+Csm?CRjphho!2e+n?@P!lWc
zKu8H_V!d*=pN9Ku!SL{0W2BUavW~T4ah6;mLopAnQE5qyET$H1jCqtCRZ_4UsY%WS
z?%4#rt>l=s+!)5_IQQC`Q)QiBZHbG|{;s{koVU?It^lGjrd8K~5opO*MtfSQ*!kgH
zhV6EU?x(TU2#?&3G<;qx#*(8?Q*<94QrL5`X{EdCnJe8fEur2BfIF70nCxFST*|G
zdj7@qhTGf4X;m9rcV{!9+{<>&MZ4CB)y6eStq;!v7Kl*_#iC!?HJ)7eVlqfj`G0wh
zN65x}VB`R93}FHcUaw+bRazhVCJs{xvL(=y-ekc$@0Ki1AGN^OX{1^
zB3c1Gxu#B94G^ROLg3}WD%yqve9eJh7uN6BLsfO`*ELf(yz(oH*$GYtmd|JJDQ0SQ
zd70VWp7)PIPt-;=xG(fNKCUO*12NoYakO22@An^n^>lSPU(64l)#!D*UN65lMrQEz
zc3%Gz)N{MPWc=sj{c$hhe*G>nb9!;JXzI$!2ppc31wD8ip0!1XpND^LmO)vym5+~c
zqw(hb^ArD?-@C2xefRM#30SyjiFJqH!?nEq>;7`C?uNIGi+3e8msxqk+r{B%=m@*%
ziT1$-7X1UPvL6+58?dHw5u(Yx8eZzDG1ApdA#=;)s+z2$<2BSOBn%8;$DFgvWdca>%#Z8&0LHxo
zfnz!%-ICo~{0&s?&LkO|wd?KIp#Z>jumoi^u9@-@^pV2=4jKIoV{Wf|H^EZ7YjK_}
zwp}&O83<)0_4z;=L>xesa8G|iC~kyBq6k19Bu%DU4Ivx=Wg*5ak`R>`K~fQ<6pX0!
z2#B0PRC|^U1(8zZlycO$B!UV}W+IM4zz6`B2rHJS)n0L@=_PxR)ryAjzA#CWzE7cO
zfmNV^8h2EFT?k8k6(vdIQ}am~VPV1cC3~LQFr+#mhTAE
zz;28|iD%nkVj7_c*c*U7VnistfvFsE87u}w0HXR3Ia?x2;z1{jXphNdNZH-;&QT>!v>!6*3&i~iF8Hn+^bCdV(t<9?nOW_G$fn^<_6
zm$x0Pp85~6*n2+qw>D0G8T_ZAq>Vh@9=D$peBamOuTHz2u8+&}mYZ((k1zC_-w@u+WnZ&)OVy5W=_J`S+9}=$Gl-
zF2~Q+z3*-EG`g?Px09|R6EEWgrKcKZ7uu-?%9@4>anJYe?jQTMN;+ocZ8g=c&NA=H
z3L|H`2Xz;pNHYN~X-7FlQ$W4Nq{OT%dcG}g=c`?3J=br1+a3Nb{zU|2J?zqSy7F=~
z>f;U1Y516<_xCc+&YLL37-RIKwvR>0{__$?)RkI|(%?yD!9tUEFSUuo6}V{lVv}EW
zg*8lE_YCheT48MLkw7>}ti6$+vxc0{f`PLrm|oh&SQ3Yp6uJ82Ehti{F`c}s+;yxzNXlFq5
z*|IE@lVyEv!|JL~xgC^?ReB=;w0in&gS%Ufq0%#Edph5Y#;}~FkM#;NS06KRN9s)Z4==KQF)4<~|fH(+g
z027kT?#!~kd%ClrFQC9U
zz2?C_7=lLbPJ?880theji~e#P_|E~Sg~w!M9LI2$CG~R_@=ttK7kw-=K}cMd=Zx+4
zq-@e+kGT$^F{a+-E4OgmZN$l|0a*W_NOeI66dkOp-sL|+j*7T1)bMt?-Fz*M=Ep;N
ze(vb`ecz@g#O1!tk93+KF_93po@%ZJiOS@rE&I~^-DJ_lo%+8qaM{6%!U8)nqm`B4@B88K5ah7qjpKy7iyWjn7=KcyG
zkju}A#-1=8ecNQYR`@dFGq`}JOAtcmgL?wK49JdNBAX#TTSMP{-|Ju+(|9d~x4hc{
zTa1!taMy}XP`#uZL);5}MU(VxiS%Go6k&GBjFRPcXfq8;@fr;@y1AWhMHHU`j;0lQ
z@-QpITH^Hb_+60HOVgA?+mtI?)QgdfdRwa$QL%*%okmFayxv|1ieO1ij+;JTt{0$}
zi!lxPQBTrcd|Nuh=+}48FR#vOBtbf;GzyBCw0n^hTvaNVI{olGnu-d$N6?mxi<3<9
zGYo;!&`b=D-*ItDSJ@BRU3X6H1JaV8I$UF|vA>!LXb7ILnHngFp2ZC;8_UD1bJ@lS
z_iPeACQqJ?=4m5GW<`^*wK0^BAR_qrCzjnP(5b+$Jq|dWAQ1q*nm(ikTcU4P@O%DN
zF9=D8zeo_0qCVkguXS$tVD%v5t`${5GE;TX7z<(u6+uFXs&aQlNjOw~Fxemn=nUjb
z|LXvpH@^ZE>?crzq)C*yHiN{KXn3^0gf~8%u#hnOHUb~?PE$DSN-qTAEw7s1JRuRI
zfdT*%WVC=uFaS{kya9muAaVXA8Dn2QeZ6GY9|2e(eC_>zLCoxPy?az9tFxUd@!9gD93w@j8TNTQo`W@?=ngsgJOtHETR47r=f07>B`Bt$b9)Y
z4X9E)D0BfDP_@LvXtj$Nr5LJyyH=_Nki&i40*k^V7!J5Ngh)@YX8GJU;TMaR13~!!
z!#zX?em|dSJ>D+|8)d(_F6UVvshSA>9Gp~?t*o%kW_-VI
z_xyaHo_>pXG;-?B9DtC57ha66Sh-y}#DZ
z)|icwR^oDaxS6?^mYA1U=QH$plr_9O4Sy%{niv^v{Cwx!HB?e)8r5my8r>!y;rW&~
zb@59&n7H02o7Ans$V?s$WqjJvhu2hHK4#$R@Cv`jhMp<$)_t1%pKz(+HG^%xW1
zenmgR=nN39#ckfL;gUpp81~lNt}D#+(W4)4#SW1OR7
za=p3`lLMib5}u`0IikX9pK@yaIEvz_J`lAfLkJuWiF|nNLwTRL$rwi~Mo5+h=N|#X
z{ODYusz-D14+<}>k{Xx9Fs;hJYKfib&X6YdhPXORpI>F?FXJ{fT1iOys0i@NKxoBn
zABc(Zkb2g=0bt?!^-w8VyQ2XN48O!^9E4H0M6X5`0#so!O4kRVuskeBHSb-$2r>{+
zpU6{$D3Gu}_Mp5BG9%D=$lodleS}XC;(TUC6jKT;_L0v~KtN*RLwIJe~IUou9WAYO|TG9*+zD
zo}az>iiIZN0khaiJ)VZwbPsYyQ-_`~m1_nmJLXS1M
zpG^*PF?rohET6vX6
z3RifHRArXlkH3UcypWfzgbR@~KQPzia1j-LsEiT72wo2{Syuv)3;`ArdtsYZSqi=!
zaeI(IWIJyC`vt@HN>w$UZLb1O?WX1Y!$Y|t&-DNOI%_9X1+ihxGA7Kqp1GHuUTHs$<
zl2Lk2OK~oSrQ^4_|NZN8x7#`D6#iprdDbb6J#RLesU<{A)&!Lwb@IGL*YklQfcfVD
z0G8L)vfZZgn8Eb73!75e%lm4B|go43bpQO9Mf$
z8VN%!a!IfxCdzJzymi(9S6fqAtQpcsNk^9~3(vrgsx+oZM!P-KDvvUon#`arFHZv}
z^YWZmTfTvfd1EI8Wwb`t_Ub=M`iPE@L`I@zfE-^f@HevJG@I-a_);z&R8(5<1E!vM
zTBnc~vauM^jjqyyf{-J;`ysgP!`=rc4a9$tpjOaIi_u6>+8x@^dP~c2f#kFcF&ZKk
zcd=;g?3^+~ViPfxn}{-!U1S%gMF`d!E(zK@d=Wzo{@DRpA;=xPN`jy0Q;>Qc#Cas4
z4H{~-5IH~_3tuz9p9AR!Prn%uwqVeHkklF)r<}ZX2vRf&r(lc@hbV(hUI;mJvJFxk
zLKWY#r{4SVeXgnJ=kWwRkC%gqXS=z~+vWQ8Aw|uKtHo$7ZH$=;UPTq-EWXuQDpE@apW`y-ubtxZQNO+aJCz(&}utSJi)gdOmyAjShmA
zpub$a1gW;UJ6k#U-gd`RoWhRJ6PaqK=r*-@e5_2nNePWy+&{Cj-0wAWWQax%F!w3(IEu?AZ3Hk1~V(;0L%JPh^3JCeLe
zN7<2#2q?e2owVGf|7|8F_PXHAQ09(O12?2z>_JDE#b%lLgkOsNNJ#pRI+fuW50df)
zI(xmqh{x#*KR{5MCfMm0p!X2TCtqA|)JR=PPLJN-!Zi`3-Gh4ldlM2qz;UZ9mG{Vy
z1L%bw#4Rq#zbC4gv_^*?)dFsQT(HgtG(HujgV7~gC=JEWKH1G37E=pA1aAq5I7U*M
z_=>2YT#j9<&8>-~2nb*-pP=Hu6H)Es6NTBGu}ib9FR<{BB|KbNgR_l4yl;67bcPXJ
z9*WQS)_m_HOI1{I49(dP+0Lz;y;Tfo)4{}+>
z>ST*YoOf-=mCS7-uLi>5ZM|~*LFs}648MFklReq-vHt1tE#q_j&iO-7&Pi=b04YBt
zw4ysoa|=v!CJ&aF9uRM(1&A|Of>93B2m+o=5RYgf28#(i3E+B))Rb+NwtEhG|La10
z3u;U()jY?FrYr=o7(U9wiX0KetgZuuY=GdMg40ick&GKp9X(W$JeH|)S3cjm!F~`$pQU3VG=9L6
z$cQ2+uKB#wc?e+;C)hI>RREiapr75cG5D%7D_)o(Hav`h&OSa}F?N@t(Xba!hL%XhGH=>QlYz+}CS=u`X;ZKI9G&&I{_@IE;H?ZbV&W!d$7?O(;&
z?EoK4?Jw^5elD!k?RbA*uAR{9eLj`tb^Co>Z?Na}{B!#`%bD5c@pd-*x}S2Y
zvcu==cDuWOI{Iyn^L>0jW&N@UKj+UmFYtNUyw0zuyR!?}?7!^`A3Kw$so^QNmm57D
zT|OQTcbl`r_05DkpDTF!TDxp*TY9=HI?6nYi)?cnem)M*=1#wZ)4Q;d8R=B^ZEnwd
z>6cx@KW=)mbB0RFkYR+bZw5Il;i{F%8u|NfRJlGrE@=UQ5CP)E_hK~X-#Zd1c(
zQB<8vOI`n&NuQ>UY&Bd43pQT!Y91>xGS^P%_6SF$j5T1+m%^8sf}3YfRlQBS4nE40bfmi}y0*_7t81fMhla@;m
zeTX$O&SujQGz8Jelf0`kcw})1YYQWQKuQvX?h*$G4U!3v{u
zY&hnkU{_n3hpRaN(6MIq4ix_Kq&7eU&}v8qSi<=Q{smgJqRM24->>tW4vqJD#07(1
zvb&H&2$_hGzw`s3)}LmDDOHGI8&++2IOmn-eTm5Ux?
z+$?O(oc`|x2c5f(^`(x6?SVw=mtXIOus?nbjWgAh$1QbxK?7I7B@HpN7oY)^@m)qx
zX0dTQ6zHPeO#$|4p01Exerh818M2@h5vykFVF6RNKqi{Fj;`)@+sh#5&W{CJi1GM5
zjl_OwVV4qWzac*+$eoMQ+eMo1fQm%wg1f)~iK)y{tjTyD-S>-McOLBg!$x%$5)Q%i
z^qrX!=F!{h=OxX9I8EVNr}3m=H7=Qjh|_0=ZXT?nXOyt`UPf)@vj&?iCay8@@V#w=
z7-gI|zI}5zSc4;BElrOM7Y&S71HaVoB$q*^$WUV5Z|25}*(dg`Xag{sFAf|%%hZ#!
zT|=xNiE7!{RfuT{^(+2^+#A|a!)?Q=E{?lLE00F*(w4XC!U9ja(S(Ifk$QutrqNK@Ab=5>(WJ53|}f%={g(sRqh$<4=HU(>vg
zwmDAk%P)Q3AXcv{G;u&W_CKL--24&KiF*vUYnvv!44EEewhe8Ic}w?Y0XuX*ayI2Y
z-}t`P?&v>nqMV(t-_qJ&pMPJ`hPqDlI{&fbhj2>pS&{$R1{ktm6^y@!*vq|qs
zJmRc~zYh1Cpg685!^pI-s{DPu-Y*_J!7fj&;tZ`tz~A7gJm_%s(0LG!S)lm|AVu7R
zmLWCqrK^@LYuntXo@Cz>k4^GL2;CyjRR4`b2u%h@Lu3DbZ*T5%OtQzatY`ek_SHKhWbPi5k3t2q;a#AX
z=VwV(dbGP8X@!`@@J?u3c55Zm*YH3<_cKUFoDJ1*?1=PHUqMEP1-`GAuqTl@5$80Z
zi1+f!h;J<6t>dejxD&G$|L*SijWHC%K(FIpTdm)$zGp^F{b_9hr(N(H)q>Ywx*)HY
zX=)2%fp42U&o?~Jmus5&c`Wr|UzGgJnD#seBi>XJFn#CmP?ZeUNCoETq81E(Cb&se
z5^z}(;Jg(AJSGlEe?txP6Jx$6c&HQgTPAC7Gt{F#|FU${duvWf`Yew2)12UlbI4&JoE)|j^1U+~
zFEr+X>X#G?bjOfY|3o(NJ`CaRV?WHQ(ZVwFSNZb*o3}Zv7Z`4GNZd)9ml!_Gs&&y8
z0Cs5um4$89x-3ti(G@`6^2B)-Hde!7_AL)x7poz=`?qeqRHTCnzXOk(Mtd$ARw8ij
zF8qr9F0}1~W^PwSWRqHCwG#n!xmSD*95kFgEeF4w81vj3=Gjz3R^E+NjixLn{+%;M
zV!Y8m&Cy4UC^Q}wTqBwHwUtK@!UL6^NbY$U?rhadG1rm`kR4Zgw~)tpFzGb1gak9u
zdh!$CNPll_Ez@ej3hiWVJVyU+H?g!?)unn13R9=jgPcBzo`$Tkm1uy^Ba^qTYdl<$
zWI+!paRFN_G>L)4nW4l1?&nwz(2s1`V*dbAa%}@x=w)-z@sSDNL`7H@;bYHOJ{Sj!
zwCO%&{Z^POC*L5TUieF2;4xIp_hW_?6J%{l%aL^qvFg-6pEFWWZd#Fr*~yrD4_D5E
z%1+l<&^X&z5KkHta<;0#oxi6_l$sBZc7ySOOnNPg5?k58A7Z71^Jt4;u1e#^KDYSH
zLMy8?F4w^3lF!!GI~82R=5J=^3FgLn&2(eChSguoRKA@Pb04|re6{!7TCK^N70Zl2
zOgHB_J3XYNTRy^v8X_M3riCoOwFSzxT`Au|6QOV_j7A*-$8$tXk~4p_#awI3o~2pa
zI9bNbu!lV=Uf|z^o8>8q$@9*qsgoPH)4x*eTSuiHie4#rxz&qhom(bR?Y8M!ToSfD
z`4%H)K_;B404mhJ#{j$M(wu8>JBx7iy(~aRPTWwRh<5?>(B6?C5MS3>4uPiZNQKFW
zTqS}Mh}PSMfYZpN(tm*^09VZ%u@8ywpH}?5r5&GtFWua?dxT6&I~nIMrbN@^cW;2R
zDwrv*q9yoB?(U%9cc~=QdDVbI9QQ$X&VG;fca@+7AaN*p1O$IzTiW4S33d%sQ-Jer
zfC=(o$tmS!5P{eNU8xjpcN-CNsNV`9_QG#)8m3JBsR0dL%k?HCnL2@Bbb}73K5pDHNj@s>
z;Lkd))k$~cBqf^<@wwno+@Qe|3cT3TEn4jnIJG#!{fCBV)!N}oV30mfC?&$BX8;-DN(=8PhdOM^x3RF$2Ss857ob>b4Kg}RrC4f>2`lf=B+-Zj
zcbqByB#9hIvDjX5axDgsV5t>4T);SndB*=|^ZI~CqR>GP7)z~{uWB-5gp6h_^88CU
z{U^`=39p~AK0{f#wF-YG;py^J{|zJep3$3-!pI{@&LaswNHx{%IN8lKr4xuDjM-jN
zr1W%73w{*EEBv}i(nqu7$B9SCumHx3Lwk3E8x{%lK7sG#{y$}a39=z
zS`rX}`_%sAR?uU`Pp-fXxx-{$*-+Z@Xq+E(l2leI8G0`{SLL$MIaG;D7~eu|P?4^9
zkVwD!P8_BhJbh4g4DN-{{E*g%P-Gh_$UFSe|K!QPYy`t1YiSr}YpGQ*I-3^BEVe4^55z36$us~Xkj58U@Ene3bERYH
zUCtvhar7l?a6)O9Sa<^PT3cBl1|a<*1{=tJuw}p=N9@%ykJ7?(PcJrD>2mgbu~Kz%x@AAXFXCF1?;yLWhgAmK19Zb^#o
zcTS)YPuaM%sx*r_=osGABIzFvDE&y5+{c?wF}AIPFp#0dnD&?b(d#*}Opybn(QB)e
zC3!yCf&Qc-1r}OI-@~IdsTcIVf<5Y?q-VY`z1}+$nKe;$#|VSwu?+S@sW3!|Yo(2Z
zRK>s_6s8?De;rGHIQzIhdm@g`%En93t!qNd?!*xn^r^zx!=w7K52?4>etPCfKd7XQ
z6NJ;P{wWi$*mFFXwS`{?-mMRT(cCi&|8&j`1~0AIz)Y~CmHSQ{nZgx~k;{r{>cvx+
z%d&yXwbBDFRY_=5tk}|v^GJ!hTC3dY_Rq$}155;1&$VaJ!?I|9V
z?{HCR!)L>I)gEPFNlgYxXflgF*+}lRbl!-yq;%fN1;PV@7jYjf(5wW(axKNiX63MM
zpkH@2Q+m@CiLkP&Ml{6?^pu*np0C*3>P@XimTqiC0!A-mY5Xv=ME}KTYNfODs3846
zJ_kk*I^D*yb&v0s3OT1Q9#hIv9M@8_m0NyqSnfl0fEC7nWyY=(O9n_{Mul4GAc8(^
z3;cs!0_jOj2(#un$V(C_(=38bDgTU64uq+ArbHH=C0#^HDqPeAO_`m%q}<-h+}g{E
zgR)Apg{B^Ab+gEVmDH2?4HE5+_bNRhPy`J|qN+FOQvk+~016~RrF{f;=?L&r6_y>I
z*Sbr_3&wBl_Uzdw25hPRQ)FXwAr-z0MWjz1S#U*dZZAvC)MBDrDn4#SWb`1lS;YE{
z^?a*Gf>Z={fmtA-iseD~33A*Lh2-6f66&i}Zer%_)sGs-S+|GIEi){;=V`TSA3@6i
zrXVUs6zkwz+*hi{LY8UKCC&zU_mUF@EI~VzOD*lJJ*Wnd#F705se&SisIb)6N;;HN
z)RR4*Si&avi{1}iOhab!GSCf;w=_Bu&OZ=2fmT
z3?q|HIM^Cj`Ns)8w0SASxhPgotxX}ka%p}tJ9I_577heA{EMN%_iF@
z*})}enK!tLYN`kg5b{rah*zkYz;4^`1xJMG+4PKkYfi;2ViK{Kp-Iqlx`A(9c2~}$
z*9*X})qWL4nrY&qGRF)3zKlrnFG)iNaZDp)M0p;Wj3}U~RjP32BiIC}Cq=F=o?gGz
z8~Y=_EWHvEOlIV@jllP69pal2FYf)wytK^U8mjM++5*g53CrOfC}f=Q&8#&?7Y
zMYRt2-O~}tv%(-vXaNVp%n%cfq|=*&t@?Z7S~tn}iOPZBAW0D`K)f|d6<8a|^#Hx|
z{Bj9MJ&l3}ecGyUqysM!ciO!tI`0g9uR+d&n8a7Mn0B4wb6VV5hq!~z^aAfP&(?E^
zAdz(MA#H(lVYM#7-F#Cw4=KgVi+EV$wp6k)MdzqITAj-qNwl6KIZZ;Gku%7>D>vbgdtq?>8;#K10q;uF(~yoxhJsL=`9&%TtGz|nSe~V
zh;^#p=)Gfv^n8BB=jP3YP1OoJwhs-fbc+q!I`4wjqsze6nQTuH_A|Y=-4x#oAmhHr
z_Xl8xs6lql!9Xd~_`}`Xn#M3GrTH@*l>g~yqQUpHTw#+j2aLBXo5UF{-Jvvi)2N0>
zkUFAyY~BX1&Wcy=3d4Gr?7$cGRgPj*+8Ye(#oQs*!|DIz2Q5jv0l?r*^z=pjxZ
zjP{EQ7@W4x*gO*6*)fIZO|k1#qvH=QWD+(t4)S6L7TaQg9q`Xs&AlQS4_9r)TC@Y?
z3s{fL;%q#z)W8+_3&a7JO9K`G?8MqmSLz8_FNyq6;5D0{4^EMyQ8S?P=h1_aK(2`RsR
zJC~>)(L`a>r()4zFzwQv%c1Q7CLpLqe3Udu%|nrOfJ(GB5v@ksvgPVhwq#xbS7=hU
zVbiQtyIj9+s@LSzv2Mfv=imM^RZ;R$Me1>~u^e_$^08$lZK?jP09g@=om^zECb~*x
z*k3y$DI37t^;VnYe~wmy<7MAG}43$>@oyfHoJdy)xJB*KOm>RKx~a5{z9sZDwpbQ^N+2AT&@F
z6L2t<113N_l#QV}Bxs~&uMh5N0Tg+)TB5usZndKhAcK=>rDeT~NkzLu)JH5Xv{yoB
zu1sr^-j<2@Kg1qta_$a`8>C;9^$k-8mbrX;fRgK)%Y(E=OCifZ38F!ns<
z89xwf1oeB4Lj#>9pJkp~}yC`cJfduXEey&N#qu~E0
z3%ib6G<8M}ibh(a9Mk8l+A@z>HqoU2A6wrX9N8CbolGXy#7-u*ZQHhOn=`RGnb@{%
z+qP}ndHwtT`RY}@uD(_Gc2!s1UFYn5&RKiywar)Ynip*eVuKRV1+D3BL<9c~NQTNA
z8dlmwk>Ot_sd@npk4%Saji#s@FpuvcU!7K!WtX|ipo2VT><{-eS*Ev0PhD5lF3G+~
zgq&e)RTudJ9n}8x;ezkO-P=uRx(qUy^7-;ptS6NCF^>GCPj~TKHPNZ~rQX`XFpE&p
zAWBWxXu)t&WvX3dTv;M%P_UyVff1bc(@E!pM@%+vE(bLd_W9xY@o3t>&P0ooro2#OFE6|Nd85nAeXpJdtq-V4sv7wkrKa
zAKW_22?74(7FC*H6KX-0E?e_dNn+gwXW&y>reAeA>Y2b}-*@=S?(%dF;ukXQUq-Z-
z4V+|m2xcb;*>AYEFlfns_HFJ1(L4161I~A|1L$fD8;~nG@m_$H$?dC)ibTSU_lb+R
z_Q|apOJT=%F9AFeG-{;ThtX977VSfU2tYrAXoC(>^Z?DkQ?VwxfW1ib#UBBQbeoa>Jj(rwyVxnG?dRuv#hkz?~I0nx*p0J8h
z?O*bSnw754A?2mAMc}Au_rL^n|5z1#Oz*GF2-k#eYhJT-D@CmUnFPVsb%GoJ&e-?B
zqTMsGd~91Igs4gpF>I4zF#08^)^7-s7WW{PF0a!xf-QiQ(z2UNUh?*fD_DTr413Ba
zU2X|Vp}RO_jhyXllP<>nX}bOu`u|T+7~o|5??VW(R1fXn+yw^m--QDF1(=?&H8rs`
zq_?y+G&kj>bFecHSCA8jhr#~uKk$+gB1#}2KZ1ex6HvgJ4f+}6mjZkMbygA=0;!t9
zJq14eG#8W=1Ocgyf&DN92R=hPNN75PfFKO~cY!8SBj5nvq)<{sP{l*<;`1?`WH^-$
zZd(4@v->*Z{!;UL?eA=u>3EW9EGevb6!B6(NO5afT0|-qQzQyieM)J08+LhWYp5XH
zknTP9Qu`0>x2zKUQS8bKeuJ3o^H!s}I;%S7I{+jR@gBgI;Cq{V9pQ3&bIIvtCHGTF
zQ68hXGXD^>x)YqwtpRuQ{UaW<*sm@vv+7vBa$*9Y>P!h!U)tU(uDA8R(UqLF{X7>r
zedTpAc%0>R`l?IM(|o>1%Kybda50JWHzhs!;YK+ttDu|x6hq{u%3~j-YfNE}hH~Q9
zUmnsirN2D1baQ)fgcYKwjU{>fxww+nXO@$L1UkMt2yrDP#*mrLgFo6x)@v+Q1J8VcA&-Rj;cf7Ajg|R@t(Bdp
zJ6)TT;)plgoImuu`NX21Nm=LEOsA1Frwu#vglX;6BGO2BLq#@2y*MGcS|K@Yy<2VR
z-QDq5-uH|rL-oa6{fZ`
z#*jQINvJ~#fC7-X|CaLZv~)D5t=DksJ|IitrNSOj49XUvwsYw9#zUSgcxjIPX82N5Ryw!r7ox!2-}&S!Oh8
zqS6Y6j+EIp3OM
z?;n)8ah^j8`XpcyN>Jmnbk68w*@@T9PaIK~YPylj
zv$BS~Nb>A~_kCCRF#C#hdQjK7jC8@yzG{H!IYag)ELQR8G-EPZ*yhLJsV3jcVLh7-
z9Au9tQ!SQX>WNsEtVLxZs{NFk8dEH>b8zNx!jk<0O3WEcF=$cwShNCMs!TD5aK-_)
zYU=XmMN&!O9ga;l9UiSAQH5y6AO=c|X$pX1)_tsgiLn)oCG`F@+{&@w1uUt|qJ-7h
zyn&MUytCdQvpR#c(|P)59MFUP{3qpoK)o`2M)HsnpLDY7`i1kO8HFa%O#HL+a_B|)
zZ~bzMS!!*UF|x!4&3qe0iI_6e;SDyqh2{ACU_*=M*KLYVM
z<0sUL7I|;GL0&x8nB!QG^KUfe_gsZay@vU5fvIgaYXBn+^=L~os-x08!z!apsxAbrwnO#Zor$#nn${O1=ZH}BWbB5-!<;CRUt9^
z8U^^xpcyUR|G*r&PhVrL>ld?)AMOqQK4fb=!V2HsGF0l{=csXY{@o8Ex&)%J$XvD>
z(V4|sWKk%yko(K|XP;VWi7@H0rAa0i=Wx!R1)43V7y`d`1tSv
zyeZ6@l^Sa%yUbA(r;--ngi6tQrMQQdXoJQ{E2u>jZdk88lcMmQfe<}r18KlwH
zbEb*Yil6z^$8`-Xc@5pk6@fG;p^-KE-buuMWpj{&+lo?nf_`LXPHRmAPy(5YHt14N
zK5Tnlcd`bTW)_*dcz)1&X-g;FJ~@++`;*Uk95^5os50}OpF)dl`i-&}w1+90L>BQ8
z+$u_0N?WC>PZ};i+Vu_`B`(QwCD$!g9G#=k&pJ3PxcRR1aUAIpR^*nD$g;Dih})?k4jK*
zS6V4CfDXTJBmLry6@_v4Fz2D(GivJ77p9*9W0^F(@9fHkv4nV(Y5e&|YwI7(`6nhp
z{jJRq8~w-J_P(o=PLo<_>0kwS8*n&K!26{pTW8Gm@Lf6`{Z#3%RU}%(DitUXM+Y{w
zRIAlC%atFo8-GMf{?!&`^NrE$H{Sdh^gADmbv7OFG#YDG8>R<3eLXlHQ+!A302O5X
zk@7Hx4+6Bxv@Mb`IUA>U``R6Ux
z6(o_bjeI)8V}ow*g!KedV(a-VJI|^QGJ*>l6I{*qiewg6l3h`in@GxG4SY6+1}pGB
zEnWYf6!K=;dAEpC1egrc(LLXsw4Ebob8O(+J8^5WT+wL>fkn|
z_d0-Uh$b*c8M8+%JR4vA!Xv1o*l7s;b98#`vn+^!ohwEOSS~)%dD=w#QiZxyi8EG7+!apks=KZfk}+JU3+>n&Z?j^$2O$P*x7
z_kkK`G!0M~|DB_QdrJ!KFfaaFJyx*m~{|8v|
zu}tWmR>&4VQGl{O0b_B14gDN?-SxH`N)W(xN!6?zxw@!V%oJ8`*^NNg#dgHWF0PwW
zysZbT-=QPC1etl>zqJ~H^Mh%BImE|n%{qsdtFLls;zxbOYkthu`~9$g7G9~Cq;LX*
za4={+hpmj#o0Lv7(?L7Kw2saCU`b2dujM(Xml*~#QP!B?A7csv{m5KoIbVzN(_iQ9
z>D^zas{z_r4`Uia=@BVC(VFnIJGJ*V@|+u*2+q{AS3{kIoV;ip{KA!R?-beS?o<@n
zqn7I0G}!HeW&fPM9*&=>M@O>1KZ-H;A6s1fbO?G_ZpIl(5sl_j{f=?Q|1~eK5@gHh
z08IfPdIMr0kF5VhbD
zGUs3U7(|rkrtO5wHH4zQO!m^X7W021NOiAY++%;*8P8M}eypi1pp&Ua3THL5?}6OKOc(sO
zU9s-(dh~MejMcy+jVIL3s0)H72Af>5HvxN#m2ZBm$2^Ui2mG{^XMA#5Nkv$9LYfyr
z;^q^}%E;5xj_R>*O3dps3PQ9<-go+O{>atVF@>KUnJsUWB74w4?SV&s&*ior&0C;;
z+AAX1JQ4$)i4K@tv6;sYf8);Y0)(}bo?36dmH#d_7cxI4DmGj3>BAXt^^<``bLM;i
zjaiMv0$E4o^SEw=9frG+ka%jQ!*=w(QQmf=4?j#mHqxCa#JF5
z^6Y0iP_WK$`~>LeM0vG-6US!{`#ucDHG2GX&DdUvb#9dr$8KR7O7dPNd@>-vxhH0}
zE&e=k<6lI0a1d6cx_%c<6&Iz{J6|jjZpdj|T8U5qzR^
zK)V7IjuZqCIkGchySvgntcgFDMn9Gon+_nyU+-P-8e0#>DC(Jz>BKe_3RN(r8Kyi&
zkPtyTs!#)qg>tS)0t<;XLI#~_vJkY@hlJ|E4rFLsSVZ~?n@Gc}P#5uFU5+$nkEHx5
zC9fCV8Ci+!1A@$X7vAE(%_6QN@OPHk%p*_%9&>zx_3E$@^oSoP}8+qGPH1Uk}bXy9h==ncyq~&=%
zPFf+^hF1=uyE+20O*!gh+wY$Fgl#o?r(_MpSzyJ^D)cF8
zor}@hI|{XLKHOuy*PD?;rG@i==WUgXeo3g
zAM^#P(lICQFM5`|mw9N4^8M+c*3Dw!M)2!F>gz=6s`S~%n8d^Dush%LN?<#F+wm*p
zwH9_1ATjK;Ys7+3OSUMQ_S~kN
zo#vdW1Qda;f+=0`Y-P8rbgFoAb0v(VJNt@+Y1$+C$pW?W+33-eX}TyonWVB*1KMd7
z=Le5q%~Xku^y$nj>8z~C{%L?bc@fouM|c|xXW5n=uPO0YBxgShFw-2c3NzcS?w
z6jNBvZ1xLeD7P-{QJ{lK%sz{RHx~*_Rq!X`$RG+)?(Hq$H&D6&YJGlA^WJa7$8_8r
zpIrsD!KUW8trnkSR
zY`N*)@7%jR$HCmUeK((|3EIxD$lbQwZ&J;>95-FnzxKaZUB5r&`9DVD5qV!O;$yD8
z9zZ#(NssLxNO2x*;5|7K+Tj6#Q*Ht{6F8{2+AHH=E4#nXAW
z%{-b~=`@v5iNkLwg$Wo;BT1sBYK&
zRED>F+445qZnu2P8LIE|g|nt=oD&BNu5`^{??+%<9=TU+iL_vJvu
zEvV_kv-57RN!jhTSDfvSp~~&f!}VsL$MhVB(r@bRQ~i(UZ?e^)>jT`4=JwFx(=!WO
zd(OEfmy45sV6@^05#X7dm!W15ku9igX*^uDzE2+=$QHavW^##{WH0
zMUKC9-{(w!?RUEOh#hzPXcG7#6OirTF21R2@w0zD{pL15E6YY81?I_2LJ)v_OsNP!
z%`=P^aAzc;oa>X)&_alWG^)GJ_}Xj4Rw8}*M3Q8sv4YbHgCyG168T{cv47W9l|&Szsr7@r97)t)MH4)_RH_25ixRmOEcYi#mzirR#?w>j!Akq*N%
zCDm>&lMUS3jP#ZlB}Z+<;^;n>maOBshV_R_J6QUi6O&C|xT(mWFNQI{gWTijZq|7d
z;)Po{{HTXbuNW+2uvjOxRs|)m{p9YirV)$+diF!P5C>4f7*+jsc;lArqm36}i@cVY
zViyp}Tpy#lvKZmWP#-JoI0~~yu+FhKN^vGnhoz5NBVK{?h$$%nk=&%8(UP|uJ5Vil
zF3MC!*iw0d8i;{uYQ@7*2{=bFfj=USmMcDLOfje~(5pn12QEz_t&b9pk210dK-NX~
zinjbKk0&6i%}VGd7l%QY(((v`7*wpxldQH`8cAchBTKB1B;>VHYWAYB)zlKn02Mu;C+MdaKmUZ)5W_
z2U_$tcMJAcg451)B=4j|ed>DjCBmHisXoJam!cPF$8lkACcEF}2o$}D?EL2t`b-naQT3wItX1VA
zE}xdg+k}EWYa}U}0jY&4s%MR(opP2vrN0@_cGZG9sOD(Pk9BwWmc)I?hi{pq1tnu`
zgW|VsxiLQn1(&|l?YTp$o-otSr%2%^kjJ!l=
zJXNhNm^Iv?fo}uEc*{-xTpp&ws?fS*r&XP}S0z_5AlZl8jrd&z#gXV2x?!uDr-;)&
zaINr@fpk|bcq1)Vz8~VjMgRwzV#sOfQ1Du1*2izD*|pI&s+b!IHOVN#nVgIm)G$K{
zAz=gdQG+#<9MhNYDom-3q7XVBdyU>)^6|hS%mH@8t!j8n4FGK|sYy#}%HxkU0HTTG
zXbWd7EzH-h2iF*_Ko=-jpy(#7>Z+A1*w218XcjnN6}vWT?Hj&M*h@oHt<0k<3ii8r
zsMGvd@%T$wvl{C-@@NqB*<+M5Zjd4-&e2*@2Yiy_Bvv@su^y^<3!@Mwu_>cgVmLPB_?HrlbkKyL%-u16
z*ZnTR)?KTJq0qkT9W?OV{w!3CUEipR9A}lFAN8Qd&m0Eo)B(uGz1Lj~ymG7O
zZ)72ACCL{`UzwoQsV*6D65Z-X?EqJkrXw
zlkwwQU(8L;TeU%5xRsTp>WSO5MbtvUiJ^1mS|Qj+OMpWvO~5z-sVtLh@utSCd`kU@
zueTL7UN!FSPZSk4YK@;_hKi|i(pN`y%2Q3y6~Eu-8-d^Jnf=${1cBe9Rmy@mMdvW#
z4Od&|6J2s4?Q{gy?3GnTJN;avYbz}$Hy#gnq}PXC``o^QksFZm#|C<2)s^6X5s3Kx
zvKxA>4d>LXeC$-RyADzXw>LwB_AkK1dCuD|%g^~R?oWEO;PG0HwJ8P1`t|GQwI2!s
zwna7I=}fYD?pS4|p(Ez&<4Xa%6VV*H2b~Z%Uq*6l1#@_Y1`(2d_;0m86J|ptJ>8YO
zWGK@ZMZs`G1oX%qG|s-V7)7Aw@F!49(80&0VXB)wi!qA{{X-Y2Ez$UOK~
zd9TWI;*Rul>XS=IC0rCaS1at3k$J09%wu9tfc7!if)yfi(EMBtY
z)xHG9kKm5igw47mzs>@*`+g?2bdFn|1vE{*anGg;C`{|?odjm2K(N=rzUi5xYz4)w^%mgO+wP7QSmRwu%(l!9P){q~Jsd#e=b
z5qptI*!~5BIfrDP!a}ngelNYtz8ufbq1fV48KRRC)xnAL-aNlpNa$tD(!rrfE4FEg
zE^U`9)w$AXiIIx3cG2T#Qu!IE(
z8FIsCV<}j(9l3%}=9IDgH;CVlCP?@u)`^(rrX`FP{!{LV_L^Ej5_X?S}-7;jL
zoa`9eN*oAYlcgoxGTg!m@nkt`Y+NV51Krvf(?CtRq6&!+*6cy1U5wH^jfvge2%lO7
zqwZ05m5F!V)yJ=CF#Mc4?2TzOC36L%bVy>uU*e;y?
z8Qw?)Y%t86LcFlQ>u2PU9WrWGPEEL#1ySgy5pz4Ahz*=x)a!blo*he%G4ICDKiIF=
zUzf)T7)pI^#i_8fnDuVr6w#A2pqx#r+qO;h-f5@<9~m{p!Gl^eumZ=mmE*Rf
zufYrD(y7f$;}}WI=P0)>3z<-@yJ};t4s_!KM0{*P;#l;uTuP4gJm7ui85MEoD7EwT
zqx-Fbf$yr`Iuj1Fb_&G@ssfD0s`B{97ni{xcQ5YxL-CW;ma|-@(
zG-Ba4E7@?Z$7K)K`k7j#v%})X=EKCpp(}^jwHm@;?7y}5G4U#5Fo@f7)>dmO=nD~d
zbSX;3`q^#mypuJT;RtMp*hYGOfBx8)SKQp`oPmPy8sGd_?WKxsynRV+oj9isW><^M
zDL$I>Jq0l_R>j>-wQ>Kl
zdraVSI|}K>>$SbleXZnQ6W><1Bb#Z_k5o;EDM)*2b4s|F{XFj*`=R&DC`
zP=$^}MzQl(Humpk!C>fjq@L6^)Z?rEX@r8?$ywa%08c#OCWAkv7nGeC=Bm4amW)O=izdk
z@5R9PzbMp|$Mrhh8^?W+%XVND&ctGeOc+}0=QG*0Y-68<$^B9=6Z(L2y8iIUf%RdH
z##3SLY7Qk
zCXlFpJ0pTVnq>Ixq}NGeZk^_;>)@}t-(j6~lfLU>;(D|Hq0~?*p-oz*`_}8Hw*BYa
z_m@86w(qd6yU+EX>+P?TDetP6VgI(f?62Fm@ve_O;us#+Z(n)do1SFDIg%K{V~Md}003G)5~Bm(vye65T!>A&0ZK`IEcpjuAYV5|!>ptQ&S
zSRoAmw{EpQrIj;-CMqs1dF^;!&GLRc32(P~ir;??zwLRjUTIbwtCK}q#}6Lf_I+5`
z6~t7cSr+TjTyU*T@^18V_gQb6tLVoagjU5y6dj&
zyt)hG!J6BxqvIT!vpV1Od)x@vTDjThJ_K)h+oyk$efy>{-M-_toZatId;8<5lHK3>
z+{&L|_@(`WJ<(Pi;llfNRd-Sxfxzdru!tBEfna5R(AL(TYs2Z`S9N}C=<@8A(+iN)
zbU8WPwjNXKC!XMNxc}$&k4#S~nmg;L_xgaYcyMNDyVmn#L+8f4W9)nfqK|?(4wYx6
zcl(+?x&xxS8}7*=-hn&bzB?{iW~iX@01l-`6R*I}otCpXLK+
zufHxlrr%mCR4N#R)^`UWqfsc%ttUd?F#Ca8&{2%V?YStVJlqp|sPj=sLd@JqZY-nR
zv#E9bob?}_-@~P)Wtu~#rK^uarly|jW1a{z^etI~IeOG_bMU@E2o9sZtw
zM}uuIl3Ra?R_$^8Q$pS9ZIW<&DAv7|(~H*R2B
zQevs>qryWi5g
zLb7}B0xTux2)eLzKYUbWdh7f6Y)8sp^VfKvPw|oa5()^#!rYBVmEgw3sQ=~neD?X1
zaPR}F&qpFnRM>Bi1sf|KRmdV3F<=ct5gm(@<*$^=CWfL4wy;U!kb@>|(T_{x#G8F9
z%;>DdT%;h9#F_?vAR1Se6XeE_G6xSbB>Ctd#jMICZvr3hk7pKuB7hebw$p-+o?F}4
zg6e=B5hjju*BfTSQi>f;4MZCW8xkNWu^l4E#tk_eYOF*Uf2rrIaymAo0U2PplBGj)
zXSE4lEQKL4j|En^u~VhRQXn;6T^0Hl%rt87+R~+Jp;6YtL;LwaIO%+p@jYB#%vPWY
z&&yMOJ~!FB`*mEc~(yR*nHri<6$yvb4vPYkd*W4Oe!i=H(+d)Op6oIiei
z0>|Njx`YQCrr8~K^Wc@q!;f&>?lUz7Qj!^}%}J+R4&Oe-%ah*X^`ZKlfrSbO4gaAbsiJ8(Lu1lY
z`YSF$Xy&8wCS@!tFKGro4`Zipw*lXUq7+Y}RJ^XJHp7vm8fWUXSSraefXW_w8mE^_
z@LcoL;75Q8d~riQ7Oxgo!dy@4Zctg47(b?D`SAVQXdcpqN12IMg)URcgCHW#HYm-)(+wiU&(2zT_X#vRMTkCDx?HsGjJ-#+f@SXxZ>TR3rBlL`bNGlA>9H
z)?sr&6_`q<5~4|J7?`5^BAeMWYWY+aKOZaHh>FwcPKzVjR`U!?w`-UTv~XDL;WTr3
zSWUP=4_nS3QtpwhudMjbW**{FQfge^X*OF*=j{$K7lw0C4jY~G{RB6*aopU2!aN#E
zX(yDio2LfrQj<6H@wx2kCzFgeMHM*o7Vq(OFfG3=T(B-p2D$W_{+x;s`a3r=V}|y&
zkfd#Ih2x}mCLtu(PL}Xlsj!0{V81FBz65BwRg_-_7YWNZ;rU+eRq9fKDb_HMdT~V+
zVE^kEuc?7~>E~c-gitZCO&ZNGMCi%olVStV1^m5p@vTUMpO>ElZ%wlmxf$kA;Jnq$=k4oOr1%AX+Cze$~W&c
z*~VqChS@}f*O-Cro`v0P3(%PIW5S27i*~!y4RI^4f}cQuW08|U?%hghH;=tcm4jsq
zl~r`dxjaI`oHn#!vrLbQ5LO$^4QP#SY$nI8Y%uhnbE7e|hd=Prn
z4~zg3GgN3z)+V~xSnByZn5eqgp6OzJvt=A|yzHXF=ReCAr_^cZZx$eQBhjdNdQ&4D
zbI&p=HO$A!UbG$ja*gybYiQwhm~`GWvEU-f=Ehe4`q2a%WR0E=^(>l4KSt$dF(MR3
zX|h~`U}y75mryG@lUl~SEc&&Nn4$-8Mf(&>255`6h@LdT%)aES9@PGUflg*1Si-<`
zWg{Vw!3vEZ%H`0RXNg-9+SjXGU4pOy0@v~RYz}MW!!{UZyvIe~b!L`0W_B?UB2neE
z!VfZJ-e-=2nAXG@xI=?L_8l^)-`r&7s|RsZ4gUZ^xD=Ul$ZU&C!liC0W)gMVW11-q
zAzpOkFmg`BX$L|daN(OY&<)BTH?^p@(2hPc3oKeKuy)gIjb6Rs*_i63v2`=9m)$;?
z!=n;I^&3~rZsfE8G9oQX&-~FmW(->Tp;LQ5Ckx
z67G%-*cNP4AvJ^tUpg_W6Yifb`lM^xEIeW_>T;oJwH7PiJ>-ut_)4je`OkgzbQX+gf2=dX-S@qE6OrfOa(Veip3i=7z*`59Q<0NZF9?S8m+Le
z#n$3Qu$$RDbaZI}wXtrWpF3h{T#2St^Nknwt{Bi^ntCp!QM!$+k&FeY~oG1
zO-Raxv*KN!-)it^V=~;bQ$M5~Rw2lw*MPJV4DhGWdm>;zbop44nfee5DTB;{Py%Qe
zlnN>oRuc_hPD|=R+rgk#{(Xue+1D^ioLP0ICZ{IlgSBL+@@$d73qqa)1%;fy}wu3@)Ng{gob;6E4AXRt7>w
z3bb9+Zu)*QjoC-V1X`o?j=@`$w5d2L5dr-QHIhW*1E&;cf)MlV2VH{~YXD`B*e62p
zG+>FRk1>Vb483)dsabWemePkUaXa^k6AiQ&mx0XTa7kz+R$RC}F-m;W12u;*hGj2a
z$cSLOK;PyRi#JC=+}T
zU>6iC3T+vsmWaGGTj$?$5FFT*z>CA2$PBC)QYw*Oy?asITU5-0a5>hwzl|Uo;6y(b@0^);!u+!;ko*n;a
zcsv#WUs-qATotopou9QBF2gDfnuo2LthRXQM)_E#7Yzdn=kWJOgOp~B)T;3eRBu=A
zf_1P~1dW%)>sYK-^`Soth5^ePooWQ
zqcMN4Bo1bGM~R*8F|);nIeXn8mddk?at?B7jWK#GIqjbIzUBmR*&P^Ubx7T@9N~~7
zF$0)x;VXBF-Yy&u`%1^ez+?oFAJ_a#l2tv3u#kPh%#b`3H@Hfsv(1+9-J#2g$M`dIj*BrI^5127>Vjg6&
zk_d$|5eXE;($A?Zkge$TU$H5TsSZs~gCd{MlAKf}q=StGsJ=2%D815TR6bN7_hdW|
zTrZ^8Zzbj(2V=vTDYAyF;WiNe7D*t^MIg%JF+mhNF)JC=?i=guG7%84tF#fs=s_CO
zOwr>vtP)l$r9wq51HtN7EEBymnC8k!c%)*4Bi4TgY3tChs10ufT$P^gq-y?P=&Jd}
z#TS^A?3ZhUz(t6ob?MH!0-d4kdllYMuh(Epw=8T&da0^}j}~1DYB^U)0#TqG&eOF)9)2bdtvU#l7L3%@5j#;)iGX+^HjiG7
zcN{D$QStk(#=OYJ#}(jZdqvM&)kG@X=cA(q7=NFSkdji9rTlsc-5!84WEnxs=c^@=
z8p#**Oi)Ukd(!Hiepy7)B7jfLYhVnM^t-)!d++u>{@m_<@4epg`$lxQdHS%Rkvi`$
zNFrnjQb&jmc#vGpVVcp14%1!>yuwdz+%&hI4Dzye6r_cK7FB0mQVw^+(9|Pz8r_JJ
zKU`>WHy-dbV{)*9;UV{$K?tirPn9J{Kw+DRI11K`QW97;6#JD1Z;=(Jwn&`pA#wd9Z?t89R;(^3ft7b6f|1Eivzfy)#MVM~xJ=a3kv24D
zLmQs|D)+PKuKj>7bj9+bsce05)0^Mxo1MTv=t%$J*tlYQByVuyh{EzmlyLzTi(oFN
zpd&WzWAtnYiRnlXi!he6zDOg>#X2UjoIIp{Dq=_LOY%`mWr9+YQJfPl=tlNGM3dNI
zG0b-nN{Ej@no$dCPxT-bMAS}$UdN$~Xk*2tUp=IUa8K>o-FNNT`W*fpd>TalUsFTf
z-+PJMUms{M@Q1?Zg}D!0!6}K?&d@wlcE!P9ywvT`hbwaZwI$ih7?=1GP&nm9f}RdD
z7_BB=tHn-E8<3d#DTVTKKPCpQzb`R%=AoLGuIFAdEUWN~I#hkd@(fK-
zg@|p1<@Le8$#CgYe^UkGb=MAbb)tXviah`u4W`cDYjSc15fD7#ho&$c=$<@JEb-L)
zuJi?bt9O5>7a2xI>0{iTVvi?1Hi*l!5Yhdi>@=&DolLJ*_xtQ;-}+vp_kX`9@PC*U
z*It%kY8on24_Lw#hCCuMl?=7X8I5H{Vj`0iPFqqlYJ23WWs|}uAeNU^ARpSeuE??E
z(XOlfh4eT$uvpNLmY|{>CvR{CPY46~Z+mh4=Ybyvzm&BwXpj!wu2kKV#|VsNq}J-w
zxj*M;xj*l7J%P>C@_co6`YVvv-8)QS>!|VShx^f#0bNFn`hv@8urY%W*|l0BT$(fu
z3bC1)%k4~3OuwOPrA<_ck>hdwe`YQV_44yZ!l;tfv#M77lC^brd^&
zFyulP3Xxi>3|6&bsGRCbRIhfk8~XhUO!fJ{Y!UDQNo;m>lR4na1b#JK{73!KdNPP-
z;$_6Vzw8O3r*HQ8
zzh6J~KTgD>rN20ZwDN;k#k7F*aY0Vx23oA9qJBWgnv$V2o6S_vBbep5#S$E5wfxWN
zX~t^$;BB37wyJ=ilYk$U0#P=&344281wM6U$a|PftRw=UoV-H*b=KMUX$@f}txD#Yf#>n(!5w$}B+V~G+JKg(XY0$kk
z%#CS{!!~XGhVJG(D_Hl=0w`YqlN#b9`%xr};ctHO^v9l7&!@y-hJ@oIq*l;N_Mbdr
z-P$-kE`GRQvAvO44584@XFe^Xfv1~t@F}H&{ognJ&mfzK{4Xd1AH9&*pQrubP#!jd
z*@-tPKXUBA4q1Cq5MQGWk$DJ7VwMyH2=2;5U;)a^55b;qjiOJG>7@jj6CXDwZY{Oc07aFD>{Su_`T8=DY4{7-dpq4`CHBv%$PSI)fzVzEF)EutXkN_j*r&2CC$
zmU=(o6~wGnE58?IqXFz2
zQX&WzgR-DAg~e1)V5HFwiLf8usdBK-U8&zRwe-K{81n6nsO~OgPix}GsoRGbIen(w
ziI;RbLP+?F{Sf%7r38yYHItbv)G5wQy}%i}o)PUTzM
zsCw)Diy;pWXQqy)(VrZ#wv=VuvaZB!&}H0`ZpEitxYSew1>G;Jh)^Ao58)b0e^x#0
zyko}a4qfjwg%YJXCAz7wYEkqOhY9O3+a})VGDG%VC3V#J9wbWw`mT{Z8UL)0y05l5
ziZ`#%g5%>Dy;~xzE&|#4_wgzffM=U%J3S*ELX|jkr^SQav{UsZn
z94-#YL+!!(DN;#e82$6I)g`v*0<^oa7i}j8WC0}2UIL;5>VkGCC?^_jMS>!bjVgcz
zwL!!}JE}HuuFIzn-avQ>Opt|uy+U5;IN7+mDj;93+mq*gNbKpt=mMDQyT9k7?)G=y
z>r;8C9GpN@kLc!7{MZz`KsHfSc_SMuU+#MCa)mexKv@lnYqdbv;
zcK^yMVC-S~a{|>9cKb6BVaGVG7o~xFs%2M(D=MEdS|MbnVhE1qe*o=362B3~GE@l6
z4Tk22*ttP^vJzMrW*3H-r6Fo*;4kyP8&e(0F6g;#O^u0>XgUz&!1)MzL*mEK>q$tn
zaeF6P+-~duw7@h8kF=P^!a-eQ7N{!5m?N|aymTgEk4Ma0@y)Y
zn6&oggQIQ_pRByORQ}ID{$VK3^rfg$f+!`ZLYych$ZRx_
zV!fFNB)Q%+<4w^Rz?p88XbK~m$Or)Y;9EEY7&qp!V&Kg4F~mtRQ6?t(sCt>4CNFJb$x=+w$!bM>54ind;YjIc*x@hX4sm*3=h0p~er!x`k
z0bd>SLnKBsfWtUgaASs*3r(hjgNwIzshnR*zqXuxeI@tWTK@Hw!i9wt=;^uC#w5yn
z(-CO?c$~qb(CQ<;Od=Q$`&i1wAVv%!avNi*caQh~?uV;${js48UCV{5
z*>GQqDJMe+_!v=45XDF^7xrhuflLgQY1W@&e5nwkA<2aBBI`Uok$7u1{>#nsIfx5`
z)J)kwUkRS9M^28i^L^f>{?GKABfg8%-H_)*6Fs@H01rMUgWXw1m=BAy5$R8U_)3Bj
zyKP(m8|*UZ5nA=_jZx%wi=oYB>9iR-5N8J>wP?2)+u$oiTLNlmwHaH$h#ltENRSWB
z2pk3q5MQd&l<;=UAeebN7-dru5
zTgF#_pmAe*4F$*nVf`0*Ae3IWdF
zYs|#mBjv!{2)#TR-JFS?oQ|EHPoJAlFAb6B=CiLY=PxW|z=eQuU%aRPA`7+To+t0w
zyX(Ohp1kjcCmwk2v7OI7x^wpd1t`6s`QQ!J#WqBxD
zi&F!M&}@J9#7zHdizDmx!bFiB$}q#(&~P?5RtU~iB8!9RrNQh}Uu?E7+#kWFivH6R
z>Gh%LLO-)qi_Vp)`D$pf3df-uSAoX%1zRpCT8WXVL>mx%b&@n9+z1oMrAykQ!Tgb?Ek
z7&mxwI$(#yEfWjWO5veCwwfdIF>5huJ~0zN2mX0Jab_+9!2-}dGnWRlJ~^9Qok%Rz
z|7yQ^`&X{G?y`T*`3xuOsb?O#^SLJ;*!A$vCmz11`NcfwYpdl~mdocB3TNhuC#G{Nqw%GY#Nt?drJh_Gi7mqM
zNPJ-=J~tAXABirFMpwt9o0Eynsrd1!1VDRgCI#sd7%MuMOP-iYZB8WD#^Vcvk*NxF
ziXx*$iVf)G{7cqcd{(Z$?8u~TB0s(j-W?17zocI|rp
z@rPb`;?buc-TCxm4?X?By%%o_V5YHFfEKB%g>tvCczY0QCa@OL-AX!JSeygx08AWy
z2Jk}{2u1E-cY^APqx`%#MFEh#@nBCQQAf#hfLu-luqnUf>;my7TaEZqr_V^ZxFm
zyW0;u*`IOO3xUD3Z*C~EI+k9W$gPZLk5A{<#xrZ<+4YJ1#$;i0rm#MpU7yNsPUkkJ
z8}v6*h0UqV%2);(!9qPfJrtiANKDpZW7T-Q5;G~gq`ghO+{2RICVs~OG-Z)@h}*XR
z;ywKrx$5#OuKdbZuD;@mE53Z$wO3z#)fHD>y?y(RD=yn{*;QBkOFk-Fe3&_w9V*{`)Tf
z(m!7Ir7vB5`IoQy=YRgvKm4Bu@4EXN*Wa-7?tAXO{jQz&-2K3PJ0IG4&!hK0_{h%t
zAG`bBo|Xe;)|Xd*AuS{=LujaE=N%N0ovOWpA5REwt+-9;?Ex
z71=aGqr68YZI=r=B)!di-qFsEL%j9_-P|L++(VMy7EbHSoo)NO+7GlI+ueF>kF@is
z-y(J>cs`5h_HW*L@t*#RY`^@f9amm??T)L#ptoOk`Ayedzx~R~uitUqbvv%U`pWIw
zuiSpq4L8C8e0$CIt9M+sWBZrBwClkKYzm>I<&aIyS|P5Kh+B?)`>S8Q^`>up{f2Mc
z`n6kbz3J9lZu-W}*MIdJH+=Pb-?}&%ALQ@zwEwS=zr+0BU;d8qe}CC_^w7Q|`}ZE$
z`(o>{!+TzMRwn9gJ9_x&{=H2{_Ve0Xc>~1~0
zN7B<04mfK0=~p)Gc>0M)_r3Hy+{4BDx>U0M?v$^qK#8)!
z-lV4|?(0gpyWt=g6ve$gDYU(YAO`2Xy%D@C6%fKf%-56f@iReTo)Bk)f(-eIZmq7M
zBza0ypv9m?8f`vOq{XF>xEPWY=*Dz>R$gYrm9P}e%TLH_4N9xwl&YT6Uc9F-k}@N#
zhT(sSE3Bv*7S>q!C>n^01|wp$@FFH1j>+K%wJ6%JWNSr5H6rP6EX5dTuzd|gq?H)@
zb|@wXtwklHN!dtRI+~V`=g}IAse*R0sGUNKEwpoGw5Q2TQHdtv*9Gby1t2;YR{+3O
zXhsp)U|iN8Z7isXq6IYrG1(x%9GBNq^3k+%EUOsLszy_?sjPausGKRPXUi%8c)qNk
zDXIYDwLuf;`jBaJ$hv_RTc8QNTX(e$>~+rz&o?(6-oN`rFjh|6v5wZG9Zg4$9p2w^
z>`-U>5z6ZbIt~39#-SD(lw6IZO)F?p@S6-Wj!Jw?DL5wMA5jXA$$O8;dyh(c4@r9u
z3wSS!x(@Jp2YNUM_?!dW_Wd2Ld%Cy>IyvAE4s~)4@H$@Z?LvFuytwP3V+UV)`K4!G
z-t&C(k%M5_TetN&DN(`#fynW|+TbG~_mg+eXGw9)(+w602Tm!KzXv-$@ZvLWi<${INVicZ
zZ?mX7tg1GXs?DO|7!<7*WrtDTYEU#Am2GBqyUoBgXrP&(JyP;T+<&gQ4$fKlWnN!Ka_wb^i;`Jo4N#Pi)=R
z=cE!Al_)WIRPdkh@yG9+PX~p7E3(lB#u-wCER}35prXZDS^`=QD*;aAmT74pE3d{>
z7d4^)LbkdMNTAvz>g^|WRvshG%UCvqC_)l)^VT{WOPk1*D()J#iN?J6>2Ghlq8ZiVvX
zgyZD+C%*c?z8ClJe&MY*UvD|OAHpr1s^t@jklW{wSXCUCmg}|j;>Iqky2Y&R05}0f
zC=rXeiHqC2Tvm?Dg2s$N;lPPTCfXbCv5{JIZALX>L4*=*{UbWU@7T+0*$vQgns;+s
z_i|eIaGPENm(Fc@srk^edtQ2M>$W~8{b5;!k$|HvP-uguBBOwVQ_BM-T2`VUe9HP5
zFhO~VRe<~Lk85jDC0Yp=-CEYB9cZk80tg2Z>RJi`HV8HpM~iX#QIyqHqi7*yEecN-
z8iBeNQ^LUjfRRAI0XrVc8^?>LDWsQdp7c5CXTTwgM-xhfbYnmd-0V;a%uz9#kdGvk
zBPkTrM>9HTVW2}v?NCxPm@=ZhT2jU|DNU1-G6ToD;k0Qer5{Qfs$u0o3@zds%WB7S
z`l+0LreK=wGftOvixvG+zhSjzTpzR|M?GjbF=9PFWIa3PJU5P?9J{!(Yg>EsQBKQ|
z!!PgQbK8bW>9JbWZR~cbTYVOuUDImUw>yj+tFF~SEtv>^Ex|y&Mr6(Iy!weuFKqN(>Ghuhy|K(Z_&4!v`u>DQN8k*T5?p_`EpnL
zo{pv$Tbp0(XnLWeb$8Q|XIhVZaXhX?ZT$zqQw6>cn&$r?%B)=9x834t<-?*5$Ex1sq)=yoYsn#r*t;w+jxU
z-d+~(Au%qEb%xwsgp(7rb6Iz924&GoEqs%ZEd3#CBn3CR#-!fEA1MuSL2lk(vdV655FiHvb1
zp&d;bD-m@iqRWu-QcPc9wMAAF^@`G@s=+s^Oa$anpD4#DLE`~YhLRV+ONCWvrDRM~
z&*{f<`o=_H!(z>{ST!#9o0n0}W!@aIZ46mY*U>tf6Ls5PC_1A-*Xm?}atZwAPRzhX
zgp~R=v#!}|?+n#Q0-(C*>@Hl&JmRRgJjTbb?0Vd@A
z;MOv_xte2Uz*$LXlm4!-yMuDHg!eHOI9uxOg^x6WV65&JnA2Ui@IpcE;s*jn=lL9_v|ekh?p%`0OnF{(1F2A`Y=
zN&(Ikp#pSMgc1PGGrAnDt;8)UN|lf33alm{(iFqm9Ib$M05C%s8cZ4Bh9QlZt(fQg
zZD`G7%>t&pK5RWcYD1*6W1#j6v+i?^ebqp=5jH*mj2SpC14pko>@st_HXb~bbb!w~
z+cP9TA~UNF8B{F>b*mP^)2vk<)ySJv(pHtMNv&vBN{%RG$K(JgaOO~jCi(Uo$Iqt=FMmZHDbfHPUIlwS!NNyhN+T%
zv0_=Mp{?#N-qRP!I5>u^3M_a6aR;czz#pVF4HvB+%bKbH65_;FWYF4LUDPYdGx{v8
z&CuF%#2odj0uCYJ68Y_7k5xcm64E7Mz4ByGQA=3M5nW$YQ;BN9z4wJx^&A8p(_F>2
zShFuyEgQqO^4H7Jjm6^C$LQylM(I$F|Ld)m=laC0eBt6S6JP&Y%YRY{vv
zvLk@860L4+(kPA@wJngEVdfUMx!GrKE;0O6u*++0^;ug34u}ZHz-?$`hc)tp0QS~x
zeNKj=3V<1M+Oe!*AOZO&+Ap)Q)YuG2OcX2t$ymWUls1*ZnkcDL%UXp!&0=AjOu_+`
ziaO+?4zvbN!O=>&dId)#>(I#BK>g;9Y)Cd%FwT@9k%6aXUK(&N^xMId7c2IKnhUW7
zm(fDu<*I#Y$T3^JWRuR%$s|CV)lOwKlR5QdPBW3#Oy^D0dBbQ1FgBN?Xvukr)n-X`
zo^I>_=n(WJako{3nFS6L-(?YEX0*l?xA1YR$ZZvSY(lq9=(h=ygen(;$gQa+^!-uo
z5H!uKWwzo3H?~}}tq(fZhHNKC(R&Zjvs2iaN!Pi_Pkc25UChGq**Iv0qpN*@={!Ab
z7>WrZSbGTTqTHQ?i{sHBV{B~^>yfIDd#0j#rKUVv6kq6*obMB#%J+btD2UgxlBKj{
zAk>w>ItXif(86^a+MrDUcwp-mL#rE+F!LJA8{6HMcHG!hipXhuTfo-pcXS$6N37ar
zo&1Y29)nyotp-!Br?n6!>lrm9nUe?@+f1KrrevQiS_jg$7^!xer3xueB50Qg+C-u@
zk+>ZImWn$R60TatRmyl;InSW#HYhsvDy|m#goYlSsx?8%D^bOCAGl&CvWyy9-Uy)=
zzy|xC@3$-uy4Hu?(?$K~Hmm%c3`eEYIo(V_S5L{O^4clL@&MhmVI*Th0U~C~kP7h6
zc}fcw?6dOS7BOxXd8`tbS%_K0PJkH>On@ue{m_HfwTeAxT`St?GT@TXxM&FRjvGLS
z)7JjDZnk2dt=cAwI>7kEm}_MS^_tF%V`nE^ug@YnPmpc6xh0CysP0mr!vU@ruUG6iiRQ0Fo*hEUUSkca8)w4z8
zR8BLHP(dGtwDG)VjziyW(zNK+O$cUv3*>HS^GpX9kj6}qw71%|M;V-(rA2PjVZy;N
ztN*eu#%BdO49JKxkWZ<>ug;e(;7+$}Zm}Pm?sFEy`hZJ@7^=l+QL9?sB^9-c`E43S
z51i2|yA0YMy{glw={D(lv~rGC#nUOc1~nJAiA~y0lZu0zyGv13J#Sv9*&EB0U0Vi?
zRxJ+$Oy-yqUCW;Wxy`=W72?AO5oy=JXS&7
zXh+!k`d^L*4Gx)1>pTy%R&KqDwZ!CCY_BPtdi8#5%U~h>Q
zr2_n@x0}T}BN(p`l0pc~qm|0Cs9y-lOO}y?i_5brxO>R#YiV;Stjy5zBmr%$n{f5`
z?A?%=+YB9MZ7cX{qpI0rK+}U7y)3TB(Scc8o#s}%u@#bSi{_Bu){+m2yv8q{DKJyA
z%z|6a=ppfelya_YUaZ>SV7}s*uVVcPa{!Y8t_>D)u3XC1sd_ca9;K`Y9JNZ;sgZT+
z72UW^;kGF;i`3^-kzREGQ`yWSldj98={BmlCN&Rw^L2S@Hc}Wv&R0T05Q70LD`}=;7EW@|M1^x*XA#quMMBp;r^}st~|v)w0ZE
zMiz`VvTOjnWz!8xXs}?Z*CFvaq>Xh`vVc<_z-34=Nf493b?Q0mL;)X3nP*bTK&KRM9lJN*g7dlgl
zqcxB51~o^L5HHs0zL=pL(-$Ke=-ZX!x;(2GNSWc=6r-WMV%jGO;sVUlX$5Q6BLV{G
zC8N0D;`%Y3+m6;Qqh;ylR+ps>GHt8oNWlEXlYYQ6&z4N{Me9^nH(fTY4mef^T+0LQ
z**>fqHw7`dO3qctI37#`KG~oX0@zNgQX=WpD*1ptcyATjMz>ch@7Ah7I}NHXyHOCK
z%$QB=GVyJOUW>NNW#${zZIze~jBgpii7gL0kB_63>C3}NH%9UGOZn+PC$k03Y)LkNDtB=CMBJ{)tF|o>}q71)|oPNobXM6dE9w+5ynRyn?V#6b?u;VO_n?zcG{Dn9KI1
zZ38)1hS5y)2dimoz0U_{iYaTDP~?-=D5WAjBA>Iz<3v=gjai$}MQ$eCUE!dBzS9Qr)Z9@Zo0;v&3%V2XHWMksV;xam`wuP0tz5
zAkK!3I=(srVHj&{J>c9N^K4FdHYWcn^#I61*|<JO$(E)v=YE%!}7d8I=
zcfSd`WN2l&3*m<-2FzRB5?~2Z+#&;jJysc7uWXY8x?Z~!ZCl`yqlK@yI_Qy89%aa<
z4S7_QS3!HEm6&C!?5^j*pWzEN4Eh&qBWP#lQ;2;4f8|p<26UnSNTWRnPj8p^p
zs0r*i&Z130J>a*oUdkiFY+R=iZDSqs^OLkVMhF;BH|^~VI60pp{nvO0=1N8seXEZ3
zLHqiUYZ=01pL4#3;*Hb5*8^;dZjGWFY}cd{xm{`q!%8_~B2Y>@4UHWJwx|a{x2OlK
zM(Nfj0}e=KZ6do-=&}m!MrezChq1?PYMbwO&DWfOF2p%N_xOYlJofPk@A~-P^3?$F
zQpvbbGS8P0zsE?{TF*Ojq`a0gj^^BiONuadqUGlhWqo$J&(<(#w28RHWfJ0OzXFBN
zuJYNHXx9RlGU!qexEk$H45e2S@~T*`mhq@UZaM2wFkU(Ip(o4E*(x?!v@H)}C*UUQ
z*ojfstFyk>Ki$@VaPmm3lfXJ@PfwH(CTU5AX>4cf7O*~HHfmr4(l8;9kqXu)O|#m1
z)nCmy(_wu&VyNVtnYb|-Hl}07Ox#pTBQkXQQT&AL3t+-_`4Jbb+IW
zY|HQB6yl13w5AY|M1y?B*F|}F9tWCs4}N>=wmv5-D8+@IzGHm=TOV<*4Pr|*_wr=k
z=aOfmPKyrhnE(cgmL@9^frL&Ch6^fG$a{5Kp;3cy)vE+sJ42(bu=QfV7#ak!W~!W{_DF$Q#ZGdA~K-q(3
zvg{a4ng&y*!KAq_YJUH{|0G@VATB2{rOyTUA;tlePuUf2iwwfB+amGU5bpq3Fu?D3
zC;?-%l-aFrtZdeR5z}53g?6cE5D@rOj9-;ybVDi2OvSZW^Q{j1Ad`TYa(3GH>U{7o
zb{uRNG3)C_L@=Z{MN4uKMT`(e0>UUMjgayLtxB=#466sg1`F=~th1D|jaGx@j4KJ|6W5fk1&vL(Qa|B->#TEzL@YHO25kz9WMqttPB*R{S
z4Y_4GBwUScGSot~f)Ah?wIYNu0IU%J!Hv56#H4Ry!h2@!udbW`IX-Bc@6#`ptP6d1NVo=5R>*#b(&q7U
zfb}-E4M$u9>Md3YC{apO2rAg#<$Z#uU4~U2fw+a22xQ@b`=gd?9?D)i_A8r0VN1mSj
ztE>_rYc=!QfPJaY1_}Rg(ooOYYAN$b7Nu#F2QY>psv%t}0#^nxP&pzJv4bM8K>=XM
zu_5`wEpnf;v5&k5%vT-q>XD-cXoG0)c+d!e_FoAHHIX3X>N@B>4kir?{qChf&&f&u
z*=g^oG51?b7jJc2EWnQk1u05Yjwz}M)nH>kx?)@dW<62!Cqt?@rOZW)m9(Rpb5-;1
zT-;jCd-HKeoHj%VE#*5nA+E+neKA3QLfjumJ7*Ll!mZo-oU9K!APhs&cxv2te8jslg4j>&W+7&l
z8+AR1Im9Rd$7=zM^$Sq}f*Ws$qU
zZ91fgDg#$|orqGR6gQ2P%$pP5h
z0JcS*J+XwyB)lrXn06!BNH^k>ATSN2&3=c>XOnqsP#wNa4+#OJ+0b!Pz;9?T*sg~4
z>p}r!!Qp^$3*9KGZEQB9i;?%9{Hy1B1g4zbTPbMrW
z#bni#YACNA$ZCK5gL9dP0x)L%A|@b>ht!ZsWunG`k|!Kg0j>kZKqg{Ogp9OT5v9~0
z{qe2$|M12~zkloBe|-T=ne@t8LKDO#UI*I8IZA24l)bKQAJ&80IZj)<)7oEHCUzQnjq(n?qQj)*;wFjTt_EMdwSy4j
zN8AJv0suBf3G>!gLU9`Lhr}p-g3uQj#mYz!03OeqkBRHM+rIY5ymN1HID(zDb}2gIv7#|?Va+-S+DYg-@o(T
zZ{LRU!#}+9pTB?m{olNnVoV9v6bl)mw1M!*w%CATwAyKE_gXuV9b4KkQ!9nFR}-Rv
zxS&7YGmzv1(q*=@6zko(tj88p4nT^9AW3c8zmJ6mw4MK0?sXb3R78cN)$3gQ~l
zr}eocOhAXWYO)IhxBx=(iOImZ8S>mLd43)l@hgj$>@)B=Ss!$+4dKvFg^u-11+PRk
zBU#HtCBQ(R$FHNI+v7vLFd;9ZuKKw@u_S_1e@NldNf`7XRqu4?p_&gWvq(
zr>w`w`VEl);v)bH4hM~qpef#9he?FYiLfQk7{Qw+X>E>GEe`spE3UP1a&;KLFc)}h
zCG_^v#nfS2Ij$%t6nzPKB`K?=m4jJzCM1dkMPWa5nZ(c`ju47?NK;BXiz!DoZXc@9
zg|v(EsRFq4mp|V8!!KX?-Otbe?w1#S|MTh*Z^a%Q{b|6
zLJtZOY{VyFM$6A3^9nfIs%Yn}o?4=(8ta0x674Kqx*gT00v3FF!hdqidv-bq7%vR^
zVga4UCUZeX>QFgM65Oc)1T99HP9wA!qz0`3I>dVDC5u`+nqK_VhyU@xhwpvx0qFa0
zymkS1Xk86}ahDczs<8&fKBvO#LYsJzUX>rcQIf#TkC&~RQ-1K($WhOdZ!EL#tfTGR
z|C$^JfWe3darAzsiceSYsWLWD@S^-Epl@u3q@z4K3gW99!ki|E!QYj;ZBnPP*Cado
z_Jy^NK6?MX|M=a)=$B^ZQpDr8QD3@J*p
zIz}xGde`g0wNdC9ldms=ul{5!l5$*DPJ$iF5cdz_QB&mD2F3v~Mt@x{$&%aVO~qC)xG8pP&8h&n`fl`th49ub-T#WqrT>`78hat5*pK(m@qCZQ8Gd
z(rxFv9i6xx5%O9MEjA;1-9h5qVz?K~cS|d=&I%#{>fE}m&&g)p4Mu!!nm9Qg*c|tt
zoXtCr}d}9TNcG0~v;f^eDkmg}wZ>I(}w`03&{LCH&?J
z^W&3$b*U=I$sy0lQO|O}3%YiY>n_#;bA9;oSSAwGvjk+qXtygw{L|R>iuUM958A^n
z;E-d6Zo7u_(fhyu=#T$aqUk^X=|8tFSV#~EW5N=n%#G5XY|#H?7<&>lY)yuYXB(_%Y3+)
z4yfRHfi-}y4!8xN7JZ9F-vnwiG&zmO5=2*l?&^<1Jm!^HPG1Bt{$d)hGn2v7Q$E1>
z!Yp-qhF+Y=LQ?H>Y0^nQ>C?n%hu5XETa|W;+GtSNttzuYX4Z-{if$-B_~3)#T=Jt2
ze_u{BVTMNRFn{_W;4uTVUQF+CX?>WUaBBlNBEEyDSx92wrGmIDh)D_&9rTx8T?oCg
z5`JTq{=sJaC#U`@xd6!Kko)+k_xPx9zJgeP76u?jdPnkD6mnn^5HRo40K=y((+nLk!6IDpb)|^
z=@F40F;cG>03PWlLje^;;sj&!xnw4N_u@?P*FQb?%YQlj#;K_vzqxvPee~D=a{let
zm%T2D-z|Z507l%G^T7X&vs$mK$7umOZgyEa%$j3P!?6_2&rrN9#mm#2BEtiW%Pe>6
zwmv5(!COuR&(Dy6@%e?wsRi`*!|hagacz_~rz3dKZ3Mf-oLZY%g*&x?x78#!se5A#
z{^5u3|LMaISL-9OpzFgAKiDDwB79aKZuH>>k4qPH8%VE_@Iv~dVj!s@jgS@v5IL1}
zvf?;BOTIEsAp)<>#1BuT-aUc#0Q+mQI^tfh`%ct-Yoo!{k-*YmaCtDWI83JiCki^5
zrZ54yjv*A#g?wB5P5?7Xvm4}2kZ*#E{`jMh{`Ah-v+xf%>j>eBQD{TI1YwI)wnWI9
zV(h6;_?=R$HN%*55mOIWU;g;i
z&wjA+*7LGRkIf4v^q7^PN+h?QYty5yR#1;%S>fG0s)Vx$F-
zhSZ4-LOx|?0@{$@#Q5}$_Zu3&Qvv{Ayw=Ab|KeZX1?SxG&-NH12LgZ*zY|z+17LKJ
zWi2_@P-Ju`CfLn!^5kUr#3X%wF8s=3`1Qq$sRJVLDn*5#a(F@V^`{R%pxwP-#|`dN
zfgj^T4|r)hO?sgpWoClf7;ClYyH!e#MA+1N^y%rbEFk@pw>K`F8n@~>xPuRN?8Zc1
zOcZ5|gir2wi*YN@g_tK0#t@RN`lDdSF|+{{Cm!HN+${-zM0J
zW5I~e%|%X3g{KB7I%xK|)M3)Lp;dehn`$v8V#ticQ
zhabEb^jQO5OAx6!=ra+X276b)#1fFm*b)o?U|=AE`eaKZ{&Ncqbc^3yiN3p${K?78
zTgU$v#-~U9s{_H+VQPI8=`ylo;^Z_k{f29`HK?3iVH8;bY;z=N0c{X?nHb2N1IBp3
zm?rH*d3uID
zKMyc}YR6GwF4CK4dkbM9*mNl_{n=07hy_I?&IdaNcO9iwV8?EIPbuq2M$8b8eVEkm
zR{7j&g^bg3>_tx7Zcf{aJ>0!2X$x+HHX#eT6y^E`N+A2*wS#|kAL_rLzsg&
zWL{{OOt51xM-Q%dyNrG}V6XSPO3Z!eUY3S^}RO5
zt_{;`qoK7CYITGJq*q7DAHRJX`keWQE6qC6j4K{On1NkJ(Z;HXMG@I|zzSGK5a*sN
zPCDTjk#>cgfHW$R+B0DUEdacwTO@6{ux%voS{tL6M~KxrwOS|7%*RenF{h?KvEvNg
zm5&NCOm{vk%&~$pVp3JI-fj}_4&rgwq_
z+|4`K(|JH8Yc;4jUKiTvGE5l)9;w?Y2-8}xv)6|SAQ)pdE?f`*wwod6I?DKX@nBcX
z&xv^30pl%=xG&kJ`cnb_b9x%_@12Y?>9
zcD7zDMDYv@s9@O$hO%PT0bnB{McNJkgHJ}pY#|J67i~gHx{?%@WIq9z0jmX2v0Mx>
zv>~3hs4E?AV9Z))`-!CyYH=udd@8b9XP{ggr2+M=yF%Nt<`_Ppo2L0$hF^?|3lX&5
zB!Kq@@NTz*7lf1;7y4Wxh^%2!i=u2m<1q8%tkrDb>or|s!7;UhV=?wREdtCY2nDr1
zTpDnL50HcTLQ+j4B0jXqC#ciZ>T1xlg}od^EaB%xy<9+-!CSUif3|Mxb8==nd}=y$
zb{1fco|%hmOi&9WR6gOM17^}|W&^fd+#4pHRM6(f!4CtXb^@6x0=U8A1Emca?#1n3
zp+wAW4SF^U88Aa6rh^cVbxGD9CJ`wu6HrgqyvL_eiudYj{Ean0I{nV^%)2Kq*)R5U
z^3HPZ2g~`Nt`%M#3;l2@yEa6x)FFEat&On|0n2fJ0TJk7$m=q$R2YlXXhU73v@^jV
zfa4)&jJ5&BiI5ZVb1{gCEg8a605;lX7DuLxNZoL_2-=u7Y=w}#J_){!m>;4SN0`M?
zdT9i5Y77*##J<>7FFnlcIW{9WCJJHZ^jze^V*K1CPaVrT>Z3?)Haq~Ig{7M8HGq$vsEE#gdt9Z|~6
z`1R1BXKLOvbIdC%sn=JNuWzK^I-Wnj96z)8x8m{HvC!*t$#<6XZ_mVky2yO+YTvnu
z$kGtAG8#U&T>jzPuar{0QruIBd-~F3ChSS04RkTYvq!lAOMn)Uu7%uj8jm3^J}`GT
ze2ci*!d_?-VAknyV^?7YfVV>m1{hBdFo=S0keRFmrmBE+Xc1BHk)M)wZ9^Q3R8O4f
zOi+MvZ-x;T!jgPc@{6DSAb@vzU5FtOFve`1xD7dNKR8~e0GV|_joSrayVW9zJ0wo4
z(2vW)AtU5vF&5k%dU1_AdhKQoV2rq)8XSuNu-n$gdODK9?s&t9qh3VMMmmq7?R#Bc
zJlE&UZ2Z(r^z3YGYX{>C3&}I{iS^kc5io((hJyAmG=Ih#3%dZ(U;r?7h6pEO+Y6%2
zjVS=Qf%+En9y;0h3fe@3cE%Zi)|rkv;;fDG>A;#JgfSD=uZ~k^7hyDWN(57o92VN9_#m!9-hzD
z>2r2dJ~1He!+J3*V#IV=I)|&2*D1~?G18}^{3^`Grvj>U+y-Gd8L>bNcH6rxx^~=w
zc4-Dj4Xvc%sM|10(~sXAg~o(1Mj7=*x>Q8#$W~8@O;nDCr`~r0pRls7daL;
zCQ%
zx%`9m@`dT-*@@_{PF3HTOa1&OZw=*`T8=Fz$#Rk|B*=W60I;_>7SmzGt(QcUxZtS0
z$g;s+8yjTD88`YC5iGiqxq~xDgt_+Ff#_tJ81JK|`sndKaD86uE6cf8mon!UQ|A^E7Z#Izye|+ca(7hs1TT0
z=yilW5yl+}xwkg#rV!*#uS!i%;DrYI<^Gm^?ckJv9+MJrO@MlfE#UePh1x#$4w7Wa8{}
z;&(rLXR41GDl$W*aDRcVq?uBJEXIj^G?+njiheNe=~`@IB;DBW9bB|81(wZ%t$V@5
zp#>yEo*3au(9U`vJzWjei~i{X_PgWRw--|zL&Q=oczif?Vl2E|`^1jHo??N{NT4fD
z^hSILY_Mqv&nV4~O5c0$kA94Yb`!Akf?gr`YP*qZGoXd32torm;SS8&GuRjK;XmR8){#Cki^R8K6xiTV(`VgzqxF+|t3wf{Dl^44vA
zPR`6_z?9!yDi$mOsv7T%yn2rY@(!!*i4OBn+%_sLlFUR-6GLEIU5In
z*T??Wn8co4_wU*D;O?jIPk3bKrjjSd!<%)`*zvK%#%OGLfO&nfe0nN>cBVMf7x>f9
zPrkM}Fp{N*@@y>|u4b8XB24F`CT=&~LTz}#R~LmQxH
z!h%9v{;xlMGvGo*sTj(e8a8U;g1aWY5-?M6!YrY|t%x7hsA_8L9FMl=wCdWx+-=52
z47Rl6R?z0Cw-cO1GQb5d4gNXoX^FU-nFdQLV$l5SgnOrF)8`knU{bFxWdZ3o*NSg%
zppDnTwl=5Y%M*#?t5c~sqKgHG7K21I>@MfSeT67kHkfjR@q`&Spqq>a!ZZf(vyjn*
zy$KeJvhHvQgP09w4FFei{>9UiYD4C328H5UhTLC-E`=7*{COX=5_iWl$ci)8Op
z_wRZ7q1{hC_`>54zVyVstV3~PoLL#7RtMR|T4;GFyirdr55?E(nX?N6V+HEuZ2v+n
zF;${pUFrYrI~zYaJ+n4Zt|o{|JXnqqg(%W|*bAssMArK0
z^`Yo;KRunpf3%Q!wH`iRk1bUEiSZ@aa4A#v0A<^xO`nh1r
zppau{!V*yUUC`a*Mv)jfVSv-DZS^?2ErwPA6s
zH9_=5{hi25Lptq6JjW1;w-jOQJc{(MV7xINTOW&_o=u)#OkY?5J5Il`ntyA(_|AIi
zwbdeEurQ2bGhht4$yOGMY%~^3MErnpHc7=;FQA)&hm|0*Nir1+zz?>3JBrGFNY2dz
z#o%N$xID&g&cu#S$4<@0&M)RqPRG{j;n$Y4uPx=y%%#Axw{GbRW&f^wUwrD`-Mb!q
z>8Xcbc;bO)AHV;(NA9zWnuZdd<$=&*KQ&jSXZynQ)#%bta$z7hnqf~(4~%9b)o^e$
z7g-p}pPe5#KR>uoiH~GL!&!PbN7u8#sWLm=7g-xA%~WHcgKDZHzffZ)%Yn%fJyT{Ui;?kiVzdyeCE3ADw31+QtbaJm
zu8#Jfni*QJ*Ve~t8x#Gjqt&%~Wwl
z%~qJ1K58r%7)rP&i&TMj?0)ot=DioUDn@q9xVP9b0qjoJ$76f|c4ySrnWO}eX=lTt
z3@b(;g{A#DBk2Xdjk-f_M-L!sM{puOT!*pUW&(^`Ek?BaX2VOjg-PMkBnAE;7T_j{
z&NvFg9Wft=!N5x+j3L$f#Ey@JoZzm%I35d*z2Gr)4CnCUQ>hcvhy(ZBQvSkH?v0i5
z8>@YV6hW&o8TF$l>Jo*VrrN62rB(e84F
z>Mt^tOdu0=6{424iTLTc%sEK4<`7rv+4;n|h1}WsG&HZx$;9&b-x_zi`tr-3z5BbB
zpozB1o_X}XXCL4B++&YC{?NTo+<)g&58nO4Blo@d$UR+0_Kf60^#VCljgJ?Z(L!Xj
z5Ur&`eQ|1w2DdMUXmCr212<5L5XEq?8mES`)M$|%&$IOmH39!UO^;-JBbnep!q*>h
zO_!O8d@xH`q}-zio_prN3r`<<>Dhn!-~W5-uC_7otljNf+^3`yObR-$95Cw;*1`CA
z4dT--C{v6ejo6MQ*@!e66c89U7t^>bZ7wThSkNg#YPYmQ^mUk8JdTdOl%Dl+G9f_%
z^}l>mP-8n6Uhw;c7>F^x!$5s&89ZGBF-hn^O+?&dc=OIY|5rN9OtJ&D5P
zxkW^H{Kk6a_2trQE2VSu*^|@B6VvInvDlgU!qOo9+Is2NZ%zF0?C{!HVjx2dWXWne
zkYVv!fhi=3YMvU(Q_};H*`dhBOzP}>4xBSWcRqCr#p49z0cYm2CuWixlkw$|$V8c#
z?E71DeJ;Q3imSf-mCOI(D^@Y5Oxv{lw#V+h`@x-eJ+kxeNAA7r;d}0U?7n**`TlKJ
zf90Q^fB61m`<`X&Drwu{(JVPqVC%*BNFhF4fWA<2q7$YI>vC}i5mlXDQ;I3r3?DBsS6MQK)?jfj)9IEiKj^)TMf
z1O;AQ6eET3vvf$5Vg)IhpCC|N2aR|*4Ho=1#C7Xw15n`r@t`&wHQlgaWX*rYR|CeJ
z{ZH`@>=Lx>6*j%7;~$x>(lgc2=2R9e8!Y(DLhhC2@~Z&zLgDN}@#J)7eLS^18ebSq
ztke@rV~M5Fc!T0LK0h3v8;&fFMpwq7tM%ySWDFpL{QTtf7NW^Bv+2`wDQGLlC*y15
z(Us9S^kk;1>_i_kRt+nAzIbKjmRz@e$CZ~|zT=ARJGSq*>`PxZ^|mD4M%t-<;P%^g
z-gC#!yY9I6``^3jvdb>}hyV5cTfe^ZuG=5odGD<^-}KZ2ci(pN*Y5u2*YCaU>khRb
zU{$j&U5>OBC`X>O_pw+Ndhl*z!e?-6`8H{nlH1gEWcPt*o_O}5oi9D{_@1YqeBzM@
z_C5Rbt_L4@ao3|SKJnNKyB>f3iAVU&7Yznsyrn@fCae`fj&s3vvv_;R!y_H705)`;
z0Vk9(p?te1O(V0;ghUq=IdfqKoOwu)WdvZdNxB=g38Dw>{S)X!89O4(h3hv$Zv#s>
z_!MRU7%Ui>vg3=NpwGZDiCQ}LKht^W#hxQC_B6d9Y<@}Hvagm73>N~k1N7Py0`=rf
z4gfwgUpz6FJ2h9{oXs4c&TdS?SDEGU^y*k@eIm6qmOMV4U!O{CPJ`PAqlZor>Vut}
zPM@4X+Zi06POOh*mq%0JPN!<@cr`p&q6~7bsHa)d(<12n;uTq2a`lw}^7ieQU49L~
zj2Mou+WzIs_U?L&G>NCm;fL<|?tS0?{ypEn;~UpqfBjWg-+cXzx7~WnLwDYB-|e>{
zdgD94fBjY4AG!DLo%h_m^N!nhJ@nACk3RbJLk~Xt$ivS*{NVGCKK#PtkAbm1^Uy<&
z-*@+}2X;R7z=Mz6bMNC1KKS&*k39MCL%SY+WY;4PJoV^_S{GXxsO6=iwK-kM8L{vbVSGprGkx3HLyE^K+AZ^kCXIRS7K&#n#5ND`Nm~9(1J+
z$mLhZGHVmrjp^L#WO^M?pUSRHrZ=XFn^T#!$;{G7Vre8f*&m%5Ow0}@Cu_06LMR$E
zsYGqUu47VuE1!F)tK*=c^Qf@vi=)YwT(kYE>$YEg)#X=SebrUlFTdid?c29sarxC(
zUa{ly?KfR{xm_t%ceiSV-H+aL_kDNVanBuheD{`b-Fe%0uKx06JMX;X&hOp!(7pG5
z`x{?-_?~<2yW{(JeCO7CZ@&!!{O#Yqb;sqGJ#^PS|MU<4=l(nHc;KFU9)IYuyT5<;
z!w)=g|9$tse|hBo2Or=0z?1jf9mY-Bpp!DHAH8?y&DY<2_xJAJx~q$v^x&dHcn2tj
zwKPy~4Z2zh7o=lc@ZpH98jx-%bfz2c#dwY5&RFAk3;Tx2LgEH(q8$zp#tjdF_^Yv2
z_(PNn`DEIK95pgrXA86dI0mJiTfO8jrm()@`fG2v@!IYG{77EhRkVjK7=-1e|I`Z;PboNKeN>VNbKDyQ!OdxVz(E
zXWPqd$9A_Kc|PX*Tl`#CU4F&(uUv*K_=+o_ylVSZa0Y-A^R{n2eD^&M-0}T?{Gb0H`1tsJ_e1c0;BE-yJMX>o
z&VT;WKYjhi8+YDy&pmhEx$~}jAGqtD2k+SlZQ}8r_qz4+676LiI;*7Xsk`s})>psr
z)$6|Y_3OX>t($MX`}WUZOu+Mnpop~x?EnVKzaaVAvS|`+hTcM>769kb08yhgpf=F}
zp35Mbas(t~Y5;2E2jJe}408Kh&^9a>F_lwT6M=j(!Wh5~+72T}-H6SUvkCd_zmju(
z`<8E9f9AK$b!y?`>MQ^)7)(z^=Nid_ts^Qx-BBQcLDQ*{Z9ussP;deFj
zc}F@s4)VE20M{K{7Hj#nSMIp-OJDxRbysTyT_$m_Q_-vG;l}-r>o5C?T_ryH
z{H_-tf8e3JZvTh>=YKqQ@4a98AOFvR=byjkE0+@v>*M#_6?L0EI+07phyVEEV-MZ1
z{hC{E`uZ(Mzwx!}zxIvmZ~o3L-~RdyU%Tb27a7$N#^9V063Bef-Vz9PS4$9(fLsiv
zU>wrDMJ>ODG&v@;C=tkL@{f@OjXq2cH-BH2H06ufChI38bAz@A&pDH{X2Az4tzF
z@t(d&c3gG^nCvxIAzW{|;l{6Cf7A8XT(f1$H(q-koP=n-1MNI<&ToJB=4-G1
z`qekwbp7==U3=44ue<5y8@~44TfcSFwby;^hOd47t6%@dSE0P+>o?tU>&@S~<*VQP
z*4MwYbyt7qum0~Zf5-U0zx*BJzsuj{zk~eUlK(FMfA;<|OtR}t(?<30eCLCi?wRSf
zn8}i5Teg_VqLPX^nKL3Wn3!wj>wE%`(DrU?ud-{FYW&g?W&`P_I9*3NCn&juf0-x{OHM}2a$X<
zH=OLIwH-aUuerYF$idgKxqr_~^tPt@6GvMbYids%Zm2!hLu)^A~4#~sOGDs{X9lXFUeJ#`e_Zl9SvQrbr^KFpX_e0LEqJOfG8w+o9k;2yuOFl)_idP>o{!BOW$cYd93F6;oVd9
zC0gFyoAWS|wywCDmUlBUuD-0BMAFt9v(V!9u8gxUWhare^+ZiwSr;>D?M*oQB9^YW
zy*GtTCnMqLk6ZiVw*I)IA7ez++7oy7k$ESnhZ3>(ge~1sJg2=c;p$JjnB;5ueJoON
z!^_N&o<;TKoB7dKqY&Vr&-S-foI(5oVdhAL
zT?vs2ER_iPw)oK~dnm*pr8%fF9e9S(I913YLaMh^2g6}@CB_>JvC1*L5DsD_%q~aR
zWjq#psVILws6GTio-@X)M7X4yK$J6);7%raEW?1*kQgIX22Sl(
z3)%f<)ZNqcdAq8i=6GZ6iSEv}jurq=ck<|gqlaDtoFX2Z*46}K+gs{en`)09*xOQH
z127Noe;p(vWFr2N1ABXESO@A3?R~YQxt`PCEoAm)!~VF>=CP_10ZTFI3pmscgP6}~
z;xigWtTq9oh11i(>u+Rr*K&I5dHqf7t{P5n9lNIv^Q7-3!S1PN&`8n4etHeFyN=aU
z%jl}(^fmQ#p6uy3(baaOr{fsC^$4h@w;ZRn9P6dk(c4bYNF3{EJ<{2JjNXaGsIIrG
z7DslsAM2yn^!3*F((Brrj68whX;LGD0^R|;|mL%czP8HcKL!^N(lFn=(_1%bs7DWy^jaw$;za()KJ
zz&q*e&3j4R90VSMN${NY^cDQfLXb5W<&l~yA@*R1Qw*`oF~LxbKZpxDE*wejmfsjn
zOE9Ls#a}{wskn4HC&PI61YJoh;|B#v6(xdem|Y4mO8$P}Ivi$|!yHmDDZ~V{V^LDE
z1Dm8mON28TCAD=hgE1gPfZIx#JsRPU#RTPuphDGVDPuA!7>x;sL)?)lFb2T9kuVQ~
z(S(2?x?9VIhrPQ1V+9Gbu~`PjF&=)zM4XR)GR~V!@TOAy>9hbaqo2xBm0nVUnVfh!
zCz#EWm?;Qm3xdU>WHB!Rz10B2t3$Ho0nyr!WF6d=6{|zyQ=_U=6%|!vKz^#C*s6eJ
z-7e4Lsxy8z2CivDKAVCFH`Sd4
z@KD;O+T-0FEzBO;o)@2Gbaw=t=4{+66ZDxif}m67wumL1CKbPxe8q*JO(mo$_#Gl<
z6Th!s$?H(_J7laTow!RaCf_$JW;e?DZ4!2il-n%jw@P`fLT0@}(28e}@mmFqdJ(IM
z+gHP9)QdUIoZcF4UoDSO$L>AJ={?EnIl<~a!S1Q)?KsladXU#w&+V_HcO0d+AL%BQ
zhK_Z%9;J62?`%7Q=PaHaNc>lrIUx8xp-?wM?RDFpy6o6il`e1o4Gv(+>L6aedJ|=eMJj?`8
zbb(K@33PKl4x!r9UkLCZ#h8J>ro5~)QAJkP&5qfCG&zh^I0`^TSxHx4^?`XmdSJ#O
zv}7tLrB2V4H9!J-0U;@?6l4M+Xm52F=p7FB|Ln)#8;^k{_IR8~@mP#K
zk>HHQIMgJ1?gV}@=qIEYP9ZKp09_Js{#aZDqycIrMuZx_CwYxA(NIJ%M0mz	nf`
zDp4U$X|*;J0T}egcoT8KL_$ES{g8q`WEF!4nI@&)_){t2R6;PB5YD8
zJe?KI6~#*flKDJ;r6^f0N*94~NxoW=0_pV;71Wpras^VX0L&Pl8dYphsJF%euzGt8
zf~-D2WdO$Krj2JOcfW}Ki$*Fv)gC_rS?=m+?P_aoZ>npoIab}*)?C-xK;ABBsX5-+
zSle{`NX%nf7%$`^wp`Tiv&wYhZmpQE5q78qEjn?#UeaNZb{gfKI%%g?M$2PP`p^m0Q
z^wy)amLr|bhdY{%0A^s^)Udy+^=N1F5zMzW?4z}iIwp-L_nbWP%HEfrJn-7{hxWg6
z^vD%xa>>sc1k4o4@VW>hfPQlQK`>!b?BYzDp>07Hr;3k9OXOC`xtQL-{1!_0C?0#m(8
zD*eDwgJJdNr~*81j>xvgl{;g~)8m@cW7_Re<(WzSxf$d68N<0L9hA9xmcD3L(c4;%
z9oql;%P$;1wC~W~SI(Z<;jo03LvE&dRd2B+@g~b0*%Uc(5O?;l;T$EllL@}hHg~T&AKiN3A#l~vr=WFEV@ps
zwiCTY+iBKxm^2+$@}+zoCUu)p-DW0};JMAD>M*KX^@`ol%3Jixb{*-#cAHMorjfUT
zZHzHcikl?-I;oHMUtC+~jCO}t8KAl%%2Go(NWS_%U9gN{B#9>r<9jbhov=Sp1
zE99t5D%D|LipzH*B_ECo$MA!a(jmYc28&dFyBs;R6T
zF-xjr$>$2v`QpD+<@Q#TY5jwO}gb~qv#jED;%LDt7bpYn1u
zets?}O#66gFF)huB|U6RCfv+~lNqx!Q*LBE+@upei-80Oj~$9i2ExJtc=)s&R3oM{
z7)TcKI0+=hn90lMic*{n^bp~dLB)I?y>uD5@rZ&-k4Z5n#AaE!Sy8}C?~JPvAbDq0
zh5o{{;rx^y0c(9>_D{c4{VG~pbIq~CtX_I!?eVU*rvA=mlae2H>4H{8DQ^GmZ+`96
z^&4dECTY7**XvZ%b>c>qpk6O))ytux?Rt5eRtmr%r!=#MAZpWhI}P0q9nGPqI}M#)
zBQ0R*@mYJKZdTOE4B7j_*4}`*+pF(HIJNB#@T_UKlfDgM({@mOJ0@+~PHgUmy49s^
zck4Rrnl`(x-LA(mI39;}npJHkMJswkwT^+bNi8AYfUm+p1~JD>i$c^$ssr-tB|Jof
zgx4rw*7ehm(OUO`+t&Jhy`43!^#{9Jk#$3#4?wzG>h`tN9c(;#1)5wA^M``$a#%1D
z;0}lQ$dgOJ)yF_GRt`ho_)y3neeVrQsM$k7Aq0?=5{w82V08UF&_0%s5tSfi7^QHz
z!!cqRT?GcISL~U
z7tNcD38oVKu@oefJDn0?4E38zR&A|hIw_t>%kT?~AdkgsNz2CKc%{n8w0bO|D1}9N
zKW`u?&IkDz0Mt@MiXP~ue7syhlydVC8J{ri6-R9Bj89C3Fzw-?&-g(&p*`ytM#@_2tCgO1Pt)h^s^@kVYES7wFhS$inDQFIDk4@F37q^;Z9YpkGK&3+|YSKzuOj;UPJCOhPGXlnSBS^%6n7hzDnW
z5^M|E^?jX3J3d!qzzjo9RSdiWlJnkva{GteN+FethTw<&B*}#QjzB`GYPeL=CBzH?
zyXt8ZlChKwJ=`)c3DVc_JbQfUIE60GC
z>Xc+At(-_HM#+MRMM^cAkmFRu9Q^>e6qFT$vbcj6C%B5Teo5LZN`X(WU?8kax&_&w
zH0>oA15_}a@(2?ye#S4&24(qx6qAJEpeP@dq&!5ra{)ot&(DVh#fYd75*FdA5Pl@v
zqH+TNI->C`T!3VroF5q$#QB11X;8UXQm+n@>WUlGS7Za`wPAA0dS^m=dP0ZT8PkC0
z^W(a+liG7r1YoE!`ipZW#O`VOyj|tc36{rG!*Qe6K+5z*>|Cd&ODk;9OIyrpQYuj{
zs>h`daf30o8@kNuwt%IJR0i^L!d9?K5142XYj@1vlXUcCUEOI%N7~Vua?neGp6Lv4
zXVUQYhJR($P)SL=`c|i|*{N^W;5qrV3SONOIC1J^+y)V=LBeejaht`wW+5r=*C@gO
zfN>k7eDt+qPK}gbD-+hr1Sgz^wwQ+zw9-?){)`XHM1MYr<&c%}_C?6=)8W>(`iz}`
z+-IWuj9o5Wr(M;m7uOr*&9LQ!YJ`~BZ-j(jPxUoI&Iuv=xR_TX;eqq!?vDK(O|R2i
z{`JD2|7sfvlbZKaDd}hw*OnNm)F=QB3x=S&A?^sWIFhXqr-!~A6AuMBV{s`Co2CSi
z=x0s|u?4zwdDUD|JCoDS=5^CK)kIP;npBiiih-DHfE14s;R;K5L?$`isUtQ0e0HAA
z&}Y`tou)poso!nvbLe`57FN*4@|yah4tB!BOSrh10KXK46$H|X{t0LbWhJDgrNp>H+LkkzXUPTEsC~0x+ptSX9pvc_;3X&|W|&X9nb?jA048q@>hg
zNxeLzT^-Rc4XW15=FQ5#R|@UlYLiLcOiEb2Crrw_C%72T<;2il1U6?gKvy&i9|3or
z6p@P2X&KJpR9cSZax@NR)R5odxC~mF_V5S709cgs3otH*6(F`4Rwi76q#G#81|q7g
zUz!K2K~gf2RKxU3V-8-}#=$t@2H29MOF&2t%aVRzECa^)hrk1iVfjErUJOa|0dX-T
z86cIKA^7-5CrDS43g~kYX;csJeOaoq*dQ!J|aYS|v@d?l2*>*0ou5tu|Go
z-`Ekeb!C05N=&#gAdi_ELi#4ZvCXONv}@^B9nGj}QAz4G(k6|xnaH)UUd%fw;?;;q
zHOLwdL@8)CWSPZERk4}Cen)Oj2f0C=Y#73LU?tOgp-x=zyOP&#>J3qFs4lUM5U-I
z7m}sClEJvauI+ak`W@PSw~1rbFpR2xld9h!?=`C#W_6!QMS6rq&9LZ5*mNw5w%@Al
z3p)4#E6;D{1We3gNS^Tu;J1fja>Q_4k@NEgqmn{^PkaGYIdd$5YzS$y5)Npgq=k7|
zD5+LTs;!ECtD@ejXitr5H!GU0vf}(Cse25P!SI<$O;w67FIdjc7``YV@aqNV!Kw4xN1
zCcGlEvfHR;NQHDEm&RtavisYBD~Hw2=xb*7x1h%u0iL-SFi43}F1wS@p^121B0ddZ
zOL#OXmnP$PN(Jp=ZiiGr7jRm{f_AB>Q!Z}T$?0wjGwR`He4v^;5);foE(TP~gPPS5
z-SQA%#sF07ps~wCu*!OP=9NM1TG>Dtu9l1*R4)ywR);lIVLcqCT^}{9R!D|SV&qTX
zGWjxXJj$6(iRUun`HXBP1%Qbf1K`<=5M$6gpOwv$lKzSr(kmx(%HgPZFeogOLgxxd
zG1A~%fS+=42f~VhkfIcl<=v8EK%Vx9^8tAwtPENCHZ9AlVVPB+l+-vik|5k_fiZ&A
zK4lpc{YGWKMawp87#0oFOlm1INF7uX7=UV~Q_FPdm^LlLVPK(m>iV3z?qWnXnpF=*
zq~l37GN9ooQX3^C8tM8(R$Ymao0Ovo@$!&m#a-vYNQ-apJMhOc_p3
z>2{{H=VuL2V*q?%#z1)fyyW#4?JBvT-mL1d>pE?kwwRX}Ah)CF5o=e@(>)TPO$OS&
zyI@=^^78JspsCewpao3bej^RX_$^(2TbJL`4IdlQx5uVf<2=VcFNXO2yg=W&Y+>krEYU7+l*4I8qG>EG^$Z1XpjmU
zkoU?&4N7T~PT6WycUW~qd#(CTn}O7+F=^Y#AImFRbn+&>tid2_u&G+2j^4o_BkSq4
z%4_VZCcC!9Wu!UuG^LO(;3NVj8EQmjPuJ;E(|K@h5XKvT_n|n
zO@#%W$xBy*W1BP8(Gr767-3`Q413CO)&B
z)z`vdcCZ+2jNTRw_OeJ7SuV3(z@b$u%8CVa39myYq)UWdGI5toK$G*kWIVbQNb~7Z
zK8?%>=`vvl6x(SL%0-7TEdZx?3^qZOR-s5S_WKKJlRsre3h-5e{
z8qcVv@>st0(*^b75L}oPj%IxnXV`FhLccR++#1zxk896P>(9*@LGpze^Tk;s;;lK$
zTZ?~MNARk!gAsEw{YGeSSI)~BaCgl_yFXmFjD~12Q)9r`jx;!6=nNWZAya3<-jnzC
z<-PrRPk+|SOgMVt*6z5eBW-FQu+u8OzOs)o85hmvl`$KAuBZ-?s>hu1oNi;%i{Bfj
zq7>q$J^kgB6lrrI$c@|k5CdUh#tW$wCS3hlA3NvchAll2Yk$zx9k%vl{k*WfFX3TF
zolK9Z+okUz-;=HCFsW%edAm~7q*HV#L``yWlT6eoCjotK)KXtwV$*jy&D{(RAl{EUpR*P*JlDe4@mCbz!Bs`}T9%KfViLV;uw
zL8KV24{2mt0?!FkihdR1HlV@fPDHGvgy+O~tzrVqb0z)!plKwbDugr|30)!Tf&z2c
z?ObM?kW1&YJAo($2m&?~80fM(WTJlHE#!BpWGtPEr<5_kuz=gHmiB7pER_^8!ZoXT
z8d<+Z$A!DrDf-m1ZiN^mcPho*O8g)xT_@{NNxML@oZq1obt)zB;p7{gbkfFRL_C&O
z%)kT=Dp!H=xUpJXcCBm###n}cC_vqsFhhZ{>-4l8JVUoJCNf^uE|#^M6QpYM?g_e*
z29g)^;(1aiUO1nXEEQyndFfI?PL@k(bq?u?Y_6!lWj27ZY)G+@DqjqM
z&Dwraa2}ehW?I#3o0jbWsH7x0=%tEk>UqG}Z4x>RT&g@Dsc-Bsaa;zD$H>Q~OV9Kg
z8BsSc;pLT6%ITt!RO!sXTI=B;#?vaC=UKS3qGn^%cxv2&(+F#`Jx)H$b(RP+vSo7D
z`qG^F^1SJ-CF>VuufJ$l#T}hP!JbpY;&&EJ<3UE;)aKDOhYamO14OtjZlx8y{Utv$
z4QOp$5o-^iiaHn(d%wp>cj`J|O?`$=kG|b!qODE&1Lp3iy)SI*3)=dFHb&UROa+CR
zkSOWn=fc9YkCTszqAq6K#VAHZ15t6(!^-%1*vtm_7;H@V-r7i?ne(ocP0JPQ`hs&WuD0n
zL{yW>ecdI
zKBtw(>ZGK&4FCgUKB#83ONG5^Ia|b~O9VZ9PM1u^5%GHkJTOmC$MG@|L(K2NUJGZg9XUqVPeSXGt
zan=G;eQCk^#-jE7+gQ|YhdiscOpE-E}yv<;kWepaSRT2GBAjGILN-@K4HX-o*Q;Da$(7M
z(KwV+7Zb{SOkRj9MsoT}&M;OqPnN8Os5}`EP7GSoVNu-2&xEDfkQkHMuw*c;h4YVi
z_(2!f@8pI(0>6XfwlEMbbHCTda+vy@mVPA3kYbe#BsY<72$UgnZYH&QO?0=l+hgl-
z+j^X4y2Av^4Z_$k#l5=AvDMt#L^YVuxim{ZY99NFUNkMsJ2c@X0
zoH53oLO)p2bDV@^;738ICpt_7mXw%>^Y2E#;zRa~ov
zm}jewZ`TTK8f4cTyMYwCuEGp@T_&E#Dk9Yv%>p2evCB*X2>=W}AGp%S=dyyPh*&m@;0T
z`=8~_zi3za3@z}?aT`5m>vb90y=I!nO!HX*CoO2{B5w}c`U3E}_I?D!_V2#`?#||<
z%ScB)Nj~^t>81*yGZ7&ND`aOzoNPqQ#Vw^&>5y!Ez&wF~2w)
zRi(o6keiS2+L#VwkImR^(sn?K!81X6_gfzcpAccMttag6k9Zg%S6|TC>$7#aEHt~3
zAZ^!mSdc>NT8-Kk2(^)_xNcB4>QoKnBW2Qm{i^~0)wVQ1ZvQ|uz%Y1TDXBKgy0u~T
z>X3Y8ka*6G5#0)u87bwkesRcrer@>UkAJHY(PezPjEfAm3mgi#o#0R|?pH_|GEtw)
zrotFZR^7FTLkGq@2sN870VO*8=Jyjxr9^_Cgpkz$j2p)%U3JwR!cicaeo<|)c04=@Q+)Hi6#q*7OzBikHyD-V{M?*hPz;HO;_}gidMsmj>*D6Ge);oi9cnOU
z*ORKq4g(+55qGU2RAcPW^D!oOu+-od$q37UoEc!NS!N(jNM>2o92{oX@c=L>Pp&0T
zLRJJV$7vu%uB#<-F`x=;l8W@e*kcp;t)c)`r_W~-hg?#>O&E5N0`&naKWO9ot(=gJ
zpZ19gLGf%sPYJRS%hTeZVF}q*p4<@K7&V=qG+vmqg5LY4
zja1O1ZSxvBJjM=>sSDvXcl#_oxYmP?o`AJ0;^FRlO@_~=^GV0@n+?;qoJdn}`Y(SbHaq&|D>1f_kh^YoM`byrMk0=MzhLN19
zl+xy+id;;Q49n9|CCE%i6^W3vl+oiEFwVtQQJ*Lol1042s8=vHU@yeAF~1}cmc>I-
z^wEGAk&Y?74wlbJzEj&_=rQYPR`R}ghe6o}cWqR+!C>1B9jO4ky&xCirhJT~w?F1)
zM4bI0N59|R?X}Wf=1#j2LfvN3wSj!VOn6qc=oJ6@mjnK*ZJpfdRpJs~8`4l1>p}9V
zif(6uq>-DWCj8q#jhBWj(2Y+%`Q7ESt3DHdq~MhcyJVyee_xeh2&q9MsLCle&3Z8m
zwp83Flk|&_7<0S0Y*O%<$LSXGdPRa>$^Spe*hEN0{iIm5h}4T#NSO*!@tt6dq#7ZY
zGIRk$j*me^SFhiCNsy@A{M=S5r$Y^FA(`RKBKnwLJM0gb&
zV`gN|)in6@G^xIQX2!Myl4ot_sM6uvljbw9)>GEai9fwP^JN-HUM;Csi^}yu)oMw(
zR?;jNRV&mTxR|YbJfp586%$$YP*gmg(G5rC1;02SkPOGwpM3n=xv{j*49tic17@sH
zPQYd$0}5as0t3RN28Nku)pDWCRIn|;nB1Kv7{hy0cA96^32ZvP!+<9d5U`1z=1~}n
z+!mqBBm}O2wi)iz$pPCh6$nNu&9Z3{!@
zi43wc-Aqoqfz+~MM%qGE1vGDto7T(f3v)Jd`+DB`=7JqC@1Ca5+f{CJCv@1Qr@0N}
zlTto&cfble-52vP<8Efk%OVlrATFJredGLc(B2oYF`_PZ($5FFJ_ieq7ZG-YVP4E5
z7|If9P5LEK4PxisVeP3=Bf)r31^Hba)Pe1-ar4f&c?({2(y}>jT^+Gi66ABpewR!t=#cU|
z11_aZ)CJ7Is!GmO$=Dzbo6u(ozZ>Z>bXClQdF}#}U|Y<`OfMJ)%!FrNH>I?AI8!dA
zf{gp662h=V!jMUsq`<$7Nd*`t1Eqqcma(*Qwnom@D%n~!%cMhIC$L+2P7~j(VLCyA
zMPSx*px8P^ms(2GE4$6wUX!w;5a7(0v>R
zHbL@??c(BYWrQng+e3=&5jCv!+Ms-`q{5k8E~?jt3=2iw^00X@EKR$4mAGm=p_$4V
zLGnb#Fq$=e{JY;4QckZ$NU~N^Sd&j+Bln`n>vB^nikAtzF@QY=lTcc#22=}Rp?BHV
zaI9K#U)l!RH5|w?1`uHz>@-#ZqsVELIP|2%H3ZpX6+?tc6;+GGXO&PQ40@||>Pdxq
zQmx)8fh?06%1)|x0Bm8<4wV)K?YxMUTMCo3d2P(TR<}KX;(y)sebhG0@VJ0Gju7+LQn3s>NIO-G5mc8YixtP*T54$0}qXYKAls+3(
zj}AD7Gp6C3rI6GYQ>JW8mx*ZeaeXSPOhY!T~@rj}5BL&NF-b~gJzsPCob(p%`);^DwVbgbE3=~Zo5_Vmi
z$K00o_YEbu<+NZlE3BmWqiI1o$t$P$BPm`nf|aW~>Y#Ps{z
z@J3m;HD=s~=NyF^>vzUX8x_O$sBwGJx;TgMM!=5J(OXF@KW50`UKoAq{IjrNR}`aV&cZD%B+xp
zUZzyc_?%>hQqBUvYUr>W!6t#Rf~i-r^%|}jzR@Ib7zI`nd5guYBlm%jQX+-6>DUHj
z&hlP^vKKJh^nJOIaJHmbp%P$}}y%-w=9s}{)n4w%Z6?&daCvfQnM5_(tjU|Lt%d+XgGX=AjYaw|x
zb`j>CMiJmAi-HL`Ffq?=cxj8+XN4vclBt6ByMj#7EBPE_^fC;>Zc=1`t;;2g!
zb_k+&elen$DH>Ks?F$2@#X-ybfNr*+Ssc`DjM=v);chG!7M&O8?UxoDZ!Wqo&Dy@Z
z{HKfKRk&os&OXo^bM}+)FcWS@#>dPDIRg>?P(lnH8%~kG6wd~@aHLT;I|hb5oQRtQ
za@P!8u7^L6&?W58YEH&^nOmDyM^sUI734Hs+!X=5Uw7)YDOhrLkLh*ui-D+&oC
zqLjAe$
zv{E)MjaYyBqxar8w_-E!3`&j$3JK~&-7-wa#0`D7#Jg!g#ngJiG+$FtrXI5
z*BB6tNp9RP;dT@MOo=eit@>viK+HA(CS&+&jshYNXq8-*oTI@HRdBRw9zvt!YL#4U
z>Xke_W>ieQhHcPt3|h8@dVd9hgb-IPv?%D7J51y~Qmek-tnMtur7NT6)iKlhr0Fze
zs$s29&)T8SXQ%BKmOPi1ycd^ATwe8GTG_2+b46{dtUfiO-m2&}E4qyl!}5T7by&Yx
z)Xf$2%fr@@xMDhwR9Q2dHw=fQ#eggmBu)pWnlif79VQ~ke7{-bHVTlwg1TMyC{2b+
zyNm*-Ug#tw3mrP1Q%_+2f@j!lgN$h;?>4g#I(eU2%`aeyl)~cS
zm}GU-u~xCKRjf#uw=Xq{Zcoq>`167u6qs{2Lq=a`)#V!nm6qv@v2nUd$^1!*QQ5;TNR>
zl9>@t%p)918|KFXnUEalPFMU8(qu@H3@Qe*7N3phw+o_PSP$AS_c^gZ_W2zg
zm$}~sjG@C6&t7|<)j%T^6Vyn0TTJRElcvS2Zgd%2Q~thElra=%4aZp{G3HQ&F%;=5
zg?dV1GCvUMAH-ywg?>2BDMfexy8X+vjZyvfxDj4@XTo@T(zr8WK99?K#&K@iaca!I
zKJJ(*kWV}5l?StyTXyOfLH_t^8*+d1q9&1%p#DY?k#~(EqaWRK+xx
zR}Y2600lw%zEgSKR6#dCXdcgK$QY3`|N5VQk&c)GR$%}{*}xe5E#cM=!8D_ZRBH{m82u3`V+3k=|msCl}}%i1e1C{R2@(DMtRf_)E6!F(cCBGgDTm@o93u$9itsetHT?
zqx;OXcXQJ9+h6}O9W_{tT%(4il=mV*HK=$d4HrCnY*^Hlg_H}v7jlY(mWZl^0W%Ec
zgc^fG%%~JhnWRr9hSTn)Qs{0GznjbMU@%(x`&$4ro6*T*cd`0uJa!L{+ba?xL*~dO
zT&+r=*9r|Cz&n-Bi!{-;=msfmmuLj|_&&`vW%fNWqcm6+>
zCnGn33T;*N+oNVMjB|UcVqP0D;o_bznTi4NWR@^Io!8F~+Bc_3f%kxw?+3$>M28fZ
z5wB|_iL1vZcEe`F09zo}GOt+*H3o|0O(TSb+OwUQo(PUO_%sqo~|fSsTlbjU+iCFz|A0IUSV(B7aElB)vJU^wbk
z#(b(O#_@nU?t}M~BceWe%qvfL9_TVT^zt1a&Q864(LU`3Xn<}1G3gkR0$ofl-!w^As08NquN+d5eq59K1Cv^
zOUH~JJAY*+_3_W&`Ss7<{_Q`#`|&T{`_0ea|IIJn{q-;2`OPoi{T*h0_5Q#7{GEUK
z$G3j>^LMgQt<%hgue0bF&;-9jXwvjx#${oh~Ft
zzisR^s9H@bSnCd|Z_Wm}FwcXL{^2Nsfqp33GaTy%%tNu>QlzUG>Kq8uN|EkdfL;i7
zSI^X!X=kP^Ko^0*8RRyzPQ>|n&)GTG&a@j@5ROTB6?P-vpkf;o93zxa%~Q)5*bKV0
zey7^3CA;)0KIoOpSg^-pA%N$qWo)I44dJcc&4!DX^LxaffBcKtQ`^~k)MeBE=3oBl
z4}bjR(@%c;``>^3$3K4h%U}GoGMvT1Dg`mv28{sRn)PC%R`mIRB3Umo8zg1}dZEoA
zup{88jU*fN*@cg#(??al83l!
z`06Fk+pFHUSN-p8kkZyy+D?y~H%D}*Duz>(Aa9Rawt)1wWo6h5lIKdM<+6P^CLK$w
zW=qzwEcx(B2=WMFbV>-xBws}jq-8!U6&9J7j3wkAl?7@HX(j6FG~p$~iSR6%K9j0n
zE$+|=Tb29&=OWduBvl}2rHn&5jW9c06@%=^4kF8T*^d-gnphIHm8dx!+ygErtC>yDA^!Qc}z*
z#E2%B;#?95_HY`4EU08eWs2mKj{zSZax%jXR>;ZnS^Lu=X(6TzIM{I1(BWKMor)+b
z1CEJd4;*zau0{46^+Q5MK{s@g>9la7fH|ndWfAhoprXJ0@x_1s>D#~h>6^d$$s2E+
znfmapm7o9U!gM)2Hx~Qo?NyhF^YPyQ*jE%QQ&wxf%QU83zEqyx=`M_nDBS({1Za&UEJi8W)QPMZ=*1?z$Yv1PbOMJ#=r9TG7Lmg&
za+x8~yiC*pTj+C$-4?8s$d(!She!t{vn9jAuzG#WaCY8tanXaU_|lT+jYaQUE8ch4
z1Mi;-es?qQ-l@PxXa2onc>h*AH)=jxF`pf`ZkLVl*juC4tx?8aQ9s$
zSZkxAMu
zD8U_0BA~|na*AI8%&98LeF-lsXlGJR%cW+c+4$H53LyPMTR^W>KO`m4@ZzE
z(@POLU>*q3;IxM#y~J-{5y`Xmv((2SF3!0wFOX~c@}eIkuaBD6Dz*z7gFpYt4{&)w
z@hr%bwE~l#Z_)GI7D+N>^x6~_gAgKVF-SEkQ#UI%`ZOt^tS_v(C>f$yH7v)_>)gR
z`{N%!vs;vQv%+eW*-SEvK>~ok=&NBfN*pGM$0o(ER7ffjo5(kLdmu|;#?~`7KiOa3EjuP`z@9m{I<{u
z5^kB_AqLWrN-*qqDEv01&ngAdu-tyD3^0>BRb~WvGs#JPO2nw_(@Q#(+}3~khYvpa
z-9K%N4bBx(fBf|?e)Y2-eEKgxTOBC=<`+Nv10~9oIRAcqemv$?Lw=)PZOpBWx`4Dg
z=7D+E#K1Nty_$4Dm+-2SUM(W!Cy@ynl0jV}piKv`SC#ZBQa*7yAj$-Vb0sTM<&8=A
z&a`)H(zP++JT>XqnsBU)7%ngS-(3s5x9a&m%ZYGYCIC(D4LSM)b_T)N$$<|0>};=%g&w9l;uV5z^g$;-;1U+o#$wWh
zd>H36?3KIB{GeMFaLKT)Yn44Rai>h!`r$jPKmWT6Kl{-o#7};B_9q{mj<^+-qVIz@
zSH_0?Kl$M~%>VrFFINwMyK|Vi;h@Ur5@I>Y4g74T5}O!F7>(Ta}V!3g+d&#iiis8Q-PtvG0BGrV|&9Rb(|0D{D20?G~ZW
zDfQZ=9xF6N<+3Vm7P(O`Mk=dQi*#y%S|K#)$qW)^q_yM*m4Yjm^h8GFm?z7K+2Mrm{#()2tU%YvG_1yOAr=NZL3AK;>|Fcg|txP+uDw|0TlI`Z*
z9^o*_5O$;3X_mRn5|<5^xHRlh1>K5(TjsGN!z7C)u6v}EFh^KJVTe4I{^^o&ecZM+
zV}rYXXD#r~8ZpxEZ-k-4-#r!n=yc)-XA&Q7M?O0JpV8#)F-!H%|IWDi^o0HNgzYr0
z?}zG$QpvhhcH<#1u~A}fr6F8+=*g{Pq+N1oGSnF24AV=*
z*-E`pWS8I-d2JFm`8Ws9Z6+Vma_M+&;E#X&
z^=H5S#oHIo6Gf(WPY&mzE?v~4MMS*l)d?cbkYZKbr;U0w3BL{s3}_LlkUm8i)}%t}
zWI&nnE0Y0LDxgXS?
z-F5#5n}3?H5KRWm15x&1oHH0Ff(()g&(whEbBh0yzkh$G>WWPf`l=p4&yc)1X5Jcyqb8rLIWy@zJ>fV#<=L6^
zK$B06ySJu%vjxL^(YQQhU9Gs6hDqL-^g#pFaJiJHRU?Uo?~Qmg)Ga7w(5VPI<%obC
z1Et@NvC?Og!+{5>+hgP{B@6kurQ6K6sQcc1bMp^>__X@VR2xnr0hr2^vFp7z&!qz9
zs81L3>tkN<3=!5Lz%Zm3f((q40X>o5kR}-d!1~WaNAV1{)tR6=6H;b_id;}$2+N9L
z@odp>b|!Fo+Pgi4mCJo*-V0lIX~}8zf^MDRen2`}pJEB>ilkwHKP~w=sPPJFAe?z*PGkoPdj$2+7=5b|R#z
z6kXYrqV#t+`#`soiZ
z{QdXNoIf=_IUIyx*<37r@W#py-rImUdmMbDwi}OiTKFE9*kWS4ZOD-MaMWgPA1t@m
zDZn@#)mrtvCJha;Y&Z3q^hlKfGnAS73ny6r>gBEwu(!QRUixzdX
z$DHjcH!bDrOgh_>&bGL%DeG;|dD^n>EBK7p_N3#&ybmiVvKn&gm;4aqOUr@FOJT_J
z#yHW9k(?DO0b0PY)g-hSMIH+_`+I$Sq6^SBj~DY`jW1+9#iWeCgsTr%mIw
zsUgcwyUJlzR)3b;ro!?8l3gI#DsfsQ9y_d)4DLGY0|u%@P#5tjqJHJ>do92lC)~=8
zd3lRv>&~G3-o;deG7?`(wLMXU!uI2HN+ndFB%@gJT`e{>#^s-B-KYG)^%rz*CM
zihXn3y*cXIn!si4BMeV?5bG7!#;EJmxCgO3?3gZC&a6-W;KO$_L47I=0VGNo_iH1_
zUEzMcT3C#bM~U1O5p*a54tdC>B)wDhc_@PpV#rB$?N9_An1Laeo!(iXZXf=hN{tb}
zM>?}SGa7Xp<9;(3j(ZK&sCwzBN0;y$k^uumI2qi9ITbRb!w79Es7r;6)R@4G9x$g7
zL1iu^FDKM1Lr9GMr>DF-lfKi_e!S$(ap$@D!1)C~uB$hfLzkD3!UWz~{WFpQEdmUq
z&jou5;eJFuM4UFL2F9g0zmyc<&|HuovXeVrK_|y;?sJ-YV}21Fbvz&my7^uQClONE
zjlE%yFdI`_^xd$&VdN@KG4f=;3mLKux@yw0RI+XkyP4K`w5R)I7yWo&*U9FF*XwIu
zIePG!hT509I*+jW>uBu<`g@LwxQ%LQyFt}$GcfHYj@`_$n3yI*zthUG8X3``BIJ|V
zjN~3zHe-wiWmZFT3h3ej;O6Q=4g!*o*NVP=IWXHGVT1F@7xS@!+Cnf`Q}RG@^a)d=|dNn
z!sizQr)LAd{?$KjE)>IFjl(K-+Y}y)5_zf1f*eE__Ud46DVHmCniO`E++viOj0(UE
zk|_yQLYdKnb8J>~T`Hsi`?tUT$4@@_Erj=zPk#?`!7zm}to3g{`{bWJ4voj5b3>3p
zvYiB;rwX&%fnJVZ2Kwx?%L6V&$gK{!H1U8TPVrDoTGCN{z(sOq7*y(gL~+b39*D~;
zY316ueQU~oao+vjdiaA=vF~ohzIP_|;hE$Ih@HgyTe0`IV;`JO?4F=2X>U#0etIVR
z#-wX|tV*(Pd(yi-=|45$C2Ws*!SL3E7qKzw*&2s}1@WjXVMa%x0-OMqKH)bZpqyb3
zFoOZ!HN!-%q1!I7t@$FLt05<7d8
zICl9U#TXlbF*ZRmq&OASr-O!c$dn12s=rb?Y|KQeBpav!epPKIq{)WV`H*6!XxSY1
zZH$9n_o*q*DPTMan@wVC+H-b3aCs&A=1TO^Qt13bpn8_RXjfIy&G>tYF=ip$mk;&j
zg1v}*m|2Lh5Ja@&{OPjuUw-xTfVJCa>-Smv?Zz&Uj6k+*H}rUHOq-#{s_(PtdhEu2
zpM#f&b^hOdWAgFElwuVH~!#g{-aBK4fhP+eid0jUj7u
z$lM&Uwd|g%FVS#*&&~VLU%(2w6vX(_QuwX4*c+>{i%ZedbHO!AmT>|3-73FJ4MPi(
z-4Ij6Oj!3IjNdc*H0!Z*_
zQ{Yh%uVuIpo2+DG0c*%>bXyg`*zMGi=d`Qcc8$lWbt4>Fj9oUR+m6SoTy~|$sqwm$
zK9|DpQiQ!ENk*TGnFrGjSgNQ`4MC=|Wuec`b6FW7CwFDkftUH_TJYVS`1@bbyBU3F
zBl_M};{EO9yIb)OPG>$ko2{OoD{3Ds$KGEEUz&7&Zzb~Mo%H!h|IVa;bJPoH!SFg{
zdEC7*fot8jIpM`ce`Y>BTOxl~kc}Af5mPQ=%tTGus3{dRB?CqXW86<{Fhml70k#Ar
z6bUV|S*oY}Fi2Jt&hZc7)|2oWA|CQ6Vxc_-%*1`h7!=rNz#0J~jb{eE6uS5k1mkLt
zA4&xVh76z$n@QkTqT+L^0W*4CI;72pG(!pfbkVj9uQBdhAM_Qm-5`Xu>`R~1dA?O293NOUaEc4hDA&(Z9OEzYW`i&mD+KX^%
z5tI%qttR+k!XY4Z5iCg$u)!?`RgIZYJMc!-9oD
z>>VoJJrxJW-`z=l?`-aSXY(JOE9{=2D`_8YX1~9ce|I7Jy_M8Evw=&a&L5si{^)f6
z@?3CxDzH}ZY)<-#d`*zPI@p;BefQiX9$SoBb0KpfV$Mg*xv()EF=Yuq=48l#09}b7
zK^lrmX(<7lLYn9*^pK!gq*!DOHVZ%#-6a3Z#R*@4R)CO5OyQeX=aDLQllD{n1M}Xuptk!FV5(YKZ0D#
zCHFeSE~~((VJc<42>48$nxQ9~z?hEEs{2e@rcuMN=+To*7}naXV?dCt`upG#md^m^=^TtcT;b(nQ@qo$Mk%7J#HrUN}lHmJzAg1}m96%7_mtKSNMNp2i*
zbVgyPot+VTN61PF^&|YI7QeC8Z$uBCTYZM+fawbI`84ixDWv+_3Z0Pd=U=&85P27xd5pA;n5ZGFaH!pj!>CPKK=!udyngE<3Ea(r#6F
z-2~BHP$_PS*g7;`rw&w;v7I1F*oKitU@dUzsY$I1noL6LbdUpF4)R#66qM_R6l0A5
z*dSIO4eCN(6?`>B7y&g#o*ecliA1{&e{{bS3T5RPe32=y%sLAFO7-zgc)^G5XP3`u&C2
zU!DlAO@tPPJadDtm9gN;SYT}|xHjrr8}qJ>dR8jL-2JcZDsY?d
zbR|69Nl#bW*8`H{ZhFes7k76fAkLINv-4qgI>^XHNim+VyKi(r?=W>a%)Pm!n)-X-
zZs?&^-)+`*>y@201Dr6!ZDnHszl}jUs!7MR`IIpk(ZMZ)OsfHu_M5d#y{a!6F}Q6a
zow64UJ1hc|7CPLemeEwwPPl7q>Qy~DHC?MD)ugaYOji76T`$sO%;;1!ow`$_Y9n9V
zrGf~P4}^f>YJg-N#F_kYVvAMV9J13B?%t@gD-Jbw(xQOb-WjsCN9>(pTW8SR9x%5A
zEUi9Mv)9;!K45C`8LvQ-&n-qz&jv3nL@q8yFD`~JEJiOcN6#;YFTq`}L@%$#FD}O~
zF2*)zqBuAivk|laGitT*>mnNKvg=$fo!5g&gV(JmJt%dP
zM|s>jpHt_YtP1UO=}>|lp4#R%t)0JA;o;zxiRJ0ne!rTySyHKYcuuMM(Ul-7|J55q|8TB&ekO8mHg=fF1g+_yEgiHc1J-od0k#nU4_L+tx`f`ChhPk4j(N!@A(^lW{t3er
z%og+{XU3y~)>yz&jRY7b!~#@H5=%zNiUE3%oFv#Al73^7WY<_0HF2MEAZnN&@h*=B
zRz|~%BY{fFQcjuYhkT3W;C$J)1gb}U%VmQ1>ZoVAWZ5a(esSSXZ4O1Uiym{+(*FLK
zw#_(FPUVI5QVBE=(nT4vF6-b=!n?6F2CQn=}l)wm%$H
zMS|+EPmV}Mb%nI0kg`PmvVcoO{o#ZVYM%_N4eD;QzQ?Ggfnkc?4q%KQN4@jZN~tmV
zf-Zxq$*gI#YMVk1;;7@m*g;RYx?>JPa>NFbTj8#&rkXfvGcaxpSio>2X3$s9)R$>*
ztRyci$HDW3<=FWpFdVtO9Didaf&Majiew}_h^?8x$G`ja*7{T|Y;qGl)B9K2K
zVRJF#OegFCuR7>8`aOD&3*71neqKYsV+6@QY*LisAtXF{zt@Nv%u_+_!lZ|K6m=L@
zirukC5BTxpf*wN%xu4G%CimO4QNK3iRYv@3^r;A3CH@K2A&(kBCclZ!c%xm`}dDlEVRS%tn5GVdNjq4ql!K
zeSdp+y%K)w+yFt?-EfoNDwp7SY
z`k*7>woI;h+tBF-QfiRc%iY
zVK>30SABcJXH13Qt~L3v7TnGadZq_`Qzb8Ab~rFI?41M5!=9yK&tl27J?i;~t<2B1
zGZ#i(J7w=y<W(oWC!?AUfYA?ROkf!H7#Qc1=AoS3r0H?M
ziu+~xv}t(2>355a+8&F(-)Uw>d=jm))2!{oLtNw-sa63#39)!)t-Kx2X@dR(U@ZZ-
z`XNo~0P@ZgNsl$?DU8*PZc}^IjjW+J?(QNa<8?V{5nFr2+7_kykeN!4DVTvSNCwXs
z_)QHyWBu-_`V#H!^*ms{yqtJrHASdih+JBV5sayTM&VkA&Azal*q#k40rzG%+*aABa1)=LeU^(rE}RyflS3
zf+88R{6A+95Mcr^rRQ<484>f4^gHU+M?Knn)H;>-E|h!=CC^mJJzMfj4tgdBT(ddL
zQptXKA@<{KxR2~xGyc<~&eLPQtr5?uVfR+qgE&3*XP@z^UfEGQEexM&Lk~gj4m#*j
z0(MuGYVy{ryBip10wj5+ZicZZhRJ=xk-W-l?Y0}cjjDEwo=yb;7~la&cx;1;h8_Xq
zty6V^K%KHvEp4rSGp0dJH*34>#(s)$V#skAl-6tGk|Pxz*o8;=Tzr#;rj|A96zzI7
z`94jpqD@D!t(CV>ALk-(8k2ABBJ~`b;ibtJXlh&GsM8@HUIk2b5-_`aVsO-s&KOCL
z$z5xZ95l5AP0fB&6VRoi!Dns=m>a!@29K%UW4wZIy|OR_feB;?xxR)Wq`K5ZqlnKzv;)VkZXMZwh&h
z@vuD+agaV_4F${qGUPLZz$%Inzd7hNg@cxm-y8~9g4pz#d|tEPYr+5`9KhHEH3rEB
zKpyZCJ;(DzgVwOm6!IG*$l0RKRKlK1yNhXWHijQ$O2+Kf8`^HG%xRXoEn=Ttnh5F2
zdCTIcXMNhgH4{3!i1mmVkc+G2g`9^IS&Ci2;zg-3OvkxpOeQgZc|Ct&B~v{=SJV!_
z`oy7EpFH^T6Ng`Y=J2bJOZ!fa#*}9#e3$3q=Vzj4XM$&^!{=t=XC|Ykr(@@4Qx})A
zXXg@UA>A{v@2(Z!UL!rbymbS&>JXT9Zou#yjz
zbCD6?oeK@61A{3)*d9puig9;7>LFBzfj0)uT*NtEj1I(H6UFGx;wT}Um~#lPH39jB
zg(mdck}%;x8w5E<>2?y~H7C6mV$nTDzzit{!xK5rbj~qfaIKbHJEOi2S93qv$o>4x
zzpnZe-Oxyq3u8KM6VQUAn
zM35YGkN~#`Y(^Z=>aMVz22)CMOCoD<+C-T%f&N^SlZ~){@$2NOyP1%Ap7^wqDng|zydoOnS+4{W~ebDY-z3Dsip#^8a&rinoRKCJyl<#y|Grfyqdne
zR>d{`)>`VlQ+Wiaes?qX?j|(=;b420=j7@6*ydDdb&R|hx;#6OiQ=-L@-CP+l5vsj
zD;c&Yqt1NVpN_i`AUP3nCZjF@83|ZIL2J+lVo4Sq0KkM;f;vUA5%9xxV-qr7_3A{!
z-8wu;G+>H_iNfPas=5vRciYwDBWaIK;d86KPDR9{8p_%yO3uYm-^O(C)J){`eEjr$
z^z2gf!XhD-!W96g&MhSnXBT0uQ&3}!SI0b?W1csbvv}3j^K(V*@T*TD4!weS`pBMV
z_rCbl-WQ)f_S!Q|2c8Za`Zmj+v$(#e!rPO9&5Cbx%#TZdqZ~Xn7TTVO?o1~xEarEn
zQcDA#t7-{U89)pt1Eqv-AmJ~?eFIU?K+Ic$j7QzMC|tTb8+K;GE&_Z612WFXz34L`
zXC~-O2R-PM9#h(5D1}UuInUBy_`+2D-NocvbFsJP6WbNf=CF5j*t0$2-7b4q2W%S!
z+xv^Di?i`F)A5~&(5X=$Fy5|sR|j1ygU*#9*ZPQOb=bX8`7=!p*xQ13TFB8wJ|;ov
zB|Z6GD|?6E-Vt(kVQ+-G?jg%yJMHaDc>r@CY<4!x%0{?|U;g4JfA{^jgZ3Vmkyb^^
zOnf!TkO{PEx?TxC+?|caXYW8}lMAAR^%GHd~*
z@sJG+Cqg6#!yp}XVvIp7V$UYMz%L$gV30|8fcMx)daw}5CVjDxJsx&oFW|=j&jT5c
z_$^VtC7<*qu*+|T>?cD+N#NCC!il_7Fb81f9U5@%bE<=GMK*34%i9;r?zIX3)@*cp
zE_Qk$c6u&+ZZUFhF?xP6ac-W_3v@59WiKqJHz$0{W#_qti)DFD-)WKJuKK$CV2VQyd5M+7Jvj<;!`rs?i?R)Xbz2A9a&vTC*e&xB^eNVcT
zU5iEg_Ne#NsDHg2SR3)Jjd&5O<-lUew=xn~t3(l-;|au>#evDZXJb5bW`1a`lAcI;
zDmZmX&*ETgW1@I!a&TjOU~VWiGng1p`Nor;sjPp#7(PE+_~2CK=kF~2`g$iWm@!KD)fBd6Uzx~nXufMQ^w4o1L
zIw(!1lLM^n5f?q;q(kE3Ze-4VNpC+SI^knfVNL~Eo6F>WS}Cjd+j{NfgBk5kbGOgQ
zHmG5|yCBQysM>1m(a3>Zn?~89Rkf;Br1mmgG{{tnn^n?gq`pQi-RI_I;%XeJqi$kh
zMesUU$%wp)F)0BHO@^IT5-HXy8V#Ceqo&DbXxrXMgy9`Lun#>j5lHX9ptt(gF?a@?
z)tg(@PlHf8OsGb94fTF~Jz(}4>Ok_9YV!6B+;VhlI(~XKeiqhlIdfqtd3iPS##$Eo
z{PueKosHbv>$!K=3y|pdw+7zdETaElXW*Sv18;2>aK&#;N7koe8%rfT+w^E2c^65*
zg4Qa}(C0|N9`=)jITEmClJ2>w!BothNqEz756~@U1Ju9;wgGA;?tyv_6{E<&QxP~o
za|}8hFonHFNHHY3dc&;h)uG|A-1($464VXmoudP;xe?#WWN2+Vv^|&Dm;{5zDDdOUZLMeu;>7_555>8?XxB
zoXMGZt$Uw)08}4-`RPNiJhT7BCl9{z%-)xt-2ck6dtLy~kH7NFqkEoz^tERne(jk@
z+K%o?+U1Ky=W5x%GVEI#@huGc=Lh|B1OA13M>x>
z*2>Y;Fwu4Lx`C85
z=IKrQ8N~d1yEFctqz{@*i@Dlk&bBJCAxmqRe2Rzft{Ju_H=xECVm0=+d}H%V(QKH+#74K*2T9s3AgWU
z48FTD@D8Y6hvhE5wO)L0V}P0|V)6~R^!dbltGTz=iffaxRM40Xn&v8*+0kMoU`1k#
z3_0ip*g%?qJvCN<0#hPvgAP-uTgS^82r@QtFjN;kHUl1`-whGQB+NDdCJr1~alosK
z2Mv{hz{Fs1ek`##9$%kMY);2k$3v?Vf%&pyvEoFAOp<~{@EpHLd`A+hiaO`cguoS7#lVfO@GNxSxcTz&V|e?1>J%qEO$L!pU?W&g7e9C+!O11~?l
z7qa}~bNgO;{*~`M{pt%(?S0|N=bw7`rDq;{^{K~RdGfK>o__STryn`;;**_+Uo{K6
zvmV82C93DOTcy48gTbk+XQmifEvKdnq3MC>L_Rv63yqxX-ceG^&#
zRNlWl7+V~O&lSSc*}z1~J)QMVXMIx{?{wNdnf6SkT@zUH5Y=C+`@)oW;iwGLX_1J-uX9s*
z5@}v4#7zX)aX%+u>-Sjt15VDaM626%sy3Y(4w<}T1fPu1gHk9q7zVmfY(+DqTcc=2
zP#7aICT}cdqoSFL#cS>iVP*04rULzlbcpm&U9burMud?SS9?s_@QNV0yUuz|B+i}ouU{2*NGeyU8C2(dgy*(X+
zP@iASoL_>1WiPG3d1l^R%fG!=cyF_Wcz0{?t=0S+tNF{TIUGRgc^Xc2XC``jHgahx
z`yOO<#r?j_IQYp9P-&CJ{W8#q&psT#C*0y0FK%k
z^piVb0WVy%h4e0c(5?47wIP?*>s0y3-^A;~9`b3Be8Mu6u`iEDHm72z=Tqm2tw<8p
zUCvxwCb=<)J-?JVzlbEF`dYG=s`s}Rky#|qE+p|vcV^8m!Ep{#U~zm{kbPzefrTo&p!U}H}87!sfV8V_SeKc
z?Y&Jk{VgZ`deLklIGqcOr5!Vcz+^5kS&WQjgOk}X#2KuX(;)=#9!~g%6W);|24sxE
zP{Iot9|*e#B5w5HAG^w_z!(xhB(&!H^;8kh@hpvxF(??W#YtZ{G{g9eHifp}nux9NK^4;A;o>
zym08%XOHiD`N@aw|F8e&|7Z6!ecrALkatj9KM#=H29h!Mnp*=%l?mZg5STlCrZ(7b
zm~de1w;`RbzGc-#thluuR7V{>5qMfcGAk2irb8sMK^A;?j(q11AAQ8p9dY$VT>Tq!
zfm4f7x20!v&=hnr3n_))$#9ywEL!B)Ef#$T%(=(b=d<>#&xi7HNh-(<+Pl(zW-7!$
zqMr8jCOy3|Ur)r-jUP?!z&r3e(5j!@LI7sSEcy5}3GzM@Ag^jK00yE}o-ygxL4FCz
z*d+I^$?dKN%5`5E$sH$O?Woy9t9`Az{&hyvf!=z=K34l-9lv!rrk@&g%@2B)E54oC
z*1hD3wg_2OF_#f!^us=2fCsk3wG(=$ov
z{N`l*)MRXJD!x1(T`Gqb%l`H8(BhDLb=3QVi{q;m|EcNtJ6l8Fzc{%*9$6ZXERKcN
zCnAv6rE*}Y5?HJRRzT@=d}AthYC5qqlRQ12+?kJ`UWlJX>I*XrR}4^>2&hyfiNG$V
zV3;p}o?R8gQbK^BPT=$i$uSfhX`fG2#_J&)(@;3%vUqHjjyOnE|l$t|(;@jVR^5KV`
zeeBU^9)IMi#~yt8k%yjq^nu48e&Df(zV*aI-@5Cj>%V#TT{rxXzkc?Shn|1*q30iY
z@cuh*d+vz`@4M}meJ?!w`ZLeoaox3?rjsUNw?WvgVs%EXilkc)BRvpxl%h`P?L;;_
znG23*AhRLFG&HtAW+pO$v6Oc#?JXxXFP$ufxgBR#teP{0r&+mQy
zxxL?ccJGVN?|t#v{VzTD`t#51fBA*iUVQfT?*Q*tuKnx3+C5F5H;_y~tM^x=P1pq=P77F};cZ@HGcb-ii6_UA7*yYUj(d9X
z*qDoa@G~1ErZ?m71>u=6D-{6SYy_yz1v%LOC*@~>`~=ZeV${!eLjCCo35B?MGkgJh`|1#LMj`UZvIS?W#M_Rky#d
z;Xq%*en!(lM&kj19kd81itfn)@AQCweh8QWhSZt)^y!7v&O-X!GE@!#=K(q5(rV$2
z^??h^`HL%sb4$51^H~y$>C=nZorT=ybYg2Jd1^YjIh9zSNGv128jmlHMph>i%M%fx
z4ryH+4XjQ^K|bY{6WcTCjj1TW+X29{P~A8@@XlNeJ%}X?1JtDyQeui{0ybp!%nX(u
zJQe}5O|6f|*Ty4j6XBUb&)i^OrWBkW49^bx=7vI(1;5`c=Jz#n`+uy$N
z>T4eQ`Zw;s_ns#n{`O-J-T$2@AHVgwtDk(}{^uTl@T
z_$7_40qXXZ-`IlRmIU?LX++T6?$tMu4^*3oGVeleXs7~Q<+)0-M@weB267V{v3sh%
zM9cZ)K|{A&MUPknDsFr0(N|kfyiTjxPp>_I=&IRE$@PKW#-qJW$Ghu~^fnz~wH_6A
z9nbib!)a?dW1SuJO%+^g6RA_v>8+Xc+C+3~Hnlke&H*sN`1E{sYbJ$$dlrMt>G|C0
z`8;BKA-6r3-I~qdfz`lXJj3=}dUH0lF^h3#XC6-#KQ$BI29tB37tfR0nN6IYOM=fc
z^U2c-39Ke(=8@qiHYTDQlX3j4<#K3gEHXC|SQw7X4Mt`L!_%ek+(=|<&^K0aS8}e1
zM=oMCvU}VD&U~wH@#6yn-6kU$mR9yB)Vgr4~c&0j+<_|`?lNfy!Ez+?*G=`{`G%*?16_K{?<31e)xf#
zzVbH@ef?`sJp9l%zjp5vk39U`Q%~M;(@l>*^x$I;Jn%Pv^;fswe9LoBJpS;K1pd*zv@9{k2Po_*}`
zm!Etb%f!96-Tus@kK=$R9(v@dM;^oYJ5N7N;@M|jeD2xjpM3JUCrG^f%yTb1@zhIC
zJ^h`>pLqG1r}jMm>`PBR_1be!)9a2zE!x3=z38=#ggt{{FTcJ0o44M1&&_x3o~F;+
zRUShV0$04(h-mc~cFndA08zVDcZ@rsl{V%bAetkW9jf1$T65FxwNIjuBpQy
zMBM<#pvo8m;6XXVkj?5xL0!;N*m5G^)iEOCpu-X)r>(*ddLg;QB<~t#dYF2LtQvUo
zpsfQd4t~#|xsC8i{Tc*dLvuB%W3QpvL&8jn|Rd=}a
zonoZdkvG6M?Yb9eJ&05C`
zuGzuRd^t2b99SBQu1_SlW^#z_`QpyPz&2vOcxpC}Sf9#nOy`%!5^K}x)ydSxbY^`r
zu|Azzok*=sq}L|1%VX)4@yzN(7J-?S@$}MI60tIsUYW`)kEa(Z$@#I=^l)shoER(k
zCJO$soHrBHYsCx+r-MmrK(M=-`{)gQ-3>joT0qO}YU=8&?WfoGw%2sGp6KbQ>1jLJ
zQn#jK~%o=`Wpc=2G@P%D>qzw4M>LZzV2Gg
zTzmaBS7Q=;q1dbPF?ZnR`t;%NvEOX51C_vxe_?7QBSEE=Z+qy2^dZ5yg;524W=e7nB+wl8)s
zdfnGX6?_?v-1B(n7Ifyc*?DmS{r1H4zShc91);d^bX4Rc0h1*jE=#aPZ~qM@OCT3h
zh1{-I6hMWse7^s~RRv|h&KUI92MOpk|0}wZFM@RjPo@F2gRn;6vYSz%64YMJA<+Aa
z*FDI0B(H7bYD<8s^WwZd^bXS18@O(A4+_5c58e^}Pfp_l=S*l4Z>&qqgyq(ffF82A
zWfkf)iVCeA(liRyZC08`S1VYrWvAd?=Ngu{vaV-V=L|J+w3)3iFU=!vf+MruRX4d5
zGg`GTow_QY1Z}b|LNbVp8Vy62Huy`%b`@j?IuHTJxt*oJzL(|a=86LXzcQh$MyVDL
z29m3gw;SonV9qbn`l>JfwD;QxIT14hp8Uvh>waxrKkt66zTXJG&~xj$Yjt{$&()M5
zUMMr33kyG4Y8XuNvRtBAVT<%HGd56`2l6pt!=QYw_f
z0*W{lOa$BLk}q^u+ckciXOxr3!$@BTg{J?xTQlvFPWX?+rz-JtnyFzih?SMv30_pA
zBgCW1f7(Oo+Vd6D`*@t@zTN>$tf>?B^^-BP3#O{=p&FVyCNZ&|ICMOOLP2HfEBqF`
zTPZK>MZh3~cv#?_VC|VKVAmpWToblw%mv?&;8hrw?JSK0{nf6gvx7FsH8>AgMm;we%2Ka9mt0$z-;MBfifpiTO487ChH
z{Lj5~2U1ftC}i}$ioGTSyz!Yqq@o+u&?|MS%I{}@TkKO0bq9}?IwgCod>=VtVyvgRBm=j84RVj4(B
z=uSHWXOxB9Sz%?zKH;gw4#1D$Wsfp&ySOWZ&WF(h_#5Sj!-YFsboW-{TVPIN%P>9(
zj}Fl%p&E{zc^@|{ytbNzDQbw~g9Jfx`caZmdV%tX0I7J)yadG{;eRs*|qVuF~-3>^Q
ze_7Xc-hI=WbJ1}|YI_rY)%*ke=q
zOHa^Dm=B2tPnDY*D$6^`r~|CrCeO%WRK5bUL{L-vXU+M?xlj1YXYg?m>YgXvyM+T^ByEK$DgEqa}qGxv1~6cN>FP
zjvYXDM7=dojg=qSfK28Nm2`6zO#$)>YRUf
z**Wp*qJMV}L<4ZrQ2rF*!w8|2c=`K{u0CJ%ZEdUs;Fx?W7VytUO}$BHvW0n-K`~i#
z#U}kevrJ4aLgUYcc<2429cA#=x>?tK6m;qA`UVa>=P^|pja86zC
zxo}^CVlJ=0CpxF1E-ZKZ;}5dB-p6PsxBiGasSj$m?@vy3z`Ol*SKzj7Q}yDPiEg`EkH=?bz;~z3C&)4t%%EA#=(|NoH5;^zG7ng-yu
z58R0-Z-1r=CCl?I=E-g@&aN4o&CkxQEE%sWJIUvYdj39tNbO9Q&pB4#8l74yf2{}7
z?%#BYh(OK)_O`%cj7e0(@FGT}vu$m>3k8B}?$`PpwY5!UMYX@mJKppsQ
zsExVr4Y}O{>zM_fKWxK~U{Z)SySYJuk}Gv$9ti2v5;qT5bkFLPBL1hBJt@oGXg}w3g~>x+E@aiq%EB=99qfQIt)y=}Gye
z7`x|@EsVD3N~_OvNpI~fjFv}ntAS}#Z|y*$h~FJ7N7mGqf-7Jm?%7!@@)ig^c`%o}
z8@`nzQIcW@F_dI~ay&BqxAUqJoRFLf;r#NTDw>cGlj?h4GVQNVYz=fy@G`aSACXQT
zebzUi;yF2+4tV0JGd(6|7!KgD>YE-gm7R(oNsB;+JJm`NA>Sbgp3q7W!#2l|_m{C?
zAErZnGyg7vznd(J)9slck@_RyBjOi_BY$ZqNcJMXgv9|qA8Z-MMQ)1~tqcUR!C8VAd$%Q_oQ-`Kmp(~6H1wUgxly=g$mPU|NU0pH1ODM-#|^HiO+#?I_#;~sgKW=
z5$QB|eP{7F9BbLcD(|fQ@5E+xztYl4J0MUxI8fTpQM-k&N?fF@didO-cuhwhvj?mX
zDDF77R<|Ro+gd6&G@jub!O9c#{N2)kiOwsKE86UbCDqW-8nc8HEwWBJdq1=00ptEB
zm4Z!`F`3fAxe~b>cnc}-+?CdK`!boDJ@|Z_bbi2d$iOB+(YM>=qn#5sZ0_fgv<
zaU`Est+zHo6OUPsFnBqLRJKn%VDW^09+Z)btgBnXuM^z`eAqjCK`L7&mw4Wa=5y1;
z=pJEQg=~lhWhk74TK!b2D9j$P?6+6nQMfYj)U6|TwadUPE}#9d4k?Oe*bs?7N?6g4
zN^4766}kzI!jzdibH>8M@Z(vXk|zFU)|94WkY}13rtRKFAybzoPP$^&JXeTSwNMGC
z*oN6HLNQ1~sf-MTl9)Z9C1tvmc=B<&c^Kt1C*^@EeLIxICmSb`fdglC8~d%HD8zLQL23rz~E3Dpl>3pwZH
zU#%nG*R8TAnEb
zRXoI=3ZVn?usw)u3O`(%*kVrHWkl+n=@F%Nj|q6k1Uy5boLknM-_%^6H<({HSODGqC8bICcR8zZ){}?ndpINZcR>}XVVTQH;G@^foor`JGb;cJ9$_b
zsTEsaAnc2zA>j;CyAV|c@jpVi+~R`7zPfN|W{RRt>Q9}}ij7eXQ)QqT&F`uC>7IYZ
z*`zk=NmVmso?`Uj1~zDIK0btL;A0i>4xAMeCo$CAIz~D&l6yuqP9C>=mcEx9er#YY
z!CRQ40O~9`W-ZqUNUAF(5CfVMbE%|?Zk-@YN4&jx#$r%VUh~A-MrRRh5m`%1e}l-G
z6J}a-Pmm|$Vao5mXkwFD>J4nnGWFu_%6w+g?3)<$XBr(Yj@YEiwXz`ncKKH)v&1|n
zh8XD>A1Ij5`64v8sAJAMOqS>wcBLIBkcF#KiZGvImXb?2Q5u!9^DDuefi8PI&en6_
z2#$(YMS($VxcCq3(Oj6fi$(*wDkXlz!6eR~r{B(22)EMd-&oyrzKfI`L($)7ns-Zr
z{lu`J-o7MwAP#gkzzkD9g{S#>>CEMU@7U~$VE
zjBfaTCp=W0QG%bZQ(pmU1L4Zt-S-`e|IeNFB`eNvUlBwM6I0C;p
zakdI{O9!Yri3o0Z{JU!v`dO~&-SU(76&ROU##cy`laSpIWuauz>!GbWU=IJtJMU^u9V}9F3uMXY%lv&)KG+^Kv&p2v%({?ew$>Qk^ocodh08>
zzPh%uwzeWKFK04u?A08zGdE-a>vSrE*uDG%gUP8w$w^~K+=BNGU4+fLcwoRqI
ziVH>@hb~+2yI>@orf=(BxME-DztHVBqYx+J`ZlG^j-LI(;mWbu@SSJ^Nb*rL!Xs2a
z)AK(ICqw4d8v$h0-6#rvZX>AZ_GgTT6eH_Km?iSfd{oEf;m3H*{MOgh+1^E;$)IaDNo2KY6h7RuVK;wG~KR$sa-i?gK
zo4G8f0tS=RemK}NCBj6*ij^xsLbM77fP*Me@h?V~=UN=8pJ1ABm#Cl9oB@@w<1fu9
zff8UuD@{oyw%=aMSTU~L%X3IY6O{sK@O^A!WnJ&Xt)`N)D5v@GKBr=WBHT+;=mRB+
ze98jvFdMQ#i6%k~>~;_yCJ@R(K5h
zjZJxThz6~uiH6V+uW)g#IF0c+uu$}rxzlKV%3^OXN?om`SO+8c8a_&JQGUtGS~^Rp
zZW~Uaaq7G5aM)c{9PDtI|6fsfnc_Y>vzWBBpFWb@XD*ZFG&bU$4C_WdJEsv*owc;K
zU<{D%J9euPT9S9Gmk3#@Of4I5?NzSFzUxqF3>t9NxK$KPB(>-=T&cruW@;RzOiumDU&deVx{P3Es^#l%hbB
z(OL@V#5H&>Hny5bdTQxQaZy2Wawa%XNQDfp0k73fmE^hL51t{|+H-HWp80bC>q_oW
zB0Fo3P>>d0Gz~>C#n+a+D{HSbCOw!g=VK!P1rol8i*(4QVu4$C*(Jy{e>MZQv(g!p
zw5JzBSE657iPb!fP)yh0`#Mvz3127f*=yO*JJMV85pb;pc5jb4yPYzOD!F`Oz7^(3
zV~dXo9t^NEz!6)yVJgFC>@jTgQQBta+~}enNCQ2BxJIc^P(Q#bd_+z|WA)I)Ot03^
zPTKCohuxL3*OcWX$IFlovgaNftMUcb-auJ(p{8-4WQWyDE;d%L@#5DzAK%4
zH5P}>&?t()7axD6t&h))inBlr`$(a>HG(?KGxx2=nZ2G=8Kt7%T}kwd#_4}@g-#Zr
z$c-)=er2BWdUf%Jc=MBgd}cfJ?T`9!@r?etK056Ld(2jGwZctd`WDHnK6#BNi-*4h
zr2=IVtO}qY`Vk{fN>K~k(gK=(jYy9qM4ZTqAvlv
z?kI?42Ab);$7IBDrx5<5?Az8KeW7qqWPxriD^vI;*Z-+K(J>Y&5p7cZJc4_do
zwd8E8!(#I)f}{KGZ+aNCp6#J~HWTX(o!*uKB$K~3c6fXmWqQog;51J_CyBL$L3;w1
z>724XD9p0Xe0>19h2}*?2Cf){9ozP!rUNuh3E`>~kSOUFYZ7ucYG~W)gZ`asi}%%f
z=6|k3TUVh*0Lp5Qy*hG`@eJZWIaz-b7A>lqG
zK$jcRdE2hUxdbm1_Z9tsSLlQxdg2^nmP2riO}n2hZN?>1wY45ngWqq*CWH~4Cj9P&
z_|e)?m@Wc;n&968NoOO{BgF^K!eLowx*Dj#8HVSHpzNG^At0bB$ioT+Mka+((kk||
zE78cepGcomoGksm6gRY+)6!6%enfB|!23k=#N`;hkx1vh)7&SW{t@-Sk^buqeA*cL
z59ZuNPjq6v#OB|)1h{Ft-KcP!^gp3gQhZe!Em~H6|2L(C_&;bok=Aiw=E0lKpUQ^e
ziU&Vi|4D1H*t-tH?+FanM??gZrw(clnz(6yUmVI5bi}PXAQ2nNf}%*C
zK=ZOK)zFqr2UR!!QtC!~O9Sv%o%X23$fK8?V-m$g8E(Ym=@ooE5c1L_*WvHUDW)6u
zS!~U^&-qJ(k94QnMi~xHpwEtPNp9WGv~V@K`M+AuGf#lQ`4tr+|s>xD|
zckjEWy#;g~=gwx@q09099(1O;u>kd45&7&{dt2E?3{pxam_4At5i`#?-~vtO5)4>Q
zgn*m_S-#Kzl<&0V-Luy&wvZhuxJV#sqY6$KGbJ|pb;*KjAKvdr3f0NWaJEs=11
z!25fW?wyM(;pJuCWAtLOAPMr?1;=mx_Q{-*&g3DZz#m={e)5CF*H#ASfp*W#upPQ1IhD_cRSKKSL2@ZoF2za
zmFnf`OipE9?eNl)b7Qa_XHg@v9RGs`>a1^E&%(`I7#^*t-tSax+=6|~Uv)(}0+WQX
z>WJFU&izPIa>%e|7~lEkBi
zftTw43V{mIm$|ocPvWI&dUX1Ny+uGJ7+z?a(-r&PUFh39avw3)Pc)|2Bc+{MB6XDAVpj?!BLtvzJ^=BWCOTzO
zRpDbw$(5HNN;Z>WeW&hU$R2KpAtNS!(uAlaoB73IN{9R8zZxC`awBpvk)$)N)ecDj
zIYM_7IdW8N8b)AGl3DLL4Ag1?M_<-Vx3zAG!W_`H2M&`R)D}pIp{N8p;Fs+H*&&!I
zK?^=b9^41Q`Cif?>IW3&cR^!*J?Qx+e!AV(rFy~lOPM0d;Pr7ZvXPYaZp`{i1O{PZ
z^MfM27g0Azr;DUGOi$adShk%Q0_E~wtJZdoGuZVLWty^>mlc3R`^X#JZTKoaZ
zJoVBB7_7h?0Y9|9>28>gNVrP%Fns|
z7({P(i9e8^x)*Pq+f0nukW<8SpO@$l?l-8bnm+LnGYlGY_r9O=r0sMg4b|Z*CaUYE
z{hqAWxlx+z*5`-977Ovw2UpV=e%5O2wvYz$lBZLev)i)@x7(Q4czcc8#H58>owO6O
zoJTcQXYo!DoT3r<@wm8_vnBE-_2Q^~5c}j~=kGSzq;<#o)1(g&1>P}c71{Dw^8hI=
zMp+@&W2%Df1!qgPQJe+HMO29@!7d%XBHGV9t_xQQ6#{M>IqY(p^rp9FtWq(+1LgBB
zmYyz_(qTWn%<+sqpv`+p?N)rw&MO~g|HCY#O_k5v|6%FwMB;t5)=6T7QoUcs>iw|)
zwc*XF_Z{@?)U?+T=owr-A+ngJ&K9OPUK@6&OV3FI7#RphT}o;P#QR{*PVRvszWNDn
zkw*&HZVcuUeP^CQ8gBS0MBt9$wM*-6BQL{*X%;2;MR6i_XfE*-@tqo?v0oUP>92ck
zFxmMW5ZkKvn9Hbfb{>;ZQnW$X<(D2PDkMp7-yz7-~T-2T9;nH&zkUrzvU2K;L|KR*aEW>%ga*j=7Jr^4t%^?nthW>}Fx
zoZ}v+!su{I`~fu(fEf0v-}Y0NG^dC|T;mM^+TTN
zCyWEf$rjz4Isx~o)a5foJtm|NE}|V@5vrT7R1cq-Dq6T>B6+|`7r%1P<4TEGS@?*^
z`DnTNh5;6`0>`qfZ<;}Pr^{siWj0NFQZ8-4ht?IhHnAL4rlu47b0f@4fa{44UgNoz
zRN^b?i~H)!YDH-O4Ggj6^MS-GrYHwtf;j;_$Irw*;^+W8(1!%qs5qnoW?Rl0LByA(
zsXw@ZEF+GSO_Arx#BxlR&FQftNorGTQ-+3H{8n{Cck=-NK8s4|XkBwzzHBa+&Q7P6
ztVz-#v!)4;jRQmCVr45~Od|IL0mY$Rh1Ws@bI8!Q-H2CySQV?g$}wFQ0psgUo_?Lu2kcaaAvu%uae8YlJ*O2
zwLuV_+u+om>`}lX1AVW;PeG6zOLP2>P0X=uqX^Yoy89yo8~T|fiN8xcLRg0r_vzM}
zd9yH_xM@`RtKyaMEG$@ulK*ZfXlqAB&Sr9wSdR1s$P&k2mT-lL{!NnW&?Jd`Mv8bd
z%6%qW!EATE`+L#(*%^TJGG%0nY{?H15QF5fk7KmE{(LMS^ar`N7wNqQc|O=}b-b_j
zqTj=U3NUYr-UwjeK{TZ4^sH^x)`7yg)ztCNRU=$;NgzgD8A(B(<{*low5MP3c=*jf=x)`$Lg=2{xM
z*8~*1LI@e^9@tizoNf9$P9VGsOA|@zN>cHL`=Hke(;b~z5oBM4tzX6tKh1q|9-jA_@yCvq(&@bQEc|B=sGd(xf`etxS7x`7;n1r9GUWj@OA
zb_CUwgmS^GVayo$I7^|k#Mb-15a*~0bi)S1XK|H(^o3ap+2Q%f+t}5z@ZgY
z_{DrRG&Bm>OWxjwU`Em2%PzWxE)Fx1LtgqYcHYKC+35p+U9Fj@l8BKA?kv~CXpU<@
zv0@p?x(5f-k!#4WC=Lg*oRY*pZ5718x8~F|nO&lL=1cX*5XBzvW;0108AE6t>D!UQyZTf8D{+V4wV!uAuio?8R
z>H=0^EFNZdf=ZY1&A@o7TAIRJ9v3~=GOmKt<5IuZWRu}t$_sz66Pv(?uiaosjXJ>B
zFof1|t!puwTLw?m{&tO?NP9}hbD3YVG7Liyb)2%euP}z)RE6fZtC^-;>2_Hv;Qfs~
z%3A&+r)2q1EHVS+(1m6DG7|rSHRxX}OU&_)*U4sA>2p?2ZT2TJA|H+YyR?83BsWX_
zvMY-dxkO##8a>u^>X-rM&)zmDe|w_qK4=+x)Gr6K5KLRHE~@1mdx+(F(b?GBv7ROP
z2s>4OM6a!B`N6%I{=;xWOF8pI(dm;Vv%KnLb4hBWK$`zBoHyAgCq4_uQr6l8V4los
zwjvK0JT@S_x}O2IpkxOkD62bZ&gRh=+&b2ute%D0iS7y-T!w9bDcuoTUbWl``s8kh
zsC61mEt7Ro+xUC_{wIm~ONwpgLyQre_XAiM{!>V&Jnr-Tnf&hHYlJ{O$pUk{YjO5B
z6n2m!e=5Wo1z>kG#@$r)5jpHL{Tna-hc{S44{09pE&@vyijiG#BJdkT#-~
z!NkJ^NMO6)11JPUAtx)(xdNiCIh00JxvlHIAe(@G*FdmC&v^qD^=I|O7j4zu^><8<
z==o^z&A{zY_|xzc36l0VtIHst${wea@@5u-6H(%+tRHc$9W@Pk8Z62j-qh&~oc2Sp
z!v&+#yEc08+L0`frT{G~Vu{gHB}8X`Def(VN)6lvx%n<*uOdkf{j*P(hAh7gZw4e}
zI)9G4{v9JYQ37EU)F9YCm^LoWAao;^N)0cc)FmSI&^++EsRL$K>~{+2Fk!dVV*Uj-
z$SMn>*jBPDeh6Xa;glmY4XoIW=$1jskYWvU86>-cfLzVtL9#Im#BTkc0Ns7$GKqG<
zdLxGgt4rgC(0Cs9y)3XkVp6x`gDVmL$!kw!EiiRn`q1oJ6duWicd)hL&)f>lt0jVv907
zc4*AmM-s|narnDZ`Io$
z!Peg)dFxxlp2>dC3pkk-_Lm>yd*i59=b8&m_NaSNh|ePksEJuXaV7
zho39LIx|zB-Qj0k_F}d}NAYHk$N6+Sq%)~2=f!ozmouJcPCq_@l~8qW#$J(B?dH|N
zf|D_^=mX6yP6-JPA5uQvfPR{MqBPW&7FQ&pl=JA6Z#vE%%;@cA5QL0<
z-KXoZbJBa#w$qiz*elbOn4v%qd)Blvs3?v+pBdA9hOsehtGB(_*dK>6-L5hi{2Ky0%66a^{Jmz{S($+`tqW^AVFxu
zfOwE{Nb&jn^P@?G_;T2^VnG%|)2@Z3KkG22o|UlS71@`Ap@v++{C_b#{i&YT#khG@
z!wh8KzR5Xv=V?Q2P!b>dYzO^2jsf?yZ&Nl;lj}!%YFY;@8-JMnIuAE<{(Q4E`epR<
zcqywmq{s5;U*h;fRFTj_bu&=JYhp^Yi)Wf+QA~mQPOzt!nFGV-YeXf!#P^*Tnuh=f
zRyN7%5!wxfNQ%_%wy)w@zS$N{Zqh$oqKTZN4_xE|
zD@op0S734>?{Ixg*8BfGiq|b+Lxn&eB-vJejyK=BHJFzWj2g^4FUf8*@H6HzigaA-&=g>bWzA9pb4nJpcrNW0eC`Ex|i?HVE6g?
zsQ<)JOdsL;HQvfZw~x~QbV#K$_U2%8o5QuCx9B8=#jvT3N-zA}D|6F4bruciK+!2Y
zY?v+W|7wbx&mySVgecEf6cg%N=0Z&vq`R}9TYB~nXfG4fa4~E2ZTrw*-9V2ALxUpk
zs~u^*VuZC3&x!qB-edv+oOmAH)Vcxk<8d?UCJEwCaM?E`;*bN&KP{!`VQ$SN#AObp
z6$$6&?7u~J#WG7U&+WzCTSs%*o~DUj?BY%7t!LspyP|;?Y3z~IfmE)hwIw0#f5g^M
z#leWf*NYZftyCF1Z_m$7voN=+1^5e!Axhp@9*`albM&ecuMKa5`cDNRD;y10+yjp0
zl|Oh3FC6Hb4Ls;slJ-llwES^zm#nI6y=y2*>Y}4hW@q;r&#h-~>^Xw$z6hJ5@@uUj
zNWe%;&@~#?0aTWQmdIRhe10B9&%4iCoVJl!c(|>q1``gd=3M#kejm*s5$W<-r^~8O%H{tFb!RNmx
zbj~!XZBYZ_jnZnXF=stpG69=1Z;eg?
zhKzDx*W%X>4CfYjBR1daKawe9gt}rk1otYlt4anZe^+&rR*P$d2UPxic2QY~iuzUP
zM*r~yxBnM*i4x)+iDo+PqJ!d>aGHd0_Zx5UhgrE={yt7&G+O|}Zy{AWiy7b9Q}Eq-@zq3z}-~q_{1OcAafV-+$uAO
zF%fA?drO`dAN4>SE772#cgZ2*nt@&0*6_WX-RX>VB^TsU3S~QUjIW_z8*effLh1?%&7DF^Pkdx4_?242dGKDF^=KN)r3
zUa@WMSbeWz@qSeX|CTNCl;GVow*)_ofSP5KeIjZzToKA`9Sd9hJTZ)&k9Qd
zpKun$UTH<>d1NeXImxn_B6V62`j+5M4TH2Eq06M1moM%+5R5)@ckuOE
z9iYa2VL7~E{`%|S?bkmKUO7hxwy&Y9iPP&C9GQIYWuz~gdNIdc{DuKW%@Z~lPO;V>
zhI!|{P$!F-HBS=OvJgDmnsnGoc6`wLWP^{e-@1oL$*agSS;GgsoTd(FqF6b1AD@}d
z?n-abwTyQByEf5v#W)_BSZwAZfT52LZ|hPZ_4-v2Fj&*O*Nh&80DqB}W)Q5+`QbcO
zX_(QUF=&aV?NRr8&R@CIbNiI?bU#+zAg|A|_OVDibwuBO=3XX*hVsKiBvK>)?!Vb)
zl_yn32l$Ho13IX+?}1LXY{ap*T4lT7b;vkVFf__-V^RB|R`ekEQa(%tx{~8R!Y>K1ukLVO##`Tm1_avBd*vatW
z4jWF)u(eZnfO3g=zb^VNiRB>z-?SFAl~+zaG0wP@fig11Sh9A%vJX3bN#mkw9r6d_
z&&Ue8B+Qq~S{d^)$XYSmGs&_Vtj6{<=Kof;%Z=abQ|ZU>;x&R>gk*gUE;=-1>Tn<@
zL+bjsQ5cR+TBOfp=-!+hb_ECM#um)If`%(Qp~J7GGlGqVao3YD5Z022m+D9eEPZhL@>ptFQw0BY`
zXAD$n`IEZ_G!*6~VW`R@x1FrT7!A0N^Z(3}{m!NkK@z|_fZ+v}>cuMryBj^jK;J;A
z)Raxz_8k50-fA$uH*!U&38us&T@K!Nq8wMv#^b&dQf+hI7w@|J0rH=8?6&1HZ98^b
zNeI>*ZF~!e-$qPv<~9}}t;1RTJ+vfV;Ka05v_~s#u3(A$F_daSkRwsIBh2!KCzyG0kJ*4@C%7q6FdvRV!WF4p-
zbd+TE5J8v{yiqt8oc@T)uW
zb$&W{|3GlvXDonjFd2W#=XF`hI8=w236AZ;OQ*Gd3goCr7u8oAX(!ou|1BwGYHoVP
z)t`0wwA@J-rRA!eLKNP4kT3qN(;%D#!@hme8|2!v?J*;tdlS+p%JlGrcrlsMt9}iM
z3J&%t?APAdqO#n_7SsZYtbFmx
zx$0#VHblP(=I_+4GdK9OiXFY3vh3J;*9kvVr|a^U?-1Gn+-vk{LcKVMG>FPR>uaIC
zO;e4k#WYa2K~6=sWw_OCuG5u*dsIgjPSJota6CFX3U*eQIQC}6_bv<@`gX%i*pUj%!
z-vu`PWyAcIXfz4%Y|VxFQkw*ts~BUv=;_rJ>nRtS38(<+*ws8haGZP^4cTksJmJC|
zsW;ZC3u77M0scU_f0tzQh!)WJSEg)?m;Eipx!a`8Ra>PiWup@VAl+#Tavk`*es37t
z&&v*+zddd378!lyZQL>_W1s8QDuV5`UDH=T6p8&6KrUw|a8M^VQH!rqT#<9HLexE3
z!^n~o&m~W@6MKo&FaQ06INw3mzi!9=ifz#^U-i}jT9;Mf4fuVgbco(sk}Sn9U${#y
zCmdxGg#S8u($LZJCJ3cUBc?Wfofe36qPTjJ^E|96?pU6a$Z6|oHV?2Fd)nzfTCF*9SiW@b
zzqSTH+4n=t!98ZPXW#FzG{59d^Qe^>XjUq!Z;#=|cJ^
z*|-iq@VajTOMOm{`E1KXOx!n(XB{nT){B3Lg^W~uO3f`g;UeM`_w;N%eMiiLeT6k7
zn4O0yXmR&RRx%fd=`{L)i7_W%#)P8kV$I&L#kr&<&L+jVZ_w0*H@sOU%ccyb+qCU&
zfYH$nNec;y+T$&cy(_A8ZI6GA)$&q$5u{>ttr@?}PwuX|Hd%sn1~Yb{-D_H;$K#`1
zK>{VXE
z@#b`uJG6%|vUS%){t%HcbX4KaaIAUW{hU8fM9`8=p)R<@5$v$mO7;Wv125IT8j0g<
z%?Z$UT$lGFwBtO#!olcS>yL<@=TwG85yo94lw04rm7^wN*Hq^_XAmz#336X(iKJsQ
zvX(=}r|I3on}J&{G^0R2l;lP*xOC`m+RFOyN4=mTCk;AiSW-6;q
z;>?!SNY7Y|_mK!mD2sDz*{^u~n&wp&-Rf8Jr)H*DZCPot0d%!nnP1ps6oxYIPNZ@N
z;v@8Ni|Fkd27wA$Xk)i2uC9K}L_GchUH(r;eZsjyI_OuFV12UqR^bVqindlGjgm3_
z`^#?kRpjF$%kxeifjW<Xrf1i#U|U>qx8o5Pb(zP@RQH`
zfy(6i(<+od7p4i%)DI@q?Nrr;pGM|8D=5z5d7dgvK=XAFMZFtuxtrf&9=$>y^|b*r
zTqX;Aj5=o_7RSGfSDCByK4jZkcT=YzJ8
z#(n1xI{!Sz*n}AG%T+#T4rHcK;%9Cbx+y>~5KIK9XBXR}uf3d^kAWmtCdr)eG`@li
zl`ojycGFf^`Lp#x3Df<0X8#3f>v8L1S`@ov*^v@UF%)h8L(!!<*XZAE-|yn-zl(4h
zZ2u+(g(&IqCg$HvR*rtSbxk@qx2yH%B@?rJ@>6Nf^d2;vTjApMJ`TyT(B_#%Hs)J{
zZ7DY^IYM6dU%|6$3K{y!ow%Y}qB~A(y^3VOpDe6m#qRGsUO7_bX)sIaxh|gzv9NDk
z=Cb93Jemwz_;yQ`)Rh0Ja;b*rv&FJi@Kh&6fb-86Guu-CDHsV(|9EbF^}($WQwm&A
zkrLENPd@Esr`&%-5FTxj(X&Nt(s$jqbQL?UyHd_aB|DTJ4s&GytOgymR=&m=oBRwypL
zckGdzYVHm-tOlw;Mkb@M}m0;2y2>ImmcI8El
zr|h+Gs1Zp^PyGb31YDnz*xElc5LRy|lte`%PGhSL!742sGe$5Om1Ph#{H8Kxt9^52
zueyP(9Nq*
z(4yBYKh@$bvd^onBG7Q5&9X|(uz*0W>BXOx6ZZ}y(!2=t3M*eQJ$s=|>}%+@GP%3~
z$w`Q@79u9j=xD%}K+2bSVVdB_YC5C(w-H=(z;Mz@)9EIi=zvLGI~FIC_KbKdi{r|~
zkbnq;Hy!u-%k=7#bM$O$bqGJjHhQ6jTE51gv*^m}AZkTcSHByP3U=(UFlaOUe*n`!
zEWeKJwsXJZ!5NQJ|7cz~oE7%F+)jsGX?m7wuzb#1%AN_k4C+3sX+#lNl393ZYHJ3K
znjxcpWNPx37Dif&U_1oE0Wj&XZrEZRg>=JFJFMeQyUJr9cNj<9rZETEY*_1YmwD7}
z9YbbzS_T=7+wv`ui?FL(FR~Fc<5mdV|+xlGAdl4(nrcE_3{RBM
z7Du|$@M2_iJ*TU(H#aNhGIM>csNbe>TEkw)vs}`zmyL@_)j`vI)^%RY`|hp;4yUbm
zmzn*h?Wp5C?z)z9Q@0lbTUEm$l25~S3^kbctd&jMO?x-1oh_KFG4*uT67vryIaNA1
z6?6}9&VE+8jL~Je(Zd*fHnq
zg8N2{xm8VQx&=#C9G1M#g#$O@+#tM0(A#g*|EI_LeLs_pPOLVqC0?!AAjL?<%VqP<
zv}e2R-kqpIo5sP8eX`OW1R9=_bWmmcE<37iP$2uki3{LB)
z$Dx7_yDXy=l`SJ4+qla*>a~x#Y{Md}cbW#F$pP0yz%k}F4=R_G4m7it*^-UstGfZ<
zO6#Iw`Bp?!FD=7OT>bou>>;e+TJU5E42!VSkZUs7tHR+DbGQ&VTIMd+zje-i&+Ta1
zx!-o}HXJ(*J7C^v*bX7W1h8wTiE@**p7yTQo%01Vgsz*nb@TRxiod2Thn^|;X7lcu
zf_JgTHIoini4}K<0kupV>IA{rCrX9#+AAX)P1!7cCAqF|&EgJnXU>n0mR+GlOJdp;;p~-Ga*NybQv>mv&Y-@&YX6eKGN3+4PEI$e*%m+u?NzHUh-HcDR
z5_DgvN@SuUjn~AHW^iyRJ++veDzP^<>&~5Ne=9LHU$RC0x8};u!{yliyttsO7H-q+
z-AwD#{?(?tlQUPM>S{~_%h5>aTWRBL$zF-5i=oMkFj0=`Qv7gEQnj)ccm#Ab$)GC2
zj=?*Kfl=N!9OfqzvL0&8xQD#Xe#B$9?I!jfgj>f=#yubgMk2v+VEp%sE>OIG0J6+_
zp~(X%T7&KC3plUKzMFYzv{Nvog+9skb4tzu#O4v+)pvEMzH6f^(P){3M{&*$8p^6W
zAkjGE@gy)lnPCoQ0tl1J*e|(IMbHE&-tJs*z0J&*1G%un?@-xH5Y;iA2CNR*%_@Z6
zp56jilYZC$o2?zPnN)7Onw~U``CPgnYqOb0t@OrWDPRt`^&Xol=-0DuEk|dhmh-56
zPL5Bq>%91;c+Y!G|XSGa3|(MTSPR6cGl}dXyr$y}bdQ0!R*V
zK-Urh#)2s-5WrC5SkM^fjWK#gALq46L0zVKd)r!@U2CyxO=Ktl%qwX3NUXDTDg|Dp_kg2
z=H{!OS(-h^Zwn)2+L{rw(nKK&fG6U-Dke;X8I{bc#K1W39ihdcu0fR7e#_&yMI_s3
zGTH06<#!MG-Tkb)AKd+*7SfUp-%R+|_
zX4u^hb1)ZNYk^^ZCFv9cdb@G7C&E`&SwBp*l1G9XB+j}MqJigiQv>s!M#wSi6|PZUgXb~gJ&zk$uf7e#GWn-czAnF
zzOya?+S_a5<+=SIXDqJFOAgRkCbF&k}uz0NF`y{lF4W&=HY@L&!Y^XQfK
zIyj5~SiD^0mE|9_M?Kw>o+=o>xF-)lSoZhF*})VKzdf=%&CZnF)r3ADn#f2~
z*^nk5)0L8jR?*qa+Z%wk=%}X+?Sico1=#v_4oBHkOB!lPddm`GLyOs+mG19m?(e1^
z9~O4z#Pf~h!D4u`%XiD(R?$<6TjRo1DuiUB5_}NkQO-L8DJC^`5Xm08B}kvge#__T
z2gZ!+RxmIGjH99|61*ZA`yd0D2SuizhSt4`ID7gyACwtM`zGUffw%uWFOPNe<`ma2
zyI;6ERNu9M*aKy9bszq@?E}WUv|hqXp|0yYoo7+!i-IC$!qFVJ-(~k_g^gxlzT{YK
z@+X@$NTS0ElRVf9x>qC{My%#>vtbn43ysB>?AA$^aav4p(Q1=!q^Hu@L!a&D3Ak&w
zZOTDZLv_axjBVy&t9bx6+Y8ri8}~cLdCwHGpUCN1k0#(&1lbNLrh;4pX0Lt3Yw4GL
zqq8{jDFck_;XFlOnB>EGKS(}Z<^V7-K3|dUZieq}%1F!5YUne*db|RX=>?Y?^1Th|
z?#2&N<7q1d`LN^Is#&1JdoBAu1i9@#=y-Qp?uC+Vwdq-J(aaniHJR$Hy&Bcc72MsN
zeZJ(GulP$bOM=&DL)I`0XKO^1mB|&uD(fY`NeUQfWDA}-KvPOR1xD@-`iwz%Y`65%1arnqPV!$h)Zic%R-G06}U4RO(s2Gv1B
zE@YZ3xmO#3m8w?>^Pb(=AbyLj4oi)uf2YH4HQcZ~ch-V;*Mxg(=mdGl^5Y#^fcb1s
z#{S8U@Q?GxPuIM!@A;>rH?!^F1ktyb0J|)
z$=XWRS0=`wPX;_wp
z|9p`Edb&PY~sbFBr=NJyy26CbrkStdmM{|MW#lX?L
z|MseIcT+kiJ1qiK6m%Hcd$Pnqu0i%zEZLfte?Ak{{o_1|R
zkf+Jo>`%k*cn`YlM$6Yq85c_4`67_^ELD7nX6SK{&boQmY{@rQ4z%;W7^{u4igI!$
zvc!N8DEhGnt}xFi4fL5tr^!X@f*yoqz2Kpo3{$PlGl6_%ObhfP22&~W%hUIa^46GO
zjRh^SAYmL8jM&E|b6hr4Lo_913+*LyQZi$o2F~K9dV`Mc}*u%+=^pGNtKsW8EGOHRs&8@nwBS1^4O=J{$;Ku0%JtSI6n%<3${UWE~-i5_2DTL
zxXnd%<&>qEFjvynLR?qRSUM%w$~51|**j&=#(a3O&2P?!SEhp-v!Rtvu$H#2&C0WN
z-`bqiEV!1MTt1@PUWl}cu4=|s&DzTudn%%jhqT3%EfY0@Vh4l$pE3#uK&Nl=R
z_B#8nFs8c*^utldq;W8eLIXUbBo=Bs0GLH~7zX?A7z^Hh&U-81>|>mLen(%xc0K62
zc6F$}Ys2ZaMJsZcqZ#&ShB=;vbM_x}y@y@j(Ts1mpw#2gxNK9?{o
zrnzFpb=%C!-b7BDV75#;Y?DsA3P^h)=}w*BsRhh5`bwiU#%Rzi1T>6m0%j6>-iy7;
zXCL)C!2Aef?~eqAmMX5@PT*vbGB7Ok`7#f&y}KE@vnJ9M)FRClD=N+3UJYJu%C|S=
z%Pr~7hWKD7insI*(Lc2v&$!{G5s8m*45xi-Wz*g?o>45%G`lw=bYbX{=DC7vvFu;2
z`j;x6rLw!3GPN?!#fEUY)6Iv?ao!N)&_zN^dy_+o8Z#uV@Xw^Zl#MmYz%`)NBQt~H
z{|?DMZCJ725ObL|$&4k!SV@*ijY)VR!jNJ#;vz`4!~`^et1T{B2wEy@3VS>$qisxv
z3@OQwmUW$+bEARZLfY=~n@wguZ`*7JHrp^eL7L=Sq|9=@z+Ege54J=&YGC|u3tn1!
zxXwM@6JI*~_JmWK8&2}Wh=S#as;*q^aK*DUo)cAwrkT(b0W5)4=&kC}-MtUq|3#D=
zM#Y5DggBlMC(lsJ4>|5=~%kALqQv7f&y*U@zUWjil#A-QLHRqgdFtwZm4M=e%
z?Ui)8UDHT%CzbB<1mhG#U{`!@>xZ
zSz@5c{Xup>V1RL-;2QwO;2C?r=cdPb&F{K-b*R2;JM1l2Y`YPFdolQQmOYsZ9L{GPMgN#)Z&%E*lC-zTPIKitr@SMz`JM!+d8QD_2^1Z~>9P;$@Y9E)XA=A}wtzQUGMbQ8arV2JX@D6fwQWPlZhX`C6-io_d&
zEYmy_gcqrp=9~ntfnfF-3E(S?^>V<73Na>BgtLShE5&RM-x)F33~sL?v0#Y@t*E4A
zjmsveF)6TYP0F@R*pUv|(vl?=!ZXlk7;Hl^Y+A1KTOAQU_Cm?ASaI!iacsrI1u!h1
zECdf`ICPG8H-ithghx9P1o`o<_;8bh4x|1N7@t&A4rqpOWI0pG8fFs&$SOf7aMD-}>>U7C7QwuD$#ZEb}G%a?k
z{>7#+UGmM=`8x;A)ovKotp*mF!ReB}RrGc${+Sws#zK=_Xfm@kU$^Y9WgVRw)2*|`
zgb{*V&p8T7D;Tckh~!4mn~j-@DQlQl$^3Yb84*x{QQkk?gBgyR^&%ekNASBuCv&kW
zkc>)4CKB>kR2oB6j&Q?a7MeT=k`vw`CU{$xqqrTJJ&jLS16x0x1NISiwq7p&S$WS+fFE${=tp`fcL
z&OMB6<_Uuyc^FzfZZS?-O_MI08YMGIrkdB|@w?s4d_qQ+?8Z#~t>nwJ}{-LCI=k-yxGz)qho_2RL3
zw!)vR@TaT7Z2-I}lSFSy_qIY0w~68NjUR|H7$zO=xQ@{YcDzS3{B8@8(zQJu*zK^}
zZDzIMM?cs~n`&`Aty(QOkWg0Y>_U~+ex}1t#ppsLY4C~Wb(P5>8fs=K<%U_BD1y6|
z;GAhb3GP}4j1?~p!u8lIk=R6I(Tq95TEeUu6(VBZHRDEvO|6oAq(hD
zi^zc1OvITA*)tJ)Mz&@{mW*u9$fj)Al#!KXn_0(7!;fsWGb8NH1P|s!S_{-=_q*&~
z*MGSo-P;I0+?F87*x%h`h~Yi?<%2Lna_=bhwjY%vQ(0j&=I>APBgx=+GD!E_K_%s}
zj5J;dt5LbIrX15(;`-nH_Lrvzvk74=C61;@hsTp4O$rJep32A6`Gm1vbe7TQ?z_~mvwu_#2-rLB!yCvUr$=fP<=bAh`HUt@L&(>M&
z=UT#IM*^|)ZLwYPPnZ3REionOa&dDh>qvxk@vt^3siDIWaVi{~s1-d?VKT(4ByNoE
z0pc0pJOhG{GH_TJE5zUtG?kRLoYWR#lbNt8El;GwllV1bL4ui-84QEufFjHOTde0M
zNWyT@huy&00uPKY;6j)9vjvjn^F`s#N@%Zzcq#AB%dfw9`?v4C
z6J?D72gFllHxsBZ!_Z9FX;|p6=x)_gz>oErd@e0WRzmND2@TUYUPJEMq{0iJ*kHJ~
zCn>g&_wF(5w!@06@g;mi0PJ(=P#%{y;5I<^1-~xfn-W-EkkJO9!)_Y)qVb*pT=xj$
zneaKsSocI&(1h6WQgmu>2I*G<$)}6LIn6KyVXDzRp)NN=_qM_i;k#Smd%My5docv#
z%dODax_oyldUcHcnGI?Tj8A902h+~u8Q)Pma6H39hv$pd?P+ea&CHiv>rHmK9_Z#A
zIYBj#gk1Hm)R^D?`t4_rPNRZenfoyyGQ>nnG-v^|AP_1VW{hAs0w5J@E#rBHhP!BJ
z8uU`bAo+|EAg8y0c55g=IvnAUgl!St93qh?jHyIxLR9FL?Qse6>qv&|gmK6UbW;-O
zb)b<8+Z2Y)S%u_G*pv3s@-Mc?0Asz$c!+CM7=H8j%kYCPL#5-%!{Z0A)CPY}i
zT;U#W2`}!-FYkp>uN-_^jT7t;jW*Mo%F#q{9F-*Vj8j~d390ho$zn`bPS7Qa?Yt9j
z$k8x0<>Zt!k-*DB+H6EuLtj|;Pgi}Js5Toj*7B}a$ybb9%1K)_?Eufv
z7+;(TWfSIn%9@HAfN?lDskmz@D07f*d_71v*7Og^+(<4u)y$ix%a&$FS52x*@u_@t
zDn~IMHhU~CjzogPVSz4?LS_cTfEjP3ob39(%RgY4K{7A~u?WMb^8qk?dx^cX${|TA
zGcm#`g7I>AwHa7$(Hsmq?CFw(^T1`D@Yo492rsY%a(atnvmQf$+A!@})~oS(
z)LcLtldTY?-kL<-KZ#;oW1Md)D(Z?c<4nOiUoaiavZu?zGkEDW*lB_p3Jm$Z4~Dlx
z_je-qw%HwiN#`qIIC8lrUv7j>
z7Lkyp$2&Ak{o-Ee*kU@QSDlwQTEo0fm*>=&3nr^R~_P9@z?Sm01S-l1#i9JfweBB9i=p+9_4^Ox5|Fx
zZ
znF)=jLSqSOBq@)|+(3vQ5+KORxEFFY_E(4MySCGXz`3&6_-NLDI?uvCUn~aiEDLv5
z`P(bd;ULubY$3Sc4X!omQh{<-fYVEd(Md6G%LIrbGi;v%Z)gyBPA&Ed%ql!d)*6A?
zGU>3Y0kFk1Wid}#EowXTmfody_XODi{|uz@P+{1iQHq}Tx^)CI%BA(Xbodv6H0L$3
zUOnsAp*X)9xiKc0p(;T?4RoRArV}9!L3%vkMCO`YEW3B71BmyhE5gMZsj&hup$nMr
zLx*>x#PAkbYcNcN@BEOF>eE>d7(Sl$9(G-)=ovfyL*;ssgE?U)XPYa~LS>q2D$_9a
zYMouKa;1m~Z|qhh$smmk)ASE`7GQk|VAK`K%D^?rGPz}Ah=tgi5r9FmqR(Wxsgxzt
zigc5mzRJcum<7^dQee>*mu&FWDcPQu90okd^@wkR?B}dD;_U~P8UNU8TspUN!san;jSO=g4@?;^ZEygv~gszs*R#JpglOsWULSw2h3@CJSCw!8wr!g
z9#QV;HHf$Oj?{NXM%IK7X#CghU7_%719o9)3I9CR%t;PwvMQt%oARF6A
zht<$(w?lUYtzF|#WEpLTL+gUhqepN;Zw(%D)H?9&bJO||V9a}r0k4L~*^C$|TjC)L
z)EL<>CRrnZnbC5-Nxx&1_o)QGit~=vQ*^7{qXqtaRlGwb#u<8l5efS
zDZ|wMjkYvfq5d%?gDV;+j!A~NWQhq>#4w^P%rGshqRgx;+n^QEB*+2E$tXpid&!v`
zcsO7P1@KjRS(rB|YdjFPol(IKcO4VZS&)~8g-*$ibjS&qli(TtIbu)2R1>=PzcGw*
zqHS(Gr
zMGRsIY@%9YF{*6lDW`%iGO)*?#krrU?y#|@}o%yg;!Pt@yoAV+4@p9~FDRjIPK3NDK%mZM4tL@*O_MI)`AcyX5%8z%$
zPxc~D_ao2tV^4RbXa6v7ObiQS(BWKUs*up+Ba`KrrUVg=YpV%uGiQQ`O_ywV>2%Rm
zOz4VfV>Y5L#C5rZA)hqXbIxkU4lkXH>X2z+q1R`lb4_7&HnP2#g!=`<-Ev^2A*|2E
zm!?B=EwNh*w#!_nD%5iRTEPpAtrgf-iEEK2`yt2>VL%Ip!Fi(;sN_7oHeLX&E@fQ#
zv;!ogDmfPfd9D@AL=7ld>u6AwifEw8U>lkYQB_uY^wW)gxc+inHJ#Ti)`78QsSa7T
zfaJxh3CcWMf#aAgMMsO#v5ZWeT0$I+@TAGTBlVrz*&=(s2$ESMc9lrJy(EBP2=Z-O
ziz9>K)8+8xPVMv0J_)fFKX|iDdhCR&-J)VVx@geK`P8yt7a1$-GxcVVV2lxl!81e{
zWi$0irX^gEXb7*}Itg68P8}RI`URylUMRC&2NAX_z8dsGjj{K+^nSM?fK==;cs;s+
zN5}YdT)-&vrjTHb1kD1Y6#`o90dQ0_L6(EPE9pIxLH`s;PD+}!mT!N7J6*x=Mdta@
zPUPWs7)Dx|WRmgBy{$0B`Qd&H07H!*9Q+WB@635F7W@~B3=;Cm40Ae*oWdQ>^1EGT
ztIe)9{A(>{I&1G{9WdBy4R&*y1S%!N*3x9p-vLWVK-!WFS`$2wRtBXMjH$t!W2`C0
zTCNN>OIINF3aPkfxfOS#}jUm@-6
zwgeb#h(CIeLefHNOe9ai>W8>7BxGQ$tk!}c56R4}q%=}bsk=q(Oi8y;HT4+2BDrFm
zuj;!6O+7VHO-$s%<7sIuCDOcF??`>;MmoGA0OPY|?s6@7xh~ya30}f^A{8&wWdpa@
zqx*BAzyA4;hnp?YZ)BW0=&DmO&j`0(`?%oOrK7$~l=VX}NjY^iMrE5an#Limpxy1F
zv9DKhyuRl}LDPgRXH3h*GD8Z5}D=RecBpQk`n+a^r
z8e<9OC_{dmrk9n4mT=U{a2JhTi(Wk~=kl9^KA>)euO@~?dvAIP(1KpYQ7dEAAwo9?
z;f=YoF?%*n80X_I6c{cf+)4xbY|qE>yt5dy6{FU6#<@Ao9xcktHP2>?-J1!XE``ol
zB4;b|{p~0`&ZAxV>3;m)n)q}t0*qfh{`TEJvSAvIhLHxn<+!#)S0HLy8U1w5I9ImK
zmTmJj$L>lT0#Zxr3vkpaV>M+$crL^ZoeItOmXa3iLGKJwN=I61OWVuo=?Vjrywr^V
z-FBI2mD$;ryfhQ7WZc!P584ZoJJsNHML<z8E#DfK895rMX1Ev6CDls|Xw9yC_;{j99?DU0P5L;iZ`*FpNmt!&NcT$koa)_2kt6HHBoI$7v)Hb{qU2Du}S(
zqi6gk_-eEnuaTuPDMMT|(8c-nGH(nA;UsBx6uuNrTjmX|vIK@@P9w3C31NJ*!O5LXGRpdXrsmGMi0y87E=b^x3DMG;&-|3Bhnuwj^b9O0uK`GS!MKlXzke
z9gd6SiesED##>_`83kqLX@>bqkQuskQSi_r5Z
zM+->E^5tgyVl9Mt{BS3HGVgzJH}djP?A3$FtH<9S;-U#v=rD|QYziV=OY5P)-GXVZ
zVw)>l7i*5ihWppQc(2
zywH}8cdCf8E3>iLrnuaV0pnJMZz@As_yw@fM63zflnR^E5lcF1&crM!Bz_Q^a)Nfe
zCZBL-VzykuQOY0#n<2ufuqhoe$7KTwvRul*TH|<`Dj7T6HGFk8h8UwFn1f>yJ1VlY
zd|Fg67X5u;=2kv3246i}*3DH6vqg}sohhj2O4@~rexYhu#FHf*o?NIIXA0V8W-22M
zT^*|L+K6Ea#xy8>xgy+M3qIHkKiG`iTa)k5l|bQxMfq&6^WHCB%f#FPoFaac;4^xh
z6G*3iryAx~V6Bv3omvzy1I8{;>e4x^lR(j7o1(F6B>=l1;2_zi#tVpKWqugR*=iay
z8%KLXUrw7A$=U7D<6GhFP~d>q!Vt0M0CYHD33!Z**9?*aK-#Md`c0hQ$TJ2BMw+D9
zoQl{ADNizF3n>@z$edPW)L}teN?MoUY1_VoMYb1%@9#z-#SeF{bokMJ91OpBlzw)c
zfunx-!%Q_z*Kttei$(tSA~~Avy7zEa+HSKuGeKnI<*I+P#jUrQ?N0FCUL9}A$kucS
zww9tPFiwXYDaj5s25&U@BwfKAr&W_M*mjyd0=)wE7AP<@8T5w9QLBT#Ndfe_G_0G}
zX=2a0^-yDAtc-FI#wmRNkX1>-PW)T6(j#I8%vWk0b?2fUKnqs?R?boiYV0f~@g!kf
zOnTs}iwRh3V<+c0mwL|&*l;X0oy#p+*H(&a3UPHlHq|XTswtprK!ITd
z<8snc%h2R71i4#b&UPwub-q;!z(vnAf>2QiFT6D3F1Urj_I?5UK9!sgN}Gw9f#`IV
zd+FiI-Lsiz_g44YN@(j{bw@RU-M
zJvEL7Cz9dGs5HSVA0i@~GM!h?RrFK^&3sWk2aNNRGr5VmvTmlRLCseU
z*n{V}64~tDk^0W|K8pf>_ygHFF``j8@n*lGa%ma~@Dv1|DN=vUO+>$cWypgLHfGHuvKVuIs
zO#mB4=|%#^QIk<+GEF(`28(&hY14b02*6e!aP5CU+~
z<}hzc<19?Lpe@xrgFgY(SYmZyK_8V&AXx~Eg_+^aE_<}VDGE%(T95bQPYB?|Jv5Gz
z&!EGHDJU}p`Oyy=;<~fQDiiO@-~tUX1mUaa3-*mhU~`)8ShhPWE>(P6)4Z|>gvO}T
zk|jffz`cNqBGS@9kZend_IOZPWhGL9;h10py|g$a2r`xVCt9ber%Rgr8o@Q`wT(M0
zbf*-TWfT}A@&x?`*-ztPQQis*4Q|t68ih`U9iUekh{i)(F6Qo4KJLlKyv2mCknmDF
z?j~-No>3lVMx)eQGl#!Mr183PLQ}~YT16Z3
zb1|+jCXBhLE*~=@46@r|DFGyP@ZY&&}2nnj*jkpA6FbH4G&_YX*83+Y#WkRFv
zoCd->SJr}I1>>pN!o+-OvYVfn&QEoV8WhR3QfTy!)OT(tvwlT{=?dF>w2V%AxEa1r
z*Z0I9Y$h)^VmmW*szpT$>%lppXWUxls$fkpU9oSzB+1LIzsXG{`jjXx95mkWoiPjm(ZN
zw*$L#?8T~hcRTd(fX1<)x)1l`&rUNho}`}~Bp}OA4w6rfQlPqbi2kV!QhaBbzgR*E
zy_IkfIum87$pbT-r0wWj}c
zHFgX&UPKBDAI=B2rUQt_k9W{T#-1I7Up|PwcAR+qB>wJ2>gq5l+mA{~Vz^l_w2Q`>
zGD$H2p08Qws%A76>S$Q-x=K=8Od=1fmBmk*d`zE->ar1iA)(AU#f;r5n~R$ZNozh~
z0nF1CZl*4+&81+TyR~4m%%>HHR?hhU&Tu{JzrEl7^5fUO{L|}SeEh~|AHDh6pWgiZ
zqqn~N^V^?){PyP`z53_hy_k-e=&EbUkcwC!$k>DDWXP0HIAFr56ti7SJ5y29!nD-;
z%m~3Un
zQQg8+r=XrGX=lsY-jVvw?cTZw^?;*R7SI7>`Tj--b$2szcRhZ4BYv<%c?MCF3upr#
zjn}1SJ$hJK-lvy2b3E+M#C$@)=yTDW5agHUiX0k%he+I;E}~@{ZjHw|<+AryU(=E=
zx=)C9aEfk}IcPPjjQVktUS-s&EQU$5Y0B+1cwGjc+oTL@5yLc~6+pv+1dfNaXRREA
ze#9K&Z4tp5;!F|2423BqeYFCcOL)L@2!hOMK{7B72~&b^aG~xwUKSth#2@U&9`47W
z!;cRVFCAxq?)~jB(0#O*AXB{;d+GFt3~>Qt)a7#U_LA5eaX4KN&X#3p)Lg;6RQ0VY
zvb-}R9W5o_dhOBPW``C(hVAL7lK`VJCtA;(kgbWZBTfxvP)c+_im$RUDhP~mj?tPB
zDWH-3YRNOn+Qkh+Fnb7KVi@#N0b@mk|GV-@cNtJ5T$O~gQ}C>}*@FeSr^#z|&sN)iu^zd<
z9e=nTd$1LH`6%+raU2-GbC!Dh>{|xsN7byhSv0gu##X@qHJ-1T0kBd%o-H$FTKG|n
zPr*^s!s)0Q@i-IFWMaA;vS>u#+ZV_i8_OAoGH&dgZHRkoCAebztj!{yPr0gvKstt$
z>r01wmwK4z>+)BB2D)#2`p4Hl{phXFP=9*ki;vNG^V5&t_~fIvKKa8dU;OcvW<1ij>?
zeCzJ{sKl=5fPk#UEUw{9~r@w#o(?7oPSG525>L-7C?JvK7
z<+DG&_UT8j|M|n0KmOp^8&7v3zhOZub84soGy(2f@T(MYHj}ANI@(n(6E~;hkY#&_
z8E4(_(qoyJk@pU$
z&$x6vExkY-HT#`vkufF0-bl~^n=LXH#$$l5cF-c~DW6-%`^+AP&gayVsa958yKPf;
z!c~7EEfeo^Iw4-8YKeN-7=CF=(f
zkTg(ThNDgcW@{~NYtVQ>BXfMEq=(>zRd)eMaHR-%9S@I7FhjZEbMa9Fu4kxE~Pn`jYr
z+yZ)Gr>i;7=2E&*q!n5)()E0xn)kz%tuN-<)nF;-O++lour(^0p`w>3-Ov8?8Yunq
z?_NTE^xGFd`t7rimBxp^diaN5KL*bqfA|vW&%b+C$@P1Ecyg_wXn38yv$c#mVNg*&Ia^swb?yARoX5Lv_~P@=KmYWLFFwQnKK~p7@>Nvk
zp};(25$K!Sdn5;WI||SAcoum_kh4mhMZp-*DxncdC6Z00kW6bEO>xN-;x(v*tnHQ^
zN6W(HPW0Yh^kO~ua4$wl_yC%me7uKqF7w)1_SMt$TXza?-TomM-&+aZT@?|JZ&N%D
z-d>i^mqTYu;e&bkU|!mr1M$dvoyA(tagk+CutTp6>_CWlU=Eh8zPK-
zIs~Mh2_)p+kTqS{K;2e|H$#wvzA4tN3Rng_hHD`o!W4-x82r)1FGoQ_Tb_cqZj4XT9Z=
zw~};~6YgrtS&iFkDeKWv7!02*htF2R=c|#s8;J{al)Le#dx@8hQm>pOUp|UG-3`5Q
z_O0QDA5E7{kYYIJ>9PUYSi#shS2Hd&tc!KaQp0+>lmG3n-zY>U^D#|Mxvm%tr$gFS
z5kDx+Hf5v6QrZp$t`~d8W04F)lRa@+->xx1W)uvw-a*bspXwxWV~nSt@c`hP^tmuJ?Q}CO4VPo1Glj{8
zGP&p;w0|cV7|)kz4|hGC8R_Q6t`60AZI^5O12DWDg%0DOKi)~)-w5A>Chw;n>?Y4w
zX=rhwBJ3zxw>+&p-dm*I#`4#h0Ib{>7(Xe)Z*-Uw-oC7hi(p
zh#UZ@C`oWpLqNj`fJut6S4ft4TZprTd21wS3&Cefq*OS|OKCq$AiB;N4!CTJ1hx3{
zr9!&p7JIk|RrJB~(OmI<;>lt1$v#9FXB#p6=AG=T=jpfZ7T>*F>>Z+iYP-J_ytgdf
zUkxea)riNyIDEDo*`F7W7DE7dca{YCa51u`TrQRc!?CLYC+xE^q*iBIX=lR3GnAPc
zB+Cx+)ygm)`YDvm8p5nW^r#ufxZg79(%yXM<$GU$@t3c^`s#=*|MKfkfBW{E
zUwr=Q*HGlYZ8P8!45D^y>ys*yc>SDAARdQ^Va#dhq$1?
zouYmgFjw^560Llgts3U*CKRn$Y*-$ici(>PvX~%@3o&G1h_C^9m@00bF8d(G)tsx_
zaz3Jb)efj=7cOAMLfB5CY-~ZylS|{;`-#q!_`_Df5?Mp8`+(LJdj@nWY3%Uc^
zM=TIwk(q?SMt+mnshFgfIF-nbN!&R0ynh%l^Zp@V9Pm&!h8nZ(n_+G+Aq>=0s!o1V
zVR%vzWR(K2YF5E`w(#FncXQu&`Nuu-((?VSFi3u~8+)=F2g&!g5RYRp)#qz5yk@4v
zA(erXW+}vaU{Eay$rYCzVZkmaqfNchW5_S-GkKjxx5E_hm|=|Jiv1paz(Xr8owiB9
zY&Q+t_5B9b3txWum(M@{I=Ibva
zG82)!qTnP2796tRg!q5EoFU#GQZSB+_ITI@28tE5v3FJ=#i8Q``EUUYgXHk>LS(Ni9Lz}v3v_IAab@9D+zoCa$V4&#j=GSL
zGhug%ax%4*31nANb`r+4ICgZy5+!N5A>v2DFO5X+Cn@45k{L}CPy78C75E0DJ7w|{%R_Ks%O|*
znyF?_#-+%@TQ(p^ir>M2Jf>uhHo$o#k0p}^7OMd|K#8ftuR6Bs8hH=@WF=pWxa
z&%Je?d;21L^+PBdvauHQ&Xn{sB^_$6VwkTQVW$^*R}R#ycMj{neCKH`sVPJ?bM*kE
z7}=IMv;J^A&Um#;k7K3uK5{&at>lYD%(^8P#b_gBgwoa+5&ufKRCG8&}f
zkf0a2sUSN^Hyo5qxr7T&8(l+G)Kzkxbj;M#;oePr7|#Ib9fTAsH}ts?aNPjOg6F2>
zyH-i6ni=@#No3=0W_-RdF<+d7CZoDJ3dVB<;7y!=e>MKw^?KnaIH466^x|F$QhawS
zdb%tgEKr!4t%^{9us}mu$f5#k1T&ear)6|J@cG5y24?9q3jPAy*>o$i_SXqmc3<#dRAJ
zx=|P_bec5hCm3UbdbQ1*(S%bN7{7RwR@Qr@Up>pfOTTfEd*`zJ&Yj{f@0Wh{u-rRD
z|I~K5EL{~y-iV$r$)`YfUOpy_L;EwKgSqhOQuJs(wBDkbynLL7mw>TyR?uQ8gybud
z!|qJjlcJFPw-IdFkqkTFu2Z5d1%oZx!mLrIPm@rw_Td<7`sVAue(?6ouirkry}A0w
z_uu*Eo6mMy^_MSBzxhAZ7@cD!&J_|qQr$RHf(}!|UrIuX{lFN4TvhAFR&vapF3MF8W4nrX34wcM~CZN&fZ;jhZ^$+?;@
z9hypqG?lb1719FQY|I3DlObK0pFpGA;O1J=+FY`ba>(oy`fT*yK(~@-u*Z>wq6QhY
z+d5>?z3|H8t>6Fp>F<8^7#M%}t4DVaXWxJG&adCP`^#6)-+TS`+pnDb{#TFx@av~|
z4eIH=t#Hs73K}A!0j3(2iCMF8S5%~xA*gKJnhYDGk~$(zp<=Se@4ChL23hZb-*pph
zpYu8}Mge2lf3pxBZ)7Ig8C54UKARh#&8wig&|&ORfSJat^Dx^~SBL7mwuhV1$GfqI
zJJ^#Nzqp@#vYU8%kbZiYgBovj=v2$ndOa7=4U5i1%pVf%VG%#M;`gFHkSqsXP)jyo
z;Te0tXYsg@kj*^j3iwQZH_b({9-~vaw-%9X7<~WN?|%0AXNbdp{NTNXYX0Nj|9ZAw
zI9gly>@UCj=no&f|J(QRB`}QtKK}T_aL^5mWx)k*!y+2aP|y_yy`mdmib_`u$B`ao
z2QW^BZJC&>QQ)h2CK*PCH-q75uy@B+V?JtL@31E;0(AJr!_-ShFw*%~&vLJvCEvJ{
zK_q_rvZSbS`K>#--XZ#@wmU1*-4*!~r7UQ@yBWE?8s2II!0o|Y=x`x=FdsRblTQ|-
zuiWm^V&NQ5Q?&}l&QNZ(k?cq)3!#yg6N)S=%RlI@)U10v6wrfP
z$nX1azxJy)UwiY#N88={H{bl_rK9~XzxWIAz4{Tq`LYya!EhnY6rsHde<6hm6rjlo
zeVKCHRm-@VIae!d?c^QjtEtP4)EON0igafqcDfSY
zn_(XABwjknzkHl}?IisM%+7iG&GUay0AwA6txt{4_-DC1(?xYD#Ox1FDT
z_Sb4sU5KgkF+DK;yBa5CEee{9HhgtH4o#+Y8pX7;TNleI4rX}P$uPomARWQU
zVe`1g?3VuX!|v~Y{piE@9)si$e)$lN`oZbK;&k%8H!tf2_Q}2V4}STm$1phGSS-dv
z)~IZPw!@hxBRKV`kAOa8<8~NqU|h<$8YLeXmU&h0URzRWmi#N)C6j;C6gEGpwlbNGFSDh80<+=dTXccWnX_cqM$gCO+7YLxf*D&BF4LqrRPg{X7GPe{sM1?!EGxxASjb7J7&1pW1FO
ziy-;-a`5h2h%jD{!eL&nCpVgblg04UiIpHIc!En+|%b25Z
z6Eq2gNK7!tl!okpucoEfNbOM1m4&1Yf6-(}9}_h(Nj=w=^GPTCZ8kw#D?8En-eh9_>^^={on#99SYh+#*
zm5nhO=aUs8+*^`a&HKw)ct5BLsWE~vNJcgm0>eROgg)CvA=&S^iDI1BdC#?MbiAGh
z$>X);Xd^Y+OpUgZL!HdnOitBG0cMKCo$Sa=Ze%+Beb-b!+z!(PWfY9#0QlKKl1M&G
zzj&B`e3Uz1q5OtZCnB0bugKXHitMSFE1U4<5UWxwSi+N1&J4|UixnNoqN@{F3WG-Ex&S}dgs9p$;Na|7!+w$h6vwVkK9=c
z-(HX2UQgaxPaez%fibf2$ztSmDRH`zeCPGYcTP8vLMfWkVktVLIO}pT575oWy|C7q
z7_EFxgvSFa3;<@{+nOE^!3+Y{7rbj`r?aEzW(f!
zqZK4%Jna4V^@BSn#WP&3ac7&kK7q&SwM``wZn!&KJ`9=aqj1ec{L
zWt`Q#x7!q^s~lb1kij8?TAJ!bHWzoLBKBO|Q_XYL9Orkdw3E-PM*m~*){hsvDbm~D
zP<{B`BLJKW+24G+|H`Ai+eh;sy!+@6@4fiJFCRa=yCJe#m};nTJZwouEl}fB#2Vr?
zaoH&NRlIL3#7|}8mQZjqBuu1ZM&;(1gJ78V5Aps%pYvwGbIWH(HXaN(uBAd_xtOY)
z93zI4V|6qVBaOspBR14bjI@#?O(2~e?PiJLne6u+;<~?s!<~4%mwdDnqv?Uel)`Z4
z$wB7Pe(v@C#8XkgW0eIYVS6a(h(je({y02d$Q==#Atj~?tTiY&1=hv|?9gP1
zY_N;-!)aTwXMLuCQ}1_beU6Dge)t~f{ZetxUwrv#Ho`x-efrUd@3nG?zx?q-h2P%x
z<(HrTH3f_%UsUpf;a-7fIY_2D3R4}l!%@f3vqaqF^CPqZ1ZsxtM;J$J=!NNY51W%=
zeKBs@UXb?YxjP$?hkLPCPxG&x=U%^^f8!$m_FcH>(i^vn5a)LvRDbcX^3KB_g7NKD
z`GN!)CEr_*UarS4*AwT<(X-_!`o!bq=w_4IndU(<-1URwxj%gPTV(_|P)Z}6DqKOF
z6MP9Y2ycAdv>~#VXHX?O4ehzp69U#*tHx}&qIp+
zjT{*EHnZ+##?>jfW{dFE@q0=(zT5=Eaj5abz2xKlBx%EO`c+_jnt$UT)Ofm}>y`}N
zqB2ZfCN)+x86F!9n@FWA$O)vz8F?ZLhC`Zi%9@VoQ(>LNj3N@Z%KlhLgJ{|)1!fw-
zLejB1pJl
zhihoWhHKHmW@5OV8k)|Gw9{yO-+AME+cBD3+KE5jOMquu(sY!0cAR^1kiEY{f0Zvj
z|8#pXmk8NnVOKE|-oO$&m_vU5!
zwTr?Vw+nCGDJs*&rC&a%LzCZmQ2E8f>eVs&XSO>l;meiC#Y*^MC5oempm=9Jaj_gf
zTZ*18#ZOn`7psXwWt0o;lVytEz?cLut-zcN6iJpL&VHx}1Q{MX19K7cW+PsOWVmh`
z`hqemA=#0MIMQLdM@JggL$b^?(DMS<-b68NJ!w|9ujiUMunLA@qrh+(ZR}H=LUQ1W
z;WV_DpsnT^VElg+9-{ofxSsVuidz}?bjCeXaNS-@-rG!HZY1z4-`~#M-^o7M%>ZVc
zMNd(OnU{`pubdVj&R0K(vXL5hOAus@GRj4o+-m^l*%A@nTa4Mr8?q7Qp7P41aqk{_
z)71d1H8dFl2sMt&rp4)KKJMt$#Qm)@yspTo3n@=A4aevY33L@J&**%vd2
z-1wL0fA;^oceaf53t~a?%1mZ`KD)P8g&@EC(($j~x)TgcDMQm5h*(52MMCB<-OHP1
zj74S=IV}~ng+(3Nytp+X>v{~!f{G82AS<`3zWUfiuVSiMPoLzynGcT@qocK?s+t%t
zM1~9Dfofv38XKt*#zWOee=R!DN(?sR1MTGZHPtww?`}k&>}O$tz%%N}LHfyI=ILSX
z>0$ovX6pT4zVh()Mm7dz^F(E5M5cvPVFm%5va-HpZ0<@vF~FTo5giO6K9
z<1p2-Hxl;6um`|0{%T$@jCc$?9S^x^FC!AWGjTUXy9|?0Ag~}R)6ys;OvrLV)@LI6
z#a4h;nC>QDf<9anU!lRRJk1!NX313Ft^DGC?Ol-ku>SVFAA<4aO89&klt#{%W4Bl1
z@Y21yy_Prw%*(OUr5H#)S&VMAgpFys;cFwyH5AbU#^AY>#t%;zLzB^<6<2Y8E()G~
z2+T@m_5f*msH})qE^MIRk%St#I^xPDn2-MS8--tpF!m(Ezy9T$rIcJwNyQYes4ibh
zT+s_b#xs>PPf3_mmjlVzLxk&jqPI@jm>%{>h9DEnu+}+GC+}Hru$P2!>fQ!OPTk!~
zU*H$tAVGe#m&U0DdO`BbN4Zx|{xKVCdJIE{K`+{*z{=P)jbN8(q4kF!ynDD+q`ThI
zr$cC>yeb*e_O8)ShIFW?td_aSeA3>n3rAZOnVYEQeY@*rx)d{NPeyF5stgXjj#191
zwpmAv`hJtXUp?`HYUF1>{g?kwBJ6l{ck{Qudi>s7cYpEvonO6q`KveY+&P((IW^-R
z;r!#ge^TOffH}x(WlcW7k#v!hLL_zq4()g_VIr9$zlHCe(uS|!bg92e_=YB2!kJ2SaiyQEgko#
zqyCue2?t#fk@kQ}A=w=iJObwtSQ@^DY~slt;mV>bd(V6G0aGp&{OT(R^52v2mtO$r
zUgOJ8k(|H$;UL{zB57j=B8~{Q+qgza}`2>Ci2AW(*fNHYYv}Pkl1&n*82(>F0Ly$&;
zbUPpQRKwm%*jLR63)A_zMkX6(t4Xm6bkhR9AzA1+S4s#Vxs)WBQFt*}1;*s4X;_P@
zo@W{bzzl%NS}TPHOE<&G1)6#9OwqeP7rq3*o9TO7nTxgf?Tys!&Gh+t;_goR{%+>+
z0i0d##l!rw;{r~ttHY#hKLWASd9|{qYkJUb=g`oB=NVepMVCDtZ{~mZ{yUX~As5o*
zqjW7qTv8X3mTJx!6V>U6AsN+o>H=(ST+%j*-eSfPlk~}urI_@DcpZ4lr+n#{i}gQ_BsGgftJvZ3*lYzb;|NKAx$8-PjKPJcibA04yiKugIyZi~r#2ZR1$>^aW>
z>ry^5(R-71zrZ+NhzY~Fs45>D%SA_Xk&!|O=t7Fe%AtXRJXnbim%_k!upGWs4)rzS
z-&c(vY$xw;C5U8-iwMSrCxab)JTTG{6qt7joD&#FWnWk%yp^IEBUEqJ7iN2PsrB{OG<*ET7hiq;<(I_q
z7oVZPHV8l3UsV9+dKgDSJ}SuzDUOA`(J<^ZoVGVEL2uo;L;x-^A7{(T`PV81r>i2u
z5!5&vb0;JAOw5J|GhOn|*L_)rqtN@t-O8JH%CFxp
zy?$AK>t3yQi2kYVJ$$$Q%!9SqZG~Y4;PjpK)cI=Se1!yAc~WUF;h1M0pDz6MFCRA*
zLK@iTpoB~n~A)0&L{NLHSq=Si+(K0KeJC;h}c9CDIW
zx0obciwU8e48lv75s3*}zJf~Q-{SBx6iIO!hmNmhIjRhP7*T0WKMDnBk{ENp$oL7(bvk&+FVZtdl1^I1(
z;UdX$Gc(c7X{Pg9WM&%uqB3?WbjficIyF}h#DkLwNsV9(l4IgjLe^GuaAF#WVXMMJ
zlcOSim_s6LsN{U*thZGa(=i8q)~jq00vf+(Dk9r_9<{|dGBy6f=-_`0^!?lD(0}yb
z{FlD#|8uDSCu76^ZkT$(sJZU848c(g{s~}ApHC;76JbjzsFip%NS1@zY}}523tqaA
zw5OwHBxDrt8`{12E-n1#y|*b6(@M1I~y%SpF@bRl%Bcci{^yT6lqxSM{kgH)V(w3~jomwvFD
zdGV<5(n;y*QR(495r37B|MbD(W+#_qGI4)01S{(f3D7rxCKf29gknYl+esz3LMlmh
zNtV5m2>g0;MLyuyD?9|i1ZOy)=qjG{gap^}Om%IcSu4is#b{J^C&T`Dgo!G+Mv=XN
zZUiJVc$Y%8FCOv5Nt1!GHyQJ$VxB_Eugn{JAR6tmG+hZHAs3RqWZ0UC(6!=;kPa?v
zvBBKiNk2Quy?VR&>Sg&265-nG7p2$Ei?3dk-?*&3cBk_Co$6cnns484Tpgo-X8Xl?
zmYE
za1ULgx7S9Iqs|8FIZ^qiA;k*71*wt0!dRjA?-;X4$c?POTjCb${J~=UWQFF>PL>lV
zONqn9$i+tb-fq5Eceiu*_HuW3vKJf4^R@KVVN$jqDe^nj%1t%06ZMR$k)3SiG+?-q
znZo``jf>{jUpjyB!CppI#f0&=sEUdzV60ecTS!^M9Ol&$JE^Sq@DI
z6}e_52$FM2596QW16sdV?Ql#w?Gr}*pk}IXeDwLT;s2T#`}x@Lf2b#(bK6F2##=t;
z81Gk0oIwbvL2@?fh8jbP1!jT|sDLr{$%ru>HF3TXkx>Pi@sKcqpM*Y>O&Q;kxiL=p
zG&a_Ilk@lSzCO-{KGqXqkgPB~&}*R5!CPtJW*$#UeOHI-ySDo~
z;1s6;AHxfzkZyGL;V1l8)wO4HxCWW#sjd{iIBIL
z7PARH6$$ht7kVr49!Z25MwA733Vx)bJ!$PR33Vl^BRy#ax0HLSly~)BMz4%VnchCC
zJVRfKc;XQ+DiQTTlT&f{0@!=DQ4H1!0_a7+%f#H7m@64_Btq6?$d-!GX9>*LnUmG%
z)5Gj5XGLi5Yw*u^D=(ktUpdP|gkQT|LA`#b0*2pt(0=E^55f4Ay}~=kwKw*QPgbJ8
zJSzY4to|6RuHh_C!*HIjrf@2suVqeGKy~V3J#%L>ceF^edea4Qx+t~sK~y6v)U&X!
zVlBm1vOx-~S+0@+b-W6j!Hzh@*cLjzAINMh+MQ;2>bWQsW%$mCVe-RL_?9wYGe`oIF`g
z94^K7=fh`f$;<8BovqyYM&@EY3$uN9yFdne4Zm#a_QtmtV|I($Mq1SXz?n&)i)!Vx
z%`8d{p0P)}Te7rr2D~~SolJ=12}u=`=w_6?k7z)FA6j}5r2DOwmAU+?#64Y~oBbJAoSu$f0(_HpEA#xsF}dV}PU
zpbtwXQP9bv9#Wi3IeYO~xx5K%>v;cgkR9z^5uuE44fFoNAT!9)NOgZO09n4(!#E|Y
z(&3SOjBYMpjM88=>@@2C0GRd}@z&p9z5#vi9jWi!?ro<*GBo*b3}0akO@6qWyWC3O
z-^<_LqE56~7UMCft~)Ne;*tw$Tu8As{MB{`m&SGMJF?4S?{US|%R9-qQzI0l6<-GLj-wF&vjo-MezkR>;*1gud
z52t&F=%3o&JZrpr(Ryhs`|e5O>012RX5xbfo!5>^54N*sD=A18=tTkMUK?ljgFPBc
z+h1$9^HMu6w(~($omdJs^TBEk#ZxH*$OyOPOwVS6QWl!5G@!lo5R@vQDpN{G#ZcfR
z#q1LKb3DX%5WsLb!$Nx@!nKUh$e^=;8V73`v6{nQGe{VtNRxpviX@tTo%Byp}xQ%v@~dZg1rd7NbghNT09MZ{0gez3oS>
zth%0>Xo6mFn^gnj8Xjh~V7Q*XQs#CZ)|xQBeOQi*<8f(RVs2DAN`um=sI!>%x5^T-ahh(_>dD33Is74_)^^Ezv>Lm!
zoj`Cff2@~h|NS1+K$RqVm=o0pAuA9dck-+t-hhh*bd4=Qh+G=Fi?d1bfw
ztBdxlyZI+;iC>)7KfFKpY^U&Kr*O6ej5DWeS?p048@byX`LlH*xmyZ#3i5P;U~U#f
z(m+b8K`3V>1Cr6;pumJN4Oa2JHaX-pF{wNmL@C4qb>(?rOkWL_@!phBP2-zL6%d;e
zt7);K6d11HpTIwq6>C|kUXTdm9Mm{e&jMqa{B~Y!Ag*W7r_h3^TAqceo-OmItNHWI
z95TYua{Oo|b+D8?Tuz>@XHV8LXzVY>&(<^eD*CKb#d!CQQg8baj3qE`q$hh-O{zd|
zEj5J(09Mo(vDtw3$xivh-~B2sje%Y;jLIj>FmPRHE2q_2=cQ1n-_EOb~o$>28q*@UNeaXhW#&-h$$_@wmY^oPtFKVHwgykB|iv<;ZwIcvVWS9tGY
z`ssT5<&Df|FE9S(+3d@ErSp~i2|V^{4j98=pReW4)(W5e<>Sla&2BXUjHk;X1!knv
zAiOS2FI*2mqDDp{{76xWVWl9y;9M-y;Ioo}p~-2nloHD+v62+=u$ls>a*0O2(IAYe
zK`%gC#>?<+DIuqW@K)$AKr(b#iOOOQ*1t7iXAO|`v$krUJwg_l}}3;?>#KXRn_EVB{9*+
zkg0CvbkhYxt3b=Sa>@tx$E5LSTM2S&++J>9s6
z*TlmnU<|28?;!D$5K0?)$t{Y1rwJB53@x%<2MhkInCAMNKJ9~B=S
z#N@j1$aMgg5z@7k3(engdht=1Q8}FWX-aM@T
z>b(BjJJsKwWEEiXuu7VoB9fH~mNG$fvgNd-JWp?=%E~1?
zgMCIS(?h7Spm=z68FCNfT9!mxao}7%&DE4;A(dR9Qx?}c(Y>WKSUp_I9IxaKmeRZP
z@$K2zMkjo>C*k
z7;b0v?YzF8)84yS`t5Jt&L^gN)*2!V-2*ntz|yG1P5@w$QK7&vWD^es|5&ZytC!f>
zb{Lr%QXC5EdpB4N2DE}-4Sh~V9JB4X-!;w!)B(53?;1tN&kfFP8c2)%Nudt~U!4-Dt`60AZI5<~5BBo+cXN;SOON;RkN5MB
z_G$n45Wc#kRQd5i`N3ZK-s#GhUw#>nUL{-LmyCf@KAYroNv2r|r{msK9M2QI(GZ+7
zn}~Diga9&8sThYZrQ%EsK;jvNYQj?aKE!QY=mFe&m_&a;4I(@qS9r#ER^F0|G3f-8
zr)d(dko2Pv_S#i(wjIH~nqwitl#1y_>h!4yxrA$RI(WDoz1WK1-^;#uT1LHmQGey4
z_Uc9LwaW$=es)%UbXbD>czj%WcvO0NT7U7B?gjtPZcjIIk2W$-wsKE5^RFG$-Z-ki
zaoqmZow;9~*FJtY{f7sgXPe3QFPk5~H2?BJ`R-c&m9y@}a`xVK<#N0B+LNTohD;eL9R1ag30mI`G
zOSi=e2FAefOfwjhw2R#^0xj>uGZSG!mrJ=g?|4MiON<8SMnp4WShFI91Y?lZ#X>gZ
z=VS!-+f&H+5RBodGjT^5b~BIyrpqDdjvu{LOu^Vc
zNH^{Y3af<6W5Xkln2oGqjr2
z-C|aYODd_D`SLAh=DNjjnVIh`W-b+qsap+hvuA9NclI|su(La}yKn6KeNL8Sdt-j%
zw!^a<8_^k09G#naGA~qq^YeVqIhm4+j9mg#Hw`$!4{PCyJ2OyfTRA0vRd4)a$^LZC
z{QQpf*#ep2PwrShS+u@bw4s6$@#&KN<3$^`u8t9qM+WW8!BTFF0F8A3GBPepr`do?
ztJ%<|1+L{yL|3MBtqN;e(F{`L0#f7z$;q1$m=T+yn60M?9O|7et^1OFE5+w>sc97J($rxT`(fWfM~yb;Q8)D
z?-%#o$UYFCEZaC4f3o8EWX1U$-+K9X@y0J^OrY`e3H|d)p!#Un*H{!nLz{8
zJKL|C^ee}`irIes?0|l*Uq92Ynd{Rn4C?L-Y8MA|i%6}5o!^<&{*TXtKU~m19{Kg8
z8Y#3zA#!K{%XxMSpXxU)pDsB*xnp~F$NDjpe8=*1!3;5T0{#R6E^#uxV|}t715!okpgT
zH$a(ss8rdkSIOLt9#s^OhGgW(fHCgz4FY;gf0er*qaH-4Fa|E%=iM13$Re_hQ!mokj1bbM`0W+MhiL
z{-;ldzPw}o-iq&wW&dn1T`TY186EJb2izJzWb9A`>}tPN>9Z;WHjU4sLb%PKF_cVX
z_858~LWiN7l|6P{H{#{XZiv>Y?*>t+qYIXp9SITkf_ce!-ANU%MIT%WPfYa)j{
zHlS2=h`QS(J*}BNty1>CuE5PwU$L?)4`o+NCerD)MsZss%qr#Ec7)UdbPY1;d9Z$G#!>Ey|SX$(}64<*8){np`rr}=e0FL
zz?rgoen*QG0+!YBSUOD^HA|;KWA5418SM?p!-1x$fp#lotRfVXhI@oog~-w^L~t4=
z8F#@Cr;&i$(=@FqSi@+X%>7coartz`{hZiqgI1s3F+<55lQ|AkEIUv~Uj2B^bZ^@D
zw}1VYKmNfBvzCx((6njQ&00mXUMVwZ8V#Bzv!TOc>~va{L9fxECZDX=v>LSSdQBTt
z4b5}1XF`QyTM;VKa0}Nr#s$DjCG*T^rco2CY14W}jjX#-r)n~4+s(QbyQ$r6>+rjJ
z+;%uUnGxxuZ0``tZPBd~tj)n19NpnT$!v
z48<&d7aGee)9?0oBd>-%{&>>-!`0x&Q^rqFpD}%B!TqCqy+6F$_mcG|Math)aEe&18}A3H70^pAS`Q%PT+jp(ZQJ@x5}jbXGAmv@|h
z`M~`jAA4U+=^u`2?~my2kLvEyZC=0LQw}l6pYvZ$D>LDr
zT{`iKp4R$OXjsUpnZW!Q#(Cs
zF==Yr8#5tS2-R(GG3jdLorP_(EV$p6dXZ6Eg~o`^=A7=f{H8j{Qt&FEXIvLlJ!mg#
zlZl~WqyTIap%`8rxwNbJE;5FvJ)ESWDEgwN(QW6EIDwNKV7ihn>HN|%sm!e2gIpU$&A`INDF91FpYIsjXfr9r$yfd!D9_dv@~eip8#D>fkWF1xw(yxKgy+jU7f^huf~O8QWae4yPGTuN81MsNtyV
zNy7lLw$Wv7n;g>24QrN1)pPxwD`V=X^JXyl`Lgx-GB`}CM)?VYFzTPIxSlTBpDj8*
zUUotD+)wmdEs-})XC+<^s7me)%3sV_KAtpvJZ*V4X?ihd`2;Vgt>Exy3+^x10)P2z
z>?aR`U)*thG4J|p&iZUz_t}i;XAk>+bT9Dz`vW-CqvgqAzkb+n9Pt^4yv9L~VaTly
zIv{4inG2=Ytn```9*YuUCOsq5*26hN&#<*UeskCAxMLz{81?G!&G>^>rBer^+ij;j
zyqjnY6dS36mn^SFh0HLh%UuX;NW#_aR!s{{DN)m$lOd;KzE8ieV6DPwskt@xb+yW!sYx`NI+Q!(sKke&t%f;{K5O;fVIp=&z3(+t|>HRVgv`
zpdv+BNyz|L7HG_5oaNHc_>*0?-f;~XfA5R6|M(w%qV3G|+UvSn#2rmSoxG5H@&>2j
zwk8pBX{_mK%LRv98^p@aLZiB>LzdIklB=fwTCEBxx2#?Wf2-;#>S)OVUFDtmSVmEI&BwI^!QEPnJfHserY3%CQ(8}(
zK+(c8_GCHeDB+BlW1HK8D|fq1+hHP=
zw!)7=x+Yx**;mL_P11#2&4wD++fd=^
zMmkz6j*KuH+ARj+i5Z^F)a5iIGi)(yo1tOk_Bu7*y4j#=(#dPpJyojC(g9EFWMB8n
zm}Yfc{b0uQ{Emav%jtF*a&N5;_4Fev1zsu0;&;rrKXDjg;;eno+
znBAzD6mZdAV>dM1Z|}J?;+XC=`pwBlWu_58rb$kjq-r)(!cJpR
zQZ~m6K&J7h|MB1d+v9sSWFzP!Dx=w?xgOjmV+o?x0Z3ohClD8U(H%S^Rxr7|-#Q|}#uoye6rf#QA
z?zDCHdi8#X%5Cj7>04cv9<{tlMK>_kC_1X>iS3G7pRIMGw|i+qyE>tHGH-jbV0(TC
zmnUeL0@CGjX;ipx_jJ+u6lwN~`^BpN(d_T?WXy=`r^2D+t7jrZ&Zb11_i8E@105ev
znV!#DpH7<}PwAe|+8<9?o=n;vPuV`6cRyQjKNvTDHt#@uamNECznF7S&8%?Bp~x)G0N(4!minTCCqA+HH3_ki2b=hOx5+JH?PBuT5haLy*B
z$4veiV(xQl`yHAAmu_yzHR#qm3|%gkJab94gG<8kk_9U8%rrj)j#|yh7#e0B-TJmc
zr()8loN#r|`Fa+8T~Ei2|KVQnuO51Tj#Fh!eScWJM$*+S^(mM7x0RbQtTge
zHJR1<-L2wI8U455-86|xJkl?(uS!Si%T3jQVvz$k*NbG3E~mpf)}>rWf^2VuZs|XE
z@z`2Sno6UlLL)EkkY(Z$043uf*s-ye*HE3_*^+HB)ZkhG`;B*LY2bmqoQ%1y>Ghti
zMqYDWio8wK)s&|1p(~M7ljGD#?JBWFEaTA5s&_a+!=Eg>DYsm-e|gvYz57tI=R5aE$=_M^ezEEUrLhU-`O_uGr%TRf^Y%w`
zwzWyqU;f3H|MZXl#cigM4C(@9bBT~(+l*b%8>s8Dshl>2&!ux%6c$4_1k93Z3L>o<
z`s@INAyg>YZ0y!)+Bv~DKfxkSe{RW;CE456G9t^s7^bhqLCV^R{P;b|4pueZJ^K=8SlH$NuyVRcO;4
z^211{A^1fkfz!XsLwurdoQu4ECMx87#PxHxubqmxcB(=eGh}YKJE;D6#ttAqnlwC|
zFg_eNJ{UJW7&kwd#2V|9X~*M9+kBFP{AL^SLLGv{yImRFAmHJP&$IgC1ia=^1?12kizf<@Q)rJ_5B8xi?-0%qlH
zdQuIq2pN-TP|^d
zo20!_2pM;`W+J0z_bSqCXKqv(>TM>9l7N9?fK)9nG^on_t`=Dx9~y3J%!Ft;2y1$Z
z_n#hF+1InTCYtQ|N5`~;&1=cU-h|FE_0_v
z+YCR(x;?v)t)YUm1R8eR)piSM4-j@*RdzEZ-DT8vfWVYptKo_nkYSHW;jJ_@MQ*uO
zt!##>v4$+MhSuOJfb89@YjxR_7Goza7Pum4*c=kdw>2#~19%>o%m
zg`9dNs_;q4Ji9o!?QX824s1fmS%K328_Q_&!bC$sjy`eNpves=f2{A~3n&!-j!>?2O~
zpk34NAn^7(^aCt_=svqH2mxEvL93?My57qTJ55=)Sq15OEyQhv*P`~AlwPCKX;8ZK
zN~gBlp>FkPnul#YGk)FUN!RCd_Alma-&t@xpEBJWRIl`_9t>(845>lg1y}2f3FG&c
z+>a*Bk0-5nhc!>8%y1K{{lKzfxnH?5pjsK!tPB#X*MBCqe8T{9$TDiPLTr$Wpk&If
z+2lmz*v4+^{bDqRy`=tXmR)Co$u48A*HSRrOaBX&U0g
zR10La!urZ|q~cIJf_tDmlnf>_F=uo(2|8qg_T~(ED}UVAWLIW;bomaI)CTjfV1AfW
z@A}<{X()}5ZW{&cF{I1z3lx)jIVFE}8b6tXGLb*KK3j3YBEDF5ezxrXY}vI=<~7fE
z?*+d9Ac&U;XdA{7r(AtyP+Q*@Z7HP`C{Un4@dBktk>c*|UP>Xsic4^}0!50uLvbta
z5}?K1-3cxUmLNf1e*gF3&AhoY`E<`DGgY%~@-3@1K&{WqaLiD|hWMMSO4V=5)ygIjRM0vgJ>Q7DGan9pm=)6fj-3
z*JXMGuWb|i+qH|sT$0qp^=rh8YQ)>6RYIedngesF6!Om9zA#=XqvQ`x6NlsOH(cM&
z9k1FOVK*m$I1!aI`_Y}?q`>{MzRcp>Wiv-^M29>3{l%22=6y)PCv`1$u+LIv5KCQu*7kB?VP1R3-iT0SN1cj{w{%?ch@$>!3v+e#q}w@J`<lwW8tf`1==+^u`6Hd1-&N%eT_sh_e;EcWT?
zZP05oiWIv
zdaUqIshBz=!Ae%|1p5k0TplbU^(^>9QGHscIo%@;|Y0}srp4`s85y);D#@F*la
zIDj|opB0S_Zm=rxNN4x(DpDObNK-gc{PsOjCL-+iDqMQ$n6~-)r*tIF6
z#k90H9IpN`3SZ96w&x|2m)EnJX;xg6y*oGEFzj-28bnwX
zUk}+m8FurS>fx^F)T7O0OAdgCI@^iBwu#^wa1&Op(`X*GOSz?QKhg|3k$M+!ez>~f
z>v2xw?|V)2wEY->JS+&fxx{=rgCL)FCur_d#f^~F0iAd1;$UQ~co)*>$@f(J$@8$f
zi~n+;20y@gpi!VS{kr0Z#{28_z&q-q*ZpBci1wa-VaeUNGV4(mA1;SS)AfgJjOzyi
z$kA`a-_k>9+#@v3q!mADzD^65ljGW!1d~Tur+n{T)Meelux9?h{Wf?}nJ7
zlpifw!4+dLcL*Q7eojPS<<92FBtZBFQz7!l7<@VDcUJuFOnL(P
zH9*RQ%;~#xhK^mcAVa9?SL%uFx3ywfbz%mNzI6xQwI|P=#Q_+(Kg;7k8&eCXA-hWP#ZK4rAxXfZXnU9!F!R#P61ZJgeU
zs^}RQFLTO1
zWcOtp!BNi3$_}){2Fv*WlvC3q^Rx?k&{-qcT)o
zPo#7;mxmRbSKObC}
z2my%tAcqA%-|qD#(vqqhi3iYKZ6B_rs#){{wCBE;9bHnZwo5{GX-~1oe5Y3r7uF9K
zI1rg6$T4N~l%Hak7vc8Sg9yib&}^-Fh{72IBXUEQ&lZuMwA
zzPY#Kf%fKuV7_ewGPn22xu=bz*W?3KqJI5NlG-bAMQ+v-I2z))?qWGLRd@%mE4tV~
zZ+jQCQz?o1#R|aDT)rW6f#dr4OPu~|D*__uI8gebq1tkFPS6H)U3&ZkI^01_;=9
z3YU8cn1|+w=XIbT_00`Gm=0msYj-_R31^75O9Phv=X-MRHDUHN9gN8TW6yoXh?a}h
z<@|EDvLd{`W|&`bh_O0H)cavIKF&oxzdE}DrKx!uS+#8{yQI11ClEIK-ncH4UvnM&
zy9G8Zdq-}8Bg3Vj&I!RiUiBL`X*Iv@Ldu%sVxMe$OF5_-Zk6iQnB*c}@WyZK3?2W1
ze?`fdV@GHeHlrrwF6sS%J;hkJQEQo~7F>FEzb@T1Tb-K*D%1m^y}qr(*P2ubbfcJm
z;YvmHtldBu#?5|hK;lCSSi|1EN3;S@8;rn{6`A-}`{<=sDKD=^g71oGFSi3t^7KR@
zdTK50@|1u@q0?k_0pY94KHen}lao_;ZUozgG4<8Z&uyPa7%
zhX<+DsV3VOmAzf!k(Eh4oh23A6o=oko8>JS-hnxwkl);97P9R!>+Ho(n_cNI;|?tf
zywNB=(N(;b;f~W1=gzN}wb4kP*DaQ+{TfjjwRP5Gon4t;YRqu73Y=|S`vA2bImufo
z54kdm<3DFz_HD14EFW?@a#_1$E%`DGok>{aCDi7ZX;(9T!4h}OagOYgF~GL6vr^aP
zW!z-==I=%}fnc#fzi5Y~AhlmnINN<+n1HoN?5U>$RC?Aq7D~JJM;f287_Gz2#;&25
zv}TJI-@KZy`+mXBJItJP_=O9zPiEk)Jk*(l3H0q14$U^{QSdm&7Z7OPRvzVzEo&UeP$~clyUBV
zIvQxXap0{KtQgaX^)UR3OPBanlp&;EcfxXHoivU;0q@AaM3Of}Ryc=E
zD3>E)nHE`s(-j$onbfF$FDh;bdvkcBrTBoy_gO2%r)>Gt>~?sK~}G?ax}HN2v7{%D0Mq&%w2l
zr&7{2(?sKNpP_l0D!blLeT@TnN?*Ld4WFN-e-Y+JHJDX@l^tT56w01gE1wS|ux-bv
z8GBQ&s0LC0B3mpg%T=r)HQnkC$eD?QaguteDAeHm-G6%AIJ~`E&iONcmjwONVt&S*
zJ(Tu>)r>f{0IP7C4d%Sd-;#C$3QxA^!)&gca_v9I
zgu<>~?DkE{sfW`RZEi_wD>_nl3>xx2b;m0zlEodNw-5C$A>}4rH;!Pb8;<Px;5pyfI4{
zHH=^Fnqt5IBoZ>;KGQUZ#ck>@BPjmCD05b{=y2P01^om%5Q$LN%UX@Q8L)Flxy0ev
zui9TNOr9k`&a+OpqE7!_!4h;pH+%dpX4PvjT{U6h95v5NZHG0H0G_Lh^p%D2^-lM#
z`DA5&j$E8pXZD?fnKzfaE{sy+xgGw9ooMa>P>!%avOqgxVLTa!5YEO>FFBT`3}lI-
za`}{(#awMMToUk^DhoTUB&bOf-_a)H(8VQt8r|K#T5-*G?oO4ZT7S2`R8(#^u1Dag
z0Z+J6+Wk0gMc{zv_io(Gt6luX*TL>{bIB1r(A(hmcT+Cl
z;}@=RrB2=6$kOqMb28fjzwCOy;Ubf@VC$^jrV^K`l1l-IXzrgIF#sGa@z{EV94|-Z
z3HT6Xd3Sw91k`Rn`7T`_CS05C6h#^fq>oOdW^d@9Kc1Ov)C)t00>?pmU*iDBRu-=Y
zfUnXx$*h|wrDUnFErme*TASwWF}Tdfji)vlp{lp_l8Wm0T(-g|q10X4M6MN>=>2)W
z{TmkExWZomuw#psK=xOenIF;DV)rWXEh}#nTr1FVOVH{a)P^`xtY6>vB_JWPJJV{8
z?-*X)Ta9}M^sA8uDIQ-Oz%DkDK;940r_}*Imo$$Cvbs6-1-|`LjY7t1oo?rMKZ)L4
zj*VFMR2jASZ=Ezo?z88Ld!3)0SL~}Biuzq0rJLzZP`A1x6mEVdZjq|V00a}s{YB|n
zWN1H8xihtw*X`dm;-G(-bY3mUK09W--*d`!diU=#EfmmC8&+0fJ(dsY|XSsB%iWY*!apsV9MN!;wht=#qiq&e&yU7X@Jwmal*P;J?r5#vpxoE-E;z;PlvU>t&iH$U-`bc$NxMppN*SLv9#rtTJ!DuSZTh&J-Xc1E2>UoL9Qb(@6{#>SZ3lDkYh}1dtLiA5;y?E>&eK8b0HxK{Vdae3{_*%FixkubF*N1-Y3`-Un#Nj(+
z-cU|!;xFhdqvE!0RNk#?zds)eyJonf6SOFo9L<(5M;-A6m-qd)n*VfwCH9h6)M&i4
z9M$o5=a_@RI|51ZX?eC~CQ1hZ7tOSqAqvaWL7sjMJ|jSSwh}hqqWMGF-C$eC(Erw3ljIaf(dN|@
z$z09IBxvTf;9npW3z$T8vM{6!T5q*gF=a7pPw8^(n57x(|9auoY<3$KBT-Fe-8KqP
zy|gqgSFa7)e{T`!UAL524p(F$%H>YifU1e*c?t_!x<*X#9|q)s?Uep-=icb!+O0gS
z_&fssY8k^PCdB+)+T^DI#8|-fUt!GuYoSVbV4#LFG*M9&N0BRqmN!z7eQS%(sV+%<
zjyJAyBqGYhmim5>8h!92?+cS?sMO#)33u{~K=~InQ4;g^U-rJ~+N}_{bGkU6tl-V(Bs&wXy(10Yw~?t?-hzG35^@o|<$E6-W|Vaq>&s@3nVZ{oE7rF@
zD7_+JTpv`y8dJrYP{d-}T&tQ;b}qLmem>0HW#ct_<2n9dwfv+09!r|!Ir)w69I8(L
zG=lWoXr*|O(t6{|_Uz}gk?*Yg@fpiBV?xv_272U(PfxG9~QMZ=4>W@9@
zq)&TD7x5>%drbAP_#fig_492Ce$X`30J65Gx$39R(M46AEL!aa1%xc;RgnoUG}SH0)6~0
zL!&7kU3-oLZo>3psOlQ@1cZi5z{><-7yY-8R5j|SgR6)cM!Z~MRQczeeqWsic`zEG
zT%zXdy8RC5?|Of*tIf!sE#m%gH6;y#u6Ld{(u1g4yr8pN%?NYzUgd2N`HIa?&gQV}
zVXWqtn3R%-)Bo6Fz1blCD`^wI-d!7fyiXBEhqeNdg%biBpv=>s)qGK{Z`ugL90tp%
z-1BCm1$d?1=W3+aKzcC(nwl{}I^mKP&WlxPXPaz0MAUN)>cU6=G90?TSis73=TlvE
zNauI4>xoPg9M)Q#9`7qhXk>q`hPS(MBPRh`Wj26wraARDIZjM1ux%s!ni!+^^0|q2>eg1@C!PKVtyvLumOfVO0T6>a)_d
z+29X+1BIgvlEyo6d0WpzBKwP&IzkC!I~UQoDx6h*QMNaoC1Q%H>NRQVPQvW#C`OXA
zwahI)PQwr%sa;oQQkLfEW|^IXVwM>_)*M{O5L_eNfIHuV6zIH$`4aEa7yBmJK4^?Z
zV$sstw_X#gcSmy`h3P(?{c5HhS1KLme-*Ej6Iz$PWjRA?Fc8-OsWNcZ&MdNOr3z2p|EO_nYTZHQ?>sanva?B!?=5k1NxHI
zIw^bt_OkOUu5a76kAIj2j(EC@X=<1@!iQ+Soe0s0bv!N5_wTpA(^n5m39!f?jE05&
ztK8Ld@K-Fc92Z}wYLL4`yNI~~Id5fDCP^4vnZ93`{^jQRdK3g&Xm7rHVNAZnA!Fqu
zVCg3UGOuR_s4q1r%?s`q{?1{sO1sMy#Dg#Z3@z;6Ue01XgVgX@>r-=YUP`oagIk1{
z7=!PY&?Xo2lcoaD5i9Hl{Pydu=E&lO^+jyX03@7^g3mrQ|7k}Zlq+s-U%}P*R<)IP
zQsspX@~_XnT8==##o|(;`~;=AFLWoqo-sCC$o-}_Ub;j~q`?moDw@gP*=n|OTM$;A
zCFFm86Yqh5ig=s^6Tv$DF7KDXnSAI|$qC=hrA?F;Wo`9>wdYReJiOr9=ybIi`$$4AM;_&FanBf+A@tCZoBC1f0(_j9Xrju1C{2p+Fwy+b0WKCGs#i3lb#-EOf
zS+utX?d5K4MHhGZ86y6w)YV_(Si`ZD+lUECy}9{zY)0X>CVJJO0JM|>-)Q}IX|j-m_IGG!4U
z)U=(%fp24yq3Ee!GRIuwdwTNHN7`_gTbpowSE)g
zREFB&iBy>5;wqcb%fV{
zXpMZw6Vt^U)%p=5kqD%;E$uu*=Q2%KuifK3<3M^rk9*2sJZslw@sH8c5h0TA_@iNR
zG?D>!$zVMBuw=7&*$Di2*lk(ymvrP&J;gVd6*Fhli(1;5yUHgK(dcx%9O7sF`W0`r
z%Hli|<%rpQGUv#4nz{LClZb^ub`5)sL5kepub2PA3E0q9P=$rzkVAIP8P|YclpH@?
z$3s1T@tFL`;p{DY`@eVn?H+6ZCk;#=Ao6%Ao=
zUVFS^u)f%`8_nMYlB{*=
zY38@T*`txk5;wK37WTdw9irE`SRz7USJ?Z$M_PU(z++%<
zti9QOrP=;+2p=!|@eF*8fQk9tOoqXzMZ9hvE*WEBOLZ7pt?qjQ7iYKucLUAixvE(0
zw}_ZZ*y)Ntq9+*O*7vLbS5Bz2tXWxW1#m;F2*iwYu>AavFG)-_(r6}Vy1?PW+Tebf
z&p@xTwSKwChNmIfHdFa~U;f_opW^45txQEKX&KpXnH68F<8~1QT-q%5x#W?K{{(b;
zLJBVPNI7H-+npiP@~PrNF2}JVqPWK=T-~YfuIy5oEY84CZNo|DQ!(UUmnM!wSnR2zia3t!|
zC}9MYanYJ(3eA)c_v=1W3f&P274dec5?iS%@LjQGmAX5fBK3Y<`qnGD50C09egCsY
zY%|f4fD#~QMI+qy$BM@0^nP2Q5m&e1Vs_G>@upf!RfA-@4*D^@_?bdYdY?D=cF)7~
zla8Z`49U@)ipkp*MnAw(^?6t*J%Q2_*sq&uo=!5Za5cyI?)ET*aj`W
zagr+KIsD>|?R;V&$lUCr-Ghyx8O_k)FTbB=#JQ8OK~^X6%!85k^+J#S+0ug}HE{O&
zJmKk<3N}y(6en%4n7Y1-xjyf>p30*55Fh{p^PjefLpt~|8kY42s74CriwH(8!gt3@
z&8=7KRC=3Oqu!AWL{(@bk`*b2F=xh+Gl+KWc_jDy&x-LgXY|Fug!3ROlGIkiPj>g0
zvI0P)Hji9fPxHT{4XWnq?F3E-lqIWvZDWayPL%992{b8>JrXnX0Yv=f;Rk>I#HOB=
z#i%%*?EgO~vr()sUi24NW;Q!`n?d$)jV~--QNW`?9e5KR=(dljkq8^YrM6|Wv->_t
zZnnW{UaGf;J+K@R--Dfad^Kue@4LnL`hi&L#rplxS_r1csYt-dK@%>88kJz3Ur(qD
zV=R@}6{5_HrW0(r-;PB1x?bF*L*)6uh-G-}I6x-F|LWi`xcz-zCQbIw{>Pn-$AF$H
zph}AyB>U8$UTa&69#ky5p7fz#A<@)%hNv#l>_VHcj;NqMG5?mcnaBZ%)9(0%lGJSv
z987bv(s&F98HsrdY;Oz7%ks@9gGge
zDU(*^iU&ac$v1NtwYlAHpW3FLb#}vcFH5TYToL_!GwIBnKzqyTs)6bCmPhW|pH?bN
zdx4`b{@9dEHuk)nq2EhOvldXA2^E@`zV!Vtr%_h?^TM(8+uAT{R{QAHcgh4Jo#>O)
z%wSXu^Q(~$vgjjWZnvo89d=c{%Hs;s`Gp2*4MIt8)eybnnQ}HW7TW?L-l}|}e}jF1
z9SM(5nDtpz^htQG|K4^_mpJAUvFtiqXxSk-27b|k@ans{QUNYD`$x0&vg*?X%;}*B
zol`ykaCP;{nvyTy?Kp_~jP?f%i5S;O`obc%r5UjD^oO<*3MWslYC0Oivvz8-lFm#u
zvpQ;x7Yp9ul)eN|xuAbDKHd6*q#hde3c&VXd~p4XyjR;?qJqs}Ow?mcBnsz*UFMW{
z+{f;tf4ITGUlz}D5leHTg{rr~)LOsLo>*UlnUlW4I)rxvU16%NwS;#8&w@pdJH%}R
z1i~P~G(BT#1{z}ejv7N_sX2_ts7|UTx{c8BvcCoT6k37piB-Fr6zrln=zFyC6Ruqj
z-V)*jv#NM$19#Ctv--N$1_8##_rjv;8Q+q!(a83d6YFHLmh!8;>-VeKg`4cwuI@tZ
zGn?&J8pu$MyP&j9fssiqn`2aW;)hgrdMIM+
z8j&k-f%d}dZgC1M>|y5viRKQAyR7Jf*0{>v4n`3N#-_M{lKa$O6H?UV=`Sy&g`|Z7tOR
zf^Kv>C+Wxg6F_kf_MO$+V^Xm;-@DOUB1U%8ncK^S@ofB7*V}niSHVO!ZkNC4)wDcq
z>V#33E407JWnqF!J>pe7zs_rY9c^}Sdpq-Q&7@zw$Kpf=ooH)PRj;0N6;w1us^7X$
zfWO<`d<)`s^E3HWm~Sl&jn?{Y3*ojmBf795|2}^`Ii?kr_(Bn?S;s@KrRrUrL{UCJ
zRga7#7IwQ;W3x^cYQt)3W%pKesWB8{XDktNGc4m~J4%gR`$=TM4K`VWi~7d&#Busb
z`4YZrL2pyF%*EZU7*M_BWwTx#aWmnDcLsgloj$cz(x=n-V=rrytsp(Xrg&GaVkYZX
zRm8oq8vm&}@mpI(;ZU=e6aP&uf1%=5P|M_K;b+BZRVPy`cT_W(;UIlq1c6t_0iAzR
z2m4B171jChfN%LN+Nnx4wUysz$d6Y)^sV5~sLQE8$e|8WNv&LGku3P{zXgIc+vgom
zTUoHb9s7?_6i%QF86OYAq|gLWkCN<3gs4p{p|B8C)qrMPa!5_#Zi`2ed>k?LI)dz&
zhSntXg0Zp!VsT?xcziZ}*%R98|8O7ZRy-jxXPE=#S4SN7-u7lqZN8
z_ad~NWfgCylU7G(RWwaa+`su-IH!E3<+$`vET;vuY*&KpJ{&qcPclhvwwE`*BpJ-q
zd01}d@4}n7zmrqAgX8+}IfSD;7h
z*`2=7f63hYC|ZFyO0Q2<&uw#mWZfPv({{?!qrk5B#=QXAPXua`O(N2Sze!JI3Afl!
zCM+(EsQWKLnkC=qixhP?Ghp;_^`kf3ug-K7B9j<6>
zic6P{d-VkMoEy#=EiTpDRfbS548(V9CK4KSNjM+EvvS_`j}FhrsgH=WZ*gQwazhN$
zrDhCEdlpvju)_k>K5z!?S~{IBwz&=Tiyu`b3+xunSJCO3Rn^wBgFWrAgduw1gN6_MQdlyY%O|e=Hc$}w?*%q=t)wn*W1XR
zj{*jZYmHb;M1yYCs!~;x+}}_9o*k;S*B(B;oxgeK3ASci{
z58Goc7ru%P-Z#81E)xxZ@cfIqsZj_kusyB4i6ds2WFXt6XTDW3#N1?2OxP-$`m;LR
z;3KlK0IgtQH4j=^&idx9#Ya+$lKt>RXNDmRedagzogbK$-=yXyr!XkJ2vh9Omof3a
zx&vLUuugt%XtRgxRq8k_U){+ud5siDXRdpqCr8Jf_wzT|uZQp&tb0;1U#H+^^7|tj
zaX0SwkVtpZUpE(Rb$j`vT8iG%)(%R&r?!?8S%SXryu}{>Vh)Ilba?EKudOt7fk97G
z(y&~i`^PeTu|)(b_)DEq{0i|G1?>IJPB78~+Tp$RFJ2l(EqcYCS?z?p}rCRN03u%5lF+hEDymVMo$75x-0iWM-W`O5a_VxO5I}HD64VA~b`K*c@
zr7JsZN9Jb+VzLFCuPy{nJob90%t*(x9uH1#>r2$L1&5AGCVXA@R{QGr6($(R4F!A!
z9`_peE<{r6cz+)|yYpun9KCJS%?}CT_kao4Ajj}G?#_Ce#qT#Oum5Mbp<9Yu$4*<*
zea6}5mcbF7`NDT0^8h)Cu-)Yws-#bbKC+nkFSOTZw%+pl=|PQ^kjLrV$0x=
z&7eO6B1Ar!J9b=&JQMX5<4pJEdOvzjmX{D;PHPN6wn+n@%KT^Q%m%8O@u*kZ&fyOR
z{DVreV)oI+wAvfrjG-*4#F1L`RkSGdhC~qkYkl)kPC+~0c?ROF1*t<(`WaI^s>N~j
zHeDvws$o@7^>_ob&FayzVwX+#5+|8XEK;`~y?9Bo=U=#&Nv|_#xF-T}p4}OC`PXOi
zEDH7*1+vF}fvApZPaOc*azm4`7A`_Ap@rzljZXMY>ts%>u|BE&hM$O-vPU2eJivFg
z9MQrgjE0ersy@yRS2g^l;+L!tw4PEUoMYhwt#`Y)ZsrNwCs$I|-*T8*-*Zz9j*&2$
zM1g}=icF&GAeE;ZXiQtIW!MSM=qwop^dY$tN+@C#&uFBxNVMEzg9f7m>2rd@DRsN4{{!Fxm?5!nL1JKZ^J15Q!=
z8@HQpSnq1<2h_7gd{1`bA^Yk%qCU^{g3T<|b4C0p7k^x^Ttj
zTG)Z!@h}Bt@YxzPR@VP5I(gGCOB1l4Eo$J=(Fm*b!0Wi)%Rxt3fluR)&Fi9P|JiCJ
z`J6%A{jY9-*yv%}PKI
z|3Q#TE2sv_$`Pc>pY?G0bckSvj3gU6CdjeG4Bw4LQ#ZVQXZ&YbVa%EU~eEa52a7h-slAIWkcyk*=z^Z*`|{ZI2-YE0GQ(
zf?zwzN>fS4RAo>Y*}NN}#Zac1ki_IHD0co^({A}D$^F{%
ziVdhNJUa)1g$id=HL6{c!=j`@phZ~MYd_bM$u`!Ox`(p@?1daXmOTRaT7(V(*;kcn
zx2cTa5wrEVvd(11r;8R#i$$?{Tk4-0Yf4>}^$V4++TNm-h#VwP5X0GcZ*?*L`6?=z
zd~uEu5Yv;gcA=iOu*R-4w@OQ5RV2BDgjmOarB{h1yfh^sQ*3tWt6d&vu~pA5&oh4D
zzq2O^PeH#(!F|KXQVrT@us#mOJsXWXra+0k(Th{nKQi^A!tSP|vmSO!P3byd>j?yv
z!Q@Hff(OV~Iw=sxoQs1mUnc1bof3$3*qZ&5P{59(^Y_I*l;=hxe7BW}IYH(BwBrLp
zIU1h({bO%V)A8|X{E?@@?e01En-3@eXNfvrt;RzvW2wb_?$4NcHo(Y}b4Yk}wI6b4
zs-V3ICZXhi(u4oFxpAL4GoVK4ja{gr2COWf`2dUlDkQ^)jU(FI0hO&1WU##ghqf_f6Ebm=v5rw7tw5xPASG3Tr*8|gLOr;1qZazzD?UWV3I$JGQ@|xXgL>oAc_GC?*Pks{7K-X&1
zbIAiv9-7y^UGxU~h*H%$DV%P5;g?|(ls>S3L)T-!LM3CpCyO$u8={cbaU?rg)KcrV
z@6N35L^C+M{B0(=$Y=3Ab;0a?R^1|-I9uk2v4l
z*Y;S(cGSB-iUAb-00IAd^{36u{g~|4E|&$=PAz=;iH{t
zGl~oNZY`e2;p|W6_hgPljsn>H?NgPRxjklW$dz~IFtUjS-EOBxcX|_H;4WLpya%Gg
z?dBB4wV__N6DvrM(~T~lr@w2M8_U;-zhF$1UVYkJ=id-KgCaoz|9KD?JQiebK0@C+
zfJUk8Msv>@CY4_i9}|?%^XM96bSejG;e4
zwxe1vrYSWV$657?=PwbNGvhkLnuLpT3z=D=FW%mXz?-wXr_q0Y33_=JTzeOmRrlsU
zMb(vOu=T4vtek$d6@C0@Tib*^!8@x
zMk50+CmkCz7c(F0$#Ri2XbaS&J*ez;UFnC3f1;uob$2%TgPx{?n8NQeJJ<)mE8sI~
zDs_5%9EaK%5kvCcE2Vm`%2FPF=i#DXgSw@z@w#Ud9yHJUZB6D0R>CE#i7X`)LIv7U$ed0kzgjj3Qv
zRAt2Lelib`*=#82x3?!xs#DiyN>E)?H%bSZ=hrKzPYwwdX(9>R}0P%c(@41xvh
zgM+)E(TeDkjI5@ZTR3|uLisCkvOV01p>C(X86^J>!YqcHcxp(CLWSCDlHtE3!5jk>
zUnPv=C@WW{}z
z`z>^_)plWgP5Am`sS|mMj)^#3ij?s|ri}Sqqu7Mcz~fpb2c_4{BJeHG{K{_89YV^@
zB~N=U?bA?;C-f#P3?aYXMndGz%em)ns?yteYOpTc!cWg@f=mI?2s<36(v^7f5+&z6{)lAe?BNnwnnP>I`EpZmi<9ZnA2jGQDkwK2l(
zF^lgJ#v${acuS@6u$5Qx>CI_PYi7;?GS>j9X4>TpFX`lTLig6V(x4a6Ye^c@15~fIBSJcn$PdQW&k&
z_#pArdR}Z9P2H1xrX)rX8Z?7ztp|$PtUAnA=Cci&e|K80;JrJnq~L?CH^3JSV4;9E
zreCpTVt$+C;_!Xvt{J7m|uXCox%`qb-kQkaH%G5RhO2K77c
z9`~CR{D8|){iI@-S9n(xMYigQ=$d`m`x-E%O!)3+TX2b$YC)%M2257NysS}T?QgMH
z?WgD3q~tiR_Ah{xCVmVt>X5d#l!;3pq2DBu_NMIsnD14%LcbUdC%61c(B|?P0=SO+8Bp-W9(BQf?X?y&VnOV~QN9R<}!TNv~KrFvIex74e$yp4dl
z3l-HgwL^sTRer~@o#_lJtix)gMRH-l_BRy72+NK8U>D06hF&?lmHWFT?g650ItU#|
zKFmm6?Ui)#&D76&4Nn`>?>15m??nZ98FEq+-fxwh&m_D!jF18by{FH~jekF^Kyp44
z=xQSOOC|};1jkDewJEAU^QVQYlmaBU_Ra}qf;?$CRE)Peo%iN7BT$@h=OErJ
zY+c;<;zhztfjml#{|~1mL1%lXnN1FUX7qnkM$-8Sf8d|2VJDG+#p(
z-F7CC?M+aDz>0eW0C`O*;JI0e`a4h8JC9L&5$ctX2kd-W4|~H#e@5GX#J}Np3C7Gxg23^mqQlO?RZcE!`l%(-Fl&Lv{xha(L3hEKc>c0rgKVWea&Lo)KSl2Q~a0W&7&Nj4M
z%?>6Nu0+%}o6=W(>|c+H#QWh&ln?5aU5`84K33u;9@_=LZ>eJ+J@6B=i}W@wZiAH+~qSd
zzp$~`Y`+i_oq2t-7@_(#!qsn}*uK4Kdl*ddZLJkIx*4|KdR+N1x%&tfMx3n1bUh$Y
z8VeFs=Q7gd7h;%2(7wKYy|;eajt>=l_MARgx}$Z!8+s~yKDSx4?tfVc7QTjVxS{xM
zq6SRtq93Gr&jIN_e)0$VqON;yhm8+E3f
zFO2-Z>*;pamO9{nEB{-KTAypwx%dCyLJ<_TlQw7&Z^BOpT8qQ>I*f4Q%;WC?0o7H1
zjU}9USx5Yfnw{-!x!MT{NgIqx>TM{zDQr0?t(m+zQ1Jg|<7pM1mYegIhGC~@lg7kb
zNy%5m*^oz^S1~Rn>m3CH@kQcx!HhO!>g7PvD{fQz9!C|Rjh3N~r>Wg*4qgTZTHxru
z;*0zIj;w^B)tiG?{@?1}i(-I&@e`UCT3~yb0?F53<%Z;@{8Lu#hu(a!3Y}mjD1-#l
zhLBl*ja5*OQU4XK6cI^S{IRe%lyM-Ws4q-@qb-5ZN0^OIC4)SbfE1X(z?AZR_N~H*
z^NsnEuenPyVC`tOi9YCyd9}9f{9p&(?a{yP%P{Uwm*~p%=$~AAl(~C6U@BsU8NLl7
zU?Jfq5z#skQNAe{&4r-+^Qto1r>oKcn??S4*wJNL5W95O!imR$-PKcxTkX@8ip6Au
ze)O8!r-#(=i*av#fRi#nQIjt=my%g2a){*Pu6fbrOg_X^>gKSPP*SV6a->OO%b1To9*~x^z`X{i9-2GDSo0QaGa^#J0=z53y!*WsFaq7ZE@y5os-mYiz
z5>PfpK7Lp0yO4Jw!acrH`$TuQRkxL0w`$+KC0SpL>tNv7v!^RX8A%-`DpCD;ys}1Z
zyVHcPZN2l<5n#p(cRL;K$S|%Ks`oTH!wM+
z%I?oV-kTJtin2P%zu9!_leqkb&C9EuNy!~1rv^jccfLBl)Ug-4saiWiyH{kCzwAg;;)-U8inVCJZUT}B3*GbG+T
z4WvOptr6e5*C+2!0)L9BN=oQ$YMQqv3zi~zep2h^7%86;NCGq^3{Do_<}oar$#>{U
z=!FAMe$W+=qYqhZXha?v^gAJFb}PgEO*#+LGOA
z3m_Is9%5W_9L#78zqXFwLc*nE=e90EcOo(psVlbK{9`cQy_fJ-NkElR;#|c98P85F
z(>oqw1jS{oMIdnRb>?N5ikEc%y%BDMjGzrWnV2N{p)v5a_m({8mG|>%2B+#7jhi
zwcc)0yYn=F^RzPSTvyd+c;A;eT;HfKsLT1Up5T6E+O;0ri*nNE$sR$aI_xjXp)V>3
zO5dj-ZDB7y?fVwt{H-hMJevF4HuvLO?^>RB@A7*V4zm{b=suPsdR*Hc__Z84brjz^
zjkT{pXq@Ofd+*O5+r{S{0~*ji(Wp0wug?<%}er(;PFqI@{AC@tC&&fbQ
z*~cIzuKav?YdV*WpjSSObl)<#_>lQLuu3Nl4V$i8$MA|F=yk)3rbMEAmk<9I&sL^P
z^4@bk_l${d$)+dnll{5HhV5J=@SKAUtKHbha7^$w$(}_po-v!1CeSdBneby@U(g??
z+9|AaPHV-8?$>+_eR9~-XG{59T7(*k>c1dLpP7YDEPQ8AqjnYtSM;{?rMMF4ZHDWH
zab#5IFdXVlyKS?m;A5&cmi-+b#onown0x)c+UVo8zuhLy-Z@gBVtLYOVWWYT*7*T$
z7H5C6rzUb){U2Qq69;hAVG|;){BUFQ?e%FU&kh06XY*>WTL$!B06ylbZtOQ9{tp18
zKwH0i?0p_PS<
zOCeV;UjFC|7<}W}#hceJ0l*QrL!u)>qa#BJ&(|+U-oA1BMo8rC(5n~Ehuyr6TnAXb
z9dhkf$ThrG$d${{VYl%2#nzapu&Y-uuAfc6zs1LRjMAscBSa~4Jo0R3ccw>?10;hP
z9JgEw5CXu?c7c@L+4k;CTbINx&$NNx@=Q<-7zU5QT>uXy>gF~vsEo!Ol4&o1Q=Vh(
z&H{Z=0-{c39s*=#a0QsNL1lY)uB|KA-a{*GSl`V-m#B<32(-a*u!*84$I_E+l~Vx5
zX7IQ>i*~_!@EAu{TZ%|**XT-G|
zpe;oO(Q7K|H5U%rOZ#8(*bW|-4BJXa9pxwoaecRyj=L(yoE2Du%CxU`+FLW`sK9l9
z!c{r$s#rgJ{*{+L74f*wSOAjs0cOSmU=J0p1QdhX+1iuMbi(q`k
zPlV6FF&KaxWb07@6v5*m_Fmkk_4bVJ*o*sZQQ}Jht6(bIN*{m%pTPon)BC>Mv>rGn
zJ^VP
zUbcjnEafMsB}8N-M&*gqb46(dQeInqd3!^JUDxe4DMy3O@d4*(uXQM3^4nEGrv}mI
z)=dsN=Ewa@)4;HQempok>L2fSdQ5V4dtGx?L1TGNab{|vG^IeAk}pXrkS6Czl5!-8
zxl~Ecm#~$YDcOR!EPiZ`C;^cxPRbG_h|^e-@%Oaa=&h%>?^8Ih9oXlX_a-XdENpC?YrmnIkG
zq!;C7RF+68ibRzq;-;Fs+KQ~QB2j*JMz$nbkPaS4rY6D!<1ZBwAAKV}`euCOjkxfT
z_^6xl(V;OBH&f#2Hsx!V&Xd`VyoDb*AvQcV>Q>0r3!x#GZr!{JfQN-%18d=QBg1Z>
zj&ueTkBPXAxPJL!Vk}U53nn@|G$b}EJUS{22^#+NS3Wuiq9;a2#DVZvFJWugt&sJz
z>G!wz)ww=Zu8(2KDbKQWh-}?bu-4g=g_X?1aoo!FgBbv`JR7Vf9(PL}3fM|=mf$f0
zBnET=V`q1cOOcBEg)5P>fRy9sBBEX1wKadVtQ
zXbU_9+G37>2(XYa`7(e&7WqDX0X885hGMYRr_TpyeLB#Z+Th53wlB86Iuruz^nt$W
z92a0rs9r}n!+gF^o$p1`Ag8>?qk{P(Yujrq3K~lgUR?nQjdyV~KXyU$g|d
zhpf03S5JDXfn@L)G2y8g!}Z!%HRY|r%k{J8UwQE>GQDz1pEj33i!kEr5CRb#mHSx<
z$4pxRLPNm_&}+!+1B^9UWQCdI#3q>IAuEVg!r+}ZXhh_XFi*)WDN2GOcsyXr1GiwH
zN3DPy?Kof}!jTy@7mZm;(YRNei$sB5T1!Dn5D{BJzF|-hTx2}vphzo`^Z?8tC_Xm(
z{fF)Ng^Tfr!%xkk1Vrb)*DyXL@&F5=8crJYqGh{t1&bsn=QnQ#NcKr*0P0RYd!1bgw
z%A7w&d2hH5!RiF&)q!ffd^Fm4Z?N_ukr)6b3%BN$-M}x%RabC6GDj*zB9J2yq{c;y(o=GT8Ey3y176#Bzh@|5>vJ1jCWS-at?6p$Xe?EA)cS0y
zeve_S&o&$|yG&hXO|z^zx1vB$p3g7K)lEh481Crz{aT36so0U?Sod$TL%#$YPh!fFX
zkP(%VcsnT$naz!u$ZLtwH&fzn3DRQtX;FfV81Oqh^m1I(&4|z|(P1}`Ki$4@1^fl7
zk%)o5Kr*r=l%XL=xvtSO34rC0t07k|#YTo-zHkLp)@p5_Lvd>{|fWJ8CI;xwVj7
zFJYL<5u_|QCh?3qtBKR(m}wVyRvZ&Z8?}|91RCKxM*%z|j*PwFLCXhCWkY7-E_gp|
zDIW%6iLAhLIo1#2@2I0BY1mQ*I?}t4^DY`N77wx`&_`n2<%mvi#|$^JB9xu+#eN4m6iRjkF1RFM#9B6DEghpzOEGRMM;$yKw--$~iYBRdx^%+%vZvZr
zKIJMyOe5=Zl_I8H6*KM%G(+PVA7ETQ?Jk>fm$4q{%2{9ew7-1PUpnn8og)}mV&#Ib
z`VMtg!!85N#A6nmA+B2Lty=D_UILW?X?W%S8u;TCGQ`B)mHw(Vf^Pl2;RY@^$Ba!J
zn;(ugJ{)O!Ff4mG(u_LT{17A_ZFn%&cyF{G^nLQuAA`pz!RGbT=$~7@!AngRW~712
z42ntctnff6Qxann;v(r;PJ&d1+f)$`{`FRL_-%kWFH4-0Daw}ev6VB&Qc(uHb#h!Z
z>qCyoNQzI0j=+T*gvP}^B{3#GE)q5zju|jU13_9cHYLVHNO-9k*e&d)gqM;n%;;`y
zuT?V4oYfVQN%0CNiN7r%$Fu$O+i+CVRk}c
zR$^H}My@2D0*ud2F3r!N|Kun$DN7WSDFUa#X5gGCo+*gSO^0SiiG86f!VJY!9ljCm0h6Bb|B5quY55Ex=dNnR8G&1a3T=ea@$S?#A
z7z5RDk&(AUZV|0-#K+JOb?9}pBw8b`UAlmC25g31zIyTe`q}jRTLPLq1bkIMQxMb?
zdK5WMMK&xNf-{jpU}GH;aLGAtC9GSn8{QNqmFt3r0hQ;vshhVD29*4<92^B>2)fMg
zu8+vD
z;>2SZT<}a==+PCqGzIISF2rH+?(AL2Nz+FHl9l)t1%6FYP*=iWT+(YO?FBD^Jwx%U
z=rxw~o67o)fLU>$xwOwzib{|=dy7#YFqZ+AeYBM-F9U}vMqqawtru5eQz_~|GBd%{
zUk#2Tu%5HUUM;>gb&Pw|dFyD`!^P4;*27prIM)>h*`TsVndMez!;5n;CKAIOTS@>|
zI@4${}2uomFFwO4PA0@XU}5uUvulfMWiyu>)
z%e*pNEUYcaO#`Jr_;lr;{_B4xA8g3w%88H-&m|%-bfbbD8*jzels{m+0R<1;V&nnF=2kKuSI&9M!CJtWbIgpyR^{a;#WL|SB6Cfj~~z=F`RKT
z;^9~m8$zZ4cR3g{61P5^ZhJD>iZ+iY{-tMse}j;jngp6=q$cpwl0>|;xTpwTT1rl~
zBq1(}x|Gv_=BSi}*wVsW5ib?~6T?{QMX}~QD#d7Xevlc%1DmK
z3NbIWI4>KPH!UeHF*Xt96&`v`n3hnKBkE|bHtV~!$~LXMMb+6TZ>{ZUDAV;c
z7!|UqA?M7nGhkPAHx{;3X4Vx6Y6^LcW#Wc1ab1a^p-fa;BB(4#FUw6qpi)(sQC*Nx
zQ;<?Cs*fZfW*}$!iI9OtV&u_%rDPRsV>f_D-&RM>{5}RR$a`aeM|T?
zr2>>y#k|Ubw6eUEs-pCYg4BwFl&Zq?^88f11sYf8(>oSq#)IhP1!;)VJWxEYFe{-j
zGrka1&Po8n(Et?3`aDT2>L_!iv4z=*dC~+#jwm)y5)U?K3Zmh>vxU*f0}usSKyo77
zFvD;Zi)em&1kABi1U$!}LSW`a!7Jk>>VS8aI5|_4D259c#YzOR!i-n|8*LD1k7n2x
zo1{nx#MB1+N`!GDUMw#)GAZUpSjf5SmrsRWKXWVOLU`zR7EaDo~0|x)FA~;eL7&N1p9IUBqPumU)@Lc_kc`Fy){1^hIW?v=#fUzj(Ev!(yZH44
zX1o#F1Jd|l+%JRAgSuZ|(q{nvadoa>d%+1IU7$_{KbxyXQ@Q{reSu$>kDP#mC`vBK
zB^wI+OoU-@8ip93a~QtOQr3@;ZADo&NEdYSzQgv45m(iyvuXqtd&T-naN1rm>ZlxZ
zS5Nxtr+jtb@vOgL&fhrgt>bt+(T8qbQU@huJBWdfT4VC+kOJ~qRSUUFw3
z1;H3drfzd&41{p5v{4M(N@0!xV`L8#_+U2jz9SSgIbh6DKF;#6F$Zv4KItr*c9eq0
z6Ckmx3@xWXUl%+v#gr5E@+sE2O`X-A%2_XPOFh^`Xiw#|r)t()H5;g$e>rJu-bXM7
zeNl43JaN@>U(IrF{bCRRu2~3HEcREg4N~tkAkB!2csXE9{nhIh85I`fkKu#wkJR5E
zYj`-(gm^R|gD2)@ay=Sre8PClx~W^APPRRnXn#D>`gE#|JB$9=O=AMmZrjRjrCw))cAvTRvxp|Z2qsBZ3V
zEpM*PX{Zzfg!L7|#!6vRm7uADS6`CWSf1WcnpR(yURRdhP$6ilk^rbEYfJfv`f_1I
zg{ZzOu~<+C#O9~g74sU(uvJ)B#%rn))s}+9yqc2q8ni4IRu!cos*BTV
z%Xrmg>6OK)<%P)=MJbhqDK#Z&l|?YYNmz-fE$5-EDoHQROD-==MH@tEenLf2a&>8X
zO<4wBmgFUr6(knt#&ZWjr6?y3D-m3!tRU&-OQ1IUNXu|VPvKt3e3(H#r;aZcdR%g5^xpqBLx`|z%9pVt|Ar2NtnIPNQn?-#GsPN
z3^z)USS$dfBZNHcNQN8WmxAtT;dlw^^HRf85^lvrUI`C99~yEx^!lmWH_k=ex)>gM
zF)r#xYGOo6d}K`c&B$9J(P1}lUb}ql%12kPd=woW79J70escW&mOed=zy)>rKr+qC
z1$vnq_EN_$oMpB{nd8-PQ+(m!3cmZv3ikTx4_|P*W0~qxxQL6OGI94G|LZ^e1w*n&
zmG9FOu^GYz@XfH)oH6BwOVN_rXbVA24$r_6(Nqm{oJalJG`qOKr6Bk0q?WWJh>m8A
z%2bEH^y-QnsywSa8=e^c7~x}G#0-Arh=8FKIQ(VLFm(=7pzhOAuX3-cyw_C5z)2wF
z+%2%W&R0S#D{*lI;a)+PE|C;OVgfLZ0LM&Lo5M3XW@A~ezO>I!jzA^AhNbD7stf(p
zRbGP9r!N7F@d^7)>xV+%V<3QGWJSn?kPr15skb?3DC{*A4R9_BJhqhw;oWhS$2+nH
zWSZF(e3&{pDOX@gL)oCMa>!lmZ8C&v4
z0b`bR4)3f76aAGy|rw>
zxN5n-Zn?J(YZl2XQz!OvKVZzf??ByJf9*;i+Emh{t>L;gz<8wb?g+v7J}Thxa2>e&
zV5|}7eK_8P3JaRa1(ys+KOAj*Hr4v%WxygonP`4A(fnk(mCm96m*pFPF6?h|e2kc%
zE}&b9l7tzlfNOrH7?geX^f4NxCC2hn5|ZK~WsS9X2~Qjs9R`1#pDmdf9mblLhPvq6
zH&f$*-b6`8svs#LHZXLaH%dBXD6v)0T#G;(YSvOKLCC1R7`w}AMTn*v>`Nuqv^8dS$g)wgtzx#GHZ@lB
z8>%vD%TsI0QmRXVb`U)gQC0w`gVS+EIWfh#u^@VBK0!S{D~33o83WG^dz~eS$`;0;
zl=31n`H^B?7-%gOL`!&4qV!0_tD$QS+Y%m)OlOM{g=uIIP4mm(iTTmY9LMs~!qbv(
ziFkl<1V1GVyR%(@|7dYWgfJ~EBME=a>nZUeanV;I!#=tdayI13$y*`kV4x#zU5*LA
z9v2-Na`pVpo0r1FuSZA!EAW`jT0
zEkXFz#sBzU|MOq{{6`)FFi2DIk9HSpm#5tF4D~%_j`Q%j)vI
z`a+KmrZ(TD&GXVssFGJlV{@UwForQUjTzP!00Y<C0PXo5Or24tXdWE^n7Tsdf}957Y(nW!bMlE38fda&!}%d6+mOBj>I
z!AmPFW(9c0`V~>B8o+y*>D}>mKtA#VZXB0&W#d{**H*IH)=C8T@fg&LX(HImzz+o~
zVvq}K19cclaQyG0Pd<-kuTxM0LMT!C`Z4IbCb_^R2t^RK?pj3i^>
zAW}vx-Lu4IO6Sv(gH6>&hruVbVCsh028Vw9iSJj6-(f78qm3lO(+Mf
zRfD$bA$#>Ok}9s-hQ^`kXxx#9>D`t&YO<&>*z##1pLsG0Xy&j%1y
z^E7x&9n>(y3kaIV#U^n1VUBB-`)U_^YnFOzz~-gC>J!WVsOf$AV8kfNk6N9IkpH81A~@RMUY8mi^ZjWdINQ~d#tNo7^HTU0GhLtDV!qwB8jY%FN0$(B`RHkFCs
zVq40^vQlAFsi3)B)LJF#s12R%@-awNBbxCjy4S+U7cdRtyHWH)XXq
z0hy>sI+`UNGI4u@u(e*$+9>3rT_)~m6obTV4Z@BlQF|jwdP!xIxNW@xu7k%SF1R}0
zrLmd^qO-Rnx`W~z1;Ole4%n5&36;fQ
zc5+ExVo6S7K~`L@B)Tvwt}r_ekj@cB1J4p(gd{yem=Z2YkIKx55v4^);G0u#v$ykAR0Vf9S#DV@W(*1
zrigBtRpxsXc|K*npKh_G>0^Gfxu8xF7j%0r%^G_-xJ!N1)Uga$dTIQ4{cayn7VKnK
zs|tV(U?!6Rm{}@%$q<(XO(ngSGQY7HR2~46z)M@@%c$b6Zd`=};ee%rx}C|FAjshM
z89_e6Es>Rw`O+NQafAw#aGAIua@RxzkjC}*q8wn;rkG16e1hDAR@!TT&1YuEp)Sf1
zd*vvu-PB`TiOVP&_p(XU9Dsj?!DXxivzR$5y6g_oCr1W=k4;&^AX#?oUJUQceI(XR
zjrRq)DMes!QGxfGz(v+m3m7A~fnng8zKE?H48|G+0oz$U`k1nSuOpa1qh{^!5_s{uBUJVNW&t?iht
zc-&qBql|<6;M0|1Blay?pI~e)o^T-ZC_{VJnC3{sbW0fAFpV*TXBA`i>M?uGumv`>3iV+tVRF<#D8-+W{4SkK
zswE?s>V|M&OYbKnvldf94q|D4wHD;?AwN@aZgm92D
z4zcrg%u$6CgFA=0p6yw0ErLxK0Hl$PRZKa{X51BXzUp~DU|cirt44j!S2@QfbHO5$
zOYW^&=&PBhyN#=tf;B+z9b$9ko!;v830x@qYhLk~U_9J#f20X8zBf#6m|QaPxCZe6
zBnE&-8y>Ak%-lwVf7K`|PNHYQW{UDO+l@TkEpg8nRnqE2~9~Wf@In
z88R5wlGK*UjLuq-swKatDW|JGv!hN52DjCSTUj$Q#8nx@uqs|_4Zpbtc9}1$6*8|W
zZmuKi35SXX>-?*wfEi`B72FkfG-raWgxDrgD=&5ottV<;Wsf4O*XnLwYoGJ0UlSEC0CcHRF)>8
ztR-@%*OjN$mZen{rhyqzfpmka}gKIP|`L-Z6
zJUuZ~kQO0kBh!4aHXU0dV2=68w}h$GUXU6F+l`eVF+b%NS2D)qP@wf~yi85Jk(?Nk
zl5{gB>Pl$HX?8CCJ{ORf1yQ*lC^8g#Y2Fq+XoAh#$^ncC$!ePO)%&adSXT^W2KA-?
z#5$;b8k&6#%5uO4zu8T(CG-djguVo>H>js6Q~^y9a2})~QtHv|Hr42dLaubgRW-saDFO{}kP&Ci5c@D=baAX2wE@OJJ19=Gqgi()4Hn`Gi&(E%
zD@JYW*K~lKeJXqscwBPu_?nb1*l0L;h};-`0HQKH9Imj=Y8n!TEArGJP)FdyOnCuj
zyakwDI_j*%k1!i(1g$4Mb<=(tJf_)RPB6G`##=w-u9@@IPLngPn)X%S>6I<@x3F{P
zUwvUF6>gR8P#VzF%&ZX$^-Ht$rQqmtR-N~m>twC9&?o;hHORL9maHTF6^VdoVno=9Fsb(S+^~0?zn@-&S_t|
zHK>BSC;L?{H3om_swJn(vNxP#_{$<*)$!-UpKQcdGv=rRM~AI|G{@BHAzMw*RN+Tn
z%Swb#U+OcI4cKZ19CdxR+MuP{r7dx&i%`0Cr5=5$M_cSt7dn*r)}9=vs?ez_aBB;F
zG?Tw1K$$2`iE2cjxw793s8f2{i!hXXkrV4lL|$!?TZM$Uq|b;G3FlQE>!G2Xb<72R
z)6gCqp{Fvl-p%vBzYHr*R;x;MmbUV1gBdZcb`2%N5cG|tV~
zB4^A6n_1oTcw7cHKbvR)hM!HgemvFw2_d=t(U|P<1dSrYC4Vy4!A_!oej$IH#vZwq
zE#_w=$Cnl6CdP!PC&g8l6@k!#wB(=t?5FE(|L6a7*)2c++0Xv|@Bgk#R@dh?4+m`j
z?VtYfFMs-@@jla_PrWkjb7-67jfGuxx$?%mp8D*LYEer?x~x2{sVub%n5^Q-n=-ZS
z1s$MfB~Mn7(L%&UDQK?d0lKVDn1bwVJu3X>S{_1HlhIg}-c$pI30a@BxUGp;+tws%
zV~)0~McUn(iL&!$rMp?$(}Iw6H;a3k#flaQ%5Iscvq{(`6QR;06DnG;2KJZVTA$w4
zEbM6&ceRQ-TZCOLq7In=B@24ljZLiVX_Is|6RpANm%zqL;9Q7ZI+_GHemhWIm(f<6
z-d4{;wA7|I*QDVqG}ltdYSSrdGG0YvO*(=@H7X6&X|I?qtL5QaH&kcTS7SZM&Ep()
zO?gsvSwdw=e03QrNetd8RVCmz4PBQNB<4w@OY@WRrLkFph#V1hbi+nx@?#3KQ_>P{
z2vfuPsbRu&8c0r0xt#&rriD|a-xg(rA%v_V0DUvCK1{-o;-%cmNDfU)4B@4OW~7Gl
zQf~^WC{|XYXTV!p4Q<3FSX2BwV
z?^EiI{_YDZxus8EOdZ`i_+4rbJpc4ZpK><^fiAFmejJU)bU|gbWJm^&^+m9u17@1R
zgv%331a;QI;~HQKU=~aJ09_LhNLIMtf~!W=fTa?R*>Ef_C?$O$A~@uz7n1$)6YlzPXDuNU-qBMt4p8}OCn)O1JT+tP
z+Hr5)q_1((+raMpsUwR?oWljWY66!k7)`AA&?aDvGoT#I5TmZDNg^L-N$Fi^y}KHp
z7O4QxNRWo%X5Ei02*5xuF7cy|nsFDnNEdhZ5&))DW0-j$W`^Lg);%!+7zqK;&L$0w
z+A44v1xM+lGB>>b)+{+-AChh<284i?XL?_^1%$)pf3V1si)e4m4xcM
z<2oGS-h_^ADjG%`)@KXS(10i#D;=>GjyZ})V45AJlg`R1XXT8WI&wjv^`TRkV_P|g
zWUlWQJmz{GkhihFPVK0@X4F;-$^vgg=E@N(vc0+ySN*V~hH(ylx3ZVIooj~e^?jx)
z_}~DY=M@2CIRNZ8m4m@1nM^}N;t*>xt%be;G
zhqB0_E=DuAw%nyHb!$tUMCbw+Z7Q}aiV!wA)_~llTzK_(Bk;b0l}Kc3@G*i0`T)I_
ziau*)A96eDdZFxa&|D7TKosL-waH}DxdamXYH>#4JmF#zRQA=)2J7Z~0p@B1<8jUW
z`hCWA3#>yM?wJi3*Q^fJzk2$|8gt30aD&9$Jx;7b1IDNz9*i_R9&2KTSoV0l`Qb?8
zqmjnPBaIJ->mLp`VC$1f8O`3BXnj7__ME6po*3r%=~TDG^D+YsDY^v^EeC@ad3
zV>gnM~w(f;c0!yf9aio+M0-E6x#`)SYgV+N^9-x7ApbEp9{S-~Ziz
z`sq);r|B$_%W~B1`3hNfdyTNYlHXdE-ciNxsS~MWQcY`?sx_;vme*Ph*PGT-ncfPl
z!u8e)I)K#%aeJc#Wpk}S1~yj%yB*WKsH4|SI?b$u8nT)b{3I8hUZV|~_
z#fnz3vPB|q5%n|+741@WN2ax7pGJgr&bgsmF6WB
z=O*MyVlo90QeL<)?UocM<%NsV!{DKLDG}*Ow=^%}51Gq`jK%%>qFx>B
za!IcqCYarCLrkToUi7i&OK|gt2jEJXrDHv-r9krE{mozf^oK8ia5mly7fa@#kKOhI
zsMFMC7C{`As7$vT!5lNwP{ocz?hpw((U%c=$XvxZMBRD=Hq^;s3|W!;(=27UaG;2$
zsE`W;w{U$V0CTPd+@&j~3;3b>sH=8_HNypT%vnbyc7c%%6Q0HiZ#@8v0FTE!)kNi&
zG3l?L_BT%Z8fW|jDg>K*TnqO=^_P$)Dzo_2l~cg^%l=_9;;c6qCD;j9JcQY~2dlvH8q3*?gi@rBIBCH=IM+T)6|DzEH6=k)WzYyiOpJu(^%=_j
z#tPV97rd{w)TJqPs!QGKa^RK=yRyXE0|uA7byZ${wNGE=(N?(Bc#%s}%)Ke{06%lpND=%@iG!Akescvr
zYOk@p-&_gljZj|>s7x{Gs-ALJ!xPW?fZK)zfBl@VZZ3eRo%PpnNL~om-RZ5L57f=W
zEBmSAdU>E0JYMRf!DGhby48M=xM6LmVRZ-q<`~R6t6$#fbbq9Yo`pHw@MKi>WLWle
zv>EYaMD}E)@##q8li>zn_}NtZ6B;?D&g!Q$jf-wR=AH!d@oYQH@o(_QMS0l?F}Um|
z@lz9v^Rl?9TV(~g#n}>3T0*z1+G*&~b=5Uj=X5m|dQI(Peyu~>sAz`A&6GFhDrC8B
z)uPraerKIn*_@+l%GS2z>00wTsxrFZbgR-EDpFv4TiHk|EH8)HCb+%I)W)hbS!EhH
z-CiqbuNQVuuQK2V&`J?K&2Y4Ex03D_Vz8n`3g{B#+NA1Msis}3@66J7NzFak$lxsU
z9E3@pZS2WH7`ihN`VNV{Q=)4ZYuiQ2Hi4#9j8Myj2vxIC(;~qE;gZ3~?q)%cOdxOK
zt6If!RAhqgMqXDF51V?L1qwK0w2|@U@X)kIByW}g+sZa6N``PLt4o!X83>8j$y%Ho9T(xjR)a5|}~B&Dt*qoImlU7A)}
zkd!Np$`VBg(ryCJ*`nx7K~%0ZUc%;iA*6g7kQQe|WhC7arAP9TZ}U^a1gYVuWF&>9
zC*oyzT0$sZuAfc6zol1KFl?cIxxw}OD9VOR-|6&LI-UN-P)F6+g5BX*&y0N0O4{mG6h
z_`hKr2!xj$q|5t^Wy5f~E^vZuB3VNR^*nR9WiMfftA-twBe-e+fu1_*d2`o{AkfBL
zH|}W|C+;>(xEjVCb=)-+RHiqw0n)W_)g!>0n+062zhNrSK*wj&fo&TU&
z=GhX$!F77d2e}*?NS+NgO$QpM{PmQ4z!RfHBI2g@GrnqeZLM4GYg!v>T^VRz?r&QB
z-^JrG3-Ne@o?pQp@n|g?GE!&tn7w4wUNY{YNk-%L62NuB&hBWU(PbJTCg02gET48G
z*C_#yQI6V*Cke)t^c-eq#k7lp;hD@aH=~$MWg;F=Q&%lOTRHBayO>z7Lmdn;HzGS`
zuVLf3z;olcr)k($%O(R>^qH&t`ZBk=$kv_jkQeq_YkRHL;4X*@1p1AYK&;p|HLwZ{SGqKyX_-R>LRYx8RW?Nl!YVH|cNf}~r4AJ~p=Fsz
zTMi7PC3g4W_@+uPNN=q0=*zqY1l4^;T8Z$RE3qCq0r>4f0L=Q*eoIxKxiV-d3+U)h
z1lAWtW7zB6QEb-X2=zA6Bh6`kAN;YWnmSI{j6ZJb-+U118pSI%&-$z8d#jg+8kYL&
zmimC?`emwA!x^s))ZZP#>C}k0JKO{}e0QjBZIGV81uEku_iSpq&v>-y;Yictv1Y^*
zqH+@;IRLj#zdJY#CuSoo>Fn%%Lxqce`bIUiN+xwUD*`fIr?tGt-eF7ZAx1}
zlp65yemxAG5-yD0RBDhSvQp#sBscYyX$>d=W>C2jZ2o0nWlcqLby;FnSz={r
zVnqom$yH@3)#d5cWvP|LbZ1vtL1IZxe2y?OlOHZjy(LVAMUD{iq69R|3^Tnx{LE3A
zpK>cBDHJ6yITQ|i{cQUEEq+aIpS}Lssf-28pq9!VT*QpV~-h^ni#I6Q25ECk%8IVHKPP4w>1V@HPO(
z!(g_%Vcgd=>S-8q)WWiiI04!Ql*1sgy>^IAt3mXc%em>$xFoR)6Pxo))2eC07iV{d
z?Ovy
zG~MZIKr9dbOHV%fJuXu)!62xeo+L$&c!UqO(xm87Tge!VFS~b^o@n7L1(KPKE`~oI
zwH5;2Q;xDpnhp)uTRx3nz*T`=hOP9V3=X<9$C&Q21%t^7qYiWY63o@p&e~~5-IS{y
z=pA>|zzws>1jvCJ5HQ4}cKp#BaJE>wv)$UF0b5O2&H{5+
zflEh3^qZ=^dQi691J-IQ?CKIHL9_xKb*f8j@?uaH=!FAz>nd$35Eq=T;sSdCy)PL|
zw8l!WzQ%<^87duwWU|Y4Rgptg?ABu6Vv9WAp@vtcHFjk&HaRuLfH8ucF|q+ISdOP8eFxeHFWH50BEW>?-URy2u}G9i2<0ydWn
zZa0<2?ri3LvtV$wZ6e?n&;{Yl-I)jz%AQP{5{%4us&ZZI5%x}1wo{em)?~ZYSzc9^
zOD^&ty7@tca9Ec)Z7W#vS1t#upHFpuv84QbQU1L(_4n3PKYFPB^QVUI-_!iXGxJZM
zTYmh+@RO&epFA-le(=!n!w32wJ;YY+7t4z8Qe)$H*EHY1tNZSn;mdpGPgiu$7gW#Y
z6wl{XPiExz#yZwU+Lnh}CcRZYU5-ba?NVo(JB9jIfxZ=`5ZE@fQEBQF89IareY;TC
zh6?OEegvToZoWf`(6vkPgTU4sIwUG`=X^zrpu0ub*(_*p;&(O)+Uxo44e9L-Y1H-I
z1Yl>tOv6%lHX;Y2;dZc@>wc&!Pp&CXLey3y*H)%brJVI?m!V9nE=vQ3xhOA8s3?My
zrV;3>lGKXAl;WJkJV{KJAVQcL%1^y1NDCG7X!dn_;*GR~5Kx)99p=k-f|M6om
z*ssp*GZb(S5+Z+0prz*u(PRJMmEmy>C2+l7bq+%^3^A?2Cct=zFwCAh#7%$#YgzQs
z!>WK}Hv7q1O8;E}bu1I2$iq3<@G866W{{1W0@aj;J3t*+Ou{YKVLL^HsGD>_>NJ>2
zJij72_u
zS2-?Ad^7Szy@MDnxX`HVX1NP;xIfDXq@eBn!!~pD4Pr7
z>ku8uKy&2wA?+aI!o_k2q2st~!16hG_w`MHW$la~SqqFTemAs)Q>mTtktxUT2FlKY
z%Ixu$%u-XQ`mDcUHUKM61{xW_d~YKzqX^iYg+8hSU2Ix4cCVie5Q!HDnm}S)Sm%4|
zP+1vnUK{zB?(FT;_R=T$i%>ebbF
zv>a&3E5qGleZW)~FxA5cgUSr9@Wj|kyQ2i85yW6)jmKEy)>k`J}^`^
zZ(izef^S~zt6v?2Czh=aG~OL-yf@f*f2ir+Py_cguJvwe_Wv~@9*wtv#9aN}DAqSV
zWMC!+!w^q2Kb@4ZSSK-iK9`KfjOW^)&$WMYr}N{v&W~sRMSpBmwwhI~a#@+*+fp?%LQ|7qf@x|Mn_VSG(EKUbK`B`4)D+>;(`Ut>6Nys3sVfuUfyFd-z*b81
z?P5^M+?{1*&tUSXVPvxafIxr0T*^$RLh6)fI^Dia^fuE;cZi45(0T^rBP4v_PKbNm{*c9D*-EmpUP7_FtM
z7O|>T+|$JGsL$xA%V@7n@2ux_)bTp&`4kOcGrt2)x{e0}ji|364A)gq4>rf+suG$7
zh6>#eU7o^bge6y&B$O4#mKVmBXH3X%E9|lNg
zB!y%ohe-L6>u1yNZy96{(d{=D4Vp{9<1t(12+(LQ9Wv1q4@SXAYsIjseArYrXdt`X
zPm{2~;IckbF;F^Uqx&7%<917FN)emii=f%aHhPX#udx`rjMys2=~j>`AbG+`9k6uC
z<2)ZMqpu#76{J>T=&G?$9eKMdLNji)vD$~BEX>Zenr*X`K
zKYGKUv$oF)%2ovo6+u&t-%#Vh1qePvSz_qOv#ZM8x@woU%B`!isY}g@VzaW?s3-l!`U=Q4sC&5@
zu7V-3VJ^^s3b;E5a)ZQP@RAtDUV^@
zt>6$frpeO8bzk*#ux_@uo?sj#JkJO57S!uVFa0z$IOnI);^o1XmEqRqLD^DY!%`ot
zOzXXo_IqRPO9TI#`l}}#B~xInqin*qZjnJ^?q*^Hw$lGQ1QNU9fGK9Zm3Rplb0w|u
z0J=agP+d8L-`Q2g&C)`kjx{rGg7J*IcFINnni!={MFQ*uFJnmsta>L7gitJw+h5&s66%);e&K!+)D=
z0v7C5jS3=Y#Wk=tV65)5)b^Tddd=0nmfE1HHfXN%8*$hwp8?0jXRf3VzaAAHZK+#R
zR)e6ImP#a@qxemrI9s((S45AxGqC%oUC8j7kk!ouYNmWu
zlZh&0|jA4J_iNRwI$;=!#u?J+=ZpF7kLS9d&vxPE^MCnyAPXb*r^^H5ewD7RK-HA3
zYs=HM=V@AV)U7$%_B?fKZfBjiy+(+#wTjnFGopE|_53EzdzB{QLQgQRN(F;E*gWU1
zW^o62&?M-Q3DxaVr>@M#roVdtCv~1(kz?tSn!CVVkcMyU6l0BD0e740Qs#iTZe^BR
zA$9eLT-|(+To6==2lQE^mi!ra`JBIYX+X9*(h3{8G$dObXk6&8hk!?26%J*Vu}dNc
zpK8;aD^i=vQW}7t($v~A7Ulnc-u}DGk>kqZ0QC`f_w1gT5nXqe_XY1g(!wOX_qJdQ
z<-MX!EG9L+z}fcL}+BoZjFDm#C1U%YrR=CMuLjbk>$
zEvI?RMHRJf5}9l_T-MjE#vj^EuiDM8JIt@!Owb!vr=f
zx-rx+!xm$x@rLty*zua(^h1aF6;(FV4=slOwCMlKhToDI1C(1X>kYfOy2^D
z{~yaU|L^&U?|=T7V$LinSKSwgA=$Qpg9X!8*}4NGTLnsOo9xIMsI2BZmoS3Htq0DS
zib&u_Mg;;HVj<>$$po)c`9S(`*zQfRmSr><
z2LY`PchKR%RPU|OB<^;@H-N9rm|$>wMMtOT=$2gllBbh%))SUW(o!aZTB|8X
zDd9+mEneHC!${Rwt=cynhMN}M>mKW*&oS$B%=jGBE-U_JO=RQNa>f<*FGl#~dfva<
zj`Gf_oMNq|oC%DQy;F(6az18`@C#9XAt5eBxcLY_pHuYJl%<+9)zaopL7f*gb#vC$
zvXkQB4VY1Gr|H{maTrf*wY=*!=Qf)mW+_xO7NJhpb3E`Jbf|wi
z_;sN@?sBJn;RKeNIa;)!CI||F_c#+LK>IDc>cuY>JO+b7TnL{`M2BndxDNWBLt3Lk
z^MCZySDc3(*KwatJMR0=1}w}t;#Hjv{bwT{V7^+Hp_9Jvr0co9dj8Fiohl_{9X9NT
z4cdQquVGTT`x4CPK%g=!Rbhi6M$2ke&^bGG6JUJMgfk`v1HgwZ7i_W0V-?I4uV(Ya
zyA98NlcLkKez)eJc~dq$3>a@#-LS==(TL?|HIkG?1@xi=jP(l6cE;9BS-`(u-dT^E
zD>01KoV}u#Ldq$S&pjyd-MkM-hTvierCAIaJ%cjWEBaLE;s`7q^|(j
zX?rPZt|o1*oI5Hk;8JYoyfAXPh$$O3=fdV<)LM$-D>)k}XFcs`I))o2
z9=}O24m~*t;_36lf63#hf36rY;g_2UXrtU*OqhrF6&-M0lOgX+&@&bAOu-XFqI1Fr
zwy|koul=UqaZB<}D&l-Bus{obxXFYxTaN3>acwQBufZM0m#(*i1%s9OYGj_aP>s&D
zlZ)NVawomiPAsgz=0+#l@u^O7cC(~E?YJ%nzB{Y_tD*0->)frIwko<&ajBnMY9{6?
zk(snOmX>E&QuJKVbBlMpA&~jI;d6{T%{Q5DILtSkmRk<9&lyEmVBN3CfyoIE>VBn#OR8v>SopF^gf$iWbDhP18)WS;p-2
z;b1nn^}5Zd>J6*mHGte=ya5r64X>H>uTn?%IuTmWXbol?-Z0^a0q`4hT5q~-H+{}=
z(LWvFXJvktN|bQZVR1Gp%_+iEm>Y|V6Uo3-QkqN$reN!7)RI`HS`$>b-_Xuz>+!{M
zc%~4V$jdkLfgAb2SUxb7BTmmGrRlf`%_f6O5n&FaD8N{qZ|2=Mc^7e-cTr*;{-ACP
z@JxgTo&jctf&j;o7OwzVw@AE6$|y_cUQl%YSJ(2U}?a^a9CL>!-$++ct1T
zIo0<9B#>J837p2OWQ!Xv(B+81gJ8q#<28?0{5x%ReG&Z&$B}(t80NSu?sbLrhNoA;
z4bDQjsTpe{O<}-N++2*CQ(=8NY)*%5vUgeZED7F4r*+C|oHS~0>6UKjwPTRkFkvxH
znDjS|+Bfu?*NvJRdd*D(9iOzDrX3~>B_|-ab=L1(@Yv_ZoA(}Y^^&S|{mvrb5!IYrc@LZ(c}m<}1zA$>BaOGwKF_@Ol2tlMczCu@a$
zhk;(LQ0f^aPj!jGEN<+Bv4EL48E|OHRSYTU2j>cE!v3E0xwD~g+UL+gOYy(~&DcTY
zYl)*g3v}btI9Te#w)dpVf!yHt5wj_0tHS9(fMq%Af!5B$uA61wFmDY!_ub$zK9hX#
zkh@ytFNfU4kh@%kn-T78$hT>9E`ZG^xMTdE`C|0ZfzRqj^WUXB{_
zaIrb(O2Nx0OMVv}sFj9c<+nT0O2XF4d%9(=NbcEQO*mRvZz*Pr@|v)JIm9i8(cv}d
z1bmAj-;&~Al3X+BD}pW}7+$_AdlzKyV!*c?^e+V|(@8RdG!Cl^(J&C0igTvMbiV+q55b-Dd;udCz+}@ZVh%?yd81
z#w@2A9sceHe`lTAdmG%nbstR|?}(2Wj9DEn`SGr(u1J2o3&%{^Th9(;v_LZS<`I#Y
zrjQSUZyp4$FQfnI@q?nGFW{CT!v{}+#FA?~=$n>3lkmX-56wq%u$%T9g5#Fx8Vh=-
zLcXb>Z!#v%E8KL*KamX1m*U!1&Royv%87+?oF;&a%3?k+R}9Y8mAOuGagbdcW*0{J
z#Zhj4keci#$Jg?+$15iM4?NwM?{ACeL(izF>7?h&;qhW{ycnLMnO7L-z+^%kONir%
zz*Iz_Rl=fYjAF?4H(cN=&4$8H!2S|T+?LlcR&W_#^_X9C8DBx`G``|6{Fle_y5If=
zZ+|V|x)E~T2sv(~h1sk$pB86Q0;wR+=cT!bcyLXhuf*n1<&
zjm3rW7#}GOm*BpM-;Ce!1_LutO>BnT*O_0hP}qP9guUXV#O&8VXgFq|8nPMx3sgo6-)z-SW70
zd0eNRG-xM{`YDrP+Mt=xYXIYEqizZ^6gb%nhBc$A2R1O%{h#-R>QQ-
zIOQ;d&_FeD-C`KG>c{Pd2`7&0C*9^L7hW}t+YDo7E$wM$(cVIfBNqKllMdJ0gv&bZ
zvEq7IEXIuWBxGo&;hZd#L6f(vR-Icd&mKH61&sk_3KugH!yo&JlmO%q_QHQUP?J}E
z6t!BHF4v^&M!cE
z3Q*&YNpWwq>VV*4O}w)nxLOsja1ZVKFTmz?>F##$-gb}{vC!gUd>@)izP@_?%@5#~
zP5oMd+oKk7m-@J;w;Trz+dg{<9vUr7GXQ+FLVF&7+|)MJFtuZ!%^AZPt8wZ5hVyvE
zLq?gFeo-uE9b-+FxUk#uZ`Zv$4c~6lKP=jtDTAtZ#>C>cjvj%^-YLLDIy*T>HD-Vt
zZYFI|D`f}UUV6=5$up?&{VHEgTH%SiCErTX+sL@ud0#1J&xFj1pbZP!Ah!$wpFzI{
z13t;SAbJ)g?{dJem3WkY5+#wBWAf#hFV1A8}U|gE2l$1BC=#
zK<)6lAg>KEW`}ub2|rW;n*~i&)Wl_dGGIsrbeW*8O4HAlO3b*DcMPk(^#(tx`G;li
zpy(bJUBj}AjB?S|qr^s_w=|l
zosTS4)5dz*R88ng(Zyn9J_}D4nk*=jrN~q(xzI~5t!9>nshL4^Y%Mu)RGGimGrY6U
zeQ*+bxb8V=n+K_xTKHBubgQULmM?3%I}PLgmgRoSe6L}+C~J=kOJ`->
zer|Cqv%HaB9wnDL%4}7f$oX!j+&7Z08%fX2h~qWc{2#pOKX~h__&zX~H2-R%-pV^Mzx)#c
z4jK<~Z0)jtJm?<_`bYuK&7k+D!rh7j()=5R;8;B|x02KLOQvDf)-9P!(S*@_E*j4g4jwY!&=cyt7upm1S+9GRc+Z*mZM8|
zF@|B-i!JgQv=j$OW-DZ9Qj=zX;ec8CF506mEE*5=!YdP}@oLw9fR}p0A=Krm?NLN}
zx6SXa@Ovx#PMh0q`PXXhUcuJP(AvsU)Kp2@DrsjXVh#&>+^{^3IkRD0xBP}lKkl$B
zm~_+HMY!QH&C)F`v^)msG~)){q+UBgR0fPyHtQzoI1U2Xnh6N+LTl1ZS&Xwb)4bI<
zYd6h0EOU0ttlctAGEF*8V~lWM0t<7i$tTALKla)fwM)fhL%S9Hr8%3YTm0)mrd$Ai^T6yvO;>ReMec
z7z9v^nob^&?yO07*8_LfjA%^9<4
z2U`#V}T@tGv*L8C?*yVoS2}9W>!8N+t30pI6
z>*YM%oV%5Rd-e}20!5+oo@UnFD+%qaw-|K>J&TH8n+lqvycYHsrdIMSs$>Om0aTgw
z1<#`3T@-yPl9w5kmqjnIt%vY5;HM+#1bw;?80;ro%!p1Ce0-rCGVu)3Fr4Zb4c(^H)P*rl;uJzJe9o2M>SMTBc?4UwY1EaRvf{_
zPFF&cD~Z|F{PIRox0YELBw>GV9X1x9?|DAB2tD2LA2$qx`@~0+b5O0>fxi0UVj7^}Et+6zW>nSB>uu^zROI?+p!T-yLY*UDdri)W6fyywlg<>6=~6n?3F0_R{m7?paU&tZ#VQ
zGdvrZ9<1o^wGDS##=9NMRnvG{)1TJO$CN*5=_D5N;#ksmBjLN50p9!*G5=)HbxW|n
zA+puglI^BwyTQZCn_qRC$iBN(dkrKTUa{!NU!reihMN_|yaAW&bKT-RRA^J?XM(~^
zNSvism=5w(2rPh(FauP}+$25aCS>23?7v0B7j9AlynPcv&n?A!Gr>=!rO9G=uAMb@
z3zXo~NNKZy$vAgY@w^_z*XG6({1^zW_-{qUsbp|ID$fVGX}9H7m-!Wpf!Osx3ELQ%
zd2MevO|Z+aIE+7pYzCq-kbHeLeSeR=rUOXcs@S%wRDKA!rQ%a$h2fR0J9WoCEvTiX
zGPK&2?X|bxcGAKdm|cQ20h_|qbub%F+PdF%&}3wfd>CM?hD=W=Y6|*tL}eNy`w7w=
zuz^476OUPb6V8$MyYgm}ACz6)g1w!0wDUA8R!%tLve9Fmw(3Dp3NJe>^EUGw<0w4t
z1aNBxYqgVby4oeeFphw@Dw2U`2v1eL1hdL%yajIriB%a5(`NW%CW~RlYy_dFZH8&P
zamH>$t7^uMBZf)4al#1z8z)_sS+{l0ZJT%5=j`T5r*#UD29lk&X@?Epc7k&)NWNvx
zJ>#*Dd+cKYZZ6Ev#ifN}REt|4?)yVp21Yv}?$Y8;s=qGww_-VLI1ihSqn7iy`F`HZQk|{soTn1E=0b*2)Z8ucwUj&TgE7?+AUPcbYLXjf3^daUUTW=LGzCyEXs=O<=}Tcw)4g06qtw?8B!S7^lHt`iZJk9!EqS
zgic6MVXTXA8c4zTfZvYG)-HQVcKRXQEeSQA&##To{b!sR-DN$FkOZMfuh
z4(9m&mhgafIKE!*^l(RfxGUbj?hEQh5l{9-#$);ULFoBG0B-o%o&-bu{6K!TFTZ^p
zdiNyq{z>fmGWwq$KfoQ-dKEp-}jRX>79N5dB@aGPB&nDrOAA7J{Mfb2Ilj@xvV^s
zmFLp(Y$iCH3D2e#QYJi?4$Y>5GbwpGB~2!{u{aO{dEQ8RUjye#u)N}UiMv_hUoZ2o
zwgNY{;9PSHRqnqwQ*)07?k58$==-p(x!;(7&|G-Z(L8D`qVu$)W70nB>d|@LGdv#{
zpLTU`tpe4?=Y7MQL*tu$b`6gQ=BGm|
zFn_0|zuhuiH4XPx%ola-MN_|5T-Yft?Uc3ax#g{rVU*Q0!&CLpbX}Rx2c|P3G@In6
z;@n0TSjD_7}if26NnGjvK{NS$r4Hg_`*3wXpA|!jHp(E0mFkp%@LwMAr?k1%rtndabYVj++qJ
zjLU|QZ2T`E`TA=5{vJndx^wMRt=nvCwhh`pRo$S*vPwzUMz~}+T6KLYn`ZOu(GAYa
zQeYgru+9x9p0e5(R6b&_MO5BvJ5S)o$awK*1NbW3$7KwS&sOELp#(f1gT$1m#qG9z
zn+?}a%S)cP>0ht;xzBq%tZ&p!
znluw;?W9>ZWzb9-mhtMu^3tuvrJEWc8PL^F>6jfW<55v
z(=N-j$3E+{O{sF*rd`%493)iRrd;+Z&Nb(?Py3y?erCgd{HtGTrA+;z6=2?IP|nwG
z+jE2g4NdyO0pms{o%Tic%LH60jtyrFeBN6Rz}KR4wI<#HSvLZ=0cN&Vn1P(geZGn#
z)CY_Yd%lxZ{(Mb5$E!G#oxpIb!d|+!8N9m{IO%$hI_|T+kL>swy?TC~)g^)b*H_QK
z`ElF^cWs+R{bs>%)Px~suD9(xZo}QuOz=s^&2}{)Hd7{c-O7$rrDcjp*XAmzL(qlgWk|+bbV1G_b9f_;zzr{f%0MzR$1ue7b`pbeSkS=@Q)rsg
zg?M;qLx?xv-wRn}(ZI~HE-D$>d^6Z=z`>BH57Arns*R2ac-4q=6an^H8z3ws~po;V){YRxmo9STH;od1Bpi!7uuaRzun?C8~$OD>T$w7
z0Lp34Ph3&GiPaHbxdu8R}h;B;S^9Vj!a@wxT%(pq|HkeFXhF4lz`b>a2Bf_5*z
zyj#$&r{|l}jlGio9RD`z#@l@dbk??9b!@jg_J;%4y{`4LWw>k_9`y0ldC@Xnv+T6H`e+Mlkw(Z0FmgYNY#cQj!*ClH5#^
zpGgWc@XgFRkBN?(vTIy)+~OU#yzrf_Nw57D=bG@?ZaOV*xNPK-Ar;In8_kz{9XGE_
zsc@A1MT@!F$Vri?u4hD^RRuf;L1i}aOh~4%_C&x-8Qr4irr^2Bxu_DS=(;I7Z%D2;
zLY^B*X`&XJ?PhiTqG3=pH&dF7Jg#_N4ZB}e{BJ~rF@?Js=59p={8_2IXxKO5HUH3M
z{-K+eHRF3y!q@fH^!+^m1GJaBHh)U5S9+@0j)4K&(Y8jI8z=!zSIdSwCsijsvJJ+fqIq
zSQ}K`_GRtDO(S^BEHd~Ci>xC^IT
z<0tA#?RuStDU{mACg6`i<>7T4`)J^Ww}2rgFS`x~2k&l%?ra8cugi?qG{p;ovK%hT
z{9*@%lY#GiO@KK*9dTD%^6jm_~hD(N5KElNY$GqY^>7Z|CdDM1B
zV)tI%!4@)MtO-}`I$m)f(Z(2VN`t65Deb>PDZv|6&uR$<7oOM+PuwfGnrSOl?MPc!
zaxSp8msjQK7rm<$Zcz5OGtOGV(#g5Id3Q7I=oPqj)>BT}Qy~MHOA){`g*XFX$$)2&
zVP1Lo*K0cqj*|TabiKr8*`t*_cuMocfGaxeG`;N8OMa~g9^(k%9Bf{~34ktee$92V
z+Jt2FI54atS(S?FhzQ(528B1M+>MCfu2B(<_-+x&6p<{7V2TK)sA!1GhM26!TNJ!Y
zHY$={k#td6AC<^h#{_L$)MpiAUeT8#hECS8yCUtZ2+&s32Xj0q(c0w^{U$x5qH|Pq
zY&U!~_tX)A>iw>G(3AE$!hVN8?(_Rpug1+5+}jU(o~sQB*B&8x6T?C29$>tUQKooj
zesU9_X3`1nA2O#WDAyDN%M_ZXYmwDDUTB_Nhol&_a9{j71Aw{F$F!=kN|F;amiR%CHhvJOg?
zHCkqBZ)WuMq^_AZG&5AL0p23UO=p5jnUE$M)t8c%5NPV7%AgT(!E3wev)}U4-iu=(
zF*|mt;s7BitmR(
z*MEjRuSEUo^z&F+p3a6AqQW$1f8AmDPshJu{uqBj+_tD?%VvOEHC_#=+0i=<*9L7!
zX9jvf0)j!;OY2iRzO$bHyw9=eMxLV6Z1pO1$`;J1wVVJ0HEMdXDxVJ}mR=;Ct_F^W
zB>XGgZ1StP&1K!?xFZwB-9hKI&w_#uGewNyeL+@$)?%2!Q-<3K@EAw%)MlE)@#{D<
zBQadBc6rO?h=4AS4m{c%$|TNh5&_%mq4;ru&0LGTzq
z@%rldH$P6=wv!e6X$OWFSas~PDP%QXeX`;_?YM9pM@~C#h@eY}T28glhk8{X;bb_l
z6}F>umllF=HQgI^cPDFJ$(V;FC(9zX^^5SkuGNaSUvxK9rdq<-NKsJ^3QZThg95Nk
z0qS9e+i1$`b*Y_o)e^RR*q9JCaTexfQE08g8^fG2;3aDt@R7|8`k6CkbGiWrP9Paf
z1&LK8OKv>X2fPrT0?F{fIud;d>rj}Qg`+tzo{7b%iN`Mh9OezM;5bfxS2RGZqXwv1
z)S3+rh{3SJq6t(+KPp?Il0`MgG0B*aO^JXh9xz7Xj{}AXNGy|Aj!TAwWJtGx+G4NrHQgU-b*iUSFP>H
zTr)ho!M25I#umF-SWj&(I0K4rw>+B-_u)|9?TUkn6Y%R4?CVW#wdU;=?aj2YmW120
z^-K14*3?Mp+c{Gst*-;yX+yV2C19EvQ=PUh(Nc50h)s53|
zPAg+-u$|{?aa}p8%?1`*S$ivQuO+F>TQRbn4=)y@nw+wfl;_liSP5x1PNIs|QE@)P
z&nf&|h@TDdbFz
z&R$<&MW4GQB)?dPLu+yXV=`Ful>8Z$)5D+`{`hhfJRM4heQ~cR?sNpec&)~Fa-Le+
zlZ`k9_mWjVVKb7=&>QS=+#_63)1UhwDyH%Pqf
zu`hX@8mD>AW|;JtXF2vi`=!?lG!&5G*;W1UsuiaFZLb()8}y%_+Q*^IAzy2@V=eFHcFh-K+lB5X1E
zdVePba;pv)?Y-?Fjy&9p;tqI5fak9$WKHF_aKibByI_l*V2e-Jc(TPfe>?bKJNW4T
z${(L}>?a+^X&1zG0L+I?O5FmOfn-K#pxSlTb+ZUIIPIYw4%#ljm^OrHx({FM0>aYQ
zskRI&=;rSiY|Vteo3qg(w47~N@$@K5%faeqIB}z+iqm;}J!5O#s_HxZ;Z1}X=L%JGm1N8)sX5eMT0Y&dCMlG3x$YSKY%
zF08L4%>A-^8&-G)|ET@jZ62O@r!DR@h5fd))8Myi{&klBb)AFV#yterYT#rjANOb>
z!1=0pKEmaPixyX@a%UrWdriEzA>H4S3CWbzMRh+2%(UtWgqCqoO|FJ5CLSLLfnl`J
zduPi3;*WE|>5?*AkIi;cbA!xWKRLCUo_e+;{P;X}*0B!Lvz_EjO_|I~<9Ts1FHEI{
z@r*o~mL@aOL{6T}%Tv|RbTcyBODzx5+5s4x)&j<@gr*i-sz#Se%0e-`P>w8>B5WNL
zO-0Wogvo?BnUtoI;$&K!g0iq&#>%v)+1b1QGd(_V>M%1cZe>M8w7
z-rT{kL#>ROr%oxdxDNYUan=($hGg%cc_Phw894y
z+7r5B3>U#dT$+!G^U2^+TwaXu^ATY_#LtI?1w~wh(2=~;l5Yk8R(Ebj3;9`zZ`%2o
zWSrxkfJFZkTr%gpC3?oeV;JI>8$rS=M*~1Io=&L>2@`0;B8>7_
zz>jv4>@qhFNW(g_Ipzt;NBLjCGw&JW-LT6yIM*9Y)Dhe_dB>}g^Od;&Mkzc~Pb~EE
z##Tm`5yvB**A>Y7hT^?(eKmc558T2|x-h%2ycC629WcPmDhN_KD{gQnc!}{@)3q!{!m8aoPdo-?_0vEsj`+Ps
zi*ep!UNY%H-&u!k$>Y+Q;jQ(+Jbey6AO09;x@;h>)?uEvo95Jya-ucPx-1J``;y&d-?c>HNB=SpJlkf-D-(vn;295#V1v_iglzP**FNpGP5A5+VQxOg%_sO-j7ryP
zo;{jw_W~_!WhX5u29g0?{I)5=%v>y5iY;%5!0H`XVcgMn!Vh*M_je+&!Z`m0hQrXE
z%>d3_h*j_tGyD{MVpu>r|v
z1ZL-c-Lg|L0>dYSVZ3TThJjvz)C-kaIwi@1T7GLe<
zt?iVlo3%rL@u1)u7UA$by@GvEa2!Qd{feWI5L!@xh07#AL-8e%Y;g69#ym}Y{B$KY;UHbXdw
zm&gPYiNRL@m_VBh*%CpE`V=IN0ljz{GAF{2DHhbnL;847p9mQfK|?ZxPt$|S>7XGU
zGM3`DY67=+$7Yk;?}!Io`M4iA>;%B$jf!Wj@Zg~z?yy}I0Z!2(rJMeHP@OU@)80}8r(YE|>n{usH9zQz>KHq0$xsJl`
zo+xi0D=M4cIS#&a6ngvMU)HbgCZK9
z&}2@W$_bMt3S!TdLsPZLY=^eiF$}WCe$Kd(($-^3h45THJVz^_l!bz_1aKB2ntVi?
zQ#9G|GSsPvSw*Yvoq#sRUw4vhcfvwUS528KNmIA%Y3A%nnUb!v;l)gNF{>T83Q>c3X79boFs%Ck!20xMFVSteb6NC2!kk@x!X8S8{GPg{`)5dnfhqsPNz@
zceW9^+KxXyEgp};hlAkhS_Hb-OdJhE`#t$=Gk!1%Z}oyZ{qRm-*z$+tIT8sV-5FIHtWKn(^T
zb%o=;jDMw@4Ic(xa3Qohv%+_Ze7h(`Wea6anWtU$d50CGybeCUBr*DG3N(e6*-LiI
zywkqqurA_N2pE<)i_fVAnDv^8<;7cY#zw<}&u6h&mo3Icr%mgyELjZK@$G*WO)%3m
zGX?>aO^p*AmPNaH0WChC2yI<(Sr^>aML1?~+G&|{Ip!U9cu(tFnk#CVDv+&)Fc1p8h0_`n86i6;`;#SZV2>+
zCuVcQz_0>0{BSSwa8J3rC7-YQuL!*~F|5uIQ#6~k7wh8Xrg)b;aR~5MKkDIb_~CZw
z$)56fPf;(PfA{00V};IoDv2FuJ=bZ^$x^qh6uTw{JC9(L+s@N24H=J_MaIQ^%=X~g
zX#u*lLCAKS+o<_QWj8Pksns9XYu?qeYb9-lSFXi0wYa96vkr@{Zr0Yx+AvsLt@_vM
z;%ZH-B&>PGl%?%%aZ}YrDGp4NvJt^VI27Q9iHm?P$q()V%z!1R`66D;a=0k1nietv
z$<(scExZc)>SQmmndH$)9)@H4+aM0n+gu*C;K!1&pI;MsogEyA$!
z)=>yY-aMq`Pfz#7=d`QDzvS`9m*JmZDtG&)QTkRzex)G1p5rGnWLwDuvxUR}#{?{X7A@6Uhw
zBokg%_cVlXLO!yblyS}ilnyScZBALnaR?uR7N<3`mUh8TeH@8t3UOT_ZYU-UrKGu>
zGS{-!dd{}dmD(j|r|c-imRhVXc{5{Z!}}I(?YzBT^$hF2m7=Rta<8?-e$@y34{H8a
z&W=twVXS8?-7;QvwsKbdtlgn9YV)ftZnG!v41((`Lc3^h7HsXJW39pU%dSDi4T^)`
zYfYh7@pj7Ye%(K8^4+R$)RucSu9|c7>Ov`PYZN_|tfQQ<=M&~(JCKW;(h+?oYQRhA
zMCHY7+^7iik{4EWDkRSF9vIdM&NJ?JkAc1_l6|gQs&E`UW*Z^j6udCIz%5ziSa2>L
zngx%ccxW!EEWBhhxnyRSfoIhmhuFF)85WrdV160UR%e=3U<1r>%*;2#l;89_Zg7qp
zyyJ#ozaiRhgx$B2`~7b~*6)qQ{^2IWYKW#eGOF
z*?Zdap7m)~_@w7KXgf~2?yHe-XALBVq^l9-7TsPCL04;`E0(%-J`A414Y&DG#nUf(
z)|=rUzx%itxBKnWcH_9$HV1#{cP@GyOE%Mt+rGegbZ+~i-7;r3Oj(W7ZpV_tGG}Fu
z)@Gbl3GH?1z+;>B!5_OET9;FAGA)?ROIEYSYQ%>VVu4#bv&A@5
zokFIi}uZ$3)I11?KWGX1QJ7cHlznT!G}A+
zdt0*VkMH1KMhuQV*bTpoSK~PPgz8O+5~u0yxZ%@|i_~?W<09;OPgdOfL}eRnF(r1jU8fi_
zc04q@MDNn1u`53OPlahYY6M%NBriG{bdPW*#cvGz
zjrdp^2e340uvrnz3U7%?wungiS)ej5GX-B#q5w4^Sv1EaoB%2Vz2{fT%2ApT
z*sS}Gdx5ioa?}m(b;SLywBHr?SA_kJu-o#p-N${q9Y3{A|H(i)8)6(UU5w;A;PF=I
z?ndD5x_oy{ytgjg+Z66^3y&zPEA(VP@Dwm6e;j;%7
z{j00=2i^EsBRpM_XS3pLPMW1~v~(*UoGdE~mB=Dgi!Wb?okMfEzzh>@bVwKu&F8}l
zxzGZc*9g%U0)6rHTH*O*Xr_?R{_ZzF#}9k@;4mRiN4N=iVphs=Iwnph0<+2Bd@{I@
z3@qehx?EJ7QI?@xRFe)bWdQYv2K^FTZ^4dN>p4p)sV}EYfHAAQZz!iMg}4zdzzn0@
zuleDyJ0(vgY3^ez*^*XU()nH~&~`6;
z=diRpP+EBhYXb0Odd$
zzhW{t2jQ0t#Z)kpUH*q&LYi@U45D?+zMGKjy%q3|Ngg~MgMsGVgk%om0CLRm&2M<^
zulXFW@s8Kki|KoO5P*9=b#sDaP?_1_+Xz)2YDPCdeuCSBY>;QP6+J8
z`DWuR`D5LT*)VU?&s$9zx6NQT6Oyf_d6#1uEVtVhZI*ef88oGEw;H~Ni0f8Bmtxld
zu+4~{vdA3syefEToI@wWH`_^G=d#ry%#(JMyC&9!BCftqzUAjR_
zMwa!emwZ&t6V8}(E#i2)63!>QYQ!60hOP~?W5#Ej_EG*9MX?Ppp8%=)XJxt(vsO^0xkw;f0qT!36JxAK)$f
zq=yH}J(z5mMQbKV1Y0cH=b#{GtK
zqin{2@&ulE1^yVKbqm*m_jAMdt&BojZw>91I%#%Y<^*m3CS-EbeIGFO(7q6
z3||fa8x)Y3H{m$N#yLxbw~-H)C?Xw(gC`6Fw}f6;;h1bS!8ky8P6WVL8`?NJ
zA!~{VZA^rXNyQ9XoCujyVM|)Eroxadt=Kb)J&QJENe9i;5~NK`IFmX6Gx_GAzM7zI
zFotFCW?ek$g^vf}!+!9f8{BORTQ9bw=;bZjO&<$f%QTTpQ^OH(Qw6%djQ*#`57OdPN}SBd
z(}nPKB{o})EtJCZ)tIInTh6iV4)H3@@&=|eftf56q#gdz=0il{Y>;*-272Lx@w5O_
z3;)W%4B`0BY7Rf<%P;=gsR?m;CMHdzec4etk-{e^KnS?2Rog;bpI0c*osVdtLX>v4
zQTx?2x#33MQO`M=1=spYXsf4e_QU-;zdeW^ZKMxI$^BvS(OLV>VeR4h%JFu7wH@B<
zDmb&Abq?y{MmM}Sio?PltS9$Y<2e6tJ+(hdtTx3#L+Dkx!}a9;D8AJVkD3yQ-miFJ
zriXP7T5F1}yt7~BIwdboZk9Yyr^cZjwj}VrSMxTDuFbyEt#REt4=RJf&9b-Ol(tvn
z^@1BzhCeQ*tm%jWB#s4^qVhsSng@(2=S!SZOMd{&0e%K{S>~o8fEiR)ldIJvEF!TN
zEx|ItjfaFuAUUPX=VFV6#Bx5qR7`5n!P9JXA+5||V3Z8b#DlQWFB~&q%#SPlq{2^x
zXvy+eKp2<#v7j^=6baJ!SZ11UiryFU-4gw`1m8{Gdz16r@VnliIJWZ*^yWc)S4zCSR@v
zF2UpV$k|Xi>IL6@e2Aa*%ZZk5Vzn5SK~IXtC#
zT*g1uymCIH$XlE?HGsUR8eBjTJSIl6!X4zHO>^ozu}KeuyJ$7S;Lcn03ueQj#fbO9
zYU90xa8;_Yb~`jqd?0XcngyQiR{FV4>yjI?Eu(|CpjCs|YM+TwnIYV5*Wg1OHguNN
zAp)rHb?f|)N6UL@;fmm0N+`C3Vnv&b*pnf9JZOb)hVN1RF>_1H>LfH^%(=khDW7AS
z)_ply%-4?8=bH6K<}e{ic15-gkG5D
zO_^n5h3;($IKAl-wWU04dE?>@B`)kUg!aw@t#5-wI98=uUu^h
zAe;tTs~69|`=NSbU>HKwzBF10>Gh5?JIAnJDI-bnp*fitoX8~Ke&-$qpVv*{CBMwPzy0
zvlYrHW+)vtrGaFMU>mZEAp?a#7GpJGYou($ihr{yjw+sR&brm`?Xe|NJ8kZ;FQ1K+
z(|+(|5I9?fq_b7|Vl8wwkPcVi6Zi|5fi+yNfd{(*z!
zvL3n6VnJCdhL_lEu_mto#>=Isrb0WjYRhrm!A223vvC<8
zj?bJ=D@&QECL7acA{vl58zEav;pmtyAJ=80#O7Q~3)kByINK%n;YM<+ABMHvU5!`L
zwr1X4N!dWzcG0UY4Bza8H#(uK!}8f~?)Fg?gzi@S+x^H+KiVn!8d)b)OFKFx-=HS6
zi=JUa7}R*Y1sEQ+1M4e6nC8`%xZZ(v4&fX);89!J=mueYp+SR(8(!}Of!hJtT=q3f
z-bT?=%{l6M*Gk2Q@7XH2nmJbk7%sR-iCa8B%SrR)1Cll3=*G>f`@%+zbhSd!e4#)
z1%A+5k1tZPMRYEDt+OuEjN3ftHqW{&vkp*@72*H|Z6;V@n%0G91=V0TW!@SPY(5~<
zJTG{S(U2!BJ9)1W6eI>S-+b*~P4hPMf;$REQx!yj)4
zE;psiZTap_@ZrAl=pX{bk^?@7Lgc3plt)MCN1hx+pTH&W1%c^
z8W;wE&$`~Lq5pC~&iK6Vx#-iuiyn8;6EFMnMPEMd@LLTx?F`o84&aYF0$kU@3cpeJ
zk^QavcUqt_KPb66Y%`L2!qCoGhHOjhLB+jZ^TS4u%D(j~f3?4YA5CM&ZkDVttB;}b
zOih5g?#m{M39E~Gd1{$qrSLUcI!IHtptU6`0+UAYI1I89m31L1)J6T5`CqbMM`8s)
z0@Tr~>Dd&xW~YVmBY2o#d@Ou0%rT=cZ;J{xz!*OZR0fQ}U`nNC;{(+ngU9MON6XT+
z2*9b3odu|^)CP&ish~X>bYPg6BqZBXDtf`-fSIf?@z|D$IG9DYWy4lgIfb&@G9k9v
zlwv`9{gPtJgh6FfS~2CKhMc0S#7*726Mv4~7I)kaoUJLx!yqk6?n
zJEmeF)H(f^@#;D)BATWB3H)OzVKOC6ktYt!uym@~6icc?U!4Y~HZ+?G&t{Z4P&uzG
z6e($oRE$z3uTorBP3UV$19Wjn7ZAZXY088aQ-S$RXg(K#X{LZSJaHNZS^1=`
zv+h>T-K!E`SIXpHSDVsmL+n@iRf<~6Yb(J)LmbqF6>zlR?$!8i#S68|o=(-@uJ}7O
zaqX(0`RqK$=?B7p@(o~Ny&<%OuU
z5EU1~(p)ZSLQB;#S@u>4rr9?sc_)}A)za1>VG2A>vVE7!No_rAXylBwtd^A4RZ^OA
za;cP9D!@I*0Om!S;HQ}OBJhkqXd*Zr4-l0VX%g0%i9*?s8o_3EnWEVci)PJGp6J+>BtKKdw`t8SwLdo8AouY)4G7;pd(HOMAf3xV5h}2XEM&13?#tV
z3?3Wj$t4@+tt?&*EBsFwM*B~88Lb0PN%$z}g%$pX)K?+Z3KNeV8VExN=pP*y7_0-2
zCE(d>5Infs8U(La@M}4*#_wJdJjAg`Q{^bCt72K+OhF8W&aSH#UyG6%llS)6*X3}lQc{&tsZ-nk{h3{+z?`)A3rpzq1
z*a_AdZsRUZ2EzwaVwWny@L}Wuu{lbU#7D8mM=_w9^1`+Qk9H{^n>psl!~NLZ?SHkB
zOatk{8GnjGo-E_=SquJ_IW42DH^pY=Q!UEg`vf8O(-QKExz(&cuW?ruguEZO%u
z;&zMMZgXnUsEs;pOahm@+3;^-=%2gZpsAv0+bPRhm6ptc&8ubK+mDX%b3gm^52b_)
z97>QOrbH)N?IW|fSlI*;LopWb1@MT(#J}t5WP&2Yv#O{F7kf=;3NKT>l~GNNCLa5=
zAzJA~g}Q=ZFgwV$jvy-x#0J@Hbl9&Cf!~4&UYQaG1xuK>C>)7V*&5|-G0_&2tdz7R
zSun!G*CTWMVi-X)#5fW($Ae%n&}&bHS%4Z~4%wKlpQghMx)BGXFBnWdI0N)vgVv!c
z7Y2!m$JsDp_yvs3c?AN4&6$WPs~B@(V=ko2hxO%{c~JK3Q4SZ`;-f(TJXUqo$Ecm#
zYf<3(s3-5jH+TK;%9rc3X74u3LwvL!eXt#RxD&*shymgQ3@%69gDnwY2BDuHh2K6_
z-Z_cBa~whY?rH4Z69sryucH6)@dL#_9^)pH;&e&^gW0AIfoWLbWNSDhJ3BWT*Jg7_SfHCk{=XXZ&PQ|}c^0iAofU{HQt9d6n{icKyYI!G_
z+JcKZc~`CIDd(Kkg1cVw0L-<#tB|r*^3Dc@qxmNIUG{;y>pcap!V{})9p@L^D^-Fn
zo&w40!F)k9n-yO%W2+V1-KLlWi4$fZypnTf`*jZB)jsa2_yj7cHHNWwq`Y
z)@=Q3e(tt9REWnjT)I__NAm2rz~-R*`&nO}@vnD&UXr
zZBk9Ud+=LuT9p1HLsx6k

ErG#>)2cpWevdgp2s991fkY7X_)8$}dO=K?GZ zCNQ=^G+ZfbH#UIx*&JtN%&W-Myy~RnWyzyfBnuNoTB zvG`6SgK2snvQc6W!tOTPX;gyrJf%eK;fXJnSS&KV)XbSh8&8-E%Xo+poU+rW zFK*esGEbUSt&IS4=8nGgi>(Tgsnr^dDoIDk@T@eENyyMBL&XH}FGfDpA&i0X zs3g$A6A#Kd1@Zhuz_8SSlS1H*qkc}LQK*Bckh%F(yviiZh>*}p&RK2mE0vbCU#_H= zl_})wDQt^&@73rN6yTdB<9fygb?t;U7G{#sO@qehk)BH@1|ltE zk+`(bz(E-*%k)v3RY^!!43+quCNC$rKwt$;+T^7L&UB==8Amh-^?wrFt7BRDk3-QL z5C;)6l3J-|`g>oEO9U?uLMCgiEfm7s?^6^fF1|Esb$ifFOKMOYPHl z*mzJxrV*#ssiLU$b+G>}@hz!(q>r;Kg1JZLCwjn71e zk6FHWgcyP`kjt2}coiq~wujh>WQe}KN^tzFLdV(l<);3pemJ^P+ZEt@4esIC-#(><=bu<)+lQglz=EDlS;Q9YUDX%=yEBk ziJ**ufPwe&Zb7@LCMUv*g|sa_9+mi@-A5HHWN+A=Lf%i@G;2g1LEL!53GMtWIf$P+($*3g8(Xf1nxmgGKGkK#F zVo^UNILqe(!&Alq5Qm8o&lzPJrBeIuAL@D084vttR8$~^{B>_8_UkQ{k2ofN3&=Su z+Ri!|PfsNz8Wd2bQTOZiRL%rC=$yBHOm2}%jjxm{Sgt_kpeZ?Xz!Q122+mmOvG}X( zTh+N)2>yh_MrqrifXaokWuSAE%V^HYK|nP|-Ie+=E?uown~44KC9LSim)N>}yBmzH z`wOj=B1w$w7HeK3le9ab9vKkdKf^vza-3xp9b@BQjaFNj>p5!{B!vLgo^fbQ1gR6> z_1Ug%tm_mvdwIi;Nkmp_h>Myz{jK?vba7=CoPD-P0Azjym8`fJ?ovlQcHUrPBMtbs zE75hfDx|5{Q$hgE16cF_mpa=ZMRW)R%uYz?B?4h_#HytUn6Rb@pteK`4^RLA0c#iH z(veCRn~*XSRJ_{$QN3Y2^c%(X=$}@`%}$#rk|3}ZCZC9=J++WZU2nNJB%toE4wBSh zLJLn*N6bh=;~m8RbwA)?N%NDQFK?@6u@EvmHc_i4yqN-0$kS}5qiH7Nw-N~b`ZuWs zO0#pA;HOnNk*O=AEcvw^N8Gf#?3h<(xhL?}RI~D=kwn1JNDFbkm(XsG^&naM6FK&> z61T4Au$^QGHtUY2tky&WK|dLdh`WH1pQ;O5SE0Y)Wykf(CTCr&z(Cy9(Y=dYnr>g_ z?TD2XK++njBo*U9TIk&5)Ot@Q`j$*dco0`7sqRvBuTux_ zs`*`^XvS-z}q44VRpD&R>?)VNVB$iq}25Zd~rGR!wCju!Fh4 zHMFl)}fu zj@35Nwu%f)rMISwfE{E%^eA|+ax3)NJHN_V~=MatzB?#=PoSW&Sgdtn}#Y@lV#j@xa#FNapX zxQ_PlT*IP(BplY(lHvHA7MJfeYy?Y^_GX?zeDLkcVTNT#y5P8J1tY-)xRzu@Oo=r+ z_0B~Z5u(|;4?m6TG5%WMTk!TlaJ!;uhavmNs! z4MS6C@$G}@70v|Tf0>hTyNEc^Cc@|}sWwSB=gF{M5=~TZxet;rfz!)$T7DdPZynvq zWw@mkDSZ@#v+&x{Y3@x-rzW2Ar)31+2Bn38F~c$S9tgnYqB#V?&`CV3qnB>zwcg~9 zy5BHsW(R$Hx^gRF*KUO(fif&MU6fmxIW0aEa>I4`(Kt*Ao02_|Z+sg9#`Gt_+)lPKwYojj31?K~f|wS8&?#aUs^EzOdhVyM28U-zaKPSi-TNp-qUSx5P0 z1fM&{#U~=-;a!xx>)~NbJS06dpR}H|p8F`4Z-B1!${J8?e!iZ+FpHBrodK{!wQ4;O zX+bw=5(X8ZxK>|OSf?jGt8~aQA8B(fuNPD16rcZ)8KxnN55$E{%O+%6X~~J6(~7So zTqGAPUj!Dj6bQ+p@kZuPXB#98RS6mF(tOieC(RZWZWL{{TcChzYf7TGNT7>2W~6@0 zK?_Y3`oOWyMW(F2z2IJ$y$>+$_SF0pL=n>AIJE|xw7slg{K9=wrhSuW0_0NkvY;l z^V+sza?Rc6$Yah^kz^xi!jJ{8cP2cc2u`yTn+_PH5s^4=YNuj@!iRH8;?eG?;KVqNgvPNIb zwiQY3GBkWsqDgKcM6Xe11y|;@O%mxZ%KTH*G8rM>bSzn!QzC=x`B*7!VUm~0A8c74 zC2^>#{3Lv2UPR4m`s0-p#g8KPiGO#)i!T#sBmnue`1B-fB+RrTHPL7?@{cuK)fef9 zv^33pl=9Uj`|0LDL@FfH1NuxOXHY5B84l|FIVL@y+ZI(M)kQ`k$0B8@5as+e$T_`O%u6#(FcpgCPp0;%Q=;fm2Qen zJ0+A~&8d)?@US!%YHDsb(Pi_Fx(;M|M1F0=MAzW8AZi{ zX4|-rArOdUF-w9tfGHFNia>>QImK7!`Ers5Z;_D3=PE%2qOP$5X%TRF0)Wm@aed_! zo>W+3o`Dmr3T0Rfn#eJXCy7+xq zO9g^QOFb4qudF#nB`0FDI#~wa(R&YOx_>`1fBwD}-5)t-B^_tFs| zU0dIHvMf66c@Ng{!a!*ioavaQAwecd0*=40eZSxyK*S%&<~;S*#*rD4*(|+V$;CI# z=aIq{^!oA>GKdzGK$amA<-0WlH3rr(N`R+UY83m;H)<+)QDjHkG9I~>S1E-jxye%? zJ#FL_C4)L|?zbU7tH+%U%4w6}w0OF0EFz-lsZBVQ#VA4AiS2nn)#o&#q!2#5$KsM% zRLoqUAXi}#>6LS$%TeWJ0PZ7c&*^=}|Ng>qg*|4TREW2EIu9*WA#u|jREC)-%W(@Z zGfene&N(vZ)B3QsuYML&O_$da!J6-Im6$E0Z2V`@ixAQ6eG))Wsbx%}RTLWWemNJ)^U|DrGja;lr%Bsv!YUHc*K%28A@?GP%;uHN z%9PSPjVlm-5*;dY31VeY@s!nbd@K}>6m%O(C`eD6%V~V?^|*R-rJ5y0=kTsstHi<5 zMfsf+wj_#$)TY_Oq(K&5qykNdl#%>iDqqrEITf}A! zwP(H)nd%vGkopm!;dEK)MyDH@@!JaonBDoeA*$VyPH7f$O4nN-E9|_ET*9wCtp&bR zmj2dxNxytuY{?xf_pf;Kre&E}%E|c+O417?r|rC>#(?kA4izx$Cg-k-$(*0q$}G!r z@=WrXO5g`-K`5yqN|b_~G{U3Ez?ibHQ#Xdef2=9zmelk1)U(rNq@odsrzTA$mzKY~ zpcsx!nsG`*#Y3JFfKN<3jv-934?=6=6p@jmK~(|mLMiF<5lf1dX<BcO5mWH_dXR&GCT54hPo=Ml;gM*H3PEb6Px~6xYZI|Q$ zLhBYn!^j$wZwDQV4_*t&m3=y~%KW$(TQ)$`t@`semn*X2ZBP|g1q+ySWq@lS771Wi z$O;-oReQvzUvFK+d@99I`tq}Wx8IV}Hqb>aOF20?K7W!__+bq=lHB|y91Fu#Jh&;% z?aj&bry>R0tn!cIL>EAkec^~nrG?72l+TAiHWWM9BuFgGZQdfQYzX!{#RcNyS7zP@qa}VD|+jA=#N2U;Zq>PU%W>V5KATM5RpG8L3G+5-C2q zC_I#ne3nlB=?kRP&Pl8UKerUaxPGFZo> zOm{&sz>3VdZIZ@zq(ijaA5e1_W-8X~yKQ?^Pw< zte3$Fg$Qv{Gj;OTWn)KUY&jFiasZ@!Vq8@Ugji>Ii>SAWm8AAQqH=;uOnW(ADVB^t zDg!ejilcP7ITDYXaNLo5Gi7sVf`)nTd9*Ci{3SsUh5J?&P4C@*QC*9X_AL; z+tR|r-1~ZI%~I25YrR_JiaO0@U7I3^6L&4-%3gKhrtd_PE9@Ud6$fu49Jv#+?O^{@ z)-X1-5$o6l*E3kla$z&yOa-eCcs-XEaS{P62+(Q>p@QDLG6ni3*wj%#fO2E;u}0_O5tm1lPL2f!Y=l7<;6DCd|KF3@_^A^`XqLxx{ekiPY!X3A5DH5r8Y&U zVlrBV?zxqLPEge1EBGkbEJumC>4iW;fXEU>By3+O3R5`1#d<{;qLHyolbM*rC|JE8 znPn!cE$KTmw_!MX2or%ODx0>7aF7rxbZFCV-2eJCzaK@+!N@EK1p|DwfpTAyY9_%y7r zHF6FV@LR0(3jS-zo%j*6PHq`yXEsQ`Puq0*q_?TNi*q=E7z?UZuceAnVy zuoT3(>&;_kre{aCYEpnkp|UO83GY#1|F##Bb@hsn)C-OA52PdAqyB&Kr}_PHirLMaI#on%ZVIkpJ32_%wwW~Pyr zQxBO=Tv;etUNhBLnOj_ni%L~HTA7EHVkz3`iM0QsOlQY~Qb;PYPQcSi)2!-Tl|OKs z-mI3AIp}}MJeG{7zA0$g0II7c#$u9WB$yj2iwgRNGBC_2o11LS5{+#0Gc0BrV#t>mSV(Y)D^$OS z9A)aTEcy;=ZgT8(ZD1Bs1#H*93(xc5V`H^ule1+o5np=6?@@K2%p{u@)11rI!h(FB9TP^!N@|#nho+wh;lX9g` z)8{O$b{j?bKLoNfG+UntX$3iCA{5~r<^=%Y6d=q0;Ta`Jh*U@0o@q^RL`xKfPj0^! zotslFO-u}s`L$gS9&(_nB9TGwEmAy2hWhM_!Ry7ZYTWwWl>x3*Xtu0y zkdG9sqUkxNvnLEv3a`|Oxu$Td?Yrz5OT8(oCJCy`&zqM3yVP0r(h7K_s|20IELtbm zv`ol@qgCrXhCc5VijmaJ3KK6Jmi{j*!Tu7yw%Pff>Yw7mQ zI^L>r*`xi)PR`0vCoB%FJ7n@S^`yQ~t1^!}VV0$J<({TxyV0`0daGO6Ze z&S;N~N(!Obl!KUBSNM1}2+f5OfRxBYBAl6@5-3ti*SBJ$(OF_@tcfT1EE!C}3lk%v zuWXq-Rw~419G8@Z;2^rPL^mC1#}s_*ALaFPBf-(9g&7Uyvd6x8d*SD zc}71GrI&RS)9GORe0004Tfuci94i+5;1V&6k;~>?fUZb5)J>JlebVh`P z(#Q&(B-E}F4`>3eOD=H=K~6T6qKh=_u#?=aZVp*? zok@He&5^)N3bf25Dsr>tPpSrxqw?^$m}YKeM#_c$1r!_gTt3nHh{SUO%t?<+QJwab zQExo(BF;)KB{`xoLR0QxeifT%NzCn##2v>`N`4C#>@`SM?X8@eKt<>)bT!1)F#;U# zmQRD$M7jRxqKQNWOq8J|(+<@NTxSqpPqW6rmKzqeHoF%K$rdt5Wj!9G16lu#uLEQ= zftcDVF7&f*got$mlAV~ELb|#rOFo8s@^&FbG1RhDz-)0k+7kfzzyJUNasV-iKm-^7 z004jhU;qFB00RIh00;m800u-rh!6&VfdT-)000aC6o3E#18@KVuwwuK0S+(#0Euo9 znU8w_!5{$kfq2|_QZL9l4j(cRdzw)jo)s}KA5BgD$nbiQuc8;`0fUIZZ%Jopks@SD zMF3U$S(;-YwCS-(qdA-OWRf$85c(oevNLB0P&Iam z5i#Qqaz&nRJ|wZzw9=HrSd#S>Z90M4jdT^9z%*yUgW<@PGRG{OtK7;!(>H_}5{ru@ zCpwN?CxWE%%}l(zK?}tij7_9Tfw37}T174qbm$TQY{Zw8kbSC5F7#%{Y70pOvB#On z>PuNE{+dZn*EZ2AUtF0wVM5{d3I$-xCaLGRqBKj(XI1H|C7+IY{nR7y2v+m2KZVUA z-#wDy6v>}$;F_Wi&~)G+@{ccB16>|xm<84``Q6WW5cyBn>L_Y5C7gqpN3mtT=c=gS zezRLz+Cu|5qw+_j9KeVgGP3R_3C@!28RV|n$$I*#g=LnT)R<`S@0zeUbdHj(&?`WA zp&1U(C-rC5D75i!@=H~#zi~K(4w4Xbn!<`0=SVM>>g4htOT7ix^r#gy`|H;hW)sgT zZQ4>+hf9`E6;^;71i=`*7^`hZNsxUcZmPXNe#v;g3c!D|>Bgy{35|zEFHUIYb zTDYu=dNg1Rn5WXea);!WgC7l`as%rWEhi^70_c6Tz4sF?P<6Mri*y5lCB)NAbUspX z?YEPP*nx{ht4lBSi}DMYz_3=Jv@Do4nvdhS0LQcx?LFR|SF+v)s;Lnk;#J$EuTU2< z9u@7wbyY8Xr2M5Y%X~Tx1$hqO1gPD&xj5&BCA;sQt)Kdiw8`;v_`Dy9UUlZfMXlNB z`nLVIN-cW=zy@;&QRb&YXz@l4K1heroDOu<=7(pt8mic@_EX_14wcl95FDL7Zw8=! z3c(Lm@=Gh>HOBJvC#2q@{lC2rAlpH#WCTjb;|=+T0Uo1uPdqvoztV2W1E(L zQ5iNsND(H0K@yo)(c2IOAVD#a6o`t}w6v=#W<*&CsU>Hq^na)VA+QYVDoIi=QAqvj zw9sluLR=9HsHc)PrX>WbjwJG|>XP6?tYlr(P>MgbEa!^}S3lHl1@@Sk*xK0N>MThl zP#{?YD`AnJj#y7KqY+eJ0RHBD|-Y&qp1$tOAu<(>X}hXnXDF$ucNWlycCn* zq;CaYU)W{QK~KW4sFi>TOj9@m$1~w_GR9n!@E1_1B|mLhE;P zR#6aXE(*#3z&N~KD)7$i%ID9D;#x&C1k?^sesPl+jU2IlBzf{HA_;^yRv;c?wf18q?XO zo*D441qrf$!9useqFZsytW;KcW0^}VbD6_N3`oyN;t3Up_2*yi1}Q1n$1OZfMO>^^ zuuB4i*=282Q~hiFqqs|hD)Fjl&~3yJKJ(M8TAktjJf(HI6>4OSX=Ob$UX2Q3vcm2xZBED(W%=Sg_e za-lk=l0{GOa`IQ5ggyttC&8VvI&2Z)VyA;DSF^YG8NMP>8F6^BiK>731lSlx1`u~# z%0#M5VN|w>&h4^O*O!5Rl8}LB_=2~$Pb-;{BwbglTIJIQU(@5@fCCA!2H1+L$sCss zO!duW_Sr4$1+rW*tgMO8qDCq-&?{wU)tRf>PA`Em@d z4Vm6d`hn*d6}PlpBf?9P)kW%TgF&T=LAkFfe2<&OZ_w{e#Yy9YA8>Fc&=<#o7UmTx z!bp*MyD6<&gh6Pl&6CTEMEt^C1HoUoLm(&f38cN?O#|h#D3Qz^+EzUZ`3BOJkG{O< zDO!_p^yvw~O^I%7^wQaOOJP>^BkZS_ICE_T@=kH^K} zDD=}hy;lf}m!T{r?#o*JJrk~XSEh9pr!p*ylWH`2+_H?5y7vXTR~qn^qi}9Td3wp0 zGJ?{T%LATDB~`QO{%xI4ZM!l!DQF?Z^O1A@F8!c2{#)?WoE}lkx&4@^fV} zfVFBkD$^*>m`yU8;OGhCVBt}9MPTI|Gx{kJadFdS5NJ|c5?93HTu^7-mkB*Ayv@0u zzsqUto}!Y@l%1rSZTD$Gl?XUzLR|b2%B4-6%alZM5z8nb78B8#@q>&Q4g<43QhtjK z%8LtnyOIttNIeCyPg4Zgw*p z4en5LBll4U2#tOZVW(L)E2bGL1!IuPB zNy*RZ$CDkY!<2&J`Nhs9pJvz}0OtcknbcI;gk6pZ;I<`-9m#Tvw}-cIY~XELpPpkc z7-7L`S0Iuutg zuqntTD0HPuq4gqM2K~#2^&J$$mqhkD1&ZWP1wSOV^Yd0x_!e-JkDV|V%(U4>^vM>s z%ydppZ|do-y|(-e6c2^wMJiQUSMrE7*0Xvk)EUFcl&lPV;DJgXgpA3pu3Qphy}=#odxF7Y?V24csL?iSo*lIC&2>w1PfT zpIAQvTiSRk83@8I=UP`Im5ycfth;atXTzr`)^d}T00eY*CEsdkttJd0l%>O1ldsHG zB;4S-*KM&jZQjdg%V(>4f)lzX^678_fGWfheVTRPfkdFCu2zRhR>(!% zvQWui1%~^b1b?MhWU&Kw_V($Dy~kxlsv-GL-JEf+nbu5K_k#s|M25(%xfVVg z9#yESI3k+HL3eRPxMko1%bI+xc6X7>^sc^}nMC{zu8DL ze8Tv!CdJeEo+Kc4smmH&p?H->e=kk+IbjibQPxI$@g^;C*Ec>^w~MZD>hM;&@nS9= z%-5Z@JT6GMLr9M0MIwuYo)6DF!K!{i5mDHvs#Z*WxVC;Pvy?J{=BpI`Lpl)hhrnF; z%hP4tf)jG z@QJDErlYV`RVT$LA}GrD0mFO?bEg2ONI2a4dbfscyBnrR{Zxu_NWCJUS|s zE(#V|zhP;ggM<_oA?aoHBDy#wG!a$`oajC+uWKz)=>~0%fAQlY0qD9dk)d26J!wf5 z!J7xgVV(+J<>ppLL2a6`JHU!cFdN zQtagWLTIAPvN$O>qq8#aDQdMAaj&`sZ7FqvbhxhA0Np7#C3f>}6vL}!4FQ=gNh~>I zmP8c;pkc#~at_Ft;DVS~K5FxdoF)hxi^X8VFR;j!{L4mBnITbJ?4GjZwhTEY=cDu< zn!*Mp;NA?(^mJr;`H=0o4v4OkQU%4p13H&qW>97S!j1|6*9Q{uecb4)fN^fa!@B-nB#bcp82QkhC)$3R zD3*3Sb_!CVb&4vnX3V3WFr{!1bf9EJh@-FMRFo0eGPGv|T*1V-DZU$*(k@n~441`e zEsp0SK2nqwmb2rGm(-!;tg9(UgQGCF6X=Mnt0({f0eO#sq5L2i3k4Dmd{E*6(g=)V zBCwo|!0CFsH6(mSPgP?gWLDq^YUYHzczE4Y384GGhS8vn4%Uep3@K{Zokq$9xl1i)j&|d4ZDbn%@MK8cN{y#u4P-~VcI>Rl0GcpBCktBx>yPjE}H9;*rmhV;Z~}J^B&E z#Ga^=uRl)ov*aU6I1`eul15P~yGuyc9-#D;NU0p~l}sLnhpvY>)kK|60eS#X0f2yF009U900000000I6F@OjF0003ALW3{} z000000000000000D8jJ`Hh@3?004jh0EkPqVI_C~1ONucvj_xZ_~nO_%vx6zCNh6PZcIokTqw`!*uf(n3AmrBINk)>7;z z2F^oqA)oC)1>SX8PXo2)sRv4vIDYj!rjv5PH)P^SC2_9C7d)LNo(HvnyQWbPkz~9N z>9r30Jm6(_2q&=f*I3K~woR7M9@|IzffFS=nGfc`L*hZVyx_)qjluK3akjZ-IexJc zFkFcj0w|`jL_t#6o+EgAU%v~jBYmf2wZ!x)Stfsb69#2BJc*^qJ#Ao_1XGFL?4TxG ze|Ja4j|BmV$p>>%x+!@i7-UBJ4)Z0ce(&}DQr=fKE9THIU`r>TMCT68-e&x$Ot9bKzgO(5KmqQ%55ZN zlXSMu0&A*0JRMN3(eeI>mpQsvw>kx;UGlH~E1a3~Leb|3~^`9IiCGpN(SV8)X+h=yHxTQu@XX zk;U@lZp;-YOJJ}>w0m|kvTU@fN?UiE679y8^ z*>+VPydCGAMa68a39f!+`*f3yT zOiQ*aWHn4(m@R3h+zo7R9O6$MLUHx&cc@|s@Kaqw~=;eO#j)ZP<$xpek zDVI+I%~OQhiXJH^BH;Tl4vm%_vh-ZC)77Scqg^@2g*KPGRcVF-Btex2($s%2=Ku{@?8GF(V#5T{{sK#jqVt*|F}9 zFR8N)b(t)?bm1K(+>fk-SLzQr?+ymUBzNXBAmvp{r}u!mmsX`A`M@hT>cmbVLfc!D zCp6NrQi2%k$()^j*F0??UHq13EtR&Tx!%P`sPIkE%Y9ayV6G*7nvwD|taLSczSfl4? zD~pL~i%apv*$pCjc>P`cTHd5p5JoHY08((uD(`5~uyTdbWG`pgBQhjoD<=)w@TYM6 zw$3VZuM~`vbrR^cyeYfEnDz=>&451?pl&?3Mf+r1g?guh*If@k1u+@Hv3tsklN6=n z-QJ>4i1h6#$C8-QZHM^spMRKwf>`mL)D={dsyEBwsZ;vwqAACtn)b++r!IqkeFxIN zeDxaC(#l(vY@&d+mOr!63CtZMSc6jg_l#lsktlqPse6@$EtZ4ArzC5zC92?1P*7FS zEdP_{5tF{P!_+rb%&RA0L=V%yfD%I<{yab($=$q%d+t1aA>|1zwaUN_yzY|fSgU_I zf6Ol5gSRZ9$+pMc_RdGjav>1WHiFP!E+dOlr#rc`i=?$Cc(DSrRc`;x#Y&+u3X9EtsIx(oAZ`EYoFhh4aK=7|Q&Y z6qvG)-RMdy@p2GylwJ6=GQ&G~GFw-!1m|3v1xd^j^WMln^6 zingZ+6-v;kPa7^=CFe}^Wz(E37N(C4TOQ<8p=U}~Fo8+zAZnk!O7UrVV+l>Xoz~)~ z<#Jn)7TzSCGr=Ft;VO~n1QrUVBE|vZVvU5rPo_w+qOf?m|E`N^mP;I)O+ltg!tMZUdI@fQRH9^#Y9Kdz|uv{xknz72o$=GSw0IvXjx?`p7O_w%+HF>^H_`a z+mb#J&ntT`64S-O5ldRjo;+~km@M-bg<6d0o~b4Ws>n5yB45QGYHcESC~7MskAOTDFHlI6ppY!JbQ_u`#dKBJZf4}$*PWB9*$*7ajdeI9U9@nht8 zJeoR;t*}bn&a|7cBA(`*?OT>D-Spu^=eRgWDU~uJ%~7n(?Bf5HdS8<3iWk#UaL_cd zeg!`e&^Xrvb7D2I=zKaQwU*O7>P6TpDpJ1`nbS<9>DM!p#oQY+xR9!}sX-FNk=j&Q z}I*E_PwthVy2nclI|T*=RZO1Aht6Mj^{qi`D4xj zOuQa-En0sXPfZt0;?#WP{yb57r%;0}9a>V)j}_5LR(n$ZYsyH7rpHNYtQ=?Kx3n)a z?U8y3a}>zs&AG*ucVL5&yt8q(PcIDdsK6)pBycrtmY!uCug#=V9t&_{(7ik|JG}IQ z&A`~5C-aUg`|GY$dVL!94JVeCU_3Re~-SH1$|FraL;Tryp!&w&YD*aYRW2COxD_~gz+wlA%=I}tQ*pO%?;GeihW!@5C-EmNhz#;q_D0z83Sb2X&^c-PqGmHN^n@Cr{Qi6@2s0?8{e( zI%La#DT`kgD-0810nVipA#zu+>|B1zaf;-SUix5QIJ1KJI;|~z!>zxRR)m#5yo1SFP z1(iNv*gKTId?nA03!gqv;EM>P&kGehOBioV&P#%Ma9?bwu(v>{3D&WfGrrzPtaM!D z!ONZ>qrz>Y&L2%pf|ZCrInC}y1B9=O9y#@ju_2TZL6OMl+rfg9Dis$zP?S^^Fm=M2 z)Ra(O(nsFntgzcOwm3zEM8T&hBIZR(mD(<;;r(94`A0%yHK#MN3crLzhm&l;B;NbQxRgj*mBkN7@Pw;#&U%XBY?nV;}18Emm(%M|UK<@tr zLM=n`PNL;63Cei8p6co@2)t{qL+n)|a^;h+f69|zo*;{);dH+M(RwDF>ITvD^RG_V z?KmuCy;>}o`*lT$sF(Pj@M9v*KA;|$mJNdp?DiMz{2u3vNTi0`Jd@U4e*t2{3yc-z zwj!8ncmWp2M3ie<^!7D)v2X@mr)DkdN^dROYdEt+Z`ZR@$ATlm zrI&_aBAv>xNxT=$)TprruClX-hmBQMFx)wtI4+$ubko;L=q#*dKr<*H@I^PWVux0< zvF!&zaniNSgT^i-KocX~#(H_iYe<_kUoJs^sxH8`3OPMa5wh5+Ba_^MRz{Q0$BrzN zqhVVrivpW-Z)c#r6r$*Ve34w5-l^5U`JICv}@cnk8hlMvE1Gc0D(Y$zmnf1 z+Fe{)ehPSR9C$BxD;Pg*Dt<%1I$#-@w6Bd=%k}hoM89zcTCQI@f8fDUCzgRr7-y77 z)6Z2N%Fh{L+$lY;#nDjq&1Zy1QlCS-eFWpQ_-$&`8|>(p!K^_B9|GS|X3O)>Bhb4n ztgWipj?_?ce@o}np1hGuao}?0l?tx~C@x`9csTl8sb7eaWvPyV;bRHlp5^nG?B!-I z){QaKf9J<6BKbytAc^j@(wMLTzvajygKVYMt=2Npjdb$hE*3h5rB6Dpp8D$8xzScg zq7R(4%($1u5$>)l2{mVdM>PDZ)bo`D{KJ!do+ORRDyZ)dN>cQ$0QbCTL{8AP9%=09 z+24bxRW4mb?75W;xl-m;wHy^oj_gR*x!IOSW>&7ye)TlFHpjU49x`;2o2Iri=toIz z7{4@*DtTmpri|8;pqC-IYjqGy&bi%a9!^4-|6z#bCi!BI(^8V7Zu>XXy(Rc?m9Wiqt_f>@Pj zbdURtnCl!(Ad3dO$cVad9-lI*D|688ux?flA(}a$Me&lJjuib4(%G3ke&GP;q`kl3 zg)^d1UKJD*aZ|RFEjQwIb0U6u^mfWna!o}Xxq-urf>X&m#Of%KML(()R}#EO zspPtTK}~xtFgy_LSS9A6MMnLdTZo{>u8MEwrUhk8j=&1oS+|e3#CA@ZGKu-G;Tb91 zRHa!zdM5|&TzF?-CUCDU0{oE*YN;xl${V)|`A2v4v#@<`KoXsV=a% zbVwR0JYg_)o*6C|E@qheC6+aqpa1{?frbJDyeyoxrnII;;g!r2}GF zQO$W0{`3?sj}W!kldvb97`sK>BNgDyM1ql6(x0f74(|$UAuPC(j-3Mp~&4Sk7L zLQ<%nGU5+|EoX3NFs|xakfhfV#N>*J!WF64izxYEL{2B^Nc0xfd}Wh4L=~0V-r$Dw zbS&s4SBK-cWm0hEmJO1e^)_T8w9{ZDtX<$M9WwE5R8rpDnmOeN9s7iet<#{t%vB5VI;>5qOWQxDQu?d zZX}HnMG7G|W?Jt`yEiV&9vf_~cJRSBT5GJ5l>h6G7GfC;g+%d^1=B298sE|tG>PDi zG(}r3;nZ`$Ipi=*fjw0OFTRdKFvOxPN>&xqv3Ze} zl12eH4QDAza&p-?e9VnjAoLa;!{=L(yk0HiCKl30m6XV3}5nhG@@8pKn^AwuxooPa!oFM^Q4)FzR^mbiK zkvy3bJ*2c4RK)Hk_HR?I30i>IaI#F~R9>c-&+(McNMs{mmTI>qXWtgszz zRDWLe2NRz6#1;!l#)yxh97*}9xw(Q9WaS0~#!0%}r~bdTlwsxv#O%86$1_!roaE&l z!nc>1cdr(l2JYTzqxH`i6B{C{CJ6UVw7=YYAQ|vy@z2B?MG_`MkjJ|+STE}e#~y8| z+)}sBY+d^YL=wg$StPp~HrgiYX$d?0YeSKmc+T0$DCk*AsaSwuDBKd$`kc8)@)jes z`csJz+ua;?;Kf@Rjh;ctUD|3Niz$y9Jy?XsQogQ_G$t3BeY`knyY^~{i7<3UAg8O5S13^@& zQ|U!uqY!}jDX=cuKRF0Wi{SR(?V_9l+@ixFG_V-yHaXYz_QXHarrw~25m0XBE}6cF0Pzv-`3FFM5WbKscjW}Y01OAMe%QXoxoz4@7_6v49$VCQwQYmciCK0p!%NTT1}3pED3RCXpZ! z%YsXCdwF+ILYG)&%igLEG$Dzik35YwaI>Yt?$=Vek6~q$_?k?dQg*nrrw)~AqU$-d zqj8L;-KsaJMFxLz(p|R5p_qdp05ULWh;UFt0f5&$+vpITHdL}!q4%7#_T;SpQWR-S z=~QcLCy67{dM72(wEtqn!DCOP`vFA;2=$y)xHAhy?$YAUs8vS|ubF!&&*s5P! z`ut^X9*zV(_i-v+^kUORZD_X;mK2zixkAq1(39#(!v>Bjx_3oGoUl0JJ+o{x9PP|s z1OrSE6k;eDn!$f8FhW$CdWe$uyG1#96J%obNlW2sxMr9_mR4%xFPlpuxkyP+&+T^Z zV)$`Yj51;0P~0J*(Ml4DK!(=a*lggjWaOX%lW9=R<7f+H)3C36 z8fm8lE}cMT(At5?k?-V$yLEFc(p+B2@tQAGl34l-uoosfaNbXufxe!efPhGp#Hr4O ztcCUDWXmtxm0RNK3>3eFC9_HlNMgX`UYh#aX(3dx$)55OOBNd*#?j~@d_KAZt+^Y* zKok#|EdAlv-?3nz0004l7vW(Pm-D(6_srvC?^v+F`lKlO||sW>NAw? zRW4cm3Trm|EM2EjP70#ZLw@54>qMB@2(rj+P^&HiAPy~4yQ{T>N@`A`Pf5K|kuJo$ z%_d{(Ot6axxVbbewU!%w5QUbaz$l~WN-XMH?bB#x=gv|BhqmUpb();3P3{OqlL#7wPjjLOp}pq*b^F#p=7lg zNmOq2zMWfCLLf@w5oIaW`1rWIIpv#XuZ0YR#|WNIvXS3VQIHY@LKLwC8ViA49yo6_ zQpk!T2^JO;CV@Bb5xbO}l=&}*#8Dzg#|@&OmPmuJJmTXJoheXkP%N^-E}2RK&3HMo zsEzb!CH(&HBAMqwEviYgHiuV&)TZWvl9zH!3wx0{LJkrKt9V+kg?#{-2e?1iMKE## zfaOHX%<>JoE1F`1Pe94J1hH|4?x~L-CR+&i0ws1-O9F!+*@geoc4m(QVZq%fBXCK`E>s%6e*Wu$46Am#&8svP82 z+I7c0iwO-9!nwKBE2}I&87iP-`NHMq8sVZVUEW071v*Da9hMKs?4nHu(Cj+kNt=(VrxdZ#YAA9b^A1L39&_iJ#WLlZGNJHb z@F-1McHFt0IQ1G6Q|B6IP)w_0qKZGoi>s+QLpdmXDaVc63FTcad6mMH;pCX}rJcp) z+W|{V2k43li%s+Mw`Gel5Neec0Fale3Y~#j0C}H9)6_I|vUT8z1(zA<3=u=y3JQS| za;4a_*w{D3t7US6k(8LSz}8NBG38)@6uMU+obPPEPN%cOmCC+Vy(n^#Cc**MrVet% zUB*$`TbN7w5hkwdUQ#%)8@t@*Q$6P*rd3Tn%3>i?5`h4nq?&fqx4naWs^b;-D3H*h zkXg>FdQw<6#)Oxc+0c|N15%N~gPFFJtOUuti7*-E1CmTNmR!4mBva!8N5E!znzwJL zVd#4KCh?gUba+xW95`~PQiC`wuQG%atx^Tk2lyHFuoT!?A{(^!S1p*}QK`_#r9nvW zapUJe`GzB)VejCuZM-k27SEU9peLbZ)yU|esHwK^z2&WG>)L@L?y*Onj)p%o6e_FdU7B>n^qc&`|R5XaIxBYyr{iwQK`A zne}A}ZUGdFL1qF_HLV>dOr}bB`-BF9?U_8@o^oF($B~x4<-VBC5f4&1jGb)! zm!x!_77|MfCbRss{t}ve&gy3erXxlhlsF~tJIDmr&iXz3q z!L5w5_@dmD-`*5W-G8@61$@$h8mHVsjI36*3I;M3g|*nOQRc^^*B ztg^*cQg0+t(O3b$0A=6dJ7p|!J5=B|h7yn%0~@_N)?+N<|>C!oRC8AdRGl3z6dNUjM5%^EchrEVpo|UaefsH^%NKL^4-$Y`X9dV z?w#(#rt;{dSed9BnGHNu5o01PYPzZ1)zb?%C4R2hNyt}ax_c&lH~fK}s#>0M zDs`>Gkn-K=P^8ZK(?zs*W69rZc%f6m|2W+^eeTUXLB~wn5Xf9#KU;VNElxZ4TFxxI6gY6jFYz)vu1(f%N4~^Xf|lB=(DLr?*BpE^ADVYp{zvvmkR`&CL`T zkKWihV>JlxffDTZ*==2(q4ZuvdnlO&7Arysu0>6s^dDXrJCRj#Bv$-7!P$8EXV(@{ zn>{d&E*+`vLh4}T-K;DVrCX}`csSSAH?$5AZfx|v67o`-<@3XQAG)yNKZ>Wa*?5Yh z(}P5UnTWZASb;ZzAhw}Ny-&bJKiW%SHG5e~z<&DTQzZ&qoo8X$vv^E2_Hz4Vnx+pU z0DdeQsq8e6HnpIsW#8K(yZ_Ao%5WZ&KKe?l1mUiXG`9%q=ozarl<;|HhB~O@z24U+ zx&}_@@?8T%$d{+Yon1Ld@xdNq{lSDzDvOGQ+4M{*j&jPI(ZZ%XEGWHgG}u%q*mg;P z^)T*GbE%+^Cf|_(RyZmTd@x75udG>IIun$hMa8bBW9lO2Yrgp2V-iTn3u9iVk*w;mnz^Jx~k zJJq&2YJ=EHu1L}rb2iHqLc3@_fxmL5<8JpTUUz3BZ6L9-!y+FKg5%Cf(a5He!?4Xo zNw2A4P4UUoJx=MRCA`7URG!pNFR309MHuv4DJw15LUs>dWEB zL{f#?!9os+m)Rnul=ji3Za|db%+?Eq;+1U#%k79c+`^F}gEoKQ&kNMbiO|ZLipxWa zrgsZiIic3^bUkY7ZOBfn>1O>*iImn;=5bAf)g0vQ@6Ba$(PZ_UoAFYDvVxf_oXIj& z^>Okt-8=xaY5x^ZO_$s1ja^t{*5na{bNDCqs^tZ3D}`&o+6Btu zO9oQ3&;oFLpqT6sTw^$tiwz1TJQ1kz_=SgX^AzdyN2X+1kpvS8bZL~7s;#<26)W%8vkGXfUWlRbYLFs-1C&b+XYg1Gpn7Q>8%A#x z9W$e*k#SvW2Wr?dU1+Hba`3o#Fn7Ddo0e*IxKv$j;K+DC(1^HO?_04rml#d3$%p>* zlna?Y643f?T)BroI$Zhqf5TTs<9Q|#@j(5&k-bH~G1|4BzSo(ojMM=ap;~3`;OTYD zdY1N;!*8@t27$7$Lt0g`miW*W6=3au(=V=c#g%k4%WOB8@xray@@Tj%LqY3BMy*Q-B_nyiSKVt^p;iFth@DI5lOf#UsU_PxfUZ3P>qD%j<;Nn2~;E*=DG>xCNH9muL8vohwFGU~j_wiHR+a;d=^Pl*&QD7Tc!aBkCH zohLH;`k_{W4#^fM9gsJt-KYu8JE#{Wo8jePgu3*2wxXQXXO;n2qh?YamVm8pK!9EZ zZ{X3ftRk56I5$NpAXT##ASmEfU*#22a2zRf6)~%Rc||JpP>V_;F8sTckuk#YpkvV3YZ(gP_vl_x8hGIs11X@eyBIaWe7G}dHldH&nIx_ z9|BLD{QZ;7 z{Xo^vPbKc9vVN>ApH3dv12B+?f)pYS=4WL+0hPi*sHIvV*D$`GvnWut}2F5^E|Y z;?9?^m_^L6@5^{B9UNng;uU$nrm5&)7uw(Sq10C6S%|++TjgF~OO3H$FbO~`$SC*xPZ580Ke!-hU z69d7i?*`^+JR0+$>u(^57hQs)qu$ons?*}Z9u0#iPzX(qwWd6={(S>C4VljNxYE|`PZuGU=DXN29rH7n(b zSaH=zhw7yOJIcd|A1NNM`N3#a>A!iy?yzUUY12}sd`b?_L8wLH_rBz%|R8|lPsw^S~uO%VK=(axI zN!d6)3o8)UHqRwieF4eqB-#|oTd7lmpi0;*>&jJ>4a~K`DRgwB1mL{A)aR?kzhwqN z`j*9ZgGuP5GPY!Oh(j$@KV0O+yzVQ~6-mJ^2A8sLGe3U%O;XHjzB$XD!+ z9m3+*Rvh&od<+~xZ=#GTMyurp*=r?y!ddtAq>T{xy_PL(K^%CC8QEG5to{lkI*5y+ z<_mCtF>I4s5TZcy|5OSS>a+>|Xo4Yw!Py*g%!(Y~Mxeq35pkf>XX1|92c0pewz6Gz zr8N31S_c0=Q<-#nhY$b&0f~d+gN)h|1;L1#rwQv_9TM}AHX%aAY#Owzs*tqQp_&nZ zRfy>aVB=jgzR6#%Towf3AVXn5(itRv#u${`z|@yh0viAMJasfMqUTtdLQ8U$QP0Vq zc_=w~Dh-RPFvViZ2NpA(CA>;vP!;)jf)P5gOl(JHlI+ ziVf>ax@qi3-Xb=tjN!2%;D?}&HddBVysgUBg9MU$DXn?KsGu;#Dhz9PM{c-JC_qXJ zBne~eEdf0?yX=eG8kU--O5ChkL*>ISfK*{zQ*4|k^@#>NGo>!o&lJcP+;*A{EAlP# zK|Llw{?kb;NtTk}68$vSCdTN(@}SY^Q6<^McqK%2QD>fSpB2R-7(uZLtg^c8D#+$3 z92!u%qkNjRh-|ymCDnokX`K~%(^xi=c?Agc(@Jwd;Fw{*MK;kPoqqJ>Dj6$FgNP#7 zi24x005MkvXUfi?)?T>vl(M?{jIg<_e#7ZAevS5`f$|ODr&%d9WRL6#m5-6q?%ay?2{~NS-0{ZB$(rI0 zx-?1L)ytw}LL$4Rk$B2c1QGk_0jRbt3@zYWdkwJ0SeV059RzH^3BO|iAQ@_C!X{Ec zgDi2b(@ZGa8kK~#8h{8F(K+-ASKeSEOF%|PA*unao>=2$rrye3fKX0rH6}g2Zpd;< ztwf7tmZXXXATH~yArxjme>L|t0v!lY3lRt+FaaKaHX6w$ED8?8MTzj~L6LHq`=`%z5u7#rfY&377}~UlKI|M0MukUA0?%s6!|c z%nB-*n0YlVkbGnuG7CXsqM3V5-=ZsHDX~PtwuXqHj*c=MdA(UJ5Gs(8=oHaEJ+AZj zWJEo6hOS7&qMiM8HJ@lbBad`ZLyD&aY@omZ19C*ho3qxu#FFniVe)*|T3D)sbVXo6 zk{-5C%T^V3GA((QpKJ83vQR@d!+-}&TdK418}2O_b{Ag?9UTx^LUK+L#^ z#htIcjkVKFNpz--YKMcm;Q6hV$t&b_bW3Vexwazk_d*m-dL7?UQDo` zQ!;C=ri$Vv)zO;#5MEaxLns!tI+|(g5dvRA!H5tY(t5Rvsc>a#!ED8SqjhiW)L#2b zVrjUqBCj}&jF%*m#ym`g4B4gC+@esCF28P2RYin^WCV~&5TGrlIm*CuPd#^6wPc^v zl2*?=3^~HeE5YCX3uVAV@OlasA?446Xe_(IT3);I(iSCc@-hh=v`3y z=}_P7auAIm;)=Xa$nw2rjy%z0Q_DGM5jLOVfZzLF6il+TA!G#VEon5XU$P**D0QG! zged-?!s$_9(@u#7qBuL@XSN}yE_xnP(_c@{Gzk7Q%cya)lkHu3AWt|U!=x4v2e;X_ z+_)yf^i0JRsW7knK#OM(6wb63c$Lh4D2&Bu`rTRKZHAvpRVrCv5)@ejBP<@7tg_o* z4&GEPUbop>2aX@Z+r%1k0AivN5NW>ErEvfA z7tAfqC`Z}QT3Ykz_!VwY$So?8?uJhi6>-0MTUki6>s6bjd;ps(u&782{}gnm^eqg% zMHHv7{ZBetO7Y4UsfGHrfsGQyuLqE&>joW0>USg|1Ka~h>tQKjdti*U7KpGSh%3wF z2C-O$1WUltym3=dSk~dj^{5xfz!Jh{aBd0>^k-Jiw}p<2q;OCv`>3o86?fRWWs-^E zPn4_sZLYeqr#C3J{09&N0A}W#l>FIx+~d?QWH_w=Ip_0uFCAiVYCFgpU=TLiA;)Mh z;^2misKA`Q2y8&NkU!xz7UA9wq;D|5mFJuU>WnVC}2{gbIQ&E}f%R5WMx22J%Vwy;>% zUV4Vlue8Dgmy4F;JNC^B!2>p%| z6y{zg`4Ffae<<6{R}fUZ00W49IMAX!$S|?o)qabPk(ag~;X*lTP`ILW1(!OYmAnS& z=#(E2S|D$poe^>ld8&83Y10004tERw|=BPsF3VU%f!6$F(EAqlP|&?FOHD2O8q2@)iq zSZtD=nRDIrq~@lm+cncfmuo80HT3o?xr(#IS*g1czvR_unx<@(8oEhkblI>|vN&=D zD-bM@0=BFYYWXA#d#f~R0pBi9r{H!o={)j?IW+sBY1z%fO7%-v`AZ$yt2-7E-(HjV zK(}{w)8?3#D53}&^>xQY$*WG8R#mD@A_^_7loGf>T1(RRQ~8~2i7z&iArZ3Waj%rng!xj^SGDe`;;d0bRv?I#4g2FoE7@LC zXc+l}V#Y7=QwgVV9@2IO0(mJCCgs2g(Ib9UbZk0xEr13Q+#N}($DQYU5fKxcy0}7BMX1RD2fi+B*yG!45 z6-2s&mFXr+T$eON5@*;J*AfEW23ZXD|5C6mxhW9sYux1!8Qx7fx>>nwm1phONKUir zHPW+UHs^sFG~TFt8Sw`g3ndWZ!Dp&F?yq8$RA?1&#kmQ+{(Ocija=J}#q4 zkhe(?1Y*lWca=1893|y5prS5ap5BzJDX7jStckUr%;&7gh=Zw7Dksqd)X^M?m8ua& zqool=97v!*V&jQG5fUOI*p)zvs9M_V=%-RP2?04rtprXMg;@aeSrW3vMY78%tz-fI zO^_+o)PYfI>K?c?9iQ>h8Ea9J#)?PPTvzf&kFP9ym88IYI8@s} zkst|b%)nC7q=1*|HBN#f$q*34`YDQ52@G$WOJfGauJFE)Rsj@2z-Z^Q3Kej*;e~kPuN;ai;Ks6+i~1B4(O2 z9_@L>H+&rMOmtb63_={fyiqIAXz@2Y6x+VIu&f%zo*lY2qnk-bak26sCZ=j|D-I`= zLoGrUrYRMkw<*_6{H$X^7 zGoA2xv$86r7YmUx(J|8&TxVGJ*^2$@*R1)ueTz)nWo>M+1kw+yryQ^+1nu=6pAsVG zWyxel-1T|ZErE{Qh@#fSMigzL0JH#SnJd^0Dyz7PEHu#wvK#W*MA?}s@E;N+s@G!iq%ITA0_q|8js@1=ViD75G-)1-otk;p?> z$0($f2nht%B%mZd^x*#LP@DCEbl)K~rCNKQQ~8*6Td(9Tls2ST+Hsnj$EjpmWs+KT zW!h_qDcDw&@I)Zgl&D+O2DVpK94l`BvjZB?PU5UzhJiJ{Nb`vDCecL z1Pm6R2dMwM=MV_HAx*T^Q>M8$;DAt&N;NnnxSJrg*8Jk}!bFnhJ0vVthe^V8mL1CI zk^&WsWkL+gY@m|z)0Re?fjFccPGC`NXB9(Nmvhc@g7UnT$*J)^tP5fMBOnpbjAkA|#0g-&H5V^!ryitx{c}p$iNtGoZ-Tg1XeVMG{(&nlW6v_VL>@)J(B^DgJ% zZjopO?k%UWJW=cLZsjWC%Z!WyJHI@3AZcCp&y=qquhatlty?M*>RZ`}+w*#a$79G- zQ+Obh;E;D2Z1B@C6mA5qZWHs?dicC(8j4|Ih#E!_4S+#%A{3$tkX)rX&c>6dxLous z__-0uh#DNEDaNCc5@Fa{x)O6|A__2CoYJzF`zvs?r;-QZQPVZFQA$a52pp*in!HD$ zN&OEI8oi*Z@wPx!K6|q83aVq#Moi6=8ARpF{>o7F!{N6=qqeUfyy$u850(;32Y7#J zC(cMlT+!ro9xHK4Yvx6aQn<5rk_bgVLQ;88)6XxQmSN;S5P*qj4t-`@)PEM7!dA^7 za9TY(t2##JY&l_x5p`piQC?%ZyixpufNBIS7F)r|(Hxg&rA|={QW;2BD#V4lb?BH} zQ_EkM;Flx197cF4?+K^K{G?lu1L#L9$EPQOJw@vVvl&5XT z=S_E!a!XY$J-B>|NAkL%JS7?kmXK37PD}96=~;;g!i5TM=I&YQt~?}uVMK~7gPE(P zC*PYrVhB{13BJ8J{DKd2E6UPTCfkWh(vZC)u(V3jcaPXvR8>{ttmnBIMI#dN4(A)0 zC6gAkVygPIwAhX4`8sWgM#b%v4sR z?jmmROLNPGlu95?G%J`NDNp&`>=I|iVhIYVzLDal-5)EQDv=`8tx3Ow&JC=nN`CSv z+36J^RtUudB33>`fH7RmsFIdKenK}=1i~}Z8BYdSLbaTNbxxVF;Z%(vnvGAbx52S>(6!YJDQsrqVpkCmGtg^noYhGlf3@kB2 z6fsCNI~Cm`CY`x9TZPDCT9U*gmj@L$ZbkIW>1Czn1RT-a6qsOh5ptb)6g+(Ubj-BR zS$h2FV*)N!^yi_}R_P)?C{@#V^_sw0hy~91Z-Ht}&1AWaZ6-~66+L`$Cp7XDQczV? zfNRQSMDk>urRt;LIEQ$07&#Q8R|2`cIFlAET;hO*tQR}mQ?IG8?{bzjE-Jcp{huS7 zDAJ`W6)sL@S`^{~SR@oKEdBJ%vGV(QuMVIi6Uuc{kS00pKGl}Cw1K@gR~oI?B}oz} z)skat%f zq6Q@S=03T7sczYQ!jDyZf9o|mLm(Exyn zBJ(Q;3!u!DNQ661g<}>{faNH%k9qD>A&`it&RkopuTk?h#JMcwc=N4@X9oFi>Kw4{ z$b&^-&A8O%DFIRh?iVp5%F21=smO~^oyw;oucSWtmG8$$q61L3!CriKizyejA()nW zxAdW2fTgGx(NANn=W%n?zG(Fe>8F9_Gy3)^dtHPnCFN+8j1x|_2-;XQTH9L$1{{7p ze{_#EcGw~TLaR-lLRHEs5{Y>f`j+-8a#}7`$@j_G|GRDA__raU=0z_c8(gI^XG|%| zd7P+NBRT8p^;6C*v!D#L#bRiP^F>VFtksldnZq17ayEF(f|0C~sE;uk2QnyuY4ONK zIkVekzcw)~`n_M`wCzt46F~BU9!y6c zrRrv7BxM!1OrA3$BR8PypPN(m+DGT2;?t5(J|wc0Y%?+`M`t9;Kx6j>dRYj-?E=zX zf+5fQ)t=X`nD^F39^dLxI4z%hKp`)nXxrbr7oShk2FysZCNWUJc^R8vvO}POrhR+OM&fiOMDm-tL1&} zwilA@lzl^NI-p2*gHz|t;SXH8hAL3`P`jiY#JV%#w<48#!Lb^>1{-5ZVhobxxe=4U zAqBdE5`=&B50Fi|V~tncF7izJbIOq`{z?C0#ZhLMr<`(oIkR<}GK7gfX+K`lN!ZKX z4jq*5LaeHWGa|r*o;xOgRzl$7g^_Xf&D8loAcxl?j;`~K!0UQlwv_wTA!*hDZn0=u z>51okC^=soEB1n(#S%VVn?piSJ8R8 zz;cpU8EX3?T3bUaK$;9YHh~Vs(rXZfUUIzQ?m!a8a(q7#NVCYOk}N7(K2+9CHpW7xja19*0FAgv;zMdh$LGD-*Eb1f?? zGPXIRiO&uay7IPE{VQmga(*NooQVb-&8%`W%0TDkJhZ>h>cHB+pv4yJGkM91kPk~K zI$NbLkBS+{0xaSMcPxb0ej2~#A+I>ojh>qCio{@xI(mUT#Xel!qe?u9mW@B9)Gc3< z2L;8?Onb6!d&$dYNc98F0hz8L2|Y5f#I!pnVkiMa&U>v^5(!Nu&D18TV((UB+3c(r zUr?(G{1h=o6u41tmML$=VaIS$?d*k%-mL{qmOvIMt+_&;MZQtcY0*kN+>vSs6)q?h z7#QbEs2w|1zg7loEbUn-l&(ECb)r_Xm#psJk-|S7CL{R-$-T;X$JX7!eXkH+I8u&p-jY;TQ`oSX$3Cv7!hLL za&)5~1&RlIOx)siAdt$4=RIv~9=_N#U?VDpg-lZTvWQ1tg5FS5__EPwm6Yp2lX)ar zh~k=sZ!m(8f%dOSIt9y=3ORC19Jkh9uRUL^Q(QuFakK-R`3-ko=0)a{o`G8oCwbTo zyMYMupn=Oc zV$96x1lM~$nkhY!r9}cQdqskj zpwXd8K2@`m6bKix+W4yXg5S(nN3X{{;v_vD85j%SD0b4JwWI@w8tyIU3f4T6$t-x~ zdIYiZOjT2wLb~=x$ci+|Zy$l8(@{f+DX}q|IsasC|Qn0*=i5a5gp&nF%c^*Zj zSC7q7EG<8X7oorzpH-Ez~tBy305t zIuFo1B*AigKhK5ih2>W{V*dw6iP;9-HdAF*(5Iz$n)zd4Nz=_hgL6H z@m-yL5v^je_CGSM&|E)E-CkF+%#@a-$P2F(*7B~830ILq*I@X^6AYv2pHsS@iR@5D zMdA%HHkG9C941i(XE?@5)R-*QD4j)~D@K(1Gjr~Y*z%Pm1h)X8TWzO3k7jFHb}_RR zimPc=c3t)iLXF|yc!7N4%z>as_iV9v9W@>)`i?H3C%u;x<7^WNS>uu%x|C9N+acd zit<5XJE@C=&fS}z$=4|fYI0&cNZusoV7DaZ8KazR4mnIZpf07OLKEdOohca7Uq}d= zY2!`i%JEJSK0h^!G^TNiQ0P`&Xi!{e-h8b;fbESE%1JrgNve5~C2|cA0004!B8drk z5c5$+06`367ytkO000m|0e}Di000=dF32A#1~5bk3;+NC1qP%*0002esAB!kWD+1) zga85qus{F-{5?-aOBGT!EI1%w1ck%^dM1~hf@soax0T@>{r241t>bhJ$}5PWmar?a zZ!bNK(w`-NB@ta^4jnyr#Q#?RA-yGRj~mV4^A#s9$1<)2*P5zOkNBT99!k zS9vt?wY3zFCYelOL?m&IMq?HY8R<;+CDG0Kb$4i@5(yOe--;=MK1one+GO|^sP?qY ziz}ck9PX-flSyT{Z|NLw`cx=mvsrIEx?@EXw0@`KZ4zX|U~x|Z5zh^l4HN#iB8oVX zvsZSTH0` z;KdcmPZ*&;-CqkLHZ}_X85?G$B)ALYrt~dYoeZf zs2I5@qOP=iD*REBX2s~cRP*f(iG0-1lSY-wwOiYn|BI_e%SZR=Ih{+?8<|HyV3Ca+ zobp(*Z(7!^w%@u+|0dKPfNloEd;kJk03tB42Ji^X67XGB^O~~1V{1uZNGb;t$YHS~ zyK7C>{N9!4fs-wL5?w!{oV2*YdfMVbMAKSa28T6Oo&4>NUbY3fF+ct6vl&=|YSP~X zF?3(oH395_DZ=@G>T-opX=Z&?d?{oySb`d&`0+9w90&z8fo~dKB%rmQ)^H6o)R-Wr zyt>|21NofP~&0UB>B~TqTOS1`}0T^tWos(n6l@zoA_Zp!T zX<{K~g`;4!z0|S@m6AFLG6lC{7?A`S7A@)!Y^z%OaW>TDZjL$)g%l}X*Hlf6G;ShL z5VdCJ+^~L=OJW5~)2tv3t)Q9&g?h*!y+O2NNJX2z(e~+pk_yNR_W~K^#I#ed1(j$O zcafpPSze2q9A>E4}J8IEl`+FR@D6c?cB%XAWZ7av;33qGoOlQ5H)j z1w{maD}V7YS>`Nbjxh#fKPjLni44LCIaaKB3wyJ&&brT}PT0b6f$85)_LMuoLqTHyUJpz$xfN7>BgV9f` zSHi-Ate(5v&R)YrOr|0g4o;XpHK~Y%mORXuQ0`D}i#BZ4LWSjG6fDw!649-Yh*46Z zHb2cPDLlCKP~+o9+99=|Qsz?#@plW0;S|RlUM6!?wvm^jmoe;Qy#5EJNym_muGK2( zw(m4M(|p<$zWLIYuHa7g$7m|z+Ro$y>tN-FY((-=4U(G^Qq!TDe& zUKBQvzUVcAu>9(0mSg9kfCtb{NeMV$AXK+rsLyk_v@$7at*LbY>9k(xZ77;y zn(#EQm`0gAy)C$^7`u!&7-rf*ge%R86(Z;bAYuU=VRULCKm{z0THI+Go)6rnVr3J& z`WCVEX|w#502MVySYTQKB@!|0vPiO8sIXL9&J^Q8P}4$uyMX8gU6gDG!O&+T$KCq< z6=NQa8+e$bk>RvGmRa4_4_0st5GU1V$+Iy>=(ag5<(0)E!P#fwSO<_wBtoCPcC4Ca z>nj!u_K!9lhZtIIO<ifB(Sv-^*Z^!rD*gM+dD0*ixzq_Z)l zp>pz)TE(!CY}C+4VP4w#WIib8?3^<;ZS-%=ielarR;7v-3y}a;EmOvuj}kWdFNOyc z_vNvVim5!SmtRWK^CV5$IouQ{jZwV2u`us3=m}IUgSNb(2x%NGNaHPoMjD}V; z(%o%7tix$%iwm?k=AO?;Ezf}y8jrQ(73`r4^Z)<>lTJPMf8Zc2v-Tw=3qM}LZ#B`N zP~&JeuH4`?0{qJl0L|@Anv}j zsLv;EcH-8JH;HWoo8WZrn$@2J(Y&O-<1^@}ndj6SG}@X~$~F!+D-Nqq7--?bhKaxz zGjkF1zC79nDWPTfyH`i$)%7K#YaW}uiFu?OI@xQMYv&R)ao&={LZlUWtF%tyTtPHw zv?$pml38L3ts6*z-(5e%&~K#cH#pf(w}?Ux^h^`WO0fhXSPWYh(Z=d zFtRVFlV(~Xq@r7&(#0pU0z#^`4+fT6C;DT9(6_r_>M2Aj$>#D1^Y1?`Bx;rNQ`0;* z+`l*!SIK1r#VqjPR;MU@E81!lDa+X!wjI9)9+il=XgM)rE^-m45?>~h2)s&KU{7kc zMo=9ya@Zi z;g+UmwTMC}QZqkk)P#wLbFlE|Nv1=_E6N5^>}i-o5SVeZy!UjHLnyOs8-X7(b%049 zm>Xnu%>tNpkei@kVm$hsk=QJo5tRbSq`~8@d=6%R5hEE%0!w%%()kybI}Vui>rJ}> z=_BFy%*=sm#sGbsABB&u^3GmW31phSUN^Bo3iELOOU z%3kDD21SFh#Vob<$onR&P@k_nLf4d86!r{&Em*B8NT*o0s=GDGAs;-jIruA*q|Yow z#fVEm$vo*nbmmVxvdzscl8c`g-1{lfiif!a3oV>_I=zaJ$TAq%=ba)h8W@C3*-W3F z;eC9m=OXWTkq**S)S>e-l{OQSlxDw($p-=7#g9ylX`MAk^zqPnER2$z!PGMjFVe-X zO53^jz`9lBF0z@9aj3R4v!zWW29WXztG6Ilb@Na%MvpPla)$P>+H}0fu*y2N*a%li zyaT&?n$K2Hgt4rbJo@DjfzO0@q_JAM=9XuFD+m~xX_QeC zyg)O3r9{dikdv{BZ=TXU09kHbi^w5d#M>qu+ou#0Gb(xH@s4elzZU$Vo93(0KEUjs zGG#743H0q65-p^9t4J-Di5DdE%&Y>kaIX$T2?9wLikpZ?7DFGBiWam2DFD-u6%3^& zvzJ>wl9A%gZSs__(>BYpM{ll}T9|XvTRzTtqJk};>wT`B-me>2L6~t?!8*~J?U7YD zM~4tX5oTi4MHO7AJvcJ|FA||GbjkRhi!Gi-7Vqnn)wkoMPc=P49=0WZY0r1@S6-B& zOtO{1TD|LfoQD-fI$|u+0$e78pf4Uyj%yLEM0>YgVAES9LV$@&j!jsx+m29fXLp_l z`r?gIS?|@(I>{r4W@G4uUSx0G#^QZ=5%oPZ!k05Qq_U-6oj+k6HHL0g?_%{+EPN=k zQ`P%DEe^VwbC3ifNOE%cl3$gu_)>WQnoq7?OzG^m)?55Uz+R+}4>F1-QdWS)IY(Z7 z?(~_(Mv^RD*Eh&&8F$p@lnvysp9L1)i3E~{a)DS)Gc$@t&hvwKa7R0_|s|K+36^56BAxEj42?|D7IQ7OwkOyk*Aj-Ap~k*|snzNftvieq8l z3sy}zR$(TS;z}PAadRi8ksN?18bzQ4)H>pYeNMYX)~8QJ=<{pDW9X){6BONrQ}g_mlD#u)po-mrjmWb$iS?j4VdEN;V;GEmc#F{$@COrSB& z=UR4GiaF*7B(im#7RjPCy&Iy@%HGR6~uYxiZrjn+b3=?p7Hr|OO3C>O@2EK?GDp~xW-fR)F!E{(V zN`hrceh%bi1Vi)a&%Yj>7MgTVTcKzZWp4S&cOoUjfYsl+Ee(^(@k<8Bk1B&w75C4r z$wNLCyTdA#d29h4M}!65$$MO`X{FVaJeCc90Uj=v7ZKJkCH8cY^P3io`#eYsyae@Gp-4Zx?@2 z@B-=1Y7I6kldlBfACzZ{f?BYwQ9qy(rUneO%p1eCIdyCmyi(ynkTo8I zJ962pZbOLAp7?QC5}trXvW1ooAT?JWc(Cvdf05KyAz37?Dx(@ z6v8SLOQOkls8xJB&|E24;gr2uRNi(hTa2pfWU<}s;Fv1o z@blrtg9);>n_o|0D+BzqCzp~GCq;$)h@S~Rq{ z&SydtDYjIlPGMz{nPSiRu{X+#h=@|&!2fQz+pF-fGn?Vdds)Mx-%XXJtRE%MGNOD; z*I8H7g=%2+I6R(gIU>QcI$j@w-6H4Bcz0GU@1m1RO*+m7=f7q3MUd|(F9)uPl%8nx zT{;UGNhVeV01orHw-jq&Qn+`O{}u<(Au3J6JwkT)0H$;3H?dhV)69;rbo_xYP1S+B z!5I|2<9nS^9VhL+_&%+S6IJT-`ZG`JoBnBfuQX&u5 zz6|h<5P@q+5^HxWfhXxVp(%(HU<;0(h?M)U_naIk#|9~#1 zWd$8Odtm0D#RogsM=L9kBVx~UpdK&iT$j-^+ryx!df}2fB`Vl0JN&Z@$+%#nKR~zg z4p>vM@MdL4a-+TuRQRMEC{m8N1%$jnLO~(aRa48l8uA9L_o8H zc_>(Q?Ra{@vW9iAxAaF)EYUB}sb|)dC02smr7oB);jCHGxp8FA6QXxJ1$E5Ap3o({ zotq`>`#5}#<^-3%``#dDuQPUtH_3m>!odX@!gayLo2x1AM{E#%Z@Q`8UNFZ?Lp61vFg-KGG*8IY< zsLBqw?ac8Uwd}CZn*d$~@Is{g>`I=3TM%h2Gf#mCFc;BMAnx)$z`IXY+dvA6kF@kO z&rkyBu4b>XvdL>g(6%qYuS159^V56cbfh(#s#wYj!WwVq^Ld_!27@W zbZqO^;g)c;liHb6$?3B4I?n7*0lO5>xj7vLDk2#hPH2W zK<$>uxB&A&gVTe{>WV*JQFDn#EB)Yq2J+96(ccf{N6)1A>4A2{9HhaQI%D-R(}Gb% zUn<-@VEu3wndxBbq_*9{1f9zR65^2q$jVnjIKKia1(l6LFQr#{RMSj~1l1q+JiR8#;PTXsBUBuTPU=?%l!v}W5IHnD~*HXVcVU$sMw{6Nh~wKR7zWIP)YFlhO+U&9vXBY@#6_`XZD%aRQ&%0@rQf{92h1F z%SnSIBo&Fm-^9jHeHFonGFnPfB;{2ei`lRqt8=cUCE;|Q3^e+p?5QLSm~e$Ek0nit zj*Yp8k%~gWMO^EFPZ~Dpm!8nN*QgT0DctK*VUY zh4C+HA~f`#s366RQj4k6`n7!VBezUmGKy9RJDE_$k%aGQ(k>wb^+N zRAhWhl{z>FL3A1p@dqZ+#>2(zt_&uK4L&MKdFh8KY5LXngh zKNJorhQRoXiv3R&le#m=0uf`64OsAsVm%cqrV_PgYbvLFKPEXEelB)hR>m280hR!V zrbN9b;^(M6j!S)d1f5N#A!K^Tz|5O!F_5LP@|EL81#yqSrzbexq3OvPX8DqS!7XmkH_Sto4k-a3wpkKSeA>ev@8R&2ca4zkP!D(=mQV zl@j_0f?^a^$)qfIjR{4Z+rZna+o~RfhX(?bBw0z;nO!KjB%Tei(|~B?Bd1I4MH~Ys ztqds{FEa8=n(nHz#V0QNx*bPa45%W6I6G1k)B7w`_i=H@r21cY9q`bmqgwSFF#4t7 z$&DTlldi3k#U>X-jA+g&?bv5^%X*bw7T**poK}>MTEs%mACn^`>WLNQ^^nYm5S=EJ zvL+h^CkQeo)P59sJh-P`MK4BJtlO?<>+8FW3YqYgy@B8teH47LJ+wQk)!bVyO(pZW& zb_v)v0!^AQHL%(V^n9(B`kRj0D)5^uFGqocw#~4mwCT#uECX8E0dUlQ`EtRs3)E4< zZ>@VsinIuIC!NRKvk{hzlOD5{_FBn)4R0x>@>@D}5N1(OpPz)aY^a#HUSl$}7IIjZ>>OR$VBRZAlnNii`Lc54 zrF?UjmCL&YznC^z}+nvA-2f){hGYjcV9WhT5EE|m$I3|E& zZwOT~xX<^K@K_MaXoCoiN;#cYJ&)VcgY_Dkys_ zo98ex2Qan4h&A~jLYArNyy~)pt>2Qin;dC<=i)=;6=w0bRJ)&PUn*p-r3ZavX984m#RfI>e{l*)>gbu;1k`p9KV$S78q0BChx*Qlhe05hj7n9sLaxRuPy5M2|oX57z}rDa|ACBm)`E+E{^0Zw_=QUC^F z0;$8~Q>A6_S1%m9sRA~5a+g2JZo6m|6u(``O=)53Xyw`wVXIeVd$`jBtD!*?*h1xc zV+@<}haT7}wteEwVts8|jK9{RR9d__wdK8gJ+E0I@6!l?k^0nJBn}>~wHEuri_x23 z5|mKt(WidAV5F=}-%`Bndk+oEoxUKfyf)ohlYVgNkr)qL`@wj12M2Z@3FWt(UKqOe z9M6hHr!TgoD6jicrN=)5B~z|5sCS<?7Sr0fyuI>hfhtO%=_@8{BX9`!V^Et|L|&ia{9 zCG(PeAa6*~Fsb}k&SVnI!mX-qT2`>LVB?nk1gaMtEw6F*wp&Tgcd2^;&EPPHAam~I z+W=yLOR|87`8DgI1GAD~%5N!P5vrw%tP$#Zl-)>>62gRCI*L5=p=^2$l>%@fdC^Rp zKbBRgzg@hgE}`!*Dsu!&HUfdCD@1Ao!s$L6RNqoA7MV1r0s(2_J zN>OY=?ElFL(ftNuT3!(&0004-5%7|Nx=f@%l!_N3LJ&mnQA$qQvK4MPlCoUVVqsnm zb|%Dt!~x1UmMl?ybE4H$DlDSs;dEcr8o6@_tHlJbrAOC*Bq<1nzID^Z5<%1w)^*-x zg`sCa&&>*eLZHcWf~sxzpF;wrO^fqHzmY&$ zUy=Zz6a_F8?5tC9Ik=cJP%}`Al`VslXLS2Jl+FoXIlv?gW8%i{s;n$Kos72!048E6 zN>E-WueRrbj;i&8gdCyG5gj@sI3s0UY0x?+`wIrF4K47$MwkvxofU6S4zT(O5mB-puKw4yp!4KrsEa~fV$7Tz3k z*NO5@1I58Nmk|M?=?ff-23*U6oh9w4=(=_ex?Qj+h`CBk{U?;S%%b1|(77C#bm>@v z2TWw45D0#eLDJ8T##qa56(GXgKuut{Zb_=r&jS5R0iHAiuY=N;9Sri@dD72@OwNtd zWHieo#5{ZxZ2#lNoUPS^v60}1<6oUyyU4eN7D8$(8TH7akyVlT!NI|eKF!OZMM{)| zcTB(OYdWOxcR;gCvaaNHIA&OVYZV{6&vxjjK8am^c5zd@>&IX(ei-z@*XpO6NDGt7 z8CM9f*fV_$>zP4R;FMHKi+1Y?eYz`^H7^55`v+~nVKJs~%b;oZ;)N%ynL)=?tU;M9 zSgaQ=g*ZAa#(V+k*A1YwNc>3}Tbv}RYh4rr2weSwzY5tcOz5)v>ufHma&Wv#0^_$% zdnps11$$CXw4|HBFx4ptR0?RgJqO4-N>o8p_gcnD!NlJRqtfZEpHk(y0BGpw+sbKPi?;*Q_JgZ-s9 zp#*@_rgRn;5O6V~rhSy0p(2am=Z}Vntahv&mCpjy#uV47>g${s`9W@wRc8ZI17%}) z!8};;k%2(3crnJ`KNp~MR9cFot-!5)djlpIJx>QSPuyu!1qwtg9eiOpYno!hcT6;n z-O=(F!Lcv|*_F*$E3LLqMUd}Sn{bI>Y3Q$EY;@sMQCLFVHNrl4;Y*)``Nn4uzm=V# zYV=$kYH-&(oIivjg|kW3WyBb6vh1nfm8_8p!4$YKWcC5YAc4gG|1MMN@fctG7fGoR z)cp*qBBPBNg>#A?XvJjm)m74S?yJ}lQ((U!nNUwEwg#)g#1JYZSV*cY0$2eRf=MAZ z4ZNNSJuXg(J@w^nK-)|o8yZf}cz}RhX^)8IgaTroDZegQu^HP2lE!31KvGs;C@;|O z0LvYN3YrPAl2yTc<0@ZXOuHiky$^>pR4Jwenc+x?`yywnsTVTW#4LVUp1|l&HXz#R zIHsCDPlO06DpIJ<%q@T)MT3M3OxeKj1HvgY!EmO%tmkTE7%Fh2kAkA=R`6qn1Vu#o zMCZ?gl~13Zj||sK%d1N(t`)&N69?e5rB=%MLHuD>2~&aWnb2ipT9^On&+ssFn=0Ha zoQ_l+8DD@V$Z1p8px%IXGr4M=aO*D|-57INDn7^!7AaR;GCr4Q1h8sabS2>zd@sgL zY!d6F^jv%?$BH(**0c$q#mgb4^b?j0T|!%(;HQ<*OspPQG3e1CZfiMo^Jr)|YHZO{DP?>CvfZ>%tp6SbXZF2!e5=VDO=PJ z04kk0_#&XP{S{ZB_3;IBqeaerrLmNuG%pTaJf?QwRxlMWuq!YQNO5oX9`5!hD+~`6|3u!6 z{ws=ebVTTs5m***ME=t+m&*}&m$N1NqP3h?D`8%%Ot5^ZVR$9$lak9^6oBSaBIkpe z*y3N{@T_?%tniZU24)d-tr?X9bT15AFYsbVh|e{uvtegU;E#I&L8DA zu8MmXAf6!mOIN9+;4P(k1gqs52X~8}!M1!SRvMMh*4-7w!P#{|!~Mq+%GiK4Cy$SZ z5u|0676&3D;Z`vwt;j25K39sG^ZZLG{2zlP#1`NFT)m-Q!;Y(es_xSS4mqX}BxXf| zzwePJDPe-nV5j3(iV1xcG@z!_K%LiQxMXE;gmR9!!6%4NnBy z%t+!ef`~M@?O9dNM_`pv$!@NBV|B|f5mMM2>W=QVd8pNDzdXXxDN4Q%<>^5y=v`9u zjx+G99qtZO_dOiWjMv}_@&4P(wC)Sx6*5?kn(U&s`&+af)e(na#%|3zK81#)tOkut426=04&;C~I`sWN|(kEg4ikgtSxc{nZ6zwFHu;+AHRZ&13CKuigm*B?;lWAz#mk4GvW+_e3BE2K z#U;*5=BTq{iiBBHCQ(81;Rfx(s`lX(kVr#?SK?4zdbC)>IsPjTcass}$p@6Ek;g#C z*EieFNb6RzTS80b5@k%v!H%+|rL2m_VwqE5yjWnY^zl>g(hiVz_W8Y ztvZs6rK`0k@OOhAs}P9=<@B*Eb&lIKQIdJ6fju}US6Saym zS6ergL`Pq#CyG)@KKau5W-e8tSU$ll5%7Lx*3~o%9yEVp1{BD;Yf(^=U~1T|^lM9t zDQdYKXq-DMdrHu!a=YEy+#oXg1jI3f;K*;moR@sj`2G`F6qxj{hm!J6b56iDsVe~R zGd3XXsB46i!KAN%Nhbu#nq8)j<<8E1#F=BZ4$8f$Z^0`sh&4#h{%J9MZ{$dB)bHeQ!F4sFh=ezuaNjmEZ{BIjcQ9Mh}J2dJaz9)wrSGR^ym^o zxN}^i*!&z}@8HC9(GB;vr;k4ZPfVAnQ)LBqS|sO1@#CFm>i>p!a%IjZ1MPECrc)MA zMbR_m4~r?cI%;6`-{#PjgU)4a-hj{IW%lw+d27;VM7htSFXL~aa?{N~^-VLdaEQ1- z)}ZF+#lx+3NrE79yTxruDe*!?x#w)Wa+Hga-Ef1p2h#Ck$G`#LLo+Ne9unYlZgq!+ zaO2{+#1zU?kw6##00E(nfk8|p1``AfRt%zSkkZ>Kb&4{&+h(HdfNE&9jpLw-t*Yul z2kFOrIHDBI7^UqrcUQWre#~>gQry&_DYmG(f-t?q&sQj+USN`$5%Lkx4fgUc-1 zpX8EkF|OEcDI-85A7k}IxU5yRtHgnZbKWzgu9Z=kxJAcYWI7a*MJQ5fW=e95Hs=_mqexCy ziq+K;UiG0>YV3sc|Mnt?96; z$$mwNhr1DFv^;K#ILLh9%8r7wvZrbPKsbN^Vi22+Q?Tvf5(%@Z;75RXBc6RA;nOzW zSe7L15+(_@$>ke@Bp^L@0ieEF&B@R=P(DGrCZ89jmEx$klJBN8x)Hs2^!xcE?N4q)*yYwM&20f?6mSQfz-hBt^YkYYTEf zrbB}aTh!9Qpi6Ft*x^zq_O$O}|*~(Q}Zu_c61Bq6Qm_8P92@bpHMXcG9 z%~oF1_LPgONl)4$>*BG=gHq9T_dRe3Zui>Ors{!V1TBCzy2~|e29b3~J}*<^g?Qg8 zfn9?-fPX<3I(7%Hedp|b7D}&sKcr_x*^4_i)GhT1)vm1p!-X!p?e}_~glTziKtqAS z;g(%quJH_+Zz}(ti&fTtF5Vk=6A^gcIv<={!Z@Uoeh24dc@qfvWD{&9jd?v*B#Zm~ zreKkA`7rb0`TQ;cvSBCx7X>|Wlm4-#xC!k;r#)V|HZ6-*+rjjj`DK__`q9=;F z7jXoyf@{ntynbUA`wHxIF4@EiDHGop8NjWZjCMaY= z7aCc`qYtRu^@7$>%h)8HVy+<`=lZsbnYqg?H*d688(87Zbew>>MwAh|N6fj^dNnD7 zWqhz$J~BI0wBWb|$Kd1|fE?K}pAO&$2aFrxG_&{D=D(Oz=Gl6p#bl4myK5+w;D`zo z07GF$T^7@w$MgsVFX6oOBLEeI^GK@+FjBc!8g&=wdDyF2apORIz*r=hwEvzbJbi_m zr4QA;TTxOeaWtvo{cN%>5F)YyJOOMlG8cQ<*}z_}TJF+KJy0UOt`u2>N-rAq!V-|6 zl3eqmio6Cvirv3MmlQdt!P)6D+HO1SPj41L*T9KelWHqhg93S^?-ZrT1;%p*)KZVC zx;%iz_5}q7-p9`sAe&P=UZmTSa@p!7ZKk`4u*75$u6}3%(<0qOb5?ZLV!=NzVKh4W zv}s;}68pteiMe|%utkS^rU`{h4oF*h9mz5tr>M!an`|nZGHcPdI1-UlVVN;EsxJYy z$92YA-9ayI9tDO|V1>6y^)@`J-a%f;Y1eYpUm$1Amanc!>3vv~Z({O;eOl7SEi zYz_QGg`i}urILN2SphAVwMB7HBbM703rARKu~z-fp+WaTaAN7{qG0^9N2w*UcFaz- zFOf3!f^?ttDyg8`C=^v+z}R4dvdRPcwXs&oOCv?7)Kw(V2k2LEX-z+lUIyG+1%vc2 z*GKRTK$ssG0V}0ifgTRIPi+kXS2%iz#jBGliA)%30 zRn5|=@A<60v;K8tH9Tg+{QmS%18WEX7BozC>@1p33R9dWd?i!*d|Utk0izSNL2H@~ zt;)y}qP@XU&jU`_jYXpsgd`#pYt|%vkcyCqk}QEBR-&XS{Jky@2IH~%YZxR%i5d<-02!SF}6;LQy5Za{D=G61cjFLHSqJ)M(l#WUC zQz!_qXX(I6c|=l^MM_5?DF~5XNT~pk#{nGKi6bd15Tx=@OxpmEEZZc{#1!ROLTf1$ zj!;#dy2t_%1j)3;$sfrr#*c{Uzd^TCUvg-m2s)C)q9nWtv~DK43fAORlMZ2C$Wc#3&KivaC5+IH^aa!{vam6D8(u8lX*%k zAmdtzKi)cWHIj!#f?vr$3E1>NadJtHR~|vj?L)rCghBb2k5YUbp4jx{v@_q5gjJ@_ z2<6gRs#hv9&U#!-$1RgG=xwpbOu3iLQjNDFyFYD{I?h%IBsF)Ix)sDZh4)q}2bEQ2 z%3a{|K-|d|e$}9)pNh-l7%{h^w-zn7>P+oCZ^-f&%*(|q;*RwV7O$8G60dPsx##e4 zWCB@qpm$QBlH`gFv8iRVC%X(Ep=WthJoOR}r-mge07i2Z6MtnE2jQ!a1#A=m8q zc*02^FAGiB)NXw0TC5&&voaK5>=iL{z`(Wgl6J8{#rCFIPp&QkPDQ zf@&n!j5(RZ+e94##Jv0tNbu5U4zE_mScBjEF)ia16!M6+f$w`nb}DVsi-ZU(Wa&tB zsrqW_lNKA(N+)6iy-15HPqg)M)#CTUzGe4{qx*AnvV6Edm{eclRcmGrui|_8xEI75QM^v)PsxtktKg*{&Ge7_mWq36(Z5(ycoZm#;i(;n9?f1MYr9 zw@-4=I*0y;VC6`-<*3;v3Kc%^bP83rPY2vz(>Fz9(aPsj{`{MnT2=JQm}bFYSDdFy`sxBrG{k# z`vwxiqLt52L+rXL??jJFWT}oazdTrim1PIQXx4Q-SnCG(hdA-u-e=3gUj)CN4bSyP zN99GEUYH|CO+5vXN8P19wU~PFdSI4<7G1tp&Ls*U*eI7d%~j<1Y-OsPd~2RB!V+L{ zVB*Q(?g9iD>Z*PQ4AP^nwG;EHBjC@2*g_LkiE;FNX)7Ob?7x~JZdl>HTOI{9lE%2c zZ>&VlN#Kfw{?NE*1WRMTMKy6cI#cr={kT;ndSrd8j z&)!BF_@q%DK%@ab1RtCkaj#c7+V6H1A@yvccnQxQ_p3UP5A~5S#M8i)K zei_#AP5kwjAAc{Sj4~@8wAIj`2NLN?{7ApzIrCK>vO*PiImJLe9ZHr{E=E;~h^Q@7 z!kitn8<2Nck$TjmU729HHlr$hEnAj%7psh;v!hM82e(BdA_r6R3qstYa7{hK1*gTb z!ZMTQJ%HDX8Lvv&Lnrw7mDn;hUF6HX9S`bjb>3uHR+Ze1_@@yh_!QX>6W2B7@x0=2|Dy-sJ@NC=oj} z!O88eyF}%8BZHKQ3+n{UmYSR?mnXxiU&0ylT|TD8&C;^4WKr^?!)QEd>t3doIl(ms z&j4+le8KngvtYD~RD`7)xck{(6lw20 zw#SbGfhF#%hj>cYrE|7koN7`<@lav#W?3$5cD!1R;6%AHJ5zJAtmTNsG0dnunq*jR zcr*+)9O!RC^k-cMJ59iywYBuc#$A`f3z0qk9ZSU$&J`gOJR*Lm5%66!+Rh7Ga8D!~ zZCYT}=R6kqq#EU%9J{PEPL$m0^cP#IeM(EtvzA9iVxq%om6a_kiTEL@vx5urmb6Z! zi|rrPtW<$Culghe{35vn*|pI2$67Q_)$x&@|5@AbOA2P;!@Eai@z zwElrvTp)h;|B<*w&wCm{&P!c>Q0#7TrwVKK3W^983?GSWnTTl@{4%gVboD$;6s&mo zHS?$2s>jYVfuy43`4=eR(GpGvB6CP9W{4p)Uvy?*Z>8euu>o z;KpQ*=yEALf$>Q<;XL`;vh^@dys990+EfWD{92Ea%t#t>5*BEpgFesU z!LVc*pNzOeCz^q)TUO(e*ov)yB(}Py#H|=qRE{I>ey5#Fgyk1aeQ;OQ^f;cLfq}xt zj1wX6pxK!((s?l-f{l~Uy(P~XL6fh_qSoGFLas`VWvraFzUhaoufPj@HMys7&c8^qs1R9omxMAeN;`+4 zG5CE5`~*{!p9SfA={!DhIjK`wIb5biP&FxWI5n0O49{c1HEG#V_9G8h&nyBtYYIe1 zsm|F+WVpFoarHBwD3_!dN)h4-@Fz3N!@=1}^3=g46JeBUP6jX>ez;=3O=hB;^I+#t=QuAxd3~L$c}Go1>q{_$uafy6R;^ zy@(g(Y*-=M7QZBT2Om@Afe4KJtkaIP5^!Xw_^dZR6lheiOz?>2v>bVPS4Bwz4rE0- zDBLOKgyP_tPXapm7lf6L{hf(E4W3w{ghlt4Adj11|4F1pjmrlDk4@%uI@*43sJ%ho z0|wIZUEt%iPcJ{pmT^wS%NF97+vCM-!HA@Pp`{(!U&9wQ zj}gjCsc*(RiVbrg3?4lso={gOgR5_|d&BZtcq!NkRD3Juvgj2>;D4^Nr#ds2%%SE) z*l}bJ8-Mar;~j!wA7aK@#!QCFIB_#PzMTwp0rVBSk8f6l@qyE{(QVzW!*AI zilqHNaZyWWE`!92In#1bi}s$A*T)j?W2vb?+RH2VvDyVue~8Lk*!;Si$#_c*@G)hL zi4spmM)C03fA{Gs3qn$IlZb-&o7f*XD#+-MK2D9cTR_BA5 zz3y2JS*-|#ikp~NgTY*ijknCIC@bix!F)>b1i*S=D^QhD1%VqXOL#VV;-a4lRt)5E z)*dULgFv(*K*?v;$~5G}zAM*7BAS>Yt@Bts87WO-jH}C553ZWfO%w4%8-iuxt347j z<;;tn2bamSl(*y0%>T#Pl)g2`@guw+k*C>aRWv09+4X1O@+A3!dCN7%iYVA5E?%6M z`y(#x<<1({{IOAavMFj^o=a@6^PvKwdTY_(NtKnVojATyv3};t2~)Tu@JSNH6C~_Q zP-P{K>aoxxx^YD4;bjO4&Nyd_vC>lktj@91y}C-EuZ6+)17|oN|nnt|=P+ixKpNbuXdjmig<6 zL=)Voxlo<0O8u}!P(2QL(3+0y#3%uJ>8J>SMXd*jbpkdQITU>$#AJwhKsIwQ&ljI! zYsq#ejaPOs@gYkEYBCX2?co4J4k0V03ZMW0EHv=6bJ?* z0S{3kXU*0iH`GR-FFd+v1Kl3q`~hxwDR0%QM#4x9!}rV1jb2}Wb+3c>-xC(cx=H%e z?OvaD{@^H}uk42ZFQm;yBR|WaKWwJ+5ORMpJEk;?%{$-TB2>U5%7rAi5;hHx1ujCE zB(*VzP5LOd<^p4LSu-}1;tA;1@QdSRqHVT`_?JZc4|EI&!1HqTlSY&m0UyMm-`!|6 z11vhHbyNtl)=wzhBKR8Om?({PJY!33f@id@-d!nEWhC^ODOSMrjHUnFjoZy}xRKVq zT%Uq~4o{9dBNuToaa5eY$7QjQ-w_OtmJbpiikyjM&!JwGNS7N?58iLpI^86x+Zq+) zLup=iAqJ;qu$ugP6S9)$IU{xkLn!?eMcYz{SiuYEx(>MEpq=s{>^<>K2;uO)#WK zuT1-5n8a%XKi&08cuY+lM5JBQ#%u{8T*aNw0PE)Hd zbngpSLCO>sP#ORpPIBe-Ome#Hwk?t6V54YcqW;X*-K0~Ax|M_F-SzaBKvzmq$d!K( zNp;o=L(TWQFKaoJ|K@T=u*W!*r8^R+`8?>IgyE$-E~Ses%qKZS`_+}Wu!wn)ltp3$ z$ZyM8ZwOs#=RaAk&O5}S%x%FPRHY2K;|WDgnqR@(R;qSfTcqB$r1PE=Imf%Uzo*lZ z{a4b6q!4B2Dj{~{2?eTd*(E;~*ypGU>|lLd_ks_44HQ9ndh zmjDUX_jsX#&l%-{mm*rA;QW&yun+(X&G*B&f6-=PGLsXY;)+DypT$VR$8LLxX2Vj6 zxosZd!RVhmv4jvT`a1=KbzCq-d$AFZx_0NBFSkR?_}Dgojy&s#ww)g+vf`C~!;%C# z91W;@E^b-*kC&_0cN?jC%Y@qg!c99aDDfN!C%O!@yEUvsVRPA)N4U2ycHI=IwjNN= z;4J&$f-7gykzJ4Rd;4uJ0HVX5{hgn}W7;aBIm;jQ-&z!97={uxPEnHYdkS&cgHa`K zlOJHawX=21wRt6aW8mej&R86Q%jDD6>0#(2MkcvDA4}p1wRJr$9UL3+M z2^{dV*hfD+PuwSw?<~q1FAfGsp&nZ{QsBhgw_W)T*ge_JLGvy6rgDEYO+g(7l}V*& z5)5VuVy8t!2Mvk0rvA}T6`ECrw&#}jd1<U5h5)!9RAc>`_WYODu+YDF(@P8WupCL<8ugdV+4)sIZ}mQsoH_ zBtQ@a0YnupY}6Moslcl>cG{jP$0|z_d%0t)lq_|+2R+2XYkw%KOgxbda>XEsftpL| zI;0A0j9`{$Dl#yF2SLpeL|FSg(oRZpS=+3DGl1D7SgA=Y&!UCO%4VdjhC*dRS_lk8 zk|df!iKmIdS2(A{w1%wsnX;3l&7X-$A{K%gF=?n-BP&%H$`TRn^eUi|QbY#5N%mBK zwCW`E6Vy_bm^P-=^!BOKKNv~F(we4p(k?2)eI&SoiHwguMTu`}k=!VjOu$v#vvj#Z zaN4j8xo06(`X#PVYdPWkL6ON&LIZ5$<=iVcik93dgQhlca>T(QV4G_$j<`@Q3m4q$o>$!-%5DS?~0LaCsrIvENsf9;Dgs`pb;{Nd6$(PwZ%zRpSXci(r z{MQwfo_c)Z!9L?OPaVHgMd@?3g2C;{Y=1|C#1lWy2%>^5m-X;-pyAF^_F?NU1^S3P zISxg}^2cWP5SYJIUQTr_Pt0AA3q5LyZGu1^T$&bZ-ZMIJl=xNUgD5z~NFZ7huU!#Iy%j|Oa@oo5fmxKR z=Xz3%S}3mKAiaMG7pDdlpGmA3JCQ7;|DFnw#hsdTXc<+VgNvK|Tg#tm?Oh+#sGnL% zhn7#$J5km^R&t@fA5OlYtYAH+Rslww=vHO$fNRd-^R$5S<`ExYjY;73IhA{~TqX26 zKQ>o-(?wW(H;a1XfvI@V43cYGc90= zdGjoI`x3ya*Sgn6T+)}uT)ip@B!BY=6%zCxA4LZ|TLqb&SQ`&Kj}&HbRwlCQW_=Y5 zrTkE0U4oRn%Voh+ii-9l4`L5_gs0$)eier-!zD#Uql0`7b4ZhcLRz1)zi+B65XfIG zZX6tXV}PRIrIrx|i7*{Dl9hlFW5}pwuecO~WLOqleJf;34o*;0H$F9IFW}ywd8$jP znsNxU0G$@Nq5e`w()GzoqVD)or|OrkW$e@8EmxkK9U60+_JN0&+Yo<4_USt`q?)d$ zb541>xg@A71w3e%9hJ!VkHJY|gZYKcd2l^MMe>!naDyPIzGH^gEEgU=q(2U3emr=v z0!r#U5~o*-SZVwlE4VY+iERY|=ZreuO+r*bICN6u!=2h-?zSS@D8eZ}>TC*Vw<~BZ zL|Mr)sFlqdD~E>4qL1QU&Q_;oj|6z5%5RYT!O#!Ey7Yb9{65{7is92qe@XCZMVfn) zQQ=myd`MJS83}&K*;o=(RH-)X%7ptQemqGAu9`Q3IHf9%zY!fN)@NIiu$hq~#&J%M zMgzi^30>i&`ISG)EWaSqLql{o=YfwN(O$CY$D`tplPZ+NtDU&AC@Ivu8mDbY%35J6 zmF8EfTy_Pmw@;l}BbxY?QRC^kv8v@idfgnQ3RZuavIbs(cF-mg|7BpUK0BAFWDSZb zVHM7a^xBT#qvHB>Po~`ICzq+kD}YMNgL>$m2E|C}ev@7@qMekP?9L0&HZl`b5UH`O zs+iShsXMfJj|XC$7K!C>+$EyPUv zM@F7!NF8P@!+eTccr>h9beVu)#Io+8RZ9ou@Xk3VrM(~P_u{}=z*ClY*mCQD9L}y*OU$3RdT*j=|G6(P7NsiDbVdiFG(gt$xm`(-AGo z$Uis&X@%C#$<@~tMp`PP=FAmw5RiU}V>OFXr#2U}P0^Ws!R%IKp@r-y#O zDU=kG#pNx&`7-bb_LJ5y%L$VC6ujh;AmmYI-d1)X=g);SP&}NhzG9y%C#O#`EqQ4R zV!V>2^`!cK5{uxJsPxnzKQg#3OBieVR0{`#6O!Fq*zqSS9s7gkh89n<;aWD)kPJCY?=B$l)}4ZyX&;IwNIW%C-yh zIr=J6lpvpQV4nC#*1^CHhdd&`tpnX#2LKXZK6o&*8F-_xJoyGoeQRE)c8EPjmBY#_ zWMnQ!$wP5SyH-s3RjPGJ(-luvLzZ?4U8IYwh$s4Nss8PgE9+6?SnrUQ}ch$ z{kXc6Mi$Zpnk&juivo^`MGxdHEa1V!sg{UZ)~aCASwX6o6Xznn-y0EYSp`Q}WWHxb zv)N~0{(6O#l>8OxM{g7U!E- zk&R&ar-MF}3f$9Qe4cd`Qo;xPxQMcO6h**JM=!o(*1c_l9$0b~j+18BDcmho+?MPJG*w^EIhuk^$(P z{vv-Jr()oQ9+^IvSa z!f1aCCu0o0SOQpV85wt~WbjlCVyjMEO|G3{2{oxXH1Te@YoyNaAU%)I{-lXFxRA<5I(9~=*_(N^&Es_*8j2JB77 zyKH_7%Prh04pY=u$T@NX+@_s7^}}`3p+0r7E@~({DG}iHQ>KH#O35T*$llyRv^Vl_ zpA?_6|AQAau3-7vNb={6jr6z0Mf`n{R>n$<5e31vbbU!TC`t^Q4ZL(Uatbv3_piY$P>FZ*isj1>~&iFrbf7mA&efA9i?cRC1&T$1qO@NV__St4@XmTD5A--B}a} z;)&>@FIDQ4g-wO~Zix^MB^6+<2dkXO$vQ%`+nQp4u$@kJ2<#COgdTUg`1u+mL{U7V zcpz?>>@`U6sj?__<&;h+o%{L~oI%{lvf_&$cu$1Lh>S^5TtIu(`n_t_pa1{?v4uh- z3{)N|AOJO4NZTY!>xhw5*AUAYam0^kwyG#OuFQ!V>8=wU63K$I%XRmF z6;|~-pFxWY67#)=*RFkZEftH4cZ^noB@~;E(6hA%ZHV1vC23}NDS=LWL%YCKg3??M zS{1Tkg3fYV$rIOhk{1+IzWo-SJ7KM|a@a=>LWiklps4Q6qC_HfdU}y;pr}MT z?h(H5ktJ$~HI3G2fmcf27D#G_&O_}%lgp`;WkY1XS!0E&CFGo^dQGyGvEk%+$Ss=8 zv=!u6Jl)nBN~UTQLM)sR5C{Wa!YS(cImEW3(N@1Q5Lax_Je5V8OnDeyA}H|%c)|%D zNB{rzyJVX2vXz{ zU;+V*000CbAOHh$FJh0X%`gB?1OxmlP2f48NeQt$GX1tU5xL!n4gBvcGSdMhkk%!= zCzgGZbaA8;&5)JUDyH5hq<{-YVBXCNkt{!wGzxMePi2%7>mO?p+2I8~Cz6S*VkWBT zDJ{hVz6um#H4=`!MJWcU?(0)1g@AXZ`C1C}Q8v-PcOM37u89-e<`@xTVoS#^)2)zxgMCV+IxhY$ z24|Bga)^IrxDJq*3I4S^QzCnoGet|SE!gTj3))VXZlrR?u>A!RP7kEvXLpyXts)b9 z8c1+{0OG$@9PESJ2U2mEPo>u!+Op^HDvOisi+W%hmNhz9E$re2Id*T zUF)zp0cE^!)3-AM1AvmJo!F8iezyx3K)>MF+XuC8~vzz%MG!+&LwC2^4Li}S* zQgy|pC)4o#cf(+U>`tT?P4(7nr?)@gklqQ!JaKLawhj0&AP(XsgUS)Mx%)Vhmh%j1x z*L=c@E~OEq0W(e5a3aK9>cnnobwIv5SI*M{N#)i~2flP;W|D&*?Xyg?WH{{IDTI?v zlcN?2UCTuCtk=N_cw7^Ae{5OUBAF_*pL)dL7X!$;oN2@SFp9+OELkVw=Yw~=1O8ps zs$~$F7$dILgNq9%P2u$h@bv!FZGsPzJ@5+S$n78LCDuArWJ)|4*epx#?aKo6tv}1S zKnfWua~kzwqx);8&z7$>WDAa~KPi{eh}v|8b;OU9m!ZnwqAUoF&w_s342458u#xN! zsb+4{)hqbpmIz5OXi6N>R6R+ejS}l*M0xWY%lwiC>|N-m%pxAxc-#$tyqpy7HfEi~ zE7SJc&qVOkwjr@ z^!G`g3!1_1I{(lCbh*tsn23M!t`G|j%4ue}(V~CF-DfW+Ce64qfc1(I)UIv57#+GC zLAhqEd}z$vJ=>Sclqx(au{Pi2cWjLR6?H>f4~#%G+zE%f=o~<3$<8)N84OS%_gdoM zqeKBiZqI;FPdt_%>_*TceXlu26*89DjbO$m4W)|(Hw<)-~*%=*4Ke$9VCr&r=#<{NxrOw_3y`G*8 z;9VS^E=juaI9jABt$J6VCWB8ed6SK3&uWA1Bk}T z&ASnR^?*c~TM%Abr?!QnFtH(~|3-P`+w!5tRD>bn>@JN3r3$7iAifQ|MddKYG(!w9 zgHa6zD8%_dsFR-LA{GfUI3ihS$XEbDtQ)eyDy%WUbu1v=CwRRO2D9P?+!&>cSzE`q zmT#%4S?F_?d|bUcyCHEGeS7|S7N)oD^|Sx-DA0|%_^5STSm zDcXAk3K=zJX&pv%a>P(k>Jxa4Pu>4)qB)|R2vlzcT3GjUoQg3Ev`D6L;88VE2pT2QhJ=z&@CG5Gm^oN>gp3E%fUb<;=puBMuC1np^Iz{* z1s@nR$~cHTTnj5HhOHftSfda?1`;-5hSlYwCP3oHT@?hnR}I6VBTc~}{;kEUikUKx zBXu;z0-~Cv3LXuDgeG(VV(M*z;>MgB<;-jMI!4W3kcO4@^d5}`WI~)*K?R_O!=W5H z2owYwjNlKPN>&p`w9`46$igBKfGM#B#vAqY+EAE4G1G1nRY(}5AO{TDjtsKg6+9${ z`;op_uK<#2Q>!k$NEJ%(w4FF`ieQ*jc;ogGD80p?hR{GMLOei#i4ccqx2rTpA}n~y zWjtDO=~ZBdizMqy1=Zr2$csNLA4SlT^RpbjS12*h884P3+6*uiI1~g=1*5@84l#)0 zF_4&hC8QK_bl_S+#&S29$dSaJJ)_$75l`U~+gK(P%7jElV3fchYS0jgw$~uap+5Uy z0005A3xtxnQ}mGvLMf2Zz$1TgqAt*25?(LQ2zQ=SwePGXBCiPuI#qWPWPkGN#b&rX z0R^);I(oya3IKGqHIw9vg;Z6BO=`AP&fZU+D}4ez zY0dn}5F~^K3iFE|4l4C>s=+t}L0a`LCAc6=r0ZOCc%D5?je z@yl2+T~3QxBgi*XhO#oSH8k+ax(F3l1jr4}$4TKxi>rD-rmFPD4U`;NfucQeXM+|= ztoWpK%y#6mNnhOP>9|VYx|K8jrc|k5+XZA*C&qPE?5;=f_hrS)f{G(Ij2xxR8dhUp zsdFbQ1$WSh=O2r<5TE!g4ZK9@cT22!_shY{tt>A5yvQA!?h_J2SPTthc$5dM-%ApR-v8&{~lMqPjE~LR! z@Mj>tdzE?YZr=nlh;{Q8I8DKfg*hgi6Pot>6;zA4k)}3lI%TYRF9|QQ?ZM)px^wyp z3r|^4mxIC*+tn)BvB`n_XXPCQw*zg3R6)!eb?s+Es{aOg^B*UR68p#+>OkX)nk6T= zIh|nnFySeD3k2!xsL6S&zV?KZ-k?~Dm-lEK3fvg5DdjzQc`TdNoDU-Lhc}X-Km0KV z54tNjxG)!Gob~ft0TZeibXX3Gb@CDO<-vv9*mc2l_ zlkGF?rSdE$qvlfcs2t$W0eV_6)vFUv<@5?+kh93kxRcAfmbO@n$`Jfke#?^9Sp@Ox zcPF0USh1qOw!jWcDD#7=wQ@XhpR~sk;z!_yM^^45sYG*A*%QZoKz76ED+DB5aVR6L zZ1cp(EkM!^K3k@1^^CGJSvgrFn{y8@WUCl`D_mIN7PCHjVcxQqHcTZ2MO2f|2e5hY zsw0^+X?UC~@z0N18&i;alV>;b*r}L6+ zKZ0aU6BPM?LRHf=(Jt@k zzvU=hjC>Z~!X#YSK0#d{yhlYPqp(q|S??^}Wb){U-=ylc4@X0Ib0{eh;Uv$iE_A=C zYx3?ak3~@}GAT3XggV$Bs5_{sqpZ1|%snc8t(X)LAea|rEOc6y-wk_k34O|vd`WLD zBMD&e6`5wWd}~AEN1ZEpb26q!Szcz2Mf|vPLN%P8l$V67JOgPsIwM+K9V8Y~>jG^v zgs!XXZ(|SX7KF2m`Uf#k_gXEpqpZ&|G1(jzOJOhvDbvbrj zHLXwKS!r@j;&*J1^BvX-%-lT<2ZK_~j?j?eC2f2)c`??UR#eWSxzWi~DZ`ctb(SSn zSxO@e=G*1FD@;tQB*2>3AzLiigYVoNbtd?NBATbCfa^Iz33s=?FX zrAhZYOM=E!L+NpsG3XZLCaaW^pj{Lb*+EZK2JyGoDVL0M zyC%!Nj$aBs8FkVPX0xA^d-73sswi^q-ga`Nid5}bpxPv!B;JV^Vm9WTf|)-ji=XmY zBuFgoUqwcAICQl6W8Po7zE>o&xp*ZPXAo|g!Lp&V(tQ{Cm7Za71vGFk4VOh(RwD}Q zbHp%UV|V49*)MD#P5CKeqZT{~h=~wJXVuc%i?z5@Dz678DA>078!oQ{ZZ5N}<+ARI zB1TqKOoz|JNactkFd=+VuzAH-`6O5&k@N-fa3Y1}^Hbp}y0P-Tk67!)60v+c?K&P9 zdOyw|LH|p1;Egi!s${k*VwHfqrHkQQz7=3Qe3q;cC-Xd5^O=6KSI>%iy41Dt?oc%? zE2qdnfxkSg<)D8HgLuN+y=Q?dl(Hy@=&C@0D~_(6=`?+T7V^ntfZU7q{VQ&_xwdw~ zu(O4!)=_6H3l#OGqFo2A-l8gtqLtl;Si*sjop5Jl(!K_lHTSuE{*gbd#vZpVw92q| zdu7Q!4^i+2A6cq+R+ls`uQEWojW2bPT>Nwo67r3oMJR$%{7k&7WT^04ahDaBeM-AU zGC6MA>@?}Qg)+mVs*Av&R8EQvwV>+ui zjG_kLjxFoHFo@Apl)RuDM6vW}OD+(B;-)MDlEzCsnTUaG4TDRs1L+i4xn0VW!DMq2 z`Wmux>E(f<=oHRB4WrXs=s#o!<#*gv&OyCQ37Gr|gc#ZB5c55EIN-NjDwio+g;*+! zM~CnV$>_W!_`YW{`G-EM1IQ3*9lF^)y@6k$>`>@$gJsH8TvO)Bn_&~+1x4|MwPvWH$|cMWLA_biVpq;?|FKh7uQm87 z!-8I-$>qM5=S~^FC#^GFJ5$9y3U7jv4hgHJc-M{v&1;q|S83ATa|13}iXaQWX_=fj zj#>>9%@ie4`twXiU^e+4EK>dum=BAR=hwEW;(XVDZvyEow-C8?D1AVM)ljx=$yW;Q~Jl8sO~+J!J{l)~QB$rfi+R~7VDafOZaIdt7S zJfSY@+>Ti0Q7%oFiS?FQS{~(?N^WSCQGC+(O|cwzIIu-kKIv{_Q>cvM$Q>8YdbW3& zGp#|_EaJJ){6U?7H9s5`v^*=Gm0mgEuqM58#$p)3vg&Xrb_te8c2yOcQ*3sTeXlxH z=ZsMZEH*i*2X5g6IKo0PyVaPB-FH6Hm$+9>~F z{u;I`1^B&8p1yUWgv1POcF(htxVB`9G5s-ZddJD0BVX< z=$}i}SbNQUt{n`RCJ^FdLf8~RW5^`ken?xlVMJujOuIB%4_I;yX+dG-t;A4JY>cm* z6rk9V3oTkPL?l53AcrIm7cp5UaP6uTDOTqjw!u#ERMNwlU4m^nygRt!!8w9Uzu_sM zi5$Z7F57okyEZCTBPlzN*4aB4ufD-b#q?EyyU4lwg=9!H*wP2too^1 z7bWY_Iw`<2*(1{k2Mm#MJS2QUexkuDjvv#9y5yaBE)UZv+uLI8LP1Ylwa zG8qVjBoAWPf>CNW-g%mQi!f6WPF^H{`Rqm?8qaiCz*Z)rtz6_j|EH*u67-5VoOJCfEWMnxNo58QMfP*z1++`MPhLW&TJ2K9*FQvpZ2-4DgpX6DBvb>2qstXmJ z!^?oZK-=4z=Bl-dSAcS+fZ|eyrJEZCqUtda|F6p=BqPos<|CQ3CtYI8I725rYP8Iyq;AQOc;a!2{2+1042hJ z;6M=(_FS?ocdC!gFsF)pLePrPGYvczmve$}884%VkS2jJ0005Gf`S6P7!(sB09HI^Q=-D2;qdO%S)}9#Cbg(-|>m6%%IZQ7d zUxYbuwoN*^drRRoKt4HdiE{-dlrf5QOQZn`+JzEUR$nQRji8s%QK=>P7F-?iBgUYIDM_K#9)@Q%DoW4@+)FX;AyAnhuu-u#*D=1z zO8gPONLfTN3g(C8fXe1!oMS}fwlDiyL@AUcr2v5(-fy)|s8Gt0JAUw{LY1UJS-6;_ zs>xhXOjI*LGAT!GF-}Nw3<%WZn&R6WEs$H|_@PP~wLS1=lDj+F0W0t%rvBdYZBt!Snu2MW~%Dz1p2nXl*>xzK{FpovfQJ zxuY%AZ9nlt9v8P=d|sT`4oYricD=;2ih}&A1IB4(yVISHAW9->&u56?7ZPB{wMZLp zmnQ>cB}*g|>%BL>>PE2gl(*U6mQEJP$nvULty4ksk#%TJPXsnwqLGSpcvpzVM*i8! zR_K$LERLouf~1*b6U1QS7ligC+7l)DeLl@Cpp%*8qjzR}0p&`O(uynI1ETIrTiY`zqa1(oaGU_+K-hBxUV zn2EJZ_xnRs^i`2!(*AO*L2F7$$NUP?CVv4ujD)Aeq4VboBZM^b(L^aNv8N8kmiUkk zwF|@Da>KMAw_9eAyw zy}Ejpbk@GZH(4xC;2>(%#+NEtJH{0 zJGfRaT5q8olTDP2{=Q3_5h1H(F5dp0+uXVC+K+C+2gA!0w1Wj%jqy9KQEXqbS#rh2 zfo;7MUhg^8ak%CREKC7!+YjfhATO&ZQrCYt4VoUEbe(~D-m1~i{wA6I_LbTv^3*58 z0YiEpx{nclEdnNqbaferXD<`-(Lay0ykAu#FbTWtmc6Ib>JRof7xj56t+tZ?Q)5Q3 zX5Q0|+N+{KCS={bE6rX7DK-^H3;Vh-iT^7R$wj-eg;Fd$x$ud&2$wk;&F4Rd%O;pg z@bx+@ST zul5DemAzIJQqh#R;iWt}dasmtI9H@h*)71pzD&t#cTS#}QDQan)0y#S4G9XjC+Ek( z5@f)g*EJ>aZOwU`*D9G4r{#P=R#KuIo(2#$l)JFIdf-(^tch|_#TJu^(kqAy51PoZ zSL*~i)Mq*;r-@vf>WNDA2-}-;M2oQ1w@C5k%JRr#Q_#e`o`w+2AiY((FUb+NZ31W+ z=RXA@HOL6%hs81mAaVhDLTSdDYR_VsgwE zIJ>Pa>`QSe&ZtgNu8<}EN#xNjeM1pVbLrtg84_kDt4STEQ3E_klRVN5x7u3S@@fHS6oL}_t7uausFRvs z#EG1ot3Q)S$qa-jLb2M)ZttR`NdS<9MFmAEucOgGLn%G<0g53&Yg{P=Q41_l2nC6W zX?-@%yz;1~*HQSAH%X#TORe(v$ODpUneVcIW^7GDN}W-OWM~p6)!-$}6VG_%1XY#L z^cUtEJlsb>N3+kJG%Z@nCEO#04qg{s%uB~W;&w9hMRFoVhO&<9!eed{emWwdVz6tA zzK*YA1O6GMY@s zmsmQd2i!Lxj-}u@7047`FX8toIPt6tc2YI-$kdkP^n&3Zj?{Z9Ls+Yc=~`OmelY0Z?OL`5WS^n?T}zLKOtQTQKEeEVLBc%N zU&$s}=Gkn#?yhXnR7|+r29ZncO%sfZICbk&lH%@0cK}l;rFv_xQ@N2PZgkkdJEsbP z@L&h5?f@d>S#;Y9BZ|u~oHwS)o?PmK@l#e=J6i(HpYASduz&a>ts=(Xk0yvw=pv?<&|;^L#|qb&+r@X3}`a^k09fN^7LiAsQ&?K(CzAb}bx0r2UjobQ;(yD2eZY!6i zj=d8viCB->CZ1C8y}Tfg74**KZu`CSgi;~otus+wFDOLnic}X+e;O5(r(PNb|r7mqnB=|Z@IQuKo zEMUR)g7DjA!4$c(zF9J0d_`V3Yt zr{u0rEb8z@g%n4UTu^_50zkpMr9<0=Geu+7nngmqj*aSn>O5&MKCfdH`>|u)#Sl_* zhd9++hBTNwDh^Z6qUawqeDzBlDRrv(UQBY%#I9bk%PWB*Ae2woi^6EpVOCo+_PliR z^RtO;O6M+*J_y$g?m#^}7p|lKh|i#<#Z&R=e=7wSAc-Cvjpdj!%e$rzVAYY?3Zz!! z3qgZb%LNy{mjtGQ_f5+o%$5e=$a)jN0p&Z{9TS2nLhGM1KcP``Syg2PODE5OGu1(9 zQmujjwew_l1XrZJ5(mLo!#dQ-vE4FFKcp57TV(Xh=xSMZ-Btn=TvWt-HSJwF6Jniy z-hP++)(E%)p9x{jO5g?0iFA}7#hOVK?7<&TnUo(hPEdaX78GuuoAWuIhWfVv=ue2P zg2|nt<^{>Lcyd^^bh)ctY6co@kt12O@z$aS_o(@|fTEQyIy&gCt4)n^23EP`8A0CX z4*$EUp(nH9)7DYeNt#(6}Wz>1pBAhPo8`XhrXWe2kVg8~frk^j#* z=XTX1WtVX4!MZMnnaWxO6WfQ3JND!qXbu!BD&j{5}dxU9I57Us}#)N5P4MnA3Jm5y#d8M@mWji zQa($ys+l5O8#u8N>>4e~?V)9iBKJ%mkC!8`h|lo z3RM})BMG3kQLdt7D|(^%Y!nrgTr-KgSx#}ccMiaC+C5BNy2>%?J7B9Ur9y6LqSD4O4uMRBvrg- zfnZ*(or1x5%!)Y0B>SB`1Db2i@Bu2EmG-|znUTN~?slejDN^UYz64XkBCZnWc|ZI6 z%F@UKM4aWKU4*%{Ea;$Q`JXHllX&3nu}q37Q*d3*v#O%sq^Zt?shkxQ8c+uW%j=;i z`M5Sm@YbTa3Dh#ckF@23k&_VW$=&M9Nu<*_Aq;|gV36yT_-O7yD*P+*p^cpbid zGDbLVg>#mRSa!^w;ZL4?vjd8I$X@4a1?r5z@ji>f&h#Qv^F33;NQ+NLQCu6T&Pn0Z z)`Bkb_=~~K%L=(xda^U3aDJznT%7mBzfl?3!)U$-%rWp8OrrQ43g$^8!c@IpMPU$H zVS}=|7CwTgHXxd}1i4o!CpP)T5evU5wB^g;YGX-wG)tvaaGT&Ct$)(1S=V_7$UE@7 z$}ZW{`3T@%$bM&whgdz8RHW<}sf9^=Sm}{x8KA`AbyVE{^E{C{C2m>}IZA#81pkJn ziu9$z$oIuB6xZf+|HxCGlPlC;Yy-1%&64RO|d>D&7p5j_%LV5{UKZy>YlLy;ZB6P zQ_mLWcd_L^mmo}|m&~Bbi_b*)`i+|J?k2x0~6q>(3J%H^Am z3M(p}v9NHH0J#Ud%b0H$g|URZfL0>(?iglVrKgMdcXD_|oHc|;FWJS~Ym+<&;8$XxnHLn_x*kMIpaF#ea^YAbFJGVvt(RBBFYv{J2IEn+5Xi!t(LA66o?WggW)eor|4 z8Zu1WR}}U>D?K^PN8Oyr4qq#%yo#G!vj8i{&N+@O;Dg|&66>XWTg}nMrv;g6PSSU9 zdP)zFioHIR>Tou2mlS9ph`$2%Cw4fR)BU9gkwTa+N}{bi2WHGIgky64QC1BH;SNn>oemRNhW0VTdgQ597SAriEb=llzFG$hvew{Dg zpOLV$8j-f13>4aWoG5T;$&T~DTY5Mat-gJL1~YAeC0wZXrn>I)n_NjhCe(dm3t8;JDXy}K)t@5aX3(j978|H7Ub?5uWV-DxPwc;tjTwDO;^ifskeoMFCQD7`@K^E2 znHs)ZlM$0yC}uPL$Qd$ARmtYim*f-0FE3`u)0-1f@Hbh4+ZZcW=GK=9r63+ReN`Gs z{_O*DcO~yf(vHxB@pqVJ5o(<_p9I#IQ5b>uVsIf-3*1wgNY3!}+xzt-zuH3AhXU`1A-I2zf*o z>3trgzYdPzxl9H8Cu*jac>3gvlE5c2#4sQMTsoJ5w_hQwNljR#b!Y|H_3V}3?qRTb z{=@08?<&K#z0tDLa%S(durNU!O#Z-+LsYFTS_FiJt=KKZc@<+f!sIrmWvQs0 zLl{XQ45due-i=ybjIo14<>km;*AGY48B%9 zb~Ie=3tc$t-RY}@4`$^iKVVq%%L%Te^qK|danjSg#VX_r(#&OlG-V*y;~h9YuB?#a zT#ghKX;xDc+URc;6+fq)XRf}j(j+LWZ6A|TlckNeKpRGqwY0~NZk~oY@>o66!is@B zyKaaRQNK|n{@~};*DofVn{tRSW4{rJ->o4^x1$(b!>^PTF-@v?IB|#Fr?~L)2oA%` z$*z1c&FLhw0kkrrp@THm5CSaa3pLr%L*cxVS;~*vd*-UOFHv%L>r924Je5Y+!gPP; zY+@G0x#3QPf&Kl<8(R*W%PuxIiIn^&WBS{NICrDx0)`uc7r$BvvqjQ*8SYC}5NWFz zPFKmP9>!Yj6r*>3j+5OUR-hHMteqQ=SG6SgT#{J7EJ%YaqSvoIGO_u8i^ zNRF3on-UkAdM}b(s=*j*@ua%tJg&;^YQ|)Oc%^K*a1Z0b=cdbwap<+u4hN6e=5bQd zHRKt88hc>T`BfEsj8X5n-F=%xeuYJ5!5ty=TDYjsSOb3`avTH+JE`Z2z|4DB!CcNe zL(Z3QC+K<2uI=LAvGC^zX+Ts&YA)Y5;cmvEH)}y(-?N0cQt|E>y%2|6Hdlyk>veEw zTl>UJBB|P!l=~f?FDZXj%4uq9&Fxh#Zw6fEw{^7*pPN!&mosL3au>UW=vN_TH{R2F zG}7O?_jZu>!LONssB7wD{4x~I0^cuDwbtRbZCs%6;t4QLSvZ( z)?VA!z0w(DyIP+0LskFinu~ciYlce0lxW`s-Wa$C-lf;t84q$dg#Au>0s) z#BbAD;;}7>)>}Ven9|8Giqv$Oh9iCKqz8w0Q7Ve>uzYQ6Ns?HGH(Tx9-> zXmowU0Xv@{=1do7tBKbN6T=%GR}D^Y%U+g9bD~=w3{^|M(DI~ZI_Ig(01r`XuO6jE zcs#f89fsF7cbx<(rWshNMvS8SnG@mj@nr7P4GD0HY-n7g&8I4}C13nVu~paS?|y5h ztxFs6)yLAZW%84#gwtZab0 zQuq1N%sN$o_%)d;VrqF8Lx^QLZ(?qbu!fO^pp&54HTKdKxvq&fggCOj8CCO;c{0Ph zbgN`%0Vgk2juqiUfTEgbqzC$b;bZQ;#Mv~lWn7~KJ`3N3QQ9>o`29Q$QK3wumS8pJ z&sz}j%|cFo8XRR=sg^Kz3#Ib@F{^Q-dJN6jhKk%QBRMbHx@JFPZMjF+sCaQ^A_bZ- z{i|!=-?PU1)-r%qP{i-;u#n3h|k>TPfJ(%8BLJl!eSG&wQ>x?uu`^ALNaqg*@3%|J~6DA%Wnbq~0fQ zR4>+44*cu9zoZU5OL>7#xs8J8=J56vo2ygRaZ)NW2%e$#1Q)0oX~d|g3;hT(nQ)ma z%Vi<=k!WKWV`j{W+!%G}E!C#;YP!@RRJzR{o@VGSTMUd!F!hem6-gs4!}mg>Ic?Bh zh$d(_mC;h6QKRgrv1(o(x#=W9XwLe6Eb{3+G(@_h_fD!ynW|CxvE0dh&-pbwl9fU& znc`H@#2_d}DDb%IWUF6vC8$^ZxgWYB>C##zd)e4W#Y}T6jdnAXrOjPZQX3&P))EV8 z(X~WiL^X@;t}CZS2?!V|M>4S2cbkMuJwR%jv?^z#fAU>$$SoNaT`afqKn^$q4JEr0 zzCWrJIEh-CDGGN7{^IK!2a{JSKi6+Qq?72qZ@Ve;5cSh8-)-DCUcl2k_Brq3sGlwV z`mhkY+0w6=9nzrYh4|HuLKExar!i~8uUv@APcC?G&vf)+v91Em09N7Xct zziS_)?2GT8eOIxOA#evS;JIHJ?)~K+wP#N|8p6_YgLfnfR@R=E^{QOb>%;plecf}7 zZpnc+ztL&KWhf540srPe-jE)S_D0A+bxR}0h?dc2W<&LNB5^8%(*wkrU4*05q z5>gtHr(d?;qXXRVM>OeOHs@!VW+WhUHK={F6hVly;%#Y2-E0G8y37mSDCyw1Xv=_@ z>J7Uh!>mKj9lFCy2xv|k$P0poh^-wB1o#X>6uBdJNH!!A_h*X@eHbwNvU-2DiiTU{Yr5?trCi zxrnT<9WF)gSGnD*VR$p6^u=wpn3bmuj`H{m8%}YL9NlS2ZRZAhqKoT3F;-w%C{&_x zmpj|yI*3|vsktGzwe9v^;{P0(L-WecL;rw~Kx*c-l3>RrKDM@_Lyg0E@gP?z!2kpKB_8jLMD(DGrR4|2xxp6bvZIu zAw_~(l8e1jVqe*FL)gEytgHA5zH2qR*t3A79G=Nb!#blZJvjbYM0#nsRU31lp0&On zSW7~8L@?oFL(8Fvme*P|ziWvcz)Gb<&YnW-&eIrWR57Ix!}CM&P$q~|@lnXWPDT~G z{sRj~>)zz&*`2zdo~ggb;$N?(!T5%@ zag(4}TB0r9Ij?CM$%G?I#5srcs!0sWRVy~`yvu=zX8UyUGAf@xZJClV7aL6lj1g3& zhX@PK*I+Ow3S-)`U6>hd(67cr)}OCi2-b#^TZ%ASCW?@?>(* z+nV2s3(447p1InWQB$yszmOe{koxY!;gz5O_3Y$<2jAutv^nEeC?HZxH*XO4IIvCo z7ZNL72@cd7L;IO{-?dGdv#1{btGg23E~y4FeAllB$sR;^lRPfMEvao_F}0}u`mTlY ziP_-W)!oD~`GD=8S|zFF$cVE%Ka_7Gp~m@dW;Np=qa*Xay;&Td@~EZb-WB2wrgX^k z`-T?#VCJzhZR^}X(VCe(A3~x$jR2hi-{t*6Qgh)U`97Sl!TJmva-Wupw|S$6)StOd zC}!k+e#!sJs1(;VbpFA}7~d_EYmn#26gT;6Yx7fT~+2e$CzRj$m~)kuejQkrPT z3Uis#dTM&8t+XkZ&D^@U^UPP%*PKNdD;%y|eco-3cLjITU0gh7lC;|?-WP=hOJ08z zolrSxkX`dBW`0RGhg)>;lLdR0)~)dj_r2@hCBvI|^f%PZxdQ|>Z}>PHcv?C!T3BwB z#D1ERy^rdA*T843cx2=*!b(0xiyIoFLjEL|;X=5YR8(TyxO|LNzc*yvSBxPghh97M z9sf6lS0NW0uR-!A_DA%137V&SJSSU=*ybx~7K9q}yZITNM6@??;gN8di!u|tXvaUr zw_orjbz*+jL-c+Wt)5Wvd;Hs#Ez4Hd{x?_OXvmPu{wy67HkBCs_5}Bg>JCRTDPVkLrI@8YsJm9Vy+s&RQUCm(rq6GQc{ zh|H)nt1%|uJ~J7Pp$~pyy4|T7^8OlsYGvPOryq8_U8eN*=Y-6GrQo-W+=~<+;hmTA zJsql2MZ5QF5-x0hN#Dk_E{JA&2*dsg7I#$WA>hNTV9ns@b;|n7rm+FQ_?ci z6Pkkx`QZ-b#fr5lLb)S!yZJ$8gx*p10Vz@hQ3)t7(4%V1SFh5iFl+dms3`?}^haUF zxF;=j;~9J86^JVJM0t( zy@}zCY;n=YF5~WvmX2*o4D)Iibdl-aMYk0FWOf?Y;>`Eq%v+6E*0`lMyd)FsP3xfx z+?K7PI1`#<6tSp}ke9b)>s!@dO}~i887?uOlM+KdryfAwRr_l?EkE57ew=v`y@*n6 zpEr-ZCNDIQ9;JoJGj_c{d11b)(7VNT=Mzhe#e-<>iM7yid z7bc-$<5?%*rrZ0-d&@aL&Ddm7Q&D@+5?6Xiqnn;2!>ra)K(op;dRJ1;dxo7O+?9s) z=LeN;qUhRrdS9fKQUb;9cFRRt5*7)T3xY?C@*vv3U2hKg)z4EoK#*YJq zXtJnVA;#bl0i>R*S2x=Dz5 z1??)?MqRcezOVCxHSf;E^GMtR`Xrf6sgO`hcGh6o>ACMzi!-z~g9W;QG?cz!G@5y) z@xZz7$r(Y>qthw=0goxDbv9t2ELW0hCmpB-?-axI67J1b}@I-Fn4jWzHR9Y{WBLQ zyNUJfRqcB&1aAp_Q7du$W4HVe39sRVWVYbP;_zn{&8!dD-JM+@Ftbe9SW4?&omhQ5 zo@6W{Tg5z*5U`8e4)H_@()cuHQzR`fUB=6h`}uMu)6i2wsSJtl?c09w&vKHpUVfwR z?nXvBcz(DxZ#Lz%Gv)R%_2bK(ox6!oKQo57^HTOp(s3GwF&nvL%9E5V#D1^jGW5mn z=4mkW_O;{h5ufNtd=&naH7=aU(z2~azzgHrhv)mADF(SpTIs367Hx+vkG?RjA8N?uvMvHmF9F&=lw30g|pkHzs0aZ3wn03hb zQGnuRAp;)A)+EMaIjI$vyK|<=;v*ByutvmOM1p>9;g|q#McQ_*!H~r3xXDig#0hTD zULxD>d##>Ng6TL2nQ=wGoNRg-F6{-c(px2Rw;+)g&dXzB=B~-XMp-=xOnGQd@p0{Z zsAYB8kNFa)6fElGwb?Ms_{<{WFUzZZQ%6G}bPTXwf*;ooxK>WZe<2P@dAJNm=1vL@ z>v)h=Lw@11zWf`dxhh3IM6!138Im$1-ic`3r?cP33Yec2_b?WEYJ63*`xTJFc>~d~ zKdMv7f;ECogLsbFK$gtV#zl!Eni(7Qs|`hSWkQ_PY_bd{$-}#oeuGvr<#KN|OFYs{ z`Q95pd{r7tV$d44L>q5TPCOia-ma&^Y#@S5`K@lp}HvT;%nygIpdWu_mrq!Y+xE=%xy2!TVC zmQv!c*yGC2L*L%$w;)#_=AwHHFK=U_9!x+OE^!G$Izo%pt3z9ZE0C{S7p4_-RW`Su z%19FZ`g?1+>;C3l*zLqbesTMS9B&fWNeDL_pP7YqlVIC*n6^p9nT_3ERm6%TEirA7 zZ;dR>hkK3NvwFEGDzYdMl{;D|B-5&%;6^G+Z;$=doQIztw?=@4BcwDE@AZVI7~+tn zOq;s6dJkuZjzd(Ov1^o;RJ`BC&-dbuZWN8yN~={8%pircBwA|RO ztN6~Ne3l6K=J9o53`7+?Vixo{DGqeJX=8q6t4H{Ve*M(y1C-IrvCsNTv$JH2aiTGA z#yVcJ4hi+g8_kSWtISP?D^Y%2$&7wQl~OreQoO!DgKhRM1)J>Cf*K~eK-W05@g+>u zi`MNv_SfF#G9WH;q9DKN9$RM<$olx5N*MnUw#NIPw76n^n0IH8B|h8St8}coK-%kAQY~xDZ;%{HawwMuBEbeu;Y1W+&KE+-se`m9p9Mh z=wxr;RfA1eV=ukz8$7&L?>xBtjAv=0SFb*9tF`{Fujzar-Oq_j$J> zAi(wK)Wf`VSKsR4C&L>AQ|f!K!-f%GJS1!w^~zs*i0BaE@pX!BiY)DRt-z1@LeYI2 z;51lanP+|dqK!6ng7y=!iMy{P^nL|x&ku8Gkvr7nI^HVZ*e82J>5x>hS$6&PAfJKP z=9J=<*B&d?Uy2M>xxe`{yr&>B9KAK7R#8yvsM0@AS9vAXsTS+fn2GXIgWgK_%OPir zU-sWFUQJkMA;RBTXTN$_@4E6Xb!>l^E$xnfQSFbi`LwjiAL+NPeqM{ax4G$L(O=x_ z#&5W8JjK>9S(+IKo@b$X}tl>={KCE^GU<5NQc-kw zq_ydQ#&Z7swbwOCw&@LCOFtub4yEi4We$Ek?R))3a`rmY%LwK`F(iKsc+v~pC}uca zR8ito(7%{I3~4?D)Zy?D0rLMU7d$+mT!3-`$^|GFpj?1*0m=m^7w3`-hI6f4aD#3E zx&`PKpj&`$0lEd~7NA?4%Pr2iE5Z-T1t=GwT!3-`$^|GFpj?1*@o&n-6;Lifxd7z? zlnYQUK)C?r0+fq?Q!WHRxd7z?lnYQUK)C?r0+b6-F8)oq5Cr7{lnYQUK)C?r0+b6- zEFj&alSLOz$a0`TQ0y`F2GwZz*{cBTQ0y`F2GwZ&Ueej`P>40Rs?hl&@Di>0Nny~ z3(zeY0$ob!B6@ODm6E0Nny~3(ze< zw*cMZd~R{hg$wYlWuRPuaskQ(C>NkyfN}xK#lI>S;Oo{wxd7z?lnYQUK)C?r0+fq? zQ!co{l?zZVK)C?r0+b6-EFtJ3vlHElnYQUK)C?r0+b6-ERKP*U~>B*>Ph}fBM(5`=P&^@?N9pOc$nk>h)^${82 zBZ9bjPrK7%Q{RE-&frc3H4U9U8p)pCn}dbjosU^k-Q;n`8N%5(o{J?B-41Q4!-Qs1 z$c#jcy0Y=Ofxd6K-KPD4)NaBIcx z$%-3?kgDwO)2>kg(cZv3u&GIXeE#OfD5k^y_HYu z(^u&&NH)eziN`~CD!8i2GOjbLyhtahBK!CRA2UZt(pQq;a%+YjUE$sfulZVj<}{qf zsZBu!YXX`K&sr}#lP9lN=^GoTs5h2a%W1smlXS`>snYsJM16Cq4gzyTMaS6U8?|h& z6TcsP%+)6Dt4AwEs^BQ%V{_ed!G!Qh&qNtPjkMzMtE;T9hy1GK*U=O3#JS}7YB1cS z1rh4-YA9>8sia6-gT`-0&l2MHV&NMOa?mXV&0ycgsHY4Krio7?XlGAHBK>rIo~47d ztd28F(QkaBjOJPJTmf66ruxmXe$B=-IK{|-$yKI?!MBM8U*Ep`a5D;>(NQ{L?CH-Q zO;WElws=-2J4!yD7kDBU6j|NjW-O6EY53(R#NEUlSnc(~N>G=Tl3kp3$0}Vg^5&B)z{g@ zUDnE|SRAp{BI@{>XQz?(887@4!FoP-SI9K43O>KTFRZVJ2aQ)tvZd68mf@oeT$Nlz z5}^?4D9IYuCzRPq13VRfruhu37A}Ns@7HFHEQSH%Tz6%;zs3kT6#ErAhkm!0`5+fb zes}zHYr(rgmh|WC-4?l5rDpNg;g#%PU)fYdVH=0K=*Wpue}Nf`_0;q~{z1O4h=w}md+q)w)|CR++>=WOOr zhbTQnW|oOO;ONABmu0tQBBNKt68K`EET=xd;x^$!`FktEt$akkc(jqVA0kM*u32sG zjbeVEQ{L-pzu7d$;~|4VUc9rGIOrlxki9ECO(ohGLa|{{;x4EDfn*qAUR(SJ*G%Q! z3|>TLSiUyF>}yxbbnu9QZdaBX0y*C!rTpL--ryPD;2GZF8Q$O- z-ryPD;2GZF8Q%Zm8Q$Q_$H3hUaCZaT-2ittz}*dScLUtr`2Ft2KVP>1@07T7_^1f@ zs0jF|$hjUBIp4MjH~6dwxN-rmT!1SV;K~KKasjSffGZdO=E?;(c*q4P7oc2#askQ( zC>NkyfO7G#%Ec9MTLjz|0k=iKZ4q!=1l$$@w?)8hk$-brL;#cvP%c2Z0ObOd3s5dV zxd7$j-;@hMP%c2Z0ObOd3s5dVxd7z?l#AcWMY;Ut0=$3pUXj0_MD=wfczek=6c64+ z9KJF_l)en_O%*jYwcp54{lv@FRJZCU6T2p{ zf}%;^$fKd<lk_=xe5*HgGO8(EGU9BczTlOQaXZA>M0>^iR%YxM@2558(1?aQ zz0u(ny+YjaqxMS6hd}1r?cF-?c-Uo4t7-O2}d; zh%eOKVdM*wglCrG%BDtSlP1Zx$v7Z;`d}H;jD|F?R7MPGbudc$%XiJ0z%-U1b`~j( z7Cky<{{u#G^Fwv45!&o_AI7M>bMKa#%38dgq&kCyrP8OfN7MM`s&6f0E+yezj} zgpOJW67ArqtBH=l656kFYw5DkXYZD;2B50hD^Op|XJu1bM#IC9evxmld!tY>Ufk{y z>RXoxZK{qgS^0|ygdyeTWZWOL!y58abnxCJgw*+erj?($I9ZLxZ@n35uS3^h(;oO-#4Pwp??xQ>vvFwQ_{J z&k4R?pzZQwd5HIBx?DG>i=%-4dPGq{4X*Sq3Oav65p-_h?{tVr*=ds2w9@Ah3x@wa?kVPmE zj29RiAbj1{apNM27ZX2xawz6|O1}*I+I}G%pM$sqvK}cH6k5{b?(Yjo&R4J*+jF%OI$v@QFcyS3y9gtoiioPk{>t1Ey!ghud=2G_l~4|S3sqg4Kvi^e zgk3jd4ud*#_H$b5ckofv2DoKm_ykwbWK@j`bd-wkyIjS9=P$Igm`s@C(+L)&Y7D{1 zZbv;3bEunDY-YI`7BBmX&WH!~36TlG@SRz+@}@pogxMUl+c+Uu*JPMpBv!OyRf&kS z%gh?58KS_; zg2+ez!_xmo)QBe@s)_9ga-l~_=R)j^ON8v#d`3!qnzT}l*;^)74M@#`>o2b%xLr)l z=-HA=hu}>cQ_ESaD0V@fC}h(R-&od2Xe+JAvMR=j$J7~iY#v zIGNHd@85*#j5fBWE9t&#qk5wYX<9Uaze0MT!F$k9|M^V}{Oh3Voyx+-M31FMY^TWfFYrK>mbq2+_pBzD+ck)PGWWDNR0zJ69S+++~KE-Cy`xc0#E z05|P!U5+G+Xvc`%P0!BS!v>#?4>GR_Uyo}kKWzHB47>nqz%ZSK(SG*2_r_p4|C&CL zzQChPFYdh!OLXg!UTOSQE6DLBJd&(wa>HdOJALx*$57t~jXynatt59`XE|Jqi@)qS zPxP|v?s)4*cM9*qnyeht&*ROveZsEnydB9*z}9BZF>xb`o z^yj_ucIxR}6(w)#@nOzcE{ zVw4Bv+Xh#1%5fiCxccUY_A0%fv~R+jK3VS@_x^nE;QnVli>B=oiYi;rdvrfHT|{_U zD(hxz5gYfj5G;imup2AZoxZW!IFkb)q|Z!hV`2H3Kt;|{F8Sf{{5Yvq{D3&^V=?lnjVhk&IU(si&RxO3#h!odHFl=zbgU| z^fLf&;GL6(PUd#b9PCGbLVpnTw&&|X;BBdq1P}=Dm!JB|LWV%x?KuAWteb;&70oM0AGo9QYBS*qfVK8*^BhIa)cmIB;EI zcQbSRE0PmNuV|51M-1qC;W??76G{cQ;xA92c9VdXeYSQvwO~@XVNpch zBOqJ>8fq3mx_qW)ruCpHf3?};mcsSh7EAlsCQ=Z%R#KXwfjS0%0P_D9X!eblrWJ@x z0*LZ#ghN(;0P_77*q*7v&IiB@fs6Vq@U8V9fX5dH%!`y)O%kID0OkVOJ_}T^{R8m0 zR$&71+gb5pXIaAj55VIJJ_S6v{@Sig%hi@cAV=wJ!nOZ1p>Iy+o2v$Jhx_PhsZ^F_4KfxNDR8OU*ag6@=@jegQT0A7}P zl+N}BubWQ=@}J&-^Q1R8$&BJei|3vW1ag$lW+u!J<)laXt8O??W#$CY*S*v99ca== z=`5mp{1oEvFa%*mu{m?g@)->r&|1A4@DV8A-tF%EyifYnlu z`yS}3owu_SiBW=s9Hq07?C%{@&JKILup&twH(9B}fItKVpc`4MEY?vZ&>j78w+bDJ z3-fc1)_n-%D4mU@{KhfmY$QA2aU&wQ<*t6QXF5vr#ht*U`+W{)kC1$^a70NY`2;4>JPxwWkGk>~f`(w+Kves$7$5KaiTL|sjA)8;R01v+bsOjyk@x;Unf0EYuLSe_bRxPBkw!ye`GWFSTYJ7}US+MkHOuj?lf*W+S<5k^=Ony7~NC*tqB zos0+QV{51o2xcxck&g6F#NQ7wn26X^KY(%+eFRO^y!Fi$)iW3}X;h`+CE-N!mpgFuYBiqJ&n>wh3}{az=0 zr+Zog0AjWTG*MXbPekZ3=0rU=Eh^B9;(?hKkbu>&Q(tiE$HY^UHNjKnc|wrqz7Kyf z4p>M7(ph<(UVtV59n8t<(aBiM)d;L}&_f_vVek-O5_{^4%^UZqb8&X@urqgtHQDsa zY{EVihKC%bvwyo@*6~Nr=r>IJHgXS6)+&XA9Hp~G5IKzxW#6ae`=kiwZZve>aD|5) zrL#d0MiZV8{+<_|niicP@MXAmJvQJVN9k-3sYoOzh~wEA?8%v+f?9{HBOK%?oh8Wb zkU|k)R|9chZb%idj(J@M0wFzB3BcsWlI)0ZYOFk7X96Cshp{ZnQNblH3Ur#vG|-q5 zH`tg{v-gumK`}_XNeO5(d<-;(&L1}B)couO6MT0o=QS|Qgp)yIywYG}jys*drgE>M&=_E;9%d0A56RGz&H$&`l2_;m zkfU_A!PPVzW6rdCn9BisK`1%Jy>O7Dbhf#ac2Phz7ubt5dk$l}?!e`mD+ryJs5mN^ zc{#OQbW*Z{nT=#Jz|^Dq2{cAD3nm75jRuTXmv2sgZwn}kX?tkQ%NE!em=(lvXcrK3 z0oafL*5J=>N-VxR#<*CS+naM7{|U3bT@aTO7Xvl+1=$AJGk3;6pRm=qdH zy83cpC5|HpnnJw}lLE6$wD(=7(}5b|z6M<;sE4r21ZFUlQo2C{z^Jng1a!9Tf5f1M zRndP5r1BPf%4(MP|NMHu@*X$fR z7}@ZiKnEZ{XmZdPm&>p*$73iohL0z^3bPghX{Seox{5CH9%G!XjGfHQG+dmH7GGht zTZAT0{~n-!;s>S^XA4(%4R#>M!T}vfYF$r45IL~^^B5X)^E*ro*QxxR3_~Pq`sNkp zfJ_4EY{x=~M|09E{5_Jv+{PjKRYUcP4+1$#XFHaCw^NAYkqq`Oj?4zp?YnLe$Wb~Q z#J8eTgujD0wTW|*4`)Qjdxv7cz9W#%29ZK{`6M65L7ZMuKOtD#hE#NOK_ExzETP{5 zngDxG%((GWkgfrse?U5$jjqS12!Ce-=FZ#~opk3upd63V*&sBxPa%%8ApldY;O&_L zRe>x7p+hgXsl%;1=EX1ozNS>rspZcP=bH;sTv zg$MBYv;87*1I$2RN@#rWCavQ=t10n4LVmMOLREGXx_00h&TL2s0L# z16S%=fp#WFiE?(9Nim~X+xoN6y8nX1wFHT(b&E{iZ|j6x)A49pT9 zi*4TNyaa)~ONGXu=E24sPo1F4#!Iw;W*N8!-tIwTkUL>xV73}H+9;VzK&$B=fW|QX zfQ^AUD66>sO37n{KGf%n-bgy1=Lm+VQa8SdBo+3;N7tCQpm*9|Q zfe8XB0j`9zqmPO&Y|JS`IO!j<38)oz%-|tM>1_XCpLdKo(?7u6jXC`qc%XDneI;Ts z9TkfsFoe38J877^xEya}Lj4Tn&&2vRbk+Z!xhXKv z{scW+07VSvfpQ(6bas9!8t1vF$48u;pK2*^F6!~K&F81Ki=B&l{7}>Rsnl}kp>qGj zhUKGnF6!}3(&vwLLiapWuH&P0&rcOFITw}pe_dKU19HKWqU? zUgv>w{m;5O8)|;wd8q&J5R|%p6Qrog5sUIZPd#%wbLaZf&(x@B^sQ++W3)(#o^{>O+&p!fvf-s+> z1pYe3_54&3)N@h)=MZ$ZTYG|gF6uw**mp_KMTI%CK|h;y(uLfhIS=*khJ^^sVu8E< RfPWsd0e2xW1Ct!c{{bbgs&xPW literal 0 HcmV?d00001 diff --git a/data-raw/v_16.1_Breakpoint_Tables.xlsx b/data-raw/v_16.1_Breakpoint_Tables.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..6abb0a331dfff3868c1e55fdd878a1a7a72a3902 GIT binary patch literal 2679948 zcmeEtW0Pgkw&h9Nwr$(CZQE9*ZL`w0ZKKk*jY>N!yKcYk`(8)i==%d+uMd00K4_CyKxjS01!_C0H6RMfptV2>|M?5T@6&d9L-$x z=soRh2@64iDf0n;7ybY7-+2dqW$8I=5~7CvrnnZ++>&Pkvar)2J0Ib%Ev-@RA`rYz z1|0zhZI=7XcVyI3WsVu4`zbIDph0Zj9-KCBOX37nmTYlGHNZyKz<;OH~>&>~F58*nR<$40y zUA#vHW~*pzNuz#H6WoP!`dqo;dR=|{2+fT_SK6B260Afzt}2TXcB>xRbq{U9k8=nV`nuNVZ=%WA7oO{2wiY2I4vGX1OoE2TG)Vbp5?(na4i14M;~gY@>zU9= zG$SVK2~&-XsE2^n!a^%yVbrnEYnf>c%{0d+8xm5BD%Ad7O^9g5gw^9ht8rnpxX>G& zX-$tc$F&WKYyv~8!Ln8X|9OMni2lzT6k5}thD4V~MdQ#$U;Wfd-)Yv@XMdC~mafM5 z@1Eb5;+EnFfQFxs#y1*u-YxGiZoeMbXW0AFamaG? zy5f}L7*xP5%GJxWD83d&q#ELx8^-U3Y8iQqwJeW@!jYoC&nC?JFl?-lpa2IxA?v#v z;BJiE7Gk>Ri7HIkEf-Li!&@%e^GtsV{0+bFZxDdu{{dkwYK$b0f4`Cai%>9sA4_*JA0qZ~idv%hW!Vn{D*l)?t@bQ=B?F2+&84n@JE+W+*0a9BCEwM$U zINN;`xQMFQ!5|X;JwHAtH@A6XFUEmxi={2ySP)cya(D^b0wMXT&c8p(ZftH0; zu4}^T+c@$sl4rC1SJO(*;RGVMWUm%7(Z*ejE!Jy&$8Cw8-mukFEV-=ejdPv3iMzf9 zJ`hD8;`0)V?n~!#Sg7tTZU}_9Wb96+Bvv{P&nQ?&AgzmFzdE4C$?x|W&U5mL$I9CD z489(j+(gPlv!=z4MOdmk>nlcHR%bb03Z>UWQ!m5!Y#Lsqck()RqC6LXnmvHZ?_ey^6*zBC5&LX&jg?nd zui!IRY_34e8IGDghPsom;8EtULEAhUU z;l+52rbNKbl*{&r3pu{Ky-nv2_`ixZ*l%)uOE>`FLl*!*_!~rjW9`32S+%Z>!)813 z*N?yt0#yT$H)R3Rb$Me}ea@L8F#^ae+ZPcZBuZu!8xk3PDf{HEweKGYWCD_jjg*li z_PApw`;I4$oFZ^QJ}9!OfhNlL2dIY4Ekcj znPV`*NhP~Y?_Wv|=bl0|BA61?nEQuCr%BOsdJIwtri4g$KS2-1U>wjK=F@7Sw-zFE zSF7T1=rsa7Z+#iOIod8dO?JR?gR^LPKcKBB`ApmAadPH*L1q@P!8^2jjdt{pSgCqwIXzUV5@3wi z>6wU|;Yb8}PKLd--yiX}_1t03aYLTzPl*`5i#;W``E*{nSX?2TT2hci<%G%%6#}-m zAKgd^r+T(U3VIsVxL@6n;Q>2k{PF3!)$oA0%Q-QqDe*_^()-iI+BIfs*J5$Ai(oxE zQ4xMjz`Pg3v-S`NAtQXYY7Qpp6=KL(B8M5x^Qv7HiO-Tanf-&W4h<47woSK3iWsEN zzx@@|XPaBVh|kfqH*<@?5Pz{3Vaw8X=i6?kRHN)`O6b(u(|a8&CXC`|a)H|h7l%aI z$@$&hfi?FhL~x|I2}ei?I*zg8SyP%^Mb7tG(?jFe@KyZkjxWRL?$>l5yx;WK+K*=h zJVv*`UEX_|9hHb)HvK=hL0+#kc=I$5A9atj{+3|#X+AIK2y#sM#G9ASg@+%PAr~SW_o=pcp2k%-)3%ul znXbv+89C0++J7_T>_P41z4cD`?oRrD%Vaq2vNt4M&0T-C)iH5XI6{FqG~EXK21hfx zdpd=Ilm;99`S2LlGkr8D%BCEcOzv*%X*h_zuVG*+E4m$Ux;rprW`fhAQqdTsz9uKX z^lFC%30J`-Ig{$G+Pqn~OLlDOw?3-h01x+g=b3KH>eLrZiVeA{*Gw+$jY9j)?xY^A zA>b;qs@H_vSjh@TZMuPo9oXvg4(Z!2N8BjQu7|bQcIsf^P^ZNgbn?u22eY~&f((S+d6eQs<7xe9fx0%xpY{c)O zN8waxx&MkkhVI$k(+_OW>zXGFiZ@S8s_Re>v?#mxE1iCjD8yF(VEXL_vGl47MGJ*9 zWhK|fbm=+g<5FHQchBobqc(mcW13)51*|#RC}MapmJ_^4{_@8Sv~G;%q9$z_ZJJ`xVG9<4KNf*hr*bkB&M>5oB2l1xk$| z6C0dt+n5kFfHdgIXBitU|Fm6QpVZuIbB)x1*q~i`H;+SAq**QDBV=5bbn8&RVAhLU z2|05f2Iox&St;}aS6f#ww*rkl^rElCRJW^Gf66~_N5h>#|NZAZI*FnV)JsMF)VfGK zft*_1>E~{oYQNwwUaOeE$T`#@Y__pELU6beY6P(!G0{N?rWN9yU^KOPy4^$ff*TN*zO_pQP3K4{g#7u=~F z;Hz7ETLaLB@*ez%_4qV-cPW;V)(~}X(p|jp_!xx!F_Q>e-ThA&c70 zdt@GM7~e8auVyxyWw=?`VcAcYcf+oEyo7SNDxk#wzf?V(n!2Q20OF@oJ3k88=3?Cw~d!h|f znj+}}4%!*I;^7C->oIm04S0D|v+CpBmW$Exqa7HZ5hj-%Ye_7mJa`f80OjjVuu?y> zOC%>r>F|CsuTLg4M;70FfhM9tNp2cJXeUn~5UH`e2^CAf^Ko`clM93t%N1LbpNcB8 zzNv&*C;MKQ38UyXgd7ByUAiH1CSG~P7ZxS7Y8dbye^u4}1iPnkC`D`5C=1s0pMmL6zRu+^cxO2}>^9eJu9Ul?WZH-jL>&pL;>Xx#RX1)_c^i9D z8Wex5Sx&17R+i}4J{^X56|KD=PKQbZB`!2g;6S(5@EOCCQ`&zwJ}sl1#BNC1XC@s$ z=@?e8<<#Zo-YzdyVm6a{dGmLLp%;@aL}j%PA*H|1*H^Q-OeYT*Q6E!S=n%|zH>{UnFp_2Ak3L1abUCa%`6$NP2MG|Iv(#yt#oGXp@FXx zYUMjeDcP5-ZxJpgyy#o;bCfeBKF1vz#IhPhZWi9AaxM_|CEE0^uVusaY;>cC>suLf zNJbZDRavsDg_)JyYF@t;dM=ys+tAawq9dZ|Sp%77N%?VnXQww|S!+*~;icM(SmO7} zp-}XglwCHNOLkfk__ev>Ky9tYOQXGSuh3e1yY7GFQ(5bEZS}nlH2MUKs7-vKo>rnE z5XNj0Yy{tDl`y+{qX+W6W}e`pZZ=QN!lne$+!SXt_Z{9ZbyV{#6B}&&G~@Uk-x>2+ z5V}Nr%+^^V&amcEaQmF^np}XY-wToqZJ@uXWgUJ`oX}i$IC|I*C8KRmO!XmcXUld2 zNc^JZY3a?xJhiKO>lUQ!;^OHO`q?5e%@wRtv@n>Vx;niMuh#SgdH77`8?voAv?tvQ zZumPmE?WifGfabs}Ds z;(u8rZOnK%KgdpaJO@rA_3g|@AoIz3&z~(VZu26>7<#Nodq6Xll%=nbVL6U0R#wQS z`Msvv=2~Qv-Dmz{P)XX%CHaibxJ4i4VnW|TiN$bE*HdOr@P>6`KQv;RcR=bl;x~+6 zTg8X3{d{~oc%wN))5U_P|IBkT-pXAxkjjSpi`Is*`K+hs5&7;88RP!s1}S|X9@ZB*d}biW@6G-kc-RBsB)u>s-LIS3wV zEqSrxX6?}n`Q5)>l)yzKN!y_xORj z3{*)VAsE0u7x((~qYF5bQbvsu)8ASIW` zgt}sw35uge5La8r&Q#6c;HfCO`Q}(K<2y|V;<})R%a=ZQD%3HRw@tkBiDZE!NOr==}V6I2Axk@`upKClJQnZBeWiuC>K7~O3@C*E?7jl=Kjdwu5@EMJXuCY zt+dk&{<4ALtqEfUp$l5nGMy2CJH!k0wD&?7J5d^}38R0uYcVRWK`$pWuLk!T65cqe zGGlPOxGt(m%smg7UKhPA_Ucca3GVaVIV$!t;YUy&)VeSA#s921#$$6F#ufdthfs6$ zQ#+akS;OC}a3)AFEt(0ya=QQ(CL;}oVdf_IOAn6jP`58OavXKyyGC##^3A5A)Gnl% zt-=wp32ef+A?=WNhzBlcJlvJ414$$&N%L=Wg-AlMTFip1a766FE09iz z2gJi75wnPX!fi2@U{`+YQB1V>(U;~9tW}cZMrdP*rqj$9Y1DKka%^_L42;G{=deZK z!)ZG=ttdNSt^F=10%j@PjOBhCh_B^(Vo6b#gQO!Sz%J2~39CakAT^3d1S6&s1(`AL zu?SjpDCkN`Vg%u}+=GS=uU^amm|&5NNlarAA&BUOc|%@d=UGw161u&cDJ&&?z#}$D zhQ-IRiQt8GLp&kxuojAXmQh3=IlWv660z{6FbTE85OIiXLO3CvkPe83EhOX3ihEOB z-kqk#W8%zU5$Qz!>t?VNk1a<8&- zmzdy4a7!@l!(`U;{j`&98BGW#!Vtj^^M!v}U(>L~MUb7-(H4kvwY{p~@P>}djVdZT zI;-IFj)DjO#{#2I0-SX&h9e)eRXof_rsn_SaTWi1>CfpUD88`nIN0-Qk|0}tg?w$3 z@qvVBA_Nis@ORrQDkj$Pc86t6YMw(m7~-Ou)a6KBnpM;O%9;^!?R48^N1Nb5`}$Tv z9S%&-S|g5J_YN+&R7zJ{*NQFtO#OJ-zJYvtOFA~4zdAzOhQWa%rnPdkI$E=^u5-+= z-jGHj-jEH+coE!R(E~4XnoCZUdOK;W(cU%Rj(&OId{KyPlR9O&(eG2O$&QOM)guZ0 zN6`r8vW9hAKQWGEa8Y6?;bn#u$g2CGLpTLP4B_Vn+ahT^ZAJgv9Ad>%Br0W9a=ESi zaxRZeTtsxC)dIMacV@OSW;=zFmn2vo$w_U?lmJ%?v;)50`j z3u7^%zLPp$p;Hyrv8fAj6WqQVpMoq@7QNS8MTKM?f?N-3S1l{89Uvaz(r)o^H7meo z0tLTeN@B8EN<^Hb#Rk_d)M=k2>4$RsvCC#ksoEGMF1)*q{| zovAt$<-dEKP^Murr-*i~?idT_2GE=-6y95-g;a)%6zAJk;=6Z^*lWGU z>gbCRb;#p^PKf9aFVmZ?I<)N^43fgl(o=eP2ssDPbbQRWF?h^SJiTp}josFM`jrXz zJv;n(2|jqLqgeLiJInjw7W}xmz)#!T>$%bAP^j^8c{uZ@{naU1Cmx|{Y*=k+J6>TY z*5jqh=lk9%TVVFIeo#o+iRjPe_H*5mXKa;PmfUw!!*}=g7Cq%W|BU(@5lNfP<2&L> zB9GOE)zM45A*5F>s3oSE5Yp)*4rZSCh)8o(QgO(K7_J` z}O@pAMy;x zT47>AWfVaLivGrDAs;ifBm^1k+qNUDM;hEs4SeCDFA~8_LGu$ZmlLoq+N7i$+@_wb zBvwc&$4o_S_oaOy0M5!ft)HIAW{bHmBi#OOjlnp1pqp zkIH!PP3z~Uv-6}Dw6VA`_BI5<{8&EVG%c8PV{pDu_u@7xyigNmN>O!@nLHs3`Z-SG zw`S_^iRv_b{cFZjlX0LIFE9p=1R*!>+zja{%&nH-^b+E;Ya+*1F5JmS5>wH_c{^3S z=U_j8lOxV|Kyb!m`H>%byD?DjW;@B0#T#QFM`yqff=C%r z1y=Iqzo(+^emcy*Sm-|V&mUhl>$@r?4{_O@%qaHD!f_bR(BZn^dmKN#a6GXU0JKI@ zBe=}HAyLttmrmkD^u5iaFoKhFzZ5Qq*e$F>8C1c@%)m)#^X2!y^wcKY4dOUK0e~-k z0D$!WN-6)tUi+VkB@^R6-L)%SIhPGa#2$~*@4&kPj@uUv9EwHub6NQFzfxmN16X;3 zSv)EB`)`^n*QAWnIGO~bpG5jAJH5*j>)f;A0!U`AKW;t7cKGOcLo<#q(23_s#Rub;`bOAA2LdaVW0(q*b^` zf6{-?r5lrG89CE{$DRY_ppqZ?EIa?Imo2OKb9$&D zM*U-bB#T7)Kz1=NGuZ3XrT*t(Ua$#JMzH^L!)GC?(ObTS;X1n>p>oX+kW{mc|X-W+hUOj4nnsVal+KIzDVq_2eA zn_KEEVvU32B@aJxoQ0C%lEx~T^euJ#D2`|q;L!~7Y#mx%Ccx9AVTnEoMLqg;*M?O2 zxcihf~7El-g2bi?`JAnwII;lny`=HwBp(&5#f>~&Urp$4;>%`HOwZR5$ zv7+SgcHF6v^#sp(w&peBRTBcdF#(btr41@KD$25=M7P*Z^pj;*1;d<~XR$9?tEEht zM)$g3iel>5IMZ?l%6$IYwaqI9AOKYXP{Cvo0PDJH;?R3qSWf8zP2Ptb04#UKx#7B9 zd1(tfh}|aK*$os10MZ1M-vI}h#sd_FgY*mR1J99aHw8C4vVg`9^SeSI1l;UZO?rp# zcRlcS0M`~!53r|Ixs$j*N+AffxM!`D+5f@D2=E$)AQSE$`qn-UJu*55U26_!9Bf zBzs%ZFueDBSpDXveb`kgBsd_$5VC;m2C!Cb`f!3s>)N=_9syiqGpY77%uqA6##jfS z3JD{4(*RVC2p=%m%M(%rVk$I*E55Eo{jmlZF9s1jaRf?v>sj@*xu(7Y)c5c&!4Uv} z9@UWggB=goop)*g{eRxU0v8@(uLU7M1?NQoSbSGj*-8XcU7Gu@hnU`+In~*U*4UL1 z`}E!Q!ImgZN1vf0^B(^yD`oLAh{pS=be*Ttw?bE zfccBVxw&9iJJQw_Ne4=-KYn*59gMOYH`9L#I-^W1CpEEP*VaNjC`1-yqH6hieAKvLNno}o>gs@Kbpv7`zEE0^vJ83xlxFRRYtBAFvUD6PIXLyLZX=WfcAOZQ{YR3giI z8pE)c$m-L$C`ffM5PnMWWKScPgO1JNqMV>&IvZH^=ggf>g4V%OC;AAgX@~-J%sU#A z;9uSF`*CVbo>`L~uaWWzQ~g1rt46gW)2hLveajJ<89as^VIf2ERgF_)ksKLH^XQxm zTfk@QGbMi%;y5Z*F_LszXSO6dc%Jk71_@^tBr?u+P7lW-E6XuYZo~Fz9Ao<8IPQr1 zvI@mE$!}E0<3g&XYBAK1t(70|dj9b6&f+0mpP`=Sp>BEkOwGDU1wVg_p}m`DPYU7t zwST`)OH{Y{e3w^VSW|+Qn$%*%M{O*@r+cM>5Eqk@;|xlqDCJaBieqDI;+q8+Q3jj8|E;Fon)!qLMHBlNOCRoz{lm$Igwjr*GRY3IV3W;{1ld(ln+4Ryt_Ox1&= z>1k#uha@g`yQzD*XII$6v-OPRCR+A2E%T4jqk9di-cG+;V|EfMeyW9K^ncbjH#f_wRBLNplI&jwQrAc|*1tAflFiK9 zxZ2qRxIjMyAa;QmA&gp5a>BEgIkzzpH?NkxAz>Db`E<+7`PkDbLdv?0GiIv9ETWM+ z1Jvu6|Ah5YnE4M`g33dK1?D7U4`GY7E@2Y^EX$Vl**KEAdm7bp`U8;=8{Gl?xR970 zx2U6TB2JQE$Y_G9G`b$7a0Sr2+_%^*_|6p2J`iN^0f+-Yh{WwdWNROei<{qEo&aGs z1+{W^Lbv_+pdxG0%_^=3~v&HN6?5~!fEs5Ge0&WvDNGKwWi71wHe{|GThshAqH{JOCw zWlafR#3TUU{yPT<8)Q8QyV(UHh8oar0@D8z9?&=fB-q*x7)QqdtRGYm>VT_z`vP<$ z>ZF}EBXOgFBohTgT^8`B*;i_cax8&ve~bg~{ZaLV-_Bl6U3B9E{E`6xp290_N9F4! zT8rsXfEneH0JiwC1A~)Eo78_St`jEGWr$Rb2A-lxopZQ=19~%84-mYDeeue&7|RR%*f^W%do7c)SK^yL~9*23a~lhNTHDAnwx47CZRC z0l$}(YPyBbf%kNHA*BJuwm;QX@$&yDxd8%>;RzGADtQm&_rmAWO|XUeVp8!fFT|ar z(SRJ)6DvI{(?dFb$RNpxms<`x1y)Hviti&hN!iMlnP2z3yK(lAKbEZEnUts7mX^7} zUWzMm(PO+51BP{dtfYH7d&5~J07-)as#~k)_xR}W0HHGgA*3GQCju{@a}0S>6Oy3& zbR=-SP3ls?xjL1Z3JWfz-8KMG7eAnw(g0zix{M^NIj*>ZSvFn-nygC!9N=0E5PVL} z6%VZRMFpK;!xiyqBUhm&uoVX=in4}5?+{%yCzec%c2_Fm2=+MH3n?2Po#uS#A?D%VYA-7gb)bli-p?`H?0J0N zXJ;ILx$^&RApIWEP~C$908(H64cu}37r2vg*Z2bH?yl?h!U2C;WEjP_=1ifjtI$N*%^C=zUw^ru!r-0jK;rYy~Ql&kU z&Wqne*P-irmfeEAK1cO|fY!=2`SshB`!TDPdva}th#rUQM%h?K&*w#kg~P*0wO=+0 z^7IV9ul?(9d;#wsU34rT6^l){s&|VYkxeHO)>DO@`w()QXqPYH*RN$esOvd)P0g1c zd5?A5=}R4^R@pTMt7^L|W)s?Fn|>yL8f@qnuKu9Xz7qZZ9{u9+m*JQus9UQn-%;o4 z(rNE<=%#7x)}(*!+n(}o&9+&&*+snCy|Y-xScMT-|N3k+(rVbIotd~f&Mutl>@{1i zGcbw=Do~&<#^IPxm{F=Ma5?`qk)ZKwX)hh}t#YFm$y<|iIP2m7OjBf}y#d92! zsz$NXR6c0o7vtA3WVtuu+R$7?0;RJ531OwJnqd%v(mJ*S$FjlET$pv1AW^@>K#Gz9 zU#1W*%;W_ow8GMB4h4{?R9QzKQ6d=O3gzo5lw}XEph%L6_nGo4BKZ%(AO|5bPUx*< z%CtfCifG_~G!qU=wr1HDOBeCqR0VX|7rnk|Bewh=-~u?k zaVM){PjnrK4FPJHyZFdbj9^3f*sw5HRxe%Q1sKaj6~IdOm=j4sVQ%FS>59!GC>sG)AWAy;(E=pWVMjxv{JX$^oSVCnjvxFeZ#@J}aYM?G z2tq|gZdxh!6(~O$U(lhLDDinKdq;_wph;J_HEYMU6u+<2e;dOS98OL9CT119ehML} z|J0>r3A740Fycn9C0go#98*+Q`+49v3+~iz5h}Y2tUv_CNXSb($j{~t8GJOKUUe=R zR3Nr|@EXAwl6iJFDOi$OZa7r|V}>;+#SvJ{O$CDqGJqaWE~K_n5=fFPUN1q_zrRe3 z?UlXbY%-1tZDt5#Cua=Ce{nnrNEv~&NQJgsV|1Edxcpv}1O_~{!I6Y2U{(({ zvliiQJAAMo9~x8B&lo~dFu+M!#t+-q5a4*oK;oGC1* z*Onry@=!KxvPPxTm#KkV;0QETqmODOL#nQTgBbTxg>IzW_MiL{?)j_TLu+C`3HCB#d`V-w}i-Zv@- zSW+qSys|s85QQNXdh>!&oAx_a?odpEgA z2KMTMGX)PsKENM=g`BuzI9PX_0D-M9$=Kq#8!!Tz;COdMv$&P@bvDFArit57xjm}~ zTs07Z0g<|%Sc(^*JgFc;H5lcGK(yed{$fC245%J7gaAYIaaAt-fE2;3drV0lR^+AL zG`Cuq7eJE|s}K>FpB6uLWbAi0c5Lz|H!CbS?}aH18%uGUaon-eq= zbRnBQ6wvkV+>4Hg&}~J;E5%B=U!$04f@w^_H6E;pT5x$$0fobCG1?(Sq+ocEfeCw7 zq8Ky&GS6NNxrRs#K&~#-NsSSDCePG?OzJi4lwUgF5Gj$4)0+TgvJM7bmoRcku;Gn# z7^ntAHpUz-H3K+B1Zg3D{y@=7Yyb;hRm^}k?#SfBL=TP_l+%O7WJVBWRvt(&L!>;( zq`&5#_Fh4+NN!T7uFm#poAm18ot-SCZfxf5v)A%oTms{0xZ-3>Tb?3&X)5+p(y*Gy z_0%op)>V}CPgW~E4ESby4Nwd*g3S5>rZX=kCR!wULkKKXD5zsCou>cAQqLk9a@blP@BaGaRz+Fx$f-`JD z3uRNN-Vrm_o84N37be1Io-?srUk=1LW9etNH|PYF1~1p~g_Uy@OGAi@ogpO^beMBH zG=;v^ZqQpZp*<9#%f6)#I$2VVYXmW_W-xC2NAlaj`&Rvk?e+^?A5o|6G`kf?9gh08 z-K5#J{X%Y^tpuD`DK{=)Fj@?ZcTKl%gU!D-6^DfZ}r+Y0?(NZgVu)m z<*M6qo10eS%DTqfL%g2LKnH|8G3{&OjsM%9pFF0QXgX-io75H_(SE;QYR5e@mJT3- z3{8U*f0gt7MF?Tidg#|R;0!C)_FoE13cP{^#;Zn;fO#q`0<;2tDg@EJq7EY>P?4Xs z@zy$ulw;<@WajwO1;x6NpqS8RM1PEozcC9iGnk4MP)$uqDZ$O>j98eie{ucJYn5gA z*S!PFV)3a@e^bZXzcTRuQ*L4ZXM$LrI3WKYZ=7_C9PvoC4Ta1t=z%Z5>l*S3N^Y}j zUy4Rbw6%>9BHCsRhZa3;=6&z#*TNs>?=Yq#P7KOww<2(~7m1OuYTPocmQ}ZFKJd zzC?J<_#;8%n+%03a=5YX13+QyTAY> zu*25*Igi{YGCN$bi@?WVz07K%{iXKyln$y4`G{@Z*MomloZihpA?7Fyq3z^I;fd#8 zrq%C|DB?JOMJgz|f3s_B|J=1L?f(?1x@DSQB?%&OWON9_^%ov-=TPln(xd{5508E~ z#iA@hA)^Mu3}+P)T8_*+dsuLC^L1&xjI=~o!1Nlqu^ELvus8oSV7+=dj=yK2QD*OD z^SiAzYNKyxIv+zQ!>HxR#Fw73mjn~Lt1z0%39rkc=yJ75u4Lp?@Hio=l`EZU-wSS_ zX>!z+C8yxM88cj@V2XZdHM;ArA)}#pfbf3m3l4wlZo1K_&u)2m3-!1q6N~aY)j(Yu z4xQ?%k3{d;wx?-pAV1y~=4k3|;)&1*`L6VX%=WZ>J3JH+k)iqck*xPvYVnB%`-n6a zCzKOI5c~<85ROfVVEu`i0_eZB`ov_Ft8REvuh}IKkz%Rc%5!qSaRTsEfR~^BU3CCi zxvw}%0i;<4YFGmu&_diy7QzZZgaaZBKn(yaNDv0VlllU*0G85hg4m$_Rso=x3&?^z zlmSFFfX8_7If3`Si##ItT-_i8dW(DY1%vN`%GV~J**Z72%TJpf;C}N8AV$alI0gV{ zA1I+4v|!1(2QdnZNyU_VSli9UlhLaQXu6TUHnZQv%=MI(t2rB}_2{`i5SL6XlUL`9 zeBJr>4%RD@GC2cvIDNqLO* zp?K%hu*T*}7v)ChdEXD**}3W&bp!urztl(`Z}nYdkeZ1_U0_94TJT)uX!dOg7T%tVDQAP z72CCCR7giTHt#quQ($MHlvmd$vUqpLv8tf$q=sf>ZErR;j5vT`Ii#R_#u>9E7gUn0 zHpI=vftbRe%Ve^PjTolj5cFUe@v>%Z6#G&%FBb=|Qd8^R90D3^JRIL$60R|5fevhd z1TQq47O}t-U>;fmz9Xrmg8WPgfw6fI_J{98I|5?NdUdic`-0IumaWJ$ zLk|zA`cv*}((|`EuFWP>2o6#GX1>gT^JfM6e7W_i1YkWIy(7y?%AyR&PcsQch;wzR zWiU?KdCWzKlLco1Ge*s?Iq)>01r#KI^pYbjjdx*M7Hv~DuOn|P8dPD6x|BiW?|H-^Zf14f_|C&QAL;mBh{d9LP7<=vk zgR%&Y`HnY~jY$#QjS|iq_rH~{n4958ik*wi{cMmmBFWyaH`^3Go*&)yWNV=?noTp0 zXK-zVG3i|<(=wmFHp{Gx zTmA}8j|Lk#svgc}GkP-U9nzmj^b}f8#YMd%tJpLO{ha6E;9zMSkX*V(*!~3*wW-sc z^5UPl3rAy{yV>{s<&rsN@O;-wo>MT`NYDZC^7@`!;lejhSnWA^YicxDc>I`4iJf8;nt9Ae-ZaJv4WF(7V7$PE~6>$7LJ%Pz@U32 zi7i1EKUQR^H`dt9^LD&bJGbUNJlNSzBq3dFXXdbqO!#xbWM z`Z-8|vjGGemm?>1vAFXUDlcUGH@>i5Qk0y6CjjJwiM;p^>d zKlIQ{=p@F>nCOOk!&+F`zEu?wDW?JP$7l1Fuxlk2dAbh1s@bt%QTj;-3HEG(xK_4M z%--XmyxA0Vb_RVVQtu3CwDQOLg^=R>Jttc;CmRwC!uBf;s2BqZV4Z7;{KUjO|%$ zG4a3|1_2TJyaEK5A@=s+0ZT_Bc$sBZEI<29dKDp(AOqsAxr2$NX69q7?FA_9cmD@t z?-*R!yS+>bbWOu|lWd`?)Euy~F)_fXG5k(@6bN$X;OzI_QhZq4 zpwG5_5+zE+Q><7Y7(%0zv01n{ z^JkuLHjhER>y*F$N5AIMZ-1-;^lPa970ku*Z@-rPucmkCRnDp3wf)J|FmR{~JK6t* za}mHdR71i+?oxa_rCgNA+AD>^7P)g7)>+dhK5j~Ma&vX+nH63&eWN>02%%8267@(d zjbu&mEPOgRWdm+kkdSRY|aKQ5S2952&-uo;Kwl(=@f#o+^duH$|qiPmIy z&-CSvpc0R4L(M?ULY+DzR2^gTJRPrk`s7_9lOG?SAw%=YcL}DER+MLVmsy-T1YSRz zsXv4APOE!<-WbhnPv4xK1SB(vyL_*)>Pe-TFNpHe#SzAToxb-HFDS(TAP|cyv!LLJ z;>9dB1s4u9Kk)v+0ka6?K`KH40Op`A@YEa<=811*kZQmZmq3a^1UWZ|%h;GzvWTz% z!hHZ_SP*}OaKzyG#`~v9Np=w|=ypr2QDouoM%BGaz-BlAp3=Y0iYd5P1!2z}KqLnc z><ze?Lzy%8Qr+YNf`O1sR4=Os$a~%83gt$}q@VSb z9QqAaAr5_s8d4DJ%THuYCKy!yD6^y7;W&Q;Jpg@ZOh9NafC(I=F6uHv!+%O28n40t+6?+V)A_2J$zL!-P(Rl6TY33d>>~3x zKmlSKS>@y~hU2f8UIH^zN0R}iKZZXvJi<%JhY;Zef^_S_zC3~{&pU1p0H#u1lsmj5 zCy1(H(~3ZNcLSur+>C@Zyo-BjvXofx4$OEB>&~k*tzP-jp zh6%9m1^9!3#Ov&U>;MS-!4*8R%nNa-}3$8+k64ED2H7enwt*U3=z1G+G^ z%@TUds=};-m?bRU)$`fh$y61oSyLiZ>YS3YJ?|6feEzdH9p!x&DhebtjR^g>bnD+x zuYc05e`9etf)ax3*5hRa{x=whPkpon2RRx%=Ix4BWSz{G1z)W`JdKoy@%*pRwwLD1 zfwj^>p`EtH&+$RHj|h&v#FUKq%E33s4+q`{@eVnY)T82qh^HK@tMmKAsH7QQd8<3p zZj2NHY+6Oit&WAO+o5i+y+wJwXawwLx*P6 z+5Nuw4X&mG^5@E4b=43_AIk=NTLmYYY(n&a-nN^D>F~py>{N=36QetsWJww#0hx{G zBk=M~t}so2TaF28$0oZwH#>L9Z_pPYMCS7)yoMJPupZeepxg);L8TbE0uuswhsSM) zjTQ|WI4F^ z16>gHvf(BXHrP-I5|0e;AFK}`3kDDo52C|xv6 zQCd)c9csW0rE|b`{neJ#EX*B#4W%O7X z<1qN`tvW#1)v+?_d_e#z=0fov84@+~&&3Qtk`EeS(+ilVgpB8h0Z4@c;*Ckv5-0D< zc7M5=`*)BC@yz`lAACxlv5=o^uXNL6BU!inbh~yIu>Wgl`+(S0;yUmhG@o{G27sk; zTSlBsPV72VyNmpHL)dTxMHujm1JYZ91z;Zn)KP=f>0p7Z_T(cklS3EV0(Nx4^>HIW zXK(j}tohbY*Bs>4k1U|?kt0u0gj6fuk>yg)9Y$%~ub<#b|K|~7zhHl z1EvrEd!oyK;w``b8xePqEpL~_gf)DX^oUP_*a-p3?$?l_YO^B6=N#6|BLSX0NQ-66 zBmH_|rmvM{y)?LyesuT^B|K^6d1z+lYCk*MCd&Ih$6iPpL#u|bUOc$iMEnnPOV5@M zj>NL$Xt0TtE;FhYlBl{_soi$AH?arFQrKXms$r3)0ZEIhqUsgCL=mkbSw919|6+#N zSd?gmNRM*`S+{)Z;0;Am@2)&BH*j0S(=n?bs%62{DC`XT;q&ktmk|>#GcnGjg8@3p z?*-AUSaXld1F}SpHB2h~Bh-)|2e5>wv#9un8vtFYm zMSKmf!_J~Ie(iX2lNCDBb@%x$2a$zn2E!#+r)LkHN#Ne)dYyJUqv#GxV(Mi*vdCFy z&d$ArF%)9c) zdcGsez;P}XI*LH%cI1;jGh4`fRzH}N=472sblye1ie0GZQ%@~nfEd&oC%E0Gg9+k; z16+^+i+uov5yE~?GRKGUKo9`;wG35FVXYpZ7mUz9iw5A&Nemc-ku5LAtRKN8$>AG8 z`BPz2;yAp*g)((1G~^I@2rg@u4XtT6B`YOS`h~1r2z`p)8>(O6O4`lu7`9XEP@jvv z4d$;z0LT^w*u#okAAscJyFoYYhkDX_LIW=J0Zscz1`pU4wy3ax9pzaxxd)Tsm5nR} z!L$&7v&KDaNd)4NjoGnZt(@QgxF?vhbvU{PhGlVw|7Q08Mur{aNCAWIH~;^=C!mLn z=%ycQlH~>>!_4QMLj4UZhXNDqlRn?ZUDLofP)U%-7ErQA^AG8_wQe6zTvaA}&=}0e zP~oQVt;E$;kCN$8&nAXOf<`kVxJ^7XlcUL&kw~fv2htd~d?~~kNRIgqTyr?DiAWXIo@~QRWUuWuQGpEM5rNz2^rkxURtzQa^ z*%+e&?X|20(*4kverDR}@+OelY+1VYdm85U(ijyJmtDP7*C>JtV{?yQwe-Ooya&ozBsxt*&g2>Z_^`X z7PITby3c(eyM*F;Sp$E0ZGn<=p|s&VrpDv!9336iuvRatK}@;6?kUnFO}wW?W3bO$ z_%<-a<5)OjGvD%v68O7?Qzj@;YT?J&bi;Cs*8B=wCSH0vU(1ndRA1mV!G7^N_gurI zz%m$(T3TM6D+pk>+Ne`;E3uIO9vRIvR5u@Kh;P`@o$D!<^{f3ajzJCkCX0*H5?jCa zLny}`d4c;SgK=p_T)+Ku#GPzkN5lU8+qc?mU2%YknW+Az;A zFoNroJBMm1L@zQ`AZ~kD!$1qV4+4xOs`h&?0>l^W7pWBB^z$w98+Azv$BAY0RjUDp z0{Jl@3YBtfrEPIc0O1G!Nx0_TSU7-$iyc|>`L`A5+ix632w+95Cq(k3BZM6qr7Ns3 zkm;QGZB~CHa1FM+SrRWY$0YdB6aY+JK-f5(5EC!-^F+pIn2+(^09yDl-Y8jHP^Xmr zhbS`OVcEvHA_0^TPzVRY)B)}9A64R@Un1n3OM({%5+yt2f zjnjxntK7`B9wr~9dE+5>a4oo(?(v%i9bj`mv$sZpQy2sb;Jzd)UASvejs$>&Aks$$ z+=So(%1fYSldZUA+A-LPsZQCI4&MGK5%|BBUOMjXPC$F3HArh$shc4HHbMZsI%Tv> z-wiX}z6pl7aVE91ZU&ovV<6~> zf^wv2C?m{xeFRrjLs!~vT7;9|Oo9@N#2Ex{`!nAFMuiNpZ`2Ba-%cKZ>g53gbg=+> zc|?Fe!Lxj+;R5*O%!FIZE=U(zHdLE26 z#aU++teFkPO*;+kC!ymjGvllS*>A(_y#4V2)a4BR+zy2PO6OS$Tyvr8ACrN|fu-Oi zPR`9j3YEx(#{og{a*%+x%%Az?%Qui&JFFdB1D)A_o<84pcjf;_kJ%}e`^gOC z6u8FyH;?&msKh_ifkJWQ?oygBp&?=pxKO*q6rHT*)^Vs(#g?b4ex^i=VjOyDX)nb*a zHsc-Iu1K1aF)C0gwC^}p=@+IGWjx+0MOXRp)V2FhEyen_V#64lQMTRB=rxUQde7Kx zmxXQqavag@6S(c(_C1zP&^w~`OV@bgs1Z$!9FmFY_Inv|^%fqHouq!?PchcK{Yh3% z{IJ7wnj^D1Qa5pr`QmNzjZ$F%!s0$s6 z!~qO;wYPO%K3m**I;BRf_lG5l2>u4n7N|(Ng11M%6DH5MmEQDNWP$5QBgDYEK0JJf z!oxJqpY>M<7UyT_o{Ew)Hkhf(-=lgd(d%E1UnDGa zy)875RQ2dBJv;rpSnD8lFMym5 zb{!?k-yR?uX3;=i(+0hH?73RU7q>gi6?Vgj$*<%!Ih^pwq=F{L0^^pZ9VH z+q4^A-~NjC9-@_}F76C92TY)&1QK@e*+BnYh0L}4L&lyyJm?}#ZVl@{@`zPcF9v!8 zKf6K_;J)!mIlU6>E>6zCq6>usy8b|KBmEK4$sF@By0WUjPBSvd5sZs|Zh!-BVD=3}r&7-1f`i*Hz+9~L z6ya8)&~&zOAuccd=PhY)0&uqP<O$AJKcq2_?wxEd*CUXoO*(@E|(@DZ)B{4R}*2up-NQ9A- z70}g+WOs?u^-fQc?q-2DwO)#v!%vYKZwU2|&$+B|e!)s6!sVyE z&Of7tkziLR7fH;paMQh*Bnap&BW~WD>!chd)p`0r6Qlfz{%Gzx{0-bDfaN7!;(u#O zF~A7*1r+uMx%#(gMH`rNnxp(W&o^bn5kmcdz#^Y0&>!3FKc{$2$&58pcmcK1`Ad5KJ9dfX_g!wQH@3* z(Ws*erY?Kv#?T6x<2hpb6Cak3x2-E~BU$8i;!HAX0R}$=^9|n&wL}G_YJb2QUR^zE zQ`l}wlm16(Uz0T%JdObqc|MUz;~R%+95U0sMS54isJ`a6u|k#~BKaZ65gjDgFmd1f zRf855f_M-ikggyvx}jQNAyQk72F$mJA+JZB`$+KFo2#3%DcVbsps;j?vR8KR&%l;6 zHJ{6a+?FM1d>@P!_KbGK4HPhw>=o^v@7?Yz$P2_k_ze>S83I89N-#*~p3U)|;M>Z zfc%YrXxKsn|L`|ZcO-DvfR+1bq|*YqX@bmPa@KF7#ARzQPa#F@4kt}?on%CevB^}D z0O)fsyKUjx8UnY6zeroubE6xiXT4eu8tf_YSsPwomuXRpTID_QDnB_AkGCXhx+*8^ zetSIN)<)_2N!o~2s&=54JKC*3T|D*Fj?-_WTW&UK|8={}vQ@i(ZCHP{`RPl=zJU}( z^w?Qy-g7v*PR1{0V$M5DYCMiB_us@?mO zOiGXipQ}D<_K#ZvbRVbzbT6(5U<*}g$3}=bN#9>NfLzsM-ih7oCwjv{9`zwB|Cn~X zDl;UkTRn_S9qWonzK^ly@1a@;6Q<0}4D~rUfvQ1KZT0lxPbdw%7FrZEK<^{b95Hkr z#-=d1sL8#MCxx2~9w}x6Eioz6a1_z~>g*H=__L$)#_IbI5V76{YS7dvnUfyr(sg7i zi0`1qMD=Lq7sl&}$lI{1~-nLv~sjzBb%Sz$K85bL$2Y^Dp|4eyWYCatb53b|1ws01))j+KT;dk z7sZWx7ToWI8>f?EPQTfVfM<`Fm4I$3`iY%dG;j!cOpX#*CzV6RJg$EePK=CY1pm3d z1K;}?!Z6?Nu35xVuTO6;JdM?HUaI=QWl$b=8c_fjOPSbv!X-u&{T-f*8+=bUP;f)~ zoQXu*LmU)Nq@23Vf#8QZAWEW~n%fzpP|P5iLMjxI_A^an0sV}B{v}<;$Fo(=)PQ5oXh@~De-Rs%M%Lb-KiT( zcgfSJ@aXFM_D-W%W}GrZl0MseTe?t!EI~p!qY(U$cu4(f&@KfnNf1n4@FMvfBhdFp zSVBV{fxUYftGhC(&VD-@`P88-d~^|wQIpS9$g%B`WXxfo)eBd80w&6?_0?yA{c@VNn=e}X&fd#4{sVi zE>mn^dNTrUCK!;vX zCtf-qJeH*Q_hQIC0p_z;23FtqpmK65Yf9V%z@2PZ`P9aaAMl22!-1+AIgOS%SpTHvqQil1 z7Ad7-I&*{1!tD;OuV;)`H5Li3dwI{HY~IAviZ_F+&N_FUCO6h16UkXFBD6PS6}A&i zXpHO4OGST;lmIf$m)o4@a?zq=eoBry) zAX<@5FJe@^(#d7ESgn1yttFaJY?@MEJ^sE6EwO2NQBc#-!i2D)@9`UW592ViXz9Eb z&9-ne2_yBBo;ZpVIL%Z^Q;{P?_4*n{pKxsXG1&gZ__dbm*2IUmLm2C>=W@s+qW``!6io7zxy#eD?iw9^j37cUfv%j75T3|wFaGt=XtLCX)V}CK!w*0V?wSke*9~Q~ai;23 zdW?!M?XFXfC! zZi0475RvyYj)IDuKu}!PvAV(-4st6K71l&sf~!TDnoUK-ZUO=+RyYp3cmu``ME>7? zAq5?HSPFu3aYyI;eEhuLab<82?>dkjop(1*)Ki?1mE+DW>NR#Na})q~IVyBF1c~50@0LM6bgg zCY|(D+io&2V=ALH*(MXIjxA@+6DQ`_?(@dUt*70ye!r9a2)Fl__X!KAao&8%p8om= zNJ1Bmc;hE4n(G;b`!~id9=NK|i!x0UD=P6+Vpq+AB#uDWiB^f!TpOx)%P=*GBPsp( zAb5u17H5sm_f|(vn7=B^uDkUQDhkpSG*kyGEDWN$1a*3BLg=(Sml;U#hWrTua=3Fk z3xUAe^9)UO3VMpv@`>}U_PXuMUnaJXrs!w}ulbC`%w`s7(ZcxD!GM)DCro3+Bd1Iz&&)#3KI+$Ka<6Yu{?{UP*dCcqTl1QoC=H zy}xU&GX-F>3ipP?n_AuWr|}7Oi1!w}aX(KL=>7$OND&edor-{y`Gory5k|N8`ZZI! z*To=**CgO9){YW_I7bgdH&{g*$m(bz)#5gx=)n;|Y@GC_Kopgz=W0Y9R*)c(VV?-8 z_jmOxVjw8gU;#!X;Yf+kHJng*tp`#>{GxYK!0J)*nJ|UeadO{J$=URvK(Q>X?#Nvv z?lF`!>H|wW#%Q8iGgRiYi=!sja87$#W$=zOyDXp??SCa6## zO4Twcay^I=XyBl$hB28ftPRW5#G=2NBn<^&HJHn~%tnuh+i#~nApaZ4t@zJ|G1dO! z+&@QvAOdmo|DRlye>?eeHCa2H@5tS1<9_Ndvs%k_#1>hD`Q9pff=J{aAj1T%o9D6g z>)&p#c<7oCSPA2af)x;HJ*=;?Ztk9Ae6})_O>W`5nJ^%%N)S>3G?fTPfgf!jp3fQN z#6K1rnxF$WMf7tX`@-(76vib5Li*d{kzpbGBC$59kA=_`#^N=hBuPciXtBrcx!e>t z$MD>j&9m*lkb{~rnUZQSCf(Rxes{YayqH+?;Nd{5sK(IrK8M5UA}2B;Y@w9ha}EBk zOZiD1oeW=(cvoU;+J!Vd6j`8z2J`20 zVx~lvcG4Z>m>!{Fku2PoYHEqMh4mlXVz3~2vGzHlJPKc40s%7J88=4z+856z-?ays zf{iSK5Dht>{BA|^&`1l_p{80=Un zzhd3BZ|AwLU_IyG&17hL-uT@`8;%QFIXTOSk#r3excZQvWP~vW0(BT@pO>JSA`84(x9cFA{pB^?A&wVM`L=P|XuOV{l6jz`IiWI!W1IO^?neq zP<#Nybk~3VBLec5x0BUi;n;sfpyQ{3`4AOiL;_cBD@Yu|Dw;{>ox|T!o3GA`;42l3 zQ8PN*IVJrR5tRmPubQeZ30oUrjM)v_r#n1UDT!AY%a}YU8fC~l?yk$5yUI3l9M*zu z3>1YEx)`9@VPCW3(?ka$dYd&Pr^KAYTh zaszg)|5F69&a1~js6SvGcnBaiP#b{#Y-2|QHw#-cr~mWt|I94gP_>E6;za)RRr~_m zbJ|8HEC@L3vTu%Ow#QR!gfc!E8P!AKTG4sUyt(v zfWmS8P8TFi`HU-C*BvkwH^V(rcP(P53Ip1_cky{lXuf-2EbxR{iZP2q#O$+=bB8qd zdqz=QbB+$4EbIf#+nyN-S7b+i%VI3ks0iQI_9t10;U=Ws=WZLfzQfh?Dv8K6o$&cT z2JFX5PGB~P=~eu1qma74hvnA{N~_^U8{$lFj-i!COpSQ?ozD%%54Zj^bL`bB86W|ZZhya=IgOHEIxt+Bt0SPC9l+!oKmoX-P!TI zq=!AXu-X@V-)w#{L&V=kdb5YTvA^9}R;GI}nJ~)ubL|VU^qy4f6DG4n-U^OT=2k|q z0B45=X+Scr*yPhP5x&`0bP`aNWYniQ`jsgiM?MAeA$c!4b^h4W+F2~fNRuy2+{Nj2sW!=K!m%9Ea}sc4Q0yA(S$J)W9gj;V4wuwwFm1) ztd3R8E+LjeP)mKPJp$Zv|IRC#|Lypla~L2=46}ZI53R#o>eK^z(P*kaH9=S31J?4W ztaLZH(NO^YDps|(b6v8~zSc1@Bqmt1WSA22yA%U!e+m^Y`5;x(yxvmTQLC{3Tk%bW z-imO@97iyXpaqVO_gU!-;d?ILF0SLZPl-clwCrJvfG%$FRZmmjqk0kSYm4N~Nxq*AHf9%P|#Mr`s(Za^S%!HG{-qtKaK~4ez7U!S;AV^7y zDgpqYzQE@(XkZiv5j#v51HOPbDM|6SA87Zy8&?527s}b)NlgE z^}&B`kQ7?PeuyAp$9qnU{;a5eC@E*6^R2g?y9$WtGdvDizP4kR6x2x8w zDmCYNnoj+#$YeXx`wAON_ez`IXm|fRU98kvo89AaGx&rl=j}#t|NLMVyT$1SuQ(dy zi*y>YZx3)|u! zOknHdv9H?-=~CD0df*}NDp2?BWy__=tu~HdI*kYOC$XI#r^E4{l$z(=UU?Q~{8oqi z(ejW|>vUe5%kII2bm^5gKiFw?RB1tPD?{%4C+`N>sZ<*%Y#ff$+xVY#HGVu6Q+Utu z;-prFoY&8JsqQt;hiUwv`%qo2?!*yiK9H5&{i!H3TU}nCxA_dMH2L-)M~Q@2+8@vN zP@d$q{B2I?{KBt0)2)(MIzbiuZBO(SG>dmz&3V3UvGZOl1=I0g5U0SmuJ5mOI+r@! zKA0aOW(D!_?YDn+C-S=e-Zn;_Y&Y9nU*_xSgP_*belK-d>fKd**1~YT&>6HsC0j5gxrfp>Oti?o=#4|mD=g?pV4GU1196-yT8yDkEc_B zs|uKWz)fS&>2kll?t9wa=y7W^TT$2!pcffI>T!A5d+GH5`+-~5^7M1c?`3yb!1o=o zf)BVZ-!|`~t;0q=!tJlaH?OUW8lF0C#-$aUP>+%Z_fWwiM|T<grS;dy-g8Ri!gr^#BX9>oG^mVnLA#?KXhxaiva@KmOcS8x)gui*5P350f zBtnsv&5+0^y*i1HvqXaOx|ZI?I?n{Sn?9@AmbP^`KMoUoI8adJHhbQQdHYnD(*U_o zb~^1o`y1;#9E4kJU1s?o)dkaqof0^=iJ0;@PaUoME_PabRx{OSWt??3_C{v=pHtn} zwAp;0morGV@9+CDdIa830(~cq&M(&&F;@?4wqsEmhL1A)H==9F!Cn;Un`qzTL>ncT zZDrVT6`4d5|B%A4^rpBgY_P;$%jnlbn8qPY7(TfrU)fcLO2o8#9Zp_2mBv=tz3g45 zDrv2)mq0y5J3X$^SCc4B?NwTIMGuZkI+4dLIVo3$oZYHu4f6UOl4(S`F^78 zykAc*vD75CA0(k&UE-Xt@~nE=-({}Q8Q+T1&u3{=?ZMFa0yVAIJ zwNUl)Uqt|(3ytjTa4l;(+&}m8{N8QvH9C}M+}U;V^ARK3%$ScdjGg6Kyoxe;=Vd~* zHx%gaXur>-!0Sq8!BO!daF`|@DNiEXxkAMZ@EO6(a3*L!Ziu=srn|lU<@d2uGI~B= z>RX1*(2+A}Z~MM-kYV;n*DDj!)(!|;Ob)}oV^V4vBVDi_9pt-HS1Qm6Z-UOl!{L6} zI-1DyI|3@bQ*Bv-u5iEqZOk&AF8C_b{-kEyFIN^vhi8!^NgnFNukeY4q^JT6Y_*uv- zvbz@L=<9A+#2iy4rf71e~em4p-4_fzYZ$Xx( z_4KfG`BiiM!myIUnTt+`-2+1UXx=^X56j#+VjPar3Avb)F}T=Z!gIl6i=~Envt$nM z!i19#NvG-_6q&CA2Bfh;HQBvZFnfgEG97;3rvn+r1d9PHhBz*45FKzO#yv54;4`GIrzOYDp&3Q@LIWqow=tHh?2nKuO8&|dbF~VV zZ%Z>y$vSn_SN6Q_8lZwNuQvV;8w#`;7_-shZ$I~rm8j~nN}{h+i<%o|XBxpsc*x++ z&`+nv_SrR;WD(EA!(3J?;4M>K;`5Lj6pf+ue28`TQX536j9gPD$yvkC~Ia+$a|7a16vV56+}tV1%0 z7wn)*=FCnT#0`1WZ$GjZK{`#kNvg82HZb=ZJ+cYCmuTVWLAQzQA9y#ZVDKB5tkKu; z6gyQ;S|cx*S7_{Ac$Lg{+4;T`ToN`04=Ne=^pb40J6q(`I^`?{TGBF|fxAlXajY#G zl)5D4IW;cyjFs3n(TG%-H0G^9`fX3^Z!5}H5L^*bG8^C(V_GX8jW2qKF3- zU1J}if_b=pt&>DY!<{rjua`z&A)ny%ukua1&64<2(+|c>Fe&xSDM;>-v(CXPXr#x? z$ehHlJ`n3Z(5Wyw(P!4ZNNt*%lq=%Mvq8N*fWINUt$G1C%4lY4FjpT)Rw!Wxk^;HW z>-E01RE&ok{wXWRJzwM2d()THFQ!m?c{vYP&$dO^A$J-hq3u*KN?i*%A=0vrXBpq- zQqW9BKKSjq)fKs-2jLD^B2(k}(Hx!MJ4y8WFN9t2dh(uHF3eM+U>aw!7@|dw>_2vM zLAMO)aug0yx;Czq!~4ew-HKiqO`4v?>j<0o2dAr=qU z)*cmQfx4j@`>NFFW71M)^Gs zjRV<8Uc&^yF$$qXp=G(kkj`#YMUYQaVAnrO0S(dq^*vv@T02-tb9A3p*RTElVFj%l z--PkE{li9t*0!(X%SJ@D6dGEUW#p>di$54uM#V6yuA9v;kO^)OrO9SW-nh5d zJ3l{KLm9nae5qtZ=a0xczQt!$t4D~QSo@82ONx*+>P^nigrl@Yv zitKJSnHES!qQSE)CaF>|U{)kgyDbq7OD=1e1H~3HDhM_xFt8?*7oBw{3nS-R+QZD9 zgmxf%t2ANBi+M`edryAe5qJ-rf?pQIEogaYst@?i)^G%g_*Um8%V$By)MkRcaVHz9 zoTP;!dz2|#T!ii3^YUPp30|U+4_L335B4Y5I=%`9E+8p`HI}Yr{JJ2a6v*!rAv8T7 zLCDW(GsC~sh-hcq31th0$$X6$M53Lq%d^>Uif@*eqiK<%?P}J3Bh=hMMOb6OwjeEJ zWmY8ZCv!@c5gm624;!lV4xAi{pmYAz=xL$KJ(YoH^fA%QPLaJ%ipWX4odS-@-vUSIyA0+$+$n zQ~F!AR%I6`g=XO6aFS>gPI*;|!o~1@{=ngZ@I(lC*dgc+2AOBrXvDrN8{o~F%(cp& zPA=EWhf*nDw_ zED0yN3Tex2xcA8^TW}9zUkyJ8PL4be&Zso8+G#`l2l%(pmJv6L~kKV)JS2z z^ibtte>B0z3!_&}A)69hpE}&Douhs)p48v`!#OO(ruas7-v?I=G8B>xV{s{FEI!>i zcX}t>8e=;(bG3KpjMV~xlQo#qoaeF!$Eh|1cAvl|U4qg;y%N@kT{=hw&%@WUo&w!+ zkNGW+wo9S7zsfi`Cb|WsUX^+JhdAvK)!erq{5{F8ar!aeQ3zS`Qm7Z^)=Co=V;O;hj#|PT( z;3?UyW7)z)kGepHqF)jjuze}QgM;!k$o zK5=sHQBfZ3T7$U;gFj?><`6jSXr=MkzCQwEq;K~Uy@OL`-|6U;rb8Uaq3ageXrHD=6{YdoM>WgHkI^MtO{ z-KMNZys0-19lrpU(j-XEC#b>R$1z4h_CA+HO}Q}v{p7gOop@d4FD~Jknna+|WJZ3d zA%a_B9>+bbE|HZ9(U2KtK&M-}((*I^Ov6w=Tb@27=ZE_IaTNS+x_g2oM))^^nVm6s zf*@|pYvb?oHTisM@dRSQ63j=b;a){(!`|ZxqkAE!N@OfA7&Ve;cgi)R6buUre}VZp zi8ZUUG@P9*IdS@cPL>RHc`o2R7SuL@qBU?1=$v9DOG+| z(_dmVKLlex?Gz(BQ+ABhc5O}C-e~#}m=A-Ylsl8{q3B6BE3u5wZA7WfY7AwUK)2|W zW^rrlCzjxKX@6F;OS9D?5&Yuf)$L96;FTRzf-v9WT;z%y0FqNA^BXvsQ~Qjtcq5sM zo!ndek7=!ICXdR!3urJb`yFM~LHODqkaBlGA;NO0=Y>N4ltIv7o02MZl^HXVY-T~q zK9n$nwbA+UQ%a5_rZxsGMgycPT9eCe^e2CL(8QMRy$IO1VYz|nM6_3vY)I$#r?11# zBQWWSc_t?k&_>jo%#Icqpc0^0l?Sq^fi0G)B-v!H0%BVQ(;A;?Qi1Lf#;Be%Koa@- zTY?N)xH3rCQ4aBrhJptom@VavD7?IAgF8tW<(+z{j9I01%`m3<`wtbWm1pJ*UHT7@ zc>9oaGvZ@f1r^KsP@#2QOVXsSQDwq|c%cxM_tkTvo9oxDbA4&K@J#eF@-p~E_E1VR zckYPNq;>&brh(^Y=DStUMlBRX?iTPT^@z^e-q~7($j-v;z-x7wlu~$;=<-NP8m_MF z5lgWOal;CC*rsSw8Xf4Ff+-X{0!n=;&viNUx^E!TXp&_fk)jm0>flj~CX)qpsYLTq zBpD0~Tr^PU^ongNu&tW;z10@`b8$~u!DGXcwDr*5NKojurKxLW3Ma+q{wx_sBE>KB z8bZ9voRp%|*rkFYEL}yM5z+e*;D{=0Da8x!i)Nn`H@R_#=_4gr1oAArxz^rv1FY=p z@9r%x^}LN*1pF=W_KXx8YW|4?hgI##-+_vvLZZ@_WP+#KhoSTtSQtez;f)#ZNq7()Bq9rD}v@+9VNq}Im=ygN|9Z*OgA|Kv4fpJSTve(y;r&SGieH!0{%3b3(xuKDiY&kP z+gBReUV}NkM+=HKzP_yZbGoF++Bn&&?pPvhlY$180|qtK-%!u0#B^@Lp#((66! zNyHTc!N=z>tBON#?JgH7KR6`vw)Zf%CZd`jH5PV@dV_i)u!68Dq8UKKUDs1}&5CbV z6mv}mRN7~iJda?G1mV3xe!r1(yVvO=lG?QH$NA_BQrrfw+v8_WR$dP8tE=DLdbP=0 zru0*D75A);o4e0(J^dL!Psd%q1XMx%iG)xihFN~ob=h~fnrsh4$I%N~^ED8a=lL5g zwYVHFyA`Ar#;>zHfseD}t1pMAzXF$fZ-=FM)0bPX7eh$Eb;tT9z>V1I3Oh-E@m~P; zDsYpLEI-daa9e+OI$yj##L4G!zFdBabaGtku5?@ZT=nH-@$-58J(@aewbg!q;rIMP zWcxb(eDHgJ#(y6>2_hKpmNwHt=Wi*#5)_fTh{iM&qlq12$v4}*R)&-=i5a6y9S$5C zGMe)e`(-`s6vm@^RYCn{TjOhNH;4PyGsI4h&k5>u3{7k0<1DQ*3{s1qi}(EoSexr= zeN5uJSidFVC}HH=P2msJQUczo~v*ykgfNHZzz-AoS~C{Syj_R95qUvEb3S0tdq;#}2SWp7XKmX@g$`Q+8+ z)wy6I)fA5`F|yfUUvD1ut#XHb9xtykCD{FZ?N=Tcx1n%4BOkK5noS0v-q^dk%L^+x z>0K(^lmWj7BN>%%AYj?`@>~HqQ&|}0qHUN-OhY%xf`qHwb@hdxo13_?gd0z1@_y;A z01b0IIKZ$GK|~v+GTYEeZUin1lL%r+b^c@}^nzo5TQ(~_ltg^7qJvS#A1ph^IF>Wm zl+tLY7+WZwabQm0!`1xN=*FHbe^Ysvpynt_5NnEcI~8hTzSfr*X;t9Kf|9#n__QXkwV#KZSadf%ge%lRJiL zz7{a7TR6$$;YcArc`)T9YW*EPcch$UIPM72# zF3#UH>xE6TU+o+3yWzR11HnFPy{)ZwvC}SfS-5hMSq`2IVbq(tCp>CQibO}zL?l5Z z;-(5&Xi~&ptEETadIhduL^>ex1F|qEi~X|LYZ1F`YLmm7N}3}mJdDJ`X>-2!AKoE@ z%#x|u5;aGn=F0S3iAtUvGMi_j1N|3BOwQBO!tAzCO--6GAu7Np!rPkl;xltC+(Mf) zR}*H+>?{diprLWx@1>r?8aSfYA-D3>{)KaPzWU5MZ~KA8vwEjZZ1mDL*hJ9vRwy3b zpov2-Jh=f_sacw3wpJt?L>4X<(|8tvW(&rIQbYtr#?$znOBcITxl81F1ZDv0De~)O zaafUec-ywvtsAZCu!i2kuT`au!TuYjjxQ9s7zPVx=_NGoD%Ni@OD5-7=!G_Jp~f$A z$cyY!?1Z4g7oN|3=IQlSHRUrF)P;uTKleeA{G1yU zd03O6{u{h(n*)8CZI)FcJMjEd844ezzbpE^%vb0IDznrsrcMt@oDf*NaBk6SFE*#8 zHzX$1ELc)LV`k=r$t@`6n)m2~9!eWab+S|) z;7ptQ9G2nnL2WYK6X?^*GhkEm&Bj99ybL!NQ7{;WpMa~i3T+D4qlsM-JLqHUa9BDV z>T3O6@|av;#Tzf)x_DuY!@5?Hhh$+$K+_JxBDYrL+iAMXD)lJhCQTWZ_-!_Idyw~l zRqb=y*G`+T=E*0PYjWo+&$){Ao4`0}kxDIA==eZq(s)o-!U)8#6Qs^pMK-dRaOZu1gcTY{JN-fHs>_ua9uX z6xr1(U+3kcM+O7EdPQ!Xz>SFP2A&xbn6)%{W>@R=vpc>&xploo*l3Yb|LGDNs$(zDJeE<()ilN^KO0n@y)9r z6+iz>C_~5DwaiJudCyOe3$QM=GEsh(P%mkTw(@DabuAG@RZ=q zGhSJ4SDT)hu9xb+WU)prR>@F}&Y0{IY2)LZN}R)zHZCy9p#^QiT8J~sOUimCB+^Gpn&>n7poh{#n_E~6O+GN@M%LWIBdgKK;`utf zN49iq?JhsFZ{5YCJC~V_C8QZzb+v_S5vg?nTDKUB6bIQ!C#HZSEQElK_6`z zX|)K$s->SLhBk_CgU#&ytpl528m==M8i_I1e9t8;VX)O8C)-7!|X#kolOARr^CN$4L z_fqCAmVnwq2MCqlD6ku$waffwr`E0rWjtLI;4E<}9r_f;?-DR`(r zE+IVQol+QMPE`3+U+eN|6C*hyBgD7(sR_wWH8sed;3FpctMR__vganm2K?cbB?vTT zsBJTgxuzYOIINZ@+9_-`X3X#$n{9B<@N~;F8FS619J8UGCDvQH4y(9E<~N1-R8v@o zg>Sd;;5)*j(2Mw7k*&}yWwg0dWV%VLN1t=($31&-V=L}ai+NO<-P&;jRM-W3pCZ(9 zRHe$dPYEutivP}GsBO4LM_9>dD;1$)VS;%H?NJ-LAc7^A;vQkNF^o2)cx$l|6V8!Q z7B0otk~_sGXNvEN=O@HE`IWEznIlasUQHS68T9_WnIoXu&8+E%Z?86zrV8AUYZ#mE z_IQTDtq?cXf>jf!mI?mdDu3v;r`u(=i6__j+rgf<>Tg2Fr1DgzKrR!}OS5iO05_u> zH}(>qeYj^gZh#6mV4k&R_cq+4i!iL^$PufhQx%%5!oc(i)qb`@tC;Kfa|>Le5Ro=A z!bU_}$p{sXv(w>%DV#S&@>q7TSFAupvgXtPd)7Gr7==w8=S=bzlYOO}Nxtd9wxj?h zIq(njEFe|1XFX%CrA+m-v6eP8u%GX#INFsHkoac z=ysU{tKMUmHjMXcmHAd#Z_;UKs)fiC=wgvxMHzY&u9u_xNnPo87C-P-pjc z+@pgq3`pEstJtdYRnWf&cr8b7YWZdV){87rNq{%XM#VX(I2##jC1VsU%7P_$3E`|q ztc8q|iC7C2XJzB>HDa5+?_Sz^#?5WOesuv)rpa-FMN%9Q8~fz05E ze4Z!~$eyRC_Nn|Dp6F+AsN`z1`%3fURhVZpjrWRd6OFehT(!bA20E9k;xbJrK+_I? zuJA$ypD&xktyHX?N^p=#klKiN)tqQ05*=(9@0mX(2>k>Ko)xU-PH+@F8Jr%VLc`7s zv_ggRCI^f@=%G{-o|S}00}Terb2Z_CUcOU?S_U=pI>uDPnrnHiR=^v05-fA8$h3(x zdJ!*@bsXLz(zQG|m~?-TFFa~YlKvJRT6HFjtwd_2KmyJ+w5e4f>j+aV&*T%vm9)8( z@Tj6qt9iU!qE~6+a#hGzxI(M63{5-yxx(Q#dZ~??s}NwQDv;>{p2ZV6XyyScG;cb^o6HL2a)YF-AUP*k z0faLG)I^Pmlc-pcj^n8W9g5$}3d~~#=2n8{AI7f4$ChAYOGx*Xq+1E$Rz`Y2C5F&4O1jJvHM+)F6~XeEc2Fop^qU&WfrSo9XY$s$07D><@K(yjDj z)*Q*!r|EEXe@i6WWI6WJ;Yx=dw@6&PMqH5}2( z{dxErshXEs=_Sw!+o>=#^8kPoiB2?unC3&L`_j3=VqUPE6QbmXXxRalL@NumjpwLD z0o68@`*Vd8JRi$4jZHN^mhAaIGt6!|rmr~ev)tR-?`$N@IZS@Kp}HaPw(mzA-_$5{Gji`(6^fWq)-01^ryS}MvQ-(5&6B` zxqyB^eNyPm?TaUoUKmx^%*V}(r_hAY#Z%v%JO2H-P z$GbPbz53OuFHh{h^x3=LpF?v;x8Sjt;2|e(!q14FhNe|qil(0Q^tb&TAY<;J?INdc zUqw?lrw(t2{LYcihjR)iZ(i0nx*)Jmey4BoLDOyeq?5km=j1iOPv7wZ-vWyI{vOvf z%x@cDjv`Pm9Ygn^nK+cWc@dt8&;`AD5zYC4-u~mpm_LbY^5)~yA3)}#Q-?X0d5Gn= zaQ&w{u9>)ppx(Lm(}N%W`Ojbf_0NZb_Nx2?^w*#7KltGWY9(kc3xSICp1!XJWe|!e zk5vEa{`Ft)-}vQ+>%abRKJb?L)*zd8Qa ziR}ZYcCA0SzWeR=y8R6+x35Usloru6@8!ISeu)mtLJC_%ndf32b4{LejUI~#d?ATP zDty7z@#U{PHJBX!X63SjEvw#bt=v;rysN(WU{~#)=8BK@j~v^v?u(8Y9p9YT{pHcEpTEEP)AvU{JGAN3Bb&cCy6vkIJ3e`T$DxfqyQ)jKSFSj-b=~)u zK6!BayRSbuc>eSOcr0N5J+cbu`L6U96i!F_&Xqq;LH=Iu-@5eULyn>;NQC0IcWzw# z^3&6&j~w2=ebeTi);;Uiyt8%i-5o=Rwy%40uxq%fYJFq%P<{1KW6gTdrmA&Kl^a?c zxAr#g8R^--ssEiFL;E)NZ(7s1wsG|b2ljmY$;q!iJq08NAOTl2%k{&JUjbSK@Qq)7 z1c3iM_*|q#>R)CxO??;qg4V1UH4M z!bo21;f_^@x@$I<=Wke5czjFG`&;?|<~#bdA;_4!mvvmPoCc(?e{$&D$@jkf`0Xtv z`DeEE17IH=82a>`bsz8P9Z6nVKhC?=N9~{JGcdtxZLoc9fVIz8UF)kt+V8FOdaJ!Y zTA#n#7i{mJ;Jqfu(cq9fpP#h5IOg03gP$H8{N%miFOF_GwyAGp<*I-FeDmrjpI-m! z1K_c1I{n`_KK)5_27i0y>yO^ww`<2>_q#g=-rGL7cc^p!Q0Iw#BWqU|=FfX|X^?%9 zw-7tdmNMCqIMJFgUX2fuV*|vv05K*&jtf@eL)3)v*2GD+gvri`5c^y&%X1PF`qZTI z%((sA`rg_xxMzLO{*C>I-`u#dvwrtb=cx}4UOxZ%KYzUqV57<0M*@7XtM09;WnH1O z7U9Me7Ec2&90B8&pktP-Z>dVqr#cf&9!VyT4BVJz@=V7J>1Ja#Vay;5Iixv@z%npH z25!nGuyn$h3ilAEM6)~G4;aT{?(hWH)}$DdTRdru#@r!|XAIyE&o+*&S^DyOJ*$rm zwQVXdaFuGz<tTOCr9%-8aC8I6|` z*h<`7jGKyZV-aRtX7*fWHZC)H7GQ>alo|`rbfW<>%giWUjvH2xrV`3r#^KcxQ)3rv z{FSmG+lr}ypS;`q@p~J-_+abFH%H!G*ZsroJ6Aq^4-AQ`On)f{w)VfXt#9YrhQqu2 z*4GtBjQ2{OXpIY&LY>G>Ut%Q|spMP>Ia|bM3fN2@pUL5~cpUAM;)ppSIai=(bHoe= z?IL=OHoVT7;5N8ETf}CG<~gEiv5gG(@fLTfU4=3>SilL69Pv*!v5U&YX?7_x*RN*EZ05v4R-AxbE0B}J67 z#7c%(PUDcS--Vku4JUNS}X7c0$O_(jxa}{wm zOUz`6*(^DO!Dg}KJc*gZk&v0i;%~6f2uAOp$&qjH1lmU?5Hkd9wnWU8iTM`uQU@Is zEWhDYCUV4)y+hkN8&ABmbF?&nB?%_a6tgka=#gx6hcv_NS%7;sP*@pZI+7f{I?$)j zu6z(Re~Z7ZmhkM7_`x9Wn;ZI1wAHP9?WKBu=W2fFV~2T$85MiEKT`G;>S~M|BEp7e{w&Y8 z@Z6w9>J#`Lk?9rK9*J8ca_s`!j@I3?&7#nz$+e25RA7q)HUaaD!3+r;6GdVX6dp-q zF)Ws@()s>!@kDFpH1u}u?G}ilT(u?jf?PemW72bRD?Mq z1?Vnustc^*OaUIt&4Pad@J3C?4E&xen?n8gB|-9ZeW~@|Nvhd1!)#dhB zX#DLb#Zlb9^hlunp4FjE#by2Wiwyhum0R5*z*#qlVL3O5@IED}K5?&IhW@a?oI zYaLpzEOzlsH^=mG+**Mh5IE3vBEQYYxlR_>Tf||DG$0G>EYgrg+^8v#4k}_lTv6nH zMI3V42D}|@s%2nYU;#@N2uu<~=Ge5QBo-sGVKg2}<6*QZR`|m{zCX!KkpQyJ5D2uU zz(UVMYYOP7AjeXNJkP?+mbkd_fzbh8b0l_=O|6KC$$R6)#-zkByBg)~3{{l`f4{__ z!1T!z3ZHu__l2hyifm$VV0A=zM{z;kD=#h(>BhupFzibl@?yI**UHV+gg4+HQu#MT z>J5p0oj1=E&9eoxI^^%9fhC(LeD}n0y)xgz5{)!|V9v{p4BpHV{SNi5DZ$&v`R>il zXyeG!1)1-p#H^hd41d*SSB4a^*TS!nrFMyL6S+2t>yU&lMeb3>epMW_OLa0^uW)OF z9Yf=ttro7+!gtB+j%Oz~%QSp!6sf(lU#yXt?m%Z1OSEWmF-Nb`XB$AqET-@%j*a2j zD4Hm?SxYtL-J0t4;{*F0)-6H)y^1`bNPQyPC!hrZ>jWO{MwGZAkzX$fBNl0cDs8qZ zn{C$3Hf>l%`}5XYq(M>G;o}%mEnB_p>#WKKFMFS6+2H3K@^Nl@B4oA5Rj6XQm#xrh zDGl}kjA4)vEpcJopBFg%US`YWT!on<(+gE@fx^zW(4kIwu}zE(_FdwwEw)?csY1$> ziNmWa1<` zO`RALZV_iu=K7@QrFJR8TU}xk7uv+AK(9r1X^~A_U=wF4jBCT|EPdMX@1(+jrYpp^)uHq`t%G(IShyDP z6>w!YNc=`g7#6wp5%EvX&W?U ztG9ifX4&ND?6YZmrcF8(v8cu0S?$oa&3fg{sKq%JK1-9cZA#1|e?GKHRiPJY?0l7p z4zMkj6lg0-|I<%q}U&wv#+02O(awbg5nf64@q6HZt z6Oz0f*%KzEhm3Dch|3HKE`If;ap-)dpoG-1P}fNGBD_jNQ$T%9&LCo(2Wk#a0Tw#={g zah6)qzugz?-|b^x=VjgGV;_+DL4h3`F?KvD#E$=5TxprdH^)p*< zoY{W;qg{QfwB6US)uCZ5T zD=&3DHN83{puj3_316D?Z_5XMFY_$a5~r|8V-~Auvuc=~TcnUtzG}Ebo-dNg;{(g) zz82x{Od035YUYfBm!3-q@Q-uYmra?p>eUx3X1sp=;+gNSesuoxBkBJBt7pAhIBiPd zv`GciC&g;gQl45l=Z*ZApUs>$G0s<=C*X+z)<~xq;U$JSq4mh2-trQ=7#(b1_-`{w zzn6O2)XZWnpd1cqD+?*!%3y1F3O;sOz~qJa~(ssicGgGz;mGMZL{z#7PbeGm}sD} zCW&sh@L(Mq!BgX@ZBI{X)0+{wIEjp(<2O2rBYYvL80Ozm&yjH4wejN{8AQv}08v zBfX?WG8rFeolUqck??q@R{YxY(N=jegXK@1SoHjJv5K4>=zH$$!SAnpc;oWftLILf z|NOmc7f!u3&{aEcK_pKXJ~<_KQt(2`y!^?@`OiY+ON{Wggd##es)T@LGiz=^t8MT$4sT~L*S^SB4)0=#RvvE#714}G4^KkJTtONO zVT59E&og-Ry!OnOhc+GE(f!FgL!Tbpu)TZLxg*=oAKAWwB9;;6Jj_%=;*BtT5}9=x zU#oC^fsS^C2m3$hrM5}T$i#r%&rVtErM4*i$dsTxFHLX$jlnspn6HYf1H5Vje5#z< zTP4Na0nW8P_F=Txi|yy>0iIsR(?c9REKnl?TF11JXNLuDElplMy6O9mckk?4er#vU z%@22>0DQt{!*4`6q=&as4yEHW<{IbBJ5n46@eY9vFQ{1lKgDx!M+(mzJ=2!r};V( zY}#ytTNr`8J=k*L^F!A!ow|PM^wn>UUi|X#o89%%9GzlU;}ouC>7sN$N6|CWsus-4 z80U}HRry%ryrn2FAY^H*d1)o?E%5@2?U$y5ACOY>J!Pnp_Ttcfw#Q3k-ZQ71H7 zb%XXen>$6ifhTKep@e>Npk~FwW7_fbe(4Du!{XQvD+#Fty?7;FmB>WNL#H^qr|lU3e(UI zc#tvaGMg>3%dPSXo2A5xjAXyR*Sa9@4he=pGypuvQ3DJy#E`=ry@8`gcxoe$HcAih zOus;PaZEjq)zL(wz_bWVw+KEqJ0h~E9SH0uk=r04lRk*n;c}b6^YXTBej;RWd_a{Z z_B=Cn;Q48#UfK$8>vC@`&-o}5y~Ii{wh~JeJk&~tS*dW1M5~}wGEyVMELgaOj8y0t zm0kYy)U5G-5j+tkP)l*QSdmWm(c*2|_O7x|j_*3SsbeXP#|m7sLy2JVNEXi-=bt@g zLe7+NDZciKxo_l7_D>J7$9ai4(*qLy{VhHk=x1 zy>xQ-*B@-XcxunS((F96zulZ`HWU)3DjEy`-78X?pPSTW6Tri2ms!wGl^+W60^<*s zxenMEyI!V#4mwLZYBl_EN6tcx`Fk>(!K z)K8dP`@}(eG0$GY*hLuI2vZ|zs>Th~xUrT*`978$WJxgT&OYei$prS3!jLFq2H?XEg4r>(9%9Ag4@9G!GM$%Y=8!Ir+0)t0} z$Jk5{H_!}&d%EY?OoMy2$urAr$Tu5SQCJNOzyun)?QSssUfMvQy-P*GIe@Y~R;k0n zc4>SwPwjkZYAy7~Jl*c4)G-g=WTlBTpqnmG%T=iW#rN>385dAO8vA|hgAS#GrFtp6 z3rBGF5~Jw$;b@s!59ZlvcI&`R&4gzI?pcd@RH41&9%#v$9xPxTOF`#7z*7T2XuHxW zG2s5Sds&*CYNMaMWxQX@M8A~|3wT)hHle^N|0!_5pJcvDhUx%EAauzHD-o#?QC2eA zMnx!il!`|xSQu}LvJerxDOzK*$NMkE9#8dBqd6RaTuK>Jy_8H}d#aBXEfVn>pAqa8 zXP3aX=S&?JY2{*UTv~t@XJbfq_OUYJ^KVVhO9NoG4_szYY_HL1%XcWFY4NUf%f>w|q7 z1-8dqTQ_|?44j&N8wY2}bSh7!xmITJWG+vYDq^WXcD?Xq6=mv_xh)Q@k0I8O7y#S{ z3SeU%y|_m=?$Kd(Z^GOga0B34hk4Xv9?h6%D~2K?bmE3?U^5tbi5pPGc7f@!%S{Sj zXA|puw6<}+*gum>Q5d!CCU+q}B7E0XC-uDs9oTk^+?CSEeNeSVv3qS5i$F8fX)w zfGz@)Nch^a!eM74@ki%7SLOtVaPNDOrCT{f|SC7M`j>-6!^0XK`> z=BJ-1x!q7$<*D&}tKgSxGt)@&h(8@$|wam2!dR2RA zRX(;AnpB_)%QRt`%?0pZtik=gpx`ztu~a1xk5LCq0JL!qD#1a=+K70_+lV-gh_{jv zk}*m&MoXqx#T+eRY5r>6(wPywF-9a3R3=iy675`sgk=R?uLEqK6&ZUrGhxQAZe15C(l&WEJTN z7^7v8C=P{THR)MPc~;XN)wCyyPr#aLXtY+c4jeI&tl~`N99G6+d4~U40{rHPYLRM? z=sJM{$Gb&BQ7T$wgeZ)NnnbEy<69vQor?%JP%vJqXG!RK;ZIi6<~=Vz*(i^$dm57> zkjWy6FczqEoy1ujnTr-2lEnhOf+tF8Biz?#7opL0D{Lo=^@~gsSZRT2ps;e>P)3`I zaKlQ%R6!GU9KM<`t#w%1B?>Cmu5b+!RV~x2Wd^*eDlh9QO#hQ?>@dZ{1&>aQ% zuU4e~Ugn@(A|&|C^A%!_g@8eDICR4{D&7uCBsi%g2bE|ilU!;8EX@g;In}{t2P#Qc zGJBjgPQ^i?1*H4QDNa6Kqf(q)vNxaRC#8e>OBq3yf@y(iesX58Eo+=TE7+b9WX+r8 zQ}{$+ink@fE@k+lm5P5S<+vN*3ILar9za%C=!w-7TJ#DQxQgHPtrJOru#qRgJ42C3V0FDE@$5Qb99SkB=q8LU)hOI4{@ z;g%!iVboio2nCv0XqEC^3`Th#Fouh+GX14Q*y(UPgVy9)sl`@mu0qaJ@P!JBcLUr7 zfRmjxV4UP2QoP7iCz;|PQXNE^7nSNDQ{bZ)o$Ae|dGjgWbb5f09>8Y=h)De{2wHzR zGtiPAsH6v}nL*Zym!@R{UnlveI3+OYaS9VFb1@SAr@$J2l2QUK>|KR{JsVq2xK~o1 z<(M1F0P4EJw`GJoKnpFPobsq3J>es21cZkkcE!C8E&DdsqTnmWY8nOQsG&`OG-wTv z0eKpDqE-OKfvliaJkhENbv)UkaCHh_%Te_b3xl9C25)#cFES>M#}frIp2Kv2Nqq$^ zkq(^Zu}mHzt+ScP=ZIxIQOFZ3L~4aV7cp1?YtCb_4APj08)FGW9BGcH%qf&9gTeDf zvOpj!Y;uvzt^hbKY>~c{I$z}h&LUl5U{++43skO16P85aE+DeSb>ZZ$XJ1n*3%f_QLidXarbi4eIUrie-8DkY= zLh*JO(`v{d>kW1rs}rdz7!h$~HHQ}E1Hg@FgEL+uP}KsMXnNE13Dq3=_MBH%^P{VF z$Ha(GbRvew5_mjG#8X5nRiaYC9}&nD9?Jl*Q3|SqEr1tBSv;9FrvUq9CWSL6u_ox?!IcAaK?^jYNaJ--MKIJQny^yk$~0k>!j-Fk zUSa)vS)vdN6l#%1FV+BKYN-`jY*(C{MK*c?^0A3HC!Od3pP5VrbbaV^r;oe-7Jc-k zGyIsGU=#=j^zi!L^Jh<@04c#*cCeZiq+|sFx=N~DNYdCiiPGbxP_Y6PCs2t3lgQJc zNq-ES@+T=q;Zxj;%x*>4Sd>Q#n#V53A76ouEhWH1etZ?~UaT+TUx5}nk1ZkG0MSw$ zQjap+ql`c++X3Km+E7ZmqlMnIsfHt0b9e=y%V1@UzUZ4XS3p0=;ehCBo~ReuT8SyA z@lDglR|`y~K!b5!EznK+D-Dn_3s_SaZw_ZnfN_#QCJJ~Gk0py(5@!OKT}Y?#1WE-m z19jB^ISyt#l_ygKJdrcUvRDLbiem8y4rvTe#PMVtYfhKxEDH+?-F&vfq9x>jvBu^p z4A|;2O$1O&M6yz(YXz#FCt;}WD$`#|xNHW;DpV!rtMpujTBzaScGL~Sz-fsU&?T2@ zXkACRozhoeBTe-IqzM%A#+LzfGyK_{AU-!30X(`adz_j#P6LcHq4ynUPq7P$DibS` z(E=W)$Nov+X%rKOL(8>OKpzQkw8#Gy@A*G6Opg~}ZfPdBWY7PZZhSn$gqCqH!y$dF z07J{zi*UCB?C}D8EQ%pRxEKDeHI#tSrj4bPD>aleCP-H?rZU!4Em5mjQw5J#@D=+_uJB6d&=v=@q2ZgOkVmIFJUrOqhQ71G zwJd&AFX*e@;mSGq>Nr|}Ke`0^!@E~M)OR*O=21%(UGb;%6vd^wf9qjHs#|E)JId={ z{c!Wr!@yOS^%zxX?KE0Mtt-mhz4F7IE9kt8d)Fb=w>4Zvr%9ka4f=r+chRbMef9k4 z2^x9^?Q;0(k4I_zyWF{;p8#^g1h^C+DOza9?iD$*GA<6b#+ z_YztT4ba}ceCj4z?2eYCBSo85j)S`PA|UYe%_*asR?eXvD}Wz-h0xU@9EH}Eff8Ii zHhOWiiJ>v*7L z@o29K+NFZFsOW*Zkh*rPpv+x>96_sZVn7Fl0G0?>7tEv3j$Rxs&ELq~3uo?LM5=FB z0k*idtDJD{9|1)Gxb))52j6}5uYcVC*S~)K;r6$qfB#4M`N6#hcW+)h|JfJE_nkZQ z_Vuri>iC`1_o^IsMLu&y0sF6qL&lZ z4AC0p5zMZgNGOlKa$QFmw0i|bO#{7g;fM|@eD#plXj2W^Sb>g*z%U>hB`4 z>54FRT}SBNz2-U<=I0+CwbC8r-la33fG+%!w=bVY`+zP1ZBE|5{Nc@W$1j|H=kh0q zFMfRJ(nrUxet6{G)vxdWaQp798(*D0bLQ>6ht{N|}H!dJ*es@9NYXo0`?H%2N zG^%i2-=Tz5Zv@A`2ku@z3vlYtLg7&Jg49)@zZAd~A$RxNeY-YwcQolJ>a2ZuU1usv zb&Rk4c<;M^{QC31{`t>;q5pJ6$v^)2&!2z!>E3<#L)Rv=d*A-H;|Qf_x7jGJ2xdU^ z#~Z)gLwi*~AwOE0zY(+<=@Nn#(mNN=+`D+@yRSa@{OF$VzdH5Vp`E98u0OhU?Yn)g z2b#;@tjybyAKx1_uj0jNSwY^B61RXdFCdHy3DY9NG|z0DgLy8b@FZVb#Vb#@ES|9; zJ7#}f@p}MvQ`wHHg1ybTUS+-R(zr4c_?X_#L3=s0~LL|JP0=6v6Nzx-3J2 zy1HJ3E;7+4KyO|-e)ICNOQ#MT8R@-p_UKPPKKSQ9eg>=ZuLs}#>t8?pa{K(he!2Ot zpTGO(&o_Vl87#`}b0>~|xO>aRGyA@~dhGj4XxrJ%OQ>b&?EqQ{7z4eENw?Cj z0{x{RdyC+_0)+(8adpubu@-FRy<1nWe|zETwW}AeT>j?E&(D1D{)u<@AAM{02m7|~ z9qHXU(7tD==gkdk4{Tlk_O=a&_w77+^w7m`zP@_p!u|W-e|O^|bjH6v_)bR`o!o=~ z2Gr4hq#M8f_?;`v;6LvFIS$>Q#ATL$xcU*4@ayCIKRmGI%fq|h>u-LiwenzH@y4v^ zv>@+9RS3fkF_bxxCDPH}B$TG{L@HxUWzbu{6xx)+;z=BqinhAosS=sOVM!bwL7A4| z#wZJ){X}q2a_IYQm2bC{?`taGT)F(MHFa+dG=2HOo{JwI{NdY=T^)g|NWfjRw+x*p zr0+9Bti6KxdgtottDhXa^~LEQu3ZAtc=71|ef8y=@-q*0H+=Ng$d|`=esO%;=SMbw z_Wq_%-`@b~=SQ}EadhivN4I^lchkY1maQub_cqmjc5v6PKi|3f;iu=09{~SL-(9Gq zJ8BO=b+Zgk)+0BW{doJ5i>WU23qPMLbM4|6A0GeU@H=~V4)t#BY2H85_wJ5?Lp#>L zy>ac<&W3gMRfDya>l&(t8f%7|>()0_4>#9t>T1|I(6M)8-#a^o4s09TG1$JYdG+@G z&W}$Y`|#ukx2~W6NvABJ3+b=OCL`_wz>nU81oFd`kG?$m=I4iYp4~Nccx}_Z`W1Uh zQ=8_zypZsWrA%o8l?s^gcoJ<$AU)#=Ljr+zk|hzw1i}-Y_@wVvLYvR@3<}an8WTuU zJZX$W$3PhpC_@5cN@TG_o{XmPStgJ2H=cdFw%|x#?atcb?R6!6MVX(!x9!s-yTF%n z6-hrBOW!<*T&k3c(;9$x>+p^*>Y z8D5u>{>{<74<6h&zG(xp>gc?&lgLHadwsOe?CK+Tm_39Rxm0(rUHt09lZOxN80y_W zGH_(?#zQ-YHh0$TS=(}8c+KH$gCFc#KTx-#A~8Jt=?Sv}d|!3i-tcj}?roppVetGV}b*-)<>F2y%J$>iO>3dhsd~tBs_ZLpT)lv?9!-Z3Ce){gnNBal9 zdVk~FwfX(Cp0Bma-Q&I1PV(&==jac#_WJ3Y2YuB(AGOy@fwbF4?F-QQf*m~*yj%RO zb>3Qk*lX{tUHLg6{qDL?4{iMN$c}9_k~)hSVl&rFq)E=C$+m>?O8huW zT#ytSD8>drDkp@f3FEYc@mkVkN9;teC4TD53OhU4D{bMcy$vf5>>SuL+`Df>|9iVO zytT1^sI}_A_Vr(UdKz$b>3>9bcXi?3lC*SRM*@STaYQO@j@R)(9K}46jero~+?j%T#v9!dFpnhM5NC3a zHMs%O`hGIcXv{rjJBAPK89^QProlJ2Z-Fiu03I#P-$;^OjH9tsU@BNtw2KgJ>W$a85CSz* zOzx>h_f)fICT7SXu?*ZZ3peEw#sUgk#Zl1fV#Wf@ z2BnjzVY+-w|sSS_r}KRJ2%dKdF=gr zHy$E6vZf_7OK=737aXHXQC7G z$hiVFlc#3sdjn_i_)LbF&4E%gXw&Pg@eS5ATOj60#B33tEt%$9urMbR=`Y5P(`I?e z&)F>fb<0n_zkPjU?Wx22-rlicUBl{a8`q7N=5HjG!4pVhGKqRkL^w0r%?G4RHMj$D zfuNaYkL8r9O%3i!w z|6uc1CwB}MF9YYxRiM9=ee2r}Zt2{zrYhx`aVb+A(Z1|bV4i;V!)yzoZzQD95rF7K zMB)twd!4~%uqZ(B8#MMhX_~=cuaTxVAOjyM^Q*M+HFN{6Zw-Z}K+NDw&@yHT=J|>_ z+>4D0mP13dCq=F(e$gk#_wQWWb@JfO-Gl9;rTH6)Ck-erwb3KV;DPL_(H#&4g689% zWem~fWozWf{y?8r3%ABD4+Z$V8@Y7gl?zSYL#k5rbcEf1ge~;^C@#Ci6s-pbP7u{f!#)%fRWKQd&FSwuJFhpW6mBJ zIQRa>+z@BwB(KT<%Lgt-7W7ht9mnpnk>`o>?pL{FjU zB@|Z5kkA@d()bF7C}!{#ELB94c@zeXH`(}DiV0i>uvBQ{Zwia8@Di7K2`eYq!hEz# zAA;|_^~)2F+EaUAq-C*_O_^ek^rk}{v@-;JhCu3DcnM%C+91l| z3vKdD1_hy>!;^CaY8HbpaVRrc3`jha#b0Of84Nyy16+wWSR7bB*TTKdnrBNmJb8|2 zUTh;H0;RA(WxBxCEld3P{XKh!dPYn0H&5ms|d zIbnMHl^5Q7X?nLnG%?uz*{__4UVM4DcX!0X?q{c0OI)p8Y_ti@8dt*;wG!K)^1$Za z5T9MIJ~bTTGcv)inxncjxy{1XNOY+{*IDIKj;>JTRNMspae~n;(cl(iK*w$Zk6lF? zGhbp#CfQey(+U(WOJvemDv2UeNg~N?OfebqDFVn>OjD~xzJ$ihXrh{>P$*)KYG6s% zxtuO-U@5esnkDNwx|*XaIi^Bj%SE<`A+rcmDmvrU7>gNV2`m=I=^PPF8w&tqAE9uP zE%VvnFHUTB73eP|b&5UQNru{~`6@9_Y<&J*eMC!d-pu?rM_u0V%*Y5A`_2X;GQa_|gj79u@cVxWmYI#1zV zWld-csBB)KV&VSmk^p78Dt&Qs&uD4>MpBF(sYVY#Hy=0F&{#c%4?5Hq3%_^f%ezAt zb<51bw1n-iy*T*l3+w#7_b+(;SbEGCT`g~=C+vt^@^naIUuWRPxnj&Ep(jJ9JH;Q221-IWdKvW z*lCLl@D20zs*H?`8y6VnuqBNT&X_hiW7@R%kic0KwnS6r1I#iPJ3er>K+P7&g*IuS z!!lRp=E$Jz42hYgaIf>&Oc9?Y8W-Bg&>-<8+oRTyfMn>$?bZm?vDolh8XHulbpqFG zRStzMZdHXYt8(DAr?-bLt{2&T3uc|okLwKd>k`S~K%HO0aU&sKO+2yfsfhsR8oRh}&PxM+wpxy8v5M~}E&(F7sC`E53UV z4=Lcv_DeiEtx^^SL=n<;DBL>=$O_sgi31jCtwmfT3v0lbC~}ic0P{c$zishx7Km&H zOGc7-EJsIBcsPm#4{A!bkcB}gM)TjvObMTF6LnD0X|1z(e6EP%#OsIDQVVU$Ql}E; z=LF*nV9yunn2?a{r=E)r^a*p?GoE>BRoLRJCniPMt?@y@E9T7&_w`AdI3Xs`JO7mz z7Frcx@KQeq;^)NF-&gU4n;mkhSr`%w$5KpJSWiZa*Gco&85 zeEr3(PmJ3G?bp?d^#2_X`8~ty+S=U&hl@%jV81nf-dC zmvyPb+MJRa>+icnljkTx#iJB$hGi4N6{1E~J z!eJk0ufTNjbR$n4j+oyIzeZ5Nh9@WXP{amJ+VIk|^`v>wOFLSew>vJP?dfSlufNo- ziUSJ2MiRPYsYB)gwsy!{clWEUPU0`7sT7|g^0}otelNO-Enb~<7 z4~7~=-ryey&ImLzQ#vwmuP^e)zfXqi_dI%X6jn2v?0*Z7v$Z=67NKZ zA1urTey_I(Ya|ZfY?FjWfdiMNmLuzVrcs1$6`i)wsqlTOFlgoK?EI$5fjeeAKQO_s z-ywHf`BsJP^Rsrz+)%K0v%fUY*8sgPN(N+XJ8NE86? z%}y(zyVcu1h$1mKhP-V3Ue+c_Y_M9Y6cM`N!RMaJkohE;j}qumba2I=Ba{AK<|xb@ z3pK~W0C5*6+&qO|Y~vQHd`ysYE_j7=U&(*v*~;j!!Z+SXed_6jqMSAT$!$$7$wA}8 zHSguGzFM9$Huq^Xl9J9%o*!lNka6fx}Q1q?eF zxwyyI4jpj6QyqNviT5hYHd=&kz*S_yMXjK56ln^^pSYm_GpwMn3WluZ=~j_%w}3$w zhP~uUp6mcbofcs8mdODv65T2>-8QLFWZz#p6KyN9$pazY6)e&6FjVuHSb>XR@MR7y zOXjP*?3-dEhb9Ddd)YPz`>*%5_k)3jE*2>>ATWahyH4cRi`=k98c{9lt;&c)+u&p0 z5+vKoq($pv~1nsHuZst5wUe)4DapZ`j{!(BFH@laqnI<JS1u8wyLM^s(5x(kti3s&o7CEHE$pNz^GI84YWwYN{ zVwDSCdTyv>RsK^?B?Jdohec#heL7?Ec+p2=I<` zYRN$XwGoSQUwL8W+}9UKbhMv+fkH2Fic8Tc5Yi&6xWJBdo>iRt$fegHJz$V&vP))r zICA~u@$KlS52}?R27Mh}5AuN+o$!YW->nKwBGskxJu2F<-=zu-n$RGy zU>hoVYA6_;@(wa4NfNSEd4*jo0xrJzG+Y{*GJf;qkUpCVHW^GYK&ywwVTJ_`bUi4b zD~sSp^`amf(i)4@X%Po)mQ4;TGSr&1%g5)PN#nq7gRKVlY6Lw>+UVys9OT!a$ZJCU zOBJ>`B%oNc985|o^0KC=Vx0Uak902TYpF#Vw?GBwnT-sxhj~e1UUH~Ij0&(WamX=2 zKJh_*VGgBxS$@{EDW$V!rv(M)J^ggDmsifj$(iFOfp$Bk#6UR4i0bS$Y!1x3H0iQes`Q-3r7x39k+YDSC>Gy3Tz!iuE0&pVB~4= zTuu^s2G3{W0>&nd9MNl&8-d~$ zaI%q9`gv^vPW#w5 z`#6St9or|5>+<)iw#see1K$i^veK^9j1SCG_#{2}^xw&Rg<7C7i}jQ5Aq}y?WPZ%F(ca**UO74^? zIa4O&KQTGQ*C$?6GR6g$yz)ZftIwCd_QDc{&wKT$P^%E-twejvOKf~NG$5x87%z4p z`U1wIrTH5Hf;Q4%mWg(n>=sC17<%g@G0k8qS#t+ZL4MOXv;lmBLvH7(dKxdqO}U=# zd7d7529F}Msmj~_!K%FNk&Ej6yaDn8%v69Imy_lyXd)upuL(^Sc5q72khi5vVLMf! z(+)1Q)By~(@cn*{Mv2`xEu@^q_PsF8RirVQ7Jiktz4z&zH*1z{ zc6Ey;Z?;-CS!D3PHbBN{-yG<(DadCqz^l{8IXrzr@AS#XmuGf9IR)%FH(co^=#ODl(7LbY;un;v?hPZirnW8`2R`nk#-A~O)| z^W{+g8lG<9sA|f*9EQjSk9>p2a?JeMmhLMj_gp->r8#%M&4;4yD&y8}zeRvc$S^4=r=5$Sl+3 zQoFUlBKFOl)fMEsZTiFkAA6rF!*CYNGW4~>=r|nC6**-D?YBqV{j4tk%88BFKHT>G z$Ga|mFnr_mt~Lq-a}6H#7F7oN?sQsV?6kwFp&^qj4BNCGyYlv{Pw$`k!nRkQE!TwR zaRF~7$FJ~qmUvln^fQV6PUc&P#VB$LyGW%Fz#0>7XT!b3#R?VcXN&W-M%gS00Y33g zdzj3p1_x%13(T23A;r%-EztMk*C%gWK704ZC%3MBeC@)i&yK&<5g(J`@00H3$eI{X zAGxsnjTc(tqC;gq)?177(;~g3SU*dYw-oLzMR-e*erlLEii5P!{vXhFg~sUsj9GI7 zZ33j*IJ`rk;3IU&YtT`;XxH}E$$`B*)5MaMgelMHSqL4i!DDMm_*aKEo=zr`YLl*P?9Wh2;m zt1{%Yjs*E^m^`jK#IMq+ZC^O2aniUmjTN;M#}_#Na1{NYWQmmpbP=>xI@HcAwJ}lP z^{8N?xo|s|5TGr8{kcUV6Jt~3ZEDsyzgVkU_Sy>>LB0_J_w9vKx4-=u0DkYyflp5F z`}X|lG#}qYMNajx=Zp)8vC1o-owk_5QbT-mpBleN!~x)FCjhL5dyA3YGW5Z5fwpik z(O&<-G6SwC=mLuYv}@oO=WxIq#mGS&Fwus#YZBEwH4MWf7OSJN63i1iT7WiZ>|^JT zZeL$l_|{Ov08?VZ2^suN~iZ>(e){pW62Ik%8^)%fCCb`^|-~^o#tk#BT*qC1JBG_K_lv zNc;wiw8P(fbAZo=Anz8tGV;u%`T*b4CChd#no~b9sC&jsbx%!l73eQz5sGF-EwzGK zrWb2un2imyGNBq1;ou^z+!BS2@lql*Dc)*{*2LVY6T^6B#Zyz_RVl%yUb}Gm+Qkzm z4{iSH!?!s99oq9hNo;1*~ZX&shTRnycaPZXa|UJ;<1BgsvrDbNi94H$0(6CtoClEZGC-tpZ>JKyXn`S$d-Z;x+n z!Az)^1>albH%dI}p@GLR{FTKanIBNZbq=-H%epqmZ|&sZ8mC%2&aZj$xK#npTDghN=!VWA=sDpHF`Q<%u*PoEM><11c#Cc(#+ zWY^ArcIb-_58SwX>f7_juYPm%+~mCv^qi9^HKLgY}n> zY^=bH?da%D)GLE)4Sd}s2^)aQ@DaRu_~>Qpw^{m}TANcXVW|cm8(511g|C?uQs`9j z9~tjxF*i`Js14)@+ZMso37S|iC8XfV$tgkJ=|Ro}UnSAk z66Y&JTJ-#+cz-P}z_R?+>Dki)fx)At`5OT&8yFLEqZo55gN~7dD{XotGZZR?CtEnI zj=?^NTG-0q^`yDN?3ryq@s6^MZk6MGK6_^a@b#M`+W_N>Cw84XvOVR0{C}a-1zk>< z>Nuj6rv@cv!%NefVBo8YtunVh(5qFT!8mt2Bw#QMkUC@@ZRe#&U;K^9l-X>VEz+dc z2?50-TPDy=irA@1YgMUFpx5frtOi(O0|%@HrAAQK%Wkp=gCg6XoB3+K z{ZYT&LWMwK=u|u$#VVu1ZFHoSj&^V;rj?8@{?b zjOpHvmiVP#oZWl&{jF7tX5~*FSM=oMya@r}v^mKx$63Y3u!R*1X5>6IF=L!}q>YX9 z661a47^j#RAg7M^it-X-{p8};pUQeVWVAGYBf#2L{R~Jj$W1hgbfibNGP(jUG`C~i3IlArY$-VWHL$Zx1q;{^^P)6Z( zEZN4>!!~~7GZUH=bSzn?g=-TT@T!IboiLbggaNc7b!k$!L#=;!=+u}T3zs9Yt9>1% zR!fD|^7e|tcAMN|Q`XtF4Vt9~sH{h)8e!-Wme>UU086fCseT&oqp@xp?_|*U9sKnM zmT2RswR+%57&~nO%l(ht<-`(?g2T zMVWhPte?dCFymTRpfbYPhZ}kbV=r##B8<(1u@(g?L$S)BJ$4XAXbtPYfa`?Ig@;n1JyXEQ1JZt1b-!KYG4!) z`rpp-{F5}$SPgAxLb1wB0BtjLw2TP`zAneA0d>6y=G7ej)!H7g-gTs@3OAIPJ#swV zGTg^z=@@4i+_H=wpt&Z`9Fw7#FqP9dFsGHH*9ugP%(vU5HVfM!bL}ECGTs-k1e4Hi zVY?jiV1QSjL#d{)Jui)(!ig+%j?CrB{3?gK(khqmbP4nsBGb&0efoH}6Zh;!QOXdg zI<%gB7^txu^X$Mpn)EY7SDW3dF!wsly#+V4;qHSB>53`3PM`+_dY#OHOVzJRT~@Ik zoghutIMi}4=yz=^oEAWLnO%A`x(mUp0+$N)xO9{q9X=XqCu3}M1lVc|9;4AqI77UX zUqresVLf83Oq4=J@nnq1gj0q^X7?1E9Km7{v>8a8;_HYJNdP{EC*w3R|A~+#jJfFf z$!Wp16kjE4vR9Iqu=0fo3Bce$HQr0eeKG(ToHEfX{*htmK&nYF$mlHM8W`*XmH;hd z0^hjdVMsc-2#$0ei@jG~vR0;>X*2Y`HH5JQnP|5xkFkI;XqpF#M3;+st|U#B3_wdY z^JKrod{ST0t_j^T+pP)h8rLFF9WvV_z+jhY5-G6K)g*R!?yJacet4K2LN`lfvPC9G zWby>MP~Vr|V&U5ru9YPR1g3{Hb>oI^+yfm6iy;Mc^(bYA4$Q3;2Y?NAm`4qc0+lsm z?rR7Gw1z$!2L^+c9uTN?GQZ9$4>+|>tJvzWtcHhA^e?en@?;LhptA}E4mtag5v=Aa z`ldUi?#N90Z&m*lIZ`CC&0tjXSDW{@>|f>*MiwEUUif+8tnyh!AX^IBpa8_i*1q-Poodqgr9g%Tyh zSVNRdFMD!AdXO#7$!7&K;O@F{vWc-1RUqy$(}0@Ng5 zF*Oh!tQ_YfrcU%q4t&(xG>}@-0JzqW2rA%i4Gu^f8yF+_RRL>Z}d9FijMi|#I z2;e>+OOHr*3sehQXlHDo&2{KpZoHi();qK<<9%BKy=rB;(L%Rb0A03CMlpSnHRgyO ztJEygU0#-Hd&Ek<3f&Xk*i}ioFULd<<2AWTw z%=LrMh8XMtilD_kIx){?=yc8QtIe*^plk=ino}h)6%w_5`nWY5-Y1e>0(E%a>u=6^ z9!y=e%rsfJR(%Cz3yLR5HcM2qKy|4?GmsmFq@(-2RiNzFXC|-pb2f-{yCT#)Jfw9@ zx}XP-6vzyY$lh$R-1)sq|LoD+so77B0+Bo4DQC=I{`x6vjKB2 z$58M{&??NM8Zme*qAzLc=jmq3*aOYNCiVMRdjlO%hf;~D@wOH#;xY@j9Bi^G0CB-G z=j-%!73eQzk&1R3fX}>Cf13e5bDV>Yv5~PhGTx~J3}9P{SPhS|n4=^VIWoqA=ZyDC zv@&7%<7s{hpc|`D(Gs3$=TgDas#JspkFzrIb~fI|B{_xkU~96E*tF=CsyWYPPxMO< zP;w{wr1&dofm-$i@7yT?2|kZ{-vWXTl*T=v69wxE9#$3bm_Pyg^mw7BDiXz)L%{?Y z1TYFLNE_=|b2V#f5KwfgGH|CwvY0YHIZj}WA40k{Y z)@WRxh3l7@eu?g)u`bF8)NCaTV0-}A6{g2aO=HV2_e#vI2Ixy;EtIK?CHpPxI`E|I zVuOXPlG$oitZ{14wXe|Q&J_Z>pjHt826UG_a`tqdO3qWzNn_Ca>PYMK)lYO!aMFoh zRJ;{Wuo0lKnmJy@Vq{~iVoG+h5t1p@M@X_##ZQk*b_fxiAx6*ARViqXhK2On>v zlbl@kI9rOJwCd$4nZeeISDwrWv{ub|Aw59No9dtJucQWP8Nm+lyhcm&H?o>E)RD$= z!b3kj90drirV!Hbv6eAa(Vng#k#HM8TZMXPJ&YhaPaNEABXq`~t65WxfY|H%B+pcror#!4QR*+e*q@ z#Zut=q1UQ3)~#_J7N$-ldwjK30#PBewO-Z|RVdZul~%Dp6ACpU&n_0&M6k>-B6@UC z(AgGrtoKqYwMaup$<0@(B{nM3N&+^(U37@OgG{s|MUf+IM4}aoM{z;11S^^B#R9G=< zcUG`{*`$DUzyIJ>0gA4`kY%`AH3=?~XBA~A$J_v8$OEn@E-1=)z>uk0$8|LYz#CB? z?1}?Rn`@wx2ABn~z%-y(%i{oEJ%<6t&0v-RX^F05Q6SJ-{b+f(trL7{o@&;_HJZFy zpc*BvU3>VRIYl6nVT9lc70HunJe~#P1fI&{$RZJ)bF_jsm4X*d8KGqG&$kN18VkGD zCV+ETL77&v_zIp}&JxQhQz?U2GA8iF`W=>9ktjo<((qLxSt2q8JXx%8Wp;VFA{45^ za;uc5awsS$AZ?S19F}GOb|(Mt1-J{HE?DL;ja;Y_FhBw)3#@dE10C0oLcZEZgMy}b zQORCpik(Qd<4HD5KfNDMwgJXWlATVpQCWbZ7nkb8r}%Pdev+<$u9O~V$q2Hf2Wpu? zT4ta%cbq-d*OFl4Q|w}@wK!{BPPG=C#y04?rTin~?m^hIa>6CMDtD;y}g;yMc- zj5ZD58X#Xoqn;R0N1ZVPLm=c-H=uz07z}4?d8`^dYCRTcgFrwAMz@e@;(^xC2Q#&3 zS_1EJs{KLE4yUDpr%@LmfYE*!Ffu_v@m^g319ySMX($#bmdlgNc(PES02{z>1!-7; zPIC7sMWJfJaYqBPRkS&uG^OJnIg~LUl<-{1nhH_eM30rEv4C(ZqK(jnm#RX!)3Q>P ziV(EW-SPl!A=qS1DzHig8la0Jz`6?bmx9JZRtmj|v{7K37a)MCg)l~f5s{tLxeK^5 z0B{OG>rJIPQPfuy_*GAno#@*%A3hyG^<&fg`80nqBLD>j1#~k56(BA^n-QdeHHPjs zGr*eetL2aPPP7ThHZjgZM~hU9_#alQgH2wA0EW~}&%0HSo{(`dxB>^_dXy9Ha0L{; zLSXBmU{Tap(!Cb!Hh5wBkg1Nr(6E>TTMf9Pkj{00u0Q~l5oIL`dRYLtRYML`9m1F# z9OnnD9e#3BjX)1io8T(an0TJhPtV7}z0w2vA`_j-Q<*$CSwuch0LDc;QK<TH6${jD6@c$MJZAfF}zm5=RP;1AS47f`4KeJeC8FG>0wYhytDf zj8}@(3Xv}6iRCO@G-uPMRMLb(`4Yxh(iBIU(kOE#i{}d@INlkIIg3RP$&*k7QGhmA z;Q xkwdU^exhOJ(RCl{77_xyC~qgm0oIPkV|Eyq0?PzMI+!vV6JUMG|(3~>O~;p zdIP95P&VD0&H#W>WM3xTkIVEIvIB(dATd3F&jP0E+|3M7^hmEtW`HFtP)+x<A32_1uC*X-90nT%(2=paW1xyd>ilTC->p^^h#3+0(I9wc9 zY`jn)3IqbE2|aWQN5s%rG=s&mL;_DHb40dC!?-z}16<9SA^~wfuj_3b_WnP7QEXT$I#>I%lkQuv@7`qa8TZxYa6jx%81EC>b z25@9%P2z?kC!v13f5f7VgM(k)dC5ut>OV) zyaT<>U@95BQ4y*Is@L0D4^&o#b(7GMlOSWFcp_G(FDRgkVy^Sp!|=U0z?0778K43N z7-#Z$jsQLvGTNC4KO&jM<5@hG#iJO6aRQ4cFlMmrse0(&JdMj$**t~Kv9Q?|2Kc&6 z1LMpCQ&B{H6+q=zD%>h?xRgivETI;BkpgZrH6Ja~pu+6*QXBNX$dO(EewI~tp<(Qc z;;e%+jL>~|uq(rdNdtg=p~oGi-Hr2K-#Gux;h~<^$hp}e0IC9(8KDbfo&Y7o$AX}h z$ygDT0KUfaRGff9G$#s7^21m2eNQU~RpH zua=l{3PWKIP)uKnwUbM26kt40!J#LPvQdfP zRXM5a=f6(#g+VQm>O+H}Mo9Z3<^j5g*Y|$>&fd0&xw*lXoDd}^M9T?Q5yt*Xij9v~ zm}rrR<_R=|q@xS01!$9aI^{p1n_(K8V|uI*b1%l-a?OwDoAhYR=Eo7(xEtsS#A6__ zdkF?M*<(5Jco_<^4!8oM9xD*8dIooQg=mIB2ZENv${BMRi?p1_DuB%#4&1F0=?ac$ zR)s1a`ev$5;;O(WRA*Zt1JMVt#`TwRt`KY z^fFT6DlGhJnOiMV4FU@K?<&w=O1NZb18 z9$${Tfx^fFIK3Pn>-ty(oF)*i04KtgHUZ2iBsXI!p$#Qqr8#UBhk|jVFx=oj%S;6W zNRvQTu*r=IUnx*1FVZUrb1C(3<;{HB93c>q91guNaMu+`KY_;p;}ii)26O>ti3A`4 zU|=&sU8IsxhD_kiksKDzVxdUQi)jN`0_d*dMIu=u0pKi^%djv&T);S2VpI@;wH zcBR6WTewP*t{2%lo@nBTmPa1e8_K(f%f?6*i?9J}X&@_@;s`qokiciAfWGLY1ayc3 z5pE}A9RMftt$@C1V3vIuFwVf;tUx{|SkR#z4X=(gM9U3Pv;1VR$q5QLP-Lt?#)26` z&{9b}lg!bn90Qv6pZeVd&&N_tkL8-irWqbfHawPT8VhNP@$nS%*i_@=+2*l1=CN6( z$8!LF?6Ew|EguwzbSw-V3vrYJeZi!cP==M1Cn#h}X~Rm|vy?Hq!mF1urg9c9Lu#%Q z$P%#FD3Cr?i7YnNY?mADawUvLw^1r40H@g2j%YUQ$-}2w`|F41~G~d01 z0_WeohytubUJv(v3WWu|j8a#$W|Yxm>fdw)<-Q1c6m! z^Ll(}lsR(aJUm2y4vGe?M{;*%P`K~WFu`}Ooc*1m$o+co{*O=~QWV19b@8Jgu6;cE z^ZYN$4>vFUphxb%fBU~e`-8e-!K3SX@ORf0xY_j)1)0|4#lsD*Z$}mV`EOT7zjgh| zee~66jB5Scs}FQ_U3_ro$^+M9^>6RP!|z`G;V#NNxQ*hIyZ#FOqoYygQ9yDOWnK?R z4hor{?x6^`DCji`V~!%3L*8|mfJ@;yC zNKf6m1lNHDC-q3!a0Nc1dtA5accPHRh!^^?2CgvrH_x8}Qot2xw~+oma}ynafDSzX z{T^=9&p?2G;^u{u-=ixh^(!a!hyT9hNJoDoUB=vjCJTyU`Jzy-_eNvBpS}Zsd}Wlw zuBgo@Cbu499T8Yp7n#4iaO`^&EB`2>icV%dl)4^O|NLnB+Yt)-l~KlmUi;>V>nIKM z)j1bqb?WNG8_l4L4-Z(-61d zF_0E<7+nDvbYkDW3>VS$yH_6-%Ks5^f0SuRUHk-|K;}2HA;SE2Y=?f2>xwJ?Bisqs z^^*X8)cLG`lt99 zevrVuYoo^r=!`||)$^dPAoC~$D&nwXp)(eB zDi_b(y#US9McPs7-oAjyc^mP3^dsa^czI~zh!rkA{8ys~KA_Vipj$$`LWhh1z3+le zzi{IIwNHMzd*SDM7k-BH$7{dd|L&Lj*Z=Y0#y=i>_m2nP|Kt9(pKqVLf8&cEZ+vNKkLaiZ z7hPRtLwBO$jh6GfbHJm~kH4Le;;IhVi_zammoYalg9$-r73lrXnR}Pd0CiE=b!58G zkv4_d36O!#_F+VQuqY=`{vmbc~Qk)IISXTyc?5Cn}=fg%b~%sS_1Z7j?WY z4(r#E-T-~rsk-Q@Q(Zqh2h_zz__r<{g?|O^)Neq%y?F`#6~y81FQUIix9K;aXF>`e z(a{ciK=+GhkTFIk({Q_d;MJ&}%^FY^iO1o~*nWM8&XDQ+*I=V%_;!1zJ?&@7#v_z!U zZ__XSfwVeNU3sMUzC}j~=vNSp^*qvh|8-8tC|5_%20?jXvMc|K{`qI z!wBw-rUrbzI`RS!E&R+cd%=u4FUH<%Iq@SF;`t>K*&VBjawtaGF*B3{3pF6Yv(kJg+`sCfKpC1B;5r};U z(M@lDh@8MlMA1JeFj*%p!puufMOZ(Y3^I_Us?MD#!e0|M(jaZwHo45Be&oz6hr#nmZ|NCjN| zlY@4{viF-tsN-jiH}}E071C{CM+cq<8f6`=5XO?&k-Peh=wS z_iz0411Rd8(LpW`S^WUi#Z_0TbL{u}+m#2dD_|oYeuXan?tXN>4}83jdRpMBtH0Gb z4CxIhz=QvE(9a_T`rdn&Puf~FW9^HH8llRY`K6vrNcfbAY=ocUCyY|VE^T!Tc`UqOr=U*K^`04w*KK)?N z>0LXI@7R25Q}6M$E$_9jeyg!`f6elJtMm4jWxrXPxwj-^+p?rx%Tu@H#&yTc8%hZs zOkO&WxO8h?;&4WEU&5lHjL6M}iMz|Q->F~zUUTW8ma;>w<%c^e54D%S(_X&6xnytS z%H4IvJL^{LYA)H|S$(j#>Akg02f7*#^fbS}srTb|w|(`&?vD;^KDlqhXGeD5_~!V% zs~-XB^alA~6#bJz$BQ_u>*#N!%b2@YPQz~mbOq-b>6J52ObUU_u1#wSauV-dJl$Ep z3VL7{Z+}xnPVf*QbLkj5+~yK^r^jzy21OT9pA38k&OpY+rHkMvAG!9$2bVuSc<%V# zZ;rn8)d%~&`rxh4_U`)hz^;!E?E2#1zSDcRfBN>WuMh40`tbhG-re!l(Y;@s06gBk z_T{@bP~U#U^>69jFE}J{1^Dbb{|M0-dSJa&$ac6GJIZGldv!O##Zp(Vi|Fd|Okfy; zKEls*cC=@{{D0GP2I}g4BXWHq{p8FC`*v@ED?OdfIuF0)SjKgaeuImm=ziA;JijTT zG4zT$f$!b9_S27d&_PQN1s${WkAM97%P+tD{4?m!KmGL6k3atOZ~b)tyZd)MsLthZu;4E zst{l;-c<{6LcYk$! z-`7XqJb!%OhX*!)dSJ_kyEmNJxaJ@brepP6O{Kdk^LCVGZODpQ8$Z8g{!8W0P01bS zla4m$Q;TuWC75BM(Jd77j3iBwlrfeuqnR{;Ocse0iPV=26X_D2g67SL6p?ail0YP| zSR#j3G(?fc2;4K2@K{WE&M~^rF?r4>O!0P0R)~Me^V1s_&iMba_n*;GTxq{I?2qqS z?{j9xD0Fw_T%ChjIgo=B&NewG<(vZo0g@1sP!1^PECCWC=bUo}n;eY+V{n}Dd+loB z8Q<@7=05oTbk>@^uC>{X)UW>kYj<_+hVTWw>CszPr|+-KIar&ww=#D}apsod z%x&d4J1cXyl;sQ*tk~I9dU|u`$xZEt2b#|AUU%!vuKQOGJ-KlLE>Z|-1y_`8J2Ha* ze|nKsh7;E@fz5-n-#ezUc|BDT#M0DAG|h~IThLoat#AUW3#t6`yC)xib>zXhz4uP; zdw%os)7v**egn$z9Z1n{zkT=U`tfUr22ZbRJXlw}BX{}Mtc=Y$8M{`k*tL4)##LF{ z3s!E=&Dx%qwXG~?OGW;s^3{VSd7I1fHWjYiT(ojyPWI+iD>vn4Z?7mixwhr2V>=(+ zJpb(B^}Nb%2fldAP(h+%ZFkL zhAu$h8qR>-Kvy3$H6fbP3547#x(6MWM+m`O8ftK3-<~3^@Dtc;4*ELsd?rS-AVE5@`2k+jxe&^=3 zTQ@G;`ugIFCy)Vt^XpIF{;W)>=HPZHAP8;(@k8VA=x%bME%|J5fGcb&F<-gJkS2cxR2d)U?-*xx_n&T5r zbR?%J??qPm(N~8r?(aX)-ty$i#ovDW<=3Bo1W$N*d+V0fnVs?R>sMqR?`gVvbmP}& zw_ZCwaP?5%#l2k@_jF&}+i`hs`{i9N7k4&Z+|hJlbJh7xRcAL=U)Wv`aS38aBdj{V zv;M-arVG29FYRf$3@_Q!eqmqxrTy&}_qAQ#-*a()&!q!s7PD(7H(Wop>H5BPd)q1o zRxRsUny{mM)wwNQcP}0K?H@0H{qcv}r%qqmx9#@XosYjh3X%&9zrNNe*C6hwPto`QxS9iX;bp7J#69@O~**vgg zZTFV$mTlcl+xwdK4t5;e(tUVK@4gM~J9-|Wn>WY@-%2X|gN zckIrss}F8pefsDI8pTnjin!J-QFL@FzDB1O+xOjZg_QI~n zIZcz_DZUaYpVCN)ccql{jBwV)<%D8gTDpUewGGbbAz9? z&KK5NYrQP>{_gc7-0R2sRFC(o{%m|tnn(S_!HQG0I{^W}6q_s`OTh=w~+uV6z z`?>?$)@@(g+E-uJS6jNJyJ6=*$BzECJsUdq4|Z*CuWc<}*;1IbcVp+plSfV+I(YNi z`4`XbL7I*9*@3Pi(T;i8P(J+X&(nKuYxjxuP5T>)wgaxk8N2dQ+oI;Ajj)GEbTF-n zV6j+s=r-OMkT^;Oc%V=wQ;fo0(M)`R8Ri;;tD@9svM#_3h(b)FIrtEbv1*rCjY}M+ zf<~M&&s#j2>dhrV?HsRmf_6M?rgDl?qe-S~)NNCVz8kb0w6LdzYQH^GaQVm1z zg7|leQKK3@0J>x-lg)sPM`+MQa1ppOnh_3^oN|qzRH1|m1c-SIf*B8Eu|fBy12LH;=vBY^TA#~`s%UuH%{){+uPEbv1D&s{r#(_e*O8ID@RU#ee%#Z zUmyPtu22fPFCJV_zWY7zxP%QIo;NH%fBz61d5W`TL(6EHf`-}Jg~9r z==RJUYW{f3fj5%_I zAu>Q0;CEmd6=tG9GDoj9=X z*xo%?&mH^6uTMdi9rQX#9y%y*Ubg2i9?XcYn)O+XO*dELvIuvH6X*nY+*b zki|vP3X#A7Z=6bAe!0M&3gK>DnT z!&R{mhz{7kzzd?S%tfmk#w^IlTVL(G6FQ4W8J(u01z*Pgm`?cQ5_$ z@`uX@_CCCF+4sGt*(Nnj*t7>Og^}&s; zr+0O2Y$zyA2uhpuesF+ofx8en!W1{g5*eTk_2dF=^g;_c5B*>YpKBoI=&*T4^z-yN zI%1X%pQR;d%H&LmoGubGL~HJMdI4U5n~ok~pQQNYI2 zL~Obvlu3D}2!c6S`!v+K(F$D=zzkAUXCN>M z16-Yex&+(>XiULfQ!wW=QniA?R@*s;fdTrOp5q%?v zmkG?ixzpQyY#ZJg*Mg**mRPI9V{qqAIwtzwA`jVhhg6qw{R zLbaIEBm?avXtg??a7`f9fHZtmIfbW;WTq8^<0rk96R*8B1d`a#gjWvZ=KyBfXYJtvW$vl?KqOeQ~TS018 zkm}{QY8kH1P(qm^(se1OO4qoiV=j*QKo@IVP^g{LAkf^PLp`uD)XrkYnO=ZBo9k zF*m@J;cE=l(#3N>+1Hly^$AFx`>q~YfB8uN%~M-W?C9$&TXmqj=DTlhKfZDM(xDv> zuOA*dJa1SIZRtF?v3*BZ&E}SpBU@UJY;D`sTh+QMF=Vv+94nhJ-X1f;6y`02xHF5a z=&2EiRTD86C^b-XbmVk2F(Ecpz^CveB2#qCpGHlWnW+LXU81InNC1K1(~ zq0DefOqK8{a8VF6pxbi|}m=FVVoN;)fxJ1a(C+4pcmpaGz7NIFRnF5I|6cHeK0+r2^X_P93 z)&S1{bG*WHH00H|3QRcU(oh4{Q3}s!4o}tF$}Ep)s@5>dH3WB3oVIfqt%?x-Fx}Hz z*H3N(jlFze-MJmD*Y@??KE5t*+6T#ArlkRHg(Ix_-iC_dmLj`0&n#wY*=0PnQfAX> zB8}86CNyb)6Q)j4yQHXHQ#C56A<_UX1>I!?o<-vTB(zi2PC)50LIaUW;W-SoiluTG zawP;yX4AwfmPS*CvP2H*N2{`x$wHSB>ZK&U1XpHup~)ria++Gs5Q(l%$tve0wR57% zB?ycj3s6Lz{X!O7f2G7&x_e^WMS#W*XyvQz9XK zg{)QW3b`c&8W~bU3JS&;GT)xUf9E)yIy0y6);! zZP7Jp#dew9G~VaTs`SG#p?f2O`X^54nf7J(gwf3&mRdd6|L*XfQC=sa0*^%oo=%BB znG|!YrQvLP($$hx2cm*@eEI&qg)=VYEIkl3tKP%7CwR`Guz3R$$6s8LT%}_=eQkXs zJR#8oeXfysV7rW?TCBQ8i`+TFyHsH6EZQQ8&KId%ky^#mxe^1?lEqU?;baylpb2bt z4DK3BqS;xY0aqo&vm()uGlT1nP(d5z&tYgJ3}F7lRD5q;KG1XH*t(*ySs`Zq$}!$K zBP<1@EQP+tY^#u=J~;sRWixWT*s+h{LgX0!+V>?xR^~fgDu|s4K2c$I$ea zO9^Z_g=f=%B9#xHm?d)=B1f6PcNK%@Dp5d_5QPj;#1MrHS;!Iv98t)U1uVImB~~L> zOysj9*yCJwD8TSQz&^8CGLs>)7-|_!tYFA=5?jVnsU(&{sul0#igFB%YotaMj;SID zO$3RBk(vk^3x}Z8iw$gsRaoXGEwxLTe){Y&ws1E&?OmS@l}m1)>%Vlk_u8=y*H3I5 zIy`S!l0O0lLN2AW2cMiZ2ZxKabLIGXjw15~x{5afZxJ<*B)5`AZ(3r56yxl-ea7ibXS z89WV*$uvGgWPo0H)m(!#nFYU1BaD$sV?mx4bVWc?OngqMCvouE7{>&*U-IOaXkJ`m zicC$G=_xV^Y=0@LCyCfJ8N?ZsSp}ARwt-mSMlS@z?<3FklE1J@0kmf7D9@55kylP^ z-9Om8xwUrapuBmBM$=cLfn4yz2^!ZJS2XW@JY1$Vu4#np5>izm3EgI0C86&0_uBN{ z*b0$@6Dj-czqI;#Y#bY~ZIpM1-Lx+{q?)6ejk<1sk9`q=U#-p_9P7Vj+UGmtBU=MJ zt351rV}{pwyHyIz!G*JLttr0KSoLiCmJ_idmzSs9t1Q^NXx6RD{L9&C$HM2G4xjg^ zr}a|y;vHYSw|nXbCxT~g{p{U6lRxSm?y+vPf1OodCNbp_SE1u-P1+V8Yok@$=4q-i zO4VAvMrO+erdlslTcpA9{^b%|ATpVZCYPsI@l>A7XR_o9j>?ockYz}u;|Voj97m`i zXGW=kk~4!KqrosV0_QSxjFj?LguAKWeV_bM=GDV3%iW~K%FpQ2v|J2F#&DxS%gxEz7Y)ruz9tShS}u&kT1SEwQlI}ykQA(=jNN}g;sWfg_&bSlYdW@ z$vH-GI+_j^a8;;4xDu0~Es@hecy;U?lZZU6KqwOh)0268rk0(dWhZl>lh_nSGnK=q z0^2M;U8HC0_?Z$nnI>oJ#HkE6N9Ml-lgv`V-u4+HJI^3brLgHdn>OjwAiH@orOur6 z(Hw)Yz@(eT!llFr{Lc_MQ0y5J18*^10>NkIn51c1cD6}EGtWChVx~&m6p5W8(O?87 z3FI`HouTL9LNiHlOj(R3AfFDGVs_oVWAN!_BpX{Fe*@pMVU0jjc{r>p1lRsWR?V~0ix1BSl98L%y_~PA- zbEX_zv3PLiS-wz$OVaa2u6*RuuAgmIZl{~YIAr@0aGNA!wMlfS& zcsvnT$7@`pT!-e=c9ger{q##L{1T&(qT^!)I+CNp7&4e4f@va{B!fvJge1dAJV>LC zB(Yc=i^0|BHV$TjP>X!ALBGagDv-rOfh(8AHIh^zaBBcRfvXlAC^Gc|+bD32Jlibr zEdq&7w_zzpH74!9Srog51bP_|w(?pO)6@p{o923d2fi#-%If%l8 zXe!?&@CG?G#|{HmboT4^)Y0IP26-ngC>hsCIN?r zBaqDU_*8*}3>GD{54ZIjx$h{?`{bX@Lpgy z%{A%5eZ0em`z1|$XDWry(TUS&au(0dlf_`O;d8iDdAl#4^yy57P8>ISDv4Le#-@M# zN%M-#Si|oefS`L|NFammhikAHntThS>+LLAKb51=;0Q-PVmH}z?be(3N8@<4jTjV3n z@c4I+C;RsWEO9dCyqbf=Qk_eU$0how=Q?L<0;9vD+?RlbnD(5S;1>6MY_Y!qkr7+ zGtoh(lH;DV)!!Rjd$+6UYD4A8{H)zkffb&XhH?IF?~ShYv{boS+I(#FGTZKESYwtd zJPk#9ZfEGcy0HPx!#%q{9^d3+1Ml5tH@DgiZSJO%;dASGRi#KanuJKm-zaGzUJ@2*MkQsgh`7 z)3T-Tn&m82pp_c!)(V4MZ!)yITk8$lW}UWC7V8jfLNm`b@C?*|Ym3OXK_@gIc&1Yn zIwhe^5`a>OL7S;dE3VbaJzB9_D|X7L?tof{)^;e9v!mI80cMHo)XD8y36U(rHd32j zZr96QWkUEU3mJS7iv_X(vumP}S?cxQJnr>>S7sPkkW+^l{ug3FX+fq)V09XpXTTK^ zOM%|bF$(i6@XlRx+nI@7Rn)>m?!iezPxwA7q`#9~xcLP1#qQ{M1F?D)=P+-D)qXXT|Gi7FuSsUbQ z2WV#-C7^evUYKQ&W*Nj;Mq!bM88jKqH?HGn7{sYMZjwxYA&^tRa?1=@iAjP6%|MO@ zwAC{t^&Ioi6Vv`gDW_*B2k|Su}s^!dV+We;;HM)VOzq z&+(e_b9pP^y&fJuux-xNwZ66uR(Y*SSZkKMj6#=DYB$Jj2D#NBwdkZKo!A14MzP%@ zx0$qEW_hifcD+s4Z`Jqs*s87ifluElli0PRe5wSp-QRuP1iw0?(BiIdFiXugZ8PlC z!_;Y!+Tqh0gesA#Gl*+sc8!)Tm)SC&0*S7%$i)I(q2<@;r6QRv(Q=I*=6tZ$9GT4$ zD|t4HrB_NED3jw5Im%msED5oICKl4fdH^_-cL8Mdcj^=w%xj|z`}Z$jSO84Jw% zg>J@$9!B`6VZ*(`e68?-!Po=3bIjr#Gn%G&u34IC6lR(wpm(aC1(>HB1cw?!JyoW^ zGZtX3C77y=#w!{8 zROZr3jY|VXtg{+6jqvI8u(x_ztF-)Tm$x^J_S-RW!of)&t^Hs^|MV}*8LZA`*fnp; zh3pJ?moqUT>kK?V*rf+05L=DfCZiVIT#W>P@s$Ew0rDtPYqT6Bu9c9)p$YBzYFVh) ziS;_EQ7gmtttP3@t{?C+40;-xtlDaKeb;EODx+8o8J}KQqi3tM%*Js6Ef#IHmaCH4 zLXK>5H@4e!RU+MFk?Zs#nm*eop#)Q=t0b;gCzJ?Gu0)j^r7EM8O{se)1auGgD&Ux0 zna|h%!O^@0XYf3*VHCcICWBad5k;h$O^G^f1Vb+~>az^`6|$JEOpjb?Hgx!UmH>F3 zZVg6#lTPlkn7S>7E~5?%Z6im6Jc809h80`^+75x~258X?-CPIHf$E~^TtRgup%*k( z4O?Q<7@Cjruk;kEp5BYG^cSyS;2sm+GXg?~iZraxc&dDFAiI0sg89*Y0n0x8DAe0K%-ubG^w{NJPKxpKuLxQc z>gBoQvyYa2^l{GgsddT8QGPy&!-vO@3RpaD)O>@OGwGvnvmwOIJWt2Y*0ZaoPhRrL z`xOx}Qy6kSxa;x5BmCXw8u;0I4$^YC)<6w#&Nhkj%rYy@)$zt@^S0)_p0HkT8^ltG)+7KoOF*LwQAV^x5aL3^R_g~+!{*LKf-JC zJ0oiaw#gtAxw`a>3uv|KHqM;f?PaZ_@opdcx&W_^0Pp@$zU>y>hKUo}hx?Rj(X-sP z&78DW=K3xAPQBcy73*b4#5ja2&y;X4XNGH2C>@HG00uEP)hvdYKyya<$CV zn1oIrbBjr?z> zZss1lrB$zO)(UO#>A@Z=ljx(&R^Z!sww-6X&@}68m&gOa(C!kU&2@`BQeaW&kwoyu z$SNb-tnJo;_UgNIXo`IVCs<-wB}=UW-=o)Uu$nhmOn@$1a`t;qr+eB>4G8d3feeo|53_7pT=G z`uish4@d|Ykv3*r;)s!%pM0A2=_g4e1Cqy$j`8iB}xc1n{@+l!r%=I-er<|?1l!d zSVrO1EI#04YY>CIpjX;<3R1si_?kplQ3C$8rovu+WR_3pFwA0nD86=jDt20PE z1IJd7L>7&$Vo1=#QjP{$t`_-Ptq7JL+;xwU-Sffl-SZ}u8u?nYTxSs*EK-e*Z!(DW zS{@{~PUgBij9Wh#Rc{a~c(Q`02FLo*v{HbpC?XvJ8DDDtxB+pSAQK2u`BFt5ViNLO z8Kti}xfR?m$}6-j;EF-R^a7W1Ih z+-uN*ksbhXHXBh}uWylrZi}(oZ0vC}_xsp4jrQ&J^=Naq_WFC*m~@?^1G>hJXdU6R zO3M}7%!O{IQa`Va^Jf)!d#1|#3Y#%mFD|wjV|0A5#D>V+f`9w?!+%qzp;0JmmJalm zf&gv-S0uSQCfM6J&n}~emod!8GS4c^w@R^NeL}p+e|H3^9^9^Tcl zkp+{dq)wO+>F!gqC~#X{eYD-9Ejc-H)QHSaKFa)TQrh^j$zz8v9y=;&gn!CN|4^eY zNGl|d_D}Hh2sTI|R%6brsYQ$CgnQT$CXC6M_C?It;pr3KnWN`sN>rGSX^~ww-y$uv zO7OAg+a$OK&9jPgEdr?VEVDRU31Apvnx2~sj>GWp9?bpk3s~hfG*&?q5LFCO&oeC& z2dtK%scN|YH|JAmpUYTx_*g6r7s#Xe2Il3c|T18=5gnB8a+!v&BMYGmxR8TJ`fK|;>jVlB! zW)Rpiia-EU#Bz#QLE*4LHcjL+c!@G0YL&>MZ+&I1!@&1hgffY$_I2wUKVl6^bcIe2 zQKi>^}3HQCLro~B}!Z1OO726&c% zfj5Y~@BU%3^0%TyHpL((X~k5%w8WrYYSg8O?Apm6m-%}xmxR8Mz#9h-^iLSI@%?c% zX8qccK8-rL(`sA?8K&6)2hlM;492)q;<|xVP*IJCWE$4CxN7+S}Qbag(g{Slf@26gpDCp?$e6>CfydBb%Vv+2ku%c zZ*sHl@blW`@4X(}yI#A=-P#R#uU=knGk1amx0<@$Ej?cLR=cIvVmvr!QgeV;`zW6( zPq#e1G%)?kts(QWjoKVHbB00en)FGkR!q_f1;f3gBsS3`N4R8P=}K%b7AM!rLR*Y>e^qjrOoF`()w@(Axn2)KQ~S{ryw?{gQ_VET1qTdHC?m z4?oD9Fk$h?5lhC6%@{vEB_JTl&p#=^H`dc5*kmZ4H#1}Os5o!WP?K@x7au1M_sN|2 z{))+;XMH{~+S3-}X`9Xwffikerzy(Up7QSKAW!prleqY!2|+eF*j+ylEQ67U#v+>x z7%zYTjI9zdJl9=2*CqqN4w9h;Q$2K0-n^8NnkowGG|Awc%V_l)7H<$~h&7C+9&qLG z8Wvx}V2$W|4XTXAD_EjI$D@E$lOd`(vR-5xEONC#m$6tmPaQ1EKiAeY;A!eHz^TOn zW0eA3!V&o-wgOWvQ8}l%I;Xq3q^n#OLqp}VMD2=ZKUcY=JHNfeX;}KOVQItun(i`e zvC0Y57?55@;+YJ!jKG%S=;p#~3SSM0D~~2Esg_s-uu1GOutz?d(B^He08mY0lTm2Y zarH(4a_Jf^w??GFOT)#boG0rHe6NoUURx$D8k#rvwZ@POm_pi0&>v~+YEK53}#zsB+0>v<4&zg zetvfIv&%c4UETTpwVgNCm2aB`z#@PgV2BR9{VSw7r5)2z!diYu(fT`95g60_XXT0H*WP1yf$${ZszOHa?#Q;Y2K zOdT~_M=daM^9}4=J)HO4JUug4M=vn*L3TONrVX+i!n`dDZ93p~p;?advCWmZFi*>T zqZl{RJJfCtb+e|98y#-Zr@k{T#@DwZGBnI2=gpoG=jT^EYkKOa;Zb&5>ZlPbKmI6n z#E2w!k3dPvn=)xrMZwzq%*{2WRiVKvKmRms)bM0K@01b#$pL;#$Bj<(@s9Cui!kcK zjoJv4KHkfo;O`#eVJTfWH!i?8W$f7M#Mp}1kY$rU53w1i^O_KMeVDr*>V*~|*d_(L z%Yk+YQh)^(0T_nA0svlMlR=8XR0n&T7kC(EnZ(%^X_n=GpuHSXLTjp75-6?WaR9hR zAR0LeEixEzTS{rFII<1$BeS-W#cO%83BVAkI+21l&Rv$SEu7Q4D+U>cxz39ea!tCte$YzoU~$WoR9Ne2UQ9k^)6r|t2xce-0jIkMf)S}w7b zda)f6>5(3_W~o%mc8~US93n?~D~6|l-sL7;9JqgP`!bze>g`eDZC|bxS4skGQDHNd z=%l{!0o4Y1(!Mz7P3l76q`4 zGGVS=A!od_uF$DAD2R(JCTvwodU3-xBZ8Nlw-O8o{s)E!z8QsoUc6WH>#7W1|-emf_OXmvAf znJ}tUV0X>MJeFAKbyGJq)Ru5aT3!s>Ekrh ze>1t~|E|o?5^!?Q(2}$D)LbJw&%`Nu#m>>wbD@D2*+8oh=AoObr{@`&P+v3X@EjeN zIpwp3CLzMtZRtnv&Y-AJyDi$=H|vWJ7mC~>ofu-VM%Zn!K3++~{a4SNk~(7e@^{9A zgywws0noVei_hzl;~(EW|LE?yM|Vy=eR%P^$CsZ!y7cJI=|^|ZetY*^#+Z>|vK*?@ zLnFnHm_YPe|wJ&geH&_Q|gQq56l z@>4WfDqhKAYdE|PnB>7K6YVCkiYF=mF9$u%ri!D1lGjWP?Imn-uj*9t_PM64lP z_AHp*=5Bd@`_|xlV>(2pk!N7fRUBQ);DwYX8&{{RoIqn8k>cV6`R#IwJlDDA!P%Yn zPHw(`YRjFIo9~|3d=KK(mb=F{-8njV>&S)&CpPVjT9op)zkC-1;V1>1jM`ll6IzS5@K{OLPG$4Dt}B}i<#QC_SUmzlK7jJkA* zZ~S0f{n!yJP1>XNwFmQ8HTc>qt@;)ZYp0jJ*`#eY$e?U!kX_>2L`Zaz>VjeJ6$Q{( z#{}wqJdn)vC~Zd%1lVaX&j9c`i}As+zWc}f9-dmiw`=voa|64(^7i!>Jvg;)SKG?9 z<*COuta)&8$DY8+knOZ8-!S#cVy`5u9l9cj16m1Utxf_d?lzy@ig;l@Y&6sYImYDzK_q}s;6z~beLd-RQ_7d}q^gJ~45;fn%%r^ki)B*!D zQzGL1ZNct_V5>Mw#DhKbtEPW3Pe(2N^xe3TzH@k@CO#^0?6{)2v*Nt0ff8FZXYxD> zkMr?LA3J*4d+%gUd@p_U$RtnqXp1S*sN3FH@$mNPZ|E<|=hGy}Z|ZRGw6XqkIcoKS z>4gjDWK0~t_}x)4-qzUy88^x!b*%3~6Bq7j2(in-Zc-3({#>M=ImlfO@z4eVt9EUq zuT`8&<*9rbN>h03n?z7zU7P>Cz!+-AyfSrY7Laq-(Jm>a4mZyK(b}V@j17<_5-(XttZH3{uDNKWcBH%q3~rB?c)` zWb-^M8G5M$)&BOQ>nmDUCtTgv z-c_86bok=thbIRfo!)f5I%4yiTtYsF5u zg6O1;Zq_cnc7waM!>nKLX>E5ifmvv9Gk5rT)VP_JlbRyE)G*TjKwN0`aPR(EQ&-pw z#eSYC61yWga+$lOc>IV=H)Ec!+tA^8!vYQ&{iY8oEl8__TWC9kKe$ z&&wCiiSxGSeEvbS&0IKra-z5W&h?`}@5R$QpFO&8`ONOyR}bF2yzkJCu2V-hUIXKI z_w4pWy8gWif^8#S~xnAdy`%W>kWwHP+2i5w>XA2jkMl3|}NN3I3kp7G0F5 zCBoB^G}brD*Bawv4R_auSj0dRAK|VGag#xN!#(t2-iD~*wh&KUl)oA1MY(`o3imdL z`&z+8FLVQj|Kt@AN;v{mvj)sFkibCRi&Zk38lF&yMckr!%Q+0(a;->#-XeVlDF)^_ z1amp3sRDFCt3|q0nVK5%tX7Ez+g!nd4+nbHSx9(Y0NrF)r&Lf~SLejP{G~5^_Vt77 zF6`{=EKWbWy{&wCRBOrN?#dNc5BK*}t*FY5JGZm_){%jm#|G~l-*~a7I!`O1gc(;a zK_k^5zv>(cD}=WIQy{W60#h$h-3E4zh!^XHHb1u-9bYLiAiqsUsa9g^b$qqRG|NIA z`b|5HzFy{-CO1=?SqqTYi6}QN=jlqLwDjA|^+B+2MB>@)K1HB>-4M4XW(3SXZ5NeqR zJKb$UUjlC$?%irNLf%`Y<<^fIQD)KAcvy3FLXJ+T9pyhTYg)ER*YN&?5`T{@H$$dX zpJou3d$|oPn%h2a^3dUV!!i$`1%XAAq#^g?@~8K7kr=;?(f1Ta7wWEJM=NazeQ za|?CMY+e)RV_Rqx=8D8DTAen2L|Ndh*|a+SgE4a%EZNs1)@F<`>!K}&XuB!F+a7B( zrv~`tP5z{8{)}s9ci+8w6zZ$M>YY=M@1A;$p6_{P@8;&KXLj8A>hQfA$1a`RnLqjS zL^tz_iQ|(-`Q?1_PNY!^;;BUp9;Fi_bV7IbvIx65=aY%qUwpFSvkwD}!fZwz>7kGF zvqrenA7C707bAU<6bHKl#$wD!dl+N{ZhyEd z=#5GVr7oe-7ez>WIYee9tuABK2viOM3@|IQj26pbOYqOI8IM;2+Z?3IM72Pa((1LN z{jw=Et9Y-wu@SA+lrb3WJfBc!VJaXt*<~0QW?&ey-_*bUwQ1(3H;)cp-P`-sq5d1k z25%hQaP#D*Ye)L?Q-V4xmR{c9d;bj5VX)J;k8eKLUbfmG1HDVp0JRDd;AMnnC8;h@ z=&cYbpcgI~9X5UanBi+b8r$Y;LAN&>(3m-(+i2BR%WOGM0nFW=X0Xiwa5b9THg7%pWPtI(5 zc%rY~Ac3i9;+a-~hBpF%1<%~C6@gfgUs!Zt44nWrG&K5=D$uu@Ynncum}N6$+6+s~@?w*e zVbv|M{z=_H#DYmS(xAZe4CF#Hqs)#*E-;XDb=X291Kb9h*+3xKNQb(Kb0utnjs#zt zJl-e7DlO7dL0Tr<+m`+1#28<O5LnTI>DSKhzIkci-Rp-R-Z}Z?-kHbu&ON$y;_lZ+?p`}|=i1?~E+5F9^huIRG^c*?D5{VNUNznGC0o1Bgxk@+@xLd!TU?!9~ExbCr=1S@V7;I z7=umRLOmT~6~gT@M5J9_`ffnDhYl1t)Lj?mp$+zsR?YY@!q)^w8ek4ac3KYd&<`Dy zH!qb82r0IP0ft@6fLmIuLV*K3g)IRf@jL1QHV81A|fb6KiF^g6UxfzT!C?f-SCcGcB`Yrj6Y{_e>w04m^m z>*VIEhx@J_TKn~pfxD+R--QJDO!? zH=@gDu~A#36)LpoN&q?JrU0)7k?qn+z*RF#wnA`ZCr@>-R3|i8ylW`P9**weUSrG+ z+39W(eGl9QOrqZ{upPtgr!r#>WrSa;$=($+zrw67VbQOMssy%PV46g>MWEXte?UWG zD1}}tu>}vy}R8C-46^1<(ajS~PRGfeZpQ){}uoIv7Yc(7{F~1RS-V4l*zcL@Zd(Bm}qx zO4K|W)XyAg)dd^4dAL)wRU2*7g-h&QwR4iUJw#+v{5%3FJdmSfJZyc%%Wq!Yf9vZ0 zug>qfabefj7j|Dezvt-A-p=gwSWkPX%th+O2$`LyaZd4dTR>y6W^J%Q2J+O3aRI?1 zQ#5;Oyq`VBZYp0md+7%gvL}BMY1f6@5UVj>h7c1MY+^G%8X4)Sjqx@_xPy6?7QY{` z{L`_ab~(b+5bhy|xNDbuItJ4FXg^zIfO(Pq&uec5$Sk8NrCci%M9XLu$ZQQzL93w? zR)JNnVvwDNEh|}2RCO8XFpp#zFov}a7A*i=#t~&aajeQAyCpO(avFR34E23|7>HCfZ?c%76PN16Qg63(naefnSL)EfL%zUdvqXctsZ?fLY{p)9YpY&tlleA4 zi=|pws+}bvy1_iN6x2No+09VvczP|M%OULr-oQKqy->pjYh}Iz4OXLjp#k7Jfvx7* z3dl(W2Do+Hu(pP0>v^Ug%(*~yD0wwtzfR)NPLxI` zN!#acZnf$gAUw_8qy6f)w4+xn+`QZqK7{{8W#z8;wt-AcQ0v0kYA?1Sa* z<`tgiRMVfN7tUQritEr@;MOtGKbrC11ey%QQh_Eq7%(=FAz-IyBK0pS{H;1@8OWKVMtN6b|_Eh1EN)Wc@F z{w@aqZoHxxJ3%Lh~aJmTw)^J#3*-dw1+m*L%U>xPr?XW zl$RXoDM3Ve=~sR^F2qfY@G?Yt8-r|8#>Zn8n#B+=hH5YSTp>|1CIVZUcOLTr4YKRn9XXK?_oHInOY0eiXT8b_YHs0LRbGo~-KPfbC zgja^dCb>ALs#J?L8i-W%m={$#Tnk7npC*b~q8wQO3Q%m9sX-r0`v{+61G>|z#w=|Z z<=JV|p^R5XIW25fBQubkgIfmq-30F1!(6KuTTQwunJX8WYMoGLlxje+B_6WkVxB5` zJtwoHK;BEo3pCK1$kTvs97krGb!j4-X^?aD+7b^NY*eC?av7rDqHD1l>a@auw|j?P zTgMWBZVO8`lXwHAX`wW|AioN_Jq*=GsoE)ZCylj}>NZl;i@J=)k0#8 z5VWR&!Ru(Uf`tDes*)wk7#yOUB??J(F{!S=U0WEU4TK$J+%YN!R{Dwo5lvzj`YiOw^Wbz z$uesTeC;c&`XwfL8PZ;PmA`w65q(wmC(2wsIZLNmV5aAznfxgL*x{TPDa3-<1{%pA z6BP_KD6k$6f(D4Qj0froST&b-o$T`e=~$LNUH$*eV^wo0SKx2~tC>$Yh00W*pqc6X zzW`lecoC1MdRwD)e2htswHu?2Qlgt7LdOE<;WE28z+)k$4rK8_246&Jz%U0(^zyNO zN$$3c(E*D{*H8l=Yt={Ug(x@U(y{&#W@+gMYPvC4b-z~BR!++x|EUj zD7zf(E+_b!;=GNiBkl2iCQ#ti@ji*eZQ($*mp;l<2YGMCN25b*Vw8_D!b2bEq0O26 z{?I{r^8)_1jMfwbX0!?^Fi0^k2VMiKV&N^x|QU$e=`eG%p4M?#_RtR`0 zkk8_I4Eo8$))5|cG`5D;l#!|uQdNYj^Fc5%mkbqTzrzxo-cA}~`0Zp@g=Ccz)X6F* zSOkNeqH#@8yCkbz6rZe4RjUBqbdBqBLW92SrExI2rC<;QvPPs@M7Dpl*XAi7<*`JS zUZ^)qRWj3LlBz|zT3|qFYh+Ld8a)TDVU5Ir0vA#E z_RrsM@h~?Sq{{z7Z;F;rl-X1*AJ36Xbz(eEuFy+MMLyqdD)zAE8suxcc5Ypgn#&P& zCS8-o0FJyFkkE;>EYZY}4HVWy;|-*`iBLBHY(OTa1n$y;xu6<4Auwl0qZ#PMT^lji zdd#I3bE?LiD{$vB%%uc#F2-dv zl7UKunCK9N;SeJgWFUg{SeTVtAZh|-e7>L#60!NL>q1TqJs~m?Bw&jqO|S?-N1C+& zUJ!=|v6^@{!$QJ2$=4RHV}j5RmDQmfnP4{plZ!|B0?)xb5h9Sm91&yIfxyB`LIeT` zkJNH#+O_J&+s|V9J~ENvN9yIt(#%P~Np2_%uAnrfgsPBKt;SvQaF=Y%HACf`{@O(+IwLhsbU{2PD2+tG+xhKe zNR`#j=m}8hfoiH1ggS>(=TmqQOO&!?IZr{#S__6zVs=g(eRl4oMw`Cf!_sIJ>I`DF zj&lr3)pB%=$W{wiL07vqLEZJ;;w*YGXZd_S`ov}tq58dR1Yx>wR1D(3;-i~ahFbk zsL;H<26rh}04~Oz3xQs27%&V0JeOcjRk%wP?o^ApG{T-i#womuqX1w)w}VG_hI9!` zE3^^1=#J|yqugoH_S#MDHba$`-SFOswIjUpMW#^4L&jU{@0DfJwY@tEoJFO-d$v`# z%p@%{$%_rbGOKo}MOthYQ%z!u=}*!-Q%}v*5@?!t#WsWFE<)%+AZZOYQ$c0~ZKy&o za2sZZT$c#c;eiHFU~HkNiLwcST6`X-TF9w_bVQI$z#_EgQ^SIFY>0sgl}PkB0RtQF zu1|kwc(S*7o@&_A5#DoD!-5%XA?_4!H^jLaVvKyKKm;a0;|YaknDH-6gn7u@-lVyE_!86o=w&MT`5N_q+aAR&H{Y zlbo~n%F;KL@vf#DQ9HWYbst=0Vj_Cj>M(fR; zY|#s$%B^c9RY~8>D8>(Jd*1$yLkFX}wA!%Igo>F;c`xL8ov8E21`M^g*}s3Ab)oun z+9T7|X-)eJ!Xt$nOrk(IeM8(^;*{)Pp*D>isn~Mo19Mq(r$z`C_u_Rd!TtKJPegph* zI%VKVwggN1f?&>rp281(G#sB9gg5~n8QQp}DIK^OO--IH&@?<0Gk*nzrqY^&m49n; zM0BSd+~0)ZS@kY!adQ&?o2$^71_nwc&@4NKlcBd2&$aBQ0d$>Y6*krlTn29XEWwr8 zgtwSSdBoct{J_96`tFGT{bSWqIj+dHOM_aq$tVfj#<6|X9cSvdM(@0KA1)OR{)8*z zQwQd2-hsWcrNtamyaraiJkKaKgD(WLl3rE+a5DLSJu@6-m(W`tm9>GLCaHQL9MNH5 zvekcBT~ux0FeBPMlO-tE98}NbD_RO4D#9W{mQrnO#PJ9g8yD%DesBx5YCpkcIaZXy zZ3A0@=Cm+>q!wFmI6^%U>!juz-{^3Cq86LkTug*7u)eR$_@afP6mxo=y@ zMg$itN$-Rr2ZCkFz0Qgnr(bP$wa+0EUMU#Q>VE^WZHw+f2M=7 z6-wTf6Vc(b9uwJG9Es>?FnHQO^(6^}CvAMyV^BYRuG6nRLoHKw)dNNi>1_EQSMNUn ziX)&zCPnT*SlaBsbf=^k41qw(So zG8}u^O4oNBM7HPzERWM)XmIcLiYER1#3Y*hj+;reO?jWdRU==wC%BXy9V6?DBU5N$ zP`y2D{*(_E*j*GRX9$)f81R;z5&U@v!je5?-X~63K)7CjI@6w^0RaNr9|0EV`vwSy zU$Vxz7!;f(1E4xizyspc4@xmBU&NNAHegU7weu)J1NaOvqIYnFb9ZBx2z3Iva(1$6nFQ zFd4kt5sS_51b;KQJ+r;jvN85KqiQk&9Vd*8ogfLTW9jC z()HiiC8jA~w?rJb31UiD8WNgr7pxWSCN0cur77^FlbA%^B&PTL%@iJDTOG3U=eE4m zsVUy+!hQa5DIPw@Md2(Cwx&y{m-n%TZiOb@W^oM5FBKCxn%oB#b!|rX@q|n;o1xm2 zlT2v>qyf?kD4jx#2;cI7Kcox4${QchjK{_Df{5(lzH^qc@A1;ta#cX(gd%SIo`Ice zZ>vm(4lbxF3-vnmkdGB((@lW5Hay&8seb%|NH^)*vQTL^kOWj)LqD9rp*awTVyu zdf3RcVNF<@1(KoUW-(|yQ>aaFn_xSlZ(E9XItVj52Q)XFNF%;6e2j`trQC72OGnK8 z#h_h6SI{JNS@nQ{t^&iqCEFj75Q`H8RqjN;b7*#`}Ux96v?h-}{ji**by*tE<I`{aL_Z)%0Ir@j#d^Z9wtrKA6xx&>!MgeNanN}jzHBY~7KR4%YFhFo&1?$L0 zfy^}Kif`zi$fes$MQukyh2!E=Xf4n(PwuBM0dU!@zbO>ro+KR#wO?+U;exMxI!plEt83BwiM;k<7wXCtl8U5*oggNhV420@Jll+Z2R0VIe?4^Q$d6ZrTF!B2 zFsmCPlr_2NBO##)_E{!<*^aVIS`&VmC8usUmiHkbDndy%$ln>aXa^n6g9;2%)2e5< z=k+||2tF!YuW@{{P;euSHH#aW8-FHA3Pxw9N9lA+)@7HZ0RFvhSUe6R$yO~*KXx}r z)m$-~E;QywaYOLIq1C2&P3N+LDq~3olzAm70>2{QfDS+GB2TT;({vGW2gEpV8O+^C zRev1Wz6kj|crm8D+V*X*V(Qf7B(FxFO{ICn4p)V*Vbk)DB?_YXYOpON6lhM@HlhR< z`qBNH65E-29JRO-?*NL^fq|V4JGjZUd+2jhzY{iREIP|zHZxbLBCp3D8b=wu!Cz$U zADKFx$n3>E(igLexiq-rB2L%)pb2*7yQ$)iNHgsj&6=)AS$=GehE*EGoM zk#UVql6s&l@8D7lYV>kjTxyz$)p}3=UZG*%zv*2Eqz?FhX{}^BqM`y8W^^g#J1&vM zA7v=lzIt}95{)U%sen;ZBByq6#j7W)Ski zcz&8@YVS;<{2oyl07GoJPQR)Mf!gm$bYacQ(59Sqe?Q$ll<`MLo zWlEH&qxeu#_1c$%t_j>`F7HW4+*#<`^@cUZG{TUsx%X(0`HE^1sY7f|uQ{O;3x|@q zHcQkji> z@Onj&V4SCXBS>=i{NAKBbx7Z)GDlvOQEKZWo7wV8X zL7Aasf8{MObDtro4Xj8TXNPrBStxa_k&+tYj7y!0&J%>kqo&1AfYy+JeM}?(Jp4dz zV|??c6)(`Wh%{HsS!Rf6Blc3fE~ot@L9P@Meo_UupB{TT@$3ZeMibP99`$N@aTPP% zXS=r38CypY7%(A}?xfYKSv7?H9pFl_m4&I0oahIdsYbF?L=bzZO><+)Gf+#co`Q>$ zS}u;1Y?=wuSU|vQ{U*zdj-K+u+*W7ait2J=23FVQ`(cb-H0DH8r}G`Kt_e2+TuNl# zzsm5Na>`*Oh{Q=^O@<&RH5Oc&IyKWE2%VBZrHr>g6=SVjBX-5gH9#f;CaN~F=IQ!k zn8{A{1`M2H+bMH_2DdP#D_k=}nRhPu^e}cym5XA$y$GwP9T=0p6L@}NFRrd5`SQ!< z7v(v~k41}a2dhN`^wpRfnAH%;+V~Za97UFd@=AC8AoG#jWh-2b4g*!U7rHN)Of=E%ORgi~>^NpYZ?ToxS zrr7CZ!mJG%!P)|`L`9cs>nQ83)VH6u{5v?$KY$XFXr9J{ZWjJg$24&U{aIbrkcS&~ zUY+j&vBgQ3nn9&|!_2yJgX5Eq_&p^pL$_zxb3n}&z-I_CMlXzb#$Og_xvI3c+{GQ)O-i91CJ>* z$sVkh;J#zNHh7JlCaA(RG-=iOH}`5Q(u>kRxJ7)yP@Dgz&RB)6}i-) zb(_}O&;;Kp6LFP!gD#&fg44t31F(0pm(7}+_aD=e-O?8v7@K)O+JyF-A=GuZ8u~>J zZoTQ7mUIW&Dqn>Mm0_&r@hNB>#)=u`e=rp+t=Sx{=@#s|4RIRgWBV9<9$P}U2 zRC>nVk!0&IU-?=Ea{Z4sQVEg0lF3q#bJppE1R)JG@lBy7AqjEH0|rLPl7^BX++Ih# zVOwNum^UZ{`at=_0j;m>SX6^7m!?#MCN3oCWCm0#AEXcrguLnvBXan3;joS$P{1su zmpB9*d3mkRcfLFO%~&tLydxFmhZh2sa(X>(YT?$HbL&lVY$E1coLl~Z$5 z9clhscPp%2Ek`(r1;Ic34%iSel>Z=r)o}9@w8zde;w$M3+|dQ&^yZY)TaiG%PoE}3 zElFeq(MB4%^Saa`jkw3;WToSX-kDe8h0f%eS6XDHMus&LCvcl7TGOC^p&JzbP(%?U z^@t`mr6PBD;pIuao~?4p!+y&nM-;`#LvCMUUS*J#iDiXbz{bi8G2dBBni=v{z=|?j zmf;ZU`}8q5yfjOA74I+gJ0Ie&FI6lXq{vfJMUQP&S%S=e5E#CLstx&ZFxpVutav=>(uQ}A5I zJOomhB7GMSBn4^-iv@p!$7aWIf{?6zMb;wg4d1*VVT&OmK+0<;n^fLg{Mg&`?=QkN z03B9+UC- zA0@#$Cl-4|fg%P!QU_+Ya=w_U69vkV;0eal;s7iul(wA}LZIusIf~ek^mzlY1UWAq zStEYp^Lqn=LS4x=%jxPrMM?xv&Tu75>_X^(VeG5RpkafKP>gnP+rbp8ovdh6G_4k= zPJEi-(3X;o9aBgllabD$M$K+y@i!%)d?gn$0#5s6>hX6F1_#b)@n(xIYmC|+3cOAb z+Q{hEIq%UG+p?x5lM+WIyo38QcNajHeX2v_x78tnf@ga01oO4<_FX4on64C@_B&(? zp`G9BOvricoa&HwMIDN9-6yifZyASwz-Hk&QrngEki=^e**!KD;FBNUkmStIJgGROhtw;$9LmB6&R0c`v4}-(Hr-xrwMJFoMdCwr&mu+T z9R5QcD(ETRhg*w>D_Sh*8AO1MY9D4~U*Ez%s-L-87&bxRgrF$tmF)i^Mt&)|^CpU- zT}H+KjKLgt)t$IdELkizri%^P!>~~|wk{GI%-`P|_O}fQjG+E#0Blq73YNT7lT=kfj9EhfD+CohXCfJ7 z#mp#>myilzDe+^WOvZ4Mc#H)$CMjTumwQ6g@TZBr_yV5~#UX;U(L1gW1pdfM3%(hT zat|qEcExENmZN@bi~Bo9V>}P6Y6qX0wnxV##Mw@&oS>1LQH;n zV>uJ>s+;$fDiLodzV470s;~#cFX>Fcjna7??a?$y6=}VnK*9KpkKF4;A4P-fIhGHw zIY_-Q2E7r7Dq(D8yce{>sUBBYL{m@wShnMwF4Iq+;}q4GRao0%&g;m4Q;ppEiJOZx z&gsK|L0az~gf1;{a@=|zXXZ24US}}Ftgc;~!rpPHUvlRR6C8()}}!! z5W?pxQ8>O8g+ zSmiA)xsU;pq_K0$rhVB%h0dNjSF&03X#^oeMJA4+_a?xx@#F66dj*XwZ{^k$H;7WV1?wW&!O;me(KfzvKZz*y^Yn zdOfhYXLyk~PD$*z*?0=Y5&3kW1gzN*GU*Y z0`8-dw_h7XYWMHpULt8jUU9}=Blc618ist zTsntDq{K0iVPNb7IZ4t;1R2~@w_wuKALQ3Vg{lhS=&RqnL{NXeYjwqN_|z#IDTDO0 zDsh|Towu~Ys5lmP!J<6a?314=o$p`3j*O$ds1zYVT$B-{hI)D}ao;wo;r%7QeXt1Y zaiN<*t8&D9JSWm%o#K9YVZ3<_B$a|@g$Sp>e`W2eTG#`CP5h;ephnhbdlNyWtCrMW z&aITNF7y*%U630A7utd)=KRMo@MfcAwPZvp801bgSHY-|nLRBFbpxA5$C7V0T9NGK|l)NZ^>QDSUWCR;rD(r9luvMlSob z4Na=~R~+JBE@G6JgrX|0tc6D9=Cc+)b!monn*@I!+{AixhJn>FH(9~ep+sPdG@mJEkZGkgpIz*Td<>ml zYSb-1+E$#7Y$T1rd#gjq7rb)pEtH`|{E!;(vMXbHD&FyEv4#newwehY)Eht~%OnqI z3RSKuiSIXH}La2gP{4l2VBLQ;2new^3ItywWi!=nNWpgcCx! zyI+aq$lRr_k3(^eF~aq6Tc<=t*HzQKoq{d;t};2N@-Mz=SBQ&bBG7~d-3iotC_=ZJ z%k-I*B*eZ~;`iLv6u>{n3V>bGPlevRJ(xvOC1|^IeOvXXOKaW|P^2u-4BD9)+P#zN+ zx=47vkQjQcg~?}a*ZCoqx1Km)0f~*Ap2w7im>J6yWN^l$su$@51)CMhfR7a@xH(9| zdgWY{=iY+W?Z~iOm3JD+LWr6{o<`6vbRhB~3L3;c*o_qzYj7ic1pM{=f$||D-erp` zK<&gHX-WFst-vOkmllqV>~CjPI~fi$QVRkN4Pv5kEjNnKbB84ggVoZn${qWv($VN5 zqooFrQ0ggF7Di6GnJE)hK-~jtbF^BB7ijc>Osm&44D=l_IJR45NK%`6P*&qgCJZ{h zqo#u3b1aN}m=>iR^>d$Frw&q6zzcAqh*|X3(c49B`!|E8!LOaYd)c17o53$fjfirY5C3Q~uW{JL6aQ$CXELfC^`8C(JQ$h*u=mrBsey9k9b{9o z!mJj@VS9S~i&PeWbs`POF_TJnTrK#Ghxfj`?S2<9t^fxe9MuXj4$3w#DlaDUTt{k# zDWjag2Dea76RlmUlQI$lFwwGM+$W&!r5#*%FWLhSzU4cbDKC7CYNAF$&|#cssgd~8 z?f&HGmzsPvwwmu@*0MX=-|E^Bd9YZ;^xIrCQ!!D@t<%Xam3$U~xO4U~e7p>#Yl2LvImo zKj~;C?%W@M&>4J%7ETaN(XY)Gs6`%Oo_jby&7ZB7RN$#WzdQXInugVYCZLOeZcPaF z=XV#ie)rM8LAmwOJt>L>$FAV~U-0q6%x) zww$u4UGTy|st57F^Qz;0{)|CWgA3U9d8}?RO0^#EKcT)x_Nb=x2<2U43iY=bc&H4Vu#o%l5P+N8Gw6c0(kfp)y6N^!2LG$*xSSiH3w@#}Kh@)r62} zPyvkp1`L2}Zi|9rX8ea$rEp6O0535vZh!xUjotSS`!;%Gr-y%&=@lEp!`lLGY zm5H$85V4y>@REa^v&cUWGGeV4ndKyfX*H&QxWopSOzEqxX;3=XQO>DnB(Sf^w=5ZB zqM#*(6NQJHj)*>4lK%??j$c1jTkpGaD0DX0u{ApN^C!<}E|EUx|6eK}I z@CBZ;GK}9Y)=uaYB?c?VnE-h!3z?3Gc?pe90MV<&Kzq7e6s(V+j`s5(Q6++bc8mo^ zWG!U3;3F9UxeuzAH(yaAnGqw`gQ#2ZuXm`DupzhI?`3{zAT3mxc1WIyeN;RLmTn}? z_wk({WRD5n=V*FjnS=XWU-CX<7h*tD!UqPRM!;`C1UYtLuxacd5)q&>Rtc{0Tga9m zwrnL*OyrgqfN0HA$nAij5>{(A!ws_HeJoyGq*t${SMZ^uTM^BW5%@OGYB2|`BoXfg z$%#d{=|ZGQKe4k2PN8bQAl-{zcyR0RiOP}GUnApWSDHh0en3rs01d5+s1DFxzlU`a z+VMH2v-ir_JXOI7A$B9){e`sA zd@e9VLG{g@>nx>!IIZ$^#q9ai?ZokjsNc74zvf5PgZ{g{PWYRit}Hjb;4XA~yy&lm zRN-uc8%E$L-l-T6^f-u2Asj%j4e*d#Ms2PC2Dg@)@`b)4e8kc~(j|#ix@zQHQBIR8 zxc3XdL^jSj5Bu0Gi50($jDUsbeQ)i|d&m$fKsxBS+U$~~gNssZG7W|X*Teiop;BYE zWw001^j}Xp$>W{G-hZ#R=6{qvZ=YU2y*jeJ<^S))w}t=jqlK6bE2C8*^vjpE*^M=! zm$kJ|8*AbS*}ubZCf{58`9AF?>%Uc|4mn#( zw0S>Y#+h%d2JwFp+|JA#&ZDgAa+lIY&6c+9Y4aw#y?y%F9cFKGU@b8=B#G-w!cuv(2`If#`xq}XjFC$0K8qlmyy&sQM4h8P#`S+IsNE z`+e3&!)qiaE%qY-93ySNv_AcM*@0+nZq1S@1magUdh-1(p)DlkJs(2Z6LK3uX?iK7 z_Y4&7`J^TEW$Cx)opG1f1rEZs==0^nKz>WeJvN*86%L9Qr92AyZs*4Q*=e5tIwLz<{cj)a1@V99HC*z~^&qNyE{;Q(eUzS&349{z-6Td5_~LuXuX z9}MTh17vAr_=b zs<8g$GPO_)z32KZf-EwY7Ym4?jC|~}~NU}!fs!B+anEi)g ze>l6<6-0(^Ejob)N}*Pp1e<>7oWZk_O@*J1B48AH^>pgvS9-EUQU4Evw)~ScoIz>% zg2=D~8>z3l(@~l`fR8ZB;S_UR z8vRVe6fzDsv-Jr8&a0sEM?)yEWdx97DbqD0?d&9|!2v=b0Ff#8IcYmM8_13AXDx{4 z5*!Ik6%n@_@09oSL`pr{h2D?qOlBxE1+Hn4@s*~;sTNl`&jyJ@jf%SNAW-Zd7)$}- zK3Mbd6hXu!ur&7riuxM0IJQe~X$V)C7@cQiT_EuO?w;Im?i_0!v`juO+$Iir)P^^_`eWqIDG31q91i`xqMD1~c!;GV&j`Cb z+2xA4Ab|@Ww`djsW9h3cfGj$K2r|LAjdl(SxH|ijo3nQR@U+5cwElDx;TYh512d3Q zyuA!F1io$Q{|J0}T~F8uxH-5cnw8?r}XDXO5-fNd3+jAUI}owJm;u zCVYZr5w^Y<{H)?OP2-1iO`QtS?=B(qpJWh_Y!9C!5*Llm??E~xHap~magYg}m^ZXP z+IpRLl=dKEd+1pA-iU*UVtIw1uivr&OtH|!{%x!{YqqH;5`~|; ze@{~hX~eO8Yg$5`I}!Q!s~pGz!I-pf&ke64FE;>A!c7mm)9elZk8f)S1%C!0d! zAF!5iycidlugx{uTSXh-hm3;OD*lMT#B6qBRa9|Uo*(phXcd_*JteF~%_rye=IxWD z4>ogztLv?m;$G4K;Cq`Rh1L}e^dRO%a>~7>_9X9^?C{a4;G3!W|GnNY7JoinBCQ*q zq4}c~cNX8jcjGU#yEyxEehvlEqMk-_(fa2HfOF+wo%$w`E54;j+P|UmQ(oe)ip?N2$OtpeAb-Ube=E`~?v0b-ndB?9kV^ngH;{kq;XRT2u?c zb8on(2nOV2F8{@164 zFhlp6x7Xjlh%iC!+x(vIBKumG&;D&Hk7spOhv&_9R|VmjvCz%M(EM#;9Ji7PBS~)XVay^*o_D#nWeLO~j#KZ~^ zK~mV>0#b>CJs8QRy3gbTgK!f;m-}*#S!BX8eitOm}Y!-|FP;2NbJz$rQ+Sj+W`LA zTP@>UzS9({0|7=MoOZ;L3+t5+zSMNxC03d=xa90eb^mP8a5JZzumsfPT!F5z1e=K zI8ez6xH`OTvR$0aX?NP~En|a|_aVJ&(uVbNuW0JGmhwBQ+>{%p3So&bYdO@6ENiAV zxc(|9Pi66h6f%3te^{@6>|aA4>^P3`Tp&2HuUcJHbN|t@B@_76R%M%j=|(|$BF??! zZ09=s07qJ#yL3B0YOfvd&>dj*R9F+=-5U71R~WM)w7cuhs4fbB+_Uf_f621(PoVQ8 zmCV=$cTx92Plu;CEgx(`|NJZ$x>HO>TMUJrGLeIbVAi@YBLu@A5z2gk9c#uy`N)-g zd%PbhssIo8er4?AOpH!7xSPE25TiNFOW`&ID1tRPdWvJ=t!oF$GbjK9mM~7$^S$CiS1ELxsPV4An9;>2H*$5NOmM0z(Dg{aNHDcxoK9g!_C`qb`24%VR0(|DdiX6N`t%Ut z82Ab#=z%>^r7)-5sfvW?!_l5VO&?q>`Hnh95Wb=8%M?-YZEk)nr^qsf)*BW^kuk^X zI#??SL>m-gclEnwbL|cB8q}@`zI(}b#URg-aGmk={N2}vVRhkoHwhey<`R8*dEw!p zq)P4fz1-X@T@25l}hzcH28#yFzr#S$;Zv&X0L&7Vo*6UsEdOpj`KOnY(rE z;Lj!@6K%@>tD(J?RPwbewZbFK;*`;#T}T-*OdnDa^S8QgU!IyLBzb|n7^USN{SI~oFsL<+A}xsBVIiFd-IC%8 zb!VgnuSqz!sn_UbX)XGR-$+1@mg6A5^eIF;U%QO_Ys@kADR}|O!+}Ii7bF`*3Ibzf z!wFeak@R%*IIY{s|F#vU1Wj1`B3Q!Lel-$auElLsiNFg93cS0I(Ec6p@K74~{F1)$ zdU*$XV+^tsM3>L=-|^v|?nf{PkBHBx;59$w-~Ju~#1}CXFaPOf&D9FiuAD<3 zL2NT_s|WngbZ0}`aG5szOA;ZILxPjE_EL+6u^kTtPO2t( z6EvC)PK)1L|DwhHWu0)xsLt6x<|Q4rgh=mjr@uS6(nyq4rrc|IUQ_eV?bher8z`9) z5<{kj8{cUrv^-(|y>6WCn*zN zoB|dfX+!L-ZY#Syj{qh|t)efsc^|Di_X%F+-@=R(+^DAx@xB@>xV=o>H}u!S*;)54 zFFF-KM5!F0Iw_Ij9loILBQXeSl{;13P_g9YS(dse+sNkh@M8RGkI%*A_cde66_2a? zoWBvC1{*zBGtKCPp7xKA7iSGCh#Y5s{JalJDxO-5);b<43RkKrmR)wXa}c#}CAz)u zN4s`5)@Ac|moOCH5X>!dQk%v^Xv~r(X~Xm7auIKGHL^w%Z-qI-DSlSD6m@?JKf}Y8 zs|f!uSwieWafwt;{2=Itft0_c)8w>XNjYsj>yMZ`mWHG;LP5SN+|R`x*3B+wjNtz? zu2KVwug;|%uSfxpcRg>9e>o)H&@Qi3Bwn6p6C_?Pj)%250{w1|ODO|_?$wYFBj&9e zi~}B?Hm1jc`?-Oyucg`>-F`quao8@kSXtn8V_fWxw6Dz=q_)=a3Xyms${be zAFU~}xQmHbxuns2tZMvn#AY}Q&WN|O>+-P}UyFI7FcJYp7Cd3&X#oupdw;yVNpT26 zta2m-V?aa!L6zJoT!qhAjdv;>AL68ppP7|uuAV!NX(TCT2CVLSMRUC#0n3bh{$3Bg z+7T_QqP2UfDpzsRkj+1oIekp`JXx-9_fMFx@Hpn*g2e0X%gaW<6LNKPPj~Cp9pPP| z?*m}@?S8AzQNsV}Z-so%%S#7rshH=Gc)9-jyGOJm5S9-m3&c~1cIBVtP z-gd=1X%EXmx8#Y|Ci=t*pNd|a_9>;s;yVe&Yx~O!JycQBuL6rn_OPS-w8XbEQ?-9j ztr6C|@X+95>=ZZ1liIR)+8rT&YjM=`yqqxoTqW(5n#q#0q0K$y*z56nu~ta9vF`it zezGvalR~`v?(lL4F@a*O&G+s$uBOJY)9GxfZZ_gJSG4h9?lqg?&Q7A(Ge@EguJ!eCC)pV99M+~o~}$h|s29!bIma66!o!&i|#IVDJC$CMrFF zU9#jtFCt&=;B?AV9i?FL(x0RL*Ikg&9ML2AzV8n#BTALU3j%VYp;0NMDC1lLR)Ztj z8sA>ax;Bi&Z?@0k4(>M50{*RR7=xlE#Jaq%uH%(Nd=fn8PuL8b_*{?DQpY_i_38vT zY+a3R)1FUG+jK>)v>jOV+Nx+AT_29)ioHpd{_*1<*fEc-*9%)oFZ^R`6AF3IjnMzX zabobcxjf2nR~ zAecmOK;D78&1KDv^{w69!t2dKFLOKf;nuXEfPi8&CXr2eS=s!e8nSW55KV z%)p1U%NWNq(e|hL*3_qjl9Z0wfnCQ@bVqHn^c!= zp8N0c+cmh;l}9~(ciw9O?JC>KlM0TAr75)*+fNY)E!grhNary%68?7E^TWfzM zy1gz~45R~}7fchV$@-r3k4f-OOo{MMp%xjw2Ej7%Z#y0yonl>ReTg9KmWA7SSHyKqI zAv5&R3qGsE{;y zRGZA#YV1&!xkIj~c=WvRj}t;<{Isfpf@gT)n5Ya{1x$<9us$-Us z)pY}pmy3PW4#bZR=Lk#zH}^OSbuQ7bJvKFP8h9fTn81@m@3?B0b&<(eU#lE3!I#rt zg`3b^1L4Q}ZP;VH3ajKwPpP+_iMM)P&kR-j&&y_Nf4=5;zf{j{uCjMrNNzjnVAE0W zIWTXY>5#ShZ$2t+G2XG&qw(!H=|&r~ro+YJC6(5;hAcSfR`{^f#qQ#98htSV(?F!@ zXsqtTMSpVb@8)Cj)CxpbEwoC5=3>D+C*PL`dt1j`>5abU+rQ)Kcjp2AyCc7FeI2t_ zA1=luhr__%zqqx8Z(jwL-Zgnb0+HxIHBsbWdQH{8M*de1*o!y_V*mM~9j~l8ttpRw z9gK9o)cJao{vOjfcvY;^`{1tVr3Qc86(>vJIf)f;hI`~dq-t$MP*(^XKhDkYiU7i zM?q~xeQkxAySA+4M#fBc#=qD7Xy|@9+Zy`H0{^+rO1-c2aCaQlNOs5LO3N+(t$_CJ z0$xknp1XGX8O5QHzuQJ?OzH1j5s%A>>8BR-r;s@; z=CG#Gz!|Z@3^WMbvGkz#cHu*xne!D%_Vh`){r{F1!KJdq^Wu})GyT!bUde5-$aDG= zzMa+lnJJUmwT6O7u%q~Cq~z9D8zWx?`z#xdP|WRHO2L#br5(>U>>#t<{(`UFDO&pU zK7%k$VNKZiYW22|wEef^+Vyx$>BS=@by$1-o9ZWLV;>ilv2B08J;IhdBZ-F7zn?-D z<12gI@}9PH&QN{Z*-wu;8%tldCx>E0GTH4aIvT5P-2(T*s%{Qi77drw0-b$d2Fc?H zJ@^blZ>#rXd^0%C?Rz>)cV^b(m7bQ_&ulvyd#?U<=UhFtvy&fp_;kKid@JGdELI$R5cE66A-``iJM#MV~gJ4k|TV# zn>($E{$*F4g7N*&7YUyI*lq%K?)5;Ir-@5VtQj47%cqme(}yQ?U;nh|9N*$D*B0cbh}iVt@6UJ?HK1YyPaN^QjuI8|!oHXgAl@xwzWi zq{U~f`LjJCuH2zFQ!X#Nx(zQEt~^q~blgDa^^SaU&^L+Nrn`&g?g9PBTl zm~xGoHrI#WjqW?6X~%oc!w#Rr!Na$h-ScF{4*llZI7F|$gBHgKQ%bq=?t{d*f*8SD zI5BNQkkVx#j8B7rrEjRLa%E~NMaxWzJ7_rM#UuoU!Qnjp6#oabKuf<7?ht3^FeJ-R zqvsq0&yln`iq%9i>PV=0BAg}W5w2f2{Xa7(b;@Y(nvfYAvttj|W}WINKGIycr7UY> zY4+xl?DnPc{l!_3&mZk?IlZg*&iQ?hzdAN_n3RG>q#Q}FLu?(;q7ivyo=-i$50Z7} z`v<3Pp4@t6AUfSPr zX@3`77p}mi;ZXO51Kl9hSB~}_Th}m=D}dgJn`i>D49 z+PQh#x~_p1$Wfd3ZRk3(weQ%Dbw{@K?Oxk7*jT>4ws>Px`A$HzyKZk^>!E?pBb$1T zZtgv_v3)~RN!`ly)p0?~7tRR(cvvzWfHnLl?kPqte>w;DgUnZC4} zr~0@rm@p#Z(+?77e3l)(s9GoolxB*YDievU{*&_lC}0gPmZ=2U}};t4q2n z3fDH2Z|!Z^y`go-dXVVm?S0K#+Ut61iu-Cx_ikQ$IR>rr5&&>W{RE%A> zfKV?YRFG%J@gy?FJPF1aDIu+iBvnWx0a0KHkqL^bGypb@6EuJ{gs8>^I0PnPE#L~F z(CZq55JeG-YUgN`6EtEqfU!#qa0@-kT4=xy(aY7qvy<``PLXQo2sPAB;TmU$14rm$ z==tP|*>(vdUBW34YWU=uaKIQn3K9d1XJXC^B_@5mZ%xRQ?WO4_yNZsr7wxIf+f|dh zu_(K1Y08GxnY)@wkMuWPJ-l(~Fe&A&A(>U6g+Kt`KZEYLx_|c7qjR@U?>xS){n51( zPp%#M_UpsP`s>%F$865cIK95{!rt!d#|98N2iIQO-*ahi=cS#kSN3#VIna6Ic;ETK z>Vf649Sgs#d~Zb6I{{T=JZt^!HGZ}#A9J;zrQX-v;0v{-!Qa}5!q(t#fd=#|tE_cC zmO39;bgK(+uN&!EKi+T6yTe9j8ysv7>twSA`542u8+;MSl+a-wo-Eh^obYSiE zBmGwouDiIs=WuiNhOF%Vyv%zS4*vb;r$7Jj^H)a>oY}SUn;XZTKSEy!DZ&f3840g~ zE=qt=LrM5wJp6NG&Hyb+Xi)sog}!rTwmy=(W{mbJAdjd{!0HI$q=yz|`A!{<*OdGg=}C@{kHr+=dRd;LGr-m}|! z&VdK%sM@_IXM4%AJ%vj*E{iUj{9cq*4rcLCS_9cEa>eMm;-rErN?8#n3bZI?Ra7(v zS2;*ih;(QEM6K&lsTmA}FF4v>bg;eTKvT)a)tS9nsT)>jY%0zk zI!sDYz7~4zoY9v?_s&4#@$|-t2WR$OJ+ST3SErv`J#u~PkG?m{tGI-t4#-uW;Z=Vle@mju5a-+qVTh{_*q*= z*qesiYQ0SrZu%mVR5{Y4e)2o(;^*utNj$r`{Mw<`EBo3m@9VmJ0A#rrjKJ3?HlEwP zc2`5$Kwj>a%Hl^~pZe|BR}a3vaqs-e+h_N_cnFRI{@x*OhtO4AG`fEMY3)@EGni!H z_R0P0*DoA9v2VxTjq5jewQlZg*uB2xFr+bCd-i~`b=Pn2sNL34v!}P=#I~NJTRQt| z3#ymKWd+Vm{OsM}(VjDH@(eS#$WspWHADLrEyXv2MBtsWvOz!(`|fLBG2vP6xtgpag^1lSgM8|Jv{Cz-{G zBK?I;J8P6r*yr!2ht96ZPU&y2*g4p;XLIL{^=(_a8n^Yd?C5LRv!UbvN7`RT$C2!7 zzHon=5AT{YyW3JxGGk?Nm6&Xqsm*MQnPppGp=}vtkSu0quw=$&ZZ|XS-p$>+d($~H zch1Z?bLag>$$Q_o=lycsCswRjQCTTfDOJCGo+lzQ>(zUUFW#KJG0{8Q(|l#P<^!%Rn@gPAHYbGgl2LD-Jk%w;wcw9tqB%P>nR zm}+Z~YRn83S!>K(V167<2Sw&(KraaIlJJt zAvv~Xd3b0c{5iC_fUy*ESPrN$VcBVUyfn_Uc)H}p!LzSSw7xml^U7HJ)u#HzbM+4o zQ?Q`i`!7(JhMj*x-2U+4OFz8(7CiT-FWz`@u=UER%DY_`|M1@ZFWC8D zen8>+WwsBh$aM2ekHB;bbQix=nJ$3}Zb7w2L|;|hE3&;3H;BGUoF6izA*VF#k%#@t zaJV)Uu8%~!24Y>Ue*KifHpe)xRi?Z$dgk3*J)gcZ^U=$*pS(2x39|7EU%qqez2~l9 zX>FQoJoV-4PyO>>zWVEr-@Nzi^WT5?+F!qY=bwK>&@Q3-@G1q+-rq*=zx?p;|Ltdx z-0!~p@ZAT`KX~Ep(^qD0j1Pd)LYjU3skxVKOx_slyfxPG^3{=7Z;Zcsd-9DtGmG8l zY7cBZ6z)p)>)BCyQM|omxuZDVUKp(wMM;HGQeHTp?PIgtY=(nMGssjsmZVyfHT0dp zhZNgE89OLjp*l>U}(Y{SnJ!fBk`TFb6UVZW2!rjXw3j^(UXNTW>?&gDM zu06Xrc6X|OaiD#nul42oH{X8c<+omX?w|kiEkvpyzz?PP;X!%ya_?gGy|WcFrD+YT zqB9^LT9)Ne)-s+t!r~<$yto;Z4GC;;3<)LJpotB_3FbB!R)JNBslm1sT(LO>_zWs) zC_sA{RM!$xL1IU(fNrp2<}%z`ft!yJ7HBI7GtdkDD$-g7En%s|Efvs`)(XN}N!Th0 zD4J1ej_h$kvcN%M(B^0^70-JT~etjcFq_ z22&kcK%ud&BJ}MDSSo4R_)q_zk{HiaMdnkT$6udpduP56^8drb6fD8{UbMpb9dv2p zCvX1k`#=2O|LgzyD}3-zmCqfo{^r5$KfHAl+0hs0L1y2(*8kq^;g4?&P3G@yit=9a z>jN>a;W*D&jB6AW(x;DjfmLNhmqt{fPhxuzrBnw;w6H`ogEiB5Gi|#FmBKC()(eE~ z9EqJHZ0AX=5w+H{IO?A#Z5K%E13(^j?$Z~>K6`Qc!{?{r&42PT8qogz+qYhS=E}hFx~KYE z|NBqqzT{uN`Q~S@-bWX91urc^4F8C7?{B2{Z{L3R`MYnw^z@6juic%UxG~=I^wo*i zpPql^-t2P=!?(uT@6B|*c4z#RTVqep^fcPf3)0gt>#BMM?&Wh>o>6A-bv;X<~b z&Gyj1TdEyT)@(_tEm^}5sEAd-(h8j<1T7G21!990+sm8xi`YKFx=*m|7ooN8;h_WD zEqgfAKHj#Mx9t}#@UzJ}k!+AD29@fdvi*Dx2zZRWFy3Ae@63oa_Ir%YDz}`*R>^cl z>h}48=I3uszxm?rmu}53^tIod=mUUXeQNQg+n2#t&-Gkd80viOnOk?REWZBgGr;h_ z2aPn;hX>`+OMk}h>R4YUZA}AxL$Q`9WwBy#$Vgz32Zm37a1hv3h%g3pk+h;wCBPUu z=4FRLV9ie;_lsmUv;wyrwT4vUpsol@u*YRqGZ2X2w3(_2%Sp=C0G~IJYhtO>Hq%88 z-8T7zE%Z2HK1rI-&{zXyJ4smT3G)fkT1Q!r)3)Q3wVt%q5?CEgR8v?PZUJtO;1+lr za3Uy&SG1YI0)Qq1#=*!PQeZ^`UAYznGxQ$#=Lb85fH8;Va##v( z-UokUxN#|E``t_RFAraQc$k9avH$kt`+xoRt&g9+^*{dQFaP`B{_6*KXC^C;JXjq2 z;=zs2AKdu(^b#tVD`rO%%UcU8j z|N7s)|NQemJb3u&a8-NjgTGL~Je1vZY{h-gmZ*NG_@l+R?>EpA(dxyz+FYG*(2Qi5Y}$(2D}Ah*I#tK_?9P6Pz$e9H4?+F^DQ|23E^~BAW?V zEyqojn5EJdT8V|$)7H~8)~+jkhJJ~ox;Sb~6E2aqK~?G(=zc{W@w%_CUDGY`Lq6wI zySH3l9XsfdM_pRKCeC<`ai7tv3#~HK%-~%ja{&~HCV}>POXyjiIfk3gDLkAD;ABxj z+5q4q@am)$WO<36Uxg?m40bOW8e!=|bT7Yd+fdvg#LoFc85Q+0h6JnUMzdo^VHxU+Zy8@W*s1e4EI$@igFcp2iy~tdX(-s8CNM z4lO4!%L$wLIQ)?Sr_EevHPu=}p{=oo)&~2~*4fN87SusIplYhOn&Dw^9}7H$jkVBP z(X+<^c+3R#6k$F?qA%%gWNa5W`~pw5$Xu&kXm$wAZmA_)yA4QU;f|!^S}Q1QM7@i~TR(8h!o##0%F3&*dejM!5=BcuV44MbT=0 zl$;yj(p^-Ffu*9mv7>KDNzu{Qg(hj_0h!z@VS5B@H;?V&tvfmEZXQRK!*{VDr}!S8 z+R4I0au-KHXAe*A5ujt+!;*VpBMm&;b~6|}+(}z@QkE@L=nlrRown@aEbu#F=e+^} zzkd(#EMmJw%O1h9PqZd!SgM1}bhAKmPMDM*rDaEIhXV2zOT_v_7S|=dka}Qo^Xiw%i)Pm>pWV6TetBWHUG8+seG%?% zk?RoX7Kyqf(A}EQ=hk`*dC;r&YQpsT)t|I94nzbV)RezeoHr2R9|-qc64^!uJI9lC zw5^T;gAED~KHLiQ9wm^kK1^7Pt!4`~$-!?veD2eiuYCC2{Cm$#|KZhz*XG(U z9o$r`vS*^)ZSk(QaIGy&?er?`hS&;GQ((@s#910YP1&HHB&;V0OOPweam<2X0}e4@ z&s<|QRa--rK&`ffRv~(!4XH+LXq5$ZYHj9ft7)lUZ8Oz?rGXA?v7+tO@GNYxnJa@o z4xMAR5cmx>@E?K~!c299={N}%$a;z;8WrZEoja#_-#bg^^MY7-RRt?*|235wSW68hb#& z_khtAY`Zw15m-fx?Gea*A{8W!*ee37z%#ysvF>E>T@1F1!J)H*vh84OTM6LPx}CIa zCoDTC>rNWm&EVSz%P#29=ttlOf&85u29WP$Y(Vl3q|De}5#J-Am)k4hyV0wg_eofi zg1$>B#X)BV#GFVeFGkG>S9dz)wF;YaLZufp{!!l+Ygc;cU$ z1*#r5w?w!v$jsRCs2-Qr>(VZvuhc=`UD71b=Q;AcK!VdgMnZD7g0((MqP7?dErkG& zhN+Q-E;5G{m>*w)xxoBHuIYD(Wa~0CG);u&f*=Pw1&p;&_%*#VCy%~7HT3OA&wldK z)eoPYegB!MFP^{rV7@cgsaJZnrscloXh&0+-WpI^T;c_pJtr||c=8NGoFr}a1XOD+ zZmq`5)fgaWsj^xSpO%m%8jo3)Au_E1FvzBL31(>F*?Qc%)CVjdZikJ~fl656tO?s| zaT|bI1J1_+Fqp^py~?fLkHk}Oz4F;>SHAq{{?*P)H@naM`1zav z_CNmht-H4$9-c=jPtOnBpXq+)a_{T+r(VB1F?6Qv_<_yYk@mbO^=N`4KTODSQ)vz~ zhLi&6+R;}Q9SDAv{vME7iP$X?dn9_VMDIqp(t8AIH%~38>kbBkx^t0dJDvEC!w_g!++n1wrnS?+bF2!t)vBn8tQJ2fZq%)>Z8*HfNkByS$FX^ z5afN54a_#g<^zgt=_}DPy=+!M$ca)iBh=(@ZL=n=R`}d)YkSU?fAHF^2TxtSJuz~7 zYT%{Y^KZX!>-ihg*M@&JxbjG)kT4a3X(Z6pYcY~pNVB0OW>c|gS#TU^St;_#Xdnvy z<43F^$1n@T*E-zP0Fer_^t+8Nmg-=zF|T7GF}6owhaGAgNAyVaxW|}}4!gc_-AhIJ zujgkxw{OS2U7Hre9rt2=!#p+P(Pv!hh)hlC+?Y&H#stQ_#-POXGx(^=4NF`fN5jK$ zL+t0sDW}>kP@{IKPhm#ve7DF9Xvl|lfcq2aHi2o8*jAOhz*A>A?1Dg@nRF9$5N*${47J9p@Wqn8yV^h zgFzoUXVDho6p6#B;W&xa;kLh5>q(M0K@rdgO+I2;RtEn>F?;o*6d^4yiamu`-{aesR3Y(-wYuQbtDn&2pjQFHwqWZHCNY512)wv+pT zSP|c=P4p`FGEtqK=ZU#QL zLB%awann}Z4DFNHvS0^syA^|tradf@<(*4}(^epVJ7{w7EU+DEuWcKEP1|;Y&V#l~ z%wCCsSJ}ascd}rl@t`IH*jA|fWa~k@E!{;p)8inv!6_UF zw4ec&R*7o^b>+wwhP=CX*VRpHry{-0HcK-@3~17%#Lqg!m$Uc1Rekt{()?%A_RpDvzV-v?MZ;R)H7ubB zY0zO?NInVlnjapfV0r9==Vv~6cIxZ5Z`|%UUKa1G3pdU!_neP5T4VH!KB>_u9+#O@ zDpy8hRV-0O6XgU}j$6xvvtginWmW_aU<_gi^*DipR94%Na|X!;eQqHC&Ll&grO7ii z4rcodjh&*f(+FLx0iyEKM%Y5x&QdsR0m4s%C#PW_ynzN{F{mdg{1i=`gkQqb$0-~< zQVoe6XNWS(6Gf)qm6#t#|6TYWTOlBsiZM$OW-fpOL|Ka{%TW$HY3CX|VvUnO?iCwi z^b^sJBVl^s%CO(RJod$d#m`?`{Pgwfzklo2M=vifww-!-cpjy^e0}I@-`7RJUWFNbhBdpv;0jhDt!YmnR_Q?qLXU&S_5dpu+8mw<=Jego>@*hLz>oJ8+nZQEJvZU7inFx6nNp;`{9Sc*Yp z`1s5SF*`y&;FULNQiRQtwqg0b>8=l7z4hv?xtW#=uijmJcu*d_6e4Iti$QFmH9b*= z&dZQ#mmNkaH}tUi39woqwx5MF#73g*fyB-($O7fm} zGWN}C{LL6oyKPw;Y3^moDX;V1&P})1FaQ0y6aV_c-H-a)UaYUUvTw)m#$@E3 z9d&DCUgKJVuZgmO{PxMhxJw<<_-={mR3H-LXTh}cRI|!o5ExJ__!u`TLN!Gk#lTCW zrJaXyb3y3uAksrd0GE+xdOROGwjjWkU_!P&@$fJO%VS@@b^Y1#i$@Y7vo-!~g7;jU z<5HY)&ZnF*_*#jrm6>A#brc9;$TEsJjAKU$>r~LxnW@YI_7zg7xfZil0l+r% z2@-1{0Y&0GOG7X|$3Qj)KCyF5u%+<}G}cU$O%#5KAH(42!{7k$elXr_ z5NR&h=SXwbY$cm8n`{dOk6~_~$`!_vzefYDt?%kd4dw5VDy*zZw z!H+LksuI(ZRSrFBF;!SYYDo(Sz@(uLvqUG2-&~hC;diwQ%z0~QGj3f-h{?>%OkDU!jVE8&yY2qot+)2>xRsUM@6v{s$96^f`yA?AY{aMMPJZ3h z{L}pOA9_39t0?;7+{v#loq4S!`|FPLuNS7jQuk072XR8j`J~EV?aJ>=j&9yLZr(D`Y=lzrpaOoFCwv05--KE5~~@GFK}|$0;vNj zaAi<<>j>Lv{e{l8l zH*P#UJdaY2tZ*v7irtaQHNw6FfNGn7DR=m`&TWqK#PLy<(;TcY)$r8^&pkXSk6w^xHiwj$Lm=p)B^GD_qp8vwddX0mSgei4S}EI*Do)## zQK!}}v7HP#w`%!wJ2s5T!gGg<787GSar4tzDQ}&wzq^0ei^VzjGm|dw+j)6;?5*va z7B;MWDRuAbxhW6I^FQfo`J|)yrLuz8PS@Qp&A*y@;OQd;_i~bEHZC7e2#ha}TG+8^ zbZz43>iEg^D@WtQd!0&;A@;hI*>x+X6TGa2%@sg3@ThNAgu{Kn%Jg`XL=p~3Op@%;|m6@FCUDQSh*jqx(3fm!pHDg;XC)bqD9=x;Pp*@8IZmj_wrL zR)M|9GM5DI0?(X-SCoa*Jadw#>sazAZZ5?v`R33<%$j2}Wn-2+0GI;d#d1h2hq7gp z)@;&}Nm}x0bB%+q1263rYs2LevG%H1M}}8C?f@28WJF1T6<7Gl0!r0itiv`qH+2JOKa$ zy;&an4#KjJW56V*XwrU`*vC@aFjJaSPtxQA0)0?m_EK27$5pm|^&yEpD6ti*<5F}n zMUxN8!hV_E2MSCR2PAe6PwbbNeG&tb3&A_ZsX*=pbV2H2%WjZyk=rFAn30ng$O9_3 zTLh}Hod{rLq<2fUU4rR=VoL#+;bSwy#gu^jq*DpQ%sE>VA0CuPFU963g3B$?Nb(U= zXqjo*3DSDOx~xZ_dpNoaJ}na4LfQr;Zjh(m$VnT(%>#xu5Tp3Vb0k&-)yw+*7o&%;hrm-*G_L-H4z^%9qk$L>(i0WsnrP!8xrPr zJvqKS=IXZf3mX&1{KlwTANA}(yEJXssP}eplwZ>a27tsG+sv&#|RrZ+#|RJFfOr%pao%&Aj~0!re8bf z^DA5zVzhb}SBbu>S~x6FMJ!&x;CU2OA{Q#4OXB%BmT$AKM7K8Xs>-;%q* z2}6z*pi+By3b+MNyMwlFBTc(Ndr50?T+|+kFOH8%vMWc|t|?B4JGy37cSS|{x-}VY zd-J8uiQw|V_+ zz}p4cinPLs{(fBeRYM!$=x$AZkez;S+moN4IWZm^XvWMv58XR;uB?vk5a>3Z>X4ZML+F&47LmQck>g>G zUb_qopXbR2$_Cl+l3i?Ih#JaPj$1283>b!^aTEBg!^0FTk2Uz@DvhnPi$_Je zkR|gOB9|tzDI$l$vk5$h0DAFkt0fDpGJzFCxK+d-K6t-DV9!ZHr$g^`8Z8pvCh{Eu zq;tNLXL^Avz>KE{IC_w0hIqi08Q}p)WLf|Jv9$=u5`g0kojJxz16Os6S;cu(hPNs zrOIdm%yX923V%xx$Ka%8}!M+2_ZB(g%(sGV@!aw?iHzhsM7mHX1`3sMu2%c zZP`XyasuvS8`oECTvxwqYr5aHPoN9pqtXn$ba`BMWOz=%lPYt2d3HZT?x(3NhklS} zc3_se?N8?U+~w<5X4$o>^=qp)Z)!@*=qWAD^txNrxJMeZMbQ_Nbi@y;Y08iQXF!IM+f0WMnGZrDC{nY-T^Tfos6j63Ij%Z2byGp zkZju}T6YPSLk6Deq0__p%;0CRkX8okVyS_I*bciirpWN| znBeH?fUA!tdT4A|WXD#=&#qtHt|)Mde<6AIJ9+6>Hmq6Lzk9^(98{#|cWnExt>x9+ zgzini+kyu6!^da(w;r{@Adw z#HenkHWU*+=@5n#e#oh`ImNyRM}MUE+M!*S4C$Fe+xuetbMb-caL;tWIqFpIZdr3J z-U}y%ZiyPU3&URfdu90}4r$1tHB)#8$dAZOIMoqd>=ft@z*u31{6@c_wg?agu|bzM zOgs&2ZZ_+X-t!cWMPnJ2RUX4h~*ei zRA@m+gJMgM@z4i`x&QwT+lhyy3kKM+DBOdsP}_7FY$740VqPE}GpVE*@z%YvE!jb)`hUCj9w$r} zNn0n4WVV&Yz{EkPo5E%#ZgJJ}n_JdSy3`(;xU)8PP+_}SqMxT`!rk9YkBu5~m(0VK zxrB(PcWt_}dHvOu@iUSBNky6u_r0?3$(t)9-#u0Ld2jotZRZCgeRp!wZsumdD?Zau z-y^dvct{^@p3&fgM@`A}l*G&%;73nFtCLZVY&8l!EXsan!@jKs?R5A7`l$>pgW2G4{_5g7!Y ziO>ay3C@|U*44utonti}A+RcjfFHPWxa5K?wyM&o*V!fuqlPx&v=6A#m@Ezm9GnZm z3=ebcFh>Klpr1hI60~C+Jt43&03^>X+LdWp0P}NMlV)XMUJ;>%Eij%J)fa62`rN#@&q=MA<=!qC_D|ohL*BsFc!eLfVV;nt`0~`N9U2s0UflL z-i@YhAI4fVuqcl{%Jk~_apBovZjd`r#ZIY0m8o}G2OcGvINQxF}Q8}2#0BCc}n>Z2=HoZhqh$chz} ziSfme;Z^HbmqtgF#zY<8urAZ(%=UV2^!5VMr&A7%9Iq>lk3PO_bJ@y-B)eX*Vcqb_ zhT{0>!np7(pRt25rw3d)5uRjCOtMRW?m$YtnR>bHFZMTOU6a?&#OKQMb~saWes9 z#4gTywK0{OcWZ+J)u*t%GS?+DKySN1bqREr!t}e;W|r*Hq>CKcWk~3}po zSGxPM0{)3J=PNd?Y0OBvkd~6?_Z$?tY?qPkc4oU>nJ!n7$boH!#GC1|AB~AA^m|Y5 z+nMckHSXMYZvWoW#F)czQF&pWR7Hf4e0b%G(VE)c+Ukob$$MD(=&BWmMCO140G)$&e!tG632GfW91x3iSmkyIV5BK%_s9$=aBx5ijYvZn zet1wGy|goU8%tgwEW;9ae?|PXt_-u}FqkZkY$dHd0y7ike=RR*F~ZZsQ3I+l2tha6 z4*(A`iM13O5WcQWQpHsSnbb#Ptd2svCHTUV(+M)-QsEmIq~VSmB|L!Dmkw zrVKHt`OGDmYqJaO3Og8PzZ~nivnhVmt8{}=S0G4&k%kw7-^@I-W9@9Xt5;$=M6y#L zdt|PY2YTsS`?f4Bk8I_r3j*1ya1*iqPF-kXh^a_lBZ(F}KqPFk%MC12(0`Q2vRE>m z!h@AaA+Qw8md7$jG$n(;nxZ4mx?M*Z@)$+-tW1EtyIgv|*D>aHf?2;D?jLn%Abk_M z0_hae?1+Fg7R6eQ9^)9`cAN)*=}Cc^6o6qK7zT8qGc5_TvNW$M3!1d3E0NxFf^dI^&ki;r&8-#2g(cg0c;_IzNrnLLaH%Fc#QnN((2yVi@71_{ zDhCWh5(Xm;vJ8Lt4juw97-{RngYxL5iL^9P76`YXx;?7UL0bD*5=?R%X}hs`)tuWt zEOX7)&{o{i#S)j-CSKdLwimO)$LwZ=cQGO`6>tx`HQ;%)WJGTyc zjR8X$i}b!(n*Bfj>wo=kU;X~7L%d>0mkoJR6(&?+)UFJv(trf4a@_(zMRo8b$YZy} zL1gXb*)B9tDnL>jR77BSM3qPE(zHXq;?r&f^aYRF=aeVneZxL`8(J($cWWHbJEZZq zSH<=N!!p|?P%R=e<+Bec=o0sFkBTl|*To)*yGYr((53HOx5Qsy@g|k+F=W`efiOL@ zYh$lnIZY9rZpX=>|NTdK47kk*a(f7~0Ki!^37+}5*VEu~9uZhTw~nLFDrgX*C)_s_ za1R(d{0+l)bP?}3NG`Z}NTHyIpt?Lg0^IWSIEN$`DsVdiCrgO~jhzL71znYdc^UcS zIYowgS%X$wbn3S}4#4<|T?bIF*tIK$e%)nUap+eZc0d{)&cL3U0(JIbD^DpRoHgOx zJPE#Cm8b3MjMEMoctBIe{qFhbhyj;%?W z4=HS#LrMnK)w%tUcvU9ZE`SaPt9Z~Z9MpxqDzgXvI+X!{0bLMb6p4c;uO0kv*WLk% z9p$KAfR@Gv8KRfLdsuA5=Xm#2ZKq3_jdZt>mT^NG;HgPN>BTJ*EIB|}-#=YH5f`zr zYB`v}dAGh8a85l=a>Ki)Yi{Rf|MJO4fBE7w_}nh4A|x_2uK@xp z@jX1(17a%)KxrGtv~x@wOSP~>D_VU(xAP3tPLYS&CGp)N+7tA702Ev0Cl%qcAq=X_ zC5`F!$U_c!Hp(-TuY2> z;fM|hz$`WDca8)cmw0N(?`)Bn^E}b#*882>MTu?rKj=-Ra1bB(?B;SzI*Au>Y`xnB ziMN=gPTTbcMLH>P&tGc#`jwaa-HxdUU%x}0^||{Yl-ji^L!UD=5Z+;qLZiee=z`uN zrG>0A#ZfaLxdJ-{TX^K00o^%>tcYX*6nK(nL5-ok9&pa6NNnd+&|7K209>^Nhkn&% zzpNuc2BfdK>{lItv}4|`POH+KCNJ2vIlD3ezFJpj41LvM+ z9a@vbpOg3ok!w)Ii%z2k+Q`7zmQDE_3FbLpWRod8l_jzzHVLUN4gjYy*u%r~Cv1E0KyCqdInSHxyI zjPkXKMXQz{NnD*B5jdT+|LO6GV=EJ{_Vo3XAKNd=P1)Ib0srCnn5s>i%2%v95*H8h zTb`JhCdmy?Zmr+Axi~!h%&r|-K5t7_YTdf^LseDh4jm};`zlu^ltzaa_?%U%;~Sn_ zo2AKFhH_9ODpn^HMg}^Ia*wWDeNbexy^bS^QRyx@No5a#_Ue4L&%RG#;Lk~ODai(; zVuUfW(;B;1V|FX_J{1{haMZyOX-NCO`j9sO9yGH}~RT89{XRHUb)!!NOT zCuW*Wh!}N9y)4m3SYOz`W!hsOlGz@Xx){3b#^#lCtKzS3SUH5;GQSubHW_eVUza%V zwa-TSudGY#QiM;hU;FQW`sK1yz3u=FkRf&rNnnY&UXkrY)0|W*OJ8EB3l!N%5obyK z3~4(_}Q{G404w|jk;F7&DVl?@4l z9(~vlppJQzai=<<@I5j;>Q!fadY?ddas-&?L0uX#6tK{}DuiLSTNBzfp-tgN0}kl7 zN$g0t3mEQoD%}oc(CdD9n1bc8B;**$EQZdch*DW964@LQzZmANRi#G5ep2Mmh$sZM zXySZKcpoU9+cD{OTnY0|IrL#sm;s@a(7@8eX&#;#2hYqglN>XJ0Hy(5s51gH&9gHo z<$?kWmlbJF78ew8UX#EZU(vOzhJ8T;+pGYq^Qtrhf~;#`v%xSUzb!y87Oy$&H{1rI z7hJavJR1ujwu&?lsJk8Gnlb^uD#CL$+&k?t26c7VZS*>|7D>1W&O{N;YtlJ~)*j*S zONc$flNV#cE=2huIOGXz3WFz6c$Ua!FjN|YLtQ#Lk5oXQ5V|t4PXT)2vkuyehL;bi z;Eo*+Vwr8~ZWJ_UT)rytp4kmTv6f|tu+?t+T zvvI?b$jE$;`|5>eFwb?XSDoIM)Rd8SVb|`)eLFe}v(9YYQW6=+b=#{}B^3JI88V*_ z`mc+rhBkh-p?X7NmPb!PXJq0s`jF1|t9+l#&&T){BHfULyEw9g zBZeV1d$c}xgYhv)h2;b6CS}KpF z(?lwX6^eYREM`(zox@(O$t~gj6LzIR7EX)&3oT8b-@9{$!TVj>?bY$44*L*H3{#>P;W%|#_jSboC3fm=t`f%-Uj=uh-nms$UJ15t#JZ)FIATjFV5s9yJ zXaynz<~d&ihKUT0$`%=b`QhPtl#(0igwP1k?vExaHg!Pi};#Fvgc1uxEPgrHN4~Xp~4iyfUF;)9SJ{D^gT3MG@<^Y%7Y3Escpi zy=z;p*K;8yDc9pI@Q0n+v$t~Ps_K<18=l-);B=kbu<7j9E!moWI6S;8GO{ct=4f8W&ZuBEBHtty;a}%%0unwm(@K6W+9cPho`r%&zVAPp&VDj3|zd z+{aPrP9@W$703ACypw8(87?K=qog=__!H1D8>lV_vRz04hV9}K!25MD&uAgX0lSC- zu=LyM?dO>e!rVjI1~{?}x3*K(UdX*XJwRh4G;!H)Oc-((OLbA$uuNa^JKHhyC0od- zE)EGKc=ddiG>l^?T z1}b%)#Lf^{J!Yv1UeF4)7F}#(skQ`f4uMQt1sg{Lp@Pmyiz)r&v-o^Mxh>_zS$Art6bm`zuXPp|H0+I0YAhv99qza8u zjdRqJ-hyWi)+Oy_XM@Ab^NP5j${@2K+Te}Bcwctt^GUpc)z>YT`)lex2SCJT73?cIJU%yZl>oey{_HL*ey%j{AHOXP}dI!~oC zM3(ehrYrZOaVdJQi0_w4(Aa}2#9b25P12ZTorO-OM@hAF2W2uZ+I?hAR8E8w0LYDS zmad3Qb89;}YgU-+=*HD!=T2>hKyD~SQGxSG`)W6D>?$f*xY&Gl-~O`Ls3Y+)HJdlj zHC?D#w|U^`(erzf8h7qIw{2TVRP>3p>jw^(9^bINr=;j`AiRF%nsnW9V%>%_`}X!7 zIb4+(U%MtT%V{t0yGz16gmsp~c3yQGF_KWP8#4f;jgtxUQY^Phf zy=Q&DUFcW2K9%binL)6@n$RoIGg0ndi5{~{Lm~@jkPem{amW)+ts8_FnPjO)6*~la z$Y+cNob58#@3r4t6^9lG^VGw`6fBPwh-@Z9luCT1BGzh3g~*k2R8MU9X-zo^dwU(Q z(*=PY@Os9>+;ic+IRL}woOWnqAdjHBLAN}Cw3kIKPfr539H=fc%d_($2X#T_7i3{^ zX)aepre#)^#uag?PN?FTDvxXO7^>iYl_|Tr=yP86IInq~&%}h^iwxZGd2f2%*PV{r zZWprFnu4eX{&f{ZdsaafVAf%ub?A$J=X{v^N_5zCz&#!29W=B-FwzOpi>sHP7U+wb z)aG@bb86FDH(fcf@0h@zFw|N@Iim2#9BLkjaIhYte@pJ&FEe`t0w@J&!6ZWqK{o|H z)(VyC6mlXR2Q?q~bSSwjE~;i#LSf$(!<~#6yD9?Jrp)7aYH=SMp^nbp`W8hWe#My zm&1E#+Ym!cdX0Ygpo4N4(um598S1o02WDnt{rw8lt+LaRzBUD=zd4znQ_#!^$U898 z#nY_}d7i@05Y`hoh^+}^c1d!pttLSCIF8j>gZE>CYO|go@Z;#3bD$SLMG>$=1A#8Z zX=Vrr%wWF(-~r%MV&@(FxW-)4xEnjy_n_;3nF)_N2vRK4eG)sMa**v|Pmtmvl^-|M zZi$85+YJvL^03d|EpfeeaU#qGF}RJTX5+#JJ@z(%?hiQcY+tu@l$HvbF)9`LN=+)4 z`D#Tv>o#sB@2OLS{uObToc6C?efj>;;@RcV({bUGVeY9g&$wN`7U3O{IJEd_DeeXb zrGkUZ^rXm63Cx1P%?sRRkpqC|P~1iSIhc5Z<5g(61ve%MBN9I%3*b72WJnIeh^7pp zIW%d;j%4{Vkg3bT^&9+EyL#Q_xD)U_9~bphWEj|HP~aO*`+~zh1*Zc|Sp*rks}ty4 zpn$8t8t$KTIj+Qocc|jMO>1sGxo$ARdrG95b@`Ilbz|p~O#$~AUHQwx6SKqfPNYIZFr7ytdHqX*_h`*vf>X@o{H&0m&O{ z)~-4l5m6i#aeDia}f| z866p^Wnp1?4(-g=&GnnsRmI1aB_uTM-&+pJUlVf;HPcWINBGX{-BuXx?XRiG4R=+p zPi)w?tuWG)tk6j+oe9tyVzyTWjDg-%mjv{tIHe?~c*r3jhJzR{iSS+(S+?I+S_$jZ zn-V)QOE-m&@^nw|;+(47n zrqEh*Xssor)`D*2bOJmxx;YFWZL0-M#;xF@0pOE_?Hr9m4DRIUZh?UmjRaO^77TtA zoV-h!40rd4Os@>k@;yMHAudGw1|+6O0?SQKdG!%Zgg+46a*xdRDm=PZoIqb+9Ro?Y zRibaMN$3>NaQ9@u)x?wC9{u5A3YN!8B(6%6kIEbv<{DK3&wMf9ekMEVEaYAReTXlq z;+@TFx*Y0sxMw!pGbBq8FX!#rv?d2vQ?V1labqyXmjx7Y5w2jBIT|{1!RQMuU>qE^ zLOUaLWquUUg>$OR4@ttXBK6C{kRn10E(lc!#)>p4aK^yDrB~w{uZd<|XN> zu0j8qn8-UmFNp9phknIrpH#$oL%r-k<5-Z%7sI_%K3A_SUR@n`WAp0aaL?4r*hWcc z54c{dDDH@jIPZ1TD&nO`@6g6IRhn4ikSlcQh$bA?_#ElCeE1G1;GB`_0beEFp)zaNcszb>Qb2aSVez7p)#O4k4n>Q54 zg_Xs}%$_)z<8zlK#N@hMhr|6P;epfJw^YW*mBmC?#m1ILgddBIsa>(WGCHOvamDEk z>#Jj9>Xt9BTea#~OiX1=Y*}Q)v6!eF!(O*xP2Gxw<11I>+VzU~sPlWaSH;IvZ&-8w z;GT;3$m+z{WR6UdnQX6~8!##oV=@BHf`FqWK0M2<}N38KFE{9 zJl)OW9cUpmG38J|%0Prcw9x{4g&WZLP6q4b@K&CLUppJ_ylfYzHGV*3djzJFLt|8D z!5&*et4+&*)f%XPt|_G6YJnDNjp>QHWlz*R@pv`VWxuO7JpnEnIcnT?k|r7`BIvHo zCvht%FgWlIct0XDATpyWKclnHt_ZueI<`w@dQ^7EE{s4Mw9s854QkviPz$l%b`Ec2 zY&R0Zfb9;R>JixvjvDdVn`mr0VD!n{MH=rkq+6@wdnEz-cb{Cnbd;9LV@G8kRJTeK zYE)F;s4auUd)BTsdmW9k0DE+~^gHWUb{pz|U77S4SA6aXT?TZ~ipAg>3`n+s=oClK z0=gVK!vU*^VW`0lGcT|p#enzh61^ffD)LZ=Wxm^HyBrrb9TVuc%fqVB!?S|`uqqDA z0^mI<@zvL4n=IWw(7)m9B+( zAe_&5T_Zp>SpE2@RztbJZ`(OV==98e(lg8Y)1Uge;KCu$L zCBqO4qFi}Cc#}$&Tg-IwX;2M5!!5y|lkSvK90G`NvV%`|iwATL0c;QIuz@}~zpWrj zL05UAg)nt9wtk-MWo?}lGRcE1J|dF+A~oUC`dOlfBfB`FPoTP>LtFb;te3^Wc%xA+ z4RR)ZJuc8CPW^N}O`X`ju_fT`a62j=|6RS!0^C9*hFWVg)#K)q1a_XmTS0-rEC}!!=BG7K zCi;>g48{1SqrHu=iD&$077eHm#l zJVap_*aLc}B@URJP^8OY-uuZrzrQ>3%X_!}`sq{u^2Ia1ys`M+#p*tRnReR2KhHZf zwC+ll7Bu;ard(0vtFm-ek*-4Gm4tbbzYMwx#A-6^Gp8%}BKEM$=Y>5r|dikFPP^XpFP`W zPjkuX4msa%q$qs4E@ip3EJLnX8<(z14Nq>$b*iNizT;cB6nLDcwr{G4i@B7YQNL!@ z@eON^h6hUg-m}}c)U8-?EGjyKqL0QzP1KZMYdXEye0J{4@#dt1^{ZD^M1@x+M3+T| zS0}`RESLB_MJ{`RT`tg-QjfFPYgELCpWL*zVe95RkMlxuQcrPCb797jgxDmRJSdX+ zem&bG=Xli&2fS@5+Y6G*r#ZMZhX@YhA2Ap(PH~D^;l?3{6a@IU(>s9V2y3T6X%WL6 zw6&8#N;?P{n6dRxh~y3mUEe$7bqt6|Y=Q6zT>yH6=;FOBT1z}&7rG=Ggzj(Oesg`> z#uo zKl{ta&-~@n7k+x<_PgEZE^12U?|uhKI2ep=HJG&)GoK)=jU)yEIJhc{ffEO$-x;0j z;E0|GcZW-xjB?C|JH`!hOh<#yy#hVuvkx0mpUjLpx#6_G{q)+bL zzE+UCuqt6J!Z+e~&PMoWe9lo_z8mca?HvPK3z91$dM5!N3Y%=ID6= zgqMK;d_@vKHj#2FXo2K7Nq%`}`1=Q!e|hKXUq8C_w~ucB^6vFNzkl=Rx3B;5?wxU; zW6outciXQx?AOp*EBUIfT+@}?F8vxrVihD;TGYfVz_ujJ1TkLJl^L{zL%AK{zaJkt z3+X*3eA;6S8On5ocQ!7(O_QHJxUEs<8&&?=t{wBcwtU#s*ywf)tX^@_q1EeBmBP;@ z@9A8<0sx-ayXE2Gd6WX&9#lbfiG325=~oXbWHNB8GbtJk=q9NYbfChLr9$g+=5bo+NEjqF)A=~39@VSo0hLy)e4%Jpw#>dvJUtQpI9FC7I zcDpKKqUu*JuU!#;dh`04#O0YR|LjEn4`06d%MTy?`G@!a{KJReeeuS(U%zv``D_ly z9r3&S^3p3~qmKAI#a?GkT=co^8;f0fu|vxgnJkq}Wr@=GsIJ27i&VEyVJLeY4+(Fv_ z!cN-O#n`%0xP4eVX-g+%9TI8474*5Avi2e`O@N~Ym4+RLAWU*#q_JL(92BUjfMdXk zE*HBI;Tq#8aMX~KJ6W=o#x4-n)3~k93fhZ2GosfVT4ynzW$EWnRsQhCtsmaG`~6#Y zzI$-%>(_65{pz)EUcd1zY<&Cf@2?DZM}{5yFTVrfJx*Y?Hfs%Lfh2sIv|Xf$j-}x% zff;}}sql+Vp^2v#*T(lM5Pdmxae~AQ0Kg7u%pr~F;&hl}+^zOYOs|M8=%4aCI|O-7L<0Hqd;=6O8kPz zK@B=*ZVuQ6;YE9L6AbnBV%PVtU;g%uxj(*r^-u3#|K+`FfBxw9&+p#&(|gx{e&_mM z-n`x(8ajcdqtGP{lRUSeNH-n&GXd9Kj{$uk86I8*{g;GARbEi!$>6nw3&6QUAL03H z;l5{A#a@pMpANWY!@UCm_w_C7?(g2xtV`!qq1k1>m3HuM>Y;nNX_ulS+u|ZG_?=a% zSZfz64CzK@>apJx+dz2t%Xq4T0}(z53T$Wpf$JfKOf%RNods@lJQ8Sfib|!sglxZd zK%xr*&hk}p`2nLiHoPd@e}E#(mdDqwTb*ZDGgUEDQ%b@DIS&0uMEHqKYnu-2t&WR@ z$a**|aAMWU%5Z;INy$r#gEG`suQB>*2I;^_z&2u8Q{&b4`pa_#p?K@ z3E{bZy?R4@mP5#}bD3b6L4I9gj#~nNL5FjED#YLnkDL}nH!X+W}N z-udC}JKw!^`+H~s+PCg}|JLnqUc3I?gPY$zxcS*s=LJ=&0@{PKO0~h87N5jz=P9C< z0c}UOkr)v8VS!zAa@{=E=MVu`s67%58VmV$&>?qA^wS%ckLn`$e~9bTKCP9)dlYVQ zdDxIchJEfmnFv-HqA!@oo9hzJ;^w=1HZHFCwf5F%(h-3<|<6)$_8Bf;zb#zl4#<=BU_yO4Vq;O&a+WzbumUaElc zWz<1nFO6DF0?CT-?SqA{U!4I~?~kAQ>&LhM`pKPNKDhbk_iw#*z3Z2Eul@4TQ!gD( z9%Psai34LiCvulX0n+cHEH20*#NF#auc2LcsPmF|6{)cd@p~T43`>&|H*Z(3``r@` zZOY@AkM#9BwHs>_W>?1a`Q7s?V^4{6SCnUR!|LXM>!-!h=CHukl!H|=*A^Y9(Zp&) zDpUCf=c<;D&LforG7iutf#e2d7FlJLOi~{{gqmh&GM!wSPNzGN`ONYNz;HgKN*AO` zC0*kVvbNF)f7yz-La(c4&B`p9&sN3Ct7Y^($aOy`R!m3up75iLOu~Bs^ z6KWG;uC`zN^Dm$L{N1}i>_7kf(cgalA9=MgS)pe5&WSTp+zvS_w-tX#x)n ze0I`SaLfG+4zU*06%2DbWd`{LnMIM9!@I#Jb9e`Xb{k-cQJ#j{%VFKDwTrQK3;04t z%3nTue_Eg>SPJL`R3KP3k(RSIQ;j*K+G47=TF_t>gx-*4mjbTO?oNL7`t{GApZoNM z%iq0y=lgf={`l@aXhDjooC%U2V{n?!?&cxX5OY z<9smtjmHF9?b4vnu@D_L>e9zFNZ#CxuAtFiG$4#tL_(kibqxwEJVVH+t1Hj{L4o-KYL;9_Q=UUygKv2{ef#eb=Ujqzj|f< z>wBZUm~C2<;8o@%9)j*=GzG;kNc>e4sL?`8WnLDq*cG(IQkCa5Wm;3` zU3T#KgPJ@Ua6i9i%hmOXGYOIXG5%&lxw`YouBhmNV<)A#Rx`rfnezJ3cjKYshp=WjoMe03tE z<*LYt5<@>06H(wWx>64vFozrocuPF?+QgVbpCe7-x=V6vHm*7S-m^oUt#@Lb6Y*rAi*lGB_L8jwQ+(ZBuP8oe}H7uiMI z0No|$42Bt6klYT+0>t)$i)N6u28O|7FNrg{iV#GM#nFftM-1`=Wac)3d~bI8PD$Zq zhde?PJ;;sYmuL)xx4{O9ciFL!CyxDHd+ROc#r%}tzk21%m#>Upta4HcRjp$Y!XJelIY18=Q1_3IHCFm@5X~ zEKuW{SC7Z|=3+cUc40tbA*&Ba^r+7D33RtW_i92nPhN=+AJV~2tG%FqF}`k%zqTrR z(5_VJ@~oj<_Sh$#`h37W<8uxB-IrHH z-*|F$yP?A0HINYXbXIcz@`R3<2nhVMse7h&ZyVdPslo54cPce@>6rbueE7g22lW;x zr4hy&FpO%N0qGa0rcwc85L>^NZs(GLTbTePvfNUNjHjtohDK$(q}sL14@qpk+g`OY zK1UPs3^kR;PbNm^7)n{V??`0$h21+VqXH#v$FV4Xs?Bn*r}?Mv-~0Ky_x|?NM}PV8 z!(YCCANpT>@cjF)-+2ASg2(`&1mReiH;uFn<)Ia*~U?y-@W~AP1zWQ^`mSIwByaBr4chVSW(=qGKD~0 z8f|W1$d}qre(~znFJD@0tIm7xsma%G4t({-_3z%k{p@VVT<7t{zEdAQGYtTL^X9ET zzI$(Y&GPbp`p~6mH6AAJjp9 znL(KwGh_(8AlD;a9a7%a0sGOVL(hC4xWoythSn2!ycit^mvu)JI0dmX=uB#%{V zLWRs81LbksyH~`Vc4%Yk6I*=Fb3y0a;Zmog1AT@z;?hP8Wl$9tJjS>pp!JEeIL&jQ zy=Vb5M=jy{|J0z7UVzYxrjgJ?zAk;we)q+x<~Of(egD># zD_!-kU1|UEoohe8cjM=`Z~o`bX?A5c1q3o?(z zN0fuXjtn~%8TRtR@DJa-{l$kb{`}qBfBfd1&)$Fb>rY?!?A@nddv5-Xm#+Tu-P=Gf z$nRABu{>4Ir0}u`Z-FYDSh=#)=PXc!fun`>8&)4*mzbjpxpukK?<(;-f#IWZfh?DN zEHSdcr{+1uEC-((OuSI@y-KQ`J-Wh|8>W>+J8}aWFbpK;_?4naR|?PzF53NDZcegP zAm1WIr7eIlin2j~L2SGKK6ZsfIJkYrDF;WSkxB!%NU_0PgJ*Dagef!Nz zyPuq7h!KJ6X24_HS}9v20io9ns#_WQM5Sq2b?CAhi|M4mJ{WEK{VP{qyxcu;vGTe3 zuHmN2&XXmt+!%c8{zO+p@%@?BKfHSNtJki7^TthJ_;zl}k^l6c0NNTHeZ^0$)!cx- zKPgCWaNw$sC&y)GR->AEV!&?aBxr;~R)dO~QP~m5N z2D+DHP?_6!aw^(?Eg@>ar9HKAb(iofR|vURJS>nW4F$BfDd4VCgr4Z|23C2_l+>mC`SV=lN>e164Pj;id<4%Fv*~_b7sH@RJ@9@*?eO|lgR2wjGvL5uzK(9)q>SVf3qr?j>>>y#q5ys&dN3x8iDrBxh$k4gH zl)3jvPMSaz_*{o5OFD~}_#9aho$ruyWcKW??T~@<6d_0CYhoiS{q78g%pmdCua159 z#e)ytxc}MvPyg_TH(!2g_Su`GAHQ|)wP)s^xi!|OkN``*;4>hf@3smp$T z^SYxxSGLHcQ`TcKVNE-qOc$7{RSEq^N=pLnW6L88TzZyWs$3a$B*K&DRf_^T;0nT9 z;8(K@A=fMAc*I<jb z0Vh1jp?M=97HTUTr68ysl(~a40n$tI+sWGCS>U#Z$Gag9a~S-dF^};-{`sF@$~ZWI ztTkGX1sj`j%UR4)Zw{#n4XFr4&KYtqn&XxDHz(V_e*OB`#fo?CkALyXm3vcd&tC3) z^X}NEFJJ!RwX07}w*T<%{qNqo{mp}$Kfe3a-GYqL|MZ^#T68f(@T!IrnB}4N2I(CY znOT*6ar4T7fD`=lm`k4W$bAaaC6JJTyCu3$;bsDQpTzbCS5OYBd?$-8bs7mc?yZgM zUAl>?!gqtojrHAJzv4V$ySaJg!^0FTkCjVoy%lUca~?S z80zMhRX@FP`H$~h`)enCL z>@T8A9Y9(E)CI860(T|ooY54N$Uz6BcwXe^(F`!CG&e1=bGkgGN|(LHjp*<`RhaTS zAuUYDh0U#uJu9;375=Oy-`uxjeABuYN^>vx+%1vb6Aq;@;HU%#o}b>}c66?ZTRJ+A zRFYNXmXXq;pi3>G3oS(7EC&bBrfXE1MnFHq&SW{*gQ5+jI8CO~RXWEIvkfs#=MIpj zJeShAXX}wD-|78NW(rK9OG_oOhLy2}s#xsSOTCVxes{jEG;ZB=X3M%)Z;b!pk*J9C7KQ0~ZaK##LZ>3Z zm+oNl{g8p>T#r-|=_rl$WO{`BFg4o;Jj>Z$Dc!{#TN?}J`Qbr%^wLIIT1X2342BuB z7fl^e7D&A9w55x+K?V5@M&h8U4vO%S-Y(4*K?f3VCyR}`wN6d==JnUECLfqLgkBa@ z8f&Ah%><(NxW!Z%x@?KwCFgvKV_xh%3)=hn3-gd{|M2?tuim)%hc|A#dUL3u^w0}e zy1_!DQRsK>e*MO+KfeF;%)Tu(%bq}2AT52#9&T&EE$1m4(A&Y0-2yc%P%|<$5*-*t zgQgJ^9<5KJ#&sU_cGw~Hs~qeDoKO4hg9`NN9)SvC%z=^aWbhfkV^9-k!rjx6o_<{# z3Ul7xx_a=}y7JgDRX8RwC+x~8mv+*w)=5HdT;v6}aUqzG+YF`CA;ZaIHqze>Hr3;t z(&bSRU70Y(QR6IdOHZ=EEdqEJRU$|)3GHPb!3^9&3jug(^%Yty$aX|P(t)Yi>@FB2i&7RV=~M$867qp?(Id1fFF*JYW6vvDa*f| zo!%86b=v1>^c&SGf5NRE;mPOgjvTZ97U@{x7UkQZZ4SarW;mEMom!IIbfmykx}8~~ zH$?@BCP2P2H0B^{EsgRNdet1A&y?vbjW2L02ThNk+PtpFWfZ#|joUY8@l=k;9t{r^ z`<#aeYk71a)nY!s`^lewc<X; zNTjDYpr;5#o=eVk3ONR!11;ENw@?&r&+{sIel^D<6-7F7eM)JZ8-y3huUCQ=Qt{#C zfrkg>(Mua?feM)x@-2`Fe6~^M_J@*-(r*V~3>}2GwH@dUVvM{rYYTE~YX{-wh*sL# z#$oSHj=y)lVMe0*5bCz}Aid`>^9f66r75J`gq(A5!A8h&%(_sP`PoYgV2{6f7uXSx_xV`rTf(3(TkO!#^1ej=exJ>0M&nf@2Rt@Sh?)+YCzX!uCkhHaqDRUIp-D@ z@8T&)-2(!3S!eqM;-bWNI+Q`D(k;`Yc41iIhE#q?<@!N&0a}sjlbK+L?qG>N8AO=t zBBoOmuI)x z%mX|%3c?Py9P%^xVF@kyfVevkeI&U8JVayNa8eL?Fwfww7gcc~oDd zRdmn66_G>X?%Bkc3yRRJOFhwnnN4fX`;68o|66BHHii36c?>vtRU&}3GJ$;UboJ8F zd8D!=xqxn}Mjld#G&=>Vo2KDuI+3i{QdJ_|PD2H50b{@*%V3g4*iHcnhhse12A3w_ zsUkI4R*)u=<qvM%f8~eo-nre|lqd1o3|8VYns#o@=IJ7t%Mz%{ zNPnT*sEUnjKDawa7EY{Lek3ZQ(Ca+6Z)3jCeqw!mmcbQzlysHMvNL&ZG2bHlHDv~L0a`SC6@+|%Cwha1xr?*)f~Il!ph)$L^o`>DAD(|^k|X*dIn!7N zX}N@(&)Gs7tRbMf<-yz=9J^XpYYyq%ocO`LvERSA@YQQKzJKT55AWXn?%lh;fBpKW zugrh`%HlU~-uf2g_w761zjy!jjx*)|^iPnMtAhj1Rfu8JY0`QDIcK7qB|%7sMEbIW z>*H#%06*%X1TyiM?_TT@nMv*xW z9L9u0?j5$vV|HcMsZXOjKeEFN2IxYaVDJeVn`ZGjfEFZ|BZ1o)c*r7v=ULbY+@gW2 zX;gy?vs7V-q5tLmYd^j+_s2J`{P1A@n^&g3f9>)wZ(p0+ys8i5HI+oe6W**u|4xy;9}QL^vyc)8(oE7@$hh&_q$H zPNV|5b`shQJDFjpG7LHsIvSC#;pr-orV^PNmFH2?L?Vd_O{PK%JQ8rbH}s#RHd9Ebj`SRlzz6F3kdFiJwAAsuq z{Pmk(ee&XWU%dL&$1nZ4t+!CC0@;wM(!1zeCt6|IXJg;03(DMB< z*y$5nR~(5C6h#_K^nwCEJSdM|mT(2_1u|PH6SVy-)=gPJJo_2ElSVom9IUbe=#|(mj_#4zE787g zmH^d-+9xu7D%&HYs~3RY4i+DCsH1kJlcU;X?wRfDhMa0Mje&?R9i^r67zpoSmaJ36 zBOGzcE}u|^<}gir=98`L|mC40ccr7FVbF? zm;x8g;?saJjmP&9 zA-;(u+8C;Xr3VETUIlXRI8Pzk;Rkto5e>pjbe0WuSbC~h^VP<0an8ssqaiB@x=gA8<{8nO3f|bDGVN5RgGRPlCo)tbLnAZw;1rRa$=2y? zoyyW6`f}+Ko*`oS9=SZ)ebDwqS!`IEKoq)^bjp%OTMm2mLXFR1h&-7qGL&3_Ep=)c zGy$@Ce*gCOUcU0p7cc+eqv!tc(X(HE@XYT&c=q#;p1;}Od~WZKBYt-pZYtKrECx@* z%_S}sl)Ma14Wzju++80ZQ5hF`cE`p{iEiAsv1&!kx&6DV&>R(4?9+Y??q#qZaKfYs`b*sQpn)sP(hhC31?UCg1$W&IshG8my7e|1(R(R)i?SOrVPnBd zg}W#lq8BrtwT0H3Kzot=Li$A_9J=h-vd0@;>f2LoU%qnX%U7=ft3WKoT_E}EH*fyo zwd;R){pQy%UAa?PP-C+kvxb6U{zp9yp_jB>Vn}emU0|ERnF{2MFr!7`x?Iv+yssY; zFCZGcrWcJ=33Qi8&4)QB40%`+`gm{(Ec&icFb)DW9p>x+ZfRo1?}TjJ%;A?;MqXVL zGaOv_`H%8g2}@KfTp3R`*yU=OJ874je2x~syOyUP4D~;I{%pH0cH7l{r!wg^dL(ep z;)Ki(G5Dmwj4{MGLrgFPIOho(pJu=|lThb5Y93nlp$>z22IK%>2*wMtFoo{Lfo?rH z$^pRCuqw3^wpIdbp|B2gg%sV%G5tI}#M3}8>>0f35Y0BB{LC{8Jc}3>*q|Y2E{iNg z-#Li~gFP#ud827Xm^0LAhdSv{r`$$|%uYtQ2i*1^zw@HPU2>?Mk^ZZDwzY(Nn!}tY z4ds+mE#s*>#W`mqJhcv`-mM;U{1$o-DQI~{aIT0*((n`o3kF>>-3~1QoeUkIC9?om z@Xz3@6(S2Z%0#+kOXe+EDxD(QK#dEX(jnTMt1>C1sWUA(&motEJCkjXXNy!iY0204 zOvZA^`gn;Zq!Z?1T`2R~3smLA=GC)jDqp`p@x}X3zxT@3x1O87(tM)O>ne8Xc_M$r zZB)mE6*-jS%OjJqkSqqv;fXT8qb5EqmBlX|+H*8Eta1CM+SLh_DMGXhog)<05wc5@*^E?PI|I1Am@3dJinCZlgkprtJlS)x%i4z zkq-~bqZgp@p)sa{b!p0%vb0eq;29nww+tHrPR7~}I|nOLS~Lj^6@syKCfeTy`=Gnt zVE^{t|NGsv{nIkjN836{Ydc|S#!TmJrW58Tz%T>1<)M#*{8pGifkP@E|J`Yaa_iL5 zKfJsM&iR`+Z-4dR=9jNs{rb&YKfd?$mru`)?%#S^kt$4~pt?}2Y=G|4_X%ScDEtzQ zcc2MpdXOWhMRGpMb$!R0$w+6HL=8Ko0U6!fxnE|Xg1~}F?w6TSw>lr~8F$E_!yw4* z9N8(LZ{HvB*vC9Nn9yF4>(j(@qc)C>W9EO9$Ep79rPbUKwL zl?Qs~x2+#o9yPLd#YL~t6mS8+C!FeG2J2q8qRy>XJER)tZ!vyocp0KB8fpe_jBtg- zo1s&v1y+LqBYHuHQHRQLFlmx4L&j1?Ynp@=IK@nvE|2wR8{*L@R}yK;6v#u^vQ*ld zCE!IKwb-rXuy~;%6sTO0E~H|nG@I$5>36BN5Kz=TkN@WaS*p!X7Hx&Y?c7FuTx1!&7c9tVJzEc7t|IOK^M%z7~< zaQ|%i`K_6#F}Wl4K39m zdf=lgP?zo8{S7P6OKhiI=#c0et0G4=ZrZK&1$}ZCk7lI%BpMz9$^C|Sd*g~hyELE( z(=NT0CA%fIPvM6Qxf=ixnKn2RvDBsiW4^bPBWg9_s6ZW8#fu*MF^R1em^Qzw(NG(M z7b|V;e!l4tVwe&V@wtn?dq%|0J^BsH~>6B;WG>|O=6cB#4ymi5DdM+N={MO zEKN)^_!wmyAuK}_HbP;8v~7?f`)Q(!fuN7R!na4}S~;Sf!C?zTnvtN#o(?)^&}~Gl z5ENd7G16gV#RYmspywoZlBMSrVbM^hRCIMAXzzf+Uyk+<>1d^AuSdTiG8a{$&24l= z`Fi5RyJNz-5+YAK)sqedt#G!BN8ntzW!0tl$V&TfSt^vgv_eA%`9-(}B^Rk~kYR*t zmVqP}I+=C?1z;Hmbh8Z_+ANJqVL^V$Y@JUN@H8qkS7p;EOS0{WT!BcZOj#nHr!pCo zrAX!T(1Breo~ntDJh3LBJjz?MHlf6)mH73tNJoyr7I=ix zfCdU&7Ujruay6?W8n&(|4pR$#av?D6Q|dOv9$oIu^`ID>HoM@`7=uz+3Lxqdvx*9Ee#@?8L-%wCHNAh{AKu+Wok zb<(W``)oHy^%?TLO)Gl^W=IjxgfLiZff>-nE{^I)6Q7PYo^I!VO>enKmkD%*#GJM( z!dMQHIj&nd`2f|0(+vx5+K4SB>aPw2{ZuNyoqnCEet7$huXfFfa;q*2zL z1%@eNmd3{k^9+SeQPxS^JP!NdmQmastd=ptIznQ@q-}(@4p7(-O^)(RCs+;!?_}^x zg!K|-y+l~radR(W1!q19CIlttCEJWbFJKJZB6`tKHkwHWfM?Mc6ry{5T=f`N-NuL_ z%=(NLmb`%5M#J4_1*%ErfZoOJo7%(NqpRXi8tR3B(H<2z?vU&4@-a=QcS)71(6cW7 zY`AOb=sZ#Z?M+g!WE}_XT~b=q1{nruL8d@*vkkx)3^S3f;h8Fy4Lg8aR&dyoESL{5 zA!l|ynPcaYsE~uU$E%h{=4f0B5dyUsHrjr7$hs_x#}AqxZ``mv%@zvT_29DqeCEm3 z#VS|okU>jR33JodwaK>74B7_JW&+`qHJ!4Sc(tl9ciY}w>3C?iKxVL5b)+v}7mEz( z%#*810?sp=)*QkuxtiFxWo>1ASfN`v8tE!@OJ&i{d@TGZ84fj3XWp|=c^(f9+XEfT{Hw*;M3Xy0!x|@w+s?tpf|`c zYz$pO7xeZY&~~y`AQnPzJ7Z}D?15pCXlJdU1eaLs_fOsbY@~lupg^}fNlP1HZow=~ zHcO)o0bFf*ygcNIqsx9*9u#2|gH1p(YEj3G7IjouLIBhXb7-Xntg;0FK4t-W(d{N1 zNNXc$Yi5X6bbT-0%@ac+J>!s{-M6_(;(BzU7hoxHRN7l$( zjl?zRQiCS7cpax?{(9Nr&!4`3mM402v6-XCJ@zT5(n;H9bZMBz2TAK7KuFp~N$WUi z8z-%!Hq#hpo&aJo(>M-&6LjDqbjEBUh+fP*f|-Xf^B`vG$Iacir2{jy*i0?Bxd~d# zdt zTU#7Z0pQ{=ElX$5A9%7nF|065MdMh3-#%*9PFg!@4A5;NL(vi|u*AWkDKrEfggF>- z5w~a_m_}501+O>i49@zt1I!%Oj%Iyrok)|Bc|I2$ySi)$14|K_FoXOyVWx|isnHs8 z!W>ewq`=D_4~p=z3WPDByR6LgL>UASz}UR30@aXXme5M{UH+!3;GJSm6X;&;7tur! z8m|Hg?cvBlw1f$**=V=RLvC%rAq_jxtuy-30GL2$zn$ooR#q{+5`A-J6v!2z+pn;I z{jgo=5$SdYySyUo#=7_}fgX3N=*E{U+05e4>|Ec;qnltZ9i^r6Sh>VN^gYazRU%Wy zQ?)WzD{>dy_IiPB_q*$YcUL^a5f?ae!e#G+04$JGhBClXLku}Y+JN3s5K_WCgaea+ zs|5fa$AI3@F;rnouwz5*xXmBK_XZOhuR&{kVWvu#6m8 zPx+kJS40kY^|1&~lgdHp?eaSZS48zh2in41rwsY5N3FL@4KA(TQ0jDKo@)$riNdkp zlzR_?_G&@l)eyjG57%ZO&m4@q1k_9&2YPetWG=w0;h?=ab_}#PTO%_d1BZmM)r9p>}hM-y&>;TN5z?DF+CA8XVI&L$cB9LK*xZA?ufG*$)iFb&nW}V8L z2e;lxjG7E{k2&N)jRWW08(fmnFEHS%(JT=_ZU9ZxBp?c=Ac!lCP7hcXu7nhN`sD}1a<6CnCR?giUiAu^Rb4Ik@cEY%g|Z;-hQs`$(Azj*3M zVIyt3K-)UNpt|%ykp+6kgDb8k7-|q{Y3T6ZjWMX}m<_}h;W~ljHx%S|6bl`-g#@>Q z_L>H5q5W2%cUcz}(t$6#WL*aIHrbY4vV~m0mO-aExTV_`+HEuSVWIt4$OMf|G6d4z z;0kKAt}A%q;WSS|Fdm2KtD?E0X-%BerBO{Bb13~PKkhR|BitQM>6}Dg)WyNL@Rl%l zPfXYapV1cKs#dv^4haB0;Zje!)f&5SOy{c%vC{Z0gDwX(bcq5QyZSr8XpT3Sc#&I1 z7!%-}f#DnwUhvWyfy^`PFIjS6=ODe{nU932X}mduvmC-7Ph(A~Oz2_1nrHAQHm@#F zsAR&N&Ekcsn911kL^2g$mI^+Zw3c~vU^SgG=W=8oPp6UQYz8ZJYXz#1r-&5+d#Nq} zx*6!Fs9c`T66kD^2HMZ>+j?UC@)QO?5-`qeTV204vcSO~_9>-aIajA^R|QJEVzC#v zbvEu;m1i(jEBwb2yd?n@kS=gbmr}L@y(JKX{c^5X7%WXqk@2GN-?C7AskD&hON0ru z7cg!kmn7HROqyFL6KE+~dIjd0GNV}{#Hy_YgcN~o>jc}pGz1OXX-f}_4RGi({WjX% z%Hd5M(xJI%?-+~q!48B4Y71cnqX#0~2nN^|QfGbwTy$k97-=NJN1yl|s4+NdRDtK9 ziw5nj1;34ksjTNnYcqqjF=RU$Bm?0kh6HL_VlJ`>^P?l?vbc z>l=nW28J1OZ<#;=w`CkzrwSDubb4RRvM;&0w0ZWUEIB@(9KmP`i>~>os_Ma3~fb2&ES&}v>>@HWGERL)VxgyPAt$XN$1NeXX0-D87>I2Mng>Qx!KRQZb4ab#bP@;2HJ>3Y7va5u zVMbF#WG6=eko_Dnsj#z#i0%ogahrD>GdpJ?_;Z>n<&j3@&d* zZh6eF&qaIsH35C6zQkT#6*H(vXG25Y&e=ESv4alvqHjncM!dhiBkU1@0^vQ%kx&8M zBP`KqsKN(lw%bAh;5J)mD;C-u1o)C|8Nl2I z^kN}!Y8b>#BZOtZW*Q}|<1_|_8PHw2E@GS`&?STtJF5tno$83p4xr02=wUeMU#PyUAxi@6*9z)B(D>P#dhr-7;uzwNnJ`J@%V!iMSWtN)kVW z;_lL56>0(6V8ycx6nca7lAyZK1}o|Sy;&-j2R|ZNpyog-masI|lE#_yG%B4njWu3Z&#B+QX5GX;iJu{^S7MPymDFU!t>Eid-SkhjZYJf)C$9ZaEv zD+||;gzNRIBkI>g6npri5s-d8g>L@X%0T`4Xn3kT%5gN-ed*AXxegBKEe+H1z+fl- z_I1v{D#$ND2%#4Ya|`%nGB}78q#Dio2FI&fNaUQCTr|)N9=ipe1(MldRAy~}cQ1># zv(`2aoGn`O+{$AgEX@7Oci-Mfh?o$_ej4k7^8&mUjz*!8izZCxvCwmv`Lqpr>64a_ z6PD29=4B_K1Ke6oXE5_Q;1(noaZ9wZ$S`-ITf>usJhK??diKf0F1v6^;ks0=U7|W= zwp(GR1NsoU{W?9UvXgeH9}Ol`Gm)-7h3%7B5N(j5ZxtuQ48XXv^R7FN4a+xGehp} z$4vld4{qwRf&2oiNPb%|6o8@AZVm0mLi=o{ep?98I}8CBEH{{N(l$H3Bc2eL&XgQrSeN|NP? z^ZPcPeR6G8Vq6|X{T1Pr%fqW;y@gJp*emDhOv8p)@bGmj{AE%0LML0B=sUeGs(x)m zO`^BNFP8Ykb6XShT>!8jd^Nb}LZ4h7>w>lbt;AA`1In@gz-kS!&0vFp!)77`Nh^XG z$V7G;>XHHj$?Y_<&`5q!Bo404LR$cP5MgkL2xDNl4NzxoU1%H&4QRFSwx2$H|GQUS z8u4i3phjpp7YMthl`z9gG!uwnsKD@98|2~8Gd5GOMMz&DEEj?kBCRyMJv2FlR#vc7 z4@(WP{jL7x&yZKywmo7#D*OJLe)>i{@ai5&*}D)D0+HHe#m z$q^jsD%2&0;o(Ei9IT_ZWw2$~W*Pz@vCv**n<3eTblH}5SVKU8k$<)>g9@Ry!xjou z_h6v|P;E$lgAAKT2sE&sxy2Jt#+OAq0aw`JaFpZ3#yIE~ zhiU(jQ7b?caJon=Yo*fVgYHL5^@&uE zh*o6)z+jTQd1lh34#A0oM*~#-8h3qpc)!H9QZ{ry4W4cjnaK#xgjerm2oU5hnd_7I zODy$V(yqBEe-rVmFGhass6ZSQ=t_wJ)jh&tWjs;NkyVg^S-f6it6B1lDqaK^9UOB% z3+E>mKVvoZi1dgi42$%F%Rb66qYMc|jnjB=?CK%CptKWUry=VGb$AF{HjITltjIHm z_9AW(q9D9W=DF1t3aSg}g79`&(NiGKh+gEhAJRKOfPc1)(by!Mu|Rv#J$jfyo?i4i z$2AG9L6g~L!Zs4-9&o7_6b=$^t4nL~*n6V<7hU>!w+8iuE*=Nf)sgVl8)BUyRq1?{ zU8n+j9TH%?baWo6?3M9-Dgo^wv|ch8eKk;BG)06el3!qz%3D%hP~hOmbM_L+pumbP zA2w=uhGfYUE!naS;%+8y2HTv;m~&+!-(a%9KWj8((PSnxo3~~X%Z|nP@^~x_d;HYq z)x{3ECdQx36G#1eu7GDS)?$ZpEH*5Qvt_Z?EMS{~AkEdTj>(ZJkm4)>t6qirg$}VS z+$gYfg$4%^w|a%Q)FW0#+RGyJifG4~EeZKf=GbyC_~+^sVO0qLuu>lFERS;)dBtPF z!DkeD1M0~w%M1PT;Rt(4*stQ*BNcQBE*=sTSfCdTH6vn!+PEaYt$;BK#>g-OoS>+! zWauTz)PZJ_tV@tXX9-|rvpHKUYiVUr4PtEV;)%b0`TM_o`TNNz$CSbhGw4QHoeacm zC>iHj{`WtoAzQX+A>AC42Gq?X zx@ro|>UzdI-et9i1%GO(QB!Hul&bhbL0%@(w2cZuQNqLhy21lX>Sbv& zN@{_0i#aElkUtxSPvt`dqDQ^MsMPR&9n+o$qGKayL}GIwHZW%kuRsePhfr zi#~mXM~uyY%sJM>0_iTY=@+}37BKcMbTiI%qXFjy9>)2$7n3O&QX%`kG))vhyj@@Z<9>7vVQqc}^?`z?QU+|FZDy(UD`_LPwgzMq43cP&e_Tw?oI+5q>^~9KSDS z*u~J%zh1p5N{2*gs2Q?(E?pV&TWaSW751Pnys={t3;aZ9_INNooJ8z}yd}{NKFL5f zm>OYR<;OPGP>%{RA$kX8C2y4_SMid#hNB#QpOIqsNwKh*gcEBp;mf&Q7AKN zH;fsvdBUjn5B{?LpKm4T)k!)b-K@?utFs*mvyOhJ*Qm}l3I!%oZ>~WlO|e35n5l;> z4JGu;Mq(C1CsdC0EcGxI+6^$$dEl+pxbZKqmV4UrOxkSNT^)?ECPgdmocg)+DM`yq z(PlM`TIp5cIsxEC%+U$a233@npQlqT(1{6d*7;h#V5E19N`7&7|GvsHr2a{CdE*Pr znhLAF)TA!csYmCaWSql6h2S3V5VMYfC* z(oI)F&%?6Vt>9cGjImQb=TyYO@e-~f;8mbHAg@-|SPbO`?P`m@%5GXi_qD|mn-NI? zUHQDN1;g!eIw8rVN%gX(`?zI~@yQ(N8Dr7Md0G}*4a@ABfII`3!?R)XNZH6TcQ;nQ2r^)4GNXHwJncrfXb--L(rQjr23|)6}lO?^KoR zOk~oRl(MR-ZS*dsPV%iM!V0pYZBgjbB0L> zA8DO4!9CDJ=kKOj@Y?Y3QMSYn{}eXT8a~FB^vPdCyo}4=nHWCW66$MS^yg7a|2$^y zM9~W`0Q`~-oNGplorSjT20|yQi!w;-lp;pk}J7W z-i78lqE62(P_``1=wJiUWP0h5U^S_i>T2Y=t_bASP%rKJY3=NkC8*EV4e)KQA zVqb1Xf9vYsb6=F=gU^ zmFOT~fhI7s*^wZyBwY%Jj9s8!=&+EKN&19hQ{=;v6wb*AnyulS#=-PDWpYl^fO8&n z&N&q*>Auk_r7O~Au(uE%TPsu=wKTH|o|b(*UxmA+#LcvNgj3JavfWrX z!M9-Ch*&psqNgp{+ZJOru5dRmgyVHHF0|G+l2sk5z-BC6D1kXhLRy;vtp(JoaCqJ zkR;3f%*yc5wpm66BI?!Q$f*6y!W5O$6!8_b0L4=^t`XiQC>DWD@W}xdb+Cti2F$HV z@VAJwj7q?HrbPvY&ouHg%`n)azg;!Ms0{HoAT1B{)J2T21bONGy>#;?ctub0TJeup z7yijN&`TTt!JCWzI5L7@Yn}JH_tL+P4If3)4Igcn1U&DJ5sTg$7c$Bg=wn*)pKmPw z3;jy{uUnF&WEF-}=?v4G%+qQbBn_?#;HoTD>4G{FwsSVqZHnNWsRoU)mou9JO?Q<@ z+c3jSz-erBI#UA!OddE(r%XqVjjb9*l7_o=>f}nTGR>rk(<*a)th>MdpmKy;%Ucu6 zj9{!-uBYEmsvF~V(EpqINuxLZ=Np^<@mj8jzGRd~f>D)j(qx-;nMQS` zVRxZk=r-HHXB!2qA|(b?i`|VyCLPpEzn!la5IF|=WtL5^kH(*qi!55rH~e{G^%&n( zHdCHepQ__?joMOoOTI;)iLDxCrs1c*-y3NZ!}UVA0n~+nSxM?80xvOZ=V-Z=R{cD! zGR7b#S`D!#^->l2=E_grPgKcM=@z+AYSGksT1yNf@>u$kI)e^uEJ7m9%S&k-i?Zkv zr4s|M6QsL}gX5)n8jvW|n}j@^b4Da^&Pg0(JSg8)!4H#wiMq}#T#5x*f#6!H zR~Kox681B5fd6VwOQD$t-^+*FlXZNdmo3SpPBv@O-OU+j@vx@&xMhv;Sz$9Swdj#K zFQ&mNLyWtb950Xy{32mSxEWAJ+x2tZf6b^BvgNOsbiZO_&QLFVL_wTJ<5Fy@27#BK z{9(i)yKVMt%&)4To@(LYciGS~{a9?xe z7+d&A^MXGOpZD5`P+tqFceFihlr3zeEqeTLxZ>bZ)?iwOLC!`p~EQ==7sLHo#5jo^_DPhhvstc_;l({BVu2}`$W<#GQbvEz|ARFj+QYyVH zt86;@Dt0#mRGp#aOMKm$-=0YKjg0CzrL6h=za)uV*>JZU3$6>Q3SakZoof9XV{0e) zrmN|Ri=hSV6(j+pj5II-OYGGP(OQ14PFSE97s3YXl!(e=xS~pXvUR5M;b5UrF*7qKCzBBg5{o1_7{Cd-G#Du%6; zzp|1W20IRgat*rWc}JM2?s4 z_rmKggyRK!+1Qoz>HJ&ESM-HAJWBc!b{k8c=>h%0S(9u83+(mxP(iu?FYpW92A~9l z?GP;~88UVx(l+2x5$vI!4(TEcvROv?EF(0`%`~{qn>0MwLkls_HVbpdy3ZZ&v;6O` zPuIw%>14>IXX?2?n|ij1C*E3B0X9{rw-G5ZgRMH)OF!GLLjF8&(ug20Lxit6YNR#5 zO&j8=pFhznc(`%JI}_vn^R=)MM%dcrZ;#LT=G_H&Id5ZW@RV>UcBCa@gn8*-CoXuy z7rLcezT-XTzYa3H&6zkne5^;vNPE=85snY#-(R5K1m2lW0Nw=^(lF%2yP#ddGU^aB zIGn^gCqm>vE)6e90+yjMMWn&%WYIZI?V5s6xe#WVk|A9Q#i^86%hR=rRE;8C%Ry$T zIxbnONYHZeIxbejCF=MXZrBpuWvNP$>ZZ-`Fea$DWWA7T6f=Na9TCPEa zbn`9RTsF>}2f1Psm8xujmua}brXwuF^tRH}NTVi6lxLfC z*(NQdn`P2u+4LQs{xj30Ne94x`a1zHh3b?M1~J0G@QaF$mk12}!urnDL%{q()h|U|Enh0SV&~qpuT%_Mp?GD5;^mc`QyfA86gx@tC8hb#S+Kr>YlT)U zQ}eJQt4-Q+qgZLu7U@+rKK3GuzR0RyJIX6XCm?4AbrFe3o;@r%BfV06+>tOZw;7hf z>$;g1S~W}U#>Mn=r@AF>ruoeDG7Zy2E5ffk)JqzcKAnGS`I0@I57YaVO+Xze{@Nyd zV;8=*NELn>Q!fox!Qv8c#UKw=0J&eKzdIo}$O9ba0~me-+>`;Z#5RS$P2p#e1=_d( zD;Ho>`dK(=c&hr9*+$uHgX;{vY=(}=JRJmfSEDl9sGMQoLcL9ac2$svHrP`;%gp&% zRDknLq|@dT@&E04))YVjk3|qDi7`4NnT6d9vk!Lam)WYA<#oJ?^W-Z zKaN}U$I;OfyuwG?(ms0!0*)AEnKRN3Cmg|&XJ|NToCi|qsPSHl|2#g-*B0jc>qo6{ zI>qx&&>?gS>XL4iq-V;dX*LB2Ow%@~U2slhjY$x&NUDasNz5vjRJCieh*E~Fq+ShD zXi_iAq5DZR*@N$n7hGnWEf8%5|gixOkd zRnjeuNHM6=_eesLxzHdk)Cwz1nngMx!D3hr53J#qs}zrK-@deWPqvQ7hgfRW*813r^{Nu1s@ly^ zqU9^inhKq;N>G$(=xHPf7)o9R^-@0UlA&}-VOm|my|P^K$};)OE99@l${BvaWF@Y? zPUw)%yXL64T$Lh|cPY_}WqNg?PAE_-%S^gb_G9D)HhuLd4_uSdAzGuDV$mgAbZKtp z6n9JRXzyiaU6Pj-;9Y9fFSZ(%L%dy*<}7?_ z;Zc5OQb+`*L>gw;tOS$kJL|{^D`$DY{ZiTt^#<65AP;qbhY;u~AZ-qE7XsaQsSI@I zQ9{E|Zveu|`CH_(O<=E!zeN!_LLcm|2^($-_SX5^gg|#yn5S;0!6kBxJ;cKh=&l2e zXPd!Zh+mv-;bvR;U^nf8iQY2+a4Qe>2Dxb?Mw)|YLX{@iOB?E~kNJ~tn6EL+*Aza= z8uza^LcOfnU;Q)0TOT&ulK;&I;XdXtUu*O@&-i!Wj2vZ+9A%Fh>z?@Dn<2iIP-M=d zZQ-Nrp}y7?e|a^?+Z;CH*Wd4j2mw;)Fpa0dDkf$|V=AF!7g%4)u0`n6mDI~hk~eZ@ zl?=#DVL3A@$)Xcv3_hp8EvqSK#wKF2V@!+PC1y_)QWgyht&*ppu2sSqXX}-jI%SeZ zj!4rXujWDK3_YJ|AeljOka{-FeGqf>f}~-lURAbUL=-R}V@K?Q&e#P()Wz;3S~aY1 zs#-yp0N@%e?0aO9IX3DPt9HsuN&+y5nimtg@ zuEeCx*D9;5+Et>WR3}vE#S%bRtt{2>DDwq*9_NzHLA|aiO8jTAxh%ZPGR}E9=e$zs zjMaFaB9U$z$g@=R9SeDCzSy9lpQX|$R?$ZzQ;zZ^rq= zB7AHn^?q(uPPURhx<{O1<&Q#1EDF&X$(O}8uQ9pn0p13?3&9>D z)awv1Q!nY+O$fI0VV){uiHO*vk+( z!W3jz1-gj=G$bYf#WM}^xcB}PIocZJrVeJJ4eba6^cfHhP>re55hl*Ay|@ zo;~^RVI#~DqpeY+-J(Xj$Np_n0xkBW)1~ zUweR?A@Q9*hK>03>`i9lRnRApi!u(PCB{0(al|X$vSBL}E4Togi9Dv*UU97Y}3gk_c3n@vB7z@ttREg)u-8at-z`9izCz^cU&kaZ*FPS=U0 zo|aNCGme&L))d+G6<)SngC<=o#H$o-|M{mBL7r()qbH=BZPuyx2X6^`*f5$)&r znAigLieW}E6qz#=YY?L#W*y!2B_*@rt7x6b?j8yAnSf)A>Lq&BQiD21$1l-Bz^*G* zG!T8fc{4s}IEoCFA|HRAT2W-?i}idlz^hRfX}Da$6?!hx@FhAG)R@N0Qw0S{SCq#n zotF#prM&B6&IJ*xQYNYe{3UU8)sz>|G;RfbRWHP^{fTY>iP12Xt(LE$2&tN9=y_7H`Z3cdW z-Nj&3u*x(HF=LfVyD}I`wkZOwgkn^J-1uO-Fn6Rie7HWyO$>Guqefez$5;Ykp{+_t zdWK0J#PB|6v=v$n^U?*oX#%Zy2~DV{F2qwC?4=9y0a^`+@ZrV?h}PE_>1&D{X$~J{ z3LkBaedpD=@D!9Z$x4aVqs>anEASDhntupD7!hu!?hp7?V zc7iw|ctAUmV2eh`9$J-Cj?F}yfn=EA3~x-sTG%U7%cX0c>p5M`rK=Pvbi0_#1Rf}z zW{L%J!BU-&X5gV-LM#33n2>>PL}NNL!4)K=5O6MJOo=hmJatoN8R^GOG6>y7W0+nX zzm$frkXox4X8H1Q!<+u{TCPr&3_ol$Zu;x%Ic8m{w|kmam16v8##sz88pSfLa;e}Nuad>7WbuM* zC0!Jq@wpcoRORl5B7>^btVvh8Ae}DIa;wyQsZmp6(Pq&%Cm>hh64lBCjj%+J$7;kl zooc0)Um+@%^0JjGE>WX|l}*+tv&h zR>)qQ1Nn_Gtax)YC=K=oxvN4v)KG7zr{1AkZ(XR50Rhp5k09MfjWVNzZc)w|Wr-YP zi5O{#9OV}Cr?K-V!tt76chf)md&DT~oKYm&f~g;d`&j0W^O`fl7Cp*+(L^7AH*GL3 zh~vEj?Yh8UHEFt0zhV!Vw)a4CB`rrQ)&(MW&+4YO%{8|p0tYO8Co6gma5{i%$l{Yj)t}o z&{4(25p{nYkK{R7E981vi#)7pI#s^an4%FJ9}`<%3egE620mD?B>Y0jkg-ll9M+3b zdTBV`R6Y!gAR71e= zI1cQAQB~$;!vAHw;F@Dr)7YR|kzx?xz2gmHoKdwz%jb>qO7^xQVP0<0Ew}1c+6^n+ zOt8B#R?3+{T`6Z?fI2c~;FmpMw7_PN@Vms*wAkH58g?_G-SP4KJIiM_)#o%vQk>?l zqDK_i*K16puZa~V+l0@oATtC^xwItj8SXS~gT|}CUZ~egMai=VbgM$JiWuUh3iTGC z-VjeA)SVA;S4t7=&IQ{!&^X8q6=jH>M+CbGA(VKl0%50F8RDs#15FM$gnEL#Ft^%> z5&8&UeW;Hve1sml4fi!N0UIJmLckWVH+-ZiaA$xqWeR($dUG_F;+Ng*y)sy z{uVyM6zPj}+I`_9-(_!(4Rtp}`dIwT>Um>51FV`L4?}=W8({r4x7?%!T17I`l zp3EUglGb+%RsoYLe9oiatMNJWB816>@O-pG-& zCBI5TUu2#oqf0@VHa+@hP?2;|(TOP8z&%W0xST6+Wlu$458v+gM_%MdwNCWa`N~a_AN=l*W z?h){dL|Rw~fx!doRj|R!^pr@i)T@@LWXlnP%L>62J~mE(1HlKx;R8+A$P3MCIMrM& zpP{C!SAortq~=l$s%2{BT+U^onw!hJF4v1o^Qk5S2EL|KYOw@m2*i6-fl`R@8y z(KXd1rW;i&MAs$w^mWQ5$dOFy`J#M%CUsbaZ`k);(XAsl(cfc8z+#98bW6Mic$th*=R-)ne7Khw1`UJ25IIEa z#$=2NDH(M^QZEf?d8k7?)nVS+P%llGwGzMhrL28EK0i>%Q9_*%{KiV_Q(=^A|9_(fS zZy{ZOn{JkgzVTzG=_iv4{;dVfT&{eDU8$X++m+latb~T4WTepKgrRE4SW+xumMBdM zhi+qGgGJYP5pLNfSuMxD=mUxZ$Rux4FJU=>hPdcC1gM?Ko7{xR_iJW-Ls0*PMds|C< zY-vcp^+K|mEAw^F*K0C?-`7UxxfwIfx@?0cUd>mIADL~^rE0}YH)D?7fJC))_)jd! zOM!YmK+i$I;YJZEB98nMbsQf%mOJxWQv5c8a|5Umkj7wU~1gVGk|YmIq(!jd;eM~`-! zGt$0boOk$e>$2BJfw5s;=0K}9$fiTgGzhben%PFxECb>vi1@db6_73)XNG_wT~t;= zy)1vGMwSf6al~P&lZ=tn% zjdeL^B9Vq$7F_^a5;F~DA+@G-8W@LvrbL?EZGzWD@(ds)YZRcdB;5>9O46_as%Cm7 zhb*RR1!i|u$yz?kq$#i)GEHjIuojM5%rYKfnQd#A!sUzz{sK@;JG>_2)qcnw1!)1 z(8TD4>1%Z8*`oj^-9XYI zcnjUKv>A0Tq|M}eA!7&?ijD9VQ6fUonVDf$l6oO~s5jh4!$J!PNBQa^N9a(7jnG7n z)J2UlMvXEcXGR6;jT%MSa+t3XMt2UfWpcb``U9!F-ZBZlb(Iag0CidDn139?82z@=gmx*Ll3leCSp!kLH~hsuYWL`~ods zFxF>|nv1m?78+E^9u~YAB+ST@7n}79OllflX19ozfXP+^luUCZ>1#9`<5et3u~LN| z(?{t+<>Fs8=rSEv)&sgFqJCpXZcNV!erXpbBOqN1lne;dw>=Yk3BO8|Uo!Rjd#e52 zkS%N2NEOd0N>U7#pi204i1ud@fznfmfIWuJz17gIq}YhzS_IX7pTgm7 z+jV{>m7h^Fi%Hkds75(kubQP7XX<`^<_sz>SG){mF6UlZ$q!q`y-eU`?w2*byaHlo zf?UD93^7Yvp>U?mVU%)ntYiwu5n>@=He?OVLa_jeq~16YS)nsQ1@u-c;svKT!3jI2 z(w$_NB(;pjw^TCZ;mE+_MH%Rd%Rw@`1Ds0IRitV;0G0_@k%UsmB_okG&;$>xrfX?@ zYn5FG8AIFbcYW3AIw46*)0Nka@rJcbHvqHrm616nO)~nJREcUX&7f`g^Xut4RmG^` zNoszTmn~C|t*YfJdEHy|1L8vxy+ziq~l|B{8EDe6w{<=G^)8JYB_S<&m*r}w=7r+?V}F! zQbVy2Fw~2fGg2Qt$}nfN0RoO3rAGz9@N0}71EErdq&vzIJsQ$QX^k3X4kzntjT&u> z^u;DyxQ}_opT-8*aB$PY@jl3w!#zy_W;N6c>arx6>@P1+oTIz_Eq|LUj=qbkd& zMq`3nvH9&uNg`i7*0*x}s2r<4%b?A$=+{mfldcmJUe)l!4F+@OZJ zU83feYLtsL3LtcWhMTM6qDZ}R2sMCr_2XUqc$uFd_ZJj_BIhs2g9TZH$VI5QNR4u? zjt06H8&q?(%2=BL89U9sHmK(5#HChUgoc|B^;&h&263T93(P{dNRlDl1@O8IzcDsr z4ANuJSW27irWh!eLbudzfLu{u0`}SsSVcHKo_}YdL1s3wnSRQMenU|8m5pRfqtNsP zSM+S)bUQ!OjqVr$&R<%UEVZT|J(}WC%8RO3;Rg5N};zn;~FCl2#7srmG=WqA?sVf^9-KSCBSY%O&c# zcr6!)3Yg4(!yys2nHgQ^HbtvMAVVghG8AWN#SEPoFDSCj`c)p5MEdGHAs&$vSb(n-j}Nd1qL3vFuCch89vUl4lS&Ku;sjkS+)etxAfeEZV@+$TQ92 zU{07uuxKDUTp}>T?;I@+Vj+cQGdhHYdI1?V1iV1YEjMbG=v4sna+7AMQN2i~M8GP~ zQE?G!E>xum5frmUxxb3@6BV;W`7A*`Tg4$lw8~H|UQvZaeXd?yV$nxw6iY3-C>^&9 zcGt_e$PCyDi>=xPCe2L9Hj zgIr0pIG|0x9J;mYSJ;iqex-VauWjOFgk6Oab{Eo}Lcg^wPIDKLR8MyoXS%Cqu+iqP zkzKn{b`2~;!0Zx9=YYT@U{WlJmX#226ihEmm?7W@Uvuo^l93)c7DK8*os4|jAm&;0Nm?P> z&6uncpy3QRQ{CU*NYx0*Kl>dcKfRI(Sn03j0(4xk5lSWl%!aSX03*WmKrSWE&~tihSby@}U;i(cZvavY+$@bJ!{`FJOucF(#*pp|50R-CN+$3kk^a)k)4&x;o!vvC z=lE#|+TUFa_JZ|=bZNlZp+M0TyJ-qQ3!j zMexK}vZ+k!I*o~7C7nIO8v zsaz7&uJJ0@M75k{%fPaXzI2jqg}TNGu5l{YBp6-25(#s>T9E)(%mSiKrAg7s1Puo% zrWgQET7`6hTxb{qM%0Yy{fa<&0x7`e1iI>IB}s7cYQQuJcB)sST|WLotJ8a~~u zP1Fiy6Gj!-P3Y$MnAq~tY&}0yBL{x{^n9S6d0=+$7X~;K1V#z=8u(DknW1Dh4U4`* zhe_AqaKa=i3dLOH)mo0GM$>2(rPHVb#q;$v%0+1rQRuK z4(f%KWy4W4&ioadYei|ZyK1@zEHSJv8Qm{!BDzu7NWe4}Z3BMk7tE&Fg_$0F0P<%~ zC8&#lh5=PZVBz}NQ`uj?2e~r!s-lLgp)4P!BXj-6IPcpRx`oVxK}b{iB-kRvHUPl7r@89$ehs` zdX87Svb3BrnRg;{E4rjYqM|Hbl)rZ)!24?zWPq7~rTNcv`_~`>#f-qxJW9%|DSw8fS%AO*G8>Lo zAhV68dC@dAnoz74Xn?tjy9@r`Iv7~M;e7ldazLm*dn5gBFZ@?)qJaFo|TekhF>kDiwqh5mS9Us zvVIwIX{&a*-MAbnv_-QL?6qo1v=&{QMYqzdN%&P$g{E4RUz?R*S^3GNVHMO14Ntbw z4+~Cldmc!V>H9bA;%8>%S)0W zMfiwNZ=|=XXLZq`_GWB~fa&!Cc-0_qPgQY4!lJzCAKo~3I(jtyA)qcw5SZ#?EH}=b zVd^F6g11Cn2Z6C_r?h#bC31v0%+nC+rUQ8W%z__L7mDQv1OP z-Vm)S_`ka(+96=xDMs<~5(M|kVx-ofs}eG1R#{0tnTEUA z)DBjEIf2dYAn_Bihb;l31tv(5GGz3GP?>I>VmVOPIZjClGo{lkqh``|iB-9v1uq2k zCP1Ysc@ns)flcKTNwM-+m|+H6$PxmM(?HTnw9qQluA?kE6$*!2HmZCT4%8?EnoIqEUq73PQnyuAy40 z1GXqhv_=)E8)+1!Y?+d0Qm>YcQAz5hQDvHaWn%&MB2|WNEt*)1HrA|7fO<`uc(XRn ztVy!`2VM#DrG$r&gL8`2}$pmKeD)ye_F1mKb~nncY2>K;4Mp zs_W-YMfqw;x1)49(>}TO@modnu4zjBJ&6F(zxwCXiI!|awnZWA@>4Lq_bxUOs)T>hk|2Nnh!#T}YyfR-t zY@vMEBE_(U+^|L9FoeesTcmtNszZ$s^CIqLk~B8as*_Y-2JJ!ijMD7q5wJ>=g%Gho zx)Q6TUZl`;M~dz?k!V*6F4%Fo;EW3av7OCRSRuNsP`R=R3-l-sO4K3LIJF!BS%R@l zw4~KIN}j1s>eX@y6iQU$btn}HGzu-G=!8W21`kqW0{u3akY&*$TTW0bv#t6hw5XwZ zbfe+rbgRC=+XhKznsv!~HS*_WyuA6NzdJrAw!Ab&!_Ct1Gj$vc@Jy{DP|weT`!xt4 zaG*gcX*g6*lPG~=#$ITca_I<4r`b2i(yd^KSs(#J&n%tBD)Xqq9K8~-ox`$g250u< z1A7z^Y7Ezb>O!Da89)Mt`&G_hx}B+!N~NEM!&aowff@yJ><~7egi?B=5M@*$5tw7q zL>N_3W_7ep7im(>18*s9)-G^NX*NK^Bwerz+vRogkRoS5;L-ET4g0uFO?85R%5UWPnH-2UP-Wp?K*LcM&0L!nt8}l(rdwpyEV60Y zon9S~3-vA|=@M+0nbe6$mBCx1m}JtVn6xQIG1VZZ8tEf*d_4co@{Q4Ts#!M80s(VV z;A7!wtw^5LpO{6c_cNADL#R_};7XkC0e#Xh45EcOVfbEQGT6)Ja$w(Y+=OZF!fZ0Y zVlW$XhDsq$s234F9MlDk3CPl9ENGjConeN__mcGme&>yW-8Ib_X_!CO1P#v}ZJsyU zJb$cp-Z*RYSo1u>uLC_AqHs0K&>iJ zD?+-+lY!q5orZL)rxM}#Q2zZTz~w)JUH>D*^$+2)|20SchXruIN@r*lqK%aOAqu7Z z6_i+As37$&#v$T>>ap zh|ViT!Zj1H%W}bK8A{NY#`fWz+y52Lgu~D3K;5L%ljSI?cYO z13^R6WNz66X;9jsSY+MOBM{P)Ogumuppk>FvmjTEVwzeuO|6&#^{SP~=jocF#U)>f zoQ=*HEgx!7E$}cxz!4@DasiMQazzRJMwwO7(5*#_mU&FQfH2g%(1zq$x7eaxV%06T z>f>z2SgU@e1?jO4$W6k>guF#BrqI_K@zPwjOg%kj>G*j5on?x_Wx7c*&7_!aQO>aO z)97}t04q!QW$}ew{MucZ?yiP(r$U_c7z5om`jUME76eaX273v=L}2up$-ea}&{GJe zTSqi;5~(tD8|uY_y^?wn@V(Hsq~Qpp&?D4yMnby!xuf+=w1&B(P4h{pmU#@h^T*q$ z4h@eXy9)tFjzS8Jt@bEyQ@DpA#I6aUFNJoDR8i<4T{5~-0J$unUUjgRkPF^Qx(!2J z`|D?G%y9ny_`CeCK$kxR%l;!=_VQdtT2MDq@k*%c%b~KDLtXz6L41aoNy&3$uK>sk zfMTW70#fzM3zRQIz${)~qI_jBB&|fg{YnhWy_Ya?LZwhFHL@fe2{Qt#jN8MIA)^DN z4!}whCD^LS-$J@r1%4rEw4eh48P-=Lhb*B+U{XF3Iqw!MzSyHpe))T zLd;Tvjn05A!!;=!sWLzc>H2FFfd&ET`ZTqCFce>lu3w9?scHoTObMG_ApAnWG$c-= z;>hPC%t+FdbFIjkMar2i8lV{2G9t>No@XWX&bQKiqeT{)>b%$r_3D>dw9sv=g>)Nl z)Fc{JNk$bgn@Z1cLAN~nb`m~YtIYoCxcvXi7VOes&Bh;WSV$LWnGH00H1>?-n@VwDXz2mHKyr3=vFQv`!x|BSRvdkT2 zo#Shc@H9ZZ!B$OxN$@i|>@GA+)Yanuf~gm2GuR9DvhgY=T9rgyXgEwu;rLMg{biQR z{|a#agTK@N3UY;d|F8fFGqlP?D@B+qNjHq@)EFXvISiRLiPkwv{&F;j3aNboDvCcy z6$p3U#n$btL4*S#gVYFX+6+6-c_hkL`D#162lBM9u66k?=|7n z;U)D-0RbyTis%lW~oKHjE0xBG_Y(`B~W^-N->DI5T^&zHsuU93z8;X*(q&CdJO48qIB<ei{l(w)4*)N**Y!W(evu*1l}qX+@P@elM})MBx(g-PAu`Ka|1?0exE=()}f{fG1>8U`S za)nwEt5r(FSHN$wUPYyj(&=~&4K=5lH2K5rD^>C|vp!xcqD;`KkVQK_Cbqof`1kka z_vQEH|F-3K_5Qy6zWm?1{I1^Lm*1EFTbJL}`}^|y@_*~{yLx|LeqVlHeqVlHeqVmm z<#+V{zWl!YzWl!YzWl!YrprqYE*-dkao_!m`=z*dVgEfU(XtOEtDqf~y>~C}yK`yZ z-OH@JwC^^HyO;N)e&^y|s<2HI7x&)2u;a2wt zvAX-_`Q6xh<81$pv%7DeWfe41^do5X%r3S{o35YPg;mzb>a>?5q&`wNN1wCk+<*P- zF7%W-Q$=d0pj}uus^BeAU3x`F3%xhi;yCP0X%ma<=lic-K1anI`lE7T&z%bgZlB+O=i-68mk!>!co3_o+`D|} z-sOXLFQGj2!YXaLf924Fs{<@hIgGe}g#vw~%1}sKrFeL4z;V|6&o7T|UwU}^;=?-^ zAKktD=nmr2gd2KL!DpP3qdG@Xd-m`; z;@bz;pWeSF9p|SVuA&`Vr9k~DN~yx)$-S#j?_K>?S{>?hAC(&jsq?q@Z#<=t4uYdS zKcM3j`3;wQ=l9<`zwa*M!hRN1p-biYeH2ptCqWm?dl&YwKxHU~S{zqbspsAEdk{n2 z?q1kK!5S%~)xlu9(5v7*+_|v-HVahloZm+w)g6J=pSA4Ag@VP;+XrJGHods@F0LvU z56~sWQF-17BHX>W_s#_buK6sezL#)t5q&76_rU6osbl}-*8*hHWOW$zGZDHx0y zeHn34g0d_e=%u*epzKh)1dKtJ>;ao4L=j_%Z4P45>N(Jbx)HYqgW3sWQX>col(J1f zMK5t$BDd6^Iyi`X?exy;XB@$f@Ep4A4bUq}?}6TiRBgG7BsI&A| zFR(Ymdg8yC&ToRNBN&VkL|kweaUXF73d%6`G1|o59;--4#wu;43ZP4@MIG3C0F+*R zh@i%+kMCW7G8m8VU3-j{!D9lDz%3)LqeAQ?jsl;6DB<%lTV*XcG9xQPEOGJSwQq;e zi}r_XFRA}SbRebt``3;x*7Y;Dgu?r&w zDnl549xsqsx@H2L!0L-+eG$Ec&lfwhlH!H_KZ)n)WqH7J=>Av1pdwWqgkUWWR7jN} zBEA4c2M#50z8F&bF9H`C)&cuUOuYmO>;+2h;Yxxl&+~&*e{^7*s3(gTw}Q}85WFey z_c9(!=>qk^+h)Olx?7?$yCkyfvviRhBrd{{3Q#wxoj!`8kWl(!NFR%oE-=zN8d(Jg zL4Byt&qF%q^Pm5`ZP+ivUL@tRf^Zv-05G%OLcjyVOXV20J^fFj^dE z&HwzuxFy9P$;cNH*wDhjc~OGg5Ojx(<6yL3MNDY28; zR;hmf+M|2dAKgO<(6ajd>yPhKi8?BhF&*sBP|bFiyetI~l$@&+s7vi2s}w}mhu0D8 zP!2l_Y7!SESb~~^;FMrVynKPgLz^VlK6?lcJ=o0wU}}G%n^b4*?BI@5~MrY0*jwr`VrDa zU&6)^NEidi!%@JoQAqxn1w-1siw7J@If zDPHiqQVbGzD26(NpwG?g&}StDHJ%&#a2%iKU}ySZrMk4~#gMlCta0cQcAP`MSYE>4 z`2g2hcICZy84NxEf}({do1#`WW6g!~%9JHvj5_QU0sl#9&l;n?@ zvCGEn1%6blVrk)JF*g8aC2W6>b?Jp2lVlAQfAvHc> zbvR(@j{+SBD-Li{NV`Z@c!25$*DG&H*Z!R5n`uN`}Q>-6K>XP(?W_w@cHN@5<~c=qV}(|hOd6Gx9d zzJ31tr+0t+?$Hm=9y|}Me*ff$@1Oq20u`+O_`_2QYWbGp2b51}$8Ya{|K#3xkMBC- z$(?79Z-4vnCjRS@r{1}I^6r&W53ZkmaQ*b%%g1k=J9O*fk=vIBuASa<^<@9m6FV;+ z*>?VL_l1ETR4yIecI9~Q)ss7}pP}nH_yRmJv`Zyuh3gflOiqI?dLTOerSxe_K6nVa zbX9b~n1XetPwc;p!4LN5jS_LC80z3iXkG}%f5+fK1`YlH-u2$TOqNIr>3U69-YW<1 zUfKTusnEs!4=x>eJ}B+D^^3C&l>>|B2E9IM40FRcWA@%Xw}+s6i5Xu9fQKkM2;jjA ztD|H*CeQ-6h~18nYVyZJBx7T41ZWb(9Xr{QNj52Rq;;q#zS4{kP)(bkO)ZRwYAxkyn@^&D(>(3A`-qlhDDmEzhHwuyqh8HuA3>K;kqxND1cY6Kmn z%3#mI&JsZpRHs#`GxZ;0FpHs8^py6Mda`|C!6kR=*mo$XQK}GtL0kr4#$XA_(s57+ zfEgeM?e95o4? z`|-zbfB5d{(g&;d*`tiO!V+53U@P0?r$s{Lo$J!69NP=<}pNg(WwR z>z>s3Uj=rdVE-MoDphEA3d(gPzW$=c(a!dA{H?!OUb;<}W(2OexX984*D)~%`Nai5 zmxiNX05DM&ZkUaPP&BSBdg-N?Br4-Hl9(!u)U&Ib1t zjS^sn5QVy9@(}~f5ab3cLv<;bAx5KwX6Hf!j>I>@;FqrSp$UcCJt#0x&xhsK2x$&EC5F zzdeoq|Gp5+z*iO$-iFXC@oZrK4xD%;tFneRu?p2uqFt*|v-;3p4qE?L_(V|q;8v+J zw25ABaNnUuf-AkZ`;4O$L!-yEJN0*r5+kT5*dtMgh&4n$DH!}%g|U+;HE24A5IDFh zxmXH@TSp_?osP^1`aG}~+eO++od>%~$8-eiiEv<*jVB|}=O-cUi*EQsq;7*dVk@;v zjY9{K?g2~j@cLskN-$>kiJ9dEQ(r_Z<16bU)g6u4D)qz>9^G)9BER7R^io_n_)`Fr zIbl?$0b2s0l&4C0EhI*RPx}@}2fjXW3>ja#c>Wi`80&)J3C;BfA^q$_|d3?{-V|!YU?`b=^uj~5RL-((pzJBJwwNraF&Y!+}_40#THy+=+``uGm*zbS*@%!(dJ$?H4(RbfH zL!fg1=FRKp&YnMV;P~!s2YOm|w{7ZcuHUwCP4~Lh9W^Cw75Q7svbL6Hv=*ng6s9%h zr8MRyZO%>DloP)pE4CqX#is1o#+>-3+ysi8gr@Ac=DdWh#i{LOnVprn+iHuq*H!G? zT(ft}xZD_dot8RB&ZGYR^y`6Q3dK*scX}K`ab^X+i+vj(K z!IY!0{}IQ>I2a6y&zbsPhJ~D^o!*s$=OI3W%yli z7j)e!!ECPMIP^yi9!EO9u8K6!Md+_f?DSepu zV9Dt+{Y&?HaRv;|WsoXBFRilDu?qC!M3hbj*kZ?MGaU!3?1sXn-wwS)gk$Kv0;l)_ z|EO|!?{=JrOBc^WDJ>Mi7oB^gekAs$F?P){~VF z8R76A5K>RcTrx+?jx*>)8LFAnMTwT@5M@UgjKLO$&*wNKIu2HT8Nb{l?MQW?SBe+5 zN+Ioqc;5ME9ataw1RfD|8CHp`Kk>NC2R{$2KDzPrp(7lp$ZxnjxU`RgxemGw2Ty_v z<3*6zVS)=YVsQpGuPeF7yySxnJWU`_v_E!cRV=)#13&+I_xEyzDhHv&h5Q@ zcF(QTyAd}}_g_1)^Wwm^Gy6ME?cREFSL>>b@Jt_MPkRJk{HLZcqF56aDuuAANA~Z&R2s4QqJ&2C$j)|QvpmbJ1Yb45qy@~s)m zS~HfmXDmZ>q%ZAAU(%kos4ZndN9w}P)I}X>i#t*gF`a2ky3&_+q7QXm(v}{BXwO*M z=7=Rju{AxWHEr>hw3wEZ#mz|z80^oegFCnrjZVtsCg9KipA& zpl$u$*4qA->YdHiySLOH=&U=ov+3-Cj>|`SuO9EaehStL7js;+VT=C@lS)@bhZ}LY zg(bu2{OpVWCkJoH~@6?Q3Gj7xowE9kjWQAh^B|)Z#G2ECxNUR3Yxt$TJ%#U>%;{ z6=ocgAmrfj;NUH7a^QymOl)Svl7PxO(2y*%kBnqeg>m%y*IG|-Dl*cacuVf(axSD8hnRR z#=z?AZzQYj_zdY|q_hS=#Th^xl~OAPU=~DHiMVXQ*-;-tFZM#>MQ6_o{n>oF-`e#$ z0)!(FN(cnfr1J1ShTcVU84HPjQ@{CwSPS|}d)>Ptbr>WiH8LW;NK*nT1wohb62Z_* zGlSR*Iq1dOhh9rM)QiVKqx8n81ABFej%;$%%_k3UK7DlS+b4IvdwT!-Zy$dD?IVh3 zPuOVN18kMW^Hp%skp%o#!La)OqtDOcXC$Uo8XQKQjxz}C=XIczXiA;G zm3-|_iTmB78`A1`4{uOi>i_7*lm8R0_rBzJnbVN$?*pQ*6toFvT2W>k+2V`REFs8; z28U6>*2U35=y3lM4GSY4Tmpml-a%%6s_)wI?N^TWUOBq`>M_)T)!q~RZAbgI9N*b` zc5mmYovp{VH6Gj6bh5AY+@6lp{cXp#w;XKWaIj-!t354UbSxozvw zuI7VV>i2G}+TBpLyP;(FhT^_8`P<5}w-sdev#Ud= zmitdGobk!3sUNMH@?rj0@8x{{kIaw$mj1zCQ{MYa;y>R?K>X*Maqqkl`?uF)QNHuW z%D=w0^sNaCUmrbp!iaejM=p4E^rF|sEP8#+!q-M)b>VAcm;L#*<$r#C$)6_8n=~qV zlJET2M=ySJ;?lpozWkjx;@^8a^^<>OOn$du`lppaQ>wyd)I`p%n;%p+KN#i4CE?An zbK8;@b%NsQOFA=`c4aT`&W-KNU5V((UD=+qqAh!QTlUJf97JqeZd_Y#d|Ph9*4%{F zoVb>(mCc#U8`D=bWyWsFP3kPp*jAO_x2~kW9v?+HqHlf4_VvZPHdgH0QhT_o{@9MD zll`ry5PP5dm7k*=RK?)9Hsla(vzN=^ZE}z+c>CCpvXL>K6-hTPijw`48 zuAJ$k%BdY!Povy^^~CmTXLnv!R}aJ!e2x% zW~0pxDziTmZ;6JWZ_(Y~7x63^Vuo19s5^Zo2nnd{2_hOrr@szCf1ShoN`I!~^I;_= zAC$gGqr?(@9i>#EF%~*$SaLVST?%R+>WtOftdwpq;l#lIh2yOGpI;=HNst?=(<+rj zks}BCaMo>Ys>dqpaJ95B2Q7#9?O?2>&LHvBuP3v*!!iFNfJw*h#8C7!@gK7RJ>>G$7%_rw40R@eVO zmmhxo;kzHcfBHQ@{_Ue@PaiyceDB-GcfNge3sfejOT-<@1_-^xJorwDlrP30be}w8 z=>3JYb>Neg&+F2xE3)zuSsmRdq=T>+>PD9L@eRaN#3O?4cZf$sSt%qEKW|~vf+!yT zADH3HMwNkB5SInByetU42evih#Dno=-Pmw6jTj#QYad)b^yu>8CG$ei0bcgvp`O!w z+Hlc7y=UvW{q2Yg2Rbhu>OQ--?ey-gR|a~o9NvCmZ`axW_7mHi2ioiU8_Kt>&O`LB z&f8vvGIv{L_V&uGZDpC=Md{rI$=$i}U0KV!(iXQT&EK*za?|4Aby2eb)ckKg$olM` zsqgPPrDI7n|tU&3n6CA(M%ziR!mWG?DQp`{(W~xwk^qe8er|~Y+1=(~| zL^+N&L!+FcQcTnGekRQk$?95AO z%Zh8wSkauiY;)4mjY%;ZQ(~GjSG49ObQY&>U!99jva>X+y(pu-B&)NgU}t0H;qHbL zeT^q~HXZBTc&M`uF8Sz=rgI0nZl2kF|MI~{*N;5BN{?0!F_nnRDvni&vO`;k+6TKi z&Y@o{FVRfqOVaHMf-c}nC7E5edU-!6i}PmR_DvFcQO5$;i#{y&ef`DzuTL6->oPiH zl>qPpIHiGQv@j%qkqo^KpzgkN3DA{Dv-{5FJrcC;5S0n@VYPdiTvsyKh_u zy0%|GyY1@9?(+w?p4hqhP-p$Y*1F>z8;`ed8fa}i-Q97nx9i-_-iv#7UEJG$Y5(q< z$B*8eCia}RG^d3^iE)4MmH+`jtg#??o+?>>F_@cXAvzyJ2>4?q0y-Lr3>JbL); zJ-n!g>`^uhMSNGn$jK2ji zmWH4Qq05Y~gkkz92-2vd8>24))nWPpS}G~GpkO9@C!;k3HsdrI-wQ028T7skuIz*u zbg@)kpb|_4S&6dP`a=51Ht7@r7`-IG)&%4lA)%BE%4G832HR8!)~g7Cl6J_tM>) z7jIp=c>BiXySJ|0zkBn+!#m$T`{n$U=gYGno;`ki|KWo>=zRO?#VhAdojY;#%+Udg zBLgQ7?mKaC@6rAJdwV|u6;e7d%HXKZ0p>+z5Bq< zZF_n<`+GVD_U$@;Xz$6x`_3Fac=q_fxsyi`7tfu#cJ1>0dv~5a`xdWD_wjx@#pUtC z``U28^FQzWLpgTi-po`3z`$^i%FipU(>; z#y^25IuC|4s!ZKz7YBN2m31ciq8mFtgYJ#*@S=}ze*e>W&frIk!So;Te+In|FCKcx zK7wiz2faj^I!E1ALZ`vX8cCOf5FKFpVNis|Z7#e)3Aien*yqe(K%8htf|*({D`< z{UBDTR!P6NuH{3t>{l#JLXc4zpyz^ge2`Yao16tgs}z3pJF>zojW9(}e95^^R=7@9 z%D)tq-)L1+P5PO3OUNki1#eAE`uHF4&{g5nHY^EkNtnAeX+cMNOn1(T-u$>7tCIQ( zQ??hTY+IGwm7BCRBepSR*`}nJ4T*~yk``}HU%n+Lfj;Mgl&yKm8#CiJX2-XcrSGUO zKG3%A#P-d{wr$+Ebi6mRg23vG)Cq>&f!60ZClh2OsbSYbDDI6Gprwa7y$= z3ynEHCob`ZRxj_ldwDO>_sZ^Dm-=tOo}Sow_2{NwribY@%g`Tnj;2m5cH zId=E*xd*pz+`Do4{>>YY@85X(;PSJ_*B}r!iw{?u2S0vy?ct4MH&5-pa&X&)JsszE zZ9U!FbflG`v3~XL%Dip)Nj*71FUXa#TScPxRk8f9UDm z3*SDx^7P^5XHV{Y`{cpnd-osRx%c?)wcFW;JKe|~vp;4C>^X@LV~+@&eR=&*D#-RotRm(iM)EU0Cuk>W1hONQm8xwsC0eC6StD|c^Q zx_af@X6jvhOD+zstl>JCO>s`R$@hJTzT@!($v`1IVo$4a_UO+o7PlzG}d>wHt* z;qvhE0fcmy_owJR_&~Y}Lq2Es-Z<5NVW8*uu9gE`4g1^c4tH%j(bp0gFm=M{;YYhR z9B5f{pr!U8%BI>q8!G$O6!ny6brz<;sDZNG*|FUj@UKhTQx>)8+c-aHUBrw^ zSlF-LOa9keF|Umda<_b=<|lLVFJ#VN%ABSsT&62sXNj@^H5Uw+X_O(L8X=RXUsI~iAlrDk1ORy*l5@dnAYY;-9I<<(hK*2RoB@b3B zf<*Mk?kofu4vXW5;0>#>RTipIglZKbT1Bu%7NWvdS9(`?duY@sf)IK>$fOEE7{nm( zSj{2)VZK$|6khhZ>#&cV{_vsGA3kt-KZ-MO(l3X^u0r1ll3_2egS&5UbIUbZ1IrXeW?ByP@$-;$Tun7X2F`NHbO zb8A;D*pwaHQ=7l9rRH!){r;9Uef8zN^<^OO(caDH4|L;#f9uSiJ8ae!ad!~LRAE+! z-EpAHrsEv?#X{d^g>&fsB}P*RZW&guup1kf53+Wmuf$rZgA_2t8nu9{JmHp}>!rKJ zjJt#Z$?rOXk%PE;l8T_VD0XkCl1~@bK?G`OW)qR z^W(E8KYkCOKK}8$dr#puE+4;oa_`yx_G29lht`+usmkxoOWvBitR-n_Yx2@9aSNMP zMmNVTXpD>561!|`Qe0blLRVgDPjSY!lB~Y++}%}q`>PB0tuO7bujp^6+PkTGe`EE* z&4`*qjkO1xst&c*9BivO)V}6m+ghYNd$+FHv!$lLrFu_Gb$?UU&Q0aJ>P!097w=qK zxT7j>TUmZbVb<2X%q>|NjTx!UX{jwKDVq}$8se94N?h5J8n-ngu{AxRH8ZI_FLnFs zyu+<)&+YBLdg{QVJ6C^vcK`eD?mc^SUsQsqolEG$pkyhu4BO2u}c374A?{e1Dg`@lq&gbu1aeGwmnwAc|NfQV@+&of+lvx_pQG2oU5X)g4$f?%8?=m|WRZbn zaF_MG#GEbxl?@lueMIJ=uROec>F$m5H?N+#e&N*Bb0;pHId<;kk(0*`f=NdY?mfJB z*WSKuy`5WoJ6e0&TRNLIwl=J3T2s+fRkpdZXk&Q+QLr?xv9h40x^PQv@z!;vof}s7 zY_8efymsf-b-UWu?`o^x*;>D&W&O6s+U^Zi?d!|8)D|^W6>Y-4#kmb2;;O85`RQx2 zQ`hFCA!@Rcsv0_zo zWl>{QaZ^o6%bJqbbtPNZm$lVbbZ)Bd#w#|}c5bfe*ihY8SGi?f`Ifb%Th^8|*A#88 zD%en-TVIm3z9@5DQRe!R%ylK1b)~tDHDyh;<&CxFt@X8CO&fN!H}C4&x^HLqz=55| z4(~mE;_$_DC$3&Ob>;HO%NLF#ZeBfo|MmrZlJLhrJiGnP3at&FSvvFc+|U1+`meWQ|2%QQ_~GH+wm^$+ zx{CW+?(~)Gu&)TT&NF$JK(!p+lnkg5R+5Y<{i?E#SVb7q$PvLRz|RE{sB#HFDKIWl zxC9AkcSTD8>LM@+h`I!D&InXMP_+A_1z1IJgCVU-!MhGcfFoQSd$A)>yK?XdN>?g5 zTJ=ZJrsul^@XmfpXFuNAUvT#4odX1y0F^92bVVhI-ZOSbqicXl9;oJmR7CM0uv`m^ z49Bbt)+vLvN?O%&fm$v=qnNFdPv>P{D_lO84f|9!>@$V)7ouXSNfSKWZSJe1mcH|P z;zxhWo%V5M#EkkSp{+^tdU99nEKb^8mbR-nrMDolBR8%!d*zm_*w&o*maMqVDa#t- z7p+}BfA!MnH3^G1=O%Vl=JnPVbypW`t1axSFWa|u?a}R&l6~+voSO zTgCL{fR2mm|HFW@W8%Q2{gUf_k*s8b!CK~ef3|5T2)Yt_*(@!(BM9OSLKp48HcZ&{ zvpX)I=svf9%jum>$GV%2b+n$}*?0f!sb{xuK6~(hjfy>e_VmVs>nCnsIC%5au1h;N z4{R*&$xmxZSl+N8dR=tXx_R>&mc+Cq#&+kX?X4<2&{%P_WBuu!o6hWRJhQjy)V|Fp z_G~!bUw3?G-O=8)M|;;C-L__+XU&oB+9RE{1BkAw!=04_U6qGBDh{_-9PX$b=vYnB zx%zO|>LcA$!PX;P6$4$Yu>(C)h8=Lt;qIEFJ&0Po z*3s>2j_z1{yl?%8n57xvsyVqPr}&GdHa{C1LH71vT^M zG{h`gzii>=wAhYS89P?58fa^{b`r=u`ta7d@1EZK{=0`y?q9oq`OLK=2aoo29qH~m zy{Gr=zU~VLyDuNxe)Y_b8|Qc4zSK{{(R6#5?*1~1>=aeX2)=G7{`#bmqkz+Cu zDrA4LdiOH%_&)9U;MV2aSI=L&aQfn@V`q;aJUOuE=z(2__w3l;*R!jut*de4mUXpT z)>dt=cTOAO<9+dvIap+1zA&Svy#^3rfgW1*;oS4nhRgMxgxKzD!;j= zu(h_deSJko{p!y8s?H77T^p*q8z?#(s@m%+w*r~9rR0xmOSjabWR*3gEo;~+-1F+< z&6R~4D)Jl3a_WjR*A`^d=B3x>rq$-A*5;+I$xoAFU12&vTUP>R=QdWY0*1HNSF~?f zjR2~*)|YRsD+9J$*OzTsSB9-k)rA|&^XiMU>x;7Mi*e-K4dttvYRk6NRqbeNJi4#% z(%FHFX9v!nIC$>l;ZsNVA0OCr`uM)97mq)@d+EC;H@^S&)_33DdIl0d0dC3WK4C-9 z%<@tULG+g)jXWbH7(avSMf>BM-#)oXyA#6y4-7azy*BXp%AtGb_gxv-c4qh16MfCc z`)M0OHGAsI`l|DLE35g0wL9>6&5Cpga*T>KCc?_sZDvXMi8${M(TWr&Usfmhb?ff_DA zt?;8e(2D6`ups}Mmw%&DPBW;dnl;ni^noMY=l*d_{0DCr2Tb0$EVMgk*{;&WJr&8j zDw21UC2cEC>M2U-Dva+a0Et&_NLo^}Vt)0C`RfxFH)Y1Ql)D zZR4r_mSfu+4|O#h*|GWD;Z7LehgSz4Uq9+NhkmiVM33zba#!Lj^SFcVR^qN>o--Si zW{--KbEO|kz~!61JBf{I?xUH>G+4?8lh5{D*td0m^V;s!B|TN;XM5VO9X;^~`BU+1(w3i-fD;a26b+9pSptTS^54V>Mbd?|KDnHy&imgWx9c3)a zk93q_>!G%?fwtl!9Yu%RiwU-#xj1^ZfC{U0Zk5 z)$D6od#b-|HAI9OC*;5vj*cbJ@@87EIng}|KFi+ zypq1h%8_76_Z@IDuyf|OSjez4tV#x#ftHOnJBE%a2+R)pN<+tN>Jv8Ix%}|XrF%Co z+`Mw;{HcKxhxQ!ay<=Zr_ulOt{XJW^wQX+OxW2J=^~TE54W)$}N(wet6u^&mG*oQc zT;10K!&<+qt!~GbwY`lsJ)5e!8Yt0?l+jR-TA!aCa=v+Sep}%sLhG1%38UaV#Vr=6;+wBHQ901S+UjGakaUL>sF<# zFG{N`&DdCx+f-EmcsJJ+wA6y8#jWd0Tk8=eTN_HZ)Ri=^D@J3>n!@HatD4sqwyZ%N zt{12-XeiEEUyxp#om`bkMq=*V*F- zZeKa`==NorPyYO7@Zh*K1MpzbOsi*4ZX&=}qBX@$bdwsXj{~}ngE&r+-*7qHQ-7$d z?r=xl$=*$;dN&QUuG!zTdf(>CgN;=OHdgLlSG=P#r@JVvJvX6^fwnbu!Pew??MZW6 zRz%b<@UIH_GV{~F&Yv{G&u;uiBYdsmrZ67(tNCCp-DC|%=!I~D7;X^g-l~pnhz7F( zWU2tJ4*WP%D4ZmE5w`$8Vj%^Q3|rC29H+m+2{E+Ffa*%DC7L>5iB;k*aEKO(rUXvH zWGF8WQOZyWk$}o}M1*jzh)~WoOeqUPUG7Ywa0%mNp$gYvxpOGh9qplP69WCEN{9p4 z^g=j3TCmGdNbe+2?i9e{c|}2gmp_92El3>#kxvW;*bD|!aL%(i=UGZ8sv{kNzsE4Ly^RiEr@=w*u+1}QezfLNg^~vUC!P|3} z>?(@eRhrOOp0uMfdB^J1zSU{HWvLx`37gZFtWTISQukyOG z|Ngc84{qS%zT^DfmIE8AcdRbjUtfE1|2CMFhj-6iKG}QqSkJfDk6zf@ysI{6QC>gKigk_qI)%nyJua-)|5H*(bL!ZeOCO* z-wOZvX7-yC(k6{e9_y1Z$|HGu|u2~jS z6SKG}E46P!)j;p&^ZVQHUfloe+q>UBe)9D3<7>x{9qsHm+`i>hfBTh_+wNZ3ckc>~ z{5yss7;EvLDBX-F06T`4X(X9dB>K`i`><$KN z0eU6xE8VHRPn#azx_IyUx!addT|0mD!pQ?C4(&SB-?O`?wYPOs=ce^r>#CdAR5aC= zH`SE2)Rt~tTh>`$xovaJj;1v`x2)T_b$wsUnx2hS9qY^5)|PAqEJ2{E{4J~VS}Jp! zD{@*Y^R`wMbgU`vsW02Usd8sib$@fs&c>?l^`*^~xu9lc>eAws^Ya!(WJCqT1x#H$ z?X!7belX{=e@1=u_po>W68O#=et({TnEA%&Zzgz89_{wIuk}+O%O{@ZPdrQ?yBj}p zGkj>*e_+#nVAp?WN8RutYx&Sdjqh2t?;!N$d8ze(R>G0#PcQ>5sx+$~-q#@wWsb&p;4>o&6OEM?T@N7)C)A1cXix2w*BV0-PcZSKiXT@SCiA8y<*d{==udwP4O{Z zIq|z{Rvl`tKHj|^R`1lF%_sUd9_wp3)?0UU+qxs&>yCES9BHo_XsbNjRyojFeWG{W znOzNMfz`gXdmHk$7sWTmM$|@5shsg)*=K(*`|$0Of4x=s=J?!6z6F4&uRY7llI3O1 z9d0Wa=~g(_qjF(E3j$2=jy?z9OqFn)?KQjg4N1# zsGvl1r60Uq_2s{+W_(y5HMK1{vbT8o{*Bouwy!?9 z6ZuE^k!=-6x2-0$dA~o5y;rOl%Cwl6SY+1X1eZ{uY z{N|kWrqra(iE&$UlJ{<^Im+Il| zi#INxx^U{yse%6E2X`Lcy=`|-TX)mO*7a)|t1C8^7j3G5BP?!PSKhs`dVBMlovrJ4 zfwEiHqu$+6xwX1*b4m85;;hEfoR*5*_S#k5b)|r7Z$tTxjg>naYx-N(>~3ANXUm%2 z4P{Mb8RZEJQX^+An(|@jyMLbg+SpG=cz)vJ{`m;EuSdC09qm4Sw8xAw9<#=|&t~B_ z!Oef7yZE;zq?!CakKu@$7AxF6M{Z{XG!4X%*DY~c`I7#SM_z(@7>X~ zXM1CR_vXI#`fXd*b~Vrf+U)fMuu&yX;T|s7DVOC>RVduu`oox-fJ2&lW+tAar zroFy$%bJqL>cUOsc@5MptvWlgDl1{_s!W*UeZ4KGkM22j^uUn=dk^mIKYnEY)k`Pf zcYpl;?vLN!p#kcja`$HdmR4yR*Z&FE+h13 z#lh<%W|U3;G~=VcEq!ZT_;Bk?o$_mi)7P%AOp`hJ0hStNgn^IL^O0I*1Wh2~*gPWz zd09qQHZn}Zs*-h+23H-d1&UxyiG?g2BqO&v)IR7V$+p6iIBTSDqNxzE^|0nl#w#0NQE;ZLg5lYrE?TV9m1*I zHIkDv?<)(32}UDYl=3KEfj}ifAw!=iyo$m#P&N$7K^Wc@pgTx?iPi{89VFu`5m&*o z2ZA@{7T~VGY#95yCfO{k^y5s3CVKwcf!Yr491Ul@l%pr_UBzu zpZz@0=uDXnBQXMa28o09e1Mko*U|%2(?#wJh06y{fA~b{GTp9;nCQLo-9Hx0{J3iV z%#F!W-9;;RR;BjWX6{~_v#Tbjw-o0_a%*<{mdur#lVjE`kFJS{s$LZ3IEQ|*JfGqG zfD90D%fjJz_usz^-0r`Bao-(a_2~BVyF0EN?7Mz^;KqrA_pY3LdjH&=%X^P*tM9GK z+nSxQA#whu_=Q_CV!KN-4{oVCySM4$q1JQznosmK9No5Fvam-wiLyu9RwIsfR2}Q8 zKDxDHe?viUS#oFg(yj4x>LR9>eEyHTH^-!p^oTWSGCVEW!)^Ja+)IGHS4UL6Il_qJ4cS}D);GnLwnB{oBmRbOmFphERRtG>u)SY^={T69GgeeqxvSqz9mls03r%}AYX`Xal& z#LZCRjxd#Zm`Xj(C3qokyr{Lz$5uMRUN+KRI@+yllzZtYx6(20<>Nfd$9tAf@G76^ zT{_--)mZl&UwfLjIl)bb$QbQb@b?KNU%#^^^t0CZkdEwm+sjw(ug^TzUUH(h>cn<1 zxcbPp>LWe1M|)}qdTS4FTXO_FCK%VB+PmrGp3MV24cltUo3nG*$0e;#T-jQfwr6A2 z>78A7uAHGM-`_oXeEa6LlgEzl=sDcka%NA*^;0|VT-*zeN^=3EySzU!yN>Z^)%J ztuAe>ENrSOZe3f_wV`6?mNortYj?J;>1(d--L$&1u5?S)s;1KH#^TJTvh3EHg08yK z-p#A~8mo3}THRAu*15K*tvau{JgY7*p=4!rtl#8__uig9Y2=3<#(x^ce;N2s?b>gA zj59}BXOFc5qM@&Qg}vbs{)T(_>uzDM*@Gw90w!4f$5{i$+5*Pd{6?AmMww=hHqP=j z%<|RE^wmuFQO)pC&m69q;iH}5t(oDap5aL`-Ag^qQ$5u~oZ>D{^F*kod5BZp_-VAN zp5m@TJIbjZ2y~;)(>yhZDX4pCXZYx5cOE_c_l${N)5d#E9_jwRhvly(-RmlT0_Qr8 zbA8LK{doL{+3)^&N#K;M716l~b4xRqt}jh*-&o$eb={7RhVAVex;C$AsVUu1nqOCx zy`e0(b!}xxi0v)wJ2%yU%`nH!HAM}@S=CvIC5cO_vg4X-3wCvG+Sk{y zySJ-%Yx}OA?&F8|-n@F|5&o|qUI%5rdwL7;B6No;QaDbL-*9QmTG^Jlg1*ZM#7&&n z6cf5S@XPd%{$0T$gfwQ`D5HdEjNRrKVHBQ(k|wK7b_g^KbJ=_ac*_REHU z*$q+hYCtBV=JSxoeuv0}kh~_53HwSW4=92=RMLPjv%k!JJ`cw(Au=}bOXvk+ok7`1 ziHkB9#!gU^1pusYMTJolrE9bRh@#yEtC74sf_Dv9x2Bon{J`9|e>@o-~h2)j}IRKmPGy}=h$cC+3VmN1eF-(Z(M9?N zr7H(^oa^hkdUW3t`Wo)4QbG&P^D7BbXAnubqB zs3}sUU@a+XB@46*h%^e+l_?q}wx(-@46T@{6|=M|Ds`$Hy*k&R#_Q%AwRs4$HqWG8 zWziK_^aWOZflXgvHx#-X3%yN6KBl7K)}j%%;!*aZ(YE5zZpEYBi^jMYj`LVG-m_r5 zcm7z<6d!B6w`GNgF?OVT_IrO?H-Ach`HF*^bLqZvNBNPiO8Dbry|rYBx2-#h*j{&( z{Bhlhoeih=HJ&=qvUl5t#`40-r7QBIA~&SPcUI;c@7Z+!+By0U|NgtXm#>`JyYFP* z_6z%aZ=BwFhwj`U&pzy8-8CkFGwwclp7Mb2ly?zjX5O zsY81X?%LMZ(bCyi*Va(8WnD${nzEL)6rkfvZk+fEkN6|v7)1{c* zZR9tjY?Hn8lRdRlhZ|;&Hv5ma2ES?xd)_65xd!&BW2o2+?db+o2 znx`<8#S{it!GC2{er@N!aTkf% zUYcn>ni<2jNCjq(H294+`j0gSjI#z#umw)C!=3w2^7NbJHG87>j0v9KjB)>bxa|WE z^WV+7x3ua%X;g2U_5T{-Hu?3je(${uOh z>-x$qYsWVY#iZV8o=4?W?R9n$n zzovb2Ltker{)-Rp={q*C=hB5Ej~`z7@w+=eet+-#Z)se5h`ZlDzUeqce#50RWq#AL z(8|Cs6aV?Ah>>pJXt=LPk3Ng1atZ3hG8I6u3De7bS26RA7&Djph~eMddtEK39}Si*mv$CtJYF7mJD|D#b!x zHlKH0B+8{&j24w*zDkb%i1~tSAvJOfRor}0F;4`Hfn*BQ7oc6OoTmbPWphRBg^DZV zIsra{lSc{4IU+wtRO0AX^^2i|g zs)6neXZCM7y{GZSjt$4QHyqnmccgpWq0ZVvZPojmN_MX=*jryX&{}{8*bF)D##}E`-f&Ca2us08Yr!a6{%Bk7Xj{%0d-izu^l|QSBi$Feo9Ei~ODB0} zeDdeb3Bf12iq7p_cVbud(QTDSdTM~-W83LIF_Bn;abNw3T^mpAZ9d%J*uJ*1IzG8* z{-U+Xafi1wTtBh@@tw;*{_w-IXHU-^I4SeTR2-?e1#nZmMrtSGB3Cc=PHaIIWI)nh&+TWo=*Uy1v#my^X8e))h5X z=4>v_Xs*m@U%RTOp`>?1$@Wd9I~vRTx2*2pQq{G-uq4Lf#l2^14^htL{OQ+=3>-BU%E-nFGg|0!ADBe08&YG$7U#57iVmaf+Mj8@m9Y z63=Y>*LIQW6d)Y`rIkPn&S7;jutzPzmlk0%i!aP5#V;(v=O+GhladAZnUTo)83om; zG$?`FPYjBWb&5~)*ve6x5T%t-x*g8Hy{5!j64fHe1+N%^UX z``D=X1eixQfIq=q{Kiu?)k`xSzS&1V&09OwTRY81JIz-+eUxG57|ZPOcE1T8eiJ-r zjdPzd);?v7ZL+WVV{g-Y?#6%EOnTOvE)^04#qi3b^)7$G;@9J#ax4o^ut7&^nUH8VC?hVy#Ys)v67pyPH zM2CjbytWOs{o6YB?dsdw*x26EcyQ152X`*~_`{taf4Dz%Z`g5){Dw>D2)CIg%@;1O zOu^M0Ox5z?Ms<`)6QL8rHOg=eAEKhCUxL+&KtU#rh|-`a94#CBrRzSM7$sF;UTMUb zL07^6S^!tDghpA}Sg~a3$g=`4uCIj4hDFGoQHHU4q{4X)XhcAD3RgJI;a!0`@|~Ou z06d46gKZ8o3eNGedAwqw$S>rT3wdslii=Szm#MgwDlS%3tPo{OMLAZJHDWqK&F5Q< zC0_1`RaSGhR*lHj!_w%pjoJ*o8j-3KadAu4i)nflu5YP20hJ_;kgO5Xb*eP2Kv!ce zpP*63tGShGZiSkQ)o^iIWr9{n(u*i#)qK2G6{k@x6|j|$)vFha+4mUf^*!FT>}C4@$~Tkfu-!-uWK-G3UYbXg22@;yk7R-L5EMHuGEw9} zHLwl9iv#d@21P->oJYu(@v2YTDCIGn46#%xTf!OFU_%F?_n9wE#nn`zJGi`=+yCL1fnBil|8ez@!wPlUA zr;oFxjzLuJ8O%>f6%i7l#HJ4{^E=g}H&*)fJ(7U;OXG_(N#)_VX()P6lEmi5YX^YcC zr-lCGwJ&|GpIX&ZJoSEK?4hswM7-r4{zv!VNml=Hrdgv6Gs(hgXAXydRZjxfkyFxM)`qS@xDs_LeT1aYKr&OG71$!j&2m9{C!bI`_f+2j{YC0 z6gc>Y8uO7mEP!Vb`NxbA`q^X5{^P9v#AEyH3AS0|Y|{Ya5ta`<&HuC+|6KHm|FB_4bbSdwMtT-L|=N!|J-Ctg6i94J8Gg4QqCFH16u$ z+}FNwM{5HDFz#%q-cXjeIxA^)W@2+qN%!XZ&dry?Yg9zD47?Ei%8 z^%oT(8s!|l7@-xy!CkmpjWR@31PgMSZOhYhsKGQVYVeVm!GN7*!R8qa4xFMw)>h^m z=;{bFpa#E7eZ8vxIBD%WZ{>TtXIafve|oL#)p0q)-SbC}$R9Z(%fp^v(#Dz8 zxjt^`He(DgTdGnl)hHJN%qniKikqiWz&+0qU8O7tl9A1`HE)iMz64ezIY(#gr!zp`B(^yGx+LH9+Rfw!Y%WIl&OKiRJ7uCxPx3 z&r~|W4F@2{lJ3(BE;N0bhNcw(2EpH;nxR#Gp>%%F`9HqYi?h6Kj&tZ2%S#sz@40sR z*yGz*et2^I)|tJ#8%kO-V>iSvZOTgSttmU!z4`oswln)$j_=qo(6jzv*P6ra)dTHS z$GU6J>}oi*eeKS5S#=3>ii5sNdH+w*BWyuN)nXrW(m1c2*M{d#^2!|RmO0v%4FfmI zmOb2>?PbYvH)Y!mgcge~-Kb92t5fu$<@35@6(y_BSGX+Ta2z_?e1!}pR$q86+R6fTYQ$dBjte>G1)TFD zCEldVVx>!r(shZF(gjFmnIK;($d;?*%hd8^8bz#*Ptc1=26eJolVsH<+4U)I`eb)Q zBEr*{=wnLqwWN))r%rHBnBX2a$z#z7OQ=;lXS7?~d#~rt{$NdPaR0{4i~H-&?WsGl zbN!LtwMVzFgAYF5*Fdpr^XdIf$9FgF+Olp-N&beclQ|0#N8br^=iq@L^ma3eVs_ZRQ z*{wA>?RBemG?(vguj$`f-MK!0UCz?ng?@3fK3VwjUqk;gVd@zB*Tap|d`$rp?IEwS z*-Ycj{-gD?=(ekRD%_rj0Ln_^!wj)7vVtRQaJRx_z?JyQe_@7I1y%*bCkFl_pbKE5 zPy(?mlph)Rj}3ygf7fY6^96)?)5nU$ZJxi4Vl z@v*oGG<@x;p5ddLIYK{kq!B#!8)x+!Z<{gRGIgxwtC7}^eJua78~$ogy{b~YY1V!; zZbZ-re_0YRIdfT9bzWRoW5uCeP5ZZP?B2M#v0_zIRcTXoSz}FE^O~}r#&vtTn)Y-z z?`+@P)3k2O+Om!1x%EYv8%uK=%JS79uZi%&Q7&!>8mr)j% zU78iexJ%zwK~roeVRLc);pIyNIWCXPdnghFE?LE;sg=p1B1PnK^y&hGW|dx5X400L zwAosr(4w#KvK6>n3P*TWy*j4Y%bsn}rrRuKZ@$s+=|>q}_EfX3_U%8Gj`KyjpX+5S z89%c6t=B3hj4B!7Uh3^u{pz^7f4p7&r-@~weTwX+BCEd0Zd~PISv|_TVbYjNcUys0 zm8%mAEZQP>W3EY)XQIj~E9{f5z|Bnv7q}Vn?D~AWVU^8T>|rY(KdSoeKi2;J z?QBn5x|^l?!+#b3uja%5%I4ID!S-a2R0BD?)h%DiWAMVj7F) zXk3B*r%-mfBUY;#~1*oQBY9$Rv&k|guCyb?e)aqoZQ)XY+J*T z?z(}lwTIhk2DVlo>sfcAx9(7LX;)cNZA?(&dvDD!sb}i>rQwX@(2m_%aB>Qen3dEnM~Q>D zVwY&S6FUOxF092hTJEUKQQ(-Y1uv(R&sWM23wYT=fy(*3Y=Mefq~@0B`4uKryiJo} z*TuUT;@pg}Zu+Hex|Ker*b(LxBg~0oY{|gzM33bYy%vt~n5q-rSGdf1Yi!Mu*}c_? z2U`n|^;RC=x#oCZ-SHi8!*$0&;vMxT`Zk=}*Ld<^%kG}K4ds~?E9TcGFX>vHdvRdr zw~ucB@a@y6fm$y^pc`}3ebkDE2gE8sQnus@BU3BZ%wgD2R6$6Er&n*2uUXV9RrYO0sW zrZNdr01p;lyNMELLD?^?%Fivz&n!Fw{`C{1@*^Ynfq{D;o>j+aY6O|YPmHQhO`6Zl znomvYPY_1+CkFM$dX>ac)IZP?*su#g3(A6gAL)To020U~UyI5oz^#UVPX(*W*hw7a z-xs-m@v`>>_*ycuAD}1E7mcp(qFt1;fZ0{NCv}5Ark)&1tV%n+FDTIGUC>u0dzXB( zf($fzYQTONal$+t`6mVy0)Nhjcw>ZT#d{k0`x+S_jnv^2BP9?Y8u+P{6v zp5Er|TkE?v)$}&6L)lziRGXbxot;!ukm)!@e#3>nl|rN&e)NnAeRU%HRz;wcg`*;O z4Ux-&Wv)T4E1saLqRq2t(K$)slB{q^Je_$zV0P9V-fn;jO)kvtoE^I zX!sI$(`sM0Rc?lSfZ5HEYu9C2G#PNljPB_MZIVuvXiz2URf#$=Q7@zzRp};enpvA+ zHDtM&fn=l$$$C|SPKeXuS1 zs*iN7J>FY?tb0voNkYoxe+GG4X4}o--fqh#cqYC&JY^Da>yb3to-)do=4;I!<3KOMj}(M1fK3jb z$$%(eEShNQv_N7ZV=y4S7!Fuapkx4+FHpdng4r;X3RKX@SSxu`0xbm@Tp~B^4zw$o zos~*>XsQtY*}lYV^u$)67ij?j9{aLY1m4?1UJ)Z8Z{QXS${3MHxme)PvQVi&Pjn!l z()(wKMMdt){!-Z-g=>`DB?=WzMw9qam!kziGxEbZ8fZcp0Uh$PNIHR#yCI=-jgmri zjaDlb8^je>ZJdX3nU`Uir(vnPezCi5v6p_?2vh7R>&h|Kl@qKhUiDn^s`vb{9<%J4 z>F(O3&;HU=vGPoR?TNmsW6~qV#NY-P;-kRuj)v2_VTfD%dm0*x(`uJTuZv&UT~l!J z$aeZV&);y_T$bKckTqM=MEA(I ze8d0f6+F=%Fvb)x$}oGlcDfgh8-L>lM+?e|6z*WH@TFatY!kn*37=cV&&=YdW&wgZc-yYwP-)H=sq&4KQ(JVx9UGMsy-k~N>=p)E&o2eCNr!b>KvYx z8r8rpHW5(K0r9SiSO^MI0Gy1JaIPPrGggV33ZPdqwFFlHRn5_`GYv0upJ+w!^